ID 2AAB_HUMAN Reviewed; 601 AA. AC P30154; A8MY67; B0YJ69; B4DGQ6; B4DK91; B4DWW5; F8W8G1; O75620; Q8NHV8; DT 01-APR-1993, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 3. DT 28-JAN-2026, entry version 218. DE RecName: Full=Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta isoform; DE AltName: Full=PP2A subunit A isoform PR65-beta; DE AltName: Full=PP2A subunit A isoform R1-beta; GN Name=PPP2R1B; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9795170; DOI=10.1016/s0378-1119(98)00350-3; RA Baysal B.E., Farr J.E., Goss J.R., Devlin B., Richard C.W. III; RT "Genomic organization and precise physical location of protein phosphatase RT 2A regulatory subunit A beta isoform gene on chromosome band 11q23."; RL Gene 217:107-116(1998). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ARG-8; SER-65; ASP-90; RP PRO-101; GLU-343; ALA-448; GLY-504 AND ALA-545. RX PubMed=9765152; DOI=10.1126/science.282.5387.284; RA Wang S.S., Esplin E.D., Li J.L., Huang L., Gazdar A., Minna J., Evans G.A.; RT "Alterations of the PPP2R1B gene in human lung and colon cancer."; RL Science 282:284-287(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=11313745; DOI=10.1038/sj.ejhg.5200585; RA Baysal B.E., Willett-Brozick J.E., Taschner P.E.M., Dauwerse J.G., RA Devilee P., Devlin B.; RT "A high-resolution integrated map spanning the SDHD gene at 11q23: a 1.1-Mb RT BAC contig, a partial transcript map and 15 new repeat polymorphisms in a RT tumour-suppressor region."; RL Eur. J. Hum. Genet. 9:121-129(2001). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3; 4 AND 5). RC TISSUE=Brain, Testis, and Thalamus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NHLBI resequencing and genotyping service (RS&G); RL Submitted (FEB-2007) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16554811; DOI=10.1038/nature04632; RA Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K., RA Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T., RA Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G., RA Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C., RA Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A., RA Hattori M., Rogers J., Lander E.S., Sakaki Y.; RT "Human chromosome 11 DNA sequence and analysis including novel gene RT identification."; RL Nature 440:497-500(2006). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 31-601 (ISOFORM 1). RX PubMed=2159327; DOI=10.1021/bi00465a002; RA Hemmings B.A., Adams-Pearson C., Maurer F., Mueller P., Goris J., RA Merlevede W., Hofsteenge J., Stone S.R.; RT "Alpha- and beta-forms of the 65-kDa subunit of protein phosphatase 2A have RT a similar 39 amino acid repeating structure."; RL Biochemistry 29:3166-3173(1990). RN [10] RP INTERACTION WITH RAF1. RX PubMed=10801873; DOI=10.1074/jbc.m003259200; RA Abraham D., Podar K., Pacher M., Kubicek M., Welzel N., Hemmings B.A., RA Dilworth S.M., Mischak H., Kolch W., Baccarini M.; RT "Raf-1-associated protein phosphatase 2A as a positive regulator of kinase RT activation."; RL J. Biol. Chem. 275:22300-22304(2000). RN [11] RP INTERACTION WITH IPO9. RX PubMed=12670497; DOI=10.1016/s0006-291x(03)00434-0; RA Lubert E.J., Sarge K.D.; RT "Interaction between protein phosphatase 2A and members of the importin RT beta superfamily."; RL Biochem. Biophys. Res. Commun. 303:908-913(2003). RN [12] RP INTERACTION WITH SGO1. RX PubMed=16541025; DOI=10.1038/nature04663; RA Kitajima T.S., Sakuno T., Ishiguro K., Iemura S., Natsume T., RA Kawashima S.A., Watanabe Y.; RT "Shugoshin collaborates with protein phosphatase 2A to protect cohesin."; RL Nature 441:46-52(2006). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [14] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [15] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [16] RP VARIANT ASP-90. RX PubMed=10597236; DOI=10.1038/sj.onc.1203070; RA Campbell I.G., Manolitsas T.; RT "Absence of PPP2R1B gene alterations in primary ovarian cancers."; RL Oncogene 18:6367-6369(1999). RN [17] RP VARIANTS ALA-15; PRO-365; GLU-498; ILE-499 AND GLY-500. RX PubMed=10896920; DOI=10.1136/gut.47.2.268; RA Takagi Y., Futamura M., Yamaguchi K., Aoki S., Takahashi T., Saji S.; RT "Alterations of the PPP2R1B gene located at 11q23 in human colorectal RT cancers."; RL Gut 47:268-271(2000). RN [18] RP VARIANT ASP-90. RX PubMed=11996789; DOI=10.1016/s0165-4608(01)00597-0; RA Hemmer S., Wasenius V.M., Haglund C., Zhu Y., Knuutila S., Franssila K., RA Joensuu H.; RT "Alterations in the suppressor gene PPP2R1B in parathyroid hyperplasias and RT adenomas."; RL Cancer Genet. Cytogenet. 134:13-17(2002). CC -!- FUNCTION: The PR65 subunit of protein phosphatase 2A serves as a CC scaffolding molecule to coordinate the assembly of the catalytic CC subunit and a variable regulatory B subunit. CC -!- SUBUNIT: PP2A consists of a common heterodimeric core enzyme, composed CC of a 36 kDa catalytic subunit (subunit C) and a 65 kDa constant CC regulatory subunit (PR65 or subunit A), that associates with a variety CC of regulatory subunits. Proteins that associate with the core dimer CC include three families of regulatory subunits B (the R2/B/PR55/B55, CC R3/B''/PR72/PR130/PR59 and R5/B'/B56 families), the 48 kDa variable CC regulatory subunit, viral proteins, and cell signaling molecules. CC Interacts with IPO9. Interacts with SGO1. Interacts with RAF1. CC {ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:12670497, CC ECO:0000269|PubMed:16541025}. CC -!- INTERACTION: CC P30154; P67775: PPP2CA; NbExp=9; IntAct=EBI-357094, EBI-712311; CC P30154; P30153: PPP2R1A; NbExp=4; IntAct=EBI-357094, EBI-302388; CC P30154; P63151: PPP2R2A; NbExp=5; IntAct=EBI-357094, EBI-1048931; CC P30154; Q15172: PPP2R5A; NbExp=4; IntAct=EBI-357094, EBI-641666; CC P30154; Q13362: PPP2R5C; NbExp=2; IntAct=EBI-357094, EBI-1266156; CC P30154; Q14738: PPP2R5D; NbExp=3; IntAct=EBI-357094, EBI-396563; CC P30154; Q16537: PPP2R5E; NbExp=3; IntAct=EBI-357094, EBI-968374; CC P30154; P11233: RALA; NbExp=6; IntAct=EBI-357094, EBI-1036803; CC P30154; O08785: Clock; Xeno; NbExp=2; IntAct=EBI-357094, EBI-79859; CC P30154; O08722: Unc5b; Xeno; NbExp=4; IntAct=EBI-357094, EBI-4404185; CC P30154-2; O75190-2: DNAJB6; NbExp=3; IntAct=EBI-11058011, EBI-12593112; CC P30154-2; O14901: KLF11; NbExp=3; IntAct=EBI-11058011, EBI-948266; CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=5; CC Name=1; CC IsoId=P30154-1; Sequence=Displayed; CC Name=2; CC IsoId=P30154-2; Sequence=VSP_036460; CC Name=3; CC IsoId=P30154-3; Sequence=VSP_043379, VSP_036460; CC Name=4; CC IsoId=P30154-4; Sequence=VSP_045275; CC Name=5; CC IsoId=P30154-5; Sequence=VSP_046684; CC -!- DOMAIN: Each HEAT repeat appears to consist of two alpha helices joined CC by a hydrophilic region, the intrarepeat loop. The repeat units may be CC arranged laterally to form a rod-like structure. CC -!- SIMILARITY: Belongs to the phosphatase 2A regulatory subunit A family. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAA59983.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305}; CC Sequence=BAG59103.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF083439; AAC63525.1; -; Genomic_DNA. DR EMBL; AF083425; AAC63525.1; JOINED; Genomic_DNA. DR EMBL; AF083426; AAC63525.1; JOINED; Genomic_DNA. DR EMBL; AF083427; AAC63525.1; JOINED; Genomic_DNA. DR EMBL; AF083428; AAC63525.1; JOINED; Genomic_DNA. DR EMBL; AF083429; AAC63525.1; JOINED; Genomic_DNA. DR EMBL; AF083430; AAC63525.1; JOINED; Genomic_DNA. DR EMBL; AF083431; AAC63525.1; JOINED; Genomic_DNA. DR EMBL; AF083432; AAC63525.1; JOINED; Genomic_DNA. DR EMBL; AF083433; AAC63525.1; JOINED; Genomic_DNA. DR EMBL; AF083434; AAC63525.1; JOINED; Genomic_DNA. DR EMBL; AF083435; AAC63525.1; JOINED; Genomic_DNA. DR EMBL; AF083436; AAC63525.1; JOINED; Genomic_DNA. DR EMBL; AF083437; AAC63525.1; JOINED; Genomic_DNA. DR EMBL; AF083438; AAC63525.1; JOINED; Genomic_DNA. DR EMBL; AF087438; AAC69624.1; -; mRNA. DR EMBL; AF163473; AAG39644.1; -; mRNA. DR EMBL; AK294716; BAG57867.1; -; mRNA. DR EMBL; AK296455; BAG59103.1; ALT_FRAME; mRNA. DR EMBL; AK301705; BAG63177.1; -; mRNA. DR EMBL; EF445011; ACA06046.1; -; Genomic_DNA. DR EMBL; EF445011; ACA06047.1; -; Genomic_DNA. DR EMBL; AP000925; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AP001781; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471065; EAW67150.1; -; Genomic_DNA. DR EMBL; CH471065; EAW67151.1; -; Genomic_DNA. DR EMBL; BC027596; AAH27596.1; -; mRNA. DR EMBL; M65254; AAA59983.1; ALT_SEQ; mRNA. DR CCDS; CCDS53706.1; -. [P30154-3] DR CCDS; CCDS53707.1; -. [P30154-5] DR CCDS; CCDS53708.1; -. [P30154-4] DR CCDS; CCDS8348.1; -. [P30154-2] DR CCDS; CCDS8349.1; -. [P30154-1] DR PIR; B34541; B34541. DR RefSeq; NP_001171033.1; NM_001177562.2. [P30154-4] DR RefSeq; NP_001171034.1; NM_001177563.2. [P30154-5] DR RefSeq; NP_002707.3; NM_002716.4. [P30154-1] DR RefSeq; NP_859050.1; NM_181699.3. [P30154-2] DR RefSeq; NP_859051.1; NM_181700.2. [P30154-3] DR PDB; 9MF5; EM; 3.20 A; A=1-601. DR PDBsum; 9MF5; -. DR AlphaFoldDB; P30154; -. DR EMDB; EMD-48224; -. DR SMR; P30154; -. DR BioGRID; 111511; 207. DR CORUM; P30154; -. DR DIP; DIP-36616N; -. DR FunCoup; P30154; 2439. DR IntAct; P30154; 149. DR MINT; P30154; -. DR STRING; 9606.ENSP00000311344; -. DR GlyGen; P30154; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P30154; -. DR MetOSite; P30154; -. DR PhosphoSitePlus; P30154; -. DR SwissPalm; P30154; -. DR BioMuta; PPP2R1B; -. DR DMDM; 116241236; -. DR jPOST; P30154; -. DR MassIVE; P30154; -. DR PaxDb; 9606-ENSP00000311344; -. DR PeptideAtlas; P30154; -. DR ProteomicsDB; 2377; -. DR ProteomicsDB; 30144; -. DR ProteomicsDB; 54637; -. DR ProteomicsDB; 54638; -. [P30154-2] DR ProteomicsDB; 54639; -. [P30154-3] DR Pumba; P30154; -. DR Antibodypedia; 3416; 302 antibodies from 36 providers. DR DNASU; 5519; -. DR Ensembl; ENST00000311129.9; ENSP00000311344.5; ENSG00000137713.17. [P30154-2] DR Ensembl; ENST00000341980.10; ENSP00000343317.6; ENSG00000137713.17. [P30154-4] DR Ensembl; ENST00000393055.6; ENSP00000376775.2; ENSG00000137713.17. [P30154-5] DR Ensembl; ENST00000426998.6; ENSP00000410671.2; ENSG00000137713.17. [P30154-3] DR Ensembl; ENST00000527614.6; ENSP00000437193.1; ENSG00000137713.17. [P30154-1] DR GeneID; 5519; -. DR KEGG; hsa:5519; -. DR MANE-Select; ENST00000527614.6; ENSP00000437193.1; NM_002716.5; NP_002707.3. DR UCSC; uc001plw.2; human. [P30154-1] DR AGR; HGNC:9303; -. DR ClinPGx; PA33667; -. DR CTD; 5519; -. DR DisGeNET; 5519; -. DR GeneCards; PPP2R1B; -. DR HGNC; HGNC:9303; PPP2R1B. DR HPA; ENSG00000137713; Tissue enhanced (liver). DR MalaCards; PPP2R1B; -. DR MIM; 603113; gene. DR OpenTargets; ENSG00000137713; -. DR VEuPathDB; HostDB:ENSG00000137713; -. DR eggNOG; KOG0211; Eukaryota. DR GeneTree; ENSGT00950000183066; -. DR HOGENOM; CLU_015533_2_1_1; -. DR InParanoid; P30154; -. DR OMA; NRVEAMQ; -. DR OrthoDB; 340346at2759; -. DR PAN-GO; P30154; 4 GO annotations based on evolutionary models. DR PhylomeDB; P30154; -. DR PathwayCommons; P30154; -. DR Reactome; R-HSA-113501; Inhibition of replication initiation of damaged DNA by RB1/E2F1. DR Reactome; R-HSA-141444; Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal. DR Reactome; R-HSA-163767; PP2A-mediated dephosphorylation of key metabolic factors. DR Reactome; R-HSA-180024; DARPP-32 events. DR Reactome; R-HSA-195253; Degradation of beta-catenin by the destruction complex. DR Reactome; R-HSA-196299; Beta-catenin phosphorylation cascade. DR Reactome; R-HSA-198753; ERK/MAPK targets. DR Reactome; R-HSA-202670; ERKs are inactivated. DR Reactome; R-HSA-2465910; MASTL Facilitates Mitotic Progression. DR Reactome; R-HSA-2467813; Separation of Sister Chromatids. DR Reactome; R-HSA-2500257; Resolution of Sister Chromatid Cohesion. DR Reactome; R-HSA-389356; Co-stimulation by CD28. DR Reactome; R-HSA-389513; Co-inhibition by CTLA4. DR Reactome; R-HSA-432142; Platelet sensitization by LDL. DR Reactome; R-HSA-4641262; Disassembly of the destruction complex and recruitment of AXIN to the membrane. DR Reactome; R-HSA-5339716; Signaling by GSK3beta mutants. DR Reactome; R-HSA-5358747; CTNNB1 S33 mutants aren't phosphorylated. DR Reactome; R-HSA-5358749; CTNNB1 S37 mutants aren't phosphorylated. DR Reactome; R-HSA-5358751; CTNNB1 S45 mutants aren't phosphorylated. DR Reactome; R-HSA-5358752; CTNNB1 T41 mutants aren't phosphorylated. DR Reactome; R-HSA-5467337; APC truncation mutants have impaired AXIN binding. DR Reactome; R-HSA-5467340; AXIN missense mutants destabilize the destruction complex. DR Reactome; R-HSA-5467348; Truncations of AMER1 destabilize the destruction complex. DR Reactome; R-HSA-5663220; RHO GTPases Activate Formins. DR Reactome; R-HSA-5673000; RAF activation. DR Reactome; R-HSA-5675221; Negative regulation of MAPK pathway. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-68877; Mitotic Prometaphase. DR Reactome; R-HSA-69231; Cyclin D associated events in G1. DR Reactome; R-HSA-69273; Cyclin A/B1/B2 associated events during G2/M transition. DR Reactome; R-HSA-9634600; Regulation of glycolysis by fructose 2,6-bisphosphate metabolism. DR Reactome; R-HSA-9648025; EML4 and NUDC in mitotic spindle formation. DR Reactome; R-HSA-9833482; PKR-mediated signaling. DR Reactome; R-HSA-9860927; Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells. DR SignaLink; P30154; -. DR SIGNOR; P30154; -. DR Agora; ENSG00000137713; -. DR BioGRID-ORCS; 5519; 18 hits in 1163 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; PPP2R1B; human. DR GeneWiki; PPP2R1B; -. DR GenomeRNAi; 5519; -. DR Pharos; P30154; Tbio. DR PRO; PR:P30154; -. DR Proteomes; UP000005640; Chromosome 11. DR RNAct; P30154; protein. DR Bgee; ENSG00000137713; Expressed in sperm and 197 other cell types or tissues. DR ExpressionAtlas; P30154; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IBA:GO_Central. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0045121; C:membrane raft; IDA:UniProtKB. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0000159; C:protein phosphatase type 2A complex; IBA:GO_Central. DR GO; GO:0019888; F:protein phosphatase regulator activity; IBA:GO_Central. DR GO; GO:0060561; P:apoptotic process involved in morphogenesis; IMP:UniProtKB. DR GO; GO:0051754; P:meiotic sister chromatid cohesion, centromeric; IBA:GO_Central. DR GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IMP:UniProtKB. DR GO; GO:0051225; P:spindle assembly; IBA:GO_Central. DR FunFam; 1.25.10.10:FF:000011; Serine/threonine-protein phosphatase 2A regulatory subunit A alpha isoform; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1. DR InterPro; IPR055231; 2AA_helical. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR000357; HEAT. DR InterPro; IPR021133; HEAT_type_2. DR InterPro; IPR054573; PP2A/SF3B1-like_HEAT. DR InterPro; IPR051023; PP2A_Regulatory_Subunit_A. DR PANTHER; PTHR10648; SERINE/THREONINE-PROTEIN PHOSPHATASE PP2A 65 KDA REGULATORY SUBUNIT; 1. DR PANTHER; PTHR10648:SF9; SERINE_THREONINE-PROTEIN PHOSPHATASE 2A 65 KDA REGULATORY SUBUNIT A BETA ISOFORM; 1. DR Pfam; PF02985; HEAT; 2. DR Pfam; PF13646; HEAT_2; 1. DR Pfam; PF22646; PPP2R1A-like_HEAT; 1. DR Pfam; PF22956; VPS15-like_hel; 1. DR SUPFAM; SSF48371; ARM repeat; 1. DR PROSITE; PS50077; HEAT_REPEAT; 12. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Proteomics identification; KW Reference proteome; Repeat. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..601 FT /note="Serine/threonine-protein phosphatase 2A 65 kDa FT regulatory subunit A beta isoform" FT /id="PRO_0000071403" FT REPEAT 20..58 FT /note="HEAT 1" FT REPEAT 59..96 FT /note="HEAT 2" FT REPEAT 97..135 FT /note="HEAT 3" FT REPEAT 136..173 FT /note="HEAT 4" FT REPEAT 174..212 FT /note="HEAT 5" FT REPEAT 213..251 FT /note="HEAT 6" FT REPEAT 252..290 FT /note="HEAT 7" FT REPEAT 291..333 FT /note="HEAT 8" FT REPEAT 334..372 FT /note="HEAT 9" FT REPEAT 373..411 FT /note="HEAT 10" FT REPEAT 412..450 FT /note="HEAT 11" FT REPEAT 451..489 FT /note="HEAT 12" FT REPEAT 490..528 FT /note="HEAT 13" FT REPEAT 529..567 FT /note="HEAT 14" FT REPEAT 568..601 FT /note="HEAT 15" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:22814378" FT VAR_SEQ 39..102 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_043379" FT VAR_SEQ 103..229 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_046684" FT VAR_SEQ 344..388 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_045275" FT VAR_SEQ 598..601 FT /note="LALA -> VAQRLRKLEFPVKDSGEPSVPRADKNHFPRPTVPGEDMGKGPVY FT QLRGDTRDTLAQLGIAELVHFSQSTD (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_036460" FT VARIANT 8 FT /note="G -> R (in a lung cancer patient; FT dbSNP:rs142771326)" FT /evidence="ECO:0000269|PubMed:9765152" FT /id="VAR_022895" FT VARIANT 15 FT /note="G -> A (in a colorectal cancer patient)" FT /evidence="ECO:0000269|PubMed:10896920" FT /id="VAR_022896" FT VARIANT 65 FT /note="P -> S (in a lung cancer patient)" FT /evidence="ECO:0000269|PubMed:9765152" FT /id="VAR_022897" FT VARIANT 90 FT /note="G -> D (in a lung cancer patient; dbSNP:rs1805076)" FT /evidence="ECO:0000269|PubMed:10597236, FT ECO:0000269|PubMed:11996789, ECO:0000269|PubMed:9765152" FT /id="VAR_006384" FT VARIANT 101 FT /note="L -> P (in a colon adenocarcinoma)" FT /evidence="ECO:0000269|PubMed:9765152" FT /id="VAR_022898" FT VARIANT 343 FT /note="K -> E (in a lung cancer patient)" FT /evidence="ECO:0000269|PubMed:9765152" FT /id="VAR_022899" FT VARIANT 365 FT /note="S -> P (in a colorectal cancer patient; FT dbSNP:rs1442893893)" FT /evidence="ECO:0000269|PubMed:10896920" FT /id="VAR_022900" FT VARIANT 448 FT /note="V -> A (in a colon adenocarcinoma)" FT /evidence="ECO:0000269|PubMed:9765152" FT /id="VAR_022901" FT VARIANT 498 FT /note="V -> E (in a colorectal cancer patient)" FT /evidence="ECO:0000269|PubMed:10896920" FT /id="VAR_022902" FT VARIANT 499 FT /note="L -> I (in a colorectal cancer patient)" FT /evidence="ECO:0000269|PubMed:10896920" FT /id="VAR_022903" FT VARIANT 500 FT /note="V -> G (in a colorectal cancer patient)" FT /evidence="ECO:0000269|PubMed:10896920" FT /id="VAR_022904" FT VARIANT 504 FT /note="D -> G (in a lung cancer patient; FT dbSNP:rs973682124)" FT /evidence="ECO:0000269|PubMed:9765152" FT /id="VAR_022905" FT VARIANT 545 FT /note="V -> A (in a colon adenocarcinoma; FT dbSNP:rs1318084062)" FT /evidence="ECO:0000269|PubMed:9765152" FT /id="VAR_022906" FT CONFLICT 74 FT /note="E -> V (in Ref. 9; AAA59983)" FT /evidence="ECO:0000305" FT CONFLICT 178 FT /note="I -> T (in Ref. 1; AAC63525, 3; AAG39644 and 9; FT AAA59983)" FT /evidence="ECO:0000305" FT CONFLICT 211 FT /note="D -> G (in Ref. 4; BAG57867)" FT /evidence="ECO:0000305" FT CONFLICT 411 FT /note="Q -> R (in Ref. 9; AAA59983)" FT /evidence="ECO:0000305" FT CONFLICT 503 FT /note="N -> S (in Ref. 4; BAG57867)" FT /evidence="ECO:0000305" SQ SEQUENCE 601 AA; 66214 MW; 86AB20D7505210B0 CRC64; MAGASELGTG PGAAGGDGDD SLYPIAVLID ELRNEDVQLR LNSIKKLSTI ALALGVERTR SELLPFLTDT IYDEDEVLLA LAEQLGNFTG LVGGPDFAHC LLPPLENLAT VEETVVRDKA VESLRQISQE HTPVALEAYF VPLVKRLASG DWFTSRTSAC GLFSVCYPRA SNAVKAEIRQ QFRSLCSDDT PMVRRAAASK LGEFAKVLEL DSVKSEIVPL FTSLASDEQD SVRLLAVEAC VSIAQLLSQD DLETLVMPTL RQAAEDKSWR VRYMVADRFS ELQKAMGPKI TLNDLIPAFQ NLLKDCEAEV RAAAAHKVKE LGENLPIEDR ETIIMNQILP YIKELVSDTN QHVKSALASV IMGLSTILGK ENTIEHLLPL FLAQLKDECP DVRLNIISNL DCVNEVIGIR QLSQSLLPAI VELAEDAKWR VRLAIIEYMP LLAGQLGVEF FDEKLNSLCM AWLVDHVYAI REAATNNLMK LVQKFGTEWA QNTIVPKVLV MANDPNYLHR MTTLFCINAL SEACGQEITT KQMLPIVLKM AGDQVANVRF NVAKSLQKIG PILDTNALQG EVKPVLQKLG QDEDMDVKYF AQEAISVLAL A // ID AAMP_HUMAN Reviewed; 434 AA. AC Q13685; Q8WUJ9; Q96H92; DT 15-JUL-1998, integrated into UniProtKB/Swiss-Prot. DT 26-APR-2005, sequence version 2. DT 28-JAN-2026, entry version 196. DE RecName: Full=Angio-associated migratory cell protein; GN Name=AAMP; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, AND TISSUE RP SPECIFICITY. RC TISSUE=Brain; RX PubMed=7743515; RA Beckner M.E., Krutzsch H.C., Stracke M.L., Williams S.T., Gallardo J.A., RA Liotta L.A.; RT "Identification of a new immunoglobulin superfamily protein expressed in RT blood vessels with a heparin-binding consensus sequence."; RL Cancer Res. 55:2140-2149(1995). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Ovary, and Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=10329261; DOI=10.1006/mvre.1999.2144; RA Beckner M.E., Peterson V.A., Moul D.E.; RT "Angio-associated migratory cell protein is expressed as an extracellular RT protein by blood-vessel-associated mesenchymal cells."; RL Microvasc. Res. 57:347-352(1999). RN [5] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=18634987; DOI=10.1016/j.jacc.2008.03.055; RA Vogt F., Zernecke A., Beckner M., Krott N., Bosserhoff A.-K., Hoffmann R., RA Zandvoort M.A.M.J., Jahnke T., Kelm M., Weber C., Blindt R.; RT "Blockade of angio-associated migratory cell protein inhibits smooth muscle RT cell migration and neointima formation in accelerated atherosclerosis."; RL J. Am. Coll. Cardiol. 52:302-311(2008). RN [6] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [7] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-20, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). CC -!- FUNCTION: Plays a role in angiogenesis and cell migration. In smooth CC muscle cell migration, may act through the RhoA pathway. CC {ECO:0000269|PubMed:10329261, ECO:0000269|PubMed:18634987}. CC -!- INTERACTION: CC Q13685; Q8WTP8: AEN; NbExp=2; IntAct=EBI-727274, EBI-8637627; CC Q13685; Q8WTP8-2: AEN; NbExp=4; IntAct=EBI-727274, EBI-12119298; CC -!- SUBCELLULAR LOCATION: Cell membrane. Cytoplasm. CC -!- TISSUE SPECIFICITY: Expressed in metastatic melanoma, liver, skin, CC kidney, heart, lung, lymph node, skeletal muscle and brain, and also in CC A2058 melanoma cells and activated T-cells (at protein level). CC Expressed in blood vessels. Strongly expressed in endothelial cells, CC cytotrophoblasts, and poorly differentiated. colon adenocarcinoma cells CC found in lymphatics. {ECO:0000269|PubMed:10329261, CC ECO:0000269|PubMed:7743515}. CC -!- SEQUENCE CAUTION: CC Sequence=AAA68889.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC Sequence=CAG33036.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/533/AAMP"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M95627; AAA68889.1; ALT_INIT; mRNA. DR EMBL; CR456755; CAG33036.1; ALT_INIT; mRNA. DR EMBL; BC008809; AAH08809.2; -; mRNA. DR EMBL; BC020244; AAH20244.1; -; mRNA. DR EMBL; BC039866; AAH39866.2; -; mRNA. DR CCDS; CCDS33378.1; -. DR PIR; I39383; I39383. DR RefSeq; NP_001078.2; NM_001087.5. DR AlphaFoldDB; Q13685; -. DR SMR; Q13685; -. DR BioGRID; 106532; 80. DR FunCoup; Q13685; 1643. DR IntAct; Q13685; 35. DR MINT; Q13685; -. DR STRING; 9606.ENSP00000403343; -. DR GlyGen; Q13685; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q13685; -. DR PhosphoSitePlus; Q13685; -. DR BioMuta; AAMP; -. DR DMDM; 62906874; -. DR jPOST; Q13685; -. DR MassIVE; Q13685; -. DR PaxDb; 9606-ENSP00000248450; -. DR PeptideAtlas; Q13685; -. DR ProteomicsDB; 59660; -. DR Pumba; Q13685; -. DR Antibodypedia; 34259; 171 antibodies from 30 providers. DR DNASU; 14; -. DR Ensembl; ENST00000248450.9; ENSP00000248450.4; ENSG00000127837.11. DR GeneID; 14; -. DR KEGG; hsa:14; -. DR MANE-Select; ENST00000248450.9; ENSP00000248450.4; NM_001087.5; NP_001078.2. DR UCSC; uc002vhk.4; human. DR AGR; HGNC:18; -. DR ClinPGx; PA24365; -. DR CTD; 14; -. DR DisGeNET; 14; -. DR GeneCards; AAMP; -. DR HGNC; HGNC:18; AAMP. DR HPA; ENSG00000127837; Low tissue specificity. DR MalaCards; AAMP; -. DR MIM; 603488; gene. DR OpenTargets; ENSG00000127837; -. DR VEuPathDB; HostDB:ENSG00000127837; -. DR eggNOG; KOG0296; Eukaryota. DR GeneTree; ENSGT00940000153648; -. DR HOGENOM; CLU_000288_57_9_1; -. DR InParanoid; Q13685; -. DR OMA; GPDEVMW; -. DR OrthoDB; 10261640at2759; -. DR PAN-GO; Q13685; 1 GO annotation based on evolutionary models. DR PhylomeDB; Q13685; -. DR PathwayCommons; Q13685; -. DR Reactome; R-HSA-168638; NOD1/2 Signaling Pathway. DR Reactome; R-HSA-177929; Signaling by EGFR. DR Reactome; R-HSA-194138; Signaling by VEGF. DR Reactome; R-HSA-428930; Thromboxane signalling through TP receptor. DR SignaLink; Q13685; -. DR Agora; ENSG00000127837; -. DR BioGRID-ORCS; 14; 753 hits in 1174 CRISPR screens. DR ChiTaRS; AAMP; human. DR GeneWiki; AAMP_(gene); -. DR GenomeRNAi; 14; -. DR Pharos; Q13685; Tbio. DR PRO; PR:Q13685; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q13685; protein. DR Bgee; ENSG00000127837; Expressed in body of stomach and 200 other cell types or tissues. DR ExpressionAtlas; Q13685; baseline and differential. DR GO; GO:0009986; C:cell surface; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0045171; C:intercellular bridge; IDA:HPA. DR GO; GO:0015630; C:microtubule cytoskeleton; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0008201; F:heparin binding; IDA:GO_Central. DR GO; GO:0001525; P:angiogenesis; NAS:UniProtKB. DR GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW. DR GO; GO:0010595; P:positive regulation of endothelial cell migration; ISS:UniProtKB. DR GO; GO:0014909; P:smooth muscle cell migration; IEP:UniProtKB. DR CDD; cd00200; WD40; 1. DR FunFam; 2.130.10.10:FF:000074; Angio-associated migratory cell protein-like protein; 1. DR Gene3D; 2.130.10.10; YVTN repeat-like/Quinoprotein amine dehydrogenase; 1. DR InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf. DR InterPro; IPR019775; WD40_repeat_CS. DR InterPro; IPR036322; WD40_repeat_dom_sf. DR InterPro; IPR001680; WD40_rpt. DR InterPro; IPR051179; WD_repeat_multifunction. DR PANTHER; PTHR19857:SF8; ANGIO-ASSOCIATED MIGRATORY CELL PROTEIN; 1. DR PANTHER; PTHR19857; MITOCHONDRIAL DIVISION PROTEIN 1-RELATED; 1. DR Pfam; PF00400; WD40; 6. DR SMART; SM00320; WD40; 8. DR SUPFAM; SSF50978; WD40 repeat-like; 1. DR PROSITE; PS00678; WD_REPEATS_1; 1. DR PROSITE; PS50082; WD_REPEATS_2; 6. DR PROSITE; PS50294; WD_REPEATS_REGION; 1. PE 1: Evidence at protein level; KW Angiogenesis; Cell membrane; Cytoplasm; Developmental protein; KW Differentiation; Direct protein sequencing; Membrane; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; WD repeat. FT CHAIN 1..434 FT /note="Angio-associated migratory cell protein" FT /id="PRO_0000050832" FT REPEAT 89..129 FT /note="WD 1" FT REPEAT 132..171 FT /note="WD 2" FT REPEAT 173..212 FT /note="WD 3" FT REPEAT 214..254 FT /note="WD 4" FT REPEAT 258..299 FT /note="WD 5" FT REPEAT 315..354 FT /note="WD 6" FT REPEAT 356..395 FT /note="WD 7" FT REPEAT 398..433 FT /note="WD 8" FT REGION 1..63 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 39..62 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 20 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT VARIANT 250 FT /note="I -> V (in dbSNP:rs2305835)" FT /id="VAR_037061" SQ SEQUENCE 434 AA; 46751 MW; A7B8314442EBAF15 CRC64; MESESESGAA ADTPPLETLS FHGDEEIIEV VELDPGPPDP DDLAQEMEDV DFEEEEEEEG NEEGWVLEPQ EGVVGSMEGP DDSEVTFALH SASVFCVSLD PKTNTLAVTG GEDDKAFVWR LSDGELLFEC AGHKDSVTCA GFSHDSTLVA TGDMSGLLKV WQVDTKEEVW SFEAGDLEWM EWHPRAPVLL AGTADGNTWM WKVPNGDCKT FQGPNCPATC GRVLPDGKRA VVGYEDGTIR IWDLKQGSPI HVLKGTEGHQ GPLTCVAANQ DGSLILTGSV DCQAKLVSAT TGKVVGVFRP ETVASQPSLG EGEESESNSV ESLGFCSVMP LAAVGYLDGT LAIYDLATQT LRHQCQHQSG IVQLLWEAGT AVVYTCSLDG IVRLWDARTG RLLTDYRGHT AEILDFALSK DASLVVTTSG DHKAKVFCVQ RPDR // ID ABC3A_HUMAN Reviewed; 199 AA. AC P31941; A0AVM1; Q12807; Q5JZ93; Q9UH18; DT 01-JUL-1993, integrated into UniProtKB/Swiss-Prot. DT 11-JAN-2001, sequence version 3. DT 28-JAN-2026, entry version 202. DE RecName: Full=DNA dC->dU-editing enzyme APOBEC-3A; DE Short=A3A; DE EC=3.5.4.38 {ECO:0000269|PubMed:16527742, ECO:0000269|PubMed:20062055, ECO:0000269|PubMed:20615867, ECO:0000269|PubMed:21123384}; DE AltName: Full=Phorbolin-1; GN Name=APOBEC3A; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 19-27; 31-35; 53-60; RP 112-123; 129-137 AND 192-198, AND FUNCTION. RC TISSUE=Keratinocyte; RX PubMed=10469298; DOI=10.1046/j.1523-1747.1999.00682.x; RA Madsen P.P., Anant S., Rasmussen H.H., Gromov P., Vorum H., Dumanski J.P., RA Tommerup N., Collins J.E., Wright C.L., Dunham I., Macginnitie A.J., RA Davidson N.O., Celis J.E.; RT "Psoriasis upregulated phorbolin-1 shares structural but not functional RT similarity to the mRNA-editing protein apobec-1."; RL J. Invest. Dermatol. 113:162-169(1999). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84; RA Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A., RA Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J., RA Beare D.M., Dunham I.; RT "A genome annotation-driven approach to cloning the human ORFeome."; RL Genome Biol. 5:R84.1-R84.11(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=10591208; DOI=10.1038/990031; RA Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M., Clamp M., RA Smink L.J., Ainscough R., Almeida J.P., Babbage A.K., Bagguley C., RA Bailey J., Barlow K.F., Bates K.N., Beasley O.P., Bird C.P., Blakey S.E., RA Bridgeman A.M., Buck D., Burgess J., Burrill W.D., Burton J., Carder C., RA Carter N.P., Chen Y., Clark G., Clegg S.M., Cobley V.E., Cole C.G., RA Collier R.E., Connor R., Conroy D., Corby N.R., Coville G.J., Cox A.V., RA Davis J., Dawson E., Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., RA Ellington A.G., Evans K.L., Fey J.M., Fleming K., French L., Garner A.A., RA Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C., RA Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S., Hunt S.E., RA Jones M.C., Kershaw J., Kimberley A.M., King A., Laird G.K., Langford C.F., RA Leversha M.A., Lloyd C., Lloyd D.M., Martyn I.D., Mashreghi-Mohammadi M., RA Matthews L.H., Mccann O.T., Mcclay J., Mclaren S., McMurray A.A., RA Milne S.A., Mortimore B.J., Odell C.N., Pavitt R., Pearce A.V., Pearson D., RA Phillimore B.J.C.T., Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., RA Rogers L., Ross M.T., Scott C.E., Sehra H.K., Skuce C.D., Smalley S., RA Smith M.L., Soderlund C., Spragon L., Steward C.A., Sulston J.E., RA Swann R.M., Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L., RA Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L., RA Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N., RA Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J., Shintani A., RA Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S., Roe B.A., Chen F., Chu L., RA Crabtree J., Deschamps S., Do A., Do T., Dorman A., Fang F., Fu Y., Hu P., RA Hua A., Kenton S., Lai H., Lao H.I., Lewis J., Lewis S., Lin S.-P., Loh P., RA Malaj E., Nguyen T., Pan H., Phan S., Qi S., Qian Y., Ray L., Ren Q., RA Shaull S., Sloan D., Song L., Wang Q., Wang Y., Wang Z., White J., RA Willingham D., Wu H., Yao Z., Zhan M., Zhang G., Chissoe S., Murray J., RA Miller N., Minx P., Fulton R., Johnson D., Bemis G., Bentley D., RA Bradshaw H., Bourne S., Cordes M., Du Z., Fulton L., Goela D., Graves T., RA Hawkins J., Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., RA Rohlfing T., Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., RA Nelson J., Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R., RA Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S., Budarf M.L., RA McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E., Edelmann L., Kim U.J., RA Shizuya H., Simon M.I., Dumanski J.P., Peyrard M., Kedra D., Seroussi E., RA Fransson I., Tapia I., Bruder C.E., O'Brien K.P., Wilkinson P., RA Bodenteich A., Hartman K., Hu X., Khan A.S., Lane L., Tilahun Y., RA Wright H.; RT "The DNA sequence of human chromosome 22."; RL Nature 402:489-495(1999). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP PROTEIN SEQUENCE OF 53-60; 112-121 AND 129-137. RC TISSUE=Keratinocyte; RX PubMed=1286667; DOI=10.1002/elps.11501301199; RA Rasmussen H.H., van Damme J., Puype M., Gesser B., Celis J.E., RA Vandekerckhove J.; RT "Microsequences of 145 proteins recorded in the two-dimensional gel protein RT database of normal human epidermal keratinocytes."; RL Electrophoresis 13:960-969(1992). RN [6] RP GENE FAMILY ORGANIZATION, AND TISSUE SPECIFICITY. RX PubMed=11863358; DOI=10.1006/geno.2002.6718; RA Jarmuz A., Chester A., Bayliss J., Gisbourne J., Dunham I., Scott J., RA Navaratnam N.; RT "An anthropoid-specific locus of orphan C to U RNA-editing enzymes on RT chromosome 22."; RL Genomics 79:285-296(2002). RN [7] RP REVIEW ON APOBEC FAMILIES. RX PubMed=12683974; DOI=10.1016/s0168-9525(03)00054-4; RA Wedekind J.E., Dance G.S.C., Sowden M.P., Smith H.C.; RT "Messenger RNA editing in mammals: new members of the APOBEC family seeking RT roles in the family business."; RL Trends Genet. 19:207-216(2003). RN [8] RP FUNCTION IN HOST DEFENSE. RX PubMed=12859895; DOI=10.1016/s0092-8674(03)00515-4; RA Mariani R., Chen D., Schroefelbauer B., Navarro F., Koenig R., Bollman B., RA Muenk C., Nymark-McMahon H., Landau N.R.; RT "Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif."; RL Cell 114:21-31(2003). RN [9] RP FUNCTION IN HOST DEFENSE, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, RP MUTAGENESIS OF HIS-70; GLU-72 AND CYS-106, AND TISSUE SPECIFICITY. RX PubMed=16527742; DOI=10.1016/j.cub.2006.01.031; RA Chen H., Lilley C.E., Yu Q., Lee D.V., Chou J., Narvaiza I., Landau N.R., RA Weitzman M.D.; RT "APOBEC3A is a potent inhibitor of adeno-associated virus and RT retrotransposons."; RL Curr. Biol. 16:480-485(2006). RN [10] RP REVIEW. RX PubMed=18304004; DOI=10.1146/annurev.immunol.26.021607.090350; RA Chiu Y.L., Greene W.C.; RT "The APOBEC3 cytidine deaminases: an innate defensive network opposing RT exogenous retroviruses and endogenous retroelements."; RL Annu. Rev. Immunol. 26:317-353(2008). RN [11] RP FUNCTION IN AAV INHIBITION, AND SUBCELLULAR LOCATION. RX PubMed=19461882; DOI=10.1371/journal.ppat.1000439; RA Narvaiza I., Linfesty D.C., Greener B.N., Hakata Y., Pintel D.J., Logue E., RA Landau N.R., Weitzman M.D.; RT "Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine RT deaminase."; RL PLoS Pathog. 5:E1000439-E1000439(2009). RN [12] RP FUNCTION, CATALYTIC ACTIVITY, INDUCTION, AND ALTERNATIVE SPLICING (ISOFORMS RP 1 AND 2). RX PubMed=20615867; DOI=10.1074/jbc.m110.102822; RA Thielen B.K., McNevin J.P., McElrath M.J., Hunt B.V., Klein K.C., RA Lingappa J.R.; RT "Innate immune signaling induces high levels of TC-specific deaminase RT activity in primary monocyte-derived cells through expression of APOBEC3A RT isoforms."; RL J. Biol. Chem. 285:27753-27766(2010). RN [13] RP FUNCTION IN FOREIGN DNA CLEARANCE, CATALYTIC ACTIVITY, TISSUE SPECIFICITY, RP AND INDUCTION. RX PubMed=20062055; DOI=10.1038/nsmb.1744; RA Stenglein M.D., Burns M.B., Li M., Lengyel J., Harris R.S.; RT "APOBEC3 proteins mediate the clearance of foreign DNA from human cells."; RL Nat. Struct. Mol. Biol. 17:222-229(2010). RN [14] RP TISSUE SPECIFICITY. RX PubMed=20308164; DOI=10.1093/nar/gkq174; RA Refsland E.W., Stenglein M.D., Shindo K., Albin J.S., Brown W.L., RA Harris R.S.; RT "Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes RT and tissues: implications for HIV-1 restriction."; RL Nucleic Acids Res. 38:4274-4284(2010). RN [15] RP FUNCTION IN DNA DEMETHYLATION. RX PubMed=21496894; DOI=10.1016/j.cell.2011.03.022; RA Guo J.U., Su Y., Zhong C., Ming G.L., Song H.; RT "Hydroxylation of 5-methylcytosine by TET1 promotes active DNA RT demethylation in the adult brain."; RL Cell 145:423-434(2011). RN [16] RP FUNCTION. RX PubMed=21460793; DOI=10.1038/embor.2011.46; RA Landry S., Narvaiza I., Linfesty D.C., Weitzman M.D.; RT "APOBEC3A can activate the DNA damage response and cause cell-cycle RT arrest."; RL EMBO Rep. 12:444-450(2011). RN [17] RP FUNCTION IN HOST DEFENSE, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND RP MUTAGENESIS OF ARG-28; HIS-29; LYS-30; ASN-57; LYS-60; ARG-69; GLU-72; RP TRP-98; ARG-128; TYR-130; ASP-131; ASP-133 AND TYR-136. RX PubMed=21123384; DOI=10.1128/jvi.01651-10; RA Bulliard Y., Narvaiza I., Bertero A., Peddi S., Roehrig U.F., Ortiz M., RA Zoete V., Castro-Diaz N., Turelli P., Telenti A., Michielin O., RA Weitzman M.D., Trono D.; RT "Structure-function analyses point to a polynucleotide-accommodating groove RT essential for APOBEC3A restriction activities."; RL J. Virol. 85:1765-1776(2011). RN [18] RP SUBCELLULAR LOCATION. RX PubMed=21835787; DOI=10.1128/jvi.05238-11; RA Hultquist J.F., Lengyel J.A., Refsland E.W., LaRue R.S., Lackey L., RA Brown W.L., Harris R.S.; RT "Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a RT conserved capacity to restrict Vif-deficient HIV-1."; RL J. Virol. 85:11220-11234(2011). RN [19] RP FUNCTION. RX PubMed=21368204; DOI=10.1073/pnas.1009687108; RA Suspene R., Aynaud M.M., Guetard D., Henry M., Eckhoff G., Marchio A., RA Pineau P., Dejean A., Vartanian J.P., Wain-Hobson S.; RT "Somatic hypermutation of human mitochondrial and nuclear DNA by APOBEC3 RT cytidine deaminases, a pathway for DNA catabolism."; RL Proc. Natl. Acad. Sci. U.S.A. 108:4858-4863(2011). RN [20] RP REVIEW. RA Love R.; RT "Cytosine deaminases APOBEC3A, APOBEC3C, and APOBEC3H: Current RT understanding of their functional roles."; RL Student Perspec. Contemp. Virol. 0:0-0(2011). RN [21] RP REVIEW. RX PubMed=22912627; DOI=10.3389/fmicb.2012.00275; RA Arias J.F., Koyama T., Kinomoto M., Tokunaga K.; RT "Retroelements versus APOBEC3 family members: No great escape from the RT magnificent seven."; RL Front. Microbiol. 3:275-275(2012). RN [22] RP FUNCTION. RX PubMed=22896697; DOI=10.1074/jbc.m112.385161; RA Carpenter M.A., Li M., Rathore A., Lackey L., Law E.K., Land A.M., RA Leonard B., Shandilya S.M., Bohn M.F., Schiffer C.A., Brown W.L., RA Harris R.S.; RT "Methylcytosine and normal cytosine deamination by the foreign DNA RT restriction enzyme APOBEC3A."; RL J. Biol. Chem. 287:34801-34808(2012). RN [23] RP INTERACTION WITH TRIB3, AND SUBCELLULAR LOCATION. RX PubMed=22977230; DOI=10.1074/jbc.m112.372722; RA Aynaud M.M., Suspene R., Vidalain P.O., Mussil B., Guetard D., Tangy F., RA Wain-Hobson S., Vartanian J.P.; RT "Human Tribbles 3 protects nuclear DNA from cytidine deamination by RT APOBEC3A."; RL J. Biol. Chem. 287:39182-39192(2012). RN [24] RP FUNCTION IN HTLV-1 RESTRICTION. RX PubMed=22457529; DOI=10.1128/jvi.06570-11; RA Ooms M., Krikoni A., Kress A.K., Simon V., Muenk C.; RT "APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic RT virus type 1."; RL J. Virol. 86:6097-6108(2012). RN [25] RP INTERACTION WITH AGO2. RX PubMed=22915799; DOI=10.1128/jvi.00595-12; RA Phalora P.K., Sherer N.M., Wolinsky S.M., Swanson C.M., Malim M.H.; RT "HIV-1 replication and APOBEC3 antiviral activity are not regulated by P RT bodies."; RL J. Virol. 86:11712-11724(2012). RN [26] RP REVIEW. RX PubMed=22001110; DOI=10.1016/j.semcdb.2011.10.004; RA Smith H.C., Bennett R.P., Kizilyer A., McDougall W.M., Prohaska K.M.; RT "Functions and regulation of the APOBEC family of proteins."; RL Semin. Cell Dev. Biol. 23:258-268(2012). CC -!- FUNCTION: DNA deaminase (cytidine deaminase) with restriction activity CC against viruses, foreign DNA and mobility of retrotransposons. Exhibits CC antiviral activity against adeno-associated virus (AAV) and human T- CC cell leukemia virus type 1 (HTLV-1) and may inhibit the mobility of LTR CC and non-LTR retrotransposons. Selectively targets single-stranded DNA CC and can deaminate both methylcytosine and cytosine in foreign DNA. Can CC induce somatic hypermutation in the nuclear and mitochondrial DNA. May CC also play a role in the epigenetic regulation of gene expression CC through the process of active DNA demethylation. CC {ECO:0000269|PubMed:10469298, ECO:0000269|PubMed:12859895, CC ECO:0000269|PubMed:16527742, ECO:0000269|PubMed:19461882, CC ECO:0000269|PubMed:20062055, ECO:0000269|PubMed:20615867, CC ECO:0000269|PubMed:21123384, ECO:0000269|PubMed:21368204, CC ECO:0000269|PubMed:21460793, ECO:0000269|PubMed:21496894, CC ECO:0000269|PubMed:22457529, ECO:0000269|PubMed:22896697}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a 2'-deoxycytidine in single-stranded DNA + H2O + H(+) = a 2'- CC deoxyuridine in single-stranded DNA + NH4(+); Xref=Rhea:RHEA:50948, CC Rhea:RHEA-COMP:12846, Rhea:RHEA-COMP:12847, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:28938, ChEBI:CHEBI:85452, CC ChEBI:CHEBI:133902; EC=3.5.4.38; CC Evidence={ECO:0000269|PubMed:16527742, ECO:0000269|PubMed:20062055, CC ECO:0000269|PubMed:20615867, ECO:0000269|PubMed:21123384}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250}; CC -!- SUBUNIT: Interacts with AGO2. Interacts with TRIB3 (via N-terminus). CC {ECO:0000269|PubMed:22915799, ECO:0000269|PubMed:22977230}. CC -!- INTERACTION: CC P31941; Q16775-2: HAGH; NbExp=3; IntAct=EBI-13050366, EBI-17557678; CC P31941; O95630: STAMBP; NbExp=3; IntAct=EBI-13050366, EBI-396676; CC P31941; Q784Z8: C; Xeno; NbExp=4; IntAct=EBI-13050366, EBI-11666471; CC -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative initiation; Named isoforms=2; CC Name=1; Synonyms=Phorbolin-1; CC IsoId=P31941-1; Sequence=Displayed; CC Name=2; CC IsoId=P31941-2; Sequence=VSP_041723; CC -!- TISSUE SPECIFICITY: Expressed in peripheral leukocytes with higher CC expression in CD14-positive phagocytic cells. Highly expressed in CC keratinocytes and in periphery blood monocytes. Also detected in non- CC lymphoid tissues including lung and adipose tissues. Found at high CC levels in colorectal adenocarcinoma, Burkitt's lymphoma and chronic CC myelogenous leukemia. {ECO:0000269|PubMed:11863358, CC ECO:0000269|PubMed:16527742, ECO:0000269|PubMed:20062055, CC ECO:0000269|PubMed:20308164}. CC -!- INDUCTION: Up-regulated by interferon and CpG single-stranded DNA (at CC protein level). {ECO:0000269|PubMed:20062055, CC ECO:0000269|PubMed:20615867}. CC -!- MISCELLANEOUS: It is one of seven related genes or pseudogenes found in CC a cluster, thought to result from gene duplication, on chromosome 22. CC -!- MISCELLANEOUS: [Isoform 1]: Enzymatically active. CC -!- MISCELLANEOUS: [Isoform 2]: Enzymatically active. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the cytidine and deoxycytidylate deaminase CC family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U03891; AAA03706.2; -; mRNA. DR EMBL; CR456393; CAG30279.1; -; mRNA. DR EMBL; AL022318; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC126416; AAI26417.1; -; mRNA. DR CCDS; CCDS13981.1; -. [P31941-1] DR PIR; G01233; G01233. DR RefSeq; NP_001180218.1; NM_001193289.1. [P31941-1] DR RefSeq; NP_663745.1; NM_145699.4. [P31941-1] DR PDB; 2M65; NMR; -; A=1-199. DR PDB; 4XXO; X-ray; 2.84 A; A/B=1-199. DR PDB; 5KEG; X-ray; 2.20 A; A=1-199. DR PDB; 5SWW; X-ray; 3.15 A; A/B/C/D=1-196. DR PDB; 7D3V; NMR; -; A/B=1-199. DR PDB; 7D3W; NMR; -; A=1-199. DR PDB; 7D3X; NMR; -; A=1-199. DR PDB; 8FII; X-ray; 2.94 A; A/B=1-199. DR PDB; 8FIJ; X-ray; 2.80 A; A/B=1-199. DR PDB; 8FIK; X-ray; 1.91 A; A/B=1-199. DR PDB; 8FIL; X-ray; 2.01 A; A/B=1-199. DR PDB; 8FIM; X-ray; 2.22 A; A/B=1-199. DR PDBsum; 2M65; -. DR PDBsum; 4XXO; -. DR PDBsum; 5KEG; -. DR PDBsum; 5SWW; -. DR PDBsum; 7D3V; -. DR PDBsum; 7D3W; -. DR PDBsum; 7D3X; -. DR PDBsum; 8FII; -. DR PDBsum; 8FIJ; -. DR PDBsum; 8FIK; -. DR PDBsum; 8FIL; -. DR PDBsum; 8FIM; -. DR AlphaFoldDB; P31941; -. DR BMRB; P31941; -. DR SMR; P31941; -. DR BioGRID; 128318; 14. DR DIP; DIP-61365N; -. DR FunCoup; P31941; 135. DR IntAct; P31941; 9. DR STRING; 9606.ENSP00000384359; -. DR BindingDB; P31941; -. DR ChEMBL; CHEMBL1741179; -. DR iPTMnet; P31941; -. DR PhosphoSitePlus; P31941; -. DR BioMuta; APOBEC3A; -. DR DMDM; 12644206; -. DR jPOST; P31941; -. DR MassIVE; P31941; -. DR PaxDb; 9606-ENSP00000384359; -. DR PeptideAtlas; P31941; -. DR ProteomicsDB; 54806; -. [P31941-1] DR ProteomicsDB; 54807; -. [P31941-2] DR Pumba; P31941; -. DR ABCD; P31941; 1 sequenced antibody. DR Antibodypedia; 26513; 247 antibodies from 32 providers. DR DNASU; 200315; -. DR Ensembl; ENST00000249116.7; ENSP00000249116.2; ENSG00000128383.14. [P31941-1] DR Ensembl; ENST00000402255.5; ENSP00000384359.1; ENSG00000128383.14. [P31941-1] DR Ensembl; ENST00000570508.3; ENSP00000461288.1; ENSG00000262156.6. [P31941-1] DR Ensembl; ENST00000623492.3; ENSP00000485234.1; ENSG00000262156.6. [P31941-1] DR GeneID; 100913187; -. DR GeneID; 200315; -. DR KEGG; hsa:100913187; -. DR KEGG; hsa:200315; -. DR MANE-Select; ENST00000249116.7; ENSP00000249116.2; NM_145699.4; NP_663745.1. DR MANE-Select; ENST00000570508.3; ENSP00000461288.1; NM_001193289.2; NP_001180218.1. DR UCSC; uc003awn.2; human. [P31941-1] DR AGR; HGNC:17343; -. DR AGR; HGNC:44196; -. DR ClinPGx; PA24891; -. DR CTD; 100913187; -. DR CTD; 200315; -. DR DisGeNET; 100913187; -. DR DisGeNET; 200315; -. DR GeneCards; APOBEC3A; -. DR HGNC; HGNC:17343; APOBEC3A. DR HPA; ENSG00000128383; Group enriched (bone marrow, lymphoid tissue, urinary bladder). DR MIM; 607109; gene. DR OpenTargets; ENSG00000128383; -. DR VEuPathDB; HostDB:ENSG00000128383; -. DR eggNOG; KOG4075; Eukaryota. DR GeneTree; ENSGT00940000164701; -. DR HOGENOM; CLU_080056_2_0_1; -. DR InParanoid; P31941; -. DR OMA; GNRWMIL; -. DR OrthoDB; 5956704at2759; -. DR PAN-GO; P31941; 12 GO annotations based on evolutionary models. DR PhylomeDB; P31941; -. DR BRENDA; 3.5.4.38; 2681. DR PathwayCommons; P31941; -. DR Reactome; R-HSA-72200; mRNA Editing: C to U Conversion. DR Reactome; R-HSA-75094; Formation of the Editosome. DR SignaLink; P31941; -. DR SIGNOR; P31941; -. DR Agora; ENSG00000128383; -. DR BioGRID-ORCS; 100913187; 2 hits in 89 CRISPR screens. DR BioGRID-ORCS; 200315; 13 hits in 1139 CRISPR screens. DR ChiTaRS; APOBEC3A; human. DR EvolutionaryTrace; P31941; -. DR Pharos; P31941; Tchem. DR PRO; PR:P31941; -. DR Proteomes; UP000005640; Chromosome 22. DR RNAct; P31941; protein. DR Bgee; ENSG00000128383; Expressed in monocyte and 136 other cell types or tissues. DR ExpressionAtlas; P31941; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0000932; C:P-body; IBA:GO_Central. DR GO; GO:0004126; F:cytidine deaminase activity; IDA:UniProtKB. DR GO; GO:0003723; F:RNA binding; IBA:GO_Central. DR GO; GO:0008270; F:zinc ion binding; IEA:InterPro. DR GO; GO:0044355; P:clearance of foreign intracellular DNA; IDA:UniProtKB. DR GO; GO:0016554; P:cytidine to uridine editing; IBA:GO_Central. DR GO; GO:0051607; P:defense response to virus; IDA:UniProtKB. DR GO; GO:0070383; P:DNA cytosine deamination; IBA:GO_Central. DR GO; GO:0045087; P:innate immune response; IDA:UniProtKB. DR GO; GO:0045869; P:negative regulation of single stranded viral RNA replication via double stranded DNA intermediate; IBA:GO_Central. DR GO; GO:0045071; P:negative regulation of viral genome replication; IDA:UniProtKB. DR GO; GO:0044029; P:positive regulation of gene expression via chromosomal CpG island demethylation; IDA:UniProtKB. DR GO; GO:0010526; P:transposable element silencing; IDA:UniProtKB. DR CDD; cd01283; cytidine_deaminase; 1. DR FunFam; 3.40.140.10:FF:000047; Apolipoprotein B editing enzyme catalytic polypeptide-like 3H; 1. DR Gene3D; 3.40.140.10; Cytidine Deaminase, domain 2; 1. DR InterPro; IPR016192; APOBEC/CMP_deaminase_Zn-bd. DR InterPro; IPR050610; APOBEC_Cyt_Deaminase. DR InterPro; IPR002125; CMP_dCMP_dom. DR InterPro; IPR016193; Cytidine_deaminase-like. DR PANTHER; PTHR13857:SF39; DNA DC-DU-EDITING ENZYME APOBEC-3A-RELATED; 1. DR PANTHER; PTHR13857; MRNA EDITING ENZYME; 1. DR Pfam; PF18782; NAD2; 1. DR SUPFAM; SSF53927; Cytidine deaminase-like; 1. DR PROSITE; PS00903; CYT_DCMP_DEAMINASES_1; 1. DR PROSITE; PS51747; CYT_DCMP_DEAMINASES_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative initiation; Antiviral defense; Cytoplasm; KW Direct protein sequencing; Hydrolase; Immunity; Innate immunity; KW Metal-binding; Nucleus; Proteomics identification; Reference proteome; KW Zinc. FT CHAIN 1..199 FT /note="DNA dC->dU-editing enzyme APOBEC-3A" FT /id="PRO_0000171752" FT DOMAIN 27..143 FT /note="CMP/dCMP-type deaminase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01083" FT ACT_SITE 72 FT /note="Proton donor" FT /evidence="ECO:0000250" FT BINDING 70 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_note="catalytic" FT /evidence="ECO:0000250" FT BINDING 101 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_note="catalytic" FT /evidence="ECO:0000250" FT BINDING 106 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_note="catalytic" FT /evidence="ECO:0000250" FT VAR_SEQ 1..12 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_041723" FT VARIANT 19 FT /note="T -> A (in dbSNP:rs17000556)" FT /id="VAR_048721" FT MUTAGEN 28 FT /note="R->E: No effect on deaminase activity despite an FT altered restriction activity towards genetic invaders." FT /evidence="ECO:0000269|PubMed:21123384" FT MUTAGEN 29 FT /note="H->A: Altered deaminase activity and restriction FT activity towards genetic invaders." FT /evidence="ECO:0000269|PubMed:21123384" FT MUTAGEN 30 FT /note="K->F: Altered deaminase activity and restriction FT activity towards genetic invaders." FT /evidence="ECO:0000269|PubMed:21123384" FT MUTAGEN 57 FT /note="N->A: Altered deaminase activity and restriction FT activity towards genetic invaders." FT /evidence="ECO:0000269|PubMed:21123384" FT MUTAGEN 60 FT /note="K->A: Altered deaminase activity and restriction FT activity towards genetic invaders." FT /evidence="ECO:0000269|PubMed:21123384" FT MUTAGEN 69 FT /note="R->A: Altered deaminase activity and restriction FT activity towards genetic invaders." FT /evidence="ECO:0000269|PubMed:21123384" FT MUTAGEN 70 FT /note="H->R: Altered deaminase activity." FT /evidence="ECO:0000269|PubMed:16527742" FT MUTAGEN 72 FT /note="E->Q: Altered deaminase activity and restriction FT activity towards genetic invaders." FT /evidence="ECO:0000269|PubMed:16527742, FT ECO:0000269|PubMed:21123384" FT MUTAGEN 98 FT /note="W->L: Altered deaminase activity and restriction FT activity towards genetic invaders." FT /evidence="ECO:0000269|PubMed:21123384" FT MUTAGEN 106 FT /note="C->S: Altered deaminase activity." FT /evidence="ECO:0000269|PubMed:16527742" FT MUTAGEN 128 FT /note="R->A: Altered deaminase activity and restriction FT activity towards genetic invaders." FT /evidence="ECO:0000269|PubMed:21123384" FT MUTAGEN 130 FT /note="Y->A: Altered deaminase activity and restriction FT activity towards genetic invaders." FT /evidence="ECO:0000269|PubMed:21123384" FT MUTAGEN 131 FT /note="D->N: No effect on deaminase activity despite an FT altered restriction activity towards genetic invaders." FT /evidence="ECO:0000269|PubMed:21123384" FT MUTAGEN 133 FT /note="D->N: Altered deaminase activity and restriction FT activity towards genetic invaders." FT /evidence="ECO:0000269|PubMed:21123384" FT MUTAGEN 136 FT /note="Y->A: Altered deaminase activity and restriction FT activity towards genetic invaders." FT /evidence="ECO:0000269|PubMed:21123384" FT STRAND 6..8 FT /evidence="ECO:0007829|PDB:7D3W" FT HELIX 15..21 FT /evidence="ECO:0007829|PDB:8FIK" FT STRAND 24..26 FT /evidence="ECO:0007829|PDB:8FIL" FT STRAND 27..29 FT /evidence="ECO:0007829|PDB:2M65" FT STRAND 32..40 FT /evidence="ECO:0007829|PDB:8FIK" FT STRAND 41..44 FT /evidence="ECO:0007829|PDB:8FIL" FT STRAND 45..56 FT /evidence="ECO:0007829|PDB:8FIK" FT HELIX 62..64 FT /evidence="ECO:0007829|PDB:8FIK" FT HELIX 71..82 FT /evidence="ECO:0007829|PDB:8FIK" FT STRAND 88..98 FT /evidence="ECO:0007829|PDB:8FIK" FT TURN 102..105 FT /evidence="ECO:0007829|PDB:8FIL" FT HELIX 106..116 FT /evidence="ECO:0007829|PDB:8FIK" FT STRAND 120..128 FT /evidence="ECO:0007829|PDB:8FIK" FT HELIX 136..145 FT /evidence="ECO:0007829|PDB:8FIK" FT STRAND 149..152 FT /evidence="ECO:0007829|PDB:8FIK" FT HELIX 155..165 FT /evidence="ECO:0007829|PDB:8FIK" FT HELIX 179..195 FT /evidence="ECO:0007829|PDB:8FIK" FT TURN 196..198 FT /evidence="ECO:0007829|PDB:7D3V" SQ SEQUENCE 199 AA; 23012 MW; 42E99E0D7DF7AA14 CRC64; MEASPASGPR HLMDPHIFTS NFNNGIGRHK TYLCYEVERL DNGTSVKMDQ HRGFLHNQAK NLLCGFYGRH AELRFLDLVP SLQLDPAQIY RVTWFISWSP CFSWGCAGEV RAFLQENTHV RLRIFAARIY DYDPLYKEAL QMLRDAGAQV SIMTYDEFKH CWDTFVDHQG CPFQPWDGLD EHSQALSGRL RAILQNQGN // ID ABCAC_HUMAN Reviewed; 2595 AA. AC Q86UK0; Q53QE2; Q53S55; Q8IZW6; Q96JT3; Q9Y4M5; DT 16-AUG-2004, integrated into UniProtKB/Swiss-Prot. DT 24-NOV-2009, sequence version 3. DT 28-JAN-2026, entry version 186. DE RecName: Full=Glucosylceramide transporter ABCA12 {ECO:0000305}; DE EC=7.6.2.1 {ECO:0000269|PubMed:16007253, ECO:0000269|PubMed:20869849}; DE AltName: Full=ATP-binding cassette sub-family A member 12; DE AltName: Full=ATP-binding cassette transporter 12; DE Short=ATP-binding cassette 12; GN Name=ABCA12 {ECO:0000312|HGNC:HGNC:14637}; Synonyms=ABC12; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANT RP THR-777. RC TISSUE=Placenta; RX PubMed=12697999; DOI=10.1159/000069811; RA Annilo T., Shulemin S., Chen Z.Q., Arnould I., Prades C., Lemoine C., RA Maintoux-Larois C., Devaud C., Dean M., Denefle P., Rosier M.; RT "Identification and characterization of a novel ABCA subfamily member, RT ABCA12, located in the lamellar ichthyosis region on 2q34."; RL Cytogenet. Genome Res. 98:169-176(2002). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT THR-777. RC TISSUE=Retina; RA Bonner T.I., Moses T., Detera-Wadleigh S.; RT "A retinal cDNA for the ATP-binding cassette transporter ABCA12."; RL Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] OF 221-2595, AND VARIANT THR-777. RA Schaap F.G., van Wijland M., Groen A.K.; RT "Cloning of a novel ABC transporter (ABCA12) tentatively involved in lipid RT homeostatis."; RL Submitted (SEP-2001) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2400-2595. RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [6] RP TISSUE SPECIFICITY, INDUCTION, SUBCELLULAR LOCATION, FUNCTION, VARIANTS RP ARCI4B 434-ARG--SER-2595 DEL; THR-1385 DEL AND 1950-ARG--SER-2595 DEL, AND RP CATALYTIC ACTIVITY. RX PubMed=16007253; DOI=10.1172/jci24834; RA Akiyama M., Sugiyama-Nakagiri Y., Sakai K., McMillan J.R., Goto M., RA Arita K., Tsuji-Abe Y., Tabata N., Matsuoka K., Sasaki R., Sawamura D., RA Shimizu H.; RT "Mutations in lipid transporter ABCA12 in harlequin ichthyosis and RT functional recovery by corrective gene transfer."; RL J. Clin. Invest. 115:1777-1784(2005). RN [7] RP DEVELOPMENTAL STAGE, TISSUE SPECIFICITY, AND INDUCTION. RX PubMed=17591952; DOI=10.2353/ajpath.2007.061207; RA Yamanaka Y., Akiyama M., Sugiyama-Nakagiri Y., Sakai K., Goto M., RA McMillan J.R., Ota M., Sawamura D., Shimizu H.; RT "Expression of the keratinocyte lipid transporter ABCA12 in developing and RT reconstituted human epidermis."; RL Am. J. Pathol. 171:43-52(2007). RN [8] RP TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=17927575; DOI=10.1111/j.1600-0625.2007.00614.x; RA Sakai K., Akiyama M., Sugiyama-Nakagiri Y., McMillan J.R., Sawamura D., RA Shimizu H.; RT "Localization of ABCA12 from Golgi apparatus to lamellar granules in human RT upper epidermal keratinocytes."; RL Exp. Dermatol. 16:920-926(2007). RN [9] RP INDUCTION. RX PubMed=17611579; DOI=10.1038/sj.jid.5700944; RA Jiang Y.J., Lu B., Kim P., Paragh G., Schmitz G., Elias P.M., RA Feingold K.R.; RT "PPAR and LXR activators regulate ABCA12 expression in human RT keratinocytes."; RL J. Invest. Dermatol. 128:104-109(2008). RN [10] RP TISSUE SPECIFICITY, AND FUNCTION. RX PubMed=19179616; DOI=10.2353/ajpath.2009.080860; RA Thomas A.C., Tattersall D., Norgett E.E., O'Toole E.A., Kelsell D.P.; RT "Premature terminal differentiation and a reduction in specific proteases RT associated with loss of ABCA12 in Harlequin ichthyosis."; RL Am. J. Pathol. 174:970-978(2009). RN [11] RP INDUCTION. RX PubMed=19429679; DOI=10.1074/jbc.m109.006973; RA Jiang Y.J., Uchida Y., Lu B., Kim P., Mao C., Akiyama M., Elias P.M., RA Holleran W.M., Grunfeld C., Feingold K.R.; RT "Ceramide stimulates ABCA12 expression via peroxisome proliferator- RT activated receptor {delta} in human keratinocytes."; RL J. Biol. Chem. 284:18942-18952(2009). RN [12] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=20869849; DOI=10.1016/j.jdermsci.2010.08.012; RA Mitsutake S., Suzuki C., Akiyama M., Tsuji K., Yanagi T., Shimizu H., RA Igarashi Y.; RT "ABCA12 dysfunction causes a disorder in glucosylceramide accumulation RT during keratinocyte differentiation."; RL J. Dermatol. Sci. 60:128-129(2010). RN [13] RP TISSUE SPECIFICITY. RX PubMed=32072744; DOI=10.15252/embr.201948692; RA Ursino G.M., Fu Y., Cottle D.L., Mukhamedova N., Jones L.K., Low H., RA Tham M.S., Gan W.J., Mellett N.A., Das P.P., Weir J.M., Ditiatkovski M., RA Fynch S., Thorn P., Thomas H.E., Meikle P.J., Parkington H.C., Smyth I.M., RA Sviridov D.; RT "ABCA12 regulates insulin secretion from beta-cells."; RL EMBO Rep. 21:e48692-e48692(2020). RN [14] RP REVIEW ON VARIANTS, AND INVOLVEMENT IN ARCI. RX PubMed=20672373; DOI=10.1002/humu.21326; RA Akiyama M.; RT "ABCA12 mutations and autosomal recessive congenital ichthyosis: a review RT of genotype/phenotype correlations and of pathogenetic concepts."; RL Hum. Mutat. 31:1090-1096(2010). RN [15] RP VARIANTS ARCI4A SER-1380; GLU-1381; HIS-1514; LYS-1539 AND SER-1651. RX PubMed=12915478; DOI=10.1093/hmg/ddg235; RA Lefevre C., Audebert S., Jobard F., Bouadjar B., Lakhdar H., RA Boughdene-Stambouli O., Blanchet-Bardon C., Heilig R., Foglio M., RA Weissenbach J., Lathrop M., Prud'homme J.F., Fischer J.; RT "Mutations in the transporter ABCA12 are associated with lamellar RT ichthyosis type 2."; RL Hum. Mol. Genet. 12:2369-2378(2003). RN [16] RP VARIANT ASN-2365. RX PubMed=15756637; DOI=10.1086/429844; RA Kelsell D.P., Norgett E.E., Unsworth H., Teh M.-T., Cullup T., Mein C.A., RA Dopping-Hepenstal P.J., Dale B.A., Tadini G., Fleckman P., Stephens K.G., RA Sybert V.P., Mallory S.B., North B.V., Witt D.R., Sprecher E., RA Taylor A.E.M., Ilchyshyn A., Kennedy C.T., Goodyear H., Moss C., Paige D., RA Harper J.I., Young B.D., Leigh I.M., Eady R.A.J., O'Toole E.A.; RT "Mutations in ABCA12 underlie the severe congenital skin disease harlequin RT ichthyosis."; RL Am. J. Hum. Genet. 76:794-803(2005). RN [17] RP VARIANT ARCI4B ASN-387. RX PubMed=16675967; DOI=10.1038/sj.jid.5700295; RA Akiyama M., Sakai K., Sugiyama-Nakagiri Y., Yamanaka Y., McMillan J.R., RA Sawamura D., Niizeki H., Miyagawa S., Shimizu H.; RT "Compound heterozygous mutations including a de novo missense mutation in RT ABCA12 led to a case of harlequin ichthyosis with moderate clinical RT severity."; RL J. Invest. Dermatol. 126:1518-1523(2006). RN [18] RP VARIANT ARCI4B ARG-1179. RX PubMed=16902423; DOI=10.1038/sj.jid.5700455; RA Thomas A.C., Cullup T., Norgett E.E., Hill T., Barton S., Dale B.A., RA Sprecher E., Sheridan E., Taylor A.E., Wilroy R.S., DeLozier C., RA Burrows N., Goodyear H., Fleckman P., Stephens K.G., Mehta L., Watson R.M., RA Graham R., Wolf R., Slavotinek A., Martin M., Bourn D., Mein C.A., RA O'Toole E.A., Kelsell D.P.; RT "ABCA12 is the major harlequin ichthyosis gene."; RL J. Invest. Dermatol. 126:2408-2413(2006). RN [19] RP VARIANTS ARCI4A PRO-345 AND THR-1494. RX PubMed=17508018; DOI=10.1038/sj.jid.5700885; RA Natsuga K., Akiyama M., Kato N., Sakai K., Sugiyama-Nakagiri Y., RA Nishimura M., Hata H., Abe M., Arita K., Tsuji-Abe Y., Onozuka T., RA Aoyagi S., Kodama K., Ujiie H., Tomita Y., Shimizu H.; RT "Novel ABCA12 mutations identified in two cases of non-bullous congenital RT ichthyosiform erythroderma associated with multiple skin malignant RT neoplasia."; RL J. Invest. Dermatol. 127:2669-2673(2007). RN [20] RP VARIANT ARCI4A ASP-1136. RX PubMed=18284401; DOI=10.1111/j.1365-2133.2008.08439.x; RA Akiyama M., Sakai K., Hatamochi A., Yamazaki S., McMillan J.R., Shimizu H.; RT "Novel compound heterozygous nonsense and missense ABCA12 mutations lead to RT nonbullous congenital ichthyosiform erythroderma."; RL Br. J. Dermatol. 158:864-867(2008). RN [21] RP VARIANT [LARGE SCALE ANALYSIS] VAL-476. RX PubMed=18772397; DOI=10.1126/science.1164368; RA Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., RA Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., RA Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., RA Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., RA Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., RA Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., RA Velculescu V.E., Kinzler K.W.; RT "Core signaling pathways in human pancreatic cancers revealed by global RT genomic analyses."; RL Science 321:1801-1806(2008). RN [22] RP VARIANTS ARCI4A SER-1235; HIS-1514; LEU-1798 AND LYS-1980. RX PubMed=19262603; DOI=10.1038/jid.2009.23; RA Sakai K., Akiyama M., Yanagi T., McMillan J.R., Suzuki T., Tsukamoto K., RA Sugiyama H., Hatano Y., Hayashitani M., Takamori K., Nakashima K., RA Shimizu H.; RT "ABCA12 is a major causative gene for non-bullous congenital ichthyosiform RT erythroderma."; RL J. Invest. Dermatol. 129:2306-2309(2009). RN [23] RP VARIANT ARCI4A VAL-1559. RX PubMed=22257947; DOI=10.1684/ejd.2011.1638; RA Nawaz S., Tariq M., Ahmad I., Malik N.A., Baig S.M., Dahl N., Klar J.; RT "Non-bullous congenital ichthyosiform erythroderma associated with RT homozygosity for a novel missense mutation in an ATP binding domain of RT ABCA12."; RL Eur. J. Dermatol. 22:178-181(2012). CC -!- FUNCTION: Transports lipids such as glucosylceramides from the outer to CC the inner leaflet of lamellar granules (LGs) membrane, whereby the CC lipids are finally transported to the keratinocyte periphery via the CC trans-Golgi network and LGs and released to the apical surface of the CC granular keratinocytes to form lipid lamellae in the stratum corneum of CC the epidermis, which is essential for skin barrier function CC (PubMed:16007253, PubMed:20869849). In the meantime, participates in CC the transport of the lamellar granules-associated proteolytic enzymes, CC in turn regulates desquamation and keratinocyte differentiation CC (PubMed:19179616). Furthermore, is essential for the regulation of CC cellular cholesterol homeostasis by regulating ABCA1-dependent CC cholesterol efflux from macrophages through interaction with NR1H2 and CC ABCA1 (By similarity). Plays pleiotropic roles in regulating glucose CC stimulated insulin secretion from beta cells, regulating the morphology CC and fusion of insulin granules, lipid raft abundance and the actin CC cytoskeleton (By similarity). Also involved in lung surfactant CC biogenesis (By similarity). {ECO:0000250|UniProtKB:E9Q876, CC ECO:0000269|PubMed:16007253, ECO:0000269|PubMed:19179616, CC ECO:0000269|PubMed:20869849}. CC -!- CATALYTIC ACTIVITY: CC Reaction=ATP + H2O + phospholipidSide 1 = ADP + phosphate + CC phospholipidSide 2.; EC=7.6.2.1; CC Evidence={ECO:0000269|PubMed:16007253, ECO:0000269|PubMed:20869849}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a beta-D-glucosylceramide(in) + ATP + H2O = a beta-D- CC glucosylceramide(out) + ADP + phosphate + H(+); Xref=Rhea:RHEA:66660, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:43474, ChEBI:CHEBI:83264, ChEBI:CHEBI:456216; CC Evidence={ECO:0000269|PubMed:16007253, ECO:0000269|PubMed:20869849}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:66661; CC Evidence={ECO:0000305|PubMed:16007253, ECO:0000305|PubMed:20869849}; CC -!- SUBUNIT: Interacts with NR1H2 and ABCA1; this interaction is required CC for ABCA1 localization to the cell surface and is necessary for its CC normal activity and stability. {ECO:0000250|UniProtKB:E9Q876}. CC -!- INTERACTION: CC Q86UK0; O95477: ABCA1; NbExp=4; IntAct=EBI-9541582, EBI-784112; CC -!- SUBCELLULAR LOCATION: Cytoplasmic vesicle, secretory vesicle membrane CC {ECO:0000269|PubMed:16007253, ECO:0000269|PubMed:17927575}; Multi-pass CC membrane protein {ECO:0000305}. Golgi apparatus membrane CC {ECO:0000269|PubMed:17927575}. Note=Localizes in the limiting membrane CC of the lamellar granules (LGs) (PubMed:17927575). Trafficks from the CC Golgi apparatus to the lamellar granules (LGs) at the cell periphery in CC the uppermost granular layer keratinocytes where ABCA12-positive LGs CC fuse with the keratinocyte-cell membrane to secrete their lipid content CC to the extracellular space of the stratum corneum (PubMed:16007253, CC PubMed:17927575). Co-localizes through the Golgi apparatus to the cell CC periphery with glucosylceramide (PubMed:17927575). CC {ECO:0000269|PubMed:16007253, ECO:0000269|PubMed:17927575}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Comment=Additional isoforms seem to exist.; CC Name=1; CC IsoId=Q86UK0-1; Sequence=Displayed; CC Name=2; CC IsoId=Q86UK0-2; Sequence=VSP_011283, VSP_011284; CC -!- TISSUE SPECIFICITY: Mainly expressed in the stomach, placenta, testis CC and fetal brain (PubMed:12697999). Expressed in the upper epidermal CC layers, mainly the granular layers, of skin (PubMed:16007253, CC PubMed:17591952, PubMed:17927575). Expressed throughout the normal CC interfollicular epidermis with prominent expression in the stratum CC granulosum (PubMed:19179616). Expressed in alpha and beta cells of CC pancreatic islets (PubMed:32072744). {ECO:0000269|PubMed:12697999, CC ECO:0000269|PubMed:16007253, ECO:0000269|PubMed:17591952, CC ECO:0000269|PubMed:17927575, ECO:0000269|PubMed:19179616, CC ECO:0000269|PubMed:32072744}. CC -!- DEVELOPMENTAL STAGE: At about 6 to 9 weeks estimated gestational age CC (EGA), expressed in the periderm during the early period when the two- CC layered epidermis form. At 10 to 13 weeks EGA, expressed in the entire CC epidermis with high expression in periderm until to 14 to 22 weeks EGA. CC {ECO:0000269|PubMed:17591952}. CC -!- INDUCTION: Up-regulated during keratinization (PubMed:16007253). Up- CC regulated after 15 weeks estimated gestational age (EGA) CC (PubMed:17591952). Highly up-regulated by PPARG activators such as CC ciglitazone, troglitazone, and the PPARD activator GW 0742 in time- and CC dose-dependent manner but independently of keratinocyte CC differentiation. In addition, modestly up-regulated by the NR1H3 and CC NR1H2 activator TO901317 in an keratinocyte differentiation-independent CC manner (PubMed:17611579). Up-regulated by N-(hexanoyl)sphing-4-enine in CC a time- and dose-dependent manner or by glucosyltransferase inhibitors, CC ceramidase inhibitors and sphingomyelin synthase inhibitors that CC increase endogenous ceramide levels and induce ABCA12 expression via CC the PPARD signaling pathway (PubMed:19429679). Up-regulated by N- CC acetylsphingosine in a time- and dose-dependent manner via the PPARD CC signaling pathway (Probable). {ECO:0000269|PubMed:16007253, CC ECO:0000269|PubMed:17591952, ECO:0000269|PubMed:17611579, CC ECO:0000269|PubMed:19429679, ECO:0000305|PubMed:19429679}. CC -!- DOMAIN: Multifunctional polypeptide with two homologous halves, each CC containing a hydrophobic membrane-anchoring domain and an ATP binding CC cassette (ABC) domain. {ECO:0000250}. CC -!- DISEASE: Ichthyosis, congenital, autosomal recessive 4A (ARCI4A) CC [MIM:601277]: A form of autosomal recessive congenital ichthyosis, a CC disorder of keratinization with abnormal differentiation and CC desquamation of the epidermis, resulting in abnormal skin scaling over CC the whole body. The main skin phenotypes are lamellar ichthyosis (LI) CC and non-bullous congenital ichthyosiform erythroderma (NCIE), although CC phenotypic overlap within the same patient or among patients from the CC same family can occur. Lamellar ichthyosis is a condition often CC associated with an embedment in a collodion-like membrane at birth; CC skin scales later develop, covering the entire body surface. Non- CC bullous congenital ichthyosiform erythroderma characterized by fine CC whitish scaling on an erythrodermal background; larger brownish scales CC are present on the buttocks, neck and legs. CC {ECO:0000269|PubMed:12915478, ECO:0000269|PubMed:17508018, CC ECO:0000269|PubMed:18284401, ECO:0000269|PubMed:19262603, CC ECO:0000269|PubMed:22257947}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Ichthyosis, congenital, autosomal recessive 4B (ARCI4B) CC [MIM:242500]: A rare, very severe form of congenital ichthyosis, in CC which the neonate is born with a thick covering of armor-like scales. CC The skin dries out to form hard diamond-shaped plaques separated by CC fissures, resembling 'armor plating'. The normal facial features are CC severely affected, with distortion of the lips (eclabion), eyelids CC (ectropion), ears, and nostrils. Affected babies are often born CC prematurely and rarely survive the perinatal period. Babies who survive CC into infancy and beyond develop skin changes resembling severe non- CC bullous congenital ichthyosiform erythroderma. CC {ECO:0000269|PubMed:16007253, ECO:0000269|PubMed:16675967, CC ECO:0000269|PubMed:16902423}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCA family. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAN40735.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=ABCMdb; Note=Database for mutations in ABC proteins; CC URL="http://abcm2.hegelab.org/search"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY219711; AAP21093.1; -; mRNA. DR EMBL; AY033486; AAK54355.1; -; mRNA. DR EMBL; AC072062; AAY24276.1; -; Genomic_DNA. DR EMBL; AC114780; AAY24230.1; -; Genomic_DNA. DR EMBL; AF418105; AAN40735.1; ALT_INIT; mRNA. DR EMBL; AL080207; CAB45776.1; -; mRNA. DR CCDS; CCDS33372.1; -. [Q86UK0-1] DR CCDS; CCDS33373.1; -. [Q86UK0-2] DR PIR; T12512; T12512. DR RefSeq; NP_056472.2; NM_015657.3. [Q86UK0-2] DR RefSeq; NP_775099.2; NM_173076.2. [Q86UK0-1] DR AlphaFoldDB; Q86UK0; -. DR SMR; Q86UK0; -. DR BioGRID; 117585; 15. DR CORUM; Q86UK0; -. DR FunCoup; Q86UK0; 78. DR IntAct; Q86UK0; 7. DR MINT; Q86UK0; -. DR STRING; 9606.ENSP00000272895; -. DR TCDB; 3.A.1.211.13; the atp-binding cassette (abc) superfamily. DR GlyCosmos; Q86UK0; 35 sites, No reported glycans. DR GlyGen; Q86UK0; 39 sites, 4 N-linked glycans (3 sites), 2 O-linked glycans (3 sites). DR iPTMnet; Q86UK0; -. DR PhosphoSitePlus; Q86UK0; -. DR SwissPalm; Q86UK0; -. DR BioMuta; ABCA12; -. DR DMDM; 269849713; -. DR jPOST; Q86UK0; -. DR MassIVE; Q86UK0; -. DR PaxDb; 9606-ENSP00000272895; -. DR PeptideAtlas; Q86UK0; -. DR ProteomicsDB; 69821; -. [Q86UK0-1] DR ProteomicsDB; 69822; -. [Q86UK0-2] DR Antibodypedia; 34220; 139 antibodies from 25 providers. DR DNASU; 26154; -. DR Ensembl; ENST00000272895.12; ENSP00000272895.7; ENSG00000144452.15. [Q86UK0-1] DR Ensembl; ENST00000389661.4; ENSP00000374312.4; ENSG00000144452.15. [Q86UK0-2] DR GeneID; 26154; -. DR KEGG; hsa:26154; -. DR MANE-Select; ENST00000272895.12; ENSP00000272895.7; NM_173076.3; NP_775099.2. DR UCSC; uc002vev.4; human. [Q86UK0-1] DR AGR; HGNC:14637; -. DR ClinPGx; PA29604; -. DR CTD; 26154; -. DR DisGeNET; 26154; -. DR GeneCards; ABCA12; -. DR GeneReviews; ABCA12; -. DR HGNC; HGNC:14637; ABCA12. DR HPA; ENSG00000144452; Tissue enhanced (breast, skin). DR MalaCards; ABCA12; -. DR MIM; 242500; phenotype. DR MIM; 601277; phenotype. DR MIM; 607800; gene. DR OpenTargets; ENSG00000144452; -. DR Orphanet; 79394; Congenital ichthyosiform erythroderma. DR Orphanet; 457; Harlequin ichthyosis. DR Orphanet; 313; Lamellar ichthyosis. DR VEuPathDB; HostDB:ENSG00000144452; -. DR eggNOG; KOG0059; Eukaryota. DR GeneTree; ENSGT00940000157295; -. DR HOGENOM; CLU_000604_19_7_1; -. DR InParanoid; Q86UK0; -. DR OMA; TYIVREH; -. DR OrthoDB; 10255969at2759; -. DR PAN-GO; Q86UK0; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q86UK0; -. DR PathwayCommons; Q86UK0; -. DR Reactome; R-HSA-1369062; ABC transporters in lipid homeostasis. DR Reactome; R-HSA-5682294; Defective ABCA12 causes ARCI4B. DR SignaLink; Q86UK0; -. DR Agora; ENSG00000144452; -. DR BioGRID-ORCS; 26154; 6 hits in 1147 CRISPR screens. DR ChiTaRS; ABCA12; human. DR GeneWiki; ABCA12; -. DR GenomeRNAi; 26154; -. DR Pharos; Q86UK0; Tbio. DR PRO; PR:Q86UK0; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q86UK0; protein. DR Bgee; ENSG00000144452; Expressed in penis and 75 other cell types or tissues. DR ExpressionAtlas; Q86UK0; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; IEA:Ensembl. DR GO; GO:0097209; C:epidermal lamellar body; IDA:BHF-UCL. DR GO; GO:0097234; C:epidermal lamellar body membrane; IDA:UniProtKB. DR GO; GO:0000139; C:Golgi membrane; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; NAS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL. DR GO; GO:0030658; C:transport vesicle membrane; IEA:UniProtKB-SubCell. DR GO; GO:0140359; F:ABC-type transporter activity; IEA:InterPro. DR GO; GO:0034191; F:apolipoprotein A-I receptor binding; IPI:BHF-UCL. DR GO; GO:0005524; F:ATP binding; NAS:UniProtKB. DR GO; GO:0016887; F:ATP hydrolysis activity; IEA:InterPro. DR GO; GO:0140326; F:ATPase-coupled intramembrane lipid transporter activity; IEA:UniProtKB-EC. DR GO; GO:0034040; F:ATPase-coupled lipid transmembrane transporter activity; IC:BHF-UCL. DR GO; GO:0042626; F:ATPase-coupled transmembrane transporter activity; IBA:GO_Central. DR GO; GO:0005319; F:lipid transporter activity; IDA:BHF-UCL. DR GO; GO:0005102; F:signaling receptor binding; IPI:BHF-UCL. DR GO; GO:0019725; P:cellular homeostasis; NAS:UniProtKB. DR GO; GO:0006672; P:ceramide metabolic process; IDA:UniProtKB. DR GO; GO:0035627; P:ceramide transport; IDA:UniProtKB. DR GO; GO:0033344; P:cholesterol efflux; IEA:Ensembl. DR GO; GO:0003336; P:corneocyte desquamation; IMP:UniProtKB. DR GO; GO:0061436; P:establishment of skin barrier; ISS:UniProtKB. DR GO; GO:0006886; P:intracellular protein transport; IMP:UniProtKB. DR GO; GO:0031424; P:keratinization; IEA:Ensembl. DR GO; GO:0055088; P:lipid homeostasis; IEA:Ensembl. DR GO; GO:0006869; P:lipid transport; IDA:BHF-UCL. DR GO; GO:0048286; P:lung alveolus development; IEA:Ensembl. DR GO; GO:0033700; P:phospholipid efflux; IMP:BHF-UCL. DR GO; GO:0010875; P:positive regulation of cholesterol efflux; IDA:BHF-UCL. DR GO; GO:0032379; P:positive regulation of intracellular lipid transport; ISS:UniProtKB. DR GO; GO:2000010; P:positive regulation of protein localization to cell surface; IEA:Ensembl. DR GO; GO:0072659; P:protein localization to plasma membrane; IDA:BHF-UCL. DR GO; GO:0045055; P:regulated exocytosis; IMP:BHF-UCL. DR GO; GO:0061178; P:regulation of insulin secretion involved in cellular response to glucose stimulus; ISS:UniProtKB. DR GO; GO:0045616; P:regulation of keratinocyte differentiation; IMP:UniProtKB. DR GO; GO:0032940; P:secretion by cell; IMP:BHF-UCL. DR GO; GO:0043129; P:surfactant homeostasis; IEA:Ensembl. DR CDD; cd03263; ABC_subfamily_A; 2. DR FunFam; 3.40.50.300:FF:000689; ATP binding cassette subfamily A member 12; 1. DR FunFam; 3.40.50.300:FF:000298; ATP-binding cassette sub-family A member 12; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 2. DR InterPro; IPR003593; AAA+_ATPase. DR InterPro; IPR013525; ABC2_TM. DR InterPro; IPR003439; ABC_transporter-like_ATP-bd. DR InterPro; IPR017871; ABC_transporter-like_CS. DR InterPro; IPR026082; ABCA. DR InterPro; IPR027417; P-loop_NTPase. DR InterPro; IPR056264; R2_ABCA1-4-like. DR PANTHER; PTHR19229; ATP-BINDING CASSETTE TRANSPORTER SUBFAMILY A ABCA; 1. DR PANTHER; PTHR19229:SF29; GLUCOSYLCERAMIDE TRANSPORTER ABCA12; 1. DR Pfam; PF12698; ABC2_membrane_3; 2. DR Pfam; PF00005; ABC_tran; 2. DR Pfam; PF23321; R1_ABCA1; 1. DR SMART; SM00382; AAA; 2. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 2. DR PROSITE; PS00211; ABC_TRANSPORTER_1; 1. DR PROSITE; PS50893; ABC_TRANSPORTER_2; 2. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cytoplasmic vesicle; Disease variant; KW Glycoprotein; Golgi apparatus; Ichthyosis; Lipid transport; Membrane; KW Nucleotide-binding; Proteomics identification; Reference proteome; Repeat; KW Translocase; Transmembrane; Transmembrane helix; Transport. FT CHAIN 1..2595 FT /note="Glucosylceramide transporter ABCA12" FT /id="PRO_0000093300" FT TRANSMEM 23..43 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 1065..1085 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 1112..1132 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 1145..1165 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 1174..1194 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 1200..1220 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 1250..1270 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 1747..1767 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 1979..1999 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 2035..2055 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 2072..2092 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 2103..2123 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 2187..2207 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 2270..2290 FT /note="Helical" FT /evidence="ECO:0000255" FT DOMAIN 1346..1577 FT /note="ABC transporter 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00434" FT DOMAIN 2254..2489 FT /note="ABC transporter 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00434" FT REGION 2571..2595 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2574..2587 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 1378..1385 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00434" FT BINDING 2290..2297 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00434" FT CARBOHYD 156 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 174 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 214 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 275 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 333 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 367 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 383 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 412 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 435 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 528 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 543 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 577 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 608 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 623 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 648 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 752 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 826 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 920 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 963 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1170 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1524 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1663 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1704 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1769 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1819 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1835 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1876 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1921 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1952 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 2178 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 2208 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 2223 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 2318 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 2542 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 2547 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 1..318 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_011283" FT VAR_SEQ 319..328 FT /note="LLYTLDSPAQ -> MFTYIKIITS (in isoform 2)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_011284" FT VARIANT 199 FT /note="W -> C (in dbSNP:rs16853238)" FT /id="VAR_055473" FT VARIANT 237 FT /note="N -> H (in dbSNP:rs11890512)" FT /id="VAR_055474" FT VARIANT 274 FT /note="Q -> R (in dbSNP:rs11890468)" FT /id="VAR_055475" FT VARIANT 287 FT /note="R -> G (in dbSNP:rs11891778)" FT /id="VAR_055476" FT VARIANT 345 FT /note="T -> P (in ARCI4A; skin phenotype consistent with FT non-bullous congenital ichthyosiform erythroderma; FT dbSNP:rs1295935868)" FT /evidence="ECO:0000269|PubMed:17508018" FT /id="VAR_067075" FT VARIANT 387 FT /note="S -> N (in ARCI4B; dbSNP:rs746315995)" FT /evidence="ECO:0000269|PubMed:16675967" FT /id="VAR_067076" FT VARIANT 434..2595 FT /note="Missing (in ARCI4B)" FT /evidence="ECO:0000269|PubMed:16007253" FT /id="VAR_084428" FT VARIANT 459 FT /note="S -> T (in dbSNP:rs113112835)" FT /id="VAR_019597" FT VARIANT 476 FT /note="A -> V (in a pancreatic ductal adenocarcinoma FT sample; somatic mutation; dbSNP:rs370640837)" FT /evidence="ECO:0000269|PubMed:18772397" FT /id="VAR_062663" FT VARIANT 550 FT /note="E -> G (in dbSNP:rs16853149)" FT /id="VAR_027444" FT VARIANT 777 FT /note="S -> T (in dbSNP:rs7560008)" FT /evidence="ECO:0000269|PubMed:12697999, ECO:0000269|Ref.2, FT ECO:0000269|Ref.4" FT /id="VAR_027445" FT VARIANT 1136 FT /note="G -> D (in ARCI4A; skin phenotype consistent with FT non-bullous congenital ichthyosiform erythroderma)" FT /evidence="ECO:0000269|PubMed:18284401" FT /id="VAR_067077" FT VARIANT 1179 FT /note="G -> R (in ARCI4B; dbSNP:rs267606622)" FT /evidence="ECO:0000269|PubMed:16902423" FT /id="VAR_067078" FT VARIANT 1235 FT /note="W -> S (in ARCI4A; skin phenotype consistent with FT non-bullous congenital ichthyosiform erythroderma; FT dbSNP:rs2105975227)" FT /evidence="ECO:0000269|PubMed:19262603" FT /id="VAR_067079" FT VARIANT 1251 FT /note="G -> D (in dbSNP:rs13414448)" FT /id="VAR_027446" FT VARIANT 1380 FT /note="N -> S (in ARCI4A; dbSNP:rs28940269)" FT /evidence="ECO:0000269|PubMed:12915478" FT /id="VAR_019598" FT VARIANT 1381 FT /note="G -> E (in ARCI4A; dbSNP:rs28940268)" FT /evidence="ECO:0000269|PubMed:12915478" FT /id="VAR_019599" FT VARIANT 1385 FT /note="Missing (in ARCI4B; uncertain significance)" FT /evidence="ECO:0000269|PubMed:16007253" FT /id="VAR_084429" FT VARIANT 1494 FT /note="I -> T (in ARCI4A; skin phenotype consistent with FT non-bullous congenital ichthyosiform erythroderma; FT dbSNP:rs1263698595)" FT /evidence="ECO:0000269|PubMed:17508018" FT /id="VAR_067080" FT VARIANT 1514 FT /note="R -> H (in ARCI4A; dbSNP:rs28940270)" FT /evidence="ECO:0000269|PubMed:12915478, FT ECO:0000269|PubMed:19262603" FT /id="VAR_019600" FT VARIANT 1539 FT /note="E -> K (in ARCI4A; dbSNP:rs28940271)" FT /evidence="ECO:0000269|PubMed:12915478" FT /id="VAR_019601" FT VARIANT 1546 FT /note="R -> C (in dbSNP:rs13401480)" FT /id="VAR_027447" FT VARIANT 1559 FT /note="G -> V (in ARCI4A; skin phenotype consistent with FT non-bullous congenital ichthyosiform erythroderma; FT dbSNP:rs1457513156)" FT /evidence="ECO:0000269|PubMed:22257947" FT /id="VAR_067081" FT VARIANT 1651 FT /note="G -> S (in ARCI4A; dbSNP:rs28940568)" FT /evidence="ECO:0000269|PubMed:12915478" FT /id="VAR_019602" FT VARIANT 1798 FT /note="P -> L (in ARCI4A; skin phenotype consistent with FT non-bullous congenital ichthyosiform erythroderma; FT dbSNP:rs181314573)" FT /evidence="ECO:0000269|PubMed:19262603" FT /id="VAR_067082" FT VARIANT 1950..2595 FT /note="Missing (in ARCI4B; uncertain significance)" FT /evidence="ECO:0000269|PubMed:16007253" FT /id="VAR_084430" FT VARIANT 1980 FT /note="T -> K (in ARCI4A; skin phenotype consistent with FT non-bullous congenital ichthyosiform erythroderma; FT dbSNP:rs763858530)" FT /evidence="ECO:0000269|PubMed:19262603" FT /id="VAR_067083" FT VARIANT 2064 FT /note="E -> K (in dbSNP:rs1213011)" FT /id="VAR_027448" FT VARIANT 2365 FT /note="D -> N (in dbSNP:rs726070)" FT /evidence="ECO:0000269|PubMed:15756637" FT /id="VAR_027449" FT CONFLICT 651 FT /note="Y -> D (in Ref. 1; AAP21093)" FT /evidence="ECO:0000305" FT CONFLICT 811 FT /note="Y -> H (in Ref. 1; AAP21093)" FT /evidence="ECO:0000305" FT CONFLICT 826 FT /note="N -> D (in Ref. 2; AAK54355)" FT /evidence="ECO:0000305" FT CONFLICT 2079 FT /note="Y -> H (in Ref. 1; AAP21093)" FT /evidence="ECO:0000305" SQ SEQUENCE 2595 AA; 293237 MW; 5B71359B642BBAE6 CRC64; MASLFHQLQI LVWKNWLGVK RQPLWTLVLI LWPVIIFIIL AITRTKFPPT AKPTCYLAPR NLPSTGFFPF LQTLLCDTDS KCKDTPYGPQ DLLRRKGIDD ALFKDSEILR KSSNLDKDSS LSFQSTQVPE RRHASLATVF PSPSSDLEIP GTYTFNGSQV LARILGLEKL LKQNSTSEDI RRELCDSYSG YIVDDAFSWT FLGRNVFNKF CLSNMTLLES SLQELNKQFS QLSSDPNNQK IVFQEIVRML SFFSQVQEQK AVWQLLSSFP NVFQNDTSLS NLFDVLRKAN SVLLVVQKVY PRFATNEGFR TLQKSVKHLL YTLDSPAQGD SDNITHVWNE DDGQTLSPSS LAAQLLILEN FEDALLNISA NSPYIPYLAC VRNVTDSLAR GSPENLRLLQ STIRFKKSFL RNGSYEDYFP PVPEVLKSKL SQLRNLTELL CESETFSLIE KSCQLSDMSF GSLCEESEFD LQLLEAAELG TEIAASLLYH DNVISKKVRD LLTGDPSKIN LNMDQFLEQA LQMNYLENIT QLIPIIEAML HVNNSADASE KPGQLLEMFK NVEELKEDLR RTTGMSNRTI DKLLAIPIPD NRAEIISQVF WLHSCDTNIT TPKLEDAMKE FCNLSLSERS RQSYLIGLTL LHYLNIYNFT YKVFFPRKDQ KPVEKMMELF IRLKEILNQM ASGTHPLLDK MRSLKQMHLP RSVPLTQAMY RSNRMNTPQG SFSTISQALC SQGITTEYLT AMLPSSQRPK GNHTKDFLTY KLTKEQIASK YGIPINSTPF CFSLYKDIIN MPAGPVIWAF LKPMLLGRIL YAPYNPVTKA IMEKSNVTLR QLAELREKSQ EWMDKSPLFM NSFHLLNQAI PMLQNTLRNP FVQVFVKFSV GLDAVELLKQ IDELDILRLK LENNIDIIDQ LNTLSSLTVN ISSCVLYDRI QAAKTIDEME REAKRLYKSN ELFGSVIFKL PSNRSWHRGY DSGNVFLPPV IKYTIRMSLK TAQTTRSLRT KIWAPGPHNS PSHNQIYGRA FIYLQDSIER AIIELQTGRN SQEIAVQVQA IPYPCFMKDN FLTSVSYSLP IVLMVAWVVF IAAFVKKLVY EKDLRLHEYM KMMGVNSCSH FFAWLIESVG FLLVTIVILI IILKFGNILP KTNGFILFLY FSDYSFSVIA MSYLISVFFN NTNIAALIGS LIYIIAFFPF IVLVTVENEL SYVLKVFMSL LSPTAFSYAS QYIARYEEQG IGLQWENMYT SPVQDDTTSF GWLCCLILAD SFIYFLIAWY VRNVFPGTYG MAAPWYFPIL PSYWKERFGC AEVKPEKSNG LMFTNIMMQN TNPSASPEYM FSSNIEPEPK DLTVGVALHG VTKIYGSKVA VDNLNLNFYE GHITSLLGPN GAGKTTTISM LTGLFGASAG TIFVYGKDIK TDLHTVRKNM GVCMQHDVLF SYLTTKEHLL LYGSIKVPHW TKKQLHEEVK RTLKDTGLYS HRHKRVGTLS GGMKRKLSIS IALIGGSRVV ILDEPSTGVD PCSRRSIWDV ISKNKTARTI ILSTHHLDEA EVLSDRIAFL EQGGLRCCGS PFYLKEAFGD GYHLTLTKKK SPNLNANAVC DTMAVTAMIQ SHLPEAYLKE DIGGELVYVL PPFSTKVSGA YLSLLRALDN GMGDLNIGCY GISDTTVEEV FLNLTKESQK NSAMSLEHLT QKKIGNSNAN GISTPDDLSV SSSNFTDRDD KILTRGERLD GFGLLLKKIM AILIKRFHHT RRNWKGLIAQ VILPIVFVTT AMGLGTLRNS SNSYPEIQIS PSLYGTSEQT AFYANYHPST EALVSAMWDF PGIDNMCLNT SDLQCLNKDS LEKWNTSGEP ITNFGVCSCS ENVQECPKFN YSPPHRRTYS SQVIYNLTGQ RVENYLISTA NEFVQKRYGG WSFGLPLTKD LRFDITGVPA NRTLAKVWYD PEGYHSLPAY LNSLNNFLLR VNMSKYDAAR HGIIMYSHPY PGVQDQEQAT ISSLIDILVA LSILMGYSVT TASFVTYVVR EHQTKAKQLQ HISGIGVTCY WVTNFIYDMV FYLVPVAFSI GIIAIFKLPA FYSENNLGAV SLLLLLFGYA TFSWMYLLAG LFHETGMAFI TYVCVNLFFG INSIVSLSVV YFLSKEKPND PTLELISETL KRIFLIFPQF CFGYGLIELS QQQSVLDFLK AYGVEYPNET FEMNKLGAMF VALVSQGTMF FSLRLLINES LIKKLRLFFR KFNSSHVRET IDEDEDVRAE RLRVESGAAE FDLVQLYCLT KTYQLIHKKI IAVNNISIGI PAGECFGLLG VNGAGKTTIF KMLTGDIIPS SGNILIRNKT GSLGHVDSHS SLVGYCPQED ALDDLVTVEE HLYFYARVHG IPEKDIKETV HKLLRRLHLM PFKDRATSMC SYGTKRKLST ALALIGKPSI LLLDEPSSGM DPKSKRHLWK IISEEVQNKC SVILTSHSME ECEALCTRLA IMVNGKFQCI GSLQHIKSRF GRGFTVKVHL KNNKVTMETL TKFMQLHFPK TYLKDQHLSM LEYHVPVTAG GVANIFDLLE TNKTALNITN FLVSQTTLEE VFINFAKDQK SYETADTSSQ GSTISVDSQD DQMES // ID ACK1_HUMAN Reviewed; 1038 AA. AC Q07912; Q6ZMQ0; Q8N6U7; Q96H59; DT 24-OCT-2003, integrated into UniProtKB/Swiss-Prot. DT 05-MAY-2009, sequence version 3. DT 28-JAN-2026, entry version 240. DE RecName: Full=Activated CDC42 kinase 1; DE Short=ACK-1; DE EC=2.7.10.2 {ECO:0000269|PubMed:10652228, ECO:0000269|PubMed:16257963, ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:18993068, ECO:0000269|PubMed:20333297}; DE EC=2.7.11.1 {ECO:0000269|PubMed:16257963, ECO:0000269|PubMed:18993068}; DE AltName: Full=Tyrosine kinase non-receptor protein 2; GN Name=TNK2; Synonyms=ACK1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH CDC42. RC TISSUE=Hippocampus; RX PubMed=8497321; DOI=10.1038/363364a0; RA Manser E., Leung T., Salihuddin H., Tan L., Lim L.; RT "A non-receptor tyrosine kinase that inhibits the GTPase activity of RT p21cdc42."; RL Nature 363:364-367(1993). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT LEU-725. RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain, and Uterus; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP INTERACTION WITH CSPG4. RX PubMed=10587647; DOI=10.1038/70302; RA Eisenmann K.M., McCarthy J.B., Simpson M.A., Keely P.J., Guan J.-L., RA Tachibana K., Lim L., Manser E., Furcht L.T., Iida J.; RT "Melanoma chondroitin sulphate proteoglycan regulates cell spreading RT through Cdc42, Ack-1 and p130cas."; RL Nat. Cell Biol. 1:507-513(1999). RN [6] RP FUNCTION AS MCF2 KINASE, CATALYTIC ACTIVITY, AND COFACTOR. RX PubMed=10652228; DOI=10.1006/bbrc.2000.2106; RA Kato J., Kaziro Y., Satoh T.; RT "Activation of the guanine nucleotide exchange factor Dbl following ACK1- RT dependent tyrosine phosphorylation."; RL Biochem. Biophys. Res. Commun. 268:141-147(2000). RN [7] RP FUNCTION. RX PubMed=11278436; DOI=10.1074/jbc.m008795200; RA Teo M., Tan L., Lim L., Manser E.; RT "The tyrosine kinase ACK1 associates with clathrin-coated vesicles through RT a binding motif shared by arrestin and other adaptors."; RL J. Biol. Chem. 276:18392-18398(2001). RN [8] RP SUBCELLULAR LOCATION. RX PubMed=14733946; DOI=10.1016/j.bbrc.2003.12.137; RA Ahmed I., Calle Y., Sayed M.A., Kamal J.M., Rengaswamy P., Manser E., RA Meiners S., Nur-E-Kamal A.; RT "Cdc42-dependent nuclear translocation of non-receptor tyrosine kinase, RT ACK."; RL Biochem. Biophys. Res. Commun. 314:571-579(2004). RN [9] RP AUTOPHOSPHORYLATION, INTERACTION WITH HSP90AB1; MTERK AND WWOX, AND RP MUTAGENESIS OF LYS-158 AND LEU-487. RX PubMed=16288044; DOI=10.1158/0008-5472.can-05-1127; RA Mahajan N.P., Whang Y.E., Mohler J.L., Earp H.S.; RT "Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of RT Ack1 in polyubiquitination of tumor suppressor Wwox."; RL Cancer Res. 65:10514-10523(2005). RN [10] RP INTERACTION WITH SNX9, AND SUBCELLULAR LOCATION. RX PubMed=16137687; DOI=10.1016/j.febslet.2005.07.093; RA Yeow-Fong L., Lim L., Manser E.; RT "SNX9 as an adaptor for linking synaptojanin-1 to the Cdc42 effector RT ACK1."; RL FEBS Lett. 579:5040-5048(2005). RN [11] RP FUNCTION AS WAS KINASE, INTERACTION WITH WASL, CATALYTIC ACTIVITY, AND RP COFACTOR. RX PubMed=16257963; DOI=10.1074/jbc.m506996200; RA Yokoyama N., Lougheed J., Miller W.T.; RT "Phosphorylation of WASP by the Cdc42-associated kinase ACK1: dual RT hydroxyamino acid specificity in a tyrosine kinase."; RL J. Biol. Chem. 280:42219-42226(2005). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=15592455; DOI=10.1038/nbt1046; RA Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H., RA Zha X.-M., Polakiewicz R.D., Comb M.J.; RT "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells."; RL Nat. Biotechnol. 23:94-101(2005). RN [13] RP FUNCTION, AND TISSUE SPECIFICITY. RX PubMed=16247015; DOI=10.1073/pnas.0508014102; RA van der Horst E.H., Degenhardt Y.Y., Strelow A., Slavin A., Chinn L., RA Orf J., Rong M., Li S., See L.-H., Nguyen K.Q.C., Hoey T., Wesche H., RA Powers S.; RT "Metastatic properties and genomic amplification of the tyrosine kinase RT gene ACK1."; RL Proc. Natl. Acad. Sci. U.S.A. 102:15901-15906(2005). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [15] RP FUNCTION IN CELL MIGRATION, AND INTERACTION WITH BCAR1; CDC42 AND CRK. RX PubMed=17038317; DOI=10.1074/jbc.m604342200; RA Modzelewska K., Newman L.P., Desai R., Keely P.J.; RT "Ack1 mediates Cdc42-dependent cell migration and signaling to p130Cas."; RL J. Biol. Chem. 281:37527-37535(2006). RN [16] RP FUNCTION, CATALYTIC ACTIVITY, AND PHOSPHORYLATION AT TYR-284. RX PubMed=16472662; DOI=10.1016/s0076-6879(06)06018-6; RA Yokoyama N., Miller W.T.; RT "Purification and enzyme activity of ACK1."; RL Methods Enzymol. 406:250-260(2006). RN [17] RP INTERACTION WITH AR. RX PubMed=17494760; DOI=10.1073/pnas.0700420104; RA Mahajan N.P., Liu Y., Majumder S., Warren M.R., Parker C.E., Mohler J.L., RA Earp H.S., Whang Y.E.; RT "Activated Cdc42-associated kinase Ack1 promotes prostate cancer RT progression via androgen receptor tyrosine phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 104:8438-8443(2007). RN [18] RP INTERACTION WITH NPHP1. RX PubMed=18477472; DOI=10.1016/j.bbrc.2008.05.016; RA Eley L., Moochhala S.H., Simms R., Hildebrandt F., Sayer J.A.; RT "Nephrocystin-1 interacts directly with Ack1 and is expressed in human RT collecting duct."; RL Biochem. Biophys. Res. Commun. 371:877-882(2008). RN [19] RP FUNCTION. RX PubMed=18435854; DOI=10.1186/bcr2087; RA Howlin J., Rosenkvist J., Andersson T.; RT "TNK2 preserves epidermal growth factor receptor expression on the cell RT surface and enhances migration and invasion of human breast cancer cells."; RL Breast Cancer Res. 10:R36-R36(2008). RN [20] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=18262180; DOI=10.1016/j.yexcr.2007.12.017; RA Groevdal L.M., Johannessen L.E., Roedland M.S., Madshus I.H., Stang E.; RT "Dysregulation of Ack1 inhibits down-regulation of the EGF receptor."; RL Exp. Cell Res. 314:1292-1300(2008). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-881, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [22] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [23] RP INTERACTION WITH NEDD4, AND UBIQUITINATION. RX PubMed=19144635; DOI=10.1074/jbc.m806877200; RA Chan W., Tian R., Lee Y.-F., Sit S.T., Lim L., Manser E.; RT "Down-regulation of active ACK1 is mediated by association with the E3 RT ubiquitin ligase Nedd4-2."; RL J. Biol. Chem. 284:8185-8194(2009). RN [24] RP FUNCTION, AND INTERACTION WITH AXL; LTK; PDGFRL AND GRB2. RX PubMed=19815557; DOI=10.1074/jbc.m109.072660; RA Pao-Chun L., Chan P.M., Chan W., Manser E.; RT "Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is RT mediated by Grb2: an analysis of ACK1 effects on Axl signaling."; RL J. Biol. Chem. 284:34954-34963(2009). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-284 AND SER-724, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [26] RP SUBUNIT, SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-284, AND DOMAIN RP SAM-LIKE. RX PubMed=20979614; DOI=10.1186/1471-2091-11-42; RA Prieto-Echaguee V., Gucwa A., Brown D.A., Miller W.T.; RT "Regulation of Ack1 localization and activity by the amino-terminal SAM RT domain."; RL BMC Biochem. 11:42-42(2010). RN [27] RP FUNCTION, SUBCELLULAR LOCATION, VARIANTS LEU-34; GLN-99; LYS-346 AND RP ILE-409, CHARACTERIZATION OF VARIANTS LEU-34; GLN-99; LYS-346 AND ILE-409, RP AND MUTAGENESIS OF LEU-120; LEU-197 AND VAL-365. RX PubMed=20110370; DOI=10.1074/jbc.m109.060459; RA Prieto-Echaguee V., Gucwa A., Craddock B.P., Brown D.A., Miller W.T.; RT "Cancer-associated mutations activate the nonreceptor tyrosine kinase RT Ack1."; RL J. Biol. Chem. 285:10605-10615(2010). RN [28] RP FUNCTION AS AR KINASE, AND ACTIVITY REGULATION. RX PubMed=20383201; DOI=10.1038/onc.2010.103; RA Liu Y., Karaca M., Zhang Z., Gioeli D., Earp H.S., Whang Y.E.; RT "Dasatinib inhibits site-specific tyrosine phosphorylation of androgen RT receptor by Ack1 and Src kinases."; RL Oncogene 29:3208-3216(2010). RN [29] RP FUNCTION, CATALYTIC ACTIVITY, COFACTOR, INTERACTION WITH AKT1, SUBCELLULAR RP LOCATION, CHARACTERIZATION OF VARIANT LYS-346, PHOSPHORYLATION AT TYR-284, RP AND TISSUE SPECIFICITY. RX PubMed=20333297; DOI=10.1371/journal.pone.0009646; RA Mahajan K., Coppola D., Challa S., Fang B., Chen Y.A., Zhu W., Lopez A.S., RA Koomen J., Engelman R.W., Rivera C., Muraoka-Cook R.S., Cheng J.Q., RA Schoenbrunn E., Sebti S.M., Earp H.S., Mahajan N.P.; RT "Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its RT activation."; RL PLoS ONE 5:E9646-E9646(2010). RN [30] RP PHOSPHORYLATION AT TYR-284, TISSUE SPECIFICITY, AND ACTIVITY REGULATION. RX PubMed=20623637; DOI=10.1002/pros.21163; RA Mahajan K., Challa S., Coppola D., Lawrence H., Luo Y., Gevariya H., RA Zhu W., Chen Y.A., Lawrence N.J., Mahajan N.P.; RT "Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen RT receptor activity."; RL Prostate 70:1274-1285(2010). RN [31] RP PHOSPHORYLATION AT TYR-284, AND INTERACTION WITH SRC. RX PubMed=21309750; DOI=10.1042/bj20102156; RA Chan W., Sit S.T., Manser E.; RT "The Cdc42-associated kinase ACK1 is not auto-inhibited but requires Src RT for activation."; RL Biochem. J. 435:355-364(2011). RN [32] RP SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT TYR-284; TYR-518; TYR-827; RP TYR-859 AND TYR-872. RX PubMed=21169560; DOI=10.1091/mbc.e10-07-0637; RA Shen H., Ferguson S.M., Dephoure N., Park R., Yang Y., Volpicelli-Daley L., RA Gygi S., Schlessinger J., De Camilli P.; RT "Constitutive activated Cdc42-associated kinase (Ack) phosphorylation at RT arrested endocytic clathrin-coated pits of cells that lack dynamin."; RL Mol. Biol. Cell 22:493-502(2011). RN [33] RP REVIEW ON TUMOR GROWTH. RX PubMed=20432460; DOI=10.1002/jcp.22162; RA Mahajan K., Mahajan N.P.; RT "Shepherding AKT and androgen receptor by Ack1 tyrosine kinase."; RL J. Cell. Physiol. 224:327-333(2010). RN [34] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [35] RP STRUCTURE BY NMR OF 448-489. RX PubMed=10360579; DOI=10.1038/20732; RA Mott H.R., Owen D., Nietlispach D., Lowe P.N., Manser E., Lim L., RA Laue E.D.; RT "Structure of the small G protein Cdc42 bound to the GTPase-binding domain RT of ACK."; RL Nature 399:384-388(1999). RN [36] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 107-395, AND PHOSPHORYLATION AT RP TYR-284. RX PubMed=15308621; DOI=10.1074/jbc.m406703200; RA Lougheed J.C., Chen R.-H., Mak P., Stout T.J.; RT "Crystal structures of the phosphorylated and unphosphorylated kinase RT domains of the Cdc42-associated tyrosine kinase ACK1."; RL J. Biol. Chem. 279:44039-44045(2004). RN [37] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 117-392 IN COMPLEX WITH INHIBITOR, RP AND CATALYTIC ACTIVITY. RX PubMed=18993068; DOI=10.1016/j.bmcl.2008.10.092; RA Kopecky D.J., Hao X., Chen Y., Fu J., Jiao X., Jaen J.C., Cardozo M.G., RA Liu J., Wang Z., Walker N.P., Wesche H., Li S., Farrelly E., Xiao S.H., RA Kayser F.; RT "Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4- RT d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors."; RL Bioorg. Med. Chem. Lett. 18:6352-6356(2008). RN [38] RP VARIANTS LEU-34; ARG-71; GLN-99; TRP-99; MET-152; LYS-346; ILE-409; RP SER-507; LEU-725; GLN-748 AND HIS-1038. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [39] RP VARIANT MET-638, INTERACTION WITH NEDD4 AND NEDD4L, AND CHARACTERIZATION OF RP VARIANT MET-638. RX PubMed=23686771; DOI=10.1002/ana.23934; RA Hitomi Y., Heinzen E.L., Donatello S., Dahl H.H., Damiano J.A., RA McMahon J.M., Berkovic S.F., Scheffer I.E., Legros B., Rai M., RA Weckhuysen S., Suls A., De Jonghe P., Pandolfo M., Goldstein D.B., RA Van Bogaert P., Depondt C.; RT "Mutations in TNK2 in severe autosomal recessive infantile onset RT epilepsy."; RL Ann. Neurol. 74:496-501(2013). CC -!- FUNCTION: Non-receptor tyrosine-protein and serine/threonine-protein CC kinase that is implicated in cell spreading and migration, cell CC survival, cell growth and proliferation. Transduces extracellular CC signals to cytosolic and nuclear effectors. Phosphorylates AKT1, AR, CC MCF2, WASL and WWOX. Implicated in trafficking and clathrin-mediated CC endocytosis through binding to epidermal growth factor receptor (EGFR) CC and clathrin. Binds to both poly- and mono-ubiquitin and regulates CC ligand-induced degradation of EGFR, thereby contributing to the CC accumulation of EGFR at the limiting membrane of early endosomes. CC Downstream effector of CDC42 which mediates CDC42-dependent cell CC migration via phosphorylation of BCAR1. May be involved both in adult CC synaptic function and plasticity and in brain development. Activates CC AKT1 by phosphorylating it on 'Tyr-176'. Phosphorylates AR on 'Tyr-267' CC and 'Tyr-363' thereby promoting its recruitment to androgen-responsive CC enhancers (AREs). Phosphorylates WWOX on 'Tyr-287'. Phosphorylates CC MCF2, thereby enhancing its activity as a guanine nucleotide exchange CC factor (GEF) toward Rho family proteins. Contributes to the control of CC AXL receptor levels. Confers metastatic properties on cancer cells and CC promotes tumor growth by negatively regulating tumor suppressor such as CC WWOX and positively regulating pro-survival factors such as AKT1 and CC AR. Phosphorylates WASP (PubMed:20110370). CC {ECO:0000269|PubMed:10652228, ECO:0000269|PubMed:11278436, CC ECO:0000269|PubMed:16247015, ECO:0000269|PubMed:16257963, CC ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:17038317, CC ECO:0000269|PubMed:18262180, ECO:0000269|PubMed:18435854, CC ECO:0000269|PubMed:19815557, ECO:0000269|PubMed:20110370, CC ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20383201}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:10652228, ECO:0000269|PubMed:16257963, CC ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:18993068, CC ECO:0000269|PubMed:20333297}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:16257963, ECO:0000269|PubMed:18993068}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:16257963, ECO:0000269|PubMed:18993068}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:10652228, ECO:0000269|PubMed:16257963, CC ECO:0000269|PubMed:20333297}; CC -!- ACTIVITY REGULATION: Inhibited by AIM-100 (4-amino-5,6-biaryl-furo[2,3- CC d]pyrimidine), which suppresses activating phosphorylation at Tyr-284. CC Repressed by dasatinib. {ECO:0000269|PubMed:20383201, CC ECO:0000269|PubMed:20623637}. CC -!- SUBUNIT: Interacts with NEDD4 (via WW3 domain). NEDD4L and EGF promote CC association with NEDD4 (By similarity). Homodimer. Interacts with AR, CC CDC42, WWASL and WWOX. Interacts with CSPG4 (activated). Interacts with CC MERTK (activated); stimulates autophosphorylation. May interact CC (phosphorylated) with HSP90AB1; maintains kinase activity. Interacts CC with NPHP1. Interacts with SNX9 (via SH3 domain). Interacts with SRC CC (via SH2 and SH3 domain). Interacts with EGFR, and this interaction is CC dependent on EGF stimulation and kinase activity of EGFR. Interacts CC (via kinase domain) with AKT1. Part of a collagen stimulated complex CC involved in cell migration composed of CDC42, CRK, TNK2 and CC BCAR1/p130cas. Interacts with BCAR1/p130cas via SH3 domains. Forms CC complexes with GRB2 and numerous receptor tyrosine kinases (RTK) CC including LTK, AXL or PDGFRL, in which GRB2 promotes RTK recruitment by CC TNK2. {ECO:0000250, ECO:0000269|PubMed:10587647, CC ECO:0000269|PubMed:16137687, ECO:0000269|PubMed:16257963, CC ECO:0000269|PubMed:16288044, ECO:0000269|PubMed:17038317, CC ECO:0000269|PubMed:17494760, ECO:0000269|PubMed:18477472, CC ECO:0000269|PubMed:18993068, ECO:0000269|PubMed:19144635, CC ECO:0000269|PubMed:19815557, ECO:0000269|PubMed:20333297, CC ECO:0000269|PubMed:20979614, ECO:0000269|PubMed:21309750, CC ECO:0000269|PubMed:23686771, ECO:0000269|PubMed:8497321}. CC -!- INTERACTION: CC Q07912; P29972: AQP1; NbExp=3; IntAct=EBI-603457, EBI-745213; CC Q07912; P56945: BCAR1; NbExp=5; IntAct=EBI-603457, EBI-702093; CC Q07912; P60953-2: CDC42; NbExp=2; IntAct=EBI-603457, EBI-287394; CC Q07912; Q00610: CLTC; NbExp=3; IntAct=EBI-603457, EBI-354967; CC Q07912; P07902: GALT; NbExp=3; IntAct=EBI-603457, EBI-750827; CC Q07912; P62993: GRB2; NbExp=6; IntAct=EBI-603457, EBI-401755; CC Q07912; P08238: HSP90AB1; NbExp=3; IntAct=EBI-603457, EBI-352572; CC Q07912; P16333: NCK1; NbExp=4; IntAct=EBI-603457, EBI-389883; CC Q07912; Q9HC98: NEK6; NbExp=3; IntAct=EBI-603457, EBI-740364; CC Q07912; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-603457, EBI-945833; CC Q07912; O60880: SH2D1A; NbExp=3; IntAct=EBI-603457, EBI-6983382; CC Q07912; Q9Y5X1: SNX9; NbExp=4; IntAct=EBI-603457, EBI-77848; CC Q07912; Q07912: TNK2; NbExp=2; IntAct=EBI-603457, EBI-603457; CC Q07912-2; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-11994780, EBI-3867333; CC Q07912-2; Q9BQC3: DPH2; NbExp=3; IntAct=EBI-11994780, EBI-10237931; CC Q07912-2; P07902: GALT; NbExp=3; IntAct=EBI-11994780, EBI-750827; CC Q07912-2; Q92569: PIK3R3; NbExp=3; IntAct=EBI-11994780, EBI-79893; CC Q07912-2; O60880: SH2D1A; NbExp=3; IntAct=EBI-11994780, EBI-6983382; CC Q07912-2; O14796: SH2D1B; NbExp=3; IntAct=EBI-11994780, EBI-3923013; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:20333297, CC ECO:0000269|PubMed:20979614}. Nucleus {ECO:0000269|PubMed:14733946, CC ECO:0000269|PubMed:20333297}. Endosome {ECO:0000250|UniProtKB:O54967}. CC Cell junction, adherens junction {ECO:0000305}. Cytoplasmic vesicle CC membrane; Peripheral membrane protein; Cytoplasmic side CC {ECO:0000269|PubMed:16137687}. Cytoplasmic vesicle, clathrin-coated CC vesicle {ECO:0000269|PubMed:16137687, ECO:0000269|PubMed:18262180}. CC Membrane, clathrin-coated pit {ECO:0000269|PubMed:21169560}. Cytoplasm, CC perinuclear region {ECO:0000269|PubMed:20110370}. Cytoplasm, cytosol CC {ECO:0000250|UniProtKB:O54967}. Note=The Tyr-284 phosphorylated form is CC found both in the membrane and nucleus (By similarity). Co-localizes CC with EGFR on endosomes (PubMed:20333297). Nuclear translocation is CC CDC42-dependent (By similarity). Detected in long filamentous cytosolic CC structures where it co-localizes with CTPS1 (By similarity). CC {ECO:0000250|UniProtKB:O54967, ECO:0000269|PubMed:20333297}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q07912-1; Sequence=Displayed; CC Name=2; CC IsoId=Q07912-2; Sequence=VSP_008655, VSP_008656; CC Name=3; CC IsoId=Q07912-3; Sequence=VSP_037284, VSP_037285, VSP_037286; CC -!- TISSUE SPECIFICITY: The Tyr-284 phosphorylated form shows a significant CC increase in expression in breast cancers during the progressive stages CC i.e. normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS), CC invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM) CC stages. It also shows a significant increase in expression in prostate CC cancers during the progressive stages. {ECO:0000269|PubMed:16247015, CC ECO:0000269|PubMed:20333297, ECO:0000269|PubMed:20623637}. CC -!- DOMAIN: The EBD (EGFR-binding domain) domain is necessary for CC interaction with EGFR. {ECO:0000250}. CC -!- DOMAIN: The SAM-like domain is necessary for NEDD4-mediated CC ubiquitination. Promotes membrane localization and dimerization to CC allow for autophosphorylation. {ECO:0000269|PubMed:20979614}. CC -!- DOMAIN: The UBA domain binds both poly- and mono-ubiquitin. CC {ECO:0000269|PubMed:20979614}. CC -!- PTM: Autophosphorylation regulates kinase activity. Phosphorylation on CC Tyr-518 is required for interaction with SRC and is observed during CC association with clathrin-coated pits. {ECO:0000269|PubMed:15308621, CC ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:20333297, CC ECO:0000269|PubMed:20623637, ECO:0000269|PubMed:20979614, CC ECO:0000269|PubMed:21169560, ECO:0000269|PubMed:21309750}. CC -!- PTM: Polyubiquitinated by NEDD4 and NEDD4L. Degradation can be induced CC by EGF and is lysosome-dependent (By similarity). {ECO:0000250}. CC -!- MISCELLANEOUS: [Isoform 2]: May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH08884.1; Type=Miscellaneous discrepancy; Note=Unlikely isoform. Aberrant splice sites.; Evidence={ECO:0000305}; CC Sequence=BAD18675.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L13738; AAA53570.2; -; mRNA. DR EMBL; AK131539; BAD18675.1; ALT_INIT; mRNA. DR EMBL; AC124944; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC008884; AAH08884.1; ALT_SEQ; mRNA. DR EMBL; BC028164; AAH28164.1; -; mRNA. DR CCDS; CCDS33927.2; -. [Q07912-3] DR CCDS; CCDS33928.1; -. [Q07912-1] DR PIR; S33596; S33596. DR RefSeq; NP_001010938.2; NM_001010938.2. [Q07912-3] DR RefSeq; NP_001294975.1; NM_001308046.1. DR RefSeq; NP_001374642.1; NM_001387713.1. [Q07912-1] DR RefSeq; NP_001374643.1; NM_001387714.1. [Q07912-1] DR RefSeq; NP_005772.3; NM_005781.4. [Q07912-1] DR RefSeq; XP_047303107.1; XM_047447151.1. [Q07912-1] DR RefSeq; XP_047303116.1; XM_047447160.1. [Q07912-1] DR RefSeq; XP_054200839.1; XM_054344864.1. [Q07912-1] DR RefSeq; XP_054200851.1; XM_054344876.1. [Q07912-1] DR PDB; 1CF4; NMR; -; B=448-489. DR PDB; 1U46; X-ray; 2.00 A; A/B=109-395. DR PDB; 1U4D; X-ray; 2.10 A; A/B=109-395. DR PDB; 1U54; X-ray; 2.80 A; A/B=109-395. DR PDB; 3EQP; X-ray; 2.30 A; A/B=117-392. DR PDB; 3EQR; X-ray; 2.00 A; A/B=117-392. DR PDB; 4EWH; X-ray; 2.50 A; A/B=117-391. DR PDB; 4HZR; X-ray; 1.31 A; A/B=115-389. DR PDB; 4HZS; X-ray; 3.23 A; A/B/C/D=115-453. DR PDB; 4ID7; X-ray; 3.00 A; A=117-389. DR PDB; 5ZXB; X-ray; 2.20 A; A/B=117-391. DR PDB; 6VQM; X-ray; 2.87 A; A/B=109-395. DR PDB; 7KP6; X-ray; 1.79 A; A/B=110-391. DR PDB; 8FE9; X-ray; 3.20 A; A=110-391. DR PDB; 8FZ3; X-ray; 2.78 A; A/B/C/D=958-1038. DR PDB; 8HMT; X-ray; 3.17 A; A/B/C/D=117-389. DR PDB; 8Q5P; X-ray; 1.81 A; B=508-519. DR PDB; 8THA; X-ray; 1.68 A; A=954-1038. DR PDBsum; 1CF4; -. DR PDBsum; 1U46; -. DR PDBsum; 1U4D; -. DR PDBsum; 1U54; -. DR PDBsum; 3EQP; -. DR PDBsum; 3EQR; -. DR PDBsum; 4EWH; -. DR PDBsum; 4HZR; -. DR PDBsum; 4HZS; -. DR PDBsum; 4ID7; -. DR PDBsum; 5ZXB; -. DR PDBsum; 6VQM; -. DR PDBsum; 7KP6; -. DR PDBsum; 8FE9; -. DR PDBsum; 8FZ3; -. DR PDBsum; 8HMT; -. DR PDBsum; 8Q5P; -. DR PDBsum; 8THA; -. DR AlphaFoldDB; Q07912; -. DR SMR; Q07912; -. DR BioGRID; 115485; 135. DR CORUM; Q07912; -. DR DIP; DIP-33858N; -. DR FunCoup; Q07912; 728. DR IntAct; Q07912; 73. DR MINT; Q07912; -. DR STRING; 9606.ENSP00000371341; -. DR BindingDB; Q07912; -. DR ChEMBL; CHEMBL4599; -. DR DrugBank; DB18236; (R)-9b. DR DrugBank; DB00171; ATP. DR DrugBank; DB04367; Debromohymenialdisine. DR DrugBank; DB11986; Entrectinib. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q07912; -. DR GuidetoPHARMACOLOGY; 2246; -. DR GlyCosmos; Q07912; 2 sites, 1 glycan. DR GlyGen; Q07912; 6 sites, 1 O-linked glycan (5 sites). DR iPTMnet; Q07912; -. DR PhosphoSitePlus; Q07912; -. DR BioMuta; TNK2; -. DR DMDM; 229462980; -. DR CPTAC; CPTAC-1779; -. DR CPTAC; CPTAC-2789; -. DR jPOST; Q07912; -. DR MassIVE; Q07912; -. DR PaxDb; 9606-ENSP00000371341; -. DR PeptideAtlas; Q07912; -. DR ProteomicsDB; 58556; -. [Q07912-1] DR ProteomicsDB; 58557; -. [Q07912-2] DR ProteomicsDB; 58558; -. [Q07912-3] DR Pumba; Q07912; -. DR Antibodypedia; 4095; 764 antibodies from 40 providers. DR CPTC; Q07912; 5 antibodies. DR DNASU; 10188; -. DR Ensembl; ENST00000333602.14; ENSP00000329425.6; ENSG00000061938.22. [Q07912-1] DR Ensembl; ENST00000439230.6; ENSP00000395588.1; ENSG00000061938.22. [Q07912-2] DR Ensembl; ENST00000671753.1; ENSP00000499858.1; ENSG00000061938.22. [Q07912-3] DR GeneID; 10188; -. DR KEGG; hsa:10188; -. DR UCSC; uc003fvt.2; human. [Q07912-1] DR AGR; HGNC:19297; -. DR ClinPGx; PA134909759; -. DR CTD; 10188; -. DR DisGeNET; 10188; -. DR GeneCards; TNK2; -. DR HGNC; HGNC:19297; TNK2. DR HPA; ENSG00000061938; Low tissue specificity. DR MalaCards; TNK2; -. DR MIM; 606994; gene. DR OpenTargets; ENSG00000061938; -. DR Orphanet; 391316; Infantile-onset mesial temporal lobe epilepsy with severe cognitive regression. DR VEuPathDB; HostDB:ENSG00000061938; -. DR eggNOG; KOG0199; Eukaryota. DR GeneTree; ENSGT00940000160853; -. DR HOGENOM; CLU_000288_7_39_1; -. DR InParanoid; Q07912; -. DR OrthoDB; 635774at2759; -. DR PAN-GO; Q07912; 6 GO annotations based on evolutionary models. DR PhylomeDB; Q07912; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; Q07912; -. DR Reactome; R-HSA-9842663; Signaling by LTK. DR SignaLink; Q07912; -. DR SIGNOR; Q07912; -. DR Agora; ENSG00000061938; -. DR BioGRID-ORCS; 10188; 11 hits in 1191 CRISPR screens. DR ChiTaRS; TNK2; human. DR EvolutionaryTrace; Q07912; -. DR GeneWiki; TNK2; -. DR GenomeRNAi; 10188; -. DR Pharos; Q07912; Tclin. DR PRO; PR:Q07912; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q07912; protein. DR Bgee; ENSG00000061938; Expressed in right hemisphere of cerebellum and 192 other cell types or tissues. DR ExpressionAtlas; Q07912; baseline and differential. DR GO; GO:0005912; C:adherens junction; IEA:UniProtKB-SubCell. DR GO; GO:0005905; C:clathrin-coated pit; IDA:UniProtKB. DR GO; GO:0030136; C:clathrin-coated vesicle; IDA:UniProtKB. DR GO; GO:0097268; C:cytoophidium; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005768; C:endosome; ISS:UniProtKB. DR GO; GO:0070436; C:Grb2-EGFR complex; IDA:BHF-UCL. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005154; F:epidermal growth factor receptor binding; IDA:BHF-UCL. DR GO; GO:0005095; F:GTPase inhibitor activity; TAS:ProtInc. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; TAS:ProtInc. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB. DR GO; GO:0050699; F:WW domain binding; ISS:BHF-UCL. DR GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:UniProtKB. DR GO; GO:0006897; P:endocytosis; IEA:UniProtKB-KW. DR GO; GO:0016310; P:phosphorylation; IDA:UniProtKB. DR GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:2000369; P:regulation of clathrin-dependent endocytosis; IDA:UniProtKB. DR GO; GO:0007264; P:small GTPase-mediated signal transduction; TAS:ProtInc. DR CDD; cd05040; PTKc_Ack_like; 1. DR CDD; cd09539; SAM_TNK-like; 1. DR CDD; cd14274; UBA_ACK1; 1. DR CDD; cd14328; UBA_TNK1; 1. DR DisProt; DP01772; -. DR FunFam; 4.10.680.10:FF:000001; activated CDC42 kinase 1 isoform X1; 1. DR FunFam; 1.10.510.10:FF:000080; Putative activated CDC42 kinase 1; 1. DR FunFam; 3.30.200.20:FF:000107; Putative activated CDC42 kinase 1; 1. DR Gene3D; 4.10.680.10; Cdc42-like binding domain; 1. DR Gene3D; 1.10.8.10; DNA helicase RuvA subunit, C-terminal domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00276; -. DR InterPro; IPR055175; ACK/TNK-like_SAM. DR InterPro; IPR030220; Ack1_UBA_dom. DR InterPro; IPR015116; Cdc42-bd-like. DR InterPro; IPR037085; Cdc42-bd-like_dom_sf. DR InterPro; IPR052112; EGFR_SigReg_Kinase. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR021619; Mig-6. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR036028; SH3-like_dom_sf. DR InterPro; IPR001452; SH3_domain. DR InterPro; IPR049587; TNK-like_SAM. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR14254; GENE 33 POLYPEPTIDE; 1. DR PANTHER; PTHR14254:SF6; NON-SPECIFIC PROTEIN-TYROSINE KINASE; 1. DR Pfam; PF09027; GTPase_binding; 1. DR Pfam; PF11555; Inhibitor_Mig-6; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF22931; SAM_TNK; 1. DR Pfam; PF14604; SH3_9; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00326; SH3; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF50044; SH3-domain; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS50002; SH3; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell junction; KW Cell membrane; Coated pit; Cytoplasm; Cytoplasmic vesicle; Endocytosis; KW Endosome; Kinase; Magnesium; Membrane; Metal-binding; Methylation; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; SH3 domain; KW Transferase; Tyrosine-protein kinase; Ubl conjugation. FT CHAIN 1..1038 FT /note="Activated CDC42 kinase 1" FT /id="PRO_0000088058" FT DOMAIN 126..385 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 388..448 FT /note="SH3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00192" FT DOMAIN 454..466 FT /note="CRIB" FT DOMAIN 958..996 FT /note="UBA" FT REGION 1..110 FT /note="SAM-like domain" FT REGION 90..114 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 497..535 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 623..652 FT /note="Required for interaction with SRC" FT /evidence="ECO:0000269|PubMed:21309750" FT REGION 632..635 FT /note="Required for interaction with NEDD4" FT /evidence="ECO:0000250" FT REGION 659..702 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 718..840 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 733..876 FT /note="EBD domain" FT /evidence="ECO:0000250" FT REGION 917..957 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 738..749 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 772..783 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 794..805 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 252 FT /note="Proton acceptor" FT BINDING 132..140 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 158 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT MOD_RES 284 FT /note="Phosphotyrosine; by SRC and autocatalysis" FT /evidence="ECO:0000269|PubMed:15308621, FT ECO:0000269|PubMed:16472662, ECO:0000269|PubMed:20333297, FT ECO:0000269|PubMed:20623637, ECO:0000269|PubMed:20979614, FT ECO:0000269|PubMed:21169560, ECO:0000269|PubMed:21309750, FT ECO:0007744|PubMed:19369195" FT MOD_RES 518 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:21169560" FT MOD_RES 724 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 827 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:21169560" FT MOD_RES 839 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:O54967" FT MOD_RES 859 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:21169560" FT MOD_RES 872 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:21169560" FT MOD_RES 881 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT VAR_SEQ 1 FT /note="M -> MGERSAYQRLAGGEEGPQRLGGGRM (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_037284" FT VAR_SEQ 485..528 FT /note="LYLGNPMDPPDLLSVELSTSRPPQHLGGVKKPTYDPVSEDQDPL -> CPFS FT AFSPGHPPAETCGQVLWTGRREACASDPRLHPVSSRTKGL (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_008655" FT VAR_SEQ 514 FT /note="K -> KREPPPRPPQPAFFTQ (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_037285" FT VAR_SEQ 529..1038 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_008656" FT VAR_SEQ 965..994 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_037286" FT VARIANT 34 FT /note="R -> L (in a lung adenocarcinoma sample; somatic FT mutation; increased autophosphorylation at Y-284; increased FT function in phosphorylation of peptide substrates; no FT effect on subcellular localization to perinuclear region)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:20110370" FT /id="VAR_032792" FT VARIANT 71 FT /note="K -> R (in dbSNP:rs56036945)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032793" FT VARIANT 99 FT /note="R -> Q (in an ovarian mucinous carcinoma sample; FT somatic mutation; increased autophosphorylation at Y-284; FT increased function in phosphorylation of peptide substrates FT and WASP; no effect on subcellular localization to FT perinuclear region; dbSNP:rs113498671)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:20110370" FT /id="VAR_032794" FT VARIANT 99 FT /note="R -> W (in dbSNP:rs3747673)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032795" FT VARIANT 152 FT /note="T -> M (in dbSNP:rs56161912)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032796" FT VARIANT 346 FT /note="E -> K (in an ovarian endometrioid cancer sample; FT somatic mutation; undergoes autoactivation and causes FT phosphorylation on Y-284 leading to activation of AKT1; FT increased autophosphorylation at Y-284; increased function FT in phosphorylation of peptide substrates and WASP; no FT effect on catalytic activity itself as the purified kinase FT domain has activity in vitro comparable to wild-type FT protein; no effect on subcellular localization to FT perinuclear region; dbSNP:rs970946035)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:20110370, ECO:0000269|PubMed:20333297" FT /id="VAR_032797" FT VARIANT 409 FT /note="M -> I (in a gastric adenocarcinoma sample; somatic FT mutation; increased autophosphorylation at Y-284; increased FT function in phosphorylation of peptide substrates and WASP; FT no effect on subcellular localization to perinuclear FT region)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:20110370" FT /id="VAR_032798" FT VARIANT 507 FT /note="P -> S (in dbSNP:rs35759128)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032799" FT VARIANT 638 FT /note="V -> M (found in patients with childhood-onset FT epilepsy; uncertain significance; loss of interaction with FT NEDD4 and NEDD4L; increased protein abundance; FT dbSNP:rs201407161)" FT /evidence="ECO:0000269|PubMed:23686771" FT /id="VAR_076966" FT VARIANT 725 FT /note="P -> L (in dbSNP:rs56260729)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:17344846" FT /id="VAR_032800" FT VARIANT 748 FT /note="R -> Q (in dbSNP:rs57872314)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032801" FT VARIANT 802 FT /note="P -> L (in dbSNP:rs3749333)" FT /id="VAR_057115" FT VARIANT 1038 FT /note="R -> H (in dbSNP:rs13433937)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032802" FT MUTAGEN 120 FT /note="L->Q: No effect on autophosphorylation at Y-284." FT /evidence="ECO:0000269|PubMed:20110370" FT MUTAGEN 158 FT /note="K->R: Loss of autophosphorylation at Y-284." FT /evidence="ECO:0000269|PubMed:16288044, FT ECO:0000269|PubMed:20110370" FT MUTAGEN 197 FT /note="L->Q: No effect on autophosphorylation at Y-284." FT /evidence="ECO:0000269|PubMed:20110370" FT MUTAGEN 365 FT /note="V->R: Increased autophosphorylation at Y-284." FT /evidence="ECO:0000269|PubMed:20110370" FT MUTAGEN 487 FT /note="L->F: Constantly active kinase." FT /evidence="ECO:0000269|PubMed:16288044" FT CONFLICT 138 FT /note="G -> V (in Ref. 4; AAH08884)" FT /evidence="ECO:0000305" FT CONFLICT 304..352 FT /note="TRTFSHASDTWMFGVTLWEMFTYGQEPWIGLNGSQILHKIDKEGERLPR -> FT PPWRDISASSSTQFPHAVPCFPTSLLAKLLLRHSVPASSREIKLVSILC (in Ref. FT 4; AAH08884)" FT /evidence="ECO:0000305" FT CONFLICT 353..1038 FT /note="Missing (in Ref. 4; AAH08884)" FT /evidence="ECO:0000305" FT CONFLICT 586 FT /note="A -> P (in Ref. 1; AAA53570)" FT /evidence="ECO:0000305" FT CONFLICT 722 FT /note="Missing (in Ref. 1; AAA53570)" FT /evidence="ECO:0000305" FT CONFLICT 838..840 FT /note="PRA -> AG (in Ref. 1; AAA53570)" FT /evidence="ECO:0000305" FT STRAND 118..120 FT /evidence="ECO:0007829|PDB:4HZS" FT HELIX 123..125 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 126..133 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 140..146 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 148..150 FT /evidence="ECO:0007829|PDB:3EQP" FT STRAND 152..159 FT /evidence="ECO:0007829|PDB:4HZR" FT TURN 164..166 FT /evidence="ECO:0007829|PDB:3EQR" FT HELIX 171..181 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 192..196 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 198..200 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 202..206 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 209..212 FT /evidence="ECO:0007829|PDB:8FE9" FT HELIX 213..219 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 221..223 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 226..245 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 255..257 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 258..262 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 265..268 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 273..276 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 283..285 FT /evidence="ECO:0007829|PDB:1U46" FT HELIX 288..290 FT /evidence="ECO:0007829|PDB:3EQP" FT HELIX 294..296 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 299..304 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 306..308 FT /evidence="ECO:0007829|PDB:1U46" FT HELIX 309..324 FT /evidence="ECO:0007829|PDB:4HZR" FT TURN 325..327 FT /evidence="ECO:0007829|PDB:4HZS" FT TURN 330..333 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 336..344 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 358..367 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 372..374 FT /evidence="ECO:0007829|PDB:4HZR" FT HELIX 378..387 FT /evidence="ECO:0007829|PDB:4HZR" FT STRAND 392..394 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 402..404 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 412..417 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 419..421 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 423..432 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 435..439 FT /evidence="ECO:0007829|PDB:4HZS" FT HELIX 440..443 FT /evidence="ECO:0007829|PDB:4HZS" FT STRAND 449..451 FT /evidence="ECO:0007829|PDB:1CF4" FT TURN 484..486 FT /evidence="ECO:0007829|PDB:1CF4" SQ SEQUENCE 1038 AA; 114569 MW; 74A1980665BC3E6B CRC64; MQPEEGTGWL LELLSEVQLQ QYFLRLRDDL NVTRLSHFEY VKNEDLEKIG MGRPGQRRLW EAVKRRKALC KRKSWMSKVF SGKRLEAEFP PHHSQSTFRK TSPAPGGPAG EGPLQSLTCL IGEKDLRLLE KLGDGSFGVV RRGEWDAPSG KTVSVAVKCL KPDVLSQPEA MDDFIREVNA MHSLDHRNLI RLYGVVLTPP MKMVTELAPL GSLLDRLRKH QGHFLLGTLS RYAVQVAEGM GYLESKRFIH RDLAARNLLL ATRDLVKIGD FGLMRALPQN DDHYVMQEHR KVPFAWCAPE SLKTRTFSHA SDTWMFGVTL WEMFTYGQEP WIGLNGSQIL HKIDKEGERL PRPEDCPQDI YNVMVQCWAH KPEDRPTFVA LRDFLLEAQP TDMRALQDFE EPDKLHIQMN DVITVIEGRA ENYWWRGQNT RTLCVGPFPR NVVTSVAGLS AQDISQPLQN SFIHTGHGDS DPRHCWGFPD RIDELYLGNP MDPPDLLSVE LSTSRPPQHL GGVKKPTYDP VSEDQDPLSS DFKRLGLRKP GLPRGLWLAK PSARVPGTKA SRGSGAEVTL IDFGEEPVVP ALRPCAPSLA QLAMDACSLL DETPPQSPTR ALPRPLHPTP VVDWDARPLP PPPAYDDVAQ DEDDFEICSI NSTLVGAGVP AGPSQGQTNY AFVPEQARPP PPLEDNLFLP PQGGGKPPSS AQTAEIFQAL QQECMRQLQA PAGSPAPSPS PGGDDKPQVP PRVPIPPRPT RPHVQLSPAP PGEEETSQWP GPASPPRVPP REPLSPQGSR TPSPLVPPGS SPLPPRLSSS PGKTMPTTQS FASDPKYATP QVIQAPGPRA GPCILPIVRD GKKVSSTHYY LLPERPSYLE RYQRFLREAQ SPEEPTPLPV PLLLPPPSTP APAAPTATVR PMPQAALDPK ANFSTNNSNP GARPPPPRAT ARLPQRGCPG DGPEAGRPAD KIQMAMVHGV TTEECQAALQ CHGWSVQRAA QYLKVEQLFG LGLRPRGECH KVLEMFDWNL EQAGCHLLGS WGPAHHKR // ID AGRF1_HUMAN Reviewed; 910 AA. AC Q5T601; Q5KU15; Q5T5Z9; Q5T600; Q86SM1; Q8IXE3; Q8IZF8; Q96DQ1; Q9H615; DT 01-MAR-2005, integrated into UniProtKB/Swiss-Prot. DT 10-AUG-2010, sequence version 2. DT 28-JAN-2026, entry version 170. DE RecName: Full=Adhesion G-protein coupled receptor F1 {ECO:0000303|PubMed:25713288}; DE AltName: Full=G protein-coupled receptor 110 {ECO:0000303|PubMed:20149256}; DE AltName: Full=G protein-coupled receptor KPG_012; DE Contains: DE RecName: Full=Adhesion G-protein coupled receptor F1, N-terminal fragment {ECO:0000305}; DE Short=ADGRF1 N-terminal fragment {ECO:0000305}; DE Contains: DE RecName: Full=Adhesion G-protein coupled receptor F1, C-terminal fragment {ECO:0000305}; DE Short=ADGRF1 C-terminal fragment {ECO:0000305}; DE Flags: Precursor; GN Name=ADGRF1 {ECO:0000303|PubMed:35418679, ECO:0000312|HGNC:HGNC:18990}; GN Synonyms=GPR110 {ECO:0000303|PubMed:20149256}, PGR19; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Suwa M., Sato T., Okouchi I., Arita M., Futami K., Matsumoto S., RA Tsutsumi S., Aburatani H., Asai K., Akiyama Y.; RT "Genome-wide discovery and analysis of human seven transmembrane helix RT receptor genes."; RL Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Okazaki H., Inoue S., Yoshida S., Urakawa I., Mizutani S.; RT "Probable G-protein coupled receptor KPG_012."; RL Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND NUCLEOTIDE SEQUENCE RP [LARGE SCALE MRNA] OF 310-613 (ISOFORM 1). RC TISSUE=Small intestine, and Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 198-910 (ISOFORM 1). RX PubMed=12435584; DOI=10.1016/s0014-5793(02)03574-3; RA Fredriksson R., Lagerstroem M.C., Hoeglund P.J., Schioeth H.B.; RT "Novel human G protein-coupled receptors with long N-terminals containing RT GPS domains and Ser/Thr-rich regions."; RL FEBS Lett. 531:407-414(2002). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 460-636 (ISOFORM 1). RX PubMed=12679517; DOI=10.1073/pnas.0230374100; RA Vassilatis D.K., Hohmann J.G., Zeng H., Li F., Ranchalis J.E., RA Mortrud M.T., Brown A., Rodriguez S.S., Weller J.R., Wright A.C., RA Bergmann J.E., Gaitanaris G.A.; RT "The G protein-coupled receptor repertoires of human and mouse."; RL Proc. Natl. Acad. Sci. U.S.A. 100:4903-4908(2003). RN [9] RP TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND GLYCOSYLATION. RX PubMed=20149256; DOI=10.1186/1471-2407-10-40; RA Lum A.M., Wang B.B., Beck-Engeser G.B., Li L., Channa N., Wabl M.; RT "Orphan receptor GPR110, an oncogene overexpressed in lung and prostate RT cancer."; RL BMC Cancer 10:40-40(2010). RN [10] RP NOMENCLATURE. RX PubMed=25713288; DOI=10.1124/pr.114.009647; RA Hamann J., Aust G., Arac D., Engel F.B., Formstone C., Fredriksson R., RA Hall R.A., Harty B.L., Kirchhoff C., Knapp B., Krishnan A., Liebscher I., RA Lin H.H., Martinelli D.C., Monk K.R., Peeters M.C., Piao X., Promel S., RA Schoneberg T., Schwartz T.W., Singer K., Stacey M., Ushkaryov Y.A., RA Vallon M., Wolfrum U., Wright M.W., Xu L., Langenhan T., Schioth H.B.; RT "International union of basic and clinical pharmacology. XCIV. Adhesion G RT protein-coupled receptors."; RL Pharmacol. Rev. 67:338-367(2015). RN [11] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF 565-HIS--THR-567. RX PubMed=27759003; DOI=10.1038/ncomms13123; RA Lee J.W., Huang B.X., Kwon H., Rashid M.A., Kharebava G., Desai A., RA Patnaik S., Marugan J., Kim H.Y.; RT "Orphan GPR110 (ADGRF1) targeted by N-docosahexaenoylethanolamine in RT development of neurons and cognitive function."; RL Nat. Commun. 7:13123-13123(2016). RN [12] RP FUNCTION. RX PubMed=32144388; DOI=10.1038/s42003-020-0831-6; RA Huang B.X., Hu X., Kwon H.S., Fu C., Lee J.W., Southall N., Marugan J., RA Kim H.Y.; RT "Synaptamide activates the adhesion GPCR GPR110 (ADGRF1) through GAIN RT domain binding."; RL Commun. Biol. 3:109-109(2020). RN [13] {ECO:0007744|PDB:7WXU, ECO:0007744|PDB:7WXW, ECO:0007744|PDB:7WY0, ECO:0007744|PDB:7WZ7, ECO:0007744|PDB:7X2V} RP STRUCTURE BY ELECTRON MICROSCOPY (2.83 ANGSTROMS), FUNCTION, DISULFIDE RP BONDS, AND MUTAGENESIS OF PHE-569; SER-570; LEU-572; MET-573; THR-589; RP ILE-630; MET-675; ARG-729; LEU-799; LEU-800; HIS-820 AND ILE-834. RX PubMed=36127364; DOI=10.1038/s41467-022-33173-4; RA Zhu X., Qian Y., Li X., Xu Z., Xia R., Wang N., Liang J., Yin H., Zhang A., RA Guo C., Wang G., He Y.; RT "Structural basis of adhesion GPCR GPR110 activation by stalk peptide and RT G-proteins coupling."; RL Nat. Commun. 13:5513-5513(2022). RN [14] {ECO:0007744|PDB:7WU3, ECO:0007744|PDB:7WU4, ECO:0007744|PDB:7WU5} RP STRUCTURE BY ELECTRON MICROSCOPY (3.00 ANGSTROMS) OF 251-860 IN COMPLEX RP WITH GNAS; GNB1 AND GNG2, FUNCTION, ACTIVITY REGULATION, DOMAIN, DISULFIDE RP BOND, AND MUTAGENESIS OF PHE-569; LEU-572; MET-573; MET-627; PHE-672; RP MET-675; LEU-678; LEU-681; LEU-682; ALA-683; VAL-755; VAL-761; LEU-764; RP VAL-765; PRO-798; LEU-799; LEU-800; GLY-801; TRP-804; GLN-830 AND GLY-831. RX PubMed=35418679; DOI=10.1038/s41586-022-04580-w; RA Qu X., Qiu N., Wang M., Zhang B., Du J., Zhong Z., Xu W., Chu X., Ma L., RA Yi C., Han S., Shui W., Zhao Q., Wu B.; RT "Structural basis of tethered agonism of the adhesion GPCRs ADGRD1 and RT ADGRF1."; RL Nature 604:779-785(2022). RN [15] {ECO:0007744|PDB:8HC0} RP X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 207-566; 150-206 AND 567-580, RP GLYCOSYLATION AT ASN-168; ASN-282; ASN-310; ASN-329; ASN-354; ASN-368; RP ASN-389 AND ASN-455, DISULFIDE BONDS, AND MUTAGENESIS OF ASN-310 AND RP ASN-389. RX PubMed=36716818; DOI=10.1016/j.jmb.2023.167979; RA Wang F., Wang Y., Qiu W., Zhang Q., Yang H., Song G.; RT "Crystal Structure of the Extracellular Domains of GPR110."; RL J. Mol. Biol. 435:167979-167979(2023). RN [16] {ECO:0007744|PDB:8G2Y} RP STRUCTURE BY ELECTRON MICROSCOPY (3.44 ANGSTROMS) OF 567-910, FUNCTION, RP DISULFIDE BONDS, AND MUTAGENESIS OF PHE-569; LEU-572 AND MET-573. RX PubMed=37120430; DOI=10.1038/s41467-023-38083-7; RA Jones D.T.D., Dates A.N., Rawson S.D., Burruss M.M., Lipper C.H., RA Blacklow S.C.; RT "Tethered agonist activated ADGRF1 structure and signalling analysis reveal RT basis for G protein coupling."; RL Nat. Commun. 14:2490-2490(2023). CC -!- FUNCTION: Adhesion G-protein coupled receptor (aGPCR) for N- CC docosahexaenoylethanolamine (synaptamide), an omega-3 fatty acid lipid CC highly enriched in the brain (PubMed:27759003, PubMed:32144388). Ligand CC binding causes a conformation change that triggers signaling via CC guanine nucleotide-binding proteins (G proteins) and modulates the CC activity of downstream effectors, such as adenylate cyclase CC (PubMed:35418679, PubMed:36127364, PubMed:37120430). ADGRF1 is coupled CC to G(s) G proteins and mediates activation of adenylate cyclase CC activity (PubMed:35418679). Also able to couple to G(q), G(i) and CC G(12)/G(13) G proteins; additional evidence is however required to CC confirm this result in vivo (PubMed:36127364, PubMed:37120430). CC Involved in the development of neurons and cognitive function (By CC similarity). In liver, involved in fat accumulation (By similarity). CC {ECO:0000250|UniProtKB:Q8VEC3, ECO:0000269|PubMed:27759003, CC ECO:0000269|PubMed:32144388, ECO:0000269|PubMed:35418679, CC ECO:0000269|PubMed:36127364, ECO:0000269|PubMed:37120430}. CC -!- ACTIVITY REGULATION: Forms a heterodimer of 2 chains generated by CC proteolytic processing that remain associated through non-covalent CC interactions mediated by the GAIN-B domain (By similarity). In the CC inactivated receptor, the Stachel sequence (also named stalk) is CC embedded in the GAIN-B domain, where it adopts a beta-strand CC conformation (PubMed:35418679). On activation, the Stachel moves into CC the 7 transmembrane region and adopts a twisted hook-shaped CC configuration that forms contacts within the receptor, leading to CC coupling of a G-alpha protein, which activates signaling CC (PubMed:35418679). The cleaved GAIN-B and N-terminal domains can then CC dissociate from the rest of the receptor (PubMed:35418679). CC {ECO:0000255|PROSITE-ProRule:PRU00098, ECO:0000269|PubMed:35418679}. CC -!- SUBUNIT: Heterodimer of 2 chains generated by proteolytic processing; CC the large extracellular N-terminal fragment and the membrane-bound C- CC terminal fragment predominantly remain associated and non-covalently CC linked. {ECO:0000255|PROSITE-ProRule:PRU00098}. CC -!- INTERACTION: CC Q5T601; P50148: GNAQ; NbExp=2; IntAct=EBI-46447105, EBI-3909604; CC Q5T601; Q5JWF2: GNAS; NbExp=2; IntAct=EBI-46447105, EBI-4400880; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:20149256, CC ECO:0000269|PubMed:27759003}; Multi-pass membrane protein CC {ECO:0000269|PubMed:35418679}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted CC {ECO:0000269|PubMed:20149256}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q5T601-1; Sequence=Displayed; CC Name=2; CC IsoId=Q5T601-2; Sequence=VSP_039588, VSP_039589; CC -!- TISSUE SPECIFICITY: Mainly expressed in the kidney. Up-regulated in CC lung adenocarcinomas and prostate cancers. CC {ECO:0000269|PubMed:20149256}. CC -!- DOMAIN: The Stachel sequence (also named stalk) in the C-terminal part CC of the extracellular domain (ECD) functions as a tethered agonist CC (PubMed:35418679). In the inactivated receptor, the Stachel sequence CC (also named stalk) is embedded in the GAIN-B domain, where it adopts a CC beta-strand conformation (PubMed:35418679). On activation, the Stachel CC moves into the 7 transmembrane region and adopts a twisted hook-shaped CC configuration that forms contacts within the receptor, leading to CC coupling of a G-alpha protein, which activates signaling CC (PubMed:35418679). {ECO:0000269|PubMed:35418679}. CC -!- PTM: Autoproteolytically processed at the GPS region of the GAIN-B CC domain; this cleavage modulates receptor activity. CC {ECO:0000255|PROSITE-ProRule:PRU00098}. CC -!- PTM: Glycosylated (PubMed:20149256). Glycosylation at Asn-389 is CC required for secretion or folding (PubMed:36716818). CC {ECO:0000269|PubMed:20149256, ECO:0000269|PubMed:36716818}. CC -!- SIMILARITY: Belongs to the G-protein coupled receptor 2 family. CC Adhesion G-protein coupled receptor (ADGR) subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAB70874.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAB70874.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=BAC45260.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC Sequence=CAI13873.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB065679; BAC45260.1; ALT_SEQ; Genomic_DNA. DR EMBL; AB045123; BAD83599.1; -; mRNA. DR EMBL; AK026337; BAB15452.1; -; mRNA. DR EMBL; AK055208; BAB70874.1; ALT_SEQ; mRNA. DR EMBL; AL355518; CAI13873.1; ALT_SEQ; Genomic_DNA. DR EMBL; AL355518; CAI13874.1; -; Genomic_DNA. DR EMBL; AL355518; CAI13875.1; -; Genomic_DNA. DR EMBL; CH471081; EAX04311.1; -; Genomic_DNA. DR EMBL; BC113634; AAI13635.1; -; mRNA. DR EMBL; BC113636; AAI13637.1; -; mRNA. DR EMBL; AY140952; AAN46666.1; -; mRNA. DR EMBL; AY255595; AAO85107.1; -; mRNA. DR CCDS; CCDS34471.1; -. [Q5T601-1] DR CCDS; CCDS4920.1; -. [Q5T601-2] DR RefSeq; NP_079324.2; NM_025048.4. [Q5T601-2] DR RefSeq; NP_722582.2; NM_153840.4. [Q5T601-1] DR PDB; 7WU3; EM; 3.10 A; R=251-860. DR PDB; 7WU4; EM; 3.40 A; R=251-860. DR PDB; 7WU5; EM; 3.00 A; R=251-860. DR PDB; 7WXU; EM; 2.85 A; R=1-910. DR PDB; 7WXW; EM; 2.84 A; R=1-910. DR PDB; 7WY0; EM; 2.83 A; R=1-910. DR PDB; 7WZ7; EM; 2.83 A; R=1-910. DR PDB; 7X2V; EM; 3.09 A; R=1-910. DR PDB; 8G2Y; EM; 3.44 A; R=567-910. DR PDB; 8HC0; X-ray; 2.90 A; A=207-566, B=150-206, C=567-580. DR PDBsum; 7WU3; -. DR PDBsum; 7WU4; -. DR PDBsum; 7WU5; -. DR PDBsum; 7WXU; -. DR PDBsum; 7WXW; -. DR PDBsum; 7WY0; -. DR PDBsum; 7WZ7; -. DR PDBsum; 7X2V; -. DR PDBsum; 8G2Y; -. DR PDBsum; 8HC0; -. DR AlphaFoldDB; Q5T601; -. DR EMDB; EMD-32818; -. DR EMDB; EMD-32819; -. DR EMDB; EMD-32820; -. DR EMDB; EMD-32881; -. DR EMDB; EMD-32882; -. DR EMDB; EMD-32883; -. DR EMDB; EMD-32905; -. DR EMDB; EMD-32972; -. DR SMR; Q5T601; -. DR BioGRID; 129353; 101. DR FunCoup; Q5T601; 125. DR IntAct; Q5T601; 30. DR MINT; Q5T601; -. DR STRING; 9606.ENSP00000360299; -. DR ChEMBL; CHEMBL4523872; -. DR MEROPS; P02.022; -. DR MEROPS; P02.026; -. DR GlyCosmos; Q5T601; 19 sites, No reported glycans. DR GlyGen; Q5T601; 19 sites, 9 N-linked glycans (4 sites). DR iPTMnet; Q5T601; -. DR PhosphoSitePlus; Q5T601; -. DR BioMuta; ADGRF1; -. DR DMDM; 302393689; -. DR jPOST; Q5T601; -. DR MassIVE; Q5T601; -. DR PaxDb; 9606-ENSP00000360299; -. DR PeptideAtlas; Q5T601; -. DR ProteomicsDB; 64561; -. [Q5T601-1] DR ProteomicsDB; 64562; -. [Q5T601-2] DR Antibodypedia; 30773; 186 antibodies from 26 providers. DR DNASU; 266977; -. DR Ensembl; ENST00000371243.2; ENSP00000360289.2; ENSG00000153292.17. [Q5T601-2] DR Ensembl; ENST00000371253.7; ENSP00000360299.2; ENSG00000153292.17. [Q5T601-1] DR GeneID; 266977; -. DR KEGG; hsa:266977; -. DR MANE-Select; ENST00000371253.7; ENSP00000360299.2; NM_153840.4; NP_722582.2. DR UCSC; uc003oyt.4; human. [Q5T601-1] DR AGR; HGNC:18990; -. DR ClinPGx; PA128394769; -. DR CTD; 266977; -. DR DisGeNET; 266977; -. DR GeneCards; ADGRF1; -. DR HGNC; HGNC:18990; ADGRF1. DR HPA; ENSG00000153292; Group enriched (esophagus, kidney, urinary bladder). DR MIM; 617430; gene. DR OpenTargets; ENSG00000153292; -. DR VEuPathDB; HostDB:ENSG00000153292; -. DR eggNOG; KOG4193; Eukaryota. DR GeneTree; ENSGT00940000161228; -. DR InParanoid; Q5T601; -. DR OMA; TQFLSTE; -. DR OrthoDB; 10040049at2759; -. DR PAN-GO; Q5T601; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q5T601; -. DR PathwayCommons; Q5T601; -. DR Agora; ENSG00000153292; -. DR BioGRID-ORCS; 266977; 10 hits in 1147 CRISPR screens. DR ChiTaRS; ADGRF1; human. DR GeneWiki; GPR110; -. DR GenomeRNAi; 266977; -. DR Pharos; Q5T601; Tbio. DR PRO; PR:Q5T601; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q5T601; protein. DR Bgee; ENSG00000153292; Expressed in palpebral conjunctiva and 97 other cell types or tissues. DR ExpressionAtlas; Q5T601; baseline and differential. DR GO; GO:0031410; C:cytoplasmic vesicle; IBA:GO_Central. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0016020; C:membrane; TAS:GDB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0004930; F:G protein-coupled receptor activity; IDA:UniProtKB. DR GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:InterPro. DR GO; GO:0006112; P:energy reserve metabolic process; IBA:GO_Central. DR GO; GO:0045444; P:fat cell differentiation; IBA:GO_Central. DR GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:GDB. DR GO; GO:0007613; P:memory; IEA:Ensembl. DR GO; GO:0031175; P:neuron projection development; IBA:GO_Central. DR GO; GO:0019216; P:regulation of lipid metabolic process; IBA:GO_Central. DR GO; GO:0007416; P:synapse assembly; IBA:GO_Central. DR CDD; cd15932; 7tmB2_GPR116-like_Adhesion_VI; 1. DR FunFam; 2.60.220.50:FF:000015; Adhesion G protein-coupled receptor F4; 1. DR FunFam; 1.20.1070.10:FF:000058; Adhesion G protein-coupled receptor F5; 1. DR Gene3D; 1.25.40.610; -; 1. DR Gene3D; 2.60.220.50; -; 1. DR Gene3D; 1.20.1070.10; Rhodopsin 7-helix transmembrane proteins; 1. DR InterPro; IPR051587; Adhesion_GPCR. DR InterPro; IPR057244; GAIN_B. DR InterPro; IPR046338; GAIN_dom_sf. DR InterPro; IPR017981; GPCR_2-like_7TM. DR InterPro; IPR008078; GPCR_2_Ig-hepta-like_rcpt. DR InterPro; IPR000832; GPCR_2_secretin-like. DR InterPro; IPR000203; GPS. DR InterPro; IPR000082; SEA_dom. DR PANTHER; PTHR45813:SF3; ADHESION G-PROTEIN COUPLED RECEPTOR F1; 1. DR PANTHER; PTHR45813; IG-LIKE DOMAIN-CONTAINING PROTEIN; 1. DR Pfam; PF00002; 7tm_2; 1. DR Pfam; PF01825; GPS; 1. DR Pfam; PF01390; SEA; 1. DR PRINTS; PR00249; GPCRSECRETIN. DR PRINTS; PR01695; IGHEPTARCPTR. DR SMART; SM00303; GPS; 1. DR PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1. DR PROSITE; PS50221; GAIN_B; 1. DR PROSITE; PS50024; SEA; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Cell membrane; Disulfide bond; KW G-protein coupled receptor; Glycoprotein; Membrane; KW Proteomics identification; Receptor; Reference proteome; Secreted; Signal; KW Transducer; Transmembrane; Transmembrane helix. FT SIGNAL 1..19 FT /evidence="ECO:0000255" FT CHAIN 20..910 FT /note="Adhesion G-protein coupled receptor F1" FT /id="PRO_0000012891" FT CHAIN 20..566 FT /note="Adhesion G-protein coupled receptor F1, N-terminal FT fragment" FT /evidence="ECO:0000305" FT /id="PRO_0000462383" FT CHAIN 567..910 FT /note="Adhesion G-protein coupled receptor F1, C-terminal FT fragment" FT /evidence="ECO:0000305" FT /id="PRO_0000462384" FT TOPO_DOM 20..583 FT /note="Extracellular" FT /evidence="ECO:0000269|PubMed:35418679, FT ECO:0007744|PDB:7WU3, ECO:0007744|PDB:7WU4, FT ECO:0007744|PDB:7WU5" FT TRANSMEM 584..609 FT /note="Helical; Name=1" FT /evidence="ECO:0000269|PubMed:35418679, FT ECO:0007744|PDB:7WU3, ECO:0007744|PDB:7WU4, FT ECO:0007744|PDB:7WU5" FT TOPO_DOM 610..621 FT /note="Cytoplasmic" FT /evidence="ECO:0000269|PubMed:35418679, FT ECO:0007744|PDB:7WU3, ECO:0007744|PDB:7WU4, FT ECO:0007744|PDB:7WU5" FT TRANSMEM 622..646 FT /note="Helical; Name=2" FT /evidence="ECO:0000269|PubMed:35418679, FT ECO:0007744|PDB:7WU3, ECO:0007744|PDB:7WU4, FT ECO:0007744|PDB:7WU5" FT TOPO_DOM 647..658 FT /note="Extracellular" FT /evidence="ECO:0000269|PubMed:35418679, FT ECO:0007744|PDB:7WU3, ECO:0007744|PDB:7WU4, FT ECO:0007744|PDB:7WU5" FT TRANSMEM 659..684 FT /note="Helical; Name=3" FT /evidence="ECO:0000269|PubMed:35418679, FT ECO:0007744|PDB:7WU3, ECO:0007744|PDB:7WU4, FT ECO:0007744|PDB:7WU5" FT TOPO_DOM 685..696 FT /note="Cytoplasmic" FT /evidence="ECO:0000269|PubMed:35418679, FT ECO:0007744|PDB:7WU3, ECO:0007744|PDB:7WU4, FT ECO:0007744|PDB:7WU5" FT TRANSMEM 697..719 FT /note="Helical; Name=4" FT /evidence="ECO:0000269|PubMed:35418679, FT ECO:0007744|PDB:7WU3, ECO:0007744|PDB:7WU4, FT ECO:0007744|PDB:7WU5" FT TOPO_DOM 720..742 FT /note="Extracellular" FT /evidence="ECO:0000269|PubMed:35418679, FT ECO:0007744|PDB:7WU3, ECO:0007744|PDB:7WU4, FT ECO:0007744|PDB:7WU5" FT TRANSMEM 743..767 FT /note="Helical; Name=5" FT /evidence="ECO:0000269|PubMed:35418679, FT ECO:0007744|PDB:7WU3, ECO:0007744|PDB:7WU4, FT ECO:0007744|PDB:7WU5" FT TOPO_DOM 768..784 FT /note="Cytoplasmic" FT /evidence="ECO:0000269|PubMed:35418679, FT ECO:0007744|PDB:7WU3, ECO:0007744|PDB:7WU4, FT ECO:0007744|PDB:7WU5" FT TRANSMEM 785..813 FT /note="Helical; Name=6" FT /evidence="ECO:0000269|PubMed:35418679, FT ECO:0007744|PDB:7WU3, ECO:0007744|PDB:7WU4, FT ECO:0007744|PDB:7WU5" FT TOPO_DOM 814..816 FT /note="Extracellular" FT /evidence="ECO:0000269|PubMed:35418679, FT ECO:0007744|PDB:7WU3, ECO:0007744|PDB:7WU4, FT ECO:0007744|PDB:7WU5" FT TRANSMEM 817..842 FT /note="Helical; Name=7" FT /evidence="ECO:0000269|PubMed:35418679, FT ECO:0007744|PDB:7WU3, ECO:0007744|PDB:7WU4, FT ECO:0007744|PDB:7WU5" FT TOPO_DOM 843..910 FT /note="Cytoplasmic" FT /evidence="ECO:0000269|PubMed:35418679, FT ECO:0007744|PDB:7WU3, ECO:0007744|PDB:7WU4, FT ECO:0007744|PDB:7WU5" FT DOMAIN 148..256 FT /note="SEA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00188" FT DOMAIN 437..579 FT /note="GAIN-B" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00098" FT REGION 534..579 FT /note="GPS" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00098" FT REGION 568..576 FT /note="Stachel" FT /evidence="ECO:0000305|PubMed:35418679" FT SITE 566..567 FT /note="Cleavage; by autolysis" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00098" FT CARBOHYD 139 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 168 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:36716818, FT ECO:0007744|PDB:8HC0" FT CARBOHYD 205 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 282 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:36716818, FT ECO:0007744|PDB:8HC0" FT CARBOHYD 310 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:36716818, FT ECO:0007744|PDB:8HC0" FT CARBOHYD 317 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 329 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:36716818, FT ECO:0007744|PDB:8HC0" FT CARBOHYD 354 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:36716818, FT ECO:0007744|PDB:8HC0" FT CARBOHYD 368 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:36716818, FT ECO:0007744|PDB:8HC0" FT CARBOHYD 389 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:36716818" FT CARBOHYD 410 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 423 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 437 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 455 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:36716818, FT ECO:0007744|PDB:8HC0" FT CARBOHYD 512 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 528 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 553 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 736 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 739 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 257..287 FT /evidence="ECO:0000269|PubMed:36716818, FT ECO:0007744|PDB:8HC0" FT DISULFID 275..299 FT /evidence="ECO:0000269|PubMed:36716818, FT ECO:0007744|PDB:8HC0" FT DISULFID 534..561 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00098, FT ECO:0000269|PubMed:36716818, ECO:0007744|PDB:8HC0" FT DISULFID 549..563 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00098, FT ECO:0000269|PubMed:36716818, ECO:0007744|PDB:8HC0" FT DISULFID 657..733 FT /evidence="ECO:0000269|PubMed:35418679, FT ECO:0007744|PDB:7WU3, ECO:0007744|PDB:7WU4, FT ECO:0007744|PDB:7WU5" FT VAR_SEQ 205..218 FT /note="NGSIVAGYEVVGSS -> MSLLSPKLECNGTI (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_039588" FT VAR_SEQ 219..910 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_039589" FT VARIANT 787 FT /note="I -> V (in dbSNP:rs1226475)" FT /id="VAR_055928" FT MUTAGEN 310 FT /note="N->Q: No effect." FT /evidence="ECO:0000269|PubMed:36716818" FT MUTAGEN 389 FT /note="N->S: Decreased expression." FT /evidence="ECO:0000269|PubMed:36716818" FT MUTAGEN 565..567 FT /note="HLT->ALA: Abolished autprocessing, impairing G FT protein-coupled signaling." FT /evidence="ECO:0000269|PubMed:27759003" FT MUTAGEN 569 FT /note="F->A: Strongly decreased G protein-coupled receptor FT signaling." FT /evidence="ECO:0000269|PubMed:35418679, FT ECO:0000269|PubMed:36127364, ECO:0000269|PubMed:37120430" FT MUTAGEN 570 FT /note="S->A: Strongly decreased G protein-coupled receptor FT signaling." FT /evidence="ECO:0000269|PubMed:36127364" FT MUTAGEN 572 FT /note="L->A: Strongly decreased G protein-coupled receptor FT signaling." FT /evidence="ECO:0000269|PubMed:35418679, FT ECO:0000269|PubMed:36127364, ECO:0000269|PubMed:37120430" FT MUTAGEN 573 FT /note="M->A: Strongly decreased G protein-coupled receptor FT signaling." FT /evidence="ECO:0000269|PubMed:35418679, FT ECO:0000269|PubMed:36127364, ECO:0000269|PubMed:37120430" FT MUTAGEN 589 FT /note="T->A: Decreased G protein-coupled receptor FT signaling." FT /evidence="ECO:0000269|PubMed:36127364" FT MUTAGEN 627 FT /note="M->A: Strongly decreased G protein-coupled receptor FT signaling." FT /evidence="ECO:0000269|PubMed:35418679" FT MUTAGEN 630 FT /note="I->A: Strongly decreased G protein-coupled receptor FT signaling." FT /evidence="ECO:0000269|PubMed:36127364" FT MUTAGEN 672 FT /note="F->A: Strongly decreased G protein-coupled receptor FT signaling." FT /evidence="ECO:0000269|PubMed:35418679" FT MUTAGEN 675 FT /note="M->A: Strongly decreased G protein-coupled receptor FT signaling." FT /evidence="ECO:0000269|PubMed:35418679, FT ECO:0000269|PubMed:36127364" FT MUTAGEN 678 FT /note="L->A: Strongly decreased G protein-coupled receptor FT signaling." FT /evidence="ECO:0000269|PubMed:35418679" FT MUTAGEN 681 FT /note="L->A,H: Retains G protein-coupled receptor FT activity." FT /evidence="ECO:0000269|PubMed:35418679" FT MUTAGEN 682 FT /note="L->A: Strongly decreased G protein-coupled receptor FT signaling." FT /evidence="ECO:0000269|PubMed:35418679" FT MUTAGEN 683 FT /note="A->G: Strongly decreased G protein-coupled receptor FT signaling." FT /evidence="ECO:0000269|PubMed:35418679" FT MUTAGEN 729 FT /note="R->A: Decreased G protein-coupled receptor FT signaling." FT /evidence="ECO:0000269|PubMed:36127364" FT MUTAGEN 755 FT /note="V->A: Strongly decreased G protein-coupled receptor FT signaling." FT /evidence="ECO:0000269|PubMed:35418679" FT MUTAGEN 761 FT /note="V->A: Strongly decreased G protein-coupled receptor FT signaling." FT /evidence="ECO:0000269|PubMed:35418679" FT MUTAGEN 764 FT /note="L->A: Strongly decreased G protein-coupled receptor FT signaling." FT /evidence="ECO:0000269|PubMed:35418679" FT MUTAGEN 765 FT /note="V->A: Strongly decreased G protein-coupled receptor FT signaling." FT /evidence="ECO:0000269|PubMed:35418679" FT MUTAGEN 798 FT /note="P->A: Strongly decreased G protein-coupled receptor FT signaling." FT /evidence="ECO:0000269|PubMed:35418679" FT MUTAGEN 799 FT /note="L->A: Strongly decreased G protein-coupled receptor FT signaling." FT /evidence="ECO:0000269|PubMed:35418679, FT ECO:0000269|PubMed:36127364" FT MUTAGEN 800 FT /note="L->A: Strongly decreased G protein-coupled receptor FT signaling." FT /evidence="ECO:0000269|PubMed:35418679, FT ECO:0000269|PubMed:36127364" FT MUTAGEN 801 FT /note="G->A: Strongly decreased G protein-coupled receptor FT signaling." FT /evidence="ECO:0000269|PubMed:35418679" FT MUTAGEN 804 FT /note="W->A: Strongly decreased G protein-coupled receptor FT signaling." FT /evidence="ECO:0000269|PubMed:35418679" FT MUTAGEN 820 FT /note="H->A: Strongly decreased G protein-coupled receptor FT signaling." FT /evidence="ECO:0000269|PubMed:36127364" FT MUTAGEN 830 FT /note="Q->A: Strongly decreased G protein-coupled receptor FT signaling." FT /evidence="ECO:0000269|PubMed:35418679" FT MUTAGEN 831 FT /note="G->A: Strongly decreased G protein-coupled receptor FT signaling." FT /evidence="ECO:0000269|PubMed:35418679" FT MUTAGEN 834 FT /note="I->A: Strongly decreased G protein-coupled receptor FT signaling." FT /evidence="ECO:0000269|PubMed:36127364" FT CONFLICT 23 FT /note="G -> GV (in Ref. 4; CAI13874)" FT /evidence="ECO:0000305" FT CONFLICT 27 FT /note="G -> D (in Ref. 3; BAB15452)" FT /evidence="ECO:0000305" FT CONFLICT 198..203 FT /note="VQVTQF -> MDISIQ (in Ref. 7; AAN46666)" FT /evidence="ECO:0000305" FT CONFLICT 614 FT /note="I -> A (in Ref. 3; BAB70874)" FT /evidence="ECO:0000305" FT STRAND 151..160 FT /evidence="ECO:0007829|PDB:8HC0" FT HELIX 164..167 FT /evidence="ECO:0007829|PDB:8HC0" FT HELIX 172..189 FT /evidence="ECO:0007829|PDB:8HC0" FT STRAND 195..204 FT /evidence="ECO:0007829|PDB:8HC0" FT STRAND 208..218 FT /evidence="ECO:0007829|PDB:8HC0" FT HELIX 220..228 FT /evidence="ECO:0007829|PDB:8HC0" FT HELIX 231..238 FT /evidence="ECO:0007829|PDB:8HC0" FT TURN 239..241 FT /evidence="ECO:0007829|PDB:8HC0" FT STRAND 250..253 FT /evidence="ECO:0007829|PDB:8HC0" FT STRAND 256..258 FT /evidence="ECO:0007829|PDB:8HC0" FT STRAND 260..262 FT /evidence="ECO:0007829|PDB:8HC0" FT STRAND 270..274 FT /evidence="ECO:0007829|PDB:8HC0" FT STRAND 279..288 FT /evidence="ECO:0007829|PDB:8HC0" FT STRAND 291..297 FT /evidence="ECO:0007829|PDB:8HC0" FT HELIX 302..311 FT /evidence="ECO:0007829|PDB:8HC0" FT TURN 312..314 FT /evidence="ECO:0007829|PDB:8HC0" FT STRAND 315..317 FT /evidence="ECO:0007829|PDB:8HC0" FT HELIX 320..336 FT /evidence="ECO:0007829|PDB:8HC0" FT HELIX 342..362 FT /evidence="ECO:0007829|PDB:8HC0" FT HELIX 368..381 FT /evidence="ECO:0007829|PDB:8HC0" FT HELIX 384..386 FT /evidence="ECO:0007829|PDB:8HC0" FT HELIX 387..396 FT /evidence="ECO:0007829|PDB:8HC0" FT HELIX 400..412 FT /evidence="ECO:0007829|PDB:8HC0" FT HELIX 417..419 FT /evidence="ECO:0007829|PDB:8HC0" FT STRAND 421..425 FT /evidence="ECO:0007829|PDB:8HC0" FT STRAND 427..435 FT /evidence="ECO:0007829|PDB:8HC0" FT HELIX 440..443 FT /evidence="ECO:0007829|PDB:8HC0" FT STRAND 445..451 FT /evidence="ECO:0007829|PDB:8HC0" FT STRAND 460..466 FT /evidence="ECO:0007829|PDB:8HC0" FT HELIX 468..471 FT /evidence="ECO:0007829|PDB:8HC0" FT STRAND 477..485 FT /evidence="ECO:0007829|PDB:8HC0" FT HELIX 487..490 FT /evidence="ECO:0007829|PDB:8HC0" FT STRAND 495..497 FT /evidence="ECO:0007829|PDB:8HC0" FT STRAND 505..510 FT /evidence="ECO:0007829|PDB:8HC0" FT STRAND 518..523 FT /evidence="ECO:0007829|PDB:8HC0" FT STRAND 525..538 FT /evidence="ECO:0007829|PDB:8HC0" FT TURN 539..542 FT /evidence="ECO:0007829|PDB:8HC0" FT STRAND 543..545 FT /evidence="ECO:0007829|PDB:8HC0" FT STRAND 549..554 FT /evidence="ECO:0007829|PDB:8HC0" FT STRAND 556..564 FT /evidence="ECO:0007829|PDB:8HC0" FT HELIX 569..572 FT /evidence="ECO:0007829|PDB:7WY0" FT TURN 579..581 FT /evidence="ECO:0007829|PDB:7WY0" FT HELIX 582..609 FT /evidence="ECO:0007829|PDB:7WY0" FT HELIX 611..613 FT /evidence="ECO:0007829|PDB:7WY0" FT HELIX 618..646 FT /evidence="ECO:0007829|PDB:7WY0" FT TURN 649..651 FT /evidence="ECO:0007829|PDB:7WY0" FT STRAND 653..655 FT /evidence="ECO:0007829|PDB:7WY0" FT TURN 656..658 FT /evidence="ECO:0007829|PDB:7WY0" FT HELIX 659..686 FT /evidence="ECO:0007829|PDB:7WY0" FT HELIX 695..706 FT /evidence="ECO:0007829|PDB:7WY0" FT HELIX 708..721 FT /evidence="ECO:0007829|PDB:7WY0" FT HELIX 722..724 FT /evidence="ECO:0007829|PDB:7WY0" FT STRAND 727..729 FT /evidence="ECO:0007829|PDB:7WU4" FT STRAND 730..734 FT /evidence="ECO:0007829|PDB:7WY0" FT STRAND 738..740 FT /evidence="ECO:0007829|PDB:7WY0" FT HELIX 743..746 FT /evidence="ECO:0007829|PDB:7WY0" FT HELIX 748..769 FT /evidence="ECO:0007829|PDB:7WY0" FT STRAND 774..777 FT /evidence="ECO:0007829|PDB:7WU3" FT STRAND 781..783 FT /evidence="ECO:0007829|PDB:7WU5" FT HELIX 785..799 FT /evidence="ECO:0007829|PDB:7WY0" FT HELIX 803..806 FT /evidence="ECO:0007829|PDB:7WY0" FT HELIX 807..812 FT /evidence="ECO:0007829|PDB:7WY0" FT TURN 816..818 FT /evidence="ECO:0007829|PDB:7WY0" FT HELIX 820..827 FT /evidence="ECO:0007829|PDB:7WY0" FT HELIX 830..837 FT /evidence="ECO:0007829|PDB:7WY0" FT TURN 838..841 FT /evidence="ECO:0007829|PDB:7WY0" FT HELIX 843..853 FT /evidence="ECO:0007829|PDB:7WY0" SQ SEQUENCE 910 AA; 101365 MW; 07B5234A487E9F07 CRC64; MKVGVLWLIS FFTFTDGHGG FLGKNDGIKT KKELIVNKKK HLGPVEEYQL LLQVTYRDSK EKRDLRNFLK LLKPPLLWSH GLIRIIRAKA TTDCNSLNGV LQCTCEDSYT WFPPSCLDPQ NCYLHTAGAL PSCECHLNNL SQSVNFCERT KIWGTFKINE RFTNDLLNSS SAIYSKYANG IEIQLKKAYE RIQGFESVQV TQFRNGSIVA GYEVVGSSSA SELLSAIEHV AEKAKTALHK LFPLEDGSFR VFGKAQCNDI VFGFGSKDDE YTLPCSSGYR GNITAKCESS GWQVIRETCV LSLLEELNKN FSMIVGNATE AAVSSFVQNL SVIIRQNPST TVGNLASVVS ILSNISSLSL ASHFRVSNST MEDVISIADN ILNSASVTNW TVLLREEKYA SSRLLETLEN ISTLVPPTAL PLNFSRKFID WKGIPVNKSQ LKRGYSYQIK MCPQNTSIPI RGRVLIGSDQ FQRSLPETII SMASLTLGNI LPVSKNGNAQ VNGPVISTVI QNYSINEVFL FFSKIESNLS QPHCVFWDFS HLQWNDAGCH LVNETQDIVT CQCTHLTSFS ILMSPFVPST IFPVVKWITY VGLGISIGSL ILCLIIEALF WKQIKKSQTS HTRRICMVNI ALSLLIADVW FIVGATVDTT VNPSGVCTAA VFFTHFFYLS LFFWMLMLGI LLAYRIILVF HHMAQHLMMA VGFCLGYGCP LIISVITIAV TQPSNTYKRK DVCWLNWSNG SKPLLAFVVP ALAIVAVNFV VVLLVLTKLW RPTVGERLSR DDKATIIRVG KSLLILTPLL GLTWGFGIGT IVDSQNLAWH VIFALLNAFQ GFFILCFGIL LDSKLRQLLF NKLSALSSWK QTEKQNSSDL SAKPKFSKPF NPLQNKGHYA FSHTGDSSDN IMLTQFVSNE // ID AGRF2_HUMAN Reviewed; 708 AA. AC Q8IZF7; Q2PNZ1; Q86SL6; Q8NGU5; Q8TDT5; DT 15-FEB-2005, integrated into UniProtKB/Swiss-Prot. DT 01-MAR-2003, sequence version 1. DT 28-JAN-2026, entry version 163. DE RecName: Full=Putative adhesion G protein-coupled receptor F2P; DE AltName: Full=Adhesion G-protein coupled receptor F2; DE AltName: Full=G-protein coupled receptor 111; DE AltName: Full=G-protein coupled receptor PGR20; GN Name=ADGRF2P {ECO:0000312|HGNC:HGNC:18991}; Synonyms=ADGRF2, GPR111, PGR20; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=12565841; DOI=10.1016/s0006-291x(03)00026-3; RA Fredriksson R., Gloriam D.E.I., Hoeglund P.J., Lagerstroem M.C., RA Schioeth H.B.; RT "There exist at least 30 human G-protein-coupled receptors with long RT Ser/Thr-rich N-termini."; RL Biochem. Biophys. Res. Commun. 301:725-734(2003). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1). RA Suwa M., Sato T., Okouchi I., Arita M., Futami K., Matsumoto S., RA Tsutsumi S., Aburatani H., Asai K., Akiyama Y.; RT "Genome-wide discovery and analysis of human seven transmembrane helix RT receptor genes."; RL Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT VAL-467. RC TISSUE=Testis; RA Bonner T.I., Kauffman D., Nagle J.W.; RT "Complete coding sequence of GPR111."; RL Submitted (DEC-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] OF 293-708. RX PubMed=12044878; DOI=10.1016/s0014-5793(02)02775-8; RA Takeda S., Kadowaki S., Haga T., Takaesu H., Mitaku S.; RT "Identification of G protein-coupled receptor genes from the human genome RT sequence."; RL FEBS Lett. 520:97-101(2002). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 326-487 (ISOFORM 1). RX PubMed=12679517; DOI=10.1073/pnas.0230374100; RA Vassilatis D.K., Hohmann J.G., Zeng H., Li F., Ranchalis J.E., RA Mortrud M.T., Brown A., Rodriguez S.S., Weller J.R., Wright A.C., RA Bergmann J.E., Gaitanaris G.A.; RT "The G protein-coupled receptor repertoires of human and mouse."; RL Proc. Natl. Acad. Sci. U.S.A. 100:4903-4908(2003). RN [7] RP TISSUE SPECIFICITY. RX PubMed=20149256; DOI=10.1186/1471-2407-10-40; RA Lum A.M., Wang B.B., Beck-Engeser G.B., Li L., Channa N., Wabl M.; RT "Orphan receptor GPR110, an oncogene overexpressed in lung and prostate RT cancer."; RL BMC Cancer 10:40-40(2010). RN [8] RP NOMENCLATURE. RX PubMed=25713288; DOI=10.1124/pr.114.009647; RA Hamann J., Aust G., Arac D., Engel F.B., Formstone C., Fredriksson R., RA Hall R.A., Harty B.L., Kirchhoff C., Knapp B., Krishnan A., Liebscher I., RA Lin H.H., Martinelli D.C., Monk K.R., Peeters M.C., Piao X., Promel S., RA Schoneberg T., Schwartz T.W., Singer K., Stacey M., Ushkaryov Y.A., RA Vallon M., Wolfrum U., Wright M.W., Xu L., Langenhan T., Schioth H.B.; RT "International union of basic and clinical pharmacology. XCIV. Adhesion G RT protein-coupled receptors."; RL Pharmacol. Rev. 67:338-367(2015). CC -!- FUNCTION: Orphan receptor. CC -!- SUBCELLULAR LOCATION: Membrane {ECO:0000255}; Multi-pass membrane CC protein {ECO:0000255}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q8IZF7-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8IZF7-2; Sequence=VSP_040379, VSP_040380, VSP_040381; CC -!- TISSUE SPECIFICITY: High expression in kidney. Up-regulated in lung CC adenocarcinomas and prostate cancers. {ECO:0000269|PubMed:20149256}. CC -!- MISCELLANEOUS: Most adhesion GPCRs undergo autoproteolysis at the GPS CC domain. ADGRF2 is not autoproteolyzed at the GPS motif because of the CC lack of a consensus catalytic triad sequence within GPS region of the CC GAIN-B domain. {ECO:0000250|UniProtKB:E9Q4J9}. CC -!- SIMILARITY: Belongs to the G-protein coupled receptor 2 family. CC Adhesion G-protein coupled receptor (ADGR) subfamily. {ECO:0000305}. CC -!- CAUTION: Could be the product of a pseudogene. Protein coding orthologs CC in other vertebrate species. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAC05907.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY140953; AAN46667.1; -; mRNA. DR EMBL; AB065684; BAC05907.1; ALT_SEQ; Genomic_DNA. DR EMBL; DQ315369; ABC41928.1; -; mRNA. DR EMBL; AL356421; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AB083617; BAB89330.1; -; Genomic_DNA. DR EMBL; AY255612; AAO85124.1; -; mRNA. DR AlphaFoldDB; Q8IZF7; -. DR SMR; Q8IZF7; -. DR BioGRID; 128806; 1. DR IntAct; Q8IZF7; 1. DR STRING; 9606.ENSP00000296862; -. DR ChEMBL; CHEMBL4523892; -. DR GlyCosmos; Q8IZF7; 7 sites, No reported glycans. DR GlyGen; Q8IZF7; 7 sites. DR iPTMnet; Q8IZF7; -. DR PhosphoSitePlus; Q8IZF7; -. DR BioMuta; ADGRF2; -. DR DMDM; 59797952; -. DR jPOST; Q8IZF7; -. DR MassIVE; Q8IZF7; -. DR PaxDb; 9606-ENSP00000296862; -. DR ProteomicsDB; 71348; -. [Q8IZF7-1] DR Antibodypedia; 30795; 103 antibodies from 21 providers. DR DNASU; 222611; -. DR UCSC; uc003oyy.3; human. [Q8IZF7-1] DR AGR; HGNC:18991; -. DR ClinPGx; PA134984088; -. DR DisGeNET; 222611; -. DR GeneCards; ADGRF2P; -. DR HGNC; HGNC:18991; ADGRF2P. DR MIM; 620872; gene. DR VEuPathDB; HostDB:ENSG00000164393; -. DR eggNOG; KOG4193; Eukaryota. DR HOGENOM; CLU_002753_3_6_1; -. DR InParanoid; Q8IZF7; -. DR OMA; MLMQKCP; -. DR PAN-GO; Q8IZF7; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q8IZF7; -. DR PathwayCommons; Q8IZF7; -. DR SignaLink; Q8IZF7; -. DR BioGRID-ORCS; 222611; 4 hits in 261 CRISPR screens. DR ChiTaRS; ADGRF2; human. DR GeneWiki; GPR111; -. DR GenomeRNAi; 222611; -. DR Pharos; Q8IZF7; Tdark. DR PRO; PR:Q8IZF7; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q8IZF7; protein. DR Bgee; ENSG00000164393; Expressed in male germ line stem cell (sensu Vertebrata) in testis and 45 other cell types or tissues. DR ExpressionAtlas; Q8IZF7; baseline and differential. DR GO; GO:0016020; C:membrane; TAS:GDB. DR GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central. DR GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IBA:GO_Central. DR GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:InterPro. DR GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:GDB. DR CDD; cd15994; 7tmB2_GPR111_115; 1. DR FunFam; 2.60.220.50:FF:000015; Adhesion G protein-coupled receptor F4; 1. DR FunFam; 1.20.1070.10:FF:000058; Adhesion G protein-coupled receptor F5; 1. DR Gene3D; 2.60.220.50; -; 1. DR Gene3D; 1.20.1070.10; Rhodopsin 7-helix transmembrane proteins; 1. DR InterPro; IPR051587; Adhesion_GPCR. DR InterPro; IPR057244; GAIN_B. DR InterPro; IPR046338; GAIN_dom_sf. DR InterPro; IPR017981; GPCR_2-like_7TM. DR InterPro; IPR000832; GPCR_2_secretin-like. DR InterPro; IPR000203; GPS. DR PANTHER; PTHR45813:SF6; ADHESION G-PROTEIN COUPLED RECEPTOR F2; 1. DR PANTHER; PTHR45813; IG-LIKE DOMAIN-CONTAINING PROTEIN; 1. DR Pfam; PF00002; 7tm_2; 1. DR Pfam; PF01825; GPS; 1. DR PRINTS; PR00249; GPCRSECRETIN. DR PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1. DR PROSITE; PS50221; GAIN_B; 1. PE 5: Uncertain; KW Alternative splicing; Disulfide bond; G-protein coupled receptor; KW Glycoprotein; Membrane; Receptor; Reference proteome; Transducer; KW Transmembrane; Transmembrane helix. FT CHAIN 1..708 FT /note="Putative adhesion G protein-coupled receptor F2P" FT /id="PRO_0000070334" FT TOPO_DOM 1..451 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 452..472 FT /note="Helical; Name=1" FT /evidence="ECO:0000255" FT TOPO_DOM 473..487 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 488..508 FT /note="Helical; Name=2" FT /evidence="ECO:0000255" FT TOPO_DOM 509..530 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 531..551 FT /note="Helical; Name=3" FT /evidence="ECO:0000255" FT TOPO_DOM 552..557 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 558..578 FT /note="Helical; Name=4" FT /evidence="ECO:0000255" FT TOPO_DOM 579..606 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 607..627 FT /note="Helical; Name=5" FT /evidence="ECO:0000255" FT TOPO_DOM 628..650 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT TRANSMEM 651..671 FT /note="Helical; Name=6" FT /evidence="ECO:0000255" FT TOPO_DOM 672..674 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 675..695 FT /note="Helical; Name=7" FT /evidence="ECO:0000255" FT TOPO_DOM 696..708 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT DOMAIN 293..442 FT /note="GAIN-B" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00098" FT REGION 394..442 FT /note="GPS" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00098" FT CARBOHYD 21 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 220 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 252 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 260 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 305 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 313 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 358 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 394..421 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00098" FT DISULFID 409..423 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00098" FT VAR_SEQ 1..68 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.3" FT /id="VSP_040379" FT VAR_SEQ 69..92 FT /note="PSPNAVSSDQVHCSAGCTHRKCGW -> MTHILLLYYLVFLLPTESCRTLYQ FT (in isoform 2)" FT /evidence="ECO:0000303|Ref.3" FT /id="VSP_040380" FT VAR_SEQ 690..708 FT /note="VSPDASDQVQSERIHEDVL -> GFFILVFGTILDPKIREALKG (in FT isoform 2)" FT /evidence="ECO:0000303|Ref.3" FT /id="VSP_040381" FT VARIANT 148 FT /note="Q -> R (in dbSNP:rs6907125)" FT /id="VAR_024473" FT VARIANT 467 FT /note="I -> V (in dbSNP:rs9381594)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_024474" FT CONFLICT 427 FT /note="K -> E (in Ref. 3; ABC41928)" FT /evidence="ECO:0000305" SQ SEQUENCE 708 AA; 78569 MW; 3DE541DD1D723966 CRC64; MGLTAYGNRR VQPGELPFGA NLTLIHTRAQ PVICSKLLLT KRVSPISFFL SKFQNSWGED GWVQLDQLPS PNAVSSDQVH CSAGCTHRKC GWAASKSKEK VPARPHGVCD GVCTDYSQCT QPCPPDTQGN MGFSCRQKTW HKITDTCQTL NALNIFEEDS RLVQPFEDNI KISVYTGKSE TITDMLLQKC PTDLSCVIRN IQQSPWIPGN IAVIVQLLHN ISTAIWTGVD EAKMQSYSTI ANHILNSKSI SNWTFIPDRN SSYILLHSVN SFARRLFIDK HPVDISDVFI HTMGTTISGD NIGKNFTFSM RINDTSNEVT GRVLISRDEL RKVPSPSQVI SIAFPTIGAI LEASLLENVT VNGLVLSAIL PKELKRISLI FEKISKSEER RTQCVGWHSV ENRWDQQACK MIQENSQQAV CKCRPSKLFT SFSILMSPHI LESLILTYIT YVGLGISICS LILCLSIEVL VWSQVTKTEI TYLRHVCIVN IAATLLMADV WFIVASFLSG PITHHKGCVA ATFFVHFFYL SVFFWMLAKA LLILYGIMIV FHTLPKSVLV ASLFSVGYGC PLAIAAITVA ATEPGKGYLR PEICWLNWDM TKALLAFVIP ALAIVVVNLI TVTLVIVKTQ RAAIGNSMFQ EVRAIVRISK NIAILTPLLG LTWGFGVATV IDDRSLAFHI IFSLLNAFQV SPDASDQVQS ERIHEDVL // ID AMGO2_HUMAN Reviewed; 522 AA. AC Q86SJ2; Q4VBP6; Q7Z4A0; Q96CN8; DT 21-JUN-2005, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-2003, sequence version 1. DT 28-JAN-2026, entry version 187. DE RecName: Full=Amphoterin-induced protein 2; DE AltName: Full=AMIGO-2; DE AltName: Full=Alivin-1; DE AltName: Full=Differentially expressed in gastric adenocarcinomas; DE Short=DEGA; DE Flags: Precursor; GN Name=AMIGO2 {ECO:0000312|EMBL:AAH47595.1}; GN Synonyms=ALI1 {ECO:0000312|EMBL:BAC81189.1}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000312|EMBL:AAO48946.1} RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Fibrosarcoma {ECO:0000269|PubMed:12629050}; RX PubMed=12629050; DOI=10.1083/jcb.200209074; RA Kuja-Panula J., Kiiltomaeki M., Yamashiro T., Rouhiainen A., Rauvala H.; RT "AMIGO, a transmembrane protein implicated in axon tract development, RT defines a novel protein family with leucine-rich repeats."; RL J. Cell Biol. 160:963-973(2003). RN [2] {ECO:0000312|EMBL:BAC81189.1} RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Brain {ECO:0000312|EMBL:BAC81189.1}; RX PubMed=12843293; DOI=10.1523/jneurosci.23-13-05887.2003; RA Ono T., Sekino-Suzuki N., Kikkawa Y., Yonekawa H., Kawashima S.; RT "Alivin 1, a novel neuronal activity-dependent gene, inhibits apoptosis and RT promotes survival of cerebellar granule neurons."; RL J. Neurosci. 23:5887-5896(2003). RN [3] {ECO:0000305, ECO:0000312|EMBL:AAR83271.1} RP NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY. RX PubMed=15107827; DOI=10.1038/sj.onc.1207681; RA Rabenau K.E., O'Toole J.M., Bassi R., Kotanides H., Witte L., Ludwig D.L., RA Pereira D.S.; RT "DEGA/AMIGO-2, a leucine-rich repeat family member, differentially RT expressed in human gastric adenocarcinoma: effects on ploidy, chromosomal RT stability, cell adhesion/migration and tumorigenicity."; RL Oncogene 23:5056-5067(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Stomach; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [5] {ECO:0000312|EMBL:AAH47595.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Testis {ECO:0000312|EMBL:AAH47595.1}, and RC Uterus {ECO:0000312|EMBL:AAH14103.2}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). CC -!- FUNCTION: Required for depolarization-dependent survival of cultured CC cerebellar granule neurons. May mediate homophilic as well as CC heterophilic cell-cell interaction with AMIGO1 or AMIGO3. May CC contribute to signal transduction through its intracellular domain. May CC be required for tumorigenesis of a subset of gastric adenocarcinomas. CC -!- SUBUNIT: Binds itself as well as AMIGO1 and AMIGO3. {ECO:0000250}. CC -!- INTERACTION: CC Q86SJ2; O00555: CACNA1A; NbExp=2; IntAct=EBI-3866830, EBI-766279; CC Q86SJ2; Q6PL24: TMED8; NbExp=3; IntAct=EBI-3866830, EBI-11603430; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Single-pass type I CC membrane protein {ECO:0000250}. Nucleus {ECO:0000250}. Note=Associated CC with nucleus as well as plasma membrane. Restricted to somata of CC cerebellar as well as hippocampal neurons (By similarity). CC {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Highest levels in breast, ovary, cervix, and CC uterus. Lower levels in lung, colon, and rectum. Differentially CC expressed in 56% of thyroid, 57% of pancreatic and 45% of stomach CC cancers. {ECO:0000269|PubMed:15107827}. CC -!- SIMILARITY: Belongs to the immunoglobulin superfamily. AMIGO family. CC {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY237005; AAO48946.1; -; mRNA. DR EMBL; AB079074; BAC81188.1; -; mRNA. DR EMBL; AB080610; BAC81189.1; -; mRNA. DR EMBL; AY454159; AAR83271.1; -; mRNA. DR EMBL; AL833007; CAH56293.1; -; mRNA. DR EMBL; BC014103; AAH14103.2; -; mRNA. DR EMBL; BC047595; AAH47595.1; -; mRNA. DR EMBL; BC095477; AAH95477.1; -; mRNA. DR CCDS; CCDS8751.1; -. DR RefSeq; NP_001137140.1; NM_001143668.1. DR RefSeq; NP_001357228.1; NM_001370299.1. DR RefSeq; NP_862830.1; NM_181847.4. DR RefSeq; XP_047284741.1; XM_047428785.1. DR AlphaFoldDB; Q86SJ2; -. DR SMR; Q86SJ2; -. DR BioGRID; 131497; 48. DR FunCoup; Q86SJ2; 22. DR IntAct; Q86SJ2; 9. DR STRING; 9606.ENSP00000266581; -. DR GlyConnect; 1007; 4 N-Linked glycans (1 site). DR GlyCosmos; Q86SJ2; 8 sites, 4 glycans. DR GlyGen; Q86SJ2; 10 sites, 6 N-linked glycans (3 sites). DR iPTMnet; Q86SJ2; -. DR PhosphoSitePlus; Q86SJ2; -. DR SwissPalm; Q86SJ2; -. DR BioMuta; AMIGO2; -. DR DMDM; 68052338; -. DR jPOST; Q86SJ2; -. DR MassIVE; Q86SJ2; -. DR PaxDb; 9606-ENSP00000266581; -. DR PeptideAtlas; Q86SJ2; -. DR ProteomicsDB; 69596; -. DR Pumba; Q86SJ2; -. DR Antibodypedia; 13397; 235 antibodies from 31 providers. DR DNASU; 347902; -. DR Ensembl; ENST00000266581.4; ENSP00000266581.4; ENSG00000139211.8. DR Ensembl; ENST00000429635.1; ENSP00000406020.1; ENSG00000139211.8. DR Ensembl; ENST00000550413.2; ENSP00000449034.1; ENSG00000139211.8. DR GeneID; 347902; -. DR KEGG; hsa:347902; -. DR MANE-Select; ENST00000550413.2; ENSP00000449034.1; NM_001370299.1; NP_001357228.1. DR UCSC; uc001rpk.4; human. DR AGR; HGNC:24073; -. DR ClinPGx; PA142672626; -. DR CTD; 347902; -. DR DisGeNET; 347902; -. DR GeneCards; AMIGO2; -. DR HGNC; HGNC:24073; AMIGO2. DR HPA; ENSG00000139211; Low tissue specificity. DR MIM; 615690; gene. DR OpenTargets; ENSG00000139211; -. DR VEuPathDB; HostDB:ENSG00000139211; -. DR eggNOG; ENOG502R009; Eukaryota. DR GeneTree; ENSGT00950000183146; -. DR HOGENOM; CLU_030478_0_0_1; -. DR InParanoid; Q86SJ2; -. DR OMA; DFVWVGP; -. DR OrthoDB; 676979at2759; -. DR PAN-GO; Q86SJ2; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q86SJ2; -. DR PathwayCommons; Q86SJ2; -. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR Reactome; R-HSA-9013423; RAC3 GTPase cycle. DR SignaLink; Q86SJ2; -. DR Agora; ENSG00000139211; -. DR BioGRID-ORCS; 347902; 22 hits in 1166 CRISPR screens. DR GenomeRNAi; 347902; -. DR Pharos; Q86SJ2; Tbio. DR PRO; PR:Q86SJ2; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; Q86SJ2; protein. DR Bgee; ENSG00000139211; Expressed in blood vessel layer and 190 other cell types or tissues. DR ExpressionAtlas; Q86SJ2; baseline and differential. DR GO; GO:0016020; C:membrane; IBA:GO_Central. DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell. DR GO; GO:0007420; P:brain development; IBA:GO_Central. DR GO; GO:0007157; P:heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules; ISS:UniProtKB. DR GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; ISS:UniProtKB. DR GO; GO:0043069; P:negative regulation of programmed cell death; ISS:UniProtKB. DR GO; GO:0051965; P:positive regulation of synapse assembly; IBA:GO_Central. DR FunFam; 2.60.40.10:FF:001047; amphoterin-induced protein 2 isoform X1; 1. DR FunFam; 3.80.10.10:FF:000170; amphoterin-induced protein 2 isoform X1; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 1. DR Gene3D; 3.80.10.10; Ribonuclease Inhibitor; 1. DR InterPro; IPR031283; AMIGO. DR InterPro; IPR000483; Cys-rich_flank_reg_C. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR001611; Leu-rich_rpt. DR InterPro; IPR003591; Leu-rich_rpt_typical-subtyp. DR InterPro; IPR032675; LRR_dom_sf. DR PANTHER; PTHR24368; AMPHOTERIN-INDUCED PROTEIN; 1. DR PANTHER; PTHR24368:SF209; AMPHOTERIN-INDUCED PROTEIN 2; 1. DR Pfam; PF13927; Ig_3; 1. DR Pfam; PF13855; LRR_8; 1. DR SMART; SM00409; IG; 1. DR SMART; SM00369; LRR_TYP; 5. DR SMART; SM00082; LRRCT; 1. DR SUPFAM; SSF48726; Immunoglobulin; 1. DR SUPFAM; SSF52058; L domain-like; 1. DR PROSITE; PS50835; IG_LIKE; 1. DR PROSITE; PS51450; LRR; 7. PE 1: Evidence at protein level; KW Cell adhesion; Cell membrane; Disulfide bond; Glycoprotein; KW Immunoglobulin domain; Leucine-rich repeat; Membrane; Nucleus; KW Proteomics identification; Reference proteome; Repeat; Signal; KW Transmembrane; Transmembrane helix. FT SIGNAL 1..39 FT /evidence="ECO:0000255" FT CHAIN 40..522 FT /note="Amphoterin-induced protein 2" FT /evidence="ECO:0000255" FT /id="PRO_0000014509" FT TOPO_DOM 40..398 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 399..419 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 420..522 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 40..68 FT /note="LRRNT" FT REPEAT 69..90 FT /note="LRR 1" FT REPEAT 94..115 FT /note="LRR 2" FT REPEAT 118..139 FT /note="LRR 3" FT REPEAT 142..163 FT /note="LRR 4" FT REPEAT 166..187 FT /note="LRR 5" FT REPEAT 193..214 FT /note="LRR 6" FT DOMAIN 228..284 FT /note="LRRCT" FT DOMAIN 289..379 FT /note="Ig-like C2-type" FT /evidence="ECO:0000255" FT REGION 501..522 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT CARBOHYD 58 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 104 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 281 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 288 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 345 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 373 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 381 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 384 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 41..47 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 45..54 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 232..260 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 234..282 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 310..363 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" SQ SEQUENCE 522 AA; 57934 MW; 20A86E3D82C05B9B CRC64; MSLRVHTLPT LLGAVVRPGC RELLCLLMIT VTVGPGASGV CPTACICATD IVSCTNKNLS KVPGNLFRLI KRLDLSYNRI GLLDSEWIPV SFAKLNTLIL RHNNITSIST GSFSTTPNLK CLDLSSNKLK TVKNAVFQEL KVLEVLLLYN NHISYLDPSA FGGLSQLQKL YLSGNFLTQF PMDLYVGRFK LAELMFLDVS YNRIPSMPMH HINLVPGKQL RGIYLHGNPF VCDCSLYSLL VFWYRRHFSS VMDFKNDYTC RLWSDSRHSR QVLLLQDSFM NCSDSIINGS FRALGFIHEA QVGERLMVHC DSKTGNANTD FIWVGPDNRL LEPDKEMENF YVFHNGSLVI ESPRFEDAGV YSCIAMNKQR LLNETVDVTI NVSNFTVSRS HAHEAFNTAF TTLAACVASI VLVLLYLYLT PCPCKCKTKR QKNMLHQSNA HSSILSPGPA SDASADERKA GAGKRVVFLE PLKDTAAGQN GKVRLFPSEA VIAEGILKST RGKSDSDSVN SVFSDTPFVA ST // ID APC_HUMAN Reviewed; 2843 AA. AC P25054; B7Z2B6; D3DT03; Q15162; Q15163; Q93042; DT 01-MAY-1992, integrated into UniProtKB/Swiss-Prot. DT 16-MAY-2006, sequence version 2. DT 28-JAN-2026, entry version 276. DE RecName: Full=Adenomatous polyposis coli protein; DE Short=Protein APC; DE AltName: Full=Deleted in polyposis 2.5; GN Name=APC {ECO:0000312|HGNC:HGNC:583}; Synonyms=DP2.5; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1A AND 2), AND VARIANT ASP-1822. RC TISSUE=Fetal brain; RX PubMed=1678319; DOI=10.1016/0092-8674(81)90022-2; RA Joslyn G., Carlson M., Thliveris A., Albertsen H., Gelbert L., Samowitz W., RA Groden J., Stevens J., Spirio L., Robertson M., Sargeant L., Krapcho K., RA Wolff E., Burt R., Hughes J.P., Warrington J., McPherson J.D., RA Wasmuth J.J., le Paslier D., Abderrahim H., Cohen D., Leppert M., White R.; RT "Identification of deletion mutations and three new genes at the familial RT polyposis locus."; RL Cell 66:601-613(1991). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1A), AND VARIANT ASP-1822. RX PubMed=1651562; DOI=10.1126/science.1651562; RA Kinzler K.W., Nilbert M.C., Su L.-K., Vogelstein B., Bryan T.M., Levy D.B., RA Smith K.J., Preisinger A.C., Hedge P., McKechnie D., Finniear R., RA Markham A., Groffen J., Boguski M.S., Altschul S.F., Horii A.K., Ando H., RA Miyoshi Y., Miki Y., Nishisho I., Nakamura Y.; RT "Identification of FAP locus genes from chromosome 5q21."; RL Science 253:661-665(1991). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1A), FUNCTION, SUBCELLULAR LOCATION, RP INTERACTION WITH ARHGEF4, AND IDENTIFICATION IN A COMPLEX WITH ARHGEF4 AND RP CTNNB1. RX PubMed=10947987; DOI=10.1126/science.289.5482.1194; RA Kawasaki Y., Senda T., Ishidate T., Koyama R., Morishita T., Iwayama Y., RA Higuchi O., Akiyama T.; RT "Asef, a link between the tumor suppressor APC and G-protein signaling."; RL Science 289:1194-1197(2000). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASP-1822. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-1135 (ISOFORM 1B). RC TISSUE=Amygdala {ECO:0000312|EMBL:BAH11802.1}; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1506-1524. RX PubMed=1310068; RA Miki Y., Nishisho I., Horii A., Miyoshi Y., Utsunomiya J., Kinzler K.W., RA Vogelstein B., Nakamura Y.; RT "Disruption of the APC gene by a retrotransposal insertion of L1 sequence RT in a colon cancer."; RL Cancer Res. 52:643-645(1992). RN [8] RP INTERACTION WITH ALPHA- AND BETA-CATENINS. RX PubMed=8259519; DOI=10.1126/science.8259519; RA Su L.-K., Vogelstein B., Kinzler K.W.; RT "Association of the APC tumor suppressor protein with catenins."; RL Science 262:1734-1737(1993). RN [9] RP INTERACTION WITH DLG1. RX PubMed=8638125; DOI=10.1126/science.272.5264.1020; RA Matsumine A., Ogai A., Senda T., Okumura N., Satoh K., Baeg G.-H., RA Kawahara T., Kobayashi S., Okada M., Toyoshima K., Akiyama T.; RT "Binding of APC to the human homolog of the Drosophila discs large tumor RT suppressor protein."; RL Science 272:1020-1023(1996). RN [10] RP INTERACTION WITH DLG3. RC TISSUE=Fetal brain; RX PubMed=9188857; DOI=10.1038/sj.onc.1201087; RA Makino K., Kuwahara H., Masuko N., Nishiyama Y., Morisaki T., Sasaki J., RA Nakao M., Kuwano A., Nakata M., Ushio Y., Saya H.; RT "Cloning and characterization of NE-dlg: a novel human homolog of the RT Drosophila discs large (dlg) tumor suppressor protein interacts with the RT APC protein."; RL Oncogene 14:2425-2433(1997). RN [11] RP INTERACTION WITH APC2. RX PubMed=11691822; RA Jarrett C.R., Blancato J., Cao T., Bressette D.S., Cepeda M., Young P.E., RA King C.R., Byers S.W.; RT "Human APC2 localization and allelic imbalance."; RL Cancer Res. 61:7978-7984(2001). RN [12] RP INTERACTION WITH MAPRE1; MAPRE2 AND MAPRE3. RX PubMed=14514668; DOI=10.1074/jbc.m306194200; RA Bu W., Su L.-K.; RT "Characterization of functional domains of human EB1 family proteins."; RL J. Biol. Chem. 278:49721-49731(2003). RN [13] RP UBIQUITINATION. RX PubMed=15355978; DOI=10.1074/jbc.m404655200; RA Choi J., Park S.Y., Costantini F., Jho E.-H., Joo C.-K.; RT "Adenomatous polyposis coli is down-regulated by the ubiquitin-proteasome RT pathway in a process facilitated by Axin."; RL J. Biol. Chem. 279:49188-49198(2004). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [15] RP SUBCELLULAR LOCATION, INTERACTION WITH SCRIB, AND MUTAGENESIS OF THR-2841 RP AND VAL-2843. RX PubMed=16611247; DOI=10.1111/j.1365-2443.2006.00954.x; RA Takizawa S., Nagasaka K., Nakagawa S., Yano T., Nakagawa K., Yasugi T., RA Takeuchi T., Kanda T., Huibregtse J.M., Akiyama T., Taketani Y.; RT "Human scribble, a novel tumor suppressor identified as a target of high- RT risk HPV E6 for ubiquitin-mediated degradation, interacts with adenomatous RT polyposis coli."; RL Genes Cells 11:453-464(2006). RN [16] RP FUNCTION, INTERACTION WITH MAPRE1 AND ACTIN, AND PHOSPHORYLATION. RX PubMed=17293347; DOI=10.1074/jbc.m610615200; RA Moseley J.B., Bartolini F., Okada K., Wen Y., Gundersen G.G., Goode B.L.; RT "Regulated binding of adenomatous polyposis coli protein to actin."; RL J. Biol. Chem. 282:12661-12668(2007). RN [17] RP FUNCTION, AND INTERACTION WITH SPATA13. RX PubMed=17599059; DOI=10.1038/sj.onc.1210574; RA Kawasaki Y., Sagara M., Shibata Y., Shirouzu M., Yokoyama S., Akiyama T.; RT "Identification and characterization of Asef2, a guanine-nucleotide RT exchange factor specific for Rac1 and Cdc42."; RL Oncogene 26:7620-7627(2007). RN [18] RP DEUBIQUITINATION. RX PubMed=18281465; DOI=10.1101/gad.463208; RA Tran H., Hamada F., Schwarz-Romond T., Bienz M.; RT "Trabid, a new positive regulator of Wnt-induced transcription with RT preference for binding and cleaving K63-linked ubiquitin chains."; RL Genes Dev. 22:528-542(2008). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2671, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-780; SER-1042; SER-1360; RP SER-1861; SER-1863; SER-1864; THR-2151; SER-2260; SER-2270; SER-2283; RP SER-2473; SER-2535; SER-2671; SER-2674; THR-2679 AND SER-2789, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [22] RP ALTERNATIVE PROMOTER USAGE, AND TISSUE SPECIFICITY. RX PubMed=19527921; DOI=10.1016/j.canlet.2009.05.016; RA Hosoya K., Yamashita S., Ando T., Nakajima T., Itoh F., Ushijima T.; RT "Adenomatous polyposis coli 1A is likely to be methylated as a passenger in RT human gastric carcinogenesis."; RL Cancer Lett. 285:182-189(2009). RN [23] RP INTERACTION WITH MAPRE1, AND SUBCELLULAR LOCATION. RX PubMed=19632184; DOI=10.1016/j.cell.2009.04.065; RA Honnappa S., Gouveia S.M., Weisbrich A., Damberger F.F., Bhavesh N.S., RA Jawhari H., Grigoriev I., van Rijssel F.J., Buey R.M., Lawera A., RA Jelesarov I., Winkler F.K., Wuthrich K., Akhmanova A., Steinmetz M.O.; RT "An EB1-binding motif acts as a microtubule tip localization signal."; RL Cell 138:366-376(2009). RN [24] RP FUNCTION. RX PubMed=19893577; DOI=10.1038/embor.2009.233; RA Kawasaki Y., Tsuji S., Muroya K., Furukawa S., Shibata Y., Okuno M., RA Ohwada S., Akiyama T.; RT "The adenomatous polyposis coli-associated exchange factors Asef and Asef2 RT are required for adenoma formation in Apc(Min/+)mice."; RL EMBO Rep. 10:1355-1362(2009). RN [25] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=19151759; DOI=10.1038/onc.2008.478; RA Sagara M., Kawasaki Y., Iemura S.I., Natsume T., Takai Y., Akiyama T.; RT "Asef2 and Neurabin2 cooperatively regulate actin cytoskeletal organization RT and are involved in HGF-induced cell migration."; RL Oncogene 28:1357-1365(2009). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [27] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=20937854; DOI=10.1073/pnas.1000975107; RA Zaoui K., Benseddik K., Daou P., Salaun D., Badache A.; RT "ErbB2 receptor controls microtubule capture by recruiting ACF7 to the RT plasma membrane of migrating cells."; RL Proc. Natl. Acad. Sci. U.S.A. 107:18517-18522(2010). RN [28] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-744 AND SER-780, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [29] RP INTERACTION WITH AMER1. RX PubMed=21498506; DOI=10.1074/jbc.m111.224881; RA Tanneberger K., Pfister A.S., Kriz V., Bryja V., Schambony A., Behrens J.; RT "Structural and functional characterization of the Wnt inhibitor APC RT membrane recruitment 1 (Amer1)."; RL J. Biol. Chem. 286:19204-19214(2011). RN [30] RP ALTERNATIVE PROMOTER USAGE, TISSUE SPECIFICITY, AND INVOLVEMENT IN FAP1. RX PubMed=21643010; DOI=10.1038/onc.2011.201; RA Rohlin A., Engwall Y., Fritzell K., Goeransson K., Bergsten A., RA Einbeigi Z., Nilbert M., Karlsson P., Bjoerk J., Nordling M.; RT "Inactivation of promoter 1B of APC causes partial gene silencing: evidence RT for a significant role of the promoter in regulation and causative of RT familial adenomatous polyposis."; RL Oncogene 30:4977-4989(2011). RN [31] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1861; SER-1863 AND SER-1864, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [32] RP INTERACTION WITH AMER2. RX PubMed=22128170; DOI=10.1074/jbc.m111.308650; RA Pfister A.S., Tanneberger K., Schambony A., Behrens J.; RT "Amer2 protein is a novel negative regulator of Wnt/beta-Catenin signaling RT involved in neuroectodermal patterning."; RL J. Biol. Chem. 287:1734-1741(2012). RN [33] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [34] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-744; SER-748; SER-908; RP SER-1042; SER-1371; SER-1385; THR-1438; SER-1774; SER-1861; SER-2260; RP SER-2283; SER-2569; SER-2674; SER-2724 AND SER-2789, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-780, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [36] RP INTERACTION WITH JPT1. RX PubMed=25169422; DOI=10.1002/jcb.24956; RA Varisli L., Ozturk B.E., Akyuz G.K., Korkmaz K.S.; RT "HN1 negatively influences the beta-catenin/E-cadherin interaction, and RT contributes to migration in prostate cells."; RL J. Cell. Biochem. 116:170-178(2015). RN [37] RP ALTERNATIVE PROMOTER USAGE, TISSUE SPECIFICITY, AND INVOLVEMENT IN FAP1. RX PubMed=27217144; DOI=10.1038/srep26011; RA Yamaguchi K., Nagayama S., Shimizu E., Komura M., Yamaguchi R., Shibuya T., RA Arai M., Hatakeyama S., Ikenoue T., Ueno M., Miyano S., Imoto S., RA Furukawa Y.; RT "Reduced expression of APC-1B but not APC-1A by the deletion of promoter 1B RT is responsible for familial adenomatous polyposis."; RL Sci. Rep. 6:26011-26011(2016). RN [38] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 2-55. RX PubMed=10926498; DOI=10.1006/jmbi.2000.3895; RA Day C.L., Alber T.; RT "Crystal structure of the amino-terminal coiled-coil domain of the APC RT tumor suppressor."; RL J. Mol. Biol. 301:147-156(2000). RN [39] RP X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 1021-1035 IN COMPLEX WITH CTNNB1. RX PubMed=11707392; DOI=10.1093/emboj/20.22.6203; RA Eklof Spink K., Fridman S.G., Weis W.I.; RT "Molecular mechanisms of beta-catenin recognition by adenomatous polyposis RT coli revealed by the structure of an APC-beta-catenin complex."; RL EMBO J. 20:6203-6212(2001). RN [40] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 2034-2049 IN COMPLEX WITH AXIN1, RP AND INTERACTION WITH AXIN1. RX PubMed=10811618; DOI=10.1093/emboj/19.10.2270; RA Spink K.E., Polakis P., Weis W.I.; RT "Structural basis of the axin-adenomatous polyposis coli interaction."; RL EMBO J. 19:2270-2279(2000). RN [41] RP STRUCTURE BY NMR OF 1578-1596 IN COMPLEX WITH ASAP1, AND INTERACTION WITH RP ASAP1. RX PubMed=20509626; DOI=10.1021/bi100563z; RA Kaieda S., Matsui C., Mimori-Kiyosue Y., Ikegami T.; RT "Structural basis of the recognition of the SAMP motif of adenomatous RT polyposis coli by the Src-homology 3 domain."; RL Biochemistry 49:5143-5153(2010). RN [42] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 407-775, AND DOMAIN ARM REPEATS. RX PubMed=21871439; DOI=10.1016/j.bbrc.2011.08.044; RA Zhang Z., Lin K., Gao L., Chen L., Shi X., Wu G.; RT "Crystal structure of the armadillo repeat domain of adenomatous polyposis RT coli which reveals its inherent flexibility."; RL Biochem. Biophys. Res. Commun. 412:732-736(2011). RN [43] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 396-732 IN COMPLEX WITH KHDRBS1, RP INTERACTION WITH KHDRBS1, AND MUTAGENESIS OF LYS-516 AND ARG-549. RX PubMed=22000517; DOI=10.1016/j.str.2011.07.013; RA Morishita E.C., Murayama K., Kato-Murayama M., Ishizuka-Katsura Y., RA Tomabechi Y., Hayashi T., Terada T., Handa N., Shirouzu M., Akiyama T., RA Yokoyama S.; RT "Crystal structures of the armadillo repeat domain of adenomatous polyposis RT coli and its complex with the tyrosine-rich domain of Sam68."; RL Structure 19:1496-1508(2011). RN [44] RP VARIANTS FAP1. RX PubMed=1651563; DOI=10.1126/science.1651563; RA Nishisho I., Nakamura Y., Miyoshi Y., Miki Y., Ando H., Horii A., RA Koyama K., Utsunomiya J., Baba S., Hedge P., Markham A., Krush A.J., RA Petersen G.M., Hamilton S.R., Nilbert M.C., Levy D.B., Bryan T.M., RA Preisinger A.C., Smith K.J., Su L.-K., Kinzler K.W., Vogelstein B.; RT "Mutations of chromosome 5q21 genes in FAP and colorectal cancer RT patients."; RL Science 253:665-669(1991). RN [45] RP VARIANT FAP1 GLY-911. RX PubMed=1338904; DOI=10.1093/hmg/1.4.229; RA Miyoshi Y., Nagase H., Ando H., Ichii S., Nakatsuru S., Aoki T., Miki Y., RA Mori T., Nakamura Y.; RT "Somatic mutations of the APC gene in colorectal tumors: mutation cluster RT region in the APC gene."; RL Hum. Mol. Genet. 1:229-233(1992). RN [46] RP VARIANTS FAP1. RX PubMed=1338691; DOI=10.1093/hmg/1.8.559; RA Nakatsuru S., Yanagisawa A., Ichii S., Tahara E., Kato Y., Nakamura Y., RA Horii A.; RT "Somatic mutation of the APC gene in gastric cancer: frequent mutations in RT very well differentiated adenocarcinoma and signet-ring cell carcinoma."; RL Hum. Mol. Genet. 1:559-563(1992). RN [47] RP VARIANTS FAP1 MET-1292 AND TRP-1348, AND VARIANTS ASP-1118; VAL-1304 AND RP SER-2502. RX PubMed=1338764; DOI=10.1002/humu.1380010603; RA Nagase H., Miyoshi Y., Horii A., Aoki T., Petersen G.M., Vogelstein B., RA Maher E., Ogawa M., Maruyama M., Utsunomiya J., Baba S., Nakamura Y.; RT "Screening for germ-line mutations in familial adenomatous polyposis RT patients: 61 new patients and a summary of 150 unrelated patients."; RL Hum. Mutat. 1:467-473(1992). RN [48] RP VARIANTS FAP1 CYS-2621 AND PHE-2839. RX PubMed=1316610; DOI=10.1073/pnas.89.10.4452; RA Miyoshi Y., Ando H., Nagase H., Nishisho I., Horii A., Miki Y., Mori T., RA Utsunomiya J., Baba S., Petersen G.; RT "Germ-line mutations of the APC gene in 53 familial adenomatous polyposis RT patients."; RL Proc. Natl. Acad. Sci. U.S.A. 89:4452-4456(1992). RN [49] RP VARIANTS FAP1 CYS-414; THR-784 AND LEU-1176. RX PubMed=8111410; DOI=10.1002/humu.1380020602; RA Nagase H., Nakamura Y.; RT "Mutations of the APC (adenomatous polyposis coli) gene."; RL Hum. Mutat. 2:425-434(1993). RN [50] RP VARIANT FAP1 TRP-99. RC TISSUE=Peripheral blood lymphocyte; RX PubMed=7833149; DOI=10.1016/0959-8049(94)00294-f; RA Dobbie Z., Spycher M., Huerliman R., Ammann R., Ammann T., Roth J., RA Mueller A., Mueller H., Scott R.J.; RT "Mutational analysis of the first 14 exons of the adenomatous polyposis RT coli (APC) gene."; RL Eur. J. Cancer 30A:1709-1713(1994). RN [51] RP VARIANT FAP1 GLY-722. RX PubMed=7833931; DOI=10.1093/hmg/3.9.1687; RA Stella A., Montera M., Resta N., Marchese C., Susca F., Gentile M., RA Romio L., Pilia S., Prete F., Mareni C., Guanti G.; RT "Four novel mutations of the APC (adenomatous polyposis coli) gene in FAP RT patients."; RL Hum. Mol. Genet. 3:1687-1688(1994). RN [52] RP ERRATUM OF PUBMED:7833931. RA Stella A., Montera M., Resta N., Marchese C., Susca F., Gentile M., RA Romio L., Pilia S., Prete F., Mareni C., Guanti G.; RL Hum. Mol. Genet. 3:1918-1918(1994). RN [53] RP INVOLVEMENT IN FAP1. RX PubMed=7661930; DOI=10.1056/nejm199503303321302; RA Hamilton S.R., Liu B., Parsons R.E., Papadopoulos N., Jen J., Powell S.M., RA Krush A.J., Berk T., Cohen Z., Tetu B., Burger P.C., Wood P.A., Taqi F., RA Booker S.V., Petersen G.M., Offerhaus G.J.A., Tersmette A.C., RA Giardiello F.M., Vogelstein B., Kinzler K.W.; RT "The molecular basis of Turcot's syndrome."; RL N. Engl. J. Med. 332:839-847(1995). RN [54] RP INVOLVEMENT IN DESMD. RX PubMed=8940264; RA Eccles D.M., van der Luijt R.B., Breukel C., Bullman H., Bunyan D., RA Fisher A., Barber J., du Boulay C., Primrose J., Burn J., Fodde R.; RT "Hereditary desmoid disease due to a frameshift mutation at codon 1924 of RT the APC gene."; RL Am. J. Hum. Genet. 59:1193-1201(1996). RN [55] RP VARIANT HEPATOBLASTOMA CYS-1395. RX PubMed=8764128; RA Oda H., Imai Y., Nakatsuru Y., Hata J., Ishikawa T.; RT "Somatic mutations of the APC gene in sporadic hepatoblastomas."; RL Cancer Res. 56:3320-3323(1996). RN [56] RP VARIANT FAP1 ILE-171. RX PubMed=8990002; RX DOI=10.1002/(sici)1098-1004(1997)9:1<7::aid-humu2>3.0.co;2-8; RA van der Luijt R.B., Meera Khan P., Vasen H.F.A., Tops C.M.J., RA van Leeuwen-Cornelisse I.S.J., Wijnen J.T., van der Klift H.M., Plug R.J., RA Griffioen G., Fodde R.; RT "Molecular analysis of the APC gene in 105 Dutch kindreds with familial RT adenomatous polyposis: 67 germline mutations identified by DGGE, PTT, and RT southern analysis."; RL Hum. Mutat. 9:7-16(1997). RN [57] RP VARIANTS COLORECTAL CARCINOMA THR-880; ILE-890 AND VAL-1508. RX PubMed=9419979; DOI=10.1038/sj.onc.1201668; RA Miyaki M., Nishio J., Konishi M., Kikuchi-Yanoshita R., Tanaka K., RA Muraoka M., Nagato M., Chong J.-M., Koike M., Terada T., Kawahara Y., RA Fukutome A., Tomiyama J., Chuganji Y., Momoi M., Utsunomiya J.; RT "Drastic genetic instability of tumors and normal tissues in Turcot RT syndrome."; RL Oncogene 15:2877-2881(1997). RN [58] RP VARIANT LYS-1307. RX PubMed=9731522; DOI=10.1038/1666; RA Redston M., Nathanson K.L., Yuan Z.Q., Neuhausen S.L., Satagopan J., RA Wong N., Yang D., Nafa D., Abrahamson J., Ozcelik H., Antin-Ozerkis D., RA Andrulis I., Daly M., Pinsky L., Schrag D., Gallinger S., Kaback M., RA King M.-C., Woodage T., Brody L.C., Godwin A., Warner E., Weber B., RA Foulkes W., Offit K.; RT "The APC I1307K allele and breast cancer risk."; RL Nat. Genet. 20:13-14(1998). RN [59] RP VARIANTS LYS-1307 AND GLN-1317. RC TISSUE=Peripheral blood; RX PubMed=9724771; DOI=10.1073/pnas.95.18.10722; RA Frayling I.M., Beck N.E., Ilyas M., Dove-Edwin I., Goodman P., Pack K., RA Bell J.A., Williams C.B., Hodgson S.V., Thomas H.J.W., Talbot I.C., RA Bodmer W.F., Tomlinson I.P.M.; RT "The APC variants I1307K and E1317Q are associated with colorectal tumors, RT but not always with a family history."; RL Proc. Natl. Acad. Sci. U.S.A. 95:10722-10727(1998). RN [60] RP VARIANT LYS-1307. RX PubMed=9731533; DOI=10.1038/1722; RA Woodage T., King S.M., Wacholder S., Hartge P., Struewing J.P., McAdams M., RA Laken S.J., Tucker M.A., Brody L.C.; RT "The APC I1307K allele and cancer risk in a community-based study of RT Ashkenazi Jews."; RL Nat. Genet. 20:62-65(1998). RN [61] RP VARIANT LYS-1307. RX PubMed=9973276; DOI=10.1086/302262; RA Gryfe R., Di Nicola N., Lal G., Gallinger S., Redston M.; RT "Inherited colorectal polyposis and cancer risk of the APC I1307K RT polymorphism."; RL Am. J. Hum. Genet. 64:378-384(1999). RN [62] RP VARIANTS GLY-1057; CYS-1171; ASP-1822 AND THR-2738. RX PubMed=9950360; RA Wallis Y.L., Morton D.G., McKeown C.M., Macdonald F.; RT "Molecular analysis of the APC gene in 205 families: extended genotype- RT phenotype correlations in FAP and evidence for the role of APC amino acid RT changes in colorectal cancer predisposition."; RL J. Med. Genet. 36:14-20(1999). RN [63] RP VARIANT FAP1 PRO-1184. RX PubMed=10470088; DOI=10.1038/12511; RA Lamlum H., Ilyas M., Rowan A., Clark S., Johnson V., Bell J.A., RA Frayling I.M., Efstathiou J., Pack K., Payne S., Roylance R., Gorman P., RA Sheer D., Neale K., Phillips R., Talbot I.C., Bodmer W.F., RA Tomlinson I.P.M.; RT "The type of somatic mutation at APC in familial adenomatous polyposis is RT determined by the site of the germline mutation: a new facet to Knudson's RT 'two-hit' hypothesis."; RL Nat. Med. 5:1071-1075(1999). RN [64] RP VARIANTS MDB VAL-1296; ILE-1472 AND GLY-1495. RX PubMed=10666372; DOI=10.1016/s0002-9440(10)64747-5; RA Huang H., Mahler-Araujo B.M., Sankila A., Chimelli L., Yonekawa Y., RA Kleihues P., Ohgaki H.; RT "APC mutations in sporadic medulloblastomas."; RL Am. J. Pathol. 156:433-437(2000). RN [65] RP INVOLVEMENT IN DESMD. RX PubMed=10782927; DOI=10.1034/j.1399-0004.2000.570306.x; RA Couture J., Mitri A., Lagace R., Smits R., Berk T., Bouchard H.-L., RA Fodde R., Alman B., Bapat B.; RT "A germline mutation at the extreme 3' end of the APC gene results in a RT severe desmoid phenotype and is associated with overexpression of beta- RT catenin in the desmoid tumor."; RL Clin. Genet. 57:205-212(2000). RN [66] RP VARIANT [LARGE SCALE ANALYSIS] PHE-1254. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [67] RP INVOLVEMENT IN GAPPS. RX PubMed=27087319; DOI=10.1016/j.ajhg.2016.03.001; RA Li J., Woods S.L., Healey S., Beesley J., Chen X., Lee J.S., RA Sivakumaran H., Wayte N., Nones K., Waterfall J.J., Pearson J., Patch A.M., RA Senz J., Ferreira M.A., Kaurah P., Mackenzie R., Heravi-Moussavi A., RA Hansford S., Lannagan T.R.M., Spurdle A.B., Simpson P.T., da Silva L., RA Lakhani S.R., Clouston A.D., Bettington M., Grimpen F., Busuttil R.A., RA Di Costanzo N., Boussioutas A., Jeanjean M., Chong G., Fabre A., RA Olschwang S., Faulkner G.J., Bellos E., Coin L., Rioux K., Bathe O.F., RA Wen X., Martin H.C., Neklason D.W., Davis S.R., Walker R.L., Calzone K.A., RA Avital I., Heller T., Koh C., Pineda M., Rudloff U., Quezado M., RA Pichurin P.N., Hulick P.J., Weissman S.M., Newlin A., Rubinstein W.S., RA Sampson J.E., Hamman K., Goldgar D., Poplawski N., Phillips K., RA Schofield L., Armstrong J., Kiraly-Borri C., Suthers G.K., Huntsman D.G., RA Foulkes W.D., Carneiro F., Lindor N.M., Edwards S.L., French J.D., RA Waddell N., Meltzer P.S., Worthley D.L., Schrader K.A., Chenevix-Trench G.; RT "Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and RT Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis RT Variant."; RL Am. J. Hum. Genet. 98:830-842(2016). RN [68] RP INVOLVEMENT IN GAPPS. RX PubMed=27343414; DOI=10.1016/j.gie.2016.06.023; RA Repak R., Kohoutova D., Podhola M., Rejchrt S., Minarik M., Benesova L., RA Lesko M., Bures J.; RT "The first European family with gastric adenocarcinoma and proximal RT polyposis of the stomach: case report and review of the literature."; RL Gastrointest. Endosc. 84:718-725(2016). RN [69] RP INVOLVEMENT IN MDB. RX PubMed=29753700; DOI=10.1016/s1470-2045(18)30242-0; RA Waszak S.M., Northcott P.A., Buchhalter I., Robinson G.W., Sutter C., RA Groebner S., Grund K.B., Brugieres L., Jones D.T.W., Pajtler K.W., RA Morrissy A.S., Kool M., Sturm D., Chavez L., Ernst A., Brabetz S., Hain M., RA Zichner T., Segura-Wang M., Weischenfeldt J., Rausch T., Mardin B.R., RA Zhou X., Baciu C., Lawerenz C., Chan J.A., Varlet P., Guerrini-Rousseau L., RA Fults D.W., Grajkowska W., Hauser P., Jabado N., Ra Y.S., Zitterbart K., RA Shringarpure S.S., De La Vega F.M., Bustamante C.D., Ng H.K., Perry A., RA MacDonald T.J., Hernaiz Driever P., Bendel A.E., Bowers D.C., McCowage G., RA Chintagumpala M.M., Cohn R., Hassall T., Fleischhack G., Eggen T., RA Wesenberg F., Feychting M., Lannering B., Schuez J., Johansen C., RA Andersen T.V., Roeoesli M., Kuehni C.E., Grotzer M., Kjaerheim K., RA Monoranu C.M., Archer T.C., Duke E., Pomeroy S.L., Shelagh R., Frank S., RA Sumerauer D., Scheurlen W., Ryzhova M.V., Milde T., Kratz C.P., Samuel D., RA Zhang J., Solomon D.A., Marra M., Eils R., Bartram C.R., von Hoff K., RA Rutkowski S., Ramaswamy V., Gilbertson R.J., Korshunov A., Taylor M.D., RA Lichter P., Malkin D., Gajjar A., Korbel J.O., Pfister S.M.; RT "Spectrum and prevalence of genetic predisposition in medulloblastoma: a RT retrospective genetic study and prospective validation in a clinical trial RT cohort."; RL Lancet Oncol. 19:785-798(2018). RN [70] RP INVOLVEMENT IN GAPPS. RX PubMed=33242120; DOI=10.1007/s12328-020-01290-6; RA Kanemitsu K., Iwatsuki M., Yamashita K., Komohara Y., Morinaga T., RA Iwagami S., Eto K., Nagai Y., Kurashige J., Baba Y., Yoshida N., Baba H.; RT "Two Asian families with gastric adenocarcinoma and proximal polyposis of RT the stomach successfully treated via laparoscopic total gastrectomy."; RL Clin. J. Gastroenterol. 14:92-97(2021). CC -!- FUNCTION: Tumor suppressor. Promotes rapid degradation of CTNNB1 and CC participates in Wnt signaling as a negative regulator. APC activity is CC correlated with its phosphorylation state. Activates the GEF activity CC of SPATA13 and ARHGEF4. Plays a role in hepatocyte growth factor (HGF)- CC induced cell migration. Required for MMP9 up-regulation via the JNK CC signaling pathway in colorectal tumor cells. Associates with both CC microtubules and actin filaments, components of the cytoskeleton CC (PubMed:17293347). Plays a role in mediating the organization of F- CC actin into ordered bundles (PubMed:17293347). Functions downstream of CC Rho GTPases and DIAPH1 to selectively stabilize microtubules (By CC similarity). Acts as a mediator of ERBB2-dependent stabilization of CC microtubules at the cell cortex. It is required for the localization of CC MACF1 to the cell membrane and this localization of MACF1 is critical CC for its function in microtubule stabilization. CC {ECO:0000250|UniProtKB:Q61315, ECO:0000269|PubMed:10947987, CC ECO:0000269|PubMed:17293347, ECO:0000269|PubMed:17599059, CC ECO:0000269|PubMed:19151759, ECO:0000269|PubMed:19893577, CC ECO:0000269|PubMed:20937854}. CC -!- SUBUNIT: Forms homooligomers (Probable). Found in a complex consisting CC of ARHGEF4, APC and CTNNB1 (PubMed:10947987). Found in a complex CC composed of MACF1, APC, AXIN1, CTNNB1 and GSK3B (By similarity). The CC complex composed, at least, of APC, CTNNB1 and GSK3B interacts with CC JPT1; the interaction requires the inactive form of GSK3B CC (phosphorylated at 'Ser-9') (PubMed:25169422). Interacts with APC2 CC (PubMed:11691822). Interacts with DLG1 (via PDZ domains) and DLG3 (via CC PDZ domains) (PubMed:8638125, PubMed:9188857). Interacts with CC alpha- and beta-catenins (PubMed:8259519). Interacts with AXIN1 (via CC RGS domain) (PubMed:10811618). Interacts with ARHGEF4 (via N-terminus) CC (PubMed:10947987). Interacts (via C-terminal residues 2674-2843) with CC MAPRE1 (via C-terminal residues 206-211); the interaction inhibits CC association with and bundling of F-actin (PubMed:14514668, CC PubMed:17293347, PubMed:19632184). Interacts with MAPRE2 and MAPRE3 CC (via C-terminus) (PubMed:14514668). Interacts with DIAPH1; DIAPH1 acts CC as a scaffold protein for MAPRE1 and APC to stabilize microtubules and CC promote cell migration (By similarity). Interacts with DIAPH2 (By CC similarity). Interacts with SCRIB; may mediate APC targeting to CC adherens junctions of epithelial cells (PubMed:16611247). Interacts CC with SPATA13 (via N-terminus and SH3 domain) (PubMed:17599059). CC Interacts with ASAP1 (via SH3 domain) (PubMed:20509626). Interacts (at CC the cell membrane) with AMER1 and AMER2 (via ARM repeats) CC (PubMed:21498506, PubMed:22128170). Interacts with KHDRBS1 CC (PubMed:22000517). Interacts with actin; binds both to F-actin and CC actin filament bundles (PubMed:17293347). CC {ECO:0000250|UniProtKB:P70478, ECO:0000250|UniProtKB:Q61315, CC ECO:0000269|PubMed:10811618, ECO:0000269|PubMed:10947987, CC ECO:0000269|PubMed:11691822, ECO:0000269|PubMed:11707392, CC ECO:0000269|PubMed:14514668, ECO:0000269|PubMed:16611247, CC ECO:0000269|PubMed:17293347, ECO:0000269|PubMed:17599059, CC ECO:0000269|PubMed:19632184, ECO:0000269|PubMed:20509626, CC ECO:0000269|PubMed:21498506, ECO:0000269|PubMed:22000517, CC ECO:0000269|PubMed:22128170, ECO:0000269|PubMed:25169422, CC ECO:0000269|PubMed:8259519, ECO:0000269|PubMed:8638125, CC ECO:0000269|PubMed:9188857, ECO:0000305}. CC -!- INTERACTION: CC P25054; Q5JTC6: AMER1; NbExp=4; IntAct=EBI-727707, EBI-6169747; CC P25054; Q8N944: AMER3; NbExp=8; IntAct=EBI-727707, EBI-8869590; CC P25054; Q9NR80-3: ARHGEF4; NbExp=5; IntAct=EBI-727707, EBI-13639160; CC P25054; O15169: AXIN1; NbExp=17; IntAct=EBI-727707, EBI-710484; CC P25054; O14936: CASK; NbExp=2; IntAct=EBI-727707, EBI-1215506; CC P25054; P60953: CDC42; NbExp=9; IntAct=EBI-727707, EBI-81752; CC P25054; P49674: CSNK1E; NbExp=8; IntAct=EBI-727707, EBI-749343; CC P25054; P35221: CTNNA1; NbExp=3; IntAct=EBI-727707, EBI-701918; CC P25054; P35222: CTNNB1; NbExp=22; IntAct=EBI-727707, EBI-491549; CC P25054; Q12959: DLG1; NbExp=11; IntAct=EBI-727707, EBI-357481; CC P25054; Q15700: DLG2; NbExp=2; IntAct=EBI-727707, EBI-80426; CC P25054; Q92796: DLG3; NbExp=2; IntAct=EBI-727707, EBI-80440; CC P25054; P78352: DLG4; NbExp=3; IntAct=EBI-727707, EBI-80389; CC P25054; O14640: DVL1; NbExp=6; IntAct=EBI-727707, EBI-723489; CC P25054; P54792: DVL1P1; NbExp=2; IntAct=EBI-727707, EBI-7848109; CC P25054; O14641: DVL2; NbExp=2; IntAct=EBI-727707, EBI-740850; CC P25054; Q96RT1: ERBIN; NbExp=2; IntAct=EBI-727707, EBI-993903; CC P25054; P14923: JUP; NbExp=3; IntAct=EBI-727707, EBI-702484; CC P25054; Q07666: KHDRBS1; NbExp=4; IntAct=EBI-727707, EBI-1364; CC P25054; Q14114: LRP8; NbExp=2; IntAct=EBI-727707, EBI-2681187; CC P25054; Q86UL8: MAGI2; NbExp=5; IntAct=EBI-727707, EBI-311035; CC P25054; Q15691: MAPRE1; NbExp=6; IntAct=EBI-727707, EBI-1004115; CC P25054; Q14160: SCRIB; NbExp=8; IntAct=EBI-727707, EBI-357345; CC P25054; Q96N96: SPATA13; NbExp=5; IntAct=EBI-727707, EBI-13618641; CC P25054; Q96N96-1: SPATA13; NbExp=5; IntAct=EBI-727707, EBI-13638906; CC P25054; Q96N96-2: SPATA13; NbExp=2; IntAct=EBI-727707, EBI-13639118; CC P25054; O14907: TAX1BP3; NbExp=5; IntAct=EBI-727707, EBI-723259; CC P25054; P63104: YWHAZ; NbExp=2; IntAct=EBI-727707, EBI-347088; CC P25054; Q02248: Ctnnb1; Xeno; NbExp=8; IntAct=EBI-727707, EBI-397872; CC -!- SUBCELLULAR LOCATION: Cell junction, adherens junction CC {ECO:0000269|PubMed:16611247}. Cytoplasm, cytoskeleton CC {ECO:0000269|PubMed:19632184, ECO:0000269|PubMed:20937854}. Cell CC projection, lamellipodium {ECO:0000269|PubMed:19151759}. Cell CC projection, ruffle membrane {ECO:0000269|PubMed:19151759}. Cytoplasm CC {ECO:0000269|PubMed:10947987}. Cell membrane CC {ECO:0000269|PubMed:10947987, ECO:0000269|PubMed:16611247, CC ECO:0000269|PubMed:20937854}. Note=Associated with the microtubule CC network at the growing distal tip of microtubules (PubMed:19632184). CC MAPRE1 may be required for targeting to the growing microtubule plus CC ends (PubMed:19632184). Accumulates in the lamellipodium and ruffle CC membrane in response to hepatocyte growth factor (HGF) treatment CC (PubMed:19151759). The MEMO1-RHOA-DIAPH1 signaling pathway controls CC localization of the phosphorylated form to the cell membrane CC (PubMed:20937854). {ECO:0000269|PubMed:19151759, CC ECO:0000269|PubMed:19632184, ECO:0000269|PubMed:20937854}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage, Alternative splicing; Named isoforms=3; CC Name=1A {ECO:0000303|PubMed:19527921}; Synonyms=Long CC {ECO:0000303|PubMed:1678319}; CC IsoId=P25054-1; Sequence=Displayed; CC Name=2; Synonyms=Short {ECO:0000303|PubMed:1678319}; CC IsoId=P25054-2; Sequence=VSP_004115; CC Name=1B {ECO:0000303|PubMed:19527921}; CC IsoId=P25054-3; Sequence=VSP_059027, VSP_059028; CC -!- TISSUE SPECIFICITY: Expressed in a variety of tissues: brain, small CC intestine, colon, thymus, skeletal muscle, heart, prostate, lung, CC spleen, ovary, testis kidney, placenta, blood and liver CC (PubMed:21643010, PubMed:27217144). Isoform 1A: Very strongly expressed CC in brain but has relatively low expression levels in other tissues CC (PubMed:19527921, PubMed:21643010, PubMed:27217144). Isoform 1B: CC Predominant form in all tissues except for brain, including gastric CC mucosa and blood (PubMed:19527921, PubMed:21643010, PubMed:27217144). CC {ECO:0000269|PubMed:19527921, ECO:0000269|PubMed:21643010, CC ECO:0000269|PubMed:27217144}. CC -!- DOMAIN: The microtubule tip localization signal (MtLS) motif; mediates CC interaction with MAPRE1 and targeting to the growing microtubule plus CC ends. {ECO:0000250}. CC -!- DOMAIN: The basic region (residues 2167-2674) mediates the association CC with both microtubule and actin proteins and promotes the bundling of CC F-actin. {ECO:0000269|PubMed:17293347}. CC -!- PTM: Phosphorylated; phosphorylation enhances the F-actin bundling CC activity (PubMed:17293347). Phosphorylated by GSK3B. CC {ECO:0000269|PubMed:17293347}. CC -!- PTM: Ubiquitinated, leading to its degradation by the proteasome. CC Ubiquitination is facilitated by Axin. Deubiquitinated by CC ZRANB1/TRABID. {ECO:0000269|PubMed:15355978, CC ECO:0000269|PubMed:18281465}. CC -!- DISEASE: Familial adenomatous polyposis 1 (FAP1) [MIM:175100]: An CC autosomal dominant cancer predisposition syndrome characterized by CC adenomatous polyps of the colon and rectum, but also of upper CC gastrointestinal tract (ampullary, duodenal and gastric adenomas). This CC is a viciously premalignant disease with one or more polyps progressing CC through dysplasia to malignancy in untreated gene carriers with a CC median age at diagnosis of 40 years. {ECO:0000269|PubMed:10470088, CC ECO:0000269|PubMed:1316610, ECO:0000269|PubMed:1338691, CC ECO:0000269|PubMed:1338764, ECO:0000269|PubMed:1338904, CC ECO:0000269|PubMed:1651563, ECO:0000269|PubMed:21643010, CC ECO:0000269|PubMed:27217144, ECO:0000269|PubMed:7661930, CC ECO:0000269|PubMed:7833149, ECO:0000269|PubMed:7833931, CC ECO:0000269|PubMed:8111410, ECO:0000269|PubMed:8990002}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Desmoid disease, hereditary (DESMD) [MIM:135290]: An autosomal CC dominant disease characterized by multifocal fibromatosis of the CC abdominal wall and mesentery. Desmoid tumors can also affect paraspinal CC muscles, breast, occiput, arms, and lower ribs. CC {ECO:0000269|PubMed:10782927, ECO:0000269|PubMed:8940264}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Medulloblastoma (MDB) [MIM:155255]: Malignant, invasive CC embryonal tumor of the cerebellum with a preferential manifestation in CC children. {ECO:0000269|PubMed:10666372, ECO:0000269|PubMed:29753700}. CC Note=The gene represented in this entry may be involved in disease CC pathogenesis. CC -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which CC starts in the stomach, can spread to the esophagus or the small CC intestine, and can extend through the stomach wall to nearby lymph CC nodes and organs. It also can metastasize to other parts of the body. CC The term gastric cancer or gastric carcinoma refers to adenocarcinoma CC of the stomach that accounts for most of all gastric malignant tumors. CC Two main histologic types are recognized, diffuse type and intestinal CC type carcinomas. Diffuse tumors are poorly differentiated infiltrating CC lesions, resulting in thickening of the stomach. In contrast, CC intestinal tumors are usually exophytic, often ulcerating, and CC associated with intestinal metaplasia of the stomach, most often CC observed in sporadic disease. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- DISEASE: Hepatocellular carcinoma (HCC) [MIM:114550]: A primary CC malignant neoplasm of epithelial liver cells. The major risk factors CC for HCC are chronic hepatitis B virus (HBV) infection, chronic CC hepatitis C virus (HCV) infection, prolonged dietary aflatoxin CC exposure, alcoholic cirrhosis, and cirrhosis due to other causes. CC Note=The gene represented in this entry may be involved in disease CC pathogenesis. CC -!- DISEASE: Gastric adenocarcinoma and proximal polyposis of the stomach CC (GAPPS) [MIM:619182]: A familial gastric polyposis syndrome CC characterized by autosomal dominant transmission of fundic gland CC polyposis with occasional hyperplastic and adenomatous polyps, sparing CC of the gastric antrum, and a significant risk of intestinal-type CC gastric adenocarcinoma development. Colorectal polyposis is not CC observed, and family history does not include colorectal cancer. CC {ECO:0000269|PubMed:27087319, ECO:0000269|PubMed:27343414, CC ECO:0000269|PubMed:33242120}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- MISCELLANEOUS: APC mutations have led to some interesting observations. CC (1) the great majority of the mutations found to date would result in CC truncation of the APC product. (2) almost all the mutations have CC occurred within the first half of the coding sequence, and somatic CC mutations in colorectal tumors are further clustered in a particular CC region, called MCR (mutation cluster region). (3) most identified point CC mutations in the APC gene are transitions from cytosine to other CC nucleotides. (4) the location of germline mutations tends to correlate CC with the number of colorectal polyps in FAP1 patients. Inactivation of CC both alleles of the APC gene seems to be required as an early event to CC develop most adenomas and carcinomas in the colon and rectum as well as CC some of those in the stomach. CC -!- MISCELLANEOUS: [Isoform 1B]: Produced by alternative promoter usage. CC {ECO:0000269|PubMed:19527921}. CC -!- SIMILARITY: Belongs to the adenomatous polyposis coli (APC) family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Colon cancer gene variant databases Adenomatous CC Polyposis Coli (APC); Note=Leiden Open Variation Database (LOVD); CC URL="https://databases.lovd.nl/shared/genes/APC"; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/118/APC"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M73548; AAA60353.1; -; mRNA. DR EMBL; M73548; AAA60354.1; -; mRNA. DR EMBL; M74088; AAA03586.1; -; mRNA. DR EMBL; AC008575; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC136500; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471086; EAW49002.1; -; Genomic_DNA. DR EMBL; CH471086; EAW49007.1; -; Genomic_DNA. DR EMBL; AK294544; BAH11802.1; -; mRNA. DR EMBL; S78214; AAB21145.2; ALT_SEQ; Genomic_DNA. DR CCDS; CCDS4107.1; -. [P25054-1] DR PIR; A37261; RBHUAP. DR RefSeq; NP_000029.2; NM_000038.5. [P25054-1] DR RefSeq; NP_001120982.1; NM_001127510.3. [P25054-1] DR RefSeq; NP_001120983.2; NM_001127511.3. [P25054-3] DR RefSeq; NP_001341824.1; NM_001354895.2. [P25054-1] DR RefSeq; NP_001341832.1; NM_001354903.2. [P25054-2] DR RefSeq; NP_001394379.1; NM_001407450.1. [P25054-1] DR RefSeq; NP_001394387.1; NM_001407458.1. [P25054-2] DR RefSeq; NP_001394388.1; NM_001407459.1. [P25054-2] DR RefSeq; NP_001394389.1; NM_001407460.1. [P25054-2] DR PDB; 1DEB; X-ray; 2.40 A; A/B=2-55. DR PDB; 1EMU; X-ray; 1.90 A; B=2034-2049. DR PDB; 1JPP; X-ray; 3.10 A; C/D=1021-1035. DR PDB; 1M5I; X-ray; 2.00 A; A=126-250. DR PDB; 1T08; X-ray; 2.10 A; C=1484-1498. DR PDB; 1TH1; X-ray; 2.50 A; C/D=1362-1540. DR PDB; 1V18; X-ray; 2.10 A; B=1482-1528. DR PDB; 2RQU; NMR; -; B=1578-1596. DR PDB; 3AU3; X-ray; 2.10 A; A=396-732. DR PDB; 3NMW; X-ray; 1.60 A; A/B=407-751. DR PDB; 3NMX; X-ray; 2.30 A; A/B/C=407-751. DR PDB; 3NMZ; X-ray; 3.01 A; A/B=303-739. DR PDB; 3QHE; X-ray; 2.40 A; A/C=396-732. DR PDB; 3RL7; X-ray; 2.30 A; G/H/I/J/K/L=2833-2843. DR PDB; 3RL8; X-ray; 2.20 A; F=2833-2843. DR PDB; 3T7U; X-ray; 2.90 A; A/B=407-775. DR PDB; 4G69; X-ray; 2.00 A; B=2833-2843. DR PDB; 4YJE; X-ray; 1.90 A; A=407-751. DR PDB; 4YJL; X-ray; 2.10 A; A/B/C/D/E/F=407-751. DR PDB; 4YK6; X-ray; 1.70 A; A=407-751. DR PDB; 5B6G; X-ray; 1.99 A; A=407-751. DR PDB; 5IZ6; X-ray; 2.15 A; A=407-751. DR PDB; 5IZ8; X-ray; 3.06 A; A/B=407-751. DR PDB; 5IZ9; X-ray; 2.93 A; A=407-751. DR PDB; 5IZA; X-ray; 1.50 A; A=407-751. DR PDB; 5Z8H; X-ray; 1.79 A; A=407-741. DR PDB; 7F6M; X-ray; 2.40 A; A=407-751. DR PDB; 7F7O; X-ray; 2.80 A; A=407-738. DR PDB; 7XTY; X-ray; 2.10 A; C/D=2833-2843. DR PDB; 8GSJ; X-ray; 2.10 A; A=407-738. DR PDB; 8X2Q; X-ray; 2.00 A; A=126-250. DR PDBsum; 1DEB; -. DR PDBsum; 1EMU; -. DR PDBsum; 1JPP; -. DR PDBsum; 1M5I; -. DR PDBsum; 1T08; -. DR PDBsum; 1TH1; -. DR PDBsum; 1V18; -. DR PDBsum; 2RQU; -. DR PDBsum; 3AU3; -. DR PDBsum; 3NMW; -. DR PDBsum; 3NMX; -. DR PDBsum; 3NMZ; -. DR PDBsum; 3QHE; -. DR PDBsum; 3RL7; -. DR PDBsum; 3RL8; -. DR PDBsum; 3T7U; -. DR PDBsum; 4G69; -. DR PDBsum; 4YJE; -. DR PDBsum; 4YJL; -. DR PDBsum; 4YK6; -. DR PDBsum; 5B6G; -. DR PDBsum; 5IZ6; -. DR PDBsum; 5IZ8; -. DR PDBsum; 5IZ9; -. DR PDBsum; 5IZA; -. DR PDBsum; 5Z8H; -. DR PDBsum; 7F6M; -. DR PDBsum; 7F7O; -. DR PDBsum; 7XTY; -. DR PDBsum; 8GSJ; -. DR PDBsum; 8X2Q; -. DR BMRB; P25054; -. DR SMR; P25054; -. DR BioGRID; 106821; 370. DR ComplexPortal; CPX-107; Beta-catenin destruction core complex, APC-AXIN1-GSK3A variant. DR ComplexPortal; CPX-109; Beta-catenin destruction core complex, APC-AXIN1-GSK3B variant. DR ComplexPortal; CPX-439; Beta-catenin destruction core complex, APC-AXIN2-GSK3B variant. DR ComplexPortal; CPX-441; Beta-catenin destruction core complex, APC-AXIN2-GSK3A variant. DR CORUM; P25054; -. DR DIP; DIP-33556N; -. DR FunCoup; P25054; 1537. DR IntAct; P25054; 301. DR MINT; P25054; -. DR STRING; 9606.ENSP00000257430; -. DR BindingDB; P25054; -. DR ChEMBL; CHEMBL3233; -. DR GlyCosmos; P25054; 3 sites, 2 glycans. DR GlyGen; P25054; 8 sites, 3 N-linked glycans (3 sites), 1 O-linked glycan (4 sites). DR iPTMnet; P25054; -. DR PhosphoSitePlus; P25054; -. DR BioMuta; APC; -. DR DMDM; 97535708; -. DR jPOST; P25054; -. DR MassIVE; P25054; -. DR PaxDb; 9606-ENSP00000257430; -. DR PeptideAtlas; P25054; -. DR ProteomicsDB; 54247; -. [P25054-1] DR ProteomicsDB; 54248; -. [P25054-2] DR ProteomicsDB; 6428; -. DR Pumba; P25054; -. DR Antibodypedia; 1054; 757 antibodies from 45 providers. DR DNASU; 324; -. DR Ensembl; ENST00000257430.9; ENSP00000257430.4; ENSG00000134982.20. [P25054-1] DR Ensembl; ENST00000507379.6; ENSP00000423224.2; ENSG00000134982.20. [P25054-3] DR Ensembl; ENST00000508376.6; ENSP00000427089.2; ENSG00000134982.20. [P25054-1] DR Ensembl; ENST00000509732.6; ENSP00000426541.2; ENSG00000134982.20. [P25054-1] DR Ensembl; ENST00000512211.7; ENSP00000423828.3; ENSG00000134982.20. [P25054-1] DR GeneID; 324; -. DR KEGG; hsa:324; -. DR MANE-Select; ENST00000257430.9; ENSP00000257430.4; NM_000038.6; NP_000029.2. DR UCSC; uc003kpy.5; human. [P25054-1] DR UCSC; uc063gan.1; human. DR AGR; HGNC:583; -. DR CIViC; 324; 4 evidence items across 2 molecular profiles. DR ClinPGx; PA24875; -. DR CTD; 324; -. DR DisGeNET; 324; -. DR GeneCards; APC; -. DR GeneReviews; APC; -. DR HGNC; HGNC:583; APC. DR HPA; ENSG00000134982; Tissue enhanced (brain). DR MalaCards; APC; -. DR MIM; 114550; phenotype. DR MIM; 135290; phenotype. DR MIM; 155255; phenotype. DR MIM; 175100; phenotype. DR MIM; 611731; gene. DR MIM; 613659; phenotype. DR MIM; 619182; phenotype. DR OpenTargets; ENSG00000134982; -. DR Orphanet; 261584; 5q22 microdeletion syndrome. DR Orphanet; 220460; Attenuated familial adenomatous polyposis. DR Orphanet; 3258; Cenani-Lenz syndrome. DR Orphanet; 873; Desmoid tumor. DR Orphanet; 314022; Gastric adenocarcinoma and proximal polyposis of the stomach. DR VEuPathDB; HostDB:ENSG00000134982; -. DR eggNOG; KOG2122; Eukaryota. DR GeneTree; ENSGT00530000063749; -. DR HOGENOM; CLU_001012_0_0_1; -. DR InParanoid; P25054; -. DR OMA; DHEKHSP; -. DR OrthoDB; 5918429at2759; -. DR PAN-GO; P25054; 14 GO annotations based on evolutionary models. DR PhylomeDB; P25054; -. DR BioCyc; MetaCyc:ENSG00000134982-MONOMER; -. DR PathwayCommons; P25054; -. DR Reactome; R-HSA-111465; Apoptotic cleavage of cellular proteins. DR Reactome; R-HSA-195253; Degradation of beta-catenin by the destruction complex. DR Reactome; R-HSA-196299; Beta-catenin phosphorylation cascade. DR Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex. DR Reactome; R-HSA-4641262; Disassembly of the destruction complex and recruitment of AXIN to the membrane. DR Reactome; R-HSA-5339716; Signaling by GSK3beta mutants. DR Reactome; R-HSA-5358747; CTNNB1 S33 mutants aren't phosphorylated. DR Reactome; R-HSA-5358749; CTNNB1 S37 mutants aren't phosphorylated. DR Reactome; R-HSA-5358751; CTNNB1 S45 mutants aren't phosphorylated. DR Reactome; R-HSA-5358752; CTNNB1 T41 mutants aren't phosphorylated. DR Reactome; R-HSA-5467333; APC truncation mutants are not K63 polyubiquitinated. DR Reactome; R-HSA-5467337; APC truncation mutants have impaired AXIN binding. DR Reactome; R-HSA-5467340; AXIN missense mutants destabilize the destruction complex. DR Reactome; R-HSA-5467348; Truncations of AMER1 destabilize the destruction complex. DR Reactome; R-HSA-5689896; Ovarian tumor domain proteases. DR SignaLink; P25054; -. DR SIGNOR; P25054; -. DR Agora; ENSG00000134982; -. DR BioGRID-ORCS; 324; 172 hits in 1170 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; D8D47D1F; Synthetic Condensate 000297. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; APC; human. DR EvolutionaryTrace; P25054; -. DR GeneWiki; Adenomatous_polyposis_coli; -. DR GenomeRNAi; 324; -. DR Pharos; P25054; Tchem. DR PRO; PR:P25054; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; P25054; protein. DR Bgee; ENSG00000134982; Expressed in substantia nigra pars compacta and 207 other cell types or tissues. DR ExpressionAtlas; P25054; baseline and differential. DR GO; GO:0005912; C:adherens junction; IEA:UniProtKB-SubCell. DR GO; GO:0030877; C:beta-catenin destruction complex; IDA:UniProtKB. DR GO; GO:0005923; C:bicellular tight junction; IDA:UniProtKB. DR GO; GO:0016342; C:catenin complex; IDA:CACAO. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0000776; C:kinetochore; IDA:UniProtKB. DR GO; GO:0030027; C:lamellipodium; IDA:UniProtKB. DR GO; GO:0016328; C:lateral plasma membrane; IDA:MGI. DR GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:MGI. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0032587; C:ruffle membrane; IDA:UniProtKB. DR GO; GO:1990909; C:Wnt signalosome; NAS:ParkinsonsUK-UCL. DR GO; GO:0008013; F:beta-catenin binding; IDA:BHF-UCL. DR GO; GO:0070840; F:dynein complex binding; IPI:CAFA. DR GO; GO:0045295; F:gamma-catenin binding; IPI:BHF-UCL. DR GO; GO:0008017; F:microtubule binding; IDA:UniProtKB. DR GO; GO:0051010; F:microtubule plus-end binding; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IDA:DisProt. DR GO; GO:0019887; F:protein kinase regulator activity; IDA:UniProtKB. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IDA:MGI. DR GO; GO:0070830; P:bicellular tight junction assembly; NAS:UniProtKB. DR GO; GO:0007155; P:cell adhesion; NAS:UniProtKB. DR GO; GO:0001708; P:cell fate specification; IBA:GO_Central. DR GO; GO:0016477; P:cell migration; IMP:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0003203; P:endocardial cushion morphogenesis; ISS:BHF-UCL. DR GO; GO:0003170; P:heart valve development; ISS:BHF-UCL. DR GO; GO:0008286; P:insulin receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0000281; P:mitotic cytokinesis; IMP:MGI. DR GO; GO:0007094; P:mitotic spindle assembly checkpoint signaling; IMP:MGI. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:UniProtKB. DR GO; GO:1902807; P:negative regulation of cell cycle G1/S phase transition; IDA:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB. DR GO; GO:0045736; P:negative regulation of cyclin-dependent protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0007026; P:negative regulation of microtubule depolymerization; IDA:UniProtKB. DR GO; GO:0007399; P:nervous system development; IBA:GO_Central. DR GO; GO:0007389; P:pattern specification process; IBA:GO_Central. DR GO; GO:0043065; P:positive regulation of apoptotic process; IMP:MGI. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:MGI. DR GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; ISS:YuBioLab. DR GO; GO:0045732; P:positive regulation of protein catabolic process; IGI:MGI. DR GO; GO:1904781; P:positive regulation of protein localization to centrosome; IMP:CAFA. DR GO; GO:0031274; P:positive regulation of pseudopodium assembly; IMP:MGI. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; NAS:ComplexPortal. DR GO; GO:0065003; P:protein-containing complex assembly; IDA:UniProtKB. DR GO; GO:0051988; P:regulation of attachment of spindle microtubules to kinetochore; IMP:MGI. DR GO; GO:0060632; P:regulation of microtubule-based movement; IEP:UniProtKB. DR GO; GO:0032886; P:regulation of microtubule-based process; IMP:UniProtKB. DR GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW. DR DisProt; DP00519; -. DR FunFam; 1.25.10.10:FF:000035; adenomatous polyposis coli protein 2; 1. DR FunFam; 1.10.287.450:FF:000001; adenomatous polyposis coli protein isoform X1; 1. DR Gene3D; 1.20.5.10; -; 1. DR Gene3D; 1.10.287.450; Helix hairpin bin; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1. DR IDEAL; IID00035; -. DR InterPro; IPR009240; APC_15aa_rpt. DR InterPro; IPR009234; APC_basic_dom. DR InterPro; IPR026831; APC_dom. DR InterPro; IPR026818; Apc_fam. DR InterPro; IPR032038; APC_N. DR InterPro; IPR036149; APC_N_sf. DR InterPro; IPR041257; APC_rep. DR InterPro; IPR009223; APC_rpt. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR000225; Armadillo. DR InterPro; IPR009232; EB1-bd. DR InterPro; IPR009224; SAMP. DR PANTHER; PTHR12607:SF11; ADENOMATOUS POLYPOSIS COLI PROTEIN; 1. DR PANTHER; PTHR12607; ADENOMATOUS POLYPOSIS COLI PROTEIN FAMILY; 1. DR Pfam; PF05972; APC_15aa; 4. DR Pfam; PF05956; APC_basic; 1. DR Pfam; PF16689; APC_N_CC; 1. DR Pfam; PF05923; APC_r; 7. DR Pfam; PF18797; APC_rep; 1. DR Pfam; PF16634; APC_u13; 1. DR Pfam; PF16635; APC_u14; 1. DR Pfam; PF16636; APC_u15; 1. DR Pfam; PF16630; APC_u5; 1. DR Pfam; PF16633; APC_u9; 1. DR Pfam; PF00514; Arm; 3. DR Pfam; PF16629; Arm_APC_u3; 1. DR Pfam; PF05937; EB1_binding; 1. DR Pfam; PF05924; SAMP; 3. DR Pfam; PF11414; Suppressor_APC; 1. DR SMART; SM00185; ARM; 7. DR SUPFAM; SSF48371; ARM repeat; 1. DR SUPFAM; SSF58050; N-terminal coiled coil domain from apc; 1. DR SUPFAM; SSF82931; Tumor suppressor gene product Apc; 1. DR PROSITE; PS50176; ARM_REPEAT; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative promoter usage; KW Alternative splicing; Cell junction; Cell membrane; Cell projection; KW Coiled coil; Cytoplasm; Cytoskeleton; Disease variant; Membrane; KW Microtubule; Phosphoprotein; Proteomics identification; Reference proteome; KW Repeat; Tumor suppressor; Ubl conjugation; Wnt signaling pathway. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..2843 FT /note="Adenomatous polyposis coli protein" FT /id="PRO_0000064627" FT REPEAT 453..495 FT /note="ARM 1" FT REPEAT 505..547 FT /note="ARM 2" FT REPEAT 548..591 FT /note="ARM 3" FT REPEAT 592..638 FT /note="ARM 4" FT REPEAT 639..683 FT /note="ARM 5" FT REPEAT 684..725 FT /note="ARM 6" FT REPEAT 726..767 FT /note="ARM 7" FT REGION 239..305 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 828..878 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 923..943 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 958..987 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 960..1337 FT /note="Responsible for down-regulation through a process FT mediated by direct ubiquitination" FT REGION 1020..1169 FT /note="Interaction with catenins" FT /evidence="ECO:0000269|PubMed:8259519" FT REGION 1099..1169 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1190..1244 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1311..1376 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1403..1475 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1526..1569 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1583..1611 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1664..1717 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1729..1836 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1866..1893 FT /note="Highly charged" FT REGION 1881..1950 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1965..2011 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2035..2059 FT /note="Interaction with AXIN1" FT /evidence="ECO:0000269|PubMed:10811618" FT REGION 2043..2072 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2147..2635 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2167..2674 FT /note="Basic region" FT /evidence="ECO:0000269|PubMed:17293347" FT REGION 2475..2843 FT /note="Interaction with DLG1" FT /evidence="ECO:0000269|PubMed:8638125" FT REGION 2667..2714 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2674..2843 FT /note="Interaction with MAPRE1" FT /evidence="ECO:0000269|PubMed:17293347" FT REGION 2729..2843 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 2..61 FT /evidence="ECO:0000255" FT COILED 127..248 FT /evidence="ECO:0000255" FT MOTIF 2803..2806 FT /note="Microtubule tip localization signal" FT MOTIF 2841..2843 FT /note="PDZ-binding" FT COMPBIAS 241..261 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 271..282 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 290..299 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 833..843 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 844..857 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 869..878 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 927..943 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 961..971 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1107..1130 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1146..1159 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1190..1224 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1225..1244 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1335..1345 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1355..1366 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1448..1466 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1540..1564 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1683..1698 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1735..1744 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1785..1794 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1804..1813 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1881..1896 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1897..1913 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1928..1938 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1939..1950 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1979..1991 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2169..2187 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2203..2223 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2257..2271 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2286..2331 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2348..2369 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2370..2409 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2418..2427 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2459..2477 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2518..2535 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2555..2568 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2569..2579 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2580..2592 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2593..2608 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2620..2635 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2668..2679 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2741..2757 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2763..2774 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2784..2812 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 107 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 111 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 744 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 748 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 780 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:24275569" FT MOD_RES 908 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 987 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 1038 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 1042 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1360 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 1371 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1385 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1392 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 1395 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 1438 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1567 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 1774 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1861 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 1863 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692" FT MOD_RES 1864 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692" FT MOD_RES 1971 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 1973 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 2088 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2093 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2125 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61315" FT MOD_RES 2129 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2130 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2132 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2151 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2260 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2270 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2283 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2473 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2535 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2569 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2671 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18220336, FT ECO:0007744|PubMed:18669648" FT MOD_RES 2674 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2679 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2710 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P70478" FT MOD_RES 2724 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2789 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..45 FT /note="MAAASYDQLLKQVEALKMENSNLRQELEDNSNHLTKLETEASNMK -> MYA FT SLGSGPVAPLPASVPPSVLGSWSTGGSRSCVRQETKSPGGARTSGHWASVWQ (in FT isoform 1B)" FT /id="VSP_059027" FT VAR_SEQ 217..244 FT /note="Missing (in isoform 1B)" FT /id="VSP_059028" FT VAR_SEQ 312..412 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:1678319" FT /id="VSP_004115" FT VARIANT 99 FT /note="R -> W (in FAP1; benign; dbSNP:rs139196838)" FT /evidence="ECO:0000269|PubMed:7833149" FT /id="VAR_009613" FT VARIANT 171 FT /note="S -> I (in FAP1)" FT /evidence="ECO:0000269|PubMed:8990002" FT /id="VAR_005032" FT VARIANT 414 FT /note="R -> C (in FAP1; benign; dbSNP:rs137854567)" FT /evidence="ECO:0000269|PubMed:8111410" FT /id="VAR_005033" FT VARIANT 722 FT /note="S -> G (in FAP1)" FT /evidence="ECO:0000269|PubMed:7833931" FT /id="VAR_009614" FT VARIANT 784 FT /note="S -> T (in FAP1)" FT /evidence="ECO:0000269|PubMed:8111410" FT /id="VAR_005034" FT VARIANT 817 FT /note="G -> C (in gastric cancer)" FT /id="VAR_005035" FT VARIANT 870 FT /note="P -> S (in dbSNP:rs33974176)" FT /id="VAR_053976" FT VARIANT 880 FT /note="I -> T (in colorectal carcinoma and gastric cancer; FT from a patient with MMRCS; dbSNP:rs1400295986)" FT /evidence="ECO:0000269|PubMed:9419979" FT /id="VAR_005036" FT VARIANT 890 FT /note="V -> I (in colorectal carcinoma; from a patient with FT MMRCS; dbSNP:rs779998847)" FT /evidence="ECO:0000269|PubMed:9419979" FT /id="VAR_012975" FT VARIANT 906 FT /note="S -> Y (in colorectal tumor)" FT /id="VAR_005037" FT VARIANT 911 FT /note="E -> G (in FAP1 and colorectal tumor)" FT /evidence="ECO:0000269|PubMed:1338904" FT /id="VAR_005038" FT VARIANT 942 FT /note="N -> D (in gastric cancer)" FT /id="VAR_005039" FT VARIANT 1027 FT /note="Y -> C (in colorectal tumor; dbSNP:rs869312784)" FT /id="VAR_005040" FT VARIANT 1057 FT /note="E -> G (found in a family whose members exhibit FT gastrointestinal cancers and multiple pigmented cutaneous FT lesions; uncertain significance)" FT /evidence="ECO:0000269|PubMed:9950360" FT /id="VAR_009615" FT VARIANT 1118 FT /note="N -> D (in dbSNP:rs140493115)" FT /evidence="ECO:0000269|PubMed:1338764" FT /id="VAR_005041" FT VARIANT 1120 FT /note="G -> E (in gastric cancer; dbSNP:rs28933379)" FT /id="VAR_005042" FT VARIANT 1171 FT /note="R -> C (in dbSNP:rs201830995)" FT /evidence="ECO:0000269|PubMed:9950360" FT /id="VAR_008992" FT VARIANT 1171 FT /note="R -> H (in gastric cancer; dbSNP:rs372481703)" FT /id="VAR_005043" FT VARIANT 1176 FT /note="P -> L (in FAP1)" FT /evidence="ECO:0000269|PubMed:8111410" FT /id="VAR_005044" FT VARIANT 1184 FT /note="A -> P (in FAP1)" FT /evidence="ECO:0000269|PubMed:10470088" FT /id="VAR_009616" FT VARIANT 1197 FT /note="F -> S (in gastric cancer)" FT /id="VAR_005045" FT VARIANT 1254 FT /note="I -> F (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035794" FT VARIANT 1259 FT /note="I -> T (in gastric cancer)" FT /id="VAR_005046" FT VARIANT 1292 FT /note="T -> M (in FAP1; uncertain significance; FT dbSNP:rs371113837)" FT /evidence="ECO:0000269|PubMed:1338764" FT /id="VAR_005047" FT VARIANT 1296 FT /note="A -> V (in MDB; sporadic; dbSNP:rs1291513037)" FT /evidence="ECO:0000269|PubMed:10666372" FT /id="VAR_017653" FT VARIANT 1304 FT /note="I -> V (in dbSNP:rs770157475)" FT /evidence="ECO:0000269|PubMed:1338764" FT /id="VAR_005048" FT VARIANT 1307 FT /note="I -> K (probable risk factor for colon and breast FT cancer; dbSNP:rs1801155)" FT /evidence="ECO:0000269|PubMed:9724771, FT ECO:0000269|PubMed:9731522, ECO:0000269|PubMed:9731533, FT ECO:0000269|PubMed:9973276" FT /id="VAR_005049" FT VARIANT 1312 FT /note="G -> E (in gastric cancer)" FT /id="VAR_005050" FT VARIANT 1313 FT /note="T -> A (in FAP1 and colorectal tumor; FT dbSNP:rs863225349)" FT /id="VAR_005051" FT VARIANT 1317 FT /note="E -> Q (may contribute to colorectal tumor FT development; dbSNP:rs1801166)" FT /evidence="ECO:0000269|PubMed:9724771" FT /id="VAR_009617" FT VARIANT 1326 FT /note="V -> A (in gastric cancer)" FT /id="VAR_005052" FT VARIANT 1348 FT /note="R -> W (in FAP1)" FT /evidence="ECO:0000269|PubMed:1338764" FT /id="VAR_005053" FT VARIANT 1395 FT /note="S -> C (in hepatoblastoma; dbSNP:rs137854578)" FT /evidence="ECO:0000269|PubMed:8764128" FT /id="VAR_065133" FT VARIANT 1422 FT /note="D -> H (in colorectal tumor)" FT /id="VAR_005054" FT VARIANT 1472 FT /note="V -> I (in MDB; sporadic; dbSNP:rs878853445)" FT /evidence="ECO:0000269|PubMed:10666372" FT /id="VAR_017654" FT VARIANT 1495 FT /note="S -> G (in MDB; sporadic)" FT /evidence="ECO:0000269|PubMed:10666372" FT /id="VAR_017655" FT VARIANT 1496 FT /note="T -> S (in dbSNP:rs2229996)" FT /id="VAR_020141" FT VARIANT 1508 FT /note="A -> V (in colorectal carcinoma from a patient with FT MMRCS)" FT /evidence="ECO:0000269|PubMed:9419979" FT /id="VAR_012976" FT VARIANT 1822 FT /note="V -> D (in dbSNP:rs459552)" FT /evidence="ECO:0000269|PubMed:1651562, FT ECO:0000269|PubMed:1678319, ECO:0000269|PubMed:9950360, FT ECO:0000269|Ref.5" FT /id="VAR_008993" FT VARIANT 1882 FT /note="R -> T (in dbSNP:rs34157245)" FT /id="VAR_053977" FT VARIANT 1973 FT /note="S -> T (in dbSNP:rs4987109)" FT /id="VAR_020142" FT VARIANT 2499 FT /note="V -> L (in dbSNP:rs33941929)" FT /id="VAR_053978" FT VARIANT 2502 FT /note="G -> S (in dbSNP:rs2229995)" FT /evidence="ECO:0000269|PubMed:1338764" FT /id="VAR_005055" FT VARIANT 2621 FT /note="S -> C (in FAP1; benign; dbSNP:rs72541816)" FT /evidence="ECO:0000269|PubMed:1316610" FT /id="VAR_005056" FT VARIANT 2738 FT /note="I -> T (in dbSNP:rs863224552)" FT /evidence="ECO:0000269|PubMed:9950360" FT /id="VAR_008994" FT VARIANT 2839 FT /note="L -> F (in FAP1; dbSNP:rs876658156)" FT /evidence="ECO:0000269|PubMed:1316610" FT /id="VAR_005057" FT MUTAGEN 516 FT /note="K->E: Impairs interaction with KHDRBS1." FT /evidence="ECO:0000269|PubMed:22000517" FT MUTAGEN 549 FT /note="R->E: Impairs interaction with KHDRBS1." FT /evidence="ECO:0000269|PubMed:22000517" FT MUTAGEN 2841 FT /note="T->L: Loss of interaction with SCRIB." FT /evidence="ECO:0000269|PubMed:16611247" FT MUTAGEN 2843 FT /note="V->Q: Loss of interaction with SCRIB." FT /evidence="ECO:0000269|PubMed:16611247" FT CONFLICT 184 FT /note="M -> L (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 970 FT /note="S -> N (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 1309 FT /note="E -> G (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 1325..1331 FT /note="AVSQHPR -> SSVHSTLE (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 1355 FT /note="S -> P (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 1591 FT /note="A -> G (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 2723 FT /note="N -> T (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT CONFLICT 2755 FT /note="S -> P (in Ref. 1; AAA60353/AAA60354)" FT /evidence="ECO:0000305" FT HELIX 6..53 FT /evidence="ECO:0007829|PDB:1DEB" FT HELIX 132..169 FT /evidence="ECO:0007829|PDB:1M5I" FT HELIX 176..178 FT /evidence="ECO:0007829|PDB:8X2Q" FT HELIX 180..204 FT /evidence="ECO:0007829|PDB:1M5I" FT HELIX 208..238 FT /evidence="ECO:0007829|PDB:1M5I" FT HELIX 328..338 FT /evidence="ECO:0007829|PDB:3NMZ" FT HELIX 343..350 FT /evidence="ECO:0007829|PDB:3NMZ" FT HELIX 353..360 FT /evidence="ECO:0007829|PDB:3NMZ" FT HELIX 377..393 FT /evidence="ECO:0007829|PDB:3NMZ" FT HELIX 407..426 FT /evidence="ECO:0007829|PDB:5IZA" FT STRAND 429..431 FT /evidence="ECO:0007829|PDB:3AU3" FT TURN 433..435 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 441..444 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 446..456 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 460..468 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 471..486 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 492..509 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 513..521 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 523..531 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 532..534 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 538..552 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 557..565 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 568..578 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 582..596 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 600..607 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 612..619 FT /evidence="ECO:0007829|PDB:5IZA" FT STRAND 625..627 FT /evidence="ECO:0007829|PDB:3NMW" FT HELIX 629..646 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 650..658 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 661..668 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 674..687 FT /evidence="ECO:0007829|PDB:5IZA" FT STRAND 688..690 FT /evidence="ECO:0007829|PDB:5IZ8" FT HELIX 692..700 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 703..708 FT /evidence="ECO:0007829|PDB:5IZA" FT TURN 709..712 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 716..731 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 735..737 FT /evidence="ECO:0007829|PDB:5IZA" FT HELIX 739..742 FT /evidence="ECO:0007829|PDB:5IZA" FT TURN 1027..1030 FT /evidence="ECO:0007829|PDB:1JPP" FT HELIX 1470..1479 FT /evidence="ECO:0007829|PDB:1TH1" FT HELIX 1520..1524 FT /evidence="ECO:0007829|PDB:1V18" FT HELIX 2036..2045 FT /evidence="ECO:0007829|PDB:1EMU" FT STRAND 2841..2843 FT /evidence="ECO:0007829|PDB:7XTY" SQ SEQUENCE 2843 AA; 311646 MW; 77E194AE4A91DC5A CRC64; MAAASYDQLL KQVEALKMEN SNLRQELEDN SNHLTKLETE ASNMKEVLKQ LQGSIEDEAM ASSGQIDLLE RLKELNLDSS NFPGVKLRSK MSLRSYGSRE GSVSSRSGEC SPVPMGSFPR RGFVNGSRES TGYLEELEKE RSLLLADLDK EEKEKDWYYA QLQNLTKRID SLPLTENFSL QTDMTRRQLE YEARQIRVAM EEQLGTCQDM EKRAQRRIAR IQQIEKDILR IRQLLQSQAT EAERSSQNKH ETGSHDAERQ NEGQGVGEIN MATSGNGQGS TTRMDHETAS VLSSSSTHSA PRRLTSHLGT KVEMVYSLLS MLGTHDKDDM SRTLLAMSSS QDSCISMRQS GCLPLLIQLL HGNDKDSVLL GNSRGSKEAR ARASAALHNI IHSQPDDKRG RREIRVLHLL EQIRAYCETC WEWQEAHEPG MDQDKNPMPA PVEHQICPAV CVLMKLSFDE EHRHAMNELG GLQAIAELLQ VDCEMYGLTN DHYSITLRRY AGMALTNLTF GDVANKATLC SMKGCMRALV AQLKSESEDL QQVIASVLRN LSWRADVNSK KTLREVGSVK ALMECALEVK KESTLKSVLS ALWNLSAHCT ENKADICAVD GALAFLVGTL TYRSQTNTLA IIESGGGILR NVSSLIATNE DHRQILRENN CLQTLLQHLK SHSLTIVSNA CGTLWNLSAR NPKDQEALWD MGAVSMLKNL IHSKHKMIAM GSAAALRNLM ANRPAKYKDA NIMSPGSSLP SLHVRKQKAL EAELDAQHLS ETFDNIDNLS PKASHRSKQR HKQSLYGDYV FDTNRHDDNR SDNFNTGNMT VLSPYLNTTV LPSSSSSRGS LDSSRSEKDR SLERERGIGL GNYHPATENP GTSSKRGLQI STTAAQIAKV MEEVSAIHTS QEDRSSGSTT ELHCVTDERN ALRRSSAAHT HSNTYNFTKS ENSNRTCSMP YAKLEYKRSS NDSLNSVSSS DGYGKRGQMK PSIESYSEDD ESKFCSYGQY PADLAHKIHS ANHMDDNDGE LDTPINYSLK YSDEQLNSGR QSPSQNERWA RPKHIIEDEI KQSEQRQSRN QSTTYPVYTE STDDKHLKFQ PHFGQQECVS PYRSRGANGS ETNRVGSNHG INQNVSQSLC QEDDYEDDKP TNYSERYSEE EQHEEEERPT NYSIKYNEEK RHVDQPIDYS LKYATDIPSS QKQSFSFSKS SSGQSSKTEH MSSSSENTST PSSNAKRQNQ LHPSSAQSRS GQPQKAATCK VSSINQETIQ TYCVEDTPIC FSRCSSLSSL SSAEDEIGCN QTTQEADSAN TLQIAEIKEK IGTRSAEDPV SEVPAVSQHP RTKSSRLQGS SLSSESARHK AVEFSSGAKS PSKSGAQTPK SPPEHYVQET PLMFSRCTSV SSLDSFESRS IASSVQSEPC SGMVSGIISP SDLPDSPGQT MPPSRSKTPP PPPQTAQTKR EVPKNKAPTA EKRESGPKQA AVNAAVQRVQ VLPDADTLLH FATESTPDGF SCSSSLSALS LDEPFIQKDV ELRIMPPVQE NDNGNETESE QPKESNENQE KEAEKTIDSE KDLLDDSDDD DIEILEECII SAMPTKSSRK AKKPAQTASK LPPPVARKPS QLPVYKLLPS QNRLQPQKHV SFTPGDDMPR VYCVEGTPIN FSTATSLSDL TIESPPNELA AGEGVRGGAQ SGEFEKRDTI PTEGRSTDEA QGGKTSSVTI PELDDNKAEE GDILAECINS AMPKGKSHKP FRVKKIMDQV QQASASSSAP NKNQLDGKKK KPTSPVKPIP QNTEYRTRVR KNADSKNNLN AERVFSDNKD SKKQNLKNNS KVFNDKLPNN EDRVRGSFAF DSPHHYTPIE GTPYCFSRND SLSSLDFDDD DVDLSREKAE LRKAKENKES EAKVTSHTEL TSNQQSANKT QAIAKQPINR GQPKPILQKQ STFPQSSKDI PDRGAATDEK LQNFAIENTP VCFSHNSSLS SLSDIDQENN NKENEPIKET EPPDSQGEPS KPQASGYAPK SFHVEDTPVC FSRNSSLSSL SIDSEDDLLQ ECISSAMPKK KKPSRLKGDN EKHSPRNMGG ILGEDLTLDL KDIQRPDSEH GLSPDSENFD WKAIQEGANS IVSSLHQAAA AACLSRQASS DSDSILSLKS GISLGSPFHL TPDQEEKPFT SNKGPRILKP GEKSTLETKK IESESKGIKG GKKVYKSLIT GKVRSNSEIS GQMKQPLQAN MPSISRGRTM IHIPGVRNSS SSTSPVSKKG PPLKTPASKS PSEGQTATTS PRGAKPSVKS ELSPVARQTS QIGGSSKAPS RSGSRDSTPS RPAQQPLSRP IQSPGRNSIS PGRNGISPPN KLSQLPRTSS PSTASTKSSG SGKMSYTSPG RQMSQQNLTK QTGLSKNASS IPRSESASKG LNQMNNGNGA NKKVELSRMS STKSSGSESD RSERPVLVRQ STFIKEAPSP TLRRKLEESA SFESLSPSSR PASPTRSQAQ TPVLSPSLPD MSLSTHSSVQ AGGWRKLPPN LSPTIEYNDG RPAKRHDIAR SHSESPSRLP INRSGTWKRE HSKHSSSLPR VSTWRRTGSS SSILSASSES SEKAKSEDEK HVNSISGTKQ SKENQVSAKG TWRKIKENEF SPTNSTSQTV SSGATNGAES KTLIYQMAPA VSKTEDVWVR IEDCPINNPR SGRSPTGNTP PVIDSVSEKA NPNIKDSKDN QAKQNVGNGS VPMRTVGLEN RLNSFIQVDA PDQKGTEIKP GQNNPVPVSE TNESSIVERT PFSSSSSSKH SSPSGTVAAR VTPFNYNPSP RKSSADSTSA RPSQIPTPVN NNTKKRDSKT DSTESSGTQS PKRHSGSYLV TSV // ID API5_HUMAN Reviewed; 524 AA. AC Q9BZZ5; B4DGR0; B4DRJ2; B4E283; D3DR21; G3V1C3; O15441; Q9Y4J7; DT 12-APR-2005, integrated into UniProtKB/Swiss-Prot. DT 19-OCT-2011, sequence version 3. DT 28-JAN-2026, entry version 178. DE RecName: Full=Apoptosis inhibitor 5 {ECO:0000305}; DE Short=API-5; DE AltName: Full=Antiapoptosis clone 11 protein; DE Short=AAC-11; DE AltName: Full=Cell migration-inducing gene 8 protein; DE AltName: Full=Fibroblast growth factor 2-interacting factor; DE Short=FIF; DE AltName: Full=Protein XAGL; GN Name=API5 {ECO:0000312|HGNC:HGNC:594}; ORFNames=MIG8; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4). RX PubMed=9307294; RA Tewari M., Yu M., Ross B., Dean C., Giordano A., Rubin R.; RT "AAC-11, a novel cDNA that inhibits apoptosis after growth factor RT withdrawal."; RL Cancer Res. 57:4063-4069(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RX PubMed=10393420; DOI=10.1159/000015247; RA Gianfrancesco F., Esposito T., Ciccodicola A., D'Esposito M., RA Mazzarella R., D'Urso M., Forabosco A.; RT "Molecular cloning and fine mapping of API5L1, a novel human gene strongly RT related to an antiapoptotic gene."; RL Cytogenet. Cell Genet. 84:164-166(1999). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), NUCLEOTIDE SEQUENCE [MRNA] OF RP 72-524 (ISOFORM 1), IDENTIFICATION OF ISOFORM 3, SUBCELLULAR LOCATION, RP TISSUE SPECIFICITY, AND INTERACTION WITH FGF2. RC TISSUE=Liver; RX PubMed=11075807; DOI=10.1210/mend.14.11.0556; RA Van den Berghe L., Laurell H., Huez I., Zanibellato C., Prats H., RA Bugler B.; RT "FIF [fibroblast growth factor-2 (FGF-2)-interacting-factor], a nuclear RT putatively antiapoptotic factor, interacts specifically with FGF-2."; RL Mol. Endocrinol. 14:1709-1724(2000). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RA Kim J.W.; RT "Identification of a human cell migration gene."; RL Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-276; VAL-300 AND RP SER-493. RG NIEHS SNPs program; RL Submitted (MAR-2003) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 4; 5 AND 6). RC TISSUE=Brain, and Trachea; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16554811; DOI=10.1038/nature04632; RA Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K., RA Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T., RA Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G., RA Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C., RA Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A., RA Hattori M., Rogers J., Lander E.S., Sakaki Y.; RT "Human chromosome 11 DNA sequence and analysis including novel gene RT identification."; RL Nature 440:497-500(2006). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Lymph; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP PROTEIN SEQUENCE OF 2-9; 26-36; 131-148; 161-169; 244-251 AND 427-436, RP CLEAVAGE OF INITIATOR METHIONINE, AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Ovarian carcinoma; RA Bienvenut W.V., Lilla S., von Kriegsheim A., Lempens A., Kolch W.; RL Submitted (DEC-2008) to UniProtKB. RN [12] RP NUCLEOTIDE SEQUENCE [MRNA] OF 384-524 (ISOFORM 3). RX PubMed=8889549; DOI=10.1101/gr.6.9.807; RA Hillier L.D., Lennon G., Becker M., Bonaldo M.F., Chiapelli B., Chissoe S., RA Dietrich N., DuBuque T., Favello A., Gish W., Hawkins M., Hultman M., RA Kucaba T., Lacy M., Le M., Le N., Mardis E., Moore B., Morris M., RA Parsons J., Prange C., Rifkin L., Rohlfing T., Schellenberg K., RA Bento Soares M., Tan F., Thierry-Meg J., Trevaskis E., Underwood K., RA Wohldman P., Waterston R., Wilson R., Marra M.; RT "Generation and analysis of 280,000 human expressed sequence tags."; RL Genome Res. 6:807-828(1996). RN [13] RP FUNCTION, AND TISSUE SPECIFICITY. RX PubMed=10780674; DOI=10.1038/labinvest.3780063; RA Kim J.W., Cho H.S., Kim J.H., Hur S.Y., Kim T.E., Lee J.M., Kim I.K., RA Namkoong S.E.; RT "AAC-11 overexpression induces invasion and protects cervical cancer cells RT from apoptosis."; RL Lab. Invest. 80:587-594(2000). RN [14] RP TISSUE SPECIFICITY. RX PubMed=11557113; DOI=10.1016/s0169-5002(01)00213-6; RA Sasaki H., Moriyama S., Yukiue H., Kobayashi Y., Nakashima Y., Kaji M., RA Fukai I., Kiriyama M., Yamakawa Y., Fujii Y.; RT "Expression of the antiapoptosis gene, AAC-11, as a prognosis marker in RT non-small cell lung cancer."; RL Lung Cancer 34:53-57(2001). RN [15] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [16] RP FUNCTION. RX PubMed=17112319; DOI=10.1371/journal.pgen.0020196; RA Morris E.J., Michaud W.A., Ji J.Y., Moon N.S., Rocco J.W., Dyson N.J.; RT "Functional identification of Api5 as a suppressor of E2F-dependent RT apoptosis in vivo."; RL PLoS Genet. 2:E196-E196(2006). RN [17] RP TISSUE SPECIFICITY. RX PubMed=17827341; DOI=10.1189/jlb.0607425; RA Krejci P., Pejchalova K., Rosenbloom B.E., Rosenfelt F.P., Tran E.L., RA Laurell H., Wilcox W.R.; RT "The antiapoptotic protein Api5 and its partner, high molecular weight RT FGF2, are up-regulated in B cell chronic lymphoid leukemia."; RL J. Leukoc. Biol. 82:1363-1364(2007). RN [18] RP FUNCTION, INTERACTION WITH ACIN1, AND TISSUE SPECIFICITY. RX PubMed=19387494; DOI=10.1038/emboj.2009.106; RA Rigou P., Piddubnyak V., Faye A., Rain J.-C., Michel L., Calvo F., RA Poyet J.-L.; RT "The antiapoptotic protein AAC-11 interacts with and regulates Acinus- RT mediated DNA fragmentation."; RL EMBO J. 28:1576-1588(2009). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-464, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [20] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-462 AND SER-464, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [22] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-399, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-464, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [25] RP METHYLATION [LARGE SCALE ANALYSIS] AT ARG-500, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Colon carcinoma; RX PubMed=24129315; DOI=10.1074/mcp.o113.027870; RA Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M., RA Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V., RA Bedford M.T., Comb M.J.; RT "Immunoaffinity enrichment and mass spectrometry analysis of protein RT methylation."; RL Mol. Cell. Proteomics 13:372-387(2014). RN [26] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1-498 OF WILD-TYPE AND MUTANT RP GLN-251, NUCLEAR LOCALIZATION SIGNAL, ACETYLATION AT LYS-251, REPEATS, AND RP SUBUNIT. RX PubMed=22334682; DOI=10.1074/jbc.m111.317594; RA Han B.G., Kim K.H., Lee S.J., Jeong K.C., Cho J.W., Noh K.H., Kim T.W., RA Kim S.J., Yoon H.J., Suh S.W., Lee S., Lee B.I.; RT "Helical repeat structure of apoptosis inhibitor 5 reveals protein-protein RT interaction modules."; RL J. Biol. Chem. 287:10727-10737(2012). CC -!- FUNCTION: Antiapoptotic factor that may have a role in protein CC assembly. Negatively regulates ACIN1. By binding to ACIN1, it CC suppresses ACIN1 cleavage from CASP3 and ACIN1-mediated DNA CC fragmentation. Also known to efficiently suppress E2F1-induced CC apoptosis. Its depletion enhances the cytotoxic action of the CC chemotherapeutic drugs. {ECO:0000269|PubMed:10780674, CC ECO:0000269|PubMed:17112319, ECO:0000269|PubMed:19387494}. CC -!- SUBUNIT: Monomer. Interacts with FGF2 and ACIN1. CC {ECO:0000269|PubMed:11075807, ECO:0000269|PubMed:19387494, CC ECO:0000269|PubMed:22334682}. CC -!- INTERACTION: CC Q9BZZ5; Q9UKV3-3: ACIN1; NbExp=2; IntAct=EBI-1048422, EBI-6976596; CC Q9BZZ5; Q13838: DDX39B; NbExp=2; IntAct=EBI-1048422, EBI-348622; CC Q9BZZ5-2; Q9UBB4: ATXN10; NbExp=3; IntAct=EBI-10989614, EBI-702390; CC Q9BZZ5-2; A1A5D9: BICDL2; NbExp=3; IntAct=EBI-10989614, EBI-10171799; CC Q9BZZ5-2; P19404: NDUFV2; NbExp=3; IntAct=EBI-10989614, EBI-713665; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11075807}. Cytoplasm CC {ECO:0000269|PubMed:11075807}. Note=Mainly nuclear. Can also be CC cytoplasmic. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Cytoplasm. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=6; CC Comment=Additional isoforms seem to exist.; CC Name=4; CC IsoId=Q9BZZ5-4; Sequence=Displayed; CC Name=1; Synonyms=FIF-510; CC IsoId=Q9BZZ5-1; Sequence=VSP_041969, VSP_041972; CC Name=2; Synonyms=FIF-504; CC IsoId=Q9BZZ5-2; Sequence=VSP_041970, VSP_041971; CC Name=3; Synonyms=FIF C1; CC IsoId=Q9BZZ5-3; Sequence=VSP_039761, VSP_039762; CC Name=5; CC IsoId=Q9BZZ5-5; Sequence=VSP_043289, VSP_041970, VSP_041971; CC Name=6; CC IsoId=Q9BZZ5-6; Sequence=VSP_057412; CC -!- TISSUE SPECIFICITY: Expressed in all tissues tested, including heart, CC brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. CC Highest levels in heart, pancreas and placenta. Highly expressed in CC several cancers. Preferentially expressed in squamous cell carcinoma CC versus adenocarcinoma in non-small cell lung cancer. CC {ECO:0000269|PubMed:10780674, ECO:0000269|PubMed:11075807, CC ECO:0000269|PubMed:11557113, ECO:0000269|PubMed:17827341, CC ECO:0000269|PubMed:19387494}. CC -!- DOMAIN: Two regions, an N-terminal (aa 96-107) and a C-terminal (aa CC 274-311) are required for binding FGF2. CC -!- PTM: Acetylation at Lys-251 impairs antiapoptotic function. CC {ECO:0000269|PubMed:22334682}. CC -!- SIMILARITY: Belongs to the API5 family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAB86528.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=AAB86528.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U83857; AAB86528.1; ALT_SEQ; mRNA. DR EMBL; Y15906; CAA75867.1; -; mRNA. DR EMBL; AF229253; AAK00737.1; -; mRNA. DR EMBL; AF229254; AAK00738.1; -; mRNA. DR EMBL; AY311389; AAQ76714.1; -; mRNA. DR EMBL; BT007093; AAP35756.1; -; mRNA. DR EMBL; AY265973; AAO89077.1; -; Genomic_DNA. DR EMBL; AK294724; BAG57871.1; -; mRNA. DR EMBL; AK299288; BAG61304.1; -; mRNA. DR EMBL; AK304157; BAG65045.1; -; mRNA. DR EMBL; AC087276; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471064; EAW68098.1; -; Genomic_DNA. DR EMBL; CH471064; EAW68099.1; -; Genomic_DNA. DR EMBL; BC017709; AAH17709.1; -; mRNA. DR EMBL; W40304; -; NOT_ANNOTATED_CDS; mRNA. DR CCDS; CCDS31465.1; -. [Q9BZZ5-2] DR CCDS; CCDS44572.1; -. [Q9BZZ5-4] DR CCDS; CCDS44573.1; -. [Q9BZZ5-5] DR RefSeq; NP_001136402.1; NM_001142930.2. [Q9BZZ5-4] DR RefSeq; NP_001136403.1; NM_001142931.2. [Q9BZZ5-5] DR RefSeq; NP_001230676.1; NM_001243747.1. DR RefSeq; NP_006586.1; NM_006595.4. [Q9BZZ5-2] DR PDB; 3U0R; X-ray; 2.50 A; A=1-498. DR PDB; 3V6A; X-ray; 2.60 A; A=1-454. DR PDB; 6L4O; X-ray; 2.60 A; A=1-524. DR PDBsum; 3U0R; -. DR PDBsum; 3V6A; -. DR PDBsum; 6L4O; -. DR AlphaFoldDB; Q9BZZ5; -. DR SMR; Q9BZZ5; -. DR BioGRID; 114109; 198. DR CORUM; Q9BZZ5; -. DR FunCoup; Q9BZZ5; 5479. DR IntAct; Q9BZZ5; 47. DR MINT; Q9BZZ5; -. DR STRING; 9606.ENSP00000431391; -. DR GlyGen; Q9BZZ5; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q9BZZ5; -. DR PhosphoSitePlus; Q9BZZ5; -. DR SwissPalm; Q9BZZ5; -. DR BioMuta; API5; -. DR DMDM; 353526346; -. DR jPOST; Q9BZZ5; -. DR MassIVE; Q9BZZ5; -. DR PaxDb; 9606-ENSP00000431391; -. DR PeptideAtlas; Q9BZZ5; -. DR ProteomicsDB; 32325; -. DR ProteomicsDB; 79926; -. [Q9BZZ5-4] DR ProteomicsDB; 79927; -. [Q9BZZ5-1] DR ProteomicsDB; 79928; -. [Q9BZZ5-2] DR ProteomicsDB; 79929; -. [Q9BZZ5-3] DR ProteomicsDB; 79930; -. [Q9BZZ5-5] DR Pumba; Q9BZZ5; -. DR Antibodypedia; 13145; 290 antibodies from 33 providers. DR DNASU; 8539; -. DR Ensembl; ENST00000378852.7; ENSP00000368129.3; ENSG00000166181.14. [Q9BZZ5-2] DR Ensembl; ENST00000420461.6; ENSP00000402540.2; ENSG00000166181.14. [Q9BZZ5-5] DR Ensembl; ENST00000455725.6; ENSP00000399341.2; ENSG00000166181.14. [Q9BZZ5-6] DR Ensembl; ENST00000531273.6; ENSP00000431391.1; ENSG00000166181.14. [Q9BZZ5-4] DR Ensembl; ENST00000534600.5; ENSP00000434462.1; ENSG00000166181.14. [Q9BZZ5-1] DR GeneID; 8539; -. DR KEGG; hsa:8539; -. DR MANE-Select; ENST00000531273.6; ENSP00000431391.1; NM_001142930.2; NP_001136402.1. DR UCSC; uc001mxf.3; human. [Q9BZZ5-4] DR UCSC; uc010rfg.2; human. DR AGR; HGNC:594; -. DR ClinPGx; PA24881; -. DR CTD; 8539; -. DR DisGeNET; 8539; -. DR GeneCards; API5; -. DR HGNC; HGNC:594; API5. DR HPA; ENSG00000166181; Low tissue specificity. DR MIM; 609774; gene. DR OpenTargets; ENSG00000166181; -. DR VEuPathDB; HostDB:ENSG00000166181; -. DR eggNOG; KOG2213; Eukaryota. DR GeneTree; ENSGT00390000010991; -. DR HOGENOM; CLU_037809_1_0_1; -. DR InParanoid; Q9BZZ5; -. DR OMA; RCIKFLA; -. DR OrthoDB; 19224at2759; -. DR PAN-GO; Q9BZZ5; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q9BZZ5; -. DR PathwayCommons; Q9BZZ5; -. DR SignaLink; Q9BZZ5; -. DR Agora; ENSG00000166181; -. DR BioGRID-ORCS; 8539; 68 hits in 1156 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; API5; human. DR EvolutionaryTrace; Q9BZZ5; -. DR GeneWiki; API5; -. DR GenomeRNAi; 8539; -. DR Pharos; Q9BZZ5; Tbio. DR PRO; PR:Q9BZZ5; -. DR Proteomes; UP000005640; Chromosome 11. DR RNAct; Q9BZZ5; protein. DR Bgee; ENSG00000166181; Expressed in islet of Langerhans and 218 other cell types or tissues. DR ExpressionAtlas; Q9BZZ5; baseline and differential. DR GO; GO:0005737; C:cytoplasm; NAS:UniProtKB. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0016607; C:nuclear speck; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005681; C:spliceosomal complex; ISS:UniProtKB. DR GO; GO:0017134; F:fibroblast growth factor binding; IPI:UniProtKB. DR GO; GO:0003723; F:RNA binding; HDA:UniProtKB. DR GO; GO:0044346; P:fibroblast apoptotic process; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:2000270; P:negative regulation of fibroblast apoptotic process; IEA:Ensembl. DR DisProt; DP02894; -. [Q9BZZ5-2] DR FunFam; 1.25.10.10:FF:000092; apoptosis inhibitor 5 isoform X2; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1. DR InterPro; IPR008383; API5. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR PANTHER; PTHR12758:SF19; APOPTOSIS INHIBITOR 5; 1. DR PANTHER; PTHR12758; APOPTOSIS INHIBITOR 5-RELATED; 1. DR Pfam; PF05918; API5; 1. DR SUPFAM; SSF48371; ARM repeat; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; Cytoplasm; KW Direct protein sequencing; Methylation; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|Ref.11" FT CHAIN 2..524 FT /note="Apoptosis inhibitor 5" FT /id="PRO_0000064634" FT REGION 2..360 FT /note="ARM-like and Heat-like helical repeats" FT REGION 370..391 FT /note="Leucine-zipper" FT REGION 452..524 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 454..475 FT /note="Nuclear localization signal" FT /evidence="ECO:0000269|PubMed:22334682" FT COMPBIAS 462..472 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 487..497 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 251 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:22334682" FT MOD_RES 399 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 462 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 464 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569" FT MOD_RES 469 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O35841" FT MOD_RES 500 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0007744|PubMed:24129315" FT VAR_SEQ 1..23 FT /note="MPTVEELYRNYGILADATEQVGQ -> MKQRWRENGIGK (in isoform FT 6)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_057412" FT VAR_SEQ 24..77 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_043289" FT VAR_SEQ 427..431 FT /note="DLFHI -> AKESQ (in isoform 3)" FT /evidence="ECO:0000303|PubMed:8889549" FT /id="VSP_039761" FT VAR_SEQ 432..510 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:8889549" FT /id="VSP_039762" FT VAR_SEQ 498..510 FT /note="EQRGAFRGSRGGR -> GERFRLGTRNMRD (in isoform 1)" FT /evidence="ECO:0000303|PubMed:11075807" FT /id="VSP_041969" FT VAR_SEQ 499..504 FT /note="QRGAFR -> RSLQGK (in isoform 2 and isoform 5)" FT /evidence="ECO:0000303|PubMed:10393420, FT ECO:0000303|PubMed:11075807, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|Ref.4, FT ECO:0000303|Ref.5" FT /id="VSP_041970" FT VAR_SEQ 505..524 FT /note="Missing (in isoform 2 and isoform 5)" FT /evidence="ECO:0000303|PubMed:10393420, FT ECO:0000303|PubMed:11075807, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|Ref.4, FT ECO:0000303|Ref.5" FT /id="VSP_041971" FT VAR_SEQ 511..524 FT /note="Missing (in isoform 1)" FT /evidence="ECO:0000303|PubMed:11075807" FT /id="VSP_041972" FT VARIANT 276 FT /note="P -> S" FT /evidence="ECO:0000269|Ref.6" FT /id="VAR_021519" FT VARIANT 300 FT /note="M -> V (in dbSNP:rs5743240)" FT /evidence="ECO:0000269|Ref.6" FT /id="VAR_021520" FT VARIANT 493 FT /note="G -> S (in dbSNP:rs2862934)" FT /evidence="ECO:0000269|Ref.6" FT /id="VAR_021521" FT CONFLICT 371..373 FT /note="KDF -> HES (in Ref. 1; AAB86528)" FT /evidence="ECO:0000305" FT HELIX 4..16 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 18..24 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 25..33 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 34..36 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 39..52 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 53..55 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 57..59 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 60..71 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 76..85 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 86..89 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 92..94 FT /evidence="ECO:0007829|PDB:6L4O" FT HELIX 95..105 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 111..127 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 129..142 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 145..158 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 159..161 FT /evidence="ECO:0007829|PDB:3U0R" FT TURN 164..166 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 169..182 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 183..185 FT /evidence="ECO:0007829|PDB:6L4O" FT HELIX 188..199 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 202..204 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 207..221 FT /evidence="ECO:0007829|PDB:3U0R" FT TURN 222..224 FT /evidence="ECO:0007829|PDB:3U0R" FT STRAND 229..231 FT /evidence="ECO:0007829|PDB:3V6A" FT HELIX 232..245 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 246..248 FT /evidence="ECO:0007829|PDB:3U0R" FT STRAND 251..253 FT /evidence="ECO:0007829|PDB:6L4O" FT HELIX 256..265 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 267..269 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 282..294 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 303..315 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 340..354 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 359..362 FT /evidence="ECO:0007829|PDB:3U0R" FT TURN 368..370 FT /evidence="ECO:0007829|PDB:3V6A" FT HELIX 371..395 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 402..404 FT /evidence="ECO:0007829|PDB:3U0R" FT HELIX 406..427 FT /evidence="ECO:0007829|PDB:3U0R" FT STRAND 430..432 FT /evidence="ECO:0007829|PDB:6L4O" SQ SEQUENCE 524 AA; 59005 MW; A2EA6BE4D8318BB9 CRC64; MPTVEELYRN YGILADATEQ VGQHKDAYQV ILDGVKGGTK EKRLAAQFIP KFFKHFPELA DSAINAQLDL CEDEDVSIRR QAIKELPQFA TGENLPRVAD ILTQLLQTDD SAEFNLVNNA LLSIFKMDAK GTLGGLFSQI LQGEDIVRER AIKFLSTKLK TLPDEVLTKE VEELILTESK KVLEDVTGEE FVLFMKILSG LKSLQTVSGR QQLVELVAEQ ADLEQTFNPS DPDCVDRLLQ CTRQAVPLFS KNVHSTRFVT YFCEQVLPNL GTLTTPVEGL DIQLEVLKLL AEMSSFCGDM EKLETNLRKL FDKLLEYMPL PPEEAENGEN AGNEEPKLQF SYVECLLYSF HQLGRKLPDF LTAKLNAEKL KDFKIRLQYF ARGLQVYIRQ LRLALQGKTG EALKTEENKI KVVALKITNN INVLIKDLFH IPPSYKSTVT LSWKPVQKVE IGQKRASEDT TSGSPPKKSS AGPKRDARQI YNPPSGKYSS NLGNFNYEQR GAFRGSRGGR GWGTRGNRSR GRLY // ID ARP3B_HUMAN Reviewed; 418 AA. AC Q9P1U1; A8MTG1; B4DFW4; Q7Z526; Q96BT2; DT 22-JUL-2008, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-2000, sequence version 1. DT 28-JAN-2026, entry version 180. DE RecName: Full=Actin-related protein 3B; DE AltName: Full=ARP3-beta; DE AltName: Full=Actin-like protein 3B; DE AltName: Full=Actin-related protein ARP4; GN Name=ACTR3B; Synonyms=ARP11, ARP4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ALTERNATIVE SPLICING, AND TISSUE RP SPECIFICITY. RC TISSUE=Embryo; RX PubMed=10806390; DOI=10.1046/j.1432-1327.2000.01306.x; RA Jay P., Berge-Lefranc J.-L., Massacrier A., Roessler E., Wallis D., RA Muenke M., Gastaldi M., Taviaux S., Cau P., Berta P.; RT "ARP3beta, the gene encoding a new human actin-related protein, is RT alternatively spliced and predominantly expressed in brain neuronal RT cells."; RL Eur. J. Biochem. 267:2921-2928(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RA Ding J.B., Yu L., Zhang M., Dai F.Y., Jiang J.X., Zhao S.Y.; RT "Cloning of a novel human cDNA homology to human actin-related protein RT Arp3(ARP3) mRNA."; RL Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Amygdala, and Peripheral blood; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12853948; DOI=10.1038/nature01782; RA Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H., RA Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K., RA Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A., RA Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H., RA Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A., RA Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P., RA Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M., RA Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S., RA Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., RA Strowmatt C., Latreille P., Miller N., Johnson D., Murray J., RA Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., RA Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., RA Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E., RA Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E., RA Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A., RA Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A., RA Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R., RA McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H., RA Wilson R.K.; RT "The DNA sequence of human chromosome 7."; RL Nature 424:157-164(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3). RC TISSUE=Colon, and Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP TISSUE SPECIFICITY. RX PubMed=11162478; DOI=10.1006/bbrc.2000.4059; RA Shindo-Okada N., Shimizu K.; RT "Isolation of a novel actin-related gene expressed in low-metastatic PC-14 RT human lung adenocarcinoma."; RL Biochem. Biophys. Res. Commun. 280:61-67(2001). RN [7] RP FUNCTION. RX PubMed=14651955; DOI=10.1016/j.bbrc.2003.10.200; RA Shindo-Okada N., Iigo M.; RT "Expression of the Arp11 gene suppresses the tumorigenicity of PC-14 human RT lung adenocarcinoma cells."; RL Biochem. Biophys. Res. Commun. 312:889-896(2003). CC -!- FUNCTION: Plays a role in the organization of the actin cytoskeleton. CC May function as ATP-binding component of the Arp2/3 complex which is CC involved in regulation of actin polymerization and together with an CC activating nucleation-promoting factor (NPF) mediates the formation of CC branched actin networks. May decrease the metastatic potential of CC tumors. {ECO:0000269|PubMed:14651955}. CC -!- SUBUNIT: Interacts with the Arp2/3 complex composed of ARP2, ARP3, CC ARPC1B, ARPC1B/p41-ARC, ARPC2/p34-ARC, ARPC3/p21-ARC, ARPC4/p20-ARC and CC ARPC5/p16-ARC. CC -!- INTERACTION: CC Q9P1U1; P61160: ACTR2; NbExp=4; IntAct=EBI-1047175, EBI-353580; CC Q9P1U1; Q92747: ARPC1A; NbExp=4; IntAct=EBI-1047175, EBI-1020827; CC Q9P1U1; O15143: ARPC1B; NbExp=4; IntAct=EBI-1047175, EBI-1044647; CC Q9P1U1; O15144: ARPC2; NbExp=4; IntAct=EBI-1047175, EBI-352356; CC Q9P1U1; O15145: ARPC3; NbExp=4; IntAct=EBI-1047175, EBI-351829; CC Q9P1U1; P59998: ARPC4; NbExp=4; IntAct=EBI-1047175, EBI-351872; CC Q9P1U1; O15511: ARPC5; NbExp=4; IntAct=EBI-1047175, EBI-352975; CC Q9P1U1; Q9BPX5: ARPC5L; NbExp=3; IntAct=EBI-1047175, EBI-711189; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton {ECO:0000250}. Cell CC projection {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q9P1U1-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9P1U1-2; Sequence=VSP_034418; CC Name=3; CC IsoId=Q9P1U1-3; Sequence=VSP_041474; CC -!- TISSUE SPECIFICITY: Detected in fetal brain. Detected throughout the CC adult brain, in neurons from gray matter, but not in white matter. CC Detected in liver, skeletal muscle and pancreas. Detected in lung CC adenocarcinoma cells with low metastatic potential, but not in lung CC adenocarcinoma cells with high metastatic potential. CC {ECO:0000269|PubMed:10806390, ECO:0000269|PubMed:11162478}. CC -!- SIMILARITY: Belongs to the actin family. ARP3 subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAP97150.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF023453; AAC98904.1; -; mRNA. DR EMBL; AF086920; AAP97150.1; ALT_SEQ; mRNA. DR EMBL; AK294292; BAG57575.1; -; mRNA. DR EMBL; AK315534; BAG37914.1; -; mRNA. DR EMBL; AC072057; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC092180; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC015207; AAH15207.1; -; mRNA. DR EMBL; BC008682; AAH08682.1; -; mRNA. DR CCDS; CCDS34782.1; -. [Q9P1U1-3] DR CCDS; CCDS5934.1; -. [Q9P1U1-1] DR CCDS; CCDS87568.1; -. [Q9P1U1-2] DR RefSeq; NP_001035225.1; NM_001040135.3. [Q9P1U1-3] DR RefSeq; NP_001337869.1; NM_001350940.2. [Q9P1U1-2] DR RefSeq; NP_001337870.1; NM_001350941.2. [Q9P1U1-2] DR RefSeq; NP_001337871.1; NM_001350942.2. [Q9P1U1-2] DR RefSeq; NP_001337872.1; NM_001350943.2. [Q9P1U1-2] DR RefSeq; NP_065178.1; NM_020445.6. [Q9P1U1-1] DR AlphaFoldDB; Q9P1U1; -. DR SMR; Q9P1U1; -. DR BioGRID; 121429; 159. DR ComplexPortal; CPX-2490; Actin-related protein 2/3 complex, ARPC1A-ACTR3B-ARPC5 variant. DR ComplexPortal; CPX-2580; Actin-related protein 2/3 complex, ARPC1B-ACTR3B-ARPC5L variant. DR ComplexPortal; CPX-2583; Actin-related protein 2/3 complex, ARPC1B-ACTR3B-ARPC5 variant. DR ComplexPortal; CPX-2668; Actin-related protein 2/3 complex, ARPC1B-ACTR3B-ARPC5L variant. DR FunCoup; Q9P1U1; 692. DR IntAct; Q9P1U1; 55. DR MINT; Q9P1U1; -. DR STRING; 9606.ENSP00000256001; -. DR GlyGen; Q9P1U1; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q9P1U1; -. DR MetOSite; Q9P1U1; -. DR PhosphoSitePlus; Q9P1U1; -. DR SwissPalm; Q9P1U1; -. DR BioMuta; ACTR3B; -. DR DMDM; 74753111; -. DR jPOST; Q9P1U1; -. DR MassIVE; Q9P1U1; -. DR PaxDb; 9606-ENSP00000256001; -. DR PeptideAtlas; Q9P1U1; -. DR ProteomicsDB; 83666; -. [Q9P1U1-1] DR ProteomicsDB; 83667; -. [Q9P1U1-2] DR ProteomicsDB; 83668; -. [Q9P1U1-3] DR Pumba; Q9P1U1; -. DR Antibodypedia; 33062; 191 antibodies from 26 providers. DR DNASU; 57180; -. DR Ensembl; ENST00000256001.13; ENSP00000256001.8; ENSG00000133627.19. [Q9P1U1-1] DR Ensembl; ENST00000377776.7; ENSP00000367007.3; ENSG00000133627.19. [Q9P1U1-3] DR Ensembl; ENST00000397282.2; ENSP00000380452.2; ENSG00000133627.19. [Q9P1U1-2] DR GeneID; 57180; -. DR KEGG; hsa:57180; -. DR MANE-Select; ENST00000256001.13; ENSP00000256001.8; NM_020445.6; NP_065178.1. DR UCSC; uc003wle.3; human. [Q9P1U1-1] DR AGR; HGNC:17256; -. DR ClinPGx; PA142672645; -. DR CTD; 57180; -. DR DisGeNET; 57180; -. DR GeneCards; ACTR3B; -. DR HGNC; HGNC:17256; ACTR3B. DR HPA; ENSG00000133627; Tissue enhanced (brain). DR OpenTargets; ENSG00000133627; -. DR VEuPathDB; HostDB:ENSG00000133627; -. DR eggNOG; KOG0678; Eukaryota. DR GeneTree; ENSGT00940000158304; -. DR HOGENOM; CLU_027965_3_2_1; -. DR InParanoid; Q9P1U1; -. DR OMA; DVMEEYW; -. DR OrthoDB; 421448at2759; -. DR PAN-GO; Q9P1U1; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q9P1U1; -. DR PathwayCommons; Q9P1U1; -. DR SignaLink; Q9P1U1; -. DR Agora; ENSG00000133627; -. DR BioGRID-ORCS; 57180; 15 hits in 1162 CRISPR screens. DR ChiTaRS; ACTR3B; human. DR GeneWiki; ACTR3B; -. DR GenomeRNAi; 57180; -. DR Pharos; Q9P1U1; Tbio. DR PRO; PR:Q9P1U1; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; Q9P1U1; protein. DR Bgee; ENSG00000133627; Expressed in cortical plate and 158 other cell types or tissues. DR GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0030027; C:lamellipodium; IEA:UniProtKB-ARBA. DR GO; GO:0003779; F:actin binding; IEA:UniProtKB-KW. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR CDD; cd10221; ASKHA_NBD_Arp3-like; 1. DR FunFam; 3.30.420.40:FF:000029; Actin-related protein 3; 1. DR FunFam; 3.30.420.40:FF:000315; Actin-related protein 3; 1. DR FunFam; 3.30.420.40:FF:000803; Actin-related protein 3; 1. DR FunFam; 3.90.640.10:FF:000006; Actin-related protein 3 (ARP3); 1. DR FunFam; 2.30.36.70:FF:000002; actin-related protein 3 isoform X1; 1. DR Gene3D; 3.30.420.40; -; 2. DR Gene3D; 2.30.36.70; Actin, Chain A, domain 2; 1. DR Gene3D; 3.90.640.10; Actin, Chain A, domain 4; 1. DR InterPro; IPR004000; Actin. DR InterPro; IPR020902; Actin/actin-like_CS. DR InterPro; IPR043129; ATPase_NBD. DR PANTHER; PTHR11937; ACTIN; 1. DR Pfam; PF00022; Actin; 1. DR SMART; SM00268; ACTIN; 1. DR SUPFAM; SSF53067; Actin-like ATPase domain; 2. DR PROSITE; PS01132; ACTINS_ACT_LIKE; 1. PE 1: Evidence at protein level; KW Actin-binding; Alternative splicing; ATP-binding; Cell projection; KW Cytoplasm; Cytoskeleton; Nucleotide-binding; Proteomics identification; KW Reference proteome. FT CHAIN 1..418 FT /note="Actin-related protein 3B" FT /id="PRO_0000342358" FT VAR_SEQ 1..88 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, ECO:0000303|Ref.2" FT /id="VSP_034418" FT VAR_SEQ 318..387 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_041474" FT VARIANT 250 FT /note="R -> Q (in dbSNP:rs2260545)" FT /id="VAR_048188" SQ SEQUENCE 418 AA; 47608 MW; BC1040ED5D3B832F CRC64; MAGSLPPCVV DCGTGYTKLG YAGNTEPQFI IPSCIAIRES AKVVDQAQRR VLRGVDDLDF FIGDEAIDKP TYATKWPIRH GIIEDWDLME RFMEQVVFKY LRAEPEDHYF LMTEPPLNTP ENREYLAEIM FESFNVPGLY IAVQAVLALA ASWTSRQVGE RTLTGIVIDS GDGVTHVIPV AEGYVIGSCI KHIPIAGRDI TYFIQQLLRE REVGIPPEQS LETAKAIKEK YCYICPDIVK EFAKYDVDPR KWIKQYTGIN AINQKKFVID VGYERFLGPE IFFHPEFANP DFMESISDVV DEVIQNCPID VRRPLYKNVV LSGGSTMFRD FGRRLQRDLK RVVDARLRLS EELSGGRIKP KPVEVQVVTH HMQRYAVWFG GSMLASTPEF FQVCHTKKDY EEYGPSICRH NPVFGVMS // ID ARP3C_HUMAN Reviewed; 210 AA. AC Q9C0K3; Q5CZI4; DT 18-MAR-2008, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-2001, sequence version 1. DT 28-JAN-2026, entry version 151. DE RecName: Full=Actin-related protein 3C; DE AltName: Full=Actin-related protein 11; DE Flags: Precursor; GN Name=ACTR3C; Synonyms=ARP11; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND TISSUE SPECIFICITY. RC TISSUE=Lung; RX PubMed=11162478; DOI=10.1006/bbrc.2000.4059; RA Shindo-Okada N., Shimizu K.; RT "Isolation of a novel actin-related gene expressed in low-metastatic PC-14 RT human lung adenocarcinoma."; RL Biochem. Biophys. Res. Commun. 280:61-67(2001). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Fetal kidney; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). CC -!- FUNCTION: May play a role in the suppression of metastatic potential in CC lung adenoma carcinoma cells. {ECO:0000269|PubMed:11162478}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q9C0K3-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9C0K3-2; Sequence=VSP_032218; CC -!- TISSUE SPECIFICITY: Expressed in kidney, stomach, spleen, bone marrow, CC uterus, testis, placenta, skeletal muscle, mammary gland, lung, fetal CC liver, and fetal kidney, but not detected in small intestine, brain, CC and thymus. Expressed in low-metastatic lung adenocarcinoma cells but CC not in high-metastatic ones. {ECO:0000269|PubMed:11162478}. CC -!- SIMILARITY: Belongs to the actin family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB039791; BAB21501.1; -; mRNA. DR EMBL; BX640643; CAI56711.1; -; mRNA. DR CCDS; CCDS47744.1; -. [Q9C0K3-1] DR PIR; JC7580; JC7580. DR RefSeq; NP_001157930.1; NM_001164458.2. [Q9C0K3-1] DR RefSeq; NP_001157931.1; NM_001164459.2. [Q9C0K3-1] DR RefSeq; XP_011514808.1; XM_011516506.4. [Q9C0K3-1] DR RefSeq; XP_011514809.1; XM_011516507.3. [Q9C0K3-1] DR RefSeq; XP_011514810.1; XM_011516508.3. [Q9C0K3-1] DR AlphaFoldDB; Q9C0K3; -. DR SMR; Q9C0K3; -. DR BioGRID; 576126; 10. DR FunCoup; Q9C0K3; 499. DR IntAct; Q9C0K3; 6. DR STRING; 9606.ENSP00000252071; -. DR GlyGen; Q9C0K3; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q9C0K3; -. DR PhosphoSitePlus; Q9C0K3; -. DR BioMuta; ACTR3C; -. DR DMDM; 74739414; -. DR jPOST; Q9C0K3; -. DR MassIVE; Q9C0K3; -. DR PaxDb; 9606-ENSP00000252071; -. DR PeptideAtlas; Q9C0K3; -. DR ProteomicsDB; 80071; -. [Q9C0K3-1] DR Pumba; Q9C0K3; -. DR Antibodypedia; 66353; 6 antibodies from 6 providers. DR DNASU; 653857; -. DR Ensembl; ENST00000252071.8; ENSP00000252071.4; ENSG00000106526.13. [Q9C0K3-1] DR Ensembl; ENST00000683684.1; ENSP00000507618.1; ENSG00000106526.13. [Q9C0K3-1] DR GeneID; 653857; -. DR KEGG; hsa:653857; -. DR MANE-Select; ENST00000683684.1; ENSP00000507618.1; NM_001164458.2; NP_001157930.1. DR UCSC; uc003wgu.3; human. [Q9C0K3-1] DR AGR; HGNC:37282; -. DR ClinPGx; PA165617588; -. DR CTD; 653857; -. DR DisGeNET; 653857; -. DR GeneCards; ACTR3C; -. DR HGNC; HGNC:37282; ACTR3C. DR HPA; ENSG00000106526; Tissue enhanced (parathyroid). DR OpenTargets; ENSG00000106526; -. DR VEuPathDB; HostDB:ENSG00000106526; -. DR eggNOG; KOG0678; Eukaryota. DR GeneTree; ENSGT00940000158304; -. DR InParanoid; Q9C0K3; -. DR OMA; PRILECW; -. DR OrthoDB; 421448at2759; -. DR PAN-GO; Q9C0K3; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q9C0K3; -. DR PathwayCommons; Q9C0K3; -. DR SignaLink; Q9C0K3; -. DR Agora; ENSG00000106526; -. DR BioGRID-ORCS; 653857; 55 hits in 1078 CRISPR screens. DR ChiTaRS; ACTR3C; human. DR GenomeRNAi; 653857; -. DR Pharos; Q9C0K3; Tdark. DR PRO; PR:Q9C0K3; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; Q9C0K3; protein. DR Bgee; ENSG00000106526; Expressed in right lobe of liver and 108 other cell types or tissues. DR ExpressionAtlas; Q9C0K3; baseline and differential. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0003779; F:actin binding; IEA:UniProtKB-KW. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR FunFam; 3.90.640.10:FF:000006; Actin-related protein 3 (ARP3); 1. DR Gene3D; 3.30.420.40; -; 2. DR Gene3D; 3.90.640.10; Actin, Chain A, domain 4; 1. DR InterPro; IPR004000; Actin. DR InterPro; IPR043129; ATPase_NBD. DR PANTHER; PTHR11937; ACTIN; 1. DR Pfam; PF00022; Actin; 1. DR SMART; SM00268; ACTIN; 1. DR SUPFAM; SSF53067; Actin-like ATPase domain; 1. PE 2: Evidence at transcript level; KW Actin-binding; Alternative splicing; ATP-binding; Nucleotide-binding; KW Reference proteome; Signal. FT SIGNAL 1..21 FT /evidence="ECO:0000255" FT CHAIN 22..210 FT /note="Actin-related protein 3C" FT /id="PRO_0000324333" FT VAR_SEQ 1..163 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_032218" FT CONFLICT 189 FT /note="M -> V (in Ref. 2; CAI56711)" FT /evidence="ECO:0000305" SQ SEQUENCE 210 AA; 23712 MW; AB94A33B440CD35B CRC64; MFESFNVPGL YIAVQAVLAL AASWTSRQVG ERTLTGIVID SGDGVTHVIP VAEGYVIGSC IKHIPIAGRD ITYFIQQLLR EREVGIPPEQ SLETAKAIKE KYCYICPDIV KEFAKYDVDP QKWIKQYTGI NAINQKKFVI DVGYERFLGP EIFFHPEFAN PDSMESISDV VDEVIQNCPI DVRRPLYKME QIPLSYPQGH GFHPLSPPFH // ID ATD3A_HUMAN Reviewed; 586 AA. AC Q9NVI7; B3KPB3; D2K8Q1; G3V1I6; Q5SV23; Q8N275; Q96A50; DT 13-SEP-2005, integrated into UniProtKB/Swiss-Prot. DT 09-APR-2025, sequence version 3. DT 28-JAN-2026, entry version 205. DE RecName: Full=ATPase family AAA domain-containing protein 3A {ECO:0000305}; DE EC=3.6.1.- {ECO:0000269|PubMed:20154147, ECO:0000305|PubMed:39116259}; GN Name=ATAD3A {ECO:0000303|PubMed:37832546, ECO:0000312|HGNC:HGNC:25567}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RC TISSUE=Lung adenocarcinoma; RX PubMed=20332122; DOI=10.1242/jcs.062034; RA Fang H.Y., Chang C.L., Hsu S.H., Huang C.Y., Chiang S.F., Chiou S.H., RA Huang C.H., Hsiao Y.T., Lin T.Y., Chiang I.P., Hsu W.H., Sugano S., RA Chen C.Y., Lin C.Y., Ko W.J., Chow K.C.; RT "ATPase family AAA domain-containing 3A is a novel anti-apoptotic factor in RT lung adenocarcinoma cells."; RL J. Cell Sci. 123:1171-1180(2010). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3). RC TISSUE=Teratocarcinoma, and Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT ASP-15. RC TISSUE=Brain, and Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP PROTEIN SEQUENCE OF 2-9; 202-208; 228-238; 291-298; 395-403; 431-439 AND RP 558-568 (ISOFORMS 1/2), PROTEIN SEQUENCE OF 93-104 (ISOFORM 2), CLEAVAGE OF RP INITIATOR METHIONINE, ACETYLATION AT SER-2, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RC TISSUE=Colon carcinoma; RA Bienvenut W.V., Heiserich L., Boulahbel H., Gottlieb E.; RL Submitted (JUL-2007) to UniProtKB. RN [7] RP FUNCTION, SUBCELLULAR LOCATION, AND ASSOCIATION WITH NUCLEOIDS. RX PubMed=17210950; DOI=10.1083/jcb.200609158; RA He J., Mao C.C., Reyes A., Sembongi H., Di Re M., Granycome C., RA Clippingdale A.B., Fearnley I.M., Harbour M., Robinson A.J., Reichelt S., RA Spelbrink J.N., Walker J.E., Holt I.J.; RT "The AAA+ protein ATAD3 has displacement loop binding properties and is RT involved in mitochondrial nucleoid organization."; RL J. Cell Biol. 176:141-146(2007). RN [8] RP SUBCELLULAR LOCATION, TOPOLOGY, AND ASSOCIATION WITH NUCLEOIDS. RX PubMed=18063578; DOI=10.1074/jbc.m708444200; RA Bogenhagen D.F., Rousseau D., Burke S.; RT "The layered structure of human mitochondrial DNA nucleoids."; RL J. Biol. Chem. 283:3665-3675(2008). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [10] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-491, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [11] RP SUBCELLULAR LOCATION, AND TOPOLOGY. RX PubMed=20349121; DOI=10.1007/s10863-010-9269-8; RA Hubstenberger A., Merle N., Charton R., Brandolin G., Rousseau D.; RT "Topological analysis of ATAD3A insertion in purified human mitochondria."; RL J. Bioenerg. Biomembr. 42:143-150(2010). RN [12] RP FUNCTION, CATALYTIC ACTIVITY, HOMOOLIGOMERIZATION, INDUCTION, SUBCELLULAR RP LOCATION, TOPOLOGY, AND MUTAGENESIS OF LYS-358 AND ASP-411. RX PubMed=20154147; DOI=10.1128/mcb.00007-10; RA Gilquin B., Taillebourg E., Cherradi N., Hubstenberger A., Gay O., RA Merle N., Assard N., Fauvarque M.O., Tomohiro S., Kuge O., Baudier J.; RT "The AAA+ ATPase ATAD3A controls mitochondrial dynamics at the interface of RT the inner and outer membranes."; RL Mol. Cell. Biol. 30:1984-1996(2010). RN [13] RP INTERACTION WITH S100B, AND MUTAGENESIS OF VAL-293; LEU-297 AND RP 301-ILE-GLN-302. RX PubMed=20351179; DOI=10.1128/mcb.01468-09; RA Gilquin B., Cannon B.R., Hubstenberger A., Moulouel B., Falk E., Merle N., RA Assard N., Kieffer S., Rousseau D., Wilder P.T., Weber D.J., Baudier J.; RT "The calcium-dependent interaction between S100B and the mitochondrial AAA RT ATPase ATAD3A and the role of this complex in the cytoplasmic processing of RT ATAD3A."; RL Mol. Cell. Biol. 30:2724-2736(2010). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [15] RP INTERACTION WITH ATAD3B AND HSPD1. RX PubMed=22664726; DOI=10.1016/j.mito.2012.05.005; RA Merle N., Feraud O., Gilquin B., Hubstenberger A., Kieffer-Jacquinot S., RA Assard N., Bennaceur-Griscelli A., Honnorat J., Baudier J.; RT "ATAD3B is a human embryonic stem cell specific mitochondrial protein, re- RT expressed in cancer cells, that functions as dominant negative for the RT ubiquitous ATAD3A."; RL Mitochondrion 12:441-448(2012). RN [16] RP FUNCTION, INTERACTION WITH PROTEINS INVOLVED IN MITOCHONDRIAL TRANSLATION; RP RNA METABOLISM; LIPID METABOLISM; GADD45GIP1 AND FAM210A, AND INDUCTION. RX PubMed=22453275; DOI=10.1093/nar/gks266; RA He J., Cooper H.M., Reyes A., Di Re M., Sembongi H., Litwin T.R., Gao J., RA Neuman K.C., Fearnley I.M., Spinazzola A., Walker J.E., Holt I.J.; RT "Mitochondrial nucleoid interacting proteins support mitochondrial protein RT synthesis."; RL Nucleic Acids Res. 40:6109-6121(2012). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-321, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [18] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [19] RP INTERACTION WITH CLPB, AND FUNCTION. RX PubMed=31522117; DOI=10.1016/j.isci.2019.08.056; RA Yoshinaka T., Kosako H., Yoshizumi T., Furukawa R., Hirano Y., Kuge O., RA Tamada T., Koshiba T.; RT "Structural Basis of Mitochondrial Scaffolds by Prohibitin Complexes: RT Insight into a Role of the Coiled-Coil Region."; RL IScience 19:1065-1078(2019). RN [20] RP FUNCTION. RX PubMed=37832546; DOI=10.1016/j.molcel.2023.09.026; RA Fu Y., Sacco O., DeBitetto E., Kanshin E., Ueberheide B., Sfeir A.; RT "Mitochondrial DNA breaks activate an integrated stress response to RT reestablish homeostasis."; RL Mol. Cell 83:3740-3753(2023). RN [21] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH EIF2AK3, AND MUTAGENESIS RP OF GLU-412. RX PubMed=39116259; DOI=10.1126/science.adp7114; RA Brar K.K., Hughes D.T., Morris J.L., Subramanian K., Krishna S., Gao F., RA Rieder L.S., Uhrig S., Freeman J., Smith H.L., Jukes-Jones R., Avezov E., RA Nunnari J., Prudent J., Butcher A.J., Mallucci G.R.; RT "PERK-ATAD3A interaction provides a subcellular safe haven for protein RT synthesis during ER stress."; RL Science 0:0-0(2024). RN [22] RP VARIANTS HAYOS ILE-53 AND TRP-528, AND INVOLVEMENT IN HAYOS. RX PubMed=27640307; DOI=10.1016/j.ajhg.2016.08.007; RG Baylor-Hopkins Center for Mendelian Genomics; RG University of Washington Center for Mendelian Genomics; RA Harel T., Yoon W.H., Garone C., Gu S., Coban-Akdemir Z., Eldomery M.K., RA Posey J.E., Jhangiani S.N., Rosenfeld J.A., Cho M.T., Fox S., Withers M., RA Brooks S.M., Chiang T., Duraine L., Erdin S., Yuan B., Shao Y., RA Moussallem E., Lamperti C., Donati M.A., Smith J.D., McLaughlin H.M., RA Eng C.M., Walkiewicz M., Xia F., Pippucci T., Magini P., Seri M., RA Zeviani M., Hirano M., Hunter J.V., Srour M., Zanigni S., Lewis R.A., RA Muzny D.M., Lotze T.E., Boerwinkle E., Gibbs R.A., Hickey S.E., RA Graham B.H., Yang Y., Buhas D., Martin D.M., Potocki L., Graziano C., RA Bellen H.J., Lupski J.R.; RT "Recurrent de novo and biallelic variation of ATAD3A, encoding a RT mitochondrial membrane protein, Results in distinct neurological RT syndromes."; RL Am. J. Hum. Genet. 99:831-845(2016). RN [23] RP VARIANTS PHRINL ARG-77 AND 164-GLN--SER-586 DEL, AND INVOLVEMENT IN PHRINL. RX PubMed=29053797; DOI=10.1093/brain/awx239; RA Peeters-Scholte C.M.P.C.D., Adama van Scheltema P.N., Klumper F.J.C.M., RA Everwijn S.M.P., Koopmans M., Hoffer M.J.V., Koopmann T.T., RA Ruivenkamp C.A.L., Steggerda S.J., van der Knaap M.S., Santen G.W.E.; RT "Genotype-phenotype correlation in ATAD3A deletions: not just of scientific RT relevance."; RL Brain 140:e66-e66(2017). RN [24] RP VARIANT PHRINL ARG-406, INVOLVEMENT IN PHRINL, AND CHARACTERIZATION OF RP VARIANT PHRINL ARG-406. RX PubMed=31727539; DOI=10.1016/j.ymgme.2019.10.012; RA Peralta S., Gonzalez-Quintana A., Ybarra M., Delmiro A., Perez-Perez R., RA Docampo J., Arenas J., Blazquez A., Ugalde C., Martin M.A.; RT "Novel ATAD3A recessive mutation associated to fatal cerebellar hypoplasia RT with multiorgan involvement and mitochondrial structural abnormalities."; RL Mol. Genet. Metab. 128:452-462(2019). CC -!- FUNCTION: Essential for mitochondrial network organization, CC mitochondrial metabolism and cell growth at organism and cellular level CC (PubMed:17210950, PubMed:20154147, PubMed:22453275, PubMed:31522117, CC PubMed:37832546, PubMed:39116259). May play an important role in CC mitochondrial protein synthesis (PubMed:22453275). May also participate CC in mitochondrial DNA replication (PubMed:17210950). May bind to CC mitochondrial DNA D-loops and contribute to nucleoid stability CC (PubMed:17210950). Required for enhanced channeling of cholesterol for CC hormone-dependent steroidogenesis (PubMed:22453275). Involved in CC mitochondrial-mediated antiviral innate immunity (PubMed:31522117). CC Required to protect mitochondria from the PERK-mediated unfolded CC protein response: specifically inhibits the activity of EIF2AK3/PERK at CC mitochondria-endoplasmic reticulum contact sites, thereby providing a CC safe haven for mitochondrial protein translation during endoplasmic CC reticulum stress (PubMed:39116259). Ability to inhibit EIF2AK3/PERK is CC independent of its ATPase activity (PubMed:39116259). Also involved in CC the mitochondrial DNA damage response by promoting signaling between CC damaged genomes and the mitochondrial membrane, leading to activation CC of the integrated stress response (ISR) (PubMed:37832546). CC {ECO:0000269|PubMed:17210950, ECO:0000269|PubMed:20154147, CC ECO:0000269|PubMed:22453275, ECO:0000269|PubMed:31522117, CC ECO:0000269|PubMed:37832546, ECO:0000269|PubMed:39116259}. CC -!- CATALYTIC ACTIVITY: CC Reaction=ATP + H2O = ADP + phosphate + H(+); Xref=Rhea:RHEA:13065, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; CC Evidence={ECO:0000269|PubMed:20154147, ECO:0000305|PubMed:39116259}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:13066; CC Evidence={ECO:0000269|PubMed:20154147, ECO:0000305|PubMed:39116259}; CC -!- SUBUNIT: Can form homooligomers (PubMed:20154147). Homodimer formation CC at the N-terminus may be regulated by ATP and is required for the CC interaction with the inner surface of the mitochondrial outer membrane CC and correct mitochondrial homeostasis (PubMed:20154147). Interacts with CC components of the mitochondrial ribosome and with other proteins CC involved in mitochondrial RNA metabolism (PubMed:22453275). May also CC interact with protein involved in lipid metabolism, including STARD9 CC (PubMed:22453275). May interact with FAM210A (PubMed:22453275). CC Interacts with GADD45GIP1 (PubMed:22453275). Interacts with S100B in a CC Ca(+2)- and Zn(+2)-dependent manner; this interaction probably occurs CC in the cytosol prior to mitochondrial targeting (PubMed:20351179). CC S100B could assist ATAD3A cytoplasmic processing, preventing CC aggregation and favoring mitochondrial localization (PubMed:20351179). CC Interacts with HSP60/HSPD1 (PubMed:22664726). Forms heterooligomers CC with ATAD3B; this interaction may affect ATAD3A activity CC (PubMed:22664726). Interacts with CLPB (PubMed:31522117). Interacts CC with EIF2AK3/PERK; ATAD3A and EIF2S1/eIF-2-alpha occupy a common CC binding site within the cytoplasmic loop of EIF2AK3/PERK, leading to CC prevent EIF2AK3/PERK association with its substrate EIF2S1/eIF-2-alpha CC (PubMed:39116259). {ECO:0000269|PubMed:20154147, CC ECO:0000269|PubMed:20351179, ECO:0000269|PubMed:22453275, CC ECO:0000269|PubMed:22664726, ECO:0000269|PubMed:31522117, CC ECO:0000269|PubMed:39116259}. CC -!- INTERACTION: CC Q9NVI7; O00429: DNM1L; NbExp=4; IntAct=EBI-352007, EBI-724571; CC Q9NVI7; P10809: HSPD1; NbExp=4; IntAct=EBI-352007, EBI-352528; CC Q9NVI7-2; Q9NVI7-2: ATAD3A; NbExp=2; IntAct=EBI-5456381, EBI-5456381; CC Q9NVI7-2; O00429: DNM1L; NbExp=5; IntAct=EBI-5456381, EBI-724571; CC -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane CC {ECO:0000269|PubMed:18063578, ECO:0000269|PubMed:20154147, CC ECO:0000269|PubMed:20332122, ECO:0000269|PubMed:20349121}; Single-pass CC membrane protein {ECO:0000269|PubMed:20154147, CC ECO:0000269|PubMed:20349121}. Mitochondrion matrix, mitochondrion CC nucleoid {ECO:0000269|PubMed:17210950, ECO:0000269|PubMed:18063578}. CC Note=In the mitochondrial inner membrane, enriched in sites with the CC potential to form contacts with the outer membrane (PubMed:20154147, CC PubMed:20349121). The N-terminal domain interacts with the inner CC surface of the mitochondrial outer membrane and the C-terminal domain CC localizes in a specific matrix compartment, where it is associated with CC nucleoids (PubMed:18063578). Also present at mitochondria-endoplasmic CC reticulum contact sites; where it interacts with EIF2AK3/PERK CC (PubMed:39116259). {ECO:0000269|PubMed:18063578, CC ECO:0000269|PubMed:20154147, ECO:0000269|PubMed:20349121, CC ECO:0000269|PubMed:39116259}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=2; CC IsoId=Q9NVI7-2; Sequence=Displayed; CC Name=1; CC IsoId=Q9NVI7-1; Sequence=VSP_062536; CC Name=3; CC IsoId=Q9NVI7-3; Sequence=VSP_062535; CC -!- TISSUE SPECIFICITY: Overexpressed in lung adenocarcinomas (at protein CC level). {ECO:0000269|PubMed:20332122}. CC -!- INDUCTION: Up-regulated by Angiotensin/AGT. CC {ECO:0000269|PubMed:20154147, ECO:0000269|PubMed:22453275}. CC -!- DOMAIN: The transmembrane domain and a C-terminal adjacent region CC contain all information necessary for mitochondrial targeting. CC {ECO:0000269|PubMed:20154147}. CC -!- DISEASE: Harel-Yoon syndrome (HAYOS) [MIM:617183]: A syndrome CC characterized by global developmental delay, hypotonia, intellectual CC disability, and axonal neuropathy. Some patients have optic atrophy and CC hypertrophic cardiomyopathy. HAYOS inheritance can be autosomal CC dominant or autosomal recessive. {ECO:0000269|PubMed:27640307}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Pontocerebellar hypoplasia, hypotonia, and respiratory CC insufficiency syndrome, neonatal lethal (PHRINL) [MIM:618810]: An CC autosomal recessive multisystem disorder with onset in utero and death CC in the neonatal period. Affected infants show respiratory insufficiency CC and almost no spontaneous movement at birth. Additional features CC include corneal clouding, seizures, dysmorphic facies, contractures, CC and progressive pontocerebellar hypoplasia with simplified gyral CC pattern and white matter abnormalities. Some patients may have cardiac CC anomalies or cardiac hypertrophy. {ECO:0000269|PubMed:29053797, CC ECO:0000269|PubMed:31727539}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the AAA ATPase family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; GU189416; ACZ80514.1; -; mRNA. DR EMBL; AK001571; BAA91764.1; -; mRNA. DR EMBL; AK056099; BAG51625.1; -; mRNA. DR EMBL; AK091144; BAC03595.1; -; mRNA. DR EMBL; AL645728; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471183; EAW56187.1; -; Genomic_DNA. DR EMBL; CH471183; EAW56190.1; -; Genomic_DNA. DR EMBL; BC007803; AAH07803.1; -; mRNA. DR EMBL; BC011814; AAH11814.1; -; mRNA. DR EMBL; BC014101; AAH14101.1; -; mRNA. DR EMBL; BC033109; AAH33109.1; -; mRNA. DR EMBL; BC063607; AAH63607.1; -; mRNA. DR CCDS; CCDS31.1; -. [Q9NVI7-1] DR CCDS; CCDS53259.1; -. [Q9NVI7-2] DR CCDS; CCDS53260.1; -. [Q9NVI7-3] DR RefSeq; NP_001164006.1; NM_001170535.3. [Q9NVI7-2] DR RefSeq; NP_001164007.1; NM_001170536.3. [Q9NVI7-3] DR RefSeq; NP_060658.3; NM_018188.4. [Q9NVI7-1] DR AlphaFoldDB; Q9NVI7; -. DR SMR; Q9NVI7; -. DR BioGRID; 120506; 374. DR DIP; DIP-33194N; -. DR FunCoup; Q9NVI7; 2296. DR IntAct; Q9NVI7; 295. DR MINT; Q9NVI7; -. DR STRING; 9606.ENSP00000368030; -. DR iPTMnet; Q9NVI7; -. DR MetOSite; Q9NVI7; -. DR PhosphoSitePlus; Q9NVI7; -. DR SwissPalm; Q9NVI7; -. DR BioMuta; ATAD3A; -. DR DMDM; 84028405; -. DR jPOST; Q9NVI7; -. DR MassIVE; Q9NVI7; -. DR PaxDb; 9606-ENSP00000368030; -. DR PeptideAtlas; Q9NVI7; -. DR PRIDE; Q9NVI7; -. DR ProteomicsDB; 32346; -. DR ProteomicsDB; 82815; -. [Q9NVI7-1] DR ProteomicsDB; 82816; -. [Q9NVI7-2] DR Pumba; Q9NVI7; -. DR Antibodypedia; 26400; 166 antibodies from 25 providers. DR DNASU; 55210; -. DR Ensembl; ENST00000378755.9; ENSP00000368030.5; ENSG00000197785.15. [Q9NVI7-1] DR Ensembl; ENST00000378756.8; ENSP00000368031.3; ENSG00000197785.15. [Q9NVI7-2] DR Ensembl; ENST00000536055.6; ENSP00000439290.1; ENSG00000197785.15. [Q9NVI7-3] DR GeneID; 55210; -. DR KEGG; hsa:55210; -. DR MANE-Select; ENST00000378756.8; ENSP00000368031.3; NM_001170535.3; NP_001164006.1. DR UCSC; uc001afz.3; human. [Q9NVI7-2] DR AGR; HGNC:25567; -. DR ClinPGx; PA134872099; -. DR CTD; 55210; -. DR DisGeNET; 55210; -. DR GeneCards; ATAD3A; -. DR HGNC; HGNC:25567; ATAD3A. DR HPA; ENSG00000197785; Low tissue specificity. DR MalaCards; ATAD3A; -. DR MIM; 612316; gene. DR MIM; 617183; phenotype. DR MIM; 618810; phenotype. DR OpenTargets; ENSG00000197785; -. DR Orphanet; 656279; 1p36.33 duplication syndrome. DR Orphanet; 615983; Lethal pontocerebellar hypoplasia-hypotonia-respiratory insufficiency syndrome due to a point mutation. DR Orphanet; 615986; Lethal pontocerebellar hypoplasia-hypotonia-respiratory insufficiency syndrome due to biallelic deletions in the ATAD3 gene cluster. DR Orphanet; 496790; Ocular anomalies-axonal neuropathy-developmental delay syndrome. DR VEuPathDB; HostDB:ENSG00000197785; -. DR eggNOG; KOG0742; Eukaryota. DR GeneTree; ENSGT00730000111059; -. DR HOGENOM; CLU_011488_2_0_1; -. DR InParanoid; Q9NVI7; -. DR OMA; HKSITGG; -. DR OrthoDB; 199596at2759; -. DR PAN-GO; Q9NVI7; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q9NVI7; -. DR PathwayCommons; Q9NVI7; -. DR SignaLink; Q9NVI7; -. DR Agora; ENSG00000197785; -. DR BioGRID-ORCS; 55210; 46 hits in 1120 CRISPR screens. DR CD-CODE; 232F8A39; P-body. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; ATAD3A; human. DR GenomeRNAi; 55210; -. DR Pharos; Q9NVI7; Tbio. DR PRO; PR:Q9NVI7; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q9NVI7; protein. DR Bgee; ENSG00000197785; Expressed in sural nerve and 179 other cell types or tissues. DR ExpressionAtlas; Q9NVI7; baseline and differential. DR GO; GO:0044233; C:mitochondria-associated endoplasmic reticulum membrane contact site; IDA:UniProtKB. DR GO; GO:0005743; C:mitochondrial inner membrane; IDA:UniProtKB. DR GO; GO:0042645; C:mitochondrial nucleoid; IEA:UniProtKB-SubCell. DR GO; GO:0005739; C:mitochondrion; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IMP:FlyBase. DR GO; GO:0016887; F:ATP hydrolysis activity; IMP:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0030291; F:protein serine/threonine kinase inhibitor activity; IDA:UniProtKB. DR GO; GO:0140374; P:antiviral innate immune response; IMP:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0140468; P:HRI-mediated signaling; IDA:UniProtKB. DR GO; GO:0007005; P:mitochondrion organization; IMP:FlyBase. DR GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:1903898; P:negative regulation of PERK-mediated unfolded protein response; IDA:UniProtKB. DR GO; GO:0001558; P:regulation of cell growth; IMP:UniProtKB. DR CDD; cd19512; RecA-like_ATAD3-like; 1. DR FunFam; 3.40.50.300:FF:000470; ATPase family, AAA domain containing 3A; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1. DR InterPro; IPR003593; AAA+_ATPase. DR InterPro; IPR021911; ATAD3_N. DR InterPro; IPR003959; ATPase_AAA_core. DR InterPro; IPR027417; P-loop_NTPase. DR PANTHER; PTHR23075:SF5; ATPASE FAMILY AAA DOMAIN-CONTAINING PROTEIN 3A; 1. DR PANTHER; PTHR23075; PUTATIVE ATP-ASE; 1. DR Pfam; PF00004; AAA; 1. DR Pfam; PF12037; ATAD3_N; 1. DR SMART; SM00382; AAA; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. PE 1: Evidence at protein level; KW Acetylation; Alternative splicing; ATP-binding; Coiled coil; KW Direct protein sequencing; Disease variant; Hydrolase; Membrane; KW Mitochondrion; Mitochondrion inner membrane; Mitochondrion nucleoid; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Transmembrane; Transmembrane helix. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|Ref.6" FT CHAIN 2..586 FT /note="ATPase family AAA domain-containing protein 3A" FT /id="PRO_0000084799" FT TOPO_DOM 2..246 FT /note="Mitochondrial intermembrane" FT /evidence="ECO:0000255" FT TRANSMEM 247..264 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 265..586 FT /note="Mitochondrial matrix" FT /evidence="ECO:0000255" FT REGION 1..55 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2..50 FT /note="Required for interaction with the inner surface of FT the mitochondrial outer membrane" FT /evidence="ECO:0000269|PubMed:18063578" FT REGION 111..134 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 290..305 FT /note="S100B-binding" FT /evidence="ECO:0000269|PubMed:20351179" FT COILED 86..219 FT /evidence="ECO:0000255" FT COMPBIAS 17..26 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 32..48 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 111..125 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 352..359 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0000269|Ref.6" FT MOD_RES 321 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 491 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT VAR_SEQ 1..79 FT /note="Missing (in isoform 3)" FT /id="VSP_062535" FT VAR_SEQ 94 FT /note="K -> KMRLEALSLLHTLVWAWSLCRAGAVQTQERLSGSASPEQVPAGECCA FT LQ (in isoform 1)" FT /id="VSP_062536" FT VARIANT 15 FT /note="G -> D (in dbSNP:rs2274435)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_023526" FT VARIANT 53 FT /note="T -> I (in HAYOS; dbSNP:rs1057517687)" FT /evidence="ECO:0000269|PubMed:27640307" FT /id="VAR_082788" FT VARIANT 77 FT /note="L -> R (in PHRINL; dbSNP:rs1570319915)" FT /evidence="ECO:0000269|PubMed:29053797" FT /id="VAR_083867" FT VARIANT 164..586 FT /note="Missing (in PHRINL; dbSNP:rs760826883)" FT /evidence="ECO:0000269|PubMed:29053797" FT /id="VAR_083868" FT VARIANT 406 FT /note="L -> R (in PHRINL; decreased protein levels in FT patient cells; dbSNP:rs1570345942)" FT /evidence="ECO:0000269|PubMed:31727539" FT /id="VAR_083869" FT VARIANT 528 FT /note="R -> W (in HAYOS; dbSNP:rs1057517686)" FT /evidence="ECO:0000269|PubMed:27640307" FT /id="VAR_082789" FT MUTAGEN 293 FT /note="V->S: Loss of S100B-binding; when associated with S- FT 297." FT /evidence="ECO:0000269|PubMed:20351179" FT MUTAGEN 297 FT /note="L->S: Loss of S100B-binding; when associated with S- FT 293." FT /evidence="ECO:0000269|PubMed:20351179" FT MUTAGEN 301..302 FT /note="Missing: Decrease in S100B-binding." FT /evidence="ECO:0000269|PubMed:20351179" FT MUTAGEN 358 FT /note="K->E: No effect on homooligomerization. Immediate FT fragmentation of the mitochondrial network." FT /evidence="ECO:0000269|PubMed:20154147" FT MUTAGEN 411 FT /note="D->Q: No effect on homooligomerization. Immediate FT fragmentation of the mitochondrial network." FT /evidence="ECO:0000269|PubMed:20154147" FT MUTAGEN 412 FT /note="E->Q: Abolished ATPase activity without affecting FT its ability to interact with and inhibit EIF2AK3/PERK." FT /evidence="ECO:0000269|PubMed:39116259" FT CONFLICT 176 FT /note="R -> Q (in Ref. 2; BAG51625)" FT /evidence="ECO:0000305" FT CONFLICT 207 FT /note="I -> T (in Ref. 2; BAC03595)" FT /evidence="ECO:0000305" SQ SEQUENCE 586 AA; 66218 MW; 1E83D08AE33D550F CRC64; MSWLFGINKG PKGEGAGPPP PLPPAQPGAE GGGDRGLGDR PAPKDKWSNF DPTGLERAAK AARELEHSRY AKDALNLAQM QEQTLQLEQQ SKLKEYEAAV EQLKSEQIRA QAEERRKTLS EETRQHQARA QYQDKLARQR YEDQLKQQQL LNEENLRKQE ESVQKQEAMR RATVEREMEL RHKNEMLRVE AEARARAKAE RENADIIREQ IRLKAAEHRQ TVLESIRTAG TLFGEGFRAF VTDWDKVTAT VAGLTLLAVG VYSAKNATLV AGRFIEARLG KPSLVRETSR ITVLEALRHP IQVSRRLLSR PQDALEGVVL SPSLEARVRD IAIATRNTKK NRSLYRNILM YGPPGTGKTL FAKKLALHSG MDYAIMTGGD VAPMGREGVT AMHKLFDWAN TSRRGLLLFV DEADAFLRKR ATEKISEDLR ATLNAFLYRT GQHSNKFMLV LASNQPEQFD WAINDRINEM VHFDLPGQEE RERLVRMYFD KYVLKPATEG KQRLKLAQFD YGRKCSEVAR LTEGMSGREI AQLAVSWQAT AYASEDGVLT EAMMDTRVQD AVQQHQQKMC WLKAEGPGRG DEPSPS // ID ATM_HUMAN Reviewed; 3056 AA. AC Q13315; B2RNX5; O15429; Q12758; Q16551; Q93007; Q9NP02; Q9UCX7; DT 27-APR-2001, integrated into UniProtKB/Swiss-Prot. DT 22-JAN-2014, sequence version 4. DT 28-JAN-2026, entry version 269. DE RecName: Full=Serine-protein kinase ATM; DE EC=2.7.11.1 {ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:15790808, ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:28508083, ECO:0000269|PubMed:30886146, ECO:0000269|PubMed:8988033, ECO:0000269|PubMed:9843217}; DE AltName: Full=Ataxia telangiectasia mutated; DE Short=A-T mutated; GN Name=ATM; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT AT ASP-3003. RX PubMed=8589678; DOI=10.1093/hmg/4.11.2025; RA Savitsky K., Sfez S., Tagle D.A., Ziv Y., Sartiel A., Collins F.S., RA Shiloh Y., Rotman G.; RT "The complete sequence of the coding region of the ATM gene reveals RT similarity to cell cycle regulators in different species."; RL Hum. Mol. Genet. 4:2025-2032(1995). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], VARIANT AT ASP-3003, AND VARIANTS RP CYS-49; ARG-1054; PHE-1420; ILE-2079 AND ALA-2287. RX PubMed=8665503; RA Vorechovsky I., Rasio D., Luo L., Monaco C., Hammarstroem L., RA Webster A.D.B., Zaloudik J., Barbanti-Brodano G., James M.R., Russo G., RA Croce C.M., Negrini M.; RT "The ATM gene and susceptibility to breast cancer: analysis of 38 breast RT tumors reveals no evidence for mutation."; RL Cancer Res. 56:2726-2732(1996). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9199932; DOI=10.1101/gr.7.6.592; RA Platzer M., Rotman G., Bauer D., Uziel T., Savitsky K., Bar-Shira A., RA Gilad S., Shiloh Y., Rosenthal A.; RT "Ataxia-telangiectasia locus: sequence analysis of 184 kb of human genomic RT DNA containing the entire ATM gene."; RL Genome Res. 7:592-605(1997). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASN-1983. RX PubMed=16554811; DOI=10.1038/nature04632; RA Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K., RA Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T., RA Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G., RA Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C., RA Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A., RA Hattori M., Rogers J., Lander E.S., Sakaki Y.; RT "Human chromosome 11 DNA sequence and analysis including novel gene RT identification."; RL Nature 440:497-500(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-2756. RG NIEHS SNPs program; RL Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-1369, AND VARIANT AT 2546-SER--ILE-2548 RP DEL. RX PubMed=8789452; DOI=10.1093/hmg/5.1.145; RA Byrd P.J., McConville C.M., Cooper P., Parkhill J., Stankovic T., RA McGuire G.M., Thick J.A., Taylor A.M.R.; RT "Mutations revealed by sequencing the 5' half of the gene for ataxia RT telangiectasia."; RL Hum. Mol. Genet. 5:145-149(1996). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-24. RX PubMed=9108147; DOI=10.1093/nar/25.9.1678; RA Savitsky K., Platzer M., Uziel T., Gilad S., Sartiel A., Rosenthal A., RA Elroy-Stein O., Shiloh Y., Rotman G.; RT "Ataxia-telangiectasia: structural diversity of untranslated sequences RT suggests complex post-transcriptional regulation of ATM gene expression."; RL Nucleic Acids Res. 25:1678-1684(1997). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1332-3056, AND VARIANTS 2427-LEU-ARG-2428 RP DEL; 2546-SER--ILE-2548 DEL; SER-2860 DEL AND ASP-3003. RC TISSUE=Fibroblast; RX PubMed=7792600; DOI=10.1126/science.7792600; RA Savitsky K., Bar-Shira A., Gilad S., Rotman G., Ziv Y., Vanagaite L., RA Tagle D.A., Smith S., Uziel T., Sfez S., Ashkenazi M., Pecker I., RA Frydman M., Harnik R., Patanjali S.R., Simmons A., Clines G.A., Sartiel A., RA Gatti R.A., Chessa L., Sanal O., Lavin M.F., Jaspers N.G.J., Taylor A.M.R., RA Arlett C.F., Miki T., Weissman S.M., Lovett M., Collins F.S., Shiloh Y.; RT "A single ataxia telangiectasia gene with a product similar to PI-3 RT kinase."; RL Science 268:1749-1753(1995). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1332-3056. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1349-3056. RX PubMed=8521392; RA Rasio D., Negrini M., Croce C.M.; RT "Genomic organization of the ATM locus involved in ataxia-telangiectasia."; RL Cancer Res. 55:6053-6057(1995). RN [12] RP PHOSPHORYLATION. RX PubMed=8969240; DOI=10.1074/jbc.271.52.33693; RA Chen G., Lee E.Y.-H.P.; RT "The product of the ATM gene is a 370-kDa nuclear phosphoprotein."; RL J. Biol. Chem. 271:33693-33697(1996). RN [13] RP SUBCELLULAR LOCATION. RX PubMed=9050866; DOI=10.1073/pnas.94.5.1840; RA Brown K.D., Ziv Y., Sadanandan S.N., Chessa L., Collins F.S., Shiloh Y., RA Tagle D.A.; RT "The ataxia-telangiectasia gene product, a constitutively expressed nuclear RT protein that is not up-regulated following genome damage."; RL Proc. Natl. Acad. Sci. U.S.A. 94:1840-1845(1997). RN [14] RP SUBCELLULAR LOCATION, AND VARIANTS 2546-SER--ILE-2548 DEL AND TYR-2824. RX PubMed=9150358; DOI=10.1038/sj.onc.1201037; RA Watters D., Khanna K.K., Beamish H., Birrell G., Spring K., Kedar P., RA Gatei M., Stenzel D., Hobson K., Kozlov S., Zhang N., Farrell A., RA Ramsay J., Gatti R.A., Lavin M.F.; RT "Cellular localisation of the ataxia-telangiectasia (ATM) gene product and RT discrimination between mutated and normal forms."; RL Oncogene 14:1911-1921(1997). RN [15] RP CATALYTIC ACTIVITY. RX PubMed=8988033; RA Jung M., Kondratyev A., Lee S.A., Dimtchev A., Dritschilo A.; RT "ATM gene product phosphorylates I kappa B-alpha."; RL Cancer Res. 57:24-27(1997). RN [16] RP INTERACTION WITH ABL1. RX PubMed=9168117; DOI=10.1038/387520a0; RA Shafman T., Khanna K.K., Kedar P., Spring K., Kozlov S., Yen T., Hobson K., RA Gatei M., Zhang N., Watters D., Egerton M., Shiloh Y., Kharbanda S., RA Kufe D., Lavin M.F.; RT "Interaction between ATM protein and c-Abl in response to DNA damage."; RL Nature 387:520-523(1997). RN [17] RP ACTIVITY REGULATION. RX PubMed=9766667; RA Sarkaria J.N., Tibbetts R.S., Busby E.C., Kennedy A.P., Hill D.E., RA Abraham R.T.; RT "Inhibition of phosphoinositide 3-kinase related kinases by the RT radiosensitizing agent wortmannin."; RL Cancer Res. 58:4375-4382(1998). RN [18] RP FUNCTION, INTERACTION WITH TP53, AND CATALYTIC ACTIVITY. RX PubMed=9843217; DOI=10.1038/3882; RA Khanna K.K., Keating K.E., Kozlov S., Scott S., Gatei M., Hobson K., RA Taya Y., Gabrielli B., Chan D., Lees-Miller S.P., Lavin M.F.; RT "ATM associates with and phosphorylates p53: mapping the region of RT interaction."; RL Nat. Genet. 20:398-400(1998). RN [19] RP SUBCELLULAR LOCATION. RX PubMed=9707615; DOI=10.1073/pnas.95.17.10146; RA Lim D.-S., Kirsch D.G., Canman C.E., Ahn J.-H., Ziv Y., Newman L.S., RA Darnell R.B., Shiloh Y., Kastan M.B.; RT "ATM binds to beta-adaptin in cytoplasmic vesicles."; RL Proc. Natl. Acad. Sci. U.S.A. 95:10146-10151(1998). RN [20] RP FUNCTION IN PHOSPHORYLATION OF TP53. RX PubMed=9733514; DOI=10.1126/science.281.5383.1674; RA Banin S., Moyal L., Shieh S.-Y., Taya Y., Anderson C.W., Chessa L., RA Smorodinsky N.I., Prives C., Reiss Y., Shiloh Y., Ziv Y.; RT "Enhanced phosphorylation of p53 by ATM in response to DNA damage."; RL Science 281:1674-1677(1998). RN [21] RP FUNCTION IN PHOSPHORYLATION OF TP53, AND MUTAGENESIS OF ASP-2870 AND RP ASN-2875. RX PubMed=9733515; DOI=10.1126/science.281.5383.1677; RA Canman C.E., Lim D.-S., Cimprich K.A., Taya Y., Tamai K., Sakaguchi K., RA Appella E., Kastan M.B., Siliciano J.D.; RT "Activation of the ATM kinase by ionizing radiation and phosphorylation of RT p53."; RL Science 281:1677-1679(1998). RN [22] RP DNA-BINDING. RX PubMed=10500142; DOI=10.1073/pnas.96.20.11134; RA Smith G.C.M., Cary R.B., Lakin N.D., Hann B.C., Teo S.-H., Chen D.J., RA Jackson S.P.; RT "Purification and DNA binding properties of the ataxia-telangiectasia gene RT product ATM."; RL Proc. Natl. Acad. Sci. U.S.A. 96:11134-11139(1999). RN [23] RP FUNCTION IN PHOSPHORYLATION OF BRCA1. RX PubMed=10550055; DOI=10.1126/science.286.5442.1162; RA Cortez D., Wang Y., Qin J., Elledge S.J.; RT "Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage RT response to double-strand breaks."; RL Science 286:1162-1166(1999). RN [24] RP IDENTIFICATION OF ATM AS MEMBER OF BASC. RX PubMed=10783165; RA Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J.; RT "BASC, a super complex of BRCA1-associated proteins involved in the RT recognition and repair of aberrant DNA structures."; RL Genes Dev. 14:927-939(2000). RN [25] RP FUNCTION IN PHOSPHORYLATION OF NBN. RX PubMed=10766245; DOI=10.1038/35007091; RA Lim D.-S., Kim S.-T., Xu B., Maser R.S., Lin J., Petrini J.H.J., RA Kastan M.B.; RT "ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway."; RL Nature 404:613-617(2000). RN [26] RP FUNCTION IN PHOSPHORYLATION OF NBN. RX PubMed=10839545; DOI=10.1038/35013089; RA Wu X., Ranganathan V., Weisman D.S., Heine W.F., Ciccone D.N., RA O'Neill T.B., Crick K.E., Pierce K.A., Lane W.S., Rathbun G., RA Livingston D.M., Weaver D.T.; RT "ATM phosphorylation of Nijmegen breakage syndrome protein is required in a RT DNA damage response."; RL Nature 405:477-482(2000). RN [27] RP FUNCTION IN PHOSPHORYLATION OF CTIP. RX PubMed=10910365; DOI=10.1038/35018134; RA Li S., Ting N.S.Y., Zheng L., Chen P.-L., Ziv Y., Shiloh Y., Lee E.Y.-H.P., RA Lee W.-H.; RT "Functional link of BRCA1 and ataxia telangiectasia gene product in DNA RT damage response."; RL Nature 406:210-215(2000). RN [28] RP FUNCTION IN PHOSPHORYLATION OF NBN. RX PubMed=10802669; DOI=10.1038/75508; RA Gatei M., Young D., Cerosaletti K.M., Desai-Mehta A., Spring K., Kozlov S., RA Lavin M.F., Gatti R.A., Concannon P., Khanna K.K.; RT "ATM-dependent phosphorylation of nibrin in response to radiation RT exposure."; RL Nat. Genet. 25:115-119(2000). RN [29] RP FUNCTION IN PHOSPHORYLATION OF CHEK2. RX PubMed=10973490; DOI=10.1073/pnas.190030497; RA Matsuoka S., Rotman G., Ogawa A., Shiloh Y., Tamai K., Elledge S.J.; RT "Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro."; RL Proc. Natl. Acad. Sci. U.S.A. 97:10389-10394(2000). RN [30] RP FUNCTION IN PHOSPHORYLATION OF TERF1. RX PubMed=11375976; DOI=10.1074/jbc.m011534200; RA Kishi S., Zhou X.Z., Ziv Y., Khoo C., Hill D.E., Shiloh Y., Lu K.P.; RT "Telomeric protein Pin2/TRF1 as an important ATM target in response to RT double strand DNA breaks."; RL J. Biol. Chem. 276:29282-29291(2001). RN [31] RP INTERACTION WITH RAD17. RX PubMed=11418864; DOI=10.1038/35082110; RA Bao S., Tibbetts R.S., Brumbaugh K.M., Fang Y., Richardson D.A., Ali A., RA Chen S.M., Abraham R.T., Wang X.-F.; RT "ATR/ATM-mediated phosphorylation of human Rad17 is required for genotoxic RT stress responses."; RL Nature 411:969-974(2001). RN [32] RP FUNCTION IN PHOSPHORYLATION OF FANCD2. RX PubMed=12086603; DOI=10.1016/s0092-8674(02)00747-x; RA Taniguchi T., Garcia-Higuera I., Xu B., Andreassen P.R., Gregory R.C., RA Kim S.-T., Lane W.S., Kastan M.B., D'Andrea A.D.; RT "Convergence of the Fanconi anemia and ataxia telangiectasia signaling RT pathways."; RL Cell 109:459-472(2002). RN [33] RP PHOSPHORYLATION BY NUAK1. RX PubMed=12409306; DOI=10.1074/jbc.m206025200; RA Suzuki A., Kusakai G., Kishimoto A., Lu J., Ogura T., Lavin M.F., Esumi H.; RT "Identification of a novel protein kinase mediating Akt survival signaling RT to the ATM protein."; RL J. Biol. Chem. 278:48-53(2003). RN [34] RP PHOSPHORYLATION AT SER-1981, SUBUNIT, FUNCTION, AND MUTAGENESIS OF RP SER-1981. RX PubMed=12556884; DOI=10.1038/nature01368; RA Bakkenist C.J., Kastan M.B.; RT "DNA damage activates ATM through intermolecular autophosphorylation and RT dimer dissociation."; RL Nature 421:499-506(2003). RN [35] RP FUNCTION IN DNA DAMAGE RESPONSE. RX PubMed=14871926; DOI=10.1101/gad.1176004; RA Ali A., Zhang J., Bao S., Liu I., Otterness D., Dean N.M., Abraham R.T., RA Wang X.F.; RT "Requirement of protein phosphatase 5 in DNA-damage-induced ATM RT activation."; RL Genes Dev. 18:249-254(2004). RN [36] RP FUNCTION IN PHOSPHORYLATION OF DCLRE1C. RX PubMed=15456891; DOI=10.1128/mcb.24.20.9207-9220.2004; RA Zhang X., Succi J., Feng Z., Prithivirajsingh S., Story M.D., RA Legerski R.J.; RT "Artemis is a phosphorylation target of ATM and ATR and is involved in the RT G2/M DNA damage checkpoint response."; RL Mol. Cell. Biol. 24:9207-9220(2004). RN [37] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=15448695; DOI=10.1038/ncb1170; RA Demonacos C., Krstic-Demonacos M., Smith L., Xu D., O'Connor D.P., RA Jansson M., La Thangue N.B.; RT "A new effector pathway links ATM kinase with the DNA damage response."; RL Nat. Cell Biol. 6:968-976(2004). RN [38] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=15064416; DOI=10.1126/science.1091496; RA Lee J.-H., Paull T.T.; RT "Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 RT complex."; RL Science 304:93-96(2004). RN [39] RP INTERACTION WITH EEF1E1. RX PubMed=15680327; DOI=10.1016/j.cell.2004.11.054; RA Park B.-J., Kang J.W., Lee S.W., Choi S.-J., Shin Y.K., Ahn Y.H., RA Choi Y.H., Choi D., Lee K.S., Kim S.; RT "The haploinsufficient tumor suppressor p18 upregulates p53 via RT interactions with ATM/ATR."; RL Cell 120:209-221(2005). RN [40] RP FUNCTION. RX PubMed=15916964; DOI=10.1016/j.molcel.2005.04.015; RA Bhoumik A., Takahashi S., Breitweiser W., Shiloh Y., Jones N., Ronai Z.; RT "ATM-dependent phosphorylation of ATF2 is required for the DNA damage RT response."; RL Mol. Cell 18:577-587(2005). RN [41] RP INTERACTION WITH KAT8. RX PubMed=15923642; DOI=10.1128/mcb.25.12.5292-5305.2005; RA Gupta A., Sharma G.G., Young C.S.H., Agarwal M., Smith E.R., Paull T.T., RA Lucchesi J.C., Khanna K.K., Ludwig T., Pandita T.K.; RT "Involvement of human MOF in ATM function."; RL Mol. Cell. Biol. 25:5292-5305(2005). RN [42] RP FUNCTION IN HISTONE MRNA DEGRADATION ACTIVITY. RX PubMed=16086026; DOI=10.1038/nsmb972; RA Kaygun H., Marzluff W.F.; RT "Regulated degradation of replication-dependent histone mRNAs requires both RT ATR and Upf1."; RL Nat. Struct. Mol. Biol. 12:794-800(2005). RN [43] RP PHOSPHORYLATION AT SER-1981, AND ACETYLATION. RX PubMed=16141325; DOI=10.1073/pnas.0504211102; RA Sun Y., Jiang X., Chen S., Fernandes N., Price B.D.; RT "A role for the Tip60 histone acetyltransferase in the acetylation and RT activation of ATM."; RL Proc. Natl. Acad. Sci. U.S.A. 102:13182-13187(2005). RN [44] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, SUBUNIT, AND RP PHOSPHORYLATION AT SER-1981. RX PubMed=15790808; DOI=10.1126/science.1108297; RA Lee J.H., Paull T.T.; RT "ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 RT complex."; RL Science 308:551-554(2005). RN [45] RP PHOSPHORYLATION AT SER-367; SER-1893 AND SER-1981, FUNCTION, CATALYTIC RP ACTIVITY, MUTAGENESIS OF SER-367; SER-1893 AND SER-1981, AND IDENTIFICATION RP BY MASS SPECTROMETRY. RX PubMed=16858402; DOI=10.1038/sj.emboj.7601231; RA Kozlov S.V., Graham M.E., Peng C., Chen P., Robinson P.J., Lavin M.F.; RT "Involvement of novel autophosphorylation sites in ATM activation."; RL EMBO J. 25:3504-3514(2006). RN [46] RP INTERACTION WITH ATMIN. RX PubMed=17525732; DOI=10.1038/sj.emboj.7601733; RA Kanu N., Behrens A.; RT "ATMIN defines an NBS1-independent pathway of ATM signalling."; RL EMBO J. 26:2933-2941(2007). RN [47] RP ACETYLATION AT LYS-3016, FUNCTION, AND MUTAGENESIS OF LYS-3016 AND RP LYS-3018. RX PubMed=17923702; DOI=10.1128/mcb.01382-07; RA Sun Y., Xu Y., Roy K., Price B.D.; RT "DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase RT activity."; RL Mol. Cell. Biol. 27:8502-8509(2007). RN [48] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1981 AND SER-1983, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [49] RP INTERACTION WITH CEP164. RX PubMed=18283122; DOI=10.1101/gad.1627708; RA Sivasubramaniam S., Sun X., Pan Y.R., Wang S., Lee E.Y.; RT "Cep164 is a mediator protein required for the maintenance of genomic RT stability through modulation of MDC1, RPA, and CHK1."; RL Genes Dev. 22:587-600(2008). RN [50] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2996, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [51] RP INTERACTION WITH NABP2. RX PubMed=18449195; DOI=10.1038/nature06883; RA Richard D.J., Bolderson E., Cubeddu L., Wadsworth R.I.M., Savage K., RA Sharma G.G., Nicolette M.L., Tsvetanov S., McIlwraith M.J., Pandita R.K., RA Takeda S., Hay R.T., Gautier J., West S.C., Paull T.T., Pandita T.K., RA White M.F., Khanna K.K.; RT "Single-stranded DNA-binding protein hSSB1 is critical for genomic RT stability."; RL Nature 453:677-681(2008). RN [52] RP INTERACTION WITH DDX1. RX PubMed=18710941; DOI=10.1128/mcb.01053-08; RA Li L., Monckton E.A., Godbout R.; RT "A role for DEAD box 1 at DNA double-strand breaks."; RL Mol. Cell. Biol. 28:6413-6425(2008). RN [53] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2996, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [54] RP FUNCTION AS DYRK2 KINASE. RX PubMed=19965871; DOI=10.1074/jbc.m109.042341; RA Taira N., Yamamoto H., Yamaguchi T., Miki Y., Yoshida K.; RT "ATM augments nuclear stabilization of DYRK2 by inhibiting MDM2 in the RT apoptotic response to DNA damage."; RL J. Biol. Chem. 285:4909-4919(2010). RN [55] RP INTERACTION WITH TTI1. RX PubMed=20810650; DOI=10.1101/gad.1934210; RA Hurov K.E., Cotta-Ramusino C., Elledge S.J.; RT "A genetic screen identifies the Triple T complex required for DNA damage RT signaling and ATM and ATR stability."; RL Genes Dev. 24:1939-1950(2010). RN [56] RP INTERACTION WITH TELO2. RX PubMed=20801936; DOI=10.1101/gad.1956410; RA Takai H., Xie Y., de Lange T., Pavletich N.P.; RT "Tel2 structure and function in the Hsp90-dependent maturation of mTOR and RT ATR complexes."; RL Genes Dev. 24:2019-2030(2010). RN [57] RP INTERACTION WITH TELO2 AND TTI1. RX PubMed=20427287; DOI=10.1074/jbc.m110.121699; RA Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K., RA Iemura S., Natsume T., Mizushima N.; RT "Tti1 and Tel2 are critical factors in mammalian target of rapamycin RT complex assembly."; RL J. Biol. Chem. 285:20109-20116(2010). RN [58] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [59] RP PHOSPHORYLATION AT SER-1981. RX PubMed=21144835; DOI=10.1016/j.bbrc.2010.12.005; RA Kang Y., Cheong H.M., Lee J.H., Song P.I., Lee K.H., Kim S.Y., Jun J.Y., RA You H.J.; RT "Protein phosphatase 5 is necessary for ATR-mediated DNA repair."; RL Biochem. Biophys. Res. Commun. 404:476-481(2011). RN [60] RP INTERACTION WITH BRAT1. RX PubMed=22977523; DOI=10.3892/etm.2011.232; RA So E.Y., Ouchi T.; RT "Functional interaction of BRCA1/ATM-associated BAAT1 with the DNA-PK RT catalytic subunit."; RL Exp. Ther. Med. 2:443-447(2011). RN [61] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=21757780; DOI=10.1074/jbc.m111.258152; RA Gatei M., Jakob B., Chen P., Kijas A.W., Becherel O.J., Gueven N., RA Birrell G., Lee J.H., Paull T.T., Lerenthal Y., Fazry S., RA Taucher-Scholz G., Kalb R., Schindler D., Waltes R., Doerk T., Lavin M.F.; RT "ATM protein-dependent phosphorylation of Rad50 protein regulates DNA RT repair and cell cycle control."; RL J. Biol. Chem. 286:31542-31556(2011). RN [62] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22223895; DOI=10.1074/mcp.m111.015131; RA Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T., RA Giglione C.; RT "Comparative large-scale characterisation of plant vs. mammal proteins RT reveals similar and idiosyncratic N-alpha acetylation features."; RL Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012). RN [63] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [64] RP FUNCTION. RX PubMed=24534091; DOI=10.1002/embj.201386064; RA Wang Q., Goldstein M., Alexander P., Wakeman T.P., Sun T., Feng J., Lou Z., RA Kastan M.B., Wang X.F.; RT "Rad17 recruits the MRE11-RAD50-NBS1 complex to regulate the cellular RT response to DNA double-strand breaks."; RL EMBO J. 33:862-877(2014). RN [65] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [66] RP FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, INTERACTION WITH PEX5, RP AND MUTAGENESIS OF ARG-3047. RX PubMed=26344566; DOI=10.1038/ncb3230; RA Zhang J., Tripathi D.N., Jing J., Alexander A., Kim J., Powell R.T., RA Dere R., Tait-Mulder J., Lee J.H., Paull T.T., Pandita R.K., Charaka V.K., RA Pandita T.K., Kastan M.B., Walker C.L.; RT "ATM functions at the peroxisome to induce pexophagy in response to ROS."; RL Nat. Cell Biol. 17:1259-1269(2015). RN [67] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=26240375; DOI=10.1093/nar/gkv754; RA Kijas A.W., Lim Y.C., Bolderson E., Cerosaletti K., Gatei M., Jakob B., RA Tobias F., Taucher-Scholz G., Gueven N., Oakley G., Concannon P., RA Wolvetang E., Khanna K.K., Wiesmueller L., Lavin M.F.; RT "ATM-dependent phosphorylation of MRE11 controls extent of resection during RT homology directed repair by signalling through Exonuclease 1."; RL Nucleic Acids Res. 43:8352-8367(2015). RN [68] RP FUNCTION IN PHOSPHORYLATION OF FBXW7. RX PubMed=26774286; DOI=10.1016/j.molcel.2015.12.010; RA Zhang Q., Karnak D., Tan M., Lawrence T.S., Morgan M.A., Sun Y.; RT "FBXW7 facilitates nonhomologous end-joining via K63-linked RT polyubiquitylation of XRCC4."; RL Mol. Cell 61:419-433(2016). RN [69] RP FUNCTION. RX PubMed=29203878; DOI=10.1038/s41467-017-02114-x; RA Batenburg N.L., Walker J.R., Noordermeer S.M., Moatti N., Durocher D., RA Zhu X.D.; RT "ATM and CDK2 control chromatin remodeler CSB to inhibit RIF1 in DSB repair RT pathway choice."; RL Nat. Commun. 8:1921-1921(2017). RN [70] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=30171069; DOI=10.1074/jbc.ra118.005354; RA Choppara S., Ganga S., Manne R., Dutta P., Singh S., Santra M.K.; RT "The SCFFBXO46 ubiquitin ligase complex mediates degradation of the tumor RT suppressor FBXO31 and thereby prevents premature cellular senescence."; RL J. Biol. Chem. 293:16291-16306(2018). RN [71] RP FUNCTION. RX PubMed=30612738; DOI=10.1016/j.cell.2018.11.024; RA Jachimowicz R.D., Beleggia F., Isensee J., Velpula B.B., Goergens J., RA Bustos M.A., Doll M.A., Shenoy A., Checa-Rodriguez C., Wiederstein J.L., RA Baranes-Bachar K., Bartenhagen C., Hertwig F., Teper N., Nishi T., RA Schmitt A., Distelmaier F., Luedecke H.J., Albrecht B., Krueger M., RA Schumacher B., Geiger T., Hoon D.S.B., Huertas P., Fischer M., Hucho T., RA Peifer M., Ziv Y., Reinhardt H.C., Wieczorek D., Shiloh Y.; RT "UBQLN4 represses homologous recombination and is overexpressed in RT aggressive tumors."; RL Cell 0:0-0(2019). RN [72] RP FUNCTION IN PHOSPHORYLATION OF UFL1, AND CATALYTIC ACTIVITY. RX PubMed=30886146; DOI=10.1038/s41467-019-09175-0; RA Qin B., Yu J., Nowsheen S., Wang M., Tu X., Liu T., Li H., Wang L., Lou Z.; RT "UFL1 promotes histone H4 ufmylation and ATM activation."; RL Nat. Commun. 10:1242-1242(2019). RN [73] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=30952868; DOI=10.1038/s41467-019-09641-9; RA Ha G.H., Ji J.H., Chae S., Park J., Kim S., Lee J.K., Kim Y., Min S., RA Park J.M., Kang T.H., Lee H., Cho H., Lee C.W.; RT "Pellino1 regulates reversible ATM activation via NBS1 ubiquitination at RT DNA double-strand breaks."; RL Nat. Commun. 10:1577-1577(2019). RN [74] RP ACETYLATION AT LYS-3016, PHOSPHORYLATION AT SER-1981, AND MUTAGENESIS OF RP LYS-3016. RX PubMed=30944854; DOI=10.1126/sciadv.aav1118; RA Tang M., Li Z., Zhang C., Lu X., Tu B., Cao Z., Li Y., Chen Y., Jiang L., RA Wang H., Wang L., Wang J., Liu B., Xu X., Wang H., Zhu W.G.; RT "SIRT7-mediated ATM deacetylation is essential for its deactivation and DNA RT damage repair."; RL Sci. Adv. 5:EAAV1118-EAAV1118(2019). RN [75] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=38128537; DOI=10.1016/j.cell.2023.11.022; RA Chen Y., Wu J., Zhai L., Zhang T., Yin H., Gao H., Zhao F., Wang Z., RA Yang X., Jin M., Huang B., Ding X., Li R., Yang J., He Y., Wang Q., RA Wang W., Kloeber J.A., Li Y., Hao B., Zhang Y., Wang J., Tan M., Li K., RA Wang P., Lou Z., Yuan J.; RT "Metabolic regulation of homologous recombination repair by MRE11 RT lactylation."; RL Cell 187:294-311(2024). RN [76] {ECO:0007744|PDB:5NP0, ECO:0007744|PDB:5NP1} RP STRUCTURE BY ELECTRON MICROSCOPY (5.70 ANGSTROMS), CATALYTIC ACTIVITY, AND RP SUBUNIT. RX PubMed=28508083; DOI=10.1126/sciadv.1700933; RA Baretic D., Pollard H.K., Fisher D.I., Johnson C.M., Santhanam B., RA Truman C.M., Kouba T., Fersht A.R., Phillips C., Williams R.L.; RT "Structures of closed and open conformations of dimeric human ATM."; RL Sci. Adv. 3:E1700933-E1700933(2017). RN [77] {ECO:0007744|PDB:7SIC, ECO:0007744|PDB:7SID} RP STRUCTURE BY ELECTRON MICROSCOPY (2.51 ANGSTROMS) IN COMPLEX WITH NBN, RP FUNCTION, INTERACTION WITH NBN, AND ACTIVITY REGULATION. RX PubMed=35076389; DOI=10.7554/elife.74218; RA Warren C., Pavletich N.P.; RT "Structure of the human ATM kinase and mechanism of Nbs1 binding."; RL Elife 11:0-0(2022). RN [78] RP VARIANTS GLY-2424; 2546-SER--ILE-2548 DEL AND CYS-2827. RX PubMed=8755918; RA McConville C.M., Stankovic T., Byrd P.J., McGuire G.M., Yao Q.-Y., RA Lennox G.G., Taylor A.M.R.; RT "Mutations associated with variant phenotypes in ataxia-telangiectasia."; RL Am. J. Hum. Genet. 59:320-330(1996). RN [79] RP VARIANT AT 2546-SER--ILE-2548 DEL, AND VARIANT ILE-2438. RX PubMed=8808599; RA Wright J., Teraoka S., Onengut S., Tolun A., Gatti R.A., Ochs H.D., RA Concannon P.; RT "A high frequency of distinct ATM gene mutations in ataxia- RT telangiectasia."; RL Am. J. Hum. Genet. 59:839-846(1996). RN [80] RP VARIANTS 705-TYR--SER-707 DELINS PHE-ILE-PRO AND 2546-SER--ILE-2548 DEL, RP AND VARIANTS CYS-49; LEU-858; ARG-1054; PHE-1420 AND ARG-1691. RX PubMed=8797579; RA Vorechovsky I., Luo L., Lindblom A., Negrini M., Webster A.D.B., RA Croce C.M., Hammarstroem L.; RT "ATM mutations in cancer families."; RL Cancer Res. 56:4130-4133(1996). RN [81] RP VARIANT AT 705-TYR--SER-707 DELINS PHE-ILE-PRO, AND VARIANTS LEU-858 AND RP ARG-1054. RX PubMed=9043869; DOI=10.1159/000472231; RA Vorechovsky I., Luo L., Prudente S., Chessa L., Russo G., Kanariou M., RA James M.R., Negrini M., Webster A.D.B., Hammarstroem L.; RT "Exon-scanning mutation analysis of the ATM gene in patients with ataxia- RT telangiectasia."; RL Eur. J. Hum. Genet. 4:352-355(1996). RN [82] RP VARIANT AT ARG-2867. RX PubMed=8698354; DOI=10.1007/s004390050202; RA Baumer A., Bernthaler U., Wolz W., Hoehn H., Schindler D.; RT "New mutations in the ataxia telangiectasia gene."; RL Hum. Genet. 98:246-249(1996). RN [83] RP VARIANTS 2427-LEU-ARG-2428 DEL; 2546-SER--ILE-2548 DEL; SER-2860 DEL AND RP GLY-2904. RX PubMed=8845835; DOI=10.1093/hmg/5.4.433; RA Gilad S., Khosravi R., Shkedy D., Uziel T., Ziv Y., Savitsky K., Rotman G., RA Smith S., Chessa L., Jorgensen T.J., Harnik R., Frydman M., Sanal O., RA Portnoi S., Goldwicz Z., Jaspers N.G.J., Gatti R.A., Lenoir G., Lavin M.F., RA Tatsumi K., Wegner R.-D., Shiloh Y., Bar-Shira A.; RT "Predominance of null mutations in ataxia-telangiectasia."; RL Hum. Mol. Genet. 5:433-439(1996). RN [84] RP POSSIBLE INVOLVEMENT IN TPLL AND BNHL, AND VARIANTS VAL-1040; THR-1407; RP SER-1463; HIS-1682; HIS-1910; LYS-2164; SER-2396; GLY-2424; PRO-2442; RP 2546-SER--ILE-2548 DEL; ALA-2695; ARG-2722; VAL-2725; LEU-2732; LYS-2810 RP DEL; CYS-2832 AND 2871-ARG-HIS-2872 DELINS SER AND VAL-2890. RX PubMed=9288106; DOI=10.1038/ng0997-96; RA Vorechovsky I., Luo L., Dyer M.J.S., Catovsky D., Amlot P.L., Yaxley J.C., RA Foroni L., Hammarstroem L., Webster A.D.B., Yuille M.A.R.; RT "Clustering of missense mutations in the ataxia-telangiectasia gene in a RT sporadic T-cell leukaemia."; RL Nat. Genet. 17:96-99(1997). RN [85] RP POSSIBLE INVOLVEMENT IN TPLL, AND VARIANTS GLY-2725; PRO-3006 AND CYS-3008. RX PubMed=9334731; DOI=10.1038/nm1097-1155; RA Stilgenbauer S., Schaffner C., Litterst A., Liebisch P., Gilad S., RA Bar-Shira A., James M.R., Lichter P., Doehner H.; RT "Biallelic mutations in the ATM gene in T-prolymphocytic leukemia."; RL Nat. Med. 3:1155-1159(1997). RN [86] RP VARIANT AT CYS-2832. RX PubMed=9443866; DOI=10.1086/301673; RA Telatar M., Teraoka S., Wang Z., Chun H.H., Liang T., Castellvi-Bel S., RA Udar N., Boerresen-Dale A.-L., Chessa L., Bernatowska-Matuszkiewicz E., RA Porras O., Watanabe M., Junker A., Concannon P., Gatti R.A.; RT "Ataxia-telangiectasia: identification and detection of founder-effect RT mutations in the ATM gene in ethnic populations."; RL Am. J. Hum. Genet. 62:86-97(1998). RN [87] RP POSSIBLE INVOLVEMENT IN TALL, AND VARIANTS AT LEU-292; ASP-768; GLN-1001; RP ARG-1691; ILE-1743; GLY-2424; 2427-LEU-ARG-2428 DEL; 2546-SER--ILE-2548 RP DEL; ASP-2554; GLY-2668 AND CYS-2827. RX PubMed=9463314; DOI=10.1086/301706; RA Stankovic T., Kidd A.M.J., Sutcliffe A., McGuire G.M., Robinson P., RA Weber P., Bedenham T., Bradwell A.R., Easton D.F., Lennox G.G., Haites N., RA Byrd P.J., Taylor A.M.R.; RT "ATM mutations and phenotypes in ataxia-telangiectasia families in the RT British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, RT and breast cancer."; RL Am. J. Hum. Genet. 62:334-345(1998). RN [88] RP VARIANT AT 1812-ALA-PHE-1813 DELINS VAL. RX PubMed=9497252; DOI=10.1086/301755; RA Gilad S., Chessa L., Khosravi R., Russell P., Galanty Y., Piane M., RA Gatti R.A., Jorgensen T.J., Shiloh Y., Bar-Shira A.; RT "Genotype-phenotype relationships in ataxia-telangiectasia and variants."; RL Am. J. Hum. Genet. 62:551-561(1998). RN [89] RP VARIANT AT PRO-2656. RX PubMed=9450874; RX DOI=10.1002/(sici)1096-8628(19980113)75:2<141::aid-ajmg4>3.3.co;2-8; RA Toyoshima M., Hara T., Zhang H., Yamamoto T., Akaboshi S., Nanba E., RA Ohno K., Hori N., Sato K., Takeshita K.; RT "Ataxia-telangiectasia without immunodeficiency: novel point mutations RT within and adjacent to the phosphatidylinositol 3-kinase-like domain."; RL Am. J. Med. Genet. 75:141-144(1998). RN [90] RP VARIANT TPLL GLY-2486. RX PubMed=9573030; RA Stoppa-Lyonnet D., Soulier J., Lauge A., Dastot H., Garand R., Sigaux F., RA Stern M.-H.; RT "Inactivation of the ATM gene in T-cell prolymphocytic leukemias."; RL Blood 91:3920-3926(1998). RN [91] RP VARIANTS 2855-SER-VAL-2856 DELINS ARG-ILE AND CYS-3008, AND VARIANT RP VAL-1853. RX PubMed=9872980; DOI=10.1101/gr.8.12.1245; RA Hacia J.G., Sun B., Hunt N., Edgemon K., Mosbrook D., Robbins C., RA Fodor S.P.A., Tagle D.A., Collins F.S.; RT "Strategies for mutational analysis of the large multiexon ATM gene using RT high-density oligonucleotide arrays."; RL Genome Res. 8:1245-1258(1998). RN [92] RP VARIANT AT 2625-ASP-ALA-2626 DELINS GLU-PRO. RX PubMed=9521587; DOI=10.1007/s004390050675; RA van Belzen M.J., Hiel J.A.P., Weemaes C.M.R., Gabreeels F.J.M., RA van Engelen B.G.M., Smeets D.F.C.M., van den Heuvel L.P.W.J.; RT "A double missense mutation in the ATM gene of a Dutch family with ataxia RT telangiectasia."; RL Hum. Genet. 102:187-191(1998). RN [93] RP VARIANT AT LEU-2829, AND VARIANTS GLU-126; ASP-514 AND ASN-1853. RX PubMed=9711876; RX DOI=10.1002/(sici)1098-1004(1998)12:3<186::aid-humu6>3.0.co;2-f; RA Sasaki T., Tian H., Kukita Y., Inazuka M., Tahira T., Imai T., Yamauchi M., RA Saito T., Hori T., Hashimoto-Tamaoki T., Komatsu K., Nikaido O., RA Hayashi K.; RT "ATM mutations in patients with ataxia telangiectasia screened by a RT hierarchical strategy."; RL Hum. Mutat. 12:186-195(1998). RN [94] RP VARIANTS AT LEU-858; ARG-1054; ASP-1091 AND ARG-1566. RX PubMed=9792409; RX DOI=10.1002/(sici)1098-1004(1998)12:5<330::aid-humu6>3.0.co;2-h; RA Broeks A., de Klein A., Floore A.N., Muijtjens M., Kleijer W.J., RA Jaspers N.G.J., van 't Veer L.J.; RT "ATM germline mutations in classical ataxia-telangiectasia patients in the RT Dutch population."; RL Hum. Mutat. 12:330-337(1998). RN [95] RP VARIANTS AT ARG-2491 AND GLY-2909. RX PubMed=9792410; RX DOI=10.1002/(sici)1098-1004(1998)12:5<338::aid-humu7>3.0.co;2-9; RA Fukao T., Song X.-Q., Yoshida T., Tashita H., Kaneko H., Teramoto T., RA Inoue R., Katamura K., Mayumi M., Hiratani M., Taniguchi N., Arai J., RA Wakiguchi H., Bar-Shira A., Shiloh Y., Kondo N.; RT "Ataxia-telangiectasia in the Japanese population: identification of RT R1917X, W2491R, R2909G, IVS33+2T-->A, and 7883del5, the latter two being RT relatively common mutations."; RL Hum. Mutat. 12:338-343(1998). RN [96] RP VARIANTS TPLL GLY-2139; VAL-2890 AND CYS-3008. RX PubMed=9488043; DOI=10.1038/sj.onc.1201603; RA Yuille M.A.R., Coignet L.J.A., Abraham S.M., Yaqub F., Luo L., Matutes E., RA Brito-Babapulle V., Vorechovsky I., Dyer M.J.S., Catovsky D.; RT "ATM is usually rearranged in T-cell prolymphocytic leukaemia."; RL Oncogene 16:789-796(1998). RN [97] RP ERRATUM OF PUBMED:9488043. RA Yuille M.A.R., Coignet L.J.A., Abraham S.M., Yaqub F., Luo L., Matutes E., RA Brito-Babapulle V., Vorechovsky I., Dyer M.J.S., Catovsky D.; RL Oncogene 16:2955-2955(1998). RN [98] RP POSSIBLE INVOLVEMENT IN BCLL AND MCL, AND VARIANTS ASN-1853; VAL-1853; RP ARG-1953; LYS-2418 INS; PRO-2420; GLY-2423; HIS-3008 AND ASN-3018. RX PubMed=10397742; RA Schaffner C., Stilgenbauer S., Rappold G.A., Doehner H., Lichter P.; RT "Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic RT lymphocytic leukemia."; RL Blood 94:748-753(1999). RN [99] RP POSSIBLE INVOLVEMENT IN BCLL, AND VARIANTS CYS-332; ARG-1691 AND GLY-2424. RX PubMed=9892178; RA Bullrich F., Rasio D., Kitada S., Starostik P., Kipps T., Keating M., RA Albitar M., Reed J.C., Croce C.M.; RT "ATM mutations in B-cell chronic lymphocytic leukemia."; RL Cancer Res. 59:24-27(1999). RN [100] RP VARIANT AT PRO-1465. RX PubMed=10234507; DOI=10.1038/sj.ejhg.5200288; RA Izatt L., Vessey C., Hodgson S.V., Solomon E.; RT "Rapid and efficient ATM mutation detection by fluorescent chemical RT cleavage of mismatch: identification of four novel mutations."; RL Eur. J. Hum. Genet. 7:310-320(1999). RN [101] RP VARIANTS CYS-49; LEU-182; PRO-707; LEU-858; PHE-1420; ALA-1570; ASN-1853 RP AND SER-2765. RX PubMed=10534763; RX DOI=10.1002/(sici)1098-2264(199912)26:4<286::aid-gcc2>3.3.co;2-o; RA Izatt L., Greenman J., Hodgson S.V., Ellis D., Watts S., Scott G., RA Jacobs C., Liebmann R., Zvelebil M.J., Mathew C., Solomon E.; RT "Identification of germline missense mutations and rare allelic variants in RT the ATM gene in early-onset breast cancer."; RL Genes Chromosomes Cancer 26:286-294(1999). RN [102] RP VARIANTS AT SER-570; CYS-785; GLY-1913; GLY-2016; ASP-2067; CYS-2227; RP ASP-2470; VAL-2662 DEL; PRO-2849 AND ARG-2867, AND VARIANTS CYS-49; RP LEU-858; ARG-1054; ASN-1853 AND VAL-1853. RX PubMed=9887333; DOI=10.1093/hmg/8.1.69; RA Sandoval N., Platzer M., Rosenthal A., Doerk T., Bendix R., Skawran B., RA Stuhrmann M., Wegner R.-D., Sperling K., Banin S., Shiloh Y., Baumer A., RA Bernthaler U., Sennefelder H., Brohm M., Weber B.H.F., Schindler D.; RT "Characterization of ATM gene mutations in 66 ataxia telangiectasia RT families."; RL Hum. Mol. Genet. 8:69-79(1999). RN [103] RP VARIANTS AT 375-GLN--VAL-3056 DEL; 1466-ARG--VAL-3056 DEL; RP 1730-ARG--VAL-3056 DEL; GLY-2016; 2224-MET--ARG-2227 DELINS ILE-SER; RP 2246-CYS--THR-2252 DELINS HIS; VAL-2664 DEL; VAL-2726; 2849-ARG--VAL-3056 RP DEL AND ARG-2855, AND VARIANT CYS-49. RX PubMed=10425038; RX DOI=10.1002/(sici)1098-1004(1999)14:2<156::aid-humu7>3.0.co;2-e; RA Castellvi-Bel S., Sheikhavandi S., Telatar M., Tai L.-Q., Hwang M.J., RA Wang Z., Yang Z., Cheng R., Gatti R.A.; RT "New mutations, polymorphisms, and rare variants in the ATM gene detected RT by a novel SSCP strategy."; RL Hum. Mutat. 14:156-162(1999). RN [104] RP POSSIBLE INVOLVEMENT IN BCLL, AND VARIANTS THR-350; THR-352; ARG-1054; RP THR-2274 AND ALA-2695. RX PubMed=10023947; DOI=10.1016/s0140-6736(98)10117-4; RA Stankovic T., Weber P., Stewart G., Bedenham T., Murray J., Byrd P.J., RA Moss P.A.H., Taylor A.M.R.; RT "Inactivation of ataxia telangiectasia mutated gene in B-cell chronic RT lymphocytic leukaemia."; RL Lancet 353:26-29(1999). RN [105] RP VARIANT ARG-1054. RX PubMed=10217116; DOI=10.1016/s0140-6736(05)75199-0; RA Vorechovsky I., Luo L., Ortmann E., Steinmann D., Doerk T.; RT "Missense mutations at ATM gene and cancer risk."; RL Lancet 353:1276-1276(1999). RN [106] RP ERRATUM OF PUBMED:10217116. RA Vorechovsky I., Luo L., Ortmann E., Steinmann D., Doerk T.; RL Lancet 354:780-780(1999). RN [107] RP VARIANTS AT GLU-224; VAL-323; PRO-1420; CYS-2218; 2546-SER--ILE-2548 DEL; RP GLN-2625; CYS-2832; 2855-SER-VAL-2856 DELINS ARG-ILE AND CYS-3008, AND RP VARIANTS VAL-1853 AND ILE-2438. RX PubMed=10817650; RX DOI=10.1002/(sici)1096-8628(20000529)92:3<170::aid-ajmg3>3.0.co;2-#; RA Li A., Swift M.; RT "Mutations at the ataxia-telangiectasia locus and clinical phenotypes of A- RT T patients."; RL Am. J. Med. Genet. 92:170-177(2000). RN [108] RP VARIANTS AT 35-ARG--VAL-3056 DEL; LEU-292; 393-TRP--VAL-3056 DEL; ARG-950; RP LEU-1082; 1171-GLN--VAL-3056 DEL; 1839-GLN--VAL-3056 DEL; GLU-2063; RP CYS-2227; 2246-CYS--THR-2252 DELINS HIS; 2547-ARG--SER-2549 DEL; GLU-2625; RP PRO-2626 AND ARG-2702, AND VARIANT CYS-49. RX PubMed=10873394; DOI=10.1006/mgme.2000.2998; RA Becker-Catania S.G., Chen G., Hwang M.J., Wang Z., Sun X., Sanal O., RA Bernatowska-Matuszkiewicz E., Chessa L., Lee E.Y.-H.P., Gatti R.A.; RT "Ataxia-telangiectasia: phenotype/genotype studies of ATM protein RT expression, mutations, and radiosensitivity."; RL Mol. Genet. Metab. 70:122-133(2000). RN [109] RP VARIANTS MCL LYS-2418 INS; GLY-2423 AND CYS-3008. RX PubMed=10706620; DOI=10.1073/pnas.050400997; RA Schaffner C., Idler I., Stilgenbauer S., Doehner H., Lichter P.; RT "Mantle cell lymphoma is characterized by inactivation of the ATM gene."; RL Proc. Natl. Acad. Sci. U.S.A. 97:2773-2778(2000). RN [110] RP VARIANTS TRP-45 AND CYS-49. RX PubMed=11897822; DOI=10.1136/jmg.39.3.192; RA Allinen M., Launonen V., Laake K., Jansen L., Huusko P., Kaeaeriaeinen H., RA Boerresen-Dale A.L., Winqvist R.; RT "ATM mutations in Finnish breast cancer patients."; RL J. Med. Genet. 39:192-196(2002). RN [111] RP VARIANTS [LARGE SCALE ANALYSIS] GLN-23; CYS-49; GLU-126; HIS-140; GLN-250; RP PHE-333; CYS-337; HIS-337; ALA-410; SER-504; ASP-514; TYR-540; VAL-546; RP LEU-582; PRO-707; GLN-848; LEU-858; SER-872; TRP-924; ALA-935; ARG-1054; RP PHE-1179; ILE-1321; TYR-1380; SER-1382; PHE-1420; MET-1469; CYS-1475; RP SER-1650; THR-1739; ASN-1853; VAL-1853; ILE-1916; THR-1945; CYS-1961; RP ASP-1991; PHE-2307; PRO-2332; PHE-2356; LEU-2408; PRO-2442; GLN-2443; RP ARG-2464; ARG-2492; ALA-2666; HIS-2719; ARG-2842 AND ASN-2870. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [112] RP VARIANTS CYS-49; LEU-858; ARG-1054; VAL-1255; ASN-1853; THR-2105; SER-2396 RP AND HIS-2719. RX PubMed=18384426; DOI=10.1111/j.1399-0004.2008.00987.x; RA Brunet J., Gutierrez-Enriquez S., Torres A., Berez V., Sanjose S., RA Galceran J., Izquierdo A., Menendez J.A., Guma J., Borras J.; RT "ATM germline mutations in Spanish early-onset breast cancer patients RT negative for BRCA1/BRCA2 mutations."; RL Clin. Genet. 73:465-473(2008). RN [113] RP FUNCTION, CHARACTERIZATION OF VARIANTS AT LEU-292; PRO-1465; ILE-1743; RP THR-2274; GLY-2424; 2427-LEU-ARG-2428 DEL; 2546-SER--ILE-2548 DEL; RP ASP-2554; GLY-2668; CYS-2827; 2855-SER-VAL-2856 DELINS ARG-ILE AND RP CYS-3008, CHARACTERIZATION OF VARIANTS VAL-546; ARG-1054; ILE-1322; RP ARG-1691; CYS-1961 AND SER-2765, VARIANT ILE-1322, AND MUTAGENESIS OF RP LYS-1807; VAL-1941; TYR-2019; GLU-2039; LEU-2338; SER-2394; LEU-2452; RP SER-2685; PRO-2699; ASP-2708 AND GLN-2730. RX PubMed=19431188; DOI=10.1002/humu.21034; RA Barone G., Groom A., Reiman A., Srinivasan V., Byrd P.J., Taylor A.M.; RT "Modeling ATM mutant proteins from missense changes confirms retained RT kinase activity."; RL Hum. Mutat. 30:1222-1230(2009). RN [114] RP VARIANTS ALA-661; PRO-707; LEU-858; TRP-924; ARG-1054; ARG-1691 AND RP VAL-1853. RX PubMed=28202063; DOI=10.1186/s12920-017-0244-7; RA Jalkh N., Chouery E., Haidar Z., Khater C., Atallah D., Ali H., RA Marafie M.J., Al-Mulla M.R., Al-Mulla F., Megarbane A.; RT "Next-generation sequencing in familial breast cancer patients from RT Lebanon."; RL BMC Med. Genomics 10:8-8(2017). RN [115] RP VARIANTS AT VAL-323; PRO-1046; ARG-2023; SER-2068; ASP-2080; HIS-2627; RP LEU-2834 AND ASP-3003, CHARACTERIZATION OF VARIANTS AT VAL-323; PRO-1046; RP ARG-2023; SER-2068; ASP-2080; HIS-2627; LEU-2834 AND ASP-3003, AND RP PHOSPHORYLATION. RX PubMed=27664052; DOI=10.1007/s12017-016-8440-8; RA Carranza D., Vega A.K., Torres-Rusillo S., Montero E., Martinez L.J., RA Santamaria M., Santos J.L., Molina I.J.; RT "Molecular and functional characterization of a cohort of Spanish patients RT with ataxia-telangiectasia."; RL NeuroMolecular Med. 19:161-174(2017). RN [116] RP VARIANTS VAL-68; ILE-341; LEU-597; GLY-699; GLY-759; SER-813; GLY-869; RP ILE-897; ASP-1474; VAL-1488; CYS-1961; ALA-2287; PHE-2307; ARG-2464; RP PRO-2524; THR-2531; GLN-2810; HIS-2832; LEU-2974; ASP-3029 AND LEU-3056. RX PubMed=28726808; DOI=10.1038/gim.2017.85; RA Chaffee K.G., Oberg A.L., McWilliams R.R., Majithia N., Allen B.A., RA Kidd J., Singh N., Hartman A.R., Wenstrup R.J., Petersen G.M.; RT "Prevalence of germ-line mutations in cancer genes among pancreatic cancer RT patients with a positive family history."; RL Genet. Med. 20:119-127(2018). CC -!- FUNCTION: Serine/threonine protein kinase which activates checkpoint CC signaling upon double strand breaks (DSBs), apoptosis and genotoxic CC stresses such as ionizing ultraviolet A light (UVA), thereby acting as CC a DNA damage sensor (PubMed:10550055, PubMed:10839545, PubMed:10910365, CC PubMed:12556884, PubMed:14871926, PubMed:15064416, PubMed:15448695, CC PubMed:15456891, PubMed:15790808, PubMed:15916964, PubMed:17923702, CC PubMed:21757780, PubMed:24534091, PubMed:35076389, PubMed:9733514). CC Recognizes the substrate consensus sequence [ST]-Q (PubMed:10550055, CC PubMed:10839545, PubMed:10910365, PubMed:12556884, PubMed:14871926, CC PubMed:15448695, PubMed:15456891, PubMed:15916964, PubMed:17923702, CC PubMed:24534091, PubMed:9733514). Phosphorylates 'Ser-139' of histone CC variant H2AX at double strand breaks (DSBs), thereby regulating DNA CC damage response mechanism (By similarity). Also plays a role in pre-B CC cell allelic exclusion, a process leading to expression of a single CC immunoglobulin heavy chain allele to enforce clonality and monospecific CC recognition by the B-cell antigen receptor (BCR) expressed on CC individual B-lymphocytes. After the introduction of DNA breaks by the CC RAG complex on one immunoglobulin allele, acts by mediating a CC repositioning of the second allele to pericentromeric heterochromatin, CC preventing accessibility to the RAG complex and recombination of the CC second allele. Also involved in signal transduction and cell cycle CC control. May function as a tumor suppressor. Necessary for activation CC of ABL1 and SAPK. Phosphorylates DYRK2, CHEK2, p53/TP53, FBXW7, FANCD2, CC NFKBIA, BRCA1, CREBBP/CBP, RBBP8/CTIP, FBXO46, MRE11, nibrin (NBN), CC RAD50, RAD17, PELI1, TERF1, UFL1, RAD9, UBQLN4 and DCLRE1C CC (PubMed:10550055, PubMed:10766245, PubMed:10802669, PubMed:10839545, CC PubMed:10910365, PubMed:10973490, PubMed:11375976, PubMed:12086603, CC PubMed:15456891, PubMed:19965871, PubMed:21757780, PubMed:24534091, CC PubMed:26240375, PubMed:26774286, PubMed:30171069, PubMed:30612738, CC PubMed:30886146, PubMed:30952868, PubMed:38128537, PubMed:9733515, CC PubMed:9843217). May play a role in vesicle and/or protein transport. CC Could play a role in T-cell development, gonad and neurological CC function. Plays a role in replication-dependent histone mRNA CC degradation. Binds DNA ends. Phosphorylation of DYRK2 in nucleus in CC response to genotoxic stress prevents its MDM2-mediated ubiquitination CC and subsequent proteasome degradation (PubMed:19965871). Phosphorylates CC ATF2 which stimulates its function in DNA damage response CC (PubMed:15916964). Phosphorylates ERCC6 which is essential for its CC chromatin remodeling activity at DNA double-strand breaks CC (PubMed:29203878). Phosphorylates TTC5/STRAP at 'Ser-203' in the CC cytoplasm in response to DNA damage, which promotes TTC5/STRAP nuclear CC localization (PubMed:15448695). Also involved in pexophagy by mediating CC phosphorylation of PEX5: translocated to peroxisomes in response to CC reactive oxygen species (ROS), and catalyzes phosphorylation of PEX5, CC promoting PEX5 ubiquitination and induction of pexophagy CC (PubMed:26344566). {ECO:0000250|UniProtKB:Q62388, CC ECO:0000269|PubMed:10550055, ECO:0000269|PubMed:10766245, CC ECO:0000269|PubMed:10802669, ECO:0000269|PubMed:10839545, CC ECO:0000269|PubMed:10910365, ECO:0000269|PubMed:10973490, CC ECO:0000269|PubMed:11375976, ECO:0000269|PubMed:12086603, CC ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:14871926, CC ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:15456891, CC ECO:0000269|PubMed:15916964, ECO:0000269|PubMed:16086026, CC ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:17923702, CC ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:19965871, CC ECO:0000269|PubMed:21757780, ECO:0000269|PubMed:24534091, CC ECO:0000269|PubMed:26240375, ECO:0000269|PubMed:26344566, CC ECO:0000269|PubMed:26774286, ECO:0000269|PubMed:29203878, CC ECO:0000269|PubMed:30171069, ECO:0000269|PubMed:30612738, CC ECO:0000269|PubMed:30886146, ECO:0000269|PubMed:30952868, CC ECO:0000269|PubMed:35076389, ECO:0000269|PubMed:38128537, CC ECO:0000269|PubMed:9733514, ECO:0000269|PubMed:9733515, CC ECO:0000269|PubMed:9843217}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:15790808, CC ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:26240375, CC ECO:0000269|PubMed:26344566, ECO:0000269|PubMed:28508083, CC ECO:0000269|PubMed:30171069, ECO:0000269|PubMed:30886146, CC ECO:0000269|PubMed:30952868, ECO:0000269|PubMed:38128537, CC ECO:0000269|PubMed:8988033, ECO:0000269|PubMed:9843217}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:15790808, ECO:0000269|PubMed:21757780, CC ECO:0000269|PubMed:26240375, ECO:0000269|PubMed:30952868, CC ECO:0000269|PubMed:9843217, ECO:0000305|PubMed:15448695}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:24534091, ECO:0000269|PubMed:28508083, CC ECO:0000269|PubMed:30952868, ECO:0000269|PubMed:8988033, CC ECO:0000269|PubMed:9843217}; CC -!- ACTIVITY REGULATION: Activated by the MRN (MRE11-RAD50-NBS1) complex in CC response to DNA double strand breaks (DSBs), which recruits ATM to DSBs CC and promotes its activation (PubMed:15064416, PubMed:15790808, CC PubMed:35076389). Inhibited by wortmannin (PubMed:9766667). CC {ECO:0000269|PubMed:15064416, ECO:0000269|PubMed:15790808, CC ECO:0000269|PubMed:35076389, ECO:0000269|PubMed:9766667}. CC -!- SUBUNIT: Homodimer (PubMed:12556884, PubMed:15790808, PubMed:28508083). CC Dimers or tetramers in inactive state (PubMed:12556884, CC PubMed:15790808, PubMed:28508083). On DNA damage, autophosphorylation CC dissociates ATM into monomers rendering them catalytically active CC (PubMed:12556884, PubMed:28508083). Binds p53/TP53, ABL1, BRCA1 and CC TERF1 (PubMed:15790808, PubMed:9168117, PubMed:9843217). Interacts with CC NBN (via FxF/Y motif) (PubMed:35076389). Part of the BRCA1-associated CC genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, CC MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBN protein complex CC (PubMed:10783165). This association could be a dynamic process changing CC throughout the cell cycle and within subnuclear domains CC (PubMed:10783165). Interacts with RAD17; DNA damage promotes the CC association (PubMed:11418864). Interacts with EEF1E1; the interaction, CC induced on DNA damage, up-regulates TP53 (PubMed:15680327). Interacts CC with KAT8, NABP2, ATMIN and CEP164 (PubMed:15923642, PubMed:17525732, CC PubMed:18283122, PubMed:18449195). Interacts with AP2B1 and AP3B2; the CC interaction occurs in cytoplasmic vesicles (By similarity). Interacts CC with TELO2 and TTI1 (PubMed:20427287, PubMed:20801936, CC PubMed:20810650). Interacts with DDX1 (PubMed:18710941). Interacts with CC BRAT1 (PubMed:22977523). Interacts with CYREN (via XLF motif) (By CC similarity). Interacts (via microbody targeting signal) with PEX5; CC promoting translocation to peroxisomes in response to reactive oxygen CC species (ROS) (PubMed:26344566). {ECO:0000250|UniProtKB:Q62388, CC ECO:0000269|PubMed:10783165, ECO:0000269|PubMed:11418864, CC ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:15680327, CC ECO:0000269|PubMed:15790808, ECO:0000269|PubMed:15923642, CC ECO:0000269|PubMed:17525732, ECO:0000269|PubMed:18283122, CC ECO:0000269|PubMed:18449195, ECO:0000269|PubMed:18710941, CC ECO:0000269|PubMed:20427287, ECO:0000269|PubMed:20801936, CC ECO:0000269|PubMed:20810650, ECO:0000269|PubMed:22977523, CC ECO:0000269|PubMed:26344566, ECO:0000269|PubMed:28508083, CC ECO:0000269|PubMed:35076389, ECO:0000269|PubMed:9168117, CC ECO:0000269|PubMed:9843217}. CC -!- INTERACTION: CC Q13315; Q9NY61: AATF; NbExp=3; IntAct=EBI-495465, EBI-372428; CC Q13315; P00519: ABL1; NbExp=4; IntAct=EBI-495465, EBI-375543; CC Q13315; P31749: AKT1; NbExp=5; IntAct=EBI-495465, EBI-296087; CC Q13315; O43313: ATMIN; NbExp=5; IntAct=EBI-495465, EBI-7422202; CC Q13315; Q6PJG6: BRAT1; NbExp=3; IntAct=EBI-495465, EBI-10826195; CC Q13315; P62508-3: ESRRG; NbExp=3; IntAct=EBI-495465, EBI-12001340; CC Q13315; Q5XUX0: FBXO31; NbExp=2; IntAct=EBI-495465, EBI-6162477; CC Q13315; Q9Y6K9: IKBKG; NbExp=4; IntAct=EBI-495465, EBI-81279; CC Q13315; Q13007: IL24; NbExp=2; IntAct=EBI-495465, EBI-3915542; CC Q13315; Q14676: MDC1; NbExp=3; IntAct=EBI-495465, EBI-495644; CC Q13315; Q9BQ15: NABP2; NbExp=4; IntAct=EBI-495465, EBI-2120336; CC Q13315; P11245: NAT2; NbExp=2; IntAct=EBI-495465, EBI-9057228; CC Q13315; O60934: NBN; NbExp=2; IntAct=EBI-495465, EBI-494844; CC Q13315; P46531: NOTCH1; NbExp=8; IntAct=EBI-495465, EBI-636374; CC Q13315; Q9BZ95: NSD3; NbExp=3; IntAct=EBI-495465, EBI-3390132; CC Q13315; Q7LG56: RRM2B; NbExp=3; IntAct=EBI-495465, EBI-9009083; CC Q13315; Q9Y4R8: TELO2; NbExp=4; IntAct=EBI-495465, EBI-1043674; CC Q13315; P54274: TERF1; NbExp=3; IntAct=EBI-495465, EBI-710997; CC Q13315; P54274-2: TERF1; NbExp=5; IntAct=EBI-495465, EBI-711018; CC Q13315; Q15554: TERF2; NbExp=2; IntAct=EBI-495465, EBI-706637; CC Q13315; Q12888: TP53BP1; NbExp=2; IntAct=EBI-495465, EBI-396540; CC Q13315; O43156: TTI1; NbExp=5; IntAct=EBI-495465, EBI-1055680; CC Q13315; PRO_0000037577 [P27958]; Xeno; NbExp=3; IntAct=EBI-495465, EBI-6904388; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9050866, CC ECO:0000269|PubMed:9150358}. Cytoplasmic vesicle CC {ECO:0000269|PubMed:9050866, ECO:0000269|PubMed:9150358}. Cytoplasm, CC cytoskeleton, microtubule organizing center, centrosome CC {ECO:0000250|UniProtKB:Q62388}. Peroxisome matrix CC {ECO:0000269|PubMed:26344566}. Note=Primarily nuclear (PubMed:9050866, CC PubMed:9150358). Found also in endocytic vesicles in association with CC beta-adaptin (PubMed:9707615). Translocated to peroxisomes in response CC to reactive oxygen species (ROS) by PEX5 (PubMed:26344566). CC {ECO:0000269|PubMed:26344566, ECO:0000269|PubMed:9050866, CC ECO:0000269|PubMed:9150358, ECO:0000269|PubMed:9707615}. CC -!- TISSUE SPECIFICITY: Found in pancreas, kidney, skeletal muscle, liver, CC lung, placenta, brain, heart, spleen, thymus, testis, ovary, small CC intestine, colon and leukocytes. CC -!- INDUCTION: By ionizing radiation. CC -!- DOMAIN: The FATC domain is required for interaction with KAT5. CC {ECO:0000269|PubMed:16141325}. CC -!- PTM: Phosphorylated by NUAK1/ARK5 (PubMed:12409306). CC Autophosphorylation on Ser-367, Ser-1893, Ser-1981 correlates with DNA CC damage-mediated activation of the kinase (PubMed:12556884, CC PubMed:15790808, PubMed:16141325, PubMed:16858402, PubMed:21144835, CC PubMed:27664052). During the late stages of DNA damage response, CC dephosphorylated following deacetylation by SIRT7, leading to ATM CC deactivation (PubMed:30944854). {ECO:0000269|PubMed:12409306, CC ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:15790808, CC ECO:0000269|PubMed:16141325, ECO:0000269|PubMed:16858402, CC ECO:0000269|PubMed:21144835, ECO:0000269|PubMed:27664052, CC ECO:0000269|PubMed:30944854}. CC -!- PTM: Acetylation, on DNA damage, is required for activation of the CC kinase activity, dimer-monomer transition, and subsequent CC autophosphorylation on Ser-1981 (PubMed:12556884, PubMed:16141325, CC PubMed:16858402, PubMed:17923702, PubMed:21144835). Acetylated in vitro CC by KAT5/TIP60 (PubMed:16141325). Deacetylated by SIRT7 during the late CC stages of DNA damage response, promoting ATM dephosphorylation and CC subsequent deactivation (PubMed:30944854). CC {ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:16141325, CC ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:17923702, CC ECO:0000269|PubMed:21144835, ECO:0000269|PubMed:30944854}. CC -!- DISEASE: Ataxia telangiectasia (AT) [MIM:208900]: A rare recessive CC disorder characterized by progressive cerebellar ataxia, dilation of CC the blood vessels in the conjunctiva and eyeballs, immunodeficiency, CC growth retardation and sexual immaturity. Patients have a strong CC predisposition to cancer; about 30% of patients develop tumors, CC particularly lymphomas and leukemias. Cells from affected individuals CC are highly sensitive to damage by ionizing radiation and resistant to CC inhibition of DNA synthesis following irradiation. CC {ECO:0000269|PubMed:10234507, ECO:0000269|PubMed:10425038, CC ECO:0000269|PubMed:10817650, ECO:0000269|PubMed:10873394, CC ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:27664052, CC ECO:0000269|PubMed:7792600, ECO:0000269|PubMed:8589678, CC ECO:0000269|PubMed:8665503, ECO:0000269|PubMed:8698354, CC ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:8789452, CC ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:8808599, CC ECO:0000269|PubMed:8845835, ECO:0000269|PubMed:9043869, CC ECO:0000269|PubMed:9150358, ECO:0000269|PubMed:9443866, CC ECO:0000269|PubMed:9450874, ECO:0000269|PubMed:9463314, CC ECO:0000269|PubMed:9497252, ECO:0000269|PubMed:9521587, CC ECO:0000269|PubMed:9711876, ECO:0000269|PubMed:9792409, CC ECO:0000269|PubMed:9792410, ECO:0000269|PubMed:9872980, CC ECO:0000269|PubMed:9887333}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Note=Defects in ATM may contribute to T-cell acute CC lymphoblastic leukemia (TALL) and T-prolymphocytic leukemia (TPLL). CC TPLL is characterized by a high white blood cell count, with a CC predominance of prolymphocytes, marked splenomegaly, lymphadenopathy, CC skin lesions and serous effusion. The clinical course is highly CC aggressive, with poor response to chemotherapy and short survival time. CC TPLL occurs both in adults as a sporadic disease and in younger AT CC patients. {ECO:0000269|PubMed:9288106, ECO:0000269|PubMed:9334731, CC ECO:0000269|PubMed:9463314, ECO:0000269|PubMed:9488043, CC ECO:0000269|PubMed:9573030}. CC -!- DISEASE: Note=Defects in ATM may contribute to B-cell non-Hodgkin CC lymphomas (BNHL), including mantle cell lymphoma (MCL). CC {ECO:0000269|PubMed:10397742, ECO:0000269|PubMed:10706620, CC ECO:0000269|PubMed:9288106}. CC -!- DISEASE: Note=Defects in ATM may contribute to B-cell chronic CC lymphocytic leukemia (BCLL). BCLL is the commonest form of leukemia in CC the elderly. It is characterized by the accumulation of mature CD5+ B- CC lymphocytes, lymphadenopathy, immunodeficiency and bone marrow failure. CC {ECO:0000269|PubMed:10023947, ECO:0000269|PubMed:10397742, CC ECO:0000269|PubMed:9892178}. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. ATM subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAA86520.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=AAA86520.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=AAI37170.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=AAI37170.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=EAW67111.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/123/ATM"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=Ataxia telangiectasia mutated entry; CC URL="https://en.wikipedia.org/wiki/Ataxia_telangiectasia_mutated"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U33841; AAC50289.1; -; mRNA. DR EMBL; U55757; AAB38309.1; -; Genomic_DNA. DR EMBL; U55704; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55705; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55707; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55708; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55709; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55710; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55711; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55712; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55713; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55714; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55715; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55716; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55717; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55718; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55719; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55720; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55721; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55722; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55723; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55724; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55725; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55726; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55727; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55728; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55729; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55730; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55731; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55732; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55733; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55734; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55735; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55736; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55737; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55738; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55739; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55740; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55741; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55742; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55743; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55744; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55745; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55746; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55747; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55748; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55749; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55750; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55751; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55752; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55753; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55754; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55755; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55756; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55757; AAB38310.1; -; Genomic_DNA. DR EMBL; U55726; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55727; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55728; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55729; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55730; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55731; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55732; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55733; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55734; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55735; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55736; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55737; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55738; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55739; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55740; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55741; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55742; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55743; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55744; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55745; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55746; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55747; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55748; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55749; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55750; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55751; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55752; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55753; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55754; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55755; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55756; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U82828; AAB65827.1; -; Genomic_DNA. DR EMBL; AP001925; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AP005718; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; KF455499; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471065; EAW67111.1; ALT_SEQ; Genomic_DNA. DR EMBL; X91196; CAA62603.1; -; mRNA. DR EMBL; U67092; AAC51298.1; -; Genomic_DNA. DR EMBL; AY220758; AAO26044.1; -; Genomic_DNA. DR EMBL; U26455; AAA86520.1; ALT_SEQ; mRNA. DR EMBL; BC137169; AAI37170.1; ALT_SEQ; mRNA. DR CCDS; CCDS31669.1; -. DR PIR; A43100; A43100. DR RefSeq; NP_000042.3; NM_000051.3. DR RefSeq; NP_001338763.1; NM_001351834.2. DR RefSeq; XP_005271619.2; XM_005271562.6. DR RefSeq; XP_006718906.1; XM_006718843.5. DR RefSeq; XP_006718908.1; XM_006718845.1. DR RefSeq; XP_011541142.1; XM_011542840.4. DR RefSeq; XP_016873279.1; XM_017017790.3. DR RefSeq; XP_047282931.1; XM_047426975.1. DR RefSeq; XP_047282932.1; XM_047426976.1. DR RefSeq; XP_054224846.1; XM_054368871.1. DR RefSeq; XP_054224847.1; XM_054368872.1. DR RefSeq; XP_054224848.1; XM_054368873.1. DR RefSeq; XP_054224849.1; XM_054368874.1. DR RefSeq; XP_054224850.1; XM_054368875.1. DR RefSeq; XP_054224851.1; XM_054368876.1. DR PDB; 5NP0; EM; 5.70 A; A/B=1-3056. DR PDB; 5NP1; EM; 5.70 A; A=1-3056. DR PDB; 6HKA; NMR; -; A=3024-3056. DR PDB; 6K9K; EM; 7.82 A; A=1-3056. DR PDB; 6K9L; EM; 4.27 A; A/B=1-3056. DR PDB; 7NI4; EM; 3.00 A; A/B=1-3056. DR PDB; 7NI5; EM; 2.78 A; A/B=1-3056. DR PDB; 7NI6; EM; 2.80 A; A/B=1-3056. DR PDB; 7SIC; EM; 2.51 A; A/B=1-3056. DR PDB; 7SID; EM; 2.53 A; A/C=1-3056. DR PDB; 8OXM; EM; 3.30 A; A/B=1-3056. DR PDB; 8OXO; EM; 3.00 A; A/B=1-3056. DR PDB; 8OXP; EM; 2.60 A; A/B=1-3056. DR PDB; 8OXQ; EM; 2.50 A; A/B=1-3056. DR PDBsum; 5NP0; -. DR PDBsum; 5NP1; -. DR PDBsum; 6HKA; -. DR PDBsum; 6K9K; -. DR PDBsum; 6K9L; -. DR PDBsum; 7NI4; -. DR PDBsum; 7NI5; -. DR PDBsum; 7NI6; -. DR PDBsum; 7SIC; -. DR PDBsum; 7SID; -. DR PDBsum; 8OXM; -. DR PDBsum; 8OXO; -. DR PDBsum; 8OXP; -. DR PDBsum; 8OXQ; -. DR EMDB; EMD-12350; -. DR EMDB; EMD-12351; -. DR EMDB; EMD-12352; -. DR EMDB; EMD-17265; -. DR EMDB; EMD-17266; -. DR EMDB; EMD-17267; -. DR EMDB; EMD-17268; -. DR EMDB; EMD-25140; -. DR EMDB; EMD-25141; -. DR EMDB; EMD-3669; -. DR EMDB; EMD-3672; -. DR EMDB; EMD-9949; -. DR EMDB; EMD-9950; -. DR SMR; Q13315; -. DR BioGRID; 106962; 345. DR CORUM; Q13315; -. DR DIP; DIP-182N; -. DR FunCoup; Q13315; 3527. DR IntAct; Q13315; 175. DR MINT; Q13315; -. DR STRING; 9606.ENSP00000278616; -. DR BindingDB; Q13315; -. DR ChEMBL; CHEMBL3797; -. DR DrugBank; DB02289; 2-Aminopropanedioic Acid. DR DrugBank; DB00201; Caffeine. DR GuidetoPHARMACOLOGY; 1934; -. DR GlyCosmos; Q13315; 4 sites, 2 glycans. DR GlyGen; Q13315; 7 sites, 2 O-linked glycans (6 sites). DR iPTMnet; Q13315; -. DR PhosphoSitePlus; Q13315; -. DR BioMuta; ATM; -. DR DMDM; 317373479; -. DR CPTAC; CPTAC-2874; -. DR CPTAC; CPTAC-2875; -. DR CPTAC; CPTAC-2876; -. DR CPTAC; CPTAC-3210; -. DR CPTAC; CPTAC-3211; -. DR CPTAC; CPTAC-3212; -. DR CPTAC; CPTAC-3213; -. DR CPTAC; CPTAC-5976; -. DR CPTAC; CPTAC-5977; -. DR CPTAC; CPTAC-5978; -. DR CPTAC; CPTAC-5979; -. DR CPTAC; CPTAC-912; -. DR CPTAC; CPTAC-913; -. DR jPOST; Q13315; -. DR MassIVE; Q13315; -. DR PaxDb; 9606-ENSP00000278616; -. DR PeptideAtlas; Q13315; -. DR ProteomicsDB; 59303; -. DR Pumba; Q13315; -. DR Antibodypedia; 3596; 1462 antibodies from 49 providers. DR CPTC; Q13315; 4 antibodies. DR DNASU; 472; -. DR Ensembl; ENST00000278616.10; ENSP00000278616.4; ENSG00000149311.23. DR Ensembl; ENST00000452508.7; ENSP00000388058.2; ENSG00000149311.23. DR Ensembl; ENST00000601453.3; ENSP00000469471.2; ENSG00000149311.23. DR Ensembl; ENST00000675843.1; ENSP00000501606.1; ENSG00000149311.23. DR Ensembl; ENST00000713844.1; ENSP00000519149.1; ENSG00000149311.23. DR GeneID; 472; -. DR KEGG; hsa:472; -. DR MANE-Select; ENST00000675843.1; ENSP00000501606.1; NM_000051.4; NP_000042.3. DR UCSC; uc001pkb.1; human. DR AGR; HGNC:795; -. DR CIViC; 472; 50 evidence items across 37 molecular profiles. DR ClinPGx; PA61; -. DR CTD; 472; -. DR DisGeNET; 472; -. DR GeneCards; ATM; -. DR GeneReviews; ATM; -. DR HGNC; HGNC:795; ATM. DR HPA; ENSG00000149311; Low tissue specificity. DR MalaCards; ATM; -. DR MIM; 208900; phenotype. DR MIM; 607585; gene. DR OpenTargets; ENSG00000149311; -. DR Orphanet; 100; Ataxia-telangiectasia. DR Orphanet; 370109; Ataxia-telangiectasia variant. DR Orphanet; 67038; B-cell chronic lymphocytic leukemia. DR Orphanet; 440437; Familial colorectal cancer Type X. DR Orphanet; 1331; Familial prostate cancer. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR Orphanet; 227535; Hereditary breast cancer. DR Orphanet; 52416; Mantle cell lymphoma. DR VEuPathDB; HostDB:ENSG00000149311; -. DR eggNOG; KOG0892; Eukaryota. DR GeneTree; ENSGT00670000098061; -. DR HOGENOM; CLU_000178_3_1_1; -. DR InParanoid; Q13315; -. DR OMA; SEVYMKW; -. DR OrthoDB; 381190at2759; -. DR PAN-GO; Q13315; 7 GO annotations based on evolutionary models. DR PhylomeDB; Q13315; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q13315; -. DR Reactome; R-HSA-2559586; DNA Damage/Telomere Stress Induced Senescence. DR Reactome; R-HSA-3371453; Regulation of HSF1-mediated heat shock response. DR Reactome; R-HSA-349425; Autodegradation of the E3 ubiquitin ligase COP1. DR Reactome; R-HSA-5685938; HDR through Single Strand Annealing (SSA). DR Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR). DR Reactome; R-HSA-5693548; Sensing of DNA Double Strand Breaks. DR Reactome; R-HSA-5693554; Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA). DR Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks. DR Reactome; R-HSA-5693568; Resolution of D-loop Structures through Holliday Junction Intermediates. DR Reactome; R-HSA-5693571; Nonhomologous End-Joining (NHEJ). DR Reactome; R-HSA-5693579; Homologous DNA Pairing and Strand Exchange. DR Reactome; R-HSA-5693607; Processing of DNA double-strand break ends. DR Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release. DR Reactome; R-HSA-6803207; TP53 Regulates Transcription of Caspase Activators and Caspases. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-6804760; Regulation of TP53 Activity through Methylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-69541; Stabilization of p53. DR Reactome; R-HSA-912446; Meiotic recombination. DR Reactome; R-HSA-9664873; Pexophagy. DR Reactome; R-HSA-9701192; Defective homologous recombination repair (HRR) due to BRCA1 loss of function. DR Reactome; R-HSA-9704331; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function. DR Reactome; R-HSA-9704646; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function. DR Reactome; R-HSA-9709570; Impaired BRCA2 binding to RAD51. DR Reactome; R-HSA-9709603; Impaired BRCA2 binding to PALB2. DR SignaLink; Q13315; -. DR SIGNOR; Q13315; -. DR Agora; ENSG00000149311; -. DR BioGRID-ORCS; 472; 54 hits in 1215 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; A0DCDA94; DNA damage foci. DR ChiTaRS; ATM; human. DR GeneWiki; Ataxia_telangiectasia_mutated; -. DR GenomeRNAi; 472; -. DR Pharos; Q13315; Tchem. DR PRO; PR:Q13315; -. DR Proteomes; UP000005640; Chromosome 11. DR RNAct; Q13315; protein. DR Bgee; ENSG00000149311; Expressed in calcaneal tendon and 207 other cell types or tissues. DR ExpressionAtlas; Q13315; baseline and differential. DR GO; GO:0005813; C:centrosome; ISS:UniProtKB. DR GO; GO:0005694; C:chromosome; IBA:GO_Central. DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:1990391; C:DNA repair complex; IDA:MGI. DR GO; GO:0098850; C:extrinsic component of synaptic vesicle membrane; IEA:Ensembl. DR GO; GO:0005730; C:nucleolus; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:ParkinsonsUK-UCL. DR GO; GO:0005782; C:peroxisomal matrix; IDA:UniProtKB. DR GO; GO:0035861; C:site of double-strand break; IDA:UniProtKB. DR GO; GO:0005819; C:spindle; IEA:Ensembl. DR GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; IMP:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW. DR GO; GO:0004677; F:DNA-dependent protein kinase activity; IDA:BHF-UCL. DR GO; GO:0035979; F:histone H2AXS139 kinase activity; ISS:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:BHF-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0044877; F:protein-containing complex binding; IDA:BHF-UCL. DR GO; GO:0007420; P:brain development; IEA:Ensembl. DR GO; GO:0071480; P:cellular response to gamma radiation; IDA:CAFA. DR GO; GO:0071500; P:cellular response to nitrosative stress; IDA:ParkinsonsUK-UCL. DR GO; GO:0034614; P:cellular response to reactive oxygen species; IDA:UniProt. DR GO; GO:0071300; P:cellular response to retinoic acid; ISS:ARUK-UCL. DR GO; GO:0033554; P:cellular response to stress; IDA:UniProt. DR GO; GO:0071481; P:cellular response to X-ray; IDA:ParkinsonsUK-UCL. DR GO; GO:0090398; P:cellular senescence; TAS:Reactome. DR GO; GO:0008340; P:determination of adult lifespan; IEA:Ensembl. DR GO; GO:0000077; P:DNA damage checkpoint signaling; IDA:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:CAFA. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0000729; P:DNA double-strand break processing; IDA:UniProt. DR GO; GO:0006302; P:double-strand break repair; IDA:UniProtKB. DR GO; GO:0000724; P:double-strand break repair via homologous recombination; IDA:UniProt. DR GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; TAS:Reactome. DR GO; GO:0097695; P:establishment of protein-containing complex localization to telomere; IMP:BHF-UCL. DR GO; GO:0097694; P:establishment of RNA localization to telomere; IMP:BHF-UCL. DR GO; GO:0007143; P:female meiotic nuclear division; IEA:Ensembl. DR GO; GO:0007507; P:heart development; IEA:Ensembl. DR GO; GO:0071044; P:histone mRNA catabolic process; IDA:UniProtKB. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IBA:GO_Central. DR GO; GO:0042159; P:lipoprotein catabolic process; IEA:Ensembl. DR GO; GO:0007140; P:male meiotic nuclear division; IEA:Ensembl. DR GO; GO:0045141; P:meiotic telomere clustering; IEA:Ensembl. DR GO; GO:0007095; P:mitotic G2 DNA damage checkpoint signaling; IMP:BHF-UCL. DR GO; GO:0007094; P:mitotic spindle assembly checkpoint signaling; IMP:UniProtKB. DR GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl. DR GO; GO:0030889; P:negative regulation of B cell proliferation; IMP:UniProtKB. DR GO; GO:1904354; P:negative regulation of telomere capping; IMP:BHF-UCL. DR GO; GO:1904262; P:negative regulation of TORC1 signaling; IMP:ParkinsonsUK-UCL. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0048599; P:oocyte development; IEA:Ensembl. DR GO; GO:0001541; P:ovarian follicle development; IEA:Ensembl. DR GO; GO:0036289; P:peptidyl-serine autophosphorylation; IMP:MGI. DR GO; GO:0000425; P:pexophagy; IDA:UniProtKB. DR GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:0045785; P:positive regulation of cell adhesion; ISS:ARUK-UCL. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL. DR GO; GO:0043517; P:positive regulation of DNA damage response, signal transduction by p53 class mediator; IMP:BHF-UCL. DR GO; GO:2000781; P:positive regulation of double-strand break repair; IMP:BHF-UCL. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:1904884; P:positive regulation of telomerase catalytic core complex assembly; IMP:BHF-UCL. DR GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; ISS:BHF-UCL. DR GO; GO:1904358; P:positive regulation of telomere maintenance via telomere lengthening; IMP:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:ARUK-UCL. DR GO; GO:0009791; P:post-embryonic development; IEA:Ensembl. DR GO; GO:0002331; P:pre-B cell allelic exclusion; ISS:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0050821; P:protein stabilization; IDA:UniProt. DR GO; GO:0007131; P:reciprocal meiotic recombination; TAS:ProtInc. DR GO; GO:0042981; P:regulation of apoptotic process; TAS:Reactome. DR GO; GO:2000785; P:regulation of autophagosome assembly; IC:UniProt. DR GO; GO:0010506; P:regulation of autophagy; IMP:ParkinsonsUK-UCL. DR GO; GO:0051726; P:regulation of cell cycle; IMP:BHF-UCL. DR GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0032210; P:regulation of telomere maintenance via telomerase; IGI:BHF-UCL. DR GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL. DR GO; GO:0010212; P:response to ionizing radiation; IDA:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0042770; P:signal transduction in response to DNA damage; IDA:UniProtKB. DR GO; GO:0001756; P:somitogenesis; IEA:Ensembl. DR GO; GO:0000723; P:telomere maintenance; IBA:GO_Central. DR GO; GO:0048538; P:thymus development; IEA:Ensembl. DR GO; GO:0033151; P:V(D)J recombination; IEA:Ensembl. DR CDD; cd05171; PIKKc_ATM; 1. DR FunFam; 1.10.1070.11:FF:000011; Serine-protein kinase ATM; 1. DR FunFam; 3.30.1010.10:FF:000015; Serine-protein kinase ATM; 1. DR Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1. DR Gene3D; 3.30.1010.10; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 4; 1. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR038980; ATM_plant. DR InterPro; IPR003152; FATC_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR036940; PI3/4_kinase_cat_sf. DR InterPro; IPR018936; PI3/4_kinase_CS. DR InterPro; IPR003151; PIK-rel_kinase_FAT. DR InterPro; IPR014009; PIK_FAT. DR InterPro; IPR044107; PIKKc_ATM. DR InterPro; IPR021668; TAN. DR PANTHER; PTHR37079; SERINE/THREONINE-PROTEIN KINASE ATM; 1. DR PANTHER; PTHR37079:SF4; SERINE_THREONINE-PROTEIN KINASE ATM; 1. DR Pfam; PF02259; FAT; 1. DR Pfam; PF02260; FATC; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR Pfam; PF11640; TAN; 1. DR SMART; SM01343; FATC; 1. DR SMART; SM00146; PI3Kc; 1. DR SMART; SM01342; TAN; 1. DR SUPFAM; SSF48371; ARM repeat; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51189; FAT; 1. DR PROSITE; PS51190; FATC; 1. DR PROSITE; PS00915; PI3_4_KINASE_1; 1. DR PROSITE; PS00916; PI3_4_KINASE_2; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; ATP-binding; Cell cycle; Cytoplasm; KW Cytoplasmic vesicle; Cytoskeleton; Disease variant; DNA damage; KW DNA-binding; Kinase; Neurodegeneration; Nucleotide-binding; Nucleus; KW Peroxisome; Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Tumor suppressor. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22223895" FT CHAIN 2..3056 FT /note="Serine-protein kinase ATM" FT /id="PRO_0000088840" FT DOMAIN 1940..2566 FT /note="FAT" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534" FT DOMAIN 2686..2998 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT DOMAIN 3024..3056 FT /note="FATC" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534, FT ECO:0000255|PROSITE-ProRule:PRU00535" FT REGION 1373..1382 FT /note="Interaction with ABL1" FT /evidence="ECO:0000269|PubMed:9168117" FT REGION 2692..2698 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2867..2875 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2887..2911 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT MOTIF 3046..3048 FT /note="Microbody targeting signal; atypical" FT /evidence="ECO:0000269|PubMed:26344566" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:22223895" FT MOD_RES 367 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16858402" FT MOD_RES 1893 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16858402" FT MOD_RES 1981 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12556884, FT ECO:0000269|PubMed:15790808, ECO:0000269|PubMed:16141325, FT ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:21144835, FT ECO:0000269|PubMed:30944854, ECO:0007744|PubMed:17525332" FT MOD_RES 1983 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17525332" FT MOD_RES 2996 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195" FT MOD_RES 3016 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:17923702, FT ECO:0000269|PubMed:30944854" FT VARIANT 23 FT /note="R -> Q (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs587779858)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041545" FT VARIANT 35..3056 FT /note="Missing (in AT; dbSNP:rs55861249)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085060" FT VARIANT 45 FT /note="R -> W (found in a patient with breast cancer; FT uncertain significance; dbSNP:rs3218684)" FT /evidence="ECO:0000269|PubMed:11897822" FT /id="VAR_056678" FT VARIANT 49 FT /note="S -> C (in dbSNP:rs1800054)" FT /evidence="ECO:0000269|PubMed:10425038, FT ECO:0000269|PubMed:10534763, ECO:0000269|PubMed:10873394, FT ECO:0000269|PubMed:11897822, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:18384426, ECO:0000269|PubMed:8665503, FT ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:9887333" FT /id="VAR_010798" FT VARIANT 68 FT /note="I -> V (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083373" FT VARIANT 126 FT /note="D -> E (in dbSNP:rs2234997)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9711876" FT /id="VAR_010799" FT VARIANT 140 FT /note="D -> H (in dbSNP:rs55633650)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041546" FT VARIANT 182 FT /note="V -> L (in dbSNP:rs3218707)" FT /evidence="ECO:0000269|PubMed:10534763" FT /id="VAR_010800" FT VARIANT 224 FT /note="K -> E (in AT; uncertain significance; FT dbSNP:rs145053092)" FT /evidence="ECO:0000269|PubMed:10817650" FT /id="VAR_010801" FT VARIANT 250 FT /note="R -> Q (in dbSNP:rs56123940)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041547" FT VARIANT 292 FT /note="P -> L (in AT; decrease phosphorylation of target FT proteins; increases protein abundance; dbSNP:rs747727055)" FT /evidence="ECO:0000269|PubMed:10873394, FT ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:9463314" FT /id="VAR_010802" FT VARIANT 323 FT /note="I -> V (in AT; loss of protein expression; FT dbSNP:rs587781511)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:27664052" FT /id="VAR_010803" FT VARIANT 332 FT /note="Y -> C (in B-cell chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9892178" FT /id="VAR_010804" FT VARIANT 333 FT /note="S -> F (in dbSNP:rs28904919)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041548" FT VARIANT 337 FT /note="R -> C (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs138398778)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041549" FT VARIANT 337 FT /note="R -> H (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs202160435)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041550" FT VARIANT 341 FT /note="V -> I (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083374" FT VARIANT 350 FT /note="A -> T (in B-cell chronic lymphocytic leukemia; FT dbSNP:rs371713984)" FT /evidence="ECO:0000269|PubMed:10023947" FT /id="VAR_010805" FT VARIANT 352 FT /note="I -> T (in B-cell chronic lymphocytic leukemia; FT dbSNP:rs369203092)" FT /evidence="ECO:0000269|PubMed:10023947" FT /id="VAR_010806" FT VARIANT 374..3056 FT /note="Missing (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085061" FT VARIANT 393..3056 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs587776547)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085062" FT VARIANT 410 FT /note="V -> A (in dbSNP:rs56128736)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041551" FT VARIANT 504 FT /note="N -> S (in dbSNP:rs56365018)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041552" FT VARIANT 514 FT /note="G -> D (in dbSNP:rs2235000)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9711876" FT /id="VAR_010807" FT VARIANT 540 FT /note="C -> Y (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041553" FT VARIANT 546 FT /note="L -> V (no effect on phosphorylation of target FT proteins; dbSNP:rs2227924)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:19431188" FT /id="VAR_041554" FT VARIANT 570 FT /note="F -> S (in AT; dbSNP:rs777301065)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010808" FT VARIANT 582 FT /note="F -> L (in dbSNP:rs2235006)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041555" FT VARIANT 597 FT /note="P -> L (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083375" FT VARIANT 661 FT /note="D -> A (found in a patient with familial breast FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28202063" FT /id="VAR_083376" FT VARIANT 699 FT /note="E -> G (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083377" FT VARIANT 705..707 FT /note="YSS -> FIP (in AT)" FT /evidence="ECO:0000269|PubMed:8797579, FT ECO:0000269|PubMed:9043869" FT /id="VAR_010809" FT VARIANT 707 FT /note="S -> P (in dbSNP:rs4986761)" FT /evidence="ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:28202063" FT /id="VAR_010810" FT VARIANT 759 FT /note="S -> G (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083378" FT VARIANT 761 FT /note="T -> S (in dbSNP:rs2235011)" FT /id="VAR_056679" FT VARIANT 768 FT /note="N -> D (in AT)" FT /evidence="ECO:0000269|PubMed:9463314" FT /id="VAR_010812" FT VARIANT 785 FT /note="R -> C (in AT; dbSNP:rs587778065)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010813" FT VARIANT 788 FT /note="S -> R (in dbSNP:rs641252)" FT /id="VAR_056680" FT VARIANT 813 FT /note="N -> S (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083379" FT VARIANT 814 FT /note="D -> E (in dbSNP:rs3218695)" FT /id="VAR_056681" FT VARIANT 848 FT /note="E -> Q (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs879254046)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041556" FT VARIANT 858 FT /note="F -> L (in dbSNP:rs1800056)" FT /evidence="ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:18384426, FT ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:8797579, FT ECO:0000269|PubMed:9043869, ECO:0000269|PubMed:9792409, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010814" FT VARIANT 869 FT /note="A -> G (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083380" FT VARIANT 872 FT /note="P -> S (in dbSNP:rs3218673)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041557" FT VARIANT 897 FT /note="F -> I (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083381" FT VARIANT 924 FT /note="R -> W (found in a patient with familial breast FT cancer; uncertain significance; dbSNP:rs55723361)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:28202063" FT /id="VAR_041558" FT VARIANT 935 FT /note="T -> A (in dbSNP:rs35813135)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041559" FT VARIANT 935 FT /note="T -> M (in dbSNP:rs3218708)" FT /id="VAR_056682" FT VARIANT 942 FT /note="L -> F (in dbSNP:rs3218688)" FT /id="VAR_056683" FT VARIANT 950 FT /note="L -> R (in AT; dbSNP:rs786203054)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_010815" FT VARIANT 1001 FT /note="L -> Q (in AT; risk factor for T-cell acute FT lymphoblastic leukemia)" FT /evidence="ECO:0000269|PubMed:9463314" FT /id="VAR_010816" FT VARIANT 1040 FT /note="M -> V (in dbSNP:rs3092857)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010817" FT VARIANT 1046 FT /note="L -> P (in AT; loss of protein expression; FT dbSNP:rs568461905)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077237" FT VARIANT 1054 FT /note="P -> R (in AT; likely benign; no effect on FT phosphorylation of target proteins; dbSNP:rs1800057)" FT /evidence="ECO:0000269|PubMed:10023947, FT ECO:0000269|PubMed:10217116, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:18384426, ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:8665503, FT ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:9043869, FT ECO:0000269|PubMed:9792409, ECO:0000269|PubMed:9887333" FT /id="VAR_010818" FT VARIANT 1082 FT /note="H -> L (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_010819" FT VARIANT 1091 FT /note="E -> D (in AT)" FT /evidence="ECO:0000269|PubMed:9792409" FT /id="VAR_010820" FT VARIANT 1171..3056 FT /note="Missing (in AT; uncertain significance; increases FT protein abundance)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085063" FT VARIANT 1179 FT /note="S -> F (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041560" FT VARIANT 1255 FT /note="L -> V (found in a patient with early-onset breast FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:18384426" FT /id="VAR_083382" FT VARIANT 1313 FT /note="E -> Q (in dbSNP:rs3092841)" FT /id="VAR_056684" FT VARIANT 1321 FT /note="M -> I (in dbSNP:rs35184530)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041561" FT VARIANT 1322 FT /note="L -> I (no effect on phosphorylation of target FT proteins; dbSNP:rs144535256)" FT /evidence="ECO:0000269|PubMed:19431188" FT /id="VAR_080300" FT VARIANT 1380 FT /note="H -> Y (in dbSNP:rs3092856)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041562" FT VARIANT 1382 FT /note="P -> S (in dbSNP:rs55859590)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041563" FT VARIANT 1407 FT /note="I -> T (in T-prolymphocytic leukemia; FT dbSNP:rs1234250980)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010821" FT VARIANT 1420 FT /note="L -> F (in dbSNP:rs1800058)" FT /evidence="ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:8665503, FT ECO:0000269|PubMed:8797579" FT /id="VAR_010822" FT VARIANT 1420 FT /note="L -> P (in AT)" FT /evidence="ECO:0000269|PubMed:10817650" FT /id="VAR_010823" FT VARIANT 1427 FT /note="A -> T (in dbSNP:rs2229021)" FT /id="VAR_056685" FT VARIANT 1463 FT /note="F -> S (found in B-cell non-Hodgkin lymphoma; FT uncertain significance)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010825" FT VARIANT 1465 FT /note="L -> P (in AT; decreased phosphorylation of target FT proteins; dbSNP:rs730881391)" FT /evidence="ECO:0000269|PubMed:10234507, FT ECO:0000269|PubMed:19431188" FT /id="VAR_010826" FT VARIANT 1466..3056 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs730881369)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085064" FT VARIANT 1469 FT /note="I -> M (in a renal papillary cancer sample; somatic FT mutation; dbSNP:rs775047783)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041564" FT VARIANT 1474 FT /note="H -> D (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083383" FT VARIANT 1475 FT /note="Y -> C (in dbSNP:rs34640941)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041565" FT VARIANT 1488 FT /note="L -> V (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083384" FT VARIANT 1541 FT /note="L -> F (in dbSNP:rs3092849)" FT /id="VAR_056686" FT VARIANT 1566 FT /note="P -> R (in AT)" FT /evidence="ECO:0000269|PubMed:9792409" FT /id="VAR_010827" FT VARIANT 1570 FT /note="V -> A (in dbSNP:rs140856217)" FT /evidence="ECO:0000269|PubMed:10534763" FT /id="VAR_010828" FT VARIANT 1650 FT /note="N -> S (in dbSNP:rs55870064)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041566" FT VARIANT 1682 FT /note="D -> H (in T-prolymphocytic leukemia; FT dbSNP:rs121434217)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010829" FT VARIANT 1691 FT /note="S -> R (in AT, B-cell chronic lymphocytic leukemia FT and familial cancer patients; no effect on phosphorylation FT of target proteins; dbSNP:rs1800059)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:8797579, FT ECO:0000269|PubMed:9463314, ECO:0000269|PubMed:9892178" FT /id="VAR_010830" FT VARIANT 1729 FT /note="V -> L (in dbSNP:rs3092907)" FT /id="VAR_056687" FT VARIANT 1730..3056 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs764389018)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085065" FT VARIANT 1739 FT /note="N -> T (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041567" FT VARIANT 1743 FT /note="T -> I (in AT; decreased phosphorylation of target FT proteins; dbSNP:rs587779844)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:9463314" FT /id="VAR_010831" FT VARIANT 1812..1813 FT /note="AF -> V (in AT)" FT /evidence="ECO:0000269|PubMed:9497252" FT /id="VAR_010832" FT VARIANT 1839..3056 FT /note="Missing (in AT; uncertain significance; reduces FT protein abundance)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085066" FT VARIANT 1853 FT /note="D -> N (in dbSNP:rs1801516)" FT /evidence="ECO:0000269|PubMed:10397742, FT ECO:0000269|PubMed:10425038, ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:18384426, FT ECO:0000269|PubMed:9711876, ECO:0000269|PubMed:9887333" FT /id="VAR_010833" FT VARIANT 1853 FT /note="D -> V (might contribute to B-cell chronic FT lymphocytic leukemia; dbSNP:rs1801673)" FT /evidence="ECO:0000269|PubMed:10397742, FT ECO:0000269|PubMed:10817650, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:9872980, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010834" FT VARIANT 1910 FT /note="L -> H (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010835" FT VARIANT 1913 FT /note="V -> G (in AT; dbSNP:rs1060501688)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010836" FT VARIANT 1916 FT /note="M -> I (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041568" FT VARIANT 1945 FT /note="A -> T (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041569" FT VARIANT 1953 FT /note="T -> R (in B-cell chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:10397742" FT /id="VAR_010837" FT VARIANT 1961 FT /note="Y -> C (found in a patient with familial pancreatic FT cancer; uncertain significance; also found in a lung FT adenocarcinoma sample; uncertain significance; decreased FT phosphorylation of target proteins; dbSNP:rs56399311)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:28726808" FT /id="VAR_041570" FT VARIANT 1983 FT /note="S -> N (in dbSNP:rs659243)" FT /evidence="ECO:0000269|PubMed:16554811" FT /id="VAR_041571" FT VARIANT 1991 FT /note="E -> D (in a renal clear cell carcinoma sample; FT somatic mutation; dbSNP:rs587782274)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041572" FT VARIANT 2016 FT /note="D -> G (in AT; uncertain significance; FT dbSNP:rs587781302)" FT /evidence="ECO:0000269|PubMed:10425038, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010838" FT VARIANT 2023 FT /note="G -> R (in AT; loss of protein expression; FT dbSNP:rs11212587)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077238" FT VARIANT 2034 FT /note="R -> Q (in dbSNP:rs3218670)" FT /id="VAR_056688" FT VARIANT 2063 FT /note="G -> E (in AT; uncertain significance; reduces FT protein abundance; dbSNP:rs866290641)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_010839" FT VARIANT 2067 FT /note="A -> D (in AT; dbSNP:rs397514577)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010840" FT VARIANT 2068 FT /note="L -> S (in AT; decreased protein abundance; loss of FT DNA damage induced protein autophosphorylation; FT dbSNP:rs1555114558)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077239" FT VARIANT 2079 FT /note="V -> I (in dbSNP:rs1800060)" FT /evidence="ECO:0000269|PubMed:8665503" FT /id="VAR_010841" FT VARIANT 2080 FT /note="Y -> D (in AT; loss of DNA damage induced protein FT autophosphorylation; dbSNP:rs1064795467)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077240" FT VARIANT 2105 FT /note="R -> T (found in a patient with early-onset breast FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:18384426" FT /id="VAR_083385" FT VARIANT 2139 FT /note="E -> G (in T-prolymphocytic leukemia; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:9488043" FT /id="VAR_010842" FT VARIANT 2164 FT /note="E -> K (in T-prolymphocytic leukemia; FT dbSNP:rs1317619286)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010843" FT VARIANT 2218 FT /note="S -> C (in AT)" FT /evidence="ECO:0000269|PubMed:10817650" FT /id="VAR_010844" FT VARIANT 2224..2227 FT /note="MALR -> IS (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_010845" FT VARIANT 2227 FT /note="R -> C (in AT; uncertain significance; reduces FT protein abundance; dbSNP:rs564652222)" FT /evidence="ECO:0000269|PubMed:10873394, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010846" FT VARIANT 2246..2252 FT /note="CIKDILT -> H (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10425038, FT ECO:0000269|PubMed:10873394" FT /id="VAR_010847" FT VARIANT 2274 FT /note="A -> T (in B-cell chronic lymphocytic leukemia; FT uncertain significance; no effect on phosphorylation of FT target proteins; dbSNP:rs567060474)" FT /evidence="ECO:0000269|PubMed:10023947, FT ECO:0000269|PubMed:19431188" FT /id="VAR_010848" FT VARIANT 2287 FT /note="G -> A (found in a patient with familial pancreatic FT cancer; uncertain significance; dbSNP:rs1800061)" FT /evidence="ECO:0000269|PubMed:28726808, FT ECO:0000269|PubMed:8665503" FT /id="VAR_010849" FT VARIANT 2307 FT /note="L -> F (found in patients with familial pancreatic FT cancer; uncertain significance; also found in a lung FT adenocarcinoma sample; uncertain significance; FT dbSNP:rs56009889)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:28726808" FT /id="VAR_041573" FT VARIANT 2332 FT /note="L -> P (in dbSNP:rs4988111)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041574" FT VARIANT 2335 FT /note="T -> K (in dbSNP:rs3092831)" FT /id="VAR_056689" FT VARIANT 2356 FT /note="I -> F (in a renal clear cell carcinoma sample; FT somatic mutation; dbSNP:rs876658517)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041575" FT VARIANT 2396 FT /note="T -> S (found in a patient with T-prolymphocytic FT leukemia; uncertain significance; also found in a patient FT with early-onset breast cancer; uncertain significance; FT dbSNP:rs370559102)" FT /evidence="ECO:0000269|PubMed:18384426, FT ECO:0000269|PubMed:9288106" FT /id="VAR_010850" FT VARIANT 2408 FT /note="S -> L (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs730881315)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041576" FT VARIANT 2418 FT /note="K -> KK (in mantle cell lymphoma)" FT /evidence="ECO:0000269|PubMed:10397742, FT ECO:0000269|PubMed:10706620" FT /id="VAR_010851" FT VARIANT 2420 FT /note="A -> P (in B-cell chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:10397742" FT /id="VAR_010852" FT VARIANT 2423 FT /note="E -> G (in mantle cell lymphoma; dbSNP:rs121434221)" FT /evidence="ECO:0000269|PubMed:10397742, FT ECO:0000269|PubMed:10706620" FT /id="VAR_010853" FT VARIANT 2424 FT /note="V -> G (in AT; also found in B-cell chronic FT lymphocytic leukemia and T-prolymphocytic leukemia; risk FT factor for breast cancer; decreased phosphorylation of FT target proteins; dbSNP:rs28904921)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:9288106, FT ECO:0000269|PubMed:9463314, ECO:0000269|PubMed:9892178" FT /id="VAR_010854" FT VARIANT 2427..2428 FT /note="Missing (in AT; also found in T-prolymphocytic FT leukemia; lack of phosphorylation of target proteins)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:7792600, ECO:0000269|PubMed:8845835, FT ECO:0000269|PubMed:9463314" FT /id="VAR_010855" FT VARIANT 2438 FT /note="T -> I (in dbSNP:rs147604227)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:8808599" FT /id="VAR_010856" FT VARIANT 2442 FT /note="Q -> P (in T-prolymphocytic leukemia; also in a lung FT adenocarcinoma sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9288106" FT /id="VAR_010857" FT VARIANT 2443 FT /note="R -> Q (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs587782310)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041577" FT VARIANT 2464 FT /note="C -> R (found in patients with familial pancreatic FT cancer; uncertain significance; also found in a small cell FT lung cancer sample; uncertain significance; FT dbSNP:rs55801750)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:28726808" FT /id="VAR_041578" FT VARIANT 2470 FT /note="Y -> D (in AT; dbSNP:rs876659365)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010858" FT VARIANT 2486 FT /note="R -> G (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9573030" FT /id="VAR_010859" FT VARIANT 2491 FT /note="W -> R (in AT)" FT /evidence="ECO:0000269|PubMed:9792410" FT /id="VAR_010860" FT VARIANT 2492 FT /note="L -> R (in dbSNP:rs56399857)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041579" FT VARIANT 2524 FT /note="A -> P (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083386" FT VARIANT 2531 FT /note="M -> T (found in patients with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083387" FT VARIANT 2546..2548 FT /note="Missing (in AT; also found in T-prolymphocytic FT leukemia and T-cell acute lymphoblastic leukemia; lack of FT phosphorylation of target proteins)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:7792600, FT ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:8789452, FT ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:8808599, FT ECO:0000269|PubMed:8845835, ECO:0000269|PubMed:9150358, FT ECO:0000269|PubMed:9288106, ECO:0000269|PubMed:9463314" FT /id="VAR_010861" FT VARIANT 2547..2549 FT /note="Missing (in AT; dbSNP:rs587776547)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085067" FT VARIANT 2554 FT /note="H -> D (in AT; lack of phosphorylation of target FT proteins)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:9463314" FT /id="VAR_010862" FT VARIANT 2570 FT /note="E -> G (in dbSNP:rs28904920)" FT /id="VAR_056690" FT VARIANT 2625..2626 FT /note="DA -> EP (in AT; dbSNP:rs267606668)" FT /evidence="ECO:0000269|PubMed:9521587" FT /id="VAR_010864" FT VARIANT 2625 FT /note="D -> E (in AT; uncertain significance; FT dbSNP:rs1196903858)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085068" FT VARIANT 2625 FT /note="D -> Q (in AT; requires 2 nucleotide substitutions)" FT /evidence="ECO:0000269|PubMed:10817650" FT /id="VAR_010863" FT VARIANT 2626 FT /note="A -> P (in AT; uncertain significance; FT dbSNP:rs267606669)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085069" FT VARIANT 2627 FT /note="Y -> H (in AT; loss of protein expression)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077241" FT VARIANT 2640 FT /note="T -> I (in dbSNP:rs4988125)" FT /id="VAR_056691" FT VARIANT 2656 FT /note="L -> P (in AT; dbSNP:rs121434218)" FT /evidence="ECO:0000269|PubMed:9450874" FT /id="VAR_010865" FT VARIANT 2662 FT /note="Missing (in AT)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010866" FT VARIANT 2664 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs1471563800)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085070" FT VARIANT 2666 FT /note="T -> A (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs745775382)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041580" FT VARIANT 2668 FT /note="E -> G (in AT; uncertain significance; no effect on FT phosphorylation of target proteins)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:9463314" FT /id="VAR_010868" FT VARIANT 2695 FT /note="G -> A (in T-prolymphocytic leukemia and B-cell FT chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:10023947, FT ECO:0000269|PubMed:9288106" FT /id="VAR_010869" FT VARIANT 2702 FT /note="I -> R (in AT; dbSNP:rs876659735)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_010870" FT VARIANT 2709 FT /note="G -> S (in dbSNP:rs3218680)" FT /id="VAR_056692" FT VARIANT 2719 FT /note="R -> H (found in a patient with early-onset breast FT cancer; uncertain significance; dbSNP:rs55982963)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:18384426" FT /id="VAR_041581" FT VARIANT 2722 FT /note="L -> R (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010871" FT VARIANT 2725 FT /note="D -> G (found in T-prolymphocytic leukemia; FT uncertain significance; dbSNP:rs1555128314)" FT /evidence="ECO:0000269|PubMed:9334731" FT /id="VAR_010872" FT VARIANT 2725 FT /note="D -> V (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010873" FT VARIANT 2726 FT /note="A -> V (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_010874" FT VARIANT 2732 FT /note="F -> L (in T-prolymphocytic leukemia; FT dbSNP:rs876659619)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010875" FT VARIANT 2765 FT /note="G -> S (may contribute to breast cancer; lack of FT phosphorylation of target proteins; dbSNP:rs748634900)" FT /evidence="ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:19431188" FT /id="VAR_010876" FT VARIANT 2810 FT /note="K -> Q (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083388" FT VARIANT 2810 FT /note="Missing (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010877" FT VARIANT 2824 FT /note="C -> Y (in AT; dbSNP:rs876660927)" FT /evidence="ECO:0000269|PubMed:9150358" FT /id="VAR_010878" FT VARIANT 2827 FT /note="F -> C (in AT; mild; decreased phosphorylation of FT target proteins; dbSNP:rs121434216)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:9463314" FT /id="VAR_010879" FT VARIANT 2829 FT /note="P -> L (in AT; dbSNP:rs938431501)" FT /evidence="ECO:0000269|PubMed:9711876" FT /id="VAR_010880" FT VARIANT 2832 FT /note="R -> C (in AT; also found in B-cell non-Hodgkin FT lymphoma; increases protein abundance; dbSNP:rs587779872)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:10873394, ECO:0000269|PubMed:9288106, FT ECO:0000269|PubMed:9443866" FT /id="VAR_010881" FT VARIANT 2832 FT /note="R -> H (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083389" FT VARIANT 2834 FT /note="F -> L (in AT; decreased protein abundance)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077242" FT VARIANT 2842 FT /note="P -> R (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs879254065)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041582" FT VARIANT 2849..3056 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs587778080)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085071" FT VARIANT 2849 FT /note="R -> P (in AT; dbSNP:rs587782202)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010882" FT VARIANT 2855..2856 FT /note="SV -> RI (in AT; lack of phosphorylation of target FT proteins; dbSNP:rs587781353)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:9872980" FT /id="VAR_010884" FT VARIANT 2855 FT /note="S -> R (in AT; uncertain significance; FT dbSNP:rs780905851)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_010883" FT VARIANT 2860 FT /note="Missing (in AT)" FT /evidence="ECO:0000269|PubMed:7792600, FT ECO:0000269|PubMed:8845835" FT /id="VAR_010885" FT VARIANT 2867 FT /note="G -> R (in AT)" FT /evidence="ECO:0000269|PubMed:8698354, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010886" FT VARIANT 2870 FT /note="D -> N (in dbSNP:rs55798854)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041583" FT VARIANT 2871..2872 FT /note="RH -> S (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010887" FT VARIANT 2890 FT /note="L -> V (in T-prolymphocytic leukemia; FT dbSNP:rs587779874)" FT /evidence="ECO:0000269|PubMed:9288106, FT ECO:0000269|PubMed:9488043" FT /id="VAR_010888" FT VARIANT 2904 FT /note="E -> G (in AT; dbSNP:rs786202826)" FT /evidence="ECO:0000269|PubMed:8845835" FT /id="VAR_010889" FT VARIANT 2909 FT /note="R -> G (in AT)" FT /evidence="ECO:0000269|PubMed:9792410" FT /id="VAR_010890" FT VARIANT 2974 FT /note="P -> L (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083390" FT VARIANT 3003 FT /note="N -> D (in AT; decreased protein abundance; FT dbSNP:rs1137889)" FT /evidence="ECO:0000269|PubMed:27664052, FT ECO:0000269|PubMed:7792600, ECO:0000269|PubMed:8589678, FT ECO:0000269|PubMed:8665503" FT /id="VAR_077243" FT VARIANT 3006 FT /note="A -> P (found in T-prolymphocytic leukemia; FT uncertain significance; dbSNP:rs876658767)" FT /evidence="ECO:0000269|PubMed:9334731" FT /id="VAR_010892" FT VARIANT 3008 FT /note="R -> C (in AT; also found in T-prolymphocytic FT leukemia and mantle cell lymphoma; lack of phosphorylation FT of target proteins; dbSNP:rs587782292)" FT /evidence="ECO:0000269|PubMed:10706620, FT ECO:0000269|PubMed:10817650, ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:9334731, ECO:0000269|PubMed:9488043, FT ECO:0000269|PubMed:9872980" FT /id="VAR_010893" FT VARIANT 3008 FT /note="R -> H (in B-cell chronic lymphocytic leukemia; FT dbSNP:rs587781894)" FT /evidence="ECO:0000269|PubMed:10397742" FT /id="VAR_010894" FT VARIANT 3018 FT /note="K -> N (in B-cell chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:10397742" FT /id="VAR_010895" FT VARIANT 3029 FT /note="G -> D (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083391" FT VARIANT 3056 FT /note="V -> L (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083392" FT MUTAGEN 367 FT /note="S->A: Loss of IR-induced S-367 autophosphorylation. FT Reduced correction of cell cycle checkpoint defects and FT DNA-repair activity. No effect on S-1893 nor S-1981 FT autophosphorylation." FT /evidence="ECO:0000269|PubMed:16858402" FT MUTAGEN 1807 FT /note="K->E: Decreased phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 1893 FT /note="S->A: Loss of IR-induced S-1893 autophosphorylation. FT Reduced correction of cell cycle checkpoint defects and FT DNA-repair activity. No effect on S-367 nor S-1981 FT autophosphorylation." FT /evidence="ECO:0000269|PubMed:16858402" FT MUTAGEN 1941 FT /note="V->L: Decreased phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 1981 FT /note="S->A: Loss of IR-induced S-1981 autophosphorylation. FT Reduced correction of cell cycle checkpoint defects and FT DNA-repair activity. No effect on S-367 nor S-1893 FT autophosphorylation. No dimer disruption." FT /evidence="ECO:0000269|PubMed:12556884, FT ECO:0000269|PubMed:16858402" FT MUTAGEN 1981 FT /note="S->D,E: Disrupts the dimer." FT /evidence="ECO:0000269|PubMed:12556884, FT ECO:0000269|PubMed:16858402" FT MUTAGEN 2019 FT /note="Y->C: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2039 FT /note="E->K: Decreased phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2338 FT /note="L->P: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2394 FT /note="S->L: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2452 FT /note="L->P: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2685 FT /note="S->T: No effect on phosphorylation of target FT proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2699 FT /note="P->L: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2708 FT /note="D->N: Decreased phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2730 FT /note="Q->P: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2870 FT /note="D->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:9733515" FT MUTAGEN 2875 FT /note="N->K: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:9733515" FT MUTAGEN 3016 FT /note="K->Q: Mimics acetylation, preventing FT dephosphorylation and subsequent ATM deactivation during FT the late stage of DNA damage response." FT /evidence="ECO:0000269|PubMed:30944854" FT MUTAGEN 3016 FT /note="K->R: Loss of DNA damage-inducible acetylation. FT Retains constitutive kinase activity, but blocks DNA FT damage-induced kinase activation. Disrupts dimer and FT abolishes S-1981 autophosphorylation." FT /evidence="ECO:0000269|PubMed:17923702" FT MUTAGEN 3018 FT /note="K->R: Retains DNA damage-inducible acetylation and FT S-1981 autophosphorylation." FT /evidence="ECO:0000269|PubMed:17923702" FT MUTAGEN 3047 FT /note="R->Q: Abolished interaction with PEX5 and FT translocation to peroxisomes in response to reactive oxygen FT species (ROS)." FT /evidence="ECO:0000269|PubMed:26344566" FT CONFLICT 46 FT /note="H -> N (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 56 FT /note="N -> I (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 313 FT /note="Y -> N (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 488 FT /note="W -> G (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 554 FT /note="T -> A (in Ref. 1; AAC50289)" FT /evidence="ECO:0000305" FT CONFLICT 750 FT /note="K -> N (in Ref. 1; AAC50289)" FT /evidence="ECO:0000305" FT CONFLICT 754 FT /note="Q -> K (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 887 FT /note="E -> G (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 1003 FT /note="Q -> L (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 1049 FT /note="L -> W (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 1089 FT /note="A -> V (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT HELIX 6..17 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 20..33 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 36..41 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 57..73 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 90..108 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 109..112 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 117..129 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 130..133 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 135..148 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 149..151 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 153..158 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 161..176 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 183..201 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 207..209 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 210..222 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 223..225 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 229..242 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 244..246 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 248..268 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 273..290 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 292..294 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 298..300 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 306..323 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 324..326 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 343..356 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 393..402 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 407..409 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 410..422 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 424..426 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 429..431 FT /evidence="ECO:0007829|PDB:7SID" FT HELIX 432..442 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 445..447 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 452..466 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 474..492 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 493..496 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 498..500 FT /evidence="ECO:0007829|PDB:7SID" FT HELIX 501..513 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 521..524 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 525..527 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 528..530 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 536..548 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 572..580 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 597..600 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 605..607 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 608..615 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 617..619 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 620..628 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 634..636 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 646..655 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 684..704 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 707..709 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 713..731 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 732..735 FT /evidence="ECO:0007829|PDB:8OXP" FT HELIX 737..741 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 744..765 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 771..786 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 792..794 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 795..806 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 809..822 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 887..889 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 892..911 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 920..930 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 933..935 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 941..953 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 957..959 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 963..970 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 973..979 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 980..982 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 984..994 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 995..997 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 998..1002 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1009..1030 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 1031..1033 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 1036..1052 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 1060..1063 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 1066..1069 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1070..1076 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1077..1079 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1083..1092 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1093..1096 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1113..1132 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 1136..1138 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 1144..1164 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1169..1181 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1187..1201 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1206..1212 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1214..1223 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1227..1229 FT /evidence="ECO:0007829|PDB:7NI5" FT TURN 1231..1233 FT /evidence="ECO:0007829|PDB:7SID" FT HELIX 1236..1238 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1244..1261 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1265..1275 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1279..1285 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1287..1294 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1295..1297 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 1299..1303 FT /evidence="ECO:0007829|PDB:8OXM" FT HELIX 1306..1322 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 1325..1327 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1328..1330 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1332..1338 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1340..1348 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1383..1396 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 1397..1399 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1404..1408 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1413..1428 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1432..1450 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1453..1455 FT /evidence="ECO:0007829|PDB:7SID" FT TURN 1456..1460 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 1461..1477 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1485..1508 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1513..1515 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1517..1527 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1528..1530 FT /evidence="ECO:0007829|PDB:7SID" FT HELIX 1532..1545 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1546..1551 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1553..1560 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1567..1569 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1572..1582 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1583..1585 FT /evidence="ECO:0007829|PDB:7NI6" FT HELIX 1590..1601 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1607..1610 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1611..1623 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1625..1634 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1635..1637 FT /evidence="ECO:0007829|PDB:8OXP" FT HELIX 1639..1641 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1643..1658 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1661..1663 FT /evidence="ECO:0007829|PDB:8OXM" FT HELIX 1664..1677 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1694..1702 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1706..1721 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1723..1725 FT /evidence="ECO:0007829|PDB:8OXO" FT HELIX 1727..1742 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1744..1753 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1754..1756 FT /evidence="ECO:0007829|PDB:7NI4" FT HELIX 1759..1763 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1764..1767 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1785..1789 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1792..1795 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1802..1815 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1822..1825 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1828..1831 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1835..1851 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1857..1874 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1903..1917 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1922..1924 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1927..1930 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1938..1947 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1951..1973 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1986..1997 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2001..2012 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2016..2019 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2023..2028 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 2029..2038 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2042..2051 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2057..2070 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2074..2087 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2093..2105 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2124..2136 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2140..2159 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2166..2168 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2170..2190 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2195..2210 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2211..2214 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2217..2236 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2240..2242 FT /evidence="ECO:0007829|PDB:8OXP" FT HELIX 2245..2264 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2269..2281 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2290..2301 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2305..2322 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2328..2348 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2353..2359 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2361..2370 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2377..2406 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2408..2421 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2437..2475 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2481..2483 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2484..2493 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2494..2496 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2498..2507 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2508..2510 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2513..2516 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2520..2525 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2529..2531 FT /evidence="ECO:0007829|PDB:7SID" FT STRAND 2533..2535 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2537..2551 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2553..2564 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2565..2567 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2568..2572 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2593..2612 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2614..2632 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2637..2640 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2652..2655 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2659..2663 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2665..2667 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2673..2675 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2682..2686 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2688..2692 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2695..2697 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2700..2706 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2707..2709 FT /evidence="ECO:0007829|PDB:7NI4" FT STRAND 2711..2717 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2723..2740 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2743..2748 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2757..2759 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2761..2763 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2765..2768 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2773..2775 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2776..2780 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2783..2785 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2787..2791 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2798..2807 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2808..2810 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2813..2825 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2833..2838 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2842..2866 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2873..2875 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2876..2879 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2880..2882 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2885..2887 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2894..2899 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2900..2902 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2906..2908 FT /evidence="ECO:0007829|PDB:8OXP" FT HELIX 2912..2916 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2920..2925 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2926..2940 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2942..2953 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2964..2970 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 3002..3017 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 3020..3025 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 3028..3040 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 3042..3047 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 3050..3052 FT /evidence="ECO:0007829|PDB:8OXQ" SQ SEQUENCE 3056 AA; 350687 MW; C0B4866E1E3199E2 CRC64; MSLVLNDLLI CCRQLEHDRA TERKKEVEKF KRLIRDPETI KHLDRHSDSK QGKYLNWDAV FRFLQKYIQK ETECLRIAKP NVSASTQASR QKKMQEISSL VKYFIKCANR RAPRLKCQEL LNYIMDTVKD SSNGAIYGAD CSNILLKDIL SVRKYWCEIS QQQWLELFSV YFRLYLKPSQ DVHRVLVARI IHAVTKGCCS QTDGLNSKFL DFFSKAIQCA RQEKSSSGLN HILAALTIFL KTLAVNFRIR VCELGDEILP TLLYIWTQHR LNDSLKEVII ELFQLQIYIH HPKGAKTQEK GAYESTKWRS ILYNLYDLLV NEISHIGSRG KYSSGFRNIA VKENLIELMA DICHQVFNED TRSLEISQSY TTTQRESSDY SVPCKRKKIE LGWEVIKDHL QKSQNDFDLV PWLQIATQLI SKYPASLPNC ELSPLLMILS QLLPQQRHGE RTPYVLRCLT EVALCQDKRS NLESSQKSDL LKLWNKIWCI TFRGISSEQI QAENFGLLGA IIQGSLVEVD REFWKLFTGS ACRPSCPAVC CLTLALTTSI VPGTVKMGIE QNMCEVNRSF SLKESIMKWL LFYQLEGDLE NSTEVPPILH SNFPHLVLEK ILVSLTMKNC KAAMNFFQSV PECEHHQKDK EELSFSEVEE LFLQTTFDKM DFLTIVRECG IEKHQSSIGF SVHQNLKESL DRCLLGLSEQ LLNNYSSEIT NSETLVRCSR LLVGVLGCYC YMGVIAEEEA YKSELFQKAK SLMQCAGESI TLFKNKTNEE FRIGSLRNMM QLCTRCLSNC TKKSPNKIAS GFFLRLLTSK LMNDIADICK SLASFIKKPF DRGEVESMED DTNGNLMEVE DQSSMNLFND YPDSSVSDAN EPGESQSTIG AINPLAEEYL SKQDLLFLDM LKFLCLCVTT AQTNTVSFRA ADIRRKLLML IDSSTLEPTK SLHLHMYLML LKELPGEEYP LPMEDVLELL KPLSNVCSLY RRDQDVCKTI LNHVLHVVKN LGQSNMDSEN TRDAQGQFLT VIGAFWHLTK ERKYIFSVRM ALVNCLKTLL EADPYSKWAI LNVMGKDFPV NEVFTQFLAD NHHQVRMLAA ESINRLFQDT KGDSSRLLKA LPLKLQQTAF ENAYLKAQEG MREMSHSAEN PETLDEIYNR KSVLLTLIAV VLSCSPICEK QALFALCKSV KENGLEPHLV KKVLEKVSET FGYRRLEDFM ASHLDYLVLE WLNLQDTEYN LSSFPFILLN YTNIEDFYRS CYKVLIPHLV IRSHFDEVKS IANQIQEDWK SLLTDCFPKI LVNILPYFAY EGTRDSGMAQ QRETATKVYD MLKSENLLGK QIDHLFISNL PEIVVELLMT LHEPANSSAS QSTDLCDFSG DLDPAPNPPH FPSHVIKATF AYISNCHKTK LKSILEILSK SPDSYQKILL AICEQAAETN NVYKKHRILK IYHLFVSLLL KDIKSGLGGA WAFVLRDVIY TLIHYINQRP SCIMDVSLRS FSLCCDLLSQ VCQTAVTYCK DALENHLHVI VGTLIPLVYE QVEVQKQVLD LLKYLVIDNK DNENLYITIK LLDPFPDHVV FKDLRITQQK IKYSRGPFSL LEEINHFLSV SVYDALPLTR LEGLKDLRRQ LELHKDQMVD IMRASQDNPQ DGIMVKLVVN LLQLSKMAIN HTGEKEVLEA VGSCLGEVGP IDFSTIAIQH SKDASYTKAL KLFEDKELQW TFIMLTYLNN TLVEDCVKVR SAAVTCLKNI LATKTGHSFW EIYKMTTDPM LAYLQPFRTS RKKFLEVPRF DKENPFEGLD DINLWIPLSE NHDIWIKTLT CAFLDSGGTK CEILQLLKPM CEVKTDFCQT VLPYLIHDIL LQDTNESWRN LLSTHVQGFF TSCLRHFSQT SRSTTPANLD SESEHFFRCC LDKKSQRTML AVVDYMRRQK RPSSGTIFND AFWLDLNYLE VAKVAQSCAA HFTALLYAEI YADKKSMDDQ EKRSLAFEEG SQSTTISSLS EKSKEETGIS LQDLLLEIYR SIGEPDSLYG CGGGKMLQPI TRLRTYEHEA MWGKALVTYD LETAIPSSTR QAGIIQALQN LGLCHILSVY LKGLDYENKD WCPELEELHY QAAWRNMQWD HCTSVSKEVE GTSYHESLYN ALQSLRDREF STFYESLKYA RVKEVEEMCK RSLESVYSLY PTLSRLQAIG ELESIGELFS RSVTHRQLSE VYIKWQKHSQ LLKDSDFSFQ EPIMALRTVI LEILMEKEMD NSQRECIKDI LTKHLVELSI LARTFKNTQL PERAIFQIKQ YNSVSCGVSE WQLEEAQVFW AKKEQSLALS ILKQMIKKLD ASCAANNPSL KLTYTECLRV CGNWLAETCL ENPAVIMQTY LEKAVEVAGN YDGESSDELR NGKMKAFLSL ARFSDTQYQR IENYMKSSEF ENKQALLKRA KEEVGLLREH KIQTNRYTVK VQRELELDEL ALRALKEDRK RFLCKAVENY INCLLSGEEH DMWVFRLCSL WLENSGVSEV NGMMKRDGMK IPTYKFLPLM YQLAARMGTK MMGGLGFHEV LNNLISRISM DHPHHTLFII LALANANRDE FLTKPEVARR SRITKNVPKQ SSQLDEDRTE AANRIICTIR SRRPQMVRSV EALCDAYIIL ANLDATQWKT QRKGINIPAD QPITKLKNLE DVVVPTMEIK VDHTGEYGNL VTIQSFKAEF RLAGGVNLPK IIDCVGSDGK ERRQLVKGRD DLRQDAVMQQ VFQMCNTLLQ RNTETRKRKL TICTYKVVPL SQRSGVLEWC TGTVPIGEFL VNNEDGAHKR YRPNDFSAFQ CQKKMMEVQK KSFEEKYEVF MDVCQNFQPV FRYFCMEKFL DPAIWFEKRL AYTRSVATSS IVGYILGLGD RHVQNILINE QSAELVHIDL GVAFEQGKIL PTPETVPFRL TRDIVDGMGI TGVEGVFRRC CEKTMEVMRN SQETLLTIVE VLLYDPLFDW TMNPLKALYL QQRPEDETEL HPTLNADDQE CKRNLSDIDQ SFNKVAERVL MRLQEKLKGV EEGTVLSVGG QVNLLIQQAI DPKNLSRLFP GWKAWV // ID ATR_HUMAN Reviewed; 2644 AA. AC Q13535; Q59HB2; Q7KYL3; Q93051; Q9BXK4; DT 29-MAR-2005, integrated into UniProtKB/Swiss-Prot. DT 05-JUL-2004, sequence version 3. DT 28-JAN-2026, entry version 219. DE RecName: Full=Serine/threonine-protein kinase ATR; DE EC=2.7.11.1 {ECO:0000269|PubMed:21705319, ECO:0000269|PubMed:21777809, ECO:0000269|PubMed:27723717, ECO:0000269|PubMed:27723720}; DE AltName: Full=Ataxia telangiectasia and Rad3-related protein; DE AltName: Full=FRAP-related protein 1; GN Name=ATR {ECO:0000303|PubMed:14729973, ECO:0000312|HGNC:HGNC:882}; GN Synonyms=FRP1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=8978690; DOI=10.1002/j.1460-2075.1996.tb01054.x; RA Bentley N.J., Holtzman D.A., Flaggs G., Keegan K.S., DeMaggio A., RA Ford J.C., Hoekstra M., Carr A.M.; RT "The Schizosaccharomyces pombe rad3 checkpoint gene."; RL EMBO J. 15:6641-6651(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY. RC TISSUE=T-cell; RX PubMed=8610130; DOI=10.1073/pnas.93.7.2850; RA Cimprich K.A., Shin T.B., Keith C.T., Schreiber S.L.; RT "cDNA cloning and gene mapping of a candidate human cell cycle checkpoint RT protein."; RL Proc. Natl. Acad. Sci. U.S.A. 93:2850-2855(1996). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 433-526 (ISOFORMS 1 AND 2), AND RP TISSUE SPECIFICITY. RX PubMed=11470508; DOI=10.1016/s0378-1119(01)00543-1; RA Mannino J.L., Kim W.-J., Wernick M., Nguyen S.V., Braquet R., Adamson A.W., RA Den Z., Batzer M.A., Collins C.C., Brown K.D.; RT "Evidence for alternate splicing within the mRNA transcript encoding the RT DNA damage response kinase ATR."; RL Gene 272:35-43(2001). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2155-2644 (ISOFORM 3). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=8843195; DOI=10.1101/gad.10.19.2423; RA Keegan K.S., Holtzman D.A., Plug A.W., Christenson E.R., Brainerd E.E., RA Flaggs G., Bentley N.J., Taylor E.M., Meyn M.S., Moss S.B., Carr A.M., RA Ashley T., Hoekstra M.F.; RT "The Atr and Atm protein kinases associate with different sites along RT meiotically pairing chromosomes."; RL Genes Dev. 10:2423-2437(1996). RN [6] RP ACTIVITY REGULATION. RX PubMed=9766667; RA Sarkaria J.N., Tibbetts R.S., Busby E.C., Kennedy A.P., Hill D.E., RA Abraham R.T.; RT "Inhibition of phosphoinositide 3-kinase related kinases by the RT radiosensitizing agent wortmannin."; RL Cancer Res. 58:4375-4382(1998). RN [7] RP FUNCTION, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF ASP-2475. RX PubMed=9427750; DOI=10.1093/emboj/17.1.159; RA Cliby W.A., Roberts C.J., Cimprich K.A., Stringer C.M., Lamb J.R., RA Schreiber S.L., Friend S.H.; RT "Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA- RT damaging agents and defects in cell cycle checkpoints."; RL EMBO J. 17:159-169(1998). RN [8] RP FUNCTION, AND MUTAGENESIS OF ASP-2494. RX PubMed=9636169; DOI=10.1073/pnas.95.13.7445; RA Wright J.A., Keegan K.S., Herendeen D.R., Bentley N.J., Carr A.M., RA Hoekstra M.F., Concannon P.; RT "Protein kinase mutants of human ATR increase sensitivity to UV and RT ionizing radiation and abrogate cell cycle checkpoint control."; RL Proc. Natl. Acad. Sci. U.S.A. 95:7445-7450(1998). RN [9] RP INTERACTION WITH HDAC2, AND IDENTIFICATION IN A COMPLEX CONTAINING HDAC2 RP AND CHD4. RX PubMed=10545197; DOI=10.1021/bi991614n; RA Schmidt D.R., Schreiber S.L.; RT "Molecular association between ATR and two components of the nucleosome RT remodeling and deacetylating complex, HDAC2 and CHD4."; RL Biochemistry 38:14711-14717(1999). RN [10] RP FUNCTION, AND MUTAGENESIS OF LYS-2327 AND ASP-2475. RX PubMed=9925639; DOI=10.1101/gad.13.2.152; RA Tibbetts R.S., Brumbaugh K.M., Williams J.M., Sarkaria J.N., Cliby W.A., RA Shieh S.-Y., Taya Y., Prives C., Abraham R.T.; RT "A role for ATR in the DNA damage-induced phosphorylation of p53."; RL Genes Dev. 13:152-157(1999). RN [11] RP COFACTOR, AND FUNCTION. RX PubMed=10608806; DOI=10.1074/jbc.274.53.37538; RA Kim S.-T., Lim D.-S., Canman C.E., Kastan M.B.; RT "Substrate specificities and identification of putative substrates of ATM RT kinase family members."; RL J. Biol. Chem. 274:37538-37543(1999). RN [12] RP FUNCTION, AUTOPHOSPHORYLATION, MUTAGENESIS OF ASP-2494, AND ACTIVITY RP REGULATION. RX PubMed=10597277; DOI=10.1038/sj.onc.1203077; RA Hall-Jackson C.A., Cross D.A.E., Morrice N., Smythe C.; RT "ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate RT specificity distinct from DNA-PK."; RL Oncogene 18:6707-6713(1999). RN [13] RP FUNCTION. RX PubMed=10859164; RA Liu Q., Guntuku S., Cui X.-S., Matsuoka S., Cortez D., Tamai K., Luo G., RA Carattini-Rivera S., DeMayo F., Bradley A., Donehower L.A., Elledge S.J.; RT "Chk1 is an essential kinase that is regulated by Atr and required for the RT G(2)/M DNA damage checkpoint."; RL Genes Dev. 14:1448-1459(2000). RN [14] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-2327. RX PubMed=11114888; DOI=10.1101/gad.851000; RA Tibbetts R.S., Cortez D., Brumbaugh K.M., Scully R., Livingston D., RA Elledge S.J., Abraham R.T.; RT "Functional interactions between BRCA1 and the checkpoint kinase ATR during RT genotoxic stress."; RL Genes Dev. 14:2989-3002(2000). RN [15] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=11673449; DOI=10.1074/jbc.c100569200; RA Ward I.M., Chen J.; RT "Histone H2AX is phosphorylated in an ATR-dependent manner in response to RT replicational stress."; RL J. Biol. Chem. 276:47759-47762(2001). RN [16] RP FUNCTION. RX PubMed=11418864; DOI=10.1038/35082110; RA Bao S., Tibbetts R.S., Brumbaugh K.M., Fang Y., Richardson D.A., Ali A., RA Chen S.M., Abraham R.T., Wang X.-F.; RT "ATR/ATM-mediated phosphorylation of human Rad17 is required for genotoxic RT stress responses."; RL Nature 411:969-974(2001). RN [17] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH ATRIP. RX PubMed=11721054; DOI=10.1126/science.1065521; RA Cortez D., Guntuku S., Qin J., Elledge S.J.; RT "ATR and ATRIP: partners in checkpoint signaling."; RL Science 294:1713-1716(2001). RN [18] RP FUNCTION. RX PubMed=12526805; DOI=10.1016/s0092-8674(02)01113-3; RA Casper A.M., Nghiem P., Arlt M.F., Glover T.W.; RT "ATR regulates fragile site stability."; RL Cell 111:779-789(2002). RN [19] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=11865061; DOI=10.1128/mcb.22.6.1834-1843.2002; RA Hammond E.M., Denko N.C., Dorie M.J., Abraham R.T., Giaccia A.J.; RT "Hypoxia links ATR and p53 through replication arrest."; RL Mol. Cell. Biol. 22:1834-1843(2002). RN [20] RP DNA-BINDING, AND MUTAGENESIS OF LYS-2327. RX PubMed=12011431; DOI=10.1073/pnas.102167799; RA Uensal-Kacmaz K., Makhov A.M., Griffith J.D., Sancar A.; RT "Preferential binding of ATR protein to UV-damaged DNA."; RL Proc. Natl. Acad. Sci. U.S.A. 99:6673-6678(2002). RN [21] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASP-2475. RX PubMed=12814551; DOI=10.1016/s0960-9822(03)00376-2; RA Barr S.M., Leung C.G., Chang E.E., Cimprich K.A.; RT "ATR kinase activity regulates the intranuclear translocation of ATR and RT RPA following ionizing radiation."; RL Curr. Biol. 13:1047-1051(2003). RN [22] RP INTERACTION WITH CLSPN. RX PubMed=12766152; DOI=10.1074/jbc.m301136200; RA Chini C.C.S., Chen J.; RT "Human claspin is required for replication checkpoint control."; RL J. Biol. Chem. 278:30057-30062(2003). RN [23] RP FUNCTION, INTERACTION WITH MSH2, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=14657349; DOI=10.1073/pnas.2536810100; RA Wang Y., Qin J.; RT "MSH2 and ATR form a signaling module and regulate two branches of the RT damage response to DNA methylation."; RL Proc. Natl. Acad. Sci. U.S.A. 100:15387-15392(2003). RN [24] RP FUNCTION, DNA-BINDING, AND IDENTIFICATION IN A COMPLEX WITH RPA AND ATRIP. RX PubMed=12791985; DOI=10.1126/science.1083430; RA Zou L., Elledge S.J.; RT "Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes."; RL Science 300:1542-1548(2003). RN [25] RP INTERACTION WITH BCR-ABL. RX PubMed=15050919; DOI=10.1016/s1535-6108(04)00056-x; RA Dierov J., Dierova R., Carroll M.; RT "BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S RT phase checkpoint."; RL Cancer Cell 5:275-285(2004). RN [26] RP FUNCTION. RX PubMed=14742437; DOI=10.1074/jbc.c300554200; RA Ward I.M., Minn K., Chen J.; RT "UV-induced ataxia-telangiectasia-mutated and Rad3-related (ATR) activation RT requires replication stress."; RL J. Biol. Chem. 279:9677-9680(2004). RN [27] RP DNA-BINDING, AND SUBCELLULAR LOCATION. RX PubMed=14871897; DOI=10.1074/jbc.m314212200; RA Dart D.A., Adams K.E., Akerman I., Lakin N.D.; RT "Recruitment of the cell cycle checkpoint kinase ATR to chromatin during S- RT phase."; RL J. Biol. Chem. 279:16433-16440(2004). RN [28] RP FUNCTION. RX PubMed=15314022; DOI=10.1101/gad.1196104; RA Andreassen P.R., D'Andrea A.D., Taniguchi T.; RT "ATR couples FANCD2 monoubiquitination to the DNA-damage response."; RL Genes Dev. 18:1958-1963(2004). RN [29] RP FUNCTION. RX PubMed=15496423; DOI=10.1093/hmg/ddh335; RA Alderton G.K., Joenje H., Varon R., Borglum A.D., Jeggo P.A., RA O'Driscoll M.; RT "Seckel syndrome exhibits cellular features demonstrating defects in the RT ATR-signalling pathway."; RL Hum. Mol. Genet. 13:3127-3138(2004). RN [30] RP FUNCTION, SUBUNIT, IDENTIFICATION IN A COMPLEX WITH ATRIP AND RPA1, RP DNA-BINDING, AND ACTIVITY REGULATION. RX PubMed=14729973; DOI=10.1128/mcb.24.3.1292-1300.2003; RA Uensal-Kacmaz K., Sancar A.; RT "Quaternary structure of ATR and effects of ATRIP and replication protein A RT on its DNA binding and kinase activities."; RL Mol. Cell. Biol. 24:1292-1300(2004). RN [31] RP FUNCTION. RX PubMed=15210935; DOI=10.1073/pnas.0403410101; RA Cortez D., Glick G., Elledge S.J.; RT "Minichromosome maintenance proteins are direct targets of the ATM and ATR RT checkpoint kinases."; RL Proc. Natl. Acad. Sci. U.S.A. 101:10078-10083(2004). RN [32] RP INTERACTION WITH EEF1E1. RX PubMed=15680327; DOI=10.1016/j.cell.2004.11.054; RA Park B.-J., Kang J.W., Lee S.W., Choi S.-J., Shin Y.K., Ahn Y.H., RA Choi Y.H., Choi D., Lee K.S., Kim S.; RT "The haploinsufficient tumor suppressor p18 upregulates p53 via RT interactions with ATM/ATR."; RL Cell 120:209-221(2005). RN [33] RP INTERACTION WITH ATRIP. RX PubMed=15758953; DOI=10.1038/nature03442; RA Falck J., Coates J., Jackson S.P.; RT "Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA RT damage."; RL Nature 434:605-611(2005). RN [34] RP ACTIVITY REGULATION. RX PubMed=16530042; DOI=10.1016/j.cell.2005.12.041; RA Kumagai A., Lee J., Yoo H.Y., Dunphy W.G.; RT "TopBP1 activates the ATR-ATRIP complex."; RL Cell 124:943-955(2006). RN [35] RP INTERACTION WITH CEP164, AND SUBCELLULAR LOCATION. RX PubMed=18283122; DOI=10.1101/gad.1627708; RA Sivasubramaniam S., Sun X., Pan Y.R., Wang S., Lee E.Y.; RT "Cep164 is a mediator protein required for the maintenance of genomic RT stability through modulation of MDC1, RPA, and CHK1."; RL Genes Dev. 22:587-600(2008). RN [36] RP INVOLVEMENT IN SCKL1. RX PubMed=12640452; DOI=10.1038/ng1129; RA O'Driscoll M., Ruiz-Perez V.L., Woods C.G., Jeggo P.A., Goodship J.A.; RT "A splicing mutation affecting expression of ataxia-telangiectasia and RT Rad3-related protein (ATR) results in Seckel syndrome."; RL Nat. Genet. 33:497-501(2003). RN [37] RP FUNCTION IN DNA DAMAGE RESPONSE, AUTOPHOSPHORYLATION, AND SUBCELLULAR RP LOCATION. RX PubMed=16260606; DOI=10.1128/mcb.25.22.9910-9919.2005; RA Zhang J., Bao S., Furumai R., Kucera K.S., Ali A., Dean N.M., Wang X.F.; RT "Protein phosphatase 5 is required for ATR-mediated checkpoint RT activation."; RL Mol. Cell. Biol. 25:9910-9919(2005). RN [38] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-428 AND THR-1989, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [39] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [40] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [41] RP INTERACTION WITH TTI1. RX PubMed=20810650; DOI=10.1101/gad.1934210; RA Hurov K.E., Cotta-Ramusino C., Elledge S.J.; RT "A genetic screen identifies the Triple T complex required for DNA damage RT signaling and ATM and ATR stability."; RL Genes Dev. 24:1939-1950(2010). RN [42] RP INTERACTION WITH TELO2. RX PubMed=20801936; DOI=10.1101/gad.1956410; RA Takai H., Xie Y., de Lange T., Pavletich N.P.; RT "Tel2 structure and function in the Hsp90-dependent maturation of mTOR and RT ATR complexes."; RL Genes Dev. 24:2019-2030(2010). RN [43] RP INTERACTION WITH TELO2 AND TTI1. RX PubMed=20427287; DOI=10.1074/jbc.m110.121699; RA Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K., RA Iemura S., Natsume T., Mizushima N.; RT "Tti1 and Tel2 are critical factors in mammalian target of rapamycin RT complex assembly."; RL J. Biol. Chem. 285:20109-20116(2010). RN [44] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [45] RP FUNCTION IN DNA REPAIR, AND PHOSPHORYLATION AT SER-428. RX PubMed=21144835; DOI=10.1016/j.bbrc.2010.12.005; RA Kang Y., Cheong H.M., Lee J.H., Song P.I., Lee K.H., Kim S.Y., Jun J.Y., RA You H.J.; RT "Protein phosphatase 5 is necessary for ATR-mediated DNA repair."; RL Biochem. Biophys. Res. Commun. 404:476-481(2011). RN [46] RP PHOSPHORYLATION AT THR-1989, AND MUTAGENESIS OF THR-1989. RX PubMed=21705319; DOI=10.1074/jbc.m111.248914; RA Nam E.A., Zhao R., Glick G.G., Bansbach C.E., Friedman D.B., Cortez D.; RT "Thr-1989 phosphorylation is a marker of active ataxia telangiectasia- RT mutated and Rad3-related (ATR) kinase."; RL J. Biol. Chem. 286:28707-28714(2011). RN [47] RP FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-428; SER-435 AND RP THR-1989, ACTIVITY REGULATION, AND INTERACTION WITH ATRIP AND TOPBP1. RX PubMed=21777809; DOI=10.1016/j.molcel.2011.06.019; RA Liu S., Shiotani B., Lahiri M., Marechal A., Tse A., Leung C.C., RA Glover J.N., Yang X.H., Zou L.; RT "ATR autophosphorylation as a molecular switch for checkpoint activation."; RL Mol. Cell 43:192-202(2011). RN [48] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [49] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-435; SER-436 AND THR-1989, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [50] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=23273981; DOI=10.1016/j.molcel.2012.11.020; RA Peterson S.E., Li Y., Wu-Baer F., Chait B.T., Baer R., Yan H., RA Gottesman M.E., Gautier J.; RT "Activation of DSB processing requires phosphorylation of CtIP by ATR."; RL Mol. Cell 49:657-667(2013). RN [51] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=25083873; DOI=10.1016/j.cell.2014.05.046; RA Kumar A., Mazzanti M., Mistrik M., Kosar M., Beznoussenko G.V., RA Mironov A.A., Garre M., Parazzoli D., Shivashankar G.V., Scita G., RA Bartek J., Foiani M.; RT "ATR mediates a checkpoint at the nuclear envelope in response to RT mechanical stress."; RL Cell 158:633-646(2014). RN [52] RP FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND ACTIVITY RP REGULATION. RX PubMed=27723720; DOI=10.1038/ncb3415; RA Bass T.E., Luzwick J.W., Kavanaugh G., Carroll C., Dungrawala H., RA Glick G.G., Feldkamp M.D., Putney R., Chazin W.J., Cortez D.; RT "ETAA1 acts at stalled replication forks to maintain genome integrity."; RL Nat. Cell Biol. 18:1185-1195(2016). RN [53] RP FUNCTION, CATALYTIC ACTIVITY, AND ACTIVITY REGULATION. RX PubMed=27723717; DOI=10.1038/ncb3422; RA Haahr P., Hoffmann S., Tollenaere M.A., Ho T., Toledo L.I., Mann M., RA Bekker-Jensen S., Raeschle M., Mailand N.; RT "Activation of the ATR kinase by the RPA-binding protein ETAA1."; RL Nat. Cell Biol. 18:1196-1207(2016). RN [54] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=30139873; DOI=10.1126/science.aap9346; RA Saldivar J.C., Hamperl S., Bocek M.J., Chung M., Bass T.E., RA Cisneros-Soberanis F., Samejima K., Xie L., Paulson J.R., Earnshaw W.C., RA Cortez D., Meyer T., Cimprich K.A.; RT "An intrinsic S/G2 checkpoint enforced by ATR."; RL Science 361:806-810(2018). RN [55] RP FUNCTION, AND INTERACTION WITH UHRF2. RX PubMed=33848395; DOI=10.1111/gtc.12851; RA Hanaki S., Habara M., Shimada M.; RT "UV-induced activation of ATR is mediated by UHRF2."; RL Genes Cells 26:447-454(2021). RN [56] RP FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION. RX PubMed=37788673; DOI=10.1016/j.molcel.2023.09.003; RA Joo Y.K., Black E.M., Trier I., Haakma W., Zou L., Kabeche L.; RT "ATR promotes clearance of damaged DNA and damaged cells by rupturing RT micronuclei."; RL Mol. Cell 83:3642-3658(2023). RN [57] RP FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION. RX PubMed=37832547; DOI=10.1016/j.molcel.2023.09.023; RA Kovacs M.T., Vallette M., Wiertsema P., Dingli F., Loew D., Nader G.P.F., RA Piel M., Ceccaldi R.; RT "DNA damage induces nuclear envelope rupture through ATR-mediated RT phosphorylation of lamin A/C."; RL Mol. Cell 83:3659-3668(2023). RN [58] RP VARIANTS [LARGE SCALE ANALYSIS] ALA-64; TYR-90; ASN-297; ILE-316; MET-959; RP HIS-1087; GLY-1213; PRO-1488; ASN-1607; SER-1612; GLY-2002; ALA-2120; RP ASP-2132; ILE-2233; GLN-2425; ALA-2434; LYS-2438 AND GLN-2537. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [59] RP VARIANT FCTCS ARG-2144. RX PubMed=22341969; DOI=10.1016/j.ajhg.2012.01.007; RA Tanaka A., Weinel S., Nagy N., O'Driscoll M., Lai-Cheong J.E., RA Kulp-Shorten C.L., Knable A., Carpenter G., Fisher S.A., Hiragun M., RA Yanase Y., Hide M., Callen J., McGrath J.A.; RT "Germline mutation in ATR in autosomal- dominant oropharyngeal cancer RT syndrome."; RL Am. J. Hum. Genet. 90:511-517(2012). CC -!- FUNCTION: Serine/threonine protein kinase which activates checkpoint CC signaling upon genotoxic stresses such as ionizing radiation (IR), CC ultraviolet light (UV), or DNA replication stalling, thereby acting as CC a DNA damage sensor (PubMed:10597277, PubMed:10608806, PubMed:10859164, CC PubMed:11721054, PubMed:12791985, PubMed:12814551, PubMed:14657349, CC PubMed:14729973, PubMed:14742437, PubMed:15210935, PubMed:15496423, CC PubMed:16260606, PubMed:21144835, PubMed:21777809, PubMed:23273981, CC PubMed:25083873, PubMed:27723717, PubMed:27723720, PubMed:30139873, CC PubMed:33848395, PubMed:37788673, PubMed:37832547, PubMed:9427750, CC PubMed:9636169). Recognizes the substrate consensus sequence [ST]-Q CC (PubMed:10597277, PubMed:10608806, PubMed:10859164, PubMed:11721054, CC PubMed:12791985, PubMed:12814551, PubMed:14657349, PubMed:14729973, CC PubMed:14742437, PubMed:15210935, PubMed:15496423, PubMed:16260606, CC PubMed:21144835, PubMed:23273981, PubMed:27723717, PubMed:27723720, CC PubMed:33848395, PubMed:9427750, PubMed:9636169). Phosphorylates BRCA1, CC CHEK1, MCM2, RAD17, RBBP8, RPA2, SMC1 and p53/TP53, which collectively CC inhibit DNA replication and mitosis and promote DNA repair, CC recombination and apoptosis (PubMed:11114888, PubMed:11418864, CC PubMed:11865061, PubMed:21777809, PubMed:23273981, PubMed:25083873, CC PubMed:9925639). Phosphorylates 'Ser-139' of histone variant H2AX at CC sites of DNA damage, thereby regulating DNA damage response mechanism CC (PubMed:11673449). Required for FANCD2 ubiquitination CC (PubMed:15314022). Critical for maintenance of fragile site stability CC and efficient regulation of centrosome duplication (PubMed:12526805). CC Acts as a regulator of the S-G2 transition by restricting the activity CC of CDK1 during S-phase to prevent premature entry into G2 CC (PubMed:30139873). Acts as a regulator of the nuclear envelope CC integrity in response to DNA damage and stress (PubMed:25083873, CC PubMed:37788673, PubMed:37832547). Acts as a mechanical stress sensor CC at the nuclear envelope: relocalizes to the nuclear envelope in CC response to mechanical stress and mediates a checkpoint via CC phosphorylation of CHEK1 (PubMed:25083873). Also promotes nuclear CC envelope rupture in response to DNA damage by mediating phosphorylation CC of LMNA at 'Ser-282', leading to lamin disassembly (PubMed:37832547). CC Involved in the inflammatory response to genome instability and double- CC stranded DNA breaks: acts by localizing to micronuclei arising from CC genome instability and catalyzing phosphorylation of LMNA at 'Ser-395', CC priming LMNA for subsequent phosphorylation by CDK1 and micronuclei CC envelope rupture (PubMed:37788673). The rupture of micronuclear CC envelope triggers the cGAS-STING pathway thereby activating the type I CC interferon response and innate immunity (PubMed:37788673). Positively CC regulates the restart of stalled replication forks following activation CC by the KHDC3L-OOEP scaffold complex (By similarity). CC {ECO:0000250|UniProtKB:Q9JKK8, ECO:0000269|PubMed:10597277, CC ECO:0000269|PubMed:10608806, ECO:0000269|PubMed:10859164, CC ECO:0000269|PubMed:11114888, ECO:0000269|PubMed:11418864, CC ECO:0000269|PubMed:11673449, ECO:0000269|PubMed:11721054, CC ECO:0000269|PubMed:11865061, ECO:0000269|PubMed:12526805, CC ECO:0000269|PubMed:12791985, ECO:0000269|PubMed:12814551, CC ECO:0000269|PubMed:14657349, ECO:0000269|PubMed:14729973, CC ECO:0000269|PubMed:14742437, ECO:0000269|PubMed:15210935, CC ECO:0000269|PubMed:15314022, ECO:0000269|PubMed:15496423, CC ECO:0000269|PubMed:16260606, ECO:0000269|PubMed:21144835, CC ECO:0000269|PubMed:21777809, ECO:0000269|PubMed:23273981, CC ECO:0000269|PubMed:25083873, ECO:0000269|PubMed:27723717, CC ECO:0000269|PubMed:27723720, ECO:0000269|PubMed:30139873, CC ECO:0000269|PubMed:33848395, ECO:0000269|PubMed:37788673, CC ECO:0000269|PubMed:37832547, ECO:0000269|PubMed:9427750, CC ECO:0000269|PubMed:9636169, ECO:0000269|PubMed:9925639}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:23273981, ECO:0000269|PubMed:27723717, CC ECO:0000269|PubMed:27723720, ECO:0000269|PubMed:37788673, CC ECO:0000269|PubMed:37832547}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:23273981, ECO:0000269|PubMed:27723717, CC ECO:0000269|PubMed:27723720, ECO:0000269|PubMed:37788673, CC ECO:0000269|PubMed:37832547}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21705319, ECO:0000269|PubMed:21777809, CC ECO:0000269|PubMed:27723717, ECO:0000269|PubMed:27723720}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609; CC Evidence={ECO:0000269|PubMed:21705319, ECO:0000269|PubMed:21777809, CC ECO:0000269|PubMed:27723717, ECO:0000269|PubMed:27723720}; CC -!- COFACTOR: CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; CC Evidence={ECO:0000269|PubMed:10608806}; CC -!- ACTIVITY REGULATION: Serine/threonine-protein kinase activity is CC directly stimulated by TOPBP1 (PubMed:16530042, PubMed:21777809). ATR CC kinase activity is also directly activated by ETAA1, independently of CC TOPBP1 (PubMed:27723717, PubMed:27723720, PubMed:30139873). Activated CC by DNA and inhibited by BCR-ABL oncogene (PubMed:10597277). Slightly CC activated by ATRIP (PubMed:14729973). Inhibited by caffeine, wortmannin CC and LY294002 (PubMed:9766667). {ECO:0000269|PubMed:10597277, CC ECO:0000269|PubMed:14729973, ECO:0000269|PubMed:16530042, CC ECO:0000269|PubMed:21777809, ECO:0000269|PubMed:27723717, CC ECO:0000269|PubMed:27723720, ECO:0000269|PubMed:30139873, CC ECO:0000269|PubMed:9766667}. CC -!- SUBUNIT: Forms a heterodimer with ATRIP, forming the ATR-ATRIP complex CC (PubMed:11721054, PubMed:12791985, PubMed:14729973, PubMed:15758953, CC PubMed:21777809). Present in a complex containing ATRIP and RPA-coated CC single-stranded DNA (PubMed:12791985, PubMed:14729973). Binds to DNA, CC and to UV-damaged DNA with higher affinity (PubMed:12791985). Interacts CC with MSH2 and HDAC2 (PubMed:14657349). Present in a complex containing CC CHD4 and HDAC2 (PubMed:10545197). Interacts with EEF1E1, the CC interaction is enhanced by UV irradiation (PubMed:15680327). Interacts CC with CLSPN and CEP164 (PubMed:12766152, PubMed:18283122). Interacts CC with TELO2 and TTI1 (PubMed:20427287, PubMed:20801936, CC PubMed:20810650). Interacts with BCR-ABL after genotoxic stress CC (PubMed:15050919). Interacts with UHRF2; this interaction promotes ATR CC activation (PubMed:33848395). Interacts (when phosphorylated) with CC TOPBP1; interaction takes place when ATR is autophosphorylated at Thr- CC 1989, leading to ATR activation by TOPBP1 (PubMed:21705319, CC PubMed:21777809). {ECO:0000269|PubMed:10545197, CC ECO:0000269|PubMed:11721054, ECO:0000269|PubMed:12766152, CC ECO:0000269|PubMed:12791985, ECO:0000269|PubMed:14657349, CC ECO:0000269|PubMed:14729973, ECO:0000269|PubMed:15050919, CC ECO:0000269|PubMed:15680327, ECO:0000269|PubMed:15758953, CC ECO:0000269|PubMed:18283122, ECO:0000269|PubMed:20427287, CC ECO:0000269|PubMed:20801936, ECO:0000269|PubMed:20810650, CC ECO:0000269|PubMed:21705319, ECO:0000269|PubMed:21777809, CC ECO:0000269|PubMed:33848395}. CC -!- INTERACTION: CC Q13535; Q8WXE1: ATRIP; NbExp=5; IntAct=EBI-968983, EBI-747353; CC Q13535; Q99459: CDC5L; NbExp=3; IntAct=EBI-968983, EBI-374880; CC Q13535; P50750: CDK9; NbExp=3; IntAct=EBI-968983, EBI-1383449; CC Q13535; Q9BW66: CINP; NbExp=5; IntAct=EBI-968983, EBI-739784; CC Q13535; Q9Y6K9: IKBKG; NbExp=2; IntAct=EBI-968983, EBI-81279; CC Q13535; O43156: TTI1; NbExp=2; IntAct=EBI-968983, EBI-1055680; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11114888, CC ECO:0000269|PubMed:11721054, ECO:0000269|PubMed:11865061, CC ECO:0000269|PubMed:12814551, ECO:0000269|PubMed:14871897, CC ECO:0000269|PubMed:16260606, ECO:0000269|PubMed:18283122, CC ECO:0000269|PubMed:27723720, ECO:0000269|PubMed:8843195}. Chromosome CC {ECO:0000269|PubMed:11673449}. Nucleus envelope CC {ECO:0000269|PubMed:25083873, ECO:0000269|PubMed:37788673, CC ECO:0000269|PubMed:37832547}. Note=Depending on the cell type, it can CC also be found in PML nuclear bodies (PubMed:12814551). Recruited to CC chromatin during S-phase (PubMed:14871897). Redistributes to discrete CC nuclear foci upon DNA damage, hypoxia or replication fork stalling CC (PubMed:27723720). Relocalizes to the nuclear envelope in response to CC mechanical stress or DNA damage (PubMed:25083873, PubMed:37832547). CC Also localizes to the micronuclear envelope in response to response to CC genome instability (PubMed:37788673). {ECO:0000269|PubMed:12814551, CC ECO:0000269|PubMed:25083873, ECO:0000269|PubMed:27723720, CC ECO:0000269|PubMed:37788673, ECO:0000269|PubMed:37832547}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q13535-1; Sequence=Displayed; CC Name=2; CC IsoId=Q13535-2; Sequence=VSP_013305, VSP_013304; CC Name=3; CC IsoId=Q13535-3; Sequence=VSP_036907, VSP_036908; CC -!- TISSUE SPECIFICITY: Ubiquitous, with highest expression in testis. CC {ECO:0000269|PubMed:11470508, ECO:0000269|PubMed:8610130, CC ECO:0000269|PubMed:8843195}. CC -!- TISSUE SPECIFICITY: [Isoform 2]: Isoform 2 is found in pancreas, CC placenta and liver but not in heart, testis and ovary. CC {ECO:0000269|PubMed:11470508}. CC -!- PTM: Phosphorylated (PubMed:21144835). Autophosphorylation at Thr-1989 CC in response to DNA damage promotes interaction with TOPBP1 and CC activation of ATR (PubMed:21705319, PubMed:21777809). CC {ECO:0000269|PubMed:21144835, ECO:0000269|PubMed:21705319, CC ECO:0000269|PubMed:21777809}. CC -!- DISEASE: Seckel syndrome 1 (SCKL1) [MIM:210600]: A rare autosomal CC recessive disorder characterized by proportionate dwarfism of prenatal CC onset associated with low birth weight, growth retardation, severe CC microcephaly with a bird-headed like appearance, and intellectual CC disability. {ECO:0000269|PubMed:12640452}. Note=The disease is caused CC by variants affecting the gene represented in this entry. CC -!- DISEASE: Cutaneous telangiectasia and cancer syndrome, familial (FCTCS) CC [MIM:614564]: A disease characterized by cutaneous telangiectases in CC infancy with patchy alopecia over areas of affected skin, thinning of CC the lateral eyebrows, and mild dental and nail anomalies. Affected CC individuals are at increased risk of developing oropharyngeal cancer, CC and other malignancies have been reported as well. CC {ECO:0000269|PubMed:22341969}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. ATM subfamily. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/728/ATR"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; Y09077; CAA70298.1; -; mRNA. DR EMBL; U76308; AAC50929.1; -; mRNA. DR EMBL; U49844; AAC50405.1; -; mRNA. DR EMBL; AF325699; AAK26749.1; -; Genomic_DNA. DR EMBL; AB208847; BAD92084.1; -; mRNA. DR CCDS; CCDS3124.1; -. [Q13535-1] DR CCDS; CCDS93402.1; -. [Q13535-2] DR RefSeq; NP_001175.2; NM_001184.4. [Q13535-1] DR RefSeq; NP_001341508.1; NM_001354579.2. [Q13535-2] DR PDB; 5YZ0; EM; 4.70 A; A/B=1-2644. DR PDB; 9L40; EM; 2.87 A; A/B=1-2644. DR PDB; 9L43; EM; 3.83 A; A/B=1-2644. DR PDB; 9L45; EM; 3.95 A; A/B=1-2644. DR PDB; 9L46; EM; 6.29 A; A/B=1-2644. DR PDB; 9L4B; EM; 3.20 A; A/B=1-2644. DR PDB; 9L4C; EM; 4.06 A; A/B=1-2644. DR PDB; 9L4D; EM; 3.79 A; A/B=8-2644. DR PDB; 9L4F; EM; 6.22 A; A/B=1-2644. DR PDBsum; 5YZ0; -. DR PDBsum; 9L40; -. DR PDBsum; 9L43; -. DR PDBsum; 9L45; -. DR PDBsum; 9L46; -. DR PDBsum; 9L4B; -. DR PDBsum; 9L4C; -. DR PDBsum; 9L4D; -. DR PDBsum; 9L4F; -. DR AlphaFoldDB; Q13535; -. DR EMDB; EMD-62801; -. DR EMDB; EMD-62804; -. DR EMDB; EMD-62806; -. DR EMDB; EMD-62807; -. DR EMDB; EMD-62808; -. DR EMDB; EMD-62809; -. DR EMDB; EMD-62811; -. DR EMDB; EMD-62812; -. DR EMDB; EMD-6862; -. DR SMR; Q13535; -. DR BioGRID; 107027; 243. DR ComplexPortal; CPX-3622; ATR-ATRIP DNA damage-sensing kinase complex. DR CORUM; Q13535; -. DR DIP; DIP-35308N; -. DR FunCoup; Q13535; 3607. DR IntAct; Q13535; 96. DR MINT; Q13535; -. DR STRING; 9606.ENSP00000343741; -. DR BindingDB; Q13535; -. DR ChEMBL; CHEMBL5024; -. DR DrugBank; DB11794; Berzosertib. DR DrugBank; DB14917; Ceralasertib. DR DrugBank; DB19041; Elimusertib. DR GuidetoPHARMACOLOGY; 1935; -. DR CarbonylDB; Q13535; -. DR GlyGen; Q13535; 3 sites, 1 O-linked glycan (2 sites). DR iPTMnet; Q13535; -. DR PhosphoSitePlus; Q13535; -. DR BioMuta; ATR; -. DR DMDM; 62286460; -. DR CPTAC; CPTAC-3214; -. DR CPTAC; CPTAC-3215; -. DR jPOST; Q13535; -. DR MassIVE; Q13535; -. DR PaxDb; 9606-ENSP00000343741; -. DR PeptideAtlas; Q13535; -. DR ProteomicsDB; 59521; -. [Q13535-1] DR ProteomicsDB; 59522; -. [Q13535-2] DR ProteomicsDB; 59523; -. [Q13535-3] DR Pumba; Q13535; -. DR Antibodypedia; 18078; 557 antibodies from 41 providers. DR CPTC; Q13535; 1 antibody. DR DNASU; 545; -. DR Ensembl; ENST00000350721.9; ENSP00000343741.4; ENSG00000175054.17. [Q13535-1] DR Ensembl; ENST00000661310.1; ENSP00000499589.1; ENSG00000175054.17. [Q13535-2] DR GeneID; 545; -. DR KEGG; hsa:545; -. DR MANE-Select; ENST00000350721.9; ENSP00000343741.4; NM_001184.4; NP_001175.2. DR UCSC; uc003eux.5; human. [Q13535-1] DR AGR; HGNC:882; -. DR CIViC; 545; 2 evidence items across 2 molecular profiles. DR ClinPGx; PA74; -. DR CTD; 545; -. DR DisGeNET; 545; -. DR GeneCards; ATR; -. DR HGNC; HGNC:882; ATR. DR HPA; ENSG00000175054; Low tissue specificity. DR MalaCards; ATR; -. DR MIM; 210600; phenotype. DR MIM; 601215; gene. DR MIM; 614564; phenotype. DR OpenTargets; ENSG00000175054; -. DR Orphanet; 313846; Familial cutaneous telangiectasia and oropharyngeal cancer predisposition syndrome. DR Orphanet; 808; Seckel syndrome. DR VEuPathDB; HostDB:ENSG00000175054; -. DR eggNOG; KOG0890; Eukaryota. DR GeneTree; ENSGT00940000155714; -. DR HOGENOM; CLU_000178_2_1_1; -. DR InParanoid; Q13535; -. DR OMA; SMYIGWC; -. DR OrthoDB; 381190at2759; -. DR PAN-GO; Q13535; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q13535; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q13535; -. DR Reactome; R-HSA-1221632; Meiotic synapsis. DR Reactome; R-HSA-176187; Activation of ATR in response to replication stress. DR Reactome; R-HSA-3371453; Regulation of HSF1-mediated heat shock response. DR Reactome; R-HSA-5685938; HDR through Single Strand Annealing (SSA). DR Reactome; R-HSA-5693607; Processing of DNA double-strand break ends. DR Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange. DR Reactome; R-HSA-6783310; Fanconi Anemia Pathway. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-9709570; Impaired BRCA2 binding to RAD51. DR SignaLink; Q13535; -. DR SIGNOR; Q13535; -. DR Agora; ENSG00000175054; -. DR BioGRID-ORCS; 545; 746 hits in 1209 CRISPR screens. DR CD-CODE; 804901D1; Nuclear speckle. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; A0DCDA94; DNA damage foci. DR CD-CODE; B5B9A610; PML body. DR CD-CODE; D3B9EAFD; Synthetic Condensate 000362. DR ChiTaRS; ATR; human. DR GeneWiki; Ataxia_telangiectasia_and_Rad3_related; -. DR GenomeRNAi; 545; -. DR Pharos; Q13535; Tchem. DR PRO; PR:Q13535; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q13535; protein. DR Bgee; ENSG00000175054; Expressed in Brodmann (1909) area 23 and 205 other cell types or tissues. DR ExpressionAtlas; Q13535; baseline and differential. DR GO; GO:0070310; C:ATR-ATRIP complex; IPI:ComplexPortal. DR GO; GO:0005694; C:chromosome; ISS:UniProtKB. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0005635; C:nuclear envelope; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0016605; C:PML body; IDA:UniProtKB. DR GO; GO:0090734; C:site of DNA damage; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW. DR GO; GO:0035979; F:histone H2AXS139 kinase activity; IDA:UniProtKB. DR GO; GO:0032405; F:MutLalpha complex binding; IDA:MGI. DR GO; GO:0032407; F:MutSalpha complex binding; IDA:MGI. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0071480; P:cellular response to gamma radiation; IDA:BHF-UCL. DR GO; GO:0034644; P:cellular response to UV; IMP:BHF-UCL. DR GO; GO:0000077; P:DNA damage checkpoint signaling; IDA:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0006281; P:DNA repair; IBA:GO_Central. DR GO; GO:0006260; P:DNA replication; TAS:Reactome. DR GO; GO:0006302; P:double-strand break repair; IDA:UniProt. DR GO; GO:0097695; P:establishment of protein-containing complex localization to telomere; IC:BHF-UCL. DR GO; GO:0097694; P:establishment of RNA localization to telomere; IMP:BHF-UCL. DR GO; GO:0036297; P:interstrand cross-link repair; TAS:Reactome. DR GO; GO:0044818; P:mitotic G2/M transition checkpoint; IDA:UniProt. DR GO; GO:0008156; P:negative regulation of DNA replication; IMP:UniProtKB. DR GO; GO:0051081; P:nuclear membrane disassembly; IDA:UniProtKB. DR GO; GO:0006139; P:nucleobase-containing compound metabolic process; NAS:ComplexPortal. DR GO; GO:0043517; P:positive regulation of DNA damage response, signal transduction by p53 class mediator; IDA:BHF-UCL. DR GO; GO:1904884; P:positive regulation of telomerase catalytic core complex assembly; IMP:BHF-UCL. DR GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; ISS:BHF-UCL. DR GO; GO:0070198; P:protein localization to chromosome, telomeric region; IMP:BHF-UCL. DR GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome. DR GO; GO:2000779; P:regulation of double-strand break repair; NAS:ComplexPortal. DR GO; GO:0031297; P:replication fork processing; ISS:UniProtKB. DR GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL. DR GO; GO:0046685; P:response to arsenic-containing substance; IEA:Ensembl. DR GO; GO:0009612; P:response to mechanical stimulus; IDA:UniProtKB. DR GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0000723; P:telomere maintenance; IBA:GO_Central. DR CDD; cd00892; PIKKc_ATR; 1. DR FunFam; 1.10.1070.11:FF:000009; Putative serine/threonine-protein kinase ATR; 1. DR FunFam; 1.25.10.10:FF:000149; Serine/threonine-protein kinase ATR; 1. DR FunFam; 1.25.40.10:FF:000142; Serine/threonine-protein kinase ATR; 1. DR FunFam; 3.30.1010.10:FF:000011; serine/threonine-protein kinase ATR; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 2. DR Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1. DR Gene3D; 3.30.1010.10; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 4; 1. DR Gene3D; 1.25.40.10; Tetratricopeptide repeat domain; 1. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR056802; ATR-like_M-HEAT. DR InterPro; IPR056803; ATR-like_N-HEAT. DR InterPro; IPR050517; DDR_Repair_Kinase. DR InterPro; IPR003152; FATC_dom. DR InterPro; IPR057564; HEAT_ATR. DR InterPro; IPR021133; HEAT_type_2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR036940; PI3/4_kinase_cat_sf. DR InterPro; IPR018936; PI3/4_kinase_CS. DR InterPro; IPR003151; PIK-rel_kinase_FAT. DR InterPro; IPR014009; PIK_FAT. DR InterPro; IPR011990; TPR-like_helical_dom_sf. DR InterPro; IPR012993; UME. DR PANTHER; PTHR11139; ATAXIA TELANGIECTASIA MUTATED ATM -RELATED; 1. DR PANTHER; PTHR11139:SF69; SERINE_THREONINE-PROTEIN KINASE ATR; 1. DR Pfam; PF02259; FAT; 1. DR Pfam; PF02260; FATC; 1. DR Pfam; PF23593; HEAT_ATR; 1. DR Pfam; PF25030; M-HEAT_ATR; 1. DR Pfam; PF25032; N-HEAT_ATR; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR Pfam; PF08064; UME; 1. DR SMART; SM01343; FATC; 1. DR SMART; SM00146; PI3Kc; 1. DR SMART; SM00802; UME; 1. DR SUPFAM; SSF48371; ARM repeat; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF48452; TPR-like; 1. DR PROSITE; PS51189; FAT; 1. DR PROSITE; PS51190; FATC; 1. DR PROSITE; PS50077; HEAT_REPEAT; 1. DR PROSITE; PS00916; PI3_4_KINASE_2; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Chromosome; KW Disease variant; DNA damage; DNA repair; DNA-binding; Dwarfism; KW Intellectual disability; Kinase; Manganese; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..2644 FT /note="Serine/threonine-protein kinase ATR" FT /id="PRO_0000088844" FT REPEAT 799..835 FT /note="HEAT 1" FT REPEAT 1329..1365 FT /note="HEAT 2" FT DOMAIN 1640..2185 FT /note="FAT" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534" FT DOMAIN 2296..2604 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT DOMAIN 2612..2644 FT /note="FATC" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534, FT ECO:0000255|PROSITE-ProRule:PRU00535" FT REGION 418..450 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2302..2308 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2472..2480 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2492..2516 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT MOD_RES 428 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:21144835, FT ECO:0000269|PubMed:21777809, ECO:0007744|PubMed:18691976" FT MOD_RES 435 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:21777809, FT ECO:0007744|PubMed:23186163" FT MOD_RES 436 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1989 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:21705319, FT ECO:0000269|PubMed:21777809, ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 450 FT /note="E -> D (in isoform 2)" FT /evidence="ECO:0000303|PubMed:11470508" FT /id="VSP_013305" FT VAR_SEQ 451..514 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:11470508" FT /id="VSP_013304" FT VAR_SEQ 2588..2610 FT /note="AKTHVLDIEQRLQGVIKTRNRVT -> VSRRYSLIWAVVLISTNELDMQL FT (in isoform 3)" FT /evidence="ECO:0000303|Ref.4" FT /id="VSP_036907" FT VAR_SEQ 2611..2644 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|Ref.4" FT /id="VSP_036908" FT VARIANT 64 FT /note="T -> A (in dbSNP:rs35306038)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041584" FT VARIANT 90 FT /note="H -> Y (in dbSNP:rs28897763)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041585" FT VARIANT 211 FT /note="M -> T (in dbSNP:rs2227928)" FT /id="VAR_050532" FT VARIANT 297 FT /note="K -> N (in dbSNP:rs2229033)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041586" FT VARIANT 316 FT /note="V -> I (in dbSNP:rs28897764)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041587" FT VARIANT 959 FT /note="V -> M (in dbSNP:rs28910271)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041588" FT VARIANT 1087 FT /note="Y -> H (in dbSNP:rs34253059)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041589" FT VARIANT 1213 FT /note="S -> G (in dbSNP:rs34766606)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041590" FT VARIANT 1488 FT /note="A -> P (in a lung squamous cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041591" FT VARIANT 1526 FT /note="I -> V (in dbSNP:rs34124242)" FT /id="VAR_050533" FT VARIANT 1607 FT /note="S -> N (in dbSNP:rs55724025)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041592" FT VARIANT 1612 FT /note="N -> S (in dbSNP:rs55894265)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041593" FT VARIANT 2002 FT /note="A -> G (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041594" FT VARIANT 2120 FT /note="G -> A (in dbSNP:rs35134774)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041595" FT VARIANT 2132 FT /note="Y -> D (in dbSNP:rs28910273)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041596" FT VARIANT 2144 FT /note="Q -> R (in FCTCS; dbSNP:rs387906797)" FT /evidence="ECO:0000269|PubMed:22341969" FT /id="VAR_067919" FT VARIANT 2233 FT /note="S -> I (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041597" FT VARIANT 2425 FT /note="R -> Q (in dbSNP:rs2229032)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041598" FT VARIANT 2434 FT /note="P -> A (in dbSNP:rs33972295)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041599" FT VARIANT 2438 FT /note="E -> K (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation; dbSNP:rs2108261462)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041600" FT VARIANT 2537 FT /note="E -> Q (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041601" FT MUTAGEN 1989 FT /note="T->A: Impaired autophosphorylation, leading to FT decreased activation of ATR." FT /evidence="ECO:0000269|PubMed:21705319" FT MUTAGEN 2327 FT /note="K->R: Abolishes kinase activity." FT /evidence="ECO:0000269|PubMed:11114888, FT ECO:0000269|PubMed:12011431, ECO:0000269|PubMed:9925639" FT MUTAGEN 2475 FT /note="D->A: Abolishes kinase activity; increases FT sensitivity to IR and impairs translocation to nuclear foci FT upon DNA damage." FT /evidence="ECO:0000269|PubMed:12814551, FT ECO:0000269|PubMed:9427750, ECO:0000269|PubMed:9925639" FT MUTAGEN 2494 FT /note="D->E: Abolishes kinase activity; reduces cell FT viability, augments sensitivity to IR and UV." FT /evidence="ECO:0000269|PubMed:10597277, FT ECO:0000269|PubMed:9636169" FT CONFLICT 92 FT /note="A -> R (in Ref. 1; CAA70298/AAC50929)" FT /evidence="ECO:0000305" SQ SEQUENCE 2644 AA; 301367 MW; 11BC22297FB9A802 CRC64; MGEHGLELAS MIPALRELGS ATPEEYNTVV QKPRQILCQF IDRILTDVNV VAVELVKKTD SQPTSVMLLD FIQHIMKSSP LMFVNVSGSH EAKGSCIEFS NWIITRLLRI AATPSCHLLH KKICEVICSL LFLFKSKSPA IFGVLTKELL QLFEDLVYLH RRNVMGHAVE WPVVMSRFLS QLDEHMGYLQ SAPLQLMSMQ NLEFIEVTLL MVLTRIIAIV FFRRQELLLW QIGCVLLEYG SPKIKSLAIS FLTELFQLGG LPAQPASTFF SSFLELLKHL VEMDTDQLKL YEEPLSKLIK TLFPFEAEAY RNIEPVYLNM LLEKLCVMFE DGVLMRLKSD LLKAALCHLL QYFLKFVPAG YESALQVRKV YVRNICKALL DVLGIEVDAE YLLGPLYAAL KMESMEIIEE IQCQTQQENL SSNSDGISPK RRRLSSSLNP SKRAPKQTEE IKHVDMNQKS ILWSALKQKA ESLQISLEYS GLKNPVIEML EGIAVVLQLT ALCTVHCSHQ NMNCRTFKDC QHKSKKKPSV VITWMSLDFY TKVLKSCRSL LESVQKLDLE ATIDKVVKIY DALIYMQVNS SFEDHILEDL CGMLSLPWIY SHSDDGCLKL TTFAANLLTL SCRISDSYSP QAQSRCVFLL TLFPRRIFLE WRTAVYNWAL QSSHEVIRAS CVSGFFILLQ QQNSCNRVPK ILIDKVKDDS DIVKKEFASI LGQLVCTLHG MFYLTSSLTE PFSEHGHVDL FCRNLKATSQ HECSSSQLKA SVCKPFLFLL KKKIPSPVKL AFIDNLHHLC KHLDFREDET DVKAVLGTLL NLMEDPDKDV RVAFSGNIKH ILESLDSEDG FIKELFVLRM KEAYTHAQIS RNNELKDTLI LTTGDIGRAA KGDLVPFALL HLLHCLLSKS ASVSGAAYTE IRALVAAKSV KLQSFFSQYK KPICQFLVES LHSSQMTALP NTPCQNADVR KQDVAHQREM ALNTLSEIAN VFDFPDLNRF LTRTLQVLLP DLAAKASPAA SALIRTLGKQ LNVNRREILI NNFKYIFSHL VCSCSKDELE RALHYLKNET EIELGSLLRQ DFQGLHNELL LRIGEHYQQV FNGLSILASF ASSDDPYQGP RDIISPELMA DYLQPKLLGI LAFFNMQLLS SSVGIEDKKM ALNSLMSLMK LMGPKHVSSV RVKMMTTLRT GLRFKDDFPE LCCRAWDCFV RCLDHACLGS LLSHVIVALL PLIHIQPKET AAIFHYLIIE NRDAVQDFLH EIYFLPDHPE LKKIKAVLQE YRKETSESTD LQTTLQLSMK AIQHENVDVR IHALTSLKET LYKNQEKLIK YATDSETVEP IISQLVTVLL KGCQDANSQA RLLCGECLGE LGAIDPGRLD FSTTETQGKD FTFVTGVEDS SFAYGLLMEL TRAYLAYADN SRAQDSAAYA IQELLSIYDC REMETNGPGH QLWRRFPEHV REILEPHLNT RYKSSQKSTD WSGVKKPIYL SKLGSNFAEW SASWAGYLIT KVRHDLASKI FTCCSIMMKH DFKVTIYLLP HILVYVLLGC NQEDQQEVYA EIMAVLKHDD QHTINTQDIA SDLCQLSTQT VFSMLDHLTQ WARHKFQALK AEKCPHSKSN RNKVDSMVST VDYEDYQSVT RFLDLIPQDT LAVASFRSKA YTRAVMHFES FITEKKQNIQ EHLGFLQKLY AAMHEPDGVA GVSAIRKAEP SLKEQILEHE SLGLLRDATA CYDRAIQLEP DQIIHYHGVV KSMLGLGQLS TVITQVNGVH ANRSEWTDEL NTYRVEAAWK LSQWDLVENY LAADGKSTTW SVRLGQLLLS AKKRDITAFY DSLKLVRAEQ IVPLSAASFE RGSYQRGYEY IVRLHMLCEL EHSIKPLFQH SPGDSSQEDS LNWVARLEMT QNSYRAKEPI LALRRALLSL NKRPDYNEMV GECWLQSARV ARKAGHHQTA YNALLNAGES RLAELYVERA KWLWSKGDVH QALIVLQKGV ELCFPENETP PEGKNMLIHG RAMLLVGRFM EETANFESNA IMKKYKDVTA CLPEWEDGHF YLAKYYDKLM PMVTDNKMEK QGDLIRYIVL HFGRSLQYGN QFIYQSMPRM LTLWLDYGTK AYEWEKAGRS DRVQMRNDLG KINKVITEHT NYLAPYQFLT AFSQLISRIC HSHDEVFVVL MEIIAKVFLA YPQQAMWMMT AVSKSSYPMR VNRCKEILNK AIHMKKSLEK FVGDATRLTD KLLELCNKPV DGSSSTLSMS THFKMLKKLV EEATFSEILI PLQSVMIPTL PSILGTHANH ASHEPFPGHW AYIAGFDDMV EILASLQKPK KISLKGSDGK FYIMMCKPKD DLRKDCRLME FNSLINKCLR KDAESRRREL HIRTYAVIPL NDECGIIEWV NNTAGLRPIL TKLYKEKGVY MTGKELRQCM LPKSAALSEK LKVFREFLLP RHPPIFHEWF LRTFPDPTSW YSSRSAYCRS TAVMSMVGYI LGLGDRHGEN ILFDSLTGEC VHVDFNCLFN KGETFEVPEI VPFRLTHNMV NGMGPMGTEG LFRRACEVTM RLMRDQREPL MSVLKTFLHD PLVEWSKPVK GHSKAPLNET GEVVNEKAKT HVLDIEQRLQ GVIKTRNRVT GLPLSIEGHV HYLIQEATDE NLLCQMYLGW TPYM // ID AURKC_HUMAN Reviewed; 309 AA. AC Q9UQB9; O60681; O75442; Q6AZY8; Q6DLZ0; Q9UPK5; DT 17-JAN-2003, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-2000, sequence version 1. DT 28-JAN-2026, entry version 213. DE RecName: Full=Aurora kinase C; DE EC=2.7.11.1; DE AltName: Full=Aurora 3; DE AltName: Full=Aurora/IPL1-related kinase 3; DE Short=ARK-3; DE Short=Aurora-related kinase 3; DE AltName: Full=Aurora/IPL1/Eg2 protein 2; DE AltName: Full=Serine/threonine-protein kinase 13; DE AltName: Full=Serine/threonine-protein kinase aurora-C; GN Name=AURKC; Synonyms=AIE2, AIK3, AIRK3, ARK3, STK13; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND SUBCELLULAR LOCATION. RC TISSUE=Testis; RX PubMed=9809744; DOI=10.1089/dna.1998.17.823; RA Tseng T.-C., Chen S.-H., Hsu Y.-P.P., Tang T.K.; RT "Protein kinase profile of sperm and eggs: cloning and characterization of RT two novel testis-specific protein kinases (AIE1, AIE2) related to yeast and RT fly chromosome segregation regulators."; RL DNA Cell Biol. 17:823-833(1998). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RC TISSUE=Placenta; RX PubMed=9799611; DOI=10.1006/geno.1998.5522; RA Bernard M., Sanseau P., Henry C., Couturier A., Prigent C.; RT "Cloning of STK13, a third human protein kinase related to Drosophila RT aurora and budding yeast Ipl1 that maps on chromosome 19q13.3-ter."; RL Genomics 53:406-409(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INDUCTION, AND SUBCELLULAR RP LOCATION. RC TISSUE=Testis; RX PubMed=10066797; DOI=10.1074/jbc.274.11.7334; RA Kimura M., Matsuda Y., Yoshioka T., Okano Y.; RT "Cell cycle-dependent expression and centrosome localization of a third RT human Aurora/Ipl1-related protein kinase, AIK3."; RL J. Biol. Chem. 274:7334-7340(1999). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), TISSUE SPECIFICITY, FUNCTION, RP MUTAGENESIS OF THR-198, AND SUBCELLULAR LOCATION. RX PubMed=15670791; DOI=10.1016/j.bbrc.2004.12.168; RA Yan X., Wu Y., Li Q., Cao L., Liu X., Saiyin H., Yu L.; RT "Cloning and characterization of a novel human Aurora C splicing variant."; RL Biochem. Biophys. Res. Commun. 328:353-361(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP INDUCTION, FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH INCENP, AND RP MUTAGENESIS OF LYS-72. RX PubMed=15499654; DOI=10.1002/cm.20039; RA Sasai K., Katayama H., Stenoien D.L., Fujii S., Honda R., Kimura M., RA Okano Y., Tatsuka M., Suzuki F., Nigg E.A., Earnshaw W.C., Brinkley W.R., RA Sen S.; RT "Aurora-C kinase is a novel chromosomal passenger protein that can RT complement Aurora-B kinase function in mitotic cells."; RL Cell Motil. Cytoskeleton 59:249-263(2004). RN [9] RP IDENTIFICATION IN THE CDC COMPLEX, SUBCELLULAR LOCATION, ACTIVITY RP REGULATION, FUNCTION, AND MUTAGENESIS OF LYS-72 AND THR-198. RX PubMed=15316025; DOI=10.1074/jbc.m403029200; RA Li X., Sakashita G., Matsuzaki H., Sugimoto K., Kimura K., Hanaoka F., RA Taniguchi H., Furukawa K., Urano T.; RT "Direct association with inner centromere protein (INCENP) activates the RT novel chromosomal passenger protein, Aurora-C."; RL J. Biol. Chem. 279:47201-47211(2004). RN [10] RP IDENTIFICATION IN THE CDC COMPLEX, INTERACTION WITH BIRC5, SUBCELLULAR RP LOCATION, FUNCTION, AND MUTAGENESIS OF ASP-166. RX PubMed=15938719; DOI=10.1111/j.1365-2443.2005.00863.x; RA Yan X., Cao L., Li Q., Wu Y., Zhang H., Saiyin H., Liu X., Zhang X., RA Shi Q., Yu L.; RT "Aurora C is directly associated with Survivin and required for RT cytokinesis."; RL Genes Cells 10:617-626(2005). RN [11] RP INVOLVEMENT IN SPGF5. RX PubMed=17435757; DOI=10.1038/ng2027; RA Dieterich K., Soto Rifo R., Faure A.K., Hennebicq S., Ben Amar B., Zahi M., RA Perrin J., Martinez D., Sele B., Jouk P.-S., Ohlmann T., Rousseaux S., RA Lunardi J., Ray P.F.; RT "Homozygous mutation of AURKC yields large-headed polyploid spermatozoa and RT causes male infertility."; RL Nat. Genet. 39:661-665(2007). RN [12] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH TACC1. RX PubMed=21531210; DOI=10.1016/j.bbrc.2011.04.078; RA Gabillard J.C., Ulisse S., Baldini E., Sorrenti S., Cremet J.Y., RA Coccaro C., Prigent C., D'Armiento M., Arlot-Bonnemains Y.; RT "Aurora-C interacts with and phosphorylates the transforming acidic coiled- RT coil 1 protein."; RL Biochem. Biophys. Res. Commun. 408:647-653(2011). RN [13] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=21493633; DOI=10.1093/humrep/der111; RA Avo Santos M., van de Werken C., de Vries M., Jahr H., Vromans M.J., RA Laven J.S., Fauser B.C., Kops G.J., Lens S.M., Baart E.B.; RT "A role for Aurora C in the chromosomal passenger complex during human RT preimplantation embryo development."; RL Hum. Reprod. 26:1868-1881(2011). RN [14] RP INVOLVEMENT IN SPGF5. RX PubMed=21733974; DOI=10.1093/molehr/gar050; RA Ben Khelifa M., Zouari R., Harbuz R., Halouani L., Arnoult C., Lunardi J., RA Ray P.F.; RT "A new AURKC mutation causing macrozoospermia: implications for human RT spermatogenesis and clinical diagnosis."; RL Mol. Hum. Reprod. 17:762-768(2011). RN [15] RP INTERACTION WITH BIRC5, SUBUNIT, FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=27332895; DOI=10.1371/journal.pone.0157305; RA Sasai K., Katayama H., Hawke D.H., Sen S.; RT "Aurora-C interactions with survivin and INCENP reveal shared and distinct RT features compared with Aurora-B chromosome passenger protein complex."; RL PLoS ONE 11:E0157305-E0157305(2016). RN [16] RP VARIANTS [LARGE SCALE ANALYSIS] GLU-52; GLN-148 AND GLN-244. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase component of the chromosomal CC passenger complex (CPC), a complex that acts as a key regulator of CC mitosis. The CPC complex has essential functions at the centromere in CC ensuring correct chromosome alignment and segregation and is required CC for chromatin-induced microtubule stabilization and spindle assembly. CC Also plays a role in meiosis and more particularly in spermatogenesis. CC Has redundant cellular functions with AURKB and can rescue an AURKB CC knockdown. Like AURKB, AURKC phosphorylates histone H3 at 'Ser-10' and CC 'Ser-28'. AURKC phosphorylates the CPC complex subunits BIRC5/survivin CC and INCENP leading to increased AURKC activity. Phosphorylates TACC1, CC another protein involved in cell division, at 'Ser-228'. CC {ECO:0000269|PubMed:15316025, ECO:0000269|PubMed:15499654, CC ECO:0000269|PubMed:15670791, ECO:0000269|PubMed:15938719, CC ECO:0000269|PubMed:21493633, ECO:0000269|PubMed:21531210, CC ECO:0000269|PubMed:27332895}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- ACTIVITY REGULATION: Okadaic acid, an inhibitor of protein phosphatase CC 1 (PP1), protein phosphatase 2A (PP2A) and protein phosphatase 5 (PP5), CC increases AURKC activity. AURKC is also stabilized through its CC interaction with INCENP, which also acts as an activator. CC {ECO:0000269|PubMed:15316025}. CC -!- SUBUNIT: Component of the chromosomal passenger complex (CPC) composed CC of at least BIRC5/survivin, CDCA8/borealin, INCENP, AURKB or AURKC; CC predominantly independent AURKB- and AURKC-containing complexes exist; CC in the complex interacts directly with BIRC5/survivin and INCENP. CC Interacts with TACC1. {ECO:0000269|PubMed:15316025, CC ECO:0000269|PubMed:15499654, ECO:0000269|PubMed:15938719, CC ECO:0000269|PubMed:21531210, ECO:0000269|PubMed:27332895}. CC -!- INTERACTION: CC Q9UQB9; O15392: BIRC5; NbExp=10; IntAct=EBI-3926851, EBI-518823; CC Q9UQB9; Q96CA5: BIRC7; NbExp=3; IntAct=EBI-3926851, EBI-517623; CC Q9UQB9; A2RRN7: CADPS; NbExp=3; IntAct=EBI-3926851, EBI-10179719; CC Q9UQB9; Q9NQS7: INCENP; NbExp=20; IntAct=EBI-3926851, EBI-307907; CC Q9UQB9; P32243-2: OTX2; NbExp=4; IntAct=EBI-3926851, EBI-9087860; CC -!- SUBCELLULAR LOCATION: Nucleus. Chromosome. Chromosome, centromere CC {ECO:0000269|PubMed:27332895}. Cytoplasm, cytoskeleton, spindle CC {ECO:0000269|PubMed:15938719}. Note=Distributes in the condensed CC chromosomes during prophase to metaphase. After entering anaphase, CC there is a dissociation from separated chromosomes and a redistribution CC to midzone microtubules, and finally remains in the midbody during CC cytokinesis. {ECO:0000269|PubMed:21531210}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q9UQB9-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9UQB9-2; Sequence=VSP_004872; CC Name=3; Synonyms=Aurora C-SV; CC IsoId=Q9UQB9-3; Sequence=VSP_041095; CC -!- TISSUE SPECIFICITY: Isoform 1 and isoform 2 are expressed in testis. CC Elevated expression levels were seen only in a subset of cancer cell CC lines such as Hep-G2, Huh-7 and HeLa. Expression is maximum at M phase. CC {ECO:0000269|PubMed:15670791}. CC -!- INDUCTION: Expression is cell cycle-regulated, with an increase during CC G2 and M phases. {ECO:0000269|PubMed:10066797, CC ECO:0000269|PubMed:15499654}. CC -!- DISEASE: Spermatogenic failure 5 (SPGF5) [MIM:243060]: An infertility CC disorder caused by spermatogenesis defects. Semen from affected men CC show close to 100% morphologically abnormal multiflagellar spermatozoa CC with low motility, oversized irregular heads, and abnormal midpiece and CC acrosome. {ECO:0000269|PubMed:17435757, ECO:0000269|PubMed:21733974}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. Aurora subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF054621; AAC25955.1; -; mRNA. DR EMBL; AF059681; AAC77369.1; -; mRNA. DR EMBL; AB017332; BAA76292.1; -; mRNA. DR EMBL; AY661554; AAT64422.1; -; mRNA. DR EMBL; AC005261; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471135; EAW72485.1; -; Genomic_DNA. DR EMBL; BC075064; AAH75064.2; -; mRNA. DR CCDS; CCDS33128.1; -. [Q9UQB9-1] DR CCDS; CCDS46205.1; -. [Q9UQB9-3] DR CCDS; CCDS46206.1; -. [Q9UQB9-2] DR RefSeq; NP_001015878.1; NM_001015878.2. [Q9UQB9-1] DR RefSeq; NP_001015879.1; NM_001015879.2. [Q9UQB9-3] DR RefSeq; NP_003151.2; NM_003160.3. [Q9UQB9-2] DR PDB; 6GR8; X-ray; 1.75 A; A=36-305. DR PDB; 6GR9; X-ray; 2.25 A; A=36-305. DR PDB; 9ESA; X-ray; 2.80 A; AAA/BBB=13-309. DR PDBsum; 6GR8; -. DR PDBsum; 6GR9; -. DR PDBsum; 9ESA; -. DR AlphaFoldDB; Q9UQB9; -. DR SMR; Q9UQB9; -. DR BioGRID; 112671; 42. DR FunCoup; Q9UQB9; 312. DR IntAct; Q9UQB9; 31. DR STRING; 9606.ENSP00000302898; -. DR BindingDB; Q9UQB9; -. DR ChEMBL; CHEMBL3935; -. DR DrugBank; DB08039; (3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE. DR DrugBank; DB17197; AMG-900. DR DrugBank; DB11778; Danusertib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB11694; Ilorasertib. DR DrugBank; DB08454; N-(5-METHYL-1H-PYRAZOL-3-YL)-2-PHENYLQUINAZOLIN-4-AMINE. DR DrugBank; DB07545; N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE. DR DrugBank; DB06134; SNS-314. DR DrugCentral; Q9UQB9; -. DR GuidetoPHARMACOLOGY; 1938; -. DR iPTMnet; Q9UQB9; -. DR PhosphoSitePlus; Q9UQB9; -. DR BioMuta; AURKC; -. DR DMDM; 27805738; -. DR jPOST; Q9UQB9; -. DR MassIVE; Q9UQB9; -. DR PaxDb; 9606-ENSP00000302898; -. DR PeptideAtlas; Q9UQB9; -. DR ProteomicsDB; 85538; -. [Q9UQB9-1] DR ProteomicsDB; 85539; -. [Q9UQB9-2] DR ProteomicsDB; 85540; -. [Q9UQB9-3] DR Pumba; Q9UQB9; -. DR Antibodypedia; 33237; 506 antibodies from 29 providers. DR DNASU; 6795; -. DR Ensembl; ENST00000302804.12; ENSP00000302898.6; ENSG00000105146.15. [Q9UQB9-1] DR Ensembl; ENST00000415300.6; ENSP00000407162.1; ENSG00000105146.15. [Q9UQB9-3] DR Ensembl; ENST00000598785.5; ENSP00000471830.1; ENSG00000105146.15. [Q9UQB9-2] DR GeneID; 6795; -. DR KEGG; hsa:6795; -. DR MANE-Select; ENST00000302804.12; ENSP00000302898.6; NM_001015878.2; NP_001015878.1. DR UCSC; uc002qoc.4; human. [Q9UQB9-1] DR AGR; HGNC:11391; -. DR ClinPGx; PA36200; -. DR CTD; 6795; -. DR DisGeNET; 6795; -. DR GeneCards; AURKC; -. DR HGNC; HGNC:11391; AURKC. DR HPA; ENSG00000105146; Tissue enriched (testis). DR MalaCards; AURKC; -. DR MIM; 243060; phenotype. DR MIM; 603495; gene. DR OpenTargets; ENSG00000105146; -. DR Orphanet; 137893; Male infertility due to large-headed multiflagellar polyploid spermatozoa. DR VEuPathDB; HostDB:ENSG00000105146; -. DR eggNOG; KOG0580; Eukaryota. DR GeneTree; ENSGT00940000161619; -. DR HOGENOM; CLU_000288_63_0_1; -. DR InParanoid; Q9UQB9; -. DR OMA; KELQKCH; -. DR OrthoDB; 377346at2759; -. DR PAN-GO; Q9UQB9; 7 GO annotations based on evolutionary models. DR PhylomeDB; Q9UQB9; -. DR PathwayCommons; Q9UQB9; -. DR SignaLink; Q9UQB9; -. DR SIGNOR; Q9UQB9; -. DR Agora; ENSG00000105146; -. DR BioGRID-ORCS; 6795; 17 hits in 1190 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR GeneWiki; AURKC; -. DR GenomeRNAi; 6795; -. DR Pharos; Q9UQB9; Tchem. DR PRO; PR:Q9UQB9; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q9UQB9; protein. DR Bgee; ENSG00000105146; Expressed in oocyte and 101 other cell types or tissues. DR ExpressionAtlas; Q9UQB9; baseline and differential. DR GO; GO:0005813; C:centrosome; IBA:GO_Central. DR GO; GO:0032133; C:chromosome passenger complex; IBA:GO_Central. DR GO; GO:0000793; C:condensed chromosome; IDA:UniProtKB. DR GO; GO:0000776; C:kinetochore; IBA:GO_Central. DR GO; GO:0030496; C:midbody; IDA:UniProtKB. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005819; C:spindle; TAS:UniProtKB. DR GO; GO:0005876; C:spindle microtubule; IBA:GO_Central. DR GO; GO:0051233; C:spindle midzone; IDA:UniProtKB. DR GO; GO:0000922; C:spindle pole; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; TAS:UniProtKB. DR GO; GO:0008608; P:attachment of spindle microtubules to kinetochore; TAS:UniProtKB. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:0051321; P:meiotic cell cycle; IEA:UniProtKB-KW. DR GO; GO:0051256; P:mitotic spindle midzone assembly; TAS:UniProtKB. DR GO; GO:0007052; P:mitotic spindle organization; IBA:GO_Central. DR GO; GO:0032467; P:positive regulation of cytokinesis; TAS:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0032465; P:regulation of cytokinesis; IBA:GO_Central. DR CDD; cd14117; STKc_Aurora-B_like; 1. DR FunFam; 1.10.510.10:FF:000887; Aurora B kinase; 1. DR FunFam; 3.30.200.20:FF:000042; Aurora kinase A; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR030616; Aur-like. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24350; SERINE/THREONINE-PROTEIN KINASE IAL-RELATED; 1. DR Pfam; PF00069; Pkinase; 1. DR PIRSF; PIRSF000654; Integrin-linked_kinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell cycle; Cell division; KW Centromere; Chromosome; Cytoplasm; Cytoskeleton; Kinase; Meiosis; Mitosis; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase. FT CHAIN 1..309 FT /note="Aurora kinase C" FT /id="PRO_0000085660" FT DOMAIN 43..293 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..33 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 292..309 FT /note="Interaction with BIRC5" FT /evidence="ECO:0000269|PubMed:27332895" FT COMPBIAS 22..32 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 166 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 49..57 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 72 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 198 FT /note="Phosphothreonine; by PKA" FT /evidence="ECO:0000250|UniProtKB:O88445" FT VAR_SEQ 1..34 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:9799611" FT /id="VSP_004872" FT VAR_SEQ 1..20 FT /note="MSSPRAVVQLGKAQPAGEEL -> M (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15670791" FT /id="VSP_041095" FT VARIANT 52 FT /note="G -> E (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs2122802401)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040385" FT VARIANT 148 FT /note="E -> Q (in a lung squamous cell carcinoma sample; FT somatic mutation; dbSNP:rs2087514266)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040386" FT VARIANT 244 FT /note="H -> Q (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040387" FT MUTAGEN 72 FT /note="K->R: Impairs kinase activity." FT /evidence="ECO:0000269|PubMed:15316025, FT ECO:0000269|PubMed:15499654" FT MUTAGEN 166 FT /note="D->Y: Impairs kinase activity, and keeps AURKC with FT the chromosomes until the end of mitosis." FT /evidence="ECO:0000269|PubMed:15938719" FT MUTAGEN 198 FT /note="T->A: Impairs kinase activity." FT /evidence="ECO:0000269|PubMed:15316025, FT ECO:0000269|PubMed:15670791" FT CONFLICT 109 FT /note="Y -> H (in Ref. 1; AAC25955)" FT /evidence="ECO:0000305" FT CONFLICT 150 FT /note="L -> V (in Ref. 2; AAC77369)" FT /evidence="ECO:0000305" FT CONFLICT 193..195 FT /note="SLR -> LPE (in Ref. 2; AAC77369)" FT /evidence="ECO:0000305" FT HELIX 40..42 FT /evidence="ECO:0007829|PDB:6GR8" FT STRAND 43..52 FT /evidence="ECO:0007829|PDB:6GR8" FT STRAND 55..62 FT /evidence="ECO:0007829|PDB:6GR8" FT TURN 63..65 FT /evidence="ECO:0007829|PDB:6GR8" FT STRAND 68..75 FT /evidence="ECO:0007829|PDB:6GR8" FT HELIX 76..82 FT /evidence="ECO:0007829|PDB:6GR8" FT HELIX 85..97 FT /evidence="ECO:0007829|PDB:6GR8" FT STRAND 106..111 FT /evidence="ECO:0007829|PDB:6GR8" FT STRAND 113..120 FT /evidence="ECO:0007829|PDB:6GR8" FT HELIX 128..135 FT /evidence="ECO:0007829|PDB:6GR8" FT HELIX 140..159 FT /evidence="ECO:0007829|PDB:6GR8" FT HELIX 169..171 FT /evidence="ECO:0007829|PDB:6GR8" FT STRAND 172..174 FT /evidence="ECO:0007829|PDB:6GR8" FT STRAND 180..182 FT /evidence="ECO:0007829|PDB:6GR8" FT HELIX 203..205 FT /evidence="ECO:0007829|PDB:6GR8" FT HELIX 208..211 FT /evidence="ECO:0007829|PDB:6GR8" FT HELIX 220..234 FT /evidence="ECO:0007829|PDB:6GR8" FT HELIX 244..252 FT /evidence="ECO:0007829|PDB:6GR8" FT HELIX 264..273 FT /evidence="ECO:0007829|PDB:6GR8" FT HELIX 278..280 FT /evidence="ECO:0007829|PDB:6GR8" FT HELIX 284..289 FT /evidence="ECO:0007829|PDB:6GR8" FT HELIX 291..296 FT /evidence="ECO:0007829|PDB:6GR8" SQ SEQUENCE 309 AA; 35591 MW; 41B7DFCA91704201 CRC64; MSSPRAVVQL GKAQPAGEEL ATANQTAQQP SSPAMRRLTV DDFEIGRPLG KGKFGNVYLA RLKESHFIVA LKVLFKSQIE KEGLEHQLRR EIEIQAHLQH PNILRLYNYF HDARRVYLIL EYAPRGELYK ELQKSEKLDE QRTATIIEEL ADALTYCHDK KVIHRDIKPE NLLLGFRGEV KIADFGWSVH TPSLRRKTMC GTLDYLPPEM IEGRTYDEKV DLWCIGVLCY ELLVGYPPFE SASHSETYRR ILKVDVRFPL SMPLGARDLI SRLLRYQPLE RLPLAQILKH PWVQAHSRRV LPPCAQMAS // ID BAP1_HUMAN Reviewed; 729 AA. AC Q92560; A8K993; Q6LEM0; Q7Z5E8; DT 05-JUL-2005, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1998, sequence version 2. DT 28-JAN-2026, entry version 194. DE RecName: Full=Ubiquitin carboxyl-terminal hydrolase BAP1 {ECO:0000305}; DE EC=3.4.19.12 {ECO:0000269|PubMed:20436459, ECO:0000269|PubMed:30258054, ECO:0000269|PubMed:9528852}; DE AltName: Full=BRCA1-associated protein 1 {ECO:0000303|PubMed:9528852}; DE AltName: Full=Cerebral protein 6 {ECO:0000303|Ref.2}; GN Name=BAP1 {ECO:0000303|PubMed:9528852, ECO:0000312|HGNC:HGNC:950}; GN Synonyms=KIAA0272 {ECO:0000303|PubMed:9039502}; GN ORFNames=hucep-6 {ECO:0000303|Ref.2}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], ENZYME ACTIVITY, MUTAGENESIS OF CYS-91 AND RP LEU-691, INTERACTION WITH BRCA1, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, RP AND MISCELLANEOUS. RC TISSUE=B-cell; RX PubMed=9528852; DOI=10.1038/sj.onc.1201861; RA Jensen D.E., Proctor M., Marquis S.T., Gardner H.P., Ha S.I., Chodosh L.A., RA Ishov A.M., Tommerup N., Vissing H., Sekido Y., Minna J., Borodovsky A., RA Schultz D.C., Wilkinson K.D., Maul G.G., Barlev N., Berger S., RA Prendergast G.C., Rauscher F.J. III; RT "BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and RT enhances BRCA1-mediated cell growth suppression."; RL Oncogene 16:1097-1112(1998). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Brain; RA Yoshimoto M., Yazaki M., Takayama K., Matsumoto K.; RT "Biological functions of a novel human gene, hucep-6, which is specifically RT expressed in the central nervous system."; RL Submitted (NOV-1996) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=9039502; DOI=10.1093/dnares/3.5.321; RA Nagase T., Seki N., Ishikawa K., Ohira M., Kawarabayasi Y., Ohara O., RA Tanaka A., Kotani H., Miyajima N., Nomura N.; RT "Prediction of the coding sequences of unidentified human genes. VI. The RT coding sequences of 80 new genes (KIAA0201-KIAA0280) deduced by analysis of RT cDNA clones from cell line KG-1 and brain."; RL DNA Res. 3:321-329(1996). RN [4] RP SEQUENCE REVISION. RX PubMed=12168954; DOI=10.1093/dnares/9.3.99; RA Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.; RT "Construction of expression-ready cDNA clones for KIAA genes: manual RT curation of 330 KIAA cDNA clones."; RL DNA Res. 9:99-106(2002). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 164-729. RC TISSUE=Medulloblastoma; RX PubMed=12800201; DOI=10.1002/ijc.11208; RA Behrends U., Schneider I., Roessler S., Frauenknecht H., Golbeck A., RA Lechner B., Eigenstetter G., Zobywalski C., Mueller-Weihrich S., RA Graubner U., Schmid I., Sackerer D., Spaeth M., Goetz C., Prantl F., RA Asmuss H.-P., Bise K., Mautner J.; RT "Novel tumor antigens identified by autologous antibody screening of RT childhood medulloblastoma cDNA libraries."; RL Int. J. Cancer 106:244-251(2003). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-292; SER-369; SER-521; RP SER-537; SER-585 AND SER-597, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [15] RP VARIANTS ASP-95 AND VAL-178. RX PubMed=10546591; DOI=10.1016/s0304-3835(99)90004-6; RA Jensen D.E., Rauscher F.J. III; RT "Defining biochemical functions for the BRCA1 tumor suppressor protein: RT analysis of the BRCA1 binding protein BAP1."; RL Cancer Lett. 143:S13-S17(1999). RN [16] RP FUNCTION. RX PubMed=12485996; DOI=10.1093/emboj/cdf691; RA Mallery D.L., Vandenberg C.J., Hiom K.; RT "Activation of the E3 ligase function of the BRCA1/BARD1 complex by RT polyubiquitin chains."; RL EMBO J. 21:6755-6762(2002). RN [17] RP FUNCTION, SUBCELLULAR LOCATION, NUCLEAR LOCALIZATION SIGNAL, MUTAGENESIS OF RP CYS-91; 656-LYS--ARG-661 AND 717-ARG--ARG-722, AND CHARACTERIZATION OF RP VARIANTS ASP-95 AND VAL-178. RX PubMed=18757409; DOI=10.1158/0008-5472.can-08-0365; RA Ventii K.H., Devi N.S., Friedrich K.L., Chernova T.A., Tighiouart M., RA Van Meir E.G., Wilkinson K.D.; RT "BRCA1-associated protein-1 is a tumor suppressor that requires RT deubiquitinating activity and nuclear localization."; RL Cancer Res. 68:6953-6962(2008). RN [18] RP FUNCTION, INTERACTION WITH BARD1 AND BRCA1, AND CHARACTERIZATION OF VARIANT RP KURIS SER-91. RX PubMed=19117993; DOI=10.1158/0008-5472.can-08-3355; RA Nishikawa H., Wu W., Koike A., Kojima R., Gomi H., Fukuda M., Ohta T.; RT "BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer RT activity."; RL Cancer Res. 69:111-119(2009). RN [19] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH HCFC1, MUTAGENESIS OF RP 363-ASN--TYR-366, AND CHARACTERIZATION OF VARIANT KURIS SER-91. RX PubMed=19815555; DOI=10.1074/jbc.m109.046755; RA Machida Y.J., Machida Y., Vashisht A.A., Wohlschlegel J.A., Dutta A.; RT "The deubiquitinating enzyme BAP1 regulates cell growth via interaction RT with HCF-1."; RL J. Biol. Chem. 284:34179-34188(2009). RN [20] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH HCFC1, AND MUTAGENESIS OF RP CYS-91 AND 363-ASN--TYR-366. RX PubMed=19188440; DOI=10.1128/mcb.01517-08; RA Misaghi S., Ottosen S., Izrael-Tomasevic A., Arnott D., Lamkanfi M., RA Lee J., Liu J., O'Rourke K., Dixit V.M., Wilson A.C.; RT "Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 RT with cell cycle regulator host cell factor 1."; RL Mol. Cell. Biol. 29:2181-2192(2009). RN [21] RP FUNCTION, IDENTIFICATION IN THE PR-DUB COMPLEX, INTERACTION WITH YY1 AND RP HCFC1, IDENTIFICATION BY MASS SPECTROMETRY, AND CHARACTERIZATION OF VARIANT RP KURIS SER-91. RX PubMed=20805357; DOI=10.1128/mcb.00396-10; RA Yu H., Mashtalir N., Daou S., Hammond-Martel I., Ross J., Sui G., RA Hart G.W., Rauscher F.J. III, Drobetsky E., Milot E., Shi Y., Affar el B.; RT "The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and RT HCF-1 and is a critical regulator of gene expression."; RL Mol. Cell. Biol. 30:5071-5085(2010). RN [22] RP FUNCTION, CATALYTIC ACTIVITY, IDENTIFICATION IN THE PR-DUB COMPLEX, AND RP INTERACTION WITH ASXL1. RX PubMed=20436459; DOI=10.1038/nature08966; RA Scheuermann J.C., de Ayala Alonso A.G., Oktaba K., Ly-Hartig N., RA McGinty R.K., Fraterman S., Wilm M., Muir T.W., Muller J.; RT "Histone H2A deubiquitinase activity of the Polycomb repressive complex PR- RT DUB."; RL Nature 465:243-247(2010). RN [23] RP FUNCTION, SUBCELLULAR LOCATION, UBIQUITINATION, NUCLEAR LOCALIZATION RP SIGNAL, AND MUTAGENESIS OF 691-LEU--LYS-711. RX PubMed=24703950; DOI=10.1016/j.molcel.2014.03.002; RA Mashtalir N., Daou S., Barbour H., Sen N.N., Gagnon J., Hammond-Martel I., RA Dar H.H., Therrien M., Affar E.B.; RT "Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic RT sequestration mediated by the atypical ubiquitin ligase UBE2O."; RL Mol. Cell 54:392-406(2014). RN [24] RP SUBCELLULAR LOCATION, AND INTERACTION WITH FOXK2. RX PubMed=24748658; DOI=10.1093/nar/gku274; RA Ji Z., Mohammed H., Webber A., Ridsdale J., Han N., Carroll J.S., RA Sharrocks A.D.; RT "The forkhead transcription factor FOXK2 acts as a chromatin targeting RT factor for the BAP1-containing histone deubiquitinase complex."; RL Nucleic Acids Res. 42:6232-6242(2014). RN [25] RP IDENTIFICATION IN THE PR-DUB COMPLEX, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RX PubMed=24634419; DOI=10.1002/pmic.201400013; RA Baymaz H.I., Fournier A., Laget S., Ji Z., Jansen P.W., Smits A.H., RA Ferry L., Mensinga A., Poser I., Sharrocks A., Defossez P.A., Vermeulen M.; RT "MBD5 and MBD6 interact with the human PR-DUB complex through their methyl- RT CpG-binding domain."; RL Proteomics 14:2179-2189(2014). RN [26] RP CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, DOMAIN, AND RP MUTAGENESIS OF ASN-251; LEU-635 AND 713-ARG--GLN-729. RX PubMed=30258054; DOI=10.1038/s41467-018-06186-1; RA Foglizzo M., Middleton A.J., Burgess A.E., Crowther J.M., Dobson R.C.J., RA Murphy J.M., Day C.L., Mace P.D.; RT "A bidentate Polycomb Repressive-Deubiquitinase complex is required for RT efficient activity on nucleosomes."; RL Nat. Commun. 9:3932-3932(2018). RN [27] RP FUNCTION, IDENTIFICATION IN THE PR-DUB COMPLEX, SUBCELLULAR LOCATION, AND RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=30664650; DOI=10.1038/s41467-018-08255-x; RA Campagne A., Lee M.K., Zielinski D., Michaud A., Le Corre S., Dingli F., RA Chen H., Shahidian L.Z., Vassilev I., Servant N., Loew D., Pasmant E., RA Postel-Vinay S., Wassef M., Margueron R.; RT "BAP1 complex promotes transcription by opposing PRC1-mediated H2A RT ubiquitylation."; RL Nat. Commun. 10:348-348(2019). RN [28] RP FUNCTION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE. RX PubMed=34170818; DOI=10.7554/elife.63254; RA Perez-Garcia V., Lea G., Lopez-Jimenez P., Okkenhaug H., Burton G.J., RA Moffett A., Turco M.Y., Hemberger M.; RT "BAP1/ASXL complex modulation regulates epithelial-mesenchymal transition RT during trophoblast differentiation and invasion."; RL Elife 10:0-0(2021). RN [29] RP FUNCTION, IDENTIFICATION IN THE PR-DUB COMPLEX, INTERACTION WITH ASXL1, AND RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=36180891; DOI=10.1186/s13059-022-02776-x; RA Tsuboyama N., Szczepanski A.P., Zhao Z., Wang L.; RT "MBD5 and MBD6 stabilize the BAP1 complex and promote BAP1-dependent RT cancer."; RL Genome Biol. 23:206-206(2022). RN [30] {ECO:0007744|PDB:7VPW} RP X-RAY CRYSTALLOGRAPHY (3.76 ANGSTROMS) OF 706-724, SUBUNIT, INTERACTION RP WITH TNPO1; KPNA1 AND KPNA2, SUBCELLULAR LOCATION, DOMAIN NLS, RP UBIQUITINATION, MUTAGENESIS OF 684-GLN--GLN-729, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RX PubMed=35446349; DOI=10.1083/jcb.202201094; RA Yang T.J., Li T.N., Huang R.S., Pan M.Y., Lin S.Y., Lin S., Wu K.P., RA Wang L.H., Hsu S.D.; RT "Tumor suppressor BAP1 nuclear import is governed by transportin-1."; RL J. Cell Biol. 221:0-0(2022). RN [31] {ECO:0007744|PDB:8H1T} RP STRUCTURE BY ELECTRON MICROSCOPY (3.00 ANGSTROMS) IN COMPLEX WITH ASXL1; RP UBB AND THE CHROMATOSOME COMPLEX, INTERACTION WITH ASXL1 AND CHROMATOSOME RP COMPLEX, DOMAIN C-TERMINAL TAIL AND UCH, AND MUTAGENESIS OF 56-ARG--ARG-60; RP 697-SER--GLN-729; 699-ARG--GLN-702; ARG-699; ARG-700; ARG-701; GLN-702; RP GLY-703; ARG-708; 711-LYS--ARG-718; 711-LYS--GLN-729; ARG-713 AND RP 718-ARG--GLN-729. RX PubMed=36991118; DOI=10.1038/s41586-023-05841-y; RA Ge W., Yu C., Li J., Yu Z., Li X., Zhang Y., Liu C.P., Li Y., Tian C., RA Zhang X., Li G., Zhu B., Xu R.M.; RT "Basis of the H2AK119specificity of the Polycomb repressive RT deubiquitinase."; RL Nature 616:176-182(2023). RN [32] {ECO:0007744|PDB:8SVF} RP STRUCTURE BY ELECTRON MICROSCOPY (3.20 ANGSTROMS) IN COMPLEX WITH ASXL1; RP UBC AND THE XENOPUS NUCLEOSOME COMPLEX, INTERACTION WITH ASXL1 AND THE RP NUCLEOSOME COMPLEX, DOMAIN UCH AND ARG-FINGER, AND MUTAGENESIS OF RP 56-ARG--ARG-60; ARG-56; ARG-59; 699-ARG--ARG-701; 699-ARG-ARG-700; ARG-699 RP AND ARG-701. RX PubMed=37556531; DOI=10.1126/sciadv.adg9832; RA Thomas J.F., Valencia-Sanchez M.I., Tamburri S., Gloor S.L., RA Rustichelli S., Godinez-Lopez V., De Ioannes P., Lee R., Abini-Agbomson S., RA Gretarsson K., Burg J.M., Hickman A.R., Sun L., Gopinath S., Taylor H.F., RA Sun Z.W., Ezell R.J., Vaidya A., Meiners M.J., Cheek M.A., Rice W.J., RA Svetlov V., Nudler E., Lu C., Keogh M.C., Pasini D., Armache K.J.; RT "Structural basis of histone H2A lysine 119 deubiquitination by Polycomb RT repressive deubiquitinase BAP1/ASXL1."; RL Sci. Adv. 9:eadg9832-eadg9832(2023). RN [33] RP VARIANT TPDS1 267-GLN--GLN-729 DEL, AND INVOLVEMENT IN TPDS1. RX PubMed=21941004; DOI=10.1136/jmedgenet-2011-100156; RA Abdel-Rahman M.H., Pilarski R., Cebulla C.M., Massengill J.B., RA Christopher B.N., Boru G., Hovland P., Davidorf F.H.; RT "Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, RT meningioma, and other cancers."; RL J. Med. Genet. 48:856-859(2011). RN [34] RP INVOLVEMENT IN MESOM, AND VARIANTS CYS-63; VAL-81; TRP-91; ASP-95; ALA-315 RP AND VAL-685. RX PubMed=21642991; DOI=10.1038/ng.855; RA Bott M., Brevet M., Taylor B.S., Shimizu S., Ito T., Wang L., Creaney J., RA Lake R.A., Zakowski M.F., Reva B., Sander C., Delsite R., Powell S., RA Zhou Q., Shen R., Olshen A., Rusch V., Ladanyi M.; RT "The nuclear deubiquitinase BAP1 is commonly inactivated by somatic RT mutations and 3p21.1 losses in malignant pleural mesothelioma."; RL Nat. Genet. 43:668-672(2011). RN [35] RP INVOLVEMENT IN TPDS1. RX PubMed=21874003; DOI=10.1038/ng.910; RA Wiesner T., Obenauf A.C., Murali R., Fried I., Griewank K.G., Ulz P., RA Windpassinger C., Wackernagel W., Loy S., Wolf I., Viale A., Lash A.E., RA Pirun M., Socci N.D., Rutten A., Palmedo G., Abramson D., Offit K., Ott A., RA Becker J.C., Cerroni L., Kutzner H., Bastian B.C., Speicher M.R.; RT "Germline mutations in BAP1 predispose to melanocytic tumors."; RL Nat. Genet. 43:1018-1021(2011). RN [36] RP INVOLVEMENT IN TPDS1 AND MESOM. RX PubMed=21874000; DOI=10.1038/ng.912; RA Testa J.R., Cheung M., Pei J., Below J.E., Tan Y., Sementino E., Cox N.J., RA Dogan A.U., Pass H.I., Trusa S., Hesdorffer M., Nasu M., Powers A., RA Rivera Z., Comertpay S., Tanji M., Gaudino G., Yang H., Carbone M.; RT "Germline BAP1 mutations predispose to malignant mesothelioma."; RL Nat. Genet. 43:1022-1025(2011). RN [37] RP VARIANT TPDS1 ALA-93. RX PubMed=23684012; DOI=10.1016/j.ajhg.2013.04.012; RA Popova T., Hebert L., Jacquemin V., Gad S., Caux-Moncoutier V., RA Dubois-d'Enghien C., Richaudeau B., Renaudin X., Sellers J., Nicolas A., RA Sastre-Garau X., Desjardins L., Gyapay G., Raynal V., Sinilnikova O.M., RA Andrieu N., Manie E., de Pauw A., Gesta P., Bonadona V., Maugard C.M., RA Penet C., Avril M.F., Barillot E., Cabaret O., Delattre O., Richard S., RA Caron O., Benfodda M., Hu H.H., Soufir N., Bressac-de Paillerets B., RA Stoppa-Lyonnet D., Stern M.H.; RT "Germline BAP1 mutations predispose to renal cell carcinomas."; RL Am. J. Hum. Genet. 92:974-980(2013). RN [38] RP VARIANT PHE-47. RX PubMed=25080371; DOI=10.1111/cge.12472; RA de la Fouchardiere A., Cabaret O., Savin L., Combemale P., Schvartz H., RA Penet C., Bonadona V., Soufir N., Bressac-de Paillerets B.; RT "Germline BAP1 mutations predispose also to multiple basal cell RT carcinomas."; RL Clin. Genet. 88:273-277(2015). RN [39] RP FUNCTION, INTERACTION WITH FOXK1 AND FOXK2, PHOSPHORYLATION AT THR-493, RP MUTAGENESIS OF SER-489; SER-492; THR-493 AND THR-495, AND CHARACTERIZATION RP OF VARIANT KURIS SER-91. RX PubMed=25451922; DOI=10.1074/jbc.m114.609834; RA Okino Y., Machida Y., Frankland-Searby S., Machida Y.J.; RT "BRCA1-associated protein 1 (BAP1) deubiquitinase antagonizes the RT ubiquitin-mediated activation of FoxK2 target genes."; RL J. Biol. Chem. 290:1580-1591(2015). RN [40] RP INVOLVEMENT IN UVM2. RX PubMed=25687217; DOI=10.3109/13816810.2015.1010734; RA Cebulla C.M., Binkley E.M., Pilarski R., Massengill J.B., Rai K., RA Liebner D.A., Marino M.J., Singh A.D., Abdel-Rahman M.H.; RT "Analysis of BAP1 Germline gene mutation in young uveal melanoma RT patients."; RL Ophthalmic Genet. 36:126-131(2015). RN [41] RP CHARACTERIZATION OF VARIANTS PHE-47; VAL-81; ASP-95 AND VAL-178. RX PubMed=26680512; DOI=10.1038/srep18462; RA Bhattacharya S., Hanpude P., Maiti T.K.; RT "Cancer associated missense mutations in BAP1 catalytic domain induce RT amyloidogenic aggregation: A new insight in enzymatic inactivation."; RL Sci. Rep. 5:18462-18462(2015). RN [42] RP INVOLVEMENT IN UVM2. RX PubMed=32002398; DOI=10.1159/000499570; RA Yu M.D., Masoomian B., Shields J.A., Shields C.L.; RT "BAP1 germline mutation associated with bilateral primary uveal melanoma."; RL Ocul. Oncol. Pathol. 6:10-14(2020). RN [43] RP VARIANTS KURIS ALA-12; THR-12; LYS-31; PRO-49; ARG-91; GLY-91; SER-91; RP ARG-169 AND GLN-718, CHARACTERIZATION OF VARIANTS KURIS THR-12; ARG-91; RP SER-91; ARG-169 AND GLN-718, INVOLVEMENT IN KURIS, FUNCTION, AND RP SUBCELLULAR LOCATION. RX PubMed=35051358; DOI=10.1016/j.ajhg.2021.12.011; RG Undiagnosed Diseases Network; RA Kuery S., Ebstein F., Molle A., Besnard T., Lee M.K., Vignard V., Hery T., RA Nizon M., Mancini G.M.S., Giltay J.C., Cogne B., McWalter K., Deb W., RA Mor-Shaked H., Li H., Schnur R.E., Wentzensen I.M., Denomme-Pichon A.S., RA Fourgeux C., Verheijen F.W., Faurie E., Schot R., Stevens C.A., Smits D.J., RA Barr E., Sheffer R., Bernstein J.A., Stimach C.L., Kovitch E., Shashi V., RA Schoch K., Smith W., van Jaarsveld R.H., Hurst A.C.E., Smith K., RA Baugh E.H., Bohm S.G., Vyhnalkova E., Ryba L., Delnatte C., Neira J., RA Bonneau D., Toutain A., Rosenfeld J.A., Audebert-Bellanger S., RA Gilbert-Dussardier B., Odent S., Laumonnier F., Berger S.I., Smith A.C.M., RA Bourdeaut F., Stern M.H., Redon R., Krueger E., Margueron R., Bezieau S., RA Poschmann J., Isidor B.; RT "Rare germline heterozygous missense variants in BRCA1-associated protein RT 1, BAP1, cause a syndromic neurodevelopmental disorder."; RL Am. J. Hum. Genet. 109:361-372(2022). CC -!- FUNCTION: Deubiquitinating enzyme that plays a key role in chromatin by CC mediating deubiquitination of histone H2A and HCFC1 (PubMed:12485996, CC PubMed:18757409, PubMed:20436459, PubMed:25451922, PubMed:35051358). CC Catalytic component of the polycomb repressive deubiquitinase (PR-DUB) CC complex, a complex that specifically mediates deubiquitination of CC histone H2A monoubiquitinated at 'Lys-120' (H2AK119ub1) CC (PubMed:20436459, PubMed:25451922, PubMed:30664650, PubMed:35051358). CC Does not deubiquitinate monoubiquitinated histone H2B (PubMed:20436459, CC PubMed:30664650). The PR-DUB complex is an epigenetic regulator of gene CC expression and acts as a transcriptional coactivator, affecting genes CC involved in development, cell communication, signaling, cell CC proliferation and cell viability (PubMed:20805357, PubMed:30664650, CC PubMed:36180891). Antagonizes PRC1 mediated H2AK119ub1 CC monoubiquitination (PubMed:30664650). As part of the PR-DUB complex, CC associates with chromatin enriched in histone marks H3K4me1, H3K4me3, CC and H3K27Ac, but not in H3K27me3 (PubMed:36180891). Recruited to CC specific gene-regulatory regions by YY1 (PubMed:20805357). Acts as a CC regulator of cell growth by mediating deubiquitination of HCFC1 N- CC terminal and C-terminal chains, with some specificity toward 'Lys-48'- CC linked polyubiquitin chains compared to 'Lys-63'-linked polyubiquitin CC chains (PubMed:19188440, PubMed:19815555). Deubiquitination of HCFC1 CC does not lead to increase stability of HCFC1 (PubMed:19188440, CC PubMed:19815555). Interferes with the BRCA1 and BARD1 heterodimer CC activity by inhibiting their ability to mediate ubiquitination and CC autoubiquitination (PubMed:19117993). It however does not mediate CC deubiquitination of BRCA1 and BARD1 (PubMed:19117993). Able to mediate CC autodeubiquitination via intramolecular interactions to counteract CC monoubiquitination at the nuclear localization signal (NLS), thereby CC protecting it from cytoplasmic sequestration (PubMed:24703950). CC Negatively regulates epithelial-mesenchymal transition (EMT) of CC trophoblast stem cells during placental development by regulating genes CC involved in epithelial cell integrity, cell adhesion and cytoskeletal CC organization (PubMed:34170818). {ECO:0000269|PubMed:12485996, CC ECO:0000269|PubMed:18757409, ECO:0000269|PubMed:19117993, CC ECO:0000269|PubMed:19188440, ECO:0000269|PubMed:19815555, CC ECO:0000269|PubMed:20436459, ECO:0000269|PubMed:20805357, CC ECO:0000269|PubMed:24703950, ECO:0000269|PubMed:25451922, CC ECO:0000269|PubMed:30664650, ECO:0000269|PubMed:34170818, CC ECO:0000269|PubMed:35051358, ECO:0000269|PubMed:36180891}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide CC and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76- CC residue protein attached to proteins as an intracellular targeting CC signal).; EC=3.4.19.12; Evidence={ECO:0000269|PubMed:20436459, CC ECO:0000269|PubMed:30258054, ECO:0000269|PubMed:9528852}; CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=4.7 uM for ubiquitin-7-amido-4-methylcoumarin (UB-AMC) CC {ECO:0000269|PubMed:30258054}; CC -!- SUBUNIT: Core component of the polycomb repressive deubiquitinase (PR- CC DUB) complex, at least composed of BAP1, one of ASXL1, ASXL2 or CC (probably) ASXL3, and one of MBD5 or MBD6 (PubMed:20436459, CC PubMed:24634419, PubMed:30664650, PubMed:36180891). The PR-DUB core CC associates with a number of accessory proteins, including FOXK1, FOXK2, CC KDM1B, HCFC1, YY1 and OGT; KDM1B specifically associates with ASXL2 PR- CC DUB complexes (Probable) (PubMed:20805357, PubMed:30664650). The BAP1 CC deubiquitinase activity is not required for PR-DUB assembly CC (PubMed:20805357). Homodimerizes (via coiled-coil hinge-region between CC the UCH and ULD domains) to mediate assembly of 2 copies of the BAP1- CC ASXL heterodimer into a bisymmetric tetramer; dimerization enhances CC association with nucleosomes (PubMed:30258054, PubMed:35446349). The CC PR-DUB complex associates with nucleosomes to mediate deubiquitination CC of 'lys-120' of histone H2AK118ub1 substrates; the association requires CC the positively charged C-terminal tail of BAP1 (PubMed:30258054, CC PubMed:36991118, PubMed:37556531). Interacts (via ULD domain) with CC ASXL1 (via DEUBAD domain); the interaction is direct and forms a CC ubiquitin binding cleft (PubMed:36180891, PubMed:36991118, CC PubMed:37556531). The interaction with ASXL1 stabilizes BAP1 but is not CC required for nucleosome binding (PubMed:36180891). Associates (via C- CC terminus) with nucleosome and chromatosome complexes through direct CC interaction with DNA and the histone3/4 dimer; this association CC displaces the histone-2A C-terminal tail, extending and orienting the CC H2AK118ub1 substrate towards the BAP1 deubiquitinase active site CC (PubMed:36991118, PubMed:37556531). Also interacts (via arginine CC finger) directly with the histone H2A-H2B acidic patch; this CC interaction is not critical for nucleosome-chromatosome association but CC may play a role in orienting the H2AK118ub1 substrate towards the PR- CC DUB complex active site (PubMed:36991118). Interacts with BRCA1 (via CC the RING finger) (PubMed:19117993, PubMed:9528852). Interacts (via HBM- CC like motif) with HCFC1 (PubMed:19188440, PubMed:19815555, CC PubMed:20805357). Interacts (via a C-terminal region overlapping the CC ULD domain) with YY1; the interaction is direct and requires the CC interaction with HCFC1 (PubMed:20805357). Interacts (when CC phosphorylated at Thr-493) with FOXK1 (PubMed:25451922). Interacts CC (when phosphorylated at Thr-493) with FOXK2; leading to recruitment of CC the PR-DUB complex and repression of FOXK2 target genes CC (PubMed:24748658, PubMed:25451922). Interacts (via non-classical PY- CC NLS) with TNPO1/transportin-1 (via HEAT repeats 8-12); the interaction CC is direct, mediates BAP1 nuclear localization and disrupts BAP1 CC homodimerization (PubMed:35446349). Interacts (via C-terminus) with CC KPNA1/importin alpha5 and KPNA2/importin alpha1; these interactions can CC contribute to BAP1 nuclear localization but are less important than the CC interaction with TNPO1/transportin-1 (PubMed:35446349). The interaction CC with TNPO1/transportin-1 disrupts homodimerization and blocks CC ubiquitination by UBE2O (PubMed:35446349). CC {ECO:0000269|PubMed:19117993, ECO:0000269|PubMed:19188440, CC ECO:0000269|PubMed:19815555, ECO:0000269|PubMed:20436459, CC ECO:0000269|PubMed:20805357, ECO:0000269|PubMed:24634419, CC ECO:0000269|PubMed:24748658, ECO:0000269|PubMed:25451922, CC ECO:0000269|PubMed:30258054, ECO:0000269|PubMed:30664650, CC ECO:0000269|PubMed:35446349, ECO:0000269|PubMed:36180891, CC ECO:0000269|PubMed:36991118, ECO:0000269|PubMed:37556531, CC ECO:0000269|PubMed:9528852, ECO:0000305|PubMed:24634419}. CC -!- INTERACTION: CC Q92560; Q8IXJ9: ASXL1; NbExp=9; IntAct=EBI-1791447, EBI-1646500; CC Q92560; P15056: BRAF; NbExp=4; IntAct=EBI-1791447, EBI-365980; CC Q92560; P38398: BRCA1; NbExp=3; IntAct=EBI-1791447, EBI-349905; CC Q92560; P38398-5: BRCA1; NbExp=2; IntAct=EBI-1791447, EBI-2015072; CC Q92560; P51610: HCFC1; NbExp=6; IntAct=EBI-1791447, EBI-396176; CC Q92560; Q14573: ITPR3; NbExp=12; IntAct=EBI-1791447, EBI-351055; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:18757409, CC ECO:0000269|PubMed:19188440, ECO:0000269|PubMed:19815555, CC ECO:0000269|PubMed:24703950}. Nucleus {ECO:0000269|PubMed:18757409, CC ECO:0000269|PubMed:19188440, ECO:0000269|PubMed:19815555, CC ECO:0000269|PubMed:24703950, ECO:0000269|PubMed:24748658, CC ECO:0000269|PubMed:30664650, ECO:0000269|PubMed:35051358, CC ECO:0000269|PubMed:35446349, ECO:0000269|PubMed:9528852}. Chromosome CC {ECO:0000269|PubMed:30664650}. Note=Mainly nuclear (PubMed:24703950, CC PubMed:30664650). Binds to chromatin (PubMed:30664650). Localizes to CC the cytoplasm when monoubiquitinated by the E2/E3 hybrid ubiquitin- CC protein ligase UBE2O (PubMed:24703950). Recruitment to chromatin is CC dependent on ASXL1/2/3 and recruitment to specific genes on FOXK1/2 (By CC similarity). Nuclear localization is redundantly mediated by the CC importin and transportin systems; TNPO1/transportin-1 is the major CC mediator of nuclear localization (PubMed:35446349). CC {ECO:0000250|UniProtKB:Q99PU7, ECO:0000269|PubMed:24703950, CC ECO:0000269|PubMed:30664650, ECO:0000269|PubMed:35446349}. CC -!- TISSUE SPECIFICITY: Highly expressed in testis, placenta and ovary CC (PubMed:9528852). Expressed in breast (PubMed:9528852). levels in the CC placenta increase over the course of pregnancy (PubMed:34170818). CC {ECO:0000269|PubMed:34170818, ECO:0000269|PubMed:9528852}. CC -!- DEVELOPMENTAL STAGE: Expressed in trophoblast stem cells during CC placenta development (at protein levels) (PubMed:34170818). Decreased CC expression levels correlate with epithelial-mesenchymal transition CC (EMT) during trophoblast cell differentiation (at protein level) CC (PubMed:34170818). {ECO:0000269|PubMed:34170818}. CC -!- DOMAIN: Possesses 2 overlapping nuclear localization sequences (NLS), a CC classic bipartite NLS and a non-classical PY-NLS (PubMed:35446349). The CC classical NLS probably mediates import via the importin alpha/beta CC system while the PY-NLS mediates nuclear import via the transportin CC system (PubMed:35446349). {ECO:0000269|PubMed:35446349}. CC -!- DOMAIN: The positively charged C-terminal tail stabilizes the CC interaction with nucleosomes/chromatosomes through interaction with the CC DNA backbone (PubMed:30258054, PubMed:36991118). Binding of ASXL1 just CC upstream of the positively charged C-terminal tail may stabilize its CC orientation to align the PR-DUB with its H2AK118ub1 substrate CC (PubMed:36991118). {ECO:0000269|PubMed:30258054, CC ECO:0000269|PubMed:36991118}. CC -!- DOMAIN: The ubiquitin C-terminal hydrolase (UCH) domain, together with CC the DEUBAD domain of ASXL1, forms the ubiquitin binding cleft of the CC PR-DUB complex. {ECO:0000269|PubMed:36991118, CC ECO:0000269|PubMed:37556531}. CC -!- DOMAIN: The positively charged Arg-finger motif mediates interaction CC with the histone H2A-H2B acidic patch; this interaction is critical for CC nucleosomal H2AK119ub1 deubiquitination activity but not nucleosomal CC binding. {ECO:0000269|PubMed:37556531}. CC -!- PTM: Ubiquitinated: monoubiquitinated at multiple sites within its CC nuclear localization signal (NLS) BY UBE2O, leading to cytoplasmic CC retention (PubMed:24703950). Able to mediate autodeubiquitination via CC intramolecular interactions to counteract cytoplasmic retention CC (PubMed:24703950). Monoubiquitinated on at least 4 sites near or within CC its PY-NLS (PubMed:35446349). {ECO:0000269|PubMed:24703950, CC ECO:0000269|PubMed:35446349}. CC -!- DISEASE: Mesothelioma, malignant (MESOM) [MIM:156240]: An aggressive CC neoplasm of the serosal lining of the chest. It appears as broad sheets CC of cells, with some regions containing spindle-shaped, sarcoma-like CC cells and other regions showing adenomatous patterns. Pleural CC mesotheliomas have been linked to exposure to asbestos. CC {ECO:0000269|PubMed:21642991, ECO:0000269|PubMed:21874000}. Note=The CC gene represented in this entry is involved in disease pathogenesis. CC -!- DISEASE: Tumor predisposition syndrome 1 (TPDS1) [MIM:614327]: An CC autosomal dominant condition characterized by predisposition to develop CC a variety of tumors, including benign melanocytic tumors as well as CC several malignant tumors, including uveal melanoma, cutaneous melanoma, CC malignant mesothelioma on exposure to asbestos, lung adenocarcinoma and CC meningioma. {ECO:0000269|PubMed:21874000, ECO:0000269|PubMed:21874003, CC ECO:0000269|PubMed:21941004, ECO:0000269|PubMed:23684012}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Melanoma, uveal, 2 (UVM2) [MIM:606661]: Most common CC intraocular malignancy, arising from melanocytes in the iris, ciliary CC body, or choroid. Metastases develop in more than 30% of case patients, CC almost invariably in the liver, with poor prognosis. CC {ECO:0000269|PubMed:25687217, ECO:0000269|PubMed:32002398}. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. CC -!- DISEASE: Kury-Isidor syndrome (KURIS) [MIM:619762]: An autosomal CC dominant neurodevelopmental disorder characterized mainly by mild CC global developmental delay apparent from infancy or early childhood, CC and behavioral problems, including autism in most patients. CC Intellectual development may be mildly delayed, borderline, or even CC normal. Additional variable systemic features may include poor overall CC growth, hypotonia, distal skeletal anomalies, seizures, and non- CC specific dysmorphic facial features. {ECO:0000269|PubMed:19117993, CC ECO:0000269|PubMed:19815555, ECO:0000269|PubMed:20805357, CC ECO:0000269|PubMed:25451922, ECO:0000269|PubMed:35051358}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- MISCELLANEOUS: May act as a tumor suppressor. CC {ECO:0000269|PubMed:9528852}. CC -!- SIMILARITY: Belongs to the peptidase C12 family. BAP1 subfamily. CC {ECO:0000305}. CC -!- CAUTION: According to a report, interaction with FOXK2 is not dependent CC on phosphorylation of BAP1 (PubMed:24748658). However, it was later CC shown that phosphorylation at Thr-493 promotes interaction with FOXK2 CC (PubMed:25451922). {ECO:0000269|PubMed:24748658, CC ECO:0000269|PubMed:25451922}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA13401.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/755/BAP1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF045581; AAC15970.1; -; mRNA. DR EMBL; D88812; BAB46921.1; -; mRNA. DR EMBL; D87462; BAA13401.2; ALT_INIT; mRNA. DR EMBL; AK292608; BAF85297.1; -; mRNA. DR EMBL; CH471055; EAW65220.1; -; Genomic_DNA. DR EMBL; BC001596; AAH01596.1; -; mRNA. DR EMBL; AY130008; AAN05092.1; -; mRNA. DR CCDS; CCDS2853.1; -. DR RefSeq; NP_004647.1; NM_004656.4. DR PDB; 7VPW; X-ray; 3.76 A; B=706-724. DR PDB; 8H1T; EM; 3.00 A; L=1-729. DR PDB; 8SVF; EM; 3.20 A; K=1-729. DR PDBsum; 7VPW; -. DR PDBsum; 8H1T; -. DR PDBsum; 8SVF; -. DR AlphaFoldDB; Q92560; -. DR EMDB; EMD-34431; -. DR EMDB; EMD-40789; -. DR SMR; Q92560; -. DR BioGRID; 113911; 1328. DR ComplexPortal; CPX-414; PR-DUB complex. DR CORUM; Q92560; -. DR DIP; DIP-47004N; -. DR FunCoup; Q92560; 3418. DR IntAct; Q92560; 113. DR MINT; Q92560; -. DR STRING; 9606.ENSP00000417132; -. DR BindingDB; Q92560; -. DR ChEMBL; CHEMBL1293314; -. DR MEROPS; C12.004; -. DR GlyGen; Q92560; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q92560; -. DR MetOSite; Q92560; -. DR PhosphoSitePlus; Q92560; -. DR BioMuta; BAP1; -. DR DMDM; 68565074; -. DR jPOST; Q92560; -. DR MassIVE; Q92560; -. DR PaxDb; 9606-ENSP00000417132; -. DR PeptideAtlas; Q92560; -. DR ProteomicsDB; 75316; -. DR Pumba; Q92560; -. DR Antibodypedia; 3812; 492 antibodies from 39 providers. DR DNASU; 8314; -. DR Ensembl; ENST00000460680.6; ENSP00000417132.1; ENSG00000163930.10. DR GeneID; 8314; -. DR KEGG; hsa:8314; -. DR MANE-Select; ENST00000460680.6; ENSP00000417132.1; NM_004656.4; NP_004647.1. DR UCSC; uc003ddx.5; human. DR AGR; HGNC:950; -. DR CIViC; 8314; 18 evidence items across 13 molecular profiles. DR ClinPGx; PA25254; -. DR CTD; 8314; -. DR DisGeNET; 8314; -. DR GeneCards; BAP1; -. DR GeneReviews; BAP1; -. DR HGNC; HGNC:950; BAP1. DR HPA; ENSG00000163930; Low tissue specificity. DR MalaCards; BAP1; -. DR MIM; 156240; phenotype. DR MIM; 603089; gene. DR MIM; 606661; phenotype. DR MIM; 614327; phenotype. DR MIM; 619762; phenotype. DR OpenTargets; ENSG00000163930; -. DR Orphanet; 289539; BAP1-related tumor predisposition syndrome. DR Orphanet; 618; Familial melanoma. DR Orphanet; 2495; Meningioma. DR Orphanet; 528084; Non-specific syndromic intellectual disability. DR Orphanet; 50251; Pleural mesothelioma. DR Orphanet; 39044; Uveal melanoma. DR VEuPathDB; HostDB:ENSG00000163930; -. DR eggNOG; KOG2778; Eukaryota. DR GeneTree; ENSGT00940000156388; -. DR HOGENOM; CLU_018316_5_0_1; -. DR InParanoid; Q92560; -. DR OMA; RIAYEQK; -. DR OrthoDB; 1924260at2759; -. DR PAN-GO; Q92560; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q92560; -. DR BRENDA; 3.4.19.12; 2681. DR PathwayCommons; Q92560; -. DR Reactome; R-HSA-5689603; UCH proteinases. DR Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks. DR SignaLink; Q92560; -. DR SIGNOR; Q92560; -. DR Agora; ENSG00000163930; -. DR BioGRID-ORCS; 8314; 488 hits in 1221 CRISPR screens. DR ChiTaRS; BAP1; human. DR GeneWiki; BAP1; -. DR GenomeRNAi; 8314; -. DR Pharos; Q92560; Tbio. DR PRO; PR:Q92560; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q92560; protein. DR Bgee; ENSG00000163930; Expressed in left testis and 164 other cell types or tissues. DR ExpressionAtlas; Q92560; baseline and differential. DR GO; GO:0005694; C:chromosome; IEA:UniProtKB-SubCell. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0035517; C:PR-DUB complex; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0031490; F:chromatin DNA binding; IEA:Ensembl. DR GO; GO:0004843; F:cysteine-type deubiquitinase activity; IDA:UniProtKB. DR GO; GO:0140950; F:histone H2A deubiquitinase activity; IMP:UniProtKB. DR GO; GO:0008233; F:peptidase activity; NAS:UniProtKB. DR GO; GO:0035726; P:common myeloid progenitor cell proliferation; IEA:Ensembl. DR GO; GO:0043249; P:erythrocyte maturation; IEA:Ensembl. DR GO; GO:0010467; P:gene expression; IEA:Ensembl. DR GO; GO:0061484; P:hematopoietic stem cell homeostasis; IEA:Ensembl. DR GO; GO:0031507; P:heterochromatin formation; IBA:GO_Central. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0070661; P:leukocyte proliferation; IEA:Ensembl. DR GO; GO:0061519; P:macrophage homeostasis; IEA:Ensembl. DR GO; GO:0000278; P:mitotic cell cycle; IEA:Ensembl. DR GO; GO:0035520; P:monoubiquitinated protein deubiquitination; IDA:UniProtKB. DR GO; GO:0033028; P:myeloid cell apoptotic process; IEA:Ensembl. DR GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:ProtInc. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0070050; P:neuron cellular homeostasis; IEA:Ensembl. DR GO; GO:0030223; P:neutrophil differentiation; IEA:Ensembl. DR GO; GO:0043363; P:nucleate erythrocyte differentiation; IEA:Ensembl. DR GO; GO:0036344; P:platelet morphogenesis; IEA:Ensembl. DR GO; GO:1903955; P:positive regulation of protein targeting to mitochondrion; HMP:ParkinsonsUK-UCL. DR GO; GO:0016579; P:protein deubiquitination; IDA:UniProtKB. DR GO; GO:0071108; P:protein K48-linked deubiquitination; IMP:UniProtKB. DR GO; GO:0036211; P:protein modification process; NAS:UniProtKB. DR GO; GO:0051726; P:regulation of cell cycle; IMP:UniProtKB. DR GO; GO:0001558; P:regulation of cell growth; IMP:UniProtKB. DR GO; GO:1900015; P:regulation of cytokine production involved in inflammatory response; IEA:Ensembl. DR GO; GO:0050727; P:regulation of inflammatory response; IEA:Ensembl. DR GO; GO:0002574; P:thrombocyte differentiation; IEA:Ensembl. DR GO; GO:0001894; P:tissue homeostasis; IEA:Ensembl. DR GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IEA:InterPro. DR CDD; cd09617; Peptidase_C12_UCH37_BAP1; 1. DR FunFam; 1.20.58.860:FF:000002; Ubiquitin carboxyl-terminal hydrolase; 1. DR FunFam; 3.40.532.10:FF:000002; Ubiquitin carboxyl-terminal hydrolase; 1. DR Gene3D; 1.20.58.860; -; 1. DR Gene3D; 3.40.532.10; Peptidase C12, ubiquitin carboxyl-terminal hydrolase; 1. DR InterPro; IPR038765; Papain-like_cys_pep_sf. DR InterPro; IPR001578; Peptidase_C12_UCH. DR InterPro; IPR036959; Peptidase_C12_UCH_sf. DR InterPro; IPR041507; UCH_C. DR PANTHER; PTHR10589; UBIQUITIN CARBOXYL-TERMINAL HYDROLASE; 1. DR PANTHER; PTHR10589:SF28; UBIQUITIN CARBOXYL-TERMINAL HYDROLASE BAP1; 1. DR Pfam; PF01088; Peptidase_C12; 1. DR Pfam; PF18031; UCH_C; 1. DR PRINTS; PR00707; UBCTHYDRLASE. DR SUPFAM; SSF54001; Cysteine proteinases; 1. DR PROSITE; PS52048; UCH_DOMAIN; 1. DR PROSITE; PS52049; ULD; 1. PE 1: Evidence at protein level; KW 3D-structure; Chromatin regulator; Chromosome; Coiled coil; Cytoplasm; KW Developmental protein; Differentiation; Disease variant; Hydrolase; KW Intellectual disability; Nucleus; Phosphoprotein; Protease; KW Proteomics identification; Reference proteome; Thiol protease; KW Ubl conjugation; Ubl conjugation pathway. FT CHAIN 1..729 FT /note="Ubiquitin carboxyl-terminal hydrolase BAP1" FT /id="PRO_0000211069" FT DOMAIN 4..235 FT /note="UCH catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01393" FT DOMAIN 670..698 FT /note="ULD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01394" FT REGION 301..351 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 372..435 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 464..524 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 575..623 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 596..721 FT /note="Interaction with BRCA1" FT REGION 642..686 FT /note="Interaction with YY1" FT /evidence="ECO:0000269|PubMed:20805357" FT REGION 699..701 FT /note="Interaction with nucleosomal DNA forming a DNA clamp FT with ASXL1" FT /evidence="ECO:0000269|PubMed:37556531" FT REGION 703..729 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 713..729 FT /note="Positively charged C-terminal extension (CTE)" FT /evidence="ECO:0000269|PubMed:30258054, FT ECO:0000269|PubMed:36991118" FT COILED 636..656 FT /evidence="ECO:0000255" FT MOTIF 56..60 FT /note="Arg-finger motif" FT /evidence="ECO:0000269|PubMed:37556531" FT MOTIF 363..366 FT /note="HBM-like motif" FT /evidence="ECO:0000269|PubMed:19188440, FT ECO:0000269|PubMed:19815555, ECO:0000269|PubMed:20805357, FT ECO:0000269|PubMed:25451922" FT MOTIF 699..722 FT /note="Classical bipartite Nuclear localization signal FT (NLS)" FT /evidence="ECO:0000269|PubMed:18757409, FT ECO:0000269|PubMed:24703950, ECO:0000269|PubMed:35446349" FT MOTIF 717..724 FT /note="Non-classical PY-nuclear localization signal (PY- FT NLS)" FT /evidence="ECO:0000269|PubMed:35446349" FT COMPBIAS 395..409 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 480..524 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 582..598 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 599..614 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 91 FT /note="Nucleophile" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01393, FT ECO:0000269|PubMed:18757409, ECO:0000269|PubMed:19117993, FT ECO:0000269|PubMed:19188440, ECO:0000269|PubMed:19815555, FT ECO:0000269|PubMed:25451922, ECO:0000269|PubMed:9528852" FT ACT_SITE 169 FT /note="Proton donor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01393" FT SITE 85 FT /note="Transition state stabilizer" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01393" FT SITE 184 FT /note="Important for enzyme activity" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01393" FT MOD_RES 292 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 369 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 395 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q99PU7" FT MOD_RES 493 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:25451922" FT MOD_RES 521 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 537 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 585 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 597 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VARIANT 12 FT /note="P -> A (in KURIS; dbSNP:rs2153228682)" FT /evidence="ECO:0000269|PubMed:35051358" FT /id="VAR_086937" FT VARIANT 12 FT /note="P -> T (in KURIS; loss-of-function variant; FT increased steady-state levels of ubiquitinated H2A are FT found in patient cells; unable to rescue impaired H2AK119ub FT deubiquitination when expressed in BAP1-deficient cells; FT does not affect localization to the nucleus; FT dbSNP:rs2153228682)" FT /evidence="ECO:0000269|PubMed:35051358" FT /id="VAR_086938" FT VARIANT 31 FT /note="E -> K (in KURIS; uncertain significance; FT dbSNP:rs2153228535)" FT /evidence="ECO:0000269|PubMed:35051358" FT /id="VAR_086939" FT VARIANT 47 FT /note="I -> F (found in a primary uveal melanoma; somatic FT mutation; induces cytoplasmic accumulation; loss of FT deubiquitinase activity; up-regulates heat shock response; FT induces formation of amyloid-beta aggregates; FT dbSNP:rs2153228345)" FT /evidence="ECO:0000269|PubMed:25080371, FT ECO:0000269|PubMed:26680512" FT /id="VAR_075251" FT VARIANT 49 FT /note="L -> P (in KURIS; uncertain significance; FT dbSNP:rs2153228340)" FT /evidence="ECO:0000269|PubMed:35051358" FT /id="VAR_086940" FT VARIANT 63 FT /note="S -> C (found in a malignant pleural mesothelioma FT sample; somatic mutation; dbSNP:rs747311942)" FT /evidence="ECO:0000269|PubMed:21642991" FT /id="VAR_065976" FT VARIANT 81 FT /note="F -> V (found in a malignant pleural mesothelioma FT sample; somatic mutation; induces cytoplasmic accumulation; FT loss of deubiquitinase activity; up-regulates heat shock FT response; induces formation of amyloid-beta aggregates)" FT /evidence="ECO:0000269|PubMed:21642991, FT ECO:0000269|PubMed:26680512" FT /id="VAR_065977" FT VARIANT 91 FT /note="C -> G (in KURIS; dbSNP:rs1705222655)" FT /evidence="ECO:0000269|PubMed:35051358" FT /id="VAR_086941" FT VARIANT 91 FT /note="C -> R (in KURIS; loss-of-function variant; unable FT to rescue impaired H2AK119ub deubiquitination when FT expressed in BAP1-deficient cells; does not affect FT localization to the nucleus; dbSNP:rs1705222655)" FT /evidence="ECO:0000269|PubMed:35051358" FT /id="VAR_086942" FT VARIANT 91 FT /note="C -> S (in KURIS; loss-of-function variant; FT increased steady-state level of ubiquitinated H2A are found FT in patient cells; unable to rescue impaired H2AK119ub FT deubiquitination when expressed in BAP1-deficient cells; FT abolishes deubiquitinase activity; does not affect its FT ability to interfere with BRCA1 E3 ligase activity; does FT not affect localization to the nucleus; has a dominant FT negative effect on cell growth; does not affect interaction FT with FOXK1 and FOXK2; has no effect on PR-DUB complex FT assembly; unable to activate transcription; FT dbSNP:rs1559591264)" FT /evidence="ECO:0000269|PubMed:19117993, FT ECO:0000269|PubMed:19815555, ECO:0000269|PubMed:20805357, FT ECO:0000269|PubMed:25451922, ECO:0000269|PubMed:35051358" FT /id="VAR_086943" FT VARIANT 91 FT /note="C -> W (found in a malignant pleural mesothelioma FT sample; dbSNP:rs2153228144)" FT /evidence="ECO:0000269|PubMed:21642991" FT /id="VAR_065978" FT VARIANT 93 FT /note="T -> A (in TPDS1; significantly increased risk for FT renal cell carcinoma; dbSNP:rs375129361)" FT /evidence="ECO:0000269|PubMed:23684012" FT /id="VAR_087531" FT VARIANT 95 FT /note="A -> D (in a lung cancer sample; also found in a FT malignant pleural mesothelioma cell line; induces FT cytoplasmic accumulation; loss of deubiquitinase activity; FT up-regulates heat shock response; induces formation of FT amyloid-beta aggregates)" FT /evidence="ECO:0000269|PubMed:10546591, FT ECO:0000269|PubMed:18757409, ECO:0000269|PubMed:21642991, FT ECO:0000269|PubMed:26680512" FT /id="VAR_063498" FT VARIANT 169 FT /note="H -> R (in KURIS; loss-of-function variant; unable FT to rescue impaired H2AK119ub deubiquitination when FT expressed in BAP1-deficient cells; does not affect FT localization to the nucleus; dbSNP:rs2153227828)" FT /evidence="ECO:0000269|PubMed:35051358" FT /id="VAR_086944" FT VARIANT 178 FT /note="G -> V (in a lung cancer sample; induces cytoplasmic FT accumulation; impairs deubiquitinase activity; up-regulates FT heat shock response; induces formation of beta-amyloid FT aggregates; dbSNP:rs2153227803)" FT /evidence="ECO:0000269|PubMed:10546591, FT ECO:0000269|PubMed:18757409, ECO:0000269|PubMed:26680512" FT /id="VAR_063499" FT VARIANT 267..729 FT /note="Missing (in TPDS1)" FT /evidence="ECO:0000269|PubMed:21941004" FT /id="VAR_087532" FT VARIANT 315 FT /note="E -> A (found in a malignant pleural mesothelioma FT sample; dbSNP:rs149974450)" FT /evidence="ECO:0000269|PubMed:21642991" FT /id="VAR_065979" FT VARIANT 616 FT /note="V -> E (in dbSNP:rs35353781)" FT /id="VAR_051517" FT VARIANT 685 FT /note="E -> V (found in a malignant pleural mesothelioma FT cell line)" FT /evidence="ECO:0000269|PubMed:21642991" FT /id="VAR_065980" FT VARIANT 718 FT /note="R -> Q (in KURIS; uncertain significance; able to FT rescue impaired H2AK119ub deubiquitination when expressed FT in BAP1-deficient cells; does not affect localization to FT the nucleus; dbSNP:rs1440748203)" FT /evidence="ECO:0000269|PubMed:35051358" FT /id="VAR_086945" FT MUTAGEN 56..60 FT /note="RRSRR->AASAA: Probably disrupts interaction with the FT histone H2A-H2B acidic patch. Severely attenuates FT deubiquitination of histone H2AK119ub1 substrates in the FT context of the nucleosome but does not disrupt nucleosome FT interaction." FT /evidence="ECO:0000269|PubMed:36991118, FT ECO:0000269|PubMed:37556531" FT MUTAGEN 56 FT /note="R->C: Reduces deubiquitination activity towards FT H2AK119ub1 substrates in the context of the nucleosome." FT /evidence="ECO:0000269|PubMed:37556531" FT MUTAGEN 59 FT /note="R->W: Reduces deubiquitination activity towards FT H2AK119ub1 substrates in the context of the nucleosome." FT /evidence="ECO:0000269|PubMed:37556531" FT MUTAGEN 91 FT /note="C->A: Abolishes deubiquitinase activity. Has no FT effect on interaction with HCFC1." FT /evidence="ECO:0000269|PubMed:18757409, FT ECO:0000269|PubMed:19188440, ECO:0000269|PubMed:9528852" FT MUTAGEN 251 FT /note="N->R: Severely attenuates deubiquitination of FT histone H2AK119ub1 substrates, possibly due to disruption FT of homodimerization." FT /evidence="ECO:0000269|PubMed:30258054" FT MUTAGEN 363..366 FT /note="NHNY->AAAA: Abolishes interaction with HCFC1 without FT affecting interaction with FOXK1 and FOXK2." FT /evidence="ECO:0000269|PubMed:19188440, FT ECO:0000269|PubMed:19815555, ECO:0000269|PubMed:25451922" FT MUTAGEN 489 FT /note="S->A: Does not affect interaction with FOXK1 and FT FOXK2." FT /evidence="ECO:0000269|PubMed:25451922" FT MUTAGEN 492 FT /note="S->A: Does not affect interaction with FOXK1 and FT FOXK2." FT /evidence="ECO:0000269|PubMed:25451922" FT MUTAGEN 493 FT /note="T->A,L: Abolished interaction with FOXK1 and FOXK2." FT /evidence="ECO:0000269|PubMed:25451922" FT MUTAGEN 495 FT /note="T->A: Does not affect interaction with FOXK1 and FT FOXK2." FT /evidence="ECO:0000269|PubMed:25451922" FT MUTAGEN 635 FT /note="L->A: Severely attenuated deubiquitination of FT histone H2AK119ub1 substrates, possibly due to disruption FT of homodimerization. No effect on intrinsic catalytic FT activity." FT /evidence="ECO:0000269|PubMed:30258054" FT MUTAGEN 656..661 FT /note="KRKKFK->AAAAAA: Does not affect nuclear FT localization." FT /evidence="ECO:0000269|PubMed:18757409" FT MUTAGEN 684..729 FT /note="Missing: Predominantly localizes to the cytosol." FT /evidence="ECO:0000269|PubMed:35446349" FT MUTAGEN 691..711 FT /note="Missing: Abolishes ubiquitination by UBE2O." FT /evidence="ECO:0000269|PubMed:24703950" FT MUTAGEN 691 FT /note="L->P: Abolishes interaction with BRCA1." FT /evidence="ECO:0000269|PubMed:9528852" FT MUTAGEN 697..729 FT /note="Missing: Abolishes deubiquitination activity towards FT H2AK119ub1 substrates in the context of the nucleosome, FT probably due to disruption of nucleosome interaction. Does FT not affect deubiquitination of H2AK119ub1 on free FT histones." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 699..702 FT /note="Missing: Severely reduces deubiquitination activity FT towards H2AK119ub1 substrates in the context of the FT nucleosome but only mildly disrupts nucleosome FT interaction." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 699..701 FT /note="RRR->AAA: Reduced nucleosomal binding." FT /evidence="ECO:0000269|PubMed:37556531" FT MUTAGEN 699..700 FT /note="RR->DD: Reduced nucleosomal binding." FT /evidence="ECO:0000269|PubMed:37556531" FT MUTAGEN 699 FT /note="R->W: Slight or no reduction of deubiquitination FT efficiency towards H2AK119ub1 substrates in the context of FT the nucleosome." FT /evidence="ECO:0000269|PubMed:36991118, FT ECO:0000269|PubMed:37556531" FT MUTAGEN 700 FT /note="R->Q: Slightly reduces deubiquitination activity FT towards H2AK119ub1 substrates in the context of the FT nucleosome." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 701 FT /note="R->C: Reduces deubiquitination activity towards FT H2AK119ub1 substrates in the context of the nucleosome." FT /evidence="ECO:0000269|PubMed:36991118, FT ECO:0000269|PubMed:37556531" FT MUTAGEN 702 FT /note="Missing: Slightly reduces deubiquitination activity FT towards H2AK119ub1 substrates in the context of the FT nucleosome." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 703 FT /note="G->P,R: Reduces deubiquitination activity towards FT H2AK119ub1 substrates in the context of the nucleosome." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 708 FT /note="R->A: Reduces deubiquitination activity towards FT H2AK119ub1 substrates in the context of the nucleosome." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 711..729 FT /note="Missing: Disrupts nucleosome interaction and FT abolishes deubiquitination activity towards H2AK119ub1 FT substrates in the context of the nucleosome. Does not FT affect deubiquitination of H2AK119ub1 on free histones." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 711..718 FT /note="Missing: Reduces deubiquitination activity towards FT H2AK119ub1 substrates in the context of the nucleosome, FT probably due to disruption of nucleosome interaction. Does FT not affect deubiquitination of H2AK119ub1 on free FT histones." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 713..729 FT /note="Missing: Impairs deubiquitination activity of FT histone H2AK118ub1 substrates, probably due to disruption FT of nucleosome association." FT /evidence="ECO:0000269|PubMed:30258054" FT MUTAGEN 713 FT /note="R->A: Reduces deubiquitination activity towards FT H2AK119ub1 substrates in the context of the nucleosome." FT /evidence="ECO:0000269|PubMed:36991118" FT MUTAGEN 717..722 FT /note="RRKRSR->AAAAAA: Abolishes nuclear localization." FT /evidence="ECO:0000269|PubMed:18757409" FT MUTAGEN 718..729 FT /note="Missing: Disrupts nucleosome interaction and reduces FT deubiquitination activity towards H2AK119ub1 substrates in FT the context of the nucleosome." FT /evidence="ECO:0000269|PubMed:36991118" FT HELIX 12..22 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 28..30 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 37..39 FT /evidence="ECO:0007829|PDB:8SVF" FT STRAND 46..52 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 55..59 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 68..70 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 75..79 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 91..101 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 105..107 FT /evidence="ECO:0007829|PDB:8SVF" FT HELIX 110..119 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 120..122 FT /evidence="ECO:0007829|PDB:8SVF" FT HELIX 124..132 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 135..143 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 148..151 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 167..175 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 178..186 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 187..189 FT /evidence="ECO:0007829|PDB:8SVF" FT STRAND 191..195 FT /evidence="ECO:0007829|PDB:8SVF" FT STRAND 198..200 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 203..217 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 220..222 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 228..234 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 237..242 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 648..667 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 672..685 FT /evidence="ECO:0007829|PDB:8H1T" FT HELIX 688..694 FT /evidence="ECO:0007829|PDB:8H1T" FT STRAND 700..703 FT /evidence="ECO:0007829|PDB:8H1T" FT TURN 710..712 FT /evidence="ECO:0007829|PDB:8SVF" SQ SEQUENCE 729 AA; 80362 MW; 031DA03AE1841D85 CRC64; MNKGWLELES DPGLFTLLVE DFGVKGVQVE EIYDLQSKCQ GPVYGFIFLF KWIEERRSRR KVSTLVDDTS VIDDDIVNNM FFAHQLIPNS CATHALLSVL LNCSSVDLGP TLSRMKDFTK GFSPESKGYA IGNAPELAKA HNSHARPEPR HLPEKQNGLS AVRTMEAFHF VSYVPITGRL FELDGLKVYP IDHGPWGEDE EWTDKARRVI MERIGLATAG EPYHDIRFNL MAVVPDRRIK YEARLHVLKV NRQTVLEALQ QLIRVTQPEL IQTHKSQESQ LPEESKSASN KSPLVLEANR APAASEGNHT DGAEEAAGSC AQAPSHSPPN KPKLVVKPPG SSLNGVHPNP TPIVQRLPAF LDNHNYAKSP MQEEEDLAAG VGRSRVPVRP PQQYSDDEDD YEDDEEDDVQ NTNSALRYKG KGTGKPGALS GSADGQLSVL QPNTINVLAE KLKESQKDLS IPLSIKTSSG AGSPAVAVPT HSQPSPTPSN ESTDTASEIG SAFNSPLRSP IRSANPTRPS SPVTSHISKV LFGEDDSLLR VDCIRYNRAV RDLGPVISTG LLHLAEDGVL SPLALTEGGK GSSPSIRPIQ GSQGSSSPVE KEVVEATDSR EKTGMVRPGE PLSGEKYSPK ELLALLKCVE AEIANYEACL KEEVEKRKKF KIDDQRRTHN YDEFICTFIS MLAQEGMLAN LVEQNISVRR RQGVSIGRLH KQRKPDRRKR SRPYKAKRQ // ID BAX_HUMAN Reviewed; 192 AA. AC Q07812; A8K4W1; P55269; Q07814; Q07815; Q8WZ49; Q9NR76; Q9NYG7; Q9UCZ6; AC Q9UCZ7; Q9UQD6; DT 01-FEB-1995, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1995, sequence version 1. DT 28-JAN-2026, entry version 246. DE RecName: Full=Apoptosis regulator BAX; DE AltName: Full=Bcl-2-like protein 4; DE Short=Bcl2-L-4; GN Name=BAX; Synonyms=BCL2L4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA; BETA AND GAMMA), FUNCTION, RP SUBUNIT, AND SUBCELLULAR LOCATION. RC TISSUE=B-cell; RX PubMed=8358790; DOI=10.1016/0092-8674(93)90509-o; RA Oltvai Z.N., Milliman C.L., Korsmeyer S.J.; RT "Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that RT accelerates programmed cell death."; RL Cell 74:609-619(1993). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM DELTA). RX PubMed=7607685; DOI=10.1016/0888-7543(95)80180-t; RA Apte S.S., Mattei M.-G., Olsen B.R.; RT "Mapping of the human BAX gene to chromosome 19q13.3-q13.4 and isolation of RT a novel alternatively spliced transcript, BAX delta."; RL Genomics 26:592-594(1995). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM EPSILON). RC TISSUE=Brain; RX PubMed=9920818; DOI=10.1006/bbrc.1998.0130; RA Shi B., Triebe D., Kajiji S., Iwata K.K., Bruskin A., Mahajna J.; RT "Identification and characterization of baxepsilon, a novel bax variant RT missing the BH2 and the transmembrane domains."; RL Biochem. Biophys. Res. Commun. 254:779-785(1999). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA AND SIGMA), FUNCTION, RP INTERACTION WITH BCL2A1 AND BCL2L1, AND TISSUE SPECIFICITY. RX PubMed=10772918; DOI=10.1006/bbrc.2000.2537; RA Schmitt E., Paquet C., Beauchemin M., Dever-Bertrand J., Bertrand R.; RT "Characterization of Bax-sigma, a cell death-inducing isoform of Bax."; RL Biochem. Biophys. Res. Commun. 270:868-879(2000). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PSI), AND TISSUE SPECIFICITY. RX PubMed=11912183; DOI=10.1093/hmg/11.6.675; RA Cartron P.F., Oliver L., Martin S., Moreau C., LeCabellec M.T., RA Jezequel P., Meflah K., Vallette F.M.; RT "The expression of a new variant of the pro-apoptotic molecule Bax, Baxpsi, RT is correlated with an increased survival of glioblastoma multiforme RT patients."; RL Hum. Mol. Genet. 11:675-687(2002). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ZETA). RC TISSUE=Ovarian carcinoma; RA Perez R.P., Sanville H.; RT "Bax mRNA splice variant lacking exons 2 and 3."; RL Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA). RC TISSUE=Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 63-77 AND 98-118, AND VARIANTS ARG-67 AND RP VAL-108. RX PubMed=7475270; RA Meijerink J.P.P., Smetsers T.F.C.M., Sloetjes A.W., Linders E.H.P., RA Mensink E.J.B.M.; RT "Bax mutations in cell lines derived from hematological malignancies."; RL Leukemia 9:1828-1832(1995). RN [12] RP MUTAGENESIS, AND FUNCTION OF BH3 MOTIF. RX PubMed=8521816; DOI=10.1002/j.1460-2075.1995.tb00246.x; RA Chittenden T., Flemington C., Houghton A.B., Ebb R.G., Gallo G.J., RA Elangovan B., Chinnadurai G., Lutz R.J.; RT "A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death RT and protein binding functions."; RL EMBO J. 14:5589-5596(1995). RN [13] RP SUBCELLULAR LOCATION, AND MUTAGENESIS OF SER-184. RX PubMed=10228148; DOI=10.1093/emboj/18.9.2330; RA Nechushtan A., Smith C.L., Hsu Y.-T., Youle R.J.; RT "Conformation of the Bax C-terminus regulates subcellular location and cell RT death."; RL EMBO J. 18:2330-2341(1999). RN [14] RP FUNCTION, AND INTERACTION WITH MOAP1. RX PubMed=11060313; DOI=10.1074/jbc.m008955200; RA Tan K.O., Tan K.M.L., Chan S.-L., Yee K.S.Y., Bevort M., Ang K.C., Yu V.C.; RT "MAP-1, a novel proapoptotic protein containing a BH3-like motif that RT associates with Bax through its Bcl-2 homology domains."; RL J. Biol. Chem. 276:2802-2807(2001). RN [15] RP INTERACTION WITH SH3GLB1. RX PubMed=11259440; DOI=10.1074/jbc.m101527200; RA Cuddeback S.M., Yamaguchi H., Komatsu K., Miyashita T., Yamada M., Wu C., RA Singh S., Wang H.-G.; RT "Molecular cloning and characterization of Bif-1. A novel Src homology 3 RT domain-containing protein that associates with Bax."; RL J. Biol. Chem. 276:20559-20565(2001). RN [16] RP INTERACTION WITH ADENOVIRUS PROTEIN E1B 19K. RX PubMed=11462023; DOI=10.1128/jvi.75.16.7506-7516.2001; RA Sundararajan R., White E.; RT "E1B 19K blocks Bax oligomerization and tumor necrosis factor alpha- RT mediated apoptosis."; RL J. Virol. 75:7506-7516(2001). RN [17] RP INTERACTION WITH HUMANIN. RX PubMed=12732850; DOI=10.1038/nature01627; RA Guo B., Zhai D., Cabezas E., Welsh K., Nouraini S., Satterthwait A.C., RA Reed J.C.; RT "Humanin peptide suppresses apoptosis by interfering with Bax activation."; RL Nature 423:456-461(2003). RN [18] RP INTERACTION WITH SFN AND YWHAZ, AND SUBCELLULAR LOCATION. RX PubMed=15071501; DOI=10.1038/sj.emboj.7600194; RA Tsuruta F., Sunayama J., Mori Y., Hattori S., Shimizu S., Tsujimoto Y., RA Yoshioka K., Masuyama N., Gotoh Y.; RT "JNK promotes Bax translocation to mitochondria through phosphorylation of RT 14-3-3 proteins."; RL EMBO J. 23:1889-1899(2004). RN [19] RP INTERACTION WITH NOL3. RX PubMed=15004034; DOI=10.1074/jbc.m400695200; RA Gustafsson A.B., Tsai J.G., Logue S.E., Crow M.T., Gottlieb R.A.; RT "Apoptosis repressor with caspase recruitment domain protects against cell RT death by interfering with Bax activation."; RL J. Biol. Chem. 279:21233-21238(2004). RN [20] RP INTERACTION WITH HHV-5 PROTEIN UL37. RX PubMed=15004026; DOI=10.1074/jbc.m308408200; RA Poncet D., Larochette N., Pauleau A.L., Boya P., Jalil A.A., Cartron P.F., RA Vallette F., Schnebelen C., Bartle L.M., Skaletskaya A., Boutolleau D., RA Martinou J.C., Goldmacher V.S., Kroemer G., Zamzami N.; RT "An anti-apoptotic viral protein that recruits Bax to mitochondria."; RL J. Biol. Chem. 279:22605-22614(2004). RN [21] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CLU. RX PubMed=16113678; DOI=10.1038/ncb1291; RA Zhang H., Kim J.K., Edwards C.A., Xu Z., Taichman R., Wang C.Y.; RT "Clusterin inhibits apoptosis by interacting with activated Bax."; RL Nat. Cell Biol. 7:909-915(2005). RN [22] RP FUNCTION, AND INTERACTION WITH MOAP1. RX PubMed=16199525; DOI=10.1073/pnas.0503524102; RA Tan K.O., Fu N.Y., Sukumaran S.K., Chan S.L., Kang J.H., Poon K.L., RA Chen B.S., Yu V.C.; RT "MAP-1 is a mitochondrial effector of Bax."; RL Proc. Natl. Acad. Sci. U.S.A. 102:14623-14628(2005). RN [23] RP INTERACTION WITH FAIM2/LFG2. RX PubMed=16964429; RA Reimers K., Choi C.Y., Mau-Thek E., Vogt P.M.; RT "Sequence analysis shows that Lifeguard belongs to a new evolutionarily RT conserved cytoprotective family."; RL Int. J. Mol. Med. 18:729-734(2006). RN [24] RP INTERACTION WITH GIMAP3 AND GIMAP5. RX PubMed=16509771; DOI=10.1371/journal.pbio.0040103; RA Nitta T., Nasreen M., Seike T., Goji A., Ohigashi I., Miyazaki T., Ohta T., RA Kanno M., Takahama Y.; RT "IAN family critically regulates survival and development of T RT lymphocytes."; RL PLoS Biol. 4:593-605(2006). RN [25] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [26] RP INTERACTION WITH RNF144B. RX PubMed=20300062; DOI=10.1038/emboj.2010.39; RA Benard G., Neutzner A., Peng G., Wang C., Livak F., Youle R.J., RA Karbowski M.; RT "IBRDC2, an IBR-type E3 ubiquitin ligase, is a regulatory factor for Bax RT and apoptosis activation."; RL EMBO J. 29:1458-1471(2010). RN [27] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [28] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH BCL2L1. RX PubMed=21458670; DOI=10.1016/j.cell.2011.02.034; RA Edlich F., Banerjee S., Suzuki M., Cleland M.M., Arnoult D., Wang C., RA Neutzner A., Tjandra N., Youle R.J.; RT "Bcl-x(L) retrotranslocates Bax from the mitochondria into the cytosol."; RL Cell 145:104-116(2011). RN [29] RP INTERACTION WITH BCL2L10. RX PubMed=23235460; DOI=10.1038/cddis.2012.178; RA Rautureau G.J., Yabal M., Yang H., Huang D.C., Kvansakul M., Hinds M.G.; RT "The restricted binding repertoire of Bcl-B leaves Bim as the universal RT BH3-only prosurvival Bcl-2 protein antagonist."; RL Cell Death Dis. 3:e443-e443(2012). RN [30] RP INTERACTION WITH RTL10/BOP. RX PubMed=23055042; DOI=10.1007/s13238-012-2069-7; RA Zhang X., Weng C., Li Y., Wang X., Jiang C., Li X., Xu Y., Chen Q., Pan L., RA Tang H.; RT "Human Bop is a novel BH3-only member of the Bcl-2 protein family."; RL Protein Cell 3:790-801(2012). RN [31] RP FUNCTION, INTERACTION WITH IRF3 AND BCL2, AND SUBCELLULAR LOCATION. RX PubMed=25609812; DOI=10.1128/jvi.02959-14; RA Wei B., Cui Y., Huang Y., Liu H., Li L., Li M., Ruan K.C., Zhou Q., RA Wang C.; RT "Tom70 mediates Sendai virus-induced apoptosis on mitochondria."; RL J. Virol. 89:3804-3818(2015). RN [32] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [33] RP INTERACTION WITH ENTEROVIRUS 71 PROTEIN 2B, AND SUBCELLULAR LOCATION. RX PubMed=27558414; DOI=10.1128/jvi.01499-16; RA Cong H., Du N., Yang Y., Song L., Zhang W., Tien P.; RT "Enterovirus 71 2B induces cell apoptosis by directly inducing the RT conformational activation of the proapoptotic protein Bax."; RL J. Virol. 90:9862-9877(2016). RN [34] RP SUBUNIT, AND SUBCELLULAR LOCATION. RX PubMed=29531808; DOI=10.1038/s41420-017-0006-5; RA Kuriyama S., Tsuji T., Sakuma T., Yamamoto T., Tanaka M.; RT "PLEKHN1 promotes apoptosis by enhancing Bax-Bak hetero-oligomerization RT through interaction with Bid in human colon cancer."; RL Cell. Death. Discov. 4:11-11(2018). RN [35] RP FORMATION OF FIBERS WITH HUMANIN, AND MUTAGENESIS OF 172-THR--GLY-192 AND RP SER-184. RX PubMed=31690630; DOI=10.1074/jbc.ra119.011297; RA Morris D.L., Kastner D.W., Johnson S., Strub M.P., He Y., Bleck C.K.E., RA Lee D.Y., Tjandra N.; RT "Humanin induces conformational changes in the apoptosis regulator BAX and RT sequesters it into fibers, preventing mitochondrial outer-membrane RT permeabilization."; RL J. Biol. Chem. 294:19055-19065(2019). RN [36] RP FUNCTION, DEUBIQUITINATION BY USP12, MUTAGENESIS OF LYS-128; LYS-189 AND RP LYS-190, SUBCELLULAR LOCATION, AND UBIQUITINATION AT LYS-128 AND LYS-190. RX PubMed=36361894; DOI=10.3390/ijms232113107; RA Choi H.S., Lim E.S., Baek K.H.; RT "Deubiquitinating Enzyme USP12 Regulates the Pro-Apoptosis Protein Bax."; RL Int. J. Mol. Sci. 23:0-0(2022). RN [37] RP STRUCTURE BY NMR, SUBCELLULAR LOCATION, AND SUBUNIT. RX PubMed=11106734; DOI=10.1016/s0092-8674(00)00167-7; RA Suzuki M., Youle R.J., Tjandra N.; RT "Structure of Bax: coregulation of dimer formation and intracellular RT localization."; RL Cell 103:645-654(2000). RN [38] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 13-19 IN COMPLEX WITH ANTIBODY RP FRAGMENT. RX PubMed=16946732; DOI=10.1038/sj.cdd.4402025; RA Peyerl F.W., Dai S., Murphy G.A., Crawford F., White J., Marrack P., RA Kappler J.W.; RT "Elucidation of some Bax conformational changes through crystallization of RT an antibody-peptide complex."; RL Cell Death Differ. 14:447-452(2007). RN [39] RP STRUCTURE BY NMR IN COMPLEX WITH BCL2L11, FUNCTION, SUBUNIT, MUTAGENESIS OF RP LYS-21, AND INTERACTION WITH BCL2L11. RX PubMed=18948948; DOI=10.1038/nature07396; RA Gavathiotis E., Suzuki M., Davis M.L., Pitter K., Bird G.H., Katz S.G., RA Tu H.C., Kim H., Cheng E.H., Tjandra N., Walensky L.D.; RT "BAX activation is initiated at a novel interaction site."; RL Nature 455:1076-1081(2008). RN [40] RP X-RAY CRYSTALLOGRAPHY (2.49 ANGSTROMS) OF 48-81 IN COMPLEXES WITH BCL2L1 RP AND MCL1, INTERACTION WITH MCL1; BCL2; BCL2L1 AND BCL2L2, FUNCTION, AND RP MUTAGENESIS OF MET-74. RX PubMed=21199865; DOI=10.1074/jbc.m110.161281; RA Czabotar P.E., Lee E.F., Thompson G.V., Wardak A.Z., Fairlie W.D., RA Colman P.M.; RT "Mutation to Bax beyond the BH3 domain disrupts interactions with pro- RT survival proteins and promotes apoptosis."; RL J. Biol. Chem. 286:7123-7131(2011). RN [41] RP VARIANTS GLU-11; ARG-67 AND VAL-108. RX PubMed=9531611; RA Meijerink J.P.P., Mensink E.J.B.M., Wang K., Sedlak T.W., Sloetjes A.W., RA de Witte T., Waksman G., Korsmeyer S.J.; RT "Hematopoietic malignancies demonstrate loss-of-function mutations of RT BAX."; RL Blood 91:2991-2997(1998). RN [42] RP INTERACTION WITH XRCC6. RX PubMed=15023334; DOI=10.1016/s1097-2765(04)00094-2; RA Cohen H.Y., Lavu S., Bitterman K.J., Hekking B., Imahiyerobo T.A., RA Miller C., Frye R., Ploegh H., Kessler B.M., Sinclair D.A.; RT "Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax- RT mediated apoptosis."; RL Mol. Cell 13:627-638(2004). RN [43] RP UBIQUITINATION. RX PubMed=18362350; DOI=10.1073/pnas.0706700105; RA Amsel A.D., Rathaus M., Kronman N., Cohen H.Y.; RT "Regulation of the proapoptotic factor Bax by Ku70-dependent RT deubiquitylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:5117-5122(2008). CC -!- FUNCTION: Plays a role in the mitochondrial apoptotic process CC (PubMed:10772918, PubMed:11060313, PubMed:16113678, PubMed:16199525, CC PubMed:18948948, PubMed:21199865, PubMed:21458670, PubMed:25609812, CC PubMed:36361894, PubMed:8358790, PubMed:8521816). Under normal CC conditions, BAX is largely cytosolic via constant retrotranslocation CC from mitochondria to the cytosol mediated by BCL2L1/Bcl-xL, which CC avoids accumulation of toxic BAX levels at the mitochondrial outer CC membrane (MOM) (PubMed:21458670). Under stress conditions, undergoes a CC conformation change that causes translocation to the mitochondrion CC membrane, leading to the release of cytochrome c that then triggers CC apoptosis (PubMed:10772918, PubMed:11060313, PubMed:16113678, CC PubMed:16199525, PubMed:18948948, PubMed:21199865, PubMed:21458670, CC PubMed:25609812, PubMed:8358790, PubMed:8521816). Promotes activation CC of CASP3, and thereby apoptosis (PubMed:10772918, PubMed:11060313, CC PubMed:16113678, PubMed:16199525, PubMed:18948948, PubMed:21199865, CC PubMed:21458670, PubMed:25609812, PubMed:8358790, PubMed:8521816). CC {ECO:0000269|PubMed:10772918, ECO:0000269|PubMed:11060313, CC ECO:0000269|PubMed:16113678, ECO:0000269|PubMed:16199525, CC ECO:0000269|PubMed:18948948, ECO:0000269|PubMed:21199865, CC ECO:0000269|PubMed:21458670, ECO:0000269|PubMed:25609812, CC ECO:0000269|PubMed:36361894, ECO:0000269|PubMed:8358790, CC ECO:0000269|PubMed:8521816}. CC -!- SUBUNIT: Homodimer. Forms higher oligomers under stress conditions. CC Forms heterooligomers with BAK (PubMed:29531808). Interacts with CC BCL2L11. Interaction with BCL2L11 promotes BAX oligomerization and CC association with mitochondrial membranes, with subsequent release of CC cytochrome c. Forms heterodimers with BCL2, BCL2L1 isoform Bcl-X(L), CC BCL2L2, MCL1 and A1 (PubMed:25609812). Interacts with SH3GLB1. CC Interacts with humanin; forms fibers with humanin which results in BAX CC conformational changes and sequestering of BAX into the fibers, CC preventing BAX activation (PubMed:12732850, PubMed:31690630). Interacts CC with SFN and YWHAZ; the interaction occurs in the cytoplasm. Under CC stress conditions, JNK-mediated phosphorylation of SFN and YWHAZ, CC releases BAX to mitochondria. Interacts with RNF144B, which regulates CC the ubiquitin-dependent stability of BAX. Interacts with CLU under CC stress conditions that cause a conformation change leading to BAX CC oligomerization and association with mitochondria. Does not interact CC with CLU in unstressed cells. Interacts with FAIM2/LFG2. Interacts with CC RTL10/BOP. Interacts (via a C-terminal 33 residues) with NOL3 (via CARD CC domain); inhibits BAX activation and translocation and consequently CC cytochrome c release from mitochondria. Interacts with GIMAP3/IAN4 and CC GIMAP5/IAN5; this interaction is increased, when cells initiate CC apoptosis upon IL2 withdrawal (PubMed:16509771). Interacts with IRF3; CC the interaction is direct, increases upon Sendai virus infection and CC mediates the formation of the apoptosis complex CC TOMM70:HSP90AA1:IRF3:BAX (PubMed:25609812). Interacts with MOAP1, CC facilitating BAX-dependent mitochondrial outer membrane CC permeabilization and apoptosis (PubMed:11060313, PubMed:16199525). CC Interacts with BCL2L10/BCL-B (PubMed:23235460). Interacts with non- CC acetylated XRCC6/Ku70; this interaction leads to BAX sequestration in CC the cytosol, away from the mitochondria, preventing BAX-mediated CC apoptosis (PubMed:15023334). {ECO:0000269|PubMed:11060313, CC ECO:0000269|PubMed:11106734, ECO:0000269|PubMed:11259440, CC ECO:0000269|PubMed:12732850, ECO:0000269|PubMed:15004026, CC ECO:0000269|PubMed:15004034, ECO:0000269|PubMed:15023334, CC ECO:0000269|PubMed:15071501, ECO:0000269|PubMed:16113678, CC ECO:0000269|PubMed:16199525, ECO:0000269|PubMed:16509771, CC ECO:0000269|PubMed:16946732, ECO:0000269|PubMed:16964429, CC ECO:0000269|PubMed:18948948, ECO:0000269|PubMed:20300062, CC ECO:0000269|PubMed:21199865, ECO:0000269|PubMed:23055042, CC ECO:0000269|PubMed:23235460, ECO:0000269|PubMed:25609812, CC ECO:0000269|PubMed:29531808, ECO:0000269|PubMed:31690630, CC ECO:0000269|PubMed:8358790}. CC -!- SUBUNIT: [Isoform Sigma]: Interacts with BCL2A1 and BCL2L1 isoform Bcl- CC X(L). {ECO:0000269|PubMed:10772918}. CC -!- SUBUNIT: (Microbial infection) Interacts with adenovirus E1B 19K CC protein; this interaction blocks BAX oligomerization (PubMed:11462023). CC {ECO:0000269|PubMed:11462023}. CC -!- SUBUNIT: (Microbial infection) Interacts with human CC cytomegalovirus/HHV-5 protein vMIA/UL37. {ECO:0000269|PubMed:15004026}. CC -!- SUBUNIT: (Microbial infection) Interacts with enterovirus protein 2B; CC this interaction activates BAX-induced apoptosis. CC {ECO:0000269|PubMed:27558414}. CC -!- INTERACTION: CC Q07812; Q16611: BAK1; NbExp=6; IntAct=EBI-516580, EBI-519866; CC Q07812; Q07812: BAX; NbExp=29; IntAct=EBI-516580, EBI-516580; CC Q07812; P10415: BCL2; NbExp=16; IntAct=EBI-516580, EBI-77694; CC Q07812; Q07817-1: BCL2L1; NbExp=24; IntAct=EBI-516580, EBI-287195; CC Q07812; Q9HD36: BCL2L10; NbExp=3; IntAct=EBI-516580, EBI-2126349; CC Q07812; O43521: BCL2L11; NbExp=22; IntAct=EBI-516580, EBI-526406; CC Q07812; Q9HB09: BCL2L12; NbExp=3; IntAct=EBI-516580, EBI-3940897; CC Q07812; Q92843: BCL2L2; NbExp=8; IntAct=EBI-516580, EBI-707714; CC Q07812; P55957: BID; NbExp=17; IntAct=EBI-516580, EBI-519672; CC Q07812; O75460: ERN1; NbExp=2; IntAct=EBI-516580, EBI-371750; CC Q07812; O75031: HSF2BP; NbExp=3; IntAct=EBI-516580, EBI-7116203; CC Q07812; P22001: KCNA3; NbExp=2; IntAct=EBI-516580, EBI-8627664; CC Q07812; Q07820: MCL1; NbExp=11; IntAct=EBI-516580, EBI-1003422; CC Q07812; Q8IVG9: MT-RNR2; NbExp=5; IntAct=EBI-516580, EBI-8643752; CC Q07812; Q9ULZ3: PYCARD; NbExp=7; IntAct=EBI-516580, EBI-751215; CC Q07812; Q7Z419: RNF144B; NbExp=5; IntAct=EBI-516580, EBI-2129982; CC Q07812; Q7L3V2: RTL10; NbExp=2; IntAct=EBI-516580, EBI-10697720; CC Q07812; Q9Y371-1: SH3GLB1; NbExp=2; IntAct=EBI-516580, EBI-5291808; CC Q07812; P37840: SNCA; NbExp=4; IntAct=EBI-516580, EBI-985879; CC Q07812; Q9P2Y5: UVRAG; NbExp=6; IntAct=EBI-516580, EBI-2952704; CC Q07812; P12956: XRCC6; NbExp=2; IntAct=EBI-516580, EBI-353208; CC Q07812; P70444: Bid; Xeno; NbExp=2; IntAct=EBI-516580, EBI-783400; CC Q07812; PRO_0000223236 [P70444]: Bid; Xeno; NbExp=2; IntAct=EBI-516580, EBI-2128640; CC Q07812; Q99MI6: Gimap3; Xeno; NbExp=2; IntAct=EBI-516580, EBI-15572304; CC Q07812; Q8BWF2: Gimap5; Xeno; NbExp=2; IntAct=EBI-516580, EBI-15572348; CC Q07812; P97287: Mcl1; Xeno; NbExp=2; IntAct=EBI-516580, EBI-707292; CC Q07812; P17361: OPG035; Xeno; NbExp=3; IntAct=EBI-516580, EBI-7115640; CC Q07812; P49334: TOM22; Xeno; NbExp=3; IntAct=EBI-516580, EBI-12527; CC Q07812; P23644: TOM40; Xeno; NbExp=2; IntAct=EBI-516580, EBI-12539; CC Q07812; P24391: tom40; Xeno; NbExp=2; IntAct=EBI-516580, EBI-1791540; CC Q07812; P07213: TOM70; Xeno; NbExp=2; IntAct=EBI-516580, EBI-12551; CC Q07812; P16778: UL37; Xeno; NbExp=2; IntAct=EBI-516580, EBI-16026491; CC Q07812; PRO_0000037647 [P26662]; Xeno; NbExp=3; IntAct=EBI-516580, EBI-9099462; CC -!- SUBCELLULAR LOCATION: [Isoform Alpha]: Mitochondrion outer membrane CC {ECO:0000269|PubMed:25609812, ECO:0000269|PubMed:29531808}; Single-pass CC membrane protein {ECO:0000255}. Cytoplasm {ECO:0000269|PubMed:27558414, CC ECO:0000269|PubMed:29531808}. Nucleus {ECO:0000269|PubMed:36361894}. CC Note=Colocalizes with 14-3-3 proteins in the cytoplasm. Under stress CC conditions, undergoes a conformation change that causes release from CC JNK-phosphorylated 14-3-3 proteins and translocation to the CC mitochondrion membrane. Upon Sendai virus infection, recruited to the CC mitochondrion through interaction with IRF3 (PubMed:25609812). CC {ECO:0000269|PubMed:25609812}. CC -!- SUBCELLULAR LOCATION: [Isoform Beta]: Cytoplasm. CC -!- SUBCELLULAR LOCATION: [Isoform Gamma]: Cytoplasm. CC -!- SUBCELLULAR LOCATION: [Isoform Delta]: Cytoplasm {ECO:0000305}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=8; CC Name=Alpha; CC IsoId=Q07812-1; Sequence=Displayed; CC Name=Beta; CC IsoId=Q07812-2, Q07814-1; CC Sequence=VSP_031237; CC Name=Gamma; CC IsoId=Q07812-3, Q07815-1; CC Sequence=VSP_031234, VSP_031236; CC Name=Delta; CC IsoId=Q07812-4, P55269-1; CC Sequence=VSP_031235; CC Name=Epsilon; CC IsoId=Q07812-5; Sequence=VSP_031240; CC Name=Zeta; CC IsoId=Q07812-6; Sequence=VSP_031239; CC Name=Psi; CC IsoId=Q07812-7; Sequence=VSP_031238; CC Name=Sigma; CC IsoId=Q07812-8; Sequence=VSP_037475; CC -!- TISSUE SPECIFICITY: Expressed in a wide variety of tissues. Isoform Psi CC is found in glial tumors. Isoform Alpha is expressed in spleen, breast, CC ovary, testis, colon and brain, and at low levels in skin and lung. CC Isoform Sigma is expressed in spleen, breast, ovary, testis, lung, CC colon, brain and at low levels in skin. Isoform Alpha and isoform Sigma CC are expressed in pro-myelocytic leukemia, histiocytic lymphoma, CC Burkitt's lymphoma, T-cell lymphoma, lymphoblastic leukemia, breast CC adenocarcinoma, ovary adenocarcinoma, prostate carcinoma, prostate CC adenocarcinoma, lung carcinoma, epidermoid carcinoma, small cell lung CC carcinoma and colon adenocarcinoma cell lines. CC {ECO:0000269|PubMed:10772918, ECO:0000269|PubMed:11912183}. CC -!- DOMAIN: Intact BH3 motif is required by BIK, BID, BAK, BAD and BAX for CC their pro-apoptotic activity and for their interaction with anti- CC apoptotic members of the Bcl-2 family. {ECO:0000269|PubMed:8521816}. CC -!- PTM: Ubiquitinated in the absence of XRCC6/Ku70 (PubMed:18362350). CC Ubiquitination promotes protein degradation (PubMed:18362350). CC Ubiquitinated on Lys-128 and Lys-190. 'Lys-63'-linked polyubiquitin CC chains on Lys-128 are removed by USP12. {ECO:0000269|PubMed:18362350, CC ECO:0000269|PubMed:36361894}. CC -!- SIMILARITY: Belongs to the Bcl-2 family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/128/BAX"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L22473; AAA03619.1; -; mRNA. DR EMBL; L22474; AAA03620.1; -; mRNA. DR EMBL; L22475; AAA03621.1; -; mRNA. DR EMBL; U19599; AAC50142.1; -; mRNA. DR EMBL; AF007826; AAD22706.1; -; mRNA. DR EMBL; AF247393; AAF71267.1; -; mRNA. DR EMBL; AJ417988; CAD10744.1; -; mRNA. DR EMBL; AF250190; AAF82094.1; -; mRNA. DR EMBL; AK291076; BAF83765.1; -; mRNA. DR EMBL; AY217036; AAO22992.1; -; Genomic_DNA. DR EMBL; CH471177; EAW52418.1; -; Genomic_DNA. DR EMBL; CH471177; EAW52417.1; -; Genomic_DNA. DR EMBL; BC014175; AAH14175.1; -; mRNA. DR CCDS; CCDS12742.1; -. [Q07812-1] DR CCDS; CCDS12743.1; -. [Q07812-4] DR CCDS; CCDS12744.1; -. [Q07812-2] DR CCDS; CCDS12745.2; -. [Q07812-8] DR PIR; A47538; A47538. DR PIR; B47538; B47538. DR PIR; C47538; C47538. DR PIR; I38921; I38921. DR PIR; JC7255; JC7255. DR RefSeq; NP_001278357.1; NM_001291428.1. DR RefSeq; NP_001278360.1; NM_001291431.2. [Q07812-6] DR RefSeq; NP_004315.1; NM_004324.4. [Q07812-2] DR RefSeq; NP_620116.1; NM_138761.4. [Q07812-1] DR RefSeq; NP_620118.1; NM_138763.4. [Q07812-4] DR RefSeq; NP_620119.2; NM_138764.5. [Q07812-8] DR PDB; 1F16; NMR; -; A=1-192. DR PDB; 2G5B; X-ray; 2.30 A; I/J/K/L=13-19. DR PDB; 2K7W; NMR; -; A=1-192. DR PDB; 2LR1; NMR; -; A=1-192. DR PDB; 3PK1; X-ray; 2.49 A; B/D=48-81. DR PDB; 3PL7; X-ray; 2.61 A; C=48-81. DR PDB; 4BD2; X-ray; 2.21 A; A=1-171. DR PDB; 4BD6; X-ray; 2.49 A; A=1-171, C=48-81. DR PDB; 4BD7; X-ray; 2.80 A; A/B/C/D=1-171. DR PDB; 4BD8; X-ray; 2.22 A; A/B/C/D=1-171. DR PDB; 4BDU; X-ray; 3.00 A; A/B/C/D=53-128. DR PDB; 4S0O; X-ray; 1.90 A; A/B=1-192. DR PDB; 4S0P; X-ray; 3.25 A; A/B=1-192. DR PDB; 4UF2; X-ray; 3.00 A; B=50-77. DR PDB; 4ZIE; X-ray; 1.80 A; A=1-166. DR PDB; 4ZIF; X-ray; 2.40 A; A=1-166. DR PDB; 4ZIG; X-ray; 2.20 A; A=1-166. DR PDB; 4ZIH; X-ray; 2.50 A; A=1-164. DR PDB; 4ZII; X-ray; 2.19 A; A=1-170. DR PDB; 5W5X; X-ray; 2.50 A; A=1-192. DR PDB; 5W5Z; X-ray; 2.00 A; A=32-192. DR PDB; 5W60; X-ray; 1.80 A; A=1-192. DR PDB; 5W61; X-ray; 2.30 A; A=1-192. DR PDB; 6EB6; X-ray; 2.02 A; A=1-192. DR PDB; 6L8V; NMR; -; A/B=53-128. DR PDB; 6L95; NMR; -; A/B=166-192. DR PDB; 6TRR; X-ray; 2.12 A; B=50-77. DR PDB; 6XY6; X-ray; 2.91 A; B/D/F/H/J/L/N/P=50-77. DR PDB; 7ADT; X-ray; 2.21 A; C/U=50-77. DR PDB; 8G1T; X-ray; 2.09 A; A/B/C/D/E/F/G/H=53-128. DR PDB; 8SPE; X-ray; 2.30 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X/Y/Z/a/b/c/d=53-128. DR PDB; 8SPF; X-ray; 2.20 A; A/B/C/D/E/F=53-128. DR PDB; 8SPZ; X-ray; 2.40 A; A/B/C/D=53-128. DR PDB; 8SRX; X-ray; 2.09 A; B/D=53-128. DR PDB; 8SRY; X-ray; 2.40 A; B/D=53-128. DR PDB; 8SVK; X-ray; 2.25 A; A/B/C/D=53-128. DR PDB; 9IXU; EM; 3.19 A; A/B/C/D/E/F/G/H=1-192. DR PDBsum; 1F16; -. DR PDBsum; 2G5B; -. DR PDBsum; 2K7W; -. DR PDBsum; 2LR1; -. DR PDBsum; 3PK1; -. DR PDBsum; 3PL7; -. DR PDBsum; 4BD2; -. DR PDBsum; 4BD6; -. DR PDBsum; 4BD7; -. DR PDBsum; 4BD8; -. DR PDBsum; 4BDU; -. DR PDBsum; 4S0O; -. DR PDBsum; 4S0P; -. DR PDBsum; 4UF2; -. DR PDBsum; 4ZIE; -. DR PDBsum; 4ZIF; -. DR PDBsum; 4ZIG; -. DR PDBsum; 4ZIH; -. DR PDBsum; 4ZII; -. DR PDBsum; 5W5X; -. DR PDBsum; 5W5Z; -. DR PDBsum; 5W60; -. DR PDBsum; 5W61; -. DR PDBsum; 6EB6; -. DR PDBsum; 6L8V; -. DR PDBsum; 6L95; -. DR PDBsum; 6TRR; -. DR PDBsum; 6XY6; -. DR PDBsum; 7ADT; -. DR PDBsum; 8G1T; -. DR PDBsum; 8SPE; -. DR PDBsum; 8SPF; -. DR PDBsum; 8SPZ; -. DR PDBsum; 8SRX; -. DR PDBsum; 8SRY; -. DR PDBsum; 8SVK; -. DR PDBsum; 9IXU; -. DR AlphaFoldDB; Q07812; -. DR BMRB; Q07812; -. DR EMDB; EMD-60977; -. DR SASBDB; Q07812; -. DR SMR; Q07812; -. DR BioGRID; 107057; 150. DR ComplexPortal; CPX-1988; BAX oligomer. DR CORUM; Q07812; -. DR DIP; DIP-232N; -. DR FunCoup; Q07812; 1141. DR IntAct; Q07812; 87. DR MINT; Q07812; -. DR STRING; 9606.ENSP00000293288; -. DR BindingDB; Q07812; -. DR ChEMBL; CHEMBL5318; -. DR DrugBank; DB12756; TAK-901. DR DrugBank; DB16447; Thymoquinone. DR TCDB; 1.A.21.1.2; the bcl-2 (bcl-2) family. DR GlyGen; Q07812; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q07812; -. DR MetOSite; Q07812; -. DR PhosphoSitePlus; Q07812; -. DR SwissPalm; Q07812; -. DR BioMuta; BAX; -. DR DMDM; 728945; -. DR jPOST; Q07812; -. DR MassIVE; Q07812; -. DR PaxDb; 9606-ENSP00000293288; -. DR PeptideAtlas; Q07812; -. DR ProteomicsDB; 58529; -. [Q07812-1] DR ProteomicsDB; 58530; -. [Q07812-2] DR ProteomicsDB; 58531; -. [Q07812-3] DR ProteomicsDB; 58532; -. [Q07812-4] DR ProteomicsDB; 58533; -. [Q07812-5] DR ProteomicsDB; 58534; -. [Q07812-6] DR ProteomicsDB; 58535; -. [Q07812-7] DR ProteomicsDB; 58536; -. [Q07812-8] DR Pumba; Q07812; -. DR TopDownProteomics; Q07812-1; -. [Q07812-1] DR TopDownProteomics; Q07812-2; -. [Q07812-2] DR TopDownProteomics; Q07812-5; -. [Q07812-5] DR TopDownProteomics; Q07812-6; -. [Q07812-6] DR TopDownProteomics; Q07812-8; -. [Q07812-8] DR ABCD; Q07812; 22 sequenced antibodies. DR Antibodypedia; 3777; 2176 antibodies from 53 providers. DR CPTC; Q07812; 1 antibody. DR DNASU; 581; -. DR Ensembl; ENST00000293288.12; ENSP00000293288.8; ENSG00000087088.22. [Q07812-2] DR Ensembl; ENST00000345358.12; ENSP00000263262.9; ENSG00000087088.22. [Q07812-1] DR Ensembl; ENST00000354470.7; ENSP00000346461.3; ENSG00000087088.22. [Q07812-4] DR Ensembl; ENST00000356483.8; ENSP00000348871.4; ENSG00000087088.22. [Q07812-5] DR Ensembl; ENST00000415969.6; ENSP00000389971.2; ENSG00000087088.22. [Q07812-8] DR Ensembl; ENST00000515540.5; ENSP00000426328.1; ENSG00000087088.22. [Q07812-3] DR GeneID; 581; -. DR KEGG; hsa:581; -. DR MANE-Select; ENST00000345358.12; ENSP00000263262.9; NM_138761.4; NP_620116.1. DR UCSC; uc002plf.2; human. [Q07812-1] DR AGR; HGNC:959; -. DR CIViC; 581; 2 evidence items across 3 molecular profiles. DR ClinPGx; PA25269; -. DR CTD; 581; -. DR DisGeNET; 581; -. DR GeneCards; BAX; -. DR HGNC; HGNC:959; BAX. DR HPA; ENSG00000087088; Low tissue specificity. DR MalaCards; BAX; -. DR MIM; 600040; gene. DR OpenTargets; ENSG00000087088; -. DR VEuPathDB; HostDB:ENSG00000087088; -. DR eggNOG; KOG4728; Eukaryota. DR GeneTree; ENSGT01130000278292; -. DR HOGENOM; CLU_3279262_0_0_1; -. DR InParanoid; Q07812; -. DR OMA; QCCGDSE; -. DR OrthoDB; 6080198at2759; -. DR PAN-GO; Q07812; 9 GO annotations based on evolutionary models. DR PhylomeDB; Q07812; -. DR PathwayCommons; Q07812; -. DR Reactome; R-HSA-111457; Release of apoptotic factors from the mitochondria. DR Reactome; R-HSA-114294; Activation, translocation and oligomerization of BAX. DR Reactome; R-HSA-5620971; Pyroptosis. DR Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release. DR Reactome; R-HSA-6804114; TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest. DR Reactome; R-HSA-8878166; Transcriptional regulation by RUNX2. DR Reactome; R-HSA-9603505; NTRK3 as a dependence receptor. DR SignaLink; Q07812; -. DR SIGNOR; Q07812; -. DR Agora; ENSG00000087088; -. DR BioGRID-ORCS; 581; 32 hits in 1176 CRISPR screens. DR ChiTaRS; BAX; human. DR EvolutionaryTrace; Q07812; -. DR GeneWiki; Bcl-2-associated_X_protein; -. DR GenomeRNAi; 581; -. DR Pharos; Q07812; Tchem. DR PRO; PR:Q07812; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q07812; protein. DR Bgee; ENSG00000087088; Expressed in mucosa of transverse colon and 168 other cell types or tissues. DR ExpressionAtlas; Q07812; baseline and differential. DR GO; GO:0097145; C:BAK complex; IDA:ARUK-UCL. DR GO; GO:0097144; C:BAX complex; IDA:UniProtKB. DR GO; GO:0097136; C:Bcl-2 family protein complex; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:HGNC-UCL. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:HGNC-UCL. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0005741; C:mitochondrial outer membrane; IDA:UniProtKB. DR GO; GO:0005757; C:mitochondrial permeability transition pore complex; IDA:HGNC-UCL. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0005635; C:nuclear envelope; IDA:AgBase. DR GO; GO:0005634; C:nucleus; IDA:AgBase. DR GO; GO:0046930; C:pore complex; IDA:BHF-UCL. DR GO; GO:0051434; F:BH3 domain binding; IDA:UniProtKB. DR GO; GO:0015267; F:channel activity; IDA:BHF-UCL. DR GO; GO:0030544; F:Hsp70 protein binding; IEA:Ensembl. DR GO; GO:0042802; F:identical protein binding; IPI:UniProtKB. DR GO; GO:0008289; F:lipid binding; IDA:HGNC-UCL. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:HGNC-UCL. DR GO; GO:0042803; F:protein homodimerization activity; IDA:HGNC-UCL. DR GO; GO:0008637; P:apoptotic mitochondrial changes; IDA:HGNC-UCL. DR GO; GO:0006915; P:apoptotic process; IDA:DIBU. DR GO; GO:1902262; P:apoptotic process involved in blood vessel morphogenesis; IEA:Ensembl. DR GO; GO:1902263; P:apoptotic process involved in embryonic digit morphogenesis; IEA:Ensembl. DR GO; GO:0060057; P:apoptotic process involved in mammary gland involution; IEA:Ensembl. DR GO; GO:0097190; P:apoptotic signaling pathway; IDA:HGNC-UCL. DR GO; GO:0001783; P:B cell apoptotic process; IDA:HGNC-UCL. DR GO; GO:0001782; P:B cell homeostasis; IEA:Ensembl. DR GO; GO:0002358; P:B cell homeostatic proliferation; IEA:Ensembl. DR GO; GO:0002352; P:B cell negative selection; IEA:Ensembl. DR GO; GO:1990117; P:B cell receptor apoptotic signaling pathway; IDA:BHF-UCL. DR GO; GO:0001974; P:blood vessel remodeling; IEA:Ensembl. DR GO; GO:0060402; P:calcium ion transport into cytosol; IEA:Ensembl. DR GO; GO:0034620; P:cellular response to unfolded protein; TAS:ParkinsonsUK-UCL. DR GO; GO:0034644; P:cellular response to UV; IEA:Ensembl. DR GO; GO:0098586; P:cellular response to virus; IDA:UniProtKB. DR GO; GO:0021987; P:cerebral cortex development; IEA:Ensembl. DR GO; GO:0045136; P:development of secondary sexual characteristics; IEA:Ensembl. DR GO; GO:0035234; P:ectopic germ cell programmed cell death; IEA:Ensembl. DR GO; GO:0032469; P:endoplasmic reticulum calcium ion homeostasis; TAS:UniProtKB. DR GO; GO:1904019; P:epithelial cell apoptotic process; IEA:Ensembl. DR GO; GO:0010248; P:establishment or maintenance of transmembrane electrochemical gradient; IDA:HGNC-UCL. DR GO; GO:0097194; P:execution phase of apoptosis; IMP:HGNC-UCL. DR GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IDA:BHF-UCL. DR GO; GO:0097192; P:extrinsic apoptotic signaling pathway in absence of ligand; IBA:GO_Central. DR GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IC:BHF-UCL. DR GO; GO:0009566; P:fertilization; IEA:Ensembl. DR GO; GO:0007281; P:germ cell development; IEA:Ensembl. DR GO; GO:0006687; P:glycosphingolipid metabolic process; IEA:Ensembl. DR GO; GO:0048873; P:homeostasis of number of cells within a tissue; IEA:Ensembl. DR GO; GO:0021854; P:hypothalamus development; IEA:Ensembl. DR GO; GO:0097193; P:intrinsic apoptotic signaling pathway; IDA:HGNC-UCL. DR GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IEA:Ensembl. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IDA:HGNC-UCL. DR GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; TAS:ParkinsonsUK-UCL. DR GO; GO:0001822; P:kidney development; IEA:Ensembl. DR GO; GO:0043653; P:mitochondrial fragmentation involved in apoptotic process; IDA:HGNC-UCL. DR GO; GO:0008053; P:mitochondrial fusion; IDA:HGNC-UCL. DR GO; GO:0097049; P:motor neuron apoptotic process; IEA:Ensembl. DR GO; GO:0002262; P:myeloid cell homeostasis; IEA:Ensembl. DR GO; GO:2001234; P:negative regulation of apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0032471; P:negative regulation of endoplasmic reticulum calcium ion concentration; IEA:Ensembl. DR GO; GO:0048147; P:negative regulation of fibroblast proliferation; IEA:Ensembl. DR GO; GO:0010917; P:negative regulation of mitochondrial membrane potential; IDA:UniProtKB. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0032091; P:negative regulation of protein binding; IDA:UniProtKB. DR GO; GO:0001764; P:neuron migration; IEA:Ensembl. DR GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl. DR GO; GO:0001541; P:ovarian follicle development; IEA:Ensembl. DR GO; GO:1902512; P:positive regulation of apoptotic DNA fragmentation; IMP:BHF-UCL. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0060058; P:positive regulation of apoptotic process involved in mammary gland involution; IEA:Ensembl. DR GO; GO:0002904; P:positive regulation of B cell apoptotic process; IEA:Ensembl. DR GO; GO:0010524; P:positive regulation of calcium ion transport into cytosol; IEA:Ensembl. DR GO; GO:0048087; P:positive regulation of developmental pigmentation; IEA:Ensembl. DR GO; GO:1904037; P:positive regulation of epithelial cell apoptotic process; IEA:Ensembl. DR GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB. DR GO; GO:1903896; P:positive regulation of IRE1-mediated unfolded protein response; TAS:ParkinsonsUK-UCL. DR GO; GO:1902110; P:positive regulation of mitochondrial membrane permeability involved in apoptotic process; IEA:Ensembl. DR GO; GO:2000673; P:positive regulation of motor neuron apoptotic process; IEA:Ensembl. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; IDA:HGNC-UCL. DR GO; GO:0031334; P:positive regulation of protein-containing complex assembly; IDA:UniProtKB. DR GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; IDA:UniProtKB. DR GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IEA:Ensembl. DR GO; GO:2000243; P:positive regulation of reproductive process; IEA:Ensembl. DR GO; GO:0048597; P:post-embryonic camera-type eye morphogenesis; IEA:Ensembl. DR GO; GO:0051204; P:protein insertion into mitochondrial membrane; IEA:Ensembl. DR GO; GO:0042981; P:regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0051726; P:regulation of cell cycle; IEA:Ensembl. DR GO; GO:0033599; P:regulation of mammary gland epithelial cell proliferation; IEA:Ensembl. DR GO; GO:1902445; P:regulation of mitochondrial membrane permeability involved in programmed necrotic cell death; IEA:Ensembl. DR GO; GO:0051881; P:regulation of mitochondrial membrane potential; IDA:HGNC-UCL. DR GO; GO:0006808; P:regulation of nitrogen utilization; IEA:Ensembl. DR GO; GO:0001836; P:release of cytochrome c from mitochondria; IDA:UniProtKB. DR GO; GO:0032976; P:release of matrix enzymes from mitochondria; IDA:HGNC-UCL. DR GO; GO:0051209; P:release of sequestered calcium ion into cytosol; IEA:Ensembl. DR GO; GO:0048678; P:response to axon injury; IEA:Ensembl. DR GO; GO:0010332; P:response to gamma radiation; IEA:Ensembl. DR GO; GO:0009651; P:response to salt stress; IEA:Ensembl. DR GO; GO:0009636; P:response to toxic substance; IDA:HGNC-UCL. DR GO; GO:0060041; P:retina development in camera-type eye; IEA:Ensembl. DR GO; GO:0046666; P:retinal cell programmed cell death; IEA:Ensembl. DR GO; GO:0060011; P:Sertoli cell proliferation; IEA:Ensembl. DR GO; GO:0048515; P:spermatid differentiation; IEA:Ensembl. DR GO; GO:0097435; P:supramolecular fiber organization; IDA:UniProtKB. DR GO; GO:0001777; P:T cell homeostatic proliferation; IEA:Ensembl. DR GO; GO:0070242; P:thymocyte apoptotic process; IEA:Ensembl. DR GO; GO:0060068; P:vagina development; IEA:Ensembl. DR CDD; cd06845; Bcl-2_like; 1. DR DisProt; DP02540; -. DR FunFam; 1.10.437.10:FF:000004; apoptosis regulator BAX isoform X2; 1. DR Gene3D; 1.10.437.10; Blc2-like; 1. DR InterPro; IPR036834; Bcl-2-like_sf. DR InterPro; IPR046371; Bcl-2_BH1-3. DR InterPro; IPR026298; Bcl-2_fam. DR InterPro; IPR002475; Bcl2-like. DR InterPro; IPR020717; Bcl2_BH1_motif_CS. DR InterPro; IPR020726; Bcl2_BH2_motif_CS. DR InterPro; IPR020728; Bcl2_BH3_motif_CS. DR PANTHER; PTHR11256:SF42; APOPTOSIS REGULATOR BAX; 1. DR PANTHER; PTHR11256; BCL-2 RELATED; 1. DR Pfam; PF00452; Bcl-2; 1. DR PRINTS; PR01862; BCL2FAMILY. DR SMART; SM00337; BCL; 1. DR SUPFAM; SSF56854; Bcl-2 inhibitors of programmed cell death; 1. DR PROSITE; PS50062; BCL2_FAMILY; 1. DR PROSITE; PS01080; BH1; 1. DR PROSITE; PS01258; BH2; 1. DR PROSITE; PS01259; BH3; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; Cytoplasm; KW Host-virus interaction; Isopeptide bond; Membrane; Mitochondrion; KW Mitochondrion outer membrane; Nucleus; Proteomics identification; KW Reference proteome; Transmembrane; Transmembrane helix; Tumor suppressor; KW Ubl conjugation. FT CHAIN 1..192 FT /note="Apoptosis regulator BAX" FT /id="PRO_0000143053" FT TRANSMEM 172..192 FT /note="Helical" FT /evidence="ECO:0000255" FT MOTIF 59..73 FT /note="BH3" FT /evidence="ECO:0000269|PubMed:8521816" FT MOTIF 98..118 FT /note="BH1" FT MOTIF 150..165 FT /note="BH2" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:25944712" FT CROSSLNK 128 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:36361894" FT CROSSLNK 190 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:36361894" FT VAR_SEQ 1..78 FT /note="Missing (in isoform Zeta)" FT /evidence="ECO:0000303|Ref.6" FT /id="VSP_031239" FT VAR_SEQ 1..19 FT /note="Missing (in isoform Psi)" FT /evidence="ECO:0000303|PubMed:11912183" FT /id="VSP_031238" FT VAR_SEQ 12..41 FT /note="GPTSSEQIMKTGALLLQGFIQDRAGRMGGE -> VSSRIEQGEWGGRHPSWP FT WTRCLRMRPPRS (in isoform Gamma)" FT /evidence="ECO:0000303|PubMed:8358790" FT /id="VSP_031234" FT VAR_SEQ 30..78 FT /note="Missing (in isoform Delta)" FT /evidence="ECO:0000303|PubMed:7607685" FT /id="VSP_031235" FT VAR_SEQ 42..192 FT /note="Missing (in isoform Gamma)" FT /evidence="ECO:0000303|PubMed:8358790" FT /id="VSP_031236" FT VAR_SEQ 125..192 FT /note="LCTKVPELIRTIMGWTLDFLRERLLGWIQDQGGWDGLLSYFGTPTWQTVTIF FT VAGVLTASLTIWKKMG -> GVKWRDLGSLQPLPPGFKRFTCLSIPRSWDYRPCAPRCR FT N (in isoform Epsilon)" FT /evidence="ECO:0000303|PubMed:9920818" FT /id="VSP_031240" FT VAR_SEQ 159..192 FT /note="DGLLSYFGTPTWQTVTIFVAGVLTASLTIWKKMG -> VRLLKPPHPHHRAL FT TTAPAPPSLPPATPLGPWAFWSRSQWCPLPIFRSSDVVYNAFSLRV (in isoform FT Beta)" FT /evidence="ECO:0000303|PubMed:8358790" FT /id="VSP_031237" FT VAR_SEQ 159..171 FT /note="Missing (in isoform Sigma)" FT /evidence="ECO:0000303|PubMed:10772918" FT /id="VSP_037475" FT VARIANT 11 FT /note="G -> E (in a plasmacytoma cell line; FT dbSNP:rs555248599)" FT /evidence="ECO:0000269|PubMed:9531611" FT /id="VAR_013575" FT VARIANT 39 FT /note="G -> R (in dbSNP:rs36017265)" FT /id="VAR_047053" FT VARIANT 67 FT /note="G -> R (in a T-cell acute lymphoblastic leukemia FT cell line; loss of heterodimerization with Bcl-2 or Bcl- FT X(L); dbSNP:rs398122513)" FT /evidence="ECO:0000269|PubMed:7475270, FT ECO:0000269|PubMed:9531611" FT /id="VAR_007809" FT VARIANT 108 FT /note="G -> V (in a Burkitt lymphoma; loss of FT homodimerization)" FT /evidence="ECO:0000269|PubMed:7475270, FT ECO:0000269|PubMed:9531611" FT /id="VAR_013576" FT MUTAGEN 21 FT /note="K->E: Reduces interaction with BCL2L11, FT homooligomerization and triggering of apoptosis." FT /evidence="ECO:0000269|PubMed:18948948" FT MUTAGEN 74 FT /note="M->D,E: Strongly reduced interaction with MCL1, FT BCL2, BCL2L1 and BCL2L2. No effect on cytochrome c release FT and subsequent apoptosis triggered by etoposide." FT /evidence="ECO:0000269|PubMed:21199865" FT MUTAGEN 128 FT /note="K->R: Partial loss of polyubiquitination." FT /evidence="ECO:0000269|PubMed:36361894" FT MUTAGEN 172..192 FT /note="Missing: Enhanced fiber formation with humanin." FT /evidence="ECO:0000269|PubMed:31690630" FT MUTAGEN 184 FT /note="S->D,E,H,K: Constitutive cytoplasmic location." FT /evidence="ECO:0000269|PubMed:10228148" FT MUTAGEN 184 FT /note="S->V: Constitutive mitochondrial location. Enhanced FT fiber formation with humanin." FT /evidence="ECO:0000269|PubMed:10228148, FT ECO:0000269|PubMed:31690630" FT MUTAGEN 189 FT /note="K->R: No loss of polyubiquitination." FT /evidence="ECO:0000269|PubMed:36361894" FT MUTAGEN 190 FT /note="K->R: Partial loss of polyubiquitination." FT /evidence="ECO:0000269|PubMed:36361894" FT TURN 2..4 FT /evidence="ECO:0007829|PDB:2K7W" FT STRAND 10..14 FT /evidence="ECO:0007829|PDB:1F16" FT HELIX 16..34 FT /evidence="ECO:0007829|PDB:4ZIE" FT HELIX 36..38 FT /evidence="ECO:0007829|PDB:2K7W" FT STRAND 39..41 FT /evidence="ECO:0007829|PDB:5W60" FT HELIX 43..45 FT /evidence="ECO:0007829|PDB:5W60" FT HELIX 54..71 FT /evidence="ECO:0007829|PDB:4ZIE" FT HELIX 74..82 FT /evidence="ECO:0007829|PDB:4ZIE" FT STRAND 85..87 FT /evidence="ECO:0007829|PDB:5W60" FT HELIX 88..99 FT /evidence="ECO:0007829|PDB:4ZIE" FT TURN 100..102 FT /evidence="ECO:0007829|PDB:4ZIE" FT HELIX 107..147 FT /evidence="ECO:0007829|PDB:4ZIE" FT HELIX 149..154 FT /evidence="ECO:0007829|PDB:4ZIE" FT TURN 155..158 FT /evidence="ECO:0007829|PDB:4ZIE" FT HELIX 159..164 FT /evidence="ECO:0007829|PDB:4ZIE" FT TURN 167..169 FT /evidence="ECO:0007829|PDB:5W60" FT HELIX 170..187 FT /evidence="ECO:0007829|PDB:5W60" SQ SEQUENCE 192 AA; 21184 MW; 6C0CDB0A7DEE4994 CRC64; MDGSGEQPRG GGPTSSEQIM KTGALLLQGF IQDRAGRMGG EAPELALDPV PQDASTKKLS ECLKRIGDEL DSNMELQRMI AAVDTDSPRE VFFRVAADMF SDGNFNWGRV VALFYFASKL VLKALCTKVP ELIRTIMGWT LDFLRERLLG WIQDQGGWDG LLSYFGTPTW QTVTIFVAGV LTASLTIWKK MG // ID BIRC5_HUMAN Reviewed; 142 AA. AC O15392; A2SUH6; B2R4R1; Q2I3N8; Q4VGX0; Q53F61; Q5MGC6; Q6FHL2; Q75SP2; AC Q9P2W8; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 21-MAR-2012, sequence version 3. DT 28-JAN-2026, entry version 252. DE RecName: Full=Baculoviral IAP repeat-containing protein 5; DE AltName: Full=Apoptosis inhibitor 4; DE AltName: Full=Apoptosis inhibitor survivin; GN Name=BIRC5; Synonyms=API4, IAP4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1). RX PubMed=9256286; DOI=10.1038/nm0897-917; RA Ambrosini G., Adida C., Altieri D.C.; RT "A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma."; RL Nat. Med. 3:917-921(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3), FUNCTION, AND TISSUE RP SPECIFICITY. RX PubMed=10626797; RA Mahotka C., Wenzel M., Springer E., Gabbert H.E., Gerharz C.D.; RT "Survivin-deltaEx3 and survivin-2B: two novel splice variants of the RT apoptosis inhibitor survivin with different antiapoptotic properties."; RL Cancer Res. 59:6097-6102(1999). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND SUBCELLULAR LOCATION. RX PubMed=11084331; DOI=10.1016/s0960-9822(00)00769-7; RA Uren A.G., Wong L., Pakusch M., Fowler K.J., Burrows F.J., Vaux D.L., RA Choo K.H.; RT "Survivin and the inner centromere protein INCENP show similar cell-cycle RT localization and gene knockout phenotype."; RL Curr. Biol. 10:1319-1328(2000). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), AND TISSUE SPECIFICITY. RC TISSUE=Myeloid leukemia cell; RX PubMed=14741722; DOI=10.1016/j.bbrc.2003.12.178; RA Badran A., Yoshida A., Ishikawa K., Goi T., Yamaguchi A., Ueda T., RA Inuzuka M.; RT "Identification of a novel splice variant of the human anti-apoptosis gene RT survivin."; RL Biochem. Biophys. Res. Commun. 314:902-907(2004). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), AND TISSUE SPECIFICITY. RC TISSUE=Mammary cancer; RX PubMed=16329164; DOI=10.1080/10425170500226490; RA Zheng W., Ma X., Wei D., Wang T., Ma Y., Yang S.; RT "Molecular cloning and bioinformatics analysis of a novel spliced variant RT of survivin from human breast cancer cells."; RL DNA Seq. 16:321-328(2005). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RC TISSUE=Neuroblastoma; RA Kageyama H., Islam A., Takayasu H., Nakagawara A.; RT "An isoform of survivin (survivin-beta) which has 23 amino acids insertion RT into the BIR domain."; RL Submitted (JUN-1999) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 7). RA Caldas H., Honsey L.E., Altura R.A.; RT "Survivin 2 alpha: a novel survivin splice variant expressed in human RT malignancies."; RL Submitted (FEB-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 6). RC TISSUE=Myeloid leukemia cell; RA Vietri M.T., Cioffi M., Sessa M., Sica V., Molinari A.M.; RT "Identification of a novel survivin splicing variant 3alpha in acute RT myeloid leukemia."; RL Submitted (NOV-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.; RL Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases. RN [13] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLU-129. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [14] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [15] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Lung, Mammary gland, and Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [16] RP FUNCTION. RX PubMed=9859993; DOI=10.1038/25141; RA Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., RA Altieri D.C.; RT "Control of apoptosis and mitotic spindle checkpoint by survivin."; RL Nature 396:580-584(1998). RN [17] RP PHOSPHORYLATION AT THR-34. RX PubMed=11069302; DOI=10.1073/pnas.240390697; RA O'Connor D.S., Grossman D., Plescia J., Li F., Zhang H., Villa A., RA Tognin S., Marchisio P.C., Altieri D.C.; RT "Regulation of apoptosis at cell division by p34cdc2 phosphorylation of RT survivin."; RL Proc. Natl. Acad. Sci. U.S.A. 97:13103-13107(2000). RN [18] RP FUNCTION IN APOPTOSIS SUPPRESSION, INTERACTION WITH LAMTOR5/HBXIP, RP MUTAGENESIS OF THR-34, AND SUBCELLULAR LOCATION. RX PubMed=12773388; DOI=10.1093/emboj/cdg263; RA Marusawa H., Matsuzawa S., Welsh K., Zou H., Armstrong R., Tamm I., RA Reed J.C.; RT "HBXIP functions as a cofactor of survivin in apoptosis suppression."; RL EMBO J. 22:2729-2740(2003). RN [19] RP INTERACTION WITH INCENP, SUBCELLULAR LOCATION, PHOSPHORYLATION AT THR-117, RP AND MUTAGENESIS OF THR-117. RX PubMed=14610074; DOI=10.1074/jbc.m311299200; RA Wheatley S.P., Henzing A.J., Dodson H., Khaled W., Earnshaw W.C.; RT "Aurora-B phosphorylation in vitro identifies a residue of survivin that is RT essential for its localization and binding to inner centromere protein RT (INCENP) in vivo."; RL J. Biol. Chem. 279:5655-5660(2004). RN [20] RP INTERACTION WITH CDCA8. RX PubMed=15249581; DOI=10.1083/jcb.200404001; RA Gassmann R., Carvalho A., Henzing A.J., Ruchaud S., Hudson D.F., Honda R., RA Nigg E.A., Gerloff D.L., Earnshaw W.C.; RT "Borealin: a novel chromosomal passenger required for stability of the RT bipolar mitotic spindle."; RL J. Cell Biol. 166:179-191(2004). RN [21] RP SUBCELLULAR LOCATION, AND INTERACTION WITH BIRC2/C-IAP1. RX PubMed=15665297; DOI=10.1158/0008-5472.210.65.1; RA Samuel T., Okada K., Hyer M., Welsh K., Zapata J.M., Reed J.C.; RT "cIAP1 Localizes to the nuclear compartment and modulates the cell cycle."; RL Cancer Res. 65:210-218(2005). RN [22] RP REVIEW ON FUNCTION. RX PubMed=16344111; DOI=10.1016/s0074-7696(05)47002-3; RA Wheatley S.P., McNeish I.A.; RT "Survivin: a protein with dual roles in mitosis and apoptosis."; RL Int. Rev. Cytol. 247:35-88(2005). RN [23] RP FUNCTION, INTERACTION WITH USP9X, SUBCELLULAR LOCATION, UBIQUITINATION, AND RP MUTAGENESIS OF LYS-23; LYS-62; LYS-78 AND LYS-79. RX PubMed=16322459; DOI=10.1126/science.1120160; RA Vong Q.P., Cao K., Li H.Y., Iglesias P.A., Zheng Y.; RT "Chromosome alignment and segregation regulated by ubiquitination of RT survivin."; RL Science 310:1499-1504(2005). RN [24] RP MUTAGENESIS OF ASP-70; ASP-71 AND 70-ASP--ASP-71. RX PubMed=16762323; DOI=10.1016/j.bbrc.2006.05.131; RA Cao L., Yan X., Wu Y., Hu H., Li Q., Zhou T., Jiang S., Yu L.; RT "Survivin mutant (Surv-DD70, 71AA) disrupts the interaction of Survivin RT with Aurora B and causes multinucleation in HeLa cells."; RL Biochem. Biophys. Res. Commun. 346:400-407(2006). RN [25] RP INTERACTION WITH CDCA8. RX PubMed=16239925; DOI=10.1038/sj.embor.7400562; RA Vader G., Kauw J.J.W., Medema R.H., Lens S.M.A.; RT "Survivin mediates targeting of the chromosomal passenger complex to the RT centromere and midbody."; RL EMBO Rep. 7:85-92(2006). RN [26] RP INTERACTION WITH CDCA8. RX PubMed=16427043; DOI=10.1016/j.yexcr.2005.12.015; RA Chang J.-L., Chen T.-H., Wang C.-F., Chiang Y.-H., Huang Y.-L., Wong F.-H., RA Chou C.-K., Chen C.-M.; RT "Borealin/Dasra B is a cell cycle-regulated chromosomal passenger protein RT and its nuclear accumulation is linked to poor prognosis for human gastric RT cancer."; RL Exp. Cell Res. 312:962-973(2006). RN [27] RP INTERACTION WITH EVI5. RX PubMed=16764853; DOI=10.1016/j.yexcr.2006.03.032; RA Faitar S.L., Sossey-Alaoui K., Ranalli T.A., Cowell J.K.; RT "EVI5 protein associates with the INCENP-aurora B kinase-survivin RT chromosomal passenger complex and is involved in the completion of RT cytokinesis."; RL Exp. Cell Res. 312:2325-2335(2006). RN [28] RP FUNCTION, AND INTERACTION WITH CDCA8. RX PubMed=16291752; DOI=10.1074/jbc.m508773200; RA Noton E.A., Colnaghi R., Tate S., Starck C., Carvalho A., Ko Ferrigno P., RA Wheatley S.P.; RT "Molecular analysis of survivin isoforms: evidence that alternatively RT spliced variants do not play a role in mitosis."; RL J. Biol. Chem. 281:1286-1295(2006). RN [29] RP INTERACTION WITH CDCA8. RX PubMed=16436504; DOI=10.1091/mbc.e05-08-0727; RA Lens S.M.A., Rodriguez J.A., Vader G., Span S.W., Giaccone G., Medema R.H.; RT "Uncoupling the central spindle-associated function of the chromosomal RT passenger complex from its role at centromeres."; RL Mol. Biol. Cell 17:1897-1909(2006). RN [30] RP INTERACTION WITH BIRC6/BRUCE. RX PubMed=18329369; DOI=10.1016/j.cell.2008.01.012; RA Pohl C., Jentsch S.; RT "Final stages of cytokinesis and midbody ring formation are controlled by RT BRUCE."; RL Cell 132:832-845(2008). RN [31] RP INDUCTION. RX PubMed=17993464; DOI=10.1074/jbc.m704035200; RA Gagarina V., Carlberg A.L., Pereira-Mouries L., Hall D.J.; RT "Cartilage oligomeric matrix protein protects cells against death by RT elevating members of the IAP family of survival proteins."; RL J. Biol. Chem. 283:648-659(2008). RN [32] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-34, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [33] RP FUNCTION, INTERACTION WITH RAN; AURKB AND CDCA8, SUBCELLULAR LOCATION, RP DEVELOPMENTAL STAGE, AND MUTAGENESIS OF GLU-65. RX PubMed=18591255; DOI=10.1128/mcb.02039-07; RA Xia F., Canovas P.M., Guadagno T.M., Altieri D.C.; RT "A survivin-ran complex regulates spindle formation in tumor cells."; RL Mol. Cell. Biol. 28:5299-5311(2008). RN [34] RP FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=21364656; DOI=10.1038/cddis.2010.25; RA Knauer S.K., Heinrich U.R., Bier C., Habtemichael N., Docter D., RA Helling K., Mann W.J., Stauber R.H.; RT "An otoprotective role for the apoptosis inhibitor protein survivin."; RL Cell Death Dis. 1:E51-E51(2010). RN [35] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH STAT3 AND XPO1/CRM1, RP ACETYLATION AT LYS-23; LYS-90; LYS-110; LYS-112; LYS-115; LYS-121 AND RP LYS-129, MUTAGENESIS OF LYS-129, AND CHARACTERIZATION OF VARIANT GLU-129. RX PubMed=20826784; DOI=10.1074/jbc.m110.152777; RA Wang H., Holloway M.P., Ma L., Cooper Z.A., Riolo M., Samkari A., RA Elenitoba-Johnson K.S., Chin Y.E., Altura R.A.; RT "Acetylation directs survivin nuclear localization to repress STAT3 RT oncogenic activity."; RL J. Biol. Chem. 285:36129-36137(2010). RN [36] RP FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=20627126; DOI=10.1016/j.mcn.2010.07.003; RA Habtemichael N., Heinrich U.R., Knauer S.K., Schmidtmann I., Bier C., RA Docter D., Brochhausen C., Helling K., Brieger J., Stauber R.H., Mann W.J.; RT "Expression analysis suggests a potential cytoprotective role of Birc5 in RT the inner ear."; RL Mol. Cell. Neurosci. 45:297-305(2010). RN [37] RP FUNCTION, HISTONE-BINDING, AND MUTAGENESIS OF ARG-18; TRP-25; CYS-33; RP CYS-57 AND TRP-67. RX PubMed=20929775; DOI=10.1126/science.1194498; RA Yamagishi Y., Honda T., Tanno Y., Watanabe Y.; RT "Two histone marks establish the inner centromere and chromosome bi- RT orientation."; RL Science 330:239-243(2010). RN [38] RP PHOSPHORYLATION AT THR-48, AND MUTAGENESIS OF THR-48. RX PubMed=21252625; DOI=10.4161/cc.10.3.14758; RA Barrett R.M., Colnaghi R., Wheatley S.P.; RT "Threonine 48 in the BIR domain of survivin is critical to its mitotic and RT anti-apoptotic activities and can be phosphorylated by CK2 in vitro."; RL Cell Cycle 10:538-548(2011). RN [39] RP INTERACTION WITH JTB. RX PubMed=21225229; DOI=10.3892/ijo.2011.900; RA Platica M., Ionescu A., Ivan E., Holland J.F., Mandeli J., Platica O.; RT "PAR, a protein involved in the cell cycle, is functionally related to RT chromosomal passenger proteins."; RL Int. J. Oncol. 38:777-785(2011). RN [40] RP FUNCTION, SUBUNIT, AND INTERACTION WITH XIAP/BIRC4 AND DIABLO/SMAC. RX PubMed=21536684; DOI=10.1074/jbc.m111.237586; RA Pavlyukov M.S., Antipova N.V., Balashova M.V., Vinogradova T.V., RA Kopantzev E.P., Shakhparonov M.I.; RT "Survivin monomer plays an essential role in apoptosis regulation."; RL J. Biol. Chem. 286:23296-23307(2011). RN [41] RP PHOSPHORYLATION AT THR-34 BY CDK15. RX PubMed=24866247; DOI=10.1016/j.bbrc.2014.05.070; RA Park M.H., Kim S.Y., Kim Y.J., Chung Y.H.; RT "ALS2CR7 (CDK15) attenuates TRAIL induced apoptosis by inducing RT phosphorylation of survivin Thr34."; RL Biochem. Biophys. Res. Commun. 450:129-134(2014). RN [42] RP UBIQUITINATION. RX PubMed=24793696; DOI=10.1016/j.molcel.2014.03.046; RA Li Z., Pei X.H., Yan J., Yan F., Cappell K.M., Whitehurst A.W., Xiong Y.; RT "CUL9 mediates the functions of the 3M complex and ubiquitylates survivin RT to maintain genome integrity."; RL Mol. Cell 54:805-819(2014). RN [43] RP FUNCTION, INTERACTION WITH FBXL7, AND MUTAGENESIS OF 90-LYS-LYS-91 AND RP GLU-126. RX PubMed=25778398; DOI=10.1074/jbc.m114.629931; RA Liu Y., Lear T., Iannone O., Shiva S., Corey C., Rajbhandari S., Jerome J., RA Chen B.B., Mallampalli R.K.; RT "The Proapoptotic F-box Protein Fbxl7 Regulates Mitochondrial Function by RT Mediating the Ubiquitylation and Proteasomal Degradation of Survivin."; RL J. Biol. Chem. 290:11843-11852(2015). RN [44] RP SUBUNIT, AND PHOSPHORYLATION AT SER-20. RX PubMed=27332895; DOI=10.1371/journal.pone.0157305; RA Sasai K., Katayama H., Hawke D.H., Sen S.; RT "Aurora-C interactions with survivin and INCENP reveal shared and distinct RT features compared with Aurora-B chromosome passenger protein complex."; RL PLoS ONE 11:E0157305-E0157305(2016). RN [45] RP FUNCTION, AND INTERACTION WITH FBXL7. RX PubMed=28218735; DOI=10.1038/oncsis.2016.80; RA Kamran M., Long Z.J., Xu D., Lv S.S., Liu B., Wang C.L., Xu J., Lam E.W., RA Liu Q.; RT "Aurora kinase A regulates Survivin stability through targeting FBXL7 in RT gastric cancer drug resistance and prognosis."; RL Oncogenesis 6:E298-E298(2017). RN [46] RP INTERACTION WITH EPSTEIN-BARR VIRUS EBNA1 (MICROBIAL INFECTION). RX PubMed=28077791; DOI=10.18632/oncotarget.14540; RA Dheekollu J., Malecka K., Wiedmer A., Delecluse H.J., Chiang A.K., RA Altieri D.C., Messick T.E., Lieberman P.M.; RT "Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal RT latency."; RL Oncotarget 8:7248-7264(2017). RN [47] RP DEUBIQUITINATION BY USP35 AND USP38. RX PubMed=34438346; DOI=10.1016/j.bbrc.2021.08.050; RA Wang W., Lin H., Zheng E., Hou Z., Liu Y., Huang W., Chen D., Feng J., RA Li J., Li L.; RT "Regulation of survivin protein stability by USP35 is evolutionarily RT conserved."; RL Biochem. Biophys. Res. Commun. 574:48-55(2021). RN [48] RP X-RAY CRYSTALLOGRAPHY (2.71 ANGSTROMS) OF ISOFORM 1. RX PubMed=10949039; DOI=10.1016/s1097-2765(05)00020-1; RA Chantalat L., Skoufias D.A., Kleman J.P., Jung B., Dideberg O., RA Margolis R.L.; RT "Crystal structure of human survivin reveals a bow tie-shaped dimer with RT two unusual alpha-helical extensions."; RL Mol. Cell 6:183-189(2000). RN [49] RP X-RAY CRYSTALLOGRAPHY (2.58 ANGSTROMS) OF ISOFORM 1. RX PubMed=10876248; DOI=10.1038/76838; RA Verdecia M.A., Huang H., Dutil E., Kaiser D.A., Hunter T., Noel J.P.; RT "Structure of the human anti-apoptotic protein survivin reveals a dimeric RT arrangement."; RL Nat. Struct. Biol. 7:602-608(2000). RN [50] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) IN COMPLEX WITH ZINC IONS, SUBUNIT, RP AND INTERACTION WITH CDCA8 AND INCENP. RX PubMed=17956729; DOI=10.1016/j.cell.2007.07.045; RA Jeyaprakash A.A., Klein U.R., Lindner D., Ebert J., Nigg E.A., Conti E.; RT "Structure of a Survivin-Borealin-INCENP core complex reveals how RT chromosomal passengers travel together."; RL Cell 131:271-285(2007). RN [51] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS). RX PubMed=19530738; DOI=10.1021/bi900530v; RA Bourhis E., Lingel A., Phung Q., Fairbrother W.J., Cochran A.G.; RT "Phosphorylation of a borealin dimerization domain is required for proper RT chromosome segregation."; RL Biochemistry 48:6783-6793(2009). CC -!- FUNCTION: Multitasking protein that has dual roles in promoting cell CC proliferation and preventing apoptosis (PubMed:20627126, CC PubMed:21364656, PubMed:25778398, PubMed:28218735, PubMed:9859993). CC Component of a chromosome passage protein complex (CPC) which is CC essential for chromosome alignment and segregation during mitosis and CC cytokinesis (PubMed:16322459). Acts as an important regulator of the CC localization of this complex; directs CPC movement to different CC locations from the inner centromere during prometaphase to midbody CC during cytokinesis and participates in the organization of the center CC spindle by associating with polymerized microtubules (PubMed:20826784). CC Involved in the recruitment of CPC to centromeres during early mitosis CC via association with histone H3 phosphorylated at 'Thr-3' (H3pT3) CC during mitosis (PubMed:20929775). The complex with RAN plays a role in CC mitotic spindle formation by serving as a physical scaffold to help CC deliver the RAN effector molecule TPX2 to microtubules CC (PubMed:18591255). May counteract a default induction of apoptosis in CC G2/M phase (PubMed:9859993). The acetylated form represses STAT3 CC transactivation of target gene promoters (PubMed:20826784). May play a CC role in neoplasia (PubMed:10626797). Inhibitor of CASP3 and CASP7 CC (PubMed:21536684). Essential for the maintenance of mitochondrial CC integrity and function (PubMed:25778398). Isoform 2 and isoform 3 do CC not appear to play vital roles in mitosis (PubMed:12773388, CC PubMed:16291752). Isoform 3 shows a marked reduction in its anti- CC apoptotic effects when compared with the displayed wild-type isoform CC (PubMed:10626797). {ECO:0000269|PubMed:10626797, CC ECO:0000269|PubMed:12773388, ECO:0000269|PubMed:16291752, CC ECO:0000269|PubMed:16322459, ECO:0000269|PubMed:18591255, CC ECO:0000269|PubMed:20627126, ECO:0000269|PubMed:20826784, CC ECO:0000269|PubMed:20929775, ECO:0000269|PubMed:21364656, CC ECO:0000269|PubMed:21536684, ECO:0000269|PubMed:25778398, CC ECO:0000269|PubMed:28218735, ECO:0000269|PubMed:9859993}. CC -!- SUBUNIT: Monomer or homodimer. Exists as a homodimer in the apo state CC and as a monomer in the CPC-bound state. The monomer protects cells CC against apoptosis more efficiently than the dimer. Only the dimeric CC form is capable of enhancing tubulin stability in cells. When CC phosphorylated, interacts with LAMTOR5/HBXIP; the resulting complex CC binds pro-CASP9, as well as active CASP9, but much less efficiently. CC Component of the chromosomal passenger complex (CPC) composed of at CC least BIRC5/survivin, CDCA8/borealin, INCENP, AURKB or AURKC; in the CC complex forms a triple-helix bundle-based subcomplex with INCENP and CC CDCA8 (PubMed:17956729). Interacts with JTB. Interacts (via BIR domain) CC with histone H3 phosphorylated at 'Thr-3' (H3pT3). Interacts with EVI5. CC Interacts with GTP-bound RAN in both the S and M phases of the cell CC cycle. Interacts with USP9X. Interacts with tubulin. Interacts with CC BIRC2/c-IAP1. The acetylated form at Lys-129 interacts with STAT3. The CC monomeric form deacetylated at Lys-129 interacts with XPO1/CRM1. The CC monomeric form interacts with XIAP/BIRC4. Both the dimeric and CC monomeric form can interact with DIABLO/SMAC. Interacts with CC BIRC6/bruce. Interacts with FBXL7; this interaction facilitates the CC polyubiquitination and subsequent proteasomal degradation of BIRC5 by CC the SCF(FBXL7) E3 ubiquitin-protein ligase complex (PubMed:25778398, CC PubMed:28218735). {ECO:0000269|PubMed:12773388, CC ECO:0000269|PubMed:14610074, ECO:0000269|PubMed:15249581, CC ECO:0000269|PubMed:15665297, ECO:0000269|PubMed:16239925, CC ECO:0000269|PubMed:16291752, ECO:0000269|PubMed:16322459, CC ECO:0000269|PubMed:16427043, ECO:0000269|PubMed:16436504, CC ECO:0000269|PubMed:16764853, ECO:0000269|PubMed:17956729, CC ECO:0000269|PubMed:18329369, ECO:0000269|PubMed:18591255, CC ECO:0000269|PubMed:20826784, ECO:0000269|PubMed:21225229, CC ECO:0000269|PubMed:21536684, ECO:0000269|PubMed:25778398, CC ECO:0000269|PubMed:28218735}. CC -!- SUBUNIT: (Microbial infection) Interacts with Epstein-Barr virus (EBV) CC EBNA1; this interaction is probably important for EBV episome CC maintenance in Burkitt's lymphoma cells. {ECO:0000269|PubMed:28077791}. CC -!- INTERACTION: CC O15392; Q92870-2: APBB2; NbExp=3; IntAct=EBI-518823, EBI-21535880; CC O15392; P05067: APP; NbExp=3; IntAct=EBI-518823, EBI-77613; CC O15392; P05067-2: APP; NbExp=3; IntAct=EBI-518823, EBI-17264467; CC O15392; O14965: AURKA; NbExp=2; IntAct=EBI-518823, EBI-448680; CC O15392; Q96GD4: AURKB; NbExp=13; IntAct=EBI-518823, EBI-624291; CC O15392; Q9UQB9: AURKC; NbExp=10; IntAct=EBI-518823, EBI-3926851; CC O15392; Q14457: BECN1; NbExp=3; IntAct=EBI-518823, EBI-949378; CC O15392; O15392: BIRC5; NbExp=2; IntAct=EBI-518823, EBI-518823; CC O15392; Q15834: CCDC85B; NbExp=3; IntAct=EBI-518823, EBI-739674; CC O15392; Q53HL2: CDCA8; NbExp=21; IntAct=EBI-518823, EBI-979174; CC O15392; P06493: CDK1; NbExp=6; IntAct=EBI-518823, EBI-444308; CC O15392; Q14203-5: DCTN1; NbExp=3; IntAct=EBI-518823, EBI-25840379; CC O15392; Q9NR28: DIABLO; NbExp=2; IntAct=EBI-518823, EBI-517508; CC O15392; Q86XJ1: GAS2L3; NbExp=4; IntAct=EBI-518823, EBI-9248152; CC O15392; Q8TB36: GDAP1; NbExp=3; IntAct=EBI-518823, EBI-11110431; CC O15392; P42858: HTT; NbExp=15; IntAct=EBI-518823, EBI-466029; CC O15392; Q9NQS7: INCENP; NbExp=11; IntAct=EBI-518823, EBI-307907; CC O15392; O43504: LAMTOR5; NbExp=3; IntAct=EBI-518823, EBI-713382; CC O15392; Q96CV9: OPTN; NbExp=3; IntAct=EBI-518823, EBI-748974; CC O15392; Q7Z412: PEX26; NbExp=3; IntAct=EBI-518823, EBI-752057; CC O15392; Q9BXM7: PINK1; NbExp=3; IntAct=EBI-518823, EBI-2846068; CC O15392; P62826: RAN; NbExp=7; IntAct=EBI-518823, EBI-286642; CC O15392; P37840: SNCA; NbExp=3; IntAct=EBI-518823, EBI-985879; CC O15392; Q13148: TARDBP; NbExp=6; IntAct=EBI-518823, EBI-372899; CC O15392; P09936: UCHL1; NbExp=3; IntAct=EBI-518823, EBI-714860; CC O15392; O14980: XPO1; NbExp=2; IntAct=EBI-518823, EBI-355867; CC O15392-1; Q96GD4: AURKB; NbExp=2; IntAct=EBI-518838, EBI-624291; CC O15392-1; O15392-1: BIRC5; NbExp=2; IntAct=EBI-518838, EBI-518838; CC O15392-1; O15392-2: BIRC5; NbExp=2; IntAct=EBI-518838, EBI-518842; CC O15392-1; Q53HL2: CDCA8; NbExp=2; IntAct=EBI-518838, EBI-979174; CC O15392-2; Q96GD4: AURKB; NbExp=2; IntAct=EBI-518842, EBI-624291; CC O15392-2; Q53HL2: CDCA8; NbExp=2; IntAct=EBI-518842, EBI-979174; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:20627126, CC ECO:0000269|PubMed:20826784, ECO:0000269|PubMed:21364656}. Nucleus CC {ECO:0000269|PubMed:20627126, ECO:0000269|PubMed:20826784, CC ECO:0000269|PubMed:21364656}. Chromosome {ECO:0000269|PubMed:14610074}. CC Chromosome, centromere {ECO:0000269|PubMed:11084331, CC ECO:0000269|PubMed:14610074, ECO:0000269|PubMed:16322459}. Cytoplasm, CC cytoskeleton, spindle {ECO:0000269|PubMed:11084331}. Chromosome, CC centromere, kinetochore {ECO:0000269|PubMed:11084331}. Midbody CC {ECO:0000269|PubMed:15665297}. Note=Localizes at the centromeres from CC prophase to metaphase, at the spindle midzone during anaphase and a the CC midbody during telophase and cytokinesis. Accumulates in the nucleus CC upon treatment with leptomycin B (LMB), a XPO1/CRM1 nuclear export CC inhibitor (By similarity). Localizes on chromosome arms and inner CC centromeres from prophase through metaphase. Localizes to kinetochores CC in metaphase, distributes to the midzone microtubules in anaphase and CC at telophase, localizes exclusively to the midbody (PubMed:11084331). CC Colocalizes with AURKB at mitotic chromosomes (PubMed:14610074). CC Acetylation at Lys-129 directs its localization to the nucleus by CC enhancing homodimerization and thereby inhibiting XPO1/CRM1-mediated CC nuclear export (PubMed:20826784). {ECO:0000250|UniProtKB:E3SCZ8, CC ECO:0000269|PubMed:11084331, ECO:0000269|PubMed:14610074, CC ECO:0000269|PubMed:20826784}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=7; CC Name=1; Synonyms=Alpha; CC IsoId=O15392-1; Sequence=Displayed; CC Name=2; Synonyms=2B, Beta; CC IsoId=O15392-2; Sequence=VSP_002454; CC Name=3; Synonyms=DeltaEx3; CC IsoId=O15392-3; Sequence=VSP_020338; CC Name=4; Synonyms=3B; CC IsoId=O15392-4; Sequence=VSP_020342; CC Name=5; Synonyms=SI; CC IsoId=O15392-5; Sequence=VSP_020341; CC Name=6; Synonyms=3 alpha; CC IsoId=O15392-6; Sequence=VSP_020339; CC Name=7; Synonyms=2 alpha; CC IsoId=O15392-7; Sequence=VSP_020340; CC -!- TISSUE SPECIFICITY: Expressed only in fetal kidney and liver, and to CC lesser extent, lung and brain (PubMed:10626797). Abundantly expressed CC in adenocarcinoma (lung, pancreas, colon, breast, and prostate) and in CC high-grade lymphomas (PubMed:14741722, PubMed:16329164). Also expressed CC in various renal cell carcinoma cell lines (PubMed:10626797). Expressed CC in cochlea including the organ of Corti, the lateral wall, the CC interdental cells of the Limbus as well as in Schwann cells and cells CC of the cochlear nerve and the spiral ganglions (at protein level). Not CC expressed in cells of the inner and outer sulcus or the Reissner's CC membrane (at protein level) (PubMed:20627126, PubMed:21364656). CC {ECO:0000269|PubMed:10626797, ECO:0000269|PubMed:14741722, CC ECO:0000269|PubMed:16329164, ECO:0000269|PubMed:20627126, CC ECO:0000269|PubMed:21364656}. CC -!- DEVELOPMENTAL STAGE: Expression is cell cycle-dependent and peaks at CC mitosis. {ECO:0000269|PubMed:18591255}. CC -!- INDUCTION: Up-regulated by COMP. {ECO:0000269|PubMed:17993464}. CC -!- DOMAIN: The BIR repeat is necessary and sufficient for LAMTOR5 binding. CC {ECO:0000269|PubMed:12773388}. CC -!- PTM: Ubiquitinated by the Cul9-RING ubiquitin-protein ligase complex, CC leading to its degradation. Ubiquitination is required for centrosomal CC targeting. Deubiquitinated by USP35 or USP38; leading to stabilization CC (PubMed:34438346). {ECO:0000269|PubMed:16322459, CC ECO:0000269|PubMed:24793696, ECO:0000269|PubMed:34438346}. CC -!- PTM: In vitro phosphorylation at Thr-117 by AURKB prevents interaction CC with INCENP and localization to mitotic chromosomes (PubMed:14610074). CC Phosphorylation at Thr-48 by CK2 is critical for its mitotic and anti- CC apoptotic activities (PubMed:21252625). Phosphorylation at Thr-34 by CC CDK15 is critical for its anti-apoptotic activity (PubMed:24866247). CC Phosphorylation at Ser-20 by AURKC is critical for regulation of proper CC chromosome alignment and segregation, and possibly cytokinesis. CC {ECO:0000269|PubMed:11069302, ECO:0000269|PubMed:14610074, CC ECO:0000269|PubMed:21252625, ECO:0000269|PubMed:24866247, CC ECO:0000269|PubMed:27332895}. CC -!- PTM: Acetylation at Lys-129 by CBP results in its homodimerization, CC while deacetylation promotes the formation of monomers which CC heterodimerize with XPO1/CRM1 which facilitates its nuclear export. The CC acetylated form represses STAT3 transactivation. The dynamic CC equilibrium between its acetylation and deacetylation at Lys-129 CC determines its interaction with XPO1/CRM1, its subsequent subcellular CC localization, and its ability to inhibit STAT3 transactivation. CC {ECO:0000269|PubMed:20826784}. CC -!- SIMILARITY: Belongs to the IAP family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U75285; AAC51660.1; -; Genomic_DNA. DR EMBL; AF077350; AAD34226.1; -; mRNA. DR EMBL; AB154416; BAD11155.1; -; mRNA. DR EMBL; AY830084; AAW22624.1; -; mRNA. DR EMBL; AB028869; BAA93676.1; -; mRNA. DR EMBL; AY927772; AAY15202.1; -; mRNA. DR EMBL; DQ227257; ABB76601.1; -; mRNA. DR EMBL; DQ310375; ABC42341.1; -; mRNA. DR EMBL; DQ310376; ABC42342.1; -; mRNA. DR EMBL; DQ310377; ABC42343.1; -; mRNA. DR EMBL; DQ310378; ABC42344.1; -; mRNA. DR EMBL; DQ310379; ABC42345.1; -; mRNA. DR EMBL; CR541740; CAG46540.1; -; mRNA. DR EMBL; AK223428; BAD97148.1; -; mRNA. DR EMBL; AK311917; BAG34858.1; -; mRNA. DR EMBL; AY795969; AAV40840.1; -; Genomic_DNA. DR EMBL; AC087645; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471099; EAW89514.1; -; Genomic_DNA. DR EMBL; BC008718; AAH08718.1; -; mRNA. DR EMBL; BC034148; AAH34148.1; -; mRNA. DR EMBL; BC065497; AAH65497.1; -; mRNA. DR CCDS; CCDS11755.1; -. [O15392-1] DR CCDS; CCDS32751.1; -. [O15392-3] DR CCDS; CCDS32752.1; -. [O15392-2] DR RefSeq; NP_001012270.1; NM_001012270.2. [O15392-3] DR RefSeq; NP_001012271.1; NM_001012271.1. DR RefSeq; NP_001159.2; NM_001168.2. DR PDB; 1E31; X-ray; 2.71 A; A/B=1-142. DR PDB; 1F3H; X-ray; 2.58 A; A/B=1-142. DR PDB; 1XOX; NMR; -; A/B=1-117. DR PDB; 2QFA; X-ray; 1.40 A; A=1-142. DR PDB; 2RAW; X-ray; 2.40 A; A=1-142. DR PDB; 2RAX; X-ray; 3.30 A; A/E/X=1-120. DR PDB; 3UEC; X-ray; 2.18 A; A=1-142. DR PDB; 3UED; X-ray; 2.70 A; A/C=1-142. DR PDB; 3UEE; X-ray; 2.61 A; A/C=1-142. DR PDB; 3UEF; X-ray; 2.45 A; A/C=1-142. DR PDB; 3UEG; X-ray; 2.80 A; A/B=1-142. DR PDB; 3UEH; X-ray; 2.60 A; A/B=1-142. DR PDB; 3UEI; X-ray; 2.70 A; A/B=1-142. DR PDB; 3UIG; X-ray; 2.40 A; A/B=1-142. DR PDB; 3UIH; X-ray; 2.40 A; A/B=1-142. DR PDB; 3UII; X-ray; 2.60 A; A/B=1-142. DR PDB; 3UIJ; X-ray; 2.70 A; A/B=1-142. DR PDB; 3UIK; X-ray; 2.70 A; A/B=1-142. DR PDB; 4A0I; X-ray; 2.60 A; A/B=1-142. DR PDB; 4A0J; X-ray; 2.80 A; A/B=1-142. DR PDB; 4A0N; X-ray; 2.74 A; A=1-142. DR PDB; 6SHO; X-ray; 3.20 A; A/B=1-142. DR PDB; 6YIE; X-ray; 3.49 A; A/D=1-142. DR PDB; 6YIF; X-ray; 1.81 A; A=1-142. DR PDB; 6YIH; X-ray; 2.55 A; A=1-142. DR PDB; 7LBK; X-ray; 2.70 A; A/B=1-142. DR PDB; 7LBO; X-ray; 2.50 A; A/B=1-142. DR PDB; 7LBP; X-ray; 2.60 A; A/C=1-142. DR PDB; 7LBQ; X-ray; 2.69 A; A=1-142. DR PDB; 8RUP; EM; 2.42 A; K=1-142. DR PDBsum; 1E31; -. DR PDBsum; 1F3H; -. DR PDBsum; 1XOX; -. DR PDBsum; 2QFA; -. DR PDBsum; 2RAW; -. DR PDBsum; 2RAX; -. DR PDBsum; 3UEC; -. DR PDBsum; 3UED; -. DR PDBsum; 3UEE; -. DR PDBsum; 3UEF; -. DR PDBsum; 3UEG; -. DR PDBsum; 3UEH; -. DR PDBsum; 3UEI; -. DR PDBsum; 3UIG; -. DR PDBsum; 3UIH; -. DR PDBsum; 3UII; -. DR PDBsum; 3UIJ; -. DR PDBsum; 3UIK; -. DR PDBsum; 4A0I; -. DR PDBsum; 4A0J; -. DR PDBsum; 4A0N; -. DR PDBsum; 6SHO; -. DR PDBsum; 6YIE; -. DR PDBsum; 6YIF; -. DR PDBsum; 6YIH; -. DR PDBsum; 7LBK; -. DR PDBsum; 7LBO; -. DR PDBsum; 7LBP; -. DR PDBsum; 7LBQ; -. DR PDBsum; 8RUP; -. DR AlphaFoldDB; O15392; -. DR BMRB; O15392; -. DR EMDB; EMD-19513; -. DR SASBDB; O15392; -. DR SMR; O15392; -. DR BioGRID; 106829; 111. DR ComplexPortal; CPX-111; Survivin homodimer complex. DR ComplexPortal; CPX-116; Chromosomal passenger complex. DR CORUM; O15392; -. DR DIP; DIP-34662N; -. DR ELM; O15392; -. DR FunCoup; O15392; 1567. DR IntAct; O15392; 57. DR MINT; O15392; -. DR STRING; 9606.ENSP00000301633; -. DR BindingDB; O15392; -. DR ChEMBL; CHEMBL5989; -. DR DrugBank; DB16095; APG-1387. DR DrugBank; DB04115; Berberine. DR DrugBank; DB12085; LCL-161. DR DrugBank; DB05141; LY2181308. DR DrugBank; DB00206; Reserpine. DR DrugBank; DB16305; Xevinapant. DR DrugCentral; O15392; -. DR GuidetoPHARMACOLOGY; 2795; -. DR MEROPS; I32.005; -. DR iPTMnet; O15392; -. DR PhosphoSitePlus; O15392; -. DR BioMuta; BIRC5; -. DR jPOST; O15392; -. DR MassIVE; O15392; -. DR PeptideAtlas; O15392; -. DR ProteomicsDB; 48627; -. [O15392-1] DR ProteomicsDB; 48628; -. [O15392-2] DR ProteomicsDB; 48629; -. [O15392-3] DR ProteomicsDB; 48630; -. [O15392-4] DR ProteomicsDB; 48631; -. [O15392-5] DR ProteomicsDB; 48632; -. [O15392-6] DR ProteomicsDB; 48633; -. [O15392-7] DR Pumba; O15392; -. DR ABCD; O15392; 5 sequenced antibodies. DR Antibodypedia; 1073; 1831 antibodies from 53 providers. DR DNASU; 332; -. DR Ensembl; ENST00000374948.6; ENSP00000364086.1; ENSG00000089685.16. [O15392-3] DR Ensembl; ENST00000590449.1; ENSP00000465868.1; ENSG00000089685.16. [O15392-7] DR Ensembl; ENST00000590925.6; ENSP00000467336.1; ENSG00000089685.16. [O15392-4] DR Ensembl; ENST00000592734.5; ENSP00000466617.1; ENSG00000089685.16. [O15392-6] DR GeneID; 332; -. DR KEGG; hsa:332; -. DR UCSC; uc002jvh.4; human. [O15392-1] DR AGR; HGNC:593; -. DR CIViC; 332; 2 evidence items across 2 molecular profiles. DR ClinPGx; PA25362; -. DR CTD; 332; -. DR DisGeNET; 332; -. DR GeneCards; BIRC5; -. DR HGNC; HGNC:593; BIRC5. DR HPA; ENSG00000089685; Tissue enhanced (bone marrow, lymphoid tissue, testis). DR MIM; 603352; gene. DR OpenTargets; ENSG00000089685; -. DR VEuPathDB; HostDB:ENSG00000089685; -. DR GeneTree; ENSGT00510000047537; -. DR HOGENOM; CLU_1869818_0_0_1; -. DR InParanoid; O15392; -. DR OrthoDB; 2196114at2759; -. DR PAN-GO; O15392; 6 GO annotations based on evolutionary models. DR PathwayCommons; O15392; -. DR Reactome; R-HSA-141444; Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal. DR Reactome; R-HSA-2467813; Separation of Sister Chromatids. DR Reactome; R-HSA-2500257; Resolution of Sister Chromatid Cohesion. DR Reactome; R-HSA-4615885; SUMOylation of DNA replication proteins. DR Reactome; R-HSA-5663220; RHO GTPases Activate Formins. DR Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling. DR Reactome; R-HSA-6803205; TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain. DR Reactome; R-HSA-68877; Mitotic Prometaphase. DR Reactome; R-HSA-8951664; Neddylation. DR Reactome; R-HSA-9648025; EML4 and NUDC in mitotic spindle formation. DR SignaLink; O15392; -. DR SIGNOR; O15392; -. DR Agora; ENSG00000089685; -. DR BioGRID-ORCS; 332; 826 hits in 1161 CRISPR screens. DR CD-CODE; 3F4CB227; Synthetic Condensate 000322. DR CD-CODE; 45F3D8EC; Synthetic Condensate 000342. DR CD-CODE; 7230F6EA; Synthetic Condensate 000328. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; BIRC5; human. DR EvolutionaryTrace; O15392; -. DR GeneWiki; Survivin; -. DR GenomeRNAi; 332; -. DR Pharos; O15392; Tchem. DR PRO; PR:O15392; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; O15392; protein. DR Bgee; ENSG00000089685; Expressed in ventricular zone and 127 other cell types or tissues. DR ExpressionAtlas; O15392; baseline and differential. DR GO; GO:0005814; C:centriole; IDA:UniProtKB. DR GO; GO:0032133; C:chromosome passenger complex; IPI:UniProtKB. DR GO; GO:0000775; C:chromosome, centromeric region; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005881; C:cytoplasmic microtubule; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0031021; C:interphase microtubule organizing center; IDA:UniProtKB. DR GO; GO:0000776; C:kinetochore; IDA:UniProtKB. DR GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW. DR GO; GO:0015630; C:microtubule cytoskeleton; IDA:ComplexPortal. DR GO; GO:0030496; C:midbody; IDA:UniProtKB. DR GO; GO:0000228; C:nuclear chromosome; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB. DR GO; GO:0005876; C:spindle microtubule; IDA:UniProtKB. DR GO; GO:0051233; C:spindle midzone; IBA:GO_Central. DR GO; GO:1990713; C:survivin complex; IPI:ComplexPortal. DR GO; GO:0050897; F:cobalt ion binding; NAS:UniProtKB. DR GO; GO:0004869; F:cysteine-type endopeptidase inhibitor activity; IEA:UniProtKB-KW. DR GO; GO:0043027; F:cysteine-type endopeptidase inhibitor activity involved in apoptotic process; IMP:UniProtKB. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0008017; F:microtubule binding; IDA:UniProtKB. DR GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0051087; F:protein-folding chaperone binding; IPI:UniProtKB. DR GO; GO:0031267; F:small GTPase binding; IPI:UniProtKB. DR GO; GO:0015631; F:tubulin binding; IDA:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0051301; P:cell division; IMP:UniProtKB. DR GO; GO:0050000; P:chromosome localization; IMP:UniProtKB. DR GO; GO:0007059; P:chromosome segregation; IBA:GO_Central. DR GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IDA:UniProtKB. DR GO; GO:0000278; P:mitotic cell cycle; TAS:UniProtKB. DR GO; GO:0000281; P:mitotic cytokinesis; IMP:UniProtKB. DR GO; GO:0090307; P:mitotic spindle assembly; NAS:ComplexPortal. DR GO; GO:0007094; P:mitotic spindle assembly checkpoint signaling; IMP:UniProtKB. DR GO; GO:0051256; P:mitotic spindle midzone assembly; NAS:ComplexPortal. DR GO; GO:0007052; P:mitotic spindle organization; IBA:GO_Central. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IMP:UniProtKB. DR GO; GO:1902425; P:positive regulation of attachment of mitotic spindle microtubules to kinetochore; NAS:ComplexPortal. DR GO; GO:0008284; P:positive regulation of cell population proliferation; TAS:UniProtKB. DR GO; GO:0031536; P:positive regulation of exit from mitosis; IMP:UniProtKB. DR GO; GO:0045931; P:positive regulation of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0090267; P:positive regulation of mitotic cell cycle spindle assembly checkpoint; NAS:ComplexPortal. DR GO; GO:1903490; P:positive regulation of mitotic cytokinesis; NAS:ComplexPortal. DR GO; GO:1901970; P:positive regulation of mitotic sister chromatid separation; NAS:ComplexPortal. DR GO; GO:0031503; P:protein-containing complex localization; IMP:UniProtKB. DR GO; GO:0007605; P:sensory perception of sound; IEP:UniProtKB. DR CDD; cd00022; BIR; 1. DR DisProt; DP03719; -. DR FunFam; 1.10.1170.10:FF:000009; Baculoviral IAP repeat-containing protein 5; 1. DR Gene3D; 1.10.1170.10; Inhibitor Of Apoptosis Protein (2mihbC-IAP-1), Chain A; 1. DR IDEAL; IID00186; -. DR InterPro; IPR051190; Baculoviral_IAP. DR InterPro; IPR001370; BIR_rpt. DR PANTHER; PTHR46771:SF3; BACULOVIRAL IAP REPEAT-CONTAINING PROTEIN 5; 1. DR PANTHER; PTHR46771; DETERIN; 1. DR Pfam; PF00653; BIR; 1. DR SMART; SM00238; BIR; 1. DR SUPFAM; SSF57924; Inhibitor of apoptosis (IAP) repeat; 1. DR PROSITE; PS50143; BIR_REPEAT_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; Cell cycle; KW Cell division; Centromere; Chromosome; Chromosome partition; Cytoplasm; KW Cytoskeleton; Host-virus interaction; Kinetochore; Metal-binding; KW Microtubule; Mitosis; Nucleus; Phosphoprotein; Protease inhibitor; KW Proteomics identification; Reference proteome; Repressor; KW Thiol protease inhibitor; Transcription; Transcription regulation; KW Ubl conjugation; Zinc. FT CHAIN 1..142 FT /note="Baculoviral IAP repeat-containing protein 5" FT /id="PRO_0000122356" FT REPEAT 18..88 FT /note="BIR" FT BINDING 57 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:17956729, FT ECO:0007744|PDB:2QFA" FT BINDING 60 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:17956729, FT ECO:0007744|PDB:2QFA" FT BINDING 77 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:17956729, FT ECO:0007744|PDB:2QFA" FT BINDING 84 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:17956729, FT ECO:0007744|PDB:2QFA" FT SITE 126 FT /note="Interaction with FBXL7" FT /evidence="ECO:0000269|PubMed:25778398" FT MOD_RES 20 FT /note="Phosphoserine; by AURKC" FT /evidence="ECO:0000269|PubMed:27332895" FT MOD_RES 23 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT MOD_RES 34 FT /note="Phosphothreonine; by CDK1 and CDK15" FT /evidence="ECO:0000269|PubMed:11069302, FT ECO:0000269|PubMed:24866247, ECO:0007744|PubMed:18691976" FT MOD_RES 48 FT /note="Phosphothreonine; by CK2; in vitro" FT /evidence="ECO:0000269|PubMed:21252625" FT MOD_RES 90 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT MOD_RES 110 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT MOD_RES 112 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT MOD_RES 115 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT MOD_RES 117 FT /note="Phosphothreonine; by AURKB" FT /evidence="ECO:0000269|PubMed:14610074" FT MOD_RES 121 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT MOD_RES 129 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:20826784" FT VAR_SEQ 74..142 FT /note="IEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKNKIAKETNNKKKEFE FT ETAKKVRRAIEQLAAMD -> MQRKPTIRRKNLRKLRRKCAVPSSSWLPWIEASGRSCL FT VPEWLHHFQGLFPGATSLPVGPLAMS (in isoform 3)" FT /evidence="ECO:0000303|PubMed:10626797" FT /id="VSP_020338" FT VAR_SEQ 74..142 FT /note="IEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKNKIAKETNNKKKEFE FT ETAKKVRRAIEQLAAMD -> MRELC (in isoform 6)" FT /evidence="ECO:0000303|Ref.8" FT /id="VSP_020339" FT VAR_SEQ 74..142 FT /note="IEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKNKIAKETNNKKKEFE FT ETAKKVRRAIEQLAAMD -> M (in isoform 7)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_020340" FT VAR_SEQ 74 FT /note="I -> IGPGTVAYACNTSTLGGRGGRITR (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10626797, ECO:0000303|Ref.6" FT /id="VSP_002454" FT VAR_SEQ 105..142 FT /note="DRERAKNKIAKETNNKKKEFEETAKKVRRAIEQLAAMD -> VRETLPPPRS FT FIR (in isoform 5)" FT /evidence="ECO:0000303|PubMed:16329164" FT /id="VSP_020341" FT VAR_SEQ 114..142 FT /note="AKETNNKKKEFEETAKKVRRAIEQLAAMD -> ERALLAE (in isoform FT 4)" FT /evidence="ECO:0000303|PubMed:14741722" FT /id="VSP_020342" FT VARIANT 129 FT /note="K -> E (loss of acetylation; localization primarily FT within the cytoplasm; increased likelihood of existing as FT monomer; stronger binding to XPO1/CRM1; dbSNP:rs2071214)" FT /evidence="ECO:0000269|PubMed:16625196, FT ECO:0000269|PubMed:20826784" FT /id="VAR_021071" FT MUTAGEN 18 FT /note="R->A: Disrupts interaction with histone H3pT3, no FT effect on interaction with INCENP." FT /evidence="ECO:0000269|PubMed:20929775" FT MUTAGEN 23 FT /note="K->R: Increases ubiquitination and blocks FT dissociation from centromeres; when associated with R-62; FT R-78 and R-79." FT /evidence="ECO:0000269|PubMed:16322459" FT MUTAGEN 25 FT /note="W->A: Disrupts interaction with histone H3pT3, no FT effect on interaction with INCENP." FT /evidence="ECO:0000269|PubMed:20929775" FT MUTAGEN 33 FT /note="C->R: Disrupts interaction with histone H3pT3, no FT effect on interaction with INCENP." FT /evidence="ECO:0000269|PubMed:20929775" FT MUTAGEN 34 FT /note="T->A: Loss of LAMTOR5 binding." FT /evidence="ECO:0000269|PubMed:12773388" FT MUTAGEN 34 FT /note="T->E: Higher affinity for LAMTOR5 binding." FT /evidence="ECO:0000269|PubMed:12773388" FT MUTAGEN 48 FT /note="T->A,E: Localizes normally during mitosis but cannot FT support cell proliferation. Increased affinity for FT CDCA8/borealin." FT /evidence="ECO:0000269|PubMed:21252625" FT MUTAGEN 57 FT /note="C->A: Disrupts interaction with histone H3pT3, no FT effect on interaction with INCENP." FT /evidence="ECO:0000269|PubMed:20929775" FT MUTAGEN 62 FT /note="K->R: Increases ubiquitination and blocks FT dissociation from centromeres; when associated with R-23; FT R-78 and R-79." FT /evidence="ECO:0000269|PubMed:16322459" FT MUTAGEN 65 FT /note="E->A: Almost abolishes RAN-binding. Does not disrupt FT binding to AURKB or CDCA8. Disrupts mitotic spindle FT assembly. Does not disrupt nuclear export." FT /evidence="ECO:0000269|PubMed:18591255" FT MUTAGEN 67 FT /note="W->A: Disrupts interaction with histone H3pT3, no FT effect on interaction with INCENP." FT /evidence="ECO:0000269|PubMed:20929775" FT MUTAGEN 70 FT /note="D->A: No change. Loss of interaction with AURKB; FT when associated with A-71." FT /evidence="ECO:0000269|PubMed:16762323" FT MUTAGEN 71 FT /note="D->A: No change. Loss of interaction with AURKB; FT when associated with A-70." FT /evidence="ECO:0000269|PubMed:16762323" FT MUTAGEN 78 FT /note="K->R: Increases ubiquitination and blocks FT dissociation from centromeres; when associated with R-23; FT R-62 and R-79." FT /evidence="ECO:0000269|PubMed:16322459" FT MUTAGEN 79 FT /note="K->R: Increases ubiquitination and blocks FT dissociation from centromeres; when associated with R-23; FT R-62 and R-78." FT /evidence="ECO:0000269|PubMed:16322459" FT MUTAGEN 84 FT /note="C->A: Loss of cytoprotection." FT MUTAGEN 90..91 FT /note="KK->RR: Loss of FBXL7 mediated polyubiquitination." FT /evidence="ECO:0000269|PubMed:25778398" FT MUTAGEN 117 FT /note="T->A: Prevents phosphorylation by AURKB. Still able FT to localize correctly but prevents interaction with FT INCENP." FT /evidence="ECO:0000269|PubMed:14610074" FT MUTAGEN 117 FT /note="T->E: Mimics phosphorylation. Disrupts subcellular FT localization during mitosis and prevents interaction with FT INCENP." FT /evidence="ECO:0000269|PubMed:14610074" FT MUTAGEN 126 FT /note="E->A: Loss of FBXL7 binding." FT /evidence="ECO:0000269|PubMed:25778398" FT MUTAGEN 129 FT /note="K->A,Q: Mimics acetylation. Localization primarily FT within the nucleus." FT /evidence="ECO:0000269|PubMed:20826784" FT MUTAGEN 129 FT /note="K->R: Loss of acetylation. Localization primarily FT within the cytoplasm." FT /evidence="ECO:0000269|PubMed:20826784" FT CONFLICT 57..58 FT /note="CF -> WV (in Ref. 5; AAW22624)" FT /evidence="ECO:0000305" FT CONFLICT 58 FT /note="F -> L (in Ref. 11; BAD97148)" FT /evidence="ECO:0000305" FT CONFLICT 128 FT /note="A -> V (in Ref. 9; CAG46540)" FT /evidence="ECO:0000305" FT TURN 8..10 FT /evidence="ECO:0007829|PDB:2QFA" FT HELIX 11..13 FT /evidence="ECO:0007829|PDB:2QFA" FT HELIX 15..20 FT /evidence="ECO:0007829|PDB:2QFA" FT STRAND 29..32 FT /evidence="ECO:0007829|PDB:6YIF" FT HELIX 35..40 FT /evidence="ECO:0007829|PDB:2QFA" FT STRAND 43..45 FT /evidence="ECO:0007829|PDB:2QFA" FT STRAND 49..51 FT /evidence="ECO:0007829|PDB:3UIG" FT STRAND 55..57 FT /evidence="ECO:0007829|PDB:2QFA" FT TURN 58..60 FT /evidence="ECO:0007829|PDB:2QFA" FT STRAND 63..65 FT /evidence="ECO:0007829|PDB:6YIF" FT HELIX 73..80 FT /evidence="ECO:0007829|PDB:2QFA" FT TURN 81..83 FT /evidence="ECO:0007829|PDB:1F3H" FT HELIX 85..88 FT /evidence="ECO:0007829|PDB:2QFA" FT HELIX 93..95 FT /evidence="ECO:0007829|PDB:2QFA" FT HELIX 98..139 FT /evidence="ECO:0007829|PDB:2QFA" SQ SEQUENCE 142 AA; 16389 MW; 9E7CADCDF2822286 CRC64; MGAPTLPPAW QPFLKDHRIS TFKNWPFLEG CACTPERMAE AGFIHCPTEN EPDLAQCFFC FKELEGWEPD DDPIEEHKKH SSGCAFLSVK KQFEELTLGE FLKLDRERAK NKIAKETNNK KKEFEETAKK VRRAIEQLAA MD // ID BRAF_HUMAN Reviewed; 766 AA. AC P15056; A4D1T4; B6HY61; B6HY62; B6HY63; B6HY64; B6HY65; B6HY66; Q13878; AC Q3MIN6; Q9UDP8; Q9Y6T3; DT 01-NOV-1990, integrated into UniProtKB/Swiss-Prot. DT 19-JUL-2004, sequence version 4. DT 28-JAN-2026, entry version 267. DE RecName: Full=Serine/threonine-protein kinase B-raf {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126}; DE AltName: Full=Proto-oncogene B-Raf; DE AltName: Full=p94; DE AltName: Full=v-Raf murine sarcoma viral oncogene homolog B1; GN Name=BRAF {ECO:0000312|HGNC:HGNC:1097}; Synonyms=BRAF1, RAFB1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, FUNCTION, AND RP PHOSPHORYLATION AT THR-373. RC TISSUE=Testis; RX PubMed=1508179; DOI=10.1128/mcb.12.9.3733-3742.1992; RA Stephens R.M., Sithanandam G., Copeland T.D., Kaplan D.R., Rapp U.R., RA Morrison D.K.; RT "95-kilodalton B-Raf serine/threonine kinase: identification of the protein RT and its major autophosphorylation site."; RL Mol. Cell. Biol. 12:3733-3742(1992). RN [2] RP SEQUENCE REVISION TO 31-33. RA Albert S., Wixler L., Rapp U.R.; RL Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (MAR-2008) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12690205; DOI=10.1126/science.1083423; RA Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K., RA Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R., RA Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A., RA Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D., RA Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S., RA Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R., RA Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N., RA Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E., RA Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R., RA Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T., RA Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W., RA Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A., RA Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X., RA Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E., RA Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H., RA Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J., RA Adams M.D., Tsui L.-C.; RT "Human chromosome 7: DNA sequence and biology."; RL Science 300:767-772(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12853948; DOI=10.1038/nature01782; RA Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H., RA Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K., RA Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A., RA Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H., RA Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A., RA Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P., RA Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M., RA Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S., RA Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., RA Strowmatt C., Latreille P., Miller N., Johnson D., Murray J., RA Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., RA Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., RA Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E., RA Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E., RA Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A., RA Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A., RA Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R., RA McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H., RA Wilson R.K.; RT "The DNA sequence of human chromosome 7."; RL Nature 424:157-164(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Liver; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-200. RC TISSUE=Placenta; RX PubMed=1630826; RA Eychene A., Barnier J.V., Apiou F., Dutrillaux B., Calothy G.; RT "Chromosomal assignment of two human B-raf(Rmil) proto-oncogene loci: B- RT raf-1 encoding the p94Braf/Rmil and B-raf-2, a processed pseudogene."; RL Oncogene 7:1657-1660(1992). RN [8] RP PROTEIN SEQUENCE OF 2-51; 56-95; 151-158; 189-199; 253-260; 294-354; RP 361-424; 444-507; 510-522; 559-570; 579-626; 663-680; 692-698; 702-719; RP 727-735 AND 753-766, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT RP ALA-2, PHOSPHORYLATION AT SER-365; THR-396; SER-399; THR-401 AND SER-729, RP AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Colon carcinoma, and Hepatoma; RA Bienvenut W.V., Boldt K., von Kriegsheim A.F., Zebisch A., Kolch W.; RL Submitted (DEC-2008) to UniProtKB. RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 117-766. RC TISSUE=Testis; RX PubMed=2284096; RA Sithanandam G., Kolch W., Duh F.-M., Rapp U.R.; RT "Complete coding sequence of a human B-raf cDNA and detection of B-raf RT protein kinase with isozyme specific antibodies."; RL Oncogene 5:1775-1780(1990). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] OF 381-766, DISEASE, AND CHROMOSOMAL RP REARRANGEMENT. RC TISSUE=Brain; RX PubMed=18974108; DOI=10.1158/0008-5472.can-08-2097; RA Jones D.T.W., Kocialkowski S., Liu L., Pearson D.M., Backlund L.M., RA Ichimura K., Collins V.P.; RT "Tandem duplication producing a novel oncogenic BRAF fusion gene defines RT the majority of pilocytic astrocytomas."; RL Cancer Res. 68:8673-8677(2008). RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 439-766. RX PubMed=3043188; DOI=10.1128/mcb.8.6.2651-2654.1988; RA Ikawa S., Fukui M., Ueyama Y., Tamaoki N., Yamamoto T., Toyoshima K.; RT "B-raf, a new member of the raf family, is activated by DNA RT rearrangement."; RL Mol. Cell. Biol. 8:2651-2654(1988). RN [12] RP PHOSPHORYLATION AT SER-365 BY SGK1. RX PubMed=11410590; DOI=10.1074/jbc.m102808200; RA Zhang B.H., Tang E.D., Zhu T., Greenberg M.E., Vojtek A.B., Guan K.L.; RT "Serum- and glucocorticoid-inducible kinase SGK phosphorylates and RT negatively regulates B-Raf."; RL J. Biol. Chem. 276:31620-31626(2001). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-401, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-401; SER-446; SER-447 AND RP SER-729, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [16] RP SUBUNIT, INTERACTION WITH DGKH, SUBCELLULAR LOCATION, AND PHOSPHORYLATION RP AT THR-753 BY MAPK1. RX PubMed=19710016; DOI=10.1074/jbc.m109.043604; RA Yasuda S., Kai M., Imai S., Takeishi K., Taketomi A., Toyota M., Kanoh H., RA Sakane F.; RT "Diacylglycerol kinase eta augments C-Raf activity and B-Raf/C-Raf RT heterodimerization."; RL J. Biol. Chem. 284:29559-29570(2009). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [18] RP INTERACTION WITH AKAP13; MAP2K1 AND KSR1. RX PubMed=21102438; DOI=10.1038/ncb2130; RA Smith F.D., Langeberg L.K., Cellurale C., Pawson T., Morrison D.K., RA Davis R.J., Scott J.D.; RT "AKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade."; RL Nat. Cell Biol. 12:1242-1249(2010). RN [19] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [20] RP INTERACTION WITH KSR2, SUBUNIT, CATALYTIC ACTIVITY, FUNCTION, AND RP MUTAGENESIS OF LYS-483. RX PubMed=21441910; DOI=10.1038/nature09860; RA Brennan D.F., Dar A.C., Hertz N.T., Chao W.C., Burlingame A.L., RA Shokat K.M., Barford D.; RT "A Raf-induced allosteric transition of KSR stimulates phosphorylation of RT MEK."; RL Nature 472:366-369(2011). RN [21] RP INTERACTION WITH PRMT5, METHYLATION AT ARG-671, CHARACTERIZATION OF VARIANT RP CRC GLU-600, AND MUTAGENESIS OF ARG-671. RX PubMed=21917714; DOI=10.1126/scisignal.2001936; RA Andreu-Perez P., Esteve-Puig R., de Torre-Minguela C., Lopez-Fauqued M., RA Bech-Serra J.J., Tenbaum S., Garcia-Trevijano E.R., Canals F., Merlino G., RA Avila M.A., Recio J.A.; RT "Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction RT amplitude and cell fate through CRAF."; RL Sci. Signal. 4:RA58-RA58(2011). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-729, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [23] RP UBIQUITINATION BY RNF149. RX PubMed=22628551; DOI=10.1074/jbc.m111.319822; RA Hong S.W., Jin D.H., Shin J.S., Moon J.H., Na Y.S., Jung K.A., Kim S.M., RA Kim J.C., Kim K.P., Hong Y.S., Lee J.L., Choi E.K., Lee J.S., Kim T.W.; RT "Ring finger protein 149 is an E3 ubiquitin ligase active on wild-type v- RT Raf murine sarcoma viral oncogene homolog B1 (BRAF)."; RL J. Biol. Chem. 287:24017-24025(2012). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-151; SER-365; THR-401; RP SER-446 AND SER-729, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [25] RP UBIQUITINATION AT LYS-578, AND MUTAGENESIS OF LYS-578. RX PubMed=23907581; DOI=10.1038/srep02344; RA An L., Jia W., Yu Y., Zou N., Liang L., Zhao Y., Fan Y., Cheng J., Shi Z., RA Xu G., Li G., Yang J., Zhang H.; RT "Lys63-linked polyubiquitination of BRAF at lysine 578 is required for RT BRAF-mediated signaling."; RL Sci. Rep. 3:2344-2344(2013). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-151, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [27] RP INTERACTION WITH FNIP1 AND FNIP2. RX PubMed=27353360; DOI=10.1038/ncomms12037; RA Woodford M.R., Dunn D.M., Blanden A.R., Capriotti D., Loiselle D., RA Prodromou C., Panaretou B., Hughes P.F., Smith A., Ackerman W., RA Haystead T.A., Loh S.N., Bourboulia D., Schmidt L.S., Marston Linehan W., RA Bratslavsky G., Mollapour M.; RT "The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance RT drug binding."; RL Nat. Commun. 7:12037-12037(2016). RN [28] RP INTERACTION WITH YWHAZ. RX PubMed=31024343; DOI=10.3389/fphys.2019.00388; RA Popov I.K., Hiatt S.M., Whalen S., Keren B., Ruivenkamp C., RA van Haeringen A., Chen M.J., Cooper G.M., Korf B.R., Chang C.; RT "A YWHAZ variant associated with cardiofaciocutaneous syndrome activates RT the RAF-ERK pathway."; RL Front. Physiol. 10:388-388(2019). RN [29] RP FUNCTION, AND SUBUNIT. RX PubMed=36402789; DOI=10.1038/s41467-022-34907-0; RA McGrail K., Granado-Martinez P., Esteve-Puig R., Garcia-Ortega S., Ding Y., RA Sanchez-Redondo S., Ferrer B., Hernandez-Losa J., Canals F., Manzano A., RA Navarro-Sabate A., Bartrons R., Yanes O., Perez-Alea M., Munoz-Couselo E., RA Garcia-Patos V., Recio J.A.; RT "BRAF activation by metabolic stress promotes glycolysis sensitizing RT NRASQ61-mutated melanomas to targeted therapy."; RL Nat. Commun. 13:7113-7113(2022). RN [30] RP DEPHOSPHORYLATION AT SER-365 BY SMP COMPLEX. RX PubMed=35768504; DOI=10.1038/s41586-022-04838-3; RA Liau N.P.D., Johnson M.C., Izadi S., Gerosa L., Hammel M., Bruning J.M., RA Wendorff T.J., Phung W., Hymowitz S.G., Sudhamsu J.; RT "Structural basis for SHOC2 modulation of RAS signalling."; RL Nature 609:400-407(2022). RN [31] RP DEPHOSPHORYLATION AT SER-365 BY SMP COMPLEX. RX PubMed=35830882; DOI=10.1038/s41586-022-05086-1; RA Hauseman Z.J., Fodor M., Dhembi A., Viscomi J., Egli D., Bleu M., Katz S., RA Park E., Jang D.M., Porter K.A., Meili F., Guo H., Kerr G., Molle S., RA Velez-Vega C., Beyer K.S., Galli G.G., Maira S.M., Stams T., Clark K., RA Eck M.J., Tordella L., Thoma C.R., King D.A.; RT "Structure of the MRAS-SHOC2-PP1C phosphatase complex."; RL Nature 609:416-423(2022). RN [32] RP X-RAY CRYSTALLOGRAPHY (2.57 ANGSTROMS) OF 444-719 IN COMPLEX WITH RP INHIBITOR. RX PubMed=18287029; DOI=10.1073/pnas.0711741105; RA Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., Bremer R., RA Gillette S., Kong J., Haass N.K., Sproesser K., Li L., Smalley K.S., RA Fong D., Zhu Y.L., Marimuthu A., Nguyen H., Lam B., Liu J., Cheung I., RA Rice J., Suzuki Y., Luu C., Settachatgul C., Shellooe R., Cantwell J., RA Kim S.H., Schlessinger J., Zhang K.Y., West B.L., Powell B., Habets G., RA Zhang C., Ibrahim P.N., Hirth P., Artis D.R., Herlyn M., Bollag G.; RT "Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent RT antimelanoma activity."; RL Proc. Natl. Acad. Sci. U.S.A. 105:3041-3046(2008). RN [33] {ECO:0007744|PDB:5VR3, ECO:0007744|PDB:5VYK} RP X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 36-110, FUNCTION, CATALYTIC RP ACTIVITY, ACTIVITY REGULATION, INTERACTION WITH KSR1; KSR2; MAP2K1 AND RP MAP2K2, AND MUTAGENESIS OF MET-53; LYS-88; ARG-509 AND ILE-666. RX PubMed=29433126; DOI=10.1038/nature25478; RA Lavoie H., Sahmi M., Maisonneuve P., Marullo S.A., Thevakumaran N., Jin T., RA Kurinov I., Sicheri F., Therrien M.; RT "MEK drives BRAF activation through allosteric control of KSR proteins."; RL Nature 554:549-553(2018). RN [34] RP VARIANTS LNCR VAL-466 AND ARG-597. RX PubMed=12460919; RA Naoki K., Chen T.-H., Richards W.G., Sugarbaker D.J., Meyerson M.; RT "Missense mutations of the BRAF gene in human lung adenocarcinoma."; RL Cancer Res. 62:7001-7003(2002). RN [35] RP VARIANTS CANCER GLU-464; VAL-464; ALA-466; GLU-466; VAL-466; ALA-469; RP GLU-469; LYS-586; LEU-595; ARG-596; ARG-597; VAL-597; GLU-600 AND ASP-600, RP AND CHARACTERIZATION OF VARIANTS CANCER VAL-464; ALA-469; VAL-597 AND RP GLU-600. RX PubMed=12068308; DOI=10.1038/nature00766; RA Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., RA Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., RA Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., RA Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., RA Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., RA Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., RA Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W.C., RA Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., RA Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.; RT "Mutations of the BRAF gene in human cancer."; RL Nature 417:949-954(2002). RN [36] RP VARIANTS CRC ILE-462; SER-463; GLU-464; GLU-600 AND GLU-601. RX PubMed=12198537; DOI=10.1038/418934a; RA Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., RA Velculescu V.E.; RT "Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status."; RL Nature 418:934-934(2002). RN [37] RP VARIANTS NHL ALA-469; ARG-469 AND GLY-594. RX PubMed=14612909; DOI=10.1038/sj.bjc.6601371; RA Lee J.W., Yoo N.J., Soung Ark W.S., Kim S.Y., Lee J.H., Park J.Y., RA Cho Y.G., Kim C.J., Ko Y.H., Kim S.H., Nam S.W., Lee J.Y., Lee S.H.; RT "BRAF mutations in non-Hodgkin's lymphoma."; RL Br. J. Cancer 89:1958-1960(2003). RN [38] RP CHARACTERIZATION OF VARIANT MELANOMA GLU-600. RX PubMed=14500344; RA Hingorani S.R., Jacobetz M.A., Robertson G.P., Herlyn M., Tuveson D.A.; RT "Suppression of BRAF(V599E) in human melanoma abrogates transformation."; RL Cancer Res. 63:5198-5202(2003). RN [39] RP VARIANTS CFC1 PRO-246; ARG-257; GLU-469; PHE-485; GLU-499; LYS-501; GLY-501 RP AND ASP-581. RX PubMed=16474404; DOI=10.1038/ng1749; RA Niihori T., Aoki Y., Narumi Y., Neri G., Cave H., Verloes A., Okamoto N., RA Hennekam R.C.M., Gillessen-Kaesbach G., Wieczorek D., Kavamura M.I., RA Kurosawa K., Ohashi H., Wilson L., Heron D., Bonneau D., Corona G., RA Kaname T., Naritomi K., Baumann C., Matsumoto N., Kato K., Kure S., RA Matsubara Y.; RT "Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome."; RL Nat. Genet. 38:294-296(2006). RN [40] RP VARIANT [LARGE SCALE ANALYSIS] GLU-600. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [41] RP VARIANTS CFC1 ARG-257; ALA-467; SER-468; GLU-469; PHE-485; GLU-499; RP LYS-501; GLY-501; ASP-581; LEU-595 AND VAL-596. RX PubMed=16439621; DOI=10.1126/science.1124642; RA Rodriguez-Viciana P., Tetsu O., Tidyman W.E., Estep A.L., Conger B.A., RA Cruz M.S., McCormick F., Rauen K.A.; RT "Germline mutations in genes within the MAPK pathway cause cardio-facio- RT cutaneous syndrome."; RL Science 311:1287-1290(2006). RN [42] RP VARIANTS [LARGE SCALE ANALYSIS] SER-301; ALA-469; VAL-469; SER-581; RP ARG-596; ARG-597; VAL-597 AND GLU-600. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [43] RP VARIANTS CFC1 PRO-241; PRO-244; PRO-246; ARG-257; LYS-262; SER-468; RP GLU-469; GLU-499; ASN-499; ASP-580; ASP-581 AND LEU-595. RX PubMed=18042262; DOI=10.1111/j.1399-0004.2007.00931.x; RA Schulz A.L., Albrecht B., Arici C., van der Burgt I., Buske A., RA Gillessen-Kaesbach G., Heller R., Horn D., Hubner C.A., Korenke G.C., RA Konig R., Kress W., Kruger G., Meinecke P., Mucke J., Plecko B., RA Rossier E., Schinzel A., Schulze A., Seemanova E., Seidel H., Spranger S., RA Tuysuz B., Uhrig S., Wieczorek D., Kutsche K., Zenker M.; RT "Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous RT and Costello syndrome."; RL Clin. Genet. 73:62-70(2008). RN [44] RP VARIANT LPRD3 PRO-241, VARIANTS NS7 ARG-241; MET-241; CYS-531 AND VAL-597, RP AND VARIANTS CFC1 PHE-245; PRO-246; ARG-257; LYS-275; GLU-469; PHE-485; RP ASN-499; LYS-501; PRO-525; LEU-595; ARG-599; GLN-601; GLU-638 AND ARG-709. RX PubMed=19206169; DOI=10.1002/humu.20955; RA Sarkozy A., Carta C., Moretti S., Zampino G., Digilio M.C., Pantaleoni F., RA Scioletti A.P., Esposito G., Cordeddu V., Lepri F., Petrangeli V., RA Dentici M.L., Mancini G.M., Selicorni A., Rossi C., Mazzanti L., Marino B., RA Ferrero G.B., Silengo M.C., Memo L., Stanzial F., Faravelli F., Stuppia L., RA Puxeddu E., Gelb B.D., Dallapiccola B., Tartaglia M.; RT "Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous RT syndromes: molecular diversity and associated phenotypic spectrum."; RL Hum. Mutat. 30:695-702(2009). RN [45] RP VARIANT CRC GLU-600. RX PubMed=23263490; DOI=10.1038/ng.2503; RG CORGI Consortium; RG WGS500 Consortium; RA Palles C., Cazier J.B., Howarth K.M., Domingo E., Jones A.M., Broderick P., RA Kemp Z., Spain S.L., Guarino Almeida E., Salguero I., Sherborne A., RA Chubb D., Carvajal-Carmona L.G., Ma Y., Kaur K., Dobbins S., Barclay E., RA Gorman M., Martin L., Kovac M.B., Humphray S., Lucassen A., Holmes C.C., RA Bentley D., Donnelly P., Taylor J., Petridis C., Roylance R., Sawyer E.J., RA Kerr D.J., Clark S., Grimes J., Kearsey S.E., Thomas H.J., McVean G., RA Houlston R.S., Tomlinson I.; RT "Germline mutations affecting the proofreading domains of POLE and POLD1 RT predispose to colorectal adenomas and carcinomas."; RL Nat. Genet. 45:136-144(2013). RN [46] RP VARIANT CRC GLU-600. RX PubMed=24455489; DOI=10.3389/fonc.2013.00333; RA D'mello S.A., Flanagan J.U., Green T.N., Leung E.Y., Askarian-Amiri M.E., RA Joseph W.R., McCrystal M.R., Isaacs R.J., Shaw J.H., Furneaux C.E., RA During M.J., Finlay G.J., Baguley B.C., Kalev-Zylinska M.L.; RT "Evidence that GRIN2A mutations in melanoma correlate with decreased RT survival."; RL Front. Oncol. 3:333-333(2014). CC -!- FUNCTION: Protein kinase involved in the transduction of mitogenic CC signals from the cell membrane to the nucleus (Probable). CC Phosphorylates MAP2K1, and thereby activates the MAP kinase signal CC transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates CC PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses CC of hippocampal neurons (PubMed:1508179). {ECO:0000269|PubMed:1508179, CC ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126, CC ECO:0000269|PubMed:36402789, ECO:0000305}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21441910}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250}; CC Note=Binds 2 Zn(2+) ions per subunit. {ECO:0000250}; CC -!- ACTIVITY REGULATION: In quiescent cells, maintained in an inactive CC state via an intramolecular interaction between the protein kinase and CC N-terminal domains. Following mitogen-mediated cell activation, binds CC via its RGB domain to active HRAS (GTP-bound) which releases the CC inhibitory intramolecular interaction between the two domains. This CC allows the MAP2K1-mediated dimerization of KSR1 or KSR2, and BRAF which CC activates BRAF. {ECO:0000269|PubMed:29433126}. CC -!- SUBUNIT: Monomer (PubMed:19710016). Homodimer (PubMed:19710016, CC PubMed:36402789). Heterodimerizes with RAF1, and the heterodimer CC possesses a highly increased kinase activity compared to the respective CC homodimers or monomers (PubMed:19710016). Heterodimerization is CC mitogen-regulated and enhanced by 14-3-3 proteins. MAPK1/ERK2 CC activation can induce a negative feedback that promotes the CC dissociation of the heterodimer by phosphorylating BRAF at Thr-753. CC Heterodimerizes (via N-terminus) with KSR1 (via N-terminus) or KSR2 CC (via N-terminus) in a MAP2K1-dependent manner (PubMed:29433126). CC Interacts with MAP2K1 and MAP2K2 (PubMed:29433126). Found in a complex CC with at least BRAF, HRAS, MAP2K1, MAPK3 and RGS14. Interacts with RIT1. CC Interacts (via N-terminus) with RGS14 (via RBD domains); the CC interaction mediates the formation of a ternary complex with RAF1, a CC ternary complex inhibited by GNAI1 (By similarity). Interacts with DGKH CC (PubMed:19710016). Interacts with PRMT5 (PubMed:21917714). Interacts CC with KSR2 (PubMed:21441910). Interacts with AKAP13, MAP2K1 and KSR1. CC Identified in a complex with AKAP13, MAP2K1 and KSR1 (PubMed:21102438). CC Interacts with FNIP1 and FNIP2 (PubMed:27353360). {ECO:0000250, CC ECO:0000269|PubMed:18287029, ECO:0000269|PubMed:19710016, CC ECO:0000269|PubMed:21102438, ECO:0000269|PubMed:21441910, CC ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:27353360, CC ECO:0000269|PubMed:29433126, ECO:0000269|PubMed:36402789}. CC -!- INTERACTION: CC P15056; P21399: ACO1; NbExp=4; IntAct=EBI-365980, EBI-2847111; CC P15056; P31749: AKT1; NbExp=4; IntAct=EBI-365980, EBI-296087; CC P15056; P10398: ARAF; NbExp=9; IntAct=EBI-365980, EBI-365961; CC P15056; P49407: ARRB1; NbExp=4; IntAct=EBI-365980, EBI-743313; CC P15056; O14965: AURKA; NbExp=5; IntAct=EBI-365980, EBI-448680; CC P15056; P25311: AZGP1; NbExp=3; IntAct=EBI-365980, EBI-2513837; CC P15056; Q92560: BAP1; NbExp=4; IntAct=EBI-365980, EBI-1791447; CC P15056; Q07817: BCL2L1; NbExp=7; IntAct=EBI-365980, EBI-78035; CC P15056; Q92843: BCL2L2; NbExp=4; IntAct=EBI-365980, EBI-707714; CC P15056; P15056: BRAF; NbExp=14; IntAct=EBI-365980, EBI-365980; CC P15056; P40259: CD79B; NbExp=3; IntAct=EBI-365980, EBI-2873732; CC P15056; Q6P1J9: CDC73; NbExp=4; IntAct=EBI-365980, EBI-930143; CC P15056; P42772: CDKN2B; NbExp=4; IntAct=EBI-365980, EBI-711280; CC P15056; P61024: CKS1B; NbExp=4; IntAct=EBI-365980, EBI-456371; CC P15056; P35221: CTNNA1; NbExp=4; IntAct=EBI-365980, EBI-701918; CC P15056; Q13618: CUL3; NbExp=2; IntAct=EBI-365980, EBI-456129; CC P15056; Q16254: E2F4; NbExp=4; IntAct=EBI-365980, EBI-448943; CC P15056; Q9GZV4: EIF5A2; NbExp=4; IntAct=EBI-365980, EBI-748028; CC P15056; Q7Z589: EMSY; NbExp=4; IntAct=EBI-365980, EBI-6598631; CC P15056; P18074: ERCC2; NbExp=3; IntAct=EBI-365980, EBI-6380590; CC P15056; P28715: ERCC5; NbExp=3; IntAct=EBI-365980, EBI-765885; CC P15056; O43524: FOXO3; NbExp=5; IntAct=EBI-365980, EBI-1644164; CC P15056; Q8WXI9: GATAD2B; NbExp=3; IntAct=EBI-365980, EBI-923440; CC P15056; P17174: GOT1; NbExp=5; IntAct=EBI-365980, EBI-727329; CC P15056; P49840: GSK3A; NbExp=6; IntAct=EBI-365980, EBI-1044067; CC P15056; O95714: HERC2; NbExp=2; IntAct=EBI-365980, EBI-1058922; CC P15056; P01112: HRAS; NbExp=9; IntAct=EBI-365980, EBI-350145; CC P15056; P08238: HSP90AB1; NbExp=5; IntAct=EBI-365980, EBI-352572; CC P15056; O75874: IDH1; NbExp=4; IntAct=EBI-365980, EBI-715695; CC P15056; O14920: IKBKB; NbExp=5; IntAct=EBI-365980, EBI-81266; CC P15056; P46940: IQGAP1; NbExp=4; IntAct=EBI-365980, EBI-297509; CC P15056; P27987: ITPKB; NbExp=4; IntAct=EBI-365980, EBI-751388; CC P15056; Q14145: KEAP1; NbExp=16; IntAct=EBI-365980, EBI-751001; CC P15056; Q02750: MAP2K1; NbExp=65; IntAct=EBI-365980, EBI-492564; CC P15056; P36507: MAP2K2; NbExp=13; IntAct=EBI-365980, EBI-1056930; CC P15056; Q13233: MAP3K1; NbExp=2; IntAct=EBI-365980, EBI-49776; CC P15056; Q15759: MAPK11; NbExp=4; IntAct=EBI-365980, EBI-298304; CC P15056; Q16659: MAPK6; NbExp=3; IntAct=EBI-365980, EBI-1384105; CC P15056; Q13164: MAPK7; NbExp=5; IntAct=EBI-365980, EBI-1213983; CC P15056; Q9NX70: MED29; NbExp=4; IntAct=EBI-365980, EBI-394656; CC P15056; O00255: MEN1; NbExp=4; IntAct=EBI-365980, EBI-592789; CC P15056; P07196: NEFL; NbExp=4; IntAct=EBI-365980, EBI-475646; CC P15056; P01111: NRAS; NbExp=8; IntAct=EBI-365980, EBI-721993; CC P15056; Q9BRP1: PDCD2L; NbExp=6; IntAct=EBI-365980, EBI-2372173; CC P15056; P48736: PIK3CG; NbExp=4; IntAct=EBI-365980, EBI-1030384; CC P15056; P27986: PIK3R1; NbExp=3; IntAct=EBI-365980, EBI-79464; CC P15056; P16885: PLCG2; NbExp=4; IntAct=EBI-365980, EBI-617403; CC P15056; Q07864: POLE; NbExp=6; IntAct=EBI-365980, EBI-348526; CC P15056; O15297: PPM1D; NbExp=4; IntAct=EBI-365980, EBI-1551512; CC P15056; Q02156: PRKCE; NbExp=3; IntAct=EBI-365980, EBI-706254; CC P15056; P57735: RAB25; NbExp=4; IntAct=EBI-365980, EBI-1050500; CC P15056; P04049: RAF1; NbExp=73; IntAct=EBI-365980, EBI-365996; CC P15056; Q12967: RALGDS; NbExp=4; IntAct=EBI-365980, EBI-365861; CC P15056; P61224: RAP1B; NbExp=4; IntAct=EBI-365980, EBI-358143; CC P15056; Q15349: RPS6KA2; NbExp=2; IntAct=EBI-365980, EBI-1384149; CC P15056; Q8N122: RPTOR; NbExp=4; IntAct=EBI-365980, EBI-1567928; CC P15056; Q8IYM1: SEPTIN12; NbExp=4; IntAct=EBI-365980, EBI-2585067; CC P15056; P31947: SFN; NbExp=6; IntAct=EBI-365980, EBI-476295; CC P15056; Q9UMX1: SUFU; NbExp=4; IntAct=EBI-365980, EBI-740595; CC P15056; P04637: TP53; NbExp=4; IntAct=EBI-365980, EBI-366083; CC P15056; Q13114: TRAF3; NbExp=2; IntAct=EBI-365980, EBI-357631; CC P15056; P40337: VHL; NbExp=7; IntAct=EBI-365980, EBI-301246; CC P15056; P31946: YWHAB; NbExp=14; IntAct=EBI-365980, EBI-359815; CC P15056; P62258: YWHAE; NbExp=11; IntAct=EBI-365980, EBI-356498; CC P15056; P61981: YWHAG; NbExp=12; IntAct=EBI-365980, EBI-359832; CC P15056; P27348: YWHAQ; NbExp=12; IntAct=EBI-365980, EBI-359854; CC P15056; P63104: YWHAZ; NbExp=15; IntAct=EBI-365980, EBI-347088; CC P15056; Q61097: Ksr1; Xeno; NbExp=3; IntAct=EBI-365980, EBI-1536336; CC P15056; P29678: MAP2K1; Xeno; NbExp=2; IntAct=EBI-365980, EBI-1631983; CC P15056; Q99N57: Raf1; Xeno; NbExp=3; IntAct=EBI-365980, EBI-397757; CC P15056; Q8CGE9: Rgs12; Xeno; NbExp=2; IntAct=EBI-365980, EBI-7340552; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250}. Cytoplasm CC {ECO:0000269|PubMed:19710016}. Cell membrane CC {ECO:0000269|PubMed:19710016}. Note=Colocalizes with RGS14 and RAF1 in CC both the cytoplasm and membranes. {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Brain and testis. CC -!- PTM: Phosphorylation at Ser-365 by SGK1 inhibits its activity (Ref.8, CC PubMed:11410590). Phosphorylation at Thr-753 by MAPK1 CC (PubMed:19710016). Dephosphorylation of Ser-365 by the SHOC2-MRAS-PP1c CC (SMP) complex consisting of SHOC2, GTP-bound M-Ras/MRAS and the CC catalytic subunit of protein phosphatase 1 (PPP1CA, PPP1CB or PPP1CC); CC this relieves inactivation and stimulates kinase activity CC (PubMed:35768504, PubMed:35830882). {ECO:0000269|PubMed:11410590, CC ECO:0000269|PubMed:19710016, ECO:0000269|PubMed:35768504, CC ECO:0000269|PubMed:35830882, ECO:0000269|Ref.8}. CC -!- PTM: Methylation at Arg-671 decreases stability and kinase activity. CC {ECO:0000269|PubMed:21917714}. CC -!- PTM: Ubiquitinated by RNF149; which leads to proteasomal degradation. CC Polyubiquitinated at Lys-578 in response to EGF. CC {ECO:0000269|PubMed:22628551, ECO:0000269|PubMed:23907581}. CC -!- DISEASE: Note=Defects in BRAF are found in a wide range of cancers. CC {ECO:0000269|PubMed:18974108}. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:12198537, CC ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:23263490, CC ECO:0000269|PubMed:24455489}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting CC tissues of the lung. The most common form of lung cancer is non-small CC cell lung cancer (NSCLC) that can be divided into 3 major histologic CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor CC prognosis. {ECO:0000269|PubMed:12460919}. Note=The gene represented in CC this entry is involved in disease pathogenesis. CC -!- DISEASE: Familial non-Hodgkin lymphoma (NHL) [MIM:605027]: Cancer that CC starts in cells of the lymph system, which is part of the body's immune CC system. NHLs can occur at any age and are often marked by enlarged CC lymph nodes, fever and weight loss. {ECO:0000269|PubMed:14612909}. CC Note=The gene represented in this entry is involved in disease CC pathogenesis. CC -!- DISEASE: Cardiofaciocutaneous syndrome 1 (CFC1) [MIM:115150]: A CC multiple congenital anomaly disorder characterized by a distinctive CC facial appearance, heart defects and intellectual disability. Heart CC defects include pulmonic stenosis, atrial septal defects and CC hypertrophic cardiomyopathy. Some affected individuals present with CC ectodermal abnormalities such as sparse, friable hair, hyperkeratotic CC skin lesions and a generalized ichthyosis-like condition. Typical CC facial features are similar to Noonan syndrome. They include high CC forehead with bitemporal constriction, hypoplastic supraorbital ridges, CC downslanting palpebral fissures, a depressed nasal bridge, and CC posteriorly angulated ears with prominent helices. CC {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404, CC ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Noonan syndrome 7 (NS7) [MIM:613706]: A form of Noonan CC syndrome, a disease characterized by short stature, facial dysmorphic CC features such as hypertelorism, a downward eyeslant and low-set CC posteriorly rotated ears, and a high incidence of congenital heart CC defects and hypertrophic cardiomyopathy. Other features can include a CC short neck with webbing or redundancy of skin, deafness, motor delay, CC variable intellectual deficits, multiple skeletal defects, CC cryptorchidism, and bleeding diathesis. Individuals with Noonan CC syndrome are at risk of juvenile myelomonocytic leukemia, a CC myeloproliferative disorder characterized by excessive production of CC myelomonocytic cells. {ECO:0000269|PubMed:19206169}. Note=The disease CC is caused by variants affecting the gene represented in this entry. CC -!- DISEASE: LEOPARD syndrome 3 (LPRD3) [MIM:613707]: A disorder CC characterized by lentigines, electrocardiographic conduction CC abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities CC of genitalia, retardation of growth, and sensorineural deafness. CC {ECO:0000269|PubMed:19206169}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Note=A chromosomal aberration involving BRAF is found in CC pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads to CC the expression of a KIAA1549-BRAF fusion protein with a constitutive CC kinase activity and inducing cell transformation. CC {ECO:0000269|PubMed:18974108}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. RAF subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAD43193.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC Sequence=CAQ43111.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43112.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43113.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43114.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43115.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43116.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/828/BRAF"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M95712; AAA35609.2; -; mRNA. DR EMBL; AC006344; AAD43193.1; ALT_SEQ; Genomic_DNA. DR EMBL; EU600171; ACD11489.1; -; Genomic_DNA. DR EMBL; AC006347; AAD15551.1; -; Genomic_DNA. DR EMBL; CH236950; EAL24023.1; -; Genomic_DNA. DR EMBL; BC101757; AAI01758.1; -; mRNA. DR EMBL; BC112079; AAI12080.1; -; mRNA. DR EMBL; X65187; CAA46301.1; -; Genomic_DNA. DR EMBL; M21001; AAA96495.1; -; mRNA. DR EMBL; AM989472; CAQ43111.1; ALT_INIT; mRNA. DR EMBL; AM989473; CAQ43112.1; ALT_INIT; mRNA. DR EMBL; AM989474; CAQ43113.1; ALT_INIT; mRNA. DR EMBL; AM989475; CAQ43114.1; ALT_INIT; mRNA. DR EMBL; AM989476; CAQ43115.1; ALT_INIT; mRNA. DR EMBL; AM989477; CAQ43116.1; ALT_INIT; mRNA. DR CCDS; CCDS5863.1; -. DR PIR; A57977; TVHUBF. DR RefSeq; NP_004324.2; NM_004333.4. DR PDB; 1UWH; X-ray; 2.95 A; A/B=448-723. DR PDB; 1UWJ; X-ray; 3.50 A; A/B=448-723. DR PDB; 2FB8; X-ray; 2.90 A; A/B=445-723. DR PDB; 2L05; NMR; -; A=149-232. DR PDB; 3C4C; X-ray; 2.57 A; A/B=444-721. DR PDB; 3D4Q; X-ray; 2.80 A; A/B=433-726. DR PDB; 3IDP; X-ray; 2.70 A; A/B=434-727. DR PDB; 3II5; X-ray; 2.79 A; A/B=432-726. DR PDB; 3NY5; X-ray; 1.99 A; A/B/C/D=153-237. DR PDB; 3OG7; X-ray; 2.45 A; A/B=448-720. DR PDB; 3PPJ; X-ray; 3.70 A; A/B=432-726. DR PDB; 3PPK; X-ray; 3.00 A; A/B=432-726. DR PDB; 3PRF; X-ray; 2.90 A; A/B=432-726. DR PDB; 3PRI; X-ray; 3.50 A; A/B=432-726. DR PDB; 3PSB; X-ray; 3.40 A; A/B=433-726. DR PDB; 3PSD; X-ray; 3.60 A; A/B=433-726. DR PDB; 3Q4C; X-ray; 3.20 A; A/B=432-726. DR PDB; 3Q96; X-ray; 3.10 A; A/B=446-727. DR PDB; 3SKC; X-ray; 3.20 A; A/B=432-726. DR PDB; 3TV4; X-ray; 3.40 A; A/B=432-726. DR PDB; 3TV6; X-ray; 3.30 A; A/B=432-726. DR PDB; 4CQE; X-ray; 2.30 A; A/B=448-723. DR PDB; 4DBN; X-ray; 3.15 A; A/B=445-726. DR PDB; 4E26; X-ray; 2.55 A; A/B=432-726. DR PDB; 4E4X; X-ray; 3.60 A; A/B=432-726. DR PDB; 4EHE; X-ray; 3.30 A; A/B=432-726. DR PDB; 4EHG; X-ray; 3.50 A; A/B=432-726. DR PDB; 4FC0; X-ray; 2.95 A; A/B=445-726. DR PDB; 4FK3; X-ray; 2.65 A; A/B=444-723. DR PDB; 4G9C; X-ray; 3.50 A; A/B=432-726. DR PDB; 4G9R; X-ray; 3.20 A; A/B=432-726. DR PDB; 4H58; X-ray; 3.10 A; A/B/C=448-722. DR PDB; 4JVG; X-ray; 3.09 A; A/B/C/D=444-723. DR PDB; 4KSP; X-ray; 2.93 A; A/B=445-726. DR PDB; 4KSQ; X-ray; 3.30 A; A/B=445-726. DR PDB; 4MBJ; X-ray; 3.60 A; A/B=432-723. DR PDB; 4MNE; X-ray; 2.85 A; B/C/F/G=432-726. DR PDB; 4MNF; X-ray; 2.80 A; A/B=432-736. DR PDB; 4PP7; X-ray; 3.40 A; A/B=432-726. DR PDB; 4R5Y; X-ray; 3.50 A; A/B=444-723. DR PDB; 4RZV; X-ray; 2.99 A; A/B=443-723. DR PDB; 4RZW; X-ray; 3.49 A; A/B=443-723. DR PDB; 4WO5; X-ray; 2.83 A; A/B=444-723. DR PDB; 4XV1; X-ray; 2.47 A; A/B=444-705. DR PDB; 4XV2; X-ray; 2.50 A; A/B=444-705. DR PDB; 4XV3; X-ray; 2.80 A; A/B=444-705. DR PDB; 4XV9; X-ray; 2.00 A; A=442-705. DR PDB; 4YHT; X-ray; 3.05 A; A/B=449-720. DR PDB; 5C9C; X-ray; 2.70 A; A/B=432-726. DR PDB; 5CSW; X-ray; 2.66 A; A/B=442-721. DR PDB; 5CSX; X-ray; 2.51 A; A=442-721. DR PDB; 5CT7; X-ray; 3.17 A; A/B=445-723. DR PDB; 5FD2; X-ray; 2.89 A; A/B=433-726. DR PDB; 5HI2; X-ray; 2.51 A; A=444-737. DR PDB; 5HID; X-ray; 2.50 A; A/B=444-737. DR PDB; 5HIE; X-ray; 3.00 A; A/B/C/D=432-726. DR PDB; 5ITA; X-ray; 1.95 A; A/B=448-723. DR PDB; 5J17; NMR; -; A=151-232. DR PDB; 5J18; NMR; -; A=151-232. DR PDB; 5J2R; NMR; -; A=151-232. DR PDB; 5JRQ; X-ray; 2.29 A; A/B=448-723. DR PDB; 5JSM; X-ray; 2.19 A; A/B/C/D=448-723. DR PDB; 5JT2; X-ray; 2.70 A; A/B/C/D=448-723. DR PDB; 5VAL; X-ray; 2.26 A; A/B=445-723. DR PDB; 5VAM; X-ray; 2.10 A; A/B=445-723. DR PDB; 5VR3; X-ray; 2.10 A; A=36-114. DR PDB; 5VYK; X-ray; 1.75 A; A/C=36-110. DR PDB; 6B8U; X-ray; 2.68 A; A/B=445-723. DR PDB; 6CAD; X-ray; 2.55 A; A/B=444-723. DR PDB; 6N0P; X-ray; 2.37 A; A/B=449-721. DR PDB; 6N0Q; X-ray; 2.04 A; A/B=445-723. DR PDB; 6NSQ; X-ray; 3.05 A; A/B=444-723. DR PDB; 6NYB; EM; 4.10 A; A=1-766. DR PDB; 6P3D; X-ray; 2.11 A; A=448-721. DR PDB; 6P7G; X-ray; 2.65 A; A/B/C/D=448-723. DR PDB; 6PP9; X-ray; 2.59 A; A=445-723. DR PDB; 6Q0J; EM; 4.90 A; A/B=1-766. DR PDB; 6Q0K; EM; 6.80 A; A/B=1-766. DR PDB; 6Q0T; EM; 5.70 A; A/B=1-766. DR PDB; 6U2G; X-ray; 2.89 A; B=432-726. DR PDB; 6U2H; X-ray; 2.50 A; C/D=447-735. DR PDB; 6UAN; EM; 3.90 A; B/C=1-766. DR PDB; 6UUO; X-ray; 3.29 A; A/B=444-723. DR PDB; 6V2U; X-ray; 3.78 A; A/B=445-723. DR PDB; 6V2W; X-ray; 3.12 A; A=445-723. DR PDB; 6V34; X-ray; 3.15 A; A/B=448-721. DR PDB; 6XAG; X-ray; 3.30 A; C/D=447-735. DR PDB; 6XFP; X-ray; 2.00 A; A=442-721. DR PDB; 6XLO; X-ray; 2.49 A; A/B=442-721. DR PDB; 7K0V; X-ray; 1.93 A; A/B/C/D=444-723. DR PDB; 7M0T; X-ray; 3.19 A; A=445-723. DR PDB; 7M0U; X-ray; 3.09 A; A=445-723. DR PDB; 7M0V; X-ray; 3.16 A; A=445-723. DR PDB; 7M0W; X-ray; 3.09 A; A=445-723. DR PDB; 7M0X; X-ray; 2.47 A; A=445-723. DR PDB; 7M0Y; X-ray; 3.45 A; A=445-723. DR PDB; 7M0Z; X-ray; 3.12 A; A=445-723. DR PDB; 7MFD; EM; 3.66 A; A=1-766. DR PDB; 7MFE; EM; 4.07 A; A=1-766. DR PDB; 7MFF; EM; 3.89 A; A/B=1-766. DR PDB; 7P3V; X-ray; 2.37 A; A/B=448-719. DR PDB; 7SHV; X-ray; 2.88 A; A/B=432-726. DR PDB; 7ZR0; EM; 3.40 A; K=1-766. DR PDB; 7ZR5; EM; 3.90 A; K=1-766. DR PDB; 7ZR6; EM; 4.20 A; K=1-766. DR PDB; 8C7X; X-ray; 1.65 A; A/B=444-721. DR PDB; 8C7Y; X-ray; 1.65 A; A/B=444-721. DR PDB; 8DGS; EM; 4.30 A; A=1-766. DR PDB; 8DGT; EM; 3.90 A; A=1-766. DR PDB; 8F7O; X-ray; 3.54 A; A/B=441-723. DR PDB; 8F7P; X-ray; 2.74 A; A/B=441-723. DR PDB; 8QQG; X-ray; 2.98 A; A/B/C=448-722. DR PDB; 8VSO; X-ray; 1.50 A; P=361-369. DR PDB; 8VYO; EM; 3.74 A; A=1-766. DR PDB; 8VYP; EM; 3.29 A; C=1-766. DR PDB; 8VYQ; EM; 4.43 A; C=360-734. DR PDB; 8VYR; EM; 4.32 A; A=1-766. DR PDB; 8VYS; EM; 3.06 A; A=1-766. DR PDB; 8VYU; EM; 4.07 A; A=1-766. DR PDB; 8VYV; EM; 5.86 A; C=1-766. DR PDB; 8VYW; EM; 4.76 A; C=360-734. DR PDB; 9AXX; X-ray; 2.07 A; B/D=445-723. DR PDB; 9AXY; X-ray; 3.60 A; A=445-723. DR PDB; 9BFB; X-ray; 1.92 A; A=445-723. DR PDB; 9BP8; X-ray; 1.73 A; A=445-723. DR PDB; 9EW6; X-ray; 1.65 A; P=361-369. DR PDB; 9F35; X-ray; 2.30 A; B=360-370. DR PDBsum; 1UWH; -. DR PDBsum; 1UWJ; -. DR PDBsum; 2FB8; -. DR PDBsum; 2L05; -. DR PDBsum; 3C4C; -. DR PDBsum; 3D4Q; -. DR PDBsum; 3IDP; -. DR PDBsum; 3II5; -. DR PDBsum; 3NY5; -. DR PDBsum; 3OG7; -. DR PDBsum; 3PPJ; -. DR PDBsum; 3PPK; -. DR PDBsum; 3PRF; -. DR PDBsum; 3PRI; -. DR PDBsum; 3PSB; -. DR PDBsum; 3PSD; -. DR PDBsum; 3Q4C; -. DR PDBsum; 3Q96; -. DR PDBsum; 3SKC; -. DR PDBsum; 3TV4; -. DR PDBsum; 3TV6; -. DR PDBsum; 4CQE; -. DR PDBsum; 4DBN; -. DR PDBsum; 4E26; -. DR PDBsum; 4E4X; -. DR PDBsum; 4EHE; -. DR PDBsum; 4EHG; -. DR PDBsum; 4FC0; -. DR PDBsum; 4FK3; -. DR PDBsum; 4G9C; -. DR PDBsum; 4G9R; -. DR PDBsum; 4H58; -. DR PDBsum; 4JVG; -. DR PDBsum; 4KSP; -. DR PDBsum; 4KSQ; -. DR PDBsum; 4MBJ; -. DR PDBsum; 4MNE; -. DR PDBsum; 4MNF; -. DR PDBsum; 4PP7; -. DR PDBsum; 4R5Y; -. DR PDBsum; 4RZV; -. DR PDBsum; 4RZW; -. DR PDBsum; 4WO5; -. DR PDBsum; 4XV1; -. DR PDBsum; 4XV2; -. DR PDBsum; 4XV3; -. DR PDBsum; 4XV9; -. DR PDBsum; 4YHT; -. DR PDBsum; 5C9C; -. DR PDBsum; 5CSW; -. DR PDBsum; 5CSX; -. DR PDBsum; 5CT7; -. DR PDBsum; 5FD2; -. DR PDBsum; 5HI2; -. DR PDBsum; 5HID; -. DR PDBsum; 5HIE; -. DR PDBsum; 5ITA; -. DR PDBsum; 5J17; -. DR PDBsum; 5J18; -. DR PDBsum; 5J2R; -. DR PDBsum; 5JRQ; -. DR PDBsum; 5JSM; -. DR PDBsum; 5JT2; -. DR PDBsum; 5VAL; -. DR PDBsum; 5VAM; -. DR PDBsum; 5VR3; -. DR PDBsum; 5VYK; -. DR PDBsum; 6B8U; -. DR PDBsum; 6CAD; -. DR PDBsum; 6N0P; -. DR PDBsum; 6N0Q; -. DR PDBsum; 6NSQ; -. DR PDBsum; 6NYB; -. DR PDBsum; 6P3D; -. DR PDBsum; 6P7G; -. DR PDBsum; 6PP9; -. DR PDBsum; 6Q0J; -. DR PDBsum; 6Q0K; -. DR PDBsum; 6Q0T; -. DR PDBsum; 6U2G; -. DR PDBsum; 6U2H; -. DR PDBsum; 6UAN; -. DR PDBsum; 6UUO; -. DR PDBsum; 6V2U; -. DR PDBsum; 6V2W; -. DR PDBsum; 6V34; -. DR PDBsum; 6XAG; -. DR PDBsum; 6XFP; -. DR PDBsum; 6XLO; -. DR PDBsum; 7K0V; -. DR PDBsum; 7M0T; -. DR PDBsum; 7M0U; -. DR PDBsum; 7M0V; -. DR PDBsum; 7M0W; -. DR PDBsum; 7M0X; -. DR PDBsum; 7M0Y; -. DR PDBsum; 7M0Z; -. DR PDBsum; 7MFD; -. DR PDBsum; 7MFE; -. DR PDBsum; 7MFF; -. DR PDBsum; 7P3V; -. DR PDBsum; 7SHV; -. DR PDBsum; 7ZR0; -. DR PDBsum; 7ZR5; -. DR PDBsum; 7ZR6; -. DR PDBsum; 8C7X; -. DR PDBsum; 8C7Y; -. DR PDBsum; 8DGS; -. DR PDBsum; 8DGT; -. DR PDBsum; 8F7O; -. DR PDBsum; 8F7P; -. DR PDBsum; 8QQG; -. DR PDBsum; 8VSO; -. DR PDBsum; 8VYO; -. DR PDBsum; 8VYP; -. DR PDBsum; 8VYQ; -. DR PDBsum; 8VYR; -. DR PDBsum; 8VYS; -. DR PDBsum; 8VYU; -. DR PDBsum; 8VYV; -. DR PDBsum; 8VYW; -. DR PDBsum; 9AXX; -. DR PDBsum; 9AXY; -. DR PDBsum; 9BFB; -. DR PDBsum; 9BP8; -. DR PDBsum; 9EW6; -. DR PDBsum; 9F35; -. DR AlphaFoldDB; P15056; -. DR BMRB; P15056; -. DR EMDB; EMD-0541; -. DR EMDB; EMD-14875; -. DR EMDB; EMD-14883; -. DR EMDB; EMD-14884; -. DR EMDB; EMD-20550; -. DR EMDB; EMD-20551; -. DR EMDB; EMD-20552; -. DR EMDB; EMD-20708; -. DR EMDB; EMD-23813; -. DR EMDB; EMD-23814; -. DR EMDB; EMD-23815; -. DR EMDB; EMD-27428; -. DR EMDB; EMD-27429; -. DR EMDB; EMD-43673; -. DR EMDB; EMD-43674; -. DR EMDB; EMD-43675; -. DR EMDB; EMD-43676; -. DR EMDB; EMD-43677; -. DR EMDB; EMD-43678; -. DR EMDB; EMD-43679; -. DR EMDB; EMD-43680; -. DR SMR; P15056; -. DR BioGRID; 107141; 185. DR CORUM; P15056; -. DR DIP; DIP-1045N; -. DR FunCoup; P15056; 5390. DR IntAct; P15056; 446. DR MINT; P15056; -. DR STRING; 9606.ENSP00000419060; -. DR BindingDB; P15056; -. DR ChEMBL; CHEMBL5145; -. DR DrugBank; DB08553; (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime. DR DrugBank; DB15068; Agerafenib. DR DrugBank; DB15254; Avutometinib. DR DrugBank; DB12854; BMS-908662. DR DrugBank; DB08912; Dabrafenib. DR DrugBank; DB11718; Encorafenib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB14773; Lifirafenib. DR DrugBank; DB07000; N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide. DR DrugBank; DB06999; PLX-4720. DR DrugBank; DB16038; PLX8394. DR DrugBank; DB05984; RAF-265. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB14840; Ripretinib. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB15266; Tovorafenib. DR DrugBank; DB08881; Vemurafenib. DR DrugBank; DB05190; XL281. DR DrugCentral; P15056; -. DR GuidetoPHARMACOLOGY; 1943; -. DR TCDB; 8.A.23.1.48; the basigin (basigin) family. DR GlyGen; P15056; 1 site. DR iPTMnet; P15056; -. DR PhosphoSitePlus; P15056; -. DR SwissPalm; P15056; -. DR BioMuta; BRAF; -. DR DMDM; 50403720; -. DR CPTAC; CPTAC-3112; -. DR CPTAC; CPTAC-3113; -. DR CPTAC; CPTAC-5771; -. DR CPTAC; CPTAC-5817; -. DR CPTAC; CPTAC-5818; -. DR CPTAC; CPTAC-5819; -. DR CPTAC; CPTAC-5820; -. DR CPTAC; CPTAC-5821; -. DR CPTAC; CPTAC-5822; -. DR CPTAC; non-CPTAC-5352; -. DR CPTAC; non-CPTAC-5353; -. DR CPTAC; non-CPTAC-5354; -. DR CPTAC; non-CPTAC-5355; -. DR CPTAC; non-CPTAC-5356; -. DR CPTAC; non-CPTAC-5357; -. DR CPTAC; non-CPTAC-5727; -. DR CPTAC; non-CPTAC-5728; -. DR CPTAC; non-CPTAC-5729; -. DR jPOST; P15056; -. DR MassIVE; P15056; -. DR PaxDb; 9606-ENSP00000288602; -. DR PeptideAtlas; P15056; -. DR ProteomicsDB; 53102; -. DR Pumba; P15056; -. DR Antibodypedia; 751; 2321 antibodies from 54 providers. DR CPTC; P15056; 7 antibodies. DR DNASU; 673; -. DR Ensembl; ENST00000646891.2; ENSP00000493543.1; ENSG00000157764.15. DR GeneID; 673; -. DR KEGG; hsa:673; -. DR MANE-Select; ENST00000646891.2; ENSP00000493543.1; NM_004333.6; NP_004324.2. DR UCSC; uc003vwc.5; human. DR AGR; HGNC:1097; -. DR CIViC; 673; 6 clinical assertions and 454 evidence items across 166 molecular profiles. DR ClinPGx; PA25408; -. DR CTD; 673; -. DR DisGeNET; 673; -. DR GeneCards; BRAF; -. DR GeneReviews; BRAF; -. DR HGNC; HGNC:1097; BRAF. DR HPA; ENSG00000157764; Low tissue specificity. DR MalaCards; BRAF; -. DR MIM; 114500; phenotype. DR MIM; 115150; phenotype. DR MIM; 164757; gene. DR MIM; 211980; phenotype. DR MIM; 605027; phenotype. DR MIM; 613706; phenotype. DR MIM; 613707; phenotype. DR OpenTargets; ENSG00000157764; -. DR Orphanet; 1340; Cardiofaciocutaneous syndrome. DR Orphanet; 58017; Classic hairy cell leukemia. DR Orphanet; 54595; Craniopharyngioma. DR Orphanet; 96253; Cushing disease. DR Orphanet; 146; Differentiated thyroid carcinoma. DR Orphanet; 389; Langerhans cell histiocytosis. DR Orphanet; 626; Large/giant congenital melanocytic nevus. DR Orphanet; 648; Noonan syndrome. DR Orphanet; 500; Noonan syndrome with multiple lentigines. DR Orphanet; 251615; Pilomyxoid astrocytoma. DR Orphanet; 840; Syringocystadenoma papilliferum. DR VEuPathDB; HostDB:ENSG00000157764; -. DR eggNOG; KOG0193; Eukaryota. DR GeneTree; ENSGT00940000156154; -. DR HOGENOM; CLU_023684_1_0_1; -. DR InParanoid; P15056; -. DR OrthoDB; 774951at2759; -. DR PAN-GO; P15056; 3 GO annotations based on evolutionary models. DR PhylomeDB; P15056; -. DR BRENDA; 2.7.10.2; 2681. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; P15056; -. DR Reactome; R-HSA-1295596; Spry regulation of FGF signaling. DR Reactome; R-HSA-170968; Frs2-mediated activation. DR Reactome; R-HSA-170984; ARMS-mediated activation. DR Reactome; R-HSA-187706; Signalling to p38 via RIT and RIN. DR Reactome; R-HSA-5673000; RAF activation. DR Reactome; R-HSA-5674135; MAP2K and MAPK activation. DR Reactome; R-HSA-5674499; Negative feedback regulation of MAPK pathway. DR Reactome; R-HSA-5675221; Negative regulation of MAPK pathway. DR Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants. DR Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF. DR Reactome; R-HSA-9649948; Signaling downstream of RAS mutants. DR Reactome; R-HSA-9656223; Signaling by RAF1 mutants. DR Reactome; R-HSA-9726840; SHOC2 M1731 mutant abolishes MRAS complex function. DR Reactome; R-HSA-9726842; Gain-of-function MRAS complexes activate RAF signaling. DR SignaLink; P15056; -. DR SIGNOR; P15056; -. DR Agora; ENSG00000157764; -. DR BioGRID-ORCS; 673; 88 hits in 1213 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; D57F7ABA; Synthetic Condensate 000274. DR ChiTaRS; BRAF; human. DR EvolutionaryTrace; P15056; -. DR GeneWiki; BRAF_(gene); -. DR GenomeRNAi; 673; -. DR Pharos; P15056; Tclin. DR PRO; PR:P15056; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; P15056; protein. DR Bgee; ENSG00000157764; Expressed in buccal mucosa cell and 183 other cell types or tissues. DR ExpressionAtlas; P15056; baseline and differential. DR GO; GO:0044297; C:cell body; IEA:Ensembl. DR GO; GO:0034451; C:centriolar satellite; IDA:HPA. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005739; C:mitochondrion; IBA:GO_Central. DR GO; GO:0043005; C:neuron projection; IEA:Ensembl. DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0098794; C:postsynapse; IEA:GOC. DR GO; GO:0098793; C:presynapse; IEA:GOC. DR GO; GO:0097229; C:sperm end piece; IDA:HPA. DR GO; GO:0097225; C:sperm midpiece; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005509; F:calcium ion binding; IDA:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0004708; F:MAP kinase kinase activity; IMP:UniProtKB. DR GO; GO:0004709; F:MAP kinase kinase kinase activity; IBA:GO_Central. DR GO; GO:0004672; F:protein kinase activity; IDA:BHF-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0097110; F:scaffold protein binding; IPI:BHF-UCL. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0009887; P:animal organ morphogenesis; TAS:ProtInc. DR GO; GO:0043369; P:CD4-positive or CD8-positive, alpha-beta T cell lineage commitment; IEA:Ensembl. DR GO; GO:0043367; P:CD4-positive, alpha-beta T cell differentiation; IEA:Ensembl. DR GO; GO:0071277; P:cellular response to calcium ion; IDA:BHF-UCL. DR GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0072577; P:endothelial cell apoptotic process; IEA:Ensembl. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0070371; P:ERK1 and ERK2 cascade; IBA:GO_Central. DR GO; GO:0090150; P:establishment of protein localization to membrane; IDA:CACAO. DR GO; GO:0060324; P:face development; IEA:Ensembl. DR GO; GO:0060323; P:head morphogenesis; IEA:Ensembl. DR GO; GO:0060291; P:long-term synaptic potentiation; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; IDA:UniProtKB. DR GO; GO:0002318; P:myeloid progenitor cell differentiation; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IEA:Ensembl. DR GO; GO:0010764; P:negative regulation of fibroblast migration; IEA:Ensembl. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:2000301; P:negative regulation of synaptic vesicle exocytosis; IEA:Ensembl. DR GO; GO:0048680; P:positive regulation of axon regeneration; IEA:Ensembl. DR GO; GO:0050772; P:positive regulation of axonogenesis; IEA:Ensembl. DR GO; GO:0010828; P:positive regulation of D-glucose transmembrane transport; IDA:CACAO. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0051496; P:positive regulation of stress fiber assembly; IEA:Ensembl. DR GO; GO:1900026; P:positive regulation of substrate adhesion-dependent cell spreading; IEA:Ensembl. DR GO; GO:0099170; P:postsynaptic modulation of chemical synaptic transmission; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0042127; P:regulation of cell population proliferation; IEA:Ensembl. DR GO; GO:0045580; P:regulation of T cell differentiation; IEA:Ensembl. DR GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl. DR GO; GO:0043149; P:stress fiber assembly; IEA:Ensembl. DR GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IEA:Ensembl. DR GO; GO:0016079; P:synaptic vesicle exocytosis; IEA:Ensembl. DR GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl. DR GO; GO:0050852; P:T cell receptor signaling pathway; IEA:Ensembl. DR GO; GO:0048538; P:thymus development; IEA:Ensembl. DR GO; GO:0030878; P:thyroid gland development; IEA:Ensembl. DR GO; GO:0008542; P:visual learning; IEA:Ensembl. DR CDD; cd20871; C1_B-Raf; 1. DR CDD; cd17134; RBD_BRAF; 1. DR CDD; cd14062; STKc_Raf; 1. DR DisProt; DP03825; -. DR FunFam; 3.10.20.90:FF:000015; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000024; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 3.30.60.20:FF:000004; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 1.10.510.10:FF:000036; RAF proto-oncogene serine/threonine-protein kinase; 1. DR Gene3D; 3.30.60.20; -; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR003116; RBD_dom. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051681; Ser/Thr_Kinases-Pseudokinases. DR InterPro; IPR029071; Ubiquitin-like_domsf. DR PANTHER; PTHR44329; SERINE/THREONINE-PROTEIN KINASE TNNI3K-RELATED; 1. DR PANTHER; PTHR44329:SF240; SERINE_THREONINE-PROTEIN KINASE B-RAF; 1. DR Pfam; PF00130; C1_1; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF02196; RBD; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 1. DR SMART; SM00455; RBD; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF54236; Ubiquitin-like; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50898; RBD; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 1. DR PROSITE; PS50081; ZF_DAG_PE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Allosteric enzyme; ATP-binding; Cardiomyopathy; KW Cell membrane; Chromosomal rearrangement; Cytoplasm; Deafness; KW Direct protein sequencing; Disease variant; Ectodermal dysplasia; KW Intellectual disability; Isopeptide bond; Kinase; Membrane; Metal-binding; KW Methylation; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Ubl conjugation; Zinc; KW Zinc-finger. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|Ref.8" FT CHAIN 2..766 FT /note="Serine/threonine-protein kinase B-raf" FT /id="PRO_0000085665" FT DOMAIN 155..227 FT /note="RBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00262" FT DOMAIN 457..717 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ZN_FING 234..280 FT /note="Phorbol-ester/DAG-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 1..38 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 308..454 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1..13 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 314..341 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 348..363 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 423..447 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 576 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 235 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 248 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 251 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 261 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 264 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 269 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 272 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 280 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 463..471 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 483 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 380..381 FT /note="Breakpoint for translocation to form KIAA1549-BRAF FT fusion protein" FT SITE 438..439 FT /note="Breakpoint for translocation to form KIAA1549-BRAF FT fusion protein" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0000269|Ref.8" FT MOD_RES 151 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 333 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P28028" FT MOD_RES 365 FT /note="Phosphoserine; by SGK1" FT /evidence="ECO:0000269|PubMed:11410590, ECO:0000269|Ref.8, FT ECO:0007744|PubMed:23186163" FT MOD_RES 373 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:1508179" FT MOD_RES 396 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|Ref.8" FT MOD_RES 399 FT /note="Phosphoserine" FT /evidence="ECO:0000269|Ref.8" FT MOD_RES 401 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|Ref.8, ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 446 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 447 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 671 FT /note="Omega-N-methylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:21917714" FT MOD_RES 729 FT /note="Phosphoserine" FT /evidence="ECO:0000269|Ref.8, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 750 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P28028" FT MOD_RES 753 FT /note="Phosphothreonine; by MAPK1" FT /evidence="ECO:0000269|PubMed:19710016" FT CROSSLNK 578 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:23907581" FT VARIANT 241 FT /note="T -> M (in NS7; dbSNP:rs387906660)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058620" FT VARIANT 241 FT /note="T -> P (in CFC1 and LPRD3; dbSNP:rs387906661)" FT /evidence="ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_058621" FT VARIANT 241 FT /note="T -> R (in NS7; dbSNP:rs387906660)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058622" FT VARIANT 244 FT /note="T -> P (in CFC1; dbSNP:rs397507465)" FT /evidence="ECO:0000269|PubMed:18042262" FT /id="VAR_065171" FT VARIANT 245 FT /note="L -> F (in CFC1; dbSNP:rs397507466)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058623" FT VARIANT 246 FT /note="A -> P (in CFC1; dbSNP:rs180177034)" FT /evidence="ECO:0000269|PubMed:16474404, FT ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169" FT /id="VAR_026113" FT VARIANT 257 FT /note="Q -> R (in CFC1; dbSNP:rs180177035)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_026114" FT VARIANT 262 FT /note="Q -> K (in CFC1; dbSNP:rs397507470)" FT /evidence="ECO:0000269|PubMed:18042262" FT /id="VAR_065172" FT VARIANT 275 FT /note="E -> K (in CFC1; dbSNP:rs2129044284)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058624" FT VARIANT 301 FT /note="P -> S (in dbSNP:rs34776339)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040391" FT VARIANT 462 FT /note="R -> I (in CRC; dbSNP:rs180177032)" FT /evidence="ECO:0000269|PubMed:12198537" FT /id="VAR_018613" FT VARIANT 463 FT /note="I -> S (in CRC; dbSNP:rs180177033)" FT /evidence="ECO:0000269|PubMed:12198537" FT /id="VAR_018614" FT VARIANT 464 FT /note="G -> E (in CRC; dbSNP:rs121913348)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12198537" FT /id="VAR_018615" FT VARIANT 464 FT /note="G -> V (in a colorectal cancer cell line; elevated FT kinase activity; efficiently induces cell transformation; FT dbSNP:rs121913348)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018616" FT VARIANT 466 FT /note="G -> A (in melanoma; dbSNP:rs121913351)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018617" FT VARIANT 466 FT /note="G -> E (in melanoma; dbSNP:rs121913351)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018618" FT VARIANT 466 FT /note="G -> V (in LNCR; dbSNP:rs121913351)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12460919" FT /id="VAR_018512" FT VARIANT 467 FT /note="S -> A (in CFC1; dbSNP:rs869025606)" FT /evidence="ECO:0000269|PubMed:16439621" FT /id="VAR_035096" FT VARIANT 468 FT /note="F -> S (in CFC1; dbSNP:rs397507473)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:18042262" FT /id="VAR_035097" FT VARIANT 469 FT /note="G -> A (in NHL; also in a lung adenocarcinoma FT sample; somatic mutation; elevated kinase activity; FT efficiently induces cell transformation; FT dbSNP:rs121913355)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:14612909, ECO:0000269|PubMed:17344846" FT /id="VAR_018620" FT VARIANT 469 FT /note="G -> E (in CFC1 and colon cancer; FT dbSNP:rs121913355)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404, FT ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169" FT /id="VAR_018621" FT VARIANT 469 FT /note="G -> R (in NHL; dbSNP:rs121913357)" FT /evidence="ECO:0000269|PubMed:14612909" FT /id="VAR_018622" FT VARIANT 469 FT /note="G -> V (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs121913355)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040392" FT VARIANT 485 FT /note="L -> F (in CFC1; dbSNP:rs180177036)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:19206169" FT /id="VAR_026115" FT VARIANT 499 FT /note="K -> E (in CFC1; dbSNP:rs180177037)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262" FT /id="VAR_026116" FT VARIANT 499 FT /note="K -> N (in CFC1; dbSNP:rs397507476)" FT /evidence="ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_058625" FT VARIANT 501 FT /note="E -> G (in CFC1; dbSNP:rs180177039)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404" FT /id="VAR_026117" FT VARIANT 501 FT /note="E -> K (in CFC1; dbSNP:rs180177038)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:19206169" FT /id="VAR_026118" FT VARIANT 525 FT /note="L -> P (in CFC1; dbSNP:rs869025340)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058626" FT VARIANT 531 FT /note="W -> C (in NS7; dbSNP:rs606231228)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058627" FT VARIANT 580 FT /note="N -> D (in CFC1; dbSNP:rs2128999571)" FT /evidence="ECO:0000269|PubMed:18042262" FT /id="VAR_065173" FT VARIANT 581 FT /note="N -> D (in CFC1; dbSNP:rs180177040)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262" FT /id="VAR_026119" FT VARIANT 581 FT /note="N -> S (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs121913370)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040393" FT VARIANT 586 FT /note="E -> K (in ovarian cancer; dbSNP:rs121913340)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018623" FT VARIANT 594 FT /note="D -> G (in NHL; dbSNP:rs121913338)" FT /evidence="ECO:0000269|PubMed:14612909" FT /id="VAR_018624" FT VARIANT 595 FT /note="F -> L (in CFC1; also found in colon cancer; FT dbSNP:rs121913341)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_018625" FT VARIANT 596 FT /note="G -> R (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs121913361)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:17344846" FT /id="VAR_018626" FT VARIANT 596 FT /note="G -> V (in CFC1; dbSNP:rs397507483)" FT /evidence="ECO:0000269|PubMed:16439621" FT /id="VAR_035098" FT VARIANT 597 FT /note="L -> R (in LNCR; also found in an ovarian serous FT carcinoma sample; somatic mutation; dbSNP:rs121913366)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12460919, ECO:0000269|PubMed:17344846" FT /id="VAR_018513" FT VARIANT 597 FT /note="L -> V (in NS7; also in a lung adenocarcinoma FT sample; somatic mutation; elevated kinase activity; FT efficiently induces cell transformation; FT dbSNP:rs121913369)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:19206169" FT /id="VAR_018627" FT VARIANT 599 FT /note="T -> R (in CFC1; dbSNP:rs121913375)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058628" FT VARIANT 600 FT /note="V -> D (in a melanoma cell line; requires 2 FT nucleotide substitutions; dbSNP:rs121913377)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018628" FT VARIANT 600 FT /note="V -> E (in CRC; also found in sarcoma, metastatic FT melanoma, ovarian serous carcinoma, pilocytic astrocytoma; FT somatic mutation; most common mutation; constitutive and FT elevated kinase activity; efficiently induces cell FT transformation; suppression of mutation in melanoma causes FT growth arrest and promotes apoptosis; loss of regulation by FT PMRT5; dbSNP:rs113488022)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12198537, ECO:0000269|PubMed:14500344, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:23263490, FT ECO:0000269|PubMed:24455489" FT /id="VAR_018629" FT VARIANT 601 FT /note="K -> E (in CRC; dbSNP:rs121913364)" FT /evidence="ECO:0000269|PubMed:12198537" FT /id="VAR_018630" FT VARIANT 601 FT /note="K -> Q (in CFC1; dbSNP:rs121913364)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058629" FT VARIANT 638 FT /note="D -> E (in CFC1; dbSNP:rs180177042)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058630" FT VARIANT 709 FT /note="Q -> R (in CFC1; dbSNP:rs397507486)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058631" FT MUTAGEN 53 FT /note="M->D: Reduces interaction with KSR1 and MAP2K1 and FT thus phosphorylation of MAP2K1." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 88 FT /note="K->E: Reduces interaction with KSR1 and MAP2K1 and FT thus phosphorylation of MAP2K1." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 483 FT /note="K->S: Reduces kinase activity with MAP2K1." FT /evidence="ECO:0000269|PubMed:21441910" FT MUTAGEN 509 FT /note="R->H: Loss of MAP2K1-mediated-BRAF-KSR1 FT dimerization." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 578 FT /note="K->R: Blocks EGF-induced ubiquitination and ERK FT activation." FT /evidence="ECO:0000269|PubMed:23907581" FT MUTAGEN 666 FT /note="I->R: No effect on MAP2K1-mediated-BRAF-KSR1 FT dimerization, however loss of BRAF-mediated phosphorylation FT of MAP2K1." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 671 FT /note="R->K: Increased kinase activity and stability in FT response to EGF treatment." FT /evidence="ECO:0000269|PubMed:21917714" FT CONFLICT 766 FT /note="H -> D (in Ref. 11; AAA96495)" FT /evidence="ECO:0000305" FT HELIX 43..68 FT /evidence="ECO:0007829|PDB:5VYK" FT HELIX 76..103 FT /evidence="ECO:0007829|PDB:5VYK" FT STRAND 156..161 FT /evidence="ECO:0007829|PDB:3NY5" FT TURN 162..164 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 165..170 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 177..186 FT /evidence="ECO:0007829|PDB:3NY5" FT TURN 187..189 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 192..194 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 195..199 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 206..208 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 214..217 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 221..226 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 448..450 FT /evidence="ECO:0007829|PDB:6P3D" FT HELIX 454..456 FT /evidence="ECO:0007829|PDB:5JRQ" FT STRAND 458..466 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 469..484 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 487..489 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 492..505 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 516..520 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 522..524 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 526..530 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 534..536 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 537..542 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 543..545 FT /evidence="ECO:0007829|PDB:6P3D" FT HELIX 550..569 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 579..581 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 582..585 FT /evidence="ECO:0007829|PDB:8C7X" FT TURN 586..588 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 589..592 FT /evidence="ECO:0007829|PDB:8C7X" FT TURN 598..600 FT /evidence="ECO:0007829|PDB:6XFP" FT TURN 602..605 FT /evidence="ECO:0007829|PDB:4RZV" FT HELIX 609..612 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 614..619 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 622..626 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 629..631 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 635..651 FT /evidence="ECO:0007829|PDB:8C7X" FT TURN 655..658 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 662..671 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 678..680 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 683..685 FT /evidence="ECO:0007829|PDB:5JRQ" FT HELIX 687..696 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 701..703 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 707..721 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 723..726 FT /evidence="ECO:0007829|PDB:6U2H" SQ SEQUENCE 766 AA; 84437 MW; 0798C2AAB487E813 CRC64; MAALSGGGGG GAEPGQALFN GDMEPEAGAG AGAAASSAAD PAIPEEVWNI KQMIKLTQEH IEALLDKFGG EHNPPSIYLE AYEEYTSKLD ALQQREQQLL ESLGNGTDFS VSSSASMDTV TSSSSSSLSV LPSSLSVFQN PTDVARSNPK SPQKPIVRVF LPNKQRTVVP ARCGVTVRDS LKKALMMRGL IPECCAVYRI QDGEKKPIGW DTDISWLTGE ELHVEVLENV PLTTHNFVRK TFFTLAFCDF CRKLLFQGFR CQTCGYKFHQ RCSTEVPLMC VNYDQLDLLF VSKFFEHHPI PQEEASLAET ALTSGSSPSA PASDSIGPQI LTSPSPSKSI PIPQPFRPAD EDHRNQFGQR DRSSSAPNVH INTIEPVNID DLIRDQGFRG DGGSTTGLSA TPPASLPGSL TNVKALQKSP GPQRERKSSS SSEDRNRMKT LGRRDSSDDW EIPDGQITVG QRIGSGSFGT VYKGKWHGDV AVKMLNVTAP TPQQLQAFKN EVGVLRKTRH VNILLFMGYS TKPQLAIVTQ WCEGSSLYHH LHIIETKFEM IKLIDIARQT AQGMDYLHAK SIIHRDLKSN NIFLHEDLTV KIGDFGLATV KSRWSGSHQF EQLSGSILWM APEVIRMQDK NPYSFQSDVY AFGIVLYELM TGQLPYSNIN NRDQIIFMVG RGYLSPDLSK VRSNCPKAMK RLMAECLKKK RDERPLFPQI LASIELLARS LPKIHRSASE PSLNRAGFQT EDFSLYACAS PKTPIQAGGY GAFPVH // ID BRDT_HUMAN Reviewed; 947 AA. AC Q58F21; A6NF68; B7Z811; B7Z890; B7ZAX7; D3DT32; O14789; Q05DQ4; Q6P5T1; AC Q7Z4A6; Q8IWI6; DT 30-MAY-2006, integrated into UniProtKB/Swiss-Prot. DT 14-APR-2009, sequence version 4. DT 28-JAN-2026, entry version 165. DE RecName: Full=Bromodomain testis-specific protein; DE AltName: Full=Cancer/testis antigen 9; DE Short=CT9; DE AltName: Full=RING3-like protein; GN Name=BRDT; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY, AND RP VARIANTS LYS-62 AND LEU-696. RX PubMed=9367677; DOI=10.1006/geno.1997.5000; RA Jones M.H., Numata M., Shimane M.; RT "Identification and characterization of BRDT: a testis-specific gene RT related to the bromodomain genes RING3 and Drosophila fsh."; RL Genomics 45:529-534(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, ALTERNATIVE SPLICING, RP TISSUE SPECIFICITY, AND VARIANTS LYS-62 AND LEU-696. RC TISSUE=Testis; RX PubMed=15647849; RA Zheng Y., Yuan W., Zhou Z., Xu M., Sha J.-H.; RT "Molecular cloning and expression of a novel alternative splice variant of RT BRDT gene."; RL Int. J. Mol. Med. 15:315-321(2005). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4), AND VARIANTS RP LYS-62 AND LEU-696. RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANTS LYS-62 AND RP LEU-696. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-462 (ISOFORM 1), AND VARIANTS RP LYS-62; ASN-238 AND LYS-410. RC TISSUE=Brain, and Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP TISSUE SPECIFICITY, AND IDENTIFICATION AS A CANCER/TESTIS ANTIGEN. RX PubMed=10704737; DOI=10.1016/s0304-3835(99)00385-7; RA Scanlan M.J., Altorki N.K., Gure A.O., Williamson B., Jungbluth A., RA Chen Y.-T., Old L.J.; RT "Expression of cancer-testis antigens in lung cancer: definition of RT bromodomain testis-specific gene (BRDT) as a new CT gene, CT9."; RL Cancer Lett. 150:155-164(2000). RN [8] RP VARIANTS [LARGE SCALE ANALYSIS] PHE-2; GLN-6; VAL-89; ASN-238; TYR-288; RP LYS-357; LYS-410 AND ALA-542. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [9] RP SUBCELLULAR LOCATION. RX PubMed=20538714; DOI=10.1530/rep-10-0139; RA Steilmann C., Cavalcanti M.C., Bartkuhn M., Pons-Kuhnemann J., RA Schuppe H.C., Weidner W., Steger K., Paradowska A.; RT "The interaction of modified histones with the bromodomain testis-specific RT (BRDT) gene and its mRNA level in sperm of fertile donors and subfertile RT men."; RL Reproduction 140:435-443(2010). RN [10] RP SUBCELLULAR LOCATION, AND MOTIF NUCLEAR LOCALIZATION SIGNAL. RX PubMed=22971749; DOI=10.1248/bpb.b12-00527; RA Fukazawa H., Masumi A.; RT "The conserved 12-amino acid stretch in the inter-bromodomain region of BET RT family proteins functions as a nuclear localization signal."; RL Biol. Pharm. Bull. 35:2064-2068(2012). RN [11] RP SUBCELLULAR LOCATION. RX PubMed=25593309; DOI=10.1101/gad.252189.114; RA Gong F., Chiu L.Y., Cox B., Aymard F., Clouaire T., Leung J.W., RA Cammarata M., Perez M., Agarwal P., Brodbelt J.S., Legube G., Miller K.M.; RT "Screen identifies bromodomain protein ZMYND8 in chromatin recognition of RT transcription-associated DNA damage that promotes homologous RT recombination."; RL Genes Dev. 29:197-211(2015). RN [12] {ECO:0007744|PDB:2RFJ} RP X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 21-137, FUNCTION, SUBUNIT, AND RP DOMAIN. RX PubMed=22464331; DOI=10.1016/j.cell.2012.02.013; RA Filippakopoulos P., Picaud S., Mangos M., Keates T., Lambert J.P., RA Barsyte-Lovejoy D., Felletar I., Volkmer R., Muller S., Pawson T., RA Gingras A.C., Arrowsmith C.H., Knapp S.; RT "Histone recognition and large-scale structural analysis of the human RT bromodomain family."; RL Cell 149:214-231(2012). RN [13] {ECO:0007744|PDB:4FLP} RP X-RAY CRYSTALLOGRAPHY (2.23 ANGSTROMS) OF 21-137 IN COMPLEX WITH JQ1, RP SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=22901802; DOI=10.1016/j.cell.2012.06.045; RA Matzuk M.M., McKeown M.R., Filippakopoulos P., Li Q., Ma L., Agno J.E., RA Lemieux M.E., Picaud S., Yu R.N., Qi J., Knapp S., Bradner J.E.; RT "Small-molecule inhibition of BRDT for male contraception."; RL Cell 150:673-684(2012). RN [14] RP VARIANT SPGF21 ASP-928, AND CHARACTERIZATION OF VARIANT SPGF21 ASP-928. RX PubMed=28199965; DOI=10.18632/oncotarget.15251; RA Li L., Sha Y., Wang X., Li P., Wang J., Kee K., Wang B.; RT "Whole-exome sequencing identified a homozygous BRDT mutation in a patient RT with acephalic spermatozoa."; RL Oncotarget 8:19914-19922(2017). CC -!- FUNCTION: Testis-specific chromatin protein that specifically binds CC histone H4 acetylated at 'Lys-5' and 'Lys-8' (H4K5ac and H4K8ac, CC respectively) and plays a key role in spermatogenesis (PubMed:22464331, CC PubMed:22901802). Required in late pachytene spermatocytes: plays a CC role in meiotic and post-meiotic cells by binding to acetylated CC histones at the promoter of specific meiotic and post-meiotic genes, CC facilitating their activation at the appropriate time CC (PubMed:22901802). In the post-meiotic phase of spermatogenesis, binds CC to hyperacetylated histones and participates in their general removal CC from DNA (PubMed:22901802). Also recognizes and binds a subset of CC butyrylated histones: able to bind histone H4 butyrylated at 'Lys-8' CC (H4K8ac), while it is not able to bind H4 butyrylated at 'Lys-5' CC (H4K5ac) (By similarity). Also acts as a component of the splicing CC machinery in pachytene spermatocytes and round spermatids and CC participates in 3'-UTR truncation of specific mRNAs in post-meiotic CC spermatids (By similarity). Required for chromocenter organization, a CC structure comprised of peri-centromeric heterochromatin. CC {ECO:0000250|UniProtKB:Q91Y44, ECO:0000269|PubMed:15647849, CC ECO:0000269|PubMed:22464331, ECO:0000269|PubMed:22901802, CC ECO:0000269|PubMed:9367677}. CC -!- SUBUNIT: Interacts with mRNA splicing machinery proteins SRSF2, DDX5, CC HNRNPK and TARDBP. Interacts with the acetylated N-terminus of histone CC H1, H2, H3 and H4. Interacts with P-TEFb components CDK9 and CC CCNT1/cyclin-T1. Interacts with SMARCE1 (By similarity). Interacts with CC the acetylated N-terminus of histone H1.4, H2A, H2B, H3 and H4. CC {ECO:0000250|UniProtKB:Q91Y44, ECO:0000269|PubMed:22464331, CC ECO:0000269|PubMed:22901802}. CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:20538714, CC ECO:0000269|PubMed:22901802, ECO:0000269|PubMed:22971749, CC ECO:0000269|PubMed:25593309}. Note=Detected on chromatin. CC {ECO:0000250|UniProtKB:Q91Y44}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=5; CC Name=1; CC IsoId=Q58F21-1; Sequence=Displayed; CC Name=2; Synonyms=BRDT-NY; CC IsoId=Q58F21-2; Sequence=VSP_019118; CC Name=3; CC IsoId=Q58F21-3; Sequence=VSP_044511; CC Name=4; CC IsoId=Q58F21-4; Sequence=VSP_044510; CC Name=5; CC IsoId=Q58F21-5; Sequence=VSP_044509; CC -!- TISSUE SPECIFICITY: Testis-specific. A 3-fold higher expression is seen CC in adult testis than in embryo testis. Expression seems to be CC correlated with histone H4 hyperacetylation during the haploid phase of CC spermatogenesis (spermiogenesis). No expression, or very low expression CC is seen in patients' testes with abnormal spermatogenesis. Expressed in CC cancers such as non-small cell lung cancer and squamous cell carcinomas CC of the head and neck as well as of esophagus, but not in melanoma or in CC cancers of the colon, breast, kidney and bladder. CC {ECO:0000269|PubMed:10704737, ECO:0000269|PubMed:15647849, CC ECO:0000269|PubMed:9367677}. CC -!- DEVELOPMENTAL STAGE: Expressed in embryo testis. CC -!- DOMAIN: Bromo domains mediate interaction with histones that have CC acetylated lysine residues at specific positions (PubMed:22464331). CC Bromo domain 1 mediates binding with histone H4 acetylated at 'Lys-5' CC and 'Lys-8' (H4K5ac and H4K8ac, respectively) (PubMed:22901802). The CC bromo domains also recognize and bind a subset of butyrylated histones: CC able to bind histone H4 butyrylated at 'Lys-8' (H4K8ac), while it is CC not able to bind H4 butyrylated at 'Lys-5' (H4K5ac) (By similarity). CC {ECO:0000250|UniProtKB:Q91Y44, ECO:0000269|PubMed:22464331, CC ECO:0000269|PubMed:22901802}. CC -!- PTM: Ubiquitinated in a SPOP-dependent manner, leading to proteasomal CC degradation. {ECO:0000250|UniProtKB:Q91Y44}. CC -!- DISEASE: Spermatogenic failure 21 (SPGF21) [MIM:617644]: An infertility CC disorder caused by spermatogenesis defects and characterized by CC acephalic spermatozoa in the semen of affected individuals. SPGF21 CC inheritance is autosomal recessive. {ECO:0000269|PubMed:28199965}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- MISCELLANEOUS: BRDT is a promising target for male contraception. CC Inhibition by thienodiazepine inhibitor (+)-JQ1 that binds Asn-109, CC prevents recognition of acetylated histone H4, causing a complete and CC reversible contraceptive effect in male mice (PubMed:22901802). CC {ECO:0000305|PubMed:22901802}. CC -!- SIMILARITY: Belongs to the BET family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH05281.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305}; CC Sequence=AAH47900.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305}; CC Sequence=AAH62700.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Protein Spotlight; Note=Asking life to be patient CC - Issue 144 of November 2012; CC URL="https://www.proteinspotlight.org/back_issues/144"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF019085; AAB87862.1; -; mRNA. DR EMBL; AY338951; AAQ16198.1; -; mRNA. DR EMBL; AK303008; BAH13876.1; -; mRNA. DR EMBL; AK302758; BAH13797.1; -; mRNA. DR EMBL; AK316442; BAH14813.1; -; mRNA. DR EMBL; AC114486; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471097; EAW73106.1; -; Genomic_DNA. DR EMBL; CH471097; EAW73107.1; -; Genomic_DNA. DR EMBL; CH471097; EAW73108.1; -; Genomic_DNA. DR EMBL; CH471097; EAW73110.1; -; Genomic_DNA. DR EMBL; CH471097; EAW73111.1; -; Genomic_DNA. DR EMBL; BC005281; AAH05281.1; ALT_SEQ; mRNA. DR EMBL; BC017582; AAH17582.1; -; mRNA. DR EMBL; BC047900; AAH47900.1; ALT_SEQ; mRNA. DR EMBL; BC062700; AAH62700.1; ALT_SEQ; mRNA. DR CCDS; CCDS55615.1; -. [Q58F21-4] DR CCDS; CCDS55616.1; -. [Q58F21-5] DR CCDS; CCDS735.1; -. [Q58F21-1] DR RefSeq; NP_001229734.2; NM_001242805.2. [Q58F21-1] DR RefSeq; NP_001229735.2; NM_001242806.2. [Q58F21-3] DR RefSeq; NP_001229736.2; NM_001242807.2. [Q58F21-4] DR RefSeq; NP_001229737.2; NM_001242808.2. [Q58F21-4] DR RefSeq; NP_001229739.2; NM_001242810.2. [Q58F21-5] DR RefSeq; NP_001717.3; NM_001726.4. [Q58F21-1] DR RefSeq; NP_997072.2; NM_207189.4. [Q58F21-1] DR RefSeq; XP_006710918.1; XM_006710855.5. [Q58F21-1] DR RefSeq; XP_006710919.1; XM_006710856.5. [Q58F21-1] DR RefSeq; XP_011540334.1; XM_011542032.4. [Q58F21-1] DR RefSeq; XP_011540336.1; XM_011542034.4. [Q58F21-1] DR RefSeq; XP_011540337.1; XM_011542035.4. [Q58F21-1] DR RefSeq; XP_011540338.1; XM_011542036.4. [Q58F21-1] DR RefSeq; XP_047284905.1; XM_047428949.1. [Q58F21-1] DR RefSeq; XP_047284911.1; XM_047428955.1. [Q58F21-1] DR RefSeq; XP_047284923.1; XM_047428967.1. [Q58F21-1] DR PDB; 2RFJ; X-ray; 2.05 A; A/B/C=21-137. DR PDB; 4FLP; X-ray; 2.23 A; A/B=21-137. DR PDB; 4KCX; X-ray; 2.00 A; A/B=21-137. DR PDB; 5VBQ; X-ray; 1.65 A; A/B=29-137. DR PDB; 5VBR; X-ray; 1.90 A; A/B=29-137. DR PDB; 7BJY; X-ray; 2.22 A; A/B=29-137. DR PDB; 7L73; X-ray; 1.46 A; A=29-137. DR PDB; 7L99; X-ray; 1.90 A; A/B/C/D=269-380. DR PDB; 7L9A; X-ray; 2.27 A; A/B=269-380. DR PDB; 7LEJ; X-ray; 1.73 A; A=266-378. DR PDB; 7LEK; X-ray; 2.75 A; A/B/C/D=266-378. DR PDB; 7LEL; X-ray; 2.15 A; A/B/C/D=266-378. DR PDB; 7LEM; X-ray; 1.89 A; A/B=29-137. DR PDB; 7MRC; X-ray; 1.55 A; A/B=29-137. DR PDB; 7MRD; X-ray; 1.39 A; A/B=29-137. DR PDB; 7MRG; X-ray; 1.99 A; A/B=29-137. DR PDB; 7MRH; X-ray; 1.98 A; A/B=29-137. DR PDB; 7UBO; X-ray; 1.82 A; A/B/C/D=29-137. DR PDB; 7UUU; X-ray; 1.52 A; A=29-137. DR PDB; 8CZA; X-ray; 2.96 A; A/B/C/D/E/F=29-137. DR PDB; 8YHS; X-ray; 1.50 A; A=21-137. DR PDBsum; 2RFJ; -. DR PDBsum; 4FLP; -. DR PDBsum; 4KCX; -. DR PDBsum; 5VBQ; -. DR PDBsum; 5VBR; -. DR PDBsum; 7BJY; -. DR PDBsum; 7L73; -. DR PDBsum; 7L99; -. DR PDBsum; 7L9A; -. DR PDBsum; 7LEJ; -. DR PDBsum; 7LEK; -. DR PDBsum; 7LEL; -. DR PDBsum; 7LEM; -. DR PDBsum; 7MRC; -. DR PDBsum; 7MRD; -. DR PDBsum; 7MRG; -. DR PDBsum; 7MRH; -. DR PDBsum; 7UBO; -. DR PDBsum; 7UUU; -. DR PDBsum; 8CZA; -. DR PDBsum; 8YHS; -. DR AlphaFoldDB; Q58F21; -. DR SASBDB; Q58F21; -. DR SMR; Q58F21; -. DR BioGRID; 107143; 78. DR FunCoup; Q58F21; 517. DR IntAct; Q58F21; 2. DR STRING; 9606.ENSP00000387822; -. DR BindingDB; Q58F21; -. DR ChEMBL; CHEMBL1795185; -. DR DrugBank; DB17021; JQ1. DR DrugCentral; Q58F21; -. DR GuidetoPHARMACOLOGY; 2729; -. DR GlyGen; Q58F21; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q58F21; -. DR PhosphoSitePlus; Q58F21; -. DR BioMuta; BRDT; -. DR DMDM; 226694198; -. DR jPOST; Q58F21; -. DR MassIVE; Q58F21; -. DR PaxDb; 9606-ENSP00000387822; -. DR PeptideAtlas; Q58F21; -. DR ProteomicsDB; 1029; -. DR ProteomicsDB; 62618; -. [Q58F21-1] DR ProteomicsDB; 62619; -. [Q58F21-2] DR Antibodypedia; 3212; 136 antibodies from 22 providers. DR DNASU; 676; -. DR Ensembl; ENST00000362005.7; ENSP00000354568.3; ENSG00000137948.19. [Q58F21-1] DR Ensembl; ENST00000370389.6; ENSP00000359416.2; ENSG00000137948.19. [Q58F21-5] DR Ensembl; ENST00000394530.7; ENSP00000378038.3; ENSG00000137948.19. [Q58F21-4] DR Ensembl; ENST00000399546.7; ENSP00000387822.3; ENSG00000137948.19. [Q58F21-1] DR Ensembl; ENST00000402388.1; ENSP00000384051.1; ENSG00000137948.19. [Q58F21-1] DR GeneID; 676; -. DR KEGG; hsa:676; -. DR MANE-Select; ENST00000399546.7; ENSP00000387822.3; NM_207189.4; NP_997072.2. DR UCSC; uc001dol.5; human. [Q58F21-1] DR AGR; HGNC:1105; -. DR ClinPGx; PA25418; -. DR CTD; 676; -. DR DisGeNET; 676; -. DR GeneCards; BRDT; -. DR HGNC; HGNC:1105; BRDT. DR HPA; ENSG00000137948; Tissue enriched (testis). DR MalaCards; BRDT; -. DR MIM; 602144; gene. DR MIM; 617644; phenotype. DR OpenTargets; ENSG00000137948; -. DR VEuPathDB; HostDB:ENSG00000137948; -. DR eggNOG; KOG1474; Eukaryota. DR GeneTree; ENSGT00940000154549; -. DR HOGENOM; CLU_001499_0_0_1; -. DR InParanoid; Q58F21; -. DR OMA; DFKTMFL; -. DR OrthoDB; 21449at2759; -. DR PAN-GO; Q58F21; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q58F21; -. DR PathwayCommons; Q58F21; -. DR SignaLink; Q58F21; -. DR SIGNOR; Q58F21; -. DR Agora; ENSG00000137948; -. DR BioGRID-ORCS; 676; 15 hits in 1166 CRISPR screens. DR ChiTaRS; BRDT; human. DR EvolutionaryTrace; Q58F21; -. DR GeneWiki; BRDT; -. DR GenomeRNAi; 676; -. DR Pharos; Q58F21; Tchem. DR PRO; PR:Q58F21; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q58F21; protein. DR Bgee; ENSG00000137948; Expressed in left testis and 97 other cell types or tissues. DR ExpressionAtlas; Q58F21; baseline and differential. DR GO; GO:0000785; C:chromatin; IBA:GO_Central. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IBA:GO_Central. DR GO; GO:0042393; F:histone binding; IDA:UniProtKB. DR GO; GO:0140008; F:histone H4 reader activity; IEA:Ensembl. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0003713; F:transcription coactivator activity; TAS:ProtInc. DR GO; GO:0006338; P:chromatin remodeling; ISS:UniProtKB. DR GO; GO:0007141; P:male meiosis I; ISS:UniProtKB. DR GO; GO:0007140; P:male meiotic nuclear division; ISS:UniProtKB. DR GO; GO:0006397; P:mRNA processing; IEA:UniProtKB-KW. DR GO; GO:0010628; P:positive regulation of gene expression; ISS:UniProtKB. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IMP:UniProtKB. DR GO; GO:0043484; P:regulation of RNA splicing; ISS:UniProtKB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central. DR GO; GO:0008380; P:RNA splicing; IEA:UniProtKB-KW. DR GO; GO:0035092; P:sperm DNA condensation; ISS:UniProtKB. DR CDD; cd05497; Bromo_Brdt_I_like; 1. DR CDD; cd05498; Bromo_Brdt_II_like; 1. DR DisProt; DP03058; -. DR FunFam; 1.20.920.10:FF:000003; Bromodomain-containing protein 2; 1. DR FunFam; 1.20.1270.220:FF:000001; bromodomain-containing protein 2 isoform X1; 1. DR FunFam; 1.20.920.10:FF:000002; Bromodomain-containing protein 4; 1. DR Gene3D; 1.20.1270.220; -; 1. DR Gene3D; 1.20.920.10; Bromodomain-like; 2. DR InterPro; IPR031354; BRD4_CDT. DR InterPro; IPR043508; Bromo_Brdt_I. DR InterPro; IPR043509; Bromo_Brdt_II. DR InterPro; IPR050935; Bromo_chromatin_reader. DR InterPro; IPR001487; Bromodomain. DR InterPro; IPR036427; Bromodomain-like_sf. DR InterPro; IPR018359; Bromodomain_CS. DR InterPro; IPR027353; NET_dom. DR InterPro; IPR038336; NET_sf. DR PANTHER; PTHR22880:SF175; BROMODOMAIN TESTIS-SPECIFIC PROTEIN; 1. DR PANTHER; PTHR22880; FALZ-RELATED BROMODOMAIN-CONTAINING PROTEINS; 1. DR Pfam; PF17035; BET; 1. DR Pfam; PF17105; BRD4_CDT; 1. DR Pfam; PF00439; Bromodomain; 2. DR PRINTS; PR00503; BROMODOMAIN. DR SMART; SM00297; BROMO; 2. DR SUPFAM; SSF47370; Bromodomain; 2. DR PROSITE; PS00633; BROMODOMAIN_1; 2. DR PROSITE; PS50014; BROMODOMAIN_2; 2. DR PROSITE; PS51525; NET; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative splicing; Bromodomain; KW Chromatin regulator; Coiled coil; Differentiation; Disease variant; KW Meiosis; mRNA processing; mRNA splicing; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; Spermatogenesis; KW Transcription; Transcription regulation; Ubl conjugation. FT CHAIN 1..947 FT /note="Bromodomain testis-specific protein" FT /id="PRO_0000239225" FT DOMAIN 27..133 FT /note="Bromo 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00035" FT DOMAIN 267..376 FT /note="Bromo 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00035" FT DOMAIN 500..582 FT /note="NET" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00857" FT REGION 202..228 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 395..420 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 444..511 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 610..698 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 882..924 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 417..470 FT /evidence="ECO:0000255" FT COILED 591..621 FT /evidence="ECO:0000255" FT MOTIF 209..220 FT /note="Nuclear localization signal" FT /evidence="ECO:0000269|PubMed:22971749" FT COMPBIAS 217..228 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 447..462 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 470..481 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 482..494 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 637..662 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 674..692 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 885..924 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 109 FT /ligand="JQ1" FT /ligand_id="ChEBI:CHEBI:137113" FT /ligand_note="inhibitor" FT /evidence="ECO:0000269|PubMed:22901802, FT ECO:0007744|PDB:4FLP" FT SITE 109 FT /note="Histone H4K5ac binding" FT /evidence="ECO:0000250|UniProtKB:Q91Y44" FT SITE 114 FT /note="Histone H4K5ac binding" FT /evidence="ECO:0000250|UniProtKB:Q91Y44" FT MOD_RES 187 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q91Y44" FT VAR_SEQ 1..73 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000305" FT /id="VSP_044509" FT VAR_SEQ 1 FT /note="M -> MTCTCRQDSKQLRM (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15647849" FT /id="VSP_019118" FT VAR_SEQ 65..110 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_044510" FT VAR_SEQ 148 FT /note="K -> KGKAG (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_044511" FT VARIANT 2 FT /note="S -> F (in dbSNP:rs55806733)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041924" FT VARIANT 6 FT /note="R -> Q (in dbSNP:rs56273490)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041925" FT VARIANT 62 FT /note="Q -> K (in dbSNP:rs10783071)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:15647849, FT ECO:0000269|PubMed:9367677, ECO:0000269|Ref.5" FT /id="VAR_026584" FT VARIANT 89 FT /note="A -> V (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs781375003)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041926" FT VARIANT 238 FT /note="K -> N (in dbSNP:rs1156281)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:17344846" FT /id="VAR_026585" FT VARIANT 288 FT /note="H -> Y (in a lung neuroendocrine carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041927" FT VARIANT 336 FT /note="K -> T (in dbSNP:rs1064567)" FT /id="VAR_047327" FT VARIANT 357 FT /note="E -> K (in dbSNP:rs34674879)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041928" FT VARIANT 410 FT /note="N -> K (in dbSNP:rs3088232)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:17344846" FT /id="VAR_026586" FT VARIANT 542 FT /note="P -> A (in dbSNP:rs55912588)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041929" FT VARIANT 605 FT /note="R -> Q (in dbSNP:rs35327986)" FT /id="VAR_047328" FT VARIANT 696 FT /note="P -> L (in dbSNP:rs10747493)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:15647849, ECO:0000269|PubMed:9367677, FT ECO:0000269|Ref.5" FT /id="VAR_047329" FT VARIANT 928 FT /note="G -> D (in SPGF21; uncertain significance; no effect FT on protein expression; dbSNP:rs754258809)" FT /evidence="ECO:0000269|PubMed:28199965" FT /id="VAR_079306" FT CONFLICT 42 FT /note="D -> N (in Ref. 3; BAH13876)" FT /evidence="ECO:0000305" FT CONFLICT 73 FT /note="P -> S (in Ref. 6; AAH05281)" FT /evidence="ECO:0000305" FT CONFLICT 80 FT /note="K -> I (in Ref. 6; AAH62700)" FT /evidence="ECO:0000305" FT CONFLICT 265 FT /note="K -> E (in Ref. 1; AAB87862)" FT /evidence="ECO:0000305" FT CONFLICT 336 FT /note="K -> S (in Ref. 1; AAB87862)" FT /evidence="ECO:0000305" FT CONFLICT 462 FT /note="E -> K (in Ref. 6; AAH17582)" FT /evidence="ECO:0000305" FT CONFLICT 477 FT /note="Q -> R (in Ref. 3; BAH13876)" FT /evidence="ECO:0000305" FT CONFLICT 552 FT /note="I -> M (in Ref. 2; AAQ16198)" FT /evidence="ECO:0000305" FT CONFLICT 686 FT /note="N -> H (in Ref. 1; AAB87862)" FT /evidence="ECO:0000305" FT CONFLICT 893 FT /note="Q -> P (in Ref. 1; AAB87862)" FT /evidence="ECO:0000305" FT CONFLICT 915 FT /note="Q -> P (in Ref. 1; AAB87862)" FT /evidence="ECO:0000305" FT HELIX 29..37 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 39..45 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 50..52 FT /evidence="ECO:0007829|PDB:7MRD" FT STRAND 53..55 FT /evidence="ECO:0007829|PDB:2RFJ" FT TURN 58..62 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 66..69 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 76..84 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 91..108 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 114..131 FT /evidence="ECO:0007829|PDB:7MRD" FT HELIX 266..284 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 286..288 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 289..292 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 293..295 FT /evidence="ECO:0007829|PDB:7LEJ" FT STRAND 296..298 FT /evidence="ECO:0007829|PDB:7L99" FT HELIX 301..304 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 309..312 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 319..327 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 334..351 FT /evidence="ECO:0007829|PDB:7LEJ" FT HELIX 357..373 FT /evidence="ECO:0007829|PDB:7LEJ" SQ SEQUENCE 947 AA; 107954 MW; 09C0FD8690E217BB CRC64; MSLPSRQTAI IVNPPPPEYI NTKKNGRLTN QLQYLQKVVL KDLWKHSFSW PFQRPVDAVK LQLPDYYTII KNPMDLNTIK KRLENKYYAK ASECIEDFNT MFSNCYLYNK PGDDIVLMAQ ALEKLFMQKL SQMPQEEQVV GVKERIKKGT QQNIAVSSAK EKSSPSATEK VFKQQEIPSV FPKTSISPLN VVQGASVNSS SQTAAQVTKG VKRKADTTTP ATSAVKASSE FSPTFTEKSV ALPPIKENMP KNVLPDSQQQ YNVVKTVKVT EQLRHCSEIL KEMLAKKHFS YAWPFYNPVD VNALGLHNYY DVVKNPMDLG TIKEKMDNQE YKDAYKFAAD VRLMFMNCYK YNPPDHEVVT MARMLQDVFE THFSKIPIEP VESMPLCYIK TDITETTGRE NTNEASSEGN SSDDSEDERV KRLAKLQEQL KAVHQQLQVL SQVPFRKLNK KKEKSKKEKK KEKVNNSNEN PRKMCEQMRL KEKSKRNQPK KRKQQFIGLK SEDEDNAKPM NYDEKRQLSL NINKLPGDKL GRVVHIIQSR EPSLSNSNPD EIEIDFETLK ASTLRELEKY VSACLRKRPL KPPAKKIMMS KEELHSQKKQ ELEKRLLDVN NQLNSRKRQT KSDKTQPSKA VENVSRLSES SSSSSSSSES ESSSSDLSSS DSSDSESEMF PKFTEVKPND SPSKENVKKM KNECIPPEGR TGVTQIGYCV QDTTSANTTL VHQTTPSHVM PPNHHQLAFN YQELEHLQTV KNISPLQILP PSGDSEQLSN GITVMHPSGD SDTTMLESEC QAPVQKDIKI KNADSWKSLG KPVKPSGVMK SSDELFNQFR KAAIEKEVKA RTQELIRKHL EQNTKELKAS QENQRDLGNG LTVESFSNKI QNKCSGEEQK EHQQSSEAQD KSKLWLLKDR DLARQKEQER RRREAMVGTI DMTLQSDIMT MFENNFD // ID BRSK1_HUMAN Reviewed; 778 AA. AC Q8TDC3; F1DG44; Q5J5B5; Q8NDD0; Q8NDR4; Q8TDC2; Q96AV4; Q96JL4; DT 29-AUG-2003, integrated into UniProtKB/Swiss-Prot. DT 21-SEP-2011, sequence version 2. DT 28-JAN-2026, entry version 200. DE RecName: Full=Serine/threonine-protein kinase BRSK1; DE EC=2.7.11.1; DE AltName: Full=Brain-selective kinase 1; DE EC=2.7.11.26; DE AltName: Full=Brain-specific serine/threonine-protein kinase 1; DE Short=BR serine/threonine-protein kinase 1; DE AltName: Full=Serine/threonine-protein kinase SAD-B; DE AltName: Full=Synapses of Amphids Defective homolog 1; DE Short=SAD1 homolog; DE Short=hSAD1; GN Name=BRSK1; Synonyms=KIAA1811, SAD1, SADB; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, ACTIVITY REGULATION, RP PHOSPHORYLATION AT THR-189, AND MUTAGENESIS OF THR-189. RX PubMed=14976552; DOI=10.1038/sj.emboj.7600110; RA Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A., Boudeau J., RA Hawley S.A., Udd L., Maekelae T.P., Hardie D.G., Alessi D.R.; RT "LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, RT including MARK/PAR-1."; RL EMBO J. 23:833-843(2004). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION, RP TISSUE SPECIFICITY, AND MUTAGENESIS OF LYS-59. RC TISSUE=Testis; RX PubMed=15150265; DOI=10.1074/jbc.m404728200; RA Lu R., Niida H., Nakanishi M.; RT "Human SAD1 kinase is involved in UV-induced DNA damage checkpoint RT function."; RL J. Biol. Chem. 279:31164-31170(2004). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=16630837; DOI=10.1016/j.neuron.2006.03.018; RA Inoue E., Mochida S., Takagi H., Higa S., Deguchi-Tawarada M., RA Takao-Rikitsu E., Inoue M., Yao I., Takeuchi K., Kitajima I., Setou M., RA Ohtsuka T., Takai Y.; RT "SAD: a presynaptic kinase associated with synaptic vesicles and the active RT zone cytomatrix that regulates neurotransmitter release."; RL Neuron 50:261-275(2006). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3). RX PubMed=19648910; DOI=10.1038/ncb1921; RA Alvarado-Kristensson M., Rodriguez M.J., Silio V., Valpuesta J.M., RA Carrera A.C.; RT "SADB phosphorylation of gamma-tubulin regulates centrosome duplication."; RL Nat. Cell Biol. 11:1081-1092(2009). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Brain; RA She X.Y., Yu L., Guo J.H.; RL Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 35-778. RC TISSUE=Brain; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 64-778. RC TISSUE=Brain; RX PubMed=11347906; DOI=10.1093/dnares/8.2.85; RA Nagase T., Nakayama M., Nakajima D., Kikuno R., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XX. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 8:85-95(2001). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 287-778. RC TISSUE=Lymph; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP PHOSPHORYLATION AT THR-189, AND MUTAGENESIS OF GLY-327. RX PubMed=18339622; DOI=10.1074/jbc.m710381200; RA Bright N.J., Carling D., Thornton C.; RT "Investigating the regulation of brain-specific kinases 1 and 2 by RT phosphorylation."; RL J. Biol. Chem. 283:14946-14954(2008). RN [11] RP PHOSPHORYLATION. RX PubMed=19958286; DOI=10.1042/bj20091372; RA Fogarty S., Hawley S.A., Green K.A., Saner N., Mustard K.J., Hardie D.G.; RT "Calmodulin-dependent protein kinase kinase-beta activates AMPK without RT forming a stable complex: synergistic effects of Ca2+ and AMP."; RL Biochem. J. 426:109-118(2010). RN [12] RP FUNCTION. RX PubMed=20026642; DOI=10.1242/jcs.058230; RA Muller M., Lutter D., Puschel A.W.; RT "Persistence of the cell-cycle checkpoint kinase Wee1 in SadA- and SadB- RT deficient neurons disrupts neuronal polarity."; RL J. Cell Sci. 123:286-294(2010). RN [13] RP CATALYTIC ACTIVITY, AND FUNCTION IN MAPT PHOSPHORYLATION. RX PubMed=21985311; DOI=10.1111/j.1471-4159.2011.07523.x; RA Yoshida H., Goedert M.; RT "Phosphorylation of microtubule-associated protein tau by AMPK-related RT kinases."; RL J. Neurochem. 120:165-176(2012). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-508, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [15] RP VARIANTS [LARGE SCALE ANALYSIS] TRP-303; ILE-319; GLU-391; ASN-531; SER-749 RP AND ALA-764. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase that plays a key role in CC polarization of neurons and centrosome duplication. Phosphorylates CC CDC25B, CDC25C, MAPT/TAU, RIMS1, TUBG1, TUBG2 and WEE1. Following CC phosphorylation and activation by STK11/LKB1, acts as a key regulator CC of polarization of cortical neurons, probably by mediating CC phosphorylation of microtubule-associated proteins such as MAPT/TAU at CC 'Thr-529' and 'Ser-579'. Also regulates neuron polarization by CC mediating phosphorylation of WEE1 at 'Ser-642' in postmitotic neurons, CC leading to down-regulate WEE1 activity in polarized neurons. In CC neurons, localizes to synaptic vesicles and plays a role in CC neurotransmitter release, possibly by phosphorylating RIMS1. Also acts CC as a positive regulator of centrosome duplication by mediating CC phosphorylation of gamma-tubulin (TUBG1 and TUBG2) at 'Ser-131', CC leading to translocation of gamma-tubulin and its associated proteins CC to the centrosome. Involved in the UV-induced DNA damage checkpoint CC response, probably by inhibiting CDK1 activity through phosphorylation CC and activation of WEE1, and inhibition of CDC25B and CDC25C. CC {ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:15150265, CC ECO:0000269|PubMed:20026642, ECO:0000269|PubMed:21985311}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21985311}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21985311}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[tau protein] + ATP = O-phospho-L-seryl-[tau protein] CC + ADP + H(+); Xref=Rhea:RHEA:12801, Rhea:RHEA-COMP:13701, Rhea:RHEA- CC COMP:13702, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.26; CC Evidence={ECO:0000269|PubMed:21985311}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[tau protein] + ATP = O-phospho-L-threonyl-[tau CC protein] + ADP + H(+); Xref=Rhea:RHEA:53904, Rhea:RHEA-COMP:13703, CC Rhea:RHEA-COMP:13704, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, CC ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; CC EC=2.7.11.26; Evidence={ECO:0000269|PubMed:21985311}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250}; CC -!- ACTIVITY REGULATION: Activated by phosphorylation on Thr-189 by CC STK11/LKB1. {ECO:0000269|PubMed:14976552}. CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15150265}. Nucleus CC {ECO:0000269|PubMed:15150265}. Cytoplasm, cytoskeleton, microtubule CC organizing center, centrosome {ECO:0000250}. Synapse CC {ECO:0000250|UniProtKB:B2DD29}. Presynaptic active zone CC {ECO:0000250|UniProtKB:B2DD29}. Cytoplasmic vesicle, secretory vesicle, CC synaptic vesicle {ECO:0000250|UniProtKB:B2DD29}. Note=Nuclear in the CC absence of DNA damage. Translocated to the nucleus in response to CC UV- or MMS-induced DNA damage (By similarity). {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=SADB-Long, L; CC IsoId=Q8TDC3-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8TDC3-2; Sequence=VSP_008158; CC Name=3; Synonyms=SADB-short, S; CC IsoId=Q8TDC3-3; Sequence=VSP_041742; CC -!- TISSUE SPECIFICITY: Widely expressed, with highest levels in brain and CC testis. Protein levels remain constant throughout the cell cycle. CC {ECO:0000269|PubMed:15150265}. CC -!- PTM: Phosphorylated at Thr-189 by STK11/LKB1 in complex with STE20- CC related adapter-alpha (STRADA) pseudo kinase and CAB39. Not CC phosphorylated at Thr-189 by CaMKK2. In contrast, it is phosphorylated CC and activated by CaMKK1. May be inactivated via dephosphorylation of CC Thr-189 by PP2C. {ECO:0000269|PubMed:14976552, CC ECO:0000269|PubMed:18339622, ECO:0000269|PubMed:19958286}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. SNF1 subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH16681.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY458602; AAS10354.1; -; mRNA. DR EMBL; AY505124; AAS86442.1; -; mRNA. DR EMBL; HQ830199; ADX95745.1; -; mRNA. DR EMBL; AF479826; AAL87697.1; -; mRNA. DR EMBL; AF479827; AAL87698.1; -; mRNA. DR EMBL; AC008974; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC020922; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL831945; CAD38595.1; -; mRNA. DR EMBL; AL834275; CAD38950.2; -; mRNA. DR EMBL; AB058714; BAB47440.1; -; mRNA. DR EMBL; BC016681; AAH16681.1; ALT_INIT; mRNA. DR CCDS; CCDS12921.1; -. [Q8TDC3-1] DR RefSeq; NP_115806.1; NM_032430.2. [Q8TDC3-1] DR AlphaFoldDB; Q8TDC3; -. DR SMR; Q8TDC3; -. DR BioGRID; 124084; 36. DR FunCoup; Q8TDC3; 1370. DR IntAct; Q8TDC3; 29. DR MINT; Q8TDC3; -. DR STRING; 9606.ENSP00000310649; -. DR BindingDB; Q8TDC3; -. DR ChEMBL; CHEMBL5650; -. DR DrugCentral; Q8TDC3; -. DR GlyGen; Q8TDC3; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q8TDC3; -. DR PhosphoSitePlus; Q8TDC3; -. DR SwissPalm; Q8TDC3; -. DR BioMuta; BRSK1; -. DR DMDM; 347595639; -. DR jPOST; Q8TDC3; -. DR MassIVE; Q8TDC3; -. DR PaxDb; 9606-ENSP00000310649; -. DR PeptideAtlas; Q8TDC3; -. DR ProteomicsDB; 74264; -. [Q8TDC3-1] DR ProteomicsDB; 74265; -. [Q8TDC3-2] DR ProteomicsDB; 74266; -. [Q8TDC3-3] DR Antibodypedia; 19545; 448 antibodies from 37 providers. DR DNASU; 84446; -. DR Ensembl; ENST00000309383.6; ENSP00000310649.1; ENSG00000160469.17. [Q8TDC3-1] DR Ensembl; ENST00000585418.1; ENSP00000467357.1; ENSG00000160469.17. [Q8TDC3-3] DR Ensembl; ENST00000590333.5; ENSP00000468190.1; ENSG00000160469.17. [Q8TDC3-2] DR GeneID; 84446; -. DR KEGG; hsa:84446; -. DR MANE-Select; ENST00000309383.6; ENSP00000310649.1; NM_032430.2; NP_115806.1. DR UCSC; uc002qkf.4; human. [Q8TDC3-1] DR AGR; HGNC:18994; -. DR ClinPGx; PA134888976; -. DR CTD; 84446; -. DR DisGeNET; 84446; -. DR GeneCards; BRSK1; -. DR HGNC; HGNC:18994; BRSK1. DR HPA; ENSG00000160469; Group enriched (brain, pituitary gland). DR MalaCards; BRSK1; -. DR MIM; 609235; gene. DR OpenTargets; ENSG00000160469; -. DR VEuPathDB; HostDB:ENSG00000160469; -. DR eggNOG; KOG0588; Eukaryota. DR GeneTree; ENSGT00940000161254; -. DR HOGENOM; CLU_000288_156_2_1; -. DR InParanoid; Q8TDC3; -. DR OMA; QHSQRNR; -. DR OrthoDB; 193931at2759; -. DR PAN-GO; Q8TDC3; 9 GO annotations based on evolutionary models. DR PhylomeDB; Q8TDC3; -. DR PathwayCommons; Q8TDC3; -. DR SignaLink; Q8TDC3; -. DR SIGNOR; Q8TDC3; -. DR Agora; ENSG00000160469; -. DR BioGRID-ORCS; 84446; 8 hits in 1189 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; BRSK1; human. DR GeneWiki; BRSK1; -. DR GenomeRNAi; 84446; -. DR Pharos; Q8TDC3; Tchem. DR PRO; PR:Q8TDC3; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q8TDC3; protein. DR Bgee; ENSG00000160469; Expressed in right frontal lobe and 121 other cell types or tissues. DR ExpressionAtlas; Q8TDC3; baseline and differential. DR GO; GO:0030054; C:cell junction; IDA:HPA. DR GO; GO:0005813; C:centrosome; ISS:UniProtKB. DR GO; GO:0098981; C:cholinergic synapse; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0150034; C:distal axon; ISS:ARUK-UCL. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0014069; C:postsynaptic density; IEA:Ensembl. DR GO; GO:0048786; C:presynaptic active zone; TAS:ARUK-UCL. DR GO; GO:0008021; C:synaptic vesicle; ISS:UniProtKB. DR GO; GO:0005524; F:ATP binding; IC:UniProtKB. DR GO; GO:0043015; F:gamma-tubulin binding; ISS:UniProtKB. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IEA:Ensembl. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0048156; F:tau protein binding; NAS:ARUK-UCL. DR GO; GO:0050321; F:tau-protein kinase activity; IDA:UniProtKB. DR GO; GO:0008306; P:associative learning; ISS:ARUK-UCL. DR GO; GO:0007409; P:axonogenesis; ISS:UniProtKB. DR GO; GO:0021953; P:central nervous system neuron differentiation; IEA:Ensembl. DR GO; GO:0051298; P:centrosome duplication; ISS:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0030010; P:establishment of cell polarity; ISS:UniProtKB. DR GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IDA:MGI. DR GO; GO:0090176; P:microtubule cytoskeleton organization involved in establishment of planar polarity; ISS:ARUK-UCL. DR GO; GO:0007095; P:mitotic G2 DNA damage checkpoint signaling; IDA:UniProtKB. DR GO; GO:0030182; P:neuron differentiation; ISS:UniProtKB. DR GO; GO:0007269; P:neurotransmitter secretion; ISS:UniProtKB. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:MGI. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0050770; P:regulation of axonogenesis; ISS:ARUK-UCL. DR GO; GO:0010975; P:regulation of neuron projection development; ISS:ARUK-UCL. DR GO; GO:0048167; P:regulation of synaptic plasticity; ISS:ARUK-UCL. DR GO; GO:2000807; P:regulation of synaptic vesicle clustering; TAS:ARUK-UCL. DR GO; GO:0010807; P:regulation of synaptic vesicle priming; IEA:Ensembl. DR GO; GO:0009411; P:response to UV; IDA:UniProtKB. DR GO; GO:0099504; P:synaptic vesicle cycle; ISS:ARUK-UCL. DR CDD; cd14081; STKc_BRSK1_2; 1. DR CDD; cd14340; UBA_BRSK; 1. DR FunFam; 1.10.510.10:FF:000064; BR serine/threonine-protein kinase 2; 1. DR FunFam; 3.30.200.20:FF:000003; Non-specific serine/threonine protein kinase; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR048622; BRSK1_2-like_UBA. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR015940; UBA. DR PANTHER; PTHR24346; MAP/MICROTUBULE AFFINITY-REGULATING KINASE; 1. DR PANTHER; PTHR24346:SF36; SERINE_THREONINE-PROTEIN KINASE BRSK1 ISOFORM X1-RELATED; 1. DR Pfam; PF21122; KA1_BRSK; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF21115; UBA_BRSK; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50030; UBA; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cell cycle; Cell projection; Cytoplasm; KW Cytoplasmic vesicle; Cytoskeleton; DNA damage; Kinase; Magnesium; KW Metal-binding; Methylation; Neurogenesis; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Synapse; Transferase. FT CHAIN 1..778 FT /note="Serine/threonine-protein kinase BRSK1" FT /id="PRO_0000085669" FT DOMAIN 34..285 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 314..356 FT /note="UBA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00212" FT REGION 1..29 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 362..548 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 719..778 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1..12 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 362..383 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 430..457 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 491..508 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 509..533 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 156 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 40..48 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 63 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 189 FT /note="Phosphothreonine; by LKB1" FT /evidence="ECO:0000269|PubMed:14976552, FT ECO:0000269|PubMed:18339622" FT MOD_RES 399 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 443 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 447 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 450 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 466 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 481 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 484 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 498 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 508 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 525 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 529 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 535 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 550 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 583 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q5RJI5" FT MOD_RES 586 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:B2DD29" FT MOD_RES 587 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:B2DD29" FT MOD_RES 601 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:B2DD29" FT VAR_SEQ 1..26 FT /note="MSSGAKEGGGGSPAYHLPHPHPHPPQ -> MVAGLTLGKGPESPDGDVSVPE FT RKDEVAGGGGEEEEAEERGR (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14976552, ECO:0000303|Ref.5" FT /id="VSP_008158" FT VAR_SEQ 344..778 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:19648910" FT /id="VSP_041742" FT VARIANT 303 FT /note="R -> W (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs144130246)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040394" FT VARIANT 319 FT /note="V -> I (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs2088591390)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040395" FT VARIANT 391 FT /note="G -> E (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040396" FT VARIANT 531 FT /note="T -> N (in dbSNP:rs55892637)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040397" FT VARIANT 749 FT /note="G -> S (in dbSNP:rs12978445)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040398" FT VARIANT 764 FT /note="P -> A (in dbSNP:rs55796422)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040399" FT MUTAGEN 59 FT /note="K->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:15150265" FT MUTAGEN 189 FT /note="T->A: Prevents phosphorylation and activation by FT STK11/LKB1 complex." FT /evidence="ECO:0000269|PubMed:14976552" FT MUTAGEN 327 FT /note="G->A: Abolishes activation of kinase activity." FT /evidence="ECO:0000269|PubMed:18339622" FT CONFLICT 762 FT /note="G -> A (in Ref. 9; AAH16681)" FT /evidence="ECO:0000305" SQ SEQUENCE 778 AA; 85087 MW; 8D1818D4E54398BB CRC64; MSSGAKEGGG GSPAYHLPHP HPHPPQHAQY VGPYRLEKTL GKGQTGLVKL GVHCITGQKV AIKIVNREKL SESVLMKVER EIAILKLIEH PHVLKLHDVY ENKKYLYLVL EHVSGGELFD YLVKKGRLTP KEARKFFRQI VSALDFCHSY SICHRDLKPE NLLLDEKNNI RIADFGMASL QVGDSLLETS CGSPHYACPE VIKGEKYDGR RADMWSCGVI LFALLVGALP FDDDNLRQLL EKVKRGVFHM PHFIPPDCQS LLRGMIEVEP EKRLSLEQIQ KHPWYLGGKH EPDPCLEPAP GRRVAMRSLP SNGELDPDVL ESMASLGCFR DRERLHRELR SEEENQEKMI YYLLLDRKER YPSCEDQDLP PRNDVDPPRK RVDSPMLSRH GKRRPERKSM EVLSITDAGG GGSPVPTRRA LEMAQHSQRS RSVSGASTGL SSSPLSSPRS PVFSFSPEPG AGDEARGGGS PTSKTQTLPS RGPRGGGAGE QPPPPSARST PLPGPPGSPR SSGGTPLHSP LHTPRASPTG TPGTTPPPSP GGGVGGAAWR SRLNSIRNSF LGSPRFHRRK MQVPTAEEMS SLTPESSPEL AKRSWFGNFI SLDKEEQIFL VLKDKPLSSI KADIVHAFLS IPSLSHSVLS QTSFRAEYKA SGGPSVFQKP VRFQVDISSS EGPEPSPRRD GSGGGGIYSV TFTLISGPSR RFKRVVETIQ AQLLSTHDQP SVQALADEKN GAQTRPAGAP PRSLQPPPGR PDPELSSSPR RGPPKDKKLL ATNGTPLP // ID C1RL_HUMAN Reviewed; 487 AA. AC Q9NZP8; Q53GX9; DT 26-FEB-2008, integrated into UniProtKB/Swiss-Prot. DT 26-FEB-2008, sequence version 2. DT 28-JAN-2026, entry version 181. DE RecName: Full=Complement C1r subcomponent-like protein; DE Short=C1r-LP; DE Short=C1r-like protein; DE EC=3.4.21.-; DE AltName: Full=C1r-like serine protease analog protein; DE Short=CLSPa; DE Flags: Precursor; GN Name=C1RL; Synonyms=C1RL1, C1RLP, CLSPA; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, TISSUE RP SPECIFICITY, INDUCTION, AND VARIANT VAL-285. RC TISSUE=Dendritic cell; RX PubMed=15358180; DOI=10.1016/j.bbrc.2004.06.127; RA Lin N., Liu S., Li N., Wu P., An H., Yu Y., Wan T., Cao X.; RT "A novel human dendritic cell-derived C1r-like serine protease analog RT inhibits complement-mediated cytotoxicity."; RL Biochem. Biophys. Res. Commun. 321:329-336(2004). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND TISSUE SPECIFICITY. RX PubMed=15527420; DOI=10.1042/bj20041196; RA Ligoudistianou C., Xu Y., Garnier G., Circolo A., Volanakis J.E.; RT "A novel human complement-related protein, C1r-like protease (C1r-LP), RT specifically cleaves pro-C1s."; RL Biochem. J. 387:165-173(2005). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Liver; RA Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y., RA Tanaka A., Yokoyama S.; RL Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16541075; DOI=10.1038/nature04569; RA Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y., RA Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C., RA Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C., RA Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., RA Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E., RA Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., RA Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., RA Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., RA Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., RA Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., RA Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., RA Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., RA Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., RA Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., RA Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K., RA Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D., RA Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R., RA David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E., RA D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N., RA Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N., RA Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R., RA Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S., RA LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H., RA Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P., RA Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G., RA Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E., RA Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S., RA Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., RA Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J., RA Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A., RA Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M., RA Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I., RA Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A., RA Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y., RA Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A., RA Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F., RA Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L., RA Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G., RA Gibbs R.A.; RT "The finished DNA sequence of human chromosome 12."; RL Nature 440:346-351(2006). RN [5] RP FUNCTION, AND MUTAGENESIS OF SER-436. RX PubMed=15385675; DOI=10.1073/pnas.0405692101; RA Wicher K.B., Fries E.; RT "Prohaptoglobin is proteolytically cleaved in the endoplasmic reticulum by RT the complement C1r-like protein."; RL Proc. Natl. Acad. Sci. U.S.A. 101:14390-14395(2004). RN [6] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-166; ASN-242 AND ASN-296. RC TISSUE=Plasma; RX PubMed=16335952; DOI=10.1021/pr0502065; RA Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J., RA Smith R.D.; RT "Human plasma N-glycoproteome analysis by immunoaffinity subtraction, RT hydrazide chemistry, and mass spectrometry."; RL J. Proteome Res. 4:2070-2080(2005). RN [7] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-147; ASN-242 AND ASN-296. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). RN [8] RP GLYCOSYLATION AT ASN-242. RX PubMed=19139490; DOI=10.1074/mcp.m800504-mcp200; RA Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F., Zheng Z.B., RA Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y., Zhang Y.K., Deng Y.L., RA Ying W.T., He S.M., Qian X.H.; RT "A strategy for precise and large scale identification of core fucosylated RT glycoproteins."; RL Mol. Cell. Proteomics 8:913-923(2009). CC -!- FUNCTION: Mediates the proteolytic cleavage of HP/haptoglobin in the CC endoplasmic reticulum. {ECO:0000269|PubMed:15358180, CC ECO:0000269|PubMed:15385675, ECO:0000269|PubMed:15527420}. CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:15358180}. CC -!- TISSUE SPECIFICITY: Highly expressed in placenta, liver, kidney, CC pancreas, moderately in lung, spleen, prostate, ovary, colon, and PBL, CC and weakly in heart, skeletal muscle, thymus, testis, and small CC intestine. Expressed in PC-3 (prostate adenocarcinoma) and SK-OV-3 CC (ovary adenocarcinoma) cells, but not in LoVo and HT-29 (colon CC adenocarcinoma), SMMC7721 (hepatocellular carcinoma), CaoV-3 (ovary CC adenocarcinoma), HeLa (cervix epithelioid carcinoma), MCF-7 (breast CC adenocarcinoma), U-251MG (glioma) or A-549 (lung carcinoma) cells. CC Widely expressed in myeloid leukemia cell lines, including K-562 CC (chronic myelogenous leukemia), THP-1 (myelomonocytic leukemia), HL-60 CC and NB4 (promyelocytic leukemia), and KG-1 (acute myelogenous leukemia) CC cells. Expressed mainly in the liver and in serum (at protein level). CC {ECO:0000269|PubMed:15358180, ECO:0000269|PubMed:15527420}. CC -!- INDUCTION: Up-regulated in monocytes and dendritic cells (DC) CC undergoing maturation or activation. {ECO:0000269|PubMed:15358180}. CC -!- SIMILARITY: Belongs to the peptidase S1 family. {ECO:0000255|PROSITE- CC ProRule:PRU00274}. CC -!- CAUTION: Does not associate with the C1 complex. According to CC PubMed:15385675, doesn't cleave the proform of complement C1s. CC {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF178985; AAF44349.1; -; mRNA. DR EMBL; AK222802; BAD96522.1; -; mRNA. DR EMBL; AC018653; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC094008; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC233309; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS8573.1; -. DR RefSeq; NP_001284569.1; NM_001297640.1. DR RefSeq; NP_057630.2; NM_016546.4. DR AlphaFoldDB; Q9NZP8; -. DR SMR; Q9NZP8; -. DR BioGRID; 119431; 11. DR FunCoup; Q9NZP8; 178. DR IntAct; Q9NZP8; 6. DR STRING; 9606.ENSP00000266542; -. DR MEROPS; S01.189; -. DR GlyConnect; 1143; 11 N-Linked glycans (3 sites). DR GlyCosmos; Q9NZP8; 6 sites, 14 glycans. DR GlyGen; Q9NZP8; 7 sites, 32 N-linked glycans (4 sites), 2 O-linked glycans (2 sites). DR iPTMnet; Q9NZP8; -. DR PhosphoSitePlus; Q9NZP8; -. DR BioMuta; C1RL; -. DR DMDM; 182705204; -. DR CPTAC; non-CPTAC-1102; -. DR jPOST; Q9NZP8; -. DR MassIVE; Q9NZP8; -. DR PaxDb; 9606-ENSP00000266542; -. DR PeptideAtlas; Q9NZP8; -. DR ProteomicsDB; 83474; -. DR Pumba; Q9NZP8; -. DR Antibodypedia; 1734; 115 antibodies from 21 providers. DR DNASU; 51279; -. DR Ensembl; ENST00000266542.9; ENSP00000266542.4; ENSG00000139178.13. DR Ensembl; ENST00000671752.1; ENSP00000500804.1; ENSG00000288124.1. DR GeneID; 51279; -. DR KEGG; hsa:51279; -. DR MANE-Select; ENST00000266542.9; ENSP00000266542.4; NM_016546.4; NP_057630.2. DR UCSC; uc001qsn.4; human. DR AGR; HGNC:21265; -. DR ClinPGx; PA134957759; -. DR CTD; 51279; -. DR DisGeNET; 51279; -. DR GeneCards; C1RL; -. DR HGNC; HGNC:21265; C1RL. DR HPA; ENSG00000139178; Tissue enhanced (liver). DR MalaCards; C1RL; -. DR MIM; 608974; gene. DR OpenTargets; ENSG00000139178; -. DR VEuPathDB; HostDB:ENSG00000139178; -. DR eggNOG; KOG3627; Eukaryota. DR GeneTree; ENSGT00940000162495; -. DR HOGENOM; CLU_006842_0_0_1; -. DR InParanoid; Q9NZP8; -. DR OMA; QHESHNF; -. DR OrthoDB; 6261922at2759; -. DR PAN-GO; Q9NZP8; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q9NZP8; -. DR BRENDA; 3.4.21.41; 2681. DR PathwayCommons; Q9NZP8; -. DR SignaLink; Q9NZP8; -. DR SIGNOR; Q9NZP8; -. DR Agora; ENSG00000139178; -. DR BioGRID-ORCS; 51279; 7 hits in 1151 CRISPR screens. DR ChiTaRS; C1RL; human. DR GenomeRNAi; 51279; -. DR Pharos; Q9NZP8; Tbio. DR PRO; PR:Q9NZP8; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; Q9NZP8; protein. DR Bgee; ENSG00000139178; Expressed in right lobe of liver and 99 other cell types or tissues. DR ExpressionAtlas; Q9NZP8; baseline and differential. DR GO; GO:0072562; C:blood microparticle; IBA:GO_Central. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005615; C:extracellular space; HDA:UniProtKB. DR GO; GO:0004252; F:serine-type endopeptidase activity; IBA:GO_Central. DR GO; GO:0006958; P:complement activation, classical pathway; IEA:UniProtKB-KW. DR GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW. DR GO; GO:0031638; P:zymogen activation; IBA:GO_Central. DR CDD; cd00041; CUB; 1. DR CDD; cd00190; Tryp_SPc; 1. DR FunFam; 2.40.10.10:FF:000035; Complement C1r subcomponent; 1. DR FunFam; 2.40.10.10:FF:000037; Complement C1r subcomponent; 1. DR FunFam; 2.60.120.290:FF:000044; Complement C1r subcomponent like; 1. DR Gene3D; 2.10.70.10; Complement Module, domain 1; 1. DR Gene3D; 2.60.120.290; Spermadhesin, CUB domain; 1. DR Gene3D; 2.40.10.10; Trypsin-like serine proteases; 2. DR InterPro; IPR000859; CUB_dom. DR InterPro; IPR009003; Peptidase_S1_PA. DR InterPro; IPR043504; Peptidase_S1_PA_chymotrypsin. DR InterPro; IPR001314; Peptidase_S1A. DR InterPro; IPR035914; Sperma_CUB_dom_sf. DR InterPro; IPR035976; Sushi/SCR/CCP_sf. DR InterPro; IPR001254; Trypsin_dom. DR InterPro; IPR033116; TRYPSIN_SER. DR PANTHER; PTHR24255:SF26; COMPLEMENT C1R SUBCOMPONENT-LIKE PROTEIN; 1. DR PANTHER; PTHR24255; COMPLEMENT COMPONENT 1, S SUBCOMPONENT-RELATED; 1. DR Pfam; PF00431; CUB; 1. DR Pfam; PF00089; Trypsin; 1. DR PRINTS; PR00722; CHYMOTRYPSIN. DR SMART; SM00042; CUB; 1. DR SMART; SM00020; Tryp_SPc; 1. DR SUPFAM; SSF57535; Complement control module/SCR domain; 1. DR SUPFAM; SSF49854; Spermadhesin, CUB domain; 1. DR SUPFAM; SSF50494; Trypsin-like serine proteases; 1. DR PROSITE; PS01180; CUB; 1. DR PROSITE; PS50240; TRYPSIN_DOM; 1. DR PROSITE; PS00135; TRYPSIN_SER; 1. PE 1: Evidence at protein level; KW Complement pathway; Disulfide bond; Glycoprotein; Hydrolase; Immunity; KW Innate immunity; Protease; Proteomics identification; Reference proteome; KW Secreted; Serine protease; Signal; Sushi. FT SIGNAL 1..35 FT /evidence="ECO:0000255" FT CHAIN 36..487 FT /note="Complement C1r subcomponent-like protein" FT /id="PRO_0000318678" FT DOMAIN 39..163 FT /note="CUB" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00059" FT DOMAIN 165..230 FT /note="Sushi" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00302" FT DOMAIN 245..484 FT /note="Peptidase S1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00274" FT ACT_SITE 283 FT /note="Charge relay system" FT /evidence="ECO:0000250" FT ACT_SITE 339 FT /note="Charge relay system" FT /evidence="ECO:0000250" FT ACT_SITE 436 FT /note="Charge relay system" FT /evidence="ECO:0000250" FT CARBOHYD 147 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19159218" FT CARBOHYD 166 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16335952" FT CARBOHYD 242 FT /note="N-linked (GlcNAc...) (complex) asparagine" FT /evidence="ECO:0000269|PubMed:16335952, FT ECO:0000269|PubMed:19139490, ECO:0000269|PubMed:19159218" FT CARBOHYD 296 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16335952, FT ECO:0000269|PubMed:19159218" FT CARBOHYD 363 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 94..112 FT /evidence="ECO:0000250" FT DISULFID 195..228 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00302" FT DISULFID 402..421 FT /evidence="ECO:0000250" FT DISULFID 432..462 FT /evidence="ECO:0000250" FT VARIANT 285 FT /note="I -> V (in dbSNP:rs3742089)" FT /evidence="ECO:0000269|PubMed:15358180" FT /id="VAR_038852" FT MUTAGEN 436 FT /note="S->A: Unable to cleave HP." FT /evidence="ECO:0000269|PubMed:15385675" FT CONFLICT 94 FT /note="C -> R (in Ref. 3; BAD96522)" FT /evidence="ECO:0000305" FT CONFLICT 99 FT /note="V -> A (in Ref. 3; BAD96522)" FT /evidence="ECO:0000305" FT CONFLICT 349 FT /note="I -> M (in Ref. 3; BAD96522)" FT /evidence="ECO:0000305" SQ SEQUENCE 487 AA; 53498 MW; 6DE7CE9EA08C7990 CRC64; MPGPRVWGKY LWRSPHSKGC PGAMWWLLLW GVLQACPTRG SVLLAQELPQ QLTSPGYPEP YGKGQESSTD IKAPEGFAVR LVFQDFDLEP SQDCAGDSVT ISFVGSDPSQ FCGQQGSPLG RPPGQREFVS SGRSLRLTFR TQPSSENKTA HLHKGFLALY QTVAVNYSQP ISEASRGSEA INAPGDNPAK VQNHCQEPYY QAAAAGALTC ATPGTWKDRQ DGEEVLQCMP VCGRPVTPIA QNQTTLGSSR AKLGNFPWQA FTSIHGRGGG ALLGDRWILT AAHTIYPKDS VSLRKNQSVN VFLGHTAIDE MLKLGNHPVH RVVVHPDYRQ NESHNFSGDI ALLELQHSIP LGPNVLPVCL PDNETLYRSG LLGYVSGFGM EMGWLTTELK YSRLPVAPRE ACNAWLQKRQ RPEVFSDNMF CVGDETQRHS VCQGDSGSVY VVWDNHAHHW VATGIVSWGI GCGEGYDFYT KVLSYVDWIK GVMNGKN // ID CDK8_HUMAN Reviewed; 464 AA. AC P49336; Q5VUF3; Q6ISB5; DT 01-FEB-1996, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1996, sequence version 1. DT 28-JAN-2026, entry version 214. DE RecName: Full=Cyclin-dependent kinase 8; DE EC=2.7.11.22; DE EC=2.7.11.23; DE AltName: Full=Cell division protein kinase 8; DE AltName: Full=Mediator complex subunit CDK8; DE AltName: Full=Mediator of RNA polymerase II transcription subunit CDK8; DE AltName: Full=Protein kinase K35; GN Name=CDK8; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Testis; RX PubMed=7568034; DOI=10.1073/pnas.92.19.8871; RA Tassan J.-P., Jaquenoud M., Leopold P., Schultz S.J., Nigg E.A.; RT "Identification of human cyclin-dependent kinase 8, a putative protein RT kinase partner for cyclin C."; RL Proc. Natl. Acad. Sci. U.S.A. 92:8871-8875(1995). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057823; DOI=10.1038/nature02379; RA Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L., RA Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S., RA Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P., RA Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L., RA Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P., RA Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P., RA Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C., RA Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P., RA Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L., RA Frankish A.G., Frankland J., French L., Garner P., Garnett J., RA Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M., RA Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D., RA Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D., RA Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., RA Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S., RA Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S., RA Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R., RA Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W., RA Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P., RA Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L., RA Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R., RA Rogers J., Ross M.T.; RT "The DNA sequence and analysis of human chromosome 13."; RL Nature 428:522-528(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE MEDIATOR RP COMPLEX. RX PubMed=9734358; DOI=10.1016/s1097-2765(00)80131-8; RA Sun X., Zhang Y., Cho H., Rickert P., Lees E., Lane W.S., Reinberg D.; RT "NAT, a human complex containing Srb polypeptides that functions as a RT negative regulator of activated transcription."; RL Mol. Cell 2:213-222(1998). RN [6] RP IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE SMCC RP COMPLEX. RX PubMed=10024883; DOI=10.1016/s1097-2765(00)80178-1; RA Gu W., Malik S., Ito M., Yuan C.-X., Fondell J.D., Zhang X., Martinez E., RA Qin J., Roeder R.G.; RT "A novel human SRB/MED-containing cofactor complex, SMCC, involved in RT transcription regulation."; RL Mol. Cell 3:97-108(1999). RN [7] RP ERRATUM OF PUBMED:10024883. RA Gu W., Malik S., Ito M., Yuan C.-X., Fondell J.D., Zhang X., Martinez E., RA Qin J., Roeder R.G.; RL Mol. Cell 3:541-541(1999). RN [8] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF ASP-173. RX PubMed=10993082; DOI=10.1038/35024111; RA Akoulitchev S., Chuikov S., Reinberg D.; RT "TFIIH is negatively regulated by cdk8-containing mediator complexes."; RL Nature 407:102-106(2000). RN [9] RP FUNCTION, AND INTERACTION WITH MAML1. RX PubMed=15546612; DOI=10.1016/j.molcel.2004.10.014; RA Fryer C.J., White J.B., Jones K.A.; RT "Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and RT coordinate activation with turnover."; RL Mol. Cell 16:509-520(2004). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE MEDIATOR RP COMPLEX. RX PubMed=15175163; DOI=10.1016/j.molcel.2004.05.006; RA Sato S., Tomomori-Sato C., Parmely T.J., Florens L., Zybailov B., RA Swanson S.K., Banks C.A.S., Jin J., Cai Y., Washburn M.P., Conaway J.W., RA Conaway R.C.; RT "A set of consensus mammalian mediator subunits identified by RT multidimensional protein identification technology."; RL Mol. Cell 14:685-691(2004). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN THE MEDIATOR RP COMPLEX, AND ASSOCIATION OF THE MEDIATOR COMPLEX WITH RNA POLYMERASE II. RX PubMed=15989967; DOI=10.1016/j.molcel.2005.05.015; RA Zhang X., Krutchinsky A., Fukuda A., Chen W., Yamamura S., Chait B.T., RA Roeder R.G.; RT "MED1/TRAP220 exists predominantly in a TRAP/Mediator subpopulation RT enriched in RNA polymerase II and is required for ER-mediated RT transcription."; RL Mol. Cell 19:89-100(2005). RN [12] RP INTERACTION WITH CTNNB1; GLI3; MED1; MED6; MED12 AND MED23. RX PubMed=17000779; DOI=10.1128/mcb.00443-06; RA Zhou H., Kim S., Ishii S., Boyer T.G.; RT "Mediator modulates Gli3-dependent Sonic hedgehog signaling."; RL Mol. Cell. Biol. 26:8667-8682(2006). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [14] RP INVOLVEMENT IN IDDHBA, VARIANTS IDDHBA LEU-27; GLY-29; SER-30; LEU-62; RP LEU-97; GLN-178; GLY-193 AND MET-223, CHARACTERIZATION OF VARIANTS IDDHBA RP LEU-27; GLY-29; SER-30; LEU-62; GLN-178; GLY-193 AND MET-223, FUNCTION, AND RP MUTAGENESIS OF ASP-173. RX PubMed=30905399; DOI=10.1016/j.ajhg.2019.02.006; RG Deciphering Developmental Disorders Study; RA Calpena E., Hervieu A., Kaserer T., Swagemakers S.M.A., Goos J.A.C., RA Popoola O., Ortiz-Ruiz M.J., Barbaro-Dieber T., Bownass L., Brilstra E.H., RA Brimble E., Foulds N., Grebe T.A., Harder A.V.E., Lees M.M., Monaghan K.G., RA Newbury-Ecob R.A., Ong K.R., Osio D., Reynoso Santos F.J., RA Ruzhnikov M.R.Z., Telegrafi A., van Binsbergen E., van Dooren M.F., RA van der Spek P.J., Blagg J., Twigg S.R.F., Mathijssen I.M.J., Clarke P.A., RA Wilkie A.O.M.; RT "De Novo Missense Substitutions in the Gene Encoding CDK8, a Regulator of RT the Mediator Complex, Cause a Syndromic Developmental Disorder."; RL Am. J. Hum. Genet. 104:709-720(2019). RN [15] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1-403 IN COMPLEX WITH CCNC AND RP INHIBITOR. RX PubMed=21806996; DOI=10.1016/j.jmb.2011.07.020; RA Schneider E.V., Bottcher J., Blaesse M., Neumann L., Huber R., Maskos K.; RT "The structure of CDK8/CycC implicates specificity in the CDK/cyclin family RT and reveals interaction with a deep pocket binder."; RL J. Mol. Biol. 412:251-266(2011). RN [16] RP VARIANTS [LARGE SCALE ANALYSIS] ASN-189 AND CYS-424. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Component of the Mediator complex, a coactivator involved in CC regulated gene transcription of nearly all RNA polymerase II-dependent CC genes. Mediator functions as a bridge to convey information from gene- CC specific regulatory proteins to the basal RNA polymerase II CC transcription machinery. Mediator is recruited to promoters by direct CC interactions with regulatory proteins and serves as a scaffold for the CC assembly of a functional pre-initiation complex with RNA polymerase II CC and the general transcription factors. Phosphorylates the CTD (C- CC terminal domain) of the large subunit of RNA polymerase II (RNAp II), CC which may inhibit the formation of a transcription initiation complex. CC Phosphorylates CCNH leading to down-regulation of the TFIIH complex and CC transcriptional repression. Recruited through interaction with MAML1 to CC hyperphosphorylate the intracellular domain of NOTCH, leading to its CC degradation. {ECO:0000269|PubMed:10993082, ECO:0000269|PubMed:15546612, CC ECO:0000269|PubMed:30905399}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.22; CC Evidence={ECO:0000269|PubMed:10993082}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.22; CC Evidence={ECO:0000269|PubMed:10993082}; CC -!- CATALYTIC ACTIVITY: CC Reaction=[DNA-directed RNA polymerase] + ATP = phospho-[DNA-directed CC RNA polymerase] + ADP + H(+); Xref=Rhea:RHEA:10216, Rhea:RHEA- CC COMP:11321, Rhea:RHEA-COMP:11322, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:30616, ChEBI:CHEBI:43176, ChEBI:CHEBI:68546, CC ChEBI:CHEBI:456216; EC=2.7.11.23; CC Evidence={ECO:0000269|PubMed:10993082}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250}; CC -!- SUBUNIT: Component of the Mediator complex, which is composed of MED1, CC MED4, MED6, MED7, MED8, MED9, MED10, MED11, MED12, MED13, MED13L, CC MED14, MED15, MED16, MED17, MED18, MED19, MED20, MED21, MED22, MED23, CC MED24, MED25, MED26, MED27, MED29, MED30, MED31, CCNC, CDK8 and CC CDC2L6/CDK11. The MED12, MED13, CCNC and CDK8 subunits form a distinct CC module termed the CDK8 module. Mediator containing the CDK8 module is CC less active than Mediator lacking this module in supporting CC transcriptional activation. Individual preparations of the Mediator CC complex lacking one or more distinct subunits have been variously CC termed ARC, CRSP, DRIP, PC2, SMCC and TRAP. The cylin/CDK pair formed CC by CCNC/CDK8 also associates with the large subunit of RNA polymerase CC II. Interacts with CTNNB1, GLI3 and MAML1. CC {ECO:0000269|PubMed:10024883, ECO:0000269|PubMed:15175163, CC ECO:0000269|PubMed:15546612, ECO:0000269|PubMed:15989967, CC ECO:0000269|PubMed:17000779, ECO:0000269|PubMed:21806996, CC ECO:0000269|PubMed:9734358}. CC -!- INTERACTION: CC P49336; P24863: CCNC; NbExp=41; IntAct=EBI-394377, EBI-395261; CC P49336; Q01094: E2F1; NbExp=3; IntAct=EBI-394377, EBI-448924; CC P49336-2; P02489: CRYAA; NbExp=3; IntAct=EBI-11039720, EBI-6875961; CC P49336-2; Q14204: DYNC1H1; NbExp=3; IntAct=EBI-11039720, EBI-356015; CC P49336-2; Q92876: KLK6; NbExp=3; IntAct=EBI-11039720, EBI-2432309; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P49336-1; Sequence=Displayed; CC Name=2; CC IsoId=P49336-2; Sequence=VSP_029970; CC -!- DISEASE: Intellectual developmental disorder with hypotonia and CC behavioral abnormalities (IDDHBA) [MIM:618748]: An autosomal dominant CC neurodevelopmental disorder with onset in infancy. IDDHBA is CC characterized by hypotonia, global developmental delay, learning CC disability, and behavioral abnormalities, such as autistic features and CC attention deficit-hyperactivity disorder. Additional variable features CC may include non-specific facial dysmorphism, congenital heart defects, CC ocular anomalies, and poor feeding. {ECO:0000269|PubMed:30905399}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr CC protein kinase family. CDC2/CDKX subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X85753; CAA59754.1; -; mRNA. DR EMBL; AL159159; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL590108; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471075; EAX08386.1; -; Genomic_DNA. DR EMBL; CH471075; EAX08387.1; -; Genomic_DNA. DR EMBL; BC069634; AAH69634.1; -; mRNA. DR EMBL; BC104492; AAI04493.1; -; mRNA. DR EMBL; BC105950; AAI05951.1; -; mRNA. DR EMBL; BC107601; AAI07602.1; -; mRNA. DR CCDS; CCDS9317.1; -. [P49336-1] DR PIR; I37227; I37227. DR RefSeq; NP_001251.1; NM_001260.3. [P49336-1] DR RefSeq; NP_001305297.1; NM_001318368.2. [P49336-2] DR PDB; 3RGF; X-ray; 2.20 A; A=1-403. DR PDB; 4CRL; X-ray; 2.40 A; A=1-403. DR PDB; 4F6S; X-ray; 2.60 A; A=1-403. DR PDB; 4F6U; X-ray; 2.10 A; A=1-403. DR PDB; 4F6W; X-ray; 2.39 A; A=1-403. DR PDB; 4F70; X-ray; 3.00 A; A=1-403. DR PDB; 4F7J; X-ray; 2.60 A; A=1-403. DR PDB; 4F7L; X-ray; 2.90 A; A=1-403. DR PDB; 4F7N; X-ray; 2.65 A; A=1-403. DR PDB; 4F7S; X-ray; 2.20 A; A=1-403. DR PDB; 4G6L; X-ray; 2.70 A; A=1-403. DR PDB; 5BNJ; X-ray; 2.64 A; A=1-403. DR PDB; 5CEI; X-ray; 2.24 A; A=1-403. DR PDB; 5FGK; X-ray; 2.36 A; A=1-362. DR PDB; 5HBE; X-ray; 2.38 A; A=1-362. DR PDB; 5HBH; X-ray; 2.50 A; A=1-362. DR PDB; 5HBJ; X-ray; 3.00 A; A=1-362. DR PDB; 5HNB; X-ray; 2.35 A; A=1-362. DR PDB; 5HVY; X-ray; 2.39 A; A=1-403. DR PDB; 5I5Z; X-ray; 2.60 A; A=1-362. DR PDB; 5ICP; X-ray; 2.18 A; A=1-362. DR PDB; 5IDN; X-ray; 2.26 A; A=1-364. DR PDB; 5IDP; X-ray; 2.65 A; A=1-364. DR PDB; 5XQX; X-ray; 2.30 A; A=1-371. DR PDB; 5XS2; X-ray; 2.04 A; A=1-371. DR PDB; 6QTG; X-ray; 2.70 A; A=1-403. DR PDB; 6QTJ; X-ray; 2.48 A; A=1-403. DR PDB; 6R3S; X-ray; 2.19 A; A=1-403. DR PDB; 6T41; X-ray; 2.45 A; A=1-404. DR PDB; 6TPA; X-ray; 2.80 A; A=1-403. DR PDB; 6Y0A; X-ray; 2.19 A; A=1-403. DR PDB; 8TQ2; EM; 3.80 A; A=1-464. DR PDB; 8TQC; EM; 3.80 A; A=1-464. DR PDB; 8TQW; EM; 8.20 A; a=1-464. DR PDB; 9H8C; X-ray; 2.57 A; A=1-403. DR PDB; 9H8S; X-ray; 2.16 A; A=1-403. DR PDBsum; 3RGF; -. DR PDBsum; 4CRL; -. DR PDBsum; 4F6S; -. DR PDBsum; 4F6U; -. DR PDBsum; 4F6W; -. DR PDBsum; 4F70; -. DR PDBsum; 4F7J; -. DR PDBsum; 4F7L; -. DR PDBsum; 4F7N; -. DR PDBsum; 4F7S; -. DR PDBsum; 4G6L; -. DR PDBsum; 5BNJ; -. DR PDBsum; 5CEI; -. DR PDBsum; 5FGK; -. DR PDBsum; 5HBE; -. DR PDBsum; 5HBH; -. DR PDBsum; 5HBJ; -. DR PDBsum; 5HNB; -. DR PDBsum; 5HVY; -. DR PDBsum; 5I5Z; -. DR PDBsum; 5ICP; -. DR PDBsum; 5IDN; -. DR PDBsum; 5IDP; -. DR PDBsum; 5XQX; -. DR PDBsum; 5XS2; -. DR PDBsum; 6QTG; -. DR PDBsum; 6QTJ; -. DR PDBsum; 6R3S; -. DR PDBsum; 6T41; -. DR PDBsum; 6TPA; -. DR PDBsum; 6Y0A; -. DR PDBsum; 8TQ2; -. DR PDBsum; 8TQC; -. DR PDBsum; 8TQW; -. DR PDBsum; 9H8C; -. DR PDBsum; 9H8S; -. DR AlphaFoldDB; P49336; -. DR EMDB; EMD-41499; -. DR EMDB; EMD-41502; -. DR EMDB; EMD-41565; -. DR SMR; P49336; -. DR BioGRID; 107458; 229. DR ComplexPortal; CPX-1969; Cyclin C-CDK8 complex. DR ComplexPortal; CPX-3232; CKM complex variant 1. DR CORUM; P49336; -. DR DIP; DIP-32595N; -. DR FunCoup; P49336; 3225. DR IntAct; P49336; 203. DR MINT; P49336; -. DR STRING; 9606.ENSP00000370938; -. DR BindingDB; P49336; -. DR ChEMBL; CHEMBL5719; -. DR DrugBank; DB03496; Alvocidib. DR DrugBank; DB18107; SEL120-34A free base. DR DrugCentral; P49336; -. DR GuidetoPHARMACOLOGY; 1980; -. DR GlyCosmos; P49336; 3 sites, 1 glycan. DR GlyGen; P49336; 10 sites, 1 O-linked glycan (10 sites). DR iPTMnet; P49336; -. DR PhosphoSitePlus; P49336; -. DR BioMuta; CDK8; -. DR DMDM; 1345718; -. DR CPTAC; CPTAC-3153; -. DR CPTAC; CPTAC-3154; -. DR jPOST; P49336; -. DR MassIVE; P49336; -. DR PaxDb; 9606-ENSP00000370938; -. DR PeptideAtlas; P49336; -. DR ProteomicsDB; 55991; -. [P49336-1] DR ProteomicsDB; 55992; -. [P49336-2] DR Pumba; P49336; -. DR Antibodypedia; 7248; 457 antibodies from 38 providers. DR DNASU; 1024; -. DR Ensembl; ENST00000381527.8; ENSP00000370938.3; ENSG00000132964.14. [P49336-1] DR GeneID; 1024; -. DR KEGG; hsa:1024; -. DR MANE-Select; ENST00000381527.8; ENSP00000370938.3; NM_001260.3; NP_001251.1. DR UCSC; uc001uqr.2; human. [P49336-1] DR AGR; HGNC:1779; -. DR ClinPGx; PA26315; -. DR CTD; 1024; -. DR DisGeNET; 1024; -. DR GeneCards; CDK8; -. DR HGNC; HGNC:1779; CDK8. DR HPA; ENSG00000132964; Low tissue specificity. DR MalaCards; CDK8; -. DR MIM; 603184; gene. DR MIM; 618748; phenotype. DR OpenTargets; ENSG00000132964; -. DR Orphanet; 528084; Non-specific syndromic intellectual disability. DR VEuPathDB; HostDB:ENSG00000132964; -. DR eggNOG; KOG0666; Eukaryota. DR GeneTree; ENSGT00940000157104; -. DR HOGENOM; CLU_000288_181_6_1; -. DR InParanoid; P49336; -. DR OMA; YFKNGGP; -. DR OrthoDB; 6284126at2759; -. DR PAN-GO; P49336; 5 GO annotations based on evolutionary models. DR PhylomeDB; P49336; -. DR BRENDA; 2.7.11.22; 2681. DR BRENDA; 2.7.11.23; 2681. DR PathwayCommons; P49336; -. DR Reactome; R-HSA-1989781; PPARA activates gene expression. DR Reactome; R-HSA-2122947; NOTCH1 Intracellular Domain Regulates Transcription. DR Reactome; R-HSA-212436; Generic Transcription Pathway. DR Reactome; R-HSA-2173796; SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription. DR Reactome; R-HSA-2644606; Constitutive Signaling by NOTCH1 PEST Domain Mutants. DR Reactome; R-HSA-2894862; Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants. DR Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation. DR Reactome; R-HSA-9833110; RSV-host interactions. DR Reactome; R-HSA-9841922; MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis. DR SignaLink; P49336; -. DR SIGNOR; P49336; -. DR Agora; ENSG00000132964; -. DR BioGRID-ORCS; 1024; 47 hits in 1097 CRISPR screens. DR ChiTaRS; CDK8; human. DR EvolutionaryTrace; P49336; -. DR GeneWiki; Cyclin-dependent_kinase_8; -. DR GenomeRNAi; 1024; -. DR Pharos; P49336; Tchem. DR PRO; PR:P49336; -. DR Proteomes; UP000005640; Chromosome 13. DR RNAct; P49336; protein. DR Bgee; ENSG00000132964; Expressed in adrenal tissue and 208 other cell types or tissues. DR ExpressionAtlas; P49336; baseline and differential. DR GO; GO:1990508; C:CKM complex; IPI:ComplexPortal. DR GO; GO:0000307; C:cyclin-dependent protein kinase holoenzyme complex; IDA:ComplexPortal. DR GO; GO:0016592; C:mediator complex; IDA:MGI. DR GO; GO:0005730; C:nucleolus; IDA:MGI. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:MGI. DR GO; GO:0032991; C:protein-containing complex; IDA:MGI. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004693; F:cyclin-dependent protein serine/threonine kinase activity; IEA:UniProtKB-EC. DR GO; GO:0004672; F:protein kinase activity; IMP:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0008353; F:RNA polymerase II CTD heptapeptide repeat kinase activity; IEA:UniProtKB-EC. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:ComplexPortal. DR CDD; cd07868; STKc_CDK8; 1. DR FunFam; 1.10.510.10:FF:000088; cyclin-dependent kinase 8 isoform X1; 1. DR FunFam; 3.30.200.20:FF:000122; cyclin-dependent kinase 8 isoform X1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR050108; CDK. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24056; CELL DIVISION PROTEIN KINASE; 1. DR PANTHER; PTHR24056:SF243; CYCLIN-DEPENDENT KINASE 8; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative splicing; ATP-binding; KW Autism spectrum disorder; Disease variant; Intellectual disability; Kinase; KW Nucleotide-binding; Nucleus; Proteomics identification; Reference proteome; KW Repressor; Serine/threonine-protein kinase; Transcription; KW Transcription regulation; Transferase. FT CHAIN 1..464 FT /note="Cyclin-dependent kinase 8" FT /id="PRO_0000085797" FT DOMAIN 21..335 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..15 FT /note="Interaction with CCNC" FT REGION 361..464 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 373..391 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 409..426 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 436..464 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 151 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 27..35 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 52 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT VAR_SEQ 370 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_029970" FT VARIANT 27 FT /note="V -> L (in IDDHBA; decreased protein kinase FT activity)" FT /evidence="ECO:0000269|PubMed:30905399" FT /id="VAR_083786" FT VARIANT 29 FT /note="R -> G (in IDDHBA; decreased protein kinase FT activity; dbSNP:rs1593218885)" FT /evidence="ECO:0000269|PubMed:30905399" FT /id="VAR_083787" FT VARIANT 30 FT /note="G -> S (in IDDHBA; decreased protein kinase FT activity; dbSNP:rs1593218890)" FT /evidence="ECO:0000269|PubMed:30905399" FT /id="VAR_083788" FT VARIANT 62 FT /note="S -> L (in IDDHBA; decreased protein kinase FT activity; dbSNP:rs1565977796)" FT /evidence="ECO:0000269|PubMed:30905399" FT /id="VAR_083789" FT VARIANT 97 FT /note="F -> L (in IDDHBA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:30905399" FT /id="VAR_083790" FT VARIANT 178 FT /note="R -> Q (in IDDHBA; decreased protein kinase FT activity; dbSNP:rs1418353379)" FT /evidence="ECO:0000269|PubMed:30905399" FT /id="VAR_083791" FT VARIANT 189 FT /note="D -> N (in a lung neuroendocrine carcinoma sample; FT somatic mutation; dbSNP:rs2138050298)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041980" FT VARIANT 193 FT /note="V -> G (in IDDHBA; decreased protein kinase FT activity; dbSNP:rs1875421510)" FT /evidence="ECO:0000269|PubMed:30905399" FT /id="VAR_083792" FT VARIANT 223 FT /note="I -> M (in IDDHBA; decreased protein kinase FT activity; dbSNP:rs1593310364)" FT /evidence="ECO:0000269|PubMed:30905399" FT /id="VAR_083793" FT VARIANT 424 FT /note="R -> C (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs2138079506)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041981" FT MUTAGEN 173 FT /note="D->A: Abrogates kinase activity and TFIIH-dependent FT transcriptional repression." FT /evidence="ECO:0000269|PubMed:10993082, FT ECO:0000269|PubMed:30905399" FT HELIX 3..12 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 16..19 FT /evidence="ECO:0007829|PDB:5XS2" FT STRAND 26..30 FT /evidence="ECO:0007829|PDB:5XS2" FT STRAND 33..44 FT /evidence="ECO:0007829|PDB:5XS2" FT STRAND 49..58 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 61..72 FT /evidence="ECO:0007829|PDB:5XS2" FT STRAND 83..87 FT /evidence="ECO:0007829|PDB:5XS2" FT TURN 88..91 FT /evidence="ECO:0007829|PDB:5XS2" FT STRAND 92..98 FT /evidence="ECO:0007829|PDB:5XS2" FT STRAND 101..103 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 104..115 FT /evidence="ECO:0007829|PDB:5XS2" FT TURN 116..118 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 125..144 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 154..156 FT /evidence="ECO:0007829|PDB:5XS2" FT STRAND 157..159 FT /evidence="ECO:0007829|PDB:5XS2" FT TURN 164..167 FT /evidence="ECO:0007829|PDB:5XS2" FT STRAND 169..171 FT /evidence="ECO:0007829|PDB:5XS2" FT TURN 174..178 FT /evidence="ECO:0007829|PDB:6TPA" FT HELIX 179..181 FT /evidence="ECO:0007829|PDB:5ICP" FT STRAND 186..188 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 202..205 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 213..229 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 249..259 FT /evidence="ECO:0007829|PDB:5XS2" FT TURN 264..266 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 268..272 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 276..282 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 285..288 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 293..299 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 307..315 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 320..322 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 326..330 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 333..335 FT /evidence="ECO:0007829|PDB:5XS2" FT STRAND 337..339 FT /evidence="ECO:0007829|PDB:5XS2" FT TURN 345..348 FT /evidence="ECO:0007829|PDB:5XS2" SQ SEQUENCE 464 AA; 53284 MW; 00CBAB6CE354605F CRC64; MDYDFKVKLS SERERVEDLF EYEGCKVGRG TYGHVYKAKR KDGKDDKDYA LKQIEGTGIS MSACREIALL RELKHPNVIS LQKVFLSHAD RKVWLLFDYA EHDLWHIIKF HRASKANKKP VQLPRGMVKS LLYQILDGIH YLHANWVLHR DLKPANILVM GEGPERGRVK IADMGFARLF NSPLKPLADL DPVVVTFWYR APELLLGARH YTKAIDIWAI GCIFAELLTS EPIFHCRQED IKTSNPYHHD QLDRIFNVMG FPADKDWEDI KKMPEHSTLM KDFRRNTYTN CSLIKYMEKH KVKPDSKAFH LLQKLLTMDP IKRITSEQAM QDPYFLEDPL PTSDVFAGCQ IPYPKREFLT EEEPDDKGDK KNQQQQQGNN HTNGTGHPGN QDSSHTQGPP LKKVRVVPPT TTSGGLIMTS DYQRSNPHAA YPNPGPSTSQ PQSSMGYSAT SQQPPQYSHQ THRY // ID CDKL2_HUMAN Reviewed; 493 AA. AC Q92772; B2R695; DT 22-NOV-2005, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1997, sequence version 1. DT 28-JAN-2026, entry version 183. DE RecName: Full=Cyclin-dependent kinase-like 2 {ECO:0000305}; DE EC=2.7.11.22; DE AltName: Full=Protein kinase p56 KKIAMRE {ECO:0000303|PubMed:9000130}; DE AltName: Full=Serine/threonine-protein kinase KKIAMRE; GN Name=CDKL2 {ECO:0000312|HGNC:HGNC:1782}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RC TISSUE=Fetal brain; RX PubMed=9000130; RA Taglienti C.A., Wysk M., Davis R.J.; RT "Molecular cloning of the epidermal growth factor-stimulated protein kinase RT p56 KKIAMRE."; RL Oncogene 13:2563-2574(1996). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Hippocampus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] {ECO:0007744|PDB:4AAA, ECO:0007744|PDB:4BBM} RP X-RAY CRYSTALLOGRAPHY (1.53 ANGSTROMS) OF 1-308 IN COMPLEX WITH SYNTHETIC RP INHIBITOR. RX PubMed=29420175; DOI=10.1016/j.celrep.2017.12.083; RA Canning P., Park K., Goncalves J., Li C., Howard C.J., Sharpe T.D., RA Holt L.J., Pelletier L., Bullock A.N., Leroux M.R.; RT "CDKL Family Kinases Have Evolved Distinct Structural Features and Ciliary RT Function."; RL Cell Rep. 22:885-894(2018). RN [6] RP VARIANTS [LARGE SCALE ANALYSIS] ILE-98; GLN-149; THR-197 AND VAL-411. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.22; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.22; CC -!- INTERACTION: CC Q92772; Q58FG0: HSP90AA5P; NbExp=3; IntAct=EBI-6381227, EBI-11323222; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:9000130}. Nucleus CC {ECO:0000269|PubMed:9000130}. CC -!- TISSUE SPECIFICITY: Expressed in testis and kidney, and at lower level CC in brain and lung. {ECO:0000269|PubMed:9000130}. CC -!- DOMAIN: The [NKR]KIAxRE motif seems to be a cyclin-binding region. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr CC protein kinase family. CDC2/CDKX subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U35146; AAC50918.1; -; mRNA. DR EMBL; AK312490; BAG35392.1; -; mRNA. DR EMBL; CH471057; EAX05740.1; -; Genomic_DNA. DR EMBL; BC093646; AAH93646.1; -; mRNA. DR EMBL; BC093981; AAH93981.1; -; mRNA. DR CCDS; CCDS3570.1; -. DR RefSeq; NP_001317653.1; NM_001330724.1. DR RefSeq; NP_003939.1; NM_003948.5. DR RefSeq; XP_016864299.1; XM_017008810.2. DR RefSeq; XP_047272340.1; XM_047416384.1. DR RefSeq; XP_054207164.1; XM_054351189.1. DR PDB; 4AAA; X-ray; 1.53 A; A=1-308. DR PDB; 4BBM; X-ray; 2.00 A; A/B=1-308. DR PDB; 8S6I; X-ray; 1.72 A; A=1-308. DR PDBsum; 4AAA; -. DR PDBsum; 4BBM; -. DR PDBsum; 8S6I; -. DR AlphaFoldDB; Q92772; -. DR SMR; Q92772; -. DR BioGRID; 114479; 71. DR FunCoup; Q92772; 1449. DR IntAct; Q92772; 67. DR STRING; 9606.ENSP00000306340; -. DR BindingDB; Q92772; -. DR ChEMBL; CHEMBL5728; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q92772; -. DR iPTMnet; Q92772; -. DR PhosphoSitePlus; Q92772; -. DR BioMuta; CDKL2; -. DR DMDM; 74762639; -. DR CPTAC; non-CPTAC-3026; -. DR CPTAC; non-CPTAC-3027; -. DR jPOST; Q92772; -. DR MassIVE; Q92772; -. DR PaxDb; 9606-ENSP00000412365; -. DR PeptideAtlas; Q92772; -. DR Antibodypedia; 24675; 254 antibodies from 28 providers. DR DNASU; 8999; -. DR Ensembl; ENST00000429927.6; ENSP00000412365.2; ENSG00000138769.12. DR GeneID; 8999; -. DR KEGG; hsa:8999; -. DR UCSC; uc003hiq.4; human. DR AGR; HGNC:1782; -. DR ClinPGx; PA26318; -. DR CTD; 8999; -. DR DisGeNET; 8999; -. DR GeneCards; CDKL2; -. DR HGNC; HGNC:1782; CDKL2. DR HPA; ENSG00000138769; Tissue enhanced (retina, testis). DR MIM; 603442; gene. DR OpenTargets; ENSG00000138769; -. DR VEuPathDB; HostDB:ENSG00000138769; -. DR eggNOG; KOG0593; Eukaryota. DR GeneTree; ENSGT00940000160368; -. DR HOGENOM; CLU_000288_136_0_1; -. DR InParanoid; Q92772; -. DR OrthoDB; 548217at2759; -. DR PAN-GO; Q92772; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q92772; -. DR PathwayCommons; Q92772; -. DR SignaLink; Q92772; -. DR Agora; ENSG00000138769; -. DR BioGRID-ORCS; 8999; 18 hits in 1177 CRISPR screens. DR ChiTaRS; CDKL2; human. DR EvolutionaryTrace; Q92772; -. DR GeneWiki; CDKL2; -. DR GenomeRNAi; 8999; -. DR Pharos; Q92772; Tchem. DR PRO; PR:Q92772; -. DR Proteomes; UP000005640; Chromosome 4. DR RNAct; Q92772; protein. DR Bgee; ENSG00000138769; Expressed in endothelial cell and 147 other cell types or tissues. DR ExpressionAtlas; Q92772; baseline and differential. DR GO; GO:0005813; C:centrosome; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004693; F:cyclin-dependent protein serine/threonine kinase activity; IEA:UniProtKB-EC. DR GO; GO:0004672; F:protein kinase activity; TAS:ProtInc. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0007548; P:sex differentiation; TAS:ProtInc. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR CDD; cd07846; STKc_CDKL2_3; 1. DR FunFam; 3.30.200.20:FF:000049; cyclin-dependent kinase-like 1 isoform X1; 1. DR FunFam; 1.10.510.10:FF:000261; cyclin-dependent kinase-like 2 isoform X2; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR050108; CDK. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24056; CELL DIVISION PROTEIN KINASE; 1. DR PANTHER; PTHR24056:SF241; CYCLIN-DEPENDENT KINASE-LIKE 2; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Cytoplasm; Kinase; Nucleotide-binding; Nucleus; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..493 FT /note="Cyclin-dependent kinase-like 2" FT /id="PRO_0000085814" FT DOMAIN 4..287 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 363..384 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 45..51 FT /note="[NKR]KIAxRE" FT ACT_SITE 126 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 10..18 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 33 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT VARIANT 77 FT /note="Y -> S (in dbSNP:rs35921414)" FT /id="VAR_053928" FT VARIANT 98 FT /note="L -> I (in an ovarian papillary serous FT adenocarcinoma sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041987" FT VARIANT 132 FT /note="I -> T (in dbSNP:rs17000707)" FT /id="VAR_053929" FT VARIANT 149 FT /note="R -> Q (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs755711267)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041988" FT VARIANT 197 FT /note="M -> T (in dbSNP:rs56343717)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041989" FT VARIANT 411 FT /note="A -> V (in dbSNP:rs56231363)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041990" FT HELIX 1..3 FT /evidence="ECO:0007829|PDB:4AAA" FT STRAND 4..9 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 10..13 FT /evidence="ECO:0007829|PDB:4AAA" FT STRAND 16..23 FT /evidence="ECO:0007829|PDB:4AAA" FT TURN 24..26 FT /evidence="ECO:0007829|PDB:4AAA" FT STRAND 29..37 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 42..57 FT /evidence="ECO:0007829|PDB:4AAA" FT STRAND 66..72 FT /evidence="ECO:0007829|PDB:4AAA" FT STRAND 75..81 FT /evidence="ECO:0007829|PDB:4AAA" FT STRAND 84..86 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 87..93 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 100..119 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 129..131 FT /evidence="ECO:0007829|PDB:4AAA" FT STRAND 132..134 FT /evidence="ECO:0007829|PDB:4AAA" FT STRAND 140..142 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 147..150 FT /evidence="ECO:0007829|PDB:4BBM" FT HELIX 154..163 FT /evidence="ECO:0007829|PDB:4BBM" FT HELIX 165..167 FT /evidence="ECO:0007829|PDB:4BBM" FT HELIX 170..173 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 182..197 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 207..218 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 223..231 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 233..235 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 249..252 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 258..267 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 272..274 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 278..283 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 285..288 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 289..291 FT /evidence="ECO:0007829|PDB:4AAA" FT HELIX 292..301 FT /evidence="ECO:0007829|PDB:4AAA" SQ SEQUENCE 493 AA; 56019 MW; 5CC20A91CBF89EFE CRC64; MEKYENLGLV GEGSYGMVMK CRNKDTGRIV AIKKFLESDD DKMVKKIAMR EIKLLKQLRH ENLVNLLEVC KKKKRWYLVF EFVDHTILDD LELFPNGLDY QVVQKYLFQI INGIGFCHSH NIIHRDIKPE NILVSQSGVV KLCDFGFART LAAPGEVYTD YVATRWYRAP ELLVGDVKYG KAVDVWAIGC LVTEMFMGEP LFPGDSDIDQ LYHIMMCLGN LIPRHQELFN KNPVFAGVRL PEIKEREPLE RRYPKLSEVV IDLAKKCLHI DPDKRPFCAE LLHHDFFQMD GFAERFSQEL QLKVQKDARN VSLSKKSQNR KKEKEKDDSL VEERKTLVVQ DTNADPKIKD YKLFKIKGSK IDGEKAEKGN RASNASCLHD SRTSHNKIVP STSLKDCSNV SVDHTRNPSV AIPPLTHNLS AVAPSINSGM GTETIPIQGY RVDEKTKKCS IPFVKPNRHS PSGIYNINVT TLVSGPPLSD DSGADLPQME HQH // ID CDN2B_HUMAN Reviewed; 138 AA. AC P42772; O15125; Q6FI09; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1995, sequence version 1. DT 28-JAN-2026, entry version 206. DE RecName: Full=Cyclin-dependent kinase 4 inhibitor B; DE AltName: Full=Multiple tumor suppressor 2; DE Short=MTS-2; DE AltName: Full=p14-INK4b; DE AltName: Full=p15-INK4b; DE Short=p15INK4B; GN Name=CDKN2B; Synonyms=MTS2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=8001816; DOI=10.1101/gad.8.24.2939; RA Guan K.-L., Jenkins C.W., Li Y., Nichols M.A., Wu X., O'Keefe C.L., RA Matera G.A., Xiong Y.; RT "Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 RT inhibitor, correlates with wild-type pRb function."; RL Genes Dev. 8:2939-2952(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=8078588; DOI=10.1038/371257a0; RA Hannon G.J., Beach D.; RT "p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest."; RL Nature 371:257-261(1994). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RX PubMed=9230210; RA Tsubari M., Tiihonen E., Laiho M.; RT "Cloning and characterization of p10, an alternatively spliced form of p15 RT cyclin-dependent kinase inhibitor."; RL Cancer Res. 57:2966-2973(1997). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S., Neubert P., RA Kstrang K., Schatten R., Shen B., Henze S., Mar W., Korn B., Zuo D., Hu Y., RA LaBaer J.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164053; DOI=10.1038/nature02465; RA Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L., RA Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R., RA Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S., RA Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., RA Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., RA Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E., RA Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M., RA Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J., RA Frankish A., Frankland J.A., French L., Fricker D.G., Garner P., RA Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S., RA Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E., RA Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D., RA Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E., RA Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K., RA Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S., RA Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J., RA Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E., RA McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V., RA Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S., RA Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K., RA Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J., RA Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., RA West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L., RA Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M., RA Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J., RA Dunham I.; RT "DNA sequence and analysis of human chromosome 9."; RL Nature 429:369-374(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 53-138. RX PubMed=8153634; DOI=10.1126/science.8153634; RA Kamb A., Gruis N.A., Weaver-Feldhaus J., Liu Q., Harshman K., RA Tavtigian S.V., Stockert E., Day R.S. III, Johnson B.E., Skolnick M.H.; RT "A cell cycle regulator potentially involved in genesis of many tumor RT types."; RL Science 264:436-440(1994). RN [9] RP STRUCTURE BY NMR. RX PubMed=10892805; DOI=10.1110/ps.9.6.1120; RA Yuan C., Selby T.L., Li J., Byeon I.J., Tsai M.D.; RT "Tumor suppressor INK4: refinement of p16INK4A structure and determination RT of p15INK4B structure by comparative modeling and NMR data."; RL Protein Sci. 9:1120-1128(2000). RN [10] RP VARIANTS LUNG ADENOCARCINOMA GLU-47 AND VAL-50. RX PubMed=7882351; RA Okamoto A., Hussain S.P., Hagiwara K., Spillare E.A., Rusin M.R., RA Demetrick D.J., Serrano M., Hannon G.J., Shiseki M., Zariwala M., Xiong Y., RA Beach D.H., Yokota J., Harris C.C.; RT "Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in RT primary and metastatic lung cancer."; RL Cancer Res. 55:1448-1451(1995). CC -!- FUNCTION: Interacts strongly with CDK4 and CDK6. Potent inhibitor. CC Potential effector of TGF-beta induced cell cycle arrest. CC -!- SUBUNIT: Heterodimer of CDKN2B with CDK4 or CDK6. Isoform 2 does not CC interact with CDK4 nor CDK6. CC -!- INTERACTION: CC P42772; Q9UI12: ATP6V1H; NbExp=3; IntAct=EBI-711280, EBI-724719; CC P42772; P15056: BRAF; NbExp=4; IntAct=EBI-711280, EBI-365980; CC P42772; P24863: CCNC; NbExp=3; IntAct=EBI-711280, EBI-395261; CC P42772; Q00537: CDK17; NbExp=3; IntAct=EBI-711280, EBI-624648; CC P42772; P11802: CDK4; NbExp=22; IntAct=EBI-711280, EBI-295644; CC P42772; Q00534: CDK6; NbExp=19; IntAct=EBI-711280, EBI-295663; CC P42772; Q6P9H4: CNKSR3; NbExp=3; IntAct=EBI-711280, EBI-10253274; CC P42772; Q0VD86: INCA1; NbExp=3; IntAct=EBI-711280, EBI-6509505; CC P42772; P43364: MAGEA11; NbExp=4; IntAct=EBI-711280, EBI-739552; CC P42772; Q9GZT8: NIF3L1; NbExp=3; IntAct=EBI-711280, EBI-740897; CC P42772; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-711280, EBI-79165; CC P42772; Q53H96: PYCR3; NbExp=3; IntAct=EBI-711280, EBI-2959680; CC P42772; A6ZKI3: RTL8C; NbExp=3; IntAct=EBI-711280, EBI-10174072; CC P42772; Q9BVN2: RUSC1; NbExp=3; IntAct=EBI-711280, EBI-6257312; CC P42772; Q9NZD8: SPG21; NbExp=6; IntAct=EBI-711280, EBI-742688; CC P42772; Q13077: TRAF1; NbExp=7; IntAct=EBI-711280, EBI-359224; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:9230210}. Note=Also CC found in the nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=p15; CC IsoId=P42772-1; Sequence=Displayed; CC Name=2; Synonyms=p10; CC IsoId=P42772-2; Sequence=VSP_043898; CC -!- TISSUE SPECIFICITY: Isoform 2 is expressed in normal (keratinocytes, CC fibroblasts) and tumor cell lines. {ECO:0000269|PubMed:9230210}. CC -!- SIMILARITY: Belongs to the CDKN2 cyclin-dependent kinase inhibitor CC family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/187/CDKN2B"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U17075; AAC50075.1; -; mRNA. DR EMBL; L36844; AAA50282.1; -; mRNA. DR EMBL; AF004819; AAB69989.1; -; mRNA. DR EMBL; CR536529; CAG38766.1; -; mRNA. DR EMBL; AF513858; AAM44859.1; -; Genomic_DNA. DR EMBL; AL449423; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC014469; AAH14469.1; -; mRNA. DR EMBL; S69805; AAD14049.1; -; Genomic_DNA. DR CCDS; CCDS6512.1; -. [P42772-1] DR CCDS; CCDS6513.1; -. [P42772-2] DR PIR; B55479; B55479. DR RefSeq; NP_004927.2; NM_004936.3. [P42772-1] DR RefSeq; NP_511042.1; NM_078487.2. [P42772-2] DR AlphaFoldDB; P42772; -. DR SMR; P42772; -. DR BioGRID; 107464; 73. DR FunCoup; P42772; 1638. DR IntAct; P42772; 28. DR MINT; P42772; -. DR STRING; 9606.ENSP00000276925; -. DR iPTMnet; P42772; -. DR PhosphoSitePlus; P42772; -. DR BioMuta; CDKN2B; -. DR DMDM; 1168869; -. DR jPOST; P42772; -. DR MassIVE; P42772; -. DR PaxDb; 9606-ENSP00000276925; -. DR PeptideAtlas; P42772; -. DR ProteomicsDB; 55555; -. [P42772-1] DR ProteomicsDB; 55556; -. [P42772-2] DR Pumba; P42772; -. DR Antibodypedia; 3605; 625 antibodies from 37 providers. DR DNASU; 1030; -. DR Ensembl; ENST00000276925.7; ENSP00000276925.6; ENSG00000147883.13. [P42772-1] DR Ensembl; ENST00000380142.5; ENSP00000369487.4; ENSG00000147883.13. [P42772-2] DR GeneID; 1030; -. DR KEGG; hsa:1030; -. DR MANE-Select; ENST00000276925.7; ENSP00000276925.6; NM_004936.4; NP_004927.2. DR UCSC; uc003zpn.4; human. [P42772-1] DR AGR; HGNC:1788; -. DR CIViC; 1030; 7 evidence items across 7 molecular profiles. DR ClinPGx; PA26321; -. DR CTD; 1030; -. DR DisGeNET; 1030; -. DR GeneCards; CDKN2B; -. DR HGNC; HGNC:1788; CDKN2B. DR HPA; ENSG00000147883; Tissue enhanced (esophagus, intestine). DR MalaCards; CDKN2B; -. DR MIM; 600431; gene. DR OpenTargets; ENSG00000147883; -. DR Orphanet; 618; Familial melanoma. DR Orphanet; 652; Multiple endocrine neoplasia type 1. DR VEuPathDB; HostDB:ENSG00000147883; -. DR eggNOG; KOG0504; Eukaryota. DR GeneTree; ENSGT00940000162423; -. DR HOGENOM; CLU_000134_37_1_1; -. DR InParanoid; P42772; -. DR OMA; SALQVMM; -. DR OrthoDB; 539213at2759; -. DR PAN-GO; P42772; 7 GO annotations based on evolutionary models. DR PhylomeDB; P42772; -. DR PathwayCommons; P42772; -. DR Reactome; R-HSA-2173796; SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription. DR Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence. DR Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP). DR Reactome; R-HSA-2559585; Oncogene Induced Senescence. DR Reactome; R-HSA-69231; Cyclin D associated events in G1. DR SignaLink; P42772; -. DR SIGNOR; P42772; -. DR Agora; ENSG00000147883; -. DR BioGRID-ORCS; 1030; 23 hits in 1175 CRISPR screens. DR GeneWiki; CDKN2B; -. DR GenomeRNAi; 1030; -. DR Pharos; P42772; Tbio. DR PRO; PR:P42772; -. DR Proteomes; UP000005640; Chromosome 9. DR RNAct; P42772; protein. DR Bgee; ENSG00000147883; Expressed in jejunal mucosa and 151 other cell types or tissues. DR ExpressionAtlas; P42772; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0004861; F:cyclin-dependent protein serine/threonine kinase inhibitor activity; IDA:BHF-UCL. DR GO; GO:0019901; F:protein kinase binding; IPI:BHF-UCL. DR GO; GO:0071460; P:cellular response to cell-matrix adhesion; IMP:BHF-UCL. DR GO; GO:0031670; P:cellular response to nutrient; IMP:BHF-UCL. DR GO; GO:0090398; P:cellular senescence; IMP:BHF-UCL. DR GO; GO:0030219; P:megakaryocyte differentiation; IEP:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:BHF-UCL. DR GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IMP:BHF-UCL. DR GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IDA:BHF-UCL. DR GO; GO:0030511; P:positive regulation of transforming growth factor beta receptor signaling pathway; IMP:BHF-UCL. DR GO; GO:0070316; P:regulation of G0 to G1 transition; IMP:BHF-UCL. DR GO; GO:2000045; P:regulation of G1/S transition of mitotic cell cycle; IBA:GO_Central. DR GO; GO:0048536; P:spleen development; IEA:Ensembl. DR GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL. DR FunFam; 1.25.40.20:FF:000107; cyclin-dependent kinase 4 inhibitor B; 1. DR Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 1. DR InterPro; IPR050776; Ank_Repeat/CDKN_Inhibitor. DR InterPro; IPR002110; Ankyrin_rpt. DR InterPro; IPR036770; Ankyrin_rpt-contain_sf. DR PANTHER; PTHR24201; ANK_REP_REGION DOMAIN-CONTAINING PROTEIN; 1. DR PANTHER; PTHR24201:SF8; CYCLIN-DEPENDENT KINASE 4 INHIBITOR B; 1. DR Pfam; PF12796; Ank_2; 1. DR SUPFAM; SSF48403; Ankyrin repeat; 1. DR PROSITE; PS50297; ANK_REP_REGION; 1. PE 1: Evidence at protein level; KW Alternative splicing; ANK repeat; Cell cycle; Cytoplasm; KW Proteomics identification; Reference proteome; Repeat; Tumor suppressor. FT CHAIN 1..138 FT /note="Cyclin-dependent kinase 4 inhibitor B" FT /id="PRO_0000144184" FT REPEAT 13..39 FT /note="ANK 1; truncated" FT REPEAT 46..74 FT /note="ANK 2" FT REPEAT 79..108 FT /note="ANK 3" FT REPEAT 112..138 FT /note="ANK 4" FT VAR_SEQ 54..138 FT /note="MMMGSARVAELLLLHGAEPNCADPATLTRPVHDAAREGFLDTLVVLHRAGAR FT LDVRDAWGRLPVDLAEERGHRDVAGYLRTATGD -> AGAPGPRRQGARERGARPRRIG FT AGT (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9230210" FT /id="VSP_043898" FT VARIANT 47 FT /note="G -> E (in lung adenocarcinoma; dbSNP:rs2131189971)" FT /evidence="ECO:0000269|PubMed:7882351" FT /id="VAR_001488" FT VARIANT 50 FT /note="A -> V (in lung adenocarcinoma; dbSNP:rs1423790481)" FT /evidence="ECO:0000269|PubMed:7882351" FT /id="VAR_001489" FT CONFLICT 20..22 FT /note="SAA -> TP (in Ref. 2; AAA50282)" FT /evidence="ECO:0000305" FT CONFLICT 32..34 FT /note="QLL -> HSW (in Ref. 2; AAA50282)" FT /evidence="ECO:0000305" SQ SEQUENCE 138 AA; 14722 MW; 0D6FFBDFA6FEAD21 CRC64; MREENKGMPS GGGSDEGLAS AAARGLVEKV RQLLEAGADP NGVNRFGRRA IQVMMMGSAR VAELLLLHGA EPNCADPATL TRPVHDAARE GFLDTLVVLH RAGARLDVRD AWGRLPVDLA EERGHRDVAG YLRTATGD // ID CEMIP_HUMAN Reviewed; 1361 AA. AC Q8WUJ3; Q6L9J5; Q9H1K5; Q9NPN9; Q9ULM1; DT 13-APR-2004, integrated into UniProtKB/Swiss-Prot. DT 13-APR-2004, sequence version 2. DT 28-JAN-2026, entry version 168. DE RecName: Full=Cell migration-inducing and hyaluronan-binding protein; DE EC=3.2.1.35 {ECO:0000269|PubMed:23509262, ECO:0000269|PubMed:24269685}; DE AltName: Full=Hyaluronan binding protein involved in hyaluronan depolymerization {ECO:0000303|PubMed:23509262}; DE Flags: Precursor; GN Name=CEMIP {ECO:0000312|HGNC:HGNC:29213}; GN Synonyms=HYBID {ECO:0000303|PubMed:23509262}, KIAA1199; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], VARIANTS CYS-187; HIS-187 AND TYR-783, AND RP VARIANTS ARG-783; ILE-1109 AND ALA-1169. RX PubMed=14577002; DOI=10.1007/s10038-003-0079-2; RA Abe S., Usami S., Nakamura Y.; RT "Mutations in the gene encoding KIAA1199 protein, an inner-ear protein RT expressed in Deiters' cells and the fibrocytes, as the cause of RT nonsyndromic hearing loss."; RL J. Hum. Genet. 48:564-570(2003). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=16157444; DOI=10.1016/j.canlet.2005.07.028; RA Michishita E., Garces G., Barrett J.C., Horikawa I.; RT "Upregulation of the KIAA1199 gene is associated with cellular mortality."; RL Cancer Lett. 239:71-77(2006). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 349-1361 (ISOFORM 1), AND TISSUE RP SPECIFICITY. RC TISSUE=Brain; RX PubMed=10574462; DOI=10.1093/dnares/6.5.337; RA Nagase T., Ishikawa K., Kikuno R., Hirosawa M., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XV. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 6:337-345(1999). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 558-1361. RG The European IMAGE consortium; RL Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 862-1361. RX PubMed=11247670; DOI=10.1006/geno.2000.6466; RA Wines M.E., Lee L., Katari M.S., Zhang L., DeRossi C., Shi Y., Perkins S., RA Feldman M., McCombie W.R., Holdener B.C.; RT "Identification of mesoderm development (mesd) candidate genes by RT comparative mapping and genome sequence analysis."; RL Genomics 72:88-98(2001). RN [8] RP TISSUE SPECIFICITY. RX PubMed=12471561; DOI=10.1086/345398; RA Abe S., Katagiri T., Saito-Hisaminato A., Usami S., Inoue Y., Tsunoda T., RA Nakamura Y.; RT "Identification of CRYM as a candidate responsible for nonsyndromic RT deafness, through cDNA microarray analysis of human cochlear and vestibular RT tissues."; RL Am. J. Hum. Genet. 72:73-82(2003). RN [9] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=19434458; DOI=10.1245/s10434-009-0469-6; RA Matsuzaki S., Tanaka F., Mimori K., Tahara K., Inoue H., Mori M.; RT "Clinicopathologic significance of KIAA1199 overexpression in human gastric RT cancer."; RL Ann. Surg. Oncol. 16:2042-2051(2009). RN [10] RP PROBABLE FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=21772334; DOI=10.1038/bjc.2011.268; RA Birkenkamp-Demtroder K., Maghnouj A., Mansilla F., Thorsen K., RA Andersen C.L., Oster B., Hahn S., Orntoft T.F.; RT "Repression of KIAA1199 attenuates Wnt-signalling and decreases the RT proliferation of colon cancer cells."; RL Br. J. Cancer 105:552-561(2011). RN [11] RP TISSUE SPECIFICITY, AND INDUCTION. RX PubMed=22970280; DOI=10.1371/journal.pone.0044661; RA Kuscu C., Evensen N., Kim D., Hu Y.J., Zucker S., Cao J.; RT "Transcriptional and epigenetic regulation of KIAA1199 gene expression in RT human breast cancer."; RL PLoS ONE 7:E44661-E44661(2012). RN [12] RP FUNCTION IN CANCER, INTERACTION WITH HSPA5, SUBCELLULAR LOCATION, AND RP TISSUE SPECIFICITY. RX PubMed=23990668; DOI=10.1093/jnci/djt224; RA Evensen N.A., Kuscu C., Nguyen H.L., Zarrabi K., Dufour A., Kadam P., RA Hu Y.J., Pulkoski-Gross A., Bahou W.F., Zucker S., Cao J.; RT "Unraveling the role of KIAA1199, a novel endoplasmic reticulum protein, in RT cancer cell migration."; RL J. Natl. Cancer Inst. 105:1402-1416(2013). RN [13] RP INTERACTION WITH EPHA2 AND ITPR3, GLYCOSYLATION, SUBCELLULAR LOCATION, AND RP TISSUE SPECIFICITY. RX PubMed=23936024; DOI=10.1371/journal.pone.0069473; RA Tiwari A., Schneider M., Fiorino A., Haider R., Okoniewski M.J., RA Roschitzki B., Uzozie A., Menigatti M., Jiricny J., Marra G.; RT "Early insights into the function of KIAA1199, a markedly overexpressed RT protein in human colorectal tumors."; RL PLoS ONE 8:E69473-E69473(2013). RN [14] RP FUNCTION IN HYALURONIC ACID DEGRADATION, CATALYTIC ACTIVITY, ACTIVITY RP REGULATION, HYALURONIC ACID-BINDING, INTERACTION WITH CLATHRIN, SUBCELLULAR RP LOCATION, INDUCTION, AND CHARACTERIZATION OF VARIANTS CYS-187; HIS-187; RP ARG-783 AND ILE-1109. RX PubMed=23509262; DOI=10.1073/pnas.1215432110; RA Yoshida H., Nagaoka A., Kusaka-Kikushima A., Tobiishi M., Kawabata K., RA Sayo T., Sakai S., Sugiyama Y., Enomoto H., Okada Y., Inoue S.; RT "KIAA1199, a deafness gene of unknown function, is a new hyaluronan binding RT protein involved in hyaluronan depolymerization."; RL Proc. Natl. Acad. Sci. U.S.A. 110:5612-5617(2013). RN [15] RP FUNCTION IN HYALURONIC ACID DEGRADATION, CATALYTIC ACTIVITY, GLYCOSYLATION, RP SUBCELLULAR LOCATION, PROTEOLYTIC PROCESSING, AND SIGNAL SEQUENCE CLEAVAGE RP SITE. RX PubMed=24269685; DOI=10.1016/j.febslet.2013.11.017; RA Yoshida H., Nagaoka A., Nakamura S., Tobiishi M., Sugiyama Y., Inoue S.; RT "N-Terminal signal sequence is required for cellular trafficking and RT hyaluronan-depolymerization of KIAA1199."; RL FEBS Lett. 588:111-116(2014). CC -!- FUNCTION: Mediates depolymerization of hyaluronic acid (HA) via the CC cell membrane-associated clathrin-coated pit endocytic pathway. Binds CC to hyaluronic acid. Hydrolyzes high molecular weight hyaluronic acid to CC produce an intermediate-sized product, a process that may occur through CC rapid vesicle endocytosis and recycling without intracytoplasmic CC accumulation or digestion in lysosomes. Involved in hyaluronan CC catabolism in the dermis of the skin and arthritic synovium. Positively CC regulates epithelial-mesenchymal transition (EMT), and hence tumor cell CC growth, invasion and cancer dissemination. In collaboration with CC HSPA5/BIP, promotes cancer cell migration in a calcium and PKC- CC dependent manner. May be involved in hearing. CC {ECO:0000269|PubMed:23509262, ECO:0000269|PubMed:23990668, CC ECO:0000269|PubMed:24269685}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Random hydrolysis of (1->4)-linkages between N-acetyl-beta-D- CC glucosamine and D-glucuronate residues in hyaluronate.; EC=3.2.1.35; CC Evidence={ECO:0000269|PubMed:23509262, ECO:0000269|PubMed:24269685}; CC -!- ACTIVITY REGULATION: Activity is up-regulated by histamine. CC {ECO:0000269|PubMed:23509262}. CC -!- SUBUNIT: Interacts with EPHA2 and ITPR3. Interacts with HSPA5/BIP; the CC interaction induces calcium leakage from the endoplasmic reticulum and CC cell migration. Interacts with clathrin heavy chain/CLTC. CC {ECO:0000269|PubMed:23509262, ECO:0000269|PubMed:23936024, CC ECO:0000269|PubMed:23990668}. CC -!- INTERACTION: CC Q8WUJ3; P53621: COPA; NbExp=2; IntAct=EBI-310606, EBI-356273; CC Q8WUJ3; Q93100: PHKB; NbExp=2; IntAct=EBI-310606, EBI-740559; CC -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Endoplasmic reticulum. Cell CC membrane. Membrane, clathrin-coated pit. Secreted. Note=Retained in the CC endoplasmic reticulum (ER) in a HSPA5/BIP-dependent manner. Colocalized CC with clathrin heavy chain/CLTC in clathrin-coated vesicles. Strongly CC detected in the cytoplasm of breast carcinoma cells, whereas poorly CC detected in adjacent normal epithelial cells, stromal cells, or benign CC breast tissues. Localized in the nucleus and cytoplasm of colon CC adenocarcinomas. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q8WUJ3-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8WUJ3-2; Sequence=VSP_009814, VSP_009815; CC -!- TISSUE SPECIFICITY: Expressed in dermal and in synovial fibroblasts. CC Strongly expressed in gastric cancers compared with the paired normal CC tissues. Strongly expressed in both ductal carcinoma and invasive CC breast cancer cells compared with benign epithelial cells (at protein CC level). Strongly expressed in brain, placenta, prostate, breast, lung CC and testis. Expressed in fibroblasts, epithelial cells and cancer CC cells. In ear, it is specifically expressed in inner ear. Expressed in CC cochlea and vestibule tissues. Strongly expressed in gastric cancers CC compared with the paired normal tissues. Strongly expressed in colon CC adenocarcinomas compared with normal colonic mucosas. Strongly CC expressed in breast cancer as compared to normal breast tissue. CC {ECO:0000269|PubMed:10574462, ECO:0000269|PubMed:12471561, CC ECO:0000269|PubMed:16157444, ECO:0000269|PubMed:19434458, CC ECO:0000269|PubMed:21772334, ECO:0000269|PubMed:22970280, CC ECO:0000269|PubMed:23936024, ECO:0000269|PubMed:23990668}. CC -!- INDUCTION: Up-regulated by histamine. Up-regulated by the adapter CC protein complex 1 (AP-1) and NF-kappaB/RELA. Down-regulated by CC transforming growth factor TGFB1. {ECO:0000269|PubMed:22970280, CC ECO:0000269|PubMed:23509262}. CC -!- DOMAIN: The signal sequence is essential in mediating its proper CC translocation, hyaluronic acid (HA) degradation activity and secretion. CC -!- PTM: N-glycosylated; glycosylation is not necessary for HA-binding. CC {ECO:0000269|PubMed:23936024, ECO:0000269|PubMed:24269685}. CC -!- SIMILARITY: Belongs to the CEMIP family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB103330; BAD02451.1; -; mRNA. DR EMBL; CH471136; EAW99111.1; -; Genomic_DNA. DR EMBL; BC020256; AAH20256.1; -; mRNA. DR EMBL; AB033025; BAA86513.1; -; mRNA. DR EMBL; AL359061; CAB94391.1; -; mRNA. DR EMBL; AY007811; AAG41059.1; -; mRNA. DR CCDS; CCDS10315.1; -. [Q8WUJ3-1] DR RefSeq; NP_001280227.1; NM_001293298.2. [Q8WUJ3-1] DR RefSeq; NP_001280233.1; NM_001293304.2. [Q8WUJ3-1] DR RefSeq; NP_061159.1; NM_018689.3. [Q8WUJ3-1] DR RefSeq; XP_047288856.1; XM_047432900.1. [Q8WUJ3-1] DR RefSeq; XP_054234488.1; XM_054378513.1. [Q8WUJ3-1] DR AlphaFoldDB; Q8WUJ3; -. DR SMR; Q8WUJ3; -. DR BioGRID; 121452; 96. DR FunCoup; Q8WUJ3; 405. DR IntAct; Q8WUJ3; 15. DR MINT; Q8WUJ3; -. DR STRING; 9606.ENSP00000378177; -. DR CarbonylDB; Q8WUJ3; -. DR GlyCosmos; Q8WUJ3; 7 sites, No reported glycans. DR GlyGen; Q8WUJ3; 8 sites, 3 N-linked glycans (2 sites), 1 O-linked glycan (1 site). DR iPTMnet; Q8WUJ3; -. DR PhosphoSitePlus; Q8WUJ3; -. DR BioMuta; CEMIP; -. DR DMDM; 46396475; -. DR jPOST; Q8WUJ3; -. DR MassIVE; Q8WUJ3; -. DR PaxDb; 9606-ENSP00000378177; -. DR PeptideAtlas; Q8WUJ3; -. DR ProteomicsDB; 74690; -. [Q8WUJ3-1] DR ProteomicsDB; 74691; -. [Q8WUJ3-2] DR Antibodypedia; 27890; 248 antibodies from 26 providers. DR DNASU; 57214; -. DR Ensembl; ENST00000220244.7; ENSP00000220244.3; ENSG00000103888.18. [Q8WUJ3-1] DR Ensembl; ENST00000356249.9; ENSP00000348583.5; ENSG00000103888.18. [Q8WUJ3-1] DR Ensembl; ENST00000394685.8; ENSP00000378177.3; ENSG00000103888.18. [Q8WUJ3-1] DR GeneID; 57214; -. DR KEGG; hsa:57214; -. DR MANE-Select; ENST00000394685.8; ENSP00000378177.3; NM_001293298.2; NP_001280227.1. DR UCSC; uc002bfw.2; human. [Q8WUJ3-1] DR AGR; HGNC:29213; -. DR ClinPGx; PA134967531; -. DR CTD; 57214; -. DR DisGeNET; 57214; -. DR GeneCards; CEMIP; -. DR HGNC; HGNC:29213; CEMIP. DR HPA; ENSG00000103888; Tissue enhanced (endometrium). DR MIM; 608366; gene. DR OpenTargets; ENSG00000103888; -. DR VEuPathDB; HostDB:ENSG00000103888; -. DR eggNOG; ENOG502QT0K; Eukaryota. DR GeneTree; ENSGT00940000153636; -. DR HOGENOM; CLU_005606_1_0_1; -. DR InParanoid; Q8WUJ3; -. DR OMA; YGRADED; -. DR OrthoDB; 120976at2759; -. DR PAN-GO; Q8WUJ3; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q8WUJ3; -. DR PathwayCommons; Q8WUJ3; -. DR Reactome; R-HSA-2160916; Hyaluronan degradation. DR SignaLink; Q8WUJ3; -. DR Agora; ENSG00000103888; -. DR BioGRID-ORCS; 57214; 16 hits in 1143 CRISPR screens. DR ChiTaRS; CEMIP; human. DR GeneWiki; KIAA1199; -. DR GenomeRNAi; 57214; -. DR Pharos; Q8WUJ3; Tbio. DR PRO; PR:Q8WUJ3; -. DR Proteomes; UP000005640; Chromosome 15. DR RNAct; Q8WUJ3; protein. DR Bgee; ENSG00000103888; Expressed in choroid plexus epithelium and 132 other cell types or tissues. DR ExpressionAtlas; Q8WUJ3; baseline and differential. DR GO; GO:0045334; C:clathrin-coated endocytic vesicle; IDA:UniProtKB. DR GO; GO:0005905; C:clathrin-coated pit; IEA:UniProtKB-SubCell. DR GO; GO:0030665; C:clathrin-coated vesicle membrane; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0001650; C:fibrillar center; IDA:HPA. DR GO; GO:0031965; C:nuclear membrane; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW. DR GO; GO:0032050; F:clathrin heavy chain binding; IDA:UniProtKB. DR GO; GO:0046923; F:ER retention sequence binding; IDA:UniProtKB. DR GO; GO:0005540; F:hyaluronic acid binding; IDA:UniProtKB. DR GO; GO:0004415; F:hyalurononglucosaminidase activity; IMP:UniProtKB. DR GO; GO:0030214; P:hyaluronan catabolic process; IMP:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB. DR GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; IDA:UniProtKB. DR GO; GO:1900020; P:positive regulation of protein kinase C activity; IDA:UniProtKB. DR GO; GO:0090314; P:positive regulation of protein targeting to membrane; IDA:UniProtKB. DR GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IDA:UniProtKB. DR GO; GO:0007605; P:sensory perception of sound; IMP:UniProtKB. DR CDD; cd13941; PANDER_like_KIAA1199; 1. DR CDD; cd13938; PANDER_like_TMEM2; 1. DR InterPro; IPR052252; CEMIP/CEMIP2. DR InterPro; IPR055401; CEMIP_beta-hel_dom. DR InterPro; IPR055400; CEMIP_X. DR InterPro; IPR019316; G8_domain. DR InterPro; IPR039477; ILEI/PANDER_dom. DR InterPro; IPR011050; Pectin_lyase_fold/virulence. DR InterPro; IPR039473; TMEM2_PANDER-like. DR InterPro; IPR025155; WxxW_domain. DR PANTHER; PTHR15535:SF15; CELL MIGRATION-INDUCING AND HYALURONAN-BINDING PROTEIN; 1. DR PANTHER; PTHR15535; TRANSMEMBRANE PROTEIN 2-RELATED; 1. DR Pfam; PF24606; CEMIP_beta-hel; 1. DR Pfam; PF24605; CEMIP_X; 1. DR Pfam; PF10162; G8; 1. DR Pfam; PF15711; ILEI; 2. DR Pfam; PF13330; Mucin2_WxxW; 2. DR SMART; SM01225; G8; 1. DR SUPFAM; SSF51126; Pectin lyase-like; 1. DR PROSITE; PS51484; G8; 1. DR PROSITE; PS52031; GG_LECTIN; 2. PE 1: Evidence at protein level; KW Alternative splicing; Cell membrane; Coated pit; Cytoplasm; KW Endoplasmic reticulum; Glycoprotein; Glycosidase; Hyaluronic acid; KW Hydrolase; Lectin; Membrane; Nucleus; Proteomics identification; KW Reference proteome; Repeat; Secreted; Signal. FT SIGNAL 1..30 FT /evidence="ECO:0000269|PubMed:24269685" FT CHAIN 31..1361 FT /note="Cell migration-inducing and hyaluronan-binding FT protein" FT /id="PRO_0000021538" FT DOMAIN 44..166 FT /note="G8" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00817" FT DOMAIN 176..317 FT /note="GG-type lectin 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01375" FT REPEAT 572..594 FT /note="PbH1 1" FT REPEAT 595..617 FT /note="PbH1 2" FT REPEAT 719..741 FT /note="PbH1 3" FT REPEAT 798..819 FT /note="PbH1 4" FT DOMAIN 1227..1361 FT /note="GG-type lectin 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01375" FT REGION 295..591 FT /note="Necessary for its endoplasmic reticulum (ER) FT retention and interaction with HSPA5" FT /evidence="ECO:0000269|PubMed:23990668" FT CARBOHYD 119 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 165 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 312 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 370 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 420 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 889 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 921 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 978..992 FT /note="NWLVRHPDCINVPDW -> KWHSLASKAASGPSG (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_009814" FT VAR_SEQ 993..1361 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_009815" FT VARIANT 187 FT /note="R -> C (in a family with non-syndromic hearing loss; FT reduces hyaluronic acid degradation activity; FT dbSNP:rs368854657)" FT /evidence="ECO:0000269|PubMed:14577002, FT ECO:0000269|PubMed:23509262" FT /id="VAR_018165" FT VARIANT 187 FT /note="R -> H (in two unrelated families with non-syndromic FT hearing loss; reduces hyaluronic acid (HA) degradation FT activity; dbSNP:rs144446375)" FT /evidence="ECO:0000269|PubMed:14577002, FT ECO:0000269|PubMed:23509262" FT /id="VAR_018166" FT VARIANT 783 FT /note="H -> R (does not inhibit hyaluronic acid degradation FT activity; dbSNP:rs12441101)" FT /evidence="ECO:0000269|PubMed:14577002, FT ECO:0000269|PubMed:23509262" FT /id="VAR_018167" FT VARIANT 783 FT /note="H -> Y (in a sporadic case of non-syndromic hearing FT loss; dbSNP:rs996035812)" FT /evidence="ECO:0000269|PubMed:14577002" FT /id="VAR_018168" FT VARIANT 1109 FT /note="V -> I (does not inhibit hyaluronic acid degradation FT activity; dbSNP:rs751807711)" FT /evidence="ECO:0000269|PubMed:14577002, FT ECO:0000269|PubMed:23509262" FT /id="VAR_018169" FT VARIANT 1169 FT /note="P -> A (in dbSNP:rs16972583)" FT /evidence="ECO:0000269|PubMed:14577002" FT /id="VAR_018170" FT CONFLICT 558..564 FT /note="HFHLAGD -> TRPPTRP (in Ref. 6; CAB94391)" FT /evidence="ECO:0000305" FT CONFLICT 862 FT /note="H -> T (in Ref. 7; AAG41059)" FT /evidence="ECO:0000305" SQ SEQUENCE 1361 AA; 152998 MW; 40CDFFB84F99516C CRC64; MGAAGRQDFL FKAMLTISWL TLTCFPGATS TVAAGCPDQS PELQPWNPGH DQDHHVHIGQ GKTLLLTSSA TVYSIHISEG GKLVIKDHDE PIVLRTRHIL IDNGGELHAG SALCPFQGNF TIILYGRADE GIQPDPYYGL KYIGVGKGGA LELHGQKKLS WTFLNKTLHP GGMAEGGYFF ERSWGHRGVI VHVIDPKSGT VIHSDRFDTY RSKKESERLV QYLNAVPDGR ILSVAVNDEG SRNLDDMARK AMTKLGSKHF LHLGFRHPWS FLTVKGNPSS SVEDHIEYHG HRGSAAARVF KLFQTEHGEY FNVSLSSEWV QDVEWTEWFD HDKVSQTKGG EKISDLWKAH PGKICNRPID IQATTMDGVN LSTEVVYKKG QDYRFACYDR GRACRSYRVR FLCGKPVRPK LTVTIDTNVN STILNLEDNV QSWKPGDTLV IASTDYSMYQ AEEFQVLPCR SCAPNQVKVA GKPMYLHIGE EIDGVDMRAE VGLLSRNIIV MGEMEDKCYP YRNHICNFFD FDTFGGHIKF ALGFKAAHLE GTELKHMGQQ LVGQYPIHFH LAGDVDERGG YDPPTYIRDL SIHHTFSRCV TVHGSNGLLI KDVVGYNSLG HCFFTEDGPE ERNTFDHCLG LLVKSGTLLP SDRDSKMCKM ITEDSYPGYI PKPRQDCNAV STFWMANPNN NLINCAAAGS EETGFWFIFH HVPTGPSVGM YSPGYSEHIP LGKFYNNRAH SNYRAGMIID NGVKTTEASA KDKRPFLSII SARYSPHQDA DPLKPREPAI IRHFIAYKNQ DHGAWLRGGD VWLDSCRFAD NGIGLTLASG GTFPYDDGSK QEIKNSLFVG ESGNVGTEMM DNRIWGPGGL DHSGRTLPIG QNFPIRGIQL YDGPINIQNC TFRKFVALEG RHTSALAFRL NNAWQSCPHN NVTGIAFEDV PITSRVFFGE PGPWFNQLDM DGDKTSVFHD VDGSVSEYPG SYLTKNDNWL VRHPDCINVP DWRGAICSGC YAQMYIQAYK TSNLRMKIIK NDFPSHPLYL EGALTRSTHY QQYQPVVTLQ KGYTIHWDQT APAELAIWLI NFNKGDWIRV GLCYPRGTTF SILSDVHNRL LKQTSKTGVF VRTLQMDKVE QSYPGRSHYY WDEDSGLLFL KLKAQNEREK FAFCSMKGCE RIKIKALIPK NAGVSDCTAT AYPKFTERAV VDVPMPKKLF GSQLKTKDHF LEVKMESSKQ HFFHLWNDFA YIEVDGKKYP SSEDGIQVVV IDGNQGRVVS HTSFRNSILQ GIPWQLFNYV ATIPDNSIVL MASKGRYVSR GPWTRVLEKL GADRGLKLKE QMAFVGFKGS FRPIWVTLDT EDHKAKIFQV VPIPVVKKKK L // ID CRNN_HUMAN Reviewed; 495 AA. AC Q9UBG3; B2RE60; Q8N613; DT 02-OCT-2007, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-2000, sequence version 1. DT 28-JAN-2026, entry version 171. DE RecName: Full=Cornulin; DE AltName: Full=53 kDa putative calcium-binding protein; DE AltName: Full=53 kDa squamous epithelial-induced stress protein; DE AltName: Full=58 kDa heat shock protein; DE AltName: Full=Squamous epithelial heat shock protein 53; DE AltName: Full=Tumor-related protein; GN Name=CRNN; GN Synonyms=C1orf10 {ECO:0000303|PubMed:30009832}, DRC1, PDRC1, GN SEP53 {ECO:0000303|PubMed:30009832}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND TISSUE SPECIFICITY. RC TISSUE=Fetal esophagus; RX PubMed=11056050; DOI=10.1006/geno.2000.6344; RA Xu Z., Wang M.-R., Xu X., Cai Y., Han Y.-L., Wu K.-M., Wang J., Chen B.-S., RA Wang X.-Q., Wu M.; RT "Novel human esophagus-specific gene c1orf10: cDNA cloning, gene structure, RT and frequent loss of expression in esophageal cancer."; RL Genomics 69:322-330(2000). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Esophagus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Skeletal muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP INDUCTION, TISSUE SPECIFICITY, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=11606197; DOI=10.1046/j.0014-2956.2001.02468.x; RA Yagui-Beltran A., Craig A.L., Lawrie L., Thompson D., Pospisilova S., RA Johnston D., Kernohan N., Hopwood D., Dillon J.F., Hupp T.R.; RT "The human oesophageal squamous epithelium exhibits a novel type of heat RT shock protein response."; RL Eur. J. Biochem. 268:5343-5355(2001). RN [7] RP SUBUNIT, INDUCTION, AND TISSUE SPECIFICITY. RX PubMed=15896671; DOI=10.1016/j.biocel.2005.02.005; RA Imai F.L., Uzawa K., Nimura Y., Moriya T., Imai M.A., Shiiba M., Bukawa H., RA Yokoe H., Tanzawa H.; RT "Chromosome 1 open reading frame 10 (C1orf10) gene is frequently down- RT regulated and inhibits cell proliferation in oral squamous cell RT carcinoma."; RL Int. J. Biochem. Cell Biol. 37:1641-1655(2005). RN [8] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=15854041; DOI=10.1111/j.0022-202x.2005.23694.x; RA Contzler R., Favre B., Huber M., Hohl D.; RT "Cornulin, a new member of the 'fused gene' family, is expressed during RT epidermal differentiation."; RL J. Invest. Dermatol. 124:990-997(2005). RN [9] RP TISSUE SPECIFICITY. RX PubMed=16466100; DOI=10.1177/000348940611500108; RA Johnston N., Dettmar P.W., Lively M.O., Postma G.N., Belafsky P.C., RA Birchall M., Koufman J.A.; RT "Effect of pepsin on laryngeal stress protein (Sep70, Sep53, and Hsp70) RT response: role in laryngopharyngeal reflux disease."; RL Ann. Otol. Rhinol. Laryngol. 115:47-58(2006). RN [10] RP INDUCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=16640557; DOI=10.1111/j.1742-4658.2006.05206.x; RA Darragh J., Hunter M., Pohler E., Nelson L., Dillon J.F., Nenutil R., RA Vojtesek B., Ross P.E., Kernohan N., Hupp T.R.; RT "The calcium-binding domain of the stress protein SEP53 is required for RT survival in response to deoxycholic acid-mediated injury."; RL FEBS J. 273:1930-1947(2006). RN [11] RP TISSUE SPECIFICITY. RX PubMed=17289885; DOI=10.1158/1078-0432.ccr-06-1577; RA Luthra M.G., Ajani J.A., Izzo J., Ensor J., Wu T.T., Rashid A., Zhang L., RA Phan A., Fukami N., Luthra R.; RT "Decreased expression of gene cluster at chromosome 1q21 defines molecular RT subgroups of chemoradiotherapy response in esophageal cancers."; RL Clin. Cancer Res. 13:912-919(2007). RN [12] RP FUNCTION, TISSUE SPECIFICITY, INDUCTION, AND POSSIBLE INVOLVEMENT IN RP PSORIASIS. RX PubMed=30009832; DOI=10.1016/j.jid.2018.06.184; RA Li C., Xiao L., Jia J., Li F., Wang X., Duan Q., Jing H., Yang P., Chen C., RA Wang Q., Liu J., Shao Y., Wang N., Zheng Y.; RT "Cornulin Is Induced in Psoriasis Lesions and Promotes Keratinocyte RT Proliferation via Phosphoinositide 3-Kinase/Akt Pathways."; RL J. Invest. Dermatol. 139:71-80(2019). RN [13] RP INVOLVEMENT IN ESCR, AND VARIANT ESCR SER-480. RX PubMed=19558548; DOI=10.1111/j.1349-7006.2009.01240.x; RA Zhang W., Chen X., Luo A., Lin D., Tan W., Liu Z.; RT "Genetic variants of C1orf10 and risk of esophageal squamous cell carcinoma RT in a Chinese population."; RL Cancer Sci. 100:1695-1700(2009). CC -!- FUNCTION: Promotes cell proliferation, G1/S cell cycle progression and CC induces expression of the cell cycle regulator CCND1 (PubMed:30009832). CC Regulates proliferation induced by pro-inflammatory cytokine response CC via activation of NFKB1 and PI3K/AKT signaling pathways CC (PubMed:30009832). {ECO:0000269|PubMed:30009832}. CC -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:15896671}. CC -!- INTERACTION: CC Q9UBG3; P61968: LMO4; NbExp=3; IntAct=EBI-3197866, EBI-2798728; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15854041, CC ECO:0000269|PubMed:16640557}. Note=Does not colocalize with TGM1. CC -!- TISSUE SPECIFICITY: Expressed in the basal skin layer (at protein CC level) (PubMed:30009832). Squamous epithelia cell-specific. Expressed CC in the esophagus (periphery of the cells of the granular and the upper CC spinous layers), foreskin (granular and lower cornified cells), scalp CC skin (granular layer), inner root sheath of the hair follicle and in CC primary keratinocytes (at protein level). Expressed in the squamous CC epithelium of the cervix, esophagus, foreskin and larynx. Expressed in CC the fetal bladder and scalp skin. Expressed at very low levels in the CC lung, kidney, uterus, skeletal muscle, heart and fetal brain. CC Undetectable or barely detectable in esophageal and oral squamous cell CC carcinoma compared with the matched adjacent normal esophageal mucosa. CC Undetectable or barely detectable in larynx and esophagus from patients CC with pH-documented laryngopharyngeal reflux (LPR). CC {ECO:0000269|PubMed:11056050, ECO:0000269|PubMed:11606197, CC ECO:0000269|PubMed:15854041, ECO:0000269|PubMed:15896671, CC ECO:0000269|PubMed:16466100, ECO:0000269|PubMed:16640557, CC ECO:0000269|PubMed:17289885, ECO:0000269|PubMed:30009832}. CC -!- INDUCTION: Up-regulated after heat shock, ponasterone A and deoxycholic CC acid (PubMed:15896671, PubMed:16640557). Induced in response to pro- CC inflammatory cytokines (PubMed:30009832). {ECO:0000269|PubMed:11606197, CC ECO:0000269|PubMed:15896671, ECO:0000269|PubMed:16640557, CC ECO:0000269|PubMed:30009832}. CC -!- DOMAIN: The EF-hand is necessary for the colony survival activity to CC protect cells from death induced by exposure to DCA. CC -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the CC esophagus. The most common types are esophageal squamous cell carcinoma CC and adenocarcinoma. Cancer of the esophagus remains a devastating CC disease because it is usually not detected until it has progressed to CC an advanced incurable stage. {ECO:0000269|PubMed:19558548}. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. CC -!- DISEASE: Note=CRNN expression is increased in psoriasis patients CC suggesting a potential role in disease pathogenesis. CC {ECO:0000269|PubMed:30009832}. CC -!- SIMILARITY: Belongs to the S100-fused protein family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF077831; AAD55747.1; -; mRNA. DR EMBL; AF185276; AAF00514.1; -; Genomic_DNA. DR EMBL; AK316568; BAG38157.1; -; mRNA. DR EMBL; AL135842; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471121; EAW53381.1; -; Genomic_DNA. DR EMBL; BC030807; AAH30807.1; -; mRNA. DR CCDS; CCDS1010.1; -. DR RefSeq; NP_057274.1; NM_016190.3. DR AlphaFoldDB; Q9UBG3; -. DR SMR; Q9UBG3; -. DR BioGRID; 119069; 104. DR FunCoup; Q9UBG3; 285. DR IntAct; Q9UBG3; 78. DR MINT; Q9UBG3; -. DR STRING; 9606.ENSP00000271835; -. DR iPTMnet; Q9UBG3; -. DR PhosphoSitePlus; Q9UBG3; -. DR BioMuta; CRNN; -. DR DMDM; 74761891; -. DR jPOST; Q9UBG3; -. DR MassIVE; Q9UBG3; -. DR PaxDb; 9606-ENSP00000271835; -. DR PeptideAtlas; Q9UBG3; -. DR PRIDE; Q9UBG3; -. DR ProteomicsDB; 83965; -. DR Pumba; Q9UBG3; -. DR Antibodypedia; 20343; 141 antibodies from 26 providers. DR DNASU; 49860; -. DR Ensembl; ENST00000271835.3; ENSP00000271835.3; ENSG00000143536.7. DR GeneID; 49860; -. DR KEGG; hsa:49860; -. DR MANE-Select; ENST00000271835.3; ENSP00000271835.3; NM_016190.3; NP_057274.1. DR UCSC; uc001ezx.3; human. DR AGR; HGNC:1230; -. DR ClinPGx; PA25601; -. DR CTD; 49860; -. DR DisGeNET; 49860; -. DR GeneCards; CRNN; -. DR HGNC; HGNC:1230; CRNN. DR HPA; ENSG00000143536; Tissue enhanced (esophagus, vagina). DR MalaCards; CRNN; -. DR MIM; 133239; phenotype. DR MIM; 611312; gene. DR OpenTargets; ENSG00000143536; -. DR VEuPathDB; HostDB:ENSG00000143536; -. DR eggNOG; ENOG502SATM; Eukaryota. DR GeneTree; ENSGT00940000162465; -. DR HOGENOM; CLU_043278_0_0_1; -. DR InParanoid; Q9UBG3; -. DR OMA; EWVDDHS; -. DR OrthoDB; 9451669at2759; -. DR PAN-GO; Q9UBG3; 6 GO annotations based on evolutionary models. DR PhylomeDB; Q9UBG3; -. DR PathwayCommons; Q9UBG3; -. DR SignaLink; Q9UBG3; -. DR Agora; ENSG00000143536; -. DR BioGRID-ORCS; 49860; 7 hits in 1136 CRISPR screens. DR GenomeRNAi; 49860; -. DR Pharos; Q9UBG3; Tbio. DR PRO; PR:Q9UBG3; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q9UBG3; protein. DR Bgee; ENSG00000143536; Expressed in lower esophagus mucosa and 91 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0005509; F:calcium ion binding; IBA:GO_Central. DR GO; GO:0048306; F:calcium-dependent protein binding; IBA:GO_Central. DR GO; GO:0046914; F:transition metal ion binding; IEA:InterPro. DR GO; GO:0098609; P:cell-cell adhesion; IDA:UniProtKB. DR GO; GO:0071345; P:cellular response to cytokine stimulus; IDA:UniProtKB. DR GO; GO:1902808; P:positive regulation of cell cycle G1/S phase transition; IMP:UniProtKB. DR GO; GO:0010838; P:positive regulation of keratinocyte proliferation; IMP:UniProtKB. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB. DR GO; GO:0010468; P:regulation of gene expression; IMP:UniProtKB. DR GO; GO:0051896; P:regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:UniProtKB. DR GO; GO:0009408; P:response to heat; IDA:UniProtKB. DR CDD; cd00213; S-100; 1. DR FunFam; 1.10.238.10:FF:000303; Cornulin; 1. DR Gene3D; 1.10.238.10; EF-hand; 1. DR InterPro; IPR011992; EF-hand-dom_pair. DR InterPro; IPR018247; EF_Hand_1_Ca_BS. DR InterPro; IPR002048; EF_hand_dom. DR InterPro; IPR034325; S-100_dom. DR InterPro; IPR013787; S100_Ca-bd_sub. DR PANTHER; PTHR11639:SF26; CORNULIN; 1. DR PANTHER; PTHR11639; S100 CALCIUM-BINDING PROTEIN; 1. DR Pfam; PF01023; S_100; 1. DR SMART; SM00054; EFh; 1. DR SMART; SM01394; S_100; 1. DR SUPFAM; SSF47473; EF-hand; 1. DR PROSITE; PS00018; EF_HAND_1; 1. DR PROSITE; PS50222; EF_HAND_2; 1. PE 1: Evidence at protein level; KW Calcium; Cytoplasm; Disease variant; Metal-binding; KW Proteomics identification; Reference proteome. FT CHAIN 1..495 FT /note="Cornulin" FT /id="PRO_0000305586" FT DOMAIN 49..84 FT /note="EF-hand" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT REGION 96..439 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 460..481 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 99..110 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 137..151 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 152..194 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 196..222 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 226..242 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 243..282 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 290..303 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 307..324 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 334..355 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 374..385 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 403..420 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 460..473 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 62 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 64 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 66 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 68 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 73 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT VARIANT 27 FT /note="A -> V (in dbSNP:rs35639220)" FT /id="VAR_048469" FT VARIANT 374 FT /note="Q -> H (in dbSNP:rs6695830)" FT /id="VAR_048470" FT VARIANT 480 FT /note="G -> S (in ESCR; dbSNP:rs3829868)" FT /evidence="ECO:0000269|PubMed:19558548" FT /id="VAR_048471" SQ SEQUENCE 495 AA; 53533 MW; C4882A11B4E64DC3 CRC64; MPQLLQNING IIEAFRRYAR TEGNCTALTR GELKRLLEQE FADVIVKPHD PATVDEVLRL LDEDHTGTVE FKEFLVLVFK VAQACFKTLS ESAEGACGSQ ESGSLHSGAS QELGEGQRSG TEVGRAGKGQ HYEGSSHRQS QQGSRGQNRP GVQTQGQATG SAWVSSYDRQ AESQSQERIS PQIQLSGQTE QTQKAGEGKR NQTTEMRPER QPQTREQDRA HQTGETVTGS GTQTQAGATQ TVEQDSSHQT GRTSKQTQEA TNDQNRGTET HGQGRSQTSQ AVTGGHAQIQ AGTHTQTPTQ TVEQDSSHQT GSTSTQTQES TNGQNRGTEI HGQGRSQTSQ AVTGGHTQIQ AGSHTETVEQ DRSQTVSHGG AREQGQTQTQ PGSGQRWMQV SNPEAGETVP GGQAQTGAST ESGRQEWSST HPRRCVTEGQ GDRQPTVVGE EWVDDHSRET VILRLDQGNL HTSVSSAQGQ DAAQSEEKRG ITARELYSYL RSTKP // ID DAPK3_HUMAN Reviewed; 454 AA. AC O43293; A0AVN4; B3KQE2; Q05JY4; DT 28-NOV-2003, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-1998, sequence version 1. DT 28-JAN-2026, entry version 218. DE RecName: Full=Death-associated protein kinase 3; DE Short=DAP kinase 3; DE EC=2.7.11.1 {ECO:0000269|PubMed:10356987, ECO:0000269|PubMed:11384979, ECO:0000269|PubMed:11781833, ECO:0000269|PubMed:15096528, ECO:0000269|PubMed:17126281, ECO:0000269|PubMed:18995835}; DE AltName: Full=DAP-like kinase; DE Short=Dlk; DE AltName: Full=MYPT1 kinase; DE AltName: Full=Zipper-interacting protein kinase; DE Short=ZIP-kinase; GN Name=DAPK3; Synonyms=ZIPK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9488481; DOI=10.1128/mcb.18.3.1642; RA Kawai T., Matsumoto M., Takeda K., Sanjo H., Akira S.; RT "ZIP kinase, a novel serine/threonine kinase which mediates apoptosis."; RL Mol. Cell. Biol. 18:1642-1651(1998). RN [2] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, AND COFACTOR. RC TISSUE=Cervix carcinoma; RX PubMed=10356987; DOI=10.1016/s0014-5793(99)00550-5; RA Murata-Hori M., Suizu F., Iwasaki T., Kikuchi A., Hosoya H.; RT "ZIP kinase identified as a novel myosin regulatory light chain kinase in RT HeLa cells."; RL FEBS Lett. 451:81-84(1999). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 165-454 (ISOFORM 2), ALTERNATIVE SPLICING, RP FUNCTION IN PHOSPHORYLATION OF MYOSIN; PPP1R12A AND MYL12B, CATALYTIC RP ACTIVITY, SUBCELLULAR LOCATION, BIOPHYSICOCHEMICAL PROPERTIES, INTERACTION RP WITH PPP1R12A AND MYOSIN, AUTOPHOSPHORYLATION, AND TISSUE SPECIFICITY. RC TISSUE=Urinary bladder; RX PubMed=17126281; DOI=10.1016/j.abb.2006.09.026; RA Takamoto N., Komatsu S., Komaba S., Niiro N., Ikebe M.; RT "Novel ZIP kinase isoform lacks leucine zipper."; RL Arch. Biochem. Biophys. 456:194-203(2006). RN [6] RP FUNCTION IN PHOSPHORYLATION OF MUSCLE MYL12B, AND CATALYTIC ACTIVITY. RX PubMed=11384979; DOI=10.1074/jbc.m102753200; RA Niiro N., Ikebe M.; RT "Zipper-interacting protein kinase induces Ca(2+)-free smooth muscle RT contraction via myosin light chain phosphorylation."; RL J. Biol. Chem. 276:29567-29574(2001). RN [7] RP FUNCTION IN PHOSPHORYLATION OF NON-MUSCLE MYL12B, AND CATALYTIC ACTIVITY. RX PubMed=11781833; DOI=10.1038/sj.onc.1205055; RA Murata-Hori M., Fukuta Y., Ueda K., Iwasaki T., Hosoya H.; RT "HeLa ZIP kinase induces diphosphorylation of myosin II regulatory light RT chain and reorganization of actin filaments in nonmuscle cells."; RL Oncogene 20:8175-8183(2001). RN [8] {ECO:0000305} RP FUNCTION IN APOPTOSIS, AND INTERACTION WITH DAXX AND PAWR. RX PubMed=12917339; DOI=10.1128/mcb.23.17.6174-6186.2003; RA Kawai T., Akira S., Reed J.C.; RT "ZIP kinase triggers apoptosis from nuclear PML oncogenic domains."; RL Mol. Cell. Biol. 23:6174-6186(2003). RN [9] RP INTERACTION WITH PPP1R12A, AND TISSUE SPECIFICITY. RX PubMed=15292222; DOI=10.1074/jbc.m403676200; RA Endo A., Surks H.K., Mochizuki S., Mochizuki N., Mendelsohn M.E.; RT "Identification and characterization of zipper-interacting protein kinase RT as the unique vascular smooth muscle myosin phosphatase-associated RT kinase."; RL J. Biol. Chem. 279:42055-42061(2004). RN [10] RP FUNCTION IN PHOSPHORYLATION OF MYL12B, AND CATALYTIC ACTIVITY. RX PubMed=15096528; DOI=10.1083/jcb.200309056; RA Komatsu S., Ikebe M.; RT "ZIP kinase is responsible for the phosphorylation of myosin II and RT necessary for cell motility in mammalian fibroblasts."; RL J. Cell Biol. 165:243-254(2004). RN [11] RP FUNCTION, PHOSPHORYLATION AT THR-299; SER-309; SER-311; SER-312; SER-318 RP AND SER-326, PHOSPHORYLATION BY DAPK1, AND SUBCELLULAR LOCATION. RX PubMed=15367680; DOI=10.1128/mcb.24.19.8611-8626.2004; RA Shani G., Marash L., Gozuacik D., Bialik S., Teitelbaum L., Shohat G., RA Kimchi A.; RT "Death-associated protein kinase phosphorylates ZIP kinase, forming a RT unique kinase hierarchy to activate its cell death functions."; RL Mol. Cell. Biol. 24:8611-8626(2004). RN [12] RP INTERACTION WITH STAT3. RX PubMed=16219639; DOI=10.1093/intimm/dxh331; RA Sato N., Kawai T., Sugiyama K., Muromoto R., Imoto S., Sekine Y., RA Ishida M., Akira S., Matsuda T.; RT "Physical and functional interactions between STAT3 and ZIP kinase."; RL Int. Immunol. 17:1543-1552(2005). RN [13] RP INTERACTION WITH TCP10L, AND SUBCELLULAR LOCATION. RX PubMed=15910542; DOI=10.1111/j.1365-2605.2005.00522.x; RA Yu H., Jiang D., Guo Z., Saiyin H., Guo J., Wang X., Yu L.; RT "TCP10L is expressed specifically in spermatogenic cells and binds to death RT associated protein kinase-3."; RL Int. J. Androl. 28:163-170(2005). RN [14] RP PHOSPHORYLATION AT THR-180; THR-225; THR-265; THR-299; THR-306 AND SER-311, RP ACTIVITY REGULATION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF THR-299; RP 299-THR-THR-300; VAL-427; VAL-434 AND LEU-441. RX PubMed=15611134; DOI=10.1074/jbc.m412538200; RA Graves P.R., Winkfield K.M., Haystead T.A.; RT "Regulation of zipper-interacting protein kinase activity in vitro and in RT vivo by multisite phosphorylation."; RL J. Biol. Chem. 280:9363-9374(2005). RN [15] RP REVIEW ON FUNCTION. RX PubMed=16756490; DOI=10.1146/annurev.biochem.75.103004.142615; RA Bialik S., Kimchi A.; RT "The death-associated protein kinases: structure, function, and beyond."; RL Annu. Rev. Biochem. 75:189-210(2006). RN [16] RP FUNCTION, ACTIVITY REGULATION, AUTOPHOSPHORYLATION, PHOSPHORYLATION AT RP THR-180; THR-265 AND THR-299, AND MUTAGENESIS OF LYS-42; ASP-161; THR-225; RP THR-265 AND THR-299. RX PubMed=17158456; DOI=10.1074/jbc.m609990200; RA Hagerty L., Weitzel D.H., Chambers J., Fortner C.N., Brush M.H., RA Loiselle D., Hosoya H., Haystead T.A.; RT "ROCK1 phosphorylates and activates zipper-interacting protein kinase."; RL J. Biol. Chem. 282:4884-4893(2007). RN [17] RP SUBCELLULAR LOCATION, AND ABSENCE OF INTERACTION WITH PARW. RX PubMed=17953487; DOI=10.1371/journal.pgen.0030180; RA Shoval Y., Pietrokovski S., Kimchi A.; RT "ZIPK: a unique case of murine-specific divergence of a conserved RT vertebrate gene."; RL PLoS Genet. 3:1884-1893(2007). RN [18] RP REVIEW ON FUNCTION. RX DOI=10.1002/sita.200600112; RA Scheidtmann K.H.; RT "Dlk/ZIP kinase, a novel Ser/Thr-specific protein kinase with multiple RT functions."; RL Signal Transduct. 7:248-259(2007). RN [19] RP FUNCTION IN PHOSPHORYLATION OF RPL13A, AND CATALYTIC ACTIVITY. RX PubMed=18995835; DOI=10.1016/j.molcel.2008.09.019; RA Mukhopadhyay R., Ray P.S., Arif A., Brady A.K., Kinter M., Fox P.L.; RT "DAPK-ZIPK-L13a axis constitutes a negative-feedback module regulating RT inflammatory gene expression."; RL Mol. Cell 32:371-382(2008). RN [20] RP FUNCTION IN ANDROGEN RECEPTOR-MEDIATED TRANSCRIPTION. RX PubMed=18084323; DOI=10.1038/sj.onc.1210995; RA Leister P., Felten A., Chasan A.I., Scheidtmann K.H.; RT "ZIP kinase plays a crucial role in androgen receptor-mediated RT transcription."; RL Oncogene 27:3292-3300(2008). RN [21] RP FUNCTION AS TUMOR SUPPRESSOR, CHARACTERIZATION OF VARIANTS MET-112; ASN-161 RP AND SER-216, MUTAGENESIS OF THR-180, AND SELF-ASSOCIATION. RX PubMed=21487036; DOI=10.1158/0008-5472.can-10-3543; RA Brognard J., Zhang Y.W., Puto L.A., Hunter T.; RT "Cancer-associated loss-of-function mutations implicate DAPK3 as a tumor- RT suppressing kinase."; RL Cancer Res. 71:3152-3161(2011). RN [22] RP PHOSPHORYLATION AT THR-299, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP 294-ARG-ARG-295. RX PubMed=20854903; DOI=10.1016/j.cellsig.2010.09.016; RA Weitzel D.H., Chambers J., Haystead T.A.; RT "Phosphorylation-dependent control of ZIPK nuclear import is species RT specific."; RL Cell. Signal. 23:297-303(2011). RN [23] RP FUNCTION IN REGULATION OF AUTOPHAGY, AND INTERACTION WITH ULK1. RX PubMed=21169990; DOI=10.1038/emboj.2010.338; RA Tang H.W., Wang Y.B., Wang S.L., Wu M.H., Lin S.Y., Chen G.C.; RT "Atg1-mediated myosin II activation regulates autophagosome formation RT during starvation-induced autophagy."; RL EMBO J. 30:636-651(2011). RN [24] RP FUNCTION, AND INTERACTION WITH NLK. RX PubMed=21454679; DOI=10.1074/jbc.m110.189829; RA Togi S., Ikeda O., Kamitani S., Nakasuji M., Sekine Y., Muromoto R., RA Nanbo A., Oritani K., Kawai T., Akira S., Matsuda T.; RT "Zipper-interacting protein kinase (ZIPK) modulates canonical Wnt/beta- RT catenin signaling through interaction with Nemo-like kinase and T-cell RT factor 4 (NLK/TCF4)."; RL J. Biol. Chem. 286:19170-19177(2011). RN [25] RP FUNCTION, AND INTERACTION WITH ATF4. RX PubMed=21408167; DOI=10.1371/journal.pone.0017344; RA Shoval Y., Berissi H., Kimchi A., Pietrokovski S.; RT "New modularity of DAP-kinases: alternative splicing of the DRP-1 gene RT produces a ZIPk-like isoform."; RL PLoS ONE 6:E17344-E17344(2011). RN [26] RP FUNCTION IN REORGANIZATION OF ACTIN CYTOSKELETON, AND INTERACTION WITH RP RHOD. RX PubMed=23454120; DOI=10.1016/j.bbrc.2013.02.046; RA Nehru V., Almeida F.N., Aspenstrom P.; RT "Interaction of RhoD and ZIP kinase modulates actin filament assembly and RT focal adhesion dynamics."; RL Biochem. Biophys. Res. Commun. 433:163-169(2013). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-312, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [28] RP FUNCTION, INTERACTION WITH LUZP1, AND SUBCELLULAR LOCATION. RX PubMed=38009294; DOI=10.1111/febs.17017; RA Hyodo T., Asano-Inami E., Ito S., Sugiyama M., Nawa A., Rahman M.L., RA Hasan M.N., Mihara Y., Lam V.Q., Karnan S., Ota A., Tsuzuki S., RA Hamaguchi M., Hosokawa Y., Konishi H.; RT "Leucine zipper protein 1 (LUZP1) regulates the constriction velocity of RT the contractile ring during cytokinesis."; RL FEBS J. 291:927-944(2024). RN [29] RP X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 1-277. RA Kursula P., Vahokoski J., Wilmanns M.; RT "Crystal structure of human ZIP kinase."; RL Submitted (JUN-2006) to the PDB data bank. RN [30] {ECO:0007744|PDB:2J90} RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 9-289 IN COMPLEX WITH PYRIDONE-6, RP ACTIVITY REGULATION, SUBUNIT, AND PHOSPHORYLATION AT SER-50 AND THR-265. RX PubMed=18239682; DOI=10.1038/emboj.2008.8; RA Pike A.C., Rellos P., Niesen F.H., Turnbull A., Oliver A.W., Parker S.A., RA Turk B.E., Pearl L.H., Knapp S.; RT "Activation segment dimerization: a mechanism for kinase RT autophosphorylation of non-consensus sites."; RL EMBO J. 27:704-714(2008). RN [31] RP VARIANTS [LARGE SCALE ANALYSIS] MET-112; ASN-161 AND SER-216. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine kinase which is involved in the regulation CC of apoptosis, autophagy, transcription, translation and actin CC cytoskeleton reorganization. Involved in the regulation of smooth CC muscle contraction. Regulates both type I (caspase-dependent) apoptotic CC and type II (caspase-independent) autophagic cell deaths signal, CC depending on the cellular setting. Involved in regulation of CC starvation-induced autophagy. Regulates myosin phosphorylation in both CC smooth muscle and non-muscle cells. In smooth muscle, regulates myosin CC either directly by phosphorylating MYL12B and MYL9 or through CC inhibition of smooth muscle myosin phosphatase (SMPP1M) via CC phosphorylation of PPP1R12A; the inhibition of SMPP1M functions to CC enhance muscle responsiveness to Ca(2+) and promote a contractile CC state. Phosphorylates MYL12B in non-muscle cells leading to CC reorganization of actin cytoskeleton. Isoform 2 can phosphorylate CC myosin, PPP1R12A and MYL12B. Overexpression leads to condensation of CC actin stress fibers into thick bundles. Involved in actin filament CC focal adhesion dynamics. The function in both reorganization of actin CC cytoskeleton and focal adhesion dissolution is modulated by RhoD. CC Positively regulates canonical Wnt/beta-catenin signaling through CC interaction with NLK and TCF7L2. Phosphorylates RPL13A on 'Ser-77' upon CC interferon-gamma activation which is causing RPL13A release from the CC ribosome, RPL13A association with the GAIT complex and its subsequent CC involvement in transcript-selective translation inhibition. Enhances CC transcription from AR-responsive promoters in a hormone- and kinase- CC dependent manner. Involved in regulation of cell cycle progression and CC cell proliferation. May be a tumor suppressor. CC {ECO:0000269|PubMed:10356987, ECO:0000269|PubMed:11384979, CC ECO:0000269|PubMed:11781833, ECO:0000269|PubMed:12917339, CC ECO:0000269|PubMed:15096528, ECO:0000269|PubMed:15367680, CC ECO:0000269|PubMed:16219639, ECO:0000269|PubMed:17126281, CC ECO:0000269|PubMed:17158456, ECO:0000269|PubMed:18084323, CC ECO:0000269|PubMed:18995835, ECO:0000269|PubMed:21169990, CC ECO:0000269|PubMed:21408167, ECO:0000269|PubMed:21454679, CC ECO:0000269|PubMed:21487036, ECO:0000269|PubMed:23454120, CC ECO:0000269|PubMed:38009294}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10356987, ECO:0000269|PubMed:11384979, CC ECO:0000269|PubMed:11781833, ECO:0000269|PubMed:15096528, CC ECO:0000269|PubMed:17126281, ECO:0000269|PubMed:18995835}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10356987, ECO:0000269|PubMed:11384979, CC ECO:0000269|PubMed:11781833, ECO:0000269|PubMed:15096528, CC ECO:0000269|PubMed:17126281, ECO:0000269|PubMed:18995835}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:10356987}; CC -!- ACTIVITY REGULATION: A sequential activation is proposed: CC autophosphorylation at consensus sites is leading to dimerization of CC the catalytic domain stabilized by phosphorylation at Ser-50 and CC activation segment exchange (producing an active confirmation of both CC kinase modules in trans) followed by phosphorylation at Thr-180 in the CC activation segment and at other regulatory sites (Probable). CC Phosphorylation at Thr-180, Thr-225 and Thr-265 is essential for CC activity. Oligomerization is required for full enzymatic activity. CC Inhibited by pyridone-6 (K00225), a potent, ATP-competitive inhibitor. CC {ECO:0000269|PubMed:15611134, ECO:0000269|PubMed:17158456, CC ECO:0000269|PubMed:18239682, ECO:0000303|PubMed:18239682}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=12 uM for myosin (isoform 2) {ECO:0000269|PubMed:17126281}; CC KM=6.2 uM for myosin (isoform 1) {ECO:0000269|PubMed:17126281}; CC KM=73 uM for MYL12B (isoform 2) {ECO:0000269|PubMed:17126281}; CC KM=10.4 uM for MYL12B (isoform 1) {ECO:0000269|PubMed:17126281}; CC Vmax=248 nmol/min/mg enzyme toward myosin (isoform 2) CC {ECO:0000269|PubMed:17126281}; CC Vmax=120 nmol/min/mg enzyme toward myosin (isoform 1) CC {ECO:0000269|PubMed:17126281}; CC Vmax=1.3 umol/min/mg enzyme toward MYL12B (isoform 2) CC {ECO:0000269|PubMed:17126281}; CC Vmax=271 nmol/min/mg enzyme toward MYL12B (isoform 1) CC {ECO:0000269|PubMed:17126281}; CC -!- SUBUNIT: Homooligomer in its kinase-active form (homotrimers and CC homodimers are reported); monomeric in its kinase-inactive form. CC Homodimerization is required for activation segment autophosphorylation CC (Probable). Isoform 1 and isoform 2 interact with myosin and PPP1R12A; CC interaction of isoform 1 with PPP1R12A is inhibited by RhoA dominant CC negative form. Interacts with NLK, DAXX, STAT3, RHOD (GTP-bound form) CC and TCP10L. Interacts with PAWR; the interaction is reported CC conflictingly: according to PubMed:17953487 does not interact with CC PAWR. Interacts with ULK1; may be a substrate of ULK1. Interacts with CC LUZP1; the interaction is likely to occur throughout the cell cycle and CC reduces the LUZP1-mediated suppression of MYL9 phosphorylation CC (PubMed:38009294). {ECO:0000269|PubMed:12917339, CC ECO:0000269|PubMed:15292222, ECO:0000269|PubMed:15910542, CC ECO:0000269|PubMed:16219639, ECO:0000269|PubMed:17126281, CC ECO:0000269|PubMed:18239682, ECO:0000269|PubMed:21169990, CC ECO:0000269|PubMed:21408167, ECO:0000269|PubMed:21454679, CC ECO:0000269|PubMed:23454120, ECO:0000269|PubMed:38009294, CC ECO:0000303|PubMed:18239682}. CC -!- INTERACTION: CC O43293; O43293: DAPK3; NbExp=3; IntAct=EBI-77293, EBI-77293; CC O43293; Q86V48: LUZP1; NbExp=3; IntAct=EBI-77293, EBI-350467; CC O43293; Q9UBE8: NLK; NbExp=3; IntAct=EBI-77293, EBI-366978; CC O43293; O14974: PPP1R12A; NbExp=5; IntAct=EBI-77293, EBI-351726; CC O43293; Q8TDR4: TCP10L; NbExp=5; IntAct=EBI-77293, EBI-3923210; CC O43293-2; Q10728: Ppp1r12a; Xeno; NbExp=2; IntAct=EBI-9691390, EBI-918263; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15367680, CC ECO:0000269|PubMed:15910542, ECO:0000269|PubMed:20854903}. Nucleus, PML CC body {ECO:0000250|UniProtKB:O54784}. Cytoplasm, cytoskeleton, CC microtubule organizing center, centrosome CC {ECO:0000250|UniProtKB:O54784}. Chromosome, centromere CC {ECO:0000269|PubMed:38009294}. Cytoplasm {ECO:0000269|PubMed:15367680, CC ECO:0000269|PubMed:15611134, ECO:0000269|PubMed:17953487, CC ECO:0000269|PubMed:20854903}. Cytoplasm, cytoskeleton, spindle CC {ECO:0000269|PubMed:38009294}. Midbody {ECO:0000269|PubMed:38009294}. CC Note=Predominantly localizes to the cytoplasm but can shuttle between CC the nucleus and cytoplasm; cytoplasmic localization is promoted by CC phosphorylation at Thr-299 and involves Rho/Rock signaling. CC {ECO:0000269|PubMed:17953487, ECO:0000269|PubMed:20854903}. CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Nucleus CC {ECO:0000269|PubMed:17126281}. Cytoplasm {ECO:0000269|PubMed:17126281}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus CC {ECO:0000269|PubMed:17126281}. Cytoplasm {ECO:0000269|PubMed:17126281}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=ZIPK-L; CC IsoId=O43293-1; Sequence=Displayed; CC Name=2; Synonyms=ZIPK-S; CC IsoId=O43293-2; Sequence=VSP_042059, VSP_042060; CC -!- TISSUE SPECIFICITY: Widely expressed. Isoform 1 and isoform 2 are CC expressed in the bladder smooth muscle. {ECO:0000269|PubMed:15292222, CC ECO:0000269|PubMed:17126281}. CC -!- PTM: The phosphorylation status is critical for kinase activity, CC oligomerization and intracellular localization. Phosphorylation at Thr- CC 180, Thr-225 and Thr-265 is essential for activity. The phosphorylated CC form is localized in the cytoplasm promoted by phosphorylation at Thr- CC 299; nuclear translocation or retention is maximal when it is not CC phosphorylated. Phosphorylation increases the trimeric form, and its CC dephosphorylation favors a kinase-inactive monomeric form. Both isoform CC 1 and isoform 2 can undergo autophosphorylation. CC {ECO:0000269|PubMed:15367680, ECO:0000269|PubMed:15611134, CC ECO:0000269|PubMed:17158456, ECO:0000269|PubMed:20854903}. CC -!- MISCELLANEOUS: [Isoform 2]: The internal splice site between exon 8 and CC the 3' UTR, which yields this truncated isoform, is non-canonical. CC {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. DAP kinase subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB007144; BAA24955.1; -; mRNA. DR EMBL; AB022341; BAA81746.1; -; mRNA. DR EMBL; AK074799; BAG52004.1; -; mRNA. DR EMBL; BC126430; AAI26431.1; -; mRNA. DR EMBL; BC126432; AAI26433.1; -; mRNA. DR EMBL; AB265224; BAF34614.1; -; mRNA. DR CCDS; CCDS12116.1; -. [O43293-1] DR RefSeq; NP_001339.1; NM_001348.3. [O43293-1] DR RefSeq; NP_001362587.1; NM_001375658.1. [O43293-1] DR PDB; 1YRP; X-ray; 3.10 A; A/B=1-277. DR PDB; 2J90; X-ray; 2.00 A; A/B=9-289. DR PDB; 3BHY; X-ray; 1.24 A; A=9-289. DR PDB; 3BQR; X-ray; 1.75 A; A=9-289. DR PDB; 5A6N; X-ray; 1.70 A; A/B=9-289. DR PDB; 5A6O; X-ray; 1.60 A; A/B=9-289. DR PDB; 5VJA; X-ray; 2.46 A; A/B/C/D=9-289. DR PDBsum; 1YRP; -. DR PDBsum; 2J90; -. DR PDBsum; 3BHY; -. DR PDBsum; 3BQR; -. DR PDBsum; 5A6N; -. DR PDBsum; 5A6O; -. DR PDBsum; 5VJA; -. DR AlphaFoldDB; O43293; -. DR SMR; O43293; -. DR BioGRID; 107983; 101. DR FunCoup; O43293; 2772. DR IntAct; O43293; 75. DR MINT; O43293; -. DR STRING; 9606.ENSP00000442973; -. DR BindingDB; O43293; -. DR ChEMBL; CHEMBL2468; -. DR DrugBank; DB07242; (4R)-7,8-dichloro-1',9-dimethyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile. DR DrugBank; DB04716; 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one. DR DrugBank; DB07125; 4-(6-{[(1R)-1-(hydroxymethyl)propyl]amino}imidazo[1,2-b]pyridazin-3-yl)benzoic acid. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; O43293; -. DR GuidetoPHARMACOLOGY; 2004; -. DR GlyGen; O43293; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; O43293; -. DR PhosphoSitePlus; O43293; -. DR BioMuta; DAPK3; -. DR CPTAC; CPTAC-3091; -. DR CPTAC; CPTAC-3092; -. DR jPOST; O43293; -. DR MassIVE; O43293; -. DR PaxDb; 9606-ENSP00000442973; -. DR PeptideAtlas; O43293; -. DR ProteomicsDB; 48863; -. [O43293-1] DR ProteomicsDB; 48864; -. [O43293-2] DR Pumba; O43293; -. DR Antibodypedia; 11137; 420 antibodies from 44 providers. DR DNASU; 1613; -. DR Ensembl; ENST00000301264.7; ENSP00000301264.3; ENSG00000167657.15. [O43293-1] DR Ensembl; ENST00000545797.7; ENSP00000442973.1; ENSG00000167657.15. [O43293-1] DR GeneID; 1613; -. DR KEGG; hsa:1613; -. DR MANE-Select; ENST00000545797.7; ENSP00000442973.1; NM_001348.3; NP_001339.1. DR UCSC; uc002lzc.2; human. [O43293-1] DR AGR; HGNC:2676; -. DR ClinPGx; PA27144; -. DR CTD; 1613; -. DR DisGeNET; 1613; -. DR GeneCards; DAPK3; -. DR HGNC; HGNC:2676; DAPK3. DR HPA; ENSG00000167657; Low tissue specificity. DR MIM; 603289; gene. DR OpenTargets; ENSG00000167657; -. DR VEuPathDB; HostDB:ENSG00000167657; -. DR eggNOG; KOG0032; Eukaryota. DR GeneTree; ENSGT00940000161753; -. DR HOGENOM; CLU_000288_63_55_1; -. DR InParanoid; O43293; -. DR OMA; LWYKEEN; -. DR OrthoDB; 74764at2759; -. DR PAN-GO; O43293; 5 GO annotations based on evolutionary models. DR PhylomeDB; O43293; -. DR PathwayCommons; O43293; -. DR Reactome; R-HSA-418889; Caspase activation via Dependence Receptors in the absence of ligand. DR SABIO-RK; O43293; -. DR SignaLink; O43293; -. DR SIGNOR; O43293; -. DR Agora; ENSG00000167657; -. DR BioGRID-ORCS; 1613; 21 hits in 1190 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; DAPK3; human. DR EvolutionaryTrace; O43293; -. DR GeneWiki; DAPK3; -. DR GenomeRNAi; 1613; -. DR Pharos; O43293; Tchem. DR PRO; PR:O43293; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; O43293; protein. DR Bgee; ENSG00000167657; Expressed in apex of heart and 188 other cell types or tissues. DR ExpressionAtlas; O43293; baseline and differential. DR GO; GO:0005813; C:centrosome; IEA:UniProtKB-SubCell. DR GO; GO:0000775; C:chromosome, centromeric region; IDA:UniProtKB. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0030496; C:midbody; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell. DR GO; GO:0005819; C:spindle; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0008140; F:cAMP response element binding protein binding; TAS:ParkinsonsUK-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0043522; F:leucine zipper domain binding; IPI:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0031267; F:small GTPase binding; IDA:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IDA:UniProtKB. DR GO; GO:0097190; P:apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0071346; P:cellular response to type II interferon; IDA:UniProtKB. DR GO; GO:0006325; P:chromatin organization; IEA:UniProtKB-KW. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0017148; P:negative regulation of translation; IDA:UniProtKB. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0032956; P:regulation of actin cytoskeleton organization; IDA:UniProtKB. DR GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB. DR GO; GO:0010506; P:regulation of autophagy; TAS:UniProtKB. DR GO; GO:2000145; P:regulation of cell motility; TAS:UniProtKB. DR GO; GO:0008360; P:regulation of cell shape; IEA:Ensembl. DR GO; GO:0006355; P:regulation of DNA-templated transcription; TAS:UniProtKB. DR GO; GO:0051893; P:regulation of focal adhesion assembly; IDA:UniProtKB. DR GO; GO:0007346; P:regulation of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0007088; P:regulation of mitotic nuclear division; TAS:UniProtKB. DR GO; GO:0043519; P:regulation of myosin II filament organization; IEA:Ensembl. DR GO; GO:0006940; P:regulation of smooth muscle contraction; TAS:UniProtKB. DR CDD; cd14105; STKc_DAPK; 1. DR FunFam; 3.30.200.20:FF:000110; Death-associated kinase 3, isoform CRA_a; 1. DR FunFam; 1.10.510.10:FF:000250; Death-associated protein kinase 3; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR042870; DAPK3_STKc. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24342:SF18; DEATH-ASSOCIATED PROTEIN KINASE 3; 1. DR PANTHER; PTHR24342; SERINE/THREONINE-PROTEIN KINASE 17; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative splicing; Apoptosis; ATP-binding; KW Centromere; Chromatin regulator; Chromosome; Cytoplasm; Cytoskeleton; KW Kinase; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transcription; Transcription regulation; KW Transferase; Translation regulation; Tumor suppressor. FT CHAIN 1..454 FT /note="Death-associated protein kinase 3" FT /id="PRO_0000085914" FT DOMAIN 13..275 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 161..204 FT /note="Activation segment" FT /evidence="ECO:0000250|UniProtKB:O96017" FT REGION 427..441 FT /note="Leucine-zipper" FT /evidence="ECO:0000303|PubMed:9488481" FT ACT_SITE 139 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 19..27 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 42 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT BINDING 94 FT /ligand="pyridone 6" FT /ligand_id="ChEBI:CHEBI:87103" FT /ligand_note="inhibitor" FT /evidence="ECO:0000269|PubMed:18239682, FT ECO:0007744|PDB:2J90" FT BINDING 96 FT /ligand="pyridone 6" FT /ligand_id="ChEBI:CHEBI:87103" FT /ligand_note="inhibitor" FT /evidence="ECO:0000269|PubMed:18239682, FT ECO:0007744|PDB:2J90" FT MOD_RES 50 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18239682" FT MOD_RES 180 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:15611134, FT ECO:0000269|PubMed:17158456" FT MOD_RES 225 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:15611134" FT MOD_RES 265 FT /note="Phosphothreonine; by autocatalysis and ROCK1" FT /evidence="ECO:0000269|PubMed:15611134, FT ECO:0000269|PubMed:17158456, ECO:0000269|PubMed:18239682" FT MOD_RES 299 FT /note="Phosphothreonine; by autocatalysis, DAPK1 and ROCK1" FT /evidence="ECO:0000269|PubMed:15367680, FT ECO:0000269|PubMed:15611134, ECO:0000269|PubMed:17158456, FT ECO:0000269|PubMed:20854903" FT MOD_RES 306 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15611134" FT MOD_RES 309 FT /note="Phosphoserine; by DAPK1" FT /evidence="ECO:0000269|PubMed:15367680" FT MOD_RES 311 FT /note="Phosphoserine; by autocatalysis and DAPK1" FT /evidence="ECO:0000269|PubMed:15367680, FT ECO:0000269|PubMed:15611134" FT MOD_RES 312 FT /note="Phosphoserine; by DAPK1" FT /evidence="ECO:0000269|PubMed:15367680, FT ECO:0007744|PubMed:23186163" FT MOD_RES 318 FT /note="Phosphoserine; by DAPK1" FT /evidence="ECO:0000269|PubMed:15367680" FT MOD_RES 326 FT /note="Phosphoserine; by DAPK1" FT /evidence="ECO:0000269|PubMed:15367680" FT VAR_SEQ 313..322 FT /note="LPPNNSYADF -> ASPIVAPVDA (in isoform 2)" FT /evidence="ECO:0000303|PubMed:17126281" FT /id="VSP_042059" FT VAR_SEQ 323..454 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:17126281" FT /id="VSP_042060" FT VARIANT 112 FT /note="T -> M (in a colorectal adenocarcinoma sample; FT somatic mutation; greatly reduces kinase activity, FT increases cell proliferation and cell survival)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:21487036" FT /id="VAR_040438" FT VARIANT 161 FT /note="D -> N (in an ovarian mucinous carcinoma sample; FT somatic mutation; greatly reduces kinase activity, FT increases cell proliferation and cell survival)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:21487036" FT /id="VAR_040439" FT VARIANT 216 FT /note="P -> S (in a lung neuroendocrine carcinoma sample; FT somatic mutation; greatly reduces kinase activity, FT increases cell proliferation, cell adhesion and cell FT survival)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:21487036" FT /id="VAR_040440" FT MUTAGEN 42 FT /note="K->A: Loss of kinase activity at low concentrations FT of ATP." FT /evidence="ECO:0000269|PubMed:17158456" FT MUTAGEN 161 FT /note="D->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:17158456" FT MUTAGEN 180 FT /note="T->A: Greatly reduced kinase activity." FT /evidence="ECO:0000269|PubMed:21487036" FT MUTAGEN 225 FT /note="T->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:17158456" FT MUTAGEN 265 FT /note="T->A: Loss of phosphorylation by ROCK1, FT catalytically inactive." FT /evidence="ECO:0000269|PubMed:17158456" FT MUTAGEN 294..295 FT /note="RR->AA: Cytoplasmic localization." FT /evidence="ECO:0000269|PubMed:20854903" FT MUTAGEN 299..300 FT /note="TT->AA: Predominantly nuclear localization." FT /evidence="ECO:0000269|PubMed:15611134" FT MUTAGEN 299 FT /note="T->A: Loss of phosphorylation by ROCK1." FT /evidence="ECO:0000269|PubMed:17158456" FT MUTAGEN 299 FT /note="T->D: Predominantly cytoplasmic localization; FT phosphomimetic." FT /evidence="ECO:0000269|PubMed:15611134" FT MUTAGEN 427 FT /note="V->A: Predominantly nuclear localization; when FT associated with A-434 and A-441." FT /evidence="ECO:0000269|PubMed:15611134" FT MUTAGEN 434 FT /note="V->A: Predominantly nuclear localization; when FT associated with A-427 and A-441." FT /evidence="ECO:0000269|PubMed:15611134" FT MUTAGEN 441 FT /note="L->A: Predominantly nuclear localization; when FT associated with A-427 and A-434." FT /evidence="ECO:0000269|PubMed:15611134" FT HELIX 9..12 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 13..21 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 23..32 FT /evidence="ECO:0007829|PDB:3BHY" FT TURN 33..35 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 38..46 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 49..51 FT /evidence="ECO:0007829|PDB:2J90" FT STRAND 53..56 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 58..70 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 79..84 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 86..94 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 101..108 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 113..132 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 142..144 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 145..148 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 150..154 FT /evidence="ECO:0007829|PDB:3BHY" FT STRAND 157..159 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 171..175 FT /evidence="ECO:0007829|PDB:5A6N" FT HELIX 176..178 FT /evidence="ECO:0007829|PDB:5A6O" FT HELIX 181..183 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 186..189 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 197..212 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 222..230 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 238..241 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 246..253 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 260..262 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 266..271 FT /evidence="ECO:0007829|PDB:3BHY" FT HELIX 273..280 FT /evidence="ECO:0007829|PDB:3BHY" SQ SEQUENCE 454 AA; 52536 MW; 56773008A6A61CF0 CRC64; MSTFRQEDVE DHYEMGEELG SGQFAIVRKC RQKGTGKEYA AKFIKKRRLS SSRRGVSREE IEREVNILRE IRHPNIITLH DIFENKTDVV LILELVSGGE LFDFLAEKES LTEDEATQFL KQILDGVHYL HSKRIAHFDL KPENIMLLDK NVPNPRIKLI DFGIAHKIEA GNEFKNIFGT PEFVAPEIVN YEPLGLEADM WSIGVITYIL LSGASPFLGE TKQETLTNIS AVNYDFDEEY FSNTSELAKD FIRRLLVKDP KRRMTIAQSL EHSWIKAIRR RNVRGEDSGR KPERRRLKTT RLKEYTIKSH SSLPPNNSYA DFERFSKVLE EAAAAEEGLR ELQRSRRLCH EDVEALAAIY EEKEAWYREE SDSLGQDLRR LRQELLKTEA LKRQAQEEAK GALLGTSGLK RRFSRLENRY EALAKQVASE MRFVQDLVRA LEQEKLQGVE CGLR // ID DCLK1_HUMAN Reviewed; 740 AA. AC O15075; B7Z3E9; Q5VZY8; Q5VZZ0; Q5VZZ1; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 30-MAY-2000, sequence version 2. DT 28-JAN-2026, entry version 221. DE RecName: Full=Serine/threonine-protein kinase DCLK1; DE EC=2.7.11.1; DE AltName: Full=Doublecortin domain-containing protein 3A; DE AltName: Full=Doublecortin-like and CAM kinase-like 1; DE AltName: Full=Doublecortin-like kinase 1; GN Name=DCLK1; Synonyms=DCAMKL1, DCDC3A, KIAA0369; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3 AND 4). RX PubMed=9747029; DOI=10.1007/s100380050063; RA Omori Y., Suzuki M., Ozaki K., Harada Y., Nakamura Y., Takahashi E., RA Fujiwara T.; RT "Expression and chromosomal localization of KIAA0369, a putative kinase RT structurally related to Doublecortin."; RL J. Hum. Genet. 43:169-177(1998). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Fetal brain; RX PubMed=10036192; DOI=10.1006/geno.1998.5718; RA Sossey-Alaoui K., Srivastava A.K.; RT "DCAMKL1, a brain-specific transmembrane protein on 13q12.3 that is similar RT to doublecortin (DCX)."; RL Genomics 56:121-126(1999). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=9205841; DOI=10.1093/dnares/4.2.141; RA Nagase T., Ishikawa K., Nakajima D., Ohira M., Seki N., Miyajima N., RA Tanaka A., Kotani H., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. VII. The RT complete sequences of 100 new cDNA clones from brain which can code for RT large proteins in vitro."; RL DNA Res. 4:141-150(1997). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Hippocampus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057823; DOI=10.1038/nature02379; RA Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L., RA Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S., RA Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P., RA Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L., RA Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P., RA Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P., RA Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C., RA Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P., RA Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L., RA Frankish A.G., Frankland J., French L., Garner P., Garnett J., RA Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M., RA Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D., RA Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D., RA Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., RA Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S., RA Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S., RA Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R., RA Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W., RA Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P., RA Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L., RA Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R., RA Rogers J., Ross M.T.; RT "The DNA sequence and analysis of human chromosome 13."; RL Nature 428:522-528(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (FEB-2008) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP TISSUE SPECIFICITY. RX PubMed=10051403; DOI=10.1006/geno.1998.5673; RA Matsumoto N., Pilz D.T., Ledbetter D.H.; RT "Genomic structure, chromosomal mapping, and expression pattern of human RT DCAMKL1 (KIAA0369), a homologue of DCX (XLIS)."; RL Genomics 56:179-183(1999). RN [9] RP INDUCTION, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=16548883; DOI=10.1111/j.1462-5822.2005.00644.x; RA Leong W.F., Chow V.T.; RT "Transcriptomic and proteomic analyses of rhabdomyosarcoma cells reveal RT differential cellular gene expression in response to enterovirus 71 RT infection."; RL Cell. Microbiol. 8:565-580(2006). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-352, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [11] RP STRUCTURE BY NMR OF 51-156. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the N-terminal DCX domain of human doublecortin-like RT kinase."; RL Submitted (NOV-2003) to the PDB data bank. RN [12] RP VARIANTS [LARGE SCALE ANALYSIS] CYS-29; MET-46; GLN-93; PHE-291 AND RP HIS-292. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Probable kinase that may be involved in a calcium-signaling CC pathway controlling neuronal migration in the developing brain. May CC also participate in functions of the mature nervous system. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- INTERACTION: CC O15075; Q96M94: KLHL15; NbExp=2; IntAct=EBI-2684263, EBI-2510129; CC O15075-2; Q9UJX2: CDC23; NbExp=3; IntAct=EBI-12324841, EBI-396137; CC O15075-2; Q5JST6: EFHC2; NbExp=3; IntAct=EBI-12324841, EBI-2349927; CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Comment=Additional isoforms seem to exist. Type A (AS and AL) and CC type B (BS and BL) isoforms differ respectively by the presence or CC absence of the doublecortin domain. An alternative splicing occurring CC in 3' of the mRNA produces the long (L) instead of the short (S) CC isoforms.; CC Name=2; Synonyms=AL; CC IsoId=O15075-1; Sequence=Displayed; CC Name=1; Synonyms=AS; CC IsoId=O15075-2; Sequence=VSP_004907; CC Name=3; Synonyms=BS; CC IsoId=O15075-3; Sequence=VSP_004905, VSP_004906, VSP_004907; CC Name=4; Synonyms=BL; CC IsoId=O15075-4; Sequence=VSP_004905, VSP_004906; CC -!- TISSUE SPECIFICITY: In fetal tissues, highly expressed in brain, CC detectable in lung and liver, but not in kidney. In adult tissues, CC expressed ubiquitously in the brain, detectable in the heart, liver, CC spleen, thymus, prostate, testis, ovary, small intestine and colon. The CC type A isoforms seem to be expressed predominantly in fetal brain CC whereas type B isoforms are expressed abundantly in both fetal and CC adult brain. {ECO:0000269|PubMed:10051403}. CC -!- INDUCTION: Up-regulated in response to enterovirus 71 (EV71) infection CC (at protein level). {ECO:0000269|PubMed:16548883}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. CaMK subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA20824.2; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB002367; BAA20824.2; ALT_INIT; mRNA. DR EMBL; AL157760; CAH70167.1; -; Genomic_DNA. DR EMBL; AL157694; CAH70167.1; JOINED; Genomic_DNA. DR EMBL; AL160392; CAH70167.1; JOINED; Genomic_DNA. DR EMBL; AL390029; CAH70167.1; JOINED; Genomic_DNA. DR EMBL; AL157760; CAH70170.1; -; Genomic_DNA. DR EMBL; AK295777; BAH12185.1; -; mRNA. DR EMBL; AL157760; CAH70168.1; -; Genomic_DNA. DR EMBL; AL157694; CAH70168.1; JOINED; Genomic_DNA. DR EMBL; AL160392; CAH70168.1; JOINED; Genomic_DNA. DR EMBL; AL390029; CAH70168.1; JOINED; Genomic_DNA. DR EMBL; AL160392; CAH70261.1; -; Genomic_DNA. DR EMBL; AL157694; CAH70261.1; JOINED; Genomic_DNA. DR EMBL; AL157760; CAH70261.1; JOINED; Genomic_DNA. DR EMBL; AL390029; CAH70261.1; JOINED; Genomic_DNA. DR EMBL; AL160392; CAH70262.1; -; Genomic_DNA. DR EMBL; AL157694; CAH70262.1; JOINED; Genomic_DNA. DR EMBL; AL157760; CAH70262.1; JOINED; Genomic_DNA. DR EMBL; AL390029; CAH70262.1; JOINED; Genomic_DNA. DR EMBL; AL157694; CAH70656.1; -; Genomic_DNA. DR EMBL; AL157760; CAH70656.1; JOINED; Genomic_DNA. DR EMBL; AL160392; CAH70656.1; JOINED; Genomic_DNA. DR EMBL; AL390029; CAH70656.1; JOINED; Genomic_DNA. DR EMBL; AL157694; CAH70657.1; -; Genomic_DNA. DR EMBL; AL157760; CAH70657.1; JOINED; Genomic_DNA. DR EMBL; AL160392; CAH70657.1; JOINED; Genomic_DNA. DR EMBL; AL390029; CAH70657.1; JOINED; Genomic_DNA. DR EMBL; AL390029; CAI15720.1; -; Genomic_DNA. DR EMBL; AL157694; CAI15720.1; JOINED; Genomic_DNA. DR EMBL; AL157760; CAI15720.1; JOINED; Genomic_DNA. DR EMBL; AL160392; CAI15720.1; JOINED; Genomic_DNA. DR EMBL; AL390029; CAI15721.1; -; Genomic_DNA. DR EMBL; AL157694; CAI15721.1; JOINED; Genomic_DNA. DR EMBL; AL157760; CAI15721.1; JOINED; Genomic_DNA. DR EMBL; AL160392; CAI15721.1; JOINED; Genomic_DNA. DR EMBL; CH471075; EAX08550.1; -; Genomic_DNA. DR EMBL; CH471075; EAX08551.1; -; Genomic_DNA. DR EMBL; BC152456; AAI52457.1; -; mRNA. DR CCDS; CCDS55895.1; -. [O15075-4] DR CCDS; CCDS73561.1; -. [O15075-3] DR CCDS; CCDS81762.1; -. [O15075-1] DR CCDS; CCDS9354.1; -. [O15075-2] DR RefSeq; NP_001182344.1; NM_001195415.2. [O15075-3] DR RefSeq; NP_001182345.1; NM_001195416.2. [O15075-4] DR RefSeq; NP_001317000.1; NM_001330071.2. [O15075-1] DR RefSeq; NP_001317001.1; NM_001330072.2. [O15075-1] DR RefSeq; NP_004725.1; NM_004734.5. [O15075-2] DR PDB; 1MFW; X-ray; 1.60 A; A=49-154. DR PDB; 1MG4; X-ray; 1.50 A; A=49-154. DR PDB; 1UF0; NMR; -; A=54-156. DR PDB; 5JZJ; X-ray; 1.71 A; A/B=372-649. DR PDB; 5JZN; X-ray; 2.85 A; A/B=372-649. DR PDB; 6KYQ; X-ray; 2.14 A; A/B=379-704. DR PDB; 6KYR; X-ray; 2.21 A; A/B=379-704. DR PDB; 7F3G; X-ray; 2.10 A; A/B=372-649. DR PDB; 7KX6; X-ray; 2.50 A; A/B=372-649. DR PDB; 7KX8; X-ray; 3.10 A; A/B=372-686. DR PDB; 7KXW; X-ray; 3.00 A; A/B=372-649. DR PDBsum; 1MFW; -. DR PDBsum; 1MG4; -. DR PDBsum; 1UF0; -. DR PDBsum; 5JZJ; -. DR PDBsum; 5JZN; -. DR PDBsum; 6KYQ; -. DR PDBsum; 6KYR; -. DR PDBsum; 7F3G; -. DR PDBsum; 7KX6; -. DR PDBsum; 7KX8; -. DR PDBsum; 7KXW; -. DR AlphaFoldDB; O15075; -. DR SMR; O15075; -. DR BioGRID; 114635; 123. DR FunCoup; O15075; 1256. DR IntAct; O15075; 121. DR MINT; O15075; -. DR STRING; 9606.ENSP00000353846; -. DR BindingDB; O15075; -. DR ChEMBL; CHEMBL5683; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; O15075; -. DR GuidetoPHARMACOLOGY; 2005; -. DR CarbonylDB; O15075; -. DR GlyGen; O15075; 1 site, 1 N-linked glycan (1 site). DR iPTMnet; O15075; -. DR PhosphoSitePlus; O15075; -. DR SwissPalm; O15075; -. DR BioMuta; DCLK1; -. DR jPOST; O15075; -. DR MassIVE; O15075; -. DR PaxDb; 9606-ENSP00000255448; -. DR PeptideAtlas; O15075; -. DR ProteomicsDB; 48428; -. [O15075-1] DR ProteomicsDB; 48429; -. [O15075-2] DR ProteomicsDB; 48430; -. [O15075-3] DR ProteomicsDB; 48431; -. [O15075-4] DR Pumba; O15075; -. DR Antibodypedia; 23046; 446 antibodies from 40 providers. DR DNASU; 9201; -. DR Ensembl; ENST00000255448.8; ENSP00000255448.4; ENSG00000133083.16. [O15075-2] DR Ensembl; ENST00000360631.8; ENSP00000353846.3; ENSG00000133083.16. [O15075-1] DR Ensembl; ENST00000379893.5; ENSP00000369223.1; ENSG00000133083.16. [O15075-4] DR Ensembl; ENST00000615680.5; ENSP00000484452.1; ENSG00000133083.16. [O15075-3] DR GeneID; 9201; -. DR KEGG; hsa:9201; -. DR MANE-Select; ENST00000360631.8; ENSP00000353846.3; NM_001330071.2; NP_001317000.1. DR UCSC; uc001uve.4; human. [O15075-1] DR AGR; HGNC:2700; -. DR ClinPGx; PA162383325; -. DR CTD; 9201; -. DR DisGeNET; 9201; -. DR GeneCards; DCLK1; -. DR HGNC; HGNC:2700; DCLK1. DR HPA; ENSG00000133083; Tissue enhanced (brain). DR MIM; 604742; gene. DR OpenTargets; ENSG00000133083; -. DR VEuPathDB; HostDB:ENSG00000133083; -. DR eggNOG; KOG0032; Eukaryota. DR eggNOG; KOG3757; Eukaryota. DR GeneTree; ENSGT00940000154956; -. DR HOGENOM; CLU_000288_63_0_1; -. DR InParanoid; O15075; -. DR OMA; CWEFEGS; -. DR OrthoDB; 1738954at2759; -. DR PAN-GO; O15075; 1 GO annotation based on evolutionary models. DR PhylomeDB; O15075; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; O15075; -. DR SignaLink; O15075; -. DR SIGNOR; O15075; -. DR Agora; ENSG00000133083; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 9201; 13 hits in 1181 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; DCLK1; human. DR EvolutionaryTrace; O15075; -. DR GeneWiki; DCLK1; -. DR GenomeRNAi; 9201; -. DR Pharos; O15075; Tchem. DR PRO; PR:O15075; -. DR Proteomes; UP000005640; Chromosome 13. DR RNAct; O15075; protein. DR Bgee; ENSG00000133083; Expressed in endothelial cell and 188 other cell types or tissues. DR ExpressionAtlas; O15075; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005886; C:plasma membrane; TAS:ProtInc. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004672; F:protein kinase activity; TAS:ProtInc. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0048675; P:axon extension; IBA:GO_Central. DR GO; GO:0007417; P:central nervous system development; TAS:ProtInc. DR GO; GO:0016197; P:endosomal transport; NAS:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro. DR GO; GO:0007399; P:nervous system development; TAS:ProtInc. DR GO; GO:0034504; P:protein localization to nucleus; IBA:GO_Central. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0009615; P:response to virus; IEP:UniProtKB. DR CDD; cd17140; DCX1_DCLK1; 1. DR CDD; cd17069; DCX2; 1. DR CDD; cd14183; STKc_DCKL1; 1. DR FunFam; 3.10.20.230:FF:000003; Neuronal migration protein doublecortin; 1. DR FunFam; 1.10.510.10:FF:000066; Serine/threonine-protein kinase DCLK1 isoform 2; 1. DR FunFam; 3.30.200.20:FF:000057; Serine/threonine-protein kinase DCLK1 isoform 2; 1. DR FunFam; 3.10.20.230:FF:000001; serine/threonine-protein kinase DCLK1 isoform X1; 1. DR Gene3D; 3.10.20.230; Doublecortin domain; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR003533; Doublecortin_dom. DR InterPro; IPR036572; Doublecortin_dom_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24347; SERINE/THREONINE-PROTEIN KINASE; 1. DR Pfam; PF03607; DCX; 2. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00537; DCX; 2. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF89837; Doublecortin (DC); 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50309; DC; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Developmental protein; KW Differentiation; Kinase; Neurogenesis; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..740 FT /note="Serine/threonine-protein kinase DCLK1" FT /id="PRO_0000085919" FT DOMAIN 57..143 FT /note="Doublecortin 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00072" FT DOMAIN 186..269 FT /note="Doublecortin 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00072" FT DOMAIN 390..647 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 287..378 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 697..740 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 297..313 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 347..362 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 366..377 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 697..707 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 511 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 396..404 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 419 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 32 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 36 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 46 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 305 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 307 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 330 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 332 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 334 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 337 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 347 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 352 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 353 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O08875" FT MOD_RES 355 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 364 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 376 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 520 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 726 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 735 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT MOD_RES 738 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9JLM8" FT VAR_SEQ 1..307 FT /note="Missing (in isoform 3 and isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:9747029" FT /id="VSP_004905" FT VAR_SEQ 308..313 FT /note="PASTSS -> MLELIE (in isoform 3 and isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:9747029" FT /id="VSP_004906" FT VAR_SEQ 687..740 FT /note="TTALDKERQVFRRRRNQDVRSRYKAQPAPPELNSESEDYSPSSSETVRSPNS FT PF -> LDHGFTIKRSGSLDYYQQPGMYWIRPPLLIRRGRFSDEDATRM (in FT isoform 1 and isoform 3)" FT /evidence="ECO:0000303|PubMed:10036192, FT ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:9205841, ECO:0000303|PubMed:9747029" FT /id="VSP_004907" FT VARIANT 29 FT /note="G -> C (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045673" FT VARIANT 46 FT /note="T -> M (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045674" FT VARIANT 93 FT /note="R -> Q (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1366698690)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045675" FT VARIANT 291 FT /note="S -> F (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045676" FT VARIANT 292 FT /note="R -> H (in dbSNP:rs56185003)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045677" FT HELIX 53..55 FT /evidence="ECO:0007829|PDB:1MFW" FT STRAND 56..63 FT /evidence="ECO:0007829|PDB:1MG4" FT STRAND 72..76 FT /evidence="ECO:0007829|PDB:1MG4" FT TURN 78..80 FT /evidence="ECO:0007829|PDB:1MG4" FT HELIX 84..95 FT /evidence="ECO:0007829|PDB:1MG4" FT STRAND 98..101 FT /evidence="ECO:0007829|PDB:1MG4" FT STRAND 107..110 FT /evidence="ECO:0007829|PDB:1MG4" FT HELIX 120..122 FT /evidence="ECO:0007829|PDB:1MG4" FT STRAND 128..135 FT /evidence="ECO:0007829|PDB:1MG4" FT TURN 142..145 FT /evidence="ECO:0007829|PDB:1MG4" FT HELIX 148..151 FT /evidence="ECO:0007829|PDB:1MG4" FT HELIX 384..389 FT /evidence="ECO:0007829|PDB:5JZJ" FT STRAND 390..398 FT /evidence="ECO:0007829|PDB:5JZJ" FT STRAND 400..409 FT /evidence="ECO:0007829|PDB:5JZJ" FT TURN 410..412 FT /evidence="ECO:0007829|PDB:5JZJ" FT STRAND 415..422 FT /evidence="ECO:0007829|PDB:5JZJ" FT TURN 423..425 FT /evidence="ECO:0007829|PDB:6KYQ" FT STRAND 427..429 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 436..440 FT /evidence="ECO:0007829|PDB:5JZJ" FT STRAND 451..456 FT /evidence="ECO:0007829|PDB:5JZJ" FT STRAND 458..466 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 473..480 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 485..504 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 514..516 FT /evidence="ECO:0007829|PDB:5JZJ" FT STRAND 517..521 FT /evidence="ECO:0007829|PDB:5JZJ" FT STRAND 523..525 FT /evidence="ECO:0007829|PDB:7KX6" FT STRAND 527..531 FT /evidence="ECO:0007829|PDB:5JZJ" FT TURN 551..553 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 556..560 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 568..582 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 596..603 FT /evidence="ECO:0007829|PDB:5JZJ" FT TURN 610..615 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 618..627 FT /evidence="ECO:0007829|PDB:5JZJ" FT TURN 632..634 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 638..643 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 645..647 FT /evidence="ECO:0007829|PDB:5JZJ" FT HELIX 662..668 FT /evidence="ECO:0007829|PDB:6KYQ" FT TURN 678..682 FT /evidence="ECO:0007829|PDB:6KYQ" FT HELIX 683..686 FT /evidence="ECO:0007829|PDB:6KYQ" FT HELIX 689..691 FT /evidence="ECO:0007829|PDB:6KYQ" SQ SEQUENCE 740 AA; 82224 MW; D7B6D855099A315C CRC64; MSFGRDMELE HFDERDKAQR YSRGSRVNGL PSPTHSAHCS FYRTRTLQTL SSEKKAKKVR FYRNGDRYFK GIVYAISPDR FRSFEALLAD LTRTLSDNVN LPQGVRTIYT IDGLKKISSL DQLVEGESYV CGSIEPFKKL EYTKNVNPNW SVNVKTTSAS RAVSSLATAK GSPSEVRENK DFIRPKLVTI IRSGVKPRKA VRILLNKKTA HSFEQVLTDI TDAIKLDSGV VKRLYTLDGK QVMCLQDFFG DDDIFIACGP EKFRYQDDFL LDESECRVVK STSYTKIASS SRRSTTKSPG PSRRSKSPAS TSSVNGTPGS QLSTPRSGKS PSPSPTSPGS LRKQRSSQHG GSSTSLASTK VCSSMDENDG PGEEVSEEGF QIPATITERY KVGRTIGDGN FAVVKECVER STAREYALKI IKKSKCRGKE HMIQNEVSIL RRVKHPNIVL LIEEMDVPTE LYLVMELVKG GDLFDAITST NKYTERDASG MLYNLASAIK YLHSLNIVHR DIKPENLLVY EHQDGSKSLK LGDFGLATIV DGPLYTVCGT PTYVAPEIIA ETGYGLKVDI WAAGVITYIL LCGFPPFRGS GDDQEVLFDQ ILMGQVDFPS PYWDNVSDSA KELITMMLLV DVDQRFSAVQ VLEHPWVNDD GLPENEHQLS VAGKIKKHFN TGPKPNSTAA GVSVIATTAL DKERQVFRRR RNQDVRSRYK AQPAPPELNS ESEDYSPSSS ETVRSPNSPF // ID DCLK3_HUMAN Reviewed; 648 AA. AC Q9C098; DT 03-OCT-2006, integrated into UniProtKB/Swiss-Prot. DT 03-OCT-2006, sequence version 2. DT 28-JAN-2026, entry version 164. DE RecName: Full=Serine/threonine-protein kinase DCLK3; DE EC=2.7.11.1; DE AltName: Full=Doublecortin domain-containing protein 3C; DE AltName: Full=Doublecortin-like and CAM kinase-like 3; DE AltName: Full=Doublecortin-like kinase 3; GN Name=DCLK3; Synonyms=DCAMKL3, DCDC3C, KIAA1765; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-105. RC TISSUE=Brain; RX PubMed=11214970; DOI=10.1093/dnares/7.6.347; RA Nagase T., Kikuno R., Hattori A., Kondo Y., Okumura K., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XIX. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 7:347-355(2000). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 41-648. RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP VARIANTS [LARGE SCALE ANALYSIS] GLN-24; LEU-108; LYS-422; ASN-472; CYS-554; RP ARG-570; ALA-596 AND ASP-633. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus {ECO:0000250}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. CaMK subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; DA523113; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AB051552; BAB21856.1; -; mRNA. DR CCDS; CCDS43064.1; -. DR RefSeq; NP_208382.1; NM_033403.1. DR AlphaFoldDB; Q9C098; -. DR SMR; Q9C098; -. DR BioGRID; 124530; 6. DR FunCoup; Q9C098; 1100. DR IntAct; Q9C098; 8. DR STRING; 9606.ENSP00000394484; -. DR BindingDB; Q9C098; -. DR ChEMBL; CHEMBL6123; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q9C098; -. DR iPTMnet; Q9C098; -. DR PhosphoSitePlus; Q9C098; -. DR BioMuta; DCLK3; -. DR DMDM; 115502142; -. DR CPTAC; CPTAC-2832; -. DR CPTAC; CPTAC-2833; -. DR jPOST; Q9C098; -. DR MassIVE; Q9C098; -. DR PaxDb; 9606-ENSP00000394484; -. DR PeptideAtlas; Q9C098; -. DR ProteomicsDB; 79972; -. DR Antibodypedia; 28151; 105 antibodies from 30 providers. DR DNASU; 85443; -. DR Ensembl; ENST00000416516.2; ENSP00000394484.2; ENSG00000163673.9. DR GeneID; 85443; -. DR KEGG; hsa:85443; -. DR UCSC; uc003cgi.2; human. DR AGR; HGNC:19005; -. DR ClinPGx; PA162383403; -. DR CTD; 85443; -. DR DisGeNET; 85443; -. DR GeneCards; DCLK3; -. DR HGNC; HGNC:19005; DCLK3. DR HPA; ENSG00000163673; Tissue enhanced (brain, testis). DR MIM; 613167; gene. DR OpenTargets; ENSG00000163673; -. DR VEuPathDB; HostDB:ENSG00000163673; -. DR eggNOG; KOG0032; Eukaryota. DR GeneTree; ENSGT00940000159476; -. DR HOGENOM; CLU_000288_94_2_1; -. DR InParanoid; Q9C098; -. DR OMA; VRAQKKW; -. DR OrthoDB; 1738954at2759; -. DR PAN-GO; Q9C098; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q9C098; -. DR PathwayCommons; Q9C098; -. DR SignaLink; Q9C098; -. DR Agora; ENSG00000163673; -. DR BioGRID-ORCS; 85443; 15 hits in 1178 CRISPR screens. DR GenomeRNAi; 85443; -. DR Pharos; Q9C098; Tchem. DR PRO; PR:Q9C098; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q9C098; protein. DR Bgee; ENSG00000163673; Expressed in sural nerve and 98 other cell types or tissues. DR ExpressionAtlas; Q9C098; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0034504; P:protein localization to nucleus; IBA:GO_Central. DR CDD; cd14185; STKc_DCKL3; 1. DR FunFam; 1.10.510.10:FF:000066; Serine/threonine-protein kinase DCLK1 isoform 2; 1. DR FunFam; 3.30.200.20:FF:000057; Serine/threonine-protein kinase DCLK1 isoform 2; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24347; SERINE/THREONINE-PROTEIN KINASE; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW ATP-binding; Cytoplasm; Kinase; Nucleotide-binding; Nucleus; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..648 FT /note="Serine/threonine-protein kinase DCLK3" FT /id="PRO_0000252254" FT DOMAIN 356..613 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 86..127 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 150..345 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 628..648 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 98..127 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 213..234 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 255..266 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 277..303 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 312..338 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 477 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 362..370 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 385 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT VARIANT 24 FT /note="R -> Q (in dbSNP:rs56070233)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040444" FT VARIANT 108 FT /note="P -> L (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040445" FT VARIANT 422 FT /note="E -> K (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs373605259)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040446" FT VARIANT 472 FT /note="S -> N (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040447" FT VARIANT 554 FT /note="R -> C (in a lung squamous cell carcinoma sample; FT somatic mutation; dbSNP:rs374711533)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040448" FT VARIANT 570 FT /note="G -> R (in a renal clear cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040449" FT VARIANT 596 FT /note="V -> A (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040450" FT VARIANT 633 FT /note="E -> D (in dbSNP:rs35704209)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040451" SQ SEQUENCE 648 AA; 73814 MW; 09E37E51920F2A21 CRC64; MGKEPLTLKS IQVAVEELYP NKARALTLAQ HSRAPSPRLR SRLFSKALKG DHRCGETETP KSCSEVAGCK AAMRHQGKIP EELSLDDRAR TQKKWGRGKW EPEPSSKPPR EATLEERHAR GEKHLGVEIE KTSGEIIRCE KCKRERELQQ SLERERLSLG TSELDMGKGP MYDVEKLVRT RSCRRSPEAN PASGEEGWKG DSHRSSPRNP TQELRRPSKS MDKKEDRGPE DQESHAQGAA KAKKDLVEVL PVTEEGLREV KKDTRPMSRS KHGGWLLREH QAGFEKLRRT RGEEKEAEKE KKPCMSGGRR MTLRDDQPAK LEKEPKTRPE ENKPERPSGR KPRPMGIIAA NVEKHYETGR VIGDGNFAVV KECRHRETRQ AYAMKIIDKS RLKGKEDMVD SEILIIQSLS HPNIVKLHEV YETDMEIYLI LEYVQGGDLF DAIIESVKFP EPDAALMIMD LCKALVHMHD KSIVHRDLKP ENLLVQRNED KSTTLKLADF GLAKHVVRPI FTVCGTPTYV APEILSEKGY GLEVDMWAAG VILYILLCGF PPFRSPERDQ DELFNIIQLG HFEFLPPYWD NISDAAKDLV SRLLVVDPKK RYTAHQVLQH PWIETAGKTN TVKRQKQVSP SSEGHFRSQH KRVVEQVS // ID DEDD2_HUMAN Reviewed; 326 AA. AC Q8WXF8; Q8NBR2; Q8NES1; Q8TAA8; Q96D35; DT 10-MAY-2004, integrated into UniProtKB/Swiss-Prot. DT 01-MAR-2002, sequence version 1. DT 28-JAN-2026, entry version 176. DE RecName: Full=DNA-binding death effector domain-containing protein 2; DE AltName: Full=DED-containing protein FLAME-3; DE AltName: Full=FADD-like anti-apoptotic molecule 3; GN Name=DEDD2; Synonyms=FLAME3; ORFNames=PSEC0004; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND INTERACTION RP WITH CASP8. RX PubMed=11741985; DOI=10.1074/jbc.m110749200; RA Roth W., Stenner-Liewen F., Pawlowski K., Godzik A., Reed J.C.; RT "Identification and characterization of DEDD2, a death effector domain- RT containing protein."; RL J. Biol. Chem. 277:7501-7508(2002). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, SUBCELLULAR RP LOCATION, AND INTERACTION WITH CASP8 AND GTF3C3. RX PubMed=11965497; DOI=10.1038/sj.cdd.4401038; RA Zhan Y., Hegde R., Srinivasula S.M., Fernandes-Alnemri T., Alnemri E.S.; RT "Death effector domain-containing proteins DEDD and FLAME-3 form nuclear RT complexes with the TFIIIC102 subunit of human transcription factor IIIC."; RL Cell Death Differ. 9:439-447(2002). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RX PubMed=12235123; DOI=10.1083/jcb.200112124; RA Lee J.C., Schickling O., Stegh A.H., Oshima R.G., Dinsdale D., Cohen G.M., RA Peter M.E.; RT "DEDD regulates degradation of intermediate filaments during apoptosis."; RL J. Cell Biol. 158:1051-1066(2002). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Teratocarcinoma; RX PubMed=16303743; DOI=10.1093/dnares/12.2.117; RA Otsuki T., Ota T., Nishikawa T., Hayashi K., Suzuki Y., Yamamoto J., RA Wakamatsu A., Kimura K., Sakamoto K., Hatano N., Kawai Y., Ishii S., RA Saito K., Kojima S., Sugiyama T., Ono T., Okano K., Yoshikawa Y., RA Aotsuka S., Sasaki N., Hattori A., Okumura K., Nagai K., Sugano S., RA Isogai T.; RT "Signal sequence and keyword trap in silico for selection of full-length RT human cDNAs encoding secretion or membrane proteins from oligo-capped cDNA RT libraries."; RL DNA Res. 12:117-126(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Brain, and Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP INTERACTION WITH CASP8 AND CASP10. RX PubMed=12527898; DOI=10.1038/sj.onc.1206099; RA Alcivar A., Hu S., Tang J., Yang X.; RT "DEDD and DEDD2 associate with caspase-8/10 and signal cell death."; RL Oncogene 22:291-297(2003). CC -!- FUNCTION: May play a critical role in death receptor-induced apoptosis CC and may target CASP8 and CASP10 to the nucleus. May regulate CC degradation of intermediate filaments during apoptosis. May play a role CC in the general transcription machinery in the nucleus and might be an CC important regulator of the activity of GTF3C3. CC -!- SUBUNIT: Interacts with CASP8, CASP10 and GTF3C3. Homodimerizes and CC heterodimerizes with DEDD. {ECO:0000269|PubMed:11741985, CC ECO:0000269|PubMed:11965497, ECO:0000269|PubMed:12527898}. CC -!- SUBCELLULAR LOCATION: Nucleus, nucleolus {ECO:0000269|PubMed:11965497}. CC Note=Nuclear, accumulated in subnuclear structures resembling nucleoli. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q8WXF8-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8WXF8-2; Sequence=VSP_010312; CC -!- TISSUE SPECIFICITY: Expressed in most tissues. High levels were found CC in liver, kidney, heart, ovary, spleen, testes, skeletal muscle and CC peripheral blood leukocytes. Expression was absent or low in colon and CC small intestine. Expression is relatively high in the tumor cell lines CC chronic myologenous leukemia K-562 and the colorectal adenocarcinoma CC SW480. Expression is moderate in the cervical carcinoma HeLa, the CC Burkitt's lymphoma Raji, the lung carcinoma A-549, and the melanoma G- CC 361. In contrast, two leukemia cell lines, HL-60 (promyelocytic CC leukemia) and MOLT-4 (lymphoblastic leukemia), show relatively low CC levels. {ECO:0000269|PubMed:11741985, ECO:0000269|PubMed:11965497}. CC -!- DOMAIN: Interactions with CASP8 and CASP10 are mediated by the DED CC domain. CC -!- SEQUENCE CAUTION: CC Sequence=AAH13372.2; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF443591; AAL48220.1; -; mRNA. DR EMBL; AF457575; AAM10835.1; -; mRNA. DR EMBL; AY125488; AAM95240.1; -; mRNA. DR EMBL; AK075328; BAC11551.1; -; mRNA. DR EMBL; BC013372; AAH13372.2; ALT_FRAME; mRNA. DR EMBL; BC027930; AAH27930.1; -; mRNA. DR CCDS; CCDS12597.1; -. [Q8WXF8-1] DR CCDS; CCDS59391.1; -. [Q8WXF8-2] DR RefSeq; NP_001257543.1; NM_001270614.2. [Q8WXF8-1] DR RefSeq; NP_001257544.1; NM_001270615.2. [Q8WXF8-2] DR RefSeq; NP_579874.1; NM_133328.4. [Q8WXF8-1] DR RefSeq; XP_047294269.1; XM_047438313.1. [Q8WXF8-1] DR RefSeq; XP_054176029.1; XM_054320054.1. [Q8WXF8-1] DR AlphaFoldDB; Q8WXF8; -. DR SMR; Q8WXF8; -. DR BioGRID; 127838; 17. DR FunCoup; Q8WXF8; 1017. DR IntAct; Q8WXF8; 8. DR MINT; Q8WXF8; -. DR STRING; 9606.ENSP00000471512; -. DR iPTMnet; Q8WXF8; -. DR PhosphoSitePlus; Q8WXF8; -. DR BioMuta; DEDD2; -. DR DMDM; 47116024; -. DR MassIVE; Q8WXF8; -. DR PaxDb; 9606-ENSP00000470082; -. DR PeptideAtlas; Q8WXF8; -. DR ProteomicsDB; 75029; -. [Q8WXF8-1] DR ProteomicsDB; 75030; -. [Q8WXF8-2] DR Antibodypedia; 17411; 201 antibodies from 30 providers. DR DNASU; 162989; -. DR Ensembl; ENST00000336034.8; ENSP00000336972.4; ENSG00000160570.15. [Q8WXF8-2] DR Ensembl; ENST00000595337.5; ENSP00000470082.1; ENSG00000160570.15. [Q8WXF8-1] DR Ensembl; ENST00000596251.6; ENSP00000471512.1; ENSG00000160570.15. [Q8WXF8-1] DR GeneID; 162989; -. DR KEGG; hsa:162989; -. DR MANE-Select; ENST00000596251.6; ENSP00000471512.1; NM_133328.4; NP_579874.1. DR UCSC; uc002osu.3; human. [Q8WXF8-1] DR AGR; HGNC:24450; -. DR ClinPGx; PA134912744; -. DR CTD; 162989; -. DR DisGeNET; 162989; -. DR GeneCards; DEDD2; -. DR HGNC; HGNC:24450; DEDD2. DR HPA; ENSG00000160570; Low tissue specificity. DR OpenTargets; ENSG00000160570; -. DR VEuPathDB; HostDB:ENSG00000160570; -. DR eggNOG; ENOG502QQKR; Eukaryota. DR GeneTree; ENSGT00390000008714; -. DR HOGENOM; CLU_053869_0_0_1; -. DR InParanoid; Q8WXF8; -. DR OMA; GHPETHW; -. DR OrthoDB; 6422954at2759; -. DR PAN-GO; Q8WXF8; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q8WXF8; -. DR PathwayCommons; Q8WXF8; -. DR SignaLink; Q8WXF8; -. DR Agora; ENSG00000160570; -. DR BioGRID-ORCS; 162989; 13 hits in 1164 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; DEDD2; human. DR GenomeRNAi; 162989; -. DR Pharos; Q8WXF8; Tbio. DR PRO; PR:Q8WXF8; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q8WXF8; protein. DR Bgee; ENSG00000160570; Expressed in granulocyte and 184 other cell types or tissues. DR ExpressionAtlas; Q8WXF8; baseline and differential. DR GO; GO:0005730; C:nucleolus; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0003677; F:DNA binding; IBA:GO_Central. DR GO; GO:0030159; F:signaling receptor complex adaptor activity; NAS:UniProtKB. DR GO; GO:0030262; P:apoptotic nuclear changes; IDA:UniProtKB. DR GO; GO:0019725; P:cellular homeostasis; NAS:UniProtKB. DR GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IMP:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; NAS:UniProtKB. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; NAS:UniProtKB. DR GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; IMP:UniProtKB. DR GO; GO:0006396; P:RNA processing; NAS:UniProtKB. DR GO; GO:0016075; P:rRNA catabolic process; NAS:UniProtKB. DR FunFam; 1.10.533.10:FF:000023; DNA-binding death effector domain-containing protein 2; 1. DR Gene3D; 1.10.533.10; Death Domain, Fas; 1. DR InterPro; IPR011029; DEATH-like_dom_sf. DR InterPro; IPR001875; DED_dom. DR InterPro; IPR038856; DEDD/DEDD2. DR InterPro; IPR049341; TRADD-like_N. DR PANTHER; PTHR15205; DEATH EFFECTOR DOMAIN-CONTAINING PROTEIN; 1. DR PANTHER; PTHR15205:SF1; DNA-BINDING DEATH EFFECTOR DOMAIN-CONTAINING PROTEIN 2; 1. DR Pfam; PF01335; DED; 1. DR Pfam; PF20694; TRADD-like_N; 1. DR SMART; SM00031; DED; 1. DR SUPFAM; SSF47986; DEATH domain; 1. DR PROSITE; PS50168; DED; 1. PE 1: Evidence at protein level; KW Alternative splicing; Apoptosis; DNA-binding; Nucleus; KW Proteomics identification; Reference proteome; Transcription; KW Transcription regulation. FT CHAIN 1..326 FT /note="DNA-binding death effector domain-containing protein FT 2" FT /id="PRO_0000191277" FT DOMAIN 25..104 FT /note="DED" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00065" FT REGION 104..194 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 104..109 FT /note="Nuclear localization signal" FT /evidence="ECO:0000255" FT MOTIF 155..173 FT /note="Bipartite nuclear localization signal" FT /evidence="ECO:0000255" FT COMPBIAS 136..146 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 155..174 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 175..191 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT VAR_SEQ 145..149 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:12235123, FT ECO:0000303|PubMed:15489334" FT /id="VSP_010312" FT CONFLICT 27 FT /note="H -> N (in Ref. 2; AAM10835)" FT /evidence="ECO:0000305" FT CONFLICT 56 FT /note="A -> G (in Ref. 2; AAM10835)" FT /evidence="ECO:0000305" FT CONFLICT 79 FT /note="D -> G (in Ref. 4; BAC11551)" FT /evidence="ECO:0000305" FT CONFLICT 207 FT /note="C -> R (in Ref. 2; AAM10835)" FT /evidence="ECO:0000305" FT CONFLICT 230 FT /note="Missing (in Ref. 5; AAH13372)" FT /evidence="ECO:0000305" SQ SEQUENCE 326 AA; 36179 MW; 3F7B0B307CC870CD CRC64; MALSGSTPAP CWEEDECLDY YGMLSLHRMF EVVGGQLTEC ELELLAFLLD EAPGAAGGLA RARSGLELLL ELERRGQCDE SNLRLLGQLL RVLARHDLLP HLARKRRRPV SPERYSYGTS SSSKRTEGSC RRRRQSSSSA NSQQGQWETG SPPTKRQRRS RGRPSGGARR RRRGAPAAPQ QQSEPARPSS EGKVTCDIRL RVRAEYCEHG PALEQGVASR RPQALARQLD VFGQATAVLR SRDLGSVVCD IKFSELSYLD AFWGDYLSGA LLQALRGVFL TEALREAVGR EAVRLLVSVD EADYEAGRRR LLLMEEEGGR RPTEAS // ID DGCR6_HUMAN Reviewed; 220 AA. AC Q14129; B2RCH5; D3DX15; G5E9J8; Q9BY28; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 26-JUL-2002, sequence version 3. DT 28-JAN-2026, entry version 175. DE RecName: Full=Protein DGCR6; DE AltName: Full=DiGeorge syndrome critical region 6; GN Name=DGCR6; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND TISSUE RP SPECIFICITY. RC TISSUE=Fetal spleen; RX PubMed=11157784; DOI=10.1101/gr.gr-1431r; RA Edelmann L., Stankiewicz P., Spiteri E., Pandita R.K., Shaffer L., RA Lupski J., Morrow B.E.; RT "Two functional copies of the DGCR6 gene are present on human chromosome RT 22q11 due to a duplication of an ancestral locus."; RL Genome Res. 11:208-217(2001). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, SUBCELLULAR RP LOCATION, AND PHOSPHORYLATION. RC TISSUE=Fetal brain; RX PubMed=15821931; DOI=10.1007/s00439-005-1267-2; RA Pfuhl T., Duerr M., Spurk A., Schwalbert B., Nord R., Mysliwietz J., RA Kremmer E., Graesser F.A.; RT "Biochemical characterisation of the proteins encoded by the DiGeorge RT critical region 6 (DGCR6) genes."; RL Hum. Genet. 117:70-80(2005). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=8733130; DOI=10.1093/hmg/5.5.633; RA Demczuk S., Thomas G., Aurias A.; RT "Isolation of a novel gene from the DiGeorge syndrome critical region with RT homology to Drosophila gdl and to human LAMC1 genes."; RL Hum. Mol. Genet. 5:633-638(1996). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RC TISSUE=Fetal brain; RX PubMed=24722188; DOI=10.1038/ncomms4650; RA Corominas R., Yang X., Lin G.N., Kang S., Shen Y., Ghamsari L., Broly M., RA Rodriguez M., Tam S., Wanamaker S.A., Fan C., Yi S., Tasan M., Lemmens I., RA Kuang X., Zhao N., Malhotra D., Michaelson J.J., Vacic V., Calderwood M.A., RA Roth F.P., Tavernier J., Horvath S., Salehi-Ashtiani K., Korkin D., RA Sebat J., Hill D.E., Hao T., Vidal M., Iakoucheva L.M.; RT "Protein interaction network of alternatively spliced isoforms from brain RT links genetic risk factors for autism."; RL Nat. Commun. 5:3650-3650(2014). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84; RA Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A., RA Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J., RA Beare D.M., Dunham I.; RT "A genome annotation-driven approach to cloning the human ORFeome."; RL Genome Biol. 5:R84.1-R84.11(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=10591208; DOI=10.1038/990031; RA Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M., Clamp M., RA Smink L.J., Ainscough R., Almeida J.P., Babbage A.K., Bagguley C., RA Bailey J., Barlow K.F., Bates K.N., Beasley O.P., Bird C.P., Blakey S.E., RA Bridgeman A.M., Buck D., Burgess J., Burrill W.D., Burton J., Carder C., RA Carter N.P., Chen Y., Clark G., Clegg S.M., Cobley V.E., Cole C.G., RA Collier R.E., Connor R., Conroy D., Corby N.R., Coville G.J., Cox A.V., RA Davis J., Dawson E., Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., RA Ellington A.G., Evans K.L., Fey J.M., Fleming K., French L., Garner A.A., RA Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C., RA Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S., Hunt S.E., RA Jones M.C., Kershaw J., Kimberley A.M., King A., Laird G.K., Langford C.F., RA Leversha M.A., Lloyd C., Lloyd D.M., Martyn I.D., Mashreghi-Mohammadi M., RA Matthews L.H., Mccann O.T., Mcclay J., Mclaren S., McMurray A.A., RA Milne S.A., Mortimore B.J., Odell C.N., Pavitt R., Pearce A.V., Pearson D., RA Phillimore B.J.C.T., Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., RA Rogers L., Ross M.T., Scott C.E., Sehra H.K., Skuce C.D., Smalley S., RA Smith M.L., Soderlund C., Spragon L., Steward C.A., Sulston J.E., RA Swann R.M., Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L., RA Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L., RA Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N., RA Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J., Shintani A., RA Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S., Roe B.A., Chen F., Chu L., RA Crabtree J., Deschamps S., Do A., Do T., Dorman A., Fang F., Fu Y., Hu P., RA Hua A., Kenton S., Lai H., Lao H.I., Lewis J., Lewis S., Lin S.-P., Loh P., RA Malaj E., Nguyen T., Pan H., Phan S., Qi S., Qian Y., Ray L., Ren Q., RA Shaull S., Sloan D., Song L., Wang Q., Wang Y., Wang Z., White J., RA Willingham D., Wu H., Yao Z., Zhan M., Zhang G., Chissoe S., Murray J., RA Miller N., Minx P., Fulton R., Johnson D., Bemis G., Bentley D., RA Bradshaw H., Bourne S., Cordes M., Du Z., Fulton L., Goela D., Graves T., RA Hawkins J., Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., RA Rohlfing T., Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., RA Nelson J., Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R., RA Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S., Budarf M.L., RA McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E., Edelmann L., Kim U.J., RA Shizuya H., Simon M.I., Dumanski J.P., Peyrard M., Kedra D., Seroussi E., RA Fransson I., Tapia I., Bruder C.E., O'Brien K.P., Wilkinson P., RA Bodenteich A., Hartman K., Hu X., Khan A.S., Lane L., Tilahun Y., RA Wright H.; RT "The DNA sequence of human chromosome 22."; RL Nature 402:489-495(1999). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Pancreas, and Spleen; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). CC -!- FUNCTION: May play a role in neural crest cell migration into the third CC and fourth pharyngeal pouches. CC -!- INTERACTION: CC Q14129; Q9ULX6: AKAP8L; NbExp=3; IntAct=EBI-12206931, EBI-357530; CC Q14129; Q96DF8: ESS2; NbExp=3; IntAct=EBI-12206931, EBI-3928124; CC Q14129; P07954: FH; NbExp=3; IntAct=EBI-12206931, EBI-1050358; CC Q14129; Q9NRY2: INIP; NbExp=5; IntAct=EBI-12206931, EBI-2881520; CC Q14129; P59991: KRTAP12-2; NbExp=3; IntAct=EBI-12206931, EBI-10176379; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15821931}. CC Note=Predominantly nuclear. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q14129-1; Sequence=Displayed; CC Name=2; Synonyms=C; CC IsoId=Q14129-2; Sequence=VSP_055898, VSP_055899; CC -!- TISSUE SPECIFICITY: Found in all tissues examined with highest CC expression in liver, heart and skeletal muscle. Lower levels in CC pancreas and placenta. Weak expression in brain. CC {ECO:0000269|PubMed:11157784, ECO:0000269|PubMed:15821931}. CC -!- INDUCTION: Increased levels in several tumor cell lines, including lung CC and colon adenocarcinomas and mammary carcinomas. Strongly induced in CC Burkitt's lymphoma and lymphocytes transformed by EBV. CC -!- SIMILARITY: Belongs to the gonadal family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=CAA65339.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF228707; AAK15584.1; -; mRNA. DR EMBL; X96484; CAA65339.1; ALT_FRAME; mRNA. DR EMBL; KJ535003; AHW56642.1; -; mRNA. DR EMBL; CR456434; CAG30320.1; -; mRNA. DR EMBL; AK315115; BAG37572.1; -; mRNA. DR EMBL; AC007326; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471176; EAX03075.1; -; Genomic_DNA. DR EMBL; CH471176; EAX03077.1; -; Genomic_DNA. DR EMBL; BC047039; AAH47039.1; -; mRNA. DR CCDS; CCDS13753.1; -. [Q14129-1] DR RefSeq; NP_005666.2; NM_005675.4. [Q14129-1] DR RefSeq; XP_047297465.1; XM_047441509.1. [Q14129-2] DR RefSeq; XP_054181927.1; XM_054325952.1. [Q14129-2] DR AlphaFoldDB; Q14129; -. DR SMR; Q14129; -. DR BioGRID; 113850; 72. DR FunCoup; Q14129; 17. DR IntAct; Q14129; 22. DR STRING; 9606.ENSP00000331681; -. DR GlyGen; Q14129; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q14129; -. DR PhosphoSitePlus; Q14129; -. DR BioMuta; DGCR6; -. DR DMDM; 22002047; -. DR jPOST; Q14129; -. DR MassIVE; Q14129; -. DR PaxDb; 9606-ENSP00000331681; -. DR PeptideAtlas; Q14129; -. DR ProteomicsDB; 33959; -. DR ProteomicsDB; 59830; -. [Q14129-1] DR Pumba; Q14129; -. DR Antibodypedia; 22788; 88 antibodies from 15 providers. DR DNASU; 8214; -. DR Ensembl; ENST00000331444.12; ENSP00000331681.6; ENSG00000183628.15. [Q14129-1] DR Ensembl; ENST00000427407.5; ENSP00000397633.2; ENSG00000183628.15. [Q14129-2] DR GeneID; 8214; -. DR KEGG; hsa:8214; -. DR MANE-Select; ENST00000331444.12; ENSP00000331681.6; NM_005675.6; NP_005666.2. DR UCSC; uc062bjm.1; human. [Q14129-1] DR AGR; HGNC:2846; -. DR ClinPGx; PA27308; -. DR CTD; 8214; -. DR DisGeNET; 8214; -. DR GeneCards; DGCR6; -. DR GeneReviews; DGCR6; -. DR HGNC; HGNC:2846; DGCR6. DR HPA; ENSG00000183628; Tissue enhanced (skeletal). DR MalaCards; DGCR6; -. DR MIM; 601279; gene. DR OpenTargets; ENSG00000183628; -. DR VEuPathDB; HostDB:ENSG00000183628; -. DR eggNOG; KOG4810; Eukaryota. DR GeneTree; ENSGT00390000017663; -. DR HOGENOM; CLU_096921_1_1_1; -. DR InParanoid; Q14129; -. DR OMA; MERYAGP; -. DR OrthoDB; 9532930at2759; -. DR PAN-GO; Q14129; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q14129; -. DR PathwayCommons; Q14129; -. DR SignaLink; Q14129; -. DR Agora; ENSG00000183628; -. DR BioGRID-ORCS; 102724770; 0 hits in 7 CRISPR screens. DR BioGRID-ORCS; 8214; 41 hits in 1060 CRISPR screens. DR ChiTaRS; DGCR6; human. DR GeneWiki; DGCR6; -. DR Pharos; Q14129; Tbio. DR PRO; PR:Q14129; -. DR Proteomes; UP000005640; Chromosome 22. DR RNAct; Q14129; protein. DR Bgee; ENSG00000183628; Expressed in skeletal muscle tissue and 99 other cell types or tissues. DR ExpressionAtlas; Q14129; baseline and differential. DR GO; GO:0031012; C:extracellular matrix; TAS:ProtInc. DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell. DR GO; GO:0009887; P:animal organ morphogenesis; TAS:ProtInc. DR GO; GO:0007155; P:cell adhesion; TAS:ProtInc. DR InterPro; IPR010849; Gonadal. DR PANTHER; PTHR13054; DIGEORGE SYNDROME CRITICAL REGION 6 DGCR6 FAMILY MEMBER; 1. DR PANTHER; PTHR13054:SF7; PROTEIN DGCR6; 1. DR Pfam; PF07324; DGCR6; 1. PE 1: Evidence at protein level; KW Alternative splicing; Coiled coil; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome. FT CHAIN 1..220 FT /note="Protein DGCR6" FT /id="PRO_0000070259" FT COILED 76..142 FT /evidence="ECO:0000255" FT VAR_SEQ 92..162 FT /note="LRQALRQKHQEAQQACRPHNLPVLQAAQQRELEAVEHRIREEQRAMDQKIVL FT ELDRKVADQQSTLEKAGVA -> PRTFWNPLETCRDSGVGGWRRLASSPVQTPLWPGCS FT AGLCSGRRCGRSTRKPSRPAGPITCLCFRRLSSEN (in isoform 2)" FT /evidence="ECO:0000303|PubMed:24722188" FT /id="VSP_055898" FT VAR_SEQ 163..220 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:24722188" FT /id="VSP_055899" FT VARIANT 117 FT /note="A -> V (in dbSNP:rs16983281)" FT /id="VAR_033866" FT CONFLICT 1..12 FT /note="MERYAGALEEVA -> PKGAKAGYQPRG (in Ref. 3)" FT /evidence="ECO:0000305" SQ SEQUENCE 220 AA; 24989 MW; DF68DEAF5BF6B8BB CRC64; MERYAGALEE VADGARQQER HYQLLSALQS LVKELPSSFQ QRLSYTTLSD LALALLDGTV FEIVQGLLEI QHLTEKSLYN QRLRLQNEHR VLRQALRQKH QEAQQACRPH NLPVLQAAQQ RELEAVEHRI REEQRAMDQK IVLELDRKVA DQQSTLEKAG VAGFYVTTNP QELMLQMNLL ELIRKLQQRG CWAGKAALGL GGPWQLPAAQ CDQKGSPVPP // ID DLEC1_HUMAN Reviewed; 1755 AA. AC Q9Y238; Q9NSW0; Q9NTG5; DT 25-OCT-2005, integrated into UniProtKB/Swiss-Prot. DT 18-MAY-2010, sequence version 2. DT 28-JAN-2026, entry version 165. DE RecName: Full=Deleted in lung and esophageal cancer protein 1; DE AltName: Full=Deleted in lung cancer protein 1; DE Short=DLC-1; GN Name=DLEC1 {ECO:0000312|EMBL:BAA77624.1}; GN Synonyms=DLC1 {ECO:0000303|PubMed:10213508}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305, ECO:0000312|EMBL:BAA77624.1} RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), ALTERNATIVE SPLICING, RP PUTATIVE FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND RP INVOLVEMENT IN LUNG CANCER; ESOPHAGEAL CANCER AND RENAL CANCER. RX PubMed=10213508; RA Daigo Y., Nishiwaki T., Kawasoe T., Tamari M., Tsuchiya E., Nakamura Y.; RT "Molecular cloning of a candidate tumor suppressor gene, DLC1, from RT chromosome 3p21.3."; RL Cancer Res. 59:1966-1972(1999). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 595-1755 (ISOFORM 2), AND RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1417-1755 (ISOFORM 3). RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [4] RP VARIANT [LARGE SCALE ANALYSIS] ARG-351. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [5] RP SUBCELLULAR LOCATION, AND INTERACTION WITH ALPHA-TUBULIN; BETA-TUBULIN; RP BBS2; BBS4; BBS5; MKKS; TCP1; CCT2; CCT3; CCT4; CCT5 AND CCT7. RX PubMed=33144677; DOI=10.1038/s41598-020-75957-y; RA Okitsu Y., Nagano M., Yamagata T., Ito C., Toshimori K., Dohra H., RA Fujii W., Yogo K.; RT "Dlec1 is required for spermatogenesis and male fertility in mice."; RL Sci. Rep. 10:18883-18883(2020). CC -!- FUNCTION: Essential for spermatogenesis and male fertility (By CC similarity). May play an important role in sperm head and tail CC formation (By similarity). May act as a tumor suppressor by inhibiting CC cell proliferation. {ECO:0000250|UniProtKB:Q8BLA1, CC ECO:0000269|PubMed:10213508}. CC -!- SUBUNIT: Interacts with alpha- and beta-tubulin (PubMed:33144677). CC Interacts with BBS2, BBS4, BBS5, MKKS, TCP1, CCT2, CCT3, CCT4, CCT5 and CC CCT7 (PubMed:33144677). {ECO:0000269|PubMed:33144677}. CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10213508, CC ECO:0000269|PubMed:33144677}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Comment=At least six differentially spliced products may exist. CC {ECO:0000303|PubMed:10213508}; CC Name=1 {ECO:0000303|PubMed:10213508}; CC IsoId=Q9Y238-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9Y238-2; Sequence=VSP_051847, VSP_051848, VSP_051849; CC Name=3; Synonyms=1S3 {ECO:0000303|PubMed:10213508}; CC IsoId=Q9Y238-3; Sequence=VSP_051850; CC -!- TISSUE SPECIFICITY: Expressed in all tissues examined. Expression is CC highest in prostate and testis. {ECO:0000269|PubMed:10213508}. CC -!- DISEASE: Note=DLEC1 silencing due to promoter methylation and aberrant CC transcription are implicated in the development of different cancers, CC including esophageal (ESCR), renal and lung cancers (LNCR). CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting CC tissues of the lung. The most common form of lung cancer is non-small CC cell lung cancer (NSCLC) that can be divided into 3 major histologic CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor CC prognosis. Note=The gene represented in this entry may be involved in CC disease pathogenesis. DLEC1 silencing due to promoter methylation and CC aberrant transcription are implicated in the development of lung CC cancer. CC -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the CC esophagus. The most common types are esophageal squamous cell carcinoma CC and adenocarcinoma. Cancer of the esophagus remains a devastating CC disease because it is usually not detected until it has progressed to CC an advanced incurable stage. {ECO:0000269|PubMed:10213508}. Note=The CC gene represented in this entry may be involved in disease pathogenesis. CC DLEC1 silencing due to promoter methylation and aberrant transcription CC may be implicated in the development of esophageal cancer. CC -!- MISCELLANEOUS: [Isoform 2]: Levels of this splice isoform may be CC increased in cancer cell lines and primary cancers. CC {ECO:0000303|PubMed:10213508, ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 3]: Levels of this splice isoform are increased CC in cancer cell lines and primary cancers. CC {ECO:0000269|PubMed:10213508}. CC -!- SEQUENCE CAUTION: CC Sequence=CAB70676.1; Type=Miscellaneous discrepancy; Note=Intron retention.; Evidence={ECO:0000305}; CC Sequence=CAB70884.2; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB026898; BAA77624.1; -; Genomic_DNA. DR EMBL; AB020522; BAA77247.1; -; mRNA. DR EMBL; AC144536; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AP006309; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL137706; CAB70884.2; ALT_INIT; Transcribed_RNA. DR EMBL; AL137282; CAB70676.1; ALT_SEQ; mRNA. DR CCDS; CCDS2672.2; -. [Q9Y238-1] DR PIR; T46351; T46351. DR PIR; T46406; T46406. DR RefSeq; NP_001308082.1; NM_001321153.1. DR RefSeq; NP_031361.2; NM_007335.4. [Q9Y238-1] DR RefSeq; NP_031363.2; NM_007337.4. [Q9Y238-3] DR AlphaFoldDB; Q9Y238; -. DR SMR; Q9Y238; -. DR BioGRID; 115266; 14. DR FunCoup; Q9Y238; 173. DR STRING; 9606.ENSP00000308597; -. DR GlyGen; Q9Y238; 1 site. DR iPTMnet; Q9Y238; -. DR PhosphoSitePlus; Q9Y238; -. DR BioMuta; DLEC1; -. DR DMDM; 296434480; -. DR jPOST; Q9Y238; -. DR MassIVE; Q9Y238; -. DR PaxDb; 9606-ENSP00000308597; -. DR PeptideAtlas; Q9Y238; -. DR ProteomicsDB; 85633; -. [Q9Y238-1] DR ProteomicsDB; 85634; -. [Q9Y238-2] DR ProteomicsDB; 85635; -. [Q9Y238-3] DR Antibodypedia; 6364; 173 antibodies from 25 providers. DR DNASU; 9940; -. DR Ensembl; ENST00000308059.11; ENSP00000308597.6; ENSG00000008226.21. [Q9Y238-1] DR Ensembl; ENST00000346219.7; ENSP00000315914.5; ENSG00000008226.21. [Q9Y238-3] DR GeneID; 9940; -. DR KEGG; hsa:9940; -. DR MANE-Select; ENST00000308059.11; ENSP00000308597.6; NM_007335.4; NP_031361.2. DR UCSC; uc003cho.2; human. [Q9Y238-1] DR AGR; HGNC:2899; -. DR ClinPGx; PA27353; -. DR CTD; 9940; -. DR DisGeNET; 9940; -. DR GeneCards; DLEC1; -. DR HGNC; HGNC:2899; DLEC1. DR HPA; ENSG00000008226; Tissue enhanced (choroid plexus, fallopian tube, testis). DR MalaCards; DLEC1; -. DR MIM; 133239; phenotype. DR MIM; 211980; phenotype. DR MIM; 604050; gene. DR OpenTargets; ENSG00000008226; -. DR Orphanet; 99977; Squamous cell carcinoma of the esophagus. DR VEuPathDB; HostDB:ENSG00000008226; -. DR eggNOG; ENOG502QQQ5; Eukaryota. DR GeneTree; ENSGT00390000006098; -. DR HOGENOM; CLU_003422_0_0_1; -. DR InParanoid; Q9Y238; -. DR OMA; LIKYTWE; -. DR OrthoDB; 2115465at2759; -. DR PAN-GO; Q9Y238; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q9Y238; -. DR PathwayCommons; Q9Y238; -. DR SignaLink; Q9Y238; -. DR Agora; ENSG00000008226; -. DR BioGRID-ORCS; 9940; 11 hits in 1140 CRISPR screens. DR ChiTaRS; DLEC1; human. DR GenomeRNAi; 9940; -. DR Pharos; Q9Y238; Tbio. DR PRO; PR:Q9Y238; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q9Y238; protein. DR Bgee; ENSG00000008226; Expressed in right uterine tube and 144 other cell types or tissues. DR ExpressionAtlas; Q9Y238; baseline and differential. DR GO; GO:0005929; C:cilium; IBA:GO_Central. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0043014; F:alpha-tubulin binding; IDA:UniProtKB. DR GO; GO:0048487; F:beta-tubulin binding; IDA:UniProtKB. DR GO; GO:0015631; F:tubulin binding; IBA:GO_Central. DR GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW. DR GO; GO:0002357; P:defense response to tumor cell; IMP:ARUK-UCL. DR GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:ProtInc. DR GO; GO:0007283; P:spermatogenesis; ISS:UniProtKB. DR FunFam; 2.60.40.10:FF:002933; Deleted in lung and esophageal cancer protein 1; 1. DR FunFam; 2.60.40.10:FF:002936; DLEC1, cilia and flagella associated protein; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 7. DR InterPro; IPR033304; DLEC1. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR059041; Ig_DLEC1_1. DR PANTHER; PTHR46348; DELETED IN LUNG AND ESOPHAGEAL CANCER PROTEIN 1; 1. DR PANTHER; PTHR46348:SF1; DELETED IN LUNG AND ESOPHAGEAL CANCER PROTEIN 1; 1. DR Pfam; PF23277; Ig_Dlec1_1; 1. DR Pfam; PF23316; Ig_DLEC1_6th; 1. PE 1: Evidence at protein level; KW Alternative splicing; Cytoplasm; Differentiation; KW Proteomics identification; Reference proteome; Spermatogenesis; KW Tumor suppressor. FT CHAIN 1..1755 FT /note="Deleted in lung and esophageal cancer protein 1" FT /id="PRO_0000079929" FT REGION 1..39 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1339..1360 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1529..1553 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1..12 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 30..39 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT VAR_SEQ 704 FT /note="E -> MARLRGGRIPAMPQPSPGQPAGTQWCFQGTVFALQ (in isoform FT 2)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_051847" FT VAR_SEQ 856..885 FT /note="GPALIINVSALQFGLLRLGQKATNSIQIRN -> PFSLVCSAWGRKPQTPSR FT SGTSASSQPHGA (in isoform 2)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_051848" FT VAR_SEQ 886..1755 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_051849" FT VAR_SEQ 1675..1755 FT /note="QQEPAKAAVAFRVSPNSGLLEARSANAPPTSIALQVFFTARSSELYESTMVV FT EGVLGEKSCTLRLRGQGSYDERYMLPHQP -> VVSCTSPRWWWKVCSVRSPAPCGSGA FT KAPMMRDTCCLTSPEAPPQPSAPGPSWRKNIAQGLGAALQHKDTDLGTWGPLGSSWNGR FT TPFHNGLSLGPHDMSSELT (in isoform 3)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_051850" FT VARIANT 79 FT /note="L -> R (in dbSNP:rs7625806)" FT /id="VAR_056860" FT VARIANT 192 FT /note="S -> F (in dbSNP:rs34012183)" FT /id="VAR_056861" FT VARIANT 351 FT /note="P -> R (in a breast cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035908" FT VARIANT 1022 FT /note="K -> N (in dbSNP:rs36012922)" FT /id="VAR_056862" FT VARIANT 1150 FT /note="N -> D (in dbSNP:rs9840172)" FT /id="VAR_056863" FT VARIANT 1227 FT /note="L -> P (in dbSNP:rs9810085)" FT /id="VAR_056864" FT CONFLICT 704 FT /note="E -> M (in Ref. 2; CAB70884)" FT /evidence="ECO:0000305" FT CONFLICT 1442 FT /note="G -> R (in Ref. 1; BAA77624/BAA77247)" FT /evidence="ECO:0000305" SQ SEQUENCE 1755 AA; 195684 MW; CD4BDB5EEF24DF98 CRC64; METRSSKTRR SLASRTNECQ GTMWAPTSPP AGSSSPSQPT WKSSLYSSLA YSEAFHYSFA ARPRRLTQLA LAQRPEPQLL RLRPSSLRTQ DISHLLTGVF RNLYSAEVIG DEVSASLIKA RGSENERHEE FVDQLQQIRE LYKQRLDEFE MLERHITQAQ ARAIAENERV MSQAGVQDLE SLVRLPPVKS VSRWCIDSEL LRKHHLISPE DYYTDTVPFH SAPKGISLPG CSKLTFSCEK RSVQKKELNK KLEDSCRKKL AEFEDELDHT VDSLTWNLTP KAKERTREPL KKASQPRNKN WMNHLRVPQR ELDRLLLARM ESRNHFLKNP RFFPPNTRYG GKSLVFPPKK PAPIGEFQST EPEQSCADTP VFLAKPPIGF FTDYEIGPVY EMVIALQNTT TTSRYLRVLP PSTPYFALGL GMFPGKGGMV APGMTCQYIV QFFPDCLGDF DDFILVETQS AHTLLIPLQA RRPPPVLTLS PVLDCGYCLI GGVKMTRFIC KNVGFSVGRF CIMPKTSWPP LSFKAIATVG FVEQPPFGIL PSVFELAPGH AILVEVLFSP KSLGKAEQTF IIMCDNCQIK ELVTIGIGQL IALDLIYISG EKSQPDPGEL TDLTAQHFIR FEPENLRSTA RKQLIIRNAT HVELAFYWQI MKPNLQPLMP GETFSMDSIK CYPDKETAFS IMPRKGVLSP HTDHEFILSF SPHELRDFHS VLQMVLEEVP EPVSSEAESL GHSSYSVDDV IVLEIEVKGS VEPFQVLLEP YALIIPGENY IGINVKKAFK MWNNSKSPIR YLWGKISDCH IIEVEPGTGV IEPSEVGDFE LNFTGGVPGP TSQDLLCEIE DSPSPVVLHI EAVFKGPALI INVSALQFGL LRLGQKATNS IQIRNVSQLP ATWRMKESPV SLQERPEDVS PFDIEPSSGQ LHSLGECRVD ITLEALHCQH LETVLELEVE NGAWSYLPVY AEVQKPHVYL QSSQVEVRNL YLGVPTKTTI TLINGTLLPT QFHWGKLLGH QAEFCMVTVS PKHGLLGPSE ECQLKLELTA HTQEELTHLA LPCHVSGMKK PLVLGISGKP QGLQVAITIS KESSDCSTEQ WPGHPKELRL DFGSAVPLRT RVTRQLILTN RSPIRTRFSL KFEYFGSPQN SLSKKTSLPN MPPALLKTVR MQEHLAKREQ LDFMESMLSH GKGAAFFPHF SQGMLGPYQQ LCIDITGCAN MWGEYWDNLI CTVGDLLPEV IPVHMAAVGC PISSLRTTSY TIDQAQKEPA MRFGTQVSGG DTVTRTLRLN NSSPCDIRLD WETYVPEDKE DRLVELLVFY GPPFPLRDQA GNELVCPDTP EGGCLLWSPG PSSSSEFSHE TDSSVEGSSS ASNRVAQKLI SVILQAHEGV PSGHLYCISP KQVVVPAGGS STIYISFTPM VLSPEILHKV ECTGYALGFM SLDSKVEREI PGKRHRLQDF AVGPLKLDLH SYVRPAQLSV ELDYGGSMEF QCQASDLIPE QPCSGVLSEL VTTHHLKLTN TTEIPHYFRL MVSRPFSVSQ DGASQDHRAP GPGQKQECEE ETASADKQLV LQAQENMLVN VSFSLSLELL SYQKLPADQT LPGVDIQQSA SGEREMVFTQ NLLLEYTNQT TQVVPLRAVV AVPELQLSTS WVDFGTCFVS QQRVREVYLM NLSGCRSYWT MLMGQQEPAK AAVAFRVSPN SGLLEARSAN APPTSIALQV FFTARSSELY ESTMVVEGVL GEKSCTLRLR GQGSYDERYM LPHQP // ID DPOD1_HUMAN Reviewed; 1107 AA. AC P28340; Q8NER3; Q96H98; DT 01-DEC-1992, integrated into UniProtKB/Swiss-Prot. DT 19-JUL-2004, sequence version 2. DT 28-JAN-2026, entry version 232. DE RecName: Full=DNA polymerase delta catalytic subunit {ECO:0000305}; DE EC=2.7.7.7 {ECO:0000269|PubMed:19074196, ECO:0000269|PubMed:20334433}; DE AltName: Full=3'-5' exodeoxyribonuclease {ECO:0000305}; DE EC=3.1.11.- {ECO:0000269|PubMed:16510448, ECO:0000269|PubMed:19074196, ECO:0000269|PubMed:20334433}; DE AltName: Full=DNA polymerase subunit delta p125; GN Name=POLD1 {ECO:0000312|HGNC:HGNC:9175}; Synonyms=POLD; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT TRP-30. RC TISSUE=Hepatoma; RX PubMed=1722322; DOI=10.1073/pnas.88.24.11197; RA Chung D.W., Zhang J., Tan C.-K., Davie E.W., So A.G., Downey K.M.; RT "Primary structure of the catalytic subunit of human DNA polymerase delta RT and chromosomal location of the gene."; RL Proc. Natl. Acad. Sci. U.S.A. 88:11197-11201(1991). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], VARIANTS HIS-119 AND ASN-173, AND INDUCTION BY RP SERUM. RC TISSUE=Cervix carcinoma; RX PubMed=1542570; DOI=10.1093/nar/20.4.735; RA Yang C.-L., Chang L.-S., Zhang P., Hao H., Zhu L., Toomey N.L., RA Lee M.Y.W.T.; RT "Molecular cloning of the cDNA for the catalytic subunit of human DNA RT polymerase delta."; RL Nucleic Acids Res. 20:735-745(1992). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HIS-19; TRP-30; HIS-119; RP ASN-173; HIS-177; HIS-849 AND GLN-1086. RG NIEHS SNPs program; RL Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT HIS-119. RC TISSUE=Lymph; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP INTERACTION WITH POLD2 AND PCNA. RX PubMed=11328591; DOI=10.1093/oxfordjournals.jbchem.a002909; RA Shikata K., Ohta S., Yamada K., Obuse C., Yoshikawa H., Tsurimoto T.; RT "The human homologue of fission Yeast cdc27, p66, is a component of active RT human DNA polymerase delta."; RL J. Biochem. 129:699-708(2001). RN [6] RP INTERACTION WITH POLD3, AND SUBCELLULAR LOCATION. RX PubMed=11595739; DOI=10.1074/jbc.m106990200; RA Ducoux M., Urbach S., Baldacci G., Huebscher U., Koundrioukoff S., RA Christensen J., Hughes P.; RT "Mediation of proliferating cell nuclear antigen (PCNA)-dependent DNA RT replication through a conserved p21(Cip1)-like PCNA-binding motif present RT in the third subunit of human DNA polymerase delta."; RL J. Biol. Chem. 276:49258-49266(2001). RN [7] RP INTERACTION WITH PCNA AND POLD4, AND CHARACTERIZATION OF POL-DELTA2 AND RP POL-DELTA4 COMPLEXES. RX PubMed=12403614; DOI=10.1021/bi0262707; RA Xie B., Mazloum N., Liu L., Rahmeh A., Li H., Lee M.Y.; RT "Reconstitution and characterization of the human DNA polymerase delta RT four-subunit holoenzyme."; RL Biochemistry 41:13133-13142(2002). RN [8] RP INTERACTION WITH POLD2 AND POLDIP2, AND STIMULATION BY PCNA. RX PubMed=12522211; DOI=10.1074/jbc.m208694200; RA Liu L., Rodriguez-Belmonte E.M., Mazloum N., Xie B., Lee M.Y.W.T.; RT "Identification of a novel protein, PDIP38, that interacts with the p50 RT subunit of DNA polymerase delta and proliferating cell nuclear antigen."; RL J. Biol. Chem. 278:10041-10047(2003). RN [9] RP INTERACTION WITH WRNIP1. RX PubMed=15670210; DOI=10.1111/j.1365-2443.2004.00812.x; RA Tsurimoto T., Shinozaki A., Yano M., Seki M., Enomoto T.; RT "Human Werner helicase interacting protein 1 (WRNIP1) functions as a novel RT modulator for DNA polymerase delta."; RL Genes Cells 10:13-22(2005). RN [10] RP FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH POLD2; POLD4 AND PCNA. RX PubMed=16510448; DOI=10.1074/jbc.m600322200; RA Li H., Xie B., Zhou Y., Rahmeh A., Trusa S., Zhang S., Gao Y., Lee E.Y., RA Lee M.Y.; RT "Functional roles of p12, the fourth subunit of human DNA polymerase RT delta."; RL J. Biol. Chem. 281:14748-14755(2006). RN [11] RP IDENTIFICATION IN POL-DELTA COMPLEX. RX PubMed=17317665; DOI=10.1074/jbc.m610356200; RA Zhang S., Zhou Y., Trusa S., Meng X., Lee E.Y., Lee M.Y.; RT "A novel DNA damage response: rapid degradation of the p12 subunit of dna RT polymerase delta."; RL J. Biol. Chem. 282:15330-15340(2007). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [13] RP FUNCTION, CATALYTIC ACTIVITY, MUTAGENESIS OF ASP-402, CHARACTERIZATION OF RP POL-DELTA3 AND POL-DELTA4, AND ACTIVITY REGULATION. RX PubMed=19074196; DOI=10.1093/nar/gkn1000; RA Meng X., Zhou Y., Zhang S., Lee E.Y., Frick D.N., Lee M.Y.; RT "DNA damage alters DNA polymerase delta to a form that exhibits increased RT discrimination against modified template bases and mismatched primers."; RL Nucleic Acids Res. 37:647-657(2009). RN [14] RP FUNCTION, CATALYTIC ACTIVITY, CHARACTERIZATION OF POL-DELTA3 AND RP POL-DELTA4, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF ASP-402. RX PubMed=20334433; DOI=10.1021/bi100042b; RA Meng X., Zhou Y., Lee E.Y., Lee M.Y., Frick D.N.; RT "The p12 subunit of human polymerase delta modulates the rate and fidelity RT of DNA synthesis."; RL Biochemistry 49:3545-3554(2010). RN [15] RP FUNCTION IN NUCLEOTIDE EXCISION REPAIR, AND SUBCELLULAR LOCATION. RX PubMed=20227374; DOI=10.1016/j.molcel.2010.02.009; RA Ogi T., Limsirichaikul S., Overmeer R.M., Volker M., Takenaka K., RA Cloney R., Nakazawa Y., Niimi A., Miki Y., Jaspers N.G., Mullenders L.H., RA Yamashita S., Fousteri M.I., Lehmann A.R.; RT "Three DNA polymerases, recruited by different mechanisms, carry out NER RT repair synthesis in human cells."; RL Mol. Cell 37:714-727(2010). RN [16] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [17] RP SUBCELLULAR LOCATION, IDENTIFICATION IN POLD COMPLEX, AND DEVELOPMENTAL RP STAGE. RX PubMed=22801543; DOI=10.4161/cc.21280; RA Chea J., Zhang S., Zhao H., Zhang Z., Lee E.Y., Darzynkiewicz Z., Lee M.Y.; RT "Spatiotemporal recruitment of human DNA polymerase delta to sites of UV RT damage."; RL Cell Cycle 11:2885-2895(2012). RN [18] RP INTERACTION WITH CIAO1. RX PubMed=23891004; DOI=10.1016/j.cmet.2013.06.015; RA Stehling O., Mascarenhas J., Vashisht A.A., Sheftel A.D., Niggemeyer B., RA Roesser R., Pierik A.J., Wohlschlegel J.A., Lill R.; RT "Human CIA2A-FAM96A and CIA2B-FAM96B integrate iron homeostasis and RT maturation of different subsets of cytosolic-nuclear iron-sulfur RT proteins."; RL Cell Metab. 18:187-198(2013). RN [19] RP ERRATUM OF PUBMED:23891004. RX PubMed=29320706; DOI=10.1016/j.cmet.2017.12.009; RA Stehling O., Mascarenhas J., Vashisht A.A., Sheftel A.D., Niggemeyer B., RA Roesser R., Pierik A.J., Wohlschlegel J.A., Lill R.; RT "Human CIA2A-FAM96A and CIA2B-FAM96B Integrate Iron Homeostasis and RT Maturation of Different Subsets of Cytosolic-Nuclear Iron-Sulfur RT Proteins."; RL Cell Metab. 27:263-263(2018). RN [20] RP FUNCTION IN OKAZAKI FRAGMENT PROCESSING. RX PubMed=24035200; DOI=10.1016/j.dnarep.2013.08.008; RA Lin S.H., Wang X., Zhang S., Zhang Z., Lee E.Y., Lee M.Y.; RT "Dynamics of enzymatic interactions during short flap human Okazaki RT fragment processing by two forms of human DNA polymerase delta."; RL DNA Repair 12:922-935(2013). RN [21] RP POL-DELTA3 COMPLEX EXPRESSION DURING CELL CYCLE. RX PubMed=23913683; DOI=10.1074/jbc.m113.490466; RA Zhang S., Zhao H., Darzynkiewicz Z., Zhou P., Zhang Z., Lee E.Y., Lee M.Y.; RT "A novel function of CRL4(Cdt2): regulation of the subunit structure of DNA RT polymerase delta in response to DNA damage and during the S phase."; RL J. Biol. Chem. 288:29550-29561(2013). RN [22] RP FUNCTION, AND INTERACTION WITH PCNA. RX PubMed=24022480; DOI=10.1074/jbc.c113.505586; RA Terai K., Shibata E., Abbas T., Dutta A.; RT "Degradation of p12 subunit by CRL4Cdt2 E3 ligase inhibits fork progression RT after DNA damage."; RL J. Biol. Chem. 288:30509-30514(2013). RN [23] RP TISSUE SPECIFICITY, AND VARIANT MDPL SER-605 DEL. RX PubMed=23770608; DOI=10.1038/ng.2670; RA Weedon M.N., Ellard S., Prindle M.J., Caswell R., Allen H.L., Oram R., RA Godbole K., Yajnik C.S., Sbraccia P., Novelli G., Turnpenny P., McCann E., RA Goh K.J., Wang Y., Fulford J., McCulloch L.J., Savage D.B., O'Rahilly S., RA Kos K., Loeb L.A., Semple R.K., Hattersley A.T.; RT "An in-frame deletion at the polymerase active site of POLD1 causes a RT multisystem disorder with lipodystrophy."; RL Nat. Genet. 45:947-950(2013). RN [24] RP FUNCTION, AND INTERACTION WITH POLDIP2. RX PubMed=24191025; DOI=10.1073/pnas.1308760110; RA Maga G., Crespan E., Markkanen E., Imhof R., Furrer A., Villani G., RA Huebscher U., van Loon B.; RT "DNA polymerase delta-interacting protein 2 is a processivity factor for RT DNA polymerase lambda during 8-oxo-7,8-dihydroguanine bypass."; RL Proc. Natl. Acad. Sci. U.S.A. 110:18850-18855(2013). RN [25] RP METHYLATION [LARGE SCALE ANALYSIS] AT ARG-19, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Colon carcinoma; RX PubMed=24129315; DOI=10.1074/mcp.o113.027870; RA Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M., RA Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V., RA Bedford M.T., Comb M.J.; RT "Immunoaffinity enrichment and mass spectrometry analysis of protein RT methylation."; RL Mol. Cell. Proteomics 13:372-387(2014). RN [26] RP INTERACTION WITH PCNA. RX PubMed=24939902; DOI=10.1093/nar/gku533; RA Cazzalini O., Sommatis S., Tillhon M., Dutto I., Bachi A., Rapp A., RA Nardo T., Scovassi A.I., Necchi D., Cardoso M.C., Stivala L.A., RA Prosperi E.; RT "CBP and p300 acetylate PCNA to link its degradation with nucleotide RT excision repair synthesis."; RL Nucleic Acids Res. 42:8433-8448(2014). RN [27] RP FUNCTION IN BIR. RX PubMed=24310611; DOI=10.1126/science.1243211; RA Costantino L., Sotiriou S.K., Rantala J.K., Magin S., Mladenov E., RA Helleday T., Haber J.E., Iliakis G., Kallioniemi O.P., Halazonetis T.D.; RT "Break-induced replication repair of damaged forks induces genomic RT duplications in human cells."; RL Science 343:88-91(2014). RN [28] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-574, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [29] RP VARIANTS ASP-145; HIS-461; ASN-478; LEU-787; HIS-808 AND THR-864, AND RP INVOLVEMENT IN CRCS10. RX PubMed=23263490; DOI=10.1038/ng.2503; RG CORGI Consortium; RG WGS500 Consortium; RA Palles C., Cazier J.B., Howarth K.M., Domingo E., Jones A.M., Broderick P., RA Kemp Z., Spain S.L., Guarino Almeida E., Salguero I., Sherborne A., RA Chubb D., Carvajal-Carmona L.G., Ma Y., Kaur K., Dobbins S., Barclay E., RA Gorman M., Martin L., Kovac M.B., Humphray S., Lucassen A., Holmes C.C., RA Bentley D., Donnelly P., Taylor J., Petridis C., Roylance R., Sawyer E.J., RA Kerr D.J., Clark S., Grimes J., Kearsey S.E., Thomas H.J., McVean G., RA Houlston R.S., Tomlinson I.; RT "Germline mutations affecting the proofreading domains of POLE and POLD1 RT predispose to colorectal adenomas and carcinomas."; RL Nat. Genet. 45:136-144(2013). RN [30] RP VARIANT CRCS10 PRO-474. RX PubMed=24501277; DOI=10.1093/hmg/ddu058; RA Valle L., Hernandez-Illan E., Bellido F., Aiza G., Castillejo A., RA Castillejo M.I., Navarro M., Segui N., Vargas G., Guarinos C., Juarez M., RA Sanjuan X., Iglesias S., Alenda C., Egoavil C., Segura A., Juan M.J., RA Rodriguez-Soler M., Brunet J., Gonzalez S., Jover R., Lazaro C., RA Capella G., Pineda M., Soto J.L., Blanco I.; RT "New insights into POLE and POLD1 germline mutations in familial colorectal RT cancer and polyposis."; RL Hum. Mol. Genet. 23:3506-3512(2014). RN [31] RP INVOLVEMENT IN IMD120, VARIANTS IMD120 HIS-684; TRP-939 AND TRP-1074, RP CHARACTERIZATION OF VARIANTS IMD120 HIS-684; TRP-939 AND TRP-1074, RP FUNCTION, INTERACTION WITH POLD2 AND POLD3, AND MUTAGENESIS OF ASP-602 AND RP ASP-757. RX PubMed=31449058; DOI=10.1172/jci128903; RA Conde C.D., Petronczki O.Y., Baris S., Willmann K.L., Girardi E., RA Salzer E., Weitzer S., Ardy R.C., Krolo A., Ijspeert H., Kiykim A., RA Karakoc-Aydiner E., Foerster-Waldl E., Kager L., Pickl W.F., RA Superti-Furga G., Martinez J., Loizou J.I., Ozen A., van der Burg M., RA Boztug K.; RT "Polymerase delta deficiency causes syndromic immunodeficiency with RT replicative stress."; RL J. Clin. Invest. 129:4194-4206(2019). RN [32] RP INVOLVEMENT IN IMD120, VARIANT IMD120 CYS-1060, CHARACTERIZATION OF VARIANT RP IMD120 CYS-1060, AND INTERACTION WITH POLD2 AND RFC1. RX PubMed=31629014; DOI=10.1016/j.jaci.2019.10.004; RA Cui Y., Keles S., Charbonnier L.M., Jule A.M., Henderson L., Celik S.C., RA Reisli I., Shen C., Xie W.J., Schmitz-Abe K., Wu H., Chatila T.A.; RT "Combined immunodeficiency caused by a loss-of-function mutation in DNA RT polymerase delta 1."; RL J. Allergy Clin. Immunol. 145:391-401.e8(2020). CC -!- FUNCTION: As the catalytic component of the trimeric (Pol-delta3 CC complex) and tetrameric DNA polymerase delta complexes (Pol-delta4 CC complex), plays a crucial role in high fidelity genome replication, CC including in lagging strand synthesis, and repair (PubMed:16510448, CC PubMed:19074196, PubMed:20334433, PubMed:24022480, PubMed:24035200, CC PubMed:31449058). Exhibits both DNA polymerase and 3'- to 5'- CC exonuclease activities (PubMed:16510448, PubMed:19074196, CC PubMed:20334433, PubMed:24022480, PubMed:24035200). Requires the CC presence of accessory proteins POLD2, POLD3 and POLD4 for full CC activity. Depending upon the absence (Pol-delta3) or the presence of CC POLD4 (Pol-delta4), displays differences in catalytic activity. Most CC notably, expresses higher proofreading activity in the context of Pol- CC delta3 compared with that of Pol-delta4 (PubMed:19074196, CC PubMed:20334433). Although both Pol-delta3 and Pol-delta4 process CC Okazaki fragments in vitro, Pol-delta3 may be better suited to fulfill CC this task, exhibiting near-absence of strand displacement activity CC compared to Pol-delta4 and stalling on encounter with the 5'-blocking CC oligonucleotides. Pol-delta3 idling process may avoid the formation of CC a gap, while maintaining a nick that can be readily ligated CC (PubMed:24035200). Along with DNA polymerase kappa, DNA polymerase CC delta carries out approximately half of nucleotide excision repair CC (NER) synthesis following UV irradiation (PubMed:20227374). Under CC conditions of DNA replication stress, in the presence of POLD3 and CC POLD4, may catalyze the repair of broken replication forks through CC break-induced replication (BIR) (PubMed:24310611). Involved in the CC translesion synthesis (TLS) of templates carrying O6-methylguanine, CC 8oxoG or abasic sites (PubMed:19074196, PubMed:24191025). CC {ECO:0000269|PubMed:16510448, ECO:0000269|PubMed:19074196, CC ECO:0000269|PubMed:20227374, ECO:0000269|PubMed:20334433, CC ECO:0000269|PubMed:24022480, ECO:0000269|PubMed:24035200, CC ECO:0000269|PubMed:24191025, ECO:0000269|PubMed:24310611, CC ECO:0000269|PubMed:31449058}. CC -!- CATALYTIC ACTIVITY: CC Reaction=DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + CC diphosphate; Xref=Rhea:RHEA:22508, Rhea:RHEA-COMP:17339, Rhea:RHEA- CC COMP:17340, ChEBI:CHEBI:33019, ChEBI:CHEBI:61560, ChEBI:CHEBI:173112; CC EC=2.7.7.7; Evidence={ECO:0000269|PubMed:19074196, CC ECO:0000269|PubMed:20334433}; CC -!- COFACTOR: CC Name=[4Fe-4S] cluster; Xref=ChEBI:CHEBI:49883; Evidence={ECO:0000250}; CC Note=Binds 1 [4Fe-4S] cluster. {ECO:0000250}; CC -!- ACTIVITY REGULATION: Regulated by alteration of quaternary structure. CC Exhibits burst rates of DNA synthesis are about 5 times faster in the CC presence of POLD4 (Pol-delta4 complex) than in its absence (Pol-delta3 CC complex), while the affinity of the enzyme for its DNA and dNTP CC substrates appears unchanged. The Pol-delta3 complex is more likely to CC proofread DNA synthesis because it cleaves single-stranded DNA twice as CC fast and transfers mismatched DNA from the polymerase to the CC exonuclease sites 9 times faster compared to the Pol-delta3 complex. CC Pol-delta3 also extends mismatched primers 3 times more slowly in the CC absence of POLD4. The conversion of Pol-delta4 into Pol-delta3 is CC induced by genotoxic stress or by replication stress leading POLD4 CC degradation (PubMed:19074196, PubMed:20334433). Stimulated in the CC presence of PCNA (PubMed:11328591, PubMed:12403614, PubMed:12522211, CC PubMed:16510448, PubMed:24022480, PubMed:24939902). This stimulation is CC further increased in the presence of KCTD13/PDIP1, most probably via CC direct interaction between KCTD13 and POLD2 (By similarity). CC {ECO:0000250|UniProtKB:P28339, ECO:0000269|PubMed:11328591, CC ECO:0000269|PubMed:12403614, ECO:0000269|PubMed:12522211, CC ECO:0000269|PubMed:16510448, ECO:0000269|PubMed:19074196, CC ECO:0000269|PubMed:20334433, ECO:0000269|PubMed:24022480, CC ECO:0000269|PubMed:24939902}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC Note=kcat is 87 sec(-1) for DNA synthesis by Pol-delta4 and 19 sec(- CC 1) for Pol-delta3. kcat for exonuclease activity determined using a CC 26mer/40mer duplex DNA gives a value of 0.003 sec(-1) for Pol-delta4 CC and 0.026 sec(-1) for Pol-delta3. When using a 26mer/40mer with a T:G CC mismatch at the primer terminus, the switching rates from the CC polymerase to the exonuclease site for Pol-delta4 and Pol-delta3 are CC increased 20- and 10-fold, respectively, but the rate constant for CC Pol-delta3 is still 5-fold faster than that for Pol-delta4.; CC -!- SUBUNIT: Component of the tetrameric DNA polymerase delta complex (Pol- CC delta4), which consists of POLD1/p125, POLD2/p50, POLD3/p66/p68 and CC POLD4/p12, with POLD1 bearing both DNA polymerase and 3' to 5' CC proofreading exonuclease activities (PubMed:11595739, PubMed:12522211, CC PubMed:17317665, PubMed:22801543, PubMed:31449058, PubMed:31629014). CC Within Pol-delta4, directly interacts with POLD2 and POLD4 CC (PubMed:11328591, PubMed:12403614, PubMed:16510448). Following CC genotoxic stress by DNA-damaging agents, such as ultraviolet light and CC methyl methanesulfonate, or by replication stress induced by treatment CC with hydroxyurea or aphidicolin, Pol-delta4 is converted into a CC trimeric form of the complex (Pol-delta3) by POLD4 degradation. Pol- CC delta3 is the major form at S phase replication sites and DNA damage CC sites (PubMed:17317665, PubMed:22801543). POLD1 displays different CC catalytic properties depending upon the complex it is found in CC (PubMed:17317665). It exhibits higher proofreading activity and CC fidelity than Pol-delta4, making it particularly well suited to respond CC to DNA damage (PubMed:19074196, PubMed:20334433). Directly interacts CC with PCNA, as do POLD3 and POLD4; this interaction stimulates Pol- CC delta4 polymerase activity (PubMed:11328591, PubMed:12403614, CC PubMed:12522211, PubMed:16510448, PubMed:24022480, PubMed:24939902). As CC POLD2 and POLD4, directly interacts with WRNIP1; this interaction CC stimulates DNA polymerase delta-mediated DNA synthesis, independently CC of the presence of PCNA. This stimulation may be due predominantly to CC an increase of initiation frequency and also to increased processivity CC (PubMed:15670210). Also observed as a dimeric complex with POLD2 (Pol- CC delta2 complex). Pol-delta2 is relatively insensitive to the PCNA CC stimulation (2-5-fold) compared to Pol-delta4 that is stimulated by CC over 50-fold (PubMed:12403614). The DNA polymerase delta complex CC interacts with POLDIP2; this interaction is probably mediated through CC direct binding to POLD2 (PubMed:12522211). Interacts with CIAO1 CC (PubMed:23891004). Interacts with POLDIP2 (PubMed:24191025). Interacts CC with RFC1 (PubMed:31629014). {ECO:0000269|PubMed:11328591, CC ECO:0000269|PubMed:11595739, ECO:0000269|PubMed:12403614, CC ECO:0000269|PubMed:12522211, ECO:0000269|PubMed:15670210, CC ECO:0000269|PubMed:16510448, ECO:0000269|PubMed:17317665, CC ECO:0000269|PubMed:19074196, ECO:0000269|PubMed:20334433, CC ECO:0000269|PubMed:22801543, ECO:0000269|PubMed:23891004, CC ECO:0000269|PubMed:24022480, ECO:0000269|PubMed:24191025, CC ECO:0000269|PubMed:24939902, ECO:0000269|PubMed:31449058, CC ECO:0000269|PubMed:31629014}. CC -!- INTERACTION: CC P28340; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-716569, EBI-10173507; CC P28340; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-716569, EBI-3867333; CC P28340; Q53G59: KLHL12; NbExp=3; IntAct=EBI-716569, EBI-740929; CC P28340; Q14847-2: LASP1; NbExp=3; IntAct=EBI-716569, EBI-9088686; CC P28340; P12004: PCNA; NbExp=3; IntAct=EBI-716569, EBI-358311; CC P28340; P49005: POLD2; NbExp=16; IntAct=EBI-716569, EBI-372354; CC P28340; Q9HCU8: POLD4; NbExp=14; IntAct=EBI-716569, EBI-864968; CC P28340; Q13485: SMAD4; NbExp=7; IntAct=EBI-716569, EBI-347263; CC P28340; Q9NYB0: TERF2IP; NbExp=2; IntAct=EBI-716569, EBI-750109; CC P28340; Q96S55: WRNIP1; NbExp=2; IntAct=EBI-716569, EBI-2513471; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11595739, CC ECO:0000269|PubMed:20227374, ECO:0000269|PubMed:22801543}. CC Note=Colocalizes with PCNA and POLD3 at S phase replication sites CC (PubMed:11595739). After UV irradiation, recruited to DNA damage sites CC within 2 hours, independently of the cell cycle phase, nor on PCNA CC ubiquitination. This recruitment requires POLD3, PCNA and RFC1- CC replication factor C complex (PubMed:20227374, PubMed:22801543). CC {ECO:0000269|PubMed:11595739, ECO:0000269|PubMed:20227374, CC ECO:0000269|PubMed:22801543}. CC -!- TISSUE SPECIFICITY: Widely expressed, with high levels of expression in CC heart and lung. {ECO:0000269|PubMed:23770608}. CC -!- DEVELOPMENTAL STAGE: Expression is cell cycle-dependent, with highest CC levels in G2/M phase and lowest in G1. {ECO:0000269|PubMed:22801543}. CC -!- INDUCTION: Up-regulated by serum stimulation. CC {ECO:0000269|PubMed:1542570}. CC -!- DOMAIN: The CysB motif binds 1 4Fe-4S cluster and is required for the CC formation of polymerase complexes. {ECO:0000250}. CC -!- DISEASE: Colorectal cancer 10 (CRCS10) [MIM:612591]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:23263490, CC ECO:0000269|PubMed:24501277}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Mandibular hypoplasia, deafness, progeroid features, and CC lipodystrophy syndrome (MDPL) [MIM:615381]: An autosomal dominant CC systemic disorder characterized by prominent loss of subcutaneous fat, CC metabolic abnormalities including insulin resistance and diabetes CC mellitus, sclerodermatous skin, and a facial appearance characterized CC by mandibular hypoplasia. Sensorineural deafness occurs late in the CC first or second decades of life. {ECO:0000269|PubMed:23770608}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Immunodeficiency 120 (IMD120) [MIM:620836]: An autosomal CC recessive immunologic disorder manifesting in early childhood with CC recurrent upper and lower respiratory tract infections, lymphopenia, CC and hypogammaglobulinemia. Affected individuals may also develop CC persistent viral infections, particularly of the herpes family. CC Additional variable features include hearing loss, speech delay, short CC stature, and mildly impaired intellectual development. CC {ECO:0000269|PubMed:31449058, ECO:0000269|PubMed:31629014}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the DNA polymerase type-B family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M80397; AAA58439.1; -; mRNA. DR EMBL; M81735; AAA35768.1; -; mRNA. DR EMBL; AY129569; AAM76971.1; -; Genomic_DNA. DR EMBL; BC008800; AAH08800.1; -; mRNA. DR CCDS; CCDS12795.1; -. DR PIR; A41618; A41618. DR RefSeq; NP_001243778.1; NM_001256849.1. DR RefSeq; NP_001425141.1; NM_001438212.1. DR RefSeq; NP_001425142.1; NM_001438213.1. DR RefSeq; NP_002682.2; NM_002691.4. DR RefSeq; XP_011525340.1; XM_011527038.2. DR RefSeq; XP_047294903.1; XM_047438947.1. DR RefSeq; XP_054177208.1; XM_054321233.1. DR RefSeq; XP_054177209.1; XM_054321234.1. DR PDB; 6S1M; EM; 4.27 A; A=1-1107. DR PDB; 6S1N; EM; 4.86 A; A=1-1107. DR PDB; 6S1O; EM; 8.10 A; A=1-1107. DR PDB; 6TNY; EM; 3.08 A; A=1-1107. DR PDB; 6TNZ; EM; 4.05 A; A=1-1107. DR PDB; 9EKB; EM; 3.65 A; A=1-1107. DR PDBsum; 6S1M; -. DR PDBsum; 6S1N; -. DR PDBsum; 6S1O; -. DR PDBsum; 6TNY; -. DR PDBsum; 6TNZ; -. DR PDBsum; 9EKB; -. DR AlphaFoldDB; P28340; -. DR EMDB; EMD-10080; -. DR EMDB; EMD-10081; -. DR EMDB; EMD-10082; -. DR EMDB; EMD-10539; -. DR EMDB; EMD-10540; -. DR EMDB; EMD-48117; -. DR SMR; P28340; -. DR BioGRID; 111420; 365. DR ComplexPortal; CPX-2097; DNA polymerase delta complex. DR CORUM; P28340; -. DR FunCoup; P28340; 2398. DR IntAct; P28340; 125. DR MINT; P28340; -. DR STRING; 9606.ENSP00000472445; -. DR BindingDB; P28340; -. DR ChEMBL; CHEMBL2735; -. DR DrugBank; DB12151; Brincidofovir. DR DrugCentral; P28340; -. DR GlyGen; P28340; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; P28340; -. DR PhosphoSitePlus; P28340; -. DR BioMuta; POLD1; -. DR DMDM; 50403732; -. DR jPOST; P28340; -. DR MassIVE; P28340; -. DR PaxDb; 9606-ENSP00000406046; -. DR PeptideAtlas; P28340; -. DR ProteomicsDB; 54478; -. DR Pumba; P28340; -. DR Antibodypedia; 3821; 357 antibodies from 38 providers. DR CPTC; P28340; 1 antibody. DR DNASU; 5424; -. DR Ensembl; ENST00000440232.7; ENSP00000406046.1; ENSG00000062822.17. DR Ensembl; ENST00000593887.2; ENSP00000472607.2; ENSG00000062822.17. DR Ensembl; ENST00000599857.7; ENSP00000473052.1; ENSG00000062822.17. DR Ensembl; ENST00000601098.6; ENSP00000472600.2; ENSG00000062822.17. DR Ensembl; ENST00000687454.1; ENSP00000510052.1; ENSG00000062822.17. DR GeneID; 5424; -. DR KEGG; hsa:5424; -. DR MANE-Select; ENST00000440232.7; ENSP00000406046.1; NM_002691.4; NP_002682.2. DR UCSC; uc002psb.6; human. DR AGR; HGNC:9175; -. DR CIViC; 5424; 3 evidence items across 3 molecular profiles. DR ClinPGx; PA33496; -. DR CTD; 5424; -. DR DisGeNET; 5424; -. DR GeneCards; POLD1; -. DR HGNC; HGNC:9175; POLD1. DR HPA; ENSG00000062822; Low tissue specificity. DR MalaCards; POLD1; -. DR MIM; 174761; gene. DR MIM; 612591; phenotype. DR MIM; 615381; phenotype. DR MIM; 620836; phenotype. DR OpenTargets; ENSG00000062822; -. DR Orphanet; 440437; Familial colorectal cancer Type X. DR Orphanet; 363649; Mandibular hypoplasia-deafness-progeroid features-lipodystrophy syndrome. DR Orphanet; 447877; Polymerase proofreading-related polyposis. DR VEuPathDB; HostDB:ENSG00000062822; -. DR eggNOG; KOG0969; Eukaryota. DR GeneTree; ENSGT00560000077365; -. DR HOGENOM; CLU_000203_2_0_1; -. DR InParanoid; P28340; -. DR OrthoDB; 2414538at2759; -. DR PAN-GO; P28340; 7 GO annotations based on evolutionary models. DR PhylomeDB; P28340; -. DR BRENDA; 2.7.7.7; 2681. DR PathwayCommons; P28340; -. DR Reactome; R-HSA-110314; Recognition of DNA damage by PCNA-containing replication complex. DR Reactome; R-HSA-174411; Polymerase switching on the C-strand of the telomere. DR Reactome; R-HSA-174414; Processive synthesis on the C-strand of the telomere. DR Reactome; R-HSA-174417; Telomere C-strand (Lagging Strand) Synthesis. DR Reactome; R-HSA-174437; Removal of the Flap Intermediate from the C-strand. DR Reactome; R-HSA-2564830; Cytosolic iron-sulfur cluster assembly. DR Reactome; R-HSA-5358565; Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha). DR Reactome; R-HSA-5358606; Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta). DR Reactome; R-HSA-5651801; PCNA-Dependent Long Patch Base Excision Repair. DR Reactome; R-HSA-5656169; Termination of translesion DNA synthesis. DR Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR). DR Reactome; R-HSA-5696397; Gap-filling DNA repair synthesis and ligation in GG-NER. DR Reactome; R-HSA-5696400; Dual Incision in GG-NER. DR Reactome; R-HSA-6782135; Dual incision in TC-NER. DR Reactome; R-HSA-6782210; Gap-filling DNA repair synthesis and ligation in TC-NER. DR Reactome; R-HSA-69091; Polymerase switching. DR Reactome; R-HSA-69166; Removal of the Flap Intermediate. DR Reactome; R-HSA-69183; Processive synthesis on the lagging strand. DR SignaLink; P28340; -. DR SIGNOR; P28340; -. DR Agora; ENSG00000062822; -. DR BioGRID-ORCS; 5424; 795 hits in 1163 CRISPR screens. DR ChiTaRS; POLD1; human. DR GeneWiki; POLD1; -. DR GenomeRNAi; 5424; -. DR Pharos; P28340; Tclin. DR PRO; PR:P28340; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; P28340; protein. DR Bgee; ENSG00000062822; Expressed in mucosa of transverse colon and 96 other cell types or tissues. DR ExpressionAtlas; P28340; baseline and differential. DR GO; GO:0016235; C:aggresome; IDA:HPA. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0043625; C:delta DNA polymerase complex; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0000109; C:nucleotide-excision repair complex; IDA:UniProtKB. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0008296; F:3'-5'-DNA exonuclease activity; IBA:GO_Central. DR GO; GO:0051539; F:4 iron, 4 sulfur cluster binding; IEA:UniProtKB-KW. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0003684; F:damaged DNA binding; IDA:UniProtKB. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0003887; F:DNA-directed DNA polymerase activity; IMP:UniProtKB. DR GO; GO:0019899; F:enzyme binding; IEA:Ensembl. DR GO; GO:0000166; F:nucleotide binding; IEA:InterPro. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0006287; P:base-excision repair, gap-filling; IDA:UniProtKB. DR GO; GO:0034644; P:cellular response to UV; IDA:UniProtKB. DR GO; GO:0071897; P:DNA biosynthetic process; IDA:UniProtKB. DR GO; GO:0006281; P:DNA repair; TAS:ProtInc. DR GO; GO:0006260; P:DNA replication; IMP:UniProtKB. DR GO; GO:0045004; P:DNA replication proofreading; IBA:GO_Central. DR GO; GO:0000731; P:DNA synthesis involved in DNA repair; IDA:UniProtKB. DR GO; GO:0006261; P:DNA-templated DNA replication; IDA:ComplexPortal. DR GO; GO:0070987; P:error-free translesion synthesis; IDA:UniProtKB. DR GO; GO:0055089; P:fatty acid homeostasis; IMP:UniProtKB. DR GO; GO:0006297; P:nucleotide-excision repair, DNA gap filling; IMP:UniProtKB. DR GO; GO:0009411; P:response to UV; TAS:ProtInc. DR CDD; cd05777; DNA_polB_delta_exo; 1. DR CDD; cd05533; POLBc_delta; 1. DR FunFam; 1.10.132.60:FF:000001; DNA polymerase; 1. DR FunFam; 1.10.287.690:FF:000001; DNA polymerase; 1. DR FunFam; 3.30.342.10:FF:000003; DNA polymerase; 1. DR FunFam; 3.30.420.10:FF:000351; DNA polymerase; 1. DR Gene3D; 1.10.132.60; DNA polymerase family B, C-terminal domain; 1. DR Gene3D; 3.30.342.10; DNA Polymerase, chain B, domain 1; 1. DR Gene3D; 1.10.287.690; Helix hairpin bin; 1. DR Gene3D; 3.90.1600.10; Palm domain of DNA polymerase; 1. DR Gene3D; 3.30.420.10; Ribonuclease H-like superfamily/Ribonuclease H; 1. DR InterPro; IPR006172; DNA-dir_DNA_pol_B. DR InterPro; IPR017964; DNA-dir_DNA_pol_B_CS. DR InterPro; IPR006133; DNA-dir_DNA_pol_B_exonuc. DR InterPro; IPR006134; DNA-dir_DNA_pol_B_multi_dom. DR InterPro; IPR043502; DNA/RNA_pol_sf. DR InterPro; IPR042087; DNA_pol_B_thumb. DR InterPro; IPR023211; DNA_pol_palm_dom_sf. DR InterPro; IPR050240; DNA_pol_type-B. DR InterPro; IPR056435; DPOD/Z_N. DR InterPro; IPR012337; RNaseH-like_sf. DR InterPro; IPR036397; RNaseH_sf. DR InterPro; IPR025687; Znf-C4pol. DR NCBIfam; TIGR00592; pol2; 1. DR PANTHER; PTHR10322; DNA POLYMERASE CATALYTIC SUBUNIT; 1. DR PANTHER; PTHR10322:SF23; DNA POLYMERASE DELTA CATALYTIC SUBUNIT; 1. DR Pfam; PF00136; DNA_pol_B; 1. DR Pfam; PF03104; DNA_pol_B_exo1; 1. DR Pfam; PF24055; POL3_N; 1. DR Pfam; PF14260; zf-C4pol; 1. DR PRINTS; PR00106; DNAPOLB. DR SMART; SM00486; POLBc; 1. DR SUPFAM; SSF56672; DNA/RNA polymerases; 1. DR SUPFAM; SSF53098; Ribonuclease H-like; 1. DR PROSITE; PS00116; DNA_POLYMERASE_B; 1. PE 1: Evidence at protein level; KW 3D-structure; 4Fe-4S; Disease variant; DNA damage; DNA excision; KW DNA repair; DNA replication; DNA-binding; DNA-directed DNA polymerase; KW Exonuclease; Hydrolase; Iron; Iron-sulfur; Isopeptide bond; Metal-binding; KW Methylation; Nuclease; Nucleotidyltransferase; Nucleus; KW Proteomics identification; Reference proteome; Transferase; KW Ubl conjugation; Zinc; Zinc-finger. FT CHAIN 1..1107 FT /note="DNA polymerase delta catalytic subunit" FT /id="PRO_0000046442" FT ZN_FING 1012..1029 FT /note="CysA-type" FT REGION 1..34 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 4..19 FT /note="Nuclear localization signal" FT /evidence="ECO:0000255" FT MOTIF 1058..1076 FT /note="CysB motif" FT BINDING 1012 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250" FT BINDING 1015 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250" FT BINDING 1026 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250" FT BINDING 1029 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250" FT BINDING 1058 FT /ligand="[4Fe-4S] cluster" FT /ligand_id="ChEBI:CHEBI:49883" FT /evidence="ECO:0000250" FT BINDING 1061 FT /ligand="[4Fe-4S] cluster" FT /ligand_id="ChEBI:CHEBI:49883" FT /evidence="ECO:0000250" FT BINDING 1071 FT /ligand="[4Fe-4S] cluster" FT /ligand_id="ChEBI:CHEBI:49883" FT /evidence="ECO:0000250" FT BINDING 1076 FT /ligand="[4Fe-4S] cluster" FT /ligand_id="ChEBI:CHEBI:49883" FT /evidence="ECO:0000250" FT MOD_RES 19 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0007744|PubMed:24129315" FT CROSSLNK 574 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VARIANT 5 FT /note="R -> W (in dbSNP:rs9282830)" FT /id="VAR_048878" FT VARIANT 19 FT /note="R -> H (in dbSNP:rs3218773)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_019340" FT VARIANT 21 FT /note="G -> C (in dbSNP:rs9282831)" FT /id="VAR_048879" FT VARIANT 30 FT /note="R -> W (in dbSNP:rs3218772)" FT /evidence="ECO:0000269|PubMed:1722322, ECO:0000269|Ref.3" FT /id="VAR_016146" FT VARIANT 119 FT /note="R -> H (in dbSNP:rs1726801)" FT /evidence="ECO:0000269|PubMed:1542570, FT ECO:0000269|PubMed:15489334, ECO:0000269|Ref.3" FT /id="VAR_019341" FT VARIANT 145 FT /note="A -> D (found in a colorectal sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069333" FT VARIANT 173 FT /note="S -> N (in dbSNP:rs1726803)" FT /evidence="ECO:0000269|PubMed:1542570, ECO:0000269|Ref.3" FT /id="VAR_019342" FT VARIANT 177 FT /note="R -> H (in dbSNP:rs3218750)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_019343" FT VARIANT 347 FT /note="P -> L (in dbSNP:rs2230243)" FT /id="VAR_048880" FT VARIANT 461 FT /note="Q -> H (found in a colorectal sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069334" FT VARIANT 474 FT /note="L -> P (in CRCS10; dbSNP:rs587777627)" FT /evidence="ECO:0000269|PubMed:24501277" FT /id="VAR_071966" FT VARIANT 478 FT /note="S -> N (risk factor for CRCS10; dbSNP:rs397514632)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069335" FT VARIANT 605 FT /note="Missing (in MDPL; the mutant enzyme lacks DNA FT polymerase ability; has decreased exonuclease activity; can FT bind DNA but is unable to interact with and incorporate FT dNTPs)" FT /evidence="ECO:0000269|PubMed:23770608" FT /id="VAR_070231" FT VARIANT 684 FT /note="Q -> H (in IMD120; uncertain significance; does not FT affect interaction with POLD2 and POLD3; does not affect FT protein stability when tested in a heterologous system; FT strongly decreased polymerase activity, when tested in FT transfected HEK293 cells in association with W-939)" FT /evidence="ECO:0000269|PubMed:31449058" FT /id="VAR_089633" FT VARIANT 787 FT /note="P -> L (found in a colorectal sample; somatic FT mutation; dbSNP:rs199783227)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069336" FT VARIANT 808 FT /note="R -> H (found in a colorectal sample; somatic FT mutation; dbSNP:rs771700024)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069337" FT VARIANT 849 FT /note="R -> H (in dbSNP:rs3218775)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_019344" FT VARIANT 864 FT /note="A -> T (found in a colorectal sample; somatic FT mutation; dbSNP:rs765437818)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069338" FT VARIANT 939 FT /note="S -> W (in IMD120; uncertain significance; does not FT affect interaction with POLD2 and POLD3; strongly decreased FT polymerase activity, when tested in transfected HEK293 FT cells in association with H-684)" FT /evidence="ECO:0000269|PubMed:31449058" FT /id="VAR_089634" FT VARIANT 1060 FT /note="R -> C (in IMD120; likely pathogenic; strongly FT reduced interaction with POLD2 and RFC1; leads to lower T FT cell proliferation following cell activation)" FT /evidence="ECO:0000269|PubMed:31629014" FT /id="VAR_089635" FT VARIANT 1074 FT /note="R -> W (in IMD120; uncertain significance; decreased FT polymerase activity, when tested in transfected HEK293 FT cells; does not affect protein stability when tested in a FT heterologous system; does not affect interaction with POLD2 FT and POLD3)" FT /evidence="ECO:0000269|PubMed:31449058" FT /id="VAR_089636" FT VARIANT 1086 FT /note="R -> Q (in dbSNP:rs3219457)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_019345" FT MUTAGEN 402 FT /note="D->A: Loss of exonuclease activity. No effect on DNA FT polymerase activity." FT /evidence="ECO:0000269|PubMed:19074196, FT ECO:0000269|PubMed:20334433" FT MUTAGEN 602 FT /note="D->A: Loss of polymerase activity; when associated FT with A-757." FT /evidence="ECO:0000269|PubMed:31449058" FT MUTAGEN 757 FT /note="D->A: Loss of polymerase activity; when associated FT with A-602." FT /evidence="ECO:0000269|PubMed:31449058" FT CONFLICT 472 FT /note="Y -> H (in Ref. 1; AAA58439)" FT /evidence="ECO:0000305" FT CONFLICT 776 FT /note="R -> G (in Ref. 2; AAA35768)" FT /evidence="ECO:0000305" FT TURN 89..91 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 94..105 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 123..134 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 136..142 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 147..151 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 154..157 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 161..168 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 174..176 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 177..179 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 180..183 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 192..195 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 197..200 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 207..213 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 217..219 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 220..227 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 228..230 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 234..238 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 250..258 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 265..268 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 285..291 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 296..298 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 302..305 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 311..319 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 329..331 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 334..343 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 346..348 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 350..358 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 366..370 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 374..388 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 391..397 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 398..401 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 402..412 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 416..419 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 422..424 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 431..438 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 439..441 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 442..449 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 455..458 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 459..466 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 474..481 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 494..498 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 502..525 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 528..539 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 545..547 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 552..563 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 564..567 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 592..594 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 598..605 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 606..613 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 618..620 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 624..629 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 634..636 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 637..639 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 641..643 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 645..647 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 649..651 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 656..674 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 680..704 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 707..710 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 714..738 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 741..744 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 745..747 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 750..762 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 768..782 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 784..786 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 792..805 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 808..819 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 824..829 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 830..832 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 834..836 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 838..852 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 857..872 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 878..881 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 883..886 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 890..894 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 899..905 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 920..927 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 937..940 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 942..948 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 954..959 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 960..962 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 963..970 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 977..989 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 1002..1004 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 1013..1015 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 1020..1022 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 1034..1055 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 1057..1062 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 1065..1067 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 1078..1095 FT /evidence="ECO:0007829|PDB:6TNY" SQ SEQUENCE 1107 AA; 123631 MW; 9D04D34AB4AEE810 CRC64; MDGKRRPGPG PGVPPKRARG GLWDDDDAPR PSQFEEDLAL MEEMEAEHRL QEQEEEELQS VLEGVADGQV PPSAIDPRWL RPTPPALDPQ TEPLIFQQLE IDHYVGPAQP VPGGPPPSRG SVPVLRAFGV TDEGFSVCCH IHGFAPYFYT PAPPGFGPEH MGDLQRELNL AISRDSRGGR ELTGPAVLAV ELCSRESMFG YHGHGPSPFL RITVALPRLV APARRLLEQG IRVAGLGTPS FAPYEANVDF EIRFMVDTDI VGCNWLELPA GKYALRLKEK ATQCQLEADV LWSDVVSHPP EGPWQRIAPL RVLSFDIECA GRKGIFPEPE RDPVIQICSL GLRWGEPEPF LRLALTLRPC APILGAKVQS YEKEEDLLQA WSTFIRIMDP DVITGYNIQN FDLPYLISRA QTLKVQTFPF LGRVAGLCSN IRDSSFQSKQ TGRRDTKVVS MVGRVQMDML QVLLREYKLR SYTLNAVSFH FLGEQKEDVQ HSIITDLQNG NDQTRRRLAV YCLKDAYLPL RLLERLMVLV NAVEMARVTG VPLSYLLSRG QQVKVVSQLL RQAMHEGLLM PVVKSEGGED YTGATVIEPL KGYYDVPIAT LDFSSLYPSI MMAHNLCYTT LLRPGTAQKL GLTEDQFIRT PTGDEFVKTS VRKGLLPQIL ENLLSARKRA KAELAKETDP LRRQVLDGRQ LALKVSANSV YGFTGAQVGK LPCLEISQSV TGFGRQMIEK TKQLVESKYT VENGYSTSAK VVYGDTDSVM CRFGVSSVAE AMALGREAAD WVSGHFPSPI RLEFEKVYFP YLLISKKRYA GLLFSSRPDA HDRMDCKGLE AVRRDNCPLV ANLVTASLRR LLIDRDPEGA VAHAQDVISD LLCNRIDISQ LVITKELTRA ASDYAGKQAH VELAERMRKR DPGSAPSLGD RVPYVIISAA KGVAAYMKSE DPLFVLEHSL PIDTQYYLEQ QLAKPLLRIF EPILGEGRAE AVLLRGDHTR CKTVLTGKVG GLLAFAKRRN CCIGCRTVLS HQGAVCEFCQ PRESELYQKE VSHLNALEER FSRLWTQCQR CQGSLHEDVI CTSRDCPIFY MRKKVRKDLE DQEQLLRRFG PPGPEAW // ID DYRK2_HUMAN Reviewed; 601 AA. AC Q92630; B2R9V9; Q9BRB5; DT 27-APR-2001, integrated into UniProtKB/Swiss-Prot. DT 12-JUN-2007, sequence version 3. DT 28-JAN-2026, entry version 229. DE RecName: Full=Dual specificity tyrosine-phosphorylation-regulated kinase 2; DE EC=2.7.12.1 {ECO:0000269|PubMed:22998443}; GN Name=DYRK2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, COFACTOR, RP PHOSPHORYLATION, AND TISSUE SPECIFICITY. RC TISSUE=Fetal brain; RX PubMed=9748265; DOI=10.1074/jbc.273.40.25893; RA Becker W., Weber Y., Wetzel K., Eirmbter K., Tejedor F.J., Joost H.-G.; RT "Sequence characteristics, subcellular localization, and substrate RT specificity of DYRK-related kinases, a novel family of dual specificity RT protein kinases."; RL J. Biol. Chem. 273:25893-25902(1998). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Muscle, and Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 320-528 (ISOFORMS 1/2). RC TISSUE=Placenta; RA Becker W., Joost H.-G.; RL Submitted (NOV-1996) to the EMBL/GenBank/DDBJ databases. RN [6] RP FUNCTION. RX PubMed=11311121; DOI=10.1042/bj3550609; RA Woods Y.L., Cohen P., Becker W., Jakes R., Goedert M., Wang X., Proud C.G.; RT "The kinase DYRK phosphorylates protein-synthesis initiation factor RT eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at RT Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming RT kinase."; RL Biochem. J. 355:609-615(2001). RN [7] RP INDUCTION IN CANCER. RX PubMed=12874018; RA Miller C.T., Aggarwal S., Lin T.K., Dagenais S.L., Contreras J.I., RA Orringer M.B., Glover T.W., Beer D.G., Lin L.; RT "Amplification and overexpression of the dual-specificity tyrosine-(Y)- RT phosphorylation regulated kinase 2 (DYRK2) gene in esophageal and lung RT adenocarcinomas."; RL Cancer Res. 63:4136-4143(2003). RN [8] RP FUNCTION. RX PubMed=12588975; DOI=10.1128/mcb.23.5.1546-1557.2003; RA Wang X., Li W., Parra J.L., Beugnet A., Proud C.G.; RT "The C terminus of initiation factor 4E-binding protein 1 contains multiple RT regulatory features that influence its function and phosphorylation."; RL Mol. Cell. Biol. 23:1546-1557(2003). RN [9] RP FUNCTION. RX PubMed=14593110; DOI=10.1074/jbc.m301769200; RA Skurat A.V., Dietrich A.D.; RT "Phosphorylation of Ser640 in muscle glycogen synthase by DYRK family RT protein kinases."; RL J. Biol. Chem. 279:2490-2498(2004). RN [10] RP INTERACTION WITH CCNL2. RX PubMed=14623875; DOI=10.1074/jbc.m310794200; RA de Graaf K., Hekerman P., Spelten O., Herrmann A., Packman L.C., Bussow K., RA Muller-Newen G., Becker W.; RT "Characterization of cyclin L2, a novel cyclin with an arginine/serine-rich RT domain: phosphorylation by DYRK1A and colocalization with splicing RT factors."; RL J. Biol. Chem. 279:4612-4624(2004). RN [11] RP FUNCTION. RX PubMed=15910284; DOI=10.1042/bj20050733; RA Auld G.C., Campbell D.G., Morrice N., Cohen P.; RT "Identification of calcium-regulated heat-stable protein of 24 kDa RT (CRHSP24) as a physiological substrate for PKB and RSK using KESTREL."; RL Biochem. J. 389:775-783(2005). RN [12] RP FUNCTION AS CRMP4/DPYSL3 KINASE, AND ACTIVITY REGULATION BY PURVALANOL. RX PubMed=16611631; DOI=10.1074/jbc.m513344200; RA Cole A.R., Causeret F., Yadirgi G., Hastie C.J., McLauchlan H., RA McManus E.J., Hernandez F., Eickholt B.J., Nikolic M., Sutherland C.; RT "Distinct priming kinases contribute to differential regulation of RT collapsin response mediator proteins by glycogen synthase kinase-3 in RT vivo."; RL J. Biol. Chem. 281:16591-16598(2006). RN [13] RP FUNCTION, AND INTERACTION WITH NFATC1. RX PubMed=16511445; DOI=10.1038/nature04631; RA Gwack Y., Sharma S., Nardone J., Tanasa B., Iuga A., Srikanth S., RA Okamura H., Bolton D., Feske S., Hogan P.G., Rao A.; RT "A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as RT regulators of NFAT."; RL Nature 441:646-650(2006). RN [14] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=17349958; DOI=10.1016/j.molcel.2007.02.007; RA Taira N., Nihira K., Yamaguchi T., Miki Y., Yoshida K.; RT "DYRK2 is targeted to the nucleus and controls p53 via Ser46 RT phosphorylation in the apoptotic response to DNA damage."; RL Mol. Cell 25:725-738(2007). RN [15] RP FUNCTION IN APOPTOSIS AS P53/TP53 KINASE, SUBCELLULAR LOCATION, RP PHOSPHORYLATION BY ATM, AND GENE FAMILY. RX PubMed=18599021; DOI=10.1016/j.bcp.2008.05.021; RA Yoshida K.; RT "Role for DYRK family kinases on regulation of apoptosis."; RL Biochem. Pharmacol. 76:1389-1394(2008). RN [16] RP FUNCTION, AND PHOSPHORYLATION AT THR-381 AND SER-449. RX PubMed=18455992; DOI=10.1016/j.cell.2008.02.047; RA Varjosalo M., Bjorklund M., Cheng F., Syvanen H., Kivioja T., Kilpinen S., RA Sun Z., Kallioniemi O., Stunnenberg H.G., He W.W., Ojala P., Taipale J.; RT "Application of active and kinase-deficient kinome collection for RT identification of kinases regulating hedgehog signaling."; RL Cell 133:537-548(2008). RN [17] RP SUBCELLULAR LOCATION. RX PubMed=18539531; DOI=10.1016/j.molmed.2008.05.003; RA Yoshida K.; RT "Nuclear trafficking of pro-apoptotic kinases in response to DNA damage."; RL Trends Mol. Med. 14:305-313(2008). RN [18] RP ACTIVITY REGULATION BY HARMINE. RX PubMed=19796173; DOI=10.1111/j.1742-4658.2009.07346.x; RA Goeckler N., Jofre G., Papadopoulos C., Soppa U., Tejedor F.J., Becker W.; RT "Harmine specifically inhibits protein kinase DYRK1A and interferes with RT neurite formation."; RL FEBS J. 276:6324-6337(2009). RN [19] RP FUNCTION IN E3 LIGASE REGULATION, FUNCTION AS KATNA1 KINASE, AND RP INTERACTION WITH EDVP COMPLEX. RX PubMed=19287380; DOI=10.1038/ncb1848; RA Maddika S., Chen J.; RT "Protein kinase DYRK2 is a scaffold that facilitates assembly of an E3 RT ligase."; RL Nat. Cell Biol. 11:409-419(2009). RN [20] RP ACTIVITY REGULATION BY ACRIDINE ANALOGS. RX PubMed=20836251; DOI=10.1016/j.bmcl.2010.04.150; RA Cuny G.D., Robin M., Ulyanova N.P., Patnaik D., Pique V., Casano G., RA Liu J.-F., Lin X., Xian J., Glicksman M.A., Stein R.L., Higgins J.M.G.; RT "Structure-activity relationship study of acridine analogs as haspin and RT DYRK2 kinase inhibitors."; RL Bioorg. Med. Chem. Lett. 20:3491-3494(2010). RN [21] RP SUBCELLULAR LOCATION, PHOSPHORYLATION AT THR-106 AND SER-442 BY ATM, RP UBIQUITINATION BY MDM2, INTERACTION WITH MDM2, MUTAGENESIS OF THR-106; RP SER-442 AND 189-LYS--ARG-191, NUCLEAR LOCALIZATION SIGNAL, AND INDUCTION BY RP DNA DAMAGE. RX PubMed=19965871; DOI=10.1074/jbc.m109.042341; RA Taira N., Yamamoto H., Yamaguchi T., Miki Y., Yoshida K.; RT "ATM augments nuclear stabilization of DYRK2 by inhibiting MDM2 in the RT apoptotic response to DNA damage."; RL J. Biol. Chem. 285:4909-4919(2010). RN [22] RP FUNCTION. RX PubMed=22307329; DOI=10.1172/jci60818; RA Taira N., Mimoto R., Kurata M., Yamaguchi T., Kitagawa M., Miki Y., RA Yoshida K.; RT "DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle RT progression in human cancer cells."; RL J. Clin. Invest. 122:859-872(2012). RN [23] RP FUNCTION, AND UBIQUITINATION BY SIAH2. RX PubMed=22878263; DOI=10.1093/jmcb/mjs047; RA Perez M., Garcia-Limones C., Zapico I., Marina A., Schmitz M.L., Munoz E., RA Calzado M.A.; RT "Mutual regulation between SIAH2 and DYRK2 controls hypoxic and genotoxic RT signaling pathways."; RL J. Mol. Cell Biol. 4:316-330(2012). RN [24] RP FUNCTION, AND MUTAGENESIS OF LYS-251. RX PubMed=23362280; DOI=10.1074/jbc.m112.416792; RA Jung H.Y., Wang X., Jun S., Park J.I.; RT "Dyrk2-associated EDD-DDB1-VprBP E3 ligase inhibits telomerase by TERT RT degradation."; RL J. Biol. Chem. 288:7252-7262(2013). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-30, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [26] RP X-RAY CRYSTALLOGRAPHY (2.28 ANGSTROMS) OF 146-552 IN COMPLEX WITH RP INDIRUBIN. RG Structural genomics consortium (SGC); RT "Crystal structure of dual-specificity tyrosine phosphorylation regulated RT kinase 2 (DYRK2) in complex with an indirubin ligand."; RL Submitted (JAN-2010) to the PDB data bank. RN [27] RP X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS) OF 146-540 IN COMPLEX WITH RP LEUCETTAMINE DERIVATIVE, PHOSPHORYLATION AT TYR-382, AUTOPHOSPHORYLATION, RP ACTIVITY REGULATION, AND CATALYTIC ACTIVITY. RX PubMed=22998443; DOI=10.1021/jm301034u; RA Tahtouh T., Elkins J.M., Filippakopoulos P., Soundararajan M., Burgy G., RA Durieu E., Cochet C., Schmid R.S., Lo D.C., Delhommel F., Oberholzer A.E., RA Pearl L.H., Carreaux F., Bazureau J.P., Knapp S., Meijer L.; RT "Selectivity, cocrystal structures, and neuroprotective properties of RT leucettines, a family of protein kinase inhibitors derived from the marine RT sponge alkaloid leucettamine B."; RL J. Med. Chem. 55:9312-9330(2012). RN [28] RP X-RAY CRYSTALLOGRAPHY (2.36 ANGSTROMS) OF 146-552. RX PubMed=23665168; DOI=10.1016/j.str.2013.03.012; RA Soundararajan M., Roos A.K., Savitsky P., Filippakopoulos P., RA Kettenbach A.N., Olsen J.V., Gerber S.A., Eswaran J., Knapp S., RA Elkins J.M.; RT "Structures of Down syndrome kinases, DYRKs, reveal mechanisms of kinase RT activation and substrate recognition."; RL Structure 21:986-996(2013). RN [29] RP VARIANTS [LARGE SCALE ANALYSIS] GLY-98; LEU-198; ASN-245; SER-295; GLN-451 RP AND TYR-455. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase involved in the regulation of CC the mitotic cell cycle, cell proliferation, apoptosis, organization of CC the cytoskeleton and neurite outgrowth. Functions in part via its role CC in ubiquitin-dependent proteasomal protein degradation. Functions CC downstream of ATM and phosphorylates p53/TP53 at 'Ser-46', and thereby CC contributes to the induction of apoptosis in response to DNA damage. CC Phosphorylates NFATC1, and thereby inhibits its accumulation in the CC nucleus and its transcription factor activity. Phosphorylates EIF2B5 at CC 'Ser-544', enabling its subsequent phosphorylation and inhibition by CC GSK3B. Likewise, phosphorylation of NFATC1, CRMP2/DPYSL2 and CC CRMP4/DPYSL3 promotes their subsequent phosphorylation by GSK3B. May CC play a general role in the priming of GSK3 substrates. Inactivates GYS1 CC by phosphorylation at 'Ser-641', and potentially also a second CC phosphorylation site, thus regulating glycogen synthesis. Mediates EDVP CC E3 ligase complex formation and is required for the phosphorylation and CC subsequent degradation of KATNA1. Phosphorylates TERT at 'Ser-457', CC promoting TERT ubiquitination by the EDVP complex. Phosphorylates CC SIAH2, and thereby increases its ubiquitin ligase activity. Promotes CC the proteasomal degradation of MYC and JUN, and thereby regulates CC progress through the mitotic cell cycle and cell proliferation. CC Promotes proteasomal degradation of GLI2 and GLI3, and thereby plays a CC role in smoothened and sonic hedgehog signaling. Plays a role in CC cytoskeleton organization and neurite outgrowth via its phosphorylation CC of DCX and DPYSL2. Phosphorylates CRMP2/DPYSL2, CRMP4/DPYSL3, DCX, CC EIF2B5, EIF4EBP1, GLI2, GLI3, GYS1, JUN, MDM2, MYC, NFATC1, p53/TP53, CC TAU/MAPT and KATNA1. Can phosphorylate histone H1, histone H3 and CC histone H2B (in vitro). Can phosphorylate CARHSP1 (in vitro). CC {ECO:0000269|PubMed:11311121, ECO:0000269|PubMed:12588975, CC ECO:0000269|PubMed:14593110, ECO:0000269|PubMed:15910284, CC ECO:0000269|PubMed:16511445, ECO:0000269|PubMed:16611631, CC ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:18455992, CC ECO:0000269|PubMed:18599021, ECO:0000269|PubMed:19287380, CC ECO:0000269|PubMed:22307329, ECO:0000269|PubMed:22878263, CC ECO:0000269|PubMed:23362280, ECO:0000269|PubMed:9748265}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.12.1; CC Evidence={ECO:0000269|PubMed:22998443}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.12.1; CC Evidence={ECO:0000269|PubMed:22998443}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.12.1; CC Evidence={ECO:0000269|PubMed:22998443}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:9748265}; CC -!- COFACTOR: CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; CC Evidence={ECO:0000269|PubMed:9748265}; CC -!- ACTIVITY REGULATION: Activated by autophosphorylation on the second CC tyrosine residue in the Tyr-X-Tyr motif in the activation loop. CC Inhibited by acridine analogs, purvalanol, and barely by harmine. CC Inhibited by leucettine and leucettine derivatives. CC {ECO:0000269|PubMed:16611631, ECO:0000269|PubMed:19796173, CC ECO:0000269|PubMed:20836251, ECO:0000269|PubMed:22998443}. CC -!- SUBUNIT: Component of an E3 ligase complex containing DYRK2, EDD/UBR5, CC DDB1 and DCAF1 (EDVP complex). Interacts directly with EDD/UBR5, DDB1 CC and DCAF1. Interacts with SIAH2 and MDM2. Interacts with MAP3K10 and CC NFATC1. May also interact with CCNL2. {ECO:0000269|PubMed:14623875, CC ECO:0000269|PubMed:16511445, ECO:0000269|PubMed:19287380, CC ECO:0000269|PubMed:19965871, ECO:0000269|PubMed:22998443, CC ECO:0000269|Ref.26}. CC -!- INTERACTION: CC Q92630; Q9NR20: DYRK4; NbExp=3; IntAct=EBI-749432, EBI-3914009; CC Q92630; Q13422: IKZF1; NbExp=3; IntAct=EBI-749432, EBI-745305; CC Q92630; Q9BQD3: KXD1; NbExp=3; IntAct=EBI-749432, EBI-739657; CC Q92630; Q9BRK4: LZTS2; NbExp=3; IntAct=EBI-749432, EBI-741037; CC Q92630; P23497: SP100; NbExp=3; IntAct=EBI-749432, EBI-751145; CC Q92630; O43379: WDR62; NbExp=3; IntAct=EBI-749432, EBI-714790; CC Q92630; P62258: YWHAE; NbExp=2; IntAct=EBI-749432, EBI-356498; CC Q92630; Q96C00: ZBTB9; NbExp=3; IntAct=EBI-749432, EBI-395708; CC -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Translocates into the CC nucleus following DNA damage. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q92630-1; Sequence=Displayed; CC Name=2; CC IsoId=Q92630-2; Sequence=VSP_026115; CC -!- TISSUE SPECIFICITY: Testis, after the onset of spermatogenesis. CC {ECO:0000269|PubMed:9748265}. CC -!- INDUCTION: Accumulates in nucleus upon DNA damage. Induced in both CC esophageal and lung adenocarcinomas. {ECO:0000269|PubMed:12874018, CC ECO:0000269|PubMed:19965871}. CC -!- PTM: Autophosphorylates cotranslationally on the second tyrosine CC residue in the Tyr-X-Tyr motif in the activation loop, but once mature, CC does not have any protein tyrosine kinase activity. Phosphorylated at CC Thr-106 and Ser-442 by ATM in response to genotoxic stress. CC {ECO:0000269|PubMed:19965871}. CC -!- PTM: Under normal conditions, polyubiquitinated in the nucleus by MDM2, CC leading to its proteasomal degradation. Phosphorylation on Thr-106 and CC Ser-442 by ATM in response to genotoxic stress disrupts MDM2 binding CC and prevents MDM2-mediated ubiquitination and subsequent proteasomal CC degradation. Polyubiquitinated by SIAH2, leading to its proteasomal CC degradation. Polyubiquitinated by SIAH2 occurs under normal conditions, CC and is enhanced in response to hypoxia. {ECO:0000269|PubMed:19965871, CC ECO:0000269|PubMed:22878263}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr CC protein kinase family. MNB/DYRK subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=CAA73885.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; Y13493; CAA73885.1; ALT_INIT; mRNA. DR EMBL; AK313937; BAG36656.1; -; mRNA. DR EMBL; CH471054; EAW97176.1; -; Genomic_DNA. DR EMBL; BC005809; AAH05809.1; -; mRNA. DR EMBL; BC006375; AAH06375.1; -; mRNA. DR EMBL; Y09216; CAA70418.1; -; mRNA. DR CCDS; CCDS8978.1; -. [Q92630-1] DR CCDS; CCDS8979.1; -. [Q92630-2] DR RefSeq; NP_003574.1; NM_003583.4. [Q92630-2] DR RefSeq; NP_006473.2; NM_006482.3. [Q92630-1] DR RefSeq; XP_016875521.1; XM_017020032.2. [Q92630-2] DR PDB; 3K2L; X-ray; 2.36 A; A=146-552. DR PDB; 3KVW; X-ray; 2.28 A; A=146-552. DR PDB; 4AZF; X-ray; 2.55 A; A=146-540. DR PDB; 5LXC; X-ray; 2.15 A; A/B=146-552. DR PDB; 5LXD; X-ray; 2.58 A; A/B=146-552. DR PDB; 5ZTN; X-ray; 2.50 A; A/B=146-552. DR PDB; 6HDP; X-ray; 2.30 A; A=146-552. DR PDB; 6HDR; X-ray; 2.20 A; A=146-552. DR PDB; 6K0J; X-ray; 2.35 A; A=212-536. DR PDB; 7AKF; X-ray; 2.60 A; A=146-552. DR PDB; 7AKH; X-ray; 2.85 A; A=146-552. DR PDB; 7DG4; X-ray; 2.58 A; A=215-538. DR PDB; 7DH3; X-ray; 2.33 A; A=213-538. DR PDB; 7DH9; X-ray; 2.19 A; A=215-538. DR PDB; 7DHC; X-ray; 2.59 A; A=215-538. DR PDB; 7DHH; X-ray; 2.49 A; A=215-538. DR PDB; 7DHK; X-ray; 2.34 A; A=215-538. DR PDB; 7DHN; X-ray; 2.38 A; A=215-538. DR PDB; 7DHO; X-ray; 3.29 A; A=215-538. DR PDB; 7DHV; X-ray; 2.68 A; A=212-538. DR PDB; 7DJO; X-ray; 2.50 A; A=215-538. DR PDB; 7DL6; X-ray; 2.65 A; A=215-538. DR PDB; 7EJV; X-ray; 2.50 A; A=151-537, B=153-543. DR PDB; 8HLT; X-ray; 2.80 A; A/B=145-537. DR PDBsum; 3K2L; -. DR PDBsum; 3KVW; -. DR PDBsum; 4AZF; -. DR PDBsum; 5LXC; -. DR PDBsum; 5LXD; -. DR PDBsum; 5ZTN; -. DR PDBsum; 6HDP; -. DR PDBsum; 6HDR; -. DR PDBsum; 6K0J; -. DR PDBsum; 7AKF; -. DR PDBsum; 7AKH; -. DR PDBsum; 7DG4; -. DR PDBsum; 7DH3; -. DR PDBsum; 7DH9; -. DR PDBsum; 7DHC; -. DR PDBsum; 7DHH; -. DR PDBsum; 7DHK; -. DR PDBsum; 7DHN; -. DR PDBsum; 7DHO; -. DR PDBsum; 7DHV; -. DR PDBsum; 7DJO; -. DR PDBsum; 7DL6; -. DR PDBsum; 7EJV; -. DR PDBsum; 8HLT; -. DR AlphaFoldDB; Q92630; -. DR SMR; Q92630; -. DR BioGRID; 114023; 171. DR CORUM; Q92630; -. DR FunCoup; Q92630; 2020. DR IntAct; Q92630; 253. DR MINT; Q92630; -. DR STRING; 9606.ENSP00000342105; -. DR BindingDB; Q92630; -. DR ChEMBL; CHEMBL4376; -. DR DrugBank; DB04719; DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE. DR DrugBank; DB07919; Harmine. DR DrugCentral; Q92630; -. DR GuidetoPHARMACOLOGY; 2011; -. DR GlyGen; Q92630; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q92630; -. DR PhosphoSitePlus; Q92630; -. DR BioMuta; DYRK2; -. DR DMDM; 148887370; -. DR CPTAC; non-CPTAC-5645; -. DR CPTAC; non-CPTAC-5646; -. DR jPOST; Q92630; -. DR MassIVE; Q92630; -. DR PaxDb; 9606-ENSP00000342105; -. DR PeptideAtlas; Q92630; -. DR ProteomicsDB; 75387; -. [Q92630-1] DR ProteomicsDB; 75388; -. [Q92630-2] DR Antibodypedia; 16684; 343 antibodies from 37 providers. DR DNASU; 8445; -. DR Ensembl; ENST00000344096.4; ENSP00000342105.4; ENSG00000127334.12. [Q92630-1] DR Ensembl; ENST00000393555.3; ENSP00000377186.3; ENSG00000127334.12. [Q92630-2] DR GeneID; 8445; -. DR KEGG; hsa:8445; -. DR MANE-Select; ENST00000344096.4; ENSP00000342105.4; NM_006482.3; NP_006473.2. DR UCSC; uc001str.5; human. [Q92630-1] DR AGR; HGNC:3093; -. DR ClinPGx; PA27550; -. DR CTD; 8445; -. DR DisGeNET; 8445; -. DR GeneCards; DYRK2; -. DR HGNC; HGNC:3093; DYRK2. DR HPA; ENSG00000127334; Low tissue specificity. DR MIM; 603496; gene. DR OpenTargets; ENSG00000127334; -. DR VEuPathDB; HostDB:ENSG00000127334; -. DR eggNOG; KOG0667; Eukaryota. DR GeneTree; ENSGT00940000158113; -. DR HOGENOM; CLU_000288_5_13_1; -. DR InParanoid; Q92630; -. DR OMA; HTVGGNK; -. DR OrthoDB; 9332038at2759; -. DR PAN-GO; Q92630; 6 GO annotations based on evolutionary models. DR PhylomeDB; Q92630; -. DR BRENDA; 2.7.12.1; 2681. DR PathwayCommons; Q92630; -. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR SignaLink; Q92630; -. DR SIGNOR; Q92630; -. DR Agora; ENSG00000127334; -. DR BioGRID-ORCS; 8445; 16 hits in 1188 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; DYRK2; human. DR EvolutionaryTrace; Q92630; -. DR GeneWiki; DYRK2; -. DR GenomeRNAi; 8445; -. DR Pharos; Q92630; Tchem. DR PRO; PR:Q92630; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; Q92630; protein. DR Bgee; ENSG00000127334; Expressed in jejunal mucosa and 205 other cell types or tissues. DR ExpressionAtlas; Q92630; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005856; C:cytoskeleton; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:1990904; C:ribonucleoprotein complex; IEA:Ensembl. DR GO; GO:0000151; C:ubiquitin ligase complex; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0030145; F:manganese ion binding; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IEA:UniProtKB-EC. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IEP:UniProtKB. DR GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IDA:UniProtKB. DR GO; GO:0070885; P:negative regulation of calcineurin-NFAT signaling cascade; IMP:UniProtKB. DR GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0007224; P:smoothened signaling pathway; IMP:UniProtKB. DR CDD; cd14224; PKc_DYRK2_3; 1. DR FunFam; 3.30.10.30:FF:000001; Dual specificity tyrosine-phosphorylation-regulated kinase 2; 1. DR FunFam; 1.10.510.10:FF:000112; Putative dual specificity tyrosine-phosphorylation-regulated kinase 2; 1. DR FunFam; 3.30.200.20:FF:000127; Putative dual specificity tyrosine-phosphorylation-regulated kinase 2; 1. DR Gene3D; 3.30.10.30; DYRK; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR042521; DYRK. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR050494; Ser_Thr_dual-spec_kinase. DR PANTHER; PTHR24058; DUAL SPECIFICITY PROTEIN KINASE; 1. DR PANTHER; PTHR24058:SF51; DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 2; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Apoptosis; ATP-binding; Cytoplasm; KW Kinase; Magnesium; Manganese; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Tyrosine-protein kinase; KW Ubl conjugation; Ubl conjugation pathway. FT CHAIN 1..601 FT /note="Dual specificity tyrosine-phosphorylation-regulated FT kinase 2" FT /id="PRO_0000085936" FT DOMAIN 222..535 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..24 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 189..191 FT /note="Nuclear localization signal" FT /evidence="ECO:0000305|PubMed:19965871" FT ACT_SITE 348 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 228..236 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT BINDING 251 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT BINDING 301..304 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT MOD_RES 30 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 106 FT /note="Phosphothreonine; by ATM" FT /evidence="ECO:0000269|PubMed:19965871" FT MOD_RES 381 FT /note="Phosphothreonine; by MAP3K10" FT /evidence="ECO:0000269|PubMed:18455992" FT MOD_RES 382 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:22998443" FT MOD_RES 442 FT /note="Phosphoserine; by ATM" FT /evidence="ECO:0000269|PubMed:19965871" FT MOD_RES 449 FT /note="Phosphoserine; by MAP3K10" FT /evidence="ECO:0000269|PubMed:18455992" FT VAR_SEQ 1..73 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_026115" FT VARIANT 98 FT /note="S -> G (in dbSNP:rs35139851)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040458" FT VARIANT 198 FT /note="P -> L (in a glioblastoma multiforme sample; somatic FT mutation; dbSNP:rs1384093596)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040459" FT VARIANT 245 FT /note="H -> N (in dbSNP:rs34166200)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040460" FT VARIANT 295 FT /note="N -> S (in dbSNP:rs56293072)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040461" FT VARIANT 451 FT /note="R -> Q (in dbSNP:rs35688869)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040462" FT VARIANT 455 FT /note="F -> Y (in dbSNP:rs55774594)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040463" FT MUTAGEN 106 FT /note="T->A: Impaired ATM-mediated phosphorylation, reduced FT affinity with MDM2 and altered MDM2-triggered FT ubiquitination." FT /evidence="ECO:0000269|PubMed:19965871" FT MUTAGEN 189..191 FT /note="KKR->NNN: Impaired nuclear translocation." FT /evidence="ECO:0000269|PubMed:19965871" FT MUTAGEN 251 FT /note="K->R: Abolishes protein serine/threonine kinase FT activity." FT /evidence="ECO:0000269|PubMed:23362280" FT MUTAGEN 442 FT /note="S->A: Impaired ATM-mediated phosphorylation, reduced FT affinity with MDM2 and altered MDM2-triggered FT ubiquitination." FT /evidence="ECO:0000269|PubMed:19965871" FT CONFLICT 37 FT /note="A -> P (in Ref. 1; CAA73885)" FT /evidence="ECO:0000305" FT STRAND 150..152 FT /evidence="ECO:0007829|PDB:6HDR" FT HELIX 156..163 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 164..166 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 169..174 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 175..177 FT /evidence="ECO:0007829|PDB:5LXC" FT STRAND 179..181 FT /evidence="ECO:0007829|PDB:3K2L" FT HELIX 198..202 FT /evidence="ECO:0007829|PDB:5LXC" FT STRAND 206..208 FT /evidence="ECO:0007829|PDB:3K2L" FT TURN 219..221 FT /evidence="ECO:0007829|PDB:5LXC" FT STRAND 222..231 FT /evidence="ECO:0007829|PDB:5LXC" FT STRAND 234..241 FT /evidence="ECO:0007829|PDB:5LXC" FT TURN 242..245 FT /evidence="ECO:0007829|PDB:5LXC" FT STRAND 246..253 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 257..274 FT /evidence="ECO:0007829|PDB:5LXC" FT STRAND 278..280 FT /evidence="ECO:0007829|PDB:7AKH" FT STRAND 287..292 FT /evidence="ECO:0007829|PDB:5LXC" FT STRAND 297..301 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 308..314 FT /evidence="ECO:0007829|PDB:5LXC" FT TURN 315..317 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 322..341 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 351..353 FT /evidence="ECO:0007829|PDB:5LXC" FT STRAND 354..358 FT /evidence="ECO:0007829|PDB:5LXC" FT STRAND 364..366 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 369..371 FT /evidence="ECO:0007829|PDB:8HLT" FT HELIX 375..377 FT /evidence="ECO:0007829|PDB:7DHK" FT HELIX 386..388 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 391..395 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 402..417 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 427..438 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 443..447 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 452..455 FT /evidence="ECO:0007829|PDB:5LXC" FT STRAND 458..460 FT /evidence="ECO:0007829|PDB:6HDP" FT STRAND 465..469 FT /evidence="ECO:0007829|PDB:5LXC" FT STRAND 471..473 FT /evidence="ECO:0007829|PDB:5LXC" FT STRAND 475..478 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 496..499 FT /evidence="ECO:0007829|PDB:5LXC" FT TURN 500..502 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 506..515 FT /evidence="ECO:0007829|PDB:5LXC" FT TURN 520..522 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 526..529 FT /evidence="ECO:0007829|PDB:5LXC" FT HELIX 533..535 FT /evidence="ECO:0007829|PDB:5LXC" SQ SEQUENCE 601 AA; 66652 MW; A7BEE25CDF944436 CRC64; MLTRKPSAAA PAAYPTGRGG DSAVRQLQAS PGLGAGATRS GVGTGPPSPI ALPPLRASNA AAAAHTIGGS KHTMNDHLHV GSHAHGQIQV QQLFEDNSNK RTVLTTQPNG LTTVGKTGLP VVPERQLDSI HRRQGSSTSL KSMEGMGKVK ATPMTPEQAM KQYMQKLTAF EHHEIFSYPE IYFLGLNAKK RQGMTGGPNN GGYDDDQGSY VQVPHDHVAY RYEVLKVIGK GSFGQVVKAY DHKVHQHVAL KMVRNEKRFH RQAAEEIRIL EHLRKQDKDN TMNVIHMLEN FTFRNHICMT FELLSMNLYE LIKKNKFQGF SLPLVRKFAH SILQCLDALH KNRIIHCDLK PENILLKQQG RSGIKVIDFG SSCYEHQRVY TYIQSRFYRA PEVILGARYG MPIDMWSLGC ILAELLTGYP LLPGEDEGDQ LACMIELLGM PSQKLLDASK RAKNFVSSKG YPRYCTVTTL SDGSVVLNGG RSRRGKLRGP PESREWGNAL KGCDDPLFLD FLKQCLEWDP AVRMTPGQAL RHPWLRRRLP KPPTGEKTSV KRITESTGAI TSISKLPPPS SSASKLRTNL AQMTDANGNI QQRTVLPKLV S // ID E2AK1_HUMAN Reviewed; 630 AA. AC Q9BQI3; A8K2R2; Q549K6; Q8NBW3; Q9HC02; Q9NYE0; Q9P0V6; Q9P1J5; Q9P2H8; AC Q9UHG4; DT 11-JUL-2001, integrated into UniProtKB/Swiss-Prot. DT 20-JUN-2003, sequence version 2. DT 28-JAN-2026, entry version 217. DE RecName: Full=Eukaryotic translation initiation factor 2-alpha kinase 1 {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:32132707, ECO:0000269|PubMed:38340717}; DE AltName: Full=Heme-controlled repressor; DE Short=HCR; DE AltName: Full=Heme-regulated eukaryotic initiation factor eIF-2-alpha kinase {ECO:0000303|Ref.3}; DE AltName: Full=Heme-regulated inhibitor {ECO:0000303|PubMed:11101152}; DE Short=hHRI {ECO:0000303|PubMed:11101152}; DE AltName: Full=Hemin-sensitive initiation factor 2-alpha kinase {ECO:0000303|Ref.2}; GN Name=EIF2AK1 {ECO:0000312|HGNC:HGNC:24921}; GN Synonyms=HRI {ECO:0000303|PubMed:11101152}, GN KIAA1369 {ECO:0000303|PubMed:10718198}; ORFNames=PRO1362; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Hair follicle dermal papilla; RX PubMed=11101152; DOI=10.1007/s10059-000-0584-5; RA Hwang S.-Y., Kim M.-K., Kim J.-C.; RT "Cloning of hHRI, human heme-regulated eukaryotic initiation factor 2alpha RT kinase: down-regulated in epithelial ovarian cancers."; RL Mol. Cells 10:584-591(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Tu Q., Yu L., Hu P.R., Fu Q., Cui Y.Y., Zhao S.Y.; RT "Cloning and sequencing of a novel human cDNA homologous to rat hemin- RT sensitive initiation factor 2a kinase mRNA."; RL Submitted (OCT-1998) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Skin; RA Cannon G., Naik S.M., Boss J.M., Caughman S.W.; RT "Cloning of the human heme-regulated eukaryotic initiation factor 2-alpha RT kinase from TNF-alpha stimulated dermal microvascular endothelial cells."; RL Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=10718198; DOI=10.1093/dnares/7.1.65; RA Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XVI. The RT complete sequences of 150 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 7:65-73(2000). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Hypothalamus; RX PubMed=10931946; DOI=10.1073/pnas.160270997; RA Hu R.-M., Han Z.-G., Song H.-D., Peng Y.-D., Huang Q.-H., Ren S.-X., RA Gu Y.-J., Huang C.-H., Li Y.-B., Jiang C.-L., Fu G., Zhang Q.-H., Gu B.-W., RA Dai M., Mao Y.-F., Gao G.-F., Rong R., Ye M., Zhou J., Xu S.-H., Gu J., RA Shi J.-X., Jin W.-R., Zhang C.-K., Wu T.-M., Huang G.-Y., Chen Z., RA Chen M.-D., Chen J.-L.; RT "Gene expression profiling in the human hypothalamus-pituitary-adrenal axis RT and full-length cDNA cloning."; RL Proc. Natl. Acad. Sci. U.S.A. 97:9543-9548(2000). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Amygdala; RX PubMed=11230166; DOI=10.1101/gr.gr1547r; RA Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S., RA Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H., Lauber J., RA Duesterhoeft A., Beyer A., Koehrer K., Strack N., Mewes H.-W., RA Ottenwaelder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B., RA Klein M., Poustka A.; RT "Towards a catalog of human genes and proteins: sequencing and analysis of RT 500 novel complete protein coding human cDNAs."; RL Genome Res. 11:422-435(2001). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RC TISSUE=Bone marrow; RX PubMed=12391722; DOI=10.1080/10425170290023428; RA Omasa T., Chen Y.-G., Mantalaris A., Tsai Y.C., Wu J.H.; RT "Molecular cloning and sequencing of the human heme-regulated eukaryotic RT initiation factor 2 alpha (eIF-2 alpha) kinase from bone marrow culture."; RL DNA Seq. 13:133-137(2002). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-558. RC TISSUE=Placenta, and Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Amygdala; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12690205; DOI=10.1126/science.1083423; RA Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K., RA Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R., RA Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A., RA Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D., RA Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S., RA Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R., RA Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N., RA Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E., RA Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R., RA Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T., RA Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W., RA Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A., RA Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X., RA Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E., RA Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H., RA Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J., RA Adams M.D., Tsui L.-C.; RT "Human chromosome 7: DNA sequence and biology."; RL Science 300:767-772(2003). RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Ovary; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [13] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 450-630, AND VARIANT ARG-558. RC TISSUE=Fetal liver; RA Zhang C., Yu Y., Zhang S., Wei H., Zhou G., Ouyang S., Luo L., Bi J., RA Liu M., He F.; RT "Functional prediction of the coding sequences of 121 new genes deduced by RT analysis of cDNA clones from human fetal liver."; RL Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases. RN [14] RP INTERACTION WITH CDC37 AND THE HSP90 COMPLEX. RX PubMed=11036079; DOI=10.1074/jbc.m007583200; RA Shao J., Grammatikakis N., Scroggins B.T., Uma S., Huang W., Chen J.-J., RA Hartson S.D., Matts R.L.; RT "Hsp90 regulates p50(cdc37) function during the biogenesis of the active RT conformation of the heme-regulated eIF2 alpha kinase."; RL J. Biol. Chem. 276:206-214(2001). RN [15] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [16] RP RETRACTED PAPER. RX PubMed=20071449; DOI=10.1124/mol.109.061259; RA Acharya P., Chen J.J., Correia M.A.; RT "Hepatic heme-regulated inhibitor (HRI) eukaryotic initiation factor 2alpha RT kinase: a protagonist of heme-mediated translational control of CYP2B RT enzymes and a modulator of basal endoplasmic reticulum stress tone."; RL Mol. Pharmacol. 77:575-592(2010). RN [17] RP RETRACTION NOTICE OF PUBMED:20071449. RX PubMed=34404736; DOI=10.1124/mol.109.061259retraction; RA Acharya P., Chen J.J., Correia M.A.; RT "Notice of Retraction: Acharya P, Chen J-J, Correia MA (2010) Hepatic heme- RT regulated inhibitor (HRI) eukaryotic initiation factor 2alpha kinase: a RT protagonist of heme-mediated translational control of CYP2B enzymes and a RT modulator of basal endoplasmic reticulum stress tone. Mol Pharmacol RT 77(4):575-592; doi:10.1124/mol.109.061259."; RL Mol. Pharmacol. 100:65-65(2021). RN [18] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [19] RP INVOLVEMENT IN LEMSPAD, FUNCTION, VARIANT LEMSPAD VAL-448, AND RP CHARACTERIZATION OF VARIANT LEMSPAD VAL-448. RX PubMed=32197074; DOI=10.1016/j.ajhg.2020.02.016; RG Undiagnosed Diseases Network; RA Mao D., Reuter C.M., Ruzhnikov M.R.Z., Beck A.E., Farrow E.G., Emrick L.T., RA Rosenfeld J.A., Mackenzie K.M., Robak L., Wheeler M.T., Burrage L.C., RA Jain M., Liu P., Calame D., Kuery S., Sillesen M., Schmitz-Abe K., RA Tonduti D., Spaccini L., Iascone M., Genetti C.A., Koenig M.K., Graf M., RA Tran A., Alejandro M., Lee B.H., Thiffault I., Agrawal P.B., RA Bernstein J.A., Bellen H.J., Chao H.T.; RT "De novo EIF2AK1 and EIF2AK2 variants are associated with developmental RT delay, leukoencephalopathy, and neurologic decompensation."; RL Am. J. Hum. Genet. 106:570-583(2020). RN [20] RP FUNCTION, ACTIVITY REGULATION, AND INTERACTION WITH DELE1. RX PubMed=32132706; DOI=10.1038/s41586-020-2076-4; RA Fessler E., Eckl E.M., Schmitt S., Mancilla I.A., Meyer-Bender M.F., RA Hanf M., Philippou-Massier J., Krebs S., Zischka H., Jae L.T.; RT "A pathway coordinated by DELE1 relays mitochondrial stress to the RT cytosol."; RL Nature 579:433-437(2020). RN [21] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND INTERACTION WITH RP DELE1. RX PubMed=32132707; DOI=10.1038/s41586-020-2078-2; RA Guo X., Aviles G., Liu Y., Tian R., Unger B.A., Lin Y.T., Wiita A.P., RA Xu K., Correia M.A., Kampmann M.; RT "Mitochondrial stress is relayed to the cytosol by an OMA1-DELE1-HRI RT pathway."; RL Nature 579:427-432(2020). RN [22] RP FUNCTION, ACTIVITY REGULATION, AND INTERACTION WITH DELE1. RX PubMed=37327776; DOI=10.1016/j.molcel.2023.05.031; RA Sekine Y., Houston R., Eckl E.M., Fessler E., Narendra D.P., Jae L.T., RA Sekine S.; RT "A mitochondrial iron-responsive pathway regulated by DELE1."; RL Mol. Cell 83:2059-2076(2023). RN [23] RP FUNCTION, ACTIVITY REGULATION, AND INTERACTION WITH DELE1. RX PubMed=37550454; DOI=10.1038/s41594-023-01061-0; RA Yang J., Baron K.R., Pride D.E., Schneemann A., Guo X., Chen W., Song A.S., RA Aviles G., Kampmann M., Wiseman R.L., Lander G.C.; RT "DELE1 oligomerization promotes integrated stress response activation."; RL Nat. Struct. Mol. Biol. 30:1295-1302(2023). RN [24] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND INTERACTION WITH RP DELE1. RX PubMed=38340717; DOI=10.1016/j.molcel.2024.01.016; RA Chakrabarty Y., Yang Z., Chen H., Chan D.C.; RT "The HRI branch of the integrated stress response selectively triggers RT mitophagy."; RL Mol. Cell 84:1090-1100(2024). RN [25] RP UBIQUITINATION. RX PubMed=38297121; DOI=10.1038/s41586-023-06985-7; RA Haakonsen D.L., Heider M., Ingersoll A.J., Vodehnal K., Witus S.R., RA Uenaka T., Wernig M., Rape M.; RT "Stress response silencing by an E3 ligase mutated in neurodegeneration."; RL Nature 626:874-880(2024). RN [26] RP VARIANTS [LARGE SCALE ANALYSIS] THR-117; THR-132; LYS-134; SER-139; RP HIS-145; SER-202; LEU-292; HIS-319 AND ARG-558. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [27] RP VARIANT ARG-558. RX PubMed=28501589; DOI=10.1016/j.clim.2017.05.009; RA Sadovnick A.D., Traboulsee A.L., Zhao Y., Bernales C.Q., Encarnacion M., RA Ross J.P., Yee I.M., Criscuoli M.G., Vilarino-Gueell C.; RT "Genetic modifiers of multiple sclerosis progression, severity and onset."; RL Clin. Immunol. 180:100-105(2017). CC -!- FUNCTION: Metabolic-stress sensing protein kinase that phosphorylates CC the alpha subunit of eukaryotic translation initiation factor 2 CC (EIF2S1/eIF-2-alpha) in response to various stress conditions CC (PubMed:32132706, PubMed:32132707, PubMed:37327776, PubMed:37550454, CC PubMed:38340717). Key activator of the integrated stress response (ISR) CC required for adaptation to various stress, such as heme deficiency, CC oxidative stress, osmotic shock, mitochondrial dysfunction and heat CC shock (PubMed:32132706, PubMed:32132707, PubMed:37327776, CC PubMed:37550454, PubMed:38340717). EIF2S1/eIF-2-alpha phosphorylation CC in response to stress converts EIF2S1/eIF-2-alpha in a global protein CC synthesis inhibitor, leading to a global attenuation of cap-dependent CC translation, while concomitantly initiating the preferential CC translation of ISR-specific mRNAs, such as the transcriptional CC activator ATF4, and hence allowing ATF4-mediated reprogramming CC (PubMed:32132706, PubMed:32132707, PubMed:37327776). Acts as a key CC sensor of heme-deficiency: in normal conditions, binds hemin via a CC cysteine thiolate and histidine nitrogenous coordination, leading to CC inhibit the protein kinase activity (By similarity). This binding CC occurs with moderate affinity, allowing it to sense the heme CC concentration within the cell: heme depletion relieves inhibition and CC stimulates kinase activity, activating the ISR (By similarity). Thanks CC to this unique heme-sensing capacity, plays a crucial role to shut off CC protein synthesis during acute heme-deficient conditions (By CC similarity). In red blood cells (RBCs), controls hemoglobin synthesis CC ensuring a coordinated regulation of the synthesis of its heme and CC globin moieties (By similarity). It thereby plays an essential CC protective role for RBC survival in anemias of iron deficiency (By CC similarity). Iron deficiency also triggers activation by full-length CC DELE1 (PubMed:37327776). Also activates the ISR in response to CC mitochondrial dysfunction: HRI/EIF2AK1 protein kinase activity is CC activated upon binding to the processed form of DELE1 (S-DELE1), CC thereby promoting the ATF4-mediated reprogramming (PubMed:32132706, CC PubMed:32132707). Also acts as an activator of mitophagy in response to CC mitochondrial damage: catalyzes phosphorylation of eIF-2-alpha (EIF2S1) CC following activation by S-DELE1, thereby promoting mitochondrial CC localization of EIF2S1, triggering PRKN-independent mitophagy CC (PubMed:38340717). {ECO:0000250|UniProtKB:Q9Z2R9, CC ECO:0000269|PubMed:32132706, ECO:0000269|PubMed:32132707, CC ECO:0000269|PubMed:32197074, ECO:0000269|PubMed:37550454, CC ECO:0000269|PubMed:38340717}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:32132707, ECO:0000269|PubMed:38340717}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:32132707, ECO:0000269|PubMed:38340717}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000250|UniProtKB:Q9Z2R9}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609; CC Evidence={ECO:0000250|UniProtKB:Q9Z2R9}; CC -!- ACTIVITY REGULATION: In normal conditions, the protein kinase activity CC is inhibited; inhibition is relieved by various stress conditions (By CC similarity). Inhibited by heme: in presence of heme, forms a disulfide- CC linked inactive homodimer (By similarity). Heme depletion relieves CC inhibition and stimulates kinase activity by autophosphorylation. CC Inhibited by the heme metabolites biliverdin and bilirubin (By CC similarity). Induced by oxidative stress generated by arsenite CC treatment. Binding of nitric oxide (NO) to the heme iron in the N- CC terminal heme-binding domain activates the kinase activity, while CC binding of carbon monoxide (CO) suppresses kinase activity (By CC similarity). Protein kinase activity is also activated upon binding to CC DELE1 in response to various stress, triggering the integrated stress CC response (ISR): activated by full-length DELE1 in response to iron CC deficiency, while it is activated by the processed form of DELE1 (S- CC DELE1) in response to mitochondrial stress (PubMed:32132706, CC PubMed:32132707, PubMed:37327776, PubMed:37550454, PubMed:38340717). CC {ECO:0000250|UniProtKB:P33279, ECO:0000250|UniProtKB:Q9Z2R9, CC ECO:0000269|PubMed:32132706, ECO:0000269|PubMed:32132707, CC ECO:0000269|PubMed:37327776, ECO:0000269|PubMed:37550454, CC ECO:0000269|PubMed:38340717}. CC -!- SUBUNIT: Synthesized in an inactive form that binds to the N-terminal CC domain of CDC37 (PubMed:11036079). Has to be associated with a CC multiprotein complex containing Hsp90, CDC37 and PPP5C for maturation CC and activation by autophosphorylation (PubMed:11036079). The CC phosphatase PPP5C modulates this activation (PubMed:11036079). CC Homodimer; homodimerizes in presence of heme, forming a disulfide- CC linked inactive homodimer (By similarity). Interacts with DELE1; binds CC both to full-length DELE1 and processed form of DELE1 (S-DELE1) in CC response to stress, leading to activate its protein kinase activity and CC trigger the integrated stress response (ISR) (PubMed:32132706, CC PubMed:32132707, PubMed:37327776, PubMed:37550454, PubMed:38340717). CC {ECO:0000250|UniProtKB:P33279, ECO:0000269|PubMed:11036079, CC ECO:0000269|PubMed:32132706, ECO:0000269|PubMed:32132707, CC ECO:0000269|PubMed:37327776, ECO:0000269|PubMed:37550454, CC ECO:0000269|PubMed:38340717}. CC -!- INTERACTION: CC Q9BQI3; P08238: HSP90AB1; NbExp=2; IntAct=EBI-640377, EBI-352572; CC Q9BQI3; P11142: HSPA8; NbExp=2; IntAct=EBI-640377, EBI-351896; CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q9BQI3-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9BQI3-2; Sequence=VSP_007589; CC -!- PTM: Activated by autophosphorylation; phosphorylated predominantly on CC serine and threonine residues, but also on tyrosine residues. CC Autophosphorylation at Thr-488 is required for kinase activation. The CC active autophosphorylated form apparently is largely refractory to CC cellular heme fluctuations. {ECO:0000250|UniProtKB:Q9Z2R9}. CC -!- PTM: Ubiquitinated and degraded by the SIFI complex once the CC mitochondrial stress has been resolved, thereby providing stress CC response silencing (PubMed:38297121). Within the SIFI complex, UBR4 CC initiates ubiquitin chain that are further elongated or branched by CC KCMF1 (PubMed:38297121). {ECO:0000269|PubMed:38297121}. CC -!- DISEASE: Leukoencephalopathy, motor delay, spasticity, and dysarthria CC syndrome (LEMSPAD) [MIM:618878]: A disorder characterized by delayed CC motor development, speech delay with dysarthria, hypertonia, CC progressive spasticity, hyperreflexia, and bradykinesia. Cognition is CC normal. Patients manifest anxiety and attention deficit-hyperactivity CC disorder. {ECO:0000269|PubMed:32197074}. Note=The disease may be caused CC by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. GCN2 subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- CAUTION: Was reported to be expressed predominantly in erythroid cells CC and at much lower levels in hepatocytes. However, this paper has been CC retracted because there was improper manipulation, reuse and analyses. CC {ECO:0000305|PubMed:20071449, ECO:0000305|PubMed:34404736}. CC -!- SEQUENCE CAUTION: CC Sequence=AAF70289.1; Type=Frameshift; Evidence={ECO:0000305}; CC Sequence=AAF71057.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAA92607.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF255050; AAF70289.1; ALT_FRAME; mRNA. DR EMBL; AF100784; AAP97223.1; -; mRNA. DR EMBL; AF181071; AAF18391.1; -; mRNA. DR EMBL; AB037790; BAA92607.1; ALT_INIT; mRNA. DR EMBL; AF183414; AAG09683.1; -; mRNA. DR EMBL; AL136563; CAB66498.1; -; mRNA. DR EMBL; AF147094; AAF66736.1; -; mRNA. DR EMBL; AK075192; BAC11461.1; -; mRNA. DR EMBL; AK290327; BAF83016.1; -; mRNA. DR EMBL; AL834494; CAD39152.1; -; mRNA. DR EMBL; CH236963; EAL23714.1; -; Genomic_DNA. DR EMBL; CH878731; EAW55049.1; -; Genomic_DNA. DR EMBL; BC006524; AAH06524.1; -; mRNA. DR EMBL; AF116634; AAF71057.1; ALT_INIT; mRNA. DR CCDS; CCDS5345.1; -. [Q9BQI3-1] DR RefSeq; NP_001127807.1; NM_001134335.2. [Q9BQI3-2] DR RefSeq; NP_055228.2; NM_014413.3. [Q9BQI3-1] DR AlphaFoldDB; Q9BQI3; -. DR SMR; Q9BQI3; -. DR BioGRID; 118002; 31. DR FunCoup; Q9BQI3; 1893. DR IntAct; Q9BQI3; 28. DR STRING; 9606.ENSP00000199389; -. DR BindingDB; Q9BQI3; -. DR ChEMBL; CHEMBL6029; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q9BQI3; -. DR GuidetoPHARMACOLOGY; 2015; -. DR iPTMnet; Q9BQI3; -. DR PhosphoSitePlus; Q9BQI3; -. DR BioMuta; EIF2AK1; -. DR DMDM; 32172458; -. DR CPTAC; CPTAC-3035; -. DR jPOST; Q9BQI3; -. DR MassIVE; Q9BQI3; -. DR PaxDb; 9606-ENSP00000199389; -. DR PeptideAtlas; Q9BQI3; -. DR ProteomicsDB; 78682; -. [Q9BQI3-1] DR ProteomicsDB; 78683; -. [Q9BQI3-2] DR Pumba; Q9BQI3; -. DR Antibodypedia; 11579; 315 antibodies from 30 providers. DR DNASU; 27102; -. DR Ensembl; ENST00000199389.11; ENSP00000199389.6; ENSG00000086232.14. [Q9BQI3-1] DR GeneID; 27102; -. DR KEGG; hsa:27102; -. DR MANE-Select; ENST00000199389.11; ENSP00000199389.6; NM_014413.4; NP_055228.2. DR UCSC; uc003spp.4; human. [Q9BQI3-1] DR AGR; HGNC:24921; -. DR ClinPGx; PA134919097; -. DR CTD; 27102; -. DR DisGeNET; 27102; -. DR GeneCards; EIF2AK1; -. DR HGNC; HGNC:24921; EIF2AK1. DR HPA; ENSG00000086232; Low tissue specificity. DR MalaCards; EIF2AK1; -. DR MIM; 613635; gene. DR MIM; 618878; phenotype. DR OpenTargets; ENSG00000086232; -. DR VEuPathDB; HostDB:ENSG00000086232; -. DR eggNOG; KOG1035; Eukaryota. DR GeneTree; ENSGT00940000157605; -. DR HOGENOM; CLU_000288_134_1_1; -. DR InParanoid; Q9BQI3; -. DR OMA; WDWIADR; -. DR OrthoDB; 1405469at2759; -. DR PAN-GO; Q9BQI3; 1 GO annotation based on evolutionary models. DR PhylomeDB; Q9BQI3; -. DR PathwayCommons; Q9BQI3; -. DR Reactome; R-HSA-9648895; Response of EIF2AK1 (HRI) to heme deficiency. DR Reactome; R-HSA-9840373; Cellular response to mitochondrial stress. DR SignaLink; Q9BQI3; -. DR SIGNOR; Q9BQI3; -. DR Agora; ENSG00000086232; -. DR BioGRID-ORCS; 27102; 21 hits in 1192 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; EIF2AK1; human. DR GeneWiki; EIF2AK1; -. DR GenomeRNAi; 27102; -. DR Pharos; Q9BQI3; Tchem. DR PRO; PR:Q9BQI3; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; Q9BQI3; protein. DR Bgee; ENSG00000086232; Expressed in trabecular bone tissue and 200 other cell types or tissues. DR ExpressionAtlas; Q9BQI3; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:UniProt. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004694; F:eukaryotic translation initiation factor 2alpha kinase activity; IDA:UniProtKB. DR GO; GO:0020037; F:heme binding; ISS:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0002526; P:acute inflammatory response; IEA:Ensembl. DR GO; GO:0051649; P:establishment of localization in cell; IEA:Ensembl. DR GO; GO:0140468; P:HRI-mediated signaling; IDA:UniProtKB. DR GO; GO:0140467; P:integrated stress response signaling; IDA:UniProtKB. DR GO; GO:0030225; P:macrophage differentiation; IEA:Ensembl. DR GO; GO:0060586; P:multicellular organismal-level iron ion homeostasis; IEA:Ensembl. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl. DR GO; GO:0046986; P:negative regulation of hemoglobin biosynthetic process; ISS:UniProtKB. DR GO; GO:0045993; P:negative regulation of translational initiation by iron; NAS:UniProtKB. DR GO; GO:0006909; P:phagocytosis; IEA:Ensembl. DR GO; GO:1901526; P:positive regulation of mitophagy; IDA:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB. DR GO; GO:0070585; P:protein localization to mitochondrion; IDA:UniProt. DR GO; GO:0046501; P:protoporphyrinogen IX metabolic process; IEA:Ensembl. DR GO; GO:0006446; P:regulation of translational initiation; IBA:GO_Central. DR GO; GO:1990641; P:response to iron ion starvation; IDA:UniProtKB. DR CDD; cd14049; STKc_EIF2AK1_HRI; 1. DR FunFam; 3.30.200.20:FF:000380; Eukaryotic translation initiation factor 2 alpha kinase 1; 1. DR FunFam; 1.10.510.10:FF:000375; Putative eukaryotic translation initiation factor 2-alpha kinase 1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR050339; CC_SR_Kinase. DR InterPro; IPR054521; HRI2_3H. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR11042:SF160; EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 1; 1. DR PANTHER; PTHR11042; EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE EIF2-ALPHA KINASE -RELATED; 1. DR Pfam; PF22949; HRI2_3H; 1. DR Pfam; PF00069; Pkinase; 2. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Disulfide bond; Kinase; KW Nucleotide-binding; Phosphoprotein; Protein synthesis inhibitor; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase; Ubl conjugation. FT CHAIN 1..630 FT /note="Eukaryotic translation initiation factor 2-alpha FT kinase 1" FT /id="PRO_0000085941" FT DOMAIN 167..583 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REPEAT 410..415 FT /note="HRM 1" FT REPEAT 552..557 FT /note="HRM 2" FT REGION 1..40 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 259..301 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 85..104 FT /note="SIFI-degron" FT /evidence="ECO:0000269|PubMed:38297121" FT COMPBIAS 285..294 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 442 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 173..181 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 196 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 80 FT /note="Heme-binding" FT /evidence="ECO:0000250|UniProtKB:P33279" FT MOD_RES 285 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q63185" FT MOD_RES 486 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q9Z2R9" FT MOD_RES 488 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q9Z2R9" FT MOD_RES 493 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q9Z2R9" FT VAR_SEQ 244 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:11230166, FT ECO:0000303|PubMed:12391722, ECO:0000303|PubMed:17974005" FT /id="VSP_007589" FT VARIANT 117 FT /note="R -> T (in dbSNP:rs34889754)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040466" FT VARIANT 132 FT /note="K -> T (in dbSNP:rs34851195)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040467" FT VARIANT 134 FT /note="R -> K (in dbSNP:rs55744865)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040468" FT VARIANT 139 FT /note="P -> S (in dbSNP:rs55963745)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040469" FT VARIANT 145 FT /note="R -> H (in dbSNP:rs55971369)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040470" FT VARIANT 202 FT /note="G -> S (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs1216460058)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040471" FT VARIANT 292 FT /note="F -> L (in dbSNP:rs55982710)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040472" FT VARIANT 319 FT /note="L -> H (in dbSNP:rs34909691)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040473" FT VARIANT 448 FT /note="I -> V (in LEMSPAD; uncertain significance; mildly FT reduced phosphorylation of eukaryotic translation FT initiation factor 2-alpha; dbSNP:rs1583476115)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084259" FT VARIANT 558 FT /note="K -> R (in dbSNP:rs2640)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:28501589, FT ECO:0000269|Ref.13" FT /id="VAR_015732" FT CONFLICT 2 FT /note="Q -> L (in Ref. 3; AAF18391)" FT /evidence="ECO:0000305" FT CONFLICT 4 FT /note="G -> D (in Ref. 8; BAF83016)" FT /evidence="ECO:0000305" FT CONFLICT 24..32 FT /note="PPAIDFPAE -> RRHRLSRR (in Ref. 1; AAF70289)" FT /evidence="ECO:0000305" FT CONFLICT 137 FT /note="Q -> R (in Ref. 1; AAF70289)" FT /evidence="ECO:0000305" FT CONFLICT 149 FT /note="I -> T (in Ref. 8; BAF83016)" FT /evidence="ECO:0000305" FT CONFLICT 171 FT /note="A -> V (in Ref. 3; AAF18391)" FT /evidence="ECO:0000305" FT CONFLICT 206 FT /note="T -> P (in Ref. 7; AAF66736)" FT /evidence="ECO:0000305" SQ SEQUENCE 630 AA; 71106 MW; D63021651806620B CRC64; MQGGNSGVRK REEEGDGAGA VAAPPAIDFP AEGPDPEYDE SDVPAEIQVL KEPLQQPTFP FAVANQLLLV SLLEHLSHVH EPNPLRSRQV FKLLCQTFIK MGLLSSFTCS DEFSSLRLHH NRAITHLMRS AKERVRQDPC EDISRIQKIR SREVALEAQT SRYLNEFEEL AILGKGGYGR VYKVRNKLDG QYYAIKKILI KGATKTVCMK VLREVKVLAG LQHPNIVGYH TAWIEHVHVI QPRADRAAIE LPSLEVLSDQ EEDREQCGVK NDESSSSSII FAEPTPEKEK RFGESDTENQ NNKSVKYTTN LVIRESGELE STLELQENGL AGLSASSIVE QQLPLRRNSH LEESFTSTEE SSEENVNFLG QTEAQYHLML HIQMQLCELS LWDWIVERNK RGREYVDESA CPYVMANVAT KIFQELVEGV FYIHNMGIVH RDLKPRNIFL HGPDQQVKIG DFGLACTDIL QKNTDWTNRN GKRTPTHTSR VGTCLYASPE QLEGSEYDAK SDMYSLGVVL LELFQPFGTE MERAEVLTGL RTGQLPESLR KRCPVQAKYI QHLTRRNSSQ RPSAIQLLQS ELFQNSGNVN LTLQMKIIEQ EKEIAELKKQ LNLLSQDKGV RDDGKDGGVG // ID E2AK2_HUMAN Reviewed; 551 AA. AC P19525; A8K3P0; D6W584; E9PC80; Q52M43; Q7Z6F6; Q9UIR4; DT 01-FEB-1991, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-1991, sequence version 2. DT 28-JAN-2026, entry version 260. DE RecName: Full=Interferon-induced, double-stranded RNA-activated protein kinase; DE EC=2.7.11.1; DE AltName: Full=Eukaryotic translation initiation factor 2-alpha kinase 2; DE Short=eIF-2A protein kinase 2; DE AltName: Full=Interferon-inducible RNA-dependent protein kinase; DE AltName: Full=P1/eIF-2A protein kinase; DE AltName: Full=Protein kinase RNA-activated; DE Short=PKR; DE Short=Protein kinase R {ECO:0000303|PubMed:11438532}; DE AltName: Full=Tyrosine-protein kinase EIF2AK2; DE EC=2.7.10.2; DE AltName: Full=p68 kinase; GN Name=EIF2AK2; Synonyms=PKR, PRKR; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 101-118 AND RP 309-325, AND INDUCTION. RX PubMed=1695551; DOI=10.1016/0092-8674(90)90374-n; RA Meurs E., Chong K., Galabru J., Thomas N.S.B., Kerr I.M., Williams B.R.G., RA Hovanessian A.G.; RT "Molecular cloning and characterization of the human double-stranded RNA- RT activated protein kinase induced by interferon."; RL Cell 62:379-390(1990). RN [2] RP SEQUENCE REVISION. RA Meurs E.; RL Submitted (AUG-1990) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=1373553; DOI=10.1016/0042-6822(92)90732-5; RA Thomis D.C., Doohan J.P., Samuel C.E.; RT "Mechanism of interferon action: cDNA structure, expression, and regulation RT of the interferon-induced, RNA-dependent P1/eIF-2 alpha protein kinase from RT human cells."; RL Virology 188:33-46(1992). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1). RX PubMed=8921913; DOI=10.1016/0378-1119(96)00314-9; RA Kuhen K.L., Shen X., Samuel C.E.; RT "Mechanism of interferon action sequence of the human interferon-inducible RT RNA-dependent protein kinase (PKR) deduced from genomic clones."; RL Gene 178:191-193(1996). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RC TISSUE=Placenta; RX PubMed=8812437; DOI=10.1006/geno.1996.0446; RA Kuhen K.L., Shen X., Carlisle E.R., Richardson A.L., Weier H.-U.G., RA Tanaka H., Samuel C.E.; RT "Structural organization of the human gene (PKR) encoding an interferon- RT inducible RNA-dependent protein kinase (PKR) and differences from its mouse RT homolog."; RL Genomics 36:197-201(1996). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9726442; DOI=10.1089/jir.1998.18.609; RA Xu Z., Williams B.R.; RT "Genomic features of human PKR: alternative splicing and a polymorphic CGG RT repeat in the 5'-untranslated region."; RL J. Interferon Cytokine Res. 18:609-616(1998). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RA Li H., Huang F., Shen C., Zhou G., Zheng G., Ke R., Lin L., Yang S.; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain, and Embryo; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [13] RP PROTEIN SEQUENCE OF 2-18; 27-40; 70-77; 414-426 AND 430-440, CLEAVAGE OF RP INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RC TISSUE=Prostatic carcinoma; RA Bienvenut W.V., Gao M., Leug H.; RL Submitted (JUN-2009) to UniProtKB. RN [14] RP INTERACTION WITH DNAJC3. RX PubMed=8576172; DOI=10.1074/jbc.271.3.1702; RA Polyak S.J., Tang N., Wambach M., Barber G.N., Katze M.G.; RT "The P58 cellular inhibitor complexes with the interferon-induced, double- RT stranded RNA-dependent protein kinase, PKR, to regulate its RT autophosphorylation and activity."; RL J. Biol. Chem. 271:1702-1707(1996). RN [15] RP INTERACTION WITH HIV-1 TAT. RX PubMed=9079663; DOI=10.1074/jbc.272.13.8388; RA Brand S.R., Kobayashi R., Mathews M.B.; RT "The Tat protein of human immunodeficiency virus type 1 is a substrate and RT inhibitor of the interferon-induced, virally activated protein kinase, RT PKR."; RL J. Biol. Chem. 272:8388-8395(1997). RN [16] RP INTERACTION WITH HCV NON-STRUCTURAL PROTEIN 5A (MICROBIAL INFECTION). RX PubMed=9143277; DOI=10.1006/viro.1997.8493; RA Gale M.J. Jr., Korth M.J., Tang N.M., Tan S.-L., Hopkins D.A., Dever T.E., RA Polyak S.J., Gretch D.R., Katze M.G.; RT "Evidence that hepatitis C virus resistance to interferon is mediated RT through repression of the PKR protein kinase by the nonstructural 5A RT protein."; RL Virology 230:217-227(1997). RN [17] RP INTERACTION WITH HCV NON-STRUCTURAL PROTEIN 5A (MICROBIAL INFECTION). RX PubMed=9710605; DOI=10.1128/mcb.18.9.5208; RA Gale M.J. Jr., Blakely C.M., Kwieciszewski B., Tan S.-L., Dossett M., RA Tang N.M., Korth M.J., Polyak S.J., Gretch D.R., Katze M.G.; RT "Control of PKR protein kinase by hepatitis C virus nonstructural 5A RT protein: molecular mechanisms of kinase regulation."; RL Mol. Cell. Biol. 18:5208-5218(1998). RN [18] RP INTERACTION WITH INFLUENZA A NS1 PROTEIN. RX PubMed=9781815; DOI=10.1089/jir.1998.18.757; RA Tan S.L., Katze M.G.; RT "Biochemical and genetic evidence for complex formation between the RT influenza A virus NS1 protein and the interferon-induced PKR protein RT kinase."; RL J. Interferon Cytokine Res. 18:757-766(1998). RN [19] RP INTERACTION WITH HCV ENVELOPE GLYCOPROTEIN E2 (MICROBIAL INFECTION). RX PubMed=10390359; DOI=10.1126/science.285.5424.107; RA Taylor D.R., Shi S.T., Romano P.R., Barber G.N., Lai M.M.C.; RT "Inhibition of the interferon-inducible protein kinase PKR by HCV E2 RT protein."; RL Science 285:107-110(1999). RN [20] RP FUNCTION, AND INTERACTION WITH IKBKB. RX PubMed=10848580; DOI=10.1128/mcb.20.13.4532-4542.2000; RA Bonnet M.C., Weil R., Dam E., Hovanessian A.G., Meurs E.F.; RT "PKR stimulates NF-kappaB irrespective of its kinase function by RT interacting with the IkappaB kinase complex."; RL Mol. Cell. Biol. 20:4532-4542(2000). RN [21] RP INTERACTION WITH TARBP2. RX PubMed=11438532; DOI=10.1074/jbc.m103584200; RA Daher A., Longuet M., Dorin D., Bois F., Segeral E., Bannwarth S., RA Battisti P.-L., Purcell D.F., Benarous R., Vaquero C., Meurs E.F., RA Gatignol A.; RT "Two dimerization domains in the trans-activation response RNA-binding RT protein (TRBP) individually reverse the protein kinase R inhibition of HIV- RT 1 long terminal repeat expression."; RL J. Biol. Chem. 276:33899-33905(2001). RN [22] RP PHOSPHORYLATION AT SER-83; THR-88; THR-89; THR-90; SER-242; THR-255 AND RP THR-258, MUTAGENESIS OF SER-83; THR-88; THR-89; THR-90; SER-242; THR-255; RP THR-258 AND LYS-296, AND INHIBITION BY HCV E2 ENVELOPE PROTEIN. RX PubMed=11152499; DOI=10.1128/jvi.75.3.1265-1273.2001; RA Taylor D.R., Tian B., Romano P.R., Hinnebusch A.G., Lai M.M.C., RA Mathews M.B.; RT "Hepatitis C virus envelope protein E2 does not inhibit PKR by simple RT competition with autophosphorylation sites in the RNA-binding domain."; RL J. Virol. 75:1265-1273(2001). RN [23] RP MUTAGENESIS OF LYS-60; ALA-67; THR-446 AND THR-451, AND PHOSPHORYLATION AT RP THR-446 AND THR-451. RX PubMed=11337501; DOI=10.1074/jbc.m102108200; RA Zhang F., Romano P.R., Nagamura-Inoue T., Tian B., Dever T.E., RA Mathews M.B., Ozato K., Hinnebusch A.G.; RT "Binding of double-stranded RNA to protein kinase PKR is required for RT dimerization and promotes critical autophosphorylation events in the RT activation loop."; RL J. Biol. Chem. 276:24946-24958(2001). RN [24] RP INTERACTION WITH HHV-8 PROTEIN VIRF2 (MICROBIAL INFECTION). RX PubMed=11160738; DOI=10.1128/jvi.75.5.2345-2352.2001; RA Burysek L., Pitha P.M.; RT "Latently expressed human herpesvirus 8-encoded interferon regulatory RT factor 2 inhibits double-stranded RNA-activated protein kinase."; RL J. Virol. 75:2345-2352(2001). RN [25] RP FUNCTION, AND INTERACTION WITH HHV-1 US11 (MICROBIAL INFECTION). RX PubMed=11836380; DOI=10.1128/jvi.76.5.2029-2035.2002; RA Cassady K.A., Gross M.; RT "The herpes simplex virus type 1 U(S)11 protein interacts with protein RT kinase R in infected cells and requires a 30-amino-acid sequence adjacent RT to a kinase substrate domain."; RL J. Virol. 76:2029-2035(2002). RN [26] RP INTERACTION WITH NPM1, AND ACTIVITY REGULATION. RX PubMed=12882984; DOI=10.1074/jbc.m301392200; RA Pang Q., Christianson T.A., Koretsky T., Carlson H., David L., Keeble W., RA Faulkner G.R., Speckhart A., Bagby G.C.; RT "Nucleophosmin interacts with and inhibits the catalytic function of RT eukaryotic initiation factor 2 kinase PKR."; RL J. Biol. Chem. 278:41709-41717(2003). RN [27] RP FUNCTION, AND INTERACTION WITH MAP2K6. RX PubMed=15229216; DOI=10.1074/jbc.m406554200; RA Silva A.M., Whitmore M., Xu Z., Jiang Z., Li X., Williams B.R.; RT "Protein kinase R (PKR) interacts with and activates mitogen-activated RT protein kinase kinase 6 (MKK6) in response to double-stranded RNA RT stimulation."; RL J. Biol. Chem. 279:37670-37676(2004). RN [28] RP IDENTIFICATION IN A COMPLEX WITH FANCA; FANCC; FANCG AND HSP70. RX PubMed=15299030; DOI=10.1074/jbc.m403884200; RA Zhang X., Li J., Sejas D.P., Rathbun K.R., Bagby G.C., Pang Q.; RT "The Fanconi anemia proteins functionally interact with the protein kinase RT regulated by RNA (PKR)."; RL J. Biol. Chem. 279:43910-43919(2004). RN [29] RP FUNCTION, INTERACTION WITH TRAF2; TRAF5 AND TRAF6, AND SUBCELLULAR RP LOCATION. RX PubMed=15121867; DOI=10.1128/mcb.24.10.4502-4512.2004; RA Gil J., Garcia M.A., Gomez-Puertas P., Guerra S., Rullas J., Nakano H., RA Alcami J., Esteban M.; RT "TRAF family proteins link PKR with NF-kappa B activation."; RL Mol. Cell. Biol. 24:4502-4512(2004). RN [30] RP INHIBITION BY VACCINIA VIRUS PROTEIN E3 (MICROBIAL INFECTION). RX PubMed=15207627; DOI=10.1016/j.virol.2004.03.012; RA Langland J.O., Jacobs B.L.; RT "Inhibition of PKR by vaccinia virus: role of the N- and C-terminal domains RT of E3L."; RL Virology 324:419-429(2004). RN [31] RP REVIEW. RX PubMed=17158706; DOI=10.1128/mmbr.00027-06; RA Garcia M.A., Gil J., Ventoso I., Guerra S., Domingo E., Rivas C., RA Esteban M.; RT "Impact of protein kinase PKR in cell biology: from antiviral to RT antiproliferative action."; RL Microbiol. Mol. Biol. Rev. 70:1032-1060(2006). RN [32] RP INTERACTION WITH HCMV TRS1 (MICROBIAL INFECTION). RX PubMed=16987971; DOI=10.1128/jvi.00957-06; RA Hakki M., Marshall E.E., De Niro K.L., Geballe A.P.; RT "Binding and nuclear relocalization of protein kinase R by human RT cytomegalovirus TRS1."; RL J. Virol. 80:11817-11826(2006). RN [33] RP PHOSPHORYLATION AT TYR-101; TYR-162 AND TYR-293. RX PubMed=16373505; DOI=10.1073/pnas.0508207103; RA Su Q., Wang S., Baltzis D., Qu L.K., Wong A.H., Koromilas A.E.; RT "Tyrosine phosphorylation acts as a molecular switch to full-scale RT activation of the eIF2alpha RNA-dependent protein kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 103:63-68(2006). RN [34] RP INTERACTION WITH HCV NON-STRUCTURAL PROTEIN 5A (MICROBIAL INFECTION). RX PubMed=16951545; DOI=10.1016/s1016-8478(23)17385-7; RA Liang Y., Kang C.B., Yoon H.S.; RT "Molecular and structural characterization of the domain 2 of hepatitis C RT virus non-structural protein 5A."; RL Mol. Cells 22:13-20(2006). RN [35] RP INTERACTION WITH HCV NON-STRUCTURAL PROTEIN 5A (MICROBIAL INFECTION). RX PubMed=17451199; DOI=10.3748/wjg.v13.i8.1195; RA Veillon P., Payan C., Le Guillou-Guillemette H., Gaudy C., Lunel F.; RT "Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b RT during interferon or combined interferon-ribavirin therapy."; RL World J. Gastroenterol. 13:1195-1203(2007). RN [36] RP INTERACTION WITH HCV MATURE CORE PROTEIN (MICROBIAL INFECTION). RX PubMed=17267064; DOI=10.1016/j.virusres.2006.12.010; RA Yan X.B., Battaglia S., Boucreux D., Chen Z., Brechot C., Pavio N.; RT "Mapping of the interacting domains of hepatitis C virus core protein and RT the double-stranded RNA-activated protein kinase PKR."; RL Virus Res. 125:79-87(2007). RN [37] RP INTERACTION WITH ADAR. RX PubMed=17079286; DOI=10.1128/jvi.01527-06; RA Nie Y., Hammond G.L., Yang J.H.; RT "Double-stranded RNA deaminase ADAR1 increases host susceptibility to virus RT infection."; RL J. Virol. 81:917-923(2007). RN [38] RP REVIEW ON ACTIVITY REGULATION. RX PubMed=17196820; DOI=10.1016/j.tibs.2006.12.003; RA Cole J.L.; RT "Activation of PKR: an open and shut case?"; RL Trends Biochem. Sci. 32:57-62(2007). RN [39] RP FUNCTION, INTERACTION WITH NCK1, AND ACTIVITY REGULATION. RX PubMed=18835251; DOI=10.1016/j.bbrc.2008.09.112; RA Cardin E., Larose L.; RT "Nck-1 interacts with PKR and modulates its activation by dsRNA."; RL Biochem. Biophys. Res. Commun. 377:231-235(2008). RN [40] RP INTERACTION WITH DUS2L, AND ACTIVITY REGULATION. RX PubMed=18096616; DOI=10.1093/nar/gkm1129; RA Mittelstadt M., Frump A., Khuu T., Fowlkes V., Handy I., Patel C.V., RA Patel R.C.; RT "Interaction of human tRNA-dihydrouridine synthase-2 with interferon- RT induced protein kinase PKR."; RL Nucleic Acids Res. 36:998-1008(2008). RN [41] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83 AND SER-456, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [42] RP MUTAGENESIS OF ASP-486, AND INTERACTION WITH VACCINIA VIRUS PROTEIN K3 RP (MICROBIAL INFECTION). RX PubMed=18971339; DOI=10.1073/pnas.0805524105; RA Seo E.J., Liu F., Kawagishi-Kobayashi M., Ung T.L., Cao C., Dar A.C., RA Sicheri F., Dever T.E.; RT "Protein kinase PKR mutants resistant to the poxvirus pseudosubstrate K3L RT protein."; RL Proc. Natl. Acad. Sci. U.S.A. 105:16894-16899(2008). RN [43] RP FUNCTION. RX PubMed=19507191; DOI=10.1002/jcp.21848; RA Blalock W.L., Grimaldi C., Fala F., Follo M., Horn S., Basecke J., RA Martinelli G., Cocco L., Martelli A.M.; RT "PKR activity is required for acute leukemic cell maintenance and growth: a RT role for PKR-mediated phosphatase activity to regulate GSK-3 RT phosphorylation."; RL J. Cell. Physiol. 221:232-241(2009). RN [44] RP FUNCTION, AND INTERACTION WITH DHX9. RX PubMed=19229320; DOI=10.1371/journal.ppat.1000311; RA Sadler A.J., Latchoumanin O., Hawkes D., Mak J., Williams B.R.; RT "An antiviral response directed by PKR phosphorylation of the RNA helicase RT A."; RL PLoS Pathog. 5:E1000311-E1000311(2009). RN [45] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [46] RP FUNCTION IN HCV RESTRICTION. RX PubMed=19189853; DOI=10.1016/j.virusres.2009.01.007; RA Kang J.I., Kwon S.N., Park S.H., Kim Y.K., Choi S.Y., Kim J.P., Ahn B.Y.; RT "PKR protein kinase is activated by hepatitis C virus and inhibits viral RT replication through translational control."; RL Virus Res. 142:51-56(2009). RN [47] RP FUNCTION. RX PubMed=20171114; DOI=10.1016/j.cyto.2010.01.008; RA Lin S.S., Lee D.C., Law A.H., Fang J.W., Chua D.T., Lau A.S.; RT "A role for protein kinase PKR in the mediation of Epstein-Barr virus RT latent membrane protein-1-induced IL-6 and IL-10 expression."; RL Cytokine 50:210-219(2010). RN [48] RP FUNCTION AS CDK1 KINASE UPON DNA DAMAGE, AND FUNCTION AS TYROSINE-PROTEIN RP KINASE. RX PubMed=20395957; DOI=10.1038/embor.2010.45; RA Yoon C.-H., Miah M.A., Kim K.P., Bae Y.-S.; RT "New Cdc2 Tyr 4 phosphorylation by dsRNA-activated protein kinase triggers RT Cdc2 polyubiquitination and G2 arrest under genotoxic stresses."; RL EMBO Rep. 11:393-399(2010). RN [49] RP FUNCTION. RX PubMed=21123651; DOI=10.1101/gad.1965010; RA Harashima A., Guettouche T., Barber G.N.; RT "Phosphorylation of the NFAR proteins by the dsRNA-dependent protein kinase RT PKR constitutes a novel mechanism of translational regulation and cellular RT defense."; RL Genes Dev. 24:2640-2653(2010). RN [50] RP INTERACTION WITH HRSV NUCLEOPROTEIN (MICROBIAL INFECTION). RX PubMed=20519500; DOI=10.1074/jbc.m109.077321; RA Groskreutz D.J., Babor E.C., Monick M.M., Varga S.M., Hunninghake G.W.; RT "Respiratory syncytial virus limits alpha subunit of eukaryotic translation RT initiation factor 2 (eIF2alpha) phosphorylation to maintain translation and RT viral replication."; RL J. Biol. Chem. 285:24023-24031(2010). RN [51] RP FUNCTION IN HCV RESTRICTION. RX PubMed=19840259; DOI=10.1111/j.1478-3231.2009.02144.x; RA Chang J.H., Kato N., Muroyama R., Taniguchi H., Guleng B., Dharel N., RA Shao R.X., Tateishi K., Jazag A., Kawabe T., Omata M.; RT "Double-stranded RNA-activated protein kinase inhibits hepatitis C virus RT replication but may be not essential in interferon treatment."; RL Liver Int. 30:311-318(2010). RN [52] RP FUNCTION, AND PHOSPHORYLATION AT THR-451. RX PubMed=20685959; DOI=10.1091/mbc.e10-06-0481; RA Yang X., Nath A., Opperman M.J., Chan C.; RT "The double-stranded RNA-dependent protein kinase differentially regulates RT insulin receptor substrates 1 and 2 in HepG2 cells."; RL Mol. Biol. Cell 21:3449-3458(2010). RN [53] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [54] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [55] RP SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND PHOSPHORYLATION. RX PubMed=21029237; DOI=10.1111/j.1750-3639.2010.00437.x; RA Bose A., Mouton-Liger F., Paquet C., Mazot P., Vigny M., Gray F., Hugon J.; RT "Modulation of tau phosphorylation by the kinase PKR: implications in RT Alzheimer's disease."; RL Brain Pathol. 21:189-200(2011). RN [56] RP REVIEW. RX PubMed=21924887; DOI=10.1016/j.coi.2011.08.009; RA Pfaller C.K., Li Z., George C.X., Samuel C.E.; RT "Protein kinase PKR and RNA adenosine deaminase ADAR1: new roles for old RT players as modulators of the interferon response."; RL Curr. Opin. Immunol. 23:573-582(2011). RN [57] RP REVIEW. RX PubMed=21166592; DOI=10.1089/jir.2010.0099; RA Pindel A., Sadler A.; RT "The role of protein kinase R in the interferon response."; RL J. Interferon Cytokine Res. 31:59-70(2011). RN [58] RP FUNCTION, SUBCELLULAR LOCATION, IDENTIFICATION BY MASS SPECTROMETRY, AND RP PHOSPHORYLATION. RX PubMed=21072047; DOI=10.1038/leu.2010.264; RA Blalock W.L., Bavelloni A., Piazzi M., Tagliavini F., Faenza I., RA Martelli A.M., Follo M.Y., Cocco L.; RT "Multiple forms of PKR present in the nuclei of acute leukemia cells RT represent an active kinase that is responsive to stress."; RL Leukemia 25:236-245(2011). RN [59] RP FUNCTION IN HBV RESTRICTION. RX PubMed=21710204; DOI=10.1007/s10059-011-1059-6; RA Park I.H., Baek K.W., Cho E.Y., Ahn B.Y.; RT "PKR-dependent mechanisms of interferon-? for inhibiting hepatitis B virus RT replication."; RL Mol. Cells 32:167-172(2011). RN [60] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=22214662; DOI=10.4161/cc.11.2.18999; RA Bennett R.L., Pan Y., Christian J., Hui T., May W.S. Jr.; RT "The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and RT activation, leading to G(1) arrest."; RL Cell Cycle 11:407-417(2012). RN [61] RP REVIEW. RX PubMed=22633454; DOI=10.1016/j.immuni.2012.05.010; RA Lacy-Hulbert A., Stuart L.M.; RT "Penetration resistance: PKR's other talent."; RL Immunity 36:695-696(2012). RN [62] RP FUNCTION. RX PubMed=22948139; DOI=10.1074/jbc.m112.390039; RA McAllister C.S., Taghavi N., Samuel C.E.; RT "Protein kinase PKR amplification of interferon beta induction occurs RT through initiation factor eIF-2alpha-mediated translational control."; RL J. Biol. Chem. 287:36384-36392(2012). RN [63] RP FUNCTION, AND INTERACTION WITH STAT3. RX PubMed=23084476; DOI=10.1016/j.molcel.2012.09.013; RA Shen S., Niso-Santano M., Adjemian S., Takehara T., Malik S.A., Minoux H., RA Souquere S., Marino G., Lachkar S., Senovilla L., Galluzzi L., Kepp O., RA Pierron G., Maiuri M.C., Hikita H., Kroemer R., Kroemer G.; RT "Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity."; RL Mol. Cell 48:667-680(2012). RN [64] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22223895; DOI=10.1074/mcp.m111.015131; RA Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T., RA Giglione C.; RT "Comparative large-scale characterisation of plant vs. mammal proteins RT reveals similar and idiosyncratic N-alpha acetylation features."; RL Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012). RN [65] RP FUNCTION, INTERACTION WITH NLRP1; NLRP3; NLRC4 AND AIM2, AND RP AUTOPHOSPHORYLATION. RX PubMed=22801494; DOI=10.1038/nature11290; RA Lu B., Nakamura T., Inouye K., Li J., Tang Y., Lundbaeck P., RA Valdes-Ferrer S.I., Olofsson P.S., Kalb T., Roth J., Zou Y., RA Erlandsson-Harris H., Yang H., Ting J.P., Wang H., Andersson U., RA Antoine D.J., Chavan S.S., Hotamisligil G.S., Tracey K.J.; RT "Novel role of PKR in inflammasome activation and HMGB1 release."; RL Nature 488:670-674(2012). RN [66] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [67] RP REVIEW. RX PubMed=23092889; DOI=10.1126/scisignal.2003511; RA Kang R., Tang D.; RT "PKR-dependent inflammatory signals."; RL Sci. Signal. 5:PE47-PE47(2012). RN [68] RP FUNCTION. RX PubMed=22381929; DOI=10.1016/j.virol.2012.01.029; RA Taghavi N., Samuel C.E.; RT "Protein kinase PKR catalytic activity is required for the PKR-dependent RT activation of mitogen-activated protein kinases and amplification of RT interferon beta induction following virus infection."; RL Virology 427:208-216(2012). RN [69] RP REVIEW. RX PubMed=23202496; DOI=10.3390/v4112598; RA Dabo S., Meurs E.F.; RT "dsRNA-dependent protein kinase PKR and its role in stress, signaling and RT HCV infection."; RL Viruses 4:2598-2635(2012). RN [70] RP TISSUE SPECIFICITY. RX PubMed=23403623; DOI=10.1182/blood-2012-09-456400; RA Liu X., Bennett R.L., Cheng X., Byrne M., Reinhard M.K., May W.S. Jr.; RT "PKR regulates proliferation, differentiation and survival of murine RT hematopoietic stem/progenitor cells."; RL Blood 121:3364-3374(2013). RN [71] RP REVIEW. RX PubMed=23354059; DOI=10.1007/s00018-012-1252-6; RA Donnelly N., Gorman A.M., Gupta S., Samali A.; RT "The eIF2alpha kinases: their structures and functions."; RL Cell. Mol. Life Sci. 70:3493-3511(2013). RN [72] RP FUNCTION, ISGYLATION AT LYS-69 AND LYS-159, AND ACTIVITY REGULATION. RX PubMed=23229543; DOI=10.1074/jbc.m112.401851; RA Okumura F., Okumura A.J., Uematsu K., Hatakeyama S., Zhang D.E., Kamura T.; RT "Activation of double-stranded RNA-activated protein kinase (PKR) by RT interferon-stimulated gene 15 (ISG15) modification down-regulates protein RT translation."; RL J. Biol. Chem. 288:2839-2847(2013). RN [73] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-542, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [74] RP INTERACTION WITH TOSCANA VIRUS PROTEIN NSS (MICROBIAL INFECTION), AND RP ACTIVITY REGULATION. RX PubMed=23325696; DOI=10.1128/jvi.02506-12; RA Kalveram B., Ikegami T.; RT "Toscana virus NSs protein promotes degradation of double-stranded RNA- RT dependent protein kinase."; RL J. Virol. 87:3710-3718(2013). RN [75] RP FUNCTION IN MV RESTRICTION. RX PubMed=23115276; DOI=10.1128/jvi.02270-12; RA Okonski K.M., Samuel C.E.; RT "Stress granule formation induced by measles virus is protein kinase PKR RT dependent and impaired by RNA adenosine deaminase ADAR1."; RL J. Virol. 87:756-766(2013). RN [76] RP FUNCTION. RX PubMed=23372823; DOI=10.1371/journal.pone.0055108; RA Li Y., Xie J., Wu S., Xia J., Zhang P., Liu C., Zhang P., Huang X.; RT "Protein kinase regulated by dsRNA downregulates the interferon production RT in dengue virus- and dsrna-stimulated human lung epithelial cells."; RL PLoS ONE 8:E55108-E55108(2013). RN [77] RP FUNCTION IN HCV RESTRICTION. RX PubMed=23399035; DOI=10.1016/j.virol.2013.01.015; RA Zhang L., Alter H.J., Wang H., Jia S., Wang E., Marincola F.M., Shih J.W., RA Wang R.Y.; RT "The modulation of hepatitis C virus 1a replication by PKR is dependent on RT NF-kB mediated interferon beta response in Huh7.5.1 cells."; RL Virology 438:28-36(2013). RN [78] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [79] RP INTERACTION WITH VACCINIA VIRUS PROTEIN E3 (MICROBIAL INFECTION). RX PubMed=25740987; DOI=10.1128/jvi.03288-14; RA Dueck K.J., Hu Y.S., Chen P., Deschambault Y., Lee J., Varga J., Cao J.; RT "Mutational analysis of vaccinia virus E3 protein: the biological functions RT do not correlate with its biochemical capacity to bind double-stranded RT RNA."; RL J. Virol. 89:5382-5394(2015). RN [80] RP INTERACTION WITH MBIP AND MOCS2B, SUBCELLULAR LOCATION, AND RP PHOSPHORYLATION. RX PubMed=26705305; DOI=10.1093/jmcb/mjv070; RA Suganuma T., Swanson S.K., Florens L., Washburn M.P., Workman J.L.; RT "Moco biosynthesis and the ATAC acetyltransferase engage translation RT initiation by inhibiting latent PKR activity."; RL J. Mol. Cell Biol. 8:44-50(2016). RN [81] RP MUTAGENESIS OF PHE-489; THR-496; ILE-502; LYS-510 AND GLN-516, RP CHARACTERIZATION OF VARIANT VAL-506, AND INTERACTION WITH HCMV TRS1 RP (MICROBIAL INFECTION). RX PubMed=27780231; DOI=10.1371/journal.ppat.1005966; RA Carpentier K.S., Esparo N.M., Child S.J., Geballe A.P.; RT "A Single Amino Acid Dictates Protein Kinase R Susceptibility to Unrelated RT Viral Antagonists."; RL PLoS Pathog. 12:e1005966-e1005966(2016). RN [82] RP INTERACTION WITH HUMAN HERPES VIRUS 8 PROTEIN KTA/ORF57 (MICROBIAL RP INFECTION). RX PubMed=29084250; DOI=10.1371/journal.ppat.1006677; RA Sharma N.R., Majerciak V., Kruhlak M.J., Zheng Z.M.; RT "KSHV inhibits stress granule formation by viral ORF57 blocking PKR RT activation."; RL PLoS Pathog. 13:e1006677-e1006677(2017). RN [83] {ECO:0007744|PDB:1QU6} RP STRUCTURE BY NMR OF 1-170, AND DOMAIN. RX PubMed=9736623; DOI=10.1093/emboj/17.18.5458; RA Nanduri S., Carpick B.W., Yang Y., Williams B.R.G., Qin J.; RT "Structure of the double-stranded RNA-binding domain of the protein kinase RT PKR reveals the molecular basis of its dsRNA-mediated activation."; RL EMBO J. 17:5458-5465(1998). RN [84] {ECO:0007744|PDB:2A19, ECO:0007744|PDB:2A1A} RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 258-550 IN COMPLEX WITH RP EIF2S1/EIF-2ALPHA, PHOSPHORYLATION AT THR-446, DOMAIN, SUBUNIT, COFACTOR, RP AND INTERACTION WITH EIF2S1/EIF-2ALPHA. RX PubMed=16179258; DOI=10.1016/j.cell.2005.06.044; RA Dar A.C., Dever T.E., Sicheri F.; RT "Higher-order substrate recognition of eIF2alpha by the RNA-dependent RT protein kinase PKR."; RL Cell 122:887-900(2005). RN [85] {ECO:0007744|PDB:6D3K, ECO:0007744|PDB:6D3L} RP X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 229-551, AND SUBUNIT. RX PubMed=31246429; DOI=10.1021/acs.biochem.9b00161; RA Mayo C.B., Erlandsen H., Mouser D.J., Feinstein A.G., Robinson V.L., RA May E.R., Cole J.L.; RT "Structural Basis of Protein Kinase R Autophosphorylation."; RL Biochemistry 58:2967-2977(2019). RN [86] RP INVOLVEMENT IN LEUDEN, FUNCTION, VARIANTS LEUDEN LEU-11; SER-32; PHE-97; RP SER-109; VAL-109; PHE-133; SER-325 AND CYS-461, CHARACTERIZATION OF RP VARIANTS LEUDEN LEU-11; PHE-133 AND CYS-461, AND VARIANT GLN-114. RX PubMed=32197074; DOI=10.1016/j.ajhg.2020.02.016; RG Undiagnosed Diseases Network; RA Mao D., Reuter C.M., Ruzhnikov M.R.Z., Beck A.E., Farrow E.G., Emrick L.T., RA Rosenfeld J.A., Mackenzie K.M., Robak L., Wheeler M.T., Burrage L.C., RA Jain M., Liu P., Calame D., Kuery S., Sillesen M., Schmitz-Abe K., RA Tonduti D., Spaccini L., Iascone M., Genetti C.A., Koenig M.K., Graf M., RA Tran A., Alejandro M., Lee B.H., Thiffault I., Agrawal P.B., RA Bernstein J.A., Bellen H.J., Chao H.T.; RT "De novo EIF2AK1 and EIF2AK2 variants are associated with developmental RT delay, leukoencephalopathy, and neurologic decompensation."; RL Am. J. Hum. Genet. 106:570-583(2020). RN [87] RP VARIANTS [LARGE SCALE ANALYSIS] GLU-428; VAL-439 AND VAL-506. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [88] RP VARIANTS DYT33 THR-32; ARG-130 AND ALA-138, CHARACTERIZATION OF VARIANTS RP DYT33 THR-32 AND ARG-130, AND INVOLVEMENT IN DYT33. RX PubMed=33236446; DOI=10.1002/ana.25973; RA Kuipers D.J.S., Mandemakers W., Lu C.S., Olgiati S., Breedveld G.J., RA Fevga C., Tadic V., Carecchio M., Osterman B., Sagi-Dain L., Wu-Chou Y.H., RA Chen C.C., Chang H.C., Wu S.L., Yeh T.H., Weng Y.H., Elia A.E., RA Panteghini C., Marotta N., Pauly M.G., Kuehn A.A., Volkmann J., Lace B., RA Meijer I.A., Kandaswamy K., Quadri M., Garavaglia B., Lohmann K., Bauer P., RA Mencacci N.E., Lubbe S.J., Klein C., Bertoli-Avella A.M., Bonifati V.; RT "EIF2AK2 Missense Variants Associated with Early Onset Generalized RT Dystonia."; RL Ann. Neurol. 89:485-497(2021). RN [89] RP VARIANT DYT33 ARG-130, AND INVOLVEMENT IN DYT33. RX PubMed=33866603; DOI=10.1002/ana.26081; RA Musacchio T., Zech M., Reich M.M., Winkelmann J., Volkmann J.; RT "A Recurrent EIF2AK2 Missense Variant Causes Autosomal-Dominant Isolated RT Dystonia."; RL Ann. Neurol. 89:1257-1258(2021). RN [90] RP VARIANT DYT33 ARG-130. RX PubMed=35146068; DOI=10.1002/mdc3.13371; RA Magrinelli F., Moualek D., Tazir M., Pacha L.A., Verghese A., Bhatia K.P., RA Maroofian R., Houlden H.; RT "Heterozygous EIF2AK2 Variant Causes Adolescence-Onset Generalized Dystonia RT Partially Responsive to DBS."; RL Mov. Disord. Clin. Pract. 9:268-271(2022). CC -!- FUNCTION: IFN-induced dsRNA-dependent serine/threonine-protein kinase CC that phosphorylates the alpha subunit of eukaryotic translation CC initiation factor 2 (EIF2S1/eIF-2-alpha) and plays a key role in the CC innate immune response to viral infection (PubMed:18835251, CC PubMed:19189853, PubMed:19507191, PubMed:21072047, PubMed:21123651, CC PubMed:22381929, PubMed:22948139, PubMed:23229543). Inhibits viral CC replication via the integrated stress response (ISR): EIF2S1/eIF-2- CC alpha phosphorylation in response to viral infection converts CC EIF2S1/eIF-2-alpha in a global protein synthesis inhibitor, resulting CC to a shutdown of cellular and viral protein synthesis, while CC concomitantly initiating the preferential translation of ISR-specific CC mRNAs, such as the transcriptional activator ATF4 (PubMed:19189853, CC PubMed:21123651, PubMed:22948139, PubMed:23229543). Exerts its CC antiviral activity on a wide range of DNA and RNA viruses including CC hepatitis C virus (HCV), hepatitis B virus (HBV), measles virus (MV) CC and herpes simplex virus 1 (HHV-1) (PubMed:11836380, PubMed:19189853, CC PubMed:19840259, PubMed:20171114, PubMed:21710204, PubMed:23115276, CC PubMed:23399035). Also involved in the regulation of signal CC transduction, apoptosis, cell proliferation and differentiation: CC phosphorylates other substrates including p53/TP53, PPP2R5A, DHX9, CC ILF3, IRS1 and the HHV-1 viral protein US11 (PubMed:11836380, CC PubMed:19229320, PubMed:22214662). In addition to serine/threonine- CC protein kinase activity, also has tyrosine-protein kinase activity and CC phosphorylates CDK1 at 'Tyr-4' upon DNA damage, facilitating its CC ubiquitination and proteasomal degradation (PubMed:20395957). Either as CC an adapter protein and/or via its kinase activity, can regulate various CC signaling pathways (p38 MAP kinase, NF-kappa-B and insulin signaling CC pathways) and transcription factors (JUN, STAT1, STAT3, IRF1, ATF3) CC involved in the expression of genes encoding pro-inflammatory cytokines CC and IFNs (PubMed:22948139, PubMed:23084476, PubMed:23372823). Activates CC the NF-kappa-B pathway via interaction with IKBKB and TRAF family of CC proteins and activates the p38 MAP kinase pathway via interaction with CC MAP2K6 (PubMed:10848580, PubMed:15121867, PubMed:15229216). Can act as CC both a positive and negative regulator of the insulin signaling pathway CC (ISP) (PubMed:20685959). Negatively regulates ISP by inducing the CC inhibitory phosphorylation of insulin receptor substrate 1 (IRS1) at CC 'Ser-312' and positively regulates ISP via phosphorylation of PPP2R5A CC which activates FOXO1, which in turn up-regulates the expression of CC insulin receptor substrate 2 (IRS2) (PubMed:20685959). Can regulate CC NLRP3 inflammasome assembly and the activation of NLRP3, NLRP1, AIM2 CC and NLRC4 inflammasomes (PubMed:22801494). Plays a role in the CC regulation of the cytoskeleton by binding to gelsolin (GSN), CC sequestering the protein in an inactive conformation away from actin CC (By similarity). {ECO:0000250|UniProtKB:Q03963, CC ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11836380, CC ECO:0000269|PubMed:15121867, ECO:0000269|PubMed:15229216, CC ECO:0000269|PubMed:18835251, ECO:0000269|PubMed:19189853, CC ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:19507191, CC ECO:0000269|PubMed:19840259, ECO:0000269|PubMed:20171114, CC ECO:0000269|PubMed:20395957, ECO:0000269|PubMed:20685959, CC ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:21123651, CC ECO:0000269|PubMed:21710204, ECO:0000269|PubMed:22214662, CC ECO:0000269|PubMed:22381929, ECO:0000269|PubMed:22801494, CC ECO:0000269|PubMed:22948139, ECO:0000269|PubMed:23084476, CC ECO:0000269|PubMed:23115276, ECO:0000269|PubMed:23229543, CC ECO:0000269|PubMed:23372823, ECO:0000269|PubMed:23399035, CC ECO:0000269|PubMed:32197074}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10027}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:16179258, ECO:0000303|PubMed:31246429}; CC -!- ACTIVITY REGULATION: Initially produced in an inactive form and is CC activated by binding to viral dsRNA, which causes dimerization and CC autophosphorylation in the activation loop and stimulation of function. CC ISGylation can activate it in the absence of viral infection. Can also CC be activated by heparin, pro-inflammatory stimuli, growth factors, CC cytokines, oxidative stress and the cellular protein PRKRA. Activity is CC markedly stimulated by manganese ions. Activation is blocked by the CC viral components HIV-1 Tat protein and large amounts of HIV-1 trans- CC activation response (TAR) RNA element as well as by the cellular CC proteins TARBP2, DUS2L, NPM1, NCK1 and ADAR. Down-regulated by Toscana CC virus (TOS) and Rift valley fever virus (RVFV) NSS which promote its CC proteasomal degradation. Inhibited by vaccinia virus protein E3, CC probably via dsRNA sequestering. {ECO:0000269|PubMed:12882984, CC ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18835251, CC ECO:0000269|PubMed:23229543, ECO:0000269|PubMed:23325696}. CC -!- SUBUNIT: Homodimer (PubMed:16179258, PubMed:31246429). Interacts with CC STRBP (By similarity). Interacts with DNAJC3. Forms a complex with CC FANCA, FANCC, FANCG and HSP70. Interacts with ADAR/ADAR1. Interacts CC with IRS1 (By similarity). The inactive form interacts with NCK1 and CC GSN. Interacts (via the kinase catalytic domain) with STAT3 (via SH2 CC domain), TRAF2 (C-terminus), TRAF5 (C-terminus) and TRAF6 (C-terminus). CC Interacts with MAP2K6, IKBKB/IKKB, NPM1, TARBP2, NLRP1, NLRP3, NLRC4 CC and AIM2. Interacts (via DRBM 1 domain) with DUS2L (via DRBM domain). CC Interacts with DHX9 (via N-terminus) and this interaction is dependent CC upon activation of the kinase. Interacts with EIF2S1/EIF-2ALPHA; this CC interaction induces a conformational change in EIF2S1 and its CC phosphorylation by EIF2AK2 (PubMed:16179258). Interacts with MBIP; the CC interaction is direct and leads to inhibition of EIF2AK2 self- CC activating autophosphorylation (PubMed:26705305). Interacts with the CC molybdopterin synthase complex subunit MOCS2B; the interaction is CC direct and enhances the interaction between EIF2AK2 and MBIP CC (PubMed:26705305). {ECO:0000250|UniProtKB:Q03963, CC ECO:0000269|PubMed:10390359, ECO:0000269|PubMed:10848580, CC ECO:0000269|PubMed:11438532, ECO:0000269|PubMed:12882984, CC ECO:0000269|PubMed:15121867, ECO:0000269|PubMed:15229216, CC ECO:0000269|PubMed:15299030, ECO:0000269|PubMed:16179258, CC ECO:0000269|PubMed:17079286, ECO:0000269|PubMed:18096616, CC ECO:0000269|PubMed:18835251, ECO:0000269|PubMed:19229320, CC ECO:0000269|PubMed:22801494, ECO:0000269|PubMed:23084476, CC ECO:0000269|PubMed:25740987, ECO:0000269|PubMed:26705305, CC ECO:0000269|PubMed:31246429, ECO:0000269|PubMed:8576172, CC ECO:0000269|PubMed:9079663, ECO:0000269|PubMed:9143277, CC ECO:0000269|PubMed:9781815}. CC -!- SUBUNIT: (Microbial infection) Interacts with human cytomegalovirus CC (HCMV) TRS1; this interaction retains EIF2AK2 to the nucleus and CC prevents its activation. {ECO:0000269|PubMed:16987971, CC ECO:0000269|PubMed:27780231}. CC -!- SUBUNIT: (Microbial infection) Interacts with vaccinia virus protein K3 CC (K3L); this interaction inhibits EIF2AK2. CC {ECO:0000269|PubMed:18971339}. CC -!- SUBUNIT: (Microbial infection) Interacts with human herpes simplex CC virus 1 (HHV-1) protein US11 in an RNA-dependent manner. CC {ECO:0000269|PubMed:11836380}. CC -!- SUBUNIT: (Microbial infection) The inactive form interacts with Toscana CC virus (TOS) NSS. {ECO:0000269|PubMed:23325696}. CC -!- SUBUNIT: (Microbial infection) Interacts with herpes virus 8 protein v- CC IRF2; this interaction inhibits EIF2AK2 activation. CC {ECO:0000269|PubMed:11160738}. CC -!- SUBUNIT: (Microbial infection) Interacts with vaccinia protein E3. CC {ECO:0000269|PubMed:25740987}. CC -!- SUBUNIT: (Microbial infection) Interacts (via N-terminus) with CC Hepatitis C virus (HCV) mature core protein (via N-terminus); this CC interaction induces the autophosphorylation of EIF2AK2. CC {ECO:0000269|PubMed:17267064}. CC -!- SUBUNIT: (Microbial infection) Interacts with Hepatitis C virus (HCV) CC non-structural protein 5A (NS5A); this interaction leads to disruption CC of EIF2AK2 dimerization by NS5A. {ECO:0000269|PubMed:16951545, CC ECO:0000269|PubMed:17451199, ECO:0000269|PubMed:9143277, CC ECO:0000269|PubMed:9710605}. CC -!- SUBUNIT: (Microbial infection) Interacts with Hepatitis C virus (HCV) CC envelope glycoprotein E2; this interaction inhibits EIF2AK2 and blocks CC its inhibitory effect on protein synthesis and cell growth. CC {ECO:0000269|PubMed:9143277}. CC -!- SUBUNIT: (Microbial infection) Interacts with human respiratory CC syncytial virus (HRSV) nucleoprotein; this interaction inhibits EIF2AK2 CC phosphorylation of EIF2S1 and blocks EIF2AK2-mediated translation CC shutoff. {ECO:0000269|PubMed:20519500}. CC -!- SUBUNIT: (Microbial infection) Interacts with human herpesvirus 8 CC protein MTA/ORF57; this interaction inhibits stress granule formation. CC {ECO:0000269|PubMed:29084250}. CC -!- INTERACTION: CC P19525; P78563-4: ADARB1; NbExp=3; IntAct=EBI-640775, EBI-12002366; CC P19525; P06493: CDK1; NbExp=4; IntAct=EBI-640775, EBI-444308; CC P19525; Q7L2E3: DHX30; NbExp=4; IntAct=EBI-640775, EBI-1211456; CC P19525; Q96C10: DHX58; NbExp=2; IntAct=EBI-640775, EBI-744193; CC P19525; Q08211: DHX9; NbExp=4; IntAct=EBI-640775, EBI-352022; CC P19525; Q9UPY3: DICER1; NbExp=2; IntAct=EBI-640775, EBI-395506; CC P19525; Q6P2E9: EDC4; NbExp=2; IntAct=EBI-640775, EBI-1006038; CC P19525; P19525: EIF2AK2; NbExp=2; IntAct=EBI-640775, EBI-640775; CC P19525; P05198: EIF2S1; NbExp=5; IntAct=EBI-640775, EBI-1056162; CC P19525; P56537: EIF6; NbExp=2; IntAct=EBI-640775, EBI-372243; CC P19525; Q8IY81: FTSJ3; NbExp=3; IntAct=EBI-640775, EBI-744088; CC P19525; Q9HCE1: MOV10; NbExp=3; IntAct=EBI-640775, EBI-1055820; CC P19525; Q96P20: NLRP3; NbExp=6; IntAct=EBI-640775, EBI-6253230; CC P19525; P06748: NPM1; NbExp=4; IntAct=EBI-640775, EBI-78579; CC P19525; O75569: PRKRA; NbExp=6; IntAct=EBI-640775, EBI-713955; CC P19525; O75569-1: PRKRA; NbExp=3; IntAct=EBI-640775, EBI-15588172; CC P19525; Q9NUL3: STAU2; NbExp=3; IntAct=EBI-640775, EBI-722938; CC P19525; Q15633: TARBP2; NbExp=2; IntAct=EBI-640775, EBI-978581; CC P19525; Q9H0E2: TOLLIP; NbExp=2; IntAct=EBI-640775, EBI-74615; CC P19525; Q9UL40: ZNF346; NbExp=4; IntAct=EBI-640775, EBI-2462313; CC P19525; Q27968: DNAJC3; Xeno; NbExp=5; IntAct=EBI-640775, EBI-640793; CC P19525; P0DTC9: N; Xeno; NbExp=8; IntAct=EBI-640775, EBI-25475856; CC P19525; P20639: OPG041; Xeno; NbExp=3; IntAct=EBI-640775, EBI-8674942; CC P19525; P04487: US11; Xeno; NbExp=3; IntAct=EBI-640775, EBI-6150681; CC P19525; Q2HR71: vIRF-2; Xeno; NbExp=2; IntAct=EBI-640775, EBI-8876177; CC P19525; PRO_0000278746 [O92972]; Xeno; NbExp=2; IntAct=EBI-640775, EBI-6918883; CC P19525; PRO_0000037570 [P27958]; Xeno; NbExp=4; IntAct=EBI-640775, EBI-6904269; CC P19525; PRO_0000037576 [P27958]; Xeno; NbExp=5; IntAct=EBI-640775, EBI-8753518; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15121867, CC ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:22214662, CC ECO:0000269|PubMed:26705305}. Nucleus {ECO:0000269|PubMed:21029237, CC ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:26705305}. Cytoplasm, CC perinuclear region {ECO:0000269|PubMed:15121867}. Note=Nuclear CC localization is elevated in acute leukemia, myelodysplastic syndrome CC (MDS), melanoma, breast, colon, prostate and lung cancer patient CC samples or cell lines as well as neurocytes from advanced Creutzfeldt- CC Jakob disease patients. {ECO:0000269|PubMed:21072047}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P19525-1; Sequence=Displayed; CC Name=2; CC IsoId=P19525-2; Sequence=VSP_046177; CC -!- TISSUE SPECIFICITY: Highly expressed in thymus, spleen and bone marrow CC compared to non-hematopoietic tissues such as small intestine, liver, CC or kidney tissues. Colocalizes with GSK3B and TAU in the Alzheimer CC disease (AD) brain. Elevated levels seen in breast and colon CC carcinomas, and which correlates with tumor progression and CC invasiveness or risk of progression. {ECO:0000269|PubMed:21029237, CC ECO:0000269|PubMed:23403623}. CC -!- INDUCTION: By type I interferons. {ECO:0000269|PubMed:1695551}. CC -!- DOMAIN: Contains 2 dsRNA-binding domain (DRBM) (PubMed:9736623). The N- CC terminus contains the catalytic domain dimerization. The C-terminus CC binds EIF2S1/EIF2-alpha (PubMed:16179258). CC {ECO:0000269|PubMed:16179258, ECO:0000269|PubMed:9736623}. CC -!- PTM: Autophosphorylated on several Ser, Thr and Tyr residues. CC Autophosphorylation of Thr-451 is dependent on Thr-446 and is CC stimulated by dsRNA binding and dimerization. Autophosphorylation CC apparently leads to the activation of the kinase. Tyrosine CC autophosphorylation is essential for efficient dsRNA-binding, CC dimerization, and kinase activation. Autophosphorylation is inhibited CC by the concerted action of ATAC complex subunit MBIP and molybdopterin CC synthase complex subunit MOCS2B (PubMed:26705305). CC {ECO:0000269|PubMed:11152499, ECO:0000269|PubMed:11337501, CC ECO:0000269|PubMed:16179258, ECO:0000269|PubMed:16373505, CC ECO:0000269|PubMed:20685959, ECO:0000269|PubMed:21029237, CC ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:26705305}. CC -!- DISEASE: Leukoencephalopathy, developmental delay, and episodic CC neurologic regression syndrome (LEUDEN) [MIM:618877]: An autosomal CC dominant disorder characterized by global developmental delay apparent CC in early childhood, cognitive impairment, ataxia, poor or absent speech CC with dysarthria, hypotonia, hypertonia, extrapyramidal signs, tremor, CC and abnormal involuntary movements. Affected individuals also exhibit CC neurological regression in the setting of febrile illness or infection. CC Many patients have seizures. Brain imaging shows diffuse white matter CC abnormalities with poor myelination. {ECO:0000269|PubMed:32197074}. CC Note=The disease may be caused by variants affecting the gene CC represented in this entry. CC -!- DISEASE: Dystonia 33 (DYT33) [MIM:619687]: A form of dystonia, a CC disorder defined by the presence of sustained involuntary muscle CC contraction, often leading to abnormal postures. DYT33 is a slowly CC progressive form characterized by onset of focal or generalized CC dystonia in the first decades of life. Disease manifestations are CC variable. Some patients show ambulation difficulties, dysarthria, or CC dysphagia. Some affected individuals may manifest motor delay, lower CC limb spasticity, and mild developmental delay with intellectual CC disability. DYT33 penetrance is incomplete. Inheritance can be CC autosomal dominant or recessive. {ECO:0000269|PubMed:33236446, CC ECO:0000269|PubMed:33866603, ECO:0000269|PubMed:35146068}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. GCN2 subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41866/EIF2AK2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M35663; AAA36409.1; -; mRNA. DR EMBL; M85294; AAA18253.1; -; mRNA. DR EMBL; U50648; AAC50768.1; -; Genomic_DNA. DR EMBL; U50634; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50635; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50636; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50637; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50638; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50639; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50640; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50641; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50642; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50643; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50644; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50645; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50646; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; U50647; AAC50768.1; JOINED; Genomic_DNA. DR EMBL; AF167472; AAF13156.1; -; Genomic_DNA. DR EMBL; AF167460; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167462; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167463; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167464; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167465; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167466; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167468; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AF167470; AAF13156.1; JOINED; Genomic_DNA. DR EMBL; AY302136; AAP57628.1; -; mRNA. DR EMBL; AK290655; BAF83344.1; -; mRNA. DR EMBL; AK313818; BAG36554.1; -; mRNA. DR EMBL; AY228338; AAO38055.1; -; Genomic_DNA. DR EMBL; AC007899; AAY24317.1; -; Genomic_DNA. DR EMBL; CH471053; EAX00407.1; -; Genomic_DNA. DR EMBL; CH471053; EAX00408.1; -; Genomic_DNA. DR EMBL; CH471053; EAX00409.1; -; Genomic_DNA. DR EMBL; BC093676; AAH93676.1; -; mRNA. DR EMBL; BC101475; AAI01476.1; -; mRNA. DR CCDS; CCDS1786.1; -. [P19525-1] DR CCDS; CCDS46259.1; -. [P19525-2] DR PIR; JC5225; JC5225. DR RefSeq; NP_001129123.1; NM_001135651.3. [P19525-1] DR RefSeq; NP_001129124.1; NM_001135652.2. [P19525-2] DR RefSeq; NP_002750.1; NM_002759.4. [P19525-1] DR RefSeq; XP_011531289.1; XM_011532987.3. [P19525-1] DR RefSeq; XP_054198993.1; XM_054343018.1. [P19525-1] DR PDB; 1QU6; NMR; -; A=1-170. DR PDB; 2A19; X-ray; 2.50 A; B/C=258-550. DR PDB; 2A1A; X-ray; 2.80 A; B=258-550. DR PDB; 3UIU; X-ray; 2.90 A; A/B=254-551. DR PDB; 6D3K; X-ray; 2.60 A; A/B/C=229-551. DR PDB; 6D3L; X-ray; 3.10 A; A=229-551. DR PDB; 7OBK; X-ray; 1.80 A; B=541-551. DR PDB; 7OBL; X-ray; 1.80 A; B=541-551. DR PDB; 8BI7; X-ray; 1.40 A; B=541-551. DR PDB; 8I9J; EM; 6.39 A; A=1-170. DR PDB; 8IZN; EM; 6.67 A; A=1-170. DR PDBsum; 1QU6; -. DR PDBsum; 2A19; -. DR PDBsum; 2A1A; -. DR PDBsum; 3UIU; -. DR PDBsum; 6D3K; -. DR PDBsum; 6D3L; -. DR PDBsum; 7OBK; -. DR PDBsum; 7OBL; -. DR PDBsum; 8BI7; -. DR PDBsum; 8I9J; -. DR PDBsum; 8IZN; -. DR AlphaFoldDB; P19525; -. DR BMRB; P19525; -. DR EMDB; EMD-35274; -. DR EMDB; EMD-35866; -. DR SMR; P19525; -. DR BioGRID; 111596; 395. DR DIP; DIP-2657N; -. DR FunCoup; P19525; 998. DR IntAct; P19525; 176. DR MINT; P19525; -. DR STRING; 9606.ENSP00000233057; -. DR BindingDB; P19525; -. DR ChEMBL; CHEMBL5785; -. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB07995; H-89. DR DrugBank; DB00328; Indomethacin. DR DrugCentral; P19525; -. DR GuidetoPHARMACOLOGY; 2016; -. DR GlyGen; P19525; 2 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; P19525; -. DR PhosphoSitePlus; P19525; -. DR SwissPalm; P19525; -. DR BioMuta; EIF2AK2; -. DR DMDM; 125527; -. DR jPOST; P19525; -. DR MassIVE; P19525; -. DR PaxDb; 9606-ENSP00000233057; -. DR PeptideAtlas; P19525; -. DR ProteomicsDB; 19391; -. DR ProteomicsDB; 53670; -. [P19525-1] DR Pumba; P19525; -. DR TopDownProteomics; P19525-1; -. [P19525-1] DR Antibodypedia; 3548; 1196 antibodies from 44 providers. DR DNASU; 5610; -. DR Ensembl; ENST00000233057.9; ENSP00000233057.4; ENSG00000055332.20. [P19525-1] DR Ensembl; ENST00000395127.6; ENSP00000378559.2; ENSG00000055332.20. [P19525-1] DR Ensembl; ENST00000405334.5; ENSP00000385014.1; ENSG00000055332.20. [P19525-2] DR Ensembl; ENST00000647926.1; ENSP00000497534.1; ENSG00000055332.20. [P19525-1] DR Ensembl; ENST00000679507.1; ENSP00000506024.1; ENSG00000055332.20. [P19525-1] DR Ensembl; ENST00000681463.1; ENSP00000505138.1; ENSG00000055332.20. [P19525-1] DR Ensembl; ENST00000681507.1; ENSP00000505772.1; ENSG00000055332.20. [P19525-1] DR GeneID; 5610; -. DR KEGG; hsa:5610; -. DR MANE-Select; ENST00000233057.9; ENSP00000233057.4; NM_001135651.3; NP_001129123.1. DR UCSC; uc010fab.3; human. [P19525-1] DR AGR; HGNC:9437; -. DR ClinPGx; PA33779; -. DR CTD; 5610; -. DR DisGeNET; 5610; -. DR GeneCards; EIF2AK2; -. DR HGNC; HGNC:9437; EIF2AK2. DR HPA; ENSG00000055332; Low tissue specificity. DR MalaCards; EIF2AK2; -. DR MIM; 176871; gene. DR MIM; 618877; phenotype. DR MIM; 619687; phenotype. DR OpenTargets; ENSG00000055332; -. DR Orphanet; 256; Early-onset generalized limb-onset dystonia. DR VEuPathDB; HostDB:ENSG00000055332; -. DR eggNOG; KOG1033; Eukaryota. DR GeneTree; ENSGT00940000160736; -. DR HOGENOM; CLU_023682_1_0_1; -. DR InParanoid; P19525; -. DR OMA; KIACEMM; -. DR OrthoDB; 341578at2759; -. DR PAN-GO; P19525; 2 GO annotations based on evolutionary models. DR PhylomeDB; P19525; -. DR PathwayCommons; P19525; -. DR Reactome; R-HSA-1169408; ISG15 antiviral mechanism. DR Reactome; R-HSA-169131; Inhibition of PKR. DR Reactome; R-HSA-4755510; SUMOylation of immune response proteins. DR Reactome; R-HSA-909733; Interferon alpha/beta signaling. DR Reactome; R-HSA-9833109; Evasion by RSV of host interferon responses. DR Reactome; R-HSA-9833482; PKR-mediated signaling. DR SignaLink; P19525; -. DR SIGNOR; P19525; -. DR Agora; ENSG00000055332; -. DR BioGRID-ORCS; 5610; 13 hits in 1193 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; DEE660B4; Stress granule. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; EIF2AK2; human. DR EvolutionaryTrace; P19525; -. DR GeneWiki; Protein_kinase_R; -. DR GenomeRNAi; 5610; -. DR Pharos; P19525; Tchem. DR PRO; PR:P19525; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; P19525; protein. DR Bgee; ENSG00000055332; Expressed in endometrium epithelium and 211 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB. DR GO; GO:0005840; C:ribosome; TAS:AgBase. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0003725; F:double-stranded RNA binding; IDA:MGI. DR GO; GO:0004694; F:eukaryotic translation initiation factor 2alpha kinase activity; IMP:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0016301; F:kinase activity; IDA:UniProt. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IEA:UniProtKB-EC. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0019888; F:protein phosphatase regulator activity; TAS:ProtInc. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProt. DR GO; GO:0003723; F:RNA binding; HDA:UniProtKB. DR GO; GO:0140374; P:antiviral innate immune response; IDA:UniProt. DR GO; GO:0034198; P:cellular response to amino acid starvation; IMP:UniProtKB. DR GO; GO:0051607; P:defense response to virus; IEP:ARUK-UCL. DR GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl. DR GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:ProtInc. DR GO; GO:0033689; P:negative regulation of osteoblast proliferation; IMP:UniProtKB. DR GO; GO:0017148; P:negative regulation of translation; IDA:UniProtKB. DR GO; GO:0045071; P:negative regulation of viral genome replication; IMP:UniProtKB. DR GO; GO:0032722; P:positive regulation of chemokine production; ISS:UniProtKB. DR GO; GO:0001819; P:positive regulation of cytokine production; ISS:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB. DR GO; GO:1901224; P:positive regulation of non-canonical NF-kappaB signal transduction; ISS:UniProtKB. DR GO; GO:0032874; P:positive regulation of stress-activated MAPK cascade; ISS:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:1901532; P:regulation of hematopoietic progenitor cell differentiation; ISS:UniProtKB. DR GO; GO:1902036; P:regulation of hematopoietic stem cell differentiation; ISS:UniProtKB. DR GO; GO:1902033; P:regulation of hematopoietic stem cell proliferation; ISS:UniProtKB. DR GO; GO:1900225; P:regulation of NLRP3 inflammasome complex assembly; ISS:UniProtKB. DR GO; GO:0006446; P:regulation of translational initiation; IBA:GO_Central. DR GO; GO:0035455; P:response to interferon-alpha; IDA:UniProtKB. DR GO; GO:0009615; P:response to virus; IMP:UniProtKB. DR GO; GO:0006412; P:translation; IEA:Ensembl. DR CDD; cd19903; DSRM_EIF2AK2_rpt1; 1. DR CDD; cd19904; DSRM_EIF2AK2_rpt2; 1. DR CDD; cd14047; STKc_EIF2AK2_PKR; 1. DR DisProt; DP03944; -. DR FunFam; 3.30.160.20:FF:000045; Eukaryotic translation initiation factor 2-alpha kinase 2; 1. DR FunFam; 3.30.160.20:FF:000062; Eukaryotic translation initiation factor 2-alpha kinase 2; 1. DR FunFam; 3.30.200.20:FF:000536; Eukaryotic translation initiation factor 2-alpha kinase 2; 1. DR FunFam; 1.10.510.10:FF:000251; eukaryotic translation initiation factor 2-alpha kinase 3; 1. DR Gene3D; 3.30.160.20; -; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00443; -. DR InterPro; IPR050339; CC_SR_Kinase. DR InterPro; IPR014720; dsRBD_dom. DR InterPro; IPR044452; EIF2AK2_DSRM_1. DR InterPro; IPR044453; EIF2AK2_DSRM_2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR11042; EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE EIF2-ALPHA KINASE -RELATED; 1. DR PANTHER; PTHR11042:SF163; INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE; 1. DR Pfam; PF00035; dsrm; 2. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00358; DSRM; 2. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF54768; dsRNA-binding domain-like; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50137; DS_RBD; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Antiviral defense; KW ATP-binding; Cytoplasm; Direct protein sequencing; Disease variant; KW Dystonia; Host-virus interaction; Immunity; Innate immunity; KW Isopeptide bond; Kinase; Magnesium; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW RNA-binding; Serine/threonine-protein kinase; Transcription; KW Transcription regulation; Transferase; Tyrosine-protein kinase; KW Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|Ref.13, ECO:0007744|PubMed:22223895, FT ECO:0007744|PubMed:22814378" FT CHAIN 2..551 FT /note="Interferon-induced, double-stranded RNA-activated FT protein kinase" FT /id="PRO_0000085945" FT DOMAIN 9..77 FT /note="DRBM 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00266, FT ECO:0000269|PubMed:9736623" FT DOMAIN 100..167 FT /note="DRBM 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00266, FT ECO:0000269|PubMed:9736623" FT DOMAIN 267..538 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REPEAT 331..343 FT /note="1" FT REPEAT 345..357 FT /note="2" FT REGION 2..180 FT /note="(Microbial infection) Interaction with HCV NS5A" FT /evidence="ECO:0000269|PubMed:17267064" FT REGION 202..222 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 266..551 FT /note="Interaction with TRAF5" FT /evidence="ECO:0000269|PubMed:15121867" FT REGION 266..362 FT /note="Dimerization" FT /evidence="ECO:0000269|PubMed:16179258" FT REGION 331..357 FT /note="2 X 13 AA approximate repeats" FT REGION 379..496 FT /note="Interaction with EIF2S1/EIF-2ALPHA" FT /evidence="ECO:0000269|PubMed:16179258" FT COMPBIAS 202..215 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 414 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 273..281 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 296 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 432 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /evidence="ECO:0000305|PubMed:16179258, FT ECO:0000305|PubMed:31246429" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0000269|Ref.13, ECO:0007744|PubMed:22223895, FT ECO:0007744|PubMed:22814378" FT MOD_RES 83 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:11152499, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231" FT MOD_RES 88 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 89 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 90 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 101 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16373505" FT MOD_RES 162 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16373505" FT MOD_RES 242 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 255 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 258 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:11152499" FT MOD_RES 293 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16373505" FT MOD_RES 446 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11337501, FT ECO:0000269|PubMed:16179258" FT MOD_RES 451 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11337501, FT ECO:0000269|PubMed:20685959" FT MOD_RES 456 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 542 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 69 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ISG15)" FT /evidence="ECO:0000269|PubMed:23229543" FT CROSSLNK 159 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ISG15)" FT /evidence="ECO:0000269|PubMed:23229543" FT VAR_SEQ 263..303 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_046177" FT VARIANT 11 FT /note="M -> L (in LEUDEN; uncertain significance; reduced FT phosphorylation of eukaryotic translation initiation factor FT 2-alpha in patient cells)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084260" FT VARIANT 32 FT /note="N -> S (in LEUDEN; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084261" FT VARIANT 32 FT /note="N -> T (in DYT33; uncertain significance; gain-of- FT function variant resulting in increased levels of FT phosphorylated EIF2AK2 and EIF2A in patient cells compared FT to controls)" FT /evidence="ECO:0000269|PubMed:33236446" FT /id="VAR_086715" FT VARIANT 97 FT /note="S -> F (in LEUDEN; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084262" FT VARIANT 109 FT /note="A -> S (in LEUDEN; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084263" FT VARIANT 109 FT /note="A -> V (in LEUDEN; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084264" FT VARIANT 114 FT /note="L -> Q (found in a patient with dysmorphic facies, FT syndactyly, congenital microcephaly and global FT developmental delay; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084265" FT VARIANT 130 FT /note="G -> R (in DYT33; gain-of-function variant resulting FT in increased levels of phosphorylated EIF2AK2 and EIF2A in FT patient cells compared to controls)" FT /evidence="ECO:0000269|PubMed:33236446, FT ECO:0000269|PubMed:33866603, ECO:0000269|PubMed:35146068" FT /id="VAR_086716" FT VARIANT 133 FT /note="Y -> F (in LEUDEN; uncertain significance; reduced FT phosphorylation of eukaryotic translation initiation factor FT 2-alpha in patient cells)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084266" FT VARIANT 138 FT /note="G -> A (in DYT33; uncertain significance)" FT /evidence="ECO:0000269|PubMed:33236446" FT /id="VAR_086717" FT VARIANT 325 FT /note="G -> S (in LEUDEN; uncertain significance)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084267" FT VARIANT 428 FT /note="V -> E (in dbSNP:rs56219559)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040474" FT VARIANT 439 FT /note="L -> V (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040475" FT VARIANT 461 FT /note="S -> C (in LEUDEN; uncertain significance; reduced FT phosphorylation of eukaryotic translation initiation factor FT 2-alpha in patient cells)" FT /evidence="ECO:0000269|PubMed:32197074" FT /id="VAR_084268" FT VARIANT 506 FT /note="I -> V (no effect on PKR inhibition by HCMV protein FT TRS1; dbSNP:rs34821155)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:27780231" FT /id="VAR_040476" FT MUTAGEN 59..60 FT /note="SK->AA: In FL-PKR-2AI; moderate loss of activity but FT no effect on dsRNA binding." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 60 FT /note="K->A: Impairs dsRNA binding but not dimerization or FT activity." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 67 FT /note="A->E: Significant loss of activity; loss of dsRNA FT binding and dimerization." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 83 FT /note="S->A: No effect on enzymatic activity; when FT associated with A-88; A-89 and A-90." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 88 FT /note="T->A: No effect on enzymatic activity; when FT associated with A-83; A-89 and A-90." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 89 FT /note="T->A: No effect on enzymatic activity; when FT associated with A-83; A-88 and A-90." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 90 FT /note="T->A: No effect on enzymatic activity; when FT associated with A-83; A-88 and A-89." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 149..150 FT /note="TK->AA: In FL-PKR-2AII; no effect on activity." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 242 FT /note="S->A: Moderate loss of activity; when associated FT with A-255 and A-258." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 244..296 FT /note="Missing: Loss of activity." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 255 FT /note="T->A: Moderate loss of activity; when associated FT with A-242 and A-255." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 258 FT /note="T->A: Moderate loss of activity." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 296 FT /note="K->R: Loss of activity." FT /evidence="ECO:0000269|PubMed:11152499" FT MUTAGEN 446 FT /note="T->A: Significant loss of activity and impairs FT autophosphorylation of T-451." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 451 FT /note="T->A: Loss of activity." FT /evidence="ECO:0000269|PubMed:11337501" FT MUTAGEN 486 FT /note="D->V: 15-fold decrease in K3L binding affinity and FT thus resistance of mutated PKR to K3L inhibition." FT /evidence="ECO:0000269|PubMed:18971339" FT MUTAGEN 489 FT /note="F->S: Loss of PKR inhibition by HCMV protein TRS1." FT /evidence="ECO:0000269|PubMed:27780231" FT MUTAGEN 496 FT /note="T->K: No effect on PKR inhibition by HCMV protein FT TRS1." FT /evidence="ECO:0000269|PubMed:27780231" FT MUTAGEN 502 FT /note="I->T: No effect on PKR inhibition by HCMV protein FT TRS1." FT /evidence="ECO:0000269|PubMed:27780231" FT MUTAGEN 510 FT /note="K->R: No effect on PKR inhibition by HCMV protein FT TRS1." FT /evidence="ECO:0000269|PubMed:27780231" FT MUTAGEN 516 FT /note="Q->E: No effect on PKR inhibition by HCMV protein FT TRS1." FT /evidence="ECO:0000269|PubMed:27780231" FT CONFLICT 102 FT /note="I -> M (in Ref. 7; AAP57628)" FT /evidence="ECO:0000305" FT CONFLICT 224 FT /note="S -> R (in Ref. 7; AAP57628)" FT /evidence="ECO:0000305" FT CONFLICT 512 FT /note="K -> E (in Ref. 6; AAF13156)" FT /evidence="ECO:0000305" FT STRAND 5..7 FT /evidence="ECO:0007829|PDB:1QU6" FT HELIX 10..21 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 26..32 FT /evidence="ECO:0007829|PDB:1QU6" FT TURN 35..37 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 41..50 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 54..56 FT /evidence="ECO:0007829|PDB:1QU6" FT HELIX 61..76 FT /evidence="ECO:0007829|PDB:1QU6" FT HELIX 102..111 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 115..123 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 125..138 FT /evidence="ECO:0007829|PDB:1QU6" FT STRAND 144..149 FT /evidence="ECO:0007829|PDB:1QU6" FT HELIX 150..167 FT /evidence="ECO:0007829|PDB:1QU6" FT HELIX 261..266 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 267..274 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 276..278 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 281..286 FT /evidence="ECO:0007829|PDB:2A19" FT TURN 287..289 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 292..299 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 303..305 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 306..314 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 323..332 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 358..366 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 374..380 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 381..383 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 388..407 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 410..412 FT /evidence="ECO:0007829|PDB:2A1A" FT HELIX 417..419 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 420..424 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 427..430 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 433..435 FT /evidence="ECO:0007829|PDB:6D3L" FT STRAND 437..440 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 457..461 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 468..482 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 488..499 FT /evidence="ECO:0007829|PDB:2A19" FT STRAND 505..507 FT /evidence="ECO:0007829|PDB:3UIU" FT HELIX 509..518 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 523..525 FT /evidence="ECO:0007829|PDB:2A19" FT HELIX 529..539 FT /evidence="ECO:0007829|PDB:2A19" SQ SEQUENCE 551 AA; 62094 MW; 815AD83ACAB45DA3 CRC64; MAGDLSAGFF MEELNTYRQK QGVVLKYQEL PNSGPPHDRR FTFQVIIDGR EFPEGEGRSK KEAKNAAAKL AVEILNKEKK AVSPLLLTTT NSSEGLSMGN YIGLINRIAQ KKRLTVNYEQ CASGVHGPEG FHYKCKMGQK EYSIGTGSTK QEAKQLAAKL AYLQILSEET SVKSDYLSSG SFATTCESQS NSLVTSTLAS ESSSEGDFSA DTSEINSNSD SLNSSSLLMN GLRNNQRKAK RSLAPRFDLP DMKETKYTVD KRFGMDFKEI ELIGSGGFGQ VFKAKHRIDG KTYVIKRVKY NNEKAEREVK ALAKLDHVNI VHYNGCWDGF DYDPETSDDS LESSDYDPEN SKNSSRSKTK CLFIQMEFCD KGTLEQWIEK RRGEKLDKVL ALELFEQITK GVDYIHSKKL IHRDLKPSNI FLVDTKQVKI GDFGLVTSLK NDGKRTRSKG TLRYMSPEQI SSQDYGKEVD LYALGLILAE LLHVCDTAFE TSKFFTDLRD GIISDIFDKK EKTLLQKLLS KKPEDRPNTS EILRTLTVWK KSPEKNERHT C // ID ECT2_HUMAN Reviewed; 914 AA. AC Q9H8V3; Q0MT80; Q2M269; Q6U836; Q9NSV8; Q9NVW9; DT 26-SEP-2001, integrated into UniProtKB/Swiss-Prot. DT 16-NOV-2011, sequence version 4. DT 28-JAN-2026, entry version 195. DE RecName: Full=Protein ECT2; DE AltName: Full=Epithelial cell-transforming sequence 2 oncogene; GN Name=ECT2 {ECO:0000312|HGNC:HGNC:3155}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, PHOSPHORYLATION, AND RP SUBCELLULAR LOCATION. RX PubMed=10579713; DOI=10.1083/jcb.147.5.921; RA Tatsumoto T., Xie X., Blumenthal R., Okamoto I., Miki T.; RT "Human ECT2 is an exchange factor for Rho GTPases, phosphorylated in G2/M RT phases, and involved in cytokinesis."; RL J. Cell Biol. 147:921-928(1999). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RX PubMed=14587037; DOI=10.1002/jcb.10688; RA Saito S., Tatsumoto T., Lorenzi M.V., Chedid M., Kapoor V., Sakata H., RA Rubin J.S., Miki T.; RT "Rho exchange factor ECT2 is induced by growth factors and regulates RT cytokinesis through the N-terminal cell cycle regulator-related domains."; RL J. Cell. Biochem. 90:819-836(2003). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH PKP4, AND RP SUBCELLULAR LOCATION. RX PubMed=17115030; DOI=10.1038/ncb1504; RA Wolf A., Keil R., Gotzl O., Mun A., Schwarze K., Lederer M., RA Huttelmaier S., Hatzfeld M.; RT "The armadillo protein p0071 regulates Rho signalling during cytokinesis."; RL Nat. Cell Biol. 8:1432-1440(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Teratocarcinoma, and Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 662-914 (ISOFORM 3). RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [8] RP FUNCTION, HOMODIMERIZATION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP 379-ARG--ARG-381; 402-ARG--ARG-404 AND 596-PRO--ARG-599. RX PubMed=14645260; DOI=10.1074/jbc.m306725200; RA Saito S., Liu X.F., Kamijo K., Raziuddin R., Tatsumoto T., Okamoto I., RA Chen X., Lee C.C., Lorenzi M.V., Ohara N., Miki T.; RT "Deregulation and mislocalization of the cytokinesis regulator ECT2 RT activate the Rho signaling pathways leading to malignant transformation."; RL J. Biol. Chem. 279:7169-7179(2004). RN [9] RP FUNCTION, INTERACTION WITH PARD3; PARD6A; PARD6B AND PRKCQ, INDUCTION, AND RP SUBCELLULAR LOCATION. RX PubMed=15254234; DOI=10.1128/mcb.24.15.6665-6675.2004; RA Liu X.F., Ishida H., Raziuddin R., Miki T.; RT "Nucleotide exchange factor ECT2 interacts with the polarity protein RT complex Par6/Par3/protein kinase Czeta (PKCzeta) and regulates PKCzeta RT activity."; RL Mol. Cell. Biol. 24:6665-6675(2004). RN [10] RP FUNCTION, HOMODIMERIZATION, HOMOOLIGOMERIZATION, AND MUTAGENESIS OF RP TRP-336. RX PubMed=15545273; DOI=10.1074/jbc.m409298200; RA Kim J.E., Billadeau D.D., Chen J.; RT "The tandem BRCT domains of Ect2 are required for both negative and RT positive regulation of Ect2 in cytokinesis."; RL J. Biol. Chem. 280:5733-5739(2005). RN [11] RP FUNCTION. RX PubMed=15642749; DOI=10.1083/jcb.200408085; RA Oceguera-Yanez F., Kimura K., Yasuda S., Higashida C., Kitamura T., RA Hiraoka Y., Haraguchi T., Narumiya S.; RT "Ect2 and MgcRacGAP regulate the activation and function of Cdc42 in RT mitosis."; RL J. Cell Biol. 168:221-232(2005). RN [12] RP FUNCTION, INTERACTION WITH RACGAP1, MUTAGENESIS OF THR-373, AND SUBCELLULAR RP LOCATION. RX PubMed=16103226; DOI=10.1083/jcb.200501097; RA Yuce O., Piekny A., Glotzer M.; RT "An ECT2-centralspindlin complex regulates the localization and function of RT RhoA."; RL J. Cell Biol. 170:571-582(2005). RN [13] RP INTERACTION WITH RACGAP1. RX PubMed=16129829; DOI=10.1073/pnas.0504145102; RA Zhao W.-M., Fang G.; RT "MgcRacGAP controls the assembly of the contractile ring and the initiation RT of cytokinesis."; RL Proc. Natl. Acad. Sci. U.S.A. 102:13158-13163(2005). RN [14] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=16495035; DOI=10.1016/j.cellsig.2006.01.007; RA Liu X.F., Ohno S., Miki T.; RT "Nucleotide exchange factor ECT2 regulates epithelial cell polarity."; RL Cell. Signal. 18:1604-1615(2006). RN [15] RP INTERACTION WITH NEDD9, AND SUBCELLULAR LOCATION. RX PubMed=16394104; DOI=10.1091/mbc.e05-03-0237; RA Dadke D., Jarnik M., Pugacheva E.N., Singh M.K., Golemis E.A.; RT "Deregulation of HEF1 impairs M-phase progression by disrupting the RhoA RT activation cycle."; RL Mol. Biol. Cell 17:1204-1217(2006). RN [16] RP FUNCTION, IDENTIFICATION IN THE CENTRALSPINDLIN COMPLEX, INTERACTION WITH RP KIF23 AND RACGAP1, AND SUBCELLULAR LOCATION. RX PubMed=16236794; DOI=10.1091/mbc.e05-06-0569; RA Kamijo K., Ohara N., Abe M., Uchimura T., Hosoya H., Lee J.S., Miki T.; RT "Dissecting the role of Rho-mediated signaling in contractile ring RT formation."; RL Mol. Biol. Cell 17:43-55(2006). RN [17] RP FUNCTION, HOMODIMERIZATION, PHOSPHORYLATION AT THR-373, AND MUTAGENESIS OF RP THR-373. RX PubMed=16170345; DOI=10.1038/sj.onc.1209078; RA Hara T., Abe M., Inoue H., Yu L.R., Veenstra T.D., Kang Y.H., Lee K.S., RA Miki T.; RT "Cytokinesis regulator ECT2 changes its conformation through RT phosphorylation at Thr-341 in G2/M phase."; RL Oncogene 25:566-578(2006). RN [18] RP PHOSPHORYLATION AT THR-444, INTERACTION WITH PLK1, AND MUTAGENESIS OF RP THR-444 AND THR-846. RX PubMed=16247472; DOI=10.1038/sj.onc.1209124; RA Niiya F., Tatsumoto T., Lee K.S., Miki T.; RT "Phosphorylation of the cytokinesis regulator ECT2 at G2/M phase stimulates RT association of the mitotic kinase Plk1 and accumulation of GTP-bound RT RhoA."; RL Oncogene 25:827-837(2006). RN [19] RP INTERACTION WITH RAB11FIP3. RX PubMed=18511905; DOI=10.1038/emboj.2008.112; RA Simon G.C., Schonteich E., Wu C.C., Piekny A., Ekiert D., Yu X., RA Gould G.W., Glotzer M., Prekeris R.; RT "Sequential Cyk-4 binding to ECT2 and FIP3 regulates cleavage furrow RT ingression and abscission during cytokinesis."; RL EMBO J. 27:1791-1803(2008). RN [20] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-367; SER-370; THR-373; RP SER-376; SER-842 AND THR-846, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [22] RP FUNCTION. RX PubMed=19129481; DOI=10.1091/mbc.e08-01-0001; RA Asiedu M., Wu D., Matsumura F., Wei Q.; RT "Centrosome/spindle pole-associated protein regulates cytokinesis via RT promoting the recruitment of MyoGEF to the central spindle."; RL Mol. Biol. Cell 20:1428-1440(2009). RN [23] RP FUNCTION, INTERACTION WITH PARD6A AND PRKCI, SUBCELLULAR LOCATION, AND RP TISSUE SPECIFICITY. RX PubMed=19617897; DOI=10.1038/onc.2009.217; RA Justilien V., Fields A.P.; RT "Ect2 links the PKCiota-Par6alpha complex to Rac1 activation and cellular RT transformation."; RL Oncogene 28:3597-3607(2009). RN [24] RP FUNCTION, INTERACTION WITH KIF23 AND RACGAP1, SUBCELLULAR LOCATION, AND RP MUTAGENESIS OF THR-184 AND LYS-226. RX PubMed=19468300; DOI=10.1371/journal.pbio.1000110; RA Wolfe B.A., Takaki T., Petronczki M., Glotzer M.; RT "Polo-like kinase 1 directs assembly of the HsCyk-4 RhoGAP/Ect2 RhoGEF RT complex to initiate cleavage furrow formation."; RL PLoS Biol. 7:E1000110-E1000110(2009). RN [25] RP INTERACTION WITH RACGAP1. RX PubMed=19468302; DOI=10.1371/journal.pbio.1000111; RA Burkard M.E., Maciejowski J., Rodriguez-Bravo V., Repka M., Lowery D.M., RA Clauser K.R., Zhang C., Shokat K.M., Carr S.A., Yaffe M.B., RA Jallepalli P.V.; RT "Plk1 self-organization and priming phosphorylation of HsCYK-4 at the RT spindle midzone regulate the onset of division in human cells."; RL PLoS Biol. 7:E1000111-E1000111(2009). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-359, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [28] RP FUNCTION, PHOSPHORYLATION AT THR-359, MUTAGENESIS OF THR-359, AND RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=21189248; DOI=10.1074/jbc.m110.196113; RA Justilien V., Jameison L., Der C.J., Rossman K.L., Fields A.P.; RT "Oncogenic activity of Ect2 is regulated through protein kinase C iota- RT mediated phosphorylation."; RL J. Biol. Chem. 286:8149-8157(2011). RN [29] RP FUNCTION, AND INDUCTION. RX PubMed=21373644; DOI=10.1371/journal.pone.0017108; RA Srougi M.C., Burridge K.; RT "The nuclear guanine nucleotide exchange factors Ect2 and Net1 regulate RT RhoB-mediated cell death after DNA damage."; RL PLoS ONE 6:E17108-E17108(2011). RN [30] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-359, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [31] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [32] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-359; SER-367; SER-716; RP SER-861 AND SER-866, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [33] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-611, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [34] RP X-RAY CRYSTALLOGRAPHY (1.48 ANGSTROMS) OF 268-361. RG Structural genomics consortium (SGC); RT "Crystal structure of the second BRCT domain of epithelial cell RT transforming 2 (ECT2)."; RL Submitted (JAN-2010) to the PDB data bank. RN [35] {ECO:0007744|PDB:4N40} RP X-RAY CRYSTALLOGRAPHY (3.11 ANGSTROMS) OF 45-356, FUNCTION, ACTIVITY RP REGULATION, INTERACTION WITH RACGAP1, AND MUTAGENESIS OF THR-184 AND RP LYS-226. RX PubMed=25068414; DOI=10.1016/j.febslet.2014.07.019; RA Zou Y., Shao Z., Peng J., Li F., Gong D., Wang C., Zuo X., Zhang Z., Wu J., RA Shi Y., Gong Q.; RT "Crystal structure of triple-BRCT-domain of ECT2 and insights into the RT binding characteristics to CYK-4."; RL FEBS Lett. 588:2911-2920(2014). RN [36] {ECO:0007744|PDB:6L30} RP X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 173-865, FUNCTION, ACTIVITY RP REGULATION, INTERACTION WITH RHOA, DOMAIN, IDENTIFICATION BY MASS RP SPECTROMETRY, AND MUTAGENESIS OF TRP-338; ARG-488; ARG-570; ALA-573; RP ARG-586; PRO-601; PHE-652; TYR-656; ARG-670; PRO-734 AND CYS-796. RX PubMed=31888991; DOI=10.1073/pnas.1913054117; RA Chen M., Pan H., Sun L., Shi P., Zhang Y., Li L., Huang Y., Chen J., RA Jiang P., Fang X., Wu C., Chen Z.; RT "Structure and regulation of human epithelial cell transforming 2 RT protein."; RL Proc. Natl. Acad. Sci. U.S.A. 117:1027-1035(2020). RN [37] RP VARIANT [LARGE SCALE ANALYSIS] PRO-833. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). CC -!- FUNCTION: Guanine nucleotide exchange factor (GEF) that catalyzes the CC exchange of GDP for GTP. Promotes guanine nucleotide exchange on the CC Rho family members of small GTPases, like RHOA, RHOC, RAC1 and CDC42. CC Required for signal transduction pathways involved in the regulation of CC cytokinesis. Component of the centralspindlin complex that serves as a CC microtubule-dependent and Rho-mediated signaling required for the CC myosin contractile ring formation during the cell cycle cytokinesis. CC Regulates the translocation of RHOA from the central spindle to the CC equatorial region. Plays a role in the control of mitotic spindle CC assembly; regulates the activation of CDC42 in metaphase for the CC process of spindle fibers attachment to kinetochores before chromosome CC congression. Involved in the regulation of epithelial cell polarity; CC participates in the formation of epithelial tight junctions in a CC polarity complex PARD3-PARD6-protein kinase PRKCQ-dependent manner. CC Plays a role in the regulation of neurite outgrowth. Inhibits CC phenobarbital (PB)-induced NR1I3 nuclear translocation. Stimulates the CC activity of RAC1 through its association with the oncogenic PARD6A- CC PRKCI complex in cancer cells, thereby acting to coordinately drive CC tumor cell proliferation and invasion. Also stimulates genotoxic CC stress-induced RHOB activity in breast cancer cells leading to their CC cell death. {ECO:0000269|PubMed:10579713, ECO:0000269|PubMed:14645260, CC ECO:0000269|PubMed:15254234, ECO:0000269|PubMed:15545273, CC ECO:0000269|PubMed:15642749, ECO:0000269|PubMed:16103226, CC ECO:0000269|PubMed:16170345, ECO:0000269|PubMed:16236794, CC ECO:0000269|PubMed:16495035, ECO:0000269|PubMed:19129481, CC ECO:0000269|PubMed:19468300, ECO:0000269|PubMed:19617897, CC ECO:0000269|PubMed:21189248, ECO:0000269|PubMed:21373644, CC ECO:0000269|PubMed:25068414, ECO:0000269|PubMed:31888991}. CC -!- ACTIVITY REGULATION: Autoinhibited by the C-terminal PH domain which CC folds back and binds to the surface of the DH domain, blocking binding CC of RHOA to the catalytic center of the DH domain (PubMed:31888991). The CC 2nd BRCT domain is also involved in inhibition, probably by helping to CC impede RHOA binding (PubMed:31888991). Allosterically activated by CC binding of activated GTP-bound RHOA to the PH domain which stimulates CC the release of PH inhibition and promotes the binding of substrate RHOA CC to the catalytic center (PubMed:31888991). Binding of phosphorylated CC RACGAP1 to the N-terminal BRCT domain-containing region also releases CC autoinhibition (PubMed:25068414). {ECO:0000269|PubMed:25068414, CC ECO:0000269|PubMed:31888991}. CC -!- SUBUNIT: Homodimer (PubMed:14645260, PubMed:15545273, PubMed:16170345). CC Homooligomer (PubMed:15545273). Found in the centralspindlin complex CC (PubMed:16236794). Interacts with NR1I3 (By similarity). Interacts CC (Thr-359 phosphorylated form) with PARD6A; the interaction is observed CC in cancer cells (PubMed:15254234, PubMed:19617897). Interacts (Thr-359 CC phosphorylated form) with PRKCI; the interaction is observed in cancer CC cells (PubMed:19617897). Interacts with PKP4; the interaction is CC observed at the midbody (PubMed:22814378). Interacts with RACGAP1/CYK4; CC the interaction is direct, occurs in a microtubule-dependent manner, CC occurs at anaphase and during cytokinesis, is inhibited in metaphase by CC phosphorylation of ECT2 on Thr-373 and is stimulated in early anaphase CC by dephosphorylation of ECT2 probably on Thr-373 through CDK1 activity CC (PubMed:16103226, PubMed:16129829, PubMed:16236794, PubMed:19468300, CC PubMed:19468302, PubMed:25068414). Interacts with PLK1; the interaction CC is stimulated upon its phosphorylation on Thr-444 (PubMed:16247472). CC Interacts with RHOA; the interaction results in allosteric activation CC of ECT2 (PubMed:31888991). Interacts with KIF23, PARD3, PARD6B and CC PRKCQ (PubMed:15254234, PubMed:16236794). Interacts with NEDD9/HEF1 CC (PubMed:16394104). {ECO:0000250|UniProtKB:Q07139, CC ECO:0000269|PubMed:14645260, ECO:0000269|PubMed:15254234, CC ECO:0000269|PubMed:15545273, ECO:0000269|PubMed:16103226, CC ECO:0000269|PubMed:16129829, ECO:0000269|PubMed:16170345, CC ECO:0000269|PubMed:16236794, ECO:0000269|PubMed:16247472, CC ECO:0000269|PubMed:16394104, ECO:0000269|PubMed:19468300, CC ECO:0000269|PubMed:19468302, ECO:0000269|PubMed:19617897, CC ECO:0000269|PubMed:22814378, ECO:0000269|PubMed:25068414, CC ECO:0000269|PubMed:31888991}. CC -!- INTERACTION: CC Q9H8V3; P12830: CDH1; NbExp=3; IntAct=EBI-1054039, EBI-727477; CC Q9H8V3; P35221: CTNNA1; NbExp=3; IntAct=EBI-1054039, EBI-701918; CC Q9H8V3; Q02241: KIF23; NbExp=2; IntAct=EBI-1054039, EBI-306852; CC Q9H8V3; P16333: NCK1; NbExp=3; IntAct=EBI-1054039, EBI-389883; CC Q9H8V3; O00444: PLK4; NbExp=3; IntAct=EBI-1054039, EBI-746202; CC Q9H8V3; Q9H0H5: RACGAP1; NbExp=15; IntAct=EBI-1054039, EBI-717233; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:10579713, CC ECO:0000269|PubMed:14645260, ECO:0000269|PubMed:15254234, CC ECO:0000269|PubMed:16103226, ECO:0000269|PubMed:16495035, CC ECO:0000269|PubMed:19617897}. Cytoplasm {ECO:0000269|PubMed:10579713, CC ECO:0000269|PubMed:16236794, ECO:0000269|PubMed:16394104}. Cytoplasm, CC cytoskeleton, spindle {ECO:0000269|PubMed:10579713, CC ECO:0000269|PubMed:16103226, ECO:0000269|PubMed:16236794, CC ECO:0000269|PubMed:17115030, ECO:0000269|PubMed:19468300}. Cleavage CC furrow {ECO:0000269|PubMed:10579713}. Midbody CC {ECO:0000269|PubMed:15254234, ECO:0000269|PubMed:16394104, CC ECO:0000269|PubMed:17115030}. Cell junction CC {ECO:0000269|PubMed:15254234, ECO:0000269|PubMed:16495035}. Cell CC junction, tight junction {ECO:0000269|PubMed:15254234}. Cytoplasm, CC cytoskeleton, microtubule organizing center, centrosome CC {ECO:0000269|PubMed:17115030}. Note=Sequestered within the nucleus CC during interphase (PubMed:10579713). Dispersed throughout the cytoplasm CC upon breakdown of the nuclear envelope during mitosis CC (PubMed:10579713). Colocalizes with the centralspindlin complex to the CC mitotic spindles during anaphase/metaphase, the cleavage furrow during CC telophase and at the midbody at the end of cytokinesis CC (PubMed:10579713). Colocalized with RhoA at the midbody CC (PubMed:10579713). Its subcellular localization to tight junction is CC increased by calcium (PubMed:15254234). {ECO:0000269|PubMed:10579713, CC ECO:0000269|PubMed:15254234}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=Q9H8V3-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9H8V3-2; Sequence=VSP_041976, VSP_041977; CC Name=3; CC IsoId=Q9H8V3-3; Sequence=VSP_041978; CC Name=4; CC IsoId=Q9H8V3-4; Sequence=VSP_041977; CC -!- TISSUE SPECIFICITY: Expressed in lung epithelial cells (at protein CC level). Expressed in squamous cell carcinoma, primary non-small cell CC lung cancer tumors and lung adenocarcinoma. CC {ECO:0000269|PubMed:19617897}. CC -!- INDUCTION: Up-regulated by calcium in cells forming cell-cell contact CC sites. Up-regulated by DNA damaging agents like H(2)O(2) or ionizing CC radiation (IR). {ECO:0000269|PubMed:15254234, CC ECO:0000269|PubMed:21373644}. CC -!- DOMAIN: The BRCT domains 1 and 2 are required for intramolecular CC interaction, but not for intermolecular oligomerization CC (PubMed:15545273). The BRCT domains negatively inhibit its GEF activity CC in interphase cells (PubMed:15545273, PubMed:31888991). The same BRCT CC domains may act as a positive regulatory motif for the completion of CC cytokinesis after the breakdown of nuclear membrane during mitosis CC (PubMed:15545273). {ECO:0000269|PubMed:15545273, CC ECO:0000269|PubMed:31888991}. CC -!- PTM: Phosphorylated by PLK1 in vitro. Hyperphosphorylated during the G2 CC phase of the cell cycle. Phosphorylation at Thr-373 occurs during the CC G2/M phase, relieves its auto-inhibition status and stimulates its GEF CC activity. Phosphorylation at Thr-444 in G2/M phase is required for CC subsequent binding with PLK1 and Rho exchange activation. CC Dephosphorylated at the time of cytokinesis. Phosphorylation at Thr-359 CC is required for its transformation activity in cancer cells. CC {ECO:0000269|PubMed:10579713, ECO:0000269|PubMed:16170345, CC ECO:0000269|PubMed:16247472, ECO:0000269|PubMed:21189248}. CC -!- MISCELLANEOUS: [Isoform 3]: May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA91624.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40400/ECT2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY376439; AAQ83675.1; -; mRNA. DR EMBL; DQ847274; ABH10140.1; -; mRNA. DR EMBL; AK001323; BAA91624.1; ALT_INIT; mRNA. DR EMBL; AK023267; BAB14498.1; -; mRNA. DR EMBL; AK314581; BAG37157.1; -; mRNA. DR EMBL; AC108667; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC112086; AAI12087.1; -; mRNA. DR EMBL; AL137710; CAB70886.1; -; mRNA. DR CCDS; CCDS3220.1; -. [Q9H8V3-4] DR CCDS; CCDS58860.1; -. [Q9H8V3-1] DR CCDS; CCDS87168.1; -. [Q9H8V3-2] DR RefSeq; NP_001245244.1; NM_001258315.2. [Q9H8V3-1] DR RefSeq; NP_001245245.1; NM_001258316.2. [Q9H8V3-4] DR RefSeq; NP_001336023.1; NM_001349094.2. [Q9H8V3-3] DR RefSeq; NP_001336024.1; NM_001349095.2. [Q9H8V3-3] DR RefSeq; NP_001336025.1; NM_001349096.2. [Q9H8V3-3] DR RefSeq; NP_001336027.1; NM_001349098.2. [Q9H8V3-1] DR RefSeq; NP_001336028.1; NM_001349099.2. [Q9H8V3-1] DR RefSeq; NP_001336029.1; NM_001349100.2. [Q9H8V3-1] DR RefSeq; NP_001336031.1; NM_001349102.2. [Q9H8V3-2] DR RefSeq; NP_060568.3; NM_018098.5. [Q9H8V3-4] DR RefSeq; XP_047303563.1; XM_047447607.1. [Q9H8V3-3] DR RefSeq; XP_047303564.1; XM_047447608.1. [Q9H8V3-3] DR RefSeq; XP_047303565.1; XM_047447609.1. [Q9H8V3-3] DR RefSeq; XP_047303573.1; XM_047447617.1. [Q9H8V3-1] DR RefSeq; XP_047303574.1; XM_047447618.1. [Q9H8V3-1] DR RefSeq; XP_047303583.1; XM_047447627.1. [Q9H8V3-4] DR RefSeq; XP_047303584.1; XM_047447628.1. [Q9H8V3-4] DR RefSeq; XP_047303585.1; XM_047447629.1. [Q9H8V3-4] DR RefSeq; XP_047303586.1; XM_047447630.1. [Q9H8V3-4] DR RefSeq; XP_054201507.1; XM_054345532.1. [Q9H8V3-3] DR RefSeq; XP_054201508.1; XM_054345533.1. [Q9H8V3-3] DR RefSeq; XP_054201509.1; XM_054345534.1. [Q9H8V3-3] DR RefSeq; XP_054201517.1; XM_054345542.1. [Q9H8V3-1] DR RefSeq; XP_054201518.1; XM_054345543.1. [Q9H8V3-1] DR RefSeq; XP_054201528.1; XM_054345553.1. [Q9H8V3-4] DR RefSeq; XP_054201529.1; XM_054345554.1. [Q9H8V3-4] DR RefSeq; XP_054201530.1; XM_054345555.1. [Q9H8V3-4] DR RefSeq; XP_054201531.1; XM_054345556.1. [Q9H8V3-4] DR PDB; 3L46; X-ray; 1.48 A; A/B=268-361. DR PDB; 4N40; X-ray; 3.11 A; A=45-356. DR PDB; 6L30; X-ray; 2.80 A; A=173-865. DR PDBsum; 3L46; -. DR PDBsum; 4N40; -. DR PDBsum; 6L30; -. DR AlphaFoldDB; Q9H8V3; -. DR SMR; Q9H8V3; -. DR BioGRID; 108223; 896. DR CORUM; Q9H8V3; -. DR DIP; DIP-47496N; -. DR FunCoup; Q9H8V3; 1534. DR IntAct; Q9H8V3; 46. DR MINT; Q9H8V3; -. DR STRING; 9606.ENSP00000376457; -. DR GlyGen; Q9H8V3; 6 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (5 sites). DR iPTMnet; Q9H8V3; -. DR MetOSite; Q9H8V3; -. DR PhosphoSitePlus; Q9H8V3; -. DR SwissPalm; Q9H8V3; -. DR BioMuta; ECT2; -. DR DMDM; 357529579; -. DR jPOST; Q9H8V3; -. DR MassIVE; Q9H8V3; -. DR PaxDb; 9606-ENSP00000376457; -. DR PeptideAtlas; Q9H8V3; -. DR ProteomicsDB; 81243; -. [Q9H8V3-1] DR ProteomicsDB; 81244; -. [Q9H8V3-2] DR ProteomicsDB; 81245; -. [Q9H8V3-3] DR Pumba; Q9H8V3; -. DR Antibodypedia; 33733; 365 antibodies from 31 providers. DR DNASU; 1894; -. DR Ensembl; ENST00000232458.9; ENSP00000232458.5; ENSG00000114346.15. [Q9H8V3-4] DR Ensembl; ENST00000392692.8; ENSP00000376457.3; ENSG00000114346.15. [Q9H8V3-1] DR Ensembl; ENST00000417960.5; ENSP00000415876.1; ENSG00000114346.15. [Q9H8V3-2] DR Ensembl; ENST00000441497.6; ENSP00000412259.2; ENSG00000114346.15. [Q9H8V3-4] DR Ensembl; ENST00000540509.5; ENSP00000443160.2; ENSG00000114346.15. [Q9H8V3-4] DR GeneID; 1894; -. DR KEGG; hsa:1894; -. DR MANE-Select; ENST00000392692.8; ENSP00000376457.3; NM_001258315.2; NP_001245244.1. DR UCSC; uc003fih.4; human. [Q9H8V3-1] DR AGR; HGNC:3155; -. DR ClinPGx; PA27600; -. DR CTD; 1894; -. DR DisGeNET; 1894; -. DR GeneCards; ECT2; -. DR HGNC; HGNC:3155; ECT2. DR HPA; ENSG00000114346; Low tissue specificity. DR MIM; 600586; gene. DR OpenTargets; ENSG00000114346; -. DR VEuPathDB; HostDB:ENSG00000114346; -. DR eggNOG; KOG3524; Eukaryota. DR GeneTree; ENSGT00940000156299; -. DR HOGENOM; CLU_008187_0_0_1; -. DR InParanoid; Q9H8V3; -. DR OMA; PIYDVHK; -. DR OrthoDB; 9997817at2759; -. DR PAN-GO; Q9H8V3; 5 GO annotations based on evolutionary models. DR PathwayCommons; Q9H8V3; -. DR Reactome; R-HSA-193648; NRAGE signals death through JNK. DR Reactome; R-HSA-416482; G alpha (12/13) signalling events. DR Reactome; R-HSA-8980692; RHOA GTPase cycle. DR Reactome; R-HSA-9013026; RHOB GTPase cycle. DR Reactome; R-HSA-9013148; CDC42 GTPase cycle. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR SignaLink; Q9H8V3; -. DR SIGNOR; Q9H8V3; -. DR Agora; ENSG00000114346; -. DR BioGRID-ORCS; 1894; 654 hits in 1167 CRISPR screens. DR ChiTaRS; ECT2; human. DR EvolutionaryTrace; Q9H8V3; -. DR GeneWiki; ECT2; -. DR GenomeRNAi; 1894; -. DR Pharos; Q9H8V3; Tbio. DR PRO; PR:Q9H8V3; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q9H8V3; protein. DR Bgee; ENSG00000114346; Expressed in secondary oocyte and 166 other cell types or tissues. DR ExpressionAtlas; Q9H8V3; baseline and differential. DR GO; GO:0005923; C:bicellular tight junction; IDA:UniProtKB. DR GO; GO:0005938; C:cell cortex; IBA:GO_Central. DR GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB. DR GO; GO:0097149; C:centralspindlin complex; IDA:UniProtKB. DR GO; GO:0005813; C:centrosome; IEA:UniProtKB-SubCell. DR GO; GO:0032154; C:cleavage furrow; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0030496; C:midbody; IDA:UniProtKB. DR GO; GO:0072686; C:mitotic spindle; IDA:UniProtKB. DR GO; GO:0016604; C:nuclear body; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005096; F:GTPase activator activity; IMP:UniProtKB. DR GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; IDA:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0031267; F:small GTPase binding; IEA:Ensembl. DR GO; GO:0090630; P:activation of GTPase activity; IDA:UniProtKB. DR GO; GO:0032147; P:activation of protein kinase activity; IDA:UniProtKB. DR GO; GO:0070830; P:bicellular tight junction assembly; IMP:UniProtKB. DR GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW. DR GO; GO:0000902; P:cell morphogenesis; IEA:Ensembl. DR GO; GO:0071277; P:cellular response to calcium ion; IDA:UniProtKB. DR GO; GO:0070301; P:cellular response to hydrogen peroxide; IDA:UniProtKB. DR GO; GO:0071479; P:cellular response to ionizing radiation; IDA:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro. DR GO; GO:0000281; P:mitotic cytokinesis; IMP:UniProtKB. DR GO; GO:0007399; P:nervous system development; IBA:GO_Central. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; HMP:UniProtKB. DR GO; GO:0032467; P:positive regulation of cytokinesis; IDA:UniProtKB. DR GO; GO:0043547; P:positive regulation of GTPase activity; IDA:UniProtKB. DR GO; GO:1903438; P:positive regulation of mitotic cytokinetic process; IMP:UniProt. DR GO; GO:0045666; P:positive regulation of neuron differentiation; ISS:UniProtKB. DR GO; GO:0042307; P:positive regulation of protein import into nucleus; ISS:UniProtKB. DR GO; GO:0051260; P:protein homooligomerization; IDA:UniProtKB. DR GO; GO:0015031; P:protein transport; IEA:UniProtKB-KW. DR GO; GO:0051988; P:regulation of attachment of spindle microtubules to kinetochore; IMP:UniProtKB. DR GO; GO:2000431; P:regulation of cytokinesis, actomyosin contractile ring assembly; IEA:InterPro. DR GO; GO:0045859; P:regulation of protein kinase activity; IDA:UniProtKB. DR GO; GO:0051056; P:regulation of small GTPase mediated signal transduction; TAS:Reactome. DR CDD; cd17733; BRCT_Ect2_rpt1; 1. DR CDD; cd17732; BRCT_Ect2_rpt2; 1. DR CDD; cd01229; PH_Ect2; 1. DR CDD; cd00160; RhoGEF; 1. DR FunFam; 3.40.50.10190:FF:000058; Epithelial cell transforming 2; 1. DR FunFam; 1.20.900.10:FF:000022; protein ECT2 isoform X1; 1. DR FunFam; 3.40.50.10190:FF:000015; protein ECT2 isoform X1; 1. DR FunFam; 2.30.29.30:FF:000162; protein ECT2 isoform X2; 1. DR FunFam; 3.40.50.10190:FF:000016; protein ECT2 isoform X3; 1. DR Gene3D; 3.40.50.10190; BRCT domain; 3. DR Gene3D; 1.20.900.10; Dbl homology (DH) domain; 1. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR InterPro; IPR001357; BRCT_dom. DR InterPro; IPR036420; BRCT_dom_sf. DR InterPro; IPR035899; DBL_dom_sf. DR InterPro; IPR000219; DH_dom. DR InterPro; IPR026817; Ect2. DR InterPro; IPR049396; ECT2_BRCT0. DR InterPro; IPR049395; ECT2_PH. DR InterPro; IPR001331; GDS_CDC24_CS. DR InterPro; IPR011993; PH-like_dom_sf. DR PANTHER; PTHR16777; PROTEIN ECT2; 1. DR PANTHER; PTHR16777:SF2; PROTEIN ECT2; 1. DR Pfam; PF00533; BRCT; 1. DR Pfam; PF21243; ECT2_BRCT0; 1. DR Pfam; PF21242; ECT2_PH; 1. DR Pfam; PF12738; PTCB-BRCT; 1. DR Pfam; PF00621; RhoGEF; 1. DR SMART; SM00292; BRCT; 2. DR SMART; SM00325; RhoGEF; 1. DR SUPFAM; SSF52113; BRCT domain; 2. DR SUPFAM; SSF48065; DBL homology domain (DH-domain); 1. DR SUPFAM; SSF50729; PH domain-like; 1. DR PROSITE; PS50172; BRCT; 2. DR PROSITE; PS00741; DH_1; 1. DR PROSITE; PS50010; DH_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Cell cycle; Cell division; KW Cell junction; Cytoplasm; Cytoskeleton; Differentiation; KW Guanine-nucleotide releasing factor; Isopeptide bond; Neurogenesis; KW Nucleus; Oncogene; Phosphoprotein; Protein transport; KW Proteomics identification; Reference proteome; Repeat; Tight junction; KW Transport; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..914 FT /note="Protein ECT2" FT /id="PRO_0000080938" FT DOMAIN 171..260 FT /note="BRCT 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00033" FT DOMAIN 266..354 FT /note="BRCT 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00033" FT DOMAIN 452..641 FT /note="DH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00062" FT DOMAIN 675..794 FT /note="PH" FT REGION 388..449 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 857..884 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 378..382 FT /note="Nuclear localization signal" FT MOTIF 401..405 FT /note="Nuclear localization signal" FT COMPBIAS 418..429 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 432..449 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 359 FT /note="Phosphothreonine; by PKC/PRKCI" FT /evidence="ECO:0000269|PubMed:21189248, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 367 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 370 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 373 FT /note="Phosphothreonine; by CDK1" FT /evidence="ECO:0000269|PubMed:16170345, FT ECO:0007744|PubMed:18669648" FT MOD_RES 376 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 444 FT /note="Phosphothreonine; by CDK1" FT /evidence="ECO:0000269|PubMed:16247472" FT MOD_RES 716 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 842 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 846 FT /note="Phosphothreonine; by CDK1" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 861 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 866 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 611 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 44 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10579713, FT ECO:0000303|PubMed:14587037, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_041976" FT VAR_SEQ 71..101 FT /note="Missing (in isoform 2 and isoform 4)" FT /evidence="ECO:0000303|PubMed:10579713, FT ECO:0000303|PubMed:14587037, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_041977" FT VAR_SEQ 886..914 FT /note="GIPSPSLVSLPSFFERRSHTLSRSTTHLI -> ITHSVSTSNVIGFTKHVYV FT QRLNSTGGRSQYSWFQSVRHSAFRASFSEILEGNTDFSNFKKVLSKSSLTFVKN (in FT isoform 3)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_041978" FT VARIANT 15 FT /note="S -> T (in dbSNP:rs34703432)" FT /id="VAR_047064" FT VARIANT 833 FT /note="T -> P (in a breast cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035975" FT MUTAGEN 184 FT /note="T->A: Inhibits interaction with RACGAP1. Abolishes FT targeting to the central spindle." FT /evidence="ECO:0000269|PubMed:19468300, FT ECO:0000269|PubMed:25068414" FT MUTAGEN 226 FT /note="K->A: Inhibits interaction with RACGAP1. Abolishes FT targeting to the central spindle." FT /evidence="ECO:0000269|PubMed:19468300, FT ECO:0000269|PubMed:25068414" FT MUTAGEN 336 FT /note="W->R: Inhibits homodimerization. Increases binding FT with RhoA and GEF activity." FT /evidence="ECO:0000269|PubMed:15545273" FT MUTAGEN 338 FT /note="W->A: 2-fold increase in GEF activity." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 359 FT /note="T->A: Inhibits its phosphorylation and anchorage- FT independent growth and invasion in cancer cells. Does not FT inhibit its GEF activity." FT /evidence="ECO:0000269|PubMed:21189248" FT MUTAGEN 373 FT /note="T->A: Does not inhibit its Rho exchange activity. FT Increases interaction with RACGAP1. Does not inhibit FT anchorage-independent growth and invasion in cancer cells." FT /evidence="ECO:0000269|PubMed:16103226, FT ECO:0000269|PubMed:16170345" FT MUTAGEN 373 FT /note="T->D: Does not inhibit subcellular localization or FT homodimerization. Enhances its Rho exchange activity." FT /evidence="ECO:0000269|PubMed:16103226, FT ECO:0000269|PubMed:16170345" FT MUTAGEN 379..381 FT /note="KRR->AAA: Shows both nuclear and cytoplasmic FT localization and activates its transforming activity." FT /evidence="ECO:0000269|PubMed:14645260" FT MUTAGEN 402..404 FT /note="RKR->AKA: Shows both nuclear and cytoplasmic FT localization and activates its transforming activity." FT /evidence="ECO:0000269|PubMed:14645260" FT MUTAGEN 444 FT /note="T->A: Diminishes its phosphorylation status. Reduces FT its interaction with PLK1 and Rho exchange activity. Does FT not change its subcellular localization. Does not inhibit FT anchorage-independent growth and invasion in cancer cells." FT /evidence="ECO:0000269|PubMed:16247472" FT MUTAGEN 444 FT /note="T->D: Does not reduce its interaction with PLK1, FT change its subcellular localization and Rho exchange FT activity." FT /evidence="ECO:0000269|PubMed:16247472" FT MUTAGEN 488 FT /note="R->C: Partially releases inhibition." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 570 FT /note="R->D: 2-fold increase in GEF activity." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 573 FT /note="A->D: 2-fold increase in GEF activity." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 586 FT /note="R->Q: Complete loss of GEF activity and failure to FT support cytokinesis." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 596..599 FT /note="PVQR->AAAA: Inhibits activation of the transforming FT activity." FT /evidence="ECO:0000269|PubMed:14645260" FT MUTAGEN 601 FT /note="P->S: Complete loss of GEF activity and failure to FT support cytokinesis." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 652 FT /note="F->A: No effect on GEF activity but severely FT decreases ECT2 activation by RHOA. Localizes correctly but FT fails to rescue the cytokinesis defect caused by knockdown FT of endogenous ECT2 in contrast to the wild-type protein FT which rescues this defect." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 656 FT /note="Y->A: No effect on GEF activity but severely FT decreases ECT2 activation by RHOA. Fails to rescue the FT cytokinesis defect caused by knockdown of endogenous ECT2 FT in contrast to the wild-type protein which rescues this FT defect." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 670 FT /note="R->Q: Marked increase in GEF activity and rescues FT the cytokinesis defect caused by depletion of endogenous FT ECT2. When expressed in a cancer cell line, causes faster FT cell proliferation than the wild-type protein." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 734 FT /note="P->D: More than 10-fold increase in GEF activity. FT Overexpression causes noticeable changes in interphase cell FT morphology such as cell rounding and formation of stress FT fibers, suggesting ectopic RhoA activation." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 796 FT /note="C->K: More than 10-fold increase in GEF activity. FT Overexpression causes noticeable changes in interphase cell FT morphology such as cell rounding and formation of stress FT fibers, suggesting ectopic RHOA activation." FT /evidence="ECO:0000269|PubMed:31888991" FT MUTAGEN 846 FT /note="T->A: Diminishes its phosphorylation status." FT /evidence="ECO:0000269|PubMed:16247472" FT CONFLICT 66 FT /note="I -> T (in Ref. 5; BAB14498)" FT /evidence="ECO:0000305" FT CONFLICT 276 FT /note="L -> F (in Ref. 5; BAB14498)" FT /evidence="ECO:0000305" FT CONFLICT 393 FT /note="E -> D (in Ref. 5; BAB14498)" FT /evidence="ECO:0000305" FT STRAND 51..56 FT /evidence="ECO:0007829|PDB:4N40" FT HELIX 57..59 FT /evidence="ECO:0007829|PDB:4N40" FT HELIX 63..70 FT /evidence="ECO:0007829|PDB:4N40" FT STRAND 107..112 FT /evidence="ECO:0007829|PDB:4N40" FT HELIX 115..119 FT /evidence="ECO:0007829|PDB:4N40" FT STRAND 124..129 FT /evidence="ECO:0007829|PDB:4N40" FT HELIX 136..143 FT /evidence="ECO:0007829|PDB:4N40" FT STRAND 147..149 FT /evidence="ECO:0007829|PDB:4N40" FT HELIX 151..159 FT /evidence="ECO:0007829|PDB:4N40" FT TURN 173..178 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 180..184 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 189..201 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 215..224 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 225..233 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 241..249 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 260..263 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 264..266 FT /evidence="ECO:0007829|PDB:6L30" FT TURN 270..273 FT /evidence="ECO:0007829|PDB:3L46" FT STRAND 278..280 FT /evidence="ECO:0007829|PDB:3L46" FT HELIX 283..295 FT /evidence="ECO:0007829|PDB:3L46" FT STRAND 309..313 FT /evidence="ECO:0007829|PDB:3L46" FT TURN 315..317 FT /evidence="ECO:0007829|PDB:3L46" FT STRAND 318..320 FT /evidence="ECO:0007829|PDB:3L46" FT STRAND 330..333 FT /evidence="ECO:0007829|PDB:3L46" FT HELIX 334..343 FT /evidence="ECO:0007829|PDB:3L46" FT HELIX 349..351 FT /evidence="ECO:0007829|PDB:3L46" FT HELIX 453..477 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 479..483 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 495..502 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 505..522 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 532..552 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 554..567 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 569..579 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 582..584 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 589..611 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 622..634 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 635..637 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 642..657 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 664..667 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 672..687 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 691..697 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 700..706 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 726..734 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 735..737 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 738..744 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 748..758 FT /evidence="ECO:0007829|PDB:6L30" FT TURN 761..763 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 767..773 FT /evidence="ECO:0007829|PDB:6L30" FT HELIX 780..795 FT /evidence="ECO:0007829|PDB:6L30" FT STRAND 803..807 FT /evidence="ECO:0007829|PDB:6L30" SQ SEQUENCE 914 AA; 103505 MW; F40FC4F982FB8C78 CRC64; MAENSVLTST TGRTSLADSS IFDSKVTEIS KENLLIGSTS YVEEEMPQIE TRVILVQEAG KQEELIKALK TIKIMEVPVI KIKESCPGKS DEKLIKSVIN MDIKVGFVKM ESVEEFEGLD SPEFENVFVV TDFQDSVFND LYKADCRVIG PPVVLNCSQK GEPLPFSCRP LYCTSMMNLV LCFTGFRKKE ELVRLVTLVH HMGGVIRKDF NSKVTHLVAN CTQGEKFRVA VSLGTPIMKP EWIYKAWERR NEQDFYAAVD DFRNEFKVPP FQDCILSFLG FSDEEKTNME EMTEMQGGKY LPLGDERCTH LVVEENIVKD LPFEPSKKLY VVKQEWFWGS IQMDARAGET MYLYEKANTP ELKKSVSMLS LNTPNSNRKR RRLKETLAQL SRETDVSPFP PRKRPSAEHS LSIGSLLDIS NTPESSINYG DTPKSCTKSS KSSTPVPSKQ SARWQVAKEL YQTESNYVNI LATIIQLFQV PLEEEGQRGG PILAPEEIKT IFGSIPDIFD VHTKIKDDLE DLIVNWDESK SIGDIFLKYS KDLVKTYPPF VNFFEMSKET IIKCEKQKPR FHAFLKINQA KPECGRQSLV ELLIRPVQRL PSVALLLNDL KKHTADENPD KSTLEKAIGS LKEVMTHINE DKRKTEAQKQ IFDVVYEVDG CPANLLSSHR SLVQRVETIS LGEHPCDRGE QVTLFLFNDC LEIARKRHKV IGTFRSPHGQ TRPPASLKHI HLMPLSQIKK VLDIRETEDC HNAFALLVRP PTEQANVLLS FQMTSDELPK ENWLKMLCRH VANTICKADA ENLIYTADPE SFEVNTKDMD STLSRASRAI KKTSKKVTRA FSFSKTPKRA LRRALMTSHG SVEGRSPSSN DKHVMSRLSS TSSLAGIPSP SLVSLPSFFE RRSHTLSRST THLI // ID EGFR_HUMAN Reviewed; 1210 AA. AC P00533; O00688; O00732; P06268; Q14225; Q68GS5; Q92795; Q9BZS2; Q9GZX1; AC Q9H2C9; Q9H3C9; Q9UMD7; Q9UMD8; Q9UMG5; DT 21-JUL-1986, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1997, sequence version 2. DT 28-JAN-2026, entry version 299. DE RecName: Full=Epidermal growth factor receptor {ECO:0000305}; DE EC=2.7.10.1; DE AltName: Full=Proto-oncogene c-ErbB-1; DE AltName: Full=Receptor tyrosine-protein kinase erbB-1; DE Flags: Precursor; GN Name=EGFR {ECO:0000312|HGNC:HGNC:3236}; Synonyms=ERBB, ERBB1, HER1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PROTEIN SEQUENCE OF 25-32. RX PubMed=6328312; DOI=10.1038/309418a0; RA Ullrich A., Coussens L., Hayflick J.S., Dull T.J., Gray A., Tam A.W., RA Lee J., Yarden Y., Libermann T.A., Schlessinger J., Downward J., RA Mayes E.L.V., Whittle N., Waterfield M.D., Seeburg P.H.; RT "Human epidermal growth factor receptor cDNA sequence and aberrant RT expression of the amplified gene in A431 epidermoid carcinoma cells."; RL Nature 309:418-425(1984). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RC TISSUE=Placenta; RX PubMed=7654368; DOI=10.1002/mrd.1080410205; RA Ilekis J.V., Stark B.C., Scoccia B.; RT "Possible role of variant RNA transcripts in the regulation of epidermal RT growth factor receptor expression in human placenta."; RL Mol. Reprod. Dev. 41:149-156(1995). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 2). RC TISSUE=Placenta; RX PubMed=8918811; DOI=10.1093/nar/24.20.4050; RA Reiter J.L., Maihle N.J.; RT "A 1.8 kb alternative transcript from the human epidermal growth factor RT receptor gene encodes a truncated form of the receptor."; RL Nucleic Acids Res. 24:4050-4056(1996). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RC TISSUE=Placenta; RX PubMed=9103388; DOI=10.1006/gyno.1996.4526; RA Ilekis J.V., Gariti J., Niederberger C., Scoccia B.; RT "Expression of a truncated epidermal growth factor receptor-like protein RT (TEGFR) in ovarian cancer."; RL Gynecol. Oncol. 65:36-41(1997). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 3 AND 4). RC TISSUE=Placenta; RX PubMed=11161793; DOI=10.1006/geno.2000.6341; RA Reiter J.L., Threadgill D.W., Eley G.D., Strunk K.E., Danielsen A.J., RA Schehl Sinclair C., Pearsall R.S., Green P.J., Yee D., Lampland A.L., RA Balasubramaniam S., Crossley T.D., Magnuson T.R., James C.D., Maihle N.J.; RT "Comparative genomic sequence analysis and isolation of human and mouse RT alternative EGFR transcripts encoding truncated receptor isoforms."; RL Genomics 71:1-20(2001). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RA Xu L., Hong A., He X.; RT "Cloning of the cDNA for a short EGF receptor from human placenta."; RL Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLN-98; ARG-266; LYS-521; RP ILE-674; GLY-962 AND PRO-988. RG NIEHS SNPs program; RL Submitted (APR-2004) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 575-687. RA Reiter J.L., Threadgill D.W., Danielsen A.J., Schehl C.M., Lampland A.L., RA Balasubramaniam S., Crossley T.O., Magnuson T.R., Maihle N.J.; RT "Human and mouse alternative EGFR transcripts encoding only the RT extracellular domain of the receptor."; RL Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 713-924. RX PubMed=6326261; DOI=10.1126/science.6326261; RA Lin C.R., Chen W.S., Kruiger W., Stolarsky L.S., Weber W., Evans R.M., RA Verma I.M., Gill G.N., Rosenfeld M.G.; RT "Expression cloning of human EGF receptor complementary DNA: gene RT amplification and three related messenger RNA products in A431 cells."; RL Science 224:843-848(1984). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] OF 150-962. RX PubMed=6330563; DOI=10.1038/309806a0; RA Xu Y.H., Ishii S., Clark A.J.L., Sullivan M., Wilson R.K., Ma D.P., RA Roe B.A., Merlino G.T., Pastan I.; RT "Human epidermal growth factor receptor cDNA is homologous to a variety of RT RNAs overproduced in A431 carcinoma cells."; RL Nature 309:806-810(1984). RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1028-1210. RX PubMed=6093780; DOI=10.1016/0006-291x(84)90926-4; RA Simmen F.A., Gope M.L., Schulz T.Z., Wright D.A., Carpenter G., RA O'Malley B.W.; RT "Isolation of an evolutionarily conserved epidermal growth factor receptor RT cDNA from human A431 carcinoma cells."; RL Biochem. Biophys. Res. Commun. 124:125-132(1984). RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-29. RX PubMed=3329716; RA Haley J.D., Whittle N., Bennett P., Kinchington D., Ullrich A., RA Waterfield M.D.; RT "The human EGF receptor gene: structure of the 110 kb locus and RT identification of sequences regulating its transcription."; RL Oncogene Res. 1:375-396(1987). RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-29. RX PubMed=1988448; DOI=10.1016/s0021-9258(18)52359-0; RA Haley J.D., Waterfield M.D.; RT "Contributory effects of de novo transcription and premature transcript RT termination in the regulation of human epidermal growth factor receptor RT proto-oncogene RNA synthesis."; RL J. Biol. Chem. 266:1746-1753(1991). RN [14] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-29. RX PubMed=2991899; DOI=10.1073/pnas.82.15.4920; RA Ishii S., Xu Y.H., Stratton R.H., Roe B.A., Merlino G.T., Pastan I.; RT "Characterization and sequence of the promoter region of the human RT epidermal growth factor receptor gene."; RL Proc. Natl. Acad. Sci. U.S.A. 82:4920-4924(1985). RN [15] RP NUCLEOTIDE SEQUENCE [MRNA] OF 25-49. RX PubMed=6324343; DOI=10.1126/science.6324343; RA Weber W., Gill G.N., Spiess J.; RT "Production of an epidermal growth factor receptor-related protein."; RL Science 224:294-297(1984). RN [16] RP PROTEIN SEQUENCE OF 540. RA Kohda D.; RL Submitted (SEP-1997) to UniProtKB. RN [17] RP PROTEIN SEQUENCE OF 687-705; 986-998; 1000-1023; 1026-1030 AND 1068-1077, RP AND PHOSPHORYLATION AT THR-693; SER-695; SER-1070 AND SER-1071. RX PubMed=3138233; DOI=10.1016/s0021-9258(18)37684-1; RA Heisermann G.J., Gill G.N.; RT "Epidermal growth factor receptor threonine and serine residues RT phosphorylated in vivo."; RL J. Biol. Chem. 263:13152-13158(1988). RN [18] RP PROTEIN SEQUENCE OF 25-39. RX PubMed=15340161; DOI=10.1110/ps.04682504; RA Zhang Z., Henzel W.J.; RT "Signal peptide prediction based on analysis of experimentally verified RT cleavage sites."; RL Protein Sci. 13:2819-2824(2004). RN [19] RP PROTEIN SEQUENCE OF 740-744 AND 746-747. RX PubMed=2985580; DOI=10.1016/s0021-9258(18)89002-0; RA Russo M.W., Lukas T.J., Cohen S., Staros J.V.; RT "Identification of residues in the nucleotide binding site of the epidermal RT growth factor receptor/kinase."; RL J. Biol. Chem. 260:5205-5208(1985). RN [20] RP PROTEIN SEQUENCE OF 861-875 AND 914-932, UBIQUITINATION AT LYS-716; RP LYS-737; LYS-754; LYS-867; LYS-929 AND LYS-970, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RX PubMed=16543144; DOI=10.1016/j.molcel.2006.02.018; RA Huang F., Kirkpatrick D., Jiang X., Gygi S.P., Sorkin A.; RT "Differential regulation of EGF receptor internalization and degradation by RT multiubiquitination within the kinase domain."; RL Mol. Cell 21:737-748(2006). RN [21] RP PARTIAL PROTEIN SEQUENCE, AND DISULFIDE BONDS. RX PubMed=9556602; DOI=10.1074/jbc.273.18.11150; RA Abe Y., Odaka M., Inagaki F., Lax I., Schlessinger J., Kohda D.; RT "Disulfide bond structure of human epidermal growth factor receptor."; RL J. Biol. Chem. 273:11150-11157(1998). RN [22] RP RECEPTOR ACTIVITY. RX PubMed=6325948; DOI=10.1038/309270a0; RA Mroczkowski B., Mosig G., Cohen S.; RT "ATP-stimulated interaction between epidermal growth factor receptor and RT supercoiled DNA."; RL Nature 309:270-273(1984). RN [23] RP REVIEW. RX PubMed=3039909; DOI=10.1146/annurev.bi.56.070187.004313; RA Carpenter G.; RT "Receptors for epidermal growth factor and other polypeptide mitogens."; RL Annu. Rev. Biochem. 56:881-914(1987). RN [24] RP FUNCTION, SUBCELLULAR LOCATION, AND LIGAND-BINDING. RX PubMed=2790960; DOI=10.1016/0092-8674(89)90867-2; RA Chen W.S., Lazar C.S., Lund K.A., Welsh J.B., Chang C.P., Walton G.M., RA Der C.J., Wiley H.S., Gill G.N., Rosenfeld M.G.; RT "Functional independence of the epidermal growth factor receptor from a RT domain required for ligand-induced internalization and calcium RT regulation."; RL Cell 59:33-43(1989). RN [25] RP PHOSPHORYLATION AT TYR-1110. RX PubMed=2543678; DOI=10.1016/s0021-9258(18)81674-x; RA Margolis B.L., Lax I., Kris R., Dombalagian M., Honegger A.M., Howk R., RA Givol D., Ullrich A., Schlessinger J.; RT "All autophosphorylation sites of epidermal growth factor (EGF) receptor RT and HER2/neu are located in their carboxyl-terminal tails. Identification RT of a novel site in EGF receptor."; RL J. Biol. Chem. 264:10667-10671(1989). RN [26] RP IDENTIFICATION OF AREG AS LIGAND, AND FUNCTION. RX PubMed=7679104; DOI=10.1016/s0021-9258(18)53862-x; RA Johnson G.R., Kannan B., Shoyab M., Stromberg K.; RT "Amphiregulin induces tyrosine phosphorylation of the epidermal growth RT factor receptor and p185erbB2. Evidence that amphiregulin acts exclusively RT through the epidermal growth factor receptor at the surface of human RT epithelial cells."; RL J. Biol. Chem. 268:2924-2931(1993). RN [27] RP INTERACTION WITH ZPR1. RX PubMed=8650580; DOI=10.1126/science.272.5269.1797; RA Galcheva-Gargova Z., Konstantinov K.N., Wu I.-H., Klier F.G., Barrett T., RA Davis R.J.; RT "Binding of zinc finger protein ZPR1 to the epidermal growth factor RT receptor."; RL Science 272:1797-1802(1996). RN [28] RP INTERACTION WITH ZPR1. RX PubMed=9852145; DOI=10.1083/jcb.143.6.1471; RA Gangwani L., Mikrut M., Galcheva-Gargova Z., Davis R.J.; RT "Interaction of ZPR1 with translation elongation factor-1alpha in RT proliferating cells."; RL J. Cell Biol. 143:1471-1484(1998). RN [29] RP PHOSPHORYLATION AT THR-678 AND THR-693. RX PubMed=10523301; DOI=10.1093/emboj/18.20.5567; RA Bagowski C.P., Stein-Gerlach M., Choidas A., Ullrich A.; RT "Cell-type specific phosphorylation of threonines T654 and T669 by PKD RT defines the signal capacity of the EGF receptor."; RL EMBO J. 18:5567-5576(1999). RN [30] RP IDENTIFICATION OF BETACELLULIN/BTC AS LIGAND. RX PubMed=8144591; DOI=10.1016/s0021-9258(17)36977-6; RA Watanabe T., Shintani A., Nakata M., Shing Y., Folkman J., Igarashi K., RA Sasada R.; RT "Recombinant human betacellulin. Molecular structure, biological RT activities, and receptor interaction."; RL J. Biol. Chem. 269:9966-9973(1994). RN [31] RP FUNCTION IN PHOSPHORYLATION OF CBL, AND INTERACTION WITH CBL. RX PubMed=7657591; DOI=10.1074/jbc.270.35.20242; RA Galisteo M.L., Dikic I., Batzer A.G., Langdon W.Y., Schlessinger J.; RT "Tyrosine phosphorylation of the c-cbl proto-oncogene protein product and RT association with epidermal growth factor (EGF) receptor upon EGF RT stimulation."; RL J. Biol. Chem. 270:20242-20245(1995). RN [32] RP GLYCOSYLATION AT ASN-128; ASN-175; ASN-413; ASN-444 AND ASN-528. RX PubMed=8962717; DOI=10.3109/08977199609034572; RA Smith K.D., Davies M.J., Bailey D., Renouf D.V., Hounsell E.F.; RT "Analysis of the glycosylation patterns of the extracellular domain of the RT epidermal growth factor receptor expressed in Chinese hamster ovary RT fibroblasts."; RL Growth Factors 13:121-132(1996). RN [33] RP IDENTIFICATION OF EPIREGULIN/EREG AS LIGAND, AND FUNCTION. RX PubMed=9419975; DOI=10.1038/sj.onc.1201458; RA Komurasaki T., Toyoda H., Uchida D., Morimoto S.; RT "Epiregulin binds to epidermal growth factor receptor and ErbB-4 and RT induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB- RT 2, ErbB-3 and ErbB-4."; RL Oncogene 15:2841-2848(1997). RN [34] RP PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPN1 AND PTPN2. RX PubMed=9488479; DOI=10.1128/mcb.18.3.1622; RA Tiganis T., Bennett A.M., Ravichandran K.S., Tonks N.K.; RT "Epidermal growth factor receptor and the adaptor protein p52Shc are RT specific substrates of T-cell protein tyrosine phosphatase."; RL Mol. Cell. Biol. 18:1622-1634(1998). RN [35] RP INTERACTION WITH AP2M1. RX PubMed=10228163; DOI=10.1093/emboj/18.9.2489; RA Nesterov A., Carter R.E., Sorkina T., Gill G.N., Sorkin A.; RT "Inhibition of the receptor-binding function of clathrin adaptor protein RT AP-2 by dominant-negative mutant mu2 subunit and its effects on RT endocytosis."; RL EMBO J. 18:2489-2499(1999). RN [36] RP INTERACTION WITH GRB2; NCK1 AND NCK2. RX PubMed=10026169; DOI=10.1074/jbc.274.9.5542; RA Braverman L.E., Quilliam L.A.; RT "Identification of Grb4/Nckbeta, a src homology 2 and 3 domain-containing RT adapter protein having similar binding and biological properties to Nck."; RL J. Biol. Chem. 274:5542-5549(1999). RN [37] RP GLYCOSYLATION AT ASN-56; ASN-352; ASN-361; ASN-568 AND ASN-603. RX PubMed=10731668; DOI=10.1093/oxfordjournals.jbchem.a022585; RA Sato C., Kim J.-H., Abe Y., Saito K., Yokoyama S., Kohda D.; RT "Characterization of the N-oligosaccharides attached to the atypical Asn-X- RT Cys sequence of recombinant human epidermal growth factor receptor."; RL J. Biochem. 127:65-72(2000). RN [38] RP FUNCTION IN PHOSPHORYLATION OF RGS16. RX PubMed=11602604; DOI=10.1074/jbc.m108862200; RA Derrien A., Druey K.M.; RT "RGS16 function is regulated by epidermal growth factor receptor-mediated RT tyrosine phosphorylation."; RL J. Biol. Chem. 276:48532-48538(2001). RN [39] RP GLYCOSYLATION AT ASN-56; ASN-128; ASN-175; ASN-196; ASN-352; ASN-361; RP ASN-413; ASN-444; ASN-528; ASN-568; ASN-603 AND ASN-623. RX PubMed=12731890; DOI=10.1021/bi027101p; RA Zhen Y., Caprioli R.M., Staros J.V.; RT "Characterization of glycosylation sites of the epidermal growth factor RT receptor."; RL Biochemistry 42:5478-5492(2003). RN [40] RP FUNCTION IN CELL PROLIFERATION, INTERACTION WITH STAT3, AND PHOSPHORYLATION RP AT TYR-1092 AND TYR-1110. RX PubMed=12873986; RA Shao H., Cheng H.Y., Cook R.G., Tweardy D.J.; RT "Identification and characterization of signal transducer and activator of RT transcription 3 recruitment sites within the epidermal growth factor RT receptor."; RL Cancer Res. 63:3923-3930(2003). RN [41] RP ACTIVITY REGULATION, AND INTERACTION WITH LRIG1. RX PubMed=15282549; DOI=10.1038/sj.emboj.7600342; RA Gur G., Rubin C., Katz M., Amit I., Citri A., Nilsson J., Amariglio N., RA Henriksson R., Rechavi G., Hedman H., Wides R., Yarden Y.; RT "LRIG1 restricts growth factor signaling by enhancing receptor RT ubiquitylation and degradation."; RL EMBO J. 23:3270-3281(2004). RN [42] RP FUNCTION IN EGFR SIGNALING, IDENTIFICATION IN A COMPLEX WITH PIK3C2A AND RP ERBB2, IDENTIFICATION IN A COMPLEX WITH PIK3C2B AND ERBB2, INTERACTION WITH RP PIK3C2B, AND MUTAGENESIS OF TYR-1016; TYR-1092; TYR-1110; TYR-1172 AND RP TYR-1197. RX PubMed=10805725; DOI=10.1128/mcb.20.11.3817-3830.2000; RA Arcaro A., Zvelebil M.J., Wallasch C., Ullrich A., Waterfield M.D., RA Domin J.; RT "Class II phosphoinositide 3-kinases are downstream targets of activated RT polypeptide growth factor receptors."; RL Mol. Cell. Biol. 20:3817-3830(2000). RN [43] RP FUNCTION IN NF-KAPPA-B ACTIVATION, AND INTERACTION WITH RIPK1. RX PubMed=11116146; DOI=10.1074/jbc.m008458200; RA Habib A.A., Chatterjee S., Park S.-K., Ratan R.R., Lefebvre S., RA Vartanian T.; RT "The epidermal growth factor receptor engages receptor interacting protein RT and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF- RT kappa B. Identification of a novel receptor-tyrosine kinase signalosome."; RL J. Biol. Chem. 276:8865-8874(2001). RN [44] RP FUNCTION IN PHOSPHORYLATION OF MUC1, AND INTERACTION WITH MUC1. RX PubMed=11483589; DOI=10.1074/jbc.c100359200; RA Li Y., Ren J., Yu W., Li Q., Kuwahara H., Yin L., Carraway K.L. III, RA Kufe D.; RT "The epidermal growth factor receptor regulates interaction of the human RT DF3/MUC1 carcinoma antigen with c-Src and beta-catenin."; RL J. Biol. Chem. 276:35239-35242(2001). RN [45] RP FUNCTION, ACTIVITY REGULATION, AND INTERACTION WITH SOCS5. RX PubMed=15590694; DOI=10.1074/jbc.m408575200; RA Kario E., Marmor M.D., Adamsky K., Citri A., Amit I., Amariglio N., RA Rechavi G., Yarden Y.; RT "Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor RT receptor signaling."; RL J. Biol. Chem. 280:7038-7048(2005). RN [46] RP IDENTIFICATION OF EPIGEN/EPGN AS A LIGAND, AND FUNCTION. RX PubMed=15611079; DOI=10.1074/jbc.m413919200; RA Kochupurakkal B.S., Harari D., Di-Segni A., Maik-Rachline G., Lyass L., RA Gur G., Kerber G., Citri A., Lavi S., Eilam R., Chalifa-Caspi V., RA Eshhar Z., Pikarsky E., Pinkas-Kramarski R., Bacus S.S., Yarden Y.; RT "Epigen, the last ligand of ErbB receptors, reveals intricate relationships RT between affinity and mitogenicity."; RL J. Biol. Chem. 280:8503-8512(2005). RN [47] RP GLYCOSYLATION AT ASN-56; ASN-128; ASN-175; ASN-196; ASN-352; ASN-361; RP ASN-413; ASN-444; ASN-528; ASN-568 AND ASN-603, PHOSPHORYLATION AT THR-693; RP SER-991 AND SER-1026, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=16083266; DOI=10.1021/pr050113n; RA Wu S.L., Kim J., Hancock W.S., Karger B.; RT "Extended Range Proteomic Analysis (ERPA): a new and sensitive LC-MS RT platform for high sequence coverage of complex proteins with extensive RT post-translational modifications-comprehensive analysis of beta-casein and RT epidermal growth factor receptor (EGFR)."; RL J. Proteome Res. 4:1155-1170(2005). RN [48] RP INTERACTION WITH PELP1. RX PubMed=16140940; DOI=10.1158/0008-5472.can-05-0614; RA Vadlamudi R.K., Manavathi B., Balasenthil S., Nair S.S., Yang Z., RA Sahin A.A., Kumar R.; RT "Functional implications of altered subcellular localization of PELP1 in RT breast cancer cells."; RL Cancer Res. 65:7724-7732(2005). RN [49] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1172 AND TYR-1197, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [50] RP FUNCTION IN CELL PROLIFERATION, FUNCTION IN PCNA PHOSPHORYLATION, RP INTERACTION WITH PCNA, AND SUBCELLULAR LOCATION. RX PubMed=17115032; DOI=10.1038/ncb1501; RA Wang S.C., Nakajima Y., Yu Y.L., Xia W., Chen C.T., Yang C.C., RA McIntush E.W., Li L.Y., Hawke D.H., Kobayashi R., Hung M.C.; RT "Tyrosine phosphorylation controls PCNA function through protein RT stability."; RL Nat. Cell Biol. 8:1359-1368(2006). RN [51] RP INTERACTION WITH STX19. RX PubMed=16420529; DOI=10.1111/j.1600-0854.2005.00378.x; RA Wang Y., Foo L.Y., Guo K., Gan B.Q., Zeng Q., Hong W., Tang B.L.; RT "Syntaxin 9 is enriched in skin hair follicle epithelium and interacts with RT the epidermal growth factor receptor."; RL Traffic 7:216-226(2006). RN [52] RP INTERACTION WITH PIKFYVE, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=17909029; DOI=10.1158/0008-5472.can-07-1333; RA Kim J., Jahng W.J., Di Vizio D., Lee J.S., Jhaveri R., Rubin M.A., RA Shisheva A., Freeman M.R.; RT "The phosphoinositide kinase PIKfyve mediates epidermal growth factor RT receptor trafficking to the nucleus."; RL Cancer Res. 67:9229-9237(2007). RN [53] RP TISSUE SPECIFICITY. RX PubMed=17671655; DOI=10.1172/jci31680; RA Groenestege W.M.T., Thebault S., van der Wijst J., van den Berg D., RA Janssen R., Tejpar S., van den Heuvel L.P., van Cutsem E., Hoenderop J.G., RA Knoers N.V., Bindels R.J.; RT "Impaired basolateral sorting of pro-EGF causes isolated recessive renal RT hypomagnesemia."; RL J. Clin. Invest. 117:2260-2267(2007). RN [54] RP INTERACTION WITH TNF2, AND SUBCELLULAR LOCATION. RX PubMed=17182860; DOI=10.1091/mbc.e06-02-0142; RA Shen F., Lin Q., Gu Y., Childress C., Yang W.; RT "Activated Cdc42-associated kinase 1 is a component of EGF receptor RT signaling complex and regulates EGF receptor degradation."; RL Mol. Biol. Cell 18:732-742(2007). RN [55] RP INTERACTION WITH NEU3, AND ACTIVITY REGULATION. RX PubMed=17334392; DOI=10.1038/sj.onc.1210341; RA Wada T., Hata K., Yamaguchi K., Shiozaki K., Koseki K., Moriya S., RA Miyagi T.; RT "A crucial role of plasma membrane-associated sialidase in the survival of RT human cancer cells."; RL Oncogene 26:2483-2490(2007). RN [56] RP INTERACTION WITH ATXN2. RX PubMed=18602463; DOI=10.1016/j.cellsig.2008.05.018; RA Nonis D., Schmidt M.H., van de Loo S., Eich F., Dikic I., Nowock J., RA Auburger G.; RT "Ataxin-2 associates with the endocytosis complex and affects EGF receptor RT trafficking."; RL Cell. Signal. 20:1725-1739(2008). RN [57] RP INTERACTION WITH GAB2. RX PubMed=19172738; DOI=10.1038/emboj.2008.159; RA Brummer T., Larance M., Herrera Abreu M.T., Lyons R.J., Timpson P., RA Emmerich C.H., Fleuren E.D.G., Lehrbach G.M., Schramek D., Guilhaus M., RA James D.E., Daly R.J.; RT "Phosphorylation-dependent binding of 14-3-3 terminates signalling by the RT Gab2 docking protein."; RL EMBO J. 27:2305-2316(2008). RN [58] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [59] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-693; SER-695; SER-1064; RP SER-1081; SER-1166 AND TYR-1197, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [60] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-991; SER-995; TYR-998; RP SER-1039; THR-1041; SER-1042; SER-1064 AND SER-1166, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [61] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [62] RP ACTIVITY REGULATION BY PTPRJ AND PTPRK, PHOSPHORYLATION AT TYR-1197, RP DEPHOSPHORYLATION BY PTPRJ, SUBCELLULAR LOCATION, AND INTERACTION WITH CBL RP AND GRB2. RX PubMed=19836242; DOI=10.1016/j.cub.2009.09.048; RA Tarcic G., Boguslavsky S.K., Wakim J., Kiuchi T., Liu A., Reinitz F., RA Nathanson D., Takahashi T., Mischel P.S., Ng T., Yarden Y.; RT "An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase RT controlling EGFR endocytosis."; RL Curr. Biol. 19:1788-1798(2009). RN [63] RP INTERACTION WITH GAREM1. RX PubMed=19509291; DOI=10.1074/jbc.m109.021139; RA Tashiro K., Tsunematsu T., Okubo H., Ohta T., Sano E., Yamauchi E., RA Taniguchi H., Konishi H.; RT "GAREM, a novel adaptor protein for growth factor receptor-bound protein 2, RT contributes to cellular transformation through the activation of RT extracellular signal-regulated kinase signaling."; RL J. Biol. Chem. 284:20206-20214(2009). RN [64] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-352; ASN-413 AND ASN-568. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). RN [65] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [66] RP INTERACTION WITH GPER1. RX PubMed=19749156; DOI=10.1210/me.2009-0120; RA Vivacqua A., Lappano R., De Marco P., Sisci D., Aquila S., De Amicis F., RA Fuqua S.A., Ando S., Maggiolini M.; RT "G protein-coupled receptor 30 expression is up-regulated by EGF and TGF RT alpha in estrogen receptor alpha-positive cancer cells."; RL Mol. Endocrinol. 23:1815-1826(2009). RN [67] RP MUTAGENESIS OF 525-SER--ALA-1210; ASP-587; HIS-590 AND LYS-609. RX PubMed=19718021; DOI=10.1038/nature08297; RA Alvarado D., Klein D.E., Lemmon M.A.; RT "ErbB2 resembles an autoinhibited invertebrate epidermal growth factor RT receptor."; RL Nature 461:287-291(2009). RN [68] RP INTERACTION WITH COPG1, SUBCELLULAR LOCATION, AND TOPOLOGY. RX PubMed=20674546; DOI=10.1016/j.bbrc.2010.07.096; RA Wang Y.N., Wang H., Yamaguchi H., Lee H.J., Lee H.H., Hung M.C.; RT "COPI-mediated retrograde trafficking from the Golgi to the ER regulates RT EGFR nuclear transport."; RL Biochem. Biophys. Res. Commun. 399:498-504(2010). RN [69] RP INTERACTION WITH GPER1, AND SUBCELLULAR LOCATION. RX PubMed=20551055; DOI=10.1158/0008-5472.can-10-0408; RA Madeo A., Maggiolini M.; RT "Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol- RT induced gene expression and migration in breast cancer-associated RT fibroblasts."; RL Cancer Res. 70:6036-6046(2010). RN [70] RP FUNCTION, IDENTIFICATION IN COMPLEX WITH CCDC88A AND GNAI3, SUBCELLULAR RP LOCATION, AND PHOSPHORYLATION. RX PubMed=20462955; DOI=10.1091/mbc.e10-01-0028; RA Ghosh P., Beas A.O., Bornheimer S.J., Garcia-Marcos M., Forry E.P., RA Johannson C., Ear J., Jung B.H., Cabrera B., Carethers J.M., Farquhar M.G.; RT "A G{alpha}i-GIV molecular complex binds epidermal growth factor receptor RT and determines whether cells migrate or proliferate."; RL Mol. Biol. Cell 21:2338-2354(2010). RN [71] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-693; SER-991; SER-1064 AND RP TYR-1197, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [72] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [73] RP PHOSPHORYLATION AT SER-229. RX PubMed=21487020; DOI=10.1074/jbc.m111.240796; RA Huang W.C., Chen Y.J., Li L.Y., Wei Y.L., Hsu S.C., Tsai S.L., Chiu P.C., RA Huang W.P., Wang Y.N., Chen C.H., Chang W.C., Chang W.C., Chen A.J., RA Tsai C.H., Hung M.C.; RT "Nuclear translocation of epidermal growth factor receptor by Akt-dependent RT phosphorylation enhances breast cancer-resistant protein expression in RT gefitinib-resistant cells."; RL J. Biol. Chem. 286:20558-20568(2011). RN [74] RP FUNCTION IN CELL PROLIFERATION AND CELL MIGRATION, METHYLATION AT ARG-1199 RP BY PRMT5, AND INTERACTION WITH PRMT5 AND PTPN6. RX PubMed=21258366; DOI=10.1038/ncb2158; RA Hsu J.M., Chen C.T., Chou C.K., Kuo H.P., Li L.Y., Lin C.Y., Lee H.J., RA Wang Y.N., Liu M., Liao H.W., Shi B., Lai C.C., Bedford M.T., Tsai C.H., RA Hung M.C.; RT "Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation RT negatively modulates EGFR-mediated ERK activation."; RL Nat. Cell Biol. 13:174-181(2011). RN [75] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=21516087; DOI=10.1038/nm.2341; RA Lupberger J., Zeisel M.B., Xiao F., Thumann C., Fofana I., Zona L., RA Davis C., Mee C.J., Turek M., Gorke S., Royer C., Fischer B., Zahid M.N., RA Lavillette D., Fresquet J., Cosset F.L., Rothenberg S.M., Pietschmann T., RA Patel A.H., Pessaux P., Doffoel M., Raffelsberger W., Poch O., RA McKeating J.A., Brino L., Baumert T.F.; RT "EGFR and EphA2 are host factors for hepatitis C virus entry and possible RT targets for antiviral therapy."; RL Nat. Med. 17:589-595(2011). RN [76] RP INTERACTION WITH FER, AND PHOSPHORYLATION. RX PubMed=21518868; DOI=10.1073/pnas.1105369108; RA Guo C., Stark G.R.; RT "FER tyrosine kinase (FER) overexpression mediates resistance to quinacrine RT through EGF-dependent activation of NF-kappaB."; RL Proc. Natl. Acad. Sci. U.S.A. 108:7968-7973(2011). RN [77] RP INTERACTION WITH ANKRD13A; ANKRD13B AND ANKRD13D, UBIQUITINATION, AND RP SUBCELLULAR LOCATION. RX PubMed=22298428; DOI=10.1091/mbc.e11-09-0817; RA Tanno H., Yamaguchi T., Goto E., Ishido S., Komada M.; RT "The Ankrd 13 family of UIM-bearing proteins regulates EGF receptor RT endocytosis from the plasma membrane."; RL Mol. Biol. Cell 23:1343-1353(2012). RN [78] RP UBIQUITINATION, AND DEUBIQUITINATION BY OTUD7B. RX PubMed=22179831; DOI=10.1038/onc.2011.587; RA Pareja F., Ferraro D.A., Rubin C., Cohen-Dvashi H., Zhang F., Aulmann S., RA Ben-Chetrit N., Pines G., Navon R., Crosetto N., Kostler W., Carvalho S., RA Lavi S., Schmitt F., Dikic I., Yakhini Z., Sinn P., Mills G.B., Yarden Y.; RT "Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression."; RL Oncogene 31:4599-4608(2012). RN [79] RP INTERACTION WITH CBL, AND PHOSPHORYLATION AT TYR-869; TYR-1016; TYR-1069; RP TYR-1092 AND TYR-1197. RX PubMed=23774213; DOI=10.1158/0008-5472.can-12-4441; RA Hong S.Y., Shih Y.P., Li T., Carraway K.L. III, Lo S.H.; RT "CTEN prolongs signaling by EGFR through reducing its ligand-induced RT degradation."; RL Cancer Res. 73:5266-5276(2013). RN [80] RP INTERACTION WITH RNF115 AND RNF126. RX PubMed=23418353; DOI=10.1242/jcs.116129; RA Smith C.J., Berry D.M., McGlade C.J.; RT "The E3 ubiquitin ligases RNF126 and Rabring7 regulate endosomal sorting of RT the epidermal growth factor receptor."; RL J. Cell Sci. 126:1366-1380(2013). RN [81] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-693 AND SER-1064, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [82] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-693; SER-991; SER-1026 AND RP SER-1166, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [83] RP INTERACTION WITH CCDC88A AND GNAI3. RX PubMed=25187647; DOI=10.1091/mbc.e14-05-0978; RA Lin C., Ear J., Midde K., Lopez-Sanchez I., Aznar N., Garcia-Marcos M., RA Kufareva I., Abagyan R., Ghosh P.; RT "Structural basis for activation of trimeric Gi proteins by multiple growth RT factor receptors via GIV/Girdin."; RL Mol. Biol. Cell 25:3654-3671(2014). RN [84] RP SUBCELLULAR LOCATION, AND INTERACTION WITH CD44. RX PubMed=23589287; DOI=10.1074/jbc.m113.451336; RA Midgley A.C., Rogers M., Hallett M.B., Clayton A., Bowen T., Phillips A.O., RA Steadman R.; RT "Transforming growth factor-beta1 (TGF-beta1)-stimulated fibroblast to RT myofibroblast differentiation is mediated by hyaluronan (HA)-facilitated RT epidermal growth factor receptor (EGFR) and CD44 co-localization in lipid RT rafts."; RL J. Biol. Chem. 288:14824-14838(2013). RN [85] RP INTERACTION WITH GPRC5A. RX PubMed=25311788; DOI=10.1186/1476-4598-13-233; RA Lin X., Zhong S., Ye X., Liao Y., Yao F., Yang X., Sun B., Zhang J., Li Q., RA Gao Y., Wang Y., Liu J., Han B., Chin Y.E., Zhou B.P., Deng J.; RT "EGFR phosphorylates and inhibits lung tumor suppressor GPRC5A in lung RT cancer."; RL Mol. Cancer 13:233-233(2014). RN [86] RP INTERACTION WITH FAM83B. RX PubMed=23912460; DOI=10.1038/onc.2013.293; RA Cipriano R., Bryson B.L., Miskimen K.L., Bartel C.A., Hernandez-Sanchez W., RA Bruntz R.C., Scott S.A., Lindsley C.W., Brown H.A., Jackson M.W.; RT "Hyperactivation of EGFR and downstream effector phospholipase D1 by RT oncogenic FAM83B."; RL Oncogene 33:3298-3306(2014). RN [87] RP GLYCOSYLATION AT ASN-528, AND ACTIVITY REGULATION. RX PubMed=25922362; DOI=10.1093/glycob/cwv026; RA Mozzi A., Forcella M., Riva A., Difrancesco C., Molinari F., Martin V., RA Papini N., Bernasconi B., Nonnis S., Tedeschi G., Mazzucchelli L., RA Monti E., Fusi P., Frattini M.; RT "NEU3 activity enhances EGFR activation without affecting EGFR expression RT and acts on its sialylation levels."; RL Glycobiology 25:855-868(2015). RN [88] RP FUNCTION, PALMITOYLATION AT CYS-1049 AND CYS-1146, IDENTIFICATION BY MASS RP SPECTROMETRY, UBIQUITINATION, PHOSPHORYLATION AT TYR-1092; TYR-1172 AND RP TYR-1197, SUBCELLULAR LOCATION, AND MUTAGENESIS OF 1048-ALA--ALA-1210; RP CYS-1049 AND CYS-1146. RX PubMed=27153536; DOI=10.1016/j.molcel.2016.04.003; RA Runkle K.B., Kharbanda A., Stypulkowski E., Cao X.J., Wang W., Garcia B.A., RA Witze E.S.; RT "Inhibition of DHHC20-Mediated EGFR Palmitoylation Creates a Dependence on RT EGFR Signaling."; RL Mol. Cell 62:385-396(2016). RN [89] RP INTERACTION WITH PGRMC1. RX PubMed=26988023; DOI=10.1038/ncomms11030; RA Kabe Y., Nakane T., Koike I., Yamamoto T., Sugiura Y., Harada E., RA Sugase K., Shimamura T., Ohmura M., Muraoka K., Yamamoto A., Uchida T., RA Iwata S., Yamaguchi Y., Krayukhina E., Noda M., Handa H., Ishimori K., RA Uchiyama S., Kobayashi T., Suematsu M.; RT "Haem-dependent dimerization of PGRMC1/Sigma-2 receptor facilitates cancer RT proliferation and chemoresistance."; RL Nat. Commun. 7:11030-11030(2016). RN [90] RP SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT TYR-1172. RX PubMed=26918609; DOI=10.18632/oncotarget.7675; RA Overmiller A.M., McGuinn K.P., Roberts B.J., Cooper F., RA Brennan-Crispi D.M., Deguchi T., Peltonen S., Wahl J.K. III, Mahoney M.G.; RT "c-Src/Cav1-dependent activation of the EGFR by Dsg2."; RL Oncotarget 7:37536-37555(2016). RN [91] RP INTERACTION WITH LAPTM4B. RX PubMed=28479384; DOI=10.1016/j.gene.2017.05.006; RA Tian M., Chen Y., Tian D., Qiao X., Ma Z., Li J.; RT "Beclin1 antagonizes LAPTM4B-mediated EGFR overactivation in gastric cancer RT cells."; RL Gene 626:48-53(2017). RN [92] RP HYDROXYBUTYRYLATION AT LYS-745. RX PubMed=29192674; DOI=10.1038/cr.2017.149; RA Huang H., Luo Z., Qi S., Huang J., Xu P., Wang X., Gao L., Li F., Wang J., RA Zhao W., Gu W., Chen Z., Dai L., Dai J., Zhao Y.; RT "Landscape of the regulatory elements for lysine 2-hydroxyisobutyrylation RT pathway."; RL Cell Res. 28:111-125(2018). RN [93] RP INTERACTION WITH TRAF4. RX PubMed=30352854; DOI=10.1073/pnas.1809599115; RA Cai G., Zhu L., Chen X., Sun K., Liu C., Sen G.C., Stark G.R., Qin J., RA Li X.; RT "TRAF4 binds to the juxtamembrane region of EGFR directly and promotes RT kinase activation."; RL Proc. Natl. Acad. Sci. U.S.A. 115:11531-11536(2018). RN [94] RP UBIQUITINATION BY ZNRF1 AND CBL. RX PubMed=33996800; DOI=10.3389/fcell.2021.642625; RA Shen C.H., Chou C.C., Lai T.Y., Hsu J.E., Lin Y.S., Liu H.Y., Chen Y.K., RA Ho I.L., Hsu P.H., Chuang T.H., Lee C.Y., Hsu L.C.; RT "ZNRF1 Mediates Epidermal Growth Factor Receptor Ubiquitination to Control RT Receptor Lysosomal Trafficking and Degradation."; RL Front. Cell Dev. Biol. 9:642625-642625(2021). RN [95] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CD82. RX PubMed=35538033; DOI=10.3724/abbs.2022011; RA Bu J., Zhong W., Li M., He S., Zhang M., Zhang Y., Li Y.; RT "CD82 palmitoylation site mutations at Cys5+Cys74 affect EGFR RT internalization and metabolism through recycling pathway."; RL Acta Biochim. Biophys. Sin. 54:400-408(2022). RN [96] RP INTERACTION WITH SNX32. RX PubMed=39073202; DOI=10.1111/tra.12952; RA Wang D., Zhao X., Wang P., Liu J.J.; RT "SNX32 regulates sorting and trafficking of activated EGFR to the lysosomal RT degradation pathway."; RL Traffic 25:e12952-e12952(2024). RN [97] {ECO:0007744|PDB:1MOX} RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 25-525 IN COMPLEX WITH TGFA, RP FUNCTION, GLYCOSYLATION AT ASN-56; ASN-196 AND ASN-352, AND DISULFIDE RP BONDS. RX PubMed=12297049; DOI=10.1016/s0092-8674(02)00940-6; RA Garrett T.P., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., RA Zhu H.J., Walker F., Frenkel M.J., Hoyne P.A., Jorissen R.N., Nice E.C., RA Burgess A.W., Ward C.W.; RT "Crystal structure of a truncated epidermal growth factor receptor RT extracellular domain bound to transforming growth factor alpha."; RL Cell 110:763-773(2002). RN [98] {ECO:0007744|PDB:1IVO} RP X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 25-646 IN COMPLEX WITH EGF, RP FUNCTION IN MAPK1 AND/OR MAPK3 ACTIVATION, SUBUNIT, SUBCELLULAR LOCATION, RP MUTAGENESIS OF TYR-275; PHE-287; ARG-309 AND ARG-429, DISULFIDE BONDS, AND RP GLYCOSYLATION AT ASN-56; ASN-175; ASN-196; ASN-352; ASN-361 AND ASN-444. RX PubMed=12297050; DOI=10.1016/s0092-8674(02)00963-7; RA Ogiso H., Ishitani R., Nureki O., Fukai S., Yamanaka M., Kim J.H., RA Saito K., Sakamoto A., Inoue M., Shirouzu M., Yokoyama S.; RT "Crystal structure of the complex of human epidermal growth factor and RT receptor extracellular domains."; RL Cell 110:775-787(2002). RN [99] {ECO:0007744|PDB:1NQL} RP X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 25-642 IN COMPLEX WITH EGF, RP FUNCTION, SUBUNIT, MUTAGENESIS OF 587-ASP--HIS-590 AND LYS-609, DISULFIDE RP BONDS, AND GLYCOSYLATION AT ASN-352; ASN-361; ASN-444; ASN-528; ASN-568 AND RP ASN-603. RX PubMed=12620237; DOI=10.1016/s1097-2765(03)00047-9; RA Ferguson K.M., Berger M.B., Mendrola J.M., Cho H.S., Leahy D.J., RA Lemmon M.A.; RT "EGF activates its receptor by removing interactions that autoinhibit RT ectodomain dimerization."; RL Mol. Cell 11:507-517(2003). RN [100] {ECO:0007744|PDB:1XKK} RP X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 695-1022 IN COMPLEX WITH RP GW572016, CATALYTIC ACTIVITY, AND FUNCTION. RX PubMed=15374980; DOI=10.1158/0008-5472.can-04-1168; RA Wood E.R., Truesdale A.T., McDonald O.B., Yuan D., Hassell A., RA Dickerson S.H., Ellis B., Pennisi C., Horne E., Lackey K., Alligood K.J., RA Rusnak D.W., Gilmer T.M., Shewchuk L.; RT "A unique structure for epidermal growth factor receptor bound to GW572016 RT (Lapatinib): relationships among protein conformation, inhibitor off-rate, RT and receptor activity in tumor cells."; RL Cancer Res. 64:6652-6659(2004). RN [101] {ECO:0007744|PDB:1YY9} RP X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 25-642 IN COMPLEX WITH CETUXIMAB. RX PubMed=15837620; DOI=10.1016/j.ccr.2005.03.003; RA Li S., Schmitz K.R., Jeffrey P.D., Wiltzius J.J., Kussie P., Ferguson K.M.; RT "Structural basis for inhibition of the epidermal growth factor receptor by RT cetuximab."; RL Cancer Cell 7:301-311(2005). RN [102] RP STRUCTURE BY NMR OF 669-721. RX PubMed=15840573; DOI=10.1074/jbc.m502698200; RA Choowongkomon K., Carlin C.R., Sonnichsen F.D.; RT "A structural model for the membrane-bound form of the juxtamembrane domain RT of the epidermal growth factor receptor."; RL J. Biol. Chem. 280:24043-24052(2005). RN [103] {ECO:0007744|PDB:2ITN, ECO:0007744|PDB:2ITO, ECO:0007744|PDB:2ITP, ECO:0007744|PDB:2ITQ, ECO:0007744|PDB:2ITT, ECO:0007744|PDB:2ITU, ECO:0007744|PDB:2ITV, ECO:0007744|PDB:2J6M} RP X-RAY CRYSTALLOGRAPHY (2.47 ANGSTROMS) OF 696-1022 OF WILD-TYPE AND RP VARIANTS SER-719 AND ARG-858 IN COMPLEXES WITH ATP ANALOGS AND SYNTHETIC RP INHIBITORS, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND CHARACTERIZATION RP OF VARIANTS SER-719 AND ARG-858. RX PubMed=17349580; DOI=10.1016/j.ccr.2006.12.017; RA Yun C.H., Boggon T.J., Li Y., Woo M.S., Greulich H., Meyerson M., Eck M.J.; RT "Structures of lung cancer-derived EGFR mutants and inhibitor complexes: RT mechanism of activation and insights into differential inhibitor RT sensitivity."; RL Cancer Cell 11:217-227(2007). RN [104] RP X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 702-1022 IN COMPLEX WITH ERRFI1, RP ACTIVITY REGULATION, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, SUBUNIT, AND RP INTERACTION WITH ERRFI1. RX PubMed=18046415; DOI=10.1038/nature05998; RA Zhang X., Pickin K.A., Bose R., Jura N., Cole P.A., Kuriyan J.; RT "Inhibition of the EGF receptor by binding of MIG6 to an activating kinase RT domain interface."; RL Nature 450:741-744(2007). RN [105] {ECO:0007744|PDB:2JIT, ECO:0007744|PDB:2JIU, ECO:0007744|PDB:2JIV} RP X-RAY CRYSTALLOGRAPHY (3.05 ANGSTROMS) OF 695-1022 OF VARIANT MET-790, RP CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANT MET-790. RX PubMed=18227510; DOI=10.1073/pnas.0709662105; RA Yun C.H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H., Wong K.K., RA Meyerson M., Eck M.J.; RT "The T790M mutation in EGFR kinase causes drug resistance by increasing the RT affinity for ATP."; RL Proc. Natl. Acad. Sci. U.S.A. 105:2070-2075(2008). RN [106] {ECO:0007744|PDB:3GT8} RP X-RAY CRYSTALLOGRAPHY (2.96 ANGSTROMS) OF 696-1022, CATALYTIC ACTIVITY, RP PHOSPHORYLATION AT TYR-998; TYR-1016 AND TYR-1197, MUTAGENESIS OF LEU-688; RP GLU-690; LEU-692; ARG-977 AND 1005-GLU-ASP-1006, AND SUBUNIT. RX PubMed=19563760; DOI=10.1016/j.cell.2009.04.025; RA Jura N., Endres N.F., Engel K., Deindl S., Das R., Lamers M.H., RA Wemmer D.E., Zhang X., Kuriyan J.; RT "Mechanism for activation of the EGF receptor catalytic domain by the RT juxtamembrane segment."; RL Cell 137:1293-1307(2009). RN [107] RP X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 669-1022 OF MUTANT MET-745, RP CATALYTIC ACTIVITY, FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, RP AUTOPHOSPHORYLATION, AND MUTAGENESIS OF LEU-688; VAL-689; GLU-690; LEU-692; RP THR-693; PRO-694; PRO-699; ASN-700; LEU-704; ARG-705; ILE-706 AND LYS-745. RX PubMed=19560417; DOI=10.1016/j.molcel.2009.04.034; RA Red Brewer M., Choi S.H., Alvarado D., Moravcevic K., Pozzi A., RA Lemmon M.A., Carpenter G.; RT "The juxtamembrane region of the EGF receptor functions as an activation RT domain."; RL Mol. Cell 34:641-651(2009). RN [108] RP STRUCTURE BY NMR OF 634-677 IN COMPLEX WITH ERBB2, AND SUBUNIT. RX PubMed=20471394; DOI=10.1016/j.jmb.2010.05.016; RA Mineev K.S., Bocharov E.V., Pustovalova Y.E., Bocharova O.V., Chupin V.V., RA Arseniev A.S.; RT "Spatial structure of the transmembrane domain heterodimer of ErbB1 and RT ErbB2 receptor tyrosine kinases."; RL J. Mol. Biol. 400:231-243(2010). RN [109] {ECO:0007744|PDB:3NJP} RP X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 25-638 IN COMPLEX WITH EGF, RP FUNCTION, SUBUNIT, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-56; ASN-73; RP ASN-175; ASN-196; ASN-352; ASN-361; ASN-444 AND ASN-528. RX PubMed=20837704; DOI=10.1128/mcb.00742-10; RA Lu C., Mi L.Z., Grey M.J., Zhu J., Graef E., Yokoyama S., Springer T.A.; RT "Structural evidence for loose linkage between ligand binding and kinase RT activation in the epidermal growth factor receptor."; RL Mol. Cell. Biol. 30:5432-5443(2010). RN [110] RP X-RAY CRYSTALLOGRAPHY (2.27 ANGSTROMS) OF 1066-1076 IN COMPLEX WITH CBLB, RP AND INTERACTION WITH CBLB. RG Structural genomics consortium; RT "Crystal structure of Cbl-b TKB domain in complex with EGFR pY1069 RT peptide."; RL Submitted (OCT-2010) to the PDB data bank. RN [111] RP X-RAY CRYSTALLOGRAPHY (1.52 ANGSTROMS) OF 1062-1074 IN COMPLEX WITH CBLC, RP PHOSPHORYLATION AT TYR-1069, INTERACTION WITH CBLC, AND MUTAGENESIS OF RP GLN-1067; ARG-1068 AND TYR-1069. RX PubMed=22888118; DOI=10.1093/jb/mvs085; RA Takeshita K., Tezuka T., Isozaki Y., Yamashita E., Suzuki M., Kim M., RA Yamanashi Y., Yamamoto T., Nakagawa A.; RT "Structural flexibility regulates phosphopeptide-binding activity of the RT tyrosine kinase binding domain of Cbl-c."; RL J. Biochem. 152:487-495(2012). RN [112] RP VARIANTS ALA-709; GLY-709; CYS-719; SER-719; 746-GLU--ALA-750 DEL; RP 746-GLU--THR-751 DELINS ALA; 746-GLU--SER-752 DELINS ASP; 747-LEU--THR-751 RP DEL; ILE-768; MET-769; VAL-833; LEU-835; VAL-838; ARG-858 AND GLN-861. RX PubMed=15623594; DOI=10.1158/1078-0432.ccr-04-1245; RA Huang S.F., Liu H.P., Li L.H., Ku Y.C., Fu Y.N., Tsai H.Y., Chen Y.T., RA Lin Y.F., Chang W.C., Kuo H.P., Wu Y.C., Chen Y.R., Tsai S.F.; RT "High frequency of epidermal growth factor receptor mutations with complex RT patterns in non-small cell lung cancers related to gefitinib responsiveness RT in Taiwan."; RL Clin. Cancer Res. 10:8195-8203(2004). RN [113] RP VARIANTS SER-719 AND ARG-858, AND POSSIBLE INVOLVEMENT IN LUNG CANCER. RX PubMed=15118125; DOI=10.1126/science.1099314; RA Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., RA Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., RA Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M.; RT "EGFR mutations in lung cancer: correlation with clinical response to RT gefitinib therapy."; RL Science 304:1497-1500(2004). RN [114] RP VARIANTS ALA-709; LYS-709; ALA-719; ASP-719; CYS-719; SER-719; SER-724; RP LYS-734; GLU-746 DEL; PHE-747; 747-LEU--GLU-749 DEL; PRO-748; RP 752-SER--ILE-759 DEL; ARG-787; MET-790; VAL-833; LEU-834; MET-858; ARG-858; RP GLN-861 AND GLU-873, AND POSSIBLE INVOLVEMENT IN LUNG CANCER. RX PubMed=16533793; DOI=10.1158/1078-0432.ccr-05-1981; RA Tam I.Y.S., Chung L.P., Suen W.S., Wang E., Wong M.C.M., Ho K.K., Lam W.K., RA Chiu S.W., Girard L., Minna J.D., Gazdar A.F., Wong M.P.; RT "Distinct epidermal growth factor receptor and KRAS mutation patterns in RT non-small cell lung cancer patients with different tobacco exposure and RT clinicopathologic features."; RL Clin. Cancer Res. 12:1647-1653(2006). RN [115] RP CHARACTERIZATION OF VARIANTS ALA-709; GLY-709; SER-719; ILE-768; VAL-833; RP LEU-835; VAL-838; ARG-858 AND GLN-861. RX PubMed=16205628; DOI=10.1038/sj.onc.1209159; RA Chen Y.R., Fu Y.N., Lin C.H., Yang S.T., Hu S.F., Chen Y.T., Tsai S.F., RA Huang S.F.; RT "Distinctive activation patterns in constitutively active and gefitinib- RT sensitive EGFR mutants."; RL Oncogene 25:1205-1215(2006). RN [116] RP VARIANT 30-VAL--ARG-297 DEL, AND POSSIBLE INVOLVEMENT IN LUNG CANCER. RX PubMed=16672372; DOI=10.1073/pnas.0510284103; RA Ji H., Zhao X., Yuza Y., Shimamura T., Li D., Protopopov A., Jung B.L., RA McNamara K., Xia H., Glatt K.A., Thomas R.K., Sasaki H., Horner J.W., RA Eck M., Mitchell A., Sun Y., Al-Hashem R., Bronson R.T., Rabindran S.K., RA Discafani C.M., Maher E., Shapiro G.I., Meyerson M., Wong K.K.; RT "Epidermal growth factor receptor variant III mutations in lung RT tumorigenesis and sensitivity to tyrosine kinase inhibitors."; RL Proc. Natl. Acad. Sci. U.S.A. 103:7817-7822(2006). RN [117] RP VARIANTS [LARGE SCALE ANALYSIS] LYS-521; ARG-1034 AND VAL-1210. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [118] RP VARIANT NNCIS ASP-428, CHARACTERIZATION OF VARIANT NNCIS ASP-428, AND RP INVOLVEMENT IN NNCIS. RX PubMed=24691054; DOI=10.1038/jid.2014.164; RA Campbell P., Morton P.E., Takeichi T., Salam A., Roberts N., RA Proudfoot L.E., Mellerio J.E., Aminu K., Wellington C., Patil S.N., RA Akiyama M., Liu L., McMillan J.R., Aristodemou S., Ishida-Yamamoto A., RA Abdul-Wahab A., Petrof G., Fong K., Harnchoowong S., Stone K.L., RA Harper J.I., McLean W.H., Simpson M.A., Parsons M., McGrath J.A.; RT "Epithelial inflammation resulting from an inherited loss-of-function RT mutation in EGFR."; RL J. Invest. Dermatol. 134:2570-2578(2014). CC -!- FUNCTION: Receptor tyrosine kinase binding ligands of the EGF family CC and activating several signaling cascades to convert extracellular cues CC into appropriate cellular responses (PubMed:10805725, PubMed:27153536, CC PubMed:2790960, PubMed:35538033). Known ligands include EGF, TGFA/TGF- CC alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and CC HBEGF/heparin-binding EGF (PubMed:12297049, PubMed:15611079, CC PubMed:17909029, PubMed:20837704, PubMed:27153536, PubMed:2790960, CC PubMed:7679104, PubMed:8144591, PubMed:9419975). Ligand binding CC triggers receptor homo- and/or heterodimerization and CC autophosphorylation on key cytoplasmic residues. The phosphorylated CC receptor recruits adapter proteins like GRB2 which in turn activates CC complex downstream signaling cascades. Activates at least 4 major CC downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 CC kinase-AKT, PLCgamma-PKC and STATs modules (PubMed:27153536). May also CC activate the NF-kappa-B signaling cascade (PubMed:11116146). Also CC directly phosphorylates other proteins like RGS16, activating its CC GTPase activity and probably coupling the EGF receptor signaling to the CC G protein-coupled receptor signaling (PubMed:11602604). Also CC phosphorylates MUC1 and increases its interaction with SRC and CC CTNNB1/beta-catenin (PubMed:11483589). Positively regulates cell CC migration via interaction with CCDC88A/GIV which retains EGFR at the CC cell membrane following ligand stimulation, promoting EGFR signaling CC which triggers cell migration (PubMed:20462955). Plays a role in CC enhancing learning and memory performance (By similarity). Plays a role CC in mammalian pain signaling (long-lasting hypersensitivity) (By CC similarity). {ECO:0000250|UniProtKB:Q01279, CC ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:11116146, CC ECO:0000269|PubMed:11483589, ECO:0000269|PubMed:11602604, CC ECO:0000269|PubMed:12297049, ECO:0000269|PubMed:12297050, CC ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:12873986, CC ECO:0000269|PubMed:15374980, ECO:0000269|PubMed:15590694, CC ECO:0000269|PubMed:15611079, ECO:0000269|PubMed:17115032, CC ECO:0000269|PubMed:17909029, ECO:0000269|PubMed:19560417, CC ECO:0000269|PubMed:20462955, ECO:0000269|PubMed:20837704, CC ECO:0000269|PubMed:21258366, ECO:0000269|PubMed:27153536, CC ECO:0000269|PubMed:2790960, ECO:0000269|PubMed:35538033, CC ECO:0000269|PubMed:7679104, ECO:0000269|PubMed:8144591, CC ECO:0000269|PubMed:9419975}. CC -!- FUNCTION: Isoform 2 may act as an antagonist of EGF action. CC -!- FUNCTION: (Microbial infection) Acts as a receptor for hepatitis C CC virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV CC entry by promoting the formation of the CD81-CLDN1 receptor complexes CC that are essential for HCV entry and by enhancing membrane fusion of CC cells expressing HCV envelope glycoproteins. CC {ECO:0000269|PubMed:21516087}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:15374980, ECO:0000269|PubMed:17349580, CC ECO:0000269|PubMed:18046415, ECO:0000269|PubMed:18227510, CC ECO:0000269|PubMed:19560417, ECO:0000269|PubMed:19563760}; CC -!- ACTIVITY REGULATION: Endocytosis and inhibition of the activated EGFR CC by phosphatases like PTPRJ and PTPRK constitute immediate regulatory CC mechanisms. Upon EGF-binding phosphorylates EPS15 that regulates EGFR CC endocytosis and activity. Moreover, inducible feedback inhibitors CC including LRIG1, SOCS4, SOCS5 and ERRFI1 constitute alternative CC regulatory mechanisms for the EGFR signaling. Up-regulated by NEU3- CC mediated desialylation of N-linked glycan at Asn-528. CC {ECO:0000269|PubMed:15282549, ECO:0000269|PubMed:15590694, CC ECO:0000269|PubMed:17334392, ECO:0000269|PubMed:18046415, CC ECO:0000269|PubMed:19836242, ECO:0000269|PubMed:25922362}. CC -!- SUBUNIT: Binding of the ligand triggers homo- and/or heterodimerization CC of the receptor triggering its autophosphorylation. Heterodimer with CC ERBB2 (PubMed:10805725). Forms a complex with CCDC88A/GIV (via SH2-like CC regions) and GNAI3 which leads to enhanced EGFR signaling and CC triggering of cell migration; binding to CCDC88A requires CC autophosphorylation of the EGFR C-terminal region, and ligand CC stimulation is required for recruitment of GNAI3 to the complex CC (PubMed:20462955, PubMed:25187647). Interacts with ERRFI1; inhibits CC dimerization of the kinase domain and autophosphorylation CC (PubMed:18046415). Part of a complex with ERBB2 and either PIK3C2A or CC PIK3C2B (PubMed:10805725). Interacts with GRB2; an adapter protein CC coupling the receptor to downstream signaling pathways. Interacts with CC GAB2; involved in signaling downstream of EGFR. Interacts with STAT3; CC mediates EGFR downstream signaling in cell proliferation. Interacts CC with RIPK1; involved in NF-kappa-B activation. Interacts CC (autophosphorylated) with CBL, CBLB and CBLC; involved in EGFR CC ubiquitination and regulation; interaction with CBL is reduced in the CC presence of tensin TNS4 (PubMed:23774213). Interacts with SOCS5; CC regulates EGFR degradation through ELOC- and ELOB-mediated CC ubiquitination and proteasomal degradation. Interacts with PRMT5; CC methylates EGFR and enhances interaction with PTPN6. Interacts CC (phosphorylated) with PTPN6; inhibits EGFR-dependent activation of CC MAPK/ERK. Interacts with COPG1; essential for regulation of EGF- CC dependent nuclear transport of EGFR by retrograde trafficking from the CC Golgi to the ER. Interacts with TNK2; this interaction is dependent on CC EGF stimulation and kinase activity of EGFR. Interacts with PCNA; CC positively regulates PCNA (PubMed:17115032). Interacts with PELP1. CC Interacts with MUC1. Interacts with AP2M1. Interacts with FER. May CC interact with EPS8; mediates EPS8 phosphorylation. Interacts (via SH2 CC domains) with GRB2, NCK1 and NCK2 (PubMed:10026169). Interacts with CC ATXN2. Interacts with GAREM1. Interacts (ubiquitinated) with CC ANKRD13A/B/D; the interaction is direct and may regulate EGFR CC internalization after EGF stimulation. Interacts with GPER1; the CC interaction occurs in an estrogen-dependent manner. Interacts (via C- CC terminal cytoplasmic kinase domain) with ZPR1 (via zinc fingers). CC Interacts with RNF115 and RNF126 (PubMed:23418353). Interacts with CC GPRC5A (via its transmembrane domain) (PubMed:25311788). Interacts with CC FAM83B; positively regulates EGFR inducing its autophosphorylation in CC absence of stimulation by EGF (PubMed:23912460). Interacts with CC LAPTM4B; positively correlates with EGFR activation (PubMed:28479384). CC Interacts with STX19 (PubMed:16420529). Interacts with CD44 CC (PubMed:23589287). Interacts with PGRMC1; the interaction requires CC PGRMC1 homodimerization (PubMed:26988023). Interacts with PIKFYVE CC (PubMed:17909029). Interacts with NEU3. Interacts with TRAF4 CC (PubMed:30352854). Interacts with the ant venom OMEGA- CC myrmeciitoxin(02)-Mg1a (By similarity). Interacts with CD82; this CC interaction facilitates ligand-induced endocytosis of the receptor and CC its subsequent desensitization (PubMed:35538033). Interacts with SNX32; CC the interaction is required for endolysosomal EGFR trafficking CC (PubMed:39073202). {ECO:0000250|UniProtKB:Q01279, CC ECO:0000269|PubMed:10026169, ECO:0000269|PubMed:10228163, CC ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:11116146, CC ECO:0000269|PubMed:11483589, ECO:0000269|PubMed:12297050, CC ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:12873986, CC ECO:0000269|PubMed:15282549, ECO:0000269|PubMed:15374980, CC ECO:0000269|PubMed:15590694, ECO:0000269|PubMed:15837620, CC ECO:0000269|PubMed:16140940, ECO:0000269|PubMed:16420529, CC ECO:0000269|PubMed:17115032, ECO:0000269|PubMed:17182860, CC ECO:0000269|PubMed:17334392, ECO:0000269|PubMed:17909029, CC ECO:0000269|PubMed:18046415, ECO:0000269|PubMed:18602463, CC ECO:0000269|PubMed:19172738, ECO:0000269|PubMed:19509291, CC ECO:0000269|PubMed:19560417, ECO:0000269|PubMed:19563760, CC ECO:0000269|PubMed:19749156, ECO:0000269|PubMed:19836242, CC ECO:0000269|PubMed:20462955, ECO:0000269|PubMed:20471394, CC ECO:0000269|PubMed:20551055, ECO:0000269|PubMed:20674546, CC ECO:0000269|PubMed:20837704, ECO:0000269|PubMed:21258366, CC ECO:0000269|PubMed:21518868, ECO:0000269|PubMed:22298428, CC ECO:0000269|PubMed:22888118, ECO:0000269|PubMed:23418353, CC ECO:0000269|PubMed:23589287, ECO:0000269|PubMed:23774213, CC ECO:0000269|PubMed:23912460, ECO:0000269|PubMed:25187647, CC ECO:0000269|PubMed:25311788, ECO:0000269|PubMed:26988023, CC ECO:0000269|PubMed:28479384, ECO:0000269|PubMed:35538033, CC ECO:0000269|PubMed:39073202, ECO:0000269|PubMed:7657591, CC ECO:0000269|PubMed:8650580, ECO:0000269|PubMed:9852145, CC ECO:0000269|Ref.110}. CC -!- INTERACTION: CC P00533; P00519: ABL1; NbExp=3; IntAct=EBI-297353, EBI-375543; CC P00533; P42684: ABL2; NbExp=9; IntAct=EBI-297353, EBI-1102694; CC P00533; Q15109: AGER; NbExp=2; IntAct=EBI-297353, EBI-1646426; CC P00533; Q9UKV8: AGO2; NbExp=11; IntAct=EBI-297353, EBI-528269; CC P00533; Q09666: AHNAK; NbExp=4; IntAct=EBI-297353, EBI-2555881; CC P00533; O00170: AIP; NbExp=2; IntAct=EBI-297353, EBI-704197; CC P00533; Q02952: AKAP12; NbExp=3; IntAct=EBI-297353, EBI-2562430; CC P00533; P31749: AKT1; NbExp=4; IntAct=EBI-297353, EBI-296087; CC P00533; P49418: AMPH; NbExp=2; IntAct=EBI-297353, EBI-7121510; CC P00533; Q92625: ANKS1A; NbExp=7; IntAct=EBI-297353, EBI-1048612; CC P00533; P04083: ANXA1; NbExp=5; IntAct=EBI-297353, EBI-354007; CC P00533; P07355: ANXA2; NbExp=4; IntAct=EBI-297353, EBI-352622; CC P00533; Q10567: AP1B1; NbExp=4; IntAct=EBI-297353, EBI-1171303; CC P00533; Q96CW1: AP2M1; NbExp=8; IntAct=EBI-297353, EBI-297683; CC P00533; O00213: APBB1; NbExp=4; IntAct=EBI-297353, EBI-81694; CC P00533; Q92870: APBB2; NbExp=7; IntAct=EBI-297353, EBI-79277; CC P00533; O95704: APBB3; NbExp=2; IntAct=EBI-297353, EBI-286427; CC P00533; Q9UKG1: APPL1; NbExp=3; IntAct=EBI-297353, EBI-741243; CC P00533; P49407: ARRB1; NbExp=3; IntAct=EBI-297353, EBI-743313; CC P00533; P32121: ARRB2; NbExp=3; IntAct=EBI-297353, EBI-714559; CC P00533; O14965: AURKA; NbExp=5; IntAct=EBI-297353, EBI-448680; CC P00533; P30530: AXL; NbExp=5; IntAct=EBI-297353, EBI-2850927; CC P00533; Q9UQB8: BAIAP2; NbExp=4; IntAct=EBI-297353, EBI-525456; CC P00533; Q9BXH1: BBC3; NbExp=10; IntAct=EBI-297353, EBI-519884; CC P00533; Q14457: BECN1; NbExp=8; IntAct=EBI-297353, EBI-949378; CC P00533; P51451: BLK; NbExp=3; IntAct=EBI-297353, EBI-2105445; CC P00533; P62158: CALM3; NbExp=6; IntAct=EBI-297353, EBI-397435; CC P00533; P49069: CAMLG; NbExp=3; IntAct=EBI-297353, EBI-1748958; CC P00533; Q03135: CAV1; NbExp=7; IntAct=EBI-297353, EBI-603614; CC P00533; P51636: CAV2; NbExp=3; IntAct=EBI-297353, EBI-603607; CC P00533; P22681: CBL; NbExp=26; IntAct=EBI-297353, EBI-518228; CC P00533; Q16543: CDC37; NbExp=13; IntAct=EBI-297353, EBI-295634; CC P00533; P12830: CDH1; NbExp=4; IntAct=EBI-297353, EBI-727477; CC P00533; P06493: CDK1; NbExp=3; IntAct=EBI-297353, EBI-444308; CC P00533; P23528: CFL1; NbExp=3; IntAct=EBI-297353, EBI-352733; CC P00533; Q9BZP6: CHIA; NbExp=2; IntAct=EBI-297353, EBI-14357960; CC P00533; Q9NSE2: CISH; NbExp=4; IntAct=EBI-297353, EBI-617866; CC P00533; Q7Z7G1: CLNK; NbExp=2; IntAct=EBI-297353, EBI-7878194; CC P00533; Q8IZV2: CMTM8; NbExp=3; IntAct=EBI-297353, EBI-7868911; CC P00533; Q8WXI2: CNKSR2; NbExp=2; IntAct=EBI-297353, EBI-1045119; CC P00533; P46108: CRK; NbExp=4; IntAct=EBI-297353, EBI-886; CC P00533; P46108-1: CRK; NbExp=3; IntAct=EBI-297353, EBI-287556; CC P00533; P46109: CRKL; NbExp=5; IntAct=EBI-297353, EBI-910; CC P00533; P41240: CSK; NbExp=3; IntAct=EBI-297353, EBI-1380630; CC P00533; O60716: CTNND1; NbExp=5; IntAct=EBI-297353, EBI-701927; CC P00533; Q14247: CTTN; NbExp=4; IntAct=EBI-297353, EBI-351886; CC P00533; Q7L591: DOK3; NbExp=2; IntAct=EBI-297353, EBI-2834978; CC P00533; Q6PKX4: DOK6; NbExp=2; IntAct=EBI-297353, EBI-2880244; CC P00533; P01133: EGF; NbExp=29; IntAct=EBI-297353, EBI-640857; CC P00533; P00533: EGFR; NbExp=31; IntAct=EBI-297353, EBI-297353; CC P00533; Q6UW88: EPGN; NbExp=3; IntAct=EBI-297353, EBI-15482510; CC P00533; Q12929: EPS8; NbExp=4; IntAct=EBI-297353, EBI-375576; CC P00533; P04626: ERBB2; NbExp=25; IntAct=EBI-297353, EBI-641062; CC P00533; P21860: ERBB3; NbExp=15; IntAct=EBI-297353, EBI-720706; CC P00533; Q15303: ERBB4; NbExp=4; IntAct=EBI-297353, EBI-80371; CC P00533; P07992: ERCC1; NbExp=21; IntAct=EBI-297353, EBI-750962; CC P00533; O14944: EREG; NbExp=3; IntAct=EBI-297353, EBI-17272224; CC P00533; Q9UJM3: ERRFI1; NbExp=16; IntAct=EBI-297353, EBI-2941912; CC P00533; P03372: ESR1; NbExp=3; IntAct=EBI-297353, EBI-78473; CC P00533; P03372-4: ESR1; NbExp=4; IntAct=EBI-297353, EBI-4309277; CC P00533; Q92731: ESR2; NbExp=8; IntAct=EBI-297353, EBI-78505; CC P00533; Q96A65: EXOC4; NbExp=2; IntAct=EBI-297353, EBI-355383; CC P00533; P15311: EZR; NbExp=3; IntAct=EBI-297353, EBI-1056902; CC P00533; Q9BXW9: FANCD2; NbExp=3; IntAct=EBI-297353, EBI-359343; CC P00533; P09769: FGR; NbExp=3; IntAct=EBI-297353, EBI-1383732; CC P00533; Q13451: FKBP5; NbExp=2; IntAct=EBI-297353, EBI-306914; CC P00533; Q14318: FKBP8; NbExp=4; IntAct=EBI-297353, EBI-724839; CC P00533; Q13480: GAB1; NbExp=5; IntAct=EBI-297353, EBI-517684; CC P00533; Q9UQC2: GAB2; NbExp=3; IntAct=EBI-297353, EBI-975200; CC P00533; P60520: GABARAPL2; NbExp=3; IntAct=EBI-297353, EBI-720116; CC P00533; P47869: GABRA2; NbExp=2; IntAct=EBI-297353, EBI-2685723; CC P00533; P04406: GAPDH; NbExp=7; IntAct=EBI-297353, EBI-354056; CC P00533; Q8NBJ4: GOLM1; NbExp=13; IntAct=EBI-297353, EBI-712073; CC P00533; P17174: GOT1; NbExp=3; IntAct=EBI-297353, EBI-727329; CC P00533; Q14956: GPNMB; NbExp=3; IntAct=EBI-297353, EBI-7250369; CC P00533; Q14956-1: GPNMB; NbExp=2; IntAct=EBI-297353, EBI-16191078; CC P00533; O75791: GRAP2; NbExp=3; IntAct=EBI-297353, EBI-740418; CC P00533; Q13322: GRB10; NbExp=4; IntAct=EBI-297353, EBI-80275; CC P00533; P62993: GRB2; NbExp=59; IntAct=EBI-297353, EBI-401755; CC P00533; P25098: GRK2; NbExp=3; IntAct=EBI-297353, EBI-3904795; CC P00533; Q99075: HBEGF; NbExp=3; IntAct=EBI-297353, EBI-7211558; CC P00533; P08631: HCK; NbExp=3; IntAct=EBI-297353, EBI-346340; CC P00533; Q9UBN7: HDAC6; NbExp=12; IntAct=EBI-297353, EBI-301697; CC P00533; Q8WUI4: HDAC7; NbExp=3; IntAct=EBI-297353, EBI-1048378; CC P00533; P07900: HSP90AA1; NbExp=8; IntAct=EBI-297353, EBI-296047; CC P00533; P08238: HSP90AB1; NbExp=10; IntAct=EBI-297353, EBI-352572; CC P00533; Q6PK50: HSP90AB1; NbExp=2; IntAct=EBI-297353, EBI-9356629; CC P00533; P08107: HSPA1B; NbExp=6; IntAct=EBI-297353, EBI-629985; CC P00533; P34932: HSPA4; NbExp=3; IntAct=EBI-297353, EBI-356933; CC P00533; P11142: HSPA8; NbExp=7; IntAct=EBI-297353, EBI-351896; CC P00533; P38646: HSPA9; NbExp=5; IntAct=EBI-297353, EBI-354932; CC P00533; P17936: IGFBP3; NbExp=3; IntAct=EBI-297353, EBI-715709; CC P00533; P46940: IQGAP1; NbExp=4; IntAct=EBI-297353, EBI-297509; CC P00533; O14654: IRS4; NbExp=2; IntAct=EBI-297353, EBI-356594; CC P00533; Q9NZM3: ITSN2; NbExp=3; IntAct=EBI-297353, EBI-308689; CC P00533; P14923: JUP; NbExp=3; IntAct=EBI-297353, EBI-702484; CC P00533; Q86VI4: LAPTM4B; NbExp=10; IntAct=EBI-297353, EBI-3267258; CC P00533; O43561: LAT; NbExp=3; IntAct=EBI-297353, EBI-1222766; CC P00533; Q13094: LCP2; NbExp=3; IntAct=EBI-297353, EBI-346946; CC P00533; Q96FE5: LINGO1; NbExp=2; IntAct=EBI-297353, EBI-719955; CC P00533; Q96JA1: LRIG1; NbExp=6; IntAct=EBI-297353, EBI-2865191; CC P00533; O94898: LRIG2; NbExp=4; IntAct=EBI-297353, EBI-2830372; CC P00533; Q38SD2: LRRK1; NbExp=2; IntAct=EBI-297353, EBI-1050422; CC P00533; P07948: LYN; NbExp=7; IntAct=EBI-297353, EBI-79452; CC P00533; P07948-1: LYN; NbExp=2; IntAct=EBI-297353, EBI-6895930; CC P00533; Q9BRK4: LZTS2; NbExp=2; IntAct=EBI-297353, EBI-741037; CC P00533; Q12852: MAP3K12; NbExp=3; IntAct=EBI-297353, EBI-710223; CC P00533; Q9UQF2: MAPK8IP1; NbExp=3; IntAct=EBI-297353, EBI-78404; CC P00533; Q13387: MAPK8IP2; NbExp=5; IntAct=EBI-297353, EBI-722813; CC P00533; Q9Y2H9: MAST1; NbExp=3; IntAct=EBI-297353, EBI-3385920; CC P00533; Q9NS73: MBIP; NbExp=3; IntAct=EBI-297353, EBI-741953; CC P00533; P08581: MET; NbExp=8; IntAct=EBI-297353, EBI-1039152; CC P00533; P14174: MIF; NbExp=3; IntAct=EBI-297353, EBI-372712; CC P00533; P15941: MUC1; NbExp=6; IntAct=EBI-297353, EBI-2804728; CC P00533; P16333: NCK1; NbExp=6; IntAct=EBI-297353, EBI-389883; CC P00533; P46934: NEDD4; NbExp=3; IntAct=EBI-297353, EBI-726944; CC P00533; P04150: NR3C1; NbExp=3; IntAct=EBI-297353, EBI-493507; CC P00533; Q16620: NTRK2; NbExp=3; IntAct=EBI-297353, EBI-3904881; CC P00533; P49757: NUMB; NbExp=2; IntAct=EBI-297353, EBI-915016; CC P00533; Q9Y6R0: NUMBL; NbExp=2; IntAct=EBI-297353, EBI-945925; CC P00533; Q13438: OS9; NbExp=3; IntAct=EBI-297353, EBI-725454; CC P00533; Q8WUM4: PDCD6IP; NbExp=4; IntAct=EBI-297353, EBI-310624; CC P00533; P16234: PDGFRA; NbExp=4; IntAct=EBI-297353, EBI-2861522; CC P00533; O00750: PIK3C2B; NbExp=10; IntAct=EBI-297353, EBI-641107; CC P00533; P27986: PIK3R1; NbExp=7; IntAct=EBI-297353, EBI-79464; CC P00533; O00459: PIK3R2; NbExp=5; IntAct=EBI-297353, EBI-346930; CC P00533; Q92569: PIK3R3; NbExp=7; IntAct=EBI-297353, EBI-79893; CC P00533; P19174: PLCG1; NbExp=6; IntAct=EBI-297353, EBI-79387; CC P00533; P16885: PLCG2; NbExp=7; IntAct=EBI-297353, EBI-617403; CC P00533; P35813: PPM1A; NbExp=2; IntAct=EBI-297353, EBI-989143; CC P00533; P17252: PRKCA; NbExp=3; IntAct=EBI-297353, EBI-1383528; CC P00533; Q05397: PTK2; NbExp=7; IntAct=EBI-297353, EBI-702142; CC P00533; Q13882: PTK6; NbExp=2; IntAct=EBI-297353, EBI-1383632; CC P00533; P18031: PTPN1; NbExp=9; IntAct=EBI-297353, EBI-968788; CC P00533; Q06124: PTPN11; NbExp=10; IntAct=EBI-297353, EBI-297779; CC P00533; Q05209: PTPN12; NbExp=5; IntAct=EBI-297353, EBI-2266035; CC P00533; Q9Y2R2: PTPN22; NbExp=3; IntAct=EBI-297353, EBI-1211241; CC P00533; P18433: PTPRA; NbExp=3; IntAct=EBI-297353, EBI-2609645; CC P00533; P23467: PTPRB; NbExp=3; IntAct=EBI-297353, EBI-1265766; CC P00533; P08575: PTPRC; NbExp=2; IntAct=EBI-297353, EBI-1341; CC P00533; P23470: PTPRG; NbExp=3; IntAct=EBI-297353, EBI-2258115; CC P00533; Q9HD43: PTPRH; NbExp=3; IntAct=EBI-297353, EBI-1267176; CC P00533; Q9UJ41: RABGEF1; NbExp=4; IntAct=EBI-297353, EBI-913954; CC P00533; P04049: RAF1; NbExp=3; IntAct=EBI-297353, EBI-365996; CC P00533; Q70E73: RAPH1; NbExp=2; IntAct=EBI-297353, EBI-3940924; CC P00533; P20936: RASA1; NbExp=7; IntAct=EBI-297353, EBI-1026476; CC P00533; Q13671: RIN1; NbExp=3; IntAct=EBI-297353, EBI-366017; CC P00533; Q01973: ROR1; NbExp=8; IntAct=EBI-297353, EBI-6082337; CC P00533; Q92622: RUBCN; NbExp=4; IntAct=EBI-297353, EBI-2952709; CC P00533; P26447: S100A4; NbExp=6; IntAct=EBI-297353, EBI-717058; CC P00533; P61619: SEC61A1; NbExp=2; IntAct=EBI-297353, EBI-358919; CC P00533; Q9UBV2: SEL1L; NbExp=2; IntAct=EBI-297353, EBI-358766; CC P00533; P31947: SFN; NbExp=9; IntAct=EBI-297353, EBI-476295; CC P00533; Q9NRF2: SH2B1; NbExp=4; IntAct=EBI-297353, EBI-310491; CC P00533; Q9UQQ2: SH2B3; NbExp=2; IntAct=EBI-297353, EBI-7879749; CC P00533; Q9BRG2: SH2D3A; NbExp=3; IntAct=EBI-297353, EBI-2339271; CC P00533; O75368: SH3BGRL; NbExp=3; IntAct=EBI-297353, EBI-2854777; CC P00533; Q99962: SH3GL2; NbExp=4; IntAct=EBI-297353, EBI-77938; CC P00533; Q96B97: SH3KBP1; NbExp=4; IntAct=EBI-297353, EBI-346595; CC P00533; P29353: SHC1; NbExp=44; IntAct=EBI-297353, EBI-78835; CC P00533; P29353-7: SHC1; NbExp=4; IntAct=EBI-297353, EBI-9691288; CC P00533; P98077: SHC2; NbExp=3; IntAct=EBI-297353, EBI-7256023; CC P00533; Q6S5L8: SHC4; NbExp=3; IntAct=EBI-297353, EBI-9453524; CC P00533; O75563: SKAP2; NbExp=2; IntAct=EBI-297353, EBI-2483161; CC P00533; Q13239: SLA; NbExp=3; IntAct=EBI-297353, EBI-726214; CC P00533; P13866: SLC5A1; NbExp=3; IntAct=EBI-297353, EBI-1772443; CC P00533; Q07889: SOS1; NbExp=3; IntAct=EBI-297353, EBI-297487; CC P00533; P12931: SRC; NbExp=10; IntAct=EBI-297353, EBI-621482; CC P00533; P42224: STAT1; NbExp=7; IntAct=EBI-297353, EBI-1057697; CC P00533; P40763: STAT3; NbExp=16; IntAct=EBI-297353, EBI-518675; CC P00533; P42229: STAT5A; NbExp=4; IntAct=EBI-297353, EBI-749537; CC P00533; P51692: STAT5B; NbExp=2; IntAct=EBI-297353, EBI-1186119; CC P00533; P31948: STIP1; NbExp=3; IntAct=EBI-297353, EBI-1054052; CC P00533; Q9UNE7: STUB1; NbExp=4; IntAct=EBI-297353, EBI-357085; CC P00533; O43752: STX6; NbExp=3; IntAct=EBI-297353, EBI-2695795; CC P00533; P43405: SYK; NbExp=7; IntAct=EBI-297353, EBI-78302; CC P00533; Q15750: TAB1; NbExp=3; IntAct=EBI-297353, EBI-358643; CC P00533; Q9Y6A5: TACC3; NbExp=3; IntAct=EBI-297353, EBI-2554984; CC P00533; P01135: TGFA; NbExp=4; IntAct=EBI-297353, EBI-1034374; CC P00533; Q9Y490: TLN1; NbExp=2; IntAct=EBI-297353, EBI-2462036; CC P00533; O60603: TLR2; NbExp=3; IntAct=EBI-297353, EBI-973722; CC P00533; Q9Y6Q6-2: TNFRSF11A; NbExp=3; IntAct=EBI-297353, EBI-20899422; CC P00533; Q68CZ2: TNS3; NbExp=5; IntAct=EBI-297353, EBI-1220488; CC P00533; Q8IZW8: TNS4; NbExp=2; IntAct=EBI-297353, EBI-7543499; CC P00533; O75674: TOM1L1; NbExp=6; IntAct=EBI-297353, EBI-712991; CC P00533; Q12933: TRAF2; NbExp=4; IntAct=EBI-297353, EBI-355744; CC P00533; Q71U36: TUBA1A; NbExp=4; IntAct=EBI-297353, EBI-302552; CC P00533; Q13885: TUBB2A; NbExp=2; IntAct=EBI-297353, EBI-711595; CC P00533; P10599: TXN; NbExp=5; IntAct=EBI-297353, EBI-594644; CC P00533; P09936: UCHL1; NbExp=3; IntAct=EBI-297353, EBI-714860; CC P00533; Q8TEY7: USP33; NbExp=2; IntAct=EBI-297353, EBI-719283; CC P00533; Q9P0L0: VAPA; NbExp=4; IntAct=EBI-297353, EBI-1059156; CC P00533; Q9UPY6: WASF3; NbExp=3; IntAct=EBI-297353, EBI-3907133; CC P00533; P07947: YES1; NbExp=3; IntAct=EBI-297353, EBI-515331; CC P00533; P27348: YWHAQ; NbExp=7; IntAct=EBI-297353, EBI-359854; CC P00533; P63104: YWHAZ; NbExp=6; IntAct=EBI-297353, EBI-347088; CC P00533; P43403: ZAP70; NbExp=3; IntAct=EBI-297353, EBI-1211276; CC P00533; Q53FC7; NbExp=3; IntAct=EBI-297353, EBI-9356749; CC P00533; Q96BE0; NbExp=2; IntAct=EBI-297353, EBI-9356686; CC P00533; P62161: Calm3; Xeno; NbExp=6; IntAct=EBI-297353, EBI-397530; CC P00533; P22682: Cbl; Xeno; NbExp=2; IntAct=EBI-297353, EBI-640919; CC P00533; P62994: Grb2; Xeno; NbExp=5; IntAct=EBI-297353, EBI-401775; CC P00533; Q9QZC5: Grb7; Xeno; NbExp=7; IntAct=EBI-297353, EBI-22085551; CC P00533; P97313: Prkdc; Xeno; NbExp=4; IntAct=EBI-297353, EBI-2272005; CC P00533; P20417: Ptpn1; Xeno; NbExp=11; IntAct=EBI-297353, EBI-916819; CC P00533; Q80U62: Rubcn; Xeno; NbExp=2; IntAct=EBI-297353, EBI-3506572; CC P00533; P0DTC2: S; Xeno; NbExp=4; IntAct=EBI-297353, EBI-25474821; CC P00533; Q8K424: Trpv3; Xeno; NbExp=2; IntAct=EBI-297353, EBI-2650739; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:17182860, CC ECO:0000269|PubMed:20462955, ECO:0000269|PubMed:23589287, CC ECO:0000269|PubMed:26918609, ECO:0000269|PubMed:27153536, CC ECO:0000269|PubMed:2790960, ECO:0000269|PubMed:35538033}; Single-pass CC type I membrane protein {ECO:0000269|PubMed:27153536}. Endoplasmic CC reticulum membrane {ECO:0000269|PubMed:27153536}; Single-pass type I CC membrane protein. Golgi apparatus membrane; Single-pass type I membrane CC protein. Nucleus membrane; Single-pass type I membrane protein. CC Endosome {ECO:0000269|PubMed:17182860, ECO:0000269|PubMed:27153536}. CC Endosome membrane. Nucleus {ECO:0000269|PubMed:17115032, CC ECO:0000269|PubMed:17909029, ECO:0000269|PubMed:20551055, CC ECO:0000269|PubMed:20674546}. Note=In response to EGF, translocated CC from the cell membrane to the nucleus via Golgi and ER CC (PubMed:17909029, PubMed:20674546). Endocytosed upon activation by CC ligand (PubMed:17182860, PubMed:17909029, PubMed:27153536, CC PubMed:2790960). Colocalized with GPER1 in the nucleus of estrogen CC agonist-induced cancer-associated fibroblasts (CAF) (PubMed:20551055). CC {ECO:0000269|PubMed:17182860, ECO:0000269|PubMed:17909029, CC ECO:0000269|PubMed:20674546, ECO:0000269|PubMed:27153536, CC ECO:0000269|PubMed:2790960}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; Synonyms=p170; CC IsoId=P00533-1; Sequence=Displayed; CC Name=2; Synonyms=p60, Truncated, TEGFR; CC IsoId=P00533-2; Sequence=VSP_002887, VSP_002888; CC Name=3; Synonyms=p110; CC IsoId=P00533-3; Sequence=VSP_002889, VSP_002890; CC Name=4; CC IsoId=P00533-4; Sequence=VSP_002891, VSP_002892; CC -!- TISSUE SPECIFICITY: Ubiquitously expressed. Isoform 2 is also expressed CC in ovarian cancers. {ECO:0000269|PubMed:17671655}. CC -!- PTM: Phosphorylated on Tyr residues in response to EGF CC (PubMed:20462955, PubMed:27153536). Phosphorylation at Ser-695 is CC partial and occurs only if Thr-693 is phosphorylated. Phosphorylation CC at Thr-678 and Thr-693 by PRKD1 inhibits EGF-induced MAPK8/JNK1 CC activation. Dephosphorylation by PTPRJ prevents endocytosis and CC stabilizes the receptor at the plasma membrane. Autophosphorylation at CC Tyr-1197 is stimulated by methylation at Arg-1199 and enhances CC interaction with PTPN6. Autophosphorylation at Tyr-1092 and/or Tyr-1110 CC recruits STAT3. Dephosphorylated by PTPN1 and PTPN2. CC {ECO:0000269|PubMed:10523301, ECO:0000269|PubMed:12873986, CC ECO:0000269|PubMed:16083266, ECO:0000269|PubMed:19563760, CC ECO:0000269|PubMed:19836242, ECO:0000269|PubMed:20462955, CC ECO:0000269|PubMed:21258366, ECO:0000269|PubMed:2543678, CC ECO:0000269|PubMed:27153536, ECO:0000269|PubMed:3138233}. CC -!- PTM: Monoubiquitinated and polyubiquitinated upon EGF stimulation; CC which does not affect tyrosine kinase activity or signaling capacity CC but may play a role in lysosomal targeting (PubMed:27153536). CC Polyubiquitin linkage is mainly through 'Lys-63', but linkage through CC 'Lys-48', 'Lys-11' and 'Lys-29' also occurs. Deubiquitination by OTUD7B CC prevents degradation. Ubiquitinated by RNF115 and RNF126 (By CC similarity). Ubiquitinated by ZNRF1 or CBL at different lysines in CC response to EGF stimulation; leading to recruitment of the ESCRT CC machinery and subsequent degradation in the lysosomes CC (PubMed:33996800). Deubiquitinated by UCHL1 leading to the inhibition CC of its degradation (By similarity). {ECO:0000250|UniProtKB:Q01279, CC ECO:0000269|PubMed:16543144, ECO:0000269|PubMed:22179831, CC ECO:0000269|PubMed:22298428, ECO:0000269|PubMed:27153536, CC ECO:0000269|PubMed:33996800}. CC -!- PTM: Palmitoylated on Cys residues by ZDHHC20. Palmitoylation inhibits CC internalization after ligand binding, and increases the persistence of CC tyrosine-phosphorylated EGFR at the cell membrane. Palmitoylation CC increases the amplitude and duration of EGFR signaling. CC {ECO:0000269|PubMed:27153536}. CC -!- PTM: Methylated. Methylation at Arg-1199 by PRMT5 stimulates CC phosphorylation at Tyr-1197. {ECO:0000269|PubMed:19563760, CC ECO:0000269|PubMed:19836242, ECO:0000269|PubMed:21258366}. CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting CC tissues of the lung. The most common form of lung cancer is non-small CC cell lung cancer (NSCLC) that can be divided into 3 major histologic CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor CC prognosis. {ECO:0000269|PubMed:15118125, ECO:0000269|PubMed:16533793, CC ECO:0000269|PubMed:16672372}. Note=The gene represented in this entry CC is involved in disease pathogenesis. CC -!- DISEASE: Neonatal nephrocutaneous inflammatory syndrome (NNCIS) CC [MIM:616069]: An autosomal recessive disorder characterized by CC intrauterine growth retardation, premature birth, fragile skin, CC recurrent skin infections and sepsis, failure to thrive, CC nephrocalcinosis, and nephromegaly with tubular dysfunction. Some CC patients have chronic diarrhea, and necrotizing enterocolitis. CC {ECO:0000269|PubMed:24691054}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Wikipedia; Note=EGFR entry; CC URL="https://en.wikipedia.org/wiki/Epidermal_growth_factor_receptor"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X00588; CAA25240.1; -; mRNA. DR EMBL; U95089; AAB53063.1; -; mRNA. DR EMBL; U48722; AAC50802.1; -; mRNA. DR EMBL; U48723; AAC50804.1; -; Genomic_DNA. DR EMBL; U48724; AAC50796.1; -; Genomic_DNA. DR EMBL; U48725; AAC50797.1; -; Genomic_DNA. DR EMBL; U48726; AAC50798.1; -; Genomic_DNA. DR EMBL; U48727; AAC50799.1; -; Genomic_DNA. DR EMBL; U48728; AAC50800.1; -; Genomic_DNA. DR EMBL; U48729; AAC50801.1; -; Genomic_DNA. DR EMBL; AF288738; AAG35786.1; -; Genomic_DNA. DR EMBL; AF288738; AAG35787.1; -; Genomic_DNA. DR EMBL; AF288738; AAG35788.1; -; Genomic_DNA. DR EMBL; AF288738; AAG35789.1; -; Genomic_DNA. DR EMBL; AF288738; AAG35790.1; -; Genomic_DNA. DR EMBL; AY698024; AAT97979.1; -; mRNA. DR EMBL; AY588246; AAS83109.1; -; Genomic_DNA. DR EMBL; AF277897; AAK01080.1; -; mRNA. DR EMBL; AF125253; AAG43240.1; -; mRNA. DR EMBL; AF125539; AAG43243.1; -; Genomic_DNA. DR EMBL; AF125538; AAG43243.1; JOINED; Genomic_DNA. DR EMBL; X06370; CAA29668.1; -; Genomic_DNA. DR EMBL; X00663; CAA25282.1; -; mRNA. DR EMBL; M38425; AAA63171.1; -; Genomic_DNA. DR EMBL; M11234; AAA52370.1; -; Genomic_DNA. DR CCDS; CCDS47587.1; -. [P00533-2] DR CCDS; CCDS5514.1; -. [P00533-1] DR CCDS; CCDS5515.1; -. [P00533-3] DR CCDS; CCDS5516.1; -. [P00533-4] DR PIR; A00641; GQHUE. DR RefSeq; NP_005219.2; NM_005228.4. [P00533-1] DR RefSeq; NP_958439.1; NM_201282.2. [P00533-4] DR RefSeq; NP_958440.1; NM_201283.2. [P00533-2] DR RefSeq; NP_958441.1; NM_201284.2. [P00533-3] DR PDB; 1IVO; X-ray; 3.30 A; A/B=25-646. DR PDB; 1M14; X-ray; 2.60 A; A=695-1022. DR PDB; 1M17; X-ray; 2.60 A; A=695-1022. DR PDB; 1MOX; X-ray; 2.50 A; A/B=25-525. DR PDB; 1NQL; X-ray; 2.80 A; A=25-642. DR PDB; 1XKK; X-ray; 2.40 A; A=695-1022. DR PDB; 1YY9; X-ray; 2.60 A; A=25-642. DR PDB; 1Z9I; NMR; -; A=669-721. DR PDB; 2EB2; X-ray; 2.50 A; A=695-1022. DR PDB; 2EB3; X-ray; 2.84 A; A=695-1022. DR PDB; 2GS2; X-ray; 2.80 A; A=696-1022. DR PDB; 2GS6; X-ray; 2.60 A; A=696-1022. DR PDB; 2GS7; X-ray; 2.60 A; A/B=696-1022. DR PDB; 2ITN; X-ray; 2.47 A; A=696-1022. DR PDB; 2ITO; X-ray; 3.25 A; A=696-1022. DR PDB; 2ITP; X-ray; 2.74 A; A=696-1022. DR PDB; 2ITQ; X-ray; 2.68 A; A=696-1022. DR PDB; 2ITT; X-ray; 2.73 A; A=696-1022. DR PDB; 2ITU; X-ray; 2.80 A; A=696-1022. DR PDB; 2ITV; X-ray; 2.47 A; A=696-1022. DR PDB; 2ITW; X-ray; 2.88 A; A=696-1022. DR PDB; 2ITX; X-ray; 2.98 A; A=696-1022. DR PDB; 2ITY; X-ray; 3.42 A; A=696-1022. DR PDB; 2ITZ; X-ray; 2.72 A; A=696-1022. DR PDB; 2J5E; X-ray; 3.10 A; A=696-1022. DR PDB; 2J5F; X-ray; 3.00 A; A=696-1022. DR PDB; 2J6M; X-ray; 3.10 A; A=696-1022. DR PDB; 2JIT; X-ray; 3.10 A; A/B=696-1022. DR PDB; 2JIU; X-ray; 3.05 A; A/B=695-1022. DR PDB; 2JIV; X-ray; 3.50 A; A/B=695-1022. DR PDB; 2KS1; NMR; -; B=634-677. DR PDB; 2M0B; NMR; -; A/B=634-677. DR PDB; 2M20; NMR; -; A/B=642-697. DR PDB; 2N5S; NMR; -; A=642-690. DR PDB; 2RF9; X-ray; 3.50 A; A/B=696-1022. DR PDB; 2RFD; X-ray; 3.60 A; A/B=702-1022. DR PDB; 2RFE; X-ray; 2.90 A; A/B/C/D=702-1022. DR PDB; 2RGP; X-ray; 2.00 A; A=702-1016. DR PDB; 3B2U; X-ray; 2.58 A; A/B/E/I/M/P/S/V=335-538. DR PDB; 3B2V; X-ray; 3.30 A; A=25-642. DR PDB; 3BEL; X-ray; 2.30 A; A=702-1016. DR PDB; 3BUO; X-ray; 2.60 A; A/C=1063-1075. DR PDB; 3C09; X-ray; 3.20 A; A/D=336-538. DR PDB; 3G5V; X-ray; 2.00 A; C=311-326. DR PDB; 3G5Y; X-ray; 1.59 A; E=311-326. DR PDB; 3GOP; X-ray; 2.80 A; A=669-1022. DR PDB; 3GT8; X-ray; 2.96 A; A/B/C/D=696-1022. DR PDB; 3IKA; X-ray; 2.90 A; A/B=694-1022. DR PDB; 3LZB; X-ray; 2.70 A; A/B/C/D/E/F/G/H=696-983. DR PDB; 3NJP; X-ray; 3.30 A; A/B=25-638. DR PDB; 3OB2; X-ray; 2.10 A; A=1063-1074. DR PDB; 3OP0; X-ray; 2.52 A; C/D=1066-1076. DR PDB; 3P0Y; X-ray; 1.80 A; A=334-538. DR PDB; 3PFV; X-ray; 2.27 A; C/D=1066-1076. DR PDB; 3POZ; X-ray; 1.50 A; A=696-1022. DR PDB; 3QWQ; X-ray; 2.75 A; A=1-642. DR PDB; 3UG1; X-ray; 2.75 A; A=695-1022. DR PDB; 3UG2; X-ray; 2.50 A; A=695-1022. DR PDB; 3VJN; X-ray; 2.34 A; A=695-1022. DR PDB; 3VJO; X-ray; 2.64 A; A=695-1022. DR PDB; 3VRP; X-ray; 1.52 A; B=1062-1074. DR PDB; 3VRR; X-ray; 2.00 A; C=1062-1074. DR PDB; 3W2O; X-ray; 2.35 A; A=698-1022. DR PDB; 3W2P; X-ray; 2.05 A; A=698-1022. DR PDB; 3W2Q; X-ray; 2.20 A; A=698-1022. DR PDB; 3W2R; X-ray; 2.05 A; A=698-1022. DR PDB; 3W2S; X-ray; 1.90 A; A=696-1022. DR PDB; 3W32; X-ray; 1.80 A; A=696-1022. DR PDB; 3W33; X-ray; 1.70 A; A=696-1022. DR PDB; 4G5J; X-ray; 2.80 A; A=696-1022. DR PDB; 4G5P; X-ray; 3.17 A; A/B=696-1022. DR PDB; 4HJO; X-ray; 2.75 A; A=696-1022. DR PDB; 4I1Z; X-ray; 3.00 A; A=695-1022. DR PDB; 4I20; X-ray; 3.34 A; A=695-1022. DR PDB; 4I21; X-ray; 3.37 A; A/B=695-1022. DR PDB; 4I22; X-ray; 1.71 A; A=695-1022. DR PDB; 4I23; X-ray; 2.80 A; A=695-1022. DR PDB; 4I24; X-ray; 1.80 A; A/B=695-1022. DR PDB; 4JQ7; X-ray; 2.73 A; A=696-1021. DR PDB; 4JQ8; X-ray; 2.83 A; A=696-1021. DR PDB; 4JR3; X-ray; 2.70 A; A=696-1021. DR PDB; 4JRV; X-ray; 2.80 A; A=696-1021. DR PDB; 4KRL; X-ray; 2.85 A; A=335-538. DR PDB; 4KRM; X-ray; 2.66 A; A/C/E/G/I/K=335-538. DR PDB; 4KRO; X-ray; 3.05 A; A=25-642. DR PDB; 4KRP; X-ray; 2.82 A; A=25-642. DR PDB; 4LI5; X-ray; 2.64 A; A=696-1020. DR PDB; 4LL0; X-ray; 4.00 A; A/B=694-1022. DR PDB; 4LQM; X-ray; 2.50 A; A=694-1022. DR PDB; 4LRM; X-ray; 3.53 A; A/B/C/D/E=694-1022. DR PDB; 4R3P; X-ray; 2.90 A; A=696-1018. DR PDB; 4R3R; X-ray; 3.25 A; A=696-1018. DR PDB; 4R5S; X-ray; 3.00 A; A=696-1022. DR PDB; 4RIW; X-ray; 3.10 A; B/D=682-1022. DR PDB; 4RIX; X-ray; 3.10 A; B/D=682-1022. DR PDB; 4RIY; X-ray; 2.98 A; B/D=682-1022. DR PDB; 4RJ4; X-ray; 2.78 A; A=695-1022. DR PDB; 4RJ5; X-ray; 3.10 A; A=695-1022. DR PDB; 4RJ6; X-ray; 2.70 A; A=695-1022. DR PDB; 4RJ7; X-ray; 2.55 A; A=695-1022. DR PDB; 4RJ8; X-ray; 2.50 A; A=695-1022. DR PDB; 4TKS; X-ray; 3.20 A; A=695-1022. DR PDB; 4UIP; X-ray; 2.95 A; A=26-637. DR PDB; 4UV7; X-ray; 2.10 A; A=25-645. DR PDB; 4WD5; X-ray; 3.30 A; A/B=694-1022. DR PDB; 4WKQ; X-ray; 1.85 A; A=696-1022. DR PDB; 4WRG; X-ray; 1.90 A; A=696-1022. DR PDB; 4ZAU; X-ray; 2.80 A; A=696-1022. DR PDB; 4ZJV; X-ray; 2.70 A; A/B=695-1022. DR PDB; 4ZSE; X-ray; 1.97 A; A/B/C/D=695-1022. DR PDB; 5C8K; X-ray; 3.00 A; A=695-1022. DR PDB; 5C8M; X-ray; 2.90 A; A=695-1022. DR PDB; 5C8N; X-ray; 2.40 A; A=695-1022. DR PDB; 5CAL; X-ray; 2.70 A; A=695-1022. DR PDB; 5CAN; X-ray; 2.80 A; A=695-1022. DR PDB; 5CAO; X-ray; 2.60 A; A=695-1022. DR PDB; 5CAP; X-ray; 2.40 A; A=695-1022. DR PDB; 5CAQ; X-ray; 2.50 A; A=695-1022. DR PDB; 5CAS; X-ray; 2.10 A; A=695-1022. DR PDB; 5CAU; X-ray; 2.25 A; A=695-1022. DR PDB; 5CAV; X-ray; 2.73 A; A=695-1022. DR PDB; 5CNN; X-ray; 1.90 A; A/B=696-1042. DR PDB; 5CNO; X-ray; 1.55 A; A/B/X=696-1022. DR PDB; 5CZH; X-ray; 2.80 A; A=694-1022. DR PDB; 5CZI; X-ray; 2.60 A; A=694-1022. DR PDB; 5D41; X-ray; 2.31 A; A/B=695-1022. DR PDB; 5EDP; X-ray; 2.90 A; A=695-1022. DR PDB; 5EDQ; X-ray; 2.80 A; A=695-1022. DR PDB; 5EDR; X-ray; 2.60 A; A=695-1022. DR PDB; 5EM5; X-ray; 2.65 A; A=695-1022. DR PDB; 5EM6; X-ray; 2.78 A; A=695-1022. DR PDB; 5EM7; X-ray; 2.81 A; A=695-1022. DR PDB; 5EM8; X-ray; 2.80 A; A=695-1022. DR PDB; 5FED; X-ray; 2.65 A; A=696-1022. DR PDB; 5FEE; X-ray; 2.70 A; A=696-1022. DR PDB; 5FEQ; X-ray; 3.40 A; A=696-1022. DR PDB; 5GMP; X-ray; 2.80 A; A=696-1022. DR PDB; 5GNK; X-ray; 1.80 A; A=696-988. DR PDB; 5GTY; X-ray; 3.14 A; A/B/C/D/E/F/G/H=696-1022. DR PDB; 5GTZ; X-ray; 3.00 A; A=696-1022. DR PDB; 5HCX; X-ray; 2.60 A; A=696-1022. DR PDB; 5HCY; X-ray; 2.46 A; A=696-1022. DR PDB; 5HCZ; X-ray; 2.62 A; A=696-1022. DR PDB; 5HG5; X-ray; 1.52 A; A=695-1022. DR PDB; 5HG7; X-ray; 1.85 A; A=695-1022. DR PDB; 5HG8; X-ray; 1.42 A; A=695-1022. DR PDB; 5HG9; X-ray; 2.15 A; A=695-1022. DR PDB; 5HIB; X-ray; 2.85 A; A=695-1022. DR PDB; 5HIC; X-ray; 2.60 A; A=695-1022. DR PDB; 5J9Y; X-ray; 2.80 A; A=697-1019. DR PDB; 5J9Z; X-ray; 2.50 A; A=696-1020. DR PDB; 5JEB; X-ray; 3.30 A; A=696-1022. DR PDB; 5LV6; NMR; -; A/B=634-677. DR PDB; 5SX4; X-ray; 2.80 A; M/N=335-525. DR PDB; 5SX5; X-ray; 2.50 A; M/N=335-525. DR PDB; 5U8L; X-ray; 1.60 A; A=695-1022. DR PDB; 5UG8; X-ray; 1.46 A; A=695-1022. DR PDB; 5UG9; X-ray; 1.33 A; A=695-1022. DR PDB; 5UGA; X-ray; 1.82 A; A=695-1022. DR PDB; 5UGB; X-ray; 2.53 A; A=695-1022. DR PDB; 5UGC; X-ray; 1.58 A; A=695-1022. DR PDB; 5UWD; X-ray; 3.06 A; A=695-1022. DR PDB; 5WB7; X-ray; 2.94 A; A/B/C/D=25-525. DR PDB; 5WB8; X-ray; 3.00 A; A/D=25-525. DR PDB; 5X26; X-ray; 2.95 A; A=696-1022. DR PDB; 5X27; X-ray; 2.95 A; A=696-1022. DR PDB; 5X28; X-ray; 2.95 A; A=696-1022. DR PDB; 5X2A; X-ray; 1.85 A; A/B/C/D=696-1022. DR PDB; 5X2C; X-ray; 2.05 A; A/B=696-1022. DR PDB; 5X2F; X-ray; 2.20 A; A/B/C/D=696-1022. DR PDB; 5X2K; X-ray; 3.20 A; A=696-1022. DR PDB; 5XDK; X-ray; 2.35 A; A=696-1022. DR PDB; 5XDL; X-ray; 2.70 A; A=696-1022. DR PDB; 5XGM; X-ray; 2.95 A; A=696-1022. DR PDB; 5XGN; X-ray; 3.00 A; A/B=696-1022. DR PDB; 5XWD; X-ray; 2.89 A; A=1-643. DR PDB; 5Y25; X-ray; 3.10 A; A=698-1022. DR PDB; 5Y9T; X-ray; 3.25 A; A=695-1022. DR PDB; 5YU9; X-ray; 1.95 A; A/B/C/D=696-1022. DR PDB; 5ZTO; X-ray; 2.65 A; A=696-1022. DR PDB; 5ZWJ; X-ray; 2.90 A; A=675-1022. DR PDB; 6ARU; X-ray; 3.20 A; A=25-640. DR PDB; 6B3S; X-ray; 2.80 A; A/B/E/I=335-538. DR PDB; 6D8E; X-ray; 2.54 A; A=696-1022. DR PDB; 6DUK; X-ray; 2.20 A; A/B/C/D/E/F=695-1022. DR PDB; 6JRJ; X-ray; 2.94 A; A=696-1022. DR PDB; 6JRK; X-ray; 2.80 A; A=696-1022. DR PDB; 6JRX; X-ray; 2.20 A; A=696-1022. DR PDB; 6JWL; X-ray; 2.55 A; A=696-1022. DR PDB; 6JX0; X-ray; 2.53 A; A=696-1022. DR PDB; 6JX4; X-ray; 2.53 A; A=696-1022. DR PDB; 6JXT; X-ray; 2.31 A; A=696-1022. DR PDB; 6JZ0; X-ray; 2.86 A; A=696-1021. DR PDB; 6LUB; X-ray; 2.31 A; A=695-1022. DR PDB; 6LUD; X-ray; 2.05 A; A=695-1022. DR PDB; 6P1D; X-ray; 2.40 A; A/B/C/D=696-1022. DR PDB; 6P1L; X-ray; 2.80 A; A/B/C/D=696-1022. DR PDB; 6P8Q; X-ray; 1.90 A; A/B/C/D=696-1022. DR PDB; 6S89; X-ray; 2.70 A; A=695-1022. DR PDB; 6S8A; X-ray; 2.60 A; A=695-1022. DR PDB; 6S9B; X-ray; 3.25 A; A=697-1022. DR PDB; 6S9C; X-ray; 2.73 A; A=696-1022. DR PDB; 6S9D; X-ray; 2.67 A; A=696-1022. DR PDB; 6TFU; X-ray; 2.00 A; A/B=695-1022. DR PDB; 6TFV; X-ray; 1.50 A; A/B=695-1022. DR PDB; 6TFW; X-ray; 2.00 A; A/B=695-1022. DR PDB; 6TFY; X-ray; 1.70 A; A/B=695-1022. DR PDB; 6TFZ; X-ray; 1.80 A; A/B=695-1022. DR PDB; 6TG0; X-ray; 1.50 A; A/B=695-1022. DR PDB; 6TG1; X-ray; 1.60 A; A/B=695-1022. DR PDB; 6V5N; X-ray; 2.40 A; A/B/C/D=695-1022. DR PDB; 6V5P; X-ray; 2.30 A; A/B/C/D=695-1022. DR PDB; 6V66; X-ray; 1.79 A; A/B/C/D=696-1022. DR PDB; 6V6K; X-ray; 2.20 A; A/B/C/D/E/F/G/H=696-1022. DR PDB; 6V6O; X-ray; 2.10 A; A/B/C/D/E/F/G/H=696-1022. DR PDB; 6VH4; X-ray; 2.80 A; A=696-1022. DR PDB; 6VHN; X-ray; 2.40 A; A=696-1022. DR PDB; 6VHP; X-ray; 3.60 A; A=696-1022. DR PDB; 6WA2; X-ray; 2.40 A; A/B/C/D=695-1022. DR PDB; 6WAK; X-ray; 2.40 A; A/B/C/D=695-1022. DR PDB; 6WXN; X-ray; 1.76 A; A/B/C/D=695-1022. DR PDB; 6XL4; X-ray; 2.06 A; A/B/C/D=695-1022. DR PDB; 6Z4B; X-ray; 2.50 A; A/B=695-1022. DR PDB; 6Z4D; X-ray; 2.00 A; A/B=695-1022. DR PDB; 7A2A; X-ray; 1.90 A; A/B=695-1022. DR PDB; 7A6I; X-ray; 2.40 A; A=695-1022. DR PDB; 7A6J; X-ray; 2.00 A; A/B=695-1022. DR PDB; 7A6K; X-ray; 2.00 A; A/B/C/D=695-1022. DR PDB; 7AEI; X-ray; 2.65 A; A=695-1022. DR PDB; 7AEM; X-ray; 2.65 A; A=695-1022. DR PDB; 7B85; X-ray; 2.50 A; A=695-1022. DR PDB; 7ER2; X-ray; 2.66 A; A=696-1022. DR PDB; 7JXI; X-ray; 3.00 A; A/B/C/D=695-1022. DR PDB; 7JXK; X-ray; 3.10 A; A/B/C/D/E/F=695-1022. DR PDB; 7JXL; X-ray; 2.40 A; A/B/C/D=695-1022. DR PDB; 7JXM; X-ray; 2.19 A; A/B/C/D=695-1022. DR PDB; 7JXP; X-ray; 2.16 A; A/B/C/D/E/F=695-1022. DR PDB; 7JXQ; X-ray; 1.83 A; A/B/C/D=695-1022. DR PDB; 7JXW; X-ray; 2.50 A; A/B/C/D=695-1022. DR PDB; 7K1H; X-ray; 2.60 A; A/B/C/D/E/F=695-1022. DR PDB; 7K1I; X-ray; 3.20 A; A=695-1022. DR PDB; 7KXZ; X-ray; 2.40 A; A=695-1022. DR PDB; 7KY0; X-ray; 3.10 A; A/B/C/D=695-1022. DR PDB; 7LEN; X-ray; 2.90 A; A/B=25-525. DR PDB; 7LFR; X-ray; 3.20 A; A/B=25-525. DR PDB; 7LFS; X-ray; 3.50 A; A/B/C/D=25-525. DR PDB; 7LG8; X-ray; 2.93 A; A/B/C/D=695-1022. DR PDB; 7LGS; X-ray; 3.10 A; A/B/C/D=696-1022. DR PDB; 7LTX; X-ray; 2.30 A; A/B/C/D=695-1022. DR PDB; 7OM4; X-ray; 6.05 A; A=25-645. DR PDB; 7OXB; X-ray; 2.56 A; A=696-1020. DR PDB; 7SI1; X-ray; 1.60 A; A=695-1022. DR PDB; 7SYD; EM; 3.10 A; A/B=1-1210. DR PDB; 7SYE; EM; 3.30 A; A/B=1-1210. DR PDB; 7SZ0; EM; 3.30 A; A/B=1-1210. DR PDB; 7SZ1; EM; 3.40 A; A/B=1-1210. DR PDB; 7SZ5; EM; 3.60 A; A/B=1-1210. DR PDB; 7SZ7; EM; 3.40 A; A/B=1-1210. DR PDB; 7T4I; X-ray; 2.61 A; A=696-1022. DR PDB; 7T4J; X-ray; 2.20 A; A/B=696-1022. DR PDB; 7TVD; X-ray; 2.96 A; A=696-1022. DR PDB; 7U98; X-ray; 3.42 A; A/B/C/D=695-1022. DR PDB; 7U99; X-ray; 2.50 A; A=695-1022. DR PDB; 7U9A; X-ray; 2.60 A; A=695-1022. DR PDB; 7UKV; X-ray; 2.40 A; A=695-1022. DR PDB; 7UKW; X-ray; 2.60 A; A/B/C/D=695-1022. DR PDB; 7VRA; X-ray; 2.41 A; A=696-1022. DR PDB; 7VRE; X-ray; 2.51 A; A=696-1022. DR PDB; 7ZYM; X-ray; 2.50 A; A=695-1022. DR PDB; 7ZYN; X-ray; 2.30 A; A=695-1022. DR PDB; 7ZYP; X-ray; 2.80 A; A=695-1022. DR PDB; 7ZYQ; X-ray; 2.10 A; A/B=695-1022. DR PDB; 8A27; X-ray; 1.07 A; A=700-1022. DR PDB; 8A2A; X-ray; 1.43 A; A=700-1022. DR PDB; 8A2B; X-ray; 1.69 A; A=700-1022. DR PDB; 8A2D; X-ray; 1.11 A; A=700-1022. DR PDB; 8D73; X-ray; 2.17 A; A/B=695-1022. DR PDB; 8D76; X-ray; 2.40 A; A/B=695-1022. DR PDB; 8DSW; X-ray; 2.39 A; A=696-1022. DR PDB; 8EME; X-ray; 3.32 A; A/B=695-1022. DR PDB; 8F1H; X-ray; 2.80 A; A=695-1022. DR PDB; 8F1W; X-ray; 3.20 A; A/B/C/D=695-1022. DR PDB; 8F1X; X-ray; 2.30 A; A=695-1022. DR PDB; 8F1Y; X-ray; 2.75 A; A=695-1022. DR PDB; 8F1Z; X-ray; 2.40 A; A=695-1022. DR PDB; 8FV3; X-ray; 2.10 A; A/B/C/D=695-1022. DR PDB; 8FV4; X-ray; 2.20 A; A/B/C/D=695-1022. DR PDB; 8G63; X-ray; 2.50 A; A=696-1022. DR PDB; 8GB4; X-ray; 2.59 A; A/B/C/D=695-1022. DR PDB; 8GK5; X-ray; 2.30 A; A/B/C/D=695-1022. DR PDB; 8H7X; X-ray; 3.40 A; A/B=696-1022. DR PDB; 8HGO; EM; 3.31 A; A=1-683. DR PDB; 8HGP; EM; 4.53 A; A=1-683. DR PDB; 8HGS; EM; 3.81 A; A/B=1-683. DR PDB; 8HV1; X-ray; 2.40 A; A=695-1022. DR PDB; 8HV2; X-ray; 2.80 A; A=694-1022. DR PDB; 8HV3; X-ray; 2.40 A; A=695-1022. DR PDB; 8HV4; X-ray; 2.20 A; A=695-1022. DR PDB; 8HV5; X-ray; 2.20 A; A=695-1022. DR PDB; 8HV6; X-ray; 2.20 A; A=695-1022. DR PDB; 8HV7; X-ray; 2.69 A; A=695-1022. DR PDB; 8HV8; X-ray; 2.40 A; A=695-1022. DR PDB; 8HV9; X-ray; 2.50 A; A=695-1022. DR PDB; 8HVA; X-ray; 2.77 A; A=695-1022. DR PDB; 8HY7; X-ray; 2.91 A; A=695-1022. DR PDB; 8KFQ; X-ray; 3.22 A; A=697-1018. DR PDB; 8PNZ; X-ray; 2.51 A; A=695-1022. DR PDB; 8PO0; X-ray; 2.52 A; A=695-1022. DR PDB; 8PO1; X-ray; 2.11 A; A=695-1022. DR PDB; 8PO2; X-ray; 2.28 A; A/B/D=695-1022. DR PDB; 8PO3; X-ray; 2.13 A; A=695-1022. DR PDB; 8PO4; X-ray; 1.62 A; A/B=695-1022. DR PDB; 8S1M; X-ray; 2.05 A; A=1076-1099. DR PDB; 8SC7; X-ray; 1.98 A; A=696-1022. DR PDB; 8TJL; X-ray; 2.70 A; A=695-1022. DR PDB; 8TO3; X-ray; 2.49 A; A/B/C/D=695-1022. DR PDB; 8TO4; X-ray; 2.99 A; A/B/C/D=695-1022. DR PDB; 8UKV; X-ray; 2.94 A; A/B=298-642. DR PDB; 8UKW; X-ray; 2.39 A; A/B=298-642. DR PDB; 8UKX; X-ray; 3.30 A; A=298-642. DR PDB; 8WD4; X-ray; 2.55 A; A=696-1022. DR PDB; 9BY4; X-ray; 2.31 A; A=696-1022. DR PDB; 9BY6; X-ray; 2.55 A; A=696-1022. DR PDB; 9D3V; X-ray; 2.32 A; A=696-1022. DR PDB; 9D3W; X-ray; 2.53 A; A=696-1022. DR PDB; 9DF2; X-ray; 2.50 A; A=696-1022. DR PDB; 9DF3; X-ray; 1.68 A; A=696-1022. DR PDB; 9DF4; X-ray; 1.78 A; A=696-1022. DR PDB; 9EWS; X-ray; 2.44 A; A=695-1022. DR PDB; 9EWT; X-ray; 3.02 A; A/B=695-1022. DR PDB; 9FQP; X-ray; 2.50 A; A=695-1022. DR PDB; 9FQS; X-ray; 1.78 A; A=695-1022. DR PDB; 9FRD; X-ray; 2.06 A; A=696-1022. DR PDB; 9GC4; X-ray; 2.42 A; A/B/D=695-1022. DR PDB; 9GC5; X-ray; 1.91 A; A/B=695-1022. DR PDB; 9GC6; X-ray; 1.90 A; A/B=695-1022. DR PDB; 9GDV; X-ray; 2.22 A; A/B=695-1022. DR PDB; 9GI9; X-ray; 3.12 A; A=696-1022. DR PDB; 9GL7; X-ray; 1.88 A; A=695-1022. DR PDB; 9GL8; X-ray; 1.63 A; A=695-1022. DR PDB; 9GL9; X-ray; 2.15 A; A=696-1022. DR PDB; 9H46; X-ray; 3.16 A; A=696-1022. DR PDB; 9HBO; X-ray; 2.45 A; A/B=695-1022. DR PDB; 9IP7; EM; 3.21 A; A=25-645. DR PDB; 9IP8; EM; 3.91 A; A=25-645. DR PDB; 9IP9; EM; 3.64 A; A=25-645. DR PDB; 9IPA; EM; 3.85 A; A=25-645. DR PDB; 9IPB; EM; 2.93 A; A=25-645. DR PDB; 9IPC; EM; 3.40 A; A=25-645. DR PDB; 9IPD; EM; 3.29 A; A=25-645. DR PDB; 9IPE; EM; 3.31 A; A=25-645. DR PDBsum; 1IVO; -. DR PDBsum; 1M14; -. DR PDBsum; 1M17; -. DR PDBsum; 1MOX; -. DR PDBsum; 1NQL; -. DR PDBsum; 1XKK; -. DR PDBsum; 1YY9; -. DR PDBsum; 1Z9I; -. DR PDBsum; 2EB2; -. DR PDBsum; 2EB3; -. DR PDBsum; 2GS2; -. DR PDBsum; 2GS6; -. DR PDBsum; 2GS7; -. DR PDBsum; 2ITN; -. DR PDBsum; 2ITO; -. DR PDBsum; 2ITP; -. DR PDBsum; 2ITQ; -. DR PDBsum; 2ITT; -. DR PDBsum; 2ITU; -. DR PDBsum; 2ITV; -. DR PDBsum; 2ITW; -. DR PDBsum; 2ITX; -. DR PDBsum; 2ITY; -. DR PDBsum; 2ITZ; -. DR PDBsum; 2J5E; -. DR PDBsum; 2J5F; -. DR PDBsum; 2J6M; -. DR PDBsum; 2JIT; -. DR PDBsum; 2JIU; -. DR PDBsum; 2JIV; -. DR PDBsum; 2KS1; -. DR PDBsum; 2M0B; -. DR PDBsum; 2M20; -. DR PDBsum; 2N5S; -. DR PDBsum; 2RF9; -. DR PDBsum; 2RFD; -. DR PDBsum; 2RFE; -. DR PDBsum; 2RGP; -. DR PDBsum; 3B2U; -. DR PDBsum; 3B2V; -. DR PDBsum; 3BEL; -. DR PDBsum; 3BUO; -. DR PDBsum; 3C09; -. DR PDBsum; 3G5V; -. DR PDBsum; 3G5Y; -. DR PDBsum; 3GOP; -. DR PDBsum; 3GT8; -. DR PDBsum; 3IKA; -. DR PDBsum; 3LZB; -. DR PDBsum; 3NJP; -. DR PDBsum; 3OB2; -. DR PDBsum; 3OP0; -. DR PDBsum; 3P0Y; -. DR PDBsum; 3PFV; -. DR PDBsum; 3POZ; -. DR PDBsum; 3QWQ; -. DR PDBsum; 3UG1; -. DR PDBsum; 3UG2; -. DR PDBsum; 3VJN; -. DR PDBsum; 3VJO; -. DR PDBsum; 3VRP; -. DR PDBsum; 3VRR; -. DR PDBsum; 3W2O; -. DR PDBsum; 3W2P; -. DR PDBsum; 3W2Q; -. DR PDBsum; 3W2R; -. DR PDBsum; 3W2S; -. DR PDBsum; 3W32; -. DR PDBsum; 3W33; -. DR PDBsum; 4G5J; -. DR PDBsum; 4G5P; -. DR PDBsum; 4HJO; -. DR PDBsum; 4I1Z; -. DR PDBsum; 4I20; -. DR PDBsum; 4I21; -. DR PDBsum; 4I22; -. DR PDBsum; 4I23; -. DR PDBsum; 4I24; -. DR PDBsum; 4JQ7; -. DR PDBsum; 4JQ8; -. DR PDBsum; 4JR3; -. DR PDBsum; 4JRV; -. DR PDBsum; 4KRL; -. DR PDBsum; 4KRM; -. DR PDBsum; 4KRO; -. DR PDBsum; 4KRP; -. DR PDBsum; 4LI5; -. DR PDBsum; 4LL0; -. DR PDBsum; 4LQM; -. DR PDBsum; 4LRM; -. DR PDBsum; 4R3P; -. DR PDBsum; 4R3R; -. DR PDBsum; 4R5S; -. DR PDBsum; 4RIW; -. DR PDBsum; 4RIX; -. DR PDBsum; 4RIY; -. DR PDBsum; 4RJ4; -. DR PDBsum; 4RJ5; -. DR PDBsum; 4RJ6; -. DR PDBsum; 4RJ7; -. DR PDBsum; 4RJ8; -. DR PDBsum; 4TKS; -. DR PDBsum; 4UIP; -. DR PDBsum; 4UV7; -. DR PDBsum; 4WD5; -. DR PDBsum; 4WKQ; -. DR PDBsum; 4WRG; -. DR PDBsum; 4ZAU; -. DR PDBsum; 4ZJV; -. DR PDBsum; 4ZSE; -. DR PDBsum; 5C8K; -. DR PDBsum; 5C8M; -. DR PDBsum; 5C8N; -. DR PDBsum; 5CAL; -. DR PDBsum; 5CAN; -. DR PDBsum; 5CAO; -. DR PDBsum; 5CAP; -. DR PDBsum; 5CAQ; -. DR PDBsum; 5CAS; -. DR PDBsum; 5CAU; -. DR PDBsum; 5CAV; -. DR PDBsum; 5CNN; -. DR PDBsum; 5CNO; -. DR PDBsum; 5CZH; -. DR PDBsum; 5CZI; -. DR PDBsum; 5D41; -. DR PDBsum; 5EDP; -. DR PDBsum; 5EDQ; -. DR PDBsum; 5EDR; -. DR PDBsum; 5EM5; -. DR PDBsum; 5EM6; -. DR PDBsum; 5EM7; -. DR PDBsum; 5EM8; -. DR PDBsum; 5FED; -. DR PDBsum; 5FEE; -. DR PDBsum; 5FEQ; -. DR PDBsum; 5GMP; -. DR PDBsum; 5GNK; -. DR PDBsum; 5GTY; -. DR PDBsum; 5GTZ; -. DR PDBsum; 5HCX; -. DR PDBsum; 5HCY; -. DR PDBsum; 5HCZ; -. DR PDBsum; 5HG5; -. DR PDBsum; 5HG7; -. DR PDBsum; 5HG8; -. DR PDBsum; 5HG9; -. DR PDBsum; 5HIB; -. DR PDBsum; 5HIC; -. DR PDBsum; 5J9Y; -. DR PDBsum; 5J9Z; -. DR PDBsum; 5JEB; -. DR PDBsum; 5LV6; -. DR PDBsum; 5SX4; -. DR PDBsum; 5SX5; -. DR PDBsum; 5U8L; -. DR PDBsum; 5UG8; -. DR PDBsum; 5UG9; -. DR PDBsum; 5UGA; -. DR PDBsum; 5UGB; -. DR PDBsum; 5UGC; -. DR PDBsum; 5UWD; -. DR PDBsum; 5WB7; -. DR PDBsum; 5WB8; -. DR PDBsum; 5X26; -. DR PDBsum; 5X27; -. DR PDBsum; 5X28; -. DR PDBsum; 5X2A; -. DR PDBsum; 5X2C; -. DR PDBsum; 5X2F; -. DR PDBsum; 5X2K; -. DR PDBsum; 5XDK; -. DR PDBsum; 5XDL; -. DR PDBsum; 5XGM; -. DR PDBsum; 5XGN; -. DR PDBsum; 5XWD; -. DR PDBsum; 5Y25; -. DR PDBsum; 5Y9T; -. DR PDBsum; 5YU9; -. DR PDBsum; 5ZTO; -. DR PDBsum; 5ZWJ; -. DR PDBsum; 6ARU; -. DR PDBsum; 6B3S; -. DR PDBsum; 6D8E; -. DR PDBsum; 6DUK; -. DR PDBsum; 6JRJ; -. DR PDBsum; 6JRK; -. DR PDBsum; 6JRX; -. DR PDBsum; 6JWL; -. DR PDBsum; 6JX0; -. DR PDBsum; 6JX4; -. DR PDBsum; 6JXT; -. DR PDBsum; 6JZ0; -. DR PDBsum; 6LUB; -. DR PDBsum; 6LUD; -. DR PDBsum; 6P1D; -. DR PDBsum; 6P1L; -. DR PDBsum; 6P8Q; -. DR PDBsum; 6S89; -. DR PDBsum; 6S8A; -. DR PDBsum; 6S9B; -. DR PDBsum; 6S9C; -. DR PDBsum; 6S9D; -. DR PDBsum; 6TFU; -. DR PDBsum; 6TFV; -. DR PDBsum; 6TFW; -. DR PDBsum; 6TFY; -. DR PDBsum; 6TFZ; -. DR PDBsum; 6TG0; -. DR PDBsum; 6TG1; -. DR PDBsum; 6V5N; -. DR PDBsum; 6V5P; -. DR PDBsum; 6V66; -. DR PDBsum; 6V6K; -. DR PDBsum; 6V6O; -. DR PDBsum; 6VH4; -. DR PDBsum; 6VHN; -. DR PDBsum; 6VHP; -. DR PDBsum; 6WA2; -. DR PDBsum; 6WAK; -. DR PDBsum; 6WXN; -. DR PDBsum; 6XL4; -. DR PDBsum; 6Z4B; -. DR PDBsum; 6Z4D; -. DR PDBsum; 7A2A; -. DR PDBsum; 7A6I; -. DR PDBsum; 7A6J; -. DR PDBsum; 7A6K; -. DR PDBsum; 7AEI; -. DR PDBsum; 7AEM; -. DR PDBsum; 7B85; -. DR PDBsum; 7ER2; -. DR PDBsum; 7JXI; -. DR PDBsum; 7JXK; -. DR PDBsum; 7JXL; -. DR PDBsum; 7JXM; -. DR PDBsum; 7JXP; -. DR PDBsum; 7JXQ; -. DR PDBsum; 7JXW; -. DR PDBsum; 7K1H; -. DR PDBsum; 7K1I; -. DR PDBsum; 7KXZ; -. DR PDBsum; 7KY0; -. DR PDBsum; 7LEN; -. DR PDBsum; 7LFR; -. DR PDBsum; 7LFS; -. DR PDBsum; 7LG8; -. DR PDBsum; 7LGS; -. DR PDBsum; 7LTX; -. DR PDBsum; 7OM4; -. DR PDBsum; 7OXB; -. DR PDBsum; 7SI1; -. DR PDBsum; 7SYD; -. DR PDBsum; 7SYE; -. DR PDBsum; 7SZ0; -. DR PDBsum; 7SZ1; -. DR PDBsum; 7SZ5; -. DR PDBsum; 7SZ7; -. DR PDBsum; 7T4I; -. DR PDBsum; 7T4J; -. DR PDBsum; 7TVD; -. DR PDBsum; 7U98; -. DR PDBsum; 7U99; -. DR PDBsum; 7U9A; -. DR PDBsum; 7UKV; -. DR PDBsum; 7UKW; -. DR PDBsum; 7VRA; -. DR PDBsum; 7VRE; -. DR PDBsum; 7ZYM; -. DR PDBsum; 7ZYN; -. DR PDBsum; 7ZYP; -. DR PDBsum; 7ZYQ; -. DR PDBsum; 8A27; -. DR PDBsum; 8A2A; -. DR PDBsum; 8A2B; -. DR PDBsum; 8A2D; -. DR PDBsum; 8D73; -. DR PDBsum; 8D76; -. DR PDBsum; 8DSW; -. DR PDBsum; 8EME; -. DR PDBsum; 8F1H; -. DR PDBsum; 8F1W; -. DR PDBsum; 8F1X; -. DR PDBsum; 8F1Y; -. DR PDBsum; 8F1Z; -. DR PDBsum; 8FV3; -. DR PDBsum; 8FV4; -. DR PDBsum; 8G63; -. DR PDBsum; 8GB4; -. DR PDBsum; 8GK5; -. DR PDBsum; 8H7X; -. DR PDBsum; 8HGO; -. DR PDBsum; 8HGP; -. DR PDBsum; 8HGS; -. DR PDBsum; 8HV1; -. DR PDBsum; 8HV2; -. DR PDBsum; 8HV3; -. DR PDBsum; 8HV4; -. DR PDBsum; 8HV5; -. DR PDBsum; 8HV6; -. DR PDBsum; 8HV7; -. DR PDBsum; 8HV8; -. DR PDBsum; 8HV9; -. DR PDBsum; 8HVA; -. DR PDBsum; 8HY7; -. DR PDBsum; 8KFQ; -. DR PDBsum; 8PNZ; -. DR PDBsum; 8PO0; -. DR PDBsum; 8PO1; -. DR PDBsum; 8PO2; -. DR PDBsum; 8PO3; -. DR PDBsum; 8PO4; -. DR PDBsum; 8S1M; -. DR PDBsum; 8SC7; -. DR PDBsum; 8TJL; -. DR PDBsum; 8TO3; -. DR PDBsum; 8TO4; -. DR PDBsum; 8UKV; -. DR PDBsum; 8UKW; -. DR PDBsum; 8UKX; -. DR PDBsum; 8WD4; -. DR PDBsum; 9BY4; -. DR PDBsum; 9BY6; -. DR PDBsum; 9D3V; -. DR PDBsum; 9D3W; -. DR PDBsum; 9DF2; -. DR PDBsum; 9DF3; -. DR PDBsum; 9DF4; -. DR PDBsum; 9EWS; -. DR PDBsum; 9EWT; -. DR PDBsum; 9FQP; -. DR PDBsum; 9FQS; -. DR PDBsum; 9FRD; -. DR PDBsum; 9GC4; -. DR PDBsum; 9GC5; -. DR PDBsum; 9GC6; -. DR PDBsum; 9GDV; -. DR PDBsum; 9GI9; -. DR PDBsum; 9GL7; -. DR PDBsum; 9GL8; -. DR PDBsum; 9GL9; -. DR PDBsum; 9H46; -. DR PDBsum; 9HBO; -. DR PDBsum; 9IP7; -. DR PDBsum; 9IP8; -. DR PDBsum; 9IP9; -. DR PDBsum; 9IPA; -. DR PDBsum; 9IPB; -. DR PDBsum; 9IPC; -. DR PDBsum; 9IPD; -. DR PDBsum; 9IPE; -. DR AlphaFoldDB; P00533; -. DR BMRB; P00533; -. DR EMDB; EMD-25522; -. DR EMDB; EMD-25523; -. DR EMDB; EMD-25558; -. DR EMDB; EMD-25559; -. DR EMDB; EMD-25561; -. DR EMDB; EMD-25563; -. DR EMDB; EMD-34744; -. DR EMDB; EMD-34745; -. DR EMDB; EMD-34746; -. DR EMDB; EMD-60764; -. DR EMDB; EMD-60765; -. DR EMDB; EMD-60766; -. DR EMDB; EMD-60767; -. DR EMDB; EMD-60768; -. DR EMDB; EMD-60769; -. DR EMDB; EMD-60770; -. DR EMDB; EMD-60771; -. DR SMR; P00533; -. DR BioGRID; 108276; 3218. DR CORUM; P00533; -. DR DIP; DIP-405N; -. DR ELM; P00533; -. DR FunCoup; P00533; 3104. DR IntAct; P00533; 1179. DR MINT; P00533; -. DR STRING; 9606.ENSP00000275493; -. DR BindingDB; P00533; -. DR ChEMBL; CHEMBL203; -. DR DrugBank; DB15327; Abivertinib. DR DrugBank; DB08916; Afatinib. DR DrugBank; DB18840; Allitinib. DR DrugBank; DB16640; Almonertinib. DR DrugBank; DB03496; Alvocidib. DR DrugBank; DB16695; Amivantamab. DR DrugBank; DB06021; AV-412. DR DrugBank; DB12318; BMS-599626. DR DrugBank; DB11665; BMS-690514. DR DrugBank; DB12267; Brigatinib. DR DrugBank; DB05424; Canertinib. DR DrugBank; DB00002; Cetuximab. DR DrugBank; DB12174; CUDC-101. DR DrugBank; DB11963; Dacomitinib. DR DrugBank; DB11731; Depatuxizumab mafodotin. DR DrugBank; DB00530; Erlotinib. DR DrugBank; DB12966; Falnidamol. DR DrugBank; DB10772; Foreskin keratinocyte (neonatal). DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB00317; Gefitinib. DR DrugBank; DB11737; Icotinib. DR DrugBank; DB04988; IGN311. DR DrugBank; DB01259; Lapatinib. DR DrugBank; DB16768; Lavendustin A. DR DrugBank; DB16216; Lazertinib. DR DrugBank; DB00281; Lidocaine. DR DrugBank; DB05101; Matuzumab. DR DrugBank; DB06110; MDX-214. DR DrugBank; DB04862; Merimepodib. DR DrugBank; DB16390; Mobocertinib. DR DrugBank; DB12682; Mubritinib. DR DrugBank; DB08462; N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE. DR DrugBank; DB12036; Naquotinib. DR DrugBank; DB16250; Nazartinib. DR DrugBank; DB09559; Necitumumab. DR DrugBank; DB11828; Neratinib. DR DrugBank; DB00727; Nitroglycerin. DR DrugBank; DB13164; Olmutinib. DR DrugBank; DB09330; Osimertinib. DR DrugBank; DB01269; Panitumumab. DR DrugBank; DB08339; PD-166326. DR DrugBank; DB07662; PD-168393. DR DrugBank; DB05524; Pelitinib. DR DrugBank; DB12114; Poziotinib. DR DrugBank; DB08052; PP-121. DR DrugBank; DB14993; Pyrotinib. DR DrugBank; DB05374; Rindopepimut. DR DrugBank; DB11907; Rociletinib. DR DrugBank; DB07602; S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB14944; Tarloxotinib. DR DrugBank; DB05294; Vandetanib. DR DrugBank; DB05944; Varlitinib. DR DrugBank; DB04879; Vatalanib. DR DrugBank; DB12202; Zalutumumab. DR DrugBank; DB15035; Zanubrutinib. DR DrugCentral; P00533; -. DR GuidetoPHARMACOLOGY; 1797; -. DR MoonDB; P00533; Predicted. DR TCDB; 8.A.23.1.46; the basigin (basigin) family. DR GlyConnect; 137; 81 N-Linked glycans (10 sites). DR GlyCosmos; P00533; 17 sites, 102 glycans. DR GlyGen; P00533; 27 sites, 148 N-linked glycans (18 sites), 1 O-linked glycan (7 sites). DR iPTMnet; P00533; -. DR MetOSite; P00533; -. DR PhosphoSitePlus; P00533; -. DR SwissPalm; P00533; -. DR BioMuta; EGFR; -. DR DMDM; 2811086; -. DR CPTAC; CPTAC-1043; -. DR CPTAC; CPTAC-1560; -. DR CPTAC; CPTAC-1781; -. DR CPTAC; CPTAC-3043; -. DR CPTAC; CPTAC-3044; -. DR CPTAC; CPTAC-5784; -. DR CPTAC; CPTAC-5785; -. DR CPTAC; CPTAC-5830; -. DR CPTAC; CPTAC-5831; -. DR CPTAC; CPTAC-5832; -. DR CPTAC; CPTAC-5833; -. DR CPTAC; CPTAC-5834; -. DR CPTAC; CPTAC-5835; -. DR CPTAC; CPTAC-802; -. DR CPTAC; non-CPTAC-5380; -. DR CPTAC; non-CPTAC-5381; -. DR CPTAC; non-CPTAC-5382; -. DR CPTAC; non-CPTAC-5545; -. DR CPTAC; non-CPTAC-5546; -. DR CPTAC; non-CPTAC-5735; -. DR CPTAC; non-CPTAC-5736; -. DR CPTAC; non-CPTAC-5737; -. DR CPTAC; non-CPTAC-5738; -. DR jPOST; P00533; -. DR MassIVE; P00533; -. DR PaxDb; 9606-ENSP00000275493; -. DR PeptideAtlas; P00533; -. DR ProteomicsDB; 51261; -. [P00533-1] DR ProteomicsDB; 51262; -. [P00533-2] DR ProteomicsDB; 51263; -. [P00533-3] DR ProteomicsDB; 51264; -. [P00533-4] DR ABCD; P00533; 128 sequenced antibodies. DR Antibodypedia; 718; 10780 antibodies from 66 providers. DR CPTC; P00533; 13 antibodies. DR DNASU; 1956; -. DR Ensembl; ENST00000275493.7; ENSP00000275493.2; ENSG00000146648.22. [P00533-1] DR Ensembl; ENST00000342916.7; ENSP00000342376.3; ENSG00000146648.22. [P00533-4] DR Ensembl; ENST00000344576.7; ENSP00000345973.2; ENSG00000146648.22. [P00533-3] DR Ensembl; ENST00000420316.6; ENSP00000413843.2; ENSG00000146648.22. [P00533-2] DR GeneID; 1956; -. DR KEGG; hsa:1956; -. DR MANE-Select; ENST00000275493.7; ENSP00000275493.2; NM_005228.5; NP_005219.2. DR UCSC; uc003tqh.4; human. [P00533-1] DR AGR; HGNC:3236; -. DR CIViC; 1956; 4 clinical assertions and 612 evidence items across 318 molecular profiles. DR ClinPGx; PA7360; -. DR CTD; 1956; -. DR DisGeNET; 1956; -. DR GeneCards; EGFR; -. DR HGNC; HGNC:3236; EGFR. DR HPA; ENSG00000146648; Tissue enhanced (placenta). DR MalaCards; EGFR; -. DR MIM; 131550; gene. DR MIM; 211980; phenotype. DR MIM; 616069; phenotype. DR OpenTargets; ENSG00000146648; -. DR Orphanet; 251579; Giant cell glioblastoma. DR Orphanet; 251576; Gliosarcoma. DR Orphanet; 294023; Neonatal inflammatory skin and bowel disease. DR VEuPathDB; HostDB:ENSG00000146648; -. DR eggNOG; KOG1025; Eukaryota. DR GeneTree; ENSGT00940000155450; -. DR HOGENOM; CLU_003384_0_2_1; -. DR InParanoid; P00533; -. DR OMA; GYYYEWV; -. DR OrthoDB; 6219513at2759; -. DR PAN-GO; P00533; 11 GO annotations based on evolutionary models. DR PhylomeDB; P00533; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P00533; -. DR Reactome; R-HSA-1227986; Signaling by ERBB2. DR Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants. DR Reactome; R-HSA-1236394; Signaling by ERBB4. DR Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. DR Reactome; R-HSA-1251932; PLCG1 events in ERBB2 signaling. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-177929; Signaling by EGFR. DR Reactome; R-HSA-179812; GRB2 events in EGFR signaling. DR Reactome; R-HSA-180292; GAB1 signalosome. DR Reactome; R-HSA-180336; SHC1 events in EGFR signaling. DR Reactome; R-HSA-182971; EGFR downregulation. DR Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling. DR Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling. DR Reactome; R-HSA-212718; EGFR interacts with phospholipase C-gamma. DR Reactome; R-HSA-2179392; EGFR Transactivation by Gastrin. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-445144; Signal transduction by L1. DR Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII. DR Reactome; R-HSA-5638303; Inhibition of Signaling by Overexpressed EGFR. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6785631; ERBB2 Regulates Cell Motility. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling. DR Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis. DR Reactome; R-HSA-8856828; Clathrin-mediated endocytosis. DR Reactome; R-HSA-8857538; PTK6 promotes HIF1A stabilization. DR Reactome; R-HSA-8863795; Downregulation of ERBB2 signaling. DR Reactome; R-HSA-8866910; TFAP2 (AP-2) family regulates transcription of growth factors and their receptors. DR Reactome; R-HSA-9009391; Extra-nuclear estrogen signaling. DR Reactome; R-HSA-9013507; NOTCH3 Activation and Transmission of Signal to the Nucleus. DR Reactome; R-HSA-9609690; HCMV Early Events. DR Reactome; R-HSA-9634638; Estrogen-dependent nuclear events downstream of ESR-membrane signaling. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665348; Signaling by ERBB2 ECD mutants. DR Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants. DR Reactome; R-HSA-9820960; Respiratory syncytial virus (RSV) attachment and entry. DR Reactome; R-HSA-9927432; Developmental Lineage of Mammary Gland Myoepithelial Cells. DR SignaLink; P00533; -. DR SIGNOR; P00533; -. DR Agora; ENSG00000146648; -. DR BioGRID-ORCS; 1956; 155 hits in 1222 CRISPR screens. DR ChiTaRS; EGFR; human. DR EvolutionaryTrace; P00533; -. DR GeneWiki; Epidermal_growth_factor_receptor; -. DR GenomeRNAi; 1956; -. DR Pharos; P00533; Tclin. DR PRO; PR:P00533; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; P00533; protein. DR Bgee; ENSG00000146648; Expressed in nipple and 206 other cell types or tissues. DR ExpressionAtlas; P00533; baseline and differential. DR GO; GO:0009925; C:basal plasma membrane; IBA:GO_Central. DR GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL. DR GO; GO:0030054; C:cell junction; IDA:HPA. DR GO; GO:0009986; C:cell surface; IDA:UniProtKB. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0031901; C:early endosome membrane; IDA:UniProtKB. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005768; C:endosome; IDA:UniProtKB. DR GO; GO:0010008; C:endosome membrane; IDA:UniProtKB. DR GO; GO:0005615; C:extracellular space; NAS:UniProtKB. DR GO; GO:0005925; C:focal adhesion; HDA:UniProtKB. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell. DR GO; GO:0097708; C:intracellular vesicle; IDA:ARUK-UCL. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0045121; C:membrane raft; IDA:UniProtKB. DR GO; GO:0097489; C:multivesicular body, internal vesicle lumen; IDA:UniProtKB. DR GO; GO:0031965; C:nuclear membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IMP:ARUK-UCL. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0032587; C:ruffle membrane; IDA:ARUK-UCL. DR GO; GO:0070435; C:Shc-EGFR complex; ISS:BHF-UCL. DR GO; GO:0097229; C:sperm end piece; IDA:HPA. DR GO; GO:0097225; C:sperm midpiece; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0051015; F:actin filament binding; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0051117; F:ATPase binding; ISS:ARUK-UCL. DR GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0003690; F:double-stranded DNA binding; NAS:UniProtKB. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0048408; F:epidermal growth factor binding; IBA:GO_Central. DR GO; GO:0005006; F:epidermal growth factor receptor activity; IDA:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0019900; F:kinase binding; IPI:UniProtKB. DR GO; GO:0004709; F:MAP kinase kinase kinase activity; NAS:UniProtKB. DR GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB. DR GO; GO:0030296; F:protein tyrosine kinase activator activity; IDA:MGI. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0004888; F:transmembrane signaling receptor activity; IDA:MGI. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB. DR GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW. DR GO; GO:0000902; P:cell morphogenesis; IEA:Ensembl. DR GO; GO:0007166; P:cell surface receptor signaling pathway; IDA:MGI. DR GO; GO:0098609; P:cell-cell adhesion; IMP:UniProtKB. DR GO; GO:0071230; P:cellular response to amino acid stimulus; IEA:Ensembl. DR GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; ISS:UniProtKB. DR GO; GO:0071392; P:cellular response to estradiol stimulus; IDA:UniProtKB. DR GO; GO:0021795; P:cerebral cortex cell migration; IEA:Ensembl. DR GO; GO:0048546; P:digestive tract morphogenesis; IEA:Ensembl. DR GO; GO:0001892; P:embryonic placenta development; IEA:Ensembl. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0050673; P:epithelial cell proliferation; IEA:Ensembl. DR GO; GO:0038134; P:ERBB2-EGFR signaling pathway; IDA:MGI. DR GO; GO:0061029; P:eyelid development in camera-type eye; IEA:Ensembl. DR GO; GO:0010467; P:gene expression; IEA:Ensembl. DR GO; GO:0001942; P:hair follicle development; IEA:Ensembl. DR GO; GO:0007611; P:learning or memory; ISS:UniProtKB. DR GO; GO:0060571; P:morphogenesis of an epithelial fold; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:1905208; P:negative regulation of cardiocyte differentiation; IMP:BHF-UCL. DR GO; GO:0042059; P:negative regulation of epidermal growth factor receptor signaling pathway; TAS:Reactome. DR GO; GO:0042177; P:negative regulation of protein catabolic process; IDA:UniProtKB. DR GO; GO:0030182; P:neuron differentiation; IBA:GO_Central. DR GO; GO:0001503; P:ossification; NAS:UniProtKB. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:BHF-UCL. DR GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:BHF-UCL. DR GO; GO:0030307; P:positive regulation of cell growth; IDA:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:MGI. DR GO; GO:0045739; P:positive regulation of DNA repair; IDA:UniProtKB. DR GO; GO:0045740; P:positive regulation of DNA replication; IDA:UniProtKB. DR GO; GO:0045742; P:positive regulation of epidermal growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IDA:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB. DR GO; GO:0048146; P:positive regulation of fibroblast proliferation; IEA:Ensembl. DR GO; GO:1900087; P:positive regulation of G1/S transition of mitotic cell cycle; IMP:BHF-UCL. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:ARUK-UCL. DR GO; GO:1902895; P:positive regulation of miRNA transcription; IMP:BHF-UCL. DR GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IMP:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:BHF-UCL. DR GO; GO:0042327; P:positive regulation of phosphorylation; IDA:UniProtKB. DR GO; GO:0090037; P:positive regulation of protein kinase C signaling; IDA:ParkinsonsUK-UCL. DR GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IDA:ParkinsonsUK-UCL. DR GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0051205; P:protein insertion into membrane; TAS:UniProtKB. DR GO; GO:0016567; P:protein ubiquitination; IEA:Ensembl. DR GO; GO:0050730; P:regulation of peptidyl-tyrosine phosphorylation; IMP:UniProtKB. DR GO; GO:0070141; P:response to UV-A; IDA:BHF-UCL. DR GO; GO:0007435; P:salivary gland morphogenesis; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; IDA:UniProtKB. DR GO; GO:0070086; P:ubiquitin-dependent endocytosis; IEA:Ensembl. DR GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IEA:Ensembl. DR GO; GO:0042908; P:xenobiotic transport; IEA:Ensembl. DR CDD; cd00064; FU; 3. DR CDD; cd05108; PTKc_EGFR; 1. DR CDD; cd12093; TM_ErbB1; 1. DR DisProt; DP00309; -. DR FunFam; 1.10.510.10:FF:000027; Receptor protein-tyrosine kinase; 1. DR FunFam; 2.10.220.10:FF:000001; Receptor protein-tyrosine kinase; 1. DR FunFam; 2.10.220.10:FF:000008; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.30.200.20:FF:000044; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000005; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000006; Receptor protein-tyrosine kinase; 1. DR Gene3D; 2.10.220.10; Hormone Receptor, Insulin-like Growth Factor Receptor 1, Chain A, domain 2; 3. DR Gene3D; 1.20.5.420; Immunoglobulin FC, subunit C; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.20.20; Receptor L-domain; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00262; -. DR InterPro; IPR006211; Furin-like_Cys-rich_dom. DR InterPro; IPR006212; Furin_repeat. DR InterPro; IPR032778; GF_recep_IV. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR000494; Rcpt_L-dom. DR InterPro; IPR036941; Rcpt_L-dom_sf. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR049328; TM_ErbB1. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt. DR PANTHER; PTHR24416:SF91; EPIDERMAL GROWTH FACTOR RECEPTOR; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00757; Furin-like; 1. DR Pfam; PF14843; GF_recep_IV; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF01030; Recep_L_domain; 2. DR Pfam; PF21314; TM_ErbB1; 1. DR PIRSF; PIRSF000619; TyrPK_EGF-R; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00261; FU; 3. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 2. DR SUPFAM; SSF52058; L domain-like; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; KW Developmental protein; Direct protein sequencing; Disease variant; KW Disulfide bond; Endoplasmic reticulum; Endosome; Glycoprotein; KW Golgi apparatus; Host cell receptor for virus entry; KW Host-virus interaction; Hydroxylation; Isopeptide bond; Kinase; KW Lipoprotein; Membrane; Methylation; Nucleotide-binding; Nucleus; Palmitate; KW Phosphoprotein; Proteomics identification; Proto-oncogene; Receptor; KW Reference proteome; Repeat; Secreted; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..24 FT /evidence="ECO:0000269|PubMed:15340161, FT ECO:0000269|PubMed:6328312, ECO:0000269|Ref.16" FT CHAIN 25..1210 FT /note="Epidermal growth factor receptor" FT /id="PRO_0000016665" FT TOPO_DOM 25..645 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 646..668 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 669..1210 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT REPEAT 75..300 FT /note="Approximate" FT REPEAT 390..600 FT /note="Approximate" FT DOMAIN 712..979 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 688..704 FT /note="Important for dimerization, phosphorylation and FT activation" FT REGION 1097..1137 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1104..1115 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1128..1137 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 837 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 718..726 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:19563760, FT ECO:0007744|PDB:2GS7, ECO:0007744|PDB:3GT8, FT ECO:0007744|PDB:4ZSE, ECO:0007744|PDB:5CNN, FT ECO:0007744|PDB:5CNO, ECO:0007744|PDB:5D41" FT BINDING 745 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:17349580, FT ECO:0000269|PubMed:19563760, ECO:0007744|PDB:2EB3, FT ECO:0007744|PDB:2GS7, ECO:0007744|PDB:2ITN, FT ECO:0007744|PDB:3GT8, ECO:0007744|PDB:3VJN, FT ECO:0007744|PDB:3VJO, ECO:0007744|PDB:4RIW, FT ECO:0007744|PDB:4RIY, ECO:0007744|PDB:4ZSE, FT ECO:0007744|PDB:5CNN, ECO:0007744|PDB:5CNO, FT ECO:0007744|PDB:5D41" FT BINDING 790..791 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:17349580, FT ECO:0000269|PubMed:19563760, ECO:0007744|PDB:2EB3, FT ECO:0007744|PDB:2GS7, ECO:0007744|PDB:2ITN, FT ECO:0007744|PDB:2ITV, ECO:0007744|PDB:2ITX, FT ECO:0007744|PDB:3GT8, ECO:0007744|PDB:3VJN, FT ECO:0007744|PDB:3VJO, ECO:0007744|PDB:4RIW, FT ECO:0007744|PDB:4RIX, ECO:0007744|PDB:4RIY, FT ECO:0007744|PDB:4ZSE, ECO:0007744|PDB:5CNN, FT ECO:0007744|PDB:5CNO, ECO:0007744|PDB:5D41" FT BINDING 855 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:17349580, FT ECO:0000269|PubMed:19563760, ECO:0007744|PDB:2EB3, FT ECO:0007744|PDB:2GS7, ECO:0007744|PDB:2ITN, FT ECO:0007744|PDB:2ITV, ECO:0007744|PDB:2ITX, FT ECO:0007744|PDB:3GT8, ECO:0007744|PDB:3VJN, FT ECO:0007744|PDB:4RIW, ECO:0007744|PDB:4RIX, FT ECO:0007744|PDB:4RIY, ECO:0007744|PDB:4ZSE, FT ECO:0007744|PDB:5CNN, ECO:0007744|PDB:5CNO, FT ECO:0007744|PDB:5D41" FT SITE 1016 FT /note="Important for interaction with PIK3C2B" FT MOD_RES 229 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:21487020" FT MOD_RES 678 FT /note="Phosphothreonine; by PKC and PKD/PRKD1" FT /evidence="ECO:0000269|PubMed:10523301" FT MOD_RES 693 FT /note="Phosphothreonine; by PKD/PRKD1" FT /evidence="ECO:0000269|PubMed:10523301, FT ECO:0000269|PubMed:16083266, ECO:0000269|PubMed:3138233, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 695 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:3138233, FT ECO:0007744|PubMed:18691976" FT MOD_RES 745 FT /note="N6-(2-hydroxyisobutyryl)lysine" FT /evidence="ECO:0000269|PubMed:29192674" FT MOD_RES 869 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:23774213" FT MOD_RES 991 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:16083266, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:24275569" FT MOD_RES 995 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 998 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:19563760, FT ECO:0007744|PubMed:18669648" FT MOD_RES 1016 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:19563760, FT ECO:0000269|PubMed:23774213" FT MOD_RES 1026 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:16083266, FT ECO:0007744|PubMed:24275569" FT MOD_RES 1039 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 1041 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 1042 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 1064 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1069 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:23774213, FT ECO:0000305|PubMed:22888118" FT MOD_RES 1070 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:3138233" FT MOD_RES 1071 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:3138233" FT MOD_RES 1081 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 1092 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12873986, FT ECO:0000269|PubMed:23774213, ECO:0000269|PubMed:27153536" FT MOD_RES 1110 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12873986, FT ECO:0000269|PubMed:2543678" FT MOD_RES 1166 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:24275569" FT MOD_RES 1172 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:26918609, FT ECO:0000269|PubMed:27153536, ECO:0007744|PubMed:17081983" FT MOD_RES 1197 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:19563760, FT ECO:0000269|PubMed:19836242, ECO:0000269|PubMed:23774213, FT ECO:0000269|PubMed:27153536, ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:20068231" FT MOD_RES 1199 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000269|PubMed:21258366" FT LIPID 1049 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000269|PubMed:27153536" FT LIPID 1146 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000269|PubMed:27153536" FT CARBOHYD 56 FT /note="N-linked (GlcNAc...) (complex) asparagine; atypical; FT partial" FT /evidence="ECO:0000269|PubMed:10731668, FT ECO:0000269|PubMed:12297049, ECO:0000269|PubMed:12297050, FT ECO:0000269|PubMed:12731890, ECO:0000269|PubMed:16083266, FT ECO:0000269|PubMed:20837704, ECO:0007744|PDB:1IVO, FT ECO:0007744|PDB:1MOX, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ" FT /id="CAR_000227" FT CARBOHYD 73 FT /note="N-linked (GlcNAc...) asparagine; atypical" FT /evidence="ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:3NJP" FT CARBOHYD 128 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:12731890, FT ECO:0000269|PubMed:16083266, ECO:0000269|PubMed:8962717" FT CARBOHYD 175 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:12297050, FT ECO:0000269|PubMed:12731890, ECO:0000269|PubMed:16083266, FT ECO:0000269|PubMed:20837704, ECO:0000269|PubMed:8962717, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:3NJP" FT CARBOHYD 196 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12731890, FT ECO:0000269|PubMed:16083266, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:3NJP" FT CARBOHYD 352 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:10731668, FT ECO:0000269|PubMed:12297049, ECO:0000269|PubMed:12297050, FT ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:12731890, FT ECO:0000269|PubMed:16083266, ECO:0000269|PubMed:19159218, FT ECO:0000269|PubMed:20837704, ECO:0007744|PDB:1IVO, FT ECO:0007744|PDB:1MOX, ECO:0007744|PDB:1NQL, FT ECO:0007744|PDB:1YY9, ECO:0007744|PDB:3B2U, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3P0Y, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRL, ECO:0007744|PDB:4KRM, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7" FT CARBOHYD 361 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:10731668, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:12731890, ECO:0000269|PubMed:16083266, FT ECO:0000269|PubMed:20837704, ECO:0007744|PDB:1IVO, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2U, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRL, FT ECO:0007744|PDB:4KRM, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UV7" FT CARBOHYD 413 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:12731890, FT ECO:0000269|PubMed:16083266, ECO:0000269|PubMed:19159218, FT ECO:0000269|PubMed:8962717, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2U, ECO:0007744|PDB:3B2V, FT ECO:0007744|PDB:3P0Y, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP" FT CARBOHYD 444 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:12297050, FT ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:12731890, FT ECO:0000269|PubMed:16083266, ECO:0000269|PubMed:20837704, FT ECO:0000269|PubMed:8962717, ECO:0007744|PDB:1IVO, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2U, ECO:0007744|PDB:3B2V, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3P0Y, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRL, FT ECO:0007744|PDB:4KRM, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7" FT CARBOHYD 528 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:12731890, ECO:0000269|PubMed:16083266, FT ECO:0000269|PubMed:20837704, ECO:0000269|PubMed:25922362, FT ECO:0000269|PubMed:8962717, ECO:0007744|PDB:1NQL, FT ECO:0007744|PDB:1YY9, ECO:0007744|PDB:3B2V, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7" FT CARBOHYD 568 FT /note="N-linked (GlcNAc...) asparagine; partial" FT /evidence="ECO:0000269|PubMed:10731668, FT ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:12731890, FT ECO:0000269|PubMed:16083266, ECO:0000269|PubMed:19159218, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9" FT CARBOHYD 603 FT /note="N-linked (GlcNAc...) asparagine; partial" FT /evidence="ECO:0000269|PubMed:10731668, FT ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:12731890, FT ECO:0000269|PubMed:16083266, ECO:0007744|PDB:1NQL, FT ECO:0007744|PDB:1YY9" FT CARBOHYD 623 FT /note="N-linked (GlcNAc...) (high mannose) asparagine" FT /evidence="ECO:0000305|PubMed:12731890" FT DISULFID 31..58 FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD" FT DISULFID 157..187 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:5WB7, FT ECO:0007744|PDB:5WB8, ECO:0007744|PDB:5XWD" FT DISULFID 190..199 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5WB7, FT ECO:0007744|PDB:5WB8, ECO:0007744|PDB:5XWD" FT DISULFID 194..207 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5WB7, FT ECO:0007744|PDB:5WB8, ECO:0007744|PDB:5XWD" FT DISULFID 215..223 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD" FT DISULFID 219..231 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD" FT DISULFID 232..240 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD" FT DISULFID 236..248 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD" FT DISULFID 251..260 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD" FT DISULFID 264..291 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5WB7, FT ECO:0007744|PDB:5WB8, ECO:0007744|PDB:5XWD" FT DISULFID 295..307 FT /evidence="ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5WB7, FT ECO:0007744|PDB:5WB8, ECO:0007744|PDB:5XWD" FT DISULFID 311..326 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3G5V, FT ECO:0007744|PDB:3G5Y, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD" FT DISULFID 329..333 FT /evidence="ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5WB7, FT ECO:0007744|PDB:5WB8, ECO:0007744|PDB:5XWD" FT DISULFID 337..362 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2U, ECO:0007744|PDB:3B2V, FT ECO:0007744|PDB:3C09, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3P0Y, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRL, ECO:0007744|PDB:4KRM, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5SX4, ECO:0007744|PDB:5SX5, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD, ECO:0007744|PDB:6B3S" FT DISULFID 470..499 FT /evidence="ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2U, ECO:0007744|PDB:3B2V, FT ECO:0007744|PDB:3C09, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3P0Y, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRL, ECO:0007744|PDB:4KRM, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5SX4, ECO:0007744|PDB:5SX5, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD, ECO:0007744|PDB:6B3S" FT DISULFID 506..515 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2U, ECO:0007744|PDB:3B2V, FT ECO:0007744|PDB:3NJP, ECO:0007744|PDB:3P0Y, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRL, FT ECO:0007744|PDB:4KRM, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5SX4, FT ECO:0007744|PDB:5SX5, ECO:0007744|PDB:5WB7, FT ECO:0007744|PDB:5WB8, ECO:0007744|PDB:5XWD, FT ECO:0007744|PDB:6B3S" FT DISULFID 510..523 FT /evidence="ECO:0000269|PubMed:12297049, FT ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1IVO, ECO:0007744|PDB:1MOX, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2U, ECO:0007744|PDB:3B2V, FT ECO:0007744|PDB:3C09, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3P0Y, ECO:0007744|PDB:3QWQ, FT ECO:0007744|PDB:4KRL, ECO:0007744|PDB:4KRM, FT ECO:0007744|PDB:4KRO, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UIP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5SX4, ECO:0007744|PDB:5SX5, FT ECO:0007744|PDB:5WB7, ECO:0007744|PDB:5WB8, FT ECO:0007744|PDB:5XWD, ECO:0007744|PDB:6B3S" FT DISULFID 526..535 FT /evidence="ECO:0000269|PubMed:12297050, FT ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:15837620, FT ECO:0000269|PubMed:20837704, ECO:0007744|PDB:1IVO, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRL, FT ECO:0007744|PDB:4KRM, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5XWD" FT DISULFID 539..555 FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5XWD" FT DISULFID 558..571 FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5XWD" FT DISULFID 562..579 FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5XWD" FT DISULFID 582..591 FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UV7, FT ECO:0007744|PDB:5XWD" FT DISULFID 595..617 FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5XWD" FT DISULFID 620..628 FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRO, FT ECO:0007744|PDB:4KRP, ECO:0007744|PDB:4UIP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5XWD" FT DISULFID 624..636 FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:15837620, ECO:0000269|PubMed:20837704, FT ECO:0007744|PDB:1NQL, ECO:0007744|PDB:1YY9, FT ECO:0007744|PDB:3B2V, ECO:0007744|PDB:3NJP, FT ECO:0007744|PDB:3QWQ, ECO:0007744|PDB:4KRP, FT ECO:0007744|PDB:4UV7, ECO:0007744|PDB:5XWD" FT CROSSLNK 716 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:16543144, FT ECO:0000269|PubMed:33996800" FT CROSSLNK 737 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:16543144, FT ECO:0000269|PubMed:33996800" FT CROSSLNK 754 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:16543144, FT ECO:0000269|PubMed:33996800" FT CROSSLNK 757 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:33996800" FT CROSSLNK 867 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:16543144, FT ECO:0000269|PubMed:33996800" FT CROSSLNK 929 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:16543144" FT CROSSLNK 960 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:33996800" FT CROSSLNK 970 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:16543144" FT VAR_SEQ 404..405 FT /note="FL -> LS (in isoform 2)" FT /evidence="ECO:0000303|PubMed:7654368, FT ECO:0000303|PubMed:8918811, ECO:0000303|PubMed:9103388, FT ECO:0000303|Ref.6" FT /id="VSP_002887" FT VAR_SEQ 406..1210 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:7654368, FT ECO:0000303|PubMed:8918811, ECO:0000303|PubMed:9103388, FT ECO:0000303|Ref.6" FT /id="VSP_002888" FT VAR_SEQ 628..705 FT /note="CTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTL FT RRLLQERELVEPLTPSGEAPNQALLR -> PGNESLKAMLFCLFKLSSCNQSNDGSVSH FT QSGSPAAQESCLGWIPSLLPSEFQLGWGGCSHLHAWPSASVIITASSCH (in FT isoform 3)" FT /evidence="ECO:0000303|PubMed:11161793" FT /id="VSP_002889" FT VAR_SEQ 628 FT /note="C -> S (in isoform 4)" FT /evidence="ECO:0000303|PubMed:11161793" FT /id="VSP_002891" FT VAR_SEQ 629..1210 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:11161793" FT /id="VSP_002892" FT VAR_SEQ 706..1210 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:11161793" FT /id="VSP_002890" FT VARIANT 30..297 FT /note="Missing (variant EGFR vIII; found in a lung cancer FT sample; somatic mutation; induces lung cancer when FT exogenously expressed)" FT /evidence="ECO:0000269|PubMed:16672372" FT /id="VAR_066493" FT VARIANT 98 FT /note="R -> Q (in dbSNP:rs17289589)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_019293" FT VARIANT 266 FT /note="P -> R (in dbSNP:rs17336639)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_019294" FT VARIANT 428 FT /note="G -> D (in NNCIS; loss of function; the mutant does FT not localize to the cell membrane; has diffuse cytoplasmic FT localization; dbSNP:rs606231253)" FT /evidence="ECO:0000269|PubMed:24691054" FT /id="VAR_072435" FT VARIANT 521 FT /note="R -> K (in dbSNP:rs2227983)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.7" FT /id="VAR_019295" FT VARIANT 674 FT /note="V -> I (in dbSNP:rs17337079)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_019296" FT VARIANT 709 FT /note="E -> A (found in a lung cancer sample; more FT sensitive to gefitinib than wild-type; dbSNP:rs397517085)" FT /evidence="ECO:0000269|PubMed:15623594, FT ECO:0000269|PubMed:16205628, ECO:0000269|PubMed:16533793" FT /id="VAR_026084" FT VARIANT 709 FT /note="E -> G (found in a lung cancer sample; FT constitutively activated kinase with higher levels of basal FT autophosphorylation; more sensitive to gefitinib than wild- FT type; dbSNP:rs397517085)" FT /evidence="ECO:0000269|PubMed:15623594, FT ECO:0000269|PubMed:16205628" FT /id="VAR_069498" FT VARIANT 709 FT /note="E -> K (found in a lung cancer sample; FT dbSNP:rs727504256)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026085" FT VARIANT 719 FT /note="G -> A (found in a lung cancer sample; FT dbSNP:rs121913428)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026086" FT VARIANT 719 FT /note="G -> C (found in a lung cancer sample; FT dbSNP:rs28929495)" FT /evidence="ECO:0000269|PubMed:15623594, FT ECO:0000269|PubMed:16533793" FT /id="VAR_026087" FT VARIANT 719 FT /note="G -> D (found in a lung cancer sample; FT dbSNP:rs121913428)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026088" FT VARIANT 719 FT /note="G -> S (found in a lung cancer sample; somatic FT mutation; strongly increased kinase activity; FT constitutively activated kinase with higher levels of basal FT autophosphorylation; more sensitive to gefitinib than wild- FT type; dbSNP:rs28929495)" FT /evidence="ECO:0000269|PubMed:15118125, FT ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16205628, FT ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:17349580" FT /id="VAR_019297" FT VARIANT 724 FT /note="G -> S (found in a lung cancer sample; FT dbSNP:rs1051753269)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026089" FT VARIANT 734 FT /note="E -> K (found in a lung cancer sample; FT dbSNP:rs121913420)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026090" FT VARIANT 746..752 FT /note="ELREATS -> D (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:15623594" FT /id="VAR_069499" FT VARIANT 746..751 FT /note="ELREAT -> A (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:15623594" FT /id="VAR_069500" FT VARIANT 746..750 FT /note="Missing (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:15623594" FT /id="VAR_026092" FT VARIANT 746 FT /note="Missing (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026091" FT VARIANT 747..751 FT /note="Missing (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:15623594" FT /id="VAR_069501" FT VARIANT 747..749 FT /note="Missing (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026094" FT VARIANT 747 FT /note="L -> F (found in a lung cancer sample; FT dbSNP:rs2128954811)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026093" FT VARIANT 748 FT /note="R -> P (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026095" FT VARIANT 752..759 FT /note="Missing (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026096" FT VARIANT 768 FT /note="S -> I (found in a lung cancer sample; FT constitutively activated kinase with higher levels of basal FT autophosphorylation; more sensitive to gefitinib than wild- FT type; dbSNP:rs121913465)" FT /evidence="ECO:0000269|PubMed:15623594, FT ECO:0000269|PubMed:16205628" FT /id="VAR_069502" FT VARIANT 769 FT /note="V -> M (found in a lung cancer sample; FT dbSNP:rs147149347)" FT /evidence="ECO:0000269|PubMed:15623594" FT /id="VAR_069503" FT VARIANT 787 FT /note="Q -> R (found in a lung cancer sample)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026097" FT VARIANT 790 FT /note="T -> M (found in a lung cancer sample; increased FT kinase activity; dbSNP:rs121434569)" FT /evidence="ECO:0000269|PubMed:16533793, FT ECO:0000269|PubMed:18227510" FT /id="VAR_026098" FT VARIANT 833 FT /note="L -> V (found in a lung cancer sample; more FT sensitive to gefitinib than wild-type; dbSNP:rs397517126)" FT /evidence="ECO:0000269|PubMed:15623594, FT ECO:0000269|PubMed:16205628, ECO:0000269|PubMed:16533793" FT /id="VAR_026099" FT VARIANT 834 FT /note="V -> L (found in a lung cancer sample; FT dbSNP:rs397517127)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026100" FT VARIANT 835 FT /note="H -> L (found in a lung cancer sample; more FT sensitive to gefitinib than wild-type; dbSNP:rs397517128)" FT /evidence="ECO:0000269|PubMed:15623594, FT ECO:0000269|PubMed:16205628" FT /id="VAR_069504" FT VARIANT 838 FT /note="L -> V (found in a lung cancer sample; more FT sensitive to gefitinib than wild-type; dbSNP:rs864621996)" FT /evidence="ECO:0000269|PubMed:15623594, FT ECO:0000269|PubMed:16205628" FT /id="VAR_069505" FT VARIANT 858 FT /note="L -> M (found in a lung cancer sample; FT dbSNP:rs121913443)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026101" FT VARIANT 858 FT /note="L -> R (found in a lung cancer sample; somatic FT mutation; constitutively activated enzyme with strongly FT increased kinase activity; more sensitive to gefitinib than FT wild-type; dbSNP:rs121434568)" FT /evidence="ECO:0000269|PubMed:15118125, FT ECO:0000269|PubMed:15623594, ECO:0000269|PubMed:16205628, FT ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:17349580" FT /id="VAR_019298" FT VARIANT 861 FT /note="L -> Q (found in a lung cancer sample; FT constitutively activated kinase with higher levels of basal FT autophosphorylation; more sensitive to gefitinib than wild- FT type; dbSNP:rs121913444)" FT /evidence="ECO:0000269|PubMed:15623594, FT ECO:0000269|PubMed:16205628, ECO:0000269|PubMed:16533793" FT /id="VAR_026102" FT VARIANT 873 FT /note="G -> E (found in a lung cancer sample; FT dbSNP:rs2128964711)" FT /evidence="ECO:0000269|PubMed:16533793" FT /id="VAR_026103" FT VARIANT 962 FT /note="R -> G (in dbSNP:rs17337451)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_019299" FT VARIANT 988 FT /note="H -> P (in dbSNP:rs17290699)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_019300" FT VARIANT 1034 FT /note="L -> R (in dbSNP:rs34352568)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042095" FT VARIANT 1210 FT /note="A -> V (in dbSNP:rs35918369)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042096" FT MUTAGEN 275 FT /note="Y->A: Strongly reduced autophosphorylation and FT activation of downstream kinases; when associated with A- FT 309." FT /evidence="ECO:0000269|PubMed:12297050" FT MUTAGEN 287 FT /note="F->A: Strongly reduced autophosphorylation and FT activation of downstream kinases; when associated with A- FT 309." FT /evidence="ECO:0000269|PubMed:12297050" FT MUTAGEN 309 FT /note="R->S: Strongly reduced autophosphorylation and FT activation of downstream kinases; when associated with A- FT 275. Strongly reduced autophosphorylation and activation of FT downstream kinases; when associated with A-287." FT /evidence="ECO:0000269|PubMed:12297050" FT MUTAGEN 429 FT /note="R->E: Abolishes autophosphorylation and activation FT of downstream kinases." FT /evidence="ECO:0000269|PubMed:12297050" FT MUTAGEN 525..1210 FT /note="Missing: Increased EGF binding." FT /evidence="ECO:0000269|PubMed:19718021" FT MUTAGEN 587..590 FT /note="DGPH->AGPA: Decreases intramolecular interactions FT and facilitates EGF binding." FT /evidence="ECO:0000269|PubMed:12620237" FT MUTAGEN 587 FT /note="D->A: Increased EGF binding; when associated with A- FT 590 and A-609." FT /evidence="ECO:0000269|PubMed:19718021" FT MUTAGEN 590 FT /note="H->A: Increased EGF binding; when associated with A- FT 587; A-590 and A-609." FT /evidence="ECO:0000269|PubMed:19718021" FT MUTAGEN 609 FT /note="K->A: Decreases intramolecular interactions and FT facilitates EGF binding. Increased EGF binding; when FT associated with A-587; A-590 and A-609." FT /evidence="ECO:0000269|PubMed:12620237, FT ECO:0000269|PubMed:19718021" FT MUTAGEN 688 FT /note="L->A: Strongly reduced phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417, FT ECO:0000269|PubMed:19563760" FT MUTAGEN 689 FT /note="V->A: Reduced autophosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 689 FT /note="V->M: Constitutively activated kinase." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 690 FT /note="E->A: Reduced phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417, FT ECO:0000269|PubMed:19563760" FT MUTAGEN 692 FT /note="L->A,P: Strongly reduced phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417, FT ECO:0000269|PubMed:19563760" FT MUTAGEN 693 FT /note="T->A: Increased phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 693 FT /note="T->D: Strongly reduced phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 694 FT /note="P->A: Strongly reduced phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 699 FT /note="P->A: Reduced phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 700 FT /note="N->A: Abolishes phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 704 FT /note="L->A: Abolishes phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 705 FT /note="R->A: Abolishes phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 706 FT /note="I->A: Abolishes phosphorylation." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 745 FT /note="K->A,M: Abolishes kinase activity." FT /evidence="ECO:0000269|PubMed:19560417" FT MUTAGEN 974 FT /note="D->A: Strongly reduced phosphorylation." FT MUTAGEN 977 FT /note="R->A: Reduced phosphorylation." FT /evidence="ECO:0000269|PubMed:19563760" FT MUTAGEN 1005..1006 FT /note="ED->RK: Constitutively activated kinase." FT /evidence="ECO:0000269|PubMed:19563760" FT MUTAGEN 1016 FT /note="Y->F: 50% decrease in interaction with PIK3C2B. 65% FT decrease in interaction with PIK3C2B; when associated with FT F-1197. Abolishes interaction with PIK3C2B; when associated FT with F-1197 and F-1092." FT /evidence="ECO:0000269|PubMed:10805725" FT MUTAGEN 1048..1210 FT /note="Missing: Abolishes palmitoylation." FT /evidence="ECO:0000269|PubMed:27153536" FT MUTAGEN 1049 FT /note="C->A: Decreased palmitoylation." FT /evidence="ECO:0000269|PubMed:27153536" FT MUTAGEN 1067 FT /note="Q->G: No effect on interaction with CBLC." FT /evidence="ECO:0000269|PubMed:22888118" FT MUTAGEN 1068 FT /note="R->G: Strongly decreases interaction with CBLC." FT /evidence="ECO:0000269|PubMed:22888118" FT MUTAGEN 1069 FT /note="Y->F: Abolishes interaction with CBLC." FT /evidence="ECO:0000269|PubMed:22888118" FT MUTAGEN 1092 FT /note="Y->F: No change in interaction with PIK3C2B. FT Abolishes interaction with PIK3C2B; when associated with F- FT 1197 and F-1016." FT /evidence="ECO:0000269|PubMed:10805725" FT MUTAGEN 1110 FT /note="Y->F: No change in interaction with PIK3C2B." FT /evidence="ECO:0000269|PubMed:10805725" FT MUTAGEN 1146 FT /note="C->A: Decreased palmitoylation." FT /evidence="ECO:0000269|PubMed:27153536" FT MUTAGEN 1172 FT /note="Y->F: No change in interaction with PIK3C2B." FT /evidence="ECO:0000269|PubMed:10805725" FT MUTAGEN 1197 FT /note="Y->F: No change in interaction with PIK3C2B. 65% FT decrease in interaction with PIK3C2B; when associated with FT F-1016. Abolishes interaction with PIK3C2B; when associated FT with F-1092 and F-1016." FT /evidence="ECO:0000269|PubMed:10805725" FT CONFLICT 540 FT /note="N -> K (in Ref. 1; CAA25240)" FT /evidence="ECO:0000305" FT STRAND 40..43 FT /evidence="ECO:0007829|PDB:3QWQ" FT HELIX 44..55 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 60..69 FT /evidence="ECO:0007829|PDB:4UV7" FT HELIX 77..81 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 84..87 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 89..93 FT /evidence="ECO:0007829|PDB:4UV7" FT HELIX 101..103 FT /evidence="ECO:0007829|PDB:1IVO" FT TURN 114..116 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 117..122 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 125..129 FT /evidence="ECO:0007829|PDB:1MOX" FT STRAND 145..152 FT /evidence="ECO:0007829|PDB:4UV7" FT HELIX 159..161 FT /evidence="ECO:0007829|PDB:4UV7" FT HELIX 164..166 FT /evidence="ECO:0007829|PDB:4UV7" FT HELIX 170..173 FT /evidence="ECO:0007829|PDB:1MOX" FT STRAND 183..185 FT /evidence="ECO:0007829|PDB:5XWD" FT HELIX 195..197 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 199..204 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 211..214 FT /evidence="ECO:0007829|PDB:1MOX" FT STRAND 217..221 FT /evidence="ECO:0007829|PDB:5XWD" FT STRAND 223..227 FT /evidence="ECO:0007829|PDB:4UV7" FT HELIX 228..230 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 236..238 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 240..244 FT /evidence="ECO:0007829|PDB:4UV7" FT TURN 245..247 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 248..256 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 259..263 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 267..271 FT /evidence="ECO:0007829|PDB:4UV7" FT TURN 272..275 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 276..279 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 285..287 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 290..294 FT /evidence="ECO:0007829|PDB:4UV7" FT TURN 296..298 FT /evidence="ECO:0007829|PDB:3B2V" FT STRAND 299..301 FT /evidence="ECO:0007829|PDB:7LEN" FT STRAND 303..305 FT /evidence="ECO:0007829|PDB:4KRP" FT STRAND 306..310 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 313..315 FT /evidence="ECO:0007829|PDB:3B2V" FT STRAND 318..320 FT /evidence="ECO:0007829|PDB:3G5Y" FT STRAND 323..325 FT /evidence="ECO:0007829|PDB:3G5Y" FT STRAND 330..332 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 336..338 FT /evidence="ECO:0007829|PDB:3P0Y" FT TURN 340..342 FT /evidence="ECO:0007829|PDB:3QWQ" FT HELIX 343..345 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 349..351 FT /evidence="ECO:0007829|PDB:3P0Y" FT TURN 353..355 FT /evidence="ECO:0007829|PDB:3P0Y" FT HELIX 356..359 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 363..367 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 369..371 FT /evidence="ECO:0007829|PDB:3P0Y" FT HELIX 373..377 FT /evidence="ECO:0007829|PDB:3P0Y" FT TURN 380..383 FT /evidence="ECO:0007829|PDB:3P0Y" FT HELIX 389..397 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 400..403 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 405..407 FT /evidence="ECO:0007829|PDB:3P0Y" FT HELIX 418..420 FT /evidence="ECO:0007829|PDB:3P0Y" FT TURN 433..435 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 436..442 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 458..464 FT /evidence="ECO:0007829|PDB:3P0Y" FT HELIX 472..474 FT /evidence="ECO:0007829|PDB:3P0Y" FT HELIX 477..480 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 481..483 FT /evidence="ECO:0007829|PDB:1YY9" FT STRAND 488..494 FT /evidence="ECO:0007829|PDB:3P0Y" FT HELIX 496..501 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 508..510 FT /evidence="ECO:0007829|PDB:5SX4" FT STRAND 515..519 FT /evidence="ECO:0007829|PDB:3P0Y" FT HELIX 520..522 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 523..526 FT /evidence="ECO:0007829|PDB:3P0Y" FT STRAND 531..533 FT /evidence="ECO:0007829|PDB:4KRL" FT STRAND 534..537 FT /evidence="ECO:0007829|PDB:8UKW" FT STRAND 540..546 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 548..551 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 554..557 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 560..562 FT /evidence="ECO:0007829|PDB:4KRO" FT STRAND 566..568 FT /evidence="ECO:0007829|PDB:8UKW" FT STRAND 570..575 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 578..587 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 590..594 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 597..602 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 606..611 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 615..619 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 622..624 FT /evidence="ECO:0007829|PDB:7SYE" FT STRAND 629..632 FT /evidence="ECO:0007829|PDB:4UV7" FT HELIX 633..635 FT /evidence="ECO:0007829|PDB:4UV7" FT STRAND 643..646 FT /evidence="ECO:0007829|PDB:2KS1" FT HELIX 648..669 FT /evidence="ECO:0007829|PDB:2KS1" FT STRAND 671..673 FT /evidence="ECO:0007829|PDB:1Z9I" FT HELIX 679..684 FT /evidence="ECO:0007829|PDB:3GOP" FT HELIX 685..687 FT /evidence="ECO:0007829|PDB:3GOP" FT STRAND 688..692 FT /evidence="ECO:0007829|PDB:1Z9I" FT STRAND 694..697 FT /evidence="ECO:0007829|PDB:1Z9I" FT STRAND 703..706 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 709..711 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 712..720 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 722..731 FT /evidence="ECO:0007829|PDB:8A27" FT TURN 734..736 FT /evidence="ECO:0007829|PDB:5UG9" FT STRAND 740..749 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 753..767 FT /evidence="ECO:0007829|PDB:8A27" FT TURN 771..773 FT /evidence="ECO:0007829|PDB:8PO2" FT STRAND 777..781 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 783..785 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 787..791 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 794..797 FT /evidence="ECO:0007829|PDB:5ZWJ" FT HELIX 798..804 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 806..808 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 811..830 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 840..842 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 843..847 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 850..853 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 856..858 FT /evidence="ECO:0007829|PDB:7VRA" FT TURN 859..865 FT /evidence="ECO:0007829|PDB:8A2A" FT HELIX 866..868 FT /evidence="ECO:0007829|PDB:8A2D" FT STRAND 871..873 FT /evidence="ECO:0007829|PDB:6V66" FT STRAND 875..877 FT /evidence="ECO:0007829|PDB:5CZH" FT HELIX 878..880 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 883..888 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 893..908 FT /evidence="ECO:0007829|PDB:8A27" FT TURN 909..911 FT /evidence="ECO:0007829|PDB:7JXW" FT TURN 914..917 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 920..922 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 923..928 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 937..939 FT /evidence="ECO:0007829|PDB:8PO0" FT HELIX 941..950 FT /evidence="ECO:0007829|PDB:8A27" FT STRAND 951..953 FT /evidence="ECO:0007829|PDB:5JEB" FT HELIX 955..957 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 961..972 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 975..977 FT /evidence="ECO:0007829|PDB:8A27" FT HELIX 984..986 FT /evidence="ECO:0007829|PDB:5HG8" FT TURN 992..998 FT /evidence="ECO:0007829|PDB:5HG8" FT TURN 999..1003 FT /evidence="ECO:0007829|PDB:6S89" FT STRAND 1004..1010 FT /evidence="ECO:0007829|PDB:3W2S" FT HELIX 1013..1016 FT /evidence="ECO:0007829|PDB:8A2A" FT STRAND 1068..1070 FT /evidence="ECO:0007829|PDB:3PFV" FT STRAND 1091..1094 FT /evidence="ECO:0007829|PDB:8S1M" SQ SEQUENCE 1210 AA; 134277 MW; D8A2A50B4EFB6ED2 CRC64; MRPSGTAGAA LLALLAALCP ASRALEEKKV CQGTSNKLTQ LGTFEDHFLS LQRMFNNCEV VLGNLEITYV QRNYDLSFLK TIQEVAGYVL IALNTVERIP LENLQIIRGN MYYENSYALA VLSNYDANKT GLKELPMRNL QEILHGAVRF SNNPALCNVE SIQWRDIVSS DFLSNMSMDF QNHLGSCQKC DPSCPNGSCW GAGEENCQKL TKIICAQQCS GRCRGKSPSD CCHNQCAAGC TGPRESDCLV CRKFRDEATC KDTCPPLMLY NPTTYQMDVN PEGKYSFGAT CVKKCPRNYV VTDHGSCVRA CGADSYEMEE DGVRKCKKCE GPCRKVCNGI GIGEFKDSLS INATNIKHFK NCTSISGDLH ILPVAFRGDS FTHTPPLDPQ ELDILKTVKE ITGFLLIQAW PENRTDLHAF ENLEIIRGRT KQHGQFSLAV VSLNITSLGL RSLKEISDGD VIISGNKNLC YANTINWKKL FGTSGQKTKI ISNRGENSCK ATGQVCHALC SPEGCWGPEP RDCVSCRNVS RGRECVDKCN LLEGEPREFV ENSECIQCHP ECLPQAMNIT CTGRGPDNCI QCAHYIDGPH CVKTCPAGVM GENNTLVWKY ADAGHVCHLC HPNCTYGCTG PGLEGCPTNG PKIPSIATGM VGALLLLLVV ALGIGLFMRR RHIVRKRTLR RLLQERELVE PLTPSGEAPN QALLRILKET EFKKIKVLGS GAFGTVYKGL WIPEGEKVKI PVAIKELREA TSPKANKEIL DEAYVMASVD NPHVCRLLGI CLTSTVQLIT QLMPFGCLLD YVREHKDNIG SQYLLNWCVQ IAKGMNYLED RRLVHRDLAA RNVLVKTPQH VKITDFGLAK LLGAEEKEYH AEGGKVPIKW MALESILHRI YTHQSDVWSY GVTVWELMTF GSKPYDGIPA SEISSILEKG ERLPQPPICT IDVYMIMVKC WMIDADSRPK FRELIIEFSK MARDPQRYLV IQGDERMHLP SPTDSNFYRA LMDEEDMDDV VDADEYLIPQ QGFFSSPSTS RTPLLSSLSA TSNNSTVACI DRNGLQSCPI KEDSFLQRYS SDPTGALTED SIDDTFLPVP EYINQSVPKR PAGSVQNPVY HNQPLNPAPS RDPHYQDPHS TAVGNPEYLN TVQPTCVNST FDSPAHWAQK GSHQISLDNP DYQQDFFPKE AKPNGIFKGS TAENAEYLRV APQSSEFIGA // ID EPHA2_HUMAN Reviewed; 976 AA. AC P29317; B5A968; Q8N3Z2; DT 01-DEC-1992, integrated into UniProtKB/Swiss-Prot. DT 05-MAY-2009, sequence version 2. DT 28-JAN-2026, entry version 259. DE RecName: Full=Ephrin type-A receptor 2; DE EC=2.7.10.1; DE AltName: Full=Epithelial cell kinase; DE AltName: Full=Tyrosine-protein kinase receptor ECK; DE Flags: Precursor; GN Name=EPHA2; Synonyms=ECK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY, AND RP AUTOPHOSPHORYLATION. RC TISSUE=Epithelium; RX PubMed=2174105; DOI=10.1128/mcb.10.12.6316-6324.1990; RA Lindberg R.A., Hunter T.; RT "cDNA cloning and characterization of eck, an epithelial cell receptor RT protein-tyrosine kinase in the eph/elk family of protein kinases."; RL Mol. Cell. Biol. 10:6316-6324(1990). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING. RX PubMed=18593464; DOI=10.1186/ar2447; RA Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D., RA Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.; RT "Novel splice variants derived from the receptor tyrosine kinase RT superfamily are potential therapeutics for rheumatoid arthritis."; RL Arthritis Res. Ther. 10:R73-R73(2008). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Pancreas; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NOMENCLATURE. RX PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0; RG Eph nomenclature committee; RT "Unified nomenclature for Eph family receptors and their ligands, the RT ephrins."; RL Cell 90:403-404(1997). RN [7] RP FUNCTION IN INTEGRIN-MEDIATED CELL ADHESION, FUNCTION IN CELL MIGRATION, RP PHOSPHORYLATION, INTERACTION WITH PTK2/FAK1 AND PTPN11, AND SUBCELLULAR RP LOCATION. RX PubMed=10655584; DOI=10.1038/35000008; RA Miao H., Burnett E., Kinch M., Simon E., Wang B.; RT "Activation of EphA2 kinase suppresses integrin function and causes focal- RT adhesion-kinase dephosphorylation."; RL Nat. Cell Biol. 2:62-69(2000). RN [8] RP ONCOGENICITY. RX PubMed=11280802; RA Zelinski D.P., Zantek N.D., Stewart J.C., Irizarry A.R., Kinch M.S.; RT "EphA2 overexpression causes tumorigenesis of mammary epithelial cells."; RL Cancer Res. 61:2301-2306(2001). RN [9] RP INTERACTION WITH ACP1, AND DEPHOSPHORYLATION BY ACP1. RX PubMed=12167657; DOI=10.1074/jbc.m207127200; RA Kikawa K.D., Vidale D.R., Van Etten R.L., Kinch M.S.; RT "Regulation of the EphA2 kinase by the low molecular weight tyrosine RT phosphatase induces transformation."; RL J. Biol. Chem. 277:39274-39279(2002). RN [10] RP FUNCTION IN CELL-CELL INTERACTION, INTERACTION WITH CLDN4, AND MUTAGENESIS RP OF LYS-646. RX PubMed=16236711; DOI=10.1074/jbc.m503786200; RA Tanaka M., Kamata R., Sakai R.; RT "EphA2 phosphorylates the cytoplasmic tail of Claudin-4 and mediates RT paracellular permeability."; RL J. Biol. Chem. 280:42375-42382(2005). RN [11] RP TISSUE SPECIFICITY. RX PubMed=17332925; RA Liu D.-P., Wang Y., Koeffler H.P., Xie D.; RT "Ephrin-A1 is a negative regulator in glioma through down-regulation of RT EphA2 and FAK."; RL Int. J. Oncol. 30:865-871(2007). RN [12] RP INTERACTION WITH INPPL1. RX PubMed=17135240; DOI=10.1074/jbc.m608509200; RA Zhuang G., Hunter S., Hwang Y., Chen J.; RT "Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via RT phosphatidylinositol 3-Kinase-dependent Rac1 activation."; RL J. Biol. Chem. 282:2683-2694(2007). RN [13] RP FUNCTION IN APOPTOSIS, AND INDUCTION BY UV. RX PubMed=18339848; DOI=10.1158/0008-5472.can-07-2372; RA Zhang G., Njauw C.-N., Park J.M., Naruse C., Asano M., Tsao H.; RT "EphA2 is an essential mediator of UV radiation-induced apoptosis."; RL Cancer Res. 68:1691-1696(2008). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-570; SER-579 AND THR-647, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [15] RP SUBCELLULAR LOCATION, AND PHOSPHORYLATION. RX PubMed=18794797; DOI=10.1038/onc.2008.328; RA Wykosky J., Palma E., Gibo D.M., Ringler S., Turner C.P., Debinski W.; RT "Soluble monomeric EphrinA1 is released from tumor cells and is a RT functional ligand for the EphA2 receptor."; RL Oncogene 27:7260-7273(2008). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-570; SER-892 AND SER-901, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [17] RP DISEASE, FUNCTION IN CELL MIGRATION, SUBCELLULAR LOCATION, MUTAGENESIS OF RP ASP-739 AND SER-897, AND PHOSPHORYLATION AT SER-897 BY PKB. RX PubMed=19573808; DOI=10.1016/j.ccr.2009.04.009; RA Miao H., Li D.Q., Mukherjee A., Guo H., Petty A., Cutter J., Basilion J.P., RA Sedor J., Wu J., Danielpour D., Sloan A.E., Cohen M.L., Wang B.; RT "EphA2 mediates ligand-dependent inhibition and ligand-independent RT promotion of cell migration and invasion via a reciprocal regulatory loop RT with Akt."; RL Cancer Cell 16:9-20(2009). RN [18] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-435. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). RN [19] RP UBIQUITINATION BY STUB1. RX PubMed=19567782; DOI=10.1158/1541-7786.mcr-08-0582; RA Annamalai B., Liu X., Gopal U., Isaacs J.S.; RT "Hsp90 is an essential regulator of EphA2 receptor stability and signaling: RT implications for cancer cell migration and metastasis."; RL Mol. Cancer Res. 7:1021-1032(2009). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-570; TYR-628; THR-647 AND RP SER-869, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [21] RP FUNCTION IN CELL MIGRATION, AND INTERACTION WITH ARHGEF16; DOCK4 AND ELMO2. RX PubMed=20679435; DOI=10.1083/jcb.201005141; RA Hiramoto-Yamaki N., Takeuchi S., Ueda S., Harada K., Fujimoto S., RA Negishi M., Katoh H.; RT "Ephexin4 and EphA2 mediate cell migration through a RhoG-dependent RT mechanism."; RL J. Cell Biol. 190:461-477(2010). RN [22] RP FUNCTION IN KERATINOCYTE ADHESION AND DIFFERENTIATION, AND SUBCELLULAR RP LOCATION. RX PubMed=20861311; DOI=10.1091/mbc.e10-03-0242; RA Lin S., Gordon K., Kaplan N., Getsios S.; RT "Ligand targeting of EphA2 enhances keratinocyte adhesion and RT differentiation via desmoglein 1."; RL Mol. Biol. Cell 21:3902-3914(2010). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [24] RP SUBCELLULAR LOCATION. RX PubMed=20223987; DOI=10.1126/science.1181729; RA Salaita K., Nair P.M., Petit R.S., Neve R.M., Das D., Gray J.W., RA Groves J.T.; RT "Restriction of receptor movement alters cellular response: physical force RT sensing by EphA2."; RL Science 327:1380-1385(2010). RN [25] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [26] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=21516087; DOI=10.1038/nm.2341; RA Lupberger J., Zeisel M.B., Xiao F., Thumann C., Fofana I., Zona L., RA Davis C., Mee C.J., Turek M., Gorke S., Royer C., Fischer B., Zahid M.N., RA Lavillette D., Fresquet J., Cosset F.L., Rothenberg S.M., Pietschmann T., RA Patel A.H., Pessaux P., Doffoel M., Raffelsberger W., Poch O., RA McKeating J.A., Brino L., Baumert T.F.; RT "EGFR and EphA2 are host factors for hepatitis C virus entry and possible RT targets for antiviral therapy."; RL Nat. Med. 17:589-595(2011). RN [27] RP INTERACTION WITH ANKS1A. RX PubMed=22332920; DOI=10.1021/bi300141h; RA Mercurio F.A., Marasco D., Pirone L., Pedone E.M., Pellecchia M., Leone M.; RT "Solution structure of the first Sam domain of Odin and binding studies RT with the EphA2 receptor."; RL Biochemistry 51:2136-2145(2012). RN [28] RP INTERACTION WITH HHV-8 GLYCOPROTEIN L/GLYCOPROTEIN H (MICROBIAL INFECTION). RX PubMed=22635007; DOI=10.1038/nm.2805; RA Hahn A.S., Kaufmann J.K., Wies E., Naschberger E., Panteleev-Ivlev J., RA Schmidt K., Holzer A., Schmidt M., Chen J., Konig S., Ensser A., Myoung J., RA Brockmeyer N.H., Sturzl M., Fleckenstein B., Neipel F.; RT "The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi's RT sarcoma-associated herpesvirus."; RL Nat. Med. 18:961-966(2012). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-575; SER-892; SER-897 AND RP SER-901, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [30] RP FUNCTION IN CELL MIGRATION, PHOSPHORYLATION AT TYR-930, DEPHOSPHORYLATION RP AT TYR-930 BY PTPRF, AND INTERACTION WITH NCK1. RX PubMed=23358419; DOI=10.1128/mcb.01708-12; RA Lee H., Bennett A.M.; RT "Receptor protein tyrosine phosphatase-receptor tyrosine kinase substrate RT screen identifies EphA2 as a target for LAR in cell migration."; RL Mol. Cell. Biol. 33:1430-1441(2013). RN [31] RP INTERACTION WITH CEMIP. RX PubMed=23936024; DOI=10.1371/journal.pone.0069473; RA Tiwari A., Schneider M., Fiorino A., Haider R., Okoniewski M.J., RA Roschitzki B., Uzozie A., Menigatti M., Jiricny J., Marra G.; RT "Early insights into the function of KIAA1199, a markedly overexpressed RT protein in human colorectal tumors."; RL PLoS ONE 8:E69473-E69473(2013). RN [32] RP PHOSPHORYLATION AT SER-897 BY RPS6KA1 AND RPS6KA3, AND FUNCTION IN CELL RP MIGRATION. RX PubMed=26158630; DOI=10.1038/ncomms8679; RA Zhou Y., Yamada N., Tanaka T., Hori T., Yokoyama S., Hayakawa Y., Yano S., RA Fukuoka J., Koizumi K., Saiki I., Sakurai H.; RT "Crucial roles of RSK in cell motility by catalysing serine phosphorylation RT of EphA2."; RL Nat. Commun. 6:7679-7679(2015). RN [33] RP PHOSPHORYLATION AT SER-897 BY PKA, PHOSPHORYLATION AT SER-901, AND RP FUNCTION. RX PubMed=27385333; DOI=10.1091/mbc.e16-01-0048; RA Barquilla A., Lamberto I., Noberini R., Heynen-Genel S., Brill L.M., RA Pasquale E.B.; RT "Protein kinase A can block EphA2 receptor-mediated cell repulsion by RT increasing EphA2 S897 phosphorylation."; RL Mol. Biol. Cell 27:2757-2770(2016). RN [34] RP INTERACTION WITH EPSTEIN-BARR VIRUS/HHV-4 GLYCOPROTEIN L/GLYCOPROTEIN H RP (MICROBIAL INFECTION). RX PubMed=29292383; DOI=10.1038/s41564-017-0080-8; RA Zhang H., Li Y., Wang H.B., Zhang A., Chen M.L., Fang Z.X., Dong X.D., RA Li S.B., Du Y., Xiong D., He J.Y., Li M.Z., Liu Y.M., Zhou A.J., Zhong Q., RA Zeng Y.X., Kieff E., Zhang Z., Gewurz B.E., Zhao B., Zeng M.S.; RT "Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus RT entry."; RL Nat. Microbiol. 3:1-8(2018). RN [35] RP INTERACTION WITH EPSTEIN-BARR VIRUS/HHV-4 GLYCOPROTEIN L/GLYCOPROTEIN H RP (MICROBIAL INFECTION). RX PubMed=29292384; DOI=10.1038/s41564-017-0081-7; RA Chen J., Sathiyamoorthy K., Zhang X., Schaller S., Perez White B.E., RA Jardetzky T.S., Longnecker R.; RT "Ephrin receptor A2 is a functional entry receptor for Epstein-Barr RT virus."; RL Nat. Microbiol. 3:172-180(2018). RN [36] RP INTERACTION WITH TIMD4, AND SUBCELLULAR LOCATION. RX PubMed=34067457; DOI=10.3390/cells10061290; RA Moon B., Yang S., Kim K., Lee J., Jeong D., Park D.; RT "EphA2 Interacts with Tim-4 through Association between Its FN3 Domain and RT the IgV Domain of Tim-4."; RL Cells 10:0-0(2021). RN [37] RP FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HUMAN CYTOMEGALOVIRUS RP PROTEINS GH AND GL (MICROBIAL INFECTION). RX PubMed=37146061; DOI=10.1371/journal.ppat.1011304; RA Dong X.D., Li Y., Li Y., Sun C., Liu S.X., Duan H., Cui R., Zhong Q., RA Mou Y.G., Wen L., Yang B., Zeng M.S., Luo M.H., Zhang H.; RT "EphA2 is a functional entry receptor for HCMV infection of glioblastoma RT cells."; RL PLoS Pathog. 19:e1011304-e1011304(2023). RN [38] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 596-900. RX PubMed=12467573; DOI=10.1016/s0969-2126(02)00907-3; RA Nowakowski J., Cronin C.N., McRee D.E., Knuth M.W., Nelson C.G., RA Pavletich N.P., Rogers J., Sang B.C., Scheibe D.N., Swanson R.V., RA Thompson D.A.; RT "Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases RT from nanovolume crystallography."; RL Structure 10:1659-1667(2002). RN [39] RP STRUCTURE BY NMR OF 902-976. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the C-terminal SAM-domain of EPHAA2: ephrin type-A RT receptor 2 precursor (EC 2.7.10.1)."; RL Submitted (JAN-2008) to the PDB data bank. RN [40] RP X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 28-201, X-RAY CRYSTALLOGRAPHY RP (2.0 ANGSTROMS) OF 28-201 IN COMPLEX WITH EFNA1, SUBUNIT, DISULFIDE BOND, RP AND MUTAGENESIS OF ARG-103. RX PubMed=19525919; DOI=10.1038/embor.2009.91; RA Himanen J.P., Goldgur Y., Miao H., Myshkin E., Guo H., Buck M., Nguyen M., RA Rajashankar K.R., Wang B., Nikolov D.B.; RT "Ligand recognition by A-class Eph receptors: crystal structures of the RT EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex."; RL EMBO Rep. 10:722-728(2009). RN [41] RP X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 25-202, AND DISULFIDE BOND. RG Structural genomics consortium (SGC); RT "Ephrin A1 bound to the ligand binding domain of the human ephrin A2 RT (EPHA2) receptor protein kinase."; RL Submitted (FEB-2009) to the PDB data bank. RN [42] RP STRUCTURE BY NMR OF 523-563. RA Mayzel M.L., Bocharov E.V., Volynsky P.E., Arseniev A.S.; RT "Left-handed dimer of EPHA2 transmembrane domain helix packing diversity RT among receptor tyrosine kinases."; RL Submitted (AUG-2009) to the PDB data bank. RN [43] RP X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 23-202 IN COMPLEX WITH EFNA1, AND RP SUBUNIT. RX PubMed=20505120; DOI=10.1073/pnas.1004148107; RA Himanen J.P., Yermekbayeva L., Janes P.W., Walker J.R., Xu K., Atapattu L., RA Rajashankar K.R., Mensinga A., Lackmann M., Nikolov D.B., Dhe-Paganon S.; RT "Architecture of Eph receptor clusters."; RL Proc. Natl. Acad. Sci. U.S.A. 107:10860-10865(2010). RN [44] RP VARIANTS [LARGE SCALE ANALYSIS] ARG-391; MET-511; HIS-568; SER-777 AND RP HIS-876. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [45] RP VARIANT CTRCT6 TRP-948. RX PubMed=19005574; RA Shiels A., Bennett T.M., Knopf H.L.S., Maraini G., Li A., Jiao X., RA Hejtmancik J.F.; RT "The EPHA2 gene is associated with cataracts linked to chromosome 1p."; RL Mol. Vis. 14:2042-2055(2008). RN [46] RP VARIANT CTRCT6 ILE-940. RX PubMed=19306328; DOI=10.1002/humu.20995; RA Zhang T., Hua R., Xiao W., Burdon K.P., Bhattacharya S.S., Craig J.E., RA Shang D., Zhao X., Mackey D.A., Moore A.T., Luo Y., Zhang J., Zhang X.; RT "Mutations of the EPHA2 receptor tyrosine kinase gene cause autosomal RT dominant congenital cataract."; RL Hum. Mutat. 30:E603-E611(2009). RN [47] RP VARIANT CTRCT6 GLN-721, AND CHARACTERIZATION OF VARIANT CTRCT6 GLN-721. RX PubMed=19649315; DOI=10.1371/journal.pgen.1000584; RA Jun G., Guo H., Klein B.E., Klein R., Wang J.J., Mitchell P., Miao H., RA Lee K.E., Joshi T., Buck M., Chugha P., Bardenstein D., Klein A.P., RA Bailey-Wilson J.E., Gong X., Spector T.D., Andrew T., Hammond C.J., RA Elston R.C., Iyengar S.K., Wang B.; RT "EPHA2 is associated with age-related cortical cataract in mice and RT humans."; RL PLoS Genet. 5:E1000584-E1000584(2009). RN [48] RP CHARACTERIZATION OF VARIANTS CTRCT6 ILE-940 AND CTRCT6 TRP-948. RX PubMed=22570727; DOI=10.1371/journal.pone.0036564; RA Park J.E., Son A.I., Hua R., Wang L., Zhang X., Zhou R.; RT "Human cataract mutations in EPHA2 SAM domain alter receptor stability and RT function."; RL PLoS ONE 7:E36564-E36564(2012). CC -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously membrane- CC bound ephrin-A family ligands residing on adjacent cells, leading to CC contact-dependent bidirectional signaling into neighboring cells. The CC signaling pathway downstream of the receptor is referred to as forward CC signaling while the signaling pathway downstream of the ephrin ligand CC is referred to as reverse signaling. Activated by the ligand ephrin- CC A1/EFNA1 regulates migration, integrin-mediated adhesion, proliferation CC and differentiation of cells. Regulates cell adhesion and CC differentiation through DSG1/desmoglein-1 and inhibition of the CC ERK1/ERK2 (MAPK3/MAPK1, respectively) signaling pathway. May also CC participate in UV radiation-induced apoptosis and have a ligand- CC independent stimulatory effect on chemotactic cell migration. During CC development, may function in distinctive aspects of pattern formation CC and subsequently in development of several fetal tissues. Involved for CC instance in angiogenesis, in early hindbrain development and epithelial CC proliferation and branching morphogenesis during mammary gland CC development. Engaged by the ligand ephrin-A5/EFNA5 may regulate lens CC fiber cells shape and interactions and be important for lens CC transparency development and maintenance. With ephrin-A2/EFNA2 may play CC a role in bone remodeling through regulation of osteoclastogenesis and CC osteoblastogenesis. {ECO:0000269|PubMed:10655584, CC ECO:0000269|PubMed:16236711, ECO:0000269|PubMed:18339848, CC ECO:0000269|PubMed:19573808, ECO:0000269|PubMed:20679435, CC ECO:0000269|PubMed:20861311, ECO:0000269|PubMed:23358419, CC ECO:0000269|PubMed:26158630, ECO:0000269|PubMed:27385333}. CC -!- FUNCTION: (Microbial infection) Acts as a receptor for hepatitis C CC virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV CC entry by promoting the formation of the CD81-CLDN1 receptor complexes CC that are essential for HCV entry and by enhancing membrane fusion of CC cells expressing HCV envelope glycoproteins. CC {ECO:0000269|PubMed:21516087}. CC -!- FUNCTION: Acts as a receptor for human cytomegalovirus (HCMV) to CC mediate viral entry and fusion in glioblastoma cells. CC {ECO:0000269|PubMed:37146061}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:2174105}; CC -!- SUBUNIT: Homodimer. Interacts with SLA. Interacts (phosphorylated form) CC with VAV2, VAV3 and PI3-kinase p85 subunit (PIK3R1, PIK3R2 or PIK3R3); CC critical for the EFNA1-induced activation of RAC1 which stimulates cell CC migration (By similarity). Interacts with INPPL1; regulates activated CC EPHA2 endocytosis and degradation. Interacts (inactivated form) with CC PTK2/FAK1 and interacts (EFNA1 ligand-activated form) with PTPN11; CC regulates integrin-mediated adhesion. Interacts with ARHGEF16, DOCK4 CC and ELMO2; mediates ligand-independent activation of RAC1 which CC stimulates cell migration. Interacts with CLDN4; phosphorylates CLDN4 CC and may regulate tight junctions. Interacts with ACP1. Interacts (via CC SAM domain) with ANKS1A (via SAM domain). Interacts with CEMIP. CC Interacts with NCK1; may regulate EPHA2 activity in cell migration and CC adhesion. Interacts with TIMD4 (PubMed:34067457). CC {ECO:0000250|UniProtKB:Q03145, ECO:0000269|PubMed:10655584, CC ECO:0000269|PubMed:12167657, ECO:0000269|PubMed:16236711, CC ECO:0000269|PubMed:17135240, ECO:0000269|PubMed:19525919, CC ECO:0000269|PubMed:20505120, ECO:0000269|PubMed:20679435, CC ECO:0000269|PubMed:22332920, ECO:0000269|PubMed:23358419, CC ECO:0000269|PubMed:23936024, ECO:0000269|PubMed:34067457}. CC -!- SUBUNIT: (Microbial infection) Interacts with human herpes virus 8/HHV- CC 8 glycoprotein L/gL and glycoprotein H/gH heterodimer; this interaction CC triggers EPHA2 phosphorylation and endocytosis, allowing virus entry. CC {ECO:0000269|PubMed:22635007}. CC -!- SUBUNIT: (Microbial infection) Interacts with human cytomegalovirus CC (HCMV) glycoprotein L/gL and glycoprotein H/gH heterodimer. CC {ECO:0000269|PubMed:37146061}. CC -!- SUBUNIT: (Microbial infection) Interacts with Epstein-Barr virus/HHV-4 CC glycoprotein L/gL and glycoprotein H/gH heterodimer; this interaction CC facilitates virus internalization and fusion. CC {ECO:0000269|PubMed:29292383, ECO:0000269|PubMed:29292384}. CC -!- INTERACTION: CC P29317; P30530: AXL; NbExp=2; IntAct=EBI-702104, EBI-2850927; CC P29317; P35222: CTNNB1; NbExp=2; IntAct=EBI-702104, EBI-491549; CC P29317; P20827: EFNA1; NbExp=9; IntAct=EBI-702104, EBI-715194; CC P29317; P52803: EFNA5; NbExp=8; IntAct=EBI-702104, EBI-1753674; CC P29317; P98172: EFNB1; NbExp=3; IntAct=EBI-702104, EBI-538287; CC P29317; P29320: EPHA3; NbExp=3; IntAct=EBI-702104, EBI-1641575; CC P29317; P54756: EPHA5; NbExp=3; IntAct=EBI-702104, EBI-1383718; CC P29317; Q9UF33: EPHA6; NbExp=4; IntAct=EBI-702104, EBI-3950019; CC P29317; Q15375: EPHA7; NbExp=7; IntAct=EBI-702104, EBI-1383428; CC P29317; P08238: HSP90AB1; NbExp=2; IntAct=EBI-702104, EBI-352572; CC P29317; O15357-1: INPPL1; NbExp=3; IntAct=EBI-702104, EBI-15963021; CC P29317; P29376: LTK; NbExp=3; IntAct=EBI-702104, EBI-6596163; CC P29317; Q05397: PTK2; NbExp=3; IntAct=EBI-702104, EBI-702142; CC P29317; Q06124: PTPN11; NbExp=3; IntAct=EBI-702104, EBI-297779; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18794797, CC ECO:0000269|PubMed:19573808, ECO:0000269|PubMed:20223987, CC ECO:0000269|PubMed:20861311, ECO:0000269|PubMed:34067457}; Single-pass CC type I membrane protein {ECO:0000255}. Cell projection, ruffle membrane CC {ECO:0000269|PubMed:19573808}; Single-pass type I membrane protein CC {ECO:0000255}. Cell projection, lamellipodium membrane CC {ECO:0000269|PubMed:19573808}; Single-pass type I membrane protein CC {ECO:0000255}. Cell junction, focal adhesion CC {ECO:0000269|PubMed:10655584}. Note=Present at regions of cell-cell CC contacts but also at the leading edge of migrating cells CC (PubMed:19573808, PubMed:20861311). Relocates from the plasma membrane CC to the cytoplasmic and perinuclear regions in cancer cells CC (PubMed:18794797). {ECO:0000269|PubMed:18794797, CC ECO:0000269|PubMed:19573808, ECO:0000269|PubMed:20861311, CC ECO:0000269|PubMed:26158630}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P29317-1; Sequence=Displayed; CC Name=2; CC IsoId=P29317-2; Sequence=VSP_056014, VSP_056015; CC -!- TISSUE SPECIFICITY: Expressed in brain and glioma tissue and glioma CC cell lines (at protein level). Expressed most highly in tissues that CC contain a high proportion of epithelial cells, e.g. skin, intestine, CC lung, and ovary. {ECO:0000269|PubMed:17332925}. CC -!- INDUCTION: Up-regulated by UV irradiation via a TP53-independent, MAPK- CC dependent mechanism. {ECO:0000269|PubMed:18339848}. CC -!- PTM: Autophosphorylates. Phosphorylated on tyrosine upon binding and CC activation by EFNA1. Phosphorylated residues Tyr-588 and Tyr-594 are CC required for binding VAV2 and VAV3 while phosphorylated residues Tyr- CC 735 and Tyr-930 are required for binding PI3-kinase p85 subunit CC (PIK3R1, PIK3R2 or PIK3R3). These phosphorylated residues are critical CC for recruitment of VAV2 and VAV3 and PI3-kinase p85 subunit which CC transduce downstream signaling to activate RAC1 GTPase and cell CC migration. Dephosphorylation of Tyr-930 by PTPRF prevents the CC interaction of EPHA2 with NCK1. Phosphorylated at Ser-897 by PKB; CC serum-induced phosphorylation which targets EPHA2 to the cell leading CC edge and stimulates cell migration. Phosphorylation by PKB is inhibited CC by EFNA1-activated EPHA2 which regulates PKB activity via a reciprocal CC regulatory loop. Phosphorylated at Ser-897 in response to TNF by CC RPS6KA1 and RPS6KA3; RPS6KA-EPHA2 signaling pathway controls cell CC migration (PubMed:26158630). Phosphorylated at Ser-897 by PKA; blocks CC cell retraction induced by EPHA2 kinase activity (PubMed:27385333). CC Dephosphorylated by ACP1. {ECO:0000269|PubMed:10655584, CC ECO:0000269|PubMed:18794797, ECO:0000269|PubMed:19573808, CC ECO:0000269|PubMed:23358419, ECO:0000269|PubMed:26158630, CC ECO:0000269|PubMed:27385333}. CC -!- PTM: Ubiquitinated by CHIP/STUB1. Ubiquitination is regulated by the CC HSP90 chaperone and regulates the receptor stability and activity CC through proteasomal degradation. ANKS1A prevents ubiquitination and CC degradation (By similarity). {ECO:0000250}. CC -!- DISEASE: Cataract 6, multiple types (CTRCT6) [MIM:116600]: An CC opacification of the crystalline lens of the eye that frequently CC results in visual impairment or blindness. Opacities vary in CC morphology, are often confined to a portion of the lens, and may be CC static or progressive. CTRCT6 includes posterior polar and age-related CC cortical cataracts, among others. Posterior polar cataract is a CC subcapsular opacity, usually disk-shaped, located at the back of the CC lens. Age-related cortical cataract is a developmental punctate opacity CC restricted to the cortex. The cataract is white or cerulean, increases CC in number with age, but rarely affects vision. CC {ECO:0000269|PubMed:19005574, ECO:0000269|PubMed:19306328, CC ECO:0000269|PubMed:19649315, ECO:0000269|PubMed:22570727}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=Overexpressed in several cancer types and promotes CC malignancy. {ECO:0000269|PubMed:19573808}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40462/EPHA2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M59371; AAA53375.1; -; mRNA. DR EMBL; EU826606; ACF47642.1; -; mRNA. DR EMBL; AL451042; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471167; EAW51769.1; -; Genomic_DNA. DR EMBL; BC037166; AAH37166.1; -; mRNA. DR CCDS; CCDS169.1; -. [P29317-1] DR PIR; A36355; A36355. DR RefSeq; NP_004422.2; NM_004431.4. [P29317-1] DR PDB; 1MQB; X-ray; 2.30 A; A/B=596-900. DR PDB; 2E8N; NMR; -; A=902-976. DR PDB; 2K9Y; NMR; -; A/B=523-563. DR PDB; 2KSO; NMR; -; A=908-972. DR PDB; 2X10; X-ray; 3.00 A; A=27-534. DR PDB; 2X11; X-ray; 4.83 A; A=27-534. DR PDB; 3C8X; X-ray; 1.95 A; A=23-202. DR PDB; 3CZU; X-ray; 2.65 A; A=23-202. DR PDB; 3FL7; X-ray; 2.50 A; A=23-531. DR PDB; 3HEI; X-ray; 2.00 A; A/C/E/G/I/K/M/O=28-201. DR PDB; 3HPN; X-ray; 2.52 A; A/B/C/D/E/F=28-201. DR PDB; 3KKA; X-ray; 2.40 A; C/D/E=903-971. DR PDB; 3MBW; X-ray; 2.81 A; A=23-326. DR PDB; 3MX0; X-ray; 3.51 A; A/C=27-435. DR PDB; 3SKJ; X-ray; 2.50 A; E/F=23-202. DR PDB; 4P2K; X-ray; 1.50 A; A=590-876. DR PDB; 4PDO; X-ray; 2.10 A; A/B=590-876. DR PDB; 4TRL; X-ray; 2.45 A; A=590-876. DR PDB; 5EK7; X-ray; 1.90 A; A/B=583-876. DR PDB; 5I9U; X-ray; 1.89 A; A=596-900. DR PDB; 5I9V; X-ray; 1.46 A; A=596-900. DR PDB; 5I9W; X-ray; 1.36 A; A=596-900. DR PDB; 5I9X; X-ray; 1.43 A; A=596-900. DR PDB; 5I9Y; X-ray; 1.23 A; A=596-900. DR PDB; 5I9Z; X-ray; 1.70 A; A=596-900. DR PDB; 5IA0; X-ray; 1.95 A; A/B/C=596-900. DR PDB; 5IA1; X-ray; 2.04 A; A=596-900. DR PDB; 5IA2; X-ray; 1.62 A; A=596-900. DR PDB; 5IA3; X-ray; 1.79 A; A=596-900. DR PDB; 5IA4; X-ray; 1.80 A; A=596-900. DR PDB; 5IA5; X-ray; 1.78 A; A=596-900. DR PDB; 5NJZ; X-ray; 1.77 A; A=596-900. DR PDB; 5NK0; X-ray; 1.60 A; A=596-900. DR PDB; 5NK1; X-ray; 1.55 A; A=596-900. DR PDB; 5NK2; X-ray; 1.65 A; A=596-900. DR PDB; 5NK3; X-ray; 1.59 A; A=596-900. DR PDB; 5NK4; X-ray; 1.45 A; A=596-900. DR PDB; 5NK5; X-ray; 1.33 A; A=596-900. DR PDB; 5NK6; X-ray; 1.27 A; A=596-900. DR PDB; 5NK7; X-ray; 1.89 A; A=596-900. DR PDB; 5NK8; X-ray; 1.76 A; A=596-900. DR PDB; 5NK9; X-ray; 1.59 A; A=596-900. DR PDB; 5NKA; X-ray; 1.38 A; A=596-900. DR PDB; 5NKB; X-ray; 1.50 A; A=596-900. DR PDB; 5NKC; X-ray; 1.45 A; A=596-900. DR PDB; 5NKD; X-ray; 1.41 A; A=596-900. DR PDB; 5NKE; X-ray; 1.39 A; A=596-900. DR PDB; 5NKF; X-ray; 1.10 A; A=596-900. DR PDB; 5NKG; X-ray; 1.10 A; A=596-900. DR PDB; 5NKH; X-ray; 1.29 A; A=596-900. DR PDB; 5NKI; X-ray; 1.68 A; A=596-900. DR PDB; 5NZ9; NMR; -; A=945-969. DR PDB; 6B9L; X-ray; 3.20 A; A/B/C/D=27-200. DR PDB; 6F7M; NMR; -; A=945-969. DR PDB; 6F7N; NMR; -; A=951-963. DR PDB; 6FNF; X-ray; 1.56 A; A=596-900. DR PDB; 6FNG; X-ray; 1.04 A; A=596-900. DR PDB; 6FNH; X-ray; 1.38 A; A/B/C=596-900. DR PDB; 6HES; X-ray; 1.13 A; A=596-900. DR PDB; 6HET; X-ray; 1.21 A; A=596-900. DR PDB; 6HEU; X-ray; 1.72 A; A=596-900. DR PDB; 6HEV; X-ray; 1.28 A; A=596-900. DR PDB; 6HEW; X-ray; 1.27 A; A=596-900. DR PDB; 6HEX; X-ray; 1.41 A; A=596-900. DR PDB; 6HEY; X-ray; 1.37 A; A=596-900. DR PDB; 6NJZ; X-ray; 1.90 A; A/B=28-200. DR PDB; 6NK0; X-ray; 1.53 A; A/B=28-200. DR PDB; 6NK1; X-ray; 1.55 A; A/B=28-200. DR PDB; 6NK2; X-ray; 2.20 A; A/B=28-200. DR PDB; 6NKP; X-ray; 2.03 A; A/B=28-200. DR PDB; 6Q7B; X-ray; 1.01 A; A=596-900. DR PDB; 6Q7C; X-ray; 1.05 A; A=596-900. DR PDB; 6Q7D; X-ray; 0.98 A; A=596-900. DR PDB; 6Q7E; X-ray; 1.06 A; A=596-900. DR PDB; 6Q7F; X-ray; 1.20 A; A=596-900. DR PDB; 6Q7G; X-ray; 1.05 A; A=596-900. DR PDB; 6RW2; X-ray; 2.26 A; A=27-201. DR PDB; 7B7N; X-ray; 2.69 A; E=23-202. DR PDB; 7CZE; X-ray; 3.00 A; I/J/K/L=26-200. DR PDB; 7CZF; X-ray; 3.20 A; A/D=28-206. DR PDB; 7KJA; X-ray; 1.75 A; A/B=590-976. DR PDB; 7KJB; X-ray; 2.80 A; A=590-976. DR PDB; 7KJC; X-ray; 2.30 A; A/B=590-976. DR PDB; 8BIN; X-ray; 1.50 A; A=596-900. DR PDB; 8BIO; X-ray; 1.60 A; A=596-900. DR PDB; 8BK0; X-ray; 1.70 A; A=596-900. DR PDB; 8BM8; X-ray; 1.68 A; A=596-900. DR PDB; 8BOC; X-ray; 1.90 A; A=596-900. DR PDB; 8BOD; X-ray; 1.50 A; A=596-900. DR PDB; 8BOF; X-ray; 1.82 A; A=596-900. DR PDB; 8BOG; X-ray; 1.47 A; A=596-900. DR PDB; 8BOH; X-ray; 1.42 A; A=596-900. DR PDB; 8BOI; X-ray; 1.63 A; A=596-900. DR PDB; 8BOK; X-ray; 2.02 A; A=596-900. DR PDB; 8BOM; X-ray; 1.12 A; A=596-900. DR PDB; 8QQY; X-ray; 1.80 A; A=596-900. DR PDB; 8T9B; X-ray; 4.20 A; I/J/K/L=436-529. DR PDB; 8TRS; X-ray; 1.90 A; D=199-326. DR PDB; 8TRT; X-ray; 3.00 A; D/E=199-326. DR PDB; 8TRV; X-ray; 3.25 A; A/B=23-326. DR PDB; 8TV1; X-ray; 2.60 A; C=23-326. DR PDB; 8TV5; X-ray; 4.60 A; C/F=23-326. DR PDB; 8XPV; X-ray; 1.55 A; A=596-900. DR PDBsum; 1MQB; -. DR PDBsum; 2E8N; -. DR PDBsum; 2K9Y; -. DR PDBsum; 2KSO; -. DR PDBsum; 2X10; -. DR PDBsum; 2X11; -. DR PDBsum; 3C8X; -. DR PDBsum; 3CZU; -. DR PDBsum; 3FL7; -. DR PDBsum; 3HEI; -. DR PDBsum; 3HPN; -. DR PDBsum; 3KKA; -. DR PDBsum; 3MBW; -. DR PDBsum; 3MX0; -. DR PDBsum; 3SKJ; -. DR PDBsum; 4P2K; -. DR PDBsum; 4PDO; -. DR PDBsum; 4TRL; -. DR PDBsum; 5EK7; -. DR PDBsum; 5I9U; -. DR PDBsum; 5I9V; -. DR PDBsum; 5I9W; -. DR PDBsum; 5I9X; -. DR PDBsum; 5I9Y; -. DR PDBsum; 5I9Z; -. DR PDBsum; 5IA0; -. DR PDBsum; 5IA1; -. DR PDBsum; 5IA2; -. DR PDBsum; 5IA3; -. DR PDBsum; 5IA4; -. DR PDBsum; 5IA5; -. DR PDBsum; 5NJZ; -. DR PDBsum; 5NK0; -. DR PDBsum; 5NK1; -. DR PDBsum; 5NK2; -. DR PDBsum; 5NK3; -. DR PDBsum; 5NK4; -. DR PDBsum; 5NK5; -. DR PDBsum; 5NK6; -. DR PDBsum; 5NK7; -. DR PDBsum; 5NK8; -. DR PDBsum; 5NK9; -. DR PDBsum; 5NKA; -. DR PDBsum; 5NKB; -. DR PDBsum; 5NKC; -. DR PDBsum; 5NKD; -. DR PDBsum; 5NKE; -. DR PDBsum; 5NKF; -. DR PDBsum; 5NKG; -. DR PDBsum; 5NKH; -. DR PDBsum; 5NKI; -. DR PDBsum; 5NZ9; -. DR PDBsum; 6B9L; -. DR PDBsum; 6F7M; -. DR PDBsum; 6F7N; -. DR PDBsum; 6FNF; -. DR PDBsum; 6FNG; -. DR PDBsum; 6FNH; -. DR PDBsum; 6HES; -. DR PDBsum; 6HET; -. DR PDBsum; 6HEU; -. DR PDBsum; 6HEV; -. DR PDBsum; 6HEW; -. DR PDBsum; 6HEX; -. DR PDBsum; 6HEY; -. DR PDBsum; 6NJZ; -. DR PDBsum; 6NK0; -. DR PDBsum; 6NK1; -. DR PDBsum; 6NK2; -. DR PDBsum; 6NKP; -. DR PDBsum; 6Q7B; -. DR PDBsum; 6Q7C; -. DR PDBsum; 6Q7D; -. DR PDBsum; 6Q7E; -. DR PDBsum; 6Q7F; -. DR PDBsum; 6Q7G; -. DR PDBsum; 6RW2; -. DR PDBsum; 7B7N; -. DR PDBsum; 7CZE; -. DR PDBsum; 7CZF; -. DR PDBsum; 7KJA; -. DR PDBsum; 7KJB; -. DR PDBsum; 7KJC; -. DR PDBsum; 8BIN; -. DR PDBsum; 8BIO; -. DR PDBsum; 8BK0; -. DR PDBsum; 8BM8; -. DR PDBsum; 8BOC; -. DR PDBsum; 8BOD; -. DR PDBsum; 8BOF; -. DR PDBsum; 8BOG; -. DR PDBsum; 8BOH; -. DR PDBsum; 8BOI; -. DR PDBsum; 8BOK; -. DR PDBsum; 8BOM; -. DR PDBsum; 8QQY; -. DR PDBsum; 8T9B; -. DR PDBsum; 8TRS; -. DR PDBsum; 8TRT; -. DR PDBsum; 8TRV; -. DR PDBsum; 8TV1; -. DR PDBsum; 8TV5; -. DR PDBsum; 8XPV; -. DR AlphaFoldDB; P29317; -. DR BMRB; P29317; -. DR SMR; P29317; -. DR BioGRID; 108288; 748. DR CORUM; P29317; -. DR DIP; DIP-96N; -. DR FunCoup; P29317; 946. DR IntAct; P29317; 207. DR MINT; P29317; -. DR STRING; 9606.ENSP00000351209; -. DR BindingDB; P29317; -. DR ChEMBL; CHEMBL2068; -. DR DrugBank; DB01254; Dasatinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester. DR DrugBank; DB08896; Regorafenib. DR DrugCentral; P29317; -. DR GuidetoPHARMACOLOGY; 1822; -. DR GlyConnect; 777; 3 N-Linked glycans (1 site). DR GlyCosmos; P29317; 2 sites, 4 glycans. DR GlyGen; P29317; 4 sites, 6 N-linked glycans (2 sites), 2 O-linked glycans (2 sites). DR iPTMnet; P29317; -. DR PhosphoSitePlus; P29317; -. DR SwissPalm; P29317; -. DR BioMuta; EPHA2; -. DR DMDM; 229462861; -. DR CPTAC; CPTAC-1784; -. DR CPTAC; CPTAC-2783; -. DR CPTAC; CPTAC-3201; -. DR jPOST; P29317; -. DR MassIVE; P29317; -. DR PaxDb; 9606-ENSP00000351209; -. DR PeptideAtlas; P29317; -. DR ProteomicsDB; 54535; -. [P29317-1] DR Pumba; P29317; -. DR ABCD; P29317; 32 sequenced antibodies. DR Antibodypedia; 4183; 1411 antibodies from 48 providers. DR DNASU; 1969; -. DR Ensembl; ENST00000358432.8; ENSP00000351209.5; ENSG00000142627.14. [P29317-1] DR GeneID; 1969; -. DR KEGG; hsa:1969; -. DR MANE-Select; ENST00000358432.8; ENSP00000351209.5; NM_004431.5; NP_004422.2. DR UCSC; uc001aya.2; human. [P29317-1] DR AGR; HGNC:3386; -. DR ClinPGx; PA27818; -. DR CTD; 1969; -. DR DisGeNET; 1969; -. DR GeneCards; EPHA2; -. DR HGNC; HGNC:3386; EPHA2. DR HPA; ENSG00000142627; Tissue enhanced (esophagus). DR MalaCards; EPHA2; -. DR MIM; 116600; phenotype. DR MIM; 176946; gene. DR OpenTargets; ENSG00000142627; -. DR Orphanet; 98991; Early-onset nuclear cataract. DR Orphanet; 98993; Early-onset posterior polar cataract. DR Orphanet; 441447; Early-onset posterior subcapsular cataract. DR Orphanet; 98994; Total early-onset cataract. DR VEuPathDB; HostDB:ENSG00000142627; -. DR eggNOG; KOG0196; Eukaryota. DR GeneTree; ENSGT00940000160786; -. DR HOGENOM; CLU_000288_141_4_1; -. DR InParanoid; P29317; -. DR OMA; CLECPVH; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P29317; 8 GO annotations based on evolutionary models. DR PhylomeDB; P29317; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P29317; -. DR Reactome; R-HSA-2682334; EPH-Ephrin signaling. DR Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse. DR Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR Reactome; R-HSA-9013404; RAC2 GTPase cycle. DR Reactome; R-HSA-9013408; RHOG GTPase cycle. DR Reactome; R-HSA-9013420; RHOU GTPase cycle. DR Reactome; R-HSA-9013423; RAC3 GTPase cycle. DR Reactome; R-HSA-9013424; RHOV GTPase cycle. DR Reactome; R-HSA-9696264; RND3 GTPase cycle. DR Reactome; R-HSA-9696270; RND2 GTPase cycle. DR Reactome; R-HSA-9696273; RND1 GTPase cycle. DR SignaLink; P29317; -. DR SIGNOR; P29317; -. DR Agora; ENSG00000142627; -. DR BioGRID-ORCS; 1969; 20 hits in 1214 CRISPR screens. DR ChiTaRS; EPHA2; human. DR EvolutionaryTrace; P29317; -. DR GeneWiki; EPH_receptor_A2; -. DR GenomeRNAi; 1969; -. DR Pharos; P29317; Tclin. DR PRO; PR:P29317; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; P29317; protein. DR Bgee; ENSG00000142627; Expressed in lower esophagus mucosa and 143 other cell types or tissues. DR ExpressionAtlas; P29317; baseline and differential. DR GO; GO:0009986; C:cell surface; IDA:UniProtKB. DR GO; GO:0005925; C:focal adhesion; IDA:UniProtKB. DR GO; GO:0030027; C:lamellipodium; IDA:UniProtKB. DR GO; GO:0031258; C:lamellipodium membrane; IEA:UniProtKB-SubCell. DR GO; GO:0031256; C:leading edge membrane; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0032587; C:ruffle membrane; IEA:UniProtKB-SubCell. DR GO; GO:0070160; C:tight junction; IDA:ARUK-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL. DR GO; GO:0005003; F:ephrin receptor activity; IDA:UniProtKB. DR GO; GO:0019838; F:growth factor binding; IPI:ARUK-UCL. DR GO; GO:0140677; F:molecular function activator activity; EXP:DisProt. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW. DR GO; GO:0090630; P:activation of GTPase activity; IMP:UniProtKB. DR GO; GO:0001525; P:angiogenesis; IBA:GO_Central. DR GO; GO:0048320; P:axial mesoderm formation; IEA:Ensembl. DR GO; GO:0002043; P:blood vessel endothelial cell proliferation involved in sprouting angiogenesis; IEA:Ensembl. DR GO; GO:0046849; P:bone remodeling; ISS:UniProtKB. DR GO; GO:0060444; P:branching involved in mammary gland duct morphogenesis; ISS:UniProtKB. DR GO; GO:0046058; P:cAMP metabolic process; IMP:UniProtKB. DR GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW. DR GO; GO:0060326; P:cell chemotaxis; IMP:UniProtKB. DR GO; GO:0016477; P:cell migration; IMP:UniProtKB. DR GO; GO:0048870; P:cell motility; IMP:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0021953; P:central nervous system neuron differentiation; IEA:Ensembl. DR GO; GO:0050830; P:defense response to Gram-positive bacterium; IEA:Ensembl. DR GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0006954; P:inflammatory response; IEA:Ensembl. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IDA:UniProtKB. DR GO; GO:0030216; P:keratinocyte differentiation; IMP:UniProtKB. DR GO; GO:0070309; P:lens fiber cell morphogenesis; ISS:UniProtKB. DR GO; GO:0033598; P:mammary gland epithelial cell proliferation; ISS:UniProtKB. DR GO; GO:0016525; P:negative regulation of angiogenesis; IEA:Ensembl. DR GO; GO:0033629; P:negative regulation of cell adhesion mediated by integrin; IDA:UniProtKB. DR GO; GO:0032682; P:negative regulation of chemokine production; IEA:Ensembl. DR GO; GO:1901491; P:negative regulation of lymphangiogenesis; IEA:Ensembl. DR GO; GO:0021915; P:neural tube development; IEA:Ensembl. DR GO; GO:0060035; P:notochord cell development; IEA:Ensembl. DR GO; GO:0014028; P:notochord formation; IEA:Ensembl. DR GO; GO:0001649; P:osteoblast differentiation; ISS:UniProtKB. DR GO; GO:0030316; P:osteoclast differentiation; ISS:UniProtKB. DR GO; GO:1904238; P:pericyte cell differentiation; IEA:Ensembl. DR GO; GO:1903348; P:positive regulation of bicellular tight junction assembly; IMP:ARUK-UCL. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:ARUK-UCL. DR GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IMP:UniProtKB. DR GO; GO:0036342; P:post-anal tail morphogenesis; IEA:Ensembl. DR GO; GO:0072659; P:protein localization to plasma membrane; IMP:ARUK-UCL. DR GO; GO:0045765; P:regulation of angiogenesis; ISS:UniProtKB. DR GO; GO:0043535; P:regulation of blood vessel endothelial cell migration; ISS:UniProtKB. DR GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:0010591; P:regulation of lamellipodium assembly; IMP:UniProtKB. DR GO; GO:0070848; P:response to growth factor; IMP:UniProtKB. DR GO; GO:0001501; P:skeletal system development; IEA:Ensembl. DR GO; GO:0001570; P:vasculogenesis; IEA:Ensembl. DR CDD; cd10480; EphR_LBD_A2; 1. DR CDD; cd00063; FN3; 2. DR CDD; cd05063; PTKc_EphR_A2; 1. DR CDD; cd09543; SAM_EPH-A2; 1. DR DisProt; DP03145; -. DR FunFam; 1.10.150.50:FF:000029; Ephrin type-A receptor 1; 1. DR FunFam; 1.20.5.510:FF:000004; Ephrin type-A receptor 2; 1. DR FunFam; 2.60.120.260:FF:000023; Ephrin type-A receptor 2; 1. DR FunFam; 2.60.40.10:FF:000724; ephrin type-A receptor 2; 1. DR FunFam; 2.60.40.1770:FF:000002; ephrin type-A receptor 2; 1. DR FunFam; 1.10.510.10:FF:000019; Ephrin type-A receptor 5; 1. DR FunFam; 2.10.50.10:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 3.30.200.20:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.10:FF:000059; Ephrin type-A receptor 6; 1. DR Gene3D; 2.60.40.1770; ephrin a2 ectodomain; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.20.5.510; Single helix bin; 1. DR Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 1. DR InterPro; IPR027936; Eph_TM. DR InterPro; IPR034263; EphA2_rcpt_lig-bd. DR InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom. DR InterPro; IPR050449; Ephrin_rcpt_TKs. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001660; SAM. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016257; Tyr_kinase_ephrin_rcpt. DR InterPro; IPR001426; Tyr_kinase_rcpt_V_CS. DR PANTHER; PTHR46877; EPH RECEPTOR A5; 1. DR PANTHER; PTHR46877:SF20; RECEPTOR PROTEIN-TYROSINE KINASE; 1. DR Pfam; PF14575; EphA2_TM; 1. DR Pfam; PF25599; Ephrin_CRD; 1. DR Pfam; PF01404; Ephrin_lbd; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00536; SAM_1; 1. DR PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00615; EPH_lbd; 1. DR SMART; SM01411; Ephrin_rec_like; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00454; SAM; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS51550; EPH_LBD; 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1. DR PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1. DR PROSITE; PS50105; SAM_DOMAIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Angiogenesis; Apoptosis; ATP-binding; KW Cataract; Cell adhesion; Cell junction; Cell membrane; Cell projection; KW Differentiation; Disease variant; Disulfide bond; Glycoprotein; KW Host cell receptor for virus entry; Host-virus interaction; Kinase; KW Membrane; Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Receptor; Reference proteome; Repeat; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..23 FT /evidence="ECO:0000255" FT CHAIN 24..976 FT /note="Ephrin type-A receptor 2" FT /id="PRO_0000016800" FT TOPO_DOM 24..537 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 538..558 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 559..976 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 28..206 FT /note="Eph LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00883" FT DOMAIN 328..432 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 438..529 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 613..875 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 904..968 FT /note="SAM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00184" FT REGION 1..206 FT /note="Mediates interaction with CLDN4" FT /evidence="ECO:0000269|PubMed:16236711" FT REGION 606..906 FT /note="Mediates interaction with ARHGEF16 and ELMO2" FT /evidence="ECO:0000269|PubMed:20679435" FT REGION 886..976 FT /note="Negatively regulates interaction with ARHGEF16" FT /evidence="ECO:0000269|PubMed:20679435" FT MOTIF 974..976 FT /note="PDZ-binding" FT /evidence="ECO:0000255" FT ACT_SITE 739 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 619..627 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 646 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 570 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195" FT MOD_RES 575 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 579 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 588 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 594 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:Q03145" FT MOD_RES 628 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 647 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195" FT MOD_RES 735 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q03145" FT MOD_RES 772 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:Q03145" FT MOD_RES 869 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 892 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 897 FT /note="Phosphoserine; by PKB/AKT1, RPS6KA1, RPS6KA3 AND FT PKA" FT /evidence="ECO:0000269|PubMed:19573808, FT ECO:0000269|PubMed:26158630, ECO:0000269|PubMed:27385333, FT ECO:0007744|PubMed:23186163" FT MOD_RES 901 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:27385333, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 921 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000255" FT MOD_RES 930 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:23358419" FT CARBOHYD 407 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 435 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19159218" FT DISULFID 70..188 FT DISULFID 105..115 FT VAR_SEQ 477..497 FT /note="GDSNSYNVRRTEGFSVTLDDL -> VTPRGAGLALAGPTAGDRLVT (in FT isoform 2)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056014" FT VAR_SEQ 498..976 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056015" FT VARIANT 99 FT /note="K -> N (in dbSNP:rs1058372)" FT /id="VAR_055989" FT VARIANT 391 FT /note="G -> R (in dbSNP:rs34192549)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042121" FT VARIANT 511 FT /note="T -> M (in dbSNP:rs55747232)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042122" FT VARIANT 568 FT /note="R -> H (in dbSNP:rs56198600)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042123" FT VARIANT 631 FT /note="M -> T (in dbSNP:rs34021505)" FT /id="VAR_055990" FT VARIANT 721 FT /note="R -> Q (in CTRCT6; retained in the cytoplasm and FT constitutively active it alters EPHA2 signaling; FT dbSNP:rs116506614)" FT /evidence="ECO:0000269|PubMed:19649315" FT /id="VAR_062532" FT VARIANT 777 FT /note="G -> S (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs922655349)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042124" FT VARIANT 876 FT /note="R -> H (in dbSNP:rs35903225)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042125" FT VARIANT 940 FT /note="T -> I (in CTRCT6; reduced protein stability and FT reduced ability to stimulate cell migration in absence of FT its ephrin ligand; dbSNP:rs137853200)" FT /evidence="ECO:0000269|PubMed:19306328, FT ECO:0000269|PubMed:22570727" FT /id="VAR_058907" FT VARIANT 948 FT /note="G -> W (in CTRCT6; reduced protein stability and FT reduced ability to stimulate cell migration in absence of FT its ephrin ligand; dbSNP:rs137853199)" FT /evidence="ECO:0000269|PubMed:19005574, FT ECO:0000269|PubMed:22570727" FT /id="VAR_058908" FT MUTAGEN 103 FT /note="R->E: Significantly reduced response to EFNA1." FT /evidence="ECO:0000269|PubMed:19525919" FT MUTAGEN 646 FT /note="K->M: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:16236711" FT MUTAGEN 739 FT /note="D->N: Increases serum-induced chemotaxis. Loss of FT EFNA1-dependent regulation of cell migration." FT /evidence="ECO:0000269|PubMed:19573808" FT MUTAGEN 897 FT /note="S->A,D: Loss of serum-induced phosphorylation by FT PKB. Loss of serum-induced chemotaxis." FT /evidence="ECO:0000269|PubMed:19573808" FT CONFLICT 94..99 FT /note="IFIELK -> NNFELN (in Ref. 1; AAA53375)" FT /evidence="ECO:0000305" FT STRAND 28..33 FT /evidence="ECO:0007829|PDB:6NK0" FT HELIX 34..37 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 44..47 FT /evidence="ECO:0007829|PDB:6NK0" FT TURN 48..50 FT /evidence="ECO:0007829|PDB:6NK1" FT STRAND 53..57 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 59..62 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 64..70 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 73..75 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 79..82 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 92..103 FT /evidence="ECO:0007829|PDB:6NK0" FT HELIX 105..107 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 108..110 FT /evidence="ECO:0007829|PDB:3HEI" FT TURN 112..114 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 119..128 FT /evidence="ECO:0007829|PDB:6NK0" FT HELIX 136..138 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 140..145 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 148..151 FT /evidence="ECO:0007829|PDB:6RW2" FT HELIX 153..157 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 164..170 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 175..199 FT /evidence="ECO:0007829|PDB:6NK0" FT STRAND 204..206 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 209..211 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 214..217 FT /evidence="ECO:0007829|PDB:8TRS" FT HELIX 221..224 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 225..227 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 238..240 FT /evidence="ECO:0007829|PDB:3MBW" FT STRAND 244..247 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 253..257 FT /evidence="ECO:0007829|PDB:8TV1" FT STRAND 266..269 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 272..275 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 284..287 FT /evidence="ECO:0007829|PDB:8TRS" FT STRAND 295..298 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 304..306 FT /evidence="ECO:0007829|PDB:8TV1" FT STRAND 335..338 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 343..348 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 361..369 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 376..378 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 384..387 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 389..392 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 394..400 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 407..415 FT /evidence="ECO:0007829|PDB:3FL7" FT HELIX 419..421 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 427..433 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 441..446 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 453..457 FT /evidence="ECO:0007829|PDB:3FL7" FT TURN 460..465 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 467..475 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 483..493 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 502..510 FT /evidence="ECO:0007829|PDB:3FL7" FT STRAND 522..525 FT /evidence="ECO:0007829|PDB:3FL7" FT HELIX 536..556 FT /evidence="ECO:0007829|PDB:2K9Y" FT STRAND 557..561 FT /evidence="ECO:0007829|PDB:2K9Y" FT HELIX 591..594 FT /evidence="ECO:0007829|PDB:5EK7" FT HELIX 597..600 FT /evidence="ECO:0007829|PDB:4PDO" FT TURN 601..604 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 610..612 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 613..622 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 625..632 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 635..637 FT /evidence="ECO:0007829|PDB:5NKH" FT STRAND 641..648 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 654..669 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 678..682 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 684..693 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 700..706 FT /evidence="ECO:0007829|PDB:6Q7D" FT TURN 707..709 FT /evidence="ECO:0007829|PDB:6Q7E" FT HELIX 713..732 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 742..744 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 745..747 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 753..755 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 762..766 FT /evidence="ECO:0007829|PDB:5NKF" FT STRAND 770..772 FT /evidence="ECO:0007829|PDB:5NKF" FT STRAND 776..778 FT /evidence="ECO:0007829|PDB:5NKH" FT HELIX 781..783 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 786..791 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 796..811 FT /evidence="ECO:0007829|PDB:6Q7D" FT TURN 817..820 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 823..831 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 844..853 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 858..860 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 864..876 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 878..881 FT /evidence="ECO:0007829|PDB:6Q7D" FT STRAND 882..884 FT /evidence="ECO:0007829|PDB:6Q7D" FT HELIX 889..892 FT /evidence="ECO:0007829|PDB:8QQY" FT HELIX 909..915 FT /evidence="ECO:0007829|PDB:7KJA" FT HELIX 919..921 FT /evidence="ECO:0007829|PDB:7KJA" FT HELIX 922..927 FT /evidence="ECO:0007829|PDB:7KJA" FT HELIX 933..936 FT /evidence="ECO:0007829|PDB:7KJA" FT HELIX 941..946 FT /evidence="ECO:0007829|PDB:7KJA" FT HELIX 952..969 FT /evidence="ECO:0007829|PDB:7KJA" SQ SEQUENCE 976 AA; 108266 MW; 845D7E1BBCCAACCC CRC64; MELQAARACF ALLWGCALAA AAAAQGKEVV LLDFAAAGGE LGWLTHPYGK GWDLMQNIMN DMPIYMYSVC NVMSGDQDNW LRTNWVYRGE AERIFIELKF TVRDCNSFPG GASSCKETFN LYYAESDLDY GTNFQKRLFT KIDTIAPDEI TVSSDFEARH VKLNVEERSV GPLTRKGFYL AFQDIGACVA LLSVRVYYKK CPELLQGLAH FPETIAGSDA PSLATVAGTC VDHAVVPPGG EEPRMHCAVD GEWLVPIGQC LCQAGYEKVE DACQACSPGF FKFEASESPC LECPEHTLPS PEGATSCECE EGFFRAPQDP ASMPCTRPPS APHYLTAVGM GAKVELRWTP PQDSGGREDI VYSVTCEQCW PESGECGPCE ASVRYSEPPH GLTRTSVTVS DLEPHMNYTF TVEARNGVSG LVTSRSFRTA SVSINQTEPP KVRLEGRSTT SLSVSWSIPP PQQSRVWKYE VTYRKKGDSN SYNVRRTEGF SVTLDDLAPD TTYLVQVQAL TQEGQGAGSK VHEFQTLSPE GSGNLAVIGG VAVGVVLLLV LAGVGFFIHR RRKNQRARQS PEDVYFSKSE QLKPLKTYVD PHTYEDPNQA VLKFTTEIHP SCVTRQKVIG AGEFGEVYKG MLKTSSGKKE VPVAIKTLKA GYTEKQRVDF LGEAGIMGQF SHHNIIRLEG VISKYKPMMI ITEYMENGAL DKFLREKDGE FSVLQLVGML RGIAAGMKYL ANMNYVHRDL AARNILVNSN LVCKVSDFGL SRVLEDDPEA TYTTSGGKIP IRWTAPEAIS YRKFTSASDV WSFGIVMWEV MTYGERPYWE LSNHEVMKAI NDGFRLPTPM DCPSAIYQLM MQCWQQERAR RPKFADIVSI LDKLIRAPDS LKTLADFDPR VSIRLPSTSG SEGVPFRTVS EWLESIKMQQ YTEHFMAAGY TAIEKVVQMT NDDIKRIGVR LPGHQKRIAY SLLGLKDQVN TVGIPI // ID EPHA3_HUMAN Reviewed; 983 AA. AC P29320; Q9H2V3; Q9H2V4; DT 01-DEC-1992, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 2. DT 28-JAN-2026, entry version 240. DE RecName: Full=Ephrin type-A receptor 3; DE EC=2.7.10.1; DE AltName: Full=EPH-like kinase 4; DE Short=EK4; DE Short=hEK4; DE AltName: Full=HEK; DE Short=Human embryo kinase; DE AltName: Full=Tyrosine-protein kinase TYRO4; DE AltName: Full=Tyrosine-protein kinase receptor ETK1; DE Short=Eph-like tyrosine kinase 1; DE Flags: Precursor; GN Name=EPHA3; Synonyms=ETK, ETK1, HEK, TYRO4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ARG-924. RX PubMed=1311845; DOI=10.1073/pnas.89.5.1611; RA Wicks I.P., Wilkinson D., Salvaris E., Boyd A.W.; RT "Molecular cloning of HEK, the gene encoding a receptor tyrosine kinase RT expressed by human lymphoid tumor cell lines."; RL Proc. Natl. Acad. Sci. U.S.A. 89:1611-1615(1992). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Melanoma; RX PubMed=10987298; RA Chiari R., Hames G., Stroobant V., Texier C., Maillere B., Boon T., RA Coulie P.G.; RT "Identification of a tumor-specific shared antigen derived from an Eph RT receptor and presented to CD4 T cells on HLA class II molecules."; RL Cancer Res. 60:4855-4863(2000). RN [3] RP PROTEIN SEQUENCE OF 21-29 AND 840-860, AND CHARACTERIZATION. RX PubMed=1737782; DOI=10.1016/s0021-9258(19)50725-6; RA Boyd A.W., Ward L.D., Wicks I.P., Simpson R.J., Salvaris E., Wilks A., RA Welch K., Loudovaris M., Rockman S., Busmanis I.; RT "Isolation and characterization of a novel receptor-type protein tyrosine RT kinase (hek) from a human pre-B cell line."; RL J. Biol. Chem. 267:3262-3267(1992). RN [4] RP NOMENCLATURE. RX PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0; RG Eph nomenclature committee; RT "Unified nomenclature for Eph family receptors and their ligands, the RT ephrins."; RL Cell 90:403-404(1997). RN [5] RP FUNCTION IN CELL-CELL ADHESION, EFNA5-BINDING, SUBCELLULAR LOCATION RP (ISOFORM 1), INTERACTION WITH CRK, AND PHOSPHORYLATION AT TYR-596; TYR-602 RP AND TYR-779. RX PubMed=11870224; DOI=10.1242/jcs.115.5.1059; RA Lawrenson I.D., Wimmer-Kleikamp S.H., Lock P., Schoenwaelder S.M., Down M., RA Boyd A.W., Alewood P.F., Lackmann M.; RT "Ephrin-A5 induces rounding, blebbing and de-adhesion of EphA3-expressing RT 293T and melanoma cells by CrkII and Rho-mediated signalling."; RL J. Cell Sci. 115:1059-1072(2002). RN [6] RP FUNCTION. RX PubMed=12794130; DOI=10.4049/jimmunol.170.12.6024; RA Sharfe N., Freywald A., Toro A., Roifman C.M.; RT "Ephrin-A1 induces c-Cbl phosphorylation and EphA receptor down-regulation RT in T cells."; RL J. Immunol. 170:6024-6032(2003). RN [7] RP INVOLVEMENT IN CRC. RX PubMed=12738854; DOI=10.1126/science.1082596; RA Bardelli A., Parsons D.W., Silliman N., Ptak J., Szabo S., Saha S., RA Markowitz S., Willson J.K., Parmigiani G., Kinzler K.W., Vogelstein B., RA Velculescu V.E.; RT "Mutational analysis of the tyrosine kinome in colorectal cancers."; RL Science 300:949-949(2003). RN [8] RP EPHRIN LIGAND-BINDING, OLIGOMERIZATION, MUTAGENESIS OF VAL-133 AND PHE-152, RP AND INTERACTION WITH CRK. RX PubMed=14660665; DOI=10.1074/jbc.m309326200; RA Smith F.M., Vearing C., Lackmann M., Treutlein H., Himanen J., Chen K., RA Saul A., Nikolov D., Boyd A.W.; RT "Dissecting the EphA3/Ephrin-A5 interactions using a novel functional RT mutagenesis screen."; RL J. Biol. Chem. 279:9522-9531(2004). RN [9] RP IDENTIFICATION IN A COMPLEX WITH ADAM10 AND EFNA5. RX PubMed=16239146; DOI=10.1016/j.cell.2005.08.014; RA Janes P.W., Saha N., Barton W.A., Kolev M.V., Wimmer-Kleikamp S.H., RA Nievergall E., Blobel C.P., Himanen J.P., Lackmann M., Nikolov D.B.; RT "Adam meets Eph: an ADAM substrate recognition module acts as a molecular RT switch for ephrin cleavage in trans."; RL Cell 123:291-304(2005). RN [10] RP EFNA5 LIGAND-BINDING. RX PubMed=15901737; DOI=10.1074/jbc.m504972200; RA Day B., To C., Himanen J.P., Smith F.M., Nikolov D.B., Boyd A.W., RA Lackmann M.; RT "Three distinct molecular surfaces in ephrin-A5 are essential for a RT functional interaction with EphA3."; RL J. Biol. Chem. 280:26526-26532(2005). RN [11] RP INTERACTION WITH PTPN1, PHOSPHORYLATION, DEPHOSPHORYLATION BY PTPN1, AND RP SUBCELLULAR LOCATION (ISOFORM 2). RX PubMed=21135139; DOI=10.1083/jcb.201005035; RA Nievergall E., Janes P.W., Stegmayer C., Vail M.E., Haj F.G., Teng S.W., RA Neel B.G., Bastiaens P.I., Lackmann M.; RT "PTP1B regulates Eph receptor function and trafficking."; RL J. Cell Biol. 191:1189-1203(2010). RN [12] RP X-RAY CRYSTALLOGRAPHY (1.07 ANGSTROMS) OF 577-947 IN COMPLEX WITH ATP RP ANALOG, IDENTIFICATION BY MASS SPECTROMETRY, PHOSPHORYLATION AT TYR-596; RP TYR-602 AND TYR-701, AND MUTAGENESIS OF TYR-596; TYR-602; TYR-742 AND RP SER-768. RX PubMed=18547520; DOI=10.1016/j.str.2008.03.008; RA Davis T.L., Walker J.R., Loppnau P., Butler-Cole C., Allali-Hassani A., RA Dhe-Paganon S.; RT "Autoregulation by the juxtamembrane region of the human ephrin receptor RT tyrosine kinase A3 (EphA3)."; RL Structure 16:873-884(2008). RN [13] RP VARIANTS [LARGE SCALE ANALYSIS] LYS-37; SER-85; LEU-621 AND ASN-806. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [14] RP VARIANTS LYS-660 AND MET-933. RX PubMed=16941478; DOI=10.1002/humu.9452; RA Wood L.D., Calhoun E.S., Silliman N., Ptak J., Szabo S., Powell S.M., RA Riggins G.J., Wang T.L., Yan H., Gazdar A., Kern S.E., Pennacchio L., RA Kinzler K.W., Vogelstein B., Velculescu V.E.; RT "Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers."; RL Hum. Mutat. 27:1060-1061(2006). RN [15] RP VARIANTS [LARGE SCALE ANALYSIS] TYR-229; PHE-449; LEU-518; VAL-564; RP SER-568; PRO-590; GLU-766; GLY-777; HIS-914 AND ARG-924. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [16] RP VARIANT ASN-207. RX PubMed=20838624; DOI=10.1371/journal.pone.0012653; RA Corbo V., Ritelli R., Barbi S., Funel N., Campani D., Bardelli A., RA Scarpa A.; RT "Mutational profiling of kinases in human tumours of pancreatic origin RT identifies candidate cancer genes in ductal and ampulla of vater RT carcinomas."; RL PLoS ONE 5:E12653-E12653(2010). CC -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously membrane- CC bound ephrin family ligands residing on adjacent cells, leading to CC contact-dependent bidirectional signaling into neighboring cells. The CC signaling pathway downstream of the receptor is referred to as forward CC signaling while the signaling pathway downstream of the ephrin ligand CC is referred to as reverse signaling (PubMed:11870224, PubMed:12794130). CC Highly promiscuous for ephrin-A ligands it binds preferentially EFNA5 CC (By similarity). Upon activation by EFNA5 regulates cell-cell adhesion, CC cytoskeletal organization and cell migration (PubMed:11870224). Also CC activated by EFNA1, inhibiting epithelial-to-mesenchymal transition of CC cardiac cells and playing a role in heart development CC (PubMed:12794130). Involved in the retinotectal mapping of neurons. May CC also control the segregation but not the guidance of motor and sensory CC axons during neuromuscular circuit development (By similarity). CC {ECO:0000250|UniProtKB:P29319, ECO:0000269|PubMed:11870224, CC ECO:0000269|PubMed:12794130}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Heterotetramer upon binding of the ligand. The heterotetramer CC is composed of an ephrin dimer and a receptor dimer. Oligomerization is CC probably required to induce biological responses. Forms a ternary CC EFNA5-EPHA3-ADAM10 complex mediating EFNA5 extracellular domain CC shedding by ADAM10 which regulates the EFNA5-EPHA3 complex CC internalization and function. Interacts with NCK1 (via SH2 domain); CC mediates EFNA5-EPHA3 signaling (By similarity). Interacts CC (phosphorylated) with PTPN1; dephosphorylates EPHA3 and may regulate CC its trafficking and function. Interacts (phosphorylated) with CRK; CC mediates EFNA5-EPHA3 signaling through RHOA GTPase activation. CC {ECO:0000250, ECO:0000269|PubMed:11870224, ECO:0000269|PubMed:14660665, CC ECO:0000269|PubMed:16239146, ECO:0000269|PubMed:18547520, CC ECO:0000269|PubMed:21135139}. CC -!- INTERACTION: CC P29320; P29317: EPHA2; NbExp=3; IntAct=EBI-1641575, EBI-702104; CC P29320; Q15375: EPHA7; NbExp=4; IntAct=EBI-1641575, EBI-1383428; CC P29320; Q13485: SMAD4; NbExp=6; IntAct=EBI-1641575, EBI-347263; CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane CC {ECO:0000269|PubMed:11870224}; Single-pass type I membrane protein CC {ECO:0000255}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted CC {ECO:0000269|PubMed:21135139}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P29320-1; Sequence=Displayed; CC Name=2; CC IsoId=P29320-2; Sequence=VSP_002995, VSP_002996; CC -!- TISSUE SPECIFICITY: Widely expressed. Highest level in placenta. CC -!- PTM: Autophosphorylates upon activation by EFNA5. Phosphorylation on CC Tyr-602 mediates interaction with NCK1. Dephosphorylated by PTPN1. CC {ECO:0000269|PubMed:11870224, ECO:0000269|PubMed:18547520, CC ECO:0000269|PubMed:21135139}. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:12738854}. Note=The gene CC represented in this entry may be involved in disease pathogenesis. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40463/EPHA3"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M83941; AAA58633.1; -; mRNA. DR EMBL; AF213459; AAG43576.1; -; mRNA. DR EMBL; AF213460; AAG43577.1; -; mRNA. DR CCDS; CCDS2922.1; -. [P29320-1] DR CCDS; CCDS46875.1; -. [P29320-2] DR PIR; A38224; A38224. DR RefSeq; NP_005224.2; NM_005233.5. [P29320-1] DR RefSeq; NP_872585.1; NM_182644.3. [P29320-2] DR PDB; 2GSF; X-ray; 1.77 A; A=577-947. DR PDB; 2QO2; X-ray; 1.60 A; A=577-947. DR PDB; 2QO7; X-ray; 1.60 A; A=577-947. DR PDB; 2QO9; X-ray; 1.55 A; A=577-947. DR PDB; 2QOB; X-ray; 1.65 A; A=609-947. DR PDB; 2QOC; X-ray; 1.25 A; A=609-947. DR PDB; 2QOD; X-ray; 1.15 A; A=577-947. DR PDB; 2QOF; X-ray; 1.20 A; A=577-947. DR PDB; 2QOI; X-ray; 1.25 A; A=577-947. DR PDB; 2QOK; X-ray; 1.20 A; A=577-947. DR PDB; 2QOL; X-ray; 1.07 A; A=577-947. DR PDB; 2QON; X-ray; 1.79 A; A=577-947. DR PDB; 2QOO; X-ray; 1.25 A; A=577-947. DR PDB; 2QOQ; X-ray; 1.60 A; A=577-947. DR PDB; 3DZQ; X-ray; 1.75 A; A=609-947. DR PDB; 3FXX; X-ray; 1.70 A; A=577-947. DR PDB; 3FY2; X-ray; 1.80 A; A=577-947. DR PDB; 4G2F; X-ray; 1.70 A; A=609-947. DR PDB; 4GK2; X-ray; 2.20 A; A=609-947. DR PDB; 4GK3; X-ray; 1.90 A; A=609-947. DR PDB; 4GK4; X-ray; 2.10 A; A=609-947. DR PDB; 4L0P; X-ray; 2.26 A; A=29-201. DR PDB; 4P4C; X-ray; 1.60 A; A=609-947. DR PDB; 4P5Q; X-ray; 1.35 A; A=606-947. DR PDB; 4P5Z; X-ray; 2.00 A; A=606-947. DR PDB; 4TWN; X-ray; 1.71 A; A=609-947. DR PDB; 4TWO; X-ray; 2.05 A; A=609-947. DR PDB; 6IN0; X-ray; 1.50 A; A=612-904. DR PDBsum; 2GSF; -. DR PDBsum; 2QO2; -. DR PDBsum; 2QO7; -. DR PDBsum; 2QO9; -. DR PDBsum; 2QOB; -. DR PDBsum; 2QOC; -. DR PDBsum; 2QOD; -. DR PDBsum; 2QOF; -. DR PDBsum; 2QOI; -. DR PDBsum; 2QOK; -. DR PDBsum; 2QOL; -. DR PDBsum; 2QON; -. DR PDBsum; 2QOO; -. DR PDBsum; 2QOQ; -. DR PDBsum; 3DZQ; -. DR PDBsum; 3FXX; -. DR PDBsum; 3FY2; -. DR PDBsum; 4G2F; -. DR PDBsum; 4GK2; -. DR PDBsum; 4GK3; -. DR PDBsum; 4GK4; -. DR PDBsum; 4L0P; -. DR PDBsum; 4P4C; -. DR PDBsum; 4P5Q; -. DR PDBsum; 4P5Z; -. DR PDBsum; 4TWN; -. DR PDBsum; 4TWO; -. DR PDBsum; 6IN0; -. DR AlphaFoldDB; P29320; -. DR SMR; P29320; -. DR BioGRID; 108356; 115. DR DIP; DIP-40307N; -. DR FunCoup; P29320; 1027. DR IntAct; P29320; 85. DR MINT; P29320; -. DR STRING; 9606.ENSP00000337451; -. DR BindingDB; P29320; -. DR ChEMBL; CHEMBL4954; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; P29320; -. DR GuidetoPHARMACOLOGY; 1823; -. DR GlyCosmos; P29320; 5 sites, No reported glycans. DR GlyGen; P29320; 7 sites, 3 N-linked glycans (3 sites). DR iPTMnet; P29320; -. DR MetOSite; P29320; -. DR PhosphoSitePlus; P29320; -. DR SwissPalm; P29320; -. DR BioMuta; EPHA3; -. DR DMDM; 116241351; -. DR CPTAC; CPTAC-1774; -. DR CPTAC; CPTAC-3202; -. DR CPTAC; CPTAC-3203; -. DR jPOST; P29320; -. DR MassIVE; P29320; -. DR PaxDb; 9606-ENSP00000337451; -. DR PeptideAtlas; P29320; -. DR ProteomicsDB; 54536; -. [P29320-1] DR ProteomicsDB; 54537; -. [P29320-2] DR ABCD; P29320; 1 sequenced antibody. DR Antibodypedia; 4182; 558 antibodies from 41 providers. DR DNASU; 2042; -. DR Ensembl; ENST00000336596.7; ENSP00000337451.2; ENSG00000044524.12. [P29320-1] DR Ensembl; ENST00000452448.6; ENSP00000399926.2; ENSG00000044524.12. [P29320-2] DR GeneID; 2042; -. DR KEGG; hsa:2042; -. DR MANE-Select; ENST00000336596.7; ENSP00000337451.2; NM_005233.6; NP_005224.2. DR UCSC; uc003dqx.2; human. [P29320-1] DR AGR; HGNC:3387; -. DR ClinPGx; PA27819; -. DR CTD; 2042; -. DR DisGeNET; 2042; -. DR GeneCards; EPHA3; -. DR HGNC; HGNC:3387; EPHA3. DR HPA; ENSG00000044524; Tissue enhanced (prostate). DR MalaCards; EPHA3; -. DR MIM; 114500; phenotype. DR MIM; 179611; gene. DR OpenTargets; ENSG00000044524; -. DR VEuPathDB; HostDB:ENSG00000044524; -. DR eggNOG; KOG0196; Eukaryota. DR GeneTree; ENSGT00940000157088; -. DR HOGENOM; CLU_000288_141_3_1; -. DR InParanoid; P29320; -. DR OMA; GNTKCAK; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P29320; 8 GO annotations based on evolutionary models. DR PhylomeDB; P29320; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P29320; -. DR Reactome; R-HSA-2682334; EPH-Ephrin signaling. DR Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse. DR Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. DR SignaLink; P29320; -. DR SIGNOR; P29320; -. DR Agora; ENSG00000044524; -. DR BioGRID-ORCS; 2042; 12 hits in 1194 CRISPR screens. DR ChiTaRS; EPHA3; human. DR EvolutionaryTrace; P29320; -. DR GeneWiki; EPH_receptor_A3; -. DR GenomeRNAi; 2042; -. DR Pharos; P29320; Tchem. DR PRO; PR:P29320; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P29320; protein. DR Bgee; ENSG00000044524; Expressed in ganglionic eminence and 159 other cell types or tissues. DR ExpressionAtlas; P29320; baseline and differential. DR GO; GO:0015629; C:actin cytoskeleton; IDA:HPA. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0030425; C:dendrite; IBA:GO_Central. DR GO; GO:0005769; C:early endosome; IDA:UniProtKB. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0031965; C:nuclear membrane; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005003; F:ephrin receptor activity; IDA:ARUK-UCL. DR GO; GO:0005004; F:GPI-linked ephrin receptor activity; IDA:UniProtKB. DR GO; GO:0005005; F:transmembrane-ephrin receptor activity; IBA:GO_Central. DR GO; GO:0007411; P:axon guidance; IBA:GO_Central. DR GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW. DR GO; GO:0016477; P:cell migration; ISS:UniProtKB. DR GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL. DR GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0097156; P:fasciculation of motor neuron axon; ISS:UniProtKB. DR GO; GO:0097155; P:fasciculation of sensory neuron axon; ISS:UniProtKB. DR GO; GO:0045806; P:negative regulation of endocytosis; IDA:UniProtKB. DR GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; ISS:UniProt. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL. DR GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IDA:UniProtKB. DR GO; GO:0032956; P:regulation of actin cytoskeleton organization; IDA:UniProtKB. DR GO; GO:0022407; P:regulation of cell-cell adhesion; IDA:UniProt. DR GO; GO:0010717; P:regulation of epithelial to mesenchymal transition; ISS:UniProtKB. DR GO; GO:0051893; P:regulation of focal adhesion assembly; IDA:UniProtKB. DR GO; GO:0043087; P:regulation of GTPase activity; IDA:UniProtKB. DR GO; GO:0070507; P:regulation of microtubule cytoskeleton organization; IDA:UniProtKB. DR CDD; cd10481; EphR_LBD_A3; 1. DR CDD; cd00063; FN3; 2. DR CDD; cd05066; PTKc_EphR_A; 1. DR FunFam; 1.10.150.50:FF:000046; ephrin type-A receptor 3; 1. DR FunFam; 2.60.40.10:FF:000041; ephrin type-A receptor 3; 1. DR FunFam; 1.10.510.10:FF:000019; Ephrin type-A receptor 5; 1. DR FunFam; 2.10.50.10:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.10:FF:000045; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.1770:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 3.30.200.20:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.120.260:FF:000001; Ephrin type-A receptor 7; 1. DR Gene3D; 2.60.40.1770; ephrin a2 ectodomain; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 1. DR InterPro; IPR027936; Eph_TM. DR InterPro; IPR034266; EphA3_rcpt_lig-bd. DR InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom. DR InterPro; IPR050449; Ephrin_rcpt_TKs. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001660; SAM. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016257; Tyr_kinase_ephrin_rcpt. DR InterPro; IPR001426; Tyr_kinase_rcpt_V_CS. DR PANTHER; PTHR46877; EPH RECEPTOR A5; 1. DR PANTHER; PTHR46877:SF12; EPHRIN TYPE-A RECEPTOR 3; 1. DR Pfam; PF14575; EphA2_TM; 1. DR Pfam; PF25599; Ephrin_CRD; 1. DR Pfam; PF01404; Ephrin_lbd; 1. DR Pfam; PF07699; Ephrin_rec_like; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF07647; SAM_2; 1. DR PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1. DR PRINTS; PR00014; FNTYPEIII. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00615; EPH_lbd; 1. DR SMART; SM01411; Ephrin_rec_like; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00454; SAM; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS01186; EGF_2; 1. DR PROSITE; PS51550; EPH_LBD; 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1. DR PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1. DR PROSITE; PS50105; SAM_DOMAIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell adhesion; KW Cell membrane; Direct protein sequencing; Glycoprotein; Kinase; Membrane; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; Receptor; KW Reference proteome; Repeat; Secreted; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase. FT SIGNAL 1..20 FT /evidence="ECO:0000269|PubMed:1737782" FT CHAIN 21..983 FT /note="Ephrin type-A receptor 3" FT /id="PRO_0000016802" FT TOPO_DOM 21..541 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 542..565 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 566..983 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 29..207 FT /note="Eph LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00883" FT DOMAIN 325..435 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 436..531 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 621..882 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 911..975 FT /note="SAM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00184" FT MOTIF 981..983 FT /note="PDZ-binding" FT /evidence="ECO:0000255" FT ACT_SITE 746 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 628..633 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 653 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 700..706 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 750..751 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT MOD_RES 596 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11870224, FT ECO:0000269|PubMed:18547520" FT MOD_RES 602 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11870224, FT ECO:0000269|PubMed:18547520" FT MOD_RES 701 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18547520" FT MOD_RES 779 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11870224" FT MOD_RES 937 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:P29319" FT CARBOHYD 232 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 337 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 391 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 404 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 493 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 532..539 FT /note="SFSISGES -> CMYYFNAV (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10987298" FT /id="VSP_002995" FT VAR_SEQ 540..983 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10987298" FT /id="VSP_002996" FT VARIANT 37 FT /note="T -> K (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036086" FT VARIANT 85 FT /note="N -> S (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036087" FT VARIANT 207 FT /note="K -> N (in a pancreatic ductal adenocarcinoma FT sample; somatic mutation; dbSNP:rs200567888)" FT /evidence="ECO:0000269|PubMed:20838624" FT /id="VAR_068853" FT VARIANT 229 FT /note="S -> Y (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042126" FT VARIANT 449 FT /note="S -> F (in a lung neuroendocrine carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042127" FT VARIANT 518 FT /note="G -> L (in a lung squamous cell carcinoma sample; FT somatic mutation; requires 2 nucleotide substitutions)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042128" FT VARIANT 564 FT /note="I -> V (in dbSNP:rs55712516)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042129" FT VARIANT 568 FT /note="C -> S (in dbSNP:rs56077781)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042130" FT VARIANT 590 FT /note="L -> P (in dbSNP:rs56081642)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042131" FT VARIANT 621 FT /note="I -> L (in a colorectal cancer sample; somatic FT mutation; dbSNP:rs1414714315)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036088" FT VARIANT 660 FT /note="T -> K (in a lung carcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16941478" FT /id="VAR_065831" FT VARIANT 766 FT /note="G -> E (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042132" FT VARIANT 777 FT /note="A -> G (in dbSNP:rs34437982)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042133" FT VARIANT 806 FT /note="D -> N (in a colorectal cancer sample; somatic FT mutation; dbSNP:rs2107553474)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036089" FT VARIANT 914 FT /note="R -> H (in dbSNP:rs17801309)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_027919" FT VARIANT 924 FT /note="W -> R (in dbSNP:rs35124509)" FT /evidence="ECO:0000269|PubMed:1311845, FT ECO:0000269|PubMed:17344846" FT /id="VAR_042134" FT VARIANT 933 FT /note="T -> M (in a lung carcinoma sample; somatic FT mutation; dbSNP:rs372594677)" FT /evidence="ECO:0000269|PubMed:16941478" FT /id="VAR_065832" FT MUTAGEN 133 FT /note="V->E: Loss of EFNA5-binding ability and function." FT /evidence="ECO:0000269|PubMed:14660665" FT MUTAGEN 152 FT /note="F->L: Loss of EFNA5-binding ability and function." FT /evidence="ECO:0000269|PubMed:14660665" FT MUTAGEN 596 FT /note="Y->F: 10-fold suppression of kinase activity; when FT associated with F-602. Full kinase activity; when FT associated with F-602 and F-742. Full kinase activity; when FT associated with F-602 and A-768." FT /evidence="ECO:0000269|PubMed:18547520" FT MUTAGEN 602 FT /note="Y->F: 10-fold suppression of kinase activity; when FT associated with F-596. Full kinase activity; when FT associated with F-596 and F-742. Full kinase activity; when FT associated with F-596 and A-768." FT /evidence="ECO:0000269|PubMed:18547520" FT MUTAGEN 742 FT /note="Y->F: Full kinase activity; when associated with F- FT 596 and F-602." FT /evidence="ECO:0000269|PubMed:18547520" FT MUTAGEN 768 FT /note="S->A: Full kinase activity; when associated with F- FT 596 and F-602." FT /evidence="ECO:0000269|PubMed:18547520" FT CONFLICT 911 FT /note="T -> S (in Ref. 1; AAA58633)" FT /evidence="ECO:0000305" FT STRAND 29..34 FT /evidence="ECO:0007829|PDB:4L0P" FT TURN 38..41 FT /evidence="ECO:0007829|PDB:4L0P" FT STRAND 45..48 FT /evidence="ECO:0007829|PDB:4L0P" FT STRAND 51..58 FT /evidence="ECO:0007829|PDB:4L0P" FT STRAND 64..71 FT /evidence="ECO:0007829|PDB:4L0P" FT STRAND 75..77 FT /evidence="ECO:0007829|PDB:4L0P" FT STRAND 80..83 FT /evidence="ECO:0007829|PDB:4L0P" FT STRAND 96..104 FT /evidence="ECO:0007829|PDB:4L0P" FT HELIX 106..108 FT /evidence="ECO:0007829|PDB:4L0P" FT STRAND 117..128 FT /evidence="ECO:0007829|PDB:4L0P" FT STRAND 130..132 FT /evidence="ECO:0007829|PDB:4L0P" FT HELIX 137..139 FT /evidence="ECO:0007829|PDB:4L0P" FT STRAND 141..147 FT /evidence="ECO:0007829|PDB:4L0P" FT HELIX 154..159 FT /evidence="ECO:0007829|PDB:4L0P" FT STRAND 165..170 FT /evidence="ECO:0007829|PDB:4L0P" FT STRAND 176..200 FT /evidence="ECO:0007829|PDB:4L0P" FT TURN 610..612 FT /evidence="ECO:0007829|PDB:2QOL" FT HELIX 618..620 FT /evidence="ECO:0007829|PDB:2QOL" FT STRAND 621..629 FT /evidence="ECO:0007829|PDB:2QOL" FT STRAND 631..641 FT /evidence="ECO:0007829|PDB:2QOL" FT STRAND 647..654 FT /evidence="ECO:0007829|PDB:2QOL" FT HELIX 661..674 FT /evidence="ECO:0007829|PDB:2QOL" FT STRAND 685..689 FT /evidence="ECO:0007829|PDB:2QOL" FT STRAND 691..694 FT /evidence="ECO:0007829|PDB:2QOL" FT STRAND 696..700 FT /evidence="ECO:0007829|PDB:2QOL" FT HELIX 707..712 FT /evidence="ECO:0007829|PDB:2QOL" FT TURN 713..716 FT /evidence="ECO:0007829|PDB:2QOL" FT HELIX 720..739 FT /evidence="ECO:0007829|PDB:2QOL" FT HELIX 749..751 FT /evidence="ECO:0007829|PDB:2QOL" FT STRAND 752..754 FT /evidence="ECO:0007829|PDB:2QOL" FT STRAND 760..762 FT /evidence="ECO:0007829|PDB:2QOL" FT HELIX 765..768 FT /evidence="ECO:0007829|PDB:4TWN" FT HELIX 788..790 FT /evidence="ECO:0007829|PDB:2QOD" FT HELIX 793..798 FT /evidence="ECO:0007829|PDB:2QOL" FT HELIX 803..818 FT /evidence="ECO:0007829|PDB:2QOL" FT TURN 819..821 FT /evidence="ECO:0007829|PDB:2QO9" FT TURN 824..827 FT /evidence="ECO:0007829|PDB:2QOL" FT HELIX 830..838 FT /evidence="ECO:0007829|PDB:2QOL" FT HELIX 851..860 FT /evidence="ECO:0007829|PDB:2QOL" FT HELIX 865..867 FT /evidence="ECO:0007829|PDB:2QOL" FT HELIX 871..883 FT /evidence="ECO:0007829|PDB:2QOL" FT HELIX 885..889 FT /evidence="ECO:0007829|PDB:2QOL" FT STRAND 890..892 FT /evidence="ECO:0007829|PDB:4G2F" FT STRAND 898..903 FT /evidence="ECO:0007829|PDB:2QOC" SQ SEQUENCE 983 AA; 110131 MW; BE04DBF958245424 CRC64; MDCQLSILLL LSCSVLDSFG ELIPQPSNEV NLLDSKTIQG ELGWISYPSH GWEEISGVDE HYTPIRTYQV CNVMDHSQNN WLRTNWVPRN SAQKIYVELK FTLRDCNSIP LVLGTCKETF NLYYMESDDD HGVKFREHQF TKIDTIAADE SFTQMDLGDR ILKLNTEIRE VGPVNKKGFY LAFQDVGACV ALVSVRVYFK KCPFTVKNLA MFPDTVPMDS QSLVEVRGSC VNNSKEEDPP RMYCSTEGEW LVPIGKCSCN AGYEERGFMC QACRPGFYKA LDGNMKCAKC PPHSSTQEDG SMNCRCENNY FRADKDPPSM ACTRPPSSPR NVISNINETS VILDWSWPLD TGGRKDVTFN IICKKCGWNI KQCEPCSPNV RFLPRQFGLT NTTVTVTDLL AHTNYTFEID AVNGVSELSS PPRQFAAVSI TTNQAAPSPV LTIKKDRTSR NSISLSWQEP EHPNGIILDY EVKYYEKQEQ ETSYTILRAR GTNVTISSLK PDTIYVFQIR ARTAAGYGTN SRKFEFETSP DSFSISGESS QVVMIAISAA VAIILLTVVI YVLIGRFCGY KSKHGADEKR LHFGNGHLKL PGLRTYVDPH TYEDPTQAVH EFAKELDATN ISIDKVVGAG EFGEVCSGRL KLPSKKEISV AIKTLKVGYT EKQRRDFLGE ASIMGQFDHP NIIRLEGVVT KSKPVMIVTE YMENGSLDSF LRKHDAQFTV IQLVGMLRGI ASGMKYLSDM GYVHRDLAAR NILINSNLVC KVSDFGLSRV LEDDPEAAYT TRGGKIPIRW TSPEAIAYRK FTSASDVWSY GIVLWEVMSY GERPYWEMSN QDVIKAVDEG YRLPPPMDCP AALYQLMLDC WQKDRNNRPK FEQIVSILDK LIRNPGSLKI ITSAAARPSN LLLDQSNVDI TTFRTTGDWL NGVWTAHCKE IFTGVEYSSC DTIAKISTDD MKKVGVTVVG PQKKIISSIK ALETQSKNGP VPV // ID EPHA5_HUMAN Reviewed; 1037 AA. AC P54756; Q7Z3F2; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 22-SEP-2009, sequence version 3. DT 28-JAN-2026, entry version 228. DE RecName: Full=Ephrin type-A receptor 5; DE EC=2.7.10.1; DE AltName: Full=Brain-specific kinase; DE AltName: Full=EPH homology kinase 1; DE Short=EHK-1; DE AltName: Full=EPH-like kinase 7; DE Short=EK7; DE Short=hEK7; DE Flags: Precursor; GN Name=EPHA5; Synonyms=BSK, EHK1, HEK7, TYRO4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RC TISSUE=Brain; RX PubMed=9191074; DOI=10.1016/s0169-328x(96)00268-9; RA Miescher G.C., Taylor V., Olivieri G., Mindermann T., Shrock E., RA Steck A.J.; RT "Extensive splice variation and localization of the EHK-1 receptor tyrosine RT kinase in adult human brain and glial tumors."; RL Brain Res. Mol. Brain Res. 46:17-24(1997). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Retina; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] OF 25-1037. RC TISSUE=Brain; RX PubMed=7898931; RA Fox G.M., Holst P.L., Chute H.T., Lindberg R.A., Janssen A.M., Basu R., RA Welcher A.A.; RT "cDNA cloning and tissue distribution of five human EPH-like receptor RT protein-tyrosine kinases."; RL Oncogene 10:897-905(1995). RN [5] RP IDENTIFICATION OF EFNA5 AS LIGAND, AND PHOSPHORYLATION. RX PubMed=7748564; DOI=10.1016/0896-6273(95)90335-6; RA Winslow J.W., Moran P., Valverde J., Shih A., Yuan J.Q., Wong S.C., RA Tsai S.P., Goddard A., Henzel W.J., Hefti F., Beck K.D., Caras I.W.; RT "Cloning of AL-1, a ligand for an Eph-related tyrosine kinase receptor RT involved in axon bundle formation."; RL Neuron 14:973-981(1995). RN [6] RP NOMENCLATURE. RX PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0; RG Eph nomenclature committee; RT "Unified nomenclature for Eph family receptors and their ligands, the RT ephrins."; RL Cell 90:403-404(1997). RN [7] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=10375373; DOI=10.1177/002215549904700702; RA Olivieri G., Miescher G.C.; RT "Immunohistochemical localization of EphA5 in the adult human central RT nervous system."; RL J. Histochem. Cytochem. 47:855-861(1999). RN [8] RP VARIANTS [LARGE SCALE ANALYSIS] THR-81; ALA-235; GLN-330; GLN-417; LYS-503; RP CYS-506; GLU-582; THR-672; THR-673; ILE-856; ARG-959 AND SER-1032. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously GPI- CC anchored ephrin-A family ligands residing on adjacent cells, leading to CC contact-dependent bidirectional signaling into neighboring cells. The CC signaling pathway downstream of the receptor is referred to as forward CC signaling while the signaling pathway downstream of the ephrin ligand CC is referred to as reverse signaling. Among GPI-anchored ephrin-A CC ligands, EFNA5 most probably constitutes the cognate/functional ligand CC for EPHA5. Functions as an axon guidance molecule during development CC and may be involved in the development of the retinotectal, entorhino- CC hippocampal and hippocamposeptal pathways. Together with EFNA5 plays CC also a role in synaptic plasticity in adult brain through regulation of CC synaptogenesis. In addition to its function in the nervous system, the CC interaction of EPHA5 with EFNA5 mediates communication between CC pancreatic islet cells to regulate glucose-stimulated insulin secretion CC (By similarity). {ECO:0000250}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Heterotetramer upon binding of the ligand. The heterotetramer CC is composed of an ephrin dimer and a receptor dimer. Oligomerization is CC probably required to induce biological responses (By similarity). CC Interacts (via SAM domain) with SAMD5 (via SAM domain) (By similarity). CC {ECO:0000250, ECO:0000250|UniProtKB:Q60629}. CC -!- INTERACTION: CC P54756; P29317: EPHA2; NbExp=3; IntAct=EBI-1383718, EBI-702104; CC P54756; P54760: EPHB4; NbExp=2; IntAct=EBI-1383718, EBI-702121; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10375373}; CC Single-pass type I membrane protein {ECO:0000255}. Cell projection, CC axon {ECO:0000250|UniProtKB:P54757}. Cell projection, dendrite CC {ECO:0000269|PubMed:10375373, ECO:0000269|PubMed:9191074}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Comment=Additional isoforms seem to exist.; CC Name=1; CC IsoId=P54756-1; Sequence=Displayed; CC Name=2; CC IsoId=P54756-2; Sequence=VSP_002999; CC Name=3; CC IsoId=P54756-3; Sequence=VSP_039118, VSP_039119; CC -!- TISSUE SPECIFICITY: Almost exclusively expressed in the nervous system CC in cortical neurons, cerebellar Purkinje cells and pyramidal neurons CC within the cortex and hippocampus. Display an increasing gradient of CC expression from the forebrain to hindbrain and spinal cord. CC {ECO:0000269|PubMed:10375373, ECO:0000269|PubMed:9191074}. CC -!- PTM: Phosphorylated. Phosphorylation is stimulated by the ligand EFNA5. CC Dephosphorylation upon stimulation by glucose, inhibits EPHA5 forward CC signaling and results in insulin secretion (By similarity). CC {ECO:0000250}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X95425; CAA64700.1; -; mRNA. DR EMBL; AC018683; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC104137; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC105923; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC115223; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BX537946; CAD97914.1; -; mRNA. DR EMBL; L36644; AAA74245.1; -; mRNA. DR CCDS; CCDS3513.1; -. [P54756-1] DR CCDS; CCDS3514.1; -. [P54756-2] DR RefSeq; NP_001268694.1; NM_001281765.2. DR RefSeq; NP_001268695.1; NM_001281766.2. DR RefSeq; NP_001305690.1; NM_001318761.2. [P54756-3] DR RefSeq; NP_004430.4; NM_004439.7. [P54756-1] DR RefSeq; NP_872272.2; NM_182472.5. [P54756-2] DR PDB; 2R2P; X-ray; 2.40 A; A=653-939. DR PDB; 4ET7; X-ray; 2.60 A; A=59-235. DR PDBsum; 2R2P; -. DR PDBsum; 4ET7; -. DR AlphaFoldDB; P54756; -. DR SMR; P54756; -. DR BioGRID; 108358; 145. DR FunCoup; P54756; 1219. DR IntAct; P54756; 133. DR MINT; P54756; -. DR STRING; 9606.ENSP00000480763; -. DR BindingDB; P54756; -. DR ChEMBL; CHEMBL3987; -. DR DrugBank; DB01254; Dasatinib. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; P54756; -. DR GuidetoPHARMACOLOGY; 1825; -. DR GlyCosmos; P54756; 6 sites, No reported glycans. DR GlyGen; P54756; 10 sites, 3 N-linked glycans (3 sites). DR iPTMnet; P54756; -. DR PhosphoSitePlus; P54756; -. DR SwissPalm; P54756; -. DR BioMuta; EPHA5; -. DR DMDM; 259016353; -. DR jPOST; P54756; -. DR MassIVE; P54756; -. DR PaxDb; 9606-ENSP00000480763; -. DR PeptideAtlas; P54756; -. DR ProteomicsDB; 56712; -. [P54756-1] DR ProteomicsDB; 56713; -. [P54756-2] DR ProteomicsDB; 56714; -. [P54756-3] DR TopDownProteomics; P54756-2; -. [P54756-2] DR ABCD; P54756; 4 sequenced antibodies. DR Antibodypedia; 12603; 537 antibodies from 35 providers. DR DNASU; 2044; -. DR Ensembl; ENST00000273854.7; ENSP00000273854.3; ENSG00000145242.15. [P54756-1] DR Ensembl; ENST00000354839.8; ENSP00000346899.4; ENSG00000145242.15. [P54756-2] DR GeneID; 2044; -. DR KEGG; hsa:2044; -. DR UCSC; uc003hcy.5; human. [P54756-1] DR AGR; HGNC:3389; -. DR ClinPGx; PA27821; -. DR CTD; 2044; -. DR DisGeNET; 2044; -. DR GeneCards; EPHA5; -. DR HGNC; HGNC:3389; EPHA5. DR HPA; ENSG00000145242; Tissue enriched (brain). DR MalaCards; EPHA5; -. DR MIM; 600004; gene. DR OpenTargets; ENSG00000145242; -. DR VEuPathDB; HostDB:ENSG00000145242; -. DR eggNOG; KOG0196; Eukaryota. DR GeneTree; ENSGT00940000156266; -. DR HOGENOM; CLU_000288_141_4_1; -. DR InParanoid; P54756; -. DR OMA; VAWTWTW; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P54756; 8 GO annotations based on evolutionary models. DR PhylomeDB; P54756; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P54756; -. DR Reactome; R-HSA-2682334; EPH-Ephrin signaling. DR Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse. DR Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. DR SignaLink; P54756; -. DR SIGNOR; P54756; -. DR Agora; ENSG00000145242; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 2044; 11 hits in 1193 CRISPR screens. DR ChiTaRS; EPHA5; human. DR EvolutionaryTrace; P54756; -. DR GeneWiki; EPH_receptor_A5; -. DR GenomeRNAi; 2044; -. DR Pharos; P54756; Tchem. DR PRO; PR:P54756; -. DR Proteomes; UP000005640; Chromosome 4. DR RNAct; P54756; protein. DR Bgee; ENSG00000145242; Expressed in cortical plate and 100 other cell types or tissues. DR ExpressionAtlas; P54756; baseline and differential. DR GO; GO:0030424; C:axon; ISS:UniProtKB. DR GO; GO:0030425; C:dendrite; IDA:UniProtKB. DR GO; GO:0009897; C:external side of plasma membrane; IDA:UniProtKB. DR GO; GO:0043025; C:neuronal cell body; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0005791; C:rough endoplasmic reticulum; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005003; F:ephrin receptor activity; ISS:UniProtKB. DR GO; GO:0005004; F:GPI-linked ephrin receptor activity; ISS:UniProtKB. DR GO; GO:0005005; F:transmembrane-ephrin receptor activity; IBA:GO_Central. DR GO; GO:0007411; P:axon guidance; ISS:UniProtKB. DR GO; GO:0048013; P:ephrin receptor signaling pathway; ISS:UniProtKB. DR GO; GO:0021766; P:hippocampus development; ISS:UniProtKB. DR GO; GO:0048666; P:neuron development; IEP:UniProtKB. DR GO; GO:0032793; P:positive regulation of CREB transcription factor activity; ISS:UniProtKB. DR GO; GO:0032956; P:regulation of actin cytoskeleton organization; ISS:UniProtKB. DR GO; GO:0043087; P:regulation of GTPase activity; ISS:UniProtKB. DR GO; GO:0061178; P:regulation of insulin secretion involved in cellular response to glucose stimulus; ISS:UniProtKB. DR CDD; cd10483; EphR_LBD_A5; 1. DR CDD; cd00063; FN3; 2. DR CDD; cd05066; PTKc_EphR_A; 1. DR CDD; cd09546; SAM_EPH-A5; 1. DR FunFam; 2.60.40.10:FF:000041; ephrin type-A receptor 3; 1. DR FunFam; 1.10.150.50:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 1.10.510.10:FF:000019; Ephrin type-A receptor 5; 1. DR FunFam; 2.10.50.10:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.10:FF:000045; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.1770:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 3.30.200.20:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.120.260:FF:000001; Ephrin type-A receptor 7; 1. DR Gene3D; 2.60.40.1770; ephrin a2 ectodomain; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 1. DR InterPro; IPR027936; Eph_TM. DR InterPro; IPR034277; EphA5_rcpt_lig-bd. DR InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom. DR InterPro; IPR050449; Ephrin_rcpt_TKs. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001660; SAM. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016257; Tyr_kinase_ephrin_rcpt. DR InterPro; IPR001426; Tyr_kinase_rcpt_V_CS. DR PANTHER; PTHR46877; EPH RECEPTOR A5; 1. DR PANTHER; PTHR46877:SF13; EPHRIN TYPE-A RECEPTOR 5; 1. DR Pfam; PF14575; EphA2_TM; 1. DR Pfam; PF25599; Ephrin_CRD; 1. DR Pfam; PF01404; Ephrin_lbd; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00536; SAM_1; 1. DR PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1. DR PRINTS; PR00014; FNTYPEIII. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00615; EPH_lbd; 1. DR SMART; SM01411; Ephrin_rec_like; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00454; SAM; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS01186; EGF_2; 1. DR PROSITE; PS51550; EPH_LBD; 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1. DR PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1. DR PROSITE; PS50105; SAM_DOMAIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; KW Cell projection; Glycoprotein; Kinase; Membrane; Neurogenesis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; Receptor; KW Reference proteome; Repeat; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase. FT SIGNAL 1..24 FT /evidence="ECO:0000255" FT CHAIN 25..1037 FT /note="Ephrin type-A receptor 5" FT /id="PRO_0000016812" FT TOPO_DOM 25..573 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 574..594 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 595..1037 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 60..238 FT /note="Eph LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00883" FT DOMAIN 357..467 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 468..562 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 675..936 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 965..1029 FT /note="SAM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00184" FT REGION 1..24 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 1035..1037 FT /note="PDZ-binding" FT /evidence="ECO:0000255" FT ACT_SITE 800 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 681..689 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 707 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 650 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 656 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 833 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000255" FT MOD_RES 982 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT CARBOHYD 264 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 299 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 369 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 423 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 436 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 461 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 1..69 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_039118" FT VAR_SEQ 563 FT /note="F -> SV (in isoform 3)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_039119" FT VAR_SEQ 597..619 FT /note="SCCECGCGRASSLCAVAHPSLIW -> R (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_002999" FT VARIANT 81 FT /note="N -> T (in dbSNP:rs33932471)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042138" FT VARIANT 235 FT /note="S -> A (in dbSNP:rs55710198)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042139" FT VARIANT 330 FT /note="E -> Q (in dbSNP:rs56205382)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042140" FT VARIANT 417 FT /note="R -> Q (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs199614818)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042141" FT VARIANT 503 FT /note="E -> K (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs2149036541)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042142" FT VARIANT 506 FT /note="Y -> C (in dbSNP:rs56074660)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045912" FT VARIANT 582 FT /note="G -> E (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs1057520012)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042143" FT VARIANT 672 FT /note="A -> T (in dbSNP:rs36050417)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042144" FT VARIANT 673 FT /note="S -> T (in dbSNP:rs56359290)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042145" FT VARIANT 856 FT /note="T -> I (in a lung squamous cell carcinoma sample; FT somatic mutation; dbSNP:rs2148842583)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042146" FT VARIANT 959 FT /note="H -> R (in dbSNP:rs56312931)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042147" FT VARIANT 1032 FT /note="N -> S (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042148" FT CONFLICT 11 FT /note="R -> H (in Ref. 1; CAA64700)" FT /evidence="ECO:0000305" FT CONFLICT 87 FT /note="G -> D (in Ref. 3; CAD97914)" FT /evidence="ECO:0000305" FT CONFLICT 506 FT /note="Y -> H (in Ref. 1; CAA64700)" FT /evidence="ECO:0000305" FT CONFLICT 611 FT /note="A -> V (in Ref. 3; CAD97914)" FT /evidence="ECO:0000305" FT CONFLICT 616 FT /note="S -> I (in Ref. 1; CAA64700)" FT /evidence="ECO:0000305" FT CONFLICT 820 FT /note="G -> E (in Ref. 3; CAD97914)" FT /evidence="ECO:0000305" FT STRAND 61..65 FT /evidence="ECO:0007829|PDB:4ET7" FT TURN 66..68 FT /evidence="ECO:0007829|PDB:4ET7" FT STRAND 76..89 FT /evidence="ECO:0007829|PDB:4ET7" FT STRAND 95..101 FT /evidence="ECO:0007829|PDB:4ET7" FT STRAND 105..107 FT /evidence="ECO:0007829|PDB:4ET7" FT STRAND 111..114 FT /evidence="ECO:0007829|PDB:4ET7" FT STRAND 126..135 FT /evidence="ECO:0007829|PDB:4ET7" FT HELIX 137..139 FT /evidence="ECO:0007829|PDB:4ET7" FT STRAND 148..157 FT /evidence="ECO:0007829|PDB:4ET7" FT HELIX 166..168 FT /evidence="ECO:0007829|PDB:4ET7" FT STRAND 172..178 FT /evidence="ECO:0007829|PDB:4ET7" FT STRAND 188..192 FT /evidence="ECO:0007829|PDB:4ET7" FT STRAND 196..202 FT /evidence="ECO:0007829|PDB:4ET7" FT STRAND 207..219 FT /evidence="ECO:0007829|PDB:4ET7" FT STRAND 221..230 FT /evidence="ECO:0007829|PDB:4ET7" FT HELIX 663..665 FT /evidence="ECO:0007829|PDB:2R2P" FT HELIX 672..674 FT /evidence="ECO:0007829|PDB:2R2P" FT STRAND 675..683 FT /evidence="ECO:0007829|PDB:2R2P" FT STRAND 685..694 FT /evidence="ECO:0007829|PDB:2R2P" FT STRAND 702..708 FT /evidence="ECO:0007829|PDB:2R2P" FT HELIX 715..728 FT /evidence="ECO:0007829|PDB:2R2P" FT STRAND 739..743 FT /evidence="ECO:0007829|PDB:2R2P" FT STRAND 745..748 FT /evidence="ECO:0007829|PDB:2R2P" FT STRAND 750..754 FT /evidence="ECO:0007829|PDB:2R2P" FT HELIX 761..766 FT /evidence="ECO:0007829|PDB:2R2P" FT TURN 767..770 FT /evidence="ECO:0007829|PDB:2R2P" FT HELIX 774..793 FT /evidence="ECO:0007829|PDB:2R2P" FT HELIX 803..805 FT /evidence="ECO:0007829|PDB:2R2P" FT STRAND 806..808 FT /evidence="ECO:0007829|PDB:2R2P" FT STRAND 814..816 FT /evidence="ECO:0007829|PDB:2R2P" FT HELIX 842..844 FT /evidence="ECO:0007829|PDB:2R2P" FT HELIX 847..852 FT /evidence="ECO:0007829|PDB:2R2P" FT HELIX 857..873 FT /evidence="ECO:0007829|PDB:2R2P" FT TURN 878..881 FT /evidence="ECO:0007829|PDB:2R2P" FT HELIX 884..893 FT /evidence="ECO:0007829|PDB:2R2P" FT HELIX 905..914 FT /evidence="ECO:0007829|PDB:2R2P" FT HELIX 919..921 FT /evidence="ECO:0007829|PDB:2R2P" FT HELIX 925..936 FT /evidence="ECO:0007829|PDB:2R2P" SQ SEQUENCE 1037 AA; 114803 MW; 578C2F4D950DE419 CRC64; MRGSGPRGAG RRRPPSGGGD TPITPASLAG CYSAPRRAPL WTCLLLCAAL RTLLASPSNE VNLLDSRTVM GDLGWIAFPK NGWEEIGEVD ENYAPIHTYQ VCKVMEQNQN NWLLTSWISN EGASRIFIEL KFTLRDCNSL PGGLGTCKET FNMYYFESDD QNGRNIKENQ YIKIDTIAAD ESFTELDLGD RVMKLNTEVR DVGPLSKKGF YLAFQDVGAC IALVSVRVYY KKCPSVVRHL AVFPDTITGA DSSQLLEVSG SCVNHSVTDE PPKMHCSAEG EWLVPIGKCM CKAGYEEKNG TCQVCRPGFF KASPHIQSCG KCPPHSYTHE EASTSCVCEK DYFRRESDPP TMACTRPPSA PRNAISNVNE TSVFLEWIPP ADTGGRKDVS YYIACKKCNS HAGVCEECGG HVRYLPRQSG LKNTSVMMVD LLAHTNYTFE IEAVNGVSDL SPGARQYVSV NVTTNQAAPS PVTNVKKGKI AKNSISLSWQ EPDRPNGIIL EYEIKYFEKD QETSYTIIKS KETTITAEGL KPASVYVFQI RARTAAGYGV FSRRFEFETT PVFAASSDQS QIPVIAVSVT VGVILLAVVI GVLLSGSCCE CGCGRASSLC AVAHPSLIWR CGYSKAKQDP EEEKMHFHNG HIKLPGVRTY IDPHTYEDPN QAVHEFAKEI EASCITIERV IGAGEFGEVC SGRLKLPGKR ELPVAIKTLK VGYTEKQRRD FLGEASIMGQ FDHPNIIHLE GVVTKSKPVM IVTEYMENGS LDTFLKKNDG QFTVIQLVGM LRGISAGMKY LSDMGYVHRD LAARNILINS NLVCKVSDFG LSRVLEDDPE AAYTTRGGKI PIRWTAPEAI AFRKFTSASD VWSYGIVMWE VVSYGERPYW EMTNQDVIKA VEEGYRLPSP MDCPAALYQL MLDCWQKERN SRPKFDEIVN MLDKLIRNPS SLKTLVNASC RVSNLLAEHS PLGSGAYRSV GEWLEAIKMG RYTEIFMENG YSSMDAVAQV TLEDLRRLGV TLVGHQKKIM NSLQEMKVQL VNGMVPL // ID EPHA7_HUMAN Reviewed; 998 AA. AC Q15375; A0AUX7; B2R8W1; B7ZLJ9; B7ZLK0; Q59G40; Q5VTU0; Q8N368; Q9H124; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-2007, sequence version 3. DT 28-JAN-2026, entry version 236. DE RecName: Full=Ephrin type-A receptor 7; DE EC=2.7.10.1; DE AltName: Full=EPH homology kinase 3; DE Short=EHK-3; DE AltName: Full=EPH-like kinase 11; DE Short=EK11; DE Short=hEK11; DE Flags: Precursor; GN Name=EPHA7; Synonyms=EHK3, HEK11; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Fetal brain; RX PubMed=7898931; RA Fox G.M., Holst P.L., Chute H.T., Lindberg R.A., Janssen A.M., Basu R., RA Welcher A.A.; RT "cDNA cloning and tissue distribution of five human EPH-like receptor RT protein-tyrosine kinases."; RL Oncogene 10:897-905(1995). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2; 3 AND 4), AND RP VARIANT VAL-138. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NOMENCLATURE. RX PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0; RG Eph nomenclature committee; RT "Unified nomenclature for Eph family receptors and their ligands, the RT ephrins."; RL Cell 90:403-404(1997). RN [8] RP FUNCTION IN MAP2K1; MAP2K2; MAPK1 AND MAPK3 PHOSPHORYLATION. RX PubMed=17726105; DOI=10.1073/pnas.0703211104; RA Nakanishi H., Nakamura T., Canaani E., Croce C.M.; RT "ALL1 fusion proteins induce deregulation of EphA7 and ERK phosphorylation RT in human acute leukemias."; RL Proc. Natl. Acad. Sci. U.S.A. 104:14442-14447(2007). RN [9] RP ALTERNATIVE SPLICING (ISOFORM 5). RX PubMed=20126984; RA Tsuboi M., Mori H., Bunai T., Kageyama S., Suzuki M., Okudela K., RA Takamochi K., Ogawa H., Niwa H., Shinmura K., Sugimura H.; RT "Secreted form of EphA7 in lung cancer."; RL Int. J. Oncol. 36:635-640(2010). RN [10] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 32-204. RA Walker J.R., Yermekbayeva L., Seitova A., Kania J., Bountra C., Weigelt J., RA Arrowsmith C.H., Edwards A.M., Bochkarev A., Dhe-Paganon S.; RT "Ephrin A7 ligand binding domain."; RL Submitted (JUN-2010) to the PDB data bank. RN [11] RP VARIANT [LARGE SCALE ANALYSIS] TRP-371. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [12] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-138; LYS-170; ARG-232; SER-278 AND RP SER-903. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously GPI- CC anchored ephrin-A family ligands residing on adjacent cells, leading to CC contact-dependent bidirectional signaling into neighboring cells. The CC signaling pathway downstream of the receptor is referred to as forward CC signaling while the signaling pathway downstream of the ephrin ligand CC is referred to as reverse signaling. Among GPI-anchored ephrin-A CC ligands, EFNA5 is a cognate/functional ligand for EPHA7 and their CC interaction regulates brain development modulating cell-cell adhesion CC and repulsion. Has a repellent activity on axons and is for instance CC involved in the guidance of corticothalamic axons and in the proper CC topographic mapping of retinal axons to the colliculus. May also CC regulate brain development through a caspase(CASP3)-dependent CC proapoptotic activity. Forward signaling may result in activation of CC components of the ERK signaling pathway including MAP2K1, MAP2K2, MAPK1 CC and MAPK3 which are phosphorylated upon activation of EPHA7. CC {ECO:0000269|PubMed:17726105}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Heterotetramer upon binding of the ligand. The heterotetramer CC is composed of an ephrin dimer and a receptor dimer. Oligomerization is CC probably required to induce biological responses (By similarity). CC Interacts (via PDZ-binding motif) with GRIP1 and PICK1 (via PDZ domain) CC (By similarity). {ECO:0000250}. CC -!- INTERACTION: CC Q15375; P07333: CSF1R; NbExp=2; IntAct=EBI-1383428, EBI-2835440; CC Q15375; P52803: EFNA5; NbExp=4; IntAct=EBI-1383428, EBI-1753674; CC Q15375; P29317: EPHA2; NbExp=7; IntAct=EBI-1383428, EBI-702104; CC Q15375; P29320: EPHA3; NbExp=4; IntAct=EBI-1383428, EBI-1641575; CC Q15375; P29323: EPHB2; NbExp=2; IntAct=EBI-1383428, EBI-1059294; CC Q15375; P54760: EPHB4; NbExp=3; IntAct=EBI-1383428, EBI-702121; CC Q15375; Q9H8Y8: GORASP2; NbExp=2; IntAct=EBI-1383428, EBI-739467; CC Q15375; Q9NUP9: LIN7C; NbExp=2; IntAct=EBI-1383428, EBI-1171517; CC Q15375; Q16288: NTRK3; NbExp=2; IntAct=EBI-1383428, EBI-3936704; CC Q15375; Q8NI35: PATJ; NbExp=2; IntAct=EBI-1383428, EBI-724390; CC Q15375; P52793: Efna1; Xeno; NbExp=2; IntAct=EBI-1383428, EBI-5241529; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Single-pass type I CC membrane protein {ECO:0000305}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=5; CC Name=1; Synonyms=EPHA7-FL; CC IsoId=Q15375-1; Sequence=Displayed; CC Name=2; CC IsoId=Q15375-2; Sequence=VSP_014382; CC Name=3; CC IsoId=Q15375-3; Sequence=VSP_014380, VSP_014381; CC Name=4; CC IsoId=Q15375-4; Sequence=VSP_041945; CC Name=5; Synonyms=EPHA7-S; CC IsoId=Q15375-5; Sequence=VSP_041943, VSP_041944; CC -!- TISSUE SPECIFICITY: Widely expressed. CC -!- PTM: Phosphorylated. {ECO:0000250}. CC -!- MISCELLANEOUS: [Isoform 2]: May be due to a competing donor splice CC site. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 5]: Expressed in lung cancer cells, lacks the CC kinase domain and is most probably secreted. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=BAD92506.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40466/EPHA7"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L36642; AAA74243.1; -; mRNA. DR EMBL; AK313529; BAG36308.1; -; mRNA. DR EMBL; AB209269; BAD92506.1; ALT_INIT; mRNA. DR EMBL; AL121966; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL354857; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL591036; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471051; EAW48518.1; -; Genomic_DNA. DR EMBL; BC027940; AAH27940.1; -; mRNA. DR EMBL; BC126125; AAI26126.1; -; mRNA. DR EMBL; BC126151; AAI26152.1; -; mRNA. DR EMBL; BC143857; AAI43858.1; -; mRNA. DR EMBL; BC143858; AAI43859.1; -; mRNA. DR CCDS; CCDS5031.1; -. [Q15375-1] DR CCDS; CCDS75494.1; -. [Q15375-3] DR CCDS; CCDS93973.1; -. [Q15375-4] DR PIR; I58351; I58351. DR RefSeq; NP_001275558.1; NM_001288629.2. [Q15375-2] DR RefSeq; NP_001275559.1; NM_001288630.2. [Q15375-3] DR RefSeq; NP_001363394.1; NM_001376465.1. [Q15375-4] DR RefSeq; NP_004431.1; NM_004440.4. [Q15375-1] DR PDB; 2REI; X-ray; 1.60 A; A=590-899. DR PDB; 3DKO; X-ray; 2.00 A; A=590-899. DR PDB; 3H8M; X-ray; 2.10 A; A/B=919-990. DR PDB; 3NRU; X-ray; 2.30 A; A/B/C/D/E/F/G/H/I/J/K/L=32-204. DR PDB; 7EEC; X-ray; 3.10 A; A=599-899. DR PDB; 7EED; X-ray; 3.05 A; A=599-899. DR PDB; 7EEF; X-ray; 2.60 A; A=599-899. DR PDBsum; 2REI; -. DR PDBsum; 3DKO; -. DR PDBsum; 3H8M; -. DR PDBsum; 3NRU; -. DR PDBsum; 7EEC; -. DR PDBsum; 7EED; -. DR PDBsum; 7EEF; -. DR AlphaFoldDB; Q15375; -. DR SMR; Q15375; -. DR BioGRID; 108359; 316. DR FunCoup; Q15375; 1198. DR IntAct; Q15375; 282. DR MINT; Q15375; -. DR STRING; 9606.ENSP00000358309; -. DR BindingDB; Q15375; -. DR ChEMBL; CHEMBL4602; -. DR DrugBank; DB07970; 5-[(2-methyl-5-{[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)amino]pyridine-3-carboxamide. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q15375; -. DR GuidetoPHARMACOLOGY; 1827; -. DR GlyCosmos; Q15375; 4 sites, 1 glycan. DR GlyGen; Q15375; 5 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (2 sites). DR iPTMnet; Q15375; -. DR PhosphoSitePlus; Q15375; -. DR SwissPalm; Q15375; -. DR BioMuta; EPHA7; -. DR DMDM; 146345416; -. DR CPTAC; CPTAC-1783; -. DR CPTAC; CPTAC-2787; -. DR CPTAC; CPTAC-2830; -. DR jPOST; Q15375; -. DR MassIVE; Q15375; -. DR PaxDb; 9606-ENSP00000358309; -. DR PeptideAtlas; Q15375; -. DR ProteomicsDB; 60549; -. [Q15375-1] DR ProteomicsDB; 60550; -. [Q15375-2] DR ProteomicsDB; 60551; -. [Q15375-3] DR ProteomicsDB; 60552; -. [Q15375-4] DR ProteomicsDB; 60553; -. [Q15375-5] DR Pumba; Q15375; -. DR Antibodypedia; 642; 553 antibodies from 37 providers. DR DNASU; 2045; -. DR Ensembl; ENST00000369297.1; ENSP00000358303.1; ENSG00000135333.16. [Q15375-3] DR Ensembl; ENST00000369303.9; ENSP00000358309.4; ENSG00000135333.16. [Q15375-1] DR Ensembl; ENST00000680224.1; ENSP00000506130.1; ENSG00000135333.16. [Q15375-4] DR GeneID; 2045; -. DR KEGG; hsa:2045; -. DR MANE-Select; ENST00000369303.9; ENSP00000358309.4; NM_004440.4; NP_004431.1. DR UCSC; uc003poe.5; human. [Q15375-1] DR AGR; HGNC:3390; -. DR ClinPGx; PA27822; -. DR CTD; 2045; -. DR DisGeNET; 2045; -. DR GeneCards; EPHA7; -. DR HGNC; HGNC:3390; EPHA7. DR HPA; ENSG00000135333; Group enriched (intestine, parathyroid gland). DR MalaCards; EPHA7; -. DR MIM; 602190; gene. DR OpenTargets; ENSG00000135333; -. DR VEuPathDB; HostDB:ENSG00000135333; -. DR eggNOG; KOG0196; Eukaryota. DR GeneTree; ENSGT00940000160189; -. DR HOGENOM; CLU_000288_141_0_1; -. DR InParanoid; Q15375; -. DR OMA; ETDYNTG; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; Q15375; 8 GO annotations based on evolutionary models. DR PhylomeDB; Q15375; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; Q15375; -. DR Reactome; R-HSA-2682334; EPH-Ephrin signaling. DR Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse. DR Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. DR SignaLink; Q15375; -. DR SIGNOR; Q15375; -. DR Agora; ENSG00000135333; -. DR BioGRID-ORCS; 2045; 14 hits in 1184 CRISPR screens. DR ChiTaRS; EPHA7; human. DR EvolutionaryTrace; Q15375; -. DR GeneWiki; EPHA7; -. DR GenomeRNAi; 2045; -. DR Pharos; Q15375; Tchem. DR PRO; PR:Q15375; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q15375; protein. DR Bgee; ENSG00000135333; Expressed in cortical plate and 131 other cell types or tissues. DR GO; GO:0030425; C:dendrite; IBA:GO_Central. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0098686; C:hippocampal mossy fiber to CA3 synapse; IEA:Ensembl. DR GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl. DR GO; GO:0043025; C:neuronal cell body; IEA:Ensembl. DR GO; GO:0005886; C:plasma membrane; IDA:ARUK-UCL. DR GO; GO:0098839; C:postsynaptic density membrane; IEA:Ensembl. DR GO; GO:0098685; C:Schaffer collateral - CA1 synapse; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0008046; F:axon guidance receptor activity; ISS:UniProtKB. DR GO; GO:0045499; F:chemorepellent activity; ISS:UniProtKB. DR GO; GO:0046875; F:ephrin receptor binding; IEA:Ensembl. DR GO; GO:0005004; F:GPI-linked ephrin receptor activity; ISS:UniProtKB. DR GO; GO:0019838; F:growth factor binding; IEA:Ensembl. DR GO; GO:0004713; F:protein tyrosine kinase activity; ISS:UniProtKB. DR GO; GO:0005005; F:transmembrane-ephrin receptor activity; IBA:GO_Central. DR GO; GO:0007411; P:axon guidance; IBA:GO_Central. DR GO; GO:0007420; P:brain development; ISS:UniProtKB. DR GO; GO:0048755; P:branching morphogenesis of a nerve; ISS:UniProtKB. DR GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0050804; P:modulation of chemical synaptic transmission; IEA:Ensembl. DR GO; GO:0050919; P:negative chemotaxis; ISS:UniProtKB. DR GO; GO:0048671; P:negative regulation of collateral sprouting; IEA:Ensembl. DR GO; GO:0051898; P:negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IEA:Ensembl. DR GO; GO:0051964; P:negative regulation of synapse assembly; IEA:Ensembl. DR GO; GO:0072178; P:nephric duct morphogenesis; IEA:Ensembl. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0016310; P:phosphorylation; ISS:UniProtKB. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; ISS:UniProtKB. DR GO; GO:0022407; P:regulation of cell-cell adhesion; ISS:UniProtKB. DR GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IDA:UniProtKB. DR GO; GO:0050730; P:regulation of peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0099175; P:regulation of postsynapse organization; IEA:Ensembl. DR GO; GO:0031952; P:regulation of protein autophosphorylation; ISS:UniProtKB. DR GO; GO:0031290; P:retinal ganglion cell axon guidance; IEA:Ensembl. DR CDD; cd10485; EphR_LBD_A7; 1. DR CDD; cd00063; FN3; 2. DR CDD; cd05066; PTKc_EphR_A; 1. DR CDD; cd09548; SAM_EPH-A7; 1. DR CDD; cd00185; TNFRSF; 1. DR FunFam; 1.10.150.50:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.10.50.10:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.10:FF:000045; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.1770:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 3.30.200.20:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 1.10.510.10:FF:000130; Ephrin type-A receptor 7; 1. DR FunFam; 2.60.120.260:FF:000001; Ephrin type-A receptor 7; 1. DR FunFam; 2.60.40.10:FF:000190; Ephrin type-A receptor 7; 1. DR Gene3D; 2.60.40.1770; ephrin a2 ectodomain; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 1. DR InterPro; IPR027936; Eph_TM. DR InterPro; IPR034283; EphA7_rcpt_lig-bd. DR InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom. DR InterPro; IPR050449; Ephrin_rcpt_TKs. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001660; SAM. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016257; Tyr_kinase_ephrin_rcpt. DR InterPro; IPR001426; Tyr_kinase_rcpt_V_CS. DR PANTHER; PTHR46877; EPH RECEPTOR A5; 1. DR PANTHER; PTHR46877:SF9; EPHRIN TYPE-A RECEPTOR 7; 1. DR Pfam; PF14575; EphA2_TM; 1. DR Pfam; PF25599; Ephrin_CRD; 1. DR Pfam; PF01404; Ephrin_lbd; 1. DR Pfam; PF07699; Ephrin_rec_like; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00536; SAM_1; 1. DR PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1. DR PRINTS; PR00014; FNTYPEIII. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00615; EPH_lbd; 1. DR SMART; SM01411; Ephrin_rec_like; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00454; SAM; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS01186; EGF_2; 1. DR PROSITE; PS51550; EPH_LBD; 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1. DR PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1. DR PROSITE; PS50105; SAM_DOMAIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Apoptosis; ATP-binding; Cell membrane; KW Developmental protein; Glycoprotein; Kinase; Membrane; Neurogenesis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; Receptor; KW Reference proteome; Repeat; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase. FT SIGNAL 1..27 FT /evidence="ECO:0000255" FT CHAIN 28..998 FT /note="Ephrin type-A receptor 7" FT /id="PRO_0000016818" FT TOPO_DOM 28..555 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 556..576 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 577..998 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 32..210 FT /note="Eph LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00883" FT DOMAIN 331..441 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 442..537 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 633..894 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 923..987 FT /note="SAM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00184" FT MOTIF 996..998 FT /note="PDZ-binding" FT /evidence="ECO:0000255" FT ACT_SITE 758 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 639..647 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 665 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 608 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000255" FT MOD_RES 614 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000255" FT MOD_RES 791 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000255" FT MOD_RES 940 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000255" FT CARBOHYD 343 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 410 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 278..279 FT /note="PC -> RK (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_014380" FT VAR_SEQ 280..998 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_014381" FT VAR_SEQ 442..450 FT /note="APSQVSGVM -> GMFCVYLH (in isoform 5)" FT /evidence="ECO:0000305" FT /id="VSP_041943" FT VAR_SEQ 451..998 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000305" FT /id="VSP_041944" FT VAR_SEQ 540..544 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|Ref.3" FT /id="VSP_014382" FT VAR_SEQ 600..604 FT /note="FKFPG -> C (in isoform 4)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_041945" FT VARIANT 138 FT /note="I -> V (in dbSNP:rs2278107)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:17344846" FT /id="VAR_022105" FT VARIANT 170 FT /note="E -> K (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042150" FT VARIANT 232 FT /note="G -> R (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs2127994473)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042151" FT VARIANT 278 FT /note="P -> S (in dbSNP:rs2278106)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_022106" FT VARIANT 371 FT /note="R -> W (in a colorectal cancer sample; somatic FT mutation; dbSNP:rs371089003)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036090" FT VARIANT 903 FT /note="P -> S (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs2127846874)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042152" FT STRAND 33..37 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 48..51 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 54..61 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 67..74 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 78..80 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 83..86 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 96..106 FT /evidence="ECO:0007829|PDB:3NRU" FT TURN 109..111 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 121..132 FT /evidence="ECO:0007829|PDB:3NRU" FT HELIX 140..142 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 144..150 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 168..174 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 178..190 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 192..202 FT /evidence="ECO:0007829|PDB:3NRU" FT HELIX 611..613 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 614..616 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 617..624 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 630..632 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 633..641 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 643..652 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 655..657 FT /evidence="ECO:0007829|PDB:3DKO" FT STRAND 660..666 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 673..686 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 697..701 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 703..705 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 708..712 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 719..725 FT /evidence="ECO:0007829|PDB:2REI" FT TURN 726..728 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 732..751 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 761..763 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 764..766 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 772..774 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 800..802 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 805..810 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 815..830 FT /evidence="ECO:0007829|PDB:2REI" FT TURN 836..839 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 842..850 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 863..872 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 877..879 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 883..895 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 897..899 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 928..934 FT /evidence="ECO:0007829|PDB:3H8M" FT HELIX 938..940 FT /evidence="ECO:0007829|PDB:3H8M" FT HELIX 941..946 FT /evidence="ECO:0007829|PDB:3H8M" FT HELIX 952..956 FT /evidence="ECO:0007829|PDB:3H8M" FT HELIX 960..965 FT /evidence="ECO:0007829|PDB:3H8M" FT HELIX 971..988 FT /evidence="ECO:0007829|PDB:3H8M" FT CONFLICT Q15375-3:278 FT /note="R -> C (in Ref. 6; AAH27940)" FT /evidence="ECO:0000305" SQ SEQUENCE 998 AA; 112097 MW; 479B9CA0D2BB06EB CRC64; MVFQTRYPSW IILCYIWLLR FAHTGEAQAA KEVLLLDSKA QQTELEWISS PPNGWEEISG LDENYTPIRT YQVCQVMEPN QNNWLRTNWI SKGNAQRIFV ELKFTLRDCN SLPGVLGTCK ETFNLYYYET DYDTGRNIRE NLYVKIDTIA ADESFTQGDL GERKMKLNTE VREIGPLSKK GFYLAFQDVG ACIALVSVKV YYKKCWSIIE NLAIFPDTVT GSEFSSLVEV RGTCVSSAEE EAENAPRMHC SAEGEWLVPI GKCICKAGYQ QKGDTCEPCG RGFYKSSSQD LQCSRCPTHS FSDKEGSSRC ECEDGYYRAP SDPPYVACTR PPSAPQNLIF NINQTTVSLE WSPPADNGGR NDVTYRILCK RCSWEQGECV PCGSNIGYMP QQTGLEDNYV TVMDLLAHAN YTFEVEAVNG VSDLSRSQRL FAAVSITTGQ AAPSQVSGVM KERVLQRSVE LSWQEPEHPN GVITEYEIKY YEKDQRERTY STVKTKSTSA SINNLKPGTV YVFQIRAFTA AGYGNYSPRL DVATLEEATG KMFEATAVSS EQNPVIIIAV VAVAGTIILV FMVFGFIIGR RHCGYSKADQ EGDEELYFHF KFPGTKTYID PETYEDPNRA VHQFAKELDA SCIKIERVIG AGEFGEVCSG RLKLPGKRDV AVAIKTLKVG YTEKQRRDFL CEASIMGQFD HPNVVHLEGV VTRGKPVMIV IEFMENGALD AFLRKHDGQF TVIQLVGMLR GIAAGMRYLA DMGYVHRDLA ARNILVNSNL VCKVSDFGLS RVIEDDPEAV YTTTGGKIPV RWTAPEAIQY RKFTSASDVW SYGIVMWEVM SYGERPYWDM SNQDVIKAIE EGYRLPAPMD CPAGLHQLML DCWQKERAER PKFEQIVGIL DKMIRNPNSL KTPLGTCSRP ISPLLDQNTP DFTTFCSVGE WLQAIKMERY KDNFTAAGYN SLESVARMTI EDVMSLGITL VGHQKKIMSS IQTMRAQMLH LHGTGIQV // ID EPHA8_HUMAN Reviewed; 1005 AA. AC P29322; Q6IN80; Q8IUX6; Q9NUA9; Q9P269; DT 01-DEC-1992, integrated into UniProtKB/Swiss-Prot. DT 18-OCT-2001, sequence version 2. DT 28-JAN-2026, entry version 235. DE RecName: Full=Ephrin type-A receptor 8; DE EC=2.7.10.1; DE AltName: Full=EPH- and ELK-related kinase; DE AltName: Full=EPH-like kinase 3; DE Short=EK3; DE Short=hEK3; DE AltName: Full=Tyrosine-protein kinase receptor EEK; DE Flags: Precursor; GN Name=EPHA8; Synonyms=EEK, HEK3, KIAA1459; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain, and Eye; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 153-1005 (ISOFORM 1), AND VARIANT RP GLN-612. RC TISSUE=Brain; RX PubMed=10819331; DOI=10.1093/dnares/7.2.143; RA Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XVII. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 7:143-150(2000). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 706-726. RX PubMed=1648701; RA Chan J., Watt V.M.; RT "eek and erk, new members of the eph subclass of receptor protein-tyrosine RT kinases."; RL Oncogene 6:1057-1061(1991). RN [5] RP NOMENCLATURE. RX PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0; RG Eph nomenclature committee; RT "Unified nomenclature for Eph family receptors and their ligands, the RT ephrins."; RL Cell 90:403-404(1997). RN [6] RP INTERACTION WITH FYN. RX PubMed=10498895; DOI=10.1038/sj.onc.1202917; RA Choi S., Park S.; RT "Phosphorylation at Tyr-838 in the kinase domain of EphA8 modulates Fyn RT binding to the Tyr-615 site by enhancing tyrosine kinase activity."; RL Oncogene 18:5413-5422(1999). RN [7] RP INTERACTION WITH PIK3CG. RX PubMed=11416136; DOI=10.1128/mcb.21.14.4579-4597.2001; RA Gu C., Park S.; RT "The EphA8 receptor regulates integrin activity through p110gamma RT phosphatidylinositol-3 kinase in a tyrosine kinase activity-independent RT manner."; RL Mol. Cell. Biol. 21:4579-4597(2001). RN [8] RP INTERACTION WITH ANKS1B. RX PubMed=17875921; DOI=10.1128/mcb.00794-07; RA Shin J., Gu C., Park E., Park S.; RT "Identification of phosphotyrosine binding domain-containing proteins as RT novel downstream targets of the EphA8 signaling function."; RL Mol. Cell. Biol. 27:8113-8126(2007). RN [9] RP INTERACTION WITH TIAM1. RX PubMed=20496116; DOI=10.1007/s10059-010-0075-2; RA Yoo S., Shin J., Park S.; RT "EphA8-ephrinA5 signaling and clathrin-mediated endocytosis is regulated by RT Tiam-1, a Rac-specific guanine nucleotide exchange factor."; RL Mol. Cells 29:603-609(2010). RN [10] RP STRUCTURE BY NMR OF 437-534 AND 932-1000. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the second FN3 domain and of sterile alpha motif RT (SAM) domain of EPH receptor A8 protein."; RL Submitted (NOV-2005) to the PDB data bank. RN [11] RP VARIANTS [LARGE SCALE ANALYSIS] SER-45; LEU-60; LYS-123; CYS-179; LEU-198 RP AND LEU-860. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously GPI- CC anchored ephrin-A family ligands residing on adjacent cells, leading to CC contact-dependent bidirectional signaling into neighboring cells. The CC signaling pathway downstream of the receptor is referred to as forward CC signaling while the signaling pathway downstream of the ephrin ligand CC is referred to as reverse signaling. The GPI-anchored ephrin-A EFNA2, CC EFNA3, and EFNA5 are able to activate EPHA8 through phosphorylation. CC With EFNA5 may regulate integrin-mediated cell adhesion and migration CC on fibronectin substrate but also neurite outgrowth. During development CC of the nervous system also plays a role in axon guidance. Downstream CC effectors of the EPHA8 signaling pathway include FYN which promotes CC cell adhesion upon activation by EPHA8 and the MAP kinases in the CC stimulation of neurite outgrowth (By similarity). {ECO:0000250}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Heterotetramer upon binding of the ligand. The heterotetramer CC is composed of an ephrin dimer and a receptor dimer. Oligomerization is CC probably required to induce biological responses. May also form CC heterodimers with other ephrin receptors (By similarity). Interacts CC with FYN; possible downstream effector of EPHA8 in regulation of cell CC adhesion. Interacts with PIK3CG; regulates integrin-mediated cell CC adhesion to substrate. Interacts with TIAM1; regulates clathrin- CC mediated endocytosis of EPHA8. Interacts with ANKS1A and ANKS1B; EPHA8 CC kinase activity-independent but stimulated by EPHA8 ubiquitination. CC {ECO:0000250, ECO:0000269|PubMed:10498895, ECO:0000269|PubMed:11416136, CC ECO:0000269|PubMed:17875921, ECO:0000269|PubMed:20496116}. CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:O09127}; CC Single-pass type I membrane protein {ECO:0000255}. Cell projection CC {ECO:0000250|UniProtKB:O09127}. Early endosome membrane CC {ECO:0000250|UniProtKB:O09127}. Note=Undergoes clathrin-mediated CC endocytosis upon EFNA5-binding and is targeted to early endosomes. CC {ECO:0000250|UniProtKB:O09127}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P29322-1; Sequence=Displayed; CC Name=2; CC IsoId=P29322-2; Sequence=VSP_041946, VSP_041947; CC -!- PTM: Phosphorylated. Phosphorylation is stimulated upon binding of its CC ligands including EFNA2, EFNA3 and EFNA5. Autophosphorylation on Tyr- CC 616 is critical for association with FYN. Autophosphorylation on Tyr- CC 839 modulates tyrosine kinase activity (By similarity). {ECO:0000250}. CC -!- PTM: Ubiquitinated. Ubiquitination by CBL regulates the receptor CC stability and activity through proteasomal degradation. ANKS1A prevents CC ubiquitination and degradation (By similarity). {ECO:0000250}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=CAA41980.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AL035703; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC038796; AAH38796.1; -; mRNA. DR EMBL; BC072417; AAH72417.2; -; mRNA. DR EMBL; AB040892; BAA95983.1; -; mRNA. DR EMBL; X59291; CAA41980.1; ALT_INIT; Genomic_DNA. DR CCDS; CCDS225.1; -. [P29322-1] DR CCDS; CCDS30626.1; -. [P29322-2] DR PIR; S23361; S23361. DR RefSeq; NP_001006944.1; NM_001006943.3. [P29322-2] DR RefSeq; NP_065387.1; NM_020526.5. [P29322-1] DR PDB; 1UCV; NMR; -; A=933-1000. DR PDB; 1X5L; NMR; -; A=437-534. DR PDB; 3KUL; X-ray; 2.15 A; A/B=602-909. DR PDBsum; 1UCV; -. DR PDBsum; 1X5L; -. DR PDBsum; 3KUL; -. DR AlphaFoldDB; P29322; -. DR BMRB; P29322; -. DR SMR; P29322; -. DR BioGRID; 108360; 162. DR CORUM; P29322; -. DR FunCoup; P29322; 354. DR IntAct; P29322; 151. DR MINT; P29322; -. DR STRING; 9606.ENSP00000166244; -. DR BindingDB; P29322; -. DR ChEMBL; CHEMBL4134; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; P29322; -. DR GuidetoPHARMACOLOGY; 1828; -. DR GlyCosmos; P29322; 3 sites, No reported glycans. DR GlyGen; P29322; 4 sites, 1 O-linked glycan (1 site). DR iPTMnet; P29322; -. DR PhosphoSitePlus; P29322; -. DR BioMuta; EPHA8; -. DR DMDM; 19857975; -. DR CPTAC; CPTAC-2820; -. DR CPTAC; CPTAC-3204; -. DR jPOST; P29322; -. DR MassIVE; P29322; -. DR PaxDb; 9606-ENSP00000166244; -. DR PeptideAtlas; P29322; -. DR ProteomicsDB; 54538; -. [P29322-1] DR ProteomicsDB; 54539; -. [P29322-2] DR Antibodypedia; 4046; 174 antibodies from 33 providers. DR DNASU; 2046; -. DR Ensembl; ENST00000166244.8; ENSP00000166244.3; ENSG00000070886.12. [P29322-1] DR Ensembl; ENST00000374644.8; ENSP00000363775.4; ENSG00000070886.12. [P29322-2] DR GeneID; 2046; -. DR KEGG; hsa:2046; -. DR MANE-Select; ENST00000166244.8; ENSP00000166244.3; NM_020526.5; NP_065387.1. DR UCSC; uc001bfw.4; human. [P29322-1] DR AGR; HGNC:3391; -. DR ClinPGx; PA27823; -. DR CTD; 2046; -. DR DisGeNET; 2046; -. DR GeneCards; EPHA8; -. DR HGNC; HGNC:3391; EPHA8. DR HPA; ENSG00000070886; Tissue enriched (choroid). DR MIM; 176945; gene. DR OpenTargets; ENSG00000070886; -. DR VEuPathDB; HostDB:ENSG00000070886; -. DR eggNOG; KOG0196; Eukaryota. DR GeneTree; ENSGT00940000160469; -. DR HOGENOM; CLU_000288_141_3_1; -. DR InParanoid; P29322; -. DR OMA; MRMNIDD; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P29322; 8 GO annotations based on evolutionary models. DR PhylomeDB; P29322; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P29322; -. DR Reactome; R-HSA-2682334; EPH-Ephrin signaling. DR Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse. DR Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. DR SignaLink; P29322; -. DR SIGNOR; P29322; -. DR Agora; ENSG00000070886; -. DR BioGRID-ORCS; 2046; 11 hits in 1180 CRISPR screens. DR ChiTaRS; EPHA8; human. DR EvolutionaryTrace; P29322; -. DR GeneWiki; EPHA8; -. DR GenomeRNAi; 2046; -. DR Pharos; P29322; Tchem. DR PRO; PR:P29322; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; P29322; protein. DR Bgee; ENSG00000070886; Expressed in endothelial cell and 47 other cell types or tissues. DR GO; GO:0030425; C:dendrite; IBA:GO_Central. DR GO; GO:0031901; C:early endosome membrane; IEA:UniProtKB-SubCell. DR GO; GO:0043005; C:neuron projection; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; ISS:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005003; F:ephrin receptor activity; ISS:UniProtKB. DR GO; GO:0005004; F:GPI-linked ephrin receptor activity; ISS:UniProtKB. DR GO; GO:0019838; F:growth factor binding; IEA:Ensembl. DR GO; GO:0005005; F:transmembrane-ephrin receptor activity; IBA:GO_Central. DR GO; GO:0007411; P:axon guidance; ISS:UniProtKB. DR GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW. DR GO; GO:0071372; P:cellular response to follicle-stimulating hormone stimulus; IEA:Ensembl. DR GO; GO:0048013; P:ephrin receptor signaling pathway; ISS:UniProtKB. DR GO; GO:0031175; P:neuron projection development; ISS:UniProtKB. DR GO; GO:0016322; P:neuron remodeling; ISS:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; ISS:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; ISS:UniProtKB. DR GO; GO:0030155; P:regulation of cell adhesion; ISS:UniProtKB. DR GO; GO:0033628; P:regulation of cell adhesion mediated by integrin; ISS:UniProtKB. DR GO; GO:0006929; P:substrate-dependent cell migration; ISS:UniProtKB. DR CDD; cd00063; FN3; 2. DR CDD; cd05066; PTKc_EphR_A; 1. DR CDD; cd09550; SAM_EPH-A8; 1. DR FunFam; 2.10.50.10:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.10:FF:000045; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.1770:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 1.10.510.10:FF:000130; Ephrin type-A receptor 7; 1. DR FunFam; 2.60.120.260:FF:000001; Ephrin type-A receptor 7; 1. DR FunFam; 2.60.40.10:FF:000190; Ephrin type-A receptor 7; 1. DR FunFam; 1.10.150.50:FF:000058; ephrin type-A receptor 8; 1. DR FunFam; 3.30.200.20:FF:000143; Ephrin type-B receptor 6; 1. DR Gene3D; 2.60.40.1770; ephrin a2 ectodomain; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 1. DR InterPro; IPR027936; Eph_TM. DR InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom. DR InterPro; IPR050449; Ephrin_rcpt_TKs. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001660; SAM. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016257; Tyr_kinase_ephrin_rcpt. DR InterPro; IPR001426; Tyr_kinase_rcpt_V_CS. DR PANTHER; PTHR46877; EPH RECEPTOR A5; 1. DR PANTHER; PTHR46877:SF7; EPHRIN TYPE-A RECEPTOR 8; 1. DR Pfam; PF14575; EphA2_TM; 1. DR Pfam; PF25599; Ephrin_CRD; 1. DR Pfam; PF01404; Ephrin_lbd; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00536; SAM_1; 1. DR PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1. DR PRINTS; PR00014; FNTYPEIII. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00615; EPH_lbd; 1. DR SMART; SM01411; Ephrin_rec_like; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00454; SAM; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS01186; EGF_2; 1. DR PROSITE; PS51550; EPH_LBD; 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1. DR PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1. DR PROSITE; PS50105; SAM_DOMAIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell adhesion; KW Cell membrane; Cell projection; Developmental protein; Endosome; KW Glycoprotein; Kinase; Membrane; Neurogenesis; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome; KW Repeat; Signal; Transferase; Transmembrane; Transmembrane helix; KW Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..27 FT /evidence="ECO:0000255" FT CHAIN 28..1005 FT /note="Ephrin type-A receptor 8" FT /id="PRO_0000016822" FT TOPO_DOM 28..542 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 543..563 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 564..1005 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 31..209 FT /note="Eph LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00883" FT DOMAIN 328..438 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 439..534 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 635..896 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 930..994 FT /note="SAM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00184" FT REGION 564..570 FT /note="Mediates interaction with ANKS1A and ANKS1B" FT /evidence="ECO:0000250" FT REGION 589..644 FT /note="Mediates interaction with PIK3CG and required for FT endocytosis" FT /evidence="ECO:0000250" FT MOTIF 1003..1005 FT /note="PDZ-binding" FT /evidence="ECO:0000255" FT ACT_SITE 760 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 641..649 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 667 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 616 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:O09127" FT MOD_RES 839 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:O09127" FT CARBOHYD 340 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 407 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 432 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 439..495 FT /note="APSQVVVIRQERAGQTSVSLLWQEPEQPNGIILEYEIKYYEKDKEMQSYSTL FT KAVTT -> GRRRNSVPQRPGPPASPASDPSRDQSSAGDVLWAFRQVPLWPCAPHQDPE FT LEALHCL (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_041946" FT VAR_SEQ 496..1005 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_041947" FT VARIANT 45 FT /note="G -> S (in dbSNP:rs45498698)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042153" FT VARIANT 60 FT /note="V -> L (in dbSNP:rs56402644)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042154" FT VARIANT 123 FT /note="N -> K (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042155" FT VARIANT 179 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1557556639)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042156" FT VARIANT 198 FT /note="R -> L (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042157" FT VARIANT 321 FT /note="P -> L (in dbSNP:rs56656925)" FT /id="VAR_061292" FT VARIANT 444 FT /note="V -> M (in dbSNP:rs2295021)" FT /id="VAR_022107" FT VARIANT 612 FT /note="E -> Q (in dbSNP:rs999765)" FT /evidence="ECO:0000269|PubMed:10819331" FT /id="VAR_024514" FT VARIANT 860 FT /note="P -> L (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042158" FT CONFLICT 237 FT /note="S -> L (in Ref. 3; BAA95983)" FT /evidence="ECO:0000305" FT STRAND 456..460 FT /evidence="ECO:0007829|PDB:1X5L" FT STRAND 472..482 FT /evidence="ECO:0007829|PDB:1X5L" FT STRAND 488..499 FT /evidence="ECO:0007829|PDB:1X5L" FT STRAND 507..510 FT /evidence="ECO:0007829|PDB:1X5L" FT STRAND 512..516 FT /evidence="ECO:0007829|PDB:1X5L" FT STRAND 527..530 FT /evidence="ECO:0007829|PDB:1X5L" FT HELIX 632..634 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 635..643 FT /evidence="ECO:0007829|PDB:3KUL" FT TURN 644..646 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 647..654 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 662..669 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 675..688 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 699..703 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 705..707 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 710..714 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 721..726 FT /evidence="ECO:0007829|PDB:3KUL" FT TURN 727..730 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 734..753 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 763..765 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 766..768 FT /evidence="ECO:0007829|PDB:3KUL" FT STRAND 774..776 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 802..804 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 807..812 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 817..832 FT /evidence="ECO:0007829|PDB:3KUL" FT TURN 833..835 FT /evidence="ECO:0007829|PDB:3KUL" FT TURN 838..841 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 844..852 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 865..874 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 879..881 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 885..897 FT /evidence="ECO:0007829|PDB:3KUL" FT HELIX 935..941 FT /evidence="ECO:0007829|PDB:1UCV" FT HELIX 945..947 FT /evidence="ECO:0007829|PDB:1UCV" FT HELIX 948..953 FT /evidence="ECO:0007829|PDB:1UCV" FT HELIX 959..962 FT /evidence="ECO:0007829|PDB:1UCV" FT HELIX 967..973 FT /evidence="ECO:0007829|PDB:1UCV" FT HELIX 978..995 FT /evidence="ECO:0007829|PDB:1UCV" SQ SEQUENCE 1005 AA; 111003 MW; 6FBF85535E4212B3 CRC64; MAPARGRLPP ALWVVTAAAA AATCVSAARG EVNLLDTSTI HGDWGWLTYP AHGWDSINEV DESFQPIHTY QVCNVMSPNQ NNWLRTSWVP RDGARRVYAE IKFTLRDCNS MPGVLGTCKE TFNLYYLESD RDLGASTQES QFLKIDTIAA DESFTGADLG VRRLKLNTEV RSVGPLSKRG FYLAFQDIGA CLAILSLRIY YKKCPAMVRN LAAFSEAVTG ADSSSLVEVR GQCVRHSEER DTPKMYCSAE GEWLVPIGKC VCSAGYEERR DACVACELGF YKSAPGDQLC ARCPPHSHSA APAAQACHCD LSYYRAALDP PSSACTRPPS APVNLISSVN GTSVTLEWAP PLDPGGRSDI TYNAVCRRCP WALSRCEACG SGTRFVPQQT SLVQASLLVA NLLAHMNYSF WIEAVNGVSD LSPEPRRAAV VNITTNQAAP SQVVVIRQER AGQTSVSLLW QEPEQPNGII LEYEIKYYEK DKEMQSYSTL KAVTTRATVS GLKPGTRYVF QVRARTSAGC GRFSQAMEVE TGKPRPRYDT RTIVWICLTL ITGLVVLLLL LICKKRHCGY SKAFQDSDEE KMHYQNGQAP PPVFLPLHHP PGKLPEPQFY AEPHTYEEPG RAGRSFTREI EASRIHIEKI IGSGDSGEVC YGRLRVPGQR DVPVAIKALK AGYTERQRRD FLSEASIMGQ FDHPNIIRLE GVVTRGRLAM IVTEYMENGS LDTFLRTHDG QFTIMQLVGM LRGVGAGMRY LSDLGYVHRD LAARNVLVDS NLVCKVSDFG LSRVLEDDPD AAYTTTGGKI PIRWTAPEAI AFRTFSSASD VWSFGVVMWE VLAYGERPYW NMTNRDVISS VEEGYRLPAP MGCPHALHQL MLDCWHKDRA QRPRFSQIVS VLDALIRSPE SLRATATVSR CPPPAFVRSC FDLRGGSGGG GGLTVGDWLD SIRMGRYRDH FAAGGYSSLG MVLRMNAQDV RALGITLMGH QKKILGSIQT MRAQLTSTQG PRRHL // ID EPHB2_HUMAN Reviewed; 1055 AA. AC P29323; O43477; Q5T0U6; Q5T0U7; Q5T0U8; DT 01-DEC-1992, integrated into UniProtKB/Swiss-Prot. DT 27-SEP-2005, sequence version 5. DT 28-JAN-2026, entry version 264. DE RecName: Full=Ephrin type-B receptor 2; DE EC=2.7.10.1; DE AltName: Full=Developmentally-regulated Eph-related tyrosine kinase; DE AltName: Full=ELK-related tyrosine kinase; DE AltName: Full=EPH tyrosine kinase 3; DE AltName: Full=EPH-like kinase 5; DE Short=EK5; DE Short=hEK5; DE AltName: Full=Renal carcinoma antigen NY-REN-47; DE AltName: Full=Tyrosine-protein kinase TYRO5; DE AltName: Full=Tyrosine-protein kinase receptor EPH-3; DE Contains: DE RecName: Full=EphB2/CTF1 {ECO:0000250|UniProtKB:P54763}; DE Contains: DE RecName: Full=EphB2/CTF2 {ECO:0000250|UniProtKB:P54763}; DE Flags: Precursor; GN Name=EPHB2; Synonyms=DRT, EPHT3, EPTH3, ERK, HEK5, TYRO5; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RX PubMed=8033077; RA Kiyokawa E., Takai S., Tanaka M., Iwase T., Suzuki M., Xiang Y.Y., RA Naito Y., Yamada K., Sugimura H., Kino I.; RT "Overexpression of ERK, an EPH family receptor protein tyrosine kinase, in RT various human tumors."; RL Cancer Res. 54:3645-3650(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3). RC TISSUE=Fetal brain; RX PubMed=8589679; DOI=10.1093/hmg/4.11.2033; RA Ikegaki N., Tang X.X., Liu X.-G., Biegel J.A., Allen C., Yoshioka A., RA Sulman E.P., Brodeur G.M., Pleasure D.E.; RT "Molecular characterization and chromosomal localization of DRT (EPHT3): a RT developmentally regulated human protein-tyrosine kinase gene of the EPH RT family."; RL Hum. Mol. Genet. 4:2033-2045(1995). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Fetal brain; RX PubMed=9696046; DOI=10.1038/sj.onc.1201960; RA Tang X.X., Pleasure D.E., Brodeur G.M., Ikegaki N.; RT "A variant transcript encoding an isoform of the human protein tyrosine RT kinase EPHB2 is generated by alternative splicing and alternative use of RT polyadenylation signals."; RL Oncogene 17:521-526(1998). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 15-986 (ISOFORM 2). RC TISSUE=Brain; RX PubMed=7898931; RA Fox G.M., Holst P.L., Chute H.T., Lindberg R.A., Janssen A.M., Basu R., RA Welcher A.A.; RT "cDNA cloning and tissue distribution of five human EPH-like receptor RT protein-tyrosine kinases."; RL Oncogene 10:897-905(1995). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 509-986 (ISOFORM 2). RC TISSUE=Fetal brain; RX PubMed=7601466; DOI=10.1016/0888-7543(95)80224-a; RA Saito T., Seki N., Matsuda Y., Kitahara M., Murata M., Kanda N., Nomura N., RA Yamamoto T., Hori T.-A.; RT "Identification of the human ERK gene as a putative receptor tyrosine RT kinase and its chromosomal localization to 1p36.1: a comparative mapping of RT human, mouse, and rat chromosomes."; RL Genomics 26:382-384(1995). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 640-986 (ISOFORM 2). RC TISSUE=Gastric carcinoma; RX PubMed=7688222; DOI=10.1006/bbrc.1993.1878; RA Iwase T., Tanaka M., Suzuki M., Naito Y., Sugimura H., Kino I.; RT "Identification of protein-tyrosine kinase genes preferentially expressed RT in embryo stomach and gastric cancer."; RL Biochem. Biophys. Res. Commun. 194:698-705(1993). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 652-712. RX PubMed=1648701; RA Chan J., Watt V.M.; RT "eek and erk, new members of the eph subclass of receptor protein-tyrosine RT kinases."; RL Oncogene 6:1057-1061(1991). RN [9] RP NOMENCLATURE. RX PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0; RG Eph nomenclature committee; RT "Unified nomenclature for Eph family receptors and their ligands, the RT ephrins."; RL Cell 90:403-404(1997). RN [10] RP IDENTIFICATION AS A RENAL CANCER ANTIGEN. RC TISSUE=Renal cell carcinoma; RX PubMed=10508479; RX DOI=10.1002/(sici)1097-0215(19991112)83:4<456::aid-ijc4>3.0.co;2-5; RA Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H., RA Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T., RA Old L.J.; RT "Antigens recognized by autologous antibody in patients with renal-cell RT carcinoma."; RL Int. J. Cancer 83:456-464(1999). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-983 (ISOFORM 2), RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-984 (ISOFORM 3), AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [13] RP POLYUBIQUITINATION, AND INTERACTION WITH SPSB1 AND SPSB4. RX PubMed=28931592; DOI=10.1091/mbc.e17-07-0450; RA Okumura F., Joo-Okumura A., Obara K., Petersen A., Nishikimi A., Fukui Y., RA Nakatsukasa K., Kamura T.; RT "Ubiquitin ligase SPSB4 diminishes cell repulsive responses mediated by RT EphB2."; RL Mol. Biol. Cell 28:3532-3541(2017). RN [14] RP UBIQUITINATION BY RNF186, AND MUTAGENESIS OF LYS-787 AND LYS-891. RX PubMed=33280498; DOI=10.1080/15548627.2020.1851496; RA Zhang H., Cui Z., Cheng D., Du Y., Guo X., Gao R., Chen J., Sun W., He R., RA Ma X., Peng Q., Martin B.N., Yan W., Rong Y., Wang C.; RT "RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic RT epithelial cells for the maintenance of intestinal homeostasis."; RL Autophagy 17:3030-3047(2021). RN [15] RP X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 910-986 (ISOFORM SHORT). RX PubMed=9933164; DOI=10.1126/science.283.5403.833; RA Thanos C.D., Goodwill K.E., Bowie J.U.; RT "Oligomeric structure of the human EphB2 receptor SAM domain."; RL Science 283:833-836(1999). RN [16] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 20-195 OF HOMODIMER IN COMPLEX RP WITH ANTAGONISTIC PEPTIDE, DISULFIDE BOND, AND SUBUNIT. RX PubMed=17897949; DOI=10.1074/jbc.m706340200; RA Chrencik J.E., Brooun A., Recht M.I., Nicola G., Davis L.K., Abagyan R., RA Widmer H., Pasquale E.B., Kuhn P.; RT "Three-dimensional structure of the EphB2 receptor in complex with an RT antagonistic peptide reveals a novel mode of inhibition."; RL J. Biol. Chem. 282:36505-36513(2007). RN [17] {ECO:0007744|PDB:8EBL} RP X-RAY CRYSTALLOGRAPHY (1.37 ANGSTROMS) OF 1042-1055 IN COMPLEX WITH KLHDC2; RP ELOB AND ELOC, AND UBIQUITINATION BY CRL2(KLHDC2) E3 LIGASE COMPLEX. RX PubMed=36805027; DOI=10.1016/j.molcel.2023.01.019; RA Scott D.C., King M.T., Baek K., Gee C.T., Kalathur R., Li J., Purser N., RA Nourse A., Chai S.C., Vaithiyalingam S., Chen T., Lee R.E., Elledge S.J., RA Kleiger G., Schulman B.A.; RT "E3 ligase autoinhibition by C-degron mimicry maintains C-degron substrate RT fidelity."; RL Mol. Cell 83:770-786.e9(2023). RN [18] RP VARIANTS PROSTATE CANCER HIS-199; SER-279; ASN-679 AND MET-909, AND RP FUNCTION AS A TUMOR SUPPRESSOR. RX PubMed=15300251; DOI=10.1038/ng1408; RA Huusko P., Ponciano-Jackson D., Wolf M., Kiefer J.A., Azorsa D.O., RA Tuzmen S., Weaver D., Robbins C., Moses T., Allinen M., Hautaniemi S., RA Chen Y., Elkahloun A., Basik M., Bova G.S., Bubendorf L., Lugli A., RA Sauter G., Schleutker J., Ozcelik H., Elowe S., Pawson T., Trent J.M., RA Carpten J.D., Kallioniemi O.-P., Mousses S.; RT "Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 RT in human prostate cancer."; RL Nat. Genet. 36:979-983(2004). RN [19] RP VARIANTS PROSTATE CANCER SER-279; ALA-650 AND VAL-883. RX PubMed=16155194; DOI=10.1136/jmg.2005.035790; RA Kittles R.A., Baffoe-Bonnie A.B., Moses T.Y., Robbins C.M., Ahaghotu C., RA Huusko P., Pettaway C., Vijayakumar S., Bennett J., Hoke G., Mason T., RA Weinrich S., Trent J.M., Collins F.S., Mousses S., Bailey-Wilson J., RA Furbert-Harris P., Dunston G., Powell I.J., Carpten J.D.; RT "A common nonsense mutation in EphB2 is associated with prostate cancer RT risk in African American men with a positive family history."; RL J. Med. Genet. 43:507-511(2006). RN [20] RP VARIANTS [LARGE SCALE ANALYSIS] SER-279; GLY-289; VAL-361; ASN-678 AND RP TRP-844. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [21] RP VARIANT BDPLT22 CYS-745, INVOLVEMENT IN BDPLT22, AND FUNCTION. RX PubMed=30213874; DOI=10.1182/blood-2018-04-845644; RA Berrou E., Soukaseum C., Favier R., Adam F., Elaib Z., Kauskot A., RA Bordet J.C., Ballerini P., Loyau S., Feng M., Dias K., Muheidli A., RA Girault S., Nurden A.T., Turro E., Ouwehand W.H., Denis C.V., RA Jandrot-Perrus M., Rosa J.P., Nurden P., Bryckaert M.; RT "A mutation of the human EPHB2 gene leads to a major platelet functional RT defect."; RL Blood 132:2067-2077(2018). CC -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously CC transmembrane ephrin-B family ligands residing on adjacent cells, CC leading to contact-dependent bidirectional signaling into neighboring CC cells. The signaling pathway downstream of the receptor is referred to CC as forward signaling while the signaling pathway downstream of the CC ephrin ligand is referred to as reverse signaling. Functions in axon CC guidance during development. Involved in the guidance of commissural CC axons, that form a major interhemispheric connection between the 2 CC temporal lobes of the cerebral cortex. Also involved in guidance of CC contralateral inner ear efferent growth cones at the midline and of CC retinal ganglion cell axons to the optic disk. In addition to axon CC guidance, also regulates dendritic spines development and maturation CC and stimulates the formation of excitatory synapses. Upon activation by CC EFNB1, abolishes the ARHGEF15-mediated negative regulation on CC excitatory synapse formation. Controls other aspects of development CC including angiogenesis, palate development and in inner ear development CC through regulation of endolymph production. Forward and reverse CC signaling through the EFNB2/EPHB2 complex regulate movement and CC adhesion of cells that tubularize the urethra and septate the cloaca. CC May function as a tumor suppressor. May be involved in the regulation CC of platelet activation and blood coagulation (PubMed:30213874). CC {ECO:0000269|PubMed:15300251, ECO:0000269|PubMed:30213874}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Heterotetramer upon binding of the ligand (By similarity). The CC heterotetramer is composed of an ephrin dimer and a receptor dimer CC (PubMed:17897949). Interacts (via PDZ-binding motif) with GRIP1 and CC PICK1 (via PDZ domain) (By similarity). Interacts with ARHGEF15; CC mediates ARHGEF15 phosphorylation, ubiquitination and degradation by CC the proteasome (By similarity). Interacts with AQP1; involved in CC endolymph production in the inner ear (By similarity). Interacts with CC SPSB1 and SPSB4 (PubMed:28931592). The phosphorylated form interacts CC with RASA1 (via SH2 domain 1) (By similarity). Interacts with EFNA5 (By CC similarity). Interacts with SH2D3C (By similarity). CC {ECO:0000250|UniProtKB:P54763, ECO:0000269|PubMed:17897949, CC ECO:0000269|PubMed:28931592}. CC -!- INTERACTION: CC P29323; P07333: CSF1R; NbExp=2; IntAct=EBI-1059294, EBI-2835440; CC P29323; P98172: EFNB1; NbExp=3; IntAct=EBI-1059294, EBI-538287; CC P29323; P54764: EPHA4; NbExp=3; IntAct=EBI-1059294, EBI-5773557; CC P29323; Q15375: EPHA7; NbExp=2; IntAct=EBI-1059294, EBI-1383428; CC P29323; P49790: NUP153; NbExp=2; IntAct=EBI-1059294, EBI-286779; CC P29323-3; Q9NWW5: CLN6; NbExp=3; IntAct=EBI-25838727, EBI-6165897; CC P29323-3; P21964-2: COMT; NbExp=3; IntAct=EBI-25838727, EBI-10200977; CC P29323-3; Q8WXH2: JPH3; NbExp=3; IntAct=EBI-25838727, EBI-1055254; CC P29323-3; O14832: PHYH; NbExp=3; IntAct=EBI-25838727, EBI-721853; CC P29323-3; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-25838727, EBI-5235340; CC P29323-3; Q13148: TARDBP; NbExp=6; IntAct=EBI-25838727, EBI-372899; CC -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane CC protein. Cell projection, axon {ECO:0000250}. Cell projection, dendrite CC {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=EPHB2v, Long; CC IsoId=P29323-1; Sequence=Displayed; CC Name=2; Synonyms=Short; CC IsoId=P29323-2; Sequence=VSP_003016, VSP_003017; CC Name=3; CC IsoId=P29323-3; Sequence=VSP_015713, VSP_003016, VSP_003017; CC -!- TISSUE SPECIFICITY: Brain, heart, lung, kidney, placenta, pancreas, CC liver and skeletal muscle. Preferentially expressed in fetal brain. CC -!- PTM: Autophosphorylated; ligand binding stimulates autophosphorylation CC on tyrosine residues. {ECO:0000250|UniProtKB:P54763}. CC -!- PTM: Polyubiquitinated; ligand binding stimulates ubiquitination CC (PubMed:28931592). Ubiquitinated by RNF186 at Lys-891, mainly through CC 'Lys-27'-linked polyubiquitin chains (PubMed:33280498). Ubiquitinated CC by CRL2(KLHDC2) E3 ligase complex (PubMed:36805027). CC {ECO:0000269|PubMed:28931592, ECO:0000269|PubMed:33280498, CC ECO:0000269|PubMed:36805027}. CC -!- PTM: Ligand binding induces cleavage by matrix metalloproteinases CC (MMPs) such as MMP7/MMP9, producing an EphB2/N-terminal fragment (NTF) CC and a C-terminal long fragment (EphB2-LF). EphB2-LF is further cleaved CC by MMPs, producing EphB2/CTF1 which is further cleaved by the CC PS1/gamma-secretase producing EphB2/CTF2. CC {ECO:0000250|UniProtKB:P54763}. CC -!- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in CC tissues of the prostate. Most prostate cancers are adenocarcinomas that CC develop in the acini of the prostatic ducts. Other rare histopathologic CC types of prostate cancer that occur in approximately 5% of patients CC include small cell carcinoma, mucinous carcinoma, prostatic ductal CC carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal CC cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:15300251, CC ECO:0000269|PubMed:16155194}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. EPHB2 mutations have been CC found in a prostate cancer cell line derived from a brain metastasis. CC -!- DISEASE: Bleeding disorder, platelet-type, 22 (BDPLT22) [MIM:618462]: CC An autosomal recessive disorder characterized by increased bleeding CC tendency due to platelet dysfunction. Clinical features include CC epistaxis, hematomas, bleeding after minor injuries, and menorrhagia. CC {ECO:0000269|PubMed:30213874}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D31661; BAA06506.1; -; mRNA. DR EMBL; L41939; AAA99310.1; -; mRNA. DR EMBL; AF025304; AAB94602.1; -; mRNA. DR EMBL; AL035704; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL158086; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL512444; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; L36643; AAA74244.1; -; mRNA. DR EMBL; D37827; BAA07073.1; -; mRNA. DR EMBL; D14717; BAA03537.1; -; mRNA. DR EMBL; X59292; CAA41981.1; -; Genomic_DNA. DR CCDS; CCDS229.2; -. [P29323-2] DR CCDS; CCDS230.1; -. [P29323-3] DR CCDS; CCDS81279.1; -. [P29323-1] DR PIR; A57174; A57174. DR PIR; I78842; I78842. DR RefSeq; NP_001296122.1; NM_001309193.2. [P29323-1] DR RefSeq; NP_004433.2; NM_004442.7. [P29323-3] DR RefSeq; NP_059145.2; NM_017449.5. [P29323-2] DR PDB; 1B4F; X-ray; 1.95 A; A/B/C/D/E/F/G/H=908-985. DR PDB; 1F0M; X-ray; 2.20 A; A=908-985. DR PDB; 2QBX; X-ray; 2.30 A; A/B=20-196. DR PDB; 3ZFM; X-ray; 2.27 A; A=604-898. DR PDB; 8EBL; X-ray; 1.37 A; C/D=1042-1055. DR PDBsum; 1B4F; -. DR PDBsum; 1F0M; -. DR PDBsum; 2QBX; -. DR PDBsum; 3ZFM; -. DR PDBsum; 8EBL; -. DR AlphaFoldDB; P29323; -. DR BMRB; P29323; -. DR SMR; P29323; -. DR BioGRID; 108362; 223. DR DIP; DIP-1162N; -. DR FunCoup; P29323; 1062. DR IntAct; P29323; 154. DR MINT; P29323; -. DR STRING; 9606.ENSP00000383053; -. DR BindingDB; P29323; -. DR ChEMBL; CHEMBL3290; -. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB12843; Oleandrin. DR DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester. DR DrugBank; DB13930; Ulixertinib. DR DrugCentral; P29323; -. DR GuidetoPHARMACOLOGY; 1831; -. DR GlyCosmos; P29323; 4 sites, No reported glycans. DR GlyGen; P29323; 5 sites, 2 N-linked glycans (2 sites), 1 O-linked glycan (1 site). DR iPTMnet; P29323; -. DR PhosphoSitePlus; P29323; -. DR SwissPalm; P29323; -. DR BioMuta; EPHB2; -. DR DMDM; 76803654; -. DR CPTAC; CPTAC-2786; -. DR CPTAC; CPTAC-3205; -. DR jPOST; P29323; -. DR MassIVE; P29323; -. DR PaxDb; 9606-ENSP00000363763; -. DR PeptideAtlas; P29323; -. DR ProteomicsDB; 54540; -. [P29323-1] DR ProteomicsDB; 54541; -. [P29323-2] DR ProteomicsDB; 54542; -. [P29323-3] DR Pumba; P29323; -. DR Antibodypedia; 30106; 653 antibodies from 41 providers. DR DNASU; 2048; -. DR Ensembl; ENST00000374630.8; ENSP00000363761.3; ENSG00000133216.17. [P29323-2] DR Ensembl; ENST00000374632.7; ENSP00000363763.3; ENSG00000133216.17. [P29323-3] DR Ensembl; ENST00000400191.7; ENSP00000383053.3; ENSG00000133216.17. [P29323-1] DR GeneID; 2048; -. DR KEGG; hsa:2048; -. DR MANE-Select; ENST00000374630.8; ENSP00000363761.3; NM_017449.5; NP_059145.2. [P29323-2] DR UCSC; uc001bge.4; human. [P29323-1] DR AGR; HGNC:3393; -. DR CIViC; 2048; 2 evidence items across 2 molecular profiles. DR ClinPGx; PA27825; -. DR CTD; 2048; -. DR DisGeNET; 2048; -. DR GeneCards; EPHB2; -. DR HGNC; HGNC:3393; EPHB2. DR HPA; ENSG00000133216; Tissue enhanced (intestine). DR MalaCards; EPHB2; -. DR MIM; 176807; phenotype. DR MIM; 600997; gene. DR MIM; 603688; phenotype. DR MIM; 618462; phenotype. DR OpenTargets; ENSG00000133216; -. DR Orphanet; 1331; Familial prostate cancer. DR VEuPathDB; HostDB:ENSG00000133216; -. DR eggNOG; KOG0196; Eukaryota. DR GeneTree; ENSGT00940000155503; -. DR InParanoid; P29323; -. DR OMA; GAINCIC; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P29323; 10 GO annotations based on evolutionary models. DR PhylomeDB; P29323; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P29323; -. DR Reactome; R-HSA-2682334; EPH-Ephrin signaling. DR Reactome; R-HSA-373760; L1CAM interactions. DR Reactome; R-HSA-3928662; EPHB-mediated forward signaling. DR Reactome; R-HSA-3928664; Ephrin signaling. DR Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. DR SignaLink; P29323; -. DR SIGNOR; P29323; -. DR Agora; ENSG00000133216; -. DR BioGRID-ORCS; 2048; 11 hits in 1193 CRISPR screens. DR ChiTaRS; EPHB2; human. DR EvolutionaryTrace; P29323; -. DR GeneWiki; EPH_receptor_B2; -. DR GenomeRNAi; 2048; -. DR Pharos; P29323; Tchem. DR PRO; PR:P29323; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; P29323; protein. DR Bgee; ENSG00000133216; Expressed in ganglionic eminence and 165 other cell types or tissues. DR ExpressionAtlas; P29323; baseline and differential. DR GO; GO:0030424; C:axon; ISS:UniProtKB. DR GO; GO:0009986; C:cell surface; IEA:Ensembl. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0030425; C:dendrite; ISS:UniProtKB. DR GO; GO:0043197; C:dendritic spine; IEA:Ensembl. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0098686; C:hippocampal mossy fiber to CA3 synapse; IEA:Ensembl. DR GO; GO:0043025; C:neuronal cell body; IEA:Ensembl. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0098794; C:postsynapse; TAS:ARUK-UCL. DR GO; GO:0045211; C:postsynaptic membrane; IEA:Ensembl. DR GO; GO:0042734; C:presynaptic membrane; IEA:Ensembl. DR GO; GO:0001540; F:amyloid-beta binding; ISS:ARUK-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0008046; F:axon guidance receptor activity; IEA:Ensembl. DR GO; GO:0042802; F:identical protein binding; IEA:Ensembl. DR GO; GO:0004713; F:protein tyrosine kinase activity; ISS:UniProtKB. DR GO; GO:0044877; F:protein-containing complex binding; ISS:ARUK-UCL. DR GO; GO:0005102; F:signaling receptor binding; IEA:Ensembl. DR GO; GO:0005005; F:transmembrane-ephrin receptor activity; ISS:UniProtKB. DR GO; GO:0001525; P:angiogenesis; ISS:UniProtKB. DR GO; GO:0007411; P:axon guidance; ISS:UniProtKB. DR GO; GO:0007413; P:axonal fasciculation; ISS:UniProtKB. DR GO; GO:0042113; P:B cell activation; IMP:ARUK-UCL. DR GO; GO:0048593; P:camera-type eye morphogenesis; IEA:Ensembl. DR GO; GO:1904646; P:cellular response to amyloid-beta; IEA:Ensembl. DR GO; GO:0071222; P:cellular response to lipopolysaccharide; IEA:Ensembl. DR GO; GO:0021952; P:central nervous system projection neuron axonogenesis; IEA:Ensembl. DR GO; GO:0071679; P:commissural neuron axon guidance; ISS:UniProtKB. DR GO; GO:0022038; P:corpus callosum development; ISS:UniProtKB. DR GO; GO:0060996; P:dendritic spine development; ISS:UniProtKB. DR GO; GO:0060997; P:dendritic spine morphogenesis; ISS:UniProtKB. DR GO; GO:0048013; P:ephrin receptor signaling pathway; ISS:UniProtKB. DR GO; GO:0021934; P:hindbrain tangential cell migration; IEA:Ensembl. DR GO; GO:0042472; P:inner ear morphogenesis; ISS:UniProtKB. DR GO; GO:0007612; P:learning; ISS:ARUK-UCL. DR GO; GO:0007611; P:learning or memory; ISS:ARUK-UCL. DR GO; GO:0050771; P:negative regulation of axonogenesis; IEA:Ensembl. DR GO; GO:0007162; P:negative regulation of cell adhesion; IMP:ARUK-UCL. DR GO; GO:1900016; P:negative regulation of cytokine production involved in inflammatory response; IEA:Ensembl. DR GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; ISS:ARUK-UCL. DR GO; GO:1900450; P:negative regulation of glutamate receptor signaling pathway; ISS:ARUK-UCL. DR GO; GO:0046580; P:negative regulation of Ras protein signal transduction; ISS:ARUK-UCL. DR GO; GO:0007399; P:nervous system development; TAS:UniProtKB. DR GO; GO:1990535; P:neuron projection maintenance; ISS:ARUK-UCL. DR GO; GO:0106028; P:neuron projection retraction; ISS:ARUK-UCL. DR GO; GO:0021631; P:optic nerve morphogenesis; IEA:Ensembl. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; ISS:UniProtKB. DR GO; GO:0016310; P:phosphorylation; ISS:UniProtKB. DR GO; GO:0030890; P:positive regulation of B cell proliferation; IMP:ARUK-UCL. DR GO; GO:0030335; P:positive regulation of cell migration; IGI:ARUK-UCL. DR GO; GO:0061003; P:positive regulation of dendritic spine morphogenesis; IEA:Ensembl. DR GO; GO:0010628; P:positive regulation of gene expression; ISS:ARUK-UCL. DR GO; GO:1900451; P:positive regulation of glutamate receptor signaling pathway; ISS:ARUK-UCL. DR GO; GO:0002639; P:positive regulation of immunoglobulin production; IMP:ARUK-UCL. DR GO; GO:0048170; P:positive regulation of long-term neuronal synaptic plasticity; IEA:Ensembl. DR GO; GO:1900273; P:positive regulation of long-term synaptic potentiation; ISS:ARUK-UCL. DR GO; GO:2000010; P:positive regulation of protein localization to cell surface; IEA:Ensembl. DR GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; ISS:ARUK-UCL. DR GO; GO:0051965; P:positive regulation of synapse assembly; ISS:UniProtKB. DR GO; GO:0031915; P:positive regulation of synaptic plasticity; ISS:ARUK-UCL. DR GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IMP:ARUK-UCL. DR GO; GO:0097104; P:postsynaptic membrane assembly; IEA:Ensembl. DR GO; GO:2000822; P:regulation of behavioral fear response; IEA:Ensembl. DR GO; GO:0030193; P:regulation of blood coagulation; IMP:UniProtKB. DR GO; GO:0050878; P:regulation of body fluid levels; ISS:UniProtKB. DR GO; GO:0051489; P:regulation of filopodium assembly; IEA:Ensembl. DR GO; GO:0048168; P:regulation of neuronal synaptic plasticity; ISS:ARUK-UCL. DR GO; GO:0046425; P:regulation of receptor signaling pathway via JAK-STAT; IEA:Ensembl. DR GO; GO:2000316; P:regulation of T-helper 17 type immune response; IEA:Ensembl. DR GO; GO:0031290; P:retinal ganglion cell axon guidance; IEA:Ensembl. DR GO; GO:0060021; P:roof of mouth development; ISS:UniProtKB. DR GO; GO:0120192; P:tight junction assembly; IEA:Ensembl. DR GO; GO:0001655; P:urogenital system development; ISS:UniProtKB. DR GO; GO:0110077; P:vesicle-mediated intercellular transport; IEA:Ensembl. DR CDD; cd10477; EphR_LBD_B2; 1. DR CDD; cd00063; FN3; 2. DR CDD; cd05065; PTKc_EphR_B; 1. DR CDD; cd09552; SAM_EPH-B2; 1. DR CDD; cd00185; TNFRSF; 1. DR FunFam; 1.10.150.50:FF:000099; EPH receptor B2; 1. DR FunFam; 2.60.40.10:FF:000041; ephrin type-A receptor 3; 1. DR FunFam; 2.10.50.10:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.1770:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 3.30.200.20:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 1.10.510.10:FF:000015; Ephrin type-B receptor 2; 1. DR FunFam; 2.60.120.260:FF:000004; Ephrin type-B receptor 2; 1. DR FunFam; 2.60.40.10:FF:000110; Ephrin type-B receptor 2; 1. DR Gene3D; 2.60.40.1770; ephrin a2 ectodomain; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 1. DR InterPro; IPR027936; Eph_TM. DR InterPro; IPR034238; EphB2_rcpt_lig-bd. DR InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom. DR InterPro; IPR050449; Ephrin_rcpt_TKs. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001660; SAM. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016257; Tyr_kinase_ephrin_rcpt. DR InterPro; IPR001426; Tyr_kinase_rcpt_V_CS. DR PANTHER; PTHR46877; EPH RECEPTOR A5; 1. DR PANTHER; PTHR46877:SF11; EPHRIN TYPE-B RECEPTOR 2; 1. DR Pfam; PF14575; EphA2_TM; 1. DR Pfam; PF25599; Ephrin_CRD; 1. DR Pfam; PF01404; Ephrin_lbd; 1. DR Pfam; PF07699; Ephrin_rec_like; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00536; SAM_1; 1. DR PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1. DR PRINTS; PR00014; FNTYPEIII. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00615; EPH_lbd; 1. DR SMART; SM01411; Ephrin_rec_like; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00454; SAM; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS51550; EPH_LBD; 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1. DR PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1. DR PROSITE; PS50105; SAM_DOMAIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; KW Cell projection; Developmental protein; Disease variant; Disulfide bond; KW Glycoprotein; Isopeptide bond; Kinase; Membrane; Neurogenesis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; Receptor; KW Reference proteome; Repeat; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tumor suppressor; Tyrosine-protein kinase; KW Ubl conjugation. FT SIGNAL 1..18 FT /evidence="ECO:0000255" FT CHAIN 19..1055 FT /note="Ephrin type-B receptor 2" FT /id="PRO_0000016827" FT CHAIN 536..986 FT /note="EphB2/CTF1" FT /evidence="ECO:0000250|UniProtKB:P54763" FT /id="PRO_0000445961" FT CHAIN 562..986 FT /note="EphB2/CTF2" FT /evidence="ECO:0000250|UniProtKB:P54763" FT /id="PRO_0000445962" FT TOPO_DOM 19..543 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 544..564 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 565..1055 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 20..202 FT /note="Eph LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00883" FT DOMAIN 324..434 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 435..530 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 621..884 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 913..977 FT /note="SAM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00184" FT REGION 990..1055 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 984..986 FT /note="PDZ-binding (in isoform 2)" FT /evidence="ECO:0000255" FT COMPBIAS 991..1002 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1025..1049 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 746 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 627..635 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 653 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 535..536 FT /note="Cleavage; by a metalloproteinase" FT /evidence="ECO:0000250|UniProtKB:P54763" FT SITE 561..562 FT /note="Cleavage; by gamma-secretase/PS1" FT /evidence="ECO:0000250|UniProtKB:P54763" FT CARBOHYD 265 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 336 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 428 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 482 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 62..184 FT /evidence="ECO:0000269|PubMed:17897949" FT DISULFID 97..107 FT /evidence="ECO:0000269|PubMed:17897949" FT CROSSLNK 891 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:33280498" FT VAR_SEQ 568 FT /note="R -> RR (in isoform 3)" FT /evidence="ECO:0000303|PubMed:8589679" FT /id="VSP_015713" FT VAR_SEQ 986 FT /note="G -> V (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:7601466, FT ECO:0000303|PubMed:7688222, ECO:0000303|PubMed:7898931, FT ECO:0000303|PubMed:8033077, ECO:0000303|PubMed:8589679" FT /id="VSP_003016" FT VAR_SEQ 987..1055 FT /note="Missing (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:7601466, FT ECO:0000303|PubMed:7688222, ECO:0000303|PubMed:7898931, FT ECO:0000303|PubMed:8033077, ECO:0000303|PubMed:8589679" FT /id="VSP_003017" FT VARIANT 199 FT /note="R -> H (in prostate cancer; dbSNP:rs201754821)" FT /evidence="ECO:0000269|PubMed:15300251" FT /id="VAR_032853" FT VARIANT 279 FT /note="A -> S (in prostate cancer; dbSNP:rs35882952)" FT /evidence="ECO:0000269|PubMed:15300251, FT ECO:0000269|PubMed:16155194, ECO:0000269|PubMed:17344846" FT /id="VAR_032854" FT VARIANT 289 FT /note="C -> G" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042172" FT VARIANT 361 FT /note="I -> V (in dbSNP:rs56180036)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042173" FT VARIANT 650 FT /note="V -> A (in prostate cancer; dbSNP:rs142173175)" FT /evidence="ECO:0000269|PubMed:16155194" FT /id="VAR_032855" FT VARIANT 678 FT /note="D -> N (in dbSNP:rs28936395)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042174" FT VARIANT 679 FT /note="H -> N (in prostate cancer)" FT /evidence="ECO:0000269|PubMed:15300251" FT /id="VAR_032856" FT VARIANT 745 FT /note="R -> C (in BDPLT22; dbSNP:rs761749948)" FT /evidence="ECO:0000269|PubMed:30213874" FT /id="VAR_082702" FT VARIANT 844 FT /note="R -> W (in dbSNP:rs55826626)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042175" FT VARIANT 883 FT /note="M -> V (in prostate cancer; dbSNP:rs372653137)" FT /evidence="ECO:0000269|PubMed:16155194" FT /id="VAR_032857" FT VARIANT 909 FT /note="I -> M (in prostate cancer)" FT /evidence="ECO:0000269|PubMed:15300251" FT /id="VAR_032858" FT MUTAGEN 787 FT /note="K->R: No loss of ubiquitination by RNF186." FT /evidence="ECO:0000269|PubMed:33280498" FT MUTAGEN 891 FT /note="K->R: Complete loss of ubiquitination by RNF186." FT /evidence="ECO:0000269|PubMed:33280498" FT CONFLICT 1..20 FT /note="MALRRLGAALLLLPLLAAVE -> MWVPVLALPVCTYA (in Ref. 1; FT BAA06506)" FT /evidence="ECO:0000305" FT CONFLICT 154 FT /note="G -> D (in Ref. 1; BAA06506)" FT /evidence="ECO:0000305" FT CONFLICT 476 FT /note="K -> KQ (in Ref. 1; BAA06506)" FT /evidence="ECO:0000305" FT CONFLICT 495..496 FT /note="Missing (in Ref. 5; AAA74244)" FT /evidence="ECO:0000305" FT CONFLICT 532 FT /note="E -> D (in Ref. 1; BAA06506)" FT /evidence="ECO:0000305" FT CONFLICT 589 FT /note="M -> I (in Ref. 5; AAA74244)" FT /evidence="ECO:0000305" FT CONFLICT 671 FT /note="A -> R (in Ref. 7; BAA03537)" FT /evidence="ECO:0000305" FT CONFLICT 788 FT /note="I -> F (in Ref. 5; AAA74244)" FT /evidence="ECO:0000305" FT CONFLICT 853 FT /note="S -> A (in Ref. 1; BAA06506, 6; BAA07073 and 7; FT BAA03537)" FT /evidence="ECO:0000305" FT CONFLICT 923 FT /note="E -> K (in Ref. 1; BAA06506, 6; BAA07073 and 7; FT BAA03537)" FT /evidence="ECO:0000305" FT CONFLICT 958 FT /note="V -> L (in Ref. 2; AAA99310)" FT /evidence="ECO:0000305" FT STRAND 21..25 FT /evidence="ECO:0007829|PDB:2QBX" FT HELIX 26..28 FT /evidence="ECO:0007829|PDB:2QBX" FT STRAND 36..39 FT /evidence="ECO:0007829|PDB:2QBX" FT STRAND 44..49 FT /evidence="ECO:0007829|PDB:2QBX" FT STRAND 55..61 FT /evidence="ECO:0007829|PDB:2QBX" FT STRAND 66..68 FT /evidence="ECO:0007829|PDB:2QBX" FT STRAND 71..74 FT /evidence="ECO:0007829|PDB:2QBX" FT STRAND 84..94 FT /evidence="ECO:0007829|PDB:2QBX" FT HELIX 97..99 FT /evidence="ECO:0007829|PDB:2QBX" FT STRAND 111..120 FT /evidence="ECO:0007829|PDB:2QBX" FT STRAND 130..132 FT /evidence="ECO:0007829|PDB:2QBX" FT STRAND 135..141 FT /evidence="ECO:0007829|PDB:2QBX" FT STRAND 148..152 FT /evidence="ECO:0007829|PDB:2QBX" FT STRAND 155..166 FT /evidence="ECO:0007829|PDB:2QBX" FT STRAND 171..183 FT /evidence="ECO:0007829|PDB:2QBX" FT STRAND 185..194 FT /evidence="ECO:0007829|PDB:2QBX" FT HELIX 618..620 FT /evidence="ECO:0007829|PDB:3ZFM" FT STRAND 621..626 FT /evidence="ECO:0007829|PDB:3ZFM" FT STRAND 635..640 FT /evidence="ECO:0007829|PDB:3ZFM" FT STRAND 648..655 FT /evidence="ECO:0007829|PDB:3ZFM" FT HELIX 661..674 FT /evidence="ECO:0007829|PDB:3ZFM" FT STRAND 685..689 FT /evidence="ECO:0007829|PDB:3ZFM" FT STRAND 691..700 FT /evidence="ECO:0007829|PDB:3ZFM" FT HELIX 707..712 FT /evidence="ECO:0007829|PDB:3ZFM" FT TURN 713..716 FT /evidence="ECO:0007829|PDB:3ZFM" FT HELIX 720..739 FT /evidence="ECO:0007829|PDB:3ZFM" FT HELIX 749..751 FT /evidence="ECO:0007829|PDB:3ZFM" FT STRAND 752..754 FT /evidence="ECO:0007829|PDB:3ZFM" FT STRAND 760..762 FT /evidence="ECO:0007829|PDB:3ZFM" FT HELIX 790..792 FT /evidence="ECO:0007829|PDB:3ZFM" FT HELIX 795..800 FT /evidence="ECO:0007829|PDB:3ZFM" FT HELIX 805..820 FT /evidence="ECO:0007829|PDB:3ZFM" FT TURN 826..829 FT /evidence="ECO:0007829|PDB:3ZFM" FT HELIX 832..840 FT /evidence="ECO:0007829|PDB:3ZFM" FT HELIX 853..862 FT /evidence="ECO:0007829|PDB:3ZFM" FT HELIX 873..885 FT /evidence="ECO:0007829|PDB:3ZFM" FT HELIX 887..890 FT /evidence="ECO:0007829|PDB:3ZFM" FT HELIX 918..924 FT /evidence="ECO:0007829|PDB:1B4F" FT HELIX 928..930 FT /evidence="ECO:0007829|PDB:1B4F" FT HELIX 931..936 FT /evidence="ECO:0007829|PDB:1B4F" FT HELIX 942..945 FT /evidence="ECO:0007829|PDB:1B4F" FT HELIX 950..955 FT /evidence="ECO:0007829|PDB:1B4F" FT HELIX 961..982 FT /evidence="ECO:0007829|PDB:1B4F" FT HELIX 1050..1052 FT /evidence="ECO:0007829|PDB:8EBL" FT MOD_RES P29323-2:983 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES P29323-3:984 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" SQ SEQUENCE 1055 AA; 117493 MW; 4F8BFEDC45986483 CRC64; MALRRLGAAL LLLPLLAAVE ETLMDSTTAT AELGWMVHPP SGWEEVSGYD ENMNTIRTYQ VCNVFESSQN NWLRTKFIRR RGAHRIHVEM KFSVRDCSSI PSVPGSCKET FNLYYYEADF DSATKTFPNW MENPWVKVDT IAADESFSQV DLGGRVMKIN TEVRSFGPVS RSGFYLAFQD YGGCMSLIAV RVFYRKCPRI IQNGAIFQET LSGAESTSLV AARGSCIANA EEVDVPIKLY CNGDGEWLVP IGRCMCKAGF EAVENGTVCR GCPSGTFKAN QGDEACTHCP INSRTTSEGA TNCVCRNGYY RADLDPLDMP CTTIPSAPQA VISSVNETSL MLEWTPPRDS GGREDLVYNI ICKSCGSGRG ACTRCGDNVQ YAPRQLGLTE PRIYISDLLA HTQYTFEIQA VNGVTDQSPF SPQFASVNIT TNQAAPSAVS IMHQVSRTVD SITLSWSQPD QPNGVILDYE LQYYEKELSE YNATAIKSPT NTVTVQGLKA GAIYVFQVRA RTVAGYGRYS GKMYFQTMTE AEYQTSIQEK LPLIIGSSAA GLVFLIAVVV IAIVCNRRGF ERADSEYTDK LQHYTSGHMT PGMKIYIDPF TYEDPNEAVR EFAKEIDISC VKIEQVIGAG EFGEVCSGHL KLPGKREIFV AIKTLKSGYT EKQRRDFLSE ASIMGQFDHP NVIHLEGVVT KSTPVMIITE FMENGSLDSF LRQNDGQFTV IQLVGMLRGI AAGMKYLADM NYVHRDLAAR NILVNSNLVC KVSDFGLSRF LEDDTSDPTY TSALGGKIPI RWTAPEAIQY RKFTSASDVW SYGIVMWEVM SYGERPYWDM TNQDVINAIE QDYRLPPPMD CPSALHQLML DCWQKDRNHR PKFGQIVNTL DKMIRNPNSL KAMAPLSSGI NLPLLDRTIP DYTSFNTVDE WLEAIKMGQY KESFANAGFT SFDVVSQMMM EDILRVGVTL AGHQKKILNS IQVMRAQMNQ IQSVEGQPLA RRPRATGRTK RCQPRDVTKK TCNSNDGKKK GMGKKKTDPG RGREIQGIFF KEDSHKESND CSCGG // ID EPHB4_HUMAN Reviewed; 987 AA. AC P54760; B5A970; B5A971; B5A972; Q7Z635; Q9BTA5; Q9BXP0; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 18-OCT-2001, sequence version 2. DT 28-JAN-2026, entry version 243. DE RecName: Full=Ephrin type-B receptor 4; DE EC=2.7.10.1; DE AltName: Full=Hepatoma transmembrane kinase; DE AltName: Full=Tyrosine-protein kinase TYRO11; DE Flags: Precursor; GN Name=EPHB4; Synonyms=HTK, MYK1, TYRO11; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, RP AUTOPHOSPHORYLATION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE. RX PubMed=8188704; DOI=10.1016/s0021-9258(17)36776-5; RA Bennett B.D., Wang Z., Kuang W.J., Wang A., Groopman J.E., Goeddel D.V., RA Scadden D.T.; RT "Cloning and characterization of HTK, a novel transmembrane tyrosine kinase RT of the EPH subfamily."; RL J. Biol. Chem. 269:14211-14218(1994). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=11239002; DOI=10.1093/nar/29.6.1352; RA Wilson M.D., Riemer C., Martindale D.W., Schnupf P., Boright A.P., RA Cheung T.L., Hardy D.M., Schwartz S., Scherer S.W., Tsui L.-C., Miller W., RA Koop B.F.; RT "Comparative analysis of the gene-dense ACHE/TFR2 region on human RT chromosome 7q22 with the orthologous region on mouse chromosome 5."; RL Nucleic Acids Res. 29:1352-1365(2001). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3 AND 4), AND ALTERNATIVE SPLICING. RX PubMed=18593464; DOI=10.1186/ar2447; RA Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D., RA Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.; RT "Novel splice variants derived from the receptor tyrosine kinase RT superfamily are potential therapeutics for rheumatoid arthritis."; RL Arthritis Res. Ther. 10:R73-R73(2008). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-162. RC TISSUE=Ovary, and Pancreas; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NOMENCLATURE. RX PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0; RG Eph nomenclature committee; RT "Unified nomenclature for Eph family receptors and their ligands, the RT ephrins."; RL Cell 90:403-404(1997). RN [6] RP FUNCTION IN ANGIOGENESIS, FUNCTION IN CELL ADHESION, AND FUNCTION IN CELL RP MIGRATION. RX PubMed=12734395; DOI=10.1242/jcs.00426; RA Fueller T., Korff T., Kilian A., Dandekar G., Augustin H.G.; RT "Forward EphB4 signaling in endothelial cells controls cellular repulsion RT and segregation from ephrinB2 positive cells."; RL J. Cell Sci. 116:2461-2470(2003). RN [7] RP FUNCTION IN ANGIOGENESIS. RX PubMed=16424904; DOI=10.1038/sj.emboj.7600949; RA Erber R., Eichelsbacher U., Powajbo V., Korn T., Djonov V., Lin J., RA Hammes H.P., Grobholz R., Ullrich A., Vajkoczy P.; RT "EphB4 controls blood vascular morphogenesis during postnatal RT angiogenesis."; RL EMBO J. 25:628-641(2006). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-911 AND THR-976, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-976, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-911; THR-976 AND TYR-987, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-769; SER-770 AND THR-976, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-943, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [15] RP X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 17-196 IN COMPLEX WITH EFNB2, RP MUTAGENESIS OF LEU-95, AND DISULFIDE BOND. RX PubMed=16867992; DOI=10.1074/jbc.m605766200; RA Chrencik J.E., Brooun A., Kraus M.L., Recht M.I., Kolatkar A.R., Han G.W., RA Seifert J.M., Widmer H., Auer M., Kuhn P.; RT "Structural and biophysical characterization of the EphB4*ephrinB2 protein- RT protein interaction and receptor specificity."; RL J. Biol. Chem. 281:28185-28192(2006). RN [16] RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 17-196 IN COMPLEX WITH RP ANTAGONISTIC PEPTIDE, AND DISULFIDE BOND. RX PubMed=16472751; DOI=10.1016/j.str.2005.11.011; RA Chrencik J.E., Brooun A., Recht M.I., Kraus M.L., Koolpe M., Kolatkar A.R., RA Bruce R.H., Martiny-Baron G., Widmer H., Pasquale E.B., Kuhn P.; RT "Structure and thermodynamic characterization of the EphB4/Ephrin-B2 RT antagonist peptide complex reveals the determinants for receptor RT specificity."; RL Structure 14:321-330(2006). RN [17] RP STRUCTURE BY NMR OF 434-529. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the second FN3 domain from human ephrin type-B RT receptor 4."; RL Submitted (JUL-2007) to the PDB data bank. RN [18] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-67; ILE-113; LEU-346; VAL-371; GLU-576; RP HIS-678; THR-882; TRP-889 AND ASP-890. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [19] RP INVOLVEMENT IN LMPHM7, VARIANTS LMPHM7 GLN-739 AND SER-782, RP CHARACTERIZATION OF VARIANTS LMPHM7 GLU-739 AND SER-782, AND FUNCTION. RX PubMed=27400125; DOI=10.1172/jci85794; RA Martin-Almedina S., Martinez-Corral I., Holdhus R., Vicente A., Fotiou E., RA Lin S., Petersen K., Simpson M.A., Hoischen A., Gilissen C., Jeffery H., RA Atton G., Karapouliou C., Brice G., Gordon K., Wiseman J.W., Wedin M., RA Rockson S.G., Jeffery S., Mortimer P.S., Snyder M.P., Berland S., RA Mansour S., Makinen T., Ostergaard P.; RT "EPHB4 kinase-inactivating mutations cause autosomal dominant lymphatic- RT related hydrops fetalis."; RL J. Clin. Invest. 126:3080-3088(2016). RN [20] RP VARIANTS CMAVM2 LYS-59; PRO-74; TYR-115 DEL; 130-TRP--TYR-987 DEL; RP 161-VAL-LYS-162 DELINS LEU; PRO-187; 244-GLN--TYR-987 DEL; ARG-268; RP 352-ARG--TYR-987 DEL; 375-GLY--TYR-987 DEL; 431-ARG--TYR-987 DEL; GLY-469; RP ARG-516; 520-GLN--TYR-987 DEL; 596-TYR--TYR-987 DEL; TRP-656; LYS-664; RP THR-725; 739-ARG--TYR-987 DEL; ASP-745; ARG-789; SER-789; 806-TYR--TYR-987 RP DEL; ARG-807; LEU-820; THR-820; TRP-838; ARG-845; TYR-856; TRP-864 AND RP PRO-874, CHARACTERIZATION OF VARIANTS CMAVM2 LYS-664; TRP-838; ARG-845 AND RP TRP-864, INVOLVEMENT IN CMAVM2, AND SUBCELLULAR LOCATION. RX PubMed=28687708; DOI=10.1161/circulationaha.116.026886; RA Amyere M., Revencu N., Helaers R., Pairet E., Baselga E., Cordisco M., RA Chung W., Dubois J., Lacour J.P., Martorell L., Mazereeuw-Hautier J., RA Pyeritz R.E., Amor D.J., Bisdorff A., Blei F., Bombei H., Dompmartin A., RA Brooks D., Dupont J., Gonzalez-Ensenat M.A., Frieden I., Gerard M., RA Kvarnung M., Hanson-Kahn A.K., Hudgins L., Leaute-Labreze C., McCuaig C., RA Metry D., Parent P., Paul C., Petit F., Phan A., Quere I., Salhi A., RA Turner A., Vabres P., Vicente A., Wargon O., Watanabe S., Weibel L., RA Wilson A., Willing M., Mulliken J.B., Boon L.M., Vikkula M.; RT "Germline loss-of-function mutations in EPHB4 cause a second form of RT capillary malformation-arteriovenous malformation (CM-AVM2) deregulating RT RAS-MAPK signaling."; RL Circulation 136:1037-1048(2017). RN [21] RP VARIANT CMAVM2 GLY-802, AND INVOLVEMENT IN CMAVM2. RX PubMed=28730721; DOI=10.1111/pde.13208; RA Yu J., Streicher J.L., Medne L., Krantz I.D., Yan A.C.; RT "EPHB4 mutation implicated in capillary malformation-arteriovenous RT malformation syndrome: A case report."; RL Pediatr. Dermatol. 34:E227-E230(2017). RN [22] RP VARIANTS CMAVM2 ARG-107 AND GLU-870, AND INVOLVEMENT IN CMAVM2. RX PubMed=29444212; DOI=10.1093/brain/awy020; RA Vivanti A., Ozanne A., Grondin C., Saliou G., Quevarec L., Maurey H., RA Aubourg P., Benachi A., Gut M., Gut I., Martinovic J., Senat M.V., Tawk M., RA Melki J.; RT "Loss of function mutations in EPHB4 are responsible for vein of Galen RT aneurysmal malformation."; RL Brain 141:979-988(2018). RN [23] RP VARIANT GLY-509, CHARACTERIZATION OF VARIANT GLY-509, VARIANTS CMAVM2 RP ASN-650 AND LEU-867, CHARACTERIZATION OF VARIANTS CMAVM2 ASN-650 AND RP LEU-867, INVOLVEMENT IN CMAVM2, FUNCTION, AND INTERACTION WITH RASA1. RX PubMed=30578106; DOI=10.1016/j.neuron.2018.11.041; RA Duran D., Zeng X., Jin S.C., Choi J., Nelson-Williams C., Yatsula B., RA Gaillard J., Furey C.G., Lu Q., Timberlake A.T., Dong W., Sorscher M.A., RA Loring E., Klein J., Allocco A., Hunt A., Conine S., Karimy J.K., RA Youngblood M.W., Zhang J., DiLuna M.L., Matouk C.C., Mane S., RA Tikhonova I.R., Castaldi C., Lopez-Giraldez F., Knight J., Haider S., RA Soban M., Alper S.L., Komiyama M., Ducruet A.F., Zabramski J.M., Dardik A., RA Walcott B.P., Stapleton C.J., Aagaard-Kienitz B., Rodesch G., Jackson E., RA Smith E.R., Orbach D.B., Berenstein A., Bilguvar K., Vikkula M., Gunel M., RA Lifton R.P., Kahle K.T.; RT "Mutations in chromatin modifier and ephrin signaling genes in vein of RT Galen malformation."; RL Neuron 101:429-443(2019). CC -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously CC transmembrane ephrin-B family ligands residing on adjacent cells, CC leading to contact-dependent bidirectional signaling into neighboring CC cells. The signaling pathway downstream of the receptor is referred to CC as forward signaling while the signaling pathway downstream of the CC ephrin ligand is referred to as reverse signaling. Together with its CC cognate ligand/functional ligand EFNB2 it is involved in the regulation CC of cell adhesion and migration, and plays a central role in heart CC morphogenesis, angiogenesis and blood vessel remodeling and CC permeability. EPHB4-mediated forward signaling controls cellular CC repulsion and segregation from EFNB2-expressing cells. CC {ECO:0000269|PubMed:12734395, ECO:0000269|PubMed:16424904, CC ECO:0000269|PubMed:27400125, ECO:0000269|PubMed:30578106}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Heterotetramer upon binding of the ligand. The heterotetramer CC is composed of an ephrin dimer and a receptor dimer. Oligomerization is CC probably required to induce biological responses (By similarity). CC Interacts with RASA1; the interaction depends on EPHB4 tyrosine- CC phosphorylation (PubMed:30578106). {ECO:0000250, CC ECO:0000269|PubMed:30578106}. CC -!- INTERACTION: CC P54760; P52799: EFNB2; NbExp=7; IntAct=EBI-702121, EBI-7532268; CC P54760; P54756: EPHA5; NbExp=2; IntAct=EBI-702121, EBI-1383718; CC P54760; Q9UF33: EPHA6; NbExp=2; IntAct=EBI-702121, EBI-3950019; CC P54760; Q15375: EPHA7; NbExp=3; IntAct=EBI-702121, EBI-1383428; CC P54760; P01588: EPO; NbExp=6; IntAct=EBI-702121, EBI-1027362; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:28687708, CC ECO:0000269|PubMed:8188704}; Single-pass type I membrane protein CC {ECO:0000269|PubMed:8188704}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=P54760-1; Sequence=Displayed; CC Name=2; CC IsoId=P54760-2; Sequence=VSP_056024, VSP_056025; CC Name=3; CC IsoId=P54760-3; Sequence=VSP_056020, VSP_056021; CC Name=4; CC IsoId=P54760-4; Sequence=VSP_056022, VSP_056023; CC -!- TISSUE SPECIFICITY: Abundantly expressed in placenta but also detected CC in kidney, liver, lung, pancreas, skeletal muscle and heart. Expressed CC in primitive and myeloid, but not lymphoid, hematopoietic cells. Also CC observed in cell lines derived from liver, breast, colon, lung, CC melanocyte and cervix. {ECO:0000269|PubMed:8188704}. CC -!- DEVELOPMENTAL STAGE: Expressed in fetal heart, lung, liver and to a CC lower extent in brain. Not expressed in adult brain. CC {ECO:0000269|PubMed:8188704}. CC -!- PTM: Phosphorylated; autophosphorylation is stimulated by EFNB2. CC -!- DISEASE: Lymphatic malformation 7 (LMPHM7) [MIM:617300]: A form of CC primary lymphedema, a disease characterized by swelling of body parts CC due to developmental anomalies and functional defects of the lymphatic CC system. Patients with lymphedema may suffer from recurrent local CC infections. LMPHM7 is an autosomal dominant form with variable CC expressivity. Some individuals present with severe non-immune hydrops CC fetalis, which may cause perinatal demise or fully resolve after the CC neonatal period. Others present with no edema and have milder clinical CC features, such as atrial septal defect or varicose veins as adults. CC {ECO:0000269|PubMed:27400125}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Capillary malformation-arteriovenous malformation 2 (CMAVM2) CC [MIM:618196]: An autosomal dominant disorder characterized by multiple, CC round to oval or more irregularly shaped macules that are pinkish red CC in color and are randomly distributed across the body. These capillary CC malformations are associated with either arteriovenous malformation, CC arteriovenous fistula, or Parkes Weber syndrome. CC {ECO:0000269|PubMed:28687708, ECO:0000269|PubMed:28730721, CC ECO:0000269|PubMed:29444212, ECO:0000269|PubMed:30578106}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U07695; AAA20598.1; -; mRNA. DR EMBL; AF312032; AAK21010.1; -; Genomic_DNA. DR EMBL; EU826608; ACF47644.1; -; mRNA. DR EMBL; EU826609; ACF47645.1; -; mRNA. DR EMBL; EU826610; ACF47646.1; -; mRNA. DR EMBL; BC004264; AAH04264.1; -; mRNA. DR EMBL; BC052804; AAH52804.1; -; mRNA. DR CCDS; CCDS5706.1; -. [P54760-1] DR PIR; A54092; A54092. DR RefSeq; NP_004435.3; NM_004444.4. [P54760-1] DR PDB; 2BBA; X-ray; 1.65 A; A=17-196. DR PDB; 2E7H; NMR; -; A=434-529. DR PDB; 2HLE; X-ray; 2.05 A; A=17-196. DR PDB; 2QKQ; X-ray; 2.10 A; A/B=896-977. DR PDB; 2VWU; X-ray; 2.00 A; A=598-899. DR PDB; 2VWV; X-ray; 1.90 A; A=598-899. DR PDB; 2VWW; X-ray; 1.90 A; A=598-899. DR PDB; 2VWX; X-ray; 1.65 A; A=598-899. DR PDB; 2VWY; X-ray; 1.65 A; A=598-899. DR PDB; 2VWZ; X-ray; 1.65 A; A=598-899. DR PDB; 2VX0; X-ray; 2.10 A; A=598-899. DR PDB; 2VX1; X-ray; 1.65 A; A=598-899. DR PDB; 2X9F; X-ray; 1.75 A; A=598-899. DR PDB; 2XVD; X-ray; 1.70 A; A=598-899. DR PDB; 2YN8; X-ray; 2.11 A; A/B=598-892. DR PDB; 3ZEW; X-ray; 2.50 A; A/B=598-892. DR PDB; 4AW5; X-ray; 2.33 A; A=605-890. DR PDB; 4BB4; X-ray; 1.65 A; A=598-899. DR PDB; 6FNI; X-ray; 1.47 A; A=598-892. DR PDB; 6FNJ; X-ray; 1.24 A; A/B=598-892. DR PDB; 6FNK; X-ray; 1.05 A; A=598-892. DR PDB; 6FNL; X-ray; 1.27 A; A=598-892. DR PDB; 6FNM; X-ray; 1.16 A; A=598-892. DR PDBsum; 2BBA; -. DR PDBsum; 2E7H; -. DR PDBsum; 2HLE; -. DR PDBsum; 2QKQ; -. DR PDBsum; 2VWU; -. DR PDBsum; 2VWV; -. DR PDBsum; 2VWW; -. DR PDBsum; 2VWX; -. DR PDBsum; 2VWY; -. DR PDBsum; 2VWZ; -. DR PDBsum; 2VX0; -. DR PDBsum; 2VX1; -. DR PDBsum; 2X9F; -. DR PDBsum; 2XVD; -. DR PDBsum; 2YN8; -. DR PDBsum; 3ZEW; -. DR PDBsum; 4AW5; -. DR PDBsum; 4BB4; -. DR PDBsum; 6FNI; -. DR PDBsum; 6FNJ; -. DR PDBsum; 6FNK; -. DR PDBsum; 6FNL; -. DR PDBsum; 6FNM; -. DR AlphaFoldDB; P54760; -. DR BMRB; P54760; -. DR SASBDB; P54760; -. DR SMR; P54760; -. DR BioGRID; 108364; 154. DR FunCoup; P54760; 1222. DR IntAct; P54760; 108. DR MINT; P54760; -. DR STRING; 9606.ENSP00000350896; -. DR BindingDB; P54760; -. DR ChEMBL; CHEMBL5147; -. DR DrugBank; DB07256; 3-({4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL}AMINO)BENZAMIDE. DR DrugBank; DB07252; 3-({4-[(5-chloro-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl}amino)benzenesulfonamide. DR DrugBank; DB01254; Dasatinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB07251; N'-(3-CHLORO-4-METHOXY-PHENYL)-N-(3,4,5-TRIMETHOXYPHENYL)-1,3,5-TRIAZINE-2,4-DIAMINE. DR DrugBank; DB07250; N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3,4,5- TRIMETHOXYPHENYL)PYRIMIDINE-2,4-DIAMINE. DR DrugBank; DB07253; N'-(5-chloro-1,3-benzodioxol-4-yl)-N-(3-methylsulfonylphenyl)pyrimidine-2,4-diamine. DR DrugBank; DB07255; N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3-MORPHOLIN-4-YLPHENYL)PYRIMIDINE-2,4-DIAMINE. DR DrugBank; DB07249; N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-amine. DR DrugBank; DB07254; N-[3-[[4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL]AMINO]PHENYL]METHANESULFONAMIDE. DR DrugBank; DB11973; Tesevatinib. DR DrugCentral; P54760; -. DR GuidetoPHARMACOLOGY; 1833; -. DR TCDB; 8.A.23.1.15; the basigin (basigin) family. DR GlyConnect; 1214; 3 N-Linked glycans (1 site). DR GlyCosmos; P54760; 3 sites, 3 glycans. DR GlyGen; P54760; 4 sites, 10 N-linked glycans (3 sites). DR iPTMnet; P54760; -. DR PhosphoSitePlus; P54760; -. DR SwissPalm; P54760; -. DR BioMuta; EPHB4; -. DR DMDM; 19860819; -. DR CPTAC; CPTAC-2788; -. DR CPTAC; CPTAC-2841; -. DR CPTAC; CPTAC-2919; -. DR jPOST; P54760; -. DR MassIVE; P54760; -. DR PaxDb; 9606-ENSP00000350896; -. DR PeptideAtlas; P54760; -. DR ProteomicsDB; 56715; -. [P54760-1] DR Pumba; P54760; -. DR Antibodypedia; 4623; 752 antibodies from 43 providers. DR CPTC; P54760; 2 antibodies. DR DNASU; 2050; -. DR Ensembl; ENST00000358173.8; ENSP00000350896.3; ENSG00000196411.11. [P54760-1] DR Ensembl; ENST00000616502.4; ENSP00000482702.1; ENSG00000196411.11. [P54760-3] DR GeneID; 2050; -. DR KEGG; hsa:2050; -. DR MANE-Select; ENST00000358173.8; ENSP00000350896.3; NM_004444.5; NP_004435.3. DR UCSC; uc011kkg.2; human. [P54760-1] DR AGR; HGNC:3395; -. DR CIViC; 2050; 1 evidence item across 1 molecular profile. DR ClinPGx; PA27827; -. DR CTD; 2050; -. DR DisGeNET; 2050; -. DR GeneCards; EPHB4; -. DR GeneReviews; EPHB4; -. DR HGNC; HGNC:3395; EPHB4. DR HPA; ENSG00000196411; Low tissue specificity. DR MalaCards; EPHB4; -. DR MIM; 600011; gene. DR MIM; 617300; phenotype. DR MIM; 618196; phenotype. DR OpenTargets; ENSG00000196411; -. DR Orphanet; 693912; EPHB4-related capillary malformation-arteriovenous malformation. DR Orphanet; 568065; EPHB4-related lymphatic-related hydrops fetalis. DR Orphanet; 90186; Meige disease. DR Orphanet; 1053; Vein of Galen aneurysmal malformation. DR VEuPathDB; HostDB:ENSG00000196411; -. DR eggNOG; KOG0196; Eukaryota. DR GeneTree; ENSGT00940000160057; -. DR HOGENOM; CLU_000288_141_3_1; -. DR InParanoid; P54760; -. DR OMA; STKCRAC; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P54760; 9 GO annotations based on evolutionary models. DR PhylomeDB; P54760; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P54760; -. DR Reactome; R-HSA-2682334; EPH-Ephrin signaling. DR Reactome; R-HSA-3928662; EPHB-mediated forward signaling. DR Reactome; R-HSA-3928664; Ephrin signaling. DR Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. DR SignaLink; P54760; -. DR SIGNOR; P54760; -. DR Agora; ENSG00000196411; -. DR BioGRID-ORCS; 2050; 13 hits in 1190 CRISPR screens. DR ChiTaRS; EPHB4; human. DR EvolutionaryTrace; P54760; -. DR GeneWiki; EPH_receptor_B4; -. DR GenomeRNAi; 2050; -. DR Pharos; P54760; Tchem. DR PRO; PR:P54760; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; P54760; protein. DR Bgee; ENSG00000196411; Expressed in olfactory bulb and 209 other cell types or tissues. DR ExpressionAtlas; P54760; baseline and differential. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005003; F:ephrin receptor activity; IDA:UniProtKB. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0001525; P:angiogenesis; IDA:UniProt. DR GO; GO:0007155; P:cell adhesion; IDA:UniProtKB. DR GO; GO:0002042; P:cell migration involved in sprouting angiogenesis; IDA:UniProtKB. DR GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0003007; P:heart morphogenesis; ISS:UniProtKB. DR CDD; cd10474; EphR_LBD_B4; 1. DR CDD; cd00063; FN3; 2. DR CDD; cd05065; PTKc_EphR_B; 1. DR CDD; cd09554; SAM_EPH-B4; 1. DR FunFam; 1.10.150.50:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.10.50.10:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 3.30.200.20:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.10:FF:000059; Ephrin type-A receptor 6; 1. DR FunFam; 1.10.510.10:FF:000015; Ephrin type-B receptor 2; 1. DR FunFam; 2.60.120.260:FF:000071; Ephrin type-B receptor 4; 1. DR FunFam; 2.60.40.10:FF:000787; ephrin type-B receptor 4; 1. DR FunFam; 2.60.40.1770:FF:000003; ephrin type-B receptor 4; 1. DR Gene3D; 2.60.40.1770; ephrin a2 ectodomain; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 1. DR InterPro; IPR037636; EPH-B4_SAM. DR InterPro; IPR027936; Eph_TM. DR InterPro; IPR034290; EphB4_rcpt_lig-bd. DR InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom. DR InterPro; IPR050449; Ephrin_rcpt_TKs. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001660; SAM. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016257; Tyr_kinase_ephrin_rcpt. DR InterPro; IPR001426; Tyr_kinase_rcpt_V_CS. DR PANTHER; PTHR46877; EPH RECEPTOR A5; 1. DR PANTHER; PTHR46877:SF19; RECEPTOR PROTEIN-TYROSINE KINASE; 1. DR Pfam; PF14575; EphA2_TM; 1. DR Pfam; PF25599; Ephrin_CRD; 1. DR Pfam; PF01404; Ephrin_lbd; 1. DR Pfam; PF07699; Ephrin_rec_like; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00536; SAM_1; 1. DR PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00615; EPH_lbd; 1. DR SMART; SM01411; Ephrin_rec_like; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00454; SAM; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS01186; EGF_2; 1. DR PROSITE; PS51550; EPH_LBD; 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1. DR PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1. DR PROSITE; PS50105; SAM_DOMAIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Angiogenesis; ATP-binding; KW Cell membrane; Developmental protein; Disease variant; Disulfide bond; KW Glycoprotein; Kinase; Membrane; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Receptor; Reference proteome; Repeat; Signal; KW Transferase; Transmembrane; Transmembrane helix; Tyrosine-protein kinase. FT SIGNAL 1..15 FT /evidence="ECO:0000255" FT CHAIN 16..987 FT /note="Ephrin type-B receptor 4" FT /id="PRO_0000016834" FT TOPO_DOM 16..539 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 540..560 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 561..987 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 17..202 FT /note="Eph LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00883" FT DOMAIN 323..432 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 436..529 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 615..899 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 907..971 FT /note="SAM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00184" FT REGION 965..987 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 985..987 FT /note="PDZ-binding" FT /evidence="ECO:0000255" FT COMPBIAS 976..987 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 740 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 621..629 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 647 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 769 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 770 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 911 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195" FT MOD_RES 943 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 976 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 987 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:19369195" FT CARBOHYD 203 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 335 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 426 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 61..184 FT DISULFID 97..107 FT VAR_SEQ 270..306 FT /note="ACAQGTFKPLSGEGSCQPCPANSHSNTIGSAVCQCRV -> GRRGSQQRAVP FT EDVRKPGRAAGAEAGSQLPGAGTGAL (in isoform 3)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056020" FT VAR_SEQ 307..987 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056021" FT VAR_SEQ 406..414 FT /note="VTALNGVSS -> YLLQCLTSG (in isoform 4)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056022" FT VAR_SEQ 415..987 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056023" FT VAR_SEQ 507..516 FT /note="VRARSEAGYG -> RARAGGSSWP (in isoform 2)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056024" FT VAR_SEQ 517..987 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056025" FT VARIANT 59 FT /note="E -> K (in CMAVM2; uncertain significance; FT dbSNP:rs1584667224)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081689" FT VARIANT 67 FT /note="P -> L (in dbSNP:rs34653459)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042181" FT VARIANT 74 FT /note="R -> P (in CMAVM2; uncertain significance; FT dbSNP:rs61735971)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081690" FT VARIANT 107 FT /note="C -> R (in CMAVM2; uncertain significance; FT dbSNP:rs1562974383)" FT /evidence="ECO:0000269|PubMed:29444212" FT /id="VAR_081691" FT VARIANT 113 FT /note="V -> I (in dbSNP:rs55866373)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042182" FT VARIANT 115 FT /note="Missing (in CMAVM2; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081692" FT VARIANT 130..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081693" FT VARIANT 161..162 FT /note="VK -> L (in CMAVM2; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081694" FT VARIANT 162 FT /note="K -> R (in dbSNP:rs17854760)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_071163" FT VARIANT 187 FT /note="L -> P (in CMAVM2; uncertain significance; FT dbSNP:rs1584666053)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081695" FT VARIANT 244..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081696" FT VARIANT 268 FT /note="C -> R (in CMAVM2; uncertain significance; FT dbSNP:rs201816920)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081697" FT VARIANT 346 FT /note="P -> L (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs267601191)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042183" FT VARIANT 352..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081698" FT VARIANT 371 FT /note="A -> V (in dbSNP:rs55720981)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042184" FT VARIANT 375..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081699" FT VARIANT 431..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081700" FT VARIANT 469 FT /note="V -> G (in CMAVM2; uncertain significance; FT dbSNP:rs1584662591)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081701" FT VARIANT 509 FT /note="A -> G (does not affect tyrosine phosphorylation; FT does not affect interaction with RASA1; dbSNP:rs146937374)" FT /evidence="ECO:0000269|PubMed:30578106" FT /id="VAR_081702" FT VARIANT 516 FT /note="G -> R (in CMAVM2; uncertain significance; FT dbSNP:rs776305185)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081703" FT VARIANT 520..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081704" FT VARIANT 576 FT /note="D -> E (in dbSNP:rs36050247)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042185" FT VARIANT 596..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081705" FT VARIANT 650 FT /note="K -> N (in CMAVM2; highly decreased tyrosine FT phosphorylation; highly decreased interaction with RASA1; FT dbSNP:rs1584658113)" FT /evidence="ECO:0000269|PubMed:30578106" FT /id="VAR_081706" FT VARIANT 656 FT /note="R -> W (in CMAVM2; uncertain significance; FT dbSNP:rs745584371)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081707" FT VARIANT 664 FT /note="E -> K (in CMAVM2; the mutant protein is not FT detected by Western blot; loss of localization to cell FT membrane; dbSNP:rs1562969219)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081708" FT VARIANT 678 FT /note="R -> H (in dbSNP:rs55692440)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042186" FT VARIANT 725 FT /note="A -> T (in CMAVM2; uncertain significance; FT dbSNP:rs1159930961)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081709" FT VARIANT 739..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081710" FT VARIANT 739 FT /note="R -> Q (in LMPHM7; loss of kinase activity; FT dbSNP:rs1057519263)" FT /evidence="ECO:0000269|PubMed:27400125" FT /id="VAR_078063" FT VARIANT 745 FT /note="N -> D (in CMAVM2; dbSNP:rs1584654433)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081711" FT VARIANT 782 FT /note="I -> S (in LMPHM7; loss of kinase activity; FT dbSNP:rs1057519264)" FT /evidence="ECO:0000269|PubMed:27400125" FT /id="VAR_078064" FT VARIANT 789 FT /note="P -> R (in CMAVM2; uncertain significance; FT dbSNP:rs753075600)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081712" FT VARIANT 789 FT /note="P -> S (in CMAVM2; uncertain significance; FT dbSNP:rs1417508111)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081713" FT VARIANT 802 FT /note="D -> G (in CMAVM2; dbSNP:rs776410552)" FT /evidence="ECO:0000269|PubMed:28730721" FT /id="VAR_081714" FT VARIANT 806..987 FT /note="Missing (in CMAVM2)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081715" FT VARIANT 807 FT /note="G -> R (in CMAVM2; uncertain significance; FT dbSNP:rs1330628156)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081716" FT VARIANT 820 FT /note="P -> L (in CMAVM2; uncertain significance; FT dbSNP:rs1584653650)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081717" FT VARIANT 820 FT /note="P -> T (in CMAVM2; uncertain significance; FT dbSNP:rs1584653653)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081718" FT VARIANT 838 FT /note="R -> W (in CMAVM2; the mutant protein is not FT detected by Western blot; loss of localization to cell FT membrane; dbSNP:rs764827256)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081719" FT VARIANT 845 FT /note="C -> R (in CMAVM2; the mutant protein is not FT detected by Western blot; loss of localization to cell FT membrane; dbSNP:rs1584653054)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081720" FT VARIANT 856 FT /note="C -> Y (in CMAVM2; dbSNP:rs1584653005)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081721" FT VARIANT 864 FT /note="R -> W (in CMAVM2; the mutant protein is not FT detected by Western blot; loss of localization to cell FT membrane; dbSNP:rs769965440)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081722" FT VARIANT 867 FT /note="F -> L (in CMAVM2; loss of tyrosine phosphorylation; FT loss of interaction with RASA1; dbSNP:rs1584652949)" FT /evidence="ECO:0000269|PubMed:30578106" FT /id="VAR_081723" FT VARIANT 870 FT /note="V -> E (in CMAVM2; uncertain significance; FT dbSNP:rs1584652920)" FT /evidence="ECO:0000269|PubMed:29444212" FT /id="VAR_081724" FT VARIANT 874 FT /note="L -> P (in CMAVM2; uncertain significance; FT dbSNP:rs1584652900)" FT /evidence="ECO:0000269|PubMed:28687708" FT /id="VAR_081725" FT VARIANT 882 FT /note="A -> T (in dbSNP:rs34918225)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042187" FT VARIANT 889 FT /note="R -> W (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs762016655)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042188" FT VARIANT 890 FT /note="E -> D (in dbSNP:rs35638378)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042189" FT MUTAGEN 95 FT /note="L->R: Reduces binding affinity for EFNB2." FT /evidence="ECO:0000269|PubMed:16867992" FT CONFLICT 62 FT /note="D -> E (in Ref. 1; AAA20598)" FT /evidence="ECO:0000305" FT CONFLICT 308 FT /note="Y -> D (in Ref. 1; AAA20598)" FT /evidence="ECO:0000305" FT CONFLICT 464 FT /note="V -> W (in Ref. 1; AAA20598)" FT /evidence="ECO:0000305" FT CONFLICT 926..927 FT /note="ES -> AR (in Ref. 1; AAA20598)" FT /evidence="ECO:0000305" FT STRAND 17..22 FT /evidence="ECO:0007829|PDB:2BBA" FT HELIX 23..25 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 33..36 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 43..48 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 54..61 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 63..65 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 70..74 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 84..95 FT /evidence="ECO:0007829|PDB:2BBA" FT HELIX 97..99 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 109..121 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 130..132 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 135..142 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 147..150 FT /evidence="ECO:0007829|PDB:2HLE" FT TURN 151..153 FT /evidence="ECO:0007829|PDB:2HLE" FT STRAND 154..156 FT /evidence="ECO:0007829|PDB:2HLE" FT STRAND 160..166 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 171..182 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 184..196 FT /evidence="ECO:0007829|PDB:2BBA" FT STRAND 441..446 FT /evidence="ECO:0007829|PDB:2E7H" FT STRAND 449..453 FT /evidence="ECO:0007829|PDB:2E7H" FT STRAND 460..462 FT /evidence="ECO:0007829|PDB:2E7H" FT STRAND 466..473 FT /evidence="ECO:0007829|PDB:2E7H" FT TURN 479..481 FT /evidence="ECO:0007829|PDB:2E7H" FT STRAND 482..496 FT /evidence="ECO:0007829|PDB:2E7H" FT STRAND 503..510 FT /evidence="ECO:0007829|PDB:2E7H" FT HELIX 612..614 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 615..623 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 625..634 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 637..639 FT /evidence="ECO:0007829|PDB:6FNJ" FT STRAND 642..649 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 655..668 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 679..683 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 685..694 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 701..707 FT /evidence="ECO:0007829|PDB:6FNK" FT TURN 708..710 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 714..733 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 743..745 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 746..748 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 754..756 FT /evidence="ECO:0007829|PDB:6FNK" FT STRAND 761..763 FT /evidence="ECO:0007829|PDB:6FNI" FT HELIX 765..767 FT /evidence="ECO:0007829|PDB:2VWX" FT HELIX 784..786 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 789..794 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 799..814 FT /evidence="ECO:0007829|PDB:6FNK" FT TURN 815..817 FT /evidence="ECO:0007829|PDB:6FNI" FT TURN 820..823 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 826..834 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 847..856 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 861..863 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 867..879 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 881..884 FT /evidence="ECO:0007829|PDB:6FNK" FT HELIX 912..918 FT /evidence="ECO:0007829|PDB:2QKQ" FT HELIX 922..924 FT /evidence="ECO:0007829|PDB:2QKQ" FT HELIX 925..930 FT /evidence="ECO:0007829|PDB:2QKQ" FT HELIX 936..939 FT /evidence="ECO:0007829|PDB:2QKQ" FT HELIX 944..950 FT /evidence="ECO:0007829|PDB:2QKQ" FT HELIX 955..965 FT /evidence="ECO:0007829|PDB:2QKQ" SQ SEQUENCE 987 AA; 108270 MW; 11A004622F194706 CRC64; MELRVLLCWA SLAAALEETL LNTKLETADL KWVTFPQVDG QWEELSGLDE EQHSVRTYEV CDVQRAPGQA HWLRTGWVPR RGAVHVYATL RFTMLECLSL PRAGRSCKET FTVFYYESDA DTATALTPAW MENPYIKVDT VAAEHLTRKR PGAEATGKVN VKTLRLGPLS KAGFYLAFQD QGACMALLSL HLFYKKCAQL TVNLTRFPET VPRELVVPVA GSCVVDAVPA PGPSPSLYCR EDGQWAEQPV TGCSCAPGFE AAEGNTKCRA CAQGTFKPLS GEGSCQPCPA NSHSNTIGSA VCQCRVGYFR ARTDPRGAPC TTPPSAPRSV VSRLNGSSLH LEWSAPLESG GREDLTYALR CRECRPGGSC APCGGDLTFD PGPRDLVEPW VVVRGLRPDF TYTFEVTALN GVSSLATGPV PFEPVNVTTD REVPPAVSDI RVTRSSPSSL SLAWAVPRAP SGAVLDYEVK YHEKGAEGPS SVRFLKTSEN RAELRGLKRG ASYLVQVRAR SEAGYGPFGQ EHHSQTQLDE SEGWREQLAL IAGTAVVGVV LVLVVIVVAV LCLRKQSNGR EAEYSDKHGQ YLIGHGTKVY IDPFTYEDPN EAVREFAKEI DVSYVKIEEV IGAGEFGEVC RGRLKAPGKK ESCVAIKTLK GGYTERQRRE FLSEASIMGQ FEHPNIIRLE GVVTNSMPVM ILTEFMENGA LDSFLRLNDG QFTVIQLVGM LRGIASGMRY LAEMSYVHRD LAARNILVNS NLVCKVSDFG LSRFLEENSS DPTYTSSLGG KIPIRWTAPE AIAFRKFTSA SDAWSYGIVM WEVMSFGERP YWDMSNQDVI NAIEQDYRLP PPPDCPTSLH QLMLDCWQKD RNARPRFPQV VSALDKMIRN PASLKIVARE NGGASHPLLD QRQPHYSAFG SVGEWLRAIK MGRYEESFAA AGFGSFELVS QISAEDLLRI GVTLAGHQKK ILASVQHMKS QAKPGTPGGT GGPAPQY // ID ERBB2_HUMAN Reviewed; 1255 AA. AC P04626; B2RZG3; B4DHN3; Q14256; Q6LDV1; Q9UMK4; X5D2V5; DT 13-AUG-1987, integrated into UniProtKB/Swiss-Prot. DT 13-AUG-1987, sequence version 1. DT 28-JAN-2026, entry version 281. DE RecName: Full=Receptor tyrosine-protein kinase erbB-2; DE EC=2.7.10.1; DE AltName: Full=Metastatic lymph node gene 19 protein; DE Short=MLN 19; DE AltName: Full=Proto-oncogene Neu; DE AltName: Full=Proto-oncogene c-ErbB-2; DE AltName: Full=Tyrosine kinase-type cell surface receptor HER2; DE AltName: Full=p185erbB2; DE AltName: CD_antigen=CD340; DE Flags: Precursor; GN Name=ERBB2; Synonyms=HER2, MLN19, NEU, NGL; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3003577; DOI=10.1038/319230a0; RA Yamamoto T., Ikawa S., Akiyama T., Semba K., Nomura N., Miyajima N., RA Saito T., Toyoshima K.; RT "Similarity of protein encoded by the human c-erb-B-2 gene to epidermal RT growth factor receptor."; RL Nature 319:230-234(1986). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT ALA-1170. RX PubMed=2999974; DOI=10.1126/science.2999974; RA Coussens L., Yang-Feng T.L., Liao Y.C., Chen E., Gray A., McGrath J., RA Seeburg P.H., Libermann T.A., Schlessinger J., Francke U., Levinson A., RA Ullrich A.; RT "Tyrosine kinase receptor with extensive homology to EGF receptor shares RT chromosomal location with neu oncogene."; RL Science 230:1132-1139(1985). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-452; VAL-655 AND RP ALA-1170. RG NIEHS SNPs program; RL Submitted (DEC-2002) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4). RC TISSUE=Brain; RA Wakamatsu A., Yamamoto J., Kimura K., Ishii S., Watanabe K., Sugiyama A., RA Murakawa K., Kaida T., Tsuchiya K., Fukuzumi Y., Kumagai A., Oishi Y., RA Yamamoto S., Ono Y., Komori Y., Yamazaki M., Kisu Y., Nishikawa T., RA Sugano S., Nomura N., Isogai T.; RT "NEDO human cDNA sequencing project focused on splicing variants."; RL Submitted (OCT-2007) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-191 (ISOFORM 1). RX PubMed=3039351; DOI=10.1128/mcb.7.7.2597-2601.1987; RA Tal M., King C.R., Kraus M.H., Ullrich A., Schlessinger J., Givol D.; RT "Human HER2 (neu) promoter: evidence for multiple mechanisms for RT transcriptional initiation."; RL Mol. Cell. Biol. 7:2597-2601(1987). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-867 (ISOFORM 6). RC TISSUE=Fetal brain; RX PubMed=24722188; DOI=10.1038/ncomms4650; RA Corominas R., Yang X., Lin G.N., Kang S., Shen Y., Ghamsari L., Broly M., RA Rodriguez M., Tam S., Wanamaker S.A., Fan C., Yi S., Tasan M., Lemmens I., RA Kuang X., Zhao N., Malhotra D., Michaelson J.J., Vacic V., Calderwood M.A., RA Roth F.P., Tavernier J., Horvath S., Salehi-Ashtiani K., Korkin D., RA Sebat J., Hill D.E., Hao T., Vidal M., Iakoucheva L.M.; RT "Protein interaction network of alternatively spliced isoforms from brain RT links genetic risk factors for autism."; RL Nat. Commun. 5:3650-3650(2014). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 737-1031. RX PubMed=2995967; DOI=10.1073/pnas.82.19.6497; RA Semba K., Kamata N., Toyoshima K., Yamamoto T.; RT "A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB- RT 1/epidermal growth factor-receptor gene and is amplified in a human RT salivary gland adenocarcinoma."; RL Proc. Natl. Acad. Sci. U.S.A. 82:6497-6501(1985). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 832-909. RC TISSUE=Mammary carcinoma; RX PubMed=2992089; DOI=10.1126/science.2992089; RA King C.R., Kraus M.H., Aaronson S.A.; RT "Amplification of a novel v-erbB-related gene in a human mammary RT carcinoma."; RL Science 229:974-976(1985). RN [11] RP NUCLEOTIDE SEQUENCE OF 1081-1245, AND VARIANT ALA-1170. RX PubMed=8104414; DOI=10.1089/dna.1993.12.611; RA Sarkar F.H., Ball D.E., Li Y.W., Crissman J.D.; RT "Molecular cloning and sequencing of an intron of Her-2/neu (ERBB2) gene."; RL DNA Cell Biol. 12:611-615(1993). RN [12] RP INTERACTION WITH ERBB4, AND FUNCTION IN ACTIVATION OF STAT5A. RX PubMed=10358079; DOI=10.1074/jbc.274.24.17209; RA Olayioye M.A., Beuvink I., Horsch K., Daly J.M., Hynes N.E.; RT "ErbB receptor-induced activation of stat transcription factors is mediated RT by Src tyrosine kinases."; RL J. Biol. Chem. 274:17209-17218(1999). RN [13] RP IDENTIFICATION IN A COMPLEX WITH PIK3C2A AND EGFR, IDENTIFICATION IN A RP COMPLEX WITH PIK3C2B AND EGFR, AND INTERACTION WITH PIK3C2B. RX PubMed=10805725; DOI=10.1128/mcb.20.11.3817-3830.2000; RA Arcaro A., Zvelebil M.J., Wallasch C., Ullrich A., Waterfield M.D., RA Domin J.; RT "Class II phosphoinositide 3-kinases are downstream targets of activated RT polypeptide growth factor receptors."; RL Mol. Cell. Biol. 20:3817-3830(2000). RN [14] RP INTERACTION WITH MUC1. RX PubMed=12939402; RA Li Y., Yu W.-H., Ren J., Chen W., Huang L., Kharbanda S., Loda M., Kufe D.; RT "Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent RT on the DF3/MUC1 oncoprotein."; RL Mol. Cancer Res. 1:765-775(2003). RN [15] RP FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=15380516; DOI=10.1016/j.ccr.2004.07.012; RA Wang S.C., Lien H.C., Xia W., Chen I.F., Lo H.W., Wang Z., Ali-Seyed M., RA Lee D.F., Bartholomeusz G., Ou-Yang F., Giri D.K., Hung M.C.; RT "Binding at and transactivation of the COX-2 promoter by nuclear tyrosine RT kinase receptor ErbB-2."; RL Cancer Cell 6:251-261(2004). RN [16] RP INTERACTION WITH PLXNB1. RX PubMed=15210733; DOI=10.1083/jcb.200312094; RA Swiercz J.M., Kuner R., Offermanns S.; RT "Plexin-B1/RhoGEF-mediated RhoA activation involves the receptor tyrosine RT kinase ErbB-2."; RL J. Cell Biol. 165:869-880(2004). RN [17] RP INTERACTION WITH MEMO1. RX PubMed=15156151; DOI=10.1038/ncb1134; RA Marone R., Hess D., Dankort D., Muller W.J., Hynes N.E., Badache A.; RT "Memo mediates ErbB2-driven cell motility."; RL Nat. Cell Biol. 6:515-522(2004). RN [18] RP SUBCELLULAR LOCATION, NUCLEAR LOCALIZATION SIGNAL, AND INTERACTION WITH RP KPNB1; RANBP2; CRM1; EEA1 AND CLTC. RX PubMed=16314522; DOI=10.1128/mcb.25.24.11005-11018.2005; RA Giri D.K., Ali-Seyed M., Li L.Y., Lee D.F., Ling P., Bartholomeusz G., RA Wang S.C., Hung M.C.; RT "Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell RT surface receptor."; RL Mol. Cell. Biol. 25:11005-11018(2005). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1248, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [20] RP FUNCTION, ALTERNATIVE INITIATION (ISOFORMS 2 AND 3), SUBCELLULAR LOCATION, RP AND MUTAGENESIS OF MET-611; MET-687; MET-706 AND MET-712. RX PubMed=16794579; DOI=10.1038/sj.emboj.7601191; RA Anido J., Scaltriti M., Bech Serra J.J., Santiago Josefat B., Todo F.R., RA Baselga J., Arribas J.; RT "Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative RT initiation of translation."; RL EMBO J. 25:3234-3244(2006). RN [21] RP INTERACTION WITH ERBB4, AND AUTOPHOSPHORYLATION IN TRANS. RX PubMed=16978839; DOI=10.1016/j.cellsig.2006.07.020; RA Li Z., Mei Y., Liu X., Zhou M.; RT "Neuregulin-1 only induces trans-phosphorylation between ErbB receptor RT heterodimer partners."; RL Cell. Signal. 19:466-471(2007). RN [22] RP PHOSPHORYLATION AT TYR-1248. RX PubMed=17554007; DOI=10.1523/jneurosci.5381-06.2007; RA Deng S., Hirschberg A., Worzfeld T., Penachioni J.Y., Korostylev A., RA Swiercz J.M., Vodrazka P., Mauti O., Stoeckli E.T., Tamagnone L., RA Offermanns S., Kuner R.; RT "Plexin-B2, but not Plexin-B1, critically modulates neuronal migration and RT patterning of the developing nervous system in vivo."; RL J. Neurosci. 27:6333-6347(2007). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [25] RP INTERACTION WITH PTK6, AND ACTIVITY REGULATION. RX PubMed=18719096; DOI=10.1073/pnas.0805009105; RA Xiang B., Chatti K., Qiu H., Lakshmi B., Krasnitz A., Hicks J., Yu M., RA Miller W.T., Muthuswamy S.K.; RT "Brk is coamplified with ErbB2 to promote proliferation in breast cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 105:12463-12468(2008). RN [26] RP FUNCTION IN NUCLEUS. RX PubMed=19372587; DOI=10.1158/1541-7786.mcr-08-0316; RA Hawthorne V.S., Huang W.C., Neal C.L., Tseng L.M., Hung M.C., Yu D.; RT "ErbB2-mediated Src and signal transducer and activator of transcription 3 RT activation leads to transcriptional up-regulation of p21Cip1 and RT chemoresistance in breast cancer cells."; RL Mol. Cancer Res. 7:592-600(2009). RN [27] RP INTERACTION WITH CPNE3. RX PubMed=20010870; DOI=10.1038/onc.2009.456; RA Heinrich C., Keller C., Boulay A., Vecchi M., Bianchi M., Sack R., RA Lienhard S., Duss S., Hofsteenge J., Hynes N.E.; RT "Copine-III interacts with ErbB2 and promotes tumor cell migration."; RL Oncogene 29:1598-1610(2010). RN [28] RP FUNCTION. RX PubMed=20937854; DOI=10.1073/pnas.1000975107; RA Zaoui K., Benseddik K., Daou P., Salaun D., Badache A.; RT "ErbB2 receptor controls microtubule capture by recruiting ACF7 to the RT plasma membrane of migrating cells."; RL Proc. Natl. Acad. Sci. U.S.A. 107:18517-18522(2010). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1107, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [30] RP CHROMOSOMAL REARRANGEMENT WITH CDK12. RX PubMed=21097718; DOI=10.1158/0008-5472.can-10-1749; RA Zang Z.J., Ong C.K., Cutcutache I., Yu W., Zhang S.L., Huang D., Ler L.D., RA Dykema K., Gan A., Tao J., Lim S., Liu Y., Futreal P.A., Grabsch H., RA Furge K.A., Goh L.K., Rozen S., Teh B.T., Tan P.; RT "Genetic and structural variation in the gastric cancer kinome revealed RT through targeted deep sequencing."; RL Cancer Res. 71:29-39(2011). RN [31] RP FUNCTION IN NUCLEUS, INTERACTION WITH ACTB AND RPA194, AND SUBCELLULAR RP LOCATION. RX PubMed=21555369; DOI=10.1158/0008-5472.can-10-3504; RA Li L.Y., Chen H., Hsieh Y.H., Wang Y.N., Chu H.J., Chen Y.H., Chen H.Y., RA Chien P.J., Ma H.T., Tsai H.C., Lai C.C., Sher Y.P., Lien H.C., Tsai C.H., RA Hung M.C.; RT "Nuclear ErbB2 enhances translation and cell growth by activating RT transcription of ribosomal RNA genes."; RL Cancer Res. 71:4269-4279(2011). RN [32] RP INTERACTION WITH EGFR. RX PubMed=21190959; DOI=10.1210/en.2010-0940; RA Kharmate G., Rajput P.S., Watt H.L., Somvanshi R.K., Chaudhari N., Qiu X., RA Kumar U.; RT "Dissociation of epidermal growth factor receptor and ErbB2 heterodimers in RT the presence of somatostatin receptor 5 modulate signaling pathways."; RL Endocrinology 152:931-945(2011). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [34] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-182; SER-1054; SER-1083 AND RP THR-1166, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054 AND SER-1151, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [36] RP INTERACTION WITH HSP90AA1 AND HSP90AB1. RX PubMed=26517842; DOI=10.1371/journal.pone.0141786; RA Prince T.L., Kijima T., Tatokoro M., Lee S., Tsutsumi S., Yim K., Rivas C., RA Alarcon S., Schwartz H., Khamit-Kush K., Scroggins B.T., Beebe K., RA Trepel J.B., Neckers L.; RT "Client proteins and small molecule inhibitors display distinct binding RT preferences for constitutive and stress-induced HSP90 isoforms and their RT conformationally restricted mutants."; RL PLoS ONE 10:E0141786-E0141786(2015). RN [37] RP PHOSPHORYLATION AT TYR-1112; TYR-1139; TYR-1196 AND TYR-1248, AND RP DEPHOSPHORYLATION BY PTPN12. RX PubMed=27134172; DOI=10.1016/j.celrep.2016.04.016; RA Li H., Yang F., Liu C., Xiao P., Xu Y., Liang Z., Liu C., Wang H., Wang W., RA Zheng W., Zhang W., Ma X., He D., Song X., Cui F., Xu Z., Yi F., Sun J.P., RA Yu X.; RT "Crystal structure and substrate specificity of PTPN12."; RL Cell Rep. 15:1345-1358(2016). RN [38] RP INTERACTION WITH SORL1, AND SUBCELLULAR LOCATION. RX PubMed=31138794; DOI=10.1038/s41467-019-10275-0; RA Pietilae M., Sahgal P., Peuhu E., Jaentti N.Z., Paatero I., Naervae E., RA Al-Akhrass H., Lilja J., Georgiadou M., Andersen O.M., Padzik A., Sihto H., RA Joensuu H., Blomqvist M., Saarinen I., Bostroem P.J., Taimen P., Ivaska J.; RT "SORLA regulates endosomal trafficking and oncogenic fitness of HER2."; RL Nat. Commun. 10:2340-2340(2019). RN [39] RP INTERACTION WITH SH3BGRL, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT RP TYR-877 AND TYR-1196. RX PubMed=32381043; DOI=10.1186/s13046-020-01577-z; RA Li H., Zhang M., Wei Y., Haider F., Lin Y., Guan W., Liu Y., Zhang S., RA Yuan R., Yang X., Yang S., Wang H.; RT "SH3BGRL confers innate drug resistance in breast cancer by stabilizing RT HER2 activation on cell membrane."; RL J. Exp. Clin. Cancer Res. 39:81-81(2020). RN [40] RP SUBCELLULAR LOCATION. RX PubMed=34380438; DOI=10.1186/s12860-021-00379-1; RA Di Pisa F., Pesenti E., Bono M., Mazzarello A.N., Bernardi C., RA Lisanti M.P., Renzone G., Scaloni A., Ciccone E., Fais F., Bruno S., RA Scartezzini P., Ghiotto F.; RT "SH3BGRL3 binds to myosin 1c in a calcium dependent manner and modulates RT migration in the MDA-MB-231 cell line."; RL BMC Mol. Cell Biol. 22:41-41(2021). RN [41] RP INTERACTION WITH ROR1. RX PubMed=36949068; DOI=10.1038/s41467-023-37306-1; RA Lin W., Niu R., Park S.M., Zou Y., Kim S.S., Xia X., Xing S., Yang Q., RA Sun X., Yuan Z., Zhou S., Zhang D., Kwon H.J., Park S., Il Kim C., Koo H., RA Liu Y., Wu H., Zheng M., Yoo H., Shi B., Park J.B., Yin J.; RT "IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2- RT CREB signaling axis."; RL Nat. Commun. 14:1578-1578(2023). RN [42] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 654-662 IN COMPLEX WITH HLA AND RP BETA-2 MICROGLOBULIN. RX PubMed=10593938; DOI=10.1074/jbc.274.51.36422; RA Kuhns J.J., Batalia M.A., Yan S., Collins E.J.; RT "Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of RT interactions with the center of the peptide."; RL J. Biol. Chem. 274:36422-36427(1999). RN [43] RP X-RAY CRYSTALLOGRAPHY (1.25 ANGSTROMS) OF 1247-1255 IN COMPLEX WITH ERBIN, RP AND INTERACTION WITH ERBIN. RX PubMed=12444095; DOI=10.1074/jbc.c200571200; RA Birrane G., Chung J., Ladias J.A.; RT "Novel mode of ligand recognition by the Erbin PDZ domain."; RL J. Biol. Chem. 278:1399-1402(2003). RN [44] RP STRUCTURE BY NMR OF 1135-1144 IN COMPLEX WITH GRB7, AND INTERACTION WITH RP GRB7. RX PubMed=12975581; DOI=10.1023/a:1025498409113; RA Ivancic M., Daly R.J., Lyons B.A.; RT "Solution structure of the human Grb7-SH2 domain/erbB2 peptide complex and RT structural basis for Grb7 binding to ErbB2."; RL J. Biomol. NMR 27:205-219(2003). RN [45] RP X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 23-629 IN COMPLEX WITH THE RP ANTIBODY HERCEPTIN. RX PubMed=12610629; DOI=10.1038/nature01392; RA Cho H.-S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., RA Denney D.W. Jr., Leahy D.J.; RT "Structure of the extracellular region of HER2 alone and in complex with RT the Herceptin Fab."; RL Nature 421:756-760(2003). RN [46] RP X-RAY CRYSTALLOGRAPHY (3.25 ANGSTROMS) OF 23-646 IN COMPLEX WITH THE RP ANTIBODY PERTUZUMAB, INTERACTION WITH ERBB3, MUTAGENESIS OF RP 317-LEU-HIS-318, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-187; ASN-259 AND RP ASN-530. RX PubMed=15093539; DOI=10.1016/s1535-6108(04)00083-2; RA Franklin M.C., Carey K.D., Vajdos F.F., Leahy D.J., de Vos A.M., RA Sliwkowski M.X.; RT "Insights into ErbB signaling from the structure of the ErbB2-pertuzumab RT complex."; RL Cancer Cell 5:317-328(2004). RN [47] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 23-646 IN COMPLEX WITH THE RP ANTIBODY HERCEPTIN, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-259 AND RP ASN-530. RX PubMed=19299620; DOI=10.1126/science.1165480; RA Bostrom J., Yu S.F., Kan D., Appleton B.A., Lee C.V., Billeci K., Man W., RA Peale F., Ross S., Wiesmann C., Fuh G.; RT "Variants of the antibody herceptin that interact with HER2 and VEGF at the RT antigen binding site."; RL Science 323:1610-1614(2009). RN [48] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 23-646 IN COMPLEX WITH ENGINEERED RP ANTIBODY ZHER2, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-68; ASN-259 AND RP ASN-571. RX PubMed=20696930; DOI=10.1073/pnas.1005025107; RA Eigenbrot C., Ultsch M., Dubnovitsky A., Abrahmsen L., Hard T.; RT "Structural basis for high-affinity HER2 receptor binding by an engineered RT protein."; RL Proc. Natl. Acad. Sci. U.S.A. 107:15039-15044(2010). RN [49] RP X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 703-1029 IN COMPLEX WITH RP INHIBITOR SYR127063, CATALYTIC ACTIVITY, SUBUNIT, AND ACTIVITY REGULATION. RX PubMed=21454582; DOI=10.1074/jbc.m110.206193; RA Aertgeerts K., Skene R., Yano J., Sang B.C., Zou H., Snell G., Jennings A., RA Iwamoto K., Habuka N., Hirokawa A., Ishikawa T., Tanaka T., Miki H., RA Ohta Y., Sogabe S.; RT "Structural analysis of the mechanism of inhibition and allosteric RT activation of the kinase domain of HER2 protein."; RL J. Biol. Chem. 286:18756-18765(2011). RN [50] RP VARIANTS VAL-654 AND VAL-655. RX PubMed=8095488; DOI=10.1006/geno.1993.1081; RA Ehsani A., Low J., Wallace R.B., Wu A.M.; RT "Characterization of a new allele of the human ERBB2 gene by allele- RT specific competition hybridization."; RL Genomics 15:426-429(1993). RN [51] RP INVOLVEMENT IN CANCER, VARIANT GASC SER-776, VARIANT OC SER-857, VARIANT RP GLM LYS-914, AND VARIANTS LNCR PRO-755; ALA-TYR-VAL-MET-774 INS AND RP VAL-GLY-SER-779 INS. RX PubMed=15457249; DOI=10.1038/431525b; RG Cancer genome project and collaborative group; RA Stephens P., Hunter C., Bignell G., Edkins S., Davies H., Teague J., RA Stevens C., O'Meara S., Smith R., Parker A., Barthorpe A., Blow M., RA Brackenbury L., Butler A., Clarke O., Cole J., Dicks E., Dike A., Drozd A., RA Edwards K., Forbes S., Foster R., Gray K., Greenman C., Halliday K., RA Hills K., Kosmidou V., Lugg R., Menzies A., Perry J., Petty R., Raine K., RA Ratford L., Shepherd R., Small A., Stephens Y., Tofts C., Varian J., RA West S., Widaa S., Yates A., Brasseur F., Cooper C.S., Flanagan A.M., RA Knowles M., Leung S.Y., Louis D.N., Looijenga L.H., Malkowicz B., RA Pierotti M.A., Teh B., Chenevix-Trench G., Weber B.L., Yuen S.T., RA Harris G., Goldstraw P., Nicholson A.G., Futreal P.A., Wooster R., RA Stratton M.R.; RT "Lung cancer: intragenic ERBB2 kinase mutations in tumours."; RL Nature 431:525-526(2004). RN [52] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-654; VAL-655; SER-768; ALA-1170 AND RP ASP-1216, VARIANT GASC SER-776, AND VARIANT OC SER-857. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [53] RP INVOLVEMENT IN VSCN2, VARIANT VSCN2 VAL-710, CHARACTERIZATION OF VARIANT RP VSCN2 VAL-710, SUBCELLULAR LOCATION, AND PHOSPHORYLATION. RX PubMed=33497358; DOI=10.1172/jci145837; RA Le T.L., Galmiche L., Levy J., Suwannarat P., Hellebrekers D.M., RA Morarach K., Boismoreau F., Theunissen T.E., Lefebvre M., Pelet A., RA Martinovic J., Gelot A., Guimiot F., Calleroz A., Gitiaux C., Hully M., RA Goulet O., Chardot C., Drunat S., Capri Y., Bole-Feysot C., Nitschke P., RA Whalen S., Mouthon L., Babcock H.E., Hofstra R., de Coo I.F., Tabet A.C., RA Molina T.J., Keren B., Brooks A., Smeets H.J., Marklund U., Gordon C.T., RA Lyonnet S., Amiel J., Bondurand N.; RT "Dysregulation of the NRG1/ERBB pathway causes a developmental disorder RT with gastrointestinal dysmotility in humans."; RL J. Clin. Invest. 131:0-0(2021). CC -!- FUNCTION: Protein tyrosine kinase that is part of several cell surface CC receptor complexes, but that apparently needs a coreceptor for ligand CC binding. Essential component of a neuregulin-receptor complex, although CC neuregulins do not interact with it alone. GP30 is a potential ligand CC for this receptor. Regulates outgrowth and stabilization of peripheral CC microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 CC signaling pathway elicits the phosphorylation and thus the inhibition CC of GSK3B at cell membrane. This prevents the phosphorylation of APC and CC CLASP2, allowing its association with the cell membrane. In turn, CC membrane-bound APC allows the localization of MACF1 to the cell CC membrane, which is required for microtubule capture and stabilization. CC {ECO:0000305}. CC -!- FUNCTION: In the nucleus is involved in transcriptional regulation. CC Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter CC and activates its transcription. Implicated in transcriptional CC activation of CDKN1A; the function involves STAT3 and SRC. Involved in CC the transcription of rRNA genes by RNA Pol I and enhances protein CC synthesis and cell growth. {ECO:0000269|PubMed:10358079, CC ECO:0000269|PubMed:15380516, ECO:0000269|PubMed:21555369}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:21454582}; CC -!- ACTIVITY REGULATION: Activated by dimerization. Not activated by EGF, CC TGF-alpha and amphiregulin. Interaction with PTK6 increases its CC intrinsic kinase activity. {ECO:0000269|PubMed:18719096, CC ECO:0000269|PubMed:21454582}. CC -!- SUBUNIT: Homodimer (PubMed:21454582). Heterodimer with EGFR, ERBB3 and CC ERBB4 (PubMed:10358079, PubMed:15093539, PubMed:16978839, CC PubMed:21190959). Part of a complex with EGFR and either PIK3C2A or CC PIK3C2B. May interact with PIK3C2B when phosphorylated on Tyr-1196 CC (PubMed:10805725). Interacts with PLXNB1 (PubMed:15210733). Interacts CC (when phosphorylated on Tyr-1248) with MEMO1 (PubMed:15156151). CC Interacts with MUC1; the interaction is enhanced by heregulin (HRG) CC (PubMed:12939402). Interacts (when phosphorylated on Tyr-1139) with CC GRB7 (via SH2 domain) (PubMed:12975581). Interacts (when phosphorylated CC on Tyr-1248) with ERBIN (PubMed:12444095). Interacts with KPNB1, CC RANBP2, EEA1, CRM1 and CLTC (PubMed:16314522). Interacts with PTK6 CC (PubMed:18719096). Interacts with RPA194 and ACTB (PubMed:21555369). CC Interacts with PRKCABP, SRC and MYOC (By similarity). Interacts CC (preferentially with the tyrosine phosphorylated form) with CPNE3; this CC interaction occurs at the cell membrane and is increased in a growth CC factor heregulin-dependent manner (PubMed:20010870). Interacts with CC HSP90AA1 and HSP90AB1 in an ATP-dependent manner; the interaction CC suppresses ERBB2 kinase activity (PubMed:26517842). Interacts with CC SORL1; this interaction regulates ERBB2 subcellular distribution by CC promoting its recycling after internalization from endosomes back to CC the plasma membrane, hence stimulates ERBB2-mediated signaling CC (PubMed:31138794). Interacts with SH3BGRL (PubMed:32381043). Interacts CC with ROR1 (PubMed:36949068). {ECO:0000250|UniProtKB:P70424, CC ECO:0000269|PubMed:10358079, ECO:0000269|PubMed:10805725, CC ECO:0000269|PubMed:12939402, ECO:0000269|PubMed:12975581, CC ECO:0000269|PubMed:15093539, ECO:0000269|PubMed:15156151, CC ECO:0000269|PubMed:15210733, ECO:0000269|PubMed:16314522, CC ECO:0000269|PubMed:16978839, ECO:0000269|PubMed:18719096, CC ECO:0000269|PubMed:20010870, ECO:0000269|PubMed:21190959, CC ECO:0000269|PubMed:21454582, ECO:0000269|PubMed:21555369, CC ECO:0000269|PubMed:26517842, ECO:0000269|PubMed:31138794, CC ECO:0000269|PubMed:32381043, ECO:0000269|PubMed:36949068}. CC -!- INTERACTION: CC P04626; P00519: ABL1; NbExp=2; IntAct=EBI-641062, EBI-375543; CC P04626; P42684: ABL2; NbExp=6; IntAct=EBI-641062, EBI-1102694; CC P04626; P15309: ACP3; NbExp=2; IntAct=EBI-641062, EBI-1222012; CC P04626; P60709: ACTB; NbExp=10; IntAct=EBI-641062, EBI-353944; CC P04626; Q92625: ANKS1A; NbExp=2; IntAct=EBI-641062, EBI-1048612; CC P04626; O00213: APBB1; NbExp=2; IntAct=EBI-641062, EBI-81694; CC P04626; O75815: BCAR3; NbExp=2; IntAct=EBI-641062, EBI-702336; CC P04626; Q9HB71: CACYBP; NbExp=2; IntAct=EBI-641062, EBI-1047302; CC P04626; Q16543: CDC37; NbExp=5; IntAct=EBI-641062, EBI-295634; CC P04626; Q9NSE2: CISH; NbExp=4; IntAct=EBI-641062, EBI-617866; CC P04626; Q7Z7G1: CLNK; NbExp=2; IntAct=EBI-641062, EBI-7878194; CC P04626; P46109: CRKL; NbExp=2; IntAct=EBI-641062, EBI-910; CC P04626; Q93034: CUL5; NbExp=2; IntAct=EBI-641062, EBI-1057139; CC P04626; Q99704: DOK1; NbExp=2; IntAct=EBI-641062, EBI-1384360; CC P04626; Q8TEW6: DOK4; NbExp=2; IntAct=EBI-641062, EBI-6918542; CC P04626; Q15075: EEA1; NbExp=5; IntAct=EBI-641062, EBI-298113; CC P04626; P98172: EFNB1; NbExp=12; IntAct=EBI-641062, EBI-538287; CC P04626; P00533: EGFR; NbExp=25; IntAct=EBI-641062, EBI-297353; CC P04626; P04626: ERBB2; NbExp=12; IntAct=EBI-641062, EBI-641062; CC P04626; P21860: ERBB3; NbExp=30; IntAct=EBI-641062, EBI-720706; CC P04626; Q15303: ERBB4; NbExp=5; IntAct=EBI-641062, EBI-80371; CC P04626; Q9UJM3: ERRFI1; NbExp=4; IntAct=EBI-641062, EBI-2941912; CC P04626; P09769: FGR; NbExp=3; IntAct=EBI-641062, EBI-1383732; CC P04626; P06241: FYN; NbExp=2; IntAct=EBI-641062, EBI-515315; CC P04626; O75791: GRAP2; NbExp=2; IntAct=EBI-641062, EBI-740418; CC P04626; P62993: GRB2; NbExp=8; IntAct=EBI-641062, EBI-401755; CC P04626; Q14451: GRB7; NbExp=5; IntAct=EBI-641062, EBI-970191; CC P04626; P07900: HSP90AA1; NbExp=6; IntAct=EBI-641062, EBI-296047; CC P04626; P08238: HSP90AB1; NbExp=5; IntAct=EBI-641062, EBI-352572; CC P04626; P14625: HSP90B1; NbExp=2; IntAct=EBI-641062, EBI-359129; CC P04626; P11021: HSPA5; NbExp=3; IntAct=EBI-641062, EBI-354921; CC P04626; P46940: IQGAP1; NbExp=5; IntAct=EBI-641062, EBI-297509; CC P04626; P35568: IRS1; NbExp=2; IntAct=EBI-641062, EBI-517592; CC P04626; Q08881: ITK; NbExp=2; IntAct=EBI-641062, EBI-968552; CC P04626; P23458: JAK1; NbExp=2; IntAct=EBI-641062, EBI-1383438; CC P04626; Q14974: KPNB1; NbExp=14; IntAct=EBI-641062, EBI-286758; CC P04626; Q96JA1: LRIG1; NbExp=7; IntAct=EBI-641062, EBI-2865191; CC P04626; O75367: MACROH2A1; NbExp=6; IntAct=EBI-641062, EBI-2868511; CC P04626; O75367-3: MACROH2A1; NbExp=3; IntAct=EBI-641062, EBI-6250866; CC P04626; Q9UQF2: MAPK8IP1; NbExp=4; IntAct=EBI-641062, EBI-78404; CC P04626; Q13387: MAPK8IP2; NbExp=3; IntAct=EBI-641062, EBI-722813; CC P04626; P42679: MATK; NbExp=2; IntAct=EBI-641062, EBI-751664; CC P04626; Q9Y316: MEMO1; NbExp=6; IntAct=EBI-641062, EBI-1104564; CC P04626; O43639: NCK2; NbExp=2; IntAct=EBI-641062, EBI-713635; CC P04626; Q02297-7: NRG1; NbExp=2; IntAct=EBI-641062, EBI-2460927; CC P04626; O00750: PIK3C2B; NbExp=2; IntAct=EBI-641062, EBI-641107; CC P04626; P27986: PIK3R1; NbExp=12; IntAct=EBI-641062, EBI-79464; CC P04626; O00459: PIK3R2; NbExp=8; IntAct=EBI-641062, EBI-346930; CC P04626; Q92569: PIK3R3; NbExp=10; IntAct=EBI-641062, EBI-79893; CC P04626; P19174: PLCG1; NbExp=5; IntAct=EBI-641062, EBI-79387; CC P04626; P16885: PLCG2; NbExp=3; IntAct=EBI-641062, EBI-617403; CC P04626; O95602: POLR1A; NbExp=16; IntAct=EBI-641062, EBI-359472; CC P04626; Q13882: PTK6; NbExp=4; IntAct=EBI-641062, EBI-1383632; CC P04626; Q06124: PTPN11; NbExp=4; IntAct=EBI-641062, EBI-297779; CC P04626; Q05209: PTPN12; NbExp=4; IntAct=EBI-641062, EBI-2266035; CC P04626; Q99952: PTPN18; NbExp=6; IntAct=EBI-641062, EBI-1384210; CC P04626; Q99952-1: PTPN18; NbExp=5; IntAct=EBI-641062, EBI-12739708; CC P04626; P23467: PTPRB; NbExp=2; IntAct=EBI-641062, EBI-1265766; CC P04626; P08575: PTPRC; NbExp=2; IntAct=EBI-641062, EBI-1341; CC P04626; Q12913: PTPRJ; NbExp=2; IntAct=EBI-641062, EBI-2264500; CC P04626; Q15262: PTPRK; NbExp=2; IntAct=EBI-641062, EBI-474052; CC P04626; Q16827: PTPRO; NbExp=2; IntAct=EBI-641062, EBI-723739; CC P04626; Q15256: PTPRR; NbExp=2; IntAct=EBI-641062, EBI-2265659; CC P04626; P49792: RANBP2; NbExp=3; IntAct=EBI-641062, EBI-973138; CC P04626; P20936: RASA1; NbExp=8; IntAct=EBI-641062, EBI-1026476; CC P04626; O95980: RECK; NbExp=4; IntAct=EBI-641062, EBI-2823742; CC P04626; Q9NP31: SH2D2A; NbExp=2; IntAct=EBI-641062, EBI-490630; CC P04626; P29353: SHC1; NbExp=16; IntAct=EBI-641062, EBI-78835; CC P04626; P98077: SHC2; NbExp=3; IntAct=EBI-641062, EBI-7256023; CC P04626; Q92529: SHC3; NbExp=2; IntAct=EBI-641062, EBI-79084; CC P04626; Q9H6Q3: SLA2; NbExp=2; IntAct=EBI-641062, EBI-1222854; CC P04626; O15524: SOCS1; NbExp=2; IntAct=EBI-641062, EBI-968198; CC P04626; O43791: SPOP; NbExp=6; IntAct=EBI-641062, EBI-743549; CC P04626; P12931: SRC; NbExp=11; IntAct=EBI-641062, EBI-621482; CC P04626; P42224: STAT1; NbExp=3; IntAct=EBI-641062, EBI-1057697; CC P04626; P40763: STAT3; NbExp=9; IntAct=EBI-641062, EBI-518675; CC P04626; P31948: STIP1; NbExp=2; IntAct=EBI-641062, EBI-1054052; CC P04626; Q7KZ85: SUPT6H; NbExp=2; IntAct=EBI-641062, EBI-2515547; CC P04626; P43405: SYK; NbExp=7; IntAct=EBI-641062, EBI-78302; CC P04626; Q9Y490: TLN1; NbExp=3; IntAct=EBI-641062, EBI-2462036; CC P04626; Q63HR2: TNS2; NbExp=4; IntAct=EBI-641062, EBI-949753; CC P04626; Q68CZ2: TNS3; NbExp=2; IntAct=EBI-641062, EBI-1220488; CC P04626; Q96D37: VAV1; NbExp=2; IntAct=EBI-641062, EBI-7875353; CC P04626; P52735: VAV2; NbExp=3; IntAct=EBI-641062, EBI-297549; CC P04626; O14980: XPO1; NbExp=3; IntAct=EBI-641062, EBI-355867; CC P04626; P62258: YWHAE; NbExp=2; IntAct=EBI-641062, EBI-356498; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:32381043}; CC Single-pass type I membrane protein {ECO:0000255}. Cell projection, CC ruffle membrane {ECO:0000269|PubMed:34380438}; Single-pass type I CC membrane protein {ECO:0000255}. Note=Internalized from the cell CC membrane in response to EGF stimulation. {ECO:0000269|PubMed:32381043}. CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane CC {ECO:0000269|PubMed:31138794, ECO:0000269|PubMed:33497358}; Single-pass CC type I membrane protein {ECO:0000255}. Early endosome CC {ECO:0000269|PubMed:31138794}. Cytoplasm, perinuclear region. Nucleus. CC Note=Translocation to the nucleus requires endocytosis, probably CC endosomal sorting and is mediated by importin beta-1/KPNB1. Also CC detected in VPS35-positive endosome-to-TGN retrograde vesicles CC (PubMed:31138794). {ECO:0000269|PubMed:31138794}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm. Nucleus. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Cytoplasm. Nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing, Alternative initiation; Named isoforms=6; CC Name=1; Synonyms=ERBB2, HER2; CC IsoId=P04626-1; Sequence=Displayed; CC Name=2; Synonyms=CTF-611; CC IsoId=P04626-2; Sequence=VSP_039249; CC Name=3; Synonyms=CTF-687; CC IsoId=P04626-3; Sequence=VSP_039250; CC Name=4; CC IsoId=P04626-4; Sequence=VSP_039248; CC Name=5; CC IsoId=P04626-5; Sequence=VSP_054787; CC Name=6; Synonyms=B; CC IsoId=P04626-6; Sequence=VSP_055902, VSP_055903, VSP_055904; CC -!- TISSUE SPECIFICITY: Expressed in a variety of tumor tissues including CC primary breast tumors and tumors from small bowel, esophagus, kidney CC and mouth. {ECO:0000269|PubMed:15380516}. CC -!- PTM: Autophosphorylated. Autophosphorylation occurs in trans, i.e. one CC subunit of the dimeric receptor phosphorylates tyrosine residues on the CC other subunit (Probable). Ligand-binding increases phosphorylation on CC tyrosine residues (PubMed:27134172, PubMed:33497358). Signaling via CC SEMA4C promotes phosphorylation at Tyr-1248 (PubMed:17554007). CC Dephosphorylated by PTPN12 (PubMed:27134172). CC {ECO:0000269|PubMed:17554007, ECO:0000269|PubMed:27134172, CC ECO:0000269|PubMed:33497358, ECO:0000305}. CC -!- POLYMORPHISM: There are four alleles due to the variations in positions CC 654 and 655. Allele B1 (Ile-654/Ile-655) has a frequency of 0.782; CC allele B2 (Ile-654/Val-655) has a frequency of 0.206; allele B3 (Val- CC 654/Val-655) has a frequency of 0.012. CC -!- DISEASE: Glioma (GLM) [MIM:137800]: Gliomas are benign or malignant CC central nervous system neoplasms derived from glial cells. They CC comprise astrocytomas and glioblastoma multiforme that are derived from CC astrocytes, oligodendrogliomas derived from oligodendrocytes and CC ependymomas derived from ependymocytes. {ECO:0000269|PubMed:15457249}. CC Note=The gene represented in this entry is involved in disease CC pathogenesis. CC -!- DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer CC defines malignancies originating from ovarian tissue. Although many CC histologic types of ovarian tumors have been described, epithelial CC ovarian carcinoma is the most common form. Ovarian cancers are often CC asymptomatic and the recognized signs and symptoms, even of late-stage CC disease, are vague. Consequently, most patients are diagnosed with CC advanced disease. {ECO:0000269|PubMed:15457249, CC ECO:0000269|PubMed:17344846}. Note=The gene represented in this entry CC is involved in disease pathogenesis. CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting CC tissues of the lung. The most common form of lung cancer is non-small CC cell lung cancer (NSCLC) that can be divided into 3 major histologic CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor CC prognosis. {ECO:0000269|PubMed:15457249}. Note=The gene represented in CC this entry is involved in disease pathogenesis. CC -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which CC starts in the stomach, can spread to the esophagus or the small CC intestine, and can extend through the stomach wall to nearby lymph CC nodes and organs. It also can metastasize to other parts of the body. CC The term gastric cancer or gastric carcinoma refers to adenocarcinoma CC of the stomach that accounts for most of all gastric malignant tumors. CC Two main histologic types are recognized, diffuse type and intestinal CC type carcinomas. Diffuse tumors are poorly differentiated infiltrating CC lesions, resulting in thickening of the stomach. In contrast, CC intestinal tumors are usually exophytic, often ulcerating, and CC associated with intestinal metaplasia of the stomach, most often CC observed in sporadic disease. {ECO:0000269|PubMed:15457249, CC ECO:0000269|PubMed:17344846}. Note=The protein represented in this CC entry is involved in disease pathogenesis. CC -!- DISEASE: Note=Chromosomal aberrations involving ERBB2 may be a cause CC gastric cancer. Deletions within 17q12 region producing fusion CC transcripts with CDK12, leading to CDK12-ERBB2 fusion leading to CC truncated CDK12 protein not in-frame with ERBB2. CC {ECO:0000269|PubMed:21097718}. CC -!- DISEASE: Visceral neuropathy, familial, 2, autosomal recessive (VSCN2) CC [MIM:619465]: An autosomal recessive disorder characterized by CC intestinal dysmotility due to aganglionosis (Hirschsprung disease), CC hypoganglionosis, and/or chronic intestinal pseudoobstruction. Patients CC also show peripheral axonal neuropathy, hypotonia, mild developmental CC delay, unilateral ptosis, and sensorineural hearing loss. CC {ECO:0000269|PubMed:33497358}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform 2]: Produced by alternative initiation at Met- CC 611 of isoform 1. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative initiation at Met- CC 687 of isoform 1. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 4]: Produced by alternative splicing of isoform CC 1. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/162/ERBB2"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=ERBB2 entry; CC URL="https://en.wikipedia.org/wiki/ERBB2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AH001455; AAA35808.1; -; Genomic_DNA. DR EMBL; X03363; CAA27060.1; -; mRNA. DR EMBL; M11730; AAA75493.1; -; mRNA. DR EMBL; M12036; AAA35978.1; -; Genomic_DNA. DR EMBL; AY208911; AAO18082.1; -; Genomic_DNA. DR EMBL; AK295195; BAG58195.1; -; mRNA. DR EMBL; CH471152; EAW60597.1; -; Genomic_DNA. DR EMBL; BC167147; AAI67147.1; -; mRNA. DR EMBL; M16792; AAA58637.1; -; Genomic_DNA. DR EMBL; M16789; AAA58637.1; JOINED; Genomic_DNA. DR EMBL; M16790; AAA58637.1; JOINED; Genomic_DNA. DR EMBL; M16791; AAA58637.1; JOINED; Genomic_DNA. DR EMBL; KJ534964; AHW56604.1; -; mRNA. DR EMBL; L29395; AAA35809.1; -; Genomic_DNA. DR EMBL; M95667; AAC37531.1; -; Genomic_DNA. DR CCDS; CCDS32642.1; -. [P04626-1] DR CCDS; CCDS45667.1; -. [P04626-5] DR CCDS; CCDS74052.1; -. [P04626-4] DR PIR; A24571; A24571. DR RefSeq; NP_001005862.1; NM_001005862.3. [P04626-5] DR RefSeq; NP_001276865.1; NM_001289936.2. [P04626-4] DR RefSeq; NP_001276867.1; NM_001289938.1. DR RefSeq; NP_001369711.1; NM_001382782.1. [P04626-5] DR RefSeq; NP_001369712.1; NM_001382783.1. [P04626-5] DR RefSeq; NP_004439.2; NM_004448.4. [P04626-1] DR RefSeq; XP_047291546.1; XM_047435590.1. [P04626-4] DR PDB; 1MFG; X-ray; 1.25 A; B=1247-1255. DR PDB; 1MFL; X-ray; 1.88 A; B=1247-1255. DR PDB; 1MW4; NMR; -; B=1135-1144. DR PDB; 1N8Z; X-ray; 2.52 A; C=23-629. DR PDB; 1QR1; X-ray; 2.40 A; C/F=654-662. DR PDB; 1S78; X-ray; 3.25 A; A/B=23-646. DR PDB; 2A91; X-ray; 2.50 A; A=22-530. DR PDB; 2JWA; NMR; -; A/B=641-684. DR PDB; 2KS1; NMR; -; A=641-684. DR PDB; 2L4K; NMR; -; B=1135-1144. DR PDB; 2N2A; NMR; -; A/B=644-700. DR PDB; 3BE1; X-ray; 2.90 A; A=23-646. DR PDB; 3H3B; X-ray; 2.45 A; A/B=23-214. DR PDB; 3MZW; X-ray; 2.90 A; A=23-646. DR PDB; 3N85; X-ray; 3.20 A; A=23-646. DR PDB; 3PP0; X-ray; 2.25 A; A/B=703-1029. DR PDB; 3RCD; X-ray; 3.21 A; A/B/C/D=713-1028. DR PDB; 3WLW; X-ray; 3.09 A; A/B=23-586. DR PDB; 3WSQ; X-ray; 3.50 A; A=23-586. DR PDB; 4GFU; X-ray; 2.00 A; F=1246-1252. DR PDB; 4HRL; X-ray; 2.55 A; C=24-219. DR PDB; 4HRM; X-ray; 3.20 A; A/C=24-219. DR PDB; 4HRN; X-ray; 2.65 A; C/D=529-625. DR PDB; 4NND; X-ray; 2.50 A; C/E/F/H=1109-1114. DR PDB; 5K33; X-ray; 3.30 A; C=23-629. DR PDB; 5KWG; X-ray; 4.30 A; C=23-653. DR PDB; 5MY6; X-ray; 2.25 A; A=24-645. DR PDB; 5O4G; X-ray; 3.00 A; C=23-628. DR PDB; 5OB4; NMR; -; A/B=641-684. DR PDB; 5TQS; X-ray; 1.88 A; E/F/G/H=1218-1228. DR PDB; 6ATT; X-ray; 3.77 A; A=23-652. DR PDB; 6BGT; X-ray; 2.70 A; C=1-652. DR PDB; 6J71; X-ray; 2.92 A; A=22-639. DR PDB; 6LBX; X-ray; 2.03 A; B=531-626. DR PDB; 6OGE; EM; 4.36 A; A=23-644. DR PDB; 7JXH; X-ray; 3.27 A; A/B/C/D/E/F/G/H=703-1024. DR PDB; 7MN5; EM; 2.93 A; B=1-1029. DR PDB; 7MN6; EM; 3.09 A; B=1-1029. DR PDB; 7MN8; EM; 3.45 A; B=1-1029. DR PDB; 7PCD; X-ray; 1.77 A; A=703-1029. DR PDB; 7QVK; X-ray; 3.10 A; AAA=23-646. DR PDB; 8FFJ; EM; 7.50 A; X=23-644. DR PDB; 8HGO; EM; 3.31 A; B=1-693. DR PDB; 8HGP; EM; 4.53 A; B=1-693. DR PDB; 8JYQ; X-ray; 1.75 A; C/F=611-618. DR PDB; 8JYR; X-ray; 1.69 A; A=23-216. DR PDB; 8PWH; EM; 3.17 A; E=23-646. DR PDB; 8Q6J; EM; 3.30 A; E=23-646. DR PDB; 8U4K; EM; 4.27 A; B=24-629. DR PDB; 8U4L; EM; 3.31 A; B=24-629. DR PDB; 8U8X; X-ray; 1.69 A; A=694-1029. DR PDB; 8VB5; X-ray; 1.48 A; A=703-1029. DR PDB; 8VQD; EM; 2.61 A; A=23-652. DR PDB; 8VQE; EM; 2.67 A; A/B=23-652. DR PDB; 9IUT; X-ray; 2.09 A; C/F=611-618. DR PDB; 9L1S; EM; 3.00 A; A=23-652. DR PDBsum; 1MFG; -. DR PDBsum; 1MFL; -. DR PDBsum; 1MW4; -. DR PDBsum; 1N8Z; -. DR PDBsum; 1QR1; -. DR PDBsum; 1S78; -. DR PDBsum; 2A91; -. DR PDBsum; 2JWA; -. DR PDBsum; 2KS1; -. DR PDBsum; 2L4K; -. DR PDBsum; 2N2A; -. DR PDBsum; 3BE1; -. DR PDBsum; 3H3B; -. DR PDBsum; 3MZW; -. DR PDBsum; 3N85; -. DR PDBsum; 3PP0; -. DR PDBsum; 3RCD; -. DR PDBsum; 3WLW; -. DR PDBsum; 3WSQ; -. DR PDBsum; 4GFU; -. DR PDBsum; 4HRL; -. DR PDBsum; 4HRM; -. DR PDBsum; 4HRN; -. DR PDBsum; 4NND; -. DR PDBsum; 5K33; -. DR PDBsum; 5KWG; -. DR PDBsum; 5MY6; -. DR PDBsum; 5O4G; -. DR PDBsum; 5OB4; -. DR PDBsum; 5TQS; -. DR PDBsum; 6ATT; -. DR PDBsum; 6BGT; -. DR PDBsum; 6J71; -. DR PDBsum; 6LBX; -. DR PDBsum; 6OGE; -. DR PDBsum; 7JXH; -. DR PDBsum; 7MN5; -. DR PDBsum; 7MN6; -. DR PDBsum; 7MN8; -. DR PDBsum; 7PCD; -. DR PDBsum; 7QVK; -. DR PDBsum; 8FFJ; -. DR PDBsum; 8HGO; -. DR PDBsum; 8HGP; -. DR PDBsum; 8JYQ; -. DR PDBsum; 8JYR; -. DR PDBsum; 8PWH; -. DR PDBsum; 8Q6J; -. DR PDBsum; 8U4K; -. DR PDBsum; 8U4L; -. DR PDBsum; 8U8X; -. DR PDBsum; 8VB5; -. DR PDBsum; 8VQD; -. DR PDBsum; 8VQE; -. DR PDBsum; 9IUT; -. DR PDBsum; 9L1S; -. DR AlphaFoldDB; P04626; -. DR BMRB; P04626; -. DR EMDB; EMD-17993; -. DR EMDB; EMD-18188; -. DR EMDB; EMD-18189; -. DR EMDB; EMD-18190; -. DR EMDB; EMD-20055; -. DR EMDB; EMD-29044; -. DR EMDB; EMD-34744; -. DR EMDB; EMD-34745; -. DR EMDB; EMD-41885; -. DR EMDB; EMD-41886; -. DR EMDB; EMD-43439; -. DR EMDB; EMD-43440; -. DR EMDB; EMD-62753; -. DR SMR; P04626; -. DR BioGRID; 108376; 731. DR CORUM; P04626; -. DR DIP; DIP-8N; -. DR ELM; P04626; -. DR FunCoup; P04626; 2287. DR IntAct; P04626; 558. DR MINT; P04626; -. DR STRING; 9606.ENSP00000269571; -. DR BindingDB; P04626; -. DR ChEMBL; CHEMBL1824; -. DR DrugBank; DB08916; Afatinib. DR DrugBank; DB06021; AV-412. DR DrugBank; DB12318; BMS-599626. DR DrugBank; DB11665; BMS-690514. DR DrugBank; DB12267; Brigatinib. DR DrugBank; DB05424; Canertinib. DR DrugBank; DB12302; CP-724714. DR DrugBank; DB12174; CUDC-101. DR DrugBank; DB11963; Dacomitinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB04988; IGN311. DR DrugBank; DB01259; Lapatinib. DR DrugBank; DB14967; Margetuximab. DR DrugBank; DB00179; Masoprocol. DR DrugBank; DB04862; Merimepodib. DR DrugBank; DB12682; Mubritinib. DR DrugBank; DB06226; Nelipepimut-S. DR DrugBank; DB11828; Neratinib. DR DrugBank; DB07662; PD-168393. DR DrugBank; DB06366; Pertuzumab. DR DrugBank; DB12114; Poziotinib. DR DrugBank; DB12183; Sapitinib. DR DrugBank; DB14944; Tarloxotinib. DR DrugBank; DB11973; Tesevatinib. DR DrugBank; DB00072; Trastuzumab. DR DrugBank; DB05773; Trastuzumab emtansine. DR DrugBank; DB11652; Tucatinib. DR DrugBank; DB05944; Varlitinib. DR DrugBank; DB15471; Zanidatamab. DR DrugBank; DB15035; Zanubrutinib. DR DrugCentral; P04626; -. DR GuidetoPHARMACOLOGY; 2019; -. DR MoonDB; P04626; Predicted. DR TCDB; 8.A.23.1.39; the basigin (basigin) family. DR CarbonylDB; P04626; -. DR GlyConnect; 1710; 13 N-Linked glycans (5 sites), 1 O-Linked glycan (1 site). DR GlyCosmos; P04626; 9 sites, 13 glycans. DR GlyGen; P04626; 10 sites, 27 N-linked glycans (7 sites), 2 O-linked glycans (2 sites). DR iPTMnet; P04626; -. DR PhosphoSitePlus; P04626; -. DR SwissPalm; P04626; -. DR BioMuta; ERBB2; -. DR DMDM; 119533; -. DR CPTAC; CPTAC-192; -. DR CPTAC; CPTAC-193; -. DR CPTAC; CPTAC-194; -. DR CPTAC; CPTAC-195; -. DR CPTAC; CPTAC-3045; -. DR CPTAC; CPTAC-3046; -. DR CPTAC; CPTAC-5777; -. DR CPTAC; CPTAC-5827; -. DR CPTAC; CPTAC-5839; -. DR CPTAC; CPTAC-5864; -. DR CPTAC; CPTAC-693; -. DR CPTAC; non-CPTAC-5384; -. DR CPTAC; non-CPTAC-5385; -. DR CPTAC; non-CPTAC-5386; -. DR CPTAC; non-CPTAC-5547; -. DR CPTAC; non-CPTAC-5732; -. DR CPTAC; non-CPTAC-5733; -. DR jPOST; P04626; -. DR MassIVE; P04626; -. DR PaxDb; 9606-ENSP00000269571; -. DR PeptideAtlas; P04626; -. DR ProteomicsDB; 51718; -. [P04626-1] DR ProteomicsDB; 51719; -. [P04626-2] DR ProteomicsDB; 51720; -. [P04626-3] DR ProteomicsDB; 51721; -. [P04626-4] DR Pumba; P04626; -. DR ABCD; P04626; 341 sequenced antibodies. DR Antibodypedia; 740; 6685 antibodies from 63 providers. DR CPTC; P04626; 4 antibodies. DR DNASU; 2064; -. DR Ensembl; ENST00000269571.10; ENSP00000269571.4; ENSG00000141736.15. [P04626-1] DR Ensembl; ENST00000584601.5; ENSP00000462438.1; ENSG00000141736.15. [P04626-5] DR GeneID; 2064; -. DR KEGG; hsa:2064; -. DR MANE-Select; ENST00000269571.10; ENSP00000269571.4; NM_004448.4; NP_004439.2. DR UCSC; uc060esv.1; human. [P04626-1] DR AGR; HGNC:3430; -. DR CIViC; 2064; 2 clinical assertions and 302 evidence items across 174 molecular profiles. DR ClinPGx; PA27844; -. DR CTD; 2064; -. DR DisGeNET; 2064; -. DR GeneCards; ERBB2; -. DR HGNC; HGNC:3430; ERBB2. DR HPA; ENSG00000141736; Low tissue specificity. DR MalaCards; ERBB2; -. DR MIM; 137800; phenotype. DR MIM; 164870; gene. DR MIM; 167000; phenotype. DR MIM; 211980; phenotype. DR MIM; 613659; phenotype. DR MIM; 619465; phenotype. DR OpenTargets; ENSG00000141736; -. DR Orphanet; 99976; Adenocarcinoma of the oesophagus and oesophagogastric junction. DR Orphanet; 2800; Extramammary Paget disease. DR Orphanet; 388; Hirschsprung disease. DR Orphanet; 213726; Serous carcinoma of the corpus uteri. DR VEuPathDB; HostDB:ENSG00000141736; -. DR eggNOG; KOG1025; Eukaryota. DR GeneTree; ENSGT00940000158232; -. DR InParanoid; P04626; -. DR OMA; DRHCLPC; -. DR OrthoDB; 6219513at2759; -. DR PAN-GO; P04626; 10 GO annotations based on evolutionary models. DR PhylomeDB; P04626; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P04626; -. DR Reactome; R-HSA-1227986; Signaling by ERBB2. DR Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. DR Reactome; R-HSA-1251932; PLCG1 events in ERBB2 signaling. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1306955; GRB7 events in ERBB2 signaling. DR Reactome; R-HSA-1358803; Downregulation of ERBB2:ERBB3 signaling. DR Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling. DR Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-416572; Sema4D induced cell migration and growth-cone collapse. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6785631; ERBB2 Regulates Cell Motility. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling. DR Reactome; R-HSA-8863795; Downregulation of ERBB2 signaling. DR Reactome; R-HSA-8866910; TFAP2 (AP-2) family regulates transcription of growth factors and their receptors. DR Reactome; R-HSA-9634285; Constitutive Signaling by Overexpressed ERBB2. DR Reactome; R-HSA-9652282; Drug-mediated inhibition of ERBB2 signaling. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665233; Resistance of ERBB2 KD mutants to trastuzumab. DR Reactome; R-HSA-9665244; Resistance of ERBB2 KD mutants to sapitinib. DR Reactome; R-HSA-9665245; Resistance of ERBB2 KD mutants to tesevatinib. DR Reactome; R-HSA-9665246; Resistance of ERBB2 KD mutants to neratinib. DR Reactome; R-HSA-9665247; Resistance of ERBB2 KD mutants to osimertinib. DR Reactome; R-HSA-9665249; Resistance of ERBB2 KD mutants to afatinib. DR Reactome; R-HSA-9665250; Resistance of ERBB2 KD mutants to AEE788. DR Reactome; R-HSA-9665251; Resistance of ERBB2 KD mutants to lapatinib. DR Reactome; R-HSA-9665348; Signaling by ERBB2 ECD mutants. DR Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants. DR Reactome; R-HSA-9665737; Drug resistance in ERBB2 TMD/JMD mutants. DR Reactome; R-HSA-9927432; Developmental Lineage of Mammary Gland Myoepithelial Cells. DR Reactome; R-HSA-9938206; Developmental Lineage of Mammary Stem Cells. DR SignaLink; P04626; -. DR SIGNOR; P04626; -. DR Agora; ENSG00000141736; -. DR BioGRID-ORCS; 2064; 92 hits in 1209 CRISPR screens. DR ChiTaRS; ERBB2; human. DR EvolutionaryTrace; P04626; -. DR GeneWiki; HER2/neu; -. DR GenomeRNAi; 2064; -. DR Pharos; P04626; Tclin. DR PRO; PR:P04626; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P04626; protein. DR Bgee; ENSG00000141736; Expressed in lower esophagus mucosa and 186 other cell types or tissues. DR ExpressionAtlas; P04626; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl. DR GO; GO:0009925; C:basal plasma membrane; IBA:GO_Central. DR GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005769; C:early endosome; IEA:UniProtKB-SubCell. DR GO; GO:0010008; C:endosome membrane; IDA:UniProtKB. DR GO; GO:0038143; C:ERBB3:ERBB2 complex; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; NAS:UniProtKB. DR GO; GO:0043209; C:myelin sheath; IEA:Ensembl. DR GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0042734; C:presynaptic membrane; IEA:Ensembl. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0032587; C:ruffle membrane; IEA:UniProtKB-SubCell. DR GO; GO:0002116; C:semaphorin receptor complex; ISS:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0015026; F:coreceptor activity; ISS:BHF-UCL. DR GO; GO:0043125; F:ErbB-3 class receptor binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:UniProtKB. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:BHF-UCL. DR GO; GO:0001042; F:RNA polymerase I core binding; IDA:UniProtKB. DR GO; GO:0005102; F:signaling receptor binding; IPI:BHF-UCL. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:BHF-UCL. DR GO; GO:0004888; F:transmembrane signaling receptor activity; IDA:BHF-UCL. DR GO; GO:0008283; P:cell population proliferation; IDA:UniProt. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IDA:BHF-UCL. DR GO; GO:0007166; P:cell surface receptor signaling pathway; IDA:MGI. DR GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IMP:UniProtKB. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IDA:UniProtKB. DR GO; GO:0007167; P:enzyme-linked receptor protein signaling pathway; TAS:ProtInc. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IBA:GO_Central. DR GO; GO:0038134; P:ERBB2-EGFR signaling pathway; IDA:MGI. DR GO; GO:0038133; P:ERBB2-ERBB3 signaling pathway; IEA:Ensembl. DR GO; GO:0038135; P:ERBB2-ERBB4 signaling pathway; IEA:Ensembl. DR GO; GO:0007507; P:heart development; IEA:Ensembl. DR GO; GO:0033080; P:immature T cell proliferation in thymus; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0008045; P:motor neuron axon guidance; IEA:Ensembl. DR GO; GO:0042552; P:myelination; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IBA:GO_Central. DR GO; GO:0033088; P:negative regulation of immature T cell proliferation in thymus; IEA:Ensembl. DR GO; GO:0007528; P:neuromuscular junction development; IEA:Ensembl. DR GO; GO:0030182; P:neuron differentiation; IBA:GO_Central. DR GO; GO:0099645; P:neurotransmitter receptor localization to postsynaptic specialization membrane; IEA:Ensembl. DR GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:BHF-UCL. DR GO; GO:0045785; P:positive regulation of cell adhesion; IDA:BHF-UCL. DR GO; GO:0030307; P:positive regulation of cell growth; IMP:UniProtKB. DR GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IDA:UniProtKB. DR GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IBA:GO_Central. DR GO; GO:0090314; P:positive regulation of protein targeting to membrane; IDA:UniProtKB. DR GO; GO:0035025; P:positive regulation of Rho protein signal transduction; ISS:BHF-UCL. DR GO; GO:0045943; P:positive regulation of transcription by RNA polymerase I; IMP:UniProtKB. DR GO; GO:0045727; P:positive regulation of translation; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0045765; P:regulation of angiogenesis; NAS:UniProtKB. DR GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:0032886; P:regulation of microtubule-based process; IDA:UniProtKB. DR GO; GO:0014044; P:Schwann cell development; IEA:Ensembl. DR GO; GO:0071526; P:semaphorin-plexin signaling pathway; ISS:BHF-UCL. DR GO; GO:0007165; P:signal transduction; IDA:UniProtKB. DR GO; GO:0042060; P:wound healing; IDA:BHF-UCL. DR CDD; cd00064; FU; 3. DR CDD; cd05109; PTKc_HER2; 1. DR CDD; cd12094; TM_ErbB2; 1. DR DisProt; DP01484; -. DR FunFam; 1.20.5.100:FF:000007; Receptor protein-tyrosine kinase; 1. DR FunFam; 2.10.220.10:FF:000009; Receptor protein-tyrosine kinase; 1. DR FunFam; 2.10.220.10:FF:000010; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.30.200.20:FF:000184; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000007; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000008; Receptor protein-tyrosine kinase; 1. DR FunFam; 4.10.1140.10:FF:000001; Receptor protein-tyrosine kinase; 1. DR FunFam; 1.10.510.10:FF:002828; Receptor tyrosine-protein kinase erbB-2; 1. DR Gene3D; 1.20.5.100; Cytochrome c1, transmembrane anchor, C-terminal; 1. DR Gene3D; 2.10.220.10; Hormone Receptor, Insulin-like Growth Factor Receptor 1, Chain A, domain 2; 3. DR Gene3D; 4.10.1140.10; membrane-bound form of the juxtamembrane domain of the epidermal growth factor receptor like domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.20.20; Receptor L-domain; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00293; -. DR InterPro; IPR006211; Furin-like_Cys-rich_dom. DR InterPro; IPR006212; Furin_repeat. DR InterPro; IPR032778; GF_recep_IV. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR000494; Rcpt_L-dom. DR InterPro; IPR036941; Rcpt_L-dom_sf. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR049328; TM_ErbB1. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt. DR PANTHER; PTHR24416:SF137; RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00757; Furin-like; 1. DR Pfam; PF14843; GF_recep_IV; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF01030; Recep_L_domain; 2. DR Pfam; PF21314; TM_ErbB1; 1. DR PIRSF; PIRSF000619; TyrPK_EGF-R; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00261; FU; 3. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 2. DR SUPFAM; SSF52058; L domain-like; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative initiation; Alternative splicing; KW ATP-binding; Cell membrane; Cell projection; Chromosomal rearrangement; KW Cytoplasm; Disease variant; Disulfide bond; Endosome; Glycoprotein; Kinase; KW Membrane; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Receptor; Reference proteome; Signal; KW Transcription; Transcription regulation; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase. FT SIGNAL 1..22 FT /evidence="ECO:0000255" FT CHAIN 23..1255 FT /note="Receptor tyrosine-protein kinase erbB-2" FT /id="PRO_0000016669" FT TOPO_DOM 23..652 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 653..675 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 676..1255 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 720..987 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 676..689 FT /note="Required for interaction with KPNB1 and EEA1" FT /evidence="ECO:0000269|PubMed:16314522" FT REGION 1035..1179 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1195..1197 FT /note="Interaction with PIK3C2B" FT /evidence="ECO:0000305" FT REGION 1196..1255 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 676..689 FT /note="Nuclear localization signal" FT COMPBIAS 1146..1155 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 845 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 726..734 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 753 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 182 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 877 FT /note="Phosphotyrosine" FT /evidence="ECO:0000305|PubMed:32381043" FT MOD_RES 1054 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 1078 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P06494" FT MOD_RES 1083 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1107 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 1112 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:27134172" FT MOD_RES 1139 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:27134172" FT MOD_RES 1151 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 1166 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1196 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:27134172, FT ECO:0000305|PubMed:32381043" FT MOD_RES 1248 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:17554007, FT ECO:0000269|PubMed:27134172, ECO:0007744|PubMed:17081983" FT CARBOHYD 68 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20696930, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3MZW" FT CARBOHYD 124 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 187 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255, ECO:0007744|PDB:1N8Z, FT ECO:0007744|PDB:1S78, ECO:0007744|PDB:2A91, FT ECO:0007744|PDB:3N85" FT CARBOHYD 259 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:15093539, FT ECO:0000269|PubMed:19299620, ECO:0000269|PubMed:20696930, FT ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85" FT CARBOHYD 530 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:15093539, FT ECO:0000269|PubMed:19299620, ECO:0007744|PDB:1S78" FT CARBOHYD 571 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20696930, FT ECO:0007744|PDB:3MZW" FT CARBOHYD 629 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 26..53 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3H3B, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRL, FT ECO:0007744|PDB:4HRM" FT DISULFID 162..192 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3H3B, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRL, FT ECO:0007744|PDB:4HRM" FT DISULFID 195..204 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3H3B, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRL, FT ECO:0007744|PDB:4HRM" FT DISULFID 199..212 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3H3B, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRL, FT ECO:0007744|PDB:4HRM" FT DISULFID 220..227 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 224..235 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 236..244 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 240..252 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 255..264 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 268..295 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 299..311 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 315..331 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 334..338 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 342..367 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 475..504 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 511..520 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 515..528 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85, FT ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ" FT DISULFID 531..540 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRN" FT DISULFID 544..560 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRN" FT DISULFID 563..576 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRN" FT DISULFID 567..584 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW, FT ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRN" FT DISULFID 587..596 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78, FT ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW, FT ECO:0007744|PDB:3N85, ECO:0007744|PDB:4HRN" FT DISULFID 600..623 FT /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:3BE1, FT ECO:0007744|PDB:3N85" FT DISULFID 626..634 FT /evidence="ECO:0007744|PDB:3N85" FT DISULFID 630..642 FT /evidence="ECO:0007744|PDB:3N85" FT VAR_SEQ 1..686 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000305" FT /id="VSP_039250" FT VAR_SEQ 1..610 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_039249" FT VAR_SEQ 1..30 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000305" FT /id="VSP_054787" FT VAR_SEQ 1..23 FT /note="MELAALCRWGLLLALLPPGAAST -> MPRGSWKP (in isoform 4)" FT /evidence="ECO:0000303|Ref.4" FT /id="VSP_039248" FT VAR_SEQ 633..648 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|PubMed:24722188" FT /id="VSP_055902" FT VAR_SEQ 771..883 FT /note="AYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDL FT LNWCMQIAKGMSYLEDVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADG FT GK -> TISNLFSNFAPRGPSACCEPTCWCHSGKGQDSLPREEWGRQRRFCLWGCRGEP FT RVLDTPGRSCPSAPPSSCLQPSLRQPLLLGPGPTRAGGSTQHLQRDTYGREPRVPGSGR FT ASVNQKAKSAEALMCPQGAGKA (in isoform 6)" FT /evidence="ECO:0000303|PubMed:24722188" FT /id="VSP_055903" FT VAR_SEQ 884..1255 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|PubMed:24722188" FT /id="VSP_055904" FT VARIANT 452 FT /note="W -> C (in dbSNP:rs4252633)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_016317" FT VARIANT 654 FT /note="I -> V (in allele B3; dbSNP:rs1801201)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:8095488" FT /id="VAR_004077" FT VARIANT 655 FT /note="I -> V (in allele B2 and allele B3; FT dbSNP:rs1136201)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:8095488, ECO:0000269|Ref.3" FT /id="VAR_004078" FT VARIANT 710 FT /note="A -> V (in VSCN2; almost complete loss of ERBB2 and FT ERBB3 phosphorylation in the presence or in the absence of FT NRG1 stimulation, suggesting alteration of downstream FT signaling; does not affect the subcellular localization at FT the cell membrane; dbSNP:rs2145813505)" FT /evidence="ECO:0000269|PubMed:33497358" FT /id="VAR_086107" FT VARIANT 755 FT /note="L -> P (in LNCR; uncertain significance; somatic FT mutation; dbSNP:rs121913469)" FT /evidence="ECO:0000269|PubMed:15457249" FT /id="VAR_055432" FT VARIANT 768 FT /note="L -> S (in dbSNP:rs56366519)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042097" FT VARIANT 774 FT /note="M -> MAYVM (in LNCR; uncertain significance; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:15457249" FT /id="VAR_055433" FT VARIANT 776 FT /note="G -> S (in GASC; uncertain significance; somatic FT mutation; dbSNP:rs28933369)" FT /evidence="ECO:0000269|PubMed:15457249, FT ECO:0000269|PubMed:17344846" FT /id="VAR_042098" FT VARIANT 779 FT /note="S -> SVGS (in LNCR; uncertain significance; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:15457249" FT /id="VAR_055434" FT VARIANT 857 FT /note="N -> S (in OC; uncertain significance; somatic FT mutation; dbSNP:rs28933370)" FT /evidence="ECO:0000269|PubMed:15457249, FT ECO:0000269|PubMed:17344846" FT /id="VAR_042099" FT VARIANT 914 FT /note="E -> K (in GLM; uncertain significance; somatic FT mutation; dbSNP:rs28933368)" FT /evidence="ECO:0000269|PubMed:15457249" FT /id="VAR_055435" FT VARIANT 1170 FT /note="P -> A (in dbSNP:rs1058808)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:2999974, ECO:0000269|PubMed:8104414, FT ECO:0000269|Ref.3" FT /id="VAR_016318" FT VARIANT 1216 FT /note="A -> D (in dbSNP:rs55943169)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042100" FT MUTAGEN 317..318 FT /note="LH->AA: Reduces dimerization with ERBB3." FT /evidence="ECO:0000269|PubMed:15093539" FT MUTAGEN 611 FT /note="M->A: Prevents synthesis of isoform 2." FT /evidence="ECO:0000269|PubMed:16794579" FT MUTAGEN 687 FT /note="M->A: Prevents synthesis of isoform 3." FT /evidence="ECO:0000269|PubMed:16794579" FT MUTAGEN 706 FT /note="M->A: No effect on isoform production." FT /evidence="ECO:0000269|PubMed:16794579" FT MUTAGEN 712 FT /note="M->A: No effect on isoform production." FT /evidence="ECO:0000269|PubMed:16794579" FT STRAND 25..27 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 39..50 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 55..64 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 72..74 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 79..82 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 84..88 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 92..95 FT /evidence="ECO:0007829|PDB:3H3B" FT TURN 109..111 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 112..117 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 123..125 FT /evidence="ECO:0007829|PDB:8PWH" FT TURN 130..132 FT /evidence="ECO:0007829|PDB:3H3B" FT STRAND 139..141 FT /evidence="ECO:0007829|PDB:3H3B" FT STRAND 147..150 FT /evidence="ECO:0007829|PDB:2A91" FT STRAND 152..156 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 164..166 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 169..171 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 175..177 FT /evidence="ECO:0007829|PDB:1N8Z" FT STRAND 182..184 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 200..202 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 204..208 FT /evidence="ECO:0007829|PDB:8JYR" FT HELIX 209..211 FT /evidence="ECO:0007829|PDB:8JYR" FT STRAND 217..219 FT /evidence="ECO:0007829|PDB:1N8Z" FT HELIX 221..223 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 227..231 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 232..234 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 240..248 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 251..260 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 263..267 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 271..274 FT /evidence="ECO:0007829|PDB:5MY6" FT TURN 276..278 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 281..283 FT /evidence="ECO:0007829|PDB:5MY6" FT TURN 284..286 FT /evidence="ECO:0007829|PDB:6J71" FT STRAND 289..291 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 294..298 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 303..305 FT /evidence="ECO:0007829|PDB:1N8Z" FT STRAND 309..314 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 319..323 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 325..327 FT /evidence="ECO:0007829|PDB:8VQD" FT STRAND 329..333 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 335..337 FT /evidence="ECO:0007829|PDB:2A91" FT HELIX 348..350 FT /evidence="ECO:0007829|PDB:5MY6" FT TURN 358..360 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 361..364 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 368..376 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 378..382 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 385..387 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 394..400 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 405..408 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 410..413 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 417..421 FT /evidence="ECO:0007829|PDB:8PWH" FT HELIX 423..425 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 430..435 FT /evidence="ECO:0007829|PDB:3WLW" FT TURN 438..440 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 441..447 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 463..469 FT /evidence="ECO:0007829|PDB:5MY6" FT TURN 476..479 FT /evidence="ECO:0007829|PDB:8VQE" FT HELIX 482..485 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 488..490 FT /evidence="ECO:0007829|PDB:8VQD" FT STRAND 493..499 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 501..506 FT /evidence="ECO:0007829|PDB:5MY6" FT TURN 507..509 FT /evidence="ECO:0007829|PDB:3N85" FT HELIX 516..518 FT /evidence="ECO:0007829|PDB:5MY6" FT STRAND 520..524 FT /evidence="ECO:0007829|PDB:5MY6" FT HELIX 525..527 FT /evidence="ECO:0007829|PDB:2A91" FT STRAND 532..536 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 539..542 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 545..551 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 553..556 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 559..562 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 565..567 FT /evidence="ECO:0007829|PDB:3WSQ" FT STRAND 571..573 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 575..580 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 583..592 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 595..599 FT /evidence="ECO:0007829|PDB:6LBX" FT STRAND 602..604 FT /evidence="ECO:0007829|PDB:6J71" FT STRAND 605..608 FT /evidence="ECO:0007829|PDB:8PWH" FT STRAND 613..616 FT /evidence="ECO:0007829|PDB:8JYQ" FT STRAND 621..625 FT /evidence="ECO:0007829|PDB:1N8Z" FT STRAND 630..632 FT /evidence="ECO:0007829|PDB:6J71" FT STRAND 635..637 FT /evidence="ECO:0007829|PDB:6J71" FT HELIX 651..678 FT /evidence="ECO:0007829|PDB:2JWA" FT HELIX 684..690 FT /evidence="ECO:0007829|PDB:2N2A" FT HELIX 691..697 FT /evidence="ECO:0007829|PDB:2N2A" FT HELIX 717..719 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 720..729 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 732..739 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 748..755 FT /evidence="ECO:0007829|PDB:8U8X" FT TURN 762..765 FT /evidence="ECO:0007829|PDB:3RCD" FT HELIX 770..775 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 787..799 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 806..813 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 814..816 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 819..838 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 848..850 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 851..855 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 858..861 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 866..870 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 874..876 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 878..880 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 886..888 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 891..896 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 901..916 FT /evidence="ECO:0007829|PDB:8U8X" FT TURN 922..925 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 928..930 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 931..936 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 949..958 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 963..965 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 969..980 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 983..985 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 989..992 FT /evidence="ECO:0007829|PDB:3PP0" FT HELIX 1003..1007 FT /evidence="ECO:0007829|PDB:3PP0" FT TURN 1008..1011 FT /evidence="ECO:0007829|PDB:8U8X" FT HELIX 1020..1022 FT /evidence="ECO:0007829|PDB:8U8X" FT STRAND 1140..1142 FT /evidence="ECO:0007829|PDB:1MW4" SQ SEQUENCE 1255 AA; 137910 MW; 39E9DFDA04DCF962 CRC64; MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY QGCQVVQGNL ELTYLPTNAS LSFLQDIQEV QGYVLIAHNQ VRQVPLQRLR IVRGTQLFED NYALAVLDNG DPLNNTTPVT GASPGGLREL QLRSLTEILK GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA LTLIDTNRSR ACHPCSPMCK GSRCWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC AAGCTGPKHS DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP YNYLSTDVGS CTLVCPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL REVRAVTSAN IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLQVF ETLEEITGYL YISAWPDSLP DLSVFQNLQV IRGRILHNGA YSLTLQGLGI SWLGLRSLRE LGSGLALIHH NTHLCFVHTV PWDQLFRNPH QALLHTANRP EDECVGEGLA CHQLCARGHC WGPGPTQCVN CSQFLRGQEC VEECRVLQGL PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC PSGVKPDLSY MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP LTSIISAVVG ILLVVVLGVV FGILIKRRQQ KIRKYTMRRL LQETELVEPL TPSGAMPNQA QMRILKETEL RKVKVLGSGA FGTVYKGIWI PDGENVKIPV AIKVLRENTS PKANKEILDE AYVMAGVGSP YVSRLLGICL TSTVQLVTQL MPYGCLLDHV RENRGRLGSQ DLLNWCMQIA KGMSYLEDVR LVHRDLAARN VLVKSPNHVK ITDFGLARLL DIDETEYHAD GGKVPIKWMA LESILRRRFT HQSDVWSYGV TVWELMTFGA KPYDGIPARE IPDLLEKGER LPQPPICTID VYMIMVKCWM IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL DSTFYRSLLE DDDMGDLVDA EEYLVPQQGF FCPDPAPGAG GMVHHRHRSS STRSGGGDLT LGLEPSEEEA PRSPLAPSEG AGSDVFDGDL GMGAAKGLQS LPTHDPSPLQ RYSEDPTVPL PSETDGYVAP LTCSPQPEYV NQPDVRPQPP SPREGPLPAA RPAGATLERP KTLSPGKNGV VKDVFAFGGA VENPEYLTPQ GGAAPQPHPP PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYLG LDVPV // ID ERBB4_HUMAN Reviewed; 1308 AA. AC Q15303; B7ZLD7; B7ZLE2; B7ZLE3; Q2M1W1; Q59EW4; DT 15-DEC-1998, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 251. DE RecName: Full=Receptor tyrosine-protein kinase erbB-4; DE EC=2.7.10.1; DE AltName: Full=Proto-oncogene-like protein c-ErbB-4; DE AltName: Full=Tyrosine kinase-type cell surface receptor HER4; DE AltName: Full=p180erbB4; DE Contains: DE RecName: Full=ERBB4 intracellular domain; DE Short=4ICD; DE Short=E4ICD; DE AltName: Full=s80HER4; DE Flags: Precursor; GN Name=ERBB4; Synonyms=HER4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM JM-A CYT-1), FUNCTION AS CELL SURFACE RP RECEPTOR, AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RC TISSUE=Mammary carcinoma; RX PubMed=8383326; DOI=10.1073/pnas.90.5.1746; RA Plowman G.D., Culouscou J.-M., Whitney G.S., Green J.M., Carlton G.W., RA Foy L., Neubauer M.G., Shoyab M.; RT "Ligand-specific activation of HER4/p180erbB4, a fourth member of the RT epidermal growth factor receptor family."; RL Proc. Natl. Acad. Sci. U.S.A. 90:1746-1750(1993). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS JM-A CYT-1 AND JM-B CYT-1), TISSUE RP SPECIFICITY, FUNCTION AS CELL SURFACE RECEPTOR FOR NRG1 AND BTC, RP SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, AND PROTEOLYTIC PROCESSING. RC TISSUE=Fetal brain; RX PubMed=9334263; DOI=10.1074/jbc.272.42.26761; RA Elenius K., Corfas G., Paul S., Choi C.J., Rio C., Plowman G.D., RA Klagsbrun M.; RT "A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific RT tissue distribution and differential processing in response to phorbol RT ester."; RL J. Biol. Chem. 272:26761-26768(1997). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS JM-A CYT-1; JM-B CYT-1; RP JM-A CYT-2 AND JM-B CYT-2). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 401-1308 (ISOFORM JM-A CYT-2). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP INTERACTION WITH NRG1, AND AUTOPHOSPHORYLATION. RX PubMed=7689552; DOI=10.1016/s0021-9258(17)46636-1; RA Culouscou J.-M., Plowman G.D., Carlton G.W., Green J.M., Shoyab M.; RT "Characterization of a breast cancer cell differentiation factor that RT specifically activates the HER4/p180erbB4 receptor."; RL J. Biol. Chem. 268:18407-18410(1993). RN [6] RP INTERACTION WITH NRG1, AND AUTOPHOSPHORYLATION. RX PubMed=7902537; DOI=10.1038/366473a0; RA Plowman G.D., Green J.M., Culouscou J.M., Carlton G.W., Rothwell V.M., RA Buckley S.; RT "Heregulin induces tyrosine phosphorylation of HER4/p180erbB4."; RL Nature 366:473-475(1993). RN [7] RP FUNCTION AS NRG1 RECEPTOR IN REGULATION OF CELL PROLIFERATION, CATALYTIC RP ACTIVITY, ACTIVITY REGULATION, AUTOPHOSPHORYLATION, PHOSPHORYLATION AT RP TYR-1056; TYR-1188 AND TYR-1242, AND INTERACTION WITH EGFR; SHC1 AND RP PIK3R1. RX PubMed=8617750; DOI=10.1074/jbc.271.9.4813; RA Cohen B.D., Green J.M., Foy L., Fell H.P.; RT "HER4-mediated biological and biochemical properties in NIH 3T3 cells. RT Evidence for HER1-HER4 heterodimers."; RL J. Biol. Chem. 271:4813-4818(1996). RN [8] RP INTERACTION WITH BTC, AND AUTOPHOSPHORYLATION. RX PubMed=8570211; RA Riese D.J. II, Bermingham Y., van Raaij T.M., Buckley S., Plowman G.D., RA Stern D.F.; RT "Betacellulin activates the epidermal growth factor receptor and erbB-4, RT and induces cellular response patterns distinct from those stimulated by RT epidermal growth factor or neuregulin-beta."; RL Oncogene 12:345-353(1996). RN [9] RP FUNCTION AS HBEGF RECEPTOR; IN CELL MIGRATION; CELL PROLIFERATION AND IN RP ACTIVATION OF PIK3R1, INTERACTION WITH HBEGF AND PIK3R1, AND RP AUTOPHOSPHORYLATION. RX PubMed=9135143; DOI=10.1093/emboj/16.6.1268; RA Elenius K., Paul S., Allison G., Sun J., Klagsbrun M.; RT "Activation of HER4 by heparin-binding EGF-like growth factor stimulates RT chemotaxis but not proliferation."; RL EMBO J. 16:1268-1278(1997). RN [10] RP INTERACTION WITH NRG2, FUNCTION AS NRG2 RECEPTOR, AND PHOSPHORYLATION. RX PubMed=9168115; DOI=10.1038/387512a0; RA Carraway K.L. III, Weber J.L., Unger M.J., Ledesma J., Yu N., Gassmann M., RA Lai C.; RT "Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases."; RL Nature 387:512-516(1997). RN [11] RP INTERACTION WITH EREG, AND AUTOPHOSPHORYLATION. RX PubMed=9419975; DOI=10.1038/sj.onc.1201458; RA Komurasaki T., Toyoda H., Uchida D., Morimoto S.; RT "Epiregulin binds to epidermal growth factor receptor and ErbB-4 and RT induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB- RT 2, ErbB-3 and ErbB-4."; RL Oncogene 15:2841-2848(1997). RN [12] RP INTERACTION WITH NRG3, AND AUTOPHOSPHORYLATION. RX PubMed=9275162; DOI=10.1073/pnas.94.18.9562; RA Zhang D., Sliwkowski M.X., Mark M., Frantz G., Akita R., Sun Y., Hillan K., RA Crowley C., Brush J., Godowski P.J.; RT "Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and RT activates ErbB4."; RL Proc. Natl. Acad. Sci. U.S.A. 94:9562-9567(1997). RN [13] RP INTERACTION WITH GRB7. RX PubMed=9516479; DOI=10.1074/jbc.273.13.7717; RA Fiddes R.J., Campbell D.H., Janes P.W., Sivertsen S.P., Sasaki H., RA Wallasch C., Daly R.J.; RT "Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals RT a novel target selectivity for erbB3."; RL J. Biol. Chem. 273:7717-7724(1998). RN [14] RP INTERACTION WITH ERBB2, AND FUNCTION IN ACTIVATION OF STAT5A. RX PubMed=10358079; DOI=10.1074/jbc.274.24.17209; RA Olayioye M.A., Beuvink I., Horsch K., Daly J.M., Hynes N.E.; RT "ErbB receptor-induced activation of stat transcription factors is mediated RT by Src tyrosine kinases."; RL J. Biol. Chem. 274:17209-17218(1999). RN [15] RP ALTERNATIVE SPLICING, FUNCTION IN PHOSPHORYLATION AND ACTIVATION OF PIK3R1, RP INTERACTION WITH NRG1 AND PIKR3R1, AUTOPHOSPHORYLATION, AND TISSUE RP SPECIFICITY. RX PubMed=10353604; DOI=10.1038/sj.onc.1202612; RA Elenius K., Choi C.J., Paul S., Santiestevan E., Nishi E., Klagsbrun M.; RT "Characterization of a naturally occurring ErbB4 isoform that does not bind RT or activate phosphatidyl inositol 3-kinase."; RL Oncogene 18:2607-2615(1999). RN [16] RP FUNCTION AS NRG4 RECEPTOR IN ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1 AND IN RP CELL PROLIFERATION, INTERACTION WITH NRG4, AND SUBCELLULAR LOCATION. RX PubMed=10348342; DOI=10.1038/sj.onc.1202631; RA Harari D., Tzahar E., Romano J., Shelly M., Pierce J.H., Andrews G.C., RA Yarden Y.; RT "Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor RT tyrosine kinase."; RL Oncogene 18:2681-2689(1999). RN [17] RP FUNCTION AS NRG1 RECEPTOR IN CELL PROLIFERATION; MIGRATION; SURVIVAL AND IN RP PHOSPHORYLATION OF SHC1; ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1, AND RP ALTERNATIVE SPLICING. RX PubMed=10722704; DOI=10.1074/jbc.275.12.8641; RA Kainulainen V., Sundvall M., Maatta J.A., Santiestevan E., Klagsbrun M., RA Elenius K.; RT "A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase RT mediates proliferation but not survival or chemotaxis."; RL J. Biol. Chem. 275:8641-8649(2000). RN [18] RP PROTEOLYTIC PROCESSING. RX PubMed=10744726; DOI=10.1074/jbc.275.14.10379; RA Rio C., Buxbaum J.D., Peschon J.J., Corfas G.; RT "Tumor necrosis factor-alpha-converting enzyme is required for cleavage of RT erbB4/HER4."; RL J. Biol. Chem. 275:10379-10387(2000). RN [19] RP FUNCTION IN ACTIVATION OF AKT1; MAPK1/ERK2 AND MAPK3/ERK1, INTERACTION WITH RP PIK3R1; GRB2; SHC1; BTC; NRG1; NRG2 AND NRG3, AND LIGAND-SPECIFIC RP AUTOPHOSPHORYLATION. RX PubMed=10867024; DOI=10.1074/jbc.c901015199; RA Sweeney C., Lai C., Riese D.J. II, Diamonti A.J., Cantley L.C., RA Carraway K.L. III; RT "Ligand discrimination in signaling through an ErbB4 receptor homodimer."; RL J. Biol. Chem. 275:19803-19807(2000). RN [20] RP INTERACTION WITH DLG2; DLG3; DLG4 AND SNTB2. RX PubMed=10725395; DOI=10.1073/pnas.97.7.3596; RA Garcia R.A., Vasudevan K., Buonanno A.; RT "The neuregulin receptor ErbB-4 interacts with PDZ-containing proteins at RT neuronal synapses."; RL Proc. Natl. Acad. Sci. U.S.A. 97:3596-3601(2000). RN [21] RP FUNCTION AS NRG1 RECEPTOR AND IN ACTIVATION OF MAP KINASES, RP AUTOPHOSPHORYLATION, AND ACTIVITY REGULATION. RX PubMed=11178955; DOI=10.1006/bbrc.2001.4302; RA Egeblad M., Mortensen O.H., van Kempen L.C., Jaattela M.; RT "BIBX1382BS, but not AG1478 or PD153035, inhibits the ErbB kinases at RT different concentrations in intact cells."; RL Biochem. Biophys. Res. Commun. 281:25-31(2001). RN [22] RP MUTAGENESIS OF LYS-751, AND FUNCTION IN PROMOTING CELL DIFFERENTIATION AND RP INHIBITING CELL PROLIFERATION. RX PubMed=11390655; DOI=10.1128/mcb.21.13.4265-4275.2001; RA Sartor C.I., Zhou H., Kozlowska E., Guttridge K., Kawata E., Caskey L., RA Harrelson J., Hynes N., Ethier S., Calvo B., Earp H.S. III; RT "Her4 mediates ligand-dependent antiproliferative and differentiation RT responses in human breast cancer cells."; RL Mol. Cell. Biol. 21:4265-4275(2001). RN [23] RP FUNCTION, PROTEOLYTIC PROCESSING, SUBCELLULAR LOCATION, INTERACTION WITH RP YAP1, AND MUTAGENESIS OF TYR-1301. RX PubMed=12807903; DOI=10.1074/jbc.m305597200; RA Komuro A., Nagai M., Navin N.E., Sudol M.; RT "WW domain-containing protein YAP associates with ErbB-4 and acts as a co- RT transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that RT translocates to the nucleus."; RL J. Biol. Chem. 278:33334-33341(2003). RN [24] RP INTERACTION WITH MUC1. RX PubMed=12939402; RA Li Y., Yu W.-H., Ren J., Chen W., Huang L., Kharbanda S., Loda M., Kufe D.; RT "Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent RT on the DF3/MUC1 oncoprotein."; RL Mol. Cancer Res. 1:765-775(2003). RN [25] RP INTERACTION WITH STAT5A, SUBCELLULAR LOCATION, FUNCTION IN NUCLEAR RP LOCALIZATION OF STAT5A, DNA-BINDING, AND MUTAGENESIS OF 681-LYS--ARG-684. RX PubMed=15534001; DOI=10.1083/jcb.200403155; RA Williams C.C., Allison J.G., Vidal G.A., Burow M.E., Beckman B.S., RA Marrero L., Jones F.E.; RT "The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by RT functioning as a STAT5A nuclear chaperone."; RL J. Cell Biol. 167:469-478(2004). RN [26] RP INTERACTION WITH WWOX, DOMAIN, AND MUTAGENESIS OF TYR-1035 AND TYR-1301. RX PubMed=16061658; DOI=10.1158/0008-5472.can-05-1150; RA Aqeilan R.I., Donati V., Palamarchuk A., Trapasso F., Kaou M., Pekarsky Y., RA Sudol M., Croce C.M.; RT "WW domain-containing proteins, WWOX and YAP, compete for interaction with RT ErbB-4 and modulate its transcriptional function."; RL Cancer Res. 65:6764-6772(2005). RN [27] RP FUNCTION, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF VAL-675. RX PubMed=15746097; DOI=10.1074/jbc.m412457200; RA Vidal G.A., Naresh A., Marrero L., Jones F.E.; RT "Presenilin-dependent gamma-secretase processing regulates multiple RT ERBB4/HER4 activities."; RL J. Biol. Chem. 280:19777-19783(2005). RN [28] RP FUNCTION IN PROMOTING APOPTOSIS, SUBCELLULAR LOCATION, AND INTERACTION WITH RP BCL2. RX PubMed=16778220; DOI=10.1158/0008-5472.can-05-2368; RA Naresh A., Long W., Vidal G.A., Wimley W.C., Marrero L., Sartor C.I., RA Tovey S., Cooke T.G., Bartlett J.M., Jones F.E.; RT "The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting RT apoptosis of breast cancer cells."; RL Cancer Res. 66:6412-6420(2006). RN [29] RP INTERACTION WITH CBFA2T3. RX PubMed=16815842; DOI=10.1074/jbc.m603998200; RA Linggi B., Carpenter G.; RT "ErbB-4 s80 intracellular domain abrogates ETO2-dependent transcriptional RT repression."; RL J. Biol. Chem. 281:25373-25380(2006). RN [30] RP FUNCTION, PHOSPHORYLATION, AND SUBCELLULAR LOCATION. RX PubMed=16251361; DOI=10.1091/mbc.e05-05-0402; RA Maatta J.A., Sundvall M., Junttila T.T., Peri L., Laine V.J., Isola J., RA Egeblad M., Elenius K.; RT "Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 RT isoform promote ligand-independent survival and cancer cell growth."; RL Mol. Biol. Cell 17:67-79(2006). RN [31] RP FUNCTION IN DIFFERENTIATION OF MAMMARY EPITHELIUM, PROTEOLYTIC PROCESSING, RP AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND INTERACTION WITH STAT5A. RX PubMed=16837552; DOI=10.1091/mbc.e06-02-0101; RA Muraoka-Cook R.S., Sandahl M., Husted C., Hunter D., Miraglia L., RA Feng S.M., Elenius K., Earp H.S. III; RT "The intracellular domain of ErbB4 induces differentiation of mammary RT epithelial cells."; RL Mol. Biol. Cell 17:4118-4129(2006). RN [32] RP MUTAGENESIS OF GLN-646, AND PHOSPHORYLATION AT TYR-1056. RX PubMed=17120616; DOI=10.3727/000000006783981134; RA Pitfield S.E., Bryant I., Penington D.J., Park G., Riese D.J. II; RT "Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling RT to inhibition of colony formation by human mammary cell lines."; RL Oncol. Res. 16:179-193(2006). RN [33] RP FUNCTION OF ERBB4 INTRACELLULAR DOMAIN, PROTEOLYTIC PROCESSING, SUBCELLULAR RP LOCATION, UBIQUITINATION OF ERBB4 INTRACELLULAR DOMAIN, AND MUTAGENESIS OF RP VAL-675; LYS-751; ARG-992; LEU-995 AND ASP-1000. RX PubMed=17638867; DOI=10.1158/0008-5472.can-06-4145; RA Strunk K.E., Husted C., Miraglia L.C., Sandahl M., Rearick W.A., RA Hunter D.M., Earp H.S. III, Muraoka-Cook R.S.; RT "HER4 D-box sequences regulate mitotic progression and degradation of the RT nuclear HER4 cleavage product s80HER4."; RL Cancer Res. 67:6582-6590(2007). RN [34] RP INTERACTION WITH ERBB2, MUTAGENESIS OF ASP-843, AND AUTOPHOSPHORYLATION IN RP TRANS. RX PubMed=16978839; DOI=10.1016/j.cellsig.2006.07.020; RA Li Z., Mei Y., Liu X., Zhou M.; RT "Neuregulin-1 only induces trans-phosphorylation between ErbB receptor RT heterodimer partners."; RL Cell. Signal. 19:466-471(2007). RN [35] RP FUNCTION OF E4ICD, PHOSPHORYLATION, SUBCELLULAR LOCATION OF E4ICD, AND RP MUTAGENESIS OF LYS-751. RX PubMed=17486069; DOI=10.1038/sj.onc.1210501; RA Sundvall M., Peri L., Maatta J.A., Tvorogov D., Paatero I., Savisalo M., RA Silvennoinen O., Yarden Y., Elenius K.; RT "Differential nuclear localization and kinase activity of alternative ErbB4 RT intracellular domains."; RL Oncogene 26:6905-6914(2007). RN [36] RP PHOSPHORYLATION AT TYR-875; TYR-1035; TYR-1056; TYR-1150; TYR-1162; RP TYR-1188; TYR-1202; TYR-1242; TYR-1258 AND TYR-1284, INTERACTION WITH RP PIK3R1 AND STAT1, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=18721752; DOI=10.1016/j.chembiol.2008.07.006; RA Kaushansky A., Gordus A., Budnik B.A., Lane W.S., Rush J., MacBeath G.; RT "System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation RT that are unusually selective in their recruitment properties."; RL Chem. Biol. 15:808-817(2008). RN [37] RP INTERACTION WITH NEDD4, SUBCELLULAR LOCATION, AND UBIQUITINATION OF E4ICD1. RX PubMed=19193720; DOI=10.1096/fj.08-121947; RA Zeng F., Xu J., Harris R.C.; RT "Nedd4 mediates ErbB4 JM-a/CYT-1 ICD ubiquitination and degradation in MDCK RT II cells."; RL FASEB J. 23:1935-1945(2009). RN [38] RP FUNCTION IN ACTIVATION OF SIGNALING PATHWAYS, INTERACTION WITH ERBB2, RP CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, PHOSPHORYLATION BY ERBB2, ACTIVITY RP REGULATION, AND MUTAGENESIS OF VAL-721; ALA-773; ARG-782; GLU-810; PRO-854; RP ASP-861; GLU-872 AND THR-926. RX PubMed=19098003; DOI=10.1074/jbc.m805438200; RA Tvorogov D., Sundvall M., Kurppa K., Hollmen M., Repo S., Johnson M.S., RA Elenius K.; RT "Somatic mutations of ErbB4: selective loss-of-function phenotype affecting RT signal transduction pathways in cancer."; RL J. Biol. Chem. 284:5582-5591(2009). RN [39] RP INTERACTION WITH WWP1, AND MUTAGENESIS OF TYR-1056 AND TYR-1301. RX PubMed=19561640; DOI=10.1038/onc.2009.162; RA Li Y., Zhou Z., Alimandi M., Chen C.; RT "WW domain containing E3 ubiquitin protein ligase 1 targets the full-length RT ErbB4 for ubiquitin-mediated degradation in breast cancer."; RL Oncogene 28:2948-2958(2009). RN [40] RP INTERACTION WITH TXNL4A; DDX23; MATR3; RBM15; ILF3; TRIM28; U5S1; U2SURP; RP ITCH; HNRNPU; AP2A1; NULC; LEO1; WWP2; MDM2; HXK1 AND SRRT, FUNCTION, RP SUBCELLULAR LOCATION, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=20858735; DOI=10.1158/1541-7786.mcr-10-0042; RA Gilmore-Hebert M., Ramabhadran R., Stern D.F.; RT "Interactions of ErbB4 and Kap1 connect the growth factor and DNA damage RT response pathways."; RL Mol. Cancer Res. 8:1388-1398(2010). RN [41] RP ACTIVITY REGULATION. RX PubMed=21439954; DOI=10.1016/j.yexcr.2011.03.015; RA Carrasco-Garcia E., Saceda M., Grasso S., Rocamora-Reverte L., Conde M., RA Gomez-Martinez A., Garcia-Morales P., Ferragut J.A., Martinez-Lacaci I.; RT "Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting RT with erbB3 and erbB4 in glioblastoma cell lines."; RL Exp. Cell Res. 317:1476-1489(2011). RN [42] RP REVIEW ON ROLE IN BREAST AND NEURAL DEVELOPMENT. RX PubMed=14504474; RA Jones F.E., Golding J.P., Gassmann M.; RT "ErbB4 signaling during breast and neural development: novel genetic models RT reveal unique ErbB4 activities."; RL Cell Cycle 2:555-559(2003). RN [43] RP REVIEW. RX PubMed=15944951; DOI=10.14670/hh-20.1005; RA Zaczek A., Brandt B., Bielawski K.P.; RT "The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase RT receptors and the consequences for therapeutic approaches."; RL Histol. Histopathol. 20:1005-1015(2005). RN [44] RP REVIEW ON ROLE IN MAMMARY GLAND DEVELOPMENT. RX PubMed=18437540; DOI=10.1007/s10911-008-9080-x; RA Muraoka-Cook R.S., Feng S.M., Strunk K.E., Earp H.S. III; RT "ErbB4/HER4: role in mammary gland development, differentiation and growth RT inhibition."; RL J. Mammary Gland Biol. Neoplasia 13:235-246(2008). RN [45] RP REVIEW ON ROLE OF THE ERBB4 INTRACELLULAR DOMAIN. RX PubMed=18473151; DOI=10.1007/s10911-008-9076-6; RA Jones F.E.; RT "HER4 intracellular domain (4ICD) activity in the developing mammary gland RT and breast cancer."; RL J. Mammary Gland Biol. Neoplasia 13:247-258(2008). RN [46] RP REVIEW ON LIGAND SPECIFICITY AND SIGNALING. RX PubMed=18454307; DOI=10.1007/s10911-008-9079-3; RA Sundvall M., Iljin K., Kilpinen S., Sara H., Kallioniemi O.P., Elenius K.; RT "Role of ErbB4 in breast cancer."; RL J. Mammary Gland Biol. Neoplasia 13:259-268(2008). RN [47] RP REVIEW ON ROLE IN NRG1 SIGNALING AND CARDIOVASCULAR HEALTH. RX PubMed=20933198; DOI=10.1016/s1054-3589(10)59002-1; RA Xu Y., Li X., Liu X., Zhou M.; RT "Neuregulin-1/ErbB signaling and chronic heart failure."; RL Adv. Pharmacol. 59:31-51(2010). RN [48] RP REVIEW ON ALTERNATIVE SPLICING AND PROTEOLYTIC PROCESSING; TISSUE RP SPECIFICITY; SIGNALING AND ROLE IN DISEASE. RX PubMed=21811097; DOI=10.4161/cc.10.16.17194; RA Veikkolainen V., Vaparanta K., Halkilahti K., Iljin K., Sundvall M., RA Elenius K.; RT "Function of ERBB4 is determined by alternative splicing."; RL Cell Cycle 10:2647-2657(2011). RN [49] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 26-641, DISULFIDE BONDS, AND RP GLYCOSYLATION AT ASN-138; ASN-174; ASN-253; ASN-358; ASN-410; ASN-473; RP ASN-495 AND ASN-576. RX PubMed=16203964; DOI=10.1073/pnas.0507591102; RA Bouyain S., Longo P.A., Li S., Ferguson K.M., Leahy D.J.; RT "The extracellular region of ErbB4 adopts a tethered conformation in the RT absence of ligand."; RL Proc. Natl. Acad. Sci. U.S.A. 102:15024-15029(2005). RN [50] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 690-999 IN COMPLEX WITH INHIBITOR, RP CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF LEU-710; RP MET-766; LEU-864 AND ILE-947. RX PubMed=18287036; DOI=10.1073/pnas.0708281105; RA Wood E.R., Shewchuk L.M., Ellis B., Brignola P., Brashear R.L., RA Caferro T.R., Dickerson S.H., Dickson H.D., Donaldson K.H., Gaul M., RA Griffin R.J., Hassell A.M., Keith B., Mullin R., Petrov K.G., Reno M.J., RA Rusnak D.W., Tadepalli S.M., Ulrich J.C., Wagner C.D., Vanderwall D.E., RA Waterson A.G., Williams J.D., White W.L., Uehling D.E.; RT "6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as RT tunable covalent modifiers of ErbB kinases."; RL Proc. Natl. Acad. Sci. U.S.A. 105:2773-2778(2008). RN [51] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 702-1029 OF APOPROTEIN AND IN RP COMPLEX WITH LAPATINIB, CATALYTIC ACTIVITY, ACTIVITY REGULATION, RP AUTOPHOSPHORYLATION, AND SUBUNIT. RX PubMed=18334220; DOI=10.1016/j.str.2007.12.016; RA Qiu C., Tarrant M.K., Choi S.H., Sathyamurthy A., Bose R., Banjade S., RA Pal A., Bornmann W.G., Lemmon M.A., Cole P.A., Leahy D.J.; RT "Mechanism of activation and inhibition of the HER4/ErbB4 kinase."; RL Structure 16:460-467(2008). RN [52] RP VARIANTS [LARGE SCALE ANALYSIS] ILE-140 AND TYR-303. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [53] RP VARIANTS ALS19 GLN-927 AND TRP-1275, AND CHARACTERIZATION OF VARIANTS ASL19 RP GLN-927 AND TRP-1275. RX PubMed=24119685; DOI=10.1016/j.ajhg.2013.09.008; RA Takahashi Y., Fukuda Y., Yoshimura J., Toyoda A., Kurppa K., Moritoyo H., RA Belzil V.V., Dion P.A., Higasa K., Doi K., Ishiura H., Mitsui J., Date H., RA Ahsan B., Matsukawa T., Ichikawa Y., Moritoyo T., Ikoma M., Hashimoto T., RA Kimura F., Murayama S., Onodera O., Nishizawa M., Yoshida M., Atsuta N., RA Sobue G., Fifita J.A., Williams K.L., Blair I.P., Nicholson G.A., RA Gonzalez-Perez P., Brown R.H. Jr., Nomoto M., Elenius K., Rouleau G.A., RA Fujiyama A., Morishita S., Goto J., Tsuji S., Nakamura R., Watanabe H., RA Izumi Y., Kaji R., Morita M., Ogaki K., Taniguchi A., Aiba I., RA Mizoguchi K., Okamoto K., Hasegawa K., Aoki M., Kawata A., Nakano I., RA Abe K., Oda M., Konagaya M., Imai T., Nakagawa M., Fujita T., Sasaki H., RA Nishizawa M.; RT "ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause RT amyotrophic lateral sclerosis type 19."; RL Am. J. Hum. Genet. 93:900-905(2013). CC -!- FUNCTION: Tyrosine-protein kinase that plays an essential role as cell CC surface receptor for neuregulins and EGF family members and regulates CC development of the heart, the central nervous system and the mammary CC gland, gene transcription, cell proliferation, differentiation, CC migration and apoptosis. Required for normal cardiac muscle CC differentiation during embryonic development, and for postnatal CC cardiomyocyte proliferation. Required for normal development of the CC embryonic central nervous system, especially for normal neural crest CC cell migration and normal axon guidance. Required for mammary gland CC differentiation, induction of milk proteins and lactation. Acts as CC cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and CC the EGF family members BTC, EREG and HBEGF. Ligand binding triggers CC receptor dimerization and autophosphorylation at specific tyrosine CC residues that then serve as binding sites for scaffold proteins and CC effectors. Ligand specificity and signaling is modulated by alternative CC splicing, proteolytic processing, and by the formation of heterodimers CC with other ERBB family members, thereby creating multiple combinations CC of intracellular phosphotyrosines that trigger ligand- and context- CC specific cellular responses. Mediates phosphorylation of SHC1 and CC activation of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Isoform JM-A CC CYT-1 and isoform JM-B CYT-1 phosphorylate PIK3R1, leading to the CC activation of phosphatidylinositol 3-kinase and AKT1 and protect cells CC against apoptosis. Isoform JM-A CYT-1 and isoform JM-B CYT-1 mediate CC reorganization of the actin cytoskeleton and promote cell migration in CC response to NRG1. Isoform JM-A CYT-2 and isoform JM-B CYT-2 lack the CC phosphotyrosine that mediates interaction with PIK3R1, and hence do not CC phosphorylate PIK3R1, do not protect cells against apoptosis, and do CC not promote reorganization of the actin cytoskeleton and cell CC migration. Proteolytic processing of isoform JM-A CYT-1 and isoform JM- CC A CYT-2 gives rise to the corresponding soluble intracellular domains CC (4ICD) that translocate to the nucleus, promote nuclear import of CC STAT5A, activation of STAT5A, mammary epithelium differentiation, cell CC proliferation and activation of gene expression. The ERBB4 soluble CC intracellular domains (4ICD) colocalize with STAT5A at the CSN2 CC promoter to regulate transcription of milk proteins during lactation. CC The ERBB4 soluble intracellular domains can also translocate to CC mitochondria and promote apoptosis. {ECO:0000269|PubMed:10348342, CC ECO:0000269|PubMed:10353604, ECO:0000269|PubMed:10358079, CC ECO:0000269|PubMed:10722704, ECO:0000269|PubMed:10867024, CC ECO:0000269|PubMed:11178955, ECO:0000269|PubMed:11390655, CC ECO:0000269|PubMed:12807903, ECO:0000269|PubMed:15534001, CC ECO:0000269|PubMed:15746097, ECO:0000269|PubMed:16251361, CC ECO:0000269|PubMed:16778220, ECO:0000269|PubMed:16837552, CC ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:20858735, CC ECO:0000269|PubMed:8383326, ECO:0000269|PubMed:8617750, CC ECO:0000269|PubMed:9135143, ECO:0000269|PubMed:9168115, CC ECO:0000269|PubMed:9334263}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:18287036, ECO:0000269|PubMed:18334220, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:8617750}; CC -!- ACTIVITY REGULATION: Binding of a cognate ligand leads to dimerization CC and activation by autophosphorylation on tyrosine residues. In vitro CC kinase activity is increased by Mg(2+). Inhibited by PD153035, CC lapatinib, gefitinib (iressa, ZD1839), AG1478 and BIBX1382BS. CC {ECO:0000269|PubMed:11178955, ECO:0000269|PubMed:18334220, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:21439954, CC ECO:0000269|PubMed:8617750}. CC -!- SUBUNIT: Monomer in the absence of bound ligand. Homodimer or CC heterodimer with another ERBB family member upon ligand binding, thus CC forming heterotetramers. Interacts with EGFR and ERBB2. Interacts with CC CBFA2T3 (By similarity). Interacts with DLG2 (via its PDZ domain), DLG3 CC (via its PDZ domain), DLG4 (via its PDZ domain) and SNTB2 (via its PDZ CC domain). Interacts with MUC1. Interacts (via its PPxy motifs) with CC WWOX. Interacts (via the PPxY motif 3 of isoform JM-A CYT-2) with YAP1 CC (via the WW domain 1 of isoform 1). Interacts (isoform JM-A CYT-1 and CC isoform JM-B CYT-1) with WWP1. Interacts (via its intracellular domain) CC with TRIM28. Interacts (via the intracellular domains of both CYT-1 and CC CYT-2 isoforms) with KAP1; the interaction does not phosphorylate KAP1 CC but represses ERBB4-mediated transcriptional activity. Interacts with CC PRPU, DDX23, MATR3, RBM15, ILF3, KAP1, U5S1, U2SURP, ITCH, HNRNPU, CC AP2A1, NULC, LEO1, WWP2, IGHG1, HXK1, GRB7 and SRRT. Interacts CC (phosphorylated isoform JM-A CYT-1 and isoform JM-B CYT-1) with PIK3R1. CC Interacts with SHC1. Interacts with GRB2. Interacts (soluble CC intracellular domain) with STAT5A. Interacts (soluble intracellular CC domain) with BCL2. Interacts (phosphorylated) with STAT1. {ECO:0000250, CC ECO:0000269|PubMed:10348342, ECO:0000269|PubMed:10353604, CC ECO:0000269|PubMed:10358079, ECO:0000269|PubMed:10725395, CC ECO:0000269|PubMed:10867024, ECO:0000269|PubMed:12807903, CC ECO:0000269|PubMed:12939402, ECO:0000269|PubMed:15534001, CC ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:16778220, CC ECO:0000269|PubMed:16815842, ECO:0000269|PubMed:16837552, CC ECO:0000269|PubMed:16978839, ECO:0000269|PubMed:18287036, CC ECO:0000269|PubMed:18334220, ECO:0000269|PubMed:18721752, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:19193720, CC ECO:0000269|PubMed:19561640, ECO:0000269|PubMed:20858735, CC ECO:0000269|PubMed:7689552, ECO:0000269|PubMed:7902537, CC ECO:0000269|PubMed:8570211, ECO:0000269|PubMed:8617750, CC ECO:0000269|PubMed:9135143, ECO:0000269|PubMed:9168115, CC ECO:0000269|PubMed:9275162, ECO:0000269|PubMed:9419975, CC ECO:0000269|PubMed:9516479}. CC -!- INTERACTION: CC Q15303; P42684: ABL2; NbExp=4; IntAct=EBI-80371, EBI-1102694; CC Q15303; Q13895: BYSL; NbExp=3; IntAct=EBI-80371, EBI-358049; CC Q15303; Q12959: DLG1; NbExp=4; IntAct=EBI-80371, EBI-357481; CC Q15303; Q15700: DLG2; NbExp=3; IntAct=EBI-80371, EBI-80426; CC Q15303; Q92796: DLG3; NbExp=4; IntAct=EBI-80371, EBI-80440; CC Q15303; P78352: DLG4; NbExp=9; IntAct=EBI-80371, EBI-80389; CC Q15303; P00533: EGFR; NbExp=4; IntAct=EBI-80371, EBI-297353; CC Q15303; P04626: ERBB2; NbExp=5; IntAct=EBI-80371, EBI-641062; CC Q15303; P21860: ERBB3; NbExp=4; IntAct=EBI-80371, EBI-720706; CC Q15303; P62993: GRB2; NbExp=7; IntAct=EBI-80371, EBI-401755; CC Q15303; Q99075: HBEGF; NbExp=2; IntAct=EBI-80371, EBI-7211558; CC Q15303; P08238: HSP90AB1; NbExp=2; IntAct=EBI-80371, EBI-352572; CC Q15303; Q96J02-2: ITCH; NbExp=3; IntAct=EBI-80371, EBI-6672198; CC Q15303; Q96JA1: LRIG1; NbExp=3; IntAct=EBI-80371, EBI-2865191; CC Q15303; Q86UL8: MAGI2; NbExp=2; IntAct=EBI-80371, EBI-311035; CC Q15303; Q02297-6: NRG1; NbExp=3; IntAct=EBI-80371, EBI-15651799; CC Q15303; Q06124: PTPN11; NbExp=2; IntAct=EBI-80371, EBI-297779; CC Q15303; P26447: S100A4; NbExp=4; IntAct=EBI-80371, EBI-717058; CC Q15303; P29353: SHC1; NbExp=6; IntAct=EBI-80371, EBI-78835; CC Q15303; Q12815: TROAP; NbExp=3; IntAct=EBI-80371, EBI-2349743; CC Q15303; P46937: YAP1; NbExp=3; IntAct=EBI-80371, EBI-1044059; CC Q15303; P62258: YWHAE; NbExp=2; IntAct=EBI-80371, EBI-356498; CC Q15303-3; Q96J02-2: ITCH; NbExp=2; IntAct=EBI-15692884, EBI-6672198; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10348342, CC ECO:0000269|PubMed:12807903, ECO:0000269|PubMed:15534001, CC ECO:0000269|PubMed:16251361, ECO:0000269|PubMed:16778220, CC ECO:0000269|PubMed:16837552, ECO:0000269|PubMed:17486069, CC ECO:0000269|PubMed:17638867, ECO:0000269|PubMed:19193720, CC ECO:0000269|PubMed:20858735, ECO:0000269|PubMed:8383326, CC ECO:0000269|PubMed:9334263}; Single-pass type I membrane protein CC {ECO:0000269|PubMed:10348342, ECO:0000269|PubMed:12807903, CC ECO:0000269|PubMed:15534001, ECO:0000269|PubMed:16251361, CC ECO:0000269|PubMed:16778220, ECO:0000269|PubMed:16837552, CC ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867, CC ECO:0000269|PubMed:19193720, ECO:0000269|PubMed:20858735, CC ECO:0000269|PubMed:8383326, ECO:0000269|PubMed:9334263}. Note=In CC response to NRG1 treatment, the activated receptor is internalized. CC -!- SUBCELLULAR LOCATION: [ERBB4 intracellular domain]: Nucleus CC {ECO:0000269|PubMed:17486069}. Mitochondrion CC {ECO:0000269|PubMed:17486069}. Note=Following proteolytical processing CC E4ICD (E4ICD1 or E4ICD2 generated from the respective isoforms) is CC translocated to the nucleus. Significantly more E4ICD2 than E4ICD1 is CC found in the nucleus. E4ICD2 colocalizes with YAP1 in the nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=JM-A CYT-1; CC IsoId=Q15303-1; Sequence=Displayed; CC Name=JM-B CYT-1; CC IsoId=Q15303-2; Sequence=VSP_002895; CC Name=JM-A CYT-2; CC IsoId=Q15303-3; Sequence=VSP_022148; CC Name=JM-B CYT-2; CC IsoId=Q15303-4; Sequence=VSP_002895, VSP_022148; CC -!- TISSUE SPECIFICITY: Expressed at highest levels in brain, heart, CC kidney, in addition to skeletal muscle, parathyroid, cerebellum, CC pituitary, spleen, testis and breast. Lower levels in thymus, lung, CC salivary gland, and pancreas. Isoform JM-A CYT-1 and isoform JM-B CYT-1 CC are expressed in cerebellum, but only the isoform JM-B is expressed in CC the heart. {ECO:0000269|PubMed:10353604, ECO:0000269|PubMed:8383326, CC ECO:0000269|PubMed:9334263}. CC -!- PTM: Isoform JM-A CYT-1 and isoform JM-A CYT-2 are processed by ADAM17. CC Proteolytic processing in response to ligand or 12-O- CC tetradecanoylphorbol-13-acetate stimulation results in the production CC of 120 kDa soluble receptor forms and intermediate membrane-anchored 80 CC kDa fragments (m80HER4), which are further processed by a presenilin- CC dependent gamma-secretase to release a cytoplasmic intracellular domain CC (E4ICD; E4ICD1/s80Cyt1 or E4ICD2/s80Cyt2, depending on the isoform). CC Membrane-anchored 80 kDa fragments of the processed isoform JM-A CYT-1 CC are more readily degraded by the proteasome than fragments of isoform CC JM-A CYT-2, suggesting a prevalence of E4ICD2 over E4ICD1. Isoform JM-B CC CYT-1 and isoform JM-B CYT-2 lack the ADAM17 cleavage site and are not CC processed by ADAM17, precluding further processing by gamma-secretase. CC {ECO:0000269|PubMed:10744726, ECO:0000269|PubMed:12807903, CC ECO:0000269|PubMed:15746097, ECO:0000269|PubMed:16837552, CC ECO:0000269|PubMed:17638867, ECO:0000269|PubMed:9334263}. CC -!- PTM: Autophosphorylated on tyrosine residues in response to ligand CC binding. Autophosphorylation occurs in trans, i.e. one subunit of the CC dimeric receptor phosphorylates tyrosine residues on the other subunit. CC Ligands trigger phosphorylation at specific tyrosine residues, thereby CC creating binding sites for scaffold proteins and effectors. CC Constitutively phosphorylated at a basal level when overexpressed in CC heterologous systems; ligand binding leads to increased CC phosphorylation. Phosphorylation at Tyr-1035 is important for CC interaction with STAT1. Phosphorylation at Tyr-1056 is important for CC interaction with PIK3R1. Phosphorylation at Tyr-1242 is important for CC interaction with SHC1. Phosphorylation at Tyr-1188 may also contribute CC to the interaction with SHC1. Isoform JM-A CYT-2 is constitutively CC phosphorylated on tyrosine residues in a ligand-independent manner. CC E4ICD2 but not E4ICD1 is phosphorylated on tyrosine residues. CC {ECO:0000269|PubMed:16251361, ECO:0000269|PubMed:17120616, CC ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:18721752, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:8617750, CC ECO:0000269|PubMed:9168115}. CC -!- PTM: Ubiquitinated. During mitosis, the ERBB4 intracellular domain is CC ubiquitinated by the APC/C complex and targeted to proteasomal CC degradation. Isoform JM-A CYT-1 and isoform JM-B CYT-1 are CC ubiquitinated by WWP1. The ERBB4 intracellular domain (E4ICD1) is CC ubiquitinated, and this involves NEDD4. {ECO:0000269|PubMed:17638867, CC ECO:0000269|PubMed:19193720}. CC -!- DISEASE: Amyotrophic lateral sclerosis 19 (ALS19) [MIM:615515]: A CC neurodegenerative disorder affecting upper motor neurons in the brain CC and lower motor neurons in the brain stem and spinal cord, resulting in CC fatal paralysis. Sensory abnormalities are absent. The pathologic CC hallmarks of the disease include pallor of the corticospinal tract due CC to loss of motor neurons, presence of ubiquitin-positive inclusions CC within surviving motor neurons, and deposition of pathologic CC aggregates. The etiology of amyotrophic lateral sclerosis is likely to CC be multifactorial, involving both genetic and environmental factors. CC The disease is inherited in 5-10% of the cases. CC {ECO:0000269|PubMed:24119685}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform JM-A CYT-1]: Proteolytical processing generates CC E4ICD1 (s80Cyt1). CC -!- MISCELLANEOUS: [Isoform JM-A CYT-2]: Proteolytical processing generates CC E4ICD2 (s80Cyt2). {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- CAUTION: Conflicting reports about the role of ERBB4 in mediating CC apoptosis, differentiation, or tumor cell proliferation may be CC explained by the opposite functions of the different isoforms and their CC intracellular fragments, and by the formation of heterodimers with CC other EGF receptor family members (PubMed:18454307, PubMed:21811097). CC Thus, heterodimer formation of a kinase-dead ERBB4 mutant with ERBB2 is CC sufficient for the activation of AKT1, MAPK1/ERK2 and MAPK3/ERK1 CC (PubMed:19098003). {ECO:0000305|PubMed:19098003}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L07868; AAB59446.1; -; mRNA. DR EMBL; BC112199; AAI12200.1; -; mRNA. DR EMBL; BC143741; AAI43742.1; -; mRNA. DR EMBL; BC143747; AAI43748.1; -; mRNA. DR EMBL; BC143749; AAI43750.1; -; mRNA. DR EMBL; AB209697; BAD92934.1; -; mRNA. DR CCDS; CCDS2394.1; -. [Q15303-1] DR CCDS; CCDS42811.1; -. [Q15303-3] DR PIR; A47253; A47253. DR RefSeq; NP_001036064.1; NM_001042599.2. [Q15303-3] DR RefSeq; NP_001425934.1; NM_001439005.1. [Q15303-2] DR RefSeq; NP_001425935.1; NM_001439006.1. [Q15303-4] DR RefSeq; NP_005226.1; NM_005235.3. [Q15303-1] DR PDB; 2AHX; X-ray; 2.40 A; A/B=26-641. DR PDB; 2L2T; NMR; -; A/B=642-685. DR PDB; 2LCX; NMR; -; A/B=642-685. DR PDB; 2R4B; X-ray; 2.40 A; A/B=690-999. DR PDB; 3BBT; X-ray; 2.80 A; B/D=702-1029. DR PDB; 3BBW; X-ray; 4.00 A; A/B=702-1029. DR PDB; 3BCE; X-ray; 2.50 A; A/B/C=702-1029. DR PDB; 3U2P; X-ray; 2.57 A; A=26-522. DR PDB; 3U7U; X-ray; 3.03 A; A/B/C/D/E/F=26-640. DR PDB; 3U9U; X-ray; 3.42 A; E/F=26-650. DR PDB; 8U4I; EM; 3.38 A; A/B=26-635. DR PDB; 8U4J; EM; 3.70 A; A/B=26-635. DR PDB; 8U4K; EM; 4.27 A; A=26-634. DR PDB; 8U4L; EM; 3.31 A; A=26-634. DR PDBsum; 2AHX; -. DR PDBsum; 2L2T; -. DR PDBsum; 2LCX; -. DR PDBsum; 2R4B; -. DR PDBsum; 3BBT; -. DR PDBsum; 3BBW; -. DR PDBsum; 3BCE; -. DR PDBsum; 3U2P; -. DR PDBsum; 3U7U; -. DR PDBsum; 3U9U; -. DR PDBsum; 8U4I; -. DR PDBsum; 8U4J; -. DR PDBsum; 8U4K; -. DR PDBsum; 8U4L; -. DR AlphaFoldDB; Q15303; -. DR EMDB; EMD-41883; -. DR EMDB; EMD-41884; -. DR EMDB; EMD-41885; -. DR EMDB; EMD-41886; -. DR SMR; Q15303; -. DR BioGRID; 108378; 183. DR CORUM; Q15303; -. DR DIP; DIP-29650N; -. DR ELM; Q15303; -. DR FunCoup; Q15303; 1593. DR IntAct; Q15303; 146. DR MINT; Q15303; -. DR STRING; 9606.ENSP00000342235; -. DR BindingDB; Q15303; -. DR ChEMBL; CHEMBL3009; -. DR DrugBank; DB08916; Afatinib. DR DrugBank; DB12267; Brigatinib. DR DrugBank; DB05424; Canertinib. DR DrugBank; DB12744; CGI-1842. DR DrugBank; DB11963; Dacomitinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB12325; Idasanutlin. DR DrugBank; DB15035; Zanubrutinib. DR DrugCentral; Q15303; -. DR GuidetoPHARMACOLOGY; 1799; -. DR TCDB; 8.A.23.1.17; the basigin (basigin) family. DR GlyCosmos; Q15303; 11 sites, No reported glycans. DR GlyGen; Q15303; 11 sites, 6 N-linked glycans (4 sites). DR iPTMnet; Q15303; -. DR PhosphoSitePlus; Q15303; -. DR BioMuta; ERBB4; -. DR DMDM; 3913590; -. DR jPOST; Q15303; -. DR MassIVE; Q15303; -. DR PaxDb; 9606-ENSP00000342235; -. DR PeptideAtlas; Q15303; -. DR ProteomicsDB; 60520; -. [Q15303-1] DR ProteomicsDB; 60521; -. [Q15303-2] DR ProteomicsDB; 60522; -. [Q15303-3] DR ProteomicsDB; 60523; -. [Q15303-4] DR Pumba; Q15303; -. DR ABCD; Q15303; 1 sequenced antibody. DR Antibodypedia; 1602; 1464 antibodies from 47 providers. DR DNASU; 2066; -. DR Ensembl; ENST00000260943.11; ENSP00000260943.7; ENSG00000178568.16. [Q15303-4] DR Ensembl; ENST00000342788.9; ENSP00000342235.4; ENSG00000178568.16. [Q15303-1] DR Ensembl; ENST00000436443.5; ENSP00000403204.1; ENSG00000178568.16. [Q15303-3] DR GeneID; 2066; -. DR KEGG; hsa:2066; -. DR MANE-Select; ENST00000342788.9; ENSP00000342235.4; NM_005235.3; NP_005226.1. DR UCSC; uc002veg.2; human. [Q15303-1] DR AGR; HGNC:3432; -. DR CIViC; 2066; 9 evidence items across 8 molecular profiles. DR ClinPGx; PA27847; -. DR CTD; 2066; -. DR DisGeNET; 2066; -. DR GeneCards; ERBB4; -. DR HGNC; HGNC:3432; ERBB4. DR HPA; ENSG00000178568; Tissue enhanced (brain, fallopian tube). DR MalaCards; ERBB4; -. DR MIM; 600543; gene. DR MIM; 615515; phenotype. DR OpenTargets; ENSG00000178568; -. DR Orphanet; 803; Amyotrophic lateral sclerosis. DR Orphanet; 178469; Autosomal dominant non-syndromic intellectual disability. DR VEuPathDB; HostDB:ENSG00000178568; -. DR eggNOG; KOG1025; Eukaryota. DR GeneTree; ENSGT00940000154695; -. DR InParanoid; Q15303; -. DR OMA; VCHSECL; -. DR OrthoDB; 6219513at2759; -. DR PAN-GO; Q15303; 9 GO annotations based on evolutionary models. DR PhylomeDB; Q15303; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; Q15303; -. DR Reactome; R-HSA-1227986; Signaling by ERBB2. DR Reactome; R-HSA-1236394; Signaling by ERBB4. DR Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. DR Reactome; R-HSA-1250342; PI3K events in ERBB4 signaling. DR Reactome; R-HSA-1250347; SHC1 events in ERBB4 signaling. DR Reactome; R-HSA-1251985; Nuclear signaling by ERBB4. DR Reactome; R-HSA-1253288; Downregulation of ERBB4 signaling. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling. DR Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6785631; ERBB2 Regulates Cell Motility. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling. DR Reactome; R-HSA-8863795; Downregulation of ERBB2 signaling. DR Reactome; R-HSA-9018519; Estrogen-dependent gene expression. DR Reactome; R-HSA-9620244; Long-term potentiation. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants. DR SignaLink; Q15303; -. DR SIGNOR; Q15303; -. DR Agora; ENSG00000178568; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 2066; 33 hits in 1186 CRISPR screens. DR ChiTaRS; ERBB4; human. DR EvolutionaryTrace; Q15303; -. DR GeneWiki; ERBB4; -. DR GenomeRNAi; 2066; -. DR Pharos; Q15303; Tclin. DR PRO; PR:Q15303; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q15303; protein. DR Bgee; ENSG00000178568; Expressed in endothelial cell and 154 other cell types or tissues. DR ExpressionAtlas; Q15303; baseline and differential. DR GO; GO:0009925; C:basal plasma membrane; IBA:GO_Central. DR GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0098982; C:GABA-ergic synapse; IEA:Ensembl. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:MGI. DR GO; GO:0098839; C:postsynaptic density membrane; IEA:Ensembl. DR GO; GO:0045211; C:postsynaptic membrane; ISS:UniProtKB. DR GO; GO:0042734; C:presynaptic membrane; IEA:Ensembl. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005006; F:epidermal growth factor receptor activity; IEA:Ensembl. DR GO; GO:0005154; F:epidermal growth factor receptor binding; IPI:UniProtKB. DR GO; GO:0050811; F:GABA receptor binding; IEA:Ensembl. DR GO; GO:0038131; F:neuregulin receptor activity; IDA:MGI. DR GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IMP:UniProtKB. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0061026; P:cardiac muscle tissue regeneration; ISS:UniProtKB. DR GO; GO:0045165; P:cell fate commitment; IEA:Ensembl. DR GO; GO:0016477; P:cell migration; IDA:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IDA:UniProtKB. DR GO; GO:0007259; P:cell surface receptor signaling pathway via JAK-STAT; IEA:Ensembl. DR GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IEA:Ensembl. DR GO; GO:0021551; P:central nervous system morphogenesis; ISS:UniProtKB. DR GO; GO:0009880; P:embryonic pattern specification; ISS:UniProtKB. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IBA:GO_Central. DR GO; GO:0038135; P:ERBB2-ERBB4 signaling pathway; IEA:Ensembl. DR GO; GO:0038130; P:ERBB4 signaling pathway; IDA:MGI. DR GO; GO:0038138; P:ERBB4-ERBB4 signaling pathway; IDA:MGI. DR GO; GO:0072046; P:establishment of planar polarity involved in nephron morphogenesis; IEA:Ensembl. DR GO; GO:0007507; P:heart development; ISS:UniProtKB. DR GO; GO:0007595; P:lactation; IMP:UniProtKB. DR GO; GO:0060749; P:mammary gland alveolus development; ISS:UniProtKB. DR GO; GO:0060644; P:mammary gland epithelial cell differentiation; ISS:UniProtKB. DR GO; GO:0043653; P:mitochondrial fragmentation involved in apoptotic process; IMP:UniProtKB. DR GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:2001223; P:negative regulation of neuron migration; IEA:Ensembl. DR GO; GO:0007399; P:nervous system development; ISS:UniProtKB. DR GO; GO:0001755; P:neural crest cell migration; ISS:UniProtKB. DR GO; GO:0030182; P:neuron differentiation; IBA:GO_Central. DR GO; GO:0099645; P:neurotransmitter receptor localization to postsynaptic specialization membrane; IEA:Ensembl. DR GO; GO:0021889; P:olfactory bulb interneuron differentiation; ISS:UniProtKB. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; ISS:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IMP:UniProtKB. DR GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IBA:GO_Central. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IBA:GO_Central. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IEA:Ensembl. DR GO; GO:2000010; P:positive regulation of protein localization to cell surface; IEA:Ensembl. DR GO; GO:0001934; P:positive regulation of protein phosphorylation; TAS:UniProtKB. DR GO; GO:0046427; P:positive regulation of receptor signaling pathway via JAK-STAT; IMP:UniProtKB. DR GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; IMP:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0030334; P:regulation of cell migration; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; IDA:UniProtKB. DR GO; GO:0007416; P:synapse assembly; IEA:Ensembl. DR CDD; cd00064; FU; 3. DR CDD; cd05110; PTKc_HER4; 1. DR CDD; cd12092; TM_ErbB4; 1. DR FunFam; 2.10.220.10:FF:000001; Receptor protein-tyrosine kinase; 1. DR FunFam; 2.10.220.10:FF:000004; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.30.200.20:FF:000044; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000003; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000004; Receptor protein-tyrosine kinase; 1. DR FunFam; 1.10.510.10:FF:002828; Receptor tyrosine-protein kinase erbB-2; 1. DR Gene3D; 6.10.250.880; -; 1. DR Gene3D; 2.10.220.10; Hormone Receptor, Insulin-like Growth Factor Receptor 1, Chain A, domain 2; 3. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.20.20; Receptor L-domain; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR006211; Furin-like_Cys-rich_dom. DR InterPro; IPR006212; Furin_repeat. DR InterPro; IPR032778; GF_recep_IV. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR000494; Rcpt_L-dom. DR InterPro; IPR036941; Rcpt_L-dom_sf. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR049328; TM_ErbB1. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt. DR PANTHER; PTHR24416:SF90; RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00757; Furin-like; 1. DR Pfam; PF14843; GF_recep_IV; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF01030; Recep_L_domain; 2. DR Pfam; PF21314; TM_ErbB1; 1. DR PIRSF; PIRSF000619; TyrPK_EGF-R; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00261; FU; 5. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 2. DR SUPFAM; SSF52058; L domain-like; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative splicing; KW Amyotrophic lateral sclerosis; Apoptosis; ATP-binding; Cell membrane; KW Developmental protein; Disease variant; Disulfide bond; Glycoprotein; KW Kinase; Lactation; Membrane; Mitochondrion; Neurodegeneration; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Receptor; Reference proteome; Repeat; Signal; Transcription; KW Transcription regulation; Transferase; Transmembrane; Transmembrane helix; KW Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..25 FT /evidence="ECO:0000255" FT CHAIN 26..1308 FT /note="Receptor tyrosine-protein kinase erbB-4" FT /id="PRO_0000016674" FT CHAIN 676..1308 FT /note="ERBB4 intracellular domain" FT /evidence="ECO:0000250" FT /id="PRO_0000396797" FT TOPO_DOM 26..651 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 652..675 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 676..1308 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 718..985 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1117..1150 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 676..684 FT /note="Nuclear localization signal" FT MOTIF 1032..1035 FT /note="PPxY motif 1" FT MOTIF 1053..1056 FT /note="PPxY motif 2" FT MOTIF 1298..1301 FT /note="PPxY motif 3" FT MOTIF 1306..1308 FT /note="PDZ-binding" FT ACT_SITE 843 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 724..732 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 751 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 797..799 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 843..848 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 875 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1035 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1056 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:17120616, FT ECO:0000269|PubMed:18721752, ECO:0000269|PubMed:8617750" FT MOD_RES 1150 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1162 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1188 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752, FT ECO:0000269|PubMed:8617750" FT MOD_RES 1202 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1242 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752, FT ECO:0000269|PubMed:8617750" FT MOD_RES 1258 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1284 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT CARBOHYD 138 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 174 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 181 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 253 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 358 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 410 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 473 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 495 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 548 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 576 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 620 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 29..56 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 156..186 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 189..197 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 193..205 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 213..221 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 217..229 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 230..238 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 234..246 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 249..258 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 262..289 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 293..304 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 308..323 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 326..330 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 503..512 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 507..520 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 523..532 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 536..552 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 555..569 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 559..577 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 580..589 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 593..614 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 617..625 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 621..633 FT /evidence="ECO:0000269|PubMed:16203964" FT VAR_SEQ 626..648 FT /note="NGPTSHDCIYYPWTGHSTLPQHA -> IGSSIEDCIGLMD (in isoform FT JM-B CYT-1 and isoform JM-B CYT-2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:9334263" FT /id="VSP_002895" FT VAR_SEQ 1046..1061 FT /note="Missing (in isoform JM-A CYT-2 and isoform JM-B CYT- FT 2)" FT /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.4" FT /id="VSP_022148" FT VARIANT 140 FT /note="T -> I (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042113" FT VARIANT 303 FT /note="S -> Y (in a lung squamous cell carcinoma sample; FT somatic mutation; dbSNP:rs1484791833)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042114" FT VARIANT 927 FT /note="R -> Q (in ALS19; reduces autophosphorylation upon FT NRG1 stimulation; dbSNP:rs397514262)" FT /evidence="ECO:0000269|PubMed:24119685" FT /id="VAR_070810" FT VARIANT 1275 FT /note="R -> W (in ALS19; reduces autophosphorylation upon FT NRG1 stimulation; dbSNP:rs397514263)" FT /evidence="ECO:0000269|PubMed:24119685" FT /id="VAR_070811" FT MUTAGEN 646 FT /note="Q->C: Constitutively activated kinase." FT /evidence="ECO:0000269|PubMed:17120616" FT MUTAGEN 675 FT /note="V->A: Abolishes proteolytic processing and nuclear FT localization." FT /evidence="ECO:0000269|PubMed:15746097, FT ECO:0000269|PubMed:17638867" FT MUTAGEN 681..684 FT /note="KKKR->EIMG: Abolishes nuclear localization of the FT ERBB4 intracellular domain." FT /evidence="ECO:0000269|PubMed:15534001" FT MUTAGEN 710 FT /note="L->N: Strongly reduced autophosphorylation." FT /evidence="ECO:0000269|PubMed:18287036" FT MUTAGEN 721 FT /note="V->I: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 751 FT /note="K->R: Abolishes kinase activity. Abolishes FT phosphorylation, proteolytic processing and nuclear FT localization." FT /evidence="ECO:0000269|PubMed:11390655, FT ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867" FT MUTAGEN 766 FT /note="M->R: Strongly reduced autophosphorylation." FT /evidence="ECO:0000269|PubMed:18287036" FT MUTAGEN 773 FT /note="A->S: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 782 FT /note="R->Q: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 810 FT /note="E->K: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 843 FT /note="D->N: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:16978839" FT MUTAGEN 854 FT /note="P->Q: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 861 FT /note="D->Y: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 864 FT /note="L->R: Strongly reduced autophosphorylation." FT /evidence="ECO:0000269|PubMed:18287036" FT MUTAGEN 872 FT /note="E->K: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 926 FT /note="T->M: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 947 FT /note="I->R: Constitutively autophosphorylated." FT /evidence="ECO:0000269|PubMed:18287036" FT MUTAGEN 992 FT /note="R->A: Abolishes APC/C-mediated degradation; when FT associated with A-995 and A-1000." FT /evidence="ECO:0000269|PubMed:17638867" FT MUTAGEN 995 FT /note="L->A: Abolishes APC/C-mediated degradation; when FT associated with A-992 and A-1000." FT /evidence="ECO:0000269|PubMed:17638867" FT MUTAGEN 1000 FT /note="D->A: Abolishes APC/C-mediated degradation; when FT associated with A-992 and A-995." FT /evidence="ECO:0000269|PubMed:17638867" FT MUTAGEN 1035 FT /note="Y->A: No effect on interaction with WWOX. Abolishes FT interaction with WWOX; when associated with A-1301." FT /evidence="ECO:0000269|PubMed:16061658" FT MUTAGEN 1056 FT /note="Y->A: Abolishes interaction with NEDD4 and impairs FT ubiquitination. Promotes nuclear translocation of ERBB4 FT intracellular domain E4ICD1." FT /evidence="ECO:0000269|PubMed:19561640" FT MUTAGEN 1056 FT /note="Y->F: Abolishes interaction with WWP1; when FT associated with F-1301." FT /evidence="ECO:0000269|PubMed:19561640" FT MUTAGEN 1301 FT /note="Y->A: Abolishes interaction with NEDD4 and impairs FT ubiquitination." FT /evidence="ECO:0000269|PubMed:12807903, FT ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:19561640" FT MUTAGEN 1301 FT /note="Y->A: No effect on interaction with WWOX. Abolishes FT interaction with WWOX; when associated with A-1035. Loss of FT interaction with YAP1 and stimulation of transcription." FT /evidence="ECO:0000269|PubMed:12807903, FT ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:19561640" FT MUTAGEN 1301 FT /note="Y->F: Abolishes interaction with WWP1; when FT associated with F-1056." FT /evidence="ECO:0000269|PubMed:12807903, FT ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:19561640" FT STRAND 28..30 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 38..41 FT /evidence="ECO:0007829|PDB:3U7U" FT HELIX 42..53 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 57..61 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 63..67 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 75..79 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 82..85 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 87..91 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 95..98 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 112..114 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 115..120 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 125..128 FT /evidence="ECO:0007829|PDB:3U2P" FT STRAND 133..135 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 144..150 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 158..160 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 163..165 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 167..169 FT /evidence="ECO:0007829|PDB:8U4L" FT HELIX 173..175 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 176..178 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 191..193 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 197..201 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 202..204 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 209..213 FT /evidence="ECO:0007829|PDB:8U4L" FT STRAND 221..225 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 226..228 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 234..242 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 245..254 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 257..261 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 265..269 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 270..273 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 274..277 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 283..285 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 288..292 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 298..300 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 303..307 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 312..317 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 320..325 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 327..329 FT /evidence="ECO:0007829|PDB:3U2P" FT STRAND 333..335 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 340..342 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 350..352 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 353..356 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 360..364 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 366..368 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 370..374 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 377..379 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 386..394 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 397..400 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 402..405 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 415..417 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 425..427 FT /evidence="ECO:0007829|PDB:8U4L" FT STRAND 432..438 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 455..461 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 469..471 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 474..476 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 479..482 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 485..487 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 489..491 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 493..497 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 498..500 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 512..516 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 519..528 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 531..534 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 537..543 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 545..548 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 551..554 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 568..573 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 576..585 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 588..592 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 595..608 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 612..616 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 625..629 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 630..632 FT /evidence="ECO:0007829|PDB:8U4L" FT HELIX 651..676 FT /evidence="ECO:0007829|PDB:2L2T" FT HELIX 715..717 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 718..729 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 731..737 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 740..743 FT /evidence="ECO:0007829|PDB:3BBT" FT STRAND 746..752 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 762..773 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 778..780 FT /evidence="ECO:0007829|PDB:3BBT" FT STRAND 783..787 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 789..791 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 793..797 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 804..810 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 812..814 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 817..836 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 846..848 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 849..853 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 856..859 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 864..869 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 884..886 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 889..893 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 899..914 FT /evidence="ECO:0007829|PDB:2R4B" FT TURN 920..923 FT /evidence="ECO:0007829|PDB:2R4B" FT TURN 926..928 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 929..934 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 947..955 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 961..963 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 967..977 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 981..983 FT /evidence="ECO:0007829|PDB:2R4B" SQ SEQUENCE 1308 AA; 146808 MW; 5E4AE80985D88761 CRC64; MKPATGLWVW VSLLVAAGTV QPSDSQSVCA GTENKLSSLS DLEQQYRALR KYYENCEVVM GNLEITSIEH NRDLSFLRSV REVTGYVLVA LNQFRYLPLE NLRIIRGTKL YEDRYALAIF LNYRKDGNFG LQELGLKNLT EILNGGVYVD QNKFLCYADT IHWQDIVRNP WPSNLTLVST NGSSGCGRCH KSCTGRCWGP TENHCQTLTR TVCAEQCDGR CYGPYVSDCC HRECAGGCSG PKDTDCFACM NFNDSGACVT QCPQTFVYNP TTFQLEHNFN AKYTYGAFCV KKCPHNFVVD SSSCVRACPS SKMEVEENGI KMCKPCTDIC PKACDGIGTG SLMSAQTVDS SNIDKFINCT KINGNLIFLV TGIHGDPYNA IEAIDPEKLN VFRTVREITG FLNIQSWPPN MTDFSVFSNL VTIGGRVLYS GLSLLILKQQ GITSLQFQSL KEISAGNIYI TDNSNLCYYH TINWTTLFST INQRIVIRDN RKAENCTAEG MVCNHLCSSD GCWGPGPDQC LSCRRFSRGR ICIESCNLYD GEFREFENGS ICVECDPQCE KMEDGLLTCH GPGPDNCTKC SHFKDGPNCV EKCPDGLQGA NSFIFKYADP DRECHPCHPN CTQGCNGPTS HDCIYYPWTG HSTLPQHART PLIAAGVIGG LFILVIVGLT FAVYVRRKSI KKKRALRRFL ETELVEPLTP SGTAPNQAQL RILKETELKR VKVLGSGAFG TVYKGIWVPE GETVKIPVAI KILNETTGPK ANVEFMDEAL IMASMDHPHL VRLLGVCLSP TIQLVTQLMP HGCLLEYVHE HKDNIGSQLL LNWCVQIAKG MMYLEERRLV HRDLAARNVL VKSPNHVKIT DFGLARLLEG DEKEYNADGG KMPIKWMALE CIHYRKFTHQ SDVWSYGVTI WELMTFGGKP YDGIPTREIP DLLEKGERLP QPPICTIDVY MVMVKCWMID ADSRPKFKEL AAEFSRMARD PQRYLVIQGD DRMKLPSPND SKFFQNLLDE EDLEDMMDAE EYLVPQAFNI PPPIYTSRAR IDSNRSEIGH SPPPAYTPMS GNQFVYRDGG FAAEQGVSVP YRAPTSTIPE APVAQGATAE IFDDSCCNGT LRKPVAPHVQ EDSSTQRYSA DPTVFAPERS PRGELDEEGY MTPMRDKPKQ EYLNPVEENP FVSRRKNGDL QALDNPEYHN ASNGPPKAED EYVNEPLYLN TFANTLGKAE YLKNNILSMP EKAKKAFDNP DYWNHSLPPR STLQHPDYLQ EYSTKYFYKQ NGRIRPIVAE NPEYLSEFSL KPGTVLPPPP YRHRNTVV // ID ERN1_HUMAN Reviewed; 977 AA. AC O75460; A1L457; A8K8N8; A8MXS7; Q59EE2; DT 16-AUG-2004, integrated into UniProtKB/Swiss-Prot. DT 01-JUL-2008, sequence version 2. DT 28-JAN-2026, entry version 226. DE RecName: Full=Serine/threonine-protein kinase/endoribonuclease IRE1 {ECO:0000305}; DE AltName: Full=Endoplasmic reticulum-to-nucleus signaling 1 {ECO:0000303|PubMed:9637683}; DE AltName: Full=Inositol-requiring protein 1 {ECO:0000303|PubMed:9637683}; DE Short=hIRE1p {ECO:0000303|PubMed:9637683}; DE AltName: Full=Ire1-alpha {ECO:0000303|PubMed:11779464}; DE Short=IRE1a {ECO:0000303|PubMed:11779464}; DE Includes: DE RecName: Full=Serine/threonine-protein kinase; DE EC=2.7.11.1 {ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:9637683}; DE Includes: DE RecName: Full=Endoribonuclease; DE EC=3.1.26.- {ECO:0000269|PubMed:21317875, ECO:0000305|PubMed:30118681}; DE Flags: Precursor; GN Name=ERN1 {ECO:0000312|HGNC:HGNC:3449}; GN Synonyms=IRE1 {ECO:0000312|EMBL:AAC25991.1}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305, ECO:0000312|EMBL:AAC25991.1} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, ACTIVITY REGULATION, RP COFACTOR, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AUTOPHOSPHORYLATION, RP GLYCOSYLATION, AND MUTAGENESIS OF LYS-599. RC TISSUE=Liver {ECO:0000312|EMBL:AAC25991.1}; RX PubMed=9637683; DOI=10.1101/gad.12.12.1812; RA Tirasophon W., Welihinda A.A., Kaufman R.J.; RT "A stress response pathway from the endoplasmic reticulum to the nucleus RT requires a novel bifunctional protein kinase/endoribonuclease (Ire1p) in RT mammalian cells."; RL Genes Dev. 12:1812-1824(1998). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Endothelial cell; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE SEQUENCE RP [LARGE SCALE MRNA] OF 2-977 (ISOFORM 2). RC TISSUE=Brain, and Leukocyte; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP FUNCTION. RX PubMed=11779464; DOI=10.1016/s0092-8674(01)00611-0; RA Yoshida H., Matsui T., Yamamoto A., Okada T., Mori K.; RT "XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress RT to produce a highly active transcription factor."; RL Cell 107:881-891(2001). RN [8] RP INTERACTION WITH TAOK3 AND TRAF2. RX PubMed=11278723; DOI=10.1074/jbc.m010677200; RA Yoneda T., Imaizumi K., Oono K., Yui D., Gomi F., Katayama T., Tohyama M.; RT "Activation of caspase-12, an endoplastic reticulum (ER) resident caspase, RT through tumor necrosis factor receptor-associated factor 2-dependent RT mechanism in response to the ER stress."; RL J. Biol. Chem. 276:13935-13940(2001). RN [9] {ECO:0000305} RP FUNCTION, AND MUTAGENESIS OF LYS-599. RX PubMed=11175748; DOI=10.1038/35055065; RA Iwawaki T., Hosoda A., Okuda T., Kamigori Y., Nomura-Furuwatari C., RA Kimata Y., Tsuru A., Kohno K.; RT "Translational control by the ER transmembrane kinase/ribonuclease IRE1 RT under ER stress."; RL Nat. Cell Biol. 3:158-164(2001). RN [10] {ECO:0000305} RP FUNCTION, HOMODIMERIZATION, ACTIVITY REGULATION, INTERACTION WITH HSPA5, RP AND MUTAGENESIS OF CYS-109; CYS-148 AND CYS-332. RX PubMed=12637535; DOI=10.1074/jbc.m300418200; RA Liu C.Y., Xu Z., Kaufman R.J.; RT "Structure and intermolecular interactions of the luminal dimerization RT domain of human IRE1alpha."; RL J. Biol. Chem. 278:17680-17687(2003). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-973, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [12] RP FUNCTION, AND INTERACTION WITH TMBIM6. RX PubMed=19328063; DOI=10.1016/j.molcel.2009.02.017; RA Lisbona F., Rojas-Rivera D., Thielen P., Zamorano S., Todd D., Martinon F., RA Glavic A., Kress C., Lin J.H., Walter P., Reed J.C., Glimcher L.H., RA Hetz C.; RT "BAX inhibitor-1 is a negative regulator of the ER stress sensor RT IRE1alpha."; RL Mol. Cell 33:679-691(2009). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [14] RP ADP-RIBOSYLATION BY PARP16. RX PubMed=23103912; DOI=10.1038/ncb2593; RA Jwa M., Chang P.; RT "PARP16 is a tail-anchored endoplasmic reticulum protein required for the RT PERK-and IRE1alpha-mediated unfolded protein response."; RL Nat. Cell Biol. 14:1223-1230(2012). RN [15] RP SUBUNIT, AND INTERACTION WITH DNAJB9 AND HSPA5. RX PubMed=29198525; DOI=10.1016/j.cell.2017.10.040; RA Amin-Wetzel N., Saunders R.A., Kamphuis M.J., Rato C., Preissler S., RA Harding H.P., Ron D.; RT "A J-Protein co-chaperone recruits bip to monomerize IRE1 and repress the RT unfolded protein response."; RL Cell 171:1625-1637(2017). RN [16] RP INTERACTION WITH RNF13. RX PubMed=23378536; DOI=10.1074/jbc.m112.368829; RA Arshad M., Ye Z., Gu X., Wong C.K., Liu Y., Li D., Zhou L., Zhang Y., RA Bay W.P., Yu V.C., Li P.; RT "RNF13, a RING finger protein, mediates endoplasmic reticulum stress- RT induced apoptosis through the inositol-requiring enzyme (IRE1alpha)/c-Jun RT NH2-terminal kinase pathway."; RL J. Biol. Chem. 288:8726-8736(2013). RN [17] RP INTERACTION WITH LACC1. RX PubMed=31875558; DOI=10.1016/j.celrep.2019.11.105; RA Huang C., Hedl M., Ranjan K., Abraham C.; RT "LACC1 required for NOD2-induced, ER stress-mediated innate immune outcomes RT in human macrophages and LACC1 risk variants modulate these outcomes."; RL Cell Rep. 29:4525-4539(2019). RN [18] RP FUNCTION. RX PubMed=21884936; DOI=10.1016/j.cell.2011.07.021; RA Gee H.Y., Noh S.H., Tang B.L., Kim K.H., Lee M.G.; RT "Rescue of DeltaF508-CFTR trafficking via a GRASP-dependent unconventional RT secretion pathway."; RL Cell 146:746-760(2011). RN [19] RP FUNCTION, INTERACTION WITH PDIA6, SUBUNIT, AND MUTAGENESIS OF CYS-148. RX PubMed=24508390; DOI=10.1016/j.molcel.2014.01.004; RA Eletto D., Eletto D., Dersh D., Gidalevitz T., Argon Y.; RT "Protein disulfide isomerase A6 controls the decay of IRE1alpha signaling RT via disulfide-dependent association."; RL Mol. Cell 53:562-576(2014). RN [20] RP FUNCTION, INTERACTION WITH DDRGK1, AND PHOSPHORYLATION. RX PubMed=28128204; DOI=10.1038/ncomms14186; RA Liu J., Wang Y., Song L., Zeng L., Yi W., Liu T., Chen H., Wang M., Ju Z., RA Cong Y.S.; RT "A critical role of DDRGK1 in endoplasmic reticulum homoeostasis via RT regulation of IRE1alpha stability."; RL Nat. Commun. 8:14186-14186(2017). RN [21] RP FUNCTION. RX PubMed=28067262; DOI=10.1038/srep39887; RA Piao H., Kim J., Noh S.H., Kweon H.S., Kim J.Y., Lee M.G.; RT "Sec16A is critical for both conventional and unconventional secretion of RT CFTR."; RL Sci. Rep. 7:39887-39887(2017). RN [22] RP FUNCTION, CATALYTIC ACTIVITY, SUBUNIT, AND PHOSPHORYLATION AT SER-724 AND RP SER-729. RX PubMed=30118681; DOI=10.1016/j.molcel.2018.06.038; RA Chang T.K., Lawrence D.A., Lu M., Tan J., Harnoss J.M., Marsters S.A., RA Liu P., Sandoval W., Martin S.E., Ashkenazi A.; RT "Coordination between Two Branches of the Unfolded Protein Response RT Determines Apoptotic Cell Fate."; RL Mol. Cell 71:629-636.e5(2018). RN [23] RP INTERACTION WITH P4HB, AND MUTAGENESIS OF CYS-109; CYS-148 AND CYS-332. RX PubMed=32149426; DOI=10.15252/embj.2019103841; RA Yu J., Li T., Liu Y., Wang X., Zhang J., Wang X., Shi G., Lou J., Wang L., RA Wang C.C., Wang L.; RT "Phosphorylation switches protein disulfide isomerase activity to maintain RT proteostasis and attenuate ER stress."; RL EMBO J. 39:e103841-e103841(2020). RN [24] RP FUNCTION, INTERACTION WITH MANF AND HSPA5, INDUCTION, AND PHOSPHORYLATION RP AT SER-724. RX PubMed=36739529; DOI=10.1016/j.celrep.2023.112066; RA Kovaleva V., Yu L.Y., Ivanova L., Shpironok O., Nam J., Eesmaa A., RA Kumpula E.P., Sakson S., Toots U., Ustav M., Huiskonen J.T., RA Voutilainen M.H., Lindholm P., Karelson M., Saarma M.; RT "MANF regulates neuronal survival and UPR through its ER-located receptor RT IRE1alpha."; RL Cell Rep. 42:112066-112066(2023). RN [25] {ECO:0007744|PDB:2HZ6} RP X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 24-390, SUBUNIT, AND MUTAGENESIS RP OF GLN-105; ASP-123 AND TRP-125. RX PubMed=16973740; DOI=10.1073/pnas.0606480103; RA Zhou J., Liu C.Y., Back S.H., Clark R.L., Peisach D., Xu Z., Kaufman R.J.; RT "The crystal structure of human IRE1 luminal domain reveals a conserved RT dimerization interface required for activation of the unfolded protein RT response."; RL Proc. Natl. Acad. Sci. U.S.A. 103:14343-14348(2006). RN [26] {ECO:0007744|PDB:3P23} RP X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 547-977 IN COMPLEX WITH ADP, RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AUTOPHOSPHORYLATION, AND RP COFACTOR. RX PubMed=21317875; DOI=10.1038/emboj.2011.18; RA Ali M.M., Bagratuni T., Davenport E.L., Nowak P.R., Silva-Santisteban M.C., RA Hardcastle A., McAndrews C., Rowlands M.G., Morgan G.J., Aherne W., RA Collins I., Davies F.E., Pearl L.H.; RT "Structure of the Ire1 autophosphorylation complex and implications for the RT unfolded protein response."; RL EMBO J. 30:894-905(2011). RN [27] RP VARIANTS [LARGE SCALE ANALYSIS] SER-244; MET-418; ARG-474; TRP-635; RP SER-700; PHE-769 AND LEU-830. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase and endoribonuclease that CC acts as a key sensor for the endoplasmic reticulum unfolded protein CC response (UPR) (PubMed:11175748, PubMed:11779464, PubMed:12637535, CC PubMed:19328063, PubMed:21317875, PubMed:28128204, PubMed:30118681, CC PubMed:36739529, PubMed:9637683). In unstressed cells, the endoplasmic CC reticulum luminal domain is maintained in its inactive monomeric state CC by binding to the endoplasmic reticulum chaperone HSPA5/BiP CC (PubMed:21317875). Accumulation of misfolded proteins in the CC endoplasmic reticulum causes release of HSPA5/BiP, allowing the luminal CC domain to homodimerize, promoting autophosphorylation of the kinase CC domain and subsequent activation of the endoribonuclease activity CC (PubMed:21317875). The endoribonuclease activity is specific for XBP1 CC mRNA and excises 26 nucleotides from XBP1 mRNA (PubMed:11779464, CC PubMed:21317875, PubMed:24508390). The resulting spliced transcript of CC XBP1 encodes a transcriptional activator protein that up-regulates CC expression of UPR target genes (PubMed:11779464, PubMed:21317875, CC PubMed:24508390). Acts as an upstream signal for ER stress-induced CC GORASP2-mediated unconventional (ER/Golgi-independent) trafficking of CC CFTR to cell membrane by modulating the expression and localization of CC SEC16A (PubMed:21884936, PubMed:28067262). CC {ECO:0000269|PubMed:11175748, ECO:0000269|PubMed:11779464, CC ECO:0000269|PubMed:12637535, ECO:0000269|PubMed:19328063, CC ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:21884936, CC ECO:0000269|PubMed:28067262, ECO:0000269|PubMed:28128204, CC ECO:0000269|PubMed:30118681, ECO:0000269|PubMed:36739529, CC ECO:0000269|PubMed:9637683, ECO:0000305|PubMed:24508390}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:9637683}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:9637683}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:9637683}; CC -!- ACTIVITY REGULATION: The kinase domain is activated by trans- CC autophosphorylation following homodimerization (PubMed:12637535, CC PubMed:9637683). Kinase activity is required for activation of the CC endoribonuclease domain (PubMed:12637535, PubMed:9637683). CC Endoribonuclease activity is specifically inhibited by hydroxy-aryl- CC aldehydes (HAA) (By similarity). {ECO:0000250|UniProtKB:Q9EQY0, CC ECO:0000269|PubMed:12637535, ECO:0000269|PubMed:9637683}. CC -!- SUBUNIT: Monomer (PubMed:16973740, PubMed:29198525). Homodimer; CC disulfide-linked; homodimerization takes place in response to CC endoplasmic reticulum stress and promotes activation of the kinase and CC endoribonuclease activities (PubMed:12637535, PubMed:16973740, CC PubMed:21317875, PubMed:24508390, PubMed:30118681). Dimer formation is CC driven by hydrophobic interactions within the N-terminal luminal CC domains and stabilized by disulfide bridges (PubMed:12637535). CC Interacts (via the luminal region) with DNAJB9/ERdj4; interaction takes CC place in unstressed cells and promotes recruitment of HSPA5/BiP CC (PubMed:29198525). Interacts (via the luminal region) with HSPA5/BiP; CC HSPA5/BiP is a negative regulator of the unfolded protein response CC (UPR) that prevents homodimerization of ERN1/IRE1 and subsequent CC activation of the protein (PubMed:12637535, PubMed:29198525, CC PubMed:36739529). Interaction with HSPA5 also competitively inhibits CC ERN1 interaction with MANF (PubMed:36739529). Interacts with PDIA6, a CC negative regulator of the UPR; the interaction is direct and disrupts CC homodimerization (PubMed:24508390). Interacts with DAB2IP (via PH CC domain); the interaction occurs in a endoplasmic reticulum stress- CC induced dependent manner and is required for subsequent recruitment of CC TRAF2 to ERN1/IRE1 (By similarity). Interacts with TAOK3 and TRAF2 CC (PubMed:11278723). Interacts with RNF13 (PubMed:23378536). Interacts CC with LACC1 (PubMed:31875558). Interacts (when unphosphorylated) with CC DDRGK1; interaction is dependent on UFM1 and takes place in response to CC endoplasmic reticulum stress, regulating ERN1/IRE1-alpha stability CC (PubMed:28128204). Interacts (via N-terminus) with P4HB/PDIA1; the CC interaction is enhanced by phosphorylation of P4HB by FAM20C in CC response to endoplasmic reticulum stress and results in attenuation of CC ERN1 activity (PubMed:32149426). Interacts with TMBIM6; this CC interaction inhibits ERN1 activity (PubMed:19328063). Interacts (via CC luminal domain) with MANF (via C-terminus); the interaction is CC decreased in the presence of increasing concentrations of Ca(2+) CC (PubMed:36739529). {ECO:0000250|UniProtKB:Q9EQY0, CC ECO:0000269|PubMed:11278723, ECO:0000269|PubMed:12637535, CC ECO:0000269|PubMed:16973740, ECO:0000269|PubMed:19328063, CC ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:23378536, CC ECO:0000269|PubMed:24508390, ECO:0000269|PubMed:28128204, CC ECO:0000269|PubMed:29198525, ECO:0000269|PubMed:30118681, CC ECO:0000269|PubMed:31875558, ECO:0000269|PubMed:32149426, CC ECO:0000269|PubMed:36739529}. CC -!- INTERACTION: CC O75460; Q07812: BAX; NbExp=2; IntAct=EBI-371750, EBI-516580; CC O75460; O75460: ERN1; NbExp=2; IntAct=EBI-371750, EBI-371750; CC O75460; P11021: HSPA5; NbExp=3; IntAct=EBI-371750, EBI-354921; CC O75460; Q86TM6: SYVN1; NbExp=2; IntAct=EBI-371750, EBI-947849; CC O75460; Q9H2K8: TAOK3; NbExp=3; IntAct=EBI-371750, EBI-1384100; CC O75460; Q12933: TRAF2; NbExp=3; IntAct=EBI-371750, EBI-355744; CC O75460; Q969M3: YIPF5; NbExp=3; IntAct=EBI-371750, EBI-2124787; CC O75460; O08734: Bak1; Xeno; NbExp=2; IntAct=EBI-371750, EBI-822441; CC O75460; Q07813: Bax; Xeno; NbExp=2; IntAct=EBI-371750, EBI-700711; CC O75460; P20029: Hspa5; Xeno; NbExp=2; IntAct=EBI-371750, EBI-772325; CC O75460-1; O75460-1: ERN1; NbExp=5; IntAct=EBI-15600828, EBI-15600828; CC O75460-1; P11021: HSPA5; NbExp=4; IntAct=EBI-15600828, EBI-354921; CC O75460-1; Q13438: OS9; NbExp=2; IntAct=EBI-15600828, EBI-725454; CC O75460-1; Q9UBV2: SEL1L; NbExp=2; IntAct=EBI-15600828, EBI-358766; CC O75460-1; Q86TM6: SYVN1; NbExp=3; IntAct=EBI-15600828, EBI-947849; CC O75460-2; Q6DHV7-2: ADAL; NbExp=3; IntAct=EBI-25852368, EBI-18899653; CC O75460-2; Q96MA6: AK8; NbExp=3; IntAct=EBI-25852368, EBI-8466265; CC O75460-2; Q66PJ3-4: ARL6IP4; NbExp=3; IntAct=EBI-25852368, EBI-5280499; CC O75460-2; Q9UBL3: ASH2L; NbExp=3; IntAct=EBI-25852368, EBI-540797; CC O75460-2; Q96FT7-4: ASIC4; NbExp=3; IntAct=EBI-25852368, EBI-9089489; CC O75460-2; Q8TBE0: BAHD1; NbExp=3; IntAct=EBI-25852368, EBI-742750; CC O75460-2; Q9NNX6-10: CD209; NbExp=3; IntAct=EBI-25852368, EBI-12300031; CC O75460-2; P38936: CDKN1A; NbExp=3; IntAct=EBI-25852368, EBI-375077; CC O75460-2; Q96EY1-3: DNAJA3; NbExp=3; IntAct=EBI-25852368, EBI-11526226; CC O75460-2; Q92782-2: DPF1; NbExp=3; IntAct=EBI-25852368, EBI-23669343; CC O75460-2; O77932: DXO; NbExp=3; IntAct=EBI-25852368, EBI-372173; CC O75460-2; Q06547-2: GABPB1; NbExp=3; IntAct=EBI-25852368, EBI-618189; CC O75460-2; Q06547-3: GABPB1; NbExp=3; IntAct=EBI-25852368, EBI-9088619; CC O75460-2; P52655: GTF2A1; NbExp=3; IntAct=EBI-25852368, EBI-389518; CC O75460-2; Q0VD86: INCA1; NbExp=3; IntAct=EBI-25852368, EBI-6509505; CC O75460-2; Q92615: LARP4B; NbExp=3; IntAct=EBI-25852368, EBI-1052558; CC O75460-2; Q6PHZ7: NR2C2; NbExp=3; IntAct=EBI-25852368, EBI-2802743; CC O75460-2; Q6GQQ9-2: OTUD7B; NbExp=3; IntAct=EBI-25852368, EBI-25830200; CC O75460-2; Q8N2H9-4: PELI3; NbExp=3; IntAct=EBI-25852368, EBI-25852006; CC O75460-2; O15534: PER1; NbExp=3; IntAct=EBI-25852368, EBI-2557276; CC O75460-2; Q58EX7-2: PLEKHG4; NbExp=3; IntAct=EBI-25852368, EBI-21503705; CC O75460-2; Q5SXH7-1: PLEKHS1; NbExp=3; IntAct=EBI-25852368, EBI-26412802; CC O75460-2; Q14181: POLA2; NbExp=3; IntAct=EBI-25852368, EBI-712752; CC O75460-2; Q9UHI5: SLC7A8; NbExp=3; IntAct=EBI-25852368, EBI-13292283; CC O75460-2; O14544: SOCS6; NbExp=3; IntAct=EBI-25852368, EBI-3929549; CC O75460-2; Q496A3: SPATS1; NbExp=3; IntAct=EBI-25852368, EBI-3923692; CC O75460-2; Q8IUR5-4: TMTC1; NbExp=3; IntAct=EBI-25852368, EBI-9089156; CC O75460-2; P49459: UBE2A; NbExp=3; IntAct=EBI-25852368, EBI-2339348; CC O75460-2; Q9NX94: WBP1L; NbExp=3; IntAct=EBI-25852368, EBI-10316321; CC O75460-2; Q9BYN7-2: ZNF341; NbExp=3; IntAct=EBI-25852368, EBI-16435478; CC O75460-2; Q3KNS6-3: ZNF829; NbExp=3; IntAct=EBI-25852368, EBI-18036029; CC O75460-2; Q9BRT8: ZNG1A; NbExp=3; IntAct=EBI-25852368, EBI-1054417; CC -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane CC {ECO:0000269|PubMed:9637683}; Single-pass type I membrane protein CC {ECO:0000269|PubMed:9637683}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=O75460-1; Sequence=Displayed; CC Name=2; CC IsoId=O75460-2; Sequence=VSP_034582, VSP_034583; CC -!- TISSUE SPECIFICITY: Ubiquitously expressed. High levels observed in CC pancreatic tissue. {ECO:0000269|PubMed:9637683}. CC -!- INDUCTION: Induced by the ER stressor tunicamycin. CC {ECO:0000269|PubMed:36739529}. CC -!- PTM: Autophosphorylated following homodimerization. Autophosphorylation CC promotes activation of the endoribonuclease domain (PubMed:12637535, CC PubMed:21317875, PubMed:28128204, PubMed:9637683). In response to ER CC stress, phosphorylated at Ser-724, Ser-729 and possibly Ser-726; CC phosphorylation promotes oligomerization and endoribonuclease activity CC (PubMed:30118681). Dephosphorylated at Ser-724, Ser-729 and possibly CC Ser-726 by RPAP2 to abort failed ER-stress adaptation and trigger CC apoptosis (PubMed:30118681). Phosphorylated at Ser-724; in response to CC the ER stressor tunicamycin (PubMed:36739529). CC {ECO:0000269|PubMed:12637535, ECO:0000269|PubMed:21317875, CC ECO:0000269|PubMed:28128204, ECO:0000269|PubMed:30118681, CC ECO:0000269|PubMed:36739529, ECO:0000269|PubMed:9637683}. CC -!- PTM: ADP-ribosylated by PARP16 upon ER stress, which increases both CC kinase and endonuclease activities. {ECO:0000269|PubMed:23103912}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF059198; AAC25991.1; -; mRNA. DR EMBL; AK292403; BAF85092.1; -; mRNA. DR EMBL; DA254477; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AB209869; BAD93106.1; -; mRNA. DR EMBL; AC005803; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC025362; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471109; EAW94214.1; -; Genomic_DNA. DR EMBL; BC130405; AAI30406.1; -; mRNA. DR EMBL; BC130407; AAI30408.1; -; mRNA. DR EMBL; BI912495; -; NOT_ANNOTATED_CDS; mRNA. DR CCDS; CCDS45762.1; -. [O75460-1] DR RefSeq; NP_001424.3; NM_001433.5. [O75460-1] DR PDB; 2HZ6; X-ray; 3.10 A; A=24-390. DR PDB; 3P23; X-ray; 2.70 A; A/B/C/D=547-977. DR PDB; 4U6R; X-ray; 2.50 A; A=547-977. DR PDB; 4YZ9; X-ray; 2.46 A; A/B/C=562-966. DR PDB; 4YZC; X-ray; 2.49 A; A/B=562-966. DR PDB; 4YZD; X-ray; 3.10 A; A/B/C=562-966. DR PDB; 4Z7G; X-ray; 2.60 A; A/B=562-977. DR PDB; 4Z7H; X-ray; 2.90 A; A/B=562-977. DR PDB; 5HGI; X-ray; 2.58 A; A=547-977. DR PDB; 6HV0; X-ray; 2.73 A; A=562-977. DR PDB; 6HX1; X-ray; 2.14 A; A=562-964. DR PDB; 6SHC; X-ray; 3.55 A; A=24-390. DR PDB; 6URC; X-ray; 2.20 A; A/B=547-977. DR PDB; 6W39; X-ray; 1.74 A; A/B=547-977. DR PDB; 6W3A; X-ray; 2.61 A; A/B=547-977. DR PDB; 6W3B; X-ray; 2.57 A; A=547-977. DR PDB; 6W3C; X-ray; 2.30 A; A/B/C/D=547-977. DR PDB; 6W3E; X-ray; 2.74 A; A/B=547-977. DR PDB; 6W3K; X-ray; 2.08 A; A=547-977. DR PDB; 6XDB; X-ray; 2.45 A; A=547-977. DR PDB; 6XDD; X-ray; 2.40 A; A/B=547-977. DR PDB; 6XDF; X-ray; 2.54 A; A/B=547-977. DR PDB; 7BMK; X-ray; 1.85 A; A/B=547-977. DR PDB; 8UVL; X-ray; 2.43 A; A=547-977. DR PDBsum; 2HZ6; -. DR PDBsum; 3P23; -. DR PDBsum; 4U6R; -. DR PDBsum; 4YZ9; -. DR PDBsum; 4YZC; -. DR PDBsum; 4YZD; -. DR PDBsum; 4Z7G; -. DR PDBsum; 4Z7H; -. DR PDBsum; 5HGI; -. DR PDBsum; 6HV0; -. DR PDBsum; 6HX1; -. DR PDBsum; 6SHC; -. DR PDBsum; 6URC; -. DR PDBsum; 6W39; -. DR PDBsum; 6W3A; -. DR PDBsum; 6W3B; -. DR PDBsum; 6W3C; -. DR PDBsum; 6W3E; -. DR PDBsum; 6W3K; -. DR PDBsum; 6XDB; -. DR PDBsum; 6XDD; -. DR PDBsum; 6XDF; -. DR PDBsum; 7BMK; -. DR PDBsum; 8UVL; -. DR AlphaFoldDB; O75460; -. DR SMR; O75460; -. DR BioGRID; 108391; 71. DR CORUM; O75460; -. DR DIP; DIP-31711N; -. DR FunCoup; O75460; 1464. DR IntAct; O75460; 74. DR MINT; O75460; -. DR STRING; 9606.ENSP00000401445; -. DR BindingDB; O75460; -. DR ChEMBL; CHEMBL1163101; -. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB07382; N~2~-1H-benzimidazol-5-yl-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine. DR DrugCentral; O75460; -. DR GuidetoPHARMACOLOGY; 2020; -. DR TCDB; 8.A.104.1.9; the 5'-amp-activated protein kinase (ampk) family. DR GlyCosmos; O75460; 1 site, No reported glycans. DR GlyGen; O75460; 2 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; O75460; -. DR PhosphoSitePlus; O75460; -. DR BioMuta; ERN1; -. DR CPTAC; CPTAC-3100; -. DR CPTAC; CPTAC-3101; -. DR jPOST; O75460; -. DR MassIVE; O75460; -. DR PaxDb; 9606-ENSP00000401445; -. DR PeptideAtlas; O75460; -. DR ProteomicsDB; 50021; -. [O75460-1] DR Pumba; O75460; -. DR Antibodypedia; 4011; 736 antibodies from 44 providers. DR DNASU; 2081; -. DR Ensembl; ENST00000433197.4; ENSP00000401445.2; ENSG00000178607.17. [O75460-1] DR Ensembl; ENST00000606895.2; ENSP00000475519.1; ENSG00000178607.17. [O75460-2] DR GeneID; 2081; -. DR KEGG; hsa:2081; -. DR MANE-Select; ENST00000433197.4; ENSP00000401445.2; NM_001433.5; NP_001424.3. DR UCSC; uc002jdz.3; human. [O75460-1] DR AGR; HGNC:3449; -. DR ClinPGx; PA27861; -. DR CTD; 2081; -. DR DisGeNET; 2081; -. DR GeneCards; ERN1; -. DR HGNC; HGNC:3449; ERN1. DR HPA; ENSG00000178607; Tissue enhanced (adrenal gland, pancreas). DR MIM; 604033; gene. DR OpenTargets; ENSG00000178607; -. DR VEuPathDB; HostDB:ENSG00000178607; -. DR eggNOG; KOG1027; Eukaryota. DR GeneTree; ENSGT00940000159761; -. DR HOGENOM; CLU_004875_1_1_1; -. DR InParanoid; O75460; -. DR OMA; NYWVERF; -. DR OrthoDB; 63989at2759; -. DR PAN-GO; O75460; 6 GO annotations based on evolutionary models. DR PhylomeDB; O75460; -. DR PathwayCommons; O75460; -. DR Reactome; R-HSA-381070; IRE1alpha activates chaperones. DR SignaLink; O75460; -. DR SIGNOR; O75460; -. DR Agora; ENSG00000178607; -. DR BioGRID-ORCS; 2081; 13 hits in 1188 CRISPR screens. DR ChiTaRS; ERN1; human. DR EvolutionaryTrace; O75460; -. DR GeneWiki; ERN1; -. DR GenomeRNAi; 2081; -. DR Pharos; O75460; Tchem. DR PRO; PR:O75460; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; O75460; protein. DR Bgee; ENSG00000178607; Expressed in parotid gland and 159 other cell types or tissues. DR GO; GO:1990597; C:AIP1-IRE1 complex; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB. DR GO; GO:1990332; C:Ire1 complex; NAS:ParkinsonsUK-UCL. DR GO; GO:1990630; C:IRE1-RACK1-PP2A complex; IDA:ParkinsonsUK-UCL. DR GO; GO:1990604; C:IRE1-TRAF2-ASK1 complex; IDA:ParkinsonsUK-UCL. DR GO; GO:0005739; C:mitochondrion; IEA:Ensembl. DR GO; GO:0005637; C:nuclear inner membrane; IEA:Ensembl. DR GO; GO:0043531; F:ADP binding; IDA:ParkinsonsUK-UCL. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0030544; F:Hsp70 protein binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0051879; F:Hsp90 protein binding; IDA:ParkinsonsUK-UCL. DR GO; GO:0016787; F:hydrolase activity; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0005161; F:platelet-derived growth factor receptor binding; IPI:BHF-UCL. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0004521; F:RNA endonuclease activity; IDA:UniProtKB. DR GO; GO:0051082; F:unfolded protein binding; IBA:GO_Central. DR GO; GO:0071333; P:cellular response to glucose stimulus; IDA:ParkinsonsUK-UCL. DR GO; GO:0070301; P:cellular response to hydrogen peroxide; IEA:Ensembl. DR GO; GO:0034620; P:cellular response to unfolded protein; IDA:ParkinsonsUK-UCL. DR GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IDA:UniProtKB. DR GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; IDA:ParkinsonsUK-UCL. DR GO; GO:0001935; P:endothelial cell proliferation; IDA:UniProtKB. DR GO; GO:1901142; P:insulin metabolic process; IDA:ParkinsonsUK-UCL. DR GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; ISS:UniProtKB. DR GO; GO:0036498; P:IRE1-mediated unfolded protein response; IDA:UniProtKB. DR GO; GO:0006402; P:mRNA catabolic process; TAS:ParkinsonsUK-UCL. DR GO; GO:0070054; P:mRNA splicing, via endonucleolytic cleavage and ligation; IDA:UniProtKB. DR GO; GO:2001243; P:negative regulation of intrinsic apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:1900103; P:positive regulation of endoplasmic reticulum unfolded protein response; IMP:UniProtKB. DR GO; GO:0046330; P:positive regulation of JNK cascade; IDA:ParkinsonsUK-UCL. DR GO; GO:0033120; P:positive regulation of RNA splicing; IDA:UniProtKB. DR GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IMP:BHF-UCL. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0016241; P:regulation of macroautophagy; TAS:ParkinsonsUK-UCL. DR GO; GO:0034976; P:response to endoplasmic reticulum stress; IDA:ParkinsonsUK-UCL. DR CDD; cd09769; Luminal_IRE1; 1. DR CDD; cd10422; RNase_Ire1; 1. DR CDD; cd13982; STKc_IRE1; 1. DR FunFam; 2.130.10.10:FF:000225; Endoplasmic reticulum to nucleus-signaling 1; 1. DR FunFam; 3.30.200.20:FF:000077; Putative Serine/threonine-protein kinase/endoribonuclease IRE1; 1. DR FunFam; 1.20.1440.180:FF:000001; Serine/threonine-protein kinase/endoribonuclease IRE1; 1. DR FunFam; 1.10.510.10:FF:000215; serine/threonine-protein kinase/endoribonuclease IRE1 isoform X1; 1. DR Gene3D; 1.20.1440.180; KEN domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.130.10.10; YVTN repeat-like/Quinoprotein amine dehydrogenase; 1. DR InterPro; IPR045133; IRE1/2-like. DR InterPro; IPR010513; KEN_dom. DR InterPro; IPR038357; KEN_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR018391; PQQ_b-propeller_rpt. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR011047; Quinoprotein_ADH-like_sf. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf. DR PANTHER; PTHR13954; IRE1-RELATED; 1. DR PANTHER; PTHR13954:SF17; SERINE_THREONINE-PROTEIN KINASE_ENDORIBONUCLEASE IRE1; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF06479; Ribonuc_2-5A; 1. DR SMART; SM00564; PQQ; 5. DR SMART; SM00580; PUG; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF50998; Quinoprotein alcohol dehydrogenase-like; 1. DR PROSITE; PS51392; KEN; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; ADP-ribosylation; Alternative splicing; Apoptosis; KW ATP-binding; Disulfide bond; Endoplasmic reticulum; Glycoprotein; KW Hydrolase; Kinase; Magnesium; Membrane; Metal-binding; KW Multifunctional enzyme; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Signal; Transcription; KW Transcription regulation; Transferase; Transmembrane; Transmembrane helix; KW Unfolded protein response. FT SIGNAL 1..18 FT /evidence="ECO:0000255" FT CHAIN 19..977 FT /note="Serine/threonine-protein kinase/endoribonuclease FT IRE1" FT /id="PRO_0000024327" FT TOPO_DOM 19..443 FT /note="Lumenal" FT /evidence="ECO:0000255" FT TRANSMEM 444..464 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 465..977 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 571..832 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 835..963 FT /note="KEN" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00725" FT REGION 410..434 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 491..559 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 906..907 FT /note="Interacts with hydroxy-aryl-aldehyde inhibitors" FT /evidence="ECO:0000250|UniProtKB:Q9EQY0" FT COMPBIAS 410..419 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 513..552 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 688 FT /note="Proton acceptor" FT /evidence="ECO:0000250|UniProtKB:P32361, FT ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE- FT ProRule:PRU10027" FT BINDING 577..585 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:P32361, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 599 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:21317875, ECO:0000269|PubMed:9637683, FT ECO:0007744|PDB:3P23" FT BINDING 643..645 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:21317875, FT ECO:0007744|PDB:3P23" FT BINDING 690..693 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:21317875, FT ECO:0007744|PDB:3P23" FT BINDING 711 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:21317875, FT ECO:0007744|PDB:3P23" FT SITE 892 FT /note="Interacts with hydroxy-aryl-aldehyde inhibitors" FT /evidence="ECO:0000250|UniProtKB:Q9EQY0" FT MOD_RES 724 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:30118681, FT ECO:0000269|PubMed:36739529" FT MOD_RES 729 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:30118681" FT MOD_RES 973 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:19369195" FT CARBOHYD 176 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 19..70 FT /note="IFGSTSTVTLPETLLFVSTLDGSLHAVSKRTGSIKWTLKEDPVLQVPTHVEE FT -> VSDRGAWGGGQLATAGSGPGQRRGAGAGVRAGSATAAARCPVSPAVGGSGRA (in FT isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_034582" FT VAR_SEQ 71..977 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_034583" FT VARIANT 244 FT /note="N -> S (in a renal clear cell carcinoma sample; FT somatic mutation; dbSNP:rs1397145500)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040488" FT VARIANT 418 FT /note="V -> M (in dbSNP:rs55869215)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040489" FT VARIANT 474 FT /note="L -> R (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs186305118)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040490" FT VARIANT 635 FT /note="R -> W (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs146710304)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040491" FT VARIANT 700 FT /note="N -> S (in dbSNP:rs918253870)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040492" FT VARIANT 769 FT /note="S -> F (in a glioblastoma multiforme sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040493" FT VARIANT 830 FT /note="P -> L (in an ovarian serous carcinoma sample; FT somatic mutation; dbSNP:rs1279653488)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040494" FT MUTAGEN 105 FT /note="Q->E: Impaired ability to homodimerize." FT /evidence="ECO:0000269|PubMed:16973740" FT MUTAGEN 109 FT /note="C->S: No effect on dimerization. No effect on FT interaction with P4HB; when associated with S-148 and S- FT 332." FT /evidence="ECO:0000269|PubMed:12637535, FT ECO:0000269|PubMed:32149426" FT MUTAGEN 123 FT /note="D->P: Abolishes ability to homodimerize." FT /evidence="ECO:0000269|PubMed:16973740" FT MUTAGEN 125 FT /note="W->A: Abolishes ability to homodimerize." FT /evidence="ECO:0000269|PubMed:16973740" FT MUTAGEN 148 FT /note="C->S: No effect on dimerization. Weakens dimer; when FT associated with S-332. Abolishes interaction with PDIA6. FT Prolonged splicing of XBP1, probably due to prolonged FT activation of PDIA6. Inhibits formation of oxidized FT multimeric forms of ERN1 in response to ER stress. No FT effect on interaction with P4HB; when associated with S-109 FT and S-332." FT /evidence="ECO:0000269|PubMed:12637535, FT ECO:0000269|PubMed:24508390, ECO:0000269|PubMed:32149426" FT MUTAGEN 332 FT /note="C->S: No effect on dimerization. Weakens dimer; when FT associated with S-148. No effect on interaction with P4HB; FT when associated with S-109 and S-148." FT /evidence="ECO:0000269|PubMed:12637535, FT ECO:0000269|PubMed:32149426" FT MUTAGEN 599 FT /note="K->A: Loss of autophosphorylation and of FT endoribonuclease activity. Inhibition of growth arrest." FT /evidence="ECO:0000269|PubMed:11175748, FT ECO:0000269|PubMed:9637683" FT CONFLICT 190..191 FT /note="DV -> EG (in Ref. 1; AAC25991)" FT /evidence="ECO:0000305" FT CONFLICT 768 FT /note="I -> V (in Ref. 1; AAC25991)" FT /evidence="ECO:0000305" FT CONFLICT 816 FT /note="D -> G (in Ref. 2; BAF85092)" FT /evidence="ECO:0000305" FT CONFLICT 824..825 FT /note="KH -> ND (in Ref. 1; AAC25991)" FT /evidence="ECO:0000305" FT CONFLICT 880 FT /note="V -> D (in Ref. 1; AAC25991)" FT /evidence="ECO:0000305" FT CONFLICT 904 FT /note="M -> T (in Ref. 2; BAF85092)" FT /evidence="ECO:0000305" FT CONFLICT 924 FT /note="S -> T (in Ref. 1; AAC25991)" FT /evidence="ECO:0000305" FT STRAND 32..37 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 40..46 FT /evidence="ECO:0007829|PDB:2HZ6" FT TURN 47..49 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 52..57 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 73..75 FT /evidence="ECO:0007829|PDB:2HZ6" FT TURN 77..79 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 82..84 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 93..95 FT /evidence="ECO:0007829|PDB:2HZ6" FT HELIX 100..104 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 120..128 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 154..164 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 168..172 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 176..182 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 197..201 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 205..209 FT /evidence="ECO:0007829|PDB:2HZ6" FT TURN 211..213 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 216..221 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 226..231 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 238..240 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 243..246 FT /evidence="ECO:0007829|PDB:2HZ6" FT HELIX 247..264 FT /evidence="ECO:0007829|PDB:2HZ6" FT HELIX 273..279 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 280..284 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 286..288 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 297..300 FT /evidence="ECO:0007829|PDB:2HZ6" FT TURN 359..361 FT /evidence="ECO:0007829|PDB:2HZ6" FT STRAND 564..566 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 569..578 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 581..583 FT /evidence="ECO:0007829|PDB:6HX1" FT STRAND 585..591 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 594..601 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 603..605 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 606..619 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 628..633 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 638..643 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 645..648 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 649..654 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 655..657 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 658..661 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 665..681 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 691..693 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 694..697 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 701..703 FT /evidence="ECO:0007829|PDB:6W3E" FT STRAND 707..709 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 711..716 FT /evidence="ECO:0007829|PDB:6HX1" FT STRAND 718..721 FT /evidence="ECO:0007829|PDB:6HV0" FT STRAND 723..727 FT /evidence="ECO:0007829|PDB:6HX1" FT STRAND 729..731 FT /evidence="ECO:0007829|PDB:6HV0" FT TURN 732..736 FT /evidence="ECO:0007829|PDB:6HV0" FT HELIX 740..743 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 744..746 FT /evidence="ECO:0007829|PDB:6XDF" FT HELIX 754..768 FT /evidence="ECO:0007829|PDB:6W39" FT TURN 778..780 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 781..787 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 793..795 FT /evidence="ECO:0007829|PDB:4YZC" FT HELIX 800..812 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 817..819 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 823..827 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 830..832 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 835..848 FT /evidence="ECO:0007829|PDB:6W39" FT TURN 849..851 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 854..856 FT /evidence="ECO:0007829|PDB:4YZ9" FT HELIX 857..863 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 866..869 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 874..876 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 880..884 FT /evidence="ECO:0007829|PDB:6W39" FT TURN 887..890 FT /evidence="ECO:0007829|PDB:6W3K" FT HELIX 897..909 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 911..913 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 916..922 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 927..936 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 940..947 FT /evidence="ECO:0007829|PDB:6W39" FT HELIX 948..951 FT /evidence="ECO:0007829|PDB:6W39" FT STRAND 952..954 FT /evidence="ECO:0007829|PDB:3P23" FT HELIX 955..957 FT /evidence="ECO:0007829|PDB:6W39" FT TURN 958..960 FT /evidence="ECO:0007829|PDB:6W39" SQ SEQUENCE 977 AA; 109735 MW; A2DF808CCE015536 CRC64; MPARRLLLLL TLLLPGLGIF GSTSTVTLPE TLLFVSTLDG SLHAVSKRTG SIKWTLKEDP VLQVPTHVEE PAFLPDPNDG SLYTLGSKNN EGLTKLPFTI PELVQASPCR SSDGILYMGK KQDIWYVIDL LTGEKQQTLS SAFADSLCPS TSLLYLGRTE YTITMYDTKT RELRWNATYF DYAASLPEDD VDYKMSHFVS NGDGLVVTVD SESGDVLWIQ NYASPVVAFY VWQREGLRKV MHINVAVETL RYLTFMSGEV GRITKWKYPF PKETEAKSKL TPTLYVGKYS TSLYASPSMV HEGVAVVPRG STLPLLEGPQ TDGVTIGDKG ECVITPSTDV KFDPGLKSKN KLNYLRNYWL LIGHHETPLS ASTKMLERFP NNLPKHRENV IPADSEKKSF EEVINLVDQT SENAPTTVSR DVEEKPAHAP ARPEAPVDSM LKDMATIILS TFLLIGWVAF IITYPLSMHQ QQQLQHQQFQ KELEKIQLLQ QQQQQLPFHP PGDTAQDGEL LDTSGPYSES SGTSSPSTSP RASNHSLCSG SSASKAGSSP SLEQDDGDEE TSVVIVGKIS FCPKDVLGHG AEGTIVYRGM FDNRDVAVKR ILPECFSFAD REVQLLRESD EHPNVIRYFC TEKDRQFQYI AIELCAATLQ EYVEQKDFAH LGLEPITLLQ QTTSGLAHLH SLNIVHRDLK PHNILISMPN AHGKIKAMIS DFGLCKKLAV GRHSFSRRSG VPGTEGWIAP EMLSEDCKEN PTYTVDIFSA GCVFYYVISE GSHPFGKSLQ RQANILLGAC SLDCLHPEKH EDVIARELIE KMIAMDPQKR PSAKHVLKHP FFWSLEKQLQ FFQDVSDRIE KESLDGPIVK QLERGGRAVV KMDWRENITV PLQTDLRKFR TYKGGSVRDL LRAMRNKKHH YRELPAEVRE TLGSLPDDFV CYFTSRFPHL LAHTYRAMEL CSHERLFQPY YFHEPPEPQP PVTPDAL // ID FASTK_HUMAN Reviewed; 549 AA. AC Q14296; A8K867; F8VTW9; Q59EM8; Q8IVA0; DT 21-FEB-2001, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 196. DE RecName: Full=Fas-activated serine/threonine kinase; DE Short=FAST kinase; DE EC=2.7.11.1 {ECO:0000269|PubMed:7544399}; DE EC=2.7.11.8 {ECO:0000269|PubMed:7544399}; GN Name=FASTK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY, RP INTERACTION WITH TIA1 AND TIAR, PHOSPHORYLATION, AND DEPHOSPHORYLATION. RC TISSUE=Peripheral blood lymphocyte; RX PubMed=7544399; DOI=10.1084/jem.182.3.865; RA Tian Q., Taupin J.-L., Elledge S., Robertson M., Anderson P.; RT "Fas-activated serine/threonine kinase (FAST) phosphorylates TIA-1 during RT Fas-mediated apoptosis."; RL J. Exp. Med. 182:865-874(1995). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RT "Homo sapiens protein coding cDNA."; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12853948; DOI=10.1038/nature01782; RA Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H., RA Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K., RA Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A., RA Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H., RA Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A., RA Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P., RA Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M., RA Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S., RA Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., RA Strowmatt C., Latreille P., Miller N., Johnson D., Murray J., RA Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., RA Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., RA Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E., RA Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E., RA Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A., RA Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A., RA Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R., RA McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H., RA Wilson R.K.; RT "The DNA sequence of human chromosome 7."; RL Nature 424:157-164(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Brain, and Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP FUNCTION, AND INTERACTION WITH TIA1 AND TIAR. RX PubMed=17135269; DOI=10.1074/jbc.c600198200; RA Izquierdo J.M., Valcarcel J.; RT "Fas-activated serine/threonine kinase (FAST K) synergizes with TIA-1/TIAR RT proteins to regulate Fas alternative splicing."; RL J. Biol. Chem. 282:1539-1543(2007). RN [8] RP FUNCTION (ISOFORM 4), SUBCELLULAR LOCATION (ISOFORM 4), DOMAIN, RP RNA-BINDING, MUTAGENESIS OF MET-35, AND ALTERNATIVE INITIATION. RX PubMed=25704814; DOI=10.1016/j.celrep.2015.01.063; RA Jourdain A.A., Koppen M., Rodley C.D., Maundrell K., Gueguen N., RA Reynier P., Guaras A.M., Enriquez J.A., Anderson P., Simarro M., RA Martinou J.C.; RT "A mitochondria-specific isoform of FASTK is present in mitochondrial RNA RT granules and regulates gene expression and function."; RL Cell Rep. 10:1110-1121(2015). RN [9] RP VARIANT [LARGE SCALE ANALYSIS] LEU-424. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Phosphorylates the splicing regulator TIA1, thereby promoting CC the inclusion of FAS exon 6, which leads to an mRNA encoding a pro- CC apoptotic form of the receptor. {ECO:0000269|PubMed:17135269, CC ECO:0000269|PubMed:7544399}. CC -!- FUNCTION: [Isoform 4]: Required for the biogenesis of some CC mitochondrial-encoded mRNAs, specifically stabilizes ND6 (NADH CC dehydrogenase complex subunit 6) mRNA, and regulates its levels. CC {ECO:0000269|PubMed:25704814}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[Fas-activated protein] + ATP = O-phospho-L-seryl- CC [Fas-activated protein] + ADP + H(+); Xref=Rhea:RHEA:15881, CC Rhea:RHEA-COMP:13713, Rhea:RHEA-COMP:13714, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, ChEBI:CHEBI:83421, CC ChEBI:CHEBI:456216; EC=2.7.11.8; CC Evidence={ECO:0000269|PubMed:7544399}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[Fas-activated protein] + ATP = O-phospho-L- CC threonyl-[Fas-activated protein] + ADP + H(+); Xref=Rhea:RHEA:53920, CC Rhea:RHEA-COMP:13715, Rhea:RHEA-COMP:13716, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, CC ChEBI:CHEBI:456216; EC=2.7.11.8; CC Evidence={ECO:0000269|PubMed:7544399}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:7544399}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:7544399}; CC -!- SUBUNIT: Interacts with TIA1; the interactions leads to TIA1 CC phosphorylation (PubMed:17135269, PubMed:7544399). Interacts with TIAR CC (PubMed:17135269, PubMed:7544399). {ECO:0000269|PubMed:17135269, CC ECO:0000269|PubMed:7544399}. CC -!- INTERACTION: CC Q14296; Q86V38: ATN1; NbExp=3; IntAct=EBI-1754067, EBI-11954292; CC Q14296; Q8IWX8: CHERP; NbExp=3; IntAct=EBI-1754067, EBI-2555370; CC Q14296; P62508-3: ESRRG; NbExp=3; IntAct=EBI-1754067, EBI-12001340; CC Q14296; Q92876: KLK6; NbExp=3; IntAct=EBI-1754067, EBI-2432309; CC Q14296; Q8WWY3: PRPF31; NbExp=3; IntAct=EBI-1754067, EBI-1567797; CC Q14296; O95985: TOP3B; NbExp=3; IntAct=EBI-1754067, EBI-373403; CC Q14296; O43516: WIPF1; NbExp=3; IntAct=EBI-1754067, EBI-346356; CC -!- SUBCELLULAR LOCATION: [Isoform 4]: Mitochondrion matrix CC {ECO:0000269|PubMed:25704814}. Note=Colocalizes with mitochondrial RNA CC granules. {ECO:0000269|PubMed:25704814}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing, Alternative initiation; Named isoforms=4; CC Name=1; CC IsoId=Q14296-1; Sequence=Displayed; CC Name=2; CC IsoId=Q14296-2; Sequence=VSP_042746, VSP_042747; CC Name=3; CC IsoId=Q14296-3; Sequence=VSP_044811; CC Name=4; CC IsoId=Q14296-4; Sequence=VSP_058246; CC -!- TISSUE SPECIFICITY: Expressed in heart, brain, placenta, lung, liver, CC skeletal muscle, kidney and pancreas. CC -!- DOMAIN: The RAP domain is essential for RNA-binding. CC {ECO:0000269|PubMed:25704814}. CC -!- PTM: Autophosphorylated on serine/threonine residues. Activated by CC dephosphorylation. {ECO:0000269|PubMed:7544399}. CC -!- SIMILARITY: Belongs to the FAST protein kinase family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAD93020.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X86779; CAA60448.1; -; mRNA. DR EMBL; AK292232; BAF84921.1; -; mRNA. DR EMBL; AB209783; BAD93020.1; ALT_INIT; mRNA. DR EMBL; AC010973; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471173; EAW54039.1; -; Genomic_DNA. DR EMBL; CH471173; EAW54043.1; -; Genomic_DNA. DR EMBL; BC011770; AAH11770.1; -; mRNA. DR EMBL; BC039026; AAH39026.1; -; mRNA. DR CCDS; CCDS59088.1; -. [Q14296-3] DR CCDS; CCDS5918.1; -. [Q14296-1] DR CCDS; CCDS5919.1; -. [Q14296-2] DR PIR; I37386; I37386. DR RefSeq; NP_001245390.1; NM_001258461.2. [Q14296-3] DR RefSeq; NP_006703.1; NM_006712.5. [Q14296-1] DR RefSeq; NP_148936.2; NM_033015.3. [Q14296-2] DR RefSeq; XP_005249989.1; XM_005249932.2. [Q14296-4] DR RefSeq; XP_054213124.1; XM_054357149.1. [Q14296-4] DR AlphaFoldDB; Q14296; -. DR SASBDB; Q14296; -. DR SMR; Q14296; -. DR BioGRID; 116126; 25. DR FunCoup; Q14296; 252. DR IntAct; Q14296; 24. DR STRING; 9606.ENSP00000297532; -. DR GlyGen; Q14296; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q14296; -. DR PhosphoSitePlus; Q14296; -. DR BioMuta; FASTK; -. DR DMDM; 13124202; -. DR jPOST; Q14296; -. DR MassIVE; Q14296; -. DR PaxDb; 9606-ENSP00000297532; -. DR PeptideAtlas; Q14296; -. DR ProteomicsDB; 28667; -. DR ProteomicsDB; 59957; -. [Q14296-1] DR ProteomicsDB; 59958; -. [Q14296-2] DR Antibodypedia; 32964; 275 antibodies from 25 providers. DR DNASU; 10922; -. DR Ensembl; ENST00000297532.11; ENSP00000297532.6; ENSG00000164896.22. [Q14296-1] DR Ensembl; ENST00000353841.6; ENSP00000324817.6; ENSG00000164896.22. [Q14296-2] DR Ensembl; ENST00000482571.2; ENSP00000418516.1; ENSG00000164896.22. [Q14296-3] DR GeneID; 10922; -. DR KEGG; hsa:10922; -. DR MANE-Select; ENST00000297532.11; ENSP00000297532.6; NM_006712.5; NP_006703.1. DR UCSC; uc003wix.3; human. [Q14296-1] DR AGR; HGNC:24676; -. DR ClinPGx; PA142671775; -. DR CTD; 10922; -. DR DisGeNET; 10922; -. DR GeneCards; FASTK; -. DR HGNC; HGNC:24676; FASTK. DR HPA; ENSG00000164896; Low tissue specificity. DR MIM; 606965; gene. DR OpenTargets; ENSG00000164896; -. DR VEuPathDB; HostDB:ENSG00000164896; -. DR eggNOG; ENOG502QXK7; Eukaryota. DR GeneTree; ENSGT01030000234607; -. DR HOGENOM; CLU_046861_0_0_1; -. DR InParanoid; Q14296; -. DR OMA; KVRTHHY; -. DR OrthoDB; 8881103at2759; -. DR PAN-GO; Q14296; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q14296; -. DR BRENDA; 2.7.11.8; 2681. DR PathwayCommons; Q14296; -. DR Reactome; R-HSA-9837092; FASTK family proteins regulate processing and stability of mitochondrial RNAs. [Q14296-4] DR SignaLink; Q14296; -. DR Agora; ENSG00000164896; -. DR BioGRID-ORCS; 10922; 18 hits in 1190 CRISPR screens. DR CD-CODE; 5965E019; mtRNA granule. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; FASTK; human. DR GeneWiki; FASTK; -. DR GenomeRNAi; 10922; -. DR Pharos; Q14296; Tbio. DR PRO; PR:Q14296; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; Q14296; protein. DR Bgee; ENSG00000164896; Expressed in apex of heart and 190 other cell types or tissues. DR ExpressionAtlas; Q14296; baseline and differential. DR GO; GO:0005759; C:mitochondrial matrix; IBA:GO_Central. DR GO; GO:0005739; C:mitochondrion; HTP:FlyBase. DR GO; GO:0035770; C:ribonucleoprotein granule; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0033867; F:Fas-activated serine/threonine kinase activity; IEA:UniProtKB-EC. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0003723; F:RNA binding; IBA:GO_Central. DR GO; GO:0097190; P:apoptotic signaling pathway; TAS:ProtInc. DR GO; GO:0000963; P:mitochondrial RNA processing; IBA:GO_Central. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0044528; P:regulation of mitochondrial mRNA stability; IBA:GO_Central. DR GO; GO:0043484; P:regulation of RNA splicing; IDA:UniProtKB. DR InterPro; IPR013579; FAST_2. DR InterPro; IPR050870; FAST_kinase. DR InterPro; IPR010622; FAST_Leu-rich. DR InterPro; IPR013584; RAP. DR PANTHER; PTHR21228:SF4; FAS-ACTIVATED SERINE_THREONINE KINASE; 1. DR PANTHER; PTHR21228; FAST LEU-RICH DOMAIN-CONTAINING; 1. DR Pfam; PF06743; FAST_1; 1. DR Pfam; PF08368; FAST_2; 1. DR Pfam; PF08373; RAP; 1. DR SMART; SM00952; RAP; 1. DR PROSITE; PS51286; RAP; 1. PE 1: Evidence at protein level; KW Alternative initiation; Alternative splicing; Apoptosis; ATP-binding; KW Kinase; Mitochondrion; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; RNA-binding; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..549 FT /note="Fas-activated serine/threonine kinase" FT /id="PRO_0000087196" FT DOMAIN 477..535 FT /note="RAP" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00619" FT REGION 1..30 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT VAR_SEQ 1..34 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:25704814" FT /id="VSP_058246" FT VAR_SEQ 28 FT /note="W -> C (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_042746" FT VAR_SEQ 29..169 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_042747" FT VAR_SEQ 202..228 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|Ref.3" FT /id="VSP_044811" FT VARIANT 424 FT /note="V -> L (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs758691941)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042200" FT VARIANT 436 FT /note="A -> V (in dbSNP:rs2288648)" FT /id="VAR_021970" FT MUTAGEN 35 FT /note="M->G: Abolishes isoform 4 expression." FT /evidence="ECO:0000269|PubMed:25704814" SQ SEQUENCE 549 AA; 61104 MW; 76D38A211B37304A CRC64; MRRPRGEPGP RAPRPTEGAT CAGPGESWSP SPNSMLRVLL SAQTSPARLS GLLLIPPVQP CCLGPSKWGD RPVGGGPSAG PVQGLQRLLE QAKSPGELLR WLGQNPSKVR AHHYSVALRR LGQLLGSRPR PPPVEQVTLQ DLSQLIIRNC PSFDIHTIHV CLHLAVLLGF PSDGPLVCAL EQERRLRLPP KPPPPLQPLL RGGQGLEAAL SCPRFLRYPR QHLISSLAEA RPEELTPHVM VLLAQHLARH RLREPQLLEA IAHFLVVQET QLSSKVVQKL VLPFGRLNYL PLEQQFMPCL ERILAREAGV APLATVNILM SLCQLRCLPF RALHFVFSPG FINYISGTPH ALIVRRYLSL LDTAVELELP GYRGPRLPRR QQVPIFPQPL ITDRARCKYS HKDIVAEGLR QLLGEEKYRQ DLTVPPGYCT DFLLCASSSG AVLPVRTQDP FLPYPPRSCP QGQAASSATT RDPAQRVVLV LRERWHFCRD GRVLLGSRAL RERHLGLMGY QLLPLPFEEL ESQRGLPQLK SYLRQKLQAL GLRWGPEGG // ID FGFR2_HUMAN Reviewed; 821 AA. AC P21802; B4DFC2; E7EVR6; E9PCR0; P18443; Q01742; Q12922; Q14300; Q14301; AC Q14302; Q14303; Q14304; Q14305; Q14672; Q14718; Q14719; Q1KHY5; Q86YI4; AC Q8IXC7; Q96KL9; Q96KM0; Q96KM1; Q96KM2; Q9NZU2; Q9NZU3; Q9UD01; Q9UD02; AC Q9UIH3; Q9UIH4; Q9UIH5; Q9UIH6; Q9UIH7; Q9UIH8; Q9UM87; Q9UMC6; Q9UNS7; AC Q9UQH7; Q9UQH8; Q9UQH9; Q9UQI0; DT 01-MAY-1991, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-1991, sequence version 1. DT 28-JAN-2026, entry version 281. DE RecName: Full=Fibroblast growth factor receptor 2; DE Short=FGFR-2; DE EC=2.7.10.1 {ECO:0000269|PubMed:16844695, ECO:0000269|PubMed:18056630, ECO:0000269|PubMed:19410646, ECO:0000269|PubMed:21454610}; DE AltName: Full=K-sam; DE Short=KGFR; DE AltName: Full=Keratinocyte growth factor receptor; DE AltName: CD_antigen=CD332; DE Flags: Precursor; GN Name=FGFR2; Synonyms=BEK, KGFR, KSAM; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Neonatal brain stem; RX PubMed=1697263; DOI=10.1002/j.1460-2075.1990.tb07454.x; RA Dionne C.A., Crumley G.R., Bellot F., Kaplow J.M., Searfoss G., Ruta M., RA Burgess W.H., Jaye M., Schlessinger J.; RT "Cloning and expression of two distinct high-affinity receptors cross- RT reacting with acidic and basic fibroblast growth factors."; RL EMBO J. 9:2685-2692(1990). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 10). RX PubMed=2172978; DOI=10.1073/pnas.87.20.8180; RA Houssaint E., Blanquet P.R., Champion-Arnaud P., Gesnel M.-C., RA Torriglia A., Courtois Y., Breathnach R.; RT "Related fibroblast growth factor receptor genes exist in the human RT genome."; RL Proc. Natl. Acad. Sci. U.S.A. 87:8180-8184(1990). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 11). RX PubMed=1647213; DOI=10.1016/0167-4781(91)90015-e; RA Seno M., Sasada R., Watanabe T., Ishimaru K., Igarashi K.; RT "Two cDNAs encoding novel human FGF receptor."; RL Biochim. Biophys. Acta 1089:244-246(1991). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4). RC TISSUE=Stomach cancer; RX PubMed=2377625; DOI=10.1073/pnas.87.15.5983; RA Hattori Y., Odagiri H., Nakatani H., Miyagawa K., Naito K., Sakamoto H., RA Katoh O., Yoshida T., Sugimura T., Terada M.; RT "K-sam, an amplified gene in stomach cancer, is a member of the heparin- RT binding growth factor receptor genes."; RL Proc. Natl. Acad. Sci. U.S.A. 87:5983-5987(1990). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5; 8; 9 AND 16). RX PubMed=1313574; DOI=10.1073/pnas.89.7.2960; RA Katoh M., Hattori Y., Sasaki H., Tanaka M., Sugano K., Yazaki Y., RA Sugimura T., Terada M.; RT "K-sam gene encodes secreted as well as transmembrane receptor tyrosine RT kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 89:2960-2964(1992). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 16), DOMAIN, AND SUBUNIT. RC TISSUE=Placenta; RX PubMed=1400433; DOI=10.1016/s0021-9258(19)36821-8; RA Dell K.R., Williams L.T.; RT "A novel form of fibroblast growth factor receptor 2. Alternative splicing RT of the third immunoglobulin-like domain confers ligand binding RT specificity."; RL J. Biol. Chem. 267:21225-21229(1992). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3; 13 AND 16), SUBUNIT, DOMAIN, AND RP VARIANT ARG-613. RC TISSUE=Mammary gland; RX PubMed=1309608; DOI=10.1073/pnas.89.1.246; RA Miki T., Bottaro D.P., Fleming T.P., Smith C.L., Burgess W.H., RA Chan A.M.-L., Aaronson S.A.; RT "Determination of ligand-binding specificity by alternative splicing: two RT distinct growth factor receptors encoded by a single gene."; RL Proc. Natl. Acad. Sci. U.S.A. 89:246-250(1992). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 13). RC TISSUE=Cornea, and Mammary gland; RX PubMed=7866434; RA Wilson S.E., Weng J., Chwang E.L., Gollahon L., Leitch A.M., Shay J.W.; RT "Hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), and RT their receptors in human breast cells and tissues: alternative receptors."; RL Cell. Mol. Biol. Res. 40:337-350(1994). RN [9] RP ERRATUM OF PUBMED:7866434. RA Wilson S.E., Weng J., Chwang E.L., Gollahon L., Leitch A.M., Shay J.W.; RL Cell. Mol. Biol. Res. 40:707-707(1994). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT CS SER-342. RC TISSUE=Blood; RA Steinberger D., Mueller U.; RL Submitted (APR-1996) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ARG-613. RX PubMed=10626794; RA Ueda T., Sasaki H., Kuwahara Y., Nezu M., Shibuya T., Sakamoto H., RA Ishii H., Yanagihara K., Mafune K., Makuuchi M., Terada M.; RT "Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology- RT mediated recombination, generating preferential expression of specific RT messenger RNAs."; RL Cancer Res. 59:6080-6086(1999). RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 5; 6; 7; 8 AND 12). RX PubMed=11856867; DOI=10.1159/000048802; RA Ingersoll R.G., Paznekas W.A., Tran A.K., Scott A.F., Jiang G., Jabs E.W.; RT "Fibroblast growth factor receptor 2 (FGFR2): genomic sequence and RT variations."; RL Cytogenet. Cell Genet. 94:121-126(2001). RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 3). RA Lind D.L., Cox D.R.; RT "Sequence and polymorphisms in fibroblast growth factor receptor 2 (FGFR2) RT gene in humans."; RL Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases. RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 17). RA Jang J.; RT "Identification of a novel variant of FGFR2."; RL Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases. RN [15] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PRO-6 AND THR-186. RG NIEHS SNPs program; RL Submitted (APR-2006) to the EMBL/GenBank/DDBJ databases. RN [16] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 15). RC TISSUE=Cerebellum; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [17] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164054; DOI=10.1038/nature02462; RA Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L., RA Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K., RA Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L., RA Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P., RA Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P., RA Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N., RA Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A., RA Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C., RA Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D., RA Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C., RA Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K., RA Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A., RA Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S., RA McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S., RA Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., RA Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., RA Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M., RA Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A., RA Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P., RA Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y., RA Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D., RA Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 10."; RL Nature 429:375-381(2004). RN [18] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 14). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [19] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 314-427. RX PubMed=10712195; DOI=10.1086/302831; RA Glaser R.L., Jiang W., Boyadjiev S.A., Tran A.K., Zachary A.A., RA Van Maldergem L., Johnson D., Walsh S., Oldridge M., Wall S.A., RA Wilkie A.O.M., Jabs E.W.; RT "Paternal origin of FGFR2 mutations in sporadic cases of Crouzon syndrome RT and Pfeiffer syndrome."; RL Am. J. Hum. Genet. 66:768-777(2000). RN [20] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-209; 212-767 AND 771-821 (ISOFORMS RP 5; 8 AND 12). RX PubMed=10196476; DOI=10.1016/s0378-1119(99)00047-5; RA Zhang Y., Gorry M.C., Post J.C., Ehrlich G.D.; RT "Genomic organization of the human fibroblast growth factor receptor 2 RT (FGFR2) gene and comparative analysis of the human FGFR gene family."; RL Gene 230:69-79(1999). RN [21] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 249-313, AND VARIANTS APRS TRP-252 AND RP ARG-253. RX PubMed=7668257; RA Park W.-J., Theda C., Maestri N.E., Meyers G.A., Fryburg J.S., Dufresne C., RA Cohen M.M. Jr., Jabs E.W.; RT "Analysis of phenotypic features and FGFR2 mutations in Apert syndrome."; RL Am. J. Hum. Genet. 57:321-328(1995). RN [22] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 251-259. RX PubMed=8676562; RA Wada C., Ishigaki M., Toyo-oka Y., Yamabe H., Ohnuki Y., Takada F., RA Yamazaki Y., Ohtani H.; RT "Nucleotide sequences at intron 6 and exon 7 junction of fibroblast growth RT factor receptor 2 and rapid mutational analysis in Apert syndrome."; RL Rinsho Byori 44:435-438(1996). RN [23] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 251-318. RX PubMed=8673103; DOI=10.1038/ng0596-48; RA Moloney D.M., Slaney S.F., Oldridge M., Wall S.A., Sahlin P., Stenman G., RA Wilkie A.O.M.; RT "Exclusive paternal origin of new mutations in Apert syndrome."; RL Nat. Genet. 13:48-53(1996). RN [24] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 263-361, AND VARIANTS CS PRO-289; RP ARG-338; SER-342; TYR-342; GLY-344 AND CYS-354. RX PubMed=7581378; DOI=10.1093/hmg/4.8.1387; RA Gorry M.C., Preston R.A., White G.J., Zhang Y., Singhal V.K., Losken H.W., RA Parker M.G., Nwokoro N.A., Post J.C., Ehrlich G.D.; RT "Crouzon syndrome: mutations in two spliceoforms of FGFR2 and a common RT point mutation shared with Jackson-Weiss syndrome."; RL Hum. Mol. Genet. 4:1387-1390(1995). RN [25] RP FUNCTION (ISOFORM 3), SUBUNIT, AND DOMAIN. RX PubMed=8961926; DOI=10.1021/bi961942c; RA Gray T.E., Eisenstein M., Yayon A., Givol D.; RT "Asparagine-344 is a key residue for ligand binding in keratinocyte growth RT factor receptor."; RL Biochemistry 35:15640-15645(1996). RN [26] RP INTERACTION WITH FGF1; FGF2; FGF3; FGF4; FGF6; FGF7 AND FGF9, AND FUNCTION RP IN CELL PROLIFERATION. RX PubMed=8663044; DOI=10.1074/jbc.271.25.15292; RA Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A., Coulier F., RA Gao G., Goldfarb M.; RT "Receptor specificity of the fibroblast growth factor family."; RL J. Biol. Chem. 271:15292-15297(1996). RN [27] RP INVOLVEMENT IN SCS, AND VARIANT SCS 269-VAL-VAL-270 DEL. RX PubMed=9585583; DOI=10.1086/301855; RA Paznekas W.A., Cunningham M.L., Howard T.D., Korf B.R., Lipson M.H., RA Grix A.W., Feingold M., Goldberg R., Borochowitz Z., Aleck K., Mulliken J., RA Yin M., Jabs E.W.; RT "Genetic heterogeneity of Saethre-Chotzen syndrome, due to TWIST and FGFR RT mutations."; RL Am. J. Hum. Genet. 62:1370-1380(1998). RN [28] RP FUNCTION IN PHOSPHORYLATION OF PAK4; REGULATION OF CELL PROLIFERATION AND RP APOPTOSIS, AND INTERACTION WITH GRB2 AND PAK4. RX PubMed=12529371; DOI=10.1074/jbc.m205875200; RA Lu Y., Pan Z.-Z., Devaux Y., Ray P.; RT "p21-activated protein kinase 4 (PAK4) interacts with the keratinocyte RT growth factor receptor and participates in keratinocyte growth factor- RT mediated inhibition of oxidant-induced cell death."; RL J. Biol. Chem. 278:10374-10380(2003). RN [29] RP FUNCTION IN OSTEOBLAST DIFFERENTIATION AND IN PHOSPHORYLATION OF CBL, RP INTERACTION WITH CBL, UBIQUITINATION, AND CHARACTERIZATION OF VARIANT APRS RP TRP-252. RX PubMed=15190072; DOI=10.1074/jbc.m402469200; RA Kaabeche K., Lemonnier J., Le Mee S., Caverzasio J., Marie P.J.; RT "Cbl-mediated degradation of Lyn and Fyn induced by constitutive fibroblast RT growth factor receptor-2 activation supports osteoblast differentiation."; RL J. Biol. Chem. 279:36259-36267(2004). RN [30] RP FUNCTION IN CELL PROLIFERATION AND ACTIVATION OF SIGNALING PATHWAYS, RP MUTAGENESIS OF TYR-769, PHOSPHORYLATION AT TYR-769, AND INTERACTION WITH RP PLCG1. RX PubMed=15629145; DOI=10.1016/j.bbrc.2004.12.031; RA Ceridono M., Belleudi F., Ceccarelli S., Torrisi M.R.; RT "Tyrosine 769 of the keratinocyte growth factor receptor is required for RT receptor signaling but not endocytosis."; RL Biochem. Biophys. Res. Commun. 327:523-532(2005). RN [31] RP INTERACTION WITH FGF1; FGF7; FGF8; FGF9; FGF10; FGF19; FGF21; FGF22 AND RP FGF23, AND FUNCTION IN STIMULATION OF CELL PROLIFERATION. RX PubMed=16597617; DOI=10.1074/jbc.m601252200; RA Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M., Ornitz D.M.; RT "Receptor specificity of the fibroblast growth factor family. The complete RT mammalian FGF family."; RL J. Biol. Chem. 281:15694-15700(2006). RN [32] RP FUNCTION IN PHOSPHORYLATION OF PLCG1 (ISOFORM 1), CATALYTIC ACTIVITY, RP AUTOPHOSPHORYLATION, GLYCOSYLATION, INTERACTION WITH PLCG1, SUBCELLULAR RP LOCATION, MUTAGENESIS OF ASN-265 AND 656-TYR-TYR-657, UBIQUITINATION, AND RP CHARACTERIZATION OF VARIANT PS PHE-278. RX PubMed=16844695; DOI=10.1074/jbc.m600448200; RA Hatch N.E., Hudson M., Seto M.L., Cunningham M.L., Bothwell M.; RT "Intracellular retention, degradation, and signaling of glycosylation- RT deficient FGFR2 and craniosynostosis syndrome-associated FGFR2C278F."; RL J. Biol. Chem. 281:27292-27305(2006). RN [33] RP INTERACTION WITH FGF19; FGF21 AND KLB, AND FUNCTION IN PHOSPHORYLATION OF RP FRS2 AND ACTIVATION OF MAP KINASES. RX PubMed=17623664; DOI=10.1074/jbc.m704165200; RA Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R., Eliseenkova A.V., RA Mohammadi M., Rosenblatt K.P., Kliewer S.A., Kuro-o M.; RT "Tissue-specific expression of betaKlotho and fibroblast growth factor RT (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21."; RL J. Biol. Chem. 282:26687-26695(2007). RN [34] RP FUNCTION IN STAT1 PHOSPHORYLATION, GLYCOSYLATION, SUBCELLULAR LOCATION, AND RP PHOSPHORYLATION. RX PubMed=17311277; DOI=10.1002/jcp.21014; RA Citores L., Bai L., Sorensen V., Olsnes S.; RT "Fibroblast growth factor receptor-induced phosphorylation of STAT1 at the RT Golgi apparatus without translocation to the nucleus."; RL J. Cell. Physiol. 212:148-156(2007). RN [35] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=18374639; DOI=10.1016/j.bone.2008.02.009; RA Dufour C., Guenou H., Kaabeche K., Bouvard D., Sanjay A., Marie P.J.; RT "FGFR2-Cbl interaction in lipid rafts triggers attenuation of PI3K/Akt RT signaling and osteoblast survival."; RL Bone 42:1032-1039(2008). RN [36] RP FUNCTION AS FGF7 RECEPTOR AND IN PHOSPHORYLATION OF PLCG1 AND FRS2, RP CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-466; TYR-586; TYR-588; TYR-656 RP AND TYR-657, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=19410646; DOI=10.1016/j.cellsig.2009.04.004; RA Luo Y., Yang C., Jin C., Xie R., Wang F., McKeehan W.L.; RT "Novel phosphotyrosine targets of FGFR2IIIb signaling."; RL Cell. Signal. 21:1370-1378(2009). RN [37] RP FUNCTION IN FIBROBLAST PROLIFERATION; ACTIVATION OF MAP KINASES AND RP PHOSPHORYLATION OF PLCG1 AND FRS2, INTERACTION WITH PLCG1 AND FRS2, RP SUBCELLULAR LOCATION, AND MUTAGENESIS OF TYR-769. RX PubMed=19103595; DOI=10.1074/jbc.m803998200; RA Cha J.Y., Maddileti S., Mitin N., Harden T.K., Der C.J.; RT "Aberrant receptor internalization and enhanced FRS2-dependent signaling RT contribute to the transforming activity of the fibroblast growth factor RT receptor 2 IIIb C3 isoform."; RL J. Biol. Chem. 284:6227-6240(2009). RN [38] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [39] RP FUNCTION, AND UBIQUITINATION. RX PubMed=21596750; DOI=10.1074/jbc.m110.197525; RA Severe N., Miraoui H., Marie P.J.; RT "The Casitas B lineage lymphoma (Cbl) mutant G306E enhances osteogenic RT differentiation in human mesenchymal stromal cells in part by decreased RT Cbl-mediated platelet-derived growth factor receptor alpha and fibroblast RT growth factor receptor 2 ubiquitination."; RL J. Biol. Chem. 286:24443-24450(2011). RN [40] RP REVIEW ON LIGAND SPECIFICITY, ALTERNATIVE SPLICING, AND SIGNALING. RX PubMed=15863030; DOI=10.1016/j.cytogfr.2005.01.001; RA Eswarakumar V.P., Lax I., Schlessinger J.; RT "Cellular signaling by fibroblast growth factor receptors."; RL Cytokine Growth Factor Rev. 16:139-149(2005). RN [41] RP REVIEW ON LIGAND SPECIFICITY, ALTERNATIVE SPLICING, SIGNALING, AND ROLE IN RP DISEASE. RX PubMed=19387476; DOI=10.1038/jid.2009.97; RA Katoh M.; RT "FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer RT pathologies."; RL J. Invest. Dermatol. 129:1861-1867(2009). RN [42] RP REVIEW ON FUNCTION IN FGF SIGNALING. RX PubMed=20094046; DOI=10.1038/nrc2780; RA Turner N., Grose R.; RT "Fibroblast growth factor signalling: from development to cancer."; RL Nat. Rev. Cancer 10:116-129(2010). RN [43] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-780, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [44] RP X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 147-366 IN COMPLEX WITH FGF2. RX PubMed=10830168; DOI=10.1016/s0092-8674(00)80851-x; RA Plotnikov A.N., Hubbard S.R., Schlessinger J., Mohammadi M.; RT "Crystal structures of two FGF-FGFR complexes reveal the determinants of RT ligand-receptor specificity."; RL Cell 101:413-424(2000). RN [45] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 148-366 IN COMPLEX WITH FGF1 AND RP HEPARIN, AND INTERACTION WITH FGF1 AND HEPARIN. RX PubMed=11069186; DOI=10.1038/35039551; RA Pellegrini L., Burke D.F., von Delft F., Mulloy B., Blundell T.L.; RT "Crystal structure of fibroblast growth factor receptor ectodomain bound to RT ligand and heparin."; RL Nature 407:1029-1034(2000). RN [46] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 147-362 IN COMPLEX WITH FGF1. RX PubMed=10618369; DOI=10.1073/pnas.97.1.49; RA Stauber D.J., DiGabriele A.D., Hendrickson W.A.; RT "Structural interactions of fibroblast growth factor receptor with its RT ligands."; RL Proc. Natl. Acad. Sci. U.S.A. 97:49-54(2000). RN [47] RP X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 147-366 OF VARIANTS APRS TRP-252 RP AND ARG-253 IN COMPLEX WITH FGF2. RX PubMed=11390973; DOI=10.1073/pnas.121183798; RA Ibrahimi O.A., Eliseenkova A.V., Plotnikov A.N., Yu K., Ornitz D.M., RA Mohammadi M.; RT "Structural basis for fibroblast growth factor receptor 2 activation in RT Apert syndrome."; RL Proc. Natl. Acad. Sci. U.S.A. 98:7182-7187(2001). RN [48] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 140-371 IN COMPLEX WITH FGF10. RX PubMed=12591959; DOI=10.1073/pnas.0436500100; RA Yeh B.K., Igarashi M., Eliseenkova A.V., Plotnikov A.N., Sher I., Ron D., RA Aaronson S.A., Mohammadi M.; RT "Structural basis by which alternative splicing confers specificity in RT fibroblast growth factor receptors."; RL Proc. Natl. Acad. Sci. U.S.A. 100:2266-2271(2003). RN [49] RP X-RAY CRYSTALLOGRAPHY (2.28 ANGSTROMS) OF 149-368 IN COMPLEX WITH FGF8, RP FUNCTION AS FGF8 RECEPTOR, INTERACTION WITH FGF8, AND DISULFIDE BONDS. RX PubMed=16384934; DOI=10.1101/gad.1365406; RA Olsen S.K., Li J.Y.H., Bromleigh C., Eliseenkova A.V., Ibrahimi O.A., RA Lao Z., Zhang F., Linhardt R.J., Joyner A.L., Mohammadi M.; RT "Structural basis by which alternative splicing modulates the organizer RT activity of FGF8 in the brain."; RL Genes Dev. 20:185-198(2006). RN [50] RP X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 458-778 IN COMPLEX WITH ATP RP ANALOG; PEPTIDE SUBSTRATE AND MAGNESIUM, ACTIVITY REGULATION, RP PHOSPHORYLATION AT TYR-586; TYR-656 AND TYR-657, MUTAGENESIS OF ASN-549 AND RP GLU-565, CHARACTERIZATION OF VARIANT FSPC GLU-526, CHARACTERIZATION OF RP VARIANT CS HIS-549, CHARACTERIZATION OF VARIANTS PS GLY-565 AND ARG-641, RP AND CHARACTERIZATION OF VARIANT CRANIOSYNOSTOSIS ASN-659. RX PubMed=17803937; DOI=10.1016/j.molcel.2007.06.028; RA Chen H., Ma J., Li W., Eliseenkova A.V., Xu C., Neubert T.A., Miller W.T., RA Mohammadi M.; RT "A molecular brake in the kinase hinge region regulates the activity of RT receptor tyrosine kinases."; RL Mol. Cell 27:717-730(2007). RN [51] RP X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 458-766 OF VARIANT LADD1 THR-628 RP IN COMPLEX WITH ATP ANALOG, CATALYTIC ACTIVITY, SUBUNIT, AND RP AUTOPHOSPHORYLATION. RX PubMed=18056630; DOI=10.1073/pnas.0709905104; RA Lew E.D., Bae J.H., Rohmann E., Wollnik B., Schlessinger J.; RT "Structural basis for reduced FGFR2 activity in LADD syndrome: Implications RT for FGFR autoinhibition and activation."; RL Proc. Natl. Acad. Sci. U.S.A. 104:19802-19807(2007). RN [52] RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 458-778 IN COMPLEX WITH ATP, RP ACTIVE SITE, IDENTIFICATION BY MASS SPECTROMETRY, AUTOPHOSPHORYLATION, AND RP PHOSPHORYLATION AT TYR-466; TYR-586; TYR-588; TYR-656; TYR-657 AND TYR-769. RX PubMed=19060208; DOI=10.1073/pnas.0807752105; RA Chen H., Xu C.F., Ma J., Eliseenkova A.V., Li W., Pollock P.M., RA Pitteloud N., Miller W.T., Neubert T.A., Mohammadi M.; RT "A crystallographic snapshot of tyrosine trans-phosphorylation in action."; RL Proc. Natl. Acad. Sci. U.S.A. 105:19660-19665(2008). RN [53] RP X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 458-768 IN COMPLEX WITH RP INHIBITOR, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND ACTIVITY RP REGULATION. RX PubMed=21454610; DOI=10.1074/jbc.m110.213736; RA Eathiraj S., Palma R., Hirschi M., Volckova E., Nakuci E., Castro J., RA Chen C.R., Chan T.C., France D.S., Ashwell M.A.; RT "A novel mode of protein kinase inhibition exploiting hydrophobic motifs of RT autoinhibited kinases: discovery of ATP-independent inhibitors of RT fibroblast growth factor receptor."; RL J. Biol. Chem. 286:20677-20687(2011). RN [54] RP VARIANTS CS HIS-340; ARG-342; SER-342; TYR-342 AND CYS-354. RX PubMed=7987400; DOI=10.1038/ng0994-98; RA Reardon W., Winter R.M., Rutland P., Pulleyn L.J., Jones B.M., Malcolm S.; RT "Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon RT syndrome."; RL Nat. Genet. 8:98-103(1994). RN [55] RP VARIANTS CS CYS-328 AND CYS-347, AND VARIANT JWS GLY-344. RX PubMed=7874170; DOI=10.1038/ng1194-275; RA Jabs E.W., Li X., Scott A.F., Meyers G.A., Chen W., Eccles M., Mao J., RA Charnas L.R., Jackson C.E., Jaye M.; RT "Jackson-Weiss and Crouzon syndromes are allelic with mutations in RT fibroblast growth factor receptor 2."; RL Nat. Genet. 8:275-279(1994). RN [56] RP VARIANTS CS PRO-267; PHE-278 AND ARG-290. RX PubMed=7655462; DOI=10.1093/hmg/4.6.1077; RA Oldridge M., Wilkie A.O.M., Slaney S.F., Poole M.D., Pulleyn L.J., RA Rutland P., Hockley A.D., Wake M.J.C., Goldin J.H., Winter R.M., RA Reardon W., Malcolm S.; RT "Mutations in the third immunoglobulin domain of the fibroblast growth RT factor receptor-2 gene in Crouzon syndrome."; RL Hum. Mol. Genet. 4:1077-1082(1995). RN [57] RP VARIANTS CS GLY-290; TRP-342 AND CYS-354, AND VARIANT JWS ARG-342. RX PubMed=8528214; DOI=10.1093/hmg/4.7.1229; RA Park W.-J., Meyers G.A., Li X., Theda C., Day D., Orlow S.J., Jones M.C., RA Jabs E.W.; RT "Novel FGFR2 mutations in Crouzon and Jackson-Weiss syndromes show allelic RT heterogeneity and phenotypic variability."; RL Hum. Mol. Genet. 4:1229-1233(1995). RN [58] RP VARIANT PS ALA-321. RX PubMed=7719333; DOI=10.1038/ng0295-108; RA Lajeunie E., Wei M.H., Bonaventure J., Munnich A., le Merrer M., Renier D.; RT "FGFR2 mutations in Pfeiffer syndrome."; RL Nat. Genet. 9:108-108(1995). RN [59] RP VARIANTS APRS TRP-252 AND ARG-253. RX PubMed=7719344; DOI=10.1038/ng0295-165; RA Wilkie A.O.M., Slaney S.F., Oldridge M., Poole M.D., Ashworth G.J., RA Hockley A.D., Hayward R.D., David D.J., Pulleyn L.J., Rutland P., RA Malcolm S., Winter R.M., Reardon W.; RT "Apert syndrome results from localized mutations of FGFR2 and is allelic RT with Crouzon syndrome."; RL Nat. Genet. 9:165-172(1995). RN [60] RP VARIANTS PS PRO-341; ARG-342 AND TYR-342. RX PubMed=7719345; DOI=10.1038/ng0295-173; RA Rutland P., Pulleyn L.J., Reardon W., Baraister M., Hayward R., Jones B.M., RA Malcolm S., Winter R.M., Oldridge M., Slaney S.F., Poole M.D., RA Wilkie A.O.M.; RT "Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon RT syndrome phenotypes."; RL Nat. Genet. 9:173-176(1995). RN [61] RP VARIANTS CS GLY-268 INS; PHE-342 AND TYR-342, VARIANTS PS PHE-278; ARG-342; RP SER-342; PRO-344 AND PHE-359, AND VARIANT JWS PRO-289. RX PubMed=8644708; RA Meyers G.A., Day D., Goldberg R., Daentl D.L., Przylepa K.A., Abrams L.J., RA Graham J.M. Jr., Feingold M., Moeschler J.B., Rawnsley E., Scott A.F., RA Jabs E.W.; RT "FGFR2 exon IIIa and IIIc mutations in Crouzon, Jackson-Weiss, and Pfeiffer RT syndromes: evidence for missense changes, insertions, and a deletion due to RT alternative RNA splicing."; RL Am. J. Hum. Genet. 58:491-498(1996). RN [62] RP VARIANTS CS CYS-105; GLU-338; CYS-351 AND ARG-384. RX PubMed=8946174; DOI=10.1159/000472215; RA Pulleyn L.J., Reardon W., Wilkes D., Rutland P., Jones B.M., Hayward R., RA Hall C.M., Brueton L., Chun N., Lammer E., Malcolm S., Winter R.M.; RT "Spectrum of craniosynostosis phenotypes associated with novel mutations at RT the fibroblast growth factor receptor 2 locus."; RL Eur. J. Hum. Genet. 4:283-291(1996). RN [63] RP VARIANTS CS ILE-331; ASN-ALA-337 INS AND 356-TRP--THR-358 DEL. RX PubMed=8956050; RX DOI=10.1002/(sici)1098-1004(1996)8:4<386::aid-humu18>3.0.co;2-z; RA Steinberger D., Mulliken J.B., Mueller U.; RT "Crouzon syndrome: previously unrecognized deletion, duplication, and point RT mutation within FGFR2 gene."; RL Hum. Mutat. 8:386-390(1996). RN [64] RP VARIANTS BSTVS CYS-372 AND CYS-375. RX PubMed=8696350; DOI=10.1038/ng0896-492; RA Przylepa K.A., Paznekas W.A., Zhang M., Golabi M., Bias W., Bamshad M.J., RA Carey J.C., Hall B.D., Stevenson R., Orlow S.J., Cohen M.M. Jr., Jabs E.W.; RT "Fibroblast growth factor receptor 2 mutations in Beare-Stevenson cutis RT gyrata syndrome."; RL Nat. Genet. 13:492-494(1996). RN [65] RP VARIANT PS CYS-290. RX PubMed=9150725; DOI=10.1007/s004390050413; RA Tartaglia M., Valeri S., Velardi F., di Rocco C., Battaglia P.A.; RT "Trp290Cys mutation in exon IIIa of the fibroblast growth factor receptor 2 RT (FGFR2) gene is associated with Pfeiffer syndrome."; RL Hum. Genet. 99:602-606(1997). RN [66] RP VARIANT JWS SER-342. RX PubMed=9385368; DOI=10.1007/s004390050584; RA Tartaglia M., Di Rocco C., Lajeunie E., Valeri S., Velardi F., RA Battaglia P.A.; RT "Jackson-Weiss syndrome: identification of two novel FGFR2 missense RT mutations shared with Crouzon and Pfeiffer craniosynostotic disorders."; RL Hum. Genet. 101:47-50(1997). RN [67] RP VARIANT LEU-252, VARIANT APRS PHE-252, AND VARIANT PS 252-SER-PRO-253 RP DELINS PHE-SER. RX PubMed=9002682; DOI=10.1093/hmg/6.1.137; RA Oldridge M., Lunt P.W., Zackai E.H., McDonald-Mcginn D.M., Muenke M., RA Moloney D.M., Twigg S.R.F., Heath J.K., Howard T.D., Hoganson G., RA Gagnon D.M., Jabs E.W., Wilkie A.O.M.; RT "Genotype-phenotype correlation for nucleotide substitutions in the IgII- RT IgIII linker of FGFR2."; RL Hum. Mol. Genet. 6:137-143(1997). RN [68] RP VARIANT CS GLU-292. RX PubMed=9152842; DOI=10.1136/jmg.34.5.420; RA Steinberger D., Collmann H., Schmalenberger B., Mueller U.; RT "A novel mutation (a886g) in exon 5 of FGFR2 in members of a family with RT Crouzon phenotype and plagiocephaly."; RL J. Med. Genet. 34:420-422(1997). RN [69] RP VARIANTS CS PHE-278; PRO-337; ARG-338; ARG-342; PHE-342 AND TYR-342, RP VARIANTS APRS TRP-252 AND ARG-253, AND VARIANT JWS PHE-278. RX PubMed=9677057; RX DOI=10.1002/(sici)1096-8628(19980707)78:3<237::aid-ajmg5>3.3.co;2-5; RA Passos-Bueno M.R., Sertie A.L., Richieri-Costa A., Alonso L.G., Zatz M., RA Alonso N., Brunoni D., Ribeiro S.F.M.; RT "Description of a new mutation and characterization of FGFR1, FGFR2, and RT FGFR3 mutations among Brazilian patients with syndromic craniosynostoses."; RL Am. J. Med. Genet. 78:237-241(1998). RN [70] RP VARIANTS CS VAL-276 AND CYS-301, AND VARIANT CRANIOSYNOSTOSIS SER-314. RX PubMed=9521581; DOI=10.1007/s004390050668; RA Steinberger D., Vriend G., Mulliken J.B., Mueller U.; RT "The mutations in FGFR2-associated craniosynostoses are clustered in five RT structural elements of immunoglobulin-like domain III of the receptor."; RL Hum. Genet. 102:145-150(1998). RN [71] RP VARIANTS APRS TRP-252 AND ARG-253. RX PubMed=9452027; DOI=10.1002/humu.1380110106; RA Tsai F.-J., Hwu W.-L., Lin S.-P., Chang J.-G., Wang T.-R., Tsai C.-H.; RT "Two common mutations 934C to G and 937C to G of fibroblast growth factor RT receptor 2 (FGFR2) gene in Chinese patients with Apert syndrome."; RL Hum. Mutat. Suppl. 1:S18-S19(1998). RN [72] RP VARIANT PS CYS-351. RX PubMed=9693549; DOI=10.1097/00001665-199805000-00004; RA Mathijssen I.M., Vaandrager J.M., Hoogeboom A.J., Hesseling-Janssen A.L.W., RA van den Ouweland A.M.W.; RT "Pfeiffer's syndrome resulting from an S351C mutation in the fibroblast RT growth factor receptor-2 gene."; RL J. Craniofac. Surg. 9:207-209(1998). RN [73] RP VARIANT PS TRP-252. RX PubMed=9719378; DOI=10.1136/jmg.35.8.677; RA Passos-Bueno M.R., Richieri-Costa A., Sertie A.L., Kneppers A.; RT "Presence of the Apert canonical S252W FGFR2 mutation in a patient without RT severe syndactyly."; RL J. Med. Genet. 35:677-679(1998). RN [74] RP VARIANT CS SER-362. RX PubMed=10574673; DOI=10.1597/1545-1569_1999_036_0533_anfgmi_2.3.co_2; RA Everett E.T., Britto D.A., Ward R.E., Hartsfield J.K. Jr.; RT "A novel FGFR2 gene mutation in Crouzon syndrome associated with apparent RT nonpenetrance."; RL Cleft Palate Craniofac. J. 36:533-541(1999). RN [75] RP VARIANTS PS CYS-340 AND GLY-342. RX PubMed=10394936; DOI=10.1007/s004390050979; RA Cornejo-Roldan L.R., Roessler E., Muenke M.; RT "Analysis of the mutational spectrum of the FGFR2 gene in Pfeiffer RT syndrome."; RL Hum. Genet. 104:425-431(1999). RN [76] RP VARIANT PS ASP-273 DEL. RX PubMed=10945669; DOI=10.1034/j.1399-0004.2000.580116.x; RA Priolo M., Lerone M., Baffico M., Baldi M., Ravazzolo R., Cama A., RA Capra V., Silengo M.; RT "Pfeiffer syndrome type 2 associated with a single amino acid deletion in RT the FGFR2 gene."; RL Clin. Genet. 58:81-83(2000). RN [77] RP VARIANTS CS/PS ARG-342 AND TYR-342, VARIANTS CS LEU-263; VAL-276; PHE-278; RP TYR-278; SER-288; PRO-289; PRO-341; TRP-342; CYS-354; TYR-354 AND PHE-359, RP AND VARIANT PS SER-342. RX PubMed=11173845; DOI=10.1159/000056833; RA Kress W., Collmann H., Buesse M., Halliger-Keller B., Mueller C.R.; RT "Clustering of FGFR2 gene mutations in patients with Pfeiffer and Crouzon RT syndromes (FGFR2-associated craniosynostoses)."; RL Cytogenet. Cell Genet. 91:134-137(2000). RN [78] RP VARIANT SER-315. RX PubMed=10951518; DOI=10.1038/sj.ejhg.5200499; RA Johnson D., Wall S.A., Mann S., Wilkie A.O.M.; RT "A novel mutation, Ala315Ser, in FGFR2: a gene-environment interaction RT leading to craniosynostosis?"; RL Eur. J. Hum. Genet. 8:571-577(2000). RN [79] RP VARIANTS ABS2 ARG-342; SER-342 AND CYS-351. RX PubMed=10633130; DOI=10.1136/jmg.37.1.26; RA Reardon W., Smith A., Honour J.W., Hindmarsh P., Das D., Rumsby G., RA Nelson I., Malcolm S., Ades L., Sillence D., Kumar D., RA DeLozier-Blanchet C., McKee S., Kelly T., McKeehan W.L., Baraitser M., RA Winter R.M.; RT "Evidence for digenic inheritance in some cases of Antley-Bixler RT syndrome?"; RL J. Med. Genet. 37:26-32(2000). RN [80] RP VARIANTS CS CYS-281; PRO-289; ARG-342 AND TYR-342. RX PubMed=11380921; DOI=10.1046/j.1442-200x.2001.01392.x; RA Tsai F.-J., Yang C.-F., Wu J.-Y., Tsai C.-H., Lee C.-C.; RT "Mutation analysis of Crouzon syndrome and identification of one novel RT mutation in Taiwanese patients."; RL Pediatr. Int. 43:263-266(2001). RN [81] RP VARIANTS CS CYS-105; PRO-267; VAL-276; CYS-281; PRO-289; ARG-338; HIS-340; RP PHE-342; TRP-342; CYS-347; CYS-354; HIS-549 AND GLY-678, VARIANTS PS RP PHE-172; 252-SER-PRO-253 DELINS PHE-SER; CYS-290; CYS-340; PRO-341; RP ARG-342; SER-342; CYS-375; GLY-565; ARG-641 AND GLU-663, VARIANTS APRS RP TRP-252 AND ARG-253, VARIANTS CS/PS PHE-278 AND TYR-342, VARIANT RP CRANIOSYNOSTOSIS ASN-659, AND VARIANTS THR-186 AND SER-315. RX PubMed=11781872; DOI=10.1086/338758; RA Kan S.-H., Elanko N., Johnson D., Cornejo-Roldan L.R., Cook J., Reich E.W., RA Tomkins S., Verloes A., Twigg S.R.F., Rannan-Eliya S., RA McDonald-McGinn D.M., Zackai E.H., Wall S.A., Muenke M., Wilkie A.O.M.; RT "Genomic screening of fibroblast growth-factor receptor 2 reveals a wide RT spectrum of mutations in patients with syndromic craniosynostosis."; RL Am. J. Hum. Genet. 70:472-486(2002). RN [82] RP VARIANT BSTVS CYS-375. RX PubMed=12000365; DOI=10.1034/j.1399-0004.2002.610309.x; RA Wang T.-J., Huang C.-B., Tsai F.-J., Wu J.-Y., Lai R.-B., Hsiao M.; RT "Mutation in the FGFR2 gene in a Taiwanese patient with Beare-Stevenson RT cutis gyrata syndrome."; RL Clin. Genet. 61:218-221(2002). RN [83] RP VARIANT FSPC GLU-526. RX PubMed=16061565; DOI=10.1136/jmg.2004.027888; RA McGillivray G., Savarirayan R., Cox T.C., Stojkoski C., McNeil R., RA Bankier A., Bateman J.F., Roscioli T., Gardner R.J.M., Lamande S.R.; RT "Familial scaphocephaly syndrome caused by a novel mutation in the FGFR2 RT tyrosine kinase domain."; RL J. Med. Genet. 42:656-662(2005). RN [84] RP VARIANTS LADD1 THR-628; THR-648 AND 649-ARG-ASP-650 DELINS SER. RX PubMed=16501574; DOI=10.1038/ng1757; RA Rohmann E., Brunner H.G., Kayserili H., Uyguner O., Nuernberg G., Lew E.D., RA Dobbie A., Eswarakumar V.P., Uzumcu A., Ulubil-Emeroglu M., Leroy J.G., RA Li Y., Becker C., Lehnerdt K., Cremers C.W.R.J., Yueksel-Apak M., RA Nuernberg P., Kubisch C., Schlessinger J., van Bokhoven H., Wollnik B.; RT "Mutations in different components of FGF signaling in LADD syndrome."; RL Nat. Genet. 38:414-417(2006). RN [85] RP VARIANT [LARGE SCALE ANALYSIS] CYS-203. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [86] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-57; THR-186; CYS-203; VAL-272; ASN-283; RP CYS-290 AND THR-612. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [87] RP VARIANTS BBDS1 ASP-381 AND ARG-391, AND CHARACTERIZATION OF VARIANT BBDS1 RP ARG-391. RX PubMed=22387015; DOI=10.1016/j.ajhg.2012.02.005; RA Merrill A.E., Sarukhanov A., Krejci P., Idoni B., Camacho N., Estrada K.D., RA Lyons K.M., Deixler H., Robinson H., Chitayat D., Curry C.J., Lachman R.S., RA Wilcox W.R., Krakow D.; RT "Bent bone dysplasia-FGFR2 type, a distinct skeletal disorder, has RT deficient canonical FGF signaling."; RL Am. J. Hum. Genet. 90:550-557(2012). RN [88] RP VARIANT LEU-57. RX PubMed=26429889; DOI=10.1136/jmedgenet-2015-103336; RA Perles Z., Moon S., Ta-Shma A., Yaacov B., Francescatto L., Edvardson S., RA Rein A.J., Elpeleg O., Katsanis N.; RT "A human laterality disorder caused by a homozygous deleterious mutation in RT MMP21."; RL J. Med. Genet. 52:840-847(2015). CC -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor CC for fibroblast growth factors and plays an essential role in the CC regulation of cell proliferation, differentiation, migration and CC apoptosis, and in the regulation of embryonic development. Required for CC normal embryonic patterning, trophoblast function, limb bud CC development, lung morphogenesis, osteogenesis and skin development. CC Plays an essential role in the regulation of osteoblast CC differentiation, proliferation and apoptosis, and is required for CC normal skeleton development. Promotes cell proliferation in CC keratinocytes and immature osteoblasts, but promotes apoptosis in CC differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand CC binding leads to the activation of several signaling cascades. CC Activation of PLCG1 leads to the production of the cellular signaling CC molecules diacylglycerol and inositol 1,4,5-trisphosphate. CC Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and CC SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the CC MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. CC FGFR2 signaling is down-regulated by ubiquitination, internalization CC and degradation. Mutations that lead to constitutive kinase activation CC or impair normal FGFR2 maturation, internalization and degradation lead CC to aberrant signaling. Over-expressed FGFR2 promotes activation of CC STAT1. {ECO:0000269|PubMed:12529371, ECO:0000269|PubMed:15190072, CC ECO:0000269|PubMed:15629145, ECO:0000269|PubMed:16384934, CC ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17311277, CC ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:18374639, CC ECO:0000269|PubMed:19103595, ECO:0000269|PubMed:19387476, CC ECO:0000269|PubMed:19410646, ECO:0000269|PubMed:21596750, CC ECO:0000269|PubMed:8663044}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:16844695, ECO:0000269|PubMed:18056630, CC ECO:0000269|PubMed:19410646, ECO:0000269|PubMed:21454610}; CC -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence CC of bound ligand. Ligand binding leads to dimerization and activation by CC autophosphorylation on tyrosine residues. Inhibited by ARQ 523 and ARQ CC 069; these compounds maintain the kinase in an inactive conformation CC and inhibit autophosphorylation. {ECO:0000269|PubMed:17803937, CC ECO:0000269|PubMed:21454610}. CC -!- SUBUNIT: Monomer. Homodimer after ligand binding. Interacts CC predominantly with FGF1 and FGF2, but can also interact with FGF3, CC FGF4, FGF6, FGF7, FGF8, FGF9, FGF10, FGF17, FGF18 and FGF22 (in vitro). CC Ligand specificity is determined by tissue-specific expression of CC isoforms, and differences in the third Ig-like domain are crucial for CC ligand specificity. Isoform 1 has high affinity for FGF1 and FGF2, but CC low affinity for FGF7. Isoform 3 has high affinity for FGF1 and FGF7, CC and has much higher affinity for FGF7 than isoform 1 (in vitro). CC Affinity for fibroblast growth factors (FGFs) is increased by heparan CC sulfate glycosaminoglycans that function as coreceptors. Likewise, KLB CC increases the affinity for FGF19 and FGF21. Interacts with PLCG1, GRB2 CC and PAK4. Interacts with FLRT2 (By similarity). CC {ECO:0000250|UniProtKB:P21803, ECO:0000269|PubMed:10618369, CC ECO:0000269|PubMed:10830168, ECO:0000269|PubMed:11069186, CC ECO:0000269|PubMed:11390973, ECO:0000269|PubMed:12529371, CC ECO:0000269|PubMed:12591959, ECO:0000269|PubMed:1309608, CC ECO:0000269|PubMed:1400433, ECO:0000269|PubMed:15190072, CC ECO:0000269|PubMed:15629145, ECO:0000269|PubMed:16384934, CC ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:16844695, CC ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:17803937, CC ECO:0000269|PubMed:18056630, ECO:0000269|PubMed:19060208, CC ECO:0000269|PubMed:19103595, ECO:0000269|PubMed:21454610, CC ECO:0000269|PubMed:8663044, ECO:0000269|PubMed:8961926}. CC -!- INTERACTION: CC P21802; P06734: FCER2; NbExp=2; IntAct=EBI-1028658, EBI-10199985; CC P21802; P05230: FGF1; NbExp=3; IntAct=EBI-1028658, EBI-698068; CC P21802; PRO_0000008908 [P05230]: FGF1; NbExp=5; IntAct=EBI-1028658, EBI-6880860; CC P21802; O15520: FGF10; NbExp=2; IntAct=EBI-1028658, EBI-1035684; CC P21802; P09038: FGF2; NbExp=5; IntAct=EBI-1028658, EBI-977447; CC P21802; P09038-2: FGF2; NbExp=2; IntAct=EBI-1028658, EBI-11122080; CC P21802; P11362: FGFR1; NbExp=3; IntAct=EBI-1028658, EBI-1028277; CC P21802; P62993: GRB2; NbExp=6; IntAct=EBI-1028658, EBI-401755; CC P21802; P03968: FGF1; Xeno; NbExp=2; IntAct=EBI-1028658, EBI-6358090; CC P21802-1; P05230-1: FGF1; NbExp=2; IntAct=EBI-15489960, EBI-15489950; CC P21802-1; P09038: FGF2; NbExp=2; IntAct=EBI-15489960, EBI-977447; CC P21802-1; P21802-1: FGFR2; NbExp=3; IntAct=EBI-15489960, EBI-15489960; CC P21802-1; P19174: PLCG1; NbExp=9; IntAct=EBI-15489960, EBI-79387; CC P21802-3; P21781: FGF7; NbExp=2; IntAct=EBI-6354683, EBI-3937699; CC P21802-3; P03968: FGF1; Xeno; NbExp=2; IntAct=EBI-6354683, EBI-6358090; CC -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane CC protein. Golgi apparatus. Cytoplasmic vesicle. Note=Detected on CC osteoblast plasma membrane lipid rafts. After ligand binding, the CC activated receptor is rapidly internalized and degraded. CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane; Single-pass type I CC membrane protein. Note=After ligand binding, the activated receptor is CC rapidly internalized and degraded. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Cell membrane; Single-pass type I CC membrane protein. Note=After ligand binding, the activated receptor is CC rapidly internalized and degraded. CC -!- SUBCELLULAR LOCATION: [Isoform 8]: Secreted. CC -!- SUBCELLULAR LOCATION: [Isoform 13]: Secreted. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=17; CC Name=1; Synonyms=BEK, FGFR2IIIc; CC IsoId=P21802-1; Sequence=Displayed; CC Name=2; Synonyms=Short; CC IsoId=P21802-2; Sequence=VSP_002978; CC Name=3; Synonyms=BFR-1, FGFR2IIIb, KGFR; CC IsoId=P21802-3; Sequence=VSP_002969, VSP_002970, VSP_002971, CC VSP_002972; CC Name=4; Synonyms=K-sam; CC IsoId=P21802-4; Sequence=VSP_002964, VSP_002969, VSP_002970, CC VSP_002971, VSP_002972, VSP_002975, CC VSP_002976; CC Name=5; Synonyms=K-sam-I, BEK, IgIIIc; CC IsoId=P21802-5; Sequence=VSP_002975; CC Name=6; Synonyms=K-sam-IIC2; CC IsoId=P21802-6; Sequence=VSP_002975, VSP_002984; CC Name=7; Synonyms=K-sam-IIC3; CC IsoId=P21802-8; Sequence=VSP_002975, VSP_002978; CC Name=8; Synonyms=K-sam-IV, Soluble KGFR; CC IsoId=P21802-14; Sequence=VSP_002965, VSP_002966; CC Name=9; Synonyms=K-sam-III; CC IsoId=P21802-15; Sequence=VSP_002968; CC Name=10; Synonyms=TK14; CC IsoId=P21802-16; Sequence=VSP_002967, VSP_002975; CC Name=11; CC IsoId=P21802-17; Sequence=VSP_002969, VSP_002970, VSP_002971, CC VSP_002972, VSP_002978; CC Name=12; Synonyms=K-sam-IIC1, KGFR, IgIIIb; CC IsoId=P21802-18; Sequence=VSP_002969, VSP_002970, VSP_002971, CC VSP_002972, VSP_002975; CC Name=13; Synonyms=Soluble KGFR; CC IsoId=P21802-19; Sequence=VSP_002969, VSP_002970, VSP_002971, CC VSP_002972, VSP_002973, VSP_002974; CC Name=14; CC IsoId=P21802-20; Sequence=VSP_019608, VSP_019609; CC Name=15; CC IsoId=P21802-21; Sequence=VSP_002964, VSP_041915; CC Name=16; CC IsoId=P21802-22; Sequence=VSP_002964, VSP_002969, VSP_002970, CC VSP_002971, VSP_002972, VSP_002978; CC Name=17; CC IsoId=P21802-23; Sequence=VSP_041914; CC -!- DOMAIN: The second and third Ig-like domains directly interact with CC fibroblast growth factors (FGF) and heparan sulfate proteoglycans. CC Alternative splicing events affecting the third Ig-like domain are CC crucial for ligand selectivity. {ECO:0000269|PubMed:1309608, CC ECO:0000269|PubMed:1400433, ECO:0000269|PubMed:8961926}. CC -!- PTM: Autophosphorylated. Binding of FGF family members together with CC heparan sulfate proteoglycan or heparin promotes receptor dimerization CC and autophosphorylation on several tyrosine residues. CC Autophosphorylation occurs in trans between the two FGFR molecules CC present in the dimer. Phosphorylation at Tyr-769 is essential for CC interaction with PLCG1. {ECO:0000269|PubMed:15629145, CC ECO:0000269|PubMed:19060208}. CC -!- PTM: N-glycosylated in the endoplasmic reticulum. The N-glycan chains CC undergo further maturation to an Endo H-resistant form in the Golgi CC apparatus. {ECO:0000269|PubMed:16844695, ECO:0000269|PubMed:17311277}. CC -!- PTM: Ubiquitinated. FGFR2 is rapidly ubiquitinated after CC autophosphorylation, leading to internalization and degradation. CC Subject to degradation both in lysosomes and by the proteasome. CC {ECO:0000269|PubMed:15190072, ECO:0000269|PubMed:16844695, CC ECO:0000269|PubMed:21596750}. CC -!- DISEASE: Crouzon syndrome (CS) [MIM:123500]: An autosomal dominant CC syndrome characterized by craniosynostosis, hypertelorism, exophthalmos CC and external strabismus, parrot-beaked nose, short upper lip, CC hypoplastic maxilla, and a relative mandibular prognathism. CC {ECO:0000269|PubMed:10574673, ECO:0000269|PubMed:11173845, CC ECO:0000269|PubMed:11380921, ECO:0000269|PubMed:11781872, CC ECO:0000269|PubMed:17803937, ECO:0000269|PubMed:7581378, CC ECO:0000269|PubMed:7655462, ECO:0000269|PubMed:7874170, CC ECO:0000269|PubMed:7987400, ECO:0000269|PubMed:8528214, CC ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:8946174, CC ECO:0000269|PubMed:8956050, ECO:0000269|PubMed:9152842, CC ECO:0000269|PubMed:9521581, ECO:0000269|PubMed:9677057, CC ECO:0000269|Ref.10}. Note=The disease is caused by variants affecting CC the gene represented in this entry. CC -!- DISEASE: Jackson-Weiss syndrome (JWS) [MIM:123150]: An autosomal CC dominant craniosynostosis syndrome characterized by craniofacial CC abnormalities and abnormality of the feet: broad great toes with medial CC deviation and tarsal-metatarsal coalescence. CC {ECO:0000269|PubMed:7874170, ECO:0000269|PubMed:8528214, CC ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9385368, CC ECO:0000269|PubMed:9677057}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Apert syndrome (APRS) [MIM:101200]: A syndrome characterized CC by facio-cranio-synostosis, osseous and membranous syndactyly of the CC four extremities, and midface hypoplasia. The craniosynostosis is CC bicoronal and results in acrocephaly of brachysphenocephalic type. CC Syndactyly of the fingers and toes may be total (mitten hands and sock CC feet) or partial affecting the second, third, and fourth digits. CC Intellectual deficit is frequent and often severe, usually being CC associated with cerebral malformations. {ECO:0000269|PubMed:11390973, CC ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:15190072, CC ECO:0000269|PubMed:7668257, ECO:0000269|PubMed:7719344, CC ECO:0000269|PubMed:9002682, ECO:0000269|PubMed:9452027, CC ECO:0000269|PubMed:9677057}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Pfeiffer syndrome (PS) [MIM:101600]: A syndrome characterized CC by the association of craniosynostosis, broad and deviated thumbs and CC big toes, and partial syndactyly of the fingers and toes. Three CC subtypes are known: mild autosomal dominant form (type 1); cloverleaf CC skull, elbow ankylosis, early death, sporadic (type 2); CC craniosynostosis, early demise, sporadic (type 3). CC {ECO:0000269|PubMed:10394936, ECO:0000269|PubMed:10945669, CC ECO:0000269|PubMed:11173845, ECO:0000269|PubMed:11781872, CC ECO:0000269|PubMed:16844695, ECO:0000269|PubMed:17803937, CC ECO:0000269|PubMed:7719333, ECO:0000269|PubMed:7719345, CC ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9002682, CC ECO:0000269|PubMed:9150725, ECO:0000269|PubMed:9693549, CC ECO:0000269|PubMed:9719378}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Beare-Stevenson cutis gyrata syndrome (BSTVS) [MIM:123790]: An CC autosomal dominant disease characterized by craniofacial anomalies, CC particularly craniosynostosis, and ear defects, cutis gyrata, CC acanthosis nigricans, anogenital anomalies, skin tags, and prominent CC umbilical stump. The skin furrows have a corrugated appearance and are CC widespread. Cutis gyrata variably affects the scalp, forehead, face, CC preauricular area, neck, trunk, hands, and feet. CC {ECO:0000269|PubMed:12000365, ECO:0000269|PubMed:8696350}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Familial scaphocephaly syndrome (FSPC) [MIM:609579]: An CC autosomal dominant craniosynostosis syndrome characterized by CC scaphocephaly, macrocephaly, hypertelorism, maxillary retrusion, and CC mild intellectual disability. Scaphocephaly is the most common of the CC craniosynostosis conditions and is characterized by a long, narrow CC head. It is due to premature fusion of the sagittal suture or from CC external deformation. {ECO:0000269|PubMed:16061565, CC ECO:0000269|PubMed:17803937}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Lacrimo-auriculo-dento-digital syndrome 1 (LADD1) CC [MIM:149730]: A form of lacrimo-auriculo-dento-digital syndrome, an CC autosomal dominant disease characterized by aplastic/hypoplastic CC lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, CC hypodontia and enamel hypoplasia, and distal limb segments anomalies. CC In addition to these cardinal features, facial dysmorphism, CC malformations of the kidney and respiratory system and abnormal CC genitalia have been reported. Craniosynostosis and severe syndactyly CC are not observed. {ECO:0000269|PubMed:16501574, CC ECO:0000269|PubMed:18056630}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Antley-Bixler syndrome, without genital anomalies or CC disordered steroidogenesis (ABS2) [MIM:207410]: A rare syndrome CC characterized by craniosynostosis, radiohumeral synostosis present from CC the perinatal period, midface hypoplasia, choanal stenosis or atresia, CC femoral bowing and multiple joint contractures. Arachnodactyly and/or CC camptodactyly have also been reported. {ECO:0000269|PubMed:10633130}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Bent bone dysplasia syndrome 1 (BBDS1) [MIM:614592]: A CC perinatal lethal skeletal dysplasia characterized by poor CC mineralization of the calvarium, craniosynostosis, dysmorphic facial CC features, prenatal teeth, hypoplastic pubis and clavicles, osteopenia, CC and bent long bones. Dysmorphic facial features included low-set ears, CC hypertelorism, midface hypoplasia, prematurely erupted fetal teeth, and CC micrognathia. {ECO:0000269|PubMed:22387015}. Note=The disease is caused CC by variants affecting the gene represented in this entry. CC -!- DISEASE: Saethre-Chotzen syndrome (SCS) [MIM:101400]: A CC craniosynostosis syndrome characterized by coronal synostosis, CC brachycephaly, low frontal hairline, facial asymmetry, hypertelorism, CC broad halluces, and clinodactyly. {ECO:0000269|PubMed:9585583}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Fibroblast growth factor receptor subfamily. CC {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA89296.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Somatic variant that appeared in a cancer cell line as a result of genome instability.; Evidence={ECO:0000305|PubMed:10626794}; CC Sequence=BAA89297.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Somatic variant that appeared in a cancer cell line as a result of genome instability.; Evidence={ECO:0000305|PubMed:10626794}; CC Sequence=BAA89298.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Somatic variant that appeared in a cancer cell line as a result of genome instability.; Evidence={ECO:0000305|PubMed:10626794}; CC Sequence=BAA89299.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Somatic variant that appeared in a cancer cell line as a result of genome instability.; Evidence={ECO:0000305|PubMed:10626794}; CC Sequence=BAA89300.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Somatic variant that appeared in a cancer cell line as a result of genome instability.; Evidence={ECO:0000305|PubMed:10626794}; CC Sequence=BAA89301.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Somatic variant that appeared in a cancer cell line as a result of genome instability.; Evidence={ECO:0000305|PubMed:10626794}; CC Sequence=BAG57383.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40570/FGFR2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X52832; CAA37014.1; -; mRNA. DR EMBL; M55614; AAA61188.1; -; mRNA. DR EMBL; X56191; CAA39654.1; -; mRNA. DR EMBL; M35718; AAA36152.1; -; mRNA. DR EMBL; M87770; AAA59470.1; -; mRNA. DR EMBL; M87771; AAA59471.1; -; mRNA. DR EMBL; M87772; AAA59472.1; -; mRNA. DR EMBL; M97193; AAA52449.1; -; mRNA. DR EMBL; U11814; AAA68514.1; -; mRNA. DR EMBL; M80634; AAA36147.1; -; mRNA. DR EMBL; Z71929; CAA96492.1; -; mRNA. DR EMBL; AB030073; BAA89296.1; ALT_SEQ; mRNA. DR EMBL; AB030074; BAA89297.1; ALT_SEQ; mRNA. DR EMBL; AB030075; BAA89298.1; ALT_SEQ; mRNA. DR EMBL; AB030076; BAA89299.1; ALT_SEQ; mRNA. DR EMBL; AB030077; BAA89300.1; ALT_SEQ; mRNA. DR EMBL; AB030078; BAA89301.1; ALT_SEQ; mRNA. DR EMBL; AF360695; AAK94205.1; -; Genomic_DNA. DR EMBL; AF410480; AAK94205.1; JOINED; Genomic_DNA. DR EMBL; AF360695; AAK94206.1; -; Genomic_DNA. DR EMBL; AF410480; AAK94206.1; JOINED; Genomic_DNA. DR EMBL; AF360695; AAK94207.1; -; Genomic_DNA. DR EMBL; AF410480; AAK94207.1; JOINED; Genomic_DNA. DR EMBL; AF360695; AAK94208.1; -; Genomic_DNA. DR EMBL; AF410480; AAK94208.1; JOINED; Genomic_DNA. DR EMBL; AF360695; AAK94209.1; -; Genomic_DNA. DR EMBL; AF410480; AAK94209.1; JOINED; Genomic_DNA. DR EMBL; AF487553; AAM74056.1; -; Genomic_DNA. DR EMBL; AB084153; BAC45037.1; -; mRNA. DR EMBL; DQ493927; ABE96832.1; -; Genomic_DNA. DR EMBL; AK294026; BAG57383.1; ALT_INIT; mRNA. DR EMBL; AC009988; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC039243; AAH39243.2; -; mRNA. DR EMBL; AF169399; AAF43273.1; -; Genomic_DNA. DR EMBL; AF169399; AAF43274.1; -; Genomic_DNA. DR EMBL; AF097353; AAD31560.1; -; Genomic_DNA. DR EMBL; AF097341; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097342; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097343; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097345; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097346; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097347; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097348; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097349; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097350; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097351; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097352; AAD31560.1; JOINED; Genomic_DNA. DR EMBL; AF097353; AAD31561.1; -; Genomic_DNA. DR EMBL; AF097341; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097342; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097344; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097345; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097346; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097347; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097348; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097349; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097350; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097351; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097352; AAD31561.1; JOINED; Genomic_DNA. DR EMBL; AF097340; AAD31562.1; -; Genomic_DNA. DR EMBL; AF097337; AAD31562.1; JOINED; Genomic_DNA. DR EMBL; AF097338; AAD31562.1; JOINED; Genomic_DNA. DR EMBL; AF097339; AAD31562.1; JOINED; Genomic_DNA. DR EMBL; AF097354; AAD31565.1; -; Genomic_DNA. DR EMBL; AF097341; AAD31567.1; -; Genomic_DNA. DR EMBL; S82438; AAD14392.1; -; Genomic_DNA. DR EMBL; Y17131; CAA76643.1; -; Genomic_DNA. DR EMBL; L49237; AAC41933.1; -; Genomic_DNA. DR EMBL; L49242; AAC41934.1; -; Genomic_DNA. DR EMBL; L49238; AAC41935.1; -; Genomic_DNA. DR EMBL; L49239; AAC41936.1; -; Genomic_DNA. DR EMBL; L49240; AAC41937.1; -; Genomic_DNA. DR EMBL; L49241; AAC41938.1; -; Genomic_DNA. DR CCDS; CCDS31298.1; -. [P21802-1] DR CCDS; CCDS44485.1; -. [P21802-20] DR CCDS; CCDS44486.1; -. [P21802-23] DR CCDS; CCDS44487.1; -. [P21802-15] DR CCDS; CCDS44488.1; -. [P21802-22] DR CCDS; CCDS44489.1; -. [P21802-17] DR CCDS; CCDS53584.1; -. [P21802-21] DR CCDS; CCDS7620.2; -. [P21802-3] DR CCDS; CCDS81515.1; -. [P21802-5] DR PIR; A35969; A35969. DR PIR; A42691; TVHUF2. DR PIR; A45081; A45081. DR PIR; C42691; C42691. DR PIR; S16236; S16236. DR RefSeq; NP_000132.3; NM_000141.5. [P21802-1] DR RefSeq; NP_001138385.1; NM_001144913.1. [P21802-17] DR RefSeq; NP_001138386.1; NM_001144914.1. [P21802-23] DR RefSeq; NP_001138387.1; NM_001144915.2. [P21802-21] DR RefSeq; NP_001138388.1; NM_001144916.1. DR RefSeq; NP_001138389.1; NM_001144917.2. [P21802-15] DR RefSeq; NP_001138390.1; NM_001144918.2. [P21802-20] DR RefSeq; NP_001138391.1; NM_001144919.2. [P21802-22] DR RefSeq; NP_001307583.1; NM_001320654.1. DR RefSeq; NP_001307587.1; NM_001320658.2. [P21802-5] DR RefSeq; NP_001428016.1; NM_001441087.1. [P21802-18] DR RefSeq; NP_075259.4; NM_022970.4. [P21802-3] DR RefSeq; NP_075418.1; NM_023029.2. DR PDB; 1DJS; X-ray; 2.40 A; A=153-362. DR PDB; 1E0O; X-ray; 2.80 A; B/D=148-366. DR PDB; 1EV2; X-ray; 2.20 A; E/F/G/H=147-366. DR PDB; 1GJO; X-ray; 2.40 A; A=456-768. DR PDB; 1II4; X-ray; 2.70 A; E/F/G/H=147-366. DR PDB; 1IIL; X-ray; 2.30 A; E/F/G/H=147-366. DR PDB; 1NUN; X-ray; 2.90 A; B=140-368. DR PDB; 1OEC; X-ray; 2.40 A; A=456-768. DR PDB; 1WVZ; NMR; -; A=147-249. DR PDB; 2FDB; X-ray; 2.28 A; P/R=149-368. DR PDB; 2PSQ; X-ray; 2.40 A; A/B=413-768. DR PDB; 2PVF; X-ray; 1.80 A; A=458-778, B=764-778. DR PDB; 2PVY; X-ray; 2.20 A; A/B/C/D=458-768. DR PDB; 2PWL; X-ray; 2.40 A; A/B=458-768. DR PDB; 2PY3; X-ray; 2.30 A; A/B=458-768. DR PDB; 2PZ5; X-ray; 2.40 A; A/B=458-768. DR PDB; 2PZP; X-ray; 2.40 A; A/B=458-768. DR PDB; 2PZR; X-ray; 3.00 A; A/B=458-768. DR PDB; 2Q0B; X-ray; 2.90 A; A/B=458-768. DR PDB; 3B2T; X-ray; 1.80 A; A/B=458-766. DR PDB; 3CAF; X-ray; 1.96 A; A=150-249. DR PDB; 3CLY; X-ray; 2.00 A; A=458-778. DR PDB; 3CU1; X-ray; 2.60 A; A/C=150-249. DR PDB; 3DAR; X-ray; 2.20 A; A/B=146-249. DR PDB; 3EUU; X-ray; 2.34 A; A/B=150-249. DR PDB; 3OJ2; X-ray; 2.20 A; C/D=140-313. DR PDB; 3OJM; X-ray; 2.10 A; B=140-313. DR PDB; 3RI1; X-ray; 2.10 A; A/B=458-768. DR PDB; 4J23; X-ray; 3.88 A; A=147-366. DR PDB; 4J95; X-ray; 2.38 A; A/B/C/D=458-768. DR PDB; 4J96; X-ray; 2.30 A; A/B=458-768. DR PDB; 4J97; X-ray; 2.55 A; A/B/C/D=458-768. DR PDB; 4J98; X-ray; 2.31 A; A/B=458-768. DR PDB; 4J99; X-ray; 1.85 A; A/B/C/D=458-768. DR PDB; 4WV1; X-ray; 2.36 A; C/F=153-251. DR PDB; 5EG3; X-ray; 2.61 A; A=458-778. DR PDB; 5UGL; X-ray; 1.86 A; A/B=458-768. DR PDB; 5UGX; X-ray; 2.35 A; A/B=458-768. DR PDB; 5UHN; X-ray; 2.91 A; A/B=458-768. DR PDB; 5UI0; X-ray; 2.05 A; A/B=458-768. DR PDB; 6AGX; X-ray; 2.95 A; A/B/C/D=467-764. DR PDB; 6LVK; X-ray; 2.29 A; A/B=459-768. DR PDB; 6LVL; X-ray; 2.98 A; A/B=459-768. DR PDB; 6V6Q; X-ray; 2.46 A; A/B/C/D=413-821. DR PDB; 7KIA; X-ray; 2.22 A; A/B=461-768. DR PDB; 7KIE; X-ray; 2.47 A; A/B=461-768. DR PDB; 7OZY; X-ray; 2.28 A; AAA/BBB=465-763. DR PDB; 8E1X; X-ray; 2.68 A; A/B=459-768. DR PDB; 8H75; X-ray; 3.75 A; A/B/C/D=459-768. DR PDB; 8STG; X-ray; 3.79 A; A/B=458-769. DR PDB; 8SWE; X-ray; 2.24 A; A/B=458-768. DR PDB; 8U1F; X-ray; 3.33 A; A/B=458-768. DR PDB; 8W2X; X-ray; 2.98 A; A/B=458-768. DR PDB; 8W38; X-ray; 2.60 A; A/B/C/D=458-768. DR PDB; 8W3B; X-ray; 2.23 A; A/B/C/D=458-768. DR PDB; 8W3D; X-ray; 2.04 A; A/B/C/D=458-768. DR PDB; 9U3N; X-ray; 3.25 A; A/B=458-768. DR PDBsum; 1DJS; -. DR PDBsum; 1E0O; -. DR PDBsum; 1EV2; -. DR PDBsum; 1GJO; -. DR PDBsum; 1II4; -. DR PDBsum; 1IIL; -. DR PDBsum; 1NUN; -. DR PDBsum; 1OEC; -. DR PDBsum; 1WVZ; -. DR PDBsum; 2FDB; -. DR PDBsum; 2PSQ; -. DR PDBsum; 2PVF; -. DR PDBsum; 2PVY; -. DR PDBsum; 2PWL; -. DR PDBsum; 2PY3; -. DR PDBsum; 2PZ5; -. DR PDBsum; 2PZP; -. DR PDBsum; 2PZR; -. DR PDBsum; 2Q0B; -. DR PDBsum; 3B2T; -. DR PDBsum; 3CAF; -. DR PDBsum; 3CLY; -. DR PDBsum; 3CU1; -. DR PDBsum; 3DAR; -. DR PDBsum; 3EUU; -. DR PDBsum; 3OJ2; -. DR PDBsum; 3OJM; -. DR PDBsum; 3RI1; -. DR PDBsum; 4J23; -. DR PDBsum; 4J95; -. DR PDBsum; 4J96; -. DR PDBsum; 4J97; -. DR PDBsum; 4J98; -. DR PDBsum; 4J99; -. DR PDBsum; 4WV1; -. DR PDBsum; 5EG3; -. DR PDBsum; 5UGL; -. DR PDBsum; 5UGX; -. DR PDBsum; 5UHN; -. DR PDBsum; 5UI0; -. DR PDBsum; 6AGX; -. DR PDBsum; 6LVK; -. DR PDBsum; 6LVL; -. DR PDBsum; 6V6Q; -. DR PDBsum; 7KIA; -. DR PDBsum; 7KIE; -. DR PDBsum; 7OZY; -. DR PDBsum; 8E1X; -. DR PDBsum; 8H75; -. DR PDBsum; 8STG; -. DR PDBsum; 8SWE; -. DR PDBsum; 8U1F; -. DR PDBsum; 8W2X; -. DR PDBsum; 8W38; -. DR PDBsum; 8W3B; -. DR PDBsum; 8W3D; -. DR PDBsum; 9U3N; -. DR AlphaFoldDB; P21802; -. DR BMRB; P21802; -. DR SMR; P21802; -. DR BioGRID; 108554; 241. DR CORUM; P21802; -. DR DIP; DIP-3788N; -. DR FunCoup; P21802; 1763. DR IntAct; P21802; 206. DR MINT; P21802; -. DR STRING; 9606.ENSP00000410294; -. DR BindingDB; P21802; -. DR ChEMBL; CHEMBL4142; -. DR DrugBank; DB02058; 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone. DR DrugBank; DB02491; 4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine. DR DrugBank; DB12558; AEE-788. DR DrugBank; DB12903; DEBIO-1347. DR DrugBank; DB12147; Erdafitinib. DR DrugBank; DB10770; Foreskin fibroblast (neonatal). DR DrugBank; DB10772; Foreskin keratinocyte (neonatal). DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB15149; Futibatinib. DR DrugBank; DB01109; Heparin. DR DrugBank; DB11886; Infigratinib. DR DrugBank; DB17587; KIN-3248. DR DrugBank; DB09078; Lenvatinib. DR DrugBank; DB11845; Lucitanib. DR DrugBank; DB13022; LY-2874455. DR DrugBank; DB09079; Nintedanib. DR DrugBank; DB00039; Palifermin. DR DrugBank; DB15102; Pemigatinib. DR DrugBank; DB08901; Ponatinib. DR DrugBank; DB15822; Pralsetinib. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB15685; Selpercatinib. DR DrugBank; DB01901; Sucrosofate. DR DrugCentral; P21802; -. DR GuidetoPHARMACOLOGY; 1809; -. DR GlyConnect; 1997; 1 N-Linked glycan (1 site). DR GlyCosmos; P21802; 9 sites, 2 glycans. DR GlyGen; P21802; 9 sites, 4 N-linked glycans (3 sites), 1 O-linked glycan (1 site). DR iPTMnet; P21802; -. DR PhosphoSitePlus; P21802; -. DR BioMuta; FGFR2; -. DR DMDM; 120049; -. DR CPTAC; CPTAC-3175; -. DR jPOST; P21802; -. DR MassIVE; P21802; -. DR PaxDb; 9606-ENSP00000410294; -. DR PeptideAtlas; P21802; -. DR ProteomicsDB; 53905; -. [P21802-1] DR ProteomicsDB; 53910; -. [P21802-14] DR ProteomicsDB; 53911; -. [P21802-15] DR ProteomicsDB; 53912; -. [P21802-16] DR ProteomicsDB; 53913; -. [P21802-17] DR ProteomicsDB; 53914; -. [P21802-18] DR ProteomicsDB; 53915; -. [P21802-19] DR ProteomicsDB; 53916; -. [P21802-2] DR ProteomicsDB; 53917; -. [P21802-20] DR ProteomicsDB; 53918; -. [P21802-21] DR ProteomicsDB; 53919; -. [P21802-22] DR ProteomicsDB; 53920; -. [P21802-23] DR ProteomicsDB; 53921; -. [P21802-3] DR ProteomicsDB; 53922; -. [P21802-4] DR ProteomicsDB; 53923; -. [P21802-5] DR ProteomicsDB; 53924; -. [P21802-6] DR ProteomicsDB; 53926; -. [P21802-8] DR TopDownProteomics; P21802-8; -. [P21802-8] DR ABCD; P21802; 5 sequenced antibodies. DR Antibodypedia; 4393; 1424 antibodies from 47 providers. DR DNASU; 2263; -. DR Ensembl; ENST00000346997.6; ENSP00000263451.5; ENSG00000066468.25. [P21802-5] DR Ensembl; ENST00000351936.11; ENSP00000309878.10; ENSG00000066468.25. [P21802-5] DR Ensembl; ENST00000356226.8; ENSP00000348559.4; ENSG00000066468.25. [P21802-20] DR Ensembl; ENST00000357555.9; ENSP00000350166.5; ENSG00000066468.25. [P21802-21] DR Ensembl; ENST00000358487.10; ENSP00000351276.6; ENSG00000066468.25. [P21802-1] DR Ensembl; ENST00000359354.6; ENSP00000352309.2; ENSG00000066468.25. [P21802-14] DR Ensembl; ENST00000360144.7; ENSP00000353262.3; ENSG00000066468.25. [P21802-22] DR Ensembl; ENST00000369056.5; ENSP00000358052.1; ENSG00000066468.25. [P21802-17] DR Ensembl; ENST00000369060.8; ENSP00000358056.4; ENSG00000066468.25. [P21802-15] DR Ensembl; ENST00000369061.8; ENSP00000358057.4; ENSG00000066468.25. [P21802-23] DR Ensembl; ENST00000457416.7; ENSP00000410294.2; ENSG00000066468.25. [P21802-3] DR Ensembl; ENST00000682550.1; ENSP00000507633.1; ENSG00000066468.25. [P21802-20] DR Ensembl; ENST00000683211.1; ENSP00000508257.1; ENSG00000066468.25. [P21802-5] DR GeneID; 2263; -. DR KEGG; hsa:2263; -. DR MANE-Select; ENST00000358487.10; ENSP00000351276.6; NM_000141.5; NP_000132.3. DR UCSC; uc010qtl.3; human. [P21802-1] DR AGR; HGNC:3689; -. DR CIViC; 2263; 42 evidence items across 27 molecular profiles. DR ClinPGx; PA28128; -. DR CTD; 2263; -. DR DisGeNET; 2263; -. DR GeneCards; FGFR2; -. DR GeneReviews; FGFR2; -. DR HGNC; HGNC:3689; FGFR2. DR HPA; ENSG00000066468; Tissue enriched (brain). DR MalaCards; FGFR2; -. DR MIM; 101200; phenotype. DR MIM; 101400; phenotype. DR MIM; 101600; phenotype. DR MIM; 123150; phenotype. DR MIM; 123500; phenotype. DR MIM; 123790; phenotype. DR MIM; 149730; phenotype. DR MIM; 176943; gene. DR MIM; 207410; phenotype. DR MIM; 609579; phenotype. DR MIM; 614592; phenotype. DR OpenTargets; ENSG00000066468; -. DR Orphanet; 596008; Antley-Bixler syndrome without genital anomaly or disorder of steroidogenesis. DR Orphanet; 87; Apert syndrome. DR Orphanet; 207; Crouzon syndrome. DR Orphanet; 1555; Cutis gyrata-acanthosis nigricans-craniosynostosis syndrome. DR Orphanet; 168624; Familial scaphocephaly syndrome, McGillivray type. DR Orphanet; 313855; FGFR2-related bent bone dysplasia. DR Orphanet; 1540; Jackson-Weiss syndrome. DR Orphanet; 2363; Lacrimoauriculodentodigital syndrome. DR Orphanet; 93258; Pfeiffer syndrome type 1. DR Orphanet; 93259; Pfeiffer syndrome type 2. DR Orphanet; 93260; Pfeiffer syndrome type 3. DR Orphanet; 794; Saethre-Chotzen syndrome. DR VEuPathDB; HostDB:ENSG00000066468; -. DR eggNOG; KOG0200; Eukaryota. DR GeneTree; ENSGT00940000155447; -. DR HOGENOM; CLU_000288_74_2_1; -. DR InParanoid; P21802; -. DR OMA; PANCTSE; -. DR OrthoDB; 5984265at2759; -. DR PAN-GO; P21802; 7 GO annotations based on evolutionary models. DR PhylomeDB; P21802; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P21802; -. DR Reactome; R-HSA-109704; PI3K Cascade. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-190375; FGFR2c ligand binding and activation. DR Reactome; R-HSA-190377; FGFR2b ligand binding and activation. DR Reactome; R-HSA-2023837; Signaling by FGFR2 amplification mutants. DR Reactome; R-HSA-2033519; Activated point mutants of FGFR2. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-5654221; Phospholipase C-mediated cascade, FGFR2. DR Reactome; R-HSA-5654695; PI-3K cascade:FGFR2. DR Reactome; R-HSA-5654699; SHC-mediated cascade:FGFR2. DR Reactome; R-HSA-5654700; FRS-mediated FGFR2 signaling. DR Reactome; R-HSA-5654727; Negative regulation of FGFR2 signaling. DR Reactome; R-HSA-5655253; Signaling by FGFR2 in disease. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8851708; Signaling by FGFR2 IIIa TM. DR Reactome; R-HSA-8853333; Signaling by FGFR2 fusions. DR SignaLink; P21802; -. DR SIGNOR; P21802; -. DR Agora; ENSG00000066468; -. DR BioGRID-ORCS; 2263; 24 hits in 1187 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; FGFR2; human. DR EvolutionaryTrace; P21802; -. DR GeneWiki; Fibroblast_growth_factor_receptor_2; -. DR GenomeRNAi; 2263; -. DR Pharos; P21802; Tclin. DR PRO; PR:P21802; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; P21802; protein. DR Bgee; ENSG00000066468; Expressed in C1 segment of cervical spinal cord and 202 other cell types or tissues. DR ExpressionAtlas; P21802; baseline and differential. DR GO; GO:0005938; C:cell cortex; IDA:UniProtKB. DR GO; GO:0009986; C:cell surface; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-SubCell. DR GO; GO:0060076; C:excitatory synapse; ISS:UniProtKB. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell. DR GO; GO:0016020; C:membrane; NAS:UniProtKB. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0017134; F:fibroblast growth factor binding; IDA:UniProtKB. DR GO; GO:0005007; F:fibroblast growth factor receptor activity; IDA:UniProtKB. DR GO; GO:0008201; F:heparin binding; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; NAS:UniProtKB. DR GO; GO:0001525; P:angiogenesis; ISS:UniProtKB. DR GO; GO:0009887; P:animal organ morphogenesis; ISS:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0007409; P:axonogenesis; ISS:UniProtKB. DR GO; GO:0060348; P:bone development; ISS:UniProtKB. DR GO; GO:0030282; P:bone mineralization; ISS:UniProtKB. DR GO; GO:0060349; P:bone morphogenesis; ISS:UniProtKB. DR GO; GO:0060667; P:branch elongation involved in salivary gland morphogenesis; ISS:UniProtKB. DR GO; GO:0060670; P:branching involved in labyrinthine layer morphogenesis; ISS:UniProtKB. DR GO; GO:0060442; P:branching involved in prostate gland morphogenesis; ISS:UniProtKB. DR GO; GO:0060445; P:branching involved in salivary gland morphogenesis; ISS:UniProtKB. DR GO; GO:0048755; P:branching morphogenesis of a nerve; ISS:UniProtKB. DR GO; GO:0060449; P:bud elongation involved in lung branching; ISS:UniProtKB. DR GO; GO:0045165; P:cell fate commitment; ISS:UniProtKB. DR GO; GO:0007267; P:cell-cell signaling; ISS:UniProtKB. DR GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl. DR GO; GO:0071300; P:cellular response to retinoic acid; IEA:Ensembl. DR GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEA:Ensembl. DR GO; GO:0048565; P:digestive tract development; ISS:UniProtKB. DR GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; IMP:BHF-UCL. DR GO; GO:0048557; P:embryonic digestive tract morphogenesis; ISS:UniProtKB. DR GO; GO:0048568; P:embryonic organ development; ISS:UniProtKB. DR GO; GO:0048562; P:embryonic organ morphogenesis; ISS:UniProtKB. DR GO; GO:0009880; P:embryonic pattern specification; ISS:UniProtKB. DR GO; GO:0003416; P:endochondral bone growth; IEA:Ensembl. DR GO; GO:0048730; P:epidermis morphogenesis; ISS:UniProtKB. DR GO; GO:0030855; P:epithelial cell differentiation; ISS:UniProtKB. DR GO; GO:0060664; P:epithelial cell proliferation involved in salivary gland morphogenesis; ISS:UniProtKB. DR GO; GO:0001837; P:epithelial to mesenchymal transition; IEA:Ensembl. DR GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0035603; P:fibroblast growth factor receptor signaling pathway involved in hemopoiesis; ISS:UniProtKB. DR GO; GO:0035602; P:fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptotic process in bone marrow cell; ISS:UniProtKB. DR GO; GO:0035607; P:fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development; ISS:UniProtKB. DR GO; GO:0035604; P:fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrow; ISS:UniProtKB. DR GO; GO:0022612; P:gland morphogenesis; ISS:UniProtKB. DR GO; GO:0031069; P:hair follicle morphogenesis; ISS:UniProtKB. DR GO; GO:0001701; P:in utero embryonic development; ISS:UniProtKB. DR GO; GO:0042472; P:inner ear morphogenesis; ISS:UniProtKB. DR GO; GO:0032808; P:lacrimal gland development; ISS:UniProtKB. DR GO; GO:0060601; P:lateral sprouting from an epithelium; ISS:UniProtKB. DR GO; GO:0060174; P:limb bud formation; ISS:UniProtKB. DR GO; GO:0048286; P:lung alveolus development; ISS:UniProtKB. DR GO; GO:0030324; P:lung development; ISS:UniProtKB. DR GO; GO:0060463; P:lung lobe morphogenesis; ISS:UniProtKB. DR GO; GO:0060484; P:lung-associated mesenchyme development; ISS:UniProtKB. DR GO; GO:0060615; P:mammary gland bud formation; ISS:UniProtKB. DR GO; GO:0003149; P:membranous septum morphogenesis; ISS:UniProtKB. DR GO; GO:0048762; P:mesenchymal cell differentiation; ISS:UniProtKB. DR GO; GO:0060915; P:mesenchymal cell differentiation involved in lung development; ISS:UniProtKB. DR GO; GO:0060916; P:mesenchymal cell proliferation involved in lung development; ISS:UniProtKB. DR GO; GO:0048333; P:mesodermal cell differentiation; IEA:Ensembl. DR GO; GO:0030901; P:midbrain development; ISS:UniProtKB. DR GO; GO:0016331; P:morphogenesis of embryonic epithelium; ISS:UniProtKB. DR GO; GO:0010839; P:negative regulation of keratinocyte proliferation; IMP:BHF-UCL. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISS:UniProtKB. DR GO; GO:0042476; P:odontogenesis; ISS:UniProtKB. DR GO; GO:0021769; P:orbitofrontal cortex development; ISS:UniProtKB. DR GO; GO:0035265; P:organ growth; ISS:UniProtKB. DR GO; GO:0030916; P:otic vesicle formation; ISS:UniProtKB. DR GO; GO:0003148; P:outflow tract septum morphogenesis; ISS:UniProtKB. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; ISS:UniProtKB. DR GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; ISS:UniProtKB. DR GO; GO:0045787; P:positive regulation of cell cycle; ISS:UniProtKB. DR GO; GO:0051781; P:positive regulation of cell division; ISS:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB. DR GO; GO:0050679; P:positive regulation of epithelial cell proliferation; ISS:UniProtKB. DR GO; GO:0060501; P:positive regulation of epithelial cell proliferation involved in lung morphogenesis; ISS:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB. DR GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; ISS:UniProtKB. DR GO; GO:0010518; P:positive regulation of phospholipase activity; IMP:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:UniProtKB. DR GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IEA:Ensembl. DR GO; GO:0030177; P:positive regulation of Wnt signaling pathway; ISS:UniProtKB. DR GO; GO:0009791; P:post-embryonic development; ISS:UniProtKB. DR GO; GO:0060527; P:prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis; ISS:UniProtKB. DR GO; GO:0060523; P:prostate epithelial cord elongation; ISS:UniProtKB. DR GO; GO:0060512; P:prostate gland morphogenesis; ISS:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0021860; P:pyramidal neuron development; ISS:UniProtKB. DR GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; ISS:UniProtKB. DR GO; GO:0060688; P:regulation of morphogenesis of a branching structure; ISS:UniProtKB. DR GO; GO:0045667; P:regulation of osteoblast differentiation; TAS:UniProtKB. DR GO; GO:0033688; P:regulation of osteoblast proliferation; TAS:UniProtKB. DR GO; GO:0051150; P:regulation of smooth muscle cell differentiation; ISS:UniProtKB. DR GO; GO:0008589; P:regulation of smoothened signaling pathway; ISS:UniProtKB. DR GO; GO:0048608; P:reproductive structure development; ISS:UniProtKB. DR GO; GO:0045471; P:response to ethanol; IEA:Ensembl. DR GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl. DR GO; GO:0048705; P:skeletal system morphogenesis; TAS:UniProtKB. DR GO; GO:0060529; P:squamous basal epithelial stem cell differentiation involved in prostate gland acinus development; ISS:UniProtKB. DR GO; GO:0001657; P:ureteric bud development; ISS:UniProtKB. DR GO; GO:0055010; P:ventricular cardiac muscle tissue morphogenesis; ISS:UniProtKB. DR GO; GO:0021847; P:ventricular zone neuroblast division; ISS:UniProtKB. DR CDD; cd04973; IgI_1_FGFR; 1. DR CDD; cd05857; IgI_2_FGFR; 1. DR CDD; cd05858; IgI_3_FGFR2; 1. DR CDD; cd05101; PTKc_FGFR2; 1. DR FunFam; 1.10.510.10:FF:000007; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000016; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000020; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000252; Fibroblast growth factor receptor; 1. DR FunFam; 3.30.200.20:FF:000011; Fibroblast growth factor receptor; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 3. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00546; -. DR InterPro; IPR016248; FGF_rcpt_fam. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR24416:SF130; FIBROBLAST GROWTH FACTOR RECEPTOR 2; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF07679; I-set; 1. DR Pfam; PF13927; Ig_3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PIRSF; PIRSF000628; FGFR; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00409; IG; 3. DR SMART; SM00408; IGc2; 3. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF48726; Immunoglobulin; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 3. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Apoptosis; ATP-binding; Cell membrane; KW Craniosynostosis; Cytoplasmic vesicle; Disease variant; Disulfide bond; KW Ectodermal dysplasia; Glycoprotein; Golgi apparatus; Heparin-binding; KW Immunoglobulin domain; Intellectual disability; Kinase; KW Lacrimo-auriculo-dento-digital syndrome; Membrane; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Proto-oncogene; Receptor; KW Reference proteome; Repeat; Secreted; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..21 FT /evidence="ECO:0000255" FT CHAIN 22..821 FT /note="Fibroblast growth factor receptor 2" FT /id="PRO_0000016783" FT TOPO_DOM 22..377 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 378..398 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 399..821 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 25..125 FT /note="Ig-like C2-type 1" FT DOMAIN 154..247 FT /note="Ig-like C2-type 2" FT DOMAIN 256..358 FT /note="Ig-like C2-type 3" FT DOMAIN 481..770 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 131..151 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 161..178 FT /note="Heparin-binding" FT COMPBIAS 131..144 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 626 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028, FT ECO:0000269|PubMed:19060208" FT BINDING 487..495 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:19060208" FT BINDING 517 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:19060208" FT BINDING 565..567 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:19060208" FT BINDING 571 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:19060208" FT MOD_RES 466 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:19060208, FT ECO:0000269|PubMed:19410646" FT MOD_RES 586 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:17803937, FT ECO:0000269|PubMed:19060208, ECO:0000269|PubMed:19410646" FT MOD_RES 588 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:19060208, FT ECO:0000269|PubMed:19410646" FT MOD_RES 656 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:17803937, FT ECO:0000269|PubMed:19060208, ECO:0000269|PubMed:19410646" FT MOD_RES 657 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:17803937, FT ECO:0000269|PubMed:19060208, ECO:0000269|PubMed:19410646" FT MOD_RES 769 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15629145, FT ECO:0000269|PubMed:19060208" FT MOD_RES 780 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT CARBOHYD 83 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 123 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 228 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 241 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 265 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 297 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 318 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 331 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 62..107 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 179..231 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:16384934" FT DISULFID 278..342 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:16384934" FT VAR_SEQ 37..152 FT /note="EPPTKYQISQPEVYVAAPGESLEVRCLLKDAAVISWTKDGVHLGPNNRTVLI FT GEYLQIKGATPRDSGLYACTASRTVDSETWYFMVNVTDAISSGDDEDDTDGAEDFVSEN FT SNNKR -> G (in isoform 14)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_019608" FT VAR_SEQ 37..125 FT /note="Missing (in isoform 4, isoform 15 and isoform 16)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:2377625" FT /id="VSP_002964" FT VAR_SEQ 250..361 FT /note="Missing (in isoform 17)" FT /evidence="ECO:0000303|Ref.14" FT /id="VSP_041914" FT VAR_SEQ 250..254 FT /note="ERSPH -> GSQGL (in isoform 8)" FT /evidence="ECO:0000303|PubMed:1313574" FT /id="VSP_002965" FT VAR_SEQ 255..821 FT /note="Missing (in isoform 8)" FT /evidence="ECO:0000303|PubMed:1313574" FT /id="VSP_002966" FT VAR_SEQ 313 FT /note="K -> KVTK (in isoform 10)" FT /evidence="ECO:0000303|PubMed:2172978" FT /id="VSP_002967" FT VAR_SEQ 314..429 FT /note="Missing (in isoform 9)" FT /evidence="ECO:0000303|PubMed:1313574" FT /id="VSP_002968" FT VAR_SEQ 314..330 FT /note="AAGVNTTDKEIEVLYIR -> HSGINSSNAEVLALF (in isoform 3, FT isoform 4, isoform 11, isoform 12, isoform 13 and isoform FT 16)" FT /evidence="ECO:0000303|PubMed:10626794, FT ECO:0000303|PubMed:1309608, ECO:0000303|PubMed:1400433, FT ECO:0000303|PubMed:1647213, ECO:0000303|PubMed:2377625, FT ECO:0000303|PubMed:7866434" FT /id="VSP_002969" FT VAR_SEQ 334..335 FT /note="FE -> EA (in isoform 3, isoform 4, isoform 11, FT isoform 12, isoform 13 and isoform 16)" FT /evidence="ECO:0000303|PubMed:10626794, FT ECO:0000303|PubMed:1309608, ECO:0000303|PubMed:1400433, FT ECO:0000303|PubMed:1647213, ECO:0000303|PubMed:2377625, FT ECO:0000303|PubMed:7866434" FT /id="VSP_002970" FT VAR_SEQ 341..353 FT /note="TCLAGNSIGISFH -> ICKVSNYIGQANQ (in isoform 3, FT isoform 4, isoform 11, isoform 12, isoform 13 and isoform FT 16)" FT /evidence="ECO:0000303|PubMed:10626794, FT ECO:0000303|PubMed:1309608, ECO:0000303|PubMed:1400433, FT ECO:0000303|PubMed:1647213, ECO:0000303|PubMed:2377625, FT ECO:0000303|PubMed:7866434" FT /id="VSP_002971" FT VAR_SEQ 361 FT /note="P -> PKQQ (in isoform 3, isoform 4, isoform 11, FT isoform 12, isoform 13 and isoform 16)" FT /evidence="ECO:0000303|PubMed:10626794, FT ECO:0000303|PubMed:1309608, ECO:0000303|PubMed:1400433, FT ECO:0000303|PubMed:1647213, ECO:0000303|PubMed:2377625, FT ECO:0000303|PubMed:7866434" FT /id="VSP_002972" FT VAR_SEQ 362..365 FT /note="APGR -> GRRC (in isoform 13)" FT /evidence="ECO:0000303|PubMed:1309608, FT ECO:0000303|PubMed:7866434" FT /id="VSP_002973" FT VAR_SEQ 366..821 FT /note="Missing (in isoform 13)" FT /evidence="ECO:0000303|PubMed:1309608, FT ECO:0000303|PubMed:7866434" FT /id="VSP_002974" FT VAR_SEQ 428..429 FT /note="Missing (in isoform 4, isoform 5, isoform 6, isoform FT 7, isoform 10 and isoform 12)" FT /evidence="ECO:0000303|PubMed:1313574, FT ECO:0000303|PubMed:2172978, ECO:0000303|PubMed:2377625" FT /id="VSP_002975" FT VAR_SEQ 429..430 FT /note="Missing (in isoform 14)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_019609" FT VAR_SEQ 761..821 FT /note="LTLTTNEEYLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQY FT PHINGSVKT -> PPNPSLMSIFRK (in isoform 4)" FT /evidence="ECO:0000303|PubMed:2377625" FT /id="VSP_002976" FT VAR_SEQ 768..821 FT /note="EYLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGSV FT KT -> I (in isoform 2, isoform 7, isoform 11 and isoform FT 16)" FT /evidence="ECO:0000303|PubMed:1647213" FT /id="VSP_002978" FT VAR_SEQ 769..821 FT /note="YLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGSVK FT T -> EKKVSGAVDCHKPPCNPSHLPCVLAVDQ (in isoform 15)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_041915" FT VAR_SEQ 778..821 FT /note="QYSPSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGSVKT -> PYSP FT CYPDPR (in isoform 6)" FT /evidence="ECO:0000305" FT /id="VSP_002984" FT VARIANT 6 FT /note="R -> P (in dbSNP:rs3750819)" FT /evidence="ECO:0000269|Ref.15" FT /id="VAR_017258" FT VARIANT 57 FT /note="S -> L (in dbSNP:rs56226109)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:26429889" FT /id="VAR_042204" FT VARIANT 105 FT /note="Y -> C (in CS; dbSNP:rs1434545235)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:8946174" FT /id="VAR_004112" FT VARIANT 172 FT /note="A -> F (in PS; requires 2 nucleotide substitutions)" FT /evidence="ECO:0000269|PubMed:11781872" FT /id="VAR_017259" FT VARIANT 186 FT /note="M -> T (in dbSNP:rs755793)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:17344846, ECO:0000269|Ref.15" FT /id="VAR_017260" FT VARIANT 203 FT /note="R -> C (in breast cancer samples; infiltrating FT ductal carcinoma; somatic mutation; dbSNP:rs2134829270)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17344846" FT /id="VAR_036380" FT VARIANT 252..253 FT /note="SP -> FS (in PS; dbSNP:rs281865420)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:9002682" FT /id="VAR_004116" FT VARIANT 252 FT /note="S -> F (in APRS; requires 2 nucleotide FT substitutions; dbSNP:rs121918498)" FT /evidence="ECO:0000269|PubMed:9002682" FT /id="VAR_004114" FT VARIANT 252 FT /note="S -> L (in dbSNP:rs79184941)" FT /evidence="ECO:0000269|PubMed:9002682" FT /id="VAR_004113" FT VARIANT 252 FT /note="S -> W (in APRS and PS; common mutation; FT dbSNP:rs79184941)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:15190072, ECO:0000269|PubMed:7668257, FT ECO:0000269|PubMed:7719344, ECO:0000269|PubMed:9452027, FT ECO:0000269|PubMed:9677057, ECO:0000269|PubMed:9719378" FT /id="VAR_004115" FT VARIANT 253 FT /note="P -> R (in APRS; common mutation; dbSNP:rs77543610)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7668257, ECO:0000269|PubMed:7719344, FT ECO:0000269|PubMed:9452027, ECO:0000269|PubMed:9677057" FT /id="VAR_004117" FT VARIANT 263 FT /note="P -> L (in CS; dbSNP:rs779326224)" FT /evidence="ECO:0000269|PubMed:11173845" FT /id="VAR_017261" FT VARIANT 267 FT /note="S -> P (in CS; dbSNP:rs121918505)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7655462" FT /id="VAR_004118" FT VARIANT 268 FT /note="T -> TG (in CS)" FT /evidence="ECO:0000269|PubMed:8644708" FT /id="VAR_004119" FT VARIANT 269..270 FT /note="Missing (in SCS)" FT /evidence="ECO:0000269|PubMed:9585583" FT /id="VAR_075856" FT VARIANT 272 FT /note="G -> V (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042205" FT VARIANT 273 FT /note="Missing (in PS; type 2; dbSNP:rs121918503)" FT /evidence="ECO:0000269|PubMed:10945669" FT /id="VAR_017262" FT VARIANT 276 FT /note="F -> V (in CS; dbSNP:rs1057519036)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:9521581" FT /id="VAR_004120" FT VARIANT 278 FT /note="C -> F (in CS, JWS and PS; forms disulfide-linked FT dimers with constitutive kinase activity, is retained in an FT intracellular compartment and not detected at the cell FT surface; dbSNP:rs776587763)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:16844695, FT ECO:0000269|PubMed:7655462, ECO:0000269|PubMed:8644708, FT ECO:0000269|PubMed:9677057" FT /id="VAR_004121" FT VARIANT 278 FT /note="C -> Y (in CS; dbSNP:rs776587763)" FT /evidence="ECO:0000269|PubMed:11173845" FT /id="VAR_017263" FT VARIANT 281 FT /note="Y -> C (in CS; dbSNP:rs1057519038)" FT /evidence="ECO:0000269|PubMed:11380921, FT ECO:0000269|PubMed:11781872" FT /id="VAR_017264" FT VARIANT 283 FT /note="D -> N (in a lung squamous cell carcinoma sample; FT somatic mutation; dbSNP:rs2134313441)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042206" FT VARIANT 287..289 FT /note="Missing (in CS)" FT /id="VAR_004122" FT VARIANT 288 FT /note="I -> S (in CS)" FT /evidence="ECO:0000269|PubMed:11173845" FT /id="VAR_017265" FT VARIANT 289 FT /note="Q -> P (in CS and JWS; dbSNP:rs121918497)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11380921, ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7581378, ECO:0000269|PubMed:8644708" FT /id="VAR_004123" FT VARIANT 290 FT /note="W -> C (in PS; severe; also in a lung squamous cell FT carcinoma sample; somatic mutation; dbSNP:rs121918499)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9150725" FT /id="VAR_004124" FT VARIANT 290 FT /note="W -> G (in CS; dbSNP:rs121918501)" FT /evidence="ECO:0000269|PubMed:8528214" FT /id="VAR_017266" FT VARIANT 290 FT /note="W -> R (in CS; dbSNP:rs121918501)" FT /evidence="ECO:0000269|PubMed:7655462" FT /id="VAR_004125" FT VARIANT 292 FT /note="K -> E (in CS; dbSNP:rs121918500)" FT /evidence="ECO:0000269|PubMed:9152842" FT /id="VAR_004126" FT VARIANT 301 FT /note="Y -> C (in CS; dbSNP:rs1554930684)" FT /evidence="ECO:0000269|PubMed:9521581" FT /id="VAR_004127" FT VARIANT 314 FT /note="A -> S (in craniosynostosis; dbSNP:rs1358919643)" FT /evidence="ECO:0000269|PubMed:9521581" FT /id="VAR_004128" FT VARIANT 315 FT /note="A -> S (in a non-syndromic craniosynostosis patient FT with abnormal intrauterine history; confers predisposition FT to craniosynostosis; dbSNP:rs121918504)" FT /evidence="ECO:0000269|PubMed:10951518, FT ECO:0000269|PubMed:11781872" FT /id="VAR_017267" FT VARIANT 321 FT /note="D -> A (in PS; dbSNP:rs121918510)" FT /evidence="ECO:0000269|PubMed:7719333" FT /id="VAR_004129" FT VARIANT 328 FT /note="Y -> C (in CS; dbSNP:rs121918493)" FT /evidence="ECO:0000269|PubMed:7874170" FT /id="VAR_004130" FT VARIANT 331 FT /note="N -> I (in CS; dbSNP:rs2134258264)" FT /evidence="ECO:0000269|PubMed:8956050" FT /id="VAR_004131" FT VARIANT 337 FT /note="A -> ANA (in CS)" FT /id="VAR_004132" FT VARIANT 337 FT /note="A -> P (in CS; dbSNP:rs387906676)" FT /evidence="ECO:0000269|PubMed:9677057" FT /id="VAR_017268" FT VARIANT 338 FT /note="G -> E (in CS; dbSNP:rs1057519044)" FT /evidence="ECO:0000269|PubMed:8946174" FT /id="VAR_004133" FT VARIANT 338 FT /note="G -> R (in CS; dbSNP:rs1057519043)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7581378, ECO:0000269|PubMed:9677057" FT /id="VAR_015011" FT VARIANT 340 FT /note="Y -> C (in PS; dbSNP:rs1554928884)" FT /evidence="ECO:0000269|PubMed:10394936, FT ECO:0000269|PubMed:11781872" FT /id="VAR_017269" FT VARIANT 340 FT /note="Y -> H (in CS; dbSNP:rs121918489)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7987400" FT /id="VAR_004134" FT VARIANT 341 FT /note="T -> P (in PS and CS; dbSNP:rs121918495)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:7719345" FT /id="VAR_004135" FT VARIANT 342 FT /note="C -> F (in CS; dbSNP:rs121918487)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9677057" FT /id="VAR_004136" FT VARIANT 342 FT /note="C -> G (in PS; dbSNP:rs121918488)" FT /evidence="ECO:0000269|PubMed:10394936" FT /id="VAR_017270" FT VARIANT 342 FT /note="C -> R (in CS, JWS, PS and ABS2; dbSNP:rs121918488)" FT /evidence="ECO:0000269|PubMed:10633130, FT ECO:0000269|PubMed:11173845, ECO:0000269|PubMed:11380921, FT ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:7719345, FT ECO:0000269|PubMed:7987400, ECO:0000269|PubMed:8528214, FT ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9677057" FT /id="VAR_004137" FT VARIANT 342 FT /note="C -> S (in CS, JWS, PS and ABS2; dbSNP:rs121918488)" FT /evidence="ECO:0000269|PubMed:10633130, FT ECO:0000269|PubMed:11173845, ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7581378, ECO:0000269|PubMed:7987400, FT ECO:0000269|PubMed:8644708, ECO:0000269|PubMed:9385368, FT ECO:0000269|Ref.10" FT /id="VAR_004138" FT VARIANT 342 FT /note="C -> W (in CS; dbSNP:rs121918496)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:8528214" FT /id="VAR_017271" FT VARIANT 342 FT /note="C -> Y (in CS and PS; dbSNP:rs121918487)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11380921, ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7581378, ECO:0000269|PubMed:7719345, FT ECO:0000269|PubMed:7987400, ECO:0000269|PubMed:8644708, FT ECO:0000269|PubMed:9677057" FT /id="VAR_004139" FT VARIANT 344 FT /note="A -> G (in CS and JWS; dbSNP:rs121918492)" FT /evidence="ECO:0000269|PubMed:7581378, FT ECO:0000269|PubMed:7874170" FT /id="VAR_004140" FT VARIANT 344 FT /note="A -> P (in CS and PS; dbSNP:rs2134256250)" FT /evidence="ECO:0000269|PubMed:8644708" FT /id="VAR_004141" FT VARIANT 347 FT /note="S -> C (in CS; dbSNP:rs121918494)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:7874170" FT /id="VAR_004142" FT VARIANT 351 FT /note="S -> C (in CS, PS and ABS2; dbSNP:rs121918502)" FT /evidence="ECO:0000269|PubMed:10633130, FT ECO:0000269|PubMed:8946174, ECO:0000269|PubMed:9693549" FT /id="VAR_004143" FT VARIANT 354 FT /note="S -> C (in CS; dbSNP:rs121918490)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:11781872, ECO:0000269|PubMed:7581378, FT ECO:0000269|PubMed:7987400, ECO:0000269|PubMed:8528214" FT /id="VAR_004144" FT VARIANT 354 FT /note="S -> Y (in CS; dbSNP:rs121918490)" FT /evidence="ECO:0000269|PubMed:11173845" FT /id="VAR_017272" FT VARIANT 356..358 FT /note="Missing (in CS)" FT /evidence="ECO:0000269|PubMed:8956050" FT /id="VAR_004145" FT VARIANT 359 FT /note="V -> F (in CS and PS; dbSNP:rs1274989878)" FT /evidence="ECO:0000269|PubMed:11173845, FT ECO:0000269|PubMed:8644708" FT /id="VAR_004146" FT VARIANT 362 FT /note="A -> S (in CS)" FT /evidence="ECO:0000269|PubMed:10574673" FT /id="VAR_017273" FT VARIANT 372 FT /note="S -> C (in BSTVS; dbSNP:rs121913477)" FT /evidence="ECO:0000269|PubMed:8696350" FT /id="VAR_017274" FT VARIANT 375 FT /note="Y -> C (in PS and BSTVS; dbSNP:rs121913478)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:12000365, ECO:0000269|PubMed:8696350" FT /id="VAR_017275" FT VARIANT 381 FT /note="Y -> D (in BBDS1; dbSNP:rs387906678)" FT /evidence="ECO:0000269|PubMed:22387015" FT /id="VAR_067977" FT VARIANT 384 FT /note="G -> R (in CS; dbSNP:rs1554927408)" FT /evidence="ECO:0000269|PubMed:8946174" FT /id="VAR_004147" FT VARIANT 391 FT /note="M -> R (in BBDS1; the mutation selectively reduces FT plasma-membrane levels of the protein and markedly FT diminishes the receptor's responsiveness to extracellular FT FGF; dbSNP:rs387906677)" FT /evidence="ECO:0000269|PubMed:22387015" FT /id="VAR_067978" FT VARIANT 526 FT /note="K -> E (in FSPC; constitutive kinase activity; FT dbSNP:rs121918507)" FT /evidence="ECO:0000269|PubMed:16061565, FT ECO:0000269|PubMed:17803937" FT /id="VAR_023788" FT VARIANT 549 FT /note="N -> H (in CS; constitutive kinase activity; FT dbSNP:rs1057519045)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:17803937" FT /id="VAR_017276" FT VARIANT 565 FT /note="E -> G (in PS; constitutive kinase activity; FT dbSNP:rs121918506)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:17803937" FT /id="VAR_017277" FT VARIANT 612 FT /note="R -> T (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs1846839725)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046071" FT VARIANT 613 FT /note="G -> R (in dbSNP:rs2133933864)" FT /evidence="ECO:0000269|PubMed:10626794, FT ECO:0000269|PubMed:1309608" FT /id="VAR_015012" FT VARIANT 628 FT /note="A -> T (in LADD1; strongly reduced kinase activity; FT dbSNP:rs121918509)" FT /evidence="ECO:0000269|PubMed:16501574" FT /id="VAR_029884" FT VARIANT 641 FT /note="K -> R (in PS; constitutive kinase activity; FT dbSNP:rs1057519047)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:17803937" FT /id="VAR_017278" FT VARIANT 648 FT /note="A -> T (in LADD1; dbSNP:rs121918508)" FT /evidence="ECO:0000269|PubMed:16501574" FT /id="VAR_029885" FT VARIANT 649..650 FT /note="RD -> S (in LADD1)" FT /evidence="ECO:0000269|PubMed:16501574" FT /id="VAR_029886" FT VARIANT 659 FT /note="K -> N (in craniosynostosis; constitutive kinase FT activity; dbSNP:rs1589722765)" FT /evidence="ECO:0000269|PubMed:11781872, FT ECO:0000269|PubMed:17803937" FT /id="VAR_017279" FT VARIANT 663 FT /note="G -> E (in PS; dbSNP:rs2133825396)" FT /evidence="ECO:0000269|PubMed:11781872" FT /id="VAR_017280" FT VARIANT 678 FT /note="R -> G (in CS; dbSNP:rs1845559552)" FT /evidence="ECO:0000269|PubMed:11781872" FT /id="VAR_017281" FT MUTAGEN 265 FT /note="N->Q: Reduced N-glycosylation. Reduced expression at FT the cell surface." FT /evidence="ECO:0000269|PubMed:16844695" FT MUTAGEN 549 FT /note="N->T: Constitutive kinase activity." FT /evidence="ECO:0000269|PubMed:17803937" FT MUTAGEN 565 FT /note="E->A: Constitutive kinase activity." FT /evidence="ECO:0000269|PubMed:17803937" FT MUTAGEN 656..657 FT /note="Missing: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:16844695" FT MUTAGEN 769 FT /note="Y->F: Increases fibroblast proliferation. Decreases FT phosphorylation of PLCG1 and FRS2. Decreases activation of FT MAP kinases." FT /evidence="ECO:0000269|PubMed:15629145, FT ECO:0000269|PubMed:19103595" FT CONFLICT 246 FT /note="L -> P (in Ref. 16; BAG57383)" FT /evidence="ECO:0000305" FT CONFLICT 310 FT /note="K -> N (in Ref. 16; BAG57383)" FT /evidence="ECO:0000305" FT STRAND 152..157 FT /evidence="ECO:0007829|PDB:3CAF" FT TURN 159..162 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 166..170 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 175..178 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 181..185 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 188..193 FT /evidence="ECO:0007829|PDB:3CAF" FT HELIX 200..202 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 203..205 FT /evidence="ECO:0007829|PDB:4WV1" FT STRAND 208..210 FT /evidence="ECO:0007829|PDB:3CAF" FT HELIX 211..213 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 215..218 FT /evidence="ECO:0007829|PDB:3CAF" FT HELIX 223..225 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 227..235 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 238..249 FT /evidence="ECO:0007829|PDB:3CAF" FT STRAND 266..269 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 274..277 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 287..293 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 296..298 FT /evidence="ECO:0007829|PDB:3OJ2" FT STRAND 299..301 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 303..305 FT /evidence="ECO:0007829|PDB:1IIL" FT STRAND 309..314 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 315..319 FT /evidence="ECO:0007829|PDB:2FDB" FT HELIX 321..323 FT /evidence="ECO:0007829|PDB:1IIL" FT STRAND 324..327 FT /evidence="ECO:0007829|PDB:3OJM" FT HELIX 334..336 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 338..346 FT /evidence="ECO:0007829|PDB:3OJM" FT STRAND 349..360 FT /evidence="ECO:0007829|PDB:3OJM" FT TURN 463..465 FT /evidence="ECO:0007829|PDB:5UI0" FT TURN 472..474 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 478..480 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 481..489 FT /evidence="ECO:0007829|PDB:2PVF" FT TURN 490..492 FT /evidence="ECO:0007829|PDB:8W3D" FT STRAND 494..500 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 504..506 FT /evidence="ECO:0007829|PDB:3CLY" FT STRAND 513..518 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 525..541 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 550..554 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 556..558 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 561..565 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 568..571 FT /evidence="ECO:0007829|PDB:1OEC" FT HELIX 572..577 FT /evidence="ECO:0007829|PDB:2PVF" FT TURN 585..588 FT /evidence="ECO:0007829|PDB:4J99" FT HELIX 590..592 FT /evidence="ECO:0007829|PDB:8W3D" FT HELIX 594..596 FT /evidence="ECO:0007829|PDB:5UI0" FT HELIX 600..619 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 629..631 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 632..634 FT /evidence="ECO:0007829|PDB:2PVF" FT TURN 636..638 FT /evidence="ECO:0007829|PDB:2PVY" FT STRAND 640..642 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 645..647 FT /evidence="ECO:0007829|PDB:5UGL" FT TURN 652..654 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 655..658 FT /evidence="ECO:0007829|PDB:2PVF" FT TURN 659..662 FT /evidence="ECO:0007829|PDB:2PZR" FT STRAND 664..666 FT /evidence="ECO:0007829|PDB:5UI0" FT HELIX 667..669 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 672..677 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 682..697 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 709..718 FT /evidence="ECO:0007829|PDB:2PVF" FT STRAND 726..728 FT /evidence="ECO:0007829|PDB:2PZ5" FT HELIX 730..739 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 744..746 FT /evidence="ECO:0007829|PDB:2PVF" FT HELIX 750..764 FT /evidence="ECO:0007829|PDB:2PVF" FT CONFLICT P21802-16:315 FT /note="T -> L (in Ref. 2; AAA61188)" FT /evidence="ECO:0000305" SQ SEQUENCE 821 AA; 92025 MW; 6CD5001C960ED82F CRC64; MVSWGRFICL VVVTMATLSL ARPSFSLVED TTLEPEEPPT KYQISQPEVY VAAPGESLEV RCLLKDAAVI SWTKDGVHLG PNNRTVLIGE YLQIKGATPR DSGLYACTAS RTVDSETWYF MVNVTDAISS GDDEDDTDGA EDFVSENSNN KRAPYWTNTE KMEKRLHAVP AANTVKFRCP AGGNPMPTMR WLKNGKEFKQ EHRIGGYKVR NQHWSLIMES VVPSDKGNYT CVVENEYGSI NHTYHLDVVE RSPHRPILQA GLPANASTVV GGDVEFVCKV YSDAQPHIQW IKHVEKNGSK YGPDGLPYLK VLKAAGVNTT DKEIEVLYIR NVTFEDAGEY TCLAGNSIGI SFHSAWLTVL PAPGREKEIT ASPDYLEIAI YCIGVFLIAC MVVTVILCRM KNTTKKPDFS SQPAVHKLTK RIPLRRQVTV SAESSSSMNS NTPLVRITTR LSSTADTPML AGVSEYELPE DPKWEFPRDK LTLGKPLGEG CFGQVVMAEA VGIDKDKPKE AVTVAVKMLK DDATEKDLSD LVSEMEMMKM IGKHKNIINL LGACTQDGPL YVIVEYASKG NLREYLRARR PPGMEYSYDI NRVPEEQMTF KDLVSCTYQL ARGMEYLASQ KCIHRDLAAR NVLVTENNVM KIADFGLARD INNIDYYKKT TNGRLPVKWM APEALFDRVY THQSDVWSFG VLMWEIFTLG GSPYPGIPVE ELFKLLKEGH RMDKPANCTN ELYMMMRDCW HAVPSQRPTF KQLVEDLDRI LTLTTNEEYL DLSQPLEQYS PSYPDTRSSC SSGDDSVFSP DPMPYEPCLP QYPHINGSVK T // ID FGFR3_HUMAN Reviewed; 806 AA. AC P22607; D3DVP9; D3DVQ0; Q14308; Q16294; Q16608; Q59FL9; DT 01-AUG-1991, integrated into UniProtKB/Swiss-Prot. DT 01-AUG-1991, sequence version 1. DT 28-JAN-2026, entry version 271. DE RecName: Full=Fibroblast growth factor receptor 3; DE Short=FGFR-3; DE EC=2.7.10.1; DE AltName: CD_antigen=CD333; DE Flags: Precursor; GN Name=FGFR3; Synonyms=JTK4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=1847508; DOI=10.1073/pnas.88.4.1095; RA Keegan K., Johnson D.E., Williams L.T., Hayman M.J.; RT "Isolation of an additional member of the fibroblast growth factor receptor RT family, FGFR-3."; RL Proc. Natl. Acad. Sci. U.S.A. 88:1095-1099(1991). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION, SUBUNIT, FGF1- AND RP FGF2-BINDING, SUBCELLULAR LOCATION, GLYCOSYLATION, AND DIMERIZATION. RC TISSUE=Squamous cell carcinoma; RX PubMed=11703096; DOI=10.1006/mcbr.2001.0306; RA Terada M., Shimizu A., Sato N., Miyakaze S.I., Katayama H., RA Kurokawa-Seo M.; RT "Fibroblast growth factor receptor 3 lacking the Ig IIIb and transmembrane RT domains secreted from human squamous cell carcinoma DJM-1 binds to FGFs."; RL Mol. Cell Biol. Res. Commun. 4:365-373(2001). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-65; LEU-384; THR-441; RP THR-717 AND PHE-726. RG NIEHS SNPs program; RL Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 76-806 (ISOFORM 1), AND TISSUE SPECIFICITY. RC TISSUE=Fetal brain; RX PubMed=1664411; DOI=10.1016/0888-7543(91)90041-c; RA Thompson L.M., Plummer S., Schalling M., Altherr M.R., Gusella J.F., RA Housman D.E., Wasmuth J.J.; RT "A gene encoding a fibroblast growth factor receptor isolated from the RT Huntington disease gene region of human chromosome 4."; RL Genomics 11:1133-1142(1991). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 614-681. RX PubMed=2247464; DOI=10.1073/pnas.87.22.8913; RA Partanen J., Maekelae T.P., Alitalo R., Lehvaeslaiho H., Alitalo K.; RT "Putative tyrosine kinases expressed in K-562 human leukemia cells."; RL Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 311-358 (ISOFORM 2). RC TISSUE=Colon tumor; RX PubMed=7923141; RA Murgue B., Tsunekawa S., Rosenberg I., deBeaumont M., Podolsky D.K.; RT "Identification of a novel variant form of fibroblast growth factor RT receptor 3 (FGFR3 IIIb) in human colonic epithelium."; RL Cancer Res. 54:5206-5211(1994). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] OF 311-358 (ISOFORM 2). RC TISSUE=Keratinocyte; RX PubMed=7495869; DOI=10.1016/0167-4781(95)00156-b; RA Scotet E., Houssaint E.; RT "The choice between alternative IIIb and IIIc exons of the FGFR-3 gene is RT not strictly tissue-specific."; RL Biochim. Biophys. Acta 1264:238-242(1995). RN [11] RP INTERACTION WITH FGF1; FGF2; FGF4; FGF8 AND FGF9, AND FUNCTION IN CELL RP PROLIFERATION. RX PubMed=8663044; DOI=10.1074/jbc.271.25.15292; RA Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A., Coulier F., RA Gao G., Goldfarb M.; RT "Receptor specificity of the fibroblast growth factor family."; RL J. Biol. Chem. 271:15292-15297(1996). RN [12] RP INVOLVEMENT IN SADDAN, VARIANT SADDAN MET-650, AND CHARACTERIZATION OF RP VARIANT SADDAN MET-650. RX PubMed=10053006; DOI=10.1086/302275; RA Tavormina P.L., Bellus G.A., Webster M.K., Bamshad M.J., Fraley A.E., RA McIntosh I., Szabo J., Jiang W., Jabs E.W., Wilcox W.R., Wasmuth J.J., RA Donoghue D.J., Thompson L.M., Francomano C.A.; RT "A novel skeletal dysplasia with developmental delay and acanthosis RT nigricans is caused by a Lys650Met mutation in the fibroblast growth factor RT receptor 3 gene."; RL Am. J. Hum. Genet. 64:722-731(1999). RN [13] RP FUNCTION AS FGF9 RECEPTOR IN CHONDROCYTES AND IN ACTIVATION OF SIGNALING RP PATHWAYS, SUBUNIT, SUBCELLULAR LOCATION, DEGRADATION, AUTOPHOSPHORYLATION, RP AND CHARACTERIZATION OF VARIANT ACH ARG-380. RX PubMed=10611230; DOI=10.1128/mcb.20.2.516-522.2000; RA Monsonego-Ornan E., Adar R., Feferman T., Segev O., Yayon A.; RT "The transmembrane mutation G380R in fibroblast growth factor receptor 3 RT uncouples ligand-mediated receptor activation from down-regulation."; RL Mol. Cell. Biol. 20:516-522(2000). RN [14] RP FUNCTION IN STIMULATION OF CELL PROLIFERATION; PHOSPHORYLATION OF PIK3R1; RP PTPN11/SHP2; STAT1; STAT3 AND MAP KINASES, PHOSPHORYLATION AT TYR-724, RP MUTAGENESIS OF TYR-577; TYR-724; TYR-760 AND TYR-770, AND CHARACTERIZATION RP OF VARIANT GLU-650. RX PubMed=11294897; DOI=10.1091/mbc.12.4.931; RA Hart K.C., Robertson S.C., Donoghue D.J.; RT "Identification of tyrosine residues in constitutively activated fibroblast RT growth factor receptor 3 involved in mitogenesis, Stat activation, and RT phosphatidylinositol 3-kinase activation."; RL Mol. Biol. Cell 12:931-942(2001). RN [15] RP UBIQUITINATION, PHOSPHORYLATION, CATALYTIC ACTIVITY, MUTAGENESIS OF RP LYS-508, CHARACTERIZATION OF VARIANT ACH ARG-380, AND CHARACTERIZATION OF RP VARIANT TD2 GLU-650. RX PubMed=12297284; DOI=10.1016/s0014-5793(02)03255-6; RA Monsonego-Ornan E., Adar R., Rom E., Yayon A.; RT "FGF receptors ubiquitylation: dependence on tyrosine kinase activity and RT role in downregulation."; RL FEBS Lett. 528:83-89(2002). RN [16] RP FUNCTION AS PROTO-ONCOGENE IN ACTIVATION OF SIGNALING AND CELL RP PROLIFERATION, FUNCTION IN PHOSPHORYLATION OF FRS2, CHARACTERIZATION OF RP VARIANT GLU-650, AND AUTOPHOSPHORYLATION. RX PubMed=14534538; DOI=10.1038/sj.onc.1206798; RA Agazie Y.M., Movilla N., Ischenko I., Hayman M.J.; RT "The phosphotyrosine phosphatase SHP2 is a critical mediator of RT transformation induced by the oncogenic fibroblast growth factor receptor RT 3."; RL Oncogene 22:6909-6918(2003). RN [17] RP INTERACTION WITH FGF1; FGF8; FGF9; FGF17; FGF18; FGF19 AND FGF20, AND RP FUNCTION IN STIMULATION OF CELL PROLIFERATION. RX PubMed=16597617; DOI=10.1074/jbc.m601252200; RA Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M., Ornitz D.M.; RT "Receptor specificity of the fibroblast growth factor family. The complete RT mammalian FGF family."; RL J. Biol. Chem. 281:15694-15700(2006). RN [18] RP INTERACTION WITH SOCS1 AND SOCS3, FUNCTION IN ACTIVATION OF STAT1 AND MAP RP KINASES, GLYCOSYLATION, PHOSPHORYLATION, MUTAGENESIS OF LYS-508, AND RP SUBCELLULAR LOCATION. RX PubMed=16410555; DOI=10.1242/jcs.02740; RA Ben-Zvi T., Yayon A., Gertler A., Monsonego-Ornan E.; RT "Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with and RT modulate fibroblast growth factor receptor signaling."; RL J. Cell Sci. 119:380-387(2006). RN [19] RP FUNCTION IN REGULATION OF CHONDROCYTE PROLIFERATION AND IN ACTIVATION OF RP PLCG1 AND STAT1, INTERACTION WITH FHF1 AND HEPARIN, SUBCELLULAR LOCATION, RP PHOSPHORYLATION, AND CHARACTERIZATION OF VARIANTS ARG-380; GLU-650 AND RP MET-650. RX PubMed=17561467; DOI=10.1016/j.bone.2006.11.030; RA Harada D., Yamanaka Y., Ueda K., Nishimura R., Morishima T., Seino Y., RA Tanaka H.; RT "Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic RT dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via RT PLCgamma-activated STAT1."; RL Bone 41:273-281(2007). RN [20] RP FUNCTION IN PHOSPHORYLATION OF CBL, UBIQUITINATION, GLYCOSYLATION, RP SUBCELLULAR LOCATION, ACTIVITY REGULATION, AND CHARACTERIZATION OF VARIANTS RP CYS-248; CYS-373 AND MET-650. RX PubMed=17509076; DOI=10.1111/j.1742-4658.2007.05835.x; RA Bonaventure J., Horne W.C., Baron R.; RT "The localization of FGFR3 mutations causing thanatophoric dysplasia type I RT differentially affects phosphorylation, processing and ubiquitylation of RT the receptor."; RL FEBS J. 274:3078-3093(2007). RN [21] RP FUNCTION IN PHOSPHORYLATION OF FRS2, CHARACTERIZATION OF VARIANT GLU-650, RP ACTIVITY REGULATION, AND CATALYTIC ACTIVITY. RX PubMed=17145761; DOI=10.1074/jbc.m606144200; RA Krejci P., Masri B., Salazar L., Farrington-Rock C., Prats H., RA Thompson L.M., Wilcox W.R.; RT "Bisindolylmaleimide I suppresses fibroblast growth factor-mediated RT activation of Erk MAP kinase in chondrocytes by preventing Shp2 association RT with the Frs2 and Gab1 adaptor proteins."; RL J. Biol. Chem. 282:2929-2936(2007). RN [22] RP INTERACTION WITH FGF19; FGF21 AND KLB. RX PubMed=17623664; DOI=10.1074/jbc.m704165200; RA Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R., Eliseenkova A.V., RA Mohammadi M., Rosenblatt K.P., Kliewer S.A., Kuro-o M.; RT "Tissue-specific expression of betaKlotho and fibroblast growth factor RT (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21."; RL J. Biol. Chem. 282:26687-26695(2007). RN [23] RP FUNCTION IN STAT1 PHOSPHORYLATION, GLYCOSYLATION, AND PHOSPHORYLATION. RX PubMed=17311277; DOI=10.1002/jcp.21014; RA Citores L., Bai L., Sorensen V., Olsnes S.; RT "Fibroblast growth factor receptor-induced phosphorylation of STAT1 at the RT Golgi apparatus without translocation to the nucleus."; RL J. Cell. Physiol. 212:148-156(2007). RN [24] RP FUNCTION IN ACTIVATION OF STAT1; STAT5; MAPK1/ERK2; MAPK3/ERK1 AND THE MAP RP KINASE SIGNALING PATHWAY. RX PubMed=19088846; DOI=10.1371/journal.pone.0003961; RA Krejci P., Salazar L., Kashiwada T.A., Chlebova K., Salasova A., RA Thompson L.M., Bryja V., Kozubik A., Wilcox W.R.; RT "Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal RT dysplasia undermines dominant role of STAT1 in FGFR3 signaling in RT cartilage."; RL PLoS ONE 3:E3961-E3961(2008). RN [25] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [26] RP FUNCTION, INTERACTION WITH PIK3R1 AND PLCG1, AND PHOSPHORYLATION AT RP TYR-760. RX PubMed=19286672; DOI=10.1093/hmg/ddp116; RA Salazar L., Kashiwada T., Krejci P., Muchowski P., Donoghue D., RA Wilcox W.R., Thompson L.M.; RT "A novel interaction between fibroblast growth factor receptor 3 and the RT p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation RT of ERK by p85 in multiple myeloma cells."; RL Hum. Mol. Genet. 18:1951-1961(2009). RN [27] RP REVIEW ON FUNCTION; ALTERNATIVE SPLICING; SIGNALING AND ROLE IN DISEASE. RX PubMed=15863030; DOI=10.1016/j.cytogfr.2005.01.001; RA Eswarakumar V.P., Lax I., Schlessinger J.; RT "Cellular signaling by fibroblast growth factor receptors."; RL Cytokine Growth Factor Rev. 16:139-149(2005). RN [28] RP REVIEW ON FUNCTION; LIGANDS; SIGNALING; ALTERNATIVE SPLICING; DOMAIN; ROLE RP IN DISEASE; UBIQUITINATION AND DEGRADATION. RX PubMed=15748888; DOI=10.1016/j.yexcr.2004.11.012; RA L'Hote C.G., Knowles M.A.; RT "Cell responses to FGFR3 signalling: growth, differentiation and RT apoptosis."; RL Exp. Cell Res. 304:417-431(2005). RN [29] RP REVIEW ON ROLE IN SKELETON DEVELOPMENT AND DISEASE. RX PubMed=19066716; DOI=10.1007/s00774-008-0009-7; RA Harada D., Yamanaka Y., Ueda K., Tanaka H., Seino Y.; RT "FGFR3-related dwarfism and cell signaling."; RL J. Bone Miner. Metab. 27:9-15(2009). RN [30] RP REVIEW ON FUNCTION IN FGF SIGNALING. RX PubMed=20094046; DOI=10.1038/nrc2780; RA Turner N., Grose R.; RT "Fibroblast growth factor signalling: from development to cancer."; RL Nat. Rev. Cancer 10:116-129(2010). RN [31] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [32] RP X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 32-365 IN COMPLEX WITH FGF1, RP ACTIVITY REGULATION, AND DOMAIN. RX PubMed=14732692; DOI=10.1073/pnas.0307287101; RA Olsen S.K., Ibrahimi O.A., Raucci A., Zhang F., Eliseenkova A.V., Yayon A., RA Basilico C., Linhardt R.J., Schlessinger J., Mohammadi M.; RT "Insights into the molecular basis for fibroblast growth factor receptor RT autoinhibition and ligand-binding promiscuity."; RL Proc. Natl. Acad. Sci. U.S.A. 101:935-940(2004). RN [33] RP VARIANT ACH ARG-380. RX PubMed=8078586; DOI=10.1038/371252a0; RA Rousseau F., Bonaventure J., Legeai-Mallet L., Pelet A., Rozet J.-M., RA Maroteaux P., le Merrer M., Munnich A.; RT "Mutations in the gene encoding fibroblast growth factor receptor-3 in RT achondroplasia."; RL Nature 371:252-254(1994). RN [34] RP VARIANT ACH ARG-380. RX PubMed=7847369; RA Bellus G.A., Hefferon T.W., de Luna R.I., Hecht J.T., Horton W.A., RA Machado M., Kaitila I., McIntosh I., Francomano C.A.; RT "Achondroplasia is defined by recurrent G380R mutations of FGFR3."; RL Am. J. Hum. Genet. 56:368-373(1995). RN [35] RP VARIANT ACH CYS-375. RX PubMed=7758520; DOI=10.1007/bf01954274; RA Superti-Furga A., Eich G., Bucher H.U., Wisser J., Giedion A., RA Gitzelmann R., Steinmann B.; RT "A glycine 375-to-cysteine substitution in the transmembrane domain of the RT fibroblast growth factor receptor-3 in a newborn with achondroplasia."; RL Eur. J. Pediatr. 154:215-219(1995). RN [36] RP VARIANT TD1 CYS-249. RX PubMed=8589699; DOI=10.1093/hmg/4.11.2175; RA Tavormina P.L., Rimoin D.L., Cohn D.H., Zhu Y.-Z., Shiang R., Wasmuth J.J.; RT "Another mutation that results in the substitution of an unpaired cysteine RT residue in the extracellular domain of FGFR3 in thanatophoric dysplasia RT type I."; RL Hum. Mol. Genet. 4:2175-2177(1995). RN [37] RP VARIANTS TD1 CYS-248 AND CYS-371, AND VARIANT TD2 GLU-650. RX PubMed=7773297; DOI=10.1038/ng0395-321; RA Tavormina P.L., Shiang R., Thompson L.M., Zhu Y.-Z., Wilkin D.J., RA Lachman R.S., Wilcox W.R., Rimoin D.L., Cohn D.H., Wasmuth J.J.; RT "Thanatophoric dysplasia (types I and II) caused by distinct mutations in RT fibroblast growth factor receptor 3."; RL Nat. Genet. 9:321-328(1995). RN [38] RP VARIANT HYPOCHONDROPLASIA LYS-540. RX PubMed=7670477; DOI=10.1038/ng0795-357; RA Bellus G.A., McIntosh I., Smith E.A., Aylsworth A.S., Kaitila I., RA Horton W.A., Greenhaw G.A., Hecht J.T., Francomano C.A.; RT "A recurrent mutation in the tyrosine kinase domain of fibroblast growth RT factor receptor 3 causes hypochondroplasia."; RL Nat. Genet. 10:357-359(1995). RN [39] RP VARIANT CAN GLU-391. RX PubMed=7493034; DOI=10.1038/ng1295-462; RA Meyers G.A., Orlow S.J., Munro I.R., Przylepa K.A., Jabs E.W.; RT "Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in RT Crouzon syndrome with acanthosis nigricans."; RL Nat. Genet. 11:462-464(1995). RN [40] RP CHARACTERIZATION OF VARIANT ACH ARG-380. RX PubMed=8599935; DOI=10.1002/j.1460-2075.1996.tb00384.x; RA Webster M.K., Donoghue D.J.; RT "Constitutive activation of fibroblast growth factor receptor 3 by the RT transmembrane domain point mutation found in achondroplasia."; RL EMBO J. 15:520-527(1996). RN [41] RP VARIANTS TD1 CYS-248; CYS-249; CYS-370 AND CYS-373. RX PubMed=8845844; DOI=10.1093/hmg/5.4.509; RA Rousseau F., el Ghouzzi V., Delezoide A.-L., Legeai-Mallet L., RA le Merrer M., Munnich A., Bonaventure J.; RT "Missense FGFR3 mutations create cysteine residues in thanatophoric RT dwarfism type I (TD1)."; RL Hum. Mol. Genet. 5:509-512(1996). RN [42] RP CHARACTERIZATION OF VARIANT TD2 GLU-650, CHARACTERIZATION OF VARIANT RP GLN-650, AND PHOSPHORYLATION AT TYR-647 AND TYR-648. RX PubMed=8754806; DOI=10.1128/mcb.16.8.4081; RA Webster M.K., D'Avis P.Y., Robertson S.C., Donoghue D.J.; RT "Profound ligand-independent kinase activation of fibroblast growth factor RT receptor 3 by the activation loop mutation responsible for a lethal RT skeletal dysplasia, thanatophoric dysplasia type II."; RL Mol. Cell. Biol. 16:4081-4087(1996). RN [43] RP VARIANT MNKS ARG-250. RX PubMed=9042914; RA Muenke M., Gripp K.W., McDonald-Mcginn D.M., Gaudenz K., Whitaker L.A., RA Bartlett S.P., Markowitz R.I., Robin N.H., Nwokoro N., Mulvihill J.J., RA Losken H.W., Mulliken J.B., Guttmacher A.E., Wilroy R.S., Clarke L.A., RA Hollway G., Ades L.C., Haan E.A., Mulley J.C., Cohen M.M. Jr., Bellus G.A., RA Francomano C.A., Moloney D.M., Wall S.A., Wilkie A.O.M., Zackai E.H.; RT "A unique point mutation in the fibroblast growth factor receptor 3 gene RT (FGFR3) defines a new craniosynostosis syndrome."; RL Am. J. Hum. Genet. 60:555-564(1997). RN [44] RP INVOLVEMENT IN MULTIPLE MYELOMA, AND VARIANTS CYS-373; GLU-650 AND MET-650. RX PubMed=9207791; DOI=10.1038/ng0797-260; RA Chesi M., Nardini E., Brents L.A., Schroeck E., Ried T., Kuehl W.M., RA Bergsagel P.L.; RT "Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is RT associated with increased expression and activating mutations of fibroblast RT growth factor receptor 3."; RL Nat. Genet. 16:260-264(1997). RN [45] RP VARIANT TD1 CYS-370. RX PubMed=9790257; DOI=10.1507/endocrj.45.suppl_s171; RA Katsumata N., Kuno T., Miyazaki S., Mikami S., Nagashima-Miyokawa A., RA Nimura A., Horikawa R., Tanaka T.; RT "G370C mutation in the FGFR3 gene in a Japanese patient with thanatophoric RT dysplasia."; RL Endocr. J. 45:S171-S174(1998). RN [46] RP VARIANT HYPOCHONDROPLASIA VAL-538. RX PubMed=10215410; RX DOI=10.1002/(sici)1098-1004(1998)11:4<333::aid-humu18>3.0.co;2-g; RA Grigelioniene G., Hagenaes L., Ekloef O., Neumeyer L., Haereid P.E., RA Anvret M.; RT "A novel missense mutation Ile538Val in the fibroblast growth factor RT receptor 3 in hypochondroplasia."; RL Hum. Mutat. 11:333-333(1998). RN [47] RP VARIANT HYPOCHONDROPLASIA THR-540. RX PubMed=9452043; DOI=10.1002/humu.1380110122; RA Deutz-Terlouw P.P., Losekoot M., Aalfs C.M., Hennekam R.C.M., Bakker E.; RT "Asn540Thr substitution in the fibroblast growth factor receptor 3 tyrosine RT kinase domain causing hypochondroplasia."; RL Hum. Mutat. Suppl. 1:S62-S65(1998). RN [48] RP VARIANT TD1 MET-650. RX PubMed=10671061; RA Kitoh H., Brodie S.G., Kupke K.G., Lachman R.S., Wilcox W.R.; RT "Lys650Met substitution in the tyrosine kinase domain of the fibroblast RT growth factor receptor gene causes thanatophoric dysplasia type I."; RL Hum. Mutat. 12:362-363(1998). RN [49] RP VARIANT ARG-250. RX PubMed=9525367; DOI=10.1016/s0140-6736(98)24012-8; RA Hollway G.E., Suthers G.K., Battese K.M., Turner A.M., David D.J., RA Mulley J.C.; RT "Deafness due to Pro250Arg mutation of FGFR3."; RL Lancet 351:877-878(1998). RN [50] RP VARIANTS TD1 CYS-248; CYS-249 AND CYS-373. RX PubMed=10360402; RX DOI=10.1002/(sici)1096-8628(19990611)84:5<476::aid-ajmg12>3.3.co;2-o; RA Brodie S.G., Kitoh H., Lachman R.S., Nolasco L.M., Mekikian P.B., RA Wilcox W.R.; RT "Platyspondylic lethal skeletal dysplasia, San Diego type, is caused by RT FGFR3 mutations."; RL Am. J. Med. Genet. 84:476-480(1999). RN [51] RP VARIANT MNKS ARG-250. RX PubMed=9950359; RA Lajeunie E., El Ghouzzi V., Le Merrer M., Munnich A., Bonaventure J., RA Renier D.; RT "Sex related expressivity of the phenotype in coronal craniosynostosis RT caused by the recurrent P250R FGFR3 mutation."; RL J. Med. Genet. 36:9-13(1999). RN [52] RP VARIANTS BLC CYS-248; CYS-249; CYS-370 AND GLU-650, AND VARIANTS CERCA RP CYS-248; CYS-249; CYS-370 AND GLU-650. RX PubMed=10471491; DOI=10.1038/12615; RA Cappellen D., De Oliveira C., Ricol D., Gil Diez de Medina S., Bourdin J., RA Sastre-Garau X., Chopin D., Thiery J.P., Radvanyi F.; RT "Frequent activating mutations of FGFR3 in human bladder and cervix RT carcinomas."; RL Nat. Genet. 23:18-20(1999). RN [53] RP VARIANT HYPOCHONDROPLASIA GLN-650. RX PubMed=11055896; DOI=10.1086/316892; RA Bellus G.A., Spector E.B., Speiser P.W., Weaver C.A., Garber A.T., RA Bryke C.R., Israel J., Rosengren S.S., Webster M.K., Donoghue D.J., RA Francomano C.A.; RT "Distinct missense mutations of the FGFR3 Lys650 codon modulate receptor RT kinase activation and the severity of the skeletal dysplasia phenotype."; RL Am. J. Hum. Genet. 67:1411-1421(2000). RN [54] RP VARIANT HYPOCHONDROPLASIA SER-540. RX PubMed=10777366; DOI=10.1136/jmg.37.3.220; RA Mortier G., Nuytinck L., Craen M., Renard J.-P., Leroy J.G., De Paepe A.; RT "Clinical and radiographic features of a family with hypochondroplasia RT owing to a novel asn540ser mutation in the fibroblast growth factor RT receptor 3 gene."; RL J. Med. Genet. 37:220-224(2000). RN [55] RP VARIANT MNKS ARG-250. RX PubMed=11746040; DOI=10.1002/ajmg.10049; RA Lowry R.B., Jabs E.W., Graham G.E., Gerritsen J., Fleming J.; RT "Syndrome of coronal craniosynostosis, Klippel-Feil anomaly, and sprengel RT shoulder with and without Pro250Arg mutation in the FGFR3 gene."; RL Am. J. Med. Genet. 104:112-119(2001). RN [56] RP INVOLVEMENT IN MULTIPLE MYELOMA, AND VARIANT CYS-248. RX PubMed=11529856; DOI=10.1046/j.1365-2141.2001.02957.x; RA Intini D., Baldini L., Fabris S., Lombardi L., Ciceri G., Maiolo A.T., RA Neri A.; RT "Analysis of FGFR3 gene mutations in multiple myeloma patients with RT t(4;14)."; RL Br. J. Haematol. 114:362-364(2001). RN [57] RP VARIANT COLORECTAL CANCER LYS-322. RX PubMed=11325814; RA Jang J.-H., Shin K.-H., Park J.-G.; RT "Mutations in fibroblast growth factor receptor 2 and fibroblast growth RT factor receptor 3 genes associated with human gastric and colorectal RT cancers."; RL Cancer Res. 61:3541-3543(2001). RN [58] RP VARIANT BLC CANCER GLN-650. RX PubMed=11314002; DOI=10.1038/sj.onc.1204110; RA Sibley K., Cuthbert-Heavens D., Knowles M.A.; RT "Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional RT cell carcinoma."; RL Oncogene 20:686-691(2001). RN [59] RP VARIANT HYPOCHONDROPLASIA SER-540. RX PubMed=12707965; DOI=10.1002/ajmg.a.10238; RA Thauvin-Robinet C., Faivre L., Lewin P., De Monleon J.-V., Francois C., RA Huet F., Couailler J.-F., Campos-Xavier A.B., Bonaventure J., Le Merrer M.; RT "Hypochondroplasia and stature within normal limits: another family with an RT Asn540-to-Ser mutation in the fibroblast growth factor receptor 3 gene."; RL Am. J. Med. Genet. A 119:81-84(2003). RN [60] RP VARIANTS KERSEB CYS-248; CYS-249; CYS-370; CYS-371; CYS-373; GLU-650 AND RP MET-650. RX PubMed=15772091; DOI=10.1093/hmg/ddi127; RA Logie A., Dunois-Larde C., Rosty C., Levrel O., Blanche M., Ribeiro A., RA Gasc J.-M., Jorcano J., Werner S., Sastre-Garau X., Thiery J.P., RA Radvanyi F.; RT "Activating mutations of the tyrosine kinase receptor FGFR3 are associated RT with benign skin tumors in mice and humans."; RL Hum. Mol. Genet. 14:1153-1160(2005). RN [61] RP VARIANT CATSHLS HIS-621. RX PubMed=17033969; DOI=10.1086/508433; RA Toydemir R.M., Brassington A.E., Bayrak-Toydemir P., Krakowiak P.A., RA Jorde L.B., Whitby F.G., Longo N., Viskochil D.H., Carey J.C., RA Bamshad M.J.; RT "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing RT loss (CATSHL) syndrome."; RL Am. J. Hum. Genet. 79:935-941(2006). RN [62] RP VARIANTS KNEN CYS-248; CYS-370 AND ARG-380. RX PubMed=16841094; DOI=10.1172/jci28163; RA Hafner C., van Oers J.M.M., Vogt T., Landthaler M., Stoehr R., Blaszyk H., RA Hofstaedter F., Zwarthoff E.C., Hartmann A.; RT "Mosaicism of activating FGFR3 mutations in human skin causes epidermal RT nevi."; RL J. Clin. Invest. 116:2201-2207(2006). RN [63] RP VARIANT LADD2 ASN-513, AND INVOLVEMENT IN LADD2. RX PubMed=16501574; DOI=10.1038/ng1757; RA Rohmann E., Brunner H.G., Kayserili H., Uyguner O., Nuernberg G., Lew E.D., RA Dobbie A., Eswarakumar V.P., Uzumcu A., Ulubil-Emeroglu M., Leroy J.G., RA Li Y., Becker C., Lehnerdt K., Cremers C.W.R.J., Yueksel-Apak M., RA Nuernberg P., Kubisch C., Schlessinger J., van Bokhoven H., Wollnik B.; RT "Mutations in different components of FGF signaling in LADD syndrome."; RL Nat. Genet. 38:414-417(2006). RN [64] RP VARIANT CAN GLU-391. RX PubMed=17935505; DOI=10.1111/j.1399-0004.2007.00884.x; RA Arnaud-Lopez L., Fragoso R., Mantilla-Capacho J., Barros-Nunez P.; RT "Crouzon with acanthosis nigricans. Further delineation of the syndrome."; RL Clin. Genet. 72:405-410(2007). RN [65] RP VARIANTS [LARGE SCALE ANALYSIS] SER-79; ARG-228; MET-338; LEU-384; ASN-646 RP AND GLU-650. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [66] RP VARIANT TGCT GLU-650. RX PubMed=19855393; DOI=10.1038/ng.470; RA Goriely A., Hansen R.M., Taylor I.B., Olesen I.A., Jacobsen G.K., RA McGowan S.J., Pfeifer S.P., McVean G.A., Rajpert-De Meyts E., Wilkie A.O.; RT "Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for RT congenital disorders and testicular tumors."; RL Nat. Genet. 41:1247-1252(2009). CC -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor CC for fibroblast growth factors and plays an essential role in the CC regulation of cell proliferation, differentiation and apoptosis. Plays CC an essential role in the regulation of chondrocyte differentiation, CC proliferation and apoptosis, and is required for normal skeleton CC development. Regulates both osteogenesis and postnatal bone CC mineralization by osteoblasts. Promotes apoptosis in chondrocytes, but CC can also promote cancer cell proliferation. Required for normal CC development of the inner ear. Phosphorylates PLCG1, CBL and FRS2. CC Ligand binding leads to the activation of several signaling cascades. CC Activation of PLCG1 leads to the production of the cellular signaling CC molecules diacylglycerol and inositol 1,4,5-trisphosphate. CC Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and CC SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the CC MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. CC Plays a role in the regulation of vitamin D metabolism. Mutations that CC lead to constitutive kinase activation or impair normal FGFR3 CC maturation, internalization and degradation lead to aberrant signaling. CC Over-expressed or constitutively activated FGFR3 promotes activation of CC PTPN11/SHP2, STAT1, STAT5A and STAT5B. Secreted isoform 3 retains its CC capacity to bind FGF1 and FGF2 and hence may interfere with FGF CC signaling. {ECO:0000269|PubMed:10611230, ECO:0000269|PubMed:11294897, CC ECO:0000269|PubMed:11703096, ECO:0000269|PubMed:14534538, CC ECO:0000269|PubMed:16410555, ECO:0000269|PubMed:16597617, CC ECO:0000269|PubMed:17145761, ECO:0000269|PubMed:17311277, CC ECO:0000269|PubMed:17509076, ECO:0000269|PubMed:17561467, CC ECO:0000269|PubMed:19088846, ECO:0000269|PubMed:19286672, CC ECO:0000269|PubMed:8663044}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:12297284, ECO:0000269|PubMed:17145761}; CC -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence CC of bound ligand. Ligand binding leads to dimerization and activation by CC autophosphorylation on tyrosine residues. Inhibited by SU5402. CC {ECO:0000269|PubMed:14732692, ECO:0000269|PubMed:17145761, CC ECO:0000269|PubMed:17509076}. CC -!- SUBUNIT: Monomer. Homodimer after ligand binding. Interacts with FGF1, CC FGF2, FGF4, FGF6; FGF8, FGF9, FGF10, FGF17, FGF18, FGF19, FGF20 and CC FGF23 (in vitro). Interacts with KLB. Affinity for fibroblast growth CC factors (FGFs) is increased by heparan sulfate glycosaminoglycans that CC function as coreceptors. Likewise, KLB increases the affinity for FGF19 CC and FGF21. Interacts with PIK3R1, PLCG1, SOCS1 and SOCS3. Isoform 3 CC forms disulfide-linked dimers. {ECO:0000269|PubMed:10611230, CC ECO:0000269|PubMed:11703096, ECO:0000269|PubMed:14732692, CC ECO:0000269|PubMed:16410555, ECO:0000269|PubMed:16597617, CC ECO:0000269|PubMed:17561467, ECO:0000269|PubMed:17623664, CC ECO:0000269|PubMed:19286672, ECO:0000269|PubMed:8663044}. CC -!- INTERACTION: CC P22607; Q6H8Q1-8: ABLIM2; NbExp=3; IntAct=EBI-348399, EBI-16436655; CC P22607; Q8NC06-3: ACBD4; NbExp=3; IntAct=EBI-348399, EBI-12811089; CC P22607; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-348399, EBI-10173507; CC P22607; Q8N302-2: AGGF1; NbExp=3; IntAct=EBI-348399, EBI-25838028; CC P22607; Q9UKV8: AGO2; NbExp=3; IntAct=EBI-348399, EBI-528269; CC P22607; P55008: AIF1; NbExp=3; IntAct=EBI-348399, EBI-9031341; CC P22607; Q99996-3: AKAP9; NbExp=3; IntAct=EBI-348399, EBI-11022349; CC P22607; Q9NQ31: AKIP1; NbExp=3; IntAct=EBI-348399, EBI-517035; CC P22607; P53677-2: AP3M2; NbExp=3; IntAct=EBI-348399, EBI-12177015; CC P22607; Q9NXL2-1: ARHGEF38; NbExp=3; IntAct=EBI-348399, EBI-18172597; CC P22607; Q9Y2Y0: ARL2BP; NbExp=3; IntAct=EBI-348399, EBI-3449344; CC P22607; Q66PJ3-4: ARL6IP4; NbExp=3; IntAct=EBI-348399, EBI-5280499; CC P22607; Q6XD76: ASCL4; NbExp=3; IntAct=EBI-348399, EBI-10254793; CC P22607; Q96FT7-4: ASIC4; NbExp=3; IntAct=EBI-348399, EBI-9089489; CC P22607; Q9UII2: ATP5IF1; NbExp=3; IntAct=EBI-348399, EBI-718459; CC P22607; Q9ULK2-2: ATXN7L1; NbExp=3; IntAct=EBI-348399, EBI-21568482; CC P22607; Q9H7T9: AUNIP; NbExp=3; IntAct=EBI-348399, EBI-10693257; CC P22607; Q8TBE0: BAHD1; NbExp=3; IntAct=EBI-348399, EBI-742750; CC P22607; Q9UQB8-6: BAIAP2; NbExp=3; IntAct=EBI-348399, EBI-9092016; CC P22607; Q16520: BATF; NbExp=3; IntAct=EBI-348399, EBI-749503; CC P22607; P54687-4: BCAT1; NbExp=3; IntAct=EBI-348399, EBI-25834445; CC P22607; Q00994: BEX3; NbExp=3; IntAct=EBI-348399, EBI-741753; CC P22607; Q5H9J7: BEX5; NbExp=3; IntAct=EBI-348399, EBI-10243741; CC P22607; Q9H2G9: BLZF1; NbExp=3; IntAct=EBI-348399, EBI-2548012; CC P22607; Q5PSV4: BRMS1L; NbExp=3; IntAct=EBI-348399, EBI-5666615; CC P22607; Q9ULD4-2: BRPF3; NbExp=3; IntAct=EBI-348399, EBI-23662416; CC P22607; Q9NSI6-4: BRWD1; NbExp=3; IntAct=EBI-348399, EBI-10693038; CC P22607; Q6P5X5: C22orf39; NbExp=3; IntAct=EBI-348399, EBI-7317823; CC P22607; Q3SXR2: C3orf36; NbExp=3; IntAct=EBI-348399, EBI-18036948; CC P22607; Q96LL4: C8orf48; NbExp=3; IntAct=EBI-348399, EBI-751596; CC P22607; P20807-4: CAPN3; NbExp=3; IntAct=EBI-348399, EBI-11532021; CC P22607; O00257-3: CBX4; NbExp=3; IntAct=EBI-348399, EBI-4392727; CC P22607; Q96HB5: CCDC120; NbExp=3; IntAct=EBI-348399, EBI-744556; CC P22607; Q6ZP82-1: CCDC141; NbExp=3; IntAct=EBI-348399, EBI-49119542; CC P22607; Q5M9N0-2: CCDC158; NbExp=3; IntAct=EBI-348399, EBI-21796846; CC P22607; Q16543: CDC37; NbExp=4; IntAct=EBI-348399, EBI-295634; CC P22607; Q96GN5-2: CDCA7L; NbExp=3; IntAct=EBI-348399, EBI-9091443; CC P22607; P24941: CDK2; NbExp=3; IntAct=EBI-348399, EBI-375096; CC P22607; O14519: CDK2AP1; NbExp=3; IntAct=EBI-348399, EBI-1052532; CC P22607; P38936: CDKN1A; NbExp=3; IntAct=EBI-348399, EBI-375077; CC P22607; O95674: CDS2; NbExp=4; IntAct=EBI-348399, EBI-3913685; CC P22607; Q9H3R5: CENPH; NbExp=3; IntAct=EBI-348399, EBI-1003700; CC P22607; Q9Y4F5-3: CEP170B; NbExp=3; IntAct=EBI-348399, EBI-12950757; CC P22607; Q86XR8: CEP57; NbExp=3; IntAct=EBI-348399, EBI-308614; CC P22607; Q494V2-2: CFAP100; NbExp=3; IntAct=EBI-348399, EBI-11953200; CC P22607; Q8WUX9: CHMP7; NbExp=3; IntAct=EBI-348399, EBI-749253; CC P22607; Q9H2A9: CHST8; NbExp=3; IntAct=EBI-348399, EBI-21642354; CC P22607; Q9Y3D0: CIAO2B; NbExp=3; IntAct=EBI-348399, EBI-744045; CC P22607; Q3SX64: CIMAP1D; NbExp=3; IntAct=EBI-348399, EBI-6660184; CC P22607; Q96BR5: COA7; NbExp=3; IntAct=EBI-348399, EBI-6269632; CC P22607; P02458-1: COL2A1; NbExp=3; IntAct=EBI-348399, EBI-12375799; CC P22607; P21964-2: COMT; NbExp=3; IntAct=EBI-348399, EBI-10200977; CC P22607; Q86WV2: COX4I1; NbExp=3; IntAct=EBI-348399, EBI-10260134; CC P22607; Q03060-25: CREM; NbExp=3; IntAct=EBI-348399, EBI-12884642; CC P22607; Q8TB03: CXorf38; NbExp=3; IntAct=EBI-348399, EBI-12024320; CC P22607; O60759: CYTIP; NbExp=3; IntAct=EBI-348399, EBI-997814; CC P22607; Q9UJU6: DBNL; NbExp=3; IntAct=EBI-348399, EBI-751783; CC P22607; Q6ZN54-2: DEF8; NbExp=3; IntAct=EBI-348399, EBI-12346463; CC P22607; Q8NDP9: DKFZp547K2416; NbExp=3; IntAct=EBI-348399, EBI-25842538; CC P22607; O60479: DLX3; NbExp=3; IntAct=EBI-348399, EBI-3908248; CC P22607; Q96EY1-3: DNAJA3; NbExp=3; IntAct=EBI-348399, EBI-11526226; CC P22607; Q9H147: DNTTIP1; NbExp=3; IntAct=EBI-348399, EBI-2795449; CC P22607; Q92782-2: DPF1; NbExp=3; IntAct=EBI-348399, EBI-23669343; CC P22607; Q7Z7J5: DPPA2; NbExp=3; IntAct=EBI-348399, EBI-741400; CC P22607; Q14117: DPYS; NbExp=3; IntAct=EBI-348399, EBI-12275416; CC P22607; Q9BPU6: DPYSL5; NbExp=3; IntAct=EBI-348399, EBI-724653; CC P22607; Q9BVC3: DSCC1; NbExp=3; IntAct=EBI-348399, EBI-11143782; CC P22607; Q9Y6W6: DUSP10; NbExp=3; IntAct=EBI-348399, EBI-3443946; CC P22607; O14641: DVL2; NbExp=3; IntAct=EBI-348399, EBI-740850; CC P22607; A0AVK6: E2F8; NbExp=3; IntAct=EBI-348399, EBI-7779316; CC P22607; Q658K8: EEF1DP3; NbExp=3; IntAct=EBI-348399, EBI-10248874; CC P22607; Q6UXG2-3: ELAPOR1; NbExp=3; IntAct=EBI-348399, EBI-12920100; CC P22607; O00472: ELL2; NbExp=3; IntAct=EBI-348399, EBI-395274; CC P22607; O43768-8: ENSA; NbExp=3; IntAct=EBI-348399, EBI-25853109; CC P22607; Q6NXG1: ESRP1; NbExp=3; IntAct=EBI-348399, EBI-10213520; CC P22607; Q15910-2: EZH2; NbExp=3; IntAct=EBI-348399, EBI-10699473; CC P22607; Q96GL9: FAM163A; NbExp=3; IntAct=EBI-348399, EBI-11793142; CC P22607; A1KXE4-2: FAM168B; NbExp=3; IntAct=EBI-348399, EBI-12193763; CC P22607; Q8NB25: FAM184A; NbExp=3; IntAct=EBI-348399, EBI-9917523; CC P22607; Q86UY5: FAM83A; NbExp=3; IntAct=EBI-348399, EBI-1384254; CC P22607; Q8IZU1: FAM9A; NbExp=3; IntAct=EBI-348399, EBI-8468186; CC P22607; Q8TC84: FANK1; NbExp=3; IntAct=EBI-348399, EBI-21975404; CC P22607; Q9UBX5: FBLN5; NbExp=3; IntAct=EBI-348399, EBI-947897; CC P22607; Q9Y3I1: FBXO7; NbExp=3; IntAct=EBI-348399, EBI-1161222; CC P22607; O94868-3: FCHSD2; NbExp=3; IntAct=EBI-348399, EBI-11958845; CC P22607; P05230: FGF1; NbExp=3; IntAct=EBI-348399, EBI-698068; CC P22607; P22607: FGFR3; NbExp=4; IntAct=EBI-348399, EBI-348399; CC P22607; P15407: FOSL1; NbExp=3; IntAct=EBI-348399, EBI-744510; CC P22607; P15408: FOSL2; NbExp=3; IntAct=EBI-348399, EBI-3893419; CC P22607; P55318: FOXA3; NbExp=3; IntAct=EBI-348399, EBI-3910364; CC P22607; Q06547-2: GABPB1; NbExp=3; IntAct=EBI-348399, EBI-618189; CC P22607; Q06547-3: GABPB1; NbExp=3; IntAct=EBI-348399, EBI-9088619; CC P22607; P15976-2: GATA1; NbExp=3; IntAct=EBI-348399, EBI-9090198; CC P22607; P23769-2: GATA2; NbExp=3; IntAct=EBI-348399, EBI-21856389; CC P22607; P23771: GATA3; NbExp=3; IntAct=EBI-348399, EBI-6664760; CC P22607; Q49A26-4: GLYR1; NbExp=3; IntAct=EBI-348399, EBI-12143817; CC P22607; Q7Z5G4: GOLGA7; NbExp=3; IntAct=EBI-348399, EBI-4403685; CC P22607; Q9NWQ4-1: GPATCH2L; NbExp=3; IntAct=EBI-348399, EBI-11959863; CC P22607; P52655: GTF2A1; NbExp=3; IntAct=EBI-348399, EBI-389518; CC P22607; Q15486: GUSBP1; NbExp=4; IntAct=EBI-348399, EBI-712457; CC P22607; Q96CS2: HAUS1; NbExp=3; IntAct=EBI-348399, EBI-2514791; CC P22607; Q9BT25: HAUS8; NbExp=3; IntAct=EBI-348399, EBI-2558143; CC P22607; Q99075: HBEGF; NbExp=3; IntAct=EBI-348399, EBI-7211558; CC P22607; A8K0U2: hCG_2001421; NbExp=3; IntAct=EBI-348399, EBI-25843825; CC P22607; Q5T447-2: HECTD3; NbExp=3; IntAct=EBI-348399, EBI-25854793; CC P22607; Q8IV36: HID1; NbExp=3; IntAct=EBI-348399, EBI-743438; CC P22607; Q4VB01: HOXB1; NbExp=3; IntAct=EBI-348399, EBI-17494170; CC P22607; P09629: HOXB7; NbExp=3; IntAct=EBI-348399, EBI-1248457; CC P22607; O43248: HOXC11; NbExp=3; IntAct=EBI-348399, EBI-2652631; CC P22607; Q53T59: HS1BP3; NbExp=3; IntAct=EBI-348399, EBI-11335623; CC P22607; Q53GQ0: HSD17B12; NbExp=4; IntAct=EBI-348399, EBI-2963255; CC P22607; P14060: HSD3B1; NbExp=3; IntAct=EBI-348399, EBI-17426018; CC P22607; P08238: HSP90AB1; NbExp=4; IntAct=EBI-348399, EBI-352572; CC P22607; Q96EW2-2: HSPBAP1; NbExp=3; IntAct=EBI-348399, EBI-25835621; CC P22607; P10809: HSPD1; NbExp=3; IntAct=EBI-348399, EBI-352528; CC P22607; Q8NDH6-2: ICA1L; NbExp=3; IntAct=EBI-348399, EBI-12141931; CC P22607; P41134: ID1; NbExp=3; IntAct=EBI-348399, EBI-1215527; CC P22607; Q8IY31-2: IFT20; NbExp=3; IntAct=EBI-348399, EBI-11742277; CC P22607; P22692: IGFBP4; NbExp=3; IntAct=EBI-348399, EBI-2831948; CC P22607; Q9NP60: IL1RAPL2; NbExp=3; IntAct=EBI-348399, EBI-20865879; CC P22607; Q9NZH6: IL37; NbExp=3; IntAct=EBI-348399, EBI-3862125; CC P22607; Q9NXX0: ILF3; NbExp=3; IntAct=EBI-348399, EBI-743980; CC P22607; Q86VI3: IQGAP3; NbExp=3; IntAct=EBI-348399, EBI-1237354; CC P22607; Q8NA54: IQUB; NbExp=3; IntAct=EBI-348399, EBI-10220600; CC P22607; Q86U28: ISCA2; NbExp=3; IntAct=EBI-348399, EBI-10258659; CC P22607; Q13352: ITGB3BP; NbExp=3; IntAct=EBI-348399, EBI-712105; CC P22607; P05412: JUN; NbExp=3; IntAct=EBI-348399, EBI-852823; CC P22607; P17275: JUNB; NbExp=3; IntAct=EBI-348399, EBI-748062; CC P22607; Q8N5Z5: KCTD17; NbExp=3; IntAct=EBI-348399, EBI-743960; CC P22607; Q7Z7F0-4: KHDC4; NbExp=3; IntAct=EBI-348399, EBI-9089060; CC P22607; Q9BVG8-5: KIFC3; NbExp=3; IntAct=EBI-348399, EBI-14069005; CC P22607; Q2M2Z5: KIZ; NbExp=3; IntAct=EBI-348399, EBI-2554344; CC P22607; Q6P597: KLC3; NbExp=3; IntAct=EBI-348399, EBI-1643885; CC P22607; P57682: KLF3; NbExp=3; IntAct=EBI-348399, EBI-8472267; CC P22607; Q9Y2M5: KLHL20; NbExp=3; IntAct=EBI-348399, EBI-714379; CC P22607; Q9UH77: KLHL3; NbExp=3; IntAct=EBI-348399, EBI-8524663; CC P22607; P08727: KRT19; NbExp=3; IntAct=EBI-348399, EBI-742756; CC P22607; Q14525: KRT33B; NbExp=3; IntAct=EBI-348399, EBI-1049638; CC P22607; Q3LI72: KRTAP19-5; NbExp=3; IntAct=EBI-348399, EBI-1048945; CC P22607; Q3SYF9: KRTAP19-7; NbExp=3; IntAct=EBI-348399, EBI-10241353; CC P22607; Q8IUC2: KRTAP8-1; NbExp=3; IntAct=EBI-348399, EBI-10261141; CC P22607; Q6IAA8: LAMTOR1; NbExp=3; IntAct=EBI-348399, EBI-715385; CC P22607; O43504: LAMTOR5; NbExp=3; IntAct=EBI-348399, EBI-713382; CC P22607; Q14847-2: LASP1; NbExp=3; IntAct=EBI-348399, EBI-9088686; CC P22607; Q9H2C1: LHX5; NbExp=3; IntAct=EBI-348399, EBI-25835523; CC P22607; Q68G74: LHX8; NbExp=3; IntAct=EBI-348399, EBI-8474075; CC P22607; Q8N0U6: LINC00518; NbExp=3; IntAct=EBI-348399, EBI-10264791; CC P22607; Q1L5Z9: LONRF2; NbExp=3; IntAct=EBI-348399, EBI-2510853; CC P22607; Q96JB6: LOXL4; NbExp=3; IntAct=EBI-348399, EBI-749562; CC P22607; Q96LR2: LURAP1; NbExp=3; IntAct=EBI-348399, EBI-741355; CC P22607; P0DP58-2: LYNX1; NbExp=3; IntAct=EBI-348399, EBI-21916939; CC P22607; P27338: MAOB; NbExp=3; IntAct=EBI-348399, EBI-3911344; CC P22607; Q9GZQ8: MAP1LC3B; NbExp=3; IntAct=EBI-348399, EBI-373144; CC P22607; Q15759: MAPK11; NbExp=3; IntAct=EBI-348399, EBI-298304; CC P22607; Q9NS73-5: MBIP; NbExp=3; IntAct=EBI-348399, EBI-10182361; CC P22607; P33993-2: MCM7; NbExp=3; IntAct=EBI-348399, EBI-11741465; CC P22607; Q96EZ8: MCRS1; NbExp=3; IntAct=EBI-348399, EBI-348259; CC P22607; Q9HAF1: MEAF6; NbExp=3; IntAct=EBI-348399, EBI-399266; CC P22607; Q8TAC0: MGC27345; NbExp=3; IntAct=EBI-348399, EBI-25851300; CC P22607; Q53S70: MGC4677; NbExp=3; IntAct=EBI-348399, EBI-10242717; CC P22607; Q5JXC2: MIIP; NbExp=3; IntAct=EBI-348399, EBI-2801965; CC P22607; A0A0A0MR05: MLST8; NbExp=3; IntAct=EBI-348399, EBI-25835557; CC P22607; Q00013: MPP1; NbExp=3; IntAct=EBI-348399, EBI-711788; CC P22607; Q8TCY5: MRAP; NbExp=3; IntAct=EBI-348399, EBI-9538727; CC P22607; Q6IN84-2: MRM1; NbExp=3; IntAct=EBI-348399, EBI-25835707; CC P22607; O60783: MRPS14; NbExp=3; IntAct=EBI-348399, EBI-1045956; CC P22607; Q96H12: MSANTD3; NbExp=3; IntAct=EBI-348399, EBI-8466227; CC P22607; P01106: MYC; NbExp=3; IntAct=EBI-348399, EBI-447544; CC P22607; Q9NPC6: MYOZ2; NbExp=3; IntAct=EBI-348399, EBI-746712; CC P22607; P41271-2: NBL1; NbExp=3; IntAct=EBI-348399, EBI-12135485; CC P22607; P14598: NCF1; NbExp=3; IntAct=EBI-348399, EBI-395044; CC P22607; Q9GZM8: NDEL1; NbExp=3; IntAct=EBI-348399, EBI-928842; CC P22607; Q8NC67-2: NETO2; NbExp=3; IntAct=EBI-348399, EBI-25852289; CC P22607; Q16621: NFE2; NbExp=3; IntAct=EBI-348399, EBI-726369; CC P22607; Q8N5V2: NGEF; NbExp=3; IntAct=EBI-348399, EBI-718372; CC P22607; Q99743: NPAS2; NbExp=3; IntAct=EBI-348399, EBI-3932727; CC P22607; Q14995: NR1D2; NbExp=3; IntAct=EBI-348399, EBI-6144053; CC P22607; F1D8P7: NR1H2; NbExp=3; IntAct=EBI-348399, EBI-10177172; CC P22607; Q6PHZ7: NR2C2; NbExp=3; IntAct=EBI-348399, EBI-2802743; CC P22607; Q9BZ95-3: NSD3; NbExp=3; IntAct=EBI-348399, EBI-22002759; CC P22607; Q96MF7: NSMCE2; NbExp=3; IntAct=EBI-348399, EBI-2557388; CC P22607; Q4KMX9: OBSCN; NbExp=3; IntAct=EBI-348399, EBI-10490715; CC P22607; A5D8V7: ODAD3; NbExp=3; IntAct=EBI-348399, EBI-8466445; CC P22607; Q5BJF6-2: ODF2; NbExp=3; IntAct=EBI-348399, EBI-9090919; CC P22607; O43482: OIP5; NbExp=3; IntAct=EBI-348399, EBI-536879; CC P22607; Q6GQQ9-2: OTUD7B; NbExp=3; IntAct=EBI-348399, EBI-25830200; CC P22607; Q8IVL6-2: P3H3; NbExp=3; IntAct=EBI-348399, EBI-12149899; CC P22607; Q9H8K7: PAAT; NbExp=3; IntAct=EBI-348399, EBI-714785; CC P22607; Q8N3R9: PALS1; NbExp=3; IntAct=EBI-348399, EBI-2513978; CC P22607; Q495U3: PANX2; NbExp=3; IntAct=EBI-348399, EBI-17242559; CC P22607; Q9NR21-5: PARP11; NbExp=3; IntAct=EBI-348399, EBI-17159452; CC P22607; Q9BR81: PCDHGC3; NbExp=3; IntAct=EBI-348399, EBI-22012354; CC P22607; Q5VU43-8: PDE4DIP; NbExp=3; IntAct=EBI-348399, EBI-25837868; CC P22607; Q13956: PDE6H; NbExp=3; IntAct=EBI-348399, EBI-10231995; CC P22607; O15534: PER1; NbExp=3; IntAct=EBI-348399, EBI-2557276; CC P22607; O15212: PFDN6; NbExp=3; IntAct=EBI-348399, EBI-356973; CC P22607; Q9BUL5: PHF23; NbExp=3; IntAct=EBI-348399, EBI-722852; CC P22607; P14618: PKM; NbExp=3; IntAct=EBI-348399, EBI-353408; CC P22607; Q9UPR0: PLCL2; NbExp=3; IntAct=EBI-348399, EBI-311059; CC P22607; Q6ZR37: PLEKHG7; NbExp=3; IntAct=EBI-348399, EBI-12891828; CC P22607; Q5SXH7-1: PLEKHS1; NbExp=3; IntAct=EBI-348399, EBI-26412802; CC P22607; Q96T60: PNKP; NbExp=3; IntAct=EBI-348399, EBI-1045072; CC P22607; P19388: POLR2E; NbExp=3; IntAct=EBI-348399, EBI-395189; CC P22607; Q07869: PPARA; NbExp=3; IntAct=EBI-348399, EBI-78615; CC P22607; Q9UNP9: PPIE; NbExp=3; IntAct=EBI-348399, EBI-591818; CC P22607; O60927: PPP1R11; NbExp=3; IntAct=EBI-348399, EBI-1048104; CC P22607; O60237-2: PPP1R12B; NbExp=3; IntAct=EBI-348399, EBI-10700351; CC P22607; Q96I34: PPP1R16A; NbExp=3; IntAct=EBI-348399, EBI-710402; CC P22607; Q6ZMI0-5: PPP1R21; NbExp=3; IntAct=EBI-348399, EBI-25835994; CC P22607; O43741: PRKAB2; NbExp=3; IntAct=EBI-348399, EBI-1053424; CC P22607; O60260-5: PRKN; NbExp=3; IntAct=EBI-348399, EBI-21251460; CC P22607; Q86UA1: PRPF39; NbExp=3; IntAct=EBI-348399, EBI-2803203; CC P22607; P62333: PSMC6; NbExp=3; IntAct=EBI-348399, EBI-357669; CC P22607; Q06323: PSME1; NbExp=3; IntAct=EBI-348399, EBI-712149; CC P22607; P06454-2: PTMA; NbExp=3; IntAct=EBI-348399, EBI-10194874; CC P22607; Q8WUD1-2: RAB2B; NbExp=3; IntAct=EBI-348399, EBI-25835884; CC P22607; Q9UNT1-2: RABL2B; NbExp=3; IntAct=EBI-348399, EBI-12256104; CC P22607; Q15311: RALBP1; NbExp=3; IntAct=EBI-348399, EBI-749285; CC P22607; Q9HD47-3: RANGRF; NbExp=3; IntAct=EBI-348399, EBI-9089733; CC P22607; Q9NS23-4: RASSF1; NbExp=3; IntAct=EBI-348399, EBI-438710; CC P22607; Q9NWB1-5: RBFOX1; NbExp=3; IntAct=EBI-348399, EBI-12123390; CC P22607; Q9BWF3: RBM4; NbExp=3; IntAct=EBI-348399, EBI-2856454; CC P22607; Q8TBY0: RBM46; NbExp=3; IntAct=EBI-348399, EBI-12068216; CC P22607; Q9P2K3-2: RCOR3; NbExp=3; IntAct=EBI-348399, EBI-1504830; CC P22607; Q04206: RELA; NbExp=3; IntAct=EBI-348399, EBI-73886; CC P22607; P47804-3: RGR; NbExp=3; IntAct=EBI-348399, EBI-25834767; CC P22607; Q15382: RHEB; NbExp=3; IntAct=EBI-348399, EBI-1055287; CC P22607; Q8IXN7: RIMKLA; NbExp=3; IntAct=EBI-348399, EBI-21890191; CC P22607; Q8WVD3: RNF138; NbExp=3; IntAct=EBI-348399, EBI-749039; CC P22607; Q9H0X6: RNF208; NbExp=3; IntAct=EBI-348399, EBI-751555; CC P22607; P62899: RPL31; NbExp=3; IntAct=EBI-348399, EBI-1053664; CC P22607; P62244: RPS15A; NbExp=3; IntAct=EBI-348399, EBI-347895; CC P22607; P62701: RPS4X; NbExp=3; IntAct=EBI-348399, EBI-354303; CC P22607; Q66K80: RUSC1-AS1; NbExp=3; IntAct=EBI-348399, EBI-10248967; CC P22607; Q9BY12-3: SCAPER; NbExp=3; IntAct=EBI-348399, EBI-25837959; CC P22607; Q86SQ7-2: SDCCAG8; NbExp=3; IntAct=EBI-348399, EBI-10696955; CC P22607; Q9NTN9-3: SEMA4G; NbExp=3; IntAct=EBI-348399, EBI-9089805; CC P22607; Q13435: SF3B2; NbExp=3; IntAct=EBI-348399, EBI-749111; CC P22607; O60902-3: SHOX2; NbExp=3; IntAct=EBI-348399, EBI-9092164; CC P22607; Q9NSD5-3: SLC6A13; NbExp=3; IntAct=EBI-348399, EBI-25831241; CC P22607; Q9UHI5: SLC7A8; NbExp=3; IntAct=EBI-348399, EBI-13292283; CC P22607; Q12824: SMARCB1; NbExp=3; IntAct=EBI-348399, EBI-358419; CC P22607; Q13573: SNW1; NbExp=3; IntAct=EBI-348399, EBI-632715; CC P22607; O14544: SOCS6; NbExp=3; IntAct=EBI-348399, EBI-3929549; CC P22607; Q02086-2: SP2; NbExp=3; IntAct=EBI-348399, EBI-9088579; CC P22607; Q7Z6I5: SPATA12; NbExp=3; IntAct=EBI-348399, EBI-10696971; CC P22607; Q86W54-2: SPATA24; NbExp=3; IntAct=EBI-348399, EBI-12041693; CC P22607; Q496A3: SPATS1; NbExp=3; IntAct=EBI-348399, EBI-3923692; CC P22607; Q7Z698: SPRED2; NbExp=3; IntAct=EBI-348399, EBI-7082156; CC P22607; Q9C004: SPRY4; NbExp=3; IntAct=EBI-348399, EBI-354861; CC P22607; Q5W111-2: SPRYD7; NbExp=3; IntAct=EBI-348399, EBI-12408727; CC P22607; Q99469: STAC; NbExp=3; IntAct=EBI-348399, EBI-2652799; CC P22607; Q92783-2: STAM; NbExp=3; IntAct=EBI-348399, EBI-12025738; CC P22607; O75886: STAM2; NbExp=3; IntAct=EBI-348399, EBI-373258; CC P22607; Q13586: STIM1; NbExp=4; IntAct=EBI-348399, EBI-448878; CC P22607; Q8N4C7: STX19; NbExp=3; IntAct=EBI-348399, EBI-8484990; CC P22607; Q15814: TBCC; NbExp=3; IntAct=EBI-348399, EBI-15695297; CC P22607; O15273: TCAP; NbExp=3; IntAct=EBI-348399, EBI-954089; CC P22607; Q86WV5: TEN1; NbExp=3; IntAct=EBI-348399, EBI-2562799; CC P22607; Q96A09: TENT5B; NbExp=3; IntAct=EBI-348399, EBI-752030; CC P22607; P54274-2: TERF1; NbExp=3; IntAct=EBI-348399, EBI-711018; CC P22607; Q6N021: TET2; NbExp=3; IntAct=EBI-348399, EBI-310727; CC P22607; Q9BXU0: TEX12; NbExp=3; IntAct=EBI-348399, EBI-12090309; CC P22607; Q5T0J7-2: TEX35; NbExp=3; IntAct=EBI-348399, EBI-12833746; CC P22607; Q8WTV1: THAP3; NbExp=3; IntAct=EBI-348399, EBI-17438286; CC P22607; Q5T1C6: THEM4; NbExp=3; IntAct=EBI-348399, EBI-7684443; CC P22607; O60830: TIMM17B; NbExp=3; IntAct=EBI-348399, EBI-2372529; CC P22607; Q9BZW5-2: TM6SF1; NbExp=3; IntAct=EBI-348399, EBI-25852210; CC P22607; Q96B77: TMEM186; NbExp=3; IntAct=EBI-348399, EBI-9089409; CC P22607; Q8N0U2: TMEM61; NbExp=3; IntAct=EBI-348399, EBI-25830583; CC P22607; Q53NU3: tmp_locus_54; NbExp=3; IntAct=EBI-348399, EBI-10242677; CC P22607; Q9H8H3: TMT1A; NbExp=3; IntAct=EBI-348399, EBI-1390168; CC P22607; Q8IUR5-4: TMTC1; NbExp=3; IntAct=EBI-348399, EBI-9089156; CC P22607; Q71RG4-4: TMUB2; NbExp=3; IntAct=EBI-348399, EBI-25831574; CC P22607; P50616: TOB1; NbExp=3; IntAct=EBI-348399, EBI-723281; CC P22607; Q9H496: TOR1AIP2; NbExp=3; IntAct=EBI-348399, EBI-2510146; CC P22607; P36406: TRIM23; NbExp=3; IntAct=EBI-348399, EBI-740098; CC P22607; Q9UPQ4-2: TRIM35; NbExp=3; IntAct=EBI-348399, EBI-17716262; CC P22607; Q86WT6-2: TRIM69; NbExp=3; IntAct=EBI-348399, EBI-11525489; CC P22607; Q9Y3Q8: TSC22D4; NbExp=3; IntAct=EBI-348399, EBI-739485; CC P22607; Q99598: TSNAX; NbExp=3; IntAct=EBI-348399, EBI-21353855; CC P22607; O60636: TSPAN2; NbExp=3; IntAct=EBI-348399, EBI-3914288; CC P22607; Q6PF05: TTC23L; NbExp=3; IntAct=EBI-348399, EBI-8656864; CC P22607; Q9UGJ1-2: TUBGCP4; NbExp=3; IntAct=EBI-348399, EBI-10964469; CC P22607; P49459: UBE2A; NbExp=3; IntAct=EBI-348399, EBI-2339348; CC P22607; Q13404: UBE2V1; NbExp=3; IntAct=EBI-348399, EBI-1050671; CC P22607; P11441: UBL4A; NbExp=3; IntAct=EBI-348399, EBI-356983; CC P22607; Q9HA47-2: UCK1; NbExp=3; IntAct=EBI-348399, EBI-16434682; CC P22607; P22415: USF1; NbExp=3; IntAct=EBI-348399, EBI-1054489; CC P22607; Q495M9: USH1G; NbExp=3; IntAct=EBI-348399, EBI-8601749; CC P22607; Q9H270: VPS11; NbExp=3; IntAct=EBI-348399, EBI-373380; CC P22607; Q8NEZ2: VPS37A; NbExp=3; IntAct=EBI-348399, EBI-2850578; CC P22607; Q9P1Q0-4: VPS54; NbExp=3; IntAct=EBI-348399, EBI-25835297; CC P22607; Q9NX94: WBP1L; NbExp=3; IntAct=EBI-348399, EBI-10316321; CC P22607; Q8TBZ3-3: WDR20; NbExp=3; IntAct=EBI-348399, EBI-9089370; CC P22607; O00755: WNT7A; NbExp=3; IntAct=EBI-348399, EBI-727198; CC P22607; P19544-6: WT1; NbExp=3; IntAct=EBI-348399, EBI-11745701; CC P22607; O43829: ZBTB14; NbExp=3; IntAct=EBI-348399, EBI-10176632; CC P22607; Q53FD0-2: ZC2HC1C; NbExp=3; IntAct=EBI-348399, EBI-14104088; CC P22607; Q9NP64: ZCCHC17; NbExp=3; IntAct=EBI-348399, EBI-746345; CC P22607; Q8WUU4: ZNF296; NbExp=3; IntAct=EBI-348399, EBI-8834821; CC P22607; Q96JL9-2: ZNF333; NbExp=3; IntAct=EBI-348399, EBI-25835852; CC P22607; Q9C0F3: ZNF436; NbExp=3; IntAct=EBI-348399, EBI-8489702; CC P22607; Q9P0T4: ZNF581; NbExp=3; IntAct=EBI-348399, EBI-745520; CC P22607; Q3KNS6-3: ZNF829; NbExp=3; IntAct=EBI-348399, EBI-18036029; CC P22607; B7Z3E8; NbExp=3; IntAct=EBI-348399, EBI-25831617; CC P22607; Q7L8T7; NbExp=3; IntAct=EBI-348399, EBI-25831943; CC P22607; Q7Z637; NbExp=3; IntAct=EBI-348399, EBI-25831475; CC P22607; Q86V28; NbExp=3; IntAct=EBI-348399, EBI-10259496; CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane; Single-pass type I CC membrane protein. Cytoplasmic vesicle. Endoplasmic reticulum. Note=The CC activated receptor is rapidly internalized and degraded. Detected in CC intracellular vesicles after internalization of the autophosphorylated CC receptor. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Cell membrane {ECO:0000250}; Single- CC pass type I membrane protein {ECO:0000250}. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Secreted. CC -!- SUBCELLULAR LOCATION: [Isoform 4]: Cell membrane {ECO:0000250}; Single- CC pass type I membrane protein {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; Synonyms=IIIc; CC IsoId=P22607-1; Sequence=Displayed; CC Name=2; Synonyms=IIIb; CC IsoId=P22607-2; Sequence=VSP_002988; CC Name=3; Synonyms=FGFR3deltaTM; CC IsoId=P22607-3; Sequence=VSP_002989; CC Name=4; CC IsoId=P22607-4; Sequence=VSP_040945; CC -!- TISSUE SPECIFICITY: Expressed in brain, kidney and testis. Very low or CC no expression in spleen, heart, and muscle. In 20- to 22-week old CC fetuses it is expressed at high level in kidney, lung, small intestine CC and brain, and to a lower degree in spleen, liver, and muscle. Isoform CC 2 is detected in epithelial cells. Isoform 1 is not detected in CC epithelial cells. Isoform 1 and isoform 2 are detected in fibroblastic CC cells. {ECO:0000269|PubMed:1664411}. CC -!- DOMAIN: The second and third Ig-like domains directly interact with CC fibroblast growth factors (FGF) and heparan sulfate proteoglycans. CC {ECO:0000269|PubMed:14732692}. CC -!- PTM: Autophosphorylated. Binding of FGF family members together with CC heparan sulfate proteoglycan or heparin promotes receptor dimerization CC and autophosphorylation on tyrosine residues. Autophosphorylation CC occurs in trans between the two FGFR molecules present in the dimer. CC Phosphorylation at Tyr-724 is essential for stimulation of cell CC proliferation and activation of PIK3R1, STAT1 and MAP kinase signaling. CC Phosphorylation at Tyr-760 is required for interaction with PIK3R1 and CC PLCG1. {ECO:0000269|PubMed:11294897, ECO:0000269|PubMed:19286672}. CC -!- PTM: Ubiquitinated. Is rapidly ubiquitinated after ligand binding and CC autophosphorylation, leading to receptor internalization and CC degradation. Subject to both proteasomal and lysosomal degradation. CC {ECO:0000269|PubMed:12297284, ECO:0000269|PubMed:17509076}. CC -!- PTM: N-glycosylated in the endoplasmic reticulum. The N-glycan chains CC undergo further maturation to an Endo H-resistant form in the Golgi CC apparatus. {ECO:0000269|PubMed:11703096, ECO:0000269|PubMed:16410555, CC ECO:0000269|PubMed:17311277, ECO:0000269|PubMed:17509076}. CC -!- DISEASE: Achondroplasia (ACH) [MIM:100800]: A frequent form of short- CC limb dwarfism. It is characterized by a long, narrow trunk, short CC extremities, particularly in the proximal (rhizomelic) segments, a CC large head with frontal bossing, hypoplasia of the midface and a CC trident configuration of the hands. ACH is an autosomal dominant CC disease. {ECO:0000269|PubMed:10611230, ECO:0000269|PubMed:12297284, CC ECO:0000269|PubMed:7758520, ECO:0000269|PubMed:7847369, CC ECO:0000269|PubMed:8078586, ECO:0000269|PubMed:8599935}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Crouzon syndrome with acanthosis nigricans (CAN) [MIM:612247]: CC Classic Crouzon disease which is caused by mutations in the FGFR2 gene CC is characterized by craniosynostosis (premature fusion of the skull CC sutures), and facial hypoplasia. Crouzon syndrome with acanthosis CC nigricans (a skin disorder characterized by pigmentation anomalies), CC CAN, is considered to be an independent disorder from classic Crouzon CC syndrome. CAN is characterized by additional more severe physical CC manifestation, such as Chiari malformation, hydrocephalus, and atresia CC or stenosis of the choanas, and is caused by a specific mutation (Ala- CC 391 to Glu) in the transmembrane domain of FGFR3. It is proposed to CC have an autosomal dominant mode of inheritance. CC {ECO:0000269|PubMed:17935505, ECO:0000269|PubMed:7493034}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Thanatophoric dysplasia 1 (TD1) [MIM:187600]: A neonatal CC lethal skeletal dysplasia. Affected individuals manifest severe CC shortening of the limbs with macrocephaly, narrow thorax, short ribs, CC and curved femurs. {ECO:0000269|PubMed:10360402, CC ECO:0000269|PubMed:10671061, ECO:0000269|PubMed:7773297, CC ECO:0000269|PubMed:8589699, ECO:0000269|PubMed:8845844, CC ECO:0000269|PubMed:9790257}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Thanatophoric dysplasia 2 (TD2) [MIM:187601]: A neonatal CC lethal skeletal dysplasia causing severe shortening of the limbs, CC narrow thorax and short ribs. Patients with thanatophoric dysplasia CC type 2 have straight femurs and cloverleaf skull. CC {ECO:0000269|PubMed:12297284, ECO:0000269|PubMed:7773297, CC ECO:0000269|PubMed:8754806}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Hypochondroplasia (HCH) [MIM:146000]: Autosomal dominant CC disease and is characterized by disproportionate short stature. It CC resembles achondroplasia, but with a less severe phenotype. CC {ECO:0000269|PubMed:10215410, ECO:0000269|PubMed:10777366, CC ECO:0000269|PubMed:11055896, ECO:0000269|PubMed:12707965, CC ECO:0000269|PubMed:7670477, ECO:0000269|PubMed:9452043}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in CC tissues of the urinary bladder. It often presents with multiple tumors CC appearing at different times and at different sites in the bladder. CC Most bladder cancers are transitional cell carcinomas that begin in CC cells that normally make up the inner lining of the bladder. Other CC types of bladder cancer include squamous cell carcinoma (cancer that CC begins in thin, flat cells) and adenocarcinoma (cancer that begins in CC cells that make and release mucus and other fluids). Bladder cancer is CC a complex disorder with both genetic and environmental influences. CC {ECO:0000269|PubMed:10471491, ECO:0000269|PubMed:11314002}. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. Somatic mutations can constitutively CC activate FGFR3. CC -!- DISEASE: Cervical cancer (CERCA) [MIM:603956]: A malignant neoplasm of CC the cervix, typically originating from a dysplastic or premalignant CC lesion previously present at the active squamocolumnar junction. The CC transformation from mild dysplastic to invasive carcinoma generally CC occurs slowly within several years, although the rate of this process CC varies widely. Carcinoma in situ is particularly known to precede CC invasive cervical cancer in most cases. Cervical cancer is strongly CC associated with infection by oncogenic types of human papillomavirus. CC {ECO:0000269|PubMed:10471491}. Note=The gene represented in this entry CC is involved in disease pathogenesis. CC -!- DISEASE: Camptodactyly, tall stature, and hearing loss syndrome CC (CATSHLS) [MIM:610474]: An autosomal dominant syndrome characterized by CC permanent and irreducible flexion of one or more fingers of the hand CC and/or feet, tall stature, scoliosis and/or a pectus excavatum, and CC hearing loss. Affected individuals have developmental delay and/or CC intellectual disability, and several of these have microcephaly. CC Radiographic findings included tall vertebral bodies with irregular CC borders and broad femoral metaphyses with long tubular shafts. On CC audiological exam, each tested member have bilateral sensorineural CC hearing loss and absent otoacoustic emissions. The hearing loss was CC congenital or developed in early infancy, progressed variably in early CC childhood, and range from mild to severe. Computed tomography and CC magnetic resonance imaging reveal that the brain, middle ear, and inner CC ear are structurally normal. {ECO:0000269|PubMed:17033969}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Multiple myeloma (MM) [MIM:254500]: A malignant tumor of CC plasma cells usually arising in the bone marrow and characterized by CC diffuse involvement of the skeletal system, hyperglobulinemia, Bence- CC Jones proteinuria and anemia. Complications of multiple myeloma are CC bone pain, hypercalcemia, renal failure and spinal cord compression. CC The aberrant antibodies that are produced lead to impaired humoral CC immunity and patients have a high prevalence of infection. Amyloidosis CC may develop in some patients. Multiple myeloma is part of a spectrum of CC diseases ranging from monoclonal gammopathy of unknown significance CC (MGUS) to plasma cell leukemia. {ECO:0000269|PubMed:11529856, CC ECO:0000269|PubMed:9207791}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. A chromosomal aberration CC involving FGFR3 is found in multiple myeloma. Translocation CC t(4;14)(p16.3;q32.3) with the IgH locus. CC -!- DISEASE: Lacrimo-auriculo-dento-digital syndrome 2 (LADD2) CC [MIM:620192]: A form of lacrimo-auriculo-dento-digital syndrome, an CC autosomal dominant disease characterized by aplastic/hypoplastic CC lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, CC hypodontia and enamel hypoplasia, and distal limb segments anomalies. CC In addition to these cardinal features, facial dysmorphism, CC malformations of the kidney and respiratory system and abnormal CC genitalia have been reported. Craniosynostosis and severe syndactyly CC are not observed. {ECO:0000269|PubMed:16501574}. Note=The disease may CC be caused by variants affecting the gene represented in this entry. CC -!- DISEASE: Keratinocytic non-epidermolytic nevus (KNEN) [MIM:162900]: CC Epidermal nevi of the common, non-organoid and non-epidermolytic type CC are benign skin lesions and may vary in their extent from a single CC (usually linear) lesion to widespread and systematized involvement. CC They may be present at birth or develop early during childhood. CC {ECO:0000269|PubMed:16841094}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Muenke syndrome (MNKS) [MIM:602849]: A condition characterized CC by premature closure of coronal suture of skull during development CC (coronal craniosynostosis), which affects the shape of the head and CC face. It may be uni- or bilateral. When bilateral, it is characterized CC by a skull with a small antero-posterior diameter (brachycephaly), CC often with a decrease in the depth of the orbits and hypoplasia of the CC maxillae. Unilateral closure of the coronal sutures leads to flattening CC of the orbit on the involved side (plagiocephaly). The intellect is CC normal. In addition to coronal craniosynostosis some affected CC individuals show skeletal abnormalities of hands and feet, CC sensorineural hearing loss, intellectual disability and respiratory CC insufficiency. {ECO:0000269|PubMed:11746040, CC ECO:0000269|PubMed:9042914, ECO:0000269|PubMed:9950359}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Keratosis, seborrheic (KERSEB) [MIM:182000]: A common benign CC skin tumor. Seborrheic keratoses usually begin with the appearance of CC one or more sharply defined, light brown, flat macules. The lesions may CC be sparse or numerous. As they initially grow, they develop a velvety CC to finely verrucous surface, followed by an uneven warty surface with CC multiple plugged follicles and a dull or lackluster appearance. CC {ECO:0000269|PubMed:15772091}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Testicular germ cell tumor (TGCT) [MIM:273300]: A common CC malignancy in males representing 95% of all testicular neoplasms. TGCTs CC have various pathologic subtypes including: unclassified intratubular CC germ cell neoplasia, seminoma (including cases with CC syncytiotrophoblastic cells), spermatocytic seminoma, embryonal CC carcinoma, yolk sac tumor, choriocarcinoma, and teratoma. CC {ECO:0000269|PubMed:19855393}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. CC -!- DISEASE: Achondroplasia, severe, with developmental delay and CC acanthosis nigricans (SADDAN) [MIM:616482]: A severe form of CC achondroplasia associated with developmental delay and acanthosis CC nigricans. Patients manifest short-limb dwarfism, with a long, narrow CC trunk, short extremities, particularly in the proximal (rhizomelic) CC segments, a large head with frontal bossing, hypoplasia of the midface CC and a trident configuration of the hands. Acanthosis nigricans is a CC skin condition characterized by brown-pigmented, velvety verrucosities CC in body folds and creases. {ECO:0000269|PubMed:10053006}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Fibroblast growth factor receptor subfamily. CC {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=BAD92678.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/99/FGFR"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M58051; AAA52450.1; -; mRNA. DR EMBL; AF245114; AAF63380.1; -; mRNA. DR EMBL; AB209441; BAD92678.1; ALT_INIT; mRNA. DR EMBL; AY768549; AAU89726.1; -; Genomic_DNA. DR EMBL; AC016773; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471131; EAW82564.1; -; Genomic_DNA. DR EMBL; CH471131; EAW82565.1; -; Genomic_DNA. DR EMBL; CH471131; EAW82566.1; -; Genomic_DNA. DR EMBL; CH471131; EAW82567.1; -; Genomic_DNA. DR EMBL; M64347; AAA58470.1; -; mRNA. DR EMBL; M59374; AAA63209.1; -; mRNA. DR EMBL; S76733; AAB33323.1; -; Genomic_DNA. DR EMBL; X84939; CAA59334.1; -; mRNA. DR EMBL; U22410; AAA67781.1; -; Genomic_DNA. DR CCDS; CCDS3353.1; -. [P22607-1] DR CCDS; CCDS3354.1; -. [P22607-3] DR CCDS; CCDS54706.1; -. [P22607-2] DR PIR; A38576; TVHUF3. DR RefSeq; NP_000133.1; NM_000142.5. [P22607-1] DR RefSeq; NP_001156685.1; NM_001163213.2. [P22607-2] DR RefSeq; NP_075254.1; NM_022965.4. [P22607-3] DR RefSeq; XP_047305780.1; XM_047449824.1. [P22607-1] DR PDB; 1RY7; X-ray; 3.20 A; B=33-365. DR PDB; 2LZL; NMR; -; A/B=357-399. DR PDB; 4K33; X-ray; 2.34 A; A=449-759. DR PDB; 6LVM; X-ray; 2.53 A; A=472-759. DR PDB; 6PNX; X-ray; 2.20 A; A/B=451-759. DR PDB; 7DHL; X-ray; 2.57 A; A=472-759. DR PDB; 7YSU; EM; 3.20 A; C/E=148-358. DR PDB; 8UDT; X-ray; 2.83 A; A/B/C=454-756. DR PDB; 8UDU; X-ray; 1.74 A; A/B=454-756. DR PDB; 8UDV; X-ray; 2.35 A; A/B/C=454-756. DR PDB; 9CD7; X-ray; 2.53 A; A/B/C=448-759. DR PDB; 9D1X; X-ray; 1.60 A; A=455-756. DR PDB; 9KFU; X-ray; 1.40 A; A=448-756. DR PDBsum; 1RY7; -. DR PDBsum; 2LZL; -. DR PDBsum; 4K33; -. DR PDBsum; 6LVM; -. DR PDBsum; 6PNX; -. DR PDBsum; 7DHL; -. DR PDBsum; 7YSU; -. DR PDBsum; 8UDT; -. DR PDBsum; 8UDU; -. DR PDBsum; 8UDV; -. DR PDBsum; 9CD7; -. DR PDBsum; 9D1X; -. DR PDBsum; 9KFU; -. DR AlphaFoldDB; P22607; -. DR BMRB; P22607; -. DR EMDB; EMD-34082; -. DR SASBDB; P22607; -. DR SMR; P22607; -. DR BioGRID; 108552; 357. DR DIP; DIP-4016N; -. DR FunCoup; P22607; 1466. DR IntAct; P22607; 608. DR MINT; P22607; -. DR STRING; 9606.ENSP00000339824; -. DR BindingDB; P22607; -. DR ChEMBL; CHEMBL2742; -. DR DrugBank; DB08577; 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE. DR DrugBank; DB12558; AEE-788. DR DrugBank; DB11865; Brivanib alaninate. DR DrugBank; DB12903; DEBIO-1347. DR DrugBank; DB12147; Erdafitinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB15149; Futibatinib. DR DrugBank; DB11886; Infigratinib. DR DrugBank; DB17587; KIN-3248. DR DrugBank; DB09078; Lenvatinib. DR DrugBank; DB11845; Lucitanib. DR DrugBank; DB09079; Nintedanib. DR DrugBank; DB06589; Pazopanib. DR DrugBank; DB15102; Pemigatinib. DR DrugBank; DB08901; Ponatinib. DR DrugBank; DB15685; Selpercatinib. DR DrugBank; DB09283; Trapidil. DR DrugBank; DB05014; XL999. DR DrugCentral; P22607; -. DR GuidetoPHARMACOLOGY; 1810; -. DR GlyCosmos; P22607; 6 sites, No reported glycans. DR GlyGen; P22607; 10 sites, 3 N-linked glycans (3 sites), 1 O-linked glycan (1 site). DR iPTMnet; P22607; -. DR PhosphoSitePlus; P22607; -. DR BioMuta; FGFR3; -. DR DMDM; 120050; -. DR CPTAC; CPTAC-3180; -. DR CPTAC; CPTAC-3181; -. DR jPOST; P22607; -. DR MassIVE; P22607; -. DR PaxDb; 9606-ENSP00000339824; -. DR PeptideAtlas; P22607; -. DR ProteomicsDB; 54005; -. [P22607-1] DR ProteomicsDB; 54006; -. [P22607-2] DR ProteomicsDB; 54007; -. [P22607-3] DR ProteomicsDB; 54008; -. [P22607-4] DR ABCD; P22607; 3 sequenced antibodies. DR Antibodypedia; 3787; 779 antibodies from 45 providers. DR DNASU; 2261; -. DR Ensembl; ENST00000340107.9; ENSP00000339824.4; ENSG00000068078.21. [P22607-2] DR Ensembl; ENST00000352904.6; ENSP00000231803.1; ENSG00000068078.21. [P22607-3] DR Ensembl; ENST00000440486.8; ENSP00000414914.2; ENSG00000068078.21. [P22607-1] DR GeneID; 2261; -. DR KEGG; hsa:2261; -. DR MANE-Select; ENST00000440486.8; ENSP00000414914.2; NM_000142.5; NP_000133.1. DR UCSC; uc003gdr.3; human. [P22607-1] DR AGR; HGNC:3690; -. DR CIViC; 2261; 3 clinical assertions and 139 evidence items across 97 molecular profiles. DR ClinPGx; PA28129; -. DR CTD; 2261; -. DR DisGeNET; 2261; -. DR GeneCards; FGFR3; -. DR GeneReviews; FGFR3; -. DR HGNC; HGNC:3690; FGFR3. DR HPA; ENSG00000068078; Tissue enhanced (brain, esophagus, skin). DR MalaCards; FGFR3; -. DR MIM; 100800; phenotype. DR MIM; 109800; phenotype. DR MIM; 134934; gene. DR MIM; 146000; phenotype. DR MIM; 162900; phenotype. DR MIM; 182000; phenotype. DR MIM; 187600; phenotype. DR MIM; 187601; phenotype. DR MIM; 254500; phenotype. DR MIM; 273300; phenotype. DR MIM; 602849; phenotype. DR MIM; 603956; phenotype. DR MIM; 610474; phenotype. DR MIM; 612247; phenotype. DR MIM; 616482; phenotype. DR MIM; 620192; phenotype. DR OpenTargets; ENSG00000068078; -. DR Orphanet; 15; Achondroplasia. DR Orphanet; 85164; Camptodactyly-tall stature-scoliosis-hearing loss syndrome. DR Orphanet; 93262; Crouzon syndrome-acanthosis nigricans syndrome. DR Orphanet; 251579; Giant cell glioblastoma. DR Orphanet; 251576; Gliosarcoma. DR Orphanet; 429; Hypochondroplasia. DR Orphanet; 2363; Lacrimoauriculodentodigital syndrome. DR Orphanet; 53271; Muenke syndrome. DR Orphanet; 35099; Non-syndromic bicoronal craniosynostosis. DR Orphanet; 794; Saethre-Chotzen syndrome. DR Orphanet; 85165; Severe achondroplasia-developmental delay-acanthosis nigricans syndrome. DR Orphanet; 1860; Thanatophoric dysplasia type 1. DR Orphanet; 93274; Thanatophoric dysplasia type 2. DR VEuPathDB; HostDB:ENSG00000068078; -. DR eggNOG; KOG0200; Eukaryota. DR GeneTree; ENSGT00940000159880; -. DR HOGENOM; CLU_000288_74_3_1; -. DR InParanoid; P22607; -. DR OMA; RPANCTH; -. DR OrthoDB; 6019866at2759; -. DR PAN-GO; P22607; 8 GO annotations based on evolutionary models. DR PhylomeDB; P22607; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P22607; -. DR Reactome; R-HSA-109704; PI3K Cascade. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1839130; Signaling by activated point mutants of FGFR3. DR Reactome; R-HSA-190371; FGFR3b ligand binding and activation. [P22607-2] DR Reactome; R-HSA-190372; FGFR3c ligand binding and activation. [P22607-1] DR Reactome; R-HSA-2033515; t(4;14) translocations of FGFR3. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-5654227; Phospholipase C-mediated cascade, FGFR3. DR Reactome; R-HSA-5654704; SHC-mediated cascade:FGFR3. DR Reactome; R-HSA-5654706; FRS-mediated FGFR3 signaling. DR Reactome; R-HSA-5654710; PI-3K cascade:FGFR3. DR Reactome; R-HSA-5654732; Negative regulation of FGFR3 signaling. DR Reactome; R-HSA-5655332; Signaling by FGFR3 in disease. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8853334; Signaling by FGFR3 fusions in cancer. DR SignaLink; P22607; -. DR SIGNOR; P22607; -. DR Agora; ENSG00000068078; -. DR BioGRID-ORCS; 2261; 15 hits in 1201 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; FGFR3; human. DR EvolutionaryTrace; P22607; -. DR GeneWiki; Fibroblast_growth_factor_receptor_3; -. DR GenomeRNAi; 2261; -. DR Pharos; P22607; Tclin. DR PRO; PR:P22607; -. DR Proteomes; UP000005640; Chromosome 4. DR RNAct; P22607; protein. DR Bgee; ENSG00000068078; Expressed in upper leg skin and 181 other cell types or tissues. DR ExpressionAtlas; P22607; baseline and differential. DR GO; GO:0009986; C:cell surface; IEA:Ensembl. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0030133; C:transport vesicle; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0017134; F:fibroblast growth factor binding; IDA:UniProtKB. DR GO; GO:0005007; F:fibroblast growth factor receptor activity; IMP:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0070977; P:bone maturation; ISS:BHF-UCL. DR GO; GO:0030282; P:bone mineralization; ISS:BHF-UCL. DR GO; GO:0060349; P:bone morphogenesis; ISS:BHF-UCL. DR GO; GO:0007259; P:cell surface receptor signaling pathway via JAK-STAT; IMP:UniProtKB. DR GO; GO:0007267; P:cell-cell signaling; IEA:Ensembl. DR GO; GO:0002062; P:chondrocyte differentiation; TAS:UniProtKB. DR GO; GO:0035988; P:chondrocyte proliferation; TAS:UniProtKB. DR GO; GO:0003416; P:endochondral bone growth; TAS:UniProtKB. DR GO; GO:0001958; P:endochondral ossification; TAS:UniProtKB. DR GO; GO:1902178; P:fibroblast growth factor receptor apoptotic signaling pathway; IMP:UniProtKB. DR GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0000165; P:MAPK cascade; TAS:ProtInc. DR GO; GO:0048640; P:negative regulation of developmental growth; ISS:BHF-UCL. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:UniProtKB. DR GO; GO:0010518; P:positive regulation of phospholipase activity; IMP:UniProtKB. DR GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; IMP:UniProtKB. DR GO; GO:0001501; P:skeletal system development; TAS:ProtInc. DR CDD; cd05857; IgI_2_FGFR; 1. DR FunFam; 1.10.510.10:FF:000007; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000016; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000020; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000423; Fibroblast growth factor receptor; 1. DR FunFam; 3.30.200.20:FF:000011; Fibroblast growth factor receptor; 1. DR Gene3D; 6.10.250.1740; -; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 3. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR016248; FGF_rcpt_fam. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR24416:SF505; FIBROBLAST GROWTH FACTOR RECEPTOR 3; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF21165; FGFR3_TM; 1. DR Pfam; PF07679; I-set; 1. DR Pfam; PF13927; Ig_3; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PIRSF; PIRSF000628; FGFR; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00409; IG; 3. DR SMART; SM00408; IGc2; 3. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF48726; Immunoglobulin; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 3. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Apoptosis; ATP-binding; Cell membrane; KW Chromosomal rearrangement; Craniosynostosis; Cytoplasmic vesicle; Deafness; KW Disease variant; Disulfide bond; Dwarfism; Ectodermal dysplasia; KW Endoplasmic reticulum; Glycoprotein; Immunoglobulin domain; Kinase; KW Lacrimo-auriculo-dento-digital syndrome; Membrane; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome; KW Repeat; Secreted; Signal; Transferase; Transmembrane; Transmembrane helix; KW Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..22 FT CHAIN 23..806 FT /note="Fibroblast growth factor receptor 3" FT /id="PRO_0000016785" FT TOPO_DOM 23..375 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 376..396 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 397..806 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 24..126 FT /note="Ig-like C2-type 1" FT DOMAIN 151..244 FT /note="Ig-like C2-type 2" FT DOMAIN 253..355 FT /note="Ig-like C2-type 3" FT DOMAIN 472..761 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 126..153 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 765..806 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 132..145 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 771..787 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 617 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 478..486 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 508 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 444 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61851" FT MOD_RES 445 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q61851" FT MOD_RES 647 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:8754806" FT MOD_RES 648 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:8754806" FT MOD_RES 724 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11294897" FT MOD_RES 760 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:19286672" FT CARBOHYD 98 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 225 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 262 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 294 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 315 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 328 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 61..109 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 176..228 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 275..339 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 311..422 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:11703096" FT /id="VSP_002989" FT VAR_SEQ 311..358 FT /note="TAGANTTDKELEVLSLHNVTFEDAGEYTCLAGNSIGFSHHSAWLVVLP -> FT SWISESVEADVRLRLANVSERDGGEYLCRATNFIGVAEKAFWLSVHGPRA (in FT isoform 2)" FT /evidence="ECO:0000303|PubMed:7495869" FT /id="VSP_002988" FT VAR_SEQ 654..806 FT /note="GRLPVKWMAPEALFDRVYTHQSDVWSFGVLLWEIFTLGGSPYPGIPVEELFK FT LLKEGHRMDKPANCTHDLYMIMRECWHAAPSQRPTFKQLVEDLDRVLTVTSTDEYLDLS FT APFEQYSPGGQDTPSSSSSGDDSVFAHDLLPPAPPSSGGSRT -> LVLWGPALGDLHA FT GGLPVPRHPCGGALQAAEGGPPHGQARQLHTRPVHDHAGVLACRALPEAHLQAAGGGPG FT PCPYRDVHRRVPGPVGAFRAVLPGWPGHPQLQLLRGRLRVCPRPAAPGPTQQWGLADVK FT GHWSPTM (in isoform 4)" FT /evidence="ECO:0000303|Ref.3" FT /id="VSP_040945" FT VARIANT 65 FT /note="G -> R (in dbSNP:rs2305178)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_022167" FT VARIANT 79 FT /note="T -> S (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042207" FT VARIANT 228 FT /note="C -> R (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042208" FT VARIANT 248 FT /note="R -> C (in KERSEB, BLC, keratinocytic non- FT epidermolytic nevus and TD1; severe and lethal; also found FT as somatic mutation in one patient with multiple myeloma; FT constitutive dimerization and kinase activation; FT dbSNP:rs121913482)" FT /evidence="ECO:0000269|PubMed:10360402, FT ECO:0000269|PubMed:10471491, ECO:0000269|PubMed:11529856, FT ECO:0000269|PubMed:15772091, ECO:0000269|PubMed:16841094, FT ECO:0000269|PubMed:17509076, ECO:0000269|PubMed:7773297, FT ECO:0000269|PubMed:8845844" FT /id="VAR_004148" FT VARIANT 249 FT /note="S -> C (in KERSEB, BLC, cervical cancer and TD1; FT dbSNP:rs121913483)" FT /evidence="ECO:0000269|PubMed:10360402, FT ECO:0000269|PubMed:10471491, ECO:0000269|PubMed:15772091, FT ECO:0000269|PubMed:8589699, ECO:0000269|PubMed:8845844" FT /id="VAR_004149" FT VARIANT 250 FT /note="P -> R (in MNKS; also some individuals with FT autosomal dominant congenital sensorineural deafness FT without craniosynostosis; dbSNP:rs4647924)" FT /evidence="ECO:0000269|PubMed:11746040, FT ECO:0000269|PubMed:9042914, ECO:0000269|PubMed:9525367, FT ECO:0000269|PubMed:9950359" FT /id="VAR_004150" FT VARIANT 322 FT /note="E -> K (in colorectal cancer; dbSNP:rs121913111)" FT /evidence="ECO:0000269|PubMed:11325814" FT /id="VAR_018388" FT VARIANT 338 FT /note="T -> M" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042209" FT VARIANT 370 FT /note="G -> C (in KERSEB, BLC, keratinocytic non- FT epidermolytic nevus and TD1; dbSNP:rs121913479)" FT /evidence="ECO:0000269|PubMed:10471491, FT ECO:0000269|PubMed:15772091, ECO:0000269|PubMed:16841094, FT ECO:0000269|PubMed:8845844, ECO:0000269|PubMed:9790257" FT /id="VAR_004151" FT VARIANT 371 FT /note="S -> C (in KERSEB and TD1; dbSNP:rs121913484)" FT /evidence="ECO:0000269|PubMed:15772091, FT ECO:0000269|PubMed:7773297" FT /id="VAR_004152" FT VARIANT 373 FT /note="Y -> C (in KERSEB and TD1; disulfide-linked dimer FT with constitutive kinase activation; dbSNP:rs121913485)" FT /evidence="ECO:0000269|PubMed:10360402, FT ECO:0000269|PubMed:15772091, ECO:0000269|PubMed:17509076, FT ECO:0000269|PubMed:8845844, ECO:0000269|PubMed:9207791" FT /id="VAR_004153" FT VARIANT 375 FT /note="G -> C (in ACH; dbSNP:rs75790268)" FT /evidence="ECO:0000269|PubMed:7758520" FT /id="VAR_004154" FT VARIANT 380 FT /note="G -> R (in keratinocytic non-epidermolytic nevus and FT ACH; very common mutation; constitutively activated kinase FT with impaired internalization and degradation, resulting in FT prolonged FGFR3 signaling; dbSNP:rs28931614)" FT /evidence="ECO:0000269|PubMed:10611230, FT ECO:0000269|PubMed:12297284, ECO:0000269|PubMed:16841094, FT ECO:0000269|PubMed:17561467, ECO:0000269|PubMed:7847369, FT ECO:0000269|PubMed:8078586, ECO:0000269|PubMed:8599935" FT /id="VAR_004155" FT VARIANT 384 FT /note="F -> L (in dbSNP:rs17881656)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.4" FT /id="VAR_022168" FT VARIANT 391 FT /note="A -> E (in CAN; dbSNP:rs28931615)" FT /evidence="ECO:0000269|PubMed:17935505, FT ECO:0000269|PubMed:7493034" FT /id="VAR_004156" FT VARIANT 441 FT /note="A -> T (in dbSNP:rs17884368)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_022169" FT VARIANT 513 FT /note="D -> N (in LADD2; uncertain significance; FT dbSNP:rs121913112)" FT /evidence="ECO:0000269|PubMed:16501574" FT /id="VAR_029887" FT VARIANT 538 FT /note="I -> V (in hypochondroplasia; dbSNP:rs80053154)" FT /evidence="ECO:0000269|PubMed:10215410" FT /id="VAR_004157" FT VARIANT 540 FT /note="N -> K (in hypochondroplasia; dbSNP:rs28933068)" FT /evidence="ECO:0000269|PubMed:7670477" FT /id="VAR_004158" FT VARIANT 540 FT /note="N -> S (in hypochondroplasia; mild; FT dbSNP:rs77722678)" FT /evidence="ECO:0000269|PubMed:10777366, FT ECO:0000269|PubMed:12707965" FT /id="VAR_018389" FT VARIANT 540 FT /note="N -> T (in hypochondroplasia; dbSNP:rs77722678)" FT /evidence="ECO:0000269|PubMed:9452043" FT /id="VAR_004159" FT VARIANT 621 FT /note="R -> H (in CATSHLS; dbSNP:rs121913113)" FT /evidence="ECO:0000269|PubMed:17033969" FT /id="VAR_029108" FT VARIANT 646 FT /note="D -> N (in dbSNP:rs1721881918)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042210" FT VARIANT 650 FT /note="K -> E (in KERSEB, TD2, TGCT and BLC; bladder FT transitional cell carcinoma; somatic mutation; FT constitutively activated kinase with impaired FT internalization and degradation, resulting in prolonged FT FGFR3 signaling; dbSNP:rs78311289)" FT /evidence="ECO:0000269|PubMed:10471491, FT ECO:0000269|PubMed:11294897, ECO:0000269|PubMed:12297284, FT ECO:0000269|PubMed:14534538, ECO:0000269|PubMed:15772091, FT ECO:0000269|PubMed:17145761, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:17561467, ECO:0000269|PubMed:19855393, FT ECO:0000269|PubMed:7773297, ECO:0000269|PubMed:8754806, FT ECO:0000269|PubMed:9207791" FT /id="VAR_004160" FT VARIANT 650 FT /note="K -> M (in KERSEB, ACH, TD1 and SADDAN; FT constitutively activated kinase with impaired FT internalization and degradation, resulting in prolonged FT FGFR3 signaling; dbSNP:rs121913105)" FT /evidence="ECO:0000269|PubMed:10053006, FT ECO:0000269|PubMed:10671061, ECO:0000269|PubMed:15772091, FT ECO:0000269|PubMed:17509076, ECO:0000269|PubMed:17561467, FT ECO:0000269|PubMed:9207791" FT /id="VAR_004161" FT VARIANT 650 FT /note="K -> Q (in hypochondroplasia and BLC; in FT hypochondroplasia the form is milder than that seen in FT individuals with the K-540 or M-650 mutations; FT constitutively activated kinase; dbSNP:rs78311289)" FT /evidence="ECO:0000269|PubMed:11055896, FT ECO:0000269|PubMed:11314002, ECO:0000269|PubMed:8754806" FT /id="VAR_018390" FT VARIANT 717 FT /note="A -> T (in dbSNP:rs17882190)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_022170" FT VARIANT 726 FT /note="I -> F (in dbSNP:rs17880763)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_022171" FT MUTAGEN 508 FT /note="K->A: Loss of kinase activity. Abolishes FT ubiquitination." FT /evidence="ECO:0000269|PubMed:12297284, FT ECO:0000269|PubMed:16410555" FT MUTAGEN 577 FT /note="Y->F: Minor effect on kinase activity." FT /evidence="ECO:0000269|PubMed:11294897" FT MUTAGEN 650 FT /note="K->D: Constitutively activated kinase." FT MUTAGEN 650 FT /note="K->L: Constitutively activated kinase." FT MUTAGEN 724 FT /note="Y->F: Strongly reduced kinase activity. Strongly FT reduced mitogen activity." FT /evidence="ECO:0000269|PubMed:11294897" FT MUTAGEN 760 FT /note="Y->F: Minor effect on kinase activity." FT /evidence="ECO:0000269|PubMed:11294897" FT MUTAGEN 770 FT /note="Y->F: Minor effect on kinase activity. Increased FT mitogen activity." FT /evidence="ECO:0000269|PubMed:11294897" FT CONFLICT 395 FT /note="L -> V (in Ref. 7; AAA58470)" FT /evidence="ECO:0000305" FT CONFLICT 421 FT /note="R -> RQ (in Ref. 3; BAD92678)" FT /evidence="ECO:0000305" FT STRAND 152..154 FT /evidence="ECO:0007829|PDB:7YSU" FT HELIX 156..158 FT /evidence="ECO:0007829|PDB:7YSU" FT STRAND 163..167 FT /evidence="ECO:0007829|PDB:1RY7" FT STRAND 172..175 FT /evidence="ECO:0007829|PDB:1RY7" FT STRAND 185..187 FT /evidence="ECO:0007829|PDB:1RY7" FT TURN 208..211 FT /evidence="ECO:0007829|PDB:1RY7" FT STRAND 212..215 FT /evidence="ECO:0007829|PDB:1RY7" FT HELIX 220..222 FT /evidence="ECO:0007829|PDB:1RY7" FT STRAND 226..232 FT /evidence="ECO:0007829|PDB:1RY7" FT STRAND 235..246 FT /evidence="ECO:0007829|PDB:1RY7" FT STRAND 263..268 FT /evidence="ECO:0007829|PDB:1RY7" FT STRAND 271..273 FT /evidence="ECO:0007829|PDB:1RY7" FT STRAND 283..289 FT /evidence="ECO:0007829|PDB:1RY7" FT HELIX 293..295 FT /evidence="ECO:0007829|PDB:1RY7" FT STRAND 302..304 FT /evidence="ECO:0007829|PDB:1RY7" FT TURN 319..321 FT /evidence="ECO:0007829|PDB:7YSU" FT STRAND 324..326 FT /evidence="ECO:0007829|PDB:1RY7" FT STRAND 331..333 FT /evidence="ECO:0007829|PDB:7YSU" FT STRAND 335..345 FT /evidence="ECO:0007829|PDB:1RY7" FT STRAND 348..357 FT /evidence="ECO:0007829|PDB:1RY7" FT STRAND 369..372 FT /evidence="ECO:0007829|PDB:2LZL" FT HELIX 374..398 FT /evidence="ECO:0007829|PDB:2LZL" FT HELIX 463..465 FT /evidence="ECO:0007829|PDB:8UDU" FT HELIX 469..471 FT /evidence="ECO:0007829|PDB:8UDU" FT STRAND 472..477 FT /evidence="ECO:0007829|PDB:8UDU" FT STRAND 480..492 FT /evidence="ECO:0007829|PDB:8UDU" FT STRAND 495..497 FT /evidence="ECO:0007829|PDB:8UDT" FT STRAND 502..508 FT /evidence="ECO:0007829|PDB:8UDU" FT HELIX 516..532 FT /evidence="ECO:0007829|PDB:8UDU" FT STRAND 541..545 FT /evidence="ECO:0007829|PDB:8UDU" FT STRAND 547..550 FT /evidence="ECO:0007829|PDB:8UDU" FT STRAND 552..556 FT /evidence="ECO:0007829|PDB:8UDU" FT HELIX 563..568 FT /evidence="ECO:0007829|PDB:8UDU" FT STRAND 571..573 FT /evidence="ECO:0007829|PDB:8UDU" FT HELIX 591..610 FT /evidence="ECO:0007829|PDB:8UDU" FT HELIX 620..622 FT /evidence="ECO:0007829|PDB:8UDU" FT STRAND 623..625 FT /evidence="ECO:0007829|PDB:8UDU" FT STRAND 631..633 FT /evidence="ECO:0007829|PDB:8UDU" FT TURN 643..645 FT /evidence="ECO:0007829|PDB:6LVM" FT STRAND 646..649 FT /evidence="ECO:0007829|PDB:4K33" FT STRAND 653..655 FT /evidence="ECO:0007829|PDB:8UDV" FT HELIX 658..660 FT /evidence="ECO:0007829|PDB:8UDU" FT HELIX 663..668 FT /evidence="ECO:0007829|PDB:8UDU" FT HELIX 673..688 FT /evidence="ECO:0007829|PDB:8UDU" FT HELIX 700..708 FT /evidence="ECO:0007829|PDB:8UDU" FT HELIX 721..730 FT /evidence="ECO:0007829|PDB:8UDU" FT HELIX 735..737 FT /evidence="ECO:0007829|PDB:8UDU" FT HELIX 741..756 FT /evidence="ECO:0007829|PDB:8UDU" SQ SEQUENCE 806 AA; 87710 MW; BC5EA75EA46F447E CRC64; MGAPACALAL CVAVAIVAGA SSESLGTEQR VVGRAAEVPG PEPGQQEQLV FGSGDAVELS CPPPGGGPMG PTVWVKDGTG LVPSERVLVG PQRLQVLNAS HEDSGAYSCR QRLTQRVLCH FSVRVTDAPS SGDDEDGEDE AEDTGVDTGA PYWTRPERMD KKLLAVPAAN TVRFRCPAAG NPTPSISWLK NGREFRGEHR IGGIKLRHQQ WSLVMESVVP SDRGNYTCVV ENKFGSIRQT YTLDVLERSP HRPILQAGLP ANQTAVLGSD VEFHCKVYSD AQPHIQWLKH VEVNGSKVGP DGTPYVTVLK TAGANTTDKE LEVLSLHNVT FEDAGEYTCL AGNSIGFSHH SAWLVVLPAE EELVEADEAG SVYAGILSYG VGFFLFILVV AAVTLCRLRS PPKKGLGSPT VHKISRFPLK RQVSLESNAS MSSNTPLVRI ARLSSGEGPT LANVSELELP ADPKWELSRA RLTLGKPLGE GCFGQVVMAE AIGIDKDRAA KPVTVAVKML KDDATDKDLS DLVSEMEMMK MIGKHKNIIN LLGACTQGGP LYVLVEYAAK GNLREFLRAR RPPGLDYSFD TCKPPEEQLT FKDLVSCAYQ VARGMEYLAS QKCIHRDLAA RNVLVTEDNV MKIADFGLAR DVHNLDYYKK TTNGRLPVKW MAPEALFDRV YTHQSDVWSF GVLLWEIFTL GGSPYPGIPV EELFKLLKEG HRMDKPANCT HDLYMIMREC WHAAPSQRPT FKQLVEDLDR VLTVTSTDEY LDLSAPFEQY SPGGQDTPSS SSSGDDSVFA HDLLPPAPPS SGGSRT // ID FGFR4_HUMAN Reviewed; 802 AA. AC P22455; G3JVM2; G3JVM5; G3JVM7; G3JVM9; O43785; Q14309; Q71TW8; Q8TDA0; AC Q96KE5; DT 01-AUG-1991, integrated into UniProtKB/Swiss-Prot. DT 27-APR-2001, sequence version 2. DT 28-JAN-2026, entry version 248. DE RecName: Full=Fibroblast growth factor receptor 4; DE Short=FGFR-4; DE EC=2.7.10.1; DE AltName: CD_antigen=CD334; DE Flags: Precursor; GN Name=FGFR4; Synonyms=JTK2, TKF; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=1709094; DOI=10.1002/j.1460-2075.1991.tb07654.x; RA Partanen J.M., Maekelae T.P., Eerola E., Korhonen J., Hirvonen H., RA Claesson-Welsh L., Alitalo K.; RT "FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct RT expression pattern."; RL EMBO J. 10:1347-1354(1991). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION AS RECEPTOR FOR FGF1 RP AND FGF2. RC TISSUE=Mammary gland; RX PubMed=7680645; DOI=10.1016/s0021-9258(18)53334-2; RA Ron D., Reich R., Chedid M., Lengel C., Cohen O.E., Chan A.M., Neufeld G., RA Miki T., Tronick S.R.; RT "Fibroblast growth factor receptor 4 is a high affinity receptor for both RT acidic and basic fibroblast growth factor but not for keratinocyte growth RT factor."; RL J. Biol. Chem. 268:5388-5394(1993). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), VARIANT LEU-136, TISSUE RP SPECIFICITY, AND SUBCELLULAR LOCATION. RC TISSUE=Intestine; RX PubMed=10631118; DOI=10.1006/bbrc.1999.2010; RA Takaishi S., Sawada M., Morita Y., Seno H., Fukuzawa H., Chiba T.; RT "Identification of a novel alternative splicing of human FGF receptor 4: RT soluble-form splice variant expressed in human gastrointestinal epithelial RT cells."; RL Biochem. Biophys. Res. Commun. 267:658-662(2000). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9457674; DOI=10.1007/s003359900703; RA Kostrzewa M., Muller U.; RT "Genomic structure and complete sequence of the human FGFR4 gene."; RL Mamm. Genome 9:131-135(1998). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANTS ILE-10 AND LEU-136, RP INVOLVEMENT IN CANCER, AND VARIANT ARG-388. RX PubMed=21882254; DOI=10.1002/mc.20848; RA Marshall A.D., van der Ent M.A., Grosveld G.C.; RT "PAX3-FOXO1 and FGFR4 in alveolar rhabdomyosarcoma."; RL Mol. Carcinog. 51:807-815(2012). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-136. RA Lind D.L., Cox D.R.; RT "Sequence variation in fibroblast growth factor receptors 3 and 4."; RL Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ILE-10; LEU-136 AND RP ARG-388. RG NIEHS SNPs program; RL Submitted (APR-2007) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT LEU-136. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 609-676. RC TISSUE=Blood; RX PubMed=2247464; DOI=10.1073/pnas.87.22.8913; RA Partanen J., Maekelae T.P., Alitalo R., Lehvaeslaiho H., Alitalo K.; RT "Putative tyrosine kinases expressed in K-562 human leukemia cells."; RL Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990). RN [12] RP RETRACTED PAPER. RX PubMed=11781352; DOI=10.1172/jci14036; RA Ezzat S., Zheng L., Zhu X.F., Wu G.E., Asa S.L.; RT "Targeted expression of a human pituitary tumor-derived isoform of FGF RT receptor-4 recapitulates pituitary tumorigenesis."; RL J. Clin. Invest. 109:69-78(2002). RN [13] RP RETRACTION NOTICE OF PUBMED:11781352. RX PubMed=26237043; DOI=10.1172/jci83399; RA Ezzat S., Zheng L., Zhu X.F., Wu G.E., Asa S.L.; RL J. Clin. Invest. 125:3303-3303(2015). RN [14] RP PROTEIN SEQUENCE OF 22-38. RX PubMed=15340161; DOI=10.1110/ps.04682504; RA Zhang Z., Henzel W.J.; RT "Signal peptide prediction based on analysis of experimentally verified RT cleavage sites."; RL Protein Sci. 13:2819-2824(2004). RN [15] RP FUNCTION AS FGF1 RECEPTOR AND IN ACTIVATION OF SIGNALING VIA PLCG1 AND RP PIK3R1, INTERACTION WITH PLCG1, PHOSPHORYLATION AT TYR-754, AND MUTAGENESIS RP OF TYR-754. RX PubMed=7518429; DOI=10.1016/s0021-9258(17)32309-8; RA Vainikka S., Joukov V., Wennstrom S., Bergman M., Pelicci P.G., Alitalo K.; RT "Signal transduction by fibroblast growth factor receptor-4 (FGFR-4). RT Comparison with FGFR-1."; RL J. Biol. Chem. 269:18320-18326(1994). RN [16] RP INTERACTION WITH FGF1; FGF2; FGF4; FGF6; FGF8 AND FGF9, AND FUNCTION IN RP CELL PROLIFERATION. RX PubMed=8663044; DOI=10.1074/jbc.271.25.15292; RA Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A., Coulier F., RA Gao G., Goldfarb M.; RT "Receptor specificity of the fibroblast growth factor family."; RL J. Biol. Chem. 271:15292-15297(1996). RN [17] RP FUNCTION IN CELL DIFFERENTIATION, MUTAGENESIS OF LYS-503, CATALYTIC RP ACTIVITY, AND IDENTIFICATION IN A COMPLEX WITH NCAM1; CDH2; PLCG1; FRS2; RP SRC; SHC; GAP43 AND CTTN. RX PubMed=11433297; DOI=10.1038/35083041; RA Cavallaro U., Niedermeyer J., Fuxa M., Christofori G.; RT "N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor RT signalling."; RL Nat. Cell Biol. 3:650-657(2001). RN [18] RP INVOLVEMENT IN CANCER. RX PubMed=11830541; RA Bange J., Prechtl D., Cheburkin Y., Specht K., Harbeck N., Schmitt M., RA Knyazeva T., Mueller S., Gaertner S., Sures I., Wang H., Imyanitov E., RA Haering H.U., Knayzev P., Iacobelli S., Hoefler H., Ullrich A.; RT "Cancer progression and tumor cell motility are associated with the FGFR4 RT Arg(388) allele."; RL Cancer Res. 62:840-847(2002). RN [19] RP INTERACTION WITH FGF1; FGF17; FGF18; FGF19; FGF21 AND FGF23, AND FUNCTION RP IN STIMULATION OF CELL PROLIFERATION. RX PubMed=16597617; DOI=10.1074/jbc.m601252200; RA Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M., Ornitz D.M.; RT "Receptor specificity of the fibroblast growth factor family. The complete RT mammalian FGF family."; RL J. Biol. Chem. 281:15694-15700(2006). RN [20] RP INTERACTION WITH FGF19; FGF21 AND KLB, AND FUNCTION IN SIGNALING AND IN RP REGULATION OF CYP7A1 AND BILE ACID SYNTHESIS. RX PubMed=17623664; DOI=10.1074/jbc.m704165200; RA Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R., Eliseenkova A.V., RA Mohammadi M., Rosenblatt K.P., Kliewer S.A., Kuro-o M.; RT "Tissue-specific expression of betaKlotho and fibroblast growth factor RT (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21."; RL J. Biol. Chem. 282:26687-26695(2007). RN [21] RP FUNCTION IN STAT1 PHOSPHORYLATION, CATALYTIC ACTIVITY, MUTAGENESIS OF RP LYS-503, GLYCOSYLATION, AND PHOSPHORYLATION. RX PubMed=17311277; DOI=10.1002/jcp.21014; RA Citores L., Bai L., Sorensen V., Olsnes S.; RT "Fibroblast growth factor receptor-induced phosphorylation of STAT1 at the RT Golgi apparatus without translocation to the nucleus."; RL J. Cell. Physiol. 212:148-156(2007). RN [22] RP INVOLVEMENT IN CANCER, AND VARIANT ARG-388. RX PubMed=18756523; DOI=10.1002/ijc.23578; RA Ma Z., Tsuchiya N., Yuasa T., Inoue T., Kumazawa T., Narita S., RA Horikawa Y., Tsuruta H., Obara T., Saito M., Satoh S., Ogawa O., RA Habuchi T.; RT "Polymorphisms of fibroblast growth factor receptor 4 have association with RT the development of prostate cancer and benign prostatic hyperplasia and the RT progression of prostate cancer in a Japanese population."; RL Int. J. Cancer 123:2574-2579(2008). RN [23] RP CATALYTIC ACTIVITY, FUNCTION AS FGF1 RECEPTOR AND IN ACTIVATION OF PLCG1; RP FRS2; MAPK1/ERK2 AND MAPK3/ERK1, ACTIVITY REGULATION, UBIQUITINATION, AND RP SUBCELLULAR LOCATION. RX PubMed=18480409; DOI=10.1091/mbc.e07-12-1219; RA Haugsten E.M., Malecki J., Bjorklund S.M., Olsnes S., Wesche J.; RT "Ubiquitination of fibroblast growth factor receptor 1 is required for its RT intracellular sorting but not for its endocytosis."; RL Mol. Biol. Cell 19:3390-3403(2008). RN [24] RP CATALYTIC ACTIVITY, FUNCTION AS FGF2 RECEPTOR AND IN STIMULATION OF CELL RP PROLIFERATION, SUBCELLULAR LOCATION, INTERACTION WITH FGF2 AND HIP1, RP PHOSPHORYLATION AT TYR-642 AND TYR-643, INVOLVEMENT IN CANCER, AND RP CHARACTERIZATION OF VARIANT ARG-388. RX PubMed=18670643; DOI=10.1593/neo.08450; RA Wang J., Yu W., Cai Y., Ren C., Ittmann M.M.; RT "Altered fibroblast growth factor receptor 4 stability promotes prostate RT cancer progression."; RL Neoplasia 10:847-856(2008). RN [25] RP INVOLVEMENT IN CANCER. RX PubMed=20638838; DOI=10.1016/j.ejca.2010.06.017; RA Xu W., Li Y., Wang X., Chen B., Wang Y., Liu S., Xu J., Zhao W., Wu J.; RT "FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis RT including 8555 subjects."; RL Eur. J. Cancer 46:3332-3338(2010). RN [26] RP FUNCTION IN FGF19 SIGNALING AND IN REGULATION OF BILE ACID SYNTHESIS VIA RP CYP7A1, INTERACTION WITH FGF19; KL AND KLB, AUTOPHOSPHORYLATION, RP SUBCELLULAR LOCATION, AND GLYCOSYLATION. RX PubMed=20683963; DOI=10.1002/hep.23708; RA Triantis V., Saeland E., Bijl N., Oude-Elferink R.P., Jansen P.L.; RT "Glycosylation of fibroblast growth factor receptor 4 is a key regulator of RT fibroblast growth factor 19-mediated down-regulation of cytochrome P450 RT 7A1."; RL Hepatology 52:656-666(2010). RN [27] RP FUNCTION IN HEPATOCYTE PROLIFERATION AND FGF19 SIGNALING. RX PubMed=20018895; DOI=10.1074/jbc.m109.068783; RA Wu X., Ge H., Lemon B., Vonderfecht S., Weiszmann J., Hecht R., Gupte J., RA Hager T., Wang Z., Lindberg R., Li Y.; RT "FGF19-induced hepatocyte proliferation is mediated through FGFR4 RT activation."; RL J. Biol. Chem. 285:5165-5170(2010). RN [28] RP FUNCTION IN DOWN-REGULATION OF MMP14, AUTOPHOSPHORYLATION, AND INTERACTION RP WITH MMP14. RX PubMed=20798051; DOI=10.1073/pnas.0914459107; RA Sugiyama N., Varjosalo M., Meller P., Lohi J., Chan K.M., Zhou Z., RA Alitalo K., Taipale J., Keski-Oja J., Lehti K.; RT "FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a RT membrane type 1 matrix metalloproteinase-FGFR4 complex."; RL Proc. Natl. Acad. Sci. U.S.A. 107:15786-15791(2010). RN [29] RP INVOLVEMENT IN CANCER, AND VARIANT ARG-388. RX PubMed=21349172; DOI=10.1186/1471-2407-11-84; RA Xu B., Tong N., Chen S.Q., Hua L.X., Wang Z.J., Zhang Z.D., Chen M.; RT "FGFR4 Gly388Arg polymorphism contributes to prostate cancer development RT and progression: a meta-analysis of 2618 cases and 2305 controls."; RL BMC Cancer 11:84-84(2011). RN [30] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [31] RP INVOLVEMENT IN CANCER. RX PubMed=21412156; DOI=10.1097/cej.0b013e3283457274; RA Frullanti E., Berking C., Harbeck N., Jezequel P., Haugen A., Mawrin C., RA Parise O. Jr., Sasaki H., Tsuchiya N., Dragani T.A.; RT "Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer RT prognostic factor."; RL Eur. J. Cancer Prev. 20:340-347(2011). RN [32] RP FUNCTION IN FGF19 SIGNALING, FUNCTION IN STIMULATION OF CELL PROLIFERATION RP AND ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1, AND INTERACTION WITH FGF19; RP KLB AND SULFATED GLYCOSAMINOGLYCANS. RX PubMed=21653700; DOI=10.1074/jbc.m111.251140; RA Nakamura M., Uehara Y., Asada M., Honda E., Nagai N., Kimata K., Suzuki M., RA Imamura T.; RT "Sulfated glycosaminoglycans are required for specific and sensitive RT fibroblast growth factor (FGF) 19 signaling via FGF receptor 4 and RT betaKlotho."; RL J. Biol. Chem. 286:26418-26423(2011). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-573, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [34] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-573, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [35] RP INTERACTION WITH STAT3, INVOLVEMENT IN CANCER, CHARACTERIZATION OF VARIANT RP ARG-388, AND PHOSPHORYLATION AT TYR-390. RX PubMed=26675719; DOI=10.1038/nature16449; RA Ulaganathan V.K., Sperl B., Rapp U.R., Ullrich A.; RT "Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding RT site."; RL Nature 528:570-574(2015). RN [36] RP VARIANTS [LARGE SCALE ANALYSIS] ILE-10; LEU-136; ALA-179; SER-426; ASN-516; RP MET-550; THR-712 AND ASN-772. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [37] RP REVIEW ON LIGAND SELECTIVITY AND SIGNALING. RX PubMed=15863030; DOI=10.1016/j.cytogfr.2005.01.001; RA Eswarakumar V.P., Lax I., Schlessinger J.; RT "Cellular signaling by fibroblast growth factor receptors."; RL Cytokine Growth Factor Rev. 16:139-149(2005). RN [38] RP REVIEW ON FUNCTION IN FGF SIGNALING. RX PubMed=20094046; DOI=10.1038/nrc2780; RA Turner N., Grose R.; RT "Fibroblast growth factor signalling: from development to cancer."; RL Nat. Rev. Cancer 10:116-129(2010). RN [39] RP CHARACTERIZATION OF VARIANT ARG-388, AND FUNCTION IN TUMOR CELL INVASION. RX PubMed=20876804; DOI=10.1158/0008-5472.can-10-1223; RA Sugiyama N., Varjosalo M., Meller P., Lohi J., Hyytiainen M., Kilpinen S., RA Kallioniemi O., Ingvarsen S., Engelholm L.H., Taipale J., Alitalo K., RA Keski-Oja J., Lehti K.; RT "Fibroblast growth factor receptor 4 regulates tumor invasion by coupling RT fibroblast growth factor signaling to extracellular matrix degradation."; RL Cancer Res. 70:7851-7861(2010). CC -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor CC for fibroblast growth factors and plays a role in the regulation of CC cell proliferation, differentiation and migration, and in regulation of CC lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D CC metabolism and phosphate homeostasis. Required for normal down- CC regulation of the expression of CYP7A1, the rate-limiting enzyme in CC bile acid synthesis, in response to FGF19. Phosphorylates PLCG1 and CC FRS2. Ligand binding leads to the activation of several signaling CC cascades. Activation of PLCG1 leads to the production of the cellular CC signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. CC Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and CC SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the CC MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. CC Promotes SRC-dependent phosphorylation of the matrix protease MMP14 and CC its lysosomal degradation. FGFR4 signaling is down-regulated by CC receptor internalization and degradation; MMP14 promotes CC internalization and degradation of FGFR4. Mutations that lead to CC constitutive kinase activation or impair normal FGFR4 inactivation lead CC to aberrant signaling. {ECO:0000269|PubMed:11433297, CC ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17311277, CC ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:18480409, CC ECO:0000269|PubMed:18670643, ECO:0000269|PubMed:20018895, CC ECO:0000269|PubMed:20683963, ECO:0000269|PubMed:20798051, CC ECO:0000269|PubMed:20876804, ECO:0000269|PubMed:21653700, CC ECO:0000269|PubMed:7518429, ECO:0000269|PubMed:7680645, CC ECO:0000269|PubMed:8663044}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:11433297, ECO:0000269|PubMed:17311277, CC ECO:0000269|PubMed:18480409, ECO:0000269|PubMed:18670643}; CC -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence CC of bound ligand. Ligand binding leads to dimerization and activation by CC autophosphorylation on tyrosine residues. CC {ECO:0000269|PubMed:18480409}. CC -!- SUBUNIT: Monomer. Homodimer after ligand binding. Interacts with FGF1, CC FGF2, FGF4, FGF6, FGF8, FGF9, FGF16, FGF17, FGF18, FGF19, FGF21 and CC FGF23 (in vitro). Binding affinity for FGF family members is enhanced CC by interactions between FGFs and heparan sulfate proteoglycans. CC Interacts with KLB; this strongly increases the affinity for FGF19 and CC FGF23. Affinity for FGF19 is strongly increased by KLB and sulfated CC glycosaminoglycans. KLB and KL both interact with the core-glycosylated CC FGFR4 in the endoplasmic reticulum and promote its degradation, so that CC only FGFR4 with fully mature N-glycans is expressed at the cell CC surface. Identified in a complex with NCAM1, CDH2, PLCG1, FRS2, SRC, CC SHC1, GAP43 and CTTN. Interacts with MMP14 and HIP1 (PubMed:11433297, CC PubMed:16597617, PubMed:17623664, PubMed:18670643, PubMed:20683963, CC PubMed:20798051, PubMed:21653700, PubMed:7518429, PubMed:8663044). CC Interacts with STAT3 (PubMed:26675719). {ECO:0000269|PubMed:11433297, CC ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17623664, CC ECO:0000269|PubMed:18670643, ECO:0000269|PubMed:20683963, CC ECO:0000269|PubMed:20798051, ECO:0000269|PubMed:21653700, CC ECO:0000269|PubMed:26675719, ECO:0000269|PubMed:7518429, CC ECO:0000269|PubMed:8663044}. CC -!- INTERACTION: CC P22455; P11362: FGFR1; NbExp=3; IntAct=EBI-6256193, EBI-1028277; CC P22455; P50281: MMP14; NbExp=6; IntAct=EBI-6256193, EBI-992788; CC P22455; P07949: RET; NbExp=2; IntAct=EBI-6256193, EBI-2480756; CC P22455; P34741: SDC2; NbExp=2; IntAct=EBI-6256193, EBI-1172957; CC P22455; Q03167: TGFBR3; NbExp=2; IntAct=EBI-6256193, EBI-2852679; CC -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane CC protein. Endosome. Endoplasmic reticulum. Note=Internalized from the CC cell membrane to recycling endosomes, and from there back to the cell CC membrane. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P22455-1; Sequence=Displayed; CC Name=2; Synonyms=Soluble-form; CC IsoId=P22455-2; Sequence=VSP_035108; CC -!- TISSUE SPECIFICITY: Expressed in gastrointestinal epithelial cells, CC pancreas, and gastric and pancreatic cancer cell lines. CC {ECO:0000269|PubMed:10631118}. CC -!- PTM: N-glycosylated. Full maturation of the glycan chains in the Golgi CC is essential for high affinity interaction with FGF19. CC -!- PTM: Ubiquitinated. Subject to proteasomal degradation when not fully CC glycosylated. {ECO:0000269|PubMed:18480409}. CC -!- PTM: Autophosphorylated. Binding of FGF family members together with CC heparan sulfate proteoglycan or heparin promotes receptor dimerization CC and autophosphorylation on tyrosine residues. Autophosphorylation CC occurs in trans between the two FGFR molecules present in the dimer. CC {ECO:0000269|PubMed:17311277, ECO:0000269|PubMed:18670643, CC ECO:0000269|PubMed:7518429}. CC -!- DISEASE: Note=FGFR4 variants may be involved in the pathogenesis of CC various cancers. Variant Arg-388 predisposes cancer patients to CC accelerated disease progression and may be associated with poor CC prognosis. It has been found in prostate cancer as well as cancers of CC the breast, colon, head and neck, larynx, lung, skin. CC {ECO:0000269|PubMed:11830541, ECO:0000269|PubMed:18670643, CC ECO:0000269|PubMed:18756523, ECO:0000269|PubMed:20638838, CC ECO:0000269|PubMed:20876804, ECO:0000269|PubMed:21349172, CC ECO:0000269|PubMed:21412156, ECO:0000269|PubMed:21882254, CC ECO:0000269|PubMed:26675719}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Fibroblast growth factor receptor subfamily. CC {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- CAUTION: An additional N-terminally truncated cytoplasmic isoform was CC previously reported to exist. However, the paper was subsequently CC retracted due to concerns regarding duplication of panels in some CC figures. {ECO:0000305|PubMed:11781352, ECO:0000305|PubMed:26237043}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/512/FGFR4"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X57205; CAA40490.1; -; mRNA. DR EMBL; L03840; AAB59389.1; -; mRNA. DR EMBL; AF202063; AAF27432.1; -; mRNA. DR EMBL; Y13901; CAA74200.1; -; Genomic_DNA. DR EMBL; AF359246; AAK51435.1; -; mRNA. DR EMBL; JN007471; AEO19712.1; -; mRNA. DR EMBL; JN007472; AEO19713.1; -; mRNA. DR EMBL; JN007473; AEO19714.1; -; mRNA. DR EMBL; JN007474; AEO19715.1; -; mRNA. DR EMBL; JN007475; AEO19716.1; -; mRNA. DR EMBL; JN007476; AEO19717.1; -; mRNA. DR EMBL; JN007477; AEO19718.1; -; mRNA. DR EMBL; JN007478; AEO19719.1; -; mRNA. DR EMBL; JN007479; AEO19720.1; -; mRNA. DR EMBL; JN007480; AEO19721.1; -; mRNA. DR EMBL; JN007481; AEO19722.1; -; mRNA. DR EMBL; JN007482; AEO19723.1; -; mRNA. DR EMBL; AF487555; AAM13666.1; -; Genomic_DNA. DR EMBL; EF571596; ABQ01235.1; -; Genomic_DNA. DR EMBL; AC027314; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471195; EAW85036.1; -; Genomic_DNA. DR EMBL; BC011847; AAH11847.1; -; mRNA. DR EMBL; M59373; AAA63208.1; -; mRNA. DR CCDS; CCDS4410.1; -. [P22455-1] DR CCDS; CCDS4411.1; -. [P22455-2] DR PIR; S15345; TVHUF4. DR RefSeq; NP_001278909.1; NM_001291980.1. DR RefSeq; NP_001341913.1; NM_001354984.2. [P22455-1] DR RefSeq; NP_002002.3; NM_002011.4. [P22455-1] DR RefSeq; NP_075252.2; NM_022963.3. [P22455-2] DR RefSeq; NP_998812.1; NM_213647.3. [P22455-1] DR PDB; 4QQ5; X-ray; 2.20 A; A=445-753. DR PDB; 4QQC; X-ray; 2.40 A; A=445-753. DR PDB; 4QQJ; X-ray; 1.68 A; A=445-753. DR PDB; 4QQT; X-ray; 1.50 A; A=445-753. DR PDB; 4QRC; X-ray; 1.90 A; A=445-753. DR PDB; 4R6V; X-ray; 2.35 A; A=445-753. DR PDB; 4TYE; X-ray; 2.80 A; A=447-753. DR PDB; 4TYG; X-ray; 2.40 A; A=447-753. DR PDB; 4TYI; X-ray; 3.40 A; A=447-753. DR PDB; 4TYJ; X-ray; 2.45 A; A=447-753. DR PDB; 4UXQ; X-ray; 1.85 A; A=447-753. DR PDB; 4XCU; X-ray; 1.71 A; A=449-751. DR PDB; 5JKG; X-ray; 2.35 A; A=445-753. DR PDB; 5NUD; X-ray; 2.50 A; A/B=449-753. DR PDB; 5NWZ; X-ray; 2.37 A; A/B=449-753. DR PDB; 5XFF; X-ray; 2.70 A; A=445-753. DR PDB; 5XFJ; X-ray; 3.25 A; A=445-753. DR PDB; 6IUO; X-ray; 2.30 A; A=445-753. DR PDB; 6IUP; X-ray; 2.00 A; A=445-753. DR PDB; 6J6Y; X-ray; 2.15 A; A/D=141-244. DR PDB; 6JPE; X-ray; 1.60 A; A=445-753. DR PDB; 6JPJ; X-ray; 2.64 A; A=445-753. DR PDB; 6NVG; X-ray; 1.99 A; A=450-751. DR PDB; 6NVH; X-ray; 1.90 A; A=450-751. DR PDB; 6NVI; X-ray; 2.12 A; A=450-751. DR PDB; 6NVJ; X-ray; 2.30 A; A=450-751. DR PDB; 6NVK; X-ray; 2.30 A; A=450-751. DR PDB; 6V9C; X-ray; 1.90 A; A=449-751. DR PDB; 6YI8; X-ray; 2.13 A; A/B=447-753. DR PDB; 7DTZ; X-ray; 2.01 A; A=445-753. DR PDB; 7F3M; X-ray; 2.29 A; A=445-753. DR PDB; 7N1J; X-ray; 2.99 A; A/C=245-355. DR PDB; 7TYD; X-ray; 2.86 A; A/C=245-355. DR PDB; 7V29; X-ray; 1.98 A; A/B=445-753. DR PDB; 7VJL; X-ray; 2.90 A; A/B=453-753. DR PDB; 7WCT; X-ray; 2.11 A; A=445-753. DR PDB; 7WCW; X-ray; 2.32 A; A=445-753. DR PDB; 7WCX; X-ray; 2.17 A; A=445-753. DR PDB; 7YBO; X-ray; 2.31 A; A=445-753. DR PDB; 7YBP; X-ray; 2.24 A; A=445-753. DR PDB; 7YBX; X-ray; 2.23 A; A=445-753. DR PDB; 7YC1; X-ray; 2.54 A; A=445-753. DR PDB; 7YC3; X-ray; 1.99 A; A=445-753. DR PDB; 7YSW; EM; 3.03 A; C/E=142-354. DR PDB; 8KH6; X-ray; 1.62 A; A=445-753. DR PDB; 8KH7; X-ray; 1.52 A; A=445-753. DR PDB; 8KH8; X-ray; 1.49 A; A=445-753. DR PDB; 8KH9; X-ray; 1.42 A; A=454-753. DR PDB; 8W5C; X-ray; 2.30 A; A/B=453-752. DR PDB; 8XLQ; X-ray; 1.95 A; A=445-753. DR PDBsum; 4QQ5; -. DR PDBsum; 4QQC; -. DR PDBsum; 4QQJ; -. DR PDBsum; 4QQT; -. DR PDBsum; 4QRC; -. DR PDBsum; 4R6V; -. DR PDBsum; 4TYE; -. DR PDBsum; 4TYG; -. DR PDBsum; 4TYI; -. DR PDBsum; 4TYJ; -. DR PDBsum; 4UXQ; -. DR PDBsum; 4XCU; -. DR PDBsum; 5JKG; -. DR PDBsum; 5NUD; -. DR PDBsum; 5NWZ; -. DR PDBsum; 5XFF; -. DR PDBsum; 5XFJ; -. DR PDBsum; 6IUO; -. DR PDBsum; 6IUP; -. DR PDBsum; 6J6Y; -. DR PDBsum; 6JPE; -. DR PDBsum; 6JPJ; -. DR PDBsum; 6NVG; -. DR PDBsum; 6NVH; -. DR PDBsum; 6NVI; -. DR PDBsum; 6NVJ; -. DR PDBsum; 6NVK; -. DR PDBsum; 6V9C; -. DR PDBsum; 6YI8; -. DR PDBsum; 7DTZ; -. DR PDBsum; 7F3M; -. DR PDBsum; 7N1J; -. DR PDBsum; 7TYD; -. DR PDBsum; 7V29; -. DR PDBsum; 7VJL; -. DR PDBsum; 7WCT; -. DR PDBsum; 7WCW; -. DR PDBsum; 7WCX; -. DR PDBsum; 7YBO; -. DR PDBsum; 7YBP; -. DR PDBsum; 7YBX; -. DR PDBsum; 7YC1; -. DR PDBsum; 7YC3; -. DR PDBsum; 7YSW; -. DR PDBsum; 8KH6; -. DR PDBsum; 8KH7; -. DR PDBsum; 8KH8; -. DR PDBsum; 8KH9; -. DR PDBsum; 8W5C; -. DR PDBsum; 8XLQ; -. DR AlphaFoldDB; P22455; -. DR EMDB; EMD-34084; -. DR SMR; P22455; -. DR BioGRID; 108555; 519. DR CORUM; P22455; -. DR DIP; DIP-5149N; -. DR FunCoup; P22455; 1427. DR IntAct; P22455; 421. DR MINT; P22455; -. DR STRING; 9606.ENSP00000292408; -. DR BindingDB; P22455; -. DR ChEMBL; CHEMBL3973; -. DR DrugBank; DB12147; Erdafitinib. DR DrugBank; DB16167; Fisogatinib. DR DrugBank; DB15149; Futibatinib. DR DrugBank; DB15169; H3B-6527. DR DrugBank; DB01109; Heparin. DR DrugBank; DB11886; Infigratinib. DR DrugBank; DB09078; Lenvatinib. DR DrugBank; DB15102; Pemigatinib. DR DrugBank; DB08901; Ponatinib. DR DrugBank; DB16845; Roblitinib. DR DrugCentral; P22455; -. DR GuidetoPHARMACOLOGY; 1811; -. DR TCDB; 8.A.23.1.9; the basigin (basigin) family. DR GlyConnect; 1938; 7 N-Linked glycans (4 sites). DR GlyCosmos; P22455; 8 sites, 8 glycans. DR GlyGen; P22455; 8 sites, 9 N-linked glycans (5 sites), 1 O-linked glycan (1 site). DR iPTMnet; P22455; -. DR PhosphoSitePlus; P22455; -. DR SwissPalm; P22455; -. DR BioMuta; FGFR4; -. DR DMDM; 13432140; -. DR CPTAC; CPTAC-1768; -. DR CPTAC; CPTAC-3178; -. DR CPTAC; CPTAC-3179; -. DR jPOST; P22455; -. DR MassIVE; P22455; -. DR PaxDb; 9606-ENSP00000292408; -. DR PeptideAtlas; P22455; -. DR ProteomicsDB; 53990; -. [P22455-1] DR ProteomicsDB; 53991; -. [P22455-2] DR ABCD; P22455; 1 sequenced antibody. DR Antibodypedia; 3922; 892 antibodies from 48 providers. DR DNASU; 2264; -. DR Ensembl; ENST00000292408.9; ENSP00000292408.4; ENSG00000160867.16. [P22455-1] DR Ensembl; ENST00000393637.5; ENSP00000377254.1; ENSG00000160867.16. [P22455-2] DR Ensembl; ENST00000502906.5; ENSP00000424960.1; ENSG00000160867.16. [P22455-1] DR GeneID; 2264; -. DR KEGG; hsa:2264; -. DR MANE-Select; ENST00000292408.9; ENSP00000292408.4; NM_213647.3; NP_998812.1. DR UCSC; uc003mfl.4; human. [P22455-1] DR AGR; HGNC:3691; -. DR CIViC; 2264; 11 evidence items across 6 molecular profiles. DR ClinPGx; PA28130; -. DR CTD; 2264; -. DR DisGeNET; 2264; -. DR GeneCards; FGFR4; -. DR HGNC; HGNC:3691; FGFR4. DR HPA; ENSG00000160867; Tissue enhanced (liver, lung). DR MalaCards; FGFR4; -. DR MIM; 134935; gene. DR OpenTargets; ENSG00000160867; -. DR VEuPathDB; HostDB:ENSG00000160867; -. DR eggNOG; KOG0200; Eukaryota. DR GeneTree; ENSGT00940000161469; -. DR HOGENOM; CLU_000288_74_3_1; -. DR InParanoid; P22455; -. DR OMA; WYKEGNR; -. DR OrthoDB; 5984265at2759; -. DR PAN-GO; P22455; 9 GO annotations based on evolutionary models. DR PhylomeDB; P22455; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P22455; -. DR Reactome; R-HSA-109704; PI3K Cascade. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1307965; betaKlotho-mediated ligand binding. DR Reactome; R-HSA-1839128; FGFR4 mutant receptor activation. DR Reactome; R-HSA-190322; FGFR4 ligand binding and activation. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-5654228; Phospholipase C-mediated cascade, FGFR4. DR Reactome; R-HSA-5654712; FRS-mediated FGFR4 signaling. DR Reactome; R-HSA-5654719; SHC-mediated cascade:FGFR4. DR Reactome; R-HSA-5654720; PI-3K cascade:FGFR4. DR Reactome; R-HSA-5654733; Negative regulation of FGFR4 signaling. DR Reactome; R-HSA-5655291; Signaling by FGFR4 in disease. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR SignaLink; P22455; -. DR SIGNOR; P22455; -. DR Agora; ENSG00000160867; -. DR BioGRID-ORCS; 2264; 21 hits in 1192 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; FGFR4; human. DR EvolutionaryTrace; P22455; -. DR GeneWiki; Fibroblast_growth_factor_receptor_4; -. DR GenomeRNAi; 2264; -. DR Pharos; P22455; Tclin. DR PRO; PR:P22455; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; P22455; protein. DR Bgee; ENSG00000160867; Expressed in right lobe of liver and 112 other cell types or tissues. DR ExpressionAtlas; P22455; baseline and differential. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB. DR GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0030133; C:transport vesicle; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0017134; F:fibroblast growth factor binding; IDA:UniProtKB. DR GO; GO:0005007; F:fibroblast growth factor receptor activity; IDA:UniProtKB. DR GO; GO:0008201; F:heparin binding; IDA:UniProtKB. DR GO; GO:0016477; P:cell migration; IMP:UniProtKB. DR GO; GO:0042632; P:cholesterol homeostasis; ISS:UniProtKB. DR GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0055062; P:phosphate ion homeostasis; ISS:UniProtKB. DR GO; GO:0043085; P:positive regulation of catalytic activity; IMP:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB. DR GO; GO:2000573; P:positive regulation of DNA biosynthetic process; IMP:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB. DR GO; GO:0045862; P:positive regulation of proteolysis; IMP:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0070857; P:regulation of bile acid biosynthetic process; IMP:UniProtKB. DR GO; GO:0010715; P:regulation of extracellular matrix disassembly; IMP:UniProtKB. DR GO; GO:0019216; P:regulation of lipid metabolic process; ISS:UniProtKB. DR CDD; cd05857; IgI_2_FGFR; 1. DR FunFam; 1.10.510.10:FF:000007; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000016; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000020; Fibroblast growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000730; Fibroblast growth factor receptor; 1. DR FunFam; 3.30.200.20:FF:000334; Fibroblast growth factor receptor; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 3. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR016248; FGF_rcpt_fam. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR24416:SF343; FIBROBLAST GROWTH FACTOR RECEPTOR 4; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF07679; I-set; 1. DR Pfam; PF13927; Ig_3; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PIRSF; PIRSF000628; FGFR; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00409; IG; 3. DR SMART; SM00408; IGc2; 3. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF48726; Immunoglobulin; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; KW Direct protein sequencing; Disulfide bond; Endoplasmic reticulum; Endosome; KW Glycoprotein; Immunoglobulin domain; Kinase; Membrane; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome; KW Repeat; Secreted; Signal; Transferase; Transmembrane; Transmembrane helix; KW Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..21 FT /evidence="ECO:0000269|PubMed:15340161" FT CHAIN 22..802 FT /note="Fibroblast growth factor receptor 4" FT /id="PRO_0000016787" FT TOPO_DOM 22..369 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 370..390 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 391..802 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 22..118 FT /note="Ig-like C2-type 1" FT DOMAIN 152..240 FT /note="Ig-like C2-type 2" FT DOMAIN 249..349 FT /note="Ig-like C2-type 3" FT DOMAIN 467..755 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 119..148 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 612 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 473..481 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 503 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 390 FT /note="Phosphotyrosine; in variant R-388" FT /evidence="ECO:0000269|PubMed:26675719" FT MOD_RES 573 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 642 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18670643" FT MOD_RES 643 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18670643" FT MOD_RES 754 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:7518429" FT CARBOHYD 112 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 258 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 290 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 311 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 322 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 57..101 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 172..224 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 271..333 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 353..416 FT /note="EEDPTWTAAAPEARYTDIILYASGSLALAVLLLLAGLYRGQALHGRHPRPPA FT TVQKLSRFPLAR -> GTGRIPHLTCDSLTPAGRTKSPTL (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10631118" FT /id="VSP_035108" FT VARIANT 10 FT /note="V -> I (in dbSNP:rs1966265)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:21882254, ECO:0000269|Ref.7" FT /id="VAR_029185" FT VARIANT 136 FT /note="P -> L (in dbSNP:rs376618)" FT /evidence="ECO:0000269|PubMed:10631118, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:21882254, FT ECO:0000269|Ref.6, ECO:0000269|Ref.7, ECO:0000269|Ref.9" FT /id="VAR_042211" FT VARIANT 179 FT /note="T -> A (in dbSNP:rs55675160)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042212" FT VARIANT 388 FT /note="G -> R (in cancer cells, may be associated with FT accelerated disease progression and increased tumor cell FT motility, possibly due to increased stability of the FT protease MMP14; leads to phosphorylation at residue Y-390, FT resulting in prolonged FGFR4 activity; increases FT interaction with STAT3, resulting in STAT3 phosphorylation FT and signaling activation.; dbSNP:rs351855)" FT /evidence="ECO:0000269|PubMed:18670643, FT ECO:0000269|PubMed:18756523, ECO:0000269|PubMed:20876804, FT ECO:0000269|PubMed:21349172, ECO:0000269|PubMed:21882254, FT ECO:0000269|PubMed:26675719, ECO:0000269|Ref.7" FT /id="VAR_014797" FT VARIANT 426 FT /note="G -> S (in dbSNP:rs55879131)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046102" FT VARIANT 516 FT /note="D -> N (in dbSNP:rs34158682)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042213" FT VARIANT 529 FT /note="R -> Q (in dbSNP:rs34284947)" FT /id="VAR_049720" FT VARIANT 550 FT /note="V -> M (in breast pleomorphic lobular sample; FT somatic mutation; dbSNP:rs774571806)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046103" FT VARIANT 712 FT /note="P -> T (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046104" FT VARIANT 772 FT /note="S -> N (in a lung neuroendocrine carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046105" FT MUTAGEN 503 FT /note="K->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:11433297, FT ECO:0000269|PubMed:17311277" FT MUTAGEN 754 FT /note="Y->F: Loss of interaction with PLCG1." FT /evidence="ECO:0000269|PubMed:7518429" FT CONFLICT 121 FT /note="L -> S (in Ref. 3; AAF27432)" FT /evidence="ECO:0000305" FT CONFLICT 194 FT /note="E -> G (in Ref. 3; AAF27432)" FT /evidence="ECO:0000305" FT CONFLICT 297 FT /note="D -> V (in Ref. 1; CAA40490)" FT /evidence="ECO:0000305" FT STRAND 145..150 FT /evidence="ECO:0007829|PDB:6J6Y" FT HELIX 152..155 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 159..163 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 168..171 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 174..178 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 181..186 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 201..203 FT /evidence="ECO:0007829|PDB:6J6Y" FT TURN 204..207 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 208..213 FT /evidence="ECO:0007829|PDB:6J6Y" FT HELIX 216..218 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 220..227 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 232..242 FT /evidence="ECO:0007829|PDB:6J6Y" FT STRAND 259..262 FT /evidence="ECO:0007829|PDB:7TYD" FT STRAND 267..271 FT /evidence="ECO:0007829|PDB:7TYD" FT STRAND 280..286 FT /evidence="ECO:0007829|PDB:7TYD" FT STRAND 292..294 FT /evidence="ECO:0007829|PDB:7TYD" FT STRAND 296..298 FT /evidence="ECO:0007829|PDB:7TYD" FT STRAND 302..306 FT /evidence="ECO:0007829|PDB:7TYD" FT STRAND 316..320 FT /evidence="ECO:0007829|PDB:7TYD" FT HELIX 325..327 FT /evidence="ECO:0007829|PDB:7TYD" FT STRAND 329..336 FT /evidence="ECO:0007829|PDB:7TYD" FT STRAND 341..351 FT /evidence="ECO:0007829|PDB:7TYD" FT HELIX 445..448 FT /evidence="ECO:0007829|PDB:4QQ5" FT TURN 458..460 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 464..466 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 467..475 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 480..487 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 489..493 FT /evidence="ECO:0007829|PDB:6NVH" FT STRAND 497..504 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 511..527 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 531..533 FT /evidence="ECO:0007829|PDB:5XFJ" FT STRAND 536..540 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 542..544 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 547..551 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 558..563 FT /evidence="ECO:0007829|PDB:8KH9" FT TURN 570..572 FT /evidence="ECO:0007829|PDB:6YI8" FT TURN 577..580 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 586..605 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 615..617 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 618..620 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 626..628 FT /evidence="ECO:0007829|PDB:8KH9" FT TURN 631..635 FT /evidence="ECO:0007829|PDB:4XCU" FT HELIX 637..639 FT /evidence="ECO:0007829|PDB:4QQT" FT STRAND 642..644 FT /evidence="ECO:0007829|PDB:4UXQ" FT HELIX 652..655 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 658..663 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 668..683 FT /evidence="ECO:0007829|PDB:8KH9" FT STRAND 689..692 FT /evidence="ECO:0007829|PDB:6NVH" FT HELIX 695..703 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 716..725 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 730..732 FT /evidence="ECO:0007829|PDB:8KH9" FT HELIX 736..750 FT /evidence="ECO:0007829|PDB:8KH9" SQ SEQUENCE 802 AA; 87954 MW; B22B259831BB889F CRC64; MRLLLALLGV LLSVPGPPVL SLEASEEVEL EPCLAPSLEQ QEQELTVALG QPVRLCCGRA ERGGHWYKEG SRLAPAGRVR GWRGRLEIAS FLPEDAGRYL CLARGSMIVL QNLTLITGDS LTSSNDDEDP KSHRDPSNRH SYPQQAPYWT HPQRMEKKLH AVPAGNTVKF RCPAAGNPTP TIRWLKDGQA FHGENRIGGI RLRHQHWSLV MESVVPSDRG TYTCLVENAV GSIRYNYLLD VLERSPHRPI LQAGLPANTT AVVGSDVELL CKVYSDAQPH IQWLKHIVIN GSSFGADGFP YVQVLKTADI NSSEVEVLYL RNVSAEDAGE YTCLAGNSIG LSYQSAWLTV LPEEDPTWTA AAPEARYTDI ILYASGSLAL AVLLLLAGLY RGQALHGRHP RPPATVQKLS RFPLARQFSL ESGSSGKSSS SLVRGVRLSS SGPALLAGLV SLDLPLDPLW EFPRDRLVLG KPLGEGCFGQ VVRAEAFGMD PARPDQASTV AVKMLKDNAS DKDLADLVSE MEVMKLIGRH KNIINLLGVC TQEGPLYVIV ECAAKGNLRE FLRARRPPGP DLSPDGPRSS EGPLSFPVLV SCAYQVARGM QYLESRKCIH RDLAARNVLV TEDNVMKIAD FGLARGVHHI DYYKKTSNGR LPVKWMAPEA LFDRVYTHQS DVWSFGILLW EIFTLGGSPY PGIPVEELFS LLREGHRMDR PPHCPPELYG LMRECWHAAP SQRPTFKQLV EALDKVLLAV SEEYLDLRLT FGPYSPSGGD ASSTCSSSDS VFSHDPLPLG SSSFPFGSGV QT // ID FOXA1_HUMAN Reviewed; 472 AA. AC P55317; B2R9H6; B7ZAP5; Q9H2A0; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 18-MAY-2010, sequence version 2. DT 28-JAN-2026, entry version 219. DE RecName: Full=Hepatocyte nuclear factor 3-alpha; DE Short=HNF-3-alpha; DE Short=HNF-3A; DE AltName: Full=Forkhead box protein A1; DE AltName: Full=Transcription factor 3A; DE Short=TCF-3A; GN Name=FOXA1; Synonyms=HNF3A, TCF3A; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ALA-72; MET-124 INS RP AND ARG-185. RC TISSUE=Lung; RX PubMed=8652662; DOI=10.1016/0167-4781(96)00058-9; RA Bingle C.D., Gowan S.; RT "Molecular cloning of the forkhead transcription factor HNF-3 alpha from a RT human pulmonary adenocarcinoma cell line."; RL Biochim. Biophys. Acta 1307:17-20(1996). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ALA-72; THR-83; MET-124 RP INS; ARG-185 AND ASN-448. RX PubMed=10899756; DOI=10.1159/000022943; RA Navas M.A., Vaisse C., Boger S., Heimesaat M., Kollee L.A., Stoffel M.; RT "The human HNF-3 genes: cloning, partial sequence and mutation screening in RT patients with impaired glucose homeostasis."; RL Hum. Hered. 50:370-381(2000). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Yu L., Takeda J.; RT "Genetic variation in the HNF-3alpha gene."; RL Submitted (SEP-2000) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Mammary gland, and Trachea; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12508121; DOI=10.1038/nature01348; RA Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C., RA Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A., RA Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H., RA Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T., RA Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B., RA Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D., RA Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R., RA Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S., RA Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C., RA Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S., RA Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., RA Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., RA Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M., RA Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V., RA Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J., RA Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F., RA Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F., RA Waterston R., Hood L., Weissenbach J.; RT "The DNA sequence and analysis of human chromosome 14."; RL Nature 421:601-607(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP TISSUE SPECIFICITY. RX PubMed=12234996; RA Lin L., Miller C.T., Contreras J.I., Prescott M.S., Dagenais S.L., Wu R., RA Yee J., Orringer M.B., Misek D.E., Hanash S.M., Glover T.W., Beer D.G.; RT "The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on RT chromosome band 14q13 is amplified and overexpressed in esophageal and lung RT adenocarcinomas."; RL Cancer Res. 62:5273-5279(2002). RN [9] RP TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=15987773; DOI=10.1242/dev.01917; RA Gao N., Ishii K., Mirosevich J., Kuwajima S., Oppenheimer S.R., RA Roberts R.L., Jiang M., Yu X., Shappell S.B., Caprioli R.M., Stoffel M., RA Hayward S.W., Matusik R.J.; RT "Forkhead box A1 regulates prostate ductal morphogenesis and promotes RT epithelial cell maturation."; RL Development 132:3431-3443(2005). RN [10] RP FUNCTION. RX PubMed=16087863; DOI=10.1073/pnas.0505575102; RA Laganiere J., Deblois G., Lefebvre C., Bataille A.R., Robert F., RA Giguere V.; RT "Location analysis of estrogen receptor alpha target promoters reveals that RT FOXA1 defines a domain of the estrogen response."; RL Proc. Natl. Acad. Sci. U.S.A. 102:11651-11656(2005). RN [11] RP FUNCTION IN CELL CYCLE REGULATION, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RX PubMed=16331276; DOI=10.1038/sj.onc.1209170; RA Williamson E.A., Wolf I., O'Kelly J., Bose S., Tanosaki S., Koeffler H.P.; RT "BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle- RT dependent kinase inhibitor p27(Kip1)."; RL Oncogene 25:1391-1399(2006). RN [12] RP INTERACTION WITH NKX2-1. RX PubMed=17220277; DOI=10.1128/mcb.01133-06; RA Minoo P., Hu L., Xing Y., Zhu N.L., Chen H., Li M., Borok Z., Li C.; RT "Physical and functional interactions between homeodomain NKX2.1 and winged RT helix/forkhead FOXA1 in lung epithelial cells."; RL Mol. Cell. Biol. 27:2155-2165(2007). RN [13] RP FUNCTION IN CELL TYPE-SPECIFIC TRANSCRIPTION, AND DIFFERENTIAL RECRUITMENT RP TO CHROMATIN. RX PubMed=18358809; DOI=10.1016/j.cell.2008.01.018; RA Lupien M., Eeckhoute J., Meyer C.A., Wang Q., Zhang Y., Li W., RA Carroll J.S., Liu X.S., Brown M.; RT "FoxA1 translates epigenetic signatures into enhancer-driven lineage- RT specific transcription."; RL Cell 132:958-970(2008). RN [14] RP FUNCTION IN REGULATION OF APOPTOSIS. RX PubMed=19127412; DOI=10.1007/s12192-008-0095-4; RA Song L., Wei X., Zhang B., Luo X., Liu J., Feng Y., Xiao X.; RT "Role of Foxa1 in regulation of bcl2 expression during oxidative-stress- RT induced apoptosis in A549 type II pneumocytes."; RL Cell Stress Chaperones 14:417-425(2009). RN [15] RP INTERACTION WITH FOXA2. RX PubMed=19919681; DOI=10.1186/gb-2009-10-11-r129; RA Motallebipour M., Ameur A., Reddy Bysani M.S., Patra K., Wallerman O., RA Mangion J., Barker M.A., McKernan K.J., Komorowski J., Wadelius C.; RT "Differential binding and co-binding pattern of FOXA1 and FOXA3 and their RT relation to H3K4me3 in HepG2 cells revealed by ChIP-seq."; RL Genome Biol. 10:R129.0-R129.0(2009). RN [16] RP FUNCTION IN ESR1-MEDIATED TRANSCRIPTION REPRESSION, DIFFERENTIAL RP RECRUITMENT TO CHROMATIN, AND INTERACTION WITH HDAC7. RX PubMed=19917725; DOI=10.1128/mcb.00907-09; RA Malik S., Jiang S., Garee J.P., Verdin E., Lee A.V., O'Malley B.W., RA Zhang M., Belaguli N.S., Oesterreich S.; RT "Histone deacetylase 7 and FoxA1 in estrogen-mediated repression of RPRM."; RL Mol. Cell. Biol. 30:399-412(2010). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-307, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-307 AND SER-331, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). CC -!- FUNCTION: Transcription factor that is involved in embryonic CC development, establishment of tissue-specific gene expression and CC regulation of gene expression in differentiated tissues. Is thought to CC act as a 'pioneer' factor opening the compacted chromatin for other CC proteins through interactions with nucleosomal core histones and CC thereby replacing linker histones at target enhancer and/or promoter CC sites. Binds DNA with the consensus sequence 5'- CC [AC]A[AT]T[AG]TT[GT][AG][CT]T[CT]-3' (By similarity). Proposed to play CC a role in translating the epigenetic signatures into cell type-specific CC enhancer-driven transcriptional programs. Its differential recruitment CC to chromatin is dependent on distribution of histone H3 methylated at CC 'Lys-5' (H3K4me2) in estrogen-regulated genes. Involved in the CC development of multiple endoderm-derived organ systems such as liver, CC pancreas, lung and prostate; FOXA1 and FOXA2 seem to have at least in CC part redundant roles (By similarity). Modulates the transcriptional CC activity of nuclear hormone receptors. Is involved in ESR1-mediated CC transcription; required for ESR1 binding to the NKX2-1 promoter in CC breast cancer cells; binds to the RPRM promoter and is required for the CC estrogen-induced repression of RPRM. Involved in regulation of CC apoptosis by inhibiting the expression of BCL2. Involved in cell cycle CC regulation by activating expression of CDKN1B, alone or in conjunction CC with BRCA1. Originally described as a transcription activator for a CC number of liver genes such as AFP, albumin, tyrosine aminotransferase, CC PEPCK, etc. Interacts with the cis-acting regulatory regions of these CC genes. Involved in glucose homeostasis. {ECO:0000250, CC ECO:0000269|PubMed:16087863, ECO:0000269|PubMed:16331276, CC ECO:0000269|PubMed:18358809, ECO:0000269|PubMed:19127412, CC ECO:0000269|PubMed:19917725}. CC -!- SUBUNIT: Binds DNA as a monomer (By similarity). Interacts with FOXA2. CC Interacts with NKX2-1. Interacts with HDAC7. Interacts with the histone CC H3-H4 heterodimer. Associates with nucleosomes containing histone H2A. CC Interacts with AR. Interacts with NR0B2 (By similarity). {ECO:0000250}. CC -!- INTERACTION: CC P55317; P10275: AR; NbExp=4; IntAct=EBI-3918034, EBI-608057; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00089, CC ECO:0000269|PubMed:15987773, ECO:0000269|PubMed:16331276}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P55317-1; Sequence=Displayed; CC Name=2; CC IsoId=P55317-2; Sequence=VSP_055094; CC -!- TISSUE SPECIFICITY: Highly expressed in prostate and ESR1-positive CC breast tumors. Overexpressed in esophageal and lung adenocarcinomas. CC {ECO:0000269|PubMed:12234996, ECO:0000269|PubMed:15987773, CC ECO:0000269|PubMed:16331276}. CC -!- WEB RESOURCE: Name=Wikipedia; Note=Hepatocyte nuclear factors entry; CC URL="https://en.wikipedia.org/wiki/Hepatocyte_nuclear_factors"; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/44403/FOXA1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U39840; AAB06493.1; -; mRNA. DR EMBL; AF176112; AAD51979.1; -; Genomic_DNA. DR EMBL; AF176111; AAD51979.1; JOINED; Genomic_DNA. DR EMBL; AF303743; AAG40847.1; -; Genomic_DNA. DR EMBL; AF303742; AAG40847.1; JOINED; Genomic_DNA. DR EMBL; AK313785; BAG36523.1; -; mRNA. DR EMBL; AK316360; BAH14731.1; -; mRNA. DR EMBL; AL121790; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471078; EAW65844.1; -; Genomic_DNA. DR EMBL; BC033890; AAH33890.1; -; mRNA. DR CCDS; CCDS9665.1; -. [P55317-1] DR PIR; S70357; S70357. DR RefSeq; NP_004487.2; NM_004496.3. [P55317-1] DR PDB; 7VOX; X-ray; 2.10 A; A/B/C/H=168-264. DR PDB; 8VFY; EM; 2.89 A; O=1-472. DR PDB; 8VFZ; EM; 4.10 A; O/P=1-472. DR PDB; 8VG1; EM; 2.48 A; O=1-472. DR PDB; 8VG2; EM; 3.04 A; O=1-472. DR PDBsum; 7VOX; -. DR PDBsum; 8VFY; -. DR PDBsum; 8VFZ; -. DR PDBsum; 8VG1; -. DR PDBsum; 8VG2; -. DR AlphaFoldDB; P55317; -. DR EMDB; EMD-43194; -. DR EMDB; EMD-43195; -. DR EMDB; EMD-43197; -. DR EMDB; EMD-43198; -. DR SMR; P55317; -. DR BioGRID; 109411; 523. DR CORUM; P55317; -. DR DIP; DIP-57138N; -. DR ELM; P55317; -. DR FunCoup; P55317; 4980. DR IntAct; P55317; 54. DR MINT; P55317; -. DR STRING; 9606.ENSP00000250448; -. DR GlyGen; P55317; 11 sites, 1 O-linked glycan (11 sites). DR iPTMnet; P55317; -. DR PhosphoSitePlus; P55317; -. DR SwissPalm; P55317; -. DR BioMuta; FOXA1; -. DR DMDM; 296434509; -. DR jPOST; P55317; -. DR MassIVE; P55317; -. DR PaxDb; 9606-ENSP00000250448; -. DR PeptideAtlas; P55317; -. DR ProteomicsDB; 56845; -. [P55317-1] DR ProteomicsDB; 7076; -. DR Pumba; P55317; -. DR Antibodypedia; 23304; 1517 antibodies from 44 providers. DR DNASU; 3169; -. DR Ensembl; ENST00000250448.5; ENSP00000250448.3; ENSG00000129514.8. [P55317-1] DR GeneID; 3169; -. DR KEGG; hsa:3169; -. DR MANE-Select; ENST00000250448.5; ENSP00000250448.3; NM_004496.5; NP_004487.2. DR UCSC; uc001wuf.5; human. [P55317-1] DR AGR; HGNC:5021; -. DR ClinPGx; PA201090; -. DR CTD; 3169; -. DR DisGeNET; 3169; -. DR GeneCards; FOXA1; -. DR HGNC; HGNC:5021; FOXA1. DR HPA; ENSG00000129514; Tissue enhanced (prostate, stomach). DR MalaCards; FOXA1; -. DR MIM; 602294; gene. DR OpenTargets; ENSG00000129514; -. DR VEuPathDB; HostDB:ENSG00000129514; -. DR eggNOG; KOG3563; Eukaryota. DR GeneTree; ENSGT00940000162043; -. DR HOGENOM; CLU_027910_4_1_1; -. DR InParanoid; P55317; -. DR OMA; WSSYYTD; -. DR OrthoDB; 5954824at2759; -. DR PAN-GO; P55317; 5 GO annotations based on evolutionary models. DR PhylomeDB; P55317; -. DR PathwayCommons; P55317; -. DR Reactome; R-HSA-9018519; Estrogen-dependent gene expression. DR Reactome; R-HSA-9796292; Formation of axial mesoderm. DR SignaLink; P55317; -. DR SIGNOR; P55317; -. DR Agora; ENSG00000129514; -. DR BioGRID-ORCS; 3169; 64 hits in 1194 CRISPR screens. DR ChiTaRS; FOXA1; human. DR GeneWiki; FOXA1; -. DR GenomeRNAi; 3169; -. DR Pharos; P55317; Tbio. DR PRO; PR:P55317; -. DR Proteomes; UP000005640; Chromosome 14. DR RNAct; P55317; protein. DR Bgee; ENSG00000129514; Expressed in endometrium epithelium and 106 other cell types or tissues. DR ExpressionAtlas; P55317; baseline and differential. DR GO; GO:0000785; C:chromatin; ISA:NTNU_SB. DR GO; GO:0001650; C:fibrillar center; IDA:HPA. DR GO; GO:0005902; C:microvillus; IEA:Ensembl. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IEA:Ensembl. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; ISS:BHF-UCL. DR GO; GO:0003700; F:DNA-binding transcription factor activity; TAS:ProtInc. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB. DR GO; GO:0019904; F:protein domain specific binding; IEA:InterPro. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:BHF-UCL. DR GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:UniProtKB. DR GO; GO:0061144; P:alveolar secondary septum development; IEA:Ensembl. DR GO; GO:0048646; P:anatomical structure formation involved in morphogenesis; IEA:Ensembl. DR GO; GO:0009653; P:anatomical structure morphogenesis; IBA:GO_Central. DR GO; GO:0030154; P:cell differentiation; IBA:GO_Central. DR GO; GO:0006338; P:chromatin remodeling; ISS:UniProtKB. DR GO; GO:0071542; P:dopaminergic neuron differentiation; TAS:ParkinsonsUK-UCL. DR GO; GO:0021904; P:dorsal/ventral neural tube patterning; IEA:Ensembl. DR GO; GO:0060743; P:epithelial cell maturation involved in prostate gland development; IEA:Ensembl. DR GO; GO:0060441; P:epithelial tube branching involved in lung morphogenesis; IEA:Ensembl. DR GO; GO:0042593; P:glucose homeostasis; IEA:Ensembl. DR GO; GO:0042445; P:hormone metabolic process; IEA:Ensembl. DR GO; GO:0060487; P:lung epithelial cell differentiation; IEA:Ensembl. DR GO; GO:0060739; P:mesenchymal-epithelial cell signaling involved in prostate gland development; IEA:Ensembl. DR GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl. DR GO; GO:0048665; P:neuron fate specification; IEA:Ensembl. DR GO; GO:0007219; P:Notch signaling pathway; IEA:Ensembl. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:2000049; P:positive regulation of cell-cell adhesion mediated by cadherin; IC:BHF-UCL. DR GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; IMP:UniProtKB. DR GO; GO:1904340; P:positive regulation of dopaminergic neuron differentiation; IEA:Ensembl. DR GO; GO:0033148; P:positive regulation of intracellular estrogen receptor signaling pathway; IMP:UniProtKB. DR GO; GO:1902895; P:positive regulation of miRNA transcription; IC:BHF-UCL. DR GO; GO:0045931; P:positive regulation of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0045880; P:positive regulation of smoothened signaling pathway; IEA:Ensembl. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0060740; P:prostate gland epithelium morphogenesis; IEA:Ensembl. DR GO; GO:0060741; P:prostate gland stromal morphogenesis; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central. DR GO; GO:1902691; P:respiratory basal cell differentiation; IEA:Ensembl. DR GO; GO:0032355; P:response to estradiol; IDA:UniProtKB. DR GO; GO:0060528; P:secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development; IEA:Ensembl. DR GO; GO:0007224; P:smoothened signaling pathway; IEA:Ensembl. DR CDD; cd20038; FH_FOXA1; 1. DR FunFam; 1.10.10.10:FF:000042; hepatocyte nuclear factor 3-beta; 1. DR Gene3D; 1.10.10.10; Winged helix-like DNA-binding domain superfamily/Winged helix DNA-binding domain; 1. DR InterPro; IPR013638; Fork-head_N. DR InterPro; IPR001766; Fork_head_dom. DR InterPro; IPR018533; Forkhead_box_C. DR InterPro; IPR050211; FOX_domain-containing. DR InterPro; IPR018122; TF_fork_head_CS_1. DR InterPro; IPR030456; TF_fork_head_CS_2. DR InterPro; IPR036388; WH-like_DNA-bd_sf. DR InterPro; IPR036390; WH_DNA-bd_sf. DR PANTHER; PTHR11829; FORKHEAD BOX PROTEIN; 1. DR PANTHER; PTHR11829:SF195; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; 1. DR Pfam; PF00250; Forkhead; 1. DR Pfam; PF08430; Forkhead_N; 1. DR Pfam; PF09354; HNF_C; 1. DR PRINTS; PR00053; FORKHEAD. DR SMART; SM00339; FH; 1. DR SUPFAM; SSF46785; Winged helix' DNA-binding domain; 1. DR PROSITE; PS00657; FORK_HEAD_1; 1. DR PROSITE; PS00658; FORK_HEAD_2; 1. DR PROSITE; PS50039; FORK_HEAD_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative splicing; Chromatin regulator; KW Developmental protein; DNA-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repressor; Transcription; KW Transcription regulation. FT CHAIN 1..472 FT /note="Hepatocyte nuclear factor 3-alpha" FT /id="PRO_0000091792" FT DNA_BIND 169..260 FT /note="Fork-head" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00089" FT REGION 269..392 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 273..289 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 322..332 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 351..366 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 307 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 331 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT VAR_SEQ 1..33 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_055094" FT VARIANT 72 FT /note="G -> A" FT /evidence="ECO:0000269|PubMed:10899756, FT ECO:0000269|PubMed:8652662" FT /id="VAR_015183" FT VARIANT 83 FT /note="A -> T (in dbSNP:rs7144658)" FT /evidence="ECO:0000269|PubMed:10899756" FT /id="VAR_013457" FT VARIANT 87 FT /note="G -> E (in dbSNP:rs35220193)" FT /id="VAR_055835" FT VARIANT 124 FT /note="M -> MM" FT /evidence="ECO:0000269|PubMed:10899756, FT ECO:0000269|PubMed:8652662" FT /id="VAR_015184" FT VARIANT 185 FT /note="Q -> R" FT /evidence="ECO:0000269|PubMed:10899756, FT ECO:0000269|PubMed:8652662" FT /id="VAR_015185" FT VARIANT 448 FT /note="S -> N (in dbSNP:rs33984772)" FT /evidence="ECO:0000269|PubMed:10899756" FT /id="VAR_013458" FT HELIX 175..184 FT /evidence="ECO:0007829|PDB:7VOX" FT HELIX 193..203 FT /evidence="ECO:0007829|PDB:7VOX" FT HELIX 205..208 FT /evidence="ECO:0007829|PDB:7VOX" FT HELIX 211..224 FT /evidence="ECO:0007829|PDB:7VOX" FT STRAND 228..231 FT /evidence="ECO:0007829|PDB:7VOX" FT STRAND 243..246 FT /evidence="ECO:0007829|PDB:7VOX" FT HELIX 248..250 FT /evidence="ECO:0007829|PDB:7VOX" FT TURN 255..257 FT /evidence="ECO:0007829|PDB:8VG1" FT STRAND 259..261 FT /evidence="ECO:0007829|PDB:8VFY" SQ SEQUENCE 472 AA; 49148 MW; B2489523459EEB4C CRC64; MLGTVKMEGH ETSDWNSYYA DTQEAYSSVP VSNMNSGLGS MNSMNTYMTM NTMTTSGNMT PASFNMSYAN PGLGAGLSPG AVAGMPGGSA GAMNSMTAAG VTAMGTALSP SGMGAMGAQQ AASMNGLGPY AAAMNPCMSP MAYAPSNLGR SRAGGGGDAK TFKRSYPHAK PPYSYISLIT MAIQQAPSKM LTLSEIYQWI MDLFPYYRQN QQRWQNSIRH SLSFNDCFVK VARSPDKPGK GSYWTLHPDS GNMFENGCYL RRQKRFKCEK QPGAGGGGGS GSGGSGAKGG PESRKDPSGA SNPSADSPLH RGVHGKTGQL EGAPAPGPAA SPQTLDHSGA TATGGASELK TPASSTAPPI SSGPGALASV PASHPAHGLA PHESQLHLKG DPHYSFNHPF SINNLMSSSE QQHKLDFKAY EQALQYSPYG STLPASLPLG SASVTTRSPI EPSALEPAYY QGVYSRPVLN TS // ID GLT12_HUMAN Reviewed; 581 AA. AC Q8IXK2; Q5TCF7; Q8NG54; Q96CT9; Q9H771; DT 16-AUG-2004, integrated into UniProtKB/Swiss-Prot. DT 20-DEC-2005, sequence version 3. DT 28-JAN-2026, entry version 192. DE RecName: Full=Polypeptide N-acetylgalactosaminyltransferase 12; DE EC=2.4.1.41; DE AltName: Full=Polypeptide GalNAc transferase 12; DE Short=GalNAc-T12; DE Short=pp-GaNTase 12; DE AltName: Full=Protein-UDP acetylgalactosaminyltransferase 12; DE AltName: Full=UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 12; GN Name=GALNT12; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ENZYME ACTIVITY, TISSUE RP SPECIFICITY, AND VARIANT VAL-119. RC TISSUE=Lung; RX PubMed=12135769; DOI=10.1016/s0014-5793(02)03007-7; RA Guo J.-M., Zhang Y., Cheng L., Iwasaki H., Wang H., Kubota T., RA Tachibana K., Narimatsu H.; RT "Molecular cloning and characterization of a novel member of the UDP- RT GalNAc:polypeptide N-acetylgalactosaminyltransferase family, pp-GalNAc- RT T12(1)."; RL FEBS Lett. 524:211-218(2002). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Bennett E.P.; RL Submitted (JAN-1999) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164053; DOI=10.1038/nature02465; RA Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L., RA Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R., RA Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S., RA Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., RA Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., RA Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E., RA Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M., RA Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J., RA Frankish A., Frankland J.A., French L., Fricker D.G., Garner P., RA Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S., RA Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E., RA Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D., RA Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E., RA Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K., RA Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S., RA Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J., RA Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E., RA McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V., RA Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S., RA Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K., RA Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J., RA Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., RA West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L., RA Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M., RA Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J., RA Dunham I.; RT "DNA sequence and analysis of human chromosome 9."; RL Nature 429:369-374(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Bone marrow; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 144-581 (ISOFORM 1). RC TISSUE=Colon; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP VARIANTS CRCS1 TRP-297; ASN-303; ASP-341; HIS-373; HIS-382; PHE-479 AND RP MET-491, CHARACTERIZATION OF VARIANTS CRCS1 TRP-297; ASN-303; ASP-341; RP HIS-373; HIS-382; PHE-479 AND MET-491, AND VARIANTS GLU-3; ARG-46; VAL-119; RP ASN-261; ARG-272 AND LYS-552. RX PubMed=19617566; DOI=10.1073/pnas.0901454106; RA Guda K., Moinova H., He J., Jamison O., Ravi L., Natale L., Lutterbaugh J., RA Lawrence E., Lewis S., Willson J.K., Lowe J.B., Wiesner G.L., RA Parmigiani G., Barnholtz-Sloan J., Dawson D.W., Velculescu V.E., RA Kinzler K.W., Papadopoulos N., Vogelstein B., Willis J., Gerken T.A., RA Markowitz S.D.; RT "Inactivating germ-line and somatic mutations in polypeptide N- RT acetylgalactosaminyltransferase 12 in human colon cancers."; RL Proc. Natl. Acad. Sci. U.S.A. 106:12921-12925(2009). RN [7] RP VARIANTS CRCS1 ASN-303 AND CYS-396. RX PubMed=22461326; DOI=10.1002/humu.22088; RA Clarke E., Green R.C., Green J.S., Mahoney K., Parfrey P.S., RA Younghusband H.B., Woods M.O.; RT "Inherited deleterious variants in GALNT12 are associated with CRC RT susceptibility."; RL Hum. Mutat. 33:1056-1058(2012). RN [8] RP INVOLVEMENT IN CRCS1. RX PubMed=24115450; DOI=10.1002/humu.22454; RA Segui N., Pineda M., Navarro M., Lazaro C., Brunet J., Infante M., RA Duran M., Soto J.L., Blanco I., Capella G., Valle L.; RT "GALNT12 is not a major contributor of familial colorectal cancer type X."; RL Hum. Mutat. 35:50-52(2014). CC -!- FUNCTION: Catalyzes the initial reaction in O-linked oligosaccharide CC biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a CC serine or threonine residue on the protein receptor. Has activity CC toward non-glycosylated peptides such as Muc5AC, Muc1a and EA2, and no CC detectable activity with Muc2 and Muc7. Displays enzymatic activity CC toward the Gal-NAc-Muc5AC glycopeptide, but no detectable activity to CC mono-GalNAc-glycosylated Muc1a, Muc2, Muc7 and EA2. May play an CC important role in the initial step of mucin-type oligosaccharide CC biosynthesis in digestive organs. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + UDP-N-acetyl-alpha-D-galactosamine = a 3- CC O-[N-acetyl-alpha-D-galactosaminyl]-L-seryl-[protein] + UDP + H(+); CC Xref=Rhea:RHEA:23956, Rhea:RHEA-COMP:9863, Rhea:RHEA-COMP:12788, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:53604, CC ChEBI:CHEBI:58223, ChEBI:CHEBI:67138; EC=2.4.1.41; CC Evidence={ECO:0000269|PubMed:12135769}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + UDP-N-acetyl-alpha-D-galactosamine = a CC 3-O-[N-acetyl-alpha-D-galactosaminyl]-L-threonyl-[protein] + UDP + CC H(+); Xref=Rhea:RHEA:52424, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11689, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:58223, CC ChEBI:CHEBI:67138, ChEBI:CHEBI:87075; EC=2.4.1.41; CC Evidence={ECO:0000269|PubMed:12135769}; CC -!- COFACTOR: CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250}; CC -!- PATHWAY: Protein modification; protein glycosylation. CC -!- INTERACTION: CC Q8IXK2; P02790: HPX; NbExp=3; IntAct=EBI-8995375, EBI-1223791; CC -!- SUBCELLULAR LOCATION: Golgi apparatus membrane {ECO:0000250}; Single- CC pass type II membrane protein {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q8IXK2-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8IXK2-2; Sequence=VSP_011217; CC -!- TISSUE SPECIFICITY: Widely expressed at different levels of expression. CC Highly expressed in digestive organs such as small intestine, stomach, CC pancreas and colon. Expressed at intermediate level in testis, thyroid CC gland and spleen. Weakly expressed in whole brain, cerebral cortex, CC cerebellum, fetal brain, bone marrow, thymus, leukocytes, heart, CC skeletal muscle, liver, lung, esophagus, kidney, adrenal gland, mammary CC gland, uterus, placenta, ovary and prostate. CC {ECO:0000269|PubMed:12135769}. CC -!- DOMAIN: There are two conserved domains in the glycosyltransferase CC region: the N-terminal domain (domain A, also called GT1 motif), which CC is probably involved in manganese coordination and substrate binding CC and the C-terminal domain (domain B, also called Gal/GalNAc-T motif), CC which is probably involved in catalytic reaction and UDP-Gal binding. CC {ECO:0000250}. CC -!- DOMAIN: The ricin B-type lectin domain binds to GalNAc and contributes CC to the glycopeptide specificity. {ECO:0000250}. CC -!- DISEASE: Colorectal cancer 1 (CRCS1) [MIM:608812]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:19617566, CC ECO:0000269|PubMed:22461326, ECO:0000269|PubMed:24115450}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. The role of GALNT12 in colon cancer CC susceptibility is however subject to discussion: studies on 103 CC probants with colorectal cancer 1 (CRCS1) suggest that it does not act CC as a major contributor of CRCS1 (PubMed:24115450). CC {ECO:0000269|PubMed:24115450}. CC -!- SIMILARITY: Belongs to the glycosyltransferase 2 family. GalNAc-T CC subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAB15027.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Functional Glycomics Gateway - GTase; CC Note=Polypeptide N-acetylgalactosaminyltransferase 12; CC URL="http://www.functionalglycomics.org/glycomics/molecule/jsp/glycoEnzyme/viewGlycoEnzyme.jsp?gbpId=gt_hum_495"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB078146; BAC07181.1; -; mRNA. DR EMBL; AJ132365; CAC80100.2; -; mRNA. DR EMBL; AL136084; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC013945; AAH13945.1; -; mRNA. DR EMBL; AK024865; BAB15027.1; ALT_INIT; mRNA. DR CCDS; CCDS6737.1; -. [Q8IXK2-1] DR RefSeq; NP_078918.3; NM_024642.4. [Q8IXK2-1] DR RefSeq; XP_006717350.1; XM_006717287.1. DR PDB; 6PXU; X-ray; 2.01 A; A/B=39-581. DR PDBsum; 6PXU; -. DR AlphaFoldDB; Q8IXK2; -. DR SMR; Q8IXK2; -. DR BioGRID; 122816; 129. DR FunCoup; Q8IXK2; 763. DR IntAct; Q8IXK2; 92. DR MINT; Q8IXK2; -. DR STRING; 9606.ENSP00000364150; -. DR CAZy; CBM13; Carbohydrate-Binding Module Family 13. DR CAZy; GT27; Glycosyltransferase Family 27. DR UniLectin; Q8IXK2; -. DR GlyGen; Q8IXK2; 3 sites, 1 O-linked glycan (3 sites). DR iPTMnet; Q8IXK2; -. DR PhosphoSitePlus; Q8IXK2; -. DR SwissPalm; Q8IXK2; -. DR BioMuta; GALNT12; -. DR DMDM; 84028209; -. DR jPOST; Q8IXK2; -. DR MassIVE; Q8IXK2; -. DR PaxDb; 9606-ENSP00000364150; -. DR PeptideAtlas; Q8IXK2; -. DR ProteomicsDB; 71019; -. [Q8IXK2-1] DR ProteomicsDB; 71020; -. [Q8IXK2-2] DR Pumba; Q8IXK2; -. DR Antibodypedia; 29005; 88 antibodies from 14 providers. DR DNASU; 79695; -. DR Ensembl; ENST00000375011.4; ENSP00000364150.3; ENSG00000119514.8. [Q8IXK2-1] DR GeneID; 79695; -. DR KEGG; hsa:79695; -. DR MANE-Select; ENST00000375011.4; ENSP00000364150.3; NM_024642.5; NP_078918.3. DR UCSC; uc004ayz.3; human. [Q8IXK2-1] DR AGR; HGNC:19877; -. DR ClinPGx; PA134929192; -. DR CTD; 79695; -. DR DisGeNET; 79695; -. DR GeneCards; GALNT12; -. DR HGNC; HGNC:19877; GALNT12. DR HPA; ENSG00000119514; Tissue enhanced (epididymis, intestine, stomach). DR MalaCards; GALNT12; -. DR MIM; 608812; phenotype. DR MIM; 610290; gene. DR OpenTargets; ENSG00000119514; -. DR VEuPathDB; HostDB:ENSG00000119514; -. DR eggNOG; KOG3736; Eukaryota. DR GeneTree; ENSGT00940000157173; -. DR HOGENOM; CLU_013477_0_3_1; -. DR InParanoid; Q8IXK2; -. DR OMA; SKSYFHY; -. DR OrthoDB; 416652at2759; -. DR PAN-GO; Q8IXK2; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q8IXK2; -. DR BRENDA; 2.4.1.41; 2681. DR PathwayCommons; Q8IXK2; -. DR Reactome; R-HSA-5083636; Defective GALNT12 causes CRCS1. DR Reactome; R-HSA-913709; O-linked glycosylation of mucins. DR SignaLink; Q8IXK2; -. DR UniPathway; UPA00378; -. DR Agora; ENSG00000119514; -. DR BioGRID-ORCS; 79695; 10 hits in 1155 CRISPR screens. DR ChiTaRS; GALNT12; human. DR GenomeRNAi; 79695; -. DR Pharos; Q8IXK2; Tbio. DR PRO; PR:Q8IXK2; -. DR Proteomes; UP000005640; Chromosome 9. DR RNAct; Q8IXK2; protein. DR Bgee; ENSG00000119514; Expressed in palpebral conjunctiva and 153 other cell types or tissues. DR ExpressionAtlas; Q8IXK2; baseline and differential. DR GO; GO:0005794; C:Golgi apparatus; IBA:GO_Central. DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome. DR GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0004653; F:polypeptide N-acetylgalactosaminyltransferase activity; IBA:GO_Central. DR GO; GO:0006493; P:protein O-linked glycosylation; IBA:GO_Central. DR GO; GO:0016266; P:protein O-linked glycosylation via N-acetyl-galactosamine; TAS:Reactome. DR CDD; cd23471; beta-trefoil_Ricin_GALNT12; 1. DR CDD; cd02510; pp-GalNAc-T; 1. DR FunFam; 2.80.10.50:FF:000057; Polypeptide N-acetylgalactosaminyltransferase; 1. DR FunFam; 3.90.550.10:FF:000021; Polypeptide N-acetylgalactosaminyltransferase; 1. DR Gene3D; 2.80.10.50; -; 1. DR Gene3D; 3.90.550.10; Spore Coat Polysaccharide Biosynthesis Protein SpsA, Chain A; 1. DR InterPro; IPR045885; GalNAc-T. DR InterPro; IPR001173; Glyco_trans_2-like. DR InterPro; IPR029044; Nucleotide-diphossugar_trans. DR InterPro; IPR035992; Ricin_B-like_lectins. DR InterPro; IPR000772; Ricin_B_lectin. DR PANTHER; PTHR11675; N-ACETYLGALACTOSAMINYLTRANSFERASE; 1. DR PANTHER; PTHR11675:SF18; POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 12; 1. DR Pfam; PF00535; Glycos_transf_2; 1. DR Pfam; PF00652; Ricin_B_lectin; 1. DR SMART; SM00458; RICIN; 1. DR SUPFAM; SSF53448; Nucleotide-diphospho-sugar transferases; 1. DR SUPFAM; SSF50370; Ricin B-like lectins; 1. DR PROSITE; PS50231; RICIN_B_LECTIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Disease variant; Disulfide bond; KW Glycosyltransferase; Golgi apparatus; Lectin; Manganese; Membrane; KW Metal-binding; Proteomics identification; Reference proteome; KW Signal-anchor; Transferase; Transmembrane; Transmembrane helix. FT CHAIN 1..581 FT /note="Polypeptide N-acetylgalactosaminyltransferase 12" FT /id="PRO_0000059128" FT TOPO_DOM 1..19 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 20..37 FT /note="Helical; Signal-anchor for type II membrane protein" FT /evidence="ECO:0000255" FT TOPO_DOM 38..581 FT /note="Lumenal" FT /evidence="ECO:0000255" FT DOMAIN 445..577 FT /note="Ricin B-type lectin" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00174" FT REGION 43..67 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 135..244 FT /note="Catalytic subdomain A" FT REGION 304..366 FT /note="Catalytic subdomain B" FT BINDING 176 FT /ligand="substrate" FT /evidence="ECO:0000250" FT BINDING 205 FT /ligand="substrate" FT /evidence="ECO:0000250" FT BINDING 228 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /evidence="ECO:0000250" FT BINDING 230 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /evidence="ECO:0000250" FT BINDING 335 FT /ligand="substrate" FT /evidence="ECO:0000250" FT BINDING 363 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /evidence="ECO:0000250" FT BINDING 371 FT /ligand="substrate" FT /evidence="ECO:0000250" FT DISULFID 125..358 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00174" FT DISULFID 349..422 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00174" FT DISULFID 458..479 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00174" FT DISULFID 506..521 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00174" FT DISULFID 547..566 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00174" FT VAR_SEQ 1..309 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_011217" FT VARIANT 3 FT /note="G -> E (in dbSNP:rs1356894484)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064352" FT VARIANT 46 FT /note="G -> R (in dbSNP:rs10987768)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064353" FT VARIANT 119 FT /note="E -> V (in dbSNP:rs1137654)" FT /evidence="ECO:0000269|PubMed:12135769, FT ECO:0000269|PubMed:19617566" FT /id="VAR_064354" FT VARIANT 261 FT /note="D -> N (in dbSNP:rs41306504)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064355" FT VARIANT 272 FT /note="G -> R (in dbSNP:rs367645298)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064356" FT VARIANT 297 FT /note="R -> W (in CRCS1; germline mutation; partial loss of FT activity; dbSNP:rs149726976)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064357" FT VARIANT 303 FT /note="D -> N (in CRCS1; germline mutation; reduction of FT activity; dbSNP:rs145236923)" FT /evidence="ECO:0000269|PubMed:19617566, FT ECO:0000269|PubMed:22461326" FT /id="VAR_064358" FT VARIANT 341 FT /note="E -> D (in CRCS1; somatic mutation; loss of FT activity)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064359" FT VARIANT 373 FT /note="R -> H (in CRCS1; germline mutation; partial loss of FT activity; dbSNP:rs920049418)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064360" FT VARIANT 382 FT /note="R -> H (in CRCS1; germline mutation; loss of FT activity; dbSNP:rs868590153)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064361" FT VARIANT 396 FT /note="Y -> C (in CRCS1; dbSNP:rs1272530441)" FT /evidence="ECO:0000269|PubMed:22461326" FT /id="VAR_068509" FT VARIANT 479 FT /note="C -> F (in CRCS1; somatic mutation; loss of FT activity)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064362" FT VARIANT 491 FT /note="T -> M (in CRCS1; germline mutation; loss of FT activity; dbSNP:rs267606840)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064363" FT VARIANT 552 FT /note="R -> K (in dbSNP:rs1285871027)" FT /evidence="ECO:0000269|PubMed:19617566" FT /id="VAR_064364" FT STRAND 61..65 FT /evidence="ECO:0007829|PDB:6PXU" FT TURN 75..78 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 88..101 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 105..108 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 123..127 FT /evidence="ECO:0007829|PDB:6PXU" FT TURN 132..134 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 138..146 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 149..162 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 165..167 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 168..175 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 181..183 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 185..191 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 197..201 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 207..218 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 221..226 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 229..233 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 238..247 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 251..260 FT /evidence="ECO:0007829|PDB:6PXU" FT TURN 262..264 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 276..279 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 285..288 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 292..297 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 315..318 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 319..324 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 334..337 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 338..348 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 352..364 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 376..387 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 389..391 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 392..398 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 400..404 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 411..419 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 425..431 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 445..454 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 457..460 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 464..467 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 475..478 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 484..486 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 488..490 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 496..498 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 500..503 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 505..508 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 517..520 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 527..529 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 531..533 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 537..541 FT /evidence="ECO:0007829|PDB:6PXU" FT TURN 542..545 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 546..551 FT /evidence="ECO:0007829|PDB:6PXU" FT TURN 554..556 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 560..564 FT /evidence="ECO:0007829|PDB:6PXU" FT HELIX 570..572 FT /evidence="ECO:0007829|PDB:6PXU" FT STRAND 573..579 FT /evidence="ECO:0007829|PDB:6PXU" SQ SEQUENCE 581 AA; 66938 MW; 8C001D58E103A523 CRC64; MWGRTARRRC PRELRRGREA LLVLLALLAL AGLGSVLRAQ RGAGAGAAEP GPPRTPRPGR REPVMPRPPV PANALGARGE AVRLQLQGEE LRLQEESVRL HQINIYLSDR ISLHRRLPER WNPLCKEKKY DYDNLPRTSV IIAFYNEAWS TLLRTVYSVL ETSPDILLEE VILVDDYSDR EHLKERLANE LSGLPKVRLI RANKREGLVR ARLLGASAAR GDVLTFLDCH CECHEGWLEP LLQRIHEEES AVVCPVIDVI DWNTFEYLGN SGEPQIGGFD WRLVFTWHTV PERERIRMQS PVDVIRSPTM AGGLFAVSKK YFEYLGSYDT GMEVWGGENL EFSFRIWQCG GVLETHPCSH VGHVFPKQAP YSRNKALANS VRAAEVWMDE FKELYYHRNP RARLEPFGDV TERKQLRDKL QCKDFKWFLE TVYPELHVPE DRPGFFGMLQ NKGLTDYCFD YNPPDENQIV GHQVILYLCH GMGQNQFFEY TSQKEIRYNT HQPEGCIAVE AGMDTLIMHL CEETAPENQK FILQEDGSLF HEQSKKCVQA ARKESSDSFV PLLRDCTNSD HQKWFFKERM L // ID GSDME_HUMAN Reviewed; 496 AA. AC O60443; A4D156; B2RAX9; B3KT05; O14590; Q08AQ8; Q9UBV3; DT 21-FEB-2001, integrated into UniProtKB/Swiss-Prot. DT 01-AUG-1999, sequence version 2. DT 28-JAN-2026, entry version 177. DE RecName: Full=Gasdermin-E {ECO:0000303|PubMed:28459430}; DE AltName: Full=Inversely correlated with estrogen receptor expression 1 {ECO:0000303|PubMed:9523727}; DE Short=ICERE-1 {ECO:0000303|PubMed:9523727}; DE AltName: Full=Non-syndromic hearing impairment protein 5 {ECO:0000303|PubMed:9771715}; DE Contains: DE RecName: Full=Gasdermin-E, N-terminal {ECO:0000303|PubMed:28459430}; DE Short=GSDME-NT {ECO:0000303|PubMed:28459430}; DE Contains: DE RecName: Full=Gasdermin-E, C-terminal {ECO:0000303|PubMed:28459430}; DE Short=GSDME-CT {ECO:0000303|PubMed:28459430}; GN Name=GSDME {ECO:0000303|PubMed:28459430, ECO:0000312|HGNC:HGNC:2810}; GN Synonyms=DFNA5 {ECO:0000303|PubMed:9771715}, GN ICERE1 {ECO:0000303|PubMed:9523727}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND INVOLVEMENT RP IN DFNA5. RC TISSUE=Cochlea; RX PubMed=9771715; DOI=10.1038/2503; RA Van Laer L., Huizing E.H., Verstreken M., van Zuijlen D., Wauters J.G., RA Bossuyt P.J., Van de Heyning P., McGuirt W.T., Smith R.J.H., Willems P.J., RA Legan P.K., Richardson G.P., Van Camp G.; RT "Nonsyndromic hearing impairment is associated with a mutation in DFNA5."; RL Nat. Genet. 20:194-197(1998). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RA Van Laer L., Van Camp G.; RL Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain; RA Mei G., Yu W., Gibbs R.A.; RL Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3). RC TISSUE=Amygdala; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12853948; DOI=10.1038/nature01782; RA Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H., RA Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K., RA Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A., RA Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H., RA Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A., RA Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P., RA Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M., RA Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S., RA Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., RA Strowmatt C., Latreille P., Miller N., Johnson D., Murray J., RA Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., RA Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., RA Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E., RA Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E., RA Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A., RA Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A., RA Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R., RA McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H., RA Wilson R.K.; RT "The DNA sequence of human chromosome 7."; RL Nature 424:157-164(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT THR-142. RX PubMed=12690205; DOI=10.1126/science.1083423; RA Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K., RA Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R., RA Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A., RA Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D., RA Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S., RA Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R., RA Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N., RA Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E., RA Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R., RA Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T., RA Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W., RA Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A., RA Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X., RA Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E., RA Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H., RA Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J., RA Adams M.D., Tsui L.-C.; RT "Human chromosome 7: DNA sequence and biology."; RL Science 300:767-772(2003). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 5-496 (ISOFORM 1). RC TISSUE=Mammary gland; RX PubMed=9523727; DOI=10.1046/j.1432-1327.1998.2520169.x; RA Thompson D.A., Weigel R.J.; RT "Characterization of a gene that is inversely correlated with estrogen RT receptor expression (ICERE-1) in breast carcinomas."; RL Eur. J. Biochem. 252:169-177(1998). RN [10] RP SEQUENCE REVISION TO C-TERMINUS. RA Thompson D.A.; RL Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases. RN [11] RP FUNCTION IN TP53-MEDIATED CELLULAR RESPONSE. RX PubMed=16897187; DOI=10.1007/s10038-006-0004-6; RA Masuda Y., Futamura M., Kamino H., Nakamura Y., Kitamura N., Ohnishi S., RA Miyamoto Y., Ichikawa H., Ohta T., Ohki M., Kiyono T., Egami H., Baba H., RA Arakawa H.; RT "The potential role of DFNA5, a hearing impairment gene, in p53-mediated RT cellular response to DNA damage."; RL J. Hum. Genet. 51:652-664(2006). RN [12] RP INVOLVEMENT IN CRC. RX PubMed=18223688; DOI=10.1038/sj.onc.1211021; RA Kim M.S., Chang X., Yamashita K., Nagpal J.K., Baek J.H., Wu G., Trink B., RA Ratovitski E.A., Mori M., Sidransky D.; RT "Aberrant promoter methylation and tumor suppressive activity of the DFNA5 RT gene in colorectal carcinoma."; RL Oncogene 27:3624-3634(2008). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [15] RP FUNCTION. RX PubMed=21522185; DOI=10.1038/ejhg.2011.63; RA Op de Beeck K., Van Camp G., Thys S., Cools N., Callebaut I., Vrijens K., RA Van Nassauw L., Van Tendeloo V.F., Timmermans J.P., Van Laer L.; RT "The DFNA5 gene, responsible for hearing loss and involved in cancer, RT encodes a novel apoptosis-inducing protein."; RL Eur. J. Hum. Genet. 19:965-973(2011). RN [16] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [17] RP INVOLVEMENT IN DFNA5. RX PubMed=19911014; DOI=10.1038/jhg.2009.114; RA Park H.J., Cho H.J., Baek J.I., Ben-Yosef T., Kwon T.J., Griffith A.J., RA Kim U.K.; RT "Evidence for a founder mutation causing DFNA5 hearing loss in East RT Asians."; RL J. Hum. Genet. 55:59-62(2010). RN [18] RP INVOLVEMENT IN DFNA5. RX PubMed=24506266; DOI=10.1111/ahg.12053; RA Nishio A., Noguchi Y., Sato T., Naruse T.K., Kimura A., Takagi A., RA Kitamura K.; RT "A DFNA5 mutation identified in Japanese families with autosomal dominant RT hereditary hearing loss."; RL Ann. Hum. Genet. 78:83-91(2014). RN [19] RP INVOLVEMENT IN DFNA5. RX PubMed=26236191; DOI=10.3389/fncel.2015.00231; RA Van Rossom S., Op de Beeck K., Hristovska V., Winderickx J., Van Camp G.; RT "The deafness gene DFNA5 induces programmed cell death through mitochondria RT and MAPK-related pathways."; RL Front. Cell. Neurosci. 9:231-231(2015). RN [20] RP FUNCTION, AND MUTAGENESIS OF ILE-313; PHE-388 AND ALA-392. RX PubMed=27281216; DOI=10.1038/nature18590; RA Ding J., Wang K., Liu W., She Y., Sun Q., Shi J., Sun H., Wang D.C., RA Shao F.; RT "Pore-forming activity and structural autoinhibition of the gasdermin RT family."; RL Nature 535:111-116(2016). RN [21] RP FUNCTION (GASDERMIN-E, N-TERMINAL), ACTIVITY REGULATION, CLEAVAGE BY CASP3, RP SUBCELLULAR LOCATION, DOMAIN, AND MUTAGENESIS OF ASP-267 AND ASP-270. RX PubMed=28459430; DOI=10.1038/nature22393; RA Wang Y., Gao W., Shi X., Ding J., Liu W., He H., Wang K., Shao F.; RT "Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a RT gasdermin."; RL Nature 547:99-103(2017). RN [22] RP FUNCTION (GASDERMIN-E, N-TERMINAL), ACTIVITY REGULATION, CLEAVAGE BY CASP3, RP SUBCELLULAR LOCATION, DOMAIN, AND MUTAGENESIS OF PHE-2; LYS-39; LYS-40; RP LYS-41 AND ASP-270. RX PubMed=28045099; DOI=10.1038/ncomms14128; RA Rogers C., Fernandes-Alnemri T., Mayes L., Alnemri D., Cingolani G., RA Alnemri E.S.; RT "Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to RT secondary necrotic/pyroptotic cell death."; RL Nat. Commun. 8:14128-14128(2017). RN [23] RP FUNCTION (GASDERMIN-E, N-TERMINAL), ACTIVITY REGULATION, CLEAVAGE BY GZMB, RP DOMAIN, MUTAGENESIS OF PHE-2 AND ASP-270, VARIANTS TYR-14; VAL-18; ASP-24; RP CYS-44; ILE-48; THR-137; GLU-199; LEU-212 AND ASN-217, AND CHARACTERIZATION RP OF VARIANTS TYR-14; VAL-18; ASP-24; CYS-44; ILE-48; THR-137; GLU-199; RP LEU-212 AND ASN-217. RX PubMed=32188940; DOI=10.1038/s41586-020-2071-9; RA Zhang Z., Zhang Y., Xia S., Kong Q., Li S., Liu X., Junqueira C., RA Meza-Sosa K.F., Mok T.M.Y., Ansara J., Sengupta S., Yao Y., Wu H., RA Lieberman J.; RT "Gasdermin E suppresses tumour growth by activating anti-tumour immunity."; RL Nature 579:415-420(2020). RN [24] RP SUCCINATION AT CYS-45; CYS-156; CYS-168; CYS-180; CYS-235; CYS-371; RP CYS-417; CYS-408 AND CYS-489. RX PubMed=32820063; DOI=10.1126/science.abb9818; RA Humphries F., Shmuel-Galia L., Ketelut-Carneiro N., Li S., Wang B., RA Nemmara V.V., Wilson R., Jiang Z., Khalighinejad F., Muneeruddin K., RA Shaffer S.A., Dutta R., Ionete C., Pesiridis S., Yang S., Thompson P.R., RA Fitzgerald K.A.; RT "Succination inactivates gasdermin D and blocks pyroptosis."; RL Science 369:1633-1637(2020). RN [25] RP FUNCTION (GASDERMIN-E, N-TERMINAL), ACTIVITY REGULATION, AND CLEAVAGE BY RP GZMB. RX PubMed=31953257; DOI=10.1126/sciimmunol.aax7969; RA Liu Y., Fang Y., Chen X., Wang Z., Liang X., Zhang T., Liu M., Zhou N., RA Lv J., Tang K., Xie J., Gao Y., Cheng F., Zhou Y., Zhang Z., Hu Y., RA Zhang X., Gao Q., Zhang Y., Huang B.; RT "Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers RT cytokine release syndrome."; RL Sci. Immunol. 5:0-0(2020). RN [26] RP FUNCTION, ACTIVITY REGULATION, AND MUTAGENESIS OF ASP-270. RX PubMed=33852854; DOI=10.1016/j.celrep.2021.108998; RA Zhou B., Abbott D.W.; RT "Gasdermin E permits interleukin-1 beta release in distinct sublytic and RT pyroptotic phases."; RL Cell Rep. 35:108998-108998(2021). RN [27] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=35972780; DOI=10.7554/elife.73792; RA Zhao Z., Li Q., Ashraf U., Yang M., Zhu W., Gu J., Chen Z., Gu C., Si Y., RA Cao S., Ye J.; RT "Zika virus causes placental pyroptosis and associated adverse fetal RT outcomes by activating GSDME."; RL Elife 11:0-0(2022). RN [28] RP FUNCTION, ACTIVITY REGULATION, AND ACTIVITY REGULATION (MICROBIAL RP INFECTION). RX PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033; RG COVID Human Genetic Effort; RA Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K., RA Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R., RA Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y., RA Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O., RA Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S., RA Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.; RT "Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung RT epithelial cells."; RL Mol. Cell 82:2385-2400(2022). RN [29] RP FUNCTION, AND UBIQUITINATION AT LYS-120 AND LYS-189. RX PubMed=36607699; DOI=10.1158/0008-5472.can-22-1812; RA Ren Y., Feng M., Hao X., Liu X., Li J., Li P., Gao J., Qi Q., Du L., RA Wang C., Wang Q., Wang Y.; RT "USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer."; RL Cancer Res. 83:1074-1093(2023). RN [30] RP PALMITOYLATION. RX PubMed=38599239; DOI=10.1038/s41586-024-07373-5; RA Du G., Healy L.B., David L., Walker C., El-Baba T.J., Lutomski C.A., RA Goh B., Gu B., Pi X., Devant P., Fontana P., Dong Y., Ma X., Miao R., RA Balasubramanian A., Puthenveetil R., Banerjee A., Luo H.R., Kagan J.C., RA Oh S.F., Robinson C.V., Lieberman J., Wu H.; RT "ROS-dependent S-palmitoylation activates cleaved and intact gasdermin D."; RL Nature 0:0-0(2024). CC -!- FUNCTION: [Gasdermin-E]: Precursor of a pore-forming protein that CC converts non-inflammatory apoptosis to pyroptosis (PubMed:27281216, CC PubMed:28459430, PubMed:33852854, PubMed:35594856, PubMed:36607699). CC This form constitutes the precursor of the pore-forming protein: upon CC cleavage, the released N-terminal moiety (Gasdermin-E, N-terminal) CC binds to membranes and forms pores, triggering pyroptosis CC (PubMed:28459430). {ECO:0000269|PubMed:27281216, CC ECO:0000269|PubMed:28459430, ECO:0000269|PubMed:33852854, CC ECO:0000269|PubMed:35594856, ECO:0000269|PubMed:36607699}. CC -!- FUNCTION: [Gasdermin-E, N-terminal]: Pore-forming protein produced by CC cleavage by CASP3 or granzyme B (GZMB), which converts non-inflammatory CC apoptosis to pyroptosis or promotes granzyme-mediated pyroptosis, CC respectively (PubMed:27281216, PubMed:28459430, PubMed:32188940, CC PubMed:33852854, PubMed:35594856). After cleavage, moves to the plasma CC membrane, homooligomerizes within the membrane and forms pores of 10-15 CC nanometers (nm) of inner diameter, allowing the release of mature CC interleukins (IL1B and IL16) and triggering pyroptosis CC (PubMed:28459430, PubMed:32188940, PubMed:33852854, PubMed:35594856). CC Binds to inner leaflet lipids, bisphosphorylated phosphatidylinositols, CC such as phosphatidylinositol (4,5)-bisphosphate (PubMed:28459430). CC Cleavage by CASP3 switches CASP3-mediated apoptosis induced by TNF or CC danger signals, such as chemotherapy drugs, to pyroptosis CC (PubMed:27281216, PubMed:28459430, PubMed:32188940). Mediates secondary CC necrosis downstream of the mitochondrial apoptotic pathway and CASP3 CC activation as well as in response to viral agents (PubMed:28045099). CC Exhibits bactericidal activity (PubMed:27281216). Cleavage by GZMB CC promotes tumor suppressor activity by triggering robust anti-tumor CC immunity (PubMed:21522185, PubMed:32188940). Suppresses tumors by CC mediating granzyme-mediated pyroptosis in target cells of natural CC killer (NK) cells: cleavage by granzyme B (GZMB), delivered to target CC cells from NK-cells, triggers pyroptosis of tumor cells and tumor CC suppression (PubMed:31953257, PubMed:32188940). May play a role in the CC p53/TP53-regulated cellular response to DNA damage (PubMed:16897187). CC {ECO:0000269|PubMed:16897187, ECO:0000269|PubMed:21522185, CC ECO:0000269|PubMed:27281216, ECO:0000269|PubMed:28045099, CC ECO:0000269|PubMed:28459430, ECO:0000269|PubMed:31953257, CC ECO:0000269|PubMed:32188940, ECO:0000269|PubMed:33852854, CC ECO:0000269|PubMed:35594856}. CC -!- FUNCTION: [Gasdermin-E, N-terminal]: (Microbial infection) Pore-forming CC protein, which promotes maternal placental pyroptosis in response to CC Zika virus infection, contributing to adverse fetal outcomes. CC {ECO:0000269|PubMed:35972780}. CC -!- ACTIVITY REGULATION: [Gasdermin-E]: The full-length protein before CC cleavage is inactive: intramolecular interactions between N- and C- CC terminal domains mediate autoinhibition in the absence of activation CC signal (PubMed:28045099, PubMed:28459430). The intrinsic pyroptosis- CC inducing activity is carried by the released N-terminal moiety CC (Gasdermin-E, N-terminal) following cleavage by CASP3 or granzyme B CC (GZMB) (PubMed:28459430, PubMed:31953257, PubMed:32188940, CC PubMed:35594856). Activated by NLRP1 in the absence of GSDMD CC expression: NLRP1 cleaves and activates CASP8, promoting downstream CC activation of CASP3 and subsequent activation of GSDME CC (PubMed:33852854, PubMed:35594856). {ECO:0000269|PubMed:28045099, CC ECO:0000269|PubMed:28459430, ECO:0000269|PubMed:31953257, CC ECO:0000269|PubMed:32188940, ECO:0000269|PubMed:33852854, CC ECO:0000269|PubMed:35594856}. CC -!- ACTIVITY REGULATION: (Microbial infection) Activated upon human CC coronavirus SARS-CoV-2 infection, leading to lung epithelial cell death CC (PubMed:35594856). Activation takes place in response to (1) activation CC of NLRP1 and (2) inactivation of GSDMD following NLRP1 and GSDMD CC cleavage by the SARS-CoV-2 3C-like proteinase nsp5 (PubMed:35594856). CC {ECO:0000269|PubMed:35594856}. CC -!- SUBUNIT: [Gasdermin-E, N-terminal]: Homooligomer; homooligomeric ring- CC shaped pore complex containing 27-28 subunits when inserted in the CC membrane. {ECO:0000250|UniProtKB:Q5Y4Y6}. CC -!- INTERACTION: CC O60443; Q96CG3: TIFA; NbExp=3; IntAct=EBI-719315, EBI-740711; CC -!- SUBCELLULAR LOCATION: [Gasdermin-E, N-terminal]: Cell membrane CC {ECO:0000269|PubMed:28045099, ECO:0000269|PubMed:28459430}; Multi-pass CC membrane protein {ECO:0000250|UniProtKB:Q5Y4Y6}. CC -!- SUBCELLULAR LOCATION: [Gasdermin-E]: Cytoplasm, cytosol CC {ECO:0000269|PubMed:28045099}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=Long; CC IsoId=O60443-1; Sequence=Displayed; CC Name=2; Synonyms=Short; CC IsoId=O60443-2; Sequence=VSP_004190; CC Name=3; CC IsoId=O60443-3; Sequence=VSP_044276; CC -!- TISSUE SPECIFICITY: Expressed in cochlea (PubMed:9771715). Low level of CC expression in heart, brain, placenta, lung, liver, skeletal muscle, CC kidney and pancreas, with highest expression in placenta CC (PubMed:9771715). {ECO:0000269|PubMed:9771715}. CC -!- DOMAIN: Intramolecular interactions between N- and C-terminal domains CC may be important for autoinhibition in the absence of activation CC signal. The intrinsic pyroptosis-inducing activity is carried by the N- CC terminal domain, that is released upon cleavage by CASP3 or granzyme B CC (GZMB). {ECO:0000269|PubMed:28045099, ECO:0000269|PubMed:28459430, CC ECO:0000269|PubMed:32188940}. CC -!- PTM: Cleavage at Asp-270 by CASP3 (mature and uncleaved precursor CC forms) or granzyme B (GZMB) relieves autoinhibition and is sufficient CC to initiate pyroptosis. {ECO:0000269|PubMed:28045099, CC ECO:0000269|PubMed:28459430, ECO:0000269|PubMed:31953257, CC ECO:0000269|PubMed:32188940}. CC -!- PTM: [Gasdermin-E]: Succination by the Krebs cycle intermediate CC fumarate, which leads to S-(2-succinyl)cysteine residues, inhibits CC processing by caspases, and ability to initiate pyroptosis CC (PubMed:32820063). Succination modification is catalyzed by a non- CC enzymatic reaction caused by an accumulation of fumarate CC (PubMed:32820063). {ECO:0000269|PubMed:32820063}. CC -!- PTM: [Gasdermin-E]: Ubiquitinated at Lys-120 and Lys-189 via 'Lys-48'- CC linked polyubiquitin chains, leading to proteasomal degradation. CC Deubiquitinated by USP48, leading to increased stability. CC {ECO:0000269|PubMed:36607699}. CC -!- PTM: Palmitoylated. {ECO:0000269|PubMed:38599239}. CC -!- DISEASE: Deafness, autosomal dominant, 5 (DFNA5) [MIM:600994]: A form CC of non-syndromic sensorineural hearing loss. Sensorineural deafness CC results from damage to the neural receptors of the inner ear, the nerve CC pathways to the brain, or the area of the brain that receives sound CC information. {ECO:0000269|PubMed:19911014, ECO:0000269|PubMed:24506266, CC ECO:0000269|PubMed:26236191, ECO:0000269|PubMed:9771715}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=Is a tumor suppressor gene with an important role in CC colorectal cancer (CRC). {ECO:0000303|PubMed:18223688}. CC -!- SIMILARITY: Belongs to the gasdermin family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAB83938.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC Sequence=AAC39635.2; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF073308; AAC69324.1; -; mRNA. DR EMBL; AF075171; AAC69326.1; -; mRNA. DR EMBL; AF131765; AAD20039.1; -; mRNA. DR EMBL; AK094714; BAG52917.1; -; mRNA. DR EMBL; AK314402; BAG37026.1; -; mRNA. DR EMBL; AC003093; AAB83938.1; ALT_SEQ; Genomic_DNA. DR EMBL; CH236948; EAL24246.1; -; Genomic_DNA. DR EMBL; CH471073; EAW93813.1; -; Genomic_DNA. DR EMBL; BC125065; AAI25066.1; -; mRNA. DR EMBL; AF007790; AAC39635.2; ALT_INIT; mRNA. DR CCDS; CCDS47563.1; -. [O60443-3] DR CCDS; CCDS5389.1; -. [O60443-1] DR RefSeq; NP_001120925.1; NM_001127453.2. [O60443-1] DR RefSeq; NP_001120926.1; NM_001127454.2. [O60443-3] DR RefSeq; NP_001424988.1; NM_001438059.1. [O60443-3] DR RefSeq; NP_004394.1; NM_004403.3. [O60443-1] DR RefSeq; XP_024302438.1; XM_024446670.2. [O60443-1] DR RefSeq; XP_054213373.1; XM_054357398.1. [O60443-1] DR AlphaFoldDB; O60443; -. DR BioGRID; 108049; 65. DR FunCoup; O60443; 518. DR IntAct; O60443; 158. DR MINT; O60443; -. DR STRING; 9606.ENSP00000339587; -. DR TCDB; 1.C.123.1.5; the pore-forming gasdermin (gasdermin) family. DR GlyGen; O60443; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; O60443; -. DR PhosphoSitePlus; O60443; -. DR SwissPalm; O60443; -. DR BioMuta; GSDME; -. DR jPOST; O60443; -. DR MassIVE; O60443; -. DR PaxDb; 9606-ENSP00000339587; -. DR PeptideAtlas; O60443; -. DR ProteomicsDB; 3659; -. DR ProteomicsDB; 49403; -. [O60443-1] DR ProteomicsDB; 49404; -. [O60443-2] DR Antibodypedia; 1157; 225 antibodies from 32 providers. DR DNASU; 1687; -. DR Ensembl; ENST00000342947.9; ENSP00000339587.3; ENSG00000105928.17. [O60443-1] DR Ensembl; ENST00000409970.6; ENSP00000387119.1; ENSG00000105928.17. [O60443-3] DR Ensembl; ENST00000419307.6; ENSP00000401332.1; ENSG00000105928.17. [O60443-3] DR Ensembl; ENST00000645220.1; ENSP00000494186.1; ENSG00000105928.17. [O60443-1] DR GeneID; 1687; -. DR KEGG; hsa:1687; -. DR MANE-Select; ENST00000645220.1; ENSP00000494186.1; NM_001127453.2; NP_001120925.1. DR UCSC; uc003sxa.2; human. [O60443-1] DR AGR; HGNC:2810; -. DR ClinPGx; PA27281; -. DR CTD; 1687; -. DR DisGeNET; 1687; -. DR GeneCards; GSDME; -. DR GeneReviews; GSDME; -. DR HGNC; HGNC:2810; GSDME. DR HPA; ENSG00000105928; Low tissue specificity. DR MalaCards; GSDME; -. DR MIM; 600994; phenotype. DR MIM; 608798; gene. DR OpenTargets; ENSG00000105928; -. DR Orphanet; 90635; Rare autosomal dominant non-syndromic sensorineural deafness type DFNA. DR VEuPathDB; HostDB:ENSG00000105928; -. DR eggNOG; ENOG502QRAB; Eukaryota. DR GeneTree; ENSGT00940000155880; -. DR HOGENOM; CLU_042999_0_0_1; -. DR InParanoid; O60443; -. DR OMA; EMTNDCL; -. DR OrthoDB; 8815334at2759; -. DR PAN-GO; O60443; 2 GO annotations based on evolutionary models. DR PhylomeDB; O60443; -. DR PathwayCommons; O60443; -. DR Reactome; R-HSA-111457; Release of apoptotic factors from the mitochondria. DR Reactome; R-HSA-5620971; Pyroptosis. DR Reactome; R-HSA-5686938; Regulation of TLR by endogenous ligand. DR Reactome; R-HSA-9710421; Defective pyroptosis. DR SignaLink; O60443; -. DR Agora; ENSG00000105928; -. DR BioGRID-ORCS; 1687; 9 hits in 1147 CRISPR screens. DR ChiTaRS; DFNA5; human. DR GeneWiki; DFNA5; -. DR GenomeRNAi; 1687; -. DR Pharos; O60443; Tbio. DR PRO; PR:O60443; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; O60443; protein. DR Bgee; ENSG00000105928; Expressed in germinal epithelium of ovary and 190 other cell types or tissues. DR ExpressionAtlas; O60443; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:1901612; F:cardiolipin binding; IDA:UniProtKB. DR GO; GO:0005546; F:phosphatidylinositol-4,5-bisphosphate binding; IDA:UniProtKB. DR GO; GO:0022829; F:wide pore channel activity; IDA:UniProt. DR GO; GO:0071356; P:cellular response to tumor necrosis factor; IDA:UniProtKB. DR GO; GO:0098586; P:cellular response to virus; IDA:UniProtKB. DR GO; GO:0042491; P:inner ear auditory receptor cell differentiation; IEA:Ensembl. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB. DR GO; GO:0002839; P:positive regulation of immune response to tumor cell; IDA:UniProt. DR GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IDA:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB. DR GO; GO:0012501; P:programmed cell death; IMP:UniProtKB. DR GO; GO:0141201; P:pyroptotic cell death; IDA:UniProt. DR GO; GO:0070269; P:pyroptotic inflammatory response; IDA:UniProtKB. DR GO; GO:0007605; P:sensory perception of sound; TAS:ProtInc. DR InterPro; IPR040460; Gasdermin_pore. DR InterPro; IPR041263; Gasdermin_PUB. DR InterPro; IPR042377; GSDME. DR PANTHER; PTHR15207:SF1; GASDERMIN-E; 1. DR PANTHER; PTHR15207; NONSYNDROMIC HEARING IMPAIRMENT PROTEIN; 1. DR Pfam; PF04598; Gasdermin; 1. DR Pfam; PF17708; Gasdermin_C; 1. PE 1: Evidence at protein level; KW Alternative splicing; Cell membrane; Cytoplasm; Deafness; Isopeptide bond; KW Lipoprotein; Membrane; Necrosis; Non-syndromic deafness; Palmitate; KW Proteomics identification; Reference proteome; Transmembrane; KW Transmembrane beta strand; Tumor suppressor; Ubl conjugation. FT CHAIN 1..496 FT /note="Gasdermin-E" FT /id="PRO_0000148178" FT CHAIN 1..270 FT /note="Gasdermin-E, N-terminal" FT /evidence="ECO:0000269|PubMed:27281216, FT ECO:0000305|PubMed:28459430, ECO:0000305|PubMed:32188940" FT /id="PRO_0000442786" FT CHAIN 271..496 FT /note="Gasdermin-E, C-terminal" FT /evidence="ECO:0000305|PubMed:28459430" FT /id="PRO_0000442787" FT REGION 1..56 FT /note="Membrane targeting domain" FT /evidence="ECO:0000269|PubMed:28045099" FT SITE 270..271 FT /note="Cleavage; by CASP3 or granzyme B" FT /evidence="ECO:0000269|PubMed:28459430, FT ECO:0000269|PubMed:32188940" FT MOD_RES 45 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 156 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 168 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 180 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 235 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 371 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 408 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 417 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT MOD_RES 489 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000269|PubMed:32820063" FT CROSSLNK 120 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:36607699" FT CROSSLNK 189 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:36607699" FT VAR_SEQ 1..395 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.2, ECO:0000303|Ref.3" FT /id="VSP_004190" FT VAR_SEQ 1..164 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_044276" FT VARIANT 14 FT /note="D -> Y (in a breast carcinoma sample; somatic FT mutation; reduced ability to induce pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083903" FT VARIANT 18 FT /note="D -> V (in a colon adenocarcinoma sample; somatic FT mutation; reduced ability to induce pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083904" FT VARIANT 24 FT /note="N -> D (in a colon adenocarcinoma sample; somatic FT mutation; reduced ability to induce pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083905" FT VARIANT 44 FT /note="W -> C (in a lung cancer adenocarcinoma sample; FT somatic mutation; reduced ability to induce pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083906" FT VARIANT 48 FT /note="R -> I (in an uterine corpus endometrioid carcinoma FT sample; somatic mutation; reduced ability to induce FT pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083907" FT VARIANT 137 FT /note="I -> T (in an uterine corpus endometrioid carcinoma FT sample; somatic mutation; reduced ability to induce FT pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083908" FT VARIANT 142 FT /note="P -> T (in dbSNP:rs754554)" FT /evidence="ECO:0000269|PubMed:12690205" FT /id="VAR_030824" FT VARIANT 174 FT /note="M -> T (in dbSNP:rs876306)" FT /id="VAR_053102" FT VARIANT 199 FT /note="G -> E (in an uterine corpus endometrioid carcinoma FT sample; somatic mutation; reduced ability to induce FT pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083909" FT VARIANT 207 FT /note="V -> M (in dbSNP:rs12540919)" FT /id="VAR_030825" FT VARIANT 212 FT /note="P -> L (in a melanoma sample; somatic mutation; FT reduced ability to induce pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083910" FT VARIANT 217 FT /note="I -> N (in a lung cancer adenocarcinoma sample; FT somatic mutation; reduced ability to induce pyroptosis)" FT /evidence="ECO:0000269|PubMed:32188940" FT /id="VAR_083911" FT MUTAGEN 2 FT /note="F->A: No effect on plasma membrane targeting. FT Decreases induction of necrotic activity. Disrupts plasma FT membrane targeting and induction of necrotic activity; when FT associated with A-40." FT /evidence="ECO:0000269|PubMed:28045099, FT ECO:0000269|PubMed:32188940" FT MUTAGEN 39 FT /note="K->A: Disrupts plasma membrane targeting and FT induction of necrotic activity; when associated with A-40 FT and/or A-41." FT /evidence="ECO:0000269|PubMed:28045099" FT MUTAGEN 40 FT /note="K->A: No effect on plasma membrane targeting. No FT effect on induction of cytotoxivity. Disrupts plasma FT membrane targeting and induction of necrotic activity; when FT associated with A-2 or A-39 and A-41." FT /evidence="ECO:0000269|PubMed:28045099" FT MUTAGEN 41 FT /note="K->A: Disrupts plasma membrane targeting and FT induction of necrotic activity; when associated with A-39 FT and/or A-41." FT /evidence="ECO:0000269|PubMed:28045099" FT MUTAGEN 267 FT /note="D->A: Abolishes cleavage by CASP3. Abolishes FT pyroptosis induction." FT /evidence="ECO:0000269|PubMed:28459430" FT MUTAGEN 270 FT /note="D->A,E: Abolishes cleavage by CASP3 or granzyme B. FT Abolishes pyroptosis induction." FT /evidence="ECO:0000269|PubMed:28045099, FT ECO:0000269|PubMed:28459430, ECO:0000269|PubMed:32188940, FT ECO:0000269|PubMed:33852854" FT MUTAGEN 313 FT /note="I->D: No spontaneous pyroptosis-inducing activity." FT /evidence="ECO:0000269|PubMed:27281216" FT MUTAGEN 388 FT /note="F->D: Low spontaneous pyroptosis-inducing activity." FT /evidence="ECO:0000269|PubMed:27281216" FT MUTAGEN 392 FT /note="A->D: Low spontaneous pyroptosis-inducing activity." FT /evidence="ECO:0000269|PubMed:27281216" SQ SEQUENCE 496 AA; 54555 MW; A407C9AC31AA716B CRC64; MFAKATRNFL REVDADGDLI AVSNLNDSDK LQLLSLVTKK KRFWCWQRPK YQFLSLTLGD VLIEDQFPSP VVVESDFVKY EGKFANHVSG TLETALGKVK LNLGGSSRVE SQSSFGTLRK QEVDLQQLIR DSAERTINLR NPVLQQVLEG RNEVLCVLTQ KITTMQKCVI SEHMQVEEKC GGIVGIQTKT VQVSATEDGN VTKDSNVVLE IPAATTIAYG VIELYVKLDG QFEFCLLRGK QGGFENKKRI DSVYLDPLVF REFAFIDMPD AAHGISSQDG PLSVLKQATL LLERNFHPFA ELPEPQQTAL SDIFQAVLFD DELLMVLEPV CDDLVSGLSP TVAVLGELKP RQQQDLVAFL QLVGCSLQGG CPGPEDAGSK QLFMTAYFLV SALAEMPDSA AALLGTCCKL QIIPTLCHLL RALSDDGVSD LEDPTLTPLK DTERFGIVQR LFASADISLE RLKSSVKAVI LKDSKVFPLL LCITLNGLCA LGREHS // ID GUC2F_HUMAN Reviewed; 1108 AA. AC P51841; Q9UJF1; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 02-NOV-2010, sequence version 2. DT 28-JAN-2026, entry version 220. DE RecName: Full=Retinal guanylyl cyclase 2; DE Short=RETGC-2 {ECO:0000303|PubMed:7777544}; DE EC=4.6.1.2 {ECO:0000269|PubMed:7777544}; DE AltName: Full=Guanylate cyclase 2F, retinal {ECO:0000312|HGNC:HGNC:4691}; DE AltName: Full=Guanylate cyclase F; DE Short=GC-F; DE AltName: Full=Rod outer segment membrane guanylate cyclase 2; DE Short=ROS-GC2; DE Flags: Precursor; GN Name=GUCY2F; Synonyms=GUC2F, RETGC2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], VARIANT GLN-296, TISSUE SPECIFICITY, ACTIVITY RP REGULATION, AND CATALYTIC ACTIVITY. RC TISSUE=Retina; RX PubMed=7777544; DOI=10.1073/pnas.92.12.5535; RA Lowe D.G., Dizhoor A.M., Liu K., Gu Q., Spencer M., Laura R., Lu L., RA Hurley J.B.; RT "Cloning and expression of a second photoreceptor-specific membrane retina RT guanylyl cyclase (RetGC), RetGC-2."; RL Proc. Natl. Acad. Sci. U.S.A. 92:5535-5539(1995). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15772651; DOI=10.1038/nature03440; RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., RA Rogers J., Bentley D.R.; RT "The DNA sequence of the human X chromosome."; RL Nature 434:325-337(2005). RN [3] RP VARIANT [LARGE SCALE ANALYSIS] PRO-10. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [4] RP VARIANTS [LARGE SCALE ANALYSIS] CYS-40; ASN-160; TRP-230; PRO-284; GLN-305; RP CYS-308; HIS-380; ARG-434; ASP-568; GLN-628; LEU-677; LYS-794; VAL-1010; RP ARG-1052 AND ASP-1055. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [5] RP VARIANT ASP-872. RX PubMed=23033978; DOI=10.1056/nejmoa1206524; RA de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G., RA Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P., Gilissen C., RA del Rosario M., Hoischen A., Scheffer H., de Vries B.B., Brunner H.G., RA Veltman J.A., Vissers L.E.; RT "Diagnostic exome sequencing in persons with severe intellectual RT disability."; RL N. Engl. J. Med. 367:1921-1929(2012). RN [6] RP ACTIVITY REGULATION. RX PubMed=29515371; DOI=10.3389/fnmol.2018.00052; RA Wimberg H., Janssen-Bienhold U., Koch K.W.; RT "Control of the Nucleotide Cycle in Photoreceptor Cell Extracts by Retinal RT Degeneration Protein 3."; RL Front. Mol. Neurosci. 11:52-52(2018). CC -!- FUNCTION: Responsible for the synthesis of cyclic GMP (cGMP) in rods CC and cones of photoreceptors (PubMed:7777544). Plays an essential role CC in phototransduction, by mediating cGMP replenishment (By similarity). CC May also participate in the trafficking of membrane-associated proteins CC to the photoreceptor outer segment membrane (By similarity). CC {ECO:0000250|UniProtKB:Q5SDA5, ECO:0000269|PubMed:7777544}. CC -!- CATALYTIC ACTIVITY: CC Reaction=GTP = 3',5'-cyclic GMP + diphosphate; Xref=Rhea:RHEA:13665, CC ChEBI:CHEBI:33019, ChEBI:CHEBI:37565, ChEBI:CHEBI:57746; EC=4.6.1.2; CC Evidence={ECO:0000269|PubMed:7777544}; CC -!- ACTIVITY REGULATION: Activated by GUCA1B when free calcium ions CC concentration is low, and inhibited by GUCA1B when free calcium ions CC concentration is high (PubMed:15772651). Inhibited by RD3 CC (PubMed:29515371). {ECO:0000269|PubMed:15772651, CC ECO:0000269|PubMed:29515371}. CC -!- SUBUNIT: Homodimer (By similarity). Interacts with RD3; promotes the CC exit of GUCY2F from the endoplasmic reticulum and its trafficking to CC the photoreceptor outer segments (By similarity). CC {ECO:0000250|UniProtKB:P51842, ECO:0000250|UniProtKB:Q5SDA5}. CC -!- SUBCELLULAR LOCATION: Photoreceptor outer segment membrane CC {ECO:0000250|UniProtKB:O02740}; Single-pass type I membrane protein CC {ECO:0000255}. CC -!- TISSUE SPECIFICITY: Retina. Localized exclusively in the outer nuclear CC layer and inner segments of the rod and cone photoreceptor cells. CC {ECO:0000269|PubMed:7777544}. CC -!- DOMAIN: The protein kinase domain is predicted to be catalytically CC inactive. CC -!- PTM: There are 9 conserved cysteine residues in sensory guanylate CC cyclases, 6 in the extracellular domain, which may be involved in CC intra- or interchain disulfide bonds. CC -!- SIMILARITY: Belongs to the adenylyl cyclase class-4/guanylyl cyclase CC family. {ECO:0000255|PROSITE-ProRule:PRU00099}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L37378; AAA74451.1; -; mRNA. DR EMBL; AL031387; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS14545.1; -. DR PIR; I59385; I59385. DR RefSeq; NP_001513.2; NM_001522.3. DR AlphaFoldDB; P51841; -. DR SMR; P51841; -. DR BioGRID; 109241; 6. DR FunCoup; P51841; 179. DR IntAct; P51841; 6. DR MINT; P51841; -. DR STRING; 9606.ENSP00000218006; -. DR iPTMnet; P51841; -. DR PhosphoSitePlus; P51841; -. DR BioMuta; GUCY2F; -. DR DMDM; 311033391; -. DR jPOST; P51841; -. DR MassIVE; P51841; -. DR PaxDb; 9606-ENSP00000218006; -. DR PeptideAtlas; P51841; -. DR ProteomicsDB; 56431; -. DR Antibodypedia; 29460; 108 antibodies from 18 providers. DR DNASU; 2986; -. DR Ensembl; ENST00000218006.3; ENSP00000218006.2; ENSG00000101890.5. DR GeneID; 2986; -. DR KEGG; hsa:2986; -. DR MANE-Select; ENST00000218006.3; ENSP00000218006.2; NM_001522.3; NP_001513.2. DR UCSC; uc065aqx.1; human. DR AGR; HGNC:4691; -. DR ClinPGx; PA29071; -. DR CTD; 2986; -. DR DisGeNET; 2986; -. DR GeneCards; GUCY2F; -. DR HGNC; HGNC:4691; GUCY2F. DR HPA; ENSG00000101890; Tissue enriched (retina). DR MIM; 300041; gene. DR OpenTargets; ENSG00000101890; -. DR VEuPathDB; HostDB:ENSG00000101890; -. DR eggNOG; KOG1023; Eukaryota. DR GeneTree; ENSGT00940000162146; -. DR HOGENOM; CLU_001072_1_0_1; -. DR InParanoid; P51841; -. DR OMA; QDSQSMR; -. DR OrthoDB; 1890790at2759; -. DR PAN-GO; P51841; 5 GO annotations based on evolutionary models. DR PhylomeDB; P51841; -. DR BRENDA; 4.6.1.2; 2681. DR PathwayCommons; P51841; -. DR Reactome; R-HSA-2514859; Inactivation, recovery and regulation of the phototransduction cascade. DR SignaLink; P51841; -. DR BioGRID-ORCS; 2986; 10 hits in 794 CRISPR screens. DR ChiTaRS; GUCY2F; human. DR GenomeRNAi; 2986; -. DR Pharos; P51841; Tbio. DR PRO; PR:P51841; -. DR Proteomes; UP000005640; Chromosome X. DR RNAct; P51841; protein. DR Bgee; ENSG00000101890; Expressed in male germ line stem cell (sensu Vertebrata) in testis and 14 other cell types or tissues. DR GO; GO:0005640; C:nuclear outer membrane; TAS:ProtInc. DR GO; GO:0097381; C:photoreceptor disc membrane; TAS:Reactome. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0120200; C:rod photoreceptor outer segment; ISS:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:InterPro. DR GO; GO:0005525; F:GTP binding; IEA:UniProtKB-KW. DR GO; GO:0004383; F:guanylate cyclase activity; IBA:GO_Central. DR GO; GO:0042802; F:identical protein binding; IEA:Ensembl. DR GO; GO:0001653; F:peptide receptor activity; IBA:GO_Central. DR GO; GO:0004672; F:protein kinase activity; IEA:InterPro. DR GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl. DR GO; GO:0038023; F:signaling receptor activity; TAS:ProtInc. DR GO; GO:0006182; P:cGMP biosynthetic process; IBA:GO_Central. DR GO; GO:0019934; P:cGMP-mediated signaling; IEA:Ensembl. DR GO; GO:0050908; P:detection of light stimulus involved in visual perception; IEA:Ensembl. DR GO; GO:0007168; P:receptor guanylyl cyclase signaling pathway; IBA:GO_Central. DR GO; GO:0022400; P:regulation of opsin-mediated signaling pathway; TAS:Reactome. DR GO; GO:0007601; P:visual perception; TAS:ProtInc. DR CDD; cd07302; CHD; 1. DR CDD; cd06371; PBP1_sensory_GC_DEF-like; 1. DR FunFam; 1.10.510.10:FF:000404; Guanylate cyclase; 1. DR FunFam; 3.30.70.1230:FF:000013; Guanylate cyclase; 1. DR FunFam; 3.40.50.2300:FF:000114; Guanylate cyclase; 1. DR Gene3D; 3.40.50.2300; -; 2. DR Gene3D; 3.30.70.1230; Nucleotide cyclase; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR001054; A/G_cyclase. DR InterPro; IPR018297; A/G_cyclase_CS. DR InterPro; IPR001828; ANF_lig-bd_rcpt. DR InterPro; IPR050401; Cyclic_nucleotide_synthase. DR InterPro; IPR011645; HNOB_dom_associated. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR029787; Nucleotide_cyclase. DR InterPro; IPR028082; Peripla_BP_I. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR PANTHER; PTHR11920; GUANYLYL CYCLASE; 1. DR PANTHER; PTHR11920:SF349; RETINAL GUANYLYL CYCLASE 2; 1. DR Pfam; PF01094; ANF_receptor; 1. DR Pfam; PF00211; Guanylate_cyc; 1. DR Pfam; PF07701; HNOBA; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00044; CYCc; 1. DR SUPFAM; SSF55073; Nucleotide cyclase; 1. DR SUPFAM; SSF53822; Periplasmic binding protein-like I; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00452; GUANYLATE_CYCLASE_1; 1. DR PROSITE; PS50125; GUANYLATE_CYCLASE_2; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW Cell projection; cGMP biosynthesis; Disulfide bond; GTP-binding; Lyase; KW Membrane; Nucleotide-binding; Proteomics identification; KW Reference proteome; Sensory transduction; Signal; Transmembrane; KW Transmembrane helix; Vision. FT SIGNAL 1..50 FT /evidence="ECO:0000255" FT CHAIN 51..1108 FT /note="Retinal guanylyl cyclase 2" FT /id="PRO_0000012386" FT TOPO_DOM 51..467 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 468..490 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 491..1108 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 532..812 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 884..1014 FT /note="Guanylate cyclase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00099" FT DISULFID 104..132 FT /evidence="ECO:0000250" FT DISULFID 452 FT /note="Interchain" FT /evidence="ECO:0000250" FT DISULFID 460 FT /note="Interchain" FT /evidence="ECO:0000250" FT VARIANT 10 FT /note="R -> P (in a breast cancer sample; somatic mutation; FT dbSNP:rs755991142)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036419" FT VARIANT 40 FT /note="S -> C (in dbSNP:rs34228145)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042233" FT VARIANT 160 FT /note="I -> N (in dbSNP:rs33971675)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042234" FT VARIANT 230 FT /note="R -> W (in dbSNP:rs33973457)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042235" FT VARIANT 284 FT /note="L -> P (in dbSNP:rs12008095)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_009136" FT VARIANT 296 FT /note="R -> Q (in dbSNP:rs502209)" FT /evidence="ECO:0000269|PubMed:7777544" FT /id="VAR_009137" FT VARIANT 305 FT /note="R -> Q (in dbSNP:rs55966326)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042236" FT VARIANT 308 FT /note="Y -> C (in dbSNP:rs16985750)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030633" FT VARIANT 380 FT /note="Q -> H (in dbSNP:rs2272925)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030634" FT VARIANT 434 FT /note="G -> R (in dbSNP:rs56293008)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042237" FT VARIANT 568 FT /note="G -> D (in a glioblastoma multiforme sample; somatic FT mutation; dbSNP:rs779221554)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042238" FT VARIANT 628 FT /note="R -> Q (in dbSNP:rs7883913)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030635" FT VARIANT 677 FT /note="V -> L (in dbSNP:rs35474112)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042239" FT VARIANT 794 FT /note="E -> K (in dbSNP:rs35726803)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042240" FT VARIANT 872 FT /note="G -> D (in dbSNP:rs148663380)" FT /evidence="ECO:0000269|PubMed:23033978" FT /id="VAR_069424" FT VARIANT 1010 FT /note="A -> V (in dbSNP:rs55735218)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042241" FT VARIANT 1052 FT /note="K -> R (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042242" FT VARIANT 1055 FT /note="E -> D (in a lung squamous cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042243" SQ SEQUENCE 1108 AA; 124850 MW; B047BBF1A3C009F9 CRC64; MFLGLGRFSR LVLWFAAFRK LLGHHGLASA KFLWCLCLLS VMSLPQQVWT LPYKIGVVGP WACDSLFSKA LPEVAARLAI ERINRDPSFD LSYSFEYVIL NEDCQTSRAL SSFISHHQMA SGFIGPTNPG YCEAASLLGN SWDKGIFSWA CVNYELDNKI SYPTFSRTLP SPIRVLVTVM KYFQWAHAGV ISSDEDIWVH TANRVASALR SHGLPVGVVL TTGQDSQSMR KALQRIHQAD RIRIIIMCMH SALIGGETQM HLLECAHDLK MTDGTYVFVP YDALLYSLPY KHTPYRVLRN NPKLREAYDA VLTITVESQE KTFYQAFTEA AARGEIPEKL EFDQVSPLFG TIYNSIYFIA QAMNNAMKEN GQAGAASLVQ HSRNMQFHGF NQLMRTDSNG NGISEYVILD TNLKEWELHS TYTVDMEMEL LRFGGTPIHF PGGRPPRADA KCWFAEGKIC HGGIDPAFAM MVCLTLLIAL LSINGFAYFI RRRINKIQLI KGPNRILLTL EDVTFINPHF GSKRGSRASV SFQITSEVQS GRSPRLSFSS GSLTPATYEN SNIAIYEGDW VWLKKFSLGD FGDLKSIKSR ASDVFEMMKD LRHENINPLL GFFYDSGMFA IVTEFCSRGS LEDILTNQDV KLDWMFKSSL LLDLIKGMKY LHHREFVHGR LKSRNCVVDG RFVLKVTDYG FNDILEMLRL SEEESSMEEL LWTAPELLRA PRGSRLGSFA GDVYSFAIIM QEVMVRGTPF CMMDLPAQEI INRLKKPPPV YRPVVPPEHA PPECLQLMKQ CWAEAAEQRP TFDEIFNQFK TFNKGKKTNI IDSMLRMLEQ YSSNLEDLIR ERTEELEIEK QKTEKLLTQM LPPSVAESLK KGCTVEPEGF DLVTLYFSDI VGFTTISAMS EPIEVVDLLN DLYTLFDAII GSHDVYKVET IGDAYMVASG LPKRNGSRHA AEIANMSLDI LSSVGTFKMR HMPEVPVRIR IGLHSGPVVA GVVGLTMPRY CLFGDTVNTA SRMESTGLPY RIHVSLSTVT ILQNLSEGYE VELRGRTELK GKGTEETFWL IGKKGFMKPL PVPPPVDKDG QVGHGLQPVE IAAFQRRKAE RQLVRNKP // ID HNRDL_HUMAN Reviewed; 420 AA. AC O14979; Q6SPF2; Q7KZ74; Q7KZ75; Q96IM0; Q96S43; DT 15-MAY-2007, integrated into UniProtKB/Swiss-Prot. DT 01-AUG-1999, sequence version 3. DT 28-JAN-2026, entry version 212. DE RecName: Full=Heterogeneous nuclear ribonucleoprotein D-like; DE Short=hnRNP D-like; DE Short=hnRNP DL; DE AltName: Full=AU-rich element RNA-binding factor; DE AltName: Full=JKT41-binding protein; DE AltName: Full=Protein laAUF1; GN Name=HNRNPDL; Synonyms=HNRPDL, JKTBP; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, TISSUE RP SPECIFICITY, RNA-BINDING, AND DNA-BINDING. RC TISSUE=Erythroleukemia, and Placenta; RX PubMed=9538234; DOI=10.1093/oxfordjournals.jbchem.a021964; RA Tsuchiya N., Kamei D., Takano A., Matsui T., Yamada M.; RT "Cloning and characterization of a cDNA encoding a novel heterogeneous RT nuclear ribonucleoprotein-like protein and its expression in myeloid RT leukemia cells."; RL J. Biochem. 123:499-507(1998). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), INDUCTION, AND TISSUE RP SPECIFICITY. RC TISSUE=Placenta; RX PubMed=10072754; DOI=10.1016/s0378-1119(99)00020-7; RA Kamei D., Tsuchiya N., Yamazaki M., Meguro H., Yamada M.; RT "Two forms of expression and genomic structure of the human heterogeneous RT nuclear ribonucleoprotein D-like JKTBP gene (HNRPDL)."; RL Gene 228:13-22(1999). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), SUBCELLULAR LOCATION, AND RP RNA-BINDING. RX PubMed=11705999; DOI=10.1074/jbc.m108477200; RA Kawamura H., Tomozoe Y., Akagi T., Kamei D., Ochiai M., Yamada M.; RT "Identification of the nucleocytoplasmic shuttling sequence of RT heterogeneous nuclear ribonucleoprotein D-like protein JKTBP and its RT interaction with mRNA."; RL J. Biol. Chem. 277:2732-2739(2002). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Lung, Ovary, and Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 123-420. RC TISSUE=Brain; RX PubMed=15190078; DOI=10.1074/jbc.m403160200; RA Boopathi E., Lenka N., Prabu S.K., Fang J.-K., Wilkinson F., Atchison M., RA Giallongo A., Avadhani N.G.; RT "Regulation of murine cytochrome c oxidase Vb gene expression during RT myogenesis: YY-1 and heterogeneous nuclear ribonucleoprotein D-like protein RT (JKTBP1) reciprocally regulate transcription activity by physical RT interaction with the BERF-1/ZBP-89 factor."; RL J. Biol. Chem. 279:35242-35254(2004). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 131-420, INTERACTION WITH TNPO1, MUTAGENESIS RP OF GLY-404, INDUCTION, AND RNA-BINDING. RX PubMed=9524220; DOI=10.1016/s0167-4781(97)00223-6; RA Doi A., Shiosaka T., Takaoka Y., Yanagisawa K., Fujita S.; RT "Molecular cloning of the cDNA encoding A + U-rich element RNA binding RT factor."; RL Biochim. Biophys. Acta 1396:51-56(1998). RN [9] RP PROTEIN SEQUENCE OF 150-180; 190-209; 234-269; 275-289 AND 406-420, RP METHYLATION AT LYS-161 AND ARG-408, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RC TISSUE=Colon carcinoma, and Ovarian carcinoma; RA Bienvenut W.V., Zebisch A., Lilla S., von Kriegsheim A., Lempens A., RA Kolch W.; RL Submitted (DEC-2008) to UniProtKB. RN [10] RP PROTEIN SEQUENCE OF 235-269 AND 275-289. RC TISSUE=Fetal brain cortex; RA Lubec G., Chen W.-Q., Sun Y.; RL Submitted (DEC-2008) to UniProtKB. RN [11] RP SUBCELLULAR LOCATION, AND RNA-BINDING. RX PubMed=12406575; DOI=10.1016/s0378-1119(02)00926-5; RA Kamei D., Yamada M.; RT "Interactions of heterogeneous nuclear ribonucleoprotein D-like protein RT JKTBP and its domains with high-affinity binding sites."; RL Gene 298:49-57(2002). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-241, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-241, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [15] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-216, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-241, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-241, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-241, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [20] RP INVOLVEMENT IN LGMDD3, AND VARIANTS LGMDD3 ASN-378 AND HIS-378. RX PubMed=24647604; DOI=10.1093/hmg/ddu127; RA Vieira N.M., Naslavsky M.S., Licinio L., Kok F., Schlesinger D., RA Vainzof M., Sanchez N., Kitajima J.P., Gal L., Cavacana N., Serafini P.R., RA Chuartzman S., Vasquez C., Mimbacas A., Nigro V., Pavanello R.C., RA Schuldiner M., Kunkel L.M., Zatz M.; RT "A defect in the RNA-processing protein HNRPDL causes limb-girdle muscular RT dystrophy 1G (LGMD1G)."; RL Hum. Mol. Genet. 23:4103-4110(2014). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-241, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [22] RP METHYLATION [LARGE SCALE ANALYSIS] AT ARG-25, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Colon carcinoma; RX PubMed=24129315; DOI=10.1074/mcp.o113.027870; RA Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M., RA Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V., RA Bedford M.T., Comb M.J.; RT "Immunoaffinity enrichment and mass spectrometry analysis of protein RT methylation."; RL Mol. Cell. Proteomics 13:372-387(2014). RN [23] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-209, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). CC -!- FUNCTION: Acts as a transcriptional regulator. Promotes transcription CC repression. Promotes transcription activation in differentiated CC myotubes (By similarity). Binds to double- and single-stranded DNA CC sequences. Binds to the transcription suppressor CATR sequence of the CC COX5B promoter (By similarity). Binds with high affinity to RNA CC molecules that contain AU-rich elements (AREs) found within the 3'-UTR CC of many proto-oncogenes and cytokine mRNAs. Binds both to nuclear and CC cytoplasmic poly(A) mRNAs. Binds to poly(G) and poly(A), but not to CC poly(U) or poly(C) RNA homopolymers. Binds to the 5'-ACUAGC-3' RNA CC consensus sequence. {ECO:0000250, ECO:0000269|PubMed:9538234}. CC -!- SUBUNIT: Interacts with ZNF148 (By similarity). Interacts with TNPO1. CC {ECO:0000250, ECO:0000269|PubMed:9524220}. CC -!- INTERACTION: CC O14979; P22626: HNRNPA2B1; NbExp=2; IntAct=EBI-299727, EBI-299649; CC O14979; Q14103: HNRNPD; NbExp=2; IntAct=EBI-299727, EBI-299674; CC O14979; Q15637: SF1; NbExp=4; IntAct=EBI-299727, EBI-744603; CC O14979; P09234: SNRPC; NbExp=4; IntAct=EBI-299727, EBI-766589; CC O14979; Q13148: TARDBP; NbExp=3; IntAct=EBI-299727, EBI-372899; CC O14979; O76024: WFS1; NbExp=3; IntAct=EBI-299727, EBI-720609; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11705999, CC ECO:0000269|PubMed:12406575}. Cytoplasm {ECO:0000269|PubMed:11705999, CC ECO:0000269|PubMed:12406575}. Note=Shuttles between the nucleus and the CC cytoplasm in a TNPO1-dependent manner. {ECO:0000269|PubMed:11705999, CC ECO:0000269|PubMed:12406575}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=JKTBP2 {ECO:0000303|PubMed:10072754}; CC IsoId=O14979-1; Sequence=Displayed; CC Name=2; Synonyms=JKTBP1 {ECO:0000303|PubMed:10072754}; CC IsoId=O14979-2; Sequence=VSP_025410; CC Name=3; CC IsoId=O14979-3; Sequence=VSP_025410, VSP_025411; CC -!- TISSUE SPECIFICITY: Expressed in heart, brain, placenta, lung, liver, CC skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, CC ovary, small intestine, colon and leukocytes. Expressed in myeloid CC leukemia, gastric adenocarcinoma, cervical carcinoma, hepatoma, CC fibrosarcoma, colon adenocarcinoma, epidermoid carcinoma, osteosarcoma CC and urinary bladder carcinoma cells. {ECO:0000269|PubMed:10072754, CC ECO:0000269|PubMed:9538234}. CC -!- INDUCTION: Up-regulated by 12-O-tetradecanoylphorbol-13-acetate (TPA) CC in macrophages and retinoic acid (RA) in granulocytes (at protein CC level). Down-regulated by IL4/interleukin-4. CC {ECO:0000269|PubMed:10072754, ECO:0000269|PubMed:9524220}. CC -!- PTM: Dimethylation of Arg-408 is probably of the asymmetric type. CC -!- DISEASE: Muscular dystrophy, limb-girdle, autosomal dominant 3 (LGMDD3) CC [MIM:609115]: An autosomal dominant degenerative myopathy characterized CC by slowly progressive wasting and weakness of the proximal muscles of CC arms and legs around the pelvic or shoulder girdles, elevated creatine CC kinase levels and dystrophic features on muscle biopsy. LGMDD3 is CC characterized by a mild late-onset and is associated with progressive CC fingers and toes flexion limitation. Affected individuals may also CC develop cataracts before age 50. {ECO:0000269|PubMed:24647604}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- SEQUENCE CAUTION: CC Sequence=BAA22860.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB017019; BAA75241.1; -; mRNA. DR EMBL; D89092; BAA24361.1; -; mRNA. DR EMBL; AB066484; BAB62188.1; -; mRNA. DR EMBL; CR407623; CAG28551.1; -; mRNA. DR EMBL; AC124016; AAY40914.1; -; Genomic_DNA. DR EMBL; AB017018; BAA75239.1; -; Genomic_DNA. DR EMBL; AB017018; BAA75240.1; -; Genomic_DNA. DR EMBL; BC007392; AAH07392.2; -; mRNA. DR EMBL; BC011714; AAH11714.1; -; mRNA. DR EMBL; BC071944; AAH71944.1; -; mRNA. DR EMBL; AY453824; AAR17782.1; -; mRNA. DR EMBL; D89678; BAA22860.1; ALT_INIT; mRNA. DR CCDS; CCDS3593.1; -. [O14979-1] DR PIR; JW0079; JW0079. DR RefSeq; NP_001193929.1; NM_001207000.1. DR RefSeq; NP_112740.1; NM_031372.4. [O14979-1] DR PDB; 7ZIR; EM; 2.50 A; A/B/C/D/E=121-420. DR PDBsum; 7ZIR; -. DR AlphaFoldDB; O14979; -. DR EMDB; EMD-14738; -. DR SMR; O14979; -. DR BioGRID; 115308; 392. DR CORUM; O14979; -. DR FunCoup; O14979; 3959. DR IntAct; O14979; 166. DR MINT; O14979; -. DR STRING; 9606.ENSP00000483254; -. DR GlyGen; O14979; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; O14979; -. DR MetOSite; O14979; -. DR PhosphoSitePlus; O14979; -. DR SwissPalm; O14979; -. DR BioMuta; HNRNPDL; -. DR jPOST; O14979; -. DR MassIVE; O14979; -. DR PaxDb; 9606-ENSP00000483254; -. DR PeptideAtlas; O14979; -. DR ProteomicsDB; 48353; -. [O14979-1] DR ProteomicsDB; 48354; -. [O14979-2] DR ProteomicsDB; 48355; -. [O14979-3] DR Pumba; O14979; -. DR Antibodypedia; 25039; 160 antibodies from 24 providers. DR DNASU; 9987; -. DR Ensembl; ENST00000295470.10; ENSP00000295470.5; ENSG00000152795.19. [O14979-1] DR Ensembl; ENST00000349655.8; ENSP00000338552.5; ENSG00000152795.19. [O14979-2] DR Ensembl; ENST00000502762.4; ENSP00000422040.1; ENSG00000152795.19. [O14979-1] DR Ensembl; ENST00000507721.5; ENSP00000480156.1; ENSG00000152795.19. [O14979-2] DR Ensembl; ENST00000602300.5; ENSP00000473677.1; ENSG00000152795.19. [O14979-2] DR Ensembl; ENST00000621267.4; ENSP00000483254.1; ENSG00000152795.19. [O14979-1] DR Ensembl; ENST00000630114.2; ENSP00000486452.1; ENSG00000152795.19. [O14979-2] DR Ensembl; ENST00000630827.1; ENSP00000485954.1; ENSG00000152795.19. [O14979-2] DR GeneID; 9987; -. DR KEGG; hsa:9987; -. DR MANE-Select; ENST00000295470.10; ENSP00000295470.5; NM_031372.4; NP_112740.1. DR UCSC; uc003hmr.4; human. [O14979-1] DR AGR; HGNC:5037; -. DR ClinPGx; PA29362; -. DR CTD; 9987; -. DR DisGeNET; 9987; -. DR GeneCards; HNRNPDL; -. DR HGNC; HGNC:5037; HNRNPDL. DR HPA; ENSG00000152795; Low tissue specificity. DR MalaCards; HNRNPDL; -. DR MIM; 607137; gene. DR MIM; 609115; phenotype. DR OpenTargets; ENSG00000152795; -. DR Orphanet; 55596; HNRNPDL-related limb-girdle muscular dystrophy D3. DR VEuPathDB; HostDB:ENSG00000152795; -. DR eggNOG; KOG0118; Eukaryota. DR GeneTree; ENSGT00940000154426; -. DR HOGENOM; CLU_012062_1_1_1; -. DR InParanoid; O14979; -. DR OMA; QVDTEMN; -. DR OrthoDB; 1875751at2759; -. DR PAN-GO; O14979; 4 GO annotations based on evolutionary models. DR PhylomeDB; O14979; -. DR PathwayCommons; O14979; -. DR Reactome; R-HSA-8950505; Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation. DR SignaLink; O14979; -. DR Agora; ENSG00000152795; -. DR BioGRID-ORCS; 9987; 19 hits in 1107 CRISPR screens. DR CD-CODE; 232F8A39; P-body. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; D0F20FEF; Synthetic Condensate 000090. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; HNRNPDL; human. DR GeneWiki; HNRPDL; -. DR GenomeRNAi; 9987; -. DR Pharos; O14979; Tbio. DR PRO; PR:O14979; -. DR Proteomes; UP000005640; Chromosome 4. DR RNAct; O14979; protein. DR Bgee; ENSG00000152795; Expressed in primordial germ cell in gonad and 212 other cell types or tissues. DR ExpressionAtlas; O14979; baseline and differential. DR GO; GO:0000785; C:chromatin; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005681; C:spliceosomal complex; NAS:UniProtKB. DR GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW. DR GO; GO:0003690; F:double-stranded DNA binding; IDA:UniProtKB. DR GO; GO:0008143; F:poly(A) binding; IDA:UniProtKB. DR GO; GO:0034046; F:poly(G) binding; IDA:UniProtKB. DR GO; GO:0003723; F:RNA binding; HDA:UniProtKB. DR GO; GO:0003697; F:single-stranded DNA binding; IDA:UniProtKB. DR GO; GO:0010468; P:regulation of gene expression; IDA:UniProtKB. DR GO; GO:0006396; P:RNA processing; NAS:UniProtKB. DR CDD; cd12758; RRM1_hnRPDL; 1. DR CDD; cd12585; RRM2_hnRPDL; 1. DR FunFam; 3.30.70.330:FF:000220; Heterogeneous nuclear ribonucleoprotein D-like protein; 1. DR FunFam; 3.30.70.330:FF:000030; Heterogeneous nuclear ribonucleoprotein d0 isoform; 1. DR Gene3D; 3.30.70.330; -; 2. DR InterPro; IPR034847; hnRPDL_RRM1. DR InterPro; IPR012677; Nucleotide-bd_a/b_plait_sf. DR InterPro; IPR035979; RBD_domain_sf. DR InterPro; IPR000504; RRM_dom. DR PANTHER; PTHR48033:SF2; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN D-LIKE; 1. DR PANTHER; PTHR48033; RNA-BINDING (RRM/RBD/RNP MOTIFS) FAMILY PROTEIN; 1. DR Pfam; PF00076; RRM_1; 2. DR SMART; SM00360; RRM; 2. DR SUPFAM; SSF54928; RNA-binding domain, RBD; 2. DR PROSITE; PS50102; RRM; 2. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Activator; Alternative splicing; Cytoplasm; KW Direct protein sequencing; Disease variant; DNA-binding; Isopeptide bond; KW Limb-girdle muscular dystrophy; Methylation; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; Repressor; KW RNA-binding; Transcription; Transcription regulation; Ubl conjugation. FT CHAIN 1..420 FT /note="Heterogeneous nuclear ribonucleoprotein D-like" FT /id="PRO_0000287239" FT DOMAIN 148..230 FT /note="RRM 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00176" FT DOMAIN 233..312 FT /note="RRM 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00176" FT REGION 1..83 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 96..120 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 313..348 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 342..420 FT /note="Necessary for interaction with TNPO1" FT /evidence="ECO:0000269|PubMed:9524220" FT REGION 396..420 FT /note="Necessary for its nuclear import and export" FT REGION 398..420 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 36..52 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 323..342 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 25 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 161 FT /note="N6-methyllysine" FT /evidence="ECO:0000269|Ref.9" FT MOD_RES 216 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 241 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 408 FT /note="Dimethylated arginine; alternate" FT /evidence="ECO:0000269|Ref.9" FT MOD_RES 408 FT /note="Omega-N-methylarginine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q9Z130" FT CROSSLNK 209 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 1..119 FT /note="Missing (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:10072754, FT ECO:0000303|PubMed:11705999, ECO:0000303|PubMed:9538234" FT /id="VSP_025410" FT VAR_SEQ 341..397 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:11705999" FT /id="VSP_025411" FT VARIANT 378 FT /note="D -> H (in LGMDD3; dbSNP:rs587777669)" FT /evidence="ECO:0000269|PubMed:24647604" FT /id="VAR_072567" FT VARIANT 378 FT /note="D -> N (in LGMDD3; dbSNP:rs587777669)" FT /evidence="ECO:0000269|PubMed:24647604" FT /id="VAR_072568" FT MUTAGEN 404 FT /note="G->A: Reduces significantly its nuclear FT localization." FT /evidence="ECO:0000269|PubMed:9524220" FT STRAND 358..362 FT /evidence="ECO:0007829|PDB:7ZIR" FT STRAND 369..371 FT /evidence="ECO:0007829|PDB:7ZIR" FT STRAND 376..378 FT /evidence="ECO:0007829|PDB:7ZIR" FT STRAND 380..383 FT /evidence="ECO:0007829|PDB:7ZIR" FT STRAND 388..394 FT /evidence="ECO:0007829|PDB:7ZIR" SQ SEQUENCE 420 AA; 46438 MW; 00F631863859D0CA CRC64; MEVPPRLSHV PPPLFPSAPA TLASRSLSHW RPRPPRQLAP LLPSLAPSSA RQGARRAQRH VTAQQPSRLA GGAAIKGGRR RRPDLFRRHF KSSSIQRSAA AAAATRTARQ HPPADSSVTM EDMNEYSNIE EFAEGSKINA SKNQQDDGKM FIGGLSWDTS KKDLTEYLSR FGEVVDCTIK TDPVTGRSRG FGFVLFKDAA SVDKVLELKE HKLDGKLIDP KRAKALKGKE PPKKVFVGGL SPDTSEEQIK EYFGAFGEIE NIELPMDTKT NERRGFCFIT YTDEEPVKKL LESRYHQIGS GKCEIKVAQP KEVYRQQQQQ QKGGRGAAAG GRGGTRGRGR GQGQNWNQGF NNYYDQGYGN YNSAYGGDQN YSGYGGYDYT GYNYGNYGYG QGYADYSGQQ STYGKASRGG GNHQNNYQPY // ID HORM2_HUMAN Reviewed; 307 AA. AC Q8N7B1; B5MEB2; Q8NHR2; DT 17-APR-2007, integrated into UniProtKB/Swiss-Prot. DT 17-APR-2007, sequence version 2. DT 28-JAN-2026, entry version 136. DE RecName: Full=HORMA domain-containing protein 2; GN Name=HORMAD2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84; RA Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A., RA Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J., RA Beare D.M., Dunham I.; RT "A genome annotation-driven approach to cloning the human ORFeome."; RL Genome Biol. 5:R84.1-R84.11(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=10591208; DOI=10.1038/990031; RA Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M., Clamp M., RA Smink L.J., Ainscough R., Almeida J.P., Babbage A.K., Bagguley C., RA Bailey J., Barlow K.F., Bates K.N., Beasley O.P., Bird C.P., Blakey S.E., RA Bridgeman A.M., Buck D., Burgess J., Burrill W.D., Burton J., Carder C., RA Carter N.P., Chen Y., Clark G., Clegg S.M., Cobley V.E., Cole C.G., RA Collier R.E., Connor R., Conroy D., Corby N.R., Coville G.J., Cox A.V., RA Davis J., Dawson E., Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., RA Ellington A.G., Evans K.L., Fey J.M., Fleming K., French L., Garner A.A., RA Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C., RA Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S., Hunt S.E., RA Jones M.C., Kershaw J., Kimberley A.M., King A., Laird G.K., Langford C.F., RA Leversha M.A., Lloyd C., Lloyd D.M., Martyn I.D., Mashreghi-Mohammadi M., RA Matthews L.H., Mccann O.T., Mcclay J., Mclaren S., McMurray A.A., RA Milne S.A., Mortimore B.J., Odell C.N., Pavitt R., Pearce A.V., Pearson D., RA Phillimore B.J.C.T., Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., RA Rogers L., Ross M.T., Scott C.E., Sehra H.K., Skuce C.D., Smalley S., RA Smith M.L., Soderlund C., Spragon L., Steward C.A., Sulston J.E., RA Swann R.M., Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L., RA Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L., RA Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N., RA Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J., Shintani A., RA Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S., Roe B.A., Chen F., Chu L., RA Crabtree J., Deschamps S., Do A., Do T., Dorman A., Fang F., Fu Y., Hu P., RA Hua A., Kenton S., Lai H., Lao H.I., Lewis J., Lewis S., Lin S.-P., Loh P., RA Malaj E., Nguyen T., Pan H., Phan S., Qi S., Qian Y., Ray L., Ren Q., RA Shaull S., Sloan D., Song L., Wang Q., Wang Y., Wang Z., White J., RA Willingham D., Wu H., Yao Z., Zhan M., Zhang G., Chissoe S., Murray J., RA Miller N., Minx P., Fulton R., Johnson D., Bemis G., Bentley D., RA Bradshaw H., Bourne S., Cordes M., Du Z., Fulton L., Goela D., Graves T., RA Hawkins J., Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., RA Rohlfing T., Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., RA Nelson J., Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R., RA Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S., Budarf M.L., RA McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E., Edelmann L., Kim U.J., RA Shizuya H., Simon M.I., Dumanski J.P., Peyrard M., Kedra D., Seroussi E., RA Fransson I., Tapia I., Bruder C.E., O'Brien K.P., Wilkinson P., RA Bodenteich A., Hartman K., Hu X., Khan A.S., Lane L., Tilahun Y., RA Wright H.; RT "The DNA sequence of human chromosome 22."; RL Nature 402:489-495(1999). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP IDENTIFICATION, AND TISSUE SPECIFICITY. RX PubMed=15999985; RA Chen Y.-T., Venditti C.A., Theiler G., Stevenson B.J., Iseli C., Gure A.O., RA Jongeneel C.V., Old L.J., Simpson A.J.G.; RT "Identification of CT46/HORMAD1, an immunogenic cancer/testis antigen RT encoding a putative meiosis-related protein."; RL Cancer Immun. 5:9-9(2005). RN [7] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=22893617; DOI=10.1093/molehr/gas033; RA Liu M., Chen J., Hu L., Shi X., Zhou Z., Hu Z., Sha J.; RT "HORMAD2/CT46.2, a novel cancer/testis gene, is ectopically expressed in RT lung cancer tissues."; RL Mol. Hum. Reprod. 18:599-604(2012). CC -!- FUNCTION: Essential for synapsis surveillance during meiotic prophase CC via the recruitment of ATR activity. Plays a key role in the male mid- CC pachytene checkpoint and the female meiotic prophase checkpoint: CC required for efficient build-up of ATR activity on unsynapsed CC chromosome regions, a process believed to form the basis of meiotic CC silencing of unsynapsed chromatin (MSUC) and meiotic prophase quality CC control in both sexes. Required for the DNA double-strand break- CC independent, BRCA1-dependent activation of ATR on the sex chromosomes CC that is essential for normal sex body formation (By similarity). CC {ECO:0000250}. CC -!- SUBUNIT: Interacts with HORMAD1. {ECO:0000250}. CC -!- INTERACTION: CC Q8N7B1; O96028: NSD2; NbExp=3; IntAct=EBI-13346145, EBI-2693298; CC Q8N7B1; O00151: PDLIM1; NbExp=2; IntAct=EBI-13346145, EBI-724897; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:22893617}. Chromosome CC {ECO:0000250}. Note=Preferentially localizes to unsynapsed or CC desynapsed chromosomal regions during the male and female prophase I CC stage of meiosis. TRIP13 is required for depletion from synapsed CC chromosomes (By similarity). {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Highly expressed in testis (at protein level). CC Expressed in lung adenocarcinoma and squamous cell carcinoma (at CC protein level). Expressed at lower levels in the liver, brain and CC kidney. {ECO:0000269|PubMed:15999985, ECO:0000269|PubMed:22893617}. CC -!- PTM: Phosphorylated in a SPO11-dependent manner. {ECO:0000250}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; CR456341; CAG30227.1; -; mRNA. DR EMBL; AK098703; BAC05388.1; -; mRNA. DR EMBL; AC002378; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC003071; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471095; EAW59860.1; -; Genomic_DNA. DR EMBL; BC030013; AAH30013.1; -; mRNA. DR CCDS; CCDS46683.1; -. DR RefSeq; NP_001316386.1; NM_001329457.2. DR RefSeq; NP_001316387.1; NM_001329458.1. DR RefSeq; NP_689723.1; NM_152510.4. DR RefSeq; XP_047297112.1; XM_047441156.1. DR RefSeq; XP_054181110.1; XM_054325135.1. DR AlphaFoldDB; Q8N7B1; -. DR SMR; Q8N7B1; -. DR BioGRID; 127278; 31. DR FunCoup; Q8N7B1; 397. DR IntAct; Q8N7B1; 27. DR STRING; 9606.ENSP00000385055; -. DR GlyGen; Q8N7B1; 1 site. DR iPTMnet; Q8N7B1; -. DR PhosphoSitePlus; Q8N7B1; -. DR BioMuta; HORMAD2; -. DR DMDM; 145558934; -. DR jPOST; Q8N7B1; -. DR MassIVE; Q8N7B1; -. DR PaxDb; 9606-ENSP00000336984; -. DR PeptideAtlas; Q8N7B1; -. DR ProteomicsDB; 72278; -. DR Antibodypedia; 311; 145 antibodies from 18 providers. DR DNASU; 150280; -. DR Ensembl; ENST00000336726.11; ENSP00000336984.6; ENSG00000176635.19. DR Ensembl; ENST00000403975.1; ENSP00000385055.1; ENSG00000176635.19. DR GeneID; 150280; -. DR KEGG; hsa:150280; -. DR MANE-Select; ENST00000336726.11; ENSP00000336984.6; NM_152510.4; NP_689723.1. DR UCSC; uc003agy.4; human. DR AGR; HGNC:28383; -. DR ClinPGx; PA134889862; -. DR CTD; 150280; -. DR DisGeNET; 150280; -. DR GeneCards; HORMAD2; -. DR HGNC; HGNC:28383; HORMAD2. DR HPA; ENSG00000176635; Tissue enriched (testis). DR MIM; 618842; gene. DR OpenTargets; ENSG00000176635; -. DR VEuPathDB; HostDB:ENSG00000176635; -. DR eggNOG; KOG4652; Eukaryota. DR GeneTree; ENSGT00390000018130; -. DR HOGENOM; CLU_058638_2_0_1; -. DR InParanoid; Q8N7B1; -. DR OMA; GCFHALE; -. DR OrthoDB; 1928087at2759; -. DR PAN-GO; Q8N7B1; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q8N7B1; -. DR PathwayCommons; Q8N7B1; -. DR SignaLink; Q8N7B1; -. DR Agora; ENSG00000176635; -. DR BioGRID-ORCS; 150280; 35 hits in 1149 CRISPR screens. DR ChiTaRS; HORMAD2; human. DR GeneWiki; HORMAD2; -. DR GenomeRNAi; 150280; -. DR Pharos; Q8N7B1; Tbio. DR PRO; PR:Q8N7B1; -. DR Proteomes; UP000005640; Chromosome 22. DR RNAct; Q8N7B1; protein. DR Bgee; ENSG00000176635; Expressed in right testis and 49 other cell types or tissues. DR ExpressionAtlas; Q8N7B1; baseline and differential. DR GO; GO:0005813; C:centrosome; IDA:HPA. DR GO; GO:0005694; C:chromosome; ISS:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0000795; C:synaptonemal complex; IEA:Ensembl. DR GO; GO:0051321; P:meiotic cell cycle; ISS:UniProtKB. DR GO; GO:0051177; P:meiotic sister chromatid cohesion; ISS:UniProtKB. DR FunFam; 3.30.900.10:FF:000006; HORMA domain-containing protein 1; 1. DR Gene3D; 3.30.900.10; HORMA domain; 1. DR InterPro; IPR003511; HORMA_dom. DR InterPro; IPR036570; HORMA_dom_sf. DR InterPro; IPR051294; HORMA_MeioticProgression. DR PANTHER; PTHR48225; HORMA DOMAIN-CONTAINING PROTEIN 1; 1. DR PANTHER; PTHR48225:SF6; HORMA DOMAIN-CONTAINING PROTEIN 2; 1. DR Pfam; PF02301; HORMA; 1. DR SUPFAM; SSF56019; The spindle assembly checkpoint protein mad2; 1. DR PROSITE; PS50815; HORMA; 1. PE 1: Evidence at protein level; KW Chromosome; Meiosis; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome. FT CHAIN 1..307 FT /note="HORMA domain-containing protein 2" FT /id="PRO_0000284669" FT DOMAIN 29..234 FT /note="HORMA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00109" FT VARIANT 2 FT /note="A -> T (in dbSNP:rs34150968)" FT /id="VAR_031802" FT VARIANT 20 FT /note="V -> L (in dbSNP:rs34305723)" FT /id="VAR_031803" FT CONFLICT 217 FT /note="N -> D (in Ref. 2; BAC05388)" FT /evidence="ECO:0000305" SQ SEQUENCE 307 AA; 35284 MW; A190ABB99E374EB3 CRC64; MATAQLSHCI TIHKASKETV FPSQITNEHE SLKMVKKLFA TSISCITYLR GLFPESSYGE RHLDDLSLKI LREDKKCPGS LHIIRWIQGC FDALEKRYLR MAVLTLYTDP MGSEKVTEMY QFKFKYTKEG ATMDFDSHSS STSFESGTNN EDIKKASVLL IRKLYILMQD LEPLPNNVVL TMKLHYYNAV TPHDYQPLGF KEGVNSHFLL FDKEPINVQV GFVSTGFHSM KVKVMTEATK VIDLENNLFR ENSTTEIAHQ GLDCDEEEEC NDHIQRMNFV CSQQSSECSR KKRKVSEPVK VFIPNRK // ID IF2B3_HUMAN Reviewed; 579 AA. AC O00425; A0A4Z5; Q63HM0; Q6MZZ2; Q86VB1; DT 03-APR-2007, integrated into UniProtKB/Swiss-Prot. DT 28-JUL-2009, sequence version 2. DT 28-JAN-2026, entry version 204. DE RecName: Full=Insulin-like growth factor 2 mRNA-binding protein 3; DE Short=IGF2 mRNA-binding protein 3; DE Short=IMP-3; DE AltName: Full=IGF-II mRNA-binding protein 3; DE AltName: Full=KH domain-containing protein overexpressed in cancer; DE Short=hKOC; DE AltName: Full=VICKZ family member 3; GN Name=IGF2BP3; Synonyms=IMP3, KOC1, VICKZ3; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY. RC TISSUE=Pancreas, and Pancreatic cancer; RX PubMed=9178771; DOI=10.1038/sj.onc.1201110; RA Mueller-Pillasch F., Lacher U., Wallrapp C., Micha A., Zimmerhackl F., RA Hameister H., Varga G., Friess H., Buechler M., Beger H.G., Vila M.R., RA Adler G., Gress T.M.; RT "Cloning of a gene highly overexpressed in cancer coding for a novel KH- RT domain containing protein."; RL Oncogene 14:2729-2733(1997). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Endometrial tumor; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12853948; DOI=10.1038/nature01782; RA Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H., RA Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K., RA Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A., RA Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H., RA Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A., RA Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P., RA Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M., RA Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S., RA Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., RA Strowmatt C., Latreille P., Miller N., Johnson D., Murray J., RA Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., RA Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., RA Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E., RA Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E., RA Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A., RA Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A., RA Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R., RA McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H., RA Wilson R.K.; RT "The DNA sequence of human chromosome 7."; RL Nature 424:157-164(2003). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Eye; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP TISSUE SPECIFICITY. RX PubMed=10525192; DOI=10.1016/s0925-4773(99)00160-4; RA Mueller-Pillasch F., Pohl B., Wilda M., Lacher U., Beil M., Wallrapp C., RA Hameister H., Knoechel W., Adler G., Gress T.M.; RT "Expression of the highly conserved RNA binding protein KOC in RT embryogenesis."; RL Mech. Dev. 88:95-99(1999). RN [6] RP GENE NOMENCLATURE, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND RP RNA-BINDING. RX PubMed=9891060; DOI=10.1128/mcb.19.2.1262; RA Nielsen J., Christiansen J., Lykke-Andersen J., Johnsen A.H., Wewer U.M., RA Nielsen F.C.; RT "A family of insulin-like growth factor II mRNA-binding proteins represses RT translation in late development."; RL Mol. Cell. Biol. 19:1262-1270(1999). RN [7] RP IDENTIFICATION AS A CARCINOMA ANTIGEN. RX PubMed=11465943; DOI=10.1006/clim.2001.5048; RA Zhang J.-Y., Chan E.K., Peng X.-X., Lu M., Wang X., Mueller F., Tan E.M.; RT "Autoimmune responses to mRNA binding proteins p62 and Koc in diverse RT malignancies."; RL Clin. Immunol. 100:149-156(2001). RN [8] RP TISSUE SPECIFICITY. RX PubMed=12161597; DOI=10.1136/jmg.39.8.575; RA Monk D., Bentley L., Beechey C., Hitchins M., Peters J., Preece M.A., RA Stanier P., Moore G.E.; RT "Characterisation of the growth regulating gene IMP3, a candidate for RT Silver-Russell syndrome."; RL J. Med. Genet. 39:575-581(2002). RN [9] RP SUBCELLULAR LOCATION. RX PubMed=12921532; DOI=10.1042/bj20030943; RA Nielsen J., Adolph S.K., Rajpert-De Meyts E., Lykke-Andersen J., Koch G., RA Christiansen J., Nielsen F.C.; RT "Nuclear transit of human zipcode-binding protein IMP1."; RL Biochem. J. 376:383-391(2003). RN [10] RP REVIEW. RX PubMed=15601260; DOI=10.1042/bc20040151; RA Yisraeli J.K.; RT "VICKZ proteins: a multi-talented family of regulatory RNA-binding RT proteins."; RL Biol. Cell 97:87-96(2005). RN [11] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=15644775; DOI=10.1097/01.pas.0000149688.98333.54; RA Yantiss R.K., Woda B.A., Fanger G.R., Kalos M., Whalen G.F., Tada H., RA Andersen D.K., Rock K.L., Dresser K.; RT "KOC (K homology domain containing protein overexpressed in cancer): a RT novel molecular marker that distinguishes between benign and malignant RT lesions of the pancreas."; RL Diagn. Mol. Pathol. 29:188-195(2005). RN [12] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=16049158; DOI=10.1530/rep.1.00664; RA Hammer N.A., Hansen T.O., Byskov A.G., Rajpert-De Meyts E., Groendahl M.L., RA Bredkjaer H.E., Wewer U.M., Christiansen J., Nielsen F.C.; RT "Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular RT cancer."; RL Reproduction 130:203-212(2005). RN [13] RP FUNCTION, RNA-BINDING, AND SUBCELLULAR LOCATION. RX PubMed=16541107; DOI=10.1038/sj.emboj.7601039; RA Vikesaa J., Hansen T.V., Joenson L., Borup R., Wewer U.M., Christiansen J., RA Nielsen F.C.; RT "RNA-binding IMPs promote cell adhesion and invadopodia formation."; RL EMBO J. 25:1456-1468(2006). RN [14] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=16814207; DOI=10.1016/s1470-2045(06)70732-x; RA Jiang Z., Chu P.G., Woda B.A., Rock K.L., Liu Q., Hsieh C.-C., Li C., RA Chen W., Duan H.O., McDougal S., Wu C.-L.; RT "Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis RT of renal-cell carcinoma: a retrospective study."; RL Lancet Oncol. 7:556-564(2006). RN [15] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=17192788; DOI=10.1038/modpathol.3800735; RA Li C., Rock K.L., Woda B.A., Jiang Z., Fraire A.E., Dresser K.; RT "IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine RT cervix: an immunohistochemical study in comparison with p16(INK4a) RT expression."; RL Mod. Pathol. 20:242-247(2007). RN [16] RP INTERACTION WITH IGF2BP1. RX PubMed=17289661; DOI=10.1074/mcp.m600346-mcp200; RA Joeson L., Vikesaa J., Krogh A., Nielsen L.K., Hansen T., Borup R., RA Johnsen A.H., Christiansen J., Nielsen F.C.; RT "Molecular composition of IMP1 ribonucleoprotein granules."; RL Mol. Cell. Proteomics 6:798-811(2007). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-528, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [19] RP RNA-BINDING, AND DOMAIN. RX PubMed=20080952; DOI=10.1101/gad.1862910; RA Chao J.A., Patskovsky Y., Patel V., Levy M., Almo S.C., Singer R.H.; RT "ZBP1 recognition of beta-actin zipcode induces RNA looping."; RL Genes Dev. 24:148-158(2010). RN [20] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-184 AND THR-528, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [22] RP FUNCTION, RNA-BINDING, OLIGOMERIZATION, INTERACTION WITH ELAVL1; DHX9 AND RP HNRNPU, DOMAIN, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-213; LYS-294; RP 423-LYS-LYS-424 AND 505-LYS-GLY-506. RX PubMed=23640942; DOI=10.1515/hsz-2013-0111; RA Wachter K., Kohn M., Stohr N., Huttelmaier S.; RT "Subcellular localization and RNP formation of IGF2BPs (IGF2 mRNA-binding RT proteins) is modulated by distinct RNA-binding domains."; RL Biol. Chem. 394:1077-1090(2013). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-528, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [24] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-475, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25218447; DOI=10.1038/nsmb.2890; RA Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M., RA Vertegaal A.C.; RT "Uncovering global SUMOylation signaling networks in a site-specific RT manner."; RL Nat. Struct. Mol. Biol. 21:927-936(2014). RN [25] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [26] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-450 AND LYS-475, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [27] RP FUNCTION, INTERACTION WITH ELAVL1; MATR3 AND PABPC1, SUBCELLULAR LOCATION, RP ROLE OF KH DOMAINS, MUTAGENESIS OF LYS-213; LYS-294; 423-LYS-LYS-424 AND RP 505-LYS-GLY-506, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=29476152; DOI=10.1038/s41556-018-0045-z; RA Huang H., Weng H., Sun W., Qin X., Shi H., Wu H., Zhao B.S., Mesquita A., RA Liu C., Yuan C.L., Hu Y.C., Huettelmaier S., Skibbe J.R., Su R., Deng X., RA Dong L., Sun M., Li C., Nachtergaele S., Wang Y., Hu C., Ferchen K., RA Greis K.D., Jiang X., Wei M., Qu L., Guan J.L., He C., Yang J., Chen J.; RT "Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA RT stability and translation."; RL Nat. Cell Biol. 20:285-295(2018). RN [28] RP STRUCTURE BY NMR OF 73-161. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of RNA binding domain in insulin-like growth factor 2 RT mRNA-binding protein 3."; RL Submitted (JUN-2007) to the PDB data bank. CC -!- FUNCTION: RNA-binding factor that may recruit target transcripts to CC cytoplasmic protein-RNA complexes (mRNPs). This transcript 'caging' CC into mRNPs allows mRNA transport and transient storage. It also CC modulates the rate and location at which target transcripts encounter CC the translational apparatus and shields them from endonuclease attacks CC or microRNA-mediated degradation. Preferentially binds to N6- CC methyladenosine (m6A)-containing mRNAs and increases their stability CC (PubMed:29476152). Binds to the 3'-UTR of CD44 mRNA and stabilizes it, CC hence promotes cell adhesion and invadopodia formation in cancer cells. CC Binds to beta-actin/ACTB and MYC transcripts. Increases MYC mRNA CC stability by binding to the coding region instability determinant (CRD) CC and binding is enhanced by m6A-modification of the CRD CC (PubMed:29476152). Binds to the 5'-UTR of the insulin-like growth CC factor 2 (IGF2) mRNAs. {ECO:0000269|PubMed:16541107, CC ECO:0000269|PubMed:23640942, ECO:0000269|PubMed:29476152}. CC -!- SUBUNIT: Can form homooligomers and heterooligomers with IGF2BP1 and CC IGF2BP3 in an RNA-dependent manner (PubMed:23640942). Interacts with CC IGF2BP1 (PubMed:17289661). Interacts with ELAVL1, DHX9, HNRNPU, MATR3 CC and PABPC1 (PubMed:23640942, PubMed:29476152). CC {ECO:0000269|PubMed:17289661, ECO:0000269|PubMed:23640942, CC ECO:0000269|PubMed:29476152}. CC -!- INTERACTION: CC O00425; Q13627: DYRK1A; NbExp=3; IntAct=EBI-1058566, EBI-1053596; CC O00425; Q15365: PCBP1; NbExp=3; IntAct=EBI-1058566, EBI-946095; CC O00425; Q13148: TARDBP; NbExp=6; IntAct=EBI-1058566, EBI-372899; CC -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Cytoplasm, P-body CC {ECO:0000269|PubMed:29476152}. Cytoplasm, Stress granule CC {ECO:0000269|PubMed:29476152}. Note=Found in lamellipodia of the CC leading edge, in the perinuclear region, and beneath the plasma CC membrane. The subcytoplasmic localization is cell specific and CC regulated by cell contact and growth. Localized at the connecting piece CC and the tail of the spermatozoa. Colocalized with CD44 mRNA in RNP CC granules. In response to cellular stress, such as oxidative stress, CC recruited to stress granules. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=O00425-1; Sequence=Displayed; CC Name=2; CC IsoId=O00425-2; Sequence=VSP_024172; CC -!- TISSUE SPECIFICITY: Expressed in fetal liver, fetal lung, fetal kidney, CC fetal thymus, fetal placenta, fetal follicles of ovary and gonocytes of CC testis, growing oocytes, spermatogonia and semen (at protein level). CC Expressed in cervix adenocarcinoma, in testicular, pancreatic and CC renal-cell carcinomas (at protein level). Expressed ubiquitously during CC fetal development at 8 and 14 weeks of gestation. Expressed in ovary, CC testis, brain, placenta, pancreatic cancer tissues and pancreatic CC cancer cell lines. {ECO:0000269|PubMed:10525192, CC ECO:0000269|PubMed:12161597, ECO:0000269|PubMed:15644775, CC ECO:0000269|PubMed:16049158, ECO:0000269|PubMed:16814207, CC ECO:0000269|PubMed:17192788, ECO:0000269|PubMed:9178771, CC ECO:0000269|PubMed:9891060}. CC -!- DOMAIN: All KH domains contribute to binding to target mRNA. Domains CC KH3 and KH4 are the major RNA-binding modules, although KH1 and KH2 CC also contribute (PubMed:29476152). The KH domains are also required for CC RNA-dependent homo- and heterooligomerization. The integrity of KH CC domains does not seem to be required for localization to stress CC granules. {ECO:0000269|PubMed:20080952, ECO:0000269|PubMed:23640942, CC ECO:0000269|PubMed:29476152}. CC -!- MISCELLANEOUS: Autoantibodies against IGF2BP3 are detected in sera from CC some patients with a variety of carcinomas. CC -!- SIMILARITY: Belongs to the RRM IMP/VICKZ family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U76705; AAD09223.1; -; mRNA. DR EMBL; U97188; AAC35208.1; -; mRNA. DR EMBL; BX640800; CAE45883.1; -; mRNA. DR EMBL; BX648488; CAH56186.1; -; mRNA. DR EMBL; AC005082; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC021876; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC079780; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC065269; AAH65269.1; -; mRNA. DR CCDS; CCDS5382.1; -. [O00425-1] DR RefSeq; NP_006538.2; NM_006547.2. [O00425-1] DR PDB; 2E44; NMR; -; A=73-161. DR PDB; 6FQ1; X-ray; 1.31 A; A/B=1-161. DR PDB; 6FQR; X-ray; 2.10 A; A/B=1-161. DR PDB; 6GQE; X-ray; 2.15 A; A=192-355. DR PDB; 6GX6; X-ray; 2.00 A; A=1-161. DR PDBsum; 2E44; -. DR PDBsum; 6FQ1; -. DR PDBsum; 6FQR; -. DR PDBsum; 6GQE; -. DR PDBsum; 6GX6; -. DR AlphaFoldDB; O00425; -. DR SMR; O00425; -. DR BioGRID; 115887; 593. DR DIP; DIP-44171N; -. DR FunCoup; O00425; 2436. DR IntAct; O00425; 212. DR MINT; O00425; -. DR STRING; 9606.ENSP00000258729; -. DR GlyGen; O00425; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; O00425; -. DR MetOSite; O00425; -. DR PhosphoSitePlus; O00425; -. DR SwissPalm; O00425; -. DR BioMuta; IGF2BP3; -. DR jPOST; O00425; -. DR MassIVE; O00425; -. DR PaxDb; 9606-ENSP00000258729; -. DR PeptideAtlas; O00425; -. DR ProteomicsDB; 47882; -. [O00425-1] DR ProteomicsDB; 47883; -. [O00425-2] DR Pumba; O00425; -. DR Antibodypedia; 1056; 433 antibodies from 40 providers. DR DNASU; 10643; -. DR Ensembl; ENST00000258729.8; ENSP00000258729.3; ENSG00000136231.15. [O00425-1] DR Ensembl; ENST00000619562.4; ENSP00000480267.1; ENSG00000136231.15. [O00425-2] DR GeneID; 10643; -. DR KEGG; hsa:10643; -. DR MANE-Select; ENST00000258729.8; ENSP00000258729.3; NM_006547.3; NP_006538.2. DR UCSC; uc003swf.4; human. [O00425-1] DR AGR; HGNC:28868; -. DR ClinPGx; PA128394576; -. DR CTD; 10643; -. DR DisGeNET; 10643; -. DR GeneCards; IGF2BP3; -. DR HGNC; HGNC:28868; IGF2BP3. DR HPA; ENSG00000136231; Tissue enhanced (lymphoid tissue, placenta). DR MIM; 608259; gene. DR OpenTargets; ENSG00000136231; -. DR VEuPathDB; HostDB:ENSG00000136231; -. DR eggNOG; KOG2193; Eukaryota. DR GeneTree; ENSGT00940000154957; -. DR HOGENOM; CLU_020744_1_0_1; -. DR InParanoid; O00425; -. DR OMA; CPDEGWA; -. DR OrthoDB; 752362at2759; -. DR PAN-GO; O00425; 7 GO annotations based on evolutionary models. DR PhylomeDB; O00425; -. DR PathwayCommons; O00425; -. DR Reactome; R-HSA-428359; Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA. DR SignaLink; O00425; -. DR Agora; ENSG00000136231; -. DR BioGRID-ORCS; 10643; 23 hits in 1172 CRISPR screens. DR CD-CODE; 232F8A39; P-body. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; IGF2BP3; human. DR EvolutionaryTrace; O00425; -. DR GeneWiki; IGF2BP3; -. DR GenomeRNAi; 10643; -. DR Pharos; O00425; Tbio. DR PRO; PR:O00425; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; O00425; protein. DR Bgee; ENSG00000136231; Expressed in secondary oocyte and 134 other cell types or tissues. DR ExpressionAtlas; O00425; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL. DR GO; GO:0010494; C:cytoplasmic stress granule; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0000932; C:P-body; IDA:UniProtKB. DR GO; GO:0003730; F:mRNA 3'-UTR binding; IDA:UniProtKB. DR GO; GO:0048027; F:mRNA 5'-UTR binding; IDA:BHF-UCL. DR GO; GO:1990247; F:N6-methyladenosine-containing RNA reader activity; IDA:UniProtKB. DR GO; GO:0003723; F:RNA binding; HDA:UniProtKB. DR GO; GO:0045182; F:translation regulator activity; ISS:BHF-UCL. DR GO; GO:0009653; P:anatomical structure morphogenesis; TAS:ProtInc. DR GO; GO:0070934; P:CRD-mediated mRNA stabilization; IDA:UniProtKB. DR GO; GO:0051028; P:mRNA transport; IEA:UniProtKB-KW. DR GO; GO:0017148; P:negative regulation of translation; ISS:BHF-UCL. DR GO; GO:0007399; P:nervous system development; IBA:GO_Central. DR GO; GO:0001817; P:regulation of cytokine production; IC:BHF-UCL. DR GO; GO:0006412; P:translation; TAS:ProtInc. DR CDD; cd22492; KH-I_IGF2BP3_rpt1; 1. DR CDD; cd22498; KH-I_IGF2BP3_rpt3; 1. DR CDD; cd12627; RRM1_IGF2BP3; 1. DR CDD; cd12630; RRM2_IGF2BP3; 1. DR FunFam; 3.30.70.330:FF:000203; insulin-like growth factor 2 mRNA-binding protein 1; 1. DR FunFam; 3.30.310.210:FF:000001; insulin-like growth factor 2 mRNA-binding protein 1 isoform X1; 1. DR FunFam; 3.30.1370.10:FF:000026; Insulin-like growth factor 2 mRNA-binding protein 3; 1. DR FunFam; 3.30.1370.10:FF:000027; insulin-like growth factor 2 mRNA-binding protein 3 isoform X1; 1. DR FunFam; 3.30.70.330:FF:000099; insulin-like growth factor 2 mRNA-binding protein 3 isoform X1; 1. DR Gene3D; 3.30.310.210; -; 1. DR Gene3D; 3.30.70.330; -; 2. DR Gene3D; 3.30.1370.10; K Homology domain, type 1; 2. DR InterPro; IPR004087; KH_dom. DR InterPro; IPR004088; KH_dom_type_1. DR InterPro; IPR036612; KH_dom_type_1_sf. DR InterPro; IPR012677; Nucleotide-bd_a/b_plait_sf. DR InterPro; IPR035979; RBD_domain_sf. DR InterPro; IPR000504; RRM_dom. DR PANTHER; PTHR10288; KH DOMAIN CONTAINING RNA BINDING PROTEIN; 1. DR Pfam; PF00013; KH_1; 4. DR Pfam; PF00076; RRM_1; 2. DR SMART; SM00322; KH; 4. DR SMART; SM00360; RRM; 2. DR SUPFAM; SSF54791; Eukaryotic type KH-domain (KH-domain type I); 4. DR SUPFAM; SSF54928; RNA-binding domain, RBD; 1. DR PROSITE; PS50084; KH_TYPE_1; 4. DR PROSITE; PS50102; RRM; 2. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Cytoplasm; Isopeptide bond; KW mRNA transport; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; RNA-binding; Translation regulation; Transport; KW Ubl conjugation. FT CHAIN 1..579 FT /note="Insulin-like growth factor 2 mRNA-binding protein 3" FT /id="PRO_0000282538" FT DOMAIN 2..75 FT /note="RRM 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00176" FT DOMAIN 81..156 FT /note="RRM 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00176" FT DOMAIN 195..260 FT /note="KH 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00117" FT DOMAIN 276..343 FT /note="KH 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00117" FT DOMAIN 405..470 FT /note="KH 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00117" FT DOMAIN 487..553 FT /note="KH 4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00117" FT REGION 160..192 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 177..187 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 184 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 528 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT CROSSLNK 450 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 475 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:28112733" FT VAR_SEQ 1..381 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_024172" FT MUTAGEN 213 FT /note="K->E: Partial reduction in interaction with m6A- FT modified mRNA; when associated with E-294. Loss of FT homo- and heterooligomerization with IGF2BP1 and IGF2BP2, FT modestly impaired binding to ACTB and MYC transcripts and FT almost no effect on ELAVL1-, DHX9- and HNRNPU-binding, nor FT on subcellular location; when associated with E-294; 422-E- FT E-423 and 505-E-E-506." FT /evidence="ECO:0000269|PubMed:23640942, FT ECO:0000269|PubMed:29476152" FT MUTAGEN 294 FT /note="K->E: Partial reduction in interaction with m6A- FT modified mRNA; when associated with E-213. Loss of FT homo- and heterooligomerization with IGF2BP1 and IGF2BP2, FT modestly impaired binding to ACTB and MYC transcripts and FT almost no effect on ELAVL1-, DHX9- and HNRNPU-binding, nor FT on subcellular location; when associated with E-213; 422-E- FT E-423 and 505-E-E-506." FT /evidence="ECO:0000269|PubMed:23640942, FT ECO:0000269|PubMed:29476152" FT MUTAGEN 423..424 FT /note="KQ->EE: Loss of interaction with m6A-modified mRNA; FT when associated with 505-E-E-506. Loss of homo- and FT heterooligomerization with IGF2BP1 and IGF2BP2, modestly FT impaired binding to ACTB and MYC transcripts and almost no FT effect on ELAVL1-, DHX9- and HNRNPU-binding, nor on FT subcellular location; when associated with E-213; E-294 and FT 505-E-E-506." FT /evidence="ECO:0000269|PubMed:23640942, FT ECO:0000269|PubMed:29476152" FT MUTAGEN 505..506 FT /note="KG->EE: Loss of interaction with m6A-modified mRNA; FT when associated with 422-E-E-423. Loss of homo- and FT heterooligomerization with IGF2BP1 and IGF2BP2, modestly FT impaired binding to ACTB and MYC transcripts and almost no FT effect on ELAVL1-, DHX9- and HNRNPU-binding, nor on FT subcellular location; when associated with E-213; E-294 and FT 422-E-E-423." FT /evidence="ECO:0000269|PubMed:23640942, FT ECO:0000269|PubMed:29476152" FT CONFLICT 410 FT /note="L -> Q (in Ref. 1; AAD09223/AAC35208)" FT /evidence="ECO:0000305" FT CONFLICT 494 FT /note="V -> A (in Ref. 2; CAH56186)" FT /evidence="ECO:0000305" FT STRAND 3..8 FT /evidence="ECO:0007829|PDB:6FQ1" FT HELIX 15..24 FT /evidence="ECO:0007829|PDB:6FQ1" FT STRAND 40..43 FT /evidence="ECO:0007829|PDB:6FQ1" FT HELIX 47..57 FT /evidence="ECO:0007829|PDB:6FQ1" FT TURN 58..60 FT /evidence="ECO:0007829|PDB:6FQ1" FT STRAND 61..63 FT /evidence="ECO:0007829|PDB:6GX6" FT STRAND 69..72 FT /evidence="ECO:0007829|PDB:6FQ1" FT HELIX 76..78 FT /evidence="ECO:0007829|PDB:6FQ1" FT STRAND 80..88 FT /evidence="ECO:0007829|PDB:6FQ1" FT STRAND 90..92 FT /evidence="ECO:0007829|PDB:2E44" FT HELIX 94..101 FT /evidence="ECO:0007829|PDB:6FQ1" FT STRAND 107..112 FT /evidence="ECO:0007829|PDB:6FQ1" FT STRAND 116..128 FT /evidence="ECO:0007829|PDB:6FQ1" FT HELIX 129..139 FT /evidence="ECO:0007829|PDB:6FQ1" FT STRAND 150..153 FT /evidence="ECO:0007829|PDB:6FQ1" FT HELIX 157..159 FT /evidence="ECO:0007829|PDB:6FQ1" FT STRAND 198..203 FT /evidence="ECO:0007829|PDB:6GQE" FT HELIX 204..206 FT /evidence="ECO:0007829|PDB:6GQE" FT HELIX 207..211 FT /evidence="ECO:0007829|PDB:6GQE" FT HELIX 213..215 FT /evidence="ECO:0007829|PDB:6GQE" FT HELIX 216..225 FT /evidence="ECO:0007829|PDB:6GQE" FT STRAND 228..233 FT /evidence="ECO:0007829|PDB:6GQE" FT STRAND 241..248 FT /evidence="ECO:0007829|PDB:6GQE" FT HELIX 250..270 FT /evidence="ECO:0007829|PDB:6GQE" FT STRAND 279..284 FT /evidence="ECO:0007829|PDB:6GQE" FT HELIX 285..287 FT /evidence="ECO:0007829|PDB:6GQE" FT HELIX 289..306 FT /evidence="ECO:0007829|PDB:6GQE" FT STRAND 309..312 FT /evidence="ECO:0007829|PDB:6GQE" FT HELIX 315..317 FT /evidence="ECO:0007829|PDB:6GQE" FT STRAND 324..331 FT /evidence="ECO:0007829|PDB:6GQE" FT HELIX 333..351 FT /evidence="ECO:0007829|PDB:6GQE" SQ SEQUENCE 579 AA; 63705 MW; 78884F56A9D98CDE CRC64; MNKLYIGNLS ENAAPSDLES IFKDAKIPVS GPFLVKTGYA FVDCPDESWA LKAIEALSGK IELHGKPIEV EHSVPKRQRI RKLQIRNIPP HLQWEVLDSL LVQYGVVESC EQVNTDSETA VVNVTYSSKD QARQALDKLN GFQLENFTLK VAYIPDEMAA QQNPLQQPRG RRGLGQRGSS RQGSPGSVSK QKPCDLPLRL LVPTQFVGAI IGKEGATIRN ITKQTQSKID VHRKENAGAA EKSITILSTP EGTSAACKSI LEIMHKEAQD IKFTEEIPLK ILAHNNFVGR LIGKEGRNLK KIEQDTDTKI TISPLQELTL YNPERTITVK GNVETCAKAE EEIMKKIRES YENDIASMNL QAHLIPGLNL NALGLFPPTS GMPPPTSGPP SAMTPPYPQF EQSETETVHL FIPALSVGAI IGKQGQHIKQ LSRFAGASIK IAPAEAPDAK VRMVIITGPP EAQFKAQGRI YGKIKEENFV SPKEEVKLEA HIRVPSFAAG RVIGKGGKTV NELQNLSSAE VVVPRDQTPD ENDQVVVKIT GHFYACQVAQ RKIQEILTQV KQHQQQKALQ SGPPQSRRK // ID INSRR_HUMAN Reviewed; 1297 AA. AC P14616; O60724; Q5VZS3; DT 01-APR-1990, integrated into UniProtKB/Swiss-Prot. DT 11-JAN-2001, sequence version 2. DT 28-JAN-2026, entry version 220. DE RecName: Full=Insulin receptor-related protein; DE Short=IRR; DE EC=2.7.10.1; DE AltName: Full=IR-related receptor; DE Contains: DE RecName: Full=Insulin receptor-related protein alpha chain; DE Contains: DE RecName: Full=Insulin receptor-related protein beta chain; DE Flags: Precursor; GN Name=INSRR; Synonyms=IRR; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Kidney; RX PubMed=10226785; DOI=10.1055/s-2007-978702; RA Haenze J., Berthold A., Klammt J., Gallaher B., Siebler T., Kratzsch J., RA Elmlinger M., Kiess W.; RT "Cloning and sequencing of the complete cDNA encoding the human insulin RT receptor related receptor."; RL Horm. Metab. Res. 31:77-79(1999). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] OF 30-1297. RX PubMed=2768234; DOI=10.1016/s0021-9258(18)63737-8; RA Shier P., Watt V.M.; RT "Primary structure of a putative receptor for a ligand of the insulin RT family."; RL J. Biol. Chem. 264:14605-14608(1989). RN [5] RP VARIANTS [LARGE SCALE ANALYSIS] GLU-127; VAL-161; HIS-244; ARG-246; RP GLN-278; CYS-554; LEU-928 AND GLU-1065. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [6] RP FUNCTION, MUTAGENESIS OF 1145-TYR-TYR-1146, AND AUTOPHOSPHORYLATION. RX PubMed=21641549; DOI=10.1016/j.cmet.2011.03.022; RA Deyev I.E., Sohet F., Vassilenko K.P., Serova O.V., Popova N.V., RA Zozulya S.A., Burova E.B., Houillier P., Rzhevsky D.I., Berchatova A.A., RA Murashev A.N., Chugunov A.O., Efremov R.G., Nikol'sky N.N., Bertelli E., RA Eladari D., Petrenko A.G.; RT "Insulin receptor-related receptor as an extracellular alkali sensor."; RL Cell Metab. 13:679-689(2011). CC -!- FUNCTION: Receptor with tyrosine-protein kinase activity. Functions as CC a pH sensing receptor which is activated by increased extracellular pH. CC Activates an intracellular signaling pathway that involves IRS1 and CC AKT1/PKB. {ECO:0000269|PubMed:21641549}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Probable tetramer of 2 alpha and 2 beta chains linked by CC disulfide bonds. The alpha chains contribute to the formation of the CC ligand-binding domain, while the beta chains carry the kinase domain. CC -!- INTERACTION: CC P14616; P08238: HSP90AB1; NbExp=4; IntAct=EBI-6424336, EBI-352572; CC P14616; P06213: INSR; NbExp=6; IntAct=EBI-6424336, EBI-475899; CC P14616; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-6424336, EBI-16439278; CC -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein. CC -!- DOMAIN: The extracellular domain is required for sensing alterations in CC external pH. CC -!- PTM: Autophosphorylated on tyrosine residues between pH 7.9 and pH CC 10.5. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF064078; AAC17167.1; -; mRNA. DR EMBL; AL158169; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471121; EAW52903.1; -; Genomic_DNA. DR EMBL; J05046; AAC31759.1; -; mRNA. DR CCDS; CCDS1160.1; -. DR PIR; B36502; B36502. DR RefSeq; NP_055030.1; NM_014215.3. DR PDB; 7PL4; NMR; -; A=918-948. DR PDB; 7TYJ; EM; 3.30 A; A/B=1-1297. DR PDB; 7TYK; EM; 3.50 A; A/B=1-1297. DR PDB; 7TYM; EM; 3.40 A; A/B=1-1297. DR PDBsum; 7PL4; -. DR PDBsum; 7TYJ; -. DR PDBsum; 7TYK; -. DR PDBsum; 7TYM; -. DR AlphaFoldDB; P14616; -. DR EMDB; EMD-26181; -. DR EMDB; EMD-26183; -. DR EMDB; EMD-26185; -. DR SASBDB; P14616; -. DR SMR; P14616; -. DR BioGRID; 109856; 97. DR FunCoup; P14616; 135. DR IntAct; P14616; 82. DR MINT; P14616; -. DR STRING; 9606.ENSP00000357178; -. DR BindingDB; P14616; -. DR ChEMBL; CHEMBL5483; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; P14616; -. DR GuidetoPHARMACOLOGY; 1802; -. DR GlyCosmos; P14616; 10 sites, No reported glycans. DR GlyGen; P14616; 12 sites. DR iPTMnet; P14616; -. DR PhosphoSitePlus; P14616; -. DR BioMuta; INSRR; -. DR DMDM; 12644000; -. DR jPOST; P14616; -. DR MassIVE; P14616; -. DR PaxDb; 9606-ENSP00000357178; -. DR PeptideAtlas; P14616; -. DR Antibodypedia; 20446; 388 antibodies from 34 providers. DR DNASU; 3645; -. DR Ensembl; ENST00000368195.4; ENSP00000357178.3; ENSG00000027644.5. DR GeneID; 3645; -. DR KEGG; hsa:3645; -. DR MANE-Select; ENST00000368195.4; ENSP00000357178.3; NM_014215.3; NP_055030.1. DR UCSC; uc010pht.3; human. DR AGR; HGNC:6093; -. DR ClinPGx; PA29899; -. DR CTD; 3645; -. DR DisGeNET; 3645; -. DR GeneCards; INSRR; -. DR HGNC; HGNC:6093; INSRR. DR HPA; ENSG00000027644; Tissue enhanced (kidney, testis). DR MIM; 147671; gene. DR OpenTargets; ENSG00000027644; -. DR VEuPathDB; HostDB:ENSG00000027644; -. DR eggNOG; KOG1095; Eukaryota. DR eggNOG; KOG4258; Eukaryota. DR GeneTree; ENSGT00940000160437; -. DR HOGENOM; CLU_000288_166_0_1; -. DR InParanoid; P14616; -. DR OMA; IQRGHVY; -. DR OrthoDB; 5809444at2759; -. DR PAN-GO; P14616; 8 GO annotations based on evolutionary models. DR PhylomeDB; P14616; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P14616; -. DR SignaLink; P14616; -. DR Agora; ENSG00000027644; -. DR BioGRID-ORCS; 3645; 12 hits in 1175 CRISPR screens. DR GeneWiki; INSRR; -. DR GenomeRNAi; 3645; -. DR Pharos; P14616; Tchem. DR PRO; PR:P14616; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; P14616; protein. DR Bgee; ENSG00000027644; Expressed in adult mammalian kidney and 60 other cell types or tissues. DR GO; GO:0030424; C:axon; IBA:GO_Central. DR GO; GO:0005899; C:insulin receptor complex; IBA:GO_Central. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005009; F:insulin receptor activity; IBA:GO_Central. DR GO; GO:0043560; F:insulin receptor substrate binding; IBA:GO_Central. DR GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IEA:InterPro. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0030036; P:actin cytoskeleton organization; IDA:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; NAS:UniProtKB. DR GO; GO:0071469; P:cellular response to alkaline pH; IDA:UniProtKB. DR GO; GO:0008286; P:insulin receptor signaling pathway; IBA:GO_Central. DR GO; GO:0030238; P:male sex determination; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB. DR CDD; cd00063; FN3; 3. DR CDD; cd00064; FU; 1. DR CDD; cd05032; PTKc_InsR_like; 1. DR FunFam; 1.10.510.10:FF:000050; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.10.220.10:FF:000014; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000087; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000108; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:001636; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.30.200.20:FF:000026; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.80.20.20:FF:000001; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.80.20.20:FF:000002; Tyrosine-protein kinase receptor; 1. DR Gene3D; 2.10.220.10; Hormone Receptor, Insulin-like Growth Factor Receptor 1, Chain A, domain 2; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 4. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.20.20; Receptor L-domain; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR006211; Furin-like_Cys-rich_dom. DR InterPro; IPR006212; Furin_repeat. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR000494; Rcpt_L-dom. DR InterPro; IPR036941; Rcpt_L-dom_sf. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt. DR InterPro; IPR002011; Tyr_kinase_rcpt_2_CS. DR PANTHER; PTHR24416:SF338; INSULIN RECEPTOR-RELATED PROTEIN; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00041; fn3; 1. DR Pfam; PF00757; Furin-like; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF01030; Recep_L_domain; 2. DR PIRSF; PIRSF000620; Insulin_receptor; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00060; FN3; 3. DR SMART; SM00261; FU; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 3. DR SUPFAM; SSF57184; Growth factor receptor domain; 1. DR SUPFAM; SSF52058; L domain-like; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50853; FN3; 3. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Cleavage on pair of basic residues; KW Disulfide bond; Glycoprotein; Kinase; Membrane; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome; KW Repeat; Signal; Transferase; Transmembrane; Transmembrane helix; KW Tyrosine-protein kinase. FT SIGNAL 1..26 FT /evidence="ECO:0000255" FT CHAIN 27..1297 FT /note="Insulin receptor-related protein" FT /id="PRO_0000016701" FT CHAIN 27..742 FT /note="Insulin receptor-related protein alpha chain" FT /evidence="ECO:0000305" FT /id="PRO_0000016702" FT CHAIN 747..1297 FT /note="Insulin receptor-related protein beta chain" FT /evidence="ECO:0000305" FT /id="PRO_0000016703" FT TOPO_DOM 747..921 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 922..943 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 944..1297 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 483..603 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 607..707 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 818..913 FT /note="Fibronectin type-III 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 979..1254 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 666..687 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 732..758 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1267..1297 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 675..685 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1281..1297 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 1115 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 985..993 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 1013 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 1145 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305" FT MOD_RES 1146 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305" FT CARBOHYD 47 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 311 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 411 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 492 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 528 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 616 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 634 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 756 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 885 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 898 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 214..222 FT /evidence="ECO:0000250" FT DISULFID 216..228 FT /evidence="ECO:0000250" FT DISULFID 229..237 FT /evidence="ECO:0000250" FT DISULFID 233..246 FT /evidence="ECO:0000250" FT DISULFID 249..258 FT /evidence="ECO:0000250" FT DISULFID 262..274 FT /evidence="ECO:0000250" FT DISULFID 280..300 FT /evidence="ECO:0000250" FT DISULFID 304..317 FT /evidence="ECO:0000250" FT DISULFID 320..324 FT /evidence="ECO:0000250" FT DISULFID 657..864 FT /note="Interchain (between alpha and beta chains)" FT /evidence="ECO:0000255" FT VARIANT 127 FT /note="A -> E (in dbSNP:rs55757706)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041434" FT VARIANT 161 FT /note="A -> V (in dbSNP:rs55971900)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041435" FT VARIANT 244 FT /note="R -> H (in dbSNP:rs55951840)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041436" FT VARIANT 246 FT /note="C -> R (in dbSNP:rs56377825)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041437" FT VARIANT 278 FT /note="E -> Q (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs770398033)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041438" FT VARIANT 554 FT /note="R -> C (in dbSNP:rs56068937)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041439" FT VARIANT 928 FT /note="P -> L (in dbSNP:rs56252149)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041440" FT VARIANT 1065 FT /note="G -> E (in a glioblastoma multiforme sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041441" FT MUTAGEN 1145..1146 FT /note="YY->FF: Abolishes autophosphorylation." FT /evidence="ECO:0000269|PubMed:21641549" FT STRAND 31..37 FT /evidence="ECO:0007829|PDB:7TYJ" FT HELIX 40..45 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 51..60 FT /evidence="ECO:0007829|PDB:7TYJ" FT TURN 65..70 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 78..81 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 83..88 FT /evidence="ECO:0007829|PDB:7TYJ" FT TURN 95..97 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 113..119 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 138..142 FT /evidence="ECO:0007829|PDB:7TYJ" FT HELIX 155..157 FT /evidence="ECO:0007829|PDB:7TYJ" FT HELIX 162..164 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 169..171 FT /evidence="ECO:0007829|PDB:7TYJ" FT TURN 173..175 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 181..185 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 193..198 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 200..202 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 205..208 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 215..219 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 237..239 FT /evidence="ECO:0007829|PDB:7TYK" FT HELIX 243..245 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 247..253 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 258..261 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 266..269 FT /evidence="ECO:0007829|PDB:7TYJ" FT TURN 270..272 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 273..276 FT /evidence="ECO:0007829|PDB:7TYJ" FT HELIX 277..282 FT /evidence="ECO:0007829|PDB:7TYJ" FT HELIX 296..298 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 301..303 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 311..315 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 321..323 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 327..335 FT /evidence="ECO:0007829|PDB:7TYJ" FT HELIX 338..341 FT /evidence="ECO:0007829|PDB:7TYJ" FT HELIX 342..344 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 349..356 FT /evidence="ECO:0007829|PDB:7TYJ" FT HELIX 365..371 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 372..374 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 377..380 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 382..386 FT /evidence="ECO:0007829|PDB:7TYJ" FT TURN 409..411 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 412..417 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 430..432 FT /evidence="ECO:0007829|PDB:7TYK" FT STRAND 437..444 FT /evidence="ECO:0007829|PDB:7TYJ" FT HELIX 450..460 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 463..465 FT /evidence="ECO:0007829|PDB:7TYM" FT TURN 468..470 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 473..476 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 489..494 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 496..503 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 509..512 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 516..523 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 525..527 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 547..549 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 552..556 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 560..564 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 570..577 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 596..599 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 609..617 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 620..626 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 637..645 FT /evidence="ECO:0007829|PDB:7TYJ" FT HELIX 649..651 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 657..659 FT /evidence="ECO:0007829|PDB:7TYM" FT HELIX 704..718 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 763..776 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 782..792 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 794..797 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 805..808 FT /evidence="ECO:0007829|PDB:7TYJ" FT TURN 813..816 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 823..827 FT /evidence="ECO:0007829|PDB:7TYM" FT TURN 828..830 FT /evidence="ECO:0007829|PDB:7TYM" FT STRAND 832..835 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 846..858 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 861..866 FT /evidence="ECO:0007829|PDB:7TYJ" FT HELIX 867..873 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 874..878 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 883..896 FT /evidence="ECO:0007829|PDB:7TYJ" FT STRAND 905..909 FT /evidence="ECO:0007829|PDB:7TYJ" FT HELIX 920..926 FT /evidence="ECO:0007829|PDB:7PL4" FT HELIX 928..946 FT /evidence="ECO:0007829|PDB:7PL4" SQ SEQUENCE 1297 AA; 143720 MW; BB22C7FF61E3065D CRC64; MAVPSLWPWG ACLPVIFLSL GFGLDTVEVC PSLDIRSEVA ELRQLENCSV VEGHLQILLM FTATGEDFRG LSFPRLTQVT DYLLLFRVYG LESLRDLFPN LAVIRGTRLF LGYALVIFEM PHLRDVALPA LGAVLRGAVR VEKNQELCHL STIDWGLLQP APGANHIVGN KLGEECADVC PGVLGAAGEP CAKTTFSGHT DYRCWTSSHC QRVCPCPHGM ACTARGECCH TECLGGCSQP EDPRACVACR HLYFQGACLW ACPPGTYQYE SWRCVTAERC ASLHSVPGRA STFGIHQGSC LAQCPSGFTR NSSSIFCHKC EGLCPKECKV GTKTIDSIQA AQDLVGCTHV EGSLILNLRQ GYNLEPQLQH SLGLVETITG FLKIKHSFAL VSLGFFKNLK LIRGDAMVDG NYTLYVLDNQ NLQQLGSWVA AGLTIPVGKI YFAFNPRLCL EHIYRLEEVT GTRGRQNKAE INPRTNGDRA ACQTRTLRFV SNVTEADRIL LRWERYEPLE ARDLLSFIVY YKESPFQNAT EHVGPDACGT QSWNLLDVEL PLSRTQEPGV TLASLKPWTQ YAVFVRAITL TTEEDSPHQG AQSPIVYLRT LPAAPTVPQD VISTSNSSSH LLVRWKPPTQ RNGNLTYYLV LWQRLAEDGD LYLNDYCHRG LRLPTSNNDP RFDGEDGDPE AEMESDCCPC QHPPPGQVLP PLEAQEASFQ KKFENFLHNA ITIPISPWKV TSINKSPQRD SGRHRRAAGP LRLGGNSSDF EIQEDKVPRE RAVLSGLRHF TEYRIDIHAC NHAAHTVGCS AATFVFARTM PHREADGIPG KVAWEASSKN SVLLRWLEPP DPNGLILKYE IKYRRLGEEA TVLCVSRLRY AKFGGVHLAL LPPGNYSARV RATSLAGNGS WTDSVAFYIL GPEEEDAGGL HVLLTATPVG LTLLIVLAAL GFFYGKKRNR TLYASVNPEY FSASDMYVPD EWEVPREQIS IIRELGQGSF GMVYEGLARG LEAGEESTPV ALKTVNELAS PRECIEFLKE ASVMKAFKCH HVVRLLGVVS QGQPTLVIME LMTRGDLKSH LRSLRPEAEN NPGLPQPALG EMIQMAGEIA DGMAYLAANK FVHRDLAARN CMVSQDFTVK IGDFGMTRDV YETDYYRKGG KGLLPVRWMA PESLKDGIFT THSDVWSFGV VLWEIVTLAE QPYQGLSNEQ VLKFVMDGGV LEELEGCPLQ LQELMSRCWQ PNPRLRPSFT HILDSIQEEL RPSFRLLSFY YSPECRGARG SLPTTDAEPD SSPTPRDCSP QNGGPGH // ID INSR_HUMAN Reviewed; 1382 AA. AC P06213; Q17RW0; Q59H98; Q9UCB7; Q9UCB8; Q9UCB9; DT 01-JAN-1988, integrated into UniProtKB/Swiss-Prot. DT 05-OCT-2010, sequence version 4. DT 28-JAN-2026, entry version 294. DE RecName: Full=Insulin receptor; DE Short=IR; DE EC=2.7.10.1; DE AltName: CD_antigen=CD220; DE Contains: DE RecName: Full=Insulin receptor subunit alpha; DE Contains: DE RecName: Full=Insulin receptor subunit beta; DE Flags: Precursor; GN Name=INSR; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND VARIANTS GLY-2; HIS-171; RP THR-448 AND LYS-492. RX PubMed=2859121; DOI=10.1016/0092-8674(85)90334-4; RA Ebina Y., Ellis L., Jarnagin K., Edery M., Graf L., Clauser E., Ou J.-H., RA Masiarz F., Kan Y.W., Goldfine I.D., Roth R.A., Rutter W.J.; RT "The human insulin receptor cDNA: the structural basis for hormone- RT activated transmembrane signalling."; RL Cell 40:747-758(1985). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), PROTEIN SEQUENCE OF 28-49 AND RP 763-782, GLYCOSYLATION AT ASN-43 AND ASN-769, AND VARIANT GLY-2. RX PubMed=2983222; DOI=10.1038/313756a0; RA Ullrich A., Bell J.R., Chen E.Y., Herrera R., Petruzzelli L.M., Dull T.J., RA Gray A., Coussens L., Liao Y.-C., Tsubokawa M., Mason A., Seeburg P.H., RA Grunfeld C., Rosen O.M., Ramachandran J.; RT "Human insulin receptor and its relationship to the tyrosine kinase family RT of oncogenes."; RL Nature 313:756-761(1985). RN [3] RP SEQUENCE REVISION TO 899-900. RA Chen E.Y.; RL Submitted (JUL-1985) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLY-2. RC TISSUE=Fetal liver; RX PubMed=2210055; DOI=10.2337/diacare.39.1.123; RA Seino S., Seino M., Bell G.I.; RT "Human insulin-receptor gene. Partial sequence and amplification of exons RT by polymerase chain reaction."; RL Diabetes 39:123-128(1990). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SHORT), AND VARIANT GLY-2. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2. RX PubMed=3680248; DOI=10.1016/s0021-9258(18)47714-9; RA Araki E., Shimada F., Uzawa H., Mori M., Ebina Y.; RT "Characterization of the promoter region of the human insulin receptor RT gene. Evidence for promoter activity."; RL J. Biol. Chem. 262:16186-16191(1987). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2. RX PubMed=2806055; DOI=10.1016/0168-8227(89)90085-5; RA Araki E., Shimada F., Fukushima H., Mori M., Shichiri M., Ebina Y.; RT "Characterization of the promoter region of the human insulin receptor RT gene."; RL Diabetes Res. Clin. Pract. 7:S31-S33(1989). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2. RX PubMed=2777789; DOI=10.1016/s0021-9258(18)71612-8; RA Tewari D.S., Cook D.M., Taub R.; RT "Characterization of the promoter region and 3' end of the human insulin RT receptor gene."; RL J. Biol. Chem. 264:16238-16245(1989). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2. RC TISSUE=Skin fibroblast; RX PubMed=2280779; DOI=10.1210/mend-4-4-647; RA McKeon C., Moncada V., Pham T., Salvatore P., Kadowaki T., Accili D., RA Taylor S.I.; RT "Structural and functional analysis of the insulin receptor promoter."; RL Mol. Endocrinol. 4:647-656(1990). RN [11] RP PROTEIN SEQUENCE OF 28-44; 192-205; 299-314; 610-627 AND 763-780, ACTIVITY RP REGULATION, AND SUBUNIT. RC TISSUE=Placenta; RX PubMed=2211730; DOI=10.1016/s0021-9258(17)44805-8; RA Xu Q.-Y., Paxton R.J., Fujita-Yamaguchi Y.; RT "Substructural analysis of the insulin receptor by microsequence analyses RT of limited tryptic fragments isolated by sodium dodecyl sulfate- RT polyacrylamide gel electrophoresis in the absence or presence of RT dithiothreitol."; RL J. Biol. Chem. 265:18673-18681(1990). RN [12] RP PROTEIN SEQUENCE OF 28-45 AND 763-782, FUNCTION, AND FORMATION OF A HYBRID RP RECEPTOR WITH IGF1R. RC TISSUE=Placenta; RX PubMed=8257688; DOI=10.1021/bi00212a019; RA Kasuya J., Paz I.B., Maddux B.A., Goldfine I.D., Hefta S.A., RA Fujita-Yamaguchi Y.; RT "Characterization of human placental insulin-like growth factor-I/insulin RT hybrid receptors by protein microsequencing and purification."; RL Biochemistry 32:13531-13536(1993). RN [13] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 538-1382 (ISOFORM SHORT). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] OF 728-772 (ISOFORM LONG), AND ALTERNATIVE RP SPLICING. RX PubMed=2538124; DOI=10.1016/0006-291x(89)92439-x; RA Seino S., Bell G.I.; RT "Alternative splicing of human insulin receptor messenger RNA."; RL Biochem. Biophys. Res. Commun. 159:312-316(1989). RN [15] RP NUCLEOTIDE SEQUENCE [MRNA] OF 744-823 (ISOFORM LONG), TISSUE SPECIFICITY, RP LIGAND-BINDING, AND AUTOPHOSPHORYLATION. RX PubMed=2369896; DOI=10.1002/j.1460-2075.1990.tb07416.x; RA Mosthaf L., Grako K., Dull T.J., Coussens L., Ullrich A., McClain D.A.; RT "Functionally distinct insulin receptors generated by tissue-specific RT alternative splicing."; RL EMBO J. 9:2409-2413(1990). RN [16] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 895-1085. RX PubMed=2566545; DOI=10.2337/diab.38.6.737; RA Elbein S.C.; RT "Molecular and clinical characterization of an insertional polymorphism of RT the insulin-receptor gene."; RL Diabetes 38:737-743(1989). RN [17] RP PROTEIN SEQUENCE OF 927-956; 981-1019; 1182-1194 AND 1352-1369, AND RP PHOSPHORYLATION AT TYR-999; TYR-1355 AND TYR-1361. RC TISSUE=Placenta; RX PubMed=3166375; DOI=10.1042/bj2520607; RA Tavare J.M., Denton R.M.; RT "Studies on the autophosphorylation of the insulin receptor from human RT placenta. Analysis of the sites phosphorylated by two-dimensional peptide RT mapping."; RL Biochem. J. 252:607-615(1988). RN [18] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1006-1123. RX PubMed=2544997; DOI=10.1126/science.2544997; RA Taira M., Taira M., Hashimoto N., Shimada F., Suzuki Y., Kanatsuka A., RA Nakamura F., Ebina Y., Tatibana M., Makino H.; RT "Human diabetes associated with a deletion of the tyrosine kinase domain of RT the insulin receptor."; RL Science 245:63-66(1989). RN [19] RP PARTIAL PROTEIN SEQUENCE. RX PubMed=3447155; RA Fujita-Yamaguchi Y., Hawke D., Shively J.E., Choi S.; RT "Partial amino acid sequence analyses of human placental insulin RT receptor."; RL Protein Seq. Data Anal. 1:3-6(1987). RN [20] RP MUTAGENESIS OF LYS-1057. RX PubMed=3101064; DOI=10.1073/pnas.84.3.704; RA Ebina Y., Araki E., Taira M., Shimada F., Mori M., Craik C.S., Siddle K., RA Pierce S.B., Roth R.A., Rutter W.J.; RT "Replacement of lysine residue 1030 in the putative ATP-binding region of RT the insulin receptor abolishes insulin- and antibody-stimulated glucose RT uptake and receptor kinase activity."; RL Proc. Natl. Acad. Sci. U.S.A. 84:704-708(1987). RN [21] RP MUTAGENESIS OF TYR-999. RX PubMed=2842060; DOI=10.1016/s0092-8674(88)80008-4; RA White M.F., Livingston J.N., Backer J.M., Lauris V., Dull T.J., Ullrich A., RA Kahn C.R.; RT "Mutation of the insulin receptor at tyrosine 960 inhibits signal RT transmission but does not affect its tyrosine kinase activity."; RL Cell 54:641-649(1988). RN [22] RP AUTOPHOSPHORYLATION. RX PubMed=1321605; DOI=10.1016/s0006-291x(05)80799-5; RA Dickens M., Tavare J.M.; RT "Analysis of the order of autophosphorylation of human insulin receptor RT tyrosines 1158, 1162 and 1163."; RL Biochem. Biophys. Res. Commun. 186:244-250(1992). RN [23] RP DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-541. RX PubMed=1472036; DOI=10.1016/0006-291x(92)92250-2; RA Schaeffer L., Ljungqvist L.; RT "Identification of a disulfide bridge connecting the alpha-subunits of the RT extracellular domain of the insulin receptor."; RL Biochem. Biophys. Res. Commun. 189:650-653(1992). RN [24] RP FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R. RX PubMed=8452530; DOI=10.1042/bj2900419; RA Soos M.A., Field C.E., Siddle K.; RT "Purified hybrid insulin/insulin-like growth factor-I receptors bind RT insulin-like growth factor-I, but not insulin, with high affinity."; RL Biochem. J. 290:419-426(1993). RN [25] RP FUNCTION, AND INTERACTION WITH PIK3R1. RX PubMed=8276809; DOI=10.1016/s0021-9258(17)42304-0; RA Van Horn D.J., Myers M.G. Jr., Backer J.M.; RT "Direct activation of the phosphatidylinositol 3'-kinase by the insulin RT receptor."; RL J. Biol. Chem. 269:29-32(1994). RN [26] RP INTERACTION WITH IRS1 AND SHC1, AND MUTAGENESIS OF LEU-991; TYR-992; RP ASN-996; 996-ASN-PRO-997; PRO-997; TYR-999; LEU-1000 AND ALA-1002. RX PubMed=7559478; DOI=10.1074/jbc.270.40.23258; RA He W., O'Neill T.J., Gustafson T.A.; RT "Distinct modes of interaction of SHC and insulin receptor substrate-1 with RT the insulin receptor NPEY region via non-SH2 domains."; RL J. Biol. Chem. 270:23258-23262(1995). RN [27] RP INTERACTION WITH IRS1; SHC1 AND PIK3R1, AND MUTAGENESIS OF ASN-996; RP PRO-997; GLU-998; TYR-999 AND LYS-1057. RX PubMed=7537849; DOI=10.1128/mcb.15.5.2500; RA Gustafson T.A., He W., Craparo A., Schaub C.D., O'Neill T.J.; RT "Phosphotyrosine-dependent interaction of SHC and insulin receptor RT substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 RT domain."; RL Mol. Cell. Biol. 15:2500-2508(1995). RN [28] RP FORMATION OF A HYBRID RECEPTOR WITH IGF1R, AND TISSUE SPECIFICITY. RX PubMed=9355755; DOI=10.1042/bj3270209; RA Bailyes E.M., Nave B.T., Soos M.A., Orr S.R., Hayward A.C., Siddle K.; RT "Insulin receptor/IGF-I receptor hybrids are widely distributed in RT mammalian tissues: quantification of individual receptor species by RT selective immunoprecipitation and immunoblotting."; RL Biochem. J. 327:209-215(1997). RN [29] RP FUNCTION IN PHOSPHORYLATION OF STAT5B, MUTAGENESIS OF TYR-999, AND RP INTERACTION WITH STAT5B; IRS1 AND IRS2. RX PubMed=9428692; DOI=10.1111/j.1432-1033.1997.0411a.x; RA Sawka-Verhelle D., Filloux C., Tartare-Deckert S., Mothe I., RA Van Obberghen E.; RT "Identification of Stat 5B as a substrate of the insulin receptor."; RL Eur. J. Biochem. 250:411-417(1997). RN [30] RP INTERACTION WITH PTPRF. RX PubMed=8995282; DOI=10.1074/jbc.272.11.7519; RA Ahmad F., Goldstein B.J.; RT "Functional association between the insulin receptor and the transmembrane RT protein-tyrosine phosphatase LAR in intact cells."; RL J. Biol. Chem. 272:448-457(1997). RN [31] RP INTERACTION WITH PTPRE, AND DEPHOSPHORYLATION BY PTPRE. RX PubMed=8999839; DOI=10.1074/jbc.272.3.1639; RA Bandyopadhyay D., Kusari A., Kenner K.A., Liu F., Chernoff J., RA Gustafson T.A., Kusari J.; RT "Protein-tyrosine phosphatase 1B complexes with the insulin receptor in RT vivo and is tyrosine-phosphorylated in the presence of insulin."; RL J. Biol. Chem. 272:1639-1645(1997). RN [32] RP FORMATION OF A HYBRID RECEPTOR WITH IGF1R, AND TISSUE SPECIFICITY. RX PubMed=9202395; DOI=10.1016/s0303-7207(97)04050-1; RA Federici M., Porzio O., Zucaro L., Fusco A., Borboni P., Lauro D., RA Sesti G.; RT "Distribution of insulin/insulin-like growth factor-I hybrid receptors in RT human tissues."; RL Mol. Cell. Endocrinol. 129:121-126(1997). RN [33] RP TISSUE SPECIFICITY, AND FUNCTION AS RECEPTOR FOR IGFII (ISOFORM SHORT). RX PubMed=10207053; DOI=10.1128/mcb.19.5.3278; RA Frasca F., Pandini G., Scalia P., Sciacca L., Mineo R., Costantino A., RA Goldfine I.D., Belfiore A., Vigneri R.; RT "Insulin receptor isoform A, a newly recognized, high-affinity insulin-like RT growth factor II receptor in fetal and cancer cells."; RL Mol. Cell. Biol. 19:3278-3288(1999). RN [34] RP INTERACTION WITH ENPP1, AND ACTIVITY REGULATION. RX PubMed=10615944; DOI=10.2337/diabetes.49.1.13; RA Maddux B.A., Goldfine I.D.; RT "Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs RT via direct interaction with the receptor alpha-subunit."; RL Diabetes 49:13-19(2000). RN [35] RP PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPN1 AND PTPN2. RX PubMed=10734133; DOI=10.1074/jbc.275.13.9792; RA Waelchli S., Curchod M.L., Gobert R.P., Arkinstall S., RA Hooft van Huijsduijnen R.; RT "Identification of tyrosine phosphatases that dephosphorylate the insulin RT receptor. A brute force approach based on 'substrate-trapping' mutants."; RL J. Biol. Chem. 275:9792-9796(2000). RN [36] RP INTERACTION WITH GRB7, AND MUTAGENESIS OF LYS-1057; TYR-1189 AND TYR-1190. RX PubMed=10803466; DOI=10.1038/sj.onc.1203469; RA Kasus-Jacobi A., Bereziat V., Perdereau D., Girard J., Burnol A.F.; RT "Evidence for an interaction between the insulin receptor and Grb7. A role RT for two of its binding domains, PIR and SH2."; RL Oncogene 19:2052-2059(2000). RN [37] RP INTERACTION WITH SORBS1. RX PubMed=11374898; DOI=10.1006/geno.2001.6541; RA Lin W.-H., Huang C.-J., Liu M.-W., Chang H.-M., Chen Y.-J., Tai T.-Y., RA Chuang L.-M.; RT "Cloning, mapping, and characterization of the human sorbin and SH3 domain RT containing 1 (SORBS1) gene: a protein associated with c-Abl during insulin RT signaling in the hepatoma cell line Hep3B."; RL Genomics 74:12-20(2001). RN [38] RP CATALYTIC ACTIVITY, MUTAGENESIS OF ASP-1159 AND ARG-1163, AND ACTIVITY RP REGULATION. RX PubMed=11598120; DOI=10.1074/jbc.m107236200; RA Ablooglu A.J., Frankel M., Rusinova E., Ross J.B., Kohanski R.A.; RT "Multiple activation loop conformations and their regulatory properties in RT the insulin receptor's kinase domain."; RL J. Biol. Chem. 276:46933-46940(2001). RN [39] RP INTERACTION WITH GRB14, AND ACTIVITY REGULATION. RX PubMed=11726652; DOI=10.1074/jbc.m106574200; RA Bereziat V., Kasus-Jacobi A., Perdereau D., Cariou B., Girard J., RA Burnol A.F.; RT "Inhibition of insulin receptor catalytic activity by the molecular adapter RT Grb14."; RL J. Biol. Chem. 277:4845-4852(2002). RN [40] RP FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R. RX PubMed=12138094; DOI=10.1074/jbc.m202766200; RA Pandini G., Frasca F., Mineo R., Sciacca L., Vigneri R., Belfiore A.; RT "Insulin/insulin-like growth factor I hybrid receptors have different RT biological characteristics depending on the insulin receptor isoform RT involved."; RL J. Biol. Chem. 277:39684-39695(2002). RN [41] RP INTERACTION WITH GRB10, AND ACTIVITY REGULATION. RX PubMed=12493740; DOI=10.1074/jbc.m208518200; RA Wick K.R., Werner E.D., Langlais P., Ramos F.J., Dong L.Q., Shoelson S.E., RA Liu F.; RT "Grb10 inhibits insulin-stimulated insulin receptor substrate (IRS)- RT phosphatidylinositol 3-kinase/Akt signaling pathway by disrupting the RT association of IRS-1/IRS-2 with the insulin receptor."; RL J. Biol. Chem. 278:8460-8467(2003). RN [42] RP PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPN2. RX PubMed=12612081; DOI=10.1128/mcb.23.6.2096-2108.2003; RA Galic S., Klingler-Hoffmann M., Fodero-Tavoletti M.T., Puryer M.A., RA Meng T.C., Tonks N.K., Tiganis T.; RT "Regulation of insulin receptor signaling by the protein tyrosine RT phosphatase TCPTP."; RL Mol. Cell. Biol. 23:2096-2108(2003). RN [43] RP INTERACTION WITH SOCS7. RX PubMed=16127460; DOI=10.1172/jci23853; RA Banks A.S., Li J., McKeag L., Hribal M.L., Kashiwada M., Accili D., RA Rothman P.B.; RT "Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of RT Langerhans."; RL J. Clin. Invest. 115:2462-2471(2005). RN [44] RP FUNCTION IN PHOSPHORYLATION OF PDPK1, AND INTERACTION WITH PDPK1. RX PubMed=16314505; DOI=10.1128/mcb.25.24.10803-10814.2005; RA Fiory F., Alberobello A.T., Miele C., Oriente F., Esposito I., Corbo V., RA Ruvo M., Tizzano B., Rasmussen T.E., Gammeltoft S., Formisano P., RA Beguinot F.; RT "Tyrosine phosphorylation of phosphoinositide-dependent kinase 1 by the RT insulin receptor is necessary for insulin metabolic signaling."; RL Mol. Cell. Biol. 25:10803-10814(2005). RN [45] RP DEPHOSPHORYLATION BY PTPRE. RX PubMed=15738637; DOI=10.2108/zsj.22.169; RA Nakagawa Y., Aoki N., Aoyama K., Shimizu H., Shimano H., Yamada N., RA Miyazaki H.; RT "Receptor-type protein tyrosine phosphatase epsilon (PTPepsilonM) is a RT negative regulator of insulin signaling in primary hepatocytes and liver."; RL Zool. Sci. 22:169-175(2005). RN [46] RP FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R. RX PubMed=16831875; DOI=10.1074/jbc.m605189200; RA Slaaby R., Schaeffer L., Lautrup-Larsen I., Andersen A.S., Shaw A.C., RA Mathiasen I.S., Brandt J.; RT "Hybrid receptors formed by insulin receptor (IR) and insulin-like growth RT factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity RT irrespective of the IR splice variant."; RL J. Biol. Chem. 281:25869-25874(2006). RN [47] RP REVIEW ON SIGNALING PATHWAYS. RX PubMed=16493415; DOI=10.1038/nrm1837; RA Taniguchi C.M., Emanuelli B., Kahn C.R.; RT "Critical nodes in signalling pathways: insights into insulin action."; RL Nat. Rev. Mol. Cell Biol. 7:85-96(2006). RN [48] RP REVIEW ON REGULATION OF INSR FUNCTION. RX PubMed=17347799; DOI=10.1007/s00018-007-6359-9; RA Youngren J.F.; RT "Regulation of insulin receptor function."; RL Cell. Mol. Life Sci. 64:873-891(2007). RN [49] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-400; TYR-401 AND SER-407, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [50] RP DOMAIN, AND INSULIN-BINDING SITE. RX PubMed=19459609; DOI=10.1021/bi900261q; RA Menting J.G., Ward C.W., Margetts M.B., Lawrence M.C.; RT "A thermodynamic study of ligand binding to the first three domains of the RT human insulin receptor: relationship between the receptor alpha-chain C- RT terminal peptide and the site 1 insulin mimetic peptides."; RL Biochemistry 48:5492-5500(2009). RN [51] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-242 AND ASN-541. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). RN [52] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [53] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-445 AND ASN-920. RC TISSUE=Leukemic T-cell; RX PubMed=19349973; DOI=10.1038/nbt.1532; RA Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M., RA Schiess R., Aebersold R., Watts J.D.; RT "Mass-spectrometric identification and relative quantification of N-linked RT cell surface glycoproteins."; RL Nat. Biotechnol. 27:378-386(2009). RN [54] RP INTERACTION WITH NCK1, AND PHOSPHORYLATION AT TYR-1189 AND TYR-1190. RX PubMed=21707536; DOI=10.1042/bj20110799; RA Wu C.L., Buszard B., Teng C.H., Chen W.L., Warr C.G., Tiganis T., RA Meng T.C.; RT "Dock/Nck facilitates PTP61F/PTP1B regulation of insulin signalling."; RL Biochem. J. 439:151-159(2011). RN [55] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [56] RP INTERACTION WITH CCDC88A AND GNAI3. RX PubMed=25187647; DOI=10.1091/mbc.e14-05-0978; RA Lin C., Ear J., Midde K., Lopez-Sanchez I., Aznar N., Garcia-Marcos M., RA Kufareva I., Abagyan R., Ghosh P.; RT "Structural basis for activation of trimeric Gi proteins by multiple growth RT factor receptors via GIV/Girdin."; RL Mol. Biol. Cell 25:3654-3671(2014). RN [57] RP PHOSPHORYLATION AT TYR-1185 AND TYR-1190. RX PubMed=26584640; DOI=10.1038/cr.2015.133; RA Yin Y., Hua H., Li M., Liu S., Kong Q., Shao T., Wang J., Luo Y., Wang Q., RA Luo T., Jiang Y.; RT "mTORC2 promotes type I insulin-like growth factor receptor and insulin RT receptor activation through the tyrosine kinase activity of mTOR."; RL Cell Res. 26:46-65(2016). RN [58] RP MUTAGENESIS OF LYS-1079, AND UBIQUITINATION AT LYS-1079. RX PubMed=27577745; DOI=10.1038/ncomms12639; RA Nagarajan A., Petersen M.C., Nasiri A.R., Butrico G., Fung A., Ruan H.B., RA Kursawe R., Caprio S., Thibodeau J., Bourgeois-Daigneault M.C., Sun L., RA Gao G., Bhanot S., Jurczak M.J., Green M.R., Shulman G.I., Wajapeyee N.; RT "MARCH1 regulates insulin sensitivity by controlling cell surface insulin RT receptor levels."; RL Nat. Commun. 7:12639-12639(2016). RN [59] RP INTERACTION WITH SORL1. RX PubMed=27322061; DOI=10.1172/jci84708; RA Schmidt V., Schulz N., Yan X., Schuermann A., Kempa S., Kern M., RA Blueher M., Poy M.N., Olivecrona G., Willnow T.E.; RT "SORLA facilitates insulin receptor signaling in adipocytes and exacerbates RT obesity."; RL J. Clin. Invest. 126:2706-2720(2016). RN [60] RP SUBUNIT. RX PubMed=27617429; DOI=10.1038/nsmb.3292; RA Menting J.G., Gajewiak J., MacRaild C.A., Chou D.H., Disotuar M.M., RA Smith N.A., Miller C., Erchegyi J., Rivier J.E., Olivera B.M., Forbes B.E., RA Smith B.J., Norton R.S., Safavi-Hemami H., Lawrence M.C.; RT "A minimized human insulin-receptor-binding motif revealed in a Conus RT geographus venom insulin."; RL Nat. Struct. Mol. Biol. 23:916-920(2016). RN [61] RP S-NITROSYLATION AT CYS-1083, AND MUTAGENESIS OF CYS-462; CYS-825; CYS-834 RP AND CYS-1083. RX PubMed=38056462; DOI=10.1016/j.cell.2023.11.009; RA Zhou H.L., Grimmett Z.W., Venetos N.M., Stomberski C.T., Qian Z., RA McLaughlin P.J., Bansal P.K., Zhang R., Reynolds J.D., Premont R.T., RA Stamler J.S.; RT "An enzyme that selectively S-nitrosylates proteins to regulate insulin RT signaling."; RL Cell 0:0-0(2023). RN [62] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1005-1310. RX PubMed=7997262; DOI=10.1038/372746a0; RA Hubbard S.R., Wei L., Ellis L., Hendrickson W.A.; RT "Crystal structure of the tyrosine kinase domain of the human insulin RT receptor."; RL Nature 372:746-754(1994). RN [63] RP X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP RP ANALOG AND IRS1 PEPTIDE, CATALYTIC ACTIVITY, ACTIVE SITE, RP AUTOPHOSPHORYLATION, AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND RP TYR-1190. RX PubMed=9312016; DOI=10.1093/emboj/16.18.5572; RA Hubbard S.R.; RT "Crystal structure of the activated insulin receptor tyrosine kinase in RT complex with peptide substrate and ATP analog."; RL EMBO J. 16:5572-5581(1997). RN [64] RP X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP RP ANALOG, AND CATALYTIC ACTIVITY. RX PubMed=11124964; DOI=10.1074/jbc.m010161200; RA Till J.H., Ablooglu A.J., Frankel M., Bishop S.M., Kohanski R.A., RA Hubbard S.R.; RT "Crystallographic and solution studies of an activation loop mutant of the RT insulin receptor tyrosine kinase: insights into kinase mechanism."; RL J. Biol. Chem. 276:10049-10055(2001). RN [65] RP X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 1005-1298 OF MUTANT ASN-1159, RP CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF TYR-1011. RX PubMed=12707268; DOI=10.1074/jbc.m302425200; RA Li S., Covino N.D., Stein E.G., Till J.H., Hubbard S.R.; RT "Structural and biochemical evidence for an autoinhibitory role for RT tyrosine 984 in the juxtamembrane region of the insulin receptor."; RL J. Biol. Chem. 278:26007-26014(2003). RN [66] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP RP ANALOG AND SH2B2, AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190. RX PubMed=14690593; DOI=10.1016/s1097-2765(03)00487-8; RA Hu J., Liu J., Ghirlando R., Saltiel A.R., Hubbard S.R.; RT "Structural basis for recruitment of the adaptor protein APS to the RT activated insulin receptor."; RL Mol. Cell 12:1379-1389(2003). RN [67] RP X-RAY CRYSTALLOGRAPHY (3.20 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH GRB14, RP INTERACTION WITH GRB14, AUTOPHOSPHORYLATION, AND PHOSPHORYLATION AT RP TYR-1185; TYR-1189 AND TYR-1190. RX PubMed=16246733; DOI=10.1016/j.molcel.2005.09.001; RA Depetris R.S., Hu J., Gimpelevich I., Holt L.J., Daly R.J., Hubbard S.R.; RT "Structural basis for inhibition of the insulin receptor by the adaptor RT protein Grb14."; RL Mol. Cell 20:325-333(2005). RN [68] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH PTPN1, RP AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190. RX PubMed=16271887; DOI=10.1016/j.str.2005.07.019; RA Li S., Depetris R.S., Barford D., Chernoff J., Hubbard S.R.; RT "Crystal structure of a complex between protein tyrosine phosphatase 1B and RT the insulin receptor tyrosine kinase."; RL Structure 13:1643-1651(2005). RN [69] RP X-RAY CRYSTALLOGRAPHY (3.8 ANGSTROMS) OF 28-943 IN COMPLEX WITH INSULIN RP ANALOG, DOMAIN, AND DISULFIDE BONDS. RX PubMed=16957736; DOI=10.1038/nature05106; RA McKern N.M., Lawrence M.C., Streltsov V.A., Lou M.Z., Adams T.E., RA Lovrecz G.O., Elleman T.C., Richards K.M., Bentley J.D., Pilling P.A., RA Hoyne P.A., Cartledge K.A., Pham T.M., Lewis J.L., Sankovich S.E., RA Stoichevska V., Da Silva E., Robinson C.P., Frenkel M.J., Sparrow L.G., RA Fernley R.T., Epa V.C., Ward C.W.; RT "Structure of the insulin receptor ectodomain reveals a folded-over RT conformation."; RL Nature 443:218-221(2006). RN [70] RP X-RAY CRYSTALLOGRAPHY (2.32 ANGSTROMS) OF 28-512, GLYCOSYLATION AT ASN-43; RP ASN-52; ASN-138; ASN-242; ASN-282; ASN-364; ASN-424 AND ASN-445, AND RP DISULFIDE BONDS. RX PubMed=16894147; DOI=10.1073/pnas.0605395103; RA Lou M., Garrett T.P., McKern N.M., Hoyne P.A., Epa V.C., Bentley J.D., RA Lovrecz G.O., Cosgrove L.J., Frenkel M.J., Ward C.W.; RT "The first three domains of the insulin receptor differ structurally from RT the insulin-like growth factor 1 receptor in the regions governing ligand RT specificity."; RL Proc. Natl. Acad. Sci. U.S.A. 103:12429-12434(2006). RN [71] RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH ATP AND RP IRS2, CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-1185; TYR-1189 AND RP TYR-1190, AND INTERACTION WITH IRS2. RX PubMed=18278056; DOI=10.1038/nsmb.1388; RA Wu J., Tseng Y.D., Xu C.F., Neubert T.A., White M.F., Hubbard S.R.; RT "Structural and biochemical characterization of the KRLB region in insulin RT receptor substrate-2."; RL Nat. Struct. Mol. Biol. 15:251-258(2008). RN [72] RP X-RAY CRYSTALLOGRAPHY (3.25 ANGSTROMS) OF 1009-1310 IN COMPLEX WITH RP INHIBITORY PEPTIDE, AND PHOSPHORYLATION AT TYR-1185; TYR-1189 AND TYR-1190. RX PubMed=18767165; DOI=10.1002/prot.22207; RA Katayama N., Orita M., Yamaguchi T., Hisamichi H., Kuromitsu S., RA Kurihara H., Sakashita H., Matsumoto Y., Fujita S., Niimi T.; RT "Identification of a key element for hydrogen-bonding patterns between RT protein kinases and their inhibitors."; RL Proteins 73:795-801(2008). RN [73] RP X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH RP SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19071018; DOI=10.1016/j.bmcl.2008.11.077; RA Chamberlain S.D., Redman A.M., Wilson J.W., Deanda F., Shotwell J.B., RA Gerding R., Lei H., Yang B., Stevens K.L., Hassell A.M., Shewchuk L.M., RA Leesnitzer M.A., Smith J.L., Sabbatini P., Atkins C., Groy A., Rowand J.L., RA Kumar R., Mook R.A. Jr., Moorthy G., Patnaik S.; RT "Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R RT tyrosine kinase inhibitors towards JNK selectivity."; RL Bioorg. Med. Chem. Lett. 19:360-364(2009). RN [74] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH RP SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19056263; DOI=10.1016/j.bmcl.2008.11.046; RA Chamberlain S.D., Wilson J.W., Deanda F., Patnaik S., Redman A.M., Yang B., RA Shewchuk L., Sabbatini P., Leesnitzer M.A., Groy A., Atkins C., Gerding R., RA Hassell A.M., Lei H., Mook R.A. Jr., Moorthy G., Rowand J.L., Stevens K.L., RA Kumar R., Shotwell J.B.; RT "Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: potent RT inhibitors of the IGF-1R receptor tyrosine kinase."; RL Bioorg. Med. Chem. Lett. 19:469-473(2009). RN [75] RP X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 1017-1322 IN COMPLEX WITH RP SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19394223; DOI=10.1016/j.bmcl.2008.12.110; RA Patnaik S., Stevens K.L., Gerding R., Deanda F., Shotwell J.B., Tang J., RA Hamajima T., Nakamura H., Leesnitzer M.A., Hassell A.M., Shewchuck L.M., RA Kumar R., Lei H., Chamberlain S.D.; RT "Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent RT inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine RT kinase."; RL Bioorg. Med. Chem. Lett. 19:3136-3140(2009). RN [76] RP X-RAY CRYSTALLOGRAPHY (3.80 ANGSTROMS) OF 28-956, INSULIN-BINDING REGION, RP AND DISULFIDE BONDS. RX PubMed=20348418; DOI=10.1073/pnas.1001813107; RA Smith B.J., Huang K., Kong G., Chan S.J., Nakagawa S., Menting J.G., RA Hu S.Q., Whittaker J., Steiner D.F., Katsoyannis P.G., Ward C.W., RA Weiss M.A., Lawrence M.C.; RT "Structural resolution of a tandem hormone-binding element in the insulin RT receptor and its implications for design of peptide agonists."; RL Proc. Natl. Acad. Sci. U.S.A. 107:6771-6776(2010). RN [77] RP X-RAY CRYSTALLOGRAPHY (3.9 ANGSTROMS) OF 28-620 IN COMPLEX WITH INSULIN, RP DOMAIN, GLYCOSYLATION AT ASN-43; ASN-52; ASN-138; ASN-242 AND ASN-282, AND RP DISULFIDE BONDS. RX PubMed=23302862; DOI=10.1038/nature11781; RA Menting J.G., Whittaker J., Margetts M.B., Whittaker L.J., Kong G.K., RA Smith B.J., Watson C.J., Zakova L., Kletvikova E., Jiracek J., Chan S.J., RA Steiner D.F., Dodson G.G., Brzozowski A.M., Weiss M.A., Ward C.W., RA Lawrence M.C.; RT "How insulin engages its primary binding site on the insulin receptor."; RL Nature 493:241-245(2013). RN [78] RP VARIANT IRAN TYPE A SER-762. RX PubMed=3283938; DOI=10.1126/science.3283938; RA Yoshimasa Y., Seino S., Whittaker J., Kakehi T., Kosaki A., Kuzuya H., RA Imura H., Bell G.I., Steiner D.F.; RT "Insulin-resistant diabetes due to a point mutation that prevents insulin RT proreceptor processing."; RL Science 240:784-787(1988). RN [79] RP VARIANT LEPRCH GLU-487. RX PubMed=2834824; DOI=10.1126/science.2834824; RA Kadowaki T., Bevins C., Cama A., Ojamaa K., Marcus-Samuels B., Kadowaki H., RA Beitz L., McKeon C., Taylor S.I.; RT "Two mutant alleles of the insulin receptor gene in a patient with extreme RT insulin resistance."; RL Science 240:787-790(1988). RN [80] RP VARIANT LEPRCH PRO-260. RX PubMed=2479553; DOI=10.1002/j.1460-2075.1989.tb08387.x; RA Klinkhamer M.P., Groen N.A., van der Zon G.C.M., Lindhout D., RA Sandkuyl L.A., Krans H.M.J., Moeller W., Maassen J.A.; RT "A leucine-to-proline mutation in the insulin receptor in a family with RT insulin resistance."; RL EMBO J. 8:2503-2507(1989). RN [81] RP VARIANT IRAN TYPE A VAL-1035. RX PubMed=2544998; DOI=10.1126/science.2544998; RA Odawara M., Kadowaki T., Yamamoto R., Shibasaki Y., Tobe K., Accili D., RA Bevins C., Mikami Y., Matsuura N., Akanuma Y., Takaku F., Taylor S.I., RA Kasuga M.; RT "Human diabetes associated with a mutation in the tyrosine kinase domain of RT the insulin receptor."; RL Science 245:66-68(1989). RN [82] RP VARIANT IRAN TYPE A THR-1161. RX PubMed=2168397; DOI=10.1016/s0021-9258(18)77212-8; RA Moller D.E., Yokota A., White M.F., Pazianos A.G., Flier J.S.; RT "A naturally occurring mutation of insulin receptor alanine 1134 impairs RT tyrosine kinase function and is associated with dominantly inherited RT insulin resistance."; RL J. Biol. Chem. 265:14979-14985(1990). RN [83] RP CHARACTERIZATION OF VARIANT RMS LYS-42. RX PubMed=2121734; DOI=10.1016/s0021-9258(17)30636-1; RA Kadowaki T., Kadowaki H., Accili D., Taylor S.I.; RT "Substitution of lysine for asparagine at position 15 in the alpha-subunit RT of the human insulin receptor. A mutation that impairs transport of RT receptors to the cell surface and decreases the affinity of insulin RT binding."; RL J. Biol. Chem. 265:19143-19150(1990). RN [84] RP VARIANT RMS LYS-42, VARIANT LEPRCH ARG-236, AND VARIANT IRAN TYPE A RP SER-489. RX PubMed=2365819; DOI=10.1172/jci114693; RA Kadowaki T., Kadowaki H., Rechler M.M., Serrano-Rios M., Roth J., RA Gorden P., Taylor S.I.; RT "Five mutant alleles of the insulin receptor gene in patients with genetic RT forms of insulin resistance."; RL J. Clin. Invest. 86:254-264(1990). RN [85] RP VARIANT IRAN TYPE A SER-1227. RX PubMed=1963473; DOI=10.1210/mend-4-8-1183; RA Moller D.E., Yokota A., Ginsberg-Fellner F., Flier J.S.; RT "Functional properties of a naturally occurring Trp1200-->Ser1200 mutation RT of the insulin receptor."; RL Mol. Endocrinol. 4:1183-1191(1990). RN [86] RP VARIANT GLU-1095. RX PubMed=2040394; DOI=10.2337/diab.40.6.777; RA O'Rahilly S., Choi W.H., Patel P., Turner R.C., Flier J.S., Moller D.E.; RT "Detection of mutations in insulin-receptor gene in NIDDM patients by RT analysis of single-stranded conformation polymorphisms."; RL Diabetes 40:777-782(1991). RN [87] RP VARIANT IRAN TYPE A GLN-1020. RX PubMed=2002058; DOI=10.1016/s0021-9258(19)67781-1; RA Kusari J., Takata Y., Hatada E., Freidenberg G., Kolterman O., RA Olefsky J.M.; RT "Insulin resistance and diabetes due to different mutations in the tyrosine RT kinase domain of both insulin receptor gene alleles."; RL J. Biol. Chem. 266:5260-5267(1991). RN [88] RP VARIANT INS RESISTANCE ILE-1180. RX PubMed=1890161; DOI=10.1210/jcem-73-4-894; RA Cama A., de la Luz Sierra M., Ottini L., Kadowaki T., Gorden P., RA Imperato-Mcginley J., Taylor S.I.; RT "A mutation in the tyrosine kinase domain of the insulin receptor RT associated with insulin resistance in an obese woman."; RL J. Clin. Endocrinol. Metab. 73:894-901(1991). RN [89] RP VARIANTS LEPRCH ALA-55 AND ARG-393. RX PubMed=1607067; DOI=10.2337/diab.41.4.408; RA Barbetti F., Gejman P.V., Taylor S.I., Raben N., Cama A., Bonora E., RA Pizzo P., Moghetti P., Muggeo M., Roth J.; RT "Detection of mutations in insulin receptor gene by denaturing gradient gel RT electrophoresis."; RL Diabetes 41:408-415(1992). RN [90] RP VARIANT T2D GLN-1191. RX PubMed=1607076; DOI=10.2337/diab.41.4.521; RA Cocozza S., Porcellini A., Riccardi G., Monticelli A., Condorelli G., RA Ferrara A., Pianese L., Miele C., Capaldo B., Beguinot F., Varrone S.; RT "NIDDM associated with mutation in tyrosine kinase domain of insulin RT receptor gene."; RL Diabetes 41:521-526(1992). RN [91] RP VARIANT IRAN TYPE A LEU-1205. RX PubMed=1563582; DOI=10.1007/bf00400927; RA Kim H., Kadowaki H., Sakura H., Odawara M., Momomura K., Takahashi Y., RA Miyazaki Y., Ohtani T., Akanuma Y., Yazaki Y., Kasuga M., Taylor S.I., RA Kadowaki T.; RT "Detection of mutations in the insulin receptor gene in patients with RT insulin resistance by analysis of single-stranded conformational RT polymorphisms."; RL Diabetologia 35:261-266(1992). RN [92] RP VARIANT LEPRCH ARG-58. RX PubMed=1730625; DOI=10.1016/s0021-9258(18)48459-1; RA van der Vorm E.R., van der Zon G.C.M., Moeller W., Krans H.M.J., RA Lindhout D., Maassen J.A.; RT "An Arg for Gly substitution at position 31 in the insulin receptor, linked RT to insulin resistance, inhibits receptor processing and transport."; RL J. Biol. Chem. 267:66-71(1992). RN [93] RP VARIANT T2D GLN-1158. RX PubMed=1470163; RA Kasuga M., Kishimoto M., Hashiramoto M., Yonezawa K., Kazumi T., Hagino H., RA Shii K.; RT "Insulin receptor Arg1131-->Gln: a novel mutation in the catalytic loop of RT insulin receptor observed in insulin resistant diabetes."; RL Nihon Geka Gakkai Zasshi 93:968-971(1992). RN [94] RP VARIANT MET-1012. RX PubMed=8432414; DOI=10.2337/diab.42.3.429; RA Elbein S.C., Sorensen L.K., Schumacher M.C.; RT "Methionine for valine substitution in exon 17 of the insulin receptor gene RT in a pedigree with familial NIDDM."; RL Diabetes 42:429-434(1993). RN [95] RP VARIANT IRAN TYPE A ASP-1075. RX PubMed=8243830; DOI=10.2337/diab.42.12.1837; RA Haruta T., Takata Y., Iwanishi M., Maegawa H., Imamura T., Egawa K., RA Itazu T., Kobayashi M.; RT "Ala1048-->Asp mutation in the kinase domain of insulin receptor causes RT defective kinase activity and insulin resistance."; RL Diabetes 42:1837-1844(1993). RN [96] RP VARIANT MET-1012. RX PubMed=8458533; DOI=10.1007/bf00400701; RA van der Vorm E.R., Kuipers A., Bonenkamp J.W., Kleijer W.J., RA van Maldergem L., Herwig J., Maassen J.A.; RT "Patients with lipodystrophic diabetes mellitus of the Seip-Berardinelli RT type, express normal insulin receptors."; RL Diabetologia 36:172-174(1993). RN [97] RP VARIANT INS RESISTANCE LEU-1220. RX PubMed=8390949; DOI=10.1007/bf00402277; RA Iwanishi M., Haruta T., Takata Y., Ishibashi O., Sasaoka T., Egawa K., RA Imamura T., Naitou K., Itazu T., Kobayashi M.; RT "A mutation (Trp1193-->Leu1193) in the tyrosine kinase domain of the RT insulin receptor associated with type A syndrome of insulin resistance."; RL Diabetologia 36:414-422(1993). RN [98] RP VARIANT INS RESISTANCE LEU-220. RX PubMed=8242067; DOI=10.1093/hmg/2.9.1437; RA Carrera P., Cordera R., Ferrari M., Cremonesi L., Taramelli R., RA Andraghetti G., Carducci C., Dozio N., Pozza G., Taylor S.I., Micossi P., RA Barbetti F.; RT "Substitution of Leu for Pro-193 in the insulin receptor in a patient with RT a genetic form of severe insulin resistance."; RL Hum. Mol. Genet. 2:1437-1441(1993). RN [99] RP CHARACTERIZATION OF VARIANT IRAN TYPE A GLU-1162. RX PubMed=8096518; DOI=10.1016/s0021-9258(18)53063-5; RA Cama A., de la Luz Sierra M., Quon M.J., Ottini L., Gorden P., Taylor S.I.; RT "Substitution of glutamic acid for alanine 1135 in the putative 'catalytic RT loop' of the tyrosine kinase domain of the human insulin receptor. A RT mutation that impairs proteolytic processing into subunits and inhibits RT receptor tyrosine kinase activity."; RL J. Biol. Chem. 268:8060-8069(1993). RN [100] RP VARIANT IRAN TYPE A VAL-409. RX PubMed=8388389; DOI=10.1016/s0021-9258(18)82120-2; RA Lebrun C., Baron V., Kaliman P., Gautier N., Dolais-Kitabgi J., RA Taylor S.I., Accili D., van Obberghen E.; RT "Antibodies to the extracellular receptor domain restore the hormone- RT insensitive kinase and conformation of the mutant insulin receptor valine RT 382."; RL J. Biol. Chem. 268:11272-11277(1993). RN [101] RP VARIANT LEPRCH MET-146. RX PubMed=8326490; DOI=10.1136/jmg.30.6.470; RA Al-Gazali L.I., Khalil M., Devadas K.; RT "A syndrome of insulin resistance resembling leprechaunism in five sibs of RT consanguineous parents."; RL J. Med. Genet. 30:470-475(1993). RN [102] RP VARIANT LEPRCH PRO-113. RX PubMed=8419945; DOI=10.1073/pnas.90.1.60; RA Longo N., Langley S.D., Griffin L.D., Elsas L.J.; RT "Activation of glucose transport by a natural mutation in the human insulin RT receptor."; RL Proc. Natl. Acad. Sci. U.S.A. 90:60-64(1993). RN [103] RP VARIANT IRAN TYPE A GLN-1201. RX PubMed=8288049; DOI=10.2337/diab.43.2.247; RA Moller D.E., Cohen O., Yamaguchi Y., Assiz R., Grigorescu F., Eberle A., RA Morrow L.A., Moses A.C., Flier J.S.; RT "Prevalence of mutations in the insulin receptor gene in subjects with RT features of the type A syndrome of insulin resistance."; RL Diabetes 43:247-255(1994). RN [104] RP VARIANT RMS SYNDROME LEU-350, VARIANTS IRAN TYPE A LEU-1205 AND GLN-1378, RP AND VARIANT MET-1012. RX PubMed=8314008; DOI=10.2337/diab.43.3.357; RA Krook A., Kumar S., Laing I., Boulton A.J., Wass J.A., O'Rahilly S.; RT "Molecular scanning of the insulin receptor gene in syndromes of insulin RT resistance."; RL Diabetes 43:357-368(1994). RN [105] RP CHARACTERIZATION OF VARIANT IRAN TYPE A GLN-1201. RX PubMed=8082780; DOI=10.1016/0014-5793(94)00876-0; RA Moritz W., Froesch E.R., Boeni-Schnetzler M.; RT "Functional properties of a heterozygous mutation (Arg1174-->Gln) in the RT tyrosine kinase domain of the insulin receptor from a type A insulin RT resistant patient."; RL FEBS Lett. 351:276-280(1994). RN [106] RP VARIANT LEPRCH SER-439. RX PubMed=8188715; DOI=10.1016/s0021-9258(17)36788-1; RA van der Vorm E.R., Kuipers A., Kielkopf-Renner S., Krans H.M.J., Moller W., RA Maassen J.A.; RT "A mutation in the insulin receptor that impairs proreceptor processing but RT not insulin binding."; RL J. Biol. Chem. 269:14297-14302(1994). RN [107] RP CHARACTERIZATION OF VARIANTS IRAN TYPE A ASP-1206 AND LEU-1220. RX PubMed=7983039; DOI=10.1016/s0021-9258(18)47384-x; RA Imamura T., Takata Y., Sasaoka T., Takada Y., Morioka H., Haruta T., RA Sawa T., Iwanishi M., Hu Y.G., Suzuki Y., Hamada J., Kobayashi M.; RT "Two naturally occurring mutations in the kinase domain of insulin receptor RT accelerate degradation of the insulin receptor and impair the kinase RT activity."; RL J. Biol. Chem. 269:31019-31027(1994). RN [108] RP VARIANT LEPRCH MET-146. RX PubMed=7815442; DOI=10.1136/jmg.31.9.715; RA Hone J., Accili D., al-Gazali L.I., Lestringant G., Orban T., Taylor S.I.; RT "Homozygosity for a new mutation (Ile119-->Met) in the insulin receptor RT gene in five sibs with familial insulin resistance."; RL J. Med. Genet. 31:715-716(1994). RN [109] RP VARIANT T2D ALA-858, AND VARIANT CYS-1361. RX PubMed=7657032; DOI=10.2337/diab.44.9.1081; RA Kan M., Kanai F., Iida M., Jinnouchi H., Todaka M., Imanaka T., Ito K., RA Nishioka Y., Ohnishi T., Kamohara S., Hayashi H., Murakami T., Kagawa S., RA Sano H., Hashimoto N., Yoshida S., Makino H., Ebina Y.; RT "Frequency of mutations of insulin receptor gene in Japanese patients with RT NIDDM."; RL Diabetes 44:1081-1086(1995). RN [110] RP VARIANT LEPRCH ASN-308 DEL. RX PubMed=7538143; DOI=10.1210/jcem.80.5.7538143; RA Longo N., Langley S.D., Griffin L.D., Elsas L.J.; RT "Two mutations in the insulin receptor gene of a patient with RT leprechaunism: application to prenatal diagnosis."; RL J. Clin. Endocrinol. Metab. 80:1496-1501(1995). RN [111] RP VARIANT PHE-1023. RX PubMed=8890729; DOI=10.1530/eje.0.1350357; RA Moritz W., Boeni-Schnetzler M., Stevens W., Froesch E.R., Levy J.R.; RT "In-frame exon 2 deletion in insulin receptor RNA in a family with extreme RT insulin resistance in association with defective insulin binding: a case RT report."; RL Eur. J. Endocrinol. 135:357-363(1996). RN [112] RP VARIANT LEPRCH ASN-308 DEL. RX PubMed=8636294; DOI=10.1210/jcem.81.2.8636294; RA Desbois-Mouthon C., Sert-Langeron C., Magre J., Oreal E., Blivet M.J., RA Flori E., Besmond C., Capeau J., Caron M.; RT "Deletion of Asn281 in the alpha-subunit of the human insulin receptor RT causes constitutive activation of the receptor and insulin RT desensitization."; RL J. Clin. Endocrinol. Metab. 81:719-727(1996). RN [113] RP VARIANT MET-1012. RX PubMed=9199575; DOI=10.1086/515464; RA Hansen L., Hansen T., Clausen J.O., Echwald S.M., Urhammer S.A., RA Rasmussen S.K., Pedersen O.; RT "The Val985Met insulin-receptor variant in the Danish Caucasian population: RT lack of associations with non-insulin-dependent diabetes mellitus or RT insulin resistance."; RL Am. J. Hum. Genet. 60:1532-1535(1997). RN [114] RP VARIANTS IRAN TYPE A GLY-86 AND PRO-89. RX PubMed=9175790; DOI=10.1006/bbrc.1997.6695; RA Rouard M., Macari F., Bouix O., Lautier C., Brun J.F., Lefebvre P., RA Renard E., Bringer J., Jaffiol C., Grigorescu F.; RT "Identification of two novel insulin receptor mutations, Asp59Gly and RT Leu62Pro, in type A syndrome of extreme insulin resistance."; RL Biochem. Biophys. Res. Commun. 234:764-768(1997). RN [115] RP CHARACTERIZATION OF VARIANT LEPRCH MET-937. RX PubMed=9299395; DOI=10.1006/bbrc.1997.7181; RA Kadowaki H., Takahashi Y., Ando A., Momomura K., Kaburagi Y., Quin J.D., RA MacCuish A.C., Koda N., Fukushima Y., Taylor S.I., Akanuma Y., Yazaki Y., RA Kadowaki T.; RT "Four mutant alleles of the insulin receptor gene associated with genetic RT syndromes of extreme insulin resistance."; RL Biochem. Biophys. Res. Commun. 237:516-520(1997). RN [116] RP VARIANTS LEPRCH TRP-1119 AND LYS-1206. RX PubMed=9249867; RX DOI=10.1002/(sici)1097-0223(199707)17:7<657::aid-pd132>3.3.co;2-#; RA Desbois-Mouthon C., Girodon E., Ghanem N., Caron M., Pennerath A., RA Conteville P., Magre J., Besmond C., Goossens M., Capeau J., Amselem S.; RT "Molecular analysis of the insulin receptor gene for prenatal diagnosis of RT leprechaunism in two families."; RL Prenat. Diagn. 17:657-663(1997). RN [117] RP VARIANTS LEPRCH TYR-301 AND TRP-1201. RX PubMed=9703342; DOI=10.2337/diab.47.8.1362; RA Whitehead J.P., Soos M.A., Jackson R., Tasic V., Kocova M., O'Rahilly S.; RT "Multiple molecular mechanisms of insulin receptor dysfunction in a patient RT with Donohue syndrome."; RL Diabetes 47:1362-1364(1998). RN [118] RP VARIANTS RMS THR-1143 AND TRP-1158. RX PubMed=10443650; DOI=10.1210/jcem.84.8.5902; RA Longo N., Wang Y., Pasquali M.; RT "Progressive decline in insulin levels in Rabson-Mendenhall syndrome."; RL J. Clin. Endocrinol. Metab. 84:2623-2629(1999). RN [119] RP VARIANTS IRAN TYPE A LEU-167 AND VAL-1055. RX PubMed=10733238; DOI=10.1034/j.1399-0004.2000.570110.x; RA Rique S., Nogues C., Ibanez L., Marcos M.V., Ferragut J., Carrascosa A., RA Potau N.; RT "Identification of three novel mutations in the insulin receptor gene in RT type A insulin resistant patients."; RL Clin. Genet. 57:67-69(2000). RN [120] RP VARIANT IRAN TYPE A TYR-280. RX PubMed=11260230; DOI=10.1034/j.1399-0004.2001.590309.x; RA Osawa H., Nishimiya T., Ochi M., Niiya T., Onuma H., Kitamuro F., Kaino Y., RA Kida K., Makino H.; RT "Identification of novel C253Y missense and Y864X nonsense mutations in the RT insulin receptor gene in type A insulin-resistant patients."; RL Clin. Genet. 59:194-197(2001). RN [121] RP VARIANT IRAN TYPE A CYS-279. RX PubMed=12107746; DOI=10.1007/s00125-002-0798-5; RA Hamer I., Foti M., Emkey R., Cordier-Bussat M., Philippe J., De Meyts P., RA Maeder C., Kahn C.R., Carpentier J.-L.; RT "An arginine to cysteine(252) mutation in insulin receptors from a patient RT with severe insulin resistance inhibits receptor internalisation but RT preserves signalling events."; RL Diabetologia 45:657-667(2002). RN [122] RP CHARACTERIZATION OF VARIANTS LEPRCH PRO-113; VAL-119; ASN-308 DEL; THR-925 RP AND TRP-926, AND VARIANTS RMS THR-997; THR-1143; TRP-1158 AND TRP-1201. RX PubMed=12023989; DOI=10.1093/hmg/11.12.1465; RA Longo N., Wang Y., Smith S.A., Langley S.D., DiMeglio L.A., RA Giannella-Neto D.; RT "Genotype-phenotype correlation in inherited severe insulin resistance."; RL Hum. Mol. Genet. 11:1465-1475(2002). RN [123] RP VARIANT LEPRCH VAL-362 DEL. RX PubMed=12538626; DOI=10.1210/en.2002-220815; RA George S., Johansen A., Soos M.A., Mortensen H., Gammeltoft S., Saudek V., RA Siddle K., Hansen L., O'Rahilly S.; RT "Deletion of V335 from the L2 domain of the insulin receptor results in a RT conformationally abnormal receptor that is unable to bind insulin and RT causes Donohue's syndrome in a human subject."; RL Endocrinology 144:631-637(2003). RN [124] RP VARIANT IRAN TYPE A HIS-279, VARIANTS LEPRCH GLN-120; LEU-350; ASP-458 AND RP TRP-1119, CHARACTERIZATION OF VARIANT IRAN TYPE A HIS-279, AND RP CHARACTERIZATION OF VARIANTS LEPRCH GLN-120 AND ASP-458. RX PubMed=12970295; DOI=10.1210/jc.2003-030034; RA Maassen J.A., Tobias E.S., Kayserilli H., Tukel T., Yuksel-Apak M., RA D'Haens E., Kleijer W.J., Fery F., van der Zon G.C.M.; RT "Identification and functional assessment of novel and known insulin RT receptor mutations in five patients with syndromes of severe insulin RT resistance."; RL J. Clin. Endocrinol. Metab. 88:4251-4257(2003). RN [125] RP VARIANT HHF5 GLN-1201. RX PubMed=15161766; DOI=10.2337/diabetes.53.6.1592; RA Hoejlund K., Hansen T., Lajer M., Henriksen J.E., Levin K., Lindholm J., RA Pedersen O., Bech-Nielsen H.; RT "A novel syndrome of autosomal-dominant hyperinsulinemic hypoglycemia RT linked to a mutation in the human insulin receptor gene."; RL Diabetes 53:1592-1598(2004). RN [126] RP VARIANTS RMS ARG-236 AND SER-386, AND CHARACTERIZATION OF VARIANTS RMS RP ARG-236 AND SER-386. RX PubMed=17201797; DOI=10.1111/j.1365-2265.2006.02678.x; RA Tuthill A., Semple R.K., Day R., Soos M.A., Sweeney E., Seymour P.J., RA Didi M., O'Rahilly S.; RT "Functional characterization of a novel insulin receptor mutation RT contributing to Rabson-Mendenhall syndrome."; RL Clin. Endocrinol. (Oxf.) 66:21-26(2007). RN [127] RP VARIANTS [LARGE SCALE ANALYSIS] ARG-228; ARG-695; SER-811; MET-1012; RP VAL-1065 AND ALA-1282. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [128] RP VARIANTS LEPRCH CYS-818 AND 890-ARG--SER-1382 DEL. RX PubMed=22768670; DOI=10.1515/jpem-2011-0448; RA Nobile S., Semple R.K., Carnielli V.P.; RT "A novel mutation of the insulin receptor gene in a preterm infant with RT Donohue syndrome and heart failure."; RL J. Pediatr. Endocrinol. Metab. 25:363-366(2012). RN [129] RP VARIANTS LEPRCH THR-56 AND TYR-286, AND CHARACTERIZATION OF VARIANTS LEPRCH RP THR-56 AND TYR-286. RX PubMed=24498630; DOI=10.1002/mgg3.43; RA Falik Zaccai T.C., Kalfon L., Klar A., Elisha M.B., Hurvitz H., RA Weingarten G., Chechik E., Fleisher Sheffer V., Haj Yahya R., Meidan G., RA Gross-Kieselstein E., Bauman D., Hershkovitz S., Yaron Y., Orr-Urtreger A., RA Wertheimer E.; RT "Two novel mutations identified in familial cases with Donohue syndrome."; RL Mol. Genet. Genomic Med. 2:64-72(2014). RN [130] RP VARIANTS RMS CYS-256; LEU-635; ILE-835; VAL-842; LEU-874; SER-878 AND RP 999-TYR--SER-1382 DEL, VARIANTS IRAN TYPE A ASP-489 AND MET-1054, VARIANTS RP LEPRCH PHE-657; ARG-659 AND CYS-818, CHARACTERIZATION OF VARIANTS LEPRCH RP PHE-657; ARG-659; CYS-818; THR-925; TRP-926 AND MET-937, AND RP CHARACTERIZATION OF VARIANTS RMS LEU-635; ILE-835; VAL-842; LEU-874 AND RP SER-878. RX PubMed=28765322; DOI=10.2337/db17-0301; RA Hosoe J., Kadowaki H., Miya F., Aizu K., Kawamura T., Miyata I., RA Satomura K., Ito T., Hara K., Tanaka M., Ishiura H., Tsuji S., Suzuki K., RA Takakura M., Boroevich K.A., Tsunoda T., Yamauchi T., Shojima N., RA Kadowaki T.; RT "Structural Basis and Genotype-Phenotype Correlations of INSR Mutations RT Causing Severe Insulin Resistance."; RL Diabetes 66:2713-2723(2017). CC -!- FUNCTION: Receptor tyrosine kinase which mediates the pleiotropic CC actions of insulin. Binding of insulin leads to phosphorylation of CC several intracellular substrates, including, insulin receptor CC substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling CC intermediates. Each of these phosphorylated proteins serve as docking CC proteins for other signaling proteins that contain Src-homology-2 CC domains (SH2 domain) that specifically recognize different CC phosphotyrosine residues, including the p85 regulatory subunit of PI3K CC and SHP2. Phosphorylation of IRSs proteins lead to the activation of CC two main signaling pathways: the PI3K-AKT/PKB pathway, which is CC responsible for most of the metabolic actions of insulin, and the Ras- CC MAPK pathway, which regulates expression of some genes and cooperates CC with the PI3K pathway to control cell growth and differentiation. CC Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to CC the activation of PI3K and the generation of phosphatidylinositol-(3, CC 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates CC several PIP3-dependent serine/threonine kinases, such as PDPK1 and CC subsequently AKT/PKB. The net effect of this pathway is to produce a CC translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic CC vesicles to the cell membrane to facilitate glucose transport. CC Moreover, upon insulin stimulation, activated AKT/PKB is responsible CC for: anti-apoptotic effect of insulin by inducing phosphorylation of CC BAD; regulates the expression of gluconeogenic and lipogenic enzymes by CC controlling the activity of the winged helix or forkhead (FOX) class of CC transcription factors. Another pathway regulated by PI3K-AKT/PKB CC activation is mTORC1 signaling pathway which regulates cell growth and CC metabolism and integrates signals from insulin. AKT mediates insulin- CC stimulated protein synthesis by phosphorylating TSC2 thereby activating CC mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in CC mediating cell growth, survival and cellular differentiation of CC insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers CC the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to CC binding insulin, the insulin receptor can bind insulin-like growth CC factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII CC binding. When present in a hybrid receptor with IGF1R, binds IGF1. CC PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR CC isoform Long are activated with a high affinity by IGF1, with low CC affinity by IGF2 and not significantly activated by insulin, and that CC hybrid receptors composed of IGF1R and INSR isoform Short are activated CC by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that CC hybrid receptors composed of IGF1R and INSR isoform Long and hybrid CC receptors composed of IGF1R and INSR isoform Short have similar binding CC characteristics, both bind IGF1 and have a low affinity for insulin. In CC adipocytes, inhibits lipolysis (By similarity). CC {ECO:0000250|UniProtKB:P15208, ECO:0000269|PubMed:12138094, CC ECO:0000269|PubMed:16314505, ECO:0000269|PubMed:16831875, CC ECO:0000269|PubMed:8257688, ECO:0000269|PubMed:8276809, CC ECO:0000269|PubMed:8452530, ECO:0000269|PubMed:9428692}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:11124964, ECO:0000269|PubMed:11598120, CC ECO:0000269|PubMed:12707268, ECO:0000269|PubMed:18278056, CC ECO:0000269|PubMed:19056263, ECO:0000269|PubMed:19071018, CC ECO:0000269|PubMed:19394223, ECO:0000269|PubMed:9312016}; CC -!- ACTIVITY REGULATION: Activated in response to insulin. CC Autophosphorylation activates the kinase activity. PTPN1, PTPRE and CC PTPRF dephosphorylate important tyrosine residues, thereby reducing CC INSR activity. Inhibited by ENPP1. GRB10 and GRB14 inhibit the CC catalytic activity of the INSR, they block access of substrates to the CC activated receptor. SOCS1 and SOCS3 act as negative regulators of INSR CC activity, they bind to the activated INRS and interfere with the CC phosphorylation of INSR substrates. {ECO:0000269|PubMed:10615944, CC ECO:0000269|PubMed:11598120, ECO:0000269|PubMed:11726652, CC ECO:0000269|PubMed:12493740, ECO:0000269|PubMed:2211730}. CC -!- SUBUNIT: Tetramer of 2 alpha and 2 beta chains linked by disulfide CC bonds. The alpha chains carry the insulin-binding regions, while the CC beta chains carry the kinase domain. Forms a hybrid receptor with CC IGF1R, the hybrid is a tetramer consisting of 1 alpha chain and 1 beta CC chain of INSR and 1 alpha chain and 1 beta chain of IGF1R. Interacts CC with SORBS1 but dissociates from it following insulin stimulation. CC Binds SH2B2. Activated form of INSR interacts (via Tyr-999) with the CC PTB/PID domains of IRS1 and SHC1. The sequences surrounding the CC phosphorylated NPXY motif contribute differentially to either IRS1 or CC SHC1 recognition. Interacts (via tyrosines in the C-terminus) with IRS2 CC (via PTB domain and 591-786 AA); the 591-786 would be the primary CC anchor of IRS2 to INSR while the PTB domain would have a stabilizing CC action on the interaction with INSR. Interacts with the SH2 domains of CC the 85 kDa regulatory subunit of PI3K (PIK3R1) in vitro, when CC autophosphorylated on tyrosine residues. Interacts with SOCS7. CC Interacts (via the phosphorylated Tyr-999), with SOCS3. Interacts (via CC the phosphorylated Tyr-1185, Tyr-1189, Tyr-1190) with SOCS1. Interacts CC with CAV2 (tyrosine-phosphorylated form); the interaction is increased CC with 'Tyr-27'phosphorylation of CAV2 (By similarity). Interacts with CC ARRB2 (By similarity). Interacts with GRB10; this interaction blocks CC the association between IRS1/IRS2 and INSR, significantly reduces CC insulin-stimulated tyrosine phosphorylation of IRS1 and IRS2 and thus CC decreases insulin signaling. Interacts with GRB7. Interacts with PDPK1. CC Interacts (via Tyr-1190) with GRB14 (via BPS domain); this interaction CC protects the tyrosines in the activation loop from dephosphorylation, CC but promotes dephosphorylation of Tyr-999, this results in decreased CC interaction with, and phosphorylation of, IRS1. Interacts (via subunit CC alpha) with ENPP1 (via 485-599 AA); this interaction blocks CC autophosphorylation. Interacts with PTPRE; this interaction is CC dependent of Tyr-1185, Tyr-1189 and Tyr-1190 of the INSR. Interacts CC with STAT5B (via SH2 domain). Interacts with PTPRF. Interacts with CC ATIC; ATIC together with PRKAA2/AMPK2 and HACD3/PTPLAD1 is proposed to CC be part of a signaling netwok regulating INSR autophosphorylation and CC endocytosis (By similarity). Interacts with the cone snail venom CC insulin Con-Ins G1 (PubMed:27617429). Interacts with the insulin CC receptor SORL1; this interaction strongly increases its surface CC exposure, hence strengthens insulin signal reception (PubMed:27322061). CC Interacts (tyrosine phosphorylated) with CCDC88A/GIV (via SH2-like CC region); binding requires autophosphorylation of the INSR C-terminal CC region (PubMed:25187647). Interacts with GNAI3; the interaction is CC probably mediated by CCDC88A/GIV (PubMed:25187647). Interacts with CC LMBRD1 (By similarity). Interacts (in response to insulin stimulation) CC with NCK1; this interaction may recruit PTPN1 to mediate INSR CC dephosphorylation (PubMed:21707536). Interacts with CD248; this CC interaction diminishes INSR autophosphorylation (By similarity). CC {ECO:0000250|UniProtKB:P15127, ECO:0000250|UniProtKB:P15208, CC ECO:0000269|PubMed:10615944, ECO:0000269|PubMed:10803466, CC ECO:0000269|PubMed:11124964, ECO:0000269|PubMed:11374898, CC ECO:0000269|PubMed:11726652, ECO:0000269|PubMed:12493740, CC ECO:0000269|PubMed:14690593, ECO:0000269|PubMed:16127460, CC ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887, CC ECO:0000269|PubMed:16314505, ECO:0000269|PubMed:16957736, CC ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165, CC ECO:0000269|PubMed:19056263, ECO:0000269|PubMed:19071018, CC ECO:0000269|PubMed:19394223, ECO:0000269|PubMed:21707536, CC ECO:0000269|PubMed:2211730, ECO:0000269|PubMed:23302862, CC ECO:0000269|PubMed:25187647, ECO:0000269|PubMed:27322061, CC ECO:0000269|PubMed:27617429, ECO:0000269|PubMed:7537849, CC ECO:0000269|PubMed:7559478, ECO:0000269|PubMed:8276809, CC ECO:0000269|PubMed:8995282, ECO:0000269|PubMed:8999839, CC ECO:0000269|PubMed:9312016, ECO:0000269|PubMed:9428692}. CC -!- INTERACTION: CC P06213; Q99490: AGAP2; NbExp=2; IntAct=EBI-475899, EBI-2361824; CC P06213; Q8NEJ0: DUSP18; NbExp=2; IntAct=EBI-475899, EBI-10698945; CC P06213; Q13322: GRB10; NbExp=4; IntAct=EBI-475899, EBI-80275; CC P06213; P05019: IGF1; NbExp=4; IntAct=EBI-475899, EBI-7902275; CC P06213; P08069: IGF1R; NbExp=5; IntAct=EBI-475899, EBI-475981; CC P06213; P14616: INSRR; NbExp=6; IntAct=EBI-475899, EBI-6424336; CC P06213; P35568: IRS1; NbExp=5; IntAct=EBI-475899, EBI-517592; CC P06213; Q9Y4H2: IRS2; NbExp=4; IntAct=EBI-475899, EBI-1049582; CC P06213; Q15323: KRT31; NbExp=3; IntAct=EBI-475899, EBI-948001; CC P06213; Q13257: MAD2L1; NbExp=4; IntAct=EBI-475899, EBI-78203; CC P06213; P27986: PIK3R1; NbExp=9; IntAct=EBI-475899, EBI-79464; CC P06213; P19174: PLCG1; NbExp=9; IntAct=EBI-475899, EBI-79387; CC P06213; P18031: PTPN1; NbExp=33; IntAct=EBI-475899, EBI-968788; CC P06213; Q06124: PTPN11; NbExp=3; IntAct=EBI-475899, EBI-297779; CC P06213; Q15262: PTPRK; NbExp=2; IntAct=EBI-475899, EBI-474052; CC P06213; Q15256: PTPRR; NbExp=2; IntAct=EBI-475899, EBI-2265659; CC P06213; Q9NRF2: SH2B1; NbExp=6; IntAct=EBI-475899, EBI-310491; CC P06213; P29353: SHC1; NbExp=2; IntAct=EBI-475899, EBI-78835; CC P06213; P01317: INS; Xeno; NbExp=5; IntAct=EBI-475899, EBI-3989070; CC P06213; P35570: Irs1; Xeno; NbExp=5; IntAct=EBI-475899, EBI-520230; CC P06213-1; P32121: ARRB2; NbExp=2; IntAct=EBI-15558981, EBI-714559; CC P06213-1; P06213-1: INSR; NbExp=4; IntAct=EBI-15558981, EBI-15558981; CC P06213-1; P18031: PTPN1; NbExp=2; IntAct=EBI-15558981, EBI-968788; CC P06213-1; Q92485-2: SMPDL3B; NbExp=2; IntAct=EBI-15558981, EBI-21501656; CC P06213-1; P81122: Irs2; Xeno; NbExp=8; IntAct=EBI-15558981, EBI-1369862; CC P06213-1; Q1XH17: Trim72; Xeno; NbExp=2; IntAct=EBI-15558981, EBI-16034016; CC P06213-2; P01308: INS; NbExp=6; IntAct=EBI-9984921, EBI-7090529; CC P06213-2; Q13257: MAD2L1; NbExp=3; IntAct=EBI-9984921, EBI-78203; CC P06213-2; Q92485-2: SMPDL3B; NbExp=2; IntAct=EBI-9984921, EBI-21501656; CC P06213-2; P01317: INS; Xeno; NbExp=2; IntAct=EBI-9984921, EBI-3989070; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:P15208}; CC Single-pass type I membrane protein {ECO:0000305}. Late endosome CC {ECO:0000250|UniProtKB:P15208}. Lysosome CC {ECO:0000250|UniProtKB:P15208}. Note=Binding of insulin to INSR induces CC internalization and lysosomal degradation of the receptor, a means for CC down-regulating this signaling pathway after stimulation. In the CC presence of SORL1, internalized INSR molecules are redirected back to CC the cell surface, thereby preventing their lysosomal catabolism and CC strengthening insulin signal reception. {ECO:0000250|UniProtKB:P15208}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=Long; Synonyms=HIR-B; CC IsoId=P06213-1; Sequence=Displayed; CC Name=Short; Synonyms=HIR-A; CC IsoId=P06213-2; Sequence=VSP_002898; CC -!- TISSUE SPECIFICITY: Isoform Long and isoform Short are predominantly CC expressed in tissue targets of insulin metabolic effects: liver, CC adipose tissue and skeletal muscle but are also expressed in the CC peripheral nerve, kidney, pulmonary alveoli, pancreatic acini, placenta CC vascular endothelium, fibroblasts, monocytes, granulocytes, CC erythrocytes and skin. Isoform Short is preferentially expressed in CC fetal cells such as fetal fibroblasts, muscle, liver and kidney. Found CC as a hybrid receptor with IGF1R in muscle, heart, kidney, adipose CC tissue, skeletal muscle, hepatoma, fibroblasts, spleen and placenta (at CC protein level). Overexpressed in several tumors, including breast, CC colon, lung, ovary, and thyroid carcinomas. CC {ECO:0000269|PubMed:10207053, ECO:0000269|PubMed:2369896, CC ECO:0000269|PubMed:9202395, ECO:0000269|PubMed:9355755}. CC -!- DOMAIN: The tetrameric insulin receptor binds insulin via non-identical CC regions from two alpha chains, primarily via the C-terminal region of CC the first INSR alpha chain. Residues from the leucine-rich N-terminus CC of the other INSR alpha chain also contribute to this insulin binding CC site. A secondary insulin-binding site is formed by residues at the CC junction of fibronectin type-III domain 1 and 2. CC {ECO:0000269|PubMed:16957736, ECO:0000269|PubMed:19459609, CC ECO:0000269|PubMed:23302862}. CC -!- PTM: After being transported from the endoplasmic reticulum to the CC Golgi apparatus, the single glycosylated precursor is further CC glycosylated and then cleaved, followed by its transport to the plasma CC membrane. {ECO:0000269|PubMed:1472036, ECO:0000269|PubMed:16894147, CC ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:19349973, CC ECO:0000269|PubMed:23302862, ECO:0000269|PubMed:2983222}. CC -!- PTM: Autophosphorylated on tyrosine residues in response to insulin CC (PubMed:14690593, PubMed:16246733, PubMed:16271887, PubMed:18278056, CC PubMed:18767165, PubMed:3166375, PubMed:9312016). Phosphorylation of CC Tyr-999 is required for binding to IRS1, SHC1 and STAT5B CC (PubMed:14690593, PubMed:16246733, PubMed:16271887, PubMed:18278056, CC PubMed:18767165, PubMed:3166375, PubMed:9312016). Dephosphorylated by CC PTPRE at Tyr-999, Tyr-1185, Tyr-1189 and Tyr-1190 (PubMed:14690593, CC PubMed:16246733, PubMed:16271887, PubMed:18278056, PubMed:18767165, CC PubMed:3166375, PubMed:9312016). May also be phosphorylated at Tyr-1185 CC and Tyr-1190 by mTORC2 (PubMed:26584640). Dephosphorylated by PTPRF and CC PTPN1 (PubMed:8995282). Dephosphorylated by PTPN2; down-regulates CC insulin-induced signaling (PubMed:10734133, PubMed:12612081). CC Dephosphorylation at Tyr-1189 and Tyr-1190 requires the SH2/SH3 adapter CC protein NCK1, probably to recruit its interaction partner PTPN1 CC (PubMed:21707536). {ECO:0000269|PubMed:10734133, CC ECO:0000269|PubMed:12612081, ECO:0000269|PubMed:14690593, CC ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887, CC ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165, CC ECO:0000269|PubMed:21707536, ECO:0000269|PubMed:26584640, CC ECO:0000269|PubMed:3166375, ECO:0000269|PubMed:8995282, CC ECO:0000269|PubMed:9312016}. CC -!- PTM: S-nitrosylation at Cys-1083 by BLVRB inhibits the receptor CC tyrosine kinase, thereby inhibiting insulin signaling. CC {ECO:0000269|PubMed:38056462}. CC -!- PTM: Ubiquitinated by MARCHF1; leading to degradation thereby reducing CC surface INSR expression. {ECO:0000269|PubMed:27577745}. CC -!- DISEASE: Rabson-Mendenhall syndrome (RMS) [MIM:262190]: Severe insulin CC resistance syndrome characterized by insulin-resistant diabetes CC mellitus with pineal hyperplasia and somatic abnormalities. Typical CC features include coarse, senile-appearing facies, dental and skin CC abnormalities, abdominal distension, and phallic enlargement. CC Inheritance is autosomal recessive. {ECO:0000269|PubMed:10443650, CC ECO:0000269|PubMed:12023989, ECO:0000269|PubMed:17201797, CC ECO:0000269|PubMed:2121734, ECO:0000269|PubMed:2365819, CC ECO:0000269|PubMed:28765322, ECO:0000269|PubMed:8314008}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Leprechaunism (LEPRCH) [MIM:246200]: Represents the most CC severe form of insulin resistance syndrome, characterized by CC intrauterine and postnatal growth retardation and death in early CC infancy. Inheritance is autosomal recessive. CC {ECO:0000269|PubMed:12023989, ECO:0000269|PubMed:12538626, CC ECO:0000269|PubMed:12970295, ECO:0000269|PubMed:1607067, CC ECO:0000269|PubMed:1730625, ECO:0000269|PubMed:22768670, CC ECO:0000269|PubMed:2365819, ECO:0000269|PubMed:24498630, CC ECO:0000269|PubMed:2479553, ECO:0000269|PubMed:2834824, CC ECO:0000269|PubMed:28765322, ECO:0000269|PubMed:7538143, CC ECO:0000269|PubMed:7815442, ECO:0000269|PubMed:8188715, CC ECO:0000269|PubMed:8326490, ECO:0000269|PubMed:8419945, CC ECO:0000269|PubMed:8636294, ECO:0000269|PubMed:9249867, CC ECO:0000269|PubMed:9299395, ECO:0000269|PubMed:9703342}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Type 2 diabetes mellitus (T2D) [MIM:125853]: A multifactorial CC disorder of glucose homeostasis caused by a lack of sensitivity to CC insulin. Affected individuals usually have an obese body habitus and CC manifestations of a metabolic syndrome characterized by diabetes, CC insulin resistance, hypertension and hypertriglyceridemia. The disease CC results in long-term complications that affect the eyes, kidneys, CC nerves, and blood vessels. {ECO:0000269|PubMed:1470163, CC ECO:0000269|PubMed:1607076, ECO:0000269|PubMed:7657032}. Note=The gene CC represented in this entry may be involved in disease pathogenesis. CC -!- DISEASE: Hyperinsulinemic hypoglycemia, familial, 5 (HHF5) CC [MIM:609968]: A form of hyperinsulinemic hypoglycemia, a clinically and CC genetically heterogeneous disorder characterized by inappropriate CC insulin secretion from the pancreatic beta-cells in the presence of low CC blood glucose levels. HHF5 clinical features include loss of CC consciousness due to hypoglycemia and hypoglycemic seizures. HHF5 CC inheritance is autosomal dominant. {ECO:0000269|PubMed:15161766}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Insulin-resistant diabetes mellitus with acanthosis nigricans CC type A (IRAN type A) [MIM:610549]: Characterized by the association of CC severe insulin resistance (manifested by marked hyperinsulinemia and a CC failure to respond to exogenous insulin) with the skin lesion CC acanthosis nigricans and ovarian hyperandrogenism in adolescent female CC subjects. Women frequently present with hirsutism, acne, amenorrhea or CC oligomenorrhea, and virilization. This syndrome is different from the CC type B that has been demonstrated to be secondary to the presence of CC circulating autoantibodies against the insulin receptor. CC {ECO:0000269|PubMed:10733238, ECO:0000269|PubMed:11260230, CC ECO:0000269|PubMed:12107746, ECO:0000269|PubMed:12970295, CC ECO:0000269|PubMed:1563582, ECO:0000269|PubMed:1963473, CC ECO:0000269|PubMed:2002058, ECO:0000269|PubMed:2168397, CC ECO:0000269|PubMed:2365819, ECO:0000269|PubMed:2544998, CC ECO:0000269|PubMed:28765322, ECO:0000269|PubMed:3283938, CC ECO:0000269|PubMed:8243830, ECO:0000269|PubMed:8288049, CC ECO:0000269|PubMed:8314008, ECO:0000269|PubMed:8388389, CC ECO:0000269|PubMed:9175790}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Wikipedia; Note=Insulin receptor entry; CC URL="https://en.wikipedia.org/wiki/Insulin_receptor"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M10051; AAA59174.1; -; mRNA. DR EMBL; X02160; CAA26096.1; -; mRNA. DR EMBL; M32972; AAA59452.1; -; Genomic_DNA. DR EMBL; M23100; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32823; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32824; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32825; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32826; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32827; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32828; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32829; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32830; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32831; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32832; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32833; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32834; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32835; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32836; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32837; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32838; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32839; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32840; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32841; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; M32842; AAA59452.1; JOINED; Genomic_DNA. DR EMBL; AC010311; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC010526; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC010606; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC125387; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC117172; AAI17173.1; -; mRNA. DR EMBL; J03466; AAA59175.1; -; Genomic_DNA. DR EMBL; J05043; AAA59190.1; -; Genomic_DNA. DR EMBL; M76592; AAC37604.1; -; Genomic_DNA. DR EMBL; AB208861; BAD92098.1; -; mRNA. DR EMBL; M24555; AAA59178.1; -; mRNA. DR EMBL; M29929; AAA59176.1; -; Genomic_DNA. DR EMBL; M29930; AAA59177.1; -; Genomic_DNA. DR EMBL; M27197; AAA86791.1; -; Genomic_DNA. DR EMBL; M27195; AAA86791.1; JOINED; Genomic_DNA. DR CCDS; CCDS12176.1; -. [P06213-1] DR CCDS; CCDS42487.1; -. [P06213-2] DR PIR; A37348; INHUR. DR RefSeq; NP_000199.2; NM_000208.4. [P06213-1] DR RefSeq; NP_001073285.1; NM_001079817.3. [P06213-2] DR PDB; 1GAG; X-ray; 2.70 A; A=1005-1310. DR PDB; 1I44; X-ray; 2.40 A; A=1005-1310. DR PDB; 1IR3; X-ray; 1.90 A; A=1005-1310. DR PDB; 1IRK; X-ray; 2.10 A; A=1005-1310. DR PDB; 1P14; X-ray; 1.90 A; A=1005-1310. DR PDB; 1RQQ; X-ray; 2.60 A; A/B=1005-1310. DR PDB; 2AUH; X-ray; 3.20 A; A=1005-1310. DR PDB; 2B4S; X-ray; 2.30 A; B/D=1005-1310. DR PDB; 2HR7; X-ray; 2.32 A; A/B=28-512. DR PDB; 2MFR; NMR; -; A=940-988. DR PDB; 2Z8C; X-ray; 3.25 A; A=1008-1310. DR PDB; 3BU3; X-ray; 1.65 A; A=1005-1310. DR PDB; 3BU5; X-ray; 2.10 A; A=1005-1310. DR PDB; 3BU6; X-ray; 1.95 A; A=1005-1310. DR PDB; 3EKK; X-ray; 2.10 A; A=1005-1310. DR PDB; 3EKN; X-ray; 2.20 A; A=1005-1310. DR PDB; 3ETA; X-ray; 2.60 A; A/B=1017-1322. DR PDB; 3W11; X-ray; 3.90 A; E=28-337, F=731-744. DR PDB; 3W12; X-ray; 4.30 A; E=28-337, F=731-744. DR PDB; 3W13; X-ray; 4.30 A; E=28-337, F=724-744. DR PDB; 4IBM; X-ray; 1.80 A; A/B=1005-1310. DR PDB; 4OGA; X-ray; 3.50 A; E=28-337, F=731-744. DR PDB; 4XLV; X-ray; 2.30 A; A=983-1310. DR PDB; 4XSS; X-ray; 3.00 A; E=28-337. DR PDB; 4XST; X-ray; 3.00 A; E=28-337. DR PDB; 4ZXB; X-ray; 3.30 A; E=28-956. DR PDB; 5E1S; X-ray; 2.26 A; A=1005-1310. DR PDB; 5HHW; X-ray; 1.79 A; A=1005-1310. DR PDB; 5J3H; X-ray; 3.27 A; E=28-337. DR PDB; 5KQV; X-ray; 4.40 A; E/F=28-746. DR PDB; 5U1M; X-ray; 1.80 A; B=991-999. DR PDB; 6HN4; EM; 4.20 A; E/F=28-955. DR PDB; 6HN5; EM; 3.20 A; E/F=28-955. DR PDB; 6PXV; EM; 3.20 A; A/C=28-1382. DR PDB; 6PXW; EM; 3.10 A; A/B=28-1382. DR PDB; 6SOF; EM; 4.30 A; A/C=28-746, B/D=795-956. DR PDB; 6VEP; X-ray; 2.90 A; E/K/Q/W=28-337, F/L/R/X=731-746. DR PDB; 6VEQ; X-ray; 3.25 A; E/K=28-337, F/L=731-746. DR PDB; 7BW7; EM; 4.10 A; A/C=28-1382. DR PDB; 7BW8; EM; 3.80 A; A/C=28-1382. DR PDB; 7BWA; EM; 4.90 A; A/C=28-1382. DR PDB; 7KD6; X-ray; 2.60 A; E/K/Q/W=28-337. DR PDB; 7MQO; EM; 3.40 A; E/F=28-956. DR PDB; 7MQR; EM; 4.10 A; E/F=28-955. DR PDB; 7MQS; EM; 4.40 A; E/F=28-955. DR PDB; 7PG0; EM; 7.60 A; A/B=1-1382. DR PDB; 7PG2; EM; 6.70 A; A/B=1-1382. DR PDB; 7PG3; EM; 7.30 A; A/B=1-1382. DR PDB; 7PG4; EM; 9.10 A; A/B=1-1382. DR PDB; 7PHT; NMR; -; A=953-982. DR PDB; 7QID; EM; 5.00 A; A/C=28-746, B/D=763-956. DR PDB; 7S0Q; EM; 3.70 A; B=28-955. DR PDB; 7S8V; EM; 3.73 A; B=28-955. DR PDB; 7U6D; EM; 5.03 A; B/C=28-955. DR PDB; 7U6E; EM; 3.00 A; E/F=28-955. DR PDB; 7YQ3; EM; 3.60 A; E/F=28-946. DR PDB; 7YQ4; EM; 3.95 A; E/F=28-946. DR PDB; 7YQ5; EM; 4.27 A; E/F=28-946. DR PDB; 7YQ6; EM; 4.18 A; E/F=28-946. DR PDB; 8DWN; X-ray; 2.15 A; A=1005-1310. DR PDB; 8GUY; EM; 4.18 A; E/F=28-946. DR PDB; 8U4B; EM; 3.90 A; A/B=1-1382. DR PDB; 8U4C; EM; 3.60 A; A/B=1-1382. DR PDB; 8U4E; EM; 4.20 A; A/B=1-1382. DR PDB; 8VJB; EM; 3.60 A; A/B=1-1382. DR PDB; 8VJC; EM; 3.80 A; A/B=1-1382. DR PDB; 8X06; EM; 3.24 A; A/B=1-1382. DR PDB; 8X2M; EM; 3.31 A; A/B=1-1382. DR PDB; 8XJS; EM; 3.24 A; A/B=1-1382. DR PDB; 8XK1; EM; 3.31 A; A/B=1-1382. DR PDB; 8XKM; EM; 5.00 A; A/B=1-1382. DR PDB; 8XKR; EM; 3.53 A; A/B=1-1382. DR PDB; 8YSZ; EM; 3.38 A; A/B=1-1382. DR PDB; 8YYL; EM; 4.01 A; A/B=1-1382. DR PDB; 8YYS; EM; 4.14 A; A/B=1-1382. DR PDB; 8YYT; EM; 3.60 A; A/B=1-1382. DR PDBsum; 1GAG; -. DR PDBsum; 1I44; -. DR PDBsum; 1IR3; -. DR PDBsum; 1IRK; -. DR PDBsum; 1P14; -. DR PDBsum; 1RQQ; -. DR PDBsum; 2AUH; -. DR PDBsum; 2B4S; -. DR PDBsum; 2HR7; -. DR PDBsum; 2MFR; -. DR PDBsum; 2Z8C; -. DR PDBsum; 3BU3; -. DR PDBsum; 3BU5; -. DR PDBsum; 3BU6; -. DR PDBsum; 3EKK; -. DR PDBsum; 3EKN; -. DR PDBsum; 3ETA; -. DR PDBsum; 3W11; -. DR PDBsum; 3W12; -. DR PDBsum; 3W13; -. DR PDBsum; 4IBM; -. DR PDBsum; 4OGA; -. DR PDBsum; 4XLV; -. DR PDBsum; 4XSS; -. DR PDBsum; 4XST; -. DR PDBsum; 4ZXB; -. DR PDBsum; 5E1S; -. DR PDBsum; 5HHW; -. DR PDBsum; 5J3H; -. DR PDBsum; 5KQV; -. DR PDBsum; 5U1M; -. DR PDBsum; 6HN4; -. DR PDBsum; 6HN5; -. DR PDBsum; 6PXV; -. DR PDBsum; 6PXW; -. DR PDBsum; 6SOF; -. DR PDBsum; 6VEP; -. DR PDBsum; 6VEQ; -. DR PDBsum; 7BW7; -. DR PDBsum; 7BW8; -. DR PDBsum; 7BWA; -. DR PDBsum; 7KD6; -. DR PDBsum; 7MQO; -. DR PDBsum; 7MQR; -. DR PDBsum; 7MQS; -. DR PDBsum; 7PG0; -. DR PDBsum; 7PG2; -. DR PDBsum; 7PG3; -. DR PDBsum; 7PG4; -. DR PDBsum; 7PHT; -. DR PDBsum; 7QID; -. DR PDBsum; 7S0Q; -. DR PDBsum; 7S8V; -. DR PDBsum; 7U6D; -. DR PDBsum; 7U6E; -. DR PDBsum; 7YQ3; -. DR PDBsum; 7YQ4; -. DR PDBsum; 7YQ5; -. DR PDBsum; 7YQ6; -. DR PDBsum; 8DWN; -. DR PDBsum; 8GUY; -. DR PDBsum; 8U4B; -. DR PDBsum; 8U4C; -. DR PDBsum; 8U4E; -. DR PDBsum; 8VJB; -. DR PDBsum; 8VJC; -. DR PDBsum; 8X06; -. DR PDBsum; 8X2M; -. DR PDBsum; 8XJS; -. DR PDBsum; 8XK1; -. DR PDBsum; 8XKM; -. DR PDBsum; 8XKR; -. DR PDBsum; 8YSZ; -. DR PDBsum; 8YYL; -. DR PDBsum; 8YYS; -. DR PDBsum; 8YYT; -. DR AlphaFoldDB; P06213; -. DR BMRB; P06213; -. DR EMDB; EMD-10273; -. DR EMDB; EMD-10311; -. DR EMDB; EMD-13385; -. DR EMDB; EMD-13386; -. DR EMDB; EMD-13387; -. DR EMDB; EMD-13388; -. DR EMDB; EMD-20522; -. DR EMDB; EMD-20523; -. DR EMDB; EMD-23766; -. DR EMDB; EMD-23767; -. DR EMDB; EMD-23949; -. DR EMDB; EMD-23950; -. DR EMDB; EMD-24791; -. DR EMDB; EMD-24927; -. DR EMDB; EMD-26363; -. DR EMDB; EMD-30225; -. DR EMDB; EMD-30227; -. DR EMDB; EMD-30229; -. DR EMDB; EMD-30230; -. DR EMDB; EMD-30231; -. DR EMDB; EMD-34018; -. DR EMDB; EMD-34019; -. DR EMDB; EMD-34021; -. DR EMDB; EMD-34281; -. DR EMDB; EMD-37970; -. DR EMDB; EMD-38017; -. DR EMDB; EMD-38404; -. DR EMDB; EMD-38413; -. DR EMDB; EMD-38420; -. DR EMDB; EMD-38423; -. DR EMDB; EMD-39566; -. DR EMDB; EMD-39675; -. DR EMDB; EMD-39677; -. DR EMDB; EMD-39678; -. DR EMDB; EMD-41877; -. DR EMDB; EMD-41878; -. DR EMDB; EMD-41880; -. DR EMDB; EMD-43279; -. DR EMDB; EMD-43280; -. DR EMDB; EMD-61431; -. DR EMDB; EMD-61432; -. DR EMDB; EMD-61490; -. DR EMDB; EMD-7461; -. DR EMDB; EMD-7462; -. DR EMDB; EMD-7463; -. DR SASBDB; P06213; -. DR SMR; P06213; -. DR BioGRID; 109854; 380. DR DIP; DIP-480N; -. DR ELM; P06213; -. DR FunCoup; P06213; 1946. DR IntAct; P06213; 709. DR MINT; P06213; -. DR STRING; 9606.ENSP00000303830; -. DR BindingDB; P06213; -. DR ChEMBL; CHEMBL1981; -. DR DrugBank; DB08513; [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID. DR DrugBank; DB03909; Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate. DR DrugBank; DB05120; AT1391. DR DrugBank; DB16028; Azemiglitazone. DR DrugBank; DB15399; BMS-754807. DR DrugBank; DB12267; Brigatinib. DR DrugBank; DB09129; Chromic chloride. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB11564; Insulin argine. DR DrugBank; DB01306; Insulin aspart. DR DrugBank; DB09456; Insulin beef. DR DrugBank; DB09564; Insulin degludec. DR DrugBank; DB01307; Insulin detemir. DR DrugBank; DB00047; Insulin glargine. DR DrugBank; DB01309; Insulin glulisine. DR DrugBank; DB00030; Insulin human. DR DrugBank; DB16693; Insulin icodec. DR DrugBank; DB00046; Insulin lispro. DR DrugBank; DB11567; Insulin peglispro. DR DrugBank; DB00071; Insulin pork. DR DrugBank; DB11568; Insulin tregopil. DR DrugBank; DB16637; KW-2450 free base. DR DrugBank; DB06075; Linsitinib. DR DrugBank; DB01277; Mecasermin. DR DrugBank; DB14751; Mecasermin rinfabate. DR DrugBank; DB11721; Mitoglitazone. DR DrugBank; DB05115; NN344. DR DrugBank; DB12518; Raclopride. DR DrugBank; DB06156; Tesofensine. DR DrugCentral; P06213; -. DR GuidetoPHARMACOLOGY; 1800; -. DR GlyConnect; 1402; 8 N-Linked glycans (6 sites). DR GlyCosmos; P06213; 21 sites, 11 glycans. DR GlyGen; P06213; 25 sites, 79 N-linked glycans (13 sites), 4 O-linked glycans (6 sites). DR iPTMnet; P06213; -. DR PhosphoSitePlus; P06213; -. DR SwissPalm; P06213; -. DR BioMuta; INSR; -. DR DMDM; 308153655; -. DR CPTAC; CPTAC-1771; -. DR CPTAC; CPTAC-1772; -. DR CPTAC; CPTAC-2814; -. DR CPTAC; CPTAC-3053; -. DR jPOST; P06213; -. DR MassIVE; P06213; -. DR PaxDb; 9606-ENSP00000303830; -. DR PeptideAtlas; P06213; -. DR ProteomicsDB; 51872; -. [P06213-1] DR ProteomicsDB; 51873; -. [P06213-2] DR Pumba; P06213; -. DR ABCD; P06213; 3 sequenced antibodies. DR Antibodypedia; 3403; 2189 antibodies from 53 providers. DR DNASU; 3643; -. DR Ensembl; ENST00000302850.10; ENSP00000303830.4; ENSG00000171105.15. [P06213-1] DR Ensembl; ENST00000341500.9; ENSP00000342838.4; ENSG00000171105.15. [P06213-2] DR GeneID; 3643; -. DR KEGG; hsa:3643; -. DR MANE-Select; ENST00000302850.10; ENSP00000303830.4; NM_000208.4; NP_000199.2. DR UCSC; uc002mgd.2; human. [P06213-1] DR AGR; HGNC:6091; -. DR ClinPGx; PA202; -. DR CTD; 3643; -. DR DisGeNET; 3643; -. DR GeneCards; INSR; -. DR GeneReviews; INSR; -. DR HGNC; HGNC:6091; INSR. DR HPA; ENSG00000171105; Low tissue specificity. DR MalaCards; INSR; -. DR MIM; 125853; phenotype. DR MIM; 147670; gene. DR MIM; 246200; phenotype. DR MIM; 262190; phenotype. DR MIM; 609968; phenotype. DR MIM; 610549; phenotype. DR OpenTargets; ENSG00000171105; -. DR Orphanet; 508; Donohue syndrome. DR Orphanet; 263458; Hyperinsulinism due to INSR deficiency. DR Orphanet; 2297; Insulin-resistance syndrome type A. DR Orphanet; 769; Rabson-Mendenhall syndrome. DR VEuPathDB; HostDB:ENSG00000171105; -. DR eggNOG; KOG4258; Eukaryota. DR GeneTree; ENSGT00940000155404; -. DR HOGENOM; CLU_000288_166_0_1; -. DR InParanoid; P06213; -. DR OMA; AVESNTW; -. DR OrthoDB; 5809444at2759; -. DR PAN-GO; P06213; 12 GO annotations based on evolutionary models. DR PhylomeDB; P06213; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P06213; -. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-74713; IRS activation. DR Reactome; R-HSA-74749; Signal attenuation. DR Reactome; R-HSA-74751; Insulin receptor signalling cascade. DR Reactome; R-HSA-74752; Signaling by Insulin receptor. DR Reactome; R-HSA-77387; Insulin receptor recycling. DR SABIO-RK; P06213; -. DR SignaLink; P06213; -. DR SIGNOR; P06213; -. DR Agora; ENSG00000171105; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 3643; 15 hits in 1203 CRISPR screens. DR ChiTaRS; INSR; human. DR EvolutionaryTrace; P06213; -. DR GeneWiki; Insulin_receptor; -. DR GenomeRNAi; 3643; -. DR Pharos; P06213; Tclin. DR PRO; PR:P06213; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; P06213; protein. DR Bgee; ENSG00000171105; Expressed in buccal mucosa cell and 209 other cell types or tissues. DR ExpressionAtlas; P06213; baseline and differential. DR GO; GO:0030424; C:axon; IBA:GO_Central. DR GO; GO:0005901; C:caveola; IDA:BHF-UCL. DR GO; GO:0032590; C:dendrite membrane; ISS:ARUK-UCL. DR GO; GO:0010008; C:endosome membrane; TAS:Reactome. DR GO; GO:0009897; C:external side of plasma membrane; ISS:ARUK-UCL. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005899; C:insulin receptor complex; IDA:UniProtKB. DR GO; GO:0005770; C:late endosome; IEA:UniProtKB-SubCell. DR GO; GO:0005764; C:lysosome; IEA:UniProtKB-SubCell. DR GO; GO:0016020; C:membrane; IDA:BHF-UCL. DR GO; GO:0032809; C:neuronal cell body membrane; ISS:ARUK-UCL. DR GO; GO:0005886; C:plasma membrane; IDA:ARUK-UCL. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0001540; F:amyloid-beta binding; IPI:ARUK-UCL. DR GO; GO:0005524; F:ATP binding; IDA:BHF-UCL. DR GO; GO:0038024; F:cargo receptor activity; ISS:ARUK-UCL. DR GO; GO:0005525; F:GTP binding; IDA:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0043559; F:insulin binding; IDA:UniProtKB. DR GO; GO:0005009; F:insulin receptor activity; IDA:UniProtKB. DR GO; GO:0043560; F:insulin receptor substrate binding; IPI:UniProtKB. DR GO; GO:0031994; F:insulin-like growth factor I binding; IPI:BHF-UCL. DR GO; GO:0031995; F:insulin-like growth factor II binding; IPI:BHF-UCL. DR GO; GO:0005159; F:insulin-like growth factor receptor binding; IDA:BHF-UCL. DR GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IPI:UniProtKB. DR GO; GO:0019904; F:protein domain specific binding; IPI:CAFA. DR GO; GO:0030295; F:protein kinase activator activity; IMP:BHF-UCL. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0044877; F:protein-containing complex binding; IPI:ARUK-UCL. DR GO; GO:0051425; F:PTB domain binding; IPI:UniProtKB. DR GO; GO:0030325; P:adrenal gland development; IEA:Ensembl. DR GO; GO:0097242; P:amyloid-beta clearance; ISS:ARUK-UCL. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IEA:Ensembl. DR GO; GO:0032869; P:cellular response to insulin stimulus; IDA:BHF-UCL. DR GO; GO:0097062; P:dendritic spine maintenance; ISS:ARUK-UCL. DR GO; GO:0008544; P:epidermis development; IEA:Ensembl. DR GO; GO:0031017; P:exocrine pancreas development; IEA:Ensembl. DR GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0042593; P:glucose homeostasis; IMP:BHF-UCL. DR GO; GO:0003007; P:heart morphogenesis; IMP:BHF-UCL. DR GO; GO:0008286; P:insulin receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0007612; P:learning; TAS:ARUK-UCL. DR GO; GO:0008584; P:male gonad development; IEA:Ensembl. DR GO; GO:0030238; P:male sex determination; IEA:Ensembl. DR GO; GO:0007613; P:memory; TAS:ARUK-UCL. DR GO; GO:1990535; P:neuron projection maintenance; ISS:ARUK-UCL. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IGI:BHF-UCL. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:0046326; P:positive regulation of D-glucose import; IDA:BHF-UCL. DR GO; GO:0048639; P:positive regulation of developmental growth; IMP:BHF-UCL. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IEA:Ensembl. DR GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; IDA:BHF-UCL. DR GO; GO:0045821; P:positive regulation of glycolytic process; IMP:BHF-UCL. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL. DR GO; GO:0051446; P:positive regulation of meiotic cell cycle; IEA:Ensembl. DR GO; GO:0045840; P:positive regulation of mitotic nuclear division; IMP:BHF-UCL. DR GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IMP:BHF-UCL. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:BHF-UCL. DR GO; GO:0043243; P:positive regulation of protein-containing complex disassembly; ISS:ARUK-UCL. DR GO; GO:0002092; P:positive regulation of receptor internalization; IDA:CACAO. DR GO; GO:0060267; P:positive regulation of respiratory burst; IDA:BHF-UCL. DR GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB. DR GO; GO:0031623; P:receptor internalization; IEA:Ensembl. DR GO; GO:0006898; P:receptor-mediated endocytosis; ISS:ARUK-UCL. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IMP:BHF-UCL. DR GO; GO:0045995; P:regulation of embryonic development; IMP:BHF-UCL. DR GO; GO:2000194; P:regulation of female gonad development; IEA:Ensembl. DR GO; GO:0046718; P:symbiont entry into host cell; IMP:BHF-UCL. DR GO; GO:0150104; P:transport across blood-brain barrier; NAS:ARUK-UCL. DR CDD; cd00063; FN3; 2. DR CDD; cd00064; FU; 1. DR CDD; cd05061; PTKc_InsR; 1. DR FunFam; 1.10.510.10:FF:000050; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.10.220.10:FF:000005; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000087; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000108; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:001010; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.30.200.20:FF:000026; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.80.20.20:FF:000001; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.80.20.20:FF:000002; Tyrosine-protein kinase receptor; 1. DR Gene3D; 2.10.220.10; Hormone Receptor, Insulin-like Growth Factor Receptor 1, Chain A, domain 2; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 4. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.20.20; Receptor L-domain; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR006211; Furin-like_Cys-rich_dom. DR InterPro; IPR006212; Furin_repeat. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR040969; Insulin_TMD. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR000494; Rcpt_L-dom. DR InterPro; IPR036941; Rcpt_L-dom_sf. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt. DR InterPro; IPR002011; Tyr_kinase_rcpt_2_CS. DR PANTHER; PTHR24416:SF535; INSULIN RECEPTOR; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00757; Furin-like; 1. DR Pfam; PF17870; Insulin_TMD; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF01030; Recep_L_domain; 2. DR PIRSF; PIRSF000620; Insulin_receptor; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00060; FN3; 3. DR SMART; SM00261; FU; 2. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 3. DR SUPFAM; SSF57184; Growth factor receptor domain; 1. DR SUPFAM; SSF52058; L domain-like; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Carbohydrate metabolism; KW Cell membrane; Cleavage on pair of basic residues; Diabetes mellitus; KW Direct protein sequencing; Disease variant; Disulfide bond; Endosome; KW Glycoprotein; Isopeptide bond; Kinase; Lysosome; Membrane; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; Receptor; KW Reference proteome; Repeat; S-nitrosylation; Signal; Transferase; KW Transmembrane; Transmembrane helix; Tyrosine-protein kinase; KW Ubl conjugation. FT SIGNAL 1..27 FT /evidence="ECO:0000269|PubMed:2211730, FT ECO:0000269|PubMed:2983222, ECO:0000269|PubMed:8257688" FT CHAIN 28..758 FT /note="Insulin receptor subunit alpha" FT /id="PRO_0000016687" FT CHAIN 763..1382 FT /note="Insulin receptor subunit beta" FT /id="PRO_0000016689" FT TOPO_DOM 28..758 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TOPO_DOM 763..956 FT /note="Extracellular" FT /evidence="ECO:0000305" FT TRANSMEM 957..979 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 980..1382 FT /note="Cytoplasmic" FT /evidence="ECO:0000305" FT DOMAIN 624..726 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 757..842 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 853..947 FT /note="Fibronectin type-III 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 1023..1298 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 686..708 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 733..741 FT /note="Insulin-binding" FT REGION 746..766 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 999 FT /note="Important for interaction with IRS1, SHC1 and FT STAT5B" FT /evidence="ECO:0000269|PubMed:9428692" FT REGION 1360..1382 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1361..1364 FT /note="PIK3R1-binding" FT ACT_SITE 1159 FT /note="Proton donor/acceptor" FT /evidence="ECO:0000269|PubMed:9312016" FT BINDING 1033 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:18278056" FT BINDING 1057 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:18278056" FT BINDING 1104..1110 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:18278056" FT BINDING 1163..1164 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:18278056" FT BINDING 1177 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:18278056" FT SITE 66 FT /note="Insulin-binding" FT /evidence="ECO:0000305" FT MOD_RES 400 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 401 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 407 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 992 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305" FT MOD_RES 999 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:3166375" FT MOD_RES 1011 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305" FT MOD_RES 1083 FT /note="S-nitrosocysteine" FT /evidence="ECO:0000269|PubMed:38056462" FT MOD_RES 1185 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14690593, FT ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887, FT ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165, FT ECO:0000269|PubMed:26584640, ECO:0000269|PubMed:3166375, FT ECO:0000269|PubMed:9312016" FT MOD_RES 1189 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14690593, FT ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887, FT ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165, FT ECO:0000269|PubMed:3166375, ECO:0000269|PubMed:9312016" FT MOD_RES 1190 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14690593, FT ECO:0000269|PubMed:16246733, ECO:0000269|PubMed:16271887, FT ECO:0000269|PubMed:18278056, ECO:0000269|PubMed:18767165, FT ECO:0000269|PubMed:26584640, ECO:0000269|PubMed:3166375, FT ECO:0000269|PubMed:9312016" FT MOD_RES 1355 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:3166375" FT MOD_RES 1361 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:3166375" FT CARBOHYD 43 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:23302862, ECO:0000269|PubMed:2983222" FT CARBOHYD 52 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:23302862" FT CARBOHYD 105 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 138 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:23302862" FT CARBOHYD 242 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:23302862" FT CARBOHYD 282 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:23302862" FT CARBOHYD 322 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 364 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147" FT CARBOHYD 424 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147" FT CARBOHYD 445 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16894147, FT ECO:0000269|PubMed:19349973" FT CARBOHYD 541 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:1472036, FT ECO:0000269|PubMed:19159218" FT CARBOHYD 633 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 651 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 698 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 769 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:2983222" FT CARBOHYD 782 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 920 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973" FT CARBOHYD 933 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 35..53 FT DISULFID 153..182 FT DISULFID 186..209 FT DISULFID 196..215 FT DISULFID 219..228 FT DISULFID 223..234 FT DISULFID 235..243 FT DISULFID 239..252 FT DISULFID 255..264 FT DISULFID 268..280 FT DISULFID 286..311 FT DISULFID 293..301 FT DISULFID 315..328 FT DISULFID 331..335 FT DISULFID 339..360 FT DISULFID 462..495 FT /evidence="ECO:0000269|PubMed:1472036" FT DISULFID 551 FT /note="Interchain" FT /evidence="ECO:0000269|PubMed:1472036" FT DISULFID 674..899 FT DISULFID 825..834 FT CROSSLNK 1079 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:27577745" FT VAR_SEQ 745..756 FT /note="Missing (in isoform Short)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:2983222, ECO:0000303|Ref.13" FT /id="VSP_002898" FT VARIANT 2 FT /note="A -> G (in dbSNP:rs7508518)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:2210055, ECO:0000269|PubMed:2280779, FT ECO:0000269|PubMed:2777789, ECO:0000269|PubMed:2806055, FT ECO:0000269|PubMed:2859121, ECO:0000269|PubMed:2983222, FT ECO:0000269|PubMed:3680248" FT /id="VAR_058395" FT VARIANT 42 FT /note="N -> K (in RMS; impairs transport to the plasma FT membrane and reduces the affinity to bind insulin; FT dbSNP:rs121913143)" FT /evidence="ECO:0000269|PubMed:2121734, FT ECO:0000269|PubMed:2365819" FT /id="VAR_004079" FT VARIANT 55 FT /note="V -> A (in LEPRCH; Verona-1; dbSNP:rs121913152)" FT /evidence="ECO:0000269|PubMed:1607067" FT /id="VAR_004080" FT VARIANT 56 FT /note="I -> T (in LEPRCH; abolishes post-translational FT processing; dbSNP:rs1555689937)" FT /evidence="ECO:0000269|PubMed:24498630" FT /id="VAR_079535" FT VARIANT 58 FT /note="G -> R (in LEPRCH; Helmond; inhibits processing and FT transport; dbSNP:rs52836744)" FT /evidence="ECO:0000269|PubMed:1730625" FT /id="VAR_004081" FT VARIANT 86 FT /note="D -> G (in IRAN type A)" FT /evidence="ECO:0000269|PubMed:9175790" FT /id="VAR_015907" FT VARIANT 89 FT /note="L -> P (in IRAN type A)" FT /evidence="ECO:0000269|PubMed:9175790" FT /id="VAR_015908" FT VARIANT 113 FT /note="R -> P (in LEPRCH; Atlanta-1; abolishes insulin FT binding; dbSNP:rs121913153)" FT /evidence="ECO:0000269|PubMed:12023989, FT ECO:0000269|PubMed:8419945" FT /id="VAR_004082" FT VARIANT 119 FT /note="A -> V (in LEPRCH; markedly impairs insulin binding; FT dbSNP:rs1347473020)" FT /evidence="ECO:0000269|PubMed:12023989" FT /id="VAR_015909" FT VARIANT 120 FT /note="L -> Q (in LEPRCH; inhibits receptor processing)" FT /evidence="ECO:0000269|PubMed:12970295" FT /id="VAR_031518" FT VARIANT 146 FT /note="I -> M (in LEPRCH; mild; dbSNP:rs121913159)" FT /evidence="ECO:0000269|PubMed:7815442, FT ECO:0000269|PubMed:8326490" FT /id="VAR_015539" FT VARIANT 167 FT /note="V -> L (in IRAN type A; dbSNP:rs938519025)" FT /evidence="ECO:0000269|PubMed:10733238" FT /id="VAR_015910" FT VARIANT 171 FT /note="Y -> H (in dbSNP:rs1051692)" FT /evidence="ECO:0000269|PubMed:2859121" FT /id="VAR_058396" FT VARIANT 220 FT /note="P -> L (in Ins resistance; severe; FT dbSNP:rs749094324)" FT /evidence="ECO:0000269|PubMed:8242067" FT /id="VAR_004083" FT VARIANT 228 FT /note="C -> R (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041429" FT VARIANT 236 FT /note="H -> R (in RMS and LEPRCH; Winnipeg; may impair FT receptor processing; dbSNP:rs121913145)" FT /evidence="ECO:0000269|PubMed:17201797, FT ECO:0000269|PubMed:2365819" FT /id="VAR_004084" FT VARIANT 256 FT /note="R -> C (in RMS; dbSNP:rs781007453)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079536" FT VARIANT 260 FT /note="L -> P (in LEPRCH; Geldeimalsen; dbSNP:rs121913141)" FT /evidence="ECO:0000269|PubMed:2479553" FT /id="VAR_004085" FT VARIANT 279 FT /note="R -> C (in IRAN type A; inhibits receptor FT internalization; dbSNP:rs1568470274)" FT /evidence="ECO:0000269|PubMed:12107746" FT /id="VAR_015540" FT VARIANT 279 FT /note="R -> H (in IRAN type A; interferes with receptor FT processing; dbSNP:rs1329693158)" FT /evidence="ECO:0000269|PubMed:12970295" FT /id="VAR_031519" FT VARIANT 280 FT /note="C -> Y (in IRAN type A)" FT /evidence="ECO:0000269|PubMed:11260230" FT /id="VAR_015911" FT VARIANT 286 FT /note="C -> Y (in LEPRCH; abolishes post-translational FT processing)" FT /evidence="ECO:0000269|PubMed:24498630" FT /id="VAR_079537" FT VARIANT 301 FT /note="C -> Y (in LEPRCH)" FT /evidence="ECO:0000269|PubMed:9703342" FT /id="VAR_015912" FT VARIANT 308 FT /note="Missing (in LEPRCH; abolishes insulin binding)" FT /evidence="ECO:0000269|PubMed:12023989, FT ECO:0000269|PubMed:7538143, ECO:0000269|PubMed:8636294" FT /id="VAR_015913" FT VARIANT 350 FT /note="S -> L (in RMS and LEPRCH; dbSNP:rs1974095413)" FT /evidence="ECO:0000269|PubMed:12970295, FT ECO:0000269|PubMed:8314008" FT /id="VAR_015914" FT VARIANT 362 FT /note="Missing (in LEPRCH)" FT /evidence="ECO:0000269|PubMed:12538626" FT /id="VAR_015541" FT VARIANT 386 FT /note="G -> S (in RMS; may impair receptor processing; FT dbSNP:rs764221583)" FT /evidence="ECO:0000269|PubMed:17201797" FT /id="VAR_031520" FT VARIANT 393 FT /note="G -> R (in LEPRCH; Verona-1; dbSNP:rs267607184)" FT /evidence="ECO:0000269|PubMed:1607067" FT /id="VAR_004086" FT VARIANT 409 FT /note="F -> V (in IRAN type A; dbSNP:rs121913142)" FT /evidence="ECO:0000269|PubMed:8388389" FT /id="VAR_004087" FT VARIANT 439 FT /note="W -> S (in LEPRCH; impairs transport of the receptor FT to the cell surface; dbSNP:rs121913158)" FT /evidence="ECO:0000269|PubMed:8188715" FT /id="VAR_015542" FT VARIANT 448 FT /note="I -> T (in dbSNP:rs1051691)" FT /evidence="ECO:0000269|PubMed:2859121" FT /id="VAR_015915" FT VARIANT 458 FT /note="N -> D (in LEPRCH; partially inhibits receptor FT processing and autophosphorylation; strongly impairs ERK FT phosphorylation; induces wild-type levels of IRS-1 FT phosphorylation; dbSNP:rs121913160)" FT /evidence="ECO:0000269|PubMed:12970295" FT /id="VAR_031521" FT VARIANT 487 FT /note="K -> E (in LEPRCH; ARK-1; dbSNP:rs121913136)" FT /evidence="ECO:0000269|PubMed:2834824" FT /id="VAR_004088" FT VARIANT 489 FT /note="N -> D (in IRAN type A; uncertain significance; FT dbSNP:rs1135401742)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079538" FT VARIANT 489 FT /note="N -> S (in IRAN type A; dbSNP:rs121913147)" FT /evidence="ECO:0000269|PubMed:2365819" FT /id="VAR_004089" FT VARIANT 492 FT /note="Q -> K" FT /evidence="ECO:0000269|PubMed:2859121" FT /id="VAR_015916" FT VARIANT 635 FT /note="S -> L (in RMS; decreases post-translational FT processing)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079539" FT VARIANT 657 FT /note="V -> F (in LEPRCH; impairs post-translational FT processing; dbSNP:rs1135401737)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079540" FT VARIANT 659 FT /note="W -> R (in LEPRCH; impairs post-translational FT processing)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079541" FT VARIANT 695 FT /note="Q -> R (in dbSNP:rs55906835)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041430" FT VARIANT 762 FT /note="R -> S (in IRAN type A; dbSNP:rs121913138)" FT /evidence="ECO:0000269|PubMed:3283938" FT /id="VAR_004090" FT VARIANT 811 FT /note="G -> S (in dbSNP:rs35045353)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041431" FT VARIANT 818 FT /note="Y -> C (in LEPRCH; abolishes post-translational FT processing)" FT /evidence="ECO:0000269|PubMed:22768670, FT ECO:0000269|PubMed:28765322" FT /id="VAR_079542" FT VARIANT 830 FT /note="P -> L (in dbSNP:rs2162771)" FT /id="VAR_055986" FT VARIANT 835 FT /note="S -> I (in RMS; impairs post-translational FT processing; dbSNP:rs1135401739)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079543" FT VARIANT 842 FT /note="A -> V (in RMS; decreases post-translational FT processing; dbSNP:rs1135401738)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079544" FT VARIANT 858 FT /note="T -> A (in T2D; dbSNP:rs182552223)" FT /evidence="ECO:0000269|PubMed:7657032" FT /id="VAR_015917" FT VARIANT 874 FT /note="P -> L (in RMS; impairs post-translational FT processing)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079545" FT VARIANT 878 FT /note="N -> S (in RMS; impairs post-translational FT processing; dbSNP:rs887190835)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079546" FT VARIANT 890..1382 FT /note="Missing (in LEPRCH)" FT /evidence="ECO:0000269|PubMed:22768670" FT /id="VAR_079547" FT VARIANT 925 FT /note="I -> T (in LEPRCH; abolishes post-translational FT processing; abolishes insulin binding; dbSNP:rs1599881881)" FT /evidence="ECO:0000269|PubMed:12023989, FT ECO:0000269|PubMed:28765322" FT /id="VAR_015918" FT VARIANT 926 FT /note="R -> W (in LEPRCH; markedly impairs insulin FT binding;impairs post-translational processing; FT dbSNP:rs911929963)" FT /evidence="ECO:0000269|PubMed:12023989, FT ECO:0000269|PubMed:28765322" FT /id="VAR_015919" FT VARIANT 937 FT /note="T -> M (in LEPRCH; impaired receptor processing; FT impairs post-translational processing; dbSNP:rs1972802448)" FT /evidence="ECO:0000269|PubMed:28765322, FT ECO:0000269|PubMed:9299395" FT /id="VAR_015920" FT VARIANT 997 FT /note="P -> T (in RMS; reduces insulin binding)" FT /evidence="ECO:0000269|PubMed:12023989" FT /id="VAR_015921" FT VARIANT 999..1382 FT /note="Missing (in RMS)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079548" FT VARIANT 1012 FT /note="V -> M (in dbSNP:rs1799816)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:8314008, ECO:0000269|PubMed:8432414, FT ECO:0000269|PubMed:8458533, ECO:0000269|PubMed:9199575" FT /id="VAR_004091" FT VARIANT 1020 FT /note="R -> Q (in IRAN type A; dbSNP:rs121913148)" FT /evidence="ECO:0000269|PubMed:2002058" FT /id="VAR_004092" FT VARIANT 1023 FT /note="I -> F" FT /evidence="ECO:0000269|PubMed:8890729" FT /id="VAR_015922" FT VARIANT 1035 FT /note="G -> V (in IRAN type A; dbSNP:rs121913135)" FT /evidence="ECO:0000269|PubMed:2544998" FT /id="VAR_004093" FT VARIANT 1054 FT /note="V -> M (in IRAN type A; uncertain significance; FT dbSNP:rs1135401741)" FT /evidence="ECO:0000269|PubMed:28765322" FT /id="VAR_079549" FT VARIANT 1055 FT /note="A -> V (in IRAN type A; dbSNP:rs1599874183)" FT /evidence="ECO:0000269|PubMed:10733238" FT /id="VAR_015923" FT VARIANT 1065 FT /note="L -> V (in dbSNP:rs56395521)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041432" FT VARIANT 1075 FT /note="A -> D (in IRAN type A)" FT /evidence="ECO:0000269|PubMed:8243830" FT /id="VAR_004094" FT VARIANT 1095 FT /note="K -> E (in a subject with non-insulin dependent FT diabetes mellitus; dbSNP:rs909008899)" FT /evidence="ECO:0000269|PubMed:2040394" FT /id="VAR_015924" FT VARIANT 1119 FT /note="R -> W (in LEPRCH; dbSNP:rs1229730671)" FT /evidence="ECO:0000269|PubMed:12970295, FT ECO:0000269|PubMed:9249867" FT /id="VAR_015925" FT VARIANT 1143 FT /note="I -> T (in RMS; reduces insulin binding)" FT /evidence="ECO:0000269|PubMed:10443650, FT ECO:0000269|PubMed:12023989" FT /id="VAR_015926" FT VARIANT 1158 FT /note="R -> Q (in T2D)" FT /evidence="ECO:0000269|PubMed:1470163" FT /id="VAR_015927" FT VARIANT 1158 FT /note="R -> W (in RMS; abolishes insulin binding; FT dbSNP:rs111993466)" FT /evidence="ECO:0000269|PubMed:10443650, FT ECO:0000269|PubMed:12023989" FT /id="VAR_015928" FT VARIANT 1161 FT /note="A -> T (in IRAN type A; dbSNP:rs121913139)" FT /evidence="ECO:0000269|PubMed:2168397" FT /id="VAR_004095" FT VARIANT 1162 FT /note="A -> E (in IRAN type A; impairs proteolytic FT processing; dbSNP:rs121913154)" FT /evidence="ECO:0000269|PubMed:8096518" FT /id="VAR_004096" FT VARIANT 1180 FT /note="M -> I (in a patient with insulin resistance; FT dbSNP:rs121913157)" FT /evidence="ECO:0000269|PubMed:1890161" FT /id="VAR_004097" FT VARIANT 1191 FT /note="R -> Q (in T2D; dbSNP:rs121913150)" FT /evidence="ECO:0000269|PubMed:1607076" FT /id="VAR_004098" FT VARIANT 1201 FT /note="R -> Q (in HHF5 and IRAN type A; interferes with FT kinase activation by insulin; dbSNP:rs121913156)" FT /evidence="ECO:0000269|PubMed:15161766, FT ECO:0000269|PubMed:8082780, ECO:0000269|PubMed:8288049" FT /id="VAR_015929" FT VARIANT 1201 FT /note="R -> W (in LEPRCH and RMS; reduces insulin binding FT possibly due to reduced receptor levels on the cell FT surface; dbSNP:rs1568426700)" FT /evidence="ECO:0000269|PubMed:12023989, FT ECO:0000269|PubMed:9703342" FT /id="VAR_015930" FT VARIANT 1205 FT /note="P -> L (in IRAN type A; moderate; FT dbSNP:rs1295645322)" FT /evidence="ECO:0000269|PubMed:1563582, FT ECO:0000269|PubMed:8314008" FT /id="VAR_004099" FT VARIANT 1206 FT /note="E -> D (in IRAN type A; accelerates degradation of FT the protein and impairs kinase activity)" FT /evidence="ECO:0000269|PubMed:7983039" FT /id="VAR_015931" FT VARIANT 1206 FT /note="E -> K (in LEPRCH)" FT /evidence="ECO:0000269|PubMed:9249867" FT /id="VAR_015932" FT VARIANT 1220 FT /note="W -> L (in IRAN type A; accelerates degradation of FT the protein and impairs kinase activity; dbSNP:rs52800171)" FT /evidence="ECO:0000269|PubMed:7983039, FT ECO:0000269|PubMed:8390949" FT /id="VAR_004100" FT VARIANT 1227 FT /note="W -> S (in IRAN type A; dbSNP:rs121913140)" FT /evidence="ECO:0000269|PubMed:1963473" FT /id="VAR_004101" FT VARIANT 1282 FT /note="T -> A (in dbSNP:rs55875349)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041433" FT VARIANT 1361 FT /note="Y -> C (in dbSNP:rs13306449)" FT /evidence="ECO:0000269|PubMed:7657032" FT /id="VAR_015933" FT VARIANT 1378 FT /note="R -> Q (in IRAN type A; dbSNP:rs52826008)" FT /evidence="ECO:0000269|PubMed:8314008" FT /id="VAR_015934" FT MUTAGEN 462 FT /note="C->A: Does not affect S-nitrosylation." FT /evidence="ECO:0000269|PubMed:38056462" FT MUTAGEN 825 FT /note="C->A: Does not affect S-nitrosylation." FT /evidence="ECO:0000269|PubMed:38056462" FT MUTAGEN 834 FT /note="C->A: Does not affect S-nitrosylation." FT /evidence="ECO:0000269|PubMed:38056462" FT MUTAGEN 991 FT /note="L->A: Reduces interaction with IRS1 but has no FT effect on interaction with SHC1." FT /evidence="ECO:0000269|PubMed:7559478" FT MUTAGEN 992 FT /note="Y->A: Reduces interaction with IRS1 but has no FT effect on interaction with SHC1." FT /evidence="ECO:0000269|PubMed:7559478" FT MUTAGEN 996..997 FT /note="NP->AA: Abolishes interaction with IRS1. Severely FT disrupts, but does not abolish interaction with SHC1." FT /evidence="ECO:0000269|PubMed:7559478" FT MUTAGEN 996 FT /note="N->A: Abolishes interaction with IRS1 and FT significantly reduces interaction with SHC1. Has no effect FT on interaction with PIK3R1." FT /evidence="ECO:0000269|PubMed:7537849, FT ECO:0000269|PubMed:7559478" FT MUTAGEN 997 FT /note="P->A: Abolishes interaction with IRS1 and FT significantly reduces interaction with SHC1. Has no effect FT on interaction with PIK3R1." FT /evidence="ECO:0000269|PubMed:7537849, FT ECO:0000269|PubMed:7559478" FT MUTAGEN 998 FT /note="E->A: Does not affect interaction with IRS1, SHC1 or FT PIK3R1." FT /evidence="ECO:0000269|PubMed:7537849" FT MUTAGEN 999 FT /note="Y->E: Abolishes interaction with IRS1 and SHC1." FT /evidence="ECO:0000269|PubMed:2842060, FT ECO:0000269|PubMed:7537849, ECO:0000269|PubMed:7559478, FT ECO:0000269|PubMed:9428692" FT MUTAGEN 999 FT /note="Y->F: Has no effect on insulin-stimulated FT autophosphorylation, but inhibits the biological activity FT of the receptor. Abolishes interaction with IRS1 and almost FT completely prevents interaction with SHC1. Has no effect on FT interaction with PIK3R1. Abolishes interaction with FT STAT5B." FT /evidence="ECO:0000269|PubMed:2842060, FT ECO:0000269|PubMed:7537849, ECO:0000269|PubMed:7559478, FT ECO:0000269|PubMed:9428692" FT MUTAGEN 1000 FT /note="L->A,R: Severely reduces interaction with SHC1. Has FT no effect on interaction with IRS1." FT /evidence="ECO:0000269|PubMed:7559478" FT MUTAGEN 1002 FT /note="A->D: Reduces interaction with IRS1 but has no FT effect on interaction with SHC1." FT /evidence="ECO:0000269|PubMed:7559478" FT MUTAGEN 1011 FT /note="Y->A: Increases kinase activity." FT /evidence="ECO:0000269|PubMed:12707268" FT MUTAGEN 1057 FT /note="K->A: Abolishes the kinase activity and abolishes FT interaction with IRS1, SHC1, GRB7 and PIK3R1." FT /evidence="ECO:0000269|PubMed:10803466, FT ECO:0000269|PubMed:3101064, ECO:0000269|PubMed:7537849" FT MUTAGEN 1057 FT /note="K->M,R: Abolishes the kinase activity." FT /evidence="ECO:0000269|PubMed:10803466, FT ECO:0000269|PubMed:3101064, ECO:0000269|PubMed:7537849" FT MUTAGEN 1079 FT /note="K->R: Increased cell surface stability." FT /evidence="ECO:0000269|PubMed:27577745" FT MUTAGEN 1083 FT /note="C->A: Reduced S-nitrosylation by BLVRB, leading to FT increased receptor tyrosine kinase activity." FT /evidence="ECO:0000269|PubMed:38056462" FT MUTAGEN 1159 FT /note="D->N: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:11598120" FT MUTAGEN 1163 FT /note="R->Q: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:11598120" FT MUTAGEN 1189 FT /note="Y->F: Reduced interaction with GRB7." FT /evidence="ECO:0000269|PubMed:10803466" FT MUTAGEN 1190 FT /note="Y->F: Strongly reduced interaction with GRB7." FT /evidence="ECO:0000269|PubMed:10803466" FT CONFLICT 601 FT /note="D -> N (in Ref. 19; AA sequence)" FT /evidence="ECO:0000305" FT CONFLICT 830 FT /note="P -> E (in Ref. 19; AA sequence)" FT /evidence="ECO:0000305" FT CONFLICT 1278 FT /note="K -> N (in Ref. 2; CAA26096)" FT /evidence="ECO:0000305" FT STRAND 33..42 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 45..50 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 53..65 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 70..72 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 73..75 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 83..86 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 88..93 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 100..102 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 103..105 FT /evidence="ECO:0007829|PDB:8X2M" FT STRAND 115..117 FT /evidence="ECO:0007829|PDB:6PXW" FT STRAND 118..124 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 141..149 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 155..158 FT /evidence="ECO:0007829|PDB:7U6E" FT HELIX 160..162 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 167..169 FT /evidence="ECO:0007829|PDB:7KD6" FT STRAND 171..175 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 176..178 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 187..192 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 199..201 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 204..206 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 209..211 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 221..223 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 224..226 FT /evidence="ECO:0007829|PDB:8X06" FT STRAND 230..232 FT /evidence="ECO:0007829|PDB:7MQO" FT STRAND 243..247 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 251..260 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 263..267 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 273..275 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 276..278 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 279..281 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 283..295 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 298..300 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 305..307 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 310..314 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 319..321 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 323..325 FT /evidence="ECO:0007829|PDB:7KD6" FT STRAND 327..330 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 332..334 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 338..348 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 351..355 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 356..359 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 361..369 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 373..375 FT /evidence="ECO:0007829|PDB:7U6E" FT HELIX 377..385 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 390..393 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 395..399 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 404..406 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 414..416 FT /evidence="ECO:0007829|PDB:8X06" FT TURN 422..424 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 425..430 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 437..439 FT /evidence="ECO:0007829|PDB:7U6E" FT TURN 441..443 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 447..450 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 452..458 FT /evidence="ECO:0007829|PDB:2HR7" FT HELIX 463..472 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 476..478 FT /evidence="ECO:0007829|PDB:2HR7" FT TURN 481..483 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 486..490 FT /evidence="ECO:0007829|PDB:2HR7" FT STRAND 498..500 FT /evidence="ECO:0007829|PDB:6PXW" FT STRAND 504..507 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 512..515 FT /evidence="ECO:0007829|PDB:7U6E" FT HELIX 524..526 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 527..536 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 538..540 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 552..554 FT /evidence="ECO:0007829|PDB:6HN5" FT STRAND 557..561 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 570..573 FT /evidence="ECO:0007829|PDB:6HN5" FT STRAND 577..580 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 588..597 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 601..603 FT /evidence="ECO:0007829|PDB:6PXW" FT STRAND 608..610 FT /evidence="ECO:0007829|PDB:4ZXB" FT STRAND 613..616 FT /evidence="ECO:0007829|PDB:7U6E" FT STRAND 626..631 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 633..636 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 638..643 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 654..658 FT /evidence="ECO:0007829|PDB:6PXV" FT HELIX 666..669 FT /evidence="ECO:0007829|PDB:6PXV" FT HELIX 732..740 FT /evidence="ECO:0007829|PDB:7KD6" FT STRAND 798..803 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 805..809 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 817..827 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 838..843 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 858..861 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 867..870 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 881..890 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 896..901 FT /evidence="ECO:0007829|PDB:6PXV" FT HELIX 902..908 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 910..913 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 918..931 FT /evidence="ECO:0007829|PDB:6PXV" FT STRAND 940..944 FT /evidence="ECO:0007829|PDB:6PXV" FT HELIX 953..979 FT /evidence="ECO:0007829|PDB:2MFR" FT STRAND 992..995 FT /evidence="ECO:0007829|PDB:5U1M" FT TURN 1003..1005 FT /evidence="ECO:0007829|PDB:4XLV" FT HELIX 1009..1011 FT /evidence="ECO:0007829|PDB:1IR3" FT HELIX 1014..1016 FT /evidence="ECO:0007829|PDB:1IRK" FT HELIX 1020..1022 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1023..1031 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1033..1043 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1046..1048 FT /evidence="ECO:0007829|PDB:2Z8C" FT STRAND 1050..1057 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1065..1078 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1089..1093 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1095..1098 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1100..1104 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1111..1117 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1119..1121 FT /evidence="ECO:0007829|PDB:3ETA" FT HELIX 1133..1152 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1154..1156 FT /evidence="ECO:0007829|PDB:2AUH" FT HELIX 1162..1164 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1165..1167 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1173..1175 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1181..1183 FT /evidence="ECO:0007829|PDB:1IRK" FT TURN 1185..1187 FT /evidence="ECO:0007829|PDB:3BU3" FT STRAND 1190..1192 FT /evidence="ECO:0007829|PDB:5HHW" FT STRAND 1194..1198 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1200..1202 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1205..1210 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1215..1230 FT /evidence="ECO:0007829|PDB:3BU3" FT TURN 1236..1239 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1242..1250 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1263..1272 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1277..1279 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1283..1290 FT /evidence="ECO:0007829|PDB:3BU3" FT HELIX 1291..1293 FT /evidence="ECO:0007829|PDB:5HHW" FT HELIX 1298..1301 FT /evidence="ECO:0007829|PDB:3BU3" FT TURN 1303..1305 FT /evidence="ECO:0007829|PDB:4XLV" FT HELIX 1307..1309 FT /evidence="ECO:0007829|PDB:8DWN" SQ SEQUENCE 1382 AA; 156333 MW; 709A955660739066 CRC64; MATGGRRGAA AAPLLVAVAA LLLGAAGHLY PGEVCPGMDI RNNLTRLHEL ENCSVIEGHL QILLMFKTRP EDFRDLSFPK LIMITDYLLL FRVYGLESLK DLFPNLTVIR GSRLFFNYAL VIFEMVHLKE LGLYNLMNIT RGSVRIEKNN ELCYLATIDW SRILDSVEDN YIVLNKDDNE ECGDICPGTA KGKTNCPATV INGQFVERCW THSHCQKVCP TICKSHGCTA EGLCCHSECL GNCSQPDDPT KCVACRNFYL DGRCVETCPP PYYHFQDWRC VNFSFCQDLH HKCKNSRRQG CHQYVIHNNK CIPECPSGYT MNSSNLLCTP CLGPCPKVCH LLEGEKTIDS VTSAQELRGC TVINGSLIIN IRGGNNLAAE LEANLGLIEE ISGYLKIRRS YALVSLSFFR KLRLIRGETL EIGNYSFYAL DNQNLRQLWD WSKHNLTITQ GKLFFHYNPK LCLSEIHKME EVSGTKGRQE RNDIALKTNG DQASCENELL KFSYIRTSFD KILLRWEPYW PPDFRDLLGF MLFYKEAPYQ NVTEFDGQDA CGSNSWTVVD IDPPLRSNDP KSQNHPGWLM RGLKPWTQYA IFVKTLVTFS DERRTYGAKS DIIYVQTDAT NPSVPLDPIS VSNSSSQIIL KWKPPSDPNG NITHYLVFWE RQAEDSELFE LDYCLKGLKL PSRTWSPPFE SEDSQKHNQS EYEDSAGECC SCPKTDSQIL KELEESSFRK TFEDYLHNVV FVPRKTSSGT GAEDPRPSRK RRSLGDVGNV TVAVPTVAAF PNTSSTSVPT SPEEHRPFEK VVNKESLVIS GLRHFTGYRI ELQACNQDTP EERCSVAAYV SARTMPEAKA DDIVGPVTHE IFENNVVHLM WQEPKEPNGL IVLYEVSYRR YGDEELHLCV SRKHFALERG CRLRGLSPGN YSVRIRATSL AGNGSWTEPT YFYVTDYLDV PSNIAKIIIG PLIFVFLFSV VIGSIYLFLR KRQPDGPLGP LYASSNPEYL SASDVFPCSV YVPDEWEVSR EKITLLRELG QGSFGMVYEG NARDIIKGEA ETRVAVKTVN ESASLRERIE FLNEASVMKG FTCHHVVRLL GVVSKGQPTL VVMELMAHGD LKSYLRSLRP EAENNPGRPP PTLQEMIQMA AEIADGMAYL NAKKFVHRDL AARNCMVAHD FTVKIGDFGM TRDIYETDYY RKGGKGLLPV RWMAPESLKD GVFTTSSDMW SFGVVLWEIT SLAEQPYQGL SNEQVLKFVM DGGYLDQPDN CPERVTDLMR MCWQFNPKMR PTFLEIVNLL KDDLHPSFPE VSFFHSEENK APESEELEME FEDMENVPLD RSSHCQREEA GGRDGGSSLG FKRSYEEHIP YTHMNGGKKN GRILTLPRSN PS // ID IRAK1_HUMAN Reviewed; 712 AA. AC P51617; D3DWW3; D3DWW4; Q7Z5V4; Q96C06; Q96RL2; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 01-DEC-2000, sequence version 2. DT 28-JAN-2026, entry version 237. DE RecName: Full=Interleukin-1 receptor-associated kinase 1 {ECO:0000303|PubMed:16024789}; DE Short=IRAK-1 {ECO:0000303|PubMed:16024789}; DE EC=2.7.11.1; GN Name=IRAK1 {ECO:0000312|HGNC:HGNC:6112}; Synonyms=IRAK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PARTIAL PROTEIN SEQUENCE, AND RP VARIANTS SER-196 AND LEU-532. RX PubMed=8599092; DOI=10.1126/science.271.5252.1128; RA Cao Z., Henzel W.J., Gao X.; RT "IRAK: a kinase associated with the interleukin-1 receptor."; RL Science 271:1128-1131(1996). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1). RX PubMed=10723722; DOI=10.1007/s003350010035; RA Reichwald K., Thiesen J., Wiehe T., Weitzel J., Poustka W.A., Rosenthal A., RA Platzer M., Stratling W.H., Kioschis P.; RT "Comparative sequence analysis of the MECP2-locus in human and mouse RT reveals new transcribed regions."; RL Mamm. Genome 11:182-190(2000). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, TISSUE SPECIFICITY, AND RP PHOSPHORYLATION. RX PubMed=11397809; DOI=10.1074/jbc.m103815200; RA Jensen L.E., Whitehead A.S.; RT "IRAK1b, a novel alternative splice variant of interleukin-1 receptor- RT associated kinase (IRAK), mediates interleukin-1 signaling and has RT prolonged stability."; RL J. Biol. Chem. 276:29037-29044(2001). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4). RX PubMed=16024789; DOI=10.1128/mcb.25.15.6521-6532.2005; RA Rao N., Nguyen S., Ngo K., Fung-Leung W.P.; RT "A novel splice variant of interleukin-1 receptor (IL-1R)-associated kinase RT 1 plays a negative regulatory role in Toll/IL-1R-induced inflammatory RT signaling."; RL Mol. Cell. Biol. 25:6521-6532(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15772651; DOI=10.1038/nature03440; RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., RA Rogers J., Bentley D.R.; RT "The DNA sequence of the human X chromosome."; RL Nature 434:325-337(2005). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4). RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP INTERACTION WITH MYD88. RX PubMed=9430229; DOI=10.1016/s1074-7613(00)80402-1; RA Wesche H., Henzel W.J., Shillinglaw W., Li S., Cao Z.; RT "MyD88: an adapter that recruits IRAK to the IL-1 receptor complex."; RL Immunity 7:837-847(1997). RN [9] RP INTERACTION WITH TOLLIP. RX PubMed=10854325; DOI=10.1038/35014038; RA Burns K., Clatworthy J., Martin L., Martinon F., Plumpton C., Maschera B., RA Lewis A., Ray K., Tschopp J., Volpe F.; RT "Tollip, a new component of the IL-1R1 pathway, links IRAK to the IL-1 RT receptor."; RL Nat. Cell Biol. 2:346-351(2000). RN [10] RP INTERACTION WITH IRAK4. RX PubMed=11960013; DOI=10.1073/pnas.082100399; RA Li S., Strelow A., Fontana E.J., Wesche H.; RT "IRAK4: a novel member of the IRAK family with the properties of an IRAK- RT kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 99:5567-5572(2002). RN [11] RP INTERACTION WITH PELI1 AND TRAF6. RX PubMed=12496252; DOI=10.1074/jbc.m212112200; RA Jiang Z., Johnson H.J., Nie H., Qin J., Bird T.A., Li X.; RT "Pellino 1 is required for interleukin-1 (IL-1)-mediated signaling through RT its interaction with the IL-1 receptor-associated kinase 4 (IRAK4)-IRAK- RT tumor necrosis factor receptor-associated factor 6 (TRAF6) complex."; RL J. Biol. Chem. 278:10952-10956(2003). RN [12] RP FUNCTION IN PHOSPHORYLATION OF PELI2. RX PubMed=12860405; DOI=10.1016/s0014-5793(03)00697-5; RA Strelow A., Kollewe C., Wesche H.; RT "Characterization of Pellino2, a substrate of IRAK1 and IRAK4."; RL FEBS Lett. 547:157-161(2003). RN [13] RP PHOSPHORYLATION BY IRAK4. RX PubMed=12538665; DOI=10.1084/jem.20021790; RA Burns K., Janssens S., Brissoni B., Olivos N., Beyaert R., Tschopp J.; RT "Inhibition of interleukin 1 receptor/Toll-like receptor signaling through RT the alternatively spliced, short form of MyD88 is due to its failure to RT recruit IRAK-4."; RL J. Exp. Med. 197:263-268(2003). RN [14] RP INTERACTION WITH PELI3. RX PubMed=12874243; DOI=10.4049/jimmunol.171.3.1500; RA Jensen L.E., Whitehead A.S.; RT "Pellino3, a novel member of the Pellino protein family, promotes RT activation of c-Jun and Elk-1 and may act as a scaffolding protein."; RL J. Immunol. 171:1500-1506(2003). RN [15] RP FUNCTION, AND PHOSPHORYLATION AT THR-66. RX PubMed=14684752; DOI=10.1074/jbc.c300431200; RA Mamidipudi V., Lin C., Seibenhener M.L., Wooten M.W.; RT "Regulation of interleukin receptor-associated kinase (IRAK) RT phosphorylation and signaling by iota protein kinase C."; RL J. Biol. Chem. 279:4161-4165(2004). RN [16] RP PHOSPHORYLATION AT THR-209 AND THR-387, DOMAIN, AND MUTAGENESIS OF THR-209 RP AND THR-387. RX PubMed=14625308; DOI=10.1074/jbc.m309251200; RA Kollewe C., Mackensen A.C., Neumann D., Knop J., Cao P., Li S., Wesche H., RA Martin M.U.; RT "Sequential autophosphorylation steps in the interleukin-1 receptor- RT associated kinase-1 regulate its availability as an adapter in interleukin- RT 1 signaling."; RL J. Biol. Chem. 279:5227-5236(2004). RN [17] RP FUNCTION, AND MUTAGENESIS OF LYS-239. RX PubMed=15084582; DOI=10.1074/jbc.m400785200; RA Qin J., Jiang Z., Qian Y., Casanova J.-L., Li X.; RT "IRAK4 kinase activity is redundant for interleukin-1 (IL-1) receptor- RT associated kinase phosphorylation and IL-1 responsiveness."; RL J. Biol. Chem. 279:26748-26753(2004). RN [18] RP FUNCTION IN PHOSPHORYLATION OF STAT3. RX PubMed=15465816; DOI=10.1074/jbc.m410369200; RA Huang Y., Li T., Sane D.C., Li L.; RT "IRAK1 serves as a novel regulator essential for lipopolysaccharide-induced RT interleukin-10 gene expression."; RL J. Biol. Chem. 279:51697-51703(2004). RN [19] RP INTERACTION WITH IL1RL1. RX PubMed=16286016; DOI=10.1016/j.immuni.2005.09.015; RA Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K., RA Zurawski G., Moshrefi M., Qin J., Li X., Gorman D.M., Bazan J.F., RA Kastelein R.A.; RT "IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor- RT related protein ST 2 and induces T helper type 2-associated cytokines."; RL Immunity 23:479-490(2005). RN [20] RP FUNCTION IN PHOSPHORYLATION OF IRF7. RX PubMed=15767370; DOI=10.1084/jem.20042372; RA Uematsu S., Sato S., Yamamoto M., Hirotani T., Kato H., Takeshita F., RA Matsuda M., Coban C., Ishii K.J., Kawai T., Takeuchi O., Akira S.; RT "Interleukin-1 receptor-associated kinase-1 plays an essential role for RT Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} RT induction."; RL J. Exp. Med. 201:915-923(2005). RN [21] RP IDENTIFICATION IN COMPLEX WITH IRAK4; MYD88; PELI1 AND TRAF6. RX PubMed=16951688; DOI=10.1038/ni1383; RA Choi K.C., Lee Y.S., Lim S., Choi H.K., Lee C.H., Lee E.K., Hong S., RA Kim I.H., Kim S.J., Park S.H.; RT "Smad6 negatively regulates interleukin 1-receptor-Toll-like receptor RT signaling through direct interaction with the adapter Pellino-1."; RL Nat. Immunol. 7:1057-1065(2006). RN [22] RP SUMOYLATION, AND SUBCELLULAR LOCATION. RX PubMed=16690127; DOI=10.1016/j.molimm.2006.03.021; RA Su J., Richter K., Zhang C., Gu Q., Li L.; RT "Differential regulation of interleukin-1 receptor associated kinase 1 RT (IRAK1) splice variants."; RL Mol. Immunol. 44:900-905(2007). RN [23] RP FUNCTION IN PHOSPHORYLATION OF PELI1. RX PubMed=17997719; DOI=10.1042/bj20071365; RA Ordureau A., Smith H., Windheim M., Peggie M., Carrick E., Morrice N., RA Cohen P.; RT "The IRAK-catalysed activation of the E3 ligase function of Pellino RT isoforms induces the Lys63-linked polyubiquitination of IRAK1."; RL Biochem. J. 409:43-52(2008). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-131, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [25] RP UBIQUITINATION AT LYS-134 AND LYS-180 BY TRAF6, AND INTERACTION WITH RP IKBKG/NEMO. RX PubMed=18347055; DOI=10.1128/mcb.02098-07; RA Conze D.B., Wu C.J., Thomas J.A., Landstrom A., Ashwell J.D.; RT "Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 RT receptor- and toll-like receptor-mediated NF-kappaB activation."; RL Mol. Cell. Biol. 28:3538-3547(2008). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [27] RP UBIQUITINATION. RX PubMed=19675569; DOI=10.1038/nature08247; RA Xia Z.-P., Sun L., Chen X., Pineda G., Jiang X., Adhikari A., Zeng W., RA Chen Z.J.; RT "Direct activation of protein kinases by unanchored polyubiquitin chains."; RL Nature 461:114-119(2009). RN [28] RP FUNCTION IN PHOSPHORYLATION OF TIRAP. RX PubMed=20400509; DOI=10.1074/jbc.m109.098137; RA Dunne A., Carpenter S., Brikos C., Gray P., Strelow A., Wesche H., RA Morrice N., O'Neill L.A.; RT "IRAK1 and IRAK4 promote phosphorylation, ubiquitination, and degradation RT of MyD88 adaptor-like (Mal)."; RL J. Biol. Chem. 285:18276-18282(2010). RN [29] RP REVIEW ON FUNCTION. RX PubMed=17890055; DOI=10.1016/j.cellsig.2007.08.009; RA Gottipati S., Rao N.L., Fung-Leung W.P.; RT "IRAK1: a critical signaling mediator of innate immunity."; RL Cell. Signal. 20:269-276(2008). RN [30] RP INTERACTION WITH NFATC4, AND MUTAGENESIS OF ASP-340. RX PubMed=18691762; DOI=10.1016/j.molimm.2008.06.023; RA Wang D., Fasciano S., Li L.; RT "The interleukin-1 receptor associated kinase 1 contributes to the RT regulation of NFAT."; RL Mol. Immunol. 45:3902-3908(2008). RN [31] RP REVIEW ON FUNCTION. RX PubMed=19022706; DOI=10.1016/j.it.2008.10.001; RA Moynagh P.N.; RT "The Pellino family: IRAK E3 ligases with emerging roles in innate immune RT signalling."; RL Trends Immunol. 30:33-42(2009). RN [32] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-371; SER-375 AND SER-556, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [34] RP INTERACTION WITH INAVA. RX PubMed=28436939; DOI=10.1172/jci86282; RA Yan J., Hedl M., Abraham C.; RT "An inflammatory bowel disease-risk variant in INAVA decreases pattern RT recognition receptor-induced outcomes."; RL J. Clin. Invest. 127:2192-2205(2017). RN [35] RP INTERACTION WITH MUMPS VIRUS PROTEIN SH. RX PubMed=28659487; DOI=10.1128/jvi.01037-17; RA Franz S., Rennert P., Woznik M., Gruetzke J., Luedde A., Arriero Pais E.M., RA Finsterbusch T., Geyer H., Mankertz A., Friedrich N.; RT "Mumps virus SH protein inhibits NF-kappaB activation by interacting with RT tumor necrosis factor receptor 1, interleukin-1 receptor 1, and Toll-like RT receptor 3 complexes."; RL J. Virol. 91:0-0(2017). RN [36] RP INTERACTION WITH PELI1. RX PubMed=29883609; DOI=10.1016/j.molcel.2018.05.016; RA Choi S.W., Park H.H., Kim S., Chung J.M., Noh H.J., Kim S.K., Song H.K., RA Lee C.W., Morgan M.J., Kang H.C., Kim Y.S.; RT "PELI1 selectively targets kinase-active RIP3 for ubiquitylation-dependent RT proteasomal degradation."; RL Mol. Cell 70:920-935(2018). RN [37] RP INTERACTION WITH ALPHAVIRUS CAPSID PROTEINS (MICROBIAL INFECTION). RX PubMed=33673546; DOI=10.3390/v13030377; RA Landers V.D., Wilkey D.W., Merchant M.L., Mitchell T.C., Sokoloski K.J.; RT "The Alphaviral Capsid Protein Inhibits IRAK1-Dependent TLR Signaling."; RL Viruses 13:0-0(2021). RN [38] RP VARIANTS [LARGE SCALE ANALYSIS] MET-398; MET-412; HIS-421; LEU-532; RP SER-619; MET-625; TRP-638 AND GLY-690. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase that plays a critical role in CC initiating innate immune response against foreign pathogens. Involved CC in Toll-like receptor (TLR) and IL-1R signaling pathways. Is rapidly CC recruited by MYD88 to the receptor-signaling complex upon TLR CC activation. Association with MYD88 leads to IRAK1 phosphorylation by CC IRAK4 and subsequent autophosphorylation and kinase activation. CC Phosphorylates E3 ubiquitin ligases Pellino proteins (PELI1, PELI2 and CC PELI3) to promote pellino-mediated polyubiquitination of IRAK1. Then, CC the ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated CC IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the CC NEMO-IKKA-IKKB complex. In turn, MAP3K7/TAK1 activates IKKs (CHUK/IKKA CC and IKBKB/IKKB) leading to NF-kappa-B nuclear translocation and CC activation. Alternatively, phosphorylates TIRAP to promote its CC ubiquitination and subsequent degradation. Phosphorylates the CC interferon regulatory factor 7 (IRF7) to induce its activation and CC translocation to the nucleus, resulting in transcriptional activation CC of type I IFN genes, which drive the cell in an antiviral state. When CC sumoylated, translocates to the nucleus and phosphorylates STAT3. CC {ECO:0000269|PubMed:11397809, ECO:0000269|PubMed:12860405, CC ECO:0000269|PubMed:14684752, ECO:0000269|PubMed:15084582, CC ECO:0000269|PubMed:15465816, ECO:0000269|PubMed:15767370, CC ECO:0000269|PubMed:17997719, ECO:0000269|PubMed:20400509}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- SUBUNIT: Homodimer (By similarity). Forms a complex with TRAF6, PELI1, CC IRAK4 and MYD88 (PubMed:16951688). Direct binding of SMAD6 to PELI1 CC prevents complex formation and hence negatively regulates IL1R-TLR CC signaling and eventually NF-kappa-B-mediated gene expression CC (PubMed:16951688). The TRAF6-PELI1-IRAK4-MYD88 complex recruits CC MAP3K7/TAK1, TAB1 and TAB2 to mediate NF-kappa-B activation CC (PubMed:16951688). Interaction with MYD88 recruits IRAK1 to the CC stimulated receptor complex (PubMed:9430229). Interacts with TOLLIP; CC this interaction occurs in the cytosol prior to receptor activation CC (PubMed:10854325). Interacts with IL1RL1 (PubMed:16286016). Interacts CC with PELI1 and TRAF6 (PubMed:12496252). Interacts (when CC polyubiquitinated) with IKBKG/NEMO (PubMed:18347055). Interacts with CC RSAD2/viperin (By similarity). Interacts with IRAK1BP1 (By similarity). CC Interacts with PELI2 (By similarity). Interacts with ZC3H12A; this CC interaction increases the interaction between ZC3H12A and IKBKB/IKKB CC (By similarity). Interacts with IRAK4 (PubMed:11960013). Interacts with CC PELI3 (PubMed:12874243). Interacts with INAVA; the interaction takes CC place upon PRR stimulation (PubMed:28436939). Interacts (via C- CC terminus) with NFATC4 (via N-terminus) (PubMed:18691762). CC {ECO:0000250|UniProtKB:Q62406, ECO:0000269|PubMed:10854325, CC ECO:0000269|PubMed:11960013, ECO:0000269|PubMed:12496252, CC ECO:0000269|PubMed:12874243, ECO:0000269|PubMed:16286016, CC ECO:0000269|PubMed:16951688, ECO:0000269|PubMed:18347055, CC ECO:0000269|PubMed:18691762, ECO:0000269|PubMed:28436939, CC ECO:0000269|PubMed:29883609, ECO:0000269|PubMed:9430229}. CC -!- SUBUNIT: (Microbial infection) Interacts with mumps virus protein SH; CC this interaction inhibits downstream NF-kappa-B pathway activation. CC {ECO:0000269|PubMed:28659487}. CC -!- SUBUNIT: (Microbial infection) Interacts with alphaviruses SINV, CHIKV, CC RRV, VEEV and EEEV capsid proteins; the interactions lead to inhibition CC of IRAK1-dependent signaling. {ECO:0000269|PubMed:33673546}. CC -!- INTERACTION: CC P51617; O43187: IRAK2; NbExp=3; IntAct=EBI-358664, EBI-447733; CC P51617; Q9Y616: IRAK3; NbExp=3; IntAct=EBI-358664, EBI-447690; CC P51617; Q15306: IRF4; NbExp=2; IntAct=EBI-358664, EBI-751345; CC P51617; Q92985: IRF7; NbExp=2; IntAct=EBI-358664, EBI-968267; CC P51617; Q99836: MYD88; NbExp=4; IntAct=EBI-358664, EBI-447677; CC P51617; Q96FA3: PELI1; NbExp=4; IntAct=EBI-358664, EBI-448369; CC P51617; Q9HAT8: PELI2; NbExp=4; IntAct=EBI-358664, EBI-448407; CC P51617; Q8N2H9-2: PELI3; NbExp=2; IntAct=EBI-358664, EBI-448472; CC P51617; Q13526: PIN1; NbExp=10; IntAct=EBI-358664, EBI-714158; CC P51617; Q86WV6: STING1; NbExp=2; IntAct=EBI-358664, EBI-2800345; CC P51617; P58753: TIRAP; NbExp=3; IntAct=EBI-358664, EBI-528644; CC P51617; Q9Y4K3: TRAF6; NbExp=4; IntAct=EBI-358664, EBI-359276; CC P51617; Q8VCW4: Unc93b1; Xeno; NbExp=2; IntAct=EBI-358664, EBI-6116986; CC P51617; Q5D1E7: Zc3h12a; Xeno; NbExp=3; IntAct=EBI-358664, EBI-5326026; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:16690127}. Nucleus CC {ECO:0000269|PubMed:16690127}. Lipid droplet {ECO:0000250}. CC Note=Translocates to the nucleus when sumoylated. RSAD2/viperin CC recruits it to the lipid droplet (By similarity). {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; Synonyms=a; CC IsoId=P51617-1; Sequence=Displayed; CC Name=2; Synonyms=b; CC IsoId=P51617-2; Sequence=VSP_011851; CC Name=3; CC IsoId=P51617-3; Sequence=VSP_011849, VSP_011850, VSP_011851; CC Name=4; CC IsoId=P51617-4; Sequence=VSP_041950; CC -!- TISSUE SPECIFICITY: Isoform 1 and isoform 2 are ubiquitously expressed CC in all tissues examined, with isoform 1 being more strongly expressed CC than isoform 2. {ECO:0000269|PubMed:11397809}. CC -!- DOMAIN: The ProST region is composed of many proline and serine CC residues (more than 20 of each) and some threonines. This region is the CC site of IRAK-1 hyperphosphorylation. {ECO:0000269|PubMed:14625308}. CC -!- PTM: Following recruitment on the activated receptor complex, CC phosphorylated on Thr-209, probably by IRAK4, resulting in a CC conformational change of the kinase domain, allowing further CC phosphorylations to take place. Thr-387 phosphorylation in the CC activation loop is required to achieve full enzymatic activity. CC {ECO:0000269|PubMed:11397809, ECO:0000269|PubMed:12538665, CC ECO:0000269|PubMed:14625308, ECO:0000269|PubMed:14684752}. CC -!- PTM: Polyubiquitinated by TRAF6 after cell stimulation with IL-1-beta CC by PELI1, PELI2 and PELI3. Polyubiquitination occurs with polyubiquitin CC chains linked through 'Lys-63'. Ubiquitination promotes interaction CC with NEMO/IKBKG. Also sumoylated; leading to nuclear translocation. CC {ECO:0000269|PubMed:16690127, ECO:0000269|PubMed:18347055, CC ECO:0000269|PubMed:19675569}. CC -!- MISCELLANEOUS: [Isoform 2]: Inactive. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. Pelle subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L76191; AAC41949.1; -; mRNA. DR EMBL; AF030876; AAC08756.1; -; Genomic_DNA. DR EMBL; AF346607; AAK62888.1; -; mRNA. DR EMBL; DQ054788; AAY88246.1; -; mRNA. DR EMBL; U52112; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471172; EAW72762.1; -; Genomic_DNA. DR EMBL; CH471172; EAW72763.1; -; Genomic_DNA. DR EMBL; CH471172; EAW72764.1; -; Genomic_DNA. DR EMBL; CH471172; EAW72765.1; -; Genomic_DNA. DR EMBL; BC054000; AAH54000.1; -; mRNA. DR EMBL; BC014963; AAH14963.1; -; mRNA. DR CCDS; CCDS14740.1; -. [P51617-1] DR CCDS; CCDS35443.1; -. [P51617-4] DR CCDS; CCDS35444.1; -. [P51617-2] DR PIR; G02512; G02512. DR RefSeq; NP_001020413.1; NM_001025242.2. [P51617-2] DR RefSeq; NP_001020414.1; NM_001025243.2. [P51617-4] DR RefSeq; NP_001560.2; NM_001569.4. [P51617-1] DR PDB; 6BFN; X-ray; 2.26 A; A/B=194-530. DR PDBsum; 6BFN; -. DR AlphaFoldDB; P51617; -. DR SMR; P51617; -. DR BioGRID; 109863; 365. DR ComplexPortal; CPX-10281; Myddosome core complex. DR CORUM; P51617; -. DR DIP; DIP-397N; -. DR ELM; P51617; -. DR FunCoup; P51617; 1800. DR IntAct; P51617; 221. DR MINT; P51617; -. DR STRING; 9606.ENSP00000358997; -. DR BindingDB; P51617; -. DR ChEMBL; CHEMBL3357; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; P51617; -. DR GuidetoPHARMACOLOGY; 2042; -. DR GlyGen; P51617; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P51617; -. DR PhosphoSitePlus; P51617; -. DR BioMuta; IRAK1; -. DR DMDM; 8928535; -. DR CPTAC; CPTAC-2897; -. DR CPTAC; CPTAC-2898; -. DR jPOST; P51617; -. DR MassIVE; P51617; -. DR PaxDb; 9606-ENSP00000358997; -. DR PeptideAtlas; P51617; -. DR ProteomicsDB; 56349; -. [P51617-1] DR ProteomicsDB; 56350; -. [P51617-2] DR ProteomicsDB; 56351; -. [P51617-3] DR ProteomicsDB; 56352; -. [P51617-4] DR Pumba; P51617; -. DR Antibodypedia; 3845; 1016 antibodies from 48 providers. DR DNASU; 3654; -. DR Ensembl; ENST00000369974.6; ENSP00000358991.2; ENSG00000184216.16. [P51617-4] DR Ensembl; ENST00000369980.8; ENSP00000358997.3; ENSG00000184216.16. [P51617-1] DR Ensembl; ENST00000393687.6; ENSP00000377291.2; ENSG00000184216.16. [P51617-2] DR GeneID; 3654; -. DR KEGG; hsa:3654; -. DR MANE-Select; ENST00000369980.8; ENSP00000358997.3; NM_001569.4; NP_001560.2. DR UCSC; uc004fjr.2; human. [P51617-1] DR AGR; HGNC:6112; -. DR ClinPGx; PA29912; -. DR CTD; 3654; -. DR DisGeNET; 3654; -. DR GeneCards; IRAK1; -. DR HGNC; HGNC:6112; IRAK1. DR HPA; ENSG00000184216; Low tissue specificity. DR MalaCards; IRAK1; -. DR MIM; 300283; gene. DR OpenTargets; ENSG00000184216; -. DR Orphanet; 93552; Pediatric systemic lupus erythematosus. DR Orphanet; 536; Systemic lupus erythematosus. DR VEuPathDB; HostDB:ENSG00000184216; -. DR eggNOG; KOG1187; Eukaryota. DR GeneTree; ENSGT00940000160502; -. DR HOGENOM; CLU_000288_173_1_1; -. DR InParanoid; P51617; -. DR OMA; MTQVYES; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P51617; 13 GO annotations based on evolutionary models. DR PhylomeDB; P51617; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; P51617; -. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-166058; MyD88:MAL(TIRAP) cascade initiated on plasma membrane. DR Reactome; R-HSA-168638; NOD1/2 Signaling Pathway. DR Reactome; R-HSA-209543; p75NTR recruits signalling complexes. DR Reactome; R-HSA-209560; NF-kB is activated and signals survival. DR Reactome; R-HSA-445989; TAK1-dependent IKK and NF-kappa-B activation. DR Reactome; R-HSA-450302; activated TAK1 mediates p38 MAPK activation. DR Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8986944; Transcriptional Regulation by MECP2. DR Reactome; R-HSA-9020702; Interleukin-1 signaling. DR Reactome; R-HSA-937039; IRAK1 recruits IKK complex. DR Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses. DR Reactome; R-HSA-975110; TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling. DR Reactome; R-HSA-975138; TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation. DR Reactome; R-HSA-975144; IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation. DR Reactome; R-HSA-975155; MyD88 dependent cascade initiated on endosome. DR Reactome; R-HSA-975871; MyD88 cascade initiated on plasma membrane. DR SignaLink; P51617; -. DR SIGNOR; P51617; -. DR Agora; ENSG00000184216; -. DR BioGRID-ORCS; 3654; 20 hits in 816 CRISPR screens. DR ChiTaRS; IRAK1; human. DR GeneWiki; IRAK1; -. DR GenomeRNAi; 3654; -. DR Pharos; P51617; Tchem. DR PRO; PR:P51617; -. DR Proteomes; UP000005640; Chromosome X. DR RNAct; P51617; protein. DR Bgee; ENSG00000184216; Expressed in parotid gland and 203 other cell types or tissues. DR ExpressionAtlas; P51617; baseline and differential. DR GO; GO:0009986; C:cell surface; IDA:UniProt. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0010008; C:endosome membrane; TAS:Reactome. DR GO; GO:0005811; C:lipid droplet; ISS:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0031072; F:heat shock protein binding; IEA:Ensembl. DR GO; GO:0042802; F:identical protein binding; IPI:UniProtKB. DR GO; GO:0016301; F:kinase activity; IDA:MGI. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL. DR GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL. DR GO; GO:0004672; F:protein kinase activity; IDA:MGI. DR GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0007249; P:canonical NF-kappaB signal transduction; IMP:ARUK-UCL. DR GO; GO:0034605; P:cellular response to heat; IEA:Ensembl. DR GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl. DR GO; GO:0045087; P:innate immune response; IBA:GO_Central. DR GO; GO:0070498; P:interleukin-1-mediated signaling pathway; IDA:UniProt. DR GO; GO:0038172; P:interleukin-33-mediated signaling pathway; IMP:UniProt. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0007254; P:JNK cascade; IEA:Ensembl. DR GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IMP:BHF-UCL. DR GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; TAS:BHF-UCL. DR GO; GO:0043124; P:negative regulation of canonical NF-kappaB signal transduction; IMP:BHF-UCL. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IMP:MGI. DR GO; GO:1904996; P:positive regulation of leukocyte adhesion to vascular endothelial cell; IMP:ARUK-UCL. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB. DR GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl. DR GO; GO:0032481; P:positive regulation of type I interferon production; IMP:BHF-UCL. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0001959; P:regulation of cytokine-mediated signaling pathway; IMP:BHF-UCL. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IEA:UniProtKB-ARBA. DR GO; GO:0070555; P:response to interleukin-1; IMP:BHF-UCL. DR GO; GO:0032496; P:response to lipopolysaccharide; IMP:BHF-UCL. DR GO; GO:0008063; P:Toll signaling pathway; IBA:GO_Central. DR GO; GO:0034134; P:toll-like receptor 2 signaling pathway; IMP:BHF-UCL. DR GO; GO:0034142; P:toll-like receptor 4 signaling pathway; IBA:GO_Central. DR GO; GO:0034162; P:toll-like receptor 9 signaling pathway; TAS:Reactome. DR GO; GO:0002224; P:toll-like receptor signaling pathway; TAS:Reactome. DR GO; GO:0060337; P:type I interferon-mediated signaling pathway; IMP:BHF-UCL. DR CDD; cd08794; Death_IRAK1; 1. DR DisProt; DP02467; -. DR FunFam; 1.10.533.10:FF:000027; Interleukin-1 receptor-associated kinase 1 (Predicted); 1. DR FunFam; 3.30.200.20:FF:000300; Interleukin-1 receptor-associated kinase 1 (Predicted); 1. DR FunFam; 1.10.510.10:FF:000424; Putative interleukin-1 receptor-associated kinase 1; 1. DR Gene3D; 1.10.533.10; Death Domain, Fas; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011029; DEATH-like_dom_sf. DR InterPro; IPR000488; Death_dom. DR InterPro; IPR035533; Death_IRAK1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR27001:SF939; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; 1. DR PANTHER; PTHR27001; OS01G0253100 PROTEIN; 1. DR Pfam; PF00531; Death; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF47986; DEATH domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cytoplasm; KW Direct protein sequencing; Host-virus interaction; Immunity; KW Innate immunity; Isopeptide bond; Kinase; Lipid droplet; Magnesium; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase; KW Ubl conjugation. FT CHAIN 1..712 FT /note="Interleukin-1 receptor-associated kinase 1" FT /id="PRO_0000086030" FT DOMAIN 27..106 FT /note="Death" FT DOMAIN 212..521 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 105..187 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 110..211 FT /note="ProST region" FT REGION 532..591 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 613..660 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 690..712 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 115..133 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 137..154 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 543..553 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 562..575 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 643..658 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 340 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 218..226 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 239 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 342..345 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 358 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 66 FT /note="Phosphothreonine; by PKC/PRKCI" FT /evidence="ECO:0000269|PubMed:14684752" FT MOD_RES 131 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 209 FT /note="Phosphothreonine; by IRAK4" FT /evidence="ECO:0000305|PubMed:14625308" FT MOD_RES 371 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 375 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 387 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:14625308" FT MOD_RES 556 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 134 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:18347055" FT CROSSLNK 180 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:18347055" FT VAR_SEQ 45 FT /note="F -> FGGWRRAAGGREARGLLAPTPDAPRPA (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_011849" FT VAR_SEQ 435..513 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:16024789" FT /id="VSP_041950" FT VAR_SEQ 478..492 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_011850" FT VAR_SEQ 513..542 FT /note="Missing (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:11397809, FT ECO:0000303|PubMed:15489334" FT /id="VSP_011851" FT VARIANT 194 FT /note="R -> H (in dbSNP:rs11465830)" FT /id="VAR_051629" FT VARIANT 196 FT /note="F -> S (in dbSNP:rs1059702)" FT /evidence="ECO:0000269|PubMed:8599092" FT /id="VAR_051630" FT VARIANT 203 FT /note="C -> S (in dbSNP:rs10127175)" FT /id="VAR_051631" FT VARIANT 398 FT /note="T -> M (in dbSNP:rs56340948)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040573" FT VARIANT 412 FT /note="V -> M (in a glioblastoma multiforme sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040574" FT VARIANT 421 FT /note="Q -> H (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040575" FT VARIANT 532 FT /note="S -> L (in dbSNP:rs1059703)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:8599092" FT /id="VAR_040576" FT VARIANT 619 FT /note="G -> S (in dbSNP:rs34112487)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040577" FT VARIANT 625 FT /note="T -> M (in dbSNP:rs35638718)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040578" FT VARIANT 638 FT /note="R -> W (in dbSNP:rs56082801)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040579" FT VARIANT 690 FT /note="S -> G (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040580" FT MUTAGEN 209 FT /note="T->A: Completely abolishes auto-phosphorylation in FT the kinase domain." FT /evidence="ECO:0000269|PubMed:14625308" FT MUTAGEN 239 FT /note="K->S: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:15084582" FT MUTAGEN 340 FT /note="D->N: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:18691762" FT MUTAGEN 387 FT /note="T->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:14625308" FT STRAND 195..197 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 202..209 FT /evidence="ECO:0007829|PDB:6BFN" FT TURN 210..212 FT /evidence="ECO:0007829|PDB:6BFN" FT STRAND 217..220 FT /evidence="ECO:0007829|PDB:6BFN" FT STRAND 222..231 FT /evidence="ECO:0007829|PDB:6BFN" FT STRAND 234..241 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 249..265 FT /evidence="ECO:0007829|PDB:6BFN" FT STRAND 274..280 FT /evidence="ECO:0007829|PDB:6BFN" FT STRAND 283..289 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 296..301 FT /evidence="ECO:0007829|PDB:6BFN" FT STRAND 304..307 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 312..331 FT /evidence="ECO:0007829|PDB:6BFN" FT STRAND 332..334 FT /evidence="ECO:0007829|PDB:6BFN" FT STRAND 345..348 FT /evidence="ECO:0007829|PDB:6BFN" FT STRAND 354..356 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 359..361 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 388..390 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 393..397 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 403..419 FT /evidence="ECO:0007829|PDB:6BFN" FT STRAND 423..427 FT /evidence="ECO:0007829|PDB:6BFN" FT STRAND 430..433 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 434..436 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 437..445 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 464..466 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 467..476 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 487..500 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 505..507 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 511..521 FT /evidence="ECO:0007829|PDB:6BFN" FT HELIX 522..524 FT /evidence="ECO:0007829|PDB:6BFN" SQ SEQUENCE 712 AA; 76537 MW; A7ADED75D3A3981D CRC64; MAGGPGPGEP AAPGAQHFLY EVPPWVMCRF YKVMDALEPA DWCQFAALIV RDQTELRLCE RSGQRTASVL WPWINRNARV ADLVHILTHL QLLRARDIIT AWHPPAPLPS PGTTAPRPSS IPAPAEAEAW SPRKLPSSAS TFLSPAFPGS QTHSGPELGL VPSPASLWPP PPSPAPSSTK PGPESSVSLL QGARPFPFCW PLCEISRGTH NFSEELKIGE GGFGCVYRAV MRNTVYAVKR LKENADLEWT AVKQSFLTEV EQLSRFRHPN IVDFAGYCAQ NGFYCLVYGF LPNGSLEDRL HCQTQACPPL SWPQRLDILL GTARAIQFLH QDSPSLIHGD IKSSNVLLDE RLTPKLGDFG LARFSRFAGS SPSQSSMVAR TQTVRGTLAY LPEEYIKTGR LAVDTDTFSF GVVVLETLAG QRAVKTHGAR TKYLKDLVEE EAEEAGVALR STQSTLQAGL AADAWAAPIA MQIYKKHLDP RPGPCPPELG LGLGQLACCC LHRRAKRRPP MTQVYERLEK LQAVVAGVPG HSEAASCIPP SPQENSYVSS TGRAHSGAAP WQPLAAPSGA SAQAAEQLQR GPNQPVESDE SLGGLSAALR SWHLTPSCPL DPAPLREAGC PQGDTAGESS WGSGPGSRPT AVEGLALGSS ASSSSEPPQI IINPARQKMV QKLALYEDGA LDSLQLLSSS SLPGLGLEQD RQGPEESDEF QS // ID IRAK2_HUMAN Reviewed; 625 AA. AC O43187; B4DQZ6; Q08AG6; Q5K546; DT 11-JAN-2001, integrated into UniProtKB/Swiss-Prot. DT 06-FEB-2007, sequence version 2. DT 28-JAN-2026, entry version 206. DE RecName: Full=Interleukin-1 receptor-associated kinase-like 2; DE Short=IRAK-2; GN Name=IRAK2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT GLU-431. RA Rosati O., Martin M.U.; RT "Identification of Exon 13 and the 3'UTR region of human IRAK-2 and RT characterisation of the full length gene."; RL Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-590, FUNCTION, TISSUE SPECIFICITY, RP INTERACTION WITH TRAF6; MYD88 AND IL1R1, AND VARIANT GLU-431. RC TISSUE=Endothelial cell; RX PubMed=9374458; DOI=10.1126/science.278.5343.1612; RA Muzio M., Ni J., Feng P., Dixit V.M.; RT "IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 RT signaling."; RL Science 278:1612-1615(1997). RN [5] RP FUNCTION. RX PubMed=10383454; DOI=10.1074/jbc.274.27.19403; RA Wesche H., Gao X., Li X., Kirschning C.J., Stark G.R., Cao Z.; RT "IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated RT kinase (IRAK) family."; RL J. Biol. Chem. 274:19403-19410(1999). RN [6] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-144, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [7] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [8] RP X-RAY CRYSTALLOGRAPHY (3.40 ANGSTROMS) OF 2-112. RX PubMed=20485341; DOI=10.1038/nature09121; RA Lin S.-C., Lo Y.-C., Wu H.; RT "Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R RT signalling."; RL Nature 465:885-890(2010). RN [9] RP VARIANTS [LARGE SCALE ANALYSIS] GLN-43; TYR-47; VAL-99; THR-147; GLY-214; RP LEU-249; VAL-392; THR-421; GLU-431; VAL-439; ASN-469; ILE-503 AND TRP-566. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Binds to the IL-1 type I receptor following IL-1 engagement, CC triggering intracellular signaling cascades leading to transcriptional CC up-regulation and mRNA stabilization. {ECO:0000269|PubMed:10383454, CC ECO:0000269|PubMed:9374458}. CC -!- SUBUNIT: Interacts with MYD88. IL-1 stimulation leads to the formation CC of a signaling complex which dissociates from the IL-1 receptor CC following the binding of PELI1. {ECO:0000269|PubMed:9374458}. CC -!- INTERACTION: CC O43187; P10398: ARAF; NbExp=2; IntAct=EBI-447733, EBI-365961; CC O43187; P51617: IRAK1; NbExp=3; IntAct=EBI-447733, EBI-358664; CC O43187; Q9Y616: IRAK3; NbExp=3; IntAct=EBI-447733, EBI-447690; CC O43187; Q9NWZ3: IRAK4; NbExp=6; IntAct=EBI-447733, EBI-448378; CC O43187; P46977: STT3A; NbExp=2; IntAct=EBI-447733, EBI-719212; CC O43187; Q13148: TARDBP; NbExp=2; IntAct=EBI-447733, EBI-372899; CC O43187; P58753: TIRAP; NbExp=2; IntAct=EBI-447733, EBI-528644; CC O43187; Q9H0E2: TOLLIP; NbExp=2; IntAct=EBI-447733, EBI-74615; CC O43187; Q9Y4K3: TRAF6; NbExp=5; IntAct=EBI-447733, EBI-359276; CC O43187; Q5D1E8: ZC3H12A; NbExp=2; IntAct=EBI-447733, EBI-747793; CC O43187; P68467: OPG044; Xeno; NbExp=2; IntAct=EBI-447733, EBI-8022707; CC O43187; Q6PDS3: Sarm1; Xeno; NbExp=2; IntAct=EBI-447733, EBI-6117196; CC -!- TISSUE SPECIFICITY: Expressed in spleen, thymus, prostate, lung, liver, CC skeletal muscle, kidney, pancreas and peripheral blood leukocytes. CC {ECO:0000269|PubMed:9374458}. CC -!- DOMAIN: The protein kinase domain is predicted to be catalytically CC inactive. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. Pelle subfamily. {ECO:0000305}. CC -!- CAUTION: Asn-335 is present instead of the conserved Asp which is CC expected to be an active site residue. This enzyme has been shown to be CC catalytically inactive. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AJ496794; CAD43180.3; -; mRNA. DR EMBL; AK299033; BAG61108.1; -; mRNA. DR EMBL; BC125184; AAI25185.1; -; mRNA. DR EMBL; AF026273; AAB87669.1; -; mRNA. DR CCDS; CCDS33697.1; -. DR RefSeq; NP_001561.3; NM_001570.3. DR PDB; 3MOP; X-ray; 3.40 A; K/L/M/N=2-112. DR PDBsum; 3MOP; -. DR AlphaFoldDB; O43187; -. DR SMR; O43187; -. DR BioGRID; 109865; 66. DR ComplexPortal; CPX-10281; Myddosome core complex. DR CORUM; O43187; -. DR DIP; DIP-31800N; -. DR ELM; O43187; -. DR FunCoup; O43187; 1262. DR IntAct; O43187; 50. DR MINT; O43187; -. DR STRING; 9606.ENSP00000256458; -. DR BindingDB; O43187; -. DR ChEMBL; CHEMBL4105759; -. DR GlyGen; O43187; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; O43187; -. DR PhosphoSitePlus; O43187; -. DR BioMuta; IRAK2; -. DR CPTAC; CPTAC-1319; -. DR jPOST; O43187; -. DR MassIVE; O43187; -. DR PaxDb; 9606-ENSP00000256458; -. DR PeptideAtlas; O43187; -. DR ProteomicsDB; 48804; -. DR Antibodypedia; 4605; 718 antibodies from 43 providers. DR DNASU; 3656; -. DR Ensembl; ENST00000256458.5; ENSP00000256458.4; ENSG00000134070.6. DR GeneID; 3656; -. DR KEGG; hsa:3656; -. DR MANE-Select; ENST00000256458.5; ENSP00000256458.4; NM_001570.4; NP_001561.3. DR UCSC; uc003bve.2; human. DR AGR; HGNC:6113; -. DR ClinPGx; PA29913; -. DR CTD; 3656; -. DR DisGeNET; 3656; -. DR GeneCards; IRAK2; -. DR HGNC; HGNC:6113; IRAK2. DR HPA; ENSG00000134070; Tissue enhanced (bone). DR MIM; 603304; gene. DR OpenTargets; ENSG00000134070; -. DR VEuPathDB; HostDB:ENSG00000134070; -. DR eggNOG; KOG1187; Eukaryota. DR GeneTree; ENSGT00940000159835; -. DR HOGENOM; CLU_000288_173_0_1; -. DR InParanoid; O43187; -. DR OMA; ALSEWDW; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; O43187; 7 GO annotations based on evolutionary models. DR PhylomeDB; O43187; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; O43187; -. DR Reactome; R-HSA-166058; MyD88:MAL(TIRAP) cascade initiated on plasma membrane. DR Reactome; R-HSA-168638; NOD1/2 Signaling Pathway. DR Reactome; R-HSA-445989; TAK1-dependent IKK and NF-kappa-B activation. DR Reactome; R-HSA-450302; activated TAK1 mediates p38 MAPK activation. DR Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1. DR Reactome; R-HSA-9020702; Interleukin-1 signaling. DR Reactome; R-HSA-937042; IRAK2 mediated activation of TAK1 complex. DR Reactome; R-HSA-937072; TRAF6-mediated induction of TAK1 complex within TLR4 complex. DR Reactome; R-HSA-9692916; SARS-CoV-1 activates/modulates innate immune responses. DR Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses. DR Reactome; R-HSA-975138; TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation. DR Reactome; R-HSA-975155; MyD88 dependent cascade initiated on endosome. DR Reactome; R-HSA-975163; IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation. DR Reactome; R-HSA-975871; MyD88 cascade initiated on plasma membrane. DR SignaLink; O43187; -. DR SIGNOR; O43187; -. DR Agora; ENSG00000134070; -. DR BioGRID-ORCS; 3656; 7 hits in 1185 CRISPR screens. DR ChiTaRS; IRAK2; human. DR EvolutionaryTrace; O43187; -. DR GeneWiki; IRAK2; -. DR GenomeRNAi; 3656; -. DR Pharos; O43187; Tbio. DR PRO; PR:O43187; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; O43187; protein. DR Bgee; ENSG00000134070; Expressed in cartilage tissue and 149 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0010008; C:endosome membrane; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0060090; F:molecular adaptor activity; IDA:UniProt. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL. DR GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL. DR GO; GO:0004672; F:protein kinase activity; IEA:InterPro. DR GO; GO:0035591; F:signaling adaptor activity; IDA:UniProt. DR GO; GO:0007249; P:canonical NF-kappaB signal transduction; IDA:UniProt. DR GO; GO:0006954; P:inflammatory response; TAS:ProtInc. DR GO; GO:0070498; P:interleukin-1-mediated signaling pathway; IMP:BHF-UCL. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IBA:GO_Central. DR GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; TAS:BHF-UCL. DR GO; GO:0043124; P:negative regulation of canonical NF-kappaB signal transduction; IMP:BHF-UCL. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IBA:GO_Central. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0001959; P:regulation of cytokine-mediated signaling pathway; IMP:BHF-UCL. DR GO; GO:0070555; P:response to interleukin-1; IMP:BHF-UCL. DR GO; GO:0008063; P:Toll signaling pathway; IBA:GO_Central. DR GO; GO:0034142; P:toll-like receptor 4 signaling pathway; IDA:UniProt. DR CDD; cd08795; Death_IRAK2; 1. DR CDD; cd14157; STKc_IRAK2; 1. DR FunFam; 1.10.510.10:FF:000586; Interleukin-1 receptor-associated kinase-like 2; 1. DR FunFam; 1.10.533.10:FF:000030; Interleukin-1 receptor-associated kinase-like 2; 1. DR FunFam; 3.30.200.20:FF:000412; interleukin-1 receptor-associated kinase-like 2; 1. DR Gene3D; 1.10.533.10; Death Domain, Fas; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011029; DEATH-like_dom_sf. DR InterPro; IPR000488; Death_dom. DR InterPro; IPR042151; Death_IRAK2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR PANTHER; PTHR24419; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE; 1. DR PANTHER; PTHR24419:SF2; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE-LIKE 2; 1. DR Pfam; PF00531; Death; 1. DR Pfam; PF00069; Pkinase; 1. DR SUPFAM; SSF47986; DEATH domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome. FT CHAIN 1..625 FT /note="Interleukin-1 receptor-associated kinase-like 2" FT /id="PRO_0000086032" FT DOMAIN 13..94 FT /note="Death" FT DOMAIN 210..489 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 111..181 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 510..540 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 169..181 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 516..526 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 216..224 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 237 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 337..340 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 144 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VARIANT 43 FT /note="R -> Q (in dbSNP:rs34945585)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041342" FT VARIANT 47 FT /note="S -> Y (in dbSNP:rs11465864)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030527" FT VARIANT 99 FT /note="I -> V (in dbSNP:rs55898544)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041343" FT VARIANT 147 FT /note="R -> T (in dbSNP:rs56053222)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041344" FT VARIANT 214 FT /note="R -> G (in dbSNP:rs35060588)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041345" FT VARIANT 249 FT /note="S -> L (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041346" FT VARIANT 392 FT /note="L -> V (in dbSNP:rs3844283)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030528" FT VARIANT 421 FT /note="P -> T (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041347" FT VARIANT 431 FT /note="D -> E (in dbSNP:rs708035)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9374458, ECO:0000269|Ref.1" FT /id="VAR_030529" FT VARIANT 439 FT /note="L -> V (in dbSNP:rs11465927)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030530" FT VARIANT 469 FT /note="D -> N (in dbSNP:rs56242986)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041348" FT VARIANT 503 FT /note="L -> I (in dbSNP:rs9854688)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030531" FT VARIANT 566 FT /note="R -> W (in dbSNP:rs55740652)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041349" FT VARIANT 574 FT /note="D -> H (in dbSNP:rs11465930)" FT /id="VAR_030532" FT HELIX 5..7 FT /evidence="ECO:0007829|PDB:3MOP" FT HELIX 10..16 FT /evidence="ECO:0007829|PDB:3MOP" FT TURN 17..22 FT /evidence="ECO:0007829|PDB:3MOP" FT HELIX 25..32 FT /evidence="ECO:0007829|PDB:3MOP" FT TURN 33..36 FT /evidence="ECO:0007829|PDB:3MOP" FT HELIX 39..47 FT /evidence="ECO:0007829|PDB:3MOP" FT HELIX 48..50 FT /evidence="ECO:0007829|PDB:3MOP" FT HELIX 56..65 FT /evidence="ECO:0007829|PDB:3MOP" FT TURN 66..68 FT /evidence="ECO:0007829|PDB:3MOP" FT HELIX 72..76 FT /evidence="ECO:0007829|PDB:3MOP" FT TURN 77..81 FT /evidence="ECO:0007829|PDB:3MOP" FT HELIX 84..87 FT /evidence="ECO:0007829|PDB:3MOP" FT TURN 88..91 FT /evidence="ECO:0007829|PDB:3MOP" SQ SEQUENCE 625 AA; 69433 MW; 715C954BC9452710 CRC64; MACYIYQLPS WVLDDLCRNM DALSEWDWME FASYVITDLT QLRKIKSMER VQGVSITREL LWWWGMRQAT VQQLVDLLCR LELYRAAQII LNWKPAPEIR CPIPAFPDSV KPEKPLAASV RKAEDEQEEG QPVRMATFPG PGSSPARAHQ PAFLQPPEED APHSLRSDLP TSSDSKDFST SIPKQEKLLS LAGDSLFWSE ADVVQATDDF NQNRKISQGT FADVYRGHRH GKPFVFKKLR ETACSSPGSI ERFFQAELQI CLRCCHPNVL PVLGFCAARQ FHSFIYPYMA NGSLQDRLQG QGGSDPLPWP QRVSICSGLL CAVEYLHGLE IIHSNVKSSN VLLDQNLTPK LAHPMAHLCP VNKRSKYTMM KTHLLRTSAA YLPEDFIRVG QLTKRVDIFS CGIVLAEVLT GIPAMDNNRS PVYLKDLLLS DIPSSTASLC SRKTGVENVM AKEICQKYLE KGAGRLPEDC AEALATAACL CLRRRNTSLQ EVCGSVAAVE ERLRGRETLL PWSGLSEGTG SSSNTPEETD DVDNSSLDAS SSMSVAPWAG AATPLLPTEN GEGRLRVIVG READSSSEAC VGLEPPQDVT ETSWQIEINE AKRKLMENIL LYKEEKVDSI ELFGP // ID KC1E_HUMAN Reviewed; 416 AA. AC P49674; DT 01-FEB-1996, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1996, sequence version 1. DT 28-JAN-2026, entry version 234. DE RecName: Full=Casein kinase I isoform epsilon; DE Short=CKI-epsilon; DE Short=CKIe; DE EC=2.7.11.1 {ECO:0000269|PubMed:29222110}; GN Name=CSNK1E; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Placenta; RX PubMed=7797465; DOI=10.1074/jbc.270.25.14875; RA Fish K.J., Cegielska A., Getman M.E., Landes G.M., Virshup D.M.; RT "Isolation and characterization of human casein kinase I epsilon (CKI), a RT novel member of the CKI gene family."; RL J. Biol. Chem. 270:14875-14883(1995). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RA Ono K., Murata-Hori M., Hosoya H.; RT "Casein kinase I epsilon from HeLa cell."; RL Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH SOCS3, INDUCTION, AND RP FUNCTION. RC TISSUE=Hematopoietic stem cell; RX PubMed=15070676; DOI=10.1182/blood-2003-08-2768; RA Okamura A., Iwata N., Nagata A., Tamekane A., Shimoyama M., Gomyo H., RA Yakushijin K., Urahama N., Hamaguchi M., Fukui C., Chihara K., Ito M., RA Matsui T.; RT "Involvement of casein kinase Iepsilon in cytokine-induced granulocytic RT differentiation."; RL Blood 103:2997-3004(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84; RA Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A., RA Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J., RA Beare D.M., Dunham I.; RT "A genome annotation-driven approach to cloning the human ORFeome."; RL Genome Biol. 5:R84.1-R84.11(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=10591208; DOI=10.1038/990031; RA Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M., Clamp M., RA Smink L.J., Ainscough R., Almeida J.P., Babbage A.K., Bagguley C., RA Bailey J., Barlow K.F., Bates K.N., Beasley O.P., Bird C.P., Blakey S.E., RA Bridgeman A.M., Buck D., Burgess J., Burrill W.D., Burton J., Carder C., RA Carter N.P., Chen Y., Clark G., Clegg S.M., Cobley V.E., Cole C.G., RA Collier R.E., Connor R., Conroy D., Corby N.R., Coville G.J., Cox A.V., RA Davis J., Dawson E., Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., RA Ellington A.G., Evans K.L., Fey J.M., Fleming K., French L., Garner A.A., RA Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C., RA Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S., Hunt S.E., RA Jones M.C., Kershaw J., Kimberley A.M., King A., Laird G.K., Langford C.F., RA Leversha M.A., Lloyd C., Lloyd D.M., Martyn I.D., Mashreghi-Mohammadi M., RA Matthews L.H., Mccann O.T., Mcclay J., Mclaren S., McMurray A.A., RA Milne S.A., Mortimore B.J., Odell C.N., Pavitt R., Pearce A.V., Pearson D., RA Phillimore B.J.C.T., Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., RA Rogers L., Ross M.T., Scott C.E., Sehra H.K., Skuce C.D., Smalley S., RA Smith M.L., Soderlund C., Spragon L., Steward C.A., Sulston J.E., RA Swann R.M., Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L., RA Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L., RA Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N., RA Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J., Shintani A., RA Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S., Roe B.A., Chen F., Chu L., RA Crabtree J., Deschamps S., Do A., Do T., Dorman A., Fang F., Fu Y., Hu P., RA Hua A., Kenton S., Lai H., Lao H.I., Lewis J., Lewis S., Lin S.-P., Loh P., RA Malaj E., Nguyen T., Pan H., Phan S., Qi S., Qian Y., Ray L., Ren Q., RA Shaull S., Sloan D., Song L., Wang Q., Wang Y., Wang Z., White J., RA Willingham D., Wu H., Yao Z., Zhan M., Zhang G., Chissoe S., Murray J., RA Miller N., Minx P., Fulton R., Johnson D., Bemis G., Bentley D., RA Bradshaw H., Bourne S., Cordes M., Du Z., Fulton L., Goela D., Graves T., RA Hawkins J., Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., RA Rohlfing T., Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., RA Nelson J., Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R., RA Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S., Budarf M.L., RA McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E., Edelmann L., Kim U.J., RA Shizuya H., Simon M.I., Dumanski J.P., Peyrard M., Kedra D., Seroussi E., RA Fransson I., Tapia I., Bruder C.E., O'Brien K.P., Wilkinson P., RA Bodenteich A., Hartman K., Hu X., Khan A.S., Lane L., Tilahun Y., RA Wright H.; RT "The DNA sequence of human chromosome 22."; RL Nature 402:489-495(1999). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP INTERACTION WITH PER1. RX PubMed=10790862; DOI=10.1097/00001756-200004070-00011; RA Keesler G.A., Camacho F., Guo Y., Virshup D., Mondadori C., Yao Z.; RT "Phosphorylation and destabilization of human period I clock protein by RT human casein kinase I epsilon."; RL NeuroReport 11:951-955(2000). RN [8] RP ROLE IN WNT SIGNALING. RX PubMed=12556519; DOI=10.1074/jbc.m213265200; RA Hino S., Michiue T., Asashima M., Kikuchi A.; RT "Casein kinase I epsilon enhances the binding of Dvl-1 to Frat-1 and is RT essential for Wnt-3a-induced accumulation of beta-catenin."; RL J. Biol. Chem. 278:14066-14073(2003). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Lymphoblast; RX PubMed=14654843; DOI=10.1038/nature02166; RA Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.; RT "Proteomic characterization of the human centrosome by protein correlation RT profiling."; RL Nature 426:570-574(2003). RN [10] RP FUNCTION AS PER1 KINASE. RX PubMed=15917222; DOI=10.1074/jbc.m502862200; RA Shirogane T., Jin J., Ang X.L., Harper J.W.; RT "SCFbeta-TRCP controls clock-dependent transcription via casein kinase 1- RT dependent degradation of the mammalian period-1 (Per1) protein."; RL J. Biol. Chem. 280:26863-26872(2005). RN [11] RP INTERACTION WITH DBNDD2. RX PubMed=16618118; DOI=10.1021/bi052354e; RA Yin H., Laguna K.A., Li G., Kuret J.; RT "Dysbindin structural homologue CK1BP is an isoform-selective binding RT partner of human casein kinase-1."; RL Biochemistry 45:5297-5308(2006). RN [12] RP INTERACTION WITH LRP5 AND LRP6. RX PubMed=16513652; DOI=10.1074/jbc.m510580200; RA Swiatek W., Kang H., Garcia B.A., Shabanowitz J., Coombs G.S., Hunt D.F., RA Virshup D.M.; RT "Negative regulation of LRP6 function by casein kinase I epsilon RT phosphorylation."; RL J. Biol. Chem. 281:12233-12241(2006). RN [13] RP FUNCTION, AUTOPHOSPHORYLATION, DEPHOSPHORYLATION BY PPP5C, AND ACTIVITY RP REGULATION. RX PubMed=16790549; DOI=10.1073/pnas.0604138103; RA Partch C.L., Shields K.F., Thompson C.L., Selby C.P., Sancar A.; RT "Posttranslational regulation of the mammalian circadian clock by RT cryptochrome and protein phosphatase 5."; RL Proc. Natl. Acad. Sci. U.S.A. 103:10467-10472(2006). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-343; SER-354; THR-362 AND RP SER-363, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-363, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [16] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-343 AND SER-354, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-389, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [19] RP INTERACTION WITH SNAI1. RX PubMed=20305697; DOI=10.1038/onc.2010.77; RA Xu Y., Lee S.H., Kim H.S., Kim N.H., Piao S., Park S.H., Jung Y.S., RA Yook J.I., Park B.J., Ha N.C.; RT "Role of CK1 in GSK3beta-mediated phosphorylation and degradation of RT snail."; RL Oncogene 29:3124-3133(2010). RN [20] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-363, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-389; SER-405 AND SER-408, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [23] RP FUNCTION, AND INTERACTION WITH DDX3X. RX PubMed=23413191; DOI=10.1126/science.1231499; RA Cruciat C.M., Dolde C., de Groot R.E., Ohkawara B., Reinhard C., RA Korswagen H.C., Niehrs C.; RT "RNA helicase DDX3 is a regulatory subunit of casein kinase 1 in Wnt-beta- RT catenin signaling."; RL Science 339:1436-1441(2013). RN [24] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [25] RP INTERACTION WITH DDX3X, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-38. RX PubMed=29222110; DOI=10.1242/jcs.207316; RA Dolde C., Bischof J., Grueter S., Montada A., Halekotte J., Peifer C., RA Kalbacher H., Baumann U., Knippschild U., Suter B.; RT "A CK1 FRET biosensor reveals that DDX3X is an essential activator of RT CK1epsilon."; RL J. Cell Sci. 131:0-0(2018). RN [26] RP INTERACTION WITH FAM83A; FAM83B; FAM83E AND FAM83H. RX PubMed=29789297; DOI=10.1126/scisignal.aao2341; RA Fulcher L.J., Bozatzi P., Tachie-Menson T., Wu K.Z.L., Cummins T.D., RA Bufton J.C., Pinkas D.M., Dunbar K., Shrestha S., Wood N.T., Weidlich S., RA Macartney T.J., Varghese J., Gourlay R., Campbell D.G., Dingwell K.S., RA Smith J.C., Bullock A.N., Sapkota G.P.; RT "The DUF1669 domain of FAM83 family proteins anchor casein kinase 1 RT isoforms."; RL Sci. Signal. 11:0-0(2018). RN [27] RP X-RAY CRYSTALLOGRAPHY (2.74 ANGSTROMS) OF 1-294 ALONE AND IN COMPLEX WITH RP INHIBITOR, AND SUBUNIT. RX PubMed=23106386; DOI=10.1021/jm301336n; RA Long A.M., Zhao H., Huang X.; RT "Structural basis for the potent and selective inhibition of casein kinase RT 1 epsilon."; RL J. Med. Chem. 55:10307-10311(2012). RN [28] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-256 AND ARG-413. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Casein kinases are operationally defined by their CC preferential utilization of acidic proteins such as caseins as CC substrates (Probable). Participates in Wnt signaling (PubMed:12556519, CC PubMed:23413191). Phosphorylates DVL1 (PubMed:12556519). Phosphorylates CC DVL2 (PubMed:23413191). Phosphorylates NEDD9/HEF1 (By similarity). CC Central component of the circadian clock (PubMed:16790549). In balance CC with PP1, determines the circadian period length, through the CC regulation of the speed and rhythmicity of PER1 and PER2 CC phosphorylation (PubMed:15917222, PubMed:16790549). Controls PER1 and CC PER2 nuclear transport and degradation (By similarity). Inhibits CC cytokine-induced granuloytic differentiation (PubMed:15070676). CC {ECO:0000250|UniProtKB:Q9JMK2, ECO:0000269|PubMed:12556519, CC ECO:0000269|PubMed:15070676, ECO:0000269|PubMed:15917222, CC ECO:0000269|PubMed:16790549, ECO:0000269|PubMed:23413191, CC ECO:0000305|PubMed:7797465}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:29222110}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609; CC Evidence={ECO:0000269|PubMed:29222110}; CC -!- ACTIVITY REGULATION: Phosphorylation leads to a decrease of the CC catalytic activity. {ECO:0000269|PubMed:16790549}. CC -!- SUBUNIT: Monomer (PubMed:23106386). Component of the circadian core CC oscillator, which includes the CRY proteins, CLOCK, or NPAS2, CC ARTNL/BMAL1 or ARTNL2/BMAL2, CSNK1D and/or CSNK1E, TIMELESS and the PER CC proteins (By similarity). Interacts with PER1 (PubMed:10790862). CC Interacts with ANKRD6 (By similarity). Interacts with DBNDD2 CC (PubMed:16618118). Interacts with LRP5 and LRP6 (PubMed:16513652). CC Interacts with SOCS3 (PubMed:15070676). Interacts with SNAI1 (via zinc CC fingers) (PubMed:20305697). Interacts with DDX3X; this interaction CC greatly enhances CSNK1E affinity for ATP and DVL2 phosphorylation, but CC inhibits DDX3X ATPase/helicase activity. In the presence of RNA, the CC interaction is decreased (PubMed:23413191, PubMed:29222110). Interacts CC with FAM83A, FAM83B, FAM83E and FAM83H (via DUF1669) (PubMed:29789297). CC {ECO:0000250|UniProtKB:Q9JMK2, ECO:0000269|PubMed:10790862, CC ECO:0000269|PubMed:15070676, ECO:0000269|PubMed:16513652, CC ECO:0000269|PubMed:16618118, ECO:0000269|PubMed:20305697, CC ECO:0000269|PubMed:23106386, ECO:0000269|PubMed:23413191, CC ECO:0000269|PubMed:29222110, ECO:0000269|PubMed:29789297}. CC -!- INTERACTION: CC P49674; P25054: APC; NbExp=8; IntAct=EBI-749343, EBI-727707; CC P49674; O15169: AXIN1; NbExp=5; IntAct=EBI-749343, EBI-710484; CC P49674; O14640: DVL1; NbExp=6; IntAct=EBI-749343, EBI-723489; CC P49674; O14641: DVL2; NbExp=4; IntAct=EBI-749343, EBI-740850; CC P49674; Q92997: DVL3; NbExp=9; IntAct=EBI-749343, EBI-739789; CC P49674; Q9BQ89: FAM110A; NbExp=3; IntAct=EBI-749343, EBI-1752811; CC P49674; Q1W6H9: FAM110C; NbExp=4; IntAct=EBI-749343, EBI-3942563; CC P49674; Q86UY5: FAM83A; NbExp=5; IntAct=EBI-749343, EBI-1384254; CC P49674; P08238: HSP90AB1; NbExp=2; IntAct=EBI-749343, EBI-352572; CC P49674; P23508: MCC; NbExp=9; IntAct=EBI-749343, EBI-307531; CC P49674; Q00987: MDM2; NbExp=3; IntAct=EBI-749343, EBI-389668; CC P49674; Q16625: OCLN; NbExp=10; IntAct=EBI-749343, EBI-2903088; CC P49674; O15055: PER2; NbExp=9; IntAct=EBI-749343, EBI-1054296; CC P49674; O75382: TRIM3; NbExp=3; IntAct=EBI-749343, EBI-2129889; CC P49674; P62258: YWHAE; NbExp=3; IntAct=EBI-749343, EBI-356498; CC P49674; Q04917: YWHAH; NbExp=3; IntAct=EBI-749343, EBI-306940; CC P49674; Q5T7W0: ZNF618; NbExp=7; IntAct=EBI-749343, EBI-6255994; CC P49674; O70239: Axin1; Xeno; NbExp=7; IntAct=EBI-749343, EBI-6857773; CC P49674; Q60838: Dvl2; Xeno; NbExp=3; IntAct=EBI-749343, EBI-641940; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Expressed in all tissues examined, including brain, CC heart, lung, liver, pancreas, kidney, placenta and skeletal muscle. CC Expressed in monocytes and lymphocytes but not in granulocytes. CC -!- INDUCTION: Down-regulated during granulocytic differentiation. CC {ECO:0000269|PubMed:15070676}. CC -!- PTM: Autophosphorylated. Partially dephosphorylated by PPP5C. May be CC dephosphorylated by PP1. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CK1 Ser/Thr CC protein kinase family. Casein kinase I subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L37043; AAC41761.1; -; mRNA. DR EMBL; AB024597; BAA92345.1; -; mRNA. DR EMBL; AB091043; BAC10902.1; -; mRNA. DR EMBL; CR456429; CAG30315.1; -; mRNA. DR EMBL; AL020993; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC006490; AAH06490.1; -; mRNA. DR PIR; I61744; I61744. DR RefSeq; NP_001885.1; NM_001894.5. DR RefSeq; NP_689407.1; NM_152221.3. DR PDB; 4HNI; X-ray; 2.74 A; A/B=1-294. DR PDB; 4HOK; X-ray; 2.77 A; A/C/E/G/I/K/M/O/Q/S/U/W=1-294. DR PDBsum; 4HNI; -. DR PDBsum; 4HOK; -. DR AlphaFoldDB; P49674; -. DR SMR; P49674; -. DR BioGRID; 107838; 342. DR BioGRID; 3196631; 5. DR CORUM; P49674; -. DR DIP; DIP-38050N; -. DR FunCoup; P49674; 4515. DR IntAct; P49674; 209. DR MINT; P49674; -. DR STRING; 9606.ENSP00000380044; -. DR BindingDB; P49674; -. DR ChEMBL; CHEMBL4937; -. DR DrugBank; DB03083; IC261. DR DrugBank; DB06195; Seliciclib. DR DrugBank; DB14989; Umbralisib. DR DrugCentral; P49674; -. DR GuidetoPHARMACOLOGY; 1998; -. DR GlyGen; P49674; 2 sites, 1 N-linked glycan (1 site). DR iPTMnet; P49674; -. DR PhosphoSitePlus; P49674; -. DR BioMuta; CSNK1E; -. DR DMDM; 1346369; -. DR CPTAC; CPTAC-3155; -. DR jPOST; P49674; -. DR MassIVE; P49674; -. DR PaxDb; 9606-ENSP00000380044; -. DR PeptideAtlas; P49674; -. DR ProteomicsDB; 56045; -. DR Pumba; P49674; -. DR Antibodypedia; 4043; 488 antibodies from 37 providers. DR DNASU; 1454; -. DR Ensembl; ENST00000359867.7; ENSP00000352929.3; ENSG00000213923.14. DR Ensembl; ENST00000396832.6; ENSP00000380044.1; ENSG00000213923.14. DR Ensembl; ENST00000403904.5; ENSP00000384074.1; ENSG00000213923.14. DR GeneID; 1454; -. DR KEGG; hsa:102800317; -. DR KEGG; hsa:1454; -. DR MANE-Select; ENST00000396832.6; ENSP00000380044.1; NM_152221.3; NP_689407.1. DR AGR; HGNC:2453; -. DR AGR; HGNC:53829; -. DR ClinPGx; PA26953; -. DR CTD; 1454; -. DR DisGeNET; 102800317; -. DR DisGeNET; 1454; -. DR GeneCards; CSNK1E; -. DR HGNC; HGNC:2453; CSNK1E. DR HPA; ENSG00000213923; Low tissue specificity. DR MalaCards; CSNK1E; -. DR MIM; 600863; gene. DR OpenTargets; ENSG00000213923; -. DR VEuPathDB; HostDB:ENSG00000213923; -. DR eggNOG; KOG1164; Eukaryota. DR GeneTree; ENSGT00940000153536; -. DR HOGENOM; CLU_019279_2_2_1; -. DR InParanoid; P49674; -. DR OMA; HDSKTRQ; -. DR OrthoDB; 5800476at2759; -. DR PAN-GO; P49674; 8 GO annotations based on evolutionary models. DR PhylomeDB; P49674; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; P49674; -. DR Reactome; R-HSA-201688; WNT mediated activation of DVL. DR Reactome; R-HSA-2565942; Regulation of PLK1 Activity at G2/M Transition. DR Reactome; R-HSA-380259; Loss of Nlp from mitotic centrosomes. DR Reactome; R-HSA-380270; Recruitment of mitotic centrosome proteins and complexes. DR Reactome; R-HSA-380284; Loss of proteins required for interphase microtubule organization from the centrosome. DR Reactome; R-HSA-380320; Recruitment of NuMA to mitotic centrosomes. DR Reactome; R-HSA-5620912; Anchoring of the basal body to the plasma membrane. DR Reactome; R-HSA-6791226; Major pathway of rRNA processing in the nucleolus and cytosol. DR Reactome; R-HSA-8854518; AURKA Activation by TPX2. DR Reactome; R-HSA-9931521; The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex. DR Reactome; R-HSA-9931530; Phosphorylation and nuclear translocation of the CRY:PER:kinase complex. DR SABIO-RK; P49674; -. DR SignaLink; P49674; -. DR SIGNOR; P49674; -. DR Agora; ENSG00000213923; -. DR BioGRID-ORCS; 102800317; 1 hit in 108 CRISPR screens. DR BioGRID-ORCS; 1454; 11 hits in 1186 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; CSNK1E; human. DR EvolutionaryTrace; P49674; -. DR GeneWiki; CSNK1E; -. DR Pharos; P49674; Tclin. DR PRO; PR:P49674; -. DR Proteomes; UP000005640; Chromosome 22. DR RNAct; P49674; protein. DR Bgee; ENSG00000213923; Expressed in cortical plate and 199 other cell types or tissues. DR ExpressionAtlas; P49674; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:ParkinsonsUK-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0030426; C:growth cone; IEA:Ensembl. DR GO; GO:0043025; C:neuronal cell body; IEA:Ensembl. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:1990904; C:ribonucleoprotein complex; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004672; F:protein kinase activity; IDA:WormBase. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0003723; F:RNA binding; HDA:UniProtKB. DR GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:WormBase. DR GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IEA:Ensembl. DR GO; GO:0048512; P:circadian behavior; IEA:Ensembl. DR GO; GO:0032922; P:circadian regulation of gene expression; ISS:UniProtKB. DR GO; GO:0006281; P:DNA repair; TAS:ProtInc. DR GO; GO:0006897; P:endocytosis; IBA:GO_Central. DR GO; GO:0008104; P:intracellular protein localization; IEA:Ensembl. DR GO; GO:0051058; P:negative regulation of small GTPase mediated signal transduction; IDA:ARUK-UCL. DR GO; GO:0030178; P:negative regulation of Wnt signaling pathway; IEA:Ensembl. DR GO; GO:0035567; P:non-canonical Wnt signaling pathway; IDA:ARUK-UCL. DR GO; GO:1902004; P:positive regulation of amyloid-beta formation; IEA:Ensembl. DR GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IBA:GO_Central. DR GO; GO:2000052; P:positive regulation of non-canonical Wnt signaling pathway; IC:ParkinsonsUK-UCL. DR GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; ISS:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB. DR GO; GO:0032880; P:regulation of protein localization; IDA:ParkinsonsUK-UCL. DR GO; GO:0007165; P:signal transduction; IBA:GO_Central. DR CDD; cd14125; STKc_CK1_delta_epsilon; 1. DR FunFam; 1.10.510.10:FF:000194; Casein kinase I isoform delta; 1. DR FunFam; 3.30.200.20:FF:000538; Putative Casein kinase I; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR050235; CK1_Ser-Thr_kinase. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR11909; CASEIN KINASE-RELATED; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Biological rhythms; Cytoplasm; Kinase; KW Methylation; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..416 FT /note="Casein kinase I isoform epsilon" FT /id="PRO_0000192837" FT DOMAIN 9..277 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 301..416 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 301..318 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 351..365 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 128 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 15..23 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 38 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 343 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195" FT MOD_RES 354 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195" FT MOD_RES 362 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 363 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:21406692" FT MOD_RES 382 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q9JMK2" FT MOD_RES 389 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:23186163" FT MOD_RES 405 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 408 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VARIANT 256 FT /note="R -> L (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042082" FT VARIANT 413 FT /note="H -> R (in dbSNP:rs35665927)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042083" FT MUTAGEN 38 FT /note="K->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:29222110" FT TURN 6..8 FT /evidence="ECO:0007829|PDB:4HNI" FT STRAND 14..16 FT /evidence="ECO:0007829|PDB:4HNI" FT STRAND 22..28 FT /evidence="ECO:0007829|PDB:4HNI" FT TURN 29..31 FT /evidence="ECO:0007829|PDB:4HNI" FT STRAND 35..41 FT /evidence="ECO:0007829|PDB:4HNI" FT HELIX 51..56 FT /evidence="ECO:0007829|PDB:4HNI" FT TURN 57..61 FT /evidence="ECO:0007829|PDB:4HNI" FT STRAND 68..74 FT /evidence="ECO:0007829|PDB:4HNI" FT STRAND 77..83 FT /evidence="ECO:0007829|PDB:4HNI" FT HELIX 89..95 FT /evidence="ECO:0007829|PDB:4HNI" FT TURN 96..98 FT /evidence="ECO:0007829|PDB:4HNI" FT HELIX 102..120 FT /evidence="ECO:0007829|PDB:4HNI" FT TURN 121..123 FT /evidence="ECO:0007829|PDB:4HNI" FT HELIX 131..133 FT /evidence="ECO:0007829|PDB:4HNI" FT STRAND 134..136 FT /evidence="ECO:0007829|PDB:4HNI" FT HELIX 139..141 FT /evidence="ECO:0007829|PDB:4HNI" FT STRAND 145..147 FT /evidence="ECO:0007829|PDB:4HNI" FT STRAND 154..157 FT /evidence="ECO:0007829|PDB:4HNI" FT TURN 159..161 FT /evidence="ECO:0007829|PDB:4HNI" FT HELIX 177..179 FT /evidence="ECO:0007829|PDB:4HNI" FT HELIX 182..185 FT /evidence="ECO:0007829|PDB:4HNI" FT HELIX 192..208 FT /evidence="ECO:0007829|PDB:4HNI" FT TURN 212..215 FT /evidence="ECO:0007829|PDB:4HOK" FT HELIX 221..234 FT /evidence="ECO:0007829|PDB:4HNI" FT HELIX 237..240 FT /evidence="ECO:0007829|PDB:4HNI" FT TURN 241..243 FT /evidence="ECO:0007829|PDB:4HNI" FT HELIX 246..255 FT /evidence="ECO:0007829|PDB:4HNI" FT HELIX 266..280 FT /evidence="ECO:0007829|PDB:4HNI" FT HELIX 289..291 FT /evidence="ECO:0007829|PDB:4HNI" SQ SEQUENCE 416 AA; 47315 MW; EE1B1698AE914324 CRC64; MELRVGNKYR LGRKIGSGSF GDIYLGANIA SGEEVAIKLE CVKTKHPQLH IESKFYKMMQ GGVGIPSIKW CGAEGDYNVM VMELLGPSLE DLFNFCSRKF SLKTVLLLAD QMISRIEYIH SKNFIHRDVK PDNFLMGLGK KGNLVYIIDF GLAKKYRDAR THQHIPYREN KNLTGTARYA SINTHLGIEQ SRRDDLESLG YVLMYFNLGS LPWQGLKAAT KRQKYERISE KKMSTPIEVL CKGYPSEFST YLNFCRSLRF DDKPDYSYLR QLFRNLFHRQ GFSYDYVFDW NMLKFGAARN PEDVDRERRE HEREERMGQL RGSATRALPP GPPTGATANR LRSAAEPVAS TPASRIQPAG NTSPRAISRV DRERKVSMRL HRGAPANVSS SDLTGRQEVS RIPASQTSVP FDHLGK // ID KCC4_HUMAN Reviewed; 473 AA. AC Q16566; D3DSZ7; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 215. DE RecName: Full=Calcium/calmodulin-dependent protein kinase type IV; DE Short=CaMK IV; DE EC=2.7.11.17; DE AltName: Full=CaM kinase-GR; GN Name=CAMK4; Synonyms=CAMK, CAMK-GR, CAMKIV; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=8089075; DOI=10.1093/oxfordjournals.jbchem.a124387; RA Kitani T., Okuno S., Fujisawa H.; RT "cDNA cloning and expression of human calmodulin-dependent protein kinase RT IV."; RL J. Biochem. 115:637-640(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Cerebellum, and Thymus; RX PubMed=8194751; DOI=10.1016/0378-1119(94)90260-7; RA Bland M.M., Monroe R.S., Ohmstede C.A.; RT "The cDNA sequence and characterization of the Ca2+/calmodulin-dependent RT protein kinase-Gr from human brain and thymus."; RL Gene 142:191-197(1994). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Blood; RX PubMed=8107230; DOI=10.1128/jvi.68.3.1697-1705.1994; RA Mosialos G., Hanissian S.H., Jawahar S., Vara L., Kieff E., Chatila T.A.; RT "A Ca2+/calmodulin-dependent protein kinase, CaM kinase-Gr, expressed after RT transformation of primary human B lymphocytes by Epstein-Barr virus (EBV) RT is induced by the EBV oncogene LMP1."; RL J. Virol. 68:1697-1705(1994). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain, and Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP TISSUE SPECIFICITY. RX PubMed=8397199; DOI=10.1016/s0021-9258(20)80693-0; RA Hanissian S.H., Frangakis M., Bland M.M., Jawahar S., Chatila T.A.; RT "Expression of a Ca2+/calmodulin-dependent protein kinase, CaM kinase-Gr, RT in human T lymphocytes. Regulation of kinase activity by T cell receptor RT signaling."; RL J. Biol. Chem. 268:20055-20063(1993). RN [7] RP FUNCTION, TISSUE SPECIFICITY, DOMAIN AUTOINHIBITORY, AND MUTAGENESIS OF RP 309-HIS--THR-312 AND 320-PHE-ASN-321. RX PubMed=7961813; DOI=10.1016/s0021-9258(19)61953-8; RA Tokumitsu H., Brickey D.A., Glod J., Hidaka H., Sikela J., Soderling T.R.; RT "Activation mechanisms for Ca2+/calmodulin-dependent protein kinase IV. RT Identification of a brain CaM-kinase IV kinase."; RL J. Biol. Chem. 269:28640-28647(1994). RN [8] RP FUNCTION IN PHOSPHORYLATION OF CREB1, AND SUBCELLULAR LOCATION. RX PubMed=8065343; DOI=10.1128/mcb.14.9.6107-6116.1994; RA Matthews R.P., Guthrie C.R., Wailes L.M., Zhao X., Means A.R., RA McKnight G.S.; RT "Calcium/calmodulin-dependent protein kinase types II and IV differentially RT regulate CREB-dependent gene expression."; RL Mol. Cell. Biol. 14:6107-6116(1994). RN [9] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=8980227; DOI=10.1016/s0092-8674(00)81816-4; RA Bito H., Deisseroth K., Tsien R.W.; RT "CREB phosphorylation and dephosphorylation: a Ca(2+)- and stimulus RT duration-dependent switch for hippocampal gene expression."; RL Cell 87:1203-1214(1996). RN [10] RP ACTIVITY REGULATION, PHOSPHORYLATION AT SER-12; SER-13 AND THR-200, AND RP MUTAGENESIS OF SER-12 AND SER-13. RX PubMed=8702940; DOI=10.1074/jbc.271.35.21542; RA Chatila T., Anderson K.A., Ho N., Means A.R.; RT "A unique phosphorylation-dependent mechanism for the activation of RT Ca2+/calmodulin-dependent protein kinase type IV/GR."; RL J. Biol. Chem. 271:21542-21548(1996). RN [11] RP FUNCTION IN PHOSPHORYLATION OF ELK1; JUN AND ATF2, AND MUTAGENESIS OF RP THR-200. RX PubMed=8855261; DOI=10.1073/pnas.93.20.10803; RA Enslen H., Tokumitsu H., Stork P.J., Davis R.J., Soderling T.R.; RT "Regulation of mitogen-activated protein kinases by a calcium/calmodulin- RT dependent protein kinase cascade."; RL Proc. Natl. Acad. Sci. U.S.A. 93:10803-10808(1996). RN [12] RP FUNCTION IN PHOSPHORYLATION OF STMN1. RX PubMed=9154845; DOI=10.1128/mcb.17.6.3459; RA Melander Gradin H., Marklund U., Larsson N., Chatila T.A., Gullberg M.; RT "Regulation of microtubule dynamics by Ca2+/calmodulin-dependent kinase RT IV/Gr-dependent phosphorylation of oncoprotein 18."; RL Mol. Cell. Biol. 17:3459-3467(1997). RN [13] RP FUNCTION IN PHOSPHORYLATION OF MEF2D, AND MUTAGENESIS OF LYS-75. RX PubMed=10617605; DOI=10.1074/jbc.275.1.197; RA Blaeser F., Ho N., Prywes R., Chatila T.A.; RT "Ca(2+)-dependent gene expression mediated by MEF2 transcription factors."; RL J. Biol. Chem. 275:197-209(2000). RN [14] RP TISSUE SPECIFICITY. RX PubMed=12065094; DOI=10.1016/s0304-3835(02)00107-6; RA Takai N., Miyazaki T., Nishida M., Nasu K., Miyakawa I.; RT "Ca(2+)/calmodulin-dependent protein kinase IV expression in epithelial RT ovarian cancer."; RL Cancer Lett. 183:185-193(2002). RN [15] RP ACTIVITY REGULATION, INTERACTION WITH PROTEIN PHOSPHATASE 2A, RP PHOSPHORYLATION AT THR-200, AND MUTAGENESIS OF 320-PHE-ASN-321. RX PubMed=15143065; DOI=10.1074/jbc.m404523200; RA Anderson K.A., Noeldner P.K., Reece K., Wadzinski B.E., Means A.R.; RT "Regulation and function of the calcium/calmodulin-dependent protein kinase RT IV/protein serine/threonine phosphatase 2A signaling complex."; RL J. Biol. Chem. 279:31708-31716(2004). RN [16] RP ACTIVITY REGULATION, AND PROTEIN PHOSPHATASE 2A BINDING DOMAIN. RX PubMed=15769749; DOI=10.1074/jbc.m500067200; RA Chow F.A., Anderson K.A., Noeldner P.K., Means A.R.; RT "The autonomous activity of calcium/calmodulin-dependent protein kinase IV RT is required for its role in transcription."; RL J. Biol. Chem. 280:20530-20538(2005). RN [17] RP FUNCTION IN DENDRITIC CELLS LIFESPAN REGULATION, AND DEVELOPMENTAL STAGE. RX PubMed=17909078; DOI=10.1182/blood-2007-05-091173; RA Illario M., Giardino-Torchia M.L., Sankar U., Ribar T.J., Galgani M., RA Vitiello L., Masci A.M., Bertani F.R., Ciaglia E., Astone D., Maulucci G., RA Cavallo A., Vitale M., Cimini V., Pastore L., Means A.R., Rossi G., RA Racioppi L.; RT "Calmodulin-dependent kinase IV links Toll-like receptor 4 signaling with RT survival pathway of activated dendritic cells."; RL Blood 111:723-731(2008). RN [18] RP FUNCTION. RX PubMed=18829949; DOI=10.1523/jneurosci.2625-08.2008; RA Fukushima H., Maeda R., Suzuki R., Suzuki A., Nomoto M., Toyoda H., RA Wu L.J., Xu H., Zhao M.G., Ueda K., Kitamoto A., Mamiya N., Yoshida T., RA Homma S., Masushige S., Zhuo M., Kida S.; RT "Upregulation of calcium/calmodulin-dependent protein kinase IV improves RT memory formation and rescues memory loss with aging."; RL J. Neurosci. 28:9910-9919(2008). RN [19] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [20] RP GLYCOSYLATION AT THR-57 SER-58; SER-137; SER-189; SER-344; SER-345 AND RP SER-356, PHOSPHORYLATION AT THR-200, IDENTIFICATION BY MASS SPECTROMETRY, RP AND MUTAGENESIS OF 57-THR-SER-58 AND SER-189. RX PubMed=19506079; DOI=10.1074/jbc.m109.007310; RA Dias W.B., Cheung W.D., Wang Z., Hart G.W.; RT "Regulation of calcium/calmodulin-dependent kinase IV by O-GlcNAc RT modification."; RL J. Biol. Chem. 284:21327-21337(2009). RN [21] RP REVIEW ON FUNCTION, AND REVIEW ON ACTIVITY REGULATION. RX PubMed=9920409; DOI=10.1016/s0167-4889(98)00142-6; RA Krebs J.; RT "Calmodulin-dependent protein kinase IV: regulation of function and RT expression."; RL Biochim. Biophys. Acta 1448:183-189(1998). RN [22] RP REVIEW ON FUNCTION IN NEURONAL PLASTICITY. RX PubMed=18817731; DOI=10.1016/j.neuron.2008.08.021; RA Wayman G.A., Lee Y.S., Tokumitsu H., Silva A.J., Silva A., Soderling T.R.; RT "Calmodulin-kinases: modulators of neuronal development and plasticity."; RL Neuron 59:914-931(2008). RN [23] RP REVIEW ON INVOLVEMENT IN IMMUNE AND INFLAMMATORY RESPONSE. RX PubMed=18930438; DOI=10.1016/j.it.2008.08.005; RA Racioppi L., Means A.R.; RT "Calcium/calmodulin-dependent kinase IV in immune and inflammatory RT responses: novel routes for an ancient traveller."; RL Trends Immunol. 29:600-607(2008). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-360, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [25] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [27] RP X-RAY CRYSTALLOGRAPHY (2.17 ANGSTROMS) OF 15-340 IN COMPLEX WITH INHIBITOR. RA Muniz J.R.C., Rellos P., Gileadi O., Fedorov O., Filippakopoulos P., RA Salah E., Pike A., Phillips C., Niesen F., Shrestha L., Burgess-Brown N., RA Bullock A., Berridge G., Vondelft F., Edwards A.M., Bountra C., RA Arrowsmith C.H., Weigelt J., Knapp S.; RT "Crystal structure of human CAMK4 in complex with 4-amino(sulfamoyl- RT phenylamino)-triazole-carbothioic acid (2,6-difluoro-phenyl)-amide)."; RL Submitted (NOV-2008) to the PDB data bank. RN [28] RP VARIANTS [LARGE SCALE ANALYSIS] GLY-150; ASN-178; ARG-465 AND MET-469. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Calcium/calmodulin-dependent protein kinase that operates in CC the calcium-triggered CaMKK-CaMK4 signaling cascade and regulates, CC mainly by phosphorylation, the activity of several transcription CC activators, such as CREB1, MEF2D, JUN and RORA, which play pivotal CC roles in immune response, inflammation, and memory consolidation. In CC the thymus, regulates the CD4(+)/CD8(+) double positive thymocytes CC selection threshold during T-cell ontogeny. In CD4 memory T-cells, is CC required to link T-cell antigen receptor (TCR) signaling to the CC production of IL2, IFNG and IL4 (through the regulation of CREB and CC MEF2). Regulates the differentiation and survival phases of osteoclasts CC and dendritic cells (DCs). Mediates DCs survival by linking TLR4 and CC the regulation of temporal expression of BCL2. Phosphorylates the CC transcription activator CREB1 on 'Ser-133' in hippocampal neuron nuclei CC and contribute to memory consolidation and long term potentiation (LTP) CC in the hippocampus. Can activate the MAP kinases MAPK1/ERK2, MAPK8/JNK1 CC and MAPK14/p38 and stimulate transcription through the phosphorylation CC of ELK1 and ATF2. Can also phosphorylate in vitro CREBBP, PRM2, MEF2A CC and STMN1/OP18. {ECO:0000269|PubMed:10617605, CC ECO:0000269|PubMed:17909078, ECO:0000269|PubMed:18829949, CC ECO:0000269|PubMed:7961813, ECO:0000269|PubMed:8065343, CC ECO:0000269|PubMed:8855261, ECO:0000269|PubMed:8980227, CC ECO:0000269|PubMed:9154845}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.17; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.17; CC -!- ACTIVITY REGULATION: Activated by Ca(2+)/calmodulin. Binding of CC calmodulin results in conformational change that relieves intrasteric CC autoinhibition and allows phosphorylation of Thr-200 within the CC activation loop by CaMKK1 or CaMKK2. Phosphorylation of Thr-200 results CC in a 10-20-fold increase in total activity to generate CC Ca(2+)/calmodulin-independent activity. Autophosphorylation of the N- CC terminus Ser-12 and Ser-13 is required for full activation. Inactivated CC by protein phosphatase 2A (PPP2CA/PPP2CB) which dephosphorylates Thr- CC 200, thereby terminating autonomous activity and helping to maintain CC the enzyme in its autoinhibited state. {ECO:0000269|PubMed:15143065, CC ECO:0000269|PubMed:15769749, ECO:0000269|PubMed:8702940}. CC -!- SUBUNIT: Monomer (By similarity). Interacts with protein phosphatase 2A CC (PPP2CA/PPP2CB); the interaction is mutually exclusive with binding to CC Ca(2+)/calmodulin. {ECO:0000250, ECO:0000269|PubMed:15143065, CC ECO:0000269|Ref.27}. CC -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Localized in hippocampal CC neuron nuclei. In spermatids, associated with chromatin and nuclear CC matrix (By similarity). {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Expressed in brain, thymus, CD4 T-cells, testis and CC epithelial ovarian cancer tissue. {ECO:0000269|PubMed:12065094, CC ECO:0000269|PubMed:7961813, ECO:0000269|PubMed:8397199}. CC -!- DEVELOPMENTAL STAGE: Expressed during differentiation of monocyte- CC derived dendritic cells (at protein level). CC {ECO:0000269|PubMed:17909078}. CC -!- DOMAIN: The autoinhibitory domain overlaps with the calmodulin binding CC region and interacts in the inactive folded state with the catalytic CC domain as a pseudosubstrate. {ECO:0000269|PubMed:7961813}. CC -!- PTM: Phosphorylated by CaMKK1 and CaMKK2 on Thr-200. Dephosphorylated CC by protein phosphatase 2A. Autophosphorylated on Ser-12 and Ser-13. CC {ECO:0000269|PubMed:15143065, ECO:0000269|PubMed:19506079, CC ECO:0000269|PubMed:8702940}. CC -!- PTM: Glycosylation at Ser-189 modulates the phosphorylation of CaMK4 at CC Thr-200 and negatively regulates its activity toward CREB1 in basal CC conditions and during early inomycin stimulation. CC {ECO:0000269|PubMed:15143065, ECO:0000269|PubMed:19506079, CC ECO:0000269|PubMed:8702940}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. CaMK subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH16695.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D30742; BAA06403.1; -; mRNA. DR EMBL; L17000; AAA35639.1; -; mRNA. DR EMBL; L24959; AAA18251.1; -; mRNA. DR EMBL; CH471086; EAW49033.1; -; Genomic_DNA. DR EMBL; CH471086; EAW49034.1; -; Genomic_DNA. DR EMBL; BC016695; AAH16695.2; ALT_INIT; mRNA. DR EMBL; BC025687; AAH25687.1; -; mRNA. DR CCDS; CCDS4103.1; -. DR PIR; A53036; A53036. DR RefSeq; NP_001310303.1; NM_001323374.2. DR RefSeq; NP_001310304.1; NM_001323375.2. DR RefSeq; NP_001735.1; NM_001744.6. DR PDB; 2W4O; X-ray; 2.17 A; A=15-340. DR PDBsum; 2W4O; -. DR AlphaFoldDB; Q16566; -. DR SMR; Q16566; -. DR BioGRID; 107264; 53. DR CORUM; Q16566; -. DR DIP; DIP-41997N; -. DR FunCoup; Q16566; 1741. DR IntAct; Q16566; 42. DR STRING; 9606.ENSP00000282356; -. DR BindingDB; Q16566; -. DR ChEMBL; CHEMBL2494; -. DR DrugBank; DB07676; 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2'H-2,3'-biindol-2'-one. DR DrugBank; DB07664; K-00546. DR DrugCentral; Q16566; -. DR GlyCosmos; Q16566; 7 sites, 1 glycan. DR GlyGen; Q16566; 7 sites, 1 O-linked glycan (7 sites). DR iPTMnet; Q16566; -. DR MetOSite; Q16566; -. DR PhosphoSitePlus; Q16566; -. DR BioMuta; CAMK4; -. DR DMDM; 2499586; -. DR jPOST; Q16566; -. DR MassIVE; Q16566; -. DR PaxDb; 9606-ENSP00000282356; -. DR PeptideAtlas; Q16566; -. DR ProteomicsDB; 60921; -. DR Pumba; Q16566; -. DR Antibodypedia; 2084; 637 antibodies from 43 providers. DR DNASU; 814; -. DR Ensembl; ENST00000282356.9; ENSP00000282356.4; ENSG00000152495.12. DR Ensembl; ENST00000512453.5; ENSP00000422634.1; ENSG00000152495.12. DR GeneID; 814; -. DR KEGG; hsa:814; -. DR MANE-Select; ENST00000282356.9; ENSP00000282356.4; NM_001744.6; NP_001735.1. DR UCSC; uc003kpf.4; human. DR AGR; HGNC:1464; -. DR ClinPGx; PA26050; -. DR CTD; 814; -. DR DisGeNET; 814; -. DR GeneCards; CAMK4; -. DR HGNC; HGNC:1464; CAMK4. DR HPA; ENSG00000152495; Group enriched (brain, lymphoid tissue). DR MalaCards; CAMK4; -. DR MIM; 114080; gene. DR OpenTargets; ENSG00000152495; -. DR VEuPathDB; HostDB:ENSG00000152495; -. DR eggNOG; KOG0032; Eukaryota. DR GeneTree; ENSGT00940000160006; -. DR HOGENOM; CLU_000288_63_0_1; -. DR InParanoid; Q16566; -. DR OMA; VVPDYWI; -. DR OrthoDB; 40902at2759; -. DR PAN-GO; Q16566; 8 GO annotations based on evolutionary models. DR PhylomeDB; Q16566; -. DR BRENDA; 2.7.11.17; 2681. DR PathwayCommons; Q16566; -. DR Reactome; R-HSA-111932; CaMK IV-mediated phosphorylation of CREB. DR Reactome; R-HSA-2151201; Transcriptional activation of mitochondrial biogenesis. DR Reactome; R-HSA-442729; CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde. DR Reactome; R-HSA-9022535; Loss of phosphorylation of MECP2 at T308. DR Reactome; R-HSA-9022692; Regulation of MECP2 expression and activity. DR Reactome; R-HSA-9617324; Negative regulation of NMDA receptor-mediated neuronal transmission. DR SignaLink; Q16566; -. DR SIGNOR; Q16566; -. DR Agora; ENSG00000152495; -. DR BioGRID-ORCS; 814; 8 hits in 1186 CRISPR screens. DR ChiTaRS; CAMK4; human. DR EvolutionaryTrace; Q16566; -. DR GeneWiki; CAMK4; -. DR GenomeRNAi; 814; -. DR Pharos; Q16566; Tbio. DR PRO; PR:Q16566; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; Q16566; protein. DR Bgee; ENSG00000152495; Expressed in cerebellar vermis and 140 other cell types or tissues. DR ExpressionAtlas; Q16566; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0001650; C:fibrillar center; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0009931; F:calcium-dependent protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0004683; F:calcium/calmodulin-dependent protein kinase activity; IDA:CACAO. DR GO; GO:0005516; F:calmodulin binding; IBA:GO_Central. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW. DR GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0007616; P:long-term memory; IGI:UniProtKB. DR GO; GO:0043011; P:myeloid dendritic cell differentiation; IMP:UniProtKB. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0045670; P:regulation of osteoclast differentiation; TAS:UniProtKB. DR GO; GO:0033081; P:regulation of T cell differentiation in thymus; TAS:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR CDD; cd14085; STKc_CaMKIV; 1. DR FunFam; 1.10.510.10:FF:000255; Calcium/calmodulin-dependent protein kinase type IV; 1. DR FunFam; 3.30.200.20:FF:000279; Calcium/calmodulin-dependent protein kinase type IV; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24347; SERINE/THREONINE-PROTEIN KINASE; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Adaptive immunity; ATP-binding; Calcium; Calmodulin-binding; KW Cytoplasm; Glycoprotein; Immunity; Inflammatory response; Kinase; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase. FT CHAIN 1..473 FT /note="Calcium/calmodulin-dependent protein kinase type IV" FT /id="PRO_0000086106" FT DOMAIN 46..300 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 305..321 FT /note="Autoinhibitory domain" FT REGION 306..323 FT /note="PP2A-binding" FT REGION 322..341 FT /note="Calmodulin-binding" FT /evidence="ECO:0000255" FT REGION 341..368 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 445..473 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 341..350 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 164 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 52..60 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 75 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 12 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:8702940" FT MOD_RES 13 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:8702940" FT MOD_RES 200 FT /note="Phosphothreonine; by CaMKK1 and CaMKK2" FT /evidence="ECO:0000269|PubMed:15143065, FT ECO:0000269|PubMed:19506079, ECO:0000269|PubMed:8702940" FT MOD_RES 336 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:P13234" FT MOD_RES 341 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P13234" FT MOD_RES 360 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332" FT CARBOHYD 57 FT /note="O-linked (GlcNAc) threonine" FT /evidence="ECO:0000269|PubMed:19506079" FT CARBOHYD 58 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:19506079" FT CARBOHYD 137 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:19506079" FT CARBOHYD 189 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:19506079" FT CARBOHYD 344 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:19506079" FT CARBOHYD 345 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:19506079" FT CARBOHYD 356 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:19506079" FT VARIANT 150 FT /note="E -> G (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040604" FT VARIANT 178 FT /note="D -> N (in dbSNP:rs35548075)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040605" FT VARIANT 465 FT /note="Q -> R (in dbSNP:rs56360861)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040606" FT VARIANT 469 FT /note="I -> M (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs1239950009)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040607" FT MUTAGEN 12 FT /note="S->A: Loss of activity." FT /evidence="ECO:0000269|PubMed:8702940" FT MUTAGEN 13 FT /note="S->A: Loss of activity." FT /evidence="ECO:0000269|PubMed:8702940" FT MUTAGEN 57..58 FT /note="TS->AA: Loss of phosphorylation of CREB1." FT /evidence="ECO:0000269|PubMed:19506079" FT MUTAGEN 75 FT /note="K->E: Loss of activity; dominant negative form." FT /evidence="ECO:0000269|PubMed:10617605" FT MUTAGEN 189 FT /note="S->A: Increases phosphorylation of CREB1 2-fold. FT Decreases total O-linked glycosylation 2-fold. Increases FT ATP-binding affinity." FT /evidence="ECO:0000269|PubMed:19506079" FT MUTAGEN 200 FT /note="T->A: Loss of activation by CaMKK1 or CaMKK2." FT /evidence="ECO:0000269|PubMed:8855261" FT MUTAGEN 309..312 FT /note="HMDT->DEDD: Fully active Ca2+/CaM-independent FT kinase; when associated with 320-A-A-321." FT /evidence="ECO:0000269|PubMed:7961813" FT MUTAGEN 320..321 FT /note="FN->DD: Fully active Ca2+/CaM-independent kinase; FT when associated with 309-A--A-312. Loss of interaction with FT PPP2CA/PPP2CB." FT /evidence="ECO:0000269|PubMed:15143065, FT ECO:0000269|PubMed:7961813" FT STRAND 36..38 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 42..44 FT /evidence="ECO:0007829|PDB:2W4O" FT STRAND 46..54 FT /evidence="ECO:0007829|PDB:2W4O" FT STRAND 56..65 FT /evidence="ECO:0007829|PDB:2W4O" FT TURN 66..68 FT /evidence="ECO:0007829|PDB:2W4O" FT STRAND 71..78 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 91..95 FT /evidence="ECO:0007829|PDB:2W4O" FT STRAND 104..109 FT /evidence="ECO:0007829|PDB:2W4O" FT STRAND 111..118 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 126..130 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 138..157 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 167..169 FT /evidence="ECO:0007829|PDB:2W4O" FT STRAND 170..176 FT /evidence="ECO:0007829|PDB:2W4O" FT STRAND 181..183 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 205..207 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 210..213 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 221..236 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 247..255 FT /evidence="ECO:0007829|PDB:2W4O" FT TURN 263..268 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 271..278 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 285..287 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 291..296 FT /evidence="ECO:0007829|PDB:2W4O" FT TURN 298..301 FT /evidence="ECO:0007829|PDB:2W4O" FT HELIX 311..335 FT /evidence="ECO:0007829|PDB:2W4O" SQ SEQUENCE 473 AA; 51926 MW; EFEE51E5612326DC CRC64; MLKVTVPSCS ASSCSSVTAS AAPGTASLVP DYWIDGSNRD ALSDFFEVES ELGRGATSIV YRCKQKGTQK PYALKVLKKT VDKKIVRTEI GVLLRLSHPN IIKLKEIFET PTEISLVLEL VTGGELFDRI VEKGYYSERD AADAVKQILE AVAYLHENGI VHRDLKPENL LYATPAPDAP LKIADFGLSK IVEHQVLMKT VCGTPGYCAP EILRGCAYGP EVDMWSVGII TYILLCGFEP FYDERGDQFM FRRILNCEYY FISPWWDEVS LNAKDLVRKL IVLDPKKRLT TFQALQHPWV TGKAANFVHM DTAQKKLQEF NARRKLKAAV KAVVASSRLG SASSSHGSIQ ESHKASRDPS PIQDGNEDMK AIPEGEKIQG DGAQAAVKGA QAELMKVQAL EKVKGADINA EEAPKMVPKA VEDGIKVADL ELEEGLAEEK LKTVEEAAAP REGQGSSAVG FEVPQQDVIL PEY // ID KEAP1_HUMAN Reviewed; 624 AA. AC Q14145; B3KPD5; Q6LEP0; Q8WTX1; Q9BPY9; DT 27-APR-2001, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-2007, sequence version 2. DT 28-JAN-2026, entry version 235. DE RecName: Full=Kelch-like ECH-associated protein 1 {ECO:0000303|PubMed:14585973}; DE AltName: Full=Cytosolic inhibitor of Nrf2 {ECO:0000303|Ref.1}; DE Short=INrf2 {ECO:0000303|Ref.1}; DE AltName: Full=Kelch-like protein 19 {ECO:0000312|HGNC:HGNC:23177}; GN Name=KEAP1 {ECO:0000303|PubMed:14585973, ECO:0000312|HGNC:HGNC:23177}; GN Synonyms=INRF2 {ECO:0000303|Ref.1}, KIAA0132 {ECO:0000303|PubMed:8590280}, GN KLHL19 {ECO:0000312|HGNC:HGNC:23177}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA]. RA Dhakshinamoorthy S., Jaiswal A.K.; RT "Human INrf2 gene structure and nucleotide sequence."; RL Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASN-349. RC TISSUE=Bone marrow; RX PubMed=8590280; DOI=10.1093/dnares/2.4.167; RA Nagase T., Seki N., Tanaka A., Ishikawa K., Nomura N.; RT "Prediction of the coding sequences of unidentified human genes. IV. The RT coding sequences of 40 new genes (KIAA0121-KIAA0160) deduced by analysis of RT cDNA clones from human cell line KG-1."; RL DNA Res. 2:167-174(1995). RN [3] RP SEQUENCE REVISION. RA Ohara O., Nagase T., Kikuno R., Nomura N.; RL Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain, Skin, and Uterus; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP FUNCTION, MUTAGENESIS OF CYS-151; CYS-273 AND CYS-288, AND SUBCELLULAR RP LOCATION. RX PubMed=14585973; DOI=10.1128/mcb.23.22.8137-8151.2003; RA Zhang D.D., Hannink M.; RT "Distinct cysteine residues in Keap1 are required for Keap1-dependent RT ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive RT agents and oxidative stress."; RL Mol. Cell. Biol. 23:8137-8151(2003). RN [8] RP INTERACTION WITH NFE2L2 AND BPTF, FUNCTION, TISSUE SPECIFICITY, AND RP SUBCELLULAR LOCATION. RX PubMed=15379550; DOI=10.1021/bi0494166; RA Strachan G.D., Morgan K.L., Otis L.L., Caltagarone J., Gittis A., RA Bowser R., Jordan-Sciutto K.L.; RT "Fetal Alz-50 clone 1 interacts with the human orthologue of the Kelch-like RT Ech-associated protein."; RL Biochemistry 43:12113-12122(2004). RN [9] RP FUNCTION, INTERACTION WITH CUL3 AND RBX1, MUTAGENESIS OF 125-ILE--GLY-127 RP AND 162-TYR--ILE-164, AND UBIQUITINATION. RX PubMed=15572695; DOI=10.1128/mcb.24.24.10941-10953.2004; RA Zhang D.D., Lo S.-C., Cross J.V., Templeton D.J., Hannink M.; RT "Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent RT ubiquitin ligase complex."; RL Mol. Cell. Biol. 24:10941-10953(2004). RN [10] RP FUNCTION, IDENTIFICATION IN A COMPLEX WITH CUL3 AND RBX1, UBIQUITINATION, RP ACTIVITY REGULATION, AND MUTAGENESIS OF CYS-151. RX PubMed=15983046; DOI=10.1074/jbc.m501279200; RA Zhang D.D., Lo S.C., Sun Z., Habib G.M., Lieberman M.W., Hannink M.; RT "Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, RT targets Keap1 for degradation by a proteasome-independent pathway."; RL J. Biol. Chem. 280:30091-30099(2005). RN [11] RP FUNCTION, SUBCELLULAR LOCATION, IDENTIFICATION IN THE BCR(KEAP1) COMPLEX, RP INTERACTION WITH NFE2L2, AND MUTAGENESIS OF 123-VAL--GLY-127 AND RP 161-MET-TYR-162. RX PubMed=15601839; DOI=10.1128/mcb.25.1.162-171.2005; RA Furukawa M., Xiong Y.; RT "BTB protein Keap1 targets antioxidant transcription factor Nrf2 for RT ubiquitination by the Cullin 3-Roc1 ligase."; RL Mol. Cell. Biol. 25:162-171(2005). RN [12] RP INTERACTION WITH PTMA, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LEU-308 AND RP LEU-310. RX PubMed=15657435; DOI=10.1128/mcb.25.3.1089-1099.2005; RA Karapetian R.N., Evstafieva A.G., Abaeva I.S., Chichkova N.V., RA Filonov G.S., Rubtsov Y.P., Sukhacheva E.A., Melnikov S.V., Schneider U., RA Wanker E.E., Vartapetian A.B.; RT "Nuclear oncoprotein prothymosin alpha is a partner of Keap1: implications RT for expression of oxidative stress-protecting genes."; RL Mol. Cell. Biol. 25:1089-1099(2005). RN [13] RP FUNCTION, ACTIVITY REGULATION, DOMAIN, AND MUTAGENESIS OF CYS-151. RX PubMed=19489739; DOI=10.1042/bj20090471; RA Eggler A.L., Small E., Hannink M., Mesecar A.D.; RT "Cul3-mediated Nrf2 ubiquitination and antioxidant response element (ARE) RT activation are dependent on the partial molar volume at position 151 of RT Keap1."; RL Biochem. J. 422:171-180(2009). RN [14] RP FUNCTION, AND INTERACTION WITH NFE2L2. RX PubMed=16006525; DOI=10.1073/pnas.0502402102; RA Eggler A.L., Liu G., Pezzuto J.M., van Breemen R.B., Mesecar A.D.; RT "Modifying specific cysteines of the electrophile-sensing human Keap1 RT protein is insufficient to disrupt binding to the Nrf2 domain Neh2."; RL Proc. Natl. Acad. Sci. U.S.A. 102:10070-10075(2005). RN [15] RP INTERACTION WITH NFE2L1. RX PubMed=16687406; DOI=10.1074/jbc.m602802200; RA Wang W., Chan J.Y.; RT "Nrf1 is targeted to the endoplasmic reticulum membrane by an N-terminal RT transmembrane domain. Inhibition of nuclear translocation and transacting RT function."; RL J. Biol. Chem. 281:19676-19687(2006). RN [16] RP INTERACTION WITH PGAM5, FUNCTION, ACTIVITY REGULATION, DOMAIN, AND RP MUTAGENESIS OF CYS-151; TYR-334; ARG-415; ARG-483 AND TYR-572. RX PubMed=17046835; DOI=10.1074/jbc.m606539200; RA Lo S.-C., Hannink M.; RT "PGAM5, a Bcl-XL-interacting protein, is a novel substrate for the redox- RT regulated Keap1-dependent ubiquitin ligase complex."; RL J. Biol. Chem. 281:37893-37903(2006). RN [17] RP FUNCTION, ACTIVITY REGULATION, AND INTERACTION WITH CUL3. RX PubMed=17127771; DOI=10.1074/jbc.m607622200; RA Gao L., Wang J., Sekhar K.R., Yin H., Yared N.F., Schneider S.N., Sasi S., RA Dalton T.P., Anderson M.E., Chan J.Y., Morrow J.D., Freeman M.L.; RT "Novel n-3 fatty acid oxidation products activate Nrf2 by destabilizing the RT association between Keap1 and Cullin3."; RL J. Biol. Chem. 282:2529-2537(2007). RN [18] RP FUNCTION, ACTIVITY REGULATION, DOMAIN, AND MUTAGENESIS OF CYS-151. RX PubMed=18251510; DOI=10.1021/tx700302s; RA Rachakonda G., Xiong Y., Sekhar K.R., Stamer S.L., Liebler D.C., RA Freeman M.L.; RT "Covalent modification at Cys151 dissociates the electrophile sensor Keap1 RT from the ubiquitin ligase CUL3."; RL Chem. Res. Toxicol. 21:705-710(2008). RN [19] RP INTERACTION WITH NFE2L2 AND PGAM5. RX PubMed=18387606; DOI=10.1016/j.yexcr.2008.02.014; RA Lo S.-C., Hannink M.; RT "PGAM5 tethers a ternary complex containing Keap1 and Nrf2 to RT mitochondria."; RL Exp. Cell Res. 314:1789-1803(2008). RN [20] RP INTERACTION WITH ENC1, AND SUBCELLULAR LOCATION. RX PubMed=19424503; DOI=10.1371/journal.pone.0005492; RA Wang X.J., Zhang D.D.; RT "Ectodermal-neural cortex 1 down-regulates Nrf2 at the translational RT level."; RL PLoS ONE 4:E5492-E5492(2009). RN [21] RP INTERACTION WITH SQSTM1, AND ACTIVITY REGULATION. RX PubMed=20495340; DOI=10.4161/auto.6.5.12189; RA Fan W., Tang Z., Chen D., Moughon D., Ding X., Chen S., Zhu M., Zhong Q.; RT "Keap1 facilitates p62-mediated ubiquitin aggregate clearance via RT autophagy."; RL Autophagy 6:614-621(2010). RN [22] RP FUNCTION, INTERACTION WITH SQSTM1, ACTIVITY REGULATION, SUBCELLULAR RP LOCATION, AND MUTAGENESIS OF ARG-380; ASN-382; ARG-415; HIS-436; ARG-483; RP TYR-525 AND TYR-572. RX PubMed=20452972; DOI=10.1074/jbc.m110.118976; RA Jain A., Lamark T., Sjoettem E., Larsen K.B., Awuh J.A., Oevervatn A., RA McMahon M., Hayes J.D., Johansen T.; RT "p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a RT positive feedback loop by inducing antioxidant response element-driven gene RT transcription."; RL J. Biol. Chem. 285:22576-22591(2010). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [24] RP INTERACTION WITH SESN1 AND SESN2. RX PubMed=23274085; DOI=10.1016/j.cmet.2012.12.002; RA Bae S.H., Sung S.H., Oh S.Y., Lim J.M., Lee S.K., Park Y.N., Lee H.E., RA Kang D., Rhee S.G.; RT "Sestrins activate Nrf2 by promoting p62-dependent autophagic degradation RT of Keap1 and prevent oxidative liver damage."; RL Cell Metab. 17:73-84(2013). RN [25] RP INTERACTION WITH MAP1LC3B. RX PubMed=24089205; DOI=10.1038/nature12606; RA Tang Z., Lin M.G., Stowe T.R., Chen S., Zhu M., Stearns T., Franco B., RA Zhong Q.; RT "Autophagy promotes primary ciliogenesis by removing OFD1 from centriolar RT satellites."; RL Nature 502:254-257(2013). RN [26] RP INTERACTION WITH HSP90AA1 AND HSP90AB1. RX PubMed=26517842; DOI=10.1371/journal.pone.0141786; RA Prince T.L., Kijima T., Tatokoro M., Lee S., Tsutsumi S., Yim K., Rivas C., RA Alarcon S., Schwartz H., Khamit-Kush K., Scroggins B.T., Beebe K., RA Trepel J.B., Neckers L.; RT "Client proteins and small molecule inhibitors display distinct binding RT preferences for constitutive and stress-induced HSP90 isoforms and their RT conformationally restricted mutants."; RL PLoS ONE 10:E0141786-E0141786(2015). RN [27] RP INTERACTION WITH EBOLAVIRUS PROTEIN VP24 (MICROBIAL INFECTION). RX PubMed=24630991; DOI=10.1016/j.celrep.2014.01.043; RA Edwards M.R., Johnson B., Mire C.E., Xu W., Shabman R.S., Speller L.N., RA Leung D.W., Geisbert T.W., Amarasinghe G.K., Basler C.F.; RT "The Marburg virus VP24 protein interacts with Keap1 to activate the RT cytoprotective antioxidant response pathway."; RL Cell Rep. 6:1017-1025(2014). RN [28] RP FUNCTION. RX PubMed=28380357; DOI=10.1016/j.celrep.2017.03.030; RA Lee Y., Chou T.F., Pittman S.K., Keith A.L., Razani B., Weihl C.C.; RT "Keap1/cullin3 modulates p62/SQSTM1 activity via UBA domain RT ubiquitination."; RL Cell Rep. 19:188-202(2017). RN [29] RP FUNCTION, ALKYLATION AT CYS-151; CYS-257; CYS-273 AND CYS-288, ACTIVITY RP REGULATION, DOMAIN, AND MUTAGENESIS OF CYS-151. RX PubMed=29590092; DOI=10.1038/nature25986; RA Mills E.L., Ryan D.G., Prag H.A., Dikovskaya D., Menon D., Zaslona Z., RA Jedrychowski M.P., Costa A.S.H., Higgins M., Hams E., Szpyt J., RA Runtsch M.C., King M.S., McGouran J.F., Fischer R., Kessler B.M., RA McGettrick A.F., Hughes M.M., Carroll R.G., Booty L.M., Knatko E.V., RA Meakin P.J., Ashford M.L.J., Modis L.K., Brunori G., Sevin D.C., RA Fallon P.G., Caldwell S.T., Kunji E.R.S., Chouchani E.T., Frezza C., RA Dinkova-Kostova A.T., Hartley R.C., Murphy M.P., O'Neill L.A.; RT "Itaconate is an anti-inflammatory metabolite that activates Nrf2 via RT alkylation of KEAP1."; RL Nature 556:113-117(2018). RN [30] RP CROSS-LINK AT ARG-135 AND CYS-151, ACTIVITY REGULATION, DOMAIN, AND RP MUTAGENESIS OF ARG-15; ARG-135 AND CYS-151. RX PubMed=30323285; DOI=10.1038/s41586-018-0622-0; RA Bollong M.J., Lee G., Coukos J.S., Yun H., Zambaldo C., Chang J.W., RA Chin E.N., Ahmad I., Chatterjee A.K., Lairson L.L., Schultz P.G., RA Moellering R.E.; RT "A metabolite-derived protein modification integrates glycolysis with RT KEAP1-NRF2 signalling."; RL Nature 562:600-604(2018). RN [31] RP REVIEW. RX PubMed=28842501; DOI=10.1074/jbc.r117.800169; RA Suzuki T., Yamamoto M.; RT "Stress-sensing mechanisms and the physiological roles of the Keap1-Nrf2 RT system during cellular stress."; RL J. Biol. Chem. 292:16817-16824(2017). RN [32] RP UBIQUITINATION. RX PubMed=31953436; DOI=10.1038/s41467-019-14190-2; RA Liu Y., Tao S., Liao L., Li Y., Li H., Li Z., Lin L., Wan X., Yang X., RA Chen L.; RT "TRIM25 promotes the cell survival and growth of hepatocellular carcinoma RT through targeting Keap1-Nrf2 pathway."; RL Nat. Commun. 11:348-348(2020). RN [33] RP FUNCTION, AND DEUBIQUITINATION BY USP25. RX PubMed=37339955; DOI=10.1038/s41467-023-39412-6; RA Cai C., Ma H., Peng J., Shen X., Zhen X., Yu C., Zhang P., Ji F., Wang J.; RT "USP25 regulates KEAP1-NRF2 anti-oxidation axis and its inactivation RT protects acetaminophen-induced liver injury in male mice."; RL Nat. Commun. 14:3648-3648(2023). RN [34] RP INTERACTION WITH PGCKA1, AND MUTAGENESIS OF LYS-615. RX PubMed=36882524; DOI=10.1038/s41388-023-02656-z; RA Huang S., Li J., Wu S., Zheng Z., Wang C., Li H., Zhao L., Zhang X., RA Huang H., Huang C., Xie Q.; RT "C4orf19 inhibits colorectal cancer cell proliferation by competitively RT binding to Keap1 with TRIM25 via the USP17/Elk-1/CDK6 axis."; RL Oncogene 42:1333-1346(2023). RN [35] RP X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 321-609. RX PubMed=15583386; DOI=10.1107/s0907444904024825; RA Li X., Zhang D., Hannink M., Beamer L.J.; RT "Crystallization and initial crystallographic analysis of the Kelch domain RT from human Keap1."; RL Acta Crystallogr. D 60:2346-2348(2004). RN [36] RP X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS) OF 321-609. RX PubMed=16204884; DOI=10.1107/s0907444905022626; RA Beamer L.J., Li X., Bottoms C.A., Hannink M.; RT "Conserved solvent and side-chain interactions in the 1.35 Angstrom RT structure of the Kelch domain of Keap1."; RL Acta Crystallogr. D 61:1335-1342(2005). RN [37] RP X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 321-609 IN COMPLEX WITH NFE2L2, RP SUBUNIT, AND MUTAGENESIS OF TYR-334; ARG-380; ASN-382; ARG-415; HIS-436; RP PHE-478; ARG-483; TYR-525 AND TYR-572. RX PubMed=16888629; DOI=10.1038/sj.emboj.7601243; RA Lo S.-C., Li X., Henzl M.T., Beamer L.J., Hannink M.; RT "Structure of the Keap1:Nrf2 interface provides mechanistic insight into RT Nrf2 signaling."; RL EMBO J. 25:3605-3617(2006). RN [38] {ECO:0007744|PDB:4CXI, ECO:0007744|PDB:4CXJ, ECO:0007744|PDB:4CXT} RP X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 48-180, INTERACTION WITH CUL3, RP AND MUTAGENESIS OF CYS-151. RX PubMed=24896564; DOI=10.1371/journal.pone.0098896; RA Cleasby A., Yon J., Day P.J., Richardson C., Tickle I.J., Williams P.A., RA Callahan J.F., Carr R., Concha N., Kerns J.K., Qi H., Sweitzer T., Ward P., RA Davies T.G.; RT "Structure of the BTB domain of Keap1 and its interaction with the RT triterpenoid antagonist CDDO."; RL PLoS ONE 9:e98896-e98896(2014). RN [39] RP VARIANTS CYS-364 AND CYS-430, AND CHARACTERIZATION OF VARIANTS CYS-364 AND RP CYS-430. RX PubMed=16507366; DOI=10.1016/j.molcel.2006.01.013; RA Padmanabhan B., Tong K.I., Ohta T., Nakamura Y., Scharlock M., Ohtsuji M., RA Kang M., Kobayashi A., Yokoyama S., Yamamoto M.; RT "Structural basis for defects of Keap1 activity provoked by its point RT mutations in lung cancer."; RL Mol. Cell 21:689-700(2006). RN [40] RP VARIANTS PHE-167; HIS-236; LEU-284; CYS-333 AND SER-350, AND RP CHARACTERIZATION OF VARIANTS HIS-236 AND CYS-333. RX PubMed=17020408; DOI=10.1371/journal.pmed.0030420; RA Singh A., Misra V., Thimmulappa R.K., Lee H., Ames S., Hoque M.O., RA Herman J.G., Baylin S.B., Sidransky D., Gabrielson E., Brock M.V., RA Biswal S.; RT "Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer."; RL PLoS Med. 3:1865-1876(2006). RN [41] RP VARIANTS [LARGE SCALE ANALYSIS] TYR-23 AND VAL-522. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). CC -!- FUNCTION: Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 CC ubiquitin ligase complex that regulates the response to oxidative CC stress by targeting NFE2L2/NRF2 for ubiquitination (PubMed:14585973, CC PubMed:15379550, PubMed:15572695, PubMed:15601839, PubMed:15983046, CC PubMed:37339955). KEAP1 acts as a key sensor of oxidative and CC electrophilic stress: in normal conditions, the BCR(KEAP1) complex CC mediates ubiquitination and degradation of NFE2L2/NRF2, a transcription CC factor regulating expression of many cytoprotective genes CC (PubMed:15601839, PubMed:16006525). In response to oxidative stress, CC different electrophile metabolites trigger non-enzymatic covalent CC modifications of highly reactive cysteine residues in KEAP1, leading to CC inactivate the ubiquitin ligase activity of the BCR(KEAP1) complex, CC promoting NFE2L2/NRF2 nuclear accumulation and expression of phase II CC detoxifying enzymes (PubMed:16006525, PubMed:17127771, PubMed:18251510, CC PubMed:19489739, PubMed:29590092). In response to selective autophagy, CC KEAP1 is sequestered in inclusion bodies following its interaction with CC SQSTM1/p62, leading to inactivation of the BCR(KEAP1) complex and CC activation of NFE2L2/NRF2 (PubMed:20452972). The BCR(KEAP1) complex CC also mediates ubiquitination of SQSTM1/p62, increasing SQSTM1/p62 CC sequestering activity and degradation (PubMed:28380357). The BCR(KEAP1) CC complex also targets BPTF and PGAM5 for ubiquitination and degradation CC by the proteasome (PubMed:15379550, PubMed:17046835). CC {ECO:0000269|PubMed:14585973, ECO:0000269|PubMed:15379550, CC ECO:0000269|PubMed:15572695, ECO:0000269|PubMed:15601839, CC ECO:0000269|PubMed:15983046, ECO:0000269|PubMed:16006525, CC ECO:0000269|PubMed:17046835, ECO:0000269|PubMed:17127771, CC ECO:0000269|PubMed:18251510, ECO:0000269|PubMed:19489739, CC ECO:0000269|PubMed:20452972, ECO:0000269|PubMed:28380357, CC ECO:0000269|PubMed:29590092, ECO:0000269|PubMed:37339955}. CC -!- ACTIVITY REGULATION: Ubiquitin ligase activity of the BCR(KEAP1) CC complex is inhibited by oxidative stress and electrophile metabolites CC such as sulforaphane (PubMed:15983046, PubMed:17046835, CC PubMed:29590092, PubMed:30323285). Electrophile metabolites react with CC reactive cysteine residues in KEAP1 and trigger non-enzymatic covalent CC modifications of these cysteine residues, leading to inactivate the CC ubiquitin ligase activity of the BCR(KEAP1) complex (PubMed:17127771, CC PubMed:18251510, PubMed:19489739, PubMed:29590092, PubMed:30323285). CC Selective autophagy also inactivates the BCR(KEAP1) complex via CC interaction between KEAP1 and SQSTM1/p62, which sequesters the complex CC in inclusion bodies and promotes its degradation (PubMed:20452972, CC PubMed:20495340). {ECO:0000269|PubMed:15983046, CC ECO:0000269|PubMed:17046835, ECO:0000269|PubMed:17127771, CC ECO:0000269|PubMed:18251510, ECO:0000269|PubMed:19489739, CC ECO:0000269|PubMed:20452972, ECO:0000269|PubMed:20495340, CC ECO:0000269|PubMed:29590092, ECO:0000269|PubMed:30323285}. CC -!- PATHWAY: Protein modification; protein ubiquitination. CC {ECO:0000269|PubMed:14585973, ECO:0000269|PubMed:15379550, CC ECO:0000269|PubMed:15572695, ECO:0000269|PubMed:15601839, CC ECO:0000269|PubMed:15983046}. CC -!- SUBUNIT: Component of the BCR(KEAP1) E3 ubiquitin ligase complex, at CC least composed of 2 molecules of CUL3, 2 molecules of KEAP1, and RBX1 CC (PubMed:15572695, PubMed:15601839, PubMed:15983046, PubMed:17127771, CC PubMed:18251510, PubMed:24896564). Interacts with NFE2L2/NRF2; the CC interaction is direct (PubMed:15379550, PubMed:15601839, CC PubMed:16006525, PubMed:16888629, PubMed:18387606). Forms a ternary CC complex with NFE2L2/NRF2 and PGAM5 (PubMed:17046835). Interacts with CC (phosphorylated) SQSTM1/p62; the interaction is direct and inactivates CC the BCR(KEAP1) complex by sequestering it in inclusion bodies, CC promoting its degradation (PubMed:20452972, PubMed:20495340). Interacts CC with NFE2L1 (PubMed:16687406). Interacts with BPTF and PTMA CC (PubMed:15657435). Interacts with MAP1LC3B (PubMed:24089205). Interacts CC indirectly with ENC1 (PubMed:19424503). Interacts with SESN1 and SESN2 CC (PubMed:23274085). Interacts with HSP90AA1 and HSP90AB1 CC (PubMed:26517842). Interacts with PGCKA1; this interaction prevents the CC ubiquitination of KEAP1 by TRIM25, thus protecting KEAP1 from CC degradation (PubMed:36882524). {ECO:0000269|PubMed:15379550, CC ECO:0000269|PubMed:15572695, ECO:0000269|PubMed:15601839, CC ECO:0000269|PubMed:15657435, ECO:0000269|PubMed:15983046, CC ECO:0000269|PubMed:16006525, ECO:0000269|PubMed:16687406, CC ECO:0000269|PubMed:16888629, ECO:0000269|PubMed:17046835, CC ECO:0000269|PubMed:17127771, ECO:0000269|PubMed:18251510, CC ECO:0000269|PubMed:18387606, ECO:0000269|PubMed:19424503, CC ECO:0000269|PubMed:20452972, ECO:0000269|PubMed:20495340, CC ECO:0000269|PubMed:23274085, ECO:0000269|PubMed:24089205, CC ECO:0000269|PubMed:24896564, ECO:0000269|PubMed:26517842, CC ECO:0000269|PubMed:36882524}. CC -!- SUBUNIT: (Microbial infection) Interacts with ebolavirus protein VP24; CC this interaction activates transcription factor NFE2L2/NRF2 by blocking CC its interaction with KEAP1. {ECO:0000269|PubMed:24630991}. CC -!- INTERACTION: CC Q14145; Q5JTC6: AMER1; NbExp=2; IntAct=EBI-751001, EBI-6169747; CC Q14145; Q49AR9: ANKS1A; NbExp=3; IntAct=EBI-751001, EBI-11954519; CC Q14145; P45381: ASPA; NbExp=4; IntAct=EBI-751001, EBI-750475; CC Q14145; O14525-2: ASTN1; NbExp=4; IntAct=EBI-751001, EBI-21977454; CC Q14145; A9UGY9: ATG5; NbExp=3; IntAct=EBI-751001, EBI-10175276; CC Q14145; Q9H1Y0: ATG5; NbExp=3; IntAct=EBI-751001, EBI-1047414; CC Q14145; P15056: BRAF; NbExp=16; IntAct=EBI-751001, EBI-365980; CC Q14145; Q2NKX9: C2orf68; NbExp=3; IntAct=EBI-751001, EBI-11603468; CC Q14145; Q9BWT7: CARD10; NbExp=3; IntAct=EBI-751001, EBI-3866279; CC Q14145; Q9NPC3: CCNB1IP1; NbExp=4; IntAct=EBI-751001, EBI-745269; CC Q14145; P02452: COL1A1; NbExp=3; IntAct=EBI-751001, EBI-982999; CC Q14145; P02458-1: COL2A1; NbExp=3; IntAct=EBI-751001, EBI-12375799; CC Q14145; P68400: CSNK2A1; NbExp=3; IntAct=EBI-751001, EBI-347804; CC Q14145; Q13618: CUL3; NbExp=5; IntAct=EBI-751001, EBI-456129; CC Q14145; Q9NX09: DDIT4; NbExp=3; IntAct=EBI-751001, EBI-715104; CC Q14145; Q9NY33: DPP3; NbExp=13; IntAct=EBI-751001, EBI-718333; CC Q14145; Q96JC9: EAF1; NbExp=3; IntAct=EBI-751001, EBI-769261; CC Q14145; Q6P6B1: ERICH5; NbExp=3; IntAct=EBI-751001, EBI-11343491; CC Q14145; P62495: ETF1; NbExp=8; IntAct=EBI-751001, EBI-750990; CC Q14145; Q6P1L5: FAM117B; NbExp=6; IntAct=EBI-751001, EBI-3893327; CC Q14145; Q14440: GPErik; NbExp=3; IntAct=EBI-751001, EBI-10232920; CC Q14145; Q8TDV0: GPR151; NbExp=3; IntAct=EBI-751001, EBI-11955647; CC Q14145; P28799: GRN; NbExp=3; IntAct=EBI-751001, EBI-747754; CC Q14145; B8Q183: GYPA; NbExp=4; IntAct=EBI-751001, EBI-10176190; CC Q14145; P02724: GYPA; NbExp=7; IntAct=EBI-751001, EBI-702665; CC Q14145; P05362: ICAM1; NbExp=3; IntAct=EBI-751001, EBI-1035358; CC Q14145; Q9BYX4: IFIH1; NbExp=3; IntAct=EBI-751001, EBI-6115771; CC Q14145; O14920: IKBKB; NbExp=6; IntAct=EBI-751001, EBI-81266; CC Q14145; Q4KMZ1: IQCC; NbExp=3; IntAct=EBI-751001, EBI-12206419; CC Q14145; P05107: ITGB2; NbExp=3; IntAct=EBI-751001, EBI-300173; CC Q14145; O95198: KLHL2; NbExp=7; IntAct=EBI-751001, EBI-746999; CC Q14145; Q8N4I8: KLHL3; NbExp=3; IntAct=EBI-751001, EBI-10230467; CC Q14145; Q9UH77: KLHL3; NbExp=5; IntAct=EBI-751001, EBI-8524663; CC Q14145; P62310: LSM3; NbExp=6; IntAct=EBI-751001, EBI-348239; CC Q14145; Q13257: MAD2L1; NbExp=8; IntAct=EBI-751001, EBI-78203; CC Q14145; O60336: MAPKBP1; NbExp=3; IntAct=EBI-751001, EBI-947402; CC Q14145; Q9BTE3-2: MCMBP; NbExp=3; IntAct=EBI-751001, EBI-9384556; CC Q14145; Q14494: NFE2L1; NbExp=28; IntAct=EBI-751001, EBI-2804436; CC Q14145; Q16236: NFE2L2; NbExp=41; IntAct=EBI-751001, EBI-2007911; CC Q14145; Q96TA1: NIBAN2; NbExp=9; IntAct=EBI-751001, EBI-2514593; CC Q14145; Q96HA8: NTAQ1; NbExp=3; IntAct=EBI-751001, EBI-741158; CC Q14145; Q9NZJ9: NUDT4; NbExp=3; IntAct=EBI-751001, EBI-4280066; CC Q14145; Q9UKX7: NUP50; NbExp=3; IntAct=EBI-751001, EBI-2371082; CC Q14145; Q8N573-5: OXR1; NbExp=3; IntAct=EBI-751001, EBI-10265887; CC Q14145; Q86YC2: PALB2; NbExp=6; IntAct=EBI-751001, EBI-1222653; CC Q14145; Q15149: PLEC; NbExp=3; IntAct=EBI-751001, EBI-297903; CC Q14145; P54619: PRKAG1; NbExp=6; IntAct=EBI-751001, EBI-1181439; CC Q14145; P06454-2: PTMA; NbExp=6; IntAct=EBI-751001, EBI-10194874; CC Q14145; Q6P9E2: RECK; NbExp=6; IntAct=EBI-751001, EBI-10253121; CC Q14145; Q04206: RELA; NbExp=4; IntAct=EBI-751001, EBI-73886; CC Q14145; P58004: SESN2; NbExp=3; IntAct=EBI-751001, EBI-3939642; CC Q14145; Q96GM5: SMARCD1; NbExp=3; IntAct=EBI-751001, EBI-358489; CC Q14145; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-751001, EBI-5235340; CC Q14145; Q13501: SQSTM1; NbExp=21; IntAct=EBI-751001, EBI-307104; CC Q14145; Q9UGK3: STAP2; NbExp=3; IntAct=EBI-751001, EBI-1553984; CC Q14145; Q9P0N9: TBC1D7; NbExp=3; IntAct=EBI-751001, EBI-3258000; CC Q14145; P54274: TERF1; NbExp=2; IntAct=EBI-751001, EBI-710997; CC Q14145; Q9Y3Q8: TSC22D4; NbExp=5; IntAct=EBI-751001, EBI-739485; CC Q14145; Q9BRX9: WDR83; NbExp=7; IntAct=EBI-751001, EBI-7705033; CC Q14145; O76024: WFS1; NbExp=3; IntAct=EBI-751001, EBI-720609; CC Q14145; Q9P202: WHRN; NbExp=3; IntAct=EBI-751001, EBI-310886; CC Q14145; P58317: ZNF121; NbExp=3; IntAct=EBI-751001, EBI-1228269; CC Q14145; Q9NX65: ZSCAN32; NbExp=3; IntAct=EBI-751001, EBI-739949; CC Q14145; P38109: ATG42; Xeno; NbExp=3; IntAct=EBI-751001, EBI-21638; CC Q14145; P17709: GLK1; Xeno; NbExp=3; IntAct=EBI-751001, EBI-8744; CC Q14145; O88351: Ikbkb; Xeno; NbExp=2; IntAct=EBI-751001, EBI-447960; CC Q14145; P15314: Irf1; Xeno; NbExp=2; IntAct=EBI-751001, EBI-6115486; CC Q14145; Q64337: Sqstm1; Xeno; NbExp=2; IntAct=EBI-751001, EBI-645025; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:14585973, CC ECO:0000269|PubMed:15379550, ECO:0000269|PubMed:15601839, CC ECO:0000269|PubMed:15657435, ECO:0000269|PubMed:19424503}. Nucleus CC {ECO:0000269|PubMed:15657435}. Note=Mainly cytoplasmic CC (PubMed:15601839). In response to selective autophagy, relocalizes to CC inclusion bodies following interaction with SQSTM1/p62 CC (PubMed:20452972). {ECO:0000269|PubMed:15601839, CC ECO:0000269|PubMed:20452972}. CC -!- TISSUE SPECIFICITY: Broadly expressed, with highest levels in skeletal CC muscle. {ECO:0000269|PubMed:15379550}. CC -!- DOMAIN: KEAP1 contains reactive cysteine residues that act as sensors CC for endogenously produced and exogenously encountered small molecules, CC which react with sulfhydryl groups and modify the cysteine sensors, CC leading to impair ability of the BCR(KEAP1) complex to ubiquitinate CC target proteins. {ECO:0000269|PubMed:17127771, CC ECO:0000269|PubMed:18251510, ECO:0000269|PubMed:19489739, CC ECO:0000269|PubMed:29590092, ECO:0000269|PubMed:30323285}. CC -!- DOMAIN: The Kelch repeats mediate interaction with NFE2L2/NRF2, BPTF CC and PGAM5. {ECO:0000269|PubMed:17046835}. CC -!- PTM: Non-enzymatic covalent modifications of reactive cysteines by CC electrophile metabolites inactivate the BCR(KEAP1) complex CC (PubMed:17127771, PubMed:18251510, PubMed:29590092, PubMed:30323285). CC Accumulation of fumarate promotes the formation of cysteine S- CC succination (S-(2-succinyl)cysteine), leading to inactivate the CC BCR(KEAP1) complex and promote NFE2L2/NRF2 nuclear accumulation and CC activation (By similarity). Nitric oxide-dependent 8-Nitro-cGMP CC formation promotes cysteine guanylation (S-cGMP-cysteine), leading to CC NFE2L2/NRF2 nuclear accumulation and activation (By similarity). CC Itaconate, an anti-inflammatory metabolite generated in response to CC lipopolysaccharide, alkylates cysteines, activating NFE2L2/NRF2 CC (PubMed:29590092). Methylglyoxal, a reactive metabolite that CC accumulates when the glycolytic enzyme PGK1 is inhibited, promotes CC formation of a methylimidazole cross-link between proximal Cys-151 and CC Arg-135 on another KEAP1 molecule, resulting in an inactive dimer that CC inactivates the BCR(KEAP1) complex (PubMed:30323285). CC {ECO:0000250|UniProtKB:Q9Z2X8, ECO:0000269|PubMed:17127771, CC ECO:0000269|PubMed:18251510, ECO:0000269|PubMed:29590092, CC ECO:0000269|PubMed:30323285}. CC -!- PTM: Degraded via a proteasomal-independent process during selective CC autophagy: interaction with phosphorylated SQSTM1/p62 sequesters KEAP1 CC in inclusion bodies, leading to its degradation. CC {ECO:0000269|PubMed:15983046, ECO:0000269|PubMed:20452972}. CC -!- PTM: Auto-ubiquitinated by the BCR(KEAP1) complex (PubMed:15572695, CC PubMed:15983046). Quinone-induced oxidative stress, but not CC sulforaphane, increases its ubiquitination (PubMed:15572695, CC PubMed:15983046). Ubiquitination and subsequent degradation is most CC pronounced following prolonged exposure of cells to oxidative stress, CC particularly in glutathione-deficient cells that are highly susceptible CC to oxidative stress (PubMed:15572695, PubMed:15983046). Deubiquitinated CC by USP25; leading to stabilization (PubMed:37339955). Ubiquitinated by CC TRIM25; leading to degradation upon ER stress (PubMed:31953436, CC PubMed:36882524). {ECO:0000269|PubMed:15572695, CC ECO:0000269|PubMed:15983046, ECO:0000269|PubMed:31953436, CC ECO:0000269|PubMed:36882524, ECO:0000269|PubMed:37339955}. CC -!- SIMILARITY: Belongs to the KEAP1 family. {ECO:0000305}. CC -!- CAUTION: The mechanism of inactivation of the BCR(KEAP1) complex by CC covalent modifications of reactive cysteines is unclear. Covalent CC modifications were initially thought to disrupt interaction between CC KEAP1 and NFE2L2/NRF2 (By similarity). Recent publications suggest that CC cysteine modifications disrupt the interaction between KEAP1 and CUL3 CC without affecting the interaction between KEAP1 and NFE2L2/NRF2 CC (PubMed:16006525, PubMed:17127771, PubMed:18251510, PubMed:24896564). CC {ECO:0000250|UniProtKB:Q9Z2X8, ECO:0000269|PubMed:16006525, CC ECO:0000269|PubMed:17127771, ECO:0000269|PubMed:18251510, CC ECO:0000269|PubMed:24896564}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA09481.3; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF361892; AAK43722.1; -; Genomic_DNA. DR EMBL; AF361888; AAK43722.1; JOINED; Genomic_DNA. DR EMBL; AF361889; AAK43722.1; JOINED; Genomic_DNA. DR EMBL; AF361890; AAK43722.1; JOINED; Genomic_DNA. DR EMBL; AF361891; AAK43722.1; JOINED; Genomic_DNA. DR EMBL; AF361886; AAK51082.1; -; mRNA. DR EMBL; D50922; BAA09481.3; ALT_INIT; mRNA. DR EMBL; AK056204; BAG51647.1; -; mRNA. DR EMBL; AC011461; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC002417; AAH02417.1; -; mRNA. DR EMBL; BC002930; AAH02930.1; -; mRNA. DR EMBL; BC015945; AAH15945.1; -; mRNA. DR EMBL; BC021957; AAH21957.2; -; mRNA. DR CCDS; CCDS12239.1; -. DR RefSeq; NP_036421.2; NM_012289.3. DR RefSeq; NP_987096.1; NM_203500.2. DR PDB; 1U6D; X-ray; 1.85 A; X=321-609. DR PDB; 1ZGK; X-ray; 1.35 A; A=321-609. DR PDB; 2FLU; X-ray; 1.50 A; X=321-609. DR PDB; 3VNG; X-ray; 2.10 A; A=321-609. DR PDB; 3VNH; X-ray; 2.10 A; A=321-609. DR PDB; 3ZGC; X-ray; 2.20 A; A/B=321-609. DR PDB; 3ZGD; X-ray; 1.98 A; A/B=321-609. DR PDB; 4CXI; X-ray; 2.35 A; A=48-180. DR PDB; 4CXJ; X-ray; 2.80 A; A=48-180. DR PDB; 4CXT; X-ray; 2.66 A; A=48-180. DR PDB; 4IFJ; X-ray; 1.80 A; A=321-609. DR PDB; 4IFL; X-ray; 1.80 A; X=321-609. DR PDB; 4IFN; X-ray; 2.40 A; X=321-609. DR PDB; 4IN4; X-ray; 2.59 A; A/B/C=321-609. DR PDB; 4IQK; X-ray; 1.97 A; A=321-609. DR PDB; 4L7B; X-ray; 2.41 A; A/B=321-609. DR PDB; 4L7C; X-ray; 2.40 A; A/B/C=321-609. DR PDB; 4L7D; X-ray; 2.25 A; A/B/C=321-609. DR PDB; 4N1B; X-ray; 2.55 A; A/B/C=321-609. DR PDB; 4XMB; X-ray; 2.43 A; A=321-609. DR PDB; 5DAD; X-ray; 2.61 A; A=49-182. DR PDB; 5DAF; X-ray; 2.37 A; A=49-182. DR PDB; 5F72; X-ray; 1.85 A; C/K=321-611. DR PDB; 5GIT; X-ray; 2.19 A; A=48-180. DR PDB; 5NLB; X-ray; 3.45 A; A=51-204. DR PDB; 5WFL; X-ray; 1.93 A; A/B=312-624. DR PDB; 5WFV; X-ray; 1.91 A; A/B=320-612. DR PDB; 5WG1; X-ray; 2.02 A; A/B=320-612. DR PDB; 5WHL; X-ray; 2.50 A; A/B=312-624. DR PDB; 5WHO; X-ray; 2.23 A; A/B=312-624. DR PDB; 5WIY; X-ray; 2.23 A; A/B=312-624. DR PDB; 5X54; X-ray; 2.30 A; A/B=321-609. DR PDB; 6FFM; X-ray; 2.20 A; A=48-180. DR PDB; 6FMP; X-ray; 2.92 A; A/B=321-609. DR PDB; 6FMQ; X-ray; 2.10 A; A/B=321-609. DR PDB; 6HWS; X-ray; 1.75 A; A=321-609. DR PDB; 6LRZ; X-ray; 1.54 A; A=311-616. DR PDB; 6ROG; X-ray; 2.16 A; A/X=321-609. DR PDB; 6SP1; X-ray; 2.57 A; A/B=321-609. DR PDB; 6SP4; X-ray; 2.59 A; A/B/C/D/E/F=321-609. DR PDB; 6T7V; X-ray; 2.60 A; A=321-609. DR PDB; 6T7Z; X-ray; 2.00 A; A=321-609. DR PDB; 6TG8; X-ray; 2.75 A; AAA=322-609. DR PDB; 6TYM; X-ray; 1.42 A; A=321-609. DR PDB; 6TYP; X-ray; 2.50 A; A=321-609. DR PDB; 6UF0; X-ray; 1.96 A; A/B=321-609. DR PDB; 6V6Z; X-ray; 1.60 A; A/B/C/D=321-609. DR PDB; 6W66; X-ray; 3.21 A; C=48-180. DR PDB; 6W67; X-ray; 2.20 A; A=48-180. DR PDB; 6W68; X-ray; 2.55 A; A=48-180. DR PDB; 6W69; X-ray; 2.50 A; A=48-180. DR PDB; 6WCQ; EM; 8.50 A; C=1-624. DR PDB; 6Z6A; X-ray; 2.37 A; A/B=321-609. DR PDB; 7EXI; X-ray; 1.82 A; A=45-180. DR PDB; 7K28; X-ray; 2.15 A; A/B=325-614. DR PDB; 7K29; X-ray; 2.20 A; A/B=324-624. DR PDB; 7K2A; X-ray; 1.90 A; A/B=324-624. DR PDB; 7K2B; X-ray; 2.31 A; A/B=324-624. DR PDB; 7K2C; X-ray; 2.11 A; A/B=325-614. DR PDB; 7K2D; X-ray; 2.21 A; A/B=324-623. DR PDB; 7K2E; X-ray; 2.03 A; A/B=324-624. DR PDB; 7K2F; X-ray; 2.37 A; A/X=312-623. DR PDB; 7K2G; X-ray; 2.15 A; A/B=324-624. DR PDB; 7K2H; X-ray; 2.09 A; A/B=324-624. DR PDB; 7K2I; X-ray; 2.42 A; A/B=324-623. DR PDB; 7K2J; X-ray; 2.52 A; A/B=325-614. DR PDB; 7K2K; X-ray; 1.98 A; A/B=324-624. DR PDB; 7K2L; X-ray; 1.98 A; A=326-609, B=326-614. DR PDB; 7K2M; X-ray; 2.02 A; A/B=326-614. DR PDB; 7K2N; X-ray; 2.22 A; A/B=324-624. DR PDB; 7K2O; X-ray; 2.11 A; A/B=324-624. DR PDB; 7K2P; X-ray; 2.11 A; A/B=324-624. DR PDB; 7K2Q; X-ray; 2.37 A; A/B=325-614. DR PDB; 7K2R; X-ray; 2.10 A; A/B=325-614. DR PDB; 7K2S; X-ray; 2.13 A; A/B=324-624. DR PDB; 7Q5H; X-ray; 2.31 A; A/B=321-609. DR PDB; 7Q6Q; X-ray; 2.55 A; A/B=321-609. DR PDB; 7Q6S; X-ray; 2.14 A; A/B=321-609. DR PDB; 7Q8R; X-ray; 2.28 A; A/B=321-609. DR PDB; 7Q96; X-ray; 2.42 A; A/B=321-609. DR PDB; 7X4W; X-ray; 3.21 A; A/B/C/D/E/F=48-180. DR PDB; 7X4X; X-ray; 2.96 A; A/B/C/D/E/F=48-180. DR PDB; 7XM2; X-ray; 2.30 A; X=321-609. DR PDB; 7XM3; X-ray; 2.80 A; A=321-609. DR PDB; 7XM4; X-ray; 2.70 A; A=321-609. DR PDB; 7XM5; X-ray; 2.40 A; A=321-609. DR PDB; 7XOT; X-ray; 2.70 A; A=321-609. DR PDB; 8EHV; X-ray; 2.29 A; A/B=312-624. DR PDB; 8EJR; X-ray; 2.08 A; A/B=312-624. DR PDB; 8EJS; X-ray; 2.82 A; A/B=312-624. DR PDB; 8IVG; X-ray; 1.80 A; A=310-624. DR PDB; 8IVR; X-ray; 1.50 A; A=310-624. DR PDB; 8IXS; X-ray; 1.48 A; A=310-624. DR PDB; 8PKS; X-ray; 2.60 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N=471-609. DR PDB; 8PKU; X-ray; 1.73 A; A/B=312-623. DR PDB; 8PKV; X-ray; 1.55 A; A/B=312-623. DR PDB; 8PKW; X-ray; 1.54 A; A/B=312-623. DR PDB; 8PKX; X-ray; 1.79 A; A/B=312-623. DR PDB; 8WFG; X-ray; 2.25 A; A=48-180. DR PDB; 8X34; X-ray; 2.80 A; A/B=324-609. DR PDB; 8XGK; X-ray; 1.32 A; A=310-624. DR PDB; 8XGV; X-ray; 1.42 A; A=310-624. DR PDB; 9DU7; X-ray; 1.87 A; A/B=48-180. DR PDB; 9ETX; X-ray; 2.34 A; A/B=48-213. DR PDB; 9ETY; X-ray; 1.87 A; A/B=48-213. DR PDB; 9J70; X-ray; 2.50 A; A/X=322-609. DR PDB; 9J71; X-ray; 2.99 A; A/B/C/X=322-609. DR PDB; 9J7F; X-ray; 2.99 A; A/B/C/D=322-609. DR PDB; 9J7G; X-ray; 2.99 A; A/B/C/X=322-609. DR PDBsum; 1U6D; -. DR PDBsum; 1ZGK; -. DR PDBsum; 2FLU; -. DR PDBsum; 3VNG; -. DR PDBsum; 3VNH; -. DR PDBsum; 3ZGC; -. DR PDBsum; 3ZGD; -. DR PDBsum; 4CXI; -. DR PDBsum; 4CXJ; -. DR PDBsum; 4CXT; -. DR PDBsum; 4IFJ; -. DR PDBsum; 4IFL; -. DR PDBsum; 4IFN; -. DR PDBsum; 4IN4; -. DR PDBsum; 4IQK; -. DR PDBsum; 4L7B; -. DR PDBsum; 4L7C; -. DR PDBsum; 4L7D; -. DR PDBsum; 4N1B; -. DR PDBsum; 4XMB; -. DR PDBsum; 5DAD; -. DR PDBsum; 5DAF; -. DR PDBsum; 5F72; -. DR PDBsum; 5GIT; -. DR PDBsum; 5NLB; -. DR PDBsum; 5WFL; -. DR PDBsum; 5WFV; -. DR PDBsum; 5WG1; -. DR PDBsum; 5WHL; -. DR PDBsum; 5WHO; -. DR PDBsum; 5WIY; -. DR PDBsum; 5X54; -. DR PDBsum; 6FFM; -. DR PDBsum; 6FMP; -. DR PDBsum; 6FMQ; -. DR PDBsum; 6HWS; -. DR PDBsum; 6LRZ; -. DR PDBsum; 6ROG; -. DR PDBsum; 6SP1; -. DR PDBsum; 6SP4; -. DR PDBsum; 6T7V; -. DR PDBsum; 6T7Z; -. DR PDBsum; 6TG8; -. DR PDBsum; 6TYM; -. DR PDBsum; 6TYP; -. DR PDBsum; 6UF0; -. DR PDBsum; 6V6Z; -. DR PDBsum; 6W66; -. DR PDBsum; 6W67; -. DR PDBsum; 6W68; -. DR PDBsum; 6W69; -. DR PDBsum; 6WCQ; -. DR PDBsum; 6Z6A; -. DR PDBsum; 7EXI; -. DR PDBsum; 7K28; -. DR PDBsum; 7K29; -. DR PDBsum; 7K2A; -. DR PDBsum; 7K2B; -. DR PDBsum; 7K2C; -. DR PDBsum; 7K2D; -. DR PDBsum; 7K2E; -. DR PDBsum; 7K2F; -. DR PDBsum; 7K2G; -. DR PDBsum; 7K2H; -. DR PDBsum; 7K2I; -. DR PDBsum; 7K2J; -. DR PDBsum; 7K2K; -. DR PDBsum; 7K2L; -. DR PDBsum; 7K2M; -. DR PDBsum; 7K2N; -. DR PDBsum; 7K2O; -. DR PDBsum; 7K2P; -. DR PDBsum; 7K2Q; -. DR PDBsum; 7K2R; -. DR PDBsum; 7K2S; -. DR PDBsum; 7Q5H; -. DR PDBsum; 7Q6Q; -. DR PDBsum; 7Q6S; -. DR PDBsum; 7Q8R; -. DR PDBsum; 7Q96; -. DR PDBsum; 7X4W; -. DR PDBsum; 7X4X; -. DR PDBsum; 7XM2; -. DR PDBsum; 7XM3; -. DR PDBsum; 7XM4; -. DR PDBsum; 7XM5; -. DR PDBsum; 7XOT; -. DR PDBsum; 8EHV; -. DR PDBsum; 8EJR; -. DR PDBsum; 8EJS; -. DR PDBsum; 8IVG; -. DR PDBsum; 8IVR; -. DR PDBsum; 8IXS; -. DR PDBsum; 8PKS; -. DR PDBsum; 8PKU; -. DR PDBsum; 8PKV; -. DR PDBsum; 8PKW; -. DR PDBsum; 8PKX; -. DR PDBsum; 8WFG; -. DR PDBsum; 8X34; -. DR PDBsum; 8XGK; -. DR PDBsum; 8XGV; -. DR PDBsum; 9DU7; -. DR PDBsum; 9ETX; -. DR PDBsum; 9ETY; -. DR PDBsum; 9J70; -. DR PDBsum; 9J71; -. DR PDBsum; 9J7F; -. DR PDBsum; 9J7G; -. DR AlphaFoldDB; Q14145; -. DR BMRB; Q14145; -. DR EMDB; EMD-21617; -. DR SMR; Q14145; -. DR BioGRID; 115156; 368. DR ComplexPortal; CPX-8107; CRL3 E3 ubiquitin ligase complex, KEAP1 variant. DR CORUM; Q14145; -. DR DIP; DIP-42134N; -. DR ELM; Q14145; -. DR FunCoup; Q14145; 673. DR IntAct; Q14145; 211. DR MINT; Q14145; -. DR STRING; 9606.ENSP00000377245; -. DR BindingDB; Q14145; -. DR ChEMBL; CHEMBL2069156; -. DR DrugBank; DB04339; Carbocisteine. DR DrugBank; DB08908; Dimethyl fumarate. DR DrugBank; DB12513; Omaveloxolone. DR DrugCentral; Q14145; -. DR GuidetoPHARMACOLOGY; 2757; -. DR GlyCosmos; Q14145; 11 sites, 1 glycan. DR GlyGen; Q14145; 11 sites, 1 O-linked glycan (11 sites). DR iPTMnet; Q14145; -. DR PhosphoSitePlus; Q14145; -. DR SwissPalm; Q14145; -. DR BioMuta; KEAP1; -. DR DMDM; 146345444; -. DR jPOST; Q14145; -. DR MassIVE; Q14145; -. DR PaxDb; 9606-ENSP00000171111; -. DR PeptideAtlas; Q14145; -. DR ProteomicsDB; 59849; -. DR Pumba; Q14145; -. DR ABCD; Q14145; 8 sequenced antibodies. DR Antibodypedia; 1418; 709 antibodies from 40 providers. DR DNASU; 9817; -. DR Ensembl; ENST00000171111.10; ENSP00000171111.4; ENSG00000079999.15. DR Ensembl; ENST00000393623.6; ENSP00000377245.1; ENSG00000079999.15. DR GeneID; 9817; -. DR KEGG; hsa:9817; -. DR MANE-Select; ENST00000171111.10; ENSP00000171111.4; NM_203500.2; NP_987096.1. DR UCSC; uc002moq.2; human. DR AGR; HGNC:23177; -. DR CIViC; 9817; 5 evidence items across 4 molecular profiles. DR ClinPGx; PA134887774; -. DR CTD; 9817; -. DR DisGeNET; 9817; -. DR GeneCards; KEAP1; -. DR HGNC; HGNC:23177; KEAP1. DR HPA; ENSG00000079999; Tissue enhanced (skeletal). DR MalaCards; KEAP1; -. DR MIM; 606016; gene. DR OpenTargets; ENSG00000079999; -. DR Orphanet; 276399; Familial multinodular goiter. DR VEuPathDB; HostDB:ENSG00000079999; -. DR eggNOG; KOG4441; Eukaryota. DR GeneTree; ENSGT00940000159543; -. DR HOGENOM; CLU_004253_14_2_1; -. DR InParanoid; Q14145; -. DR OMA; TECLTEY; -. DR OrthoDB; 45365at2759; -. DR PAN-GO; Q14145; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q14145; -. DR PathwayCommons; Q14145; -. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-8951664; Neddylation. DR Reactome; R-HSA-9679191; Potential therapeutics for SARS. DR Reactome; R-HSA-9755511; KEAP1-NFE2L2 pathway. DR Reactome; R-HSA-9759194; Nuclear events mediated by NFE2L2. DR Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation. DR SignaLink; Q14145; -. DR SIGNOR; Q14145; -. DR UniPathway; UPA00143; -. DR Agora; ENSG00000079999; -. DR BioGRID-ORCS; 9817; 194 hits in 1230 CRISPR screens. DR CD-CODE; 5D6181E1; Synthetic Condensate 000293. DR CD-CODE; DEE660B4; Stress granule. DR CD-CODE; FBAE0D06; Synthetic Condensate 000291. DR ChiTaRS; KEAP1; human. DR EvolutionaryTrace; Q14145; -. DR GeneWiki; KEAP1; -. DR GenomeRNAi; 9817; -. DR Pharos; Q14145; Tclin. DR PRO; PR:Q14145; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q14145; protein. DR Bgee; ENSG00000079999; Expressed in hindlimb stylopod muscle and 201 other cell types or tissues. DR ExpressionAtlas; Q14145; baseline and differential. DR GO; GO:0005884; C:actin filament; IEA:Ensembl. DR GO; GO:0034451; C:centriolar satellite; IDA:HPA. DR GO; GO:0031463; C:Cul3-RING ubiquitin ligase complex; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005783; C:endoplasmic reticulum; IEA:Ensembl. DR GO; GO:0016234; C:inclusion body; IDA:UniProtKB. DR GO; GO:0030496; C:midbody; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0097718; F:disordered domain specific binding; IEA:Ensembl. DR GO; GO:0042802; F:identical protein binding; IEA:Ensembl. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0140416; F:transcription regulator inhibitor activity; IDA:ParkinsonsUK-UCL. DR GO; GO:1990756; F:ubiquitin-like ligase-substrate adaptor activity; IDA:UniProt. DR GO; GO:0071353; P:cellular response to interleukin-4; IEA:Ensembl. DR GO; GO:0034599; P:cellular response to oxidative stress; IDA:UniProtKB. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:1902883; P:negative regulation of response to oxidative stress; IDA:UniProt. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:ParkinsonsUK-UCL. DR GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; TAS:ParkinsonsUK-UCL. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IDA:UniProt. DR GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB. DR GO; GO:0010506; P:regulation of autophagy; IDA:UniProtKB. DR GO; GO:0045604; P:regulation of epidermal cell differentiation; IEA:Ensembl. DR GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:UniProtKB. DR CDD; cd18458; BACK_KLHL19_KEAP1; 1. DR CDD; cd18248; BTB_POZ_KLHL19_KEAP1; 1. DR FunFam; 2.120.10.80:FF:000024; Kelch-like ECH-associated protein 1; 1. DR FunFam; 1.25.40.420:FF:000001; Kelch-like family member 12; 1. DR FunFam; 3.30.710.10:FF:000001; Kelch-like family member 20; 1. DR Gene3D; 1.25.40.420; -; 1. DR Gene3D; 2.120.10.80; Kelch-type beta propeller; 1. DR Gene3D; 3.30.710.10; Potassium Channel Kv1.1, Chain A; 1. DR IDEAL; IID00384; -. DR InterPro; IPR011705; BACK. DR InterPro; IPR017096; BTB-kelch_protein. DR InterPro; IPR000210; BTB/POZ_dom. DR InterPro; IPR047098; KEAP1_BACK. DR InterPro; IPR030563; KEAP1_BTB_POZ_dom. DR InterPro; IPR015915; Kelch-typ_b-propeller. DR InterPro; IPR006652; Kelch_1. DR InterPro; IPR011333; SKP1/BTB/POZ_sf. DR PANTHER; PTHR24412; KELCH PROTEIN; 1. DR PANTHER; PTHR24412:SF162; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; 1. DR Pfam; PF07707; BACK; 1. DR Pfam; PF00651; BTB; 1. DR Pfam; PF01344; Kelch_1; 3. DR Pfam; PF24681; Kelch_KLHDC2_KLHL20_DRC7; 1. DR PIRSF; PIRSF037037; Kelch-like_protein_gigaxonin; 1. DR SMART; SM00875; BACK; 1. DR SMART; SM00225; BTB; 1. DR SMART; SM00612; Kelch; 6. DR SUPFAM; SSF117281; Kelch motif; 1. DR SUPFAM; SSF54695; POZ domain; 1. DR PROSITE; PS50097; BTB; 1. PE 1: Evidence at protein level; KW 3D-structure; Cytoplasm; Host-virus interaction; Kelch repeat; Nucleus; KW Proteomics identification; Reference proteome; Repeat; S-nitrosylation; KW Ubl conjugation; Ubl conjugation pathway. FT CHAIN 1..624 FT /note="Kelch-like ECH-associated protein 1" FT /id="PRO_0000119093" FT DOMAIN 77..149 FT /note="BTB" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00037" FT DOMAIN 184..286 FT /note="BACK" FT REPEAT 327..372 FT /note="Kelch 1" FT REPEAT 373..423 FT /note="Kelch 2" FT REPEAT 424..470 FT /note="Kelch 3" FT REPEAT 471..517 FT /note="Kelch 4" FT REPEAT 518..564 FT /note="Kelch 5" FT REPEAT 565..611 FT /note="Kelch 6" FT SITE 151 FT /note="Sensor for electrophilic agents" FT /evidence="ECO:0000269|PubMed:18251510, FT ECO:0000269|PubMed:29590092" FT SITE 257 FT /note="Sensor for electrophilic agents" FT /evidence="ECO:0000269|PubMed:29590092" FT SITE 273 FT /note="Sensor for electrophilic agents" FT /evidence="ECO:0000269|PubMed:29590092" FT SITE 288 FT /note="Sensor for electrophilic agents" FT /evidence="ECO:0000269|PubMed:29590092" FT SITE 434 FT /note="Sensor for electrophilic agents" FT /evidence="ECO:0000250|UniProtKB:Q9Z2X8" FT MOD_RES 38 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000250|UniProtKB:Q9Z2X8" FT MOD_RES 151 FT /note="S-(2,3-dicarboxypropyl)cysteine; alternate" FT /evidence="ECO:0000269|PubMed:29590092" FT MOD_RES 151 FT /note="S-(2-succinyl)cysteine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q9Z2X8" FT MOD_RES 151 FT /note="S-nitrosocysteine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q9Z2X8" FT MOD_RES 241 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000250|UniProtKB:Q9Z2X8" FT MOD_RES 257 FT /note="S-(2,3-dicarboxypropyl)cysteine" FT /evidence="ECO:0000269|PubMed:29590092" FT MOD_RES 273 FT /note="S-(2,3-dicarboxypropyl)cysteine" FT /evidence="ECO:0000269|PubMed:29590092" FT MOD_RES 288 FT /note="S-(2,3-dicarboxypropyl)cysteine; alternate" FT /evidence="ECO:0000269|PubMed:29590092" FT MOD_RES 288 FT /note="S-(2-succinyl)cysteine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q9Z2X8" FT MOD_RES 319 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000250|UniProtKB:Q9Z2X8" FT MOD_RES 434 FT /note="S-cGMP-cysteine" FT /evidence="ECO:0000250|UniProtKB:Q9Z2X8" FT MOD_RES 613 FT /note="S-(2-succinyl)cysteine" FT /evidence="ECO:0000250|UniProtKB:Q9Z2X8" FT CROSSLNK 135 FT /note="N5-[4-(S-L-cysteinyl)-5-methyl-1H-imidazol-2-yl]-L- FT ornithine (Arg-Cys) (interchain with C-151 in KEAP1)" FT /evidence="ECO:0000269|PubMed:30323285" FT CROSSLNK 151 FT /note="N5-[4-(S-L-cysteinyl)-5-methyl-1H-imidazol-2-yl]-L- FT ornithine (Cys-Arg) (interchain with R-135 in KEAP1)" FT /evidence="ECO:0000269|PubMed:30323285" FT VARIANT 23 FT /note="C -> Y (in a breast cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036084" FT VARIANT 167 FT /note="V -> F (in a lung adenocarcinoma patient)" FT /evidence="ECO:0000269|PubMed:17020408" FT /id="VAR_032102" FT VARIANT 236 FT /note="D -> H (in a NSCLC cell line)" FT /evidence="ECO:0000269|PubMed:17020408" FT /id="VAR_032103" FT VARIANT 284 FT /note="Q -> L (in a lung adenocarcinoma patient)" FT /evidence="ECO:0000269|PubMed:17020408" FT /id="VAR_032104" FT VARIANT 333 FT /note="G -> C (in a NSCLC cell line; strongly reduces FT interaction with NFE2L2/NRF2 and reduces repression of FT NFE2L2/NRF2-dependent gene expression)" FT /evidence="ECO:0000269|PubMed:17020408" FT /id="VAR_032105" FT VARIANT 349 FT /note="D -> N (in dbSNP:rs1048289)" FT /evidence="ECO:0000269|PubMed:8590280" FT /id="VAR_032106" FT VARIANT 350 FT /note="G -> S (in a NSCLC cell line; dbSNP:rs777308626)" FT /evidence="ECO:0000269|PubMed:17020408" FT /id="VAR_032107" FT VARIANT 364 FT /note="G -> C (in a lung adenocarcinoma cell line; also in FT NSCLC cell lines; strongly reduces interaction with NFE2L2/ FT NRF2 and reduces repression of NFE2L2/NRF2-dependent gene FT expression; dbSNP:rs1397945617)" FT /evidence="ECO:0000269|PubMed:16507366" FT /id="VAR_032108" FT VARIANT 430 FT /note="G -> C (in a lung adenocarcinoma patient; somatic FT mutation; strongly reduces interaction with NFE2L2/NRF2 and FT reduces repression of NFE2L2/NRF2-dependent gene FT expression)" FT /evidence="ECO:0000269|PubMed:16507366" FT /id="VAR_032109" FT VARIANT 522 FT /note="A -> V (in a breast cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036085" FT MUTAGEN 15 FT /note="R->A: Reduced formation of a high-molecular mass FT KEAP1 molecule when methylglyoxal accumulates." FT /evidence="ECO:0000269|PubMed:30323285" FT MUTAGEN 123..127 FT /note="VSIEG->ASAEA: Abolished interaction with FT NFE2L2/NRF2; when associated with 161-A-A-162." FT /evidence="ECO:0000269|PubMed:15601839" FT MUTAGEN 125..127 FT /note="IEG->AAA: Increases ubiquitination and proteolytic FT degradation." FT /evidence="ECO:0000269|PubMed:15572695" FT MUTAGEN 135 FT /note="R->A: Reduced formation of a high-molecular mass FT KEAP1 molecule when methylglyoxal accumulates." FT /evidence="ECO:0000269|PubMed:30323285" FT MUTAGEN 151 FT /note="C->S,N,D,L: Substitution with a small side chain FT that prevents covalent modification by an electrophile; FT promotes constitutive ubiquitination of NFE2L2/NRF2 and FT subsequent repression of phase 2 detoxifying enzymes. FT Resistance of ubiquitination of PGAM5 to inhibition by FT oxidative stress and sulforaphane. Impaired interaction FT with CUL3. Reduced formation of a high-molecular mass KEAP1 FT molecule when methylglyoxal accumulates." FT /evidence="ECO:0000269|PubMed:14585973, FT ECO:0000269|PubMed:15983046, ECO:0000269|PubMed:17046835, FT ECO:0000269|PubMed:18251510, ECO:0000269|PubMed:19489739, FT ECO:0000269|PubMed:29590092, ECO:0000269|PubMed:30323285" FT MUTAGEN 151 FT /note="C->W,Y: Substitution with a bulky side chain that FT mimicks covalent modification by an electrophile; prevents FT ubiquitination and degradation of NFE2L2/NRF2, leading to FT constitutive activation of NFE2L2/NRF2 and subsequent FT expression of phase 2 detoxifying enzymes." FT /evidence="ECO:0000269|PubMed:19489739, FT ECO:0000269|PubMed:24896564" FT MUTAGEN 161..162 FT /note="MY->AA: Abolished interaction with NFE2L2/NRF2; when FT associated with 123-A--A-127." FT /evidence="ECO:0000269|PubMed:15601839" FT MUTAGEN 162..164 FT /note="YQI->AAA: Increases ubiquitination and proteolytic FT degradation." FT /evidence="ECO:0000269|PubMed:15572695" FT MUTAGEN 273 FT /note="C->S: Abolishes repression of NFE2L2/NRF2-dependent FT gene expression. Slows down degradation of NFE2L2/NRF2." FT /evidence="ECO:0000269|PubMed:14585973" FT MUTAGEN 288 FT /note="C->S: Abolishes repression of NFE2L2/NRF2-dependent FT gene expression. Slows down degradation of NFE2L2/NRF2." FT /evidence="ECO:0000269|PubMed:14585973" FT MUTAGEN 308 FT /note="L->A: Loss of export from nucleus; when associated FT with A-310." FT /evidence="ECO:0000269|PubMed:15657435" FT MUTAGEN 310 FT /note="L->A: Loss of export from nucleus; when associated FT with A-308." FT /evidence="ECO:0000269|PubMed:15657435" FT MUTAGEN 334 FT /note="Y->A: Loss of interaction with NFE2L2/NRF2. Strongly FT reduces repression of NFE2L2/NRF2-dependent gene FT expression. Loss of interaction with PGAM5." FT /evidence="ECO:0000269|PubMed:16888629, FT ECO:0000269|PubMed:17046835" FT MUTAGEN 380 FT /note="R->A: Loss of interaction with NFE2L2/NRF2. FT Abolishes repression of NFE2L2/NRF2-dependent gene FT expression. Impaired interaction with SQSTM1/p62." FT /evidence="ECO:0000269|PubMed:16888629, FT ECO:0000269|PubMed:20452972" FT MUTAGEN 382 FT /note="N->A: Loss of interaction with NFE2L2/NRF2. Strongly FT reduces repression of NFE2L2/NRF2-dependent gene FT expression. Impaired interaction with SQSTM1/p62." FT /evidence="ECO:0000269|PubMed:16888629, FT ECO:0000269|PubMed:20452972" FT MUTAGEN 415 FT /note="R->A: Loss of interaction with NFE2L2/NRF2. FT Abolishes repression of NFE2L2/NRF2-dependent gene FT expression. Loss of interaction with PGAM5. Does not affect FT interaction with SQSTM1/p62." FT /evidence="ECO:0000269|PubMed:16888629, FT ECO:0000269|PubMed:17046835, ECO:0000269|PubMed:20452972" FT MUTAGEN 436 FT /note="H->A: Loss of interaction with NFE2L2/NRF2. FT Abolishes repression of NFE2L2/NRF2-dependent gene FT expression. Does not affect interaction with SQSTM1/p62." FT /evidence="ECO:0000269|PubMed:16888629, FT ECO:0000269|PubMed:20452972" FT MUTAGEN 478 FT /note="F->A: Abolishes repression of NFE2L2/NRF2-dependent FT gene expression." FT /evidence="ECO:0000269|PubMed:16888629" FT MUTAGEN 483 FT /note="R->A: Loss of interaction with NFE2L2/NRF2. FT Abolishes repression of NFE2L2/NRF2-dependent gene FT expression. Loss of interaction with PGAM5. Does not affect FT interaction with SQSTM1/p62." FT /evidence="ECO:0000269|PubMed:16888629, FT ECO:0000269|PubMed:17046835, ECO:0000269|PubMed:20452972" FT MUTAGEN 525 FT /note="Y->A: Loss of interaction with NFE2L2/NRF2. Strongly FT reduces repression of NFE2L2/NRF2-dependent gene FT expression. Abolishes interaction with SQSTM1/p62." FT /evidence="ECO:0000269|PubMed:16888629, FT ECO:0000269|PubMed:20452972" FT MUTAGEN 572 FT /note="Y->A: Loss of interaction with NFE2L2/NRF2. Strongly FT reduces repression of NFE2L2/NRF2-dependent gene FT expression. Loss of interaction with PGAM5. Abolishes FT interaction with SQSTM1/p62." FT /evidence="ECO:0000269|PubMed:16888629, FT ECO:0000269|PubMed:17046835, ECO:0000269|PubMed:20452972" FT MUTAGEN 615 FT /note="K->R: Decreases binding to PGCKA1. Increases protein FT half-life." FT /evidence="ECO:0000269|PubMed:36882524" FT CONFLICT 504 FT /note="N -> S (in Ref. 4; BAG51647)" FT /evidence="ECO:0000305" FT STRAND 51..55 FT /evidence="ECO:0007829|PDB:7X4X" FT HELIX 59..72 FT /evidence="ECO:0007829|PDB:7EXI" FT STRAND 79..83 FT /evidence="ECO:0007829|PDB:7EXI" FT STRAND 86..88 FT /evidence="ECO:0007829|PDB:5DAD" FT STRAND 91..95 FT /evidence="ECO:0007829|PDB:7EXI" FT HELIX 97..103 FT /evidence="ECO:0007829|PDB:7EXI" FT HELIX 105..111 FT /evidence="ECO:0007829|PDB:7EXI" FT STRAND 113..115 FT /evidence="ECO:0007829|PDB:7EXI" FT STRAND 116..119 FT /evidence="ECO:0007829|PDB:7X4W" FT STRAND 121..125 FT /evidence="ECO:0007829|PDB:7EXI" FT HELIX 130..142 FT /evidence="ECO:0007829|PDB:7EXI" FT STRAND 143..148 FT /evidence="ECO:0007829|PDB:7X4X" FT HELIX 149..151 FT /evidence="ECO:0007829|PDB:7EXI" FT HELIX 152..161 FT /evidence="ECO:0007829|PDB:7EXI" FT HELIX 165..177 FT /evidence="ECO:0007829|PDB:7EXI" FT TURN 181..183 FT /evidence="ECO:0007829|PDB:5NLB" FT HELIX 184..194 FT /evidence="ECO:0007829|PDB:5NLB" FT HELIX 199..202 FT /evidence="ECO:0007829|PDB:5NLB" FT STRAND 327..331 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 334..338 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 342..345 FT /evidence="ECO:0007829|PDB:1ZGK" FT TURN 347..349 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 352..354 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 362..364 FT /evidence="ECO:0007829|PDB:2FLU" FT STRAND 366..370 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 373..377 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 380..383 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 386..389 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 393..396 FT /evidence="ECO:0007829|PDB:1ZGK" FT TURN 398..400 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 403..405 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 417..421 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 424..428 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 440..444 FT /evidence="ECO:0007829|PDB:1ZGK" FT TURN 445..448 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 449..452 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 464..468 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 471..475 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 480..483 FT /evidence="ECO:0007829|PDB:6HWS" FT STRAND 487..491 FT /evidence="ECO:0007829|PDB:1ZGK" FT TURN 492..495 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 496..499 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 511..515 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 518..522 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 527..530 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 534..538 FT /evidence="ECO:0007829|PDB:1ZGK" FT TURN 539..542 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 543..547 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 558..562 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 565..569 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 574..577 FT /evidence="ECO:0007829|PDB:5F72" FT STRAND 580..585 FT /evidence="ECO:0007829|PDB:1ZGK" FT TURN 586..589 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 590..596 FT /evidence="ECO:0007829|PDB:1ZGK" FT STRAND 605..609 FT /evidence="ECO:0007829|PDB:1ZGK" SQ SEQUENCE 624 AA; 69666 MW; CE180F3897BB8C97 CRC64; MQPDPRPSGA GACCRFLPLQ SQCPEGAGDA VMYASTECKA EVTPSQHGNR TFSYTLEDHT KQAFGIMNEL RLSQQLCDVT LQVKYQDAPA AQFMAHKVVL ASSSPVFKAM FTNGLREQGM EVVSIEGIHP KVMERLIEFA YTASISMGEK CVLHVMNGAV MYQIDSVVRA CSDFLVQQLD PSNAIGIANF AEQIGCVELH QRAREYIYMH FGEVAKQEEF FNLSHCQLVT LISRDDLNVR CESEVFHACI NWVKYDCEQR RFYVQALLRA VRCHSLTPNF LQMQLQKCEI LQSDSRCKDY LVKIFEELTL HKPTQVMPCR APKVGRLIYT AGGYFRQSLS YLEAYNPSDG TWLRLADLQV PRSGLAGCVV GGLLYAVGGR NNSPDGNTDS SALDCYNPMT NQWSPCAPMS VPRNRIGVGV IDGHIYAVGG SHGCIHHNSV ERYEPERDEW HLVAPMLTRR IGVGVAVLNR LLYAVGGFDG TNRLNSAECY YPERNEWRMI TAMNTIRSGA GVCVLHNCIY AAGGYDGQDQ LNSVERYDVE TETWTFVAPM KHRRSALGIT VHQGRIYVLG GYDGHTFLDS VECYDPDTDT WSEVTRMTSG RSGVGVAVTM EPCRKQIDQQ NCTC // ID KGP2_HUMAN Reviewed; 762 AA. AC Q13237; B4DMX3; E7EPE6; O00125; O60916; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 209. DE RecName: Full=cGMP-dependent protein kinase 2; DE Short=cGK 2; DE Short=cGK2; DE EC=2.7.11.12; DE AltName: Full=cGMP-dependent protein kinase II; DE Short=cGKII; GN Name=PRKG2; Synonyms=PRKGR2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=8607838; DOI=10.1006/bbrc.1996.0477; RA Orstavik S., Solberg R., Taskn K., Nordahl M., Altherr M.R., Hansson V., RA Jahnsen T., Sandberg M.; RT "Molecular cloning, cDNA structure, and chromosomal localization of the RT human type II cGMP-dependent protein kinase."; RL Biochem. Biophys. Res. Commun. 220:759-765(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=7498513; DOI=10.1016/0014-5793(95)01223-2; RA Fujii M., Ogata T., Takahashi E., Yamada K., Nakabayashi K., Oishi M., RA Ayusawa D.; RT "Expression of the human cGMP-dependent protein kinase II gene is lost upon RT introduction of SV40 T antigen or immortalization in human cells."; RL FEBS Lett. 375:263-267(1995). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Heart; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-734. RX PubMed=9535793; DOI=10.1006/bbrc.1998.8399; RA Witczak O., Orstavik S., Natarajan V., Frengen E., Jahnsen T., Sandberg M.; RT "Characterization of the gene encoding the human type II cGMP-dependent RT protein kinase."; RL Biochem. Biophys. Res. Commun. 245:113-119(1998). RN [6] RP MYRISTOYLATION AT GLY-2, AND SUBCELLULAR LOCATION. RX PubMed=8636133; DOI=10.1074/jbc.271.12.7025; RA Vaandrager A.B., Ehlert E.M., Jarchau T., Lohmann S.M., de Jonge H.R.; RT "N-terminal myristoylation is required for membrane localization of cGMP- RT dependent protein kinase type II."; RL J. Biol. Chem. 271:7025-7029(1996). RN [7] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [8] RP VARIANTS [LARGE SCALE ANALYSIS] ARG-106 AND ARG-716. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [9] RP INVOLVEMENT IN SMDP, INVOLVEMENT IN AMD4, VARIANT AMD4 569-ARG--PHE-762 RP DEL, AND CHARACTERIZATION OF VARIANT AMD4 569-ARG--PHE-762 DEL. RX PubMed=34782440; DOI=10.1136/jmedgenet-2021-108027; RG Genomics England Research Consortium; RA Pagnamenta A.T., Diaz-Gonzalez F., Banos-Pinero B., Ferla M.P., Toosi M.B., RA Calder A.D., Karimiani E.G., Doosti M., Wainwright A., Wordsworth P., RA Bailey K., Ejeskaer K., Lester T., Maroofian R., Heath K.E., Tajsharghi H., RA Shears D., Taylor J.C.; RT "Variable skeletal phenotypes associated with biallelic variants in RT PRKG2."; RL J. Med. Genet. 0:0-0(2021). RN [10] RP VARIANT AMD4 569-ARG--PHE-762 DEL, CHARACTERIZATION OF VARIANT AMD4 RP 569-ARG--PHE-762 DEL, AND FUNCTION. RX PubMed=33106379; DOI=10.1136/jmedgenet-2020-107177; RA Diaz-Gonzalez F., Wadhwa S., Rodriguez-Zabala M., Kumar S., Aza-Carmona M., RA Sentchordi-Montane L., Alonso M., Ahmad I., Zahra S., Kumar D., Kushwah N., RA Shamim U., Sait H., Kapoor S., Roldan B., Nishimura G., Offiah A.C., RA Faruq M., Heath K.E.; RT "Biallelic cGMP-dependent type II protein kinase gene (PRKG2) variants RT cause a novel acromesomelic dysplasia."; RL J. Med. Genet. 59:28-38(2022). RN [11] RP X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 137-418 IN COMPLEX WITH CAMP AND RP CGMP, ACTIVITY REGULATION, AND MUTAGENESIS OF ASP-412 AND ARG-415. RX PubMed=26769964; DOI=10.1074/jbc.m115.691303; RA Campbell J.C., Kim J.J., Li K.Y., Huang G.Y., Reger A.S., Matsuda S., RA Sankaran B., Link T.M., Yuasa K., Ladbury J.E., Casteel D.E., Kim C.; RT "Structural basis of cyclic nucleotide selectivity in cGMP-dependent RT protein kinase II."; RL J. Biol. Chem. 291:5623-5633(2016). CC -!- FUNCTION: Crucial regulator of intestinal secretion and bone growth. CC Phosphorylates and activates CFTR on the plasma membrane. Plays a key CC role in intestinal secretion by regulating cGMP-dependent translocation CC of CFTR in jejunum (PubMed:33106379). Acts downstream of NMDAR to CC activate the plasma membrane accumulation of GRIA1/GLUR1 in synapse and CC increase synaptic plasticity. Phosphorylates GRIA1/GLUR1 at Ser-863 (By CC similarity). Acts as a regulator of gene expression and activator of CC the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2 in CC mechanically stimulated osteoblasts. Under fluid shear stress, mediates CC ERK activation and subsequent induction of FOS, FOSL1/FRA1, FOSL2/FRA2 CC and FOSB that play a key role in the osteoblast anabolic response to CC mechanical stimulation (By similarity). {ECO:0000250|UniProtKB:Q61410, CC ECO:0000250|UniProtKB:Q64595, ECO:0000269|PubMed:33106379}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.12; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.12; CC -!- ACTIVITY REGULATION: Binding of cGMP results in enzyme activation. CC {ECO:0000269|PubMed:26769964}. CC -!- SUBUNIT: Interacts with GRIA1/GLUR1. {ECO:0000250|UniProtKB:Q64595}. CC -!- SUBCELLULAR LOCATION: Apical cell membrane CC {ECO:0000269|PubMed:8636133}; Lipid-anchor CC {ECO:0000269|PubMed:8636133}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q13237-1; Sequence=Displayed; CC Name=2; CC IsoId=Q13237-2; Sequence=VSP_055121; CC -!- TISSUE SPECIFICITY: Highly concentrated in brain, lung and intestinal CC mucosa. CC -!- PTM: Myristoylation mediates membrane localization. CC {ECO:0000269|PubMed:8636133}. CC -!- DISEASE: Spondylometaphyseal dysplasia, Pagnamenta type (SMDP) CC [MIM:619638]: A form of spondylometaphyseal dysplasia, a group of short CC stature disorders distinguished by abnormalities in the vertebrae and CC the metaphyses of the tubular bones. SMDP is an autosomal recessive CC form characterized by short stature and mild platyspondyly with no CC disproportion between the limbs. Mild metaphyseal changes are present. CC {ECO:0000269|PubMed:34782440}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Acromesomelic dysplasia 4 (AMD4) [MIM:619636]: A form of CC acromesomelic dysplasia, a skeletal disorder characterized by short CC stature, very short limbs and hand/foot malformations. The severity of CC limb abnormalities increases from proximal to distal with profoundly CC affected hands and feet showing brachydactyly and/or rudimentary CC fingers (knob-like fingers). AMD4 radiographic hallmarks include mild CC to moderate platyspondyly, moderate brachydactyly, iliac flaring, and CC metaphyseal alterations of the long bones that progressively increase CC with age. AMD4 inheritance is autosomal recessive. CC {ECO:0000269|PubMed:33106379, ECO:0000269|PubMed:34782440}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. cGMP subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X94612; CAA64318.1; -; mRNA. DR EMBL; D70899; BAA18934.1; -; mRNA. DR EMBL; AK297673; BAG60035.1; -; mRNA. DR EMBL; AC098819; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC139722; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Y16106; CAA76073.1; -; Genomic_DNA. DR EMBL; Y16107; CAA76073.1; JOINED; Genomic_DNA. DR EMBL; Y16108; CAA76073.1; JOINED; Genomic_DNA. DR EMBL; Y16109; CAA76073.1; JOINED; Genomic_DNA. DR EMBL; Y16110; CAA76073.1; JOINED; Genomic_DNA. DR EMBL; Y16111; CAA76073.1; JOINED; Genomic_DNA. DR EMBL; Y16112; CAA76073.1; JOINED; Genomic_DNA. DR EMBL; Y16113; CAA76073.1; JOINED; Genomic_DNA. DR EMBL; Y16114; CAA76073.1; JOINED; Genomic_DNA. DR EMBL; Y16115; CAA76073.1; JOINED; Genomic_DNA. DR EMBL; Y16116; CAA76073.1; JOINED; Genomic_DNA. DR EMBL; Y16117; CAA76073.1; JOINED; Genomic_DNA. DR EMBL; Y16118; CAA76073.1; JOINED; Genomic_DNA. DR EMBL; Y16119; CAA76073.1; JOINED; Genomic_DNA. DR EMBL; Y16120; CAA76073.1; JOINED; Genomic_DNA. DR EMBL; Y16121; CAA76073.1; JOINED; Genomic_DNA. DR EMBL; Y16122; CAA76073.1; JOINED; Genomic_DNA. DR EMBL; Y16123; CAA76073.1; JOINED; Genomic_DNA. DR CCDS; CCDS3589.1; -. [Q13237-1] DR CCDS; CCDS64005.1; -. [Q13237-2] DR PIR; S68217; S68217. DR RefSeq; NP_001269409.1; NM_001282480.1. DR RefSeq; NP_001269410.1; NM_001282481.1. DR RefSeq; NP_001269411.1; NM_001282482.1. DR RefSeq; NP_001269412.1; NM_001282483.1. DR RefSeq; NP_001269414.1; NM_001282485.2. [Q13237-2] DR RefSeq; NP_001350330.1; NM_001363401.2. [Q13237-1] DR RefSeq; NP_006250.1; NM_006259.3. [Q13237-1] DR RefSeq; XP_016863904.2; XM_017008415.2. [Q13237-1] DR RefSeq; XP_016863905.2; XM_017008416.2. [Q13237-1] DR RefSeq; XP_047271919.1; XM_047415963.1. [Q13237-1] DR RefSeq; XP_054206479.1; XM_054350504.1. [Q13237-1] DR RefSeq; XP_054206480.1; XM_054350505.1. [Q13237-1] DR PDB; 5BV6; X-ray; 1.94 A; A=269-418. DR PDB; 5C6C; X-ray; 2.05 A; A/B=137-277. DR PDB; 5C8W; X-ray; 1.80 A; A/B/C/D/E/F=137-277. DR PDB; 5JIX; X-ray; 1.47 A; A=269-418. DR PDB; 5JIZ; X-ray; 1.50 A; A=269-418. DR PDB; 6BQ8; Other; 2.00 A; A=269-418. DR PDBsum; 5BV6; -. DR PDBsum; 5C6C; -. DR PDBsum; 5C8W; -. DR PDBsum; 5JIX; -. DR PDBsum; 5JIZ; -. DR PDBsum; 6BQ8; -. DR AlphaFoldDB; Q13237; -. DR SMR; Q13237; -. DR BioGRID; 111579; 12. DR FunCoup; Q13237; 1123. DR IntAct; Q13237; 6. DR STRING; 9606.ENSP00000264399; -. DR BindingDB; Q13237; -. DR ChEMBL; CHEMBL2896; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q13237; -. DR GuidetoPHARMACOLOGY; 1493; -. DR iPTMnet; Q13237; -. DR PhosphoSitePlus; Q13237; -. DR BioMuta; PRKG2; -. DR DMDM; 6226833; -. DR jPOST; Q13237; -. DR MassIVE; Q13237; -. DR PaxDb; 9606-ENSP00000264399; -. DR PeptideAtlas; Q13237; -. DR ProteomicsDB; 17341; -. DR ProteomicsDB; 59241; -. [Q13237-1] DR Antibodypedia; 1102; 255 antibodies from 31 providers. DR DNASU; 5593; -. DR Ensembl; ENST00000264399.6; ENSP00000264399.1; ENSG00000138669.12. [Q13237-1] DR Ensembl; ENST00000395578.3; ENSP00000378945.1; ENSG00000138669.12. [Q13237-1] DR Ensembl; ENST00000628926.1; ENSP00000486129.1; ENSG00000138669.12. [Q13237-2] DR GeneID; 5593; -. DR KEGG; hsa:5593; -. DR MANE-Select; ENST00000264399.6; ENSP00000264399.1; NM_006259.3; NP_006250.1. DR UCSC; uc003hmh.3; human. [Q13237-1] DR AGR; HGNC:9416; -. DR ClinPGx; PA33778; -. DR CTD; 5593; -. DR DisGeNET; 5593; -. DR GeneCards; PRKG2; -. DR HGNC; HGNC:9416; PRKG2. DR HPA; ENSG00000138669; Tissue enhanced (intestine, prostate). DR MalaCards; PRKG2; -. DR MIM; 601591; gene. DR MIM; 619636; phenotype. DR MIM; 619638; phenotype. DR OpenTargets; ENSG00000138669; -. DR VEuPathDB; HostDB:ENSG00000138669; -. DR eggNOG; KOG0614; Eukaryota. DR GeneTree; ENSGT00940000159393; -. DR HOGENOM; CLU_000288_73_2_1; -. DR InParanoid; Q13237; -. DR OMA; YSYFDRY; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; Q13237; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q13237; -. DR BRENDA; 2.7.11.12; 2681. DR PathwayCommons; Q13237; -. DR Reactome; R-HSA-1474151; Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation. DR Reactome; R-HSA-4086398; Ca2+ pathway. DR Reactome; R-HSA-418457; cGMP effects. DR Reactome; R-HSA-9648002; RAS processing. DR SignaLink; Q13237; -. DR SIGNOR; Q13237; -. DR Agora; ENSG00000138669; -. DR BioGRID-ORCS; 5593; 14 hits in 1178 CRISPR screens. DR ChiTaRS; PRKG2; human. DR EvolutionaryTrace; Q13237; -. DR GenomeRNAi; 5593; -. DR Pharos; Q13237; Tchem. DR PRO; PR:Q13237; -. DR Proteomes; UP000005640; Chromosome 4. DR RNAct; Q13237; protein. DR Bgee; ENSG00000138669; Expressed in jejunal mucosa and 111 other cell types or tissues. DR ExpressionAtlas; Q13237; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0031965; C:nuclear membrane; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0030553; F:cGMP binding; IEA:UniProtKB-KW. DR GO; GO:0004692; F:cGMP-dependent protein kinase activity; IMP:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IEA:Ensembl. DR GO; GO:0051019; F:mitogen-activated protein kinase binding; IMP:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IMP:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IMP:UniProtKB. DR GO; GO:2001226; P:negative regulation of chloride transport; IEA:Ensembl. DR GO; GO:0032332; P:positive regulation of chondrocyte differentiation; IEA:Ensembl. DR GO; GO:1903829; P:positive regulation of protein localization; IEA:Ensembl. DR GO; GO:0072659; P:protein localization to plasma membrane; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; IBA:GO_Central. DR GO; GO:0046146; P:tetrahydrobiopterin metabolic process; TAS:Reactome. DR CDD; cd00038; CAP_ED; 2. DR CDD; cd05572; STKc_cGK; 1. DR FunFam; 3.30.200.20:FF:000005; cAMP-dependent protein kinase catalytic subunit; 1. DR FunFam; 1.10.510.10:FF:000096; cGMP-dependent protein kinase; 1. DR FunFam; 2.60.120.10:FF:000038; cGMP-dependent protein kinase; 1. DR FunFam; 2.60.120.10:FF:000043; cGMP-dependent protein kinase; 1. DR Gene3D; 2.60.120.10; Jelly Rolls; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR002374; cGMP_dep_kinase. DR InterPro; IPR018488; cNMP-bd_CS. DR InterPro; IPR000595; cNMP-bd_dom. DR InterPro; IPR018490; cNMP-bd_dom_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR014710; RmlC-like_jellyroll. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR035014; STKc_cGK. DR PANTHER; PTHR24353:SF24; -; 1. DR PANTHER; PTHR24353; CYCLIC NUCLEOTIDE-DEPENDENT PROTEIN KINASE; 1. DR Pfam; PF00027; cNMP_binding; 2. DR Pfam; PF00069; Pkinase; 1. DR PIRSF; PIRSF000559; cGMP-dep_kinase; 1. DR PRINTS; PR00104; CGMPKINASE. DR SMART; SM00100; cNMP; 2. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF51206; cAMP-binding domain-like; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS00888; CNMP_BINDING_1; 2. DR PROSITE; PS00889; CNMP_BINDING_2; 2. DR PROSITE; PS50042; CNMP_BINDING_3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; cGMP; KW cGMP-binding; Coiled coil; Disease variant; Dwarfism; Kinase; Lipoprotein; KW Membrane; Myristate; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|PubMed:8636133" FT CHAIN 2..762 FT /note="cGMP-dependent protein kinase 2" FT /id="PRO_0000086123" FT DOMAIN 453..711 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 712..762 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT REGION 1..25 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 117..138 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 168..283 FT /note="cGMP-binding, high affinity; cAMP-binding, moderate FT affinity" FT /evidence="ECO:0000305|PubMed:26769964" FT REGION 286..416 FT /note="cGMP-binding, high affinity; cAMP-binding, low FT affinity" FT /evidence="ECO:0000305|PubMed:26769964" FT REGION 740..762 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 23..85 FT /evidence="ECO:0000255" FT ACT_SITE 576 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 232..235 FT /ligand="3',5'-cyclic AMP" FT /ligand_id="ChEBI:CHEBI:58165" FT /evidence="ECO:0000269|PubMed:26769964, FT ECO:0007744|PDB:5C6C" FT BINDING 232..235 FT /ligand="3',5'-cyclic GMP" FT /ligand_id="ChEBI:CHEBI:57746" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:26769964, FT ECO:0007744|PDB:5C8W" FT BINDING 242..243 FT /ligand="3',5'-cyclic AMP" FT /ligand_id="ChEBI:CHEBI:58165" FT /evidence="ECO:0000269|PubMed:26769964, FT ECO:0007744|PDB:5C6C" FT BINDING 242..243 FT /ligand="3',5'-cyclic GMP" FT /ligand_id="ChEBI:CHEBI:57746" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:26769964, FT ECO:0007744|PDB:5C8W" FT BINDING 347 FT /ligand="3',5'-cyclic GMP" FT /ligand_id="ChEBI:CHEBI:57746" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:26769964, FT ECO:0000312|PDB:5BV6" FT BINDING 356..359 FT /ligand="3',5'-cyclic GMP" FT /ligand_id="ChEBI:CHEBI:57746" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:26769964, FT ECO:0007744|PDB:5BV6" FT BINDING 366..367 FT /ligand="3',5'-cyclic GMP" FT /ligand_id="ChEBI:CHEBI:57746" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:26769964, FT ECO:0007744|PDB:5BV6" FT BINDING 412 FT /ligand="3',5'-cyclic GMP" FT /ligand_id="ChEBI:CHEBI:57746" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:26769964, FT ECO:0000312|PDB:5BV6" FT BINDING 415 FT /ligand="3',5'-cyclic GMP" FT /ligand_id="ChEBI:CHEBI:57746" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:26769964, FT ECO:0000312|PDB:5BV6" FT BINDING 459..467 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 482 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 110 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q64595" FT MOD_RES 117 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q64595" FT MOD_RES 431 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q64595" FT MOD_RES 609 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q61410" FT LIPID 2 FT /note="N-myristoyl glycine" FT /evidence="ECO:0000269|PubMed:8636133" FT VAR_SEQ 441..469 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_055121" FT VARIANT 22 FT /note="T -> S (in dbSNP:rs34956759)" FT /id="VAR_051633" FT VARIANT 106 FT /note="H -> R (in dbSNP:rs34616910)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040608" FT VARIANT 569..762 FT /note="Missing (in AMD4; decreased protein abundance; FT unable to phosphorylate RAF1 in response to FGF2 and to FT inhibit FGF2-induced MAPK signaling; unable to suppress FT SOX9-induced COL2A1 expression; unable to upregulate FT COL10A1)" FT /id="VAR_086537" FT VARIANT 716 FT /note="W -> R (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040609" FT MUTAGEN 412 FT /note="D->A: Reduces cGMP binding affinity; when associated FT with A-415." FT /evidence="ECO:0000269|PubMed:26769964" FT MUTAGEN 415 FT /note="R->A: Reduces cGMP binding affinity; when associated FT with A-412." FT /evidence="ECO:0000269|PubMed:26769964" FT CONFLICT 57..58 FT /note="QL -> HG (in Ref. 2; BAA18934)" FT /evidence="ECO:0000305" FT CONFLICT 154 FT /note="S -> I (in Ref. 5; CAA76073)" FT /evidence="ECO:0000305" FT CONFLICT 388 FT /note="N -> D (in Ref. 3; BAG60035)" FT /evidence="ECO:0000305" FT CONFLICT 460 FT /note="G -> A (in Ref. 2; BAA18934)" FT /evidence="ECO:0000305" FT HELIX 153..164 FT /evidence="ECO:0007829|PDB:5C8W" FT HELIX 169..171 FT /evidence="ECO:0007829|PDB:5C8W" FT HELIX 174..183 FT /evidence="ECO:0007829|PDB:5C8W" FT STRAND 185..189 FT /evidence="ECO:0007829|PDB:5C8W" FT STRAND 194..196 FT /evidence="ECO:0007829|PDB:5C8W" FT STRAND 204..211 FT /evidence="ECO:0007829|PDB:5C8W" FT STRAND 213..217 FT /evidence="ECO:0007829|PDB:5C8W" FT STRAND 220..224 FT /evidence="ECO:0007829|PDB:5C8W" FT STRAND 230..232 FT /evidence="ECO:0007829|PDB:5C8W" FT HELIX 233..238 FT /evidence="ECO:0007829|PDB:5C8W" FT STRAND 243..250 FT /evidence="ECO:0007829|PDB:5C8W" FT STRAND 252..258 FT /evidence="ECO:0007829|PDB:5C8W" FT HELIX 259..266 FT /evidence="ECO:0007829|PDB:5C8W" FT HELIX 270..282 FT /evidence="ECO:0007829|PDB:5JIX" FT HELIX 285..287 FT /evidence="ECO:0007829|PDB:5JIX" FT HELIX 292..301 FT /evidence="ECO:0007829|PDB:5JIX" FT STRAND 303..307 FT /evidence="ECO:0007829|PDB:5JIX" FT STRAND 312..314 FT /evidence="ECO:0007829|PDB:5JIX" FT STRAND 323..335 FT /evidence="ECO:0007829|PDB:5JIX" FT STRAND 344..350 FT /evidence="ECO:0007829|PDB:5JIX" FT HELIX 357..362 FT /evidence="ECO:0007829|PDB:5JIX" FT STRAND 368..372 FT /evidence="ECO:0007829|PDB:5JIX" FT STRAND 377..382 FT /evidence="ECO:0007829|PDB:5JIX" FT HELIX 384..389 FT /evidence="ECO:0007829|PDB:5JIX" FT HELIX 391..393 FT /evidence="ECO:0007829|PDB:5JIX" FT HELIX 395..414 FT /evidence="ECO:0007829|PDB:5JIX" SQ SEQUENCE 762 AA; 87432 MW; FA7BA149906B5996 CRC64; MGNGSVKPKH SKHPDGHSGN LTTDALRNKV TELERELRRK DAEIQEREYH LKELREQLSK QTVAIAELTE ELQNKCIQLN KLQDVVHMQG GSPLQASPDK VPLEVHRKTS GLVSLHSRRG AKAGVSAEPT TRTYDLNKPP EFSFEKARVR KDSSEKKLIT DALNKNQFLK RLDPQQIKDM VECMYGRNYQ QGSYIIKQGE PGNHIFVLAE GRLEVFQGEK LLSSIPMWTT FGELAILYNC TRTASVKAIT NVKTWALDRE VFQNIMRRTA QARDEQYRNF LRSVSLLKNL PEDKLTKIID CLEVEYYDKG DYIIREGEEG STFFILAKGK VKVTQSTEGH DQPQLIKTLQ KGEYFGEKAL ISDDVRSANI IAEENDVACL VIDRETFNQT VGTFEELQKY LEGYVANLNR DDEKRHAKRS MSNWKLSKAL SLEMIQLKEK VARFSSSSPF QNLEIIATLG VGGFGRVELV KVKNENVAFA MKCIRKKHIV DTKQQEHVYS EKRILEELCS PFIVKLYRTF KDNKYVYMLL EACLGGELWS ILRDRGSFDE PTSKFCVACV TEAFDYLHRL GIIYRDLKPE NLILDAEGYL KLVDFGFAKK IGSGQKTWTF CGTPEYVAPE VILNKGHDFS VDFWSLGILV YELLTGNPPF SGVDQMMTYN LILKGIEKMD FPRKITRRPE DLIRRLCRQN PTERLGNLKN GINDIKKHRW LNGFNWEGLK ARSLPSPLQR ELKGPIDHSY FDKYPPEKGM PPDELSGWDK DF // ID KKCC2_HUMAN Reviewed; 588 AA. AC Q96RR4; A8K7Q7; O94883; Q8IUG2; Q8IUG3; Q8N3I4; Q8WY03; Q8WY04; Q8WY05; AC Q8WY06; Q96RP1; Q96RP2; Q96RR3; Q9BWE9; Q9UER3; Q9UES2; Q9Y5N2; DT 07-DEC-2004, integrated into UniProtKB/Swiss-Prot. DT 11-JAN-2011, sequence version 2. DT 28-JAN-2026, entry version 201. DE RecName: Full=Calcium/calmodulin-dependent protein kinase kinase 2; DE Short=CaM-KK 2; DE Short=CaM-kinase kinase 2; DE Short=CaMKK 2; DE EC=2.7.11.17; DE AltName: Full=Calcium/calmodulin-dependent protein kinase kinase beta; DE Short=CaM-KK beta; DE Short=CaM-kinase kinase beta; DE Short=CaMKK beta; GN Name=CAMKK2; Synonyms=CAMKKB, KIAA0787; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1; 2; 3; 4; 5 AND 6), RP FUNCTION, AND VARIANT SER-85. RX PubMed=11395482; DOI=10.1074/jbc.m011720200; RA Hsu L.-S., Chen G.-D., Lee L.-S., Chi C.-W., Cheng J.-F., Chen J.-Y.; RT "Human Ca2+/calmodulin-dependent protein kinase kinase beta gene encodes RT multiple isoforms that display distinct kinase activity."; RL J. Biol. Chem. 276:31113-31123(2001). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Brain cortex; RX PubMed=9822657; DOI=10.1074/jbc.273.48.31880; RA Anderson K.A., Means R.L., Huang Q.-H., Kemp B.E., Goldstein E.G., RA Selbert M.A., Edelman A.M., Fremeau R.T., Means A.R.; RT "Components of a calmodulin-dependent protein kinase cascade. Molecular RT cloning, functional characterization and cellular localization of RT Ca2+/calmodulin-dependent protein kinase kinase beta."; RL J. Biol. Chem. 273:31880-31889(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND FUNCTION IN PHOSPHORYLATION OF RP CAMK1D. RX PubMed=12935886; DOI=10.1016/s0014-5793(03)00817-2; RA Ishikawa Y., Tokumitsu H., Inuzuka H., Murata-Hori M., Hosoya H., RA Kobayashi R.; RT "Identification and characterization of novel components of a RT Ca2+/calmodulin-dependent protein kinase cascade in HeLa cells."; RL FEBS Lett. 550:57-63(2003). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 7), AND VARIANT SER-85. RC TISSUE=Brain; RX PubMed=9872452; DOI=10.1093/dnares/5.5.277; RA Nagase T., Ishikawa K., Suyama M., Kikuno R., Miyajima N., Tanaka A., RA Kotani H., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XI. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 5:277-286(1998). RN [5] RP SEQUENCE REVISION. RX PubMed=12168954; DOI=10.1093/dnares/9.3.99; RA Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.; RT "Construction of expression-ready cDNA clones for KIAA genes: manual RT curation of 330 KIAA cDNA clones."; RL DNA Res. 9:99-106(2002). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Stomach; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16541075; DOI=10.1038/nature04569; RA Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y., RA Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C., RA Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C., RA Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., RA Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E., RA Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., RA Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., RA Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., RA Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., RA Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., RA Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., RA Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., RA Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., RA Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., RA Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K., RA Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D., RA Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R., RA David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E., RA D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N., RA Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N., RA Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R., RA Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S., RA LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H., RA Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P., RA Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G., RA Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E., RA Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S., RA Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., RA Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J., RA Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A., RA Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M., RA Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I., RA Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A., RA Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y., RA Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A., RA Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F., RA Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L., RA Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G., RA Gibbs R.A.; RT "The finished DNA sequence of human chromosome 12."; RL Nature 440:346-351(2006). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), NUCLEOTIDE SEQUENCE RP [LARGE SCALE MRNA] OF 233-588 (ISOFORM 5), AND VARIANT SER-85. RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 117-588 (ISOFORM 2), FUNCTION IN RP PHOSPHORYLATION OF CAMK1, AND TISSUE SPECIFICITY. RX PubMed=9662074; DOI=10.1007/bf02258368; RA Hsu L.-S., Tsou A.-P., Chi C.-W., Lee C.-H., Chen J.-Y.; RT "Cloning, expression and chromosomal localization of human Ca2+/calmodulin- RT dependent protein kinase kinase."; RL J. Biomed. Sci. 5:141-149(1998). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 254-588 (ISOFORM 7). RC TISSUE=Amygdala; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 338-533 (ISOFORM 2). RA Barrow I.K.-P., Boguski M.S., Touchman J.W., Spencer F.; RT "Full-insert sequence of mapped XREF EST."; RL Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases. RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-495, PHOSPHORYLATION [LARGE RP SCALE ANALYSIS] AT SER-522 (ISOFORM 3), PHOSPHORYLATION [LARGE SCALE RP ANALYSIS] AT SER-479 (ISOFORM 5), AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [14] RP FUNCTION, SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, PHOSPHORYLATION BY RP PKA, AND INDUCTION OF ISOFORM 1. RX PubMed=21957496; DOI=10.4161/rna.8.6.16691; RA Cao W., Sohail M., Liu G., Koumbadinga G.A., Lobo V.G., Xie J.; RT "Differential effects of PKA-controlled CaMKK2 variants on neuronal RT differentiation."; RL RNA Biol. 8:1061-1072(2011). RN [15] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-114; SER-129; SER-495 AND RP SER-511, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-495, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [18] RP VARIANTS [LARGE SCALE ANALYSIS] ASN-10; SER-85; TYR-123; LEU-127; THR-182 RP AND HIS-492. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Calcium/calmodulin-dependent protein kinase belonging to a CC proposed calcium-triggered signaling cascade involved in a number of CC cellular processes. Isoform 1, isoform 2 and isoform 3 phosphorylate CC CAMK1 and CAMK4. Isoform 3 phosphorylates CAMK1D. Isoform 4, isoform 5 CC and isoform 6 lacking part of the calmodulin-binding domain are CC inactive. Efficiently phosphorylates 5'-AMP-activated protein kinase CC (AMPK) trimer, including that consisting of PRKAA1, PRKAB1 and PRKAG1. CC This phosphorylation is stimulated in response to Ca(2+) signals (By CC similarity). Seems to be involved in hippocampal activation of CREB1 CC (By similarity). May play a role in neurite growth. Isoform 3 may CC promote neurite elongation, while isoform 1 may promoter neurite CC branching. {ECO:0000250, ECO:0000269|PubMed:11395482, CC ECO:0000269|PubMed:12935886, ECO:0000269|PubMed:21957496, CC ECO:0000269|PubMed:9662074}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.17; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.17; CC -!- ACTIVITY REGULATION: Activated by Ca(2+)/calmodulin. Binding of CC calmodulin may relieve intrasteric autoinhibition. Autophosphorylation CC does not alter activity or regulation by Ca(2+)/calmodulin. In part, CC activity is independent on Ca(2+)/calmodulin (By similarity). CC {ECO:0000250}. CC -!- SUBUNIT: Interacts with calmodulin. {ECO:0000250}. CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:21957496}. Cytoplasm CC {ECO:0000269|PubMed:21957496}. Cell projection, neuron projection CC {ECO:0000269|PubMed:21957496}. Note=Predominantly nuclear in CC unstimulated cells, relocalizes into cytoplasm and neurites after CC forskolin induction. {ECO:0000269|PubMed:21957496}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=7; CC Name=1; Synonyms=Beta1, CAMKK2+E16; CC IsoId=Q96RR4-1; Sequence=Displayed; CC Name=2; Synonyms=Beta2; CC IsoId=Q96RR4-2; Sequence=VSP_012146, VSP_012147, VSP_012149; CC Name=3; Synonyms=Beta1delta16, CAMKK2-E16; CC IsoId=Q96RR4-3; Sequence=VSP_012143, VSP_012144, VSP_012145, CC VSP_012149; CC Name=4; Synonyms=Beta1delta14; CC IsoId=Q96RR4-4; Sequence=VSP_012142; CC Name=5; Synonyms=Beta1delta14/16, beta-3x; CC IsoId=Q96RR4-5; Sequence=VSP_012142, VSP_012143, VSP_012144, CC VSP_012145, VSP_012149; CC Name=6; Synonyms=Beta2delta14; CC IsoId=Q96RR4-6; Sequence=VSP_012142, VSP_012146, VSP_012147, CC VSP_012149; CC Name=7; CC IsoId=Q96RR4-7; Sequence=VSP_012148, VSP_012149; CC -!- TISSUE SPECIFICITY: Ubiquitously expressed with higher levels in the CC brain. Intermediate levels are detected in spleen, prostate, thyroid CC and leukocytes. The lowest level is in lung. CC {ECO:0000269|PubMed:9662074}. CC -!- INDUCTION: [Isoform 1]: Up-regulated by PKA pathway. CC {ECO:0000269|PubMed:21957496}. CC -!- DOMAIN: The autoinhibitory domain overlaps with the calmodulin binding CC region and may be involved in intrasteric autoinhibition. CC -!- DOMAIN: The RP domain (arginine/proline-rich) is involved in the CC recognition of CAMKI and CAMK4 as substrates. {ECO:0000250}. CC -!- PTM: Autophosphorylated and phosphorylated by PKA. Each isoform may CC show a different pattern of phosphorylation. CC {ECO:0000269|PubMed:21957496}. CC -!- MISCELLANEOUS: [Isoform 1]: Major isoform. CC -!- MISCELLANEOUS: [Isoform 2]: Major isoform. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 5]: Inactive. Does not activate CAMK1 and CC CAMK4. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 6]: Inactive. Does not activate CAMK1 and CC CAMK4. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC72943.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAA34507.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAD38990.1; Type=Miscellaneous discrepancy; Note=Intron retention.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB081337; BAC19841.1; -; mRNA. DR EMBL; AF287630; AAK64600.1; -; mRNA. DR EMBL; AF287631; AAK64601.1; -; mRNA. DR EMBL; AF321385; AAL37215.1; -; mRNA. DR EMBL; AF321386; AAL37216.1; -; mRNA. DR EMBL; AF321387; AAL37217.1; -; mRNA. DR EMBL; AF321388; AAL37218.1; -; mRNA. DR EMBL; AF321401; AAK91830.1; -; Genomic_DNA. DR EMBL; AF321390; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321391; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321392; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321393; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321394; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321395; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321396; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321397; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321398; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321399; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321400; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321575; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321576; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321577; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321578; AAK91830.1; JOINED; Genomic_DNA. DR EMBL; AF321402; AAK91829.1; -; Genomic_DNA. DR EMBL; AF321390; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321391; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321392; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321393; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321394; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321395; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321396; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321397; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321398; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321399; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321400; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321575; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321576; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321577; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF321578; AAK91829.1; JOINED; Genomic_DNA. DR EMBL; AF140507; AAD31507.1; -; mRNA. DR EMBL; AB081336; BAC19840.1; -; mRNA. DR EMBL; AB018330; BAA34507.2; ALT_INIT; mRNA. DR EMBL; AK292072; BAF84761.1; -; mRNA. DR EMBL; AC069209; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC000318; AAH00318.2; -; mRNA. DR EMBL; BC026060; AAH26060.1; -; mRNA. DR EMBL; AF101264; AAD04566.1; -; mRNA. DR EMBL; AL834322; CAD38990.1; ALT_SEQ; mRNA. DR EMBL; AF091074; AAC72943.1; ALT_INIT; mRNA. DR CCDS; CCDS44999.1; -. [Q96RR4-2] DR CCDS; CCDS53837.1; -. [Q96RR4-6] DR CCDS; CCDS58283.1; -. [Q96RR4-7] DR CCDS; CCDS9216.1; -. [Q96RR4-1] DR CCDS; CCDS9217.1; -. [Q96RR4-4] DR CCDS; CCDS9218.1; -. [Q96RR4-3] DR CCDS; CCDS9219.1; -. [Q96RR4-5] DR PIR; JE0191; JE0191. DR RefSeq; NP_001257414.1; NM_001270485.2. [Q96RR4-1] DR RefSeq; NP_001257415.1; NM_001270486.1. [Q96RR4-7] DR RefSeq; NP_006540.3; NM_006549.3. [Q96RR4-1] DR RefSeq; NP_705719.2; NM_153499.2. [Q96RR4-3] DR RefSeq; NP_705720.1; NM_153500.2. [Q96RR4-5] DR RefSeq; NP_757363.1; NM_172214.3. [Q96RR4-2] DR RefSeq; NP_757364.1; NM_172215.3. [Q96RR4-6] DR RefSeq; NP_757365.1; NM_172216.2. [Q96RR4-4] DR RefSeq; NP_757380.1; NM_172226.3. [Q96RR4-3] DR RefSeq; XP_005253879.1; XM_005253822.3. [Q96RR4-4] DR RefSeq; XP_005253880.1; XM_005253823.1. [Q96RR4-2] DR RefSeq; XP_005253881.1; XM_005253824.3. [Q96RR4-5] DR RefSeq; XP_011536065.1; XM_011537763.1. [Q96RR4-7] DR RefSeq; XP_016874191.1; XM_017018702.3. [Q96RR4-7] DR RefSeq; XP_047284057.1; XM_047428101.1. [Q96RR4-1] DR RefSeq; XP_047284058.1; XM_047428102.1. [Q96RR4-7] DR RefSeq; XP_047284059.1; XM_047428103.1. [Q96RR4-3] DR RefSeq; XP_047284060.1; XM_047428104.1. [Q96RR4-2] DR RefSeq; XP_047284063.1; XM_047428107.1. [Q96RR4-5] DR RefSeq; XP_047284064.1; XM_047428108.1. [Q96RR4-6] DR RefSeq; XP_054226771.1; XM_054370796.1. [Q96RR4-1] DR RefSeq; XP_054226772.1; XM_054370797.1. [Q96RR4-7] DR RefSeq; XP_054226773.1; XM_054370798.1. [Q96RR4-7] DR RefSeq; XP_054226774.1; XM_054370799.1. [Q96RR4-7] DR RefSeq; XP_054226775.1; XM_054370800.1. [Q96RR4-4] DR RefSeq; XP_054226776.1; XM_054370801.1. [Q96RR4-3] DR RefSeq; XP_054226777.1; XM_054370802.1. [Q96RR4-2] DR RefSeq; XP_054226778.1; XM_054370803.1. [Q96RR4-2] DR RefSeq; XP_054226781.1; XM_054370806.1. [Q96RR4-5] DR RefSeq; XP_054226782.1; XM_054370807.1. [Q96RR4-5] DR RefSeq; XP_054226783.1; XM_054370808.1. [Q96RR4-6] DR PDB; 2ZV2; X-ray; 2.40 A; A=158-448. DR PDB; 5UY6; X-ray; 1.70 A; A=161-449. DR PDB; 5UYJ; X-ray; 1.60 A; A=161-449. DR PDB; 5VT1; X-ray; 1.90 A; A=161-449. DR PDB; 5YV8; X-ray; 1.93 A; A=158-448. DR PDB; 5YV9; X-ray; 2.53 A; A=158-448. DR PDB; 5YVA; X-ray; 2.57 A; A=158-448. DR PDB; 5YVB; X-ray; 2.02 A; A=158-448. DR PDB; 5YVC; X-ray; 2.02 A; A=158-448. DR PDB; 6BKU; X-ray; 2.00 A; A=162-449. DR PDB; 6BLE; X-ray; 1.90 A; A=161-449. DR PDB; 6BQL; X-ray; 2.00 A; A=161-449. DR PDB; 6BQP; X-ray; 1.95 A; A=161-449. DR PDB; 6BQQ; X-ray; 1.80 A; A=161-449. DR PDB; 6BRC; X-ray; 2.20 A; A/B=161-449. DR PDB; 6CMJ; X-ray; 2.40 A; A/B=149-465. DR PDB; 6EF5; X-ray; 2.44 A; Q/S=508-514. DR PDB; 6EWW; X-ray; 2.68 A; E/F/G/H=97-104. DR PDB; 6FEL; X-ray; 2.84 A; E/F/G/H=508-515. DR PDB; 6Y3O; X-ray; 1.50 A; P=97-104. DR PDB; 6Y4K; X-ray; 3.00 A; E/F=97-104. DR PDB; 6Y6B; X-ray; 3.08 A; C/D=97-104. DR PDB; 6Y8A; X-ray; 1.50 A; P=508-515. DR PDB; 8TUC; X-ray; 1.50 A; A=161-449. DR PDBsum; 2ZV2; -. DR PDBsum; 5UY6; -. DR PDBsum; 5UYJ; -. DR PDBsum; 5VT1; -. DR PDBsum; 5YV8; -. DR PDBsum; 5YV9; -. DR PDBsum; 5YVA; -. DR PDBsum; 5YVB; -. DR PDBsum; 5YVC; -. DR PDBsum; 6BKU; -. DR PDBsum; 6BLE; -. DR PDBsum; 6BQL; -. DR PDBsum; 6BQP; -. DR PDBsum; 6BQQ; -. DR PDBsum; 6BRC; -. DR PDBsum; 6CMJ; -. DR PDBsum; 6EF5; -. DR PDBsum; 6EWW; -. DR PDBsum; 6FEL; -. DR PDBsum; 6Y3O; -. DR PDBsum; 6Y4K; -. DR PDBsum; 6Y6B; -. DR PDBsum; 6Y8A; -. DR PDBsum; 8TUC; -. DR AlphaFoldDB; Q96RR4; -. DR SASBDB; Q96RR4; -. DR SMR; Q96RR4; -. DR BioGRID; 115889; 77. DR FunCoup; Q96RR4; 2743. DR IntAct; Q96RR4; 51. DR STRING; 9606.ENSP00000312741; -. DR BindingDB; Q96RR4; -. DR ChEMBL; CHEMBL5284; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q96RR4; -. DR GuidetoPHARMACOLOGY; 1957; -. DR GlyCosmos; Q96RR4; 1 site, 1 glycan. DR GlyGen; Q96RR4; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q96RR4; -. DR PhosphoSitePlus; Q96RR4; -. DR SwissPalm; Q96RR4; -. DR BioMuta; CAMKK2; -. DR DMDM; 317373374; -. DR jPOST; Q96RR4; -. DR MassIVE; Q96RR4; -. DR PaxDb; 9606-ENSP00000312741; -. DR PeptideAtlas; Q96RR4; -. DR ProteomicsDB; 78009; -. [Q96RR4-1] DR ProteomicsDB; 78010; -. [Q96RR4-2] DR ProteomicsDB; 78011; -. [Q96RR4-3] DR ProteomicsDB; 78012; -. [Q96RR4-4] DR ProteomicsDB; 78013; -. [Q96RR4-5] DR ProteomicsDB; 78014; -. [Q96RR4-6] DR ProteomicsDB; 78015; -. [Q96RR4-7] DR Pumba; Q96RR4; -. DR Antibodypedia; 19059; 384 antibodies from 36 providers. DR DNASU; 10645; -. DR Ensembl; ENST00000324774.9; ENSP00000312741.5; ENSG00000110931.20. [Q96RR4-1] DR Ensembl; ENST00000337174.7; ENSP00000336634.3; ENSG00000110931.20. [Q96RR4-3] DR Ensembl; ENST00000347034.6; ENSP00000321230.3; ENSG00000110931.20. [Q96RR4-4] DR Ensembl; ENST00000392473.2; ENSP00000376265.2; ENSG00000110931.20. [Q96RR4-2] DR Ensembl; ENST00000392474.6; ENSP00000376266.2; ENSG00000110931.20. [Q96RR4-7] DR Ensembl; ENST00000402834.8; ENSP00000384591.4; ENSG00000110931.20. [Q96RR4-1] DR Ensembl; ENST00000404169.8; ENSP00000384600.3; ENSG00000110931.20. [Q96RR4-1] DR Ensembl; ENST00000412367.6; ENSP00000388368.2; ENSG00000110931.20. [Q96RR4-3] DR Ensembl; ENST00000446440.6; ENSP00000388273.2; ENSG00000110931.20. [Q96RR4-6] DR Ensembl; ENST00000538733.5; ENSP00000445944.1; ENSG00000110931.20. [Q96RR4-5] DR Ensembl; ENST00000652382.1; ENSP00000498824.1; ENSG00000110931.20. [Q96RR4-1] DR GeneID; 10645; -. DR KEGG; hsa:10645; -. DR MANE-Select; ENST00000404169.8; ENSP00000384600.3; NM_001270485.2; NP_001257414.1. DR UCSC; uc001tzt.4; human. [Q96RR4-1] DR AGR; HGNC:1470; -. DR ClinPGx; PA26052; -. DR CTD; 10645; -. DR DisGeNET; 10645; -. DR GeneCards; CAMKK2; -. DR HGNC; HGNC:1470; CAMKK2. DR HPA; ENSG00000110931; Tissue enriched (brain). DR MIM; 615002; gene. DR OpenTargets; ENSG00000110931; -. DR VEuPathDB; HostDB:ENSG00000110931; -. DR eggNOG; KOG0585; Eukaryota. DR GeneTree; ENSGT00940000161828; -. DR HOGENOM; CLU_000288_63_0_1; -. DR InParanoid; Q96RR4; -. DR OMA; EPRSECR; -. DR OrthoDB; 68483at2759; -. DR PAN-GO; Q96RR4; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q96RR4; -. DR BRENDA; 2.7.11.17; 2681. DR PathwayCommons; Q96RR4; -. DR Reactome; R-HSA-111932; CaMK IV-mediated phosphorylation of CREB. DR Reactome; R-HSA-442729; CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde. DR Reactome; R-HSA-9619229; Activation of RAC1 downstream of NMDARs. DR Reactome; R-HSA-9619483; Activation of AMPK downstream of NMDARs. DR SignaLink; Q96RR4; -. DR SIGNOR; Q96RR4; -. DR Agora; ENSG00000110931; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 10645; 17 hits in 1185 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; CAMKK2; human. DR EvolutionaryTrace; Q96RR4; -. DR GeneWiki; CAMKK2; -. DR GenomeRNAi; 10645; -. DR Pharos; Q96RR4; Tchem. DR PRO; PR:Q96RR4; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; Q96RR4; protein. DR Bgee; ENSG00000110931; Expressed in cerebellar cortex and 202 other cell types or tissues. DR ExpressionAtlas; Q96RR4; baseline and differential. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0043005; C:neuron projection; IEA:UniProtKB-SubCell. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB. DR GO; GO:0004683; F:calcium/calmodulin-dependent protein kinase activity; IEA:UniProtKB-EC. DR GO; GO:0005516; F:calmodulin binding; TAS:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0004713; F:protein tyrosine kinase activity; TAS:UniProtKB. DR GO; GO:0019722; P:calcium-mediated signaling; TAS:UniProtKB. DR GO; GO:0061762; P:CAMKK-AMPK signaling cascade; IMP:ParkinsonsUK-UCL. DR GO; GO:0034614; P:cellular response to reactive oxygen species; TAS:ParkinsonsUK-UCL. DR GO; GO:0000165; P:MAPK cascade; TAS:UniProtKB. DR GO; GO:1903599; P:positive regulation of autophagy of mitochondrion; IMP:ParkinsonsUK-UCL. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; TAS:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0045859; P:regulation of protein kinase activity; TAS:UniProtKB. DR CDD; cd14199; STKc_CaMKK2; 1. DR FunFam; 3.30.200.20:FF:000429; Calcium/calmodulin-dependent protein kinase kinase; 1. DR FunFam; 1.10.510.10:FF:000091; Calcium/calmodulin-dependent protein kinase kinase 2 isoform 1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR43895; CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE-RELATED; 1. DR PANTHER; PTHR43895:SF39; CALCIUM_CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ATP-binding; KW Calmodulin-binding; Cell projection; Cytoplasm; Kinase; Nucleotide-binding; KW Nucleus; Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..588 FT /note="Calcium/calmodulin-dependent protein kinase kinase FT 2" FT /id="PRO_0000086144" FT DOMAIN 165..446 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..33 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 78..100 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 128..149 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 204..226 FT /note="RP domain" FT REGION 205..225 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 472..477 FT /note="Autoinhibitory domain" FT /evidence="ECO:0000250" FT REGION 475..500 FT /note="Calmodulin-binding" FT /evidence="ECO:0000250" FT REGION 497..588 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1..14 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 128..139 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 521..536 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 579..588 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 312 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 171..179 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 194 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 100 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8C078" FT MOD_RES 114 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 129 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 133 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8C078" FT MOD_RES 137 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8C078" FT MOD_RES 495 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 511 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 572 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8C078" FT VAR_SEQ 442..484 FT /note="Missing (in isoform 4, isoform 5 and isoform 6)" FT /evidence="ECO:0000303|PubMed:11395482, FT ECO:0000303|PubMed:15489334" FT /id="VSP_012142" FT VAR_SEQ 520..532 FT /note="KPTRECESLSELK -> QGSEDNLQGTDPP (in isoform 3 and FT isoform 5)" FT /evidence="ECO:0000303|PubMed:11395482, FT ECO:0000303|PubMed:12935886, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_012143" FT VAR_SEQ 533..554 FT /note="EARQRRQPPGHRPAPRGGGGSA -> GTKKKKGLDSMTSTVAAGWLDRRV FT (in isoform 7)" FT /evidence="ECO:0000303|PubMed:17974005, FT ECO:0000303|PubMed:9872452" FT /id="VSP_012148" FT VAR_SEQ 533..541 FT /note="EARQRRQPP -> PVGEEEVLL (in isoform 3 and isoform 5)" FT /evidence="ECO:0000303|PubMed:11395482, FT ECO:0000303|PubMed:12935886, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_012144" FT VAR_SEQ 533 FT /note="E -> T (in isoform 2 and isoform 6)" FT /evidence="ECO:0000303|PubMed:11395482, FT ECO:0000303|PubMed:9662074, ECO:0000303|Ref.11" FT /id="VSP_012146" FT VAR_SEQ 534..554 FT /note="Missing (in isoform 2 and isoform 6)" FT /evidence="ECO:0000303|PubMed:11395482, FT ECO:0000303|PubMed:9662074, ECO:0000303|Ref.11" FT /id="VSP_012147" FT VAR_SEQ 542..554 FT /note="Missing (in isoform 3 and isoform 5)" FT /evidence="ECO:0000303|PubMed:11395482, FT ECO:0000303|PubMed:12935886, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_012145" FT VAR_SEQ 555..588 FT /note="Missing (in isoform 2, isoform 3, isoform 5, isoform FT 6 and isoform 7)" FT /evidence="ECO:0000303|PubMed:11395482, FT ECO:0000303|PubMed:12935886, ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:17974005, FT ECO:0000303|PubMed:9662074, ECO:0000303|PubMed:9872452, FT ECO:0000303|Ref.11" FT /id="VSP_012149" FT VARIANT 10 FT /note="S -> N (in dbSNP:rs28360477)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032788" FT VARIANT 85 FT /note="T -> S (in dbSNP:rs3817190)" FT /evidence="ECO:0000269|PubMed:11395482, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9872452" FT /id="VAR_020532" FT VARIANT 123 FT /note="C -> Y (in dbSNP:rs35403710)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040610" FT VARIANT 127 FT /note="P -> L (in a lung neuroendocrine carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040611" FT VARIANT 182 FT /note="A -> T (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs1207121718)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040612" FT VARIANT 363 FT /note="R -> C (in dbSNP:rs1132780)" FT /id="VAR_020533" FT VARIANT 492 FT /note="R -> H (in dbSNP:rs34129994)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040613" FT CONFLICT 206 FT /note="G -> A (in Ref. 2; AAD31507)" FT /evidence="ECO:0000305" FT CONFLICT 331 FT /note="F -> I (in Ref. 6; BAF84761)" FT /evidence="ECO:0000305" FT CONFLICT 347 FT /note="T -> Y (in Ref. 2; AAD31507)" FT /evidence="ECO:0000305" FT CONFLICT 371 FT /note="L -> K (in Ref. 2; AAD31507)" FT /evidence="ECO:0000305" FT CONFLICT 554 FT /note="A -> H (in Ref. 1; AAK91829)" FT /evidence="ECO:0000305" FT CONFLICT 557 FT /note="R -> N (in Ref. 1; AAK91829)" FT /evidence="ECO:0000305" FT STRAND 165..172 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 175..184 FT /evidence="ECO:0007829|PDB:8TUC" FT TURN 185..188 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 189..197 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 198..204 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 231..242 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 251..255 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 260..268 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 273..275 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 286..305 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 315..317 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 318..320 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 326..328 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 338..341 FT /evidence="ECO:0007829|PDB:5UY6" FT STRAND 343..346 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 351..353 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 356..358 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 364..367 FT /evidence="ECO:0007829|PDB:6CMJ" FT HELIX 368..385 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 395..404 FT /evidence="ECO:0007829|PDB:8TUC" FT STRAND 411..413 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 417..426 FT /evidence="ECO:0007829|PDB:8TUC" FT TURN 431..433 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 437..440 FT /evidence="ECO:0007829|PDB:8TUC" FT HELIX 444..447 FT /evidence="ECO:0007829|PDB:8TUC" FT TURN 448..451 FT /evidence="ECO:0007829|PDB:6CMJ" FT HELIX 457..461 FT /evidence="ECO:0007829|PDB:6CMJ" FT MOD_RES Q96RR4-3:522 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES Q96RR4-5:479 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" SQ SEQUENCE 588 AA; 64746 MW; 04E3583561341167 CRC64; MSSCVSSQPS SNRAAPQDEL GGRGSSSSES QKPCEALRGL SSLSIHLGME SFIVVTECEP GCAVDLGLAR DRPLEADGQE VPLDTSGSQA RPHLSGRKLS LQERSQGGLA AGGSLDMNGR CICPSLPYSP VSSPQSSPRL PRRPTVESHH VSITGMQDCV QLNQYTLKDE IGKGSYGVVK LAYNENDNTY YAMKVLSKKK LIRQAGFPRR PPPRGTRPAP GGCIQPRGPI EQVYQEIAIL KKLDHPNVVK LVEVLDDPNE DHLYMVFELV NQGPVMEVPT LKPLSEDQAR FYFQDLIKGI EYLHYQKIIH RDIKPSNLLV GEDGHIKIAD FGVSNEFKGS DALLSNTVGT PAFMAPESLS ETRKIFSGKA LDVWAMGVTL YCFVFGQCPF MDERIMCLHS KIKSQALEFP DQPDIAEDLK DLITRMLDKN PESRIVVPEI KLHPWVTRHG AEPLPSEDEN CTLVEVTEEE VENSVKHIPS LATVILVKTM IRKRSFGNPF EGSRREERSL SAPGNLLTKK PTRECESLSE LKEARQRRQP PGHRPAPRGG GGSALVRGSP CVESCWAPAP GSPARMHPLR PEEAMEPE // ID KLF6_HUMAN Reviewed; 283 AA. AC Q99612; B2RE86; B4DDN0; D3DRR1; F5H3M5; Q5VUT7; Q5VUT8; Q9BT79; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 30-MAY-2000, sequence version 3. DT 28-JAN-2026, entry version 221. DE RecName: Full=Krueppel-like factor 6; DE AltName: Full=B-cell-derived protein 1; DE AltName: Full=Core promoter element-binding protein; DE AltName: Full=GC-rich sites-binding factor GBF; DE AltName: Full=Proto-oncogene BCD1; DE AltName: Full=Suppressor of tumorigenicity 12 protein; DE AltName: Full=Transcription factor Zf9; GN Name=KLF6; Synonyms=BCD1, COPEB, CPBP, ST12; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP PRELIMINARY NUCLEOTIDE SEQUENCE (ISOFORM 1). RX PubMed=9000136; RA El Rouby S., Newcomb E.W.; RT "Identification of Bcd, a novel proto-oncogene expressed in B-cells."; RL Oncogene 13:2623-2630(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Placenta; RX PubMed=9083102; DOI=10.1074/jbc.272.14.9573; RA Koritschoner N.P., Bocco J.L., Panzetta-Dutari G.M., Dumur C.I., Flury A., RA Patrito L.C.; RT "A novel human zinc finger protein that interacts with the core promoter RT element of a TATA box-less gene."; RL J. Biol. Chem. 272:9573-9580(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Hepatic stellate cell; RX PubMed=9689109; DOI=10.1073/pnas.95.16.9500; RA Ratziu V., Lalazar A., Wong L., Dang Q., Collins C., Shaulian E., RA Jensen S., Friedman S.L.; RT "Zf9, a Kruppel-like transcription factor up-regulated in vivo during early RT hepatic fibrosis."; RL Proc. Natl. Acad. Sci. U.S.A. 95:9500-9505(1998). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CHARACTERIZATION. RC TISSUE=Leukocyte; RX PubMed=9685731; DOI=10.1093/oxfordjournals.jbchem.a022124; RA Suzuki T., Yamamoto T., Kurabayashi M., Nagai R., Yazaki Y., Horikoshi M.; RT "Isolation and initial characterization of GBF, a novel DNA-binding zinc RT finger protein that binds to the GC-rich binding sites of the HIV-1 RT promoter."; RL J. Biochem. 124:389-395(1998). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Koritschoner N.P.; RT "Genomic organization of the human COPEB/CPBP locus."; RL Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164054; DOI=10.1038/nature02462; RA Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L., RA Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K., RA Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L., RA Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P., RA Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P., RA Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N., RA Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A., RA Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C., RA Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D., RA Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C., RA Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K., RA Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A., RA Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S., RA McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S., RA Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., RA Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., RA Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M., RA Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A., RA Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P., RA Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y., RA Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D., RA Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 10."; RL Nature 429:375-381(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP INACTIVATION OF 9AATAD MOTIF. RX PubMed=31375868; DOI=10.1007/s00018-019-03251-w; RA Piskacek M., Havelka M., Jendruchova K., Knight A., Keegan L.P.; RT "The evolution of the 9aaTAD domain in Sp2 proteins: inactivation with RT valines and intron reservoirs."; RL Cell. Mol. Life Sci. 77:1793-1810(2020). RN [12] RP INVOLVEMENT IN PC, VARIANTS ARG-64; PRO-116; ASP-123 AND PRO-169, AND RP CHARACTERIZATION OF VARIANTS ARG-64; PRO-116; ASP-123 AND PRO-169. RX PubMed=11752579; DOI=10.1126/science.1066326; RA Narla G., Heath K.E., Reeves H.L., Li D., Giono L.E., Kimmelman A.C., RA Glucksman M.J., Narla J., Eng F.J., Chan A.M., Ferrari A.C., RA Martignetti J.A., Friedman S.L.; RT "KLF6, a candidate tumor suppressor gene mutated in prostate cancer."; RL Science 294:2563-2566(2001). RN [13] RP INVOLVEMENT IN GASC, AND VARIANTS ARG-155; THR-172; LEU-180 AND LYS-198. RX PubMed=15824733; DOI=10.1038/sj.onc.1208670; RA Cho Y.G., Kim C.J., Park C.H., Yang Y.M., Kim S.Y., Nam S.W., Lee S.H., RA Yoo N.J., Lee J.Y., Park W.S.; RT "Genetic alterations of the KLF6 gene in gastric cancer."; RL Oncogene 24:4588-4590(2005). RN [14] RP INTERACTION WITH ZZEF1. RX PubMed=33227311; DOI=10.1016/j.jmb.2020.11.021; RA Yu Y., Tencer A., Xuan H., Kutateladze T.G., Shi X.; RT "ZZEF1 is a Histone Reader and Transcriptional Coregulator of Krueppel-Like RT Factors."; RL J. Mol. Biol. 433:166722-166722(2021). CC -!- FUNCTION: Transcriptional activator (By similarity). Binds a GC box CC motif. Could play a role in B-cell growth and development. CC {ECO:0000250}. CC -!- SUBUNIT: Interacts with ZZEF1. {ECO:0000269|PubMed:33227311}. CC -!- INTERACTION: CC Q99612; P41250: GARS1; NbExp=3; IntAct=EBI-714994, EBI-724143; CC Q99612; P02545: LMNA; NbExp=3; IntAct=EBI-714994, EBI-351935; CC Q99612; Q04206: RELA; NbExp=6; IntAct=EBI-714994, EBI-73886; CC Q99612; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-714994, EBI-5235340; CC -!- SUBCELLULAR LOCATION: Nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q99612-1; Sequence=Displayed; CC Name=2; CC IsoId=Q99612-2; Sequence=VSP_015715; CC Name=3; CC IsoId=Q99612-3; Sequence=VSP_045808; CC -!- TISSUE SPECIFICITY: Highly expressed in placenta followed by spleen, CC thymus, prostate, testis, small intestine and colon. Weakly expressed CC in pancreas, lung, liver, heart and skeletal muscle. Also expressed in CC fetal brain, spleen and thymus. CC -!- DOMAIN: The acidic N-terminal part may favor interaction with the basic CC domain of transcription factors. CC -!- DOMAIN: The 9aaTAD motif is a transactivation domain present in a large CC number of yeast and animal transcription factors. In KLF6, the motif is CC inactive. {ECO:0000269|PubMed:31375868}. CC -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which CC starts in the stomach, can spread to the esophagus or the small CC intestine, and can extend through the stomach wall to nearby lymph CC nodes and organs. It also can metastasize to other parts of the body. CC The term gastric cancer or gastric carcinoma refers to adenocarcinoma CC of the stomach that accounts for most of all gastric malignant tumors. CC Two main histologic types are recognized, diffuse type and intestinal CC type carcinomas. Diffuse tumors are poorly differentiated infiltrating CC lesions, resulting in thickening of the stomach. In contrast, CC intestinal tumors are usually exophytic, often ulcerating, and CC associated with intestinal metaplasia of the stomach, most often CC observed in sporadic disease. {ECO:0000269|PubMed:15824733}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in CC tissues of the prostate. Most prostate cancers are adenocarcinomas that CC develop in the acini of the prostatic ducts. Other rare histopathologic CC types of prostate cancer that occur in approximately 5% of patients CC include small cell carcinoma, mucinous carcinoma, prostatic ductal CC carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal CC cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:11752579}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- SIMILARITY: Belongs to the krueppel C2H2-type zinc-finger protein CC family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC23699.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAA33050.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/44002/KLF6"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U44975; AAC23699.1; ALT_INIT; mRNA. DR EMBL; AF001461; AAC39929.1; -; mRNA. DR EMBL; AB017493; BAA33050.1; ALT_INIT; mRNA. DR EMBL; AF284036; AAM73548.1; -; Genomic_DNA. DR EMBL; BT006778; AAP35424.1; -; mRNA. DR EMBL; AL513303; CAH74049.1; -; Genomic_DNA. DR EMBL; AL450322; CAH74049.1; JOINED; Genomic_DNA. DR EMBL; AK293259; BAG56791.1; -; mRNA. DR EMBL; AK316596; BAG38183.1; -; mRNA. DR EMBL; AL513303; CAH74050.1; -; Genomic_DNA. DR EMBL; AL450322; CAH74050.1; JOINED; Genomic_DNA. DR EMBL; AL450322; CAH71010.1; -; Genomic_DNA. DR EMBL; AL513303; CAH71010.1; JOINED; Genomic_DNA. DR EMBL; AL450322; CAH71011.1; -; Genomic_DNA. DR EMBL; AL513303; CAH71011.1; JOINED; Genomic_DNA. DR EMBL; CH471072; EAW86477.1; -; Genomic_DNA. DR EMBL; CH471072; EAW86479.1; -; Genomic_DNA. DR EMBL; BC000311; AAH00311.1; -; mRNA. DR CCDS; CCDS53490.1; -. [Q99612-3] DR CCDS; CCDS7060.1; -. [Q99612-1] DR PIR; JE0235; JE0235. DR RefSeq; NP_001153596.1; NM_001160124.1. DR RefSeq; NP_001153597.1; NM_001160125.2. [Q99612-3] DR RefSeq; NP_001291.3; NM_001300.5. [Q99612-1] DR AlphaFoldDB; Q99612; -. DR SMR; Q99612; -. DR BioGRID; 107711; 94. DR FunCoup; Q99612; 2033. DR IntAct; Q99612; 81. DR STRING; 9606.ENSP00000419923; -. DR GlyGen; Q99612; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q99612; -. DR PhosphoSitePlus; Q99612; -. DR BioMuta; KLF6; -. DR DMDM; 7387592; -. DR jPOST; Q99612; -. DR MassIVE; Q99612; -. DR PaxDb; 9606-ENSP00000419923; -. DR PeptideAtlas; Q99612; -. DR ProteomicsDB; 26317; -. DR ProteomicsDB; 78355; -. [Q99612-1] DR ProteomicsDB; 78356; -. [Q99612-2] DR Antibodypedia; 4619; 229 antibodies from 37 providers. DR DNASU; 1316; -. DR Ensembl; ENST00000469435.1; ENSP00000419079.1; ENSG00000067082.16. [Q99612-2] DR Ensembl; ENST00000497571.6; ENSP00000419923.1; ENSG00000067082.16. [Q99612-1] DR Ensembl; ENST00000542957.1; ENSP00000445301.1; ENSG00000067082.16. [Q99612-3] DR GeneID; 1316; -. DR KEGG; hsa:1316; -. DR MANE-Select; ENST00000497571.6; ENSP00000419923.1; NM_001300.6; NP_001291.3. DR UCSC; uc001iha.4; human. [Q99612-1] DR AGR; HGNC:2235; -. DR ClinPGx; PA26751; -. DR CTD; 1316; -. DR DisGeNET; 1316; -. DR GeneCards; KLF6; -. DR HGNC; HGNC:2235; KLF6. DR HPA; ENSG00000067082; Tissue enhanced (bone). DR MalaCards; KLF6; -. DR MIM; 176807; phenotype. DR MIM; 602053; gene. DR MIM; 613659; phenotype. DR OpenTargets; ENSG00000067082; -. DR VEuPathDB; HostDB:ENSG00000067082; -. DR eggNOG; KOG1721; Eukaryota. DR GeneTree; ENSGT00940000158085; -. DR HOGENOM; CLU_002678_33_4_1; -. DR InParanoid; Q99612; -. DR OMA; HKCHFNG; -. DR OrthoDB; 4748970at2759; -. DR PAN-GO; Q99612; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q99612; -. DR PathwayCommons; Q99612; -. DR SignaLink; Q99612; -. DR SIGNOR; Q99612; -. DR Agora; ENSG00000067082; -. DR BioGRID-ORCS; 1316; 31 hits in 1184 CRISPR screens. DR ChiTaRS; KLF6; human. DR GeneWiki; KLF6; -. DR GenomeRNAi; 1316; -. DR Pharos; Q99612; Tbio. DR PRO; PR:Q99612; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; Q99612; protein. DR Bgee; ENSG00000067082; Expressed in nipple and 214 other cell types or tissues. DR GO; GO:0000785; C:chromatin; ISA:NTNU_SB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0001650; C:fibrillar center; IDA:HPA. DR GO; GO:0005730; C:nucleolus; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; TAS:UniProtKB. DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:NTNU_SB. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:NTNU_SB. DR GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0030183; P:B cell differentiation; NAS:UniProtKB. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; TAS:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:NTNU_SB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central. DR CDD; cd21586; KLF6_N; 1. DR FunFam; 3.30.160.60:FF:000021; Basic krueppel-like factor 3; 1. DR FunFam; 3.30.160.60:FF:000018; Krueppel-like factor 15; 1. DR FunFam; 3.30.160.60:FF:000624; zinc finger protein 697; 1. DR Gene3D; 3.30.160.60; Classic Zinc Finger; 3. DR InterPro; IPR036236; Znf_C2H2_sf. DR InterPro; IPR013087; Znf_C2H2_type. DR PANTHER; PTHR23235:SF50; KRUEPPEL-LIKE FACTOR 6; 1. DR PANTHER; PTHR23235; KRUEPPEL-LIKE TRANSCRIPTION FACTOR; 1. DR Pfam; PF00096; zf-C2H2; 3. DR SMART; SM00355; ZnF_C2H2; 3. DR SUPFAM; SSF57667; beta-beta-alpha zinc fingers; 2. DR PROSITE; PS00028; ZINC_FINGER_C2H2_1; 3. DR PROSITE; PS50157; ZINC_FINGER_C2H2_2; 3. PE 1: Evidence at protein level; KW Activator; Alternative splicing; DNA-binding; Metal-binding; Nucleus; KW Proteomics identification; Reference proteome; Repeat; Transcription; KW Transcription regulation; Zinc; Zinc-finger. FT CHAIN 1..283 FT /note="Krueppel-like factor 6" FT /id="PRO_0000047171" FT ZN_FING 200..224 FT /note="C2H2-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00042" FT ZN_FING 230..254 FT /note="C2H2-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00042" FT ZN_FING 260..282 FT /note="C2H2-type 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00042" FT REGION 106..198 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 62..70 FT /note="9aaTAD; inactive" FT /evidence="ECO:0000269|PubMed:31375868" FT COMPBIAS 133..148 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 183..196 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT VAR_SEQ 227..283 FT /note="EKPYRCSWEGCEWRFARSDELTRHFRKHTGAKPFKCSHCDRCFSRSDHLALH FT MKRHL -> QCPRGPRRAAAGGRHCIAPALEGAGPGCTGCGQGRQILTSSDVFHQSIRS FT FWSSE (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_015715" FT VAR_SEQ 227..283 FT /note="EKPYRCSWEGCEWRFARSDELTRHFRKHTGAKPFKCSHCDRCFSRSDHLALH FT MKRHL -> VFPGLTTWPCT (in isoform 3)" FT /evidence="ECO:0000305" FT /id="VSP_045808" FT VARIANT 64 FT /note="W -> R (found in prostate cancer samples; somatic FT mutation; does not up-regulates CDKN1A in a p53-independent FT manner and significantly reduces cell proliferation; FT dbSNP:rs121909142)" FT /evidence="ECO:0000269|PubMed:11752579" FT /id="VAR_065136" FT VARIANT 116 FT /note="S -> P (found in prostate cancer samples; somatic FT mutation; does not up-regulates CDKN1A in a p53-independent FT manner and significantly reduces cell proliferation; FT dbSNP:rs121909139)" FT /evidence="ECO:0000269|PubMed:11752579" FT /id="VAR_065137" FT VARIANT 123 FT /note="A -> D (found in prostate cancer samples; somatic FT mutation; does not up-regulates CDKN1A in a p53-independent FT manner and significantly reduces cell proliferation; FT dbSNP:rs121909141)" FT /evidence="ECO:0000269|PubMed:11752579" FT /id="VAR_065138" FT VARIANT 155 FT /note="S -> R (found in gastric cancer samples; somatic FT mutation; dbSNP:rs121909144)" FT /evidence="ECO:0000269|PubMed:15824733" FT /id="VAR_065139" FT VARIANT 169 FT /note="L -> P (found in prostate cancer samples; somatic FT mutation; does not up-regulates CDKN1A in a p53-independent FT manner and significantly reduces cell proliferation; FT dbSNP:rs121909143)" FT /evidence="ECO:0000269|PubMed:11752579" FT /id="VAR_065140" FT VARIANT 172 FT /note="P -> T (found in gastric cancer samples; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:15824733" FT /id="VAR_065141" FT VARIANT 180 FT /note="S -> L (found in gastric cancer samples; somatic FT mutation; dbSNP:rs372338890)" FT /evidence="ECO:0000269|PubMed:15824733" FT /id="VAR_065142" FT VARIANT 198 FT /note="R -> K (found in gastric cancer samples; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:15824733" FT /id="VAR_065143" FT CONFLICT 276 FT /note="A -> G (in Ref. 3; AAC39929)" FT /evidence="ECO:0000305" SQ SEQUENCE 283 AA; 31865 MW; 84294A7E6D0A0231 CRC64; MDVLPMCSIF QELQIVHETG YFSALPSLEE YWQQTCLELE RYLQSEPCYV SASEIKFDSQ EDLWTKIILA REKKEESELK ISSSPPEDTL ISPSFCYNLE TNSLNSDVSS ESSDSSEELS PTAKFTSDPI GEVLVSSGKL SSSVTSTPPS SPELSREPSQ LWGCVPGELP SPGKVRSGTS GKPGDKGNGD ASPDGRRRVH RCHFNGCRKV YTKSSHLKAH QRTHTGEKPY RCSWEGCEWR FARSDELTRH FRKHTGAKPF KCSHCDRCFS RSDHLALHMK RHL // ID KPCD2_HUMAN Reviewed; 878 AA. AC Q9BZL6; B4DTS2; M0QZW1; M0R2R2; Q8NCK8; Q8TB08; Q9P0T6; Q9Y3X8; DT 27-MAR-2002, integrated into UniProtKB/Swiss-Prot. DT 28-MAR-2018, sequence version 3. DT 28-JAN-2026, entry version 231. DE RecName: Full=Serine/threonine-protein kinase D2; DE EC=2.7.11.13 {ECO:0000269|PubMed:11062248, ECO:0000269|PubMed:12058027, ECO:0000269|PubMed:17962809, ECO:0000269|PubMed:28428613}; DE AltName: Full=nPKC-D2; GN Name=PRKD2; Synonyms=PKD2; ORFNames=HSPC187; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY, COFACTOR, RP TISSUE SPECIFICITY, AND PHOSPHORYLATION AT SER-876. RC TISSUE=Pancreas; RX PubMed=11062248; DOI=10.1074/jbc.m008719200; RA Sturany S., Van Lint J., Mueller F., Wilda M., Hameister H., Hoecker M., RA Brey A., Gern U., Vandenheede J., Gress T., Adler G., Seufferlein T.; RT "Molecular cloning and characterization of the human protein kinase D2. A RT novel member of the protein kinase d family of serine threonine kinases."; RL J. Biol. Chem. 276:3310-3318(2001). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3). RC TISSUE=Mammary gland, and Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 337-878 (ISOFORM 1/2). RC TISSUE=Uterus; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 574-878 (ISOFORM 1/2). RC TISSUE=Umbilical cord blood; RX PubMed=11042152; DOI=10.1101/gr.140200; RA Zhang Q.-H., Ye M., Wu X.-Y., Ren S.-X., Zhao M., Zhao C.-J., Fu G., RA Shen Y., Fan H.-Y., Lu G., Zhong M., Xu X.-R., Han Z.-G., Zhang J.-W., RA Tao J., Huang Q.-H., Zhou J., Hu G.-X., Gu J., Chen S.-J., Chen Z.; RT "Cloning and functional analysis of cDNAs with open reading frames for 300 RT previously undefined genes expressed in CD34+ hematopoietic stem/progenitor RT cells."; RL Genome Res. 10:1546-1560(2000). RN [6] RP CATALYTIC ACTIVITY, COFACTOR, ACTIVITY REGULATION, AND PHOSPHORYLATION AT RP SER-706; SER-710 AND SER-876. RX PubMed=12058027; DOI=10.1074/jbc.m200934200; RA Sturany S., Van Lint J., Gilchrist A., Vandenheede J.R., Adler G., RA Seufferlein T.; RT "Mechanism of activation of protein kinase D2(PKD2) by the CCK(B)/gastrin RT receptor."; RL J. Biol. Chem. 277:29431-29436(2002). RN [7] RP FUNCTION IN NF-KAPPA-B ACTIVATION, PHOSPHORYLATION AT TYR-438, AND RP MUTAGENESIS OF TYR-438. RX PubMed=15604256; DOI=10.1158/0008-5472.can-04-0981; RA Mihailovic T., Marx M., Auer A., Van Lint J., Schmid M., Weber C., RA Seufferlein T.; RT "Protein kinase D2 mediates activation of nuclear factor kappaB by Bcr-Abl RT in Bcr-Abl+ human myeloid leukemia cells."; RL Cancer Res. 64:8939-8944(2004). RN [8] RP FUNCTION IN TRAFFICKING. RX PubMed=14743217; DOI=10.1038/ncb1090; RA Yeaman C., Ayala M.I., Wright J.R., Bard F., Bossard C., Ang A., Maeda Y., RA Seufferlein T., Mellman I., Nelson W.J., Malhotra V.; RT "Protein kinase D regulates basolateral membrane protein exit from trans- RT Golgi network."; RL Nat. Cell Biol. 6:106-112(2004). RN [9] RP FUNCTION IN ADAPTIVE IMMUNE RESPONSE. RX PubMed=17077180; DOI=10.1093/intimm/dxl108; RA Irie A., Harada K., Tsukamoto H., Kim J.R., Araki N., Nishimura Y.; RT "Protein kinase D2 contributes to either IL-2 promoter regulation or RT induction of cell death upon TCR stimulation depending on its activity in RT Jurkat cells."; RL Int. Immunol. 18:1737-1747(2006). RN [10] RP FUNCTION. RX PubMed=16928771; DOI=10.1152/ajpcell.00308.2006; RA Chiu T.T., Leung W.Y., Moyer M.P., Strieter R.M., Rozengurt E.; RT "Protein kinase D2 mediates lysophosphatidic acid-induced interleukin 8 RT production in nontransformed human colonic epithelial cells through NF- RT kappaB."; RL Am. J. Physiol. 292:C767-C777(2007). RN [11] RP FUNCTION IN PHOSPHORYLATION OF HDAC7, CATALYTIC ACTIVITY, ACTIVITY RP REGULATION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT SER-244. RX PubMed=17962809; DOI=10.1038/sj.emboj.7601891; RA von Blume J., Knippschild U., Dequiedt F., Giamas G., Beck A., Auer A., RA Van Lint J., Adler G., Seufferlein T.; RT "Phosphorylation at Ser244 by CK1 determines nuclear localization and RT substrate targeting of PKD2."; RL EMBO J. 26:4619-4633(2007). RN [12] RP FUNCTION IN CELL ADHESION. RX PubMed=17951978; DOI=10.1254/jphs.fp0070858; RA Ge X., Low B., Liang M., Fu J.; RT "Angiotensin II directly triggers endothelial exocytosis via protein kinase RT C-dependent protein kinase D2 activation."; RL J. Pharmacol. Sci. 105:168-176(2007). RN [13] RP PHORBOL-ESTER BINDING, AND MUTAGENESIS OF PRO-275. RX PubMed=18076381; DOI=10.1042/bj20071334; RA Chen J., Deng F., Li J., Wang Q.J.; RT "Selective binding of phorbol esters and diacylglycerol by individual C1 RT domains of the PKD family."; RL Biochem. J. 411:333-342(2008). RN [14] RP FUNCTION IN SECRETORY PATHWAY, AND SUBCELLULAR LOCATION. RX PubMed=18262756; DOI=10.1016/j.cellsig.2008.01.003; RA von Wichert G., Edenfeld T., von Blume J., Krisp H., Krndija D., Schmid H., RA Oswald F., Lother U., Walther P., Adler G., Seufferlein T.; RT "Protein kinase D2 regulates chromogranin A secretion in human BON RT neuroendocrine tumour cells."; RL Cell. Signal. 20:925-934(2008). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-710 AND SER-876, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-200; SER-203; SER-206; RP SER-214 AND SER-710, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [18] RP FUNCTION, AND INTERACTION WITH LCK. RX PubMed=19192391; DOI=10.5483/bmbrep.2009.42.1.035; RA Li Q., Sun X., Wu J., Lin Z., Luo Y.; RT "PKD2 interacts with Lck and regulates NFAT activity in T cells."; RL BMB Rep. 42:35-40(2009). RN [19] RP FUNCTION IN ANGIOGENESIS. RX PubMed=19001381; DOI=10.1074/jbc.m807546200; RA Hao Q., Wang L., Zhao Z.J., Tang H.; RT "Identification of protein kinase D2 as a pivotal regulator of endothelial RT cell proliferation, migration, and angiogenesis."; RL J. Biol. Chem. 284:799-806(2009). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-206; SER-518; SER-710; RP TYR-717 AND SER-876, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [22] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-203, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-197; SER-198; SER-200; RP SER-203; SER-206 AND SER-710, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-214, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [27] RP FUNCTION, INTERACTION WITH CIB1 ISOFORM 2, AND MUTAGENESIS OF SER-244; RP ASP-695; SER-706 AND SER-710. RX PubMed=23503467; DOI=10.1038/onc.2013.43; RA Armacki M., Joodi G., Nimmagadda S.C., de Kimpe L., Pusapati G.V., RA Vandoninck S., Van Lint J., Illing A., Seufferlein T.; RT "A novel splice variant of calcium and integrin-binding protein 1 mediates RT protein kinase D2-stimulated tumour growth by regulating angiogenesis."; RL Oncogene 33:1167-1180(2014). RN [28] RP FUNCTION, CATALYTIC ACTIVITY, COFACTOR, ACTIVITY REGULATION, INTERACTION RP WITH PRKCD, MOTIF, PHOSPHORYLATION AT SER-706; SER-710 AND TYR-717, AND RP MUTAGENESIS OF TYR-87; TYR-438; SER-706; SER-710; TYR-717 AND RP 724-LEU--GLN-726. RX PubMed=28428613; DOI=10.1038/s41598-017-00800-w; RA Cobbaut M., Derua R., Doeppler H., Lou H.J., Vandoninck S., Storz P., RA Turk B.E., Seufferlein T., Waelkens E., Janssens V., Van Lint J.; RT "Differential regulation of PKD isoforms in oxidative stress conditions RT through phosphorylation of a conserved Tyr in the P+1 loop."; RL Sci. Rep. 7:887-887(2017). RN [29] RP STRUCTURE BY NMR OF 395-509. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the PH domain of protein kinase C, D2 type from RT human."; RL Submitted (NOV-2005) to the PDB data bank. RN [30] RP X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 526-534. RX PubMed=18836451; DOI=10.1038/ni.1660; RA Mohammed F., Cobbold M., Zarling A.L., Salim M., Barrett-Wilt G.A., RA Shabanowitz J., Hunt D.F., Engelhard V.H., Willcox B.E.; RT "Phosphorylation-dependent interaction between antigenic peptides and MHC RT class I: a molecular basis for the presentation of transformed self."; RL Nat. Immunol. 9:1236-1243(2008). RN [31] RP VARIANTS [LARGE SCALE ANALYSIS] MET-324; VAL-496; GLY-604; ARG-773; GLU-848 RP AND GLU-870. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase that converts transient CC diacylglycerol (DAG) signals into prolonged physiological effects CC downstream of PKC, and is involved in the regulation of cell CC proliferation via MAPK1/3 (ERK1/2) signaling, oxidative stress-induced CC NF-kappa-B activation, inhibition of HDAC7 transcriptional repression, CC signaling downstream of T-cell antigen receptor (TCR) and cytokine CC production, and plays a role in Golgi membrane trafficking, CC angiogenesis, secretory granule release and cell adhesion CC (PubMed:14743217, PubMed:15604256, PubMed:16928771, PubMed:17077180, CC PubMed:17951978, PubMed:17962809, PubMed:18262756, PubMed:19001381, CC PubMed:19192391, PubMed:23503467, PubMed:28428613). May potentiate CC mitogenesis induced by the neuropeptide bombesin by mediating an CC increase in the duration of MAPK1/3 (ERK1/2) signaling, which leads to CC accumulation of immediate-early gene products including FOS that CC stimulate cell cycle progression (By similarity). In response to CC oxidative stress, is phosphorylated at Tyr-438 and Tyr-717 by ABL1, CC which leads to the activation of PRKD2 without increasing its catalytic CC activity, and mediates activation of NF-kappa-B (PubMed:15604256, CC PubMed:28428613). In response to the activation of the gastrin receptor CC CCKBR, is phosphorylated at Ser-244 by CSNK1D and CSNK1E, translocates CC to the nucleus, phosphorylates HDAC7, leading to nuclear export of CC HDAC7 and inhibition of HDAC7 transcriptional repression of NR4A1/NUR77 CC (PubMed:17962809). Upon TCR stimulation, is activated independently of CC ZAP70, translocates from the cytoplasm to the nucleus and is required CC for interleukin-2 (IL2) promoter up-regulation (PubMed:17077180). CC During adaptive immune responses, is required in peripheral T- CC lymphocytes for the production of the effector cytokines IL2 and IFNG CC after TCR engagement and for optimal induction of antibody responses to CC antigens (By similarity). In epithelial cells stimulated with CC lysophosphatidic acid (LPA), is activated through a PKC-dependent CC pathway and mediates LPA-stimulated interleukin-8 (IL8) secretion via a CC NF-kappa-B-dependent pathway (PubMed:16928771). During TCR-induced T- CC cell activation, interacts with and is activated by the tyrosine kinase CC LCK, which results in the activation of the NFAT transcription factors CC (PubMed:19192391). In the trans-Golgi network (TGN), regulates the CC fission of transport vesicles that are on their way to the plasma CC membrane and in polarized cells is involved in the transport of CC proteins from the TGN to the basolateral membrane (PubMed:14743217). CC Plays an important role in endothelial cell proliferation and migration CC prior to angiogenesis, partly through modulation of the expression of CC KDR/VEGFR2 and FGFR1, two key growth factor receptors involved in CC angiogenesis (PubMed:19001381). In secretory pathway, is required for CC the release of chromogranin-A (CHGA)-containing secretory granules from CC the TGN (PubMed:18262756). Downstream of PRKCA, plays important roles CC in angiotensin-2-induced monocyte adhesion to endothelial cells CC (PubMed:17951978). Plays a regulatory role in angiogenesis and tumor CC growth by phosphorylating a downstream mediator CIB1 isoform 2, CC resulting in vascular endothelial growth factor A (VEGFA) secretion CC (PubMed:23503467). {ECO:0000250|UniProtKB:Q8BZ03, CC ECO:0000269|PubMed:14743217, ECO:0000269|PubMed:15604256, CC ECO:0000269|PubMed:16928771, ECO:0000269|PubMed:17077180, CC ECO:0000269|PubMed:17951978, ECO:0000269|PubMed:17962809, CC ECO:0000269|PubMed:18262756, ECO:0000269|PubMed:19001381, CC ECO:0000269|PubMed:19192391, ECO:0000269|PubMed:23503467, CC ECO:0000269|PubMed:28428613}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:11062248, ECO:0000269|PubMed:12058027, CC ECO:0000269|PubMed:17962809, ECO:0000269|PubMed:28428613}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:11062248, ECO:0000269|PubMed:12058027, CC ECO:0000269|PubMed:17962809, ECO:0000269|PubMed:28428613}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:11062248, ECO:0000269|PubMed:12058027, CC ECO:0000269|PubMed:28428613}; CC -!- ACTIVITY REGULATION: Activated by DAG and phorbol esters CC (PubMed:12058027, PubMed:17962809, PubMed:28428613). Phorbol-ester/DAG- CC type domains bind DAG, mediating translocation to membranes CC (PubMed:17962809). Autophosphorylation of Ser-710 and phosphorylation CC of Ser-706 by PKC relieves auto-inhibition by the PH domain CC (PubMed:17962809). Catalytic activity is further increased by CC phosphorylation at Tyr-717 in response to oxidative stress CC (PubMed:28428613). {ECO:0000269|PubMed:12058027, CC ECO:0000269|PubMed:17962809, ECO:0000269|PubMed:28428613}. CC -!- SUBUNIT: Interacts (via C-terminus) with LCK (PubMed:19192391). CC Interacts (via N-terminal AP-rich region) with CIB1 isoform 2 CC (PubMed:23503467). Interacts (via N-terminus and zing-finger domain 1 CC and 2) with PRKCD in response to oxidative stress; the interaction is CC independent of PRKD2 tyrosine phosphorylation (PubMed:28428613). CC {ECO:0000269|PubMed:19192391, ECO:0000269|PubMed:23503467, CC ECO:0000269|PubMed:28428613}. CC -!- INTERACTION: CC Q9BZL6; Q02410: APBA1; NbExp=3; IntAct=EBI-1384325, EBI-368690; CC Q9BZL6; Q9BQQ3: GORASP1; NbExp=2; IntAct=EBI-1384325, EBI-2561458; CC Q9BZL6; Q8WUI4: HDAC7; NbExp=6; IntAct=EBI-1384325, EBI-1048378; CC Q9BZL6; Q86UL8: MAGI2; NbExp=2; IntAct=EBI-1384325, EBI-311035; CC Q9BZL6; Q15599: NHERF2; NbExp=3; IntAct=EBI-1384325, EBI-1149760; CC Q9BZL6; P26045: PTPN3; NbExp=2; IntAct=EBI-1384325, EBI-1047946; CC Q9BZL6; Q04917: YWHAH; NbExp=3; IntAct=EBI-1384325, EBI-306940; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17962809}. Cell CC membrane {ECO:0000250|UniProtKB:Q15139}. Nucleus CC {ECO:0000269|PubMed:17962809}. Golgi apparatus, trans-Golgi network CC {ECO:0000269|PubMed:18262756}. Note=Translocation to the cell membrane CC is required for kinase activation. Accumulates in the nucleus upon CK1- CC mediated phosphorylation after activation of G-protein-coupled CC receptors. Nuclear accumulation is regulated by blocking nuclear export CC of active PRKD2 rather than by increasing import. CC {ECO:0000269|PubMed:17962809}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q9BZL6-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9BZL6-2; Sequence=VSP_057279; CC Name=3; CC IsoId=Q9BZL6-3; Sequence=VSP_059398; CC -!- TISSUE SPECIFICITY: Widely expressed. {ECO:0000269|PubMed:11062248}. CC -!- PTM: Phosphorylation of Ser-876 correlates with the activation status CC of the kinase (PubMed:11062248). Ser-706 or/and Ser-710 are probably CC phosphorylated by PKC (PubMed:12058027, PubMed:28428613). CC Phosphorylation at Ser-244 by CSNK1D and CSNK1E promotes nuclear CC localization and substrate targeting (PubMed:17962809). Phosphorylation CC at Ser-244, Ser-706 and Ser-710 is required for nuclear localization CC (PubMed:17962809). Phosphorylated at Tyr-438 by ABL1 in response to CC oxidative stress (PubMed:15604256). Phosphorylated at Tyr-717 by ABL1 CC specifically in response to oxidative stress; requires prior CC phosphorylation at Ser-706 or/and Ser-710 (PubMed:28428613). CC {ECO:0000269|PubMed:11062248, ECO:0000269|PubMed:12058027, CC ECO:0000269|PubMed:15604256, ECO:0000269|PubMed:17962809, CC ECO:0000269|PubMed:28428613}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. PKD subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAF36107.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF309082; AAK01149.1; -; mRNA. DR EMBL; AK074673; BAC11127.1; -; mRNA. DR EMBL; AK095884; BAG53158.1; -; mRNA. DR EMBL; AK300339; BAG62084.1; -; mRNA. DR EMBL; AC008635; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC093503; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; KC877745; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL050147; CAB43292.1; -; mRNA. DR EMBL; AF151021; AAF36107.1; ALT_FRAME; mRNA. DR CCDS; CCDS12689.1; -. [Q9BZL6-1] DR CCDS; CCDS59401.1; -. [Q9BZL6-2] DR PIR; T08777; T08777. DR RefSeq; NP_001073349.1; NM_001079880.2. [Q9BZL6-1] DR RefSeq; NP_001073350.1; NM_001079881.2. [Q9BZL6-1] DR RefSeq; NP_001073351.1; NM_001079882.2. [Q9BZL6-2] DR RefSeq; NP_057541.2; NM_016457.4. [Q9BZL6-1] DR RefSeq; XP_005258773.2; XM_005258716.3. [Q9BZL6-2] DR RefSeq; XP_047294523.1; XM_047438567.1. [Q9BZL6-2] DR RefSeq; XP_047294524.1; XM_047438568.1. [Q9BZL6-2] DR RefSeq; XP_054176459.1; XM_054320484.1. [Q9BZL6-1] DR RefSeq; XP_054176460.1; XM_054320485.1. [Q9BZL6-1] DR RefSeq; XP_054176461.1; XM_054320486.1. [Q9BZL6-2] DR RefSeq; XP_054176462.1; XM_054320487.1. [Q9BZL6-2] DR RefSeq; XP_054176463.1; XM_054320488.1. [Q9BZL6-2] DR PDB; 2COA; NMR; -; A=398-509. DR PDB; 3BGM; X-ray; 1.60 A; C=526-534. DR PDB; 4NNX; X-ray; 2.10 A; C=526-534. DR PDB; 4NNY; X-ray; 1.90 A; C=526-534. DR PDBsum; 2COA; -. DR PDBsum; 3BGM; -. DR PDBsum; 4NNX; -. DR PDBsum; 4NNY; -. DR AlphaFoldDB; Q9BZL6; -. DR BMRB; Q9BZL6; -. DR SMR; Q9BZL6; -. DR BioGRID; 117384; 316. DR FunCoup; Q9BZL6; 2691. DR IntAct; Q9BZL6; 161. DR MINT; Q9BZL6; -. DR STRING; 9606.ENSP00000393978; -. DR BindingDB; Q9BZL6; -. DR ChEMBL; CHEMBL4900; -. DR DrugCentral; Q9BZL6; -. DR GuidetoPHARMACOLOGY; 2173; -. DR GlyGen; Q9BZL6; 3 sites, 1 O-linked glycan (2 sites). DR iPTMnet; Q9BZL6; -. DR PhosphoSitePlus; Q9BZL6; -. DR BioMuta; PRKD2; -. DR DMDM; 296434570; -. DR CPTAC; CPTAC-1364; -. DR jPOST; Q9BZL6; -. DR MassIVE; Q9BZL6; -. DR PaxDb; 9606-ENSP00000393978; -. DR PeptideAtlas; Q9BZL6; -. DR ProteomicsDB; 79872; -. [Q9BZL6-1] DR Pumba; Q9BZL6; -. DR Antibodypedia; 18122; 622 antibodies from 42 providers. DR DNASU; 25865; -. DR Ensembl; ENST00000291281.9; ENSP00000291281.3; ENSG00000105287.14. [Q9BZL6-1] DR Ensembl; ENST00000433867.5; ENSP00000393978.1; ENSG00000105287.14. [Q9BZL6-1] DR Ensembl; ENST00000595515.5; ENSP00000470804.1; ENSG00000105287.14. [Q9BZL6-3] DR Ensembl; ENST00000600194.5; ENSP00000472744.1; ENSG00000105287.14. [Q9BZL6-2] DR Ensembl; ENST00000601806.5; ENSP00000469106.1; ENSG00000105287.14. [Q9BZL6-2] DR GeneID; 25865; -. DR KEGG; hsa:25865; -. DR MANE-Select; ENST00000291281.9; ENSP00000291281.3; NM_016457.5; NP_057541.2. DR UCSC; uc002pfi.4; human. [Q9BZL6-1] DR UCSC; uc010xye.3; human. DR AGR; HGNC:17293; -. DR ClinPGx; PA134903505; -. DR CTD; 25865; -. DR DisGeNET; 25865; -. DR GeneCards; PRKD2; -. DR HGNC; HGNC:17293; PRKD2. DR HPA; ENSG00000105287; Low tissue specificity. DR MIM; 607074; gene. DR OpenTargets; ENSG00000105287; -. DR VEuPathDB; HostDB:ENSG00000105287; -. DR eggNOG; KOG4236; Eukaryota. DR GeneTree; ENSGT00950000183024; -. DR HOGENOM; CLU_009772_1_0_1; -. DR InParanoid; Q9BZL6; -. DR OMA; ASYMGRP; -. DR OrthoDB; 74314at2759; -. DR PAN-GO; Q9BZL6; 1 GO annotation based on evolutionary models. DR PhylomeDB; Q9BZL6; -. DR BRENDA; 2.7.11.13; 2681. DR PathwayCommons; Q9BZL6; -. DR Reactome; R-HSA-1660661; Sphingolipid de novo biosynthesis. DR SignaLink; Q9BZL6; -. DR SIGNOR; Q9BZL6; -. DR Agora; ENSG00000105287; -. DR BioGRID-ORCS; 25865; 31 hits in 1202 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; PRKD2; human. DR EvolutionaryTrace; Q9BZL6; -. DR GeneWiki; PRKD2; -. DR GenomeRNAi; 25865; -. DR Pharos; Q9BZL6; Tchem. DR PRO; PR:Q9BZL6; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q9BZL6; protein. DR Bgee; ENSG00000105287; Expressed in vena cava and 201 other cell types or tissues. DR ExpressionAtlas; Q9BZL6; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:BHF-UCL. DR GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; TAS:Reactome. DR GO; GO:0004672; F:protein kinase activity; IDA:BHF-UCL. DR GO; GO:0005080; F:protein kinase C binding; IPI:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IGI:BHF-UCL. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:BHF-UCL. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW. DR GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW. DR GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW. DR GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IMP:BHF-UCL. DR GO; GO:0061154; P:endothelial tube morphogenesis; TAS:BHF-UCL. DR GO; GO:0035556; P:intracellular signal transduction; IMP:BHF-UCL. DR GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; IBA:GO_Central. DR GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB. DR GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IMP:BHF-UCL. DR GO; GO:0045785; P:positive regulation of cell adhesion; IMP:UniProtKB. DR GO; GO:2000573; P:positive regulation of DNA biosynthetic process; ISS:UniProtKB. DR GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; IMP:UniProtKB. DR GO; GO:2001028; P:positive regulation of endothelial cell chemotaxis; IMP:BHF-UCL. DR GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:UniProtKB. DR GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB. DR GO; GO:0045743; P:positive regulation of fibroblast growth factor receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0032743; P:positive regulation of interleukin-2 production; ISS:UniProtKB. DR GO; GO:0032757; P:positive regulation of interleukin-8 production; IMP:UniProtKB. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB. DR GO; GO:0050862; P:positive regulation of T cell receptor signaling pathway; ISS:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL. DR GO; GO:0030949; P:positive regulation of vascular endothelial growth factor receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:CACAO. DR GO; GO:0070232; P:regulation of T cell apoptotic process; IMP:BHF-UCL. DR GO; GO:0030148; P:sphingolipid biosynthetic process; TAS:Reactome. DR GO; GO:0050852; P:T cell receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; IMP:BHF-UCL. DR CDD; cd20840; C1_PKD2_rpt1; 1. DR CDD; cd20843; C1_PKD2_rpt2; 1. DR CDD; cd01239; PH_PKD; 1. DR CDD; cd14082; STKc_PKD; 1. DR FunFam; 1.10.510.10:FF:000151; Serine/threonine-protein kinase; 1. DR FunFam; 2.30.29.30:FF:000056; Serine/threonine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000137; Serine/threonine-protein kinase; 1. DR FunFam; 3.30.60.20:FF:000007; Serine/threonine-protein kinase; 1. DR FunFam; 3.30.60.20:FF:000019; Serine/threonine-protein kinase; 1. DR Gene3D; 3.30.60.20; -; 2. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR011993; PH-like_dom_sf. DR InterPro; IPR001849; PH_domain. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR015727; Protein_Kinase_C_mu-related. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR057764; Ubiquitin_PRKD1-3_N. DR PANTHER; PTHR22968; PROTEIN KINASE C, MU; 1. DR PANTHER; PTHR22968:SF12; SERINE_THREONINE-PROTEIN KINASE D2; 1. DR Pfam; PF00130; C1_1; 2. DR Pfam; PF00169; PH; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF25525; Ubiquitin_PRKD1_N; 1. DR PIRSF; PIRSF000552; PKC_mu_nu_D2; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 2. DR SMART; SM00233; PH; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 2. DR SUPFAM; SSF50729; PH domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50003; PH_DOMAIN; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 2. DR PROSITE; PS50081; ZF_DAG_PE_2; 2. PE 1: Evidence at protein level; KW 3D-structure; Adaptive immunity; Alternative splicing; Angiogenesis; KW ATP-binding; Cell adhesion; Cell membrane; Cytoplasm; Golgi apparatus; KW Immunity; Kinase; Magnesium; Membrane; Metal-binding; Nucleotide-binding; KW Nucleus; Phosphoprotein; Proteomics identification; Reference proteome; KW Repeat; Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger. FT CHAIN 1..878 FT /note="Serine/threonine-protein kinase D2" FT /id="PRO_0000055716" FT DOMAIN 397..509 FT /note="PH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00145" FT DOMAIN 551..807 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ZN_FING 138..188 FT /note="Phorbol-ester/DAG-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT ZN_FING 264..314 FT /note="Phorbol-ester/DAG-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 1..35 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 224..247 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 343..373 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 844..869 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 724..726 FT /note="Important for ABL1-mediated Tyr-717 phosphorylation" FT /evidence="ECO:0000269|PubMed:28428613" FT COMPBIAS 1..12 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 14..35 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 236..245 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 674 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 557..565 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 580 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 30 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O94806" FT MOD_RES 87 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:Q15139" FT MOD_RES 197 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 198 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 200 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 203 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 206 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163" FT MOD_RES 212 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BZ03" FT MOD_RES 214 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:24275569" FT MOD_RES 244 FT /note="Phosphoserine; by CSNK1D and CSNK1E" FT /evidence="ECO:0000269|PubMed:17962809" FT MOD_RES 407 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:Q15139" FT MOD_RES 438 FT /note="Phosphotyrosine; by ABL1" FT /evidence="ECO:0000269|PubMed:15604256, FT ECO:0000305|PubMed:28428613" FT MOD_RES 518 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 706 FT /note="Phosphoserine; by PKC" FT /evidence="ECO:0000269|PubMed:12058027, FT ECO:0000269|PubMed:28428613" FT MOD_RES 710 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:12058027, FT ECO:0000269|PubMed:28428613, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 717 FT /note="Phosphotyrosine; by ABL1" FT /evidence="ECO:0000269|PubMed:28428613, FT ECO:0007744|PubMed:19369195" FT MOD_RES 876 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11062248, FT ECO:0000269|PubMed:12058027, ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195" FT VAR_SEQ 1..157 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_057279" FT VAR_SEQ 779 FT /note="G -> GGAWGPPTPWA (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_059398" FT VARIANT 324 FT /note="V -> M (in dbSNP:rs45455991)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042330" FT VARIANT 496 FT /note="A -> V (in dbSNP:rs55716765)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042331" FT VARIANT 604 FT /note="S -> G (in dbSNP:rs34325043)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042332" FT VARIANT 773 FT /note="W -> R (in dbSNP:rs55933311)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042333" FT VARIANT 835 FT /note="A -> V (in dbSNP:rs314665)" FT /id="VAR_061531" FT VARIANT 848 FT /note="G -> E (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042334" FT VARIANT 870 FT /note="G -> E (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042335" FT MUTAGEN 87 FT /note="Y->F: Loss of phosphorylation. No effect on the FT interaction with PRKCD. No effect on Ser-706 or/and Ser-710 FT phosphorylation." FT /evidence="ECO:0000269|PubMed:28428613" FT MUTAGEN 244 FT /note="S->E: Constitutive kinase activity; when associated FT with E-706 and E-710." FT /evidence="ECO:0000269|PubMed:23503467" FT MUTAGEN 275 FT /note="P->G: Increase in ability to bind phorbol ester, FT slight increase in ability to bind DAG." FT /evidence="ECO:0000269|PubMed:18076381" FT MUTAGEN 438 FT /note="Y->D: Slight increase in Tyr-717 phosphorylation. No FT effect on Ser-706 or/and Ser-710 phosphorylation. Increase FT in Tyr-717 phosphorylation; when associated with E-706 and FT E-710." FT /evidence="ECO:0000269|PubMed:28428613" FT MUTAGEN 438 FT /note="Y->F: Loss of phosphorylation. No effect on FT phosphorylation of Tyr-717 and on Ser-706 or/and Ser-710 FT phosphorylation." FT /evidence="ECO:0000269|PubMed:15604256, FT ECO:0000269|PubMed:28428613" FT MUTAGEN 695 FT /note="D->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:23503467" FT MUTAGEN 706 FT /note="S->A: Abolishes phosphorylation. Loss of Tyr-717 FT phosphorylation and any other tyrosine phosphorylation, and FT increases NF-kappa-B activation in response to oxidative FT stress; when associated with A-710." FT /evidence="ECO:0000269|PubMed:28428613" FT MUTAGEN 706 FT /note="S->E: Constitutive kinase activity; when associated FT with E-710 or with E-244 and E-710. Increases Tyr-717 FT phosphorylation; when associated with E-710 or with E-710 FT and D-438." FT /evidence="ECO:0000269|PubMed:23503467, FT ECO:0000269|PubMed:28428613" FT MUTAGEN 710 FT /note="S->A: Abolishes phosphorylation. Loss of Tyr-717 FT phosphorylation and any other tyrosine phosphorylation, and FT increases NF-kappa-B activation in response to oxidative FT stress; when associated with A-706." FT /evidence="ECO:0000269|PubMed:28428613" FT MUTAGEN 710 FT /note="S->E: Constitutive kinase activity; when associated FT with E-706 or with E-244 and E-706. when associated with E- FT 710 or with E-244 and E-710. Increases Tyr-717 FT phosphorylation; when associated with E-710 or with E-710 FT and D-438." FT /evidence="ECO:0000269|PubMed:23503467, FT ECO:0000269|PubMed:28428613" FT MUTAGEN 717 FT /note="Y->F: Abolishes phosphorylation. Decreases substrate FT affinity and increases catalytic efficiency. Increases Ser- FT 706 or/and Ser-710 phosphorylation. Increases NF-kappa-B FT activation in response to oxidative stress." FT /evidence="ECO:0000269|PubMed:28428613" FT MUTAGEN 724..726 FT /note="LNQ->RNK: Reduced catalytic activity. Severe FT reduction in Tyr-717 phosphorylation by ABL1 in response to FT oxidative stress. No effect on Ser-706 or/and Ser-710 FT phosphorylation and on NF-kappa-B activation in response to FT oxidative stress." FT /evidence="ECO:0000269|PubMed:28428613" FT CONFLICT 790 FT /note="V -> L (in Ref. 5; AAF36107)" FT /evidence="ECO:0000305" FT STRAND 399..406 FT /evidence="ECO:0007829|PDB:2COA" FT STRAND 409..411 FT /evidence="ECO:0007829|PDB:2COA" FT STRAND 415..421 FT /evidence="ECO:0007829|PDB:2COA" FT STRAND 423..433 FT /evidence="ECO:0007829|PDB:2COA" FT STRAND 438..442 FT /evidence="ECO:0007829|PDB:2COA" FT TURN 443..445 FT /evidence="ECO:0007829|PDB:2COA" FT STRAND 448..452 FT /evidence="ECO:0007829|PDB:2COA" FT STRAND 456..458 FT /evidence="ECO:0007829|PDB:2COA" FT STRAND 465..470 FT /evidence="ECO:0007829|PDB:2COA" FT STRAND 486..488 FT /evidence="ECO:0007829|PDB:2COA" FT HELIX 495..507 FT /evidence="ECO:0007829|PDB:2COA" SQ SEQUENCE 878 AA; 96722 MW; 8BAB45E8F99D23E7 CRC64; MATAPSYPAG LPGSPGPGSP PPPGGLELQS PPPLLPQIPA PGSGVSFHIQ IGLTREFVLL PAASELAHVK QLACSIVDQK FPECGFYGLY DKILLFKHDP TSANLLQLVR SSGDIQEGDL VEVVLSASAT FEDFQIRPHA LTVHSYRAPA FCDHCGEMLF GLVRQGLKCD GCGLNYHKRC AFSIPNNCSG ARKRRLSSTS LASGHSVRLG TSESLPCTAE ELSRSTTELL PRRPPSSSSS SSASSYTGRP IELDKMLLSK VKVPHTFLIH SYTRPTVCQA CKKLLKGLFR QGLQCKDCKF NCHKRCATRV PNDCLGEALI NGDVPMEEAT DFSEADKSAL MDESEDSGVI PGSHSENALH ASEEEEGEGG KAQSSLGYIP LMRVVQSVRH TTRKSSTTLR EGWVVHYSNK DTLRKRHYWR LDCKCITLFQ NNTTNRYYKE IPLSEILTVE SAQNFSLVPP GTNPHCFEIV TANATYFVGE MPGGTPGGPS GQGAEAARGW ETAIRQALMP VILQDAPSAP GHAPHRQASL SISVSNSQIQ ENVDIATVYQ IFPDEVLGSG QFGVVYGGKH RKTGRDVAVK VIDKLRFPTK QESQLRNEVA ILQSLRHPGI VNLECMFETP EKVFVVMEKL HGDMLEMILS SEKGRLPERL TKFLITQILV ALRHLHFKNI VHCDLKPENV LLASADPFPQ VKLCDFGFAR IIGEKSFRRS VVGTPAYLAP EVLLNQGYNR SLDMWSVGVI MYVSLSGTFP FNEDEDINDQ IQNAAFMYPA SPWSHISAGA IDLINNLLQV KMRKRYSVDK SLSHPWLQEY QTWLDLRELE GKMGERYITH ESDDARWEQF AAEHPLPGSG LPTDRDLGGA CPPQDHDMQG LAERISVL // ID KPCL_HUMAN Reviewed; 683 AA. AC P24723; B4DJN5; Q16246; Q8NE03; DT 01-MAR-1992, integrated into UniProtKB/Swiss-Prot. DT 15-DEC-2009, sequence version 4. DT 28-JAN-2026, entry version 232. DE RecName: Full=Protein kinase C eta type; DE EC=2.7.11.13 {ECO:0000269|PubMed:34593629}; DE AltName: Full=PKC-L; DE AltName: Full=nPKC-eta; GN Name=PRKCH; Synonyms=PKCL, PRKCL; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY. RC TISSUE=Lung; RX PubMed=1986216; DOI=10.1128/mcb.11.1.126-133.1991; RA Bacher N., Zisman Y., Berent E., Livneh E.; RT "Isolation and characterization of PKC-L, a new member of the protein RT kinase C-related gene family specifically expressed in lung, skin, and RT heart."; RL Mol. Cell. Biol. 11:126-133(1991). RN [2] RP ERRATUM OF PUBMED:1986216, AND SEQUENCE REVISION. RX PubMed=1545821; DOI=10.1128/mcb.12.3.1404-.1992; RA Bacher N., Zisman Y., Berent E., Livneh E.; RL Mol. Cell. Biol. 12:1404-1404(1992). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Thalamus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12508121; DOI=10.1038/nature01348; RA Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C., RA Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A., RA Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H., RA Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T., RA Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B., RA Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D., RA Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R., RA Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S., RA Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C., RA Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S., RA Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., RA Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., RA Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M., RA Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V., RA Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J., RA Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F., RA Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F., RA Waterston R., Hood L., Weissenbach J.; RT "The DNA sequence and analysis of human chromosome 14."; RL Nature 421:601-607(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 438-539 (ISOFORM 1). RX PubMed=7988719; DOI=10.1016/0014-5793(94)01202-4; RA Palmer R.H., Ridden J., Parker P.J.; RT "Identification of multiple, novel, protein kinase C-related gene RT products."; RL FEBS Lett. 356:5-8(1994). RN [8] RP FUNCTION. RX PubMed=11112424; DOI=10.1006/bbrc.2000.3903; RA Akkaraju G.R., Basu A.; RT "Overexpression of protein kinase C-eta attenuates caspase activation and RT tumor necrosis factor-alpha-induced cell death."; RL Biochem. Biophys. Res. Commun. 279:103-107(2000). RN [9] RP FUNCTION IN CELL PROLIFERATION. RX PubMed=10806212; DOI=10.1074/jbc.m003203200; RA Hussaini I.M., Karns L.R., Vinton G., Carpenter J.E., Redpath G.T., RA Sando J.J., VandenBerg S.R.; RT "Phorbol 12-myristate 13-acetate induces protein kinase ceta-specific RT proliferative response in astrocytic tumor cells."; RL J. Biol. Chem. 275:22348-22354(2000). RN [10] RP FUNCTION. RX PubMed=11772428; DOI=10.1093/neuonc/4.1.9; RA Hussaini I.M., Carpenter J.E., Redpath G.T., Sando J.J., Shaffrey M.E., RA Vandenberg S.R.; RT "Protein kinase C-eta regulates resistance to UV- and gamma-irradiation- RT induced apoptosis in glioblastoma cells by preventing caspase-9 RT activation."; RL Neuro-oncol. 4:9-21(2002). RN [11] RP FUNCTION IN CELL PROLIFERATION. RX PubMed=15489897; DOI=10.1038/sj.onc.1208093; RA Aeder S.E., Martin P.M., Soh J.W., Hussaini I.M.; RT "PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR RT signaling pathways."; RL Oncogene 23:9062-9069(2004). RN [12] RP INTERACTION WITH DGKQ. RX PubMed=15632189; DOI=10.1074/jbc.m409301200; RA van Baal J., de Widt J., Divecha N., van Blitterswijk W.J.; RT "Translocation of diacylglycerol kinase theta from cytosol to plasma RT membrane in response to activation of G protein-coupled receptors and RT protein kinase C."; RL J. Biol. Chem. 280:9870-9878(2005). RN [13] RP FUNCTION. RX PubMed=17146445; DOI=10.1038/sj.onc.1210090; RA Uht R.M., Amos S., Martin P.M., Riggan A.E., Hussaini I.M.; RT "The protein kinase C-eta isoform induces proliferation in glioblastoma RT cell lines through an ERK/Elk-1 pathway."; RL Oncogene 26:2885-2893(2007). RN [14] RP FUNCTION IN B-CELL SIGNALING. RX PubMed=18780722; DOI=10.1093/intimm/dxn101; RA Oda A., Ono T., Yamamoto M., Goitsuka R., Kitamura D.; RT "PKC eta directs induction of IRF-4 expression and Ig kappa gene RT rearrangement in pre-BCR signaling pathway."; RL Int. Immunol. 20:1417-1426(2008). RN [15] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [16] RP INDUCTION. RX PubMed=19797084; DOI=10.1128/mcb.01044-09; RA Raveh-Amit H., Maissel A., Poller J., Marom L., Elroy-Stein O., Shapira M., RA Livneh E.; RT "Translational control of protein kinase Ceta by two upstream open reading RT frames."; RL Mol. Cell. Biol. 29:6140-6148(2009). RN [17] RP FUNCTION IN PHOSPHORYLATION OF OCLN. RX PubMed=19114660; DOI=10.1073/pnas.0802741106; RA Suzuki T., Elias B.C., Seth A., Shen L., Turner J.R., Giorgianni F., RA Desiderio D., Guntaka R., Rao R.; RT "PKC eta regulates occludin phosphorylation and epithelial tight junction RT integrity."; RL Proc. Natl. Acad. Sci. U.S.A. 106:61-66(2009). RN [18] RP FUNCTION. RX PubMed=20558593; DOI=10.1124/mol.110.064394; RA Lee H.K., Yeo S., Kim J.S., Lee J.G., Bae Y.S., Lee C., Baek S.H.; RT "Protein kinase C-eta and phospholipase D2 pathway regulates foam cell RT formation via regulator of G protein signaling 2."; RL Mol. Pharmacol. 78:478-485(2010). RN [19] RP FUNCTION. RX PubMed=21820409; DOI=10.1016/j.bbrc.2011.07.090; RA Raveh-Amit H., Hai N., Rotem-Dai N., Shahaf G., Gopas J., Livneh E.; RT "Protein kinase C? activates NF-?B in response to camptothecin-induced DNA RT damage."; RL Biochem. Biophys. Res. Commun. 412:313-317(2011). RN [20] RP REVIEW. RX PubMed=12473186; DOI=10.1093/oxfordjournals.jbchem.a003297; RA Kashiwagi M., Ohba M., Chida K., Kuroki T.; RT "Protein kinase C eta (PKC eta): its involvement in keratinocyte RT differentiation."; RL J. Biochem. 132:853-857(2002). RN [21] RP FUNCTION. RX PubMed=22304920; DOI=10.1016/j.cell.2012.01.016; RA Lau E., Kluger H., Varsano T., Lee K., Scheffler I., Rimm D.L., Ideker T., RA Ronai Z.A.; RT "PKCepsilon promotes oncogenic functions of ATF2 in the nucleus while RT blocking its apoptotic function at mitochondria."; RL Cell 148:543-555(2012). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-28, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-656, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [24] RP CATALYTIC ACTIVITY, ACTIVITY REGULATION, INTERACTION WITH PRKCH UPSTREAM RP OPEN READING FRAME 2, AND PHOSPHORYLATION AT THR-656 AND SER-675. RX PubMed=34593629; DOI=10.1073/pnas.2018899118; RA Jayaram D.R., Frost S., Argov C., Liju V.B., Anto N.P., Muraleedharan A., RA Ben-Ari A., Sinay R., Smoly I., Novoplansky O., Isakov N., Toiber D., RA Keasar C., Elkabets M., Yeger-Lotem E., Livneh E.; RT "Unraveling the hidden role of a uORF-encoded peptide as a kinase inhibitor RT of PKCs."; RL Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021). RN [25] RP X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 1-138, PHOSPHORYLATION AT SER-28 RP AND SER-32, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=16973127; DOI=10.1016/j.bbrc.2006.08.160; RA Littler D.R., Walker J.R., She Y.-M., Finerty P.J. Jr., Newman E.M., RA Dhe-Paganon S.; RT "Structure of human protein kinase C eta (PKCeta) C2 domain and RT identification of phosphorylation sites."; RL Biochem. Biophys. Res. Commun. 349:1182-1189(2006). RN [26] RP ASSOCIATION OF VARIANT ILE-374 WITH ISCHSTR, AND CHARACTERIZATION OF RP VARIANT ILE-374. RX PubMed=17206144; DOI=10.1038/ng1945; RA Kubo M., Hata J., Ninomiya T., Matsuda K., Yonemoto K., Nakano T., RA Matsushita T., Yamazaki K., Ohnishi Y., Saito S., Kitazono T., Ibayashi S., RA Sueishi K., Iida M., Nakamura Y., Kiyohara Y.; RT "A nonsynonymous SNP in PRKCH (protein kinase C eta) increases the risk of RT cerebral infarction."; RL Nat. Genet. 39:212-217(2007). RN [27] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-19; ARG-65; GLN-149; GLN-359; ILE-374; RP ALA-575; ILE-594 AND SER-612. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Calcium-independent, phospholipid- and diacylglycerol (DAG)- CC dependent serine/threonine-protein kinase that is involved in the CC regulation of cell differentiation in keratinocytes and pre-B cell CC receptor, mediates regulation of epithelial tight junction integrity CC and foam cell formation, and is required for glioblastoma proliferation CC and apoptosis prevention in MCF-7 cells. In keratinocytes, binds and CC activates the tyrosine kinase FYN, which in turn blocks epidermal CC growth factor receptor (EGFR) signaling and leads to keratinocyte CC growth arrest and differentiation. Associates with the cyclin CCNE1- CC CDK2-CDKN1B complex and inhibits CDK2 kinase activity, leading to RB1 CC dephosphorylation and thereby G1 arrest in keratinocytes. In CC association with RALA activates actin depolymerization, which is CC necessary for keratinocyte differentiation. In the pre-B cell receptor CC signaling, functions downstream of BLNK by up-regulating IRF4, which in CC turn activates L chain gene rearrangement. Regulates epithelial tight CC junctions (TJs) by phosphorylating occludin (OCLN) on threonine CC residues, which is necessary for the assembly and maintenance of TJs. CC In association with PLD2 and via TLR4 signaling, is involved in CC lipopolysaccharide (LPS)-induced RGS2 down-regulation and foam cell CC formation. Upon PMA stimulation, mediates glioblastoma cell CC proliferation by activating the mTOR pathway, the PI3K/AKT pathway and CC the ERK1-dependent phosphorylation of ELK1. Involved in the protection CC of glioblastoma cells from irradiation-induced apoptosis by preventing CC caspase-9 activation. In camptothecin-treated MCF-7 cells, regulates CC NF-kappa-B upstream signaling by activating IKBKB, and confers CC protection against DNA damage-induced apoptosis. Promotes oncogenic CC functions of ATF2 in the nucleus while blocking its apoptotic function CC at mitochondria. Phosphorylates ATF2 which promotes its nuclear CC retention and transcriptional activity and negatively regulates its CC mitochondrial localization. {ECO:0000269|PubMed:10806212, CC ECO:0000269|PubMed:11112424, ECO:0000269|PubMed:11772428, CC ECO:0000269|PubMed:15489897, ECO:0000269|PubMed:17146445, CC ECO:0000269|PubMed:18780722, ECO:0000269|PubMed:19114660, CC ECO:0000269|PubMed:20558593, ECO:0000269|PubMed:21820409, CC ECO:0000269|PubMed:22304920}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:34593629}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:34593629}; CC -!- ACTIVITY REGULATION: Novel PKCs (PRKCD, PRKCE, PRKCH and PRKCQ) are CC calcium-insensitive, but activated by diacylglycerol (DAG) and CC phosphatidylserine. Three specific sites; Thr-513 (activation loop of CC the kinase domain), Thr-656 (turn motif) and Ser-675 (hydrophobic CC region), need to be phosphorylated for its full activation. Inhibited CC by PRKCH upstream open reading frame 2 (PubMed:34593629). CC {ECO:0000269|PubMed:34593629}. CC -!- SUBUNIT: Interacts with FYN (By similarity). Interacts with RALA (By CC similarity). Interacts with DGKQ (PubMed:15632189). Interacts with CC PRKCH upstream open reading frame 2; the interaction leads to CC inhibition of kinase activity (PubMed:34593629). CC {ECO:0000250|UniProtKB:P23298, ECO:0000269|PubMed:15632189, CC ECO:0000269|PubMed:34593629}. CC -!- INTERACTION: CC P24723; Q16625-1: OCLN; NbExp=2; IntAct=EBI-2865850, EBI-16115673; CC P24723; Q28269: OCLN; Xeno; NbExp=2; IntAct=EBI-2865850, EBI-16222162; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P24723-1; Sequence=Displayed; CC Name=2; CC IsoId=P24723-2; Sequence=VSP_056572; CC -!- TISSUE SPECIFICITY: Most abundant in lung, less in heart and skin. CC {ECO:0000269|PubMed:1986216}. CC -!- INDUCTION: By stress conditions caused by amino acid starvation (at CC protein level). {ECO:0000269|PubMed:19797084}. CC -!- DOMAIN: The C1 domain, containing the phorbol ester/DAG-type region 1 CC (C1A) and 2 (C1B), is the diacylglycerol sensor and the C2 domain is a CC non-calcium binding domain. CC -!- DISEASE: Ischemic stroke (ISCHSTR) [MIM:601367]: A stroke is an acute CC neurologic event leading to death of neural tissue of the brain and CC resulting in loss of motor, sensory and/or cognitive function. Ischemic CC strokes, resulting from vascular occlusion, is considered to be a CC highly complex disease consisting of a group of heterogeneous disorders CC with multiple genetic and environmental risk factors. CC {ECO:0000269|PubMed:17206144}. Note=Disease susceptibility is CC associated with variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. PKC subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M55284; AAA60100.1; -; mRNA. DR EMBL; AK290183; BAF82872.1; -; mRNA. DR EMBL; AK296158; BAG58897.1; -; mRNA. DR EMBL; AL138996; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL355916; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL359220; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471061; EAW80800.1; -; Genomic_DNA. DR EMBL; CH471061; EAW80801.1; -; Genomic_DNA. DR EMBL; BC037268; AAH37268.1; -; mRNA. DR EMBL; S74620; AAB32724.1; -; mRNA. DR CCDS; CCDS9752.1; -. [P24723-1] DR PIR; A39666; A39666. DR RefSeq; NP_006246.2; NM_006255.4. [P24723-1] DR RefSeq; XP_024305429.1; XM_024449661.2. [P24723-2] DR RefSeq; XP_024305430.1; XM_024449662.2. [P24723-2] DR RefSeq; XP_054232364.1; XM_054376389.1. [P24723-2] DR RefSeq; XP_054232365.1; XM_054376390.1. [P24723-2] DR PDB; 2FK9; X-ray; 1.75 A; A=1-138. DR PDB; 3TXO; X-ray; 2.05 A; A=333-683. DR PDB; 8FP1; X-ray; 1.85 A; A=333-683. DR PDB; 8FP3; X-ray; 2.30 A; A=333-683. DR PDBsum; 2FK9; -. DR PDBsum; 3TXO; -. DR PDBsum; 8FP1; -. DR PDBsum; 8FP3; -. DR AlphaFoldDB; P24723; -. DR SMR; P24723; -. DR BioGRID; 111569; 31. DR DIP; DIP-44588N; -. DR FunCoup; P24723; 864. DR IntAct; P24723; 14. DR MINT; P24723; -. DR STRING; 9606.ENSP00000329127; -. DR BindingDB; P24723; -. DR ChEMBL; CHEMBL3616; -. DR DrugCentral; P24723; -. DR GuidetoPHARMACOLOGY; 1487; -. DR GlyGen; P24723; 3 sites, 3 N-linked glycans (2 sites), 1 O-linked glycan (1 site). DR iPTMnet; P24723; -. DR PhosphoSitePlus; P24723; -. DR BioMuta; PRKCH; -. DR DMDM; 281185512; -. DR CPTAC; CPTAC-3187; -. DR CPTAC; CPTAC-3188; -. DR jPOST; P24723; -. DR MassIVE; P24723; -. DR PaxDb; 9606-ENSP00000329127; -. DR PeptideAtlas; P24723; -. DR ProteomicsDB; 4395; -. DR ProteomicsDB; 54223; -. [P24723-1] DR Pumba; P24723; -. DR Antibodypedia; 24422; 309 antibodies from 34 providers. DR DNASU; 5583; -. DR Ensembl; ENST00000332981.11; ENSP00000329127.5; ENSG00000027075.18. [P24723-1] DR Ensembl; ENST00000555082.6; ENSP00000450981.1; ENSG00000027075.18. [P24723-2] DR GeneID; 5583; -. DR KEGG; hsa:5583; -. DR MANE-Select; ENST00000332981.11; ENSP00000329127.5; NM_006255.5; NP_006246.2. DR UCSC; uc001xfn.4; human. [P24723-1] DR AGR; HGNC:9403; -. DR ClinPGx; PA33767; -. DR CTD; 5583; -. DR DisGeNET; 5583; -. DR GeneCards; PRKCH; -. DR HGNC; HGNC:9403; PRKCH. DR HPA; ENSG00000027075; Low tissue specificity. DR MalaCards; PRKCH; -. DR MIM; 601367; phenotype. DR MIM; 605437; gene. DR OpenTargets; ENSG00000027075; -. DR VEuPathDB; HostDB:ENSG00000027075; -. DR eggNOG; KOG0694; Eukaryota. DR GeneTree; ENSGT00940000158220; -. DR HOGENOM; CLU_000288_54_4_1; -. DR InParanoid; P24723; -. DR OMA; MTKNPNM; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; P24723; 3 GO annotations based on evolutionary models. DR PhylomeDB; P24723; -. DR BRENDA; 2.7.11.13; 2681. DR PathwayCommons; P24723; -. DR Reactome; R-HSA-114508; Effects of PIP2 hydrolysis. DR Reactome; R-HSA-418597; G alpha (z) signalling events. DR SABIO-RK; P24723; -. DR SignaLink; P24723; -. DR SIGNOR; P24723; -. DR Agora; ENSG00000027075; -. DR BioGRID-ORCS; 5583; 14 hits in 1196 CRISPR screens. DR ChiTaRS; PRKCH; human. DR EvolutionaryTrace; P24723; -. DR GeneWiki; PRKCH; -. DR GenomeRNAi; 5583; -. DR Pharos; P24723; Tchem. DR PRO; PR:P24723; -. DR Proteomes; UP000005640; Chromosome 14. DR RNAct; P24723; protein. DR Bgee; ENSG00000027075; Expressed in parotid gland and 189 other cell types or tissues. DR ExpressionAtlas; P24723; baseline and differential. DR GO; GO:0005911; C:cell-cell junction; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; ISS:UniProtKB. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; TAS:ProtInc. DR GO; GO:0004699; F:diacylglycerol-dependent, calcium-independent serine/threonine kinase activity; IEA:Ensembl. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0031267; F:small GTPase binding; IEA:Ensembl. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0034351; P:negative regulation of glial cell apoptotic process; IMP:UniProtKB. DR GO; GO:0141212; P:phospholipase C/protein kinase C signal transduction; IEA:Ensembl. DR GO; GO:0050861; P:positive regulation of B cell receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0060252; P:positive regulation of glial cell proliferation; IMP:UniProtKB. DR GO; GO:0045618; P:positive regulation of keratinocyte differentiation; ISS:UniProtKB. DR GO; GO:0010744; P:positive regulation of macrophage derived foam cell differentiation; ISS:UniProtKB. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB. DR GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; TAS:ParkinsonsUK-UCL. DR GO; GO:0006468; P:protein phosphorylation; IMP:UniProtKB. DR GO; GO:2000810; P:regulation of bicellular tight junction assembly; IMP:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR CDD; cd20835; C1_nPKC_epsilon-like_rpt1; 1. DR CDD; cd20838; C1_nPKC_epsilon-like_rpt2; 1. DR CDD; cd04014; C2_PKC_epsilon; 1. DR CDD; cd05590; STKc_nPKC_eta; 1. DR FunFam; 3.30.200.20:FF:000080; Protein kinase C; 1. DR FunFam; 3.30.60.20:FF:000003; Protein kinase C delta; 1. DR FunFam; 1.10.510.10:FF:000126; Protein kinase C epsilon; 1. DR FunFam; 2.60.40.150:FF:000056; Protein kinase C epsilon; 1. DR FunFam; 3.30.60.20:FF:000024; Protein kinase C epsilon; 1. DR Gene3D; 3.30.60.20; -; 2. DR Gene3D; 2.60.40.150; C2 domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR000008; C2_dom. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR034665; nPKC_eta. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR027431; PKC_eta. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR014376; Prot_kin_PKC_delta. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00130; C1_1; 2. DR Pfam; PF00168; C2; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR PIRSF; PIRSF000551; PKC_delta; 1. DR PIRSF; PIRSF501107; Protein_kin_C_eta; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 2. DR SMART; SM00239; C2; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50004; C2; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 2. DR PROSITE; PS50081; ZF_DAG_PE_2; 2. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cytoplasm; KW Differentiation; Kinase; Metal-binding; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger. FT CHAIN 1..683 FT /note="Protein kinase C eta type" FT /id="PRO_0000055705" FT DOMAIN 1..118 FT /note="C2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT DOMAIN 355..614 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 615..683 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT ZN_FING 171..222 FT /note="Phorbol-ester/DAG-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT ZN_FING 245..295 FT /note="Phorbol-ester/DAG-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 320..342 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 479 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 361..369 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 384 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 28 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:16973127, FT ECO:0007744|PubMed:23186163" FT MOD_RES 32 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:16973127" FT MOD_RES 317 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P23298" FT MOD_RES 513 FT /note="Phosphothreonine; by PDPK1" FT /evidence="ECO:0000305" FT MOD_RES 656 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:34593629, FT ECO:0007744|PubMed:24275569" FT MOD_RES 675 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:34593629" FT VAR_SEQ 1..161 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_056572" FT VARIANT 19 FT /note="A -> V (in dbSNP:rs55645551)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042312" FT VARIANT 65 FT /note="K -> R (in dbSNP:rs55737090)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042313" FT VARIANT 149 FT /note="R -> Q (in dbSNP:rs55848048)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042314" FT VARIANT 359 FT /note="R -> Q (in dbSNP:rs55818778)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042315" FT VARIANT 374 FT /note="V -> I (risk factor for ischemic stroke; increases FT autophosphorylation and kinase activity; dbSNP:rs2230500)" FT /evidence="ECO:0000269|PubMed:17206144, FT ECO:0000269|PubMed:17344846" FT /id="VAR_034604" FT VARIANT 497 FT /note="D -> Y (in dbSNP:rs11846991)" FT /id="VAR_060736" FT VARIANT 575 FT /note="T -> A (in a aLL TEL/AML1+ sample; somatic mutation; FT dbSNP:rs1378993559)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042316" FT VARIANT 594 FT /note="T -> I (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042317" FT VARIANT 612 FT /note="P -> S (in dbSNP:rs34159231)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042318" FT VARIANT 645 FT /note="D -> V (in dbSNP:rs35561533)" FT /id="VAR_042438" FT CONFLICT 96 FT /note="Missing (in Ref. 1; AAA60100)" FT /evidence="ECO:0000305" FT CONFLICT 109 FT /note="L -> R (in Ref. 1; AAA60100)" FT /evidence="ECO:0000305" FT CONFLICT 110 FT /note="R -> G (in Ref. 1; AAA60100)" FT /evidence="ECO:0000305" FT CONFLICT 393 FT /note="Q -> L (in Ref. 1; AAA60100)" FT /evidence="ECO:0000305" FT CONFLICT 472 FT /note="D -> E (in Ref. 7; AAB32724)" FT /evidence="ECO:0000305" FT STRAND 8..20 FT /evidence="ECO:0007829|PDB:2FK9" FT HELIX 26..30 FT /evidence="ECO:0007829|PDB:2FK9" FT TURN 31..33 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 34..37 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 43..49 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 52..56 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 67..79 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 81..88 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 91..94 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 96..104 FT /evidence="ECO:0007829|PDB:2FK9" FT HELIX 105..112 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 116..123 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 125..127 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 129..137 FT /evidence="ECO:0007829|PDB:2FK9" FT HELIX 352..354 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 355..364 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 367..374 FT /evidence="ECO:0007829|PDB:8FP1" FT TURN 375..377 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 380..387 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 388..393 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 397..409 FT /evidence="ECO:0007829|PDB:8FP1" FT TURN 410..412 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 419..424 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 426..434 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 438..440 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 441..448 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 453..472 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 482..484 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 485..487 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 493..495 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 518..520 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 523..526 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 534..549 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 559..568 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 579..588 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 593..595 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 600..602 FT /evidence="ECO:0007829|PDB:8FP1" FT TURN 603..605 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 606..609 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 612..614 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 619..623 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 646..648 FT /evidence="ECO:0007829|PDB:8FP1" FT TURN 660..662 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 663..665 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 668..671 FT /evidence="ECO:0007829|PDB:8FP1" SQ SEQUENCE 683 AA; 77828 MW; 0A29806CE31912F2 CRC64; MSSGTMKFNG YLRVRIGEAV GLQPTRWSLR HSLFKKGHQL LDPYLTVSVD QVRVGQTSTK QKTNKPTYNE EFCANVTDGG HLELAVFHET PLGYDHFVAN CTLQFQELLR TTGASDTFEG WVDLEPEGKV FVVITLTGSF TEATLQRDRI FKHFTRKRQR AMRRRVHQIN GHKFMATYLR QPTYCSHCRE FIWGVFGKQG YQCQVCTCVV HKRCHHLIVT ACTCQNNINK VDSKIAEQRF GINIPHKFSI HNYKVPTFCD HCGSLLWGIM RQGLQCKICK MNVHIRCQAN VAPNCGVNAV ELAKTLAGMG LQPGNISPTS KLVSRSTLRR QGKESSKEGN GIGVNSSNRL GIDNFEFIRV LGKGSFGKVM LARVKETGDL YAVKVLKKDV ILQDDDVECT MTEKRILSLA RNHPFLTQLF CCFQTPDRLF FVMEFVNGGD LMFHIQKSRR FDEARARFYA AEIISALMFL HDKGIIYRDL KLDNVLLDHE GHCKLADFGM CKEGICNGVT TATFCGTPDY IAPEILQEML YGPAVDWWAM GVLLYEMLCG HAPFEAENED DLFEAILNDE VVYPTWLHED ATGILKSFMT KNPTMRLGSL TQGGEHAILR HPFFKEIDWA QLNHRQIEPP FRPRIKSRED VSNFDPDFIK EEPVLTPIDE GHLPMINQDE FRNFSYVSPE LQP // ID KPCZ_HUMAN Reviewed; 592 AA. AC Q05513; A8K4N0; A8MU64; B7Z2J7; E9PCW2; Q15207; Q5SYT5; Q969S4; DT 01-FEB-1994, integrated into UniProtKB/Swiss-Prot. DT 21-JUN-2005, sequence version 4. DT 28-JAN-2026, entry version 253. DE RecName: Full=Protein kinase C zeta type; DE EC=2.7.11.13 {ECO:0000269|PubMed:15084291, ECO:0000269|PubMed:15324659, ECO:0000269|PubMed:36040231}; DE AltName: Full=nPKC-zeta; GN Name=PRKCZ; Synonyms=PKC2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Frontal cortex; RX PubMed=8224878; DOI=10.1016/0378-1119(93)90213-m; RA Barbee J.L., Loomis C.R., Deutscher S.L., Burns D.J.; RT "The cDNA sequence encoding human protein kinase C-zeta."; RL Gene 132:305-306(1993). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3). RC TISSUE=Brain, and Teratocarcinoma; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Colon, and Ovary; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 7-592. RC TISSUE=Hippocampus; RX PubMed=8375396; DOI=10.1111/j.1432-1033.1993.tb18179.x; RA Kochs G., Hummel R., Meyer D., Hug H., Marme D., Sarre T.F.; RT "Activation and substrate specificity of the human protein kinase C alpha RT and zeta isoenzymes."; RL Eur. J. Biochem. 216:597-606(1993). RN [7] RP SUBCELLULAR LOCATION. RX PubMed=7597083; DOI=10.1073/pnas.92.13.6072; RA Stuart R.O., Nigam S.K.; RT "Regulated assembly of tight junctions by protein kinase C."; RL Proc. Natl. Acad. Sci. U.S.A. 92:6072-6076(1995). RN [8] RP FUNCTION IN ACTIVATION OF MAP2K1/MEK1 AND MAPK1/ERK2. RX PubMed=9447975; DOI=10.1128/mcb.18.2.790; RA Schoenwasser D.C., Marais R.M., Marshall C.J., Parker P.J.; RT "Activation of the mitogen-activated protein kinase/extracellular signal- RT regulated kinase pathway by conventional, novel, and atypical protein RT kinase C isotypes."; RL Mol. Cell. Biol. 18:790-798(1998). RN [9] RP INTERACTION WITH SQSTM1, AND SUBCELLULAR LOCATION. RX PubMed=9566925; DOI=10.1128/mcb.18.5.3069; RA Sanchez P., De Carcer G., Sandoval I.V., Moscat J., Diaz-Meco M.T.; RT "Localization of atypical protein kinase C isoforms into lysosome-targeted RT endosomes through interaction with p62."; RL Mol. Cell. Biol. 18:3069-3080(1998). RN [10] RP PHOSPHORYLATION AT THR-410 BY PDPK1. RX PubMed=9768361; DOI=10.1016/s0960-9822(98)70444-0; RA Chou M.M., Hou W., Johnson J., Graham L.K., Lee M.H., Chen C.S., RA Newton A.C., Schaffhausen B.S., Toker A.; RT "Regulation of protein kinase C zeta by PI 3-kinase and PDK-1."; RL Curr. Biol. 8:1069-1077(1998). RN [11] RP INTERACTION WITH SQSTM1 AND IKBKB. RX PubMed=10356400; DOI=10.1093/emboj/18.11.3044; RA Sanz L., Sanchez P., Lallena M.-J., Diaz-Meco M.T., Moscat J.; RT "The interaction of p62 with RIP links the atypical PKCs to NF-kappaB RT activation."; RL EMBO J. 18:3044-3053(1999). RN [12] RP FUNCTION IN ACTIVATION OF MAPK1/ERK2. RX PubMed=11035106; DOI=10.4049/jimmunol.165.8.4632; RA Monick M.M., Carter A.B., Flaherty D.M., Peterson M.W., Hunninghake G.W.; RT "Protein kinase C zeta plays a central role in activation of the p42/44 RT mitogen-activated protein kinase by endotoxin in alveolar macrophages."; RL J. Immunol. 165:4632-4639(2000). RN [13] RP INTERACTION WITH PARD6A; PARD6B AND PARD6G. RC TISSUE=Neuroblastoma; RX PubMed=11260256; DOI=10.1046/j.1365-2443.2001.00404.x; RA Noda Y., Takeya R., Ohno S., Naito S., Ito T., Sumimoto H.; RT "Human homologues of the Caenorhabditis elegans cell polarity protein PAR6 RT as an adaptor that links the small GTPases Rac and Cdc42 to atypical RT protein kinase C."; RL Genes Cells 6:107-119(2001). RN [14] RP INTERACTION WITH PDPK1, AND PHOSPHORYLATION. RX PubMed=11781095; DOI=10.1021/bi010719z; RA Hodgkinson C.P., Sale G.J.; RT "Regulation of both PDK1 and the phosphorylation of PKC-zeta and -delta by RT a C-terminal PRK2 fragment."; RL Biochemistry 41:561-569(2002). RN [15] RP FUNCTION IN ACTIVATION OF AKT3. RX PubMed=12162751; DOI=10.1021/bi026065r; RA Hodgkinson C.P., Sale E.M., Sale G.J.; RT "Characterization of PDK2 activity against protein kinase B gamma."; RL Biochemistry 41:10351-10359(2002). RN [16] RP INTERACTION WITH SQSTM1 AND PAWR. RX PubMed=11755531; DOI=10.1016/s0014-5793(01)03224-0; RA Chang S., Kim J.H., Shin J.; RT "p62 forms a ternary complex with PKCzeta and PAR-4 and antagonizes PAR-4- RT induced PKCzeta inhibition."; RL FEBS Lett. 510:57-61(2002). RN [17] RP INTERACTION WITH PARD3. RX PubMed=12234671; DOI=10.1016/s0378-1119(02)00681-9; RA Gao L., Macara I.G., Joberty G.; RT "Multiple splice variants of Par3 and of a novel related gene, Par3L, RT produce proteins with different binding properties."; RL Gene 294:99-107(2002). RN [18] RP INTERACTION WITH ADAP1. RX PubMed=12893243; DOI=10.1016/s0006-291x(03)01187-2; RA Zemlickova E., Dubois T., Kerai P., Clokie S., Cronshaw A.D., RA Wakefield R.I.D., Johannes F.-J., Aitken A.; RT "Centaurin-alpha(1) associates with and is phosphorylated by isoforms of RT protein kinase C."; RL Biochem. Biophys. Res. Commun. 307:459-465(2003). RN [19] RP INTERACTION WITH SQSTM1 AND PARD6B, DOMAIN, AND MUTAGENESIS OF LYS-19; RP ASP-62 AND ASP-66. RX PubMed=12887891; DOI=10.1016/s1097-2765(03)00246-6; RA Wilson M.I., Gill D.J., Perisic O., Quinn M.T., Williams R.L.; RT "PB1 domain-mediated heterodimerization in NADPH oxidase and signaling RT complexes of atypical protein kinase C with Par6 and p62."; RL Mol. Cell 12:39-50(2003). RN [20] RP FUNCTION IN PHOSPHORYLATION OF MARK2 AND MARK3, AND CATALYTIC ACTIVITY. RX PubMed=15084291; DOI=10.1016/j.cub.2004.04.007; RA Hurov J.B., Watkins J.L., Piwnica-Worms H.; RT "Atypical PKC phosphorylates PAR-1 kinases to regulate localization and RT activity."; RL Curr. Biol. 14:736-741(2004). RN [21] RP FUNCTION IN PHOSPHORYLATION OF MARK2, AND CATALYTIC ACTIVITY. RX PubMed=15324659; DOI=10.1016/j.cub.2004.08.021; RA Suzuki A., Hirata M., Kamimura K., Maniwa R., Yamanaka T., Mizuno K., RA Kishikawa M., Hirose H., Amano Y., Izumi N., Miwa Y., Ohno S.; RT "aPKC acts upstream of PAR-1b in both the establishment and maintenance of RT mammalian epithelial polarity."; RL Curr. Biol. 14:1425-1435(2004). RN [22] RP PHOSPHORYLATION AT THR-410 BY PI3K. RX PubMed=15314172; DOI=10.1128/mcb.24.17.7643-7653.2004; RA Castoria G., Migliaccio A., Di Domenico M., Lombardi M., de Falco A., RA Varricchio L., Bilancio A., Barone M.V., Auricchio F.; RT "Role of atypical protein kinase C in estradiol-triggered G1/S progression RT of MCF-7 cells."; RL Mol. Cell. Biol. 24:7643-7653(2004). RN [23] RP INTERACTION WITH WDFY2. RX PubMed=16792529; DOI=10.1042/bj20060511; RA Fritzius T., Burkard G., Haas E., Heinrich J., Schweneker M., Bosse M., RA Zimmermann S., Frey A.D., Caelers A., Bachmann A.S., Moelling K.; RT "A WD-FYVE protein binds to the kinases Akt and PKCzeta/lambda."; RL Biochem. J. 399:9-20(2006). RN [24] RP FUNCTION, INTERACTION WITH VAMP2, COMPLEX FORMATION WITH VAMP2 AND WDFY2, RP AND SUBCELLULAR LOCATION. RX PubMed=17313651; DOI=10.1111/j.1742-4658.2007.05702.x; RA Fritzius T., Frey A.D., Schweneker M., Mayer D., Moelling K.; RT "WD-repeat-propeller-FYVE protein, ProF, binds VAMP2 and protein kinase RT Czeta."; RL FEBS J. 274:1552-1566(2007). RN [25] RP INTERACTION WITH WWC1 AND DDR1. RX PubMed=18190796; DOI=10.1016/j.bbamcr.2007.12.007; RA Hilton H.N., Stanford P.M., Harris J., Oakes S.R., Kaplan W., Daly R.J., RA Ormandy C.J.; RT "KIBRA interacts with discoidin domain receptor 1 to modulate collagen- RT induced signalling."; RL Biochim. Biophys. Acta 1783:383-393(2008). RN [26] RP RETRACTED PAPER. RX PubMed=18321849; DOI=10.1074/jbc.m708208200; RA Song P., Xie Z., Wu Y., Xu J., Dong Y., Zou M.H.; RT "Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation increases RT LKB1 nucleus export and apoptosis in endothelial cells."; RL J. Biol. Chem. 283:12446-12455(2008). RN [27] RP RETRACTION NOTICE OF PUBMED:18321849. RX PubMed=31519760; DOI=10.1074/jbc.w119.010661; RA Song P., Xie Z., Wu Y., Dong Y., Zou M.H.; RT "Withdrawal: Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation RT increases LKB1 nucleus export and apoptosis in endothelial cells."; RL J. Biol. Chem. 294:13831-13831(2019). RN [28] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-560, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [30] RP SUBCELLULAR LOCATION, SUBUNIT, AND PHOSPHORYLATION AT THR-410. RX PubMed=20332120; DOI=10.1242/jcs.059329; RA Lampugnani M.G., Orsenigo F., Rudini N., Maddaluno L., Boulday G., RA Chapon F., Dejana E.; RT "CCM1 regulates vascular-lumen organization by inducing endothelial RT polarity."; RL J. Cell Sci. 123:1073-1080(2010). RN [31] RP REVIEW ON FUNCTION. RX PubMed=12761192; DOI=10.1093/jb/mvg017; RA Hirai T., Chida K.; RT "Protein kinase Czeta (PKCzeta): activation mechanisms and cellular RT functions."; RL J. Biochem. 133:1-7(2003). RN [32] RP REVIEW ON FUNCTION. RX PubMed=16903823; DOI=10.1134/s0006297906070017; RA Liu L.Z., He A.B., Liu X.J., Li Y., Chang Y.S., Fang F.D.; RT "Protein kinase Czeta and glucose uptake."; RL Biochemistry (Mosc.) 71:701-706(2006). RN [33] RP REVIEW ON FUNCTION. RX PubMed=16322752; DOI=10.1038/sj.cdd.4401823; RA Moscat J., Rennert P., Diaz-Meco M.T.; RT "PKCzeta at the crossroad of NF-kappaB and Jak1/Stat6 signaling pathways."; RL Cell Death Differ. 13:702-711(2006). RN [34] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-560, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [36] RP INTERACTION WITH WWC1; WWC2 AND WWC3. RX PubMed=24682284; DOI=10.1093/molbev/msu115; RA Wennmann D.O., Schmitz J., Wehr M.C., Krahn M.P., Koschmal N., RA Gromnitza S., Schulze U., Weide T., Chekuri A., Skryabin B.V., Gerke V., RA Pavenstadt H., Duning K., Kremerskothen J.; RT "Evolutionary and Molecular Facts Link the WWC Protein Family to Hippo RT Signaling."; RL Mol. Biol. Evol. 31:1710-1723(2014). RN [37] RP INTERACTION WITH APPL1. RX PubMed=26583432; DOI=10.18632/oncotarget.6346; RA Song J., Mu Y., Li C., Bergh A., Miaczynska M., Heldin C.H., Landstroem M.; RT "APPL proteins promote TGFbeta-induced nuclear transport of the TGFbeta RT type I receptor intracellular domain."; RL Oncotarget 7:279-292(2016). RN [38] RP FUNCTION IN PHOSPHORYLATION OF LRRK1, AND CATALYTIC ACTIVITY. RX PubMed=36040231; DOI=10.1042/bcj20220308; RA Malik A.U., Karapetsas A., Nirujogi R.S., Chatterjee D., Phung T.K., RA Wightman M., Gourlay R., Morrice N., Mathea S., Knapp S., Alessi D.R.; RT "PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues RT (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain."; RL Biochem. J. 479:1941-1965(2022). RN [39] RP VARIANT [LARGE SCALE ANALYSIS] PHE-514. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [40] RP VARIANTS [LARGE SCALE ANALYSIS] HIS-84 AND CYS-519. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Calcium- and diacylglycerol-independent serine/threonine- CC protein kinase that functions in phosphatidylinositol 3-kinase (PI3K) CC pathway and mitogen-activated protein (MAP) kinase cascade, and is CC involved in NF-kappa-B activation, mitogenic signaling, cell CC proliferation, cell polarity, inflammatory response and maintenance of CC long-term potentiation (LTP). Upon lipopolysaccharide (LPS) treatment CC in macrophages, or following mitogenic stimuli, functions downstream of CC PI3K to activate MAP2K1/MEK1-MAPK1/ERK2 signaling cascade independently CC of RAF1 activation. Required for insulin-dependent activation of AKT3, CC but may function as an adapter rather than a direct activator. Upon CC insulin treatment may act as a downstream effector of PI3K and CC contribute to the activation of translocation of the glucose CC transporter SLC2A4/GLUT4 and subsequent glucose transport in CC adipocytes. In EGF-induced cells, binds and activates MAP2K5/MEK5- CC MAPK7/ERK5 independently of its kinase activity and can activate JUN CC promoter through MEF2C. Through binding with SQSTM1/p62, functions in CC interleukin-1 signaling and activation of NF-kappa-B with the specific CC adapters RIPK1 and TRAF6. Participates in TNF-dependent transactivation CC of NF-kappa-B by phosphorylating and activating IKBKB kinase, which in CC turn leads to the degradation of NF-kappa-B inhibitors. In migrating CC astrocytes, forms a cytoplasmic complex with PARD6A and is recruited by CC CDC42 to function in the establishment of cell polarity along with the CC microtubule motor and dynein. In association with FEZ1, stimulates CC neuronal differentiation in PC12 cells. In the inflammatory response, CC is required for the T-helper 2 (Th2) differentiation process, including CC interleukin production, efficient activation of JAK1 and the subsequent CC phosphorylation and nuclear translocation of STAT6. May be involved in CC development of allergic airway inflammation (asthma), a process CC dependent on Th2 immune response. In the NF-kappa-B-mediated CC inflammatory response, can relieve SETD6-dependent repression of NF- CC kappa-B target genes by phosphorylating the RELA subunit at 'Ser-311'. CC Phosphorylates VAMP2 in vitro (PubMed:17313651). Phosphorylates and CC activates LRRK1, which phosphorylates RAB proteins involved in CC intracellular trafficking (PubMed:36040231). CC {ECO:0000269|PubMed:11035106, ECO:0000269|PubMed:12162751, CC ECO:0000269|PubMed:15084291, ECO:0000269|PubMed:15324659, CC ECO:0000269|PubMed:17313651, ECO:0000269|PubMed:36040231, CC ECO:0000269|PubMed:9447975}. CC -!- FUNCTION: [Isoform 2]: Involved in late synaptic long term potention CC phase in CA1 hippocampal cells and long term memory maintenance. CC {ECO:0000250|UniProtKB:Q02956}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:15084291, ECO:0000269|PubMed:15324659, CC ECO:0000269|PubMed:36040231}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:15084291, ECO:0000269|PubMed:15324659, CC ECO:0000269|PubMed:36040231}; CC -!- ACTIVITY REGULATION: Atypical PKCs (PRKCI and PRKCZ) exhibit an CC elevated basal enzymatic activity (that may be due to the interaction CC with SMG1 or SQSTM1) and are not regulated by diacylglycerol, CC phosphatidylserine, phorbol esters or calcium ions. Two specific sites, CC Thr-410 (activation loop of the kinase domain) and Thr-560 (turn CC motif), need to be phosphorylated for its full activation. CC Phosphatidylinositol 3,4,5-trisphosphate might be a physiological CC activator (By similarity). Isoform 2: Constitutively active (By CC similarity). {ECO:0000250|UniProtKB:Q02956}. CC -!- SUBUNIT: Forms a ternary complex with SQSTM1 and KCNAB2. Forms another CC ternary complex with SQSTM1 and GABRR3. Forms a complex with SQSTM1 and CC MAP2K5 (By similarity). Interacts with PARD6A, PARD6B, PARD6G and CC SQSTM1. Part of a complex with PARD3, PARD6A or PARD6B or PARD6G and CC CDC42 or RAC1. Interacts with ADAP1/CENTA1. Forms a ternary complex CC composed of SQSTM1 and PAWR. Interacts directly with SQSTM1 (Probable). CC Interacts with IKBKB. Interacts (via the protein kinase domain) with CC WWC1. Forms a tripartite complex with WWC1 and DDR1, but predominantly CC in the absence of collagen. Component of the Par polarity complex, CC composed of at least phosphorylated PRKCZ, PARD3 and TIAM1. Interacts CC with PDPK1 (via N-terminal region). Interacts with WDFY2 (via WD CC repeats 1-3) (PubMed:16792529). Interacts with VAMP2 (PubMed:17313651). CC Forms a complex with WDFY2 and VAMP2 (PubMed:17313651). Interacts with CC APPL1 (PubMed:26583432). Interacts with WWC1, WWC2 and WWC3 CC (PubMed:24682284). {ECO:0000250|UniProtKB:P09217, CC ECO:0000269|PubMed:10356400, ECO:0000269|PubMed:11260256, CC ECO:0000269|PubMed:11755531, ECO:0000269|PubMed:11781095, CC ECO:0000269|PubMed:12234671, ECO:0000269|PubMed:12887891, CC ECO:0000269|PubMed:12893243, ECO:0000269|PubMed:16792529, CC ECO:0000269|PubMed:17313651, ECO:0000269|PubMed:18190796, CC ECO:0000269|PubMed:20332120, ECO:0000269|PubMed:24682284, CC ECO:0000269|PubMed:26583432, ECO:0000269|PubMed:9566925, ECO:0000305}. CC -!- INTERACTION: CC Q05513; Q15109: AGER; NbExp=6; IntAct=EBI-295351, EBI-1646426; CC Q05513; P31749: AKT1; NbExp=2; IntAct=EBI-295351, EBI-296087; CC Q05513; O95999: BCL10; NbExp=3; IntAct=EBI-295351, EBI-958922; CC Q05513; Q07021: C1QBP; NbExp=4; IntAct=EBI-295351, EBI-347528; CC Q05513; P08238: HSP90AB1; NbExp=2; IntAct=EBI-295351, EBI-352572; CC Q05513; P14598: NCF1; NbExp=3; IntAct=EBI-295351, EBI-395044; CC Q05513; P49757-1: NUMB; NbExp=4; IntAct=EBI-295351, EBI-7199607; CC Q05513; Q9NPB6: PARD6A; NbExp=10; IntAct=EBI-295351, EBI-81876; CC Q05513; Q9BYG5: PARD6B; NbExp=18; IntAct=EBI-295351, EBI-295391; CC Q05513; Q9BYG4: PARD6G; NbExp=9; IntAct=EBI-295351, EBI-295417; CC Q05513; P41743: PRKCI; NbExp=10; IntAct=EBI-295351, EBI-286199; CC Q05513; Q04759: PRKCQ; NbExp=3; IntAct=EBI-295351, EBI-374762; CC Q05513; P40337: VHL; NbExp=3; IntAct=EBI-295351, EBI-301246; CC Q05513; P16554: numb; Xeno; NbExp=2; IntAct=EBI-295351, EBI-429581; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17313651, CC ECO:0000269|PubMed:9566925}. Endosome {ECO:0000269|PubMed:9566925}. CC Cell junction {ECO:0000269|PubMed:7597083}. Membrane CC {ECO:0000250|UniProtKB:P09217}; Peripheral membrane protein CC {ECO:0000305}. Note=In the retina, localizes in the terminals of the CC rod bipolar cells (By similarity). Associates with endosomes CC (PubMed:9566925). Presence of KRIT1, CDH5 and RAP1B is required for its CC localization to the cell junction (PubMed:7597083). Colocalizes with CC VAMP2 and WDFY2 in intracellular vesicles (PubMed:17313651). CC Transiently translocates to the membrane of CA1 hippocampal cells in CC response to the induction of long term potentiation (By similarity). CC {ECO:0000250|UniProtKB:P09217, ECO:0000269|PubMed:17313651, CC ECO:0000269|PubMed:7597083, ECO:0000269|PubMed:9566925}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm CC {ECO:0000250|UniProtKB:P09217}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage, Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q05513-1; Sequence=Displayed; CC Name=2; Synonyms=PKMzeta {ECO:0000250|UniProtKB:P09217}; CC IsoId=Q05513-2; Sequence=VSP_041904; CC Name=3; CC IsoId=Q05513-3; Sequence=VSP_046347; CC -!- TISSUE SPECIFICITY: Expressed in brain, and to a lesser extent in lung, CC kidney and testis. CC -!- DOMAIN: The PB1 domain mediate mutually exclusive interactions with CC SQSTM1 and PARD6B. {ECO:0000269|PubMed:12887891}. CC -!- DOMAIN: The C1 domain does not bind the diacylglycerol (DAG). CC {ECO:0000269|PubMed:12887891}. CC -!- PTM: CDH5 is required for its phosphorylation at Thr-410. CC Phosphorylated by protein kinase PDPK1; phosphorylation is inhibited by CC the apoptotic C-terminal cleavage product of PKN2. Phosphorylation at CC Thr-410 by PI3K activates the kinase. {ECO:0000269|PubMed:11781095, CC ECO:0000269|PubMed:15314172, ECO:0000269|PubMed:20332120, CC ECO:0000269|PubMed:9768361}. CC -!- MISCELLANEOUS: [Isoform 2]: Produced by alternative promoter usage. CC {ECO:0000250|UniProtKB:P09217}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. PKC subfamily. {ECO:0000305}. CC -!- CAUTION: Reported to phosphorylate STK11 leading to nuclear export of CC STK11, subsequent inhibition of PI3K/Akt signaling, and increased CC apoptosis in vein endothelial cells treated with the oxidant CC peroxynitrite (PubMed:18321849). However this paper was withdrawn by CC the authors due to concerns of image duplication in the figures. Its CC role in protein phosphorylation has been confirmed in other studies CC (PubMed:15084291, PubMed:15324659). {ECO:0000269|PubMed:15084291, CC ECO:0000269|PubMed:15324659, ECO:0000269|PubMed:18321849, CC ECO:0000305|PubMed:31519760}. CC -!- SEQUENCE CAUTION: CC Sequence=CAA78813.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L14283; AAA36488.1; -; mRNA. DR EMBL; BT007082; AAP35745.1; -; mRNA. DR EMBL; AK290995; BAF83684.1; -; mRNA. DR EMBL; AK294649; BAH11833.1; -; mRNA. DR EMBL; AK294782; BAH11883.1; -; mRNA. DR EMBL; AL162271; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL391845; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL590822; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL645703; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC008058; AAH08058.1; -; mRNA. DR EMBL; BC014270; AAH14270.1; -; mRNA. DR EMBL; Z15108; CAA78813.1; ALT_INIT; mRNA. DR CCDS; CCDS37.1; -. [Q05513-1] DR CCDS; CCDS41229.1; -. [Q05513-2] DR CCDS; CCDS55563.1; -. [Q05513-3] DR PIR; JN0877; JN0877. DR RefSeq; NP_001028753.1; NM_001033581.3. [Q05513-2] DR RefSeq; NP_001028754.1; NM_001033582.3. [Q05513-2] DR RefSeq; NP_001229803.1; NM_001242874.3. [Q05513-3] DR RefSeq; NP_002735.3; NM_002744.4. [Q05513-1] DR RefSeq; XP_047281304.1; XM_047425348.1. [Q05513-2] DR RefSeq; XP_054193674.1; XM_054337699.1. [Q05513-2] DR AlphaFoldDB; Q05513; -. DR SMR; Q05513; -. DR BioGRID; 111576; 381. DR ComplexPortal; CPX-6195; PAR cell polarity complex, PARD6G-PRKCZ variant. DR ComplexPortal; CPX-6196; PAR cell polarity complex, PARD6B-PRKCZ variant. DR ComplexPortal; CPX-6197; PAR cell polarity complex, PARD6A-PRKCZ variant. DR CORUM; Q05513; -. DR ELM; Q05513; -. DR FunCoup; Q05513; 1725. DR IntAct; Q05513; 231. DR MINT; Q05513; -. DR STRING; 9606.ENSP00000367830; -. DR BindingDB; Q05513; -. DR ChEMBL; CHEMBL3438; -. DR DrugBank; DB09096; Benzoyl peroxide. DR DrugBank; DB03777; Bisindolylmaleimide I. DR DrugBank; DB04209; Dequalinium. DR DrugBank; DB17029; Go-6976. DR DrugBank; DB02010; Staurosporine. DR DrugBank; DB00675; Tamoxifen. DR DrugCentral; Q05513; -. DR GuidetoPHARMACOLOGY; 1491; -. DR MoonDB; Q05513; Predicted. DR GlyGen; Q05513; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q05513; -. DR PhosphoSitePlus; Q05513; -. DR BioMuta; PRKCZ; -. DR DMDM; 68067736; -. DR jPOST; Q05513; -. DR MassIVE; Q05513; -. DR PaxDb; 9606-ENSP00000367830; -. DR PeptideAtlas; Q05513; -. DR ProteomicsDB; 19529; -. DR ProteomicsDB; 58330; -. [Q05513-1] DR ProteomicsDB; 58331; -. [Q05513-2] DR Pumba; Q05513; -. DR Antibodypedia; 3869; 858 antibodies from 46 providers. DR DNASU; 5590; -. DR Ensembl; ENST00000378567.8; ENSP00000367830.3; ENSG00000067606.18. [Q05513-1] DR Ensembl; ENST00000400921.6; ENSP00000383712.2; ENSG00000067606.18. [Q05513-2] DR Ensembl; ENST00000461106.6; ENSP00000426412.1; ENSG00000067606.18. [Q05513-3] DR GeneID; 5590; -. DR KEGG; hsa:5590; -. DR MANE-Select; ENST00000378567.8; ENSP00000367830.3; NM_002744.6; NP_002735.3. DR UCSC; uc001aiq.3; human. [Q05513-1] DR AGR; HGNC:9412; -. DR ClinPGx; PA33775; -. DR CTD; 5590; -. DR DisGeNET; 5590; -. DR GeneCards; PRKCZ; -. DR HGNC; HGNC:9412; PRKCZ. DR HPA; ENSG00000067606; Tissue enhanced (brain). DR MalaCards; PRKCZ; -. DR MIM; 176982; gene. DR OpenTargets; ENSG00000067606; -. DR Orphanet; 1606; 1p36 deletion syndrome. DR VEuPathDB; HostDB:ENSG00000067606; -. DR eggNOG; KOG0695; Eukaryota. DR GeneTree; ENSGT00940000153497; -. DR HOGENOM; CLU_000288_63_5_1; -. DR InParanoid; Q05513; -. DR OMA; DKMAGLC; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; Q05513; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q05513; -. DR BRENDA; 2.7.11.13; 2681. DR PathwayCommons; Q05513; -. DR Reactome; R-HSA-114604; GPVI-mediated activation cascade. DR Reactome; R-HSA-2173791; TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition). DR Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation. DR Reactome; R-HSA-5668599; RHO GTPases Activate NADPH Oxidases. DR Reactome; R-HSA-9634635; Estrogen-stimulated signaling through PRKCZ. DR SignaLink; Q05513; -. DR SIGNOR; Q05513; -. DR Agora; ENSG00000067606; -. DR BioGRID-ORCS; 5590; 23 hits in 1195 CRISPR screens. DR ChiTaRS; PRKCZ; human. DR GeneWiki; Protein_kinase_M_zeta/Protein_kinase_C_zeta; -. DR GenomeRNAi; 5590; -. DR Pharos; Q05513; Tchem. DR PRO; PR:Q05513; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q05513; protein. DR Bgee; ENSG00000067606; Expressed in right hemisphere of cerebellum and 168 other cell types or tissues. DR ExpressionAtlas; Q05513; baseline and differential. DR GO; GO:0045179; C:apical cortex; IEA:Ensembl. DR GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl. DR GO; GO:0043203; C:axon hillock; IEA:Ensembl. DR GO; GO:0005923; C:bicellular tight junction; IEA:Ensembl. DR GO; GO:0030054; C:cell junction; TAS:Reactome. DR GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB. DR GO; GO:0005814; C:centriole; IDA:HPA. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; TAS:ProtInc. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0016020; C:membrane; TAS:ProtInc. DR GO; GO:0035748; C:myelin sheath abaxonal region; IEA:Ensembl. DR GO; GO:0005635; C:nuclear envelope; IEA:Ensembl. DR GO; GO:0016363; C:nuclear matrix; IEA:Ensembl. DR GO; GO:0120157; C:PAR polarity complex; ISS:ComplexPortal. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0097229; C:sperm end piece; IDA:HPA. DR GO; GO:0097225; C:sperm midpiece; IDA:HPA. DR GO; GO:0070160; C:tight junction; NAS:ComplexPortal. DR GO; GO:0031982; C:vesicle; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; EXP:Reactome. DR GO; GO:0043560; F:insulin receptor substrate binding; IDA:BHF-UCL. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:BHF-UCL. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0032869; P:cellular response to insulin stimulus; IBA:GO_Central. DR GO; GO:0030010; P:establishment of cell polarity; ISS:UniProtKB. DR GO; GO:0045197; P:establishment or maintenance of epithelial cell apical/basal polarity; ISS:ComplexPortal. DR GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0060291; P:long-term synaptic potentiation; ISS:UniProtKB. DR GO; GO:0000226; P:microtubule cytoskeleton organization; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; TAS:ProtInc. DR GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; IMP:BHF-UCL. DR GO; GO:0031333; P:negative regulation of protein-containing complex assembly; IMP:BHF-UCL. DR GO; GO:1990138; P:neuron projection extension; IEA:Ensembl. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; ISS:UniProtKB. DR GO; GO:0046628; P:positive regulation of insulin receptor signaling pathway; ISS:UniProtKB. DR GO; GO:0032733; P:positive regulation of interleukin-10 production; ISS:UniProtKB. DR GO; GO:0032736; P:positive regulation of interleukin-13 production; ISS:UniProtKB. DR GO; GO:0032753; P:positive regulation of interleukin-4 production; ISS:UniProtKB. DR GO; GO:0032754; P:positive regulation of interleukin-5 production; ISS:UniProtKB. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; ISS:UniProtKB. DR GO; GO:2000553; P:positive regulation of T-helper 2 cell cytokine production; ISS:UniProtKB. DR GO; GO:0045630; P:positive regulation of T-helper 2 cell differentiation; ISS:UniProtKB. DR GO; GO:0072659; P:protein localization to plasma membrane; IBA:GO_Central. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR CDD; cd21095; C1_aPKC_zeta; 1. DR CDD; cd06404; PB1_aPKC; 1. DR CDD; cd05617; STKc_aPKC_zeta; 1. DR FunFam; 1.10.510.10:FF:000048; Protein kinase C; 1. DR FunFam; 3.10.20.90:FF:000071; Protein kinase C; 1. DR FunFam; 3.30.200.20:FF:000070; Protein kinase C; 1. DR FunFam; 3.30.60.20:FF:000012; Protein kinase C; 1. DR Gene3D; 3.30.60.20; -; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR034662; aPKC_zeta. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR047314; C1_aPKC_zeta. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR053793; PB1-like. DR InterPro; IPR034877; PB1_aPKC. DR InterPro; IPR000270; PB1_dom. DR InterPro; IPR012233; PKC. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00130; C1_1; 1. DR Pfam; PF00564; PB1; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR PIRSF; PIRSF000554; PKC_zeta; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 1. DR SMART; SM00666; PB1; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF54277; CAD & PB1 domains; 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS51745; PB1; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 1. DR PROSITE; PS50081; ZF_DAG_PE_2; 1. PE 1: Evidence at protein level; KW Alternative promoter usage; Alternative splicing; ATP-binding; KW Cell junction; Cytoplasm; Endosome; Inflammatory response; Kinase; KW Membrane; Metal-binding; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger. FT CHAIN 1..592 FT /note="Protein kinase C zeta type" FT /id="PRO_0000055701" FT DOMAIN 15..98 FT /note="PB1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01081" FT DOMAIN 252..518 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 519..590 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT ZN_FING 130..180 FT /note="Phorbol-ester/DAG-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 79..145 FT /note="Interaction with SQSTM1" FT /evidence="ECO:0000250" FT ACT_SITE 376 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 258..266 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 281 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 410 FT /note="Phosphothreonine; by PDPK1 and PI3K" FT /evidence="ECO:0000269|PubMed:15314172, FT ECO:0000269|PubMed:20332120, ECO:0000269|PubMed:9768361" FT MOD_RES 560 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:24275569" FT MOD_RES 591 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P09217" FT VAR_SEQ 1..183 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_041904" FT VAR_SEQ 1..112 FT /note="MPSRTGPKMEGSGGRVRLKAHYGGDIFITSVDAATTFEELCEEVRDMCRLHQ FT QHPLTLKWVDSEGDPCTVSSQMELEEAFRLARQCRDEGLIIHVFPSTPEQPGLPCPGED FT K -> MLTPRTDE (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_046347" FT VARIANT 49 FT /note="R -> H (in dbSNP:rs35271800)" FT /id="VAR_050560" FT VARIANT 84 FT /note="R -> H (in dbSNP:rs56017162)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042310" FT VARIANT 514 FT /note="S -> F (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035467" FT VARIANT 519 FT /note="R -> C (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs376894109)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042311" FT MUTAGEN 19 FT /note="K->A: No effect on interaction with SQSTM1 and FT PARD6B." FT /evidence="ECO:0000269|PubMed:12887891" FT MUTAGEN 62 FT /note="D->A: Loss of interaction with SQSTM1 and PARD6B." FT /evidence="ECO:0000269|PubMed:12887891" FT MUTAGEN 66 FT /note="D->A: Loss of interaction with SQSTM1 and PARD6B." FT /evidence="ECO:0000269|PubMed:12887891" FT CONFLICT 6 FT /note="G -> D (in Ref. 1; AAA36488)" FT /evidence="ECO:0000305" FT CONFLICT 198 FT /note="K -> R (in Ref. 3; BAF83684)" FT /evidence="ECO:0000305" FT CONFLICT 262 FT /note="S -> T (in Ref. 1; AAA36488)" FT /evidence="ECO:0000305" FT CONFLICT 281 FT /note="K -> R (in Ref. 3; BAH11883)" FT /evidence="ECO:0000305" FT CONFLICT 366 FT /note="F -> L (in Ref. 3; BAF83684)" FT /evidence="ECO:0000305" FT CONFLICT 500 FT /note="R -> G (in Ref. 3; BAF83684)" FT /evidence="ECO:0000305" FT CONFLICT 522 FT /note="D -> G (in Ref. 3; BAF83684)" FT /evidence="ECO:0000305" SQ SEQUENCE 592 AA; 67660 MW; 88CCD0577E6A596C CRC64; MPSRTGPKME GSGGRVRLKA HYGGDIFITS VDAATTFEEL CEEVRDMCRL HQQHPLTLKW VDSEGDPCTV SSQMELEEAF RLARQCRDEG LIIHVFPSTP EQPGLPCPGE DKSIYRRGAR RWRKLYRANG HLFQAKRFNR RAYCGQCSER IWGLARQGYR CINCKLLVHK RCHGLVPLTC RKHMDSVMPS QEPPVDDKNE DADLPSEETD GIAYISSSRK HDSIKDDSED LKPVIDGMDG IKISQGLGLQ DFDLIRVIGR GSYAKVLLVR LKKNDQIYAM KVVKKELVHD DEDIDWVQTE KHVFEQASSN PFLVGLHSCF QTTSRLFLVI EYVNGGDLMF HMQRQRKLPE EHARFYAAEI CIALNFLHER GIIYRDLKLD NVLLDADGHI KLTDYGMCKE GLGPGDTTST FCGTPNYIAP EILRGEEYGF SVDWWALGVL MFEMMAGRSP FDIITDNPDM NTEDYLFQVI LEKPIRIPRF LSVKASHVLK GFLNKDPKER LGCRPQTGFS DIKSHAFFRS IDWDLLEKKQ ALPPFQPQIT DDYGLDNFDT QFTSEPVQLT PDDEDAIKRI DQSEFEGFEY INPLLLSTEE SV // ID KS6A2_HUMAN Reviewed; 733 AA. AC Q15349; B3KTK9; Q15419; Q59GJ3; Q5TI68; Q96J38; Q9UJN5; DT 15-DEC-1998, integrated into UniProtKB/Swiss-Prot. DT 21-MAR-2006, sequence version 2. DT 28-JAN-2026, entry version 230. DE RecName: Full=Ribosomal protein S6 kinase alpha-2; DE Short=S6K-alpha-2; DE EC=2.7.11.1; DE AltName: Full=90 kDa ribosomal protein S6 kinase 2; DE Short=p90-RSK 2; DE Short=p90RSK2; DE AltName: Full=MAP kinase-activated protein kinase 1c; DE Short=MAPK-activated protein kinase 1c; DE Short=MAPKAP kinase 1c; DE Short=MAPKAPK-1c; DE AltName: Full=Ribosomal S6 kinase 3; DE Short=RSK-3; DE AltName: Full=pp90RSK3; GN Name=RPS6KA2; Synonyms=MAPKAPK1C, RSK3; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY, AND RP SUBCELLULAR LOCATION. RX PubMed=7623830; DOI=10.1128/mcb.15.8.4353; RA Zhao Y., Bjoerbaek C., Weremowicz S., Morton C.C., Moller D.E.; RT "RSK3 encodes a novel pp90rsk isoform with a unique N-terminal sequence: RT growth factor-stimulated kinase function and nuclear translocation."; RL Mol. Cell. Biol. 15:4353-4363(1995). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-540 (ISOFORM 1). RX PubMed=8141249; DOI=10.1152/ajpcell.1994.266.2.c351; RA Moller D.E., Xia C.-H., Tang W., Zhu A.X., Jakubowski M.; RT "Human rsk isoforms: cloning and characterization of tissue-specific RT expression."; RL Am. J. Physiol. 266:C351-C359(1994). RN [7] RP ACTIVITY REGULATION, AND PHOSPHORYLATION AT SER-218. RX PubMed=10480933; DOI=10.1074/jbc.274.38.27168; RA Jensen C.J., Buch M.-B., Krag T.O., Hemmings B.A., Gammeltoft S., RA Froedin M.; RT "90-kDa ribosomal S6 kinase is phosphorylated and activated by 3- RT phosphoinositide-dependent protein kinase-1."; RL J. Biol. Chem. 274:27168-27176(1999). RN [8] RP FUNCTION IN TUMORIGENESIS, AND TISSUE SPECIFICITY. RX PubMed=16878154; DOI=10.1038/sj.onc.1209827; RA Bignone P.A., Lee K.Y., Liu Y., Emilion G., Finch J., Soosay A.E., RA Charnock F.M., Beck S., Dunham I., Mungall A.J., Ganesan T.S.; RT "RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial RT ovarian cancer."; RL Oncogene 26:683-700(2007). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [10] RP REVIEW ON FUNCTION. RX PubMed=18813292; DOI=10.1038/nrm2509; RA Anjum R., Blenis J.; RT "The RSK family of kinases: emerging roles in cellular signalling."; RL Nat. Rev. Mol. Cell Biol. 9:747-758(2008). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [12] RP VARIANTS [LARGE SCALE ANALYSIS] LYS-311 AND GLN-732. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase that acts downstream of ERK CC (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and CC stress-induced activation of transcription factors, regulates CC translation, and mediates cellular proliferation, survival, and CC differentiation. May function as tumor suppressor in epithelial ovarian CC cancer cells. {ECO:0000269|PubMed:16878154, CC ECO:0000269|PubMed:7623830}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Upon extracellular signal or mitogen stimulation, CC phosphorylated at Thr-570 in the C-terminal kinase domain (CTKD) by CC MAPK1/ERK2 and MAPK3/ERK1. The activated CTKD then autophosphorylates CC Ser-377, allowing binding of PDPK1, which in turn phosphorylates Ser- CC 218 in the N-terminal kinase domain (NTDK) leading to the full CC activation of the protein and subsequent phosphorylation of the CC substrates by the NTKD. {ECO:0000269|PubMed:10480933}. CC -!- SUBUNIT: Forms a complex with either MAPK1/ERK2 or MAPK3/ERK1 in CC quiescent cells. Transiently dissociates following mitogenic CC stimulation (By similarity). Interacts with FBXO5; cooperate to induce CC the metaphase arrest of early blastomeres; increases and stabilizes CC interaction of FBXO5 with CDC20 (By similarity). {ECO:0000250, CC ECO:0000250|UniProtKB:Q9WUT3}. CC -!- INTERACTION: CC Q15349; P05067: APP; NbExp=3; IntAct=EBI-1384149, EBI-77613; CC Q15349; P15056: BRAF; NbExp=2; IntAct=EBI-1384149, EBI-365980; CC Q15349; P67870: CSNK2B; NbExp=4; IntAct=EBI-1384149, EBI-348169; CC Q15349; O14901: KLF11; NbExp=3; IntAct=EBI-1384149, EBI-948266; CC Q15349; P28482: MAPK1; NbExp=12; IntAct=EBI-1384149, EBI-959949; CC Q15349; Q02156: PRKCE; NbExp=2; IntAct=EBI-1384149, EBI-706254; CC Q15349; Q14160: SCRIB; NbExp=9; IntAct=EBI-1384149, EBI-357345; CC Q15349; Q9Y566: SHANK1; NbExp=2; IntAct=EBI-1384149, EBI-3442234; CC Q15349; P62258: YWHAE; NbExp=2; IntAct=EBI-1384149, EBI-356498; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:7623830}. Cytoplasm CC {ECO:0000269|PubMed:7623830}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q15349-1; Sequence=Displayed; CC Name=2; CC IsoId=Q15349-2; Sequence=VSP_017732; CC Name=3; CC IsoId=Q15349-3; Sequence=VSP_041836; CC -!- TISSUE SPECIFICITY: Widely expressed with higher expression in lung, CC skeletal muscle, brain, uterus, ovary, thyroid and prostate. CC {ECO:0000269|PubMed:16878154, ECO:0000269|PubMed:7623830}. CC -!- PTM: Activated by phosphorylation at Ser-218 by PDPK1. CC Autophosphorylated on Ser-377, as part of the activation process. May CC be phosphorylated at Thr-356 and Ser-360 by MAPK1/ERK2 and MAPK3/ERK1 CC (By similarity). {ECO:0000250}. CC -!- PTM: N-terminal myristoylation results in an activated kinase in the CC absence of added growth factors. {ECO:0000250}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. S6 kinase subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC82496.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAD92353.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAG53121.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X85106; CAA59427.1; -; mRNA. DR EMBL; AB209116; BAD92353.1; ALT_INIT; mRNA. DR EMBL; AK095751; BAG53121.1; ALT_FRAME; mRNA. DR EMBL; AL022069; CAI19651.1; -; Genomic_DNA. DR EMBL; Z98049; CAI19651.1; JOINED; Genomic_DNA. DR EMBL; AL023775; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL159163; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; Z98049; CAI20579.1; -; Genomic_DNA. DR EMBL; AL022069; CAI20579.1; JOINED; Genomic_DNA. DR EMBL; BC002363; AAH02363.1; -; mRNA. DR EMBL; L07598; AAC82496.1; ALT_INIT; mRNA. DR CCDS; CCDS34570.1; -. [Q15349-3] DR CCDS; CCDS5294.1; -. [Q15349-1] DR CCDS; CCDS83148.1; -. [Q15349-2] DR PIR; A57459; A57459. DR RefSeq; NP_001006933.3; NM_001006932.3. [Q15349-3] DR RefSeq; NP_001305865.2; NM_001318936.2. DR RefSeq; NP_001305866.1; NM_001318937.1. DR RefSeq; NP_001305867.1; NM_001318938.1. DR RefSeq; NP_066958.2; NM_021135.5. [Q15349-1] DR AlphaFoldDB; Q15349; -. DR SMR; Q15349; -. DR BioGRID; 112110; 201. DR DIP; DIP-295N; -. DR FunCoup; Q15349; 3133. DR IntAct; Q15349; 62. DR MINT; Q15349; -. DR STRING; 9606.ENSP00000422435; -. DR BindingDB; Q15349; -. DR ChEMBL; CHEMBL3906; -. DR DrugCentral; Q15349; -. DR GuidetoPHARMACOLOGY; 1529; -. DR iPTMnet; Q15349; -. DR PhosphoSitePlus; Q15349; -. DR BioMuta; RPS6KA2; -. DR DMDM; 90110031; -. DR REPRODUCTION-2DPAGE; Q15349; -. DR CPTAC; CPTAC-2945; -. DR jPOST; Q15349; -. DR MassIVE; Q15349; -. DR PaxDb; 9606-ENSP00000427015; -. DR PeptideAtlas; Q15349; -. DR ProteomicsDB; 60536; -. [Q15349-1] DR ProteomicsDB; 60537; -. [Q15349-2] DR ProteomicsDB; 60538; -. [Q15349-3] DR Antibodypedia; 33522; 564 antibodies from 43 providers. DR DNASU; 6196; -. DR Ensembl; ENST00000265678.9; ENSP00000265678.4; ENSG00000071242.14. [Q15349-1] DR Ensembl; ENST00000503859.5; ENSP00000427015.1; ENSG00000071242.14. [Q15349-3] DR GeneID; 6196; -. DR KEGG; hsa:6196; -. DR MANE-Select; ENST00000265678.9; ENSP00000265678.4; NM_021135.6; NP_066958.2. DR UCSC; uc003qvb.2; human. [Q15349-1] DR AGR; HGNC:10431; -. DR ClinPGx; PA34846; -. DR CTD; 6196; -. DR DisGeNET; 6196; -. DR GeneCards; RPS6KA2; -. DR HGNC; HGNC:10431; RPS6KA2. DR HPA; ENSG00000071242; Low tissue specificity. DR MIM; 601685; gene. DR OpenTargets; ENSG00000071242; -. DR VEuPathDB; HostDB:ENSG00000071242; -. DR eggNOG; KOG0603; Eukaryota. DR GeneTree; ENSGT00940000159956; -. DR InParanoid; Q15349; -. DR OMA; GAMKATY; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; Q15349; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q15349; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q15349; -. DR Reactome; R-HSA-198753; ERK/MAPK targets. DR Reactome; R-HSA-199920; CREB phosphorylation. DR Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP). DR Reactome; R-HSA-437239; Recycling pathway of L1. DR Reactome; R-HSA-442742; CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling. DR Reactome; R-HSA-444257; RSK activation. DR Reactome; R-HSA-881907; Gastrin-CREB signalling pathway via PKC and MAPK. DR SignaLink; Q15349; -. DR SIGNOR; Q15349; -. DR Agora; ENSG00000071242; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 6196; 19 hits in 1179 CRISPR screens. DR ChiTaRS; RPS6KA2; human. DR GeneWiki; RPS6KA2; -. DR GenomeRNAi; 6196; -. DR Pharos; Q15349; Tchem. DR PRO; PR:Q15349; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q15349; protein. DR Bgee; ENSG00000071242; Expressed in inferior olivary complex and 215 other cell types or tissues. DR ExpressionAtlas; Q15349; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0072687; C:meiotic spindle; IEA:Ensembl. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0045202; C:synapse; IEA:GOC. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0000287; F:magnesium ion binding; IEA:InterPro. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:Reactome. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:MGI. DR GO; GO:0004711; F:ribosomal protein S6 kinase activity; IBA:GO_Central. DR GO; GO:0002035; P:brain renin-angiotensin system; IEA:Ensembl. DR GO; GO:0010659; P:cardiac muscle cell apoptotic process; IEA:Ensembl. DR GO; GO:0071322; P:cellular response to carbohydrate stimulus; IEA:Ensembl. DR GO; GO:0007268; P:chemical synaptic transmission; TAS:Reactome. DR GO; GO:0060047; P:heart contraction; IEA:Ensembl. DR GO; GO:0007507; P:heart development; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; TAS:ProtInc. DR GO; GO:0045786; P:negative regulation of cell cycle; IDA:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB. DR GO; GO:0045835; P:negative regulation of meiotic nuclear division; IEA:Ensembl. DR GO; GO:0001556; P:oocyte maturation; IEA:Ensembl. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl. DR GO; GO:0070613; P:regulation of protein processing; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; NAS:ProtInc. DR GO; GO:0038202; P:TORC1 signaling; IBA:GO_Central. DR CDD; cd14178; STKc_RSK3_C; 1. DR CDD; cd05582; STKc_RSK_N; 1. DR FunFam; 1.10.510.10:FF:000010; Ribosomal protein S6 kinase; 1. DR FunFam; 1.10.510.10:FF:000041; Ribosomal protein S6 kinase; 1. DR FunFam; 3.30.200.20:FF:000013; Ribosomal protein S6 kinase; 1. DR FunFam; 3.30.200.20:FF:000121; Ribosomal protein S6 kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 2. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR016239; Ribosomal_S6_kinase_II. DR InterPro; IPR042766; RSK3_STKc. DR InterPro; IPR041906; RSK_N. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00069; Pkinase; 2. DR Pfam; PF00433; Pkinase_C; 1. DR PIRSF; PIRSF000606; Ribsml_S6_kin_2; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 2. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 2. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 2. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 2. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cytoplasm; Kinase; Magnesium; KW Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase; Tumor suppressor. FT CHAIN 1..733 FT /note="Ribosomal protein S6 kinase alpha-2" FT /id="PRO_0000086201" FT DOMAIN 59..318 FT /note="Protein kinase 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 319..388 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT DOMAIN 415..672 FT /note="Protein kinase 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ACT_SITE 184 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT ACT_SITE 532 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT BINDING 65..73 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 91 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 421..429 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 444 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 218 FT /note="Phosphoserine; by PDPK1" FT /evidence="ECO:0000269|PubMed:10480933" FT MOD_RES 377 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT VAR_SEQ 1..32 FT /note="MDLSMKKFAVRRFFSVYLRRKSRSKSSSLSRL -> MPIAQLLELWKKIEVE FT PMEIETTEEDLNLDVGPATEDTAEEGKSDSAACKTKVAGSV (in isoform 2)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_017732" FT VAR_SEQ 1..32 FT /note="MDLSMKKFAVRRFFSVYLRRKSRSKSSSLSRL -> MPIAQLLELWKKIEVE FT PMEIETTEEDLNLDVEPTTEDTAE (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_041836" FT VARIANT 311 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs267600891)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040627" FT VARIANT 732 FT /note="R -> Q (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs376029388)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040628" FT CONFLICT 256 FT /note="S -> A (in Ref. 6; AAC82496)" FT /evidence="ECO:0000305" FT CONFLICT 269 FT /note="A -> S (in Ref. 6; AAC82496)" FT /evidence="ECO:0000305" FT CONFLICT 339 FT /note="V -> L (in Ref. 1; CAA59427 and 6; AAC82496)" FT /evidence="ECO:0000305" FT CONFLICT 447 FT /note="D -> G (in Ref. 6; AAC82496)" FT /evidence="ECO:0000305" FT CONFLICT Q15349-3:32 FT /note="E -> G (in Ref. 3; BAG53121)" FT /evidence="ECO:0000305" FT CONFLICT Q15349-3:34 FT /note="T -> A (in Ref. 3; BAG53121)" FT /evidence="ECO:0000305" SQ SEQUENCE 733 AA; 83239 MW; 087CFB819A313760 CRC64; MDLSMKKFAV RRFFSVYLRR KSRSKSSSLS RLEEEGVVKE IDISHHVKEG FEKADPSQFE LLKVLGQGSY GKVFLVRKVK GSDAGQLYAM KVLKKATLKV RDRVRSKMER DILAEVNHPF IVKLHYAFQT EGKLYLILDF LRGGDLFTRL SKEVMFTEED VKFYLAELAL ALDHLHSLGI IYRDLKPENI LLDEEGHIKI TDFGLSKEAI DHDKRAYSFC GTIEYMAPEV VNRRGHTQSA DWWSFGVLMF EMLTGSLPFQ GKDRKETMAL ILKAKLGMPQ FLSGEAQSLL RALFKRNPCN RLGAGIDGVE EIKRHPFFVT IDWNTLYRKE IKPPFKPAVG RPEDTFHFDP EFTARTPTDS PGVPPSANAH HLFRGFSFVA SSLIQEPSQQ DLHKVPVHPI VQQLHGNNIH FTDGYEIKED IGVGSYSVCK RCVHKATDTE YAVKIIDKSK RDPSEEIEIL LRYGQHPNII TLKDVYDDGK FVYLVMELMR GGELLDRILR QRYFSEREAS DVLCTITKTM DYLHSQGVVH RDLKPSNILY RDESGSPESI RVCDFGFAKQ LRAGNGLLMT PCYTANFVAP EVLKRQGYDA ACDIWSLGIL LYTMLAGFTP FANGPDDTPE EILARIGSGK YALSGGNWDS ISDAAKDVVS KMLHVDPHQR LTAMQVLKHP WVVNREYLSP NQLSRQDVHL VKGAMAATYF ALNRTPQAPR LEPVLSSNLA QRRGMKRLTS TRL // ID KS6A6_HUMAN Reviewed; 745 AA. AC Q9UK32; B2R854; B7ZL90; Q6FHX2; Q8WX28; Q9H4S6; DT 01-DEC-2000, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-2000, sequence version 1. DT 28-JAN-2026, entry version 207. DE RecName: Full=Ribosomal protein S6 kinase alpha-6; DE Short=S6K-alpha-6; DE EC=2.7.11.1; DE AltName: Full=90 kDa ribosomal protein S6 kinase 6; DE Short=p90-RSK 6; DE Short=p90RSK6; DE AltName: Full=Ribosomal S6 kinase 4; DE Short=RSK-4; DE AltName: Full=pp90RSK4; GN Name=RPS6KA6; Synonyms=RSK4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=10644430; DOI=10.1006/geno.1999.6004; RA Yntema H.G., van den Helm B., Kissing J., van Duijnhoven G., Poppelaars F., RA Chelly J., Moraine C., Fryns J.-P., Hamel B.C.J., Heilbronner H., RA Pander H.-J., Brunner H.G., Ropers H.-H., Cremers F.P.M., van Bokhoven H.; RT "A novel ribosomal S6-kinase (RSK4; RPS6KA6) is commonly deleted in RT patients with complex X-linked mental retardation."; RL Genomics 62:332-343(1999). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15772651; DOI=10.1038/nature03440; RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., RA Rogers J., Bentley D.R.; RT "The DNA sequence of the human X chromosome."; RL Nature 434:325-337(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Cerebellum; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP FUNCTION IN P53/TP53 SIGNALING. RX PubMed=15042092; DOI=10.1038/nature02371; RA Berns K., Hijmans E.M., Mullenders J., Brummelkamp T.R., Velds A., RA Heimerikx M., Kerkhoven R.M., Madiredjo M., Nijkamp W., Weigelt B., RA Agami R., Ge W., Cavet G., Linsley P.S., Beijersbergen R.L., Bernards R.; RT "A large-scale RNAi screen in human cells identifies new components of the RT p53 pathway."; RL Nature 428:431-437(2004). RN [8] RP FUNCTION, ACTIVITY REGULATION, INTERACTION WITH MAPK3, SUBCELLULAR RP LOCATION, PHOSPHORYLATION AT SER-232; SER-372; SER-389 AND THR-581, AND RP MUTAGENESIS OF SER-372; SER-389 AND THR-581. RX PubMed=15632195; DOI=10.1074/jbc.m408194200; RA Duemmler B.A., Hauge C., Silber J., Yntema H.G., Kruse L.S., Kofoed B., RA Hemmings B.A., Alessi D.R., Froedin M.; RT "Functional characterization of human RSK4, a new 90-kDa ribosomal S6 RT kinase, reveals constitutive activation in most cell types."; RL J. Biol. Chem. 280:13304-13314(2005). RN [9] RP REVIEW ON FUNCTION. RX PubMed=18813292; DOI=10.1038/nrm2509; RA Anjum R., Blenis J.; RT "The RSK family of kinases: emerging roles in cellular signalling."; RL Nat. Rev. Mol. Cell Biol. 9:747-758(2008). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-389, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [11] RP VARIANTS [LARGE SCALE ANALYSIS] CYS-140; THR-258 AND ASN-692. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Constitutively active serine/threonine-protein kinase that CC exhibits growth-factor-independent kinase activity and that may CC participate in p53/TP53-dependent cell growth arrest signaling and play CC an inhibitory role during embryogenesis. {ECO:0000269|PubMed:15042092, CC ECO:0000269|PubMed:15632195}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250}; CC -!- ACTIVITY REGULATION: Constitutively activated by phosphorylation at CC Ser-232, Ser-372, and Ser-389 in serum-starved cells. Does not require CC growth factor stimulation for significant kinase activity. CC {ECO:0000269|PubMed:15632195}. CC -!- SUBUNIT: Forms a complex with MAPK3/ERK1 but not with MAPK9 or MAPK14 CC in serum-starved cells. CC -!- INTERACTION: CC Q9UK32; Q7Z698: SPRED2; NbExp=3; IntAct=EBI-722467, EBI-7082156; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:15632195}. CC Nucleus {ECO:0000269|PubMed:15632195}. Note=Predominantly cytosolic. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q9UK32-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9UK32-2; Sequence=VSP_056181; CC -!- PTM: Phosphorylated at Ser-232, Ser-372, and Ser-389 in serum-starved CC cells. {ECO:0000269|PubMed:15632195}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. S6 kinase subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF184965; AAF13190.1; -; mRNA. DR EMBL; CR536566; CAG38803.1; -; mRNA. DR EMBL; AK313240; BAG36051.1; -; mRNA. DR EMBL; AL389887; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL354653; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471104; EAW98575.1; -; Genomic_DNA. DR EMBL; BC143648; AAI43649.1; -; mRNA. DR CCDS; CCDS14451.1; -. [Q9UK32-1] DR CCDS; CCDS83480.1; -. [Q9UK32-2] DR RefSeq; NP_001317441.1; NM_001330512.1. [Q9UK32-2] DR RefSeq; NP_055311.1; NM_014496.5. [Q9UK32-1] DR RefSeq; XP_011529219.1; XM_011530917.3. [Q9UK32-2] DR RefSeq; XP_054182824.1; XM_054326849.1. [Q9UK32-2] DR PDB; 6G76; X-ray; 3.00 A; A/B=48-349. DR PDB; 6G77; X-ray; 2.50 A; A/B=48-349. DR PDB; 6G78; X-ray; 2.50 A; A/B=48-349. DR PDBsum; 6G76; -. DR PDBsum; 6G77; -. DR PDBsum; 6G78; -. DR AlphaFoldDB; Q9UK32; -. DR SMR; Q9UK32; -. DR BioGRID; 118144; 74. DR FunCoup; Q9UK32; 1567. DR IntAct; Q9UK32; 47. DR MINT; Q9UK32; -. DR STRING; 9606.ENSP00000262752; -. DR BindingDB; Q9UK32; -. DR ChEMBL; CHEMBL4924; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q9UK32; -. DR GuidetoPHARMACOLOGY; 1530; -. DR GlyGen; Q9UK32; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q9UK32; -. DR PhosphoSitePlus; Q9UK32; -. DR BioMuta; RPS6KA6; -. DR DMDM; 11133131; -. DR CPTAC; CPTAC-2974; -. DR CPTAC; CPTAC-2975; -. DR jPOST; Q9UK32; -. DR MassIVE; Q9UK32; -. DR PaxDb; 9606-ENSP00000262752; -. DR PeptideAtlas; Q9UK32; -. DR ProteomicsDB; 7217; -. DR ProteomicsDB; 84712; -. [Q9UK32-1] DR Antibodypedia; 489; 251 antibodies from 32 providers. DR DNASU; 27330; -. DR Ensembl; ENST00000262752.5; ENSP00000262752.2; ENSG00000072133.13. [Q9UK32-1] DR Ensembl; ENST00000620340.4; ENSP00000483896.1; ENSG00000072133.13. [Q9UK32-2] DR GeneID; 27330; -. DR KEGG; hsa:27330; -. DR MANE-Select; ENST00000262752.5; ENSP00000262752.2; NM_014496.5; NP_055311.1. DR UCSC; uc004eej.3; human. [Q9UK32-1] DR AGR; HGNC:10435; -. DR ClinPGx; PA34850; -. DR CTD; 27330; -. DR DisGeNET; 27330; -. DR GeneCards; RPS6KA6; -. DR HGNC; HGNC:10435; RPS6KA6. DR HPA; ENSG00000072133; Low tissue specificity. DR MIM; 300303; gene. DR OpenTargets; ENSG00000072133; -. DR VEuPathDB; HostDB:ENSG00000072133; -. DR eggNOG; KOG0603; Eukaryota. DR GeneTree; ENSGT00940000159242; -. DR HOGENOM; CLU_000288_58_3_1; -. DR InParanoid; Q9UK32; -. DR OMA; HSWITCK; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; Q9UK32; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q9UK32; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q9UK32; -. DR Reactome; R-HSA-437239; Recycling pathway of L1. DR Reactome; R-HSA-442742; CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling. DR Reactome; R-HSA-444257; RSK activation. DR SignaLink; Q9UK32; -. DR SIGNOR; Q9UK32; -. DR Agora; ENSG00000072133; -. DR BioGRID-ORCS; 27330; 15 hits in 802 CRISPR screens. DR ChiTaRS; RPS6KA6; human. DR GenomeRNAi; 27330; -. DR Pharos; Q9UK32; Tchem. DR PRO; PR:Q9UK32; -. DR Proteomes; UP000005640; Chromosome X. DR RNAct; Q9UK32; protein. DR Bgee; ENSG00000072133; Expressed in buccal mucosa cell and 145 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IEA:UniProtKB-SubCell. DR GO; GO:0001650; C:fibrillar center; IDA:HPA. DR GO; GO:0005739; C:mitochondrion; IDA:HPA. DR GO; GO:0005730; C:nucleolus; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0000287; F:magnesium ion binding; IEA:InterPro. DR GO; GO:0004672; F:protein kinase activity; TAS:ProtInc. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004711; F:ribosomal protein S6 kinase activity; IBA:GO_Central. DR GO; GO:0007417; P:central nervous system development; TAS:ProtInc. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; IMP:UniProtKB. DR GO; GO:0045992; P:negative regulation of embryonic development; ISS:UniProtKB. DR GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; ISS:UniProtKB. DR GO; GO:2000381; P:negative regulation of mesoderm development; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0038202; P:TORC1 signaling; IBA:GO_Central. DR CDD; cd14177; STKc_RSK4_C; 1. DR CDD; cd05582; STKc_RSK_N; 1. DR FunFam; 1.10.510.10:FF:000010; Ribosomal protein S6 kinase; 1. DR FunFam; 1.10.510.10:FF:000041; Ribosomal protein S6 kinase; 1. DR FunFam; 3.30.200.20:FF:000013; Ribosomal protein S6 kinase; 1. DR FunFam; 3.30.200.20:FF:000121; Ribosomal protein S6 kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 2. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR016239; Ribosomal_S6_kinase_II. DR InterPro; IPR041906; RSK_N. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00069; Pkinase; 2. DR Pfam; PF00433; Pkinase_C; 1. DR PIRSF; PIRSF000606; Ribsml_S6_kin_2; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 2. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 2. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 2. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 2. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cytoplasm; Kinase; KW Magnesium; Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..745 FT /note="Ribosomal protein S6 kinase alpha-6" FT /id="PRO_0000086209" FT DOMAIN 73..330 FT /note="Protein kinase 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 331..400 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT DOMAIN 426..683 FT /note="Protein kinase 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..28 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 198 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT ACT_SITE 543 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT BINDING 79..87 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 105 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 432..440 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 455 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 232 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:15632195" FT MOD_RES 372 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:15632195" FT MOD_RES 389 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:15632195, FT ECO:0007744|PubMed:21406692" FT MOD_RES 581 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:15632195" FT VAR_SEQ 1..27 FT /note="MLPFAPQDEPWDREMEVFSGGGASSGE -> MGLSTSAIWKNTRVEIVNPYE FT VKRKVK (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_056181" FT VARIANT 140 FT /note="Y -> C (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040637" FT VARIANT 258 FT /note="S -> T (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040638" FT VARIANT 692 FT /note="D -> N (in dbSNP:rs6616890)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030670" FT MUTAGEN 372 FT /note="S->A: No effect on activity." FT /evidence="ECO:0000269|PubMed:15632195" FT MUTAGEN 389 FT /note="S->A: Strongly decreases activity." FT /evidence="ECO:0000269|PubMed:15632195" FT MUTAGEN 581 FT /note="T->A: No effect on activity." FT /evidence="ECO:0000269|PubMed:15632195" FT CONFLICT 116 FT /note="D -> G (in Ref. 2; CAG38803)" FT /evidence="ECO:0000305" FT CONFLICT 295 FT /note="F -> L (in Ref. 2; CAG38803)" FT /evidence="ECO:0000305" FT CONFLICT 341 FT /note="R -> G (in Ref. 2; CAG38803)" FT /evidence="ECO:0000305" FT STRAND 52..56 FT /evidence="ECO:0007829|PDB:6G77" FT HELIX 70..72 FT /evidence="ECO:0007829|PDB:6G77" FT STRAND 73..81 FT /evidence="ECO:0007829|PDB:6G77" FT STRAND 86..92 FT /evidence="ECO:0007829|PDB:6G77" FT TURN 96..99 FT /evidence="ECO:0007829|PDB:6G77" FT STRAND 101..115 FT /evidence="ECO:0007829|PDB:6G77" FT HELIX 126..129 FT /evidence="ECO:0007829|PDB:6G77" FT STRAND 138..144 FT /evidence="ECO:0007829|PDB:6G77" FT STRAND 147..152 FT /evidence="ECO:0007829|PDB:6G77" FT HELIX 160..165 FT /evidence="ECO:0007829|PDB:6G77" FT HELIX 172..191 FT /evidence="ECO:0007829|PDB:6G77" FT HELIX 201..203 FT /evidence="ECO:0007829|PDB:6G77" FT STRAND 204..206 FT /evidence="ECO:0007829|PDB:6G77" FT STRAND 208..210 FT /evidence="ECO:0007829|PDB:6G77" FT STRAND 212..215 FT /evidence="ECO:0007829|PDB:6G77" FT STRAND 220..222 FT /evidence="ECO:0007829|PDB:6G77" FT HELIX 226..230 FT /evidence="ECO:0007829|PDB:6G77" FT HELIX 237..239 FT /evidence="ECO:0007829|PDB:6G77" FT HELIX 242..245 FT /evidence="ECO:0007829|PDB:6G77" FT HELIX 252..268 FT /evidence="ECO:0007829|PDB:6G77" FT HELIX 278..287 FT /evidence="ECO:0007829|PDB:6G77" FT HELIX 298..307 FT /evidence="ECO:0007829|PDB:6G77" FT TURN 312..314 FT /evidence="ECO:0007829|PDB:6G78" FT TURN 316..319 FT /evidence="ECO:0007829|PDB:6G77" FT HELIX 322..325 FT /evidence="ECO:0007829|PDB:6G77" FT HELIX 328..330 FT /evidence="ECO:0007829|PDB:6G77" FT HELIX 335..339 FT /evidence="ECO:0007829|PDB:6G77" SQ SEQUENCE 745 AA; 83872 MW; 5EC5AB2FA1C19DE8 CRC64; MLPFAPQDEP WDREMEVFSG GGASSGEVNG LKMVDEPMEE GEADSCHDEG VVKEIPITHH VKEGYEKADP AQFELLKVLG QGSFGKVFLV RKKTGPDAGQ LYAMKVLKKA SLKVRDRVRT KMERDILVEV NHPFIVKLHY AFQTEGKLYL ILDFLRGGDV FTRLSKEVLF TEEDVKFYLA ELALALDHLH QLGIVYRDLK PENILLDEIG HIKLTDFGLS KESVDQEKKA YSFCGTVEYM APEVVNRRGH SQSADWWSYG VLMFEMLTGT LPFQGKDRNE TMNMILKAKL GMPQFLSAEA QSLLRMLFKR NPANRLGSEG VEEIKRHLFF ANIDWDKLYK REVQPPFKPA SGKPDDTFCF DPEFTAKTPK DSPGLPASAN AHQLFKGFSF VATSIAEEYK ITPITSANVL PIVQINGNAA QFGEVYELKE DIGVGSYSVC KRCIHATTNM EFAVKIIDKS KRDPSEEIEI LMRYGQHPNI ITLKDVFDDG RYVYLVTDLM KGGELLDRIL KQKCFSEREA SDILYVISKT VDYLHCQGVV HRDLKPSNIL YMDESASADS IRICDFGFAK QLRGENGLLL TPCYTANFVA PEVLMQQGYD AACDIWSLGV LFYTMLAGYT PFANGPNDTP EEILLRIGNG KFSLSGGNWD NISDGAKDLL SHMLHMDPHQ RYTAEQILKH SWITHRDQLP NDQPKRNDVS HVVKGAMVAT YSALTHKTFQ PVLEPVAASS LAQRRSMKKR TSTGL // ID KS6C1_HUMAN Reviewed; 1066 AA. AC Q96S38; B1APS8; B3KVM4; D3DTA4; Q8TDD3; Q9NSF4; Q9UL66; DT 02-MAY-2006, integrated into UniProtKB/Swiss-Prot. DT 02-MAY-2006, sequence version 2. DT 28-JAN-2026, entry version 189. DE RecName: Full=Ribosomal protein S6 kinase delta-1; DE Short=S6K-delta-1; DE EC=2.7.11.1; DE AltName: Full=52 kDa ribosomal protein S6 kinase; DE AltName: Full=Ribosomal S6 kinase-like protein with two PSK domains 118 kDa protein; DE AltName: Full=SPHK1-binding protein; GN Name=RPS6KC1; Synonyms=RPK118; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, INTERACTION RP WITH SPHK1 AND PHOSPHATIDYLINOSITOL 3-PHOSPHATE, SUBCELLULAR LOCATION, AND RP FUNCTION. RX PubMed=12077123; DOI=10.1074/jbc.m201442200; RA Hayashi S., Okada T., Igarashi N., Fujita T., Jahangeer S., Nakamura S.; RT "Identification and characterization of RPK118, a novel sphingosine kinase- RT 1-binding protein."; RL J. Biol. Chem. 277:33319-33324(2002). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RA Guo J.H., Yu L.; RL Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Brain, and Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RC TISSUE=Brain; RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 598-1066 (ISOFORM 1). RX PubMed=10552933; DOI=10.1006/geno.1999.5963; RA Zhang H., Yu L., Mao N., Fu Q., Tu Q., Gao J., Zhao S.; RT "Cloning, characterization, and chromosome mapping of RPS6KC1, a novel RT putative member of the ribosome protein S6 kinase family, to chromosome RT 12q12-q13.1."; RL Genomics 61:314-318(1999). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 683-1066 (ISOFORM 1). RC TISSUE=Amygdala; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [9] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PRDX3. RX PubMed=15750338; DOI=10.1016/s1016-8478(23)13134-7; RA Liu L., Yang C., Yuan J., Chen X., Xu J., Wei Y., Yang J., Lin G., Yu L.; RT "RPK118, a PX domain-containing protein, interacts with peroxiredoxin-3 RT through pseudo-kinase domains."; RL Mol. Cells 19:39-45(2005). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-423 AND SER-427, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-282; SER-423; SER-427; RP SER-455; SER-528; SER-583; SER-605; SER-661; SER-664; SER-667 AND SER-872, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-667, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [16] RP VARIANTS [LARGE SCALE ANALYSIS] THR-42; LYS-96; LEU-319; LEU-424; PRO-546; RP ILE-554; SER-575; ALA-663; PHE-853; TYR-1003 AND LYS-1022. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: May be involved in transmitting sphingosine-1 phosphate CC (SPP)-mediated signaling into the cell (PubMed:12077123). Plays a role CC in the recruitment of PRDX3 to early endosomes (PubMed:15750338). CC {ECO:0000269|PubMed:12077123, ECO:0000269|PubMed:15750338}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- SUBUNIT: Interacts with SPHK1 and phosphatidylinositol 3-phosphate CC (PubMed:12077123). Interacts (via PX domain) with PRDX3 CC (PubMed:15750338). {ECO:0000269|PubMed:12077123, CC ECO:0000269|PubMed:15750338}. CC -!- INTERACTION: CC Q96S38; Q8IWF6: DENND6A; NbExp=2; IntAct=EBI-347731, EBI-2834112; CC Q96S38; P11473-2: VDR; NbExp=3; IntAct=EBI-347731, EBI-12874016; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12077123, CC ECO:0000269|PubMed:15750338}. Membrane {ECO:0000269|PubMed:12077123}. CC Early endosome {ECO:0000269|PubMed:15750338}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q96S38-1; Sequence=Displayed; CC Name=2; CC IsoId=Q96S38-2; Sequence=VSP_046333; CC -!- TISSUE SPECIFICITY: Highly expressed in testis, skeletal muscle, brain, CC heart, placenta, kidney and liver and weakly expressed in thymus, small CC intestine, lung and colon. {ECO:0000269|PubMed:12077123}. CC -!- DOMAIN: The PX domain is essential for its localization to the early CC endosomes. {ECO:0000269|PubMed:15750338}. CC -!- DOMAIN: The first protein kinase domain appears to be a pseudokinase CC domain as it does not contain the classical characteristics, such as CC the ATP-binding motif, ATP-binding site and active site. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. S6 kinase subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- CAUTION: Instead of Lys-820, Arg-820 is found at the binding site. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=CAB92850.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB070706; BAB63956.1; -; mRNA. DR EMBL; AF477978; AAL84818.1; -; mRNA. DR EMBL; AK122921; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AK122989; BAG53836.1; -; mRNA. DR EMBL; AL645860; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL512449; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL583826; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471100; EAW93362.1; -; Genomic_DNA. DR EMBL; CH471100; EAW93363.1; -; Genomic_DNA. DR EMBL; BC104769; AAI04770.1; -; mRNA. DR EMBL; AF037447; AAF13027.1; -; mRNA. DR EMBL; AL356893; CAB92850.1; ALT_INIT; mRNA. DR CCDS; CCDS1513.1; -. [Q96S38-1] DR CCDS; CCDS44317.1; -. [Q96S38-2] DR RefSeq; NP_001129610.1; NM_001136138.4. [Q96S38-2] DR RefSeq; NP_036556.2; NM_012424.4. [Q96S38-1] DR AlphaFoldDB; Q96S38; -. DR SMR; Q96S38; -. DR BioGRID; 117810; 30. DR FunCoup; Q96S38; 1956. DR IntAct; Q96S38; 15. DR STRING; 9606.ENSP00000355927; -. DR ChEMBL; CHEMBL1795193; -. DR iPTMnet; Q96S38; -. DR PhosphoSitePlus; Q96S38; -. DR BioMuta; RPS6KC1; -. DR DMDM; 94717650; -. DR CPTAC; non-CPTAC-5679; -. DR jPOST; Q96S38; -. DR MassIVE; Q96S38; -. DR PaxDb; 9606-ENSP00000355927; -. DR PeptideAtlas; Q96S38; -. DR ProteomicsDB; 3310; -. DR ProteomicsDB; 78062; -. [Q96S38-1] DR Pumba; Q96S38; -. DR TopDownProteomics; Q96S38-1; -. [Q96S38-1] DR Antibodypedia; 34615; 162 antibodies from 27 providers. DR DNASU; 26750; -. DR Ensembl; ENST00000366959.4; ENSP00000355926.3; ENSG00000136643.13. [Q96S38-2] DR Ensembl; ENST00000366960.8; ENSP00000355927.3; ENSG00000136643.13. [Q96S38-1] DR GeneID; 26750; -. DR KEGG; hsa:26750; -. DR MANE-Select; ENST00000366960.8; ENSP00000355927.3; NM_012424.6; NP_036556.2. DR UCSC; uc001hkd.5; human. [Q96S38-1] DR AGR; HGNC:10439; -. DR ClinPGx; PA34854; -. DR CTD; 26750; -. DR DisGeNET; 26750; -. DR GeneCards; RPS6KC1; -. DR HGNC; HGNC:10439; RPS6KC1. DR HPA; ENSG00000136643; Low tissue specificity. DR MalaCards; RPS6KC1; -. DR MIM; 617517; gene. DR OpenTargets; ENSG00000136643; -. DR VEuPathDB; HostDB:ENSG00000136643; -. DR eggNOG; KOG0603; Eukaryota. DR eggNOG; KOG2101; Eukaryota. DR GeneTree; ENSGT00940000155656; -. DR HOGENOM; CLU_014272_0_0_1; -. DR InParanoid; Q96S38; -. DR OMA; GHSSELW; -. DR OrthoDB; 1278353at2759; -. DR PAN-GO; Q96S38; 1 GO annotation based on evolutionary models. DR PhylomeDB; Q96S38; -. DR PathwayCommons; Q96S38; -. DR SignaLink; Q96S38; -. DR SIGNOR; Q96S38; -. DR Agora; ENSG00000136643; -. DR BioGRID-ORCS; 26750; 8 hits in 1164 CRISPR screens. DR ChiTaRS; RPS6KC1; human. DR GeneWiki; RPS6KC1; -. DR GenomeRNAi; 26750; -. DR Pharos; Q96S38; Tdark. DR PRO; PR:Q96S38; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q96S38; protein. DR Bgee; ENSG00000136643; Expressed in sperm and 193 other cell types or tissues. DR ExpressionAtlas; Q96S38; baseline and differential. DR GO; GO:0005769; C:early endosome; IDA:UniProtKB. DR GO; GO:0005768; C:endosome; IDA:HPA. DR GO; GO:0005764; C:lysosome; IDA:HPA. DR GO; GO:0016020; C:membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0035091; F:phosphatidylinositol binding; IEA:InterPro. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:ProtInc. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR CDD; cd02677; MIT_SNX15; 1. DR CDD; cd07287; PX_RPK118_like; 1. DR CDD; cd05576; STKc_RPK118_like; 1. DR FunFam; 1.10.510.10:FF:000221; ribosomal protein S6 kinase delta-1 isoform X1; 1. DR FunFam; 1.20.58.80:FF:000005; ribosomal protein S6 kinase delta-1 isoform X1; 1. DR FunFam; 3.30.1520.10:FF:000017; ribosomal protein S6 kinase delta-1 isoform X1; 1. DR Gene3D; 1.20.58.80; Phosphotransferase system, lactose/cellobiose-type IIA subunit; 1. DR Gene3D; 3.30.1520.10; Phox-like domain; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR051866; Intracell_Sig-Traffick_Protein. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR007330; MIT_dom. DR InterPro; IPR036181; MIT_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR001683; PX_dom. DR InterPro; IPR036871; PX_dom_sf. DR InterPro; IPR042132; PX_S6K-delta-1. DR InterPro; IPR035053; STK_RPK118-like. DR PANTHER; PTHR15508; RIBOSOMAL PROTEIN S6 KINASE; 1. DR PANTHER; PTHR15508:SF2; RIBOSOMAL PROTEIN S6 KINASE DELTA-1; 1. DR Pfam; PF04212; MIT; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00787; PX; 1. DR SMART; SM00745; MIT; 1. DR SMART; SM00312; PX; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF116846; MIT domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF64268; PX domain; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS50195; PX; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cytoplasm; Endosome; Kinase; KW Lipid-binding; Membrane; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..1066 FT /note="Ribosomal protein S6 kinase delta-1" FT /id="PRO_0000233127" FT DOMAIN 8..132 FT /note="PX" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00147" FT DOMAIN 277..305 FT /note="MIT" FT DOMAIN 344..445 FT /note="Protein kinase 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 794..1056 FT /note="Protein kinase 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 207..228 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 441..509 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 553..596 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 212..223 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 448..458 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 474..483 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 492..503 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 582..593 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 929 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 801..809 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 820 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 282 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 423 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 427 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 449 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BLK9" FT MOD_RES 455 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 494 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BLK9" FT MOD_RES 528 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 583 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 605 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 608 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BLK9" FT MOD_RES 640 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BLK9" FT MOD_RES 661 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 664 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 667 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 794 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BLK9" FT MOD_RES 872 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 36..47 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_046333" FT VARIANT 42 FT /note="P -> T (in dbSNP:rs56087470)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040647" FT VARIANT 96 FT /note="E -> K (in dbSNP:rs56032860)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040648" FT VARIANT 319 FT /note="P -> L (in dbSNP:rs56369827)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040649" FT VARIANT 424 FT /note="P -> L (in dbSNP:rs56183862)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040650" FT VARIANT 546 FT /note="A -> P (in dbSNP:rs35281247)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040651" FT VARIANT 554 FT /note="L -> I (in a lung neuroendocrine carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040652" FT VARIANT 561 FT /note="P -> R (in dbSNP:rs17020314)" FT /id="VAR_051635" FT VARIANT 575 FT /note="N -> S (in dbSNP:rs56060894)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040653" FT VARIANT 663 FT /note="G -> A (in an ovarian mucinous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040654" FT VARIANT 853 FT /note="L -> F (in dbSNP:rs34080597)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040655" FT VARIANT 1003 FT /note="C -> Y (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040656" FT VARIANT 1022 FT /note="E -> K (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040657" FT CONFLICT 35 FT /note="R -> G (in Ref. 1; BAB63956)" FT /evidence="ECO:0000305" FT CONFLICT 250 FT /note="A -> V (in Ref. 1; BAB63956)" FT /evidence="ECO:0000305" FT CONFLICT 1065 FT /note="Missing (in Ref. 7)" FT /evidence="ECO:0000305" SQ SEQUENCE 1066 AA; 118682 MW; 670EE5965F3B8274 CRC64; MTSYRERSAD LARFYTVTEP QRHPRGYTVY KVTARVVSRR NPEDVQEIIV WKRYSDFKKL HKELWQIHKN LFRHSELFPP FAKGIVFGRF DETVIEERRQ CAEDLLQFSA NIPALYNSKQ LEDFFKGGII NDSSELIGPA EAHSDSLIDT FPECSTEGFS SDSDLVSLTV DVDSLAELDD GMASNQNSPI RTFGLNLSSD SSALGAVASD SEQSKTEEER ESRSLFPGSL KPKLGKRDYL EKAGELIKLA LKKEEEDDYE AASDFYRKGV DLLLEGVQGE SSPTRREAVK RRTAEYLMRA ESISSLYGKP QLDDVSQPPG SLSSRPLWNL RSPAEELKAF RVLGVIDKVL LVMDTRTEQT FILKGLRKSS EYSRNRKTII PRCVPNMVCL HKYIISEESV FLVLQHAEGG KLWSYISKFL NRSPEESFDI KEVKKPTLAK VHLQQPTSSP QDSSSFESRG SDGGSMLKAL PLKSSLTPSS QDDSNQEDDG QDSSPKWPDS GSSSEEECTT SYLTLCNEYG QEKIEPGSLN EEPFMKTEGN GVDTKAIKSF PAHLAADSDS PSTQLRAHEL KFFPNDDPEA VSSPRTSDSL SRSKNSPMEF FRIDSKDSAS ELLGLDFGEK LYSLKSEPLK PFFTLPDGDS ASRSFNTSES KVEFKAQDTI SRGSDDSVPV ISFKDAAFDD VSGTDEGRPD LLVNLPGELE STREAAAMGP TKFTQTNIGI IENKLLEAPD VLCLRLSTEQ CQAHEEKGIE ELSDPSGPKS YSITEKHYAQ EDPRMLFVAA VDHSSSGDMS LLPSSDPKFQ GLGVVESAVT ANNTEESLFR ICSPLSGANE YIASTDTLKT EEVLLFTDQT DDLAKEEPTS LFQRDSETKG ESGLVLEGDK EIHQIFEDLD KKLALASRFY IPEGCIQRWA AEMVVALDAL HREGIVCRDL NPNNILLNDR GHIQLTYFSR WSEVEDSCDS DAIERMYCAP EVGAITEETE ACDWWSLGAV LFELLTGKTL VECHPAGINT HTTLNMPECV SEEARSLIQQ LLQFNPLERL GAGVAGVEDI KSHPFFTPVD WAELMR // ID KSR2_HUMAN Reviewed; 950 AA. AC Q6VAB6; A0PJT2; Q3B828; Q8N775; DT 21-DEC-2004, integrated into UniProtKB/Swiss-Prot. DT 29-MAY-2007, sequence version 2. DT 28-JAN-2026, entry version 168. DE RecName: Full=Kinase suppressor of Ras 2 {ECO:0000305}; DE Short=hKSR2; DE EC=2.7.11.1 {ECO:0000269|PubMed:21441910}; GN Name=KSR2 {ECO:0000312|HGNC:HGNC:18610}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16541075; DOI=10.1038/nature04569; RA Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y., RA Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C., RA Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C., RA Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., RA Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E., RA Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., RA Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., RA Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., RA Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., RA Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., RA Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., RA Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., RA Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., RA Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., RA Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K., RA Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D., RA Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R., RA David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E., RA D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N., RA Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N., RA Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R., RA Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S., RA LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H., RA Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P., RA Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G., RA Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E., RA Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S., RA Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., RA Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J., RA Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A., RA Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M., RA Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I., RA Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A., RA Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y., RA Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A., RA Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F., RA Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L., RA Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G., RA Gibbs R.A.; RT "The finished DNA sequence of human chromosome 12."; RL Nature 440:346-351(2006). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] OF 122-950 (ISOFORM 1), FUNCTION, INTERACTION RP WITH MAP2K; RAS; RAF; MAPK AND MAP3K8, AND TISSUE SPECIFICITY. RC TISSUE=Testis; RX PubMed=12975377; DOI=10.1074/jbc.m306002200; RA Channavajhala P.L., Wu L., Cuozzo J.W., Hall J.P., Liu W., Lin L.-L., RA Zhang Y.; RT "Identification of a novel human kinase supporter of Ras (hKSR-2) that RT functions as a negative regulator of Cot (Tpl2) signaling."; RL J. Biol. Chem. 278:47089-47097(2003). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 122-950 (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP FUNCTION. RX PubMed=16039990; DOI=10.1016/j.bbrc.2005.07.009; RA Channavajhala P.L., Rao V.R., Spaulding V., Lin L.-L., Zhang Y.G.; RT "hKSR-2 inhibits MEKK3-activated MAP kinase and NF-kappaB pathways in RT inflammation."; RL Biochem. Biophys. Res. Commun. 334:1214-1218(2005). RN [6] RP FUNCTION, AND INTERACTION WITH BRAF; MAP2K1 AND MAP2K2. RX PubMed=29433126; DOI=10.1038/nature25478; RA Lavoie H., Sahmi M., Maisonneuve P., Marullo S.A., Thevakumaran N., Jin T., RA Kurinov I., Sicheri F., Therrien M.; RT "MEK drives BRAF activation through allosteric control of KSR proteins."; RL Nature 554:549-553(2018). RN [7] RP X-RAY CRYSTALLOGRAPHY (3.46 ANGSTROMS) OF 634-950 OF MUTANT ALA-786 IN RP COMPLEX WITH ATP AND MAP2K1, FUNCTION, CATALYTIC ACTIVITY, ACTIVITY RP REGULATION, SUBUNIT, INTERACTION WITH BRAF AND MAP2K1, ACTIVE SITE, AND RP MUTAGENESIS OF ARG-718; ASP-786 AND ALA-879. RX PubMed=21441910; DOI=10.1038/nature09860; RA Brennan D.F., Dar A.C., Hertz N.T., Chao W.C., Burlingame A.L., RA Shokat K.M., Barford D.; RT "A Raf-induced allosteric transition of KSR stimulates phosphorylation of RT MEK."; RL Nature 472:366-369(2011). RN [8] RP VARIANT [LARGE SCALE ANALYSIS] SER-676. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Location-regulated scaffold connecting MEK to RAF. Has very CC low protein kinase activity and can phosphorylate MAP2K1 at several Ser CC and Thr residues with very low efficiency (in vitro). Acts as CC MAP2K1/MEK1-dependent allosteric activator of BRAF; upon binding to CC MAP2K1/MEK1, dimerizes with BRAF and promotes BRAF-mediated CC phosphorylation of MAP2K1/MEK1 (PubMed:29433126). Interaction with BRAF CC enhances KSR2-mediated phosphorylation of MAP2K1 (in vitro). Blocks CC MAP3K8 kinase activity and MAP3K8-mediated signaling. Acts as a CC negative regulator of MAP3K3-mediated activation of ERK, JNK and NF- CC kappa-B pathways, inhibiting MAP3K3-mediated interleukin-8 production. CC {ECO:0000269|PubMed:12975377, ECO:0000269|PubMed:16039990, CC ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21441910}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21441910}; CC -!- ACTIVITY REGULATION: Kinase activity is inhibited by ASC24. CC {ECO:0000269|PubMed:21441910}. CC -!- SUBUNIT: Heterodimerizes (via N-terminus) with BRAF (via N-terminus) in CC a MAP2K1/MEK1-dependent manner (PubMed:29433126). Interacts with BRAF; CC this increases the low intrinsic protein kinase activity of KSR2 CC (PubMed:21441910). Interacts with MAP2K1, forming a heterodimer that CC can dimerize to form a heterotetramer (PubMed:12975377, CC PubMed:21441910, PubMed:29433126). Interacts with MAP3K8, MAPK, RAS and CC RAF (PubMed:12975377). {ECO:0000269|PubMed:12975377, CC ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126}. CC -!- INTERACTION: CC Q6VAB6; Q16543: CDC37; NbExp=7; IntAct=EBI-6424389, EBI-295634; CC Q6VAB6; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-6424389, EBI-3867333; CC Q6VAB6; Q13451: FKBP5; NbExp=7; IntAct=EBI-6424389, EBI-306914; CC Q6VAB6; P07900: HSP90AA1; NbExp=6; IntAct=EBI-6424389, EBI-296047; CC Q6VAB6-1; P29678: MAP2K1; Xeno; NbExp=6; IntAct=EBI-15916808, EBI-1631983; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Membrane {ECO:0000250}; CC Peripheral membrane protein {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q6VAB6-1; Sequence=Displayed; CC Name=2; CC IsoId=Q6VAB6-2; Sequence=VSP_012234, VSP_012235, VSP_012236, CC VSP_012237; CC -!- TISSUE SPECIFICITY: Mainly expressed in brain and kidney. CC {ECO:0000269|PubMed:12975377}. CC -!- DOMAIN: The protein kinase domain is predicted to be catalytically CC inactive and seems to have very low intrinsic kinase activity. This low CC kinase activity can be increased by interaction with BRAF. CC -!- PTM: Phosphorylated on Ser-474 by MARK3. {ECO:0000250}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. {ECO:0000305}. CC -!- CAUTION: KSR2 binds ATP and has very low in vitro protein kinase CC activity; the physiological relevance of this activity is unknown. KSR2 CC is proposed to be in an inactive conformation by itself or in complex CC with MAP2K1. Interaction with BRAF is proposed to induce a conformation CC change that increases the low intrinsic kinase activity CC (PubMed:21441910). {ECO:0000305|PubMed:21441910}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK098831; BAC05426.1; -; mRNA. DR EMBL; AC073864; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC079127; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC084291; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC092936; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AY345972; AAQ24226.1; -; mRNA. DR EMBL; BC107106; AAI07107.1; -; mRNA. DR EMBL; BC107107; AAI07108.1; -; mRNA. DR EMBL; BC127603; AAI27604.1; -; mRNA. DR CCDS; CCDS61250.2; -. [Q6VAB6-1] DR RefSeq; XP_011536527.1; XM_011538225.2. DR PDB; 2Y4I; X-ray; 3.46 A; B=634-950. DR PDB; 5KKR; X-ray; 3.51 A; B=634-950. DR PDB; 7JUQ; X-ray; 3.22 A; B=634-950. DR PDB; 7JUR; X-ray; 2.82 A; B=634-950. DR PDB; 7JUS; X-ray; 2.99 A; B=634-950. DR PDB; 7JUT; X-ray; 3.09 A; B=634-950. DR PDB; 7JUU; X-ray; 3.19 A; B=634-950. DR PDB; 7JUV; X-ray; 3.36 A; B=634-950. DR PDB; 7UMB; X-ray; 3.23 A; B=634-950. DR PDBsum; 2Y4I; -. DR PDBsum; 5KKR; -. DR PDBsum; 7JUQ; -. DR PDBsum; 7JUR; -. DR PDBsum; 7JUS; -. DR PDBsum; 7JUT; -. DR PDBsum; 7JUU; -. DR PDBsum; 7JUV; -. DR PDBsum; 7UMB; -. DR AlphaFoldDB; Q6VAB6; -. DR SMR; Q6VAB6; -. DR BioGRID; 129567; 45. DR CORUM; Q6VAB6; -. DR DIP; DIP-59195N; -. DR FunCoup; Q6VAB6; 999. DR IntAct; Q6VAB6; 147. DR MINT; Q6VAB6; -. DR STRING; 9606.ENSP00000389715; -. DR BindingDB; Q6VAB6; -. DR ChEMBL; CHEMBL3627583; -. DR GlyGen; Q6VAB6; 4 sites. DR iPTMnet; Q6VAB6; -. DR PhosphoSitePlus; Q6VAB6; -. DR BioMuta; KSR2; -. DR DMDM; 148886599; -. DR jPOST; Q6VAB6; -. DR MassIVE; Q6VAB6; -. DR PaxDb; 9606-ENSP00000389715; -. DR PeptideAtlas; Q6VAB6; -. DR ProteomicsDB; 67721; -. [Q6VAB6-1] DR ProteomicsDB; 67722; -. [Q6VAB6-2] DR Antibodypedia; 31354; 363 antibodies from 27 providers. DR DNASU; 283455; -. DR Ensembl; ENST00000339824.7; ENSP00000339952.4; ENSG00000171435.15. [Q6VAB6-1] DR GeneID; 283455; -. DR KEGG; hsa:283455; -. DR MANE-Select; ENST00000339824.7; ENSP00000339952.4; NM_173598.6; NP_775869.4. DR UCSC; uc058tua.1; human. [Q6VAB6-1] DR AGR; HGNC:18610; -. DR ClinPGx; PA134914125; -. DR CTD; 283455; -. DR DisGeNET; 283455; -. DR GeneCards; KSR2; -. DR HGNC; HGNC:18610; KSR2. DR HPA; ENSG00000171435; Tissue enhanced (brain, pituitary gland). DR MalaCards; KSR2; -. DR MIM; 610737; gene. DR OpenTargets; ENSG00000171435; -. DR VEuPathDB; HostDB:ENSG00000171435; -. DR eggNOG; KOG0193; Eukaryota. DR GeneTree; ENSGT00940000158519; -. DR HOGENOM; CLU_006812_1_0_1; -. DR InParanoid; Q6VAB6; -. DR OMA; DSWDRPH; -. DR OrthoDB; 774951at2759; -. DR PAN-GO; Q6VAB6; 6 GO annotations based on evolutionary models. DR PhylomeDB; Q6VAB6; -. DR BRENDA; 2.7.11.25; 2681. DR PathwayCommons; Q6VAB6; -. DR Reactome; R-HSA-5674135; MAP2K and MAPK activation. DR Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants. DR Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF. DR Reactome; R-HSA-9649948; Signaling downstream of RAS mutants. DR Reactome; R-HSA-9656223; Signaling by RAF1 mutants. DR SignaLink; Q6VAB6; -. DR SIGNOR; Q6VAB6; -. DR Agora; ENSG00000171435; -. DR BioGRID-ORCS; 283455; 13 hits in 1165 CRISPR screens. DR ChiTaRS; KSR2; human. DR EvolutionaryTrace; Q6VAB6; -. DR GenomeRNAi; 283455; -. DR Pharos; Q6VAB6; Tbio. DR PRO; PR:Q6VAB6; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; Q6VAB6; protein. DR Bgee; ENSG00000171435; Expressed in Brodmann (1909) area 23 and 84 other cell types or tissues. DR ExpressionAtlas; Q6VAB6; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IBA:GO_Central. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005078; F:MAP-kinase scaffold activity; IEA:Ensembl. DR GO; GO:0031434; F:mitogen-activated protein kinase kinase binding; IEA:Ensembl. DR GO; GO:0004672; F:protein kinase activity; IBA:GO_Central. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:FlyBase. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0019722; P:calcium-mediated signaling; IBA:GO_Central. DR GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; ISS:YuBioLab. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IEA:Ensembl. DR GO; GO:0007265; P:Ras protein signal transduction; IBA:GO_Central. DR CDD; cd14153; PK_KSR2; 1. DR FunFam; 3.30.200.20:FF:000034; Kinase suppressor of Ras 1; 1. DR FunFam; 1.10.510.10:FF:000107; kinase suppressor of Ras 1; 1. DR FunFam; 1.10.150.50:FF:000031; Kinase suppressor of Ras 2; 1. DR FunFam; 3.30.60.20:FF:000010; Putative kinase suppressor of Ras 1; 1. DR Gene3D; 3.30.60.20; -; 1. DR Gene3D; 6.10.140.1120; -; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR025561; KSR_SAM-like_dom. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR046861; SAM_KSR1_N. DR InterPro; IPR046933; SAM_KSR1_N_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR050167; Ser_Thr_protein_kinase. DR PANTHER; PTHR23257:SF775; KINASE SUPPRESSOR OF RAS 2; 1. DR PANTHER; PTHR23257; SERINE-THREONINE PROTEIN KINASE; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF13543; SAM_KSR1; 1. DR Pfam; PF20406; SAM_KSR1_N; 1. DR SMART; SM00109; C1; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 1. DR PROSITE; PS50081; ZF_DAG_PE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cytoplasm; Kinase; KW Membrane; Metal-binding; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger. FT CHAIN 1..950 FT /note="Kinase suppressor of Ras 2" FT /id="PRO_0000086231" FT DOMAIN 666..931 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ZN_FING 412..456 FT /note="Phorbol-ester/DAG-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 239..296 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 498..556 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 259..273 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 517..530 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 531..548 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 786 FT /note="Proton donor/acceptor" FT /evidence="ECO:0000305|PubMed:21441910" FT BINDING 413 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 425 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 428 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 438 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 441 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 446 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 449 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 456 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 672..680 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:21441910" FT BINDING 788 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:21441910" FT BINDING 803 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:21441910" FT MOD_RES 272 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q3UVC0" FT MOD_RES 276 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q3UVC0" FT MOD_RES 474 FT /note="Phosphoserine; by MARK3" FT /evidence="ECO:0000250" FT MOD_RES 497 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q3UVC0" FT VAR_SEQ 1..303 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_012234" FT VAR_SEQ 304..329 FT /note="GFTALHRSKSHEFQLGHRVDEAHTPK -> MYNKKAKMEPNASESAIPARRQ FT RQPR (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_012235" FT VAR_SEQ 740..742 FT /note="SLC -> RPV (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_012236" FT VAR_SEQ 743..950 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_012237" FT VARIANT 676 FT /note="R -> S (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040659" FT MUTAGEN 718 FT /note="R->H: Impairs formation of heterotetramers with FT MAP2K1, but not the formation of heterodimers." FT /evidence="ECO:0000269|PubMed:21441910" FT MUTAGEN 786 FT /note="D->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:21441910" FT MUTAGEN 879 FT /note="A->L: Impairs MAP2K1 binding." FT /evidence="ECO:0000269|PubMed:21441910" FT HELIX 656..658 FT /evidence="ECO:0007829|PDB:7JUR" FT STRAND 659..661 FT /evidence="ECO:0007829|PDB:7JUR" FT STRAND 667..673 FT /evidence="ECO:0007829|PDB:7JUR" FT STRAND 676..684 FT /evidence="ECO:0007829|PDB:7JUR" FT STRAND 688..695 FT /evidence="ECO:0007829|PDB:7JUR" FT STRAND 698..700 FT /evidence="ECO:0007829|PDB:7JUQ" FT HELIX 701..714 FT /evidence="ECO:0007829|PDB:7JUR" FT STRAND 725..727 FT /evidence="ECO:0007829|PDB:7JUR" FT STRAND 734..740 FT /evidence="ECO:0007829|PDB:7JUR" FT STRAND 744..746 FT /evidence="ECO:0007829|PDB:7JUR" FT HELIX 747..751 FT /evidence="ECO:0007829|PDB:7JUR" FT HELIX 760..779 FT /evidence="ECO:0007829|PDB:7JUR" FT HELIX 789..791 FT /evidence="ECO:0007829|PDB:7JUR" FT STRAND 792..795 FT /evidence="ECO:0007829|PDB:7JUR" FT STRAND 798..801 FT /evidence="ECO:0007829|PDB:7JUR" FT HELIX 806..809 FT /evidence="ECO:0007829|PDB:7JUR" FT STRAND 821..825 FT /evidence="ECO:0007829|PDB:7JUR" FT TURN 826..828 FT /evidence="ECO:0007829|PDB:7JUR" FT HELIX 829..831 FT /evidence="ECO:0007829|PDB:7JUR" FT HELIX 834..837 FT /evidence="ECO:0007829|PDB:7JUR" FT HELIX 846..848 FT /evidence="ECO:0007829|PDB:7JUR" FT HELIX 853..869 FT /evidence="ECO:0007829|PDB:7JUR" FT TURN 873..876 FT /evidence="ECO:0007829|PDB:7JUR" FT HELIX 879..887 FT /evidence="ECO:0007829|PDB:7JUR" FT HELIX 895..897 FT /evidence="ECO:0007829|PDB:7JUR" FT HELIX 901..910 FT /evidence="ECO:0007829|PDB:7JUR" FT HELIX 915..917 FT /evidence="ECO:0007829|PDB:7JUR" FT HELIX 921..929 FT /evidence="ECO:0007829|PDB:7JUR" SQ SEQUENCE 950 AA; 107632 MW; DFBC20F4E71077AD CRC64; MDEENMTKSE EQQPLSLQKA LQQCELVQNM IDLSISNLEG LRTKCATSND LTQKEIRTLE SKLVKYFSRQ LSCKKKVALQ ERNAELDGFP QLRHWFRIVD VRKEVLEEIS PGQLSLEDLL EMTDEQVCET VEKYGANREE CARLNASLSC LRNVHMSGGN LSKQDWTIQW PTTETGKENN PVCPPEPTPW IRTHLSQSPR VPSKCVQHYC HTSPTPGAPV YTHVDRLTVD AYPGLCPPPP LESGHRSLPP SPRQRHAVRT PPRTPNIVTT VTPPGTPPMR KKNKLKPPGT PPPSSRKLIH LIPGFTALHR SKSHEFQLGH RVDEAHTPKA KKKSKPLNLK IHSSVGSCEN IPSQQRSPLL SERSLRSFFV GHAPFLPSTP PVHTEANFSA NTLSVPRWSP QIPRRDLGNS IKHRFSTKYW MSQTCTVCGK GMLFGLKCKN CKLKCHNKCT KEAPPCHLLI IHRGDPARLV RTESVPCDIN NPLRKPPRYS DLHISQTLPK TNKINKDHIP VPYQPDSSSN PSSTTSSTPS SPAPPLPPSA TPPSPLHPSP QCTRQQKNFN LPASHYYKYK QQFIFPDVVP VPETPTRAPQ VILHPVTSNP ILEGNPLLQI EVEPTSENEE VHDEAEESED DFEEMNLSLL SARSFPRKAS QTSIFLQEWD IPFEQLEIGE LIGKGRFGQV YHGRWHGEVA IRLIDIERDN EDQLKAFKRE VMAYRQTRHE NVVLFMGACM SPPHLAIITS LCKGRTLYSV VRDAKIVLDV NKTRQIAQEI VKGMGYLHAK GILHKDLKSK NVFYDNGKVV ITDFGLFSIS GVLQAGRRED KLRIQNGWLC HLAPEIIRQL SPDTEEDKLP FSKHSDVFAL GTIWYELHAR EWPFKTQPAE AIIWQMGTGM KPNLSQIGMG KEISDILLFC WAFEQEERPT FTKLMDMLEK LPKRNRRLSH PGHFWKSAEL // ID LATS1_HUMAN Reviewed; 1130 AA. AC O95835; Q6PKD0; DT 27-SEP-2004, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-1999, sequence version 1. DT 28-JAN-2026, entry version 221. DE RecName: Full=Serine/threonine-protein kinase LATS1; DE EC=2.7.11.1 {ECO:0000269|PubMed:10518011, ECO:0000269|PubMed:15122335, ECO:0000269|PubMed:39173637}; DE AltName: Full=Large tumor suppressor homolog 1; DE AltName: Full=WARTS protein kinase; DE Short=h-warts; GN Name=LATS1 {ECO:0000312|EMBL:AAD16882.1}; GN Synonyms=WARTS {ECO:0000312|EMBL:AAD50272.1}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305, ECO:0000312|EMBL:AAD16882.1} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, PHOSPHORYLATION, AND RP INTERACTION WITH CDK1. RC TISSUE=Fetal brain {ECO:0000312|EMBL:AAD16882.1}; RX PubMed=9988268; DOI=10.1038/5960; RA Tao W., Zhang S., Turenchalk G.S., Stewart R.A., St John M.A., Chen W., RA Xu T.; RT "Human homologue of the Drosophila melanogaster lats tumour suppressor RT modulates CDC2 activity."; RL Nat. Genet. 21:177-181(1999). RN [2] {ECO:0000305, ECO:0000312|EMBL:AAD50272.1} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY, RP SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND PHOSPHORYLATION. RX PubMed=10518011; DOI=10.1016/s0014-5793(99)01224-7; RA Nishiyama Y., Hirota T., Morisaki T., Hara T., Marumoto T., Iida S., RA Makino K., Yamamoto H., Hiraoka T., Kitamura N., Saya H.; RT "A human homolog of Drosophila warts tumor suppressor, h-warts, localized RT to mitotic apparatus and specifically phosphorylated during mitosis."; RL FEBS Lett. 459:159-165(1999). RN [3] {ECO:0000305, ECO:0000312|EMBL:AAH02767.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Endometrium {ECO:0000312|EMBL:AAH02767.1}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] {ECO:0000305} RP FUNCTION, AND INTERACTION WITH ZYX. RX PubMed=10831611; DOI=10.1083/jcb.149.5.1073; RA Hirota T., Morisaki T., Nishiyama Y., Marumoto T., Tada K., Hara T., RA Masuko N., Inagaki M., Hatakeyama K., Saya H.; RT "Zyxin, a regulator of actin filament assembly, targets the mitotic RT apparatus by interacting with h-warts/LATS1 tumor suppressor."; RL J. Cell Biol. 149:1073-1086(2000). RN [5] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=15144186; DOI=10.1021/ac035352d; RA Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M., RA Peters E.C.; RT "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from RT human T cells using immobilized metal affinity chromatography and tandem RT mass spectrometry."; RL Anal. Chem. 76:2763-2772(2004). RN [6] {ECO:0000305} RP FUNCTION, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF RP LYS-734. RX PubMed=15122335; DOI=10.1038/sj.onc.1207623; RA Iida S., Hirota T., Morisaki T., Marumoto T., Hara T., Kuninaka S., RA Honda S., Kosai K., Kawasuji M., Pallas D.C., Saya H.; RT "Tumor suppressor WARTS ensures genomic integrity by regulating both RT mitotic progression and G1 tetraploidy checkpoint function."; RL Oncogene 23:5266-5274(2004). RN [7] {ECO:0000305} RP FUNCTION, AND INTERACTION WITH LIMK1. RX PubMed=15220930; DOI=10.1038/ncb1140; RA Yang X., Yu K., Hao Y., Li D.-M., Stewart R.A., Insogna K.L., Xu T.; RT "LATS1 tumour suppressor affects cytokinesis by inhibiting LIMK1."; RL Nat. Cell Biol. 6:609-617(2004). RN [8] RP PHOSPHORYLATION AT SER-909 AND THR-1079. RX PubMed=15688006; DOI=10.1038/sj.onc.1208445; RA Chan E.H.Y., Nousiainen M., Chalamalasetty R.B., Schaefer A., Nigg E.A., RA Sillje H.H.W.; RT "The Ste20-like kinase Mst2 activates the human large tumor suppressor RT kinase Lats1."; RL Oncogene 24:2076-2086(2005). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-674, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [10] RP FUNCTION, INTERACTION WITH YAP1, AND MUTAGENESIS OF TYR-559. RX PubMed=18158288; DOI=10.1074/jbc.m709037200; RA Hao Y., Chun A., Cheung K., Rashidi B., Yang X.; RT "Tumor suppressor LATS1 is a negative regulator of oncogene YAP."; RL J. Biol. Chem. 283:5496-5509(2008). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-246; SER-278 AND SER-464, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [15] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [16] RP INTERACTION WITH LIMD1; WTIP AND AJUBA. RX PubMed=20303269; DOI=10.1016/j.cub.2010.02.035; RA Das Thakur M., Feng Y., Jagannathan R., Seppa M.J., Skeath J.B., RA Longmore G.D.; RT "Ajuba LIM proteins are negative regulators of the Hippo signaling RT pathway."; RL Curr. Biol. 20:657-662(2010). RN [17] RP INTERACTION WITH MOB1A AND MOB1B. RX PubMed=19739119; DOI=10.1002/ijc.24878; RA Chow A., Hao Y., Yang X.; RT "Molecular characterization of human homologs of yeast MOB1."; RL Int. J. Cancer 126:2079-2089(2010). RN [18] RP FUNCTION, PHOSPHORYLATION AT SER-464, AND MUTAGENESIS OF SER-464. RX PubMed=19927127; DOI=10.1038/emboj.2009.342; RA Humbert N., Navaratnam N., Augert A., Da Costa M., Martien S., Wang J., RA Martinez D., Abbadie C., Carling D., de Launoit Y., Gil J., Bernard D.; RT "Regulation of ploidy and senescence by the AMPK-related kinase NUAK1."; RL EMBO J. 29:376-386(2010). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-246; SER-464 AND SER-613, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [20] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [21] RP INTERACTION WITH WWC1; WWC2 AND WWC3. RX PubMed=24682284; DOI=10.1093/molbev/msu115; RA Wennmann D.O., Schmitz J., Wehr M.C., Krahn M.P., Koschmal N., RA Gromnitza S., Schulze U., Weide T., Chekuri A., Skryabin B.V., Gerke V., RA Pavenstadt H., Duning K., Kremerskothen J.; RT "Evolutionary and Molecular Facts Link the WWC Protein Family to Hippo RT Signaling."; RL Mol. Biol. Evol. 31:1710-1723(2014). RN [22] RP FUNCTION, AND PHOSPHORYLATION BY MAP4K. RX PubMed=26437443; DOI=10.1038/ncomms9357; RA Meng Z., Moroishi T., Mottier-Pavie V., Plouffe S.W., Hansen C.G., RA Hong A.W., Park H.W., Mo J.S., Lu W., Lu S., Flores F., Yu F.X., Halder G., RA Guan K.L.; RT "MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the RT Hippo pathway."; RL Nat. Commun. 6:8357-8357(2015). RN [23] RP INTERACTION WITH STK3, AND PHOSPHORYLATION AT THR-1079. RX PubMed=28087714; DOI=10.1101/gad.284539.116; RA Kwan J., Sczaniecka A., Arash E.H., Nguyen L., Chen C.C., Ratkovic S., RA Klezovitch O., Attisano L., McNeill H., Emili A., Vasioukhin V.; RT "DLG5 connects cell polarity and Hippo signaling protein networks by RT linking PAR-1 with MST1/2."; RL Genes Dev. 30:2696-2709(2016). RN [24] RP FUNCTION, AND INTERACTION WITH DCAF13; ESR1 AND DCAF1. RX PubMed=28068668; DOI=10.1038/nature20829; RA Britschgi A., Duss S., Kim S., Couto J.P., Brinkhaus H., Koren S., RA De Silva D., Mertz K.D., Kaup D., Varga Z., Voshol H., Vissieres A., RA Leroy C., Roloff T., Stadler M.B., Scheel C.H., Miraglia L.J., Orth A.P., RA Bonamy G.M., Reddy V.A., Bentires-Alj M.; RT "The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk RT with ERalpha."; RL Nature 541:541-545(2017). RN [25] RP INTERACTION WITH SCRIB. RX PubMed=28169360; DOI=10.1038/srep42125; RA Liu J., Li J., Li P., Wang Y., Liang Z., Jiang Y., Li J., Feng C., Wang R., RA Chen H., Zhou C., Zhang J., Yang J., Liu P.; RT "Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo RT signaling pathway."; RL Sci. Rep. 7:42125-42125(2017). RN [26] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=39173637; DOI=10.1016/j.molcel.2024.08.001; RA Nie L., Fei C., Fan Y., Dang F., Zhao Z., Zhu T., Wu X., Dai T., RA Balasubramanian A., Pan J., Hu Y., Luo H.R., Wei W., Chen J.; RT "Consecutive palmitoylation and phosphorylation orchestrates NLRP3 membrane RT trafficking and inflammasome activation."; RL Mol. Cell 84:3336-3353(2024). RN [27] RP VARIANTS [LARGE SCALE ANALYSIS] TRP-96; GLY-204; GLN-237; TRP-370; SER-531; RP LEU-641; ILE-669; PRO-806 AND SER-1000. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Negative regulator of YAP1 in the Hippo signaling pathway CC that plays a pivotal role in organ size control and tumor suppression CC by restricting proliferation and promoting apoptosis (PubMed:10518011, CC PubMed:10831611, PubMed:18158288, PubMed:26437443, PubMed:28068668). CC The core of this pathway is composed of a kinase cascade wherein CC STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, CC phosphorylates and activates LATS1/2 in complex with its regulatory CC protein MOB1, which in turn phosphorylates and inactivates YAP1 CC oncoprotein and WWTR1/TAZ (PubMed:18158288, PubMed:26437443, CC PubMed:28068668). Phosphorylation of YAP1 by LATS1 inhibits its CC translocation into the nucleus to regulate cellular genes important for CC cell proliferation, cell death, and cell migration (PubMed:18158288, CC PubMed:26437443, PubMed:28068668). Acts as a tumor suppressor which CC plays a critical role in maintenance of ploidy through its actions in CC both mitotic progression and the G1 tetraploidy checkpoint CC (PubMed:15122335, PubMed:19927127). Negatively regulates G2/M CC transition by down-regulating CDK1 kinase activity (PubMed:9988268). CC Involved in the control of p53 expression (PubMed:15122335). Affects CC cytokinesis by regulating actin polymerization through negative CC modulation of LIMK1 (PubMed:15220930). May also play a role in CC endocrine function. Plays a role in mammary gland epithelial cell CC differentiation, both through the Hippo signaling pathway and the CC intracellular estrogen receptor signaling pathway by promoting the CC degradation of ESR1 (PubMed:28068668). Acts as an activator of the CC NLRP3 inflammasome by mediating phosphorylation of 'Ser-265' of NLRP3 CC following NLRP3 palmitoylation, promoting NLRP3 activation by NEK7 CC (PubMed:39173637). {ECO:0000269|PubMed:10518011, CC ECO:0000269|PubMed:10831611, ECO:0000269|PubMed:15122335, CC ECO:0000269|PubMed:15220930, ECO:0000269|PubMed:18158288, CC ECO:0000269|PubMed:19927127, ECO:0000269|PubMed:26437443, CC ECO:0000269|PubMed:28068668, ECO:0000269|PubMed:39173637, CC ECO:0000269|PubMed:9988268}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10518011, ECO:0000269|PubMed:15122335, CC ECO:0000269|PubMed:39173637}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10518011, ECO:0000269|PubMed:15122335}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- SUBUNIT: Complexes with CDK1 in early mitosis (PubMed:9988268). LATS1- CC associated CDK1 has no mitotic cyclin partner and no apparent kinase CC activity (PubMed:9988268). Binds phosphorylated ZYX, locating this CC protein to the mitotic spindle and suggesting a role for actin CC regulatory proteins during mitosis (PubMed:10831611). Binds to and CC colocalizes with LIMK1 at the actomyosin contractile ring during CC cytokinesis (PubMed:15220930). Interacts (via PPxY motif 2) with YAP1 CC (via WW domains) (PubMed:18158288). Interacts with MOB1A and MOB1B CC (PubMed:19739119). Interacts with LIMD1, WTIP and AJUBA CC (PubMed:20303269). Interacts with ESR1, DCAF1 and DCAF13; probably CC recruits DCAF1 and DCAF13 to ESR1 to promote ESR1 ubiquitination and CC ubiquitin-mediated proteasomal degradation (PubMed:28068668). Interacts CC with STK3/MST2; this interaction is inhibited in the presence of DLG5 CC (PubMed:28087714). Interacts with SCRIB in the presence of DLG5 CC (PubMed:28169360). Interacts with WWTR1/TAZ (By similarity). Interacts CC with WWC1, WWC2 and WWC3 (via their WW domains) (PubMed:24682284). CC {ECO:0000250|UniProtKB:Q8BYR2, ECO:0000269|PubMed:10831611, CC ECO:0000269|PubMed:15220930, ECO:0000269|PubMed:18158288, CC ECO:0000269|PubMed:19739119, ECO:0000269|PubMed:20303269, CC ECO:0000269|PubMed:24682284, ECO:0000269|PubMed:28068668, CC ECO:0000269|PubMed:28087714, ECO:0000269|PubMed:28169360, CC ECO:0000269|PubMed:9988268}. CC -!- INTERACTION: CC O95835; P06493: CDK1; NbExp=3; IntAct=EBI-444209, EBI-444308; CC O95835; P24941: CDK2; NbExp=4; IntAct=EBI-444209, EBI-375096; CC O95835; Q9Y4B6: DCAF1; NbExp=4; IntAct=EBI-444209, EBI-1996353; CC O95835; P03372: ESR1; NbExp=2; IntAct=EBI-444209, EBI-78473; CC O95835; P53667: LIMK1; NbExp=5; IntAct=EBI-444209, EBI-444403; CC O95835; Q9H8S9: MOB1A; NbExp=9; IntAct=EBI-444209, EBI-748229; CC O95835; Q7L9L4: MOB1B; NbExp=9; IntAct=EBI-444209, EBI-2558745; CC O95835; P35240: NF2; NbExp=4; IntAct=EBI-444209, EBI-1014472; CC O95835; O60285: NUAK1; NbExp=2; IntAct=EBI-444209, EBI-1046789; CC O95835; O43255: SIAH2; NbExp=2; IntAct=EBI-444209, EBI-948141; CC O95835; Q13485: SMAD4; NbExp=7; IntAct=EBI-444209, EBI-347263; CC O95835; Q15831: STK11; NbExp=2; IntAct=EBI-444209, EBI-306838; CC O95835; Q9GZV5: WWTR1; NbExp=5; IntAct=EBI-444209, EBI-747743; CC O95835; P46937: YAP1; NbExp=10; IntAct=EBI-444209, EBI-1044059; CC O95835; Q15942: ZYX; NbExp=10; IntAct=EBI-444209, EBI-444225; CC O95835; P46662: Nf2; Xeno; NbExp=5; IntAct=EBI-444209, EBI-644586; CC O95835-2; O15145: ARPC3; NbExp=3; IntAct=EBI-17978514, EBI-351829; CC O95835-2; Q9UHD9: UBQLN2; NbExp=3; IntAct=EBI-17978514, EBI-947187; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing CC center, centrosome {ECO:0000269|PubMed:10518011}. Cytoplasm, CC cytoskeleton, spindle {ECO:0000269|PubMed:10518011}. Midbody CC {ECO:0000269|PubMed:10518011}. Cytoplasm, cytoskeleton, microtubule CC organizing center, spindle pole body {ECO:0000269|PubMed:10518011}. CC Note=Localizes to the centrosomes throughout interphase but migrates to CC the mitotic apparatus, including spindle pole bodies, mitotic spindle, CC and midbody, during mitosis. {ECO:0000269|PubMed:10518011}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1 {ECO:0000269|PubMed:9988268}; CC IsoId=O95835-1; Sequence=Displayed; CC Name=2 {ECO:0000305}; CC IsoId=O95835-2; Sequence=VSP_051604, VSP_051605; CC -!- TISSUE SPECIFICITY: Expressed in all adult tissues examined except for CC lung and kidney. {ECO:0000269|PubMed:10518011}. CC -!- PTM: Autophosphorylated and phosphorylated during M-phase of the cell CC cycle (PubMed:10518011, PubMed:15122335, PubMed:9988268). CC Phosphorylated by STK3/MST2 at Ser-909 and Thr-1079, which results in CC its activation (PubMed:15688006). Phosphorylated by MAP4Ks; in parallel CC to STK3/MST2 and resulting to its activation (PubMed:26437443). CC Phosphorylation at Ser-464 by NUAK1 and NUAK2 leads to decreased CC protein level and is required to regulate cellular senescence and CC cellular ploidy (PubMed:19927127). {ECO:0000269|PubMed:10518011, CC ECO:0000269|PubMed:15122335, ECO:0000269|PubMed:15688006, CC ECO:0000269|PubMed:19927127, ECO:0000269|PubMed:26437443, CC ECO:0000269|PubMed:9988268}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41127/LATS1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF104413; AAD16882.1; -; mRNA. DR EMBL; AF164041; AAD50272.1; -; mRNA. DR EMBL; BC002767; AAH02767.1; -; mRNA. DR CCDS; CCDS34551.1; -. [O95835-1] DR CCDS; CCDS59040.1; -. [O95835-2] DR RefSeq; NP_001257448.1; NM_001270519.2. [O95835-2] DR RefSeq; NP_004681.1; NM_004690.4. [O95835-1] DR RefSeq; XP_047275474.1; XM_047419518.1. [O95835-1] DR RefSeq; XP_054212722.1; XM_054356747.1. [O95835-1] DR PDB; 4ZRK; X-ray; 2.32 A; E/F/G/H=69-100. DR PDB; 5B5W; X-ray; 2.96 A; U=622-704. DR PDB; 5BRK; X-ray; 2.30 A; B=602-704. DR PDB; 7LWH; X-ray; 1.61 A; B=69-91. DR PDBsum; 4ZRK; -. DR PDBsum; 5B5W; -. DR PDBsum; 5BRK; -. DR PDBsum; 7LWH; -. DR AlphaFoldDB; O95835; -. DR SMR; O95835; -. DR BioGRID; 114563; 460. DR CORUM; O95835; -. DR DIP; DIP-31516N; -. DR FunCoup; O95835; 4799. DR IntAct; O95835; 114. DR MINT; O95835; -. DR STRING; 9606.ENSP00000437550; -. DR BindingDB; O95835; -. DR ChEMBL; CHEMBL6167; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; O95835; -. DR GuidetoPHARMACOLOGY; 1515; -. DR MoonProt; O95835; -. DR GlyGen; O95835; 7 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (5 sites). DR iPTMnet; O95835; -. DR PhosphoSitePlus; O95835; -. DR BioMuta; LATS1; -. DR CPTAC; CPTAC-3110; -. DR CPTAC; CPTAC-3111; -. DR jPOST; O95835; -. DR MassIVE; O95835; -. DR PaxDb; 9606-ENSP00000437550; -. DR PeptideAtlas; O95835; -. DR ProteomicsDB; 51081; -. [O95835-1] DR ProteomicsDB; 51082; -. [O95835-2] DR Pumba; O95835; -. DR Antibodypedia; 33280; 394 antibodies from 32 providers. DR DNASU; 9113; -. DR Ensembl; ENST00000253339.9; ENSP00000253339.5; ENSG00000131023.14. [O95835-1] DR Ensembl; ENST00000392273.7; ENSP00000444678.1; ENSG00000131023.14. [O95835-2] DR Ensembl; ENST00000543571.6; ENSP00000437550.1; ENSG00000131023.14. [O95835-1] DR GeneID; 9113; -. DR KEGG; hsa:9113; -. DR MANE-Select; ENST00000543571.6; ENSP00000437550.1; NM_004690.4; NP_004681.1. DR UCSC; uc003qmu.2; human. [O95835-1] DR AGR; HGNC:6514; -. DR ClinPGx; PA30301; -. DR CTD; 9113; -. DR DisGeNET; 9113; -. DR GeneCards; LATS1; -. DR HGNC; HGNC:6514; LATS1. DR HPA; ENSG00000131023; Low tissue specificity. DR MalaCards; LATS1; -. DR MIM; 603473; gene. DR OpenTargets; ENSG00000131023; -. DR VEuPathDB; HostDB:ENSG00000131023; -. DR eggNOG; KOG0608; Eukaryota. DR GeneTree; ENSGT00940000157684; -. DR HOGENOM; CLU_004885_0_0_1; -. DR InParanoid; O95835; -. DR OMA; NHHGSRQ; -. DR OrthoDB; 3638488at2759; -. DR PAN-GO; O95835; 7 GO annotations based on evolutionary models. DR PhylomeDB; O95835; -. DR PathwayCommons; O95835; -. DR Reactome; R-HSA-2028269; Signaling by Hippo. DR SignaLink; O95835; -. DR SIGNOR; O95835; -. DR Agora; ENSG00000131023; -. DR BioGRID-ORCS; 9113; 25 hits in 1204 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; LATS1; human. DR EvolutionaryTrace; O95835; -. DR GeneWiki; LATS1; -. DR GenomeRNAi; 9113; -. DR Pharos; O95835; Tchem. DR PRO; PR:O95835; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; O95835; protein. DR Bgee; ENSG00000131023; Expressed in germinal epithelium of ovary and 183 other cell types or tissues. DR ExpressionAtlas; O95835; baseline and differential. DR GO; GO:0005813; C:centrosome; IEA:UniProtKB-SubCell. DR GO; GO:0005737; C:cytoplasm; IDA:UniProt. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005815; C:microtubule organizing center; IDA:UniProt. DR GO; GO:0030496; C:midbody; IEA:UniProtKB-SubCell. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0098794; C:postsynapse; IEA:Ensembl. DR GO; GO:0000922; C:spindle pole; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0030331; F:nuclear estrogen receptor binding; IPI:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IBA:GO_Central. DR GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IDA:UniProtKB. DR GO; GO:0035329; P:hippo signaling; IDA:BHF-UCL. DR GO; GO:0009755; P:hormone-mediated signaling pathway; ISS:UniProtKB. DR GO; GO:0001827; P:inner cell mass cell fate commitment; IEA:Ensembl. DR GO; GO:0001828; P:inner cell mass cellular morphogenesis; IEA:Ensembl. DR GO; GO:0008104; P:intracellular protein localization; IEA:Ensembl. DR GO; GO:0030216; P:keratinocyte differentiation; IEA:Ensembl. DR GO; GO:0060644; P:mammary gland epithelial cell differentiation; IMP:UniProtKB. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:BHF-UCL. DR GO; GO:0045736; P:negative regulation of cyclin-dependent protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:1900181; P:negative regulation of protein localization to nucleus; IMP:ARUK-UCL. DR GO; GO:0043065; P:positive regulation of apoptotic process; IBA:GO_Central. DR GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0030833; P:regulation of actin filament polymerization; IDA:UniProtKB. DR GO; GO:0033146; P:regulation of intracellular estrogen receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0046620; P:regulation of organ growth; IBA:GO_Central. DR GO; GO:0099151; P:regulation of postsynaptic density assembly; IEA:Ensembl. DR GO; GO:0043254; P:regulation of protein-containing complex assembly; IMP:BHF-UCL. DR GO; GO:0017015; P:regulation of transforming growth factor beta receptor signaling pathway; ISS:UniProtKB. DR GO; GO:2000058; P:regulation of ubiquitin-dependent protein catabolic process; IMP:UniProtKB. DR GO; GO:0000819; P:sister chromatid segregation; IDA:UniProtKB. DR CDD; cd21778; MobB_LATS1; 1. DR CDD; cd05625; STKc_LATS1; 1. DR CDD; cd14397; UBA_LATS1; 1. DR DisProt; DP03124; -. DR FunFam; 3.30.200.20:FF:001246; Large tumor suppressor kinase 1; 1. DR FunFam; 1.10.510.10:FF:000086; Non-specific serine/threonine protein kinase; 1. DR FunFam; 1.10.510.10:FF:000199; Non-specific serine/threonine protein kinase; 1. DR FunFam; 1.10.8.10:FF:000029; Serine/threonine-protein kinase LATS1 isoform 1; 1. DR Gene3D; 1.10.8.10; DNA helicase RuvA subunit, C-terminal domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 2. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR049761; LATS1-like_MobB. DR InterPro; IPR042706; LATS1_STKc. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR050236; Ser_Thr_kinase_AGC. DR InterPro; IPR015940; UBA. DR InterPro; IPR009060; UBA-like_sf. DR PANTHER; PTHR24356; SERINE/THREONINE-PROTEIN KINASE; 1. DR PANTHER; PTHR24356:SF138; SERINE_THREONINE-PROTEIN KINASE LATS1; 1. DR Pfam; PF00069; Pkinase; 2. DR Pfam; PF00433; Pkinase_C; 1. DR Pfam; PF00627; UBA; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF46934; UBA-like; 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50030; UBA; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell cycle; Cell division; KW Cytoplasm; Cytoskeleton; Kinase; Magnesium; Metal-binding; Mitosis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase; KW Tumor suppressor. FT CHAIN 1..1130 FT /note="Serine/threonine-protein kinase LATS1" FT /id="PRO_0000086232" FT DOMAIN 100..141 FT /note="UBA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00212" FT DOMAIN 705..1010 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 1011..1090 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT REGION 1..71 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 149..276 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 294..321 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 365..405 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 432..484 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 515..631 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 526..655 FT /note="Interaction with YAP1" FT /evidence="ECO:0000269|PubMed:18158288" FT REGION 1104..1130 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 373..376 FT /note="PPxY motif 1" FT MOTIF 556..559 FT /note="PPxY motif 2" FT COMPBIAS 1..11 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 19..30 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 46..64 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 167..179 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 235..268 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 300..312 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 381..405 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 434..447 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 454..482 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 579..609 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 621..630 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 828 FT /note="Proton acceptor" FT /evidence="ECO:0000250|UniProtKB:P22612, FT ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE- FT ProRule:PRU10027" FT BINDING 711..719 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:P22612, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 734 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:15122335" FT MOD_RES 246 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 278 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 464 FT /note="Phosphoserine; by NUAK1 and NUAK2" FT /evidence="ECO:0000269|PubMed:19927127, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 613 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 674 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17525332" FT MOD_RES 909 FT /note="Phosphoserine; by STK3/MST2" FT /evidence="ECO:0000269|PubMed:15688006" FT MOD_RES 1079 FT /note="Phosphothreonine; by STK3/MST2" FT /evidence="ECO:0000269|PubMed:15688006, FT ECO:0000269|PubMed:28087714" FT VAR_SEQ 672..690 FT /note="GLSQDAQDQMRKMLCQKES -> KPFKMSIFILNHLFAWCLF (in FT isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_051604" FT VAR_SEQ 691..1130 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_051605" FT VARIANT 96 FT /note="R -> W (in dbSNP:rs55945045)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040660" FT VARIANT 204 FT /note="S -> G (in dbSNP:rs34793526)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040661" FT VARIANT 237 FT /note="P -> Q (in dbSNP:rs56149740)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040662" FT VARIANT 370 FT /note="R -> W (in dbSNP:rs56348064)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040663" FT VARIANT 531 FT /note="P -> S (in dbSNP:rs55874734)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040664" FT VARIANT 641 FT /note="F -> L (in dbSNP:rs35163691)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040665" FT VARIANT 669 FT /note="M -> I (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs1390558952)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040666" FT VARIANT 806 FT /note="R -> P (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040667" FT VARIANT 1000 FT /note="G -> S (in dbSNP:rs56412005)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040668" FT MUTAGEN 464 FT /note="S->A: Abolishes phosphorylation by NUAK1 and NUAK2." FT /evidence="ECO:0000269|PubMed:19927127" FT MUTAGEN 559 FT /note="Y->F: Loss of interaction with YAP1." FT /evidence="ECO:0000269|PubMed:18158288" FT MUTAGEN 734 FT /note="K->A: Loss of kinase activity, autophosphorylation, FT increased ploidy, prolonged duration of mitosis and lack of FT p53 expression." FT /evidence="ECO:0000269|PubMed:15122335" FT HELIX 72..74 FT /evidence="ECO:0007829|PDB:7LWH" FT HELIX 75..85 FT /evidence="ECO:0007829|PDB:7LWH" FT HELIX 86..88 FT /evidence="ECO:0007829|PDB:7LWH" FT HELIX 637..671 FT /evidence="ECO:0007829|PDB:5BRK" FT HELIX 675..697 FT /evidence="ECO:0007829|PDB:5BRK" SQ SEQUENCE 1130 AA; 126870 MW; 11CFBCD8FD87DCD8 CRC64; MKRSEKPEGY RQMRPKTFPA SNYTVSSRQM LQEIRESLRN LSKPSDAAKA EHNMSKMSTE DPRQVRNPPK FGTHHKALQE IRNSLLPFAN ETNSSRSTSE VNPQMLQDLQ AAGFDEDMVI QALQKTNNRS IEAAIEFISK MSYQDPRREQ MAAAAARPIN ASMKPGNVQQ SVNRKQSWKG SKESLVPQRH GPPLGESVAY HSESPNSQTD VGRPLSGSGI SAFVQAHPSN GQRVNPPPPP QVRSVTPPPP PRGQTPPPRG TTPPPPSWEP NSQTKRYSGN MEYVISRISP VPPGAWQEGY PPPPLNTSPM NPPNQGQRGI SSVPVGRQPI IMQSSSKFNF PSGRPGMQNG TGQTDFMIHQ NVVPAGTVNR QPPPPYPLTA ANGQSPSALQ TGGSAAPSSY TNGSIPQSMM VPNRNSHNME LYNISVPGLQ TNWPQSSSAP AQSSPSSGHE IPTWQPNIPV RSNSFNNPLG NRASHSANSQ PSATTVTAIT PAPIQQPVKS MRVLKPELQT ALAPTHPSWI PQPIQTVQPS PFPEGTASNV TVMPPVAEAP NYQGPPPPYP KHLLHQNPSV PPYESISKPS KEDQPSLPKE DESEKSYENV DSGDKEKKQI TTSPITVRKN KKDEERRESR IQSYSPQAFK FFMEQHVENV LKSHQQRLHR KKQLENEMMR VGLSQDAQDQ MRKMLCQKES NYIRLKRAKM DKSMFVKIKT LGIGAFGEVC LARKVDTKAL YATKTLRKKD VLLRNQVAHV KAERDILAEA DNEWVVRLYY SFQDKDNLYF VMDYIPGGDM MSLLIRMGIF PESLARFYIA ELTCAVESVH KMGFIHRDIK PDNILIDRDG HIKLTDFGLC TGFRWTHDSK YYQSGDHPRQ DSMDFSNEWG DPSSCRCGDR LKPLERRAAR QHQRCLAHSL VGTPNYIAPE VLLRTGYTQL CDWWSVGVIL FEMLVGQPPF LAQTPLETQM KVINWQTSLH IPPQAKLSPE ASDLIIKLCR GPEDRLGKNG ADEIKAHPFF KTIDFSSDLR QQSASYIPKI THPTDTSNFD PVDPDKLWSD DNEEENVNDT LNGWYKNGKH PEHAFYEFTF RRFFDDNGYP YNYPKPIEYE YINSQGSEQQ SDEDDQNTGS EIKNRDLVYV // ID LATS2_HUMAN Reviewed; 1088 AA. AC Q9NRM7; B1AM47; Q9P2X1; DT 27-SEP-2004, integrated into UniProtKB/Swiss-Prot. DT 04-NOV-2008, sequence version 2. DT 28-JAN-2026, entry version 211. DE RecName: Full=Serine/threonine-protein kinase LATS2; DE EC=2.7.11.1 {ECO:0000269|PubMed:10871863, ECO:0000269|PubMed:39173637}; DE AltName: Full=Kinase phosphorylated during mitosis protein; DE AltName: Full=Large tumor suppressor homolog 2; DE AltName: Full=Serine/threonine-protein kinase kpm; DE AltName: Full=Warts-like kinase; GN Name=LATS2 {ECO:0000312|EMBL:BAA92381.1}; Synonyms=KPM; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305, ECO:0000312|EMBL:AAF80561.1} RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, RP AUTOPHOSPHORYLATION, AND MUTAGENESIS OF LYS-697. RC TISSUE=Myeloid {ECO:0000312|EMBL:AAF80561.1}; RX PubMed=10871863; DOI=10.1038/sj.onc.1203659; RA Hori T., Takaori-Kondo A., Kamikubo Y., Uchiyama T.; RT "Molecular cloning of a novel human protein kinase, kpm, that is homologous RT to warts/lats, a Drosophila tumor suppressor."; RL Oncogene 19:3101-3109(2000). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057823; DOI=10.1038/nature02379; RA Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L., RA Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S., RA Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P., RA Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L., RA Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P., RA Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P., RA Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C., RA Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P., RA Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L., RA Frankish A.G., Frankland J., French L., Garner P., Garnett J., RA Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M., RA Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D., RA Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D., RA Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., RA Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S., RA Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S., RA Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R., RA Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W., RA Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P., RA Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L., RA Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R., RA Rogers J., Ross M.T.; RT "The DNA sequence and analysis of human chromosome 13."; RL Nature 428:522-528(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] {ECO:0000305, ECO:0000312|EMBL:BAA92381.1} RP NUCLEOTIDE SEQUENCE [MRNA] OF 42-1088, TISSUE SPECIFICITY, AND VARIANT RP VAL-324. RC TISSUE=Testis {ECO:0000269|PubMed:10673337}; RX PubMed=10673337; DOI=10.1006/geno.1999.6065; RA Yabuta N., Fujii T., Copeland N.G., Gilbert D.J., Jenkins N.A., RA Nishiguchi H., Endo Y., Toji S., Tanaka H., Nishimune Y., Nojima H.; RT "Structure, expression, and chromosome mapping of LATS2, a mammalian RT homologue of the Drosophila tumor suppressor gene lats/warts."; RL Genomics 63:263-270(2000). RN [6] {ECO:0000305} RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-697 AND SER-872. RX PubMed=12853976; DOI=10.1038/sj.onc.1206603; RA Li Y., Pei J., Xia H., Ke H., Wang H., Tao W.; RT "Lats2, a putative tumor suppressor, inhibits G1/S transition."; RL Oncogene 22:4398-4405(2003). RN [7] {ECO:0000305} RP SUBCELLULAR LOCATION, INTERACTION WITH AURKA, MUTAGENESIS OF SER-83, AND RP PHOSPHORYLATION AT SER-83. RX PubMed=15147269; DOI=10.1111/j.1356-9597.2004.00732.x; RA Toji S., Yabuta N., Hosomi T., Nishihara S., Kobayashi T., Suzuki S., RA Tamai K., Nojima H.; RT "The centrosomal protein Lats2 is a phosphorylation target of Aurora-A RT kinase."; RL Genes Cells 9:383-397(2004). RN [8] {ECO:0000305} RP FUNCTION, AND INTERACTION WITH AR. RX PubMed=15131260; DOI=10.1210/me.2004-0065; RA Powzaniuk M., McElwee-Witmer S., Vogel R.L., Hayami T., Rutledge S.J., RA Chen F., Harada S., Schmidt A., Rodan G.A., Freedman L.P., Bai C.; RT "The LATS2/KPM tumor suppressor is a negative regulator of the androgen RT receptor."; RL Mol. Endocrinol. 18:2011-2023(2004). RN [9] RP PHOSPHORYLATION. RX PubMed=15688006; DOI=10.1038/sj.onc.1208445; RA Chan E.H.Y., Nousiainen M., Chalamalasetty R.B., Schaefer A., Nigg E.A., RA Sillje H.H.W.; RT "The Ste20-like kinase Mst2 activates the human large tumor suppressor RT kinase Lats1."; RL Oncogene 24:2076-2086(2005). RN [10] RP INTERACTION WITH AJUBA. RX PubMed=16413547; DOI=10.1016/j.febslet.2005.12.096; RA Abe Y., Ohsugi M., Haraguchi K., Fujimoto J., Yamamoto T.; RT "LATS2-Ajuba complex regulates gamma-tubulin recruitment to centrosomes and RT spindle organization during mitosis."; RL FEBS Lett. 580:782-788(2006). RN [11] RP FUNCTION, AND INTERACTION WITH YAP1. RX PubMed=18158288; DOI=10.1074/jbc.m709037200; RA Hao Y., Chun A., Cheung K., Rashidi B., Yang X.; RT "Tumor suppressor LATS1 is a negative regulator of oncogene YAP."; RL J. Biol. Chem. 283:5496-5509(2008). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-279, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [13] RP INTERACTION WITH LIMD1; WTIP AND AJUBA. RX PubMed=20303269; DOI=10.1016/j.cub.2010.02.035; RA Das Thakur M., Feng Y., Jagannathan R., Seppa M.J., Skeath J.B., RA Longmore G.D.; RT "Ajuba LIM proteins are negative regulators of the Hippo signaling RT pathway."; RL Curr. Biol. 20:657-662(2010). RN [14] RP INTERACTION WITH MOB1A AND MOB1B. RX PubMed=19739119; DOI=10.1002/ijc.24878; RA Chow A., Hao Y., Yang X.; RT "Molecular characterization of human homologs of yeast MOB1."; RL Int. J. Cancer 126:2079-2089(2010). RN [15] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH SNAI1, AND PHOSPHORYLATION RP AT THR-1041. RX PubMed=21952048; DOI=10.1038/emboj.2011.357; RA Zhang K., Rodriguez-Aznar E., Yabuta N., Owen R.J., Mingot J.M., Nojima H., RA Nieto M.A., Longmore G.D.; RT "Lats2 kinase potentiates Snail1 activity by promoting nuclear retention RT upon phosphorylation."; RL EMBO J. 31:29-43(2012). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-380 AND SER-576, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [18] RP INTERACTION WITH WWC1; WWC2 AND WWC3. RX PubMed=24682284; DOI=10.1093/molbev/msu115; RA Wennmann D.O., Schmitz J., Wehr M.C., Krahn M.P., Koschmal N., RA Gromnitza S., Schulze U., Weide T., Chekuri A., Skryabin B.V., Gerke V., RA Pavenstadt H., Duning K., Kremerskothen J.; RT "Evolutionary and Molecular Facts Link the WWC Protein Family to Hippo RT Signaling."; RL Mol. Biol. Evol. 31:1710-1723(2014). RN [19] RP FUNCTION, AND PHOSPHORYLATION BY MAP4K. RX PubMed=26437443; DOI=10.1038/ncomms9357; RA Meng Z., Moroishi T., Mottier-Pavie V., Plouffe S.W., Hansen C.G., RA Hong A.W., Park H.W., Mo J.S., Lu W., Lu S., Flores F., Yu F.X., Halder G., RA Guan K.L.; RT "MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the RT Hippo pathway."; RL Nat. Commun. 6:8357-8357(2015). RN [20] RP FUNCTION, AND INTERACTION WITH AMOTL2. RX PubMed=26598551; DOI=10.15252/embr.201540809; RA Kim M., Kim M., Park S.J., Lee C., Lim D.S.; RT "Role of Angiomotin-like 2 mono-ubiquitination on YAP inhibition."; RL EMBO Rep. 17:64-78(2016). RN [21] RP PHOSPHORYLATION BY NUAK2. RX PubMed=32845958; DOI=10.1084/jem.20191561; RA Bonnard C., Navaratnam N., Ghosh K., Chan P.W., Tan T.T., Pomp O., RA Ng A.Y.J., Tohari S., Changede R., Carling D., Venkatesh B., Altunoglu U., RA Kayserili H., Reversade B.; RT "A loss-of-function NUAK2 mutation in humans causes anencephaly due to RT impaired Hippo-YAP signaling."; RL J. Exp. Med. 217:0-0(2020). RN [22] RP FUNCTION. RX PubMed=34404733; DOI=10.26508/lsa.202000953; RA Hwang D., Kim M., Kim S., Kwon M.R., Kang Y.S., Kim D., Kang H.C., RA Lim D.S.; RT "AMOTL2 mono-ubiquitination by WWP1 promotes contact inhibition by RT facilitating LATS activation."; RL Life. Sci Alliance 4:0-0(2021). RN [23] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=39173637; DOI=10.1016/j.molcel.2024.08.001; RA Nie L., Fei C., Fan Y., Dang F., Zhao Z., Zhu T., Wu X., Dai T., RA Balasubramanian A., Pan J., Hu Y., Luo H.R., Wei W., Chen J.; RT "Consecutive palmitoylation and phosphorylation orchestrates NLRP3 membrane RT trafficking and inflammasome activation."; RL Mol. Cell 84:3336-3353(2024). RN [24] RP VARIANTS [LARGE SCALE ANALYSIS] GLU-40; LEU-91; VAL-799; GLY-1014 AND RP PRO-1025. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Negative regulator of YAP1 in the Hippo signaling pathway CC that plays a pivotal role in organ size control and tumor suppression CC by restricting proliferation and promoting apoptosis (PubMed:18158288, CC PubMed:26437443, PubMed:26598551, PubMed:34404733). The core of this CC pathway is composed of a kinase cascade wherein STK3/MST2 and CC STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates CC and activates LATS1/2 in complex with its regulatory protein MOB1, CC which in turn phosphorylates and inactivates YAP1 oncoprotein and CC WWTR1/TAZ (PubMed:26437443, PubMed:26598551, PubMed:34404733). CC Phosphorylation of YAP1 by LATS2 inhibits its translocation into the CC nucleus to regulate cellular genes important for cell proliferation, CC cell death, and cell migration (PubMed:26598551, PubMed:34404733). Also CC phosphorylates YAP1 in response to cell contact inhibition-driven WWP1 CC ubiquitination of AMOTL2, which results in LATS2 activation CC (PubMed:34404733). Acts as a tumor suppressor which plays a critical CC role in centrosome duplication, maintenance of mitotic fidelity and CC genomic stability (PubMed:10871863). Negatively regulates G1/S CC transition by down-regulating cyclin E/CDK2 kinase activity CC (PubMed:12853976). Negative regulator of the androgen receptor CC (PubMed:15131260). Phosphorylates SNAI1 in the nucleus leading to its CC nuclear retention and stabilization, which enhances its epithelial- CC mesenchymal transition and tumor cell invasion/migration activities CC (PubMed:21952048). This tumor-promoting activity is independent of its CC effects upon YAP1 or WWTR1/TAZ (PubMed:21952048). Acts as an activator CC of the NLRP3 inflammasome by mediating phosphorylation of 'Ser-265' of CC NLRP3 following NLRP3 palmitoylation, promoting NLRP3 activation by CC NEK7 (PubMed:39173637). {ECO:0000269|PubMed:10871863, CC ECO:0000269|PubMed:12853976, ECO:0000269|PubMed:15131260, CC ECO:0000269|PubMed:18158288, ECO:0000269|PubMed:21952048, CC ECO:0000269|PubMed:26437443, ECO:0000269|PubMed:26598551, CC ECO:0000269|PubMed:34404733, ECO:0000269|PubMed:39173637}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10871863, ECO:0000269|PubMed:39173637}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10871863}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- SUBUNIT: Interacts with and is phosphorylated by AURKA. Binds to AR. CC Interacts with AJUBA during mitosis and this complex regulates CC organization of the spindle apparatus through recruitment of gamma- CC tubulin to the centrosome. Interacts (via PPxY motif) with YAP1 (via WW CC domains). Interacts with MOB1A and MOB1B. Interacts with LIMD1, WTIP CC and AJUBA. Interacts with SNAI1. Interacts with WWC1, WWC2 and WWC3 CC (via their WW domains) (PubMed:24682284). Interacts (via UBA domain) CC with ubiquitinated AMOTL2; the interaction promotes LATS2 CC phosphorylation of YAP1 (PubMed:26598551). CC {ECO:0000269|PubMed:15131260, ECO:0000269|PubMed:15147269, CC ECO:0000269|PubMed:16413547, ECO:0000269|PubMed:18158288, CC ECO:0000269|PubMed:19739119, ECO:0000269|PubMed:20303269, CC ECO:0000269|PubMed:21952048, ECO:0000269|PubMed:24682284, CC ECO:0000269|PubMed:26598551}. CC -!- INTERACTION: CC Q9NRM7; Q96IF1: AJUBA; NbExp=7; IntAct=EBI-3506895, EBI-949782; CC Q9NRM7; Q9Y4B6: DCAF1; NbExp=2; IntAct=EBI-3506895, EBI-1996353; CC Q9NRM7; Q13643: FHL3; NbExp=4; IntAct=EBI-3506895, EBI-741101; CC Q9NRM7; Q9H8S9: MOB1A; NbExp=5; IntAct=EBI-3506895, EBI-748229; CC Q9NRM7; Q7L9L4: MOB1B; NbExp=7; IntAct=EBI-3506895, EBI-2558745; CC Q9NRM7; O43255: SIAH2; NbExp=6; IntAct=EBI-3506895, EBI-948141; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing CC center, centrosome. Cytoplasm. Cytoplasm, cytoskeleton, spindle pole. CC Nucleus. Note=Colocalizes with AURKA at the centrosomes during CC interphase, early prophase and cytokinesis. Migrates to the spindle CC poles during mitosis, and to the midbody during cytokinesis. CC Translocates to the nucleus upon mitotic stress by nocodazole CC treatment. CC -!- TISSUE SPECIFICITY: Expressed at high levels in heart and skeletal CC muscle and at lower levels in all other tissues examined. CC {ECO:0000269|PubMed:10673337, ECO:0000269|PubMed:10871863}. CC -!- PTM: Autophosphorylated and phosphorylated during M-phase and the G1/S- CC phase of the cell cycle (PubMed:15147269, PubMed:21952048). CC Phosphorylated and activated by STK3/MST2 (PubMed:15688006). CC Phosphorylated by MAP4Ks; in parallel to STK3/MST2 and resulting to its CC activation (PubMed:26437443). Phosphorylation by NUAK2 may regulate its CC activity in phosphorylation and inactivation YAP1 (PubMed:32845958). CC {ECO:0000269|PubMed:15147269, ECO:0000269|PubMed:15688006, CC ECO:0000269|PubMed:21952048, ECO:0000269|PubMed:26437443, CC ECO:0000269|PubMed:32845958}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA92381.1; Type=Frameshift; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41128/LATS2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF207547; AAF80561.1; -; mRNA. DR EMBL; AK314235; BAG36905.1; -; mRNA. DR EMBL; AL161613; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL356285; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471075; EAX08286.1; -; Genomic_DNA. DR EMBL; AB028019; BAA92381.1; ALT_FRAME; mRNA. DR CCDS; CCDS9294.1; -. DR RefSeq; NP_055387.2; NM_014572.3. DR RefSeq; XP_005266399.1; XM_005266342.1. DR RefSeq; XP_047286222.1; XM_047430266.1. DR PDB; 4ZRI; X-ray; 2.70 A; C/D=68-99. DR PDBsum; 4ZRI; -. DR AlphaFoldDB; Q9NRM7; -. DR SMR; Q9NRM7; -. DR BioGRID; 117727; 297. DR CORUM; Q9NRM7; -. DR DIP; DIP-43883N; -. DR ELM; Q9NRM7; -. DR FunCoup; Q9NRM7; 1955. DR IntAct; Q9NRM7; 94. DR MINT; Q9NRM7; -. DR STRING; 9606.ENSP00000372035; -. DR BindingDB; Q9NRM7; -. DR ChEMBL; CHEMBL5907; -. DR DrugCentral; Q9NRM7; -. DR GuidetoPHARMACOLOGY; 1516; -. DR GlyCosmos; Q9NRM7; 1 site, 1 glycan. DR GlyGen; Q9NRM7; 9 sites, 1 O-linked glycan (8 sites). DR iPTMnet; Q9NRM7; -. DR PhosphoSitePlus; Q9NRM7; -. DR BioMuta; LATS2; -. DR DMDM; 212276441; -. DR jPOST; Q9NRM7; -. DR MassIVE; Q9NRM7; -. DR PaxDb; 9606-ENSP00000372035; -. DR PeptideAtlas; Q9NRM7; -. DR ProteomicsDB; 82392; -. DR Pumba; Q9NRM7; -. DR Antibodypedia; 22361; 321 antibodies from 32 providers. DR DNASU; 26524; -. DR Ensembl; ENST00000382592.5; ENSP00000372035.4; ENSG00000150457.10. DR GeneID; 26524; -. DR KEGG; hsa:26524; -. DR MANE-Select; ENST00000382592.5; ENSP00000372035.4; NM_014572.3; NP_055387.2. DR UCSC; uc001unr.6; human. DR AGR; HGNC:6515; -. DR ClinPGx; PA30302; -. DR CTD; 26524; -. DR DisGeNET; 26524; -. DR GeneCards; LATS2; -. DR HGNC; HGNC:6515; LATS2. DR HPA; ENSG00000150457; Low tissue specificity. DR MalaCards; LATS2; -. DR MIM; 604861; gene. DR OpenTargets; ENSG00000150457; -. DR VEuPathDB; HostDB:ENSG00000150457; -. DR eggNOG; KOG0608; Eukaryota. DR GeneTree; ENSGT00940000159161; -. DR HOGENOM; CLU_004885_1_0_1; -. DR InParanoid; Q9NRM7; -. DR OMA; FNNHQQP; -. DR OrthoDB; 3638488at2759; -. DR PAN-GO; Q9NRM7; 8 GO annotations based on evolutionary models. DR PhylomeDB; Q9NRM7; -. DR PathwayCommons; Q9NRM7; -. DR Reactome; R-HSA-2028269; Signaling by Hippo. DR SignaLink; Q9NRM7; -. DR SIGNOR; Q9NRM7; -. DR Agora; ENSG00000150457; -. DR BioGRID-ORCS; 26524; 32 hits in 1200 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; LATS2; human. DR GeneWiki; LATS2; -. DR GenomeRNAi; 26524; -. DR Pharos; Q9NRM7; Tchem. DR PRO; PR:Q9NRM7; -. DR Proteomes; UP000005640; Chromosome 13. DR RNAct; Q9NRM7; protein. DR Bgee; ENSG00000150457; Expressed in epithelial cell of pancreas and 196 other cell types or tissues. DR ExpressionAtlas; Q9NRM7; baseline and differential. DR GO; GO:0034451; C:centriolar satellite; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:UniProt. DR GO; GO:0005829; C:cytosol; IDA:FlyBase. DR GO; GO:0005634; C:nucleus; IDA:MGI. DR GO; GO:0000922; C:spindle pole; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0060070; P:canonical Wnt signaling pathway; IEA:Ensembl. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IDA:UniProtKB. DR GO; GO:0035329; P:hippo signaling; IDA:BHF-UCL. DR GO; GO:0009755; P:hormone-mediated signaling pathway; IDA:UniProtKB. DR GO; GO:0001827; P:inner cell mass cell fate commitment; IEA:Ensembl. DR GO; GO:0001828; P:inner cell mass cellular morphogenesis; IEA:Ensembl. DR GO; GO:0008104; P:intracellular protein localization; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0030216; P:keratinocyte differentiation; IEA:Ensembl. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:BHF-UCL. DR GO; GO:0060243; P:negative regulation of cell growth involved in contact inhibition; IDA:UniProt. DR GO; GO:0045736; P:negative regulation of cyclin-dependent protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:1900181; P:negative regulation of protein localization to nucleus; ISS:UniProtKB. DR GO; GO:0043065; P:positive regulation of apoptotic process; IBA:GO_Central. DR GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0046620; P:regulation of organ growth; IBA:GO_Central. DR GO; GO:0017015; P:regulation of transforming growth factor beta receptor signaling pathway; ISS:UniProtKB. DR CDD; cd21777; MobB_LATS2; 1. DR CDD; cd05626; STKc_LATS2; 1. DR CDD; cd14398; UBA_LATS2; 1. DR FunFam; 3.30.200.20:FF:001246; Large tumor suppressor kinase 1; 1. DR FunFam; 1.10.510.10:FF:000086; Non-specific serine/threonine protein kinase; 1. DR FunFam; 1.10.510.10:FF:000199; Non-specific serine/threonine protein kinase; 1. DR FunFam; 1.10.8.10:FF:000029; Serine/threonine-protein kinase LATS1 isoform 1; 1. DR Gene3D; 1.10.8.10; DNA helicase RuvA subunit, C-terminal domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 2. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR050236; Ser_Thr_kinase_AGC. DR InterPro; IPR015940; UBA. DR InterPro; IPR009060; UBA-like_sf. DR PANTHER; PTHR24356; SERINE/THREONINE-PROTEIN KINASE; 1. DR PANTHER; PTHR24356:SF149; SERINE_THREONINE-PROTEIN KINASE LATS2; 1. DR Pfam; PF00069; Pkinase; 2. DR Pfam; PF00433; Pkinase_C; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF46934; UBA-like; 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50030; UBA; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Cell cycle; Cell division; Cytoplasm; KW Cytoskeleton; Kinase; Magnesium; Metal-binding; Mitosis; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase; KW Tumor suppressor. FT CHAIN 1..1088 FT /note="Serine/threonine-protein kinase LATS2" FT /id="PRO_0000086234" FT DOMAIN 98..139 FT /note="UBA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00212" FT DOMAIN 668..973 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 974..1052 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT REGION 24..49 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 101..141 FT /note="Interaction with ubiquitinated AMOTL2" FT /evidence="ECO:0000269|PubMed:26598551" FT REGION 271..323 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 383..428 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 454..483 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 543..592 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 994..1022 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1056..1088 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 515..518 FT /note="PPxY motif" FT COMPBIAS 271..280 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 404..413 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 466..478 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 553..572 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 583..592 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 791 FT /note="Proton acceptor" FT /evidence="ECO:0000250|UniProtKB:P22612, FT ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE- FT ProRule:PRU10027" FT BINDING 674..682 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:P22612, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 697 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:10871863" FT MOD_RES 83 FT /note="Phosphoserine; by AURKA" FT /evidence="ECO:0000269|PubMed:15147269" FT MOD_RES 279 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 380 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 576 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1041 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:21952048" FT VARIANT 40 FT /note="G -> E (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040669" FT VARIANT 91 FT /note="S -> L (in dbSNP:rs55842804)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040670" FT VARIANT 324 FT /note="A -> V (in dbSNP:rs558614)" FT /evidence="ECO:0000269|PubMed:10673337" FT /id="VAR_019789" FT VARIANT 363 FT /note="G -> S (in dbSNP:rs2770928)" FT /id="VAR_047077" FT VARIANT 799 FT /note="I -> V (in dbSNP:rs35368391)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040671" FT VARIANT 1014 FT /note="A -> G (in dbSNP:rs45523141)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040672" FT VARIANT 1025 FT /note="L -> P (in dbSNP:rs56116059)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040673" FT MUTAGEN 83 FT /note="S->C: Fails to localize at the centromere during FT interphase." FT /evidence="ECO:0000269|PubMed:15147269" FT MUTAGEN 83 FT /note="S->E: Fails to localize at the centromere during FT interphase." FT /evidence="ECO:0000269|PubMed:15147269" FT MUTAGEN 697 FT /note="K->A: Loss of kinase activity, autophosphorylation FT and tumor suppressor activity." FT /evidence="ECO:0000269|PubMed:10871863, FT ECO:0000269|PubMed:12853976" FT MUTAGEN 872 FT /note="S->A: Loss of tumor suppressor activity." FT /evidence="ECO:0000269|PubMed:12853976" FT CONFLICT 59..61 FT /note="RQQ -> SSK (in Ref. 5; BAA92381)" FT /evidence="ECO:0000305" FT CONFLICT 436 FT /note="T -> S (in Ref. 5; BAA92381)" FT /evidence="ECO:0000305" FT CONFLICT 711 FT /note="A -> V (in Ref. 1; AAF80561)" FT /evidence="ECO:0000305" FT CONFLICT 868 FT /note="C -> S (in Ref. 5; BAA92381)" FT /evidence="ECO:0000305" FT HELIX 74..84 FT /evidence="ECO:0007829|PDB:4ZRI" FT HELIX 85..87 FT /evidence="ECO:0007829|PDB:4ZRI" SQ SEQUENCE 1088 AA; 120136 MW; 2866F6B75637AD36 CRC64; MRPKTFPATT YSGNSRQRLQ EIREGLKQPS KSSVQGLPAG PNSDTSLDAK VLGSKDATRQ QQQMRATPKF GPYQKALREI RYSLLPFANE SGTSAAAEVN RQMLQELVNA GCDQEMAGRA LKQTGSRSIE AALEYISKMG YLDPRNEQIV RVIKQTSPGK GLMPTPVTRR PSFEGTGDSF ASYHQLSGTP YEGPSFGADG PTALEEMPRP YVDYLFPGVG PHGPGHQHQH PPKGYGASVE AAGAHFPLQG AHYGRPHLLV PGEPLGYGVQ RSPSFQSKTP PETGGYASLP TKGQGGPPGA GLAFPPPAAG LYVPHPHHKQ AGPAAHQLHV LGSRSQVFAS DSPPQSLLTP SRNSLNVDLY ELGSTSVQQW PAATLARRDS LQKPGLEAPP RAHVAFRPDC PVPSRTNSFN SHQPRPGPPG KAEPSLPAPN TVTAVTAAHI LHPVKSVRVL RPEPQTAVGP SHPAWVPAPA PAPAPAPAPA AEGLDAKEEH ALALGGAGAF PLDVEYGGPD RRCPPPPYPK HLLLRSKSEQ YDLDSLCAGM EQSLRAGPNE PEGGDKSRKS AKGDKGGKDK KQIQTSPVPV RKNSRDEEKR ESRIKSYSPY AFKFFMEQHV ENVIKTYQQK VNRRLQLEQE MAKAGLCEAE QEQMRKILYQ KESNYNRLKR AKMDKSMFVK IKTLGIGAFG EVCLACKVDT HALYAMKTLR KKDVLNRNQV AHVKAERDIL AEADNEWVVK LYYSFQDKDS LYFVMDYIPG GDMMSLLIRM EVFPEHLARF YIAELTLAIE SVHKMGFIHR DIKPDNILID LDGHIKLTDF GLCTGFRWTH NSKYYQKGSH VRQDSMEPSD LWDDVSNCRC GDRLKTLEQR ARKQHQRCLA HSLVGTPNYI APEVLLRKGY TQLCDWWSVG VILFEMLVGQ PPFLAPTPTE TQLKVINWEN TLHIPAQVKL SPEARDLITK LCCSADHRLG RNGADDLKAH PFFSAIDFSS DIRKQPAPYV PTISHPMDTS NFDPVDEESP WNDASEGSTK AWDTLTSPNN KHPEHAFYEF TFRRFFDDNG YPFRCPKPSG AEASQAESSD LESSDLVDQT EGCQPVYV // ID LMTK1_HUMAN Reviewed; 1374 AA. AC Q6ZMQ8; O75136; Q6ZN31; Q86X28; DT 05-SEP-2006, integrated into UniProtKB/Swiss-Prot. DT 05-SEP-2006, sequence version 2. DT 28-JAN-2026, entry version 168. DE RecName: Full=Serine/threonine-protein kinase LMTK1; DE EC=2.7.11.1; DE AltName: Full=Apoptosis-associated tyrosine kinase; DE Short=AATYK; DE AltName: Full=Brain apoptosis-associated tyrosine kinase; DE AltName: Full=CDK5-binding protein; DE AltName: Full=Lemur tyrosine kinase 1; DE AltName: Full=p35-binding protein; DE Short=p35BP; GN Name=AATK; Synonyms=AATYK, KIAA0641, LMR1, LMTK1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3), AND VARIANT RP CYS-703. RC TISSUE=Cerebellum, and Thalamus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 49-1374 (ISOFORM 1), AND VARIANT RP CYS-703. RC TISSUE=Brain; RX PubMed=9734811; DOI=10.1093/dnares/5.3.169; RA Ishikawa K., Nagase T., Suyama M., Miyajima N., Tanaka A., Kotani H., RA Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. X. The RT complete sequences of 100 new cDNA clones from brain which can code for RT large proteins in vitro."; RL DNA Res. 5:169-176(1998). RN [3] RP SEQUENCE REVISION. RX PubMed=12168954; DOI=10.1093/dnares/9.3.99; RA Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.; RT "Construction of expression-ready cDNA clones for KIAA genes: manual RT curation of 330 KIAA cDNA clones."; RL DNA Res. 9:99-106(2002). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 786-1374 (ISOFORM 1), AND VARIANT RP SER-1266. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP ALTERNATIVE SPLICING (ISOFORM 2), INTERACTION WITH CDK5, AND RP PHOSPHORYLATION. RX PubMed=14521924; DOI=10.1016/j.bbrc.2003.08.143; RA Honma N., Asada A., Takeshita S., Enomoto M., Yamakawa E., Tsutsumi K., RA Saito T., Satoh T., Itoh H., Kaziro Y., Kishimoto T., Hisanaga S.; RT "Apoptosis-associated tyrosine kinase is a Cdk5 activator p35 binding RT protein."; RL Biochem. Biophys. Res. Commun. 310:398-404(2003). RN [6] RP TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=10837911; DOI=10.1016/s0169-328x(00)00048-6; RA Raghunath M., Patti R., Bannerman P., Lee C.M., Baker S., Sutton L.N., RA Phillips P.C., Damodar Reddy C.; RT "A novel kinase, AATYK induces and promotes neuronal differentiation in a RT human neuroblastoma (SH-SY5Y) cell line."; RL Brain Res. Mol. Brain Res. 77:151-162(2000). RN [7] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-495 AND SER-1262, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [8] RP VARIANTS PHE-81; VAL-97; VAL-104; CYS-703; ARG-815; LEU-923; LYS-1160; RP SER-1192; SER-1266 AND THR-1332. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: May be involved in neuronal differentiation. CC {ECO:0000269|PubMed:10837911}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- SUBUNIT: Interacts with CDK5. {ECO:0000269|PubMed:14521924}. CC -!- INTERACTION: CC Q6ZMQ8; P62136: PPP1CA; NbExp=3; IntAct=EBI-2008380, EBI-357253; CC Q6ZMQ8; P36873: PPP1CC; NbExp=3; IntAct=EBI-2008380, EBI-356283; CC Q6ZMQ8; Q96N21: TEPSIN; NbExp=3; IntAct=EBI-2008380, EBI-11139477; CC Q6ZMQ8-1; Q15078: CDK5R1; NbExp=2; IntAct=EBI-2008436, EBI-746189; CC Q6ZMQ8-2; Q15078: CDK5R1; NbExp=6; IntAct=EBI-2008441, EBI-746189; CC -!- SUBCELLULAR LOCATION: Membrane {ECO:0000250}; Single-pass type I CC membrane protein {ECO:0000250}. Cytoplasm CC {ECO:0000269|PubMed:10837911}. Cytoplasm, perinuclear region CC {ECO:0000269|PubMed:10837911}. Note=Predominantly perinuclear. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q6ZMQ8-1; Sequence=Displayed; CC Name=2; Synonyms=hAATYKs-p35BP; CC IsoId=Q6ZMQ8-2; Sequence=VSP_020225, VSP_020226, VSP_020227, CC VSP_020228; CC Name=3; CC IsoId=Q6ZMQ8-3; Sequence=VSP_020226, VSP_020227, VSP_020228; CC -!- TISSUE SPECIFICITY: Expressed in brain. {ECO:0000269|PubMed:10837911}. CC -!- INDUCTION: Up-regulated during apoptosis. CC -!- PTM: Autophosphorylated. Phosphorylated by CDK5. CC {ECO:0000269|PubMed:14521924}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK131395; BAD18544.1; -; mRNA. DR EMBL; AK131529; BAD18667.1; -; mRNA. DR EMBL; AB014541; BAA31616.2; -; mRNA. DR EMBL; BC047378; AAH47378.1; -; mRNA. DR CCDS; CCDS45807.1; -. [Q6ZMQ8-1] DR RefSeq; NP_001073864.2; NM_001080395.3. [Q6ZMQ8-1] DR RefSeq; NP_004911.2; NM_004920.2. DR AlphaFoldDB; Q6ZMQ8; -. DR SMR; Q6ZMQ8; -. DR BioGRID; 114984; 194. DR FunCoup; Q6ZMQ8; 75. DR IntAct; Q6ZMQ8; 190. DR MINT; Q6ZMQ8; -. DR STRING; 9606.ENSP00000324196; -. DR TCDB; 8.A.23.1.35; the basigin (basigin) family. DR GlyGen; Q6ZMQ8; 4 sites. DR iPTMnet; Q6ZMQ8; -. DR PhosphoSitePlus; Q6ZMQ8; -. DR SwissPalm; Q6ZMQ8; -. DR BioMuta; AATK; -. DR DMDM; 114149222; -. DR jPOST; Q6ZMQ8; -. DR MassIVE; Q6ZMQ8; -. DR PaxDb; 9606-ENSP00000324196; -. DR PeptideAtlas; Q6ZMQ8; -. DR ProteomicsDB; 67901; -. [Q6ZMQ8-1] DR ProteomicsDB; 67902; -. [Q6ZMQ8-2] DR ProteomicsDB; 67903; -. [Q6ZMQ8-3] DR Antibodypedia; 2104; 203 antibodies from 28 providers. DR DNASU; 9625; -. DR Ensembl; ENST00000326724.9; ENSP00000324196.4; ENSG00000181409.15. [Q6ZMQ8-1] DR Ensembl; ENST00000374792.6; ENSP00000363924.2; ENSG00000181409.15. [Q6ZMQ8-3] DR GeneID; 9625; -. DR KEGG; hsa:9625; -. DR MANE-Select; ENST00000326724.9; ENSP00000324196.4; NM_001080395.3; NP_001073864.2. DR UCSC; uc010dia.4; human. [Q6ZMQ8-1] DR AGR; HGNC:21; -. DR ClinPGx; PA24370; -. DR CTD; 9625; -. DR DisGeNET; 9625; -. DR GeneCards; AATK; -. DR HGNC; HGNC:21; AATK. DR HPA; ENSG00000181409; Tissue enhanced (brain, intestine). DR MIM; 605276; gene. DR OpenTargets; ENSG00000181409; -. DR VEuPathDB; HostDB:ENSG00000181409; -. DR eggNOG; ENOG502RCHK; Eukaryota. DR GeneTree; ENSGT00940000154244; -. DR HOGENOM; CLU_004618_1_0_1; -. DR InParanoid; Q6ZMQ8; -. DR OMA; WEPPDYY; -. DR PAN-GO; Q6ZMQ8; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q6ZMQ8; -. DR PathwayCommons; Q6ZMQ8; -. DR SignaLink; Q6ZMQ8; -. DR SIGNOR; Q6ZMQ8; -. DR Agora; ENSG00000181409; -. DR BioGRID-ORCS; 9625; 23 hits in 1182 CRISPR screens. DR GeneWiki; AATK; -. DR GenomeRNAi; 9625; -. DR Pharos; Q6ZMQ8; Tbio. DR PRO; PR:Q6ZMQ8; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q6ZMQ8; protein. DR Bgee; ENSG00000181409; Expressed in sural nerve and 183 other cell types or tissues. DR ExpressionAtlas; Q6ZMQ8; baseline and differential. DR GO; GO:0012505; C:endomembrane system; IEA:UniProtKB-ARBA. DR GO; GO:0016020; C:membrane; IEA:UniProtKB-SubCell. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0004713; F:protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0007420; P:brain development; IBA:GO_Central. DR GO; GO:0051402; P:neuron apoptotic process; IBA:GO_Central. DR CDD; cd05087; PTKc_Aatyk1; 1. DR FunFam; 1.10.510.10:FF:000347; Apoptosis associated tyrosine kinase; 1. DR FunFam; 3.30.200.20:FF:000275; Apoptosis associated tyrosine kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR042817; LMTK1_c. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR PANTHER; PTHR24417; SERINE/THREONINE-PROTEIN KINASE LMTK1; 1. DR PANTHER; PTHR24417:SF0; SERINE_THREONINE-PROTEIN KINASE LMTK1; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR00109; TYRKINASE. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cytoplasm; Kinase; Membrane; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase; KW Transmembrane; Transmembrane helix. FT CHAIN 1..1374 FT /note="Serine/threonine-protein kinase LMTK1" FT /id="PRO_0000248300" FT TRANSMEM 32..52 FT /note="Helical" FT /evidence="ECO:0000255" FT DOMAIN 125..395 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 542..622 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 667..731 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 765..1195 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1245..1302 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1320..1374 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 606..620 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 680..690 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 719..731 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 801..831 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 847..856 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 865..878 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 900..914 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 978..987 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1063..1073 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1138..1155 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1158..1173 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1272..1291 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1321..1332 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1337..1352 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1353..1363 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1365..1374 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 253 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 131..139 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 156 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 495 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1029 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80YE4" FT MOD_RES 1168 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80YE4" FT MOD_RES 1171 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80YE4" FT MOD_RES 1184 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80YE4" FT MOD_RES 1187 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80YE4" FT MOD_RES 1262 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..433 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_020225" FT VAR_SEQ 468..503 FT /note="Missing (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_020226" FT VAR_SEQ 897..915 FT /note="VGTPDSLDSLDIPSSASDG -> WPQREESLPRLCLLLRPRG (in FT isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_020227" FT VAR_SEQ 916..1374 FT /note="Missing (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_020228" FT VARIANT 81 FT /note="S -> F (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs2060924369)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032679" FT VARIANT 97 FT /note="L -> V (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032680" FT VARIANT 104 FT /note="M -> V (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs1337040042)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032681" FT VARIANT 118 FT /note="T -> M (in dbSNP:rs8082016)" FT /id="VAR_027267" FT VARIANT 703 FT /note="G -> C (in dbSNP:rs7503604)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9734811" FT /id="VAR_032682" FT VARIANT 815 FT /note="S -> R (in dbSNP:rs56032966)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032683" FT VARIANT 923 FT /note="S -> L (in dbSNP:rs56313973)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032684" FT VARIANT 1160 FT /note="E -> K (in dbSNP:rs55793641)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032685" FT VARIANT 1192 FT /note="P -> S (in dbSNP:rs55856613)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032686" FT VARIANT 1266 FT /note="F -> S (in dbSNP:rs36000545)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:17344846" FT /id="VAR_032687" FT VARIANT 1332 FT /note="A -> T (in dbSNP:rs55713566)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_032688" FT CONFLICT 49..63 FT /note="MLACLCCKKGGIGFK -> HQVKVQGCWGRWRWQ (in Ref. 2)" FT /evidence="ECO:0000305" FT CONFLICT 511 FT /note="A -> T (in Ref. 1; BAD18667)" FT /evidence="ECO:0000305" FT CONFLICT 541 FT /note="A -> T (in Ref. 1; BAD18544)" FT /evidence="ECO:0000305" FT CONFLICT 557 FT /note="T -> I (in Ref. 1; BAD18544)" FT /evidence="ECO:0000305" FT CONFLICT 786 FT /note="A -> V (in Ref. 4; AAH47378)" FT /evidence="ECO:0000305" FT CONFLICT 790 FT /note="T -> A (in Ref. 1; BAD18667)" FT /evidence="ECO:0000305" FT CONFLICT 1028 FT /note="P -> R (in Ref. 4; AAH47378)" FT /evidence="ECO:0000305" FT CONFLICT 1271 FT /note="P -> H (in Ref. 4; AAH47378)" FT /evidence="ECO:0000305" FT CONFLICT 1324 FT /note="P -> R (in Ref. 4; AAH47378)" FT /evidence="ECO:0000305" FT CONFLICT 1360 FT /note="K -> E (in Ref. 4; AAH47378)" FT /evidence="ECO:0000305" SQ SEQUENCE 1374 AA; 144569 MW; AD46BD688AF7103E CRC64; MSSSFFNPSF AFSSHFDPDG APLSELSWPS SLAVVAVSFS GLFAVIVLML ACLCCKKGGI GFKEFENAEG DEYAADLAQG SPATAAQNGP DVYVLPLTEV SLPMAKQPGR SVQLLKSTDV GRHSLLYLKE IGRGWFGKVF LGEVNSGISS AQVVVKELQA SASVQEQMQF LEEVQPYRAL KHSNLLQCLA QCAEVTPYLL VMEFCPLGDL KGYLRSCRVA ESMAPDPRTL QRMACEVACG VLHLHRNNFV HSDLALRNCL LTADLTVKIG DYGLAHCKYR EDYFVTADQL WVPLRWIAPE LVDEVHSNLL VVDQTKSGNV WSLGVTIWEL FELGTQPYPQ HSDQQVLAYT VREQQLKLPK PQLQLTLSDR WYEVMQFCWL QPEQRPTAEE VHLLLSYLCA KGATEAEEEF ERRWRSLRPG GGGVGPGPGA AGPMLGGVVE LAAASSFPLL EQFAGDGFHA DGDDVLTVTE TSRGLNFEYK WEAGRGAEAF PATLSPGRTA RLQELCAPDG APPGVVPVLS AHSPSLGSEY FIRLEEAAPA AGHDPDCAGC APSPPATADQ DDDSDGSTAA SLAMEPLLGH GPPVDVPWGR GDHYPRRSLA RDPLCPSRSP SPSAGPLSLA EGGAEDADWG VAAFCPAFFE DPLGTSPLGS SGAPPLPLTG EDELEEVGAR RAAQRGHWRS NVSANNNSGS RCPESWDPVS AGGHAEGCPS PKQTPRASPE PGYPGEPLLG LQAASAQEPG CCPGLPHLCS AQGLAPAPCL VTPSWTETAS SGGDHPQAEP KLATEAEGTT GPRLPLPSVP SPSQEGAPLP SEEASAPDAP DALPDSPTPA TGGEVSAIKL ASALNGSSSS PEVEAPSSED EDTAEATSGI FTDTSSDGLQ ARRPDVVPAF RSLQKQVGTP DSLDSLDIPS SASDGGYEVF SPSATGPSGG QPRALDSGYD TENYESPEFV LKEAQEGCEP QAFAELASEG EGPGPETRLS TSLSGLNEKN PYRDSAYFSD LEAEAEATSG PEKKCGGDRA PGPELGLPST GQPSEQVCLR PGVSGEAQGS GPGEVLPPLL QLEGSSPEPS TCPSGLVPEP PEPQGPAKVR PGPSPSCSQF FLLTPVPLRS EGNSSEFQGP PGLLSGPAPQ KRMGGPGTPR APLRLALPGL PAALEGRPEE EEEDSEDSDE SDEELRCYSV QEPSEDSEEE APAVPVVVAE SQSARNLRSL LKMPSLLSET FCEDLERKKK AVSFFDDVTV YLFDQESPTR ELGEPFPGAK ESPPTFLRGS PGSPSAPNRP QQADGSPNGS TAEEGGGFAW DDDFPLMTAK AAFAMALDPA APAPAAPTPT PAPFSRFTVS PAPTSRFSIT HVSDSDAESK RGPEAGAGGE SKEA // ID M3K15_HUMAN Reviewed; 1313 AA. AC Q6ZN16; A2AI49; A2AI50; A6NJ61; Q5JPR4; Q6ZMV3; DT 17-OCT-2006, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 2. DT 28-JAN-2026, entry version 168. DE RecName: Full=Mitogen-activated protein kinase kinase kinase 15; DE EC=2.7.11.25 {ECO:0000269|PubMed:20362554, ECO:0000269|PubMed:26732173}; DE AltName: Full=Apoptosis signal-regulating kinase 3; DE AltName: Full=MAPK/ERK kinase kinase 15; DE Short=MEK kinase 15; DE Short=MEKK 15; GN Name=MAP3K15; Synonyms=ASK3; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3). RC TISSUE=Teratocarcinoma, and Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15772651; DOI=10.1038/nature03440; RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., RA Rogers J., Bentley D.R.; RT "The DNA sequence of the human X chromosome."; RL Nature 434:325-337(2005). RN [3] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [4] RP FUNCTION, CATALYTIC ACTIVITY, AND TISSUE SPECIFICITY. RX PubMed=20362554; DOI=10.1016/j.bbrc.2010.03.164; RA Kaji T., Yoshida S., Kawai K., Fuchigami Y., Watanabe W., Kubodera H., RA Kishimoto T.; RT "ASK3, a novel member of the apoptosis signal-regulating kinase family, is RT essential for stress-induced cell death in HeLa cells."; RL Biochem. Biophys. Res. Commun. 395:213-218(2010). RN [5] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-994, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [6] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-681. RX PubMed=26732173; DOI=10.1038/srep18710; RA Maruyama J., Kobayashi Y., Umeda T., Vandewalle A., Takeda K., Ichijo H., RA Naguro I.; RT "Osmotic stress induces the phosphorylation of WNK4 Ser575 via the p38MAPK- RT MK pathway."; RL Sci. Rep. 6:18710-18710(2016). RN [7] RP VARIANTS [LARGE SCALE ANALYSIS] THR-192; ASN-199; HIS-226; SER-255; RP GLY-456; CYS-494; LEU-562; GLN-677; SER-838; LEU-993; HIS-1029; ARG-1247 RP AND GLU-1251. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine kinase which acts as a component of the MAP CC kinase signal transduction pathway (PubMed:20362554, PubMed:26732173). CC Once activated, acts as an upstream activator of the p38 MAPK signal CC transduction cascade through the phosphorylation and activation of CC several MAP kinase kinases (PubMed:20362554, PubMed:26732173). May CC function in a signal transduction pathway that is activated by various CC cell stresses and leads to apoptosis (PubMed:20362554). Involved in CC phosphorylation of WNK4 in response to osmotic stress or hypotonic low- CC chloride stimulation via the p38 MAPK signal transduction cascade CC (PubMed:26732173). {ECO:0000269|PubMed:20362554, CC ECO:0000269|PubMed:26732173}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.25; CC Evidence={ECO:0000269|PubMed:20362554, ECO:0000269|PubMed:26732173}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.25; CC Evidence={ECO:0000269|PubMed:20362554}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000250|UniProtKB:Q99683}; CC -!- ACTIVITY REGULATION: Contains an N-terminal autoinhibitory domain. CC Activated by phosphorylation at Thr-812, inhibited by phosphorylation CC at Ser-924 and Ser-994 (By similarity). {ECO:0000250|UniProtKB:Q99683}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q6ZN16-1; Sequence=Displayed; CC Name=2; CC IsoId=Q6ZN16-2; Sequence=VSP_021038; CC Name=3; CC IsoId=Q6ZN16-3; Sequence=VSP_021039, VSP_021040; CC -!- TISSUE SPECIFICITY: Isoform 2 and isoform 3 are widely expressed. CC Isoform 2 highest levels are observed in fetal brain, and isoform 3 CC highest levels in pancreas, peripheral blood leukocytes, fetal brain CC and spleen. {ECO:0000269|PubMed:20362554}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr CC protein kinase family. MAP kinase kinase kinase subfamily. CC {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK131412; BAD18559.1; -; mRNA. DR EMBL; AK131477; BAD18622.1; -; mRNA. DR EMBL; AL732326; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL732423; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS35212.2; -. [Q6ZN16-1] DR RefSeq; NP_001001671.3; NM_001001671.4. [Q6ZN16-1] DR RefSeq; XP_011543813.1; XM_011545511.2. [Q6ZN16-2] DR RefSeq; XP_054183016.1; XM_054327041.1. [Q6ZN16-2] DR PDB; 6V0M; X-ray; 1.80 A; A/B/C=1241-1308. DR PDBsum; 6V0M; -. DR AlphaFoldDB; Q6ZN16; -. DR SMR; Q6ZN16; -. DR BioGRID; 133293; 23. DR FunCoup; Q6ZN16; 177. DR IntAct; Q6ZN16; 9. DR STRING; 9606.ENSP00000345629; -. DR BindingDB; Q6ZN16; -. DR ChEMBL; CHEMBL1163127; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q6ZN16; -. DR GlyGen; Q6ZN16; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q6ZN16; -. DR PhosphoSitePlus; Q6ZN16; -. DR BioMuta; MAP3K15; -. DR DMDM; 116248533; -. DR CPTAC; CPTAC-841; -. DR CPTAC; CPTAC-842; -. DR jPOST; Q6ZN16; -. DR MassIVE; Q6ZN16; -. DR PaxDb; 9606-ENSP00000345629; -. DR PeptideAtlas; Q6ZN16; -. DR ProteomicsDB; 67956; -. [Q6ZN16-1] DR ProteomicsDB; 67957; -. [Q6ZN16-2] DR ProteomicsDB; 67958; -. [Q6ZN16-3] DR Antibodypedia; 571; 146 antibodies from 26 providers. DR DNASU; 389840; -. DR Ensembl; ENST00000338883.9; ENSP00000345629.4; ENSG00000180815.16. [Q6ZN16-1] DR GeneID; 389840; -. DR KEGG; hsa:389840; -. DR MANE-Select; ENST00000338883.9; ENSP00000345629.4; NM_001001671.4; NP_001001671.3. DR UCSC; uc004czj.3; human. [Q6ZN16-1] DR AGR; HGNC:31689; -. DR ClinPGx; PA134935369; -. DR CTD; 389840; -. DR DisGeNET; 389840; -. DR GeneCards; MAP3K15; -. DR HGNC; HGNC:31689; MAP3K15. DR HPA; ENSG00000180815; Group enriched (adrenal gland, choroid plexus). DR MalaCards; MAP3K15; -. DR MIM; 300820; gene. DR OpenTargets; ENSG00000180815; -. DR VEuPathDB; HostDB:ENSG00000180815; -. DR eggNOG; KOG4279; Eukaryota. DR GeneTree; ENSGT00940000159562; -. DR HOGENOM; CLU_048342_0_0_1; -. DR InParanoid; Q6ZN16; -. DR OMA; CLCGRIC; -. DR OrthoDB; 275301at2759; -. DR PAN-GO; Q6ZN16; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q6ZN16; -. DR PathwayCommons; Q6ZN16; -. DR SignaLink; Q6ZN16; -. DR Agora; ENSG00000180815; -. DR BioGRID-ORCS; 389840; 3 hits in 297 CRISPR screens. DR CD-CODE; FBBE2A73; Synthetic Condensate 000275. DR ChiTaRS; MAP3K15; human. DR GenomeRNAi; 389840; -. DR Pharos; Q6ZN16; Tchem. DR PRO; PR:Q6ZN16; -. DR Proteomes; UP000005640; Chromosome X. DR RNAct; Q6ZN16; protein. DR Bgee; ENSG00000180815; Expressed in adrenal tissue and 80 other cell types or tissues. DR ExpressionAtlas; Q6ZN16; baseline and differential. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004709; F:MAP kinase kinase kinase activity; IDA:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0007254; P:JNK cascade; IBA:GO_Central. DR GO; GO:0038066; P:p38MAPK cascade; IBA:GO_Central. DR CDD; cd06624; STKc_ASK; 1. DR FunFam; 1.10.510.10:FF:000054; Mitogen-activated protein kinase kinase kinase 5; 1. DR FunFam; 3.30.200.20:FF:000067; Mitogen-activated protein kinase kinase kinase 5; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR046872; DRHyd-ASK. DR InterPro; IPR046873; HisK-N-like. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR043969; MAP3K_PH. DR InterPro; IPR025136; MAP3K_TRAF-bd. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR11584:SF363; MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 15; 1. DR PANTHER; PTHR11584; SERINE/THREONINE PROTEIN KINASE; 1. DR Pfam; PF19039; ASK_PH; 1. DR Pfam; PF20309; DRHyd-ASK; 1. DR Pfam; PF20302; HisK-N-like; 1. DR Pfam; PF13281; MAP3K_TRAF_bd; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Coiled coil; Kinase; KW Magnesium; Metal-binding; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..1313 FT /note="Mitogen-activated protein kinase kinase kinase 15" FT /id="PRO_0000253481" FT DOMAIN 652..908 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..58 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 939..958 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 1179..1225 FT /evidence="ECO:0000255" FT COMPBIAS 28..43 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 44..57 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 942..955 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 773 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 658..666 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 681 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 994 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..565 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_021038" FT VAR_SEQ 1..525 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_021039" FT VAR_SEQ 526..582 FT /note="GLRFPVLVIEPTKVYQPSYVSINNEAEERTVSLWHVSPTEMKQMHEWNFTAS FT SIKGI -> MACLTHRNETDARMEFYSLFHKGNKAGVQWHDLGSLQPLPPRFKRFSCLS FT LQSSWDY (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_021040" FT VARIANT 192 FT /note="A -> T (in dbSNP:rs5909299)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040716" FT VARIANT 199 FT /note="S -> N (in dbSNP:rs55916006)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040717" FT VARIANT 226 FT /note="D -> H (in dbSNP:rs56338727)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040718" FT VARIANT 255 FT /note="R -> S (in a lung squamous cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040719" FT VARIANT 456 FT /note="S -> G (in dbSNP:rs56212339)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040720" FT VARIANT 494 FT /note="R -> C (in dbSNP:rs41305349)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040721" FT VARIANT 562 FT /note="S -> L (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs2063704764)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040722" FT VARIANT 677 FT /note="R -> Q (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040723" FT VARIANT 838 FT /note="G -> S (in dbSNP:rs56381411)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040724" FT VARIANT 993 FT /note="S -> L (in dbSNP:rs56233219)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040725" FT VARIANT 1029 FT /note="N -> H (in dbSNP:rs55787622)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040726" FT VARIANT 1247 FT /note="W -> R (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs2063287881)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040727" FT VARIANT 1251 FT /note="Q -> E (in dbSNP:rs15943)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040728" FT MUTAGEN 681 FT /note="K->M: Abolished protein kinase activity." FT /evidence="ECO:0000269|PubMed:26732173" FT CONFLICT 793 FT /note="F -> L (in Ref. 1; BAD18622)" FT /evidence="ECO:0000305" FT HELIX 1241..1250 FT /evidence="ECO:0007829|PDB:6V0M" FT HELIX 1255..1263 FT /evidence="ECO:0007829|PDB:6V0M" FT HELIX 1268..1273 FT /evidence="ECO:0007829|PDB:6V0M" FT HELIX 1277..1282 FT /evidence="ECO:0007829|PDB:6V0M" FT HELIX 1287..1307 FT /evidence="ECO:0007829|PDB:6V0M" SQ SEQUENCE 1313 AA; 147437 MW; 60751706D6AEE3E9 CRC64; MESGGGNAPA GALGAASESP QCPPPPGVEG AAGPAEPDGA AEGAAGGSGE GESGGGPRRA LRAVYVRSES SQGGAAGGPE AGARQCLLRA CEAEGAHLTS VPFGELDFGE TAVLDAFYDA DVAVVDMSDV SRQPSLFYHL GVRESFDMAN NVILYHDTDA DTALSLKDMV TQKNTASSGN YYFIPYIVTP CADYFCCESD AQRRASEYMQ PNWDNILGPL CMPLVDRFIS LLKDIHVTSC VYYKETLLND IRKAREKYQG EELAKELARI KLRMDNTEVL TSDIIINLLL SYRDIQDYDA MVKLVETLEM LPTCDLADQH NIKFHYAFAL NRRNSTGDRE KALQIMLQVL QSCDHPGPDM FCLCGRIYKD IFLDSDCKDD TSRDSAIEWY RKGFELQSSL YSGINLAVLL IVAGQQFETS LELRKIGVRL NSLLGRKGSL EKMNNYWDVG QFFSVSMLAH DVGKAVQAAE RLFKLKPPVW YLRSLVQNLL LIRRFKKTII EHSPRQERLN FWLDIIFEAT NEVTNGLRFP VLVIEPTKVY QPSYVSINNE AEERTVSLWH VSPTEMKQMH EWNFTASSIK GISLSKFDER CCFLYVHDNS DDFQIYFSTE EQCSRFFSLV KEMITNTAGS TVELEGETDG DTLEYEYDHD ANGERVVLGK GTYGIVYAGR DLSNQVRIAI KEIPERDSRY SQPLHEEIAL HKYLKHRNIV QYLGSVSENG YIKIFMEQVP GGSLSALLRS KWGPMKEPTI KFYTKQILEG LKYLHENQIV HRDIKGDNVL VNTYSGVVKI SDFGTSKRLA GVNPCTETFT GTLQYMAPEI IDQGPRGYGA PADIWSLGCT IIEMATSKPP FHELGEPQAA MFKVGMFKIH PEIPEALSAE ARAFILSCFE PDPHKRATTA ELLREGFLRQ VNKGKKNRIA FKPSEGPRGV VLALPTQGEP MATSSSEHGS VSPDSDAQPD ALFERTRAPR HHLGHLLSVP DESSALEDRG LASSPEDRDQ GLFLLRKDSE RRAILYKILW EEQNQVASNL QECVAQSSEE LHLSVGHIKQ IIGILRDFIR SPEHRVMATT ISKLKVDLDF DSSSISQIHL VLFGFQDAVN KILRNHLIRP HWMFAMDNII RRAVQAAVTI LIPELRAHFE PTCETEGVDK DMDEAEEGYP PATGPGQEAQ PHQQHLSLQL GELRQETNRL LEHLVEKERE YQNLLRQTLE QKTQELYHLQ LKLKSNCITE NPAGPYGQRT DKELIDWLRL QGADAKTIEK IVEEGYTLSD ILNEITKEDL RYLRLRGGLL CRLWSAVSQY RRAQEASETK DKA // ID M3KCL_HUMAN Reviewed; 142 AA. AC P57077; D3DSE0; Q8TCL9; DT 01-DEC-2000, integrated into UniProtKB/Swiss-Prot. DT 07-OCT-2020, sequence version 2. DT 28-JAN-2026, entry version 170. DE RecName: Full=MAP3K7 C-terminal-like protein; DE AltName: Full=TAK1-like protein; GN Name=MAP3K7CL; Synonyms=C21orf7, TAK1L; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE (ISOFORMS 1 AND 2). RA Solans A., Domenech A., Estivill X., de la Luna S.; RT "Cloning and characterization of a new gene, C21orf7, similar to the TAB2- RT binding region of TAK1."; RL Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE (ISOFORM 1). RX PubMed=11707072; DOI=10.1006/geno.2001.6640; RA Reymond A., Friedli M., Neergaard Henrichsen C., Chapot F., Deutsch S., RA Ucla C., Rossier C., Lyle R., Guipponi M., Antonarakis S.E.; RT "From PREDs and open reading frames to cDNA isolation: revisiting the human RT chromosome 21 transcription map."; RL Genomics 78:46-54(2001). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND TISSUE SPECIFICITY. RC TISSUE=Fetal brain; RX PubMed=15168726; DOI=10.1023/b:bigi.0000020468.96238.54; RA Li J., Ji C., Yang Q., Chen J., Gu S., Ying K., Xie Y., Mao Y.; RT "Cloning and characterization of a novel human TGF-beta activated kinase- RT like gene."; RL Biochem. Genet. 42:129-137(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=10830953; DOI=10.1038/35012518; RA Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T., Park H.-S., RA Toyoda A., Ishii K., Totoki Y., Choi D.-K., Groner Y., Soeda E., Ohki M., RA Takagi T., Sakaki Y., Taudien S., Blechschmidt K., Polley A., Menzel U., RA Delabar J., Kumpf K., Lehmann R., Patterson D., Reichwald K., Rump A., RA Schillhabel M., Schudy A., Zimmermann W., Rosenthal A., Kudoh J., RA Shibuya K., Kawasaki K., Asakawa S., Shintani A., Sasaki T., Nagamine K., RA Mitsuyama S., Antonarakis S.E., Minoshima S., Shimizu N., Nordsiek G., RA Hornischer K., Brandt P., Scharfe M., Schoen O., Desario A., Reichelt J., RA Kauer G., Bloecker H., Ramser J., Beck A., Klages S., Hennig S., RA Riesselmann L., Dagand E., Wehrmeyer S., Borzym K., Gardiner K., RA Nizetic D., Francis F., Lehrach H., Reinhardt R., Yaspo M.-L.; RT "The DNA sequence of human chromosome 21."; RL Nature 405:311-319(2000). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S). RX PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8; RA Hillman R.T., Green R.E., Brenner S.E.; RT "An unappreciated role for RNA surveillance."; RL Genome Biol. 5:R8.1-R8.16(2004). CC -!- INTERACTION: CC P57077; Q13227: GPS2; NbExp=2; IntAct=EBI-748831, EBI-713355; CC P57077-4; Q96MA6: AK8; NbExp=6; IntAct=EBI-10215880, EBI-8466265; CC P57077-4; Q96D03: DDIT4L; NbExp=3; IntAct=EBI-10215880, EBI-742054; CC P57077-4; Q15323: KRT31; NbExp=3; IntAct=EBI-10215880, EBI-948001; CC P57077-4; O76011: KRT34; NbExp=3; IntAct=EBI-10215880, EBI-1047093; CC P57077-4; Q04864: REL; NbExp=3; IntAct=EBI-10215880, EBI-307352; CC P57077-4; Q8N5C8: TAB3; NbExp=6; IntAct=EBI-10215880, EBI-359964; CC P57077-4; P22415: USF1; NbExp=3; IntAct=EBI-10215880, EBI-1054489; CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=D {ECO:0000303|Ref.1}; CC IsoId=P57077-4; Sequence=Displayed; CC Name=2; Synonyms=A {ECO:0000303|Ref.1}; CC IsoId=P57077-1; Sequence=VSP_060759; CC -!- TISSUE SPECIFICITY: Detected in lung and peripheral blood leukocytes. CC Expressed predominantly in peripheral blood leukocytes and ubiquitously CC in adult and fetal tissues. Also expressed strongly in breast carcinoma CC GI-101, colon adenocarcinoma GI-112, and prostatic adenocarcinoma PC3. CC {ECO:0000269|PubMed:15168726}. CC -!- DOMAIN: Contains a C-terminal domain similar to that of the C-terminal CC section of MAP3K7. CC -!- SEQUENCE CAUTION: CC Sequence=AAF81752.1; Type=Erroneous translation; Note=Wrong choice of frame.; Evidence={ECO:0000305}; CC Sequence=AAF81753.1; Type=Erroneous translation; Note=Wrong choice of frame.; Evidence={ECO:0000305}; CC Sequence=CAB90434.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF269161; AAF81751.1; -; mRNA. DR EMBL; AF269162; AAF81752.1; ALT_SEQ; mRNA. DR EMBL; AF269163; AAF81753.1; ALT_SEQ; mRNA. DR EMBL; AF269164; AAF81754.1; -; mRNA. DR EMBL; AY033900; AAK68718.1; -; mRNA. DR EMBL; AY171599; AAO16519.1; -; mRNA. DR EMBL; AL713701; CAD28500.1; -; mRNA. DR EMBL; AL163249; CAB90434.1; ALT_SEQ; Genomic_DNA. DR EMBL; CH471079; EAX09921.1; -; Genomic_DNA. DR EMBL; CH471079; EAX09923.1; -; Genomic_DNA. DR EMBL; BC008567; AAH08567.1; -; mRNA. DR CCDS; CCDS13584.1; -. [P57077-1] DR CCDS; CCDS68182.1; -. [P57077-4] DR RefSeq; NP_001273546.1; NM_001286617.2. [P57077-4] DR RefSeq; NP_001273547.1; NM_001286618.2. [P57077-4] DR RefSeq; NP_001273548.1; NM_001286619.2. [P57077-4] DR RefSeq; NP_001273549.1; NM_001286620.2. [P57077-4] DR RefSeq; NP_001273551.1; NM_001286622.1. DR RefSeq; NP_001273553.1; NM_001286624.1. DR RefSeq; NP_001273563.1; NM_001286634.2. [P57077-1] DR RefSeq; NP_001358298.1; NM_001371369.1. [P57077-1] DR RefSeq; NP_001358301.1; NM_001371372.1. [P57077-4] DR RefSeq; NP_001358302.1; NM_001371373.1. [P57077-4] DR RefSeq; NP_001358303.1; NM_001371374.1. [P57077-4] DR RefSeq; NP_064537.1; NM_020152.4. [P57077-1] DR AlphaFoldDB; P57077; -. DR SMR; P57077; -. DR BioGRID; 121239; 11. DR FunCoup; P57077; 1750. DR IntAct; P57077; 9. DR STRING; 9606.ENSP00000382828; -. DR iPTMnet; P57077; -. DR BioMuta; MAP3K7CL; -. DR DMDM; 10719918; -. DR MassIVE; P57077; -. DR PaxDb; 9606-ENSP00000382828; -. DR PeptideAtlas; P57077; -. DR Antibodypedia; 6479; 145 antibodies from 18 providers. DR DNASU; 56911; -. DR Ensembl; ENST00000339024.8; ENSP00000345777.4; ENSG00000156265.18. [P57077-4] DR Ensembl; ENST00000341618.8; ENSP00000343212.4; ENSG00000156265.18. [P57077-1] DR Ensembl; ENST00000399925.5; ENSP00000382809.1; ENSG00000156265.18. [P57077-4] DR Ensembl; ENST00000399926.5; ENSP00000382810.1; ENSG00000156265.18. [P57077-4] DR Ensembl; ENST00000399928.6; ENSP00000382812.1; ENSG00000156265.18. [P57077-4] DR Ensembl; ENST00000399934.5; ENSP00000382816.1; ENSG00000156265.18. [P57077-4] DR Ensembl; ENST00000399935.6; ENSP00000382817.2; ENSG00000156265.18. [P57077-4] DR Ensembl; ENST00000399947.6; ENSP00000382828.2; ENSG00000156265.18. [P57077-1] DR Ensembl; ENST00000707854.1; ENSP00000517001.1; ENSG00000291525.1. [P57077-1] DR Ensembl; ENST00000707857.1; ENSP00000517004.1; ENSG00000291525.1. [P57077-1] DR Ensembl; ENST00000707858.1; ENSP00000517005.1; ENSG00000291525.1. [P57077-4] DR Ensembl; ENST00000707860.1; ENSP00000517006.1; ENSG00000291525.1. [P57077-4] DR Ensembl; ENST00000707861.1; ENSP00000517007.1; ENSG00000291525.1. [P57077-4] DR Ensembl; ENST00000707862.1; ENSP00000517008.1; ENSG00000291525.1. [P57077-4] DR GeneID; 56911; -. DR KEGG; hsa:56911; -. DR MANE-Select; ENST00000399928.6; ENSP00000382812.1; NM_001286620.2; NP_001273549.1. DR UCSC; uc002ynd.5; human. [P57077-4] DR AGR; HGNC:16457; -. DR ClinPGx; PA25864; -. DR CTD; 56911; -. DR DisGeNET; 56911; -. DR GeneCards; MAP3K7CL; -. DR HGNC; HGNC:16457; MAP3K7CL. DR HPA; ENSG00000156265; Tissue enhanced (skeletal muscle, tongue). DR MIM; 611110; gene. DR OpenTargets; ENSG00000156265; -. DR VEuPathDB; HostDB:ENSG00000156265; -. DR eggNOG; ENOG502S2UX; Eukaryota. DR GeneTree; ENSGT00770000120675; -. DR HOGENOM; CLU_100451_0_0_1; -. DR InParanoid; P57077; -. DR OMA; MAREFHH; -. DR OrthoDB; 8866809at2759; -. DR PAN-GO; P57077; 0 GO annotations based on evolutionary models. DR PhylomeDB; P57077; -. DR PathwayCommons; P57077; -. DR SignaLink; P57077; -. DR Agora; ENSG00000156265; -. DR BioGRID-ORCS; 56911; 20 hits in 1136 CRISPR screens. DR ChiTaRS; MAP3K7CL; human. DR GeneWiki; C21orf7; -. DR GenomeRNAi; 56911; -. DR Pharos; P57077; Tbio. DR PRO; PR:P57077; -. DR Proteomes; UP000005640; Chromosome 21. DR RNAct; P57077; protein. DR Bgee; ENSG00000156265; Expressed in monocyte and 127 other cell types or tissues. DR ExpressionAtlas; P57077; baseline and differential. DR GO; GO:0005829; C:cytosol; HDA:UniProtKB. DR GO; GO:0005634; C:nucleus; HDA:UniProtKB. DR InterPro; IPR042800; Map3k7cl. DR PANTHER; PTHR47140; MAP3K7 C-TERMINAL-LIKE PROTEIN; 1. DR PANTHER; PTHR47140:SF1; MAP3K7 C-TERMINAL-LIKE PROTEIN; 1. PE 1: Evidence at protein level; KW Alternative splicing; Proteomics identification; Reference proteome. FT CHAIN 1..142 FT /note="MAP3K7 C-terminal-like protein" FT /id="PRO_0000072423" FT VAR_SEQ 1..23 FT /note="MISTARVPADKPVRIAFSLNDAS -> MVQLIAPLEVMWNEAADLKPLALSR FT RLECSGGIMAHYSPDLLGPEMESRYFAQVGLEHLASSSPPAFGFLKCLDYSISVLCSAT FT SLAMLEDNPKVSKLATGDWMLTLKPKSITVPVEIPSSPL (in isoform 2)" FT /id="VSP_060759" FT CONFLICT 60 FT /note="K -> R (in Ref. 4; CAD28500)" FT /evidence="ECO:0000305" FT CONFLICT 70 FT /note="H -> L (in Ref. 4; CAD28500)" FT /evidence="ECO:0000305" FT CONFLICT 95 FT /note="K -> E (in Ref. 4; CAD28500)" FT /evidence="ECO:0000305" FT VARIANT P57077-1:112 FT /note="I -> V (in dbSNP:rs3746843)" FT /id="VAR_083830" SQ SEQUENCE 142 AA; 16372 MW; 7F9BCBAF69F25444 CRC64; MISTARVPAD KPVRIAFSLN DASDDTPPED SIPLVFPELD QQLQPLPPCH DSEESMEVFK QHCQIAEEYH EVKKEITLLE QRKKELIAKL DQAEKEKVDA AELVREFEAL TEENRTLRLA QSQCVEQLEK LRIQYQKRQG SS // ID MARK4_HUMAN Reviewed; 752 AA. AC Q96L34; Q8NG37; Q96JG7; Q96SQ2; Q9BYD8; DT 28-FEB-2003, integrated into UniProtKB/Swiss-Prot. DT 01-DEC-2001, sequence version 1. DT 28-JAN-2026, entry version 213. DE RecName: Full=MAP/microtubule affinity-regulating kinase 4 {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:14594945, ECO:0000269|PubMed:15009667, ECO:0000269|PubMed:23184942}; DE AltName: Full=MAP/microtubule affinity-regulating kinase-like 1 {ECO:0000303|PubMed:11326310}; GN Name=MARK4 {ECO:0000303|PubMed:14594945, ECO:0000312|HGNC:HGNC:13538}; GN Synonyms=KIAA1860 {ECO:0000303|PubMed:11347906}, GN MARKL1 {ECO:0000303|PubMed:11326310}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND TISSUE SPECIFICITY. RC TISSUE=Brain; RX PubMed=11326310; DOI=10.1038/sj.neo.7900132; RA Kato T., Satoh S., Okabe H., Kitahara O., Ono K., Kihara C., Tanaka T., RA Tsunoda T., Yamaoka Y., Nakamura Y., Furukawa Y.; RT "Isolation of a novel human gene, MARKL1, homologous to MARK3 and its RT involvement in hepatocellular carcinogenesis."; RL Neoplasia 3:4-9(2001). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY, RP COFACTOR, INTERACTION WITH GAMMA-TUBULIN, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RX PubMed=14594945; DOI=10.1074/jbc.m304528200; RA Trinczek B., Brajenovic M., Ebneth A., Drewes G.; RT "MARK4 is a novel microtubule-associated proteins/microtubule affinity- RT regulating kinase that binds to the cellular microtubule network and to RT centrosomes."; RL J. Biol. Chem. 279:5915-5923(2004). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, AND CATALYTIC RP ACTIVITY. RX PubMed=15009667; DOI=10.1046/j.1471-4159.2003.02228.x; RA Schneider A., Laage R., von Ahsen O., Fischer A., Rossner M., Scheek S., RA Grunewald S., Kuner R., Weber D., Kruger C., Klaussner B., Gotz B., RA Hiemisch H., Newrzella D., Martin-Villalba A., Bach A., Schwaninger M.; RT "Identification of regulated genes during permanent focal cerebral RT ischaemia: characterization of the protein kinase 9b5/MARKL1/MARK4."; RL J. Neurochem. 88:1114-1126(2004). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Brain; RA Beghini A., Magnani I., Roversi G., Piepoli T., DiTerlizzi S., Pollo B., RA Conti A.M.F., Cowell J.K., Finocchiaro G., Larizza L.; RT "Neural progenitor-restricted isoform of MARKL1 gene is upregulated by RT 19q13 amplification in human glioblastoma."; RL Submitted (JUN-2002) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain; RX PubMed=11347906; DOI=10.1093/dnares/8.2.85; RA Nagase T., Nakayama M., Nakajima D., Kikuno R., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XX. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 8:85-95(2001). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Thyroid; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP ACTIVITY REGULATION, PHOSPHORYLATION AT THR-214, AND MUTAGENESIS OF RP THR-214. RX PubMed=14976552; DOI=10.1038/sj.emboj.7600110; RA Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A., Boudeau J., RA Hawley S.A., Udd L., Maekelae T.P., Hardie D.G., Alessi D.R.; RT "LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, RT including MARK/PAR-1."; RL EMBO J. 23:833-843(2004). RN [8] RP INTERACTION WITH YWHAQ. RX PubMed=16959763; DOI=10.1074/mcp.m600147-mcp200; RA Angrand P.O., Segura I., Voelkel P., Ghidelli S., Terry R., Brajenovic M., RA Vintersten K., Klein R., Superti-Furga G., Drewes G., Kuster B., RA Bouwmeester T., Acker-Palmer A.; RT "Transgenic mouse proteomics identifies new 14-3-3-associated proteins RT involved in cytoskeletal rearrangements and cell signaling."; RL Mol. Cell. Proteomics 5:2211-2227(2006). RN [9] RP UBIQUITINATION, DEUBIQUITINATION BY USP9X, AND INTERACTION WITH USP9X. RX PubMed=18254724; DOI=10.1042/bj20080067; RA Al-Hakim A.K., Zagorska A., Chapman L., Deak M., Peggie M., Alessi D.R.; RT "Control of AMPK-related kinases by USP9X and atypical Lys(29)/Lys(33)- RT linked polyubiquitin chains."; RL Biochem. J. 411:249-260(2008). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [11] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF THR-214. RX PubMed=23184942; DOI=10.1074/jbc.c112.396903; RA Li L., Guan K.L.; RT "Microtubule-associated protein/microtubule affinity-regulating kinase 4 RT (MARK4) is a negative regulator of the mammalian target of rapamycin RT complex 1 (mTORC1)."; RL J. Biol. Chem. 288:703-708(2013). RN [12] RP FUNCTION, INTERACTION WITH ODF2, AND SUBCELLULAR LOCATION. RX PubMed=23400999; DOI=10.1083/jcb.201206013; RA Kuhns S., Schmidt K.N., Reymann J., Gilbert D.F., Neuner A., Hub B., RA Carvalho R., Wiedemann P., Zentgraf H., Erfle H., Klingmuller U., RA Boutros M., Pereira G.; RT "The microtubule affinity regulating kinase MARK4 promotes axoneme RT extension during early ciliogenesis."; RL J. Cell Biol. 200:505-522(2013). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-543, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [14] RP FUNCTION, INTERACTION WITH MAPT, AND SUBCELLULAR LOCATION. RX PubMed=23666762; DOI=10.1007/s12017-013-8232-3; RA Gu G.J., Lund H., Wu D., Blokzijl A., Classon C., von Euler G., RA Landegren U., Sunnemark D., Kamali-Moghaddam M.; RT "Role of individual MARK isoforms in phosphorylation of tau at Ser262 in RT Alzheimer's disease."; RL NeuroMolecular Med. 15:458-469(2013). RN [15] RP FUNCTION, DEVELOPMENTAL STAGE, AND PHOSPHORYLATION. RX PubMed=25123532; DOI=10.1016/j.ejcb.2014.07.004; RA Rovina D., Fontana L., Monti L., Novielli C., Panini N., Sirchia S.M., RA Erba E., Magnani I., Larizza L.; RT "Microtubule-associated protein/microtubule affinity-regulating kinase 4 RT (MARK4) plays a role in cell cycle progression and cytoskeletal dynamics."; RL Eur. J. Cell Biol. 93:355-365(2014). RN [16] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH NLRP3. RX PubMed=28656979; DOI=10.1038/ncomms15986; RA Li X., Thome S., Ma X., Amrute-Nayak M., Finigan A., Kitt L., Masters L., RA James J.R., Shi Y., Meng G., Mallat Z.; RT "MARK4 regulates NLRP3 positioning and inflammasome activation through a RT microtubule-dependent mechanism."; RL Nat. Commun. 8:15986-15986(2017). RN [17] RP VARIANTS [LARGE SCALE ANALYSIS] GLN-377 AND CYS-418. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase (PubMed:14594945, CC PubMed:15009667, PubMed:23184942, PubMed:23666762). Phosphorylates the CC microtubule-associated protein MAPT/TAU (PubMed:14594945, CC PubMed:23666762). Also phosphorylates the microtubule-associated CC proteins MAP2 and MAP4 (PubMed:14594945). Involved in regulation of the CC microtubule network, causing reorganization of microtubules into CC bundles (PubMed:14594945, PubMed:25123532). Required for the initiation CC of axoneme extension during cilium assembly (PubMed:23400999). CC Regulates the centrosomal location of ODF2 and phosphorylates ODF2 in CC vitro (PubMed:23400999). Plays a role in cell cycle progression, CC specifically in the G1/S checkpoint (PubMed:25123532). Reduces neuronal CC cell survival (PubMed:15009667). Plays a role in energy homeostasis by CC regulating satiety and metabolic rate (By similarity). Promotes CC adipogenesis by activating JNK1 and inhibiting the p38MAPK pathway, and CC triggers apoptosis by activating the JNK1 pathway (By similarity). CC Phosphorylates mTORC1 complex member RPTOR and acts as a negative CC regulator of the mTORC1 complex, probably due to disruption of the CC interaction between phosphorylated RPTOR and the RRAGA/RRAGC CC heterodimer which is required for mTORC1 activation (PubMed:23184942). CC Involved in NLRP3 positioning along microtubules by mediating NLRP3 CC recruitment to microtubule organizing center (MTOC) upon inflammasome CC activation (PubMed:28656979). {ECO:0000250|UniProtKB:Q8CIP4, CC ECO:0000269|PubMed:14594945, ECO:0000269|PubMed:15009667, CC ECO:0000269|PubMed:23184942, ECO:0000269|PubMed:23400999, CC ECO:0000269|PubMed:23666762, ECO:0000269|PubMed:25123532, CC ECO:0000269|PubMed:28656979}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:14594945, ECO:0000269|PubMed:15009667, CC ECO:0000269|PubMed:23184942}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:14594945, ECO:0000269|PubMed:15009667, CC ECO:0000269|PubMed:23184942}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:14594945}; CC -!- ACTIVITY REGULATION: Activated by phosphorylation on Thr-214. CC {ECO:0000269|PubMed:14976552}. CC -!- SUBUNIT: Interacts with MAPT/TAU (PubMed:23666762). Interacts with CC gamma-tubulin (PubMed:14594945). Interacts with ODF2 (PubMed:23400999). CC Interacts with USP9X (PubMed:18254724). Interacts with YWHAQ CC (PubMed:16959763). Interacts with NLRP3; promoting NLRP3 recruitment to CC microtubule organizing center (MTOC) (PubMed:28656979). CC {ECO:0000269|PubMed:14594945, ECO:0000269|PubMed:16959763, CC ECO:0000269|PubMed:18254724, ECO:0000269|PubMed:23400999, CC ECO:0000269|PubMed:23666762, ECO:0000269|PubMed:28656979}. CC -!- INTERACTION: CC Q96L34; Q06481-5: APLP2; NbExp=3; IntAct=EBI-302319, EBI-25646567; CC Q96L34; P05067: APP; NbExp=3; IntAct=EBI-302319, EBI-77613; CC Q96L34; P60953: CDC42; NbExp=2; IntAct=EBI-302319, EBI-81752; CC Q96L34; P48730-2: CSNK1D; NbExp=3; IntAct=EBI-302319, EBI-9087876; CC Q96L34; Q15323: KRT31; NbExp=3; IntAct=EBI-302319, EBI-948001; CC Q96L34; P07948: LYN; NbExp=3; IntAct=EBI-302319, EBI-79452; CC Q96L34; Q9BYG4: PARD6G; NbExp=2; IntAct=EBI-302319, EBI-295417; CC Q96L34; Q8ND90: PNMA1; NbExp=2; IntAct=EBI-302319, EBI-302345; CC Q96L34; P41743: PRKCI; NbExp=2; IntAct=EBI-302319, EBI-286199; CC Q96L34; Q15831: STK11; NbExp=2; IntAct=EBI-302319, EBI-306838; CC Q96L34; P23258: TUBG1; NbExp=4; IntAct=EBI-302319, EBI-302589; CC Q96L34; Q04917: YWHAH; NbExp=7; IntAct=EBI-302319, EBI-306940; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing CC center, centrosome {ECO:0000269|PubMed:14594945}. Cytoplasm, CC cytoskeleton, microtubule organizing center CC {ECO:0000269|PubMed:14594945, ECO:0000269|PubMed:28656979}. Cytoplasm, CC cytoskeleton, cilium basal body {ECO:0000269|PubMed:23400999}. CC Cytoplasm, cytoskeleton, cilium axoneme {ECO:0000269|PubMed:23400999}. CC Cytoplasm {ECO:0000269|PubMed:23400999, ECO:0000269|PubMed:23666762}. CC Cell projection, dendrite {ECO:0000269|PubMed:23666762}. Note=Localized CC at the tips of neurite-like processes in differentiated neuroblast CC cells. Detected in the cytoplasm and neuropil of the hippocampus. CC {ECO:0000269|PubMed:14594945, ECO:0000269|PubMed:23666762}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=MARK4L; CC IsoId=Q96L34-1; Sequence=Displayed; CC Name=2; Synonyms=MARKL1S, MARK4S; CC IsoId=Q96L34-2; Sequence=VSP_004946; CC -!- TISSUE SPECIFICITY: Ubiquitous. Isoform 2 is brain-specific CC (PubMed:11326310). Expressed at highest levels in brain and testis. CC Also expressed in heart, lung, liver, muscle, kidney and spleen CC (PubMed:14594945). {ECO:0000269|PubMed:11326310, CC ECO:0000269|PubMed:14594945}. CC -!- DEVELOPMENTAL STAGE: Expressed at all stages of the mitotic cell cycle. CC {ECO:0000269|PubMed:25123532}. CC -!- PTM: Ubiquitinated with 'Lys-29'- and 'Lys-33'-linked polyubiquitins CC which appear to impede LKB1-mediated phosphorylation. Deubiquitinated CC by USP9X. {ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:18254724}. CC -!- PTM: Phosphorylated at Thr-214 by STK11/LKB1 in complex with STE20- CC related adapter-alpha (STRADA) pseudo kinase and CAB39 CC (PubMed:14976552). Phosphorylated throughout the cell cycle CC (PubMed:25123532). {ECO:0000269|PubMed:14976552, CC ECO:0000269|PubMed:25123532}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. SNF1 subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAB47489.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAB55238.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/419/MARK4"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB049127; BAB39380.1; -; mRNA. DR EMBL; AB088047; BAC03375.1; -; mRNA. DR EMBL; AY057448; AAL23683.1; -; mRNA. DR EMBL; AX305105; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AX305106; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AY120867; AAM55491.1; -; mRNA. DR EMBL; AB058763; BAB47489.1; ALT_INIT; mRNA. DR EMBL; AK027619; BAB55238.1; ALT_INIT; mRNA. DR EMBL; AK075272; BAC11510.1; -; mRNA. DR CCDS; CCDS12658.1; -. [Q96L34-2] DR CCDS; CCDS56097.1; -. [Q96L34-1] DR RefSeq; NP_001186796.1; NM_001199867.2. [Q96L34-1] DR RefSeq; NP_113605.2; NM_031417.3. [Q96L34-2] DR PDB; 5ES1; X-ray; 2.80 A; A=44-370. DR PDB; 8XFL; X-ray; 3.00 A; A/B=44-370. DR PDBsum; 5ES1; -. DR PDBsum; 8XFL; -. DR AlphaFoldDB; Q96L34; -. DR SMR; Q96L34; -. DR BioGRID; 121760; 74. DR FunCoup; Q96L34; 1008. DR IntAct; Q96L34; 50. DR MINT; Q96L34; -. DR STRING; 9606.ENSP00000262891; -. DR BindingDB; Q96L34; -. DR ChEMBL; CHEMBL5754; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q96L34; -. DR GuidetoPHARMACOLOGY; 2100; -. DR GlyGen; Q96L34; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q96L34; -. DR PhosphoSitePlus; Q96L34; -. DR BioMuta; MARK4; -. DR DMDM; 29840797; -. DR CPTAC; non-CPTAC-5644; -. DR jPOST; Q96L34; -. DR MassIVE; Q96L34; -. DR PaxDb; 9606-ENSP00000262891; -. DR PeptideAtlas; Q96L34; -. DR ProteomicsDB; 77145; -. [Q96L34-1] DR ProteomicsDB; 77146; -. [Q96L34-2] DR Pumba; Q96L34; -. DR Antibodypedia; 31285; 373 antibodies from 36 providers. DR DNASU; 57787; -. DR Ensembl; ENST00000262891.9; ENSP00000262891.3; ENSG00000007047.17. [Q96L34-1] DR Ensembl; ENST00000300843.8; ENSP00000300843.3; ENSG00000007047.17. [Q96L34-2] DR GeneID; 57787; -. DR KEGG; hsa:57787; -. DR MANE-Select; ENST00000262891.9; ENSP00000262891.3; NM_001199867.2; NP_001186796.1. DR UCSC; uc002pba.3; human. [Q96L34-1] DR AGR; HGNC:13538; -. DR ClinPGx; PA30641; -. DR CTD; 57787; -. DR DisGeNET; 57787; -. DR GeneCards; MARK4; -. DR HGNC; HGNC:13538; MARK4. DR HPA; ENSG00000007047; Low tissue specificity. DR MalaCards; MARK4; -. DR MIM; 606495; gene. DR OpenTargets; ENSG00000007047; -. DR VEuPathDB; HostDB:ENSG00000007047; -. DR eggNOG; KOG0586; Eukaryota. DR GeneTree; ENSGT00940000159555; -. DR HOGENOM; CLU_000288_157_5_1; -. DR InParanoid; Q96L34; -. DR OMA; CHLPWDK; -. DR OrthoDB; 193931at2759; -. DR PAN-GO; Q96L34; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q96L34; -. DR PathwayCommons; Q96L34; -. DR Reactome; R-HSA-5620912; Anchoring of the basal body to the plasma membrane. DR SignaLink; Q96L34; -. DR SIGNOR; Q96L34; -. DR Agora; ENSG00000007047; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 57787; 12 hits in 1188 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; MARK4; human. DR EvolutionaryTrace; Q96L34; -. DR GeneWiki; MARK4; -. DR GenomeRNAi; 57787; -. DR Pharos; Q96L34; Tchem. DR PRO; PR:Q96L34; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q96L34; protein. DR Bgee; ENSG00000007047; Expressed in cortical plate and 200 other cell types or tissues. DR ExpressionAtlas; Q96L34; baseline and differential. DR GO; GO:0005930; C:axoneme; IEA:UniProtKB-SubCell. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0036064; C:ciliary basal body; IMP:CACAO. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0030425; C:dendrite; IDA:UniProtKB. DR GO; GO:0000930; C:gamma-tubulin complex; IDA:ARUK-UCL. DR GO; GO:0015630; C:microtubule cytoskeleton; IDA:UniProtKB. DR GO; GO:0005815; C:microtubule organizing center; IDA:UniProtKB. DR GO; GO:0030496; C:midbody; IDA:ARUK-UCL. DR GO; GO:0043005; C:neuron projection; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; NAS:UniProtKB. DR GO; GO:0008093; F:cytoskeletal anchor activity; IDA:UniProtKB. DR GO; GO:0043015; F:gamma-tubulin binding; IDA:UniProtKB. DR GO; GO:0008017; F:microtubule binding; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0048156; F:tau protein binding; NAS:ARUK-UCL. DR GO; GO:0050321; F:tau-protein kinase activity; IDA:UniProtKB. DR GO; GO:0043130; F:ubiquitin binding; NAS:UniProtKB. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:0044782; P:cilium organization; IGI:ARUK-UCL. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0001578; P:microtubule bundle formation; IEP:UniProtKB. DR GO; GO:0000226; P:microtubule cytoskeleton organization; IMP:UniProtKB. DR GO; GO:0007399; P:nervous system development; IDA:UniProtKB. DR GO; GO:0045787; P:positive regulation of cell cycle; IDA:ARUK-UCL. DR GO; GO:0045724; P:positive regulation of cilium assembly; IMP:ARUK-UCL. DR GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; IDA:UniProtKB. DR GO; GO:0043068; P:positive regulation of programmed cell death; NAS:UniProtKB. DR GO; GO:1904781; P:positive regulation of protein localization to centrosome; IMP:ARUK-UCL. DR GO; GO:0006468; P:protein phosphorylation; IMP:UniProtKB. DR GO; GO:0046605; P:regulation of centrosome cycle; IMP:ARUK-UCL. DR CDD; cd12197; MARK4_C; 1. DR CDD; cd14072; STKc_MARK; 1. DR CDD; cd14407; UBA_MARK3_4; 1. DR FunFam; 1.10.510.10:FF:001032; KP78b, isoform A; 1. DR FunFam; 1.10.8.10:FF:000011; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.200.20:FF:000003; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.310.80:FF:000009; Non-specific serine/threonine protein kinase; 1. DR Gene3D; 1.10.8.10; DNA helicase RuvA subunit, C-terminal domain; 1. DR Gene3D; 3.30.310.80; Kinase associated domain 1, KA1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR028375; KA1/Ssp2_C. DR InterPro; IPR001772; KA1_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR049508; MARK1-4_cat. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR015940; UBA. DR PANTHER; PTHR24346; MAP/MICROTUBULE AFFINITY-REGULATING KINASE; 1. DR PANTHER; PTHR24346:SF28; MAP_MICROTUBULE AFFINITY-REGULATING KINASE 4; 1. DR Pfam; PF02149; KA1; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00627; UBA; 1. DR SMART; SM00220; S_TKc; 1. DR SMART; SM00165; UBA; 1. DR SUPFAM; SSF103243; KA1-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50032; KA1; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50030; UBA; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell cycle; Cell division; KW Cell projection; Cilium biogenesis/degradation; Cytoplasm; Cytoskeleton; KW Kinase; Mitosis; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Ubl conjugation. FT CHAIN 1..752 FT /note="MAP/microtubule affinity-regulating kinase 4" FT /id="PRO_0000086307" FT DOMAIN 59..310 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 324..368 FT /note="UBA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00212" FT DOMAIN 703..752 FT /note="KA1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00565" FT REGION 1..36 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 385..614 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 391..406 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 544..553 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 181 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 65..73 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 88 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 214 FT /note="Phosphothreonine; by LKB1" FT /evidence="ECO:0000269|PubMed:14976552" FT MOD_RES 423 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8CIP4" FT MOD_RES 543 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 628..752 FT /note="ADEPERIGGPEVTSCHLPWDQTETAPRLLRFPWSVKLTSSRPPEALMAALRQ FT ATAAARCRCRQPQPFLLACLHGGAGGPEPLSHFEVEVCQLPRPGLRGVLFRRVAGTALA FT FRTLVTRISNDLEL -> TLDPSKRQNSNRCVSGASLPQGSKIRSQTNLRESGDLRSQV FT AIYLGIKRKPPPGCSDSPGV (in isoform 2)" FT /evidence="ECO:0000303|PubMed:11326310, FT ECO:0000303|PubMed:11347906" FT /id="VSP_004946" FT VARIANT 377 FT /note="R -> Q (in dbSNP:rs35070611)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040766" FT VARIANT 418 FT /note="R -> C (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs780763668)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040767" FT MUTAGEN 214 FT /note="T->A: Prevents phosphorylation and activation by FT STK11/LKB1 complex." FT /evidence="ECO:0000269|PubMed:14976552" FT MUTAGEN 214 FT /note="T->E: Mimicks phosphorylation state, leading to FT increased activity. Decreases mTORC1 activity." FT /evidence="ECO:0000269|PubMed:14976552, FT ECO:0000269|PubMed:23184942" FT CONFLICT 70 FT /note="F -> S (in Ref. 1; BAB39380/BAC03375)" FT /evidence="ECO:0000305" FT CONFLICT 518 FT /note="P -> L (in Ref. 6; BAB55238)" FT /evidence="ECO:0000305" FT STRAND 59..67 FT /evidence="ECO:0007829|PDB:5ES1" FT STRAND 69..78 FT /evidence="ECO:0007829|PDB:5ES1" FT TURN 79..81 FT /evidence="ECO:0007829|PDB:5ES1" FT STRAND 84..91 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 92..94 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 97..111 FT /evidence="ECO:0007829|PDB:5ES1" FT STRAND 121..126 FT /evidence="ECO:0007829|PDB:5ES1" FT STRAND 128..135 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 143..150 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 155..174 FT /evidence="ECO:0007829|PDB:5ES1" FT STRAND 186..189 FT /evidence="ECO:0007829|PDB:5ES1" FT STRAND 195..197 FT /evidence="ECO:0007829|PDB:5ES1" FT TURN 219..221 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 224..228 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 235..251 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 261..270 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 281..290 FT /evidence="ECO:0007829|PDB:5ES1" FT TURN 295..297 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 301..304 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 308..311 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 332..339 FT /evidence="ECO:0007829|PDB:5ES1" FT TURN 340..342 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 345..352 FT /evidence="ECO:0007829|PDB:5ES1" FT TURN 353..355 FT /evidence="ECO:0007829|PDB:5ES1" FT HELIX 359..366 FT /evidence="ECO:0007829|PDB:5ES1" FT TURN 367..369 FT /evidence="ECO:0007829|PDB:5ES1" SQ SEQUENCE 752 AA; 82520 MW; 4B430FFD2B150E7A CRC64; MSSRTVLAPG NDRNSDTHGT LGSGRSSDKG PSWSSRSLGA RCRNSIASCP EEQPHVGNYR LLRTIGKGNF AKVKLARHIL TGREVAIKII DKTQLNPSSL QKLFREVRIM KGLNHPNIVK LFEVIETEKT LYLVMEYASA GEVFDYLVSH GRMKEKEARA KFRQIVSAVH YCHQKNIVHR DLKAENLLLD AEANIKIADF GFSNEFTLGS KLDTFCGSPP YAAPELFQGK KYDGPEVDIW SLGVILYTLV SGSLPFDGHN LKELRERVLR GKYRVPFYMS TDCESILRRF LVLNPAKRCT LEQIMKDKWI NIGYEGEELK PYTEPEEDFG DTKRIEVMVG MGYTREEIKE SLTSQKYNEV TATYLLLGRK TEEGGDRGAP GLALARVRAP SDTTNGTSSS KGTSHSKGQR SSSSTYHRQR RHSDFCGPSP APLHPKRSPT STGEAELKEE RLPGRKASCS TAGSGSRGLP PSSPMVSSAH NPNKAEIPER RKDSTSTPNN LPPSMMTRRN TYVCTERPGA ERPSLLPNGK ENSSGTPRVP PASPSSHSLA PPSGERSRLA RGSTIRSTFH GGQVRDRRAG GGGGGGVQNG PPASPTLAHE AAPLPAGRPR PTTNLFTKLT SKLTRRVADE PERIGGPEVT SCHLPWDQTE TAPRLLRFPW SVKLTSSRPP EALMAALRQA TAAARCRCRQ PQPFLLACLH GGAGGPEPLS HFEVEVCQLP RPGLRGVLFR RVAGTALAFR TLVTRISNDL EL // ID MATK_HUMAN Reviewed; 507 AA. AC P42679; B3KNZ9; Q9NST8; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1995, sequence version 1. DT 28-JAN-2026, entry version 230. DE RecName: Full=Megakaryocyte-associated tyrosine-protein kinase; DE EC=2.7.10.2; DE AltName: Full=CSK homologous kinase; DE Short=CHK; DE AltName: Full=Hematopoietic consensus tyrosine-lacking kinase; DE AltName: Full=Protein kinase HYL; DE AltName: Full=Tyrosine-protein kinase CTK; GN Name=MATK; Synonyms=CTK, HYL; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=8134117; RA Sakano S., Iwama A., Inazawa J., Ariyama T., Ohno M., Suda T.; RT "Molecular cloning of a novel non-receptor tyrosine kinase, HYL RT (hematopoietic consensus tyrosine-lacking kinase)."; RL Oncogene 9:1155-1161(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Megakaryocyte; RX PubMed=8288563; DOI=10.1016/s0021-9258(17)42222-8; RA Bennett B.D., Cowley S., Jiang S., London R., Deng B., Grabarek J., RA Groopman J.E., Goeddel D.V., Avraham H.; RT "Identification and characterization of a novel tyrosine kinase from RT megakaryocytes."; RL J. Biol. Chem. 269:1068-1074(1994). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=7530249; DOI=10.1074/jbc.270.4.1833; RA Avraham S., Jiang S., Ota S., Fu Y., Deng B., Dowler L.L., White R.A., RA Avraham H.; RT "Structural and functional studies of the intracellular tyrosine kinase RT MATK gene and its translated product."; RL J. Biol. Chem. 270:1833-1842(1995). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Eye; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP CHARACTERIZATION. RX PubMed=7936664; RA Hamaguchi I., Iwama A., Yamaguchi N., Sakano S., Matsuda Y., Suda T.; RT "Characterization of mouse non-receptor tyrosine kinase gene, HYL."; RL Oncogene 9:3371-3374(1994). RN [10] RP FUNCTION, AND SUBCELLULAR LOCATION. RC TISSUE=Platelet; RX PubMed=9171348; DOI=10.1093/emboj/16.9.2342; RA Hirao A., Hamaguchi I., Suda T., Yamaguchi N.; RT "Translocation of the Csk homologous kinase (Chk/Hyl) controls activity of RT CD36-anchored Lyn tyrosine kinase in thrombin-stimulated platelets."; RL EMBO J. 16:2342-2351(1997). RN [11] RP INTERACTION WITH KIT. RX PubMed=9038210; DOI=10.1074/jbc.272.9.5915; RA Price D.J., Rivnay B., Fu Y., Jiang S., Avraham S., Avraham H.; RT "Direct association of Csk homologous kinase (CHK) with the RT diphosphorylated site Tyr568/570 of the activated c-KIT in RT megakaryocytes."; RL J. Biol. Chem. 272:5915-5920(1997). RN [12] RP REVIEW ON ROLE IN KIT SIGNALING. RX PubMed=16129412; DOI=10.1016/j.bbrc.2005.08.055; RA Roskoski R. Jr.; RT "Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor."; RL Biochem. Biophys. Res. Commun. 337:1-13(2005). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-501, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [15] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [16] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-501, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [19] RP STRUCTURE BY NMR OF 39-108. RG RIKEN structural genomics initiative (RSGI); RT "Solution structures of the SH3 domain of human megakaryocyte-associated RT tyrosine-protein kinase."; RL Submitted (NOV-2005) to the PDB data bank. RN [20] RP VARIANTS [LARGE SCALE ANALYSIS] THR-354; THR-496 AND GLN-503. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Could play a significant role in the signal transduction of CC hematopoietic cells. May regulate tyrosine kinase activity of SRC- CC family members in brain by specifically phosphorylating their C- CC terminal regulatory tyrosine residue which acts as a negative CC regulatory site. It may play an inhibitory role in the control of T- CC cell proliferation. {ECO:0000269|PubMed:9171348}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Interacts with KIT. {ECO:0000269|PubMed:9038210}. CC -!- INTERACTION: CC P42679; P10275: AR; NbExp=4; IntAct=EBI-751664, EBI-608057; CC P42679; Q9Y5Z0: BACE2; NbExp=3; IntAct=EBI-751664, EBI-11282723; CC P42679; P04626: ERBB2; NbExp=2; IntAct=EBI-751664, EBI-641062; CC P42679; P08238: HSP90AB1; NbExp=2; IntAct=EBI-751664, EBI-352572; CC P42679; Q92876: KLK6; NbExp=3; IntAct=EBI-751664, EBI-2432309; CC P42679; Q5S007: LRRK2; NbExp=2; IntAct=EBI-751664, EBI-5323863; CC P42679; P62258: YWHAE; NbExp=2; IntAct=EBI-751664, EBI-356498; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:9171348}. Membrane CC {ECO:0000269|PubMed:9171348}. Note=In platelets, 90% of MATK localizes CC to the membrane fraction, and translocates to the cytoskeleton upon CC thrombin stimulation. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=P42679-1; Sequence=Displayed; CC Name=2; CC IsoId=P42679-2; Sequence=VSP_043123; CC Name=3; CC IsoId=P42679-3; Sequence=VSP_044277; CC -!- TISSUE SPECIFICITY: Expressed in various myeloid cell lines, detected CC in brain and lung. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. CSK subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L18974; AAA16703.1; -; mRNA. DR EMBL; X77278; CAA54493.1; -; mRNA. DR EMBL; S75164; AAC60645.1; -; Genomic_DNA. DR EMBL; S75145; AAC60645.1; JOINED; Genomic_DNA. DR EMBL; S75147; AAC60645.1; JOINED; Genomic_DNA. DR EMBL; S75166; AAC60645.1; JOINED; Genomic_DNA. DR EMBL; S75168; AAC60645.1; JOINED; Genomic_DNA. DR EMBL; S75151; AAC60645.1; JOINED; Genomic_DNA. DR EMBL; S75153; AAC60645.1; JOINED; Genomic_DNA. DR EMBL; S75155; AAC60645.1; JOINED; Genomic_DNA. DR EMBL; S75156; AAC60645.1; JOINED; Genomic_DNA. DR EMBL; S75158; AAC60645.1; JOINED; Genomic_DNA. DR EMBL; S75159; AAC60645.1; JOINED; Genomic_DNA. DR EMBL; S75162; AAC60645.1; JOINED; Genomic_DNA. DR EMBL; AK055395; BAG51511.1; -; mRNA. DR EMBL; AL137754; CAB70906.2; -; mRNA. DR EMBL; AC005777; AAC62843.1; -; Genomic_DNA. DR EMBL; CH471139; EAW69285.1; -; Genomic_DNA. DR EMBL; BC000114; AAH00114.1; -; mRNA. DR EMBL; BC003109; AAH03109.1; -; mRNA. DR CCDS; CCDS12113.1; -. [P42679-2] DR CCDS; CCDS12114.1; -. [P42679-1] DR CCDS; CCDS42468.1; -. [P42679-3] DR PIR; A49865; A49865. DR PIR; A55625; A55625. DR RefSeq; NP_001427506.1; NM_001440577.1. [P42679-1] DR RefSeq; NP_002369.2; NM_002378.3. [P42679-2] DR RefSeq; NP_647611.1; NM_139354.3. [P42679-3] DR RefSeq; NP_647612.1; NM_139355.3. [P42679-1] DR PDB; 1JWO; X-ray; 2.50 A; A=117-213. DR PDB; 1X6G; NMR; -; A=41-108. DR PDB; 3US4; X-ray; 1.50 A; A=117-213. DR PDBsum; 1JWO; -. DR PDBsum; 1X6G; -. DR PDBsum; 3US4; -. DR AlphaFoldDB; P42679; -. DR SMR; P42679; -. DR BioGRID; 110315; 33. DR FunCoup; P42679; 601. DR IntAct; P42679; 20. DR MINT; P42679; -. DR STRING; 9606.ENSP00000378485; -. DR BindingDB; P42679; -. DR ChEMBL; CHEMBL4175; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; P42679; -. DR iPTMnet; P42679; -. DR PhosphoSitePlus; P42679; -. DR BioMuta; MATK; -. DR DMDM; 1169123; -. DR CPTAC; CPTAC-1790; -. DR jPOST; P42679; -. DR MassIVE; P42679; -. DR PaxDb; 9606-ENSP00000378485; -. DR PeptideAtlas; P42679; -. DR ProteomicsDB; 55524; -. [P42679-1] DR ProteomicsDB; 55525; -. [P42679-2] DR ProteomicsDB; 82579; -. DR Pumba; P42679; -. DR Antibodypedia; 1174; 359 antibodies from 32 providers. DR DNASU; 4145; -. DR Ensembl; ENST00000310132.11; ENSP00000308734.5; ENSG00000007264.16. [P42679-1] DR Ensembl; ENST00000395040.6; ENSP00000378481.1; ENSG00000007264.16. [P42679-3] DR Ensembl; ENST00000395045.6; ENSP00000378485.1; ENSG00000007264.16. [P42679-2] DR Ensembl; ENST00000619596.4; ENSP00000483213.1; ENSG00000007264.16. [P42679-2] DR GeneID; 4145; -. DR KEGG; hsa:4145; -. DR MANE-Select; ENST00000310132.11; ENSP00000308734.5; NM_139355.3; NP_647612.1. DR UCSC; uc002lyt.4; human. [P42679-1] DR AGR; HGNC:6906; -. DR ClinPGx; PA30649; -. DR CTD; 4145; -. DR DisGeNET; 4145; -. DR GeneCards; MATK; -. DR HGNC; HGNC:6906; MATK. DR HPA; ENSG00000007264; Tissue enhanced (bone marrow, brain). DR MIM; 600038; gene. DR OpenTargets; ENSG00000007264; -. DR VEuPathDB; HostDB:ENSG00000007264; -. DR eggNOG; KOG0197; Eukaryota. DR GeneTree; ENSGT00940000160775; -. DR HOGENOM; CLU_000288_7_2_1; -. DR InParanoid; P42679; -. DR OMA; HDSGQEG; -. DR OrthoDB; 346907at2759; -. DR PAN-GO; P42679; 1 GO annotation based on evolutionary models. DR PhylomeDB; P42679; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; P42679; -. DR Reactome; R-HSA-8863795; Downregulation of ERBB2 signaling. DR SignaLink; P42679; -. DR SIGNOR; P42679; -. DR Agora; ENSG00000007264; -. DR BioGRID-ORCS; 4145; 33 hits in 1190 CRISPR screens. DR EvolutionaryTrace; P42679; -. DR GeneWiki; Megakaryocyte-associated_tyrosine_kinase; -. DR GenomeRNAi; 4145; -. DR Pharos; P42679; Tbio. DR PRO; PR:P42679; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; P42679; protein. DR Bgee; ENSG00000007264; Expressed in granulocyte and 173 other cell types or tissues. DR ExpressionAtlas; P42679; baseline and differential. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0004713; F:protein tyrosine kinase activity; TAS:ProtInc. DR GO; GO:0008284; P:positive regulation of cell population proliferation; TAS:ProtInc. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR CDD; cd05083; PTKc_Chk; 1. DR CDD; cd09937; SH2_csk_like; 1. DR CDD; cd11811; SH3_CHK; 1. DR FunFam; 1.10.510.10:FF:000376; Tyrosine-protein kinase; 1. DR FunFam; 2.30.30.40:FF:000145; Tyrosine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000053; Tyrosine-protein kinase; 1. DR FunFam; 3.30.505.10:FF:000023; Tyrosine-protein kinase; 1. DR Gene3D; 3.30.505.10; SH2 domain; 1. DR Gene3D; 2.30.30.40; SH3 Domains; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR035027; Csk-like_SH2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR050198; Non-receptor_tyrosine_kinases. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR000980; SH2. DR InterPro; IPR036860; SH2_dom_sf. DR InterPro; IPR036028; SH3-like_dom_sf. DR InterPro; IPR001452; SH3_domain. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR24418; TYROSINE-PROTEIN KINASE; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00017; SH2; 1. DR Pfam; PF00018; SH3_1; 1. DR PRINTS; PR00401; SH2DOMAIN. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00252; SH2; 1. DR SMART; SM00326; SH3; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF55550; SH2 domain; 1. DR SUPFAM; SSF50044; SH3-domain; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS50001; SH2; 1. DR PROSITE; PS50002; SH3; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cytoplasm; Kinase; KW Membrane; Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; SH2 domain; SH3 domain; Transferase; KW Tyrosine-protein kinase. FT CHAIN 1..507 FT /note="Megakaryocyte-associated tyrosine-protein kinase" FT /id="PRO_0000088073" FT DOMAIN 48..110 FT /note="SH3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00192" FT DOMAIN 122..211 FT /note="SH2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00191" FT DOMAIN 235..482 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 482..507 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 491..507 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 352 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 241..249 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 262 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 501 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..41 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_044277" FT VAR_SEQ 1..24 FT /note="MAGRGSLVSWRAFHGCDSAEELPR -> MQGHFPAERREGRPRRGTRGQQQL FT L (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_043123" FT VARIANT 354 FT /note="A -> T (in an ovarian mucinous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041679" FT VARIANT 496 FT /note="A -> T (in dbSNP:rs35351680)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041680" FT VARIANT 503 FT /note="R -> Q (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs778726488)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041681" FT CONFLICT 107..108 FT /note="ER -> DG (in Ref. 1; AAA16703)" FT /evidence="ECO:0000305" FT CONFLICT 400 FT /note="Missing (in Ref. 1; AAA16703)" FT /evidence="ECO:0000305" FT CONFLICT 466..507 FT /note="ARRPPFRKLAEKLARELRSAGAPASVSGQDADGSTSPRSQEP -> PAGHPS FT ANWPRSWPGSYAVQVPQPPSQGRTPTVHLAPKPGALTPPGGPWPQRTERVESAAWGH FT (in Ref. 1; AAA16703)" FT /evidence="ECO:0000305" FT STRAND 52..57 FT /evidence="ECO:0007829|PDB:1X6G" FT STRAND 59..61 FT /evidence="ECO:0007829|PDB:1X6G" FT STRAND 74..79 FT /evidence="ECO:0007829|PDB:1X6G" FT STRAND 83..91 FT /evidence="ECO:0007829|PDB:1X6G" FT TURN 92..94 FT /evidence="ECO:0007829|PDB:1X6G" FT STRAND 97..101 FT /evidence="ECO:0007829|PDB:1X6G" FT HELIX 102..104 FT /evidence="ECO:0007829|PDB:1X6G" FT STRAND 105..107 FT /evidence="ECO:0007829|PDB:1X6G" FT STRAND 123..126 FT /evidence="ECO:0007829|PDB:1JWO" FT HELIX 129..135 FT /evidence="ECO:0007829|PDB:3US4" FT STRAND 144..148 FT /evidence="ECO:0007829|PDB:3US4" FT STRAND 150..152 FT /evidence="ECO:0007829|PDB:3US4" FT STRAND 156..162 FT /evidence="ECO:0007829|PDB:3US4" FT STRAND 165..174 FT /evidence="ECO:0007829|PDB:3US4" FT STRAND 177..188 FT /evidence="ECO:0007829|PDB:3US4" FT HELIX 189..198 FT /evidence="ECO:0007829|PDB:3US4" FT STRAND 203..205 FT /evidence="ECO:0007829|PDB:3US4" SQ SEQUENCE 507 AA; 56469 MW; 85721C6E024575EF CRC64; MAGRGSLVSW RAFHGCDSAE ELPRVSPRFL RAWHPPPVSA RMPTRRWAPG TQCITKCEHT RPKPGELAFR KGDVVTILEA CENKSWYRVK HHTSGQEGLL AAGALREREA LSADPKLSLM PWFHGKISGQ EAVQQLQPPE DGLFLVRESA RHPGDYVLCV SFGRDVIHYR VLHRDGHLTI DEAVFFCNLM DMVEHYSKDK GAICTKLVRP KRKHGTKSAE EELARAGWLL NLQHLTLGAQ IGEGEFGAVL QGEYLGQKVA VKNIKCDVTA QAFLDETAVM TKMQHENLVR LLGVILHQGL YIVMEHVSKG NLVNFLRTRG RALVNTAQLL QFSLHVAEGM EYLESKKLVH RDLAARNILV SEDLVAKVSD FGLAKAERKG LDSSRLPVKW TAPEALKHGK FTSKSDVWSF GVLLWEVFSY GRAPYPKMSL KEVSEAVEKG YRMEPPEGCP GPVHVLMSSC WEAEPARRPP FRKLAEKLAR ELRSAGAPAS VSGQDADGST SPRSQEP // ID MK14_HUMAN Reviewed; 360 AA. AC Q16539; A6ZJ92; A8K6P4; B0LPH0; B5TY32; O60776; Q13083; Q14084; Q8TDX0; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 23-JAN-2007, sequence version 3. DT 28-JAN-2026, entry version 267. DE RecName: Full=Mitogen-activated protein kinase 14 {ECO:0000305}; DE Short=MAP kinase 14; DE Short=MAPK 14; DE EC=2.7.11.24 {ECO:0000269|PubMed:11010976, ECO:0000269|PubMed:15284239, ECO:0000269|PubMed:35857590, ECO:0000269|PubMed:7493921}; DE AltName: Full=Cytokine suppressive anti-inflammatory drug-binding protein; DE Short=CSAID-binding protein; DE Short=CSBP; DE AltName: Full=MAP kinase MXI2; DE AltName: Full=MAX-interacting protein 2; DE AltName: Full=Mitogen-activated protein kinase p38 alpha; DE Short=MAP kinase p38 alpha; DE AltName: Full=Stress-activated protein kinase 2a; DE Short=SAPK2a; GN Name=MAPK14 {ECO:0000312|HGNC:HGNC:6876}; GN Synonyms=CSBP, CSBP1, CSBP2, CSPB1, MXI2, SAPK2A; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS CSBP1 AND CSBP2), AND PARTIAL PROTEIN RP SEQUENCE. RC TISSUE=Peripheral blood; RX PubMed=7997261; DOI=10.1038/372739a0; RA Lee J.C., Laydon J.T., McDonnell P.C., Gallagher T.F., Kumar S., Green D., RA McNulty D., Blumenthal M.J., Heys R.J., Landvatter S.W., Strickler J.E., RA McLaughlin M.M., Siemens I.R., Fisher S.M., Livi G.P., White J.R., RA Adams J.L., Young P.R.; RT "A protein kinase involved in the regulation of inflammatory cytokine RT biosynthesis."; RL Nature 372:739-746(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM CSBP2). RC TISSUE=Liver; RX PubMed=7696354; DOI=10.1016/0167-4889(95)00002-a; RA Han J., Richter B., Li Z., Kravchenko V.V., Ulevitch R.J.; RT "Molecular cloning of human p38 MAP kinase."; RL Biochim. Biophys. Acta 1265:224-227(1995). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM MXI2). RX PubMed=7479834; DOI=10.1073/pnas.92.23.10531; RA Zervos A.S., Faccio L., Gatto J.P., Kyriakis J.M., Brent R.; RT "Mxi2, a mitogen-activated protein kinase that recognizes and RT phosphorylates Max protein."; RL Proc. Natl. Acad. Sci. U.S.A. 92:10531-10534(1995). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM CSBP2). RC TISSUE=B-cell; RX PubMed=10727080; DOI=10.3109/10425179909033952; RA Herbison C.E., Sayer D.C., Bellgard M., Allcock R.J.N., Christiansen F.T., RA Price P.; RT "Structure and polymorphism of two stress-activated protein kinase genes RT centromeric of the MHC: SAPK2a and SAPK4."; RL DNA Seq. 10:229-243(1999). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM EXIP), AND ACTIVITY REGULATION. RC TISSUE=Renal cell carcinoma; RX PubMed=11866441; DOI=10.1006/bbrc.2002.6529; RA Sudo T., Yagasaki Y., Hama H., Watanabe N., Osada H.; RT "Exip, a new alternative splicing variant of p38 alpha, can induce an RT earlier onset of apoptosis in HeLa cells."; RL Biochem. Biophys. Res. Commun. 291:838-843(2002). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5). RX PubMed=19906316; DOI=10.1186/1471-2164-10-518; RA Wang P., Yu P., Gao P., Shi T., Ma D.; RT "Discovery of novel human transcript variants by analysis of intronic RT single-block EST with polyadenylation site."; RL BMC Genomics 10:518-518(2009). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM CSBP2). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM CSBP2). RA Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S., Neubert P., RA Kstrang K., Schatten R., Shen B., Henze S., Mar W., Korn B., Zuo D., Hu Y., RA LaBaer J.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NHLBI resequencing and genotyping service (RS&G); RL Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [13] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM CSBP2). RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [14] RP PROTEIN SEQUENCE OF 2-10. RC TISSUE=Platelet; RX PubMed=12665801; DOI=10.1038/nbt810; RA Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R., RA Vandekerckhove J.; RT "Exploring proteomes and analyzing protein processing by mass spectrometric RT identification of sorted N-terminal peptides."; RL Nat. Biotechnol. 21:566-569(2003). RN [15] RP PROTEIN SEQUENCE OF 174-186. RX PubMed=7923354; DOI=10.1016/0092-8674(94)90278-x; RA Freshney N.W., Rawlinson L., Guesdon F., Jones E., Cowley S., Hsuan J., RA Saklatvala J.; RT "Interleukin-1 activates a novel protein kinase cascade that results in the RT phosphorylation of Hsp27."; RL Cell 78:1039-1049(1994). RN [16] RP PHOSPHORYLATION AT THR-180 AND TYR-182, ACTIVITY REGULATION, AND RP SUBCELLULAR LOCATION. RX PubMed=7535770; DOI=10.1074/jbc.270.13.7420; RA Raingeaud J., Gupta S., Rogers J.S., Dickens M., Han J., Ulevitch R.J., RA Davis R.J.; RT "Pro-inflammatory cytokines and environmental stress cause p38 mitogen- RT activated protein kinase activation by dual phosphorylation on tyrosine and RT threonine."; RL J. Biol. Chem. 270:7420-7426(1995). RN [17] RP MUTAGENESIS OF ALA-34; LYS-53; ASP-168; THR-175; THR-180 AND TYR-182, AND RP CATALYTIC ACTIVITY. RX PubMed=7493921; DOI=10.1074/jbc.270.49.29043; RA Kumar S., McLaughlin M.M., McDonnell P.C., Lee J.C., Livi G.P., Young P.R.; RT "Human mitogen-activated protein kinase CSBP1, but not CSBP2, complements a RT hog1 deletion in yeast."; RL J. Biol. Chem. 270:29043-29046(1995). RN [18] RP PHOSPHORYLATION BY MAP2K3/MKK3 AND MAP2K6/MKK6, AND ACTIVITY REGULATION. RX PubMed=8622669; DOI=10.1128/mcb.16.3.1247; RA Raingeaud J., Whitmarsh A.J., Barrett T., Derijard B., Davis R.J.; RT "MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen- RT activated protein kinase signal transduction pathway."; RL Mol. Cell. Biol. 16:1247-1255(1996). RN [19] RP FUNCTION IN ACTIVATION OF RPS6KA5/MSK1. RX PubMed=9687510; DOI=10.1093/emboj/17.15.4426; RA Deak M., Clifton A.D., Lucocq J.M., Alessi D.R.; RT "Mitogen- and stress-activated protein kinase-1 (MSK1) is directly RT activated by MAPK and SAPK2/p38, and may mediate activation of CREB."; RL EMBO J. 17:4426-4441(1998). RN [20] RP FUNCTION IN PHOSPHORYLATION OF ATF2; ELK1 AND MBP, AND ACTIVITY REGULATION. RX PubMed=9430721; DOI=10.1074/jbc.273.3.1741; RA Enslen H., Raingeaud J., Davis R.J.; RT "Selective activation of p38 mitogen-activated protein (MAP) kinase RT isoforms by the MAP kinase kinases MKK3 and MKK6."; RL J. Biol. Chem. 273:1741-1748(1998). RN [21] RP INTERACTION WITH RPS6KA4, FUNCTION IN PHOSPHORYLATION OF RPS6KA4, AND RP SUBCELLULAR LOCATION. RX PubMed=9792677; DOI=10.1074/jbc.273.45.29661; RA Pierrat B., Correia J.D.S., Mary J.L., Tomas-Zuber M., Lesslauer W.; RT "RSK-B, a novel ribosomal S6 kinase family member, is a CREB kinase under RT dominant control of p38alpha mitogen-activated protein kinase RT (p38alphaMAPK)."; RL J. Biol. Chem. 273:29661-29671(1998). RN [22] RP INTERACTION WITH DUSP10, AND ACTIVITY REGULATION. RX PubMed=10391943; DOI=10.1074/jbc.274.28.19949; RA Tanoue T., Moriguchi T., Nishida E.; RT "Molecular cloning and characterization of a novel dual specificity RT phosphatase, MKP-5."; RL J. Biol. Chem. 274:19949-19956(1999). RN [23] RP FUNCTION IN PHOSPHORYLATION OF MEF2A. RX PubMed=9858528; DOI=10.1128/mcb.19.1.21; RA Zhao M., New L., Kravchenko V.V., Kato Y., Gram H., di Padova F., RA Olson E.N., Ulevitch R.J., Han J.-D.; RT "Regulation of the MEF2 family of transcription factors by p38."; RL Mol. Cell. Biol. 19:21-30(1999). RN [24] RP FUNCTION IN PHOSPHORYLATION OF MEF2A AND MEF2C. RX PubMed=10330143; DOI=10.1128/mcb.19.6.4028; RA Yang S.-H., Galanis A., Sharrocks A.D.; RT "Targeting of p38 mitogen-activated protein kinases to MEF2 transcription RT factors."; RL Mol. Cell. Biol. 19:4028-4038(1999). RN [25] RP FUNCTION. RC TISSUE=Hepatoma; RX PubMed=10943842; DOI=10.1016/s0092-8674(00)00027-1; RA Tamura K., Sudo T., Senftleben U., Dadak A.M., Johnson R., Karin M.; RT "Requirement for p38alpha in erythropoietin expression: a role for stress RT kinases in erythropoiesis."; RL Cell 102:221-231(2000). RN [26] RP FUNCTION (ISOFORM MXI2), COFACTOR, AND ACTIVITY REGULATION. RX PubMed=10838079; DOI=10.1016/s0014-5793(00)01598-2; RA Sanz V., Arozarena I., Crespo P.; RT "Distinct carboxy-termini confer divergent characteristics to the mitogen- RT activated protein kinase p38alpha and its splice isoform Mxi2."; RL FEBS Lett. 474:169-174(2000). RN [27] RP INTERACTION WITH CSNK2A1 AND CSNK2B, AND FUNCTION IN ACTIVATION OF CASEIN RP KINASE II. RX PubMed=10747897; DOI=10.1074/jbc.m000312200; RA Sayed M., Kim S.O., Salh B.S., Issinger O.G., Pelech S.L.; RT "Stress-induced activation of protein kinase CK2 by direct interaction with RT p38 mitogen-activated protein kinase."; RL J. Biol. Chem. 275:16569-16573(2000). RN [28] RP INTERACTION WITH MA2PK6/MKK6, PHOSPHORYLATION BY MAP2K6/MKK6, RP AUTOPHOSPHORYLATION, MUTAGENESIS OF LYS-54, AND CATALYTIC ACTIVITY. RX PubMed=11010976; DOI=10.1074/jbc.m007835200; RA Alonso G., Ambrosino C., Jones M., Nebreda A.R.; RT "Differential activation of p38 mitogen-activated protein kinase isoforms RT depending on signal strength."; RL J. Biol. Chem. 275:40641-40648(2000). RN [29] RP INTERACTION WITH DUSP1, AND ACTIVITY REGULATION. RX PubMed=11278799; DOI=10.1074/jbc.m010966200; RA Slack D.N., Seternes O.M., Gabrielsen M., Keyse S.M.; RT "Distinct binding determinants for ERK2/p38alpha and JNK map kinases RT mediate catalytic activation and substrate selectivity of map kinase RT phosphatase-1."; RL J. Biol. Chem. 276:16491-16500(2001). RN [30] RP INTERACTION WITH DUSP16, AND ACTIVITY REGULATION. RX PubMed=11359773; DOI=10.1074/jbc.m101981200; RA Tanoue T., Yamamoto T., Maeda R., Nishida E.; RT "A Novel MAPK phosphatase MKP-7 acts preferentially on JNK/SAPK and p38 RT alpha and beta MAPKs."; RL J. Biol. Chem. 276:26629-26639(2001). RN [31] RP FUNCTION AS MKNK2 KINASE. RX PubMed=11154262; DOI=10.1128/mcb.21.3.743-754.2001; RA Scheper G.C., Morrice N.A., Kleijn M., Proud C.G.; RT "The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a RT eukaryotic initiation factor 4E kinase with high levels of basal activity RT in mammalian cells."; RL Mol. Cell. Biol. 21:743-754(2001). RN [32] RP INTERACTION WITH CDC25B AND CDC25C, AND FUNCTION IN PHOSPHORYLATION OF RP CDC25B AND CDC25C. RX PubMed=11333986; DOI=10.1038/35075107; RA Bulavin D.V., Higashimoto Y., Popoff I.J., Gaarde W.A., Basrur V., RA Potapova O., Appella E., Fornace A.J. Jr.; RT "Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 RT kinase."; RL Nature 411:102-107(2001). RN [33] RP INTERACTION WITH TAB1, AUTOPHOSPHORYLATION, ACTIVITY REGULATION, AND RP CATALYTIC ACTIVITY. RX PubMed=11847341; DOI=10.1126/science.1067289; RA Ge B., Gram H., Di Padova F., Huang B., New L., Ulevitch R.J., Luo Y., RA Han J.; RT "MAPKK-independent activation of p38alpha mediated by TAB1-dependent RT autophosphorylation of p38alpha."; RL Science 295:1291-1294(2002). RN [34] RP MUTAGENESIS OF TYR-69; ASP-176; ASP-177; ALA-320; PHE-327 AND TRP-337. RX PubMed=15284239; DOI=10.1074/jbc.m404595200; RA Diskin R., Askari N., Capone R., Engelberg D., Livnah O.; RT "Active mutants of the human p38alpha mitogen-activated protein kinase."; RL J. Biol. Chem. 279:47040-47049(2004). RN [35] RP FUNCTION IN PHOSPHORYLATION OF S100A9. RX PubMed=15905572; DOI=10.4049/jimmunol.174.11.7257; RA Lominadze G., Rane M.J., Merchant M., Cai J., Ward R.A., McLeish K.R.; RT "Myeloid-related protein-14 is a p38 MAPK substrate in human neutrophils."; RL J. Immunol. 174:7257-7267(2005). RN [36] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=15592455; DOI=10.1038/nbt1046; RA Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H., RA Zha X.-M., Polakiewicz R.D., Comb M.J.; RT "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells."; RL Nat. Biotechnol. 23:94-101(2005). RN [37] RP PHOSPHORYLATION AT TYR-323, AND ACTIVITY REGULATION. RX PubMed=15735648; DOI=10.1038/ni1177; RA Salvador J.M., Mittelstadt P.R., Guszczynski T., Copeland T.D., RA Yamaguchi H., Appella E., Fornace A.J. Jr., Ashwell J.D.; RT "Alternative p38 activation pathway mediated by T cell receptor-proximal RT tyrosine kinases."; RL Nat. Immunol. 6:390-395(2005). RN [38] RP INTERACTION WITH TAB1, AUTOPHOSPHORYLATION, AND ACTIVITY REGULATION. RX PubMed=15735649; DOI=10.1038/ni1176; RA Salvador J.M., Mittelstadt P.R., Belova G.I., Fornace A.J. Jr., RA Ashwell J.D.; RT "The autoimmune suppressor Gadd45alpha inhibits the T cell alternative p38 RT activation pathway."; RL Nat. Immunol. 6:396-402(2005). RN [39] RP INTERACTION WITH SUPT20H. RX PubMed=16751104; DOI=10.1016/j.cell.2006.03.048; RA Zohn I.E., Li Y., Skolnik E.Y., Anderson K.V., Han J., Niswander L.; RT "p38 and a p38-interacting protein are critical for downregulation of E- RT cadherin during mouse gastrulation."; RL Cell 125:957-969(2006). RN [40] RP FUNCTION IN STRESS-INDUCED INTERNALIZATION OF EGFR. RX PubMed=16932740; DOI=10.1038/sj.emboj.7601297; RA Zwang Y., Yarden Y.; RT "p38 MAP kinase mediates stress-induced internalization of EGFR: RT implications for cancer chemotherapy."; RL EMBO J. 25:4195-4206(2006). RN [41] RP FUNCTION IN PHOSPHORYLATION OF SIAH2, AND ACTIVITY REGULATION. RX PubMed=17003045; DOI=10.1074/jbc.m606568200; RA Khurana A., Nakayama K., Williams S., Davis R.J., Mustelin T., Ronai Z.; RT "Regulation of the ring finger E3 ligase Siah2 by p38 MAPK."; RL J. Biol. Chem. 281:35316-35326(2006). RN [42] RP INTERACTION WITH NP60. RX PubMed=16352664; DOI=10.1242/jcs.02699; RA Fu J., Yang Z., Wei J., Han J., Gu J.; RT "Nuclear protein NP60 regulates p38 MAPK activity."; RL J. Cell Sci. 119:115-123(2006). RN [43] RP FUNCTION, PHOSPHORYLATION, SUBCELLULAR LOCATION, AND UBIQUITINATION. RX PubMed=17724032; DOI=10.1074/jbc.m703857200; RA Qi X., Pohl N.M., Loesch M., Hou S., Li R., Qin J.Z., Cuenda A., Chen G.; RT "p38alpha antagonizes p38gamma activity through c-Jun-dependent ubiquitin- RT proteasome pathways in regulating Ras transformation and stress response."; RL J. Biol. Chem. 282:31398-31408(2007). RN [44] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-263, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [45] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Platelet; RX PubMed=18088087; DOI=10.1021/pr0704130; RA Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J., RA Schuetz C., Walter U., Gambaryan S., Sickmann A.; RT "Phosphoproteome of resting human platelets."; RL J. Proteome Res. 7:526-534(2008). RN [46] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-16, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [47] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-180 AND TYR-182, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [48] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [49] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-180 AND TYR-182, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [50] RP FUNCTION IN INHIBITION OF AUTOPHAGY. RX PubMed=19893488; DOI=10.1038/emboj.2009.321; RA Webber J.L., Tooze S.A.; RT "Coordinated regulation of autophagy by p38alpha MAPK through mAtg9 and RT p38IP."; RL EMBO J. 29:27-40(2010). RN [51] RP FUNCTION IN PHOSPHORYLATION OF TIAR. RX PubMed=20932473; DOI=10.1016/j.molcel.2010.09.018; RA Reinhardt H.C., Hasskamp P., Schmedding I., Morandell S., van Vugt M.A., RA Wang X., Linding R., Ong S.E., Weaver D., Carr S.A., Yaffe M.B.; RT "DNA damage activates a spatially distinct late cytoplasmic cell-cycle RT checkpoint network controlled by MK2-mediated RNA stabilization."; RL Mol. Cell 40:34-49(2010). RN [52] RP INTERACTION WITH ADAM17, AND FUNCTION IN PHOSPHORYLATION OF ADAM17. RX PubMed=20188673; DOI=10.1016/j.molcel.2010.01.034; RA Xu P., Derynck R.; RT "Direct activation of TACE-mediated ectodomain shedding by p38 MAP kinase RT regulates EGF receptor-dependent cell proliferation."; RL Mol. Cell 37:551-566(2010). RN [53] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, PHOSPHORYLATION [LARGE SCALE RP ANALYSIS] AT SER-2; THR-180 AND TYR-182, CLEAVAGE OF INITIATOR METHIONINE RP [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE RP SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [54] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [55] RP IDENTIFICATION IN A COMPLEX WITH AKAP13; PKN1; ZAK AND MAP2K3. RX PubMed=21224381; DOI=10.1074/jbc.m110.185645; RA Cariolato L., Cavin S., Diviani D.; RT "A-kinase anchoring protein (AKAP)-Lbc anchors a PKN-based signaling RT complex involved in alpha1-adrenergic receptor-induced p38 activation."; RL J. Biol. Chem. 286:7925-7937(2011). RN [56] RP FUNCTION (MICROBIAL INFECTION). RC TISSUE=T-cell; RX PubMed=21586573; DOI=10.1074/jbc.m111.234062; RA Peng H., Wang X., Barnes P.F., Tang H., Townsend J.C., Samten B.; RT "The Mycobacterium tuberculosis early secreted antigenic target of 6 kDa RT inhibits T cell interferon-gamma production through the p38 mitogen- RT activated protein kinase pathway."; RL J. Biol. Chem. 286:24508-24518(2011). RN [57] RP ACETYLATION AT LYS-53 AND LYS-152 BY KAT2B/PCAF AND EP300, AND RP DEACETYLATION BY HDAC3. RX PubMed=21444723; DOI=10.1128/mcb.01205-10; RA Pillai V.B., Sundaresan N.R., Samant S.A., Wolfgeher D., Trivedi C.M., RA Gupta M.P.; RT "Acetylation of a conserved lysine residue in the ATP binding pocket of p38 RT augments its kinase activity during hypertrophy of cardiomyocytes."; RL Mol. Cell. Biol. 31:2349-2363(2011). RN [58] RP INTERACTION WITH CDK5RAP3 AND PPM1D, AND DEPHOSPHORYLATION BY PPM1D. RX PubMed=21283629; DOI=10.1371/journal.pone.0016427; RA An H., Lu X., Liu D., Yarbrough W.G.; RT "LZAP inhibits p38 MAPK (p38) phosphorylation and activity by facilitating RT p38 association with the wild-type p53 induced phosphatase 1 (WIP1)."; RL PLoS ONE 6:E16427-E16427(2011). RN [59] RP REVIEW ON FUNCTION. RX PubMed=12452429; DOI=10.1515/bc.2002.173; RA Shi Y., Gaestel M.; RT "In the cellular garden of forking paths: how p38 MAPKs signal for RT downstream assistance."; RL Biol. Chem. 383:1519-1536(2002). RN [60] RP REVIEW ON ACTIVITY REGULATION, AND REVIEW ON FUNCTION. RX PubMed=20626350; DOI=10.1042/bj20100323; RA Cuadrado A., Nebreda A.R.; RT "Mechanisms and functions of p38 MAPK signalling."; RL Biochem. J. 429:403-417(2010). RN [61] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2; THR-180 AND TYR-182, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [62] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [63] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [64] RP SUBCELLULAR LOCATION. RX PubMed=30878395; DOI=10.1016/j.yjmcc.2019.03.005; RA Li C., Li J., Xue K., Zhang J., Wang C., Zhang Q., Chen X., Gao C., Yu X., RA Sun L.; RT "MicroRNA-143-3p promotes human cardiac fibrosis via targeting sprouty3 RT after myocardial infarction."; RL J. Mol. Cell. Cardiol. 129:281-292(2019). RN [65] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=35857590; DOI=10.1126/science.abl6324; RA Robinson K.S., Toh G.A., Rozario P., Chua R., Bauernfried S., Sun Z., RA Firdaus M.J., Bayat S., Nadkarni R., Poh Z.S., Tham K.C., Harapas C.R., RA Lim C.K., Chu W., Tay C.W.S., Tan K.Y., Zhao T., Bonnard C., Sobota R., RA Connolly J.E., Common J., Masters S.L., Chen K.W., Ho L., Wu B., RA Hornung V., Zhong F.L.; RT "ZAKalpha-driven ribotoxic stress response activates the human NLRP1 RT inflammasome."; RL Science 377:328-335(2022). RN [66] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS). RX PubMed=8910361; DOI=10.1074/jbc.271.44.27696; RA Wilson K.P., Fitzgibbon M.J., Caron P.R., Griffith J.P., Chen W., RA McCaffrey P.G., Chambers S.P., Su M.S.-S.; RT "Crystal structure of p38 mitogen-activated protein kinase."; RL J. Biol. Chem. 271:27696-27700(1996). RN [67] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS). RX PubMed=9095200; DOI=10.1038/nsb0497-311; RA Tong L., Pav S., White D.M., Rogers S., Crane K.M., Cywin C.L., Brown M.L., RA Pargellis C.A.; RT "A highly specific inhibitor of human p38 MAP kinase binds in the ATP RT pocket."; RL Nat. Struct. Biol. 4:311-316(1997). RN [68] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS). RX PubMed=9753691; DOI=10.1016/s0969-2126(98)00113-0; RA Wang Z., Canagarajah B.J., Boehm J.C., Kassisa S., Cobb M.H., Young P.R., RA Abdel-Meguid S., Adams J.L., Goldsmith E.J.; RT "Structural basis of inhibitor selectivity in MAP kinases."; RL Structure 6:1117-1128(1998). RN [69] RP X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS). RX PubMed=10633045; DOI=10.1021/jm990401t; RA Shewchuk L., Hassell A., Wisely B., Rocque W., Holmes W., Veal J., RA Kuyper L.F.; RT "Binding mode of the 4-anilinoquinazoline class of protein kinase RT inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to RT cyclin-dependent kinase 2 and p38 kinase."; RL J. Med. Chem. 43:133-138(2000). RN [70] RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS), AND ACTIVITY REGULATION. RX PubMed=11896401; DOI=10.1038/nsb770; RA Pargellis C., Tong L., Churchill L., Cirillo P.F., Gilmore T., Graham A.G., RA Grob P.M., Hickey E.R., Moss N., Pav S., Regan J.; RT "Inhibition of p38 MAP kinase by utilizing a novel allosteric binding RT site."; RL Nat. Struct. Biol. 9:268-272(2002). RN [71] RP X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS), AND ACTIVITY REGULATION. RX PubMed=12482439; DOI=10.1016/s0960-894x(02)00752-7; RA Stelmach J.E., Liu L., Patel S.B., Pivnichny J.V., Scapin G., Singh S., RA Hop C.E., Wang Z., Strauss J.R., Cameron P.M., Nichols E.A., O'Keefe S.J., RA O'Neill E.A., Schmatz D.M., Schwartz C.D., Thompson C.M., Zaller D.M., RA Doherty J.B.; RT "Design and synthesis of potent, orally bioavailable dihydroquinazolinone RT inhibitors of p38 MAP kinase."; RL Bioorg. Med. Chem. Lett. 13:277-280(2003). RN [72] RP X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS), AND ACTIVITY REGULATION. RX PubMed=14561090; DOI=10.1021/jm0301787; RA Trejo A., Arzeno H., Browner M., Chanda S., Cheng S., Comer D.D., RA Dalrymple S.A., Dunten P., Lafargue J., Lovejoy B., Freire-Moar J., Lim J., RA Mcintosh J., Miller J., Papp E., Reuter D., Roberts R., Sanpablo F., RA Saunders J., Song K., Villasenor A., Warren S.D., Welch M., Weller P., RA Whiteley P.E., Zeng L., Goldstein D.M.; RT "Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase."; RL J. Med. Chem. 46:4702-4713(2003). RN [73] {ECO:0007744|PDB:1OUK, ECO:0007744|PDB:1OUY, ECO:0007744|PDB:1OVE} RP X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) IN COMPLEX WITH INHIBITOR. RX PubMed=12897767; DOI=10.1038/nsb949; RA Fitzgerald C.E., Patel S.B., Becker J.W., Cameron P.M., Zaller D., RA Pikounis V.B., O'Keefe S.J., Scapin G.; RT "Structural basis for p38alpha MAP kinase quinazolinone and pyridol- RT pyrimidine inhibitor specificity."; RL Nat. Struct. Biol. 10:764-769(2003). RN [74] RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS), AND ACTIVITY REGULATION. RX PubMed=14726206; DOI=10.1016/j.bbapap.2003.09.009; RA Patel S.B., Cameron P.M., Frantz-Wattley B., O'Neill E., Becker J.W., RA Scapin G.; RT "Lattice stabilization and enhanced diffraction in human p38 alpha crystals RT by protein engineering."; RL Biochim. Biophys. Acta 1696:67-73(2004). RN [75] {ECO:0007744|PDB:2BAJ, ECO:0007744|PDB:2BAK, ECO:0007744|PDB:2BAL, ECO:0007744|PDB:2BAQ} RP X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 2-359 IN COMPLEX WITH INHIBITOR. RX PubMed=16342939; DOI=10.1021/bi051714v; RA Sullivan J.E., Holdgate G.A., Campbell D., Timms D., Gerhardt S., Breed J., RA Breeze A.L., Bermingham A., Pauptit R.A., Norman R.A., Embrey K.J., RA Read J., VanScyoc W.S., Ward W.H.; RT "Prevention of MKK6-dependent activation by binding to p38alpha MAP RT kinase."; RL Biochemistry 44:16475-16490(2005). RN [76] RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 2-359, AND ACTIVITY REGULATION. RX PubMed=15837335; DOI=10.1016/j.bmcl.2005.02.010; RA Tamayo N., Liao L., Goldberg M., Powers D., Tudor Y.Y., Yu V., Wong L.M., RA Henkle B., Middleton S., Syed R., Harvey T., Jang G., Hungate R., RA Dominguez C.; RT "Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase."; RL Bioorg. Med. Chem. Lett. 15:2409-2413(2005). RN [77] RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS), AND ACTIVITY REGULATION. RX PubMed=16169718; DOI=10.1016/j.bmcl.2005.08.038; RA Michelotti E.L., Moffett K.K., Nguyen D., Kelly M.J., Shetty R., Chai X., RA Northrop K., Namboodiri V., Campbell B., Flynn G.A., Fujimoto T., RA Hollinger F.P., Bukhtiyarova M., Springman E.B., Karpusas M.; RT "Two classes of p38alpha MAP kinase inhibitors having a common RT diphenylether core but exhibiting divergent binding modes."; RL Bioorg. Med. Chem. Lett. 15:5274-5279(2005). RN [78] {ECO:0007744|PDB:1W7H, ECO:0007744|PDB:1WBO} RP X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 2-359 IN COMPLEX WITH INHIBITOR. RX PubMed=15658854; DOI=10.1021/jm0495778; RA Hartshorn M.J., Murray C.W., Cleasby A., Frederickson M., Tickle I.J., RA Jhoti H.; RT "Fragment-based lead discovery using X-ray crystallography."; RL J. Med. Chem. 48:403-413(2005). RN [79] RP X-RAY CRYSTALLOGRAPHY (4.0 ANGSTROMS) OF 2-359 IN COMPLEX WITH MAPKAPK2. RX PubMed=17255097; DOI=10.1074/jbc.m611165200; RA ter Haar E., Prabhakar P., Liu X., Lepre C.; RT "Crystal structure of the p38 alpha-MAPKAP kinase 2 heterodimer."; RL J. Biol. Chem. 282:9733-9739(2007). RN [80] RP ERRATUM OF PUBMED:17255097. RA ter Haar E., Prabhakar P., Liu X., Lepre C.; RL J. Biol. Chem. 282:14684-14684(2007). RN [81] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-51; ARG-322 AND GLY-343. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine kinase which acts as an essential component CC of the MAP kinase signal transduction pathway. MAPK14 is one of the CC four p38 MAPKs which play an important role in the cascades of cellular CC responses evoked by extracellular stimuli such as pro-inflammatory CC cytokines or physical stress leading to direct activation of CC transcription factors. Accordingly, p38 MAPKs phosphorylate a broad CC range of proteins and it has been estimated that they may have CC approximately 200 to 300 substrates each. Some of the targets are CC downstream kinases which are activated through phosphorylation and CC further phosphorylate additional targets. RPS6KA5/MSK1 and RPS6KA4/MSK2 CC can directly phosphorylate and activate transcription factors such as CC CREB1, ATF1, the NF-kappa-B isoform RELA/NFKB3, STAT1 and STAT3, but CC can also phosphorylate histone H3 and the nucleosomal protein HMGN1 CC (PubMed:9687510, PubMed:9792677). RPS6KA5/MSK1 and RPS6KA4/MSK2 play CC important roles in the rapid induction of immediate-early genes in CC response to stress or mitogenic stimuli, either by inducing chromatin CC remodeling or by recruiting the transcription machinery CC (PubMed:9687510, PubMed:9792677). On the other hand, two other kinase CC targets, MAPKAPK2/MK2 and MAPKAPK3/MK3, participate in the control of CC gene expression mostly at the post-transcriptional level, by CC phosphorylating ZFP36 (tristetraprolin) and ELAVL1, and by regulating CC EEF2K, which is important for the elongation of mRNA during CC translation. MKNK1/MNK1 and MKNK2/MNK2, two other kinases activated by CC p38 MAPKs, regulate protein synthesis by phosphorylating the initiation CC factor EIF4E2 (PubMed:11154262). MAPK14 also interacts with casein CC kinase II, leading to its activation through autophosphorylation and CC further phosphorylation of TP53/p53 (PubMed:10747897). In the CC cytoplasm, the p38 MAPK pathway is an important regulator of protein CC turnover. For example, CFLAR is an inhibitor of TNF-induced apoptosis CC whose proteasome-mediated degradation is regulated by p38 MAPK CC phosphorylation. In a similar way, MAPK14 phosphorylates the ubiquitin CC ligase SIAH2, regulating its activity towards EGLN3 (PubMed:17003045). CC MAPK14 may also inhibit the lysosomal degradation pathway of autophagy CC by interfering with the intracellular trafficking of the transmembrane CC protein ATG9 (PubMed:19893488). Another function of MAPK14 is to CC regulate the endocytosis of membrane receptors by different mechanisms CC that impinge on the small GTPase RAB5A. In addition, clathrin-mediated CC EGFR internalization induced by inflammatory cytokines and UV CC irradiation depends on MAPK14-mediated phosphorylation of EGFR itself CC as well as of RAB5A effectors (PubMed:16932740). Ectodomain shedding of CC transmembrane proteins is regulated by p38 MAPKs as well. In response CC to inflammatory stimuli, p38 MAPKs phosphorylate the membrane- CC associated metalloprotease ADAM17 (PubMed:20188673). Such CC phosphorylation is required for ADAM17-mediated ectodomain shedding of CC TGF-alpha family ligands, which results in the activation of EGFR CC signaling and cell proliferation. Another p38 MAPK substrate is FGFR1. CC FGFR1 can be translocated from the extracellular space into the cytosol CC and nucleus of target cells, and regulates processes such as rRNA CC synthesis and cell growth. FGFR1 translocation requires p38 MAPK CC activation. In the nucleus, many transcription factors are CC phosphorylated and activated by p38 MAPKs in response to different CC stimuli. Classical examples include ATF1, ATF2, ATF6, ELK1, PTPRH, CC DDIT3, TP53/p53 and MEF2C and MEF2A (PubMed:10330143, PubMed:9430721, CC PubMed:9858528). The p38 MAPKs are emerging as important modulators of CC gene expression by regulating chromatin modifiers and remodelers. The CC promoters of several genes involved in the inflammatory response, such CC as IL6, IL8 and IL12B, display a p38 MAPK-dependent enrichment of CC histone H3 phosphorylation on 'Ser-10' (H3S10ph) in LPS-stimulated CC myeloid cells. This phosphorylation enhances the accessibility of the CC cryptic NF-kappa-B-binding sites marking promoters for increased NF- CC kappa-B recruitment. Phosphorylates CDC25B and CDC25C which is required CC for binding to 14-3-3 proteins and leads to initiation of a G2 delay CC after ultraviolet radiation (PubMed:11333986). Phosphorylates TIAR CC following DNA damage, releasing TIAR from GADD45A mRNA and preventing CC mRNA degradation (PubMed:20932473). The p38 MAPKs may also have kinase- CC independent roles, which are thought to be due to the binding to CC targets in the absence of phosphorylation. Protein O-Glc-N-acylation CC catalyzed by the OGT is regulated by MAPK14, and, although OGT does not CC seem to be phosphorylated by MAPK14, their interaction increases upon CC MAPK14 activation induced by glucose deprivation. This interaction may CC regulate OGT activity by recruiting it to specific targets such as CC neurofilament H, stimulating its O-Glc-N-acylation. Required in mid- CC fetal development for the growth of embryo-derived blood vessels in the CC labyrinth layer of the placenta. Also plays an essential role in CC developmental and stress-induced erythropoiesis, through regulation of CC EPO gene expression (PubMed:10943842). Isoform MXI2 activation is CC stimulated by mitogens and oxidative stress and only poorly CC phosphorylates ELK1 and ATF2. Isoform EXIP may play a role in the early CC onset of apoptosis. Phosphorylates S100A9 at 'Thr-113' CC (PubMed:15905572). Phosphorylates NLRP1 downstream of MAP3K20/ZAK in CC response to UV-B irradiation and ribosome collisions, promoting CC activation of the NLRP1 inflammasome and pyroptosis (PubMed:35857590). CC {ECO:0000269|PubMed:10330143, ECO:0000269|PubMed:10747897, CC ECO:0000269|PubMed:10943842, ECO:0000269|PubMed:11154262, CC ECO:0000269|PubMed:11333986, ECO:0000269|PubMed:15905572, CC ECO:0000269|PubMed:16932740, ECO:0000269|PubMed:17003045, CC ECO:0000269|PubMed:17724032, ECO:0000269|PubMed:19893488, CC ECO:0000269|PubMed:20188673, ECO:0000269|PubMed:20932473, CC ECO:0000269|PubMed:35857590, ECO:0000269|PubMed:9430721, CC ECO:0000269|PubMed:9687510, ECO:0000269|PubMed:9792677, CC ECO:0000269|PubMed:9858528}. CC -!- FUNCTION: (Microbial infection) Activated by phosphorylation by CC M.tuberculosis EsxA in T-cells leading to inhibition of IFN-gamma CC production; phosphorylation is apparent within 15 minutes and is CC inhibited by kinase-specific inhibitors SB203580 and siRNA CC (PubMed:21586573). {ECO:0000269|PubMed:21586573}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.24; CC Evidence={ECO:0000269|PubMed:11010976, ECO:0000269|PubMed:35857590}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:11010976, ECO:0000269|PubMed:35857590}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.24; CC Evidence={ECO:0000269|PubMed:11010976, ECO:0000269|PubMed:35857590}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609; CC Evidence={ECO:0000269|PubMed:11010976, ECO:0000269|PubMed:35857590}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:10838079}; CC -!- ACTIVITY REGULATION: Activated by cell stresses such as DNA damage, CC heat shock, osmotic shock, anisomycin and sodium arsenite, as well as CC pro-inflammatory stimuli such as bacterial lipopolysaccharide (LPS) and CC interleukin-1. Activation occurs through dual phosphorylation of Thr- CC 180 and Tyr-182 by either of two dual specificity kinases, MAP2K3/MKK3 CC or MAP2K6/MKK6, and potentially also MAP2K4/MKK4, as well as by TAB1- CC mediated autophosphorylation. MAPK14 phosphorylated on both Thr-180 and CC Tyr-182 is 10-20-fold more active than MAPK14 phosphorylated only on CC Thr-180, whereas MAPK14 phosphorylated on Tyr-182 alone is inactive. CC whereas Thr-180 is necessary for catalysis, Tyr-182 may be required for CC auto-activation and substrate recognition. Phosphorylated at Tyr-323 by CC ZAP70 in an alternative activation pathway in response to TCR signaling CC in T-cells. This alternative pathway is inhibited by GADD45A. Inhibited CC by dual specificity phosphatases, such as DUSP1, DUSP10, and DUSP16. CC Specifically inhibited by the binding of pyridinyl-imidazole compounds, CC which are cytokine-suppressive anti-inflammatory drugs (CSAID). Isoform CC Mxi2 is 100-fold less sensitive to these agents than the other isoforms CC and is not inhibited by DUSP1. Isoform Exip is not activated by MAP2K6. CC SB203580 is an inhibitor of MAPK14. {ECO:0000269|PubMed:10391943, CC ECO:0000269|PubMed:10838079, ECO:0000269|PubMed:11278799, CC ECO:0000269|PubMed:11359773, ECO:0000269|PubMed:11847341, CC ECO:0000269|PubMed:11866441, ECO:0000269|PubMed:11896401, CC ECO:0000269|PubMed:12482439, ECO:0000269|PubMed:14561090, CC ECO:0000269|PubMed:14726206, ECO:0000269|PubMed:15735648, CC ECO:0000269|PubMed:15735649, ECO:0000269|PubMed:15837335, CC ECO:0000269|PubMed:16169718, ECO:0000269|PubMed:17003045, CC ECO:0000269|PubMed:7535770, ECO:0000269|PubMed:8622669, CC ECO:0000269|PubMed:9430721}. CC -!- SUBUNIT: Component of a signaling complex containing at least AKAP13, CC PKN1, MAPK14, ZAK and MAP2K3. Within this complex, AKAP13 interacts CC directly with PKN1, which in turn recruits MAPK14, MAP2K3 and ZAK CC (PubMed:21224381). Binds to a kinase interaction motif within the CC protein tyrosine phosphatase, PTPRR (By similarity). This interaction CC retains MAPK14 in the cytoplasm and prevents nuclear accumulation (By CC similarity). Interacts with SPAG9 and GADD45A (By similarity). CC Interacts with CDC25B, CDC25C, DUSP1, DUSP10, DUSP16, NP60, SUPT20H and CC TAB1. Interacts with casein kinase II subunits CSNK2A1 and CSNK2B. CC Interacts with PPM1D. Interacts with CDK5RAP3; recruits PPM1D to MAPK14 CC and may regulate its dephosphorylation (PubMed:21283629). Interacts CC with DUSP2; this interaction does not lead to catalytic activation of CC DUSP2 and dephosphorylation of MAPK14 (By similarity). CC {ECO:0000250|UniProtKB:P47811, ECO:0000269|PubMed:10391943, CC ECO:0000269|PubMed:10747897, ECO:0000269|PubMed:11010976, CC ECO:0000269|PubMed:11278799, ECO:0000269|PubMed:11333986, CC ECO:0000269|PubMed:11359773, ECO:0000269|PubMed:11847341, CC ECO:0000269|PubMed:12897767, ECO:0000269|PubMed:15658854, CC ECO:0000269|PubMed:15735649, ECO:0000269|PubMed:16342939, CC ECO:0000269|PubMed:16352664, ECO:0000269|PubMed:16751104, CC ECO:0000269|PubMed:17255097, ECO:0000269|PubMed:20188673, CC ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:21283629, CC ECO:0000269|PubMed:9792677}. CC -!- INTERACTION: CC Q16539; P48730-2: CSNK1D; NbExp=3; IntAct=EBI-73946, EBI-9087876; CC Q16539; P28562: DUSP1; NbExp=4; IntAct=EBI-73946, EBI-975493; CC Q16539; Q9BY84: DUSP16; NbExp=4; IntAct=EBI-73946, EBI-3443956; CC Q16539; Q16829: DUSP7; NbExp=2; IntAct=EBI-73946, EBI-1265847; CC Q16539; Q99956: DUSP9; NbExp=6; IntAct=EBI-73946, EBI-3906678; CC Q16539; P68104: EEF1A1; NbExp=3; IntAct=EBI-73946, EBI-352162; CC Q16539; Q969H0: FBXW7; NbExp=5; IntAct=EBI-73946, EBI-359574; CC Q16539; P46734: MAP2K3; NbExp=7; IntAct=EBI-73946, EBI-602462; CC Q16539; P52564: MAP2K6; NbExp=3; IntAct=EBI-73946, EBI-448135; CC Q16539; P27361: MAPK3; NbExp=5; IntAct=EBI-73946, EBI-73995; CC Q16539; P49137: MAPKAPK2; NbExp=16; IntAct=EBI-73946, EBI-993299; CC Q16539; Q16644: MAPKAPK3; NbExp=16; IntAct=EBI-73946, EBI-1384657; CC Q16539; Q6PJG2: MIDEAS; NbExp=3; IntAct=EBI-73946, EBI-2795569; CC Q16539; Q9BUB5: MKNK1; NbExp=7; IntAct=EBI-73946, EBI-73837; CC Q16539; Q9HBH9: MKNK2; NbExp=5; IntAct=EBI-73946, EBI-2864341; CC Q16539; P35813: PPM1A; NbExp=2; IntAct=EBI-73946, EBI-989143; CC Q16539; Q15256: PTPRR; NbExp=4; IntAct=EBI-73946, EBI-2265659; CC Q16539; P06400: RB1; NbExp=4; IntAct=EBI-73946, EBI-491274; CC Q16539; O75676: RPS6KA4; NbExp=10; IntAct=EBI-73946, EBI-73933; CC Q16539; O75582: RPS6KA5; NbExp=4; IntAct=EBI-73946, EBI-73869; CC Q16539; Q8NEM7: SUPT20H; NbExp=5; IntAct=EBI-73946, EBI-946984; CC Q16539; Q15750: TAB1; NbExp=4; IntAct=EBI-73946, EBI-358643; CC Q16539; Q92574: TSC1; NbExp=2; IntAct=EBI-73946, EBI-1047085; CC Q16539; Q07352: ZFP36L1; NbExp=2; IntAct=EBI-73946, EBI-721823; CC Q16539; O43257: ZNHIT1; NbExp=7; IntAct=EBI-73946, EBI-347522; CC Q16539-1; P22736-1: NR4A1; NbExp=5; IntAct=EBI-15834191, EBI-16085263; CC Q16539-1; Q15256-1: PTPRR; NbExp=6; IntAct=EBI-15834191, EBI-16067395; CC Q16539-1; P54830-1: Ptpn5; Xeno; NbExp=6; IntAct=EBI-15834191, EBI-16067443; CC Q16539-3; P28482: MAPK1; NbExp=5; IntAct=EBI-6932370, EBI-959949; CC Q16539-3; P49790: NUP153; NbExp=2; IntAct=EBI-6932370, EBI-286779; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:7535770}. Nucleus CC {ECO:0000269|PubMed:30878395, ECO:0000269|PubMed:7535770}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=5; CC Name=CSBP2; CC IsoId=Q16539-1; Sequence=Displayed; CC Name=CSBP1; CC IsoId=Q16539-2; Sequence=VSP_004842; CC Name=Mxi2; CC IsoId=Q16539-3; Sequence=VSP_004844; CC Name=Exip; Synonyms=Exon skip; CC IsoId=Q16539-4; Sequence=VSP_004843, VSP_004845; CC Name=5; CC IsoId=Q16539-5; Sequence=VSP_057194; CC -!- TISSUE SPECIFICITY: Brain, heart, placenta, pancreas and skeletal CC muscle. Expressed to a lesser extent in lung, liver and kidney. CC -!- DOMAIN: The TXY motif contains the threonine and tyrosine residues CC whose phosphorylation activates the MAP kinases. CC -!- PTM: Dually phosphorylated on Thr-180 and Tyr-182 by the MAP2Ks CC MAP2K3/MKK3, MAP2K4/MKK4 and MAP2K6/MKK6 in response to inflammatory CC citokines, environmental stress or growth factors, which activates the CC enzyme. Dual phosphorylation can also be mediated by TAB1-mediated CC autophosphorylation. TCR engagement in T-cells also leads to Tyr-323 CC phosphorylation by ZAP70. Dephosphorylated and inactivated by DUPS1, CC DUSP10 and DUSP16. PPM1D also mediates dephosphorylation and CC inactivation of MAPK14 (PubMed:21283629). {ECO:0000269|PubMed:11010976, CC ECO:0000269|PubMed:15735648, ECO:0000269|PubMed:17724032, CC ECO:0000269|PubMed:21283629, ECO:0000269|PubMed:7535770, CC ECO:0000269|PubMed:8622669}. CC -!- PTM: Acetylated at Lys-53 and Lys-152 by KAT2B and EP300. Acetylation CC at Lys-53 increases the affinity for ATP and enhances kinase activity. CC Lys-53 and Lys-152 are deacetylated by HDAC3. CC {ECO:0000269|PubMed:21444723}. CC -!- PTM: Ubiquitinated. Ubiquitination leads to degradation by the CC proteasome pathway. {ECO:0000269|PubMed:17724032}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr CC protein kinase family. MAP kinase subfamily. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Wikipedia; Note=P38 mitogen-activated protein CC kinases entry; CC URL="https://en.wikipedia.org/wiki/P38_mitogen-activated_protein_kinases"; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41292/MAPK14"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L35263; AAA57455.1; -; mRNA. DR EMBL; L35264; AAA57456.1; -; mRNA. DR EMBL; L35253; AAA74301.1; -; mRNA. DR EMBL; U19775; AAC50329.1; -; mRNA. DR EMBL; AF100544; AAF36770.1; -; mRNA. DR EMBL; AB074150; BAB85654.1; -; mRNA. DR EMBL; FJ032367; ACI00233.1; -; mRNA. DR EMBL; AK291709; BAF84398.1; -; mRNA. DR EMBL; BT006933; AAP35579.1; -; mRNA. DR EMBL; CR536505; CAG38743.1; -; mRNA. DR EMBL; EU332860; ABY87549.1; -; Genomic_DNA. DR EMBL; Z95152; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471081; EAX03869.1; -; Genomic_DNA. DR EMBL; BC000092; AAH00092.1; -; mRNA. DR EMBL; BC031574; AAH31574.1; -; mRNA. DR CCDS; CCDS4815.1; -. [Q16539-2] DR CCDS; CCDS4816.1; -. [Q16539-1] DR CCDS; CCDS4817.1; -. [Q16539-4] DR PIR; S53536; S53536. DR RefSeq; NP_001306.1; NM_001315.3. [Q16539-2] DR RefSeq; NP_620581.1; NM_139012.3. [Q16539-1] DR RefSeq; NP_620582.1; NM_139013.3. [Q16539-3] DR RefSeq; NP_620583.1; NM_139014.3. [Q16539-4] DR PDB; 1A9U; X-ray; 2.50 A; A=1-360. DR PDB; 1BL6; X-ray; 2.50 A; A=1-360. DR PDB; 1BL7; X-ray; 2.50 A; A=1-360. DR PDB; 1BMK; X-ray; 2.40 A; A=1-360. DR PDB; 1DI9; X-ray; 2.60 A; A=1-360. DR PDB; 1IAN; X-ray; 2.00 A; A=2-360. DR PDB; 1KV1; X-ray; 2.50 A; A=1-360. DR PDB; 1KV2; X-ray; 2.80 A; A=1-360. DR PDB; 1M7Q; X-ray; 2.40 A; A=1-360. DR PDB; 1OUK; X-ray; 2.50 A; A=1-360. DR PDB; 1OUY; X-ray; 2.50 A; A=1-360. DR PDB; 1OVE; X-ray; 2.10 A; A=1-360. DR PDB; 1OZ1; X-ray; 2.10 A; A=1-360. DR PDB; 1R39; X-ray; 2.30 A; A=1-360. DR PDB; 1R3C; X-ray; 2.00 A; A=1-360. DR PDB; 1W7H; X-ray; 2.21 A; A=2-360. DR PDB; 1W82; X-ray; 2.20 A; A=2-360. DR PDB; 1W83; X-ray; 2.50 A; A=2-360. DR PDB; 1W84; X-ray; 2.20 A; A=2-360. DR PDB; 1WBN; X-ray; 2.40 A; A=2-360. DR PDB; 1WBO; X-ray; 2.16 A; A=2-360. DR PDB; 1WBS; X-ray; 1.80 A; A=2-360. DR PDB; 1WBT; X-ray; 2.00 A; A=2-360. DR PDB; 1WBV; X-ray; 2.00 A; A=2-360. DR PDB; 1WBW; X-ray; 2.41 A; A=2-360. DR PDB; 1WFC; X-ray; 2.30 A; A=1-360. DR PDB; 1YQJ; X-ray; 2.00 A; A=2-360. DR PDB; 1ZYJ; X-ray; 2.00 A; A=1-360. DR PDB; 1ZZ2; X-ray; 2.00 A; A=1-360. DR PDB; 1ZZL; X-ray; 2.00 A; A=4-354. DR PDB; 2BAJ; X-ray; 2.25 A; A=2-360. DR PDB; 2BAK; X-ray; 2.20 A; A=2-360. DR PDB; 2BAL; X-ray; 2.10 A; A=2-360. DR PDB; 2BAQ; X-ray; 2.80 A; A=2-360. DR PDB; 2FSL; X-ray; 1.70 A; X=2-360. DR PDB; 2FSM; X-ray; 1.86 A; X=2-360. DR PDB; 2FSO; X-ray; 1.83 A; X=2-360. DR PDB; 2FST; X-ray; 1.45 A; X=2-360. DR PDB; 2GFS; X-ray; 1.75 A; A=2-360. DR PDB; 2I0H; X-ray; 2.00 A; A=1-360. DR PDB; 2LGC; NMR; -; A=2-354. DR PDB; 2NPQ; X-ray; 1.80 A; A=2-360. DR PDB; 2OKR; X-ray; 2.00 A; A/D=2-360. DR PDB; 2ONL; X-ray; 4.00 A; A/B=2-360. DR PDB; 2QD9; X-ray; 1.70 A; A=2-360. DR PDB; 2RG5; X-ray; 2.40 A; A=2-360. DR PDB; 2RG6; X-ray; 1.72 A; A=2-360. DR PDB; 2Y8O; X-ray; 1.95 A; A=1-360. DR PDB; 2YIS; X-ray; 2.00 A; A=2-360. DR PDB; 2YIW; X-ray; 2.00 A; A=2-360. DR PDB; 2YIX; X-ray; 2.30 A; A=4-354. DR PDB; 2ZAZ; X-ray; 1.80 A; A=1-360. DR PDB; 2ZB0; X-ray; 2.10 A; A=1-360. DR PDB; 2ZB1; X-ray; 2.50 A; A=1-360. DR PDB; 3BV2; X-ray; 2.40 A; A=2-360. DR PDB; 3BV3; X-ray; 2.59 A; A=2-360. DR PDB; 3BX5; X-ray; 2.40 A; A=2-360. DR PDB; 3C5U; X-ray; 2.80 A; A=2-360. DR PDB; 3CTQ; X-ray; 1.95 A; A=5-352. DR PDB; 3D7Z; X-ray; 2.10 A; A=1-360. DR PDB; 3D83; X-ray; 1.90 A; A=1-360. DR PDB; 3DS6; X-ray; 2.90 A; A/B/C/D=1-360. DR PDB; 3DT1; X-ray; 2.80 A; A=1-360. DR PDB; 3E92; X-ray; 2.00 A; A=1-360. DR PDB; 3E93; X-ray; 2.00 A; A=1-360. DR PDB; 3FC1; X-ray; 2.40 A; X=1-360. DR PDB; 3FI4; X-ray; 2.20 A; A=1-360. DR PDB; 3FKL; X-ray; 2.00 A; A=1-360. DR PDB; 3FKN; X-ray; 2.00 A; A=1-360. DR PDB; 3FKO; X-ray; 2.00 A; A=1-360. DR PDB; 3FL4; X-ray; 1.80 A; A=1-360. DR PDB; 3FLN; X-ray; 1.90 A; C=1-360. DR PDB; 3FLQ; X-ray; 1.90 A; A=1-360. DR PDB; 3FLS; X-ray; 2.30 A; A=1-360. DR PDB; 3FLW; X-ray; 2.10 A; A=1-360. DR PDB; 3FLY; X-ray; 1.80 A; A=1-360. DR PDB; 3FLZ; X-ray; 2.23 A; A=1-360. DR PDB; 3FMH; X-ray; 1.90 A; A=1-360. DR PDB; 3FMJ; X-ray; 2.00 A; A=1-360. DR PDB; 3FMK; X-ray; 1.70 A; A=1-360. DR PDB; 3FML; X-ray; 2.10 A; A=1-360. DR PDB; 3FMM; X-ray; 2.00 A; A=1-360. DR PDB; 3FMN; X-ray; 1.90 A; A=1-360. DR PDB; 3FSF; X-ray; 2.10 A; A=1-360. DR PDB; 3FSK; X-ray; 2.00 A; A=1-360. DR PDB; 3GC7; X-ray; 1.80 A; A=1-360. DR PDB; 3GCP; X-ray; 2.25 A; A=2-360. DR PDB; 3GCQ; X-ray; 2.00 A; A=2-360. DR PDB; 3GCS; X-ray; 2.10 A; A=2-360. DR PDB; 3GCU; X-ray; 2.10 A; A/B=2-360. DR PDB; 3GCV; X-ray; 2.30 A; A=2-360. DR PDB; 3GFE; X-ray; 2.10 A; A=1-360. DR PDB; 3GI3; X-ray; 2.40 A; A=1-360. DR PDB; 3HA8; X-ray; 2.48 A; A=1-360. DR PDB; 3HEC; X-ray; 2.50 A; A=5-352. DR PDB; 3HEG; X-ray; 2.20 A; A=5-352. DR PDB; 3HL7; X-ray; 1.88 A; A=1-360. DR PDB; 3HLL; X-ray; 1.95 A; A=1-360. DR PDB; 3HP2; X-ray; 2.15 A; A=1-360. DR PDB; 3HP5; X-ray; 2.30 A; A=1-360. DR PDB; 3HRB; X-ray; 2.20 A; A=2-360. DR PDB; 3HUB; X-ray; 2.25 A; A=2-360. DR PDB; 3HUC; X-ray; 1.80 A; A=2-360. DR PDB; 3HV3; X-ray; 2.00 A; A=2-360. DR PDB; 3HV4; X-ray; 2.60 A; A/B=2-360. DR PDB; 3HV5; X-ray; 2.25 A; A/B=2-360. DR PDB; 3HV6; X-ray; 1.95 A; A=2-360. DR PDB; 3HV7; X-ray; 2.40 A; A=2-360. DR PDB; 3HVC; X-ray; 2.10 A; A=1-360. DR PDB; 3IPH; X-ray; 2.10 A; A=1-360. DR PDB; 3ITZ; X-ray; 2.25 A; A=1-360. DR PDB; 3IW5; X-ray; 2.50 A; A=2-360. DR PDB; 3IW6; X-ray; 2.10 A; A=2-360. DR PDB; 3IW7; X-ray; 2.40 A; A=2-360. DR PDB; 3IW8; X-ray; 2.00 A; A=2-360. DR PDB; 3K3I; X-ray; 1.70 A; A=5-352. DR PDB; 3K3J; X-ray; 2.00 A; A=1-360. DR PDB; 3KF7; X-ray; 2.00 A; A=1-360. DR PDB; 3KQ7; X-ray; 1.80 A; A=1-360. DR PDB; 3L8S; X-ray; 2.35 A; A=2-360. DR PDB; 3L8X; X-ray; 2.15 A; A=2-360. DR PDB; 3LFA; X-ray; 2.10 A; A=2-360. DR PDB; 3LFB; X-ray; 2.60 A; A=2-360. DR PDB; 3LFC; X-ray; 2.80 A; A=2-360. DR PDB; 3LFD; X-ray; 3.40 A; A=2-360. DR PDB; 3LFE; X-ray; 2.30 A; A=2-360. DR PDB; 3LFF; X-ray; 1.50 A; A=2-360. DR PDB; 3LHJ; X-ray; 3.31 A; A=1-360. DR PDB; 3MGY; X-ray; 2.10 A; A=1-360. DR PDB; 3MH0; X-ray; 2.00 A; A=1-360. DR PDB; 3MH1; X-ray; 2.20 A; A=1-360. DR PDB; 3MH2; X-ray; 2.30 A; A=1-360. DR PDB; 3MH3; X-ray; 2.20 A; A=1-360. DR PDB; 3MPA; X-ray; 2.10 A; A=1-360. DR PDB; 3MPT; X-ray; 1.89 A; A=1-360. DR PDB; 3MVL; X-ray; 2.80 A; A/B=2-360. DR PDB; 3MVM; X-ray; 2.00 A; A/B=2-360. DR PDB; 3MW1; X-ray; 2.80 A; A=2-360. DR PDB; 3NEW; X-ray; 2.51 A; A=1-360. DR PDB; 3NNU; X-ray; 2.40 A; A=1-354. DR PDB; 3NNV; X-ray; 2.10 A; A=1-354. DR PDB; 3NNW; X-ray; 1.89 A; A=1-354. DR PDB; 3NNX; X-ray; 2.28 A; A=1-354. DR PDB; 3NWW; X-ray; 2.09 A; A=2-360. DR PDB; 3O8P; X-ray; 2.10 A; A=1-360. DR PDB; 3O8T; X-ray; 2.00 A; A=1-360. DR PDB; 3O8U; X-ray; 2.10 A; A=1-360. DR PDB; 3OBG; X-ray; 2.80 A; A=1-360. DR PDB; 3OBJ; X-ray; 2.40 A; A=1-360. DR PDB; 3OC1; X-ray; 2.59 A; A=1-360. DR PDB; 3OCG; X-ray; 2.21 A; A=2-360. DR PDB; 3OD6; X-ray; 2.68 A; X=1-360. DR PDB; 3ODY; X-ray; 2.20 A; X=1-360. DR PDB; 3ODZ; X-ray; 2.30 A; X=1-360. DR PDB; 3OEF; X-ray; 1.60 A; X=1-360. DR PDB; 3PG3; X-ray; 2.00 A; A=2-360. DR PDB; 3QUD; X-ray; 2.00 A; A=2-360. DR PDB; 3QUE; X-ray; 2.70 A; A=2-360. DR PDB; 3RIN; X-ray; 2.20 A; A=1-360. DR PDB; 3ROC; X-ray; 1.70 A; A=1-360. DR PDB; 3S3I; X-ray; 1.80 A; A=4-352. DR PDB; 3S4Q; X-ray; 2.27 A; A=2-360. DR PDB; 3U8W; X-ray; 2.15 A; A=1-360. DR PDB; 3UVP; X-ray; 2.40 A; A=2-360. DR PDB; 3UVQ; X-ray; 2.20 A; A=2-360. DR PDB; 3UVR; X-ray; 2.10 A; A=2-360. DR PDB; 3ZS5; X-ray; 1.60 A; A=2-360. DR PDB; 3ZSG; X-ray; 1.89 A; A=2-360. DR PDB; 3ZSH; X-ray; 2.05 A; A=2-360. DR PDB; 3ZSI; X-ray; 2.40 A; A=2-360. DR PDB; 3ZYA; X-ray; 1.90 A; A=1-360. DR PDB; 4A9Y; X-ray; 2.20 A; A=2-360. DR PDB; 4AA0; X-ray; 1.80 A; A=2-360. DR PDB; 4AA4; X-ray; 2.30 A; A=2-360. DR PDB; 4AA5; X-ray; 2.38 A; A=2-360. DR PDB; 4AAC; X-ray; 2.50 A; A=2-360. DR PDB; 4DLI; X-ray; 1.91 A; A=2-360. DR PDB; 4DLJ; X-ray; 2.60 A; A=2-360. DR PDB; 4E5A; X-ray; 1.87 A; X=1-360. DR PDB; 4E5B; X-ray; 2.00 A; A=1-360. DR PDB; 4E6A; X-ray; 2.09 A; A=1-360. DR PDB; 4E6C; X-ray; 2.39 A; A=1-360. DR PDB; 4E8A; X-ray; 2.70 A; A=1-360. DR PDB; 4EH2; X-ray; 2.00 A; A=2-360. DR PDB; 4EH3; X-ray; 2.40 A; A=2-360. DR PDB; 4EH4; X-ray; 2.50 A; A=2-360. DR PDB; 4EH5; X-ray; 2.00 A; A=2-360. DR PDB; 4EH6; X-ray; 2.10 A; A=2-360. DR PDB; 4EH7; X-ray; 2.10 A; A=2-360. DR PDB; 4EH8; X-ray; 2.20 A; A=2-360. DR PDB; 4EH9; X-ray; 2.10 A; A=2-360. DR PDB; 4EHV; X-ray; 1.60 A; A=2-360. DR PDB; 4EWQ; X-ray; 2.10 A; A=2-360. DR PDB; 4F9W; X-ray; 2.00 A; A=2-360. DR PDB; 4F9Y; X-ray; 1.85 A; A=2-360. DR PDB; 4FA2; X-ray; 2.00 A; A=2-360. DR PDB; 4GEO; X-ray; 1.66 A; A=2-360. DR PDB; 4KIN; X-ray; 1.97 A; A/B/C/D=2-360. DR PDB; 4KIP; X-ray; 2.27 A; A/B=2-360. DR PDB; 4KIQ; X-ray; 2.50 A; A/B/C/D=2-360. DR PDB; 4L8M; X-ray; 2.10 A; A=2-360. DR PDB; 4R3C; X-ray; 2.06 A; A=2-360. DR PDB; 4ZTH; X-ray; 2.15 A; A=2-360. DR PDB; 5ETA; X-ray; 2.80 A; A/B=1-360. DR PDB; 5ETC; X-ray; 2.42 A; A=1-360. DR PDB; 5ETF; X-ray; 2.40 A; A=1-360. DR PDB; 5ETI; X-ray; 2.80 A; A=1-360. DR PDB; 5ML5; X-ray; 1.90 A; A=1-360. DR PDB; 5MTX; X-ray; 1.80 A; A=1-360. DR PDB; 5MTY; X-ray; 2.31 A; A=1-360. DR PDB; 5MZ3; X-ray; 2.15 A; A=1-360. DR PDB; 5N63; X-ray; 2.40 A; A=1-360. DR PDB; 5N64; X-ray; 2.40 A; A=1-360. DR PDB; 5N65; X-ray; 2.00 A; A=1-360. DR PDB; 5N66; X-ray; 2.40 A; A=1-360. DR PDB; 5N67; X-ray; 1.90 A; A=1-360. DR PDB; 5N68; X-ray; 1.85 A; A=1-360. DR PDB; 5O8U; X-ray; 2.00 A; A=1-360. DR PDB; 5O8V; X-ray; 2.00 A; A=1-360. DR PDB; 5OMG; X-ray; 2.00 A; A=1-360. DR PDB; 5OMH; X-ray; 2.50 A; A=1-360. DR PDB; 5TBE; X-ray; 2.44 A; A=1-360. DR PDB; 5TCO; X-ray; 2.10 A; A=2-360. DR PDB; 5WJJ; X-ray; 1.60 A; A=1-360. DR PDB; 5XYX; X-ray; 2.61 A; A=1-360. DR PDB; 5XYY; X-ray; 1.70 A; A=1-360. DR PDB; 6ANL; X-ray; 2.00 A; A=1-360. DR PDB; 6HWT; X-ray; 1.70 A; A=2-360. DR PDB; 6HWU; X-ray; 2.30 A; A=2-360. DR PDB; 6HWV; X-ray; 1.70 A; A=2-360. DR PDB; 6M95; X-ray; 1.80 A; A=1-360. DR PDB; 6M9L; X-ray; 2.45 A; A=1-360. DR PDB; 6OHD; X-ray; 2.50 A; A=1-360. DR PDB; 6QDZ; X-ray; 1.73 A; A=1-360. DR PDB; 6QE1; X-ray; 1.85 A; A=1-360. DR PDB; 6QYX; X-ray; 1.66 A; A=1-166, A=197-360. DR PDB; 6RFO; X-ray; 1.70 A; A=167-196. DR PDB; 6SFI; X-ray; 1.60 A; A=1-360. DR PDB; 6SFJ; X-ray; 1.95 A; A=1-360. DR PDB; 6SFK; X-ray; 1.80 A; A=1-360. DR PDB; 6SFO; X-ray; 1.75 A; A=1-360. DR PDB; 6TCA; X-ray; 3.70 A; B/D/F/H=1-360. DR PDB; 6ZQS; X-ray; 1.95 A; A=1-360. DR PDB; 6ZWP; X-ray; 1.90 A; A=1-360. DR PDB; 8A8M; EM; 4.00 A; A=1-360. DR PDB; 8VXE; X-ray; 1.85 A; A=2-360. DR PDB; 8X3M; X-ray; 1.85 A; A=1-360. DR PDB; 8YD9; X-ray; 1.66 A; A=1-360. DR PDB; 9CJ1; X-ray; 1.80 A; A=1-360. DR PDB; 9CJ2; X-ray; 2.83 A; A/B=1-360. DR PDB; 9CJ3; X-ray; 1.95 A; A=1-360. DR PDB; 9CJ4; X-ray; 1.80 A; A=1-360. DR PDB; 9CJ5; X-ray; 3.30 A; A=1-360. DR PDB; 9MHB; X-ray; 1.65 A; A=2-360. DR PDB; 9NYT; X-ray; 2.16 A; A=1-360. DR PDB; 9O4L; X-ray; 2.27 A; A=1-360. DR PDBsum; 1A9U; -. DR PDBsum; 1BL6; -. DR PDBsum; 1BL7; -. DR PDBsum; 1BMK; -. DR PDBsum; 1DI9; -. DR PDBsum; 1IAN; -. DR PDBsum; 1KV1; -. DR PDBsum; 1KV2; -. DR PDBsum; 1M7Q; -. DR PDBsum; 1OUK; -. DR PDBsum; 1OUY; -. DR PDBsum; 1OVE; -. DR PDBsum; 1OZ1; -. DR PDBsum; 1R39; -. DR PDBsum; 1R3C; -. DR PDBsum; 1W7H; -. DR PDBsum; 1W82; -. DR PDBsum; 1W83; -. DR PDBsum; 1W84; -. DR PDBsum; 1WBN; -. DR PDBsum; 1WBO; -. DR PDBsum; 1WBS; -. DR PDBsum; 1WBT; -. DR PDBsum; 1WBV; -. DR PDBsum; 1WBW; -. DR PDBsum; 1WFC; -. DR PDBsum; 1YQJ; -. DR PDBsum; 1ZYJ; -. DR PDBsum; 1ZZ2; -. DR PDBsum; 1ZZL; -. DR PDBsum; 2BAJ; -. DR PDBsum; 2BAK; -. DR PDBsum; 2BAL; -. DR PDBsum; 2BAQ; -. DR PDBsum; 2FSL; -. DR PDBsum; 2FSM; -. DR PDBsum; 2FSO; -. DR PDBsum; 2FST; -. DR PDBsum; 2GFS; -. DR PDBsum; 2I0H; -. DR PDBsum; 2LGC; -. DR PDBsum; 2NPQ; -. DR PDBsum; 2OKR; -. DR PDBsum; 2ONL; -. DR PDBsum; 2QD9; -. DR PDBsum; 2RG5; -. DR PDBsum; 2RG6; -. DR PDBsum; 2Y8O; -. DR PDBsum; 2YIS; -. DR PDBsum; 2YIW; -. DR PDBsum; 2YIX; -. DR PDBsum; 2ZAZ; -. DR PDBsum; 2ZB0; -. DR PDBsum; 2ZB1; -. DR PDBsum; 3BV2; -. DR PDBsum; 3BV3; -. DR PDBsum; 3BX5; -. DR PDBsum; 3C5U; -. DR PDBsum; 3CTQ; -. DR PDBsum; 3D7Z; -. DR PDBsum; 3D83; -. DR PDBsum; 3DS6; -. DR PDBsum; 3DT1; -. DR PDBsum; 3E92; -. DR PDBsum; 3E93; -. DR PDBsum; 3FC1; -. DR PDBsum; 3FI4; -. DR PDBsum; 3FKL; -. DR PDBsum; 3FKN; -. DR PDBsum; 3FKO; -. DR PDBsum; 3FL4; -. DR PDBsum; 3FLN; -. DR PDBsum; 3FLQ; -. DR PDBsum; 3FLS; -. DR PDBsum; 3FLW; -. DR PDBsum; 3FLY; -. DR PDBsum; 3FLZ; -. DR PDBsum; 3FMH; -. DR PDBsum; 3FMJ; -. DR PDBsum; 3FMK; -. DR PDBsum; 3FML; -. DR PDBsum; 3FMM; -. DR PDBsum; 3FMN; -. DR PDBsum; 3FSF; -. DR PDBsum; 3FSK; -. DR PDBsum; 3GC7; -. DR PDBsum; 3GCP; -. DR PDBsum; 3GCQ; -. DR PDBsum; 3GCS; -. DR PDBsum; 3GCU; -. DR PDBsum; 3GCV; -. DR PDBsum; 3GFE; -. DR PDBsum; 3GI3; -. DR PDBsum; 3HA8; -. DR PDBsum; 3HEC; -. DR PDBsum; 3HEG; -. DR PDBsum; 3HL7; -. DR PDBsum; 3HLL; -. DR PDBsum; 3HP2; -. DR PDBsum; 3HP5; -. DR PDBsum; 3HRB; -. DR PDBsum; 3HUB; -. DR PDBsum; 3HUC; -. DR PDBsum; 3HV3; -. DR PDBsum; 3HV4; -. DR PDBsum; 3HV5; -. DR PDBsum; 3HV6; -. DR PDBsum; 3HV7; -. DR PDBsum; 3HVC; -. DR PDBsum; 3IPH; -. DR PDBsum; 3ITZ; -. DR PDBsum; 3IW5; -. DR PDBsum; 3IW6; -. DR PDBsum; 3IW7; -. DR PDBsum; 3IW8; -. DR PDBsum; 3K3I; -. DR PDBsum; 3K3J; -. DR PDBsum; 3KF7; -. DR PDBsum; 3KQ7; -. DR PDBsum; 3L8S; -. DR PDBsum; 3L8X; -. DR PDBsum; 3LFA; -. DR PDBsum; 3LFB; -. DR PDBsum; 3LFC; -. DR PDBsum; 3LFD; -. DR PDBsum; 3LFE; -. DR PDBsum; 3LFF; -. DR PDBsum; 3LHJ; -. DR PDBsum; 3MGY; -. DR PDBsum; 3MH0; -. DR PDBsum; 3MH1; -. DR PDBsum; 3MH2; -. DR PDBsum; 3MH3; -. DR PDBsum; 3MPA; -. DR PDBsum; 3MPT; -. DR PDBsum; 3MVL; -. DR PDBsum; 3MVM; -. DR PDBsum; 3MW1; -. DR PDBsum; 3NEW; -. DR PDBsum; 3NNU; -. DR PDBsum; 3NNV; -. DR PDBsum; 3NNW; -. DR PDBsum; 3NNX; -. DR PDBsum; 3NWW; -. DR PDBsum; 3O8P; -. DR PDBsum; 3O8T; -. DR PDBsum; 3O8U; -. DR PDBsum; 3OBG; -. DR PDBsum; 3OBJ; -. DR PDBsum; 3OC1; -. DR PDBsum; 3OCG; -. DR PDBsum; 3OD6; -. DR PDBsum; 3ODY; -. DR PDBsum; 3ODZ; -. DR PDBsum; 3OEF; -. DR PDBsum; 3PG3; -. DR PDBsum; 3QUD; -. DR PDBsum; 3QUE; -. DR PDBsum; 3RIN; -. DR PDBsum; 3ROC; -. DR PDBsum; 3S3I; -. DR PDBsum; 3S4Q; -. DR PDBsum; 3U8W; -. DR PDBsum; 3UVP; -. DR PDBsum; 3UVQ; -. DR PDBsum; 3UVR; -. DR PDBsum; 3ZS5; -. DR PDBsum; 3ZSG; -. DR PDBsum; 3ZSH; -. DR PDBsum; 3ZSI; -. DR PDBsum; 3ZYA; -. DR PDBsum; 4A9Y; -. DR PDBsum; 4AA0; -. DR PDBsum; 4AA4; -. DR PDBsum; 4AA5; -. DR PDBsum; 4AAC; -. DR PDBsum; 4DLI; -. DR PDBsum; 4DLJ; -. DR PDBsum; 4E5A; -. DR PDBsum; 4E5B; -. DR PDBsum; 4E6A; -. DR PDBsum; 4E6C; -. DR PDBsum; 4E8A; -. DR PDBsum; 4EH2; -. DR PDBsum; 4EH3; -. DR PDBsum; 4EH4; -. DR PDBsum; 4EH5; -. DR PDBsum; 4EH6; -. DR PDBsum; 4EH7; -. DR PDBsum; 4EH8; -. DR PDBsum; 4EH9; -. DR PDBsum; 4EHV; -. DR PDBsum; 4EWQ; -. DR PDBsum; 4F9W; -. DR PDBsum; 4F9Y; -. DR PDBsum; 4FA2; -. DR PDBsum; 4GEO; -. DR PDBsum; 4KIN; -. DR PDBsum; 4KIP; -. DR PDBsum; 4KIQ; -. DR PDBsum; 4L8M; -. DR PDBsum; 4R3C; -. DR PDBsum; 4ZTH; -. DR PDBsum; 5ETA; -. DR PDBsum; 5ETC; -. DR PDBsum; 5ETF; -. DR PDBsum; 5ETI; -. DR PDBsum; 5ML5; -. DR PDBsum; 5MTX; -. DR PDBsum; 5MTY; -. DR PDBsum; 5MZ3; -. DR PDBsum; 5N63; -. DR PDBsum; 5N64; -. DR PDBsum; 5N65; -. DR PDBsum; 5N66; -. DR PDBsum; 5N67; -. DR PDBsum; 5N68; -. DR PDBsum; 5O8U; -. DR PDBsum; 5O8V; -. DR PDBsum; 5OMG; -. DR PDBsum; 5OMH; -. DR PDBsum; 5TBE; -. DR PDBsum; 5TCO; -. DR PDBsum; 5WJJ; -. DR PDBsum; 5XYX; -. DR PDBsum; 5XYY; -. DR PDBsum; 6ANL; -. DR PDBsum; 6HWT; -. DR PDBsum; 6HWU; -. DR PDBsum; 6HWV; -. DR PDBsum; 6M95; -. DR PDBsum; 6M9L; -. DR PDBsum; 6OHD; -. DR PDBsum; 6QDZ; -. DR PDBsum; 6QE1; -. DR PDBsum; 6QYX; -. DR PDBsum; 6RFO; -. DR PDBsum; 6SFI; -. DR PDBsum; 6SFJ; -. DR PDBsum; 6SFK; -. DR PDBsum; 6SFO; -. DR PDBsum; 6TCA; -. DR PDBsum; 6ZQS; -. DR PDBsum; 6ZWP; -. DR PDBsum; 8A8M; -. DR PDBsum; 8VXE; -. DR PDBsum; 8X3M; -. DR PDBsum; 8YD9; -. DR PDBsum; 9CJ1; -. DR PDBsum; 9CJ2; -. DR PDBsum; 9CJ3; -. DR PDBsum; 9CJ4; -. DR PDBsum; 9CJ5; -. DR PDBsum; 9MHB; -. DR PDBsum; 9NYT; -. DR PDBsum; 9O4L; -. DR AlphaFoldDB; Q16539; -. DR BMRB; Q16539; -. DR EMDB; EMD-15233; -. DR SASBDB; Q16539; -. DR SMR; Q16539; -. DR BioGRID; 107819; 321. DR CORUM; Q16539; -. DR DIP; DIP-30987N; -. DR ELM; Q16539; -. DR FunCoup; Q16539; 4149. DR IntAct; Q16539; 185. DR MINT; Q16539; -. DR STRING; 9606.ENSP00000229795; -. DR BindingDB; Q16539; -. DR ChEMBL; CHEMBL260; -. DR DrugBank; DB02873; 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One. DR DrugBank; DB01948; 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One. DR DrugBank; DB02277; 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea. DR DrugBank; DB06882; 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea. DR DrugBank; DB08097; 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE. DR DrugBank; DB08395; 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE. DR DrugBank; DB03110; 2-Chlorophenol. DR DrugBank; DB07942; 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine. DR DrugBank; DB08093; 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE. DR DrugBank; DB08095; 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA. DR DrugBank; DB02195; 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine. DR DrugBank; DB02352; 3-(Benzyloxy)Pyridin-2-Amine. DR DrugBank; DB08730; 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE. DR DrugBank; DB08091; 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE. DR DrugBank; DB08092; 3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide. DR DrugBank; DB04632; 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE. DR DrugBank; DB08522; 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE. DR DrugBank; DB03980; 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole. DR DrugBank; DB07829; 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE. DR DrugBank; DB02984; 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline. DR DrugBank; DB08521; 4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine. DR DrugBank; DB07607; 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE. DR DrugBank; DB01761; 4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine. DR DrugBank; DB07459; 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE. DR DrugBank; DB07832; 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde. DR DrugBank; DB01988; 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine. DR DrugBank; DB08352; 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine. DR DrugBank; DB08096; 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM. DR DrugBank; DB08424; [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE. DR DrugBank; DB08423; [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE. DR DrugBank; DB03777; Bisindolylmaleimide I. DR DrugBank; DB12429; CI-1040. DR DrugBank; DB01254; Dasatinib. DR DrugBank; DB12140; Dilmapimod. DR DrugBank; DB03044; Doramapimod. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB01953; Inhibitor of P38 Kinase. DR DrugBank; DB05157; KC706. DR DrugBank; DB12270; Losmapimod. DR DrugBank; DB01017; Minocycline. DR DrugBank; DB08242; N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide. DR DrugBank; DB07833; N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide. DR DrugBank; DB08064; N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA. DR DrugBank; DB07834; N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide. DR DrugBank; DB01807; N-[(3Z)-5-Tert-butyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-ylidene]-N'-(4-chlorophenyl)urea. DR DrugBank; DB06991; N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide. DR DrugBank; DB08068; N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO. DR DrugBank; DB07811; N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide. DR DrugBank; DB08349; N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide. DR DrugBank; DB07307; N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide. DR DrugBank; DB08351; N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide. DR DrugBank; DB06940; N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide. DR DrugBank; DB07138; Neflamapimod. DR DrugBank; DB07835; N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide. DR DrugBank; DB12017; Ozagrel. DR DrugBank; DB19169; Pamapimod. DR DrugBank; DB08339; PD-166326. DR DrugBank; DB07941; PH-797804. DR DrugBank; DB06518; R-1487. DR DrugBank; DB04338; SB220025. DR DrugBank; DB07943; SD-0006. DR DrugBank; DB05412; Talmapimod. DR DrugBank; DB04462; Tetrabromo-2-Benzotriazole. DR DrugBank; DB04797; Triazolopyridine. DR DrugBank; DB05470; VX-702. DR DrugCentral; Q16539; -. DR GuidetoPHARMACOLOGY; 1499; -. DR GlyGen; Q16539; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q16539; -. DR MetOSite; Q16539; -. DR PhosphoSitePlus; Q16539; -. DR BioMuta; MAPK14; -. DR OGP; Q16539; -. DR CPTAC; CPTAC-1325; -. DR CPTAC; CPTAC-1355; -. DR CPTAC; CPTAC-1356; -. DR CPTAC; CPTAC-3005; -. DR CPTAC; CPTAC-3006; -. DR CPTAC; CPTAC-878; -. DR CPTAC; CPTAC-879; -. DR CPTAC; non-CPTAC-5408; -. DR CPTAC; non-CPTAC-5699; -. DR CPTAC; non-CPTAC-5700; -. DR CPTAC; non-CPTAC-5701; -. DR jPOST; Q16539; -. DR MassIVE; Q16539; -. DR PaxDb; 9606-ENSP00000229795; -. DR PeptideAtlas; Q16539; -. DR PRIDE; Q16539; -. DR ProteomicsDB; 60901; -. [Q16539-1] DR ProteomicsDB; 60902; -. [Q16539-2] DR ProteomicsDB; 60903; -. [Q16539-3] DR ProteomicsDB; 60904; -. [Q16539-4] DR Pumba; Q16539; -. DR ABCD; Q16539; 4 sequenced antibodies. DR Antibodypedia; 4142; 2328 antibodies from 55 providers. DR CPTC; Q16539; 3 antibodies. DR DNASU; 1432; -. DR Ensembl; ENST00000229794.9; ENSP00000229794.4; ENSG00000112062.14. [Q16539-1] DR Ensembl; ENST00000229795.8; ENSP00000229795.3; ENSG00000112062.14. [Q16539-2] DR Ensembl; ENST00000310795.8; ENSP00000308669.4; ENSG00000112062.14. [Q16539-4] DR GeneID; 1432; -. DR KEGG; hsa:1432; -. DR MANE-Select; ENST00000229794.9; ENSP00000229794.4; NM_139012.3; NP_620581.1. DR UCSC; uc003olp.4; human. [Q16539-1] DR AGR; HGNC:6876; -. DR ClinPGx; PA30621; -. DR CTD; 1432; -. DR DisGeNET; 1432; -. DR GeneCards; MAPK14; -. DR HGNC; HGNC:6876; MAPK14. DR HPA; ENSG00000112062; Low tissue specificity. DR MIM; 600289; gene. DR OpenTargets; ENSG00000112062; -. DR VEuPathDB; HostDB:ENSG00000112062; -. DR eggNOG; KOG0660; Eukaryota. DR GeneTree; ENSGT00940000155325; -. DR InParanoid; Q16539; -. DR OMA; NRYTDLN; -. DR OrthoDB; 9474812at2759; -. DR PAN-GO; Q16539; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q16539; -. DR BioCyc; MetaCyc:HS03507-MONOMER; -. DR BRENDA; 2.7.11.24; 2681. DR PathwayCommons; Q16539; -. DR Reactome; R-HSA-168638; NOD1/2 Signaling Pathway. DR Reactome; R-HSA-171007; p38MAPK events. DR Reactome; R-HSA-198753; ERK/MAPK targets. DR Reactome; R-HSA-2151209; Activation of PPARGC1A (PGC-1alpha) by phosphorylation. DR Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence. DR Reactome; R-HSA-418592; ADP signalling through P2Y purinoceptor 1. DR Reactome; R-HSA-432142; Platelet sensitization by LDL. DR Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway. DR Reactome; R-HSA-450302; activated TAK1 mediates p38 MAPK activation. DR Reactome; R-HSA-450341; Activation of the AP-1 family of transcription factors. DR Reactome; R-HSA-450604; KSRP (KHSRP) binds and destabilizes mRNA. DR Reactome; R-HSA-525793; Myogenesis. DR Reactome; R-HSA-5668599; RHO GTPases Activate NADPH Oxidases. DR Reactome; R-HSA-6798695; Neutrophil degranulation. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-9662834; CD163 mediating an anti-inflammatory response. DR Reactome; R-HSA-9824585; Regulation of MITF-M-dependent genes involved in pigmentation. DR SignaLink; Q16539; -. DR SIGNOR; Q16539; -. DR Agora; ENSG00000112062; -. DR BioGRID-ORCS; 1432; 83 hits in 1217 CRISPR screens. DR ChiTaRS; MAPK14; human. DR EvolutionaryTrace; Q16539; -. DR GeneWiki; MAPK14; -. DR GenomeRNAi; 1432; -. DR Pharos; Q16539; Tchem. DR PRO; PR:Q16539; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q16539; protein. DR Bgee; ENSG00000112062; Expressed in buccal mucosa cell and 205 other cell types or tissues. DR ExpressionAtlas; Q16539; baseline and differential. DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005739; C:mitochondrion; IEA:Ensembl. DR GO; GO:0016607; C:nuclear speck; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0034774; C:secretory granule lumen; TAS:Reactome. DR GO; GO:0000922; C:spindle pole; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL. DR GO; GO:0004707; F:MAP kinase activity; IDA:UniProtKB. DR GO; GO:0004708; F:MAP kinase kinase activity; TAS:ProtInc. DR GO; GO:0048273; F:mitogen-activated protein kinase p38 binding; IPI:UniProtKB. DR GO; GO:0051525; F:NFAT protein binding; ISS:BHF-UCL. DR GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0070935; P:3'-UTR-mediated mRNA stabilization; TAS:UniProtKB. DR GO; GO:0001525; P:angiogenesis; IEA:Ensembl. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0060348; P:bone development; IEA:Ensembl. DR GO; GO:0001502; P:cartilage condensation; IEA:Ensembl. DR GO; GO:0000902; P:cell morphogenesis; IEA:Ensembl. DR GO; GO:0007178; P:cell surface receptor protein serine/threonine kinase signaling pathway; IEA:Ensembl. DR GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc. DR GO; GO:0071479; P:cellular response to ionizing radiation; IMP:BHF-UCL. DR GO; GO:0071222; P:cellular response to lipopolysaccharide; IDA:MGI. DR GO; GO:0071223; P:cellular response to lipoteichoic acid; IMP:UniProtKB. DR GO; GO:0071493; P:cellular response to UV-B; IDA:UniProtKB. DR GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IMP:BHF-UCL. DR GO; GO:0098586; P:cellular response to virus; IMP:UniProtKB. DR GO; GO:0090398; P:cellular senescence; TAS:Reactome. DR GO; GO:0006935; P:chemotaxis; TAS:ProtInc. DR GO; GO:0002062; P:chondrocyte differentiation; IEA:Ensembl. DR GO; GO:0046323; P:D-glucose import; IEA:Ensembl. DR GO; GO:0000077; P:DNA damage checkpoint signaling; IEA:Ensembl. DR GO; GO:0019395; P:fatty acid oxidation; IEA:Ensembl. DR GO; GO:0006006; P:glucose metabolic process; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; ISS:BHF-UCL. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IEA:Ensembl. DR GO; GO:0035331; P:negative regulation of hippo signaling; IMP:FlyBase. DR GO; GO:0002862; P:negative regulation of inflammatory response to antigenic stimulus; TAS:Reactome. DR GO; GO:0001649; P:osteoblast differentiation; IEA:Ensembl. DR GO; GO:0030316; P:osteoclast differentiation; ISS:BHF-UCL. DR GO; GO:0038066; P:p38MAPK cascade; IDA:UniProt. DR GO; GO:0001890; P:placenta development; IEA:Ensembl. DR GO; GO:0030168; P:platelet activation; TAS:Reactome. DR GO; GO:0090336; P:positive regulation of brown fat cell differentiation; IEA:Ensembl. DR GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; IEA:Ensembl. DR GO; GO:0031281; P:positive regulation of cyclase activity; IMP:CACAO. DR GO; GO:0046326; P:positive regulation of D-glucose import; IEA:Ensembl. DR GO; GO:0045648; P:positive regulation of erythrocyte differentiation; IMP:BHF-UCL. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB. DR GO; GO:0032735; P:positive regulation of interleukin-12 production; IMP:UniProtKB. DR GO; GO:0051149; P:positive regulation of muscle cell differentiation; TAS:Reactome. DR GO; GO:0045663; P:positive regulation of myoblast differentiation; ISS:UniProtKB. DR GO; GO:1901741; P:positive regulation of myoblast fusion; ISS:UniProtKB. DR GO; GO:0010831; P:positive regulation of myotube differentiation; ISS:UniProtKB. DR GO; GO:0042307; P:positive regulation of protein import into nucleus; IEA:Ensembl. DR GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IMP:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl. DR GO; GO:1900015; P:regulation of cytokine production involved in inflammatory response; IDA:CACAO. DR GO; GO:0030278; P:regulation of ossification; IEA:Ensembl. DR GO; GO:0099179; P:regulation of synaptic membrane adhesion; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; ISS:UniProtKB. DR GO; GO:0002021; P:response to dietary excess; IEA:Ensembl. DR GO; GO:0032868; P:response to insulin; IEA:Ensembl. DR GO; GO:0032495; P:response to muramyl dipeptide; IEA:Ensembl. DR GO; GO:0035994; P:response to muscle stretch; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0042770; P:signal transduction in response to DNA damage; IMP:BHF-UCL. DR GO; GO:0007519; P:skeletal muscle tissue development; IEA:Ensembl. DR GO; GO:0048863; P:stem cell differentiation; IEA:Ensembl. DR GO; GO:0051403; P:stress-activated MAPK cascade; IDA:UniProtKB. DR GO; GO:0031098; P:stress-activated protein kinase signaling cascade; IDA:UniProt. DR GO; GO:0090400; P:stress-induced premature senescence; IMP:BHF-UCL. DR GO; GO:0051146; P:striated muscle cell differentiation; IEA:Ensembl. DR GO; GO:0006366; P:transcription by RNA polymerase II; IEA:Ensembl. DR GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; IMP:BHF-UCL. DR CDD; cd07877; STKc_p38alpha; 1. DR FunFam; 1.10.510.10:FF:000063; Mitogen-activated protein kinase 14; 1. DR FunFam; 3.30.200.20:FF:000769; Mitogen-activated protein kinase 14; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00280; -. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR003527; MAP_kinase_CS. DR InterPro; IPR050117; MAPK. DR InterPro; IPR038784; MAPK14. DR InterPro; IPR008352; MAPK_HOG-like. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR PANTHER; PTHR24055; MITOGEN-ACTIVATED PROTEIN KINASE; 1. DR Pfam; PF00069; Pkinase; 1. DR PRINTS; PR01773; P38MAPKINASE. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS01351; MAPK; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding; KW Cytoplasm; Direct protein sequencing; Kinase; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Stress response; Transcription; KW Transcription regulation; Transferase; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|PubMed:12665801, FT ECO:0007744|PubMed:20068231" FT CHAIN 2..360 FT /note="Mitogen-activated protein kinase 14" FT /id="PRO_0000186291" FT DOMAIN 24..308 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOTIF 180..182 FT /note="TXY" FT ACT_SITE 168 FT /note="Proton acceptor" FT BINDING 30..38 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 53 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 2 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 16 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 53 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:21444723" FT MOD_RES 152 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:21444723" FT MOD_RES 180 FT /note="Phosphothreonine; by MAP2K3, MAP2K4, MAP2K6 and FT autocatalysis" FT /evidence="ECO:0000269|PubMed:7535770, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 182 FT /note="Phosphotyrosine; by MAP2K3, MAP2K4, MAP2K6 and FT autocatalysis" FT /evidence="ECO:0000269|PubMed:7535770, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 263 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:17525332" FT MOD_RES 323 FT /note="Phosphotyrosine; by ZAP70" FT /evidence="ECO:0000269|PubMed:15735648" FT VAR_SEQ 230..254 FT /note="DQLKLILRLVGTPGAELLKKISSES -> NQLQQIMRLTGTPPAYLINRMPS FT HE (in isoform CSBP1)" FT /evidence="ECO:0000303|PubMed:7997261" FT /id="VSP_004842" FT VAR_SEQ 255..360 FT /note="ARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHA FT YFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES -> V FT S (in isoform 5)" FT /evidence="ECO:0000303|PubMed:19906316" FT /id="VSP_057194" FT VAR_SEQ 255..307 FT /note="ARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHA FT Y -> LSTCWRRCLYWTQIRELQRPKPLHMPTLLSTTILMMNQWPILMISPLKAGTSL FT (in isoform Exip)" FT /evidence="ECO:0000303|PubMed:11866441" FT /id="VSP_004843" FT VAR_SEQ 281..360 FT /note="AVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDL FT LIDEWKSLTYDEVISFVPPPLDQEEMES -> GKLTIYPHLMDIELVMI (in FT isoform Mxi2)" FT /evidence="ECO:0000303|PubMed:7479834" FT /id="VSP_004844" FT VAR_SEQ 308..360 FT /note="Missing (in isoform Exip)" FT /evidence="ECO:0000303|PubMed:11866441" FT /id="VSP_004845" FT VARIANT 51 FT /note="A -> V (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042270" FT VARIANT 322 FT /note="P -> R (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs1765837157)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042271" FT VARIANT 343 FT /note="D -> G (in dbSNP:rs45496794)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042272" FT MUTAGEN 34 FT /note="A->V: Lowered kinase activity." FT /evidence="ECO:0000269|PubMed:7493921" FT MUTAGEN 53 FT /note="K->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:7493921" FT MUTAGEN 54 FT /note="K->R: Impairs MAP2K6/MKK6-dependent FT autophosphorylation." FT /evidence="ECO:0000269|PubMed:11010976" FT MUTAGEN 69 FT /note="Y->H: Lowered kinase activity." FT /evidence="ECO:0000269|PubMed:15284239" FT MUTAGEN 168 FT /note="D->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:7493921" FT MUTAGEN 175 FT /note="T->A: No effect on either the kinase activity or FT tyrosine phosphorylation." FT /evidence="ECO:0000269|PubMed:7493921" FT MUTAGEN 176 FT /note="D->A: Emulation of the active state. Increase in FT activity; when associated with S-327 or L-327." FT /evidence="ECO:0000269|PubMed:15284239" FT MUTAGEN 177 FT /note="D->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:15284239" FT MUTAGEN 180 FT /note="T->E: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:7493921" FT MUTAGEN 182 FT /note="Y->F: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:7493921" FT MUTAGEN 320 FT /note="A->T: Lowered kinase activity." FT /evidence="ECO:0000269|PubMed:15284239" FT MUTAGEN 327 FT /note="F->L: Emulation of the active state. Increase in FT activity; when associated with A-176." FT /evidence="ECO:0000269|PubMed:15284239" FT MUTAGEN 327 FT /note="F->S: Emulation of the active state. Increase in FT activity; when associated with A-176." FT /evidence="ECO:0000269|PubMed:15284239" FT MUTAGEN 337 FT /note="W->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:15284239" FT CONFLICT 67 FT /note="R -> G (in Ref. 7; BAF84398)" FT /evidence="ECO:0000305" FT STRAND 8..13 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 16..21 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 24..29 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 31..33 FT /evidence="ECO:0007829|PDB:6SFI" FT TURN 34..36 FT /evidence="ECO:0007829|PDB:3BV2" FT STRAND 38..43 FT /evidence="ECO:0007829|PDB:2FST" FT TURN 44..47 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 48..54 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 62..77 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 87..90 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 96..98 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 103..107 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 110..112 FT /evidence="ECO:0007829|PDB:3LFF" FT TURN 113..115 FT /evidence="ECO:0007829|PDB:4GEO" FT TURN 116..119 FT /evidence="ECO:0007829|PDB:3LFF" FT HELIX 124..143 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 153..155 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 156..158 FT /evidence="ECO:0007829|PDB:2FST" FT TURN 160..162 FT /evidence="ECO:0007829|PDB:2RG6" FT STRAND 164..166 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 168..170 FT /evidence="ECO:0007829|PDB:4GEO" FT HELIX 173..175 FT /evidence="ECO:0007829|PDB:1ZZL" FT TURN 176..179 FT /evidence="ECO:0007829|PDB:5XYY" FT STRAND 180..182 FT /evidence="ECO:0007829|PDB:3FMK" FT TURN 185..188 FT /evidence="ECO:0007829|PDB:3LFF" FT HELIX 191..194 FT /evidence="ECO:0007829|PDB:2FST" FT STRAND 197..199 FT /evidence="ECO:0007829|PDB:4EHV" FT HELIX 204..218 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 228..239 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 244..247 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 253..260 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 270..273 FT /evidence="ECO:0007829|PDB:2FST" FT TURN 274..276 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 279..288 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 293..295 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 299..303 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 306..308 FT /evidence="ECO:0007829|PDB:2FST" FT TURN 309..311 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 314..316 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 325..327 FT /evidence="ECO:0007829|PDB:2FST" FT HELIX 334..347 FT /evidence="ECO:0007829|PDB:2FST" SQ SEQUENCE 360 AA; 41293 MW; 286C81D0487618B3 CRC64; MSQERPTFYR QELNKTIWEV PERYQNLSPV GSGAYGSVCA AFDTKTGLRV AVKKLSRPFQ SIIHAKRTYR ELRLLKHMKH ENVIGLLDVF TPARSLEEFN DVYLVTHLMG ADLNNIVKCQ KLTDDHVQFL IYQILRGLKY IHSADIIHRD LKPSNLAVNE DCELKILDFG LARHTDDEMT GYVATRWYRA PEIMLNWMHY NQTVDIWSVG CIMAELLTGR TLFPGTDHID QLKLILRLVG TPGAELLKKI SSESARNYIQ SLTQMPKMNF ANVFIGANPL AVDLLEKMLV LDSDKRITAA QALAHAYFAQ YHDPDDEPVA DPYDQSFESR DLLIDEWKSL TYDEVISFVP PPLDQEEMES // ID MLH1_HUMAN Reviewed; 756 AA. AC P40692; B4DI13; B4DQ11; E9PCU2; DT 01-FEB-1995, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1995, sequence version 1. DT 28-JAN-2026, entry version 252. DE RecName: Full=DNA mismatch repair protein Mlh1; DE AltName: Full=MutL protein homolog 1; GN Name=MLH1; Synonyms=COCA2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=8145827; DOI=10.1038/368258a0; RA Bronner C.E., Baker S.M., Morrison P.T., Warren G., Smith L.G., RA Lescoe M.K., Kane M.F., Earibino C., Lipford J., Lindblom A., RA Tannergaard P., Bollag R.J., Godwin A.R., Ward D.C., Nordenskjoeld M., RA Fishel R., Kolodner R.D., Liskay R.M.; RT "Mutation in the DNA mismatch repair gene homologue hMLH1 is associated RT with hereditary non-polyposis colon cancer."; RL Nature 368:258-261(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Gall bladder; RX PubMed=8128251; DOI=10.1126/science.8128251; RA Papadopoulos N., Nicolaides N.C., Wei Y.-F., Ruben S.M., Carter K.C., RA Rosen C.A., Haseltine W.A., Fleischmann R.D., Fraser C.M., Adams M.D., RA Venter J.C., Hamilton S.R., Petersen G.M., Watson P., Lynch H.T., RA Peltomaeki P., Mecklin J.-P., de la Chapelle A., Kinzler K.W., RA Vogelstein B.; RT "Mutation of a mutL homolog in hereditary colon cancer."; RL Science 263:1625-1629(1994). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=7812952; RA Kolodner R.D., Hall N.R., Lipford J.R., Kane M.F., Morrison P., Finan P.J., RA Burn J., Chapman P., Earabino C., Merchant E., Bishop D.T.; RT "Structure of the human MLH1 locus and analysis of a large hereditary RT nonpolyposis colorectal carcinoma kindred for mlh1 mutations."; RL Cancer Res. 55:242-248(1995). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LYNCH2 LEU-542; PRO-574; RP VAL-582 AND THR-618. RX PubMed=7757073; DOI=10.1093/hmg/4.2.237; RA Han H.-J., Maruyama M., Baba S., Park J.-G., Nakamura Y.; RT "Genomic structure of human mismatch repair gene, hMLH1, and its mutation RT analysis in patients with hereditary non-polyposis colorectal cancer RT (HNPCC)."; RL Hum. Mol. Genet. 4:237-242(1995). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-32; MET-213 AND RP VAL-219. RG NIEHS SNPs program; RL Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3). RC TISSUE=Brain, Corpus callosum, Kidney, and Substantia nigra; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP IDENTIFICATION OF MLH1 AS MEMBER OF BASC. RX PubMed=10783165; RA Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J.; RT "BASC, a super complex of BRCA1-associated proteins involved in the RT recognition and repair of aberrant DNA structures."; RL Genes Dev. 14:927-939(2000). RN [11] RP INTERACTION WITH MBD4. RX PubMed=10097147; DOI=10.1073/pnas.96.7.3969; RA Bellacosa A., Cicchillitti L., Schepis F., Riccio A., Yeung A.T., RA Matsumoto Y., Golemis E.A., Genuardi M., Neri G.; RT "MED1, a novel human methyl-CpG-binding endonuclease, interacts with DNA RT mismatch repair protein MLH1."; RL Proc. Natl. Acad. Sci. U.S.A. 96:3969-3974(1999). RN [12] RP INTERACTION WITH EXO1 AND PMS2, CHARACTERIZATION OF VARIANTS LYNCH2 RP PRO-574; LYS-616 DEL; LEU-659 AND THR-681, AND CHARACTERIZATION OF VARIANT RP MMRCS1 LYS-616 DEL. RX PubMed=11427529; DOI=10.1074/jbc.m102670200; RA Schmutte C., Sadoff M.M., Shim K.-S., Acharya S., Fishel R.; RT "The interaction of DNA mismatch repair proteins with human exonuclease RT I."; RL J. Biol. Chem. 276:33011-33018(2001). RN [13] RP INTERACTION WITH EXO1, SUBCELLULAR LOCATION, AND CHARACTERIZATION OF RP VARIANT MET-117. RX PubMed=11429708; DOI=10.1038/sj.onc.1204467; RA Jaeger A.C., Rasmussen M., Bisgaard H.C., Singh K.K., Nielsen F.C., RA Rasmussen L.J.; RT "HNPCC mutations in the human DNA mismatch repair gene hMLH1 influence RT assembly of hMutLalpha and hMLH1-hEXO1 complexes."; RL Oncogene 20:3590-3595(2001). RN [14] RP INTERACTION WITH EXO1. RX PubMed=12414623; RA Sun X., Zheng L., Shen B.; RT "Functional alterations of human exonuclease 1 mutants identified in RT atypical hereditary nonpolyposis colorectal cancer syndrome."; RL Cancer Res. 62:6026-6030(2002). RN [15] RP INTERACTION WITH EXO1, AND SUBCELLULAR LOCATION. RX PubMed=14676842; DOI=10.1038/sj.onc.1207265; RA Nielsen F.C., Jaeger A.C., Luetzen A., Bundgaard J.R., Rasmussen L.J.; RT "Characterization of human exonuclease 1 in complex with mismatch repair RT proteins, subcellular localization and association with PCNA."; RL Oncogene 23:1457-1468(2004). RN [16] RP INVOLVEMENT IN MRTES. RX PubMed=8751876; RA Bapat B., Xia L., Madlensky L., Mitri A., Tonin P., Narod S.A., RA Gallinger S.; RT "The genetic basis of Muir-Torre syndrome includes the hMLH1 locus."; RL Am. J. Hum. Genet. 59:736-739(1996). RN [17] RP FUNCTION. RX PubMed=16873062; DOI=10.1016/j.cell.2006.05.039; RA Kadyrov F.A., Dzantiev L., Constantin N., Modrich P.; RT "Endonucleolytic function of MutLalpha in human mismatch repair."; RL Cell 126:297-308(2006). RN [18] RP FUNCTION. RX PubMed=18206974; DOI=10.1016/j.molcel.2007.10.030; RA Sacho E.J., Kadyrov F.A., Modrich P., Kunkel T.A., Erie D.A.; RT "Direct visualization of asymmetric adenine nucleotide-induced RT conformational changes in MutL alpha."; RL Mol. Cell 29:112-121(2008). RN [19] RP REVIEW. RX PubMed=16188885; DOI=10.1074/jbc.m509701200; RA Constantin N., Dzantiev L., Kadyrov F.A., Modrich P.; RT "Human mismatch repair: reconstitution of a nick-directed bidirectional RT reaction."; RL J. Biol. Chem. 280:39752-39761(2005). RN [20] RP REVIEW. RX PubMed=16873053; DOI=10.1016/j.cell.2006.07.003; RA Jiricny J.; RT "MutLalpha: at the cutting edge of mismatch repair."; RL Cell 126:239-241(2006). RN [21] RP REVIEW. RX PubMed=18157157; DOI=10.1038/cr.2007.115; RA Li G.M.; RT "Mechanisms and functions of DNA mismatch repair."; RL Cell Res. 18:85-98(2008). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [24] RP INTERACTION WITH MTMR15. RX PubMed=20603073; DOI=10.1016/j.molcel.2010.06.023; RA Smogorzewska A., Desetty R., Saito T.T., Schlabach M., Lach F.P., RA Sowa M.E., Clark A.B., Kunkel T.A., Harper J.W., Colaiacovo M.P., RA Elledge S.J.; RT "A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease RT necessary for DNA interstrand crosslink repair."; RL Mol. Cell 39:36-47(2010). RN [25] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [27] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22223895; DOI=10.1074/mcp.m111.015131; RA Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T., RA Giglione C.; RT "Comparative large-scale characterisation of plant vs. mammal proteins RT reveals similar and idiosyncratic N-alpha acetylation features."; RL Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012). RN [28] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [30] RP IDENTIFICATION IN THE MMR COMPLEX, INTERACTION WITH MCM9 AND MCM8, AND RP SUBCELLULAR LOCATION. RX PubMed=26300262; DOI=10.1016/j.molcel.2015.07.010; RA Traver S., Coulombe P., Peiffer I., Hutchins J.R., Kitzmann M., RA Latreille D., Mechali M.; RT "MCM9 Is Required for Mammalian DNA Mismatch Repair."; RL Mol. Cell 59:831-839(2015). RN [31] RP SUBCELLULAR LOCATION, ACETYLATION AT LYS-33; LYS-241; LYS-361 AND LYS-377, RP DEACETYLATION BY HDAC6, AND MUTAGENESIS OF LYS-33; LYS-241; LYS-361 AND RP LYS-377. RX PubMed=30770470; DOI=10.1074/jbc.ra118.006374; RA Zhang M., Hu C., Moses N., Haakenson J., Xiang S., Quan D., Fang B., RA Yang Z., Bai W., Bepler G., Li G.M., Zhang X.M.; RT "HDAC6 regulates DNA damage response via deacetylating MLH1."; RL J. Biol. Chem. 294:5813-5826(2019). RN [32] RP FUNCTION, UBIQUITINATION BY UBR4, DEUBIQUITINATION BY USP5, INTERACTION RP WITH PSM2, AND CHARACTERIZATION OF VARIANT LEU-574 AND ALA-589. RX PubMed=39032648; DOI=10.1016/j.jbc.2024.107592; RA Mao C., Li S., Che J., Liu D., Mao X., Rao H.; RT "The ubiquitin ligase UBR4 and the deubiquitylase USP5 modulate the RT stability of DNA mismatch repair protein MLH1."; RL J. Biol. Chem. 300:107592-107592(2024). RN [33] RP X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 486-751. RA Dombrovsky L., Dong A., Wernimont A., Loppnau P., Bountra C., Weigelt J., RA Arrowsmith C.H., Edwards A.M., Min J., Wu H.; RT "Crystal structure of MutL protein homolog 1 isoform 1."; RL Submitted (MAR-2011) to the PDB data bank. RN [34] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 3-196 IN COMPLEX WITH ADP AND RP MAGNESIUM IONS. RX PubMed=26249686; DOI=10.1107/s2053230x15010183; RA Wu H., Zeng H., Lam R., Tempel W., Kerr I.D., Min J.; RT "Structure of the human MLH1 N-terminus: implications for predisposition to RT Lynch syndrome."; RL Acta Crystallogr. F 71:981-985(2015). RN [35] {ECO:0007744|PDB:5U5P} RP X-RAY CRYSTALLOGRAPHY (2.17 ANGSTROMS) OF 467-476, NUCLEAR LOCALIZATION RP SIGNAL, AND MUTAGENESIS OF LYS-471 AND ARG-472. RX PubMed=29175432; DOI=10.1016/j.biochi.2017.11.013; RA de Barros A.C., Takeda A.A.S., Dreyer T.R., Velazquez-Campoy A., Kobe B., RA Fontes M.R.M.; RT "DNA mismatch repair proteins MLH1 and PMS2 can be imported to the nucleus RT by a classical nuclear import pathway."; RL Biochimie 146:87-96(2018). RN [36] RP CHARACTERIZATION OF VARIANTS LYNCH2 CYS-31; LYS-37; HIS-38; LYS-38; PHE-44; RP ARG-67; PRO-109; PRO-111; MET-117; CYS-265; SER-265; GLN-443; PRO-550; RP GLY-578; PHE-582; ASP-589; ALA-618; CYS-646; LEU-648; LEU-654 AND PRO-659, RP CHARACTERIZATION OF VARIANTS GLY-93; VAL-219; SER-403; ASN-406 AND MET-716, RP AND FUNCTION. RX PubMed=20020535; DOI=10.1002/humu.21180; RA Drost M., Zonneveld J.B., van Dijk L., Morreau H., Tops C.M., Vasen H.F., RA Wijnen J.T., de Wind N.; RT "A cell-free assay for the functional analysis of variants of the mismatch RT repair protein MLH1."; RL Hum. Mutat. 31:247-253(2010). RN [37] RP CHARACTERIZATION OF VARIANTS LYNCH2 LEU-28; SER-29; 45-THR--ILE-47 DELINS RP CYS-PHE; GLU-63; ARG-67; GLU-71 DEL; ARG-77; VAL-80; GLU-84; ARG-107; RP ARG-155; GLY-185; PRO-247; PRO-329; ILE-330 DEL; GLN-443; ALA-460; PRO-550; RP 578-GLU--GLU-632 DEL; ASP-589; VAL-612 DEL; LYS-616 DEL; ALA-618; THR-618; RP 633-GLU--GLU-663 DEL; CYS-646; LEU-648; SER-648; LEU-654; GLN-659; PRO-659; RP THR-681 AND TRP-687, CHARACTERIZATION OF VARIANTS GLY-93; MET-213; VAL-219 RP AND MET-716, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=21120944; DOI=10.1002/humu.21409; RA Kansikas M., Kariola R., Nystroem M.; RT "Verification of the three-step model in assessing the pathogenicity of RT mismatch repair gene variants."; RL Hum. Mutat. 32:107-115(2011). RN [38] RP VARIANT LYNCH2 ARG-35. RX PubMed=8521398; RA Tannergaard P., Lipford J.R., Kolodner R., Froedin J.E., Nordenskjoeld M., RA Lindblom A.; RT "Mutation screening in the hMLH1 gene in Swedish hereditary nonpolyposis RT colon cancer families."; RL Cancer Res. 55:6092-6096(1995). RN [39] RP VARIANT MMRCS1 LYS-616 DEL. RX PubMed=7661930; DOI=10.1056/nejm199503303321302; RA Hamilton S.R., Liu B., Parsons R.E., Papadopoulos N., Jen J., Powell S.M., RA Krush A.J., Berk T., Cohen Z., Tetu B., Burger P.C., Wood P.A., Taqi F., RA Booker S.V., Petersen G.M., Offerhaus G.J.A., Tersmette A.C., RA Giardiello F.M., Vogelstein B., Kinzler K.W.; RT "The molecular basis of Turcot's syndrome."; RL N. Engl. J. Med. 332:839-847(1995). RN [40] RP VARIANT LYNCH2 LYS-616 DEL. RX PubMed=8571956; RA Wijnen J., Khan P.M., Vasen H., Menko F., van der Klift H., RA van den Broek M., van Leeuwen-Cornelisse I., Nagengast F., RA Meijers-Heijboer E.J., Lindhout D., Griffioen G., Cats A., Kleibeuker J., RA Varesco L., Bertario L., Bisgaard M.-L., Mohr J., Kolodner R.D., Fodde R.; RT "Majority of hMLH1 mutations responsible for hereditary nonpolyposis RT colorectal cancer cluster at the exonic region 15-16."; RL Am. J. Hum. Genet. 58:300-307(1996). RN [41] RP VARIANTS LYNCH2 MET-117 AND LEU-226. RX PubMed=8566964; DOI=10.1007/bf02265276; RA Maliaka Y.K., Chudina A.P., Belev N.F., Alday P., Bochkov N.P., RA Buerstedde J.-M.; RT "CpG dinucleotides in the hMSH2 and hMLH1 genes are hotspots for HNPCC RT mutations."; RL Hum. Genet. 97:251-255(1996). RN [42] RP VARIANTS LYNCH2 LYS-616 DEL AND THR-618, AND VARIANT CRC THR-492. RX PubMed=8872463; DOI=10.1093/hmg/5.9.1245; RA Moslein G., Tester D.J., Lindor N.M., Honchel R., Cunningham J.M., RA French A.J., Halling K.C., Schwab M., Goretzki P., Thibodeau S.N.; RT "Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in RT patients with sporadic, familial and hereditary colorectal cancer."; RL Hum. Mol. Genet. 5:1245-1252(1996). RN [43] RP VARIANTS LYNCH2 CYS-217; LEU-542; PRO-549 AND PRO-574. RX PubMed=8797773; DOI=10.1093/jnci/88.18.1317; RA Han H.-J., Yuan Y., Ku J.-L., Oh J.-H., Won Y.-J., Kang K.J., Kim K.Y., RA Kim S., Kim C.Y., Kim J.-P., Oh N.-G., Lee K.H., Choe K.J., Nakamura Y., RA Park J.-G.; RT "Germline mutations of hMLH1 and hMSH2 genes in Korean hereditary RT nonpolyposis colorectal cancer."; RL J. Natl. Cancer Inst. 88:1317-1319(1996). RN [44] RP VARIANTS LEU-ASN-HIS-37 INS AND ASP-384. RX PubMed=8609062; DOI=10.1111/j.1349-7006.1996.tb03151.x; RA Kobayashi K., Matsushima M., Koi S., Saito H., Sagae S., Kudo R., RA Nakamura Y.; RT "Mutational analysis of mismatch repair genes, hMLH1 and hMSH2, in sporadic RT endometrial carcinomas with microsatellite instability."; RL Jpn. J. Cancer Res. 87:141-145(1996). RN [45] RP VARIANT LYNCH2 ALA-506. RX PubMed=8574961; DOI=10.1038/nm0296-169; RA Liu B., Parsons R., Papadopoulos N., Nicolaides N.C., Lynch H.T., RA Watson P., Jass J.R., Dunlop M., Wyllie A., Peltomaeki P., RA de la Chapelle A., Hamilton S.R., Vogelstein B., Kinzler K.W.; RT "Analysis of mismatch repair genes in hereditary non-polyposis colorectal RT cancer patients."; RL Nat. Med. 2:169-174(1996). RN [46] RP VARIANTS LYNCH2 LYS-62; SER-64; LYS-616 DEL; ALA-618 AND PRO-659, RP CHARACTERIZATION OF VARIANT LYNCH2 LYS-62, AND FUNCTION. RX PubMed=9311737; DOI=10.1086/514847; RA Wijnen J., Khan P.M., Vasen H., van der Klift H., Mulder A., RA van Leeuwen-Cornelisse I., Bakker B., Losekoot M., Moeller P., Fodde R.; RT "Hereditary nonpolyposis colorectal cancer families not complying with the RT Amsterdam criteria show extremely low frequency of mismatch-repair-gene RT mutations."; RL Am. J. Hum. Genet. 61:329-335(1997). RN [47] RP VARIANT LYNCH2 LYS-616 DEL, AND VARIANT HIS-265. RX PubMed=8993976; RX DOI=10.1002/(sici)1098-2264(199701)18:1<8::aid-gcc2>3.0.co;2-7; RA Viel A., Genuardi M., Capozzi E., Leonardi F., Bellacosa A., RA Paravatou-Petsotas M., Pomponi M.G., Fornasarig M., Percesepe A., RA Roncucci L., Tamassia M.G., Benatti P., Ponz de Leon M., Valenti A., RA Covino M., Anti M., Foletto M., Boiocchi M., Neri G.; RT "Characterization of MSH2 and MLH1 mutations in Italian families with RT hereditary nonpolyposis colorectal cancer."; RL Genes Chromosomes Cancer 18:8-18(1997). RN [48] RP VARIANTS CRC GLU-54 AND VAL-244, AND VARIANTS VAL-219; GLN-325 AND ASN-406. RX PubMed=9087566; RX DOI=10.1002/(sici)1098-2264(199704)18:4<269::aid-gcc4>3.3.co;2-9; RA Wu Y., Nystroem-Lahti M., Osinga J., Looman M.W.G., Peltomaeki P., RA Aaltonen L.A., de la Chapelle A., Hofstra R.M.W., Buys C.H.C.M.; RT "MSH2 and MLH1 mutations in sporadic replication error-positive colorectal RT carcinoma as assessed by two-dimensional DNA electrophoresis."; RL Genes Chromosomes Cancer 18:269-278(1997). RN [49] RP VARIANTS LYNCH2 PRO-128 AND ASP-244, AND VARIANT VAL-219. RX PubMed=9218993; RX DOI=10.1002/(sici)1098-2264(199707)19:3<135::aid-gcc1>3.3.co;2-x; RA Pensotti V., Radice P., Presciuttini S., Calistri D., Gazzoli I., RA Grimalt Perez A.P., Mondini P., Buonsanti G., Sala P., Rossetti C., RA Ranzani G.N., Bertario L., Pierotti M.A.; RT "Mean age of tumor onset in hereditary nonpolyposis colorectal cancer RT (HNPCC) families correlates with the presence of mutations in DNA mismatch RT repair genes."; RL Genes Chromosomes Cancer 19:135-142(1997). RN [50] RP VARIANT LYNCH2 626-PHE-SER-627 DELINS SER-THR. RX PubMed=9048925; DOI=10.1007/s004390050343; RA Beck N.E., Tomlinson I.P.M., Homfray T., Frayling I., Hodgson S.V., RA Harocopos C.J., Bodmer W.F.; RT "Use of SSCP analysis to identify germline mutations in HNPCC families RT fulfilling the Amsterdam criteria."; RL Hum. Genet. 99:219-224(1997). RN [51] RP VARIANT LYNCH2 PRO-329. RX PubMed=9272156; DOI=10.1007/s004390050517; RA Wang Y., Friedl W., Lamberti C., Ruelfs C., Kruse R., Propping P.; RT "Hereditary nonpolyposis colorectal cancer: causative role of a germline RT missense mutation in the hMLH1 gene confirmed by the independent occurrence RT of the same somatic mutation in tumour tissue."; RL Hum. Genet. 100:362-364(1997). RN [52] RP VARIANT LYNCH2 ARG-67, AND VARIANT VAL-219. RX PubMed=9067757; RX DOI=10.1002/(sici)1098-1004(1997)9:2<164::aid-humu9>3.0.co;2-9; RA Sasaki S., Tokino T., Miyatsu T., Muto T., Nakamura Y.; RT "Mutational analysis of the hMLH1 gene using an automated two-dimensional RT DNA typing system."; RL Hum. Mutat. 9:164-171(1997). RN [53] RP REVIEW ON VARIANTS. RX PubMed=9259192; RX DOI=10.1002/(sici)1098-1004(1997)10:2<89::aid-humu1>3.0.co;2-h; RA Papadopoulos N., Lindblom A.; RT "Molecular basis of HNPCC: mutations of MMR genes."; RL Hum. Mutat. 10:89-99(1997). RN [54] RP VARIANT LYNCH2 LEU-28. RX PubMed=9298827; RX DOI=10.1002/(sici)1098-1004(1997)10:3<241::aid-humu12>3.0.co;2-#; RA Wehner M., Buschhausen L., Lamberti C., Kruse R., Caspari R., Propping P., RA Friedl W.; RT "Hereditary nonpolyposis colorectal cancer (HNPCC): eight novel germline RT mutations in hMSH2 or hMLH1 genes."; RL Hum. Mutat. 10:241-244(1997). RN [55] RP VARIANTS LYNCH2 GLY-182; THR-295 AND THR-551. RX PubMed=9399661; RX DOI=10.1002/(sici)1097-0215(19971210)73:6<831::aid-ijc11>3.0.co;2-7; RA Wang Q., Desseigne F., Lasset C., Saurin J.-C., Navarro C., Yagci T., RA Keser I., Bagci H., Luleci G., Gelen T., Chayvialle J.-A., Puisieux A., RA Ozturk M.; RT "Germline hMSH2 and hMLH1 gene mutations in incomplete HNPCC families."; RL Int. J. Cancer 73:831-836(1997). RN [56] RP VARIANT CRC TYR-77, AND VARIANT VAL-219. RX PubMed=9032648; DOI=10.1136/jmg.34.1.39; RA Tomlinson I.P.M., Beck N.E., Homfray T., Harocopos C.J., Bodmer W.F.; RT "Germline HNPCC gene variants have little influence on the risk for RT sporadic colorectal cancer."; RL J. Med. Genet. 34:39-42(1997). RN [57] RP VARIANTS LYNCH2 PHE-44 AND THR-441. RX PubMed=9326924; DOI=10.1038/ng1097-135; RA Hackman P., Tannergaerd P., Osei-Mensa S., Chen J., Kane M.F., RA Kolodner R.D., Lambert B., Hellgren D., Lindblom A.; RT "A human compound heterozygote for two MLH1 missense mutations."; RL Nat. Genet. 17:135-136(1997). RN [58] RP VARIANTS LYNCH2, AND VARIANTS. RX PubMed=9718327; DOI=10.1086/301996; RA Farrington S.M., Lin-Goerke J., Ling J., Wang Y., Burczak J.D., RA Robbins D.J., Dunlop M.G.; RT "Systematic analysis of hMSH2 and hMLH1 in young colon cancer patients and RT controls."; RL Am. J. Hum. Genet. 63:749-759(1998). RN [59] RP VARIANT CRC GLY-268. RX PubMed=9611074; DOI=10.1111/j.1399-0004.1998.tb02660.x; RA Liu T., Wahlberg S., Rubio C., Holmberg E., Groenberg H., Lindblom A.; RT "DGGE screening of mutations in mismatch repair genes (hMSH2 and hMLH1) in RT 34 Swedish families with colorectal cancer."; RL Clin. Genet. 53:131-135(1998). RN [60] RP VARIANT LYNCH2 CYS-217. RX PubMed=9559627; DOI=10.1007/bf02235756; RA Yuan Y., Han H.-J., Zheng S., Park J.-G.; RT "Germline mutations of hMLH1 and hMSH2 genes in patients with suspected RT hereditary nonpolyposis colorectal cancer and sporadic early-onset RT colorectal cancer."; RL Dis. Colon Rectum 41:434-440(1998). RN [61] RP VARIANT ASP-384, AND ASSOCIATION WITH HNPCC. RX PubMed=9526167; DOI=10.1159/000022786; RA Wang Y., Friedl W., Lamberti C., Noethen M.M., Kruse R., Propping P.; RT "A novel missense mutation in the DNA mismatch repair gene hMLH1 present RT among East Asians but not among Europeans."; RL Hum. Hered. 48:87-91(1998). RN [62] RP VARIANT LYNCH2 LYS-69. RX PubMed=10627141; RX DOI=10.1002/(sici)1098-1004(1998)12:1<73::aid-humu20>3.0.co;2-f; RA Herfarth K.K.-F., Ogunbiyi O.A., Moley J.F., Kodner I.J., Wells S.A. Jr., RA Goodfellow P.J.; RT "Four new mutations in the DNA mismatch repair gene MLH1 in colorectal RT cancers with microsatellite instability."; RL Hum. Mutat. 12:73-73(1998). RN [63] RP VARIANTS LYNCH2 ARG-77 AND PRO-193. RX PubMed=10660333; RA Panariello L., Scarano M.I., de Rosa M., Capasso L., Renda A., Riegler G., RA Rossi G.B., Salvatore F., Izzo P.; RT "hMLH1 mutations in hereditary nonpolyposis colorectal cancer kindreds."; RL Hum. Mutat. 12:216-217(1998). RN [64] RP VARIANT GLY-93. RX PubMed=10671064; RX DOI=10.1002/(sici)1098-1004(1998)12:6<433::aid-humu13>3.0.co;2-j; RA Quaresima B., Grandinetti C., Baudi F., Tassone P., Barbieri V., RA Conforti S., Avvedimento E.V., Costanzo F., Venuta S.; RT "Hereditary nonpolyposis colorectal cancer: identification of novel RT germline mutations in two kindreds not fulfilling the Amsterdam criteria."; RL Hum. Mutat. 12:433-433(1998). RN [65] RP VARIANTS LYNCH2 ARG-67; ILE-262 DEL; THR-551 AND PHE-565, AND VARIANTS RP VAL-219 AND MET-716. RX PubMed=9833759; RX DOI=10.1002/(sici)1097-0215(19981209)78:6<680::aid-ijc3>3.0.co;2-u; RA Hutter P., Couturier A., Membrez V., Joris F., Sappino A.-P., RA Chappuis P.O.; RT "Excess of hMLH1 germline mutations in Swiss families with hereditary non- RT polyposis colorectal cancer."; RL Int. J. Cancer 78:680-684(1998). RN [66] RP VARIANTS LYNCH2 ARG-67; ARG-117 AND GLU-485, AND VARIANT VAL-219. RX PubMed=10375096; RX DOI=10.1002/(sici)1097-0142(19990615)85:12<2512::aid-cncr4>3.0.co;2-g; RA Heinimann K., Scott R.J., Buerstedde J.-M., Weber W., Siebold K., RA Attenhofer M., Mueller H., Dobbie Z.; RT "Influence of selection criteria on mutation detection in patients with RT hereditary nonpolyposis colorectal cancer."; RL Cancer 85:2512-2518(1999). RN [67] RP VARIANT LYNCH2 TRP-67. RX PubMed=9927034; RA Wang Q., Lasset C., Desseigne F., Frappaz D., Bergeron C., Navarro C., RA Ruano E., Puisieux A.; RT "Neurofibromatosis and early onset of cancers in hMLH1-deficient RT children."; RL Cancer Res. 59:294-297(1999). RN [68] RP VARIANTS HIS-265; ALA-326; PRO-385; ASN-406; THR-618 AND MET-716. RX PubMed=10573010; DOI=10.1038/sj.ejhg.5200363; RA Genuardi M., Carrara S., Anti M., Ponz de Leon M., Viel A.; RT "Assessment of pathogenicity criteria for constitutional missense mutations RT of the hereditary nonpolyposis colorectal cancer genes MLH1 and MSH2."; RL Eur. J. Hum. Genet. 7:778-782(1999). RN [69] RP VARIANTS LYNCH2 LEU-28; GLU-84 AND PRO-329. RX PubMed=10323887; DOI=10.1136/gut.44.6.839; RA Lamberti C., Kruse R., Ruelfs C., Caspari R., Wang Y., Jungck M., RA Mathiak M., Malayeri H.R.H., Friedl W., Sauerbruch T., Propping P.; RT "Microsatellite instability, a useful diagnostic tool to select patients at RT high risk for hereditary non-polyposis colorectal cancer: a study in RT different groups of patients with colorectal cancer."; RL Gut 44:839-843(1999). RN [70] RP VARIANTS LYNCH2 TRP-67; MET-117; GLY-182 AND LYS-616 DEL, AND VARIANT HNPCC RP TRP-755. RX PubMed=10480359; DOI=10.1007/s004399900064; RA Wang Q., Lasset C., Desseigne F., Saurin J.-C., Maugard C., Navarro C., RA Ruano E., Descos L., Trillet-Lenoir V., Bosset J.-F., Puisieux A.; RT "Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 RT genes in 75 French kindreds with nonpolyposis colorectal cancer."; RL Hum. Genet. 105:79-85(1999). RN [71] RP VARIANT CRC GLY-578, AND VARIANT LYNCH2 ALA-618. RX PubMed=10598809; DOI=10.1007/s004390051127; RA Liu T., Tannergaerd P., Hackman P., Rubio C., Kressner U., Lindmark G., RA Hellgren D., Lambert B., Lindblom A.; RT "Missense mutations in hMLH1 associated with colorectal cancer."; RL Hum. Genet. 105:437-441(1999). RN [72] RP VARIANT LYNCH2 PHE-25, AND VARIANT TYR-718. RX PubMed=10386556; DOI=10.1001/jama.281.24.2316; RA Weber T.K., Chin H.-M., Rodriguez-Bigas M., Keitz B., Gilligan R., RA O'Malley L., Urf E., Diba N., Pazik J., Petrelli N.J.; RT "Novel hMLH1 and hMSH2 germline mutations in African Americans with RT colorectal cancer."; RL JAMA 281:2316-2320(1999). RN [73] RP VARIANT LYNCH2 TYR-264. RX PubMed=10413423; DOI=10.1093/jnci/91.14.1221; RA Chan T.L., Yuen S.T., Chung L.P., Ho J.W.C., Kwan K.Y.M., Chan A.S.Y., RA Ho J.C.Y., Leung S.Y., Wyllie A.H.; RT "Frequent microsatellite instability and mismatch repair gene mutations in RT young Chinese patients with colorectal cancer."; RL J. Natl. Cancer Inst. 91:1221-1226(1999). RN [74] RP VARIANTS LYNCH2 VAL-111 AND PRO-588, AND VARIANTS VAL-219 AND ASP-384. RX PubMed=10777691; DOI=10.1006/bbrc.2000.2547; RA Nomura S., Sugano K., Kashiwabara H., Taniguchi T., Fukayama N., Fujita S., RA Akasu T., Moriya Y., Ohhigashi S., Kakizoe T., Sekiya T.; RT "Enhanced detection of deleterious and other germline mutations of hMSH2 RT and hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds."; RL Biochem. Biophys. Res. Commun. 271:120-129(2000). RN [75] RP VARIANTS LYNCH2 HIS-607; ALA-618 AND LEU-659, AND VARIANT MET-213. RX PubMed=10713887; DOI=10.1038/sj.ejhg.5200393; RA Fidalgo P., Almeida M.R., West S., Gaspar C., Maia L., Wijnen J., RA Albuquerque C., Curtis A., Cravo M., Fodde R., Leitao C.N., Burn J.; RT "Detection of mutations in mismatch repair genes in Portuguese families RT with hereditary non-polyposis colorectal cancer (HNPCC) by a multi-method RT approach."; RL Eur. J. Hum. Genet. 8:49-53(2000). RN [76] RP VARIANT CRC ARG-260, AND VARIANT LYNCH2 VAL-304. RX PubMed=10882759; DOI=10.1136/jmg.37.7.e7; RA Montera M., Resta N., Simone C., Guanti G., Marchese C., Civitelli S., RA Mancini A., Pozzi S., De Salvo L., Bruzzone D., Donadini A., Romio L., RA Mareni C.; RT "Mutational germline analysis of hMSH2 and hMLH1 genes in early onset RT colorectal cancer patients."; RL J. Med. Genet. 37:E7-E7(2000). RN [77] RP ERRATUM OF PUBMED:10882759. RA Montera M., Resta N., Simone C., Guanti G., Marchese C., Civitelli S., RA Mancini A., Pozzi S., De Salvo L., Bruzzone D., Donadini A., Romio L., RA Mareni C.; RL J. Med. Genet. 40:472-472(2003). RN [78] RP VARIANTS GASTRIC CANCER ARG-106; GLN-109 AND LYS-635, VARIANTS LYNCH2 RP GLY-234; ILE-321; HIS-485 AND ALA-631, AND VARIANT CRC ILE-472. RX PubMed=12132870; RA Kim J.C., Kim H.C., Roh S.A., Koo K.H., Lee D.H., Yu C.S., Lee J.H., RA Kim T.W., Lee H.I., Beck N.E., Bodmer W.F.; RT "hMLH1 and hMSH2 mutations in families with familial clustering of gastric RT cancer and hereditary non-polyposis colorectal cancer."; RL Cancer Detect. Prev. 25:503-510(2001). RN [79] RP VARIANT HIS-607. RX PubMed=11369138; DOI=10.1016/s0304-3835(01)00448-7; RA Stone J.G., Coleman G., Gusterson B., Marossy A., Lakhani S.R., Ward A., RA Nash A., McKinna A., A'Hern R., Stratton M.R., Houlston R.S.; RT "Contribution of germline MLH1 and MSH2 mutations to lobular carcinoma in RT situ of the breast."; RL Cancer Lett. 167:171-174(2001). RN [80] RP INVOLVEMENT IN TUMORIGENESIS. RX PubMed=11389087; RA Vilkki S., Tsao J.-L., Loukola A., Poyhonen M., Vierimaa O., Herva R., RA Aaltonen L.A., Shibata D.; RT "Extensive somatic microsatellite mutations in normal human tissue."; RL Cancer Res. 61:4541-4544(2001). RN [81] RP VARIANTS LYNCH2 VAL-80; PRO-329; ARG-603; ALA-618; LEU-648; PRO-662 AND RP ARG-689. RX PubMed=11726306; RA Mueller-Koch Y., Kopp R., Lohse P., Baretton G., Stoetzer A., Aust D., RA Daum J., Kerker B., Gross M., Dietmeier W., Holinski-Feder E.; RT "Sixteen rare sequence variants of the hMLH1 and hMSH2 genes found in a RT cohort of 254 suspected HNPCC (hereditary non-polyposis colorectal cancer) RT patients: mutations or polymorphisms?"; RL Eur. J. Med. Res. 6:473-482(2001). RN [82] RP CHARACTERIZATION OF VARIANTS. RX PubMed=11555625; DOI=10.1093/hmg/10.18.1889; RA Ellison A.R., Lofing J., Bitter G.A.; RT "Functional analysis of human MLH1 and MSH2 missense variants and hybrid RT human-yeast MLH1 proteins in Saccharomyces cerevisiae."; RL Hum. Mol. Genet. 10:1889-1900(2001). RN [83] RP VARIANT LYNCH2 ARG-751. RX PubMed=11139242; DOI=10.1002/1098-1004(2001)17:1<52::aid-humu6>3.0.co;2-e; RA Jakubowska A., Gorski B., Kurzawski G., Debniak T., Hadaczek P., RA Cybulski C., Kladny J., Oszurek O., Scott R.J., Lubinski J.; RT "Optimization of experimental conditions for RNA-based sequencing of MLH1 RT and MSH2 genes."; RL Hum. Mutat. 17:52-60(2001). RN [84] RP VARIANTS LYNCH2 HIS-622 AND TRP-687. RX PubMed=11748856; DOI=10.1002/humu.1240; RA Godino J., de La Hoya M., Diaz-Rubio E., Benito M., Caldes T.; RT "Eight novel germline MLH1 and MSH2 mutations in hereditary non-polyposis RT colorectal cancer families from Spain."; RL Hum. Mutat. 18:549-549(2001). RN [85] RP VARIANTS LYNCH2 SER-338; ARG-603; THR-618 AND TYR-718. RX PubMed=12095971; DOI=10.1007/bf02573891; RA Rossi B.M., Lopes A., Oliveira Ferreira F., Nakagawa W.T., RA Napoli Ferreira C.C., Casali Da Rocha J.C., Simpson C.C., Simpson A.J.G.; RT "hMLH1 and hMSH2 gene mutation in Brazilian families with suspected RT hereditary nonpolyposis colorectal cancer."; RL Ann. Surg. Oncol. 9:555-561(2002). RN [86] RP VARIANTS LYNCH2 ASN-35; HIS-38; MET-117 AND ALA-618. RX PubMed=12373605; DOI=10.1038/sj.bjc.6600565; RA Gille J.J.P., Hogervorst F.B.L., Pals G., Wijnen J.T., van Schooten R.J., RA Dommering C.J., Meijer G.A., Craanen M.E., Nederlof P.M., de Jong D., RA McElgunn C.J., Schouten J.P., Menko F.H.; RT "Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected RT by a novel mutation detection approach."; RL Br. J. Cancer 87:892-897(2002). RN [87] RP VARIANTS VAL-219 AND VAL-655. RX PubMed=12115348; DOI=10.1002/cncr.10606; RA Baldinu P., Cossu A., Manca A., Satta M.P., Pisano M., Casula M., RA Dessole S., Pintus A., Tanda F., Palmieri G.; RT "Microsatellite instability and mutation analysis of candidate genes in RT unselected Sardinian patients with endometrial carcinoma."; RL Cancer 94:3157-3168(2002). RN [88] RP CHARACTERIZATION OF VARIANTS LYNCH2 MET-117; GLY-185; CYS-217; ASP-244 AND RP ALA-326, AND CHARACTERIZATION OF VARIANTS VAL-219 AND HIS-265. RX PubMed=11781295; DOI=10.1053/gast.2002.30296; RA Trojan J., Zeuzem S., Randolph A., Hemmerle C., Brieger A., Raedle J., RA Plotz G., Jiricny J., Marra G.; RT "Functional analysis of hMLH1 variants and HNPCC-related mutations using a RT human expression system."; RL Gastroenterology 122:211-219(2002). RN [89] RP VARIANTS LYNCH2 CYS-385; HIS-607; THR-618 AND SER-648, AND VARIANT MET-213. RX PubMed=11839723; DOI=10.1136/gut.50.3.405; RA Cravo M., Afonso A.J., Lage P., Albuquerque C., Maia L., Lacerda C., RA Fidalgo P., Chaves P., Cruz C., Nobre-Leitao C.; RT "Pathogenicity of missense and splice site mutations in hMSH2 and hMLH1 RT mismatch repair genes: implications for genetic testing."; RL Gut 50:405-412(2002). RN [90] RP CHARACTERIZATION OF VARIANTS LYNCH2 ARG-77; ARG-107 AND PRO-659, AND RP CHARACTERIZATION OF VARIANT GLY-93. RX PubMed=11793442; DOI=10.1002/gcc.1225.abs; RA Nystroem-Lahti M., Perrera C., Raeschle M., Panyushkina-Seiler E., RA Marra G., Curci A., Quaresima B., Costanzo F., D'Urso M., Venuta S., RA Jiricny J.; RT "Functional analysis of MLH1 mutations linked to hereditary nonpolyposis RT colon cancer."; RL Genes Chromosomes Cancer 33:160-167(2002). RN [91] RP VARIANT LYNCH2 PRO-662, AND VARIANT VAL-219. RX PubMed=11754112; DOI=10.1002/humu.9004; RA Krueger S., Plaschke J., Pistorius S., Jeske B., Haas S., Kraemer H., RA Hinterseher I., Bier A., Kreuz F.R., Theissig F., Saeger H.D., RA Schackert H.K.; RT "Seven novel MLH1 and MSH2 germline mutations in hereditary nonpolyposis RT colorectal cancer."; RL Hum. Mutat. 19:82-82(2002). RN [92] RP VARIANTS LYNCH2 MET-117 AND PRO-247, AND VARIANTS VAL-219; ALA-618 AND RP MET-716. RX PubMed=12200596; DOI=10.1007/s00432-002-0361-2; RA Ward R., Meldrum C., Williams R., Mokany E., Scott R., Turner J., RA Hawkins N., Burgess B., Groombridge C., Spigelman A.; RT "Impact of microsatellite testing and mismatch repair protein expression on RT the clinical interpretation of genetic testing in hereditary non-polyposis RT colorectal cancer."; RL J. Cancer Res. Clin. Oncol. 128:403-411(2002). RN [93] RP VARIANT LYNCH2 CYS-646, AND VARIANT ALA-618. RX PubMed=11870161; DOI=10.1200/jco.2002.20.5.1203; RA Scartozzi M., Bianchi F., Rosati S., Galizia E., Antolini A., Loretelli C., RA Piga A., Bearzi I., Cellerino R., Porfiri E.; RT "Mutations of hMLH1 and hMSH2 in patients with suspected hereditary RT nonpolyposis colorectal cancer: correlation with microsatellite instability RT and abnormalities of mismatch repair protein expression."; RL J. Clin. Oncol. 20:1203-1208(2002). RN [94] RP VARIANTS LYNCH2 PHE-19; LEU-28; MET-117; PRO-292; THR-681 AND TRP-687, AND RP VARIANT VAL-219. RX PubMed=12362047; DOI=10.1136/jmg.39.10.e65; RA Kurzawski G., Suchy J., Kladny J., Safranow K., Jakubowska A., Elsakov P., RA Kucinskas V., Gardovski J., Irmejs A., Sibul H., Huzarski T., Byrski T., RA Debniak T., Cybulski C., Gronwald J., Oszurek O., Clark J., Gozdz S., RA Niepsuj S., Slomski R., Plawski A., Lacka-Wojciechowska A., Rozmiarek A., RA Fiszer-Maliszewska L., Bebenek M., Sorokin D., Stawicka M., Godlewski D., RA Richter P., Brozek I., Wysocka B., Jawien A., Banaszkiewicz Z., RA Kowalczyk J., Czudowska D., Goretzki P.E., Moeslein G., Lubinski J.; RT "Germline MSH2 and MLH1 mutational spectrum in HNPCC families from Poland RT and the Baltic States."; RL J. Med. Genet. 39:E65-E65(2002). RN [95] RP VARIANTS LYNCH2 SER-29; ARG-67; LEU-185 AND ASP-244. RX PubMed=12658575; DOI=10.1086/373963; RA Wagner A., Barrows A., Wijnen J.T., van der Klift H., Franken P.F., RA Verkuijlen P., Nakagawa H., Geugien M., Jaghmohan-Changur S., Breukel C., RA Meijers-Heijboer H., Morreau H., van Puijenbroek M., Burn J., Coronel S., RA Kinarski Y., Okimoto R., Watson P., Lynch J.F., de la Chapelle A., RA Lynch H.T., Fodde R.; RT "Molecular analysis of hereditary nonpolyposis colorectal cancer in the RT United States: high mutation detection rate among clinically selected RT families and characterization of an American founder genomic deletion of RT the MSH2 gene."; RL Am. J. Hum. Genet. 72:1088-1100(2003). RN [96] RP VARIANTS CRC 325-ARG--GLN-327 DEL; ARG-618 AND PRO-749. RX PubMed=14504054; DOI=10.1093/annonc/mdg402; RA Colombino M., Cossu A., Arba A., Manca A., Curci A., Avallone A., RA Comella G., Botti G., Scintu F., Amoruso M., D'Abbicco D., d'Agnessa M.R., RA Spanu A., Tanda F., Palmieri G.; RT "Microsatellite instability and mutation analysis among southern Italian RT patients with colorectal carcinoma: detection of different alterations RT accounting for MLH1 and MSH2 inactivation in familial cases."; RL Ann. Oncol. 14:1530-1536(2003). RN [97] RP VARIANT LYNCH2 PRO-586. RX PubMed=12655562; DOI=10.1002/humu.9121; RA Kruger S., Plaschke J., Jeske B., Gorgens H., Pistorius S.R., Bier A., RA Kreuz F.R., Theissig F., Aust D.E., Saeger H.D., Schackert H.K.; RT "Identification of six novel MSH2 and MLH1 germline mutations in HNPCC."; RL Hum. Mutat. 21:445-446(2003). RN [98] RP VARIANT CRC GLY-601. RX PubMed=12655564; DOI=10.1002/humu.9123; RA Chen-Shtoyerman R., Theodor L., Harmati E., Friedman E., Dacka S., RA Kopelman Y., Sternberg A., Zarivach R., Bar-Meir S., Fireman Z.; RT "Genetic analysis of familial colorectal cancer in Israeli Arabs."; RL Hum. Mutat. 21:446-447(2003). RN [99] RP VARIANTS LYNCH2 CYS-18; ASP-101; LYS-182; CYS-379; ARG-559 AND LYS-616 DEL. RX PubMed=14635101; DOI=10.1002/humu.10291; RA Taylor C.F., Charlton R.S., Burn J., Sheridan E., Taylor G.R.; RT "Genomic deletions in MSH2 or MLH1 are a frequent cause of hereditary non- RT polyposis colorectal cancer: identification of novel and recurrent RT deletions by MLPA."; RL Hum. Mutat. 22:428-433(2003). RN [100] RP VARIANT LYNCH2 SER-648. RX PubMed=15139004; DOI=10.1002/gcc.20040; RA Raevaara T.E., Gerdes A.-M., Loennqvist K.E., Tybjaerg-Hansen A., RA Abdel-Rahman W.M., Kariola R., Peltomaeki P., Nystroem-Lahti M.; RT "HNPCC mutation MLH1 P648S makes the functional protein unstable, and RT homozygosity predisposes to mild neurofibromatosis type 1."; RL Genes Chromosomes Cancer 40:261-265(2004). RN [101] RP VARIANTS LYNCH2 CYS-217; GLY-282; LEU-542; PRO-542; PRO-549; PRO-574; RP PRO-636; SER-640 AND MET-724. RX PubMed=15365995; DOI=10.1002/humu.9277; RA Shin Y.-K., Heo S.-C., Shin J.-H., Hong S.-H., Ku J.-L., Yoo B.-C., RA Kim I.-J., Park J.-G.; RT "Germline mutations in MLH1, MSH2 and MSH6 in Korean hereditary non- RT polyposis colorectal cancer families."; RL Hum. Mutat. 24:351-351(2004). RN [102] RP ERRATUM OF PUBMED:15365995. RA Shin Y.K., Heo S.C., Shin J.H., Hong S.H., Ku J.L., Yoo B.C., Kim I.J., RA Park J.G.; RL Hum. Mutat. 25:224-224(2005). RN [103] RP VARIANTS LYNCH2 GLY-41 AND ASN-VAL-PHE-HIS-ILE-719 INS. RX PubMed=15365996; DOI=10.1002/humu.9278; RA Krueger S., Bier A., Plaschke J., Hoehl R., Aust D.E., Kreuz F.R., RA Pistorius S.R., Saeger H.D., Rothhammer V., Al-Taie O., Schackert H.K.; RT "Ten novel MSH2 and MLH1 germline mutations in families with HNPCC."; RL Hum. Mutat. 24:351-352(2004). RN [104] RP VARIANTS LYNCH2 VAL-21; ARG-67; ASN-68 AND LYS-616 DEL. RX PubMed=14961575; DOI=10.1002/ijc.11718; RA Cederquist K., Emanuelsson M., Goeransson I., Holinski-Feder E., RA Mueller-Koch Y., Golovleva I., Groenberg H.; RT "Mutation analysis of the MLH1, MSH2 and MSH6 genes in patients with double RT primary cancers of the colorectum and the endometrium: a population-based RT study in northern Sweden."; RL Int. J. Cancer 109:370-376(2004). RN [105] RP ERRATUM OF PUBMED:14961575. RA Cederquist K., Emanuelsson M., Goransson I., Holinski-Feder E., RA Muller-Koch Y., Golovleva I., Gronberg H.; RL Int. J. Cancer 115:1011-1011(2005). RN [106] RP INVOLVEMENT IN LYNCH2 BY EPIGENETIC INHERITANCE. RX PubMed=15064764; DOI=10.1038/ng1342; RA Suter C.M., Martin D.I.K., Ward R.L.; RT "Germline epimutation of MLH1 in individuals with multiple cancers."; RL Nat. Genet. 36:497-501(2004). RN [107] RP VARIANT HIS-132. RX PubMed=15184898; DOI=10.1038/ng1374; RA Lipkin S.M., Rozek L.S., Rennert G., Yang W., Chen P.-C., Hacia J., RA Hunt N., Shin B., Fodor S., Kokoris M., Greenson J.K., Fearon E., Lynch H., RA Collins F., Gruber S.B.; RT "The MLH1 D132H variant is associated with susceptibility to sporadic RT colorectal cancer."; RL Nat. Genet. 36:694-699(2004). RN [108] RP VARIANTS LYNCH2 LEU-28; 45-THR--PHE-47 DELINS CYS-PHE; GLU-63; ARG-67; RP GLU-71 DEL; ARG-77; VAL-80; GLU-84; ARG-107; ARG-155; GLY-185; PRO-247; RP PRO-329; ILE-330 DEL; PRO-550; ASP-589; VAL-612 DEL; LYS-616 DEL; LEU-648; RP SER-648; LEU-654 AND PRO-659, VARIANTS SER-29; GLY-93; GLN-443; ALA-618; RP CYS-646; GLN-659; THR-681 AND MET-716, CHARACTERIZATION OF VARIANTS LYNCH2 RP LEU-28; 45-THR--PHE-47 DELINS CYS-PHE; GLU-63; ARG-67; GLU-71 DEL; ARG-77; RP VAL-80; GLU-84; ARG-107; ARG-155; GLY-185; PRO-247; PRO-329; ILE-330 DEL; RP PRO-550; ASP-589; VAL-612 DEL; LYS-616 DEL; THR-618; LEU-648; SER-648; RP LEU-654 AND PRO-659, AND CHARACTERIZATION OF VARIANTS SER-29; GLY-93; RP MET-213; VAL-219; GLN-443; ALA-618; CYS-646; GLN-659; THR-681 AND MET-716. RX PubMed=16083711; DOI=10.1016/j.gastro.2005.06.005; RA Raevaara T.E., Korhonen M.K., Lohi H., Hampel H., Lynch E., RA Loennqvist K.E., Holinski-Feder E., Sutter C., McKinnon W., Duraisamy S., RA Gerdes A.-M., Peltomaeki P., Kohonen-Corish M., Mangold E., Macrae F., RA Greenblatt M., de la Chapelle A., Nystroem M.; RT "Functional significance and clinical phenotype of nontruncating mismatch RT repair variants of MLH1."; RL Gastroenterology 129:537-549(2005). RN [109] RP VARIANTS LYNCH2 LEU-28; LYS-35; ARG-67; VAL-111; MET-117; PRO-292; THR-441; RP LYS-618 DEL; PRO-623; ILE-657 DEL; THR-681; TRP-687 AND ARG-751. RX PubMed=16451135; DOI=10.1111/j.1399-0004.2006.00550.x; RA Kurzawski G., Suchy J., Lener M., Klujszo-Grabowska E., Kladny J., RA Safranow K., Jakubowska K., Jakubowska A., Huzarski T., Byrski T., RA Debniak T., Cybulski C., Gronwald J., Oszurek O., Oszutowska D., RA Kowalska E., Gozdz S., Niepsuj S., Slomski R., Plawski A., RA Lacka-Wojciechowska A., Rozmiarek A., Fiszer-Maliszewska L., Bebenek M., RA Sorokin D., Sasiadek M.M., Stembalska A., Grzebieniak Z., Kilar E., RA Stawicka M., Godlewski D., Richter P., Brozek I., Wysocka B., Limon J., RA Jawien A., Banaszkiewicz Z., Janiszewska H., Kowalczyk J., Czudowska D., RA Scott R.J., Lubinski J.; RT "Germline MSH2 and MLH1 mutational spectrum including large rearrangements RT in HNPCC families from Poland (update study)."; RL Clin. Genet. 69:40-47(2006). RN [110] RP VARIANT MMRCS1 ASN-35. RX PubMed=17440981; DOI=10.1002/cncr.22697; RG Rotterdam initiative on gastrointestinal hereditary tumors; RA Poley J.-W., Wagner A., Hoogmans M.M.C.P., Menko F.H., Tops C., Kros J.M., RA Reddingius R.E., Meijers-Heijboer H., Kuipers E.J., Dinjens W.N.M.; RT "Biallelic germline mutations of mismatch-repair genes: a possible cause RT for multiple pediatric malignancies."; RL Cancer 109:2349-2356(2007). RN [111] RP VARIANTS LYNCH2 LYS-102 AND GLN-474. RX PubMed=17510385; DOI=10.1158/0008-5472.can-06-3509; RA Takahashi M., Shimodaira H., Andreutti-Zaugg C., Iggo R., Kolodner R.D., RA Ishioka C.; RT "Functional analysis of human MLH1 variants using yeast and in vitro RT mismatch repair assays."; RL Cancer Res. 67:4595-4604(2007). RN [112] RP INVOLVEMENT IN LYNCH2 BY GERMLINE EPIMUTATION. RX PubMed=17301300; DOI=10.1056/nejmoa064522; RA Hitchins M.P., Wong J.J.L., Suthers G., Suter C.M., Martin D.I.K., RA Hawkins N.J., Ward R.L.; RT "Inheritance of a cancer-associated MLH1 germ-line epimutation."; RL N. Engl. J. Med. 356:697-705(2007). RN [113] RP VARIANTS CRC GLU-67 AND THR-681, AND VARIANTS ALA-22; GLY-93; SER-309; RP ASN-406; HIS-607; ALA-618; ARG-689; MET-716; TYR-718 AND ARG-751. RX PubMed=18033691; DOI=10.1002/humu.20635; RA Barnetson R.A., Cartwright N., van Vliet A., Haq N., Drew K., RA Farrington S., Williams N., Warner J., Campbell H., Porteous M.E., RA Dunlop M.G.; RT "Classification of ambiguous mutations in DNA mismatch repair genes RT identified in a population-based study of colorectal cancer."; RL Hum. Mutat. 29:367-374(2008). RN [114] RP VARIANTS LYNCH2 HIS-41; SER-101; ILE-330 DEL; PRO-619 AND ARG-689, AND RP VARIANTS ARG-67; ARG-77; SER-98; ASP-101; LYS-116; MET-117; ASN-126; RP MET-213; SER-215; SER-216; PHE-260; CYS-265; HIS-265; ASP-320; ALA-326; RP ILE-330 DEL; TRP-474; GLN-474; ASP-539; PRO-549; THR-551; ARG-585; ARG-603; RP HIS-607; SER-640; LEU-640; VAL-655; SER-656; ARG-666 AND THR-681. RX PubMed=18561205; DOI=10.1002/humu.20796; RA Tournier I., Vezain M., Martins A., Charbonnier F., Baert-Desurmont S., RA Olschwang S., Wang Q., Buisine M.P., Soret J., Tazi J., Frebourg T., RA Tosi M.; RT "A large fraction of unclassified variants of the mismatch repair genes RT MLH1 and MSH2 is associated with splicing defects."; RL Hum. Mutat. 29:1412-1424(2008). RN [115] RP VARIANTS LYNCH2 CYS-233 DEL AND TRP-389, CHARACTERIZATION OF VARIANTS RP LYNCH2 LEU-28; LYS-37; HIS-38; LYS-38; PHE-44; ARG-67; PRO-109; PRO-111; RP MET-117; CYS-233 DEL; CYS-265; TRP-389; GLN-443; PRO-550; GLY-578; PHE-582; RP ASP-589; ALA-618; CYS-646; LEU-648; LEU-654; PRO-659 AND VAL-716 DEL, RP CHARACTERIZATION OF VARIANTS GLY-93; VAL-219; SER-403; ASN-406 AND MET-716, RP INTERACTION WITH PMS2, INTERACTION WITH EXO1, AND SUBCELLULAR LOCATION. RX PubMed=22753075; DOI=10.1002/humu.22153; RA Andersen S.D., Liberti S.E., Luetzen A., Drost M., Bernstein I., RA Nilbert M., Dominguez M., Nystroem M., Hansen T.V., Christoffersen J.W., RA Jaeger A.C., de Wind N., Nielsen F.C., Toerring P.M., Rasmussen L.J.; RT "Functional characterization of MLH1 missense variants identified in Lynch RT syndrome patients."; RL Hum. Mutat. 33:1647-1655(2012). RN [116] RP VARIANTS ARG-116; LEU-213; LEU-264; THR-423 AND HIS-725, AND RP CHARACTERIZATION OF VARIANTS ARG-116; LEU-213; LEU-264; THR-423 AND RP HIS-725. RX PubMed=28494185; DOI=10.1080/15384047.2017.1326439; RA Arora S., Huwe P.J., Sikder R., Shah M., Browne A.J., Lesh R., Nicolas E., RA Deshpande S., Hall M.J., Dunbrack R.L. Jr., Golemis E.A.; RT "Functional analysis of rare variants in mismatch repair proteins augments RT results from computation-based predictive methods."; RL Cancer Biol. Ther. 18:519-533(2017). CC -!- FUNCTION: Heterodimerizes with PMS2 to form MutL alpha, a component of CC the post-replicative DNA mismatch repair system (MMR). DNA repair is CC initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH3) binding to CC a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. CC Assembly of the MutL-MutS-heteroduplex ternary complex in presence of CC RFC and PCNA is sufficient to activate endonuclease activity of PMS2. CC It introduces single-strand breaks near the mismatch and thus generates CC new entry points for the exonuclease EXO1 to degrade the strand CC containing the mismatch. DNA methylation would prevent cleavage and CC therefore assure that only the newly mutated DNA strand is going to be CC corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp CC loader subunits of DNA polymerase III, suggesting that it may play a CC role to recruit the DNA polymerase III to the site of the MMR. Also CC implicated in DNA damage signaling, a process which induces cell cycle CC arrest and can lead to apoptosis in case of major DNA damages. CC Heterodimerizes with MLH3 to form MutL gamma which plays a role in CC meiosis. {ECO:0000269|PubMed:16873062, ECO:0000269|PubMed:18206974, CC ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, CC ECO:0000269|PubMed:39032648, ECO:0000269|PubMed:9311737}. CC -!- SUBUNIT: Component of the DNA mismatch repair (MMR) complex composed at CC least of MSH2, MSH3, MSH6, PMS1 and MLH1 (PubMed:26300262). Heterodimer CC of MLH1 and PMS2 (MutL alpha), MLH1 and PMS1 (MutL beta) or MLH1 and CC MLH3 (MutL gamma). Forms a ternary complex with MutS alpha (MSH2-MSH6) CC or MutS beta (MSH2-MSH3). Part of the BRCA1-associated genome CC surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, CC ATM, BLM, PMS2 and the RAD50-MRE11-NBS1 protein complex CC (PubMed:10783165). This association could be a dynamic process changing CC throughout the cell cycle and within subnuclear domains CC (PubMed:10097147). Interacts with MCM9; the interaction recruits MLH1 CC to chromatin (PubMed:26300262). Interacts with MCM8 (PubMed:26300262). CC Interacts with PMS2; this interaction promotes MLH1 stability CC (PubMed:11427529, PubMed:22753075, PubMed:39032648). Interacts with CC MBD4 (PubMed:10097147). Interacts with EXO1 (PubMed:11427529, CC PubMed:11429708, PubMed:12414623, PubMed:14676842, PubMed:22753075). CC Interacts with MTMR15/FAN1 (PubMed:20603073). CC {ECO:0000269|PubMed:10097147, ECO:0000269|PubMed:10783165, CC ECO:0000269|PubMed:11427529, ECO:0000269|PubMed:11429708, CC ECO:0000269|PubMed:12414623, ECO:0000269|PubMed:14676842, CC ECO:0000269|PubMed:20603073, ECO:0000269|PubMed:22753075, CC ECO:0000269|PubMed:26300262, ECO:0000269|PubMed:39032648}. CC -!- INTERACTION: CC P40692; P63261: ACTG1; NbExp=6; IntAct=EBI-744248, EBI-351292; CC P40692; P07355: ANXA2; NbExp=6; IntAct=EBI-744248, EBI-352622; CC P40692; Q10567-3: AP1B1; NbExp=3; IntAct=EBI-744248, EBI-11978055; CC P40692; P63010-2: AP2B1; NbExp=8; IntAct=EBI-744248, EBI-11529439; CC P40692; Q9BX63: BRIP1; NbExp=21; IntAct=EBI-744248, EBI-3509650; CC P40692; Q9BX70: BTBD2; NbExp=3; IntAct=EBI-744248, EBI-710091; CC P40692; Q5JTZ5: C9orf152; NbExp=3; IntAct=EBI-744248, EBI-18560658; CC P40692; Q8NA61: CBY2; NbExp=6; IntAct=EBI-744248, EBI-741724; CC P40692; Q8NA61-2: CBY2; NbExp=11; IntAct=EBI-744248, EBI-11524851; CC P40692; Q8N5R6: CCDC33; NbExp=4; IntAct=EBI-744248, EBI-740841; CC P40692; Q96LY2-2: CCDC74B; NbExp=3; IntAct=EBI-744248, EBI-17967022; CC P40692; Q96GN5: CDCA7L; NbExp=4; IntAct=EBI-744248, EBI-5278764; CC P40692; O76039: CDKL5; NbExp=4; IntAct=EBI-744248, EBI-1752465; CC P40692; P07858: CTSB; NbExp=6; IntAct=EBI-744248, EBI-715062; CC P40692; P17661: DES; NbExp=6; IntAct=EBI-744248, EBI-1055572; CC P40692; Q9H0I2: ENKD1; NbExp=3; IntAct=EBI-744248, EBI-744099; CC P40692; Q86W67: FAM228A; NbExp=3; IntAct=EBI-744248, EBI-12958227; CC P40692; Q9Y247: FAM50B; NbExp=3; IntAct=EBI-744248, EBI-742802; CC P40692; Q86YD7: FAM90A1; NbExp=3; IntAct=EBI-744248, EBI-6658203; CC P40692; Q96NE9: FRMD6; NbExp=3; IntAct=EBI-744248, EBI-741729; CC P40692; Q96NE9-2: FRMD6; NbExp=4; IntAct=EBI-744248, EBI-13213391; CC P40692; Q16658: FSCN1; NbExp=7; IntAct=EBI-744248, EBI-351076; CC P40692; P11142: HSPA8; NbExp=2; IntAct=EBI-744248, EBI-351896; CC P40692; Q9ULR0: ISY1; NbExp=3; IntAct=EBI-744248, EBI-2557660; CC P40692; P52292: KPNA2; NbExp=9; IntAct=EBI-744248, EBI-349938; CC P40692; O15131: KPNA5; NbExp=3; IntAct=EBI-744248, EBI-540602; CC P40692; Q5T749: KPRP; NbExp=3; IntAct=EBI-744248, EBI-10981970; CC P40692; O95232-2: LUC7L3; NbExp=3; IntAct=EBI-744248, EBI-19157865; CC P40692; P43361: MAGEA8; NbExp=7; IntAct=EBI-744248, EBI-10182930; CC P40692; Q8WWY6: MBD3L1; NbExp=3; IntAct=EBI-744248, EBI-12516603; CC P40692; O95243-2: MBD4; NbExp=3; IntAct=EBI-744248, EBI-6448717; CC P40692; Q9UJA3: MCM8; NbExp=2; IntAct=EBI-744248, EBI-8756095; CC P40692; Q9NXL9: MCM9; NbExp=5; IntAct=EBI-744248, EBI-2804985; CC P40692; Q9UHC1: MLH3; NbExp=7; IntAct=EBI-744248, EBI-3893094; CC P40692; Q6PF18: MORN3; NbExp=3; IntAct=EBI-744248, EBI-9675802; CC P40692; P29372-4: MPG; NbExp=3; IntAct=EBI-744248, EBI-10695618; CC P40692; P20585: MSH3; NbExp=5; IntAct=EBI-744248, EBI-1164205; CC P40692; P15173: MYOG; NbExp=12; IntAct=EBI-744248, EBI-3906629; CC P40692; P60323-2: NANOS3; NbExp=3; IntAct=EBI-744248, EBI-18012223; CC P40692; Q9H3P2: NELFA; NbExp=3; IntAct=EBI-744248, EBI-5461341; CC P40692; Q14938-5: NFIX; NbExp=3; IntAct=EBI-744248, EBI-12024662; CC P40692; O00746: NME4; NbExp=3; IntAct=EBI-744248, EBI-744871; CC P40692; O15055: PER2; NbExp=3; IntAct=EBI-744248, EBI-1054296; CC P40692; P78356-2: PIP4K2B; NbExp=3; IntAct=EBI-744248, EBI-11532361; CC P40692; P54277: PMS1; NbExp=8; IntAct=EBI-744248, EBI-2893308; CC P40692; P54278: PMS2; NbExp=24; IntAct=EBI-744248, EBI-1162561; CC P40692; Q96KQ4: PPP1R13B; NbExp=3; IntAct=EBI-744248, EBI-1105153; CC P40692; Q6MZQ0: PRR5L; NbExp=3; IntAct=EBI-744248, EBI-1567866; CC P40692; P25786: PSMA1; NbExp=5; IntAct=EBI-744248, EBI-359352; CC P40692; P26045: PTPN3; NbExp=3; IntAct=EBI-744248, EBI-1047946; CC P40692; Q6NSI4: RADX; NbExp=9; IntAct=EBI-744248, EBI-8634209; CC P40692; Q5RL73: RBM48; NbExp=3; IntAct=EBI-744248, EBI-473821; CC P40692; Q86UC2: RSPH3; NbExp=3; IntAct=EBI-744248, EBI-6873025; CC P40692; Q6RVD6: SPATA8; NbExp=3; IntAct=EBI-744248, EBI-8635958; CC P40692; Q13813: SPTAN1; NbExp=6; IntAct=EBI-744248, EBI-351450; CC P40692; O95926: SYF2; NbExp=3; IntAct=EBI-744248, EBI-2557644; CC P40692; Q5VWN6: TASOR2; NbExp=6; IntAct=EBI-744248, EBI-745958; CC P40692; Q7Z6R9: TFAP2D; NbExp=5; IntAct=EBI-744248, EBI-11952651; CC P40692; Q08117-2: TLE5; NbExp=3; IntAct=EBI-744248, EBI-11741437; CC P40692; P62328: TMSB4X; NbExp=15; IntAct=EBI-744248, EBI-712598; CC P40692; Q96PP4: TSGA13; NbExp=3; IntAct=EBI-744248, EBI-12390276; CC P40692; Q01081: U2AF1; NbExp=3; IntAct=EBI-744248, EBI-632461; CC P40692; O94941: UBOX5; NbExp=7; IntAct=EBI-744248, EBI-751901; CC P40692; O75152: ZC3H11A; NbExp=8; IntAct=EBI-744248, EBI-748480; CC P40692; Q9NU63-3: ZFP57; NbExp=3; IntAct=EBI-744248, EBI-12879708; CC P40692; Q8TF47: ZFP90; NbExp=3; IntAct=EBI-744248, EBI-11419867; CC P40692; Q9UDW3: ZMAT5; NbExp=3; IntAct=EBI-744248, EBI-7850213; CC P40692; Q13360-2: ZNF177; NbExp=3; IntAct=EBI-744248, EBI-12272076; CC P40692; Q9UDV6: ZNF212; NbExp=3; IntAct=EBI-744248, EBI-1640204; CC P40692; Q6S9Z5: ZNF474; NbExp=3; IntAct=EBI-744248, EBI-17269964; CC P40692; Q6NX45: ZNF774; NbExp=3; IntAct=EBI-744248, EBI-10251462; CC P40692; P42843: SKP2; Xeno; NbExp=3; IntAct=EBI-744248, EBI-28370; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11429708, CC ECO:0000269|PubMed:14676842, ECO:0000269|PubMed:21120944, CC ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:30770470}. Chromosome CC {ECO:0000269|PubMed:26300262}. Note=Recruited to chromatin in a MCM9- CC dependent manner. {ECO:0000269|PubMed:26300262}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=P40692-1; Sequence=Displayed; CC Name=2; CC IsoId=P40692-2; Sequence=VSP_045201; CC Name=3; CC IsoId=P40692-3; Sequence=VSP_047023; CC -!- TISSUE SPECIFICITY: Colon, lymphocytes, breast, lung, spleen, testis, CC prostate, thyroid, gall bladder and heart. CC -!- PTM: Acetylated (PubMed:30770470). Deacetylated by HDAC6 which prevents CC the MutL alpha complex, formed by the MLH1-PMS2 heterodimer, from being CC recruited to the MutS alpha complex, formed by the MSH2-MSH6 CC heterodimer, leading to tolerance of DNA damage (PubMed:30770470). CC {ECO:0000269|PubMed:30770470}. CC -!- PTM: Ubiquitinated by UBR4; leading to proteasomal degradation. This CC ubiquitination is counteracted by the deubiquitinase USP5. CC {ECO:0000269|PubMed:39032648}. CC -!- DISEASE: Lynch syndrome 2 (LYNCH2) [MIM:609310]: A form of Lynch CC syndrome, an autosomal dominant disease associated with marked increase CC in cancer susceptibility. It is characterized by a familial CC predisposition to early-onset colorectal carcinoma (CRC) and extra- CC colonic tumors of the gastrointestinal, urological and female CC reproductive tracts. Lynch syndrome is reported to be the most common CC form of inherited colorectal cancer in the Western world. Clinically, CC it is often divided into two subgroups. Type I is characterized by CC hereditary predisposition to colorectal cancer, a young age of onset, CC and carcinoma observed in the proximal colon. Type II is characterized CC by increased risk for cancers in certain tissues such as the uterus, CC ovary, breast, stomach, small intestine, skin, and larynx in addition CC to the colon. Diagnosis of classical Lynch syndrome is based on the CC Amsterdam criteria: 3 or more relatives affected by colorectal cancer, CC one a first degree relative of the other two; 2 or more generation CC affected; 1 or more colorectal cancers presenting before 50 years of CC age; exclusion of hereditary polyposis syndromes. The term 'suspected CC Lynch syndrome' or 'incomplete Lynch syndrome' can be used to describe CC families who do not or only partially fulfill the Amsterdam criteria, CC but in whom a genetic basis for colon cancer is strongly suspected. CC {ECO:0000269|PubMed:10323887, ECO:0000269|PubMed:10375096, CC ECO:0000269|PubMed:10386556, ECO:0000269|PubMed:10413423, CC ECO:0000269|PubMed:10480359, ECO:0000269|PubMed:10598809, CC ECO:0000269|PubMed:10627141, ECO:0000269|PubMed:10660333, CC ECO:0000269|PubMed:10671064, ECO:0000269|PubMed:10713887, CC ECO:0000269|PubMed:10777691, ECO:0000269|PubMed:10882759, CC ECO:0000269|PubMed:11139242, ECO:0000269|PubMed:11427529, CC ECO:0000269|PubMed:11726306, ECO:0000269|PubMed:11748856, CC ECO:0000269|PubMed:11754112, ECO:0000269|PubMed:11781295, CC ECO:0000269|PubMed:11793442, ECO:0000269|PubMed:11839723, CC ECO:0000269|PubMed:11870161, ECO:0000269|PubMed:12095971, CC ECO:0000269|PubMed:12132870, ECO:0000269|PubMed:12200596, CC ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:12373605, CC ECO:0000269|PubMed:12655562, ECO:0000269|PubMed:12658575, CC ECO:0000269|PubMed:14635101, ECO:0000269|PubMed:14961575, CC ECO:0000269|PubMed:15064764, ECO:0000269|PubMed:15139004, CC ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:15365996, CC ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:16451135, CC ECO:0000269|PubMed:17301300, ECO:0000269|PubMed:17510385, CC ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:20020535, CC ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, CC ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8521398, CC ECO:0000269|PubMed:8566964, ECO:0000269|PubMed:8571956, CC ECO:0000269|PubMed:8574961, ECO:0000269|PubMed:8797773, CC ECO:0000269|PubMed:8872463, ECO:0000269|PubMed:8993976, CC ECO:0000269|PubMed:9048925, ECO:0000269|PubMed:9067757, CC ECO:0000269|PubMed:9218993, ECO:0000269|PubMed:9272156, CC ECO:0000269|PubMed:9298827, ECO:0000269|PubMed:9311737, CC ECO:0000269|PubMed:9326924, ECO:0000269|PubMed:9399661, CC ECO:0000269|PubMed:9559627, ECO:0000269|PubMed:9718327, CC ECO:0000269|PubMed:9833759, ECO:0000269|PubMed:9927034, CC ECO:0000269|Ref.5}. Note=The disease is caused by variants affecting CC the gene represented in this entry. CC -!- DISEASE: Mismatch repair cancer syndrome 1 (MMRCS1) [MIM:276300]: An CC autosomal recessive form of mismatch repair cancer syndrome, a CC childhood cancer predisposition syndrome encompassing a broad tumor CC spectrum. This includes hematological malignancies, central nervous CC system tumors, Lynch syndrome-associated malignancies such as CC colorectal tumors as well as multiple intestinal polyps, embryonic CC tumors and rhabdomyosarcoma. Multiple cafe-au-lait macules, a feature CC reminiscent of neurofibromatosis type 1, are often found as first CC manifestation of the underlying cancer. {ECO:0000269|PubMed:11427529, CC ECO:0000269|PubMed:17440981, ECO:0000269|PubMed:7661930}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Muir-Torre syndrome (MRTES) [MIM:158320]: Rare autosomal CC dominant disorder characterized by sebaceous neoplasms and visceral CC malignancy. {ECO:0000269|PubMed:8751876}. Note=The disease is caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Note=Defects in MLH1 may contribute to lobular carcinoma in CC situ (LCIS), a non-invasive neoplastic disease of the breast. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. Note=Disease susceptibility is associated with CC variants affecting the gene represented in this entry. CC -!- DISEASE: Note=Some epigenetic changes can be transmitted unchanged CC through the germline (termed 'epigenetic inheritance'). Evidence that CC this mechanism occurs in humans is provided by the identification of CC individuals in whom 1 allele of the MLH1 gene is epigenetically CC silenced throughout the soma (implying a germline event). These CC individuals are affected by Lynch syndrome but does not have CC identifiable mutations in MLH1, even though it is silenced, which CC demonstrates that an epimutation can phenocopy a genetic disease. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:10598809, CC ECO:0000269|PubMed:10882759, ECO:0000269|PubMed:12132870, CC ECO:0000269|PubMed:12655564, ECO:0000269|PubMed:14504054, CC ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:8872463, CC ECO:0000269|PubMed:9032648, ECO:0000269|PubMed:9087566, CC ECO:0000269|PubMed:9611074}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the DNA mismatch repair MutL/HexB family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/149/MLH1"; CC -!- WEB RESOURCE: Name=Colon cancer gene variant databases MutL homolog 1 CC (E.coli) (MLH1); Note=Leiden Open Variation Database (LOVD); CC URL="https://databases.lovd.nl/shared/genes/MLH1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U07343; AAC50285.1; -; mRNA. DR EMBL; U07418; AAA17374.1; -; mRNA. DR EMBL; U40978; AAA82079.1; -; Genomic_DNA. DR EMBL; U40960; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40961; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40962; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40963; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40964; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40965; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40966; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40967; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40968; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40969; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40970; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40971; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40972; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40973; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40974; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40975; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40976; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40977; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U17857; AAA85687.1; -; Genomic_DNA. DR EMBL; U17839; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17840; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17841; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17842; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17843; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17844; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17845; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17846; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17847; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17848; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17849; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17851; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17852; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17853; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17854; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17855; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17856; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; AY217549; AAO22994.1; -; Genomic_DNA. DR EMBL; AK295359; BAG58325.1; -; mRNA. DR EMBL; AK298324; BAG60576.1; -; mRNA. DR EMBL; AK298583; BAG60773.1; -; mRNA. DR EMBL; AK316074; BAH14445.1; -; mRNA. DR EMBL; AK316264; BAH14635.1; -; mRNA. DR EMBL; AC006583; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC011816; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471055; EAW64483.1; -; Genomic_DNA. DR EMBL; BC006850; AAH06850.1; -; mRNA. DR CCDS; CCDS2663.1; -. [P40692-1] DR CCDS; CCDS54562.1; -. [P40692-3] DR CCDS; CCDS54563.1; -. [P40692-2] DR PIR; S43085; S43085. DR RefSeq; NP_000240.1; NM_000249.4. [P40692-1] DR RefSeq; NP_001161089.1; NM_001167617.3. [P40692-3] DR RefSeq; NP_001161090.1; NM_001167618.3. [P40692-2] DR RefSeq; NP_001161091.1; NM_001167619.3. [P40692-2] DR RefSeq; NP_001245200.1; NM_001258271.1. DR RefSeq; NP_001245202.1; NM_001258273.2. [P40692-2] DR RefSeq; NP_001245203.1; NM_001258274.3. [P40692-2] DR RefSeq; NP_001341544.1; NM_001354615.2. [P40692-2] DR RefSeq; NP_001341545.1; NM_001354616.2. [P40692-2] DR RefSeq; NP_001341546.1; NM_001354617.2. [P40692-2] DR RefSeq; NP_001341547.1; NM_001354618.2. [P40692-2] DR RefSeq; NP_001341548.1; NM_001354619.2. [P40692-2] DR RefSeq; NP_001341549.1; NM_001354620.2. [P40692-3] DR RefSeq; XP_047304109.1; XM_047448153.1. [P40692-2] DR RefSeq; XP_047304110.1; XM_047448154.1. [P40692-2] DR RefSeq; XP_047304111.1; XM_047448155.1. [P40692-2] DR RefSeq; XP_054202541.1; XM_054346566.1. [P40692-2] DR RefSeq; XP_054202542.1; XM_054346567.1. [P40692-2] DR RefSeq; XP_054202543.1; XM_054346568.1. [P40692-2] DR PDB; 3RBN; X-ray; 2.16 A; A/B=486-751. DR PDB; 4P7A; X-ray; 2.30 A; A=1-347. DR PDB; 5U5P; X-ray; 2.17 A; B/C=467-476. DR PDB; 6WBA; X-ray; 2.15 A; B/C=466-476. DR PDB; 6WBB; X-ray; 2.66 A; B/C=466-476. DR PDB; 6WBC; X-ray; 2.15 A; B=466-476. DR PDB; 7M60; X-ray; 2.30 A; B/C=466-476. DR PDBsum; 3RBN; -. DR PDBsum; 4P7A; -. DR PDBsum; 5U5P; -. DR PDBsum; 6WBA; -. DR PDBsum; 6WBB; -. DR PDBsum; 6WBC; -. DR PDBsum; 7M60; -. DR AlphaFoldDB; P40692; -. DR SMR; P40692; -. DR BioGRID; 110438; 261. DR ComplexPortal; CPX-9901; MutLalpha endonuclease complex. DR ComplexPortal; CPX-9941; MutLabeta endonuclease complex. DR ComplexPortal; CPX-9961; MutLgamma endonuclease complex. DR CORUM; P40692; -. DR DIP; DIP-27601N; -. DR FunCoup; P40692; 2633. DR IntAct; P40692; 232. DR MINT; P40692; -. DR STRING; 9606.ENSP00000231790; -. DR GlyCosmos; P40692; 1 site, 1 glycan. DR GlyGen; P40692; 3 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; P40692; -. DR MetOSite; P40692; -. DR PhosphoSitePlus; P40692; -. DR BioMuta; MLH1; -. DR DMDM; 730028; -. DR jPOST; P40692; -. DR MassIVE; P40692; -. DR PaxDb; 9606-ENSP00000231790; -. DR PeptideAtlas; P40692; -. DR ProteomicsDB; 19516; -. DR ProteomicsDB; 4266; -. DR ProteomicsDB; 55377; -. [P40692-1] DR Pumba; P40692; -. DR Antibodypedia; 4599; 923 antibodies from 47 providers. DR CPTC; P40692; 3 antibodies. DR DNASU; 4292; -. DR Ensembl; ENST00000231790.8; ENSP00000231790.3; ENSG00000076242.19. [P40692-1] DR Ensembl; ENST00000429117.6; ENSP00000407019.2; ENSG00000076242.19. [P40692-3] DR Ensembl; ENST00000435176.5; ENSP00000402564.1; ENSG00000076242.19. [P40692-3] DR Ensembl; ENST00000455445.6; ENSP00000398272.2; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000458205.6; ENSP00000402667.2; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000466900.6; ENSP00000519069.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000485889.2; ENSP00000518946.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000492474.6; ENSP00000518393.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000536378.5; ENSP00000444286.2; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000539477.6; ENSP00000443665.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000674019.1; ENSP00000501081.1; ENSG00000076242.19. [P40692-2] DR GeneID; 4292; -. DR KEGG; hsa:4292; -. DR MANE-Select; ENST00000231790.8; ENSP00000231790.3; NM_000249.4; NP_000240.1. DR UCSC; uc003cgl.4; human. [P40692-1] DR AGR; HGNC:7127; -. DR CIViC; 4292; 30 evidence items across 33 molecular profiles. DR ClinPGx; PA240; -. DR CTD; 4292; -. DR DisGeNET; 4292; -. DR GeneCards; MLH1; -. DR GeneReviews; MLH1; -. DR HGNC; HGNC:7127; MLH1. DR HPA; ENSG00000076242; Low tissue specificity. DR MalaCards; MLH1; -. DR MIM; 114500; phenotype. DR MIM; 120436; gene. DR MIM; 158320; phenotype. DR MIM; 276300; phenotype. DR MIM; 608089; phenotype. DR MIM; 609310; phenotype. DR OpenTargets; ENSG00000076242; -. DR Orphanet; 252202; Constitutional mismatch repair deficiency syndrome. DR Orphanet; 144; Lynch syndrome. DR VEuPathDB; HostDB:ENSG00000076242; -. DR eggNOG; KOG1979; Eukaryota. DR GeneTree; ENSGT00800000124177; -. DR InParanoid; P40692; -. DR OMA; ANYHVKK; -. DR OrthoDB; 10263226at2759; -. DR PAN-GO; P40692; 4 GO annotations based on evolutionary models. DR PhylomeDB; P40692; -. DR PathwayCommons; P40692; -. DR Reactome; R-HSA-5358565; Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha). DR Reactome; R-HSA-5358606; Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta). DR Reactome; R-HSA-5545483; Defective Mismatch Repair Associated With MLH1. DR Reactome; R-HSA-5632987; Defective Mismatch Repair Associated With PMS2. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR Reactome; R-HSA-912446; Meiotic recombination. DR SignaLink; P40692; -. DR SIGNOR; P40692; -. DR Agora; ENSG00000076242; -. DR BioGRID-ORCS; 4292; 15 hits in 1172 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; MLH1; human. DR EvolutionaryTrace; P40692; -. DR GeneWiki; MLH1; -. DR GenomeRNAi; 4292; -. DR Pharos; P40692; Tbio. DR PRO; PR:P40692; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P40692; protein. DR Bgee; ENSG00000076242; Expressed in tibialis anterior and 210 other cell types or tissues. DR ExpressionAtlas; P40692; baseline and differential. DR GO; GO:0005712; C:chiasma; IEA:Ensembl. DR GO; GO:0005694; C:chromosome; ISS:UniProtKB. DR GO; GO:0005715; C:late recombination nodule; IEA:Ensembl. DR GO; GO:0001673; C:male germ cell nucleus; IEA:Ensembl. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0032389; C:MutLalpha complex; IBA:GO_Central. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0000795; C:synaptonemal complex; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016887; F:ATP hydrolysis activity; IBA:GO_Central. DR GO; GO:0140664; F:ATP-dependent DNA damage sensor activity; IEA:InterPro. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0008047; F:enzyme activator activity; IDA:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0032137; F:guanine/thymine mispair binding; IEA:Ensembl. DR GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; IEA:Ensembl. DR GO; GO:0016321; P:female meiosis chromosome segregation; IEA:Ensembl. DR GO; GO:0007129; P:homologous chromosome pairing at meiosis; IEA:Ensembl. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IEA:Ensembl. DR GO; GO:0045190; P:isotype switching; IEA:Ensembl. DR GO; GO:0007060; P:male meiosis chromosome segregation; IEA:Ensembl. DR GO; GO:0043060; P:meiotic metaphase I homologous chromosome alignment; IEA:Ensembl. DR GO; GO:0051257; P:meiotic spindle midzone assembly; IEA:Ensembl. DR GO; GO:0045141; P:meiotic telomere clustering; IEA:Ensembl. DR GO; GO:0006298; P:mismatch repair; IGI:MGI. DR GO; GO:0045950; P:negative regulation of mitotic recombination; IEA:Ensembl. DR GO; GO:0000289; P:nuclear-transcribed mRNA poly(A) tail shortening; IEA:Ensembl. DR GO; GO:0048477; P:oogenesis; IEA:Ensembl. DR GO; GO:0048298; P:positive regulation of isotype switching to IgA isotypes; IEA:Ensembl. DR GO; GO:0048304; P:positive regulation of isotype switching to IgG isotypes; IEA:Ensembl. DR GO; GO:0000712; P:resolution of meiotic recombination intermediates; IEA:Ensembl. DR GO; GO:0009617; P:response to bacterium; IEA:Ensembl. DR GO; GO:0016446; P:somatic hypermutation of immunoglobulin genes; IBA:GO_Central. DR GO; GO:0007283; P:spermatogenesis; IEA:Ensembl. DR CDD; cd16926; HATPase_MutL-MLH-PMS-like; 1. DR CDD; cd03483; MutL_Trans_MLH1; 1. DR DisProt; DP03062; -. DR FunFam; 3.30.230.10:FF:000014; DNA mismatch repair protein Mlh1; 1. DR FunFam; 3.30.565.10:FF:000034; DNA mismatch repair protein mlh1, putative; 1. DR Gene3D; 3.30.230.10; -; 1. DR Gene3D; 3.30.565.10; Histidine kinase-like ATPase, C-terminal domain; 1. DR InterPro; IPR014762; DNA_mismatch_repair_CS. DR InterPro; IPR013507; DNA_mismatch_S5_2-like. DR InterPro; IPR036890; HATPase_C_sf. DR InterPro; IPR032189; Mlh1_C. DR InterPro; IPR002099; MutL/Mlh/PMS. DR InterPro; IPR038973; MutL/Mlh/Pms-like. DR InterPro; IPR020568; Ribosomal_Su5_D2-typ_SF. DR InterPro; IPR014721; Ribsml_uS5_D2-typ_fold_subgr. DR NCBIfam; TIGR00585; mutl; 1. DR PANTHER; PTHR10073; DNA MISMATCH REPAIR PROTEIN MLH, PMS, MUTL; 1. DR PANTHER; PTHR10073:SF12; DNA MISMATCH REPAIR PROTEIN MLH1; 1. DR Pfam; PF01119; DNA_mis_repair; 1. DR Pfam; PF13589; HATPase_c_3; 1. DR Pfam; PF16413; Mlh1_C; 1. DR SMART; SM01340; DNA_mis_repair; 1. DR SUPFAM; SSF55874; ATPase domain of HSP90 chaperone/DNA topoisomerase II/histidine kinase; 1. DR SUPFAM; SSF54211; Ribosomal protein S5 domain 2-like; 1. DR PROSITE; PS00058; DNA_MISMATCH_REPAIR_1; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ATP-binding; Cell cycle; KW Chromosome; Disease variant; DNA damage; DNA repair; KW Hereditary nonpolyposis colorectal cancer; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Tumor suppressor; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22223895" FT CHAIN 2..756 FT /note="DNA mismatch repair protein Mlh1" FT /id="PRO_0000178000" FT REGION 355..378 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 400..491 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 410..650 FT /note="Interaction with EXO1" FT /evidence="ECO:0000269|PubMed:11427529, FT ECO:0000269|PubMed:11429708, ECO:0000269|PubMed:12414623, FT ECO:0000269|PubMed:14676842, ECO:0000269|PubMed:22753075" FT MOTIF 471..474 FT /note="Nuclear localization signal" FT /evidence="ECO:0000269|PubMed:29175432" FT COMPBIAS 362..375 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 443..457 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 38 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT BINDING 63 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT BINDING 82..84 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT BINDING 100..104 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:22223895" FT MOD_RES 33 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 241 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 361 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 377 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 477 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT VAR_SEQ 1..241 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_045201" FT VAR_SEQ 1..101 FT /note="MSFVAGVIRRLDETVVNRIAAGEVIQRPANAIKEMIENCLDAKSTSIQVIVK FT EGGLKLIQIQDNGTGIRKEDLDIVCERFTTSKLQSFEDLASISTYGFRG -> MAF FT (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_047023" FT VARIANT 18 FT /note="R -> C (in LYNCH2; dbSNP:rs367654552)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022663" FT VARIANT 19 FT /note="I -> F (in LYNCH2; dbSNP:rs63750648)" FT /evidence="ECO:0000269|PubMed:12362047" FT /id="VAR_043383" FT VARIANT 21 FT /note="A -> V (in LYNCH2; dbSNP:rs63750706)" FT /evidence="ECO:0000269|PubMed:14961575" FT /id="VAR_043384" FT VARIANT 22 FT /note="G -> A (in dbSNP:rs41295280)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038023" FT VARIANT 25 FT /note="I -> F (in LYNCH2; dbSNP:rs63749838)" FT /evidence="ECO:0000269|PubMed:10386556" FT /id="VAR_043385" FT VARIANT 28 FT /note="P -> L (in LYNCH2; loss of protein expression; FT normal interaction with PMS2 and EXO1; decreased mismatch FT repair activity; no effect on nuclear localization; FT dbSNP:rs63750792)" FT /evidence="ECO:0000269|PubMed:10323887, FT ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:16451135, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9298827" FT /id="VAR_004433" FT VARIANT 29 FT /note="A -> S (in LYNCH2; uncertain significance; acts FT functionally like the wild-type protein; dbSNP:rs63750656)" FT /evidence="ECO:0000269|PubMed:12658575, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_043386" FT VARIANT 31 FT /note="A -> C (in LYNCH2; decreased mismatch repair FT activity; requires 2 nucleotide substitutions; FT dbSNP:rs63749994)" FT /evidence="ECO:0000269|PubMed:20020535" FT /id="VAR_076338" FT VARIANT 32 FT /note="I -> V (in dbSNP:rs2020872)" FT /evidence="ECO:0000269|Ref.5" FT /id="VAR_014876" FT VARIANT 35 FT /note="M -> K (in LYNCH2; uncertain significance; FT dbSNP:rs63749906)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043387" FT VARIANT 35 FT /note="M -> N (in MMRCS1; requires 2 nucleotide FT substitutions; dbSNP:rs121912965)" FT /evidence="ECO:0000269|PubMed:12373605, FT ECO:0000269|PubMed:17440981" FT /id="VAR_043388" FT VARIANT 35 FT /note="M -> R (in LYNCH2; dbSNP:rs63749906)" FT /evidence="ECO:0000269|PubMed:8521398" FT /id="VAR_004434" FT VARIANT 37 FT /note="E -> ELNH (found in an endometrial cancer sample; FT somatic mutation)" FT /id="VAR_004435" FT VARIANT 37 FT /note="E -> K (in LYNCH2; decreased mismatch repair FT activity; loss of nuclear localization; dbSNP:rs63751012)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076339" FT VARIANT 38 FT /note="N -> H (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs63750580)" FT /evidence="ECO:0000269|PubMed:12373605, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:22753075" FT /id="VAR_043389" FT VARIANT 38 FT /note="N -> K (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs267607706)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076340" FT VARIANT 41 FT /note="D -> G (in LYNCH2; dbSNP:rs63751094)" FT /evidence="ECO:0000269|PubMed:15365996" FT /id="VAR_043390" FT VARIANT 41 FT /note="D -> H (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607713)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054522" FT VARIANT 44 FT /note="S -> F (in LYNCH2; no effect on MLH1 splicing; loss FT of mismatch repair activity; dbSNP:rs63751109)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9326924" FT /id="VAR_004436" FT VARIANT 45..47 FT /note="TSI -> CF (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_043391" FT VARIANT 54 FT /note="G -> E (in CRC; sporadic; somatic mutation; FT uncertain significance; dbSNP:rs63751267)" FT /evidence="ECO:0000269|PubMed:9087566" FT /id="VAR_012902" FT VARIANT 62 FT /note="Q -> K (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63751428)" FT /evidence="ECO:0000269|PubMed:9311737" FT /id="VAR_004437" FT VARIANT 63 FT /note="D -> E (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; dbSNP:rs587778955)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043392" FT VARIANT 64 FT /note="N -> S (in LYNCH2; dbSNP:rs63750952)" FT /evidence="ECO:0000269|PubMed:9311737" FT /id="VAR_004438" FT VARIANT 67 FT /note="G -> E (in CRC; dbSNP:rs63749939)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038024" FT VARIANT 67 FT /note="G -> R (in LYNCH2; no effect on MLH1 splicing; FT decreased mismatch repair activity; loss of protein FT expression; loss of nuclear localization; FT dbSNP:rs63750206)" FT /evidence="ECO:0000269|PubMed:10375096, FT ECO:0000269|PubMed:12658575, ECO:0000269|PubMed:14961575, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9067757, ECO:0000269|PubMed:9833759" FT /id="VAR_004439" FT VARIANT 67 FT /note="G -> W (in LYNCH2; dbSNP:rs63750206)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:9927034" FT /id="VAR_012903" FT VARIANT 68 FT /note="I -> N (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750281)" FT /evidence="ECO:0000269|PubMed:14961575" FT /id="VAR_004440" FT VARIANT 69 FT /note="R -> K (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63751661)" FT /evidence="ECO:0000269|PubMed:10627141" FT /id="VAR_004441" FT VARIANT 71 FT /note="Missing (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043393" FT VARIANT 77 FT /note="C -> R (in LYNCH2; decreased mismatch repair FT activity; loss of nuclear localization; normal interaction FT with PMS2; dbSNP:rs63749859)" FT /evidence="ECO:0000269|PubMed:10660333, FT ECO:0000269|PubMed:11793442, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944" FT /id="VAR_004442" FT VARIANT 77 FT /note="C -> Y (in CRC; sporadic; early onset; FT dbSNP:rs63750437)" FT /evidence="ECO:0000269|PubMed:9032648" FT /id="VAR_012904" FT VARIANT 80 FT /note="F -> V (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63749990)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_012905" FT VARIANT 84 FT /note="K -> E (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750641)" FT /evidence="ECO:0000269|PubMed:10323887, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_012906" FT VARIANT 93 FT /note="S -> G (normal interaction with PMS2; no decrease in FT mismatch repair activity; no effect on nuclear FT localization; dbSNP:rs41295282)" FT /evidence="ECO:0000269|PubMed:10671064, FT ECO:0000269|PubMed:11793442, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075" FT /id="VAR_004443" FT VARIANT 98 FT /note="G -> S (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607725)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054523" FT VARIANT 101 FT /note="G -> D (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607727)" FT /evidence="ECO:0000269|PubMed:14635101, FT ECO:0000269|PubMed:18561205" FT /id="VAR_022664" FT VARIANT 101 FT /note="G -> S (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607726)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054524" FT VARIANT 102 FT /note="E -> K (in LYNCH2; dbSNP:rs63750453)" FT /evidence="ECO:0000269|PubMed:17510385" FT /id="VAR_043394" FT VARIANT 106 FT /note="S -> R (in gastric cancer; uncertain significance; FT dbSNP:rs63750297)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043395" FT VARIANT 107 FT /note="I -> R (in LYNCH2; decreased mismatch repair FT activity; normal interaction with PMS2; loss of protein FT expression; loss of nuclear localization; FT dbSNP:rs63750507)" FT /evidence="ECO:0000269|PubMed:11793442, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_004444" FT VARIANT 109 FT /note="H -> P (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs587779004)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076341" FT VARIANT 109 FT /note="H -> Q (in gastric cancer; uncertain significance; FT dbSNP:rs63749803)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043396" FT VARIANT 111 FT /note="A -> P (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs587779005)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076342" FT VARIANT 111 FT /note="A -> V (in LYNCH2; dbSNP:rs63750539)" FT /evidence="ECO:0000269|PubMed:10777691, FT ECO:0000269|PubMed:16451135" FT /id="VAR_012907" FT VARIANT 116 FT /note="T -> K (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs63750465)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054525" FT VARIANT 116 FT /note="T -> R (no effect on protein expression; FT dbSNP:rs63750465)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079812" FT VARIANT 117 FT /note="T -> M (in LYNCH2; decreased mismatch repair FT activity; no effect on MLH1 splicing; fails to interact FT with PMS2 and EXO1; loss of nuclear localization; FT dbSNP:rs63750781)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:11429708, ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:12200596, ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:12373605, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:8566964" FT /id="VAR_004445" FT VARIANT 117 FT /note="T -> R (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750781)" FT /evidence="ECO:0000269|PubMed:10375096" FT /id="VAR_004446" FT VARIANT 126 FT /note="Y -> N (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs200076893)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054526" FT VARIANT 128 FT /note="A -> P (in LYNCH2; dbSNP:rs63750866)" FT /evidence="ECO:0000269|PubMed:9218993" FT /id="VAR_012908" FT VARIANT 132 FT /note="D -> H (decreased but not abolished ATPase activity; FT dbSNP:rs28930073)" FT /evidence="ECO:0000269|PubMed:15184898" FT /id="VAR_022665" FT VARIANT 155 FT /note="L -> R (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; dbSNP:rs63750891)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043397" FT VARIANT 182 FT /note="R -> G (in LYNCH2; incomplete; dbSNP:rs63750211)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:9399661" FT /id="VAR_012909" FT VARIANT 182 FT /note="R -> K (in LYNCH2; dbSNP:rs587779021)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022666" FT VARIANT 185 FT /note="V -> G (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; no effect on MLH1 splicing; FT dbSNP:rs63750515)" FT /evidence="ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_004447" FT VARIANT 185 FT /note="V -> L (in LYNCH2; uncertain significance; FT dbSNP:rs63750012)" FT /evidence="ECO:0000269|PubMed:12658575" FT /id="VAR_043398" FT VARIANT 193 FT /note="S -> P (in LYNCH2; dbSNP:rs63751021)" FT /evidence="ECO:0000269|PubMed:10660333" FT /id="VAR_004448" FT VARIANT 213 FT /note="V -> L (no effect on protein expression; FT dbSNP:rs2308317)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079813" FT VARIANT 213 FT /note="V -> M (no effect on MLH1 splicing; FT dbSNP:rs2308317)" FT /evidence="ECO:0000269|PubMed:10713887, FT ECO:0000269|PubMed:11839723, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944, FT ECO:0000269|Ref.5" FT /id="VAR_012910" FT VARIANT 215 FT /note="N -> S (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607775)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054527" FT VARIANT 216 FT /note="I -> S (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607776)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054528" FT VARIANT 217 FT /note="R -> C (in LYNCH2; uncertain significance; no FT decrease in mismatch repair activity; dbSNP:rs4986984)" FT /evidence="ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:8797773, FT ECO:0000269|PubMed:9559627" FT /id="VAR_004449" FT VARIANT 217 FT /note="R -> G (in dbSNP:rs4986984)" FT /id="VAR_020469" FT VARIANT 219 FT /note="I -> V (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs1799977)" FT /evidence="ECO:0000269|PubMed:10375096, FT ECO:0000269|PubMed:10777691, ECO:0000269|PubMed:11754112, FT ECO:0000269|PubMed:11781295, ECO:0000269|PubMed:12115348, FT ECO:0000269|PubMed:12200596, ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9032648, ECO:0000269|PubMed:9067757, FT ECO:0000269|PubMed:9087566, ECO:0000269|PubMed:9218993, FT ECO:0000269|PubMed:9833759, ECO:0000269|Ref.5" FT /id="VAR_004450" FT VARIANT 226..295 FT /note="Missing (in LYNCH2)" FT /id="VAR_004452" FT VARIANT 226 FT /note="R -> L (in LYNCH2; dbSNP:rs63751711)" FT /evidence="ECO:0000269|PubMed:8566964" FT /id="VAR_004451" FT VARIANT 233 FT /note="Missing (in LYNCH2; loss of nuclear localization)" FT /evidence="ECO:0000269|PubMed:22753075" FT /id="VAR_076343" FT VARIANT 234 FT /note="E -> G (in LYNCH2; uncertain significance; FT dbSNP:rs63750696)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043399" FT VARIANT 244 FT /note="G -> D (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750303)" FT /evidence="ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:12658575, ECO:0000269|PubMed:9218993" FT /id="VAR_012911" FT VARIANT 244 FT /note="G -> V (in CRC; sporadic; somatic mutation; FT uncertain significance; dbSNP:rs63750303)" FT /evidence="ECO:0000269|PubMed:9087566" FT /id="VAR_012912" FT VARIANT 247 FT /note="S -> P (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; dbSNP:rs63750948)" FT /evidence="ECO:0000269|PubMed:12200596, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_043400" FT VARIANT 260 FT /note="L -> F (in LYNCH2; uncertain significance; no effect FT on MLH1 splicing; dbSNP:rs63750642)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054529" FT VARIANT 260 FT /note="L -> R (in CRC; dbSNP:rs63751283)" FT /evidence="ECO:0000269|PubMed:10882759" FT /id="VAR_043401" FT VARIANT 262 FT /note="Missing (in LYNCH2)" FT /evidence="ECO:0000269|PubMed:9833759" FT /id="VAR_012913" FT VARIANT 264 FT /note="H -> L (no effect on protein expression; FT dbSNP:rs63751664)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079814" FT VARIANT 264 FT /note="H -> Y (in LYNCH2; dbSNP:rs63751597)" FT /evidence="ECO:0000269|PubMed:10413423" FT /id="VAR_043402" FT VARIANT 265 FT /note="R -> C (in LYNCH2; results in partial MLH1 exon 10 FT skipping on ex vivo splicing assay; decreased mismatch FT repair activity; no effect on nuclear localization; FT dbSNP:rs63751194)" FT /evidence="ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:22753075" FT /id="VAR_054530" FT VARIANT 265 FT /note="R -> H (risk factor for LYNCH2; results in partial FT MLH1 exon 10 skipping on ex vivo splicing assay; decreased FT mismatch repair activity; dbSNP:rs63751448)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11781295, ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:8993976" FT /id="VAR_012914" FT VARIANT 265 FT /note="R -> S (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63751194)" FT /evidence="ECO:0000269|PubMed:20020535" FT /id="VAR_076344" FT VARIANT 268 FT /note="E -> G (in CRC; benign; dbSNP:rs63750650)" FT /evidence="ECO:0000269|PubMed:9611074" FT /id="VAR_012915" FT VARIANT 282 FT /note="A -> G (in LYNCH2; likely benign; dbSNP:rs63750360)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043403" FT VARIANT 292 FT /note="L -> P (in LYNCH2; uncertain significance; FT dbSNP:rs63750517)" FT /evidence="ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:16451135" FT /id="VAR_043404" FT VARIANT 295 FT /note="S -> T (in LYNCH2; uncertain significance; FT dbSNP:rs63750144)" FT /evidence="ECO:0000269|PubMed:9399661" FT /id="VAR_012916" FT VARIANT 304 FT /note="D -> V (in LYNCH2; dbSNP:rs63750993)" FT /evidence="ECO:0000269|PubMed:10882759" FT /id="VAR_043405" FT VARIANT 309 FT /note="P -> S (in dbSNP:rs267607808)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038025" FT VARIANT 320 FT /note="E -> D (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607811)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054531" FT VARIANT 321 FT /note="S -> I (in LYNCH2; uncertain significance; FT dbSNP:rs63750286)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043406" FT VARIANT 325..327 FT /note="Missing (in CRC)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043407" FT VARIANT 325 FT /note="R -> Q (in dbSNP:rs63750268)" FT /evidence="ECO:0000269|PubMed:9087566" FT /id="VAR_012917" FT VARIANT 326 FT /note="V -> A (in LYNCH2; benign; no decrease in mismatch FT repair activity; dbSNP:rs63751049)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11781295, ECO:0000269|PubMed:18561205" FT /id="VAR_004453" FT VARIANT 329 FT /note="H -> P (in LYNCH2; loss of protein expression; loss FT of nuclear localization; dbSNP:rs63750710)" FT /evidence="ECO:0000269|PubMed:10323887, FT ECO:0000269|PubMed:11726306, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:9272156" FT /id="VAR_012918" FT VARIANT 330 FT /note="Missing (in LYNCH2; results in weak MLH1 exon 11 FT skipping on ex vivo splicing assay; decreased mismatch FT repair activity; loss of protein expression; loss of FT nuclear localization; dbSNP:rs63751197)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944" FT /id="VAR_043408" FT VARIANT 338 FT /note="N -> S (in LYNCH2; dbSNP:rs63751467)" FT /evidence="ECO:0000269|PubMed:12095971" FT /id="VAR_043409" FT VARIANT 379 FT /note="Y -> C (in LYNCH2; dbSNP:rs143009528)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022667" FT VARIANT 384 FT /note="V -> D (probable risk factor for HNPCC in some FT populations; dbSNP:rs63750447)" FT /evidence="ECO:0000269|PubMed:10777691, FT ECO:0000269|PubMed:8609062, ECO:0000269|PubMed:9526167" FT /id="VAR_004454" FT VARIANT 385 FT /note="R -> C (in LYNCH2; uncertain significance; FT dbSNP:rs63750760)" FT /evidence="ECO:0000269|PubMed:11839723" FT /id="VAR_043410" FT VARIANT 385 FT /note="R -> P (in LYNCH2; uncertain significance; FT dbSNP:rs63750430)" FT /evidence="ECO:0000269|PubMed:10573010" FT /id="VAR_043411" FT VARIANT 389 FT /note="R -> W (in LYNCH2; uncertain significance; no effect FT on nuclear localization; normal interaction with PMS2 and FT EXO1; dbSNP:rs61751644)" FT /evidence="ECO:0000269|PubMed:22753075" FT /id="VAR_076345" FT VARIANT 403 FT /note="P -> S (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs587778897)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076346" FT VARIANT 406 FT /note="S -> N (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs41294980)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9087566" FT /id="VAR_012919" FT VARIANT 423 FT /note="R -> T (no effect on protein expression; FT dbSNP:rs370687064)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079815" FT VARIANT 441 FT /note="A -> T (in LYNCH2; benign; dbSNP:rs63750365)" FT /evidence="ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:9326924" FT /id="VAR_012920" FT VARIANT 443 FT /note="K -> Q (in LYNCH2; uncertain significance; no FT decrease in mismatch repair activity; no effect on nuclear FT localization; dbSNP:rs34213726)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075" FT /id="VAR_043412" FT VARIANT 460 FT /note="E -> A (in LYNCH2; uncertain significance; FT dbSNP:rs202038499)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076347" FT VARIANT 472 FT /note="R -> I (in CRC; uncertain significance; FT dbSNP:rs63750498)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043413" FT VARIANT 474 FT /note="R -> Q (in LYNCH2; uncertain significance; FT dbSNP:rs63751083)" FT /evidence="ECO:0000269|PubMed:17510385, FT ECO:0000269|PubMed:18561205" FT /id="VAR_043414" FT VARIANT 474 FT /note="R -> W (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs147939838)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054532" FT VARIANT 485 FT /note="D -> E (in LYNCH2; dbSNP:rs63750956)" FT /evidence="ECO:0000269|PubMed:10375096" FT /id="VAR_043415" FT VARIANT 485 FT /note="D -> H (in LYNCH2; uncertain significance; FT dbSNP:rs63750314)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043416" FT VARIANT 492 FT /note="A -> T (in LYNCH2; also found in sporadic colorectal FT cancer; dbSNP:rs63751145)" FT /evidence="ECO:0000269|PubMed:8872463" FT /id="VAR_004455" FT VARIANT 506 FT /note="V -> A (in LYNCH2; dbSNP:rs63749909)" FT /evidence="ECO:0000269|PubMed:8574961" FT /id="VAR_004456" FT VARIANT 539 FT /note="A -> D (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607843)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054533" FT VARIANT 542 FT /note="Q -> L (in LYNCH2; type II; decreased mismatch FT repair activity; dbSNP:rs63750511)" FT /evidence="ECO:0000269|PubMed:15365995, FT ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8797773" FT /id="VAR_004457" FT VARIANT 542 FT /note="Q -> P (in LYNCH2; dbSNP:rs63750511)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043417" FT VARIANT 549 FT /note="L -> P (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs63750289)" FT /evidence="ECO:0000269|PubMed:15365995, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:8797773" FT /id="VAR_012921" FT VARIANT 550 FT /note="L -> P (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2 and EXO1; loss FT of protein expression; may lose nuclear localization; FT dbSNP:rs63750193)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075" FT /id="VAR_043418" FT VARIANT 551 FT /note="N -> T (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs63750271)" FT /evidence="ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:9399661, ECO:0000269|PubMed:9833759" FT /id="VAR_012922" FT VARIANT 559 FT /note="L -> R (in LYNCH2; uncertain significance; FT dbSNP:rs63750059)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022668" FT VARIANT 565 FT /note="I -> F (in LYNCH2; dbSNP:rs63750062)" FT /evidence="ECO:0000269|PubMed:9833759" FT /id="VAR_012923" FT VARIANT 574 FT /note="L -> P (in LYNCH2; type I; abrogates interaction FT with EXO1; loss of protein expression; dbSNP:rs63751608)" FT /evidence="ECO:0000269|PubMed:11427529, FT ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:39032648, FT ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8797773" FT /id="VAR_004458" FT VARIANT 578..632 FT /note="Missing (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076348" FT VARIANT 578 FT /note="E -> G (in LYNCH2 and CRC; benign; no decrease in FT mismatch repair activity; no effect on nuclear FT localization; dbSNP:rs63751612)" FT /evidence="ECO:0000269|PubMed:10598809, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:22753075" FT /id="VAR_004459" FT VARIANT 582 FT /note="L -> F (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs63751713)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076349" FT VARIANT 582 FT /note="L -> V (in LYNCH2; type II; dbSNP:rs63751713)" FT /evidence="ECO:0000269|PubMed:7757073" FT /id="VAR_004460" FT VARIANT 585 FT /note="L -> R (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607865)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054534" FT VARIANT 586 FT /note="A -> P (in LYNCH2; dbSNP:rs63751176)" FT /evidence="ECO:0000269|PubMed:12655562" FT /id="VAR_015689" FT VARIANT 588 FT /note="L -> P (in LYNCH2; dbSNP:rs63750575)" FT /evidence="ECO:0000269|PubMed:10777691" FT /id="VAR_012924" FT VARIANT 589 FT /note="A -> D (in LYNCH2; decreased mismatch repair FT activity; loss of interaction with PMS2 and EXO1; loss of FT protein expression; may lose nuclear localization; FT dbSNP:rs63750016)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:39032648" FT /id="VAR_043419" FT VARIANT 596 FT /note="Missing (in LYNCH2)" FT /id="VAR_043420" FT VARIANT 601 FT /note="D -> G (in CRC; uncertain significance; FT dbSNP:rs63750718)" FT /evidence="ECO:0000269|PubMed:12655564" FT /id="VAR_043421" FT VARIANT 603 FT /note="P -> R (in LYNCH2; likely benign; no effect on MLH1 FT splicing; dbSNP:rs63750876)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:12095971, ECO:0000269|PubMed:18561205" FT /id="VAR_012925" FT VARIANT 607 FT /note="L -> H (in LYNCH2; likely benign; no effect on MLH1 FT splicing; dbSNP:rs41295284)" FT /evidence="ECO:0000269|PubMed:10713887, FT ECO:0000269|PubMed:11369138, ECO:0000269|PubMed:11839723, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:18561205" FT /id="VAR_012926" FT VARIANT 612 FT /note="Missing (in LYNCH2; loss of protein expression; loss FT of nuclear localization)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043422" FT VARIANT 616 FT /note="Missing (in LYNCH2 and MMRCS1; abrogates interaction FT with EXO1; loss of protein expression; loss of nuclear FT localization; no effect on MLH1 splicing)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:11427529, ECO:0000269|PubMed:14635101, FT ECO:0000269|PubMed:14961575, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:7661930, FT ECO:0000269|PubMed:8571956, ECO:0000269|PubMed:8872463, FT ECO:0000269|PubMed:8993976, ECO:0000269|PubMed:9311737" FT /id="VAR_004461" FT VARIANT 618 FT /note="K -> A (in LYNCH2; benign; interacts weakly with FT PMS2; no decrease in mismatch repair activity; no effect on FT nuclear localization; requires 2 nucleotide substitutions; FT dbSNP:rs35502531)" FT /evidence="ECO:0000269|PubMed:10598809, FT ECO:0000269|PubMed:10713887, ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:11870161, ECO:0000269|PubMed:12200596, FT ECO:0000269|PubMed:12373605, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9311737" FT /id="VAR_004462" FT VARIANT 618 FT /note="K -> R (in CRC; likely benign; dbSNP:rs63750449)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043424" FT VARIANT 618 FT /note="K -> T (in LYNCH2; benign; type II; loss of nuclear FT localization; dbSNP:rs63750449)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11839723, ECO:0000269|PubMed:12095971, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8872463" FT /id="VAR_004463" FT VARIANT 618 FT /note="Missing (in LYNCH2; dbSNP:rs63751247)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043423" FT VARIANT 619 FT /note="A -> P (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607866)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054535" FT VARIANT 622 FT /note="L -> H (in LYNCH2; dbSNP:rs63750693)" FT /evidence="ECO:0000269|PubMed:11748856" FT /id="VAR_012927" FT VARIANT 623 FT /note="A -> P (in LYNCH2; uncertain significance; FT dbSNP:rs587778951)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043425" FT VARIANT 626..627 FT /note="FS -> ST (in LYNCH2)" FT /evidence="ECO:0000269|PubMed:9048925" FT /id="VAR_004464" FT VARIANT 631 FT /note="D -> A (in LYNCH2; uncertain significance; FT dbSNP:rs63750240)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043426" FT VARIANT 633..663 FT /note="Missing (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2; loss of FT protein expression; loss of nuclear localization)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076350" FT VARIANT 635 FT /note="N -> K (in gastric cancer; uncertain significance; FT dbSNP:rs63751047)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043427" FT VARIANT 636 FT /note="L -> P (in LYNCH2; dbSNP:rs63750825)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043428" FT VARIANT 640 FT /note="P -> L (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607875)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054536" FT VARIANT 640 FT /note="P -> S (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs63749792)" FT /evidence="ECO:0000269|PubMed:15365995, FT ECO:0000269|PubMed:18561205" FT /id="VAR_043429" FT VARIANT 646 FT /note="Y -> C (in LYNCH2; defective in interaction with FT PMS2 and EXO1; no decrease in mismatch repair activity; FT dbSNP:rs35045067)" FT /evidence="ECO:0000269|PubMed:11870161, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075" FT /id="VAR_043430" FT VARIANT 648 FT /note="P -> L (in LYNCH2; defective in interaction with FT PMS2 and EXO1; may lose nuclear localization; loss of FT protein expression; no decrease in mismatch repair FT activity; dbSNP:rs63750610)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075" FT /id="VAR_012928" FT VARIANT 648 FT /note="P -> S (in LYNCH2; the protein is unstable; loss of FT nuclear localization; loss of protein expression; no FT decrease in mismatch repair activity; dbSNP:rs63750899)" FT /evidence="ECO:0000269|PubMed:11839723, FT ECO:0000269|PubMed:15139004, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_022669" FT VARIANT 654 FT /note="P -> L (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2 and EXO1; loss FT of protein expression; may lose nuclear localization; FT dbSNP:rs63750726)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075" FT /id="VAR_043431" FT VARIANT 655 FT /note="I -> V (in LYNCH2; likely benign; also found in an FT endometrial cancer sample; no effect on MLH1 splicing; FT dbSNP:rs55907433)" FT /evidence="ECO:0000269|PubMed:12115348, FT ECO:0000269|PubMed:18561205" FT /id="VAR_043432" FT VARIANT 656 FT /note="F -> S (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607876)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054537" FT VARIANT 657 FT /note="Missing (in LYNCH2; uncertain significance)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043433" FT VARIANT 659 FT /note="R -> L (in LYNCH2; dbSNP:rs63749900)" FT /evidence="ECO:0000269|PubMed:10713887, FT ECO:0000269|PubMed:11427529" FT /id="VAR_012929" FT VARIANT 659 FT /note="R -> P (in LYNCH2; interacts only very weakly with FT PMS2; abrogates interaction with EXO1; decreased mismatch FT repair activity; may lose nuclear localization; FT dbSNP:rs63749900)" FT /evidence="ECO:0000269|PubMed:11793442, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9311737" FT /id="VAR_004465" FT VARIANT 659 FT /note="R -> Q (in LYNCH2; uncertain significance; FT dbSNP:rs63749900)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043434" FT VARIANT 662 FT /note="T -> P (in LYNCH2; dbSNP:rs587778964)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:11754112" FT /id="VAR_012930" FT VARIANT 666 FT /note="W -> R (in LYNCH2; uncertain significance; no effect FT on MLH1 splicing; dbSNP:rs267607887)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054538" FT VARIANT 681 FT /note="A -> T (in LYNCH2 and CRC; abrogates interaction FT with EXO1; no decrease in mismatch repair activity; FT dbSNP:rs63750217)" FT /evidence="ECO:0000269|PubMed:11427529, FT ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:16451135, ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944" FT /id="VAR_004466" FT VARIANT 687 FT /note="R -> W (in LYNCH2; dbSNP:rs63751275)" FT /evidence="ECO:0000269|PubMed:11748856, FT ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:21120944" FT /id="VAR_012931" FT VARIANT 689 FT /note="Q -> R (in LYNCH2; benign; dbSNP:rs63750702)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:18561205" FT /id="VAR_012932" FT VARIANT 716 FT /note="V -> M (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs35831931)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11726306, ECO:0000269|PubMed:12200596, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9833759" FT /id="VAR_012933" FT VARIANT 718 FT /note="H -> Y (in LYNCH2; benign; dbSNP:rs2020873)" FT /evidence="ECO:0000269|PubMed:10386556, FT ECO:0000269|PubMed:12095971, ECO:0000269|PubMed:18033691" FT /id="VAR_004467" FT VARIANT 719 FT /note="I -> INVFHI (in LYNCH2)" FT /id="VAR_043435" FT VARIANT 724 FT /note="L -> M (in LYNCH2; dbSNP:rs63749875)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043436" FT VARIANT 725 FT /note="R -> H (reduces by 60% protein expression; FT dbSNP:rs566928243)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079816" FT VARIANT 729 FT /note="L -> V (in dbSNP:rs1800149)" FT /id="VAR_004468" FT VARIANT 749 FT /note="L -> P (in CRC; dbSNP:rs267607894)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043437" FT VARIANT 751 FT /note="K -> R (in LYNCH2; likely benign; FT dbSNP:rs140195825)" FT /evidence="ECO:0000269|PubMed:11139242, FT ECO:0000269|PubMed:16451135, ECO:0000269|PubMed:18033691" FT /id="VAR_012934" FT VARIANT 755 FT /note="R -> W (in HNPCC; incomplete; dbSNP:rs267607900)" FT /evidence="ECO:0000269|PubMed:10480359" FT /id="VAR_012935" FT MUTAGEN 33 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 241, Q-361 and Q-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 33 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-241, R-361 and R- FT 377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 241 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 33, Q-361 and Q-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 241 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-33, R-361 and R-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 361 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 33, Q-241 and Q-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 361 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-33, R-241 and R-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 377 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 33, Q-241 and Q-361." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 377 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-33, R-241 and R-361." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 471 FT /note="K->N: Affects binding to importins alpha, including FT KPNA2, hence may affect import to the nucleus." FT /evidence="ECO:0000269|PubMed:29175432" FT MUTAGEN 472 FT /note="R->N: Affects binding to importins alpha, including FT KPNA2, hence may affect import to the nucleus." FT /evidence="ECO:0000269|PubMed:29175432" FT CONFLICT 352 FT /note="L -> H (in Ref. 6; BAG60773)" FT /evidence="ECO:0000305" FT CONFLICT 708..711 FT /note="Missing (in Ref. 4; AAA85687)" FT /evidence="ECO:0000305" FT HELIX 13..25 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 28..41 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 45..52 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 53..56 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 57..63 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 70..72 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 73..77 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 103..109 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 110..118 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 122..131 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 134..137 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 140..142 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 146..154 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 155..158 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 160..165 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 169..186 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 187..189 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 190..196 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 203..205 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 212..220 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 222..225 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 228..235 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 236..239 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 240..247 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 253..255 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 257..262 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 270..281 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 291..298 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 322..335 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 504..516 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 519..526 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 529..543 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 546..551 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 552..566 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 572..581 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 582..590 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 593..595 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 604..626 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 634..641 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 650..652 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 653..662 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 669..684 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 688..690 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 712..718 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 720..724 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 732..735 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 737..745 FT /evidence="ECO:0007829|PDB:3RBN" SQ SEQUENCE 756 AA; 84601 MW; C9231FC406C2CA20 CRC64; MSFVAGVIRR LDETVVNRIA AGEVIQRPAN AIKEMIENCL DAKSTSIQVI VKEGGLKLIQ IQDNGTGIRK EDLDIVCERF TTSKLQSFED LASISTYGFR GEALASISHV AHVTITTKTA DGKCAYRASY SDGKLKAPPK PCAGNQGTQI TVEDLFYNIA TRRKALKNPS EEYGKILEVV GRYSVHNAGI SFSVKKQGET VADVRTLPNA STVDNIRSIF GNAVSRELIE IGCEDKTLAF KMNGYISNAN YSVKKCIFLL FINHRLVEST SLRKAIETVY AAYLPKNTHP FLYLSLEISP QNVDVNVHPT KHEVHFLHEE SILERVQQHI ESKLLGSNSS RMYFTQTLLP GLAGPSGEMV KSTTSLTSSS TSGSSDKVYA HQMVRTDSRE QKLDAFLQPL SKPLSSQPQA IVTEDKTDIS SGRARQQDEE MLELPAPAEV AAKNQSLEGD TTKGTSEMSE KRGPTSSNPR KRHREDSDVE MVEDDSRKEM TAACTPRRRI INLTSVLSLQ EEINEQGHEV LREMLHNHSF VGCVNPQWAL AQHQTKLYLL NTTKLSEELF YQILIYDFAN FGVLRLSEPA PLFDLAMLAL DSPESGWTEE DGPKEGLAEY IVEFLKKKAE MLADYFSLEI DEEGNLIGLP LLIDNYVPPL EGLPIFILRL ATEVNWDEEK ECFESLSKEC AMFYSIRKQY ISEESTLSGQ QSEVPGSIPN SWKWTVEHIV YKALRSHILP PKHFTEDGNI LQLANLPDLY KVFERC // ID MOS_HUMAN Reviewed; 346 AA. AC P00540; Q3KPG9; Q3KPH0; DT 21-JUL-1986, integrated into UniProtKB/Swiss-Prot. DT 21-JUL-1986, sequence version 1. DT 28-JAN-2026, entry version 212. DE RecName: Full=Proto-oncogene serine/threonine-protein kinase mos {ECO:0000305}; DE EC=2.7.11.1; DE AltName: Full=Oocyte maturation factor mos; DE AltName: Full=Proto-oncogene c-Mos; GN Name=MOS {ECO:0000312|HGNC:HGNC:7199}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RC TISSUE=Placenta; RX PubMed=6287464; DOI=10.1073/pnas.79.13.4078; RA Watson R., Oskarsson M., Vande Woude G.F.; RT "Human DNA sequence homologous to the transforming gene (mos) of Moloney RT murine sarcoma virus."; RL Proc. Natl. Acad. Sci. U.S.A. 79:4078-4082(1982). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT SER-105. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [3] RP FUNCTION, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, INTERACTION WITH MAP2K1, RP INVOLVEMENT IN OZEMA20, VARIANTS OZEMA20 LYS-95; THR-139; HIS-246 AND RP 320-CYS--GLY-346 DEL, AND CHARACTERIZATION OF VARIANTS OZEMA20 LYS-95; RP THR-139; HIS-246 AND 320-CYS--GLY-346 DEL. RX PubMed=34779126; DOI=10.15252/emmm.202114887; RA Zhang Y.L., Zheng W., Ren P., Hu H., Tong X., Zhang S.P., Li X., Wang H., RA Jiang J.C., Jin J., Yang W., Cao L., He Y., Ma Y., Zhang Y., Gu Y., Hu L., RA Luo K., Gong F., Lu G.X., Lin G., Fan H.Y., Zhang S.; RT "Biallelic mutations in MOS cause female infertility characterized by human RT early embryonic arrest and fragmentation."; RL EMBO Mol. Med. 13:e14887-e14887(2021). RN [4] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-96; SER-105; THR-123 AND PRO-300. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [5] RP VARIANT OZEMA20 MET-197. RX PubMed=36403623; DOI=10.1080/09513590.2022.2147158; RA Jiao G., Lian H., Xing J., Chen L., Du Z., Liu X.; RT "MOS mutation causes female infertility with large polar body oocytes."; RL Gynecol. Endocrinol. 38:1158-1163(2022). RN [6] RP VARIANTS OZEMA20 LYS-95 AND HIS-319, CHARACTERIZATION OF VARIANTS OZEMA20 RP LYS-95 AND HIS-319, AND FUNCTION. RX PubMed=34997960; DOI=10.1093/humrep/deab281; RA Zeng Y., Shi J., Xu S., Shi R., Wu T., Li H., Xue X., Zhu Y., Chen B., RA Sang Q., Wang L.; RT "Bi-allelic mutations in MOS cause female infertility characterized by RT preimplantation embryonic arrest."; RL Hum. Reprod. 37:612-620(2022). RN [7] RP VARIANTS OZEMA20 LEU-199; CYS-264 AND VAL-292, CHARACTERIZATION LEU-199; RP CYS-264 AND VAL-292, FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH RP MAP2K1. RX PubMed=35670744; DOI=10.1093/humrep/deac120; RA Zhang Y.L., Zheng W., Ren P., Jin J., Hu Z., Liu Q., Fan H.Y., Gong F., RA Lu G.X., Lin G., Zhang S., Tong X.; RT "Biallelic variants in MOS cause large polar body in oocyte and human RT female infertility."; RL Hum. Reprod. 37:1932-1944(2022). CC -!- FUNCTION: Serine/threonine kinase involved in the regulation of MAPK CC signaling. Is an activator of the ERK1/2 signaling cascade playing an CC essential role in the stimulation of oocyte maturation. CC {ECO:0000269|PubMed:34779126, ECO:0000269|PubMed:34997960, CC ECO:0000269|PubMed:35670744}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- SUBUNIT: Interacts with MAP2K1/MEK1. {ECO:0000269|PubMed:34779126, CC ECO:0000269|PubMed:35670744}. CC -!- INTERACTION: CC P00540; P35609: ACTN2; NbExp=3; IntAct=EBI-1757866, EBI-77797; CC P00540; Q9NWX5: ASB6; NbExp=3; IntAct=EBI-1757866, EBI-6425205; CC P00540; Q8WXE1: ATRIP; NbExp=3; IntAct=EBI-1757866, EBI-747353; CC P00540; Q8TD16-2: BICD2; NbExp=3; IntAct=EBI-1757866, EBI-11975051; CC P00540; Q96GS4: BORCS6; NbExp=4; IntAct=EBI-1757866, EBI-10193358; CC P00540; Q13137: CALCOCO2; NbExp=8; IntAct=EBI-1757866, EBI-739580; CC P00540; Q8NA61: CBY2; NbExp=3; IntAct=EBI-1757866, EBI-741724; CC P00540; Q8NA61-2: CBY2; NbExp=3; IntAct=EBI-1757866, EBI-11524851; CC P00540; Q68D86: CCDC102B; NbExp=3; IntAct=EBI-1757866, EBI-10171570; CC P00540; Q96JN2-2: CCDC136; NbExp=3; IntAct=EBI-1757866, EBI-10171416; CC P00540; O95273: CCNDBP1; NbExp=3; IntAct=EBI-1757866, EBI-748961; CC P00540; Q16543: CDC37; NbExp=2; IntAct=EBI-1757866, EBI-295634; CC P00540; Q8WWB3: DYDC1; NbExp=3; IntAct=EBI-1757866, EBI-740680; CC P00540; Q86YF9: DZIP1; NbExp=3; IntAct=EBI-1757866, EBI-998108; CC P00540; Q13451: FKBP5; NbExp=5; IntAct=EBI-1757866, EBI-306914; CC P00540; P14136: GFAP; NbExp=3; IntAct=EBI-1757866, EBI-744302; CC P00540; Q08379: GOLGA2; NbExp=6; IntAct=EBI-1757866, EBI-618309; CC P00540; Q9NYA3: GOLGA6A; NbExp=3; IntAct=EBI-1757866, EBI-11163335; CC P00540; A6NEM1: GOLGA6L9; NbExp=3; IntAct=EBI-1757866, EBI-5916454; CC P00540; O75791: GRAP2; NbExp=3; IntAct=EBI-1757866, EBI-740418; CC P00540; Q9NSC5: HOMER3; NbExp=8; IntAct=EBI-1757866, EBI-748420; CC P00540; P07900: HSP90AA1; NbExp=2; IntAct=EBI-1757866, EBI-296047; CC P00540; P08238: HSP90AB1; NbExp=2; IntAct=EBI-1757866, EBI-352572; CC P00540; Q13422-7: IKZF1; NbExp=3; IntAct=EBI-1757866, EBI-11522367; CC P00540; Q8NC69: KCTD6; NbExp=3; IntAct=EBI-1757866, EBI-2511344; CC P00540; Q92845: KIFAP3; NbExp=3; IntAct=EBI-1757866, EBI-954040; CC P00540; Q9BVG8: KIFC3; NbExp=3; IntAct=EBI-1757866, EBI-2125614; CC P00540; A1A4E9: KRT13; NbExp=3; IntAct=EBI-1757866, EBI-10171552; CC P00540; P19012: KRT15; NbExp=6; IntAct=EBI-1757866, EBI-739566; CC P00540; Q7Z3Y8: KRT27; NbExp=3; IntAct=EBI-1757866, EBI-3044087; CC P00540; Q15323: KRT31; NbExp=3; IntAct=EBI-1757866, EBI-948001; CC P00540; Q14525: KRT33B; NbExp=3; IntAct=EBI-1757866, EBI-1049638; CC P00540; O76011: KRT34; NbExp=3; IntAct=EBI-1757866, EBI-1047093; CC P00540; Q6A162: KRT40; NbExp=3; IntAct=EBI-1757866, EBI-10171697; CC P00540; Q8IUG1: KRTAP1-3; NbExp=3; IntAct=EBI-1757866, EBI-11749135; CC P00540; Q9BRK4: LZTS2; NbExp=3; IntAct=EBI-1757866, EBI-741037; CC P00540; P36507: MAP2K2; NbExp=3; IntAct=EBI-1757866, EBI-1056930; CC P00540; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-1757866, EBI-16439278; CC P00540; Q9UJV3-2: MID2; NbExp=3; IntAct=EBI-1757866, EBI-10172526; CC P00540; Q8TD10: MIPOL1; NbExp=3; IntAct=EBI-1757866, EBI-2548751; CC P00540; Q96QG7: MTMR9; NbExp=6; IntAct=EBI-1757866, EBI-744593; CC P00540; Q5JR59-3: MTUS2; NbExp=4; IntAct=EBI-1757866, EBI-11522433; CC P00540; P0DPK4: NOTCH2NLC; NbExp=3; IntAct=EBI-1757866, EBI-22310682; CC P00540; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-1757866, EBI-79165; CC P00540; Q15172: PPP2R5A; NbExp=5; IntAct=EBI-1757866, EBI-641666; CC P00540; O43586: PSTPIP1; NbExp=3; IntAct=EBI-1757866, EBI-1050964; CC P00540; P53992: SEC24C; NbExp=4; IntAct=EBI-1757866, EBI-81134; CC P00540; Q9Y2D8: SSX2IP; NbExp=3; IntAct=EBI-1757866, EBI-2212028; CC P00540; Q9UNE7: STUB1; NbExp=2; IntAct=EBI-1757866, EBI-357085; CC P00540; Q05BL1: TP53BP2; NbExp=3; IntAct=EBI-1757866, EBI-11952721; CC P00540; Q13077: TRAF1; NbExp=6; IntAct=EBI-1757866, EBI-359224; CC P00540; Q12933: TRAF2; NbExp=3; IntAct=EBI-1757866, EBI-355744; CC P00540; P14373: TRIM27; NbExp=3; IntAct=EBI-1757866, EBI-719493; CC P00540; Q8N6Y0: USHBP1; NbExp=6; IntAct=EBI-1757866, EBI-739895; CC P00540; Q8N680: ZBTB2; NbExp=3; IntAct=EBI-1757866, EBI-2515601; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:35670744}. CC -!- TISSUE SPECIFICITY: Highly expressed in oocytes. Lower expression is CC detected in early embryo. {ECO:0000269|PubMed:34779126}. CC -!- DEVELOPMENTAL STAGE: Expression decreases after fertilization and is CC slightly increased in four-cell stage embryos. Expression gradually CC decreases from eight-cell to blastocyst embryos. CC {ECO:0000269|PubMed:34779126}. CC -!- DISEASE: Oocyte/zygote/embryo maturation arrest 20 (OZEMA20) CC [MIM:620383]: An autosomal recessive, female infertility disorder CC characterized by early embryonic arrest and fragmentation. Early embryo CC fragmentation is defined by the presence of anucleate cell fragments CC derived from the blastomeres. Excessive embryo fragmentation is CC associated with deleterious outcomes, including decreased implantation CC rate. {ECO:0000269|PubMed:34779126, ECO:0000269|PubMed:34997960, CC ECO:0000269|PubMed:35670744, ECO:0000269|PubMed:36403623}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; J00119; AAA52029.1; -; Genomic_DNA. DR EMBL; BC069569; AAH69569.1; -; mRNA. DR EMBL; BC069590; AAH69590.1; -; mRNA. DR EMBL; BC106737; AAI06738.1; -; mRNA. DR EMBL; BC106738; AAI06739.1; -; mRNA. DR CCDS; CCDS6164.1; -. DR PIR; A00649; TVHUMS. DR RefSeq; NP_005363.1; NM_005372.1. DR AlphaFoldDB; P00540; -. DR SMR; P00540; -. DR BioGRID; 110483; 74. DR FunCoup; P00540; 709. DR IntAct; P00540; 86. DR MINT; P00540; -. DR STRING; 9606.ENSP00000310722; -. DR ChEMBL; CHEMBL1075184; -. DR GlyGen; P00540; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P00540; -. DR PhosphoSitePlus; P00540; -. DR BioMuta; MOS; -. DR DMDM; 125497; -. DR jPOST; P00540; -. DR MassIVE; P00540; -. DR PaxDb; 9606-ENSP00000310722; -. DR PeptideAtlas; P00540; -. DR ProteomicsDB; 51265; -. DR Antibodypedia; 24550; 288 antibodies from 27 providers. DR DNASU; 4342; -. DR Ensembl; ENST00000311923.1; ENSP00000310722.1; ENSG00000172680.1. DR GeneID; 4342; -. DR KEGG; hsa:4342; -. DR MANE-Select; ENST00000311923.1; ENSP00000310722.1; NM_005372.1; NP_005363.1. DR UCSC; uc011leb.2; human. DR AGR; HGNC:7199; -. DR ClinPGx; PA30907; -. DR CTD; 4342; -. DR DisGeNET; 4342; -. DR GeneCards; MOS; -. DR HGNC; HGNC:7199; MOS. DR HPA; ENSG00000172680; Not detected. DR MalaCards; MOS; -. DR MIM; 190060; gene. DR MIM; 620383; phenotype. DR OpenTargets; ENSG00000172680; -. DR VEuPathDB; HostDB:ENSG00000172680; -. DR eggNOG; KOG0192; Eukaryota. DR GeneTree; ENSGT00940000160233; -. DR HOGENOM; CLU_000288_7_35_1; -. DR InParanoid; P00540; -. DR OMA; WQMTTKE; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P00540; 5 GO annotations based on evolutionary models. DR PhylomeDB; P00540; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; P00540; -. DR SignaLink; P00540; -. DR SIGNOR; P00540; -. DR BioGRID-ORCS; 4342; 19 hits in 1185 CRISPR screens. DR GeneWiki; MOS_(gene); -. DR GenomeRNAi; 4342; -. DR Pharos; P00540; Tbio. DR PRO; PR:P00540; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; P00540; protein. DR Bgee; ENSG00000172680; Expressed in oocyte and 13 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; IMP:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004709; F:MAP kinase kinase kinase activity; ISS:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IBA:GO_Central. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; ISS:UniProtKB. DR GO; GO:0006325; P:chromatin organization; ISS:UniProtKB. DR GO; GO:0051296; P:establishment of meiotic spindle orientation; ISS:UniProtKB. DR GO; GO:0000165; P:MAPK cascade; ISS:UniProtKB. DR GO; GO:0000212; P:meiotic spindle organization; ISS:UniProtKB. DR GO; GO:1902103; P:negative regulation of metaphase/anaphase transition of meiotic cell cycle; ISS:UniProtKB. DR GO; GO:0001556; P:oocyte maturation; IMP:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; ISS:UniProtKB. DR GO; GO:0040020; P:regulation of meiotic nuclear division; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; IBA:GO_Central. DR CDD; cd13979; STKc_Mos; 1. DR FunFam; 1.10.510.10:FF:000490; Proto-oncogene serine/threonine-protein kinase mos; 1. DR FunFam; 3.30.200.20:FF:000316; Proto-oncogene serine/threonine-protein kinase mos; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051681; Ser/Thr_Kinases-Pseudokinases. DR PANTHER; PTHR44329; SERINE/THREONINE-PROTEIN KINASE TNNI3K-RELATED; 1. DR PANTHER; PTHR44329:SF285; V-MOS MOLONEY MURINE SARCOMA VIRAL ONCO HOMOLOG; 1. DR Pfam; PF00069; Pkinase; 1. DR PIRSF; PIRSF000654; Integrin-linked_kinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW ATP-binding; Cytoplasm; Disease variant; Kinase; Nucleotide-binding; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..346 FT /note="Proto-oncogene serine/threonine-protein kinase mos" FT /id="PRO_0000086344" FT DOMAIN 60..341 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ACT_SITE 201 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 66..74 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 87 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT VARIANT 95 FT /note="N -> K (in OZEMA20; likely pathogenic; loss of FT function in oocyte maturation activation; results in FT severely decreased activation of the ERK1/ERK2 cascade; FT dbSNP:rs774064952)" FT /evidence="ECO:0000269|PubMed:34779126, FT ECO:0000269|PubMed:34997960" FT /id="VAR_088642" FT VARIANT 96 FT /note="R -> L (in dbSNP:rs34532635)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040813" FT VARIANT 105 FT /note="A -> S (in dbSNP:rs35392772)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:17344846" FT /id="VAR_040814" FT VARIANT 123 FT /note="A -> T (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040815" FT VARIANT 139 FT /note="M -> T (in OZEMA20; uncertain significance; results FT in decreased activation of the ERK1/ERK2 cascade)" FT /evidence="ECO:0000269|PubMed:34779126" FT /id="VAR_088643" FT VARIANT 197 FT /note="I -> M (in OZEMA20; uncertain significance)" FT /evidence="ECO:0000269|PubMed:36403623" FT /id="VAR_088644" FT VARIANT 199 FT /note="H -> L (in OZEMA20; likely pathogenic; loss of FT function in oocyte maturation activation; loss of FT activation of the ERK1/ERK2 cascade; no effect on FT localization to cytoplasm)" FT /evidence="ECO:0000269|PubMed:35670744" FT /id="VAR_088645" FT VARIANT 246 FT /note="R -> H (in OZEMA20; uncertain significance; results FT in decreased activation of the ERK1/ERK2 cascade; FT dbSNP:rs1563357810)" FT /evidence="ECO:0000269|PubMed:34779126" FT /id="VAR_088646" FT VARIANT 264 FT /note="S -> C (in OZEMA20; likely pathogenic; loss of FT function in oocyte maturation activation; loss of FT activation of the ERK1/ERK2 cascade; no effect on FT localization to cytoplasm)" FT /evidence="ECO:0000269|PubMed:35670744" FT /id="VAR_088647" FT VARIANT 292 FT /note="A -> V (in OZEMA20; likely pathogenic; loss of FT function in oocyte maturation activation; decreased FT activation of the ERK1/ERK2 cascade; no effect on FT localization to cytoplasm; dbSNP:rs1810519989)" FT /evidence="ECO:0000269|PubMed:35670744" FT /id="VAR_088648" FT VARIANT 300 FT /note="S -> P (in dbSNP:rs56300224)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040816" FT VARIANT 319 FT /note="R -> H (in OZEMA20; likely pathogenic; results in FT decreased activation of the ERK1/ERK2 cascade)" FT /evidence="ECO:0000269|PubMed:34997960" FT /id="VAR_088649" FT VARIANT 320..346 FT /note="Missing (in OZEMA20; likely pathogenic; loss of FT function in oocyte maturation activation; loss of FT activation of the ERK1/ERK2 cascade; severely decreased FT interaction with MAP2K1)" FT /evidence="ECO:0000269|PubMed:34779126" FT /id="VAR_088650" SQ SEQUENCE 346 AA; 37820 MW; 68B1AB906ED4B308 CRC64; MPSPLALRPY LRSEFSPSVD ARPCSSPSEL PAKLLLGATL PRAPRLPRRL AWCSIDWEQV CLLQRLGAGG FGSVYKATYR GVPVAIKQVN KCTKNRLASR RSFWAELNVA RLRHDNIVRV VAASTRTPAG SNSLGTIIME FGGNVTLHQV IYGAAGHPEG DAGEPHCRTG GQLSLGKCLK YSLDVVNGLL FLHSQSIVHL DLKPANILIS EQDVCKISDF GCSEKLEDLL CFQTPSYPLG GTYTHRAPEL LKGEGVTPKA DIYSFAITLW QMTTKQAPYS GERQHILYAV VAYDLRPSLS AAVFEDSLPG QRLGDVIQRC WRPSAAQRPS ARLLLVDLTS LKAELG // ID MP2K4_HUMAN Reviewed; 399 AA. AC P45985; B2R7N7; B3KYB2; D3DTS5; Q5U0B8; Q6FHX4; Q6P9H2; Q6PIE6; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1995, sequence version 1. DT 28-JAN-2026, entry version 229. DE RecName: Full=Dual specificity mitogen-activated protein kinase kinase 4; DE Short=MAP kinase kinase 4; DE Short=MAPKK 4; DE EC=2.7.12.2; DE AltName: Full=JNK-activating kinase 1; DE AltName: Full=MAPK/ERK kinase 4; DE Short=MEK 4; DE AltName: Full=SAPK/ERK kinase 1; DE Short=SEK1; DE AltName: Full=Stress-activated protein kinase kinase 1; DE Short=SAPK kinase 1; DE Short=SAPKK-1; DE Short=SAPKK1; DE AltName: Full=c-Jun N-terminal kinase kinase 1; DE Short=JNKK; GN Name=MAP2K4; Synonyms=JNKK1, MEK4, MKK4, PRKMK4, SEK1, SERK1, SKK1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=7839144; DOI=10.1126/science.7839144; RA Derijard B., Raingeaud J., Barrett T., Wu I.-H., Han J., Ulevitch R.J., RA Davis R.J.; RT "Independent human MAP-kinase signal transduction pathways defined by MEK RT and MKK isoforms."; RL Science 267:682-685(1995). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION. RX PubMed=7716521; DOI=10.1126/science.7716521; RA Lin A., Minden A., Martinetto H., Claret F.-X., Lange-Carter C., RA Mercurio F., Johnson G.L., Karin M.; RT "Identification of a dual specificity kinase that activates the Jun kinases RT and p38-Mpk2."; RL Science 268:286-290(1995). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9622070; RA Su G.H., Hilgers W., Shekher M.C., Tang D.J., Yeo C.J., Hruban R.H., RA Kern S.E.; RT "Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as RT a genetically targeted tumor suppressor gene."; RL Cancer Res. 58:2339-2342(1998). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain, and Thalamus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-16. RC TISSUE=Brain, and Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP PHOSPHORYLATION AT THR-261, ACTIVITY REGULATION, AND INTERACTION WITH RP MAP3K11/MLK3. RX PubMed=9003778; DOI=10.1002/j.1460-2075.1996.tb01094.x; RA Tibbles L.A., Ing Y.L., Kiefer F., Chan J., Iscove N., Woodgett J.R., RA Lassam N.J.; RT "MLK-3 activates the SAPK/JNK and p38/RK pathways via SEK1 and MKK3/6."; RL EMBO J. 15:7026-7035(1996). RN [12] RP CLEAVAGE BY ANTHRAX LETHAL FACTOR. RX PubMed=11104681; DOI=10.1042/bj3520739; RA Vitale G., Bernardi L., Napolitani G., Mock M., Montecucco C.; RT "Susceptibility of mitogen-activated protein kinase kinase family members RT to proteolysis by anthrax lethal factor."; RL Biochem. J. 352:739-745(2000). RN [13] RP INTERACTION WITH ARRB2. RX PubMed=11090355; DOI=10.1126/science.290.5496.1574; RA McDonald P.H., Chow C.W., Miller W.E., Laporte S.A., Field M.E., Lin F.-T., RA Davis R.J., Lefkowitz R.J.; RT "Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of RT JNK3."; RL Science 290:1574-1577(2000). RN [14] RP INTERACTION WITH MAPK8IP3/JIP3. RX PubMed=12189133; DOI=10.1074/jbc.m202004200; RA Matsuura H., Nishitoh H., Takeda K., Matsuzawa A., Amagasa T., Ito M., RA Yoshioka K., Ichijo H.; RT "Phosphorylation-dependent scaffolding role of JSAP1/JIP3 in the ASK1-JNK RT signaling pathway. A new mode of regulation of the MAP kinase cascade."; RL J. Biol. Chem. 277:40703-40709(2002). RN [15] RP DOMAIN, AND INTERACTION WITH MAPK8/JNK1; MAPK9/JNK2; MAPK10/JNK3; MAPK11 RP AND MAPK14. RX PubMed=12788955; DOI=10.1074/jbc.m304229200; RA Ho D.T., Bardwell A.J., Abdollahi M., Bardwell L.; RT "A docking site in MKK4 mediates high affinity binding to JNK MAPKs and RT competes with similar docking sites in JNK substrates."; RL J. Biol. Chem. 278:32662-32672(2003). RN [16] RP DOMAIN. RX PubMed=15866172; DOI=10.1016/j.molcel.2005.04.001; RA Takekawa M., Tatebayashi K., Saito H.; RT "Conserved docking site is essential for activation of mammalian MAP kinase RT kinases by specific MAP kinase kinase kinases."; RL Mol. Cell 18:295-306(2005). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-90, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [18] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [19] RP INTERACTION WITH ARRB1 AND ARRB2. RX PubMed=19782076; DOI=10.1016/j.febslet.2009.09.035; RA Li X., MacLeod R., Dunlop A.J., Edwards H.V., Advant N., Gibson L.C., RA Devine N.M., Brown K.M., Adams D.R., Houslay M.D., Baillie G.S.; RT "A scanning peptide array approach uncovers association sites within the RT JNK/beta arrestin signalling complex."; RL FEBS Lett. 583:3310-3316(2009). RN [20] RP REVIEW ON ACTIVITY REGULATION. RX PubMed=17496909; DOI=10.1038/sj.onc.1210392; RA Raman M., Chen W., Cobb M.H.; RT "Differential regulation and properties of MAPKs."; RL Oncogene 26:3100-3112(2007). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-257, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [22] RP REVIEW ON FUNCTION. RX PubMed=20801953; DOI=10.1093/jb/mvq098; RA Asaoka Y., Nishina H.; RT "Diverse physiological functions of MKK4 and MKK7 during early RT embryogenesis."; RL J. Biochem. 148:393-401(2010). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [24] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [25] RP REVIEW ON REGULATION, AND REVIEW ON FUNCTION. RX PubMed=21333379; DOI=10.1016/j.ejcb.2010.11.008; RA Haeusgen W., Herdegen T., Waetzig V.; RT "The bottleneck of JNK signaling: molecular and functional characteristics RT of MKK4 and MKK7."; RL Eur. J. Cell Biol. 90:536-544(2011). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-257, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [27] RP METHYLATION [LARGE SCALE ANALYSIS] AT ARG-58, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Colon carcinoma; RX PubMed=24129315; DOI=10.1074/mcp.o113.027870; RA Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M., RA Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V., RA Bedford M.T., Comb M.J.; RT "Immunoaffinity enrichment and mass spectrometry analysis of protein RT methylation."; RL Mol. Cell. Proteomics 13:372-387(2014). RN [28] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 80-399. RX PubMed=20732303; DOI=10.1016/j.bbrc.2010.08.071; RA Matsumoto T., Kinoshita T., Kirii Y., Yokota K., Hamada K., Tada T.; RT "Crystal structures of MKK4 kinase domain reveal that substrate peptide RT binds to an allosteric site and induces an auto-inhibition state."; RL Biochem. Biophys. Res. Commun. 400:369-373(2010). RN [29] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-142; TRP-154; ILE-234; ASN-251 AND RP THR-279. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Dual specificity protein kinase which acts as an essential CC component of the MAP kinase signal transduction pathway. Essential CC component of the stress-activated protein kinase/c-Jun N-terminal CC kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7, is the one of the CC only known kinase to directly activate the stress-activated protein CC kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. CC MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation, CC but they differ in their preference for the phosphorylation site in the CC Thr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation of the CC Tyr residue and MAP2K7/MKK7 for the Thr residue. The phosphorylation of CC the Thr residue by MAP2K7/MKK7 seems to be the prerequisite for JNK CC activation at least in response to pro-inflammatory cytokines, while CC other stimuli activate both MAP2K4/MKK4 and MAP2K7/MKK7 which CC synergistically phosphorylate JNKs. MAP2K4 is required for maintaining CC peripheral lymphoid homeostasis. The MKK/JNK signaling pathway is also CC involved in mitochondrial death signaling pathway, including the CC release cytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7 CC exclusively activates JNKs, MAP2K4/MKK4 additionally activates the p38 CC MAPKs MAPK11, MAPK12, MAPK13 and MAPK14. {ECO:0000269|PubMed:7716521}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.12.2; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.12.2; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.12.2; CC -!- ACTIVITY REGULATION: Activated in response to a variety of cellular CC stresses, including UV and gamma-irradiation, heat shock, CC hyperosmolarity, T-cell receptor stimulation, peroxide and inflammatory CC cytokines. Also activated by developmental cues. MAP2K4/MKK4 is CC activated by the majority of MKKKs, such as MAP3K5/ASK1, MAP3K1/MEKK1, CC MAP3K7/TAK1, MAP3K10/MLK2, MAP3K11/MLK3, MAP3K12/DLK and MAP3K13/LZK. CC {ECO:0000269|PubMed:9003778}. CC -!- SUBUNIT: Interacts with SPAG9 (By similarity). Interacts (via its D CC domain) with its substrates MAPK8/JNK1, MAPK9/JNK2, MAPK10/JNK3, MAPK11 CC and MAPK14. Interacts (via its DVD domain) with MAP3Ks activators like CC MAP3K1/MEKK1 and MAP3K11/MLK3. Interacts with ARRB1, ARRB2 and CC MAPK8IP3/JIP3. {ECO:0000250, ECO:0000269|PubMed:11090355, CC ECO:0000269|PubMed:12189133, ECO:0000269|PubMed:12788955, CC ECO:0000269|PubMed:19782076, ECO:0000269|PubMed:9003778}. CC -!- INTERACTION: CC P45985; Q13233: MAP3K1; NbExp=3; IntAct=EBI-447868, EBI-49776; CC P45985; P45983: MAPK8; NbExp=4; IntAct=EBI-447868, EBI-286483; CC P45985; P45984: MAPK9; NbExp=3; IntAct=EBI-447868, EBI-713568; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P45985-1; Sequence=Displayed; CC Name=2; CC IsoId=P45985-2; Sequence=VSP_038838; CC -!- TISSUE SPECIFICITY: Abundant expression is seen in the skeletal muscle. CC It is also widely expressed in other tissues. CC -!- DOMAIN: The DVD domain (residues 364-387) contains a conserved docking CC site and is found in the mammalian MAP kinase kinases (MAP2Ks). The DVD CC sites bind to their specific upstream MAP kinase kinase kinases CC (MAP3Ks) and are essential for activation. CC -!- DOMAIN: The D domain (residues 34-52) contains a conserved docking site CC and is required for the binding to MAPK substrates. CC -!- PTM: Activated by phosphorylation on Ser-257 and Thr-261 by MAP kinase CC kinase kinases (MAP3Ks). {ECO:0000269|PubMed:9003778}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr CC protein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/244/MAP2K4"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L36870; AAC41719.1; -; mRNA. DR EMBL; U17743; AAC50127.1; -; mRNA. DR EMBL; AF070090; AAC24130.1; -; Genomic_DNA. DR EMBL; AF070080; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070081; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070082; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070083; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070084; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070085; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070086; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070087; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070088; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; AF070089; AAC24130.1; JOINED; Genomic_DNA. DR EMBL; CR536564; CAG38801.1; -; mRNA. DR EMBL; BT019676; AAV38482.1; -; mRNA. DR EMBL; AK131544; BAG54774.1; -; mRNA. DR EMBL; AK313053; BAG35884.1; -; mRNA. DR EMBL; DQ015703; AAY22176.1; -; Genomic_DNA. DR EMBL; AC005244; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC005410; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471108; EAW89975.1; -; Genomic_DNA. DR EMBL; CH471108; EAW89974.1; -; Genomic_DNA. DR EMBL; CH471108; EAW89976.1; -; Genomic_DNA. DR EMBL; BC036032; AAH36032.1; -; mRNA. DR EMBL; BC060764; AAH60764.1; -; mRNA. DR CCDS; CCDS11162.1; -. [P45985-1] DR CCDS; CCDS62095.1; -. [P45985-2] DR PIR; I38901; I38901. DR RefSeq; NP_001268364.1; NM_001281435.2. [P45985-2] DR RefSeq; NP_003001.1; NM_003010.4. [P45985-1] DR PDB; 3ALN; X-ray; 2.30 A; A/B/C=80-399. DR PDB; 3ALO; X-ray; 2.60 A; A=80-399. DR PDB; 3VUT; X-ray; 3.50 A; A/B=80-399. DR PDB; 8YP5; X-ray; 2.50 A; A=80-399. DR PDBsum; 3ALN; -. DR PDBsum; 3ALO; -. DR PDBsum; 3VUT; -. DR PDBsum; 8YP5; -. DR AlphaFoldDB; P45985; -. DR SMR; P45985; -. DR BioGRID; 112315; 69. DR CORUM; P45985; -. DR FunCoup; P45985; 2185. DR IntAct; P45985; 26. DR MINT; P45985; -. DR STRING; 9606.ENSP00000410402; -. DR BindingDB; P45985; -. DR ChEMBL; CHEMBL2897; -. DR DrugBank; DB11718; Encorafenib. DR DrugBank; DB14904; Pimasertib. DR DrugCentral; P45985; -. DR GuidetoPHARMACOLOGY; 2065; -. DR GlyCosmos; P45985; 2 sites, 1 glycan. DR GlyGen; P45985; 4 sites, 1 O-linked glycan (2 sites). DR iPTMnet; P45985; -. DR PhosphoSitePlus; P45985; -. DR BioMuta; MAP2K4; -. DR DMDM; 1170596; -. DR CPTAC; CPTAC-816; -. DR CPTAC; CPTAC-817; -. DR jPOST; P45985; -. DR MassIVE; P45985; -. DR PaxDb; 9606-ENSP00000410402; -. DR PeptideAtlas; P45985; -. DR ProteomicsDB; 55703; -. [P45985-1] DR ProteomicsDB; 55704; -. [P45985-2] DR Pumba; P45985; -. DR Antibodypedia; 3571; 1422 antibodies from 43 providers. DR CPTC; P45985; 1 antibody. DR DNASU; 6416; -. DR Ensembl; ENST00000353533.10; ENSP00000262445.5; ENSG00000065559.16. [P45985-1] DR Ensembl; ENST00000415385.7; ENSP00000410402.3; ENSG00000065559.16. [P45985-2] DR GeneID; 6416; -. DR KEGG; hsa:6416; -. DR MANE-Select; ENST00000353533.10; ENSP00000262445.5; NM_003010.4; NP_003001.1. DR UCSC; uc002gnj.5; human. [P45985-1] DR AGR; HGNC:6844; -. DR CIViC; 6416; 2 evidence items across 3 molecular profiles. DR ClinPGx; PA30589; -. DR CTD; 6416; -. DR DisGeNET; 6416; -. DR GeneCards; MAP2K4; -. DR HGNC; HGNC:6844; MAP2K4. DR HPA; ENSG00000065559; Low tissue specificity. DR MalaCards; MAP2K4; -. DR MIM; 601335; gene. DR OpenTargets; ENSG00000065559; -. DR VEuPathDB; HostDB:ENSG00000065559; -. DR eggNOG; KOG1006; Eukaryota. DR GeneTree; ENSGT00940000154744; -. DR HOGENOM; CLU_000288_63_23_1; -. DR InParanoid; P45985; -. DR OMA; HILLEFC; -. DR OrthoDB; 10252354at2759; -. DR PAN-GO; P45985; 2 GO annotations based on evolutionary models. DR PhylomeDB; P45985; -. DR BRENDA; 2.7.12.2; 2681. DR PathwayCommons; P45985; -. DR Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence. DR Reactome; R-HSA-2871796; FCERI mediated MAPK activation. DR Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1. DR Reactome; R-HSA-5210891; Uptake and function of anthrax toxins. DR Reactome; R-HSA-5684264; MAP3K8 (TPL2)-dependent MAPK1/3 activation. DR SABIO-RK; P45985; -. DR SignaLink; P45985; -. DR SIGNOR; P45985; -. DR Agora; ENSG00000065559; -. DR BioGRID-ORCS; 6416; 53 hits in 1202 CRISPR screens. DR ChiTaRS; MAP2K4; human. DR EvolutionaryTrace; P45985; -. DR GeneWiki; MAP2K4; -. DR GenomeRNAi; 6416; -. DR Pharos; P45985; Tchem. DR PRO; PR:P45985; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P45985; protein. DR Bgee; ENSG00000065559; Expressed in lateral nuclear group of thalamus and 204 other cell types or tissues. DR ExpressionAtlas; P45985; baseline and differential. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0008545; F:JUN kinase kinase activity; TAS:Reactome. DR GO; GO:0004708; F:MAP kinase kinase activity; IBA:GO_Central. DR GO; GO:0060090; F:molecular adaptor activity; EXP:DisProt. DR GO; GO:0004672; F:protein kinase activity; TAS:ProtInc. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:UniProtKB. DR GO; GO:0090398; P:cellular senescence; TAS:Reactome. DR GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome. DR GO; GO:0036481; P:intrinsic apoptotic signaling pathway in response to hydrogen peroxide; IEA:Ensembl. DR GO; GO:0007254; P:JNK cascade; TAS:Reactome. DR GO; GO:0000165; P:MAPK cascade; IBA:GO_Central. DR GO; GO:2000672; P:negative regulation of motor neuron apoptotic process; IEA:Ensembl. DR GO; GO:0009611; P:response to wounding; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0034390; P:smooth muscle cell apoptotic process; IEA:Ensembl. DR CDD; cd06616; PKc_MKK4; 1. DR DisProt; DP01400; -. DR FunFam; 1.10.510.10:FF:000090; Dual specificity mitogen-activated protein kinase kinase 4; 1. DR FunFam; 3.30.200.20:FF:000126; Dual specificity mitogen-activated protein kinase kinase 4; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR48013:SF15; DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 4; 1. DR PANTHER; PTHR48013; DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 5-RELATED; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding; KW Cytoplasm; Kinase; Methylation; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Stress response; Transferase; KW Tyrosine-protein kinase. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:19413330" FT CHAIN 2..399 FT /note="Dual specificity mitogen-activated protein kinase FT kinase 4" FT /id="PRO_0000086381" FT DOMAIN 102..367 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..40 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 37..52 FT /note="D domain" FT REGION 364..387 FT /note="DVD domain" FT COMPBIAS 7..22 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 229 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 108..116 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 131 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 45..46 FT /note="Cleavage; by anthrax lethal factor" FT SITE 58..59 FT /note="Cleavage; by anthrax lethal factor" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:19413330" FT MOD_RES 58 FT /note="Asymmetric dimethylarginine; alternate" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 58 FT /note="Omega-N-methylarginine; alternate" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 90 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 257 FT /note="Phosphoserine; by MAP3K" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:24275569" FT MOD_RES 261 FT /note="Phosphothreonine; by MAP3K" FT /evidence="ECO:0000269|PubMed:9003778" FT VAR_SEQ 39 FT /note="G -> GFQINFCEKAQS (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_038838" FT VARIANT 16 FT /note="S -> R (in dbSNP:rs17855590)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_062963" FT VARIANT 142 FT /note="Q -> L (in a lung squamous cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040818" FT VARIANT 154 FT /note="R -> W (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs1567657403)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040819" FT VARIANT 234 FT /note="N -> I (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040820" FT VARIANT 251 FT /note="S -> N (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040821" FT VARIANT 279 FT /note="A -> T (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs753665559)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040822" FT CONFLICT 118 FT /note="K -> R (in Ref. 4; CAG38801)" FT /evidence="ECO:0000305" FT CONFLICT 179 FT /note="E -> G (in Ref. 6; BAG35884)" FT /evidence="ECO:0000305" FT CONFLICT 356 FT /note="P -> L (in Ref. 10; AAH60764)" FT /evidence="ECO:0000305" FT STRAND 81..83 FT /evidence="ECO:0007829|PDB:3VUT" FT STRAND 85..88 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 93..95 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 101..103 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 107..110 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 112..121 FT /evidence="ECO:0007829|PDB:3ALN" FT TURN 122..124 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 127..134 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 139..153 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 164..169 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 171..178 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 182..184 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 185..194 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 202..223 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 232..234 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 235..237 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 243..245 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 249..251 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 255..259 FT /evidence="ECO:0007829|PDB:3VUT" FT STRAND 267..270 FT /evidence="ECO:0007829|PDB:3ALO" FT HELIX 272..274 FT /evidence="ECO:0007829|PDB:3ALO" FT HELIX 287..302 FT /evidence="ECO:0007829|PDB:3ALN" FT STRAND 312..314 FT /evidence="ECO:0007829|PDB:3ALO" FT STRAND 316..321 FT /evidence="ECO:0007829|PDB:3ALO" FT HELIX 338..347 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 352..354 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 358..361 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 365..372 FT /evidence="ECO:0007829|PDB:3ALN" FT HELIX 377..387 FT /evidence="ECO:0007829|PDB:3ALN" SQ SEQUENCE 399 AA; 44288 MW; A472537F2F26770B CRC64; MAAPSPSGGG GSGGGSGSGT PGPVGSPAPG HPAVSSMQGK RKALKLNFAN PPFKSTARFT LNPNPTGVQN PHIERLRTHS IESSGKLKIS PEQHWDFTAE DLKDLGEIGR GAYGSVNKMV HKPSGQIMAV KRIRSTVDEK EQKQLLMDLD VVMRSSDCPY IVQFYGALFR EGDCWICMEL MSTSFDKFYK YVYSVLDDVI PEEILGKITL ATVKALNHLK ENLKIIHRDI KPSNILLDRS GNIKLCDFGI SGQLVDSIAK TRDAGCRPYM APERIDPSAS RQGYDVRSDV WSLGITLYEL ATGRFPYPKW NSVFDQLTQV VKGDPPQLSN SEEREFSPSF INFVNLCLTK DESKRPKYKE LLKHPFILMY EERAVEVACY VCKILDQMPA TPSSPMYVD // ID MRCKB_HUMAN Reviewed; 1711 AA. AC Q9Y5S2; A9JR72; Q2L7A5; Q86TJ1; Q9ULU5; DT 08-NOV-2005, integrated into UniProtKB/Swiss-Prot. DT 04-APR-2006, sequence version 2. DT 28-JAN-2026, entry version 213. DE RecName: Full=Serine/threonine-protein kinase MRCK beta; DE EC=2.7.11.1; DE AltName: Full=CDC42-binding protein kinase beta; DE Short=CDC42BP-beta; DE AltName: Full=DMPK-like beta; DE AltName: Full=Myotonic dystrophy kinase-related CDC42-binding kinase beta; DE Short=MRCK beta; DE Short=Myotonic dystrophy protein kinase-like beta; GN Name=CDC42BPB {ECO:0000312|EMBL:AAD37506.1}; GN Synonyms=KIAA1124 {ECO:0000312|EMBL:BAA86438.2}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305, ECO:0000312|EMBL:AAD37506.1} RP NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY. RC TISSUE=Brain {ECO:0000312|EMBL:AAD37506.1}; RX PubMed=10198171; DOI=10.1006/geno.1999.5769; RA Moncrieff C.L., Bailey M.E., Morrison N., Johnson K.J.; RT "Cloning and chromosomal localization of human Cdc42-binding protein kinase RT beta."; RL Genomics 57:297-300(1999). RN [2] {ECO:0000312|EMBL:BAA86438.2} RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT LYS-1203. RC TISSUE=Brain {ECO:0000312|EMBL:BAA86438.2}; RX PubMed=10574461; DOI=10.1093/dnares/6.5.329; RA Hirosawa M., Nagase T., Ishikawa K., Kikuno R., Nomura N., Ohara O.; RT "Characterization of cDNA clones selected by the GeneMark analysis from RT size-fractionated cDNA libraries from human brain."; RL DNA Res. 6:329-336(1999). RN [3] {ECO:0000305} RP SEQUENCE REVISION. RX PubMed=12168954; DOI=10.1093/dnares/9.3.99; RA Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.; RT "Construction of expression-ready cDNA clones for KIAA genes: manual RT curation of 330 KIAA cDNA clones."; RL DNA Res. 9:99-106(2002). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-1077. RG NIEHS SNPs program; RL Submitted (JAN-2006) to the EMBL/GenBank/DDBJ databases. RN [5] {ECO:0000305, ECO:0000312|EMBL:AAH47871.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LYS-1203. RC TISSUE=PNS {ECO:0000312|EMBL:AAH47871.1}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1690, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [7] RP IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, AND INTERACTION WITH LURAP1 RP AND MYO18A. RX PubMed=18854160; DOI=10.1016/j.cell.2008.09.018; RA Tan I., Yong J., Dong J.M., Lim L., Leung T.; RT "A tripartite complex containing MRCK modulates lamellar actomyosin RT retrograde flow."; RL Cell 135:123-136(2008). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1690, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1690, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [13] RP SUBCELLULAR LOCATION. RX PubMed=21240187; DOI=10.1038/emboj.2010.353; RA Huo L., Wen W., Wang R., Kam C., Xia J., Feng W., Zhang M.; RT "Cdc42-dependent formation of the ZO-1/MRCKbeta complex at the leading edge RT controls cell migration."; RL EMBO J. 30:665-678(2011). RN [14] RP FUNCTION IN PHOSPHORYLATION OF PPP1R12A AND MYL9/MLC2, AND ACTIVITY RP REGULATION. RX PubMed=21457715; DOI=10.1016/j.febslet.2011.03.054; RA Tan I., Lai J., Yong J., Li S.F., Leung T.; RT "Chelerythrine perturbs lamellar actomyosin filaments by selective RT inhibition of myotonic dystrophy kinase-related Cdc42-binding kinase."; RL FEBS Lett. 585:1260-1268(2011). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1690 AND SER-1693, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1690, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-423; SER-1680; SER-1682 AND RP SER-1686, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [18] RP METHYLATION [LARGE SCALE ANALYSIS] AT ARG-671, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Colon carcinoma; RX PubMed=24129315; DOI=10.1074/mcp.o113.027870; RA Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M., RA Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V., RA Bedford M.T., Comb M.J.; RT "Immunoaffinity enrichment and mass spectrometry analysis of protein RT methylation."; RL Mol. Cell. Proteomics 13:372-387(2014). RN [19] RP INTERACTION WITH STRP1; STRN3 AND SIKE1. RX PubMed=25743393; DOI=10.1038/ncomms7449; RA Lant B., Yu B., Goudreault M., Holmyard D., Knight J.D., Xu P., Zhao L., RA Chin K., Wallace E., Zhen M., Gingras A.C., Derry W.B.; RT "CCM-3/STRIPAK promotes seamless tube extension through endocytic RT recycling."; RL Nat. Commun. 6:6449-6449(2015). RN [20] RP PROTEOLYTIC CLEAVAGE. RX PubMed=29162624; DOI=10.1083/jcb.201703044; RA Gagliardi P.A., Somale D., Puliafito A., Chiaverina G., di Blasio L., RA Oneto M., Bianchini P., Bussolino F., Primo L.; RT "MRCKalpha is activated by caspase cleavage to assemble an apical actin RT ring for epithelial cell extrusion."; RL J. Cell Biol. 217:231-249(2018). RN [21] RP X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 2-417 IN COMPLEXES WITH FASUDIL RP AND TPCA-1, FUNCTION, SUBUNIT, AND CATALYTIC ACTIVITY. RX PubMed=21949762; DOI=10.1371/journal.pone.0024825; RA Heikkila T., Wheatley E., Crighton D., Schroder E., Boakes A., Kaye S.J., RA Mezna M., Pang L., Rushbrooke M., Turnbull A., Olson M.F.; RT "Co-crystal structures of inhibitors with MRCKbeta, a key regulator of RT tumor cell invasion."; RL PLoS ONE 6:E24825-E24825(2011). RN [22] RP VARIANTS [LARGE SCALE ANALYSIS] GLU-500; GLN-555; GLN-671; TRP-876; RP LYS-1315 AND TYR-1633. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [23] RP INVOLVEMENT IN CHOCNS, AND VARIANTS CHOCNS THR-142; TYR-175; MET-293; RP 764-ARG--THR-1711 DEL; CYS-867; PRO-871; PRO-876; TRP-876; GLN-1299 AND RP PRO-1350. RX PubMed=32031333; DOI=10.1002/ajmg.a.61505; RA Chilton I., Okur V., Vitiello G., Selicorni A., Mariani M., Goldenberg A., RA Husson T., Campion D., Lichtenbelt K.D., van Gassen K., Steinraths M., RA Rice J., Roeder E.R., Littlejohn R.O., Srour M., Sebire G., Accogli A., RA Heron D., Heide S., Nava C., Depienne C., Larson A., Niyazov D., Azage M., RA Hoganson G., Burton J., Rush E.T., Jenkins J.L., Saunders C.J., RA Thiffault I., Alaimo J.T., Fleischer J., Groepper D., Gripp K.W., RA Chung W.K.; RT "De novo heterozygous missense and loss-of-function variants in CDC42BPB RT are associated with a neurodevelopmental phenotype."; RL Am. J. Med. Genet. A 182:962-973(2020). CC -!- FUNCTION: Serine/threonine-protein kinase which is an important CC downstream effector of CDC42 and plays a role in the regulation of CC cytoskeleton reorganization and cell migration. Regulates actin CC cytoskeletal reorganization via phosphorylation of PPP1R12C and CC MYL9/MLC2 (PubMed:21457715, PubMed:21949762). In concert with MYO18A CC and LURAP1, is involved in modulating lamellar actomyosin retrograde CC flow that is crucial to cell protrusion and migration CC (PubMed:18854160). Phosphorylates PPP1R12A (PubMed:21457715). In CC concert with FAM89B/LRAP25 mediates the targeting of LIMK1 to the CC lamellipodium resulting in its activation and subsequent CC phosphorylation of CFL1 which is important for lamellipodial F-actin CC regulation (By similarity). {ECO:0000250|UniProtKB:Q7TT50, CC ECO:0000269|PubMed:18854160, ECO:0000269|PubMed:21457715, CC ECO:0000269|PubMed:21949762}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000250|UniProtKB:Q5VT25, ECO:0000269|PubMed:21949762}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000250|UniProtKB:Q5VT25, ECO:0000269|PubMed:21949762}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000250|UniProtKB:Q5VT25}; CC -!- ACTIVITY REGULATION: Maintained in an inactive, closed conformation by CC an interaction between the kinase domain and the negative CC autoregulatory C-terminal coiled-coil region. Agonist binding to the CC phorbol ester binding site disrupts this, releasing the kinase domain CC to allow N-terminus-mediated dimerization and kinase activation by CC transautophosphorylation (By similarity). Inhibited by chelerythrine CC chloride. {ECO:0000250, ECO:0000269|PubMed:21457715}. CC -!- SUBUNIT: Homodimer and homotetramer via the coiled coil regions CC (PubMed:21949762). Interacts tightly with GTP-bound but not GDP-bound CC CDC42. Interacts with TJP1, when in the presence of catalytically CC active CDC42 (By similarity). Forms a tripartite complex with MYO18A CC and LURAP1 with the latter acting as an adapter connecting CDC42BPB and CC MYO18A. LURAP1 binding results in activation of CDC42BPB by abolition CC of its negative autoregulation (PubMed:18854160). Interacts with CC STRIP1, STRN3 and SIKE1 (PubMed:25743393). Interacts with CPNE4 (via CC VWFA domain). Interacts with LURAP1. Interacts (via AGC-kinase C- CC terminal domain) with FAM89B/LRAP25 (via LRR repeat). Forms a CC tripartite complex with FAM89B/LRAP25 and LIMK1 (By similarity). CC {ECO:0000250|UniProtKB:Q7TT49, ECO:0000250|UniProtKB:Q7TT50, CC ECO:0000269|PubMed:18854160, ECO:0000269|PubMed:21949762, CC ECO:0000269|PubMed:25743393}. CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Cell membrane CC {ECO:0000269|PubMed:21240187}; Peripheral membrane protein CC {ECO:0000269|PubMed:21240187}; Cytoplasmic side CC {ECO:0000269|PubMed:21240187}. Cell junction CC {ECO:0000269|PubMed:21240187}. Cell projection, lamellipodium CC {ECO:0000250|UniProtKB:Q3UU96}. Note=Displays a dispersed punctate CC distribution and concentrates along the cell periphery, especially at CC the leading edge and cell-cell junction. This concentration is PH- CC domain dependent (By similarity). Detected at the leading edge of CC migrating cells. Localization at the leading edge of migrating cells CC requires interaction with catalytically active CDC42 (PubMed:21240187). CC Localizes in the lamellipodium in a FAM89B/LRAP25-dependent manner (By CC similarity). {ECO:0000250|UniProtKB:O54874, CC ECO:0000250|UniProtKB:Q3UU96, ECO:0000269|PubMed:21240187}. CC -!- TISSUE SPECIFICITY: Expressed in all tissues examined, with high levels CC in heart, brain, placenta and lung. {ECO:0000269|PubMed:10198171}. CC -!- PTM: Proteolytically cleaved by caspases upon apoptosis induction. CC {ECO:0000269|PubMed:29162624}. CC -!- DISEASE: Chilton-Okur-Chung neurodevelopmental syndrome (CHOCNS) CC [MIM:619841]: A disorder characterized by developmental delay, CC intellectual disability, hypotonia, and structural brain abnormalities CC including cerebellar vermis hypoplasia and agenesis or hypoplasia of CC the corpus callosum. Most patients have behavioral abnormalities, CC including autism spectrum disorder, attention deficit and hyperactivity CC disorder, and aggression. About half of patients have dysmorphic facial CC features. Rare involvement of other organ systems may be present. CC {ECO:0000269|PubMed:32031333}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. DMPK subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH47871.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305}; CC Sequence=BAA86438.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF128625; AAD37506.1; -; mRNA. DR EMBL; AB032950; BAA86438.2; ALT_INIT; mRNA. DR EMBL; DQ355971; ABC67469.1; -; Genomic_DNA. DR EMBL; BC047871; AAH47871.1; ALT_SEQ; mRNA. DR EMBL; BC155541; AAI55542.1; -; mRNA. DR CCDS; CCDS9978.1; -. DR RefSeq; NP_006026.3; NM_006035.3. DR PDB; 3QFV; X-ray; 2.65 A; A/B=1-415. DR PDB; 3TKU; X-ray; 2.15 A; A/B=2-417. DR PDB; 4UAK; X-ray; 1.73 A; A=2-417. DR PDB; 4UAL; X-ray; 1.71 A; A=2-417. DR PDB; 5OTE; X-ray; 1.68 A; A=2-417. DR PDB; 5OTF; X-ray; 2.00 A; A=2-417. DR PDBsum; 3QFV; -. DR PDBsum; 3TKU; -. DR PDBsum; 4UAK; -. DR PDBsum; 4UAL; -. DR PDBsum; 5OTE; -. DR PDBsum; 5OTF; -. DR AlphaFoldDB; Q9Y5S2; -. DR SMR; Q9Y5S2; -. DR BioGRID; 114947; 127. DR FunCoup; Q9Y5S2; 1147. DR MINT; Q9Y5S2; -. DR STRING; 9606.ENSP00000355237; -. DR BindingDB; Q9Y5S2; -. DR ChEMBL; CHEMBL5052; -. DR DrugCentral; Q9Y5S2; -. DR GlyGen; Q9Y5S2; 2 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; Q9Y5S2; -. DR MetOSite; Q9Y5S2; -. DR PhosphoSitePlus; Q9Y5S2; -. DR SwissPalm; Q9Y5S2; -. DR BioMuta; CDC42BPB; -. DR DMDM; 92090617; -. DR CPTAC; CPTAC-2986; -. DR CPTAC; non-CPTAC-2985; -. DR CPTAC; non-CPTAC-5628; -. DR CPTAC; non-CPTAC-5629; -. DR jPOST; Q9Y5S2; -. DR MassIVE; Q9Y5S2; -. DR PaxDb; 9606-ENSP00000355237; -. DR PeptideAtlas; Q9Y5S2; -. DR ProteomicsDB; 86490; -. DR Pumba; Q9Y5S2; -. DR Antibodypedia; 14692; 175 antibodies from 28 providers. DR DNASU; 9578; -. DR Ensembl; ENST00000361246.7; ENSP00000355237.2; ENSG00000198752.12. DR GeneID; 9578; -. DR KEGG; hsa:9578; -. DR MANE-Select; ENST00000361246.7; ENSP00000355237.2; NM_006035.4; NP_006026.3. DR UCSC; uc001ymi.2; human. DR AGR; HGNC:1738; -. DR ClinPGx; PA26268; -. DR CTD; 9578; -. DR DisGeNET; 9578; -. DR GeneCards; CDC42BPB; -. DR HGNC; HGNC:1738; CDC42BPB. DR HPA; ENSG00000198752; Low tissue specificity. DR MalaCards; CDC42BPB; -. DR MIM; 614062; gene. DR MIM; 619841; phenotype. DR OpenTargets; ENSG00000198752; -. DR VEuPathDB; HostDB:ENSG00000198752; -. DR eggNOG; KOG0612; Eukaryota. DR GeneTree; ENSGT01030000234517; -. DR HOGENOM; CLU_000288_140_3_1; -. DR InParanoid; Q9Y5S2; -. DR OMA; ELEALKX; -. DR OrthoDB; 10047816at2759; -. DR PAN-GO; Q9Y5S2; 6 GO annotations based on evolutionary models. DR PhylomeDB; Q9Y5S2; -. DR PathwayCommons; Q9Y5S2; -. DR Reactome; R-HSA-9013148; CDC42 GTPase cycle. DR Reactome; R-HSA-9013406; RHOQ GTPase cycle. DR Reactome; R-HSA-9013409; RHOJ GTPase cycle. DR SignaLink; Q9Y5S2; -. DR SIGNOR; Q9Y5S2; -. DR Agora; ENSG00000198752; -. DR BioGRID-ORCS; 9578; 15 hits in 1188 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; CDC42BPB; human. DR EvolutionaryTrace; Q9Y5S2; -. DR GenomeRNAi; 9578; -. DR Pharos; Q9Y5S2; Tchem. DR PRO; PR:Q9Y5S2; -. DR Proteomes; UP000005640; Chromosome 14. DR RNAct; Q9Y5S2; protein. DR Bgee; ENSG00000198752; Expressed in stromal cell of endometrium and 186 other cell types or tissues. DR ExpressionAtlas; Q9Y5S2; baseline and differential. DR GO; GO:0042641; C:actomyosin; IDA:UniProtKB. DR GO; GO:0031252; C:cell leading edge; ISS:UniProtKB. DR GO; GO:0005911; C:cell-cell junction; ISS:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005856; C:cytoskeleton; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0030027; C:lamellipodium; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005524; F:ATP binding; ISS:UniProtKB. DR GO; GO:0000287; F:magnesium ion binding; ISS:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; ISS:UniProtKB. DR GO; GO:0044877; F:protein-containing complex binding; IPI:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0030036; P:actin cytoskeleton organization; ISS:UniProtKB. DR GO; GO:0031032; P:actomyosin structure organization; IMP:UniProtKB. DR GO; GO:0016477; P:cell migration; IMP:UniProtKB. DR GO; GO:0007010; P:cytoskeleton organization; TAS:ProtInc. DR GO; GO:0007163; P:establishment or maintenance of cell polarity; TAS:ProtInc. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR CDD; cd20865; C1_MRCKbeta; 1. DR CDD; cd00132; CRIB; 1. DR CDD; cd01243; PH_MRCK; 1. DR CDD; cd05624; STKc_MRCK_beta; 1. DR FunFam; 2.30.29.30:FF:000140; CDC42 binding protein kinase beta; 1. DR FunFam; 1.10.510.10:FF:000014; Non-specific serine/threonine protein kinase; 1. DR FunFam; 1.20.5.340:FF:000010; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.60.20:FF:000005; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.200.20:FF:001044; Serine/threonine-protein kinase MRCK beta; 1. DR FunFam; 3.30.200.20:FF:001209; Serine/threonine-protein kinase MRCK beta; 1. DR Gene3D; 1.20.5.340; -; 1. DR Gene3D; 3.30.60.20; -; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR001180; CNH_dom. DR InterPro; IPR000095; CRIB_dom. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR031597; KELK. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR057529; MRCK/ROCK_PH. DR InterPro; IPR042718; MRCKB_STKc. DR InterPro; IPR014930; Myotonic_dystrophy_kinase_coil. DR InterPro; IPR011993; PH-like_dom_sf. DR InterPro; IPR001849; PH_domain. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050839; Rho-assoc_Ser/Thr_Kinase. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR22988; MYOTONIC DYSTROPHY S/T KINASE-RELATED; 1. DR PANTHER; PTHR22988:SF34; SERINE_THREONINE-PROTEIN KINASE MRCK BETA; 1. DR Pfam; PF00130; C1_1; 1. DR Pfam; PF00780; CNH; 1. DR Pfam; PF08826; DMPK_coil; 1. DR Pfam; PF15796; KELK; 1. DR Pfam; PF25346; PH_MRCK; 1. DR Pfam; PF00069; Pkinase; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 1. DR SMART; SM00036; CNH; 1. DR SMART; SM00285; PBD; 1. DR SMART; SM00233; PH; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 1. DR SUPFAM; SSF50729; PH domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50219; CNH; 1. DR PROSITE; PS50108; CRIB; 1. DR PROSITE; PS50003; PH_DOMAIN; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 1. DR PROSITE; PS50081; ZF_DAG_PE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Cell junction; Cell membrane; Cell projection; KW Coiled coil; Cytoplasm; Disease variant; Intellectual disability; Kinase; KW Magnesium; Membrane; Metal-binding; Methylation; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger. FT CHAIN 1..1711 FT /note="Serine/threonine-protein kinase MRCK beta" FT /id="PRO_0000086394" FT DOMAIN 76..342 FT /note="Protein kinase" FT /evidence="ECO:0000250|UniProtKB:Q5VT25, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 343..413 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT DOMAIN 1095..1214 FT /note="PH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00145" FT DOMAIN 1240..1513 FT /note="CNH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00795" FT DOMAIN 1583..1596 FT /note="CRIB" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00057" FT ZN_FING 1025..1075 FT /note="Phorbol-ester/DAG-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 461..484 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 969..1009 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1611..1711 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 431..815 FT /evidence="ECO:0000255" FT COILED 878..939 FT /evidence="ECO:0000255" FT COMPBIAS 463..481 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1641..1650 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1664..1675 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 200 FT /note="Proton acceptor" FT /evidence="ECO:0000250|UniProtKB:P54265, FT ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE- FT ProRule:PRU10027" FT BINDING 82..90 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:P54265, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 105 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:Q5VT25, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 221 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 233 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 239 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 423 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 671 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 954 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:Q7TT50" FT MOD_RES 1680 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 1682 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 1686 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 1690 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 1693 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT VARIANT 142 FT /note="A -> T (in CHOCNS; uncertain significance; FT dbSNP:rs1198710710)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087124" FT VARIANT 175 FT /note="D -> Y (in CHOCNS; uncertain significance; FT dbSNP:rs1595127294)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087125" FT VARIANT 293 FT /note="I -> M (in CHOCNS; uncertain significance; FT dbSNP:rs1016320330)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087126" FT VARIANT 500 FT /note="K -> E (in a breast infiltrating ductal carcinoma FT sample; somatic mutation; dbSNP:rs1158962067)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040834" FT VARIANT 555 FT /note="R -> Q (in dbSNP:rs36001612)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040835" FT VARIANT 671 FT /note="R -> Q (in dbSNP:rs55948035)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040836" FT VARIANT 764..1711 FT /note="Missing (in CHOCNS)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087127" FT VARIANT 867 FT /note="R -> C (in CHOCNS; dbSNP:rs1595472764)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087128" FT VARIANT 871 FT /note="L -> P (in CHOCNS; uncertain significance; FT dbSNP:rs1595472756)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087129" FT VARIANT 876 FT /note="R -> P (in CHOCNS; dbSNP:rs1595472739)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087130" FT VARIANT 876 FT /note="R -> W (in a colorectal adenocarcinoma sample and FT CHOCNS; somatic mutation; dbSNP:rs1595472741)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:32031333" FT /id="VAR_040837" FT VARIANT 1077 FT /note="I -> V (in dbSNP:rs34822377)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_025847" FT VARIANT 1203 FT /note="R -> K (in dbSNP:rs146298297)" FT /evidence="ECO:0000269|PubMed:10574461, FT ECO:0000269|PubMed:15489334" FT /id="VAR_070886" FT VARIANT 1299 FT /note="R -> Q (in CHOCNS; uncertain significance; FT dbSNP:rs1595450393)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087131" FT VARIANT 1315 FT /note="E -> K (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040838" FT VARIANT 1350 FT /note="R -> P (in CHOCNS; uncertain significance; FT dbSNP:rs1595450125)" FT /evidence="ECO:0000269|PubMed:32031333" FT /id="VAR_087132" FT VARIANT 1633 FT /note="S -> Y (in dbSNP:rs56412851)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040839" FT CONFLICT 1017 FT /note="A -> V (in Ref. 1; AAD37506)" FT /evidence="ECO:0000305" FT CONFLICT 1123 FT /note="D -> E (in Ref. 1; AAD37506)" FT /evidence="ECO:0000305" FT HELIX 3..20 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 21..23 FT /evidence="ECO:0007829|PDB:3QFV" FT HELIX 27..41 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 44..47 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 50..69 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 73..75 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 76..84 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 86..95 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 101..108 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 109..114 FT /evidence="ECO:0007829|PDB:5OTE" FT TURN 115..118 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 121..130 FT /evidence="ECO:0007829|PDB:5OTE" FT TURN 133..135 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 139..144 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 146..153 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 161..167 FT /evidence="ECO:0007829|PDB:5OTE" FT TURN 168..170 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 174..193 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 203..205 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 206..208 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 214..216 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 223..225 FT /evidence="ECO:0007829|PDB:5OTF" FT STRAND 227..229 FT /evidence="ECO:0007829|PDB:3QFV" FT STRAND 231..235 FT /evidence="ECO:0007829|PDB:3TKU" FT HELIX 240..242 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 245..250 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 255..258 FT /evidence="ECO:0007829|PDB:3TKU" FT HELIX 261..276 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 286..294 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 296..299 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 311..318 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 324..326 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 330..333 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 334..337 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 340..342 FT /evidence="ECO:0007829|PDB:5OTE" FT TURN 347..349 FT /evidence="ECO:0007829|PDB:5OTE" FT HELIX 350..352 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 362..365 FT /evidence="ECO:0007829|PDB:4UAK" FT HELIX 396..398 FT /evidence="ECO:0007829|PDB:5OTE" FT STRAND 403..406 FT /evidence="ECO:0007829|PDB:3QFV" FT STRAND 408..412 FT /evidence="ECO:0007829|PDB:3QFV" SQ SEQUENCE 1711 AA; 194315 MW; 041A009E0273ABE0 CRC64; MSAKVRLKKL EQLLLDGPWR NESALSVETL LDVLVCLYTE CSHSALRRDK YVAEFLEWAK PFTQLVKEMQ LHREDFEIIK VIGRGAFGEV AVVKMKNTER IYAMKILNKW EMLKRAETAC FREERDVLVN GDCQWITALH YAFQDENHLY LVMDYYVGGD LLTLLSKFED KLPEDMARFY IGEMVLAIDS IHQLHYVHRD IKPDNVLLDV NGHIRLADFG SCLKMNDDGT VQSSVAVGTP DYISPEILQA MEDGMGKYGP ECDWWSLGVC MYEMLYGETP FYAESLVETY GKIMNHEERF QFPSHVTDVS EEAKDLIQRL ICSRERRLGQ NGIEDFKKHA FFEGLNWENI RNLEAPYIPD VSSPSDTSNF DVDDDVLRNT EILPPGSHTG FSGLHLPFIG FTFTTESCFS DRGSLKSIMQ SNTLTKDEDV QRDLEHSLQM EAYERRIRRL EQEKLELSRK LQESTQTVQS LHGSSRALSN SNRDKEIKKL NEEIERLKNK IADSNRLERQ LEDTVALRQE REDSTQRLRG LEKQHRVVRQ EKEELHKQLV EASERLKSQA KELKDAHQQR KLALQEFSEL NERMAELRAQ KQKVSRQLRD KEEEMEVATQ KVDAMRQEMR RAEKLRKELE AQLDDAVAEA SKERKLREHS ENFCKQMESE LEALKVKQGG RGAGATLEHQ QEISKIKSEL EKKVLFYEEE LVRREASHVL EVKNVKKEVH DSESHQLALQ KEILMLKDKL EKSKRERHNE MEEAVGTIKD KYERERAMLF DENKKLTAEN EKLCSFVDKL TAQNRQLEDE LQDLAAKKES VAHWEAQIAE IIQWVSDEKD ARGYLQALAS KMTEELEALR SSSLGSRTLD PLWKVRRSQK LDMSARLELQ SALEAEIRAK QLVQEELRKV KDANLTLESK LKDSEAKNRE LLEEMEILKK KMEEKFRADT GLKLPDFQDS IFEYFNTAPL AHDLTFRTSS ASEQETQAPK PEASPSMSVA ASEQQEDMAR PPQRPSAVPL PTTQALALAG PKPKAHQFSI KSFSSPTQCS HCTSLMVGLI RQGYACEVCS FACHVSCKDG APQVCPIPPE QSKRPLGVDV QRGIGTAYKG HVKVPKPTGV KKGWQRAYAV VCDCKLFLYD LPEGKSTQPG VIASQVLDLR DDEFSVSSVL ASDVIHATRR DIPCIFRVTA SLLGAPSKTS SLLILTENEN EKRKWVGILE GLQSILHKNR LRNQVVHVPL EAYDSSLPLI KAILTAAIVD ADRIAVGLEE GLYVIEVTRD VIVRAADCKK VHQIELAPRE KIVILLCGRN HHVHLYPWSS LDGAEGSFDI KLPETKGCQL MATATLKRNS GTCLFVAVKR LILCYEIQRT KPFHRKFNEI VAPGSVQCLA VLRDRLCVGY PSGFCLLSIQ GDGQPLNLVN PNDPSLAFLS QQSFDALCAV ELESEEYLLC FSHMGLYVDP QGRRARAQEL MWPAAPVACS CSPTHVTVYS EYGVDVFDVR TMEWVQTIGL RRIRPLNSEG TLNLLNCEPP RLIYFKSKFS GAVLNVPDTS DNSKKQMLRT RSKRRFVFKV PEEERLQQRR EMLRDPELRS KMISNPTNFN HVAHMGPGDG MQVLMDLPLS AVPPSQEERP GPAPTNLARQ PPSRNKPYIS WPSSGGSEPS VTVPLRSMSD PDQDFDKEPD SDSTKHSTPS NSSNPSGPPS PNSPHRSQLP LEGLEQPACD T // ID MSMB_HUMAN Reviewed; 114 AA. AC P08118; B1API6; P11999; Q13125; Q6IAY9; Q9UC59; DT 01-AUG-1988, integrated into UniProtKB/Swiss-Prot. DT 01-AUG-1988, sequence version 1. DT 28-JAN-2026, entry version 207. DE RecName: Full=Beta-microseminoprotein; DE AltName: Full=Immunoglobulin-binding factor; DE Short=IGBF; DE AltName: Full=PN44; DE AltName: Full=Prostate secreted seminal plasma protein; DE AltName: Full=Prostate secretory protein of 94 amino acids; DE Short=PSP-94; DE Short=PSP94; DE AltName: Full=Seminal plasma beta-inhibin; DE Flags: Precursor; GN Name=MSMB; Synonyms=PRSP; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PSP94). RX PubMed=3829888; DOI=10.1089/dna.1987.6.23; RA Mbikay M., Nolet S., Fournier S., Benjannet S., Chapdelaine P., Paradis G., RA Dube J.Y., Tremblay R., Lazure C., Seidah N.G., Chretien M.; RT "Molecular cloning and sequence of the cDNA for a 94-amino-acid seminal RT plasma protein secreted by the human prostate."; RL DNA 6:23-29(1987). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PSP94). RX PubMed=2590204; DOI=10.1016/0006-291x(89)91812-3; RA Ulvsbaeck M., Lindstroem C., Weiber H., Abrahamsson P.-A., Lilja H., RA Lundwall A.; RT "Molecular cloning of a small prostate protein, known as beta- RT microseminoprotein, PSP94 or beta-inhibin, and demonstration of transcripts RT in non-genital tissues."; RL Biochem. Biophys. Res. Commun. 164:1310-1315(1989). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=2322265; DOI=10.1016/0006-291x(90)90648-7; RA Green C.B., Liu W.Y., Kwok S.C.M.; RT "Cloning and nucleotide sequence analysis of the human beta- RT microseminoprotein gene."; RL Biochem. Biophys. Res. Commun. 167:1184-1190(1990). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=2054385; DOI=10.1016/0167-4781(91)90016-f; RA Nolet S., Mbikay M., Chretien M.; RT "Prostatic secretory protein PSP94: gene organization and promoter sequence RT in rhesus monkey and human."; RL Biochim. Biophys. Acta 1089:247-249(1991). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PSP94). RC TISSUE=Prostate; RX PubMed=7506990; DOI=10.1016/0304-3835(93)90049-f; RA Liu A.Y., Bradner R.C., Vessella R.L.; RT "Decreased expression of prostatic secretory protein PSP94 in prostate RT cancer."; RL Cancer Lett. 74:91-99(1993). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PSP57), AND TISSUE SPECIFICITY. RC TISSUE=Prostate; RX PubMed=7566962; RA Xuan J.W., Chin J.L., Guo Y., Chambers A.F., Finkelman M.A., Clarke M.W.; RT "Alternative splicing of PSP94 (prostatic secretory protein of 94 amino RT acids) mRNA in prostate tissue."; RL Oncogene 11:1041-1047(1995). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PSP94). RA Baijal-Gupta M., Clarke M.W.; RT "Prostate specific protein (PSP94) expression in a human endometrial cell RT line (KLE)."; RL Submitted (DEC-1996) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM PSP94). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM PSP94). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164054; DOI=10.1038/nature02462; RA Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L., RA Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K., RA Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L., RA Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P., RA Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P., RA Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N., RA Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A., RA Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C., RA Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D., RA Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C., RA Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K., RA Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A., RA Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S., RA McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S., RA Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., RA Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., RA Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M., RA Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A., RA Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P., RA Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y., RA Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D., RA Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 10."; RL Nature 429:375-381(2004). RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM PSP94). RC TISSUE=Prostate; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 2-72. RX PubMed=10491085; DOI=10.1046/j.1432-1327.1999.00614.x; RA Maekinen M., Valtonen-Andre C., Lundwall A.; RT "New world, but not old world, monkeys carry several genes encoding beta- RT microseminoprotein."; RL Eur. J. Biochem. 264:407-414(1999). RN [13] RP PROTEIN SEQUENCE OF 21-113. RX PubMed=3995056; DOI=10.1016/0167-4838(85)90200-6; RA Akiyama K., Yoshioka Y., Schmid K., Offner G.D., Troxler R.F., Tsuda R., RA Hara M.; RT "The amino acid sequence of human beta-microseminoprotein."; RL Biochim. Biophys. Acta 829:288-294(1985). RN [14] RP PROTEIN SEQUENCE OF 21-114. RX PubMed=6434350; DOI=10.1016/0014-5793(84)80766-8; RA Seidah N.G., Arbatti N.J., Rochemont J., Sheth A.R., Chretien M.; RT "Complete amino acid sequence of human seminal plasma beta-inhibin. RT Prediction of post Gln-Arg cleavage as a maturation site."; RL FEBS Lett. 175:349-355(1984). RN [15] RP PROTEIN SEQUENCE OF 21-50 AND 113-114. RX PubMed=1930232; DOI=10.1016/s0006-291x(05)81300-2; RA Liang Z.G., Kamada M., Koide S.S.; RT "Structural identity of immunoglobulin binding factor and prostatic RT secretory protein of human seminal plasma."; RL Biochem. Biophys. Res. Commun. 180:356-359(1991). RN [16] RP PROTEIN SEQUENCE OF 21-41, AND TISSUE SPECIFICITY. RC TISSUE=Semen; RX PubMed=7671139; DOI=10.1016/1357-2725(95)00021-g; RA Ohkubo I., Tada T., Ochiai Y., Ueyama H., Eimoto T., Sasaki M.; RT "Human seminal plasma beta-microseminoprotein: its purification, RT characterization, and immunohistochemical localization."; RL Int. J. Biochem. Cell Biol. 27:603-611(1995). RN [17] RP PROTEIN SEQUENCE OF 21-32. RX PubMed=11788998; RX DOI=10.1002/1615-9861(200201)2:1<112::aid-prot112>3.3.co;2-e; RA Ghafouri B., Stahlbom B., Tagesson C., Lindahl M.; RT "Newly identified proteins in human nasal lavage fluid from non-smokers and RT smokers using two-dimensional gel electrophoresis and peptide mass RT fingerprinting."; RL Proteomics 2:112-120(2002). RN [18] RP INTERACTION WITH PI16. RX PubMed=15344909; DOI=10.1042/bj20040290; RA Reeves J.R., Xuan J.W., Arfanis K., Morin C., Garde S.V., Ruiz M.T., RA Wisniewski J., Panchal C., Tanner J.E.; RT "Identification, purification and characterization of a novel human blood RT protein with binding affinity for prostate secretory protein of 94 amino RT acids."; RL Biochem. J. 385:105-114(2005). RN [19] RP INVOLVEMENT IN SUSCEPTIBILITY TO HEREDITARY PROSTATE CANCER. RX PubMed=18264096; DOI=10.1038/ng.91; RA Thomas G., Jacobs K.B., Yeager M., Kraft P., Wacholder S., Orr N., Yu K., RA Chatterjee N., Welch R., Hutchinson A., Crenshaw A., Cancel-Tassin G., RA Staats B.J., Wang Z., Gonzalez-Bosquet J., Fang J., Deng X., Berndt S.I., RA Calle E.E., Feigelson H.S., Thun M.J., Rodriguez C., Albanes D., RA Virtamo J., Weinstein S., Schumacher F.R., Giovannucci E., Willett W.C., RA Cussenot O., Valeri A., Andriole G.L., Crawford E.D., Tucker M., RA Gerhard D.S., Fraumeni J.F. Jr., Hoover R., Hayes R.B., Hunter D.J., RA Chanock S.J.; RT "Multiple loci identified in a genome-wide association study of prostate RT cancer."; RL Nat. Genet. 40:310-315(2008). RN [20] RP INVOLVEMENT IN SUSCEPTIBILITY TO HEREDITARY PROSTATE CANCER. RX PubMed=22887727; DOI=10.1002/humu.22176; RA Fitzgerald L.M., Zhang X., Kolb S., Kwon E.M., Liew Y.C., Hurtado-Coll A., RA Knudsen B.S., Ostrander E.A., Stanford J.L.; RT "Investigation of the relationship between prostate cancer and MSMB and RT NCOA4 genetic variants and protein expression."; RL Hum. Mutat. 34:149-156(2013). RN [21] RP STRUCTURE BY NMR OF 21-114, AND DISULFIDE BONDS. RX PubMed=16930619; DOI=10.1016/j.jmb.2006.07.029; RA Ghasriani H., Teilum K., Johnsson Y., Fernlund P., Drakenberg T.; RT "Solution structures of human and porcine beta-microseminoprotein."; RL J. Mol. Biol. 362:502-515(2006). RN [22] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 21-114, SUBUNIT, AND DISULFIDE RP BONDS. RX PubMed=20184897; DOI=10.1016/j.jmb.2010.02.035; RA Kumar A., Jagtap D.D., Mahale S.D., Kumar M.; RT "Crystal structure of prostate secretory protein PSP94 shows an edge-to- RT edge association of two monomers to form a homodimer."; RL J. Mol. Biol. 397:947-956(2010). CC -!- SUBUNIT: Homodimer; Interacts with PI16. {ECO:0000269|PubMed:15344909, CC ECO:0000269|PubMed:20184897}. CC -!- INTERACTION: CC P08118; O43765: SGTA; NbExp=3; IntAct=EBI-10195681, EBI-347996; CC -!- SUBCELLULAR LOCATION: Secreted. Note=Sperm surface. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=PSP94; CC IsoId=P08118-1; Sequence=Displayed; CC Name=PSP57; CC IsoId=P08118-2; Sequence=VSP_003275, VSP_003276; CC -!- TISSUE SPECIFICITY: Strongly expressed in prostate, liver, kidney, CC breast and penis. Also expressed in pancreas, esophagus, stomach, CC deodenum, colon, trachea, lung, salivary glands and fallopian tube. CC PSP94 is expressed in lung and breast, whereas PSP57 is found in kidney CC and bladder. {ECO:0000269|PubMed:7566962, ECO:0000269|PubMed:7671139}. CC -!- DISEASE: Prostate cancer, hereditary, 13 (HPC13) [MIM:611928]: A CC condition associated with familial predisposition to cancer of the CC prostate. Most prostate cancers are adenocarcinomas that develop in the CC acini of the prostatic ducts. Other rare histopathologic types of CC prostate cancer that occur in approximately 5% of patients include CC small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, CC transitional cell carcinoma, squamous cell carcinoma, basal cell CC carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. Note=Disease susceptibility is CC associated with variants affecting the gene represented in this entry. CC -!- MISCELLANEOUS: Specific receptors for this protein are found on CC spermatozoa and in the prostate. CC -!- SIMILARITY: Belongs to the beta-microseminoprotein family. CC {ECO:0000305}. CC -!- CAUTION: Was originally thought to inhibit the secretion of FSH by CC pituitary cells. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M15885; AAA36635.1; -; mRNA. DR EMBL; M34376; AAA59871.1; -; Genomic_DNA. DR EMBL; M34373; AAA59871.1; JOINED; Genomic_DNA. DR EMBL; M34374; AAA59871.1; JOINED; Genomic_DNA. DR EMBL; M34375; AAA59871.1; JOINED; Genomic_DNA. DR EMBL; X57928; CAA41002.1; -; Genomic_DNA. DR EMBL; X57929; CAA41002.1; JOINED; Genomic_DNA. DR EMBL; X57930; CAA41002.1; JOINED; Genomic_DNA. DR EMBL; X57931; CAA41002.1; JOINED; Genomic_DNA. DR EMBL; S67815; AAB29732.1; -; mRNA. DR EMBL; U22178; AAA83556.1; -; mRNA. DR EMBL; U78976; AAB37355.1; -; mRNA. DR EMBL; BT006816; AAP35462.1; -; mRNA. DR EMBL; CR457015; CAG33296.1; -; mRNA. DR EMBL; AL450342; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC005257; AAH05257.1; -; mRNA. DR EMBL; AJ133356; CAB39325.1; -; Genomic_DNA. DR CCDS; CCDS73095.1; -. [P08118-2] DR CCDS; CCDS73096.1; -. [P08118-1] DR PIR; A34567; A34567. DR PIR; G01730; G01730. DR RefSeq; NP_002434.1; NM_002443.4. [P08118-1] DR RefSeq; NP_619540.1; NM_138634.3. [P08118-2] DR PDB; 2IZ3; NMR; -; A=21-114. DR PDB; 3IX0; X-ray; 2.30 A; A/B/C/D=21-114. DR PDBsum; 2IZ3; -. DR PDBsum; 3IX0; -. DR AlphaFoldDB; P08118; -. DR BMRB; P08118; -. DR SMR; P08118; -. DR BioGRID; 110583; 65. DR FunCoup; P08118; 65. DR IntAct; P08118; 36. DR MINT; P08118; -. DR STRING; 9606.ENSP00000463092; -. DR iPTMnet; P08118; -. DR PhosphoSitePlus; P08118; -. DR BioMuta; MSMB; -. DR DMDM; 131436; -. DR MassIVE; P08118; -. DR PaxDb; 9606-ENSP00000463092; -. DR PeptideAtlas; P08118; -. DR ProteomicsDB; 52068; -. [P08118-1] DR ProteomicsDB; 52069; -. [P08118-2] DR Antibodypedia; 72459; 774 antibodies from 31 providers. DR DNASU; 4477; -. DR Ensembl; ENST00000581478.5; ENSP00000462641.1; ENSG00000263639.7. [P08118-2] DR Ensembl; ENST00000582163.3; ENSP00000463092.1; ENSG00000263639.7. [P08118-1] DR GeneID; 4477; -. DR KEGG; hsa:4477; -. DR MANE-Select; ENST00000582163.3; ENSP00000463092.1; NM_002443.4; NP_002434.1. DR UCSC; uc001jiq.5; human. [P08118-1] DR AGR; HGNC:7372; -. DR ClinPGx; PA31177; -. DR CTD; 4477; -. DR DisGeNET; 4477; -. DR GeneCards; MSMB; -. DR HGNC; HGNC:7372; MSMB. DR HPA; ENSG00000263639; Tissue enriched (prostate). DR MalaCards; MSMB; -. DR MIM; 157145; gene. DR MIM; 611928; phenotype. DR OpenTargets; ENSG00000263639; -. DR Orphanet; 1331; Familial prostate cancer. DR VEuPathDB; HostDB:ENSG00000263639; -. DR eggNOG; ENOG502SF48; Eukaryota. DR GeneTree; ENSGT00940000154371; -. DR HOGENOM; CLU_2637379_0_0_1; -. DR InParanoid; P08118; -. DR OMA; ETEIICC; -. DR OrthoDB; 6076852at2759; -. DR PAN-GO; P08118; 0 GO annotations based on evolutionary models. DR PhylomeDB; P08118; -. DR PathwayCommons; P08118; -. DR SignaLink; P08118; -. DR Agora; ENSG00000263639; -. DR BioGRID-ORCS; 4477; 20 hits in 1133 CRISPR screens. DR ChiTaRS; MSMB; human. DR EvolutionaryTrace; P08118; -. DR GeneWiki; MSMB; -. DR GenomeRNAi; 4477; -. DR Pharos; P08118; Tbio. DR PRO; PR:P08118; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; P08118; protein. DR Bgee; ENSG00000263639; Expressed in trachea and 123 other cell types or tissues. DR ExpressionAtlas; P08118; baseline and differential. DR GO; GO:0005615; C:extracellular space; TAS:ProtInc. DR GO; GO:0005634; C:nucleus; TAS:ProtInc. DR FunFam; 2.10.70.10:FF:000137; Beta-microseminoprotein; 1. DR FunFam; 2.20.25.590:FF:000001; Beta-microseminoprotein; 1. DR Gene3D; 2.20.25.590; -; 1. DR Gene3D; 2.10.70.10; Complement Module, domain 1; 1. DR InterPro; IPR008735; PSP94. DR PANTHER; PTHR10500; BETA-MICROSEMINOPROTEIN; 1. DR PANTHER; PTHR10500:SF8; BETA-MICROSEMINOPROTEIN; 1. DR Pfam; PF05825; PSP94; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Direct protein sequencing; KW Disulfide bond; Proteomics identification; Reference proteome; Secreted; KW Signal. FT SIGNAL 1..20 FT /evidence="ECO:0000269|PubMed:11788998, FT ECO:0000269|PubMed:1930232, ECO:0000269|PubMed:3995056, FT ECO:0000269|PubMed:6434350, ECO:0000269|PubMed:7671139" FT CHAIN 21..114 FT /note="Beta-microseminoprotein" FT /id="PRO_0000019268" FT DISULFID 22..70 FT /evidence="ECO:0000269|PubMed:20184897" FT DISULFID 38..62 FT /evidence="ECO:0000269|PubMed:20184897" FT DISULFID 57..93 FT /evidence="ECO:0000269|PubMed:20184897" FT DISULFID 60..69 FT /evidence="ECO:0000269|PubMed:20184897" FT DISULFID 84..107 FT VAR_SEQ 37..77 FT /note="KCMDLKGNKHPINSEWQTDNCETCTCYETEISCCTLVSTPV -> MFLHLWV FT MTKTTAKESSRRRTASISWWRRRTQKRPVLSVNG (in isoform PSP57)" FT /evidence="ECO:0000303|PubMed:7566962" FT /id="VSP_003275" FT VAR_SEQ 78..114 FT /note="Missing (in isoform PSP57)" FT /evidence="ECO:0000303|PubMed:7566962" FT /id="VSP_003276" FT VARIANT 17 FT /note="L -> S (in dbSNP:rs1804776)" FT /id="VAR_011935" FT VARIANT 25 FT /note="I -> M (in dbSNP:rs1804778)" FT /id="VAR_011936" FT VARIANT 52 FT /note="W -> R (in dbSNP:rs1804780)" FT /id="VAR_011937" FT VARIANT 53 FT /note="Q -> R (in dbSNP:rs1804468)" FT /id="VAR_011938" FT VARIANT 80 FT /note="D -> A (in dbSNP:rs1802774)" FT /id="VAR_011939" FT VARIANT 87 FT /note="I -> T (in dbSNP:rs1802771)" FT /id="VAR_011940" FT VARIANT 91 FT /note="E -> G (in dbSNP:rs1804469)" FT /id="VAR_011941" FT VARIANT 92 FT /note="D -> G (in dbSNP:rs1804461)" FT /id="VAR_011942" FT VARIANT 98 FT /note="V -> L (in dbSNP:rs1804464)" FT /id="VAR_011943" FT CONFLICT 113 FT /note="I -> G (in Ref. 14; AA sequence)" FT /evidence="ECO:0000305" FT STRAND 22..26 FT /evidence="ECO:0007829|PDB:3IX0" FT STRAND 33..35 FT /evidence="ECO:0007829|PDB:3IX0" FT STRAND 51..53 FT /evidence="ECO:0007829|PDB:3IX0" FT STRAND 57..62 FT /evidence="ECO:0007829|PDB:3IX0" FT STRAND 64..71 FT /evidence="ECO:0007829|PDB:3IX0" FT STRAND 75..79 FT /evidence="ECO:0007829|PDB:3IX0" FT TURN 81..83 FT /evidence="ECO:0007829|PDB:3IX0" FT STRAND 84..89 FT /evidence="ECO:0007829|PDB:3IX0" FT HELIX 90..92 FT /evidence="ECO:0007829|PDB:3IX0" FT STRAND 94..101 FT /evidence="ECO:0007829|PDB:3IX0" FT STRAND 110..113 FT /evidence="ECO:0007829|PDB:3IX0" SQ SEQUENCE 114 AA; 12865 MW; D0B13E436D70BB1D CRC64; MNVLLGSVVI FATFVTLCNA SCYFIPNEGV PGDSTRKCMD LKGNKHPINS EWQTDNCETC TCYETEISCC TLVSTPVGYD KDNCQRIFKK EDCKYIVVEK KDPKKTCSVS EWII // ID MTA70_HUMAN Reviewed; 580 AA. AC Q86U44; O14736; Q86V05; Q9HB32; DT 25-JUL-2003, integrated into UniProtKB/Swiss-Prot. DT 25-JUL-2003, sequence version 2. DT 28-JAN-2026, entry version 179. DE RecName: Full=N(6)-adenosine-methyltransferase catalytic subunit METTL3 {ECO:0000305}; DE EC=2.1.1.348 {ECO:0000269|PubMed:27281194, ECO:0000269|PubMed:27373337, ECO:0000269|PubMed:27627798, ECO:0000269|PubMed:29348140, ECO:0000269|PubMed:29506078, ECO:0000269|PubMed:9409616}; DE AltName: Full=Methyltransferase-like protein 3 {ECO:0000305}; DE Short=hMETTL3 {ECO:0000303|PubMed:27373337}; DE AltName: Full=N(6)-adenosine-methyltransferase 70 kDa subunit; DE Short=MT-A70; GN Name=METTL3 {ECO:0000312|HGNC:HGNC:17563}; Synonyms=MTA70; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), PROTEIN SEQUENCE OF 48-56; RP 134-149 AND 509-522, FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, RP AND CATALYTIC ACTIVITY. RX PubMed=9409616; RA Bokar J.A., Shambaugh M.E., Polayes D., Matera A.G., Rottman F.M.; RT "Purification and cDNA cloning of the AdoMet-binding subunit of the human RT mRNA (N6-adenosine)-methyltransferase."; RL RNA 3:1233-1247(1997). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Placenta; RA Li W.B., Gruber C., Jessee J., Polayes D.; RT "Full-length cDNA libraries and normalization."; RL Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12508121; DOI=10.1038/nature01348; RA Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C., RA Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A., RA Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H., RA Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T., RA Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B., RA Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D., RA Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R., RA Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S., RA Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C., RA Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S., RA Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., RA Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., RA Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M., RA Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V., RA Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J., RA Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F., RA Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F., RA Waterston R., Hood L., Weissenbach J.; RT "The DNA sequence and analysis of human chromosome 14."; RL Nature 421:601-607(2003). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Lung, and Pancreas; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-43, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [6] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [7] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-43; SER-219 AND SER-243, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [8] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-43, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [12] RP FUNCTION. RX PubMed=22575960; DOI=10.1038/nature11112; RA Dominissini D., Moshitch-Moshkovitz S., Schwartz S., Salmon-Divon M., RA Ungar L., Osenberg S., Cesarkas K., Jacob-Hirsch J., Amariglio N., RA Kupiec M., Sorek R., Rechavi G.; RT "Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq."; RL Nature 485:201-206(2012). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-43; SER-219 AND THR-348, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [14] RP IDENTIFICATION IN THE WMM COMPLEX. RX PubMed=24407421; DOI=10.1038/cr.2014.3; RA Ping X.L., Sun B.F., Wang L., Xiao W., Yang X., Wang W.J., Adhikari S., RA Shi Y., Lv Y., Chen Y.S., Zhao X., Li A., Yang Y., Dahal U., Lou X.M., RA Liu X., Huang J., Yuan W.P., Zhu X.F., Cheng T., Zhao Y.L., Wang X., RA Danielsen J.M., Liu F., Yang Y.G.; RT "Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine RT methyltransferase."; RL Cell Res. 24:177-189(2014). RN [15] RP IDENTIFICATION IN THE WMM COMPLEX. RX PubMed=24981863; DOI=10.1016/j.celrep.2014.05.048; RA Schwartz S., Mumbach M.R., Jovanovic M., Wang T., Maciag K., Bushkin G.G., RA Mertins P., Ter-Ovanesyan D., Habib N., Cacchiarelli D., Sanjana N.E., RA Freinkman E., Pacold M.E., Satija R., Mikkelsen T.S., Hacohen N., Zhang F., RA Carr S.A., Lander E.S., Regev A.; RT "Perturbation of m6A writers reveals two distinct classes of mRNA RT methylation at internal and 5' sites."; RL Cell Rep. 8:284-296(2014). RN [16] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [17] RP FUNCTION. RX PubMed=24284625; DOI=10.1038/nature12730; RA Wang X., Lu Z., Gomez A., Hon G.C., Yue Y., Han D., Fu Y., Parisien M., RA Dai Q., Jia G., Ren B., Pan T., He C.; RT "N-methyladenosine-dependent regulation of messenger RNA stability."; RL Nature 505:117-120(2014). RN [18] RP FUNCTION. RX PubMed=25719671; DOI=10.1038/nature14234; RA Liu N., Dai Q., Zheng G., He C., Parisien M., Pan T.; RT "N(6)-methyladenosine-dependent RNA structural switches regulate RNA- RT protein interactions."; RL Nature 518:560-564(2015). RN [19] RP FUNCTION, AND MUTAGENESIS OF 395-ASP--TRP-398. RX PubMed=25799998; DOI=10.1038/nature14281; RA Alarcon C.R., Lee H., Goodarzi H., Halberg N., Tavazoie S.F.; RT "N6-methyladenosine marks primary microRNAs for processing."; RL Nature 519:482-485(2015). RN [20] RP FUNCTION. RX PubMed=26321680; DOI=10.1016/j.cell.2015.08.011; RA Alarcon C.R., Goodarzi H., Lee H., Liu X., Tavazoie S., Tavazoie S.F.; RT "HNRNPA2B1 is a mediator of m(6)A-dependent nuclear RNA processing RT events."; RL Cell 162:1299-1308(2015). RN [21] RP FUNCTION. RX PubMed=26593424; DOI=10.1016/j.cell.2015.10.012; RA Meyer K.D., Patil D.P., Zhou J., Zinoviev A., Skabkin M.A., Elemento O., RA Pestova T.V., Qian S.B., Jaffrey S.R.; RT "5' UTR m(6)A promotes cap-independent translation."; RL Cell 163:999-1010(2015). RN [22] RP SUBCELLULAR LOCATION. RX PubMed=26458103; DOI=10.1038/nature15377; RA Zhou J., Wan J., Gao X., Zhang X., Jaffrey S.R., Qian S.B.; RT "Dynamic m(6)A mRNA methylation directs translational control of heat shock RT response."; RL Nature 526:591-594(2015). RN [23] RP FUNCTION, SUBCELLULAR LOCATION, INDUCTION, INTERACTION WITH NCBP1; EIF4E RP AND EIF3B, AND MUTAGENESIS OF 395-ASP--TRP-398. RX PubMed=27117702; DOI=10.1016/j.molcel.2016.03.021; RA Lin S., Choe J., Du P., Triboulet R., Gregory R.I.; RT "The m(6)A methyltransferase METTL3 promotes translation in human cancer RT cells."; RL Mol. Cell 62:335-345(2016). RN [24] RP FUNCTION, AND IDENTIFICATION IN THE WMM COMPLEX. RX PubMed=27602518; DOI=10.1038/nature19342; RA Patil D.P., Chen C.K., Pickering B.F., Chow A., Jackson C., Guttman M., RA Jaffrey S.R.; RT "m(6)A RNA methylation promotes XIST-mediated transcriptional repression."; RL Nature 537:369-373(2016). RN [25] RP FUNCTION. RX PubMed=28637692; DOI=10.1101/gad.301036.117; RA Ke S., Pandya-Jones A., Saito Y., Fak J.J., Vaagboe C.B., Geula S., RA Hanna J.H., Black D.L., Darnell J.E. Jr., Darnell R.B.; RT "m(6)A mRNA modifications are deposited in nascent pre-mRNA and are not RT required for splicing but do specify cytoplasmic turnover."; RL Genes Dev. 31:990-1006(2017). RN [26] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF 395-ASP--TRP-398. RX PubMed=28297716; DOI=10.1038/nature21671; RA Xiang Y., Laurent B., Hsu C.H., Nachtergaele S., Lu Z., Sheng W., Xu C., RA Chen H., Ouyang J., Wang S., Ling D., Hsu P.H., Zou L., Jambhekar A., RA He C., Shi Y.; RT "RNA m(6)A methylation regulates the ultraviolet-induced DNA damage RT response."; RL Nature 543:573-576(2017). RN [27] RP ERRATUM OF PUBMED:28297716. RX PubMed=29186122; DOI=10.1038/nature24007; RA Xiang Y., Laurent B., Hsu C.H., Nachtergaele S., Lu Z., Sheng W., Xu C., RA Chen H., Ouyang J., Wang S., Ling D., Hsu P.H., Zou L., Jambhekar A., RA He C., Shi Y.; RL Nature 552:430-430(2017). RN [28] RP IDENTIFICATION IN THE WMM COMPLEX. RX PubMed=29507755; DOI=10.1038/s41421-018-0019-0; RA Yue Y., Liu J., Cui X., Cao J., Luo G., Zhang Z., Cheng T., Gao M., Shu X., RA Ma H., Wang F., Wang X., Shen B., Wang Y., Feng X., He C., Liu J.; RT "VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop RT codon and associates with alternative polyadenylation."; RL Cell Discov. 4:10-10(2018). RN [29] RP FUNCTION. RX PubMed=30428350; DOI=10.1016/j.celrep.2018.10.068; RA Zhong X., Yu J., Frazier K., Weng X., Li Y., Cham C.M., Dolan K., Zhu X., RA Hubert N., Tao Y., Lin F., Martinez-Guryn K., Huang Y., Wang T., Liu J., RA He C., Chang E.B., Leone V.; RT "Circadian clock regulation of hepatic lipid metabolism by modulation of RT m6A mRNA methylation."; RL Cell Rep. 25:1816-1828(2018). RN [30] RP FUNCTION, SUBCELLULAR LOCATION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, RP IDENTIFICATION IN THE WMM COMPLEX, SUMOYLATION AT LYS-177; LYS-211; LYS-212 RP AND LYS-215, AND MUTAGENESIS OF LYS-177 AND 211-LYS--LYS-215. RX PubMed=29506078; DOI=10.1093/nar/gky156; RA Du Y., Hou G., Zhang H., Dou J., He J., Guo Y., Li L., Chen R., Wang Y., RA Deng R., Huang J., Jiang B., Xu M., Cheng J., Chen G.Q., Zhao X., Yu J.; RT "SUMOylation of the m6A-RNA methyltransferase METTL3 modulates its RT function."; RL Nucleic Acids Res. 46:5195-5208(2018). RN [31] RP FUNCTION, CATALYTIC ACTIVITY, IDENTIFICATION IN THE WMM COMPLEX, RP PHOSPHORYLATION AT SER-2; SER-43; SER-48; SER-50; SER-219; SER-243; THR-348 RP AND SER-350, AND MUTAGENESIS OF SER-2; SER-43; SER-48; SER-50; SER-219; RP SER-243; 211-LYS--LYS-215 AND 348-THR--SER-350. RX PubMed=29348140; DOI=10.1261/rna.064063.117; RA Schoeller E., Weichmann F., Treiber T., Ringle S., Treiber N., Flatley A., RA Feederle R., Bruckmann A., Meister G.; RT "Interactions, localization, and phosphorylation of the m6A generating RT METTL3-METTL14-WTAP complex."; RL RNA 24:499-512(2018). RN [32] RP FUNCTION. RX PubMed=30559377; DOI=10.1038/s41590-018-0275-z; RA Winkler R., Gillis E., Lasman L., Safra M., Geula S., Soyris C., RA Nachshon A., Tai-Schmiedel J., Friedman N., Le-Trilling V.T.K., RA Trilling M., Mandelboim M., Hanna J.H., Schwartz S., Stern-Ginossar N.; RT "m6A modification controls the innate immune response to infection by RT targeting type I interferons."; RL Nat. Immunol. 20:173-182(2019). RN [33] RP FUNCTION. RX PubMed=33961823; DOI=10.1016/j.celrep.2021.109091; RA Li N., Hui H., Bray B., Gonzalez G.M., Zeller M., Anderson K.G., Knight R., RA Smith D., Wang Y., Carlin A.F., Rana T.M.; RT "METTL3 regulates viral m6A RNA modification and host cell innate immune RT responses during SARS-CoV-2 infection."; RL Cell Rep. 35:109091-109091(2021). RN [34] RP X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 354-580 IN COMPLEX WITH METTL14 RP AND S-ADENOSYL-L-METHIONINE, FUNCTION, CATALYTIC ACTIVITY, SUBUNIT, AND RP MUTAGENESIS OF ASP-395; TYR-406; ASN-549 AND GLN-550. RX PubMed=27627798; DOI=10.7554/elife.18434; RA Sledz P., Jinek M.; RT "Structural insights into the molecular mechanism of the m(6)A writer RT complex."; RL Elife 5:E18434-E18434(2016). RN [35] RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 357-580 IN COMPLEX WITH METTL14 RP AND S-ADENOSYL-L-METHIONINE, FUNCTION, CATALYTIC ACTIVITY, SUBUNIT, RP MUTAGENESIS OF CYS-294; CYS-326; ASP-395; TRP-475 AND ASN-477, VARIANT RP CYS-406, AND CHARACTERIZATION OF VARIANT CYS-406. RX PubMed=27373337; DOI=10.1016/j.molcel.2016.05.041; RA Wang P., Doxtader K.A., Nam Y.; RT "Structural basis for cooperative function of Mettl3 and Mettl14 RT methyltransferases."; RL Mol. Cell 63:306-317(2016). RN [36] RP X-RAY CRYSTALLOGRAPHY (1.61 ANGSTROMS) OF 369-580 IN COMPLEX WITH METTL14 RP AND S-ADENOSYL-L-METHIONINE, FUNCTION, CATALYTIC ACTIVITY, SUBUNIT, DOMAIN, RP AND MUTAGENESIS OF ASP-377; ASP-395; 462-GLN--GLY-479; GLU-532; ARG-536; RP HIS-538; ASN-539; ASN-549 AND GLN-550. RX PubMed=27281194; DOI=10.1038/nature18298; RA Wang X., Feng J., Xue Y., Guan Z., Zhang D., Liu Z., Gong Z., Wang Q., RA Huang J., Tang C., Zou T., Yin P.; RT "Structural basis of N(6)-adenosine methylation by the METTL3-METTL14 RT complex."; RL Nature 534:575-578(2016). CC -!- FUNCTION: The METTL3-METTL14 heterodimer forms a N6-methyltransferase CC complex that methylates adenosine residues at the N(6) position of some CC RNAs and regulates various processes such as the circadian clock, CC differentiation of embryonic and hematopoietic stem cells, cortical CC neurogenesis, response to DNA damage, differentiation of T-cells and CC primary miRNA processing (PubMed:22575960, PubMed:24284625, CC PubMed:25719671, PubMed:25799998, PubMed:26321680, PubMed:26593424, CC PubMed:27281194, PubMed:27373337, PubMed:27627798, PubMed:28297716, CC PubMed:29348140, PubMed:29506078, PubMed:30428350, PubMed:9409616). In CC the heterodimer formed with METTL14, METTL3 constitutes the catalytic CC core (PubMed:27281194, PubMed:27373337, PubMed:27627798). N6- CC methyladenosine (m6A), which takes place at the 5'-[AG]GAC-3' consensus CC sites of some mRNAs, plays a role in mRNA stability, processing, CC translation efficiency and editing (PubMed:22575960, PubMed:24284625, CC PubMed:25719671, PubMed:25799998, PubMed:26321680, PubMed:26593424, CC PubMed:28297716, PubMed:9409616). M6A acts as a key regulator of mRNA CC stability: methylation is completed upon the release of mRNA into the CC nucleoplasm and promotes mRNA destabilization and degradation CC (PubMed:28637692). In embryonic stem cells (ESCs), m6A methylation of CC mRNAs encoding key naive pluripotency-promoting transcripts results in CC transcript destabilization, promoting differentiation of ESCs (By CC similarity). M6A regulates the length of the circadian clock: acts as CC an early pace-setter in the circadian loop by putting mRNA production CC on a fast-track for facilitating nuclear processing, thereby providing CC an early point of control in setting the dynamics of the feedback loop CC (By similarity). M6A also regulates circadian regulation of hepatic CC lipid metabolism (PubMed:30428350). M6A regulates spermatogonial CC differentiation and meiosis and is essential for male fertility and CC spermatogenesis (By similarity). Also required for oogenesis (By CC similarity). Involved in the response to DNA damage: in response to CC ultraviolet irradiation, METTL3 rapidly catalyzes the formation of m6A CC on poly(A) transcripts at DNA damage sites, leading to the recruitment CC of POLK to DNA damage sites (PubMed:28297716). M6A is also required for CC T-cell homeostasis and differentiation: m6A methylation of transcripts CC of SOCS family members (SOCS1, SOCS3 and CISH) in naive T-cells CC promotes mRNA destabilization and degradation, promoting T-cell CC differentiation (By similarity). Inhibits the type I interferon CC response by mediating m6A methylation of IFNB (PubMed:30559377). M6A CC also takes place in other RNA molecules, such as primary miRNA (pri- CC miRNAs) (PubMed:25799998). Mediates m6A methylation of Xist RNA, CC thereby participating in random X inactivation: m6A methylation of Xist CC leads to target YTHDC1 reader on Xist and promote transcription CC repression activity of Xist (PubMed:27602518). M6A also regulates CC cortical neurogenesis: m6A methylation of transcripts related to CC transcription factors, neural stem cells, the cell cycle and neuronal CC differentiation during brain development promotes their destabilization CC and decay, promoting differentiation of radial glial cells (By CC similarity). METTL3 mediates methylation of pri-miRNAs, marking them CC for recognition and processing by DGCR8 (PubMed:25799998). Acts as a CC positive regulator of mRNA translation independently of the CC methyltransferase activity: promotes translation by interacting with CC the translation initiation machinery in the cytoplasm CC (PubMed:27117702). Its overexpression in a number of cancer cells CC suggests that it may participate in cancer cell proliferation by CC promoting mRNA translation (PubMed:27117702). During human coronavirus CC SARS-CoV-2 infection, adds m6A modifications in SARS-CoV-2 RNA leading CC to decreased RIGI binding and subsequently dampening the sensing and CC activation of innate immune responses (PubMed:33961823). CC {ECO:0000250|UniProtKB:Q8C3P7, ECO:0000269|PubMed:22575960, CC ECO:0000269|PubMed:24284625, ECO:0000269|PubMed:25719671, CC ECO:0000269|PubMed:25799998, ECO:0000269|PubMed:26321680, CC ECO:0000269|PubMed:26593424, ECO:0000269|PubMed:27117702, CC ECO:0000269|PubMed:27281194, ECO:0000269|PubMed:27373337, CC ECO:0000269|PubMed:27602518, ECO:0000269|PubMed:27627798, CC ECO:0000269|PubMed:28297716, ECO:0000269|PubMed:28637692, CC ECO:0000269|PubMed:29348140, ECO:0000269|PubMed:29506078, CC ECO:0000269|PubMed:30428350, ECO:0000269|PubMed:30559377, CC ECO:0000269|PubMed:33961823, ECO:0000269|PubMed:9409616}. CC -!- CATALYTIC ACTIVITY: CC Reaction=an adenosine in mRNA + S-adenosyl-L-methionine = an N(6)- CC methyladenosine in mRNA + S-adenosyl-L-homocysteine + H(+); CC Xref=Rhea:RHEA:55584, Rhea:RHEA-COMP:12414, Rhea:RHEA-COMP:12417, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:57856, ChEBI:CHEBI:59789, CC ChEBI:CHEBI:74411, ChEBI:CHEBI:74449; EC=2.1.1.348; CC Evidence={ECO:0000269|PubMed:27281194, ECO:0000269|PubMed:27373337, CC ECO:0000269|PubMed:27627798, ECO:0000269|PubMed:29348140, CC ECO:0000269|PubMed:29506078, ECO:0000269|PubMed:9409616}; CC -!- ACTIVITY REGULATION: Methyltransferase activity is regulated by miRNAs CC via a sequence pairing mechanism (By similarity). Methyltransferase CC activity is inhibited by sumoylation (PubMed:29506078). CC {ECO:0000250|UniProtKB:Q8C3P7, ECO:0000269|PubMed:29506078}. CC -!- SUBUNIT: Heterodimer; heterodimerizes with METTL14 to form an CC antiparallel heterodimer that constitutes an active methyltransferase CC (PubMed:27281194, PubMed:27373337, PubMed:27627798). Component of the CC WMM complex, a N6-methyltransferase complex composed of a catalytic CC subcomplex, named MAC, and of an associated subcomplex, named MACOM CC (PubMed:24407421, PubMed:24981863, PubMed:27602518, PubMed:29348140, CC PubMed:29506078, PubMed:29507755). The MAC subcomplex is composed of CC METTL3 and METTL14 (PubMed:24407421, PubMed:24981863, PubMed:27602518, CC PubMed:29507755). The MACOM subcomplex is composed of WTAP, ZC3H13, CC CBLL1/HAKAI, VIRMA, and, in some cases of RBM15 (RBM15 or RBM15B) CC (PubMed:27602518, PubMed:29507755). Interacts with NCBP1/CBP80 CC (PubMed:27117702). Interacts with EIF4E (PubMed:27117702). Interacts CC with EIF3B (PubMed:27117702). {ECO:0000269|PubMed:24407421, CC ECO:0000269|PubMed:24981863, ECO:0000269|PubMed:27117702, CC ECO:0000269|PubMed:27281194, ECO:0000269|PubMed:27373337, CC ECO:0000269|PubMed:27602518, ECO:0000269|PubMed:27627798, CC ECO:0000269|PubMed:29348140, ECO:0000269|PubMed:29506078, CC ECO:0000269|PubMed:29507755}. CC -!- INTERACTION: CC Q86U44; Q9HCE5: METTL14; NbExp=21; IntAct=EBI-11105430, EBI-6661081; CC Q86U44-1; Q9HCE5: METTL14; NbExp=10; IntAct=EBI-16084936, EBI-6661081; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:25719671, CC ECO:0000269|PubMed:26458103, ECO:0000269|PubMed:27117702, CC ECO:0000269|PubMed:29348140, ECO:0000269|PubMed:29506078}. Nucleus CC speckle {ECO:0000269|PubMed:9409616}. Cytoplasm CC {ECO:0000269|PubMed:27117702}. Note=Colocalizes with speckles in CC interphase nuclei, suggesting that it may be associated with nuclear CC pre-mRNA splicing components (PubMed:9409616). In response to CC ultraviolet irradiation, colocalizes to DNA damage sites however, it CC probably does not bind DNA but localizes in the vicinity of DNA damage CC sites (PubMed:28297716). {ECO:0000269|PubMed:28297716, CC ECO:0000269|PubMed:9409616}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q86U44-1; Sequence=Displayed; CC Name=2; CC IsoId=Q86U44-2; Sequence=VSP_007864, VSP_007865, VSP_007866; CC -!- TISSUE SPECIFICITY: Widely expressed at low level. Expressed in spleen, CC thymus, prostate, testis, ovary, small intestine, colon and peripheral CC blood leukocytes. {ECO:0000269|PubMed:9409616}. CC -!- INDUCTION: Overexpressed in a number of cancer tissues, such as lung CC adenocarcinoma and colon adenocarcinoma (PubMed:27117702). CC {ECO:0000269|PubMed:27117702}. CC -!- DOMAIN: Gate loop 1 and gate loop 2 regions are adjacent to the S- CC adenosyl-L-homocysteine-binding site and display large conformational CC changes upon ligand-binding. They may play an important role in CC adenosine recognition. The interface loop contributes to the CC heterodimer interaction. {ECO:0000269|PubMed:27281194}. CC -!- PTM: Sumoylation inhibits the N6-adenosine-methyltransferase activity. CC Sumoylation does not affect subcellular location or interaction with CC METTL14. Desumoylated by SENP1. {ECO:0000269|PubMed:29506078}. CC -!- SIMILARITY: Belongs to the MT-A70-like family. {ECO:0000255|PROSITE- CC ProRule:PRU00489}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF014837; AAB71850.1; -; Genomic_DNA. DR EMBL; AF283991; AAG13956.1; -; Genomic_DNA. DR EMBL; AE000658; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BX247964; CAD62303.1; -; mRNA. DR EMBL; BC003031; AAH03031.1; -; mRNA. DR EMBL; BC001650; AAH01650.1; -; mRNA. DR EMBL; BC052244; AAH52244.1; -; mRNA. DR CCDS; CCDS32044.1; -. [Q86U44-1] DR RefSeq; NP_062826.2; NM_019852.4. [Q86U44-1] DR PDB; 5IL0; X-ray; 1.88 A; A=369-580. DR PDB; 5IL1; X-ray; 1.71 A; A=369-580. DR PDB; 5IL2; X-ray; 1.61 A; A=369-580. DR PDB; 5K7M; X-ray; 1.65 A; A=357-580. DR PDB; 5K7U; X-ray; 1.70 A; A=357-580. DR PDB; 5K7W; X-ray; 1.65 A; A=357-580. DR PDB; 5L6D; X-ray; 1.85 A; A=354-580. DR PDB; 5L6E; X-ray; 1.90 A; A=354-580. DR PDB; 5TEY; X-ray; 1.80 A; A=1-580. DR PDB; 5YZ9; Other; -; A=259-357. DR PDB; 6TTP; X-ray; 2.00 A; A=1-580. DR PDB; 6TTT; X-ray; 2.30 A; A=1-580. DR PDB; 6TTV; X-ray; 2.14 A; A=1-580. DR PDB; 6TTW; X-ray; 2.20 A; A=1-580. DR PDB; 6TTX; X-ray; 2.00 A; A=1-580. DR PDB; 6TU1; X-ray; 2.31 A; A=1-580. DR PDB; 6Y4G; X-ray; 1.90 A; A=1-580. DR PDB; 7ACD; X-ray; 2.50 A; A=354-580. DR PDB; 7NHG; X-ray; 2.50 A; A=354-580. DR PDB; 7NHH; X-ray; 2.10 A; A=354-580. DR PDB; 7NHI; X-ray; 1.85 A; A=354-580. DR PDB; 7NHJ; X-ray; 2.16 A; A=354-580. DR PDB; 7NHV; X-ray; 1.91 A; A=354-580. DR PDB; 7NI7; X-ray; 2.50 A; A=354-580. DR PDB; 7NI8; X-ray; 2.20 A; A=354-580. DR PDB; 7NI9; X-ray; 2.20 A; A=354-580. DR PDB; 7NIA; X-ray; 2.30 A; A=354-580. DR PDB; 7NID; X-ray; 2.30 A; A=354-580. DR PDB; 7O08; X-ray; 2.00 A; A=354-580. DR PDB; 7O09; X-ray; 1.80 A; A=354-580. DR PDB; 7O0L; X-ray; 1.90 A; A=354-580. DR PDB; 7O0M; X-ray; 2.39 A; A=354-580. DR PDB; 7O0P; X-ray; 2.70 A; A=354-580. DR PDB; 7O0Q; X-ray; 2.49 A; A=354-580. DR PDB; 7O0R; X-ray; 2.30 A; A=354-580. DR PDB; 7O27; X-ray; 2.40 A; A=354-580. DR PDB; 7O28; X-ray; 2.47 A; A=354-580. DR PDB; 7O29; X-ray; 2.75 A; A=354-580. DR PDB; 7O2E; X-ray; 2.50 A; A=354-580. DR PDB; 7O2F; X-ray; 2.10 A; A=354-580. DR PDB; 7O2H; X-ray; 2.50 A; A=354-580. DR PDB; 7O2I; X-ray; 3.00 A; A=353-580. DR PDB; 7O2X; X-ray; 2.80 A; A=354-580. DR PDB; 7OED; X-ray; 2.00 A; A=354-580. DR PDB; 7OEE; X-ray; 2.70 A; A=354-580. DR PDB; 7OEF; X-ray; 2.03 A; A=354-580. DR PDB; 7OEG; X-ray; 2.79 A; A=354-580. DR PDB; 7OEH; X-ray; 2.01 A; A=354-580. DR PDB; 7OEI; X-ray; 2.48 A; A=354-580. DR PDB; 7OEJ; X-ray; 2.30 A; A=354-580. DR PDB; 7OEK; X-ray; 1.90 A; A=354-580. DR PDB; 7OEL; X-ray; 1.86 A; A=354-580. DR PDB; 7OEM; X-ray; 2.20 A; A=354-580. DR PDB; 7OQL; X-ray; 2.50 A; A=354-580. DR PDB; 7OQO; X-ray; 3.35 A; A=354-580. DR PDB; 7OQP; X-ray; 2.00 A; A=354-580. DR PDB; 7RX6; X-ray; 1.80 A; A=357-580. DR PDB; 7RX7; X-ray; 1.65 A; A=357-580. DR PDB; 7RX8; X-ray; 1.85 A; A=357-580. DR PDB; 8BN8; X-ray; 2.21 A; AAA=363-580. DR PDB; 8PW8; X-ray; 2.30 A; A=353-580. DR PDB; 8PW9; X-ray; 2.30 A; A=353-580. DR PDB; 8PWA; X-ray; 2.10 A; A=353-580. DR PDB; 8PWB; X-ray; 2.50 A; A=353-580. DR PDB; 9G4S; X-ray; 1.95 A; A=365-578. DR PDB; 9G4U; X-ray; 2.00 A; A=367-577. DR PDB; 9G4W; X-ray; 1.85 A; A=365-577. DR PDBsum; 5IL0; -. DR PDBsum; 5IL1; -. DR PDBsum; 5IL2; -. DR PDBsum; 5K7M; -. DR PDBsum; 5K7U; -. DR PDBsum; 5K7W; -. DR PDBsum; 5L6D; -. DR PDBsum; 5L6E; -. DR PDBsum; 5TEY; -. DR PDBsum; 5YZ9; -. DR PDBsum; 6TTP; -. DR PDBsum; 6TTT; -. DR PDBsum; 6TTV; -. DR PDBsum; 6TTW; -. DR PDBsum; 6TTX; -. DR PDBsum; 6TU1; -. DR PDBsum; 6Y4G; -. DR PDBsum; 7ACD; -. DR PDBsum; 7NHG; -. DR PDBsum; 7NHH; -. DR PDBsum; 7NHI; -. DR PDBsum; 7NHJ; -. DR PDBsum; 7NHV; -. DR PDBsum; 7NI7; -. DR PDBsum; 7NI8; -. DR PDBsum; 7NI9; -. DR PDBsum; 7NIA; -. DR PDBsum; 7NID; -. DR PDBsum; 7O08; -. DR PDBsum; 7O09; -. DR PDBsum; 7O0L; -. DR PDBsum; 7O0M; -. DR PDBsum; 7O0P; -. DR PDBsum; 7O0Q; -. DR PDBsum; 7O0R; -. DR PDBsum; 7O27; -. DR PDBsum; 7O28; -. DR PDBsum; 7O29; -. DR PDBsum; 7O2E; -. DR PDBsum; 7O2F; -. DR PDBsum; 7O2H; -. DR PDBsum; 7O2I; -. DR PDBsum; 7O2X; -. DR PDBsum; 7OED; -. DR PDBsum; 7OEE; -. DR PDBsum; 7OEF; -. DR PDBsum; 7OEG; -. DR PDBsum; 7OEH; -. DR PDBsum; 7OEI; -. DR PDBsum; 7OEJ; -. DR PDBsum; 7OEK; -. DR PDBsum; 7OEL; -. DR PDBsum; 7OEM; -. DR PDBsum; 7OQL; -. DR PDBsum; 7OQO; -. DR PDBsum; 7OQP; -. DR PDBsum; 7RX6; -. DR PDBsum; 7RX7; -. DR PDBsum; 7RX8; -. DR PDBsum; 8BN8; -. DR PDBsum; 8PW8; -. DR PDBsum; 8PW9; -. DR PDBsum; 8PWA; -. DR PDBsum; 8PWB; -. DR PDBsum; 9G4S; -. DR PDBsum; 9G4U; -. DR PDBsum; 9G4W; -. DR AlphaFoldDB; Q86U44; -. DR SMR; Q86U44; -. DR BioGRID; 121139; 295. DR ComplexPortal; CPX-21210; Methyltransferase complex, METTL3-METTL14. DR CORUM; Q86U44; -. DR DIP; DIP-60727N; -. DR FunCoup; Q86U44; 3476. DR IntAct; Q86U44; 248. DR MINT; Q86U44; -. DR STRING; 9606.ENSP00000298717; -. DR BindingDB; Q86U44; -. DR ChEMBL; CHEMBL4739695; -. DR GuidetoPHARMACOLOGY; 3181; -. DR GlyGen; Q86U44; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q86U44; -. DR PhosphoSitePlus; Q86U44; -. DR BioMuta; METTL3; -. DR DMDM; 33301371; -. DR jPOST; Q86U44; -. DR MassIVE; Q86U44; -. DR PaxDb; 9606-ENSP00000298717; -. DR PeptideAtlas; Q86U44; -. DR ProteomicsDB; 69768; -. [Q86U44-1] DR ProteomicsDB; 69769; -. [Q86U44-2] DR Pumba; Q86U44; -. DR Antibodypedia; 53; 181 antibodies from 30 providers. DR DNASU; 56339; -. DR Ensembl; ENST00000298717.9; ENSP00000298717.3; ENSG00000165819.13. [Q86U44-1] DR GeneID; 56339; -. DR KEGG; hsa:56339; -. DR MANE-Select; ENST00000298717.9; ENSP00000298717.3; NM_019852.5; NP_062826.2. DR UCSC; uc001wbc.4; human. [Q86U44-1] DR AGR; HGNC:17563; -. DR ClinPGx; PA134955499; -. DR CTD; 56339; -. DR DisGeNET; 56339; -. DR GeneCards; METTL3; -. DR HGNC; HGNC:17563; METTL3. DR HPA; ENSG00000165819; Low tissue specificity. DR MIM; 612472; gene. DR OpenTargets; ENSG00000165819; -. DR VEuPathDB; HostDB:ENSG00000165819; -. DR eggNOG; KOG2098; Eukaryota. DR GeneTree; ENSGT00550000075058; -. DR HOGENOM; CLU_018702_4_0_1; -. DR InParanoid; Q86U44; -. DR OMA; HMDMEIE; -. DR OrthoDB; 10262526at2759; -. DR PAN-GO; Q86U44; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q86U44; -. DR BRENDA; 2.1.1.348; 2681. DR PathwayCommons; Q86U44; -. DR Reactome; R-HSA-72203; Processing of Capped Intron-Containing Pre-mRNA. DR SignaLink; Q86U44; -. DR SIGNOR; Q86U44; -. DR Agora; ENSG00000165819; -. DR BioGRID-ORCS; 56339; 496 hits in 1175 CRISPR screens. DR CD-CODE; 804901D1; Nuclear speckle. DR ChiTaRS; METTL3; human. DR EvolutionaryTrace; Q86U44; -. DR GeneWiki; METTL3; -. DR GenomeRNAi; 56339; -. DR Pharos; Q86U44; Tbio. DR PRO; PR:Q86U44; -. DR Proteomes; UP000005640; Chromosome 14. DR RNAct; Q86U44; protein. DR Bgee; ENSG00000165819; Expressed in right uterine tube and 205 other cell types or tissues. DR ExpressionAtlas; Q86U44; baseline and differential. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0016604; C:nuclear body; IDA:HPA. DR GO; GO:0016607; C:nuclear speck; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0036396; C:RNA N6-methyladenosine methyltransferase complex; IDA:UniProtKB. DR GO; GO:0003729; F:mRNA binding; IDA:UniProtKB. DR GO; GO:0001734; F:mRNA m(6)A methyltransferase activity; IDA:UniProtKB. DR GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB. DR GO; GO:0008173; F:RNA methyltransferase activity; IDA:UniProtKB. DR GO; GO:1904047; F:S-adenosyl-L-methionine binding; IDA:UniProtKB. DR GO; GO:0034644; P:cellular response to UV; IDA:UniProtKB. DR GO; GO:0007623; P:circadian rhythm; ISS:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0009048; P:dosage compensation by inactivation of X chromosome; IDA:UniProtKB. DR GO; GO:0098508; P:endothelial to hematopoietic transition; ISS:UniProtKB. DR GO; GO:0021861; P:forebrain radial glial cell differentiation; ISS:UniProtKB. DR GO; GO:0042063; P:gliogenesis; ISS:UniProtKB. DR GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW. DR GO; GO:0061157; P:mRNA destabilization; ISS:UniProtKB. DR GO; GO:0016556; P:mRNA modification; IDA:UniProt. DR GO; GO:0006397; P:mRNA processing; IDA:UniProtKB. DR GO; GO:0000398; P:mRNA splicing, via spliceosome; IMP:UniProtKB. DR GO; GO:0045746; P:negative regulation of Notch signaling pathway; ISS:UniProtKB. DR GO; GO:0060339; P:negative regulation of type I interferon-mediated signaling pathway; IMP:UniProtKB. DR GO; GO:0048477; P:oogenesis; ISS:UniProtKB. DR GO; GO:1903679; P:positive regulation of cap-independent translational initiation; IMP:UniProtKB. DR GO; GO:0045727; P:positive regulation of translation; IMP:UniProtKB. DR GO; GO:0031053; P:primary miRNA processing; IDA:UniProtKB. DR GO; GO:1902036; P:regulation of hematopoietic stem cell differentiation; ISS:UniProtKB. DR GO; GO:0051445; P:regulation of meiotic cell cycle; ISS:UniProtKB. DR GO; GO:0045580; P:regulation of T cell differentiation; ISS:UniProtKB. DR GO; GO:0001510; P:RNA methylation; IMP:UniProtKB. DR GO; GO:0007283; P:spermatogenesis; ISS:UniProtKB. DR GO; GO:0019827; P:stem cell population maintenance; ISS:UniProtKB. DR Gene3D; 3.40.50.150; Vaccinia Virus protein VP39; 1. DR InterPro; IPR025848; MT-A70. DR InterPro; IPR007757; MT-A70-like. DR InterPro; IPR029063; SAM-dependent_MTases_sf. DR PANTHER; PTHR12829; N6-ADENOSINE-METHYLTRANSFERASE; 1. DR PANTHER; PTHR12829:SF7; N6-ADENOSINE-METHYLTRANSFERASE CATALYTIC SUBUNIT; 1. DR Pfam; PF05063; MT-A70; 1. DR SUPFAM; SSF53335; S-adenosyl-L-methionine-dependent methyltransferases; 1. DR PROSITE; PS51143; MT_A70; 1. DR PROSITE; PS51563; SAM_MTA70L_1; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Biological rhythms; KW Cytoplasm; Differentiation; Direct protein sequencing; DNA damage; KW Immunity; Innate immunity; Isopeptide bond; Methyltransferase; Nucleus; KW Oogenesis; Phosphoprotein; Proteomics identification; Reference proteome; KW RNA-binding; S-adenosyl-L-methionine; Spermatogenesis; Transferase; KW Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:19413330" FT CHAIN 2..580 FT /note="N(6)-adenosine-methyltransferase catalytic subunit FT METTL3" FT /id="PRO_0000207630" FT REGION 1..70 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 198..219 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 396..410 FT /note="Gate loop 1" FT /evidence="ECO:0000303|PubMed:27281194" FT REGION 450..454 FT /note="Interaction with METTL14" FT /evidence="ECO:0000269|PubMed:27281194, FT ECO:0007744|PDB:5IL0, ECO:0007744|PDB:5IL1, FT ECO:0007744|PDB:5IL2" FT REGION 462..479 FT /note="Interphase loop" FT /evidence="ECO:0000303|PubMed:27281194" FT REGION 464..480 FT /note="Interaction with METTL14" FT /evidence="ECO:0000269|PubMed:27281194, FT ECO:0007744|PDB:5IL0, ECO:0007744|PDB:5IL1, FT ECO:0007744|PDB:5IL2" FT REGION 465..478 FT /note="Positively charged region required for RNA-binding" FT /evidence="ECO:0000269|PubMed:27281194" FT REGION 507..515 FT /note="Gate loop 2" FT /evidence="ECO:0000303|PubMed:27281194" FT MOTIF 210..215 FT /note="Nuclear localization signal" FT /evidence="ECO:0000269|PubMed:29348140" FT COMPBIAS 28..37 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 377..378 FT /ligand="S-adenosyl-L-methionine" FT /ligand_id="ChEBI:CHEBI:59789" FT /evidence="ECO:0000269|PubMed:27281194, FT ECO:0000269|PubMed:27373337, ECO:0000269|PubMed:27627798, FT ECO:0007744|PDB:5IL1, ECO:0007744|PDB:5IL2, FT ECO:0007744|PDB:5K7U, ECO:0007744|PDB:5K7W, FT ECO:0007744|PDB:5L6D, ECO:0007744|PDB:5L6E" FT BINDING 395 FT /ligand="S-adenosyl-L-methionine" FT /ligand_id="ChEBI:CHEBI:59789" FT /evidence="ECO:0000269|PubMed:27281194, FT ECO:0000269|PubMed:27373337, ECO:0007744|PDB:5IL1, FT ECO:0007744|PDB:5IL2, ECO:0007744|PDB:5K7U, FT ECO:0007744|PDB:5K7W" FT BINDING 513 FT /ligand="S-adenosyl-L-methionine" FT /ligand_id="ChEBI:CHEBI:59789" FT /evidence="ECO:0000269|PubMed:27281194, FT ECO:0000269|PubMed:27373337, ECO:0007744|PDB:5IL1, FT ECO:0007744|PDB:5IL2, ECO:0007744|PDB:5K7U, FT ECO:0007744|PDB:5K7W" FT BINDING 536..539 FT /ligand="S-adenosyl-L-methionine" FT /ligand_id="ChEBI:CHEBI:59789" FT /evidence="ECO:0000269|PubMed:27281194, FT ECO:0000269|PubMed:27373337, ECO:0000269|PubMed:27627798, FT ECO:0007744|PDB:5IL1, ECO:0007744|PDB:5IL2, FT ECO:0007744|PDB:5K7U, ECO:0007744|PDB:5K7W, FT ECO:0007744|PDB:5L6D, ECO:0007744|PDB:5L6E" FT BINDING 549..550 FT /ligand="S-adenosyl-L-methionine" FT /ligand_id="ChEBI:CHEBI:59789" FT /evidence="ECO:0000269|PubMed:27281194, FT ECO:0000269|PubMed:27373337, ECO:0000269|PubMed:27627798, FT ECO:0007744|PDB:5IL1, ECO:0007744|PDB:5IL2, FT ECO:0007744|PDB:5K7U, ECO:0007744|PDB:5K7W, FT ECO:0007744|PDB:5L6D, ECO:0007744|PDB:5L6E" FT SITE 438 FT /note="Interaction with METTL14" FT /evidence="ECO:0000269|PubMed:27281194, FT ECO:0007744|PDB:5IL1, ECO:0007744|PDB:5IL2" FT SITE 441 FT /note="Interaction with METTL14" FT /evidence="ECO:0000269|PubMed:27281194, FT ECO:0007744|PDB:5IL1, ECO:0007744|PDB:5IL2" FT MOD_RES 2 FT /note="N-acetylserine; alternate" FT /evidence="ECO:0007744|PubMed:19413330" FT MOD_RES 2 FT /note="Phosphoserine; alternate" FT /evidence="ECO:0000269|PubMed:29348140" FT MOD_RES 43 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:29348140, FT ECO:0007744|PubMed:16964243, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 48 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:29348140" FT MOD_RES 50 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:29348140" FT MOD_RES 219 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:29348140, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 243 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:29348140, FT ECO:0007744|PubMed:18669648" FT MOD_RES 348 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:29348140, FT ECO:0007744|PubMed:23186163" FT MOD_RES 350 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:29348140" FT CROSSLNK 177 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO1)" FT /evidence="ECO:0000269|PubMed:29506078" FT CROSSLNK 211 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO1)" FT /evidence="ECO:0000269|PubMed:29506078" FT CROSSLNK 212 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO1)" FT /evidence="ECO:0000269|PubMed:29506078" FT CROSSLNK 215 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO1)" FT /evidence="ECO:0000269|PubMed:29506078" FT VAR_SEQ 1..284 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_007864" FT VAR_SEQ 486..505 FT /note="GVKGNPQGFNQGLDCDVIVA -> SSSGAQFNRWSTKKNHLISY (in FT isoform 2)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_007865" FT VAR_SEQ 506..580 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_007866" FT VARIANT 406 FT /note="Y -> C (found in patients with large intestine FT cancer; uncertain significance; does not affect interaction FT with METTL14; abolished RNA methyltransferase activity in FT vitro)" FT /evidence="ECO:0000269|PubMed:27373337" FT /id="VAR_076859" FT MUTAGEN 2 FT /note="S->A: Does not affect nuclear localization, FT interaction with METTL14 or WTAP or catalytic activity; FT when associated with A-43; A-48 and A-50." FT /evidence="ECO:0000269|PubMed:29348140" FT MUTAGEN 43 FT /note="S->A: Does not affect nuclear localization, FT interaction with METTL14 or WTAP or catalytic activity; FT when associated with A-2; A-48 and A-50." FT /evidence="ECO:0000269|PubMed:29348140" FT MUTAGEN 48 FT /note="S->A: Does not affect nuclear localization, FT interaction with METTL14 or WTAP or catalytic activity; FT when associated with A-2; A-43 and A-50." FT /evidence="ECO:0000269|PubMed:29348140" FT MUTAGEN 50 FT /note="S->A: Does not affect nuclear localization, FT interaction with METTL14 or WTAP or catalytic activity; FT when associated with A-2; A-43 and A-48." FT /evidence="ECO:0000269|PubMed:29348140" FT MUTAGEN 177 FT /note="K->R: In 4KR; strongly decreased sumoylation; when FT associated with 211-R--R-215." FT /evidence="ECO:0000269|PubMed:29506078" FT MUTAGEN 211..215 FT /note="KKSRK->GGSGG: Abolishes localization to the FT nucleus." FT /evidence="ECO:0000269|PubMed:29348140" FT MUTAGEN 211..215 FT /note="KKSRK->RRSRR: In 3KR; decreased sumoylation. In 4KR; FT strongly decreased sumoylation; when associated with R- FT 177." FT /evidence="ECO:0000269|PubMed:29506078" FT MUTAGEN 219 FT /note="S->A: Does not affect nuclear localization, FT interaction with METTL14 or WTAP or catalytic activity; FT when associated with A-243 and 348-A--A-350." FT /evidence="ECO:0000269|PubMed:29348140" FT MUTAGEN 243 FT /note="S->A: Does not affect nuclear localization, FT interaction with METTL14 or WTAP or catalytic activity; FT when associated with A-219 and 348-A--A-350." FT /evidence="ECO:0000269|PubMed:29348140" FT MUTAGEN 294 FT /note="C->A: Abolishes methyltransferase activity." FT /evidence="ECO:0000269|PubMed:27373337" FT MUTAGEN 326 FT /note="C->A: Abolishes methyltransferase activity." FT /evidence="ECO:0000269|PubMed:27373337" FT MUTAGEN 348..350 FT /note="TPS->APA: Does not affect nuclear localization, FT interaction with METTL14 or WTAP or catalytic activity; FT when associated with A-219 and A-243." FT /evidence="ECO:0000269|PubMed:29348140" FT MUTAGEN 377 FT /note="D->A: Abolishes methyltransferase activity." FT /evidence="ECO:0000269|PubMed:27281194" FT MUTAGEN 395..398 FT /note="DPPW->APPA: Loss of function. Abolishes ability to FT regulate primary miRNA processing. Does not affect ability FT to promote mRNA translation. Abolishes formation of m6A at FT DNA damage sites." FT /evidence="ECO:0000269|PubMed:25799998, FT ECO:0000269|PubMed:27117702, ECO:0000269|PubMed:27627798, FT ECO:0000269|PubMed:28297716" FT MUTAGEN 395 FT /note="D->A: Abolishes methyltransferase activity." FT /evidence="ECO:0000269|PubMed:27281194, FT ECO:0000269|PubMed:27373337" FT MUTAGEN 406 FT /note="Y->A: Strong reduction in methyltransferase FT activity." FT /evidence="ECO:0000269|PubMed:27627798" FT MUTAGEN 462..479 FT /note="QLQRIIRTGRTGHWLNHG->AAAAAA: Impaired RNA-binding and FT methyltransferase activities." FT /evidence="ECO:0000269|PubMed:27281194" FT MUTAGEN 475 FT /note="W->A: Decreased methyltransferase activity." FT /evidence="ECO:0000269|PubMed:27373337" FT MUTAGEN 477 FT /note="N->A: Decreased methyltransferase activity." FT /evidence="ECO:0000269|PubMed:27373337" FT MUTAGEN 532 FT /note="E->A: Abolishes methyltransferase activity." FT /evidence="ECO:0000269|PubMed:27281194" FT MUTAGEN 536 FT /note="R->A: Slight reduction in methyltransferase FT activity." FT /evidence="ECO:0000269|PubMed:27281194" FT MUTAGEN 538 FT /note="H->A: Slight reduction in methyltransferase FT activity." FT /evidence="ECO:0000269|PubMed:27281194" FT MUTAGEN 539 FT /note="N->A: Abolishes methyltransferase activity." FT /evidence="ECO:0000269|PubMed:27281194" FT MUTAGEN 549 FT /note="N->A: Slight reduction in methyltransferase FT activity. Strong reduction in methyltransferase activity; FT when associated with A-550." FT /evidence="ECO:0000269|PubMed:27281194, FT ECO:0000269|PubMed:27627798" FT MUTAGEN 550 FT /note="Q->A: Slight reduction in methyltransferase FT activity. Strong reduction in methyltransferase activity; FT when associated with A-549." FT /evidence="ECO:0000269|PubMed:27281194, FT ECO:0000269|PubMed:27627798" FT CONFLICT 251 FT /note="N -> I (in Ref. 1; AAB71850)" FT /evidence="ECO:0000305" FT CONFLICT 263..264 FT /note="KF -> I (in Ref. 1; AAB71850)" FT /evidence="ECO:0000305" FT CONFLICT 382 FT /note="D -> V (in Ref. 1; AAB71850)" FT /evidence="ECO:0000305" FT CONFLICT 568 FT /note="R -> K (in Ref. 4; AAH52244)" FT /evidence="ECO:0000305" FT STRAND 372..376 FT /evidence="ECO:0007829|PDB:5IL2" FT TURN 378..380 FT /evidence="ECO:0007829|PDB:5IL2" FT HELIX 383..386 FT /evidence="ECO:0007829|PDB:5IL2" FT STRAND 390..394 FT /evidence="ECO:0007829|PDB:5IL2" FT TURN 405..407 FT /evidence="ECO:0007829|PDB:7NID" FT HELIX 411..416 FT /evidence="ECO:0007829|PDB:5IL2" FT HELIX 419..422 FT /evidence="ECO:0007829|PDB:5IL2" FT STRAND 424..432 FT /evidence="ECO:0007829|PDB:5IL2" FT HELIX 436..446 FT /evidence="ECO:0007829|PDB:5IL2" FT STRAND 450..460 FT /evidence="ECO:0007829|PDB:5IL2" FT STRAND 464..466 FT /evidence="ECO:0007829|PDB:5IL2" FT STRAND 473..477 FT /evidence="ECO:0007829|PDB:5IL2" FT STRAND 480..489 FT /evidence="ECO:0007829|PDB:5IL2" FT STRAND 498..506 FT /evidence="ECO:0007829|PDB:5IL2" FT STRAND 510..512 FT /evidence="ECO:0007829|PDB:5IL2" FT HELIX 516..524 FT /evidence="ECO:0007829|PDB:5IL2" FT STRAND 530..534 FT /evidence="ECO:0007829|PDB:5IL2" FT HELIX 537..539 FT /evidence="ECO:0007829|PDB:5IL2" FT STRAND 544..548 FT /evidence="ECO:0007829|PDB:5IL2" FT STRAND 553..555 FT /evidence="ECO:0007829|PDB:5IL2" FT HELIX 559..568 FT /evidence="ECO:0007829|PDB:5IL2" FT STRAND 570..572 FT /evidence="ECO:0007829|PDB:7NHG" SQ SEQUENCE 580 AA; 64474 MW; 63A7F10195A3C6AC CRC64; MSDTWSSIQA HKKQLDSLRE RLQRRRKQDS GHLDLRNPEA ALSPTFRSDS PVPTAPTSGG PKPSTASAVP ELATDPELEK KLLHHLSDLA LTLPTDAVSI CLAISTPDAP ATQDGVESLL QKFAAQELIE VKRGLLQDDA HPTLVTYADH SKLSAMMGAV AEKKGPGEVA GTVTGQKRRA EQDSTTVAAF ASSLVSGLNS SASEPAKEPA KKSRKHAASD VDLEIESLLN QQSTKEQQSK KVSQEILELL NTTTAKEQSI VEKFRSRGRA QVQEFCDYGT KEECMKASDA DRPCRKLHFR RIINKHTDES LGDCSFLNTC FHMDTCKYVH YEIDACMDSE APGSKDHTPS QELALTQSVG GDSSADRLFP PQWICCDIRY LDVSILGKFA VVMADPPWDI HMELPYGTLT DDEMRRLNIP VLQDDGFLFL WVTGRAMELG RECLNLWGYE RVDEIIWVKT NQLQRIIRTG RTGHWLNHGK EHCLVGVKGN PQGFNQGLDC DVIVAEVRST SHKPDEIYGM IERLSPGTRK IELFGRPHNV QPNWITLGNQ LDGIHLLDPD VVARFKQRYP DGIISKPKNL // ID MTOR_HUMAN Reviewed; 2549 AA. AC P42345; Q4LE76; Q5TER1; Q6LE87; Q96QG3; Q9Y4I3; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1995, sequence version 1. DT 28-JAN-2026, entry version 243. DE RecName: Full=Serine/threonine-protein kinase mTOR {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:15268862, ECO:0000269|PubMed:15467718, ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:18925875, ECO:0000269|PubMed:22343943, ECO:0000269|PubMed:22576015, ECO:0000269|PubMed:22692423}; DE AltName: Full=FK506-binding protein 12-rapamycin complex-associated protein 1; DE AltName: Full=FKBP12-rapamycin complex-associated protein; DE AltName: Full=Mammalian target of rapamycin; DE Short=mTOR; DE AltName: Full=Mechanistic target of rapamycin; DE AltName: Full=Rapamycin and FKBP12 target 1; DE AltName: Full=Rapamycin target protein 1; DE AltName: Full=Tyrosine-protein kinase mTOR {ECO:0000305}; DE EC=2.7.10.2 {ECO:0000305|PubMed:26584640}; GN Name=MTOR {ECO:0000312|HGNC:HGNC:3942}; GN Synonyms=FRAP, FRAP1, FRAP2, RAFT1, RAPT1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Brain; RX PubMed=8008069; DOI=10.1038/369756a0; RA Brown E.J., Albers M.W., Shin T.B., Ichikawa K., Keith C.T., Lane W.S., RA Schreiber S.L.; RT "A mammalian protein targeted by G1-arresting rapamycin-receptor complex."; RL Nature 369:756-758(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9653645; DOI=10.1006/geno.1997.5186; RA Onyango P., Lubyova B., Gardellin P., Kurzbauer R., Weith A.; RT "Molecular cloning and expression analysis of five novel genes in RT chromosome 1p36."; RL Genomics 50:187-198(1998). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Nakajima D., Saito K., Yamakawa H., Kikuno R.F., Nakayama M., Ohara R., RA Okazaki N., Koga H., Nagase T., Ohara O.; RT "Preparation of a set of expression-ready clones of mammalian long cDNAs RT encoding large proteins by the ORF trap cloning method."; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Cerebellum; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1362-2549. RX PubMed=11426320; DOI=10.1038/sj.gene.6363745; RA Stover C., Endo Y., Takahashi M., Lynch N., Constantinescu C., RA Vorup-Jensen T., Thiel S., Friedl H., Hankeln T., Hall R., Gregory S., RA Fujita T., Schwaeble W.; RT "The human gene for mannan-binding lectin-associated serine protease-2 RT (MASP-2), the effector component of the lectin route of complement RT activation, is part of a tightly linked gene cluster on chromosome 1p36.2- RT 3."; RL Genes Immun. 2:119-127(2001). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1987-2146, AND TISSUE SPECIFICITY. RC TISSUE=B-cell; RX PubMed=7809080; DOI=10.1073/pnas.91.26.12574; RA Chiu M.I., Katz H., Berlin V.; RT "RAPT1, a mammalian homolog of yeast Tor, interacts with the RT FKBP12/rapamycin complex."; RL Proc. Natl. Acad. Sci. U.S.A. 91:12574-12578(1994). RN [8] RP SUBCELLULAR LOCATION, AND AUTOPHOSPHORYLATION. RX PubMed=9434772; DOI=10.1006/bbrc.1997.7878; RA Withers D.J., Ouwens D.M., Nave B.T., van der Zon G.C.M., Alarcon C.M., RA Cardenas M.E., Heitman J., Maassen J.A., Shepherd P.R.; RT "Expression, enzyme activity, and subcellular localization of mammalian RT target of rapamycin in insulin-responsive cells."; RL Biochem. Biophys. Res. Commun. 241:704-709(1997). RN [9] RP INTERACTION WITH UBQLN1. RX PubMed=11853878; DOI=10.1016/s0167-4889(01)00164-1; RA Wu S., Mikhailov A., Kallo-Hosein H., Hara K., Yonezawa K., Avruch J.; RT "Characterization of ubiquilin 1, an mTOR-interacting protein."; RL Biochim. Biophys. Acta 1542:41-56(2002). RN [10] RP FUNCTION IN NUTRIENT-DEPENDENT CELL GROWTH, CATALYTIC ACTIVITY, FUNCTION IN RP PHOSPHORYLATION OF RPS6KB1, AND INTERACTION WITH RPTOR. RX PubMed=12150925; DOI=10.1016/s0092-8674(02)00808-5; RA Kim D.-H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R., RA Erdjument-Bromage H., Tempst P., Sabatini D.M.; RT "mTOR interacts with raptor to form a nutrient-sensitive complex that RT signals to the growth machinery."; RL Cell 110:163-175(2002). RN [11] RP FUNCTION, AND INTERACTION WITH RPTOR. RX PubMed=12150926; DOI=10.1016/s0092-8674(02)00833-4; RA Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S., RA Tokunaga C., Avruch J., Yonezawa K.; RT "Raptor, a binding partner of target of rapamycin (TOR), mediates TOR RT action."; RL Cell 110:177-189(2002). RN [12] RP INTERACTION WITH CLIP1, FUNCTION IN PHOSPHORYLATION OF CLIP1, AND CATALYTIC RP ACTIVITY. RX PubMed=12231510; DOI=10.1093/embo-reports/kvf197; RA Choi J.H., Bertram P.G., Drenan R., Carvalho J., Zhou H.H., Zheng X.F.; RT "The FKBP12-rapamycin-associated protein (FRAP) is a CLIP-170 kinase."; RL EMBO Rep. 3:988-994(2002). RN [13] RP FUNCTION IN PHOSPHORYLATION OF RPS6KB2, AND CATALYTIC ACTIVITY. RX PubMed=12087098; DOI=10.1074/jbc.m204080200; RA Park I.H., Bachmann R., Shirazi H., Chen J.; RT "Regulation of ribosomal S6 kinase 2 by mammalian target of rapamycin."; RL J. Biol. Chem. 277:31423-31429(2002). RN [14] RP INTERACTION WITH MLST8 AND RPTOR, IDENTIFICATION IN THE MTORC1 COMPLEX, AND RP TISSUE SPECIFICITY. RX PubMed=12408816; DOI=10.1016/s1097-2765(02)00636-6; RA Loewith R., Jacinto E., Wullschleger S., Lorberg A., Crespo J.L., RA Bonenfant D., Oppliger W., Jenoe P., Hall M.N.; RT "Two TOR complexes, only one of which is rapamycin sensitive, have distinct RT roles in cell growth control."; RL Mol. Cell 10:457-468(2002). RN [15] RP SUBCELLULAR LOCATION. RX PubMed=11930000; DOI=10.1073/pnas.261702698; RA Desai B.N., Myers B.R., Schreiber S.L.; RT "FKBP12-rapamycin-associated protein associates with mitochondria and RT senses osmotic stress via mitochondrial dysfunction."; RL Proc. Natl. Acad. Sci. U.S.A. 99:4319-4324(2002). RN [16] RP ACTIVITY REGULATION, AND FUNCTION IN RESPONSE TO LOW CELLULAR ENERGY. RX PubMed=14651849; DOI=10.1016/s0092-8674(03)00929-2; RA Inoki K., Zhu T., Guan K.L.; RT "TSC2 mediates cellular energy response to control cell growth and RT survival."; RL Cell 115:577-590(2003). RN [17] RP FUNCTION, ACTIVITY REGULATION, AND INTERACTION WITH MLST8. RX PubMed=12718876; DOI=10.1016/s1097-2765(03)00114-x; RA Kim D.-H., Sarbassov D.D., Ali S.M., Latek R.R., Guntur K.V.P., RA Erdjument-Bromage H., Tempst P., Sabatini D.M.; RT "GbetaL, a positive regulator of the rapamycin-sensitive pathway required RT for the nutrient-sensitive interaction between raptor and mTOR."; RL Mol. Cell 11:895-904(2003). RN [18] RP FUNCTION IN PHOSPHORYLATION OF PRKCA, CATALYTIC ACTIVITY, FUNCTION IN RP REGULATION OF THE ACTIN CYTOSKELETON, IDENTIFICATION IN THE MTORC2 COMPLEX, RP AND INTERACTION WITH RICTOR. RX PubMed=15268862; DOI=10.1016/j.cub.2004.06.054; RA Sarbassov D.D., Ali S.M., Kim D.-H., Guertin D.A., Latek R.R., RA Erdjument-Bromage H., Tempst P., Sabatini D.M.; RT "Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive RT and raptor-independent pathway that regulates the cytoskeleton."; RL Curr. Biol. 14:1296-1302(2004). RN [19] RP ACTIVITY REGULATION, AND FUNCTION IN RESPONSE TO HYPOXIA. RX PubMed=15545625; DOI=10.1101/gad.1256804; RA Brugarolas J., Lei K., Hurley R.L., Manning B.D., Reiling J.H., Hafen E., RA Witters L.A., Ellisen L.W., Kaelin W.G. Jr.; RT "Regulation of mTOR function in response to hypoxia by REDD1 and the RT TSC1/TSC2 tumor suppressor complex."; RL Genes Dev. 18:2893-2904(2004). RN [20] RP SUBCELLULAR LOCATION. RX PubMed=14578359; DOI=10.1074/jbc.m305912200; RA Drenan R.M., Liu X., Bertram P.G., Zheng X.F.S.; RT "FKBP12-rapamycin-associated protein or mammalian target of rapamycin RT (FRAP/mTOR) localization in the endoplasmic reticulum and the Golgi RT apparatus."; RL J. Biol. Chem. 279:772-778(2004). RN [21] RP FUNCTION IN REGULATION OF THE ACTIN CYTOSKELETON, CATALYTIC ACTIVITY, RP FUNCTION IN PHOSPHORYLATION OF PXN, IDENTIFICATION IN THE MTORC2 COMPLEX, RP INTERACTION WITH RICTOR, AUTOPHOSPHORYLATION, AND ACTIVITY REGULATION. RX PubMed=15467718; DOI=10.1038/ncb1183; RA Jacinto E., Loewith R., Schmidt A., Lin S., Ruegg M.A., Hall A., Hall M.N.; RT "Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin RT insensitive."; RL Nat. Cell Biol. 6:1122-1128(2004). RN [22] RP PHOSPHORYLATION AT SER-2448. RX PubMed=15899889; DOI=10.1074/jbc.m501707200; RA Chiang G.G., Abraham R.T.; RT "Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is RT mediated by p70S6 kinase."; RL J. Biol. Chem. 280:25485-25490(2005). RN [23] RP PHOSPHORYLATION AT THR-2446 AND SER-2448. RX PubMed=15905173; DOI=10.1074/jbc.m504045200; RA Holz M.K., Blenis J.; RT "Identification of S6 kinase 1 as a novel mammalian target of rapamycin RT (mTOR)-phosphorylating kinase."; RL J. Biol. Chem. 280:26089-26093(2005). RN [24] RP FUNCTION IN PHOSPHORYLATION OF AKT1, AND CATALYTIC ACTIVITY. RX PubMed=15718470; DOI=10.1126/science.1106148; RA Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M.; RT "Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex."; RL Science 307:1098-1101(2005). RN [25] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=17517883; DOI=10.1074/jbc.m702636200; RA Oshiro N., Takahashi R., Yoshino K., Tanimura K., Nakashima A., Eguchi S., RA Miyamoto T., Hara K., Takehana K., Avruch J., Kikkawa U., Yonezawa K.; RT "The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological RT substrate of mammalian target of rapamycin complex 1."; RL J. Biol. Chem. 282:20329-20339(2007). RN [26] RP IDENTIFICATION IN THE MTORC2 COMPLEX, AND INTERACTION WITH PRR5. RX PubMed=17599906; DOI=10.1074/jbc.m704343200; RA Woo S.-Y., Kim D.-H., Jun C.-B., Kim Y.-M., Haar E.V., Lee S.-I., RA Hegg J.W., Bandhakavi S., Griffin T.J., Kim D.-H.; RT "PRR5, a novel component of mTOR complex 2, regulates platelet-derived RT growth factor receptor beta expression and signaling."; RL J. Biol. Chem. 282:25604-25612(2007). RN [27] RP INTERACTION WITH AKT1S1, AND ACTIVITY REGULATION. RX PubMed=17386266; DOI=10.1016/j.molcel.2007.03.003; RA Sancak Y., Thoreen C.C., Peterson T.R., Lindquist R.A., Kang S.A., RA Spooner E., Carr S.A., Sabatini D.M.; RT "PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase."; RL Mol. Cell 25:903-915(2007). RN [28] RP IDENTIFICATION IN THE MTORC1 AND MTORC2 COMPLEXES, CATALYTIC ACTIVITY, AND RP FUNCTION IN PHOSPHORYLATION OF RPS6KB1 AND SGK1. RX PubMed=18925875; DOI=10.1042/bj20081668; RA Garcia-Martinez J.M., Alessi D.R.; RT "mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and RT activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)."; RL Biochem. J. 416:375-385(2008). RN [29] RP FUNCTION IN LIPID SYNTHESIS AND CELL GROWTH. RX PubMed=18762023; DOI=10.1016/j.cmet.2008.07.007; RA Porstmann T., Santos C.R., Griffiths B., Cully M., Wu M., Leevers S., RA Griffiths J.R., Chung Y.L., Schulze A.; RT "SREBP activity is regulated by mTORC1 and contributes to Akt-dependent RT cell growth."; RL Cell Metab. 8:224-236(2008). RN [30] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=18372248; DOI=10.1074/jbc.m800723200; RA Wang L., Harris T.E., Lawrence J.C. Jr.; RT "Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by RT mammalian target of rapamycin complex 1 (mTORC1)-mediated RT phosphorylation."; RL J. Biol. Chem. 283:15619-15627(2008). RN [31] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-567, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [32] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2478 AND SER-2481, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [33] RP FUNCTION, ACTIVITY REGULATION, AND SUBCELLULAR LOCATION. RX PubMed=18497260; DOI=10.1126/science.1157535; RA Sancak Y., Peterson T.R., Shaul Y.D., Lindquist R.A., Thoreen C.C., RA Bar-Peled L., Sabatini D.M.; RT "The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1."; RL Science 320:1496-1501(2008). RN [34] RP INTERACTION WITH DEPTOR, AND ACTIVITY REGULATION. RX PubMed=19446321; DOI=10.1016/j.cell.2009.03.046; RA Peterson T.R., Laplante M., Thoreen C.C., Sancak Y., Kang S.A., Kuehl W.M., RA Gray N.S., Sabatini D.M.; RT "DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma RT cells and required for their survival."; RL Cell 137:873-886(2009). RN [35] RP PHOSPHORYLATION AT SER-1261, AND ACTIVITY REGULATION. RX PubMed=19487463; DOI=10.1128/mcb.01665-08; RA Acosta-Jaquez H.A., Keller J.A., Foster K.G., Ekim B., Soliman G.A., RA Feener E.P., Ballif B.A., Fingar D.C.; RT "Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and RT cell growth."; RL Mol. Cell. Biol. 29:4308-4324(2009). RN [36] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-567, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [37] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-1218, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [38] RP PHOSPHORYLATION AT SER-2448. RX PubMed=19145465; DOI=10.1007/s00726-008-0230-7; RA Rosner M., Siegel N., Valli A., Fuchs C., Hengstschlager M.; RT "mTOR phosphorylated at S2448 binds to raptor and rictor."; RL Amino Acids 38:223-228(2010). RN [39] RP SUBCELLULAR LOCATION, AND ACTIVITY REGULATION. RX PubMed=20381137; DOI=10.1016/j.cell.2010.02.024; RA Sancak Y., Bar-Peled L., Zoncu R., Markhard A.L., Nada S., Sabatini D.M.; RT "Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is RT necessary for its activation by amino acids."; RL Cell 141:290-303(2010). RN [40] RP FUNCTION IN PHOSPHORYLATION OF DAP, FUNCTION IN AUTOPHAGY, AND CATALYTIC RP ACTIVITY. RX PubMed=20537536; DOI=10.1016/j.cub.2010.04.041; RA Koren I., Reem E., Kimchi A.; RT "DAP1, a novel substrate of mTOR, negatively regulates autophagy."; RL Curr. Biol. 20:1093-1098(2010). RN [41] RP FUNCTION, CATALYTIC ACTIVITY, AND PHOSPHORYLATION AT SER-2481. RX PubMed=20022946; DOI=10.1074/jbc.m109.096222; RA Soliman G.A., Acosta-Jaquez H.A., Dunlop E.A., Ekim B., Maj N.E., Tee A.R., RA Fingar D.C.; RT "mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic RT activity and clarifies rapamycin mechanism of action."; RL J. Biol. Chem. 285:7866-7879(2010). RN [42] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=21376236; DOI=10.1016/j.cell.2011.02.014; RA Zinzalla V., Stracka D., Oppliger W., Hall M.N.; RT "Activation of mTORC2 by association with the ribosome."; RL Cell 144:757-768(2011). RN [43] RP INTERACTION WITH TTI1. RX PubMed=20810650; DOI=10.1101/gad.1934210; RA Hurov K.E., Cotta-Ramusino C., Elledge S.J.; RT "A genetic screen identifies the Triple T complex required for DNA damage RT signaling and ATM and ATR stability."; RL Genes Dev. 24:1939-1950(2010). RN [44] RP INTERACTION WITH TELO2. RX PubMed=20801936; DOI=10.1101/gad.1956410; RA Takai H., Xie Y., de Lange T., Pavletich N.P.; RT "Tel2 structure and function in the Hsp90-dependent maturation of mTOR and RT ATR complexes."; RL Genes Dev. 24:2019-2030(2010). RN [45] RP INTERACTION WITH TELO2 AND TTI1. RX PubMed=20427287; DOI=10.1074/jbc.m110.121699; RA Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K., RA Iemura S., Natsume T., Mizushima N.; RT "Tti1 and Tel2 are critical factors in mammalian target of rapamycin RT complex assembly."; RL J. Biol. Chem. 285:20109-20116(2010). RN [46] RP FUNCTION IN REGULATION OF RNA POLYMERASE III TRANSCRIPTION, FUNCTION IN RP PHOSPHORYLATION OF MAF1, AND CATALYTIC ACTIVITY. RX PubMed=20516213; DOI=10.1128/mcb.00319-10; RA Michels A.A., Robitaille A.M., Buczynski-Ruchonnet D., Hodroj W., RA Reina J.H., Hall M.N., Hernandez N.; RT "mTORC1 directly phosphorylates and regulates human MAF1."; RL Mol. Cell. Biol. 30:3749-3757(2010). RN [47] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-567 AND THR-1162, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [48] RP SUBCELLULAR LOCATION. RX PubMed=21867682; DOI=10.1016/j.bbrc.2011.08.034; RA Boulbes D.R., Shaiken T., Sarbassov D.D.; RT "Endoplasmic reticulum is a main localization site of mTORC2."; RL Biochem. Biophys. Res. Commun. 413:46-52(2011). RN [49] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [50] RP PHOSPHORYLATION AT SER-2159; THR-2164 AND SER-2481, AND MUTAGENESIS OF RP SER-2159 AND THR-2164. RX PubMed=21576368; DOI=10.1128/mcb.05437-11; RA Ekim B., Magnuson B., Acosta-Jaquez H.A., Keller J.A., Feener E.P., RA Fingar D.C.; RT "mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, RT and cell cycle progression."; RL Mol. Cell. Biol. 31:2787-2801(2011). RN [51] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [52] RP FUNCTION IN PHOSPHORYLATION OF GRB10, CATALYTIC ACTIVITY, AND FUNCTION IN RP INSR-DEPENDENT SIGNALING. RX PubMed=21659604; DOI=10.1126/science.1199498; RA Hsu P.P., Kang S.A., Rameseder J., Zhang Y., Ottina K.A., Lim D., RA Peterson T.R., Choi Y., Gray N.S., Yaffe M.B., Marto J.A., Sabatini D.M.; RT "The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated RT inhibition of growth factor signaling."; RL Science 332:1317-1322(2011). RN [53] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=22576015; DOI=10.4161/auto.19653; RA Martina J.A., Chen Y., Gucek M., Puertollano R.; RT "MTORC1 functions as a transcriptional regulator of autophagy by preventing RT nuclear transport of TFEB."; RL Autophagy 8:903-914(2012). RN [54] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=22343943; DOI=10.1038/emboj.2012.32; RA Settembre C., Zoncu R., Medina D.L., Vetrini F., Erdin S., Erdin S., RA Huynh T., Ferron M., Karsenty G., Vellard M.C., Facchinetti V., RA Sabatini D.M., Ballabio A.; RT "A lysosome-to-nucleus signalling mechanism senses and regulates the RT lysosome via mTOR and TFEB."; RL EMBO J. 31:1095-1108(2012). RN [55] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=22692423; DOI=10.1126/scisignal.2002790; RA Roczniak-Ferguson A., Petit C.S., Froehlich F., Qian S., Ky J., RA Angarola B., Walther T.C., Ferguson S.M.; RT "The transcription factor TFEB links mTORC1 signaling to transcriptional RT control of lysosome homeostasis."; RL Sci. Signal. 5:RA42-RA42(2012). RN [56] RP INTERACTION WITH HTR6. RX PubMed=23027611; DOI=10.1002/emmm.201201410; RA Meffre J., Chaumont-Dubel S., Mannoury la Cour C., Loiseau F., Watson D.J., RA Dekeyne A., Seveno M., Rivet J.M., Gaven F., Deleris P., Herve D., RA Fone K.C., Bockaert J., Millan M.J., Marin P.; RT "5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed RT cognition in schizophrenia."; RL EMBO Mol. Med. 4:1043-1056(2012). RN [57] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [58] RP FUNCTION, AND INTERACTION WITH TPCN1 AND TPCN2. RX PubMed=23394946; DOI=10.1016/j.cell.2013.01.023; RA Cang C., Zhou Y., Navarro B., Seo Y.J., Aranda K., Shi L., RA Battaglia-Hsu S., Nissim I., Clapham D.E., Ren D.; RT "mTOR regulates lysosomal ATP-sensitive two-pore Na(+) channels to adapt to RT metabolic state."; RL Cell 152:778-790(2013). RN [59] RP FUNCTION. RX PubMed=23426360; DOI=10.1074/jbc.m112.441493; RA Eaton J.M., Mullins G.R., Brindley D.N., Harris T.E.; RT "Phosphorylation of lipin 1 and charge on the phosphatidic acid head group RT control its phosphatidic acid phosphatase activity and membrane RT association."; RL J. Biol. Chem. 288:9933-9945(2013). RN [60] RP INTERACTION WITH BRAT1. RX PubMed=25657994; RA So E.Y., Ouchi T.; RT "The potential role of BRCA1-associated ATM activator-1 (BRAT1) in RT regulation of mTOR."; RL J. Cancer Biol. Res. 1:0-0(2013). RN [61] RP PHOSPHORYLATION AT THR-2173, AND MUTAGENESIS OF THR-2173. RX PubMed=24247430; DOI=10.1083/jcb.201305103; RA Halova L., Du W., Kirkham S., Smith D.L., Petersen J.; RT "Phosphorylation of the TOR ATP binding domain by AGC kinase constitutes a RT novel mode of TOR inhibition."; RL J. Cell Biol. 203:595-604(2013). RN [62] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1261, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [63] RP FUNCTION IN PHOSPHORYLATION OF AMBRA1. RX PubMed=23524951; DOI=10.1038/ncb2708; RA Nazio F., Strappazzon F., Antonioli M., Bielli P., Cianfanelli V., RA Bordi M., Gretzmeier C., Dengjel J., Piacentini M., Fimia G.M., Cecconi F.; RT "mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self- RT association and function through AMBRA1 and TRAF6."; RL Nat. Cell Biol. 15:406-416(2013). RN [64] RP INTERACTION WITH NBN. RX PubMed=23762398; DOI=10.1371/journal.pone.0065586; RA Wang J.Q., Chen J.H., Chen Y.C., Chen M.Y., Hsieh C.Y., Teng S.C., Wu K.J.; RT "Interaction between NBS1 and the mTOR/Rictor/SIN1 complex through specific RT domains."; RL PLoS ONE 8:E65586-E65586(2013). RN [65] RP FUNCTION, AND REGULATION OF PYRIMIDINE SYNTHESIS. RX PubMed=23429704; DOI=10.1126/science.1228771; RA Robitaille A.M., Christen S., Shimobayashi M., Cornu M., Fava L.L., RA Moes S., Prescianotto-Baschong C., Sauer U., Jenoe P., Hall M.N.; RT "Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine RT synthesis."; RL Science 339:1320-1323(2013). RN [66] RP FUNCTION, AND REGULATION OF PYRIMIDINE SYNTHESIS. RX PubMed=23429703; DOI=10.1126/science.1228792; RA Ben-Sahra I., Howell J.J., Asara J.M., Manning B.D.; RT "Stimulation of de novo pyrimidine synthesis by growth signaling through RT mTOR and S6K1."; RL Science 339:1323-1328(2013). RN [67] RP FUNCTION, AND IDENTIFICATION IN THE MTORC1 COMPLEX. RX PubMed=24403073; DOI=10.1074/jbc.m113.482067; RA Coffman K., Yang B., Lu J., Tetlow A.L., Pelliccio E., Lu S., Guo D.C., RA Tang C., Dong M.Q., Tamanoi F.; RT "Characterization of the Raptor/4E-BP1 interaction by chemical cross- RT linking coupled with mass spectrometry analysis."; RL J. Biol. Chem. 289:4723-4734(2014). RN [68] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2448, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [69] RP FUNCTION. RX PubMed=24670654; DOI=10.1038/nature13079; RA Liu P., Begley M., Michowski W., Inuzuka H., Ginzberg M., Gao D., Tsou P., RA Gan W., Papa A., Kim B.M., Wan L., Singh A., Zhai B., Yuan M., Wang Z., RA Gygi S.P., Lee T.H., Lu K.P., Toker A., Pandolfi P.P., Asara J.M., RA Kirschner M.W., Sicinski P., Cantley L., Wei W.; RT "Cell-cycle-regulated activation of Akt kinase by phosphorylation at its RT carboxyl terminus."; RL Nature 508:541-545(2014). RN [70] RP FUNCTION. RX PubMed=24448649; DOI=10.1126/scisignal.2004754; RA Martina J.A., Diab H.I., Lishu L., Jeong-A L., Patange S., Raben N., RA Puertollano R.; RT "The nutrient-responsive transcription factor TFE3 promotes autophagy, RT lysosomal biogenesis, and clearance of cellular debris."; RL Sci. Signal. 7:ra9-ra9(2014). RN [71] RP INVOLVEMENT IN SKS, VARIANT SKS LYS-1799, AND CHARACTERIZATION OF VARIANT RP SKS LYS-1799. RX PubMed=25851998; DOI=10.1002/ajmg.a.37070; RA Baynam G., Overkov A., Davis M., Mina K., Schofield L., Allcock R., RA Laing N., Cook M., Dawkins H., Goldblatt J.; RT "A germline MTOR mutation in Aboriginal Australian siblings with RT intellectual disability, dysmorphism, macrocephaly, and small thoraces."; RL Am. J. Med. Genet. A 167:1659-1667(2015). RN [72] RP FUNCTION, INVOLVEMENT IN FCORD2, VARIANTS FCORD2 ASP-1459; PRO-1460; RP PHE-2215 AND TYR-2215, AND CHARACTERIZATION OF VARIANTS FCORD2 ASP-1459; RP PRO-1460; PHE-2215 AND TYR-2215. RX PubMed=26018084; DOI=10.1002/ana.24444; RA Nakashima M., Saitsu H., Takei N., Tohyama J., Kato M., Kitaura H., RA Shiina M., Shirozu H., Masuda H., Watanabe K., Ohba C., Tsurusaki Y., RA Miyake N., Zheng Y., Sato T., Takebayashi H., Ogata K., Kameyama S., RA Kakita A., Matsumoto N.; RT "Somatic mutations in the MTOR gene cause focal cortical dysplasia type RT IIb."; RL Ann. Neurol. 78:375-386(2015). RN [73] RP INVOLVEMENT IN SKS, VARIANT SKS LYS-1799, AND CHARACTERIZATION OF VARIANT RP SKS LYS-1799. RX PubMed=26542245; DOI=10.1186/s12881-015-0240-8; RA Mroske C., Rasmussen K., Shinde D.N., Huether R., Powis Z., Lu H.M., RA Baxter R.M., McPherson E., Tang S.; RT "Germline activating MTOR mutation arising through gonadal mosaicism in two RT brothers with megalencephaly and neurodevelopmental abnormalities."; RL BMC Med. Genet. 16:102-102(2015). RN [74] RP FUNCTION IN PHOSPHORYLATION OF AMBRA1. RX PubMed=25438055; DOI=10.1038/ncb3072; RA Cianfanelli V., Fuoco C., Lorente M., Salazar M., Quondamatteo F., RA Gherardini P.F., De Zio D., Nazio F., Antonioli M., D'Orazio M., Skobo T., RA Bordi M., Rohde M., Dalla Valle L., Helmer-Citterich M., Gretzmeier C., RA Dengjel J., Fimia G.M., Piacentini M., Di Bartolomeo S., Velasco G., RA Cecconi F.; RT "AMBRA1 links autophagy to cell proliferation and tumorigenesis by RT promoting c-Myc dephosphorylation and degradation."; RL Nat. Cell Biol. 17:20-30(2015). RN [75] RP ERRATUM OF PUBMED:25438055. RX PubMed=25925585; DOI=10.1038/ncb3171; RA Cianfanelli V., Fuoco C., Lorente M., Salazar M., Quondamatteo F., RA Gherardini P.F., De Zio D., Nazio F., Antonioli M., D'Orazio M., Skobo T., RA Bordi M., Rohde M., Dalla Valle L., Helmer-Citterich M., Gretzmeier C., RA Dengjel J., Fimia G.M., Piacentini M., Di Bartolomeo S., Velasco G., RA Cecconi F.; RL Nat. Cell Biol. 17:706-706(2015). RN [76] RP FUNCTION, INVOLVEMENT IN FCORD2, VARIANTS FCORD2 HIS-624; ASP-1450; RP ARG-1483; HIS-1709; LYS-1977; CYS-2193; PHE-2215; GLN-2427 AND PRO-2427, RP AND CHARACTERIZATION OF VARIANTS FCORD2 ARG-1483; GLN-2427 AND PRO-2427. RX PubMed=25799227; DOI=10.1038/nm.3824; RA Lim J.S., Kim W.I., Kang H.C., Kim S.H., Park A.H., Park E.K., Cho Y.W., RA Kim S., Kim H.M., Kim J.A., Kim J., Rhee H., Kang S.G., Kim H.D., Kim D., RA Kim D.S., Lee J.H.; RT "Brain somatic mutations in MTOR cause focal cortical dysplasia type II RT leading to intractable epilepsy."; RL Nat. Med. 21:395-400(2015). RN [77] RP ACTIVITY REGULATION. RX PubMed=25561175; DOI=10.1038/nature14107; RA Rebsamen M., Pochini L., Stasyk T., de Araujo M.E., Galluccio M., RA Kandasamy R.K., Snijder B., Fauster A., Rudashevskaya E.L., Bruckner M., RA Scorzoni S., Filipek P.A., Huber K.V., Bigenzahn J.W., Heinz L.X., RA Kraft C., Bennett K.L., Indiveri C., Huber L.A., Superti-Furga G.; RT "SLC38A9 is a component of the lysosomal amino acid sensing machinery that RT controls mTORC1."; RL Nature 519:477-481(2015). RN [78] RP INVOLVEMENT IN FCORD2, AND VARIANT FCORD2 GLY-1456. RX PubMed=25878179; DOI=10.1212/wnl.0000000000001594; RA Leventer R.J., Scerri T., Marsh A.P., Pope K., Gillies G., Maixner W., RA MacGregor D., Harvey A.S., Delatycki M.B., Amor D.J., Crino P., Bahlo M., RA Lockhart P.J.; RT "Hemispheric cortical dysplasia secondary to a mosaic somatic mutation in RT MTOR."; RL Neurology 84:2029-2032(2015). RN [79] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [80] RP ACTIVITY REGULATION. RX PubMed=25567906; DOI=10.1126/science.1257132; RA Wang S., Tsun Z.Y., Wolfson R.L., Shen K., Wyant G.A., Plovanich M.E., RA Yuan E.D., Jones T.D., Chantranupong L., Comb W., Wang T., Bar-Peled L., RA Zoncu R., Straub C., Kim C., Park J., Sabatini B.L., Sabatini D.M.; RT "Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine RT sufficiency to mTORC1."; RL Science 347:188-194(2015). RN [81] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=26584640; DOI=10.1038/cr.2015.133; RA Yin Y., Hua H., Li M., Liu S., Kong Q., Shao T., Wang J., Luo Y., Wang Q., RA Luo T., Jiang Y.; RT "mTORC2 promotes type I insulin-like growth factor receptor and insulin RT receptor activation through the tyrosine kinase activity of mTOR."; RL Cell Res. 26:46-65(2016). RN [82] RP INTERACTION WITH WAC. RX PubMed=26812014; DOI=10.1016/j.devcel.2015.12.019; RA David-Morrison G., Xu Z., Rui Y.N., Charng W.L., Jaiswal M., Yamamoto S., RA Xiong B., Zhang K., Sandoval H., Duraine L., Zuo Z., Zhang S., Bellen H.J.; RT "WAC regulates mTOR activity by acting as an adaptor for the TTT and RT Pontin/Reptin complexes."; RL Dev. Cell 36:139-151(2016). RN [83] RP SUBCELLULAR LOCATION. RX PubMed=27623384; DOI=10.1016/j.devcel.2016.08.001; RA Krishna S., Palm W., Lee Y., Yang W., Bandyopadhyay U., Xu H., Florey O., RA Thompson C.B., Overholtzer M.; RT "PIKfyve Regulates Vacuole Maturation and Nutrient Recovery following RT Engulfment."; RL Dev. Cell 38:536-547(2016). RN [84] RP INVOLVEMENT IN FCORD2, VARIANTS GLU-1376 AND VAL-2501, VARIANTS FCORD2 RP SER-1459; PRO-1460; PHE-2215 AND TYR-2215, AND VARIANTS SKS ARG-1490; RP ILE-1595; THR-1832; CYS-1888 AND ILE-2327. RX PubMed=27830187; DOI=10.1212/nxg.0000000000000118; RA Moeller R.S., Weckhuysen S., Chipaux M., Marsan E., Taly V., Bebin E.M., RA Hiatt S.M., Prokop J.W., Bowling K.M., Mei D., Conti V., de la Grange P., RA Ferrand-Sorbets S., Dorfmueller G., Lambrecq V., Larsen L.H., Leguern E., RA Guerrini R., Rubboli G., Cooper G.M., Baulac S.; RT "Germline and somatic mutations in the MTOR gene in focal cortical RT dysplasia and epilepsy."; RL Neurol. Genet. 2:E118-E118(2016). RN [85] RP FUNCTION. RX PubMed=30171069; DOI=10.1074/jbc.ra118.005354; RA Choppara S., Ganga S., Manne R., Dutta P., Singh S., Santra M.K.; RT "The SCFFBXO46 ubiquitin ligase complex mediates degradation of the tumor RT suppressor FBXO31 and thereby prevents premature cellular senescence."; RL J. Biol. Chem. 293:16291-16306(2018). RN [86] RP SUBCELLULAR LOCATION, AND INTERACTION WITH MEAK7. RX PubMed=29750193; DOI=10.1126/sciadv.aao5838; RA Nguyen J.T., Ray C., Fox A.L., Mendonca D.B., Kim J.K., Krebsbach P.H.; RT "Mammalian EAK-7 activates alternative mTOR signaling to regulate cell RT proliferation and migration."; RL Sci. Adv. 4:EAAO5838-EAAO5838(2018). RN [87] RP FUNCTION, CATALYTIC ACTIVITY, PHOSPHORYLATION AT SER-2159, AND MUTAGENESIS RP OF SER-2159. RX PubMed=29150432; DOI=10.15252/embj.201696164; RA Bodur C., Kazyken D., Huang K., Ekim Ustunel B., Siroky K.A., Tooley A.S., RA Gonzalez I.E., Foley D.H., Acosta-Jaquez H.A., Barnes T.M., Steinl G.K., RA Cho K.W., Lumeng C.N., Riddle S.M., Myers M.G. Jr., Fingar D.C.; RT "The IKK-related kinase TBK1 activates mTORC1 directly in response to RT growth factors and innate immune agonists."; RL EMBO J. 37:19-38(2018). RN [88] RP INTERACTION WITH TM4SF5, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASP-2357 RP AND VAL-2364. RX PubMed=30956113; DOI=10.1016/j.cmet.2019.03.005; RA Jung J.W., Macalino S.J.Y., Cui M., Kim J.E., Kim H.J., Song D.G., RA Nam S.H., Kim S., Choi S., Lee J.W.; RT "Transmembrane 4 L six family member 5 senses arginine for mTORC1 RT signaling."; RL Cell Metab. 29:1306-1319(2019). RN [89] RP FUNCTION. RX PubMed=30704899; DOI=10.1016/j.molcel.2018.12.017; RA Cheng X., Ma X., Zhu Q., Song D., Ding X., Li L., Jiang X., Wang X., RA Tian R., Su H., Shen Z., Chen S., Liu T., Gong W., Liu W., Sun Q.; RT "Pacer is a mediator of mTORC1 and GSK3-TIP60 signaling in regulation of RT autophagosome maturation and lipid metabolism."; RL Mol. Cell 73:1-15(2019). RN [90] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=31112131; DOI=10.7554/elife.43038; RA Jewell J.L., Fu V., Hong A.W., Yu F.X., Meng D., Melick C.H., Wang H., RA Lam W.M., Yuan H.X., Taylor S.S., Guan K.L.; RT "GPCR signaling inhibits mTORC1 via PKA phosphorylation of Raptor."; RL Elife 8:0-0(2019). RN [91] RP FUNCTION. RX PubMed=31695197; DOI=10.1038/s41586-019-1738-6; RA MacVicar T., Ohba Y., Nolte H., Mayer F.C., Tatsuta T., Sprenger H.G., RA Lindner B., Zhao Y., Li J., Bruns C., Krueger M., Habich M., Riemer J., RA Schwarzer R., Pasparakis M., Henschke S., Bruening J.C., Zamboni N., RA Langer T.; RT "Lipid signalling drives proteolytic rewiring of mitochondria by YME1L."; RL Nature 575:361-365(2019). RN [92] RP INTERACTION WITH GPR137B. RX PubMed=31036939; DOI=10.1038/s41556-019-0321-6; RA Gan L., Seki A., Shen K., Iyer H., Han K., Hayer A., Wollman R., Ge X., RA Lin J.R., Dey G., Talbot W.S., Meyer T.; RT "The lysosomal GPCR-like protein GPR137B regulates Rag and mTORC1 RT localization and activity."; RL Nat. Cell Biol. 21:614-626(2019). RN [93] RP FUNCTION. RX PubMed=31601708; DOI=10.1126/science.aay0166; RA Rogala K.B., Gu X., Kedir J.F., Abu-Remaileh M., Bianchi L.F., RA Bottino A.M.S., Dueholm R., Niehaus A., Overwijn D., Fils A.P., Zhou S.X., RA Leary D., Laqtom N.N., Brignole E.J., Sabatini D.M.; RT "Structural basis for the docking of mTORC1 on the lysosomal surface."; RL Science 366:468-475(2019). RN [94] RP INTERACTION WITH RICTOR. RX PubMed=33378666; DOI=10.1016/j.celrep.2020.108564; RA Wrobel L., Siddiqi F.H., Hill S.M., Son S.M., Karabiyik C., Kim H., RA Rubinsztein D.C.; RT "mTORC2 Assembly Is Regulated by USP9X-Mediated Deubiquitination of RT RICTOR."; RL Cell Rep. 33:108564-108564(2020). RN [95] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=32612235; DOI=10.1038/s41586-020-2444-0; RA Napolitano G., Di Malta C., Esposito A., de Araujo M.E.G., Pece S., RA Bertalot G., Matarese M., Benedetti V., Zampelli A., Stasyk T., RA Siciliano D., Venuta A., Cesana M., Vilardo C., Nusco E., Monfregola J., RA Calcagni A., Di Fiore P.P., Huber L.A., Ballabio A.; RT "A substrate-specific mTORC1 pathway underlies Birt-Hogg-Dube syndrome."; RL Nature 585:597-602(2020). RN [96] RP FUNCTION. RX PubMed=32561715; DOI=10.1038/s41467-020-16886-2; RA Son S.M., Park S.J., Stamatakou E., Vicinanza M., Menzies F.M., RA Rubinsztein D.C.; RT "Leucine regulates autophagy via acetylation of the mTORC1 component RT raptor."; RL Nat. Commun. 11:3148-3148(2020). RN [97] RP INTERACTION WITH NCKAP1L. RX PubMed=32647003; DOI=10.1126/science.aay5663; RA Cook S.A., Comrie W.A., Poli M.C., Similuk M., Oler A.J., Faruqi A.J., RA Kuhns D.B., Yang S., Vargas-Hernandez A., Carisey A.F., Fournier B., RA Anderson D.E., Price S., Smelkinson M., Abou Chahla W., Forbes L.R., RA Mace E.M., Cao T.N., Coban-Akdemir Z.H., Jhangiani S.N., Muzny D.M., RA Gibbs R.A., Lupski J.R., Orange J.S., Cuvelier G.D.E., Al Hassani M., RA Al Kaabi N., Al Yafei Z., Jyonouchi S., Raje N., Caldwell J.W., Huang Y., RA Burkhardt J.K., Latour S., Chen B., ElGhazali G., Rao V.K., Chinn I.K., RA Lenardo M.J.; RT "HEM1 deficiency disrupts mTORC2 and F-actin control in inherited RT immunodysregulatory disease."; RL Science 369:202-207(2020). RN [98] RP FUNCTION. RX PubMed=34289345; DOI=10.1016/j.cell.2021.06.028; RA Evavold C.L., Hafner-Bratkovic I., Devant P., D'Andrea J.M., Ngwa E.M., RA Borsic E., Doench J.G., LaFleur M.W., Sharpe A.H., Thiagarajah J.R., RA Kagan J.C.; RT "Control of gasdermin D oligomerization and pyroptosis by the Ragulator- RT Rag-mTORC1 pathway."; RL Cell 184:4495-4511(2021). RN [99] RP INTERACTION WITH SLC38A7. RX PubMed=35561222; DOI=10.1073/pnas.2123261119; RA Meng D., Yang Q., Jeong M.H., Curukovic A., Tiwary S., Melick C.H., RA Lama-Sherpa T.D., Wang H., Huerta-Rosario M., Urquhart G., Zacharias L.G., RA Lewis C., DeBerardinis R.J., Jewell J.L.; RT "SNAT7 regulates mTORC1 via macropinocytosis."; RL Proc. Natl. Acad. Sci. U.S.A. 119:e2123261119-e2123261119(2022). RN [100] RP INTERACTION WITH TSPAN8. RX PubMed=35904232; DOI=10.1002/cbin.11870; RA Zhuang L., Jin G., Hu X., Yang Q., Pei X., Zhao W.; RT "TSPAN8 alleviates high glucose-induced apoptosis and autophagy via RT targeting mTORC2."; RL Cell Biol. Int. 46:1693-1703(2022). RN [101] RP FUNCTION. RX PubMed=36691768; DOI=10.15252/embj.2022112344; RA Shetty S., Hofstetter J., Battaglioni S., Ritz D., Hall M.N.; RT "TORC1 phosphorylates and inhibits the ribosome preservation factor Stm1 to RT activate dormant ribosomes."; RL EMBO J. 42:e112344-e112344(2023). RN [102] RP SUBCELLULAR LOCATION. RX PubMed=37057673; DOI=10.1016/j.gim.2023.100838; RA Reijnders M.R.F., Seibt A., Brugger M., Lamers I.J.C., Ott T., Klaas O., RA Horvath J., Rose A.M.S., Craghill I.M., Brunet T., Graf E., Mayerhanser K., RA Hellebrekers D., Pauck D., Neuen-Jacob E., Rodenburg R.J.T., Wieczorek D., RA Klee D., Mayatepek E., Driessen G., Bindermann R., Averdunk L., RA Lohmeier K., Sinnema M., Stegmann A.P.A., Roepman R., Poulter J.A., RA Distelmaier F.; RT "De novo missense variants in RRAGC lead to a fatal mTORopathy of early RT childhood."; RL Genet. Med. 25:100838-100838(2023). RN [103] RP FUNCTION. RX PubMed=36608670; DOI=10.1016/j.molcel.2022.12.013; RA Nardone C., Palanski B.A., Scott D.C., Timms R.T., Barber K.W., Gu X., RA Mao A., Leng Y., Watson E.V., Schulman B.A., Cole P.A., Elledge S.J.; RT "A central role for regulated protein stability in the control of TFE3 and RT MITF by nutrients."; RL Mol. Cell 83:57-73(2023). RN [104] RP FUNCTION, UBIQUITINATION AT LYS-2066, AND MUTAGENESIS OF LYS-2066. RX PubMed=37979583; DOI=10.1016/j.cmet.2023.10.016; RA Ge M.K., Zhang C., Zhang N., He P., Cai H.Y., Li S., Wu S., Chu X.L., RA Zhang Y.X., Ma H.M., Xia L., Yang S., Yu J.X., Yao S.Y., Zhou X.L., Su B., RA Chen G.Q., Shen S.M.; RT "The tRNA-GCN2-FBXO22-axis-mediated mTOR ubiquitination senses amino acid RT insufficiency."; RL Cell Metab. 35:2216-2230.e8(2023). RN [105] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=37751742; DOI=10.1016/j.molcel.2023.08.032; RA He L., Chen J., Deng P., Huang S., Liu P., Wang C., Huang X., Li Y., RA Chen B., Shi D., Xiao Y., Chen X., Ouyang Y., Song L., Lin C.; RT "Lysosomal cyst(e)ine storage potentiates tolerance to oxidative stress in RT cancer cells."; RL Mol. Cell 83:3502-3519(2023). RN [106] RP X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 2018-2112 IN COMPLEX WITH FKBP1A RP AND INHIBITOR RAPAMYCIN, AND ACTIVITY REGULATION. RX PubMed=8662507; DOI=10.1126/science.273.5272.239; RA Choi J., Chen J., Schreiber S.L., Clardy J.; RT "Structure of the FKBP12-rapamycin complex interacting with the binding RT domain of human FRAP."; RL Science 273:239-242(1996). RN [107] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 2018-2112 IN COMPLEX WITH FKBP1A RP AND INHIBITOR RAPAMYCIN, AND ACTIVITY REGULATION. RX PubMed=10089303; DOI=10.1107/s0907444998014747; RA Liang J., Choi J., Clardy J.; RT "Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 A RT resolution."; RL Acta Crystallogr. D 55:736-744(1999). RN [108] RP 3D-STRUCTURE MODELING, HEAT-REPEATS, AND TPR-REPEATS. RX PubMed=20060908; DOI=10.1016/j.jsb.2010.01.002; RA Knutson B.A.; RT "Insights into the domain and repeat architecture of target of rapamycin."; RL J. Struct. Biol. 170:354-363(2010). RN [109] RP STRUCTURE BY ELECTRON MICROSCOPY (26 ANGSTROMS) OF MTORC1 COMPLEX, AND RP SUBUNIT. RX PubMed=20542007; DOI=10.1016/j.molcel.2010.05.017; RA Yip C.K., Murata K., Walz T., Sabatini D.M., Kang S.A.; RT "Structure of the human mTOR complex I and its implications for rapamycin RT inhibition."; RL Mol. Cell 38:768-774(2010). RN [110] RP X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 1376-2549 IN COMPLEX WITH MLST8, RP SUBUNIT, TPR-REPEATS, DOMAINS, AND MUTAGENESIS OF HIS-2340. RX PubMed=23636326; DOI=10.1038/nature12122; RA Yang H., Rudge D.G., Koos J.D., Vaidialingam B., Yang H.J., Pavletich N.P.; RT "mTOR kinase structure, mechanism and regulation."; RL Nature 497:217-223(2013). RN [111] {ECO:0007744|PDB:5H64} RP STRUCTURE BY ELECTRON MICROSCOPY (4.40 ANGSTROMS) IN COMPLEX WITH RPTOR AND RP MLST8, AND IDENTIFICATION IN THE MTORC1 COMPLEX. RX PubMed=27909983; DOI=10.1007/s13238-016-0346-6; RA Yang H., Wang J., Liu M., Chen X., Huang M., Tan D., Dong M.Q., Wong C.C., RA Wang J., Xu Y., Wang H.W.; RT "4.4 Aa Resolution Cryo-EM structure of human mTOR Complex 1."; RL Protein Cell 7:878-887(2016). RN [112] {ECO:0007744|PDB:5FLC} RP STRUCTURE BY ELECTRON MICROSCOPY (5.90 ANGSTROMS) IN COMPLEX WITH MLST8. RX PubMed=26678875; DOI=10.1126/science.aaa3870; RA Aylett C.H., Sauer E., Imseng S., Boehringer D., Hall M.N., Ban N., RA Maier T.; RT "Architecture of human mTOR complex 1."; RL Science 351:48-52(2016). RN [113] {ECO:0007744|PDB:5WBH, ECO:0007744|PDB:5WBU, ECO:0007744|PDB:5WBY, ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX} RP STRUCTURE BY ELECTRON MICROSCOPY (3.43 ANGSTROMS) IN COMPLEX WITH ATP; RP MAGNESIUM; MLST8; RPTOR; RHEB; AKT1S1; RPS6KB1 AND EIF4EBP1, FUNCTION, RP CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND IDENTIFICATION IN THE MTORC1 RP COMPLEX. RX PubMed=29236692; DOI=10.1038/nature25023; RA Yang H., Jiang X., Li B., Yang H.J., Miller M., Yang A., Dhar A., RA Pavletich N.P.; RT "Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40."; RL Nature 552:368-373(2017). RN [114] {ECO:0007744|PDB:5ZCS} RP STRUCTURE BY ELECTRON MICROSCOPY (4.90 ANGSTROMS) OF THE MTORC2 COMPLEX, RP AND IDENTIFICATION IN THE MTORC2 COMPLEX. RX PubMed=29567957; DOI=10.1038/s41422-018-0029-3; RA Chen X., Liu M., Tian Y., Li J., Qi Y., Zhao D., Wu Z., Huang M., RA Wong C.C.L., Wang H.W., Wang J., Yang H., Xu Y.; RT "Cryo-EM structure of human mTOR complex 2."; RL Cell Res. 28:518-528(2018). RN [115] RP STRUCTURE BY ELECTRON MICROSCOPY OF THE MTORC2 COMPLEX, AND IDENTIFICATION RP IN THE MTORC2 COMPLEX. RX PubMed=29424687; DOI=10.7554/elife.33101; RA Stuttfeld E., Aylett C.H., Imseng S., Boehringer D., Scaiola A., Sauer E., RA Hall M.N., Maier T., Ban N.; RT "Architecture of the human mTORC2 core complex."; RL Elife 7:0-0(2018). RN [116] {ECO:0007744|PDB:6SB0, ECO:0007744|PDB:6SB2} RP STRUCTURE BY ELECTRON MICROSCOPY (5.50 ANGSTROMS) IN COMPLEX WITH RRAGA; RP RRAGC; RPTOR; MLST8 AND AKT1S1, IDENTIFICATION IN THE MTORC1 COMPLEX, AND RP SUBCELLULAR LOCATION. RX PubMed=31601764; DOI=10.1126/science.aax3939; RA Anandapadamanaban M., Masson G.R., Perisic O., Berndt A., Kaufman J., RA Johnson C.M., Santhanam B., Rogala K.B., Sabatini D.M., Williams R.L.; RT "Architecture of human Rag GTPase heterodimers and their complex with RT mTORC1."; RL Science 366:203-210(2019). RN [117] {ECO:0007744|PDB:6ZWM, ECO:0007744|PDB:6ZWO} RP STRUCTURE BY ELECTRON MICROSCOPY (3.00 ANGSTROMS) OF THE MTORC2 COMPLEX IN RP COMPLEX WITH 1D-MYO-INOSITOL HEXAKISPHOSPHATE, AND IDENTIFICATION IN THE RP MTORC2 COMPLEX. RX PubMed=33158864; DOI=10.1126/sciadv.abc1251; RA Scaiola A., Mangia F., Imseng S., Boehringer D., Berneiser K., RA Shimobayashi M., Stuttfeld E., Hall M.N., Ban N., Maier T.; RT "The 3.2-Aa resolution structure of human mTORC2."; RL Sci. Adv. 6:0-0(2020). RN [118] {ECO:0007744|PDB:7PE7, ECO:0007744|PDB:7PE8, ECO:0007744|PDB:7PE9, ECO:0007744|PDB:7PEA, ECO:0007744|PDB:7PEB, ECO:0007744|PDB:7PEC} RP X-RAY CRYSTALLOGRAPHY (1.93 ANGSTROMS) OF 1-230 IN COMPLEX WITH DEPTOR; RP MLST8; MAPKAP1; RICTOR AND RPTOR, ACTIVITY REGULATION, IDENTIFICATION IN RP THE MTORC1 COMPLEX, AND IDENTIFICATION IN THE MTORC2 COMPLEX. RX PubMed=34519268; DOI=10.7554/elife.70871; RA Waelchli M., Berneiser K., Mangia F., Imseng S., Craigie L.M., RA Stuttfeld E., Hall M.N., Maier T.; RT "Regulation of human mTOR complexes by DEPTOR."; RL Elife 10:0-0(2021). RN [119] {ECO:0007744|PDB:7OWG} RP STRUCTURE BY ELECTRON MICROSCOPY (4.70 ANGSTROMS) IN COMPLEX WITH DEPTOR; RP MLST8 AND RPTOR, ACTIVITY REGULATION, IDENTIFICATION IN THE MTORC1 COMPLEX, RP AND FUNCTION. RX PubMed=34519269; DOI=10.7554/elife.68799; RA Heimhalt M., Berndt A., Wagstaff J., Anandapadamanaban M., Perisic O., RA Maslen S., McLaughlin S., Yu C.W., Masson G.R., Boland A., Ni X., RA Yamashita K., Murshudov G.N., Skehel M., Freund S.M., Williams R.L.; RT "Bipartite binding and partial inhibition links DEPTOR and mTOR in a RT mutually antagonistic embrace."; RL Elife 10:0-0(2021). RN [120] {ECO:0007744|PDB:7TZO} RP STRUCTURE BY ELECTRON MICROSCOPY (3.28 ANGSTROMS) OF THE MTORC2 COMPLEX, RP FUNCTION, AND IDENTIFICATION IN THE MTORC2 COMPLEX. RX PubMed=35926713; DOI=10.1016/j.jbc.2022.102288; RA Yu Z., Chen J., Takagi E., Wang F., Saha B., Liu X., Joubert L.M., RA Gleason C.E., Jin M., Li C., Nowotny C., Agard D., Cheng Y., Pearce D.; RT "Interactions between mTORC2 core subunits Rictor and mSin1 dictate RT selective and context-dependent phosphorylation of substrate kinases SGK1 RT and Akt."; RL J. Biol. Chem. 298:102288-102288(2022). RN [121] {ECO:0007744|PDB:7UXC, ECO:0007744|PDB:7UXH} RP STRUCTURE BY ELECTRON MICROSCOPY (2.90 ANGSTROMS) IN COMPLEX WITH RRAGA; RP RRAGC; LAMTOR1; LAMTOR2; LAMTOR3; LAMTOR4; LAMTOR5; RPTOR; MLST8 AND TFEB, RP FUNCTION, ACTIVITY REGULATION, AND IDENTIFICATION IN THE MTORC1 COMPLEX. RX PubMed=36697823; DOI=10.1038/s41586-022-05652-7; RA Cui Z., Napolitano G., de Araujo M.E.G., Esposito A., Monfregola J., RA Huber L.A., Ballabio A., Hurley J.H.; RT "Structure of the lysosomal mTORC1-TFEB-Rag-Ragulator megacomplex."; RL Nature 614:572-579(2023). RN [122] RP VARIANTS [LARGE SCALE ANALYSIS] SER-8; THR-135; VAL-1083; VAL-1134; RP PHE-1178; VAL-2011; TYR-2215 AND LEU-2476. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [123] RP VARIANTS PHE-2220 AND ALA-2406. RX PubMed=21248752; DOI=10.1038/nature09639; RA Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P., Davies H., RA Jones D., Lin M.L., Teague J., Bignell G., Butler A., Cho J., RA Dalgliesh G.L., Galappaththige D., Greenman C., Hardy C., Jia M., RA Latimer C., Lau K.W., Marshall J., McLaren S., Menzies A., Mudie L., RA Stebbings L., Largaespada D.A., Wessels L.F.A., Richard S., Kahnoski R.J., RA Anema J., Tuveson D.A., Perez-Mancera P.A., Mustonen V., Fischer A., RA Adams D.J., Rust A., Chan-On W., Subimerb C., Dykema K., Furge K., RA Campbell P.J., Teh B.T., Stratton M.R., Futreal P.A.; RT "Exome sequencing identifies frequent mutation of the SWI/SNF complex gene RT PBRM1 in renal carcinoma."; RL Nature 469:539-542(2011). CC -!- FUNCTION: Serine/threonine protein kinase which is a central regulator CC of cellular metabolism, growth and survival in response to hormones, CC growth factors, nutrients, energy and stress signals (PubMed:12087098, CC PubMed:12150925, PubMed:12150926, PubMed:12231510, PubMed:12718876, CC PubMed:14651849, PubMed:15268862, PubMed:15467718, PubMed:15545625, CC PubMed:15718470, PubMed:18497260, PubMed:18762023, PubMed:18925875, CC PubMed:20516213, PubMed:20537536, PubMed:21659604, PubMed:23429703, CC PubMed:23429704, PubMed:25799227, PubMed:26018084, PubMed:29150432, CC PubMed:29236692, PubMed:31112131, PubMed:31601708, PubMed:32561715, CC PubMed:34519269, PubMed:37751742). MTOR directly or indirectly CC regulates the phosphorylation of at least 800 proteins CC (PubMed:15268862, PubMed:15467718, PubMed:17517883, PubMed:18372248, CC PubMed:18497260, PubMed:18925875, PubMed:20516213, PubMed:21576368, CC PubMed:21659604, PubMed:23429704, PubMed:30171069, PubMed:29236692, CC PubMed:37751742). Functions as part of 2 structurally and functionally CC distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2) CC (PubMed:15268862, PubMed:15467718, PubMed:18497260, PubMed:18925875, CC PubMed:20516213, PubMed:21576368, PubMed:21659604, PubMed:23429704, CC PubMed:29424687, PubMed:29567957, PubMed:35926713). In response to CC nutrients, growth factors or amino acids, mTORC1 is recruited to the CC lysosome membrane and promotes protein, lipid and nucleotide synthesis CC by phosphorylating key regulators of mRNA translation and ribosome CC synthesis (PubMed:12087098, PubMed:12150925, PubMed:12150926, CC PubMed:12231510, PubMed:12718876, PubMed:14651849, PubMed:15268862, CC PubMed:15467718, PubMed:15545625, PubMed:15718470, PubMed:18497260, CC PubMed:18762023, PubMed:18925875, PubMed:20516213, PubMed:20537536, CC PubMed:21659604, PubMed:23429703, PubMed:23429704, PubMed:25799227, CC PubMed:26018084, PubMed:29150432, PubMed:29236692, PubMed:31112131, CC PubMed:34519269). This includes phosphorylation of EIF4EBP1 and release CC of its inhibition toward the elongation initiation factor 4E (eiF4E) CC (PubMed:24403073, PubMed:29236692). Moreover, phosphorylates and CC activates RPS6KB1 and RPS6KB2 that promote protein synthesis by CC modulating the activity of their downstream targets including ribosomal CC protein S6, eukaryotic translation initiation factor EIF4B, and the CC inhibitor of translation initiation PDCD4 (PubMed:12087098, CC PubMed:12150925, PubMed:18925875, PubMed:29150432, PubMed:29236692). CC Stimulates the pyrimidine biosynthesis pathway, both by acute CC regulation through RPS6KB1-mediated phosphorylation of the biosynthetic CC enzyme CAD, and delayed regulation, through transcriptional enhancement CC of the pentose phosphate pathway which produces 5-phosphoribosyl-1- CC pyrophosphate (PRPP), an allosteric activator of CAD at a later step in CC synthesis, this function is dependent on the mTORC1 complex CC (PubMed:23429703, PubMed:23429704). Regulates ribosome synthesis by CC activating RNA polymerase III-dependent transcription through CC phosphorylation and inhibition of MAF1 an RNA polymerase III-repressor CC (PubMed:20516213). Activates dormant ribosomes by mediating CC phosphorylation of SERBP1, leading to SERBP1 inactivation and CC reactivation of translation (PubMed:36691768). In parallel to protein CC synthesis, also regulates lipid synthesis through SREBF1/SREBP1 and CC LPIN1 (PubMed:23426360). To maintain energy homeostasis mTORC1 may also CC regulate mitochondrial biogenesis through regulation of PPARGC1A (By CC similarity). In the same time, mTORC1 inhibits catabolic pathways: CC negatively regulates autophagy through phosphorylation of ULK1 CC (PubMed:32561715). Under nutrient sufficiency, phosphorylates ULK1 at CC 'Ser-758', disrupting the interaction with AMPK and preventing CC activation of ULK1 (PubMed:32561715). Also prevents autophagy through CC phosphorylation of the autophagy inhibitor DAP (PubMed:20537536). Also CC prevents autophagy by phosphorylating RUBCNL/Pacer under nutrient-rich CC conditions (PubMed:30704899). Prevents autophagy by mediating CC phosphorylation of AMBRA1, thereby inhibiting AMBRA1 ability to mediate CC ubiquitination of ULK1 and interaction between AMBRA1 and PPP2CA CC (PubMed:23524951, PubMed:25438055). mTORC1 exerts a feedback control on CC upstream growth factor signaling that includes phosphorylation and CC activation of GRB10 a INSR-dependent signaling suppressor CC (PubMed:21659604). Among other potential targets mTORC1 may CC phosphorylate CLIP1 and regulate microtubules (PubMed:12231510). The CC mTORC1 complex is inhibited in response to starvation and amino acid CC depletion (PubMed:12150925, PubMed:12150926, PubMed:24403073, CC PubMed:31695197). The non-canonical mTORC1 complex, which acts CC independently of RHEB, specifically mediates phosphorylation of MiT/TFE CC factors MITF, TFEB and TFE3 in the presence of nutrients, promoting CC their cytosolic retention and inactivation (PubMed:22343943, CC PubMed:22576015, PubMed:22692423, PubMed:24448649, PubMed:32612235, CC PubMed:36608670, PubMed:36697823). Upon starvation or lysosomal stress, CC inhibition of mTORC1 induces dephosphorylation and nuclear CC translocation of TFEB and TFE3, promoting their transcription factor CC activity (PubMed:22343943, PubMed:22576015, PubMed:22692423, CC PubMed:24448649, PubMed:32612235, PubMed:36608670). The mTORC1 complex CC regulates pyroptosis in macrophages by promoting GSDMD oligomerization CC (PubMed:34289345). MTOR phosphorylates RPTOR which in turn inhibits CC mTORC1 (By similarity). As part of the mTORC2 complex, MTOR transduces CC signals from growth factors to pathways involved in proliferation, CC cytoskeletal organization, lipogenesis and anabolic output CC (PubMed:15268862, PubMed:15467718, PubMed:24670654, PubMed:29424687, CC PubMed:29567957, PubMed:35926713). In response to growth factors, CC mTORC2 phosphorylates and activates AGC protein kinase family members, CC including AKT (AKT1, AKT2 and AKT3), PKC (PRKCA, PRKCB and PRKCE) and CC SGK1 (PubMed:15268862, PubMed:15467718, PubMed:21376236, CC PubMed:24670654, PubMed:29424687, PubMed:29567957, PubMed:35926713). In CC contrast to mTORC1, mTORC2 is nutrient-insensitive (PubMed:15467718). CC mTORC2 plays a critical role in AKT1 activation by mediating CC phosphorylation of different sites depending on the context, such as CC 'Thr-450', 'Ser-473', 'Ser-477' or 'Thr-479', facilitating the CC phosphorylation of the activation loop of AKT1 on 'Thr-308' by CC PDPK1/PDK1 which is a prerequisite for full activation CC (PubMed:15718470, PubMed:21376236, PubMed:24670654, PubMed:29424687, CC PubMed:29567957). mTORC2 also regulates the phosphorylation of SGK1 at CC 'Ser-422' (PubMed:18925875). mTORC2 may regulate the actin CC cytoskeleton, through phosphorylation of PRKCA, PXN and activation of CC the Rho-type guanine nucleotide exchange factors RHOA and RAC1A or CC RAC1B (PubMed:15268862). The mTORC2 complex also phosphorylates various CC proteins involved in insulin signaling, such as FBXW8 and IGF2BP1 (By CC similarity). May also regulate insulin signaling by acting as a CC tyrosine protein kinase that catalyzes phosphorylation of IGF1R and CC INSR; additional evidence are however required to confirm this result CC in vivo (PubMed:26584640). Regulates osteoclastogenesis by adjusting CC the expression of CEBPB isoforms (By similarity). Plays an important CC regulatory role in the circadian clock function; regulates period CC length and rhythm amplitude of the suprachiasmatic nucleus (SCN) and CC liver clocks (By similarity). {ECO:0000250|UniProtKB:Q9JLN9, CC ECO:0000269|PubMed:12087098, ECO:0000269|PubMed:12150925, CC ECO:0000269|PubMed:12150926, ECO:0000269|PubMed:12231510, CC ECO:0000269|PubMed:12718876, ECO:0000269|PubMed:14651849, CC ECO:0000269|PubMed:15268862, ECO:0000269|PubMed:15467718, CC ECO:0000269|PubMed:15545625, ECO:0000269|PubMed:15718470, CC ECO:0000269|PubMed:17517883, ECO:0000269|PubMed:18372248, CC ECO:0000269|PubMed:18497260, ECO:0000269|PubMed:18762023, CC ECO:0000269|PubMed:18925875, ECO:0000269|PubMed:20516213, CC ECO:0000269|PubMed:20537536, ECO:0000269|PubMed:21376236, CC ECO:0000269|PubMed:21576368, ECO:0000269|PubMed:21659604, CC ECO:0000269|PubMed:22343943, ECO:0000269|PubMed:22576015, CC ECO:0000269|PubMed:22692423, ECO:0000269|PubMed:23426360, CC ECO:0000269|PubMed:23429703, ECO:0000269|PubMed:23429704, CC ECO:0000269|PubMed:23524951, ECO:0000269|PubMed:24403073, CC ECO:0000269|PubMed:24448649, ECO:0000269|PubMed:24670654, CC ECO:0000269|PubMed:25438055, ECO:0000269|PubMed:25799227, CC ECO:0000269|PubMed:26018084, ECO:0000269|PubMed:26584640, CC ECO:0000269|PubMed:29150432, ECO:0000269|PubMed:29236692, CC ECO:0000269|PubMed:29424687, ECO:0000269|PubMed:29567957, CC ECO:0000269|PubMed:30171069, ECO:0000269|PubMed:30704899, CC ECO:0000269|PubMed:31112131, ECO:0000269|PubMed:31601708, CC ECO:0000269|PubMed:31695197, ECO:0000269|PubMed:32561715, CC ECO:0000269|PubMed:32612235, ECO:0000269|PubMed:34289345, CC ECO:0000269|PubMed:34519269, ECO:0000269|PubMed:35926713, CC ECO:0000269|PubMed:36608670, ECO:0000269|PubMed:36691768, CC ECO:0000269|PubMed:36697823, ECO:0000269|PubMed:37751742}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12087098, ECO:0000269|PubMed:12150925, CC ECO:0000269|PubMed:12231510, ECO:0000269|PubMed:15268862, CC ECO:0000269|PubMed:15467718, ECO:0000269|PubMed:15718470, CC ECO:0000269|PubMed:17517883, ECO:0000269|PubMed:18372248, CC ECO:0000269|PubMed:18925875, ECO:0000269|PubMed:20022946, CC ECO:0000269|PubMed:20516213, ECO:0000269|PubMed:20537536, CC ECO:0000269|PubMed:21659604, ECO:0000269|PubMed:22343943, CC ECO:0000269|PubMed:22576015, ECO:0000269|PubMed:22692423, CC ECO:0000269|PubMed:29150432}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12087098, ECO:0000269|PubMed:12150925, CC ECO:0000269|PubMed:12231510, ECO:0000269|PubMed:15268862, CC ECO:0000269|PubMed:15467718, ECO:0000269|PubMed:15718470, CC ECO:0000269|PubMed:18925875, ECO:0000269|PubMed:20516213, CC ECO:0000269|PubMed:20537536, ECO:0000269|PubMed:21659604, CC ECO:0000269|PubMed:29150432, ECO:0000269|PubMed:29236692, CC ECO:0000269|PubMed:37751742}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000305|PubMed:26584640}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:10597; CC Evidence={ECO:0000305|PubMed:26584640}; CC -!- ACTIVITY REGULATION: The mTORC1 complex is activated in response to CC nutrients, growth factors or amino acids: activation requires CC relocalization of the mTORC1 complex to lysosomes that is mediated by CC the Ragulator complex, SLC38A9, and the Rag GTPases RagA/RRAGA, CC RagB/RRAGB, RagC/RRAGC and RagD/RRAGD (PubMed:18497260, CC PubMed:20381137, PubMed:25561175, PubMed:25567906). Activation of CC mTORC1 by growth factors such as insulin involves AKT1-mediated CC phosphorylation of TSC1-TSC2, which leads to the activation of the RHEB CC GTPase a potent activator of the protein kinase activity of mTORC1 CC (PubMed:14651849, PubMed:15545625, PubMed:29236692). Insulin-stimulated CC and amino acid-dependent phosphorylation at Ser-1261 promotes CC autophosphorylation and the activation of mTORC1 (PubMed:19487463). On CC the other hand, low cellular energy levels can inhibit mTORC1 through CC activation of PRKAA1 while hypoxia inhibits mTORC1 through a REDD1- CC dependent mechanism which may also require PRKAA1 (PubMed:14651849, CC PubMed:15545625). The kinase activity of MTOR within the mTORC1 complex CC is positively regulated by MLST8 (PubMed:12718876). The kinase activity CC of MTOR is inhibited by DEPTOR and AKT1S1 (PubMed:17386266, CC PubMed:19446321, PubMed:29236692, PubMed:34519268, PubMed:34519269). CC The non-canonical mTORC1 complex is independent of the RHEB GTPase and CC specifically mediates phosphorylation of MiT/TFE factors TFEB and TFE3 CC but not other mTORC1 substrates: it is activated by FLCN, which CC activates Rag GTPases RagC/RRAGC and RagD/RRAGD (PubMed:32612235, CC PubMed:36697823). MTOR is the target of the immunosuppressive and anti- CC cancer drug rapamycin which acts in complex with FKBP1A/FKBP12, and CC specifically inhibits its kinase activity (PubMed:10089303, CC PubMed:8662507). mTORC2 is also activated by growth factors, but seems CC to be nutrient-insensitive (PubMed:15467718). mTORC2 associates and is CC directly activated by ribosomes (PubMed:21376236). mTORC2 may also be CC regulated by RHEB but in an indirect manner through the PI3K signaling CC pathway (PubMed:15467718). {ECO:0000269|PubMed:10089303, CC ECO:0000269|PubMed:12718876, ECO:0000269|PubMed:14651849, CC ECO:0000269|PubMed:15467718, ECO:0000269|PubMed:15545625, CC ECO:0000269|PubMed:17386266, ECO:0000269|PubMed:18497260, CC ECO:0000269|PubMed:19446321, ECO:0000269|PubMed:19487463, CC ECO:0000269|PubMed:20381137, ECO:0000269|PubMed:21376236, CC ECO:0000269|PubMed:25561175, ECO:0000269|PubMed:25567906, CC ECO:0000269|PubMed:29236692, ECO:0000269|PubMed:32612235, CC ECO:0000269|PubMed:34519268, ECO:0000269|PubMed:34519269, CC ECO:0000269|PubMed:36697823, ECO:0000269|PubMed:8662507}. CC -!- SUBUNIT: Part of the mechanistic target of rapamycin complex 1 (mTORC1) CC which contains MTOR, MLST8 and RPTOR (PubMed:12150925, PubMed:12150926, CC PubMed:12408816, PubMed:12718876, PubMed:18925875, PubMed:20542007, CC PubMed:23636326, PubMed:24403073, PubMed:26678875, PubMed:27909983, CC PubMed:29236692, PubMed:31601764, PubMed:34519268, PubMed:34519269, CC PubMed:36697823). The mTORC1 complex is a 1 Md obligate dimer of two CC stoichiometric heterotetramers with overall dimensions of 290 A x 210 A CC x 135 A (PubMed:20542007, PubMed:23636326). It has a rhomboid shape and CC a central cavity, the dimeric interfaces are formed by interlocking CC interactions between the two MTOR and the two RPTOR subunits CC (PubMed:20542007, PubMed:23636326, PubMed:27909983). The MLST8 subunit CC forms distal foot-like protuberances, and contacts only one MTOR within CC the complex, while the small AKT1S1/PRAS40 localizes to the midsection CC of the central core, in close proximity to RPTOR (PubMed:20542007, CC PubMed:23636326, PubMed:27909983, PubMed:29236692). mTORC1 associates CC with AKT1S1/PRAS40, which inhibits its activity by blocking MTOR CC substrate-recruitment site (PubMed:17386266, PubMed:29236692). CC Component of the mechanistic target of rapamycin complex 2 (mTORC2), CC consisting in two heterotretramers composed of MTOR, MLST8, RICTOR and CC MAPKAP1/SIN1 (PubMed:15268862, PubMed:15467718, PubMed:17599906, CC PubMed:18925875, PubMed:29424687, PubMed:29567957, PubMed:33158864, CC PubMed:35926713). Interacts with PLPP7 and PML (By similarity). CC Interacts with PRR5 and RICTOR; the interaction is direct within the CC mTORC2 complex and interaction with RICTOR is enhanced by CC deubiquitination of RICTOR by USP9X (PubMed:17599906, PubMed:33378666, CC PubMed:29424687, PubMed:34519268). mTORC1 and mTORC2 associate with CC DEPTOR, which regulates their activity (PubMed:19446321, CC PubMed:34519268, PubMed:34519269). Interacts with WAC; WAC positively CC regulates MTOR activity by promoting the assembly of the TTT complex CC composed of TELO2, TTI1 and TTI2 and the RUVBL complex composed of CC RUVBL1 and RUVBL2 into the TTT-RUVBL complex which leads to the CC dimerization of the mTORC1 complex and its subsequent activation CC (PubMed:26812014). Interacts with UBQLN1 (PubMed:11853878). Interacts CC with TTI1 and TELO2 (PubMed:20427287, PubMed:20801936, CC PubMed:20810650). Interacts with CLIP1; phosphorylates and regulates CC CLIP1 (PubMed:12231510). Interacts with NBN (PubMed:23762398). CC Interacts with HTR6 (PubMed:23027611). Interacts with BRAT1 CC (PubMed:25657994). Interacts with MEAK7 (via C-terminal domain); the CC interaction increases upon nutrient stimulation (PubMed:29750193). CC Interacts with TM4SF5; the interaction is positively regulated by CC arginine and is negatively regulated by leucine (PubMed:30956113). CC Interacts with GPR137B (PubMed:31036939). Interacts with NCKAP1L CC (PubMed:32647003). Interacts with TPCN1 and TPCN2; the interaction is CC required for TPCN1 and TPCN2 sensitivity to ATP (PubMed:23394946). CC Interacts with ATP6V1A and with CRYAB, forming a ternary complex (By CC similarity). Interacts with SLC38A7; this interaction mediates the CC recruitment of mTORC1 to the lysosome and its subsequent activation CC (PubMed:35561222). Interacts with TSPAN8 (PubMed:35904232). CC {ECO:0000250|UniProtKB:Q9JLN9, ECO:0000269|PubMed:11853878, CC ECO:0000269|PubMed:12150925, ECO:0000269|PubMed:12150926, CC ECO:0000269|PubMed:12231510, ECO:0000269|PubMed:12408816, CC ECO:0000269|PubMed:12718876, ECO:0000269|PubMed:15268862, CC ECO:0000269|PubMed:15467718, ECO:0000269|PubMed:17386266, CC ECO:0000269|PubMed:17599906, ECO:0000269|PubMed:18925875, CC ECO:0000269|PubMed:19446321, ECO:0000269|PubMed:20427287, CC ECO:0000269|PubMed:20542007, ECO:0000269|PubMed:20801936, CC ECO:0000269|PubMed:20810650, ECO:0000269|PubMed:23027611, CC ECO:0000269|PubMed:23394946, ECO:0000269|PubMed:23636326, CC ECO:0000269|PubMed:23762398, ECO:0000269|PubMed:24403073, CC ECO:0000269|PubMed:25657994, ECO:0000269|PubMed:26678875, CC ECO:0000269|PubMed:26812014, ECO:0000269|PubMed:27909983, CC ECO:0000269|PubMed:29236692, ECO:0000269|PubMed:29424687, CC ECO:0000269|PubMed:29567957, ECO:0000269|PubMed:29750193, CC ECO:0000269|PubMed:30956113, ECO:0000269|PubMed:31036939, CC ECO:0000269|PubMed:31601764, ECO:0000269|PubMed:32647003, CC ECO:0000269|PubMed:33158864, ECO:0000269|PubMed:33378666, CC ECO:0000269|PubMed:34519268, ECO:0000269|PubMed:34519269, CC ECO:0000269|PubMed:35561222, ECO:0000269|PubMed:35904232, CC ECO:0000269|PubMed:35926713, ECO:0000269|PubMed:36697823}. CC -!- INTERACTION: CC P42345; P31749: AKT1; NbExp=6; IntAct=EBI-359260, EBI-296087; CC P42345; Q07817-1: BCL2L1; NbExp=4; IntAct=EBI-359260, EBI-287195; CC P42345; Q6UXB4: CLEC4G; NbExp=4; IntAct=EBI-359260, EBI-2114729; CC P42345; Q8TB45: DEPTOR; NbExp=5; IntAct=EBI-359260, EBI-2359040; CC P42345; Q13541: EIF4EBP1; NbExp=2; IntAct=EBI-359260, EBI-74090; CC P42345; Q969H0: FBXW7; NbExp=5; IntAct=EBI-359260, EBI-359574; CC P42345; P62942: FKBP1A; NbExp=5; IntAct=EBI-359260, EBI-1027571; CC P42345; P24522: GADD45A; NbExp=4; IntAct=EBI-359260, EBI-448167; CC P42345; Q8WUA4: GTF3C2; NbExp=3; IntAct=EBI-359260, EBI-1237062; CC P42345; Q9BVC4: MLST8; NbExp=7; IntAct=EBI-359260, EBI-1387471; CC P42345; Q9BVC4-1: MLST8; NbExp=7; IntAct=EBI-359260, EBI-16056342; CC P42345; Q13615: MTMR3; NbExp=3; IntAct=EBI-359260, EBI-371938; CC P42345; P42345: MTOR; NbExp=2; IntAct=EBI-359260, EBI-359260; CC P42345; Q9Y4G2: PLEKHM1; NbExp=6; IntAct=EBI-359260, EBI-473814; CC P42345; Q8TCU6: PREX1; NbExp=11; IntAct=EBI-359260, EBI-1046542; CC P42345; P62820: RAB1A; NbExp=4; IntAct=EBI-359260, EBI-716845; CC P42345; Q15382: RHEB; NbExp=4; IntAct=EBI-359260, EBI-1055287; CC P42345; Q6R327: RICTOR; NbExp=37; IntAct=EBI-359260, EBI-1387196; CC P42345; Q8N122: RPTOR; NbExp=48; IntAct=EBI-359260, EBI-1567928; CC P42345; Q96EB6: SIRT1; NbExp=2; IntAct=EBI-359260, EBI-1802965; CC P42345; O14894: TM4SF5; NbExp=7; IntAct=EBI-359260, EBI-19125949; CC P42345; Q92544: TM9SF4; NbExp=4; IntAct=EBI-359260, EBI-6138615; CC P42345; Q8NHX9: TPCN2; NbExp=2; IntAct=EBI-359260, EBI-5239949; CC P42345; O75385: ULK1; NbExp=7; IntAct=EBI-359260, EBI-908831; CC P42345; P63104: YWHAZ; NbExp=3; IntAct=EBI-359260, EBI-347088; CC -!- SUBCELLULAR LOCATION: Lysosome membrane {ECO:0000269|PubMed:18497260, CC ECO:0000269|PubMed:20381137, ECO:0000269|PubMed:29750193, CC ECO:0000269|PubMed:30956113, ECO:0000269|PubMed:31112131, CC ECO:0000269|PubMed:31601764, ECO:0000269|PubMed:37057673}; Peripheral CC membrane protein {ECO:0000269|PubMed:30956113, CC ECO:0000269|PubMed:31112131}; Cytoplasmic side CC {ECO:0000269|PubMed:30956113, ECO:0000269|PubMed:31112131}. Endoplasmic CC reticulum membrane {ECO:0000269|PubMed:14578359}; Peripheral membrane CC protein {ECO:0000269|PubMed:14578359}; Cytoplasmic side CC {ECO:0000269|PubMed:14578359}. Golgi apparatus membrane CC {ECO:0000269|PubMed:14578359}; Peripheral membrane protein CC {ECO:0000269|PubMed:14578359}; Cytoplasmic side CC {ECO:0000269|PubMed:14578359}. Cell membrane CC {ECO:0000269|PubMed:21867682}; Peripheral membrane protein CC {ECO:0000269|PubMed:14578359}. Mitochondrion outer membrane CC {ECO:0000269|PubMed:11930000, ECO:0000269|PubMed:14578359}; Peripheral CC membrane protein {ECO:0000269|PubMed:11930000, CC ECO:0000269|PubMed:14578359}; Cytoplasmic side CC {ECO:0000269|PubMed:11930000, ECO:0000269|PubMed:14578359}. Cytoplasm CC {ECO:0000269|PubMed:11930000, ECO:0000269|PubMed:18497260}. Nucleus CC {ECO:0000250|UniProtKB:Q9JLN9}. Nucleus, PML body CC {ECO:0000250|UniProtKB:Q9JLN9}. Microsome membrane CC {ECO:0000269|PubMed:9434772}. Cytoplasmic vesicle, phagosome CC {ECO:0000269|PubMed:27623384}. Note=Shuttles between cytoplasm and CC nucleus. Accumulates in the nucleus in response to hypoxia (By CC similarity). Targeting to lysosomes depends on amino acid availability CC and RRAGA and RRAGB (PubMed:18497260, PubMed:20381137). Lysosome CC targeting also depends on interaction with MEAK7. Translocates to the CC lysosome membrane in the presence of TM4SF5 (PubMed:30956113). The CC mTORC2 complex localizes to membranes: mTORC2 is active at the plasma CC membrane, endoplasmic reticulum membrane and lysosomes CC (PubMed:21867682). {ECO:0000250|UniProtKB:Q9JLN9, CC ECO:0000269|PubMed:18497260, ECO:0000269|PubMed:20381137, CC ECO:0000269|PubMed:21867682, ECO:0000269|PubMed:29750193, CC ECO:0000269|PubMed:30956113}. CC -!- TISSUE SPECIFICITY: Expressed in numerous tissues, with highest levels CC in testis. {ECO:0000269|PubMed:12408816, ECO:0000269|PubMed:7809080}. CC -!- DOMAIN: The kinase domain (PI3K/PI4K) is intrinsically active but has a CC highly restricted catalytic center. {ECO:0000269|PubMed:23636326}. CC -!- DOMAIN: The FAT domain forms three discontinuous subdomains of alpha- CC helical TPR repeats plus a single subdomain of HEAT repeats. The four CC domains pack sequentially to form a C-shaped a-solenoid that clamps CC onto the kinase domain (PubMed:23636326). CC {ECO:0000269|PubMed:23636326}. CC -!- PTM: Autophosphorylates when part of mTORC1 or mTORC2 (PubMed:15467718, CC PubMed:20022946, PubMed:9434772). Phosphorylation at Ser-1261, Ser-2159 CC and Thr-2164 promotes autophosphorylation (PubMed:19487463). CC Phosphorylated at Ser-2448 by RPS6KB1 (PubMed:15899889, CC PubMed:15905173, PubMed:19145465). Phosphorylation in the kinase domain CC modulates the interactions of MTOR with RPTOR and AKT1S1/PRAS40 and CC leads to increased intrinsic mTORC1 kinase activity (PubMed:15905173, CC PubMed:19145465, PubMed:21576368). Phosphorylation at Ser-2159 by TBK1 CC in response to growth factors and pathogen recognition receptors CC promotes mTORC1 activity (PubMed:29150432). Phosphorylation at Ser-2159 CC by TBK1 in response to EGF growth factor promotes mTORC2 activity, CC leading to AKT1 phosphorylation and activation (By similarity). CC Phosphorylation at Thr-2173 in the ATP-binding region by AKT1 strongly CC reduces kinase activity (PubMed:24247430). CC {ECO:0000250|UniProtKB:Q9JLN9, ECO:0000269|PubMed:15467718, CC ECO:0000269|PubMed:15905173, ECO:0000269|PubMed:19145465, CC ECO:0000269|PubMed:19487463, ECO:0000269|PubMed:20022946, CC ECO:0000269|PubMed:21576368, ECO:0000269|PubMed:24247430, CC ECO:0000269|PubMed:29150432, ECO:0000269|PubMed:9434772}. CC -!- PTM: Ubiquitinated at Lys-2066 by the SCF(FBXO22) complex via 'Lys-27'- CC linked ubiquitination prevents mTORC1 substrate recruitment. CC {ECO:0000269|PubMed:37979583}. CC -!- DISEASE: Smith-Kingsmore syndrome (SKS) [MIM:616638]: An autosomal CC dominant syndrome characterized by intellectual disability, CC macrocephaly, seizures, umbilical hernia, and facial dysmorphic CC features. {ECO:0000269|PubMed:25851998, ECO:0000269|PubMed:26542245, CC ECO:0000269|PubMed:27830187}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Focal cortical dysplasia 2 (FCORD2) [MIM:607341]: A form of CC focal cortical dysplasia, a malformation of cortical development that CC results in medically refractory epilepsy in the pediatric population CC and in adults. FCORD2 is a severe form, with onset usually in CC childhood, characterized by disrupted cortical lamination and specific CC cytological abnormalities. It is classified in 2 subtypes: type IIA CC characterized by dysmorphic neurons and lack of balloon cells; type IIB CC with dysmorphic neurons and balloon cells. CC {ECO:0000269|PubMed:25799227, ECO:0000269|PubMed:25878179, CC ECO:0000269|PubMed:26018084, ECO:0000269|PubMed:27830187}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC39933.1; Type=Frameshift; Evidence={ECO:0000305}; CC Sequence=BAE06077.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40639/FRAP1"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=Mammalian target of rapamycin entry; CC URL="https://en.wikipedia.org/wiki/Mammalian_target_of_rapamycin"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L34075; AAA58486.1; -; mRNA. DR EMBL; U88966; AAC39933.1; ALT_FRAME; mRNA. DR EMBL; AB209995; BAE06077.1; ALT_INIT; mRNA. DR EMBL; AL109811; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL391561; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL049653; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC117166; AAI17167.1; -; mRNA. DR EMBL; AJ300188; CAC15570.1; -; Genomic_DNA. DR EMBL; L35478; AAC41713.1; -; mRNA. DR CCDS; CCDS127.1; -. DR PIR; S45340; S45340. DR RefSeq; NP_001373429.1; NM_001386500.1. DR RefSeq; NP_004949.1; NM_004958.4. DR PDB; 1AUE; X-ray; 2.33 A; A/B=2015-2114. DR PDB; 1FAP; X-ray; 2.70 A; B=2018-2112. DR PDB; 1NSG; X-ray; 2.20 A; B=2019-2112. DR PDB; 2FAP; X-ray; 2.20 A; B=2019-2112. DR PDB; 2GAQ; NMR; -; A=2015-2114. DR PDB; 2NPU; NMR; -; A=2015-2114. DR PDB; 2RSE; NMR; -; B=2019-2112. DR PDB; 3FAP; X-ray; 1.85 A; B=2019-2112. DR PDB; 3JBZ; EM; 28.00 A; A=1385-2549. DR PDB; 4DRH; X-ray; 2.30 A; B/E=2025-2114. DR PDB; 4DRI; X-ray; 1.45 A; B=2025-2114. DR PDB; 4DRJ; X-ray; 1.80 A; B=2025-2114. DR PDB; 4FAP; X-ray; 2.80 A; B=2019-2112. DR PDB; 4JSN; X-ray; 3.20 A; A/B=1376-2549. DR PDB; 4JSP; X-ray; 3.30 A; A/B=1376-2549. DR PDB; 4JSV; X-ray; 3.50 A; A/B=1376-2549. DR PDB; 4JSX; X-ray; 3.50 A; A/B=1376-2549. DR PDB; 4JT5; X-ray; 3.45 A; A/B=1376-2549. DR PDB; 4JT6; X-ray; 3.60 A; A/B=1376-2549. DR PDB; 5FLC; EM; 5.90 A; B/F=1382-2549. DR PDB; 5GPG; X-ray; 1.67 A; B=2021-2112. DR PDB; 5H64; EM; 4.40 A; A/a=1-2549. DR PDB; 5WBH; X-ray; 1.75 A; A/B/C/D/E=2018-2114. DR PDB; 5WBU; X-ray; 3.42 A; A/B=1376-2549. DR PDB; 5WBY; X-ray; 3.10 A; A/B=1376-2549. DR PDB; 5ZCS; EM; 4.90 A; A/B=1-2549. DR PDB; 6BCU; EM; 3.43 A; A/B=1-2549. DR PDB; 6BCX; EM; 3.00 A; A/B=1-2549. DR PDB; 6M4U; X-ray; 2.20 A; B/F=2021-2113. DR PDB; 6M4W; X-ray; 3.11 A; G/H/I=2021-2113. DR PDB; 6SB0; EM; 5.50 A; A/B=60-2549. DR PDB; 6SB2; EM; 6.20 A; A/B=54-2549. DR PDB; 6ZWM; EM; 3.20 A; A/B=1-2549. DR PDB; 6ZWO; EM; 3.00 A; B=1-2549. DR PDB; 7EPD; EM; 3.90 A; B=2019-2114. DR PDB; 7OWG; EM; 4.70 A; B=1-2549. DR PDB; 7PE7; EM; 3.41 A; A/B=1-2549. DR PDB; 7PE8; EM; 3.20 A; A=1-2549. DR PDB; 7PE9; EM; 3.70 A; A=1-2549. DR PDB; 7PEA; EM; 4.07 A; A/B=1-2549. DR PDB; 7PEB; EM; 3.67 A; A=1-2549. DR PDB; 7PEC; EM; 4.24 A; A=1-2549. DR PDB; 7TZO; EM; 3.28 A; A/B=1-2549. DR PDB; 7UXC; EM; 3.20 A; A=1-2549. DR PDB; 7UXH; EM; 3.20 A; A/C=1-2549. DR PDB; 8ER6; X-ray; 2.81 A; B/D/F=2019-2112. DR PDB; 8ER7; X-ray; 3.07 A; B/D/F=2019-2112. DR PDB; 8ERA; EM; 2.86 A; A=1-2549. DR PDB; 8PPZ; X-ray; 1.85 A; B=2025-2114. DR PDB; 8RCH; EM; 4.00 A; A/B=1-2549. DR PDB; 8RCK; EM; 3.40 A; B=1-2549. DR PDB; 8RCN; EM; 3.10 A; B=1-2549. DR PDB; 9F44; EM; 3.68 A; A/B=1-2549. DR PDB; 9F45; EM; 3.74 A; A/B=1-2549. DR PDBsum; 1AUE; -. DR PDBsum; 1FAP; -. DR PDBsum; 1NSG; -. DR PDBsum; 2FAP; -. DR PDBsum; 2GAQ; -. DR PDBsum; 2NPU; -. DR PDBsum; 2RSE; -. DR PDBsum; 3FAP; -. DR PDBsum; 3JBZ; -. DR PDBsum; 4DRH; -. DR PDBsum; 4DRI; -. DR PDBsum; 4DRJ; -. DR PDBsum; 4FAP; -. DR PDBsum; 4JSN; -. DR PDBsum; 4JSP; -. DR PDBsum; 4JSV; -. DR PDBsum; 4JSX; -. DR PDBsum; 4JT5; -. DR PDBsum; 4JT6; -. DR PDBsum; 5FLC; -. DR PDBsum; 5GPG; -. DR PDBsum; 5H64; -. DR PDBsum; 5WBH; -. DR PDBsum; 5WBU; -. DR PDBsum; 5WBY; -. DR PDBsum; 5ZCS; -. DR PDBsum; 6BCU; -. DR PDBsum; 6BCX; -. DR PDBsum; 6M4U; -. DR PDBsum; 6M4W; -. DR PDBsum; 6SB0; -. DR PDBsum; 6SB2; -. DR PDBsum; 6ZWM; -. DR PDBsum; 6ZWO; -. DR PDBsum; 7EPD; -. DR PDBsum; 7OWG; -. DR PDBsum; 7PE7; -. DR PDBsum; 7PE8; -. DR PDBsum; 7PE9; -. DR PDBsum; 7PEA; -. DR PDBsum; 7PEB; -. DR PDBsum; 7PEC; -. DR PDBsum; 7TZO; -. DR PDBsum; 7UXC; -. DR PDBsum; 7UXH; -. DR PDBsum; 8ER6; -. DR PDBsum; 8ER7; -. DR PDBsum; 8ERA; -. DR PDBsum; 8PPZ; -. DR PDBsum; 8RCH; -. DR PDBsum; 8RCK; -. DR PDBsum; 8RCN; -. DR PDBsum; 9F44; -. DR PDBsum; 9F45; -. DR AlphaFoldDB; P42345; -. DR BMRB; P42345; -. DR EMDB; EMD-10132; -. DR EMDB; EMD-10133; -. DR EMDB; EMD-11488; -. DR EMDB; EMD-11489; -. DR EMDB; EMD-11490; -. DR EMDB; EMD-11491; -. DR EMDB; EMD-11492; -. DR EMDB; EMD-13097; -. DR EMDB; EMD-13347; -. DR EMDB; EMD-13348; -. DR EMDB; EMD-13349; -. DR EMDB; EMD-13350; -. DR EMDB; EMD-13351; -. DR EMDB; EMD-13352; -. DR EMDB; EMD-19052; -. DR EMDB; EMD-19053; -. DR EMDB; EMD-19056; -. DR EMDB; EMD-26213; -. DR EMDB; EMD-26857; -. DR EMDB; EMD-26861; -. DR EMDB; EMD-28551; -. DR EMDB; EMD-3212; -. DR EMDB; EMD-3213; -. DR EMDB; EMD-50183; -. DR EMDB; EMD-50184; -. DR EMDB; EMD-6668; -. DR EMDB; EMD-6913; -. DR EMDB; EMD-7086; -. DR EMDB; EMD-7087; -. DR SMR; P42345; -. DR BioGRID; 108757; 392. DR ComplexPortal; CPX-4402; mTORC2 complex. DR ComplexPortal; CPX-503; mTORC1 complex. DR CORUM; P42345; -. DR DIP; DIP-790N; -. DR FunCoup; P42345; 4303. DR IntAct; P42345; 203. DR MINT; P42345; -. DR STRING; 9606.ENSP00000354558; -. DR BindingDB; P42345; -. DR ChEMBL; CHEMBL2842; -. DR DrugBank; DB12180; Apitolisib. DR DrugBank; DB12774; AZD-8055. DR DrugBank; DB14846; Bimiralisib. DR DrugBank; DB11651; Dactolisib. DR DrugBank; DB01590; Everolimus. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB13072; GDC-0349. DR DrugBank; DB11896; Gedatolisib. DR DrugBank; DB11978; Glasdegib. DR DrugBank; DB11962; GSK-1059615. DR DrugBank; DB12167; LY-3023414. DR DrugBank; DB13062; ME-344. DR DrugBank; DB19085; Novolimus. DR DrugBank; DB12843; Oleandrin. DR DrugBank; DB12570; Onatasertib. DR DrugBank; DB12387; OSI-027. DR DrugBank; DB11974; PF-04691502. DR DrugBank; DB00337; Pimecrolimus. DR DrugBank; DB08052; PP-121. DR DrugBank; DB06233; Ridaforolimus. DR DrugBank; DB04974; Rimiducid. DR DrugBank; DB12681; Salirasib. DR DrugBank; DB11836; Sapanisertib. DR DrugBank; DB05210; SF1126. DR DrugBank; DB00877; Sirolimus. DR DrugBank; DB06287; Temsirolimus. DR DrugBank; DB11925; Vistusertib. DR DrugBank; DB12400; Voxtalisib. DR DrugBank; DB12986; VS-5584. DR DrugBank; DB05241; XL765. DR DrugBank; DB18761; Zotarolimus. DR DrugCentral; P42345; -. DR GuidetoPHARMACOLOGY; 2109; -. DR GlyGen; P42345; 5 sites, 2 N-linked glycans (2 sites), 1 O-linked glycan (1 site). DR iPTMnet; P42345; -. DR MetOSite; P42345; -. DR PhosphoSitePlus; P42345; -. DR SwissPalm; P42345; -. DR BioMuta; MTOR; -. DR DMDM; 1169735; -. DR CPTAC; CPTAC-1360; -. DR CPTAC; CPTAC-1361; -. DR CPTAC; CPTAC-3133; -. DR CPTAC; CPTAC-3134; -. DR CPTAC; CPTAC-5752; -. DR CPTAC; CPTAC-5753; -. DR CPTAC; CPTAC-5754; -. DR CPTAC; CPTAC-5755; -. DR CPTAC; CPTAC-5756; -. DR CPTAC; CPTAC-5793; -. DR CPTAC; CPTAC-5794; -. DR CPTAC; CPTAC-5795; -. DR CPTAC; CPTAC-5796; -. DR CPTAC; CPTAC-5797; -. DR CPTAC; CPTAC-5798; -. DR CPTAC; CPTAC-5799; -. DR CPTAC; CPTAC-5800; -. DR CPTAC; non-CPTAC-5421; -. DR CPTAC; non-CPTAC-5422; -. DR CPTAC; non-CPTAC-5423; -. DR CPTAC; non-CPTAC-5424; -. DR CPTAC; non-CPTAC-5425; -. DR CPTAC; non-CPTAC-5560; -. DR CPTAC; non-CPTAC-5561; -. DR CPTAC; non-CPTAC-5562; -. DR CPTAC; non-CPTAC-5563; -. DR CPTAC; non-CPTAC-5709; -. DR CPTAC; non-CPTAC-5710; -. DR CPTAC; non-CPTAC-5711; -. DR CPTAC; non-CPTAC-5712; -. DR jPOST; P42345; -. DR MassIVE; P42345; -. DR PaxDb; 9606-ENSP00000354558; -. DR PeptideAtlas; P42345; -. DR ProteomicsDB; 55511; -. DR Pumba; P42345; -. DR Antibodypedia; 3566; 1829 antibodies from 54 providers. DR CPTC; P42345; 10 antibodies. DR DNASU; 2475; -. DR Ensembl; ENST00000361445.9; ENSP00000354558.4; ENSG00000198793.15. DR Ensembl; ENST00000703143.2; ENSP00000515200.2; ENSG00000198793.15. DR GeneID; 2475; -. DR KEGG; hsa:2475; -. DR MANE-Select; ENST00000361445.9; ENSP00000354558.4; NM_004958.4; NP_004949.1. DR UCSC; uc001asd.4; human. DR AGR; HGNC:3942; -. DR CIViC; 2475; 31 evidence items across 26 molecular profiles. DR ClinPGx; PA28360; -. DR CTD; 2475; -. DR DisGeNET; 2475; -. DR GeneCards; MTOR; -. DR HGNC; HGNC:3942; MTOR. DR HPA; ENSG00000198793; Low tissue specificity. DR MalaCards; MTOR; -. DR MIM; 601231; gene. DR MIM; 607341; phenotype. DR MIM; 616638; phenotype. DR OpenTargets; ENSG00000198793; -. DR Orphanet; 99802; Hemimegalencephaly. DR Orphanet; 269001; Isolated focal cortical dysplasia type IIa. DR Orphanet; 269008; Isolated focal cortical dysplasia type IIb. DR Orphanet; 457485; Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome. DR VEuPathDB; HostDB:ENSG00000198793; -. DR eggNOG; KOG0891; Eukaryota. DR GeneTree; ENSGT00930000151037; -. DR HOGENOM; CLU_000178_7_1_1; -. DR InParanoid; P42345; -. DR OMA; MRQHSAK; -. DR OrthoDB; 2250022at2759; -. DR PAN-GO; P42345; 7 GO annotations based on evolutionary models. DR PhylomeDB; P42345; -. DR PathwayCommons; P42345; -. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1632852; Macroautophagy. DR Reactome; R-HSA-165159; MTOR signalling. DR Reactome; R-HSA-166208; mTORC1-mediated signalling. DR Reactome; R-HSA-3371571; HSF1-dependent transactivation. DR Reactome; R-HSA-380972; Energy dependent regulation of mTOR by LKB1-AMPK. DR Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling. DR Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-8943724; Regulation of PTEN gene transcription. DR Reactome; R-HSA-9639288; Amino acids regulate mTORC1. DR Reactome; R-HSA-9856530; High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells. DR SABIO-RK; P42345; -. DR SignaLink; P42345; -. DR SIGNOR; P42345; -. DR Agora; ENSG00000198793; -. DR BioGRID-ORCS; 2475; 805 hits in 1184 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; MTOR; human. DR EvolutionaryTrace; P42345; -. DR GeneWiki; Mammalian_target_of_rapamycin; -. DR GenomeRNAi; 2475; -. DR Pharos; P42345; Tclin. DR PRO; PR:P42345; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; P42345; protein. DR Bgee; ENSG00000198793; Expressed in primordial germ cell in gonad and 132 other cell types or tissues. DR ExpressionAtlas; P42345; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProt. DR GO; GO:0030425; C:dendrite; IEA:Ensembl. DR GO; GO:0012505; C:endomembrane system; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell. DR GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB. DR GO; GO:0005764; C:lysosome; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0005741; C:mitochondrial outer membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005635; C:nuclear envelope; IDA:CACAO. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0045335; C:phagocytic vesicle; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell. DR GO; GO:0031931; C:TORC1 complex; IDA:UniProtKB. DR GO; GO:0031932; C:TORC2 complex; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0000822; F:inositol hexakisphosphate binding; IDA:UniProtKB. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IEA:UniProtKB-EC. DR GO; GO:0051219; F:phosphoprotein binding; IPI:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:WormBase. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0043022; F:ribosome binding; IDA:UniProtKB. DR GO; GO:0001002; F:RNA polymerase III type 1 promoter sequence-specific DNA binding; IDA:UniProtKB. DR GO; GO:0001003; F:RNA polymerase III type 2 promoter sequence-specific DNA binding; IDA:UniProtKB. DR GO; GO:0001006; F:RNA polymerase III type 3 promoter sequence-specific DNA binding; IDA:UniProtKB. DR GO; GO:0001156; F:TFIIIC-class transcription factor complex binding; IDA:UniProtKB. DR GO; GO:0044325; F:transmembrane transporter binding; IEA:Ensembl. DR GO; GO:0006207; P:'de novo' pyrimidine nucleobase biosynthetic process; IEA:Ensembl. DR GO; GO:0043276; P:anoikis; NAS:ParkinsonsUK-UCL. DR GO; GO:0048266; P:behavioral response to pain; IEA:Ensembl. DR GO; GO:0033173; P:calcineurin-NFAT signaling cascade; IEA:Ensembl. DR GO; GO:0055013; P:cardiac muscle cell development; IEA:Ensembl. DR GO; GO:0060048; P:cardiac muscle contraction; IEA:Ensembl. DR GO; GO:0030030; P:cell projection organization; IEA:Ensembl. DR GO; GO:0034198; P:cellular response to amino acid starvation; IDA:UniProtKB. DR GO; GO:0071230; P:cellular response to amino acid stimulus; IDA:CAFA. DR GO; GO:0071456; P:cellular response to hypoxia; ISS:UniProtKB. DR GO; GO:0032869; P:cellular response to insulin stimulus; IDA:UniProt. DR GO; GO:0071233; P:cellular response to L-leucine; IDA:CAFA. DR GO; GO:1990253; P:cellular response to leucine starvation; IDA:CAFA. DR GO; GO:0061431; P:cellular response to methionine; IDA:UniProt. DR GO; GO:0031670; P:cellular response to nutrient; IDA:UniProt. DR GO; GO:0031669; P:cellular response to nutrient levels; IDA:UniProt. DR GO; GO:0071470; P:cellular response to osmotic stress; NAS:ComplexPortal. DR GO; GO:0009267; P:cellular response to starvation; IDA:UniProtKB. DR GO; GO:0007010; P:cytoskeleton organization; NAS:ComplexPortal. DR GO; GO:0006974; P:DNA damage response; NAS:ComplexPortal. DR GO; GO:0006112; P:energy reserve metabolic process; IEA:Ensembl. DR GO; GO:0007281; P:germ cell development; IEA:Ensembl. DR GO; GO:0003007; P:heart morphogenesis; IEA:Ensembl. DR GO; GO:0003179; P:heart valve morphogenesis; IEA:Ensembl. DR GO; GO:0006954; P:inflammatory response; IEA:Ensembl. DR GO; GO:0016236; P:macroautophagy; IEA:Ensembl. DR GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; NAS:ComplexPortal. DR GO; GO:0010507; P:negative regulation of autophagy; IDA:UniProtKB. DR GO; GO:0070885; P:negative regulation of calcineurin-NFAT signaling cascade; IEA:Ensembl. DR GO; GO:0045792; P:negative regulation of cell size; IEA:Ensembl. DR GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; ISS:UniProt. DR GO; GO:1905672; P:negative regulation of lysosome organization; IDA:UniProtKB. DR GO; GO:0016242; P:negative regulation of macroautophagy; IDA:MGI. DR GO; GO:1900181; P:negative regulation of protein localization to nucleus; IDA:UniProtKB. DR GO; GO:0019228; P:neuronal action potential; IEA:Ensembl. DR GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:0030838; P:positive regulation of actin filament polymerization; IEA:Ensembl. DR GO; GO:0030307; P:positive regulation of cell growth; NAS:ComplexPortal. DR GO; GO:1904690; P:positive regulation of cytoplasmic translational initiation; TAS:ARUK-UCL. DR GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0045821; P:positive regulation of glycolytic process; NAS:ComplexPortal. DR GO; GO:0051549; P:positive regulation of keratinocyte migration; IMP:BHF-UCL. DR GO; GO:0010592; P:positive regulation of lamellipodium assembly; IEA:Ensembl. DR GO; GO:0046889; P:positive regulation of lipid biosynthetic process; IMP:UniProtKB. DR GO; GO:0010831; P:positive regulation of myotube differentiation; IEA:Ensembl. DR GO; GO:0048714; P:positive regulation of oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:1905857; P:positive regulation of pentose-phosphate shunt; NAS:ComplexPortal. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; TAS:Reactome. DR GO; GO:1900029; P:positive regulation of ruffle assembly; IEA:Ensembl. DR GO; GO:0062027; P:positive regulation of SCF-dependent proteasomal ubiquitin-dependent catabolic process; IDA:UniProt. DR GO; GO:0051496; P:positive regulation of stress fiber assembly; IEA:Ensembl. DR GO; GO:0045945; P:positive regulation of transcription by RNA polymerase III; IMP:UniProtKB. DR GO; GO:1901838; P:positive regulation of transcription of nucleolar large rRNA by RNA polymerase I; IMP:UniProtKB. DR GO; GO:0045727; P:positive regulation of translation; IDA:UniProtKB. DR GO; GO:0045948; P:positive regulation of translational initiation; IDA:UniProt. DR GO; GO:2000060; P:positive regulation of ubiquitin-dependent protein catabolic process; IDA:UniProtKB. DR GO; GO:1903691; P:positive regulation of wound healing, spreading of epidermal cells; IMP:BHF-UCL. DR GO; GO:0009791; P:post-embryonic development; IEA:Ensembl. DR GO; GO:0031648; P:protein destabilization; IDA:UniProt. DR GO; GO:0050821; P:protein stabilization; ISS:UniProt. DR GO; GO:0032956; P:regulation of actin cytoskeleton organization; IMP:UniProtKB. DR GO; GO:2000785; P:regulation of autophagosome assembly; IDA:UniProt. DR GO; GO:0001558; P:regulation of cell growth; IDA:UniProtKB. DR GO; GO:0008361; P:regulation of cell size; IMP:CAFA. DR GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome. DR GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB. DR GO; GO:1904059; P:regulation of locomotor rhythm; ISS:UniProtKB. DR GO; GO:1905671; P:regulation of lysosome organization; IDA:UniProtKB. DR GO; GO:0016241; P:regulation of macroautophagy; TAS:Reactome. DR GO; GO:0090559; P:regulation of membrane permeability; IEA:Ensembl. DR GO; GO:0031641; P:regulation of myelination; IEA:Ensembl. DR GO; GO:0045670; P:regulation of osteoclast differentiation; ISS:UniProtKB. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0043200; P:response to amino acid; IDA:UniProtKB. DR GO; GO:0009408; P:response to heat; IEA:Ensembl. DR GO; GO:0031667; P:response to nutrient levels; IDA:UniProtKB. DR GO; GO:0009615; P:response to virus; IEA:Ensembl. DR GO; GO:0031295; P:T cell costimulation; TAS:Reactome. DR GO; GO:0002296; P:T-helper 1 cell lineage commitment; IEA:Ensembl. DR GO; GO:0031929; P:TOR signaling; IMP:UniProtKB. DR GO; GO:0038202; P:TORC1 signaling; IDA:UniProtKB. DR GO; GO:0038203; P:TORC2 signaling; IDA:UniProtKB. DR GO; GO:0097700; P:vascular endothelial cell response to laminar fluid shear stress; TAS:Reactome. DR GO; GO:0050882; P:voluntary musculoskeletal movement; IEA:Ensembl. DR CDD; cd05169; PIKKc_TOR; 1. DR DisProt; DP03874; -. DR FunFam; 1.10.1070.11:FF:000074; DJ576K7.1 (FK506 binding protein 12-rapamycin associated protein 1); 1. DR FunFam; 1.10.1070.11:FF:000058; MTOR isoform 6; 1. DR FunFam; 1.25.10.10:FF:000060; Serine/threonine-protein kinase mTOR; 1. DR FunFam; 1.25.10.10:FF:000094; Serine/threonine-protein kinase mTOR; 1. DR FunFam; 1.25.10.10:FF:000532; Serine/threonine-protein kinase mTOR; 1. DR FunFam; 1.20.120.150:FF:000001; Serine/threonine-protein kinase TOR; 1. DR FunFam; 1.25.10.10:FF:000083; Serine/threonine-protein kinase TOR; 1. DR FunFam; 3.30.1010.10:FF:000004; Serine/threonine-protein kinase TOR; 1. DR Gene3D; 1.20.120.150; FKBP12-rapamycin binding domain; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 4. DR Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1. DR Gene3D; 3.30.1010.10; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 4; 1. DR Gene3D; 1.25.40.10; Tetratricopeptide repeat domain; 1. DR IDEAL; IID00598; -. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR050517; DDR_Repair_Kinase. DR InterPro; IPR003152; FATC_dom. DR InterPro; IPR009076; FRB_dom. DR InterPro; IPR036738; FRB_sf. DR InterPro; IPR057564; HEAT_ATR. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR024585; mTOR_dom. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR036940; PI3/4_kinase_cat_sf. DR InterPro; IPR018936; PI3/4_kinase_CS. DR InterPro; IPR003151; PIK-rel_kinase_FAT. DR InterPro; IPR014009; PIK_FAT. DR InterPro; IPR026683; TOR_cat. DR InterPro; IPR011990; TPR-like_helical_dom_sf. DR PANTHER; PTHR11139; ATAXIA TELANGIECTASIA MUTATED ATM -RELATED; 1. DR PANTHER; PTHR11139:SF9; SERINE_THREONINE-PROTEIN KINASE MTOR; 1. DR Pfam; PF02259; FAT; 1. DR Pfam; PF02260; FATC; 1. DR Pfam; PF08771; FRB_dom; 1. DR Pfam; PF23593; HEAT_ATR; 1. DR Pfam; PF11865; mTOR_dom; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR SMART; SM01346; DUF3385; 1. DR SMART; SM01343; FATC; 1. DR SMART; SM00146; PI3Kc; 1. DR SMART; SM01345; Rapamycin_bind; 1. DR SUPFAM; SSF48371; ARM repeat; 2. DR SUPFAM; SSF47212; FKBP12-rapamycin-binding domain of FKBP-rapamycin-associated protein (FRAP); 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51189; FAT; 1. DR PROSITE; PS51190; FATC; 1. DR PROSITE; PS00915; PI3_4_KINASE_1; 1. DR PROSITE; PS00916; PI3_4_KINASE_2; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; ATP-binding; Cell membrane; Cytoplasm; KW Cytoplasmic vesicle; Disease variant; Endoplasmic reticulum; Epilepsy; KW Golgi apparatus; Intellectual disability; Isopeptide bond; Kinase; KW Lysosome; Membrane; Microsome; Mitochondrion; Mitochondrion outer membrane; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Serine/threonine-protein kinase; TPR repeat; KW Transferase; Ubl conjugation. FT CHAIN 1..2549 FT /note="Serine/threonine-protein kinase mTOR" FT /id="PRO_0000088808" FT REPEAT 16..53 FT /note="HEAT 1" FT REPEAT 55..99 FT /note="HEAT 2" FT REPEAT 100..137 FT /note="HEAT 3" FT REPEAT 138..179 FT /note="HEAT 4" FT REPEAT 180..220 FT /note="HEAT 5" FT REPEAT 222..276 FT /note="HEAT 6" FT REPEAT 277..313 FT /note="HEAT 7" FT REPEAT 314..364 FT /note="HEAT 8" FT REPEAT 365..409 FT /note="HEAT 9" FT REPEAT 410..445 FT /note="HEAT 10" FT REPEAT 446..494 FT /note="HEAT 11" FT REPEAT 495..529 FT /note="HEAT 12" FT REPEAT 530..563 FT /note="HEAT 13" FT REPEAT 564..596 FT /note="HEAT 14" FT REPEAT 597..636 FT /note="HEAT 15" FT REPEAT 637..683 FT /note="HEAT 16" FT REPEAT 686..724 FT /note="HEAT 17" FT REPEAT 727..766 FT /note="HEAT 18" FT REPEAT 769..811 FT /note="HEAT 19" FT REPEAT 814..853 FT /note="HEAT 20" FT REPEAT 857..893 FT /note="HEAT 21" FT REPEAT 894..942 FT /note="HEAT 22" FT REPEAT 943..988 FT /note="HEAT 23" FT REPEAT 989..1027 FT /note="HEAT 24" FT REPEAT 1029..1068 FT /note="HEAT 25" FT REPEAT 1069..1105 FT /note="HEAT 26" FT REPEAT 1106..1144 FT /note="HEAT 27" FT REPEAT 1145..1188 FT /note="HEAT 28" FT REPEAT 1189..1225 FT /note="HEAT 29" FT REPEAT 1226..1273 FT /note="HEAT 30" FT REPEAT 1274..1311 FT /note="HEAT 31" FT REPEAT 1312..1345 FT /note="HEAT 32" FT REPEAT 1346..1382 FT /note="TPR 1" FT DOMAIN 1382..1982 FT /note="FAT" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534" FT REPEAT 1383..1408 FT /note="TPR 2" FT REPEAT 1409..1442 FT /note="TPR 3" FT REPEAT 1443..1473 FT /note="TPR 4" FT REPEAT 1474..1507 FT /note="TPR 5" FT REPEAT 1508..1541 FT /note="TPR 6" FT REPEAT 1542..1574 FT /note="TPR 7" FT REPEAT 1575..1614 FT /note="TPR 8" FT REPEAT 1615..1649 FT /note="TPR 9" FT REPEAT 1650..1693 FT /note="TPR 10" FT REPEAT 1694..1731 FT /note="TPR 11" FT REPEAT 1732..1786 FT /note="TPR 12" FT REPEAT 1787..1846 FT /note="TPR 13" FT REPEAT 1898..1930 FT /note="TPR 14" FT REPEAT 1931..1970 FT /note="TPR 15" FT REPEAT 1971..2005 FT /note="TPR 16" FT DOMAIN 2156..2469 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT DOMAIN 2517..2549 FT /note="FATC" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534, FT ECO:0000255|PROSITE-ProRule:PRU00535" FT REGION 1..651 FT /note="Interaction with NBN" FT /evidence="ECO:0000269|PubMed:23762398" FT REGION 1812..1867 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2012..2144 FT /note="Sufficient for interaction with the FKBP1A/rapamycin FT complex" FT /evidence="ECO:0000250|UniProtKB:Q9JLN9" FT REGION 2162..2168 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2258..2296 FT /note="Interaction with MLST8" FT REGION 2335..2343 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2355..2380 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT COMPBIAS 1820..1860 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 1662 FT /ligand="1D-myo-inositol hexakisphosphate" FT /ligand_id="ChEBI:CHEBI:58130" FT /evidence="ECO:0000269|PubMed:33158864, FT ECO:0007744|PDB:6ZWM" FT BINDING 1702 FT /ligand="1D-myo-inositol hexakisphosphate" FT /ligand_id="ChEBI:CHEBI:58130" FT /evidence="ECO:0000269|PubMed:33158864, FT ECO:0007744|PDB:6ZWM" FT BINDING 1749 FT /ligand="1D-myo-inositol hexakisphosphate" FT /ligand_id="ChEBI:CHEBI:58130" FT /evidence="ECO:0000269|PubMed:33158864, FT ECO:0007744|PDB:6ZWM" FT BINDING 2165 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2167 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2185 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2187 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCX" FT BINDING 2190 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2225 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2238 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2239 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2240 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2245 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2343 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCX" FT BINDING 2345 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2356 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2357 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCX" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 567 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:20068231" FT MOD_RES 1162 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 1218 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 1261 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:19487463, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2159 FT /note="Phosphoserine; by TBK1" FT /evidence="ECO:0000269|PubMed:21576368, FT ECO:0000269|PubMed:29150432" FT MOD_RES 2164 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:21576368" FT MOD_RES 2173 FT /note="Phosphothreonine; by PKB/AKT1" FT /evidence="ECO:0000269|PubMed:24247430" FT MOD_RES 2446 FT /note="Phosphothreonine; by RPS6KB1" FT /evidence="ECO:0000269|PubMed:15905173" FT MOD_RES 2448 FT /note="Phosphoserine; by RPS6KB1" FT /evidence="ECO:0000269|PubMed:15899889, FT ECO:0000269|PubMed:15905173, ECO:0000269|PubMed:19145465, FT ECO:0007744|PubMed:24275569" FT MOD_RES 2478 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2481 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:20022946, FT ECO:0000269|PubMed:21576368, ECO:0007744|PubMed:18669648" FT CROSSLNK 2066 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:37979583" FT VARIANT 8 FT /note="A -> S (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs748801456)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041537" FT VARIANT 135 FT /note="M -> T (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041538" FT VARIANT 624 FT /note="R -> H (in FCORD2; uncertain significance; somatic FT mutation; dbSNP:rs913197212)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078824" FT VARIANT 1083 FT /note="M -> V (in dbSNP:rs56164650)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041539" FT VARIANT 1134 FT /note="A -> V (in dbSNP:rs28730685)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041540" FT VARIANT 1178 FT /note="S -> F (in dbSNP:rs55975118)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041541" FT VARIANT 1376 FT /note="D -> E (found in a patient with focal epilepsy; FT uncertain significance; dbSNP:rs975577894)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078825" FT VARIANT 1450 FT /note="Y -> D (in FCORD2; somatic mutation)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078826" FT VARIANT 1456 FT /note="W -> G (in FCORD2; somatic mutation; FT dbSNP:rs1085307114)" FT /evidence="ECO:0000269|PubMed:25878179" FT /id="VAR_078827" FT VARIANT 1459 FT /note="A -> D (in FCORD2; somatic mutation; increased TOR FT signaling; dbSNP:rs1644347782)" FT /evidence="ECO:0000269|PubMed:26018084" FT /id="VAR_078828" FT VARIANT 1459 FT /note="A -> S (in FCORD2; uncertain significance; somatic FT mutation; dbSNP:rs1644347846)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078829" FT VARIANT 1460 FT /note="L -> P (in FCORD2; somatic mutation; increased TOR FT signaling; dbSNP:rs1057519779)" FT /evidence="ECO:0000269|PubMed:26018084, FT ECO:0000269|PubMed:27830187" FT /id="VAR_078830" FT VARIANT 1483 FT /note="C -> R (in FCORD2; somatic mutation; increased TOR FT signaling; increased kinase activity; dbSNP:rs1057519914)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078831" FT VARIANT 1490 FT /note="W -> R (in SKS; dbSNP:rs2100566800)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078832" FT VARIANT 1595 FT /note="M -> I (in SKS; dbSNP:rs869312671)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078833" FT VARIANT 1709 FT /note="R -> H (in FCORD2; uncertain significance; somatic FT mutation; dbSNP:rs587777895)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078834" FT VARIANT 1799 FT /note="E -> K (in SKS; results in increased mTOR signaling; FT dbSNP:rs863225264)" FT /evidence="ECO:0000269|PubMed:25851998, FT ECO:0000269|PubMed:26542245" FT /id="VAR_075072" FT VARIANT 1832 FT /note="A -> T (in SKS; dbSNP:rs369088781)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078835" FT VARIANT 1888 FT /note="F -> C (in SKS; dbSNP:rs869312666)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078836" FT VARIANT 1977 FT /note="T -> K (in FCORD2; somatic mutation; FT dbSNP:rs587777893)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078837" FT VARIANT 2011 FT /note="M -> V (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs2100412651)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041542" FT VARIANT 2193 FT /note="R -> C (in FCORD2; somatic mutation; FT dbSNP:rs1642723200)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078838" FT VARIANT 2215 FT /note="S -> F (in FCORD2; somatic mutation; increased TOR FT signaling; dbSNP:rs587777894)" FT /evidence="ECO:0000269|PubMed:25799227, FT ECO:0000269|PubMed:26018084, ECO:0000269|PubMed:27830187" FT /id="VAR_078839" FT VARIANT 2215 FT /note="S -> Y (in FCORD2; also found in a colorectal FT adenocarcinoma sample; somatic mutation; increased TOR FT signaling; dbSNP:rs587777894)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:26018084, ECO:0000269|PubMed:27830187" FT /id="VAR_041543" FT VARIANT 2220 FT /note="L -> F (found in a renal cell carcinoma sample; FT somatic mutation; dbSNP:rs2100381099)" FT /evidence="ECO:0000269|PubMed:21248752" FT /id="VAR_064733" FT VARIANT 2327 FT /note="M -> I (in SKS; dbSNP:rs878855328)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078840" FT VARIANT 2406 FT /note="V -> A (found in a renal cell carcinoma sample; FT somatic mutation; dbSNP:rs2100316251)" FT /evidence="ECO:0000269|PubMed:21248752" FT /id="VAR_064734" FT VARIANT 2427 FT /note="L -> P (in FCORD2; somatic mutation; increased TOR FT signaling; increased kinase activity; dbSNP:rs1085307113)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078841" FT VARIANT 2427 FT /note="L -> Q (in FCORD2; somatic mutation; increased TOR FT signaling; increased kinase activity; dbSNP:rs1085307113)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078842" FT VARIANT 2476 FT /note="P -> L (in a glioblastoma multiforme sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041544" FT VARIANT 2501 FT /note="I -> V (found in a patient with non-lesional FT nocturnal frontal epilepsy; uncertain significance; FT dbSNP:rs968817513)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078843" FT MUTAGEN 2066 FT /note="K->R: Complete loss ubiquitination by the FT SCF(FBXO22) complex." FT /evidence="ECO:0000269|PubMed:37979583" FT MUTAGEN 2159 FT /note="S->A: Reduces mTORC1-associated S-2481 FT autophosphorylation; when associated with A-2164. Reduced FT activity of the mTORC1 complex." FT /evidence="ECO:0000269|PubMed:21576368, FT ECO:0000269|PubMed:29150432" FT MUTAGEN 2159 FT /note="S->D: Mimics phosphorylation; leading to stronger FT phosphorylation of RPS6KB1; when associated with E-2164. FT Increased activity of the mTORC1 complex." FT /evidence="ECO:0000269|PubMed:21576368, FT ECO:0000269|PubMed:29150432" FT MUTAGEN 2164 FT /note="T->A: Reduces mTORC1-associated S-2481 FT autophosphorylation; when associated with A-2159." FT /evidence="ECO:0000269|PubMed:21576368" FT MUTAGEN 2164 FT /note="T->E: Stronger phosphorylation of RPS6KB1; when FT associated with D-2159." FT /evidence="ECO:0000269|PubMed:21576368" FT MUTAGEN 2173 FT /note="T->A: Increased mTOR kinase activity." FT /evidence="ECO:0000269|PubMed:24247430" FT MUTAGEN 2340 FT /note="H->A: Barely detectable kinase activity." FT /evidence="ECO:0000269|PubMed:23636326" FT MUTAGEN 2357 FT /note="D->E: Kinase-dead mutant, loss of interaction with FT TM4SF5 and loss of lysosome membrane localization; when FT associated with I-2364." FT /evidence="ECO:0000269|PubMed:30956113" FT MUTAGEN 2364 FT /note="V->I: Kinase-dead mutant, loss of interaction with FT TM4SF5 and loss of lysosome membrane localization; when FT associated with E-2357." FT /evidence="ECO:0000269|PubMed:30956113" FT CONFLICT 353 FT /note="K -> N (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 359 FT /note="S -> N (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 364 FT /note="D -> N (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 390 FT /note="M -> L (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 430 FT /note="R -> L (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 455..457 FT /note="VLD -> GVE (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 461 FT /note="A -> G (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 482..484 FT /note="VFT -> FFN (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 489 FT /note="L -> V (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 513 FT /note="L -> I (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 539 FT /note="L -> V (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 553 FT /note="R -> C (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 857 FT /note="P -> L (in Ref. 3; BAE06077)" FT /evidence="ECO:0000305" FT CONFLICT 1075 FT /note="I -> S (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT HELIX 19..29 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 38..52 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 61..73 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 83..93 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 94..96 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 102..114 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 115..117 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 123..134 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 141..155 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 165..178 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 180..183 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 184..186 FT /evidence="ECO:0007829|PDB:7UXC" FT HELIX 188..197 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 204..222 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 234..245 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 259..275 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 277..288 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 357..360 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 362..375 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 376..378 FT /evidence="ECO:0007829|PDB:7PE8" FT HELIX 380..382 FT /evidence="ECO:0007829|PDB:7UXC" FT HELIX 387..402 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 404..409 FT /evidence="ECO:0007829|PDB:7UXC" FT HELIX 413..424 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 427..443 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 446..448 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 449..451 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 452..462 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 463..465 FT /evidence="ECO:0007829|PDB:7PE8" FT HELIX 479..490 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 495..497 FT /evidence="ECO:0007829|PDB:7UXC" FT HELIX 499..510 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 517..527 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 530..532 FT /evidence="ECO:0007829|PDB:6ZWM" FT HELIX 533..548 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 580..588 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 601..611 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 616..629 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 646..648 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 649..665 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 667..669 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 670..677 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 681..683 FT /evidence="ECO:0007829|PDB:6ZWM" FT TURN 685..688 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 690..699 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 703..705 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 706..717 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 718..721 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 723..742 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 749..762 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 765..767 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 769..771 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 772..783 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 792..808 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 811..813 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 814..816 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 817..828 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 831..833 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 838..851 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 856..860 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 864..870 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 871..873 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 878..891 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 896..902 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 934..937 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 943..958 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 964..982 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 986..989 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 990..1002 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1006..1008 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1009..1023 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1024..1030 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1031..1040 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1046..1062 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1065..1069 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1071..1083 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1088..1090 FT /evidence="ECO:0007829|PDB:7PE8" FT HELIX 1091..1103 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1104..1107 FT /evidence="ECO:0007829|PDB:7UXC" FT TURN 1108..1110 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1111..1123 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1125..1127 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1129..1142 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1143..1145 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1150..1152 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 1153..1163 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1167..1169 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 1170..1182 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1185..1191 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1192..1202 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1207..1218 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1222..1226 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 1229..1237 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 1263..1269 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1277..1293 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1298..1301 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1304..1309 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1311..1315 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1318..1328 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1331..1347 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1351..1366 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1367..1369 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1375..1379 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1380..1390 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1393..1406 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1410..1422 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1426..1439 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1441..1444 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1447..1452 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1456..1469 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1474..1487 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1490..1499 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1501..1504 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 1506..1523 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1526..1533 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1538..1540 FT /evidence="ECO:0007829|PDB:5WBY" FT HELIX 1541..1553 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1557..1579 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1584..1586 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1587..1602 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1603..1605 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1606..1608 FT /evidence="ECO:0007829|PDB:4JSP" FT HELIX 1609..1611 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1612..1623 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1630..1640 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1641..1643 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1646..1648 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1650..1662 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1666..1677 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1681..1683 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1685..1687 FT /evidence="ECO:0007829|PDB:6ZWO" FT STRAND 1691..1693 FT /evidence="ECO:0007829|PDB:7UXC" FT HELIX 1694..1706 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1710..1730 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1737..1758 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1759..1762 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1766..1768 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1769..1782 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1783..1785 FT /evidence="ECO:0007829|PDB:5WBY" FT HELIX 1787..1809 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1810..1813 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1868..1877 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1878..1880 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1881..1893 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1896..1898 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1900..1913 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1917..1929 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1933..1935 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1936..1938 FT /evidence="ECO:0007829|PDB:7PE7" FT HELIX 1939..1943 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1944..1947 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1951..1966 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1970..1972 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1973..1980 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1985..1999 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2005..2019 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2020..2022 FT /evidence="ECO:0007829|PDB:2NPU" FT HELIX 2025..2039 FT /evidence="ECO:0007829|PDB:4DRI" FT HELIX 2044..2058 FT /evidence="ECO:0007829|PDB:4DRI" FT HELIX 2065..2091 FT /evidence="ECO:0007829|PDB:4DRI" FT HELIX 2094..2111 FT /evidence="ECO:0007829|PDB:4DRI" FT HELIX 2115..2117 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2120..2122 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2123..2126 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2128..2132 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2137..2139 FT /evidence="ECO:0007829|PDB:6ZWO" FT TURN 2141..2143 FT /evidence="ECO:0007829|PDB:5WBY" FT STRAND 2146..2148 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2152..2156 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2158..2162 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2164..2167 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2170..2179 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2181..2187 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2194..2210 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2213..2216 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 2217..2219 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2227..2229 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2231..2233 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2235..2238 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2241..2245 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2246..2256 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2263..2271 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 2273..2277 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2280..2292 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2298..2305 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2308..2310 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2311..2334 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2341..2343 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2344..2350 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2353..2355 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2362..2364 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 2365..2367 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2369..2371 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2381..2385 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 2392..2394 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2395..2409 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2411..2422 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 2425..2428 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2429..2432 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2433..2435 FT /evidence="ECO:0007829|PDB:5WBY" FT HELIX 2493..2509 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2512..2516 FT /evidence="ECO:0007829|PDB:4JT5" FT HELIX 2521..2532 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2535..2539 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2543..2545 FT /evidence="ECO:0007829|PDB:8ERA" SQ SEQUENCE 2549 AA; 288892 MW; 7D9AD6E784882AB4 CRC64; MLGTGPAAAT TAATTSSNVS VLQQFASGLK SRNEETRAKA AKELQHYVTM ELREMSQEES TRFYDQLNHH IFELVSSSDA NERKGGILAI ASLIGVEGGN ATRIGRFANY LRNLLPSNDP VVMEMASKAI GRLAMAGDTF TAEYVEFEVK RALEWLGADR NEGRRHAAVL VLRELAISVP TFFFQQVQPF FDNIFVAVWD PKQAIREGAV AALRACLILT TQREPKEMQK PQWYRHTFEE AEKGFDETLA KEKGMNRDDR IHGALLILNE LVRISSMEGE RLREEMEEIT QQQLVHDKYC KDLMGFGTKP RHITPFTSFQ AVQPQQSNAL VGLLGYSSHQ GLMGFGTSPS PAKSTLVESR CCRDLMEEKF DQVCQWVLKC RNSKNSLIQM TILNLLPRLA AFRPSAFTDT QYLQDTMNHV LSCVKKEKER TAAFQALGLL SVAVRSEFKV YLPRVLDIIR AALPPKDFAH KRQKAMQVDA TVFTCISMLA RAMGPGIQQD IKELLEPMLA VGLSPALTAV LYDLSRQIPQ LKKDIQDGLL KMLSLVLMHK PLRHPGMPKG LAHQLASPGL TTLPEASDVG SITLALRTLG SFEFEGHSLT QFVRHCADHF LNSEHKEIRM EAARTCSRLL TPSIHLISGH AHVVSQTAVQ VVADVLSKLL VVGITDPDPD IRYCVLASLD ERFDAHLAQA ENLQALFVAL NDQVFEIREL AICTVGRLSS MNPAFVMPFL RKMLIQILTE LEHSGIGRIK EQSARMLGHL VSNAPRLIRP YMEPILKALI LKLKDPDPDP NPGVINNVLA TIGELAQVSG LEMRKWVDEL FIIIMDMLQD SSLLAKRQVA LWTLGQLVAS TGYVVEPYRK YPTLLEVLLN FLKTEQNQGT RREAIRVLGL LGALDPYKHK VNIGMIDQSR DASAVSLSES KSSQDSSDYS TSEMLVNMGN LPLDEFYPAV SMVALMRIFR DQSLSHHHTM VVQAITFIFK SLGLKCVQFL PQVMPTFLNV IRVCDGAIRE FLFQQLGMLV SFVKSHIRPY MDEIVTLMRE FWVMNTSIQS TIILLIEQIV VALGGEFKLY LPQLIPHMLR VFMHDNSPGR IVSIKLLAAI QLFGANLDDY LHLLLPPIVK LFDAPEAPLP SRKAALETVD RLTESLDFTD YASRIIHPIV RTLDQSPELR STAMDTLSSL VFQLGKKYQI FIPMVNKVLV RHRINHQRYD VLICRIVKGY TLADEEEDPL IYQHRMLRSG QGDALASGPV ETGPMKKLHV STINLQKAWG AARRVSKDDW LEWLRRLSLE LLKDSSSPSL RSCWALAQAY NPMARDLFNA AFVSCWSELN EDQQDELIRS IELALTSQDI AEVTQTLLNL AEFMEHSDKG PLPLRDDNGI VLLGERAAKC RAYAKALHYK ELEFQKGPTP AILESLISIN NKLQQPEAAA GVLEYAMKHF GELEIQATWY EKLHEWEDAL VAYDKKMDTN KDDPELMLGR MRCLEALGEW GQLHQQCCEK WTLVNDETQA KMARMAAAAA WGLGQWDSME EYTCMIPRDT HDGAFYRAVL ALHQDLFSLA QQCIDKARDL LDAELTAMAG ESYSRAYGAM VSCHMLSELE EVIQYKLVPE RREIIRQIWW ERLQGCQRIV EDWQKILMVR SLVVSPHEDM RTWLKYASLC GKSGRLALAH KTLVLLLGVD PSRQLDHPLP TVHPQVTYAY MKNMWKSARK IDAFQHMQHF VQTMQQQAQH AIATEDQQHK QELHKLMARC FLKLGEWQLN LQGINESTIP KVLQYYSAAT EHDRSWYKAW HAWAVMNFEA VLHYKHQNQA RDEKKKLRHA SGANITNATT AATTAATATT TASTEGSNSE SEAESTENSP TPSPLQKKVT EDLSKTLLMY TVPAVQGFFR SISLSRGNNL QDTLRVLTLW FDYGHWPDVN EALVEGVKAI QIDTWLQVIP QLIARIDTPR PLVGRLIHQL LTDIGRYHPQ ALIYPLTVAS KSTTTARHNA ANKILKNMCE HSNTLVQQAM MVSEELIRVA ILWHEMWHEG LEEASRLYFG ERNVKGMFEV LEPLHAMMER GPQTLKETSF NQAYGRDLME AQEWCRKYMK SGNVKDLTQA WDLYYHVFRR ISKQLPQLTS LELQYVSPKL LMCRDLELAV PGTYDPNQPI IRIQSIAPSL QVITSKQRPR KLTLMGSNGH EFVFLLKGHE DLRQDERVMQ LFGLVNTLLA NDPTSLRKNL SIQRYAVIPL STNSGLIGWV PHCDTLHALI RDYREKKKIL LNIEHRIMLR MAPDYDHLTL MQKVEVFEHA VNNTAGDDLA KLLWLKSPSS EVWFDRRTNY TRSLAVMSMV GYILGLGDRH PSNLMLDRLS GKILHIDFGD CFEVAMTREK FPEKIPFRLT RMLTNAMEVT GLDGNYRITC HTVMEVLREH KDSVMAVLEA FVYDPLLNWR LMDTNTKGNK RSRTRTDSYS AGQSVEILDG VELGEPAHKK TGTTVPESIH SFIGDGLVKP EALNKKAIQI INRVRDKLTG RDFSHDDTLD VPTQVELLIK QATSHENLCQ CYIGWCPFW // ID MUC24_HUMAN Reviewed; 197 AA. AC Q04900; B4DQ85; E1P5E7; E1P5E8; E1P5E9; O95413; Q5JSU6; Q9BPV0; Q9NR26; DT 01-JUN-1994, integrated into UniProtKB/Swiss-Prot. DT 01-SEP-2009, sequence version 2. DT 28-JAN-2026, entry version 178. DE RecName: Full=Sialomucin core protein 24; DE Short=MUC-24; DE AltName: Full=Endolyn; DE AltName: Full=Multi-glycosylated core protein 24; DE Short=MGC-24; DE Short=MGC-24v; DE AltName: CD_antigen=CD164; DE Flags: Precursor; GN Name=CD164; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY, AND RP GLYCOSYLATION. RC TISSUE=Gastric carcinoma; RX PubMed=1478919; DOI=10.1093/oxfordjournals.jbchem.a123948; RA Masuzawa Y., Miyauchi T., Hamanoue M., Ando S., Yoshida J., Takao S., RA Shimazu H., Adachi M., Muramatsu T.; RT "A novel core protein as well as polymorphic epithelial mucin carry peanut RT agglutinin binding sites in human gastric carcinoma cells: sequence RT analysis and examination of gene expression."; RL J. Biochem. 112:609-615(1992). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), FUNCTION, SUBUNIT, AND TISSUE RP SPECIFICITY. RC TISSUE=Bone marrow; RX PubMed=9763543; RA Zannettino A.C.W., Buehring H.-J., Niutta S., Watt S.M., Benton M.A., RA Simmons P.J.; RT "The sialomucin CD164 (MGC-24v) is an adhesive glycoprotein expressed by RT human hematopoietic progenitors and bone marrow stromal cells that serves RT as a potent negative regulator of hematopoiesis."; RL Blood 92:2613-2628(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY. RX PubMed=10878358; DOI=10.4049/jimmunol.165.2.840; RA Doyonnas R., Chan J.Y.-H., Butler L.H., Rappold I., Lee-Prudhoe J.E., RA Zannettino A.C.W., Simmons P.J., Buehring H.-J., Levesque J.-P., Watt S.M.; RT "CD164 monoclonal antibodies that block hemopoietic progenitor cell RT adhesion and proliferation interact with the first mucin domain of the RT CD164 receptor."; RL J. Immunol. 165:840-851(2000). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1; 3 AND 4), ALTERNATIVE RP SPLICING, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=11027692; DOI=10.1074/jbc.m007965200; RA Chan J.Y.-H., Lee-Prudhoe J.E., Jorgensen B., Ihrke G., Doyonnas R., RA Zannettino A.C.W., Buckle V.J., Ward C.J., Simmons P.J., Watt S.M.; RT "Relationship between novel isoforms, functionally important domains, and RT subcellular distribution of CD164/endolyn."; RL J. Biol. Chem. 276:2139-2152(2001). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 3; 4 AND 5). RC TISSUE=Amygdala, Astrocyte, Neutrophil, and Thymus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Colon; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP FUNCTION, INDUCTION, AND TISSUE SPECIFICITY. RX PubMed=16859559; DOI=10.1186/1471-2407-6-195; RA Havens A.M., Jung Y., Sun Y.X., Wang J., Shah R.B., Buehring H.J., RA Pienta K.J., Taichman R.S.; RT "The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer RT metastasis."; RL BMC Cancer 6:195-195(2006). RN [10] RP FUNCTION, AND INTERACTION WITH CXCR4. RX PubMed=17077324; DOI=10.1182/blood-2006-05-023028; RA Forde S., Tye B.J., Newey S.E., Roubelakis M., Smythe J., McGuckin C.P., RA Pettengell R., Watt S.M.; RT "Endolyn (CD164) modulates the CXCL12-mediated migration of umbilical cord RT blood CD133+ cells."; RL Blood 109:1825-1833(2007). RN [11] RP SUBCELLULAR LOCATION, AND INVOLVEMENT IN DFNA66. RX PubMed=26197441; DOI=10.1371/journal.pgen.1005386; RA Nyegaard M., Rendtorff N.D., Nielsen M.S., Corydon T.J., Demontis D., RA Starnawska A., Hedemand A., Buniello A., Niola F., Overgaard M.T., RA Leal S.M., Ahmad W., Wikman F.P., Petersen K.B., Crueger D.G., Oostrik J., RA Kremer H., Tommerup N., Froedin M., Steel K.P., Tranebjaerg L., RA Boerglum A.D.; RT "A novel locus harbouring a functional CD164 nonsense mutation identified RT in a large Danish family with nonsyndromic hearing impairment."; RL PLoS Genet. 11:E1005386-E1005386(2015). CC -!- FUNCTION: Sialomucin that may play a key role in hematopoiesis by CC facilitating the adhesion of CD34(+) cells to the stroma and by CC negatively regulating CD34(+)CD38(lo/-) cell proliferation. Modulates CC the migration of umbilical cord blood CD133+ cells and this is mediated CC through the CXCL12/CXCR4 axis. May play an important role in prostate CC cancer metastasis and the infiltration of bone marrow by cancer cells. CC Promotes myogenesis by enhancing CXCR4-dependent cell motility. CC Positively regulates myoblast migration and promotes myoblast fusion CC into myotubes (By similarity). {ECO:0000250|UniProtKB:Q9R0L9, CC ECO:0000269|PubMed:16859559, ECO:0000269|PubMed:17077324, CC ECO:0000269|PubMed:9763543}. CC -!- SUBUNIT: Homodimer (isoform 4). Interacts with CXCR4. CC {ECO:0000269|PubMed:17077324, ECO:0000269|PubMed:9763543}. CC -!- INTERACTION: CC Q04900; P61073: CXCR4; NbExp=2; IntAct=EBI-2115896, EBI-489411; CC Q04900; P49639: HOXA1; NbExp=3; IntAct=EBI-2115896, EBI-740785; CC Q04900; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-2115896, EBI-945833; CC Q04900; P0DPK4: NOTCH2NLC; NbExp=3; IntAct=EBI-2115896, EBI-22310682; CC -!- SUBCELLULAR LOCATION: Lysosome membrane {ECO:0000269|PubMed:11027692}; CC Single-pass type I membrane protein {ECO:0000269|PubMed:11027692}. CC Endosome membrane {ECO:0000269|PubMed:11027692}; Single-pass type I CC membrane protein {ECO:0000269|PubMed:11027692}. Cell membrane CC {ECO:0000269|PubMed:11027692, ECO:0000269|PubMed:26197441}; Single-pass CC type I membrane protein {ECO:0000269|PubMed:11027692}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted {ECO:0000305}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=5; CC Name=1; Synonyms=CD164(E1-6); CC IsoId=Q04900-1; Sequence=Displayed; CC Name=2; CC IsoId=Q04900-2; Sequence=VSP_037974; CC Name=3; Synonyms=CD164(Delta 4); CC IsoId=Q04900-3; Sequence=VSP_037972; CC Name=4; Synonyms=CD164(Delta 5); CC IsoId=Q04900-4; Sequence=VSP_037973; CC Name=5; CC IsoId=Q04900-5; Sequence=VSP_038018, VSP_038019; CC -!- TISSUE SPECIFICITY: Isoform 1 and isoform 3 are expressed in CC hematopoietic and non-hematopoietic tissues. Isoform 1 is expressed by CC prostate cancer tumors and prostate cancer cell lines. The expression CC is greater in bone metastases than in primary tumors. Expression in CC osseous metastasis is greater than that in soft tissue metastasis. CC Isoform 2 is expressed in the small intestine, colon, lung, thyroid and CC in colorectal and pancreatic adenocarcinoma. Isoform 4 is expressed by CC both hematopoietic progenitor cells and bone marrow stromal cells. CC {ECO:0000269|PubMed:10878358, ECO:0000269|PubMed:11027692, CC ECO:0000269|PubMed:1478919, ECO:0000269|PubMed:16859559, CC ECO:0000269|PubMed:9763543}. CC -!- INDUCTION: Up-regulated by CXCL12 in prostate cancer cell lines. CC {ECO:0000269|PubMed:16859559}. CC -!- PTM: Highly N- and O-glycosylated; contains sialic acid. CC {ECO:0000269|PubMed:1478919}. CC -!- PTM: The motif Ser-Gly may serve as the site of attachment of a CC glycosaminoglycan side chain. CC -!- DISEASE: Deafness, autosomal dominant, 66 (DFNA66) [MIM:616969]: A form CC of non-syndromic sensorineural hearing loss. Sensorineural deafness CC results from damage to the neural receptors of the inner ear, the nerve CC pathways to the brain, or the area of the brain that receives sound CC information. {ECO:0000269|PubMed:26197441}. Note=The disease is caused CC by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the CD164 family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D14043; BAA03130.1; -; mRNA. DR EMBL; AF106518; AAC82473.1; -; mRNA. DR EMBL; AF263279; AAF85965.1; -; mRNA. DR EMBL; AF299341; AAG53906.1; -; mRNA. DR EMBL; AF299342; AAG53907.1; -; mRNA. DR EMBL; AF299343; AAG53908.1; -; mRNA. DR EMBL; AF299340; AAG53903.1; -; Genomic_DNA. DR EMBL; AF299340; AAG53904.1; -; Genomic_DNA. DR EMBL; AF299340; AAG53905.1; -; Genomic_DNA. DR EMBL; AK298684; BAG60847.1; -; mRNA. DR EMBL; AK303525; BAG64553.1; -; mRNA. DR EMBL; AK312357; BAG35275.1; -; mRNA. DR EMBL; AK315908; BAH14279.1; -; mRNA. DR EMBL; AL359711; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471051; EAW48348.1; -; Genomic_DNA. DR EMBL; CH471051; EAW48352.1; -; Genomic_DNA. DR EMBL; CH471051; EAW48349.1; -; Genomic_DNA. DR EMBL; CH471051; EAW48353.1; -; Genomic_DNA. DR EMBL; CH471051; EAW48354.1; -; Genomic_DNA. DR EMBL; CH471051; EAW48355.1; -; Genomic_DNA. DR EMBL; BC011522; AAH11522.1; -; mRNA. DR CCDS; CCDS47462.1; -. [Q04900-5] DR CCDS; CCDS47463.1; -. [Q04900-2] DR CCDS; CCDS47464.1; -. [Q04900-3] DR CCDS; CCDS47465.1; -. [Q04900-4] DR CCDS; CCDS5073.1; -. [Q04900-1] DR PIR; JX0235; JX0235. DR RefSeq; NP_001135873.1; NM_001142401.3. [Q04900-3] DR RefSeq; NP_001135874.1; NM_001142402.3. [Q04900-4] DR RefSeq; NP_001135875.1; NM_001142403.3. [Q04900-2] DR RefSeq; NP_001135876.1; NM_001142404.3. [Q04900-5] DR RefSeq; NP_001333429.1; NM_001346500.1. DR RefSeq; NP_006007.2; NM_006016.5. [Q04900-1] DR AlphaFoldDB; Q04900; -. DR SMR; Q04900; -. DR BioGRID; 114297; 8. DR DIP; DIP-43970N; -. DR FunCoup; Q04900; 915. DR IntAct; Q04900; 13. DR MINT; Q04900; -. DR STRING; 9606.ENSP00000309376; -. DR GlyConnect; 1744; 5 N-Linked glycans (2 sites). DR GlyCosmos; Q04900; 12 sites, 8 glycans. DR GlyGen; Q04900; 16 sites, 32 N-linked glycans (5 sites), 4 O-linked glycans (5 sites). DR iPTMnet; Q04900; -. DR PhosphoSitePlus; Q04900; -. DR SwissPalm; Q04900; -. DR BioMuta; CD164; -. DR DMDM; 257051036; -. DR CPTAC; CPTAC-1481; -. DR MassIVE; Q04900; -. DR PaxDb; 9606-ENSP00000309376; -. DR PeptideAtlas; Q04900; -. DR ProteomicsDB; 58289; -. [Q04900-1] DR ProteomicsDB; 58290; -. [Q04900-2] DR ProteomicsDB; 58291; -. [Q04900-3] DR ProteomicsDB; 58292; -. [Q04900-4] DR ProteomicsDB; 58293; -. [Q04900-5] DR Pumba; Q04900; -. DR Antibodypedia; 2460; 288 antibodies from 29 providers. DR DNASU; 8763; -. DR Ensembl; ENST00000275080.11; ENSP00000275080.7; ENSG00000135535.18. [Q04900-3] DR Ensembl; ENST00000310786.10; ENSP00000309376.4; ENSG00000135535.18. [Q04900-1] DR Ensembl; ENST00000324953.9; ENSP00000314177.5; ENSG00000135535.18. [Q04900-4] DR Ensembl; ENST00000413644.6; ENSP00000402237.2; ENSG00000135535.18. [Q04900-2] DR Ensembl; ENST00000512821.5; ENSP00000427546.1; ENSG00000135535.18. [Q04900-5] DR GeneID; 8763; -. DR KEGG; hsa:8763; -. DR MANE-Select; ENST00000310786.10; ENSP00000309376.4; NM_006016.6; NP_006007.2. DR UCSC; uc003ptd.4; human. [Q04900-1] DR AGR; HGNC:1632; -. DR ClinPGx; PA26191; -. DR CTD; 8763; -. DR DisGeNET; 8763; -. DR GeneCards; CD164; -. DR HGNC; HGNC:1632; CD164. DR HPA; ENSG00000135535; Low tissue specificity. DR MalaCards; CD164; -. DR MIM; 603356; gene. DR MIM; 616969; phenotype. DR OpenTargets; ENSG00000135535; -. DR Orphanet; 90635; Rare autosomal dominant non-syndromic sensorineural deafness type DFNA. DR VEuPathDB; HostDB:ENSG00000135535; -. DR eggNOG; ENOG502S7HA; Eukaryota. DR GeneTree; ENSGT00530000063929; -. DR HOGENOM; CLU_101414_0_0_1; -. DR InParanoid; Q04900; -. DR OrthoDB; 6160056at2759; -. DR PAN-GO; Q04900; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q04900; -. DR PathwayCommons; Q04900; -. DR SignaLink; Q04900; -. DR Agora; ENSG00000135535; -. DR BioGRID-ORCS; 8763; 21 hits in 1158 CRISPR screens. DR ChiTaRS; CD164; human. DR GeneWiki; CD164; -. DR GenomeRNAi; 8763; -. DR Pharos; Q04900; Tbio. DR PRO; PR:Q04900; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q04900; protein. DR Bgee; ENSG00000135535; Expressed in mucosa of sigmoid colon and 215 other cell types or tissues. DR ExpressionAtlas; Q04900; baseline and differential. DR GO; GO:0005768; C:endosome; IDA:UniProtKB. DR GO; GO:0010008; C:endosome membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0005765; C:lysosomal membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005764; C:lysosome; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0007155; P:cell adhesion; IDA:MGI. DR GO; GO:0030097; P:hemopoiesis; NAS:UniProtKB. DR GO; GO:0007157; P:heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules; IDA:MGI. DR GO; GO:0006955; P:immune response; TAS:ProtInc. DR GO; GO:0007517; P:muscle organ development; IEA:UniProtKB-KW. DR GO; GO:0007162; P:negative regulation of cell adhesion; NAS:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR InterPro; IPR007947; CD164_MGC24. DR PANTHER; PTHR11337; MUCIN/PORIMIN; 1. DR PANTHER; PTHR11337:SF12; SIALOMUCIN CORE PROTEIN 24; 1. DR Pfam; PF05283; MGC-24; 1. DR PRINTS; PR01701; CD164ANTIGEN. PE 1: Evidence at protein level; KW Alternative splicing; Cell adhesion; Cell membrane; Deafness; Endosome; KW Glycoprotein; Lysosome; Membrane; Myogenesis; Non-syndromic deafness; KW Proteoglycan; Proteomics identification; Reference proteome; Secreted; KW Signal; Transmembrane; Transmembrane helix. FT SIGNAL 1..23 FT /evidence="ECO:0000255" FT CHAIN 24..197 FT /note="Sialomucin core protein 24" FT /id="PRO_0000019292" FT TOPO_DOM 24..162 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 163..183 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 184..197 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT REGION 118..154 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 191..197 FT /note="Required for endosomal and lysosomal localization" FT /evidence="ECO:0000250" FT COMPBIAS 125..154 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT CARBOHYD 26 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 32 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 41 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 72 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 77 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 94 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 104 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 121 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 142 FT /note="O-linked (Xyl...) (glycosaminoglycan) serine" FT /evidence="ECO:0000255" FT CARBOHYD 146 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 111..123 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:11027692, FT ECO:0000303|PubMed:14702039" FT /id="VSP_037972" FT VAR_SEQ 124..142 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:11027692, FT ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:9763543" FT /id="VSP_037973" FT VAR_SEQ 143..157 FT /note="GTTNNTVTPTSQPVR -> EIRCHTRNYIPDLKK (in isoform 5)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_038018" FT VAR_SEQ 158..197 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_038019" FT VAR_SEQ 175..197 FT /note="GVQAVIFFLYKFCKSKERNYHTL -> EIRCHTRNYIPDLKK (in FT isoform 2)" FT /evidence="ECO:0000303|PubMed:1478919" FT /id="VSP_037974" SQ SEQUENCE 197 AA; 20917 MW; 4855E02646F4CB35 CRC64; MSRLSRSLLW AATCLGVLCV LSADKNTTQH PNVTTLAPIS NVTSAPVTSL PLVTTPAPET CEGRNSCVSC FNVSVVNTTC FWIECKDESY CSHNSTVSDC QVGNTTDFCS VSTATPVPTA NSTAKPTVQP SPSTTSKTVT TSGTTNNTVT PTSQPVRKST FDAASFIGGI VLVLGVQAVI FFLYKFCKSK ERNYHTL // ID MUTYH_HUMAN Reviewed; 546 AA. AC Q9UIF7; D3DPZ4; Q15830; Q9UBP2; Q9UBS7; Q9UIF4; Q9UIF5; Q9UIF6; DT 07-JUN-2004, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-2000, sequence version 1. DT 28-JAN-2026, entry version 216. DE RecName: Full=Adenine DNA glycosylase; DE EC=3.2.2.31 {ECO:0000269|PubMed:20418187}; DE AltName: Full=MutY homolog; DE Short=hMYH; GN Name=MUTYH; Synonyms=MYH; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM ALPHA-3). RX PubMed=8682794; DOI=10.1128/jb.178.13.3885-3892.1996; RA Slupska M.M., Baikalov C., Luther W.M., Chiang J.H., Wei Y.F., Miller J.H.; RT "Cloning and sequencing a human homolog (hMYH) of the Escherichia coli mutY RT gene whose function is required for the repair of oxidative DNA damage."; RL J. Bacteriol. 178:3885-3892(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA-1; ALPHA-2; ALPHA-3; BETA-1; RP GAMMA-2 AND GAMMA-3), AND FUNCTION. RX PubMed=10684930; DOI=10.1093/nar/28.6.1355; RA Ohtsubo T., Nishioka K., Imaiso Y., Iwai S., Shimokawa H., Oda H., RA Fujikawa T., Nakabeppu Y.; RT "Identification of human MutY homolog (hMYH) as a repair enzyme for 2- RT hydroxyadenine in DNA and detection of multiple forms of hMYH located in RT nuclei and mitochondria."; RL Nucleic Acids Res. 28:1355-1364(2000). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=20843780; DOI=10.1093/nar/gkq750; RA Wang W., Shen P., Thiyagarajan S., Lin S., Palm C., Horvath R., RA Klopstock T., Cutler D., Pique L., Schrijver I., Davis R.W., Mindrinos M., RA Speed T.P., Scharfe C.; RT "Identification of rare DNA variants in mitochondrial disorders with RT improved array-based sequencing."; RL Nucleic Acids Res. 39:44-58(2011). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS MET-22; HIS-335; GLU-500; RP MET-526 AND GLN-531. RG NIEHS SNPs program; RL Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA-3). RC TISSUE=Kidney; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP STRUCTURE BY NMR OF 356-497. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the NUDIX domain from human A/G-specific adenine DNA RT glycosylase alpha-3 splice isoform."; RL Submitted (NOV-2005) to the PDB data bank. RN [9] RP VARIANTS FAP2 CYS-176 AND ASP-393. RX PubMed=11818965; DOI=10.1038/ng828; RA Al-Tassan N., Chmiel N.H., Maynard J., Fleming N., Livingston A.L., RA Williams G.T., Hodges A.K., Davies D.R., David S.S., Sampson J.R., RA Cheadle J.P.; RT "Inherited variants of MYH associated with somatic G:C-->T:A mutations in RT colorectal tumors."; RL Nat. Genet. 30:227-232(2002). RN [10] RP VARIANTS FAP2 ARG-128; CYS-176 AND ASP-393. RX PubMed=12853198; DOI=10.1016/s0140-6736(03)13805-6; RA Sampson J.R., Dolwani S., Jones S., Eccles D., Ellis A., Evans D.G., RA Frayling I., Jordan S., Maher E.R., Mak T., Maynard J., Pigatto F., RA Shaw J., Cheadle J.P.; RT "Autosomal recessive colorectal adenomatous polyposis due to inherited RT mutations of MYH."; RL Lancet 362:39-41(2003). RN [11] RP VARIANTS FAP2 CYS-176 AND ASP-393, AND VARIANTS MET-22; HIS-335 AND RP PHE-512. RX PubMed=12606733; DOI=10.1056/nejmoa025283; RA Sieber O.M., Lipton L., Crabtree M., Heinimann K., Fidalgo P., RA Phillips R.K.S., Bisgaard M.-L., Orntoft T.F., Aaltonen L.A., Hodgson S.V., RA Thomas H.J.W., Tomlinson I.P.M.; RT "Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line RT mutations in MYH."; RL N. Engl. J. Med. 348:791-799(2003). RN [12] RP VARIANTS FAP2 HIS-125; HIS-179 AND TRP-238. RX PubMed=15366000; DOI=10.1002/humu.9282; RA Isidro G., Laranjeira F., Pires A., Leite J., Regateiro F., RA Castro e Sousa F., Soares J., Castro C., Giria J., Brito M.J., Medeira A., RA Teixeira R., Morna H., Gaspar I., Marinho C., Jorge R., Brehm A., RA Ramos J.S., Boavida M.G.; RT "Germline MUTYH (MYH) mutations in Portuguese individuals with multiple RT colorectal adenomas."; RL Hum. Mutat. 24:353-354(2004). RN [13] RP VARIANTS GASC SER-402 AND ARG-411. RX PubMed=15273732; DOI=10.1038/sj.onc.1207574; RA Kim C.J., Cho Y.G., Park C.H., Kim S.Y., Nam S.W., Lee S.H., Yoo N.J., RA Lee J.Y., Park W.S.; RT "Genetic alterations of the MYH gene in gastric cancer."; RL Oncogene 23:6820-6822(2004). RN [14] RP VARIANTS FAP2 CYS-176; HIS-242; TRP-271; PRO-385; ASP-393; CYS-423 AND RP GLU-477 DEL, AND VARIANTS MET-22 AND HIS-335. RX PubMed=16134147; DOI=10.1002/humu.9370; RA Aceto G., Curia M.C., Veschi S., De Lellis L., Mammarella S., Catalano T., RA Stuppia L., Palka G., Valanzano R., Tonelli F., Casale V., Stigliano V., RA Cetta F., Battista P., Mariani-Costantini R., Cama A.; RT "Mutations of APC and MYH in unrelated Italian patients with adenomatous RT polyposis coli."; RL Hum. Mutat. 26:394-394(2005). RN [15] RP VARIANTS FAP2 CYS-176; SER-177; VAL-280; LEU-292; PRO-385 AND ASP-393, AND RP VARIANTS MET-22; HIS-335 AND PHE-512. RX PubMed=16941501; DOI=10.1002/humu.9460; RG PAFNORD Group; RA Lejeune S., Guillemot F., Triboulet J.P., Cattan S., Mouton C., Porchet N., RA Manouvrier S., Buisine M.P.; RT "Low frequency of AXIN2 mutations and high frequency of MUTYH mutations in RT patients with multiple polyposis."; RL Hum. Mutat. 27:1064-1064(2006). RN [16] RP VARIANTS FAP2 ILE-TRP-148 INS; CYS-176; GLN-182; VAL-220; HIS-242 AND RP ASP-393, AND VARIANTS MET-22 AND HIS-335. RX PubMed=16287072; DOI=10.1002/ijc.21470; RA Russell A.M., Zhang J., Luz J., Hutter P., Chappuis P.O., Berthod C.R., RA Maillet P., Mueller H., Heinimann K.; RT "Prevalence of MYH germline mutations in Swiss APC mutation-negative RT polyposis patients."; RL Int. J. Cancer 118:1937-1940(2006). RN [17] RP VARIANTS FAP2 LEU-154; CYS-176; HIS-179; HIS-242; TRP-271; LEU-292; RP CYS-306; ASP-393; LEU-402; CYS-423; GLU-477 DEL AND PHE-490. RX PubMed=16557584; DOI=10.1002/ijc.21905; RA Aretz S., Uhlhaas S., Goergens H., Siberg K., Vogel M., Pagenstecher C., RA Mangold E., Caspari R., Propping P., Friedl W.; RT "MUTYH-associated polyposis: 70 of 71 patients with biallelic mutations RT present with an attenuated or atypical phenotype."; RL Int. J. Cancer 119:807-814(2006). RN [18] RP VARIANTS FAP2 CYS-176; CYS-179; TRP-182 AND ASP-393. RX PubMed=18091433; DOI=10.1097/gim.0b013e31815bf940; RA Cattaneo F., Molatore S., Mihalatos M., Apessos A., Venesio T., Bione S., RA Grignani P., Nasioulas G., Ranzani G.N.; RT "Heterogeneous molecular mechanisms underlie attenuated familial RT adenomatous polyposis."; RL Genet. Med. 9:836-841(2007). RN [19] RP VARIANTS FAP2 GLU-213; SER-235 AND MET-474. RX PubMed=18515411; DOI=10.1136/gut.2007.145748; RA Dallosso A.R., Dolwani S., Jones N., Jones S., Colley J., Maynard J., RA Idziaszczyk S., Humphreys V., Arnold J., Donaldson A., Eccles D., Ellis A., RA Evans D.G., Frayling I.M., Hes F.J., Houlston R.S., Maher E.R., Nielsen M., RA Parry S., Tyler E., Moskvina V., Cheadle J.P., Sampson J.R.; RT "Inherited predisposition to colorectal adenomas caused by multiple rare RT alleles of MUTYH but not OGG1, NUDT1, NTH1 or NEIL 1, 2 or 3."; RL Gut 57:1252-1255(2008). RN [20] RP CHARACTERIZATION OF VARIANTS FAP2 ILE-TRP-148 INS; CYS-176; TRP-182; RP ASP-393 AND GLU-477 DEL, FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=20418187; DOI=10.1016/j.dnarep.2010.03.008; RA D'Agostino V.G., Minoprio A., Torreri P., Marinoni I., Bossa C., RA Petrucci T.C., Albertini A.M., Ranzani G.N., Bignami M., Mazzei F.; RT "Functional analysis of MUTYH mutated proteins associated with familial RT adenomatous polyposis."; RL DNA Repair 9:700-707(2010). RN [21] RP VARIANTS FAP2 ILE-TRP-148 INS; TRP-182 AND GLU-477 DEL, AND RP CHARACTERIZATION OF VARIANTS FAP2 ILE-TRP-148 INS; CYS-176; TRP-182; RP ASP-393 AND GLU-477 DEL. RX PubMed=19953527; DOI=10.1002/humu.21158; RA Molatore S., Russo M.T., D'Agostino V.G., Barone F., Matsumoto Y., RA Albertini A.M., Minoprio A., Degan P., Mazzei F., Bignami M., Ranzani G.N.; RT "MUTYH mutations associated with familial adenomatous polyposis: functional RT characterization by a mammalian cell-based assay."; RL Hum. Mutat. 31:159-166(2010). RN [22] RP CHARACTERIZATION OF VARIANTS FAP2 CYS-176; HIS-179; VAL-220; VAL-280; RP CYS-306; PRO-385; ASP-393; LEU-402 AND GLU-477 DEL, CHARACTERIZATION OF RP VARIANTS GLU-72; VAL-370 AND PHE-512, FUNCTION, AND MUTAGENESIS OF ASP-233. RX PubMed=20848659; DOI=10.1002/humu.21363; RA Goto M., Shinmura K., Nakabeppu Y., Tao H., Yamada H., Tsuneyoshi T., RA Sugimura H.; RT "Adenine DNA glycosylase activity of 14 human MutY homolog (MUTYH) variant RT proteins found in patients with colorectal polyposis and cancer."; RL Hum. Mutat. 31:E1861-E1874(2010). RN [23] RP CHARACTERIZATION OF VARIANTS FAP2 LEU-18; HIS-125; ARG-128; LEU-154; RP CYS-176; CYS-179; HIS-179; GLN-182; GLU-186; VAL-220; TRP-238; HIS-242; RP TRP-271; GLU-283; LEU-292; CYS-306; THR-377; PRO-385; ASP-393; LEU-402; RP MET-417; CYS-423; ASP-470; THR-470; GLU-477 DEL; THR-486 AND PHE-490, RP CHARACTERIZATION OF VARIANTS GASC SER-402 AND ARG-411, CHARACTERIZATION OF RP VARIANTS MET-22; ASP-25; ARG-100; ASN-102; VAL-224; MET-231; CYS-242; RP PHE-243; TRP-287; HIS-335; ARG-335; GLN-434; PRO-434; GLU-500; PHE-512; RP LEU-513; MET-526 AND GLN-531, FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=25820570; DOI=10.1002/humu.22794; RA Komine K., Shimodaira H., Takao M., Soeda H., Zhang X., Takahashi M., RA Ishioka C.; RT "Functional complementation assay for 47 MUTYH variants in a MutY-disrupted RT Escherichia coli strain."; RL Hum. Mutat. 36:704-711(2015). RN [24] RP CHARACTERIZATION OF VARIANT FAP2 SER-235, CHARACTERIZATION OF VARIANTS RP ASN-102; MET-231; GLY-244; ASN-319; HIS-520 AND ALA-536, FUNCTION, AND RP MUTAGENESIS OF ASP-121. RX PubMed=26694661; DOI=10.1002/humu.22949; RA Shinmura K., Kato H., Goto M., Yamada H., Tao H., Nakamura S., Sugimura H.; RT "Functional evaluation of nine missense-type variants of the human DNA RT glycosylase enzyme MUTYH in the Japanese population."; RL Hum. Mutat. 37:350-353(2016). CC -!- FUNCTION: Involved in oxidative DNA damage repair. Initiates repair of CC A*oxoG to C*G by removing the inappropriately paired adenine base from CC the DNA backbone. Possesses both adenine and 2-OH-A DNA glycosylase CC activities. {ECO:0000269|PubMed:10684930, ECO:0000269|PubMed:20418187, CC ECO:0000269|PubMed:20848659, ECO:0000269|PubMed:25820570, CC ECO:0000269|PubMed:26694661}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Hydrolyzes free adenine bases from 7,8-dihydro-8- CC oxoguanine:adenine mismatched double-stranded DNA, leaving an CC apurinic site.; EC=3.2.2.31; Evidence={ECO:0000269|PubMed:20418187}; CC -!- COFACTOR: CC Name=[4Fe-4S] cluster; Xref=ChEBI:CHEBI:49883; Evidence={ECO:0000250}; CC Note=Binds 1 [4Fe-4S] cluster. The cluster does not appear to play a CC role in catalysis, but is probably involved in the proper positioning CC of the enzyme along the DNA strand. {ECO:0000250}; CC -!- INTERACTION: CC Q9UIF7-3; Q6RW13: AGTRAP; NbExp=3; IntAct=EBI-10321956, EBI-741181; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:25820570}. CC Mitochondrion {ECO:0000250|UniProtKB:Q99P21}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=6; CC Name=Alpha-1; CC IsoId=Q9UIF7-1; Sequence=Displayed; CC Name=Alpha-2; CC IsoId=Q9UIF7-2; Sequence=VSP_010549; CC Name=Alpha-3; CC IsoId=Q9UIF7-3; Sequence=VSP_010550; CC Name=Beta-1; CC IsoId=Q9UIF7-4; Sequence=VSP_010548; CC Name=Gamma-2; CC IsoId=Q9UIF7-5; Sequence=VSP_010548, VSP_010549; CC Name=Gamma-3; CC IsoId=Q9UIF7-6; Sequence=VSP_010548, VSP_010550; CC -!- DISEASE: Familial adenomatous polyposis 2 (FAP2) [MIM:608456]: A CC condition characterized by the development of multiple colorectal CC adenomatous polyps, benign neoplasms derived from glandular epithelium. CC Some affected individuals may develop colorectal carcinoma. CC {ECO:0000269|PubMed:11818965, ECO:0000269|PubMed:12606733, CC ECO:0000269|PubMed:12853198, ECO:0000269|PubMed:15366000, CC ECO:0000269|PubMed:16134147, ECO:0000269|PubMed:16287072, CC ECO:0000269|PubMed:16557584, ECO:0000269|PubMed:16941501, CC ECO:0000269|PubMed:18091433, ECO:0000269|PubMed:18515411, CC ECO:0000269|PubMed:19953527, ECO:0000269|PubMed:20418187, CC ECO:0000269|PubMed:20848659, ECO:0000269|PubMed:25820570, CC ECO:0000269|PubMed:26694661}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which CC starts in the stomach, can spread to the esophagus or the small CC intestine, and can extend through the stomach wall to nearby lymph CC nodes and organs. It also can metastasize to other parts of the body. CC The term gastric cancer or gastric carcinoma refers to adenocarcinoma CC of the stomach that accounts for most of all gastric malignant tumors. CC Two main histologic types are recognized, diffuse type and intestinal CC type carcinomas. Diffuse tumors are poorly differentiated infiltrating CC lesions, resulting in thickening of the stomach. In contrast, CC intestinal tumors are usually exophytic, often ulcerating, and CC associated with intestinal metaplasia of the stomach, most often CC observed in sporadic disease. {ECO:0000269|PubMed:15273732, CC ECO:0000269|PubMed:25820570}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. Somatic mutations contribute CC to the development of a sub-set of sporadic gastric cancers in carriers CC of Helicobacter pylori (PubMed:15273732). CC {ECO:0000269|PubMed:15273732}. CC -!- SIMILARITY: Belongs to the Nth/MutY family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA89339.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAA89339.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=BAA89345.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAA89345.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41464/mutyh-(muty-homolog-(e-coli))"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U63329; AAC50618.1; -; Genomic_DNA. DR EMBL; AB032920; BAA89336.1; -; mRNA. DR EMBL; AB032921; BAA89337.1; -; mRNA. DR EMBL; AB032922; BAA89338.1; -; mRNA. DR EMBL; AB032923; BAA89339.1; ALT_SEQ; mRNA. DR EMBL; AB032924; BAA89340.1; -; mRNA. DR EMBL; AB032925; BAA89341.1; -; mRNA. DR EMBL; AB032926; BAA89342.1; -; mRNA. DR EMBL; AB032927; BAA89343.1; -; mRNA. DR EMBL; AB032928; BAA89344.1; -; mRNA. DR EMBL; AB032929; BAA89345.1; ALT_SEQ; mRNA. DR EMBL; HQ205466; ADP90937.1; -; Genomic_DNA. DR EMBL; HQ205468; ADP90947.1; -; Genomic_DNA. DR EMBL; HQ205469; ADP90952.1; -; Genomic_DNA. DR EMBL; HQ205470; ADP90957.1; -; Genomic_DNA. DR EMBL; HQ205472; ADP90967.1; -; Genomic_DNA. DR EMBL; HQ205473; ADP90972.1; -; Genomic_DNA. DR EMBL; HQ205474; ADP90977.1; -; Genomic_DNA. DR EMBL; HQ205475; ADP90982.1; -; Genomic_DNA. DR EMBL; HQ205476; ADP90987.1; -; Genomic_DNA. DR EMBL; HQ205477; ADP90992.1; -; Genomic_DNA. DR EMBL; HQ205479; ADP91002.1; -; Genomic_DNA. DR EMBL; HQ205480; ADP91007.1; -; Genomic_DNA. DR EMBL; HQ205481; ADP91012.1; -; Genomic_DNA. DR EMBL; HQ205482; ADP91017.1; -; Genomic_DNA. DR EMBL; HQ205483; ADP91022.1; -; Genomic_DNA. DR EMBL; HQ205484; ADP91027.1; -; Genomic_DNA. DR EMBL; HQ205485; ADP91032.1; -; Genomic_DNA. DR EMBL; HQ205486; ADP91037.1; -; Genomic_DNA. DR EMBL; HQ205487; ADP91042.1; -; Genomic_DNA. DR EMBL; HQ205488; ADP91047.1; -; Genomic_DNA. DR EMBL; HQ205489; ADP91052.1; -; Genomic_DNA. DR EMBL; HQ205490; ADP91057.1; -; Genomic_DNA. DR EMBL; HQ205491; ADP91062.1; -; Genomic_DNA. DR EMBL; HQ205492; ADP91067.1; -; Genomic_DNA. DR EMBL; HQ205493; ADP91072.1; -; Genomic_DNA. DR EMBL; HQ205494; ADP91077.1; -; Genomic_DNA. DR EMBL; HQ205495; ADP91082.1; -; Genomic_DNA. DR EMBL; HQ205496; ADP91087.1; -; Genomic_DNA. DR EMBL; HQ205497; ADP91092.1; -; Genomic_DNA. DR EMBL; HQ205498; ADP91097.1; -; Genomic_DNA. DR EMBL; HQ205499; ADP91102.1; -; Genomic_DNA. DR EMBL; HQ205500; ADP91107.1; -; Genomic_DNA. DR EMBL; HQ205501; ADP91112.1; -; Genomic_DNA. DR EMBL; HQ205502; ADP91117.1; -; Genomic_DNA. DR EMBL; HQ205503; ADP91122.1; -; Genomic_DNA. DR EMBL; HQ205505; ADP91132.1; -; Genomic_DNA. DR EMBL; AF527839; AAM78555.1; -; Genomic_DNA. DR EMBL; AL359540; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471059; EAX06993.1; -; Genomic_DNA. DR EMBL; CH471059; EAX06996.1; -; Genomic_DNA. DR EMBL; CH471059; EAX06997.1; -; Genomic_DNA. DR EMBL; BC003178; AAH03178.1; -; mRNA. DR CCDS; CCDS41321.1; -. [Q9UIF7-5] DR CCDS; CCDS41322.1; -. [Q9UIF7-6] DR CCDS; CCDS520.1; -. [Q9UIF7-1] DR CCDS; CCDS72776.1; -. [Q9UIF7-4] DR CCDS; CCDS72777.1; -. [Q9UIF7-2] DR RefSeq; NP_001041636.2; NM_001048171.2. [Q9UIF7-6] DR RefSeq; NP_001041637.1; NM_001048172.2. [Q9UIF7-5] DR RefSeq; NP_001041638.1; NM_001048173.2. [Q9UIF7-6] DR RefSeq; NP_001041639.1; NM_001048174.2. [Q9UIF7-6] DR RefSeq; NP_001121897.1; NM_001128425.1. DR RefSeq; NP_001280119.1; NM_001293190.2. [Q9UIF7-2] DR RefSeq; NP_001280120.1; NM_001293191.2. [Q9UIF7-4] DR RefSeq; NP_001280121.1; NM_001293192.1. DR RefSeq; NP_001280124.1; NM_001293195.2. [Q9UIF7-6] DR RefSeq; NP_001280125.1; NM_001293196.1. DR RefSeq; NP_001393999.1; NM_001407070.1. [Q9UIF7-6] DR RefSeq; NP_001394000.1; NM_001407071.1. [Q9UIF7-5] DR RefSeq; NP_001394001.1; NM_001407072.1. [Q9UIF7-6] DR RefSeq; NP_001394006.1; NM_001407077.1. [Q9UIF7-4] DR RefSeq; NP_001394007.1; NM_001407078.1. [Q9UIF7-5] DR RefSeq; NP_001394010.1; NM_001407081.1. [Q9UIF7-6] DR RefSeq; NP_001394015.1; NM_001407086.1. [Q9UIF7-5] DR RefSeq; NP_001394017.1; NM_001407088.1. [Q9UIF7-6] DR RefSeq; NP_001394018.1; NM_001407089.1. [Q9UIF7-6] DR RefSeq; NP_036354.1; NM_012222.3. [Q9UIF7-1] DR PDB; 1X51; NMR; -; A=356-497. DR PDB; 3N5N; X-ray; 2.30 A; X/Y=76-362. DR PDB; 8FAY; X-ray; 1.91 A; A/D=64-516. DR PDBsum; 1X51; -. DR PDBsum; 3N5N; -. DR PDBsum; 8FAY; -. DR AlphaFoldDB; Q9UIF7; -. DR SMR; Q9UIF7; -. DR BioGRID; 110681; 29. DR DIP; DIP-41972N; -. DR FunCoup; Q9UIF7; 1732. DR IntAct; Q9UIF7; 26. DR MINT; Q9UIF7; -. DR STRING; 9606.ENSP00000500891; -. DR iPTMnet; Q9UIF7; -. DR PhosphoSitePlus; Q9UIF7; -. DR BioMuta; MUTYH; -. DR DMDM; 48428272; -. DR jPOST; Q9UIF7; -. DR MassIVE; Q9UIF7; -. DR PaxDb; 9606-ENSP00000361170; -. DR PeptideAtlas; Q9UIF7; -. DR ProteomicsDB; 84500; -. [Q9UIF7-1] DR ProteomicsDB; 84501; -. [Q9UIF7-2] DR ProteomicsDB; 84502; -. [Q9UIF7-3] DR ProteomicsDB; 84503; -. [Q9UIF7-4] DR ProteomicsDB; 84504; -. [Q9UIF7-5] DR ProteomicsDB; 84505; -. [Q9UIF7-6] DR Pumba; Q9UIF7; -. DR Antibodypedia; 1869; 332 antibodies from 40 providers. DR CPTC; Q9UIF7; 1 antibody. DR DNASU; 4595; -. DR Ensembl; ENST00000354383.10; ENSP00000346354.6; ENSG00000132781.23. [Q9UIF7-5] DR Ensembl; ENST00000355498.6; ENSP00000347685.2; ENSG00000132781.23. [Q9UIF7-6] DR Ensembl; ENST00000372098.7; ENSP00000361170.3; ENSG00000132781.23. [Q9UIF7-1] DR Ensembl; ENST00000372104.5; ENSP00000361176.1; ENSG00000132781.23. [Q9UIF7-6] DR Ensembl; ENST00000372110.7; ENSP00000361182.3; ENSG00000132781.23. [Q9UIF7-2] DR Ensembl; ENST00000372115.7; ENSP00000361187.3; ENSG00000132781.23. [Q9UIF7-3] DR Ensembl; ENST00000435155.2; ENSP00000403655.2; ENSG00000132781.23. [Q9UIF7-4] DR Ensembl; ENST00000448481.5; ENSP00000409718.1; ENSG00000132781.23. [Q9UIF7-4] DR Ensembl; ENST00000456914.7; ENSP00000407590.2; ENSG00000132781.23. [Q9UIF7-6] DR Ensembl; ENST00000672314.2; ENSP00000500828.2; ENSG00000132781.23. [Q9UIF7-6] DR Ensembl; ENST00000672818.3; ENSP00000500891.1; ENSG00000132781.23. [Q9UIF7-1] DR Ensembl; ENST00000713750.1; ENSP00000519051.1; ENSG00000132781.23. [Q9UIF7-6] DR GeneID; 4595; -. DR KEGG; hsa:4595; -. DR MANE-Select; ENST00000456914.7; ENSP00000407590.2; NM_001048174.2; NP_001041639.1. [Q9UIF7-6] DR UCSC; uc001cnf.4; human. [Q9UIF7-1] DR AGR; HGNC:7527; -. DR ClinPGx; PA31328; -. DR CTD; 4595; -. DR DisGeNET; 4595; -. DR GeneCards; MUTYH; -. DR GeneReviews; MUTYH; -. DR HGNC; HGNC:7527; MUTYH. DR HPA; ENSG00000132781; Low tissue specificity. DR MalaCards; MUTYH; -. DR MIM; 604933; gene. DR MIM; 608456; phenotype. DR MIM; 613659; phenotype. DR OpenTargets; ENSG00000132781; -. DR Orphanet; 440437; Familial colorectal cancer Type X. DR Orphanet; 247798; MUTYH-related polyposis. DR VEuPathDB; HostDB:ENSG00000132781; -. DR eggNOG; KOG2457; Eukaryota. DR GeneTree; ENSGT00510000047220; -. DR HOGENOM; CLU_012862_0_0_1; -. DR InParanoid; Q9UIF7; -. DR OMA; CRPGDFN; -. DR OrthoDB; 10248838at2759; -. DR PAN-GO; Q9UIF7; 7 GO annotations based on evolutionary models. DR PhylomeDB; Q9UIF7; -. DR PathwayCommons; Q9UIF7; -. DR Reactome; R-HSA-110330; Recognition and association of DNA glycosylase with site containing an affected purine. DR Reactome; R-HSA-110331; Cleavage of the damaged purine. DR Reactome; R-HSA-110357; Displacement of DNA glycosylase by APEX1. DR Reactome; R-HSA-9608287; Defective MUTYH substrate binding. [Q9UIF7-3] DR Reactome; R-HSA-9608290; Defective MUTYH substrate processing. DR SignaLink; Q9UIF7; -. DR SIGNOR; Q9UIF7; -. DR Agora; ENSG00000132781; -. DR BioGRID-ORCS; 4595; 18 hits in 1164 CRISPR screens. DR EvolutionaryTrace; Q9UIF7; -. DR GeneWiki; MUTYH; -. DR GenomeRNAi; 4595; -. DR Pharos; Q9UIF7; Tbio. DR PRO; PR:Q9UIF7; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q9UIF7; protein. DR Bgee; ENSG00000132781; Expressed in cerebellar hemisphere and 95 other cell types or tissues. DR ExpressionAtlas; Q9UIF7; baseline and differential. DR GO; GO:0005739; C:mitochondrion; HTP:FlyBase. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0051539; F:4 iron, 4 sulfur cluster binding; IEA:UniProtKB-KW. DR GO; GO:0034039; F:8-oxo-7,8-dihydroguanine DNA N-glycosylase activity; IBA:GO_Central. DR GO; GO:0035485; F:adenine/guanine mispair binding; IBA:GO_Central. DR GO; GO:0019104; F:DNA N-glycosylase activity; TAS:Reactome. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0032407; F:MutSalpha complex binding; IDA:HGNC-UCL. DR GO; GO:0032357; F:oxidized purine DNA binding; IBA:GO_Central. DR GO; GO:0000701; F:purine-specific mismatch base pair DNA N-glycosylase activity; IMP:UniProtKB. DR GO; GO:0006284; P:base-excision repair; IBA:GO_Central. DR GO; GO:0045007; P:depurination; TAS:Reactome. DR GO; GO:0006281; P:DNA repair; TAS:ProtInc. DR GO; GO:0006298; P:mismatch repair; IBA:GO_Central. DR GO; GO:0060546; P:negative regulation of necroptotic process; IEA:Ensembl. DR CDD; cd00056; ENDO3c; 1. DR CDD; cd03431; NUDIX_DNA_Glycosylase_C-MutY; 1. DR FunFam; 1.10.1670.10:FF:000002; Adenine DNA glycosylase; 1. DR FunFam; 1.10.340.30:FF:000002; Adenine DNA glycosylase; 1. DR FunFam; 3.90.79.10:FF:000026; Adenine DNA glycosylase; 1. DR Gene3D; 1.10.1670.10; Helix-hairpin-Helix base-excision DNA repair enzymes (C-terminal); 1. DR Gene3D; 1.10.340.30; Hypothetical protein, domain 2; 1. DR Gene3D; 3.90.79.10; Nucleoside Triphosphate Pyrophosphohydrolase; 1. DR InterPro; IPR011257; DNA_glycosylase. DR InterPro; IPR004036; Endonuclease-III-like_CS2. DR InterPro; IPR003651; Endonuclease3_FeS-loop_motif. DR InterPro; IPR004035; Endouclease-III_FeS-bd_BS. DR InterPro; IPR003265; HhH-GPD_domain. DR InterPro; IPR023170; HhH_base_excis_C. DR InterPro; IPR000445; HhH_motif. DR InterPro; IPR044298; MIG/MutY. DR InterPro; IPR029119; MutY_C. DR InterPro; IPR015797; NUDIX_hydrolase-like_dom_sf. DR InterPro; IPR000086; NUDIX_hydrolase_dom. DR PANTHER; PTHR42944; ADENINE DNA GLYCOSYLASE; 1. DR PANTHER; PTHR42944:SF1; ADENINE DNA GLYCOSYLASE; 1. DR Pfam; PF00633; HHH; 1. DR Pfam; PF00730; HhH-GPD; 1. DR Pfam; PF14815; NUDIX_4; 1. DR SMART; SM00478; ENDO3c; 1. DR SMART; SM00525; FES; 1. DR SUPFAM; SSF48150; DNA-glycosylase; 1. DR SUPFAM; SSF55811; Nudix; 1. DR PROSITE; PS00764; ENDONUCLEASE_III_1; 1. DR PROSITE; PS01155; ENDONUCLEASE_III_2; 1. DR PROSITE; PS51462; NUDIX; 1. PE 1: Evidence at protein level; KW 3D-structure; 4Fe-4S; Alternative splicing; Disease variant; DNA damage; KW DNA repair; Glycosidase; Hydrolase; Iron; Iron-sulfur; Metal-binding; KW Mitochondrion; Nucleus; Proteomics identification; Reference proteome; KW Tumor suppressor. FT CHAIN 1..546 FT /note="Adenine DNA glycosylase" FT /id="PRO_0000102239" FT DOMAIN 364..495 FT /note="Nudix hydrolase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00794" FT REGION 19..51 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 404..426 FT /note="Nudix box" FT ACT_SITE 131 FT /note="Proton donor/acceptor" FT /evidence="ECO:0000250|UniProtKB:P83847" FT BINDING 287 FT /ligand="[4Fe-4S] cluster" FT /ligand_id="ChEBI:CHEBI:49883" FT /evidence="ECO:0000250" FT BINDING 294 FT /ligand="[4Fe-4S] cluster" FT /ligand_id="ChEBI:CHEBI:49883" FT /evidence="ECO:0000250" FT BINDING 297 FT /ligand="[4Fe-4S] cluster" FT /ligand_id="ChEBI:CHEBI:49883" FT /evidence="ECO:0000250" FT BINDING 303 FT /ligand="[4Fe-4S] cluster" FT /ligand_id="ChEBI:CHEBI:49883" FT /evidence="ECO:0000250" FT SITE 233 FT /note="Transition state stabilizer" FT /evidence="ECO:0000250|UniProtKB:P83847" FT VAR_SEQ 1..14 FT /note="Missing (in isoform Beta-1, isoform Gamma-2 and FT isoform Gamma-3)" FT /evidence="ECO:0000303|PubMed:10684930" FT /id="VSP_010548" FT VAR_SEQ 53..63 FT /note="Missing (in isoform Alpha-3 and isoform Gamma-3)" FT /evidence="ECO:0000303|PubMed:10684930, FT ECO:0000303|PubMed:15489334" FT /id="VSP_010550" FT VAR_SEQ 53..62 FT /note="Missing (in isoform Alpha-2 and isoform Gamma-2)" FT /evidence="ECO:0000303|PubMed:10684930" FT /id="VSP_010549" FT VARIANT 18 FT /note="P -> L (in FAP2; uncertain significance; decreased FT function in DNA repair; dbSNP:rs79777494)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077640" FT VARIANT 22 FT /note="V -> M (does not affect function in DNA repair; FT dbSNP:rs3219484)" FT /evidence="ECO:0000269|PubMed:12606733, FT ECO:0000269|PubMed:16134147, ECO:0000269|PubMed:16287072, FT ECO:0000269|PubMed:16941501, ECO:0000269|PubMed:25820570, FT ECO:0000269|Ref.4" FT /id="VAR_018872" FT VARIANT 25 FT /note="G -> D (does not affect function in DNA repair; FT dbSNP:rs75321043)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077641" FT VARIANT 72 FT /note="V -> E (does not affect DNA glycosylase activity; FT dbSNP:rs1557487179)" FT /evidence="ECO:0000269|PubMed:20848659" FT /id="VAR_077642" FT VARIANT 100 FT /note="W -> R (found in sporadic hepatocellular carcinoma; FT uncertain significance; loss of function in DNA repair; FT dbSNP:rs1140507)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077643" FT VARIANT 102 FT /note="D -> N (found in multiple polyposis and sporadic FT colorectal cancer cases; uncertain significance; does not FT affect DNA glycosylase activity; does not affect function FT in DNA repair; dbSNP:rs587780746)" FT /evidence="ECO:0000269|PubMed:25820570, FT ECO:0000269|PubMed:26694661" FT /id="VAR_077644" FT VARIANT 125 FT /note="Y -> H (in FAP2; decreased function in DNA repair)" FT /evidence="ECO:0000269|PubMed:15366000, FT ECO:0000269|PubMed:25820570" FT /id="VAR_026045" FT VARIANT 128 FT /note="W -> R (in FAP2; loss of function in DNA repair; FT dbSNP:rs730881832)" FT /evidence="ECO:0000269|PubMed:12853198, FT ECO:0000269|PubMed:25820570" FT /id="VAR_026046" FT VARIANT 148 FT /note="G -> GIW (in FAP2; reduced DNA glycosylase activity; FT decreased DNA binding; loss of function in DNA repair)" FT /evidence="ECO:0000269|PubMed:16287072, FT ECO:0000269|PubMed:19953527, ECO:0000269|PubMed:20418187" FT /id="VAR_064938" FT VARIANT 154 FT /note="P -> L (in FAP2; decreased function in DNA repair; FT dbSNP:rs777184451)" FT /evidence="ECO:0000269|PubMed:16557584, FT ECO:0000269|PubMed:25820570" FT /id="VAR_077646" FT VARIANT 176 FT /note="Y -> C (in FAP2; loss of DNA glycosylase activity; FT decreased DNA binding; loss of function in DNA repair; FT dbSNP:rs34612342)" FT /evidence="ECO:0000269|PubMed:11818965, FT ECO:0000269|PubMed:12606733, ECO:0000269|PubMed:12853198, FT ECO:0000269|PubMed:16134147, ECO:0000269|PubMed:16287072, FT ECO:0000269|PubMed:16557584, ECO:0000269|PubMed:16941501, FT ECO:0000269|PubMed:18091433, ECO:0000269|PubMed:19953527, FT ECO:0000269|PubMed:20418187, ECO:0000269|PubMed:20848659, FT ECO:0000269|PubMed:25820570" FT /id="VAR_018873" FT VARIANT 177 FT /note="Y -> S (in FAP2)" FT /evidence="ECO:0000269|PubMed:16941501" FT /id="VAR_077647" FT VARIANT 179 FT /note="R -> C (in FAP2; also found in multiple polyposis FT and colorectal cancer cases; loss of function in DNA FT repair; dbSNP:rs747993448)" FT /evidence="ECO:0000269|PubMed:18091433, FT ECO:0000269|PubMed:25820570" FT /id="VAR_064939" FT VARIANT 179 FT /note="R -> H (in FAP2; loss of DNA glycosylase activity; FT loss of function in DNA repair; dbSNP:rs143353451)" FT /evidence="ECO:0000269|PubMed:15366000, FT ECO:0000269|PubMed:16557584, ECO:0000269|PubMed:20848659, FT ECO:0000269|PubMed:25820570" FT /id="VAR_026047" FT VARIANT 182 FT /note="R -> Q (in FAP2; loss of function in DNA repair; FT dbSNP:rs533899702)" FT /evidence="ECO:0000269|PubMed:16287072, FT ECO:0000269|PubMed:25820570" FT /id="VAR_077648" FT VARIANT 182 FT /note="R -> W (in FAP2; loss of DNA glycosylase activity; FT loss of DNA binding; loss of function in DNA repair; FT dbSNP:rs750592289)" FT /evidence="ECO:0000269|PubMed:18091433, FT ECO:0000269|PubMed:19953527, ECO:0000269|PubMed:20418187" FT /id="VAR_064940" FT VARIANT 186 FT /note="G -> E (in FAP2; decreased function in DNA repair; FT dbSNP:rs754155145)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077649" FT VARIANT 213 FT /note="G -> E (in FAP2; dbSNP:rs768553551)" FT /evidence="ECO:0000269|PubMed:18515411" FT /id="VAR_077650" FT VARIANT 220 FT /note="I -> V (in FAP2; uncertain significance; reduced DNA FT glycosylase activity; no effect on function in DNA repair; FT dbSNP:rs200872702)" FT /evidence="ECO:0000269|PubMed:16287072, FT ECO:0000269|PubMed:20848659, ECO:0000269|PubMed:25820570" FT /id="VAR_077651" FT VARIANT 224 FT /note="A -> V (decreased function in DNA repair; FT dbSNP:rs11545695)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077652" FT VARIANT 231 FT /note="V -> M (found in familial colorectal cancer; likely FT pathogenic; no significant effect on DNA glycosylase FT activity; slightly decreased function in DNA repair; FT dbSNP:rs200165598)" FT /evidence="ECO:0000269|PubMed:25820570, FT ECO:0000269|PubMed:26694661" FT /id="VAR_077653" FT VARIANT 235 FT /note="N -> S (in FAP2; loss of DNA glycosylase activity; FT loss of function in DNA repair; dbSNP:rs1057517765)" FT /evidence="ECO:0000269|PubMed:18515411, FT ECO:0000269|PubMed:26694661" FT /id="VAR_077654" FT VARIANT 238 FT /note="R -> W (in FAP2; uncertain significance; decreased FT function in DNA repair; dbSNP:rs34126013)" FT /evidence="ECO:0000269|PubMed:15366000, FT ECO:0000269|PubMed:25820570" FT /id="VAR_026048" FT VARIANT 242 FT /note="R -> C (found in colorectal polyposis; likely FT pathogenic; decreased function in DNA repair; FT dbSNP:rs200495564)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077655" FT VARIANT 242 FT /note="R -> H (in FAP2; loss of function in DNA repair; FT dbSNP:rs140342925)" FT /evidence="ECO:0000269|PubMed:16134147, FT ECO:0000269|PubMed:16287072, ECO:0000269|PubMed:16557584, FT ECO:0000269|PubMed:25820570" FT /id="VAR_077656" FT VARIANT 243 FT /note="V -> F (does not affect function; FT dbSNP:rs587780749)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077657" FT VARIANT 244 FT /note="R -> G (reduced DNA glycosylase activity; decreased FT function in DNA repair; dbSNP:rs587782885)" FT /evidence="ECO:0000269|PubMed:26694661" FT /id="VAR_077658" FT VARIANT 271 FT /note="R -> W (in FAP2; loss of function in DNA repair; FT dbSNP:rs769237459)" FT /evidence="ECO:0000269|PubMed:16134147, FT ECO:0000269|PubMed:16557584, ECO:0000269|PubMed:25820570" FT /id="VAR_077659" FT VARIANT 280 FT /note="M -> V (in FAP2; reduced DNA glycosylase activity; FT dbSNP:rs876659676)" FT /evidence="ECO:0000269|PubMed:16941501, FT ECO:0000269|PubMed:20848659" FT /id="VAR_077660" FT VARIANT 283 FT /note="G -> E (in FAP2; uncertain significance; does not FT affect function in DNA repair; dbSNP:rs730881833)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077661" FT VARIANT 287 FT /note="C -> W (found in a case of sporadic lung cancer; FT uncertain significance; loss of function in DNA repair)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077662" FT VARIANT 292 FT /note="P -> L (in FAP2; also found in multiple polyposis FT cases; loss of function in DNA repair; dbSNP:rs374950566)" FT /evidence="ECO:0000269|PubMed:16557584, FT ECO:0000269|PubMed:16941501, ECO:0000269|PubMed:25820570" FT /id="VAR_077663" FT VARIANT 306 FT /note="R -> C (in FAP2; uncertain significance; does not FT affect DNA glycosylase activity; slightly decreased FT function in DNA repair; dbSNP:rs138089183)" FT /evidence="ECO:0000269|PubMed:16557584, FT ECO:0000269|PubMed:20848659, ECO:0000269|PubMed:25820570" FT /id="VAR_077664" FT VARIANT 319 FT /note="S -> N (does not affect DNA glycosylase activity; FT does not affect function in DNA repair; dbSNP:rs587781810)" FT /evidence="ECO:0000269|PubMed:26694661" FT /id="VAR_077665" FT VARIANT 335 FT /note="Q -> H (does not affect function in DNA repair; FT dbSNP:rs3219489)" FT /evidence="ECO:0000269|PubMed:12606733, FT ECO:0000269|PubMed:16134147, ECO:0000269|PubMed:16287072, FT ECO:0000269|PubMed:16941501, ECO:0000269|PubMed:25820570, FT ECO:0000269|Ref.4" FT /id="VAR_018874" FT VARIANT 335 FT /note="Q -> R (found in a family with non-polyposis FT colorectal cancer-like syndrome; uncertain significance; FT does not affect function in DNA repair; dbSNP:rs199742231)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077666" FT VARIANT 370 FT /note="A -> V (does not affect DNA glycosylase activity; FT dbSNP:rs35352891)" FT /evidence="ECO:0000269|PubMed:20848659" FT /id="VAR_048262" FT VARIANT 377 FT /note="P -> T (in FAP2; decreased function in DNA repair)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077667" FT VARIANT 385 FT /note="L -> P (in FAP2; also found in multiple polyposis FT cases; loss of DNA glycosylase activity; loss of function FT in DNA repair; dbSNP:rs1060501335)" FT /evidence="ECO:0000269|PubMed:16134147, FT ECO:0000269|PubMed:16941501, ECO:0000269|PubMed:20848659, FT ECO:0000269|PubMed:25820570" FT /id="VAR_077668" FT VARIANT 393 FT /note="G -> D (in FAP2; reduced DNA glycosylase activity; FT decreased DNA binding; decreased function in DNA repair; FT dbSNP:rs36053993)" FT /evidence="ECO:0000269|PubMed:11818965, FT ECO:0000269|PubMed:12606733, ECO:0000269|PubMed:12853198, FT ECO:0000269|PubMed:16134147, ECO:0000269|PubMed:16287072, FT ECO:0000269|PubMed:16557584, ECO:0000269|PubMed:16941501, FT ECO:0000269|PubMed:18091433, ECO:0000269|PubMed:19953527, FT ECO:0000269|PubMed:20418187, ECO:0000269|PubMed:20848659, FT ECO:0000269|PubMed:25820570" FT /id="VAR_018875" FT VARIANT 402 FT /note="P -> L (in FAP2; also found in multiple polyposis FT and colorectal cancer cases; loss of DNA glycosylase FT activity; loss of function in DNA repair; FT dbSNP:rs529008617)" FT /evidence="ECO:0000269|PubMed:16557584, FT ECO:0000269|PubMed:20848659, ECO:0000269|PubMed:25820570" FT /id="VAR_077669" FT VARIANT 402 FT /note="P -> S (in GASC; sporadic; decreased function in DNA FT repair; dbSNP:rs121908382)" FT /evidence="ECO:0000269|PubMed:15273732, FT ECO:0000269|PubMed:25820570" FT /id="VAR_026049" FT VARIANT 411 FT /note="Q -> R (in GASC; uncertain significance; does not FT affect function in DNA repair; dbSNP:rs121908383)" FT /evidence="ECO:0000269|PubMed:15273732, FT ECO:0000269|PubMed:25820570" FT /id="VAR_026050" FT VARIANT 417 FT /note="L -> M (in FAP2; uncertain significance; also found FT in a family with non-polyposis colorectal cancer-like FT syndrome; uncertain significance; does not affect function FT in DNA repair; dbSNP:rs144079536)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077670" FT VARIANT 423 FT /note="R -> C (in FAP2; uncertain significance; does not FT affect function in DNA repair; dbSNP:rs150792276)" FT /evidence="ECO:0000269|PubMed:16134147, FT ECO:0000269|PubMed:16557584, ECO:0000269|PubMed:25820570" FT /id="VAR_077671" FT VARIANT 434 FT /note="R -> P (found in sporadic colorectal cancer cases; FT uncertain significance; decreased function in DNA repair)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077672" FT VARIANT 434 FT /note="R -> Q (does not affect function in DNA repair; FT dbSNP:rs587782120)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077673" FT VARIANT 470 FT /note="A -> D (in FAP2; loss of function in DNA repair; FT dbSNP:rs200844166)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077674" FT VARIANT 470 FT /note="A -> T (found in patient with multiple polyposis; FT uncertain significance; does not affect function in DNA FT repair; dbSNP:rs192816572)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077675" FT VARIANT 474 FT /note="T -> M (in FAP2; uncertain significance; FT dbSNP:rs767747402)" FT /evidence="ECO:0000269|PubMed:18515411" FT /id="VAR_077676" FT VARIANT 477 FT /note="Missing (in FAP2; also found in a case of sporadic FT colorectal cancer; loss of DNA glycosylase activity; loss FT of DNA binding; loss of function in DNA repair)" FT /evidence="ECO:0000269|PubMed:16134147, FT ECO:0000269|PubMed:16557584, ECO:0000269|PubMed:19953527, FT ECO:0000269|PubMed:20418187, ECO:0000269|PubMed:20848659, FT ECO:0000269|PubMed:25820570" FT /id="VAR_064941" FT VARIANT 486 FT /note="A -> T (in FAP2; decreased function in DNA repair; FT dbSNP:rs587782263)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077677" FT VARIANT 490 FT /note="V -> F (in FAP2; uncertain significance; decreased FT function in DNA repair; dbSNP:rs587782228)" FT /evidence="ECO:0000269|PubMed:16557584, FT ECO:0000269|PubMed:25820570" FT /id="VAR_077678" FT VARIANT 500 FT /note="G -> E (decreased function in DNA repair; FT dbSNP:rs3219494)" FT /evidence="ECO:0000269|PubMed:25820570, ECO:0000269|Ref.4" FT /id="VAR_018876" FT VARIANT 512 FT /note="S -> F (does not affect DNA glycosylase activity; FT does not affect function in DNA repair; dbSNP:rs140118273)" FT /evidence="ECO:0000269|PubMed:12606733, FT ECO:0000269|PubMed:16941501, ECO:0000269|PubMed:20848659, FT ECO:0000269|PubMed:25820570" FT /id="VAR_026051" FT VARIANT 513 FT /note="P -> L (does not affect function in DNA repair; FT dbSNP:rs587778542)" FT /evidence="ECO:0000269|PubMed:25820570" FT /id="VAR_077679" FT VARIANT 520 FT /note="R -> H (does not affect DNA glycosylase activity; FT does not affect function in DNA repair; dbSNP:rs374655042)" FT /evidence="ECO:0000269|PubMed:26694661" FT /id="VAR_077680" FT VARIANT 526 FT /note="L -> M (does not affect function in DNA repair; FT dbSNP:rs3219496)" FT /evidence="ECO:0000269|PubMed:25820570, ECO:0000269|Ref.4" FT /id="VAR_018877" FT VARIANT 531 FT /note="R -> Q (does not affect function in DNA repair; FT dbSNP:rs3219497)" FT /evidence="ECO:0000269|PubMed:25820570, ECO:0000269|Ref.4" FT /id="VAR_018878" FT VARIANT 536 FT /note="T -> A (does not affect DNA glycosylase activity; FT does not affect function in DNA repair; dbSNP:rs151196169)" FT /evidence="ECO:0000269|PubMed:26694661" FT /id="VAR_077681" FT MUTAGEN 121 FT /note="D->G: Does not affect DNA glycosylase activity. Does FT not affect function in DNA repair." FT /evidence="ECO:0000269|PubMed:26694661" FT MUTAGEN 233 FT /note="D->N: Loss of DNA glycosylase activity." FT /evidence="ECO:0000269|PubMed:20848659" FT HELIX 87..104 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 109..116 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 120..134 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 139..142 FT /evidence="ECO:0007829|PDB:8FAY" FT TURN 143..145 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 146..152 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 156..161 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 164..171 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 178..193 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 202..208 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 214..225 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 234..243 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 253..266 FT /evidence="ECO:0007829|PDB:8FAY" FT STRAND 269..271 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 272..285 FT /evidence="ECO:0007829|PDB:8FAY" FT STRAND 289..291 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 294..296 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 300..302 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 304..314 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 330..332 FT /evidence="ECO:0007829|PDB:3N5N" FT HELIX 348..354 FT /evidence="ECO:0007829|PDB:8FAY" FT STRAND 358..360 FT /evidence="ECO:0007829|PDB:1X51" FT STRAND 365..376 FT /evidence="ECO:0007829|PDB:8FAY" FT STRAND 383..388 FT /evidence="ECO:0007829|PDB:8FAY" FT STRAND 391..393 FT /evidence="ECO:0007829|PDB:8FAY" FT TURN 394..397 FT /evidence="ECO:0007829|PDB:8FAY" FT STRAND 403..405 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 410..425 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 430..432 FT /evidence="ECO:0007829|PDB:8FAY" FT STRAND 434..442 FT /evidence="ECO:0007829|PDB:8FAY" FT STRAND 444..456 FT /evidence="ECO:0007829|PDB:8FAY" FT STRAND 470..474 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 475..479 FT /evidence="ECO:0007829|PDB:8FAY" FT STRAND 481..483 FT /evidence="ECO:0007829|PDB:8FAY" FT HELIX 485..497 FT /evidence="ECO:0007829|PDB:8FAY" SQ SEQUENCE 546 AA; 60069 MW; 6C79BDB34345DD10 CRC64; MTPLVSRLSR LWAIMRKPRA AVGSGHRKQA ASQEGRQKHA KNNSQAKPSA CDGMIAECPG APAGLARQPE EVVLQASVSS YHLFRDVAEV TAFRGSLLSW YDQEKRDLPW RRRAEDEMDL DRRAYAVWVS EVMLQQTQVA TVINYYTGWM QKWPTLQDLA SASLEEVNQL WAGLGYYSRG RRLQEGARKV VEELGGHMPR TAETLQQLLP GVGRYTAGAI ASIAFGQATG VVDGNVARVL CRVRAIGADP SSTLVSQQLW GLAQQLVDPA RPGDFNQAAM ELGATVCTPQ RPLCSQCPVE SLCRARQRVE QEQLLASGSL SGSPDVEECA PNTGQCHLCL PPSEPWDQTL GVVNFPRKAS RKPPREESSA TCVLEQPGAL GAQILLVQRP NSGLLAGLWE FPSVTWEPSE QLQRKALLQE LQRWAGPLPA THLRHLGEVV HTFSHIKLTY QVYGLALEGQ TPVTTVPPGA RWLTQEEFHT AAVSTAMKKV FRVYQGQQPG TCMGSKRSQV SSPCSRKKPR MGQQVLDNFF RSHISTDAHS LNSAAQ // ID MXI1_HUMAN Reviewed; 228 AA. AC P50539; B1ANN7; D3DR25; D3DRA9; Q15887; Q6FHW2; Q96E53; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 2. DT 28-JAN-2026, entry version 212. DE RecName: Full=Max-interacting protein 1; DE Short=Max interactor 1; DE AltName: Full=Class C basic helix-loop-helix protein 11; DE Short=bHLHc11; GN Name=MXI1; Synonyms=BHLHC11; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=8425219; DOI=10.1016/0092-8674(93)90662-a; RA Zervos A.S., Gyuris J., Brent R.; RT "Mxi1, a protein that specifically interacts with Max to bind Myc-Max RT recognition sites."; RL Cell 72:223-232(1993). RN [2] RP ERRATUM OF PUBMED:8425219. RA Zervos A.S., Gyuris J., Brent R.; RL Cell 79:388-388(1994). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=8838813; DOI=10.1006/geno.1996.0144; RA Wechsler D.S., Shelly C.A., Dang C.V.; RT "Genomic organization of human MXI1, a putative tumor suppressor gene."; RL Genomics 32:466-470(1996). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RX PubMed=8918230; DOI=10.1016/0378-1119(96)00206-5; RA Shimizu E., Shirasawa H., Kodama K., Sato T., Shimizu B.; RT "Expression, regulation and polymorphism of the mxi1 genes."; RL Gene 176:45-48(1996). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S., Neubert P., RA Kstrang K., Schatten R., Shen B., Henze S., Mar W., Korn B., Zuo D., Hu Y., RA LaBaer J.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164054; DOI=10.1038/nature02462; RA Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L., RA Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K., RA Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L., RA Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P., RA Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P., RA Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N., RA Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A., RA Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C., RA Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D., RA Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C., RA Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K., RA Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A., RA Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S., RA McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S., RA Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., RA Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., RA Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M., RA Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A., RA Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P., RA Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y., RA Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D., RA Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 10."; RL Nature 429:375-381(2004). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4). RC TISSUE=Hippocampus, and Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 216-228. RX PubMed=7789959; DOI=10.1007/bf00209493; RA Albarosa R., Didonato S., Finocchiaro G.; RT "Redefinition of the coding sequence of the MXI1 gene and identification of RT a polymorphic repeat in the 3' non-coding region that allows the detection RT of loss of heterozygosity of chromosome 10q25 in glioblastomas."; RL Hum. Genet. 95:709-711(1995). RN [11] RP VARIANT PROSTATE CANCER ALA-152. RX PubMed=7773287; DOI=10.1038/ng0395-249; RA Eagle L.R., Yin X., Brothman A.R., Williams B.J., Atkin N.B., RA Prochownik E.V.; RT "Mutation of the MXI1 gene in prostate cancer."; RL Nat. Genet. 9:249-255(1995). CC -!- FUNCTION: Transcriptional repressor. MXI1 binds with MAX to form a CC sequence-specific DNA-binding protein complex which recognizes the core CC sequence 5'-CAC[GA]TG-3'. MXI1 thus antagonizes MYC transcriptional CC activity by competing for MAX. CC -!- SUBUNIT: Interacts with SMC3 (By similarity). Efficient DNA binding CC requires dimerization with another bHLH protein. Binds DNA as a CC heterodimer with MAX. Interacts with RNF17 (By similarity). CC {ECO:0000250}. CC -!- INTERACTION: CC P50539; Q13137: CALCOCO2; NbExp=3; IntAct=EBI-752241, EBI-739580; CC P50539; Q53RC5: DKFZp547I014; NbExp=3; IntAct=EBI-752241, EBI-10212065; CC P50539; O75356: ENTPD5; NbExp=3; IntAct=EBI-752241, EBI-7416931; CC P50539; P61244: MAX; NbExp=10; IntAct=EBI-752241, EBI-751711; CC P50539; P61244-2: MAX; NbExp=3; IntAct=EBI-752241, EBI-10218525; CC P50539-3; Q13137: CALCOCO2; NbExp=6; IntAct=EBI-10211940, EBI-739580; CC P50539-3; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-10211940, EBI-3867333; CC P50539-3; O95967: EFEMP2; NbExp=3; IntAct=EBI-10211940, EBI-743414; CC P50539-3; Q15323: KRT31; NbExp=3; IntAct=EBI-10211940, EBI-948001; CC P50539-3; Q6A162: KRT40; NbExp=3; IntAct=EBI-10211940, EBI-10171697; CC P50539-3; Q07627: KRTAP1-1; NbExp=3; IntAct=EBI-10211940, EBI-11959885; CC P50539-3; Q8IUG1: KRTAP1-3; NbExp=3; IntAct=EBI-10211940, EBI-11749135; CC P50539-3; P60370: KRTAP10-5; NbExp=3; IntAct=EBI-10211940, EBI-10172150; CC P50539-3; P60409: KRTAP10-7; NbExp=3; IntAct=EBI-10211940, EBI-10172290; CC P50539-3; P60410: KRTAP10-8; NbExp=6; IntAct=EBI-10211940, EBI-10171774; CC P50539-3; P60411: KRTAP10-9; NbExp=3; IntAct=EBI-10211940, EBI-10172052; CC P50539-3; Q6L8G8: KRTAP5-7; NbExp=3; IntAct=EBI-10211940, EBI-11987425; CC P50539-3; Q99750: MDFI; NbExp=3; IntAct=EBI-10211940, EBI-724076; CC P50539-3; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-10211940, EBI-945833; CC P50539-3; P0DPK4: NOTCH2NLC; NbExp=3; IntAct=EBI-10211940, EBI-22310682; CC P50539-3; Q5VY43: PEAR1; NbExp=3; IntAct=EBI-10211940, EBI-1249608; CC P50539-3; Q8N720: ZNF655; NbExp=3; IntAct=EBI-10211940, EBI-625509; CC P50539-4; Q6A162: KRT40; NbExp=3; IntAct=EBI-16436111, EBI-10171697; CC P50539-4; Q8N6Y0: USHBP1; NbExp=3; IntAct=EBI-16436111, EBI-739895; CC -!- SUBCELLULAR LOCATION: Nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=P50539-1; Sequence=Displayed; CC Name=2; CC IsoId=P50539-2; Sequence=VSP_012825; CC Name=3; CC IsoId=P50539-3; Sequence=VSP_037943; CC Name=4; CC IsoId=P50539-4; Sequence=VSP_012825, VSP_043170; CC -!- TISSUE SPECIFICITY: High levels found in the brain, heart and lung CC while lower levels are seen in the liver, kidney and skeletal muscle. CC -!- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in CC tissues of the prostate. Most prostate cancers are adenocarcinomas that CC develop in the acini of the prostatic ducts. Other rare histopathologic CC types of prostate cancer that occur in approximately 5% of patients CC include small cell carcinoma, mucinous carcinoma, prostatic ductal CC carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal CC cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:7773287}. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/209/MXI1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L07648; AAA75508.1; -; mRNA. DR EMBL; U32515; AAC50446.1; -; Genomic_DNA. DR EMBL; U32512; AAC50446.1; JOINED; Genomic_DNA. DR EMBL; U32513; AAC50446.1; JOINED; Genomic_DNA. DR EMBL; U32514; AAC50446.1; JOINED; Genomic_DNA. DR EMBL; D63940; BAA09972.1; -; mRNA. DR EMBL; BT007069; AAP35732.1; -; mRNA. DR EMBL; CR536576; CAG38813.1; -; mRNA. DR EMBL; AL360182; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471066; EAW49565.1; -; Genomic_DNA. DR EMBL; CH471066; EAW49567.1; -; Genomic_DNA. DR EMBL; CH471066; EAW49568.1; -; Genomic_DNA. DR EMBL; CH471066; EAW49569.1; -; Genomic_DNA. DR EMBL; CH471066; EAW49570.1; -; Genomic_DNA. DR EMBL; BC012907; AAH12907.1; -; mRNA. DR EMBL; BC035128; AAH35128.2; -; mRNA. DR EMBL; S78470; AAD14282.1; -; Genomic_DNA. DR CCDS; CCDS31284.1; -. [P50539-4] DR CCDS; CCDS7563.1; -. [P50539-3] DR CCDS; CCDS7564.2; -. [P50539-1] DR PIR; A45182; A45182. DR RefSeq; NP_001008541.1; NM_001008541.1. [P50539-4] DR RefSeq; NP_005953.4; NM_005962.4. [P50539-1] DR RefSeq; NP_569157.2; NM_130439.3. [P50539-3] DR AlphaFoldDB; P50539; -. DR SMR; P50539; -. DR BioGRID; 110686; 49. DR ComplexPortal; CPX-2515; MXI1-MAX transcriptional repressor complex. DR CORUM; P50539; -. DR DIP; DIP-205N; -. DR ELM; P50539; -. DR FunCoup; P50539; 3452. DR IntAct; P50539; 25. DR MINT; P50539; -. DR STRING; 9606.ENSP00000331152; -. DR GlyGen; P50539; 2 sites, 1 O-linked glycan (2 sites). DR iPTMnet; P50539; -. DR PhosphoSitePlus; P50539; -. DR BioMuta; MXI1; -. DR DMDM; 116242666; -. DR jPOST; P50539; -. DR MassIVE; P50539; -. DR PaxDb; 9606-ENSP00000331152; -. DR PeptideAtlas; P50539; -. DR ProteomicsDB; 56235; -. [P50539-1] DR ProteomicsDB; 56236; -. [P50539-2] DR ProteomicsDB; 56237; -. [P50539-3] DR ProteomicsDB; 56238; -. [P50539-4] DR Antibodypedia; 18346; 250 antibodies from 31 providers. DR DNASU; 4601; -. DR Ensembl; ENST00000239007.11; ENSP00000239007.7; ENSG00000119950.21. [P50539-1] DR Ensembl; ENST00000332674.9; ENSP00000331152.5; ENSG00000119950.21. [P50539-3] DR Ensembl; ENST00000361248.8; ENSP00000354606.4; ENSG00000119950.21. [P50539-4] DR Ensembl; ENST00000369612.1; ENSP00000358625.1; ENSG00000119950.21. [P50539-2] DR Ensembl; ENST00000650644.1; ENSP00000498900.1; ENSG00000119950.21. [P50539-2] DR Ensembl; ENST00000650696.1; ENSP00000499158.1; ENSG00000119950.21. [P50539-2] DR Ensembl; ENST00000650810.1; ENSP00000498390.1; ENSG00000119950.21. [P50539-2] DR Ensembl; ENST00000650843.1; ENSP00000498547.1; ENSG00000119950.21. [P50539-2] DR Ensembl; ENST00000650900.1; ENSP00000499209.1; ENSG00000119950.21. [P50539-2] DR Ensembl; ENST00000650952.1; ENSP00000499161.1; ENSG00000119950.21. [P50539-2] DR Ensembl; ENST00000651004.1; ENSP00000498396.1; ENSG00000119950.21. [P50539-2] DR Ensembl; ENST00000651167.1; ENSP00000498764.1; ENSG00000119950.21. [P50539-2] DR Ensembl; ENST00000651467.1; ENSP00000499128.1; ENSG00000119950.21. [P50539-2] DR Ensembl; ENST00000651495.1; ENSP00000498536.1; ENSG00000119950.21. [P50539-2] DR Ensembl; ENST00000651516.1; ENSP00000498873.1; ENSG00000119950.21. [P50539-2] DR Ensembl; ENST00000651613.1; ENSP00000498554.1; ENSG00000119950.21. [P50539-2] DR Ensembl; ENST00000651811.1; ENSP00000498472.1; ENSG00000119950.21. [P50539-2] DR Ensembl; ENST00000651848.1; ENSP00000498238.1; ENSG00000119950.21. [P50539-2] DR Ensembl; ENST00000651866.1; ENSP00000498306.1; ENSG00000119950.21. [P50539-2] DR Ensembl; ENST00000652028.1; ENSP00000498928.1; ENSG00000119950.21. [P50539-2] DR Ensembl; ENST00000652463.1; ENSP00000499087.1; ENSG00000119950.21. [P50539-2] DR Ensembl; ENST00000652506.1; ENSP00000498573.1; ENSG00000119950.21. [P50539-2] DR Ensembl; ENST00000652604.1; ENSP00000498971.1; ENSG00000119950.21. [P50539-4] DR GeneID; 4601; -. DR KEGG; hsa:4601; -. DR MANE-Select; ENST00000332674.9; ENSP00000331152.5; NM_130439.3; NP_569157.2. [P50539-3] DR UCSC; uc001kyy.3; human. [P50539-1] DR AGR; HGNC:7534; -. DR ClinPGx; PA31335; -. DR CTD; 4601; -. DR DisGeNET; 4601; -. DR GeneCards; MXI1; -. DR HGNC; HGNC:7534; MXI1. DR HPA; ENSG00000119950; Low tissue specificity. DR MalaCards; MXI1; -. DR MIM; 176807; phenotype. DR MIM; 600020; gene. DR OpenTargets; ENSG00000119950; -. DR VEuPathDB; HostDB:ENSG00000119950; -. DR eggNOG; KOG2483; Eukaryota. DR GeneTree; ENSGT00940000155809; -. DR HOGENOM; CLU_082604_0_0_1; -. DR InParanoid; P50539; -. DR OMA; ECTRHTT; -. DR OrthoDB; 5920083at2759; -. DR PAN-GO; P50539; 3 GO annotations based on evolutionary models. DR PhylomeDB; P50539; -. DR PathwayCommons; P50539; -. DR SignaLink; P50539; -. DR SIGNOR; P50539; -. DR Agora; ENSG00000119950; -. DR BioGRID-ORCS; 4601; 11 hits in 1178 CRISPR screens. DR ChiTaRS; MXI1; human. DR GeneWiki; MXI1; -. DR GenomeRNAi; 4601; -. DR Pharos; P50539; Tbio. DR PRO; PR:P50539; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; P50539; protein. DR Bgee; ENSG00000119950; Expressed in cranial nerve II and 218 other cell types or tissues. DR ExpressionAtlas; P50539; baseline and differential. DR GO; GO:0000785; C:chromatin; ISA:NTNU_SB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005730; C:nucleolus; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; TAS:ProtInc. DR GO; GO:0090575; C:RNA polymerase II transcription regulator complex; IDA:NTNU_SB. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB. DR GO; GO:0046983; F:protein dimerization activity; IEA:InterPro. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central. DR GO; GO:0001825; P:blastocyst formation; IEA:Ensembl. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:NTNU_SB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central. DR CDD; cd18930; bHLHzip_MXI1; 1. DR FunFam; 4.10.280.10:FF:000014; Max dimerization protein 1; 1. DR Gene3D; 4.10.280.10; Helix-loop-helix DNA-binding domain; 1. DR InterPro; IPR011598; bHLH_dom. DR InterPro; IPR036638; HLH_DNA-bd_sf. DR PANTHER; PTHR11969; MAX DIMERIZATION, MAD; 1. DR PANTHER; PTHR11969:SF13; MAX-INTERACTING PROTEIN 1; 1. DR Pfam; PF00010; HLH; 1. DR SMART; SM00353; HLH; 1. DR SUPFAM; SSF47459; HLH, helix-loop-helix DNA-binding domain; 1. DR PROSITE; PS50888; BHLH; 1. PE 1: Evidence at protein level; KW Alternative splicing; Disease variant; DNA-binding; Nucleus; KW Proteomics identification; Proto-oncogene; Reference proteome; Repressor; KW Transcription; Transcription regulation. FT CHAIN 1..228 FT /note="Max-interacting protein 1" FT /id="PRO_0000127285" FT DOMAIN 67..119 FT /note="bHLH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00981" FT REGION 29..76 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 161..228 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 43..56 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 57..70 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 173..183 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 216..228 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT VAR_SEQ 1..36 FT /note="Missing (in isoform 2 and isoform 4)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:8918230, ECO:0000303|Ref.5" FT /id="VSP_012825" FT VAR_SEQ 1..25 FT /note="MERVKMINVQRLLEAAEFLERRERE -> MGKRGRPRKEARCEGAGLAPAAP FT PAVPPAVAAPQPPALPEDPAGAKPRCPFSDIFNTSENSMEKHINTFLQNVQILLEAASY FT LEQIEKENKK (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_037943" FT VAR_SEQ 68..77 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.5" FT /id="VSP_043170" FT VARIANT 152 FT /note="E -> A (in prostate cancer; dbSNP:rs137852603)" FT /evidence="ECO:0000269|PubMed:7773287" FT /id="VAR_004499" FT CONFLICT 61 FT /note="S -> T (in Ref. 1; AAA75508)" FT /evidence="ECO:0000305" SQ SEQUENCE 228 AA; 26062 MW; 82F83F499B907DD3 CRC64; MERVKMINVQ RLLEAAEFLE RRERECEHGY ASSFPSMPSP RLQHSKPPRR LSRAQKHSSG SSNTSTANRS THNELEKNRR AHLRLCLERL KVLIPLGPDC TRHTTLGLLN KAKAHIKKLE EAERKSQHQL ENLEREQRFL KWRLEQLQGP QEMERIRMDS IGSTISSDRS DSEREEIEVD VESTEFSHGE VDNISTTSIS DIDDHSSLPS IGSDEGYSSA SVKLSFTS // ID MXRA5_HUMAN Reviewed; 2828 AA. AC Q9NR99; Q6P1M7; Q9Y3Y8; DT 31-OCT-2006, integrated into UniProtKB/Swiss-Prot. DT 11-JAN-2011, sequence version 3. DT 28-JAN-2026, entry version 175. DE RecName: Full=Matrix-remodeling-associated protein 5; DE AltName: Full=Adhesion protein with leucine-rich repeats and immunoglobulin domains related to perlecan; DE Short=Adlican; DE Flags: Precursor; GN Name=MXRA5; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS VAL-824; VAL-1128; ASP-1394; RP SER-2000 AND VAL-2531. RC TISSUE=Placenta; RA Crowl R.M., Luk D.; RT "Identification of the gene encoding adlican, a novel protein expressed in RT human arthritic tissues."; RL Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], AND DEVELOPMENTAL STAGE. RX PubMed=15609104; DOI=10.1007/s10522-004-3188-1; RA Chondrogianni N., Simoes D.C.M., Franceschi C., Gonos E.S.; RT "Cloning of differentially expressed genes in skin fibroblasts from RT centenarians."; RL Biogerontology 5:401-409(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15772651; DOI=10.1038/nature03440; RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., RA Rogers J., Bentley D.R.; RT "The DNA sequence of the human X chromosome."; RL Nature 434:325-337(2005). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-739. RC TISSUE=Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2245-2828. RC TISSUE=Brain; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [6] RP SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND GLYCOSYLATION AT SER-702. RX PubMed=25326458; DOI=10.1074/mcp.m114.043703; RA Noborn F., Gomez Toledo A., Sihlbom C., Lengqvist J., Fries E., Kjellen L., RA Nilsson J., Larson G.; RT "Identification of chondroitin sulfate linkage region glycopeptides reveals RT prohormones as a novel class of proteoglycans."; RL Mol. Cell. Proteomics 14:41-49(2015). RN [7] RP FUNCTION, INDUCTION BY TGFB1, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=27599751; DOI=10.1111/jcmm.12953; RA Poveda J., Sanz A.B., Fernandez-Fernandez B., Carrasco S., Ruiz-Ortega M., RA Cannata-Ortiz P., Ortiz A., Sanchez-Nino M.D.; RT "MXRA5 is a TGF-beta1-regulated human protein with anti-inflammatory and RT anti-fibrotic properties."; RL J. Cell. Mol. Med. 21:154-164(2017). RN [8] RP TISSUE SPECIFICITY, AND GLYCOSYLATION AT SER-702. RX PubMed=32337544; DOI=10.1093/glycob/cwaa039; RA Toledo A.G., Pihl J., Spliid C.B., Persson A., Nilsson J., Pereira M.A., RA Gustavsson T., Choudhary S., Oo H.Z., Black P.C., Daugaard M., Esko J.D., RA Larson G., Salanti A., Clausen T.M.; RT "An affinity chromatography and glycoproteomics workflow to profile the RT chondroitin sulfate proteoglycans that interact with malarial VAR2CSA in RT the placenta and in cancer."; RL Glycobiology 30:989-1002(2020). RN [9] RP TISSUE SPECIFICITY, AND GLYCOSYLATION AT SER-702. RX PubMed=36213313; DOI=10.1007/s42485-022-00092-3; RA Ramarajan M.G., Saraswat M., Budhraja R., Garapati K., Raymond K., RA Pandey A.; RT "Mass spectrometric analysis of chondroitin sulfate-linked peptides."; RL J. Proteins Proteom. 13:187-203(2022). RN [10] RP VARIANTS LNCR ASP-98; HIS-481; CYS-611; ASN-862; PHE-1028; ALA-1491; RP HIS-2300; TRP-2349; ARG-2678; ALA-2716 AND GLY-2763. RX PubMed=22696596; DOI=10.1093/carcin/bgs210; RA Xiong D., Li G., Li K., Xu Q., Pan Z., Ding F., Vedell P., Liu P., Cui P., RA Hua X., Jiang H., Yin Y., Zhu Z., Li X., Zhang B., Ma D., Wang Y., You M.; RT "Exome sequencing identifies MXRA5 as a novel cancer gene frequently RT mutated in non-small cell lung carcinoma from Chinese patients."; RL Carcinogenesis 33:1797-1805(2012). RN [11] RP VARIANTS HIS-1163 AND TRP-2663. RX PubMed=23092983; DOI=10.1038/tp.2012.102; RA Nava C., Lamari F., Heron D., Mignot C., Rastetter A., Keren B., Cohen D., RA Faudet A., Bouteiller D., Gilleron M., Jacquette A., Whalen S., Afenjar A., RA Perisse D., Laurent C., Dupuits C., Gautier C., Gerard M., Huguet G., RA Caillet S., Leheup B., Leboyer M., Gillberg C., Delorme R., Bourgeron T., RA Brice A., Depienne C.; RT "Analysis of the chromosome X exome in patients with autism spectrum RT disorders identified novel candidate genes, including TMLHE."; RL Transl. Psychiatry 2:E179-E179(2012). RN [12] RP VARIANT ASP-2426. RX PubMed=26566883; DOI=10.1136/jmedgenet-2015-103179; RA Rafiullah R., Aslamkhan M., Paramasivam N., Thiel C., Mustafa G., RA Wiemann S., Schlesner M., Wade R.C., Rappold G.A., Berkel S.; RT "Homozygous missense mutation in the LMAN2L gene segregates with RT intellectual disability in a large consanguineous Pakistani family."; RL J. Med. Genet. 53:138-144(2016). CC -!- FUNCTION: In kidney, has anti-inflammatory and anti-fibrotic properties CC by limiting the induction of chemokines, fibronectin and collagen CC expression in response to TGB1 and pro-inflammatory stimuli. CC {ECO:0000269|PubMed:27599751}. CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:25326458, CC ECO:0000269|PubMed:27599751}. CC -!- TISSUE SPECIFICITY: Detected in placenta (at protein level) CC (PubMed:32337544). Detected in cerebrospinal fluid and fibroblasts (at CC protein level) (PubMed:25326458, PubMed:36213313). Highly expressed in CC kidney, also detected on liver and spleen (PubMed:27599751). Expressed CC by proximal tubular cells of the kidney (at protein level) CC (PubMed:27599751). Expression highly increases during chronic kidney CC disease and autosomal dominant polycystic kidney disease, where is CC detected in cysts (PubMed:27599751). {ECO:0000269|PubMed:25326458, CC ECO:0000269|PubMed:27599751, ECO:0000269|PubMed:32337544, CC ECO:0000269|PubMed:36213313}. CC -!- DEVELOPMENTAL STAGE: Over-expressed in centenarians. Expression is CC reduced from young to old but increased from old to centenarians. CC {ECO:0000269|PubMed:15609104}. CC -!- INDUCTION: Expression is induced by TGFB1, in kidney tubular cells. CC This induction is inhibited by the vitamin D receptor activator CC paricalcitol (at protein level). {ECO:0000269|PubMed:27599751}. CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting CC tissues of the lung. The most common form of lung cancer is non-small CC cell lung cancer (NSCLC) that can be divided into 3 major histologic CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor CC prognosis. {ECO:0000269|PubMed:22696596}. Note=Disease susceptibility CC may be associated with variants affecting the gene represented in this CC entry. CC -!- SEQUENCE CAUTION: CC Sequence=AAH11846.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305}; CC Sequence=AAH64986.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305}; CC Sequence=AAH80586.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF245505; AAF86402.1; -; mRNA. DR EMBL; AC004616; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC011846; AAH11846.1; ALT_SEQ; mRNA. DR EMBL; BC064986; AAH64986.1; ALT_SEQ; mRNA. DR EMBL; BC080586; AAH80586.1; ALT_SEQ; mRNA. DR EMBL; AL049946; CAB43220.1; -; mRNA. DR CCDS; CCDS14124.1; -. DR PIR; T08678; T08678. DR RefSeq; NP_056234.2; NM_015419.4. DR BioGRID; 117392; 9. DR FunCoup; Q9NR99; 45. DR IntAct; Q9NR99; 18. DR STRING; 9606.ENSP00000217939; -. DR GlyConnect; 1495; 24 N-Linked glycans (7 sites). DR GlyCosmos; Q9NR99; 24 sites, 27 glycans. DR GlyGen; Q9NR99; 36 sites, 53 N-linked glycans (9 sites), 6 O-linked glycans (21 sites). DR iPTMnet; Q9NR99; -. DR PhosphoSitePlus; Q9NR99; -. DR BioMuta; MXRA5; -. DR DMDM; 317373412; -. DR jPOST; Q9NR99; -. DR MassIVE; Q9NR99; -. DR PaxDb; 9606-ENSP00000217939; -. DR PeptideAtlas; Q9NR99; -. DR ProteomicsDB; 82314; -. DR Pumba; Q9NR99; -. DR Antibodypedia; 362; 69 antibodies from 22 providers. DR DNASU; 25878; -. DR Ensembl; ENST00000217939.7; ENSP00000217939.5; ENSG00000101825.8. DR GeneID; 25878; -. DR KEGG; hsa:25878; -. DR MANE-Select; ENST00000217939.7; ENSP00000217939.5; NM_015419.4; NP_056234.2. DR UCSC; uc004crg.6; human. DR AGR; HGNC:7539; -. DR ClinPGx; PA31340; -. DR CTD; 25878; -. DR DisGeNET; 25878; -. DR GeneCards; MXRA5; -. DR HGNC; HGNC:7539; MXRA5. DR HPA; ENSG00000101825; Tissue enhanced (cervix). DR MalaCards; MXRA5; -. DR MIM; 211980; phenotype. DR MIM; 300938; gene. DR OpenTargets; ENSG00000101825; -. DR VEuPathDB; HostDB:ENSG00000101825; -. DR eggNOG; KOG0619; Eukaryota. DR GeneTree; ENSGT00940000159942; -. DR HOGENOM; CLU_000580_0_0_1; -. DR InParanoid; Q9NR99; -. DR OMA; KMNCMAM; -. DR OrthoDB; 676979at2759; -. DR PAN-GO; Q9NR99; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q9NR99; -. DR PathwayCommons; Q9NR99; -. DR SignaLink; Q9NR99; -. DR Agora; ENSG00000101825; -. DR BioGRID-ORCS; 25878; 8 hits in 771 CRISPR screens. DR ChiTaRS; MXRA5; human. DR GeneWiki; MXRA5; -. DR GenomeRNAi; 25878; -. DR Pharos; Q9NR99; Tbio. DR PRO; PR:Q9NR99; -. DR Proteomes; UP000005640; Chromosome X. DR RNAct; Q9NR99; protein. DR Bgee; ENSG00000101825; Expressed in tendon of biceps brachii and 174 other cell types or tissues. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0031012; C:extracellular matrix; HDA:BHF-UCL. DR GO; GO:0005201; F:extracellular matrix structural constituent; HDA:BHF-UCL. DR GO; GO:0071559; P:response to transforming growth factor beta; IMP:UniProtKB. DR CDD; cd00096; Ig; 4. DR FunFam; 2.60.40.10:FF:000621; Immunoglobulin superfamily member 10; 1. DR FunFam; 3.80.10.10:FF:000103; Immunoglobulin superfamily member 10; 1. DR FunFam; 2.60.40.10:FF:000537; immunoglobulin superfamily member 10; 1. DR FunFam; 2.60.40.10:FF:001017; Matrix remodeling associated 5; 1. DR FunFam; 2.60.40.10:FF:001146; Matrix remodeling associated 5; 1. DR FunFam; 2.60.40.10:FF:001248; Matrix remodeling associated 5; 1. DR FunFam; 2.60.40.10:FF:001290; Matrix remodeling associated 5; 1. DR FunFam; 2.60.40.10:FF:001306; Matrix remodeling associated 5; 1. DR FunFam; 2.60.40.10:FF:001377; Matrix remodeling associated 5; 1. DR FunFam; 2.60.40.10:FF:001402; Matrix remodeling associated 5; 1. DR FunFam; 2.60.40.10:FF:001433; Matrix remodeling associated 5; 1. DR FunFam; 2.60.40.10:FF:001502; Matrix remodeling associated 5; 1. DR FunFam; 2.60.40.10:FF:002119; Matrix remodeling associated 5; 1. DR FunFam; 3.80.10.10:FF:000322; Matrix remodeling associated 5; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 12. DR Gene3D; 3.80.10.10; Ribonuclease Inhibitor; 2. DR InterPro; IPR000483; Cys-rich_flank_reg_C. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR001611; Leu-rich_rpt. DR InterPro; IPR003591; Leu-rich_rpt_typical-subtyp. DR InterPro; IPR050467; LRFN. DR InterPro; IPR032675; LRR_dom_sf. DR InterPro; IPR000372; LRRNT. DR PANTHER; PTHR45842:SF4; MATRIX-REMODELING-ASSOCIATED PROTEIN 5; 1. DR PANTHER; PTHR45842; SYNAPTIC ADHESION-LIKE MOLECULE SALM; 1. DR Pfam; PF07679; I-set; 6. DR Pfam; PF13927; Ig_3; 5. DR Pfam; PF13855; LRR_8; 1. DR SMART; SM00409; IG; 12. DR SMART; SM00408; IGc2; 12. DR SMART; SM00369; LRR_TYP; 6. DR SMART; SM00082; LRRCT; 1. DR SMART; SM00013; LRRNT; 1. DR SUPFAM; SSF48726; Immunoglobulin; 12. DR SUPFAM; SSF52058; L domain-like; 1. DR PROSITE; PS50835; IG_LIKE; 12. PE 1: Evidence at protein level; KW Disulfide bond; Glycoprotein; Leucine-rich repeat; Proteoglycan; KW Proteomics identification; Reference proteome; Repeat; Secreted; Signal. FT SIGNAL 1..26 FT /evidence="ECO:0000255" FT CHAIN 27..2828 FT /note="Matrix-remodeling-associated protein 5" FT /id="PRO_0000254131" FT DOMAIN 27..55 FT /note="LRRNT" FT REPEAT 56..77 FT /note="LRR 1" FT REPEAT 80..101 FT /note="LRR 2" FT REPEAT 104..125 FT /note="LRR 3" FT REPEAT 128..149 FT /note="LRR 4" FT REPEAT 152..173 FT /note="LRR 5" FT REPEAT 184..205 FT /note="LRR 6" FT DOMAIN 217..277 FT /note="LRRCT" FT DOMAIN 481..571 FT /note="Ig-like C2-type 1" FT DOMAIN 575..669 FT /note="Ig-like C2-type 2" FT REPEAT 1410..1434 FT /note="LRR 7" FT DOMAIN 1853..1946 FT /note="Ig-like C2-type 3" FT DOMAIN 1950..2041 FT /note="Ig-like C2-type 4" FT DOMAIN 2046..2140 FT /note="Ig-like C2-type 5" FT DOMAIN 2146..2239 FT /note="Ig-like C2-type 6" FT DOMAIN 2242..2343 FT /note="Ig-like C2-type 7" FT DOMAIN 2345..2432 FT /note="Ig-like C2-type 8" FT DOMAIN 2440..2534 FT /note="Ig-like C2-type 9" FT DOMAIN 2542..2630 FT /note="Ig-like C2-type 10" FT DOMAIN 2637..2722 FT /note="Ig-like C2-type 11" FT DOMAIN 2733..2828 FT /note="Ig-like C2-type 12" FT REGION 671..715 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 933..962 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1068..1190 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1204..1275 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1367..1389 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1479..1499 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1536..1566 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1579..1603 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1669..1689 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1700..1719 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 695..708 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 951..962 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1090..1107 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1146..1168 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1169..1190 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1204..1214 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1229..1243 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1542..1566 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT CARBOHYD 287 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 321 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 633 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 702 FT /note="O-linked (Xyl...) (chondroitin sulfate) serine" FT /evidence="ECO:0000269|PubMed:25326458, FT ECO:0000269|PubMed:32337544, ECO:0000269|PubMed:36213313" FT CARBOHYD 1403 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1735 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 2007 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 2056 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 2693 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 501..555 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 599..651 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 1875..1928 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 1972..2025 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 2069..2122 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 2168..2221 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 2265..2324 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 2368..2418 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 2466..2518 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 2564..2616 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 2659..2711 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 2755..2810 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VARIANT 98 FT /note="A -> D (in LNCR; uncertain significance; FT dbSNP:rs1921642741)" FT /evidence="ECO:0000269|PubMed:22696596" FT /id="VAR_072405" FT VARIANT 481 FT /note="P -> H (in LNCR; uncertain significance; FT dbSNP:rs759222135)" FT /evidence="ECO:0000269|PubMed:22696596" FT /id="VAR_072406" FT VARIANT 611 FT /note="W -> C (in LNCR; uncertain significance)" FT /evidence="ECO:0000269|PubMed:22696596" FT /id="VAR_072407" FT VARIANT 764 FT /note="V -> L (in dbSNP:rs5983120)" FT /id="VAR_056057" FT VARIANT 824 FT /note="I -> V (in dbSNP:rs5983119)" FT /evidence="ECO:0000269|Ref.1" FT /id="VAR_060357" FT VARIANT 862 FT /note="S -> N (in LNCR)" FT /evidence="ECO:0000269|PubMed:22696596" FT /id="VAR_072408" FT VARIANT 1028 FT /note="V -> F (in LNCR; uncertain significance)" FT /evidence="ECO:0000269|PubMed:22696596" FT /id="VAR_072409" FT VARIANT 1128 FT /note="A -> V (in dbSNP:rs1635246)" FT /evidence="ECO:0000269|Ref.1" FT /id="VAR_060358" FT VARIANT 1163 FT /note="R -> H (in dbSNP:rs139106444)" FT /evidence="ECO:0000269|PubMed:23092983" FT /id="VAR_076257" FT VARIANT 1394 FT /note="G -> D (in dbSNP:rs1726199)" FT /evidence="ECO:0000269|Ref.1" FT /id="VAR_060359" FT VARIANT 1484 FT /note="T -> A (in dbSNP:rs12396910)" FT /id="VAR_056058" FT VARIANT 1491 FT /note="P -> A (in LNCR; uncertain significance; FT dbSNP:rs754393038)" FT /evidence="ECO:0000269|PubMed:22696596" FT /id="VAR_072410" FT VARIANT 1665 FT /note="P -> S (in dbSNP:rs1974522)" FT /id="VAR_056059" FT VARIANT 2000 FT /note="G -> S (in dbSNP:rs1635242)" FT /evidence="ECO:0000269|Ref.1" FT /id="VAR_060360" FT VARIANT 2300 FT /note="R -> H (in LNCR; uncertain significance; FT dbSNP:rs776590689)" FT /evidence="ECO:0000269|PubMed:22696596" FT /id="VAR_072411" FT VARIANT 2349 FT /note="R -> W (in LNCR; uncertain significance; FT dbSNP:rs369042203)" FT /evidence="ECO:0000269|PubMed:22696596" FT /id="VAR_072412" FT VARIANT 2426 FT /note="E -> D (in dbSNP:rs148675322)" FT /evidence="ECO:0000269|PubMed:26566883" FT /id="VAR_076437" FT VARIANT 2531 FT /note="L -> V (in dbSNP:rs1726208)" FT /evidence="ECO:0000269|Ref.1" FT /id="VAR_028821" FT VARIANT 2663 FT /note="G -> W (in dbSNP:rs143264543)" FT /evidence="ECO:0000269|PubMed:23092983" FT /id="VAR_076258" FT VARIANT 2678 FT /note="H -> R (in LNCR; uncertain significance)" FT /evidence="ECO:0000269|PubMed:22696596" FT /id="VAR_072413" FT VARIANT 2716 FT /note="E -> A (in LNCR; uncertain significance; FT dbSNP:rs1419255508)" FT /evidence="ECO:0000269|PubMed:22696596" FT /id="VAR_072414" FT VARIANT 2763 FT /note="A -> G (in LNCR; uncertain significance)" FT /evidence="ECO:0000269|PubMed:22696596" FT /id="VAR_072415" FT CONFLICT 55 FT /note="K -> R (in Ref. 1; AAF86402)" FT /evidence="ECO:0000305" FT CONFLICT 1565 FT /note="Q -> R (in Ref. 1; AAF86402)" FT /evidence="ECO:0000305" FT CONFLICT 2245 FT /note="I -> V (in Ref. 5; CAB43220)" FT /evidence="ECO:0000305" FT CONFLICT 2353 FT /note="Y -> C (in Ref. 5; CAB43220)" FT /evidence="ECO:0000305" FT CONFLICT 2640 FT /note="N -> S (in Ref. 5; CAB43220)" FT /evidence="ECO:0000305" SQ SEQUENCE 2828 AA; 312150 MW; 0534732CE87C9A8F CRC64; MPKRAHWGAL SVVLILLWGH PRVALACPHP CACYVPSEVH CTFRSLASVP AGIAKHVERI NLGFNSIQAL SETSFAGLTK LELLMIHGNE IPSIPDGALR DLSSLQVFKF SYNKLRVITG QTLQGLSNLM RLHIDHNKIE FIHPQAFNGL TSLRLLHLEG NLLHQLHPST FSTFTFLDYF RLSTIRHLYL AENMVRTLPA SMLRNMPLLE NLYLQGNPWT CDCEMRWFLE WDAKSRGILK CKKDKAYEGG QLCAMCFSPK KLYKHEIHKL KDMTCLKPSI ESPLRQNRSR SIEEEQEQEE DGGSQLILEK FQLPQWSISL NMTDEHGNMV NLVCDIKKPM DVYKIHLNQT DPPDIDINAT VALDFECPMT RENYEKLWKL IAYYSEVPVK LHRELMLSKD PRVSYQYRQD ADEEALYYTG VRAQILAEPE WVMQPSIDIQ LNRRQSTAKK VLLSYYTQYS QTISTKDTRQ ARGRSWVMIE PSGAVQRDQT VLEGGPCQLS CNVKASESPS IFWVLPDGSI LKAPMDDPDS KFSILSSGWL RIKSMEPSDS GLYQCIAQVR DEMDRMVYRV LVQSPSTQPA EKDTVTIGKN PGESVTLPCN ALAIPEAHLS WILPNRRIIN DLANTSHVYM LPNGTLSIPK VQVSDSGYYR CVAVNQQGAD HFTVGITVTK KGSGLPSKRG RRPGAKALSR VREDIVEDEG GSGMGDEENT SRRLLHPKDQ EVFLKTKDDA INGDKKAKKG RRKLKLWKHS EKEPETNVAE GRRVFESRRR INMANKQINP ERWADILAKV RGKNLPKGTE VPPLIKTTSP PSLSLEVTPP FPAISPPSAS PVQTVTSAEE SSADVPLLGE EEHVLGTISS ASMGLEHNHN GVILVEPEVT STPLEEVVDD LSEKTEEITS TEGDLKGTAA PTLISEPYEP SPTLHTLDTV YEKPTHEETA TEGWSAADVG SSPEPTSSEY EPPLDAVSLA ESEPMQYFDP DLETKSQPDE DKMKEDTFAH LTPTPTIWVN DSSTSQLFED STIGEPGVPG QSHLQGLTDN IHLVKSSLST QDTLLIKKGM KEMSQTLQGG NMLEGDPTHS RSSESEGQES KSITLPDSTL GIMSSMSPVK KPAETTVGTL LDKDTTTATT TPRQKVAPSS TMSTHPSRRR PNGRRRLRPN KFRHRHKQTP PTTFAPSETF STQPTQAPDI KISSQVESSL VPTAWVDNTV NTPKQLEMEK NAEPTSKGTP RRKHGKRPNK HRYTPSTVSS RASGSKPSPS PENKHRNIVT PSSETILLPR TVSLKTEGPY DSLDYMTTTR KIYSSYPKVQ ETLPVTYKPT SDGKEIKDDV ATNVDKHKSD ILVTGESITN AIPTSRSLVS TMGEFKEESS PVGFPGTPTW NPSRTAQPGR LQTGIPVTTS GENLTDPPLL KELEDVDFTS EFLSSLTVST PFHQEEAGSS TTLSSIKVEV ASSQAETTTL DQDHLETTVA ILLSETRPQN HTPTAARMKE PASSSPSTIL MSLGQTTTTK PALPSPRISQ ASRDSKENVF LNYVGNPETE ATPVNNEGTQ HMSGPNELST PSSDQDAFNL STKLELEKQV FGSRSLPRGP DSQRQDGRVH ASHQLTRVPA KPILPTATVR LPEMSTQSAS RYFVTSQSPR HWTNKPEITT YPSGALPENK QFTTPRLSST TIPLPLHMSK PSIPSKFTDR RTDQFNGYSK VFGNNNIPEA RNPVGKPPSP RIPHYSNGRL PFFTNKTLSF PQLGVTRRPQ IPTSPAPVMR ERKVIPGSYN RIHSHSTFHL DFGPPAPPLL HTPQTTGSPS TNLQNIPMVS STQSSISFIT SSVQSSGSFH QSSSKFFAGG PPASKFWSLG EKPQILTKSP QTVSVTAETD TVFPCEATGK PKPFVTWTKV STGALMTPNT RIQRFEVLKN GTLVIRKVQV QDRGQYMCTA SNLHGLDRMV VLLSVTVQQP QILASHYQDV TVYLGDTIAM ECLAKGTPAP QISWIFPDRR VWQTVSPVEG RITLHENRTL SIKEASFSDR GVYKCVASNA AGADSLAIRL HVAALPPVIH QEKLENISLP PGLSIHIHCT AKAAPLPSVR WVLGDGTQIR PSQFLHGNLF VFPNGTLYIR NLAPKDSGRY ECVAANLVGS ARRTVQLNVQ RAAANARITG TSPRRTDVRY GGTLKLDCSA SGDPWPRILW RLPSKRMIDA LFSFDSRIKV FANGTLVVKS VTDKDAGDYL CVARNKVGDD YVVLKVDVVM KPAKIEHKEE NDHKVFYGGD LKVDCVATGL PNPEISWSLP DGSLVNSFMQ SDDSGGRTKR YVVFNNGTLY FNEVGMREEG DYTCFAENQV GKDEMRVRVK VVTAPATIRN KTYLAVQVPY GDVVTVACEA KGEPMPKVTW LSPTNKVIPT SSEKYQIYQD GTLLIQKAQR SDSGNYTCLV RNSAGEDRKT VWIHVNVQPP KINGNPNPIT TVREIAAGGS RKLIDCKAEG IPTPRVLWAF PEGVVLPAPY YGNRITVHGN GSLDIRSLRK SDSVQLVCMA RNEGGEARLI LQLTVLEPME KPIFHDPISE KITAMAGHTI SLNCSAAGTP TPSLVWVLPN GTDLQSGQQL QRFYHKADGM LHISGLSSVD AGAYRCVARN AAGHTERLVS LKVGLKPEAN KQYHNLVSII NGETLKLPCT PPGAGQGRFS WTLPNGMHLE GPQTLGRVSL LDNGTLTVRE ASVFDRGTYV CRMETEYGPS VTSIPVIVIA YPPRITSEPT PVIYTRPGNT VKLNCMAMGI PKADITWELP DKSHLKAGVQ ARLYGNRFLH PQGSLTIQHA TQRDAGFYKC MAKNILGSDS KTTYIHVF // ID MY18B_HUMAN Reviewed; 2567 AA. AC Q8IUG5; A0A075B6F5; B2RWP3; F5GXR6; F5GYU7; Q8NDI8; Q8TE65; Q8WWS0; Q96KH2; AC Q96KR8; Q96KR9; DT 11-JUL-2003, integrated into UniProtKB/Swiss-Prot. DT 28-MAR-2018, sequence version 2. DT 28-JAN-2026, entry version 186. DE RecName: Full=Unconventional myosin-XVIIIb; GN Name=MYO18B; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1 AND 2), VARIANTS RP VAL-234; ASN-347; GLN-379; CYS-389; MET-590; GLY-835; LEU-1095; GLN-1195; RP GLN-1238; THR-1238; LYS-1708; ASP-1715; GLU-1970; CYS-2295; HIS-2381 AND RP GLU-2554, AND POSSIBLE ROLE IN TUMOR SUPPRESSION. RC TISSUE=Skeletal muscle; RX PubMed=12209013; DOI=10.1073/pnas.192445899; RA Nishioka M., Kohno T., Tani M., Yanaihara N., Tomizawa Y., Otsuka A., RA Sasaki S., Kobayashi K., Niki T., Maeshima A., Sekido Y., Minna J.D., RA Sone S., Yokota J.; RT "MYO18B, a candidate tumor suppressor gene at chromosome 22q12.1, deleted, RT mutated, and methylated in human lung cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 99:12269-12274(2002). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), CHARACTERIZATION, AND RP VARIANTS ARG-661 AND LEU-925. RC TISSUE=Skeletal muscle; RX PubMed=12547197; DOI=10.1016/s0022-2836(02)01335-9; RA Salamon M., Millino C., Raffaello A., Mongillo M., Sandri C., Bean C., RA Negrisolo E., Pallavicini A., Valle G., Zaccolo M., Schiaffino S., RA Lanfranchi G.; RT "Human MYO18B, a novel unconventional myosin heavy chain expressed in RT striated muscles moves into the myonuclei upon differentiation."; RL J. Mol. Biol. 326:137-149(2003). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS CYS-547; ARG-661 AND RP GLN-1119. RA Gu Y., Ji Y., Penn S.G., Hanzel D.K., Rank D.R., Chen W., Shannon M.E.; RT "Myosin-like gene expressed in human heart and muscle."; RL Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=10591208; DOI=10.1038/990031; RA Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M., Clamp M., RA Smink L.J., Ainscough R., Almeida J.P., Babbage A.K., Bagguley C., RA Bailey J., Barlow K.F., Bates K.N., Beasley O.P., Bird C.P., Blakey S.E., RA Bridgeman A.M., Buck D., Burgess J., Burrill W.D., Burton J., Carder C., RA Carter N.P., Chen Y., Clark G., Clegg S.M., Cobley V.E., Cole C.G., RA Collier R.E., Connor R., Conroy D., Corby N.R., Coville G.J., Cox A.V., RA Davis J., Dawson E., Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., RA Ellington A.G., Evans K.L., Fey J.M., Fleming K., French L., Garner A.A., RA Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C., RA Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S., Hunt S.E., RA Jones M.C., Kershaw J., Kimberley A.M., King A., Laird G.K., Langford C.F., RA Leversha M.A., Lloyd C., Lloyd D.M., Martyn I.D., Mashreghi-Mohammadi M., RA Matthews L.H., Mccann O.T., Mcclay J., Mclaren S., McMurray A.A., RA Milne S.A., Mortimore B.J., Odell C.N., Pavitt R., Pearce A.V., Pearson D., RA Phillimore B.J.C.T., Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., RA Rogers L., Ross M.T., Scott C.E., Sehra H.K., Skuce C.D., Smalley S., RA Smith M.L., Soderlund C., Spragon L., Steward C.A., Sulston J.E., RA Swann R.M., Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L., RA Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L., RA Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N., RA Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J., Shintani A., RA Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S., Roe B.A., Chen F., Chu L., RA Crabtree J., Deschamps S., Do A., Do T., Dorman A., Fang F., Fu Y., Hu P., RA Hua A., Kenton S., Lai H., Lao H.I., Lewis J., Lewis S., Lin S.-P., Loh P., RA Malaj E., Nguyen T., Pan H., Phan S., Qi S., Qian Y., Ray L., Ren Q., RA Shaull S., Sloan D., Song L., Wang Q., Wang Y., Wang Z., White J., RA Willingham D., Wu H., Yao Z., Zhan M., Zhang G., Chissoe S., Murray J., RA Miller N., Minx P., Fulton R., Johnson D., Bemis G., Bentley D., RA Bradshaw H., Bourne S., Cordes M., Du Z., Fulton L., Goela D., Graves T., RA Hawkins J., Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., RA Rohlfing T., Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., RA Nelson J., Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R., RA Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S., Budarf M.L., RA McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E., Edelmann L., Kim U.J., RA Shizuya H., Simon M.I., Dumanski J.P., Peyrard M., Kedra D., Seroussi E., RA Fransson I., Tapia I., Bruder C.E., O'Brien K.P., Wilkinson P., RA Bodenteich A., Hartman K., Hu X., Khan A.S., Lane L., Tilahun Y., RA Wright H.; RT "The DNA sequence of human chromosome 22."; RL Nature 402:489-495(1999). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 2343-2567. RC TISSUE=Skeletal muscle; RA Stanchi F., Lanfranchi G.; RT "Full-length sequencing of 100 cDNA clones from human adult skeletal RT muscle."; RL Submitted (FEB-2000) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS CYS-547; RP ARG-661; GLN-1119 AND ARG-2347. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2359-2567. RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [8] RP POSSIBLE INVOLVEMENT IN SUPPRESSION OF CELL ANCHORAGE-INDEPENDENT GROWTH. RX PubMed=12741677; DOI=10.1023/a:1022978932215; RA Yokota J., Nishioka M., Tani M., Kohno T.; RT "Genetic alterations responsible for metastatic phenotypes of lung cancer RT cells."; RL Clin. Exp. Metastasis 20:189-193(2003). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Lymphoblast; RX PubMed=14654843; DOI=10.1038/nature02166; RA Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.; RT "Proteomic characterization of the human centrosome by protein correlation RT profiling."; RL Nature 426:570-574(2003). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Platelet; RX PubMed=18088087; DOI=10.1021/pr0704130; RA Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J., RA Schuetz C., Walter U., Gambaryan S., Sickmann A.; RT "Phosphoproteome of resting human platelets."; RL J. Proteome Res. 7:526-534(2008). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1829, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1216; SER-2193; SER-2296; RP SER-2309 AND SER-2377, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [14] RP INVOLVEMENT IN KFS4. RX PubMed=25748484; DOI=10.1136/jmedgenet-2014-102964; RA Alazami A.M., Kentab A.Y., Faqeih E., Mohamed J.Y., Alkhalidi H., RA Hijazi H., Alkuraya F.S.; RT "A novel syndrome of Klippel-Feil anomaly, myopathy, and characteristic RT facies is linked to a null mutation in MYO18B."; RL J. Med. Genet. 52:400-404(2015). CC -!- FUNCTION: May be involved in intracellular trafficking of the muscle CC cell when in the cytoplasm, whereas entering the nucleus, may be CC involved in the regulation of muscle specific genes. May play a role in CC the control of tumor development and progression; restored MYO18B CC expression in lung cancer cells suppresses anchorage-independent CC growth. CC -!- SUBUNIT: Homodimer. May interact with F actin through the GPA motif CC (Gly/Pro/Ala-rich). CC -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cytoplasm, myofibril, CC sarcomere. Note=Punctate pattern in undifferentiated myoblasts. CC Nuclear, on primary cardiomyocytes and adult muscle. A partial CC sarcomeric location was found in some cardiomyocytes. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q8IUG5-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8IUG5-2; Sequence=VSP_007764, VSP_007765; CC Name=3; CC IsoId=Q8IUG5-3; Sequence=VSP_059434; CC -!- TISSUE SPECIFICITY: Selectively expressed in cardiac and skeletal CC muscles. Weakly expressed in testis, pancreas, placenta, prostate, lung CC and thymus. CC -!- DEVELOPMENTAL STAGE: Reaches an expression peak in the third day after CC induction and remains at similar level during successive myotubule CC maturation. CC -!- DISEASE: Klippel-Feil syndrome 4, autosomal recessive, with nemaline CC myopathy and facial dysmorphism (KFS4) [MIM:616549]: A form of Klippel- CC Feil syndrome, a skeletal disorder characterized by congenital fusion CC of cervical vertebrae. It is due to a failure in the normal CC segmentation of vertebrae during the early weeks of fetal development. CC The clinical triad consists of short neck, low posterior hairline, and CC limited neck movement. KFS4 features additionally include myopathy, CC mild short stature, microcephaly, and distinctive facies. CC {ECO:0000269|PubMed:25748484}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: Frequently deleted, mutated, and hypermethylated in lung CC cancers. CC -!- SIMILARITY: Belongs to the TRAFAC class myosin-kinesin ATPase CC superfamily. Myosin family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB075376; BAC16363.1; -; mRNA. DR EMBL; AB042648; BAB55550.2; -; mRNA. DR EMBL; AJ310931; CAC70712.2; -; mRNA. DR EMBL; AJ310932; CAC70714.3; -; Genomic_DNA. DR EMBL; AY077700; AAL75811.1; -; mRNA. DR EMBL; Z98949; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL080245; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL022329; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL079300; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; KF457380; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; KF457381; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; KF457390; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; KF511427; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC144597; AAI44598.1; -; mRNA. DR EMBL; BC150626; AAI50627.1; -; mRNA. DR EMBL; AJ271918; CAC81082.1; -; mRNA. DR EMBL; AL833890; CAD38746.1; -; mRNA. DR CCDS; CCDS54507.1; -. [Q8IUG5-1] DR CCDS; CCDS82703.1; -. [Q8IUG5-3] DR RefSeq; NP_001305174.1; NM_001318245.2. [Q8IUG5-3] DR RefSeq; NP_115997.5; NM_032608.6. [Q8IUG5-1] DR AlphaFoldDB; Q8IUG5; -. DR SMR; Q8IUG5; -. DR BioGRID; 124214; 17. DR FunCoup; Q8IUG5; 217. DR IntAct; Q8IUG5; 17. DR STRING; 9606.ENSP00000386096; -. DR GlyGen; Q8IUG5; 3 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; Q8IUG5; -. DR PhosphoSitePlus; Q8IUG5; -. DR BioMuta; MYO18B; -. DR DMDM; 32699565; -. DR jPOST; Q8IUG5; -. DR MassIVE; Q8IUG5; -. DR PaxDb; 9606-ENSP00000334563; -. DR PeptideAtlas; Q8IUG5; -. DR ProteomicsDB; 24501; -. DR ProteomicsDB; 24848; -. DR ProteomicsDB; 70563; -. [Q8IUG5-1] DR ProteomicsDB; 70564; -. [Q8IUG5-2] DR Pumba; Q8IUG5; -. DR Antibodypedia; 264; 77 antibodies from 22 providers. DR DNASU; 84700; -. DR Ensembl; ENST00000335473.12; ENSP00000334563.8; ENSG00000133454.16. [Q8IUG5-1] DR Ensembl; ENST00000407587.6; ENSP00000386096.2; ENSG00000133454.16. [Q8IUG5-3] DR Ensembl; ENST00000536101.5; ENSP00000441229.1; ENSG00000133454.16. [Q8IUG5-1] DR GeneID; 84700; -. DR KEGG; hsa:84700; -. DR MANE-Select; ENST00000335473.12; ENSP00000334563.8; NM_032608.7; NP_115997.5. DR UCSC; uc003abz.1; human. DR UCSC; uc062com.1; human. [Q8IUG5-1] DR AGR; HGNC:18150; -. DR ClinPGx; PA38300; -. DR CTD; 84700; -. DR DisGeNET; 84700; -. DR GeneCards; MYO18B; -. DR HGNC; HGNC:18150; MYO18B. DR HPA; ENSG00000133454; Tissue enhanced (heart muscle, skeletal muscle, tongue). DR MalaCards; MYO18B; -. DR MIM; 607295; gene. DR MIM; 616549; phenotype. DR OpenTargets; ENSG00000133454; -. DR Orphanet; 447974; Klippel-Feil anomaly-myopathy-facial dysmorphism syndrome. DR VEuPathDB; HostDB:ENSG00000133454; -. DR eggNOG; KOG0161; Eukaryota. DR GeneTree; ENSGT00940000158067; -. DR HOGENOM; CLU_1326008_0_0_1; -. DR InParanoid; Q8IUG5; -. DR OMA; MLQAHKQ; -. DR OrthoDB; 2505895at2759; -. DR PAN-GO; Q8IUG5; 6 GO annotations based on evolutionary models. DR PhylomeDB; Q8IUG5; -. DR PathwayCommons; Q8IUG5; -. DR SignaLink; Q8IUG5; -. DR Agora; ENSG00000133454; -. DR BioGRID-ORCS; 84700; 12 hits in 1153 CRISPR screens. DR ChiTaRS; MYO18B; human. DR GeneWiki; MYO18B; -. DR GenomeRNAi; 84700; -. DR Pharos; Q8IUG5; Tbio. DR PRO; PR:Q8IUG5; -. DR Proteomes; UP000005640; Chromosome 22. DR RNAct; Q8IUG5; protein. DR Bgee; ENSG00000133454; Expressed in apex of heart and 100 other cell types or tissues. DR ExpressionAtlas; Q8IUG5; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0031941; C:filamentous actin; IEA:Ensembl. DR GO; GO:0032982; C:myosin filament; IBA:GO_Central. DR GO; GO:0016460; C:myosin II complex; IBA:GO_Central. DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell. DR GO; GO:0016461; C:unconventional myosin complex; IDA:UniProtKB. DR GO; GO:0030018; C:Z disc; IEA:Ensembl. DR GO; GO:0051015; F:actin filament binding; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0003774; F:cytoskeletal motor activity; IEA:InterPro. DR GO; GO:0055013; P:cardiac muscle cell development; IEA:Ensembl. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0001570; P:vasculogenesis; IEA:Ensembl. DR CDD; cd01386; MYSc_Myo18; 1. DR FunFam; 1.10.10.820:FF:000004; unconventional myosin-XVIIIa isoform X1; 1. DR FunFam; 1.20.58.530:FF:000011; unconventional myosin-XVIIIa isoform X2; 1. DR Gene3D; 1.10.10.820; -; 1. DR Gene3D; 1.20.58.530; -; 1. DR Gene3D; 6.20.240.20; -; 1. DR Gene3D; 3.40.850.10; Kinesin motor domain; 1. DR Gene3D; 1.20.120.720; Myosin VI head, motor domain, U50 subdomain; 1. DR Gene3D; 4.10.270.10; Myosin, subunit A; 1. DR InterPro; IPR036961; Kinesin_motor_dom_sf. DR InterPro; IPR001609; Myosin_head_motor_dom-like. DR InterPro; IPR036064; MYSc_Myo18. DR InterPro; IPR027417; P-loop_NTPase. DR PANTHER; PTHR45615; MYOSIN HEAVY CHAIN, NON-MUSCLE; 1. DR PANTHER; PTHR45615:SF8; UNCONVENTIONAL MYOSIN-XVIIIB; 1. DR Pfam; PF00063; Myosin_head; 1. DR PRINTS; PR00193; MYOSINHEAVY. DR SMART; SM00242; MYSc; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. DR PROSITE; PS50096; IQ; 1. DR PROSITE; PS51456; MYOSIN_MOTOR; 1. PE 1: Evidence at protein level; KW Actin-binding; Alternative splicing; ATP-binding; Coiled coil; Cytoplasm; KW Motor protein; Myosin; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome. FT CHAIN 1..2567 FT /note="Unconventional myosin-XVIIIb" FT /id="PRO_0000123478" FT DOMAIN 571..1333 FT /note="Myosin motor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00782" FT DOMAIN 1336..1365 FT /note="IQ" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00116" FT REGION 41..508 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1208..1232 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1213..1240 FT /note="GPA" FT /evidence="ECO:0000255" FT REGION 1426..2083 FT /note="Tail" FT REGION 2139..2194 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2217..2249 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2357..2376 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2444..2471 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2494..2567 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 1396..1783 FT /evidence="ECO:0000255" FT COILED 1825..1961 FT /evidence="ECO:0000255" FT COILED 2014..2090 FT /evidence="ECO:0000255" FT COMPBIAS 44..54 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 71..104 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 105..116 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 160..176 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 196..206 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 251..265 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 278..287 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 326..349 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 350..362 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 367..377 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 410..420 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 471..485 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 492..508 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2139..2153 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2158..2167 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2168..2185 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2227..2238 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2494..2504 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2506..2520 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2537..2556 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 660..667 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255" FT MOD_RES 1216 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1829 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2193 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2296 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2309 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2377 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..487 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:12209013" FT /id="VSP_007764" FT VAR_SEQ 488..503 FT /note="PAPQEEGKGGQSRDSD -> MGSGAICWFNLRDVGS (in isoform 2)" FT /evidence="ECO:0000303|PubMed:12209013" FT /id="VSP_007765" FT VAR_SEQ 1019 FT /note="S -> SQ (in isoform 3)" FT /evidence="ECO:0000305" FT /id="VSP_059434" FT VARIANT 44 FT /note="G -> E (in dbSNP:rs133885)" FT /id="VAR_056190" FT VARIANT 177 FT /note="P -> L (in dbSNP:rs13058434)" FT /id="VAR_056191" FT VARIANT 234 FT /note="G -> V (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:12209013" FT /id="VAR_015862" FT VARIANT 347 FT /note="K -> N (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:12209013" FT /id="VAR_015863" FT VARIANT 379 FT /note="R -> Q (in a lung small cell carcinoma sample; FT somatic mutation; dbSNP:rs750078923)" FT /evidence="ECO:0000269|PubMed:12209013" FT /id="VAR_015864" FT VARIANT 389 FT /note="W -> C (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:12209013" FT /id="VAR_015865" FT VARIANT 547 FT /note="W -> C (in dbSNP:rs3859866)" FT /evidence="ECO:0000269|PubMed:15489334, ECO:0000269|Ref.3" FT /id="VAR_056192" FT VARIANT 590 FT /note="T -> M (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs370187232)" FT /evidence="ECO:0000269|PubMed:12209013" FT /id="VAR_015866" FT VARIANT 661 FT /note="W -> R (in dbSNP:rs5761170)" FT /evidence="ECO:0000269|PubMed:12547197, FT ECO:0000269|PubMed:15489334, ECO:0000269|Ref.3" FT /id="VAR_015867" FT VARIANT 835 FT /note="A -> G (in a lung squamous cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:12209013" FT /id="VAR_015868" FT VARIANT 925 FT /note="S -> L (in dbSNP:rs9624909)" FT /evidence="ECO:0000269|PubMed:12547197" FT /id="VAR_056193" FT VARIANT 1037 FT /note="W -> S (in dbSNP:rs17704912)" FT /id="VAR_056194" FT VARIANT 1095 FT /note="R -> L (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:12209013" FT /id="VAR_015869" FT VARIANT 1119 FT /note="H -> Q (in dbSNP:rs5761268)" FT /evidence="ECO:0000269|PubMed:15489334, ECO:0000269|Ref.3" FT /id="VAR_056195" FT VARIANT 1195 FT /note="R -> Q (in a lung small cell carcinoma sample; FT somatic mutation; dbSNP:rs1429133479)" FT /evidence="ECO:0000269|PubMed:12209013" FT /id="VAR_015870" FT VARIANT 1238 FT /note="P -> Q (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:12209013" FT /id="VAR_015871" FT VARIANT 1238 FT /note="P -> T (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:12209013" FT /id="VAR_015872" FT VARIANT 1390 FT /note="S -> F (in dbSNP:rs35578357)" FT /id="VAR_056196" FT VARIANT 1399 FT /note="I -> V (in dbSNP:rs695633)" FT /id="VAR_056197" FT VARIANT 1444 FT /note="S -> T (in dbSNP:rs33928909)" FT /id="VAR_056198" FT VARIANT 1708 FT /note="E -> K (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:12209013" FT /id="VAR_015873" FT VARIANT 1715 FT /note="E -> D (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:12209013" FT /id="VAR_015874" FT VARIANT 1970 FT /note="A -> E (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:12209013" FT /id="VAR_015875" FT VARIANT 2294 FT /note="A -> D (in dbSNP:rs35370367)" FT /id="VAR_056199" FT VARIANT 2295 FT /note="G -> C (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:12209013" FT /id="VAR_015876" FT VARIANT 2347 FT /note="Q -> R (in dbSNP:rs2236005)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_015877" FT VARIANT 2381 FT /note="R -> H (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs200567905)" FT /evidence="ECO:0000269|PubMed:12209013" FT /id="VAR_015878" FT VARIANT 2395 FT /note="G -> A (in dbSNP:rs6004901)" FT /id="VAR_056200" FT VARIANT 2513 FT /note="G -> S (in dbSNP:rs7284177)" FT /id="VAR_056201" FT VARIANT 2532 FT /note="R -> Q (in dbSNP:rs34875296)" FT /id="VAR_056202" FT VARIANT 2554 FT /note="D -> E (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs780180192)" FT /evidence="ECO:0000269|PubMed:12209013" FT /id="VAR_015879" FT CONFLICT 3 FT /note="I -> M (in Ref. 2; CAC70712)" FT /evidence="ECO:0000305" FT CONFLICT 828 FT /note="A -> T (in Ref. 6; AAI50627/AAI44598)" FT /evidence="ECO:0000305" FT CONFLICT 1020 FT /note="Q -> QQ (in Ref. 3; AAL75811)" FT /evidence="ECO:0000305" FT CONFLICT 1060 FT /note="A -> T (in Ref. 3; AAL75811)" FT /evidence="ECO:0000305" FT CONFLICT 1510 FT /note="N -> D (in Ref. 3; AAL75811)" FT /evidence="ECO:0000305" FT CONFLICT 1515 FT /note="Missing (in Ref. 6; AAI50627/AAI44598)" FT /evidence="ECO:0000305" FT CONFLICT 2343..2344 FT /note="KS -> LT (in Ref. 5)" FT /evidence="ECO:0000305" SQ SEQUENCE 2567 AA; 285215 MW; C36BFD5C6FB4258B CRC64; MAISSRLALW EQKIREEDKS PPPSSPPPLF SVIPGGFIKQ LVRGTEKEAK EARQRKQLAV ASPEREIPEI SISQPNSKSS SGTRSGSQQI SQDDQSSSPG SSDILGKESE GSRSPDPEQM TSINGEKAQE LGSSATPTKK TVPFKRGVRR GDVLLMVAKL DPDSAKPEKT HPHDAPPCKT SPPATDTGKE KKGETSRTPC GSQASTEILA PKAEKTRTGG LGDPGQGTVA LKKGEEGQSI VGKGLGTPKT TELKEAEPQG KDRQGTRPQA QGPGEGVRPG KAEKEGAEPT NTVEKGNVSK DVGSEGKHVR PQIPGRKWGG FLGRRSKWDG PQNKKDKEGV LLSKAEKTGE PQTQMEKTSQ VQGELGDDLR MGEKAGELRS TTGKAGESWD KKEKMGQPQG KSGNAGEARS QTEKGCEAPK EVSTMVESPA APGKGGWPGS RGQEAEEPCS RAGDGAGALE TELEGPSQPA LEKDAERPRI RKENQDGPAP QEEGKGGQSR DSDQAPEDRW YEAEKVWLAQ KDGFTLATVL KPDEGTADLP AGRVRLWIDA DKTITEVDEE HVHRANPPEL DQVEDLASLI SVNESSVLNT LLQRYKAQLL HTCTGPDLIV LQPRGPSVPS AGKVPKGRRD GLPAHIGSMA QRAYWALLNQ RRDQSIVALG WSGAGKTTCC EQVLEHLVGM AGSVDGRVSV EKIRATFTVL RAFGSVSMAH SRSATRFSMV MSLDFNATGR ITAAQLQTML LEKSRVARQP EGESNFLVFS QMLAGLDLDL RTELNLHQMA DSSSFGMGVW SKPEDKQKAA AAFAQLQGAM EMLGISESEQ RAVWRVLAAI YHLGAAGACK VGRKQFMRFE WANYAAEALG CEYEELNTAT FKHHLRQIIQ QMTFGPSRWG LEDEETSSGL KMTGVDCVEG MASGLYQELF AAVVSLINRS FSSHHLSMAS IMVVDSPGFQ NPRHQGKDRA ATFEELCHNY AHERLQLLFY QRTFVSTLQR YQEEGVPVQF DLPDPSPGTT VAVVDQNPSQ VRLPAGGGAQ DARGLFWVLD EEVHVEGSSD SVVLERLCAA FEKKGAGTEG SSALRTCEQP LQCEIFHQLG WDPVRYDLTG WLHRAKPNLS ALDAPQVLHQ SKREELRSLF QARAKLPPVC RAVAGLEGTS QQALQRSRMV RRTFASSLAA VRRKAPCSQI KLQMDALTSM IKRSRLHFIH CLVPNPVVES RSGQESPPPP QPGRDKPGAG GPLALDIPAL RVQLAGFHIL EALRLHRTGY ADHMGLTRFR RQFQVLDAPL LKKLMSTSEG IDERKAVEEL LETLDLEKKA VAVGHSQVFL KAGVISRLEK QREKLVSQSI VLFQAACKGF LSRQEFKKLK IRRLAAQCIQ KNVAVFLAVK DWPWWQLLGS LQPLLSATIG TEQLRAKEEE LTTLRRKLEK SEKLRNELRQ NTDLLESKIA DLTSDLADER FKGDVACQVL ESERAERLQA FREVQELKSK HEQVQKKLGD VNKQLEEAQQ KIQLNDLERN PTGGADEWQM RFDCAQMENE FLRKRLQQCE ERLDSELTAR KELEQKLGEL QSAYDGAKKM AHQLKRKCHH LTCDLEDTCV LLENQQSRNH ELEKKQKKFD LQLAQALGES VFEKGLREKV TQENTSVRWE LGQLQQQLKQ KEQEASQLKQ QVEMLQDHKR ELLGSPSLGE NCVAGLKERL WKLESSALEQ QKIQSQQENT IKQLEQLRQR FELEIERMKQ MHQKDREDQE EELEDVRQSC QKRLHQLEMQ LEQEYEEKQM VLHEKQDLEG LIGTLCDQIG HRDFDVEKRL RRDLRRTHAL LSDVQLLLGT MEDGKTSVSK EELEKVHSQL EQSEAKCEEA LKTQKVLTAD LESMHSELEN MTRNKSLVDE QLYRLQFEKA DLLKRIDEDQ DDLNELMQKH KDLIAQSAAD IGQIQELQLQ LEEAKKEKHK LQEQLQVAQM RIEYLEQSTV DRAIVSRQEA VICDLENKTE FQKVQIKRFE VLVIRLRDSL IKMGEELSQA ATSESQQRES SQYYQRRLEE LKADMEELVQ REAEASRRCM ELEKYVEELA AVRQTLQTDL ETSIRRIADL QAALEEVASS DSDTESVQTA VDCGSSGRKE MDNVSILSSQ PEGSLQSWLS CTLSLATDTM RTPSRQSATS SRILSPRINE EAGDTERTQS ALALSRARST NVHSKTSGDK PVSPHFVRRQ KYCHFGDGEV LAVQRKSTER LEPASSPLAS RSTNTSPLSR EKLPSPSAAL SEFVEGLRRK RAQRGQGSTL GLEDWPTLPI YQTTGASTLR RGRAGSDEGN LSLRVGAKSP LEIEGAAGGL LRSTSLKCIS SDGVGGTTLL PEKSKTQFSS CESLLESRPS MGRKLSSPTT PRDMLLSPTL RPRRRCLESS VDDAGCPDLG KEPLVFQNRQ FAHLMEEPLG SDPFSWKLPS LDYERKTKVD FDDFLPAIRK PQTPTSLAGS AKGGQDGSQR SSIHFETEEA NRSFLSGIKT ILKKSPEPKE DPAHLSDSSS SSGSIVSFKS ADSIKSRPGI PRLAGDGGER TSPERREPGT GRKDDDVASI MKKYLQK // ID NDOR1_HUMAN Reviewed; 597 AA. AC Q9UHB4; D3YTG6; D3YTH9; Q5VSG4; Q86US9; Q96BC6; DT 26-FEB-2008, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-2000, sequence version 1. DT 28-JAN-2026, entry version 183. DE RecName: Full=NADPH-dependent diflavin oxidoreductase 1 {ECO:0000255|HAMAP-Rule:MF_03178}; DE EC=1.18.1.- {ECO:0000255|HAMAP-Rule:MF_03178, ECO:0000269|PubMed:23596212, ECO:0000269|PubMed:28648056}; DE AltName: Full=NADPH-dependent FMN and FAD-containing oxidoreductase {ECO:0000255|HAMAP-Rule:MF_03178}; DE AltName: Full=Novel reductase 1 {ECO:0000303|PubMed:10625700}; GN Name=NDOR1 {ECO:0000255|HAMAP-Rule:MF_03178}; GN Synonyms=NR1 {ECO:0000303|PubMed:10625700}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, COFACTOR, RP BIOPHYSICOCHEMICAL PROPERTIES, AND SUBCELLULAR LOCATION. RX PubMed=10625700; DOI=10.1074/jbc.275.2.1471; RA Paine M.J., Garner A.P., Powell D., Sibbald J., Sales M., Pratt N., RA Smith T., Tew D.G., Wolf C.R.; RT "Cloning and characterization of a novel human dual flavin reductase."; RL J. Biol. Chem. 275:1471-1478(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RC TISSUE=Brain; RX PubMed=12871939; DOI=10.1074/jbc.m306355200; RA Kwasnicka D.A., Krakowiak A., Thacker C., Brenner C., Vincent S.R.; RT "Coordinate expression of NADPH-dependent flavin reductase, Fre-1, and RT Hint-related 7meGMP-directed hydrolase, DCS-1."; RL J. Biol. Chem. 278:39051-39058(2003). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3). RC TISSUE=Hippocampus, and Umbilical vein endothelial cell; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164053; DOI=10.1038/nature02465; RA Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L., RA Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R., RA Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S., RA Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., RA Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., RA Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E., RA Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M., RA Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J., RA Frankish A., Frankland J.A., French L., Fricker D.G., Garner P., RA Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S., RA Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E., RA Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D., RA Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E., RA Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K., RA Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S., RA Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J., RA Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E., RA McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V., RA Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S., RA Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K., RA Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J., RA Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., RA West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L., RA Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M., RA Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J., RA Dunham I.; RT "DNA sequence and analysis of human chromosome 9."; RL Nature 429:369-374(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ILE-522. RC TISSUE=Brain, and Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP PROTEIN SEQUENCE OF 1-8, FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=12871938; DOI=10.1074/jbc.m306282200; RA Olteanu H., Banerjee R.; RT "Redundancy in the pathway for redox regulation of mammalian methionine RT synthase: reductive activation by the dual flavoprotein, novel reductase RT 1."; RL J. Biol. Chem. 278:38310-38314(2003). RN [7] RP FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=12631275; DOI=10.1046/j.1432-1033.2003.03474.x; RA Finn R.D., Basran J., Roitel O., Wolf C.R., Munro A.W., Paine M.J., RA Scrutton N.S.; RT "Determination of the redox potentials and electron transfer properties of RT the FAD- and FMN-binding domains of the human oxidoreductase NR1."; RL Eur. J. Biochem. 270:1164-1175(2003). RN [8] RP INTERACTION WITH DCPS, AND CYTOTOXICITY. RX PubMed=16140270; DOI=10.1016/j.bbrc.2005.08.129; RA Kwasnicka-Crawford D.A., Vincent S.R.; RT "Role of a novel dual flavin reductase (NR1) and an associated histidine RT triad protein (DCS-1) in menadione-induced cytotoxicity."; RL Biochem. Biophys. Res. Commun. 336:565-571(2005). RN [9] RP FUNCTION, AND INTERACTION WITH CIAPIN1. RX PubMed=20802492; DOI=10.1038/nchembio.432; RA Netz D.J., Stumpfig M., Dore C., Muhlenhoff U., Pierik A.J., Lill R.; RT "Tah18 transfers electrons to Dre2 in cytosolic iron-sulfur protein RT biogenesis."; RL Nat. Chem. Biol. 6:758-765(2010). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [11] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=28648056; DOI=10.1021/jacs.7b05003; RA Camponeschi F., Ciofi-Baffoni S., Banci L.; RT "Anamorsin/Ndor1 Complex Reduces [2Fe-2S]-MitoNEET via a Transient Protein- RT Protein Interaction."; RL J. Am. Chem. Soc. 139:9479-9482(2017). RN [12] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1-161 IN COMPLEX WITH FMN, RP FUNCTION, COFACTOR, INTERACTION WITH CIAPIN1, AND CATALYTIC ACTIVITY. RX PubMed=23596212; DOI=10.1073/pnas.1302378110; RA Banci L., Bertini I., Calderone V., Ciofi-Baffoni S., Giachetti A., RA Jaiswal D., Mikolajczyk M., Piccioli M., Winkelmann J.; RT "Molecular view of an electron transfer process essential for iron-sulfur RT protein biogenesis."; RL Proc. Natl. Acad. Sci. U.S.A. 110:7136-7141(2013). RN [13] RP VARIANT ILE-522, CHARACTERIZATION OF VARIANT ILE-522, FUNCTION, AND RP BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=15900210; DOI=10.1097/01213011-200506000-00002; RA Finn R.D., Wilkie M., Smith G., Paine M.J.; RT "Identification of a functionally impaired allele of human novel RT oxidoreductase 1 (NDOR1), NDOR1*1."; RL Pharmacogenet. Genomics 15:381-386(2005). CC -!- FUNCTION: NADPH-dependent reductase which is a central component of the CC cytosolic iron-sulfur (Fe-S) protein assembly (CIA) machinery CC (PubMed:10625700, PubMed:15900210, PubMed:20802492, PubMed:23596212, CC PubMed:28648056). Transfers electrons from NADPH via its FAD and FMN CC prosthetic groups to the [2Fe-2S] cluster of CIAPIN1, another key CC component of the CIA machinery (PubMed:20802492, PubMed:23596212, CC PubMed:28648056). In turn, this reduced cluster provides electrons for CC assembly of cytosolic iron-sulfur cluster proteins (PubMed:20802492, CC PubMed:23596212). It can also reduce the [2Fe-2S] cluster of CISD1 and CC activate this protein implicated in Fe/S cluster repair CC (PubMed:28648056). In vitro can fully activate methionine synthase/MTR CC in the presence of soluble cytochrome b5/CYB5A (PubMed:12871938). CC {ECO:0000255|HAMAP-Rule:MF_03178, ECO:0000269|PubMed:10625700, CC ECO:0000269|PubMed:12871938, ECO:0000269|PubMed:15900210, CC ECO:0000269|PubMed:20802492, ECO:0000269|PubMed:23596212, CC ECO:0000269|PubMed:28648056}. CC -!- CATALYTIC ACTIVITY: CC Reaction=2 oxidized [2Fe-2S]-[protein] + NADPH = 2 reduced [2Fe-2S]- CC [protein] + NADP(+) + H(+); Xref=Rhea:RHEA:67716, Rhea:RHEA- CC COMP:17327, Rhea:RHEA-COMP:17328, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:33737, ChEBI:CHEBI:33738, ChEBI:CHEBI:57783, CC ChEBI:CHEBI:58349; Evidence={ECO:0000255|HAMAP-Rule:MF_03178, CC ECO:0000269|PubMed:23596212, ECO:0000269|PubMed:28648056}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:67717; CC Evidence={ECO:0000255|HAMAP-Rule:MF_03178, CC ECO:0000305|PubMed:23596212}; CC -!- COFACTOR: CC Name=FAD; Xref=ChEBI:CHEBI:57692; CC Evidence={ECO:0000255|HAMAP-Rule:MF_03178, CC ECO:0000269|PubMed:10625700}; CC -!- COFACTOR: CC Name=FMN; Xref=ChEBI:CHEBI:58210; CC Evidence={ECO:0000255|HAMAP-Rule:MF_03178, CC ECO:0000269|PubMed:10625700, ECO:0000269|PubMed:23596212}; CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=21 uM for cytochrome c {ECO:0000269|PubMed:10625700}; CC KM=1.08 uM for NADPH {ECO:0000269|PubMed:12631275, CC ECO:0000269|PubMed:15900210, ECO:0000269|PubMed:23596212}; CC Vmax=1.2 umol/min/ug enzyme for cytochrome c reduction CC {ECO:0000269|PubMed:10625700}; CC Vmax=1.98 umol/min/ug enzyme for cytochrome c reduction CC {ECO:0000269|PubMed:12871938}; CC Vmax=2.8 umol/min/ug enzyme for methionine synthase reductive CC activation {ECO:0000269|PubMed:12871938}; CC pH dependence: CC Optimum pH is about 8.0. {ECO:0000305|PubMed:10625700}; CC Redox potential: CC E(0) is -315 +/- 5 mV for the FAD oxidized/semiquinone couple, E(0) CC is -365 +/- 15 mV for the FAD semiquinone/dihydroquinone couple, E(0) CC is -146 +/- 5 mV for the FMN oxidized/semiquinone couple, and E(0) is CC -305 +/- 5 mV for the FMN semiquinone/dihydroquinone couple. CC {ECO:0000269|PubMed:12631275}; CC -!- SUBUNIT: Interacts with CIAPIN1; as part of the cytosolic iron-sulfur CC (Fe-S) protein assembly (CIA) machinery (By similarity) CC (PubMed:20802492, PubMed:23596212). Interacts with DCPS CC (PubMed:16140270). {ECO:0000255|HAMAP-Rule:MF_03178, CC ECO:0000269|PubMed:16140270, ECO:0000269|PubMed:20802492, CC ECO:0000269|PubMed:23596212}. CC -!- INTERACTION: CC Q9UHB4; Q86UT8: CENATAC; NbExp=3; IntAct=EBI-10249760, EBI-11028020; CC Q9UHB4; Q6FI81: CIAPIN1; NbExp=16; IntAct=EBI-10249760, EBI-750511; CC Q9UHB4; Q5JST6: EFHC2; NbExp=3; IntAct=EBI-10249760, EBI-2349927; CC Q9UHB4; O95995: GAS8; NbExp=3; IntAct=EBI-10249760, EBI-1052570; CC Q9UHB4; O76003: GLRX3; NbExp=2; IntAct=EBI-10249760, EBI-374781; CC Q9UHB4; Q13227: GPS2; NbExp=5; IntAct=EBI-10249760, EBI-713355; CC Q9UHB4; P14652: HOXB2; NbExp=3; IntAct=EBI-10249760, EBI-5329558; CC Q9UHB4; Q6ZU52: KIAA0408; NbExp=3; IntAct=EBI-10249760, EBI-739493; CC Q9UHB4; P25791-3: LMO2; NbExp=3; IntAct=EBI-10249760, EBI-11959475; CC Q9UHB4; Q8TAP4-4: LMO3; NbExp=3; IntAct=EBI-10249760, EBI-11742507; CC Q9UHB4; Q8TBB1: LNX1; NbExp=3; IntAct=EBI-10249760, EBI-739832; CC Q9UHB4; P50221: MEOX1; NbExp=3; IntAct=EBI-10249760, EBI-2864512; CC Q9UHB4; Q5JR59: MTUS2; NbExp=4; IntAct=EBI-10249760, EBI-742948; CC Q9UHB4; Q5JR59-3: MTUS2; NbExp=3; IntAct=EBI-10249760, EBI-11522433; CC Q9UHB4; Q15742: NAB2; NbExp=3; IntAct=EBI-10249760, EBI-8641936; CC Q9UHB4; Q9UBE8: NLK; NbExp=3; IntAct=EBI-10249760, EBI-366978; CC Q9UHB4; P28072: PSMB6; NbExp=3; IntAct=EBI-10249760, EBI-359288; CC Q9UHB4; P15884: TCF4; NbExp=4; IntAct=EBI-10249760, EBI-533224; CC Q9UHB4; P15884-3: TCF4; NbExp=3; IntAct=EBI-10249760, EBI-13636688; CC Q9UHB4; Q9BT92: TCHP; NbExp=7; IntAct=EBI-10249760, EBI-740781; CC Q9UHB4; Q96N21: TEPSIN; NbExp=3; IntAct=EBI-10249760, EBI-11139477; CC Q9UHB4; Q08117-2: TLE5; NbExp=3; IntAct=EBI-10249760, EBI-11741437; CC Q9UHB4; Q9UMX0: UBQLN1; NbExp=3; IntAct=EBI-10249760, EBI-741480; CC Q9UHB4; Q9UHD9: UBQLN2; NbExp=3; IntAct=EBI-10249760, EBI-947187; CC Q9UHB4; B2RXF5: ZBTB42; NbExp=5; IntAct=EBI-10249760, EBI-12287587; CC Q9UHB4; Q53FD0-2: ZC2HC1C; NbExp=3; IntAct=EBI-10249760, EBI-14104088; CC Q9UHB4; Q6ZNG0: ZNF620; NbExp=3; IntAct=EBI-10249760, EBI-4395669; CC Q9UHB4; Q6NX45: ZNF774; NbExp=3; IntAct=EBI-10249760, EBI-10251462; CC -!- SUBCELLULAR LOCATION: Cytoplasm, perinuclear region {ECO:0000255|HAMAP- CC Rule:MF_03178, ECO:0000269|PubMed:10625700, CC ECO:0000269|PubMed:12871939}. Note=Concentrated in perinuclear CC structure. {ECO:0000255|HAMAP-Rule:MF_03178, CC ECO:0000269|PubMed:12871939}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=Q9UHB4-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9UHB4-2; Sequence=VSP_031487; CC Name=3; CC IsoId=Q9UHB4-3; Sequence=VSP_046313, VSP_046314; CC Name=4; CC IsoId=Q9UHB4-4; Sequence=VSP_053807; CC -!- TISSUE SPECIFICITY: Low expression in brain, heart, kidney, pancreas, CC prostate and skeletal muscle. Highest levels in the placenta. Expressed CC in cancer cell lines including promyelocytic leukemia, HeLaS3, chronic CC myelagenous leukemia, lymphoblastic leukemia, Burkitt's lymphoma, CC colorectal adenocarcinoma, lung carcinoma, and melanoma G-361. CC {ECO:0000269|PubMed:12871939}. CC -!- SIMILARITY: Belongs to the NADPH-dependent diflavin oxidoreductase CC NDOR1 family. {ECO:0000255|HAMAP-Rule:MF_03178}. CC -!- SIMILARITY: In the N-terminal section; belongs to the flavodoxin CC family. {ECO:0000255|HAMAP-Rule:MF_03178}. CC -!- SIMILARITY: In the C-terminal section; belongs to the flavoprotein CC pyridine nucleotide cytochrome reductase family. {ECO:0000255|HAMAP- CC Rule:MF_03178}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF199509; AAF25205.1; -; mRNA. DR EMBL; AY077845; AAL77754.1; -; mRNA. DR EMBL; AK074403; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AK290026; BAF82715.1; -; mRNA. DR EMBL; AL929554; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BX255925; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC015735; AAH15735.1; -; mRNA. DR EMBL; BC093782; AAH93782.1; -; mRNA. DR EMBL; BC111943; AAI11944.1; -; mRNA. DR CCDS; CCDS48061.1; -. [Q9UHB4-2] DR CCDS; CCDS48062.1; -. [Q9UHB4-4] DR CCDS; CCDS48063.1; -. [Q9UHB4-3] DR CCDS; CCDS7036.1; -. [Q9UHB4-1] DR RefSeq; NP_001137498.1; NM_001144026.3. [Q9UHB4-2] DR RefSeq; NP_001137499.1; NM_001144027.3. [Q9UHB4-3] DR RefSeq; NP_001137500.1; NM_001144028.3. [Q9UHB4-4] DR RefSeq; NP_055249.1; NM_014434.4. [Q9UHB4-1] DR PDB; 4H2D; X-ray; 1.80 A; A/B=1-161. DR PDBsum; 4H2D; -. DR AlphaFoldDB; Q9UHB4; -. DR SMR; Q9UHB4; -. DR BioGRID; 118038; 54. DR ComplexPortal; CPX-26562; Anamorsin-NDOR1 complex. DR FunCoup; Q9UHB4; 2917. DR IntAct; Q9UHB4; 41. DR STRING; 9606.ENSP00000360576; -. DR GlyCosmos; Q9UHB4; 2 sites, 1 glycan. DR GlyGen; Q9UHB4; 2 sites, 1 O-linked glycan (2 sites). DR iPTMnet; Q9UHB4; -. DR PhosphoSitePlus; Q9UHB4; -. DR BioMuta; NDOR1; -. DR DMDM; 74735011; -. DR jPOST; Q9UHB4; -. DR MassIVE; Q9UHB4; -. DR PaxDb; 9606-ENSP00000360576; -. DR PeptideAtlas; Q9UHB4; -. DR ProteomicsDB; 12813; -. DR ProteomicsDB; 12819; -. DR ProteomicsDB; 84294; -. [Q9UHB4-1] DR ProteomicsDB; 84295; -. [Q9UHB4-2] DR Pumba; Q9UHB4; -. DR Antibodypedia; 18959; 224 antibodies from 25 providers. DR DNASU; 27158; -. DR Ensembl; ENST00000371521.8; ENSP00000360576.4; ENSG00000188566.16. [Q9UHB4-2] DR Ensembl; ENST00000427047.6; ENSP00000394309.1; ENSG00000188566.16. [Q9UHB4-3] DR Ensembl; ENST00000458322.2; ENSP00000389905.1; ENSG00000188566.16. [Q9UHB4-4] DR Ensembl; ENST00000684003.1; ENSP00000507194.1; ENSG00000188566.16. [Q9UHB4-1] DR GeneID; 27158; -. DR KEGG; hsa:27158; -. DR MANE-Select; ENST00000684003.1; ENSP00000507194.1; NM_014434.4; NP_055249.1. DR UCSC; uc004clw.4; human. [Q9UHB4-1] DR AGR; HGNC:29838; -. DR ClinPGx; PA134885020; -. DR CTD; 27158; -. DR DisGeNET; 27158; -. DR GeneCards; NDOR1; -. DR HGNC; HGNC:29838; NDOR1. DR HPA; ENSG00000188566; Low tissue specificity. DR MIM; 606073; gene. DR OpenTargets; ENSG00000188566; -. DR VEuPathDB; HostDB:ENSG00000188566; -. DR eggNOG; KOG1159; Eukaryota. DR GeneTree; ENSGT00930000151050; -. DR HOGENOM; CLU_001570_17_6_1; -. DR InParanoid; Q9UHB4; -. DR OMA; DIMSIPR; -. DR OrthoDB; 1856718at2759; -. DR PAN-GO; Q9UHB4; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q9UHB4; -. DR BRENDA; 1.5.1.30; 2681. DR PathwayCommons; Q9UHB4; -. DR Reactome; R-HSA-2564830; Cytosolic iron-sulfur cluster assembly. DR SignaLink; Q9UHB4; -. DR Agora; ENSG00000188566; -. DR BioGRID-ORCS; 27158; 656 hits in 1148 CRISPR screens. DR ChiTaRS; NDOR1; human. DR EvolutionaryTrace; Q9UHB4; -. DR GeneWiki; NDOR1; -. DR GenomeRNAi; 27158; -. DR Pharos; Q9UHB4; Tbio. DR PRO; PR:Q9UHB4; -. DR Proteomes; UP000005640; Chromosome 9. DR RNAct; Q9UHB4; protein. DR Bgee; ENSG00000188566; Expressed in granulocyte and 94 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0045111; C:intermediate filament cytoskeleton; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0009055; F:electron transfer activity; IDA:UniProtKB. DR GO; GO:0071949; F:FAD binding; IDA:UniProtKB. DR GO; GO:0050660; F:flavin adenine dinucleotide binding; IBA:GO_Central. DR GO; GO:0010181; F:FMN binding; IDA:UniProtKB. DR GO; GO:0050661; F:NADP binding; IDA:UniProtKB. DR GO; GO:0070402; F:NADPH binding; IDA:UniProtKB. DR GO; GO:0003958; F:NADPH-hemoprotein reductase activity; IDA:UniProtKB. DR GO; GO:0160246; F:NADPH-iron-sulfur [2Fe-2S] protein oxidoreductase activity; IDA:UniProtKB. DR GO; GO:0016491; F:oxidoreductase activity; IBA:GO_Central. DR GO; GO:0016653; F:oxidoreductase activity, acting on NAD(P)H, heme protein as acceptor; IDA:UniProtKB. DR GO; GO:0022900; P:electron transport chain; IDA:UniProtKB. DR GO; GO:0016226; P:iron-sulfur cluster assembly; TAS:ARUK-UCL. DR FunFam; 1.20.990.10:FF:000008; NADPH-dependent diflavin oxidoreductase 1; 1. DR FunFam; 3.40.50.360:FF:000015; NADPH-dependent diflavin oxidoreductase 1; 1. DR FunFam; 3.40.50.80:FF:000055; NADPH-dependent diflavin oxidoreductase 1; 1. DR Gene3D; 3.40.50.360; -; 1. DR Gene3D; 1.20.990.10; NADPH-cytochrome p450 Reductase, Chain A, domain 3; 1. DR Gene3D; 3.40.50.80; Nucleotide-binding domain of ferredoxin-NADP reductase (FNR) module; 1. DR Gene3D; 2.40.30.10; Translation factors; 1. DR HAMAP; MF_03178; NDOR1; 1. DR InterPro; IPR003097; CysJ-like_FAD-binding. DR InterPro; IPR017927; FAD-bd_FR_type. DR InterPro; IPR001094; Flavdoxin-like. DR InterPro; IPR008254; Flavodoxin/NO_synth. DR InterPro; IPR001709; Flavoprot_Pyr_Nucl_cyt_Rdtase. DR InterPro; IPR029039; Flavoprotein-like_sf. DR InterPro; IPR039261; FNR_nucleotide-bd. DR InterPro; IPR023173; NADPH_Cyt_P450_Rdtase_alpha. DR InterPro; IPR028879; NDOR1. DR InterPro; IPR001433; OxRdtase_FAD/NAD-bd. DR InterPro; IPR017938; Riboflavin_synthase-like_b-brl. DR PANTHER; PTHR19384:SF10; NADPH-DEPENDENT DIFLAVIN OXIDOREDUCTASE 1; 1. DR PANTHER; PTHR19384; NITRIC OXIDE SYNTHASE-RELATED; 1. DR Pfam; PF00667; FAD_binding_1; 1. DR Pfam; PF00258; Flavodoxin_1; 1. DR Pfam; PF00175; NAD_binding_1; 1. DR PRINTS; PR00369; FLAVODOXIN. DR PRINTS; PR00371; FPNCR. DR SUPFAM; SSF52343; Ferredoxin reductase-like, C-terminal NADP-linked domain; 1. DR SUPFAM; SSF52218; Flavoproteins; 1. DR SUPFAM; SSF63380; Riboflavin synthase domain-like; 1. DR PROSITE; PS51384; FAD_FR; 1. DR PROSITE; PS50902; FLAVODOXIN_LIKE; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Cytoplasm; Direct protein sequencing; KW FAD; Flavoprotein; FMN; NADP; Oxidoreductase; Proteomics identification; KW Reference proteome. FT CHAIN 1..597 FT /note="NADPH-dependent diflavin oxidoreductase 1" FT /id="PRO_0000319539" FT DOMAIN 6..150 FT /note="Flavodoxin-like" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178" FT DOMAIN 206..447 FT /note="FAD-binding FR-type" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178" FT REGION 188..207 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 12..17 FT /ligand="FMN" FT /ligand_id="ChEBI:CHEBI:58210" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178, FT ECO:0000269|PubMed:23596212" FT BINDING 59..62 FT /ligand="FMN" FT /ligand_id="ChEBI:CHEBI:58210" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178, FT ECO:0000269|PubMed:23596212" FT BINDING 97..106 FT /ligand="FMN" FT /ligand_id="ChEBI:CHEBI:58210" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178, FT ECO:0000269|PubMed:23596212" FT BINDING 132 FT /ligand="FMN" FT /ligand_id="ChEBI:CHEBI:58210" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178, FT ECO:0000269|PubMed:23596212" FT BINDING 350 FT /ligand="FAD" FT /ligand_id="ChEBI:CHEBI:57692" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178" FT BINDING 382..385 FT /ligand="FAD" FT /ligand_id="ChEBI:CHEBI:57692" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178" FT BINDING 416..419 FT /ligand="FAD" FT /ligand_id="ChEBI:CHEBI:57692" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178" FT BINDING 460 FT /ligand="NADP(+)" FT /ligand_id="ChEBI:CHEBI:58349" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178" FT BINDING 515..516 FT /ligand="NADP(+)" FT /ligand_id="ChEBI:CHEBI:58349" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178" FT BINDING 521..525 FT /ligand="NADP(+)" FT /ligand_id="ChEBI:CHEBI:58349" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178" FT BINDING 558 FT /ligand="NADP(+)" FT /ligand_id="ChEBI:CHEBI:58349" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178" FT BINDING 596 FT /ligand="FAD" FT /ligand_id="ChEBI:CHEBI:57692" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03178" FT VAR_SEQ 138..171 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_046313" FT VAR_SEQ 392..398 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000305" FT /id="VSP_053807" FT VAR_SEQ 518 FT /note="Q -> QPPALFSALQ (in isoform 2)" FT /evidence="ECO:0000303|PubMed:12871939" FT /id="VSP_031487" FT VAR_SEQ 543..597 FT /note="GAYFYLAGNAKSMPADVSEALMSIFQEEGGLCSPDAAAYLARLQQTRRFQTE FT TWA -> ATPSPCQRTSRKP (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_046314" FT VARIANT 522 FT /note="V -> I (in allele NDOR1*1; shows a decrease in FT affinity for NADPH and a reduction in ferricyanide FT reductase activity; dbSNP:rs62587579)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:15900210" FT /id="VAR_039010" FT STRAND 5..11 FT /evidence="ECO:0007829|PDB:4H2D" FT STRAND 13..15 FT /evidence="ECO:0007829|PDB:4H2D" FT HELIX 16..30 FT /evidence="ECO:0007829|PDB:4H2D" FT STRAND 34..39 FT /evidence="ECO:0007829|PDB:4H2D" FT TURN 40..42 FT /evidence="ECO:0007829|PDB:4H2D" FT HELIX 45..50 FT /evidence="ECO:0007829|PDB:4H2D" FT STRAND 52..59 FT /evidence="ECO:0007829|PDB:4H2D" FT HELIX 62..64 FT /evidence="ECO:0007829|PDB:4H2D" FT HELIX 68..70 FT /evidence="ECO:0007829|PDB:4H2D" FT HELIX 71..77 FT /evidence="ECO:0007829|PDB:4H2D" FT TURN 84..89 FT /evidence="ECO:0007829|PDB:4H2D" FT STRAND 91..98 FT /evidence="ECO:0007829|PDB:4H2D" FT STRAND 102..104 FT /evidence="ECO:0007829|PDB:4H2D" FT HELIX 107..118 FT /evidence="ECO:0007829|PDB:4H2D" FT STRAND 122..125 FT /evidence="ECO:0007829|PDB:4H2D" FT STRAND 128..131 FT /evidence="ECO:0007829|PDB:4H2D" FT TURN 135..138 FT /evidence="ECO:0007829|PDB:4H2D" FT HELIX 139..156 FT /evidence="ECO:0007829|PDB:4H2D" SQ SEQUENCE 597 AA; 66763 MW; 0D1340D7280A4D8F CRC64; MPSPQLLVLF GSQTGTAQDV SERLGREARR RRLGCRVQAL DSYPVVNLIN EPLVIFVCAT TGQGDPPDNM KNFWRFIFRK NLPSTALCQM DFAVLGLGDS SYAKFNFVAK KLHRRLLQLG GSALLPVCLG DDQHELGPDA AVDPWLRDLW DRVLGLYPPP PGLTEIPPGV PLPSKFTLLF LQEAPSTGSE GQRVAHPGSQ EPPSESKPFL APMISNQRVT GPSHFQDVRL IEFDILGSGI SFAAGDVVLI QPSNSAAHVQ RFCQVLGLDP DQLFMLQPRE PDVSSPTRLP QPCSMRHLVS HYLDIASVPR RSFFELLACL SLHELEREKL LEFSSAQGQE ELFEYCNRPR RTILEVLCDF PHTAAAIPPD YLLDLIPVIR PRAFSIASSL LTHPSRLQIL VAVVQFQTRL KEPRRGLCSS WLASLDPGQG PVRVPLWVRP GSLAFPETPD TPVIMVGPGT GVAPFRAAIQ ERVAQGQTGN FLFFGCRWRD QDFYWEAEWQ ELEKRDCLTL IPAFSREQEQ KVYVQHRLRE LGSLVWELLD RQGAYFYLAG NAKSMPADVS EALMSIFQEE GGLCSPDAAA YLARLQQTRR FQTETWA // ID NDRG1_HUMAN Reviewed; 394 AA. AC Q92597; B3KR80; B7Z446; O15207; Q6IBG2; Q9NYR6; Q9UK29; DT 15-JUL-1999, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1997, sequence version 1. DT 28-JAN-2026, entry version 219. DE RecName: Full=Protein NDRG1; DE AltName: Full=Differentiation-related gene 1 protein; DE Short=DRG-1; DE AltName: Full=N-myc downstream-regulated gene 1 protein; DE AltName: Full=Nickel-specific induction protein Cap43; DE AltName: Full=Reducing agents and tunicamycin-responsive protein; DE Short=RTP; DE AltName: Full=Rit42; GN Name=NDRG1; Synonyms=CAP43, DRG1, RTP; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INDUCTION, AND TISSUE SPECIFICITY. RC TISSUE=Umbilical vein endothelial cell; RX PubMed=8939898; DOI=10.1074/jbc.271.47.29659; RA Kokame K., Kato H., Miyata T.; RT "Homocysteine-respondent genes in vascular endothelial cells identified by RT differential display analysis. GRP78/BiP and novel genes."; RL J. Biol. Chem. 271:29659-29665(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INDUCTION, SUBCELLULAR LOCATION, RP AND TISSUE SPECIFICITY. RX PubMed=9251681; RA van Belzen N., Dinjens W.N.M., Diesveld M.P.G., Groen N.A., RA van der Made A.C.J., Nozawa Y., Vlietstra R., Trapman J., Bosman F.T.; RT "A novel gene which is up-regulated during colon epithelial cell RT differentiation and down-regulated in colorectal neoplasms."; RL Lab. Invest. 77:85-92(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND INDUCTION. RC TISSUE=Lung; RX PubMed=9605764; RA Zhou D., Salnikow K., Costa M.; RT "Cap43, a novel gene specifically induced by Ni2+ compounds."; RL Cancer Res. 58:2182-2189(1998). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INDUCTION. RX PubMed=10395947; DOI=10.1016/s0167-4889(99)00056-7; RA Piquemal D., Joulia D., Balaguer P., Basset A., Marti J., Commes T.; RT "Differential expression of the RTP/Drg1/Ndr1 gene product in proliferating RT and growth arrested cells."; RL Biochim. Biophys. Acta 1450:364-373(1999). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3). RC TISSUE=Brain, and Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16421571; DOI=10.1038/nature04406; RA Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M., RA Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L., RA Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S., RA Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A., RA Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III, RA Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., RA Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P., RA Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H., RA Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B., RA O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K., RA Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L., RA Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G., RA Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W., RA Platzer M., Shimizu N., Lander E.S.; RT "DNA sequence and analysis of human chromosome 8."; RL Nature 439:331-335(2006). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Kidney; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-21 (ISOFORM 1). RC TISSUE=Brain; RA Angelicheva D., Kalaydjieva L.; RL Submitted (FEB-2000) to the EMBL/GenBank/DDBJ databases. RN [11] RP PROTEIN SEQUENCE OF 4-19; 54-70; 133-148; 199-212; 286-300; 307-322; RP 328-341 AND 364-388, AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Fetal brain cortex; RA Lubec G., Chen W.-Q., Sun Y.; RL Submitted (DEC-2008) to UniProtKB. RN [12] RP FUNCTION, AND INDUCTION. RX PubMed=9766676; RA Kurdistani S.K., Arizti P., Reimer C.L., Sugrue M.M., Aaronson S.A., RA Lee S.W.; RT "Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 RT and DNA damage."; RL Cancer Res. 58:4439-4444(1998). RN [13] RP INVOLVEMENT IN CMT4D. RX PubMed=10831399; DOI=10.1086/302978; RA Kalaydjieva L., Gresham D., Gooding R., Heather L., Baas F., de Jonge R., RA Blechschmidt K., Angelicheva D., Chandler D., Worsley P., Rosenthal A., RA King R.H.M., Thomas P.K.; RT "N-myc downstream-regulated gene 1 is mutated in hereditary motor and RT sensory neuropathy-Lom."; RL Am. J. Hum. Genet. 67:47-58(2000). RN [14] RP PHOSPHORYLATION, AND SUBCELLULAR LOCATION. RX PubMed=10860807; DOI=10.1006/bbrc.2000.2833; RA Agarwala K.L., Kokame K., Kato H., Miyata T.; RT "Phosphorylation of RTP, an ER stress-responsive cytoplasmic protein."; RL Biochem. Biophys. Res. Commun. 272:641-647(2000). RN [15] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=12432451; DOI=10.1007/s00418-002-0460-9; RA Lachat P., Shaw P., Gebhard S., van Belzen N., Chaubert P., Bosman F.T.; RT "Expression of NDRG1, a differentiation-related gene, in human tissues."; RL Histochem. Cell Biol. 118:399-408(2002). RN [16] RP PHOSPHORYLATION AT THR-328; SER-330; THR-346; THR-356 AND THR-366. RX PubMed=15461589; DOI=10.1042/bj20041057; RA Murray J.T., Campbell D.G., Morrice N., Auld G.C., Shpiro N., Marquez R., RA Peggie M., Bain J., Bloomberg G.B., Grahammer F., Lang F., Wulff P., RA Kuhl D., Cohen P.; RT "Exploitation of KESTREL to identify NDRG family members as physiological RT substrates for SGK1 and GSK3."; RL Biochem. J. 384:477-488(2004). RN [17] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=15247272; DOI=10.1074/jbc.m400781200; RA Kim K.T., Ongusaha P.P., Hong Y.K., Kurdistani S.K., Nakamura M., Lu K.P., RA Lee S.W.; RT "Function of Drg1/Rit42 in p53-dependent mitotic spindle checkpoint."; RL J. Biol. Chem. 279:38597-38602(2004). RN [18] RP FUNCTION. RX PubMed=15377670; DOI=10.1074/jbc.m400386200; RA Stein S., Thomas E.K., Herzog B., Westfall M.D., Rocheleau J.V., RA Jackson R.S. II, Wang M., Liang P.; RT "NDRG1 is necessary for p53-dependent apoptosis."; RL J. Biol. Chem. 279:48930-48940(2004). RN [19] RP INTERACTION WITH APOA1; APOA2; PRA1 AND RTN1, AND POSSIBLE FUNCTION. RX PubMed=15922294; DOI=10.1016/j.bbrc.2005.05.050; RA Hunter M., Angelicheva D., Tournev I., Ingley E., Chan D.C., Watts G.F., RA Kremensky I., Kalaydjieva L.; RT "NDRG1 interacts with APO A-I and A-II and is a functional candidate for RT the HDL-C QTL on 8q24."; RL Biochem. Biophys. Res. Commun. 332:982-992(2005). RN [20] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-330 AND SER-333, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [22] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Prostate cancer; RX PubMed=17487921; DOI=10.1002/elps.200600782; RA Giorgianni F., Zhao Y., Desiderio D.M., Beranova-Giorgianni S.; RT "Toward a global characterization of the phosphoproteome in prostate cancer RT cells: identification of phosphoproteins in the LNCaP cell line."; RL Electrophoresis 28:2027-2034(2007). RN [23] RP SUBCELLULAR LOCATION, AND INDUCTION. RX PubMed=17316623; DOI=10.1016/j.febslet.2007.01.080; RA Sibold S., Roh V., Keogh A., Studer P., Tiffon C., Angst E., RA Vorburger S.A., Weimann R., Candinas D., Stroka D.; RT "Hypoxia increases cytoplasmic expression of NDRG1, but is insufficient for RT its membrane localization in human hepatocellular carcinoma."; RL FEBS Lett. 581:989-994(2007). RN [24] RP INTERACTION WITH RAB4A, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=17786215; DOI=10.1371/journal.pone.0000844; RA Kachhap S.K., Faith D., Qian D.Z., Shabbeer S., Galloway N.L., Pili R., RA Denmeade S.R., DeMarzo A.M., Carducci M.A.; RT "The N-Myc down regulated Gene1 (NDRG1) is a Rab4a effector involved in RT vesicular recycling of E-cadherin."; RL PLoS ONE 2:E844-E844(2007). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-326; SER-330; SER-333; RP SER-336; SER-364 AND THR-375, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [26] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [27] RP PHOSPHORYLATION AT THR-346; THR-356 AND THR-366. RX PubMed=18787837; DOI=10.1007/s00424-008-0587-1; RA Inglis S.K., Gallacher M., Brown S.G., McTavish N., Getty J., Husband E.M., RA Murray J.T., Wilson S.M.; RT "SGK1 activity in Na+ absorbing airway epithelial cells monitored by RT assaying NDRG1-Thr346/356/366 phosphorylation."; RL Pflugers Arch. 457:1287-1301(2009). RN [28] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-328 AND SER-330, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-333, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [30] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [31] RP PHOSPHORYLATION, AND SUBCELLULAR LOCATION. RX PubMed=21708134; DOI=10.1016/j.bbrc.2011.06.092; RA McCaig C., Potter L., Abramczyk O., Murray J.T.; RT "Phosphorylation of NDRG1 is temporally and spatially controlled during the RT cell cycle."; RL Biochem. Biophys. Res. Commun. 411:227-234(2011). RN [32] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2; THR-328; SER-330; SER-333; RP SER-336; SER-364; THR-366 AND THR-375, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-328; SER-332 AND SER-333, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). CC -!- FUNCTION: Stress-responsive protein involved in hormone responses, cell CC growth, and differentiation. Acts as a tumor suppressor in many cell CC types. Necessary but not sufficient for p53/TP53-mediated caspase CC activation and apoptosis. Has a role in cell trafficking, notably of CC the Schwann cell, and is necessary for the maintenance and development CC of the peripheral nerve myelin sheath. Required for vesicular recycling CC of CDH1 and TF. May also function in lipid trafficking. Protects cells CC from spindle disruption damage. Functions in p53/TP53-dependent mitotic CC spindle checkpoint. Regulates microtubule dynamics and maintains CC euploidy. {ECO:0000269|PubMed:15247272, ECO:0000269|PubMed:15377670, CC ECO:0000269|PubMed:17786215, ECO:0000269|PubMed:9766676}. CC -!- SUBUNIT: Interacts with RAB4A (membrane-bound form); the interaction CC involves NDRG1 in vesicular recycling of CDH1. CC {ECO:0000269|PubMed:15922294, ECO:0000269|PubMed:17786215}. CC -!- INTERACTION: CC Q92597; P05023: ATP1A1; NbExp=2; IntAct=EBI-716486, EBI-358778; CC Q92597; P27824: CANX; NbExp=2; IntAct=EBI-716486, EBI-355947; CC Q92597; Q9H6J7-2: CSTPP1; NbExp=3; IntAct=EBI-716486, EBI-13328871; CC Q92597; P35222: CTNNB1; NbExp=3; IntAct=EBI-716486, EBI-491549; CC Q92597; Q9H816: DCLRE1B; NbExp=3; IntAct=EBI-716486, EBI-3508943; CC Q92597; Q3SYB3: FOXD4L6; NbExp=3; IntAct=EBI-716486, EBI-6425864; CC Q92597; Q9BYZ2: LDHAL6B; NbExp=3; IntAct=EBI-716486, EBI-1108377; CC Q92597; Q9H204: MED28; NbExp=3; IntAct=EBI-716486, EBI-514199; CC Q92597; Q9Y3D2: MSRB2; NbExp=3; IntAct=EBI-716486, EBI-9092052; CC Q92597; Q6ZNA4-2: RNF111; NbExp=3; IntAct=EBI-716486, EBI-21535400; CC Q92597; Q8N488: RYBP; NbExp=3; IntAct=EBI-716486, EBI-752324; CC Q92597; O75446: SAP30; NbExp=3; IntAct=EBI-716486, EBI-632609; CC Q92597; Q99932-2: SPAG8; NbExp=3; IntAct=EBI-716486, EBI-11959123; CC Q92597; Q8IUW3: SPATA2L; NbExp=3; IntAct=EBI-716486, EBI-2510414; CC Q92597; Q6PID6: TTC33; NbExp=3; IntAct=EBI-716486, EBI-2555404; CC Q92597; P12956: XRCC6; NbExp=2; IntAct=EBI-716486, EBI-353208; CC Q92597; P61981: YWHAG; NbExp=3; IntAct=EBI-716486, EBI-359832; CC Q92597; Q96NC0: ZMAT2; NbExp=3; IntAct=EBI-716486, EBI-2682299; CC Q92597-3; Q9Y3D8: AK6; NbExp=3; IntAct=EBI-10278703, EBI-2896123; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol. Cytoplasm, cytoskeleton, CC microtubule organizing center, centrosome. Nucleus. Cell membrane. CC Note=Mainly cytoplasmic but differentially localized to other regions. CC Associates with the plasma membrane in intestinal epithelia and CC lactating mammary gland. Translocated to the nucleus in a p53/TP53- CC dependent manner. In prostate epithelium and placental chorion, located CC in both the cytoplasm and in the nucleus. No nuclear localization in CC colon epithelium cells. In intestinal mucosa, prostate and renal CC cortex, located predominantly adjacent to adherens junctions. CC Cytoplasmic with granular staining in proximal tubular cells of the CC kidney and salivary gland ducts. Recruits to the membrane of CC recycling/sorting and late endosomes via binding to CC phosphatidylinositol 4-phosphate. Associates with microtubules. CC Colocalizes with TUBG1 in the centrosome. Cytoplasmic location CC increased with hypoxia. Phosphorylated form found associated with CC centromeres during S-phase of mitosis and with the plasma membrane. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q92597-1; Sequence=Displayed; CC Name=2; CC IsoId=Q92597-2; Sequence=VSP_045038; CC Name=3; CC IsoId=Q92597-3; Sequence=VSP_045037; CC -!- TISSUE SPECIFICITY: Ubiquitous; expressed most prominently in placental CC membranes and prostate, kidney, small intestine, and ovary tissues. CC Also expressed in heart, brain, skeletal muscle, lung, liver and CC pancreas. Low levels in peripheral blood leukocytes and in tissues of CC the immune system. Expressed mainly in epithelial cells. Also found in CC Schwann cells of peripheral neurons. Reduced expression in CC adenocarcinomas compared to normal tissues. In colon, prostate and CC placental membranes, the cells that border the lumen show the highest CC expression. {ECO:0000269|PubMed:12432451, ECO:0000269|PubMed:8939898, CC ECO:0000269|PubMed:9251681, ECO:0000269|PubMed:9605764}. CC -!- INDUCTION: By homocysteine, 2-mercaptoethanol, tunicamycin in CC endothelial cells. Induced approximately 20-fold during in vitro CC differentiation of the colon carcinoma cell lines HT-29-D4 and Caco-2. CC Induced by oxidative stress in colon cancers. Decreased expression in CC colon adenomas and adenocarcinomas. Induced by nickel compounds in all CC tested cell lines. The primary signal for its induction is an elevation CC of free intracellular calcium ion caused by nickel ion exposure. CC Okadaic acid, a serine/threonine phosphatase inhibitor, induced its CC expression more rapidly and more efficiently than nickel. CC {ECO:0000269|PubMed:10395947, ECO:0000269|PubMed:17316623, CC ECO:0000269|PubMed:8939898, ECO:0000269|PubMed:9251681, CC ECO:0000269|PubMed:9605764, ECO:0000269|PubMed:9766676}. CC -!- PTM: Under stress conditions, phosphorylated in the C-terminal on many CC serine and threonine residues. Phosphorylated in vitro by PKA. CC Phosphorylation enhanced by increased intracellular cAMP levels. CC Homocysteine induces dephosphorylation. Phosphorylation by SGK1 is cell CC cycle dependent. {ECO:0000269|PubMed:10860807, CC ECO:0000269|PubMed:15461589, ECO:0000269|PubMed:18787837, CC ECO:0000269|PubMed:21708134}. CC -!- DISEASE: Charcot-Marie-Tooth disease, demyelinating, type 4D (CMT4D) CC [MIM:601455]: A recessive demyelinating form of Charcot-Marie-Tooth CC disease, a disorder of the peripheral nervous system, characterized by CC progressive weakness and atrophy, initially of the peroneal muscles and CC later of the distal muscles of the arms. Charcot-Marie-Tooth disease is CC classified in two main groups on the basis of electrophysiologic CC properties and histopathology: primary peripheral demyelinating CC neuropathies (designated CMT1 when they are dominantly inherited) and CC primary peripheral axonal neuropathies (CMT2). Demyelinating CC neuropathies are characterized by severely reduced nerve conduction CC velocities (less than 38 m/sec), segmental demyelination and CC remyelination with onion bulb formations on nerve biopsy, slowly CC progressive distal muscle atrophy and weakness, absent deep tendon CC reflexes, and hollow feet. By convention autosomal recessive forms of CC demyelinating Charcot-Marie-Tooth disease are designated CMT4. CC {ECO:0000269|PubMed:10831399}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the NDRG family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41512/NDRG1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D87953; BAA13505.1; -; mRNA. DR EMBL; X92845; CAA63430.1; -; mRNA. DR EMBL; AF004162; AAC13419.1; -; mRNA. DR EMBL; AF186190; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CR456842; CAG33123.1; -; mRNA. DR EMBL; AK091147; BAG52292.1; -; mRNA. DR EMBL; AK126924; BAG54400.1; -; mRNA. DR EMBL; AK296794; BAH12432.1; -; mRNA. DR EMBL; AF192304; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471060; EAW92164.1; -; Genomic_DNA. DR EMBL; BC003175; AAH03175.1; -; mRNA. DR EMBL; AF230380; AAF71305.1; -; mRNA. DR CCDS; CCDS34945.1; -. [Q92597-1] DR CCDS; CCDS59113.1; -. [Q92597-2] DR RefSeq; NP_001128714.1; NM_001135242.2. [Q92597-1] DR RefSeq; NP_001245361.1; NM_001258432.2. [Q92597-2] DR RefSeq; NP_001245362.1; NM_001258433.2. [Q92597-3] DR RefSeq; NP_001361774.1; NM_001374845.1. [Q92597-1] DR RefSeq; NP_001361775.1; NM_001374846.1. [Q92597-1] DR RefSeq; NP_001361776.1; NM_001374847.1. [Q92597-2] DR RefSeq; NP_006087.2; NM_006096.3. [Q92597-1] DR PDB; 6ZMM; X-ray; 2.96 A; A/B=31-319. DR PDBsum; 6ZMM; -. DR AlphaFoldDB; Q92597; -. DR SMR; Q92597; -. DR BioGRID; 115669; 247. DR FunCoup; Q92597; 1492. DR IntAct; Q92597; 165. DR MINT; Q92597; -. DR STRING; 9606.ENSP00000404854; -. DR ChEMBL; CHEMBL4295916; -. DR ESTHER; human-NDRG1; Ndr_family. DR MEROPS; S33.988; -. DR GlyGen; Q92597; 3 sites, 2 O-linked glycans (3 sites). DR iPTMnet; Q92597; -. DR MetOSite; Q92597; -. DR PhosphoSitePlus; Q92597; -. DR SwissPalm; Q92597; -. DR BioMuta; NDRG1; -. DR DMDM; 6166568; -. DR jPOST; Q92597; -. DR MassIVE; Q92597; -. DR PaxDb; 9606-ENSP00000404854; -. DR PeptideAtlas; Q92597; -. DR ProteomicsDB; 3585; -. DR ProteomicsDB; 6569; -. DR ProteomicsDB; 75343; -. [Q92597-1] DR Pumba; Q92597; -. DR TopDownProteomics; Q92597-1; -. [Q92597-1] DR Antibodypedia; 1521; 643 antibodies from 43 providers. DR DNASU; 10397; -. DR Ensembl; ENST00000323851.13; ENSP00000319977.8; ENSG00000104419.17. [Q92597-1] DR Ensembl; ENST00000414097.6; ENSP00000404854.2; ENSG00000104419.17. [Q92597-1] DR Ensembl; ENST00000522476.5; ENSP00000427894.1; ENSG00000104419.17. [Q92597-2] DR GeneID; 10397; -. DR KEGG; hsa:10397; -. DR MANE-Select; ENST00000323851.13; ENSP00000319977.8; NM_006096.4; NP_006087.2. DR UCSC; uc003yug.3; human. [Q92597-1] DR AGR; HGNC:7679; -. DR ClinPGx; PA31482; -. DR CTD; 10397; -. DR DisGeNET; 10397; -. DR GeneCards; NDRG1; -. DR GeneReviews; NDRG1; -. DR HGNC; HGNC:7679; NDRG1. DR HPA; ENSG00000104419; Low tissue specificity. DR MalaCards; NDRG1; -. DR MIM; 601455; phenotype. DR MIM; 605262; gene. DR OpenTargets; ENSG00000104419; -. DR Orphanet; 99950; Charcot-Marie-Tooth disease type 4D. DR VEuPathDB; HostDB:ENSG00000104419; -. DR eggNOG; KOG2931; Eukaryota. DR GeneTree; ENSGT00950000182872; -. DR HOGENOM; CLU_035361_1_0_1; -. DR InParanoid; Q92597; -. DR OMA; LVEKGEX; -. DR OrthoDB; 741027at2759; -. DR PAN-GO; Q92597; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q92597; -. DR PathwayCommons; Q92597; -. DR Reactome; R-HSA-6803205; TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain. DR SignaLink; Q92597; -. DR SIGNOR; Q92597; -. DR Agora; ENSG00000104419; -. DR BioGRID-ORCS; 10397; 11 hits in 1163 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; NDRG1; human. DR GeneWiki; NDRG1; -. DR GenomeRNAi; 10397; -. DR Pharos; Q92597; Tbio. DR PRO; PR:Q92597; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; Q92597; protein. DR Bgee; ENSG00000104419; Expressed in olfactory bulb and 205 other cell types or tissues. DR ExpressionAtlas; Q92597; baseline and differential. DR GO; GO:0005912; C:adherens junction; IDA:UniProtKB. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005874; C:microtubule; IDA:UniProtKB. DR GO; GO:0015630; C:microtubule cytoskeleton; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0055038; C:recycling endosome membrane; IDA:UniProtKB. DR GO; GO:0097229; C:sperm end piece; IDA:HPA. DR GO; GO:0120238; C:sperm glycocalyx; IDA:HPA. DR GO; GO:0120212; C:sperm head-tail coupling apparatus; IDA:HPA. DR GO; GO:0097225; C:sperm midpiece; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0045296; F:cadherin binding; IDA:UniProtKB. DR GO; GO:0043015; F:gamma-tubulin binding; IDA:UniProtKB. DR GO; GO:0008017; F:microtubule binding; IDA:UniProtKB. DR GO; GO:0016151; F:nickel cation binding; IPI:DisProt. DR GO; GO:0031267; F:small GTPase binding; IDA:UniProtKB. DR GO; GO:0071456; P:cellular response to hypoxia; IEP:UniProtKB. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; IEP:UniProtKB. DR GO; GO:0045576; P:mast cell activation; IEA:Ensembl. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl. DR GO; GO:0032287; P:peripheral nervous system myelin maintenance; IEA:Ensembl. DR GO; GO:0010038; P:response to metal ion; TAS:ProtInc. DR GO; GO:0007165; P:signal transduction; IBA:GO_Central. DR DisProt; DP03990; -. DR FunFam; 3.40.50.1820:FF:000006; NDRG family member 3; 1. DR Gene3D; 3.40.50.1820; alpha/beta hydrolase; 1. DR InterPro; IPR029058; AB_hydrolase_fold. DR InterPro; IPR004142; NDRG. DR PANTHER; PTHR11034; N-MYC DOWNSTREAM REGULATED; 1. DR Pfam; PF03096; Ndr; 1. DR SUPFAM; SSF53474; alpha/beta-Hydrolases; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Cell membrane; KW Charcot-Marie-Tooth disease; Cytoplasm; Cytoskeleton; KW Direct protein sequencing; Membrane; Microtubule; Neurodegeneration; KW Neuropathy; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:19413330" FT CHAIN 2..394 FT /note="Protein NDRG1" FT /id="PRO_0000159573" FT REPEAT 339..348 FT /note="1" FT REPEAT 349..358 FT /note="2" FT REPEAT 359..368 FT /note="3" FT REGION 325..394 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 339..368 FT /note="3 X 10 AA tandem repeats of G-T-R-S-R-S-H-T-S-E" FT COMPBIAS 327..339 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 345..371 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:19413330" FT MOD_RES 2 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 319 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62433" FT MOD_RES 326 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 328 FT /note="Phosphothreonine; by SGK1" FT /evidence="ECO:0000269|PubMed:15461589, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 330 FT /note="Phosphoserine; by SGK1" FT /evidence="ECO:0000269|PubMed:15461589, FT ECO:0007744|PubMed:16964243, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163" FT MOD_RES 332 FT /note="Phosphoserine; by SGK1" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 333 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 335 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q62433" FT MOD_RES 336 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 340 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q62433" FT MOD_RES 342 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62433" FT MOD_RES 346 FT /note="Phosphothreonine; by SGK1" FT /evidence="ECO:0000269|PubMed:15461589, FT ECO:0000269|PubMed:18787837" FT MOD_RES 352 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q6JE36" FT MOD_RES 356 FT /note="Phosphothreonine; by SGK1" FT /evidence="ECO:0000269|PubMed:15461589, FT ECO:0000269|PubMed:18787837" FT MOD_RES 362 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q6JE36" FT MOD_RES 364 FT /note="Phosphoserine; by SGK1" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 366 FT /note="Phosphothreonine; by SGK1" FT /evidence="ECO:0000269|PubMed:15461589, FT ECO:0000269|PubMed:18787837, ECO:0007744|PubMed:23186163" FT MOD_RES 375 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..81 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_045037" FT VAR_SEQ 1..66 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_045038" FT VARIANT 67 FT /note="M -> V (in dbSNP:rs2233319)" FT /id="VAR_050234" FT VARIANT 111 FT /note="M -> L (in dbSNP:rs2233328)" FT /id="VAR_050235" FT CONFLICT 145 FT /note="I -> T (in Ref. 2; CAA63430)" FT /evidence="ECO:0000305" FT STRAND 33..39 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 42..48 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 58..62 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 69..72 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 74..77 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 80..82 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 83..88 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 90..95 FT /evidence="ECO:0007829|PDB:6ZMM" FT TURN 97..99 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 115..120 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 122..128 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 134..139 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 141..152 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 154..156 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 157..164 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 187..195 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 209..217 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 221..232 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 255..260 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 266..274 FT /evidence="ECO:0007829|PDB:6ZMM" FT TURN 278..280 FT /evidence="ECO:0007829|PDB:6ZMM" FT STRAND 281..286 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 293..296 FT /evidence="ECO:0007829|PDB:6ZMM" FT HELIX 298..311 FT /evidence="ECO:0007829|PDB:6ZMM" SQ SEQUENCE 394 AA; 42835 MW; 4C816B9C85E3756F CRC64; MSREMQDVDL AEVKPLVEKG ETITGLLQEF DVQEQDIETL HGSVHVTLCG TPKGNRPVIL TYHDIGMNHK TCYNPLFNYE DMQEITQHFA VCHVDAPGQQ DGAASFPAGY MYPSMDQLAE MLPGVLQQFG LKSIIGMGTG AGAYILTRFA LNNPEMVEGL VLINVNPCAE GWMDWAASKI SGWTQALPDM VVSHLFGKEE MQSNVEVVHT YRQHIVNDMN PGNLHLFINA YNSRRDLEIE RPMPGTHTVT LQCPALLVVG DSSPAVDAVV ECNSKLDPTK TTLLKMADCG GLPQISQPAK LAEAFKYFVQ GMGYMPSASM TRLMRSRTAS GSSVTSLDGT RSRSHTSEGT RSRSHTSEGT RSRSHTSEGA HLDITPNSGA AGNSAGPKSM EVSC // ID NEK11_HUMAN Reviewed; 645 AA. AC Q8NG66; A6NHD7; Q5JPC0; Q8NG65; Q8TBY1; Q9H5F4; DT 13-SEP-2005, integrated into UniProtKB/Swiss-Prot. DT 30-NOV-2010, sequence version 2. DT 28-JAN-2026, entry version 181. DE RecName: Full=Serine/threonine-protein kinase Nek11; DE EC=2.7.11.1 {ECO:0000269|PubMed:12154088, ECO:0000269|PubMed:15161910}; DE AltName: Full=Never in mitosis A-related kinase 11; DE Short=NimA-related protein kinase 11; GN Name=NEK11 {ECO:0000312|HGNC:HGNC:18593}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305, ECO:0000312|EMBL:BAC06350.1} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, CATALYTIC RP ACTIVITY, COFACTOR, ACTIVITY REGULATION, DEVELOPMENTAL STAGE, TISSUE RP SPECIFICITY, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-61, AND VARIANT RP VAL-488. RC TISSUE=Cervix carcinoma; RX PubMed=12154088; DOI=10.1074/jbc.m204599200; RA Noguchi K., Fukazawa H., Murakami Y., Uehara Y.; RT "Nek11, a new member of the NIMA family of kinases, involved in DNA RT replication and genotoxic stress responses."; RL J. Biol. Chem. 277:39655-39665(2002). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4), AND VARIANT VAL-488. RC TISSUE=Cervix; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [4] {ECO:0000305, ECO:0000312|EMBL:CAI46114.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] {ECO:0000305, ECO:0000312|EMBL:AAH28587.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Testis {ECO:0000312|EMBL:AAH28587.1}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] {ECO:0000305, ECO:0000312|EMBL:BAB15672.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 162-645 (ISOFORM 1), AND VARIANT RP VAL-488. RC TISSUE=Lung {ECO:0000312|EMBL:BAB15672.1}; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] {ECO:0000305} RP CATALYTIC ACTIVITY, COFACTOR, SUBCELLULAR LOCATION, ACTIVITY REGULATION, RP AND INTERACTION WITH NEK2. RX PubMed=15161910; DOI=10.1074/jbc.m404104200; RA Noguchi K., Fukazawa H., Murakami Y., Uehara Y.; RT "Nucleolar Nek11 is a novel target of Nek2A in G1/S-arrested cells."; RL J. Biol. Chem. 279:32716-32727(2004). RN [8] RP FUNCTION, AND PHOSPHORYLATION AT SER-273. RX PubMed=19734889; DOI=10.1038/ncb1969; RA Melixetian M., Klein D.K., Soerensen C.S., Helin K.; RT "NEK11 regulates CDC25A degradation and the IR-induced G2/M checkpoint."; RL Nat. Cell Biol. 11:1247-1253(2009). RN [9] RP FUNCTION, AND PHOSPHORYLATION AT SER-273. RX PubMed=20090422; DOI=10.4161/cc.9.3.10513; RA Soerensen C.S., Melixetian M., Klein D.K., Helin K.; RT "NEK11: linking CHK1 and CDC25A in DNA damage checkpoint signaling."; RL Cell Cycle 9:450-455(2010). RN [10] RP VARIANTS [LARGE SCALE ANALYSIS] MET-108; CYS-123; LEU-213; VAL-263; RP LYS-451; VAL-488; LYS-492; THR-548; ALA-562; LYS-606 AND ASN-617. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Protein kinase which plays an important role in the G2/M CC checkpoint response to DNA damage. Controls degradation of CDC25A by CC directly phosphorylating it on residues whose phosphorylation is CC required for BTRC-mediated polyubiquitination and degradation. CC {ECO:0000269|PubMed:12154088, ECO:0000269|PubMed:19734889, CC ECO:0000269|PubMed:20090422}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12154088, ECO:0000269|PubMed:15161910}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12154088, ECO:0000269|PubMed:15161910}; CC -!- COFACTOR: CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; CC Evidence={ECO:0000269|PubMed:12154088, ECO:0000269|PubMed:15161910}; CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:12154088, ECO:0000269|PubMed:15161910}; CC -!- ACTIVITY REGULATION: Autorepressed by intramolecular binding of the C- CC terminus which dissociates following phosphorylation by NEK2 isoform 1 CC in G1/S-arrested cells. NEK2 isoform 2 is largely not present in the CC nucleolus, and does not appear to phosphorylate NEK11. Activated in CC response to DNA damage. Inhibited by zinc. CC {ECO:0000269|PubMed:12154088, ECO:0000269|PubMed:15161910}. CC -!- SUBUNIT: Interacts with isoform 1 of NEK2. CC {ECO:0000269|PubMed:15161910}. CC -!- INTERACTION: CC Q8NG66; P08238: HSP90AB1; NbExp=2; IntAct=EBI-633195, EBI-352572; CC Q8NG66; P51955: NEK2; NbExp=5; IntAct=EBI-633195, EBI-633182; CC Q8NG66; P51955-1: NEK2; NbExp=2; IntAct=EBI-633195, EBI-687792; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12154088}. Nucleus, CC nucleolus {ECO:0000269|PubMed:15161910}. Note=Nuclear during interphase CC but moves to the polar microtubules during prometaphase and metaphase CC (PubMed:12154088). Accumulates in the nucleolus in G1/S-arrested cells CC (PubMed:15161910). {ECO:0000269|PubMed:12154088, CC ECO:0000269|PubMed:15161910}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1 {ECO:0000269|PubMed:12154088}; Synonyms=Long CC {ECO:0000303|PubMed:12154088}; CC IsoId=Q8NG66-1; Sequence=Displayed; CC Name=2 {ECO:0000269|PubMed:12154088}; Synonyms=Short CC {ECO:0000303|PubMed:12154088}; CC IsoId=Q8NG66-2; Sequence=VSP_051821, VSP_051822; CC Name=3 {ECO:0000305}; CC IsoId=Q8NG66-3; Sequence=VSP_051820, VSP_051823; CC Name=4; CC IsoId=Q8NG66-4; Sequence=VSP_040080, VSP_040081; CC -!- TISSUE SPECIFICITY: Poorly expressed in cerebellum, trachea, lung, CC appendix, and uterus. {ECO:0000269|PubMed:12154088}. CC -!- DEVELOPMENTAL STAGE: Predominantly expressed at S/G2/M phase. CC {ECO:0000269|PubMed:12154088}. CC -!- PTM: Phosphorylated by NEK2. Phosphorylation at Ser-273 is important CC for its activation. {ECO:0000269|PubMed:19734889, CC ECO:0000269|PubMed:20090422}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. NEK Ser/Thr CC protein kinase family. NIMA subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAB15672.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB071996; BAC06350.1; -; mRNA. DR EMBL; AB071997; BAC06351.1; -; mRNA. DR EMBL; AL833472; CAI46114.1; -; mRNA. DR EMBL; AC055733; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471052; EAW79213.1; -; Genomic_DNA. DR EMBL; BC028587; AAH28587.1; -; mRNA. DR EMBL; AK027148; BAB15672.1; ALT_INIT; mRNA. DR CCDS; CCDS3069.1; -. [Q8NG66-1] DR CCDS; CCDS46915.1; -. [Q8NG66-2] DR CCDS; CCDS54639.1; -. [Q8NG66-4] DR CCDS; CCDS82836.1; -. [Q8NG66-3] DR RefSeq; NP_001139475.1; NM_001146003.2. [Q8NG66-4] DR RefSeq; NP_001308149.1; NM_001321220.2. [Q8NG66-1] DR RefSeq; NP_001308150.1; NM_001321221.1. DR RefSeq; NP_001308151.1; NM_001321222.1. DR RefSeq; NP_001308152.1; NM_001321223.1. [Q8NG66-3] DR RefSeq; NP_001308153.1; NM_001321224.1. DR RefSeq; NP_001339952.1; NM_001353023.2. [Q8NG66-1] DR RefSeq; NP_001339957.1; NM_001353028.2. [Q8NG66-4] DR RefSeq; NP_001339958.1; NM_001353029.2. [Q8NG66-4] DR RefSeq; NP_079076.3; NM_024800.4. [Q8NG66-1] DR RefSeq; NP_665917.1; NM_145910.4. [Q8NG66-2] DR RefSeq; XP_047304926.1; XM_047448970.1. [Q8NG66-1] DR RefSeq; XP_047304927.1; XM_047448971.1. [Q8NG66-1] DR RefSeq; XP_047304928.1; XM_047448972.1. [Q8NG66-1] DR RefSeq; XP_047304935.1; XM_047448979.1. [Q8NG66-2] DR RefSeq; XP_054203914.1; XM_054347939.1. [Q8NG66-2] DR AlphaFoldDB; Q8NG66; -. DR SMR; Q8NG66; -. DR BioGRID; 122947; 36. DR CORUM; Q8NG66; -. DR FunCoup; Q8NG66; 986. DR IntAct; Q8NG66; 16. DR STRING; 9606.ENSP00000372857; -. DR BindingDB; Q8NG66; -. DR ChEMBL; CHEMBL5638; -. DR DrugBank; DB08912; Dabrafenib. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q8NG66; -. DR GuidetoPHARMACOLOGY; 2116; -. DR iPTMnet; Q8NG66; -. DR PhosphoSitePlus; Q8NG66; -. DR BioMuta; NEK11; -. DR DMDM; 313104142; -. DR CPTAC; non-CPTAC-5648; -. DR CPTAC; non-CPTAC-5649; -. DR jPOST; Q8NG66; -. DR MassIVE; Q8NG66; -. DR PaxDb; 9606-ENSP00000372857; -. DR PeptideAtlas; Q8NG66; -. DR ProteomicsDB; 73438; -. [Q8NG66-1] DR ProteomicsDB; 73439; -. [Q8NG66-2] DR ProteomicsDB; 73440; -. [Q8NG66-3] DR ProteomicsDB; 73441; -. [Q8NG66-4] DR Antibodypedia; 2071; 293 antibodies from 25 providers. DR DNASU; 79858; -. DR Ensembl; ENST00000356918.8; ENSP00000349389.5; ENSG00000114670.15. [Q8NG66-2] DR Ensembl; ENST00000383366.9; ENSP00000372857.4; ENSG00000114670.15. [Q8NG66-1] DR Ensembl; ENST00000507910.5; ENSP00000426662.1; ENSG00000114670.15. [Q8NG66-3] DR Ensembl; ENST00000508196.5; ENSP00000421851.1; ENSG00000114670.15. [Q8NG66-1] DR Ensembl; ENST00000510688.5; ENSP00000423458.1; ENSG00000114670.15. [Q8NG66-4] DR Ensembl; ENST00000511262.5; ENSP00000425114.1; ENSG00000114670.15. [Q8NG66-2] DR GeneID; 79858; -. DR KEGG; hsa:79858; -. DR MANE-Select; ENST00000383366.9; ENSP00000372857.4; NM_024800.5; NP_079076.3. DR UCSC; uc003enx.4; human. [Q8NG66-1] DR AGR; HGNC:18593; -. DR ClinPGx; PA38595; -. DR CTD; 79858; -. DR DisGeNET; 79858; -. DR GeneCards; NEK11; -. DR HGNC; HGNC:18593; NEK11. DR HPA; ENSG00000114670; Tissue enhanced (choroid). DR MIM; 609779; gene. DR OpenTargets; ENSG00000114670; -. DR VEuPathDB; HostDB:ENSG00000114670; -. DR eggNOG; KOG0589; Eukaryota. DR GeneTree; ENSGT00940000160525; -. DR HOGENOM; CLU_000288_63_39_1; -. DR InParanoid; Q8NG66; -. DR OrthoDB; 248923at2759; -. DR PAN-GO; Q8NG66; 8 GO annotations based on evolutionary models. DR PhylomeDB; Q8NG66; -. DR PathwayCommons; Q8NG66; -. DR SignaLink; Q8NG66; -. DR SIGNOR; Q8NG66; -. DR Agora; ENSG00000114670; -. DR BioGRID-ORCS; 79858; 11 hits in 1182 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; NEK11; human. DR GenomeRNAi; 79858; -. DR Pharos; Q8NG66; Tchem. DR PRO; PR:Q8NG66; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q8NG66; protein. DR Bgee; ENSG00000114670; Expressed in right uterine tube and 137 other cell types or tissues. DR ExpressionAtlas; Q8NG66; baseline and differential. DR GO; GO:0005730; C:nucleolus; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0031573; P:mitotic intra-S DNA damage checkpoint signaling; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:1901990; P:regulation of mitotic cell cycle phase transition; IMP:CACAO. DR CDD; cd08222; STKc_Nek11; 1. DR FunFam; 1.10.510.10:FF:000436; NIMA related kinase 11; 1. DR FunFam; 3.30.200.20:FF:000332; NIMA related kinase 11; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR051131; NEK_Ser/Thr_kinase_NIMA. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR44899; CAMK FAMILY PROTEIN KINASE; 1. DR PANTHER; PTHR44899:SF8; NIMA-RELATED KINASE 11; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cell cycle; Coiled coil; Kinase; KW Magnesium; Manganese; Metal-binding; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..645 FT /note="Serine/threonine-protein kinase Nek11" FT /id="PRO_0000086438" FT DOMAIN 29..287 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 399..445 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 346..385 FT /evidence="ECO:0000250|UniProtKB:P51957, ECO:0000255" FT ACT_SITE 158 FT /note="Proton acceptor" FT /evidence="ECO:0000250|UniProtKB:P51957, FT ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE- FT ProRule:PRU10027" FT BINDING 35..43 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:P51957, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 61 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000269|PubMed:12154088" FT MOD_RES 273 FT /note="Phosphoserine; by CHEK1" FT /evidence="ECO:0000269|PubMed:19734889, FT ECO:0000269|PubMed:20090422" FT VAR_SEQ 467..482 FT /note="EIPEDPLVAEEYYADA -> GDCNLISLDEYWKNEK (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_051820" FT VAR_SEQ 467..470 FT /note="EIPE -> ATHS (in isoform 2)" FT /evidence="ECO:0000303|PubMed:12154088" FT /id="VSP_051821" FT VAR_SEQ 471..645 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:12154088" FT /id="VSP_051822" FT VAR_SEQ 483..645 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_051823" FT VAR_SEQ 542..599 FT /note="TKTITTMAEDMSPGPPIFNSVMARTKMKRMRESAMQKLGTEVFEEVYNYLKR FT ARHQNA -> QPCRSWGQKYLKRSIITSREQGIRMLAKQRSASVWKKWCLKPATVLKWT FT SSCTLKSSC (in isoform 4)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_040080" FT VAR_SEQ 600..645 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_040081" FT VARIANT 108 FT /note="T -> M (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs200709914)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040935" FT VARIANT 123 FT /note="Y -> C (in dbSNP:rs55806123)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040936" FT VARIANT 213 FT /note="S -> L (in dbSNP:rs55920129)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040937" FT VARIANT 263 FT /note="I -> V (in dbSNP:rs35567155)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040938" FT VARIANT 451 FT /note="E -> K (in dbSNP:rs35409692)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040939" FT VARIANT 488 FT /note="E -> V (in dbSNP:rs3738000)" FT /evidence="ECO:0000269|PubMed:12154088, FT ECO:0000269|PubMed:14702039, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:17974005" FT /id="VAR_040940" FT VARIANT 492 FT /note="E -> K (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs140599545)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040941" FT VARIANT 548 FT /note="M -> T (in dbSNP:rs55813244)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040942" FT VARIANT 562 FT /note="V -> A (in dbSNP:rs16836266)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_033907" FT VARIANT 606 FT /note="E -> K (in dbSNP:rs55944737)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040943" FT VARIANT 617 FT /note="D -> N (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs765563230)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040944" FT MUTAGEN 61 FT /note="K->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:12154088" SQ SEQUENCE 645 AA; 74192 MW; 7D11AE1D89711DEC CRC64; MLKFQEAAKC VSGSTAISTY PKTLIARRYV LQQKLGSGSF GTVYLVSDKK AKRGEELKVL KEISVGELNP NETVQANLEA QLLSKLDHPA IVKFHASFVE QDNFCIITEY CEGRDLDDKI QEYKQAGKIF PENQIIEWFI QLLLGVDYMH ERRILHRDLK SKNVFLKNNL LKIGDFGVSR LLMGSCDLAT TLTGTPHYMS PEALKHQGYD TKSDIWSLAC ILYEMCCMNH AFAGSNFLSI VLKIVEGDTP SLPERYPKEL NAIMESMLNK NPSLRPSAIE ILKIPYLDEQ LQNLMCRYSE MTLEDKNLDC QKEAAHIINA MQKRIHLQTL RALSEVQKMT PRERMRLRKL QAADEKARKL KKIVEEKYEE NSKRMQELRS RNFQQLSVDV LHEKTHLKGM EEKEEQPEGR LSCSPQDEDE ERWQGREEES DEPTLENLPE SQPIPSMDLH ELESIVEDAT SDLGYHEIPE DPLVAEEYYA DAFDSYCEES DEEEEEIALE RPEKEIRNEG SQPAYRTNQQ DSDIEALARC LENVLGCTSL DTKTITTMAE DMSPGPPIFN SVMARTKMKR MRESAMQKLG TEVFEEVYNY LKRARHQNAS EAEIRECLEK VVPQASDCFE VDQLLYFEEQ LLITMGKEPT LQNHL // ID NEK1_HUMAN Reviewed; 1258 AA. AC Q96PY6; G5E9Z3; Q05DG5; Q14CB7; Q5H9T1; Q6PIB8; Q96SS2; Q9H6P7; Q9Y594; DT 13-AUG-2002, integrated into UniProtKB/Swiss-Prot. DT 13-AUG-2002, sequence version 2. DT 28-JAN-2026, entry version 212. DE RecName: Full=Serine/threonine-protein kinase Nek1; DE EC=2.7.11.1 {ECO:0000269|PubMed:20230784}; DE AltName: Full=Never in mitosis A-related kinase 1; DE Short=NimA-related protein kinase 1; DE AltName: Full=Renal carcinoma antigen NY-REN-55; GN Name=NEK1; Synonyms=KIAA1901; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=11572484; DOI=10.1093/dnares/8.4.179; RA Nagase T., Kikuno R., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XXI. The RT complete sequences of 60 new cDNA clones from brain which code for large RT proteins."; RL DNA Res. 8:179-187(2001). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT GLY-724. RC TISSUE=Uterus; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4). RC TISSUE=Bone marrow, and Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 91-1258 (ISOFORM 5), AND RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 865-1258. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 444-1258 (ISOFORM 2), AND IDENTIFICATION AS A RP RENAL CANCER ANTIGEN. RC TISSUE=Renal cell carcinoma; RX PubMed=10508479; RX DOI=10.1002/(sici)1097-0215(19991112)83:4<456::aid-ijc4>3.0.co;2-5; RA Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H., RA Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T., RA Old L.J.; RT "Antigens recognized by autologous antibody in patients with renal-cell RT carcinoma."; RL Int. J. Cancer 83:456-464(1999). RN [8] RP SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=15604234; DOI=10.1158/0008-5472.can-04-2243; RA Polci R., Peng A., Chen P.L., Riley D.J., Chen Y.; RT "NIMA-related protein kinase 1 is involved early in the ionizing radiation- RT induced DNA damage response."; RL Cancer Res. 64:8800-8803(2004). RN [9] RP SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=18843199; DOI=10.4161/cc.7.20.6815; RA Chen Y., Chen P.L., Chen C.F., Jiang X., Riley D.J.; RT "Never-in-mitosis related kinase 1 functions in DNA damage response and RT checkpoint control."; RL Cell Cycle 7:3194-3201(2008). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-414; SER-418; SER-428; RP SER-653; SER-798; SER-834; SER-868 AND SER-881, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [13] RP FUNCTION IN PHOSPHORYLATION OF VDAC1, AND CATALYTIC ACTIVITY. RX PubMed=20230784; DOI=10.1016/j.bbrc.2010.03.077; RA Chen Y., Gaczynska M., Osmulski P., Polci R., Riley D.J.; RT "Phosphorylation by Nek1 regulates opening and closing of voltage dependent RT anion channel 1."; RL Biochem. Biophys. Res. Commun. 394:798-803(2010). RN [14] RP FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND INVOLVEMENT IN RP DIGENIC SHORT-RIB THORACIC DYSPLASIA 3/6 WITH POLYDACTYLY. RX PubMed=21211617; DOI=10.1016/j.ajhg.2010.12.004; RA Thiel C., Kessler K., Giessl A., Dimmler A., Shalev S.A., von der Haar S., RA Zenker M., Zahnleiter D., Stoess H., Beinder E., Abou Jamra R., Ekici A.B., RA Schroeder-Kress N., Aigner T., Kirchner T., Reis A., Brandstaetter J.H., RA Rauch A.; RT "NEK1 mutations cause short-rib polydactyly syndrome type majewski."; RL Am. J. Hum. Genet. 88:106-114(2011). RN [15] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-156; SER-428; THR-661; RP SER-664; SER-868; SER-881 AND SER-1052, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1052, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [18] RP IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN A COMPLEX WITH RP CFAP410 AND SPATA7 BY MASS SPECTROMETRY, AND INTERACTION WITH CFAP410. RX PubMed=26167768; DOI=10.1038/ncb3201; RG UK10K Consortium; RG University of Washington Center for Mendelian Genomics; RA Wheway G., Schmidts M., Mans D.A., Szymanska K., Nguyen T.M., Racher H., RA Phelps I.G., Toedt G., Kennedy J., Wunderlich K.A., Sorusch N., RA Abdelhamed Z.A., Natarajan S., Herridge W., van Reeuwijk J., Horn N., RA Boldt K., Parry D.A., Letteboer S.J., Roosing S., Adams M., Bell S.M., RA Bond J., Higgins J., Morrison E.E., Tomlinson D.C., Slaats G.G., RA van Dam T.J., Huang L., Kessler K., Giessl A., Logan C.V., Boyle E.A., RA Shendure J., Anazi S., Aldahmesh M., Al Hazzaa S., Hegele R.A., Ober C., RA Frosk P., Mhanni A.A., Chodirker B.N., Chudley A.E., Lamont R., RA Bernier F.P., Beaulieu C.L., Gordon P., Pon R.T., Donahue C., RA Barkovich A.J., Wolf L., Toomes C., Thiel C.T., Boycott K.M., McKibbin M., RA Inglehearn C.F., Stewart F., Omran H., Huynen M.A., Sergouniotis P.I., RA Alkuraya F.S., Parboosingh J.S., Innes A.M., Willoughby C.E., Giles R.H., RA Webster A.R., Ueffing M., Blacque O., Gleeson J.G., Wolfrum U., RA Beales P.L., Gibson T., Doherty D., Mitchison H.M., Roepman R., RA Johnson C.A.; RT "An siRNA-based functional genomics screen for the identification of RT regulators of ciliogenesis and ciliopathy genes."; RL Nat. Cell Biol. 17:1074-1087(2015). RN [19] RP INVOLVEMENT IN OFD2, AND VARIANTS OFD2 THR-155 AND 409-TRP--GLU-1258 DEL. RX PubMed=27530628; DOI=10.1038/ejhg.2016.103; RA Monroe G.R., Kappen I.F., Stokman M.F., Terhal P.A., van den Boogaard M.H., RA Savelberg S.M., van der Veken L.T., van Es R.J., Lens S.M., Hengeveld R.C., RA Creton M.A., Janssen N.G., Mink van der Molen A.B., Ebbeling M.B., RA Giles R.H., Knoers N.V., van Haaften G.; RT "Compound heterozygous NEK1 variants in two siblings with oral-facial- RT digital syndrome type II (Mohr syndrome)."; RL Eur. J. Hum. Genet. 24:1752-1760(2016). RN [20] RP VARIANTS [LARGE SCALE ANALYSIS] PHE-10; LYS-25; VAL-76; PRO-294; GLY-355; RP VAL-463; THR-598; GLY-724; ASN-745; GLU-883 AND ASN-1180. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [21] RP VARIANTS SRTD6 ARG-145 AND SER-253. RX PubMed=22499340; DOI=10.1136/jmedgenet-2011-100717; RA El Hokayem J., Huber C., Couve A., Aziza J., Baujat G., Bouvier R., RA Cavalcanti D.P., Collins F.A., Cordier M.P., Delezoide A.L., Gonzales M., RA Johnson D., Le Merrer M., Levy-Mozziconacci A., Loget P., RA Martin-Coignard D., Martinovic J., Mortier G.R., Perez M.J., Roume J., RA Scarano G., Munnich A., Cormier-Daire V.; RT "NEK1 and DYNC2H1 are both involved in short rib polydactyly Majewski type RT but not in Beemer Langer cases."; RL J. Med. Genet. 49:227-233(2012). RN [22] RP INVOLVEMENT IN ALS24, AND VARIANTS 784-ARG--GLU-1258 DEL AND RP 1008-SER--GLU-1258 DEL. RX PubMed=26945885; DOI=10.1093/brain/aww033; RA Brenner D., Mueller K., Wieland T., Weydt P., Boehm S., Lule D., RA Huebers A., Neuwirth C., Weber M., Borck G., Wahlqvist M., Danzer K.M., RA Volk A.E., Meitinger T., Strom T.M., Otto M., Kassubek J., Ludolph A.C., RA Andersen P.M., Weishaupt J.H.; RT "NEK1 mutations in familial amyotrophic lateral sclerosis."; RL Brain 139:E28-E28(2016). RN [23] RP INVOLVEMENT IN ALS24, AND VARIANTS HIS-261 AND 550-ARG--GLU-1258 DEL. RX PubMed=27455347; DOI=10.1038/ng.3626; RA Kenna K.P., van Doormaal P.T., Dekker A.M., Ticozzi N., Kenna B.J., RA Diekstra F.P., van Rheenen W., van Eijk K.R., Jones A.R., Keagle P., RA Shatunov A., Sproviero W., Smith B.N., van Es M.A., Topp S.D., Kenna A., RA Miller J.W., Fallini C., Tiloca C., McLaughlin R.L., Vance C., Troakes C., RA Colombrita C., Mora G., Calvo A., Verde F., Al-Sarraj S., King A., RA Calini D., de Belleroche J., Baas F., van der Kooi A.J., de Visser M., RA Ten Asbroek A.L., Sapp P.C., McKenna-Yasek D., Polak M., Asress S., RA Munoz-Blanco J.L., Strom T.M., Meitinger T., Morrison K.E., Lauria G., RA Williams K.L., Leigh P.N., Nicholson G.A., Blair I.P., Leblond C.S., RA Dion P.A., Rouleau G.A., Pall H., Shaw P.J., Turner M.R., Talbot K., RA Taroni F., Boylan K.B., Van Blitterswijk M., Rademakers R., RA Esteban-Perez J., Garcia-Redondo A., Van Damme P., Robberecht W., Chio A., RA Gellera C., Drepper C., Sendtner M., Ratti A., Glass J.D., Mora J.S., RA Basak N.A., Hardiman O., Ludolph A.C., Andersen P.M., Weishaupt J.H., RA Brown R.H. Jr., Al-Chalabi A., Silani V., Shaw C.E., van den Berg L.H., RA Veldink J.H., Landers J.E.; RT "NEK1 variants confer susceptibility to amyotrophic lateral sclerosis."; RL Nat. Genet. 48:1037-1042(2016). CC -!- FUNCTION: Phosphorylates serines and threonines, but also appears to CC possess tyrosine kinase activity (PubMed:20230784). Involved in DNA CC damage checkpoint control and for proper DNA damage repair CC (PubMed:20230784). In response to injury that includes DNA damage, NEK1 CC phosphorylates VDAC1 to limit mitochondrial cell death CC (PubMed:20230784). May be implicated in the control of meiosis (By CC similarity). Involved in cilium assembly (PubMed:21211617). CC {ECO:0000250|UniProtKB:P51954, ECO:0000269|PubMed:20230784, CC ECO:0000269|PubMed:21211617}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:20230784}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:20230784}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- SUBUNIT: Binds to CBY2 (By similarity). Found in a complex with CC CFAP410, NEK1 and SPATA7 (PubMed:26167768). Interacts with CFAP410 CC (PubMed:26167768). Interacts (via Ser-1052 phosphorylated form) with CC 14-3-3 proteins (By similarity). {ECO:0000250|UniProtKB:P51954, CC ECO:0000269|PubMed:26167768}. CC -!- INTERACTION: CC Q96PY6; Q96Q42: ALS2; NbExp=2; IntAct=EBI-373615, EBI-1044902; CC Q96PY6; Q99689: FEZ1; NbExp=2; IntAct=EBI-373615, EBI-396435; CC Q96PY6; Q9UHY8: FEZ2; NbExp=2; IntAct=EBI-373615, EBI-396453; CC Q96PY6; Q5S007: LRRK2; NbExp=2; IntAct=EBI-373615, EBI-5323863; CC Q96PY6; Q04917: YWHAH; NbExp=6; IntAct=EBI-373615, EBI-306940; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15604234, CC ECO:0000305|PubMed:21211617}. Cytoplasm, cytoskeleton, microtubule CC organizing center, centrosome {ECO:0000250|UniProtKB:P51954}. Cytoplasm CC {ECO:0000269|PubMed:18843199}. Note=Associated with the pericentriolar CC material (PubMed:21211617). Localizes to centrosome during interphase CC and mitosis (By similarity). Translocated from cytoplasm to discrete CC nuclear foci at sites of DNA damage (PubMed:15604234). CC {ECO:0000250|UniProtKB:P51954, ECO:0000269|PubMed:15604234, CC ECO:0000269|PubMed:21211617}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=6; CC Name=1; CC IsoId=Q96PY6-1; Sequence=Displayed; CC Name=2; CC IsoId=Q96PY6-2; Sequence=VSP_004870; CC Name=3; CC IsoId=Q96PY6-3; Sequence=VSP_035439; CC Name=4; CC IsoId=Q96PY6-4; Sequence=VSP_035435, VSP_035436; CC Name=5; CC IsoId=Q96PY6-5; Sequence=VSP_035437, VSP_035438; CC Name=6; CC IsoId=Q96PY6-6; Sequence=VSP_035436, VSP_035439; CC -!- TISSUE SPECIFICITY: High fetal expression in the brain and kidney. CC {ECO:0000269|PubMed:21211617}. CC -!- DISEASE: Short-rib thoracic dysplasia 6 with or without polydactyly CC (SRTD6) [MIM:263520]: A form of short-rib thoracic dysplasia, a group CC of autosomal recessive ciliopathies that are characterized by a CC constricted thoracic cage, short ribs, shortened tubular bones, and a CC 'trident' appearance of the acetabular roof. Polydactyly is variably CC present. Non-skeletal involvement can include cleft lip/palate as well CC as anomalies of major organs such as the brain, eye, heart, kidneys, CC liver, pancreas, intestines, and genitalia. Some forms of the disease CC are lethal in the neonatal period due to respiratory insufficiency CC secondary to a severely restricted thoracic cage, whereas others are CC compatible with life. Disease spectrum encompasses Ellis-van Creveld CC syndrome, asphyxiating thoracic dystrophy (Jeune syndrome), Mainzer- CC Saldino syndrome, and short rib-polydactyly syndrome. CC {ECO:0000269|PubMed:22499340}. Note=The disease is caused by variants CC affecting the gene represented in this entry. In some cases NEK1 CC mutations result in disease phenotype in the presence of mutations in CC DYNC2H1 indicating digenic inheritance (digenic short rib-polydactyly CC syndrome 3/6 with polydactyly) (PubMed:21211617). CC {ECO:0000269|PubMed:21211617}. CC -!- DISEASE: Amyotrophic lateral sclerosis 24 (ALS24) [MIM:617892]: A form CC of amyotrophic lateral sclerosis, a neurodegenerative disorder CC affecting upper motor neurons in the brain and lower motor neurons in CC the brain stem and spinal cord, resulting in fatal paralysis. Sensory CC abnormalities are absent. The pathologic hallmarks of the disease CC include pallor of the corticospinal tract due to loss of motor neurons, CC presence of ubiquitin-positive inclusions within surviving motor CC neurons, and deposition of pathologic aggregates. The etiology of CC amyotrophic lateral sclerosis is likely to be multifactorial, involving CC both genetic and environmental factors. The disease is inherited in 5- CC 10% of the cases. {ECO:0000269|PubMed:26945885, CC ECO:0000269|PubMed:27455347}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Orofaciodigital syndrome 2 (OFD2) [MIM:252100]: A form of CC orofaciodigital syndrome, a group of heterogeneous disorders CC characterized by malformations of the oral cavity, face and digits, and CC associated phenotypic abnormalities that lead to the delineation of CC various subtypes. OFD2 is an autosomal recessive form characterized by CC cleft lip/palate, lobulated tongue with nodules, dental anomalies, CC maxillary hypoplasia, conductive hearing loss, polydactyly, syndactyly, CC brachydactyly, and mesomelic lower limb shortening. CC {ECO:0000269|PubMed:27530628}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. NEK Ser/Thr CC protein kinase family. NIMA subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH15147.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305}; CC Sequence=BAB15207.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAB55209.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAB67794.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB067488; BAB67794.1; ALT_INIT; mRNA. DR EMBL; CR933642; CAI45943.1; -; mRNA. DR EMBL; AC116615; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC116621; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC084724; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471056; EAX04791.1; -; Genomic_DNA. DR EMBL; BC015147; AAH15147.1; ALT_SEQ; mRNA. DR EMBL; BC037790; AAH37790.1; -; mRNA. DR EMBL; BC114491; AAI14492.1; -; mRNA. DR EMBL; AK025658; BAB15207.1; ALT_INIT; mRNA. DR EMBL; AK027580; BAB55209.1; ALT_INIT; mRNA. DR EMBL; AF155113; AAD42879.1; -; mRNA. DR CCDS; CCDS47162.1; -. [Q96PY6-1] DR CCDS; CCDS56348.1; -. [Q96PY6-4] DR CCDS; CCDS56349.1; -. [Q96PY6-2] DR CCDS; CCDS56350.1; -. [Q96PY6-6] DR CCDS; CCDS56351.1; -. [Q96PY6-3] DR RefSeq; NP_001186326.1; NM_001199397.3. [Q96PY6-3] DR RefSeq; NP_001186327.1; NM_001199398.3. [Q96PY6-6] DR RefSeq; NP_001186328.1; NM_001199399.3. [Q96PY6-4] DR RefSeq; NP_001186329.1; NM_001199400.3. [Q96PY6-2] DR RefSeq; NP_001361347.1; NM_001374418.1. [Q96PY6-3] DR RefSeq; NP_001361348.1; NM_001374419.1. [Q96PY6-1] DR RefSeq; NP_036356.1; NM_012224.4. [Q96PY6-1] DR RefSeq; XP_011530306.1; XM_011532004.2. [Q96PY6-2] DR RefSeq; XP_047271687.1; XM_047415731.1. [Q96PY6-6] DR PDB; 4APC; X-ray; 2.10 A; A/B=1-328. DR PDB; 4B9D; X-ray; 1.90 A; A/B=1-328. DR PDBsum; 4APC; -. DR PDBsum; 4B9D; -. DR AlphaFoldDB; Q96PY6; -. DR SMR; Q96PY6; -. DR BioGRID; 110825; 92. DR CORUM; Q96PY6; -. DR FunCoup; Q96PY6; 4026. DR IntAct; Q96PY6; 63. DR MINT; Q96PY6; -. DR STRING; 9606.ENSP00000424757; -. DR BindingDB; Q96PY6; -. DR ChEMBL; CHEMBL5855; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q96PY6; -. DR GuidetoPHARMACOLOGY; 2114; -. DR GlyGen; Q96PY6; 3 sites, 2 N-linked glycans (2 sites), 1 O-linked glycan (1 site). DR iPTMnet; Q96PY6; -. DR PhosphoSitePlus; Q96PY6; -. DR BioMuta; NEK1; -. DR DMDM; 22256934; -. DR jPOST; Q96PY6; -. DR MassIVE; Q96PY6; -. DR PaxDb; 9606-ENSP00000424757; -. DR PeptideAtlas; Q96PY6; -. DR ProteomicsDB; 34091; -. DR ProteomicsDB; 77788; -. [Q96PY6-1] DR ProteomicsDB; 77789; -. [Q96PY6-2] DR ProteomicsDB; 77790; -. [Q96PY6-3] DR ProteomicsDB; 77791; -. [Q96PY6-4] DR ProteomicsDB; 77792; -. [Q96PY6-5] DR Pumba; Q96PY6; -. DR TopDownProteomics; Q96PY6-3; -. [Q96PY6-3] DR Antibodypedia; 28454; 148 antibodies from 27 providers. DR DNASU; 4750; -. DR Ensembl; ENST00000439128.6; ENSP00000408020.2; ENSG00000137601.19. [Q96PY6-1] DR Ensembl; ENST00000507142.6; ENSP00000424757.2; ENSG00000137601.19. [Q96PY6-3] DR Ensembl; ENST00000510533.5; ENSP00000427653.1; ENSG00000137601.19. [Q96PY6-2] DR Ensembl; ENST00000511633.5; ENSP00000423332.1; ENSG00000137601.19. [Q96PY6-6] DR Ensembl; ENST00000512193.5; ENSP00000424938.1; ENSG00000137601.19. [Q96PY6-4] DR GeneID; 4750; -. DR KEGG; hsa:4750; -. DR MANE-Select; ENST00000507142.6; ENSP00000424757.2; NM_001199397.3; NP_001186326.1. [Q96PY6-3] DR UCSC; uc003isb.3; human. [Q96PY6-1] DR AGR; HGNC:7744; -. DR ClinPGx; PA31545; -. DR CTD; 4750; -. DR DisGeNET; 4750; -. DR GeneCards; NEK1; -. DR HGNC; HGNC:7744; NEK1. DR HPA; ENSG00000137601; Low tissue specificity. DR MalaCards; NEK1; -. DR MIM; 252100; phenotype. DR MIM; 263520; phenotype. DR MIM; 604588; gene. DR MIM; 617892; phenotype. DR OpenTargets; ENSG00000137601; -. DR Orphanet; 803; Amyotrophic lateral sclerosis. DR Orphanet; 2751; Orofaciodigital syndrome type 2. DR Orphanet; 93269; Short rib-polydactyly syndrome, Majewski type. DR VEuPathDB; HostDB:ENSG00000137601; -. DR eggNOG; KOG0589; Eukaryota. DR GeneTree; ENSGT00940000158460; -. DR HOGENOM; CLU_000288_60_1_1; -. DR InParanoid; Q96PY6; -. DR OMA; ELNEEWH; -. DR OrthoDB; 248923at2759; -. DR PAN-GO; Q96PY6; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q96PY6; -. DR PathwayCommons; Q96PY6; -. DR Reactome; R-HSA-9861718; Regulation of pyruvate metabolism. DR SignaLink; Q96PY6; -. DR SIGNOR; Q96PY6; -. DR Agora; ENSG00000137601; -. DR BioGRID-ORCS; 4750; 51 hits in 1199 CRISPR screens. DR ChiTaRS; NEK1; human. DR EvolutionaryTrace; Q96PY6; -. DR GeneWiki; NEK1; -. DR GenomeRNAi; 4750; -. DR Pharos; Q96PY6; Tchem. DR PRO; PR:Q96PY6; -. DR Proteomes; UP000005640; Chromosome 4. DR RNAct; Q96PY6; protein. DR Bgee; ENSG00000137601; Expressed in secondary oocyte and 212 other cell types or tissues. DR ExpressionAtlas; Q96PY6; baseline and differential. DR GO; GO:0034451; C:centriolar satellite; IDA:HPA. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:MGI. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:MGI. DR GO; GO:0000242; C:pericentriolar material; IDA:UniProtKB. DR GO; GO:0071889; F:14-3-3 protein binding; ISS:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016301; F:kinase activity; IMP:CACAO. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0004672; F:protein kinase activity; IDA:MGI. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:0060271; P:cilium assembly; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:CACAO. DR CDD; cd08218; STKc_Nek1; 1. DR FunFam; 3.30.200.20:FF:000097; Probable serine/threonine-protein kinase nek1; 1. DR FunFam; 1.10.510.10:FF:000172; serine/threonine-protein kinase Nek1 isoform X1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR051131; NEK_Ser/Thr_kinase_NIMA. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR44899; CAMK FAMILY PROTEIN KINASE; 1. DR PANTHER; PTHR44899:SF4; SERINE_THREONINE-PROTEIN KINASE NEK1; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Amyotrophic lateral sclerosis; KW ATP-binding; Cell cycle; Cell division; Ciliopathy; KW Cilium biogenesis/degradation; Cytoplasm; Cytoskeleton; Kinase; Magnesium; KW Metal-binding; Mitosis; Neurodegeneration; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Tyrosine-protein kinase. FT CHAIN 1..1258 FT /note="Serine/threonine-protein kinase Nek1" FT /id="PRO_0000086418" FT DOMAIN 4..258 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 330..360 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 578..600 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 648..669 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 685..704 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1118..1171 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 344..360 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 579..591 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 691..700 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 128 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 10..18 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 33 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 156 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 162 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 414 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 418 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 428 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 438 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P51954" FT MOD_RES 653 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 661 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 664 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 798 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 834 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 868 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 881 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1052 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 1126 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P51954" FT VAR_SEQ 398..422 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_035435" FT VAR_SEQ 477..520 FT /note="Missing (in isoform 4 and isoform 6)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_035436" FT VAR_SEQ 478..521 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10508479" FT /id="VSP_004870" FT VAR_SEQ 522..527 FT /note="QKGQLA -> LDCDDP (in isoform 5)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_035437" FT VAR_SEQ 528..1258 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_035438" FT VAR_SEQ 555 FT /note="M -> MGILQNLAAMYGGRPSSSRGGKPRNKEEE (in isoform 3 and FT isoform 6)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_035439" FT VARIANT 10 FT /note="I -> F (in dbSNP:rs34214559)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040900" FT VARIANT 25 FT /note="E -> K (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040901" FT VARIANT 76 FT /note="L -> V (in dbSNP:rs35093214)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040902" FT VARIANT 145 FT /note="G -> R (in SRTD6; dbSNP:rs431905508)" FT /evidence="ECO:0000269|PubMed:22499340" FT /id="VAR_069617" FT VARIANT 155 FT /note="S -> T (in OFD2; uncertain significance; the FT nucleotide substitution creating this missense variant may FT predominantly result in aberrant splicing, with skipping of FT exon 6 and creation of a premature stop codon, possibly FT leading to nonsense-mediated mRNA decay)" FT /evidence="ECO:0000269|PubMed:27530628" FT /id="VAR_089300" FT VARIANT 253 FT /note="L -> S (in SRTD6)" FT /evidence="ECO:0000269|PubMed:22499340" FT /id="VAR_069618" FT VARIANT 261 FT /note="R -> H (risk factor for ALS24; dbSNP:rs200161705)" FT /evidence="ECO:0000269|PubMed:27455347" FT /id="VAR_080694" FT VARIANT 294 FT /note="A -> P (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040903" FT VARIANT 355 FT /note="R -> G (in dbSNP:rs35763578)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040904" FT VARIANT 409..1258 FT /note="Missing (in OFD2; uncertain significance; the FT nucleotide substitution creating this nonsense variant may FT predominantly result in aberrant splicing)" FT /evidence="ECO:0000269|PubMed:27530628" FT /id="VAR_089301" FT VARIANT 463 FT /note="A -> V (in dbSNP:rs34540355)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040905" FT VARIANT 550..1258 FT /note="Missing (risk factor for ALS24)" FT /evidence="ECO:0000269|PubMed:27455347" FT /id="VAR_080695" FT VARIANT 598 FT /note="A -> T (in dbSNP:rs33933790)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046486" FT VARIANT 717 FT /note="N -> K (in dbSNP:rs34324114)" FT /id="VAR_061743" FT VARIANT 724 FT /note="E -> G (in dbSNP:rs34099167)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:17974005" FT /id="VAR_051651" FT VARIANT 745 FT /note="K -> N" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040906" FT VARIANT 784..1258 FT /note="Missing (risk factor for ALS24)" FT /evidence="ECO:0000269|PubMed:26945885" FT /id="VAR_080696" FT VARIANT 883 FT /note="Q -> E (in dbSNP:rs6828134)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046488" FT VARIANT 1008..1258 FT /note="Missing (risk factor for ALS24)" FT /evidence="ECO:0000269|PubMed:26945885" FT /id="VAR_080697" FT VARIANT 1180 FT /note="D -> N (in dbSNP:rs35503975)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046489" FT CONFLICT 250 FT /note="N -> D (in Ref. 2; CAI45943)" FT /evidence="ECO:0000305" FT CONFLICT 602 FT /note="R -> RK (in Ref. 2; CAI45943)" FT /evidence="ECO:0000305" FT CONFLICT 1232 FT /note="G -> E (in Ref. 7; AAD42879)" FT /evidence="ECO:0000305" FT STRAND 4..9 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 18..23 FT /evidence="ECO:0007829|PDB:4B9D" FT TURN 24..26 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 29..36 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 42..57 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 66..72 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 75..81 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 88..94 FT /evidence="ECO:0007829|PDB:4B9D" FT TURN 95..97 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 102..121 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 131..133 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 134..136 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 142..144 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 149..151 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 155..164 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 172..175 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 182..198 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 208..217 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 229..238 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 243..245 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 249..253 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 256..259 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 260..264 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 268..275 FT /evidence="ECO:0007829|PDB:4B9D" SQ SEQUENCE 1258 AA; 142828 MW; 339C4BFA56612530 CRC64; MEKYVRLQKI GEGSFGKAIL VKSTEDGRQY VIKEINISRM SSKEREESRR EVAVLANMKH PNIVQYRESF EENGSLYIVM DYCEGGDLFK RINAQKGVLF QEDQILDWFV QICLALKHVH DRKILHRDIK SQNIFLTKDG TVQLGDFGIA RVLNSTVELA RTCIGTPYYL SPEICENKPY NNKSDIWALG CVLYELCTLK HAFEAGSMKN LVLKIISGSF PPVSLHYSYD LRSLVSQLFK RNPRDRPSVN SILEKGFIAK RIEKFLSPQL IAEEFCLKTF SKFGSQPIPA KRPASGQNSI SVMPAQKITK PAAKYGIPLA YKKYGDKKLH EKKPLQKHKQ AHQTPEKRVN TGEERRKISE EAARKRRLEF IEKEKKQKDQ IISLMKAEQM KRQEKERLER INRAREQGWR NVLSAGGSGE VKAPFLGSGG TIAPSSFSSR GQYEHYHAIF DQMQQQRAED NEAKWKREIY GRGLPERGIL PGVRPGFPYG AAGHHHFPDA DDIRKTLKRL KAVSKQANAN RQKGQLAVER AKQVEEFLQR KREAMQNKAR AEGHMVYLAR LRQIRLQNFN ERQQIKAKLR GEKKEANHSE GQEGSEEADM RRKKIESLKA HANARAAVLK EQLERKRKEA YEREKKVWEE HLVAKGVKSS DVSPPLGQHE TGGSPSKQQM RSVISVTSAL KEVGVDSSLT DTRETSEEMQ KTNNAISSKR EILRRLNENL KAQEDEKGKQ NLSDTFEINV HEDAKEHEKE KSVSSDRKKW EAGGQLVIPL DELTLDTSFS TTERHTVGEV IKLGPNGSPR RAWGKSPTDS VLKILGEAEL QLQTELLENT TIRSEISPEG EKYKPLITGE KKVQCISHEI NPSAIVDSPV ETKSPEFSEA SPQMSLKLEG NLEEPDDLET EILQEPSGTN KDESLPCTIT DVWISEEKET KETQSADRIT IQENEVSEDG VSSTVDQLSD IHIEPGTNDS QHSKCDVDKS VQPEPFFHKV VHSEHLNLVP QVQSVQCSPE ESFAFRSHSH LPPKNKNKNS LLIGLSTGLF DANNPKMLRT CSLPDLSKLF RTLMDVPTVG DVRQDNLEID EIEDENIKEG PSDSEDIVFE ETDTDLQELQ ASMEQLLREQ PGEEYSEEEE SVLKNSDVEP TANGTDVADE DDNPSSESAL NEEWHSDNSD GEIASECECD SVFNHLEELR LHLEQEMGFE KFFEVYEKIK AIHEDEDENI EICSKIVQNI LGNEHQHLYA KILHLVMADG AYQEDNDE // ID NEK4_HUMAN Reviewed; 841 AA. AC P51957; A5YM70; B2R633; B7Z200; Q6P576; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 05-MAY-2009, sequence version 2. DT 28-JAN-2026, entry version 211. DE RecName: Full=Serine/threonine-protein kinase Nek4; DE EC=2.7.11.1 {ECO:0000250|UniProtKB:Q9Z1J2}; DE AltName: Full=Never in mitosis A-related kinase 4; DE Short=NimA-related protein kinase 4; DE AltName: Full=Serine/threonine-protein kinase 2; DE AltName: Full=Serine/threonine-protein kinase NRK2; GN Name=NEK4; Synonyms=STK2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT ALA-225, AND TISSUE RP SPECIFICITY. RC TISSUE=Mammary gland; RX PubMed=8208544; RA Levedakou E.N., He M., Baptist E.W., Craven R.J., Cance W.G., Welcsh P.L., RA Simmons A., Naylor S.L., Leach R.J., Lewis T.B., Bowcock A., Liu E.T.; RT "Two novel human serine/threonine kinases with homologies to the cell cycle RT regulating Xenopus MO15, and NIMA kinases: cloning and characterization of RT their expression pattern."; RL Oncogene 9:1977-1988(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-225. RA Schupp I.; RL Submitted (APR-2007) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3). RC TISSUE=Amygdala, and Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT ALA-225. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [7] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-563, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [8] RP INTERACTION WITH RPGRIP1 AND RPGRIP1L, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RX PubMed=21685204; DOI=10.1093/hmg/ddr280; RA Coene K.L., Mans D.A., Boldt K., Gloeckner C.J., van Reeuwijk J., Bolat E., RA Roosing S., Letteboer S.J., Peters T.A., Cremers F.P., Ueffing M., RA Roepman R.; RT "The ciliopathy-associated protein homologs RPGRIP1 and RPGRIP1L are linked RT to cilium integrity through interaction with Nek4 serine/threonine RT kinase."; RL Hum. Mol. Genet. 20:3592-3605(2011). RN [9] RP FUNCTION. RX PubMed=22851694; DOI=10.1128/mcb.00436-12; RA Nguyen C.L., Possemato R., Bauerlein E.L., Xie A., Scully R., Hahn W.C.; RT "Nek4 regulates entry into replicative senescence and the response to DNA RT damage in human fibroblasts."; RL Mol. Cell. Biol. 32:3963-3977(2012). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-340; SER-343; SER-461 AND RP SER-563, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [11] RP METHYLATION [LARGE SCALE ANALYSIS] AT LYS-622, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Colon carcinoma; RX PubMed=24129315; DOI=10.1074/mcp.o113.027870; RA Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M., RA Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V., RA Bedford M.T., Comb M.J.; RT "Immunoaffinity enrichment and mass spectrometry analysis of protein RT methylation."; RL Mol. Cell. Proteomics 13:372-387(2014). RN [12] RP VARIANTS [LARGE SCALE ANALYSIS] ALA-225; GLY-239; LEU-250; ILE-357; RP GLU-456; LEU-567 AND LYS-777. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Protein kinase that seems to act exclusively upon threonine CC residues (By similarity). Required for normal entry into proliferative CC arrest after a limited number of cell divisions, also called CC replicative senescence. Required for normal cell cycle arrest in CC response to double-stranded DNA damage. {ECO:0000250|UniProtKB:Q9Z1J2, CC ECO:0000269|PubMed:22851694}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000250|UniProtKB:Q9Z1J2}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000250|UniProtKB:Q9Z1J2}; CC -!- COFACTOR: CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; CC Evidence={ECO:0000250|UniProtKB:Q9Z1J2}; CC -!- SUBUNIT: Interacts with RPGRIP1 and RPGRIP1L. CC {ECO:0000269|PubMed:21685204}. CC -!- INTERACTION: CC P51957; Q96KN7: RPGRIP1; NbExp=5; IntAct=EBI-8798332, EBI-1050213; CC P51957; Q68CZ1: RPGRIP1L; NbExp=4; IntAct=EBI-8798332, EBI-5235485; CC -!- SUBCELLULAR LOCATION: Cell projection, cilium CC {ECO:0000269|PubMed:21685204}. Cytoplasm {ECO:0000269|PubMed:21685204}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=P51957-1; Sequence=Displayed; CC Name=2; CC IsoId=P51957-2; Sequence=VSP_037123, VSP_037124; CC Name=3; CC IsoId=P51957-3; Sequence=VSP_043334; CC -!- TISSUE SPECIFICITY: Highest expression in adult heart, followed by CC pancreas, skeletal muscle, brain, testis, retina, liver, kidney, lung CC and placenta. Present in most primary carcinomas. CC {ECO:0000269|PubMed:21685204, ECO:0000269|PubMed:8208544}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. NEK Ser/Thr CC protein kinase family. NIMA subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L20321; AAA36658.1; -; mRNA. DR EMBL; EF560744; ABQ59054.1; -; mRNA. DR EMBL; AK294165; BAH11686.1; -; mRNA. DR EMBL; AK312420; BAG35330.1; -; mRNA. DR EMBL; AC006254; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC104446; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC063044; AAH63044.1; -; mRNA. DR CCDS; CCDS2863.1; -. [P51957-1] DR CCDS; CCDS54593.1; -. [P51957-3] DR CCDS; CCDS87089.1; -. [P51957-2] DR PIR; I78885; I78885. DR RefSeq; NP_001180462.1; NM_001193533.3. [P51957-3] DR RefSeq; NP_001335342.1; NM_001348413.2. [P51957-2] DR RefSeq; NP_003148.2; NM_003157.6. [P51957-1] DR AlphaFoldDB; P51957; -. DR SMR; P51957; -. DR BioGRID; 112663; 582. DR FunCoup; P51957; 2781. DR IntAct; P51957; 567. DR MINT; P51957; -. DR STRING; 9606.ENSP00000233027; -. DR BindingDB; P51957; -. DR ChEMBL; CHEMBL5819; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; P51957; -. DR GlyGen; P51957; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P51957; -. DR PhosphoSitePlus; P51957; -. DR BioMuta; NEK4; -. DR DMDM; 229462924; -. DR jPOST; P51957; -. DR MassIVE; P51957; -. DR PaxDb; 9606-ENSP00000233027; -. DR PeptideAtlas; P51957; -. DR ProteomicsDB; 56459; -. [P51957-1] DR ProteomicsDB; 56460; -. [P51957-2] DR ProteomicsDB; 56461; -. [P51957-3] DR Pumba; P51957; -. DR Antibodypedia; 14725; 213 antibodies from 30 providers. DR DNASU; 6787; -. DR Ensembl; ENST00000233027.10; ENSP00000233027.5; ENSG00000114904.14. [P51957-1] DR Ensembl; ENST00000383721.8; ENSP00000373227.4; ENSG00000114904.14. [P51957-2] DR Ensembl; ENST00000535191.5; ENSP00000437703.1; ENSG00000114904.14. [P51957-3] DR GeneID; 6787; -. DR KEGG; hsa:6787; -. DR MANE-Select; ENST00000233027.10; ENSP00000233027.5; NM_003157.6; NP_003148.2. DR UCSC; uc003dfq.5; human. [P51957-1] DR AGR; HGNC:11399; -. DR ClinPGx; PA31548; -. DR CTD; 6787; -. DR DisGeNET; 6787; -. DR GeneCards; NEK4; -. DR HGNC; HGNC:11399; NEK4. DR HPA; ENSG00000114904; Tissue enhanced (testis). DR MIM; 601959; gene. DR OpenTargets; ENSG00000114904; -. DR VEuPathDB; HostDB:ENSG00000114904; -. DR eggNOG; KOG0589; Eukaryota. DR GeneTree; ENSGT00940000157448; -. DR HOGENOM; CLU_017439_0_0_1; -. DR InParanoid; P51957; -. DR OMA; CLREHMG; -. DR OrthoDB; 248923at2759; -. DR PAN-GO; P51957; 2 GO annotations based on evolutionary models. DR PhylomeDB; P51957; -. DR PathwayCommons; P51957; -. DR SignaLink; P51957; -. DR Agora; ENSG00000114904; -. DR BioGRID-ORCS; 6787; 13 hits in 1191 CRISPR screens. DR ChiTaRS; NEK4; human. DR GenomeRNAi; 6787; -. DR Pharos; P51957; Tchem. DR PRO; PR:P51957; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P51957; protein. DR Bgee; ENSG00000114904; Expressed in bronchial epithelial cell and 200 other cell types or tissues. DR ExpressionAtlas; P51957; baseline and differential. DR GO; GO:0036064; C:ciliary basal body; IEA:Ensembl. DR GO; GO:0097014; C:ciliary plasm; IEA:Ensembl. DR GO; GO:0035253; C:ciliary rootlet; IEA:Ensembl. DR GO; GO:0035869; C:ciliary transition zone; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0030145; F:manganese ion binding; ISS:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; ISS:UniProtKB. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:0006974; P:DNA damage response; IMP:UniProtKB. DR GO; GO:0000278; P:mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IMP:CACAO. DR GO; GO:0006468; P:protein phosphorylation; ISS:UniProtKB. DR GO; GO:2000772; P:regulation of cellular senescence; IMP:UniProtKB. DR CDD; cd08223; STKc_Nek4; 1. DR FunFam; 1.10.510.10:FF:001276; NEK4 isoform 4; 1. DR FunFam; 3.30.200.20:FF:000247; serine/threonine-protein kinase Nek4 isoform X1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR051131; NEK_Ser/Thr_kinase_NIMA. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR44899; CAMK FAMILY PROTEIN KINASE; 1. DR PANTHER; PTHR44899:SF7; NIMA-RELATED KINASE; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cell cycle; Cell division; KW Cell projection; Cytoplasm; Kinase; Magnesium; Metal-binding; Methylation; KW Mitosis; Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase. FT CHAIN 1..841 FT /note="Serine/threonine-protein kinase Nek4" FT /id="PRO_0000086425" FT DOMAIN 6..261 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 517..700 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 523..533 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 541..557 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 591..606 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 607..616 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 131 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 12..20 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 35 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 165 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 340 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 343 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 461 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 563 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:23186163" FT MOD_RES 622 FT /note="N6-methyllysine" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 723 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9Z1J2" FT VAR_SEQ 32..120 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_043334" FT VAR_SEQ 457..502 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_037123" FT VAR_SEQ 813..841 FT /note="RLREHMGEKYTTYSVKARQLKFFEENMNF -> SVSLTVSRCLCYRIF (in FT isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_037124" FT VARIANT 225 FT /note="P -> A (in dbSNP:rs1029871)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:8208544, FT ECO:0000269|Ref.2" FT /id="VAR_040915" FT VARIANT 239 FT /note="R -> G (in dbSNP:rs35778416)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040916" FT VARIANT 250 FT /note="P -> L (in dbSNP:rs56408749)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040917" FT VARIANT 357 FT /note="T -> I (in dbSNP:rs2230537)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040918" FT VARIANT 456 FT /note="Q -> E (in dbSNP:rs56019351)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040919" FT VARIANT 567 FT /note="F -> L (in dbSNP:rs34986855)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040920" FT VARIANT 777 FT /note="R -> K (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040921" FT CONFLICT 63 FT /note="P -> L (in Ref. 3; BAG35330)" FT /evidence="ECO:0000305" FT CONFLICT 64 FT /note="N -> D (in Ref. 2; ABQ59054)" FT /evidence="ECO:0000305" FT CONFLICT 333 FT /note="R -> K (in Ref. 3; BAG35330)" FT /evidence="ECO:0000305" SQ SEQUENCE 841 AA; 94597 MW; 43E8F11BA4007263 CRC64; MPLAAYCYLR VVGKGSYGEV TLVKHRRDGK QYVIKKLNLR NASSRERRAA EQEAQLLSQL KHPNIVTYKE SWEGGDGLLY IVMGFCEGGD LYRKLKEQKG QLLPENQVVE WFVQIAMALQ YLHEKHILHR DLKTQNVFLT RTNIIKVGDL GIARVLENHC DMASTLIGTP YYMSPELFSN KPYNYKSDVW ALGCCVYEMA TLKHAFNAKD MNSLVYRIIE GKLPPMPRDY SPELAELIRT MLSKRPEERP SVRSILRQPY IKRQISFFLE ATKIKTSKNN IKNGDSQSKP FATVVSGEAE SNHEVIHPQP LSSEGSQTYI MGEGKCLSQE KPRASGLLKS PASLKAHTCK QDLSNTTELA TISSVNIDIL PAKGRDSVSD GFVQENQPRY LDASNELGGI CSISQVEEEM LQDNTKSSAQ PENLIPMWSS DIVTGEKNEP VKPLQPLIKE QKPKDQSLAL SPKLECSGTI LAHSNLRLLG SSDSPASASR VAGITGVCHH AQDQVAGECI IEKQGRIHPD LQPHNSGSEP SLSRQRRQKR REQTEHRGEK RQVRRDLFAF QESPPRFLPS HPIVGKVDVT STQKEAENQR RVVTGSVSSS RSSEMSSSKD RPLSARERRR LKQSQEEMSS SGPSVRKASL SVAGPGKPQE EDQPLPARRL SSDCSVTQER KQIHCLSEDE LSSSTSSTDK SDGDYGEGKG QTNEINALVQ LMTQTLKLDS KESCEDVPVA NPVSEFKLHR KYRDTLILHG KVAEEAEEIH FKELPSAIMP GSEKIRRLVE VLRTDVIRGL GVQLLEQVYD LLEEEDEFDR EVRLREHMGE KYTTYSVKAR QLKFFEENMN F // ID NF1_HUMAN Reviewed; 2839 AA. AC P21359; O00662; Q14284; Q14930; Q14931; Q9UMK3; DT 01-MAY-1991, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-1994, sequence version 2. DT 28-JAN-2026, entry version 262. DE RecName: Full=Neurofibromin; DE AltName: Full=Neurofibromatosis-related protein NF-1; DE Contains: DE RecName: Full=Neurofibromin truncated; GN Name=NF1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS I AND II). RX PubMed=1457041; DOI=10.1089/dna.1992.11.727; RA Bernards A., Haase V.H., Murthy A.E., Menon A., Hannigan G.E., RA Gusella J.F.; RT "Complete human NF1 cDNA sequence: two alternatively spliced mRNAs and RT absence of expression in a neuroblastoma line."; RL DNA Cell Biol. 11:727-734(1992). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM I). RX PubMed=2134734; DOI=10.1126/science.2134734; RA Wallace M.R., Marchuk D.A., Andersen L.B., Letcher R., Odeh H.M., RA Saulino A.M., Fountain J.W., Brereton A., Nicholson J., Mitchell A.L., RA Brownstein B.H., Collins F.S.; RT "Type 1 neurofibromatosis gene: identification of a large transcript RT disrupted in three NF1 patients."; RL Science 249:181-186(1990). RN [3] RP ERRATUM OF PUBMED:2134734. RX PubMed=2125369; RA Wallace M.R., Marchuk D.A., Andersen L.B., Letcher R., Odeh H.M., RA Saulino A.M., Fountain J.W., Brereton A., Nicholson J., Mitchell A.L., RA Brownstein B.H., Collins F.S.; RL Science 250:1749-1749(1990). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM I). RX PubMed=1783401; DOI=10.1016/0888-7543(91)90017-9; RA Marchuk D.A., Saulino A.M., Tavakkol R., Swaroop M., Wallace M.R., RA Andersen L.B., Mitchell A.L., Gutmann D.H., Boguski M.S., Collins F.S.; RT "cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of RT the NF1 gene product."; RL Genomics 11:931-940(1991). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND ALTERNATIVE SPLICING. RC TISSUE=Placenta; RX PubMed=1339276; DOI=10.1016/0006-291x(92)91294-z; RA Suzuki H., Takahashi K., Kubota Y., Shibahara S.; RT "Molecular cloning of a cDNA coding for neurofibromatosis type 1 protein RT isoform lacking the domain related to ras GTPase-activating protein."; RL Biochem. Biophys. Res. Commun. 187:984-990(1992). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5). RC TISSUE=Kidney; RX PubMed=7570581; DOI=10.1620/tjem.175.225; RA Suzuki H., Takahashi K., Shibahara S.; RT "Evidence for the presence of two amino-terminal isoforms of neurofibromin, RT a gene product responsible for neurofibromatosis type 1."; RL Tohoku J. Exp. Med. 175:225-233(1995). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-80; LEU-678; HIS-1422 RP AND LEU-2511. RG NIEHS SNPs program; RL Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 335-2839 (ISOFORM I), AND RP VARIANT NF1 PRO-1953. RX PubMed=2114220; DOI=10.1016/0092-8674(90)90253-b; RA Cawthon R.M., Weiss R., Xu G., Viskochil D., Culver M., Stevens J., RA Robertson M., Dunn D., Gesteland R., O'Connell P., White R.; RT "A major segment of the neurofibromatosis type 1 gene: cDNA sequence, RT genomic structure, and point mutations."; RL Cell 62:193-201(1990). RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 335-2839 (ISOFORMS I AND 6). RX PubMed=2116237; DOI=10.1016/0092-8674(90)90024-9; RA Xu G., O'Connell P., Viskochil D., Cawthon R.M., Robertson M., Culver M., RA Dunn D., Stevens J., Gesteland R., White R., Weiss R.; RT "The neurofibromatosis type 1 gene encodes a protein related to GAP."; RL Cell 62:599-608(1990). RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 707-782. RX PubMed=9002664; DOI=10.1093/hmg/6.1.9; RA Regnier V., Meddeb M., Lecointre G., Richard F., Duverger A., Nguyen V.C., RA Dutrillaux B., Bernheim A., Danglot G.; RT "Emergence and scattering of multiple neurofibromatosis (NF1)-related RT sequences during hominoid evolution suggest a process of pericentromeric RT interchromosomal transposition."; RL Hum. Mol. Genet. 6:9-16(1997). RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 751-1611 (ISOFORMS I AND II). RX PubMed=7774960; DOI=10.1016/0888-7543(95)80104-t; RA Li Y., O'Connell P., Breidenbach H.H., Cawthon R.M., Stevens J., Xu G., RA Neil S., Robertson M., White R., Viskochil D.; RT "Genomic organization of the neurofibromatosis 1 gene (NF1)."; RL Genomics 25:9-18(1995). RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1090-1598 (ISOFORM 4). RX PubMed=2121370; DOI=10.1016/0092-8674(90)90150-d; RA Martin G.A., Viskochil D., Bollag G., McCabe P.C., Crosier W.J., RA Haubruck H., Conroy L., Clark R., O'Connell P., Cawthon R.M., Innis M., RA McCormick F.; RT "The GAP-related domain of the neurofibromatosis type 1 gene product RT interacts with ras p21."; RL Cell 63:843-849(1990). RN [15] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1168-1566 (ISOFORMS I AND II). RX PubMed=1923522; RA Nishi T., Lee P.S., Oka K., Levin V.A., Tanase S., Morino Y., Saya H.; RT "Differential expression of two types of the neurofibromatosis type 1 (NF1) RT gene transcripts related to neuronal differentiation."; RL Oncogene 6:1555-1559(1991). RN [16] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1371-1391 (ISOFORM II), FUNCTION, AND TISSUE RP SPECIFICITY. RX PubMed=8417346; DOI=10.1128/mcb.13.1.487-495.1993; RA Andersen L.B., Ballester R., Marchuk D.A., Chang E., Gutmann D.H., RA Saulino A.M., Camonis J., Wigler M., Collins F.S.; RT "A conserved alternative splice in the von Recklinghausen neurofibromatosis RT (NF1) gene produces two neurofibromin isoforms, both of which have GTPase- RT activating protein activity."; RL Mol. Cell. Biol. 13:487-495(1993). RN [17] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1371-1391 (ISOFORM II). RX PubMed=1662505; DOI=10.1016/0006-291x(91)92029-j; RA Suzuki Y., Suzuki H., Kayama T., Yoshimoto T., Shibahara S.; RT "Brain tumors predominantly express the neurofibromatosis type 1 gene RT transcripts containing the 63 base insert in the region coding for GTPase RT activating protein-related domain."; RL Biochem. Biophys. Res. Commun. 181:955-961(1991). RN [18] RP FUNCTION. RX PubMed=2121371; DOI=10.1016/0092-8674(90)90151-4; RA Ballester R., Marchuk D.A., Boguski M.S., Saulino A.M., Letcher R., RA Wigler M., Collins F.S.; RT "The NF1 locus encodes a protein functionally related to mammalian GAP and RT yeast IRA proteins."; RL Cell 63:851-859(1990). RN [19] RP RNA EDITING. RX PubMed=8602361; DOI=10.1093/nar/24.3.478; RA Skuse G.R., Cappione A.J., Sowden M., Metheny L.J., Smith H.C.; RT "The neurofibromatosis type I messenger RNA undergoes base-modification RNA RT editing."; RL Nucleic Acids Res. 24:478-485(1996). RN [20] RP RNA EDITING. RX PubMed=11727199; DOI=10.1086/337952; RA Mukhopadhyay D., Anant S., Lee R.M., Kennedy S., Viskochil D., RA Davidson N.O.; RT "C-->U editing of neurofibromatosis 1 mRNA occurs in tumors that express RT both the type II transcript and apobec-1, the catalytic subunit of the RT apolipoprotein B mRNA-editing enzyme."; RL Am. J. Hum. Genet. 70:38-50(2002). RN [21] RP REVIEW ON VARIANTS. RX PubMed=7981724; DOI=10.1002/humu.1380040202; RA Upadhyaya M., Shaw D.J., Harper P.S.; RT "Molecular basis of neurofibromatosis type 1 (NF1): mutation analysis and RT polymorphisms in the NF1 gene."; RL Hum. Mutat. 4:83-101(1994). RN [22] RP REVIEW ON VARIANTS. RX PubMed=8825042; DOI=10.1136/jmg.33.1.2; RA Shen M.H., Harper P.S., Upadhyaya M.; RT "Molecular genetics of neurofibromatosis type 1 (NF1)."; RL J. Med. Genet. 33:2-17(1996). RN [23] RP SUBCELLULAR LOCATION, AND NUCLEAR LOCALIZATION SIGNAL. RX PubMed=14988005; DOI=10.1016/s0014-5793(04)00078-x; RA Vandenbroucke I., Van Oostveldt P., Coene E., De Paepe A., Messiaen L.; RT "Neurofibromin is actively transported to the nucleus."; RL FEBS Lett. 560:98-102(2004). RN [24] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [25] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-864; SER-2188; SER-2515; RP SER-2521 AND SER-2543, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [27] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [28] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-864; SER-876 AND SER-2515, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [30] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-864 AND SER-2817, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [31] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [32] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2543 AND SER-2817, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [33] RP INTERACTION WITH HTR6. RX PubMed=23027611; DOI=10.1002/emmm.201201410; RA Meffre J., Chaumont-Dubel S., Mannoury la Cour C., Loiseau F., Watson D.J., RA Dekeyne A., Seveno M., Rivet J.M., Gaven F., Deleris P., Herve D., RA Fone K.C., Bockaert J., Millan M.J., Marin P.; RT "5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed RT cognition in schizophrenia."; RL EMBO Mol. Med. 4:1043-1056(2012). RN [34] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-864; SER-876; SER-2188; RP SER-2515; SER-2521; SER-2523; SER-2543; THR-2565; SER-2597 AND SER-2802, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2543 AND SER-2817, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [36] RP INTERACTION WITH SPRED2, AND SUBCELLULAR LOCATION. RX PubMed=34626534; DOI=10.1016/j.ajhg.2021.09.007; RA Motta M., Fasano G., Gredy S., Brinkmann J., Bonnard A.A., RA Simsek-Kiper P.O., Gulec E.Y., Essaddam L., Utine G.E., RA Guarnetti Prandi I., Venditti M., Pantaleoni F., Radio F.C., Ciolfi A., RA Petrini S., Consoli F., Vignal C., Hepbasli D., Ullrich M., de Boer E., RA Vissers L.E.L.M., Gritli S., Rossi C., De Luca A., Ben Becher S., RA Gelb B.D., Dallapiccola B., Lauri A., Chillemi G., Schuh K., Cave H., RA Zenker M., Tartaglia M.; RT "SPRED2 loss-of-function causes a recessive Noonan syndrome-like RT phenotype."; RL Am. J. Hum. Genet. 108:2112-2129(2021). RN [37] RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 1198-1551. RX PubMed=9687500; DOI=10.1093/emboj/17.15.4313; RA Scheffzek K., Ahmadian M.R., Wiesmuller L., Kabsch W., Stege P., RA Schmitz F., Wittinghofer A.; RT "Structural analysis of the GAP-related domain from neurofibromin and its RT implications."; RL EMBO J. 17:4313-4327(1998). RN [38] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 1581-1837, LIPID-BINDING, DOMAIN, RP AND MUTAGENESIS OF LYS-1691; ARG-1695; ARG-1769 AND LYS-1771. RX PubMed=16397625; DOI=10.1038/sj.embor.7400602; RA D'Angelo I., Welti S., Bonneau F., Scheffzek K.; RT "A novel bipartite phospholipid-binding module in the neurofibromatosis RT type 1 protein."; RL EMBO Rep. 7:174-179(2006). RN [39] RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 1566-1837 IN COMPLEX WITH RP PHOSPHOLIPID, LIPID-BINDING, AND DOMAIN. RX PubMed=17187824; DOI=10.1016/j.jmb.2006.11.055; RA Welti S., Fraterman S., D'Angelo I., Wilm M., Scheffzek K.; RT "The sec14 homology module of neurofibromin binds cellular RT glycerophospholipids: mass spectrometry and structure of a lipid complex."; RL J. Mol. Biol. 366:551-562(2007). RN [40] RP X-RAY CRYSTALLOGRAPHY (2.19 ANGSTROMS) OF 1581-1837 OF VARIANT NF1 VAL-1605 RP AND MUTANT LYS-1771 DEL IN COMPLEX WITH LIPID, CHARACTERIZATION OF VARIANT RP NF1 VAL-1605, MUTAGENESIS OF LYS-1771, LIPID-BINDING, AND DOMAIN. RX PubMed=21089070; DOI=10.1002/humu.21405; RA Welti S., Kuhn S., D'Angelo I., Brugger B., Kaufmann D., Scheffzek K.; RT "Structural and biochemical consequences of NF1 associated nontruncating RT mutations in the Sec14-PH module of neurofibromin."; RL Hum. Mutat. 32:191-197(2011). RN [41] RP VARIANT GLU-1444. RX PubMed=1568247; DOI=10.1016/0092-8674(92)90408-5; RA Li Y., Bollag G., Clark R., Stevens J., Conroy L., Fults D., Ward K., RA Friedman E., Samowitz W., Robertson M., Bradley P., McCormick F., White R., RA Cawthon R.M.; RT "Somatic mutations in the neurofibromatosis 1 gene in human tumors."; RL Cell 69:275-281(1992). RN [42] RP VARIANTS NF1 MET-2164 AND ASN-2192. RX PubMed=1302608; DOI=10.1093/hmg/1.9.735; RA Upadhyaya M., Shen M.H., Cherryson A., Farnham J., Maynard J., Huson S.M., RA Harper P.S.; RT "Analysis of mutations at the neurofibromatosis 1 (NF1) locus."; RL Hum. Mol. Genet. 1:735-740(1992). RN [43] RP VARIANT GLY-HIS-GLU-GLN-GLN-LYS-LEU-PRO-ALA-ALA-THR-LEU-ALA-LEU-1733 INS. RX PubMed=8317503; RA Tassabehji M., Strachan T., Sharland M., Colley A., Donnai D., Harris R., RA Thakker N.; RT "Tandem duplication within a neurofibromatosis type 1 (NF1) gene exon in a RT family with features of Watson syndrome and Noonan syndrome."; RL Am. J. Hum. Genet. 53:90-95(1993). RN [44] RP VARIANT MET-991 DEL. RX PubMed=7904209; DOI=10.1093/hmg/2.11.1861; RA Shen M.H., Harper P.S., Upadhyaya M.; RT "Neurofibromatosis type 1 (NF1): the search for mutations by PCR- RT heteroduplex analysis on Hydrolink gels."; RL Hum. Mol. Genet. 2:1861-1864(1993). RN [45] RP VARIANTS NF1 ASP-1166 AND ARG-1440. RX PubMed=7981679; DOI=10.1093/hmg/3.7.1109; RA Purandare S.M., Lanyon W.G., Connor J.M.; RT "Characterisation of inherited and sporadic mutations in neurofibromatosis RT type-1."; RL Hum. Mol. Genet. 3:1109-1115(1994). RN [46] RP VARIANT NF1 2387-ASN-PHE-2388 DEL. RX PubMed=8081387; DOI=10.1002/humu.1380030404; RA Abernathy C.R., Colman S.D., Kousseff B.G., Wallace M.R.; RT "Two NF1 mutations: frameshift in the GAP-related domain, and loss of two RT codons toward the 3' end of the gene."; RL Hum. Mutat. 3:347-352(1994). RN [47] RP VARIANT NF1 ALA-2631. RX PubMed=8544190; DOI=10.1136/jmg.32.9.706; RA Upadhyaya M., Maynard J., Osborn M.J., Huson S.M., Ponder M., RA Ponder B.A.J., Harper P.S.; RT "Characterisation of germline mutations in the neurofibromatosis type 1 RT (NF1) gene."; RL J. Med. Genet. 32:706-710(1995). RN [48] RP VARIANT NF1 ARG-629. RX PubMed=8834249; DOI=10.1007/bf02267073; RA Gasparini P., D'Agruma L., de Cillis G.P., Balestrazzi P., Mingarelli R., RA Zelante L.; RT "Scanning the first part of the neurofibromatosis type 1 gene by RNA-SSCP: RT identification of three novel mutations and of two new polymorphisms."; RL Hum. Genet. 97:492-495(1996). RN [49] RP VARIANT NF1 ARG-1035. RX PubMed=8807336; RX DOI=10.1002/(sici)1098-1004(1996)8:1<51::aid-humu7>3.0.co;2-s; RA Wu R., Legius E., Robberecht W., Dumoulin M., Cassiman J.-J., Fryns J.-P.; RT "Neurofibromatosis type I gene mutation in a patient with features of RT LEOPARD syndrome."; RL Hum. Mutat. 8:51-56(1996). RN [50] RP VARIANTS NF1 SER-1412; GLN-1440; GLU-1444 AND GLY-1489. RX PubMed=9003501; DOI=10.1007/s004390050317; RA Upadhyaya M., Osborn M.J., Maynard J., Kim M.R., Tamanoi F., Cooper D.N.; RT "Mutational and functional analysis of the neurofibromatosis type 1 (NF1) RT gene."; RL Hum. Genet. 99:88-92(1997). RN [51] RP VARIANTS NF1 ARG-844 AND PRO-898. RX PubMed=9150739; DOI=10.1007/s004390050427; RA Maynard J., Krawczak M., Upadhyaya M.; RT "Characterization and significance of nine novel mutations in exon 16 of RT the neurofibromatosis type 1 (NF1) gene."; RL Hum. Genet. 99:674-676(1997). RN [52] RP VARIANT NF1 ARG-1952. RX PubMed=9101300; RX DOI=10.1002/(sici)1098-1004(1997)9:4<366::aid-humu12>3.0.co;2-0; RA Hudson J., Wu C.L., Tassabehji M., Summers E.M., Simon S., Super M., RA Donnai D., Thakker N.; RT "Novel and recurrent mutations in the neurofibromatosis type 1 (NF1) RT gene."; RL Hum. Mutat. 9:366-367(1997). RN [53] RP VARIANTS NF1 GLY-338 AND TRP-1611. RX PubMed=9298829; RX DOI=10.1002/(sici)1098-1004(1997)10:3<248::aid-humu14>3.0.co;2-#; RA Upadhyaya M., Maynard J., Osborn M.J., Harper P.S.; RT "Six novel mutations in the neurofibromatosis type 1 (NF1) gene."; RL Hum. Mutat. 10:248-250(1997). RN [54] RP VARIANT NF1 PRO-1276. RX PubMed=9668168; DOI=10.1093/hmg/7.8.1261; RA Klose A., Ahmadian M.R., Schuelke M., Scheffzek K., Hoffmeyer S., RA Gewies A., Schmitz F., Kaufmann D., Peters H., Wittinghofer A., RA Nuernberg P.; RT "Selective disactivation of neurofibromin GAP activity in neurofibromatosis RT type 1 (NF1)."; RL Hum. Mol. Genet. 7:1261-1268(1998). RN [55] RP VARIANTS NF1 HIS-765 AND GLY-1204. RX PubMed=10336779; RX DOI=10.1002/(sici)1098-1004(1998)11:5<411::aid-humu11>3.0.co;2-2; RA Krkljus S., Abernathy C.R., Johnson J.S., Williams C.A., Driscoll D.J., RA Zori R., Stalker H.J., Rasmussen S.A., Collins F.S., Kousseff B.G., RA Baumbach L., Wallace M.R.; RT "Analysis of CpG C-to-T mutations in neurofibromatosis type 1."; RL Hum. Mutat. 11:411-411(1998). RN [56] RP VARIANT NF1 PRO-508. RX PubMed=11258625; DOI=10.1097/00125817-199909000-00002; RA Messiaen L.M., Callens T., Roux K.J., Mortier G.R., De Paepe A., RA Abramowicz M., Pericak-Vance M.A., Vance J.M., Wallace M.R.; RT "Exon 10b of the NF1 gene represents a mutational hotspot and harbors a RT recurrent missense mutation Y489C associated with aberrant splicing."; RL Genet. Med. 1:248-253(1999). RN [57] RP VARIANT NF1 PRO-1446. RX PubMed=10220149; RX DOI=10.1002/(sici)1098-1004(1999)13:4<337::aid-humu12>3.0.co;2-f; RA Peters H., Hess D., Fahsold R., Schuelke M.; RT "A novel mutation L1425P in the GAP-region of the NF1 gene detected by RT temperature gradient gel electrophoresis (TGGE)."; RL Hum. Mutat. 13:337-337(1999). RN [58] RP VARIANTS NF1 PRO-216; PRO-357; CYS-491; PRO-549; THR-581; ARG-583; PHE-665; RP PRO-695; PRO-763; SER-777; LYS-780; PRO-781; PRO-847; SER-1156; PRO-1250; RP GLN-1276; PRO-1276; PRO-1446; VAL-1605 AND ILE-2507, AND VARIANT GLU-176. RX PubMed=10712197; DOI=10.1086/302809; RA Fahsold R., Hoffmeyer S., Mischung C., Gille C., Ehlers C., RA Kuecuekceylan N., Abdel-Nour M., Gewies A., Peters H., Kaufmann D., RA Buske A., Tinschert S., Nuernberg P.; RT "Minor lesion mutational spectrum of the entire NF1 gene does not explain RT its high mutability but points to a functional domain upstream of the GAP- RT related domain."; RL Am. J. Hum. Genet. 66:790-818(2000). RN [59] RP VARIANTS NF1 SER-117; TRP-1204; PRO-1446 AND 2387-ASN-PHE-2388 DEL. RX PubMed=10607834; DOI=10.1093/hmg/9.2.237; RA Ars E., Serra E., Garcia J., Kruyer H., Gaona A., Lazaro C., Estivill X.; RT "Mutations affecting mRNA splicing are the most common molecular defects in RT patients with neurofibromatosis type 1."; RL Hum. Mol. Genet. 9:237-247(2000). RN [60] RP ERRATUM OF PUBMED:10607834. RA Ars E., Serra E., Garcia J., Kruyer H., Gaona A., Lazaro C., Estivill X.; RL Hum. Mol. Genet. 9:659-659(2000). RN [61] RP VARIANT NF1 PHE-844. RX PubMed=10980545; RX DOI=10.1002/1098-1004(200009)16:3<274::aid-humu21>3.3.co;2-6; RA Boulandet E.G., Pantel J., Cazeneuve C., Van Gijn M., Vidaud D., Lemay S., RA Martin J., Zeller J., Revuz J., Goossens M., Amselem S., Wolkenstein P.; RT "NF1 gene analysis focused on CpG-rich exons in a cohort of 93 patients RT with neurofibromatosis type 1."; RL Hum. Mutat. 16:274-275(2000). RN [62] RP VARIANT SPINAL FSNF PRO-2088. RX PubMed=11704931; DOI=10.1086/324648; RA Kaufmann D., Mueller R., Bartelt B., Wolf M., Kunzi-Rapp K., Hanemann C.O., RA Fahsold R., Hein C., Vogel W., Assum G.; RT "Spinal neurofibromatosis without cafe-au-lait macules in two families with RT null mutations of the NF1 gene."; RL Am. J. Hum. Genet. 69:1395-1400(2001). RN [63] RP VARIANTS NF1 LYS-780; CYS-784; PRO-1147; CYS-1193; ARG-1444; SER-1785; RP ASN-2012 AND LYS-2357. RX PubMed=11735023; DOI=10.1007/s004390100594; RA Han S.S., Cooper D.N., Upadhyaya M.N.; RT "Evaluation of denaturing high performance liquid chromatography (DHPLC) RT for the mutational analysis of the neurofibromatosis type 1 (NF1) gene."; RL Hum. Genet. 109:487-497(2001). RN [64] RP VARIANTS NF1 PHE-82; ARG-784 AND GLU-1444. RX PubMed=11857752; DOI=10.1002/humu.9018; RA Kluwe L., Friedrich R.E., Korf B., Fahsold R., Mautner V.-F.; RT "NF1 mutations in neurofibromatosis 1 patients with plexiform RT neurofibromas."; RL Hum. Mutat. 19:309-309(2002). RN [65] RP VARIANT NFNS GLU-1459 DEL. RX PubMed=12707950; DOI=10.1002/ajmg.a.20023; RA Baralle D., Mattocks C., Kalidas K., Elmslie F., Whittaker J., Lees M., RA Ragge N., Patton M.A., Winter R.M., ffrench-Constant C.; RT "Different mutations in the NF1 gene are associated with neurofibromatosis- RT Noonan syndrome (NFNS)."; RL Am. J. Med. Genet. A 119:1-8(2003). RN [66] RP VARIANTS NF1 TYR-93; VAL-604; ARG-844 AND PRO-898, AND VARIANTS ASP-74; RP GLU-176; ARG-712 AND GLN-1276. RX PubMed=12522551; DOI=10.1007/s00439-002-0858-4; RA Wang Q., Montmain G., Ruano E., Upadhyaya M., Dudley S., Liskay R.M., RA Thibodeau S.N., Puisieux A.; RT "Neurofibromatosis type 1 gene as a mutational target in a mismatch repair- RT deficient cell type."; RL Hum. Genet. 112:117-123(2003). RN [67] RP VARIANTS NF1 LYS-780; PRO-847; GLU-848 AND ARG-968; ASN-1444; LEU-1953 DEL RP AND ARG-2001. RX PubMed=12552569; DOI=10.1002/humu.9111; RA De Luca A., Buccino A., Gianni D., Mangino M., Giustini S., Richetta A., RA Divona L., Calvieri S., Mingarelli R., Dallapiccola B.; RT "NF1 gene analysis based on DHPLC."; RL Hum. Mutat. 21:171-172(2003). RN [68] RP VARIANTS NF1 ARG-578; PRO-920 AND ALA-2221. RX PubMed=12746402; DOI=10.1136/jmg.40.5.368; RA Kluwe L., Tatagiba M., Fuensterer C., Mautner V.F.; RT "NF1 mutations and clinical spectrum in patients with spinal RT neurofibromas."; RL J. Med. Genet. 40:368-371(2003). RN [69] RP VARIANT NF1 VAL-186, AND CHARACTERIZATION OF VARIANT NF1 VAL-186. RX PubMed=15523642; DOI=10.1002/humu.20103; RA Zatkova A., Messiaen L., Vandenbroucke I., Wieser R., Fonatsch C., RA Krainer A.R., Wimmer K.; RT "Disruption of exonic splicing enhancer elements is the principal cause of RT exon skipping associated with seven nonsense or missense alleles of NF1."; RL Hum. Mutat. 24:491-501(2004). RN [70] RP VARIANTS NF1 ASN-157; ARG-629; SER-777; LYS-780; ARG-784; PRO-847; GLU-848; RP ARG-968; ASN-1444; LEU-1953 DEL AND ARG-2001, AND VARIANT GLU-176. RX PubMed=15146469; DOI=10.1002/humu.9245; RA De Luca A., Schirinzi A., Buccino A., Bottillo I., Sinibaldi L., RA Torrente I., Ciavarella A., Dottorini T., Porciello R., Giustini S., RA Calvieri S., Dallapiccola B.; RT "Novel and recurrent mutations in the NF1 gene in Italian patients with RT neurofibromatosis type 1."; RL Hum. Mutat. 23:629-629(2004). RN [71] RP VARIANTS NF1 ARG-31; PRO-145; ARG-324; VAL-337; CYS-489; PRO-532; ARG-574; RP ARG-629; PHE-665; PHE-844; PRO-844; MET-991 DEL; VAL-1073; ARG-1196; RP GLY-1276; GLN-1276; GLU-1430; GLU-1459 DEL AND GLY-1489, AND VARIANTS RP GLU-176 AND CYS-873. RX PubMed=15060124; DOI=10.1136/jmg.2003.011890; RA Mattocks C., Baralle D., Tarpey P., ffrench-Constant C., Bobrow M., RA Whittaker J.; RT "Automated comparative sequence analysis identifies mutations in 89% of NF1 RT patients and confirms a mutation cluster in exons 11-17 distinct from the RT GAP related domain."; RL J. Med. Genet. 41:E48-E48(2004). RN [72] RP VARIANT NF1 PRO-1243. RX PubMed=15520408; DOI=10.1136/jmg.2004.021683; RA Ferner R.E., Hughes R.A.C., Hall S.M., Upadhyaya M., Johnson M.R.; RT "Neurofibromatous neuropathy in neurofibromatosis 1 (NF1)."; RL J. Med. Genet. 41:837-841(2004). RN [73] RP VARIANT NF1 ARG-844. RX PubMed=15948193; DOI=10.1002/ajmg.a.30813; RA Bertola D.R., Pereira A.C., Passetti F., de Oliveira P.S.L., Messiaen L., RA Gelb B.D., Kim C.A., Krieger J.E.; RT "Neurofibromatosis-Noonan syndrome: molecular evidence of the concurrence RT of both disorders in a patient."; RL Am. J. Med. Genet. A 136:242-245(2005). RN [74] RP VARIANTS NFNS ARG-194; GLU-1444; THR-1451; LEU-1453 AND GLU-1459 DEL. RX PubMed=16380919; DOI=10.1086/498454; RA De Luca A., Bottillo I., Sarkozy A., Carta C., Neri C., Bellacchio E., RA Schirinzi A., Conti E., Zampino G., Battaglia A., Majore S., Rinaldi M.M., RA Carella M., Marino B., Pizzuti A., Digilio M.C., Tartaglia M., RA Dallapiccola B.; RT "NF1 gene mutations represent the major molecular event underlying RT neurofibromatosis-Noonan syndrome."; RL Am. J. Hum. Genet. 77:1092-1101(2005). RN [75] RP VARIANTS [LARGE SCALE ANALYSIS] ILE-1187; LEU-1951 AND ARG-2745. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [76] RP VARIANT NF1 MET-991 DEL. RX PubMed=17160901; DOI=10.1086/510781; RA Upadhyaya M., Huson S.M., Davies M., Thomas N., Chuzhanova N., RA Giovannini S., Evans D.G., Howard E., Kerr B., Griffiths S., Consoli C., RA Side L., Adams D., Pierpont M., Hachen R., Barnicoat A., Li H., Wallace P., RA Van Biervliet J.P., Stevenson D., Viskochil D., Baralle D., Haan E., RA Riccardi V., Turnpenny P., Lazaro C., Messiaen L.; RT "An absence of cutaneous neurofibromas associated with a 3-bp inframe RT deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a RT clinically significant NF1 genotype-phenotype correlation."; RL Am. J. Hum. Genet. 80:140-151(2007). RN [77] RP VARIANT NFNS PHE-1411. RX PubMed=19845691; DOI=10.1111/j.1399-0004.2009.01233.x; RA Nystrom A.M., Ekvall S., Allanson J., Edeby C., Elinder M., Holmstrom G., RA Bondeson M.L., Anneren G.; RT "Noonan syndrome and neurofibromatosis type I in a family with a novel RT mutation in NF1."; RL Clin. Genet. 76:524-534(2009). RN [78] RP VARIANT NF1 THR-160. RX PubMed=21838856; DOI=10.1186/1897-4287-9-6; RA Ponti G., Losi L., Martorana D., Priola M., Boni E., Pollio A., Neri T.M., RA Seidenari S.; RT "Clinico-pathological and biomolecular findings in Italian patients with RT multiple cutaneous neurofibromas."; RL Hered. Cancer Clin. Pract. 9:6-6(2011). RN [79] RP VARIANTS GLU-176; THR-330; ASP-393; LEU-393; PRO-519; THR-776 AND PHE-1484. RX PubMed=22108604; DOI=10.1038/ejhg.2011.207; RA Thomas L., Spurlock G., Eudall C., Thomas N.S., Mort M., Hamby S.E., RA Chuzhanova N., Brems H., Legius E., Cooper D.N., Upadhyaya M.; RT "Exploring the somatic NF1 mutational spectrum associated with NF1 RT cutaneous neurofibromas."; RL Eur. J. Hum. Genet. 20:411-419(2012). RN [80] RP VARIANTS NF1 TRP-93; ARG-1048; ARG-1189; ARG-1661 (ISOFORM I) AND THR-1918 RP (ISOFORM I). RX PubMed=23758643; DOI=10.1111/ahg.12026; RA Nemethova M., Bolcekova A., Ilencikova D., Durovcikova D., Hlinkova K., RA Hlavata A., Kovacs L., Kadasi L., Zatkova A.; RT "Thirty-nine novel neurofibromatosis 1 (NF1) gene mutations identified in RT Slovak patients."; RL Ann. Hum. Genet. 77:364-379(2013). RN [81] RP VARIANT NF1 PRO-2125. RX PubMed=24413922; DOI=10.1007/s00381-013-2352-9; RA Ben-Salem S., Al-Shamsi A.M., Ali B.R., Al-Gazali L.; RT "The mutational spectrum of the NF1 gene in neurofibromatosis type I RT patients from UAE."; RL Childs Nerv. Syst. 30:1183-1189(2014). CC -!- FUNCTION: Stimulates the GTPase activity of Ras. NF1 shows greater CC affinity for Ras GAP, but lower specific activity. May be a regulator CC of Ras activity. {ECO:0000269|PubMed:2121371, CC ECO:0000269|PubMed:8417346}. CC -!- SUBUNIT: Interacts with HTR6 (PubMed:23027611). Interacts with SPRED2 CC (PubMed:34626534). {ECO:0000269|PubMed:23027611, CC ECO:0000269|PubMed:34626534}. CC -!- INTERACTION: CC P21359; P05067: APP; NbExp=3; IntAct=EBI-1172917, EBI-77613; CC P21359; P01112: HRAS; NbExp=3; IntAct=EBI-1172917, EBI-350145; CC P21359; P34741: SDC2; NbExp=4; IntAct=EBI-1172917, EBI-1172957; CC P21359; Q7Z699: SPRED1; NbExp=6; IntAct=EBI-1172917, EBI-5235340; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:14988005}. Nucleus, CC nucleolus {ECO:0000269|PubMed:14988005}. Cell membrane CC {ECO:0000269|PubMed:34626534}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=6; CC Comment=Experimental confirmation may be lacking for some isoforms.; CC Name=II {ECO:0000303|PubMed:1923522}; CC IsoId=P21359-1; Sequence=Displayed; CC Name=I {ECO:0000303|PubMed:1923522}; CC IsoId=P21359-2; Sequence=VSP_001628; CC Name=3; CC IsoId=P21359-3; Sequence=VSP_001629, VSP_001630; CC Name=4; CC IsoId=P21359-4; Sequence=VSP_001631, VSP_001632; CC Name=5; CC IsoId=P21359-5; Sequence=VSP_043467, VSP_043468; CC Name=6; CC IsoId=P21359-6; Sequence=VSP_001628, VSP_053587; CC -!- TISSUE SPECIFICITY: Detected in brain, peripheral nerve, lung, colon CC and muscle. {ECO:0000269|PubMed:8417346}. CC -!- DOMAIN: Binds phospholipids via its C-terminal CRAL-TRIO domain. Binds CC primarily glycerophospholipids with monounsaturated C18:1 and/or C16:1 CC fatty acid moieties and a phosphatidylethanolamine or CC phosphatidylcholine headgroup. Has lesser affinity for lipids CC containing phosphatidylserine and phosphatidylinositol. CC {ECO:0000269|PubMed:16397625, ECO:0000269|PubMed:17187824, CC ECO:0000269|PubMed:21089070}. CC -!- PTM: Ubiquitinated by RNF7/RBX2, leading to its degradation. CC {ECO:0000250|UniProtKB:Q04690}. CC -!- RNA EDITING: Modified_positions=1306 {ECO:0000269|PubMed:11727199, CC ECO:0000269|PubMed:8602361}; Note=The stop codon (UGA) at position 1306 CC is created by RNA editing. Various levels of RNA editing occurs in CC peripheral nerve-sheath tumor samples (PNSTs) from patients with NF1. CC Preferentially observed in transcripts containing exon 23A.; CC -!- DISEASE: Neurofibromatosis 1 (NF1) [MIM:162200]: A disease CC characterized by patches of skin pigmentation (cafe-au-lait spots), CC Lisch nodules of the iris, tumors in the peripheral nervous system and CC fibromatous skin tumors. Individuals with the disorder have increased CC susceptibility to the development of benign and malignant tumors. CC {ECO:0000269|PubMed:10220149, ECO:0000269|PubMed:10336779, CC ECO:0000269|PubMed:10607834, ECO:0000269|PubMed:10712197, CC ECO:0000269|PubMed:10980545, ECO:0000269|PubMed:11258625, CC ECO:0000269|PubMed:11735023, ECO:0000269|PubMed:11857752, CC ECO:0000269|PubMed:12522551, ECO:0000269|PubMed:12552569, CC ECO:0000269|PubMed:12746402, ECO:0000269|PubMed:1302608, CC ECO:0000269|PubMed:15060124, ECO:0000269|PubMed:15146469, CC ECO:0000269|PubMed:15520408, ECO:0000269|PubMed:15523642, CC ECO:0000269|PubMed:15948193, ECO:0000269|PubMed:17160901, CC ECO:0000269|PubMed:21089070, ECO:0000269|PubMed:2114220, CC ECO:0000269|PubMed:21838856, ECO:0000269|PubMed:23758643, CC ECO:0000269|PubMed:24413922, ECO:0000269|PubMed:7981679, CC ECO:0000269|PubMed:8081387, ECO:0000269|PubMed:8544190, CC ECO:0000269|PubMed:8807336, ECO:0000269|PubMed:8834249, CC ECO:0000269|PubMed:9003501, ECO:0000269|PubMed:9101300, CC ECO:0000269|PubMed:9150739, ECO:0000269|PubMed:9298829, CC ECO:0000269|PubMed:9668168}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An CC aggressive pediatric myelodysplastic syndrome/myeloproliferative CC disorder characterized by malignant transformation in the hematopoietic CC stem cell compartment with proliferation of differentiated progeny. CC Patients have splenomegaly, enlarged lymph nodes, rashes, and CC hemorrhages. Note=The disease is caused by variants affecting the gene CC represented in this entry. CC -!- DISEASE: Watson syndrome (WTSN) [MIM:193520]: A syndrome characterized CC by the presence of pulmonary stenosis, cafe-au-lait spots, and CC intellectual disability. It is considered as an atypical form of CC neurofibromatosis. Note=The disease is caused by variants affecting the CC gene represented in this entry. CC -!- DISEASE: Familial spinal neurofibromatosis (FSNF) [MIM:162210]: CC Considered to be an alternative form of neurofibromatosis, showing CC multiple spinal tumors. {ECO:0000269|PubMed:11704931}. Note=The disease CC is caused by variants affecting the gene represented in this entry. CC -!- DISEASE: Neurofibromatosis-Noonan syndrome (NFNS) [MIM:601321]: CC Characterized by manifestations of both NF1 and Noonan syndrome (NS). CC NS is a disorder characterized by dysmorphic facial features, short CC stature, hypertelorism, cardiac anomalies, deafness, motor delay, and a CC bleeding diathesis. {ECO:0000269|PubMed:12707950, CC ECO:0000269|PubMed:16380919, ECO:0000269|PubMed:19845691}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. Note=The gene represented in this entry may be CC involved in disease pathogenesis. CC -!- CAUTION: Was originally thought to be associated with LEOPARD (LS), an CC autosomal dominant syndrome. {ECO:0000305|PubMed:8807336}. CC -!- SEQUENCE CAUTION: CC Sequence=AAA59923.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/134/NF1"; CC -!- WEB RESOURCE: Name=Mendelian genes neurofibromin 1 (NF1); Note=Leiden CC Open Variation Database (LOVD); CC URL="https://databases.lovd.nl/shared/genes/NF1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M89914; AAA59925.1; -; mRNA. DR EMBL; M82814; AAA59924.1; -; mRNA. DR EMBL; M60496; AAA59928.1; -; mRNA. DR EMBL; D12625; BAA02150.1; -; mRNA. DR EMBL; M38106; AAA74897.1; -; mRNA. DR EMBL; M38107; AAB59558.1; -; mRNA. DR EMBL; D42072; BAA07669.1; -; mRNA. DR EMBL; AY796305; AAV50004.1; -; Genomic_DNA. DR EMBL; AC004222; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC079915; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC134669; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC135724; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC138207; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC139072; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471147; EAW80272.1; -; Genomic_DNA. DR EMBL; CH471147; EAW80275.1; -; Genomic_DNA. DR EMBL; AH000834; AAA18483.1; -; Genomic_DNA. DR EMBL; Y07853; CAA69179.1; -; Genomic_DNA. DR EMBL; U17690; AAB48380.1; -; Genomic_DNA. DR EMBL; U17680; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17681; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17682; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17683; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17684; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17685; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17686; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17687; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17688; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17689; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17690; AAB48379.1; -; Genomic_DNA. DR EMBL; U17680; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17681; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17682; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17683; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17684; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17685; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17687; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17688; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17689; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17656; AAB48373.1; -; Genomic_DNA. DR EMBL; U17659; AAB48374.1; -; Genomic_DNA. DR EMBL; U17662; AAB48375.1; -; Genomic_DNA. DR EMBL; U17668; AAB48376.1; -; Genomic_DNA. DR EMBL; U17667; AAB48376.1; JOINED; Genomic_DNA. DR EMBL; U17673; AAB48377.1; -; Genomic_DNA. DR EMBL; U17677; AAB48378.1; -; Genomic_DNA. DR EMBL; U17676; AAB48378.1; JOINED; Genomic_DNA. DR EMBL; M60915; AAA59921.1; -; mRNA. DR EMBL; M60915; AAA59922.1; -; mRNA. DR EMBL; M61213; AAA59923.1; ALT_INIT; mRNA. DR EMBL; S51751; AAB24636.1; -; mRNA. DR EMBL; D10490; BAA01371.1; -; mRNA. DR CCDS; CCDS11264.1; -. [P21359-2] DR CCDS; CCDS42292.1; -. [P21359-1] DR CCDS; CCDS45645.1; -. [P21359-5] DR PIR; B55282; B55282. DR PIR; I78852; I78852. DR RefSeq; NP_000258.1; NM_000267.4. [P21359-2] DR RefSeq; NP_001035957.1; NM_001042492.3. [P21359-1] DR RefSeq; NP_001121619.1; NM_001128147.3. [P21359-5] DR PDB; 1NF1; X-ray; 2.50 A; A=1198-1551. DR PDB; 2D4Q; X-ray; 2.30 A; A/B=1581-1837. DR PDB; 2E2X; X-ray; 2.50 A; A/B=1566-1837. DR PDB; 3P7Z; X-ray; 2.65 A; A/B=1566-1837. DR PDB; 3PEG; X-ray; 2.52 A; A=1566-1837. DR PDB; 3PG7; X-ray; 2.19 A; A/B=1581-1837. DR PDB; 6OB2; X-ray; 2.85 A; B/D=1209-1484. DR PDB; 6OB3; X-ray; 2.10 A; B/D=1209-1484. DR PDB; 6V65; X-ray; 2.76 A; B=1203-1551. DR PDB; 6V6F; X-ray; 2.54 A; B=1203-1551. DR PDB; 7MOC; EM; 4.56 A; A/B=2-2839. DR PDB; 7MP5; EM; 5.60 A; A/B=2-2839. DR PDB; 7MP6; EM; 6.25 A; A/B=2-2839. DR PDB; 7PGP; EM; 3.10 A; F/N=1-2839. DR PDB; 7PGQ; EM; 3.50 A; F/N=1-2839. DR PDB; 7PGR; EM; 4.00 A; F/N=1-2839. DR PDB; 7PGS; EM; 3.40 A; F/N=1-2839. DR PDB; 7PGT; EM; 4.80 A; F/N=1-2839. DR PDB; 7PGU; EM; 3.30 A; F/N=1-2839. DR PDB; 7R03; EM; 3.60 A; A/B=1-2839. DR PDB; 7R04; EM; 3.70 A; A/B=1-2839. DR PDB; 8E20; EM; 3.60 A; A/B=1-2839. DR PDB; 8EDL; EM; 3.70 A; A=1-2839. DR PDB; 8EDM; EM; 3.60 A; A/B=1-2839. DR PDB; 8EDN; EM; 3.80 A; A=1-2839. DR PDB; 8EDO; EM; 3.40 A; A/B=1039-2302. DR PDBsum; 1NF1; -. DR PDBsum; 2D4Q; -. DR PDBsum; 2E2X; -. DR PDBsum; 3P7Z; -. DR PDBsum; 3PEG; -. DR PDBsum; 3PG7; -. DR PDBsum; 6OB2; -. DR PDBsum; 6OB3; -. DR PDBsum; 6V65; -. DR PDBsum; 6V6F; -. DR PDBsum; 7MOC; -. DR PDBsum; 7MP5; -. DR PDBsum; 7MP6; -. DR PDBsum; 7PGP; -. DR PDBsum; 7PGQ; -. DR PDBsum; 7PGR; -. DR PDBsum; 7PGS; -. DR PDBsum; 7PGT; -. DR PDBsum; 7PGU; -. DR PDBsum; 7R03; -. DR PDBsum; 7R04; -. DR PDBsum; 8E20; -. DR PDBsum; 8EDL; -. DR PDBsum; 8EDM; -. DR PDBsum; 8EDN; -. DR PDBsum; 8EDO; -. DR EMDB; EMD-13391; -. DR EMDB; EMD-13392; -. DR EMDB; EMD-13393; -. DR EMDB; EMD-13394; -. DR EMDB; EMD-13395; -. DR EMDB; EMD-13396; -. DR EMDB; EMD-14218; -. DR EMDB; EMD-14219; -. DR EMDB; EMD-23924; -. DR EMDB; EMD-23929; -. DR EMDB; EMD-23930; -. DR EMDB; EMD-27826; -. DR EMDB; EMD-28035; -. DR EMDB; EMD-28036; -. DR EMDB; EMD-28037; -. DR EMDB; EMD-28038; -. DR SMR; P21359; -. DR BioGRID; 110836; 239. DR CORUM; P21359; -. DR FunCoup; P21359; 3476. DR IntAct; P21359; 149. DR MINT; P21359; -. DR STRING; 9606.ENSP00000351015; -. DR GlyGen; P21359; 5 sites, 1 O-linked glycan (3 sites). DR iPTMnet; P21359; -. DR PhosphoSitePlus; P21359; -. DR SwissPalm; P21359; -. DR BioMuta; NF1; -. DR DMDM; 548350; -. DR CPTAC; CPTAC-1622; -. DR jPOST; P21359; -. DR MassIVE; P21359; -. DR PaxDb; 9606-ENSP00000351015; -. DR PeptideAtlas; P21359; -. DR ProteomicsDB; 53861; -. [P21359-1] DR ProteomicsDB; 53862; -. [P21359-2] DR ProteomicsDB; 53863; -. [P21359-3] DR ProteomicsDB; 53864; -. [P21359-4] DR ProteomicsDB; 53865; -. [P21359-5] DR Pumba; P21359; -. DR Antibodypedia; 3471; 481 antibodies from 39 providers. DR CPTC; P21359; 3 antibodies. DR DNASU; 4763; -. DR Ensembl; ENST00000356175.7; ENSP00000348498.3; ENSG00000196712.20. [P21359-2] DR Ensembl; ENST00000358273.9; ENSP00000351015.4; ENSG00000196712.20. [P21359-1] DR Ensembl; ENST00000431387.8; ENSP00000412921.4; ENSG00000196712.20. [P21359-5] DR Ensembl; ENST00000487476.5; ENSP00000491589.1; ENSG00000196712.20. [P21359-3] DR GeneID; 4763; -. DR KEGG; hsa:4763; -. DR MANE-Select; ENST00000358273.9; ENSP00000351015.4; NM_001042492.3; NP_001035957.1. DR UCSC; uc002hgf.3; human. [P21359-1] DR AGR; HGNC:7765; -. DR CIViC; 4763; 58 evidence items across 51 molecular profiles. DR ClinPGx; PA31572; -. DR CTD; 4763; -. DR DisGeNET; 4763; -. DR GeneCards; NF1; -. DR GeneReviews; NF1; -. DR HGNC; HGNC:7765; NF1. DR HPA; ENSG00000196712; Low tissue specificity. DR MalaCards; NF1; -. DR MIM; 114500; phenotype. DR MIM; 162200; phenotype. DR MIM; 162210; phenotype. DR MIM; 193520; phenotype. DR MIM; 601321; phenotype. DR MIM; 607785; phenotype. DR MIM; 613113; gene. DR OpenTargets; ENSG00000196712; -. DR Orphanet; 97685; 17q11 microdeletion syndrome. DR Orphanet; 139474; 17q11.2 microduplication syndrome. DR Orphanet; 99756; Alveolar rhabdomyosarcoma. DR Orphanet; 99757; Embryonal rhabdomyosarcoma. DR Orphanet; 29072; Hereditary pheochromocytoma-paraganglioma. DR Orphanet; 86834; Juvenile myelomonocytic leukemia. DR Orphanet; 363700; Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion. DR Orphanet; 638; Neurofibromatosis-Noonan syndrome. DR Orphanet; 293199; Pleomorphic rhabdomyosarcoma. DR VEuPathDB; HostDB:ENSG00000196712; -. DR eggNOG; KOG1826; Eukaryota. DR GeneTree; ENSGT00550000074797; -. DR HOGENOM; CLU_036305_0_0_1; -. DR InParanoid; P21359; -. DR OMA; TKEPYMF; -. DR OrthoDB; 28245at2759; -. DR PAN-GO; P21359; 0 GO annotations based on evolutionary models. DR PhylomeDB; P21359; -. DR PathwayCommons; P21359; -. DR Reactome; R-HSA-5658442; Regulation of RAS by GAPs. DR Reactome; R-HSA-6802953; RAS signaling downstream of NF1 loss-of-function variants. DR SignaLink; P21359; -. DR SIGNOR; P21359; -. DR Agora; ENSG00000196712; -. DR BioGRID-ORCS; 4763; 62 hits in 1192 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; NF1; human. DR EvolutionaryTrace; P21359; -. DR GeneWiki; Neurofibromin_1; -. DR GenomeRNAi; 4763; -. DR Pharos; P21359; Tbio. DR PRO; PR:P21359; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P21359; protein. DR Bgee; ENSG00000196712; Expressed in colonic epithelium and 202 other cell types or tissues. DR ExpressionAtlas; P21359; baseline and differential. DR GO; GO:0030424; C:axon; IDA:HGNC-UCL. DR GO; GO:0005737; C:cytoplasm; ISS:HGNC-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0030425; C:dendrite; IDA:HGNC-UCL. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0005730; C:nucleolus; IEA:UniProtKB-SubCell. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; ISS:HGNC-UCL. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0098793; C:presynapse; IEA:GOC. DR GO; GO:0005096; F:GTPase activator activity; IDA:UniProtKB. DR GO; GO:0031210; F:phosphatidylcholine binding; IDA:UniProtKB. DR GO; GO:0008429; F:phosphatidylethanolamine binding; IDA:UniProtKB. DR GO; GO:0030036; P:actin cytoskeleton organization; ISS:HGNC-UCL. DR GO; GO:0030325; P:adrenal gland development; ISS:HGNC-UCL. DR GO; GO:0021764; P:amygdala development; IEA:Ensembl. DR GO; GO:0001525; P:angiogenesis; IEA:Ensembl. DR GO; GO:0048844; P:artery morphogenesis; ISS:HGNC-UCL. DR GO; GO:0007420; P:brain development; ISS:HGNC-UCL. DR GO; GO:0048593; P:camera-type eye morphogenesis; ISS:HGNC-UCL. DR GO; GO:0007154; P:cell communication; ISS:HGNC-UCL. DR GO; GO:0034605; P:cellular response to heat; IEA:Ensembl. DR GO; GO:0021987; P:cerebral cortex development; ISS:HGNC-UCL. DR GO; GO:0050890; P:cognition; IMP:HGNC-UCL. DR GO; GO:0030199; P:collagen fibril organization; ISS:HGNC-UCL. DR GO; GO:0001935; P:endothelial cell proliferation; IEA:Ensembl. DR GO; GO:0030198; P:extracellular matrix organization; ISS:HGNC-UCL. DR GO; GO:0097192; P:extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl. DR GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl. DR GO; GO:0048144; P:fibroblast proliferation; IEA:Ensembl. DR GO; GO:0021897; P:forebrain astrocyte development; ISS:HGNC-UCL. DR GO; GO:0048853; P:forebrain morphogenesis; ISS:HGNC-UCL. DR GO; GO:0061534; P:gamma-aminobutyric acid secretion, neurotransmission; IEA:Ensembl. DR GO; GO:0061535; P:glutamate secretion, neurotransmission; IEA:Ensembl. DR GO; GO:0048820; P:hair follicle maturation; IEA:Ensembl. DR GO; GO:0007507; P:heart development; ISS:HGNC-UCL. DR GO; GO:0001889; P:liver development; ISS:HGNC-UCL. DR GO; GO:0060291; P:long-term synaptic potentiation; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; ISS:HGNC-UCL. DR GO; GO:0033024; P:mast cell apoptotic process; IEA:Ensembl. DR GO; GO:0070662; P:mast cell proliferation; IEA:Ensembl. DR GO; GO:0001656; P:metanephros development; ISS:HGNC-UCL. DR GO; GO:0022011; P:myelination in peripheral nervous system; ISS:HGNC-UCL. DR GO; GO:0097529; P:myeloid leukocyte migration; IEA:Ensembl. DR GO; GO:0016525; P:negative regulation of angiogenesis; IEA:Ensembl. DR GO; GO:0048712; P:negative regulation of astrocyte differentiation; IEA:Ensembl. DR GO; GO:0030336; P:negative regulation of cell migration; IMP:MGI. DR GO; GO:0001953; P:negative regulation of cell-matrix adhesion; IEA:Ensembl. DR GO; GO:0001937; P:negative regulation of endothelial cell proliferation; IMP:MGI. DR GO; GO:0048147; P:negative regulation of fibroblast proliferation; ISS:UniProtKB. DR GO; GO:0002686; P:negative regulation of leukocyte migration; IEA:Ensembl. DR GO; GO:0043409; P:negative regulation of MAPK cascade; IMP:MGI. DR GO; GO:0070667; P:negative regulation of mast cell proliferation; IEA:Ensembl. DR GO; GO:0007406; P:negative regulation of neuroblast proliferation; ISS:HGNC-UCL. DR GO; GO:0046929; P:negative regulation of neurotransmitter secretion; IEA:Ensembl. DR GO; GO:0048715; P:negative regulation of oligodendrocyte differentiation; ISS:HGNC-UCL. DR GO; GO:0045671; P:negative regulation of osteoclast differentiation; IEA:Ensembl. DR GO; GO:0042308; P:negative regulation of protein import into nucleus; IEA:Ensembl. DR GO; GO:0035021; P:negative regulation of Rac protein signal transduction; IEA:Ensembl. DR GO; GO:0046580; P:negative regulation of Ras protein signal transduction; IEA:Ensembl. DR GO; GO:1900148; P:negative regulation of Schwann cell migration; IEA:Ensembl. DR GO; GO:0010626; P:negative regulation of Schwann cell proliferation; IEA:Ensembl. DR GO; GO:2000647; P:negative regulation of stem cell proliferation; IEA:Ensembl. DR GO; GO:1904753; P:negative regulation of vascular associated smooth muscle cell migration; IEA:Ensembl. DR GO; GO:0021915; P:neural tube development; IEA:Ensembl. DR GO; GO:0007405; P:neuroblast proliferation; IEA:Ensembl. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0098597; P:observational learning; IEA:Ensembl. DR GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:0001649; P:osteoblast differentiation; ISS:HGNC-UCL. DR GO; GO:0030316; P:osteoclast differentiation; IEA:Ensembl. DR GO; GO:0007422; P:peripheral nervous system development; ISS:HGNC-UCL. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; ISS:HGNC-UCL. DR GO; GO:0043473; P:pigmentation; ISS:HGNC-UCL. DR GO; GO:0043065; P:positive regulation of apoptotic process; ISS:HGNC-UCL. DR GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IEA:Ensembl. DR GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl. DR GO; GO:0043547; P:positive regulation of GTPase activity; IDA:UniProtKB. DR GO; GO:0033027; P:positive regulation of mast cell apoptotic process; IEA:Ensembl. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; ISS:HGNC-UCL. DR GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IEA:Ensembl. DR GO; GO:0006606; P:protein import into nucleus; IEA:Ensembl. DR GO; GO:0016601; P:Rac protein signal transduction; IEA:Ensembl. DR GO; GO:0007265; P:Ras protein signal transduction; ISS:HGNC-UCL. DR GO; GO:0045765; P:regulation of angiogenesis; IMP:HGNC-UCL. DR GO; GO:0043535; P:regulation of blood vessel endothelial cell migration; IMP:HGNC-UCL. DR GO; GO:0045124; P:regulation of bone resorption; ISS:HGNC-UCL. DR GO; GO:0001952; P:regulation of cell-matrix adhesion; ISS:HGNC-UCL. DR GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IEA:Ensembl. DR GO; GO:0010468; P:regulation of gene expression; IEA:Ensembl. DR GO; GO:0045685; P:regulation of glial cell differentiation; ISS:HGNC-UCL. DR GO; GO:1902531; P:regulation of intracellular signal transduction; IBA:GO_Central. DR GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; IEA:Ensembl. DR GO; GO:1900271; P:regulation of long-term synaptic potentiation; IEA:Ensembl. DR GO; GO:0099175; P:regulation of postsynapse organization; IEA:Ensembl. DR GO; GO:0032228; P:regulation of synaptic transmission, GABAergic; IEA:Ensembl. DR GO; GO:0001666; P:response to hypoxia; ISS:HGNC-UCL. DR GO; GO:0014044; P:Schwann cell development; ISS:HGNC-UCL. DR GO; GO:0036135; P:Schwann cell migration; IEA:Ensembl. DR GO; GO:0014010; P:Schwann cell proliferation; IEA:Ensembl. DR GO; GO:0007519; P:skeletal muscle tissue development; IEA:Ensembl. DR GO; GO:0048745; P:smooth muscle tissue development; ISS:HGNC-UCL. DR GO; GO:0021510; P:spinal cord development; ISS:HGNC-UCL. DR GO; GO:0072089; P:stem cell proliferation; IEA:Ensembl. DR GO; GO:0048485; P:sympathetic nervous system development; ISS:HGNC-UCL. DR GO; GO:1904738; P:vascular associated smooth muscle cell migration; IEA:Ensembl. DR GO; GO:1990874; P:vascular associated smooth muscle cell proliferation; IEA:Ensembl. DR GO; GO:0008542; P:visual learning; ISS:HGNC-UCL. DR GO; GO:0042060; P:wound healing; ISS:HGNC-UCL. DR CDD; cd13313; PH_NF1; 1. DR CDD; cd05130; RasGAP_Neurofibromin; 1. DR CDD; cd00170; SEC14; 1. DR FunFam; 2.30.29.30:FF:000070; Neurofibromin 1; 1. DR FunFam; 3.40.525.10:FF:000004; Neurofibromin 1; 1. DR FunFam; 1.10.506.10:FF:000015; Neurofibromin isoform 1; 1. DR FunFam; 1.10.506.10:FF:000023; Neurofibromin isoform 1; 1. DR Gene3D; 3.40.525.10; CRAL-TRIO lipid binding domain; 1. DR Gene3D; 1.10.506.10; GTPase Activation - p120gap, domain 1; 2. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR001251; CRAL-TRIO_dom. DR InterPro; IPR036865; CRAL-TRIO_dom_sf. DR InterPro; IPR011993; PH-like_dom_sf. DR InterPro; IPR054071; PH_NF1. DR InterPro; IPR039360; Ras_GTPase. DR InterPro; IPR023152; RasGAP_CS. DR InterPro; IPR001936; RasGAP_dom. DR InterPro; IPR008936; Rho_GTPase_activation_prot. DR PANTHER; PTHR10194:SF142; NEUROFIBROMIN; 1. DR PANTHER; PTHR10194; RAS GTPASE-ACTIVATING PROTEINS; 1. DR Pfam; PF13716; CRAL_TRIO_2; 1. DR Pfam; PF21877; PH_NF1; 1. DR Pfam; PF00616; RasGAP; 1. DR SMART; SM00323; RasGAP; 1. DR SMART; SM00516; SEC14; 1. DR SUPFAM; SSF48371; ARM repeat; 1. DR SUPFAM; SSF48350; GTPase activation domain, GAP; 1. DR PROSITE; PS50191; CRAL_TRIO; 1. DR PROSITE; PS00509; RAS_GTPASE_ACTIV_1; 1. DR PROSITE; PS50018; RAS_GTPASE_ACTIV_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Cell membrane; KW Disease variant; GTPase activation; Lipid-binding; Membrane; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; RNA editing; KW Tumor suppressor; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000250|UniProtKB:P97526" FT CHAIN 2..2839 FT /note="Neurofibromin" FT /id="PRO_0000010773" FT CHAIN 2..1305 FT /note="Neurofibromin truncated" FT /id="PRO_0000010774" FT DOMAIN 1251..1482 FT /note="Ras-GAP" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00167" FT DOMAIN 1580..1738 FT /note="CRAL-TRIO" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00056" FT REGION 1580..1837 FT /note="Lipid binding" FT REGION 2787..2839 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 2555..2571 FT /note="Bipartite nuclear localization signal" FT COMPBIAS 2801..2827 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT SITE 1276 FT /note="Arginine finger; crucial for GTP hydrolysis by FT stabilizing the transition state" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00167" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0000250|UniProtKB:P97526" FT MOD_RES 864 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 876 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2188 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2467 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q04690" FT MOD_RES 2514 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q04690" FT MOD_RES 2515 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163" FT MOD_RES 2521 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2523 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2543 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 2565 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2597 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2802 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2817 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569" FT VAR_SEQ 548..551 FT /note="ALLV -> VRGK (in isoform 3)" FT /evidence="ECO:0000303|PubMed:1339276" FT /id="VSP_001629" FT VAR_SEQ 552..2839 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:1339276" FT /id="VSP_001630" FT VAR_SEQ 574..593 FT /note="SSQMLFYICKKLTSHQMLSS -> RYMYFYFLNSTFKFYFVFLS (in FT isoform 5)" FT /evidence="ECO:0000303|PubMed:7570581" FT /id="VSP_043467" FT VAR_SEQ 594..2839 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:7570581" FT /id="VSP_043468" FT VAR_SEQ 1371..1391 FT /note="Missing (in isoform I and isoform 6)" FT /evidence="ECO:0000303|PubMed:1457041, FT ECO:0000303|PubMed:1783401, ECO:0000303|PubMed:1923522, FT ECO:0000303|PubMed:2114220, ECO:0000303|PubMed:2116237, FT ECO:0000303|PubMed:2134734" FT /id="VSP_001628" FT VAR_SEQ 1591..1598 FT /note="SIFYQAGT -> TPPPEPET (in isoform 4)" FT /evidence="ECO:0000303|PubMed:2121370" FT /id="VSP_001631" FT VAR_SEQ 1599..2839 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:2121370" FT /id="VSP_001632" FT VAR_SEQ 2792 FT /note="P -> PASLPCSNSAVFMQLFPHQ (in isoform 6)" FT /evidence="ECO:0000303|PubMed:2116237" FT /id="VSP_053587" FT VARIANT 31 FT /note="H -> R (in NF1; dbSNP:rs199474725)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032459" FT VARIANT 74 FT /note="A -> D (in mismatch repair deficient cancer cells; FT dbSNP:rs199474726)" FT /evidence="ECO:0000269|PubMed:12522551" FT /id="VAR_017550" FT VARIANT 80 FT /note="Y -> C (in dbSNP:rs4795581)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_022254" FT VARIANT 80 FT /note="Y -> S (in dbSNP:rs4795581)" FT /id="VAR_049135" FT VARIANT 82 FT /note="S -> F (in NF1; dbSNP:rs199474729)" FT /evidence="ECO:0000269|PubMed:11857752" FT /id="VAR_021730" FT VARIANT 93 FT /note="C -> W (in NF1; dbSNP:rs1597629882)" FT /evidence="ECO:0000269|PubMed:23758643" FT /id="VAR_071668" FT VARIANT 93 FT /note="C -> Y (in NF1; dbSNP:rs199474728)" FT /evidence="ECO:0000269|PubMed:12522551" FT /id="VAR_017551" FT VARIANT 117 FT /note="I -> S (in NF1; dbSNP:rs199474731)" FT /evidence="ECO:0000269|PubMed:10607834" FT /id="VAR_010989" FT VARIANT 145 FT /note="L -> P (in NF1; dbSNP:rs199474734)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032460" FT VARIANT 157 FT /note="I -> N (in NF1; dbSNP:rs199474744)" FT /evidence="ECO:0000269|PubMed:15146469" FT /id="VAR_021731" FT VARIANT 160 FT /note="R -> T (in NF1; dbSNP:rs199474752)" FT /evidence="ECO:0000269|PubMed:21838856" FT /id="VAR_065888" FT VARIANT 176 FT /note="D -> E (found in mismatch repair deficient cancer FT cells; also found in a cutaneous neurofibroma from a FT patient with neurofibromatosis; somatic mutation; FT dbSNP:rs112306990)" FT /evidence="ECO:0000269|PubMed:10712197, FT ECO:0000269|PubMed:12522551, ECO:0000269|PubMed:15060124, FT ECO:0000269|PubMed:15146469, ECO:0000269|PubMed:22108604" FT /id="VAR_017552" FT VARIANT 186 FT /note="D -> V (in NF1; reduced splicing enhancement; FT dbSNP:rs1567820771)" FT /evidence="ECO:0000269|PubMed:15523642" FT /id="VAR_032461" FT VARIANT 194 FT /note="L -> R (in NFNS; dbSNP:rs199474753)" FT /evidence="ECO:0000269|PubMed:16380919" FT /id="VAR_032462" FT VARIANT 216 FT /note="L -> P (in NF1; dbSNP:rs199474756)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021732" FT VARIANT 324 FT /note="C -> R (in NF1; dbSNP:rs199474735)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032463" FT VARIANT 330 FT /note="A -> T (in a cutaneous neurofibroma from a patient FT with neurofibromatosis; somatic mutation; FT dbSNP:rs199474767)" FT /evidence="ECO:0000269|PubMed:22108604" FT /id="VAR_067201" FT VARIANT 337 FT /note="E -> V (in NF1; dbSNP:rs199474736)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032464" FT VARIANT 338 FT /note="D -> G (in NF1; dbSNP:rs199474773)" FT /evidence="ECO:0000269|PubMed:9298829" FT /id="VAR_010990" FT VARIANT 357 FT /note="L -> P (in NF1; dbSNP:rs137854563)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021733" FT VARIANT 393 FT /note="H -> D (in a cutaneous neurofibroma from a patient FT with neurofibromatosis; somatic mutation; FT dbSNP:rs199474768)" FT /evidence="ECO:0000269|PubMed:22108604" FT /id="VAR_067202" FT VARIANT 393 FT /note="H -> L (in a cutaneous neurofibroma from a patient FT with neurofibromatosis; somatic mutation; FT dbSNP:rs199474769)" FT /evidence="ECO:0000269|PubMed:22108604" FT /id="VAR_067203" FT VARIANT 489 FT /note="Y -> C (in NF1; dbSNP:rs137854557)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032465" FT VARIANT 491 FT /note="Y -> C (in NF1; dbSNP:rs199474757)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021734" FT VARIANT 508 FT /note="L -> P (in NF1; dbSNP:rs137854558)" FT /evidence="ECO:0000269|PubMed:11258625" FT /id="VAR_010991" FT VARIANT 519 FT /note="Q -> P (in a cutaneous neurofibroma from a patient FT with neurofibromatosis; somatic mutation; FT dbSNP:rs199474770)" FT /evidence="ECO:0000269|PubMed:22108604" FT /id="VAR_067204" FT VARIANT 532 FT /note="L -> P (in NF1; dbSNP:rs199474737)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032466" FT VARIANT 549 FT /note="L -> P (in NF1; dbSNP:rs199474758)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021735" FT VARIANT 574 FT /note="S -> R (in NF1; dbSNP:rs2144015494 and FT dbSNP:rs2066929440)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032467" FT VARIANT 578 FT /note="L -> R (in NF1; dbSNP:rs199474774)" FT /evidence="ECO:0000269|PubMed:12746402" FT /id="VAR_021736" FT VARIANT 581 FT /note="I -> T (in NF1; dbSNP:rs199474759)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021737" FT VARIANT 583 FT /note="K -> R (in NF1; dbSNP:rs199474760)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021738" FT VARIANT 604 FT /note="L -> V (in NF1; dbSNP:rs142712751)" FT /evidence="ECO:0000269|PubMed:12522551" FT /id="VAR_017553" FT VARIANT 629 FT /note="G -> R (in NF1; affects splicing by creating a novel FT splice acceptor site; dbSNP:rs199474738)" FT /evidence="ECO:0000269|PubMed:15060124, FT ECO:0000269|PubMed:15146469, ECO:0000269|PubMed:8834249" FT /id="VAR_002653" FT VARIANT 665 FT /note="S -> F (in NF1; uncertain significance; FT dbSNP:rs145891889)" FT /evidence="ECO:0000269|PubMed:10712197, FT ECO:0000269|PubMed:15060124" FT /id="VAR_021739" FT VARIANT 678 FT /note="P -> L (in dbSNP:rs17881753)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_022255" FT VARIANT 695 FT /note="L -> P (in NF1; dbSNP:rs199474761)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021740" FT VARIANT 712 FT /note="H -> R (in mismatch repair deficient cancer cells; FT dbSNP:rs199474727)" FT /evidence="ECO:0000269|PubMed:12522551" FT /id="VAR_017554" FT VARIANT 763 FT /note="L -> P (in NF1; dbSNP:rs199474762)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021741" FT VARIANT 765 FT /note="R -> H (in NF1; uncertain significance; FT dbSNP:rs199474777)" FT /evidence="ECO:0000269|PubMed:10336779" FT /id="VAR_021742" FT VARIANT 776 FT /note="A -> T (in a cutaneous neurofibroma from a patient FT with neurofibromatosis; somatic mutation; FT dbSNP:rs199474771)" FT /evidence="ECO:0000269|PubMed:22108604" FT /id="VAR_067205" FT VARIANT 777 FT /note="W -> S (in NF1; dbSNP:rs199474745)" FT /evidence="ECO:0000269|PubMed:10712197, FT ECO:0000269|PubMed:15146469" FT /id="VAR_021743" FT VARIANT 780 FT /note="T -> K (in NF1; dbSNP:rs199474746)" FT /evidence="ECO:0000269|PubMed:10712197, FT ECO:0000269|PubMed:11735023, ECO:0000269|PubMed:12552569, FT ECO:0000269|PubMed:15146469" FT /id="VAR_021744" FT VARIANT 781 FT /note="H -> P (in NF1; dbSNP:rs199474763)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021745" FT VARIANT 784 FT /note="W -> C (in NF1; dbSNP:rs199474778)" FT /evidence="ECO:0000269|PubMed:11735023" FT /id="VAR_021746" FT VARIANT 784 FT /note="W -> R (in NF1; dbSNP:rs199474730)" FT /evidence="ECO:0000269|PubMed:11857752, FT ECO:0000269|PubMed:15146469" FT /id="VAR_021747" FT VARIANT 844 FT /note="L -> F (in NF1; dbSNP:rs199474785)" FT /evidence="ECO:0000269|PubMed:10980545, FT ECO:0000269|PubMed:15060124" FT /id="VAR_010992" FT VARIANT 844 FT /note="L -> P (in NF1; dbSNP:rs137854566)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032468" FT VARIANT 844 FT /note="L -> R (in NF1; sporadic; dbSNP:rs137854566)" FT /evidence="ECO:0000269|PubMed:12522551, FT ECO:0000269|PubMed:15948193, ECO:0000269|PubMed:9150739" FT /id="VAR_002654" FT VARIANT 847 FT /note="L -> P (in NF1; dbSNP:rs199474747)" FT /evidence="ECO:0000269|PubMed:10712197, FT ECO:0000269|PubMed:12552569, ECO:0000269|PubMed:15146469" FT /id="VAR_021748" FT VARIANT 848 FT /note="G -> E (in NF1; dbSNP:rs199474748)" FT /evidence="ECO:0000269|PubMed:12552569, FT ECO:0000269|PubMed:15146469" FT /id="VAR_021749" FT VARIANT 873 FT /note="R -> C (in dbSNP:rs199474739)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032469" FT VARIANT 898 FT /note="L -> P (in NF1; sporadic; dbSNP:rs199474786)" FT /evidence="ECO:0000269|PubMed:12522551, FT ECO:0000269|PubMed:9150739" FT /id="VAR_002655" FT VARIANT 920 FT /note="L -> P (in NF1; patient with cafe-au-lait spots; may FT be a distinct form of NF1; dbSNP:rs199474775)" FT /evidence="ECO:0000269|PubMed:12746402" FT /id="VAR_021750" FT VARIANT 968 FT /note="M -> R (in NF1; dbSNP:rs199474749)" FT /evidence="ECO:0000269|PubMed:12552569, FT ECO:0000269|PubMed:15146469" FT /id="VAR_021751" FT VARIANT 991 FT /note="Missing (in NF1; most patients carrying the mutation FT do not manifest cutaneous neurofibromas)" FT /evidence="ECO:0000269|PubMed:15060124, FT ECO:0000269|PubMed:17160901, ECO:0000269|PubMed:7904209" FT /id="VAR_002656" FT VARIANT 1035 FT /note="M -> R (in NF1; dbSNP:rs137854553)" FT /evidence="ECO:0000269|PubMed:8807336" FT /id="VAR_002657" FT VARIANT 1048 FT /note="W -> R (in NF1; dbSNP:rs1555614634)" FT /evidence="ECO:0000269|PubMed:23758643" FT /id="VAR_071669" FT VARIANT 1073 FT /note="M -> V (in NF1; dbSNP:rs199474740)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032470" FT VARIANT 1147 FT /note="L -> P (in NF1; dbSNP:rs199474779)" FT /evidence="ECO:0000269|PubMed:11735023" FT /id="VAR_021752" FT VARIANT 1156 FT /note="N -> S (in NF1; dbSNP:rs199474764)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021753" FT VARIANT 1166 FT /note="G -> D (in NF1; dbSNP:rs199474787)" FT /evidence="ECO:0000269|PubMed:7981679" FT /id="VAR_010993" FT VARIANT 1187 FT /note="L -> I (in a colorectal cancer sample; somatic FT mutation; dbSNP:rs2067142260)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035543" FT VARIANT 1189 FT /note="Q -> R (in NF1; dbSNP:rs752039618)" FT /evidence="ECO:0000269|PubMed:23758643" FT /id="VAR_071670" FT VARIANT 1193 FT /note="F -> C (in NF1; dbSNP:rs199474780)" FT /evidence="ECO:0000269|PubMed:11735023" FT /id="VAR_021754" FT VARIANT 1196 FT /note="L -> R (in NF1; dbSNP:rs199474741)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032471" FT VARIANT 1204 FT /note="R -> G (in NF1; dbSNP:rs199474732)" FT /evidence="ECO:0000269|PubMed:10336779" FT /id="VAR_021755" FT VARIANT 1204 FT /note="R -> W (in NF1; dbSNP:rs199474732)" FT /evidence="ECO:0000269|PubMed:10607834" FT /id="VAR_010994" FT VARIANT 1243 FT /note="L -> P (in NF1; with neurofibromatous neuropathy; FT dbSNP:rs137854564)" FT /evidence="ECO:0000269|PubMed:15520408" FT /id="VAR_032472" FT VARIANT 1250 FT /note="R -> P (in NF1; dbSNP:rs199474765)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021756" FT VARIANT 1276 FT /note="R -> G (in NF1; dbSNP:rs199474742)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032473" FT VARIANT 1276 FT /note="R -> P (in NF1; complete loss of GAP activity; FT dbSNP:rs137854556)" FT /evidence="ECO:0000269|PubMed:10712197, FT ECO:0000269|PubMed:9668168" FT /id="VAR_010995" FT VARIANT 1276 FT /note="R -> Q (in NF1 and mismatch repair deficient cancer FT cells; dbSNP:rs137854556)" FT /evidence="ECO:0000269|PubMed:10712197, FT ECO:0000269|PubMed:12522551, ECO:0000269|PubMed:15060124" FT /id="VAR_017555" FT VARIANT 1411 FT /note="L -> F (in NFNS; dbSNP:rs199474789)" FT /evidence="ECO:0000269|PubMed:19845691" FT /id="VAR_065236" FT VARIANT 1412 FT /note="R -> S (in NF1; significant reduction of GAP FT activity; dbSNP:rs137854554)" FT /evidence="ECO:0000269|PubMed:9003501" FT /id="VAR_010996" FT VARIANT 1422 FT /note="Y -> H (in dbSNP:rs17884349)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_022256" FT VARIANT 1430 FT /note="K -> E (in NF1)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032474" FT VARIANT 1440 FT /note="K -> Q (in NF1; dbSNP:rs199474790)" FT /evidence="ECO:0000269|PubMed:9003501" FT /id="VAR_010997" FT VARIANT 1440 FT /note="K -> R (in NF1; dbSNP:rs199474788)" FT /evidence="ECO:0000269|PubMed:7981679" FT /id="VAR_002658" FT VARIANT 1444 FT /note="K -> E (in NF1 and NFNS; significant reduction of FT intrinsic GAP activity; dbSNP:rs137854550)" FT /evidence="ECO:0000269|PubMed:11857752, FT ECO:0000269|PubMed:1568247, ECO:0000269|PubMed:16380919, FT ECO:0000269|PubMed:9003501" FT /id="VAR_002659" FT VARIANT 1444 FT /note="K -> N (in NF1; dbSNP:rs199474750)" FT /evidence="ECO:0000269|PubMed:12552569, FT ECO:0000269|PubMed:15146469" FT /id="VAR_021757" FT VARIANT 1444 FT /note="K -> R (in NF1; dbSNP:rs199474781)" FT /evidence="ECO:0000269|PubMed:11735023" FT /id="VAR_021758" FT VARIANT 1446 FT /note="L -> P (in NF1; dbSNP:rs199474733)" FT /evidence="ECO:0000269|PubMed:10220149, FT ECO:0000269|PubMed:10607834, ECO:0000269|PubMed:10712197" FT /id="VAR_008129" FT VARIANT 1451 FT /note="N -> T (in NFNS; dbSNP:rs199474754)" FT /evidence="ECO:0000269|PubMed:16380919" FT /id="VAR_032475" FT VARIANT 1453 FT /note="V -> L (in NFNS; dbSNP:rs199474755)" FT /evidence="ECO:0000269|PubMed:16380919" FT /id="VAR_032476" FT VARIANT 1459 FT /note="Missing (in NFNS; dbSNP:rs267606607)" FT /evidence="ECO:0000269|PubMed:12707950, FT ECO:0000269|PubMed:15060124, ECO:0000269|PubMed:16380919" FT /id="VAR_032477" FT VARIANT 1484 FT /note="S -> F (in a cutaneous neurofibroma from a patient FT with neurofibromatosis; somatic mutation; FT dbSNP:rs199474772)" FT /evidence="ECO:0000269|PubMed:22108604" FT /id="VAR_067206" FT VARIANT 1489 FT /note="S -> G (in NF1; dbSNP:rs199474743)" FT /evidence="ECO:0000269|PubMed:15060124, FT ECO:0000269|PubMed:9003501" FT /id="VAR_010998" FT VARIANT 1605 FT /note="I -> V (in NF1; reduces protein stability; FT dbSNP:rs199474766)" FT /evidence="ECO:0000269|PubMed:10712197, FT ECO:0000269|PubMed:21089070" FT /id="VAR_021759" FT VARIANT 1611 FT /note="R -> W (in NF1; dbSNP:rs1060500316)" FT /evidence="ECO:0000269|PubMed:9298829" FT /id="VAR_002660" FT VARIANT 1733 FT /note="L -> LGHEQQKLPAATLAL (in NF1)" FT /evidence="ECO:0000269|PubMed:8317503" FT /id="VAR_002661" FT VARIANT 1785 FT /note="A -> S (in NF1; dbSNP:rs199474782)" FT /evidence="ECO:0000269|PubMed:11735023" FT /id="VAR_021760" FT VARIANT 1951 FT /note="P -> L (in a colorectal cancer sample; somatic FT mutation; dbSNP:rs2151550343)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035544" FT VARIANT 1952 FT /note="W -> R (in NF1; dbSNP:rs199474791)" FT /evidence="ECO:0000269|PubMed:9101300" FT /id="VAR_002662" FT VARIANT 1953 FT /note="L -> P (in NF1; dbSNP:rs199474792)" FT /evidence="ECO:0000269|PubMed:2114220" FT /id="VAR_002663" FT VARIANT 1953 FT /note="Missing (in NF1)" FT /evidence="ECO:0000269|PubMed:12552569, FT ECO:0000269|PubMed:15146469" FT /id="VAR_021761" FT VARIANT 2001 FT /note="G -> R (in NF1; dbSNP:rs199474751)" FT /evidence="ECO:0000269|PubMed:12552569, FT ECO:0000269|PubMed:15146469" FT /id="VAR_021762" FT VARIANT 2012 FT /note="D -> N (in NF1; dbSNP:rs199474783)" FT /evidence="ECO:0000269|PubMed:11735023" FT /id="VAR_021763" FT VARIANT 2088 FT /note="L -> P (in FSNF; no cafe-au-lait macules; null FT mutation; 50% reduction of protein level; FT dbSNP:rs137854561)" FT /evidence="ECO:0000269|PubMed:11704931" FT /id="VAR_017669" FT VARIANT 2125 FT /note="L -> P (in NF1; dbSNP:rs1597843129)" FT /evidence="ECO:0000269|PubMed:24413922" FT /id="VAR_071671" FT VARIANT 2164 FT /note="L -> M (in NF1; dbSNP:rs137854551)" FT /evidence="ECO:0000269|PubMed:1302608" FT /id="VAR_002664" FT VARIANT 2192 FT /note="Y -> N (in NF1; dbSNP:rs267606598)" FT /evidence="ECO:0000269|PubMed:1302608" FT /id="VAR_002665" FT VARIANT 2221 FT /note="P -> A (in NF1; dbSNP:rs199474776)" FT /evidence="ECO:0000269|PubMed:12746402" FT /id="VAR_021764" FT VARIANT 2357 FT /note="E -> K (in NF1; dbSNP:rs199474784)" FT /evidence="ECO:0000269|PubMed:11735023" FT /id="VAR_021765" FT VARIANT 2387..2388 FT /note="Missing (in NF1)" FT /evidence="ECO:0000269|PubMed:10607834, FT ECO:0000269|PubMed:8081387" FT /id="VAR_002666" FT VARIANT 2507 FT /note="T -> I (in NF1; dbSNP:rs149055633)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021766" FT VARIANT 2511 FT /note="V -> L (in dbSNP:rs2230850)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_022257" FT VARIANT 2631 FT /note="T -> A (in NF1; dbSNP:rs199474793)" FT /evidence="ECO:0000269|PubMed:8544190" FT /id="VAR_002667" FT VARIANT 2745 FT /note="G -> R (in a breast cancer sample; somatic mutation; FT dbSNP:rs2151587866)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035545" FT MUTAGEN 1691 FT /note="K->A: Reduces phospholipid binding; when associated FT with A-1695; A-1769 and A-1771." FT /evidence="ECO:0000269|PubMed:16397625" FT MUTAGEN 1695 FT /note="R->A: Reduces phospholipid binding; when associated FT with A-1691; A-1769 and A-1771." FT /evidence="ECO:0000269|PubMed:16397625" FT MUTAGEN 1769 FT /note="R->A: Reduces phospholipid binding; when associated FT with A-1691; A-1695 and A-1771." FT /evidence="ECO:0000269|PubMed:16397625" FT MUTAGEN 1771 FT /note="K->A: Reduces phospholipid binding; when associated FT with A-1691; A-169 and A-1769." FT /evidence="ECO:0000269|PubMed:16397625, FT ECO:0000269|PubMed:21089070" FT MUTAGEN 1771 FT /note="Missing: Reduces protein stability." FT /evidence="ECO:0000269|PubMed:16397625, FT ECO:0000269|PubMed:21089070" FT CONFLICT 496 FT /note="M -> I (in Ref. 11; AAA74897/AAB59558)" FT /evidence="ECO:0000305" FT CONFLICT 1094..1095 FT /note="EL -> ST (in Ref. 14; AAA59923)" FT /evidence="ECO:0000305" FT CONFLICT 1576 FT /note="H -> HH (in Ref. 11; AAA74897/AAB59558)" FT /evidence="ECO:0000305" FT HELIX 5..18 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 31..33 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 34..46 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 47..49 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 51..66 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 73..96 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 106..111 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 114..121 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 130..146 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 150..166 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 174..181 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 187..201 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 206..226 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 228..236 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 240..256 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 260..276 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 278..285 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 294..307 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 314..331 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 336..338 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 341..357 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 360..362 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 367..371 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 373..386 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 387..389 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 394..398 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 399..402 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 404..419 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 424..426 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 429..435 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 436..454 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 483..502 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 505..508 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 516..518 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 522..530 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 531..534 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 539..551 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 555..558 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 559..561 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 566..568 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 569..587 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 593..617 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 678..691 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 693..696 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 700..708 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 711..720 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 724..727 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 728..730 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 735..745 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 752..762 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 763..765 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 771..793 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 832..846 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 849..851 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 890..899 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 900..903 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 907..909 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 910..923 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 927..929 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 930..942 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 947..949 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 955..973 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 979..983 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 989..1000 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1006..1021 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 1026..1028 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1034..1046 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 1049..1052 FT /evidence="ECO:0007829|PDB:8EDO" FT HELIX 1053..1056 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1060..1063 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1064..1080 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 1091..1093 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 1095..1116 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1135..1155 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1157..1160 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1162..1167 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1173..1190 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1197..1200 FT /evidence="ECO:0007829|PDB:7PGU" FT TURN 1201..1204 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 1208..1216 FT /evidence="ECO:0007829|PDB:1NF1" FT TURN 1217..1219 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 1220..1228 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1233..1235 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1236..1249 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1253..1267 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1271..1273 FT /evidence="ECO:0007829|PDB:6OB3" FT STRAND 1277..1279 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 1280..1309 FT /evidence="ECO:0007829|PDB:6OB3" FT TURN 1310..1312 FT /evidence="ECO:0007829|PDB:6V6F" FT HELIX 1315..1317 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1323..1325 FT /evidence="ECO:0007829|PDB:6OB3" FT STRAND 1328..1330 FT /evidence="ECO:0007829|PDB:6V65" FT HELIX 1332..1351 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1354..1356 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1359..1370 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1392..1394 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1398..1400 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1401..1411 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1414..1419 FT /evidence="ECO:0007829|PDB:6OB3" FT TURN 1421..1425 FT /evidence="ECO:0007829|PDB:6OB3" FT STRAND 1426..1429 FT /evidence="ECO:0007829|PDB:6V6F" FT HELIX 1433..1451 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1459..1464 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1465..1483 FT /evidence="ECO:0007829|PDB:6OB3" FT STRAND 1490..1492 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 1510..1514 FT /evidence="ECO:0007829|PDB:1NF1" FT HELIX 1517..1520 FT /evidence="ECO:0007829|PDB:1NF1" FT HELIX 1531..1533 FT /evidence="ECO:0007829|PDB:7PGS" FT HELIX 1535..1544 FT /evidence="ECO:0007829|PDB:1NF1" FT HELIX 1569..1578 FT /evidence="ECO:0007829|PDB:3P7Z" FT TURN 1582..1586 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1587..1590 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1592..1598 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1604..1609 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1610..1612 FT /evidence="ECO:0007829|PDB:3PG7" FT TURN 1615..1617 FT /evidence="ECO:0007829|PDB:2D4Q" FT HELIX 1620..1631 FT /evidence="ECO:0007829|PDB:3PG7" FT TURN 1632..1636 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1639..1644 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1650..1652 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1656..1661 FT /evidence="ECO:0007829|PDB:3PG7" FT TURN 1662..1664 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1668..1672 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1674..1681 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1684..1692 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1694..1697 FT /evidence="ECO:0007829|PDB:3PG7" FT TURN 1698..1702 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1706..1711 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1714..1717 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1721..1723 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1728..1732 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1738..1749 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1751..1757 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1759..1767 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1770..1772 FT /evidence="ECO:0007829|PDB:2D4Q" FT STRAND 1775..1777 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1780..1784 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1785..1787 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1788..1795 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1798..1803 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1810..1813 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1817..1833 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1847..1849 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1851..1861 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1867..1884 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1906..1918 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1920..1922 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1923..1936 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1939..1949 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1950..1952 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1957..1960 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 1961..1963 FT /evidence="ECO:0007829|PDB:8EDO" FT STRAND 1965..1967 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1968..1984 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1989..2000 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2004..2006 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2007..2021 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2026..2041 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2043..2057 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2058..2060 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2061..2063 FT /evidence="ECO:0007829|PDB:8EDO" FT HELIX 2069..2071 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2075..2089 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2090..2092 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2096..2108 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2109..2112 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2116..2134 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 2137..2139 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2143..2155 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2159..2165 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2173..2177 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2180..2184 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2199..2219 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2225..2237 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2242..2244 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2245..2250 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2252..2255 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2261..2280 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2285..2287 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2289..2301 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2302..2304 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2311..2314 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2317..2323 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2328..2347 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 2351..2354 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2356..2363 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2365..2367 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2368..2378 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2382..2384 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2386..2392 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2393..2395 FT /evidence="ECO:0007829|PDB:7PGS" FT HELIX 2396..2399 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2403..2424 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2427..2429 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2434..2436 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2437..2441 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2443..2445 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2447..2452 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2607..2609 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2613..2629 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2633..2649 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2651..2653 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2654..2657 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2658..2671 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2675..2690 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2700..2702 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2704..2706 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2709..2715 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2728..2742 FT /evidence="ECO:0007829|PDB:7PGP" FT VARIANT P21359-2:1661 FT /note="C -> R (in NF1; dbSNP:rs1597829901)" FT /evidence="ECO:0000269|PubMed:23758643" FT /id="VAR_082822" FT VARIANT P21359-2:1918 FT /note="I -> T (in NF1; dbSNP:rs1304057833)" FT /evidence="ECO:0000269|PubMed:23758643" FT /id="VAR_082823" SQ SEQUENCE 2839 AA; 319372 MW; C079475139DBD51E CRC64; MAAHRPVEWV QAVVSRFDEQ LPIKTGQQNT HTKVSTEHNK ECLINISKYK FSLVISGLTT ILKNVNNMRI FGEAAEKNLY LSQLIILDTL EKCLAGQPKD TMRLDETMLV KQLLPEICHF LHTCREGNQH AAELRNSASG VLFSLSCNNF NAVFSRISTR LQELTVCSED NVDVHDIELL QYINVDCAKL KRLLKETAFK FKALKKVAQL AVINSLEKAF WNWVENYPDE FTKLYQIPQT DMAECAEKLF DLVDGFAEST KRKAAVWPLQ IILLILCPEI IQDISKDVVD ENNMNKKLFL DSLRKALAGH GGSRQLTESA AIACVKLCKA STYINWEDNS VIFLLVQSMV VDLKNLLFNP SKPFSRGSQP ADVDLMIDCL VSCFRISPHN NQHFKICLAQ NSPSTFHYVL VNSLHRIITN SALDWWPKID AVYCHSVELR NMFGETLHKA VQGCGAHPAI RMAPSLTFKE KVTSLKFKEK PTDLETRSYK YLLLSMVKLI HADPKLLLCN PRKQGPETQG STAELITGLV QLVPQSHMPE IAQEAMEALL VLHQLDSIDL WNPDAPVETF WEISSQMLFY ICKKLTSHQM LSSTEILKWL REILICRNKF LLKNKQADRS SCHFLLFYGV GCDIPSSGNT SQMSMDHEEL LRTPGASLRK GKGNSSMDSA AGCSGTPPIC RQAQTKLEVA LYMFLWNPDT EAVLVAMSCF RHLCEEADIR CGVDEVSVHN LLPNYNTFME FASVSNMMST GRAALQKRVM ALLRRIEHPT AGNTEAWEDT HAKWEQATKL ILNYPKAKME DGQAAESLHK TIVKRRMSHV SGGGSIDLSD TDSLQEWINM TGFLCALGGV CLQQRSNSGL ATYSPPMGPV SERKGSMISV MSSEGNADTP VSKFMDRLLS LMVCNHEKVG LQIRTNVKDL VGLELSPALY PMLFNKLKNT ISKFFDSQGQ VLLTDTNTQF VEQTIAIMKN LLDNHTEGSS EHLGQASIET MMLNLVRYVR VLGNMVHAIQ IKTKLCQLVE VMMARRDDLS FCQEMKFRNK MVEYLTDWVM GTSNQAADDD VKCLTRDLDQ ASMEAVVSLL AGLPLQPEEG DGVELMEAKS QLFLKYFTLF MNLLNDCSEV EDESAQTGGR KRGMSRRLAS LRHCTVLAMS NLLNANVDSG LMHSIGLGYH KDLQTRATFM EVLTKILQQG TEFDTLAETV LADRFERLVE LVTMMGDQGE LPIAMALANV VPCSQWDELA RVLVTLFDSR HLLYQLLWNM FSKEVELADS MQTLFRGNSL ASKIMTFCFK VYGATYLQKL LDPLLRIVIT SSDWQHVSFE VDPTRLEPSE SLEENQRNLL QMTEKFFHAI ISSSSEFPPQ LRSVCHCLYQ ATCHSLLNKA TVKEKKENKK SVVSQRFPQN SIGAVGSAMF LRFINPAIVS PYEAGILDKK PPPRIERGLK LMSKILQSIA NHVLFTKEEH MRPFNDFVKS NFDAARRFFL DIASDCPTSD AVNHSLSFIS DGNVLALHRL LWNNQEKIGQ YLSSNRDHKA VGRRPFDKMA TLLAYLGPPE HKPVADTHWS SLNLTSSKFE EFMTRHQVHE KEEFKALKTL SIFYQAGTSK AGNPIFYYVA RRFKTGQING DLLIYHVLLT LKPYYAKPYE IVVDLTHTGP SNRFKTDFLS KWFVVFPGFA YDNVSAVYIY NCNSWVREYT KYHERLLTGL KGSKRLVFID CPGKLAEHIE HEQQKLPAAT LALEEDLKVF HNALKLAHKD TKVSIKVGST AVQVTSAERT KVLGQSVFLN DIYYASEIEE ICLVDENQFT LTIANQGTPL TFMHQECEAI VQSIIHIRTR WELSQPDSIP QHTKIRPKDV PGTLLNIALL NLGSSDPSLR SAAYNLLCAL TCTFNLKIEG QLLETSGLCI PANNTLFIVS ISKTLAANEP HLTLEFLEEC ISGFSKSSIE LKHLCLEYMT PWLSNLVRFC KHNDDAKRQR VTAILDKLIT MTINEKQMYP SIQAKIWGSL GQITDLLDVV LDSFIKTSAT GGLGSIKAEV MADTAVALAS GNVKLVSSKV IGRMCKIIDK TCLSPTPTLE QHLMWDDIAI LARYMLMLSF NNSLDVAAHL PYLFHVVTFL VATGPLSLRA STHGLVINII HSLCTCSQLH FSEETKQVLR LSLTEFSLPK FYLLFGISKV KSAAVIAFRS SYRDRSFSPG SYERETFALT SLETVTEALL EIMEACMRDI PTCKWLDQWT ELAQRFAFQY NPSLQPRALV VFGCISKRVS HGQIKQIIRI LSKALESCLK GPDTYNSQVL IEATVIALTK LQPLLNKDSP LHKALFWVAV AVLQLDEVNL YSAGTALLEQ NLHTLDSLRI FNDKSPEEVF MAIRNPLEWH CKQMDHFVGL NFNSNFNFAL VGHLLKGYRH PSPAIVARTV RILHTLLTLV NKHRNCDKFE VNTQSVAYLA ALLTVSEEVR SRCSLKHRKS LLLTDISMEN VPMDTYPIHH GDPSYRTLKE TQPWSSPKGS EGYLAATYPT VGQTSPRARK SMSLDMGQPS QANTKKLLGT RKSFDHLISD TKAPKRQEME SGITTPPKMR RVAETDYEME TQRISSSQQH PHLRKVSVSE SNVLLDEEVL TDPKIQALLL TVLATLVKYT TDEFDQRILY EYLAEASVVF PKVFPVVHNL LDSKINTLLS LCQDPNLLNP IHGIVQSVVY HEESPPQYQT SYLQSFGFNG LWRFAGPFSK QTQIPDYAEL IVKFLDALID TYLPGIDEET SEESLLTPTS PYPPALQSQL SITANLNLSN SMTSLATSQH SPGIDKENVE LSPTTGHCNS GRTRHGSASQ VQKQRSAGSF KRNSIKKIV // ID NTRK2_HUMAN Reviewed; 822 AA. AC Q16620; B1ANZ4; B4DFV9; Q16675; Q59GJ1; Q8WXJ5; Q8WXJ6; Q8WXJ7; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 249. DE RecName: Full=BDNF/NT-3 growth factors receptor; DE EC=2.7.10.1 {ECO:0000269|PubMed:15494731}; DE AltName: Full=GP145-TrkB; DE Short=Trk-B; DE AltName: Full=Neurotrophic tyrosine kinase receptor type 2; DE AltName: Full=TrkB tyrosine kinase; DE AltName: Full=Tropomyosin-related kinase B; DE Flags: Precursor; GN Name=NTRK2; Synonyms=TRKB; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKB). RC TISSUE=Hippocampus; RX PubMed=7789988; DOI=10.1016/0888-7543(95)80055-q; RA Nakagawara A., Liu X.-G., Ikegaki N., White P.S., Yamashiro D.J., RA Nycum L.M., Biegel J.A., Brodeur G.M.; RT "Cloning and chromosomal localization of the human TRK-B tyrosine kinase RT receptor gene (NTRK2)."; RL Genomics 25:538-546(1995). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS TRKB AND TRKB-T1). RC TISSUE=Brain; RX PubMed=7823156; DOI=10.1523/jneurosci.15-01-00477.1995; RA Shelton D.L., Sutherland J., Gripp J., Camerato T., Armanini M.P., RA Phillips H.S., Carroll K., Spencer S.D., Levinson A.D.; RT "Human trks: molecular cloning, tissue distribution, and expression of RT extracellular domain immunoadhesins."; RL J. Neurosci. 15:477-491(1995). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKB-T1), TISSUE SPECIFICITY, AND RP DEVELOPMENTAL STAGE. RC TISSUE=Hippocampus; RX PubMed=7936202; DOI=10.1016/0306-4522(94)90507-x; RA Allen S.J., Dawbarn D., Eckford S.D., Wilcock G.K., Ashcroft M., RA Colebrook S.M., Feeney R., Macgowan S.H.; RT "Cloning of a non-catalytic form of human trkB and distribution of RT messenger RNA for trkB in human brain."; RL Neuroscience 60:825-834(1994). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS TRKB; TRKB-T1; TRKB-T-SHC; 4 AND 5), RP ALTERNATIVE SPLICING, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=11798182; DOI=10.1006/bbrc.2001.6301; RA Stoilov P., Castren E., Stamm S.; RT "Analysis of the human TrkB gene genomic organization reveals novel TrkB RT isoforms, unusual gene length, and splicing mechanism."; RL Biochem. Biophys. Res. Commun. 290:1054-1065(2002). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKB-T1), AND VARIANT ARG-309. RA Steinbeck J.A., Thomsen S., Wessig J., Leypoldt F., Lewerenz J., RA Methner A.; RT "Full length truncated TrkB sequence identified in a screen for genes RT regulated by ischemic preconditioning."; RL Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKB-N-T1). RC TISSUE=Amygdala; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKB-T-TK). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RT "Homo sapiens protein coding cDNA."; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164053; DOI=10.1038/nature02465; RA Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L., RA Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R., RA Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S., RA Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., RA Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., RA Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E., RA Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M., RA Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J., RA Frankish A., Frankland J.A., French L., Fricker D.G., Garner P., RA Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S., RA Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E., RA Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D., RA Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E., RA Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K., RA Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S., RA Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J., RA Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E., RA McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V., RA Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S., RA Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K., RA Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J., RA Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., RA West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L., RA Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M., RA Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J., RA Dunham I.; RT "DNA sequence and analysis of human chromosome 9."; RL Nature 429:369-374(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKB-T1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP FUNCTION, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-67; ASN-95; ASN-121; RP ASN-178; ASN-205; ASN-241; ASN-254; ASN-280; ASN-338 AND ASN-412. RX PubMed=7574684; DOI=10.1006/abbi.1995.1460; RA Haniu M., Talvenheimo J., Le J., Katta V., Welcher A., Rohde M.F.; RT "Extracellular domain of neurotrophin receptor trkB: disulfide structure, RT N-glycosylation sites, and ligand binding."; RL Arch. Biochem. Biophys. 322:256-264(1995). RN [12] RP INTERACTION WITH FRS2. RX PubMed=10092678; DOI=10.1074/jbc.274.14.9861; RA Meakin S.O., MacDonald J.I.S., Gryz E.A., Kubu C.J., Verdi J.M.; RT "The signaling adapter FRS-2 competes with Shc for binding to the nerve RT growth factor receptor TrkA. A model for discriminating proliferation and RT differentiation."; RL J. Biol. Chem. 274:9861-9870(1999). RN [13] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-67; ASN-121 AND ASN-254. RC TISSUE=Plasma; RX PubMed=16335952; DOI=10.1021/pr0502065; RA Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J., RA Smith R.D.; RT "Human plasma N-glycoproteome analysis by immunoaffinity subtraction, RT hydrazide chemistry, and mass spectrometry."; RL J. Proteome Res. 4:2070-2080(2005). RN [14] RP ALTERNATIVE SPLICING (ISOFORMS TRKB-T-TK AND TRKB-N-T1). RX PubMed=20193039; DOI=10.1111/j.1471-4159.2010.06662.x; RA Luberg K., Wong J., Weickert C.S., Timmusk T.; RT "Human TrkB gene: novel alternative transcripts, protein isoforms and RT expression pattern in the prefrontal cerebral cortex during postnatal RT development."; RL J. Neurochem. 113:952-964(2010). RN [15] {ECO:0007744|PDB:1WWB} RP X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 283-385, AND DISULFIDE BONDS. RX PubMed=10388563; DOI=10.1006/jmbi.1999.2816; RA Ultsch M.H., Wiesmann C., Simmons L.C., Henrich J., Yang M., Reilly D., RA Bass S.H., de Vos A.M.; RT "Crystal structures of the neurotrophin-binding domain of TrkA, TrkB and RT TrkC."; RL J. Mol. Biol. 290:149-159(1999). RN [16] {ECO:0007744|PDB:1HCF} RP X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 284-383 IN COMPLEX WITH NTF4, AND RP DISULFIDE BONDS. RX PubMed=11738045; DOI=10.1016/s0969-2126(01)00681-5; RA Banfield M.J., Naylor R.L., Robertson A.G., Allen S.J., Dawbarn D., RA Brady R.L.; RT "Specificity in Trk receptor:neurotrophin interactions: the crystal RT structure of TrkB-d5 in complex with neurotrophin-4/5."; RL Structure 9:1191-1199(2001). RN [17] RP INTERACTION WITH SLITRK2. RX PubMed=35840571; DOI=10.1038/s41467-022-31566-z; RA El Chehadeh S., Han K.A., Kim D., Jang G., Bakhtiari S., Lim D., Kim H.Y., RA Kim J., Kim H., Wynn J., Chung W.K., Vitiello G., Cutcutache I., Page M., RA Gecz J., Harper K., Han A.R., Kim H.M., Wessels M., Bayat A., Jaen A.F., RA Selicorni A., Maitz S., de Brouwer A.P.M., Silfhout A.V., Armstrong M., RA Symonds J., Kuery S., Isidor B., Cogne B., Nizon M., Feger C., Muller J., RA Torti E., Grange D.K., Willems M., Kruer M.C., Ko J., Piton A., Um J.W.; RT "SLITRK2 variants associated with neurodevelopmental disorders impair RT excitatory synaptic function and cognition in mice."; RL Nat. Commun. 13:4112-4112(2022). RN [18] RP VARIANT OBHD CYS-706, CHARACTERIZATION OF VARIANT OBHD CYS-706, FUNCTION AS RP A BDNF-ACTIVATED RECEPTOR, CATALYTIC ACTIVITY, PHOSPHORYLATION, AND RP SUBCELLULAR LOCATION. RX PubMed=15494731; DOI=10.1038/nn1336; RA Yeo G.S., Connie Hung C.C., Rochford J., Keogh J., Gray J., RA Sivaramakrishnan S., O'Rahilly S., Farooqi I.S.; RT "A de novo mutation affecting human TrkB associated with severe obesity and RT developmental delay."; RL Nat. Neurosci. 7:1187-1189(2004). RN [19] RP VARIANT [LARGE SCALE ANALYSIS] PHE-138. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [20] RP VARIANTS ILE-697; GLY-699 AND CYS-718. RX PubMed=18293376; DOI=10.1002/humu.20707; RA Marchetti A., Felicioni L., Pelosi G., Del Grammastro M., Fumagalli C., RA Sciarrotta M., Malatesta S., Chella A., Barassi F., Mucilli F., RA Camplese P., D'Antuono T., Sacco R., Buttitta F.; RT "Frequent mutations in the neurotrophic tyrosine receptor kinase gene RT family in large cell neuroendocrine carcinoma of the lung."; RL Hum. Mutat. 29:609-616(2008). RN [21] RP VARIANT OBHD 444-GLY--GLY-822 DEL. RX PubMed=27884935; DOI=10.1136/jmedgenet-2016-104215; RA Miller K.A., Twigg S.R., McGowan S.J., Phipps J.M., Fenwick A.L., RA Johnson D., Wall S.A., Noons P., Rees K.E., Tidey E.A., Craft J., RA Taylor J., Taylor J.C., Goos J.A., Swagemakers S.M., Mathijssen I.M., RA van der Spek P.J., Lord H., Lester T., Abid N., Cilliers D., Hurst J.A., RA Morton J.E., Sweeney E., Weber A., Wilson L.C., Wilkie A.O.; RT "Diagnostic value of exome and whole genome sequencing in RT craniosynostosis."; RL J. Med. Genet. 54:260-268(2017). RN [22] RP VARIANT DEE58 CYS-434, VARIANT OBHD ILE-704, AND INVOLVEMENT IN DEE58. RX PubMed=29100083; DOI=10.1016/j.ajhg.2017.09.008; RG Deciphering Developmental Disorders Study; RA Hamdan F.F., Myers C.T., Cossette P., Lemay P., Spiegelman D., RA Laporte A.D., Nassif C., Diallo O., Monlong J., Cadieux-Dion M., RA Dobrzeniecka S., Meloche C., Retterer K., Cho M.T., Rosenfeld J.A., Bi W., RA Massicotte C., Miguet M., Brunga L., Regan B.M., Mo K., Tam C., RA Schneider A., Hollingsworth G., FitzPatrick D.R., Donaldson A., Canham N., RA Blair E., Kerr B., Fry A.E., Thomas R.H., Shelagh J., Hurst J.A., RA Brittain H., Blyth M., Lebel R.R., Gerkes E.H., Davis-Keppen L., Stein Q., RA Chung W.K., Dorison S.J., Benke P.J., Fassi E., Corsten-Janssen N., RA Kamsteeg E.J., Mau-Them F.T., Bruel A.L., Verloes A., Ounap K., RA Wojcik M.H., Albert D.V.F., Venkateswaran S., Ware T., Jones D., Liu Y.C., RA Mohammad S.S., Bizargity P., Bacino C.A., Leuzzi V., Martinelli S., RA Dallapiccola B., Tartaglia M., Blumkin L., Wierenga K.J., Purcarin G., RA O'Byrne J.J., Stockler S., Lehman A., Keren B., Nougues M.C., Mignot C., RA Auvin S., Nava C., Hiatt S.M., Bebin M., Shao Y., Scaglia F., Lalani S.R., RA Frye R.E., Jarjour I.T., Jacques S., Boucher R.M., Riou E., Srour M., RA Carmant L., Lortie A., Major P., Diadori P., Dubeau F., D'Anjou G., RA Bourque G., Berkovic S.F., Sadleir L.G., Campeau P.M., Kibar Z., RA Lafreniere R.G., Girard S.L., Mercimek-Mahmutoglu S., Boelman C., RA Rouleau G.A., Scheffer I.E., Mefford H.C., Andrade D.M., Rossignol E., RA Minassian B.A., Michaud J.L.; RT "High rate of recurrent de novo mutations in developmental and epileptic RT encephalopathies."; RL Am. J. Hum. Genet. 101:664-685(2017). CC -!- FUNCTION: Receptor tyrosine kinase involved in the development and the CC maturation of the central and the peripheral nervous systems through CC regulation of neuron survival, proliferation, migration, CC differentiation, and synapse formation and plasticity (By similarity). CC Receptor for BDNF/brain-derived neurotrophic factor and CC NTF4/neurotrophin-4. Alternatively can also bind NTF3/neurotrophin-3 CC which is less efficient in activating the receptor but regulates neuron CC survival through NTRK2 (PubMed:15494731, PubMed:7574684). Upon ligand- CC binding, undergoes homodimerization, autophosphorylation and activation CC (PubMed:15494731). Recruits, phosphorylates and/or activates several CC downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that CC regulate distinct overlapping signaling cascades. Through SHC1, FRS2, CC SH2B1, SH2B2 activates the GRB2-Ras-MAPK cascade that regulates for CC instance neuronal differentiation including neurite outgrowth. Through CC the same effectors controls the Ras-PI3 kinase-AKT1 signaling cascade CC that mainly regulates growth and survival. Through PLCG1 and the CC downstream protein kinase C-regulated pathways controls synaptic CC plasticity. Thereby, plays a role in learning and memory by regulating CC both short term synaptic function and long-term potentiation. PLCG1 CC also leads to NF-Kappa-B activation and the transcription of genes CC involved in cell survival. Hence, it is able to suppress anoikis, the CC apoptosis resulting from loss of cell-matrix interactions. May also CC play a role in neutrophin-dependent calcium signaling in glial cells CC and mediate communication between neurons and glia. CC {ECO:0000250|UniProtKB:P15209, ECO:0000269|PubMed:15494731, CC ECO:0000269|PubMed:7574684}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:15494731}; CC -!- ACTIVITY REGULATION: The neuronal activity and the influx of calcium CC positively regulate the kinase activity and the internalization of the CC receptor which are both important for active signaling. Regulated by CC NGFR that may control the internalization of the receptor. NGFR may CC also stimulate the activation by BDNF compared to NTF3 and NTF4. SH2D1A CC inhibits the autophosphorylation of the receptor, and alters the CC recruitment and activation of downstream effectors and signaling CC cascades. The formation of active receptors dimers able to fully CC transduce the ligand-mediated signal, may be negatively regulated by CC the formation of inactive heterodimers with the non-catalytic isoforms CC (By similarity). {ECO:0000250|UniProtKB:P15209, CC ECO:0000250|UniProtKB:Q63604}. CC -!- SUBUNIT: Exists in a dynamic equilibrium between monomeric (low CC affinity) and dimeric (high affinity) structures. Interacts CC (phosphorylated upon activation by BDNF) with SHC1; mediates SHC1 CC phosphorylation and activation. Interacts (phosphorylated upon CC activation by BDNF) with PLCG1 and/or PLCG2; mediates PLCG1 CC phosphorylation and activation. Interacts with SH2B1 and SH2B2. CC Interacts with NGFR; may regulate the ligand specificity of the CC receptor (By similarity). Interacts with SORCS2; this interaction is CC important for normal targeting to post-synaptic densities in response CC to high-frequency stimulation (By similarity). Interacts CC (phosphorylated upon ligand-binding) with SH2D1A; regulates NTRK2. CC Interacts with SQSTM1 and KIDINS220 (By similarity). Interacts CC (phosphorylated upon ligand-binding) with FRS2; activates the MAPK CC signaling pathway (PubMed:10092678). Interacts with APPL1 (By CC similarity). Interacts with MAPK8IP3/JIP3 and KLC1; interaction with CC KLC1 is mediated by MAPK8IP3/JIP3 (By similarity). Interacts with CC SORL1; this interaction facilitates NTRK2 trafficking between synaptic CC plasma membranes, postsynaptic densities and cell soma, hence CC positively regulates BDNF signaling (By similarity). Interacts with CC SLITRK2 (PubMed:35840571). {ECO:0000250|UniProtKB:P04629, CC ECO:0000250|UniProtKB:P15209, ECO:0000250|UniProtKB:Q63604, CC ECO:0000269|PubMed:10092678, ECO:0000269|PubMed:11738045, CC ECO:0000269|PubMed:35840571}. CC -!- INTERACTION: CC Q16620; P00533: EGFR; NbExp=3; IntAct=EBI-3904881, EBI-297353; CC Q16620; Q16288: NTRK3; NbExp=3; IntAct=EBI-3904881, EBI-3936704; CC Q16620; Q13485: SMAD4; NbExp=4; IntAct=EBI-3904881, EBI-347263; CC Q16620; Q03114: Cdk5; Xeno; NbExp=3; IntAct=EBI-3904881, EBI-2008531; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:15494731}; CC Single-pass type I membrane protein {ECO:0000305}. Endosome membrane CC {ECO:0000250|UniProtKB:P15209}; Single-pass type I membrane protein CC {ECO:0000250|UniProtKB:P15209}. Early endosome membrane CC {ECO:0000250|UniProtKB:P15209}. Cell projection, axon CC {ECO:0000250|UniProtKB:Q63604}. Cell projection, dendrite CC {ECO:0000250|UniProtKB:Q63604}. Cytoplasm, perinuclear region CC {ECO:0000250|UniProtKB:Q63604}. Postsynaptic density CC {ECO:0000250|UniProtKB:P15209}. Note=Internalized to endosomes upon CC ligand-binding. {ECO:0000250|UniProtKB:P15209}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=7; CC Comment=Additional isoforms seem to exist.; CC Name=TrkB; Synonyms=gp145-TrkB; CC IsoId=Q16620-1; Sequence=Displayed; CC Name=TrkB-T1; CC IsoId=Q16620-2; Sequence=VSP_002901, VSP_002902; CC Name=TrkB-T-Shc; CC IsoId=Q16620-3; Sequence=VSP_002903, VSP_002904; CC Name=4; CC IsoId=Q16620-4; Sequence=VSP_041942; CC Name=5; CC IsoId=Q16620-5; Sequence=VSP_041942, VSP_002903, VSP_002904; CC Name=TrkB-T-TK; CC IsoId=Q16620-6; Sequence=VSP_042178, VSP_042179; CC Name=TrkB-N-T1; CC IsoId=Q16620-7; Sequence=VSP_042177, VSP_002901, VSP_002902; CC -!- TISSUE SPECIFICITY: Isoform TrkB is expressed in the central and CC peripheral nervous system. In the central nervous system (CNS), CC expression is observed in the cerebral cortex, hippocampus, thalamus, CC choroid plexus, granular layer of the cerebellum, brain stem, and CC spinal cord. In the peripheral nervous system, it is expressed in many CC cranial ganglia, the ophthalmic nerve, the vestibular system, multiple CC facial structures, the submaxillary glands, and dorsal root ganglia. CC Isoform TrkB-T1 is mainly expressed in the brain but also detected in CC other tissues including pancreas, kidney and heart. Isoform TrkB-T-Shc CC is predominantly expressed in the brain. {ECO:0000269|PubMed:11798182, CC ECO:0000269|PubMed:7936202}. CC -!- DEVELOPMENTAL STAGE: Widely expressed in fetal brain. CC {ECO:0000269|PubMed:7936202}. CC -!- PTM: Phosphorylated. Undergoes ligand-mediated autophosphorylation that CC is required for interaction with SHC1 and PLCG1 and other downstream CC effectors. Isoform TrkB-T-Shc is not phosphorylated. CC {ECO:0000269|PubMed:15494731}. CC -!- PTM: Ubiquitinated. Undergoes polyubiquitination upon activation; CC regulated by NGFR. Ubiquitination regulates the internalization of the CC receptor (By similarity). {ECO:0000250}. CC -!- DISEASE: Developmental and epileptic encephalopathy 58 (DEE58) CC [MIM:617830]: A form of epileptic encephalopathy, a heterogeneous group CC of severe early-onset epilepsies characterized by refractory seizures, CC neurodevelopmental impairment, and poor prognosis. Development is CC normal prior to seizure onset, after which cognitive and motor delays CC become apparent. DEE58 is an autosomal dominant condition characterized CC by onset of refractory seizures in the first days or months of life. CC {ECO:0000269|PubMed:29100083}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Obesity, hyperphagia, and developmental delay (OBHD) CC [MIM:613886]: A disorder characterized by early-onset obesity, CC hyperphagia, and severe developmental delay in motor function, speech, CC and language. {ECO:0000269|PubMed:15494731, CC ECO:0000269|PubMed:27884935, ECO:0000269|PubMed:29100083}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- MISCELLANEOUS: Trk also stands for tropomyosin-related kinase since the CC first Trk was isolated as an oncogenic protein which was the result of CC a fusion between the tropomyosin gene TPM3 and NTRK1. CC -!- MISCELLANEOUS: [Isoform TrkB-T1]: Non-catalytic isoform. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41589/NTRK2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U12140; AAC51371.1; -; mRNA. DR EMBL; S76473; AAB33109.1; -; mRNA. DR EMBL; S76474; AAB33110.1; -; mRNA. DR EMBL; X75958; CAA53571.1; -; mRNA. DR EMBL; AF410899; AAL67965.1; -; mRNA. DR EMBL; AF410900; AAL67966.1; -; mRNA. DR EMBL; AF410901; AAL67967.1; -; mRNA. DR EMBL; AF508964; AAM77876.1; -; mRNA. DR EMBL; AB209118; BAD92355.1; -; mRNA. DR EMBL; AK294285; BAG57570.1; -; mRNA. DR EMBL; AL390777; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL445532; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL596132; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471089; EAW62688.1; -; Genomic_DNA. DR EMBL; BC031835; AAH31835.1; -; mRNA. DR CCDS; CCDS35050.1; -. [Q16620-1] DR CCDS; CCDS35051.1; -. [Q16620-5] DR CCDS; CCDS35052.1; -. [Q16620-3] DR CCDS; CCDS35053.1; -. [Q16620-2] DR CCDS; CCDS6671.1; -. [Q16620-4] DR CCDS; CCDS94429.1; -. [Q16620-7] DR PIR; A56853; A56853. DR PIR; I73631; I73631. DR RefSeq; NP_001007098.1; NM_001007097.3. [Q16620-2] DR RefSeq; NP_001018074.1; NM_001018064.3. [Q16620-1] DR RefSeq; NP_001018075.1; NM_001018065.2. [Q16620-5] DR RefSeq; NP_001018076.1; NM_001018066.3. [Q16620-3] DR RefSeq; NP_001356461.1; NM_001369532.1. [Q16620-1] DR RefSeq; NP_001356462.1; NM_001369533.1. [Q16620-1] DR RefSeq; NP_001356466.1; NM_001369537.1. [Q16620-5] DR RefSeq; NP_001356467.1; NM_001369538.1. [Q16620-3] DR RefSeq; NP_001356468.1; NM_001369539.1. [Q16620-2] DR RefSeq; NP_001356469.1; NM_001369540.1. [Q16620-2] DR RefSeq; NP_001356470.1; NM_001369541.1. [Q16620-2] DR RefSeq; NP_001356471.1; NM_001369542.1. [Q16620-2] DR RefSeq; NP_001356472.1; NM_001369543.1. [Q16620-2] DR RefSeq; NP_001356473.1; NM_001369544.1. [Q16620-2] DR RefSeq; NP_001356474.1; NM_001369545.1. [Q16620-2] DR RefSeq; NP_001356477.1; NM_001369548.1. [Q16620-2] DR RefSeq; NP_001356478.1; NM_001369549.1. [Q16620-2] DR RefSeq; NP_001356479.1; NM_001369550.1. [Q16620-7] DR RefSeq; NP_001356480.1; NM_001369551.1. [Q16620-7] DR RefSeq; NP_001356481.1; NM_001369552.1. [Q16620-7] DR RefSeq; NP_006171.2; NM_006180.4. [Q16620-4] DR RefSeq; XP_005252058.1; XM_005252001.4. [Q16620-4] DR RefSeq; XP_005252060.1; XM_005252003.4. [Q16620-4] DR RefSeq; XP_005252061.1; XM_005252004.3. [Q16620-4] DR RefSeq; XP_011517020.1; XM_011518718.4. [Q16620-1] DR RefSeq; XP_016870240.1; XM_017014751.3. [Q16620-4] DR RefSeq; XP_016870241.1; XM_017014752.2. [Q16620-1] DR RefSeq; XP_016870242.1; XM_017014753.3. [Q16620-1] DR RefSeq; XP_016870244.1; XM_017014755.1. [Q16620-5] DR RefSeq; XP_016870249.1; XM_017014760.3. [Q16620-2] DR RefSeq; XP_047279388.1; XM_047423432.1. [Q16620-4] DR RefSeq; XP_047279389.1; XM_047423433.1. [Q16620-4] DR RefSeq; XP_054218993.1; XM_054363018.1. [Q16620-4] DR RefSeq; XP_054218994.1; XM_054363019.1. [Q16620-4] DR RefSeq; XP_054218995.1; XM_054363020.1. [Q16620-4] DR RefSeq; XP_054218996.1; XM_054363021.1. [Q16620-4] DR RefSeq; XP_054218997.1; XM_054363022.1. [Q16620-4] DR RefSeq; XP_054218998.1; XM_054363023.1. [Q16620-4] DR RefSeq; XP_054218999.1; XM_054363024.1. [Q16620-1] DR RefSeq; XP_054219000.1; XM_054363025.1. [Q16620-1] DR RefSeq; XP_054219001.1; XM_054363026.1. [Q16620-1] DR RefSeq; XP_054219002.1; XM_054363027.1. [Q16620-5] DR RefSeq; XP_054219003.1; XM_054363028.1. [Q16620-2] DR PDB; 1HCF; X-ray; 2.70 A; X/Y=286-383. DR PDB; 1WWB; X-ray; 2.10 A; X=283-385. DR PDB; 2MFQ; NMR; -; B=497-519. DR PDB; 4ASZ; X-ray; 1.70 A; A=527-822. DR PDB; 4AT3; X-ray; 1.77 A; A=527-822. DR PDB; 4AT4; X-ray; 2.36 A; A=527-822. DR PDB; 4AT5; X-ray; 1.71 A; A=527-822. DR PDB; 5MO9; X-ray; 2.59 A; X=278-426. DR PDB; 8OYD; NMR; -; A/B=422-466. DR PDBsum; 1HCF; -. DR PDBsum; 1WWB; -. DR PDBsum; 2MFQ; -. DR PDBsum; 4ASZ; -. DR PDBsum; 4AT3; -. DR PDBsum; 4AT4; -. DR PDBsum; 4AT5; -. DR PDBsum; 5MO9; -. DR PDBsum; 8OYD; -. DR AlphaFoldDB; Q16620; -. DR SMR; Q16620; -. DR BioGRID; 110970; 137. DR DIP; DIP-5720N; -. DR FunCoup; Q16620; 1218. DR IntAct; Q16620; 116. DR MINT; Q16620; -. DR STRING; 9606.ENSP00000277120; -. DR BindingDB; Q16620; -. DR ChEMBL; CHEMBL4898; -. DR DrugBank; DB00321; Amitriptyline. DR DrugBank; DB11986; Entrectinib. DR DrugBank; DB11823; Esketamine. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB16056; GZ-389988. DR DrugBank; DB14723; Larotrectinib. DR DrugBank; DB16826; Repotrectinib. DR DrugCentral; Q16620; -. DR GuidetoPHARMACOLOGY; 1818; -. DR TCDB; 8.A.23.1.38; the basigin (basigin) family. DR GlyConnect; 1029; 12 N-Linked glycans (7 sites). DR GlyCosmos; Q16620; 13 sites, 14 glycans. DR GlyGen; Q16620; 13 sites, 21 N-linked glycans (8 sites), 1 O-linked glycan (1 site). DR iPTMnet; Q16620; -. DR PhosphoSitePlus; Q16620; -. DR SwissPalm; Q16620; -. DR BioMuta; NTRK2; -. DR DMDM; 2497560; -. DR jPOST; Q16620; -. DR MassIVE; Q16620; -. DR PaxDb; 9606-ENSP00000277120; -. DR PeptideAtlas; Q16620; -. DR ProteomicsDB; 60955; -. [Q16620-1] DR ProteomicsDB; 60956; -. [Q16620-2] DR ProteomicsDB; 60957; -. [Q16620-3] DR ProteomicsDB; 60958; -. [Q16620-4] DR ProteomicsDB; 60959; -. [Q16620-5] DR ProteomicsDB; 60960; -. [Q16620-6] DR ProteomicsDB; 60961; -. [Q16620-7] DR ABCD; Q16620; 146 sequenced antibodies. DR Antibodypedia; 2081; 1498 antibodies from 49 providers. DR DNASU; 4915; -. DR Ensembl; ENST00000277120.8; ENSP00000277120.3; ENSG00000148053.19. [Q16620-4] DR Ensembl; ENST00000304053.11; ENSP00000306167.7; ENSG00000148053.19. [Q16620-3] DR Ensembl; ENST00000359847.4; ENSP00000352906.3; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000376208.6; ENSP00000365381.1; ENSG00000148053.19. [Q16620-3] DR Ensembl; ENST00000376213.6; ENSP00000365386.1; ENSG00000148053.19. [Q16620-1] DR Ensembl; ENST00000395882.6; ENSP00000379221.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000685720.1; ENSP00000509031.1; ENSG00000148053.19. [Q16620-5] DR Ensembl; ENST00000686259.1; ENSP00000509743.1; ENSG00000148053.19. [Q16620-1] DR Ensembl; ENST00000686322.1; ENSP00000510032.1; ENSG00000148053.19. [Q16620-7] DR Ensembl; ENST00000686324.1; ENSP00000510134.1; ENSG00000148053.19. [Q16620-4] DR Ensembl; ENST00000686443.1; ENSP00000509093.1; ENSG00000148053.19. [Q16620-3] DR Ensembl; ENST00000686496.1; ENSP00000510060.1; ENSG00000148053.19. [Q16620-1] DR Ensembl; ENST00000687148.1; ENSP00000510717.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000687596.1; ENSP00000509999.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000687636.1; ENSP00000508829.1; ENSG00000148053.19. [Q16620-5] DR Ensembl; ENST00000688013.1; ENSP00000508443.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000689685.1; ENSP00000509169.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000689815.1; ENSP00000510451.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000690281.1; ENSP00000510757.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000691415.1; ENSP00000509058.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000691788.1; ENSP00000509401.1; ENSG00000148053.19. [Q16620-1] DR Ensembl; ENST00000692181.1; ENSP00000510619.1; ENSG00000148053.19. [Q16620-1] DR Ensembl; ENST00000692389.1; ENSP00000508497.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000692506.1; ENSP00000508622.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000692762.1; ENSP00000510071.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000693109.1; ENSP00000509456.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000693539.1; ENSP00000510640.1; ENSG00000148053.19. [Q16620-5] DR GeneID; 4915; -. DR KEGG; hsa:4915; -. DR MANE-Select; ENST00000277120.8; ENSP00000277120.3; NM_006180.6; NP_006171.2. [Q16620-4] DR UCSC; uc004anz.1; human. [Q16620-1] DR AGR; HGNC:8032; -. DR CIViC; 4915; 5 evidence items across 2 molecular profiles. DR ClinPGx; PA31818; -. DR CTD; 4915; -. DR DisGeNET; 4915; -. DR GeneCards; NTRK2; -. DR HGNC; HGNC:8032; NTRK2. DR HPA; ENSG00000148053; Tissue enhanced (brain, thyroid gland). DR MalaCards; NTRK2; -. DR MIM; 600456; gene. DR MIM; 613886; phenotype. DR MIM; 617830; phenotype. DR OpenTargets; ENSG00000148053; -. DR Orphanet; 99704; Early-onset obesity-hyperphagia-severe developmental delay syndrome. DR Orphanet; 697160; Infantile epileptic spasms syndrome. DR Orphanet; 442835; Non-specific early-onset epileptic encephalopathy. DR Orphanet; 251615; Pilomyxoid astrocytoma. DR VEuPathDB; HostDB:ENSG00000148053; -. DR eggNOG; KOG1026; Eukaryota. DR GeneTree; ENSGT00940000155181; -. DR HOGENOM; CLU_000288_74_1_1; -. DR InParanoid; Q16620; -. DR OMA; HIAMQIA; -. DR OrthoDB; 10005095at2759; -. DR PAN-GO; Q16620; 16 GO annotations based on evolutionary models. DR PhylomeDB; Q16620; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; Q16620; -. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-187024; NGF-independant TRKA activation. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-9024909; BDNF activates NTRK2 (TRKB) signaling. DR Reactome; R-HSA-9025046; NTF3 activates NTRK2 (TRKB) signaling. DR Reactome; R-HSA-9026357; NTF4 activates NTRK2 (TRKB) signaling. DR Reactome; R-HSA-9026519; Activated NTRK2 signals through RAS. DR Reactome; R-HSA-9026527; Activated NTRK2 signals through PLCG1. DR Reactome; R-HSA-9028335; Activated NTRK2 signals through PI3K. DR Reactome; R-HSA-9028731; Activated NTRK2 signals through FRS2 and FRS3. DR Reactome; R-HSA-9032500; Activated NTRK2 signals through FYN. DR Reactome; R-HSA-9032759; NTRK2 activates RAC1. DR Reactome; R-HSA-9032845; Activated NTRK2 signals through CDK5. DR SignaLink; Q16620; -. DR SIGNOR; Q16620; -. DR Agora; ENSG00000148053; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 4915; 10 hits in 1188 CRISPR screens. DR ChiTaRS; NTRK2; human. DR EvolutionaryTrace; Q16620; -. DR GeneWiki; TrkB_receptor; -. DR GenomeRNAi; 4915; -. DR Pharos; Q16620; Tclin. DR PRO; PR:Q16620; -. DR Proteomes; UP000005640; Chromosome 9. DR RNAct; Q16620; protein. DR Bgee; ENSG00000148053; Expressed in cranial nerve II and 196 other cell types or tissues. DR ExpressionAtlas; Q16620; baseline and differential. DR GO; GO:0030424; C:axon; ISS:UniProtKB. DR GO; GO:0043679; C:axon terminus; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IEA:Ensembl. DR GO; GO:0030425; C:dendrite; ISS:UniProtKB. DR GO; GO:0043197; C:dendritic spine; IBA:GO_Central. DR GO; GO:0005769; C:early endosome; ISS:UniProtKB. DR GO; GO:0031901; C:early endosome membrane; IEA:UniProtKB-SubCell. DR GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0014069; C:postsynaptic density; ISS:ARUK-UCL. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0043195; C:terminal bouton; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0048403; F:brain-derived neurotrophic factor binding; ISS:UniProtKB. DR GO; GO:0060175; F:brain-derived neurotrophic factor receptor activity; IMP:UniProtKB. DR GO; GO:0043121; F:neurotrophin binding; IDA:UniProtKB. DR GO; GO:0002020; F:protease binding; IPI:ARUK-UCL. DR GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB. DR GO; GO:0031547; P:brain-derived neurotrophic factor receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0071230; P:cellular response to amino acid stimulus; IEA:Ensembl. DR GO; GO:1990416; P:cellular response to brain-derived neurotrophic factor stimulus; IBA:GO_Central. DR GO; GO:0021954; P:central nervous system neuron development; ISS:UniProtKB. DR GO; GO:0021987; P:cerebral cortex development; ISS:UniProtKB. DR GO; GO:0007623; P:circadian rhythm; IEA:Ensembl. DR GO; GO:0007631; P:feeding behavior; IEA:Ensembl. DR GO; GO:0014047; P:glutamate secretion; IEA:Ensembl. DR GO; GO:0007612; P:learning; ISS:UniProtKB. DR GO; GO:0060291; P:long-term synaptic potentiation; IEA:Ensembl. DR GO; GO:0042490; P:mechanoreceptor differentiation; IEA:Ensembl. DR GO; GO:0022011; P:myelination in peripheral nervous system; IEA:Ensembl. DR GO; GO:1902430; P:negative regulation of amyloid-beta formation; IGI:ARUK-UCL. DR GO; GO:2000811; P:negative regulation of anoikis; IEA:Ensembl. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:UniProtKB. DR GO; GO:0030182; P:neuron differentiation; ISS:UniProtKB. DR GO; GO:0001764; P:neuron migration; ISS:UniProtKB. DR GO; GO:0019227; P:neuronal action potential propagation; IEA:Ensembl. DR GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:0048935; P:peripheral nervous system neuron development; IEA:Ensembl. DR GO; GO:0050772; P:positive regulation of axonogenesis; ISS:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; ISS:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; ISS:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; ISS:UniProtKB. DR GO; GO:0010976; P:positive regulation of neuron projection development; ISS:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; ISS:UniProtKB. DR GO; GO:0051965; P:positive regulation of synapse assembly; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB. DR GO; GO:0043087; P:regulation of GTPase activity; ISS:UniProtKB. DR GO; GO:0046548; P:retinal rod cell development; IEA:Ensembl. DR GO; GO:0099183; P:trans-synaptic signaling by BDNF, modulating synaptic transmission; IEA:Ensembl. DR GO; GO:0001570; P:vasculogenesis; IEA:Ensembl. DR CDD; cd05855; IgI_TrkB_d5; 1. DR CDD; cd05093; PTKc_TrkB; 1. DR DisProt; DP03945; -. DR FunFam; 2.60.40.10:FF:000239; BDNF/NT-3 growth factors receptor; 1. DR FunFam; 3.80.10.10:FF:000048; BDNF/NT-3 growth factors receptor; 1. DR FunFam; 1.10.510.10:FF:000034; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000486; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.30.200.20:FF:000033; Tyrosine-protein kinase receptor; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.10.10; Ribonuclease Inhibitor; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00672; -. DR InterPro; IPR000483; Cys-rich_flank_reg_C. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR001611; Leu-rich_rpt. DR InterPro; IPR032675; LRR_dom_sf. DR InterPro; IPR000372; LRRNT. DR InterPro; IPR020777; NTRK. DR InterPro; IPR020455; NTRK2. DR InterPro; IPR031635; NTRK_LRRCT. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR002011; Tyr_kinase_rcpt_2_CS. DR PANTHER; PTHR24416:SF136; BDNF_NT-3 GROWTH FACTORS RECEPTOR; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF07679; I-set; 2. DR Pfam; PF13855; LRR_8; 1. DR Pfam; PF16920; LRRCT_2; 1. DR Pfam; PF01462; LRRNT; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR01939; NTKRECEPTOR. DR PRINTS; PR01941; NTKRECEPTOR2. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00409; IG; 1. DR SMART; SM00408; IGc2; 1. DR SMART; SM00082; LRRCT; 1. DR SMART; SM00013; LRRNT; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF48726; Immunoglobulin; 2. DR SUPFAM; SSF52058; L domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; KW Cell projection; Cytoplasm; Developmental protein; Differentiation; KW Disease variant; Disulfide bond; Endosome; Epilepsy; Glycoprotein; KW Immunoglobulin domain; Kinase; Leucine-rich repeat; Membrane; Neurogenesis; KW Nucleotide-binding; Obesity; Phosphoprotein; Proteomics identification; KW Receptor; Reference proteome; Repeat; Signal; Synapse; Transferase; KW Transmembrane; Transmembrane helix; Tyrosine-protein kinase; KW Ubl conjugation. FT SIGNAL 1..31 FT CHAIN 32..822 FT /note="BDNF/NT-3 growth factors receptor" FT /id="PRO_0000016727" FT TOPO_DOM 32..430 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 431..454 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 455..822 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 32..61 FT /note="LRRNT" FT REPEAT 92..113 FT /note="LRR 1" FT REPEAT 116..137 FT /note="LRR 2" FT DOMAIN 148..196 FT /note="LRRCT" FT DOMAIN 197..282 FT /note="Ig-like C2-type 1" FT DOMAIN 295..365 FT /note="Ig-like C2-type 2" FT DOMAIN 538..807 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 455..466 FT /note="Interaction with MAPK8IP3/JIP3" FT /evidence="ECO:0000250|UniProtKB:Q63604" FT REGION 475..498 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 485..495 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 676 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 544..552 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 572 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 516 FT /note="Interaction with SHC1" FT /evidence="ECO:0000250" FT SITE 706 FT /note="Interaction with SH2D1A" FT /evidence="ECO:0000250" FT SITE 817 FT /note="Interaction with PLCG1" FT /evidence="ECO:0000250" FT MOD_RES 516 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:P15209" FT MOD_RES 702 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q63604" FT MOD_RES 706 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q63604" FT MOD_RES 707 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q63604" FT MOD_RES 817 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q63604" FT CARBOHYD 67 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16335952, FT ECO:0000269|PubMed:7574684" FT CARBOHYD 95 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 121 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16335952, FT ECO:0000269|PubMed:7574684" FT CARBOHYD 178 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 205 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 241 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 254 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16335952, FT ECO:0000269|PubMed:7574684" FT CARBOHYD 280 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 325 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 338 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 412 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT DISULFID 32..38 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:7574684" FT DISULFID 36..45 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:7574684" FT DISULFID 152..176 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:7574684" FT DISULFID 154..194 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:7574684" FT DISULFID 218..266 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:7574684" FT DISULFID 302..345 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:10388563, ECO:0000269|PubMed:11738045, FT ECO:0000269|PubMed:7574684, ECO:0007744|PDB:1HCF, FT ECO:0007744|PDB:1WWB, ECO:0007744|PDB:5MO9" FT VAR_SEQ 1..156 FT /note="Missing (in isoform TrkB-N-T1)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_042177" FT VAR_SEQ 465 FT /note="K -> KDFSWFGFGKVKSRQGV (in isoform 4 and isoform 5)" FT /evidence="ECO:0000303|PubMed:11798182" FT /id="VSP_041942" FT VAR_SEQ 467..477 FT /note="PASVISNDDDS -> FVLFHKIPLDG (in isoform TrkB-T1 and FT isoform TrkB-N-T1)" FT /evidence="ECO:0000303|PubMed:11798182, FT ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:7823156, ECO:0000303|PubMed:7936202, FT ECO:0000303|Ref.5" FT /id="VSP_002901" FT VAR_SEQ 478..822 FT /note="Missing (in isoform TrkB-T1 and isoform TrkB-N-T1)" FT /evidence="ECO:0000303|PubMed:11798182, FT ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:7823156, ECO:0000303|PubMed:7936202, FT ECO:0000303|Ref.5" FT /id="VSP_002902" FT VAR_SEQ 529..537 FT /note="FVQHIKRHN -> WPRGSPKTA (in isoform TrkB-T-Shc and FT isoform 5)" FT /evidence="ECO:0000303|PubMed:11798182" FT /id="VSP_002903" FT VAR_SEQ 538..822 FT /note="Missing (in isoform TrkB-T-Shc and isoform 5)" FT /evidence="ECO:0000303|PubMed:11798182" FT /id="VSP_002904" FT VAR_SEQ 710..735 FT /note="GGHTMLPIRWMPPESIMYRKFTTESD -> SSCADQRPQGPLSLRDPCCICL FT LRLS (in isoform TrkB-T-TK)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_042178" FT VAR_SEQ 736..822 FT /note="Missing (in isoform TrkB-T-TK)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_042179" FT VARIANT 138 FT /note="L -> F (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041470" FT VARIANT 309 FT /note="G -> R" FT /evidence="ECO:0000269|Ref.5" FT /id="VAR_016320" FT VARIANT 338 FT /note="N -> Y (in dbSNP:rs1047856)" FT /id="VAR_011973" FT VARIANT 434 FT /note="Y -> C (in DEE58; uncertain significance; FT dbSNP:rs886041091)" FT /evidence="ECO:0000269|PubMed:29100083" FT /id="VAR_080659" FT VARIANT 444..822 FT /note="Missing (in OBHD)" FT /evidence="ECO:0000269|PubMed:27884935" FT /id="VAR_080660" FT VARIANT 545 FT /note="G -> V (in dbSNP:rs1075108)" FT /id="VAR_049715" FT VARIANT 697 FT /note="M -> I (in a lung carcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046518" FT VARIANT 699 FT /note="R -> G (in a lung carcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046519" FT VARIANT 704 FT /note="T -> I (in OBHD; uncertain significance; FT dbSNP:rs1554774973)" FT /evidence="ECO:0000269|PubMed:29100083" FT /id="VAR_080661" FT VARIANT 706 FT /note="Y -> C (in OBHD; expressed normally on the cell FT surface; results in markedly impaired ligand-induced FT phosphorylation as well as impaired downstream MAPK1 FT phosphorylation; dbSNP:rs121434633)" FT /evidence="ECO:0000269|PubMed:15494731" FT /id="VAR_065890" FT VARIANT 718 FT /note="R -> C (in a lung carcinoma sample; somatic FT mutation; dbSNP:rs1324578301)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046520" FT STRAND 285..292 FT /evidence="ECO:0007829|PDB:5MO9" FT STRAND 300..308 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 314..319 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 322..324 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 328..337 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 339..350 FT /evidence="ECO:0007829|PDB:1WWB" FT HELIX 353..355 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 357..364 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 369..376 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 380..382 FT /evidence="ECO:0007829|PDB:5MO9" FT HELIX 428..460 FT /evidence="ECO:0007829|PDB:8OYD" FT STRAND 462..464 FT /evidence="ECO:0007829|PDB:8OYD" FT STRAND 500..503 FT /evidence="ECO:0007829|PDB:2MFQ" FT STRAND 506..512 FT /evidence="ECO:0007829|PDB:2MFQ" FT TURN 515..517 FT /evidence="ECO:0007829|PDB:2MFQ" FT HELIX 535..537 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 538..545 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 552..557 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 567..574 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 579..592 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 603..607 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 609..618 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 625..631 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 634..638 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 641..643 FT /evidence="ECO:0007829|PDB:4AT5" FT HELIX 650..669 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 679..681 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 682..684 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 686..688 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 690..692 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 698..701 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 703..705 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 707..709 FT /evidence="ECO:0007829|PDB:4ASZ" FT TURN 710..712 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 713..715 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 717..719 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 722..727 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 732..747 FT /evidence="ECO:0007829|PDB:4ASZ" FT TURN 748..750 FT /evidence="ECO:0007829|PDB:4ASZ" FT TURN 753..756 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 759..768 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 780..789 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 794..796 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 800..813 FT /evidence="ECO:0007829|PDB:4ASZ" SQ SEQUENCE 822 AA; 91999 MW; 2FEB9159948F0D13 CRC64; MSSWIRWHGP AMARLWGFCW LVVGFWRAAF ACPTSCKCSA SRIWCSDPSP GIVAFPRLEP NSVDPENITE IFIANQKRLE IINEDDVEAY VGLRNLTIVD SGLKFVAHKA FLKNSNLQHI NFTRNKLTSL SRKHFRHLDL SELILVGNPF TCSCDIMWIK TLQEAKSSPD TQDLYCLNES SKNIPLANLQ IPNCGLPSAN LAAPNLTVEE GKSITLSCSV AGDPVPNMYW DVGNLVSKHM NETSHTQGSL RITNISSDDS GKQISCVAEN LVGEDQDSVN LTVHFAPTIT FLESPTSDHH WCIPFTVKGN PKPALQWFYN GAILNESKYI CTKIHVTNHT EYHGCLQLDN PTHMNNGDYT LIAKNEYGKD EKQISAHFMG WPGIDDGANP NYPDVIYEDY GTAANDIGDT TNRSNEIPST DVTDKTGREH LSVYAVVVIA SVVGFCLLVM LFLLKLARHS KFGMKGPASV ISNDDDSASP LHHISNGSNT PSSSEGGPDA VIIGMTKIPV IENPQYFGIT NSQLKPDTFV QHIKRHNIVL KRELGEGAFG KVFLAECYNL CPEQDKILVA VKTLKDASDN ARKDFHREAE LLTNLQHEHI VKFYGVCVEG DPLIMVFEYM KHGDLNKFLR AHGPDAVLMA EGNPPTELTQ SQMLHIAQQI AAGMVYLASQ HFVHRDLATR NCLVGENLLV KIGDFGMSRD VYSTDYYRVG GHTMLPIRWM PPESIMYRKF TTESDVWSLG VVLWEIFTYG KQPWYQLSNN EVIECITQGR VLQRPRTCPQ EVYELMLGCW QREPHMRKNI KGIHTLLQNL AKASPVYLDI LG // ID NTRK3_HUMAN Reviewed; 839 AA. AC Q16288; B7Z4C5; E9PG56; H0YND1; O75682; Q12827; Q16289; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 06-MAR-2007, sequence version 2. DT 28-JAN-2026, entry version 243. DE RecName: Full=NT-3 growth factor receptor; DE EC=2.7.10.1; DE AltName: Full=GP145-TrkC; DE Short=Trk-C; DE AltName: Full=Neurotrophic tyrosine kinase receptor type 3; DE AltName: Full=TrkC tyrosine kinase; DE Flags: Precursor; GN Name=NTRK3; Synonyms=TRKC; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3). RC TISSUE=Fetal brain; RX PubMed=7806211; DOI=10.1006/geno.1994.1383; RA McGregor L.M., Baylin S.B., Griffin C.A., Hawkins A.L., Nelkin B.D.; RT "Molecular cloning of the cDNA for human TrkC (NTRK3), chromosomal RT assignment, and evidence for a splice variant."; RL Genomics 22:267-272(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), AND PARTIAL PROTEIN RP SEQUENCE. RC TISSUE=Brain; RX PubMed=7823156; DOI=10.1523/jneurosci.15-01-00477.1995; RA Shelton D.L., Sutherland J., Gripp J., Camerato T., Armanini M.P., RA Phillips H.S., Carroll K., Spencer S.D., Levinson A.D.; RT "Human trks: molecular cloning, tissue distribution, and expression of RT extracellular domain immunoadhesins."; RL J. Neurosci. 15:477-491(1995). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9778053; DOI=10.1038/sj.onc.1202100; RA Ichaso N., Rodriguez R.E., Martin-Zanca D., Gonzalez-Sarmiento R.; RT "Genomic characterization of the human trkC gene."; RL Oncogene 17:1871-1875(1998). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5). RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16572171; DOI=10.1038/nature04601; RA Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K., RA Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K., RA FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N., RA Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S., RA Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K., RA DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J., RA Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E., RA Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B., RA Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R., RA O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B., RA Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S., RA Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.; RT "Analysis of the DNA sequence and duplication history of human chromosome RT 15."; RL Nature 440:671-675(2006). RN [6] RP FUNCTION, PHOSPHORYLATION AT TYR-516, INVOLVEMENT IN CHD, VARIANTS PHE-21; RP VAL-71; MET-93; ILE-163; PHE-533 AND MET-817, CHARACTERIZATION OF VARIANTS RP MET-93; ILE-163; PHE-533 AND MET-817, AND MUTAGENESIS OF LYS-572. RX PubMed=25196463; DOI=10.1002/humu.22688; RA Werner P., Paluru P., Simpson A.M., Latney B., Iyer R., Brodeur G.M., RA Goldmuntz E.; RT "Mutations in NTRK3 suggest a novel signaling pathway in human congenital RT heart disease."; RL Hum. Mutat. 35:1459-1468(2014). RN [7] RP INTERACTION WITH PTPRS. RX PubMed=25385546; DOI=10.1038/ncomms6209; RA Coles C.H., Mitakidis N., Zhang P., Elegheert J., Lu W., Stoker A.W., RA Nakagawa T., Craig A.M., Jones E.Y., Aricescu A.R.; RT "Structural basis for extracellular cis and trans RPTPsigma signal RT competition in synaptogenesis."; RL Nat. Commun. 5:5209-5209(2014). RN [8] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 297-401, AND DISULFIDE BOND. RX PubMed=10388563; DOI=10.1006/jmbi.1999.2816; RA Ultsch M.H., Wiesmann C., Simmons L.C., Henrich J., Yang M., Reilly D., RA Bass S.H., de Vos A.M.; RT "Crystal structures of the neurotrophin-binding domain of TrkA, TrkB and RT TrkC."; RL J. Mol. Biol. 290:149-159(1999). RN [9] RP VARIANTS [LARGE SCALE ANALYSIS] ARG-149; CYS-306; LEU-307; GLN-336; RP TYR-677; GLN-678; ARG-768 AND LYS-781. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [10] RP VARIANTS SER-664; TYR-677; CYS-736; PRO-745 AND PHE-766. RX PubMed=18293376; DOI=10.1002/humu.20707; RA Marchetti A., Felicioni L., Pelosi G., Del Grammastro M., Fumagalli C., RA Sciarrotta M., Malatesta S., Chella A., Barassi F., Mucilli F., RA Camplese P., D'Antuono T., Sacco R., Buttitta F.; RT "Frequent mutations in the neurotrophic tyrosine receptor kinase gene RT family in large cell neuroendocrine carcinoma of the lung."; RL Hum. Mutat. 29:609-616(2008). CC -!- FUNCTION: Receptor tyrosine kinase involved in nervous system and CC probably heart development. Upon binding of its ligand CC NTF3/neurotrophin-3, NTRK3 autophosphorylates and activates different CC signaling pathways, including the phosphatidylinositol 3-kinase/AKT and CC the MAPK pathways, that control cell survival and differentiation. CC {ECO:0000269|PubMed:25196463}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Exists in a dynamic equilibrium between monomeric (low CC affinity) and dimeric (high affinity) structures (By similarity). Binds CC SH2B2. Interacts with SQSTM1 and KIDINS220 (By similarity). Interacts CC with PTPRS (PubMed:25385546). Interacts with MAPK8IP3/JIP3 (By CC similarity). {ECO:0000250|UniProtKB:P04629, CC ECO:0000250|UniProtKB:Q03351, ECO:0000269|PubMed:25385546}. CC -!- INTERACTION: CC Q16288; Q16832: DDR2; NbExp=2; IntAct=EBI-3936704, EBI-1381484; CC Q16288; Q6PKX4: DOK6; NbExp=3; IntAct=EBI-3936704, EBI-2880244; CC Q16288; Q15375: EPHA7; NbExp=2; IntAct=EBI-3936704, EBI-1383428; CC Q16288; P08581: MET; NbExp=2; IntAct=EBI-3936704, EBI-1039152; CC Q16288; P04629: NTRK1; NbExp=2; IntAct=EBI-3936704, EBI-1028226; CC Q16288; Q16620: NTRK2; NbExp=3; IntAct=EBI-3936704, EBI-3904881; CC Q16288; P18031: PTPN1; NbExp=2; IntAct=EBI-3936704, EBI-968788; CC Q16288; Q13332: PTPRS; NbExp=4; IntAct=EBI-3936704, EBI-711536; CC Q16288; P61619: SEC61A1; NbExp=2; IntAct=EBI-3936704, EBI-358919; CC Q16288; Q9UBV2: SEL1L; NbExp=2; IntAct=EBI-3936704, EBI-358766; CC Q16288; P31947: SFN; NbExp=2; IntAct=EBI-3936704, EBI-476295; CC Q16288; Q99523: SORT1; NbExp=2; IntAct=EBI-3936704, EBI-1057058; CC Q16288; P62258: YWHAE; NbExp=2; IntAct=EBI-3936704, EBI-356498; CC -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=5; CC Comment=Additional isoforms seem to exist.; CC Name=1; Synonyms=A; CC IsoId=Q16288-1; Sequence=Displayed; CC Name=2; Synonyms=B; CC IsoId=Q16288-2; Sequence=VSP_002925, VSP_002926; CC Name=3; Synonyms=C; CC IsoId=Q16288-3; Sequence=VSP_002927; CC Name=4; Synonyms=D; CC IsoId=Q16288-4; Sequence=VSP_002924; CC Name=5; Synonyms=E; CC IsoId=Q16288-5; Sequence=VSP_002924, VSP_002927; CC -!- TISSUE SPECIFICITY: Widely expressed but mainly in nervous tissue. CC Isoform 2 is expressed at higher levels in adult brain than in fetal CC brain. CC -!- PTM: Ligand-mediated auto-phosphorylation. CC -!- DISEASE: Note=Defects in NTRK3 are associated with susceptibility to CC congenital heart defects (CHD). A disease characterized by congenital CC developmental abnormalities involving structures of the heart. CHD are CC the most common major birth defects and the leading cause of death from CC congenital malformations. {ECO:0000269|PubMed:25196463}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/433/NTRK3"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U05012; AAA75374.1; -; mRNA. DR EMBL; S76475; AAB33111.1; -; mRNA. DR EMBL; S76476; AAB33112.1; -; mRNA. DR EMBL; AJ224521; CAA12029.1; -; Genomic_DNA. DR EMBL; AJ224522; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224523; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224524; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224525; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224526; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224527; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224528; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224529; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224530; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224531; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224532; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224533; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224534; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AJ224535; CAA12029.1; JOINED; Genomic_DNA. DR EMBL; AK297160; BAH12511.1; -; mRNA. DR EMBL; AC009711; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC011966; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC021677; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS10340.1; -. [Q16288-3] DR CCDS; CCDS32322.1; -. [Q16288-1] DR CCDS; CCDS32323.1; -. [Q16288-2] DR CCDS; CCDS58399.1; -. [Q16288-5] DR PIR; A55178; A55178. DR PIR; I73632; I73632. DR PIR; I73633; I73633. DR RefSeq; NP_001007157.1; NM_001007156.3. [Q16288-2] DR RefSeq; NP_001012338.1; NM_001012338.3. [Q16288-1] DR RefSeq; NP_001230030.1; NM_001243101.2. [Q16288-5] DR RefSeq; NP_001307063.1; NM_001320134.1. DR RefSeq; NP_001307064.1; NM_001320135.1. DR RefSeq; NP_001362739.1; NM_001375810.1. [Q16288-1] DR RefSeq; NP_001362740.1; NM_001375811.1. [Q16288-3] DR RefSeq; NP_001362741.1; NM_001375812.1. [Q16288-5] DR RefSeq; NP_001362742.1; NM_001375813.1. [Q16288-2] DR RefSeq; NP_002521.2; NM_002530.4. [Q16288-3] DR RefSeq; XP_016877729.1; XM_017022240.2. [Q16288-3] DR RefSeq; XP_024305702.1; XM_024449934.2. [Q16288-2] DR RefSeq; XP_054234029.1; XM_054378054.1. [Q16288-3] DR RefSeq; XP_054234036.1; XM_054378061.1. [Q16288-2] DR PDB; 1WWC; X-ray; 1.90 A; A=297-422. DR PDB; 3V5Q; X-ray; 2.20 A; A/B=530-832. DR PDB; 4YMJ; X-ray; 2.00 A; A/B=530-839. DR PDB; 6KZC; X-ray; 2.00 A; A=528-839. DR PDB; 6KZD; X-ray; 1.71 A; A=528-839. DR PDBsum; 1WWC; -. DR PDBsum; 3V5Q; -. DR PDBsum; 4YMJ; -. DR PDBsum; 6KZC; -. DR PDBsum; 6KZD; -. DR AlphaFoldDB; Q16288; -. DR SMR; Q16288; -. DR BioGRID; 110971; 372. DR DIP; DIP-5723N; -. DR FunCoup; Q16288; 657. DR IntAct; Q16288; 355. DR MINT; Q16288; -. DR STRING; 9606.ENSP00000354207; -. DR BindingDB; Q16288; -. DR ChEMBL; CHEMBL5608; -. DR DrugBank; DB17191; Altiratinib. DR DrugBank; DB11986; Entrectinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB16056; GZ-389988. DR DrugBank; DB17140; JNJ-28312141. DR DrugBank; DB14723; Larotrectinib. DR DrugBank; DB15822; Pralsetinib. DR DrugBank; DB16826; Repotrectinib. DR DrugCentral; Q16288; -. DR GuidetoPHARMACOLOGY; 1819; -. DR GlyCosmos; Q16288; 13 sites, No reported glycans. DR GlyGen; Q16288; 14 sites, 2 N-linked glycans (1 site). DR iPTMnet; Q16288; -. DR PhosphoSitePlus; Q16288; -. DR BioMuta; NTRK3; -. DR DMDM; 134035335; -. DR CPTAC; CPTAC-3001; -. DR CPTAC; CPTAC-3002; -. DR jPOST; Q16288; -. DR MassIVE; Q16288; -. DR PaxDb; 9606-ENSP00000354207; -. DR PeptideAtlas; Q16288; -. DR ProteomicsDB; 20249; -. DR ProteomicsDB; 40524; -. DR ProteomicsDB; 60850; -. [Q16288-1] DR ProteomicsDB; 60851; -. [Q16288-2] DR ProteomicsDB; 60852; -. [Q16288-3] DR ProteomicsDB; 60853; -. [Q16288-4] DR ABCD; Q16288; 8 sequenced antibodies. DR Antibodypedia; 3979; 851 antibodies from 42 providers. DR DNASU; 4916; -. DR Ensembl; ENST00000317501.9; ENSP00000318328.3; ENSG00000140538.18. [Q16288-2] DR Ensembl; ENST00000357724.6; ENSP00000350356.2; ENSG00000140538.18. [Q16288-4] DR Ensembl; ENST00000394480.6; ENSP00000377990.1; ENSG00000140538.18. [Q16288-3] DR Ensembl; ENST00000557856.5; ENSP00000453959.1; ENSG00000140538.18. [Q16288-5] DR Ensembl; ENST00000629765.3; ENSP00000485864.1; ENSG00000140538.18. [Q16288-1] DR Ensembl; ENST00000695462.1; ENSP00000511942.1; ENSG00000140538.18. [Q16288-1] DR GeneID; 4916; -. DR KEGG; hsa:4916; -. DR MANE-Select; ENST00000629765.3; ENSP00000485864.1; NM_001012338.3; NP_001012338.1. DR UCSC; uc059mwc.1; human. [Q16288-1] DR AGR; HGNC:8033; -. DR CIViC; 4916; 14 evidence items across 14 molecular profiles. DR ClinPGx; PA31819; -. DR CTD; 4916; -. DR DisGeNET; 4916; -. DR GeneCards; NTRK3; -. DR HGNC; HGNC:8033; NTRK3. DR HPA; ENSG00000140538; Tissue enhanced (brain). DR MalaCards; NTRK3; -. DR MIM; 191316; gene. DR OpenTargets; ENSG00000140538; -. DR Orphanet; 2665; Congenital mesoblastic nephroma. DR Orphanet; 146; Differentiated thyroid carcinoma. DR Orphanet; 2030; Fibrosarcoma. DR VEuPathDB; HostDB:ENSG00000140538; -. DR eggNOG; KOG1026; Eukaryota. DR GeneTree; ENSGT00940000155645; -. DR HOGENOM; CLU_000288_74_1_1; -. DR InParanoid; Q16288; -. DR OMA; YREVTHP; -. DR OrthoDB; 10005095at2759; -. DR PAN-GO; Q16288; 13 GO annotations based on evolutionary models. DR PhylomeDB; Q16288; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; Q16288; -. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-388844; Receptor-type tyrosine-protein phosphatases. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-9034013; NTF3 activates NTRK3 signaling. DR Reactome; R-HSA-9034015; Signaling by NTRK3 (TRKC). DR Reactome; R-HSA-9034793; Activated NTRK3 signals through PLCG1. DR Reactome; R-HSA-9034864; Activated NTRK3 signals through RAS. DR Reactome; R-HSA-9603381; Activated NTRK3 signals through PI3K. DR Reactome; R-HSA-9603505; NTRK3 as a dependence receptor. DR SignaLink; Q16288; -. DR SIGNOR; Q16288; -. DR Agora; ENSG00000140538; -. DR BioGRID-ORCS; 4916; 12 hits in 1191 CRISPR screens. DR ChiTaRS; NTRK3; human. DR EvolutionaryTrace; Q16288; -. DR GeneWiki; TrkC_receptor; -. DR GenomeRNAi; 4916; -. DR Pharos; Q16288; Tclin. DR PRO; PR:Q16288; -. DR Proteomes; UP000005640; Chromosome 15. DR RNAct; Q16288; protein. DR Bgee; ENSG00000140538; Expressed in Brodmann (1909) area 10 and 175 other cell types or tissues. DR ExpressionAtlas; Q16288; baseline and differential. DR GO; GO:0030424; C:axon; IBA:GO_Central. DR GO; GO:0005737; C:cytoplasm; IEA:Ensembl. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0045211; C:postsynaptic membrane; IEA:Ensembl. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005004; F:GPI-linked ephrin receptor activity; IEA:Ensembl. DR GO; GO:0043121; F:neurotrophin binding; IBA:GO_Central. DR GO; GO:0005030; F:neurotrophin receptor activity; IDA:BHF-UCL. DR GO; GO:0002039; F:p53 binding; IPI:BHF-UCL. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0048677; P:axon extension involved in regeneration; IEA:Ensembl. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IDA:BHF-UCL. DR GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IBA:GO_Central. DR GO; GO:0071300; P:cellular response to retinoic acid; IEA:Ensembl. DR GO; GO:0007623; P:circadian rhythm; IEA:Ensembl. DR GO; GO:0090102; P:cochlea development; IEA:Ensembl. DR GO; GO:0007507; P:heart development; IMP:UniProtKB. DR GO; GO:0070306; P:lens fiber cell differentiation; IEA:Ensembl. DR GO; GO:0042490; P:mechanoreceptor differentiation; IEA:Ensembl. DR GO; GO:0022011; P:myelination in peripheral nervous system; IEA:Ensembl. DR GO; GO:0048712; P:negative regulation of astrocyte differentiation; IEA:Ensembl. DR GO; GO:0048665; P:neuron fate specification; IEA:Ensembl. DR GO; GO:0001764; P:neuron migration; IEA:Ensembl. DR GO; GO:0019227; P:neuronal action potential propagation; IEA:Ensembl. DR GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl. DR GO; GO:0048691; P:positive regulation of axon extension involved in regeneration; IEA:Ensembl. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:0010628; P:positive regulation of gene expression; IDA:BHF-UCL. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL. DR GO; GO:0010976; P:positive regulation of neuron projection development; IBA:GO_Central. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:BHF-UCL. DR GO; GO:0050927; P:positive regulation of positive chemotaxis; IDA:BHF-UCL. DR GO; GO:0051965; P:positive regulation of synapse assembly; IEA:Ensembl. DR GO; GO:0097107; P:postsynaptic density assembly; IEA:Ensembl. DR GO; GO:2000177; P:regulation of neural precursor cell proliferation; IEA:Ensembl. DR GO; GO:1905606; P:regulation of presynapse assembly; IEA:Ensembl. DR GO; GO:0051412; P:response to corticosterone; IEA:Ensembl. DR GO; GO:0045471; P:response to ethanol; IEA:Ensembl. DR CDD; cd04971; IgI_TrKABC_d5; 1. DR CDD; cd05094; PTKc_TrkC; 1. DR FunFam; 1.10.510.10:FF:000701; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000251; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000265; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.30.200.20:FF:000033; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.80.10.10:FF:000035; Tyrosine-protein kinase receptor; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.10.10; Ribonuclease Inhibitor; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000483; Cys-rich_flank_reg_C. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR013151; Immunoglobulin_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR001611; Leu-rich_rpt. DR InterPro; IPR032675; LRR_dom_sf. DR InterPro; IPR000372; LRRNT. DR InterPro; IPR020777; NTRK. DR InterPro; IPR020446; NTRK3. DR InterPro; IPR031635; NTRK_LRRCT. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR002011; Tyr_kinase_rcpt_2_CS. DR PANTHER; PTHR24416:SF66; NT-3 GROWTH FACTOR RECEPTOR; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF07679; I-set; 1. DR Pfam; PF00047; ig; 1. DR Pfam; PF13855; LRR_8; 1. DR Pfam; PF16920; LRRCT_2; 1. DR Pfam; PF01462; LRRNT; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR01939; NTKRECEPTOR. DR PRINTS; PR01942; NTKRECEPTOR3. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00409; IG; 1. DR SMART; SM00082; LRRCT; 1. DR SMART; SM00013; LRRNT; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF48726; Immunoglobulin; 2. DR SUPFAM; SSF52058; L domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 1. DR PROSITE; PS51450; LRR; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Developmental protein; KW Differentiation; Direct protein sequencing; Disulfide bond; Glycoprotein; KW Immunoglobulin domain; Kinase; Leucine-rich repeat; Membrane; Neurogenesis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; Receptor; KW Reference proteome; Repeat; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase. FT SIGNAL 1..31 FT CHAIN 32..839 FT /note="NT-3 growth factor receptor" FT /id="PRO_0000016731" FT TOPO_DOM 32..429 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 430..453 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 454..839 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT REPEAT 104..125 FT /note="LRR 1" FT REPEAT 128..149 FT /note="LRR 2" FT DOMAIN 160..209 FT /note="LRRCT" FT DOMAIN 210..300 FT /note="Ig-like C2-type 1" FT DOMAIN 309..382 FT /note="Ig-like C2-type 2" FT DOMAIN 538..839 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ACT_SITE 679 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 544..552 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 572 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 516 FT /note="Interaction with SHC1" FT /evidence="ECO:0000250" FT SITE 834 FT /note="Interaction with PLC-gamma-1" FT /evidence="ECO:0000250" FT MOD_RES 493 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q6VNS1" FT MOD_RES 516 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:25196463" FT MOD_RES 705 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 709 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 710 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT CARBOHYD 72 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 79 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 133 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 163 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 203 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 218 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 232 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 259 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 267 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 272 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 294 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 375 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 388 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 32..38 FT /evidence="ECO:0000250|UniProtKB:Q91044" FT DISULFID 36..45 FT /evidence="ECO:0000250|UniProtKB:Q91044" FT DISULFID 164..189 FT /evidence="ECO:0000250|UniProtKB:Q91044" FT DISULFID 166..207 FT /evidence="ECO:0000250|UniProtKB:Q91044" FT DISULFID 231..284 FT /evidence="ECO:0000250|UniProtKB:Q91044" FT DISULFID 320..362 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:10388563, ECO:0007744|PDB:1WWC" FT VAR_SEQ 402..410 FT /note="ESTDNFILF -> V (in isoform 4 and isoform 5)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_002924" FT VAR_SEQ 529..612 FT /note="YVQHIKRRDIVLKRELGEGAFGKVFLAECYNLSPTKDKMLVAVKALKDPTLA FT ARKDFQREAELLTNLQHEHIVKFYGVCGDGDP -> WVFSNIDNHGILNLKDNRDHLVP FT STHYIYEEPEVQSGEVSYPRSHGFREIMLNPISLPGHSKPLNHGIYVEDVNVYFSKGRH FT GF (in isoform 2)" FT /evidence="ECO:0000303|PubMed:7823156" FT /id="VSP_002925" FT VAR_SEQ 613..839 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:7823156" FT /id="VSP_002926" FT VAR_SEQ 712..725 FT /note="Missing (in isoform 3 and isoform 5)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:7806211, ECO:0000303|PubMed:7823156" FT /id="VSP_002927" FT VARIANT 21 FT /note="V -> F (in dbSNP:rs200822610)" FT /evidence="ECO:0000269|PubMed:25196463" FT /id="VAR_074601" FT VARIANT 71 FT /note="I -> V (found in patients with CHD; uncertain FT significance; dbSNP:rs200923715)" FT /evidence="ECO:0000269|PubMed:25196463" FT /id="VAR_074602" FT VARIANT 93 FT /note="T -> M (found in patients with congenital heart FT defects; uncertain significance; significantly reduced FT autophosphorylation; decreased NTRK3 signaling and FT decreased apoptosis in absence of NTF3; dbSNP:rs147992979)" FT /evidence="ECO:0000269|PubMed:25196463" FT /id="VAR_074603" FT VARIANT 149 FT /note="T -> R (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs368222977)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041471" FT VARIANT 163 FT /note="N -> I (found in patients with congenital heart FT defects; uncertain significance; no change in FT autophosphorylation; no effect on NTRK3 signaling; FT dbSNP:rs547862658)" FT /evidence="ECO:0000269|PubMed:25196463" FT /id="VAR_074604" FT VARIANT 306 FT /note="R -> C (in dbSNP:rs56386352)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041472" FT VARIANT 307 FT /note="V -> L (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs1388363572)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041473" FT VARIANT 336 FT /note="L -> Q (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041474" FT VARIANT 533 FT /note="I -> F (found in patients with congenital heart FT defects; uncertain significance; no change in FT autophosphorylation; changed NTRK3 signaling with decreased FT apoptosis in absence of NTF3; dbSNP:rs869112057)" FT /evidence="ECO:0000269|PubMed:25196463" FT /id="VAR_074605" FT VARIANT 664 FT /note="A -> S (in a lung carcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046521" FT VARIANT 677 FT /note="H -> Y (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:18293376" FT /id="VAR_041475" FT VARIANT 678 FT /note="R -> Q (in dbSNP:rs55890138)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041476" FT VARIANT 735 FT /note="R -> F (in a lung large cell carcinoma sample; FT somatic mutation; requires 2 nucleotide substitutions)" FT /id="VAR_046770" FT VARIANT 736 FT /note="W -> C (in a lung carcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046522" FT VARIANT 745 FT /note="R -> P (in a lung carcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046523" FT VARIANT 766 FT /note="Y -> F (in a lung carcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046524" FT VARIANT 768 FT /note="K -> R (in dbSNP:rs55770052)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046771" FT VARIANT 781 FT /note="E -> K (in dbSNP:rs56393451)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046772" FT VARIANT 817 FT /note="I -> M (found in patients with congenital heart FT defects; uncertain significance; no change in FT autophosphorylation; changed NTRK3 signaling with decreased FT apoptosis in absence of NTF3; dbSNP:rs869209165)" FT /evidence="ECO:0000269|PubMed:25196463" FT /id="VAR_074606" FT MUTAGEN 572 FT /note="K->N: Loss of autophosphorylation and loss of NTRK3 FT signaling." FT /evidence="ECO:0000269|PubMed:25196463" FT CONFLICT 65 FT /note="S -> G (in Ref. 4; BAH12511)" FT /evidence="ECO:0000305" FT CONFLICT 70 FT /note="S -> N (in Ref. 2; AAB33111/AAB33112)" FT /evidence="ECO:0000305" FT CONFLICT 635 FT /note="D -> N (in Ref. 1; AAA75374)" FT /evidence="ECO:0000305" FT STRAND 318..326 FT /evidence="ECO:0007829|PDB:1WWC" FT STRAND 332..337 FT /evidence="ECO:0007829|PDB:1WWC" FT STRAND 345..354 FT /evidence="ECO:0007829|PDB:1WWC" FT STRAND 356..367 FT /evidence="ECO:0007829|PDB:1WWC" FT HELIX 370..372 FT /evidence="ECO:0007829|PDB:1WWC" FT STRAND 374..382 FT /evidence="ECO:0007829|PDB:1WWC" FT STRAND 385..393 FT /evidence="ECO:0007829|PDB:1WWC" FT HELIX 535..537 FT /evidence="ECO:0007829|PDB:6KZD" FT STRAND 538..547 FT /evidence="ECO:0007829|PDB:6KZD" FT STRAND 550..559 FT /evidence="ECO:0007829|PDB:6KZD" FT STRAND 567..576 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 579..594 FT /evidence="ECO:0007829|PDB:6KZD" FT STRAND 603..606 FT /evidence="ECO:0007829|PDB:6KZD" FT STRAND 609..618 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 625..631 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 653..672 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 682..684 FT /evidence="ECO:0007829|PDB:6KZD" FT STRAND 685..687 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 689..691 FT /evidence="ECO:0007829|PDB:6KZD" FT STRAND 693..695 FT /evidence="ECO:0007829|PDB:6KZD" FT STRAND 700..704 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 706..708 FT /evidence="ECO:0007829|PDB:4YMJ" FT HELIX 734..736 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 739..744 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 749..764 FT /evidence="ECO:0007829|PDB:6KZD" FT TURN 765..767 FT /evidence="ECO:0007829|PDB:6KZD" FT TURN 770..773 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 776..784 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 797..806 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 811..813 FT /evidence="ECO:0007829|PDB:6KZD" FT HELIX 817..827 FT /evidence="ECO:0007829|PDB:6KZD" SQ SEQUENCE 839 AA; 94428 MW; 7FE8846830083C08 CRC64; MDVSLCPAKC SFWRIFLLGS VWLDYVGSVL ACPANCVCSK TEINCRRPDD GNLFPLLEGQ DSGNSNGNAS INITDISRNI TSIHIENWRS LHTLNAVDME LYTGLQKLTI KNSGLRSIQP RAFAKNPHLR YINLSSNRLT TLSWQLFQTL SLRELQLEQN FFNCSCDIRW MQLWQEQGEA KLNSQNLYCI NADGSQLPLF RMNISQCDLP EISVSHVNLT VREGDNAVIT CNGSGSPLPD VDWIVTGLQS INTHQTNLNW TNVHAINLTL VNVTSEDNGF TLTCIAENVV GMSNASVALT VYYPPRVVSL EEPELRLEHC IEFVVRGNPP PTLHWLHNGQ PLRESKIIHV EYYQEGEISE GCLLFNKPTH YNNGNYTLIA KNPLGTANQT INGHFLKEPF PESTDNFILF DEVSPTPPIT VTHKPEEDTF GVSIAVGLAA FACVLLVVLF VMINKYGRRS KFGMKGPVAV ISGEEDSASP LHHINHGITT PSSLDAGPDT VVIGMTRIPV IENPQYFRQG HNCHKPDTYV QHIKRRDIVL KRELGEGAFG KVFLAECYNL SPTKDKMLVA VKALKDPTLA ARKDFQREAE LLTNLQHEHI VKFYGVCGDG DPLIMVFEYM KHGDLNKFLR AHGPDAMILV DGQPRQAKGE LGLSQMLHIA SQIASGMVYL ASQHFVHRDL ATRNCLVGAN LLVKIGDFGM SRDVYSTDYY RLFNPSGNDF CIWCEVGGHT MLPIRWMPPE SIMYRKFTTE SDVWSFGVIL WEIFTYGKQP WFQLSNTEVI ECITQGRVLE RPRVCPKEVY DVMLGCWQRE PQQRLNIKEI YKILHALGKA TPIYLDILG // ID P53_HUMAN Reviewed; 393 AA. AC P04637; Q15086; Q15087; Q15088; Q16535; Q16807; Q16808; Q16809; Q16810; AC Q16811; Q16848; Q2XN98; Q3LRW1; Q3LRW2; Q3LRW3; Q3LRW4; Q3LRW5; Q86UG1; AC Q8J016; Q99659; Q9BTM4; Q9HAQ8; Q9NP68; Q9NPJ2; Q9NZD0; Q9UBI2; Q9UQ61; DT 13-AUG-1987, integrated into UniProtKB/Swiss-Prot. DT 24-NOV-2009, sequence version 4. DT 28-JAN-2026, entry version 313. DE RecName: Full=Cellular tumor antigen p53; DE AltName: Full=Antigen NY-CO-13; DE AltName: Full=Phosphoprotein p53; DE AltName: Full=Tumor suppressor p53; GN Name=TP53; Synonyms=P53; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=4006916; DOI=10.1002/j.1460-2075.1985.tb03768.x; RA Zakut-Houri R., Bienz-Tadmor B., Givol D., Oren M.; RT "Human p53 cellular tumor antigen: cDNA sequence and expression in COS RT cells."; RL EMBO J. 4:1251-1255(1985). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT GLY-76. RX PubMed=2946935; DOI=10.1128/mcb.6.5.1379-1385.1986; RA Lamb P., Crawford L.; RT "Characterization of the human p53 gene."; RL Mol. Cell. Biol. 6:1379-1385(1986). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3894933; DOI=10.1128/mcb.5.7.1601-1610.1985; RA Harlow E., Williamson N.M., Ralston R., Helfman D.M., Adams T.E.; RT "Molecular cloning and in vitro expression of a cDNA clone for human RT cellular tumor antigen p53."; RL Mol. Cell. Biol. 5:1601-1610(1985). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3025664; DOI=10.1128/mcb.6.12.4650-4656.1986; RA Harris N., Brill E., Shohat O., Prokocimer M., Wolf D., Arai N., Rotter V.; RT "Molecular basis for heterogeneity of the human p53 protein."; RL Mol. Cell. Biol. 6:4650-4656(1986). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=2905688; DOI=10.1016/0378-1119(88)90196-5; RA Buchman V.L., Chumakov P.M., Ninkina N.N., Samarina O.P., Georgiev G.P.; RT "A variation in the structure of the protein-coding region of the human p53 RT gene."; RL Gene 70:245-252(1988). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS SPORADIC CANCERS. RX PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x; RA Farrell P.J., Allan G., Shanahan F., Vousden K.H., Crook T.; RT "p53 is frequently mutated in Burkitt's lymphoma cell lines."; RL EMBO J. 10:2879-2887(1991). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286. RX PubMed=8316628; DOI=10.2307/3578196; RA Allalunis-Turner M.J., Barron G.M., Day R.S. III, Dobler K.D., RA Mirzayans R.; RT "Isolation of two cell lines from a human malignant glioma specimen RT differing in sensitivity to radiation and chemotherapeutic drugs."; RL Radiat. Res. 134:349-354(1993). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH WWOX. RX PubMed=11058590; DOI=10.1074/jbc.m007140200; RA Chang N.-S., Pratt N., Heath J., Schultz L., Sleve D., Carey G.B., RA Zevotek N.; RT "Hyaluronidase induction of a WW domain-containing oxidoreductase that RT enhances tumor necrosis factor cytotoxicity."; RL J. Biol. Chem. 276:3361-3370(2001). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 7; 8 AND 9), SUBCELLULAR RP LOCATION, TISSUE SPECIFICITY, ALTERNATIVE PROMOTER USAGE, ALTERNATIVE RP SPLICING, INDUCTION, AND VARIANT ARG-72. RC TISSUE=Colon; RX PubMed=16131611; DOI=10.1101/gad.1339905; RA Bourdon J.C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A., RA Xirodimas D.P., Saville M.K., Lane D.P.; RT "p53 isoforms can regulate p53 transcriptional activity."; RL Genes Dev. 19:2122-2137(2005). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Chumakov P.M., Almazov V.P., Jenkins J.R.; RL Submitted (JUN-1991) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Rozemuller E.H., Tilanus M.G.J.; RT "P53 genomic sequence. Corrections and polymorphism."; RL Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-47; LYS-339 AND RP ALA-366. RG NIEHS SNPs program; RL Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases. RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286. RX PubMed=11023613; DOI=10.1667/0033-7587(2000)154[0473:htftmg]2.0.co;2; RA Anderson C.W., Allalunis-Turner M.J.; RT "Human TP53 from the malignant glioma-derived cell lines M059J and M059K RT has a cancer-associated mutation in exon 8."; RL Radiat. Res. 154:473-476(2000). RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS HIS-273 AND SER-309. RA Azuma K., Shichijo S., Itoh K.; RT "Identification of a tumor-rejection antigen recognized by HLA-B46 RT restricted CTL."; RL Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases. RN [15] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-72. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [16] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [17] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ARG-72. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [18] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ALA-278. RC TISSUE=Kidney; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [19] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-379 (ISOFORM 1), AND VARIANTS ASN-139 AND RP PRO-155. RC TISSUE=Lung carcinoma; RX PubMed=14660794; DOI=10.1073/pnas.2536558100; RA Kanashiro C.A., Schally A.V., Groot K., Armatis P., Bernardino A.L., RA Varga J.L.; RT "Inhibition of mutant p53 expression and growth of DMS-153 small cell lung RT carcinoma by antagonists of growth hormone-releasing hormone and RT bombesin."; RL Proc. Natl. Acad. Sci. U.S.A. 100:15836-15841(2003). RN [20] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 101-393. RX PubMed=6396087; DOI=10.1002/j.1460-2075.1984.tb02287.x; RA Matlashewski G., Lamb P., Pim D., Peacock J., Crawford L., Benchimol S.; RT "Isolation and characterization of a human p53 cDNA clone: expression of RT the human p53 gene."; RL EMBO J. 3:3257-3262(1984). RN [21] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 126-185. RA Pan X.L., Zhang A.H.; RT "Study on the effect of tumor suppressor gene p53 in arsenism patients."; RL Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases. RN [22] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 261-298, AND VARIANT GLN-282. RC TISSUE=Blood; RA Nimri L.F., Owais W., Momani E.; RT "Detection of P53 gene mutations and serum p53 antibodies associated with RT cigarette smoking."; RL Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases. RN [23] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 262-306, AND VARIANT VAL-262. RC TISSUE=Ovarian adenocarcinoma; RA Filippini G., Soldati G.; RL Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases. RN [24] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260. RC TISSUE=Glial cell, and Glial tumor; RA Thompson-Hehir J., Davies M.P.A., Green J.A., Halliwell N., Joyce K.A., RA Salisbury J., Sibson D.R., Vergote I., Walker C.; RT "Mutation detection utilizing a novel PCR approach for amplification of the RT p53 gene from microdissected tissue: application to archival tumor RT samples."; RL Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases. RN [25] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260. RA Yavuz A.S., Farner N.L., Yavuz S., Grammer A.C., Girschick H.J., RA Lipsky P.E.; RT "Bcl6 and P53 gene mutations in tonsillar B cells."; RL Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases. RN [26] RP PROTEIN SEQUENCE OF 320-337, SUBUNIT, INTERACTION WITH PRMT5, SUBCELLULAR RP LOCATION, METHYLATION AT ARG-333; ARG-335 AND ARG-337 BY PRMT5, RP IDENTIFICATION BY MASS SPECTROMETRY, AND MUTAGENESIS OF 333-ARG--ARG-337. RX PubMed=19011621; DOI=10.1038/ncb1802; RA Jansson M., Durant S.T., Cho E.C., Sheahan S., Edelmann M., Kessler B., RA La Thangue N.B.; RT "Arginine methylation regulates the p53 response."; RL Nat. Cell Biol. 10:1431-1439(2008). RN [27] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 332-366. RA Pinto E.M., Mendonca B.B., Latronico A.C.; RT "Allelic variant in intron 9 of TP53 gene."; RL Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases. RN [28] RP INTERACTION WITH HUMAN PAPILLOMAVIRUS TYPE 6 AND 11 PROTEIN E6 (MICROBIAL RP INFECTION). RX PubMed=2175676; DOI=10.1016/0092-8674(90)90409-8; RA Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M.; RT "The E6 oncoprotein encoded by human papillomavirus types 16 and 18 RT promotes the degradation of p53."; RL Cell 63:1129-1136(1990). RN [29] RP NUCLEAR LOCALIZATION SIGNAL, AND MUTAGENESIS OF LYS-319; LYS-320 AND RP LYS-321. RX PubMed=2156209; RA Addison C., Jenkins J.R., Sturzbecher H.-W.; RT "The p53 nuclear localisation signal is structurally linked to a p34cdc2 RT kinase motif."; RL Oncogene 5:423-426(1990). RN [30] RP PHOSPHORYLATION BY P60/CDC2 AND CYCLIN B/CDC2. RX PubMed=2141171; DOI=10.1073/pnas.87.12.4766; RA Bischoff J.R., Friedman P.N., Marshak D.R., Prives C., Beach D.; RT "Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2."; RL Proc. Natl. Acad. Sci. U.S.A. 87:4766-4770(1990). RN [31] RP PHOSPHORYLATION. RX PubMed=1705009; DOI=10.1128/mcb.11.3.1598-1606.1991; RA Samad A., Carroll R.B.; RT "The tumor suppressor p53 is bound to RNA by a stable covalent linkage."; RL Mol. Cell. Biol. 11:1598-1606(1991). RN [32] RP DEPHOSPHORYLATION BY PP2A. RX PubMed=1848668; DOI=10.1128/mcb.11.4.1996-2003.1991; RA Scheidtmann K.H., Mumby M.C., Rundell K., Walter G.; RT "Dephosphorylation of simian virus 40 large-T antigen and p53 protein by RT protein phosphatase 2A: inhibition by small-t antigen."; RL Mol. Cell. Biol. 11:1996-2003(1991). RN [33] RP ALTERNATIVE SPLICING. RX PubMed=8632903; RA Flaman J.-M., Waridel F., Estreicher A., Vannier A., Limacher J.-M., RA Gilbert D., Iggo R., Frebourg T.; RT "The human tumour suppressor gene p53 is alternatively spliced in normal RT cells."; RL Oncogene 12:813-818(1996). RN [34] RP GLYCOSYLATION. RX PubMed=8632915; RA Shaw P., Freeman J., Bovey R., Iggo R.; RT "Regulation of specific DNA binding by p53: evidence for a role for O- RT glycosylation and charged residues at the carboxy-terminus."; RL Oncogene 12:921-930(1996). RN [35] RP PHOSPHORYLATION AT SER-33. RX PubMed=9372954; DOI=10.1128/mcb.17.12.7220; RA Ko L.J., Shieh S.-Y., Chen X., Jayaraman L., Tamai K., Taya Y., Prives C., RA Pan Z.-Q.; RT "p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner."; RL Mol. Cell. Biol. 17:7220-7229(1997). RN [36] RP FUNCTION, AND IDENTIFICATION IN COMPLEX WITH CAK. RX PubMed=9840937; DOI=10.1038/sj.onc.1202504; RA Schneider E., Montenarh M., Wagner P.; RT "Regulation of CAK kinase activity by p53."; RL Oncogene 17:2733-2741(1998). RN [37] RP SUMOYLATION AT LYS-386, AND MUTAGENESIS OF LYS-386. RA Gostissa M., Hengstermann A., Fogal V., Sandy P., Schwarz S.E., RA Scheffner M., Del Sal G.; RT "Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1."; RL EMBO J. 18:6462-6471(1999). RN [38] RP PHOSPHORYLATION AT THR-18 BY CSNK1D/CK1. RX PubMed=10606744; DOI=10.1016/s0014-5793(99)01647-6; RA Dumaz N., Milne D.M., Meek D.W.; RT "Protein kinase CK1 is a p53-threonine 18 kinase which requires prior RT phosphorylation of serine 15."; RL FEBS Lett. 463:312-316(1999). RN [39] RP BIPARTITE NUCLEAR LOCALIZATION SIGNAL, AND CHARACTERIZATION OF VARIANT RP ASN-305. RX PubMed=10551826; DOI=10.1074/jbc.274.46.32699; RA Liang S.H., Clarke M.F.; RT "A bipartite nuclear localization signal is required for p53 nuclear import RT regulated by a carboxyl-terminal domain."; RL J. Biol. Chem. 274:32699-32703(1999). RN [40] RP PHOSPHORYLATION AT SER-15 AND SER-20, INDUCTION BY DNA DAMAGE, RP CHARACTERIZATION OF LFS VARIANT HIS-273, MUTAGENESIS OF THR-18; SER-20 AND RP 22-LEU-TRP-23, SUBCELLULAR LOCATION, AND INTERACTION WITH PML AND MDM2. RX PubMed=10570149; DOI=10.1073/pnas.96.24.13777; RA Chehab N.H., Malikzay A., Stavridi E.S., Halazonetis T.D.; RT "Phosphorylation of Ser-20 mediates stabilization of human p53 in response RT to DNA damage."; RL Proc. Natl. Acad. Sci. U.S.A. 96:13777-13782(1999). RN [41] RP UBIQUITINATION. RX PubMed=10722742; DOI=10.1074/jbc.275.12.8945; RA Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., Weissman A.M.; RT "Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and RT p53."; RL J. Biol. Chem. 275:8945-8951(2000). RN [42] RP ACETYLATION AT LYS-373 AND LYS-382. RX PubMed=10656795; DOI=10.1006/jmbi.1999.3415; RA Abraham J., Kelly J., Thibault P., Benchimol S.; RT "Post-translational modification of p53 protein in response to ionizing RT radiation analyzed by mass spectrometry."; RL J. Mol. Biol. 295:853-864(2000). RN [43] RP PHOSPHORYLATION AT SER-315 AND SER-392 BY CDK2, AND MUTAGENESIS OF LYS-382; RP LEU-383 AND PHE-385. RX PubMed=10884347; DOI=10.1006/jmbi.2000.3830; RA Luciani M.G., Hutchins J.R.A., Zheleva D., Hupp T.R.; RT "The C-terminal regulatory domain of p53 contains a functional docking site RT for cyclin A."; RL J. Mol. Biol. 300:503-518(2000). RN [44] RP FUNCTION, INTERACTION WITH PML, AND SUBCELLULAR LOCATION. RX PubMed=11025664; DOI=10.1038/35036365; RA Guo A., Salomoni P., Luo J., Shih A., Zhong S., Gu W., Pandolfi P.P.; RT "The function of PML in p53-dependent apoptosis."; RL Nat. Cell Biol. 2:730-736(2000). RN [45] RP INTERACTION WITH E4F1. RX PubMed=10644996; DOI=10.1038/sj.onc.1203250; RA Sandy P., Gostissa M., Fogal V., Cecco L.D., Szalay K., Rooney R.J., RA Schneider C., Del Sal G.; RT "p53 is involved in the p120E4F-mediated growth arrest."; RL Oncogene 19:188-199(2000). RN [46] RP PHOSPHORYLATION AT THR-18. RX PubMed=10951572; DOI=10.1038/sj.onc.1203709; RA Lopez-Borges S., Lazo P.A.; RT "The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 RT within the mdm-2 binding site of the p53 tumour suppressor protein."; RL Oncogene 19:3656-3664(2000). RN [47] RP REVIEW ON ZINC-BINDING PROPERTIES. RX PubMed=11554448; DOI=10.1089/15230860152542961; RA Hainaut P., Mann K.; RT "Zinc binding and redox control of p53 structure and function."; RL Antioxid. Redox Signal. 3:611-623(2001). RN [48] RP PHOSPHORYLATION AT SER-15. RX PubMed=11554766; DOI=10.1006/bbrc.2001.5627; RA Imamura K., Ogura T., Kishimoto A., Kaminishi M., Esumi H.; RT "Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated RT protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D- RT ribofuranoside, in a human hepatocellular carcinoma cell line."; RL Biochem. Biophys. Res. Commun. 287:562-567(2001). RN [49] RP DEACETYLATION AT LYS-382 BY SIRT1. RX PubMed=11672523; DOI=10.1016/s0092-8674(01)00527-x; RA Vaziri H., Dessain S.K., Ng Eaton E., Imai S., Frye R.A., Pandita T.K., RA Guarente L., Weinberg R.A.; RT "hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase."; RL Cell 107:149-159(2001). RN [50] RP MINIMAL REPRESSION DOMAIN. RX PubMed=11007800; DOI=10.1074/jbc.m008231200; RA Hong T.M., Chen J.J., Peck K., Yang P.C., Wu C.W.; RT "p53 amino acids 339-346 represent the minimal p53 repression domain."; RL J. Biol. Chem. 276:1510-1515(2001). RN [51] RP PHOSPHORYLATION AT SER-20 BY PLK3. RX PubMed=11447225; DOI=10.1074/jbc.m104157200; RA Xie S., Wang Q., Wu H., Cogswell J., Lu L., Jhanwar-Uniyal M., Dai W.; RT "Reactive oxygen species-induced phosphorylation of p53 on serine 20 is RT mediated in part by polo-like kinase-3."; RL J. Biol. Chem. 276:36194-36199(2001). RN [52] RP PHOSPHORYLATION AT SER-20 BY PLK3. RX PubMed=11551930; DOI=10.1074/jbc.m106050200; RA Xie S., Wu H., Wang Q., Cogswell J.P., Husain I., Conn C., Stambrook P., RA Jhanwar-Uniyal M., Dai W.; RT "Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at RT least in part via the p53 pathway."; RL J. Biol. Chem. 276:43305-43312(2001). RN [53] RP SUMOYLATION AT LYS-386, SUBCELLULAR LOCATION, AND MUTAGENESIS OF PHE-385; RP LYS-386; THR-387 AND GLU-388. RX PubMed=11124955; DOI=10.1074/jbc.m009476200; RA Rodriguez M.S., Dargemont C., Hay R.T.; RT "SUMO-1 conjugation in vivo requires both a consensus modification motif RT and nuclear targeting."; RL J. Biol. Chem. 276:12654-12659(2001). RN [54] RP PHOSPHORYLATION BY PRPK. RX PubMed=11546806; DOI=10.1074/jbc.m105669200; RA Abe Y., Matsumoto S., Wei S., Nezu K., Miyoshi A., Kito K., Ueda N., RA Shigemoto K., Hitsumoto Y., Nikawa J., Enomoto Y.; RT "Cloning and characterization of a p53-related protein kinase expressed in RT interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and RT the testes."; RL J. Biol. Chem. 276:44003-44011(2001). RN [55] RP PHOSPHORYLATION AT SER-392. RX PubMed=11239457; DOI=10.1016/s1097-2765(01)00176-9; RA Keller D.M., Zeng X., Wang Y., Zhang Q.H., Kapoor M., Shu H., Goodman R., RA Lozano G., Zhao Y., Lu H.; RT "A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, RT and SSRP1."; RL Mol. Cell 7:283-292(2001). RN [56] RP INTERACTION WITH USP7. RX PubMed=12507430; DOI=10.1016/s0092-8674(02)01199-6; RA Hu M., Li P., Li M., Li W., Yao T., Wu J.-W., Gu W., Cohen R.E., Shi Y.; RT "Crystal structure of a UBP-family deubiquitinating enzyme in isolation and RT in complex with ubiquitin aldehyde."; RL Cell 111:1041-1054(2002). RN [57] RP IDENTIFICATION IN A COMPLEX WITH CABLES1 AND TP73. RX PubMed=11706030; DOI=10.1074/jbc.m108535200; RA Tsuji K., Mizumoto K., Yamochi T., Nishimoto I., Matsuoka M.; RT "Differential effect of ik3-1/cables on p53- and p73-induced cell death."; RL J. Biol. Chem. 277:2951-2957(2002). RN [58] RP INTERACTION WITH HIPK2. RX PubMed=11925430; DOI=10.1074/jbc.m200153200; RA Kim E.-J., Park J.-S., Um S.-J.; RT "Identification and characterization of HIPK2 interacting with p73 and RT modulating functions of the p53 family in vivo."; RL J. Biol. Chem. 277:32020-32028(2002). RN [59] RP INTERACTION WITH HIPK2, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF RP SER-46 AND LYS-382. RX PubMed=11740489; DOI=10.1038/ncb715; RA Hofmann T.G., Moeller A., Sirma H., Zentgraf H., Taya Y., Droege W., RA Will H., Schmitz M.L.; RT "Regulation of p53 activity by its interaction with homeodomain-interacting RT protein kinase-2."; RL Nat. Cell Biol. 4:1-10(2002). RN [60] RP INTERACTION WITH HIPK2, AND PHOSPHORYLATION AT SER-46. RX PubMed=11780126; DOI=10.1038/ncb714; RA D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y., Saito S., RA Gostissa M., Coen S., Marchetti A., Del Sal G., Piaggio G., Fanciulli M., RA Appella E., Soddu S.; RT "Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and RT mediates apoptosis."; RL Nat. Cell Biol. 4:11-19(2002). RN [61] RP INTERACTION WITH ING4. RX PubMed=12750254; RA Shiseki M., Nagashima M., Pedeux R.M., Kitahama-Shiseki M., Miura K., RA Okamura S., Onogi H., Higashimoto Y., Appella E., Yokota J., Harris C.C.; RT "p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity."; RL Cancer Res. 63:2373-2378(2003). RN [62] RP ACETYLATION AT LYS-305. RX PubMed=12724314; DOI=10.1074/jbc.m212574200; RA Wang Y.H., Tsay Y.G., Tan B.C., Lo W.Y., Lee S.C.; RT "Identification and characterization of a novel p300-mediated p53 RT acetylation site, lysine 305."; RL J. Biol. Chem. 278:25568-25576(2003). RN [63] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH CHEK2 AND PML, RP UBIQUITINATION BY MDM2, AND PHOSPHORYLATION AT SER-20. RX PubMed=12810724; DOI=10.1074/jbc.m301264200; RA Louria-Hayon I., Grossman T., Sionov R.V., Alsheich O., Pandolfi P.P., RA Haupt Y.; RT "The promyelocytic leukemia protein protects p53 from Mdm2-mediated RT inhibition and degradation."; RL J. Biol. Chem. 278:33134-33141(2003). RN [64] RP INTERACTION WITH TP53INP1. RX PubMed=12851404; DOI=10.1074/jbc.m301979200; RA Tomasini R., Samir A.A., Carrier A., Isnardon D., Cecchinelli B., Soddu S., RA Malissen B., Dagorn J.-C., Iovanna J.L., Dusetti N.J.; RT "TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are RT partners in regulating p53 activity."; RL J. Biol. Chem. 278:37722-37729(2003). RN [65] RP NUCLEOCYTOPLASMIC SHUTTLING, AND NUCLEAR EXPORT SIGNAL. RX PubMed=12944468; DOI=10.1128/mcb.23.18.6396-6405.2003; RA O'Keefe K., Li H., Zhang Y.; RT "Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated RT cytoplasmic degradation but not ubiquitination."; RL Mol. Cell. Biol. 23:6396-6405(2003). RN [66] RP FUNCTION, AND INTERACTION WITH PPP1R13L; PPP1R13B AND TP53BP2. RX PubMed=12524540; DOI=10.1038/ng1070; RA Bergamaschi D., Samuels Y., O'Neil N.J., Trigiante G., Crook T., RA Hsieh J.-K., O'Connor D.J., Zhong S., Campargue I., Tomlinson M.L., RA Kuwabara P.E., Lu X.; RT "iASPP oncoprotein is a key inhibitor of p53 conserved from worm to RT human."; RL Nat. Genet. 33:162-167(2003). RN [67] RP INTERACTION WITH HIPK1. RX PubMed=12702766; DOI=10.1073/pnas.0530308100; RA Kondo S., Lu Y., Debbas M., Lin A.W., Sarosi I., Itie A., Wakeham A., RA Tuan J., Saris C., Elliott G., Ma W., Benchimol S., Lowe S.W., Mak T.W., RA Thukral S.K.; RT "Characterization of cells and gene-targeted mice deficient for the p53- RT binding kinase homeodomain-interacting protein kinase 1 (HIPK1)."; RL Proc. Natl. Acad. Sci. U.S.A. 100:5431-5436(2003). RN [68] RP INTERACTION WITH CDKN2AIP. RX PubMed=15109303; DOI=10.1042/bj20040337; RA Hasan M.K., Yaguchi T., Minoda Y., Hirano T., Taira K., Wadhwa R., RA Kaul S.C.; RT "Alternative reading frame protein (ARF)-independent function of CARF RT (collaborator of ARF) involves its interactions with p53: evidence for a RT novel p53-activation pathway and its negative feedback control."; RL Biochem. J. 380:605-610(2004). RN [69] RP INTERACTION WITH HRMT1L2; EP300 AND CARM1, AND FUNCTION. RX PubMed=15186775; DOI=10.1016/j.cell.2004.05.009; RA An W., Kim J., Roeder R.G.; RT "Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional RT activation by p53."; RL Cell 117:735-748(2004). RN [70] RP INTERACTION WITH ANKRD2. RX PubMed=15136035; DOI=10.1016/j.jmb.2004.03.071; RA Kojic S., Medeot E., Guccione E., Krmac H., Zara I., Martinelli V., RA Valle G., Faulkner G.; RT "The Ankrd2 protein, a link between the sarcomere and the nucleus in RT skeletal muscle."; RL J. Mol. Biol. 339:313-325(2004). RN [71] RP PHOSPHORYLATION AT THR-55, MUTAGENESIS OF THR-55, AND INTERACTION WITH RP TAF1. RX PubMed=15053879; DOI=10.1016/s1097-2765(04)00123-6; RA Li H.-H., Li A.G., Sheppard H.M., Liu X.; RT "Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for RT TAF1 in cell G1 progression."; RL Mol. Cell 13:867-878(2004). RN [72] RP DEUBIQUITINATION BY USP7. RX PubMed=15053880; DOI=10.1016/s1097-2765(04)00157-1; RA Li M., Brooks C.L., Kon N., Gu W.; RT "A dynamic role of HAUSP in the p53-Mdm2 pathway."; RL Mol. Cell 13:879-886(2004). RN [73] RP ALTERNATIVE SPLICING (ISOFORM 4), FUNCTION, SUBCELLULAR LOCATION, AND RP UBIQUITINATION. RX PubMed=15340061; DOI=10.1128/mcb.24.18.7987-7997.2004; RA Ghosh A., Stewart D., Matlashewski G.; RT "Regulation of human p53 activity and cell localization by alternative RT splicing."; RL Mol. Cell. Biol. 24:7987-7997(2004). RN [74] RP METHYLATION AT LYS-372, AND MUTAGENESIS OF LYS-372. RX PubMed=15525938; DOI=10.1038/nature03117; RA Chuikov S., Kurash J.K., Wilson J.R., Xiao B., Justin N., Ivanov G.S., RA McKinney K., Tempst P., Prives C., Gamblin S.J., Barlev N.A., Reinberg D.; RT "Regulation of p53 activity through lysine methylation."; RL Nature 432:353-360(2004). RN [75] RP ACETYLATION AT LYS-382. RX PubMed=15448695; DOI=10.1038/ncb1170; RA Demonacos C., Krstic-Demonacos M., Smith L., Xu D., O'Connor D.P., RA Jansson M., La Thangue N.B.; RT "A new effector pathway links ATM kinase with the DNA damage response."; RL Nat. Cell Biol. 6:968-976(2004). RN [76] RP INTERACTION WITH AURKA, AND PHOSPHORYLATION AT SER-315. RX PubMed=14702041; DOI=10.1038/ng1279; RA Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F., RA Fujii S., Arlinghaus R.B., Czerniak B.A., Sen S.; RT "Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization RT and inhibition of p53."; RL Nat. Genet. 36:55-62(2004). RN [77] RP INTERACTION WITH NQO1. RX PubMed=15687255; DOI=10.1101/gad.319905; RA Asher G., Tsvetkov P., Kahana C., Shaul Y.; RT "A mechanism of ubiquitin-independent proteasomal degradation of the tumor RT suppressors p53 and p73."; RL Genes Dev. 19:316-321(2005). RN [78] RP INTERACTION WITH NOC2L. RX PubMed=16322561; DOI=10.1101/gad.351205; RA Hublitz P., Kunowska N., Mayer U.P., Muller J.M., Heyne K., Yin N., RA Fritzsche C., Poli C., Miguet L., Schupp I.W., van Grunsven L.A., RA Potiers N., van Dorsselaer A., Metzger E., Roemer K., Schule R.; RT "NIR is a novel INHAT repressor that modulates the transcriptional activity RT of p53."; RL Genes Dev. 19:2912-2924(2005). RN [79] RP RETRACTED PAPER. RX PubMed=15701641; DOI=10.1074/jbc.m413200200; RA Jalota-Badhwar A., Singh K., Pavithra L., Kaul-Ghanekar R., Jameel S., RA Chattopadhyay S.; RT "Tumor suppressor SMAR1 activates and stabilizes p53 through its arginine- RT serine-rich motif."; RL J. Biol. Chem. 280:16019-16029(2005). RN [80] RP RETRACTION NOTICE OF PUBMED:15701641. RX PubMed=32144153; DOI=10.1074/jbc.w120.012894; RA Jalota A., Singh K., Pavithra L., Kaul-Ghanekar R., Jameel S., RA Chattopadhyay S.; RL J. Biol. Chem. 295:3390-3390(2020). RN [81] RP INTERACTION WITH PTK2/FAK1. RX PubMed=15855171; DOI=10.1074/jbc.m414172200; RA Golubovskaya V.M., Finch R., Cance W.G.; RT "Direct interaction of the N-terminal domain of focal adhesion kinase with RT the N-terminal transactivation domain of p53."; RL J. Biol. Chem. 280:25008-25021(2005). RN [82] RP INTERACTION WITH WWOX, AND MUTAGENESIS OF SER-46. RX PubMed=16219768; DOI=10.1074/jbc.m505590200; RA Chang N.-S., Doherty J., Ensign A., Schultz L., Hsu L.-J., Hong Q.; RT "WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, RT and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds RT and stabilizes serine 46-phosphorylated p53."; RL J. Biol. Chem. 280:43100-43108(2005). RN [83] RP PHOSPHORYLATION AT SER-15. RX PubMed=15866171; DOI=10.1016/j.molcel.2005.03.027; RA Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J., RA Thompson C.B.; RT "AMP-activated protein kinase induces a p53-dependent metabolic RT checkpoint."; RL Mol. Cell 18:283-293(2005). RN [84] RP INTERACTION WITH STK11/LKB1, AND PHOSPHORYLATION AT SER-15 AND SER-392. RX PubMed=17108107; DOI=10.1158/0008-5472.can-06-0999; RA Zeng P.Y., Berger S.L.; RT "LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate RT transcriptional activation."; RL Cancer Res. 66:10701-10708(2006). RN [85] RP PHOSPHORYLATION AT THR-18. RX PubMed=16704422; DOI=10.1111/j.1742-4658.2006.05256.x; RA Blanco S., Klimcakova L., Vega F.M., Lazo P.A.; RT "The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms RT determines their different effect on p53 stability in tumour cell lines."; RL FEBS J. 273:2487-2504(2006). RN [86] RP INTERACTION WITH YWHAZ. RX PubMed=16376338; DOI=10.1016/j.febslet.2005.12.024; RA Gu Y.-M., Jin Y.-H., Choi J.-K., Baek K.-H., Yeo C.-Y., Lee K.-Y.; RT "Protein kinase A phosphorylates and regulates dimerization of 14-3-3 RT epsilon."; RL FEBS Lett. 580:305-310(2006). RN [87] RP PHOSPHORYLATION AT SER-46, AND INTERACTION WITH PRKCG. RX PubMed=16377624; DOI=10.1074/jbc.m512074200; RA Yoshida K., Liu H., Miki Y.; RT "Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor RT suppressor in the apoptotic response to DNA damage."; RL J. Biol. Chem. 281:5734-5740(2006). RN [88] RP FUNCTION, ACETYLATION AT LYS-120, VARIANTS ARG-120; GLU-120 AND MET-120, RP AND CHARACTERIZATION OF VARIANTS ARG-120; GLU-120 AND MET-120. RX PubMed=17189187; DOI=10.1016/j.molcel.2006.11.026; RA Sykes S.M., Mellert H.S., Holbert M.A., Li K., Marmorstein R., Lane W.S., RA McMahon S.B.; RT "Acetylation of the p53 DNA-binding domain regulates apoptosis induction."; RL Mol. Cell 24:841-851(2006). RN [89] RP METHYLATION AT LYS-370, AND MUTAGENESIS OF LYS-370. RX PubMed=17108971; DOI=10.1038/nature05287; RA Huang J., Perez-Burgos L., Placek B.J., Sengupta R., Richter M., RA Dorsey J.A., Kubicek S., Opravil S., Jenuwein T., Berger S.L.; RT "Repression of p53 activity by Smyd2-mediated methylation."; RL Nature 444:629-632(2006). RN [90] RP INTERACTION WITH DAXX. RX PubMed=16845383; DOI=10.1038/ncb1442; RA Tang J., Qu L.K., Zhang J., Wang W., Michaelson J.S., Degenhardt Y.Y., RA El-Deiry W.S., Yang X.; RT "Critical role for Daxx in regulating Mdm2."; RL Nat. Cell Biol. 8:855-862(2006). RN [91] RP MOTIF, AND METHYLATION AT LYS-372. RX PubMed=16415881; DOI=10.1038/nsmb1045; RA Couture J.-F., Collazo E., Hauk G., Trievel R.C.; RT "Structural basis for the methylation site specificity of SET7/9."; RL Nat. Struct. Mol. Biol. 13:140-146(2006). RN [92] RP INTERACTION WITH POU4F2. RX PubMed=17145718; DOI=10.1093/nar/gkl878; RA Budhram-Mahadeo V.S., Bowen S., Lee S., Perez-Sanchez C., Ensor E., RA Morris P.J., Latchman D.S.; RT "Brn-3b enhances the pro-apoptotic effects of p53 but not its induction of RT cell cycle arrest by cooperating in trans-activation of bax expression."; RL Nucleic Acids Res. 34:6640-6652(2006). RN [93] RP PHOSPHORYLATION AT SER-37, AND MUTAGENESIS OF SER-37. RX PubMed=17254968; DOI=10.1016/j.cell.2006.11.050; RA Sun P., Yoshizuka N., New L., Moser B.A., Li Y., Liao R., Xie C., Chen J., RA Deng Q., Yamout M., Dong M.Q., Frangou C.G., Yates J.R. III, Wright P.E., RA Han J.; RT "PRAK is essential for ras-induced senescence and tumor suppression."; RL Cell 128:295-308(2007). RN [94] RP INTERACTION WITH ZNF385A, AND CHARACTERIZATION OF VARIANTS ALA-143; HIS-175 RP AND PRO-175. RX PubMed=17719541; DOI=10.1016/j.cell.2007.06.013; RA Das S., Raj L., Zhao B., Kimura Y., Bernstein A., Aaronson S.A., Lee S.W.; RT "Hzf Determines cell survival upon genotoxic stress by modulating p53 RT transactivation."; RL Cell 130:624-637(2007). RN [95] RP UBIQUITINATION, INTERACTION WITH SYVN1, AND SUBCELLULAR LOCATION. RX PubMed=17170702; DOI=10.1038/sj.emboj.7601490; RA Yamasaki S., Yagishita N., Sasaki T., Nakazawa M., Kato Y., Yamadera T., RA Bae E., Toriyama S., Ikeda R., Zhang L., Fujitani K., Yoo E., RA Tsuchimochi K., Ohta T., Araya N., Fujita H., Aratani S., Eguchi K., RA Komiya S., Maruyama I., Higashi N., Sato M., Senoo H., Ochi T., RA Yokoyama S., Amano T., Kim J., Gay S., Fukamizu A., Nishioka K., Tanaka K., RA Nakajima T.; RT "Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident RT ubiquitin ligase 'Synoviolin'."; RL EMBO J. 26:113-122(2007). RN [96] RP INTERACTION WITH PPP2CA; PPP2R1A; PPP2R2A AND PPP2R5C. RX PubMed=17245430; DOI=10.1038/sj.emboj.7601519; RA Li H.H., Cai X., Shouse G.P., Piluso L.G., Liu X.; RT "A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced RT dephosphorylation of p53 at Thr55."; RL EMBO J. 26:402-411(2007). RN [97] RP INTERACTION WITH ARMC10. RX PubMed=17904127; DOI=10.1016/j.febslet.2007.09.025; RA Zhou X., Yang G., Huang R., Chen X., Hu G.; RT "SVH-B interacts directly with p53 and suppresses the transcriptional RT activity of p53."; RL FEBS Lett. 581:4943-4948(2007). RN [98] RP PHOSPHORYLATION AT SER-9. RX PubMed=18022393; DOI=10.1016/j.febslet.2007.11.022; RA Arai S., Matsushita A., Du K., Yagi K., Okazaki Y., Kurokawa R.; RT "Novel homeodomain-interacting protein kinase family member, HIPK4, RT phosphorylates human p53 at serine 9."; RL FEBS Lett. 581:5649-5657(2007). RN [99] RP DOMAIN. RX PubMed=17467953; DOI=10.1016/j.ygeno.2007.02.003; RA Piskacek S., Gregor M., Nemethova M., Grabner M., Kovarik P., Piskacek M.; RT "Nine-amino-acid transactivation domain: establishment and prediction RT utilities."; RL Genomics 89:756-768(2007). RN [100] RP INTERACTION WITH RFFL AND RNF34. RX PubMed=17121812; DOI=10.1074/jbc.m610793200; RA Yang W., Rozan L.M., McDonald E.R. III, Navaraj A., Liu J.J., Matthew E.M., RA Wang W., Dicker D.T., El-Deiry W.S.; RT "CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho- RT p53ser20 degradation."; RL J. Biol. Chem. 282:3273-3281(2007). RN [101] RP FUNCTION, AND INTERACTION WITH MAML1. RX PubMed=17317671; DOI=10.1074/jbc.m608974200; RA Zhao Y., Katzman R.B., Delmolino L.M., Bhat I., Zhang Y., Gurumurthy C.B., RA Germaniuk-Kurowska A., Reddi H.V., Solomon A., Zeng M.S., Kung A., Ma H., RA Gao Q., Dimri G., Stanculescu A., Miele L., Wu L., Griffin J.D., RA Wazer D.E., Band H., Band V.; RT "The notch regulator MAML1 interacts with p53 and functions as a RT coactivator."; RL J. Biol. Chem. 282:11969-11981(2007). RN [102] RP PHOSPHORYLATION AT SER-15; SER-33 AND SER-46, INTERACTION WITH CDK5, AND RP SUBCELLULAR LOCATION. RX PubMed=17591690; DOI=10.1242/jcs.03468; RA Lee J.-H., Kim H.-S., Lee S.-J., Kim K.-T.; RT "Stabilization and activation of p53 induced by Cdk5 contributes to RT neuronal cell death."; RL J. Cell Sci. 120:2259-2271(2007). RN [103] RP INTERACTION WITH MORC3. RX PubMed=17332504; DOI=10.1091/mbc.e06-08-0747; RA Takahashi K., Yoshida N., Murakami N., Kawata K., Ishizaki H., RA Tanaka-Okamoto M., Miyoshi J., Zinn A.R., Shime H., Inoue N.; RT "Dynamic regulation of p53 subnuclear localization and senescence by RT MORC3."; RL Mol. Biol. Cell 18:1701-1709(2007). RN [104] RP FUNCTION, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF SER-46. RX PubMed=17349958; DOI=10.1016/j.molcel.2007.02.007; RA Taira N., Nihira K., Yamaguchi T., Miki Y., Yoshida K.; RT "DYRK2 is targeted to the nucleus and controls p53 via Ser46 RT phosphorylation in the apoptotic response to DNA damage."; RL Mol. Cell 25:725-738(2007). RN [105] RP DEMETHYLATION BY KDM1A. RX PubMed=17805299; DOI=10.1038/nature06092; RA Huang J., Sengupta R., Espejo A.B., Lee M.G., Dorsey J.A., Richter M., RA Opravil S., Shiekhattar R., Bedford M.T., Jenuwein T., Berger S.L.; RT "p53 is regulated by the lysine demethylase LSD1."; RL Nature 449:105-108(2007). RN [106] RP METHYLATION AT LYS-382, AND MUTAGENESIS OF LYS-382. RX PubMed=17707234; DOI=10.1016/j.molcel.2007.07.012; RA Shi X., Kachirskaia I., Yamaguchi H., West L.E., Wen H., Wang E.W., RA Dutta S., Appella E., Gozani O.; RT "Modulation of p53 function by SET8-mediated methylation at lysine 382."; RL Mol. Cell 27:636-646(2007). RN [107] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [108] RP ACETYLATION, AND DEACETYLATION BY SIRT2. RX PubMed=18249187; DOI=10.1016/j.bbrc.2008.01.114; RA Jin Y.H., Kim Y.J., Kim D.W., Baek K.H., Kang B.Y., Yeo C.Y., Lee K.Y.; RT "Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of RT p53."; RL Biochem. Biophys. Res. Commun. 368:690-695(2008). RN [109] RP INTERACTION WITH SETD2. RX PubMed=18585004; DOI=10.1016/j.cellsig.2008.05.012; RA Xie P., Tian C., An L., Nie J., Lu K., Xing G., Zhang L., He F.; RT "Histone methyltransferase protein SETD2 interacts with p53 and selectively RT regulates its downstream genes."; RL Cell. Signal. 20:1671-1678(2008). RN [110] RP INTERACTION WITH NUPR1. RX PubMed=18690848; DOI=10.2174/156800908785133196; RA Clark D.W., Mitra A., Fillmore R.A., Jiang W.G., Samant R.S., Fodstad O., RA Shevde L.A.; RT "NUPR1 interacts with p53, transcriptionally regulates p21 and rescues RT breast epithelial cells from doxorubicin-induced genotoxic stress."; RL Curr. Cancer Drug Targets 8:421-430(2008). RN [111] RP UBIQUITINATION, AND SUBCELLULAR LOCATION. RX PubMed=18206965; DOI=10.1016/j.molcel.2007.11.031; RA Lim S.T., Chen X.L., Lim Y., Hanson D.A., Vo T.T., Howerton K., RA Larocque N., Fisher S.J., Schlaepfer D.D., Ilic D.; RT "Nuclear FAK promotes cell proliferation and survival through FERM-enhanced RT p53 degradation."; RL Mol. Cell 29:9-22(2008). RN [112] RP INTERACTION WITH KAT7. RX PubMed=17954561; DOI=10.1128/mcb.00662-07; RA Iizuka M., Sarmento O.F., Sekiya T., Scrable H., Allis C.D., Smith M.M.; RT "Hbo1 Links p53-dependent stress signaling to DNA replication licensing."; RL Mol. Cell. Biol. 28:140-153(2008). RN [113] RP INTERACTION WITH PPP2CA; PPP2R1A AND PPP2R5C, PHOSPHORYLATION AT SER-15 BY RP ATM, AND MUTAGENESIS OF SER-15. RX PubMed=17967874; DOI=10.1128/mcb.00983-07; RA Shouse G.P., Cai X., Liu X.; RT "Serine 15 phosphorylation of p53 directs its interaction with B56gamma and RT the tumor suppressor activity of B56gamma-specific protein phosphatase RT 2A."; RL Mol. Cell. Biol. 28:448-456(2008). RN [114] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [115] RP INTERACTION WITH MKRN1, MUTAGENESIS OF 291-LYS-LYS-292, AND UBIQUITINATION RP AT LYS-291 AND LYS-292 BY MKRN1. RX PubMed=19536131; DOI=10.1038/emboj.2009.164; RA Lee E.-W., Lee M.-S., Camus S., Ghim J., Yang M.-R., Oh W., Ha N.-C., RA Lane D.P., Song J.; RT "Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell RT cycle arrest and apoptosis."; RL EMBO J. 28:2100-2113(2009). RN [116] RP UBIQUITINATION BY TOPORS. RX PubMed=19473992; DOI=10.1074/jbc.c109.001560; RA Yang X., Li H., Zhou Z., Wang W.H., Deng A., Andrisani O., Liu X.; RT "Plk1-mediated phosphorylation of Topors regulates p53 stability."; RL J. Biol. Chem. 284:18588-18592(2009). RN [117] RP UBIQUITINATION AT LYS-351 AND LYS-357, AND SUBCELLULAR LOCATION. RX PubMed=19033443; DOI=10.1074/jbc.m805658200; RA Kruse J.P., Gu W.; RT "MSL2 promotes Mdm2-independent cytoplasmic localization of p53."; RL J. Biol. Chem. 284:3250-3263(2009). RN [118] RP INTERACTION WITH MTA1 AND COP1, AND UBIQUITINATION. RX PubMed=19837670; DOI=10.1074/jbc.m109.056499; RA Li D.Q., Divijendra Natha Reddy S., Pakala S.B., Wu X., Zhang Y., RA Rayala S.K., Kumar R.; RT "MTA1 coregulator regulates p53 stability and function."; RL J. Biol. Chem. 284:34545-34552(2009). RN [119] RP INTERACTION WITH HHV-5 PROTEIN UL123 (MICROBIAL INFECTION). RX PubMed=19776115; DOI=10.1128/jvi.00304-09; RA Hwang E.S., Zhang Z., Cai H., Huang D.Y., Huong S.M., Cha C.Y., Huang E.S.; RT "Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53- RT dependent transactivation by a mechanism different from that of IE2-86 RT protein."; RL J. Virol. 83:12388-12398(2009). RN [120] RP ACETYLATION AT LYS-120. RX PubMed=19854137; DOI=10.1016/j.molcel.2009.07.031; RA Li X., Wu L., Corsa C.A., Kunkel S., Dou Y.; RT "Two mammalian MOF complexes regulate transcription activation by distinct RT mechanisms."; RL Mol. Cell 36:290-301(2009). RN [121] RP INTERACTION WITH FBXO42. RX PubMed=19509332; DOI=10.1073/pnas.0901864106; RA Sun L., Shi L., Li W., Yu W., Liang J., Zhang H., Yang X., Wang Y., Li R., RA Yao X., Yi X., Shang Y.; RT "JFK, a Kelch domain-containing F-box protein, links the SCF complex to p53 RT regulation."; RL Proc. Natl. Acad. Sci. U.S.A. 106:10195-10200(2009). RN [122] RP FUNCTION, UBIQUITINATION, AND INTERACTION WITH TRIM24. RX PubMed=19556538; DOI=10.1073/pnas.0813177106; RA Allton K., Jain A.K., Herz H.M., Tsai W.W., Jung S.Y., Qin J., Bergmann A., RA Johnson R.L., Barton M.C.; RT "Trim24 targets endogenous p53 for degradation."; RL Proc. Natl. Acad. Sci. U.S.A. 106:11612-11616(2009). RN [123] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-381 AND LYS-382, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [124] RP INTERACTION WITH TAF6 ISOFORMS 1 AND 4. RX PubMed=20096117; DOI=10.1186/1471-2199-11-10; RA Wilhelm E., Kornete M., Targat B., Vigneault-Edwards J., Frontini M., RA Tora L., Benecke A., Bell B.; RT "TAF6delta orchestrates an apoptotic transcriptome profile and interacts RT functionally with p53."; RL BMC Mol. Biol. 11:10-10(2010). RN [125] RP UBIQUITINATION, AND DEUBIQUITINATION BY USP10. RX PubMed=20096447; DOI=10.1016/j.cell.2009.12.032; RA Yuan J., Luo K., Zhang L., Cheville J.C., Lou Z.; RT "USP10 regulates p53 localization and stability by deubiquitinating p53."; RL Cell 140:384-396(2010). RN [126] RP FUNCTION. RX PubMed=20673990; DOI=10.1016/j.cell.2010.06.040; RA Huarte M., Guttman M., Feldser D., Garber M., Koziol M.J., RA Kenzelmann-Broz D., Khalil A.M., Zuk O., Amit I., Rabani M., Attardi L.D., RA Regev A., Lander E.S., Jacks T., Rinn J.L.; RT "A large intergenic noncoding RNA induced by p53 mediates global gene RT repression in the p53 response."; RL Cell 142:409-419(2010). RN [127] RP PHOSPHORYLATION AT SER-20 BY CSNK1D/CK1. RX PubMed=20041275; DOI=10.1007/s00018-009-0236-7; RA Venerando A., Marin O., Cozza G., Bustos V.H., Sarno S., Pinna L.A.; RT "Isoform specific phosphorylation of p53 by protein kinase CK1."; RL Cell. Mol. Life Sci. 67:1105-1118(2010). RN [128] RP INTERACTION WITH SNAI1, CHARACTERIZATION OF VARIANTS LEU-110; PRO-155; RP HIS-175; SER-232; SER-249; HIS-273 AND TRP-282, AND MUTAGENESIS OF ARG-248. RX PubMed=20385133; DOI=10.1016/j.febslet.2010.04.006; RA Lim S.O., Kim H., Jung G.; RT "p53 inhibits tumor cell invasion via the degradation of snail protein in RT hepatocellular carcinoma."; RL FEBS Lett. 584:2231-2236(2010). RN [129] RP INTERACTION WITH PTK2B/PYK2 AND MDM2, UBIQUITINATION, AND SUBCELLULAR RP LOCATION. RX PubMed=19880522; DOI=10.1074/jbc.m109.064212; RA Lim S.T., Miller N.L., Nam J.O., Chen X.L., Lim Y., Schlaepfer D.D.; RT "Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating RT cell proliferation and survival."; RL J. Biol. Chem. 285:1743-1753(2010). RN [130] RP METHYLATION AT LYS-373, AND MUTAGENESIS OF LYS-373. RX PubMed=20118233; DOI=10.1074/jbc.m109.062588; RA Huang J., Dorsey J., Chuikov S., Perez-Burgos L., Zhang X., Jenuwein T., RA Reinberg D., Berger S.L.; RT "G9a and Glp methylate lysine 373 in the tumor suppressor p53."; RL J. Biol. Chem. 285:9636-9641(2010). RN [131] RP ERRATUM OF PUBMED:20118233. RA Huang J., Dorsey J., Chuikov S., Perez-Burgos L., Zhang X., Jenuwein T., RA Reinberg D., Berger S.L.; RL J. Biol. Chem. 285:18122-18122(2010). RN [132] RP PHOSPHORYLATION AT THR-55, AND INTERACTION WITH GRK5. RX PubMed=20124405; DOI=10.1074/jbc.m109.094243; RA Chen X., Zhu H., Yuan M., Fu J., Zhou Y., Ma L.; RT "G-protein-coupled receptor kinase 5 phosphorylates p53 and inhibits DNA RT damage-induced apoptosis."; RL J. Biol. Chem. 285:12823-12830(2010). RN [133] RP INTERACTION WITH BRD7, AND ACETYLATION AT LYS-382. RX PubMed=20228809; DOI=10.1038/ncb2038; RA Drost J., Mantovani F., Tocco F., Elkon R., Comel A., Holstege H., RA Kerkhoven R., Jonkers J., Voorhoeve P.M., Agami R., Del Sal G.; RT "BRD7 is a candidate tumour suppressor gene required for p53 function."; RL Nat. Cell Biol. 12:380-389(2010). RN [134] RP UBIQUITINATION BY RFWD3. RX PubMed=20173098; DOI=10.1073/pnas.0912094107; RA Fu X., Yucer N., Liu S., Li M., Yi P., Mu J.J., Yang T., Chu J., Jung S.Y., RA O'Malley B.W., Gu W., Qin J., Wang Y.; RT "RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53 stability in RT response to DNA damage."; RL Proc. Natl. Acad. Sci. U.S.A. 107:4579-4584(2010). RN [135] RP INTERACTION WITH BRD7. RX PubMed=20660729; DOI=10.1073/pnas.1009559107; RA Burrows A.E., Smogorzewska A., Elledge S.J.; RT "Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are RT critical regulators of p53 required for induction of replicative RT senescence."; RL Proc. Natl. Acad. Sci. U.S.A. 107:14280-14285(2010). RN [136] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [137] RP INTERACTION WITH UHRF2. RX PubMed=21952639; DOI=10.4161/cc.10.19.17176; RA Mori T., Ikeda D.D., Fukushima T., Takenoshita S., Kochi H.; RT "NIRF constitutes a nodal point in the cell cycle network and is a RT candidate tumor suppressor."; RL Cell Cycle 10:3284-3299(2011). RN [138] RP INTERACTION WITH MUL1, SUBCELLULAR LOCATION, UBIQUITINATION AT LYS-24 BY RP MUL1, AND MUTAGENESIS OF LYS-24. RX PubMed=21597459; DOI=10.1038/cdd.2011.57; RA Jung J.H., Bae S., Lee J.Y., Woo S.R., Cha H.J., Yoon Y., Suh K.S., RA Lee S.J., Park I.C., Jin Y.W., Lee K.H., An S., Lee J.H.; RT "E3 ubiquitin ligase Hades negatively regulates the exonuclear function of RT p53."; RL Cell Death Differ. 18:1865-1875(2011). RN [139] RP FUNCTION, INTERACTION WITH AURKB AND NOC2L, PHOSPHORYLATION AT SER-183; RP SER-269 AND THR-284, CHARACTERIZATION OF VARIANT ALA-284, MUTAGENESIS OF RP SER-183; SER-269 AND THR-284, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=20959462; DOI=10.1074/jbc.m110.174755; RA Wu L., Ma C.A., Zhao Y., Jain A.; RT "Aurora B interacts with NIR-p53, leading to p53 phosphorylation in its RT DNA-binding domain and subsequent functional suppression."; RL J. Biol. Chem. 286:2236-2244(2011). RN [140] RP INTERACTION WITH ALDOB AND G6PD. RX PubMed=35122041; DOI=10.1038/s43018-020-0086-7; RA Li M., He X., Guo W., Yu H., Zhang S., Wang N., Liu G., Sa R., Shen X., RA Jiang Y., Tang Y., Zhuo Y., Yin C., Tu Q., Li N., Nie X., Li Y., Hu Z., RA Zhu H., Ding J., Li Z., Liu T., Zhang F., Zhou H., Li S., Yue J., Yan Z., RA Cheng S., Tao Y., Yin H.; RT "Aldolase B suppresses hepatocellular carcinogenesis by inhibiting G6PD and RT pentose phosphate pathways."; RL Nat. Cancer 1:735-747(2020). RN [141] RP INVOLVEMENT IN BCC7. RX PubMed=21946351; DOI=10.1038/ng.926; RA Stacey S.N., Sulem P., Jonasdottir A., Masson G., Gudmundsson J., RA Gudbjartsson D.F., Magnusson O.T., Gudjonsson S.A., Sigurgeirsson B., RA Thorisdottir K., Ragnarsson R., Benediktsdottir K.R., Nexo B.A., RA Tjonneland A., Overvad K., Rudnai P., Gurzau E., Koppova K., Hemminki K., RA Corredera C., Fuentelsaz V., Grasa P., Navarrete S., Fuertes F., RA Garcia-Prats M.D., Sanambrosio E., Panadero A., De Juan A., Garcia A., RA Rivera F., Planelles D., Soriano V., Requena C., Aben K.K., RA van Rossum M.M., Cremers R.G., van Oort I.M., van Spronsen D.J., RA Schalken J.A., Peters W.H., Helfand B.T., Donovan J.L., Hamdy F.C., RA Badescu D., Codreanu O., Jinga M., Csiki I.E., Constantinescu V., Badea P., RA Mates I.N., Dinu D.E., Constantin A., Mates D., Kristjansdottir S., RA Agnarsson B.A., Jonsson E., Barkardottir R.B., Einarsson G.V., RA Sigurdsson F., Moller P.H., Stefansson T., Valdimarsson T., RA Johannsson O.T., Sigurdsson H., Jonsson T., Jonasson J.G., RA Tryggvadottir L., Rice T., Hansen H.M., Xiao Y., Lachance D.H., RA O'Neill B.P., Kosel M.L., Decker P.A., Thorleifsson G., Johannsdottir H., RA Helgadottir H.T., Sigurdsson A., Steinthorsdottir V., Lindblom A., RA Sandler R.S., Keku T.O., Banasik K., Jorgensen T., Witte D.R., Hansen T., RA Pedersen O., Jinga V., Neal D.E., Catalona W.J., Wrensch M., Wiencke J., RA Jenkins R.B., Nagore E., Vogel U., Kiemeney L.A., Kumar R., Mayordomo J.I., RA Olafsson J.H., Kong A., Thorsteinsdottir U., Rafnar T., Stefansson K.; RT "A germline variant in the TP53 polyadenylation signal confers cancer RT susceptibility."; RL Nat. Genet. 43:1098-1103(2011). RN [142] RP INTERACTION WITH NUAK1, AND PHOSPHORYLATION AT SER-15 AND SER-392. RX PubMed=21317932; DOI=10.1038/onc.2011.19; RA Hou X., Liu J.E., Liu W., Liu C.Y., Liu Z.Y., Sun Z.Y.; RT "A new role of NUAK1: directly phosphorylating p53 and regulating cell RT proliferation."; RL Oncogene 30:2933-2942(2011). RN [143] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PPIF. RX PubMed=22726440; DOI=10.1016/j.cell.2012.05.014; RA Vaseva A.V., Marchenko N.D., Ji K., Tsirka S.E., Holzmann S., Moll U.M.; RT "p53 opens the mitochondrial permeability transition pore to trigger RT necrosis."; RL Cell 149:1536-1548(2012). RN [144] RP INTERACTION WITH UBC9, PHOSPHORYLATION AT SER-392, AND SUMOYLATION AT RP LYS-386. RX PubMed=22214662; DOI=10.4161/cc.11.2.18999; RA Bennett R.L., Pan Y., Christian J., Hui T., May W.S. Jr.; RT "The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and RT activation, leading to G(1) arrest."; RL Cell Cycle 11:407-417(2012). RN [145] RP INTERACTION WITH NOP53. RX PubMed=22522597; DOI=10.1038/cdd.2012.40; RA Lee S., Kim J.Y., Kim Y.J., Seok K.O., Kim J.H., Chang Y.J., Kang H.Y., RA Park J.H.; RT "Nucleolar protein GLTSCR2 stabilizes p53 in response to ribosomal RT stresses."; RL Cell Death Differ. 19:1613-1622(2012). RN [146] RP INTERACTION WITH ZNF385B. RX PubMed=22945289; DOI=10.1002/eji.201242530; RA Iijima K., Yamada H., Miharu M., Imadome K., Miyagawa Y., Akimoto S., RA Kobayashi K., Okita H., Nakazawa A., Fujiwara S., Fujimoto J., Kiyokawa N.; RT "ZNF385B is characteristically expressed in germinal center B cells and RT involved in B-cell apoptosis."; RL Eur. J. Immunol. 42:3405-3415(2012). RN [147] RP METHYLATION AT LYS-370 AND LYS-382. RX PubMed=22864287; DOI=10.1038/nsmb.2353; RA Cui G., Park S., Badeaux A.I., Kim D., Lee J., Thompson J.R., Yan F., RA Kaneko S., Yuan Z., Botuyan M.V., Bedford M.T., Cheng J.Q., Mer G.; RT "PHF20 is an effector protein of p53 double lysine methylation that RT stabilizes and activates p53."; RL Nat. Struct. Mol. Biol. 19:916-924(2012). RN [148] RP FUNCTION. RX PubMed=24051492; DOI=10.1038/ncomms3444; RA Miki T., Matsumoto T., Zhao Z., Lee C.C.; RT "p53 regulates Period2 expression and the circadian clock."; RL Nat. Commun. 4:2444-2444(2013). RN [149] RP ACETYLATION AT LYS-120 AND LYS-382. RX PubMed=23431171; DOI=10.1073/pnas.1300490110; RA Rokudai S., Laptenko O., Arnal S.M., Taya Y., Kitabayashi I., Prives C.; RT "MOZ increases p53 acetylation and premature senescence through its complex RT formation with PML."; RL Proc. Natl. Acad. Sci. U.S.A. 110:3895-3900(2013). RN [150] RP INTERACTION WITH HSPA9, AND SUBCELLULAR LOCATION. RX PubMed=24625977; DOI=10.1038/cddis.2014.100; RA Sane S., Abdullah A., Boudreau D.A., Autenried R.K., Gupta B.K., Wang X., RA Wang H., Schlenker E.H., Zhang D., Telleria C., Huang L., Chauhan S.C., RA Rezvani K.; RT "Ubiquitin-like (UBX)-domain-containing protein, UBXN2A, promotes cell RT death by interfering with the p53-Mortalin interactions in colon cancer RT cells."; RL Cell Death Dis. 5:e1118-e1118(2014). RN [151] RP INTERACTION WITH S100A4, AND SUBCELLULAR LOCATION. RX PubMed=23752197; DOI=10.1038/onc.2013.213; RA Orre L.M., Panizza E., Kaminskyy V.O., Vernet E., Graeslund T., RA Zhivotovsky B., Lehtioe J.; RT "S100A4 interacts with p53 in the nucleus and promotes p53 degradation."; RL Oncogene 32:5531-5540(2013). RN [152] RP FUNCTION. RX PubMed=24652652; DOI=10.1093/jnci/dju053; RA Polato F., Rusconi P., Zangrossi S., Morelli F., Boeri M., Musi A., RA Marchini S., Castiglioni V., Scanziani E., Torri V., Broggini M.; RT "DRAGO (KIAA0247), a new DNA damage-responsive, p53-inducible gene that RT cooperates with p53 as oncosuppressor. [Corrected]."; RL J. Natl. Cancer Inst. 106:1-10(2014). RN [153] RP INTERACTION WITH UBD. RX PubMed=25422469; DOI=10.1073/pnas.1403383111; RA Theng S.S., Wang W., Mah W.C., Chan C., Zhuo J., Gao Y., Qin H., Lim L., RA Chong S.S., Song J., Lee C.G.; RT "Disruption of FAT10-MAD2 binding inhibits tumor progression."; RL Proc. Natl. Acad. Sci. U.S.A. 111:E5282-E5291(2014). RN [154] RP INTERACTION WITH TTC5, AND SUBCELLULAR LOCATION. RX PubMed=25168243; DOI=10.1038/cdd.2014.135; RA Maniam S., Coutts A.S., Stratford M.R., McGouran J., Kessler B., RA La Thangue N.B.; RT "Cofactor Strap regulates oxidative phosphorylation and mitochondrial p53 RT activity through ATP synthase."; RL Cell Death Differ. 22:156-163(2015). RN [155] RP SUBCELLULAR LOCATION. RX PubMed=26634371; DOI=10.1007/s12192-015-0661-5; RA Sane S., Abdullah A., Nelson M.E., Wang H., Chauhan S.C., Newton S.S., RA Rezvani K.; RT "Structural studies of UBXN2A and mortalin interaction and the putative RT role of silenced UBXN2A in preventing response to chemotherapy."; RL Cell Stress Chaperones 21:313-326(2016). RN [156] RP UBIQUITINATION. RX PubMed=25591766; DOI=10.1159/000369691; RA Yang L., Zhou B., Li X., Lu Z., Li W., Huo X., Miao Z.; RT "RNF125 is a ubiquitin-protein ligase that promotes p53 degradation."; RL Cell. Physiol. Biochem. 35:237-245(2015). RN [157] RP INTERACTION WITH HADV5 E1B-55K (MICROBIAL INFECTION). RX PubMed=25772236; DOI=10.1038/onc.2015.63; RA Wimmer P., Berscheminski J., Blanchette P., Groitl P., Branton P.E., RA Hay R.T., Dobner T., Schreiner S.; RT "PML isoforms IV and V contribute to adenovirus-mediated oncogenic RT transformation by functionally inhibiting the tumor-suppressor p53."; RL Oncogene 35:69-82(2016). RN [158] RP INTERACTION WITH FBXO22, AND UBIQUITINATION. RX PubMed=26868148; DOI=10.1038/ncomms10574; RA Johmura Y., Sun J., Kitagawa K., Nakanishi K., Kuno T., Naiki-Ito A., RA Sawada Y., Miyamoto T., Okabe A., Aburatani H., Li S., Miyoshi I., RA Takahashi S., Kitagawa M., Nakanishi M.; RT "SCF(Fbxo22)-KDM4A targets methylated p53 for degradation and regulates RT senescence."; RL Nat. Commun. 7:10574-10574(2016). RN [159] RP INTERACTION WITH AFG1L, AND SUBCELLULAR LOCATION. RX PubMed=27323408; DOI=10.18632/oncotarget.9959; RA Cesnekova J., Spacilova J., Hansikova H., Houstek J., Zeman J., RA Stiburek L.; RT "LACE1 interacts with p53 and mediates its mitochondrial translocation and RT apoptosis."; RL Oncotarget 7:47687-47698(2016). RN [160] RP INTERACTION WITH DDX3X AND GAMMA-TUBULIN, SUBCELLULAR LOCATION, AND RP PHOSPHORYLATION AT SER-15. RX PubMed=28842590; DOI=10.1038/s41598-017-09779-w; RA Chen W.J., Wang W.T., Tsai T.Y., Li H.K., Lee Y.W.; RT "DDX3 localizes to the centrosome and prevents multipolar mitosis by RT epigenetically and translationally modulating p53 expression."; RL Sci. Rep. 7:9411-9411(2017). RN [161] RP DEUBIQUITINATION BY USP3. RX PubMed=28807825; DOI=10.1016/j.bbrc.2017.08.036; RA Fu S., Shao S., Wang L., Liu H., Hou H., Wang Y., Wang H., Huang X., Lv R.; RT "USP3 stabilizes p53 protein through its deubiquitinase activity."; RL Biochem. Biophys. Res. Commun. 492:178-183(2017). RN [162] RP INTERACTION WITH DAZAP2. RX PubMed=33591310; DOI=10.1093/nar/gkab084; RA Liebl M.C., Moehlenbrink J., Becker H., Raddatz G., Abdeen S.K., RA Aqeilan R.I., Lyko F., Hofmann T.G.; RT "DAZAP2 acts as specifier of the p53 response to DNA damage."; RL Nucleic Acids Res. 49:2759-2776(2021). RN [163] RP INVOLVEMENT IN BMFS5. RX PubMed=30146126; DOI=10.1016/j.ajhg.2018.07.020; RA Toki T., Yoshida K., Wang R., Nakamura S., Maekawa T., Goi K., Katoh M.C., RA Mizuno S., Sugiyama F., Kanezaki R., Uechi T., Nakajima Y., Sato Y., RA Okuno Y., Sato-Otsubo A., Shiozawa Y., Kataoka K., Shiraishi Y., Sanada M., RA Chiba K., Tanaka H., Terui K., Sato T., Kamio T., Sakaguchi H., Ohga S., RA Kuramitsu M., Hamaguchi I., Ohara A., Kanno H., Miyano S., Kojima S., RA Ishiguro A., Sugita K., Kenmochi N., Takahashi S., Eto K., Ogawa S., RA Ito E.; RT "De novo mutations activating germline TP53 in an inherited bone-marrow- RT failure syndrome."; RL Am. J. Hum. Genet. 103:440-447(2018). RN [164] RP INTERACTION WITH MORN3, DEACETYLATION AT LYS-382, AND UBQIQUITINATION. RX PubMed=29681526; DOI=10.1016/j.chembiol.2018.03.010; RA Liang L., Wang H., Shi H., Li Z., Yao H., Bu Z., Song N., Li C., Xiang D., RA Zhang Y., Wang J., Hu Y., Xu Q., Ma Y., Cheng Z., Wang Y., Zhao S., RA Qian J., Chen Y., Fang J.Y., Xu J.; RT "A Designed Peptide Targets Two Types of Modifications of p53 with Anti- RT cancer Activity."; RL Cell Chem. Biol. 25:761-774.e5(2018). RN [165] RP ACETYLATION AT LYS-381, DEACETYLATION BY SIRT6, AND MUTAGENESIS OF LYS-381. RX PubMed=29474172; DOI=10.7554/elife.32127; RA Ghosh S., Wong S.K., Jiang Z., Liu B., Wang Y., Hao Q., Gorbunova V., RA Liu X., Zhou Z.; RT "Haploinsufficiency of Trp53 dramatically extends the lifespan of Sirt6- RT deficient mice."; RL Elife 7:0-0(2018). RN [166] RP PHOSPHORYLATION AT THR-18 BY VRK1. RX PubMed=31527692; DOI=10.1038/s41598-019-49821-7; RA Martin-Doncel E., Rojas A.M., Cantarero L., Lazo P.A.; RT "VRK1 functional insufficiency due to alterations in protein stability or RT kinase activity of human VRK1 pathogenic variants implicated in neuromotor RT syndromes."; RL Sci. Rep. 9:13381-13381(2019). RN [167] RP DOMAIN, AND MUTAGENESIS OF SER-392. RX PubMed=31953488; DOI=10.1038/s41598-020-57521-w; RA Kamagata K., Kanbayashi S., Honda M., Itoh Y., Takahashi H., Kameda T., RA Nagatsugi F., Takahashi S.; RT "Liquid-like droplet formation by tumor suppressor p53 induced by RT multivalent electrostatic interactions between two disordered domains."; RL Sci. Rep. 10:580-580(2020). RN [168] RP INTERACTION WITH KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS/HHV-8 PROTEIN RP ORF45 (MICROBIAL INFECTION). RX PubMed=34523970; DOI=10.1128/jvi.01459-21; RA Alzhanova D., Meyo J.O., Juarez A., Dittmer D.P.; RT "The ORF45 protein of Kaposi Sarcoma-associated Herpesvirus (KSHV) is an RT inhibitor of p53 signaling during viral reactivation."; RL J. Virol. 0:0-0(2021). RN [169] RP INTERACTION WITH ZNF768. RX PubMed=34404770; DOI=10.1038/s41467-021-24932-w; RA Villot R., Poirier A., Bakan I., Boulay K., Fernandez E., Devillers R., RA Gama-Braga L., Tribouillard L., Gagne A., Duchesne E., Caron D., RA Berube J.S., Berube J.C., Coulombe Y., Orain M., Gelinas Y., Gobeil S., RA Bosse Y., Masson J.Y., Elowe S., Bilodeau S., Manem V., Joubert P., RA Mallette F.A., Laplante M.; RT "ZNF768 links oncogenic RAS to cellular senescence."; RL Nat. Commun. 12:4841-4841(2021). RN [170] RP FUNCTION, DOMAIN, PHOSPHORYLATION AT SER-392, AND MUTAGENESIS OF SER-392. RX PubMed=35618207; DOI=10.1016/j.bbagrm.2022.194827; RA Dai Z., Li G., Chen Q., Yang X.; RT "Ser392 phosphorylation modulated a switch between p53 and transcriptional RT condensates."; RL Biochim. Biophys. Acta 1865:194827-194827(2022). RN [171] RP DOMAIN, SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANTS LFS CYS-337; RP HIS-337 AND PRO-344, AND CHARACTERIZATION OF VARIANT PRO-337. RX PubMed=36108750; DOI=10.1016/j.ijbiomac.2022.09.087; RA Chen C., Fu G., Guo Q., Xue S., Luo S.Z.; RT "Phase separation of p53 induced by its unstructured basic region and RT prevented by oncogenic mutations in tetramerization domain."; RL Int. J. Biol. Macromol. 222:207-216(2022). RN [172] RP FUNCTION, AND DOMAIN. RX PubMed=36634798; DOI=10.1016/j.ijbiomac.2023.123221; RA Chen Q., Wu Y., Dai Z., Zhang Z., Yang X.; RT "Phosphorylation and specific DNA improved the incorporation ability of p53 RT into functional condensates."; RL Int. J. Biol. Macromol. 230:123221-123221(2023). RN [173] RP FUNCTION, DOMAIN, LACTYLATION AT LYS-120 AND LYS-139, AND CHARACTERIZATION RP OF VARIANTS GLU-120; GLN-120; ASN-139; THR-139; GLN-139 AND GLU-139. RX PubMed=38653238; DOI=10.1016/j.cell.2024.04.002; RA Zong Z., Xie F., Wang S., Wu X., Zhang Z., Yang B., Zhou F.; RT "Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase RT that lactylates p53 and contributes to tumorigenesis."; RL Cell 187:2375-2392(2024). RN [174] RP STRUCTURE BY NMR OF 319-360. RX PubMed=8023159; DOI=10.1126/science.8023159; RA Clore G.M., Omichinski J.G., Sakaguchi K., Zambrano N., Sakamoto H., RA Appella E., Gronenborn A.M.; RT "High-resolution structure of the oligomerization domain of p53 by RT multidimensional NMR."; RL Science 265:386-391(1994). RN [175] RP STRUCTURE BY NMR OF 325-355. RX PubMed=7773777; DOI=10.1038/nsb1294-877; RA Lee W., Harvey T.S., Yin Y., Yau P., Litchfield D., Arrowsmith C.H.; RT "Solution structure of the tetrameric minimum transforming domain of p53."; RL Nat. Struct. Biol. 1:877-890(1994). RN [176] RP STRUCTURE BY NMR OF 326-354. RX PubMed=9321402; DOI=10.1093/emboj/16.20.6230; RA McCoy M., Stavridi E.S., Waterman J.L., Wieczorek A.M., Opella S.J., RA Halazonetis T.D.; RT "Hydrophobic side-chain size is a determinant of the three-dimensional RT structure of the p53 oligomerization domain."; RL EMBO J. 16:6230-6236(1997). RN [177] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 94-289. RX PubMed=8023157; DOI=10.1126/science.8023157; RA Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P.; RT "Crystal structure of a p53 tumor suppressor-DNA complex: understanding RT tumorigenic mutations."; RL Science 265:346-355(1994). RN [178] RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 325-356. RX PubMed=7878469; DOI=10.1126/science.7878469; RA Jeffrey P.D., Gorina S., Pavletich N.P.; RT "Crystal structure of the tetramerization domain of the p53 tumor RT suppressor at 1.7 angstroms."; RL Science 267:1498-1502(1995). RN [179] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 13-29 IN COMPLEX WITH MDM2. RX PubMed=8875929; DOI=10.1126/science.274.5289.948; RA Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J., RA Pavletich N.P.; RT "Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor RT transactivation domain."; RL Science 274:948-953(1996). RN [180] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 97-287 IN COMPLEX WITH 53BP2. RX PubMed=8875926; DOI=10.1126/science.274.5289.1001; RA Gorina S., Pavletich N.P.; RT "Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains RT of 53BP2."; RL Science 274:1001-1005(1996). RN [181] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 94-312 IN COMPLEX WITH ZINC IONS, RP AND SUBUNIT. RX PubMed=14534297; DOI=10.1074/jbc.m309732200; RA Joerger A.C., Allen M.D., Fersht A.R.; RT "Crystal structure of a superstable mutant of human p53 core domain. RT Insights into the mechanism of rescuing oncogenic mutations."; RL J. Biol. Chem. 279:1291-1296(2004). RN [182] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 94-293 IN COMPLEX WITH DNA AND RP ZINC IONS, AND SUBUNIT. RX PubMed=16793544; DOI=10.1016/j.molcel.2006.05.015; RA Kitayner M., Rozenberg H., Kessler N., Rabinovich D., Shaulov L., RA Haran T.E., Shakked Z.; RT "Structural basis of DNA recognition by p53 tetramers."; RL Mol. Cell 22:741-753(2006). RN [183] RP X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 358-367 IN COMPLEX WITH USP7, AND RP INTERACTION WITH USP7. RX PubMed=16474402; DOI=10.1038/nsmb1067; RA Sheng Y., Saridakis V., Sarkari F., Duan S., Wu T., Arrowsmith C.H., RA Frappier L.; RT "Molecular recognition of p53 and MDM2 by USP7/HAUSP."; RL Nat. Struct. Mol. Biol. 13:285-291(2006). RN [184] RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 360-368 IN COMPLEX WITH USP7, RP MUTAGENESIS OF PRO-359; GLY-361 AND SER-362, AND INTERACTION WITH USP7. RX PubMed=16402859; DOI=10.1371/journal.pbio.0040027; RA Hu M., Gu L., Li M., Jeffrey P.D., Gu W., Shi Y.; RT "Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: RT implications for the regulation of the p53-MDM2 pathway."; RL PLoS Biol. 4:228-239(2006). RN [185] RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 377-386, METHYLATION AT LYS-382, RP MUTAGENESIS OF LYS-382, AND INTERACTION WITH L3MBTL1. RX PubMed=20870725; DOI=10.1074/jbc.m110.139527; RA West L.E., Roy S., Lachmi-Weiner K., Hayashi R., Shi X., Appella E., RA Kutateladze T.G., Gozani O.; RT "The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at lysine RT 382 to target gene repression."; RL J. Biol. Chem. 285:37725-37732(2010). RN [186] RP REVIEW. RX PubMed=8266092; DOI=10.1126/science.8266092; RA Harris C.C.; RT "p53: at the crossroads of molecular carcinogenesis and risk assessment."; RL Science 262:1980-1981(1993). RN [187] RP REVIEW ON VARIANTS. RX PubMed=1905840; DOI=10.1126/science.1905840; RA Hoolstein M., Sidransky D., Vogelstein B., Harris C.C.; RT "p53 mutations in human cancers."; RL Science 253:49-53(1991). RN [188] RP REVIEW ON VARIANTS. RX PubMed=8829653; RX DOI=10.1002/(sici)1098-1004(1996)7:3<202::aid-humu4>3.0.co;2-c; RA de Vries E.M.G., Ricke D.O., de Vries T.N., Hartmann A., Blaszyk H., RA Liao D., Soussi T., Kovach J.S., Sommer S.S.; RT "Database of mutations in the p53 and APC tumor suppressor genes designed RT to facilitate molecular epidemiological analyses."; RL Hum. Mutat. 7:202-213(1996). RN [189] RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 94-312 IN COMPLEX WITH ZINC IONS. RX PubMed=17015838; DOI=10.1073/pnas.0607286103; RA Joerger A.C., Ang H.C., Fersht A.R.; RT "Structural basis for understanding oncogenic p53 mutations and designing RT rescue drugs."; RL Proc. Natl. Acad. Sci. U.S.A. 103:15056-15061(2006). RN [190] RP X-RAY CRYSTALLOGRAPHY (1.54 ANGSTROMS) OF 94-292 OF VARIANT GLN-282. RX PubMed=18453682; DOI=10.1107/s0907444908003338; RA Tu C., Tan Y.H., Shaw G., Zhou Z., Bai Y., Luo R., Ji X.; RT "Impact of low-frequency hotspot mutation R282Q on the structure of p53 RT DNA-binding domain as revealed by crystallography at 1.54 angstroms RT resolution."; RL Acta Crystallogr. D 64:471-477(2008). RN [191] RP X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 94-312 OF VARIANT CYS-202 IN RP COMPLEX WITH ZINC IONS AND PHIKAN083. RX PubMed=18650397; DOI=10.1073/pnas.0805326105; RA Boeckler F.M., Joerger A.C., Jaggi G., Rutherford T.J., Veprintsev D.B., RA Fersht A.R.; RT "Targeted rescue of a destabilized mutant of p53 by an in silico screened RT drug."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10360-10365(2008). RN [192] RP X-RAY CRYSTALLOGRAPHY (1.2 ANGSTROMS) OF 94-293 OF VARIANT SER-249 IN RP COMPLEX WITH DNA. RX PubMed=18996393; DOI=10.1016/j.jmb.2008.10.063; RA Suad O., Rozenberg H., Brosh R., Diskin-Posner Y., Kessler N., Shimon L.J., RA Frolow F., Liran A., Rotter V., Shakked Z.; RT "Structural basis of restoring sequence-specific DNA binding and RT transactivation to mutant p53 by suppressor mutations."; RL J. Mol. Biol. 385:249-265(2009). RN [193] RP X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 94-310 IN COMPLEX WITH ZINC IONS. RX PubMed=19515728; DOI=10.1093/protein/gzp018; RA Khoo K.H., Joerger A.C., Freund S.M., Fersht A.R.; RT "Stabilising the DNA-binding domain of p53 by rational design of its RT hydrophobic core."; RL Protein Eng. Des. Sel. 22:421-430(2009). RN [194] RP X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 94-312 OF VARIANT CYS-220 IN RP COMPLEX WITH ZINC IONS. RX PubMed=20142040; DOI=10.1016/j.chembiol.2009.12.011; RA Basse N., Kaar J.L., Settanni G., Joerger A.C., Rutherford T.J., RA Fersht A.R.; RT "Toward the rational design of p53-stabilizing drugs: probing the surface RT of the oncogenic Y220C mutant."; RL Chem. Biol. 17:46-56(2010). RN [195] RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 94-293 IN COMPLEX WITH DNA AND RP ZINC IONS, AND SUBUNIT. RX PubMed=20364130; DOI=10.1038/nsmb.1800; RA Kitayner M., Rozenberg H., Rohs R., Suad O., Rabinovich D., Honig B., RA Shakked Z.; RT "Diversity in DNA recognition by p53 revealed by crystal structures with RT Hoogsteen base pairs."; RL Nat. Struct. Mol. Biol. 17:423-429(2010). RN [196] {ECO:0007744|PDB:6T58} RP X-RAY CRYSTALLOGRAPHY (3.10 ANGSTROMS) OF 17-56, AND INTERACTION WITH RP S100A4. RX PubMed=32442400; DOI=10.1016/j.str.2020.05.001; RA Ecsedi P., Gogl G., Hof H., Kiss B., Harmat V., Nyitray L.; RT "Structure Determination of the Transactivation Domain of p53 in Complex RT with S100A4Using Annexin A2 as a Crystallization Chaperone."; RL Structure 28:943-953.e4(2020). RN [197] RP VARIANT ARG-72. RX PubMed=1999338; DOI=10.1007/bf00201836; RA Olschwang S., Laurent-Puig P., Vassal A., Salmon R.-J., Thomas G.; RT "Characterization of a frequent polymorphism in the coding sequence of the RT Tp53 gene in colonic cancer patients and a control population."; RL Hum. Genet. 86:369-370(1991). RN [198] RP VARIANT LFS THR-133. RX PubMed=1933902; RA Law J.C., Strong L.C., Chidambaram A., Ferrell R.E.; RT "A germ line mutation in exon 5 of the p53 gene in an extended cancer RT family."; RL Cancer Res. 51:6385-6387(1991). RN [199] RP VARIANTS LFS CYS-245; TRP-248; PRO-252 AND LYS-258. RX PubMed=1978757; DOI=10.1126/science.1978757; RA Malkin D., Li F.P., Strong L.C., Fraumeni J.F. Jr., Nelson C.E., Kim D.H., RA Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A., Friend S.H.; RT "Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, RT and other neoplasms."; RL Science 250:1233-1238(1990). RN [200] RP VARIANT LFS ASP-245. RX PubMed=2259385; DOI=10.1038/348747a0; RA Srivastava S., Zou Z., Pirollo K., Blattner W., Chang E.H.; RT "Germ-line transmission of a mutated p53 gene in a cancer-prone family with RT Li-Fraumeni syndrome."; RL Nature 348:747-749(1990). RN [201] RP VARIANT LFS LEU-272. RX PubMed=1737852; DOI=10.1172/jci115630; RA Felix C.A., Nau M.M., Takahashi T., Mitsudomi T., Chiba I., Poplack D.G., RA Reaman G.H., Cole D.E., Letterio J.J., Whang-Peng J., Knutsen T., RA Minna J.D.; RT "Hereditary and acquired p53 gene mutations in childhood acute RT lymphoblastic leukemia."; RL J. Clin. Invest. 89:640-647(1992). RN [202] RP VARIANTS LFS HIS-273 AND VAL-325. RX PubMed=1565144; DOI=10.1056/nejm199205143262002; RA Malkin D., Jolly K.W., Barbier N., Look A.T., Friend S.H., Gebhardt M.C., RA Andersen T.I., Boerresen A.-L., Li F.P., Garber J., Strong L.C.; RT "Germline mutations of the p53 tumor-suppressor gene in children and young RT adults with second malignant neoplasms."; RL N. Engl. J. Med. 326:1309-1315(1992). RN [203] RP VARIANTS SPORADIC CANCERS GLN-132; SER-249; LYS-280 AND LYS-285. RX PubMed=1694291; RA Bartek J., Iggo R., Gannon J., Lane D.P.; RT "Genetic and immunochemical analysis of mutant p53 in human breast cancer RT cell lines."; RL Oncogene 5:893-899(1990). RN [204] RP VARIANTS SPORADIC CANCERS PHE-241 AND HIS-273. RX PubMed=1699228; DOI=10.1073/pnas.87.19.7555; RA Rodrigues N.R., Rowan A., Smith M.E.F., Kerr I.B., Bodmer W.F., RA Gannon J.V., Lane D.P.; RT "p53 mutations in colorectal cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 87:7555-7559(1990). RN [205] RP VARIANTS SPORADIC CANCER VAL-154; VAL-245; GLN-248; LEU-278 AND SER-278. RX PubMed=2263646; DOI=10.1073/pnas.87.24.9958; RA Hollstein M.C., Metcalf R.A., Welsh J.A., Montesano R., Harris C.C.; RT "Frequent mutation of the p53 gene in human esophageal cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 87:9958-9961(1990). RN [206] RP VARIANTS SPORADIC CANCERS. RX PubMed=1647768; DOI=10.1016/0006-291x(91)90623-f; RA Ishioka C., Sato T., Gamoh M., Suzuki T., Shibata H., Kanamaru R., RA Wakui A., Yamazaki T.; RT "Mutations of the P53 gene, including an intronic point mutation, in RT colorectal tumors."; RL Biochem. Biophys. Res. Commun. 177:901-906(1991). RN [207] RP VARIANTS SPORADIC CANCERS LEU-152; ALA-155; HIS-175; PHE-176 AND HIS-273. RX PubMed=1868473; RA Casson A.G., Mukhopadhyay T., Cleary K.R., Ro J.Y., Levin B., Roth J.A.; RT "p53 gene mutations in Barrett's epithelium and esophageal cancer."; RL Cancer Res. 51:4495-4499(1991). RN [208] RP VARIANTS SPORADIC CANCERS IN CHINA. RX PubMed=1849234; DOI=10.1038/350427a0; RA Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C.; RT "Mutational hotspot in the p53 gene in human hepatocellular carcinomas."; RL Nature 350:427-428(1991). RN [209] RP VARIANTS SPORADIC CANCERS IN SOUTH AFRICA. RX PubMed=1672732; DOI=10.1038/350429a0; RA Bressac B., Kew M., Wands J., Ozturk M.; RT "Selective G to T mutations of p53 gene in hepatocellular carcinoma from RT southern Africa."; RL Nature 350:429-431(1991). RN [210] RP VARIANTS SPORADIC CANCERS PHE-176; PHE-242; CYS-245; LEU-248 AND HIS-273. RX PubMed=1394225; RA Somers K.D., Merrick M.A., Lopez M.E., Incognito L.S., Schechter G.L., RA Casey G.; RT "Frequent p53 mutations in head and neck cancer."; RL Cancer Res. 52:5997-6000(1992). RN [211] RP VARIANTS SPORADIC CANCERS. RX PubMed=1327751; DOI=10.1002/j.1460-2075.1992.tb05487.x; RA Crook T., Vousden K.H.; RT "Properties of p53 mutations detected in primary and secondary cervical RT cancers suggest mechanisms of metastasis and involvement of environmental RT carcinogens."; RL EMBO J. 11:3935-3940(1992). RN [212] RP VARIANTS SPORADIC CANCERS CYS-205; GLU-281 AND LYS-285. RX PubMed=1459726; DOI=10.1002/ijc.2910520606; RA Sakai E., Rikimaru K., Ueda M., Matsumoto Y., Ishii N., Enomoto S., RA Yamamoto H., Tsuchida N.; RT "The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous- RT cell carcinoma."; RL Int. J. Cancer 52:867-872(1992). RN [213] RP VARIANT PRO-HIS-PRO-178 INS. RX PubMed=1303181; DOI=10.1093/hmg/1.3.207; RA Bhatia K., Guiterrez M.I., Magrath I.T.; RT "A novel mutation in the p53 gene in a Burkitt's lymphoma cell line."; RL Hum. Mol. Genet. 1:207-208(1992). RN [214] RP VARIANTS SPORADIC CANCERS. RX PubMed=1437144; RA Duthu A., Debuire B., Romano J.W., Ehrhart J.C., Fiscella M., May E., RA Appella E., May P.; RT "p53 mutations in Raji cells: characterization and localization relative to RT other Burkitt's lymphomas."; RL Oncogene 7:2161-2167(1992). RN [215] RP VARIANT SPORADIC CANCER THR-280. RX PubMed=1631151; DOI=10.1073/pnas.89.14.6516; RA Sun Y., Hegamyer G., Heng Y.-J., Hildesheim A., Chen J.-Y., Chen I.-H., RA Cao Y., Yao K.-T., Colburn N.H.; RT "An infrequent point mutation of the p53 gene in human nasopharyngeal RT carcinoma."; RL Proc. Natl. Acad. Sci. U.S.A. 89:6516-6520(1992). RN [216] RP VARIANTS SPORADIC CANCERS SER-151; PRO-156; LYS-174; ARG-194; CYS-220; RP GLN-248; LEU-248 AND HIS-273. RX PubMed=7682763; RA Caamano J., Zhang S.Y., Rosvold E.A., Bauer B., Klein-Szanto A.J.P.; RT "p53 alterations in human squamous cell carcinomas and carcinoma cell RT lines."; RL Am. J. Pathol. 142:1131-1139(1993). RN [217] RP VARIANTS SPORADIC CANCERS. RX PubMed=8402617; RA Boyle J.O., Hakim J., Koch W., van der Riet P., Hruban R.H., Roa R.A., RA Correo R., Eby Y.J., Ruppert J.M., Sidransky D.; RT "The incidence of p53 mutations increases with progression of head and neck RT cancer."; RL Cancer Res. 53:4477-4480(1993). RN [218] RP VARIANTS SPORADIC CANCERS. RX PubMed=8336944; RA Hamelin R., Jego N., Laurent-Puig P., Vidaud M., Thomas G.; RT "Efficient screening of p53 mutations by denaturing gradient gel RT electrophoresis in colorectal tumors."; RL Oncogene 8:2213-2220(1993). RN [219] RP VARIANTS, AND INVOLVEMENT IN LFL. RX PubMed=8118819; RA Birch J.M., Hartley A.L., Tricker K.J., Prosser J., Condie A., Kelsey A.M., RA Harris M., Jones P.H., Binchy A., Crowther D., Craft A.W., Eden O.B., RA Evans D.G.R., Thompson E., Mann J.R., Martin J., Mitchell E.L.D., RA Santibanez-Koref M.F.; RT "Prevalence and diversity of constitutional mutations in the p53 gene among RT 21 Li-Fraumeni families."; RL Cancer Res. 54:1298-1304(1994). RN [220] RP CHARACTERIZATION OF VARIANT ALA-143. RX PubMed=8013454; DOI=10.1002/j.1460-2075.1994.tb06543.x; RA Zhang W., Guo X.-Y., Hu G.-Y., Liu W.-B., Shay J.W., Deisseroth A.B.; RT "A temperature-sensitive mutant of human p53."; RL EMBO J. 13:2535-2544(1994). RN [221] RP VARIANTS LFS HIS-175; ARG-193; GLN-248; CYS-273 AND TYR-275. RX PubMed=7887414; RA Frebourg T., Barbier N., Yan Y.-X., Garber J.E., Dreyfus M., RA Fraumeni J.F. Jr., Li F.P., Friend S.H.; RT "Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome."; RL Am. J. Hum. Genet. 56:608-615(1995). RN [222] RP VARIANTS, AND INVOLVEMENT IN LFL. RX PubMed=8718514; RA Eeles R.A.; RT "Germline mutations in the TP53 gene."; RL Cancer Surv. 25:101-124(1995). RN [223] RP VARIANT LFS HIS-175. RX PubMed=8825920; DOI=10.1136/jmg.32.12.942; RA Varley J.M., McGrown G., Thorncroft M., Tricker K.J., Teare M.D., RA Santibanez-Koref M.F., Houlston R.S., Martin J., Birch J.M., Evans D.G.R.; RT "An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 RT mutation in TP53."; RL J. Med. Genet. 32:942-945(1995). RN [224] RP VARIANTS SPORADIC CANCERS PHE-176; SER-245; TRP-248; TRP-282 AND GLN-286. RX PubMed=8829627; RX DOI=10.1002/(sici)1098-1004(1996)7:2<109::aid-humu4>3.0.co;2-7; RA Audrezet M.-P., Robaszkiewicz M., Mercier B., Nousbaum J.-B., Hardy E., RA Bail J.-P., Volant A., Lozac'H P., Gouerou H., Ferec C.; RT "Molecular analysis of the TP53 gene in Barrett's adenocarcinoma."; RL Hum. Mutat. 7:109-113(1996). RN [225] RP VARIANTS SPORADIC CANCERS. RX PubMed=9101296; RX DOI=10.1002/(sici)1098-1004(1997)9:4<348::aid-humu8>3.0.co;2-1; RA Guldberg P., Nedergaard T., Nielsen H.J., Olsen A.C., Ahrenkiel V., RA Zeuthen J.; RT "Single-step DGGE-based mutation scanning of the p53 gene: application to RT genetic diagnosis of colorectal cancer."; RL Hum. Mutat. 9:348-355(1997). RN [226] RP VARIANT SPORADIC CANCER ILE-157. RX PubMed=9419979; DOI=10.1038/sj.onc.1201668; RA Miyaki M., Nishio J., Konishi M., Kikuchi-Yanoshita R., Tanaka K., RA Muraoka M., Nagato M., Chong J.-M., Koike M., Terada T., Kawahara Y., RA Fukutome A., Tomiyama J., Chuganji Y., Momoi M., Utsunomiya J.; RT "Drastic genetic instability of tumors and normal tissues in Turcot RT syndrome."; RL Oncogene 15:2877-2881(1997). RN [227] RP VARIANTS SER-152; ILE-169; PHE-176; THR-195; CYS-220; ILE-230; CYS-273 AND RP SER-278. RX PubMed=9450901; RX DOI=10.1002/(sici)1098-1004(1998)11:1<39::aid-humu6>3.0.co;2-g; RA van Rensburg E.J., Engelbrecht S., van Heerden W.F.P., Kotze M.J., RA Raubenheimer E.J.; RT "Detection of p53 gene mutations in oral squamous cell carcinomas of a RT black African population sample."; RL Hum. Mutat. 11:39-44(1998). RN [228] RP VARIANT NON-CLASSICAL LFS CYS-337. RX PubMed=9452042; DOI=10.1002/humu.1380110121; RA Luca J.W., Strong L.C., Hansen M.F.; RT "A germline missense mutation R337C in exon 10 of the human p53 gene."; RL Hum. Mutat. Suppl. 1:S58-S61(1998). RN [229] RP VARIANT LFS ILE-292. RX PubMed=10484981; DOI=10.1016/s0165-4608(98)00276-3; RA Gueran S., Tunca Y., Imirzalioglu N.; RT "Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in a Li- RT Fraumeni syndrome family."; RL Cancer Genet. Cytogenet. 113:145-151(1999). RN [230] RP VARIANTS. RX PubMed=10549356; DOI=10.1016/s0065-230x(08)60785-x; RA Hainaut P., Hollstein M.; RT "p53 and human cancer: the first ten thousand mutations."; RL Adv. Cancer Res. 77:81-137(2000). RN [231] RP VARIANT ADCC HIS-337. RX PubMed=11481490; DOI=10.1073/pnas.161479898; RA Ribeiro R.C., Sandrini F., Figueiredo B., Zambetti G.P., Michalkiewicz E., RA Lafferty A.R., DeLacerda L., Rabin M., Cadwell C., Sampaio G., Cat I., RA Stratakis C.A., Sandrini R.; RT "An inherited p53 mutation that contributes in a tissue-specific manner to RT pediatric adrenal cortical carcinoma."; RL Proc. Natl. Acad. Sci. U.S.A. 98:9330-9335(2001). RN [232] RP INVOLVEMENT IN CPP. RX PubMed=12085209; DOI=10.1038/sj.bjc.6600269; RA Rutherford J., Chu C.E., Duddy P.M., Charlton R.S., Chumas P., Taylor G.R., RA Lu X., Barnes D.M., Camplejohn R.S.; RT "Investigations on a clinically and functionally unusual and novel germline RT p53 mutation."; RL Br. J. Cancer 86:1592-1596(2002). RN [233] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-134; PHE-157; CYS-163; HIS-175; RP ARG-177; ARG-193; PRO-213; PHE-241; PHE-242; GLN-248; TRP-248; SER-249; RP TRP-267; LYS-271; CYS-273; HIS-273; LEU-273; SER-278; ILE-280 AND HIS-281. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [234] RP VARIANTS PRO-110; VAL-113; VAL-138; CYS-163; HIS-163; THR-195; MET-216; RP ALA-241; MET-249; SER-251; TYR-259 AND CYS-273. RX PubMed=17224074; DOI=10.1186/bcr1637; RA Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A., Presswalla S., RA Kaaresen R., Strausberg R.L., Gerhard D.S., Kristensen V., Perou C.M., RA Boerresen-Dale A.-L.; RT "Somatic sequence alterations in twenty-one genes selected by expression RT profile analysis of breast carcinomas."; RL Breast Cancer Res. 9:R5-R5(2007). RN [235] RP VARIANTS. RX PubMed=17311302; DOI=10.1002/humu.20495; RA Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., RA Olivier M.; RT "Impact of mutant p53 functional properties on TP53 mutation patterns and RT tumor phenotype: lessons from recent developments in the IARC TP53 RT database."; RL Hum. Mutat. 28:622-629(2007). RN [236] RP CHARACTERIZATION OF VARIANT SPORADIC CANCER LYS-280, UBIQUITINATION, RP PROTEASOMAL DEGRADATION, AND INTERACTION WITH CCAR2. RX PubMed=25732823; DOI=10.1016/j.celrep.2015.01.066; RA Qin B., Minter-Dykhouse K., Yu J., Zhang J., Liu T., Zhang H., Lee S., RA Kim J., Wang L., Lou Z.; RT "DBC1 functions as a tumor suppressor by regulating p53 stability."; RL Cell Rep. 10:1324-1334(2015). RN [237] RP VARIANTS VAL-138; HIS-175; ILE-237; TRP-248 AND PRO-273. RX PubMed=27657329; DOI=10.1371/journal.pbio.1002555; RA Guan Y., Huang D., Chen F., Gao C., Tao T., Shi H., Zhao S., Liao Z., RA Lo L.J., Wang Y., Chen J., Peng J.; RT "Phosphorylation of Def Regulates Nucleolar p53 Turnover and Cell Cycle RT Progression through Def Recruitment of Calpain3."; RL PLoS Biol. 14:e1002555-e1002555(2016). CC -!- FUNCTION: Multifunctional transcription factor that induces cell cycle CC arrest, DNA repair or apoptosis upon binding to its target DNA sequence CC (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, CC PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, CC PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, CC PubMed:24652652, PubMed:35618207, PubMed:36634798, PubMed:38653238, CC PubMed:9840937). Acts as a tumor suppressor in many tumor types; CC induces growth arrest or apoptosis depending on the physiological CC circumstances and cell type (PubMed:11025664, PubMed:12524540, CC PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17189187, CC PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, CC PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, CC PubMed:38653238, PubMed:9840937). Negatively regulates cell division by CC controlling expression of a set of genes required for this process CC (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, CC PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, CC PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, CC PubMed:24652652, PubMed:9840937). One of the activated genes is an CC inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be CC mediated either by stimulation of BAX and FAS antigen expression, or by CC repression of Bcl-2 expression (PubMed:12524540, PubMed:17189187). Its CC pro-apoptotic activity is activated via its interaction with CC PPP1R13B/ASPP1 or TP53BP2/ASPP2 (PubMed:12524540). However, this CC activity is inhibited when the interaction with PPP1R13B/ASPP1 or CC TP53BP2/ASPP2 is displaced by PPP1R13L/iASPP (PubMed:12524540). In CC cooperation with mitochondrial PPIF is involved in activating oxidative CC stress-induced necrosis; the function is largely independent of CC transcription. Induces the transcription of long intergenic non-coding CC RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in CC TP53-dependent transcriptional repression leading to apoptosis and CC seems to have an effect on cell-cycle regulation. Implicated in Notch CC signaling cross-over. Prevents CDK7 kinase activity when associated to CC CAK complex in response to DNA damage, thus stopping cell cycle CC progression. Isoform 2 enhances the transactivation activity of isoform CC 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses CC transactivation activity and impairs growth suppression mediated by CC isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates CC the circadian clock by repressing CLOCK-BMAL1-mediated transcriptional CC activation of PER2 (PubMed:24051492). {ECO:0000269|PubMed:11025664, CC ECO:0000269|PubMed:12524540, ECO:0000269|PubMed:12810724, CC ECO:0000269|PubMed:15186775, ECO:0000269|PubMed:15340061, CC ECO:0000269|PubMed:17189187, ECO:0000269|PubMed:17317671, CC ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:19556538, CC ECO:0000269|PubMed:20673990, ECO:0000269|PubMed:20959462, CC ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:24051492, CC ECO:0000269|PubMed:24652652, ECO:0000269|PubMed:35618207, CC ECO:0000269|PubMed:36634798, ECO:0000269|PubMed:38653238, CC ECO:0000269|PubMed:9840937}. CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; CC Evidence={ECO:0000269|PubMed:14534297, ECO:0000269|PubMed:16793544, CC ECO:0000269|PubMed:17015838, ECO:0000269|PubMed:18650397, CC ECO:0000269|PubMed:19515728, ECO:0000269|PubMed:20142040, CC ECO:0000269|PubMed:20364130}; CC Note=Binds 1 zinc ion per subunit. {ECO:0000269|PubMed:14534297, CC ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, CC ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, CC ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130}; CC -!- SUBUNIT: Forms homodimers and homotetramers (PubMed:19011621). Binds CC DNA as a homotetramer (PubMed:36108750). Interacts with AXIN1. Probably CC part of a complex consisting of TP53, HIPK2 and AXIN1 (By similarity). CC Interacts with histone acetyltransferases EP300 and methyltransferases CC HRMT1L2 and CARM1, and recruits them to promoters. Interacts (via C- CC terminus) with TAF1; when TAF1 is part of the TFIID complex. Interacts CC with ING4; this interaction may be indirect. Found in a complex with CC CABLES1 and TP73. Interacts with HIPK1, HIPK2, and TP53INP1. Interacts CC with WWOX. May interact with HCV core protein. Interacts with USP7 and CC SYVN1. Interacts with HSP90AB1. Interacts with CHD8; leading to recruit CC histone H1 and prevent transactivation activity (By similarity). CC Interacts with ARMC10, CDKN2AIP, NUAK1, STK11/LKB1, UHRF2 and E4F1. CC Interacts with YWHAZ; the interaction enhances TP53 transcriptional CC activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this CC interaction. Interacts (via DNA-binding domain) with MAML1 (via N- CC terminus). Interacts with MKRN1. Interacts with PML (via C-terminus). CC Interacts with MDM2; leading to ubiquitination and proteasomal CC degradation of TP53. Directly interacts with FBXO42; leading to CC ubiquitination and degradation of TP53. Interacts (phosphorylated at CC Ser-15 by ATM) with the phosphatase PP2A-PPP2R5C holoenzyme; regulates CC stress-induced TP53-dependent inhibition of cell proliferation. CC Interacts with PPP2R2A. Interacts with AURKA, DAXX, BRD7 and TRIM24. CC Interacts (when monomethylated at Lys-382) with L3MBTL1. Isoform 1 CC interacts with isoform 2 and with isoform 4. Interacts with GRK5. Binds CC to the CAK complex (CDK7, cyclin H and MAT1) in response to DNA damage. CC Interacts with CDK5 in neurons. Interacts with AURKB, SETD2, UHRF2 and CC NOC2L. Interacts (via N-terminus) with PTK2/FAK1; this promotes CC ubiquitination by MDM2. Interacts with PTK2B/PYK2; this promotes CC ubiquitination by MDM2. Interacts with PRKCG. Interacts with PPIF; the CC association implicates preferentially tetrameric TP53, is induced by CC oxidative stress and is impaired by cyclosporin A (CsA). Interacts with CC SNAI1; the interaction induces SNAI1 degradation via MDM2-mediated CC ubiquitination and inhibits SNAI1-induced cell invasion. Interacts with CC UBC9. Interacts with ZNF385B; the interaction is direct. Interacts (via CC DNA-binding domain) with ZNF385A; the interaction is direct and CC enhances p53/TP53 transactivation functions on cell-cycle arrest target CC genes, resulting in growth arrest. Interacts with ANKRD2. Interacts CC with RFFL and RNF34; involved in p53/TP53 ubiquitination. Interacts CC with MTA1 and COP1. Interacts with CCAR2 (via N-terminus). Interacts CC with MORC3 (PubMed:17332504). Interacts (via C-terminus) with POU4F2 CC isoform 1 (via C-terminus) (PubMed:17145718). Interacts (via CC oligomerization region) with NOP53; the interaction is direct and may CC prevent the MDM2-mediated proteasomal degradation of TP53 CC (PubMed:22522597). Interacts with AFG1L; mediates mitochondrial CC translocation of TP53 (PubMed:27323408). Interacts with UBD CC (PubMed:25422469). Interacts with TAF6 isoform 1 and isoform 4 CC (PubMed:20096117). Interacts with C10orf90/FATS; the interaction CC inhibits binding of TP53 and MDM2 (By similarity). Interacts with CC NUPR1; interaction is stress-dependent (PubMed:18690848). Forms a CC complex with EP300 and NUPR1; this complex binds CDKN1A promoter CC leading to transcriptional induction of CDKN1A (PubMed:18690848). CC Interacts with PRMT5 in response to DNA damage; the interaction is CC TTC5/STRAP dependent (PubMed:19011621). Interacts with PPP1R13L (via CC SH3 domain and ANK repeats); the interaction inhibits pro-apoptotic CC activity of p53/TP53 (PubMed:12524540). Interacts with PPP1R13B/ASPP1 CC and TP53BP2/ASPP2; the interactions promotes pro-apoptotic activity CC (PubMed:12524540). When phosphorylated at Ser-15, interacts with DDX3X CC and gamma-tubulin (PubMed:28842590). Interacts with KAT7/HBO1; leading CC to inhibit histone acetyltransferase activity of KAT7/HBO1 CC (PubMed:17954561). Interacts (via N-terminus) with E3 ubiquitin-protein CC ligase MUL1; the interaction results in ubiquitination of cytoplasmic CC TP53 at Lys-24 and subsequent proteasomal degradation CC (PubMed:21597459). Interacts with S100A4; this interaction promotes CC TP53 degradation (PubMed:23752197, PubMed:32442400). Interacts with CC BANP (By similarity). Interacts with TTC5/STRAP; the interaction may CC result in increased mitochondrial-dependent apoptosis CC (PubMed:25168243). Interacts with NQO1; this interaction is NADH- CC dependent, stabilizes TP53 in response to oxidative stress and protects CC it from ubiquitin-independent degradation by the 20S proteasome CC (PubMed:15687255). Interacts with DAZAP2 at TP53 target gene promoters; CC the interaction is triggered by DNA damage and leads to modulation of CC the expression of a subset of TP53 target genes, reducing DNA damage- CC induced cell death by limiting the expression of cell death-mediating CC TP53 target genes (PubMed:33591310). Interacts (via N-terminus) with CC ZNF768 (via zinc-finger domains); interaction might be facilitated by CC TP53 oligomerization state (PubMed:34404770). Forms a ternary complex CC with ALDOB and G6PD; this interaction is direct. ALDOB stabilizes the CC complex inhibiting G6PD activity and keeping oxidative pentose CC phosphate metabolism in check. Interacts with MORN3; the interactions CC mediate post-transcriptional modifications of TP53 by MDM2 and SIRT1 CC (PubMed:29681526). Interacts with HSPA9/MOT-2; the interaction promotes CC the degradation of TP53 (PubMed:24625977). Interacts with FBXO22; this CC interaction promotes TP53 proteasomal degradation (PubMed:26868148). CC {ECO:0000250|UniProtKB:P02340, ECO:0000250|UniProtKB:P10361, CC ECO:0000269|PubMed:12524540, ECO:0000269|PubMed:12750254, CC ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:12851404, CC ECO:0000269|PubMed:14534297, ECO:0000269|PubMed:14702041, CC ECO:0000269|PubMed:15053879, ECO:0000269|PubMed:15109303, CC ECO:0000269|PubMed:15136035, ECO:0000269|PubMed:15186775, CC ECO:0000269|PubMed:15687255, ECO:0000269|PubMed:15855171, CC ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:16322561, CC ECO:0000269|PubMed:16376338, ECO:0000269|PubMed:16377624, CC ECO:0000269|PubMed:16402859, ECO:0000269|PubMed:16474402, CC ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:16845383, CC ECO:0000269|PubMed:17015838, ECO:0000269|PubMed:17108107, CC ECO:0000269|PubMed:17121812, ECO:0000269|PubMed:17145718, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17245430, CC ECO:0000269|PubMed:17317671, ECO:0000269|PubMed:17332504, CC ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17719541, CC ECO:0000269|PubMed:17904127, ECO:0000269|PubMed:17954561, CC ECO:0000269|PubMed:17967874, ECO:0000269|PubMed:18585004, CC ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:18690848, CC ECO:0000269|PubMed:18996393, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:19509332, ECO:0000269|PubMed:19515728, CC ECO:0000269|PubMed:19536131, ECO:0000269|PubMed:19556538, CC ECO:0000269|PubMed:19837670, ECO:0000269|PubMed:19880522, CC ECO:0000269|PubMed:20096117, ECO:0000269|PubMed:20124405, CC ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20228809, CC ECO:0000269|PubMed:20364130, ECO:0000269|PubMed:20385133, CC ECO:0000269|PubMed:20660729, ECO:0000269|PubMed:20870725, CC ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:21317932, CC ECO:0000269|PubMed:21952639, ECO:0000269|PubMed:22214662, CC ECO:0000269|PubMed:22522597, ECO:0000269|PubMed:22726440, CC ECO:0000269|PubMed:22945289, ECO:0000269|PubMed:23431171, CC ECO:0000269|PubMed:23752197, ECO:0000269|PubMed:24625977, CC ECO:0000269|PubMed:25168243, ECO:0000269|PubMed:25422469, CC ECO:0000269|PubMed:25732823, ECO:0000269|PubMed:26868148, CC ECO:0000269|PubMed:27323408, ECO:0000269|PubMed:28842590, CC ECO:0000269|PubMed:29681526, ECO:0000269|PubMed:32442400, CC ECO:0000269|PubMed:33591310, ECO:0000269|PubMed:34404770, CC ECO:0000269|PubMed:35122041, ECO:0000269|PubMed:8875926, CC ECO:0000269|PubMed:8875929, ECO:0000269|PubMed:9840937}. CC -!- SUBUNIT: (Microbial infection) Interacts with cancer-associated/HPV E6 CC viral proteins leading to ubiquitination and degradation of TP53 giving CC a possible model for cell growth regulation. This complex formation CC requires an additional factor, E6-AP, which stably associates with TP53 CC in the presence of E6. {ECO:0000269|PubMed:2175676}. CC -!- SUBUNIT: (Microbial infection) Interacts with human CC cytomegalovirus/HHV-5 protein UL123. {ECO:0000269|PubMed:19776115}. CC -!- SUBUNIT: (Microbial infection) Interacts (via N-terminus) with human CC adenovirus 5 E1B-55K protein; this interaction leads to the inhibition CC of TP53 function and/or its degradation. {ECO:0000269|PubMed:25772236}. CC -!- SUBUNIT: (Microbial infection) Interacts with Kaposi's sarcoma- CC associated herpesvirus/HHV-8 protein ORF45; this interaction results in CC the cytoplasmic localization of TP53 thereby decreasing its CC transcriptional activity. {ECO:0000269|PubMed:34523970}. CC -!- INTERACTION: CC P04637; P00519: ABL1; NbExp=2; IntAct=EBI-366083, EBI-375543; CC P04637; Q13155: AIMP2; NbExp=6; IntAct=EBI-366083, EBI-745226; CC P04637; O95376: ARIH2; NbExp=5; IntAct=EBI-366083, EBI-711158; CC P04637; P49407: ARRB1; NbExp=5; IntAct=EBI-366083, EBI-743313; CC P04637; Q9UBL3: ASH2L; NbExp=8; IntAct=EBI-366083, EBI-540797; CC P04637; O95352-2: ATG7; NbExp=4; IntAct=EBI-366083, EBI-15980880; CC P04637; O15169: AXIN1; NbExp=4; IntAct=EBI-366083, EBI-710484; CC P04637; Q8N9N5: BANP; NbExp=3; IntAct=EBI-366083, EBI-744695; CC P04637; P10415: BCL2; NbExp=5; IntAct=EBI-366083, EBI-77694; CC P04637; Q07817-1: BCL2L1; NbExp=26; IntAct=EBI-366083, EBI-287195; CC P04637; O14503: BHLHE40; NbExp=11; IntAct=EBI-366083, EBI-711810; CC P04637; P15056: BRAF; NbExp=4; IntAct=EBI-366083, EBI-365980; CC P04637; P38398: BRCA1; NbExp=2; IntAct=EBI-366083, EBI-349905; CC P04637; P51587: BRCA2; NbExp=7; IntAct=EBI-366083, EBI-79792; CC P04637; Q9NPI1: BRD7; NbExp=9; IntAct=EBI-366083, EBI-711221; CC P04637; Q9BX70: BTBD2; NbExp=2; IntAct=EBI-366083, EBI-710091; CC P04637; Q9Y297: BTRC; NbExp=2; IntAct=EBI-366083, EBI-307461; CC P04637; P55212: CASP6; NbExp=3; IntAct=EBI-366083, EBI-718729; CC P04637; Q9BWC9: CCDC106; NbExp=3; IntAct=EBI-366083, EBI-711501; CC P04637; P48643: CCT5; NbExp=3; IntAct=EBI-366083, EBI-355710; CC P04637; P38936: CDKN1A; NbExp=6; IntAct=EBI-366083, EBI-375077; CC P04637; P17676: CEBPB; NbExp=4; IntAct=EBI-366083, EBI-969696; CC P04637; Q03701: CEBPZ; NbExp=2; IntAct=EBI-366083, EBI-1046778; CC P04637; O14757: CHEK1; NbExp=2; IntAct=EBI-366083, EBI-974488; CC P04637; O96017: CHEK2; NbExp=3; IntAct=EBI-366083, EBI-1180783; CC P04637; Q8NHY2: COP1; NbExp=5; IntAct=EBI-366083, EBI-1176214; CC P04637; Q92793: CREBBP; NbExp=17; IntAct=EBI-366083, EBI-81215; CC P04637; P55060: CSE1L; NbExp=5; IntAct=EBI-366083, EBI-286709; CC P04637; Q14999: CUL7; NbExp=19; IntAct=EBI-366083, EBI-308606; CC P04637; Q8IWT3: CUL9; NbExp=16; IntAct=EBI-366083, EBI-311123; CC P04637; Q9P0U4: CXXC1; NbExp=7; IntAct=EBI-366083, EBI-949911; CC P04637; Q9UER7: DAXX; NbExp=13; IntAct=EBI-366083, EBI-77321; CC P04637; Q92841: DDX17; NbExp=3; IntAct=EBI-366083, EBI-746012; CC P04637; P17844: DDX5; NbExp=6; IntAct=EBI-366083, EBI-351962; CC P04637; Q9NRR4: DROSHA; NbExp=5; IntAct=EBI-366083, EBI-528367; CC P04637; Q9BV47: DUSP26; NbExp=9; IntAct=EBI-366083, EBI-2924519; CC P04637; O14641: DVL2; NbExp=6; IntAct=EBI-366083, EBI-740850; CC P04637; Q09472: EP300; NbExp=22; IntAct=EBI-366083, EBI-447295; CC P04637; P15036: ETS2; NbExp=4; IntAct=EBI-366083, EBI-1646991; CC P04637; Q86XK2: FBXO11; NbExp=4; IntAct=EBI-366083, EBI-1047804; CC P04637; P21333-2: FLNA; NbExp=3; IntAct=EBI-366083, EBI-9641086; CC P04637; P51114: FXR1; NbExp=2; IntAct=EBI-366083, EBI-713291; CC P04637; P49841: GSK3B; NbExp=3; IntAct=EBI-366083, EBI-373586; CC P04637; P32780: GTF2H1; NbExp=12; IntAct=EBI-366083, EBI-715539; CC P04637; Q13547: HDAC1; NbExp=8; IntAct=EBI-366083, EBI-301834; CC P04637; Q86Z02: HIPK1; NbExp=2; IntAct=EBI-366083, EBI-692891; CC P04637; Q9H2X6: HIPK2; NbExp=3; IntAct=EBI-366083, EBI-348345; CC P04637; P09429: HMGB1; NbExp=9; IntAct=EBI-366083, EBI-389432; CC P04637; P41235: HNF4A; NbExp=3; IntAct=EBI-366083, EBI-1049011; CC P04637; P61978: HNRNPK; NbExp=2; IntAct=EBI-366083, EBI-304185; CC P04637; P61978-2: HNRNPK; NbExp=2; IntAct=EBI-366083, EBI-7060731; CC P04637; Q9BUJ2: HNRNPUL1; NbExp=12; IntAct=EBI-366083, EBI-1018153; CC P04637; P38646: HSPA9; NbExp=6; IntAct=EBI-366083, EBI-354932; CC P04637; P04792: HSPB1; NbExp=3; IntAct=EBI-366083, EBI-352682; CC P04637; P42858: HTT; NbExp=19; IntAct=EBI-366083, EBI-466029; CC P04637; Q7Z6Z7: HUWE1; NbExp=3; IntAct=EBI-366083, EBI-625934; CC P04637; Q16666-2: IFI16; NbExp=6; IntAct=EBI-366083, EBI-6273540; CC P04637; O14920: IKBKB; NbExp=3; IntAct=EBI-366083, EBI-81266; CC P04637; Q9UHH9: IP6K2; NbExp=4; IntAct=EBI-366083, EBI-747509; CC P04637; Q6NYC1: JMJD6; NbExp=7; IntAct=EBI-366083, EBI-8464037; CC P04637; Q92993: KAT5; NbExp=3; IntAct=EBI-366083, EBI-399080; CC P04637; Q9H7Z6: KAT8; NbExp=2; IntAct=EBI-366083, EBI-896414; CC P04637; O60341-1: KDM1A; NbExp=6; IntAct=EBI-366083, EBI-15599570; CC P04637; Q8IZD2: KMT2E; NbExp=4; IntAct=EBI-366083, EBI-2689959; CC P04637; P13473-2: LAMP2; NbExp=3; IntAct=EBI-366083, EBI-21591415; CC P04637; P43356: MAGEA2B; NbExp=7; IntAct=EBI-366083, EBI-5650739; CC P04637; Q96M61: MAGEB18; NbExp=3; IntAct=EBI-366083, EBI-741835; CC P04637; Q9UBF1: MAGEC2; NbExp=3; IntAct=EBI-366083, EBI-5651487; CC P04637; P46821: MAP1B; NbExp=6; IntAct=EBI-366083, EBI-764611; CC P04637; Q15759: MAPK11; NbExp=2; IntAct=EBI-366083, EBI-298304; CC P04637; Q8IW41: MAPKAPK5; NbExp=2; IntAct=EBI-366083, EBI-1201460; CC P04637; Q00987: MDM2; NbExp=119; IntAct=EBI-366083, EBI-389668; CC P04637; O15151: MDM4; NbExp=24; IntAct=EBI-366083, EBI-398437; CC P04637; Q15648: MED1; NbExp=3; IntAct=EBI-366083, EBI-394459; CC P04637; Q9UHC7: MKRN1; NbExp=8; IntAct=EBI-366083, EBI-373524; CC P04637; O75970: MPDZ; NbExp=3; IntAct=EBI-366083, EBI-821405; CC P04637; P04731: MT1A; NbExp=3; IntAct=EBI-366083, EBI-8045030; CC P04637; P19338: NCL; NbExp=2; IntAct=EBI-366083, EBI-346967; CC P04637; Q9Y618: NCOR2; NbExp=7; IntAct=EBI-366083, EBI-80830; CC P04637; Q99608: NDN; NbExp=4; IntAct=EBI-366083, EBI-718177; CC P04637; P23511: NFYA; NbExp=11; IntAct=EBI-366083, EBI-389739; CC P04637; P25208: NFYB; NbExp=6; IntAct=EBI-366083, EBI-389728; CC P04637; Q9Y3T9: NOC2L; NbExp=8; IntAct=EBI-366083, EBI-751547; CC P04637; O60936: NOL3; NbExp=3; IntAct=EBI-366083, EBI-740992; CC P04637; P06748: NPM1; NbExp=6; IntAct=EBI-366083, EBI-78579; CC P04637; P06748-1: NPM1; NbExp=3; IntAct=EBI-366083, EBI-354150; CC P04637; Q15466: NR0B2; NbExp=3; IntAct=EBI-366083, EBI-3910729; CC P04637; P22736: NR4A1; NbExp=6; IntAct=EBI-366083, EBI-721550; CC P04637; O43847: NRDC; NbExp=6; IntAct=EBI-366083, EBI-2371631; CC P04637; O60285: NUAK1; NbExp=5; IntAct=EBI-366083, EBI-1046789; CC P04637; P49757: NUMB; NbExp=5; IntAct=EBI-366083, EBI-915016; CC P04637; Q96FW1: OTUB1; NbExp=8; IntAct=EBI-366083, EBI-1058491; CC P04637; Q8TEW0: PARD3; NbExp=3; IntAct=EBI-366083, EBI-81968; CC P04637; P09874: PARP1; NbExp=5; IntAct=EBI-366083, EBI-355676; CC P04637; Q96KB5: PBK; NbExp=7; IntAct=EBI-366083, EBI-536853; CC P04637; Q7Z412: PEX26; NbExp=3; IntAct=EBI-366083, EBI-752057; CC P04637; P35232: PHB1; NbExp=6; IntAct=EBI-366083, EBI-354213; CC P04637; O75925: PIAS1; NbExp=4; IntAct=EBI-366083, EBI-629434; CC P04637; Q8N2W9: PIAS4; NbExp=2; IntAct=EBI-366083, EBI-473160; CC P04637; Q92569: PIK3R3; NbExp=5; IntAct=EBI-366083, EBI-79893; CC P04637; Q13526: PIN1; NbExp=14; IntAct=EBI-366083, EBI-714158; CC P04637; P53350: PLK1; NbExp=6; IntAct=EBI-366083, EBI-476768; CC P04637; P29590: PML; NbExp=4; IntAct=EBI-366083, EBI-295890; CC P04637; A0A6Q8PF08: PMP22; NbExp=3; IntAct=EBI-366083, EBI-50433196; CC P04637; P30405: PPIF; NbExp=4; IntAct=EBI-366083, EBI-5544229; CC P04637; P36873-1: PPP1CC; NbExp=2; IntAct=EBI-366083, EBI-356289; CC P04637; Q8WUF5: PPP1R13L; NbExp=12; IntAct=EBI-366083, EBI-5550163; CC P04637; P30153: PPP2R1A; NbExp=3; IntAct=EBI-366083, EBI-302388; CC P04637; Q13362: PPP2R5C; NbExp=4; IntAct=EBI-366083, EBI-1266156; CC P04637; O43741: PRKAB2; NbExp=3; IntAct=EBI-366083, EBI-1053424; CC P04637; Q05655: PRKCD; NbExp=4; IntAct=EBI-366083, EBI-704279; CC P04637; P61289: PSME3; NbExp=7; IntAct=EBI-366083, EBI-355546; CC P04637; Q05397: PTK2; NbExp=13; IntAct=EBI-366083, EBI-702142; CC P04637; Q06609: RAD51; NbExp=2; IntAct=EBI-366083, EBI-297202; CC P04637; Q06330: RBPJ; NbExp=5; IntAct=EBI-366083, EBI-632552; CC P04637; Q96PM5: RCHY1; NbExp=13; IntAct=EBI-366083, EBI-947779; CC P04637; Q6PCD5: RFWD3; NbExp=5; IntAct=EBI-366083, EBI-2129159; CC P04637; Q06587: RING1; NbExp=7; IntAct=EBI-366083, EBI-752313; CC P04637; P23396: RPS3; NbExp=4; IntAct=EBI-366083, EBI-351193; CC P04637; Q9Y265: RUVBL1; NbExp=10; IntAct=EBI-366083, EBI-353675; CC P04637; Q8N488: RYBP; NbExp=4; IntAct=EBI-366083, EBI-752324; CC P04637; P23297: S100A1; NbExp=3; IntAct=EBI-366083, EBI-743686; CC P04637; P31949: S100A11; NbExp=2; IntAct=EBI-366083, EBI-701862; CC P04637; P29034: S100A2; NbExp=4; IntAct=EBI-366083, EBI-752230; CC P04637; P33764: S100A3; NbExp=2; IntAct=EBI-366083, EBI-1044747; CC P04637; P26447: S100A4; NbExp=9; IntAct=EBI-366083, EBI-717058; CC P04637; P33763: S100A5; NbExp=2; IntAct=EBI-366083, EBI-7211732; CC P04637; P06703: S100A6; NbExp=3; IntAct=EBI-366083, EBI-352877; CC P04637; P04271: S100B; NbExp=3; IntAct=EBI-366083, EBI-458391; CC P04637; P25815: S100P; NbExp=2; IntAct=EBI-366083, EBI-743700; CC P04637; Q15424: SAFB; NbExp=5; IntAct=EBI-366083, EBI-348298; CC P04637; Q8WTS6: SETD7; NbExp=11; IntAct=EBI-366083, EBI-1268586; CC P04637; P31947: SFN; NbExp=5; IntAct=EBI-366083, EBI-476295; CC P04637; Q96ST3: SIN3A; NbExp=2; IntAct=EBI-366083, EBI-347218; CC P04637; Q96EB6: SIRT1; NbExp=18; IntAct=EBI-366083, EBI-1802965; CC P04637; Q15796: SMAD2; NbExp=7; IntAct=EBI-366083, EBI-1040141; CC P04637; Q9NRG4: SMYD2; NbExp=6; IntAct=EBI-366083, EBI-1055671; CC P04637; O95863: SNAI1; NbExp=2; IntAct=EBI-366083, EBI-1045459; CC P04637; Q06945: SOX4; NbExp=4; IntAct=EBI-366083, EBI-6672525; CC P04637; P08047: SP1; NbExp=6; IntAct=EBI-366083, EBI-298336; CC P04637; Q12772: SREBF2; NbExp=3; IntAct=EBI-366083, EBI-465059; CC P04637; Q96SB4: SRPK1; NbExp=3; IntAct=EBI-366083, EBI-539478; CC P04637; P31948: STIP1; NbExp=4; IntAct=EBI-366083, EBI-1054052; CC P04637; P63165: SUMO1; NbExp=3; IntAct=EBI-366083, EBI-80140; CC P04637; Q86TM6: SYVN1; NbExp=5; IntAct=EBI-366083, EBI-947849; CC P04637; Q9HBM6: TAF9B; NbExp=2; IntAct=EBI-366083, EBI-751601; CC P04637; P20226: TBP; NbExp=2; IntAct=EBI-366083, EBI-355371; CC P04637; P15884: TCF4; NbExp=2; IntAct=EBI-366083, EBI-533224; CC P04637; Q96GM8: TOE1; NbExp=3; IntAct=EBI-366083, EBI-717460; CC P04637; P04637: TP53; NbExp=34; IntAct=EBI-366083, EBI-366083; CC P04637; Q12888: TP53BP1; NbExp=8; IntAct=EBI-366083, EBI-396540; CC P04637; Q12888-1: TP53BP1; NbExp=17; IntAct=EBI-366083, EBI-8022649; CC P04637; Q13625: TP53BP2; NbExp=9; IntAct=EBI-366083, EBI-77642; CC P04637; Q9H3D4: TP63; NbExp=5; IntAct=EBI-366083, EBI-2337775; CC P04637; P13693: TPT1; NbExp=7; IntAct=EBI-366083, EBI-1783169; CC P04637; O15164: TRIM24; NbExp=3; IntAct=EBI-366083, EBI-2130378; CC P04637; Q15672: TWIST1; NbExp=10; IntAct=EBI-366083, EBI-1797287; CC P04637; P0CG48: UBC; NbExp=15; IntAct=EBI-366083, EBI-3390054; CC P04637; P63279: UBE2I; NbExp=5; IntAct=EBI-366083, EBI-80168; CC P04637; Q05086: UBE3A; NbExp=6; IntAct=EBI-366083, EBI-954357; CC P04637; P09936: UCHL1; NbExp=3; IntAct=EBI-366083, EBI-714860; CC P04637; Q96PU4: UHRF2; NbExp=3; IntAct=EBI-366083, EBI-625304; CC P04637; Q9H9J4: USP42; NbExp=2; IntAct=EBI-366083, EBI-2513638; CC P04637; Q9H9J4-2: USP42; NbExp=2; IntAct=EBI-366083, EBI-9118105; CC P04637; Q93009: USP7; NbExp=23; IntAct=EBI-366083, EBI-302474; CC P04637; P11473: VDR; NbExp=6; IntAct=EBI-366083, EBI-286357; CC P04637; Q99986: VRK1; NbExp=11; IntAct=EBI-366083, EBI-1769146; CC P04637; Q14191: WRN; NbExp=5; IntAct=EBI-366083, EBI-368417; CC P04637; Q9NZC7: WWOX; NbExp=2; IntAct=EBI-366083, EBI-4320739; CC P04637; O14980: XPO1; NbExp=3; IntAct=EBI-366083, EBI-355867; CC P04637; P12956: XRCC6; NbExp=2; IntAct=EBI-366083, EBI-353208; CC P04637; P61981: YWHAG; NbExp=5; IntAct=EBI-366083, EBI-359832; CC P04637; P63104: YWHAZ; NbExp=3; IntAct=EBI-366083, EBI-347088; CC P04637; Q8TAQ5: ZNF420; NbExp=4; IntAct=EBI-366083, EBI-3923307; CC P04637; Q7L7W2; NbExp=2; IntAct=EBI-366083, EBI-7210801; CC P04637; P29066: Arrb1; Xeno; NbExp=3; IntAct=EBI-366083, EBI-4303019; CC P04637; Q9ESJ1: Cables1; Xeno; NbExp=3; IntAct=EBI-366083, EBI-604411; CC P04637; P45481: Crebbp; Xeno; NbExp=10; IntAct=EBI-366083, EBI-296306; CC P04637; P03120: E2; Xeno; NbExp=3; IntAct=EBI-366083, EBI-1779322; CC P04637; P03126: E6; Xeno; NbExp=5; IntAct=EBI-366083, EBI-1177242; CC P04637; P04019: E6; Xeno; NbExp=2; IntAct=EBI-366083, EBI-1177232; CC P04637; P06463: E6; Xeno; NbExp=5; IntAct=EBI-366083, EBI-1186926; CC P04637; P02829: HSP82; Xeno; NbExp=8; IntAct=EBI-366083, EBI-8659; CC P04637; Q08619: Ifi205b; Xeno; NbExp=2; IntAct=EBI-366083, EBI-8064290; CC P04637; P89055: NSP1; Xeno; NbExp=6; IntAct=EBI-366083, EBI-9522973; CC P04637; Q923E4: Sirt1; Xeno; NbExp=4; IntAct=EBI-366083, EBI-1802585; CC P04637; Q8R5A0: Smyd2; Xeno; NbExp=3; IntAct=EBI-366083, EBI-15612527; CC P04637; P32776: TFB1; Xeno; NbExp=7; IntAct=EBI-366083, EBI-19146; CC P04637; O88898: Tp63; Xeno; NbExp=2; IntAct=EBI-366083, EBI-2338025; CC P04637; P26687: Twist1; Xeno; NbExp=4; IntAct=EBI-366083, EBI-6123119; CC P04637; Q9PST7: znf585b.S; Xeno; NbExp=3; IntAct=EBI-366083, EBI-1782562; CC P04637; P03070; Xeno; NbExp=25; IntAct=EBI-366083, EBI-617698; CC P04637; PRO_0000037536 [P26663]; Xeno; NbExp=9; IntAct=EBI-366083, EBI-6838571; CC P04637; Q8QW27; Xeno; NbExp=2; IntAct=EBI-366083, EBI-6863726; CC P04637-1; P17844: DDX5; NbExp=2; IntAct=EBI-3895849, EBI-351962; CC P04637-1; P55209: NAP1L1; NbExp=2; IntAct=EBI-3895849, EBI-356392; CC P04637-1; P03126: E6; Xeno; NbExp=2; IntAct=EBI-3895849, EBI-1177242; CC P04637-7; P17844: DDX5; NbExp=2; IntAct=EBI-3895873, EBI-351962; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15340061, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:19033443, ECO:0000269|PubMed:21597459, CC ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:24625977, CC ECO:0000269|PubMed:26634371}. Nucleus {ECO:0000269|PubMed:15340061, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17591690, CC ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:21597459, ECO:0000269|PubMed:24625977, CC ECO:0000269|PubMed:26634371}. Nucleus, PML body CC {ECO:0000269|PubMed:11025664, ECO:0000269|PubMed:12810724, CC ECO:0000269|PubMed:36108750}. Endoplasmic reticulum CC {ECO:0000269|PubMed:17170702}. Mitochondrion matrix CC {ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:25168243, CC ECO:0000269|PubMed:27323408}. Cytoplasm, cytoskeleton, microtubule CC organizing center, centrosome {ECO:0000269|PubMed:28842590}. CC Note=Recruited into PML bodies together with CHEK2 (PubMed:12810724). CC Translocates to mitochondria upon oxidative stress (PubMed:22726440). CC Translocates to mitochondria in response to mitomycin C treatment CC (PubMed:27323408). Competitive inhibition of TP53 interaction with CC HSPA9/MOT-2 by UBXN2A results in increased protein abundance and CC subsequent translocation of TP53 to the nucleus (PubMed:24625977). CC {ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:22726440, CC ECO:0000269|PubMed:24625977, ECO:0000269|PubMed:27323408}. CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Nucleus CC {ECO:0000269|PubMed:23752197}. Cytoplasm. Note=Predominantly nuclear CC but localizes to the cytoplasm when expressed with isoform 4. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus. Cytoplasm. Note=Localized CC mainly in the nucleus with minor staining in the cytoplasm. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Nucleus. Cytoplasm. Note=Localized CC in the nucleus in most cells but found in the cytoplasm in some cells. CC -!- SUBCELLULAR LOCATION: [Isoform 4]: Nucleus. Cytoplasm. CC Note=Predominantly nuclear but translocates to the cytoplasm following CC cell stress. CC -!- SUBCELLULAR LOCATION: [Isoform 7]: Nucleus. Cytoplasm. Note=Localized CC mainly in the nucleus with minor staining in the cytoplasm. CC -!- SUBCELLULAR LOCATION: [Isoform 8]: Nucleus. Cytoplasm. Note=Localized CC in both nucleus and cytoplasm in most cells. In some cells, forms foci CC in the nucleus that are different from nucleoli. CC -!- SUBCELLULAR LOCATION: [Isoform 9]: Cytoplasm. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage, Alternative splicing; Named isoforms=9; CC Name=1; Synonyms=p53, p53alpha; CC IsoId=P04637-1; Sequence=Displayed; CC Name=2; Synonyms=I9RET, p53beta; CC IsoId=P04637-2; Sequence=VSP_006535, VSP_006536; CC Name=3; Synonyms=p53gamma; CC IsoId=P04637-3; Sequence=VSP_040560, VSP_040561; CC Name=4; Synonyms=Del40-p53, Del40-p53alpha, p47; CC IsoId=P04637-4; Sequence=VSP_040832; CC Name=5; Synonyms=Del40-p53beta; CC IsoId=P04637-5; Sequence=VSP_040832, VSP_006535, VSP_006536; CC Name=6; Synonyms=Del40-p53gamma; CC IsoId=P04637-6; Sequence=VSP_040832, VSP_040560, VSP_040561; CC Name=7; Synonyms=Del133-p53, Del133-p53alpha; CC IsoId=P04637-7; Sequence=VSP_040833; CC Name=8; Synonyms=Del133-p53beta; CC IsoId=P04637-8; Sequence=VSP_040833, VSP_006535, VSP_006536; CC Name=9; Synonyms=Del133-p53gamma; CC IsoId=P04637-9; Sequence=VSP_040833, VSP_040560, VSP_040561; CC -!- TISSUE SPECIFICITY: Ubiquitous. Isoforms are expressed in a wide range CC of normal tissues but in a tissue-dependent manner. Isoform 2 is CC expressed in most normal tissues but is not detected in brain, lung, CC prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3 CC is expressed in most normal tissues but is not detected in lung, CC spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is CC expressed in most normal tissues but is not detected in prostate, CC uterus, skeletal muscle and breast. Isoform 8 is detected only in CC colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is CC expressed in most normal tissues but is not detected in brain, heart, CC lung, fetal liver, salivary gland, breast or intestine. CC {ECO:0000269|PubMed:16131611}. CC -!- INDUCTION: Up-regulated in response to DNA damage. Isoform 2 is not CC induced in tumor cells in response to stress. CC {ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:16131611}. CC -!- DOMAIN: The N-terminal and C-terminal disordered regions undergo CC liquid-liquid phase separation (LLPS) following homotetramerization and CC activation (PubMed:31953488, PubMed:35618207, PubMed:36108750, CC PubMed:36634798, PubMed:38653238). Post-translational modifications, CC such as phosphorylation or lactylation affect the ability to undergo CC LLPS (PubMed:31953488, PubMed:35618207, PubMed:36634798, CC PubMed:38653238). {ECO:0000269|PubMed:31953488, CC ECO:0000269|PubMed:35618207, ECO:0000269|PubMed:36108750, CC ECO:0000269|PubMed:36634798, ECO:0000269|PubMed:38653238}. CC -!- DOMAIN: The nuclear export signal acts as a transcriptional repression CC domain. The TADI and TADII motifs (residues 17 to 25 and 48 to 56) CC correspond both to 9aaTAD motifs which are transactivation domains CC present in a large number of yeast and animal transcription factors. CC {ECO:0000269|PubMed:17467953}. CC -!- PTM: Acetylation of Lys-382 by CREBBP enhances transcriptional activity CC (PubMed:10656795, PubMed:15448695, PubMed:20228809, PubMed:23431171). CC Acetylation of Lys-382 by EP300 (PubMed:10656795, PubMed:15448695, CC PubMed:20228809, PubMed:23431171). Deacetylation of Lys-382 by SIRT1 CC impairs its ability to induce proapoptotic program and modulate cell CC senescence (PubMed:10656795, PubMed:15448695, PubMed:20228809, CC PubMed:23431171). Deacetylation by SIRT2 impairs its ability to induce CC transcription activation in a AKT-dependent manner (PubMed:10656795, CC PubMed:15448695, PubMed:20228809, PubMed:23431171, PubMed:29681526). CC Acetylation at Lys-381 increases stability (PubMed:29474172). CC Deacetylation at Lys-381 by SIRT6 decreases its stability, thereby CC regulating cell senescence (PubMed:29474172). Acetylated at Lys-120 by CC KAT5, KAT6A and KAT8; regulating its ability to induce proapoptotic CC program (PubMed:17189187, PubMed:19854137, PubMed:23431171). CC {ECO:0000269|PubMed:10656795, ECO:0000269|PubMed:15448695, CC ECO:0000269|PubMed:17189187, ECO:0000269|PubMed:19854137, CC ECO:0000269|PubMed:20228809, ECO:0000269|PubMed:23431171, CC ECO:0000269|PubMed:29474172, ECO:0000269|PubMed:29681526}. CC -!- PTM: Lactylation by AARS1 prevents ability to undergo liquid-liquid CC phase separation (LLPS), thereby inhibiting transcription factor CC activity. {ECO:0000269|PubMed:38653238}. CC -!- PTM: Phosphorylation on Ser residues mediates transcriptional CC activation. Phosphorylated by HIPK1 (By similarity). Phosphorylation at CC Ser-9 by HIPK4 increases repression activity on BIRC5 promoter. CC Phosphorylated on Thr-18 by VRK1, which may prevent the interaction CC with MDM2 (PubMed:10951572, PubMed:31527692). Phosphorylated on Ser-20 CC by CHEK2 in response to DNA damage, which prevents ubiquitination by CC MDM2. Phosphorylated on Ser-20 by PLK3 in response to reactive oxygen CC species (ROS), promoting p53/TP53-mediated apoptosis. Phosphorylated on CC Thr-55 by TAF1, which promotes MDM2-mediated degradation. CC Phosphorylated on Ser-33 by CDK7 in a CAK complex in response to DNA CC damage. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. CC Phosphorylation on Ser-46 is required for acetylation by CREBBP. CC Phosphorylated on Ser-392 following UV but not gamma irradiation. CC Phosphorylated by NUAK1 at Ser-15 and Ser-392; was initially thought to CC be mediated by STK11/LKB1 but it was later shown that it is indirect CC and that STK11/LKB1-dependent phosphorylation is probably mediated by CC downstream NUAK1 (PubMed:21317932). It is unclear whether AMP directly CC mediates phosphorylation at Ser-15. Phosphorylated on Thr-18 by isoform CC 1 and isoform 2 of VRK2. Phosphorylation on Thr-18 by isoform 2 of VRK2 CC results in a reduction in ubiquitination by MDM2 and an increase in CC acetylation by EP300. Stabilized by CDK5-mediated phosphorylation in CC response to genotoxic and oxidative stresses at Ser-15, Ser-33 and Ser- CC 46, leading to accumulation of p53/TP53, particularly in the nucleus, CC thus inducing the transactivation of p53/TP53 target genes. CC Phosphorylated by DYRK2 at Ser-46 in response to genotoxic stress. CC Phosphorylated at Ser-315 and Ser-392 by CDK2 in response to DNA- CC damage. Phosphorylation at Ser-15 is required for interaction with CC DDX3X and gamma-tubulin (PubMed:28842590). Phosphorylation at Ser-392 CC regulates its ability to undergo liquid-liquid phase separation by CC increasing fluidity of TP53/p53 condensates (PubMed:35618207). CC {ECO:0000250, ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:10606744, CC ECO:0000269|PubMed:10884347, ECO:0000269|PubMed:10951572, CC ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:11447225, CC ECO:0000269|PubMed:11546806, ECO:0000269|PubMed:11551930, CC ECO:0000269|PubMed:11554766, ECO:0000269|PubMed:11740489, CC ECO:0000269|PubMed:11780126, ECO:0000269|PubMed:12810724, CC ECO:0000269|PubMed:14702041, ECO:0000269|PubMed:15053879, CC ECO:0000269|PubMed:15866171, ECO:0000269|PubMed:16377624, CC ECO:0000269|PubMed:16704422, ECO:0000269|PubMed:1705009, CC ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:17254968, CC ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:17591690, CC ECO:0000269|PubMed:17967874, ECO:0000269|PubMed:18022393, CC ECO:0000269|PubMed:20041275, ECO:0000269|PubMed:20124405, CC ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:21317932, CC ECO:0000269|PubMed:2141171, ECO:0000269|PubMed:22214662, CC ECO:0000269|PubMed:28842590, ECO:0000269|PubMed:31527692, CC ECO:0000269|PubMed:9372954}. CC -!- PTM: Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small CC T antigen inhibits the dephosphorylation by the AC form of PP2A. CC -!- PTM: May be O-glycosylated in the C-terminal basic region. Studied in CC EB-1 cell line. {ECO:0000269|PubMed:8632915}. CC -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal CC degradation (PubMed:10722742, PubMed:12810724, PubMed:15340061, CC PubMed:17170702, PubMed:19880522, PubMed:29681526). Ubiquitinated by CC RFWD3, which works in cooperation with MDM2 and may catalyze the CC formation of short polyubiquitin chains on p53/TP53 that are not CC targeted to the proteasome (PubMed:10722742, PubMed:12810724, CC PubMed:20173098). Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which CC leads to proteasomal degradation (PubMed:19536131). Deubiquitinated by CC USP10, leading to its stabilization (PubMed:20096447). Ubiquitinated by CC TRIM24, RFFL, RNF34 and RNF125, which leads to proteasomal degradation CC (PubMed:19556538). Ubiquitination by TOPORS induces degradation CC (PubMed:19473992). Deubiquitination by USP7, leading to stabilization CC (PubMed:15053880). Isoform 4 is monoubiquitinated in an MDM2- CC independent manner (PubMed:15340061). Ubiquitinated by COP1, which CC leads to proteasomal degradation (PubMed:19837670). Ubiquitination and CC subsequent proteasomal degradation is negatively regulated by CCAR2 CC (PubMed:25732823). Polyubiquitinated by C10orf90/FATS, CC polyubiquitination is 'Lys-48'-linkage independent and non-proteolytic, CC leading to TP53 stabilization (By similarity). Polyubiquitinated by CC MUL1 at Lys-24 which leads to proteasomal degradation CC (PubMed:21597459). Deubiquitinated by USP3, leading to stabilization CC (PubMed:28807825). Ubiquitinated by MSL2, promoting its cytoplasmic CC localization (PubMed:19033443). Also ubiquitinated by the SCF(FBXO22)- CC KDMA4A complex; leading to proteasomal degradation (PubMed:26868148). CC {ECO:0000250|UniProtKB:P02340, ECO:0000269|PubMed:10722742, CC ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:15053880, CC ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:17170702, CC ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19033443, CC ECO:0000269|PubMed:19473992, ECO:0000269|PubMed:19536131, CC ECO:0000269|PubMed:19556538, ECO:0000269|PubMed:19837670, CC ECO:0000269|PubMed:19880522, ECO:0000269|PubMed:20096447, CC ECO:0000269|PubMed:20173098, ECO:0000269|PubMed:21597459, CC ECO:0000269|PubMed:25591766, ECO:0000269|PubMed:25732823, CC ECO:0000269|PubMed:26868148, ECO:0000269|PubMed:28807825, CC ECO:0000269|PubMed:29681526}. CC -!- PTM: Monomethylated at Lys-372 by SETD7, leading to stabilization and CC increased transcriptional activation (PubMed:15525938, CC PubMed:16415881). Monomethylated at Lys-370 by SMYD2, leading to CC decreased DNA-binding activity and subsequent transcriptional CC regulation activity (PubMed:17108971). Lys-372 monomethylation prevents CC interaction with SMYD2 and subsequent monomethylation at Lys-370 CC (PubMed:17108971). Dimethylated at Lys-373 by EHMT1 and EHMT2 CC (PubMed:20118233). Monomethylated at Lys-382 by KMT5A, promoting CC interaction with L3MBTL1 and leading to repress transcriptional CC activity (PubMed:17707234). Dimethylation at Lys-370 and Lys-382 CC diminishes p53 ubiquitination, through stabilizing association with the CC methyl reader PHF20 (PubMed:22864287). Demethylation of dimethylated CC Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53- CC mediated transcriptional activation (PubMed:17805299). Monomethylated CC at Arg-333 and dimethylated at Arg-335 and Arg-337 by PRMT5; CC methylation is increased after DNA damage and might possibly affect CC TP53 target gene specificity (PubMed:19011621). CC {ECO:0000269|PubMed:15525938, ECO:0000269|PubMed:16415881, CC ECO:0000269|PubMed:17108971, ECO:0000269|PubMed:17707234, CC ECO:0000269|PubMed:17805299, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:20118233, ECO:0000269|PubMed:22864287}. CC -!- PTM: Sumoylated with SUMO1. Sumoylated at Lys-386 by UBC9. CC {ECO:0000269|PubMed:11124955, ECO:0000269|PubMed:22214662, CC ECO:0000269|Ref.37}. CC -!- DISEASE: Note=TP53 is found in increased amounts in a wide variety of CC transformed cells. TP53 is frequently mutated or inactivated in about CC 60% of cancers. TP53 defects are found in Barrett metaplasia a CC condition in which the normally stratified squamous epithelium of the CC lower esophagus is replaced by a metaplastic columnar epithelium. The CC condition develops as a complication in approximately 10% of patients CC with chronic gastroesophageal reflux disease and predisposes to the CC development of esophageal adenocarcinoma. CC -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the CC esophagus. The most common types are esophageal squamous cell carcinoma CC and adenocarcinoma. Cancer of the esophagus remains a devastating CC disease because it is usually not detected until it has progressed to CC an advanced incurable stage. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Li-Fraumeni syndrome (LFS) [MIM:151623]: An autosomal dominant CC familial cancer syndrome that in its classic form is defined by the CC existence of a proband affected by a sarcoma before 45 years with a CC first degree relative affected by any tumor before 45 years and another CC first degree relative with any tumor before 45 years or a sarcoma at CC any age. Other clinical definitions for LFS have been proposed and CC called Li-Fraumeni like syndrome (LFL). In these families affected CC relatives develop a diverse set of malignancies at unusually early CC ages. Four types of cancers account for 80% of tumors occurring in TP53 CC germline mutation carriers: breast cancers, soft tissue and bone CC sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. CC Less frequent tumors include choroid plexus carcinoma or papilloma CC before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, CC Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers. CC {ECO:0000269|PubMed:10484981, ECO:0000269|PubMed:1565144, CC ECO:0000269|PubMed:1737852, ECO:0000269|PubMed:1933902, CC ECO:0000269|PubMed:1978757, ECO:0000269|PubMed:2259385, CC ECO:0000269|PubMed:36108750, ECO:0000269|PubMed:7887414, CC ECO:0000269|PubMed:8825920, ECO:0000269|PubMed:9452042}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) CC [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. CC The hallmark of cutaneous SCC is malignant transformation of normal CC epidermal keratinocytes. Note=The gene represented in this entry is CC involved in disease pathogenesis. CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting CC tissues of the lung. The most common form of lung cancer is non-small CC cell lung cancer (NSCLC) that can be divided into 3 major histologic CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor CC prognosis. Note=The disease is caused by variants affecting the gene CC represented in this entry. CC -!- DISEASE: Papilloma of choroid plexus (CPP) [MIM:260500]: A benign tumor CC of neuroectodermal origin that generally occurs in childhood, but has CC also been reported in adults. Although generally found within the CC ventricular system, choroid plexus papillomas can arise ectopically in CC the brain parenchyma or disseminate throughout the neuraxis. Patients CC present with signs and symptoms of increased intracranial pressure CC including headache, hydrocephalus, papilledema, nausea, vomiting, CC cranial nerve deficits, gait impairment, and seizures. CC {ECO:0000269|PubMed:12085209}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Adrenocortical carcinoma (ADCC) [MIM:202300]: A malignant CC neoplasm of the adrenal cortex and a rare childhood tumor. It occurs CC with increased frequency in patients with Beckwith-Wiedemann syndrome CC and Li-Fraumeni syndrome. {ECO:0000269|PubMed:11481490}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Basal cell carcinoma 7 (BCC7) [MIM:614740]: A common malignant CC skin neoplasm that typically appears on hair-bearing skin, most CC commonly on sun-exposed areas. It is slow growing and rarely CC metastasizes, but has potentialities for local invasion and CC destruction. It usually develops as a flat, firm, pale area that is CC small, raised, pink or red, translucent, shiny, and waxy, and the area CC may bleed following minor injury. Tumor size can vary from a few CC millimeters to several centimeters in diameter. CC {ECO:0000269|PubMed:21946351}. Note=Disease susceptibility is CC associated with variants affecting the gene represented in this entry. CC -!- DISEASE: Bone marrow failure syndrome 5 (BMFS5) [MIM:618165]: A form of CC bone marrow failure syndrome, a heterogeneous group of life-threatening CC disorders characterized by hematopoietic defects in association with a CC range of variable extra-hematopoietic manifestations. BMFS5 is an CC autosomal dominant form characterized by infantile onset of severe red CC cell anemia requiring transfusion. Additional features include CC hypogammaglobulinemia, poor growth with microcephaly, developmental CC delay, and seizures. {ECO:0000269|PubMed:30146126}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform 2]: Expressed in quiescent lymphocytes. Seems CC to be non-functional. May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 3]: Expressed in quiescent lymphocytes. Seems CC to be non-functional. May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 7]: Produced by alternative promoter usage. CC {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 8]: Produced by alternative promoter usage and CC alternative splicing. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 9]: Produced by alternative promoter usage and CC alternative splicing. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}. CC -!- CAUTION: Interaction with BANP was reported to enhance phosphorylation CC on Ser-15 upon ultraviolet irradiation (PubMed:15701641). However, the CC publication has been retracted due to image duplication and CC manipulation. Interaction with BANP has been confirmed in mouse studies CC (By similarity). Phosphorylation at Ser-15 has been confirmed by other CC studies (PubMed:10570149, PubMed:11554766, PubMed:15866171, CC PubMed:16219768, PubMed:17317671, PubMed:17954561, PubMed:20959462, CC PubMed:25772236). Its nuclear and cytoplasmic localization has been CC confirmed by other studies (PubMed:15340061, PubMed:17170702, CC PubMed:17591690, PubMed:18206965, PubMed:19011621, PubMed:21597459, CC PubMed:22726440). {ECO:0000250|UniProtKB:P02340, CC ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:11554766, CC ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:15701641, CC ECO:0000269|PubMed:15866171, ECO:0000269|PubMed:16219768, CC ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17317671, CC ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17954561, CC ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19011621, CC ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:21597459, CC ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:25772236, CC ECO:0000305|PubMed:32144153}. CC -!- WEB RESOURCE: Name=The TP53 Database; CC URL="https://tp53.cancer.gov/"; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/88/P53"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=P53 entry; CC URL="https://en.wikipedia.org/wiki/P53"; CC -!- WEB RESOURCE: Name=Protein Spotlight; Note=On the right track - Issue CC 206 of August 2018; CC URL="https://www.proteinspotlight.org/back_issues/206/"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X02469; CAA26306.1; -; mRNA. DR EMBL; M13121; AAA59987.1; -; Genomic_DNA. DR EMBL; M13112; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13113; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13114; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13115; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13116; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13117; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13118; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13119; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; M13120; AAA59987.1; JOINED; Genomic_DNA. DR EMBL; K03199; AAA59989.1; -; mRNA. DR EMBL; M14694; AAA61211.1; -; mRNA. DR EMBL; M14695; AAA61212.1; -; mRNA. DR EMBL; M22898; AAA59988.1; -; Genomic_DNA. DR EMBL; M22882; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22883; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22884; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22887; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22888; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22894; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22895; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22896; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; M22897; AAA59988.1; JOINED; Genomic_DNA. DR EMBL; X01405; CAA25652.1; -; mRNA. DR EMBL; X60011; CAA42626.1; -; mRNA. DR EMBL; X60012; CAA42627.1; ALT_TERM; mRNA. DR EMBL; X60013; CAA42628.1; -; mRNA. DR EMBL; X60014; CAA42629.1; -; mRNA. DR EMBL; X60015; CAA42630.1; -; mRNA. DR EMBL; X60016; CAA42631.1; -; mRNA. DR EMBL; X60017; CAA42632.1; -; mRNA. DR EMBL; X60018; CAA42633.1; -; mRNA. DR EMBL; X60019; CAA42634.1; -; mRNA. DR EMBL; X60020; CAA42635.1; -; mRNA. DR EMBL; AF307851; AAG28785.1; -; mRNA. DR EMBL; DQ186648; ABA29753.1; -; mRNA. DR EMBL; DQ186649; ABA29754.1; -; mRNA. DR EMBL; DQ186650; ABA29755.1; -; mRNA. DR EMBL; DQ186651; ABA29756.1; -; mRNA. DR EMBL; DQ186652; ABA29757.1; -; mRNA. DR EMBL; DQ191317; ABB80262.1; -; mRNA. DR EMBL; DQ286964; ABB80266.1; -; mRNA. DR EMBL; X54156; CAA38095.1; -; Genomic_DNA. DR EMBL; U94788; AAC12971.1; -; Genomic_DNA. DR EMBL; AY838896; AAV80424.1; -; Genomic_DNA. DR EMBL; AF135121; AAD28535.1; -; Genomic_DNA. DR EMBL; AF135120; AAD28535.1; JOINED; Genomic_DNA. DR EMBL; AF136271; AAD28628.1; -; Genomic_DNA. DR EMBL; AF136270; AAD28628.1; JOINED; Genomic_DNA. DR EMBL; AB082923; BAC16799.1; -; mRNA. DR EMBL; AK312568; BAG35463.1; -; mRNA. DR EMBL; AC007421; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC087388; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471108; EAW90143.1; -; Genomic_DNA. DR EMBL; CH471108; EAW90144.1; -; Genomic_DNA. DR EMBL; BC003596; AAH03596.1; -; mRNA. DR EMBL; AY429684; AAR10356.1; -; mRNA. DR EMBL; AY390341; AAQ90158.1; -; Genomic_DNA. DR EMBL; AY359814; AAR13239.1; -; Genomic_DNA. DR EMBL; U63714; AAB39322.1; -; Genomic_DNA. DR EMBL; AF209136; AAF36362.1; -; Genomic_DNA. DR EMBL; AF209128; AAF36354.1; -; Genomic_DNA. DR EMBL; AF209129; AAF36355.1; -; Genomic_DNA. DR EMBL; AF209130; AAF36356.1; -; Genomic_DNA. DR EMBL; AF209131; AAF36357.1; -; Genomic_DNA. DR EMBL; AF209132; AAF36358.1; -; Genomic_DNA. DR EMBL; AF209133; AAF36359.1; -; Genomic_DNA. DR EMBL; AF209134; AAF36360.1; -; Genomic_DNA. DR EMBL; AF209135; AAF36361.1; -; Genomic_DNA. DR EMBL; AF209148; AAF36374.1; -; Genomic_DNA. DR EMBL; AF209149; AAF36375.1; -; Genomic_DNA. DR EMBL; AF209150; AAF36376.1; -; Genomic_DNA. DR EMBL; AF209151; AAF36377.1; -; Genomic_DNA. DR EMBL; AF209152; AAF36378.1; -; Genomic_DNA. DR EMBL; AF209153; AAF36379.1; -; Genomic_DNA. DR EMBL; AF209154; AAF36380.1; -; Genomic_DNA. DR EMBL; AF209155; AAF36381.1; -; Genomic_DNA. DR EMBL; AF209156; AAF36382.1; -; Genomic_DNA. DR EMBL; AF210309; AAF63442.1; -; Genomic_DNA. DR EMBL; AF210308; AAF63442.1; JOINED; Genomic_DNA. DR EMBL; AF210310; AAF63443.1; -; Genomic_DNA. DR EMBL; AF240684; AAK76358.1; -; Genomic_DNA. DR EMBL; AF240685; AAK76359.1; -; Genomic_DNA. DR EMBL; AY270155; AAP30003.1; -; Genomic_DNA. DR CCDS; CCDS11118.1; -. [P04637-1] DR CCDS; CCDS45605.1; -. [P04637-3] DR CCDS; CCDS45606.1; -. [P04637-2] DR CCDS; CCDS73966.1; -. [P04637-7] DR CCDS; CCDS73967.1; -. [P04637-9] DR CCDS; CCDS73968.1; -. [P04637-8] DR CCDS; CCDS73969.1; -. [P04637-4] DR CCDS; CCDS73970.1; -. [P04637-6] DR CCDS; CCDS73971.1; -. [P04637-5] DR PIR; A25224; DNHU53. DR RefSeq; NP_000537.3; NM_000546.5. [P04637-1] DR RefSeq; NP_001119584.1; NM_001126112.3. [P04637-1] DR RefSeq; NP_001119585.1; NM_001126113.3. [P04637-3] DR RefSeq; NP_001119586.1; NM_001126114.3. [P04637-2] DR RefSeq; NP_001119587.1; NM_001126115.2. [P04637-7] DR RefSeq; NP_001119588.1; NM_001126116.2. [P04637-8] DR RefSeq; NP_001119589.1; NM_001126117.2. [P04637-9] DR RefSeq; NP_001119590.1; NM_001126118.2. [P04637-4] DR RefSeq; NP_001263624.1; NM_001276695.3. [P04637-6] DR RefSeq; NP_001263625.1; NM_001276696.3. [P04637-5] DR RefSeq; NP_001263626.1; NM_001276697.1. DR RefSeq; NP_001263627.1; NM_001276698.1. DR RefSeq; NP_001263628.1; NM_001276699.1. DR RefSeq; NP_001263689.1; NM_001276760.3. [P04637-4] DR RefSeq; NP_001263690.1; NM_001276761.3. [P04637-4] DR RefSeq; NP_001394191.1; NM_001407262.1. [P04637-1] DR RefSeq; NP_001394192.1; NM_001407263.1. [P04637-4] DR RefSeq; NP_001394193.1; NM_001407264.1. [P04637-1] DR RefSeq; NP_001394194.1; NM_001407265.1. [P04637-4] DR RefSeq; NP_001394195.1; NM_001407266.1. [P04637-1] DR RefSeq; NP_001394196.1; NM_001407267.1. [P04637-4] DR RefSeq; NP_001394197.1; NM_001407268.1. [P04637-2] DR RefSeq; NP_001394198.1; NM_001407269.1. [P04637-5] DR RefSeq; NP_001394199.1; NM_001407270.1. [P04637-2] DR RefSeq; NP_001394200.1; NM_001407271.1. [P04637-5] DR PDB; 1A1U; NMR; -; A/C=324-358. DR PDB; 1AIE; X-ray; 1.50 A; A=326-356. DR PDB; 1C26; X-ray; 1.70 A; A=325-356. DR PDB; 1DT7; NMR; -; X/Y=367-388. DR PDB; 1GZH; X-ray; 2.60 A; A/C=95-292. DR PDB; 1H26; X-ray; 2.24 A; E=376-386. DR PDB; 1HS5; NMR; -; A/B=324-357. DR PDB; 1JSP; NMR; -; A=367-386. DR PDB; 1KZY; X-ray; 2.50 A; A/B=95-289. DR PDB; 1MA3; X-ray; 2.00 A; B=372-389. DR PDB; 1OLG; NMR; -; A/B/C/D=319-360. DR PDB; 1OLH; NMR; -; A/B/C/D=319-360. DR PDB; 1PES; NMR; -; A/B/C/D=325-355. DR PDB; 1PET; NMR; -; A/B/C/D=325-355. DR PDB; 1SAE; NMR; -; A/B/C/D=319-360. DR PDB; 1SAF; NMR; -; A/B/C/D=319-360. DR PDB; 1SAK; NMR; -; A/B/C/D=319-360. DR PDB; 1SAL; NMR; -; A/B/C/D=319-360. DR PDB; 1TSR; X-ray; 2.20 A; A/B/C=94-312. DR PDB; 1TUP; X-ray; 2.20 A; A/B/C=94-312. DR PDB; 1UOL; X-ray; 1.90 A; A/B=94-312. DR PDB; 1XQH; X-ray; 1.75 A; B/F=369-377. DR PDB; 1YC5; X-ray; 1.40 A; B=372-389. DR PDB; 1YCQ; X-ray; 2.30 A; B=13-29. DR PDB; 1YCR; X-ray; 2.60 A; B=15-29. DR PDB; 1YCS; X-ray; 2.20 A; A=94-292. DR PDB; 2AC0; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 2ADY; X-ray; 2.50 A; A/B=94-293. DR PDB; 2AHI; X-ray; 1.85 A; A/B/C/D=94-293. DR PDB; 2ATA; X-ray; 2.20 A; A/B/C/D=94-293. DR PDB; 2B3G; X-ray; 1.60 A; B=33-60. DR PDB; 2BIM; X-ray; 1.98 A; A/B=94-312. DR PDB; 2BIN; X-ray; 1.90 A; A=94-312. DR PDB; 2BIO; X-ray; 1.90 A; A=94-312. DR PDB; 2BIP; X-ray; 1.80 A; A=94-312. DR PDB; 2BIQ; X-ray; 1.80 A; A=94-312. DR PDB; 2F1X; X-ray; 2.30 A; A/B=359-368. DR PDB; 2FEJ; NMR; -; A=94-297. DR PDB; 2FOJ; X-ray; 1.60 A; B=361-367. DR PDB; 2FOO; X-ray; 2.20 A; B=358-363. DR PDB; 2GS0; NMR; -; B=20-73. DR PDB; 2H1L; X-ray; 3.16 A; M/N/O/P/Q/R/S/T/U/V/W/X=92-292. DR PDB; 2H2D; X-ray; 1.70 A; B=372-389. DR PDB; 2H2F; X-ray; 2.20 A; B=372-389. DR PDB; 2H4F; X-ray; 2.00 A; D=372-389. DR PDB; 2H4H; X-ray; 1.99 A; B=372-389. DR PDB; 2H4J; X-ray; 2.10 A; D=372-389. DR PDB; 2H59; X-ray; 1.90 A; D/E=372-389. DR PDB; 2J0Z; NMR; -; A/B/C/D=326-356. DR PDB; 2J10; NMR; -; A/B/C/D=326-356. DR PDB; 2J11; NMR; -; A/B/C/D=326-356. DR PDB; 2J1W; X-ray; 1.80 A; A/B=94-312. DR PDB; 2J1X; X-ray; 1.65 A; A/B=94-312. DR PDB; 2J1Y; X-ray; 1.69 A; A/B/C/D=94-293. DR PDB; 2J1Z; X-ray; 1.80 A; A/B=94-312. DR PDB; 2J20; X-ray; 1.80 A; A/B=94-312. DR PDB; 2J21; X-ray; 1.60 A; A/B=94-312. DR PDB; 2K8F; NMR; -; B=1-39. DR PDB; 2L14; NMR; -; B=13-61. DR PDB; 2LY4; NMR; -; B=1-93. DR PDB; 2MEJ; NMR; -; B=96-312. DR PDB; 2MWO; NMR; -; B=363-377. DR PDB; 2MWP; NMR; -; B=376-387. DR PDB; 2MWY; NMR; -; B=15-29. DR PDB; 2MZD; NMR; -; B=35-59. DR PDB; 2OCJ; X-ray; 2.05 A; A/B/C/D=94-312. DR PDB; 2PCX; X-ray; 1.54 A; A=94-292. DR PDB; 2RUK; NMR; -; A=41-62. DR PDB; 2VUK; X-ray; 1.50 A; A/B=94-312. DR PDB; 2WGX; X-ray; 1.75 A; A/B=94-312. DR PDB; 2X0U; X-ray; 1.60 A; A/B=94-312. DR PDB; 2X0V; X-ray; 1.80 A; A/B=94-312. DR PDB; 2X0W; X-ray; 2.10 A; A/B=94-312. DR PDB; 2XWR; X-ray; 1.68 A; A/B=89-293. DR PDB; 2YBG; X-ray; 1.90 A; A/B/C/D=94-293. DR PDB; 2YDR; X-ray; 2.75 A; P=144-154. DR PDB; 2Z5S; X-ray; 2.30 A; P/Q/R=15-29. DR PDB; 2Z5T; X-ray; 2.30 A; P/Q/R=15-29. DR PDB; 3D05; X-ray; 1.70 A; A=94-293. DR PDB; 3D06; X-ray; 1.20 A; A=94-293. DR PDB; 3D07; X-ray; 2.20 A; A/B=94-293. DR PDB; 3D08; X-ray; 1.40 A; A=94-293. DR PDB; 3D09; X-ray; 1.90 A; A=94-293. DR PDB; 3D0A; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 3DAB; X-ray; 1.90 A; B/D/F/H=15-29. DR PDB; 3DAC; X-ray; 1.80 A; B/P=17-37. DR PDB; 3IGK; X-ray; 1.70 A; A=94-293. DR PDB; 3IGL; X-ray; 1.80 A; A=94-293. DR PDB; 3KMD; X-ray; 2.15 A; A/B/C/D=92-291. DR PDB; 3KZ8; X-ray; 1.91 A; A/B=94-293. DR PDB; 3LW1; X-ray; 1.28 A; P=385-393. DR PDB; 3OQ5; X-ray; 2.50 A; D/E=377-386. DR PDB; 3PDH; X-ray; 1.80 A; D=372-389. DR PDB; 3Q01; X-ray; 2.10 A; A/B=94-356. DR PDB; 3Q05; X-ray; 2.40 A; A/B/C/D=94-356. DR PDB; 3Q06; X-ray; 3.20 A; A/B/C/D=96-354. DR PDB; 3SAK; NMR; -; A/B/C/D=319-360. DR PDB; 3TG5; X-ray; 2.30 A; B=365-375. DR PDB; 3TS8; X-ray; 2.80 A; A/B/C/D=94-356. DR PDB; 3ZME; X-ray; 1.35 A; A/B=94-312. DR PDB; 4AGL; X-ray; 1.70 A; A/B=94-312. DR PDB; 4AGM; X-ray; 1.52 A; A/B=94-312. DR PDB; 4AGN; X-ray; 1.60 A; A/B=94-312. DR PDB; 4AGO; X-ray; 1.45 A; A/B=94-312. DR PDB; 4AGP; X-ray; 1.50 A; A/B=94-312. DR PDB; 4AGQ; X-ray; 1.42 A; A/B=94-312. DR PDB; 4BUZ; X-ray; 1.90 A; P=379-386. DR PDB; 4BV2; X-ray; 3.30 A; E/H=376-388. DR PDB; 4HFZ; X-ray; 2.69 A; B/D=15-29. DR PDB; 4HJE; X-ray; 1.91 A; A/B/C/D=92-291. DR PDB; 4IBQ; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 4IBS; X-ray; 1.78 A; A/B/C/D=94-293. DR PDB; 4IBT; X-ray; 1.70 A; A/B/C/D=94-293. DR PDB; 4IBU; X-ray; 1.70 A; A/B/C/D=94-293. DR PDB; 4IBV; X-ray; 2.10 A; A=94-293. DR PDB; 4IBW; X-ray; 1.79 A; A=94-293. DR PDB; 4IBY; X-ray; 1.45 A; A/B=94-293. DR PDB; 4IBZ; X-ray; 1.92 A; A/B/C/D=94-293. DR PDB; 4IJT; X-ray; 1.78 A; A=94-293. DR PDB; 4KVP; X-ray; 1.50 A; A/B/C/D=94-312. DR PDB; 4LO9; X-ray; 2.50 A; A/B/C/D=94-312. DR PDB; 4LOE; X-ray; 1.85 A; A/B/C/D=94-312. DR PDB; 4LOF; X-ray; 2.00 A; A=94-312. DR PDB; 4MZI; X-ray; 1.25 A; A=94-292. DR PDB; 4MZR; X-ray; 2.90 A; A/B/C/D=94-358. DR PDB; 4QO1; X-ray; 1.92 A; B=92-312. DR PDB; 4RP6; X-ray; 1.70 A; Z=252-258. DR PDB; 4RP7; X-ray; 1.58 A; Z=253-258. DR PDB; 4X34; X-ray; 1.80 A; C/D=377-386. DR PDB; 4XR8; X-ray; 2.25 A; C/D=94-292. DR PDB; 4ZZJ; X-ray; 2.74 A; B=379-383. DR PDB; 5A7B; X-ray; 1.40 A; A/B=94-312. DR PDB; 5AB9; X-ray; 1.36 A; A/B=94-312. DR PDB; 5ABA; X-ray; 1.62 A; A/B=94-312. DR PDB; 5AOI; X-ray; 1.78 A; A/B=94-312. DR PDB; 5AOJ; X-ray; 1.47 A; A/B=94-312. DR PDB; 5AOK; X-ray; 1.35 A; A/B=94-312. DR PDB; 5AOL; X-ray; 1.50 A; A/B=94-312. DR PDB; 5AOM; X-ray; 1.74 A; A/B=94-312. DR PDB; 5BUA; X-ray; 1.81 A; A=94-293. DR PDB; 5ECG; X-ray; 3.00 A; A/B=95-312. DR PDB; 5G4M; X-ray; 1.38 A; A/B=94-312. DR PDB; 5G4N; X-ray; 1.35 A; A/B=94-312. DR PDB; 5G4O; X-ray; 1.48 A; A/B=94-312. DR PDB; 5HOU; NMR; -; A=1-61. DR PDB; 5HP0; NMR; -; A=37-61. DR PDB; 5HPD; NMR; -; A=2-61. DR PDB; 5LAP; X-ray; 1.42 A; A/B=94-312. DR PDB; 5LGY; X-ray; 2.92 A; A/B/C/D=94-291. DR PDB; 5MCT; X-ray; 1.45 A; A/B=94-293. DR PDB; 5MCU; X-ray; 1.70 A; A/B=94-293. DR PDB; 5MCV; X-ray; 1.60 A; A/B=94-293. DR PDB; 5MCW; X-ray; 1.90 A; A/B=94-293. DR PDB; 5MF7; X-ray; 1.59 A; A/B=94-293. DR PDB; 5MG7; X-ray; 1.45 A; A/B=94-293. DR PDB; 5MHC; X-ray; 1.20 A; P=382-393. DR PDB; 5MOC; X-ray; 1.80 A; P=382-393. DR PDB; 5O1A; X-ray; 1.44 A; A/B=94-312. DR PDB; 5O1B; X-ray; 1.43 A; A/B=94-312. DR PDB; 5O1C; X-ray; 1.32 A; A/B=94-312. DR PDB; 5O1D; X-ray; 1.36 A; A/B=94-312. DR PDB; 5O1E; X-ray; 1.30 A; A/B=94-312. DR PDB; 5O1F; X-ray; 1.38 A; A/B=94-312. DR PDB; 5O1G; X-ray; 1.35 A; A/B=94-312. DR PDB; 5O1H; X-ray; 1.32 A; A/B=94-312. DR PDB; 5O1I; X-ray; 1.40 A; A/B=94-312. DR PDB; 5OL0; X-ray; 1.99 A; C/D=372-389. DR PDB; 5UN8; X-ray; 2.13 A; E/F/G/H=144-154. DR PDB; 5XZC; EM; 10.70 A; B/C/D/E=92-356. DR PDB; 6FF9; X-ray; 2.00 A; A/B/C/D=97-289. DR PDB; 6FJ5; X-ray; 2.05 A; A/B/C/D=94-293. DR PDB; 6GGA; X-ray; 1.55 A; A/B=94-312. DR PDB; 6GGB; X-ray; 1.32 A; A/B=94-312. DR PDB; 6GGC; X-ray; 1.24 A; A/B=94-312. DR PDB; 6GGD; X-ray; 1.40 A; A/B=94-312. DR PDB; 6GGE; X-ray; 1.25 A; A/B=94-312. DR PDB; 6GGF; X-ray; 1.32 A; A/B=94-312. DR PDB; 6LHD; X-ray; 2.50 A; A/B=96-292. DR PDB; 6R5L; X-ray; 1.88 A; P=382-393. DR PDB; 6RJZ; X-ray; 1.58 A; P=382-393. DR PDB; 6RK8; X-ray; 1.60 A; P=382-393. DR PDB; 6RKI; X-ray; 1.88 A; P=382-393. DR PDB; 6RKK; X-ray; 1.88 A; P=382-393. DR PDB; 6RKM; X-ray; 1.88 A; P=382-393. DR PDB; 6RL3; X-ray; 1.30 A; P=382-393. DR PDB; 6RL4; X-ray; 1.60 A; P=382-393. DR PDB; 6RL6; X-ray; 1.60 A; P=382-393. DR PDB; 6RM5; X-ray; 1.88 A; P=382-393. DR PDB; 6RM7; X-ray; 1.60 A; P=382-393. DR PDB; 6RWH; X-ray; 1.68 A; P=382-393. DR PDB; 6RWI; X-ray; 1.65 A; P=382-393. DR PDB; 6RWS; X-ray; 1.53 A; P=382-393. DR PDB; 6RWU; X-ray; 1.46 A; P=382-393. DR PDB; 6RX2; X-ray; 1.82 A; P=382-393. DR PDB; 6RZ3; X-ray; 4.23 A; A=62-292. DR PDB; 6S39; X-ray; 1.88 A; P=382-393. DR PDB; 6S3C; X-ray; 2.00 A; P=382-393. DR PDB; 6S40; X-ray; 1.90 A; P=382-393. DR PDB; 6S9Q; X-ray; 1.69 A; P=382-393. DR PDB; 6SHZ; X-ray; 1.24 A; A/B=94-311. DR PDB; 6SI0; X-ray; 1.53 A; A/B=94-312. DR PDB; 6SI1; X-ray; 1.44 A; A/B=94-312. DR PDB; 6SI2; X-ray; 1.50 A; A/B=94-312. DR PDB; 6SI3; X-ray; 1.40 A; A/B=94-312. DR PDB; 6SI4; X-ray; 1.80 A; A/B=94-312. DR PDB; 6SIN; X-ray; 1.64 A; P=382-393. DR PDB; 6SIO; X-ray; 1.60 A; P=382-393. DR PDB; 6SIP; X-ray; 1.60 A; P=382-393. DR PDB; 6SIQ; X-ray; 1.60 A; P=382-393. DR PDB; 6SL6; X-ray; 1.67 A; A=89-311. DR PDB; 6SLV; X-ray; 1.90 A; P=382-393. DR PDB; 6T58; X-ray; 3.10 A; A/B=17-56. DR PDB; 6V4F; X-ray; 1.35 A; B=14-29. DR PDB; 6V4H; X-ray; 1.53 A; B/D=14-29. DR PDB; 6VQO; X-ray; 3.00 A; P/Q=168-176. DR PDB; 6VR1; X-ray; 2.37 A; P/Q=168-176. DR PDB; 6VR5; X-ray; 2.38 A; P/Q=168-176. DR PDB; 6VRM; X-ray; 2.61 A; P=168-176. DR PDB; 6VRN; X-ray; 2.46 A; P=168-176. DR PDB; 6W51; X-ray; 3.53 A; C/F/I/L=168-176. DR PDB; 6XRE; EM; 4.60 A; M=1-393. DR PDB; 6ZNC; X-ray; 1.64 A; A=94-293. DR PDB; 7B46; X-ray; 2.02 A; A/B/C/D=94-293. DR PDB; 7B47; X-ray; 1.80 A; A/B/C/D=94-293. DR PDB; 7B48; X-ray; 2.05 A; A/B/C/D=94-293. DR PDB; 7B49; X-ray; 1.42 A; A/B=94-293. DR PDB; 7B4A; X-ray; 1.90 A; A/B=94-293. DR PDB; 7B4B; X-ray; 1.76 A; A/B/C/D=94-293. DR PDB; 7B4C; X-ray; 1.71 A; A/B/C/D=94-293. DR PDB; 7B4D; X-ray; 1.85 A; A=94-293. DR PDB; 7B4E; X-ray; 1.58 A; A=94-293. DR PDB; 7B4F; X-ray; 1.78 A; A=94-293. DR PDB; 7B4G; X-ray; 1.86 A; A=94-293. DR PDB; 7B4H; X-ray; 1.39 A; A=94-293. DR PDB; 7B4N; X-ray; 1.32 A; A=94-293. DR PDB; 7BWN; X-ray; 2.40 A; B/D/G/I/K/L/N/P=326-356. DR PDB; 7DHY; X-ray; 2.15 A; A/B/C/D=94-293. DR PDB; 7DHZ; X-ray; 1.74 A; A/B=94-293. DR PDB; 7DVD; X-ray; 2.59 A; A/B/C/D=92-290. DR PDB; 7EAX; X-ray; 2.55 A; A/B/C/D=96-289. DR PDB; 7EDS; X-ray; 1.77 A; A=94-293. DR PDB; 7EEU; X-ray; 2.90 A; A/B/C/D/E/F/G/H=94-293. DR PDB; 7EL4; X-ray; 2.11 A; A=23-29. DR PDB; 7NMI; X-ray; 2.10 A; A=17-56. DR PDB; 7RM4; X-ray; 3.33 A; C/H/M/R=168-176. DR PDB; 7V97; X-ray; 2.02 A; A/B/C/D=94-293. DR PDB; 7XZX; EM; 4.53 A; K/L/M/N=94-293. DR PDB; 7XZZ; EM; 4.07 A; K/L/M/N=1-393. DR PDB; 7YGI; X-ray; 2.10 A; A/B=92-289. DR PDB; 8A31; X-ray; 1.46 A; A/B=94-312. DR PDB; 8A32; X-ray; 1.47 A; A/B=94-312. DR PDB; 8A92; X-ray; 1.37 A; A/B=94-312. DR PDB; 8CG7; X-ray; 1.53 A; A/B=94-312. DR PDB; 8DC4; X-ray; 2.40 A; A/B/C/D=94-312. DR PDB; 8DC6; X-ray; 1.60 A; A/B/C/D=94-312. DR PDB; 8DC7; X-ray; 1.99 A; A=94-312. DR PDB; 8DC8; X-ray; 1.72 A; A=94-312. DR PDB; 8E7A; X-ray; 1.30 A; A=93-312. DR PDB; 8E7B; X-ray; 2.50 A; A/B=93-312. DR PDB; 8GCR; EM; 3.38 A; B=94-312. DR PDB; 8HLL; X-ray; 2.62 A; A=95-290. DR PDB; 8HLM; X-ray; 2.52 A; A=95-290. DR PDB; 8HLN; X-ray; 2.35 A; A=95-290. DR PDB; 8J8N; EM; 9.02 A; A/B/C/D=92-292. DR PDB; 8OXM; EM; 3.30 A; E/F=11-22. DR PDB; 8OXO; EM; 3.00 A; E/F=11-22. DR PDB; 8QWK; X-ray; 1.69 A; A=94-312. DR PDB; 8QWL; X-ray; 1.65 A; A=94-312. DR PDB; 8QWM; X-ray; 1.54 A; A/B=94-312. DR PDB; 8QWN; X-ray; 1.44 A; A=94-312. DR PDB; 8QWO; X-ray; 1.38 A; A/B=94-312. DR PDB; 8QWP; X-ray; 2.10 A; A/B=94-312. DR PDB; 8R1F; EM; 3.67 A; C=1-393. DR PDB; 8R1G; EM; 3.99 A; C/F=1-393. DR PDB; 8RBA; X-ray; 1.57 A; A/B=94-312. DR PDB; 8RBB; X-ray; 1.69 A; A/B=94-312. DR PDB; 8RBC; X-ray; 2.06 A; A/B=94-312. DR PDB; 8RCI; X-ray; 1.50 A; A=94-294. DR PDB; 8UQR; X-ray; 1.22 A; A/B/C/D=326-356. DR PDB; 8WD2; X-ray; 1.85 A; A/B=94-312. DR PDB; 8XP5; X-ray; 2.55 A; A/B=95-292. DR PDB; 9BR3; X-ray; 1.90 A; A/B=94-312. DR PDB; 9BR4; X-ray; 1.70 A; A/B=94-312. DR PDB; 9C5S; X-ray; 1.01 A; A/B/C/D=17-30. DR PDB; 9CHT; EM; 3.54 A; B=1-312. DR PDB; 9FZB; X-ray; 1.44 A; A=94-294. DR PDBsum; 1A1U; -. DR PDBsum; 1AIE; -. DR PDBsum; 1C26; -. DR PDBsum; 1DT7; -. DR PDBsum; 1GZH; -. DR PDBsum; 1H26; -. DR PDBsum; 1HS5; -. DR PDBsum; 1JSP; -. DR PDBsum; 1KZY; -. DR PDBsum; 1MA3; -. DR PDBsum; 1OLG; -. DR PDBsum; 1OLH; -. DR PDBsum; 1PES; -. DR PDBsum; 1PET; -. DR PDBsum; 1SAE; -. DR PDBsum; 1SAF; -. DR PDBsum; 1SAK; -. DR PDBsum; 1SAL; -. DR PDBsum; 1TSR; -. DR PDBsum; 1TUP; -. DR PDBsum; 1UOL; -. DR PDBsum; 1XQH; -. DR PDBsum; 1YC5; -. DR PDBsum; 1YCQ; -. DR PDBsum; 1YCR; -. DR PDBsum; 1YCS; -. DR PDBsum; 2AC0; -. DR PDBsum; 2ADY; -. DR PDBsum; 2AHI; -. DR PDBsum; 2ATA; -. DR PDBsum; 2B3G; -. DR PDBsum; 2BIM; -. DR PDBsum; 2BIN; -. DR PDBsum; 2BIO; -. DR PDBsum; 2BIP; -. DR PDBsum; 2BIQ; -. DR PDBsum; 2F1X; -. DR PDBsum; 2FEJ; -. DR PDBsum; 2FOJ; -. DR PDBsum; 2FOO; -. DR PDBsum; 2GS0; -. DR PDBsum; 2H1L; -. DR PDBsum; 2H2D; -. DR PDBsum; 2H2F; -. DR PDBsum; 2H4F; -. DR PDBsum; 2H4H; -. DR PDBsum; 2H4J; -. DR PDBsum; 2H59; -. DR PDBsum; 2J0Z; -. DR PDBsum; 2J10; -. DR PDBsum; 2J11; -. DR PDBsum; 2J1W; -. DR PDBsum; 2J1X; -. DR PDBsum; 2J1Y; -. DR PDBsum; 2J1Z; -. DR PDBsum; 2J20; -. DR PDBsum; 2J21; -. DR PDBsum; 2K8F; -. DR PDBsum; 2L14; -. DR PDBsum; 2LY4; -. DR PDBsum; 2MEJ; -. DR PDBsum; 2MWO; -. DR PDBsum; 2MWP; -. DR PDBsum; 2MWY; -. DR PDBsum; 2MZD; -. DR PDBsum; 2OCJ; -. DR PDBsum; 2PCX; -. DR PDBsum; 2RUK; -. DR PDBsum; 2VUK; -. DR PDBsum; 2WGX; -. DR PDBsum; 2X0U; -. DR PDBsum; 2X0V; -. DR PDBsum; 2X0W; -. DR PDBsum; 2XWR; -. DR PDBsum; 2YBG; -. DR PDBsum; 2YDR; -. DR PDBsum; 2Z5S; -. DR PDBsum; 2Z5T; -. DR PDBsum; 3D05; -. DR PDBsum; 3D06; -. DR PDBsum; 3D07; -. DR PDBsum; 3D08; -. DR PDBsum; 3D09; -. DR PDBsum; 3D0A; -. DR PDBsum; 3DAB; -. DR PDBsum; 3DAC; -. DR PDBsum; 3IGK; -. DR PDBsum; 3IGL; -. DR PDBsum; 3KMD; -. DR PDBsum; 3KZ8; -. DR PDBsum; 3LW1; -. DR PDBsum; 3OQ5; -. DR PDBsum; 3PDH; -. DR PDBsum; 3Q01; -. DR PDBsum; 3Q05; -. DR PDBsum; 3Q06; -. DR PDBsum; 3SAK; -. DR PDBsum; 3TG5; -. DR PDBsum; 3TS8; -. DR PDBsum; 3ZME; -. DR PDBsum; 4AGL; -. DR PDBsum; 4AGM; -. DR PDBsum; 4AGN; -. DR PDBsum; 4AGO; -. DR PDBsum; 4AGP; -. DR PDBsum; 4AGQ; -. DR PDBsum; 4BUZ; -. DR PDBsum; 4BV2; -. DR PDBsum; 4HFZ; -. DR PDBsum; 4HJE; -. DR PDBsum; 4IBQ; -. DR PDBsum; 4IBS; -. DR PDBsum; 4IBT; -. DR PDBsum; 4IBU; -. DR PDBsum; 4IBV; -. DR PDBsum; 4IBW; -. DR PDBsum; 4IBY; -. DR PDBsum; 4IBZ; -. DR PDBsum; 4IJT; -. DR PDBsum; 4KVP; -. DR PDBsum; 4LO9; -. DR PDBsum; 4LOE; -. DR PDBsum; 4LOF; -. DR PDBsum; 4MZI; -. DR PDBsum; 4MZR; -. DR PDBsum; 4QO1; -. DR PDBsum; 4RP6; -. DR PDBsum; 4RP7; -. DR PDBsum; 4X34; -. DR PDBsum; 4XR8; -. DR PDBsum; 4ZZJ; -. DR PDBsum; 5A7B; -. DR PDBsum; 5AB9; -. DR PDBsum; 5ABA; -. DR PDBsum; 5AOI; -. DR PDBsum; 5AOJ; -. DR PDBsum; 5AOK; -. DR PDBsum; 5AOL; -. DR PDBsum; 5AOM; -. DR PDBsum; 5BUA; -. DR PDBsum; 5ECG; -. DR PDBsum; 5G4M; -. DR PDBsum; 5G4N; -. DR PDBsum; 5G4O; -. DR PDBsum; 5HOU; -. DR PDBsum; 5HP0; -. DR PDBsum; 5HPD; -. DR PDBsum; 5LAP; -. DR PDBsum; 5LGY; -. DR PDBsum; 5MCT; -. DR PDBsum; 5MCU; -. DR PDBsum; 5MCV; -. DR PDBsum; 5MCW; -. DR PDBsum; 5MF7; -. DR PDBsum; 5MG7; -. DR PDBsum; 5MHC; -. DR PDBsum; 5MOC; -. DR PDBsum; 5O1A; -. DR PDBsum; 5O1B; -. DR PDBsum; 5O1C; -. DR PDBsum; 5O1D; -. DR PDBsum; 5O1E; -. DR PDBsum; 5O1F; -. DR PDBsum; 5O1G; -. DR PDBsum; 5O1H; -. DR PDBsum; 5O1I; -. DR PDBsum; 5OL0; -. DR PDBsum; 5UN8; -. DR PDBsum; 5XZC; -. DR PDBsum; 6FF9; -. DR PDBsum; 6FJ5; -. DR PDBsum; 6GGA; -. DR PDBsum; 6GGB; -. DR PDBsum; 6GGC; -. DR PDBsum; 6GGD; -. DR PDBsum; 6GGE; -. DR PDBsum; 6GGF; -. DR PDBsum; 6LHD; -. DR PDBsum; 6R5L; -. DR PDBsum; 6RJZ; -. DR PDBsum; 6RK8; -. DR PDBsum; 6RKI; -. DR PDBsum; 6RKK; -. DR PDBsum; 6RKM; -. DR PDBsum; 6RL3; -. DR PDBsum; 6RL4; -. DR PDBsum; 6RL6; -. DR PDBsum; 6RM5; -. DR PDBsum; 6RM7; -. DR PDBsum; 6RWH; -. DR PDBsum; 6RWI; -. DR PDBsum; 6RWS; -. DR PDBsum; 6RWU; -. DR PDBsum; 6RX2; -. DR PDBsum; 6RZ3; -. DR PDBsum; 6S39; -. DR PDBsum; 6S3C; -. DR PDBsum; 6S40; -. DR PDBsum; 6S9Q; -. DR PDBsum; 6SHZ; -. DR PDBsum; 6SI0; -. DR PDBsum; 6SI1; -. DR PDBsum; 6SI2; -. DR PDBsum; 6SI3; -. DR PDBsum; 6SI4; -. DR PDBsum; 6SIN; -. DR PDBsum; 6SIO; -. DR PDBsum; 6SIP; -. DR PDBsum; 6SIQ; -. DR PDBsum; 6SL6; -. DR PDBsum; 6SLV; -. DR PDBsum; 6T58; -. DR PDBsum; 6V4F; -. DR PDBsum; 6V4H; -. DR PDBsum; 6VQO; -. DR PDBsum; 6VR1; -. DR PDBsum; 6VR5; -. DR PDBsum; 6VRM; -. DR PDBsum; 6VRN; -. DR PDBsum; 6W51; -. DR PDBsum; 6XRE; -. DR PDBsum; 6ZNC; -. DR PDBsum; 7B46; -. DR PDBsum; 7B47; -. DR PDBsum; 7B48; -. DR PDBsum; 7B49; -. DR PDBsum; 7B4A; -. DR PDBsum; 7B4B; -. DR PDBsum; 7B4C; -. DR PDBsum; 7B4D; -. DR PDBsum; 7B4E; -. DR PDBsum; 7B4F; -. DR PDBsum; 7B4G; -. DR PDBsum; 7B4H; -. DR PDBsum; 7B4N; -. DR PDBsum; 7BWN; -. DR PDBsum; 7DHY; -. DR PDBsum; 7DHZ; -. DR PDBsum; 7DVD; -. DR PDBsum; 7EAX; -. DR PDBsum; 7EDS; -. DR PDBsum; 7EEU; -. DR PDBsum; 7EL4; -. DR PDBsum; 7NMI; -. DR PDBsum; 7RM4; -. DR PDBsum; 7V97; -. DR PDBsum; 7XZX; -. DR PDBsum; 7XZZ; -. DR PDBsum; 7YGI; -. DR PDBsum; 8A31; -. DR PDBsum; 8A32; -. DR PDBsum; 8A92; -. DR PDBsum; 8CG7; -. DR PDBsum; 8DC4; -. DR PDBsum; 8DC6; -. DR PDBsum; 8DC7; -. DR PDBsum; 8DC8; -. DR PDBsum; 8E7A; -. DR PDBsum; 8E7B; -. DR PDBsum; 8GCR; -. DR PDBsum; 8HLL; -. DR PDBsum; 8HLM; -. DR PDBsum; 8HLN; -. DR PDBsum; 8J8N; -. DR PDBsum; 8OXM; -. DR PDBsum; 8OXO; -. DR PDBsum; 8QWK; -. DR PDBsum; 8QWL; -. DR PDBsum; 8QWM; -. DR PDBsum; 8QWN; -. DR PDBsum; 8QWO; -. DR PDBsum; 8QWP; -. DR PDBsum; 8R1F; -. DR PDBsum; 8R1G; -. DR PDBsum; 8RBA; -. DR PDBsum; 8RBB; -. DR PDBsum; 8RBC; -. DR PDBsum; 8RCI; -. DR PDBsum; 8UQR; -. DR PDBsum; 8WD2; -. DR PDBsum; 8XP5; -. DR PDBsum; 9BR3; -. DR PDBsum; 9BR4; -. DR PDBsum; 9C5S; -. DR PDBsum; 9CHT; -. DR PDBsum; 9FZB; -. DR AlphaFoldDB; P04637; -. DR BMRB; P04637; -. DR EMDB; EMD-0378; -. DR EMDB; EMD-17265; -. DR EMDB; EMD-17266; -. DR EMDB; EMD-18809; -. DR EMDB; EMD-18810; -. DR EMDB; EMD-22294; -. DR EMDB; EMD-22827; -. DR EMDB; EMD-29941; -. DR EMDB; EMD-33533; -. DR EMDB; EMD-33535; -. DR EMDB; EMD-36075; -. DR EMDB; EMD-45601; -. DR EMDB; EMD-53478; -. DR EMDB; EMD-53532; -. DR EMDB; EMD-53536; -. DR EMDB; EMD-53537; -. DR EMDB; EMD-6791; -. DR EMDB; EMD-8926; -. DR EMDB; EMD-8927; -. DR SMR; P04637; -. DR BioGRID; 113010; 2577. DR ComplexPortal; CPX-6093; p53-MDM2-MDM4 transcriptional regulation complex. DR ComplexPortal; CPX-663; p53-MDM4 transcriptional regulation complex. DR ComplexPortal; CPX-759; p53-MDM2 transcriptional regulation complex. DR CORUM; P04637; -. DR DIP; DIP-368N; -. DR ELM; P04637; -. DR FunCoup; P04637; 3248. DR IntAct; P04637; 850. DR MINT; P04637; -. DR STRING; 9606.ENSP00000269305; -. DR BindingDB; P04637; -. DR ChEMBL; CHEMBL4096; -. DR DrugBank; DB08363; 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine. DR DrugBank; DB13010; 4-isothioureidobutyronitrile. DR DrugBank; DB00945; Acetylsalicylic acid. DR DrugBank; DB17549; Alrizomadlin. DR DrugBank; DB05404; AZD 3355. DR DrugBank; DB17507; COTI-2. DR DrugBank; DB11684; Eprenetapopt. DR DrugBank; DB17039; Nutlin-3. DR DrugBank; DB12541; SAR-405838. DR DrugBank; DB16331; Siremadlin. DR DrugBank; DB16447; Thymoquinone. DR DrugBank; DB03347; Triethyl phosphate. DR DrugBank; DB01593; Zinc. DR DrugBank; DB14487; Zinc acetate. DR DrugBank; DB14533; Zinc chloride. DR DrugBank; DB14548; Zinc sulfate, unspecified form. DR MoonDB; P04637; Predicted. DR TCDB; 1.C.110.1.1; the pore-forming pnc-27 peptide of 32 aas from the p53 tumor suppressor protein (pnc-27) family. DR GlyCosmos; P04637; 1 site, 1 glycan. DR GlyGen; P04637; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; P04637; -. DR MetOSite; P04637; -. DR PhosphoSitePlus; P04637; -. DR SwissPalm; P04637; -. DR BioMuta; TP53; -. DR DMDM; 269849759; -. DR CPTAC; CPTAC-5895; -. DR CPTAC; CPTAC-5896; -. DR CPTAC; CPTAC-951; -. DR jPOST; P04637; -. DR MassIVE; P04637; -. DR PaxDb; 9606-ENSP00000269305; -. DR PeptideAtlas; P04637; -. DR ProteomicsDB; 51728; -. [P04637-1] DR ProteomicsDB; 51729; -. [P04637-2] DR ProteomicsDB; 51730; -. [P04637-3] DR ProteomicsDB; 51731; -. [P04637-4] DR ProteomicsDB; 51732; -. [P04637-5] DR ProteomicsDB; 51733; -. [P04637-6] DR ProteomicsDB; 51734; -. [P04637-7] DR ProteomicsDB; 51735; -. [P04637-8] DR ProteomicsDB; 51736; -. [P04637-9] DR Pumba; P04637; -. DR ABCD; P04637; 67 sequenced antibodies. DR Antibodypedia; 3525; 9660 antibodies from 66 providers. DR CPTC; P04637; 2 antibodies. DR DNASU; 7157; -. DR Ensembl; ENST00000269305.9; ENSP00000269305.4; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000420246.6; ENSP00000391127.2; ENSG00000141510.20. [P04637-2] DR Ensembl; ENST00000445888.6; ENSP00000391478.2; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000455263.6; ENSP00000398846.2; ENSG00000141510.20. [P04637-3] DR Ensembl; ENST00000503591.2; ENSP00000426252.2; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000504290.5; ENSP00000484409.1; ENSG00000141510.20. [P04637-9] DR Ensembl; ENST00000504937.5; ENSP00000481179.1; ENSG00000141510.20. [P04637-7] DR Ensembl; ENST00000508793.6; ENSP00000424104.2; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000509690.6; ENSP00000425104.2; ENSG00000141510.20. [P04637-7] DR Ensembl; ENST00000510385.5; ENSP00000478499.1; ENSG00000141510.20. [P04637-8] DR Ensembl; ENST00000610292.4; ENSP00000478219.1; ENSG00000141510.20. [P04637-4] DR Ensembl; ENST00000610538.4; ENSP00000480868.1; ENSG00000141510.20. [P04637-6] DR Ensembl; ENST00000619485.4; ENSP00000482537.1; ENSG00000141510.20. [P04637-4] DR Ensembl; ENST00000620739.4; ENSP00000481638.1; ENSG00000141510.20. [P04637-4] DR Ensembl; ENST00000622645.4; ENSP00000482222.1; ENSG00000141510.20. [P04637-5] DR Ensembl; ENST00000714357.1; ENSP00000519624.1; ENSG00000141510.20. [P04637-1] DR Ensembl; ENST00000714359.1; ENSP00000519626.1; ENSG00000141510.20. [P04637-1] DR GeneID; 7157; -. DR KEGG; hsa:7157; -. DR MANE-Select; ENST00000269305.9; ENSP00000269305.4; NM_000546.6; NP_000537.3. DR UCSC; uc002gij.4; human. [P04637-1] DR AGR; HGNC:11998; -. DR CIViC; 7157; 387 evidence items across 280 molecular profiles. DR ClinPGx; PA36679; -. DR CTD; 7157; -. DR DisGeNET; 7157; -. DR GeneCards; TP53; -. DR GeneReviews; TP53; -. DR HGNC; HGNC:11998; TP53. DR HPA; ENSG00000141510; Low tissue specificity. DR MalaCards; TP53; -. DR MIM; 133239; phenotype. DR MIM; 151623; phenotype. DR MIM; 191170; gene+phenotype. DR MIM; 202300; phenotype. DR MIM; 211980; phenotype. DR MIM; 260500; phenotype. DR MIM; 275355; phenotype. DR MIM; 614740; phenotype. DR MIM; 618165; phenotype. DR OpenTargets; ENSG00000141510; -. DR Orphanet; 1501; Adrenocortical carcinoma. DR Orphanet; 210159; Adult hepatocellular carcinoma. DR Orphanet; 99756; Alveolar rhabdomyosarcoma. DR Orphanet; 67038; B-cell chronic lymphocytic leukemia. DR Orphanet; 585909; B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2). DR Orphanet; 667662; Breast implant-associated anaplastic large cell lymphoma. DR Orphanet; 251899; Choroid plexus carcinoma. DR Orphanet; 96253; Cushing disease. DR Orphanet; 99757; Embryonal rhabdomyosarcoma. DR Orphanet; 3318; Essential thrombocythemia. DR Orphanet; 1333; Familial pancreatic carcinoma. DR Orphanet; 251579; Giant cell glioblastoma. DR Orphanet; 251576; Gliosarcoma. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR Orphanet; 524; Li-Fraumeni syndrome. DR Orphanet; 52688; Myelodysplastic syndrome. DR Orphanet; 668; Osteosarcoma. DR Orphanet; 2807; Papilloma of choroid plexus. DR Orphanet; 293199; Pleomorphic rhabdomyosarcoma. DR Orphanet; 70573; Small cell lung cancer. DR VEuPathDB; HostDB:ENSG00000141510; -. DR eggNOG; ENOG502QVY3; Eukaryota. DR GeneTree; ENSGT00950000183153; -. DR InParanoid; P04637; -. DR OMA; HKKGEPC; -. DR OrthoDB; 5915660at2759; -. DR PAN-GO; P04637; 3 GO annotations based on evolutionary models. DR PhylomeDB; P04637; -. DR PathwayCommons; P04637; -. DR Reactome; R-HSA-111448; Activation of NOXA and translocation to mitochondria. DR Reactome; R-HSA-139915; Activation of PUMA and translocation to mitochondria. DR Reactome; R-HSA-1912408; Pre-NOTCH Transcription and Translation. DR Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence. DR Reactome; R-HSA-2559584; Formation of Senescence-Associated Heterochromatin Foci (SAHF). DR Reactome; R-HSA-2559585; Oncogene Induced Senescence. DR Reactome; R-HSA-2559586; DNA Damage/Telomere Stress Induced Senescence. DR Reactome; R-HSA-3232118; SUMOylation of transcription factors. DR Reactome; R-HSA-349425; Autodegradation of the E3 ubiquitin ligase COP1. DR Reactome; R-HSA-390471; Association of TriC/CCT with target proteins during biosynthesis. DR Reactome; R-HSA-5620971; Pyroptosis. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-5689896; Ovarian tumor domain proteases. DR Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks. DR Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release. DR Reactome; R-HSA-6803205; TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain. DR Reactome; R-HSA-6803207; TP53 Regulates Transcription of Caspase Activators and Caspases. DR Reactome; R-HSA-6803211; TP53 Regulates Transcription of Death Receptors and Ligands. DR Reactome; R-HSA-6804114; TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest. DR Reactome; R-HSA-6804115; TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain. DR Reactome; R-HSA-6804116; TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest. DR Reactome; R-HSA-6804754; Regulation of TP53 Expression. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-6804758; Regulation of TP53 Activity through Acetylation. DR Reactome; R-HSA-6804759; Regulation of TP53 Activity through Association with Co-factors. DR Reactome; R-HSA-6804760; Regulation of TP53 Activity through Methylation. DR Reactome; R-HSA-6811555; PI5P Regulates TP53 Acetylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-69481; G2/M Checkpoints. DR Reactome; R-HSA-69541; Stabilization of p53. DR Reactome; R-HSA-69895; Transcriptional activation of cell cycle inhibitor p21. DR Reactome; R-HSA-8852276; The role of GTSE1 in G2/M progression after G2 checkpoint. DR Reactome; R-HSA-8853884; Transcriptional Regulation by VENTX. DR Reactome; R-HSA-8941855; RUNX3 regulates CDKN1A transcription. DR Reactome; R-HSA-8943724; Regulation of PTEN gene transcription. DR Reactome; R-HSA-9723905; Loss of function of TP53 in cancer due to loss of tetramerization ability. DR Reactome; R-HSA-9725370; Signaling by ALK fusions and activated point mutants. DR Reactome; R-HSA-9758274; Regulation of NF-kappa B signaling. DR Reactome; R-HSA-9819196; Zygotic genome activation (ZGA). DR Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production. DR Reactome; R-HSA-9833482; PKR-mediated signaling. DR SABIO-RK; P04637; -. DR SignaLink; P04637; -. DR SIGNOR; P04637; -. DR Agora; ENSG00000141510; -. DR BioGRID-ORCS; 7157; 66 hits in 1218 CRISPR screens. DR CD-CODE; 1A18FFC4; Paraspeckle. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; A1A97FAB; Synthetic Condensate 000191. DR CD-CODE; B5B9A610; PML body. DR CD-CODE; E11B6BAB; Synthetic Condensate 000195. DR ChiTaRS; TP53; human. DR EvolutionaryTrace; P04637; -. DR GeneWiki; P53; -. DR GenomeRNAi; 7157; -. DR Pharos; P04637; Tchem. DR PRO; PR:P04637; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P04637; protein. DR Bgee; ENSG00000141510; Expressed in ventricular zone and 144 other cell types or tissues. DR ExpressionAtlas; P04637; baseline and differential. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0000785; C:chromatin; IDA:BHF-UCL. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell. DR GO; GO:0043073; C:germ cell nucleus; IEA:Ensembl. DR GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0016363; C:nuclear matrix; IDA:UniProtKB. DR GO; GO:0005730; C:nucleolus; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0016605; C:PML body; IDA:UniProtKB. DR GO; GO:0032991; C:protein-containing complex; IDA:CAFA. DR GO; GO:0005657; C:replication fork; IEA:Ensembl. DR GO; GO:0035861; C:site of double-strand break; IEA:Ensembl. DR GO; GO:0005667; C:transcription regulator complex; IGI:ARUK-UCL. DR GO; GO:0017053; C:transcription repressor complex; IPI:ComplexPortal. DR GO; GO:0071889; F:14-3-3 protein binding; EXP:DisProt. DR GO; GO:0036310; F:ATP-dependent DNA/DNA annealing activity; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; IDA:ARUK-UCL. DR GO; GO:0005507; F:copper ion binding; IDA:UniProtKB. DR GO; GO:0001046; F:core promoter sequence-specific DNA binding; IDA:CAFA. DR GO; GO:0097718; F:disordered domain specific binding; IPI:CAFA. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:GO_Central. DR GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:UniProtKB. DR GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:ARUK-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL. DR GO; GO:0140296; F:general transcription initiation factor binding; IPI:BHF-UCL. DR GO; GO:0042826; F:histone deacetylase binding; IPI:CAFA. DR GO; GO:0035033; F:histone deacetylase regulator activity; IEA:Ensembl. DR GO; GO:0042802; F:identical protein binding; IPI:UniProtKB. DR GO; GO:0097371; F:MDM2/MDM4 family protein binding; IEA:Ensembl. DR GO; GO:0140693; F:molecular condensate scaffold activity; IDA:UniProtKB. DR GO; GO:0140677; F:molecular function activator activity; IPI:DisProt. DR GO; GO:0003730; F:mRNA 3'-UTR binding; IDA:CAFA. DR GO; GO:0002039; F:p53 binding; IPI:CAFA. DR GO; GO:1990841; F:promoter-specific chromatin binding; IDA:UniProtKB. DR GO; GO:0002020; F:protease binding; IPI:UniProtKB. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB. DR GO; GO:0051721; F:protein phosphatase 2A binding; IPI:UniProtKB. DR GO; GO:0051087; F:protein-folding chaperone binding; IPI:UniProtKB. DR GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:BHF-UCL. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:ARUK-UCL. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:UniProtKB. DR GO; GO:0001094; F:TFIID-class transcription factor complex binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:BHF-UCL. DR GO; GO:0001223; F:transcription coactivator binding; IPI:BHF-UCL. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; TAS:UniProtKB. DR GO; GO:0006914; P:autophagy; IMP:CAFA. DR GO; GO:0002326; P:B cell lineage commitment; IEA:Ensembl. DR GO; GO:0048539; P:bone marrow development; IMP:UniProtKB. DR GO; GO:0010659; P:cardiac muscle cell apoptotic process; IEA:Ensembl. DR GO; GO:0060411; P:cardiac septum morphogenesis; IEA:Ensembl. DR GO; GO:0072717; P:cellular response to actinomycin D; IDA:CAFA. DR GO; GO:0071480; P:cellular response to gamma radiation; IDA:CAFA. DR GO; GO:0042149; P:cellular response to glucose starvation; IDA:UniProtKB. DR GO; GO:0071456; P:cellular response to hypoxia; IEP:UniProtKB. DR GO; GO:0071479; P:cellular response to ionizing radiation; IMP:BHF-UCL. DR GO; GO:0034644; P:cellular response to UV; IDA:CAFA. DR GO; GO:0071494; P:cellular response to UV-C; IEA:Ensembl. DR GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEP:UniProtKB. DR GO; GO:0090398; P:cellular senescence; IMP:GO_Central. DR GO; GO:0021549; P:cerebellum development; IEA:Ensembl. DR GO; GO:0051276; P:chromosome organization; IEA:Ensembl. DR GO; GO:0048512; P:circadian behavior; ISS:UniProtKB. DR GO; GO:0008340; P:determination of adult lifespan; ISS:BHF-UCL. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; IDA:BHF-UCL. DR GO; GO:0006302; P:double-strand break repair; IEA:Ensembl. DR GO; GO:0048568; P:embryonic organ development; IEA:Ensembl. DR GO; GO:0043153; P:entrainment of circadian clock by photoperiod; ISS:UniProtKB. DR GO; GO:0006983; P:ER overload response; IDA:MGI. DR GO; GO:0048144; P:fibroblast proliferation; IEA:Ensembl. DR GO; GO:0007369; P:gastrulation; IEA:Ensembl. DR GO; GO:0014009; P:glial cell proliferation; IEA:Ensembl. DR GO; GO:0019661; P:glucose catabolic process to lactate via pyruvate; IEA:Ensembl. DR GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IMP:UniProtKB. DR GO; GO:0060218; P:hematopoietic stem cell differentiation; IMP:UniProtKB. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0008104; P:intracellular protein localization; IDA:UniProtKB. DR GO; GO:0097193; P:intrinsic apoptotic signaling pathway; TAS:HGNC-UCL. DR GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IMP:UniProtKB. DR GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IDA:UniProtKB. DR GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; IEA:Ensembl. DR GO; GO:1990144; P:intrinsic apoptotic signaling pathway in response to hypoxia; IEA:Ensembl. DR GO; GO:0043504; P:mitochondrial DNA repair; IEA:Ensembl. DR GO; GO:0000423; P:mitophagy; IEA:Ensembl. DR GO; GO:0031571; P:mitotic G1 DNA damage checkpoint signaling; IMP:BHF-UCL. DR GO; GO:0009299; P:mRNA transcription; IMP:UniProtKB. DR GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl. DR GO; GO:0070266; P:necroptotic process; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0030308; P:negative regulation of cell growth; IMP:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:CACAO. DR GO; GO:0008156; P:negative regulation of DNA replication; IEA:Ensembl. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0048147; P:negative regulation of fibroblast proliferation; IMP:UniProtKB. DR GO; GO:1903451; P:negative regulation of G1 to G0 transition; IDA:CAFA. DR GO; GO:0060253; P:negative regulation of glial cell proliferation; IEA:Ensembl. DR GO; GO:1904024; P:negative regulation of glucose catabolic process to lactate via pyruvate; IEA:Ensembl. DR GO; GO:0051097; P:negative regulation of helicase activity; TAS:UniProtKB. DR GO; GO:1903799; P:negative regulation of miRNA processing; IEA:Ensembl. DR GO; GO:1901525; P:negative regulation of mitophagy; IEA:Ensembl. DR GO; GO:0007406; P:negative regulation of neuroblast proliferation; IEA:Ensembl. DR GO; GO:1905856; P:negative regulation of pentose-phosphate shunt; IMP:CACAO. DR GO; GO:0045861; P:negative regulation of proteolysis; IEA:Ensembl. DR GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; IEA:Ensembl. DR GO; GO:2000647; P:negative regulation of stem cell proliferation; IEA:Ensembl. DR GO; GO:0032211; P:negative regulation of telomere maintenance via telomerase; IDA:BHF-UCL. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:ARUK-UCL. DR GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IEA:Ensembl. DR GO; GO:0007405; P:neuroblast proliferation; IEA:Ensembl. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0006289; P:nucleotide-excision repair; IMP:UniProtKB. DR GO; GO:0097252; P:oligodendrocyte apoptotic process; IDA:UniProtKB. DR GO; GO:0090403; P:oxidative stress-induced premature senescence; IMP:BHF-UCL. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0010666; P:positive regulation of cardiac muscle cell apoptotic process; IEA:Ensembl. DR GO; GO:2000774; P:positive regulation of cellular senescence; IDA:UniProt. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IMP:AgBase. DR GO; GO:0010628; P:positive regulation of gene expression; IDA:CAFA. DR GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB. DR GO; GO:1902895; P:positive regulation of miRNA transcription; IDA:BHF-UCL. DR GO; GO:0035794; P:positive regulation of mitochondrial membrane permeability; IEA:Ensembl. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0062100; P:positive regulation of programmed necrotic cell death; IEA:Ensembl. DR GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IMP:BHF-UCL. DR GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; IDA:UniProtKB. DR GO; GO:0045899; P:positive regulation of RNA polymerase II transcription preinitiation complex assembly; IDA:BHF-UCL. DR GO; GO:0070245; P:positive regulation of thymocyte apoptotic process; ISS:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0006606; P:protein import into nucleus; IEA:Ensembl. DR GO; GO:0050821; P:protein stabilization; IEA:Ensembl. DR GO; GO:0051262; P:protein tetramerization; IEA:InterPro. DR GO; GO:0065003; P:protein-containing complex assembly; IDA:UniProtKB. DR GO; GO:0007265; P:Ras protein signal transduction; IEP:BHF-UCL. DR GO; GO:0072593; P:reactive oxygen species metabolic process; IEA:Ensembl. DR GO; GO:0042981; P:regulation of apoptotic process; IDA:MGI. DR GO; GO:0051726; P:regulation of cell cycle; IDA:BHF-UCL. DR GO; GO:1902749; P:regulation of cell cycle G2/M phase transition; IMP:UniProtKB. DR GO; GO:0043516; P:regulation of DNA damage response, signal transduction by p53 class mediator; IEA:Ensembl. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:2000269; P:regulation of fibroblast apoptotic process; IEA:Ensembl. DR GO; GO:1902253; P:regulation of intrinsic apoptotic signaling pathway by p53 class mediator; IEA:Ensembl. DR GO; GO:1902108; P:regulation of mitochondrial membrane permeability involved in apoptotic process; IEA:Ensembl. DR GO; GO:0034103; P:regulation of tissue remodeling; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:ARUK-UCL. DR GO; GO:0001836; P:release of cytochrome c from mitochondria; IEA:Ensembl. DR GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL. DR GO; GO:0046677; P:response to antibiotic; IEP:UniProtKB. DR GO; GO:0010332; P:response to gamma radiation; IMP:BHF-UCL. DR GO; GO:0002931; P:response to ischemia; IEA:Ensembl. DR GO; GO:0009651; P:response to salt stress; IEA:Ensembl. DR GO; GO:0010165; P:response to X-ray; IEA:Ensembl. DR GO; GO:0009303; P:rRNA transcription; IEA:Ensembl. DR GO; GO:0072331; P:signal transduction by p53 class mediator; IDA:CAFA. DR GO; GO:0001756; P:somitogenesis; IEA:Ensembl. DR GO; GO:0072089; P:stem cell proliferation; IEA:Ensembl. DR GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl. DR GO; GO:0002360; P:T cell lineage commitment; IEA:Ensembl. DR GO; GO:0002309; P:T cell proliferation involved in immune response; IEA:Ensembl. DR GO; GO:0070242; P:thymocyte apoptotic process; IEA:Ensembl. DR GO; GO:0045815; P:transcription initiation-coupled chromatin remodeling; IDA:GO_Central. DR GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IEA:Ensembl. DR GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IGI:BHF-UCL. DR GO; GO:0060333; P:type II interferon-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0016032; P:viral process; IMP:CACAO. DR CDD; cd08367; P53; 1. DR DisProt; DP00086; -. DR FunFam; 2.60.40.720:FF:000003; Cellular tumor antigen p53; 1. DR FunFam; 4.10.170.10:FF:000003; Cellular tumor antigen p53; 1. DR Gene3D; 2.60.40.720; -; 1. DR Gene3D; 6.10.50.20; -; 1. DR Gene3D; 4.10.170.10; p53-like tetramerisation domain; 1. DR IDEAL; IID00015; -. DR InterPro; IPR008967; p53-like_TF_DNA-bd_sf. DR InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf. DR InterPro; IPR057064; P53_central_site. DR InterPro; IPR011615; p53_DNA-bd. DR InterPro; IPR040926; p53_TAD2. DR InterPro; IPR036674; p53_tetramer_sf. DR InterPro; IPR010991; p53_tetrameristn. DR InterPro; IPR013872; p53_transactivation_domain. DR InterPro; IPR002117; p53_tumour_suppressor. DR PANTHER; PTHR11447; CELLULAR TUMOR ANTIGEN P53; 1. DR PANTHER; PTHR11447:SF6; CELLULAR TUMOR ANTIGEN P53; 1. DR Pfam; PF00870; P53; 1. DR Pfam; PF08563; P53_TAD; 1. DR Pfam; PF07710; P53_tetramer; 1. DR Pfam; PF18521; TAD2; 1. DR PRINTS; PR00386; P53SUPPRESSR. DR SUPFAM; SSF47719; p53 tetramerization domain; 1. DR SUPFAM; SSF49417; p53-like transcription factors; 1. DR PROSITE; PS00348; P53; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Activator; Alternative promoter usage; KW Alternative splicing; Apoptosis; Biological rhythms; Cell cycle; Cytoplasm; KW Cytoskeleton; Direct protein sequencing; Disease variant; DNA-binding; KW Endoplasmic reticulum; Glycoprotein; Host-virus interaction; KW Isopeptide bond; Li-Fraumeni syndrome; Metal-binding; Methylation; KW Mitochondrion; Necrosis; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repressor; Transcription; KW Transcription regulation; Tumor suppressor; Ubl conjugation; Zinc. FT CHAIN 1..393 FT /note="Cellular tumor antigen p53" FT /id="PRO_0000185703" FT DNA_BIND 102..292 FT /evidence="ECO:0000269|PubMed:16793544, FT ECO:0000269|PubMed:18996393, ECO:0000269|PubMed:20364130" FT REGION 1..320 FT /note="Interaction with CCAR2" FT /evidence="ECO:0000269|PubMed:25732823" FT REGION 1..83 FT /note="Interaction with HRMT1L2" FT /evidence="ECO:0000269|PubMed:15186775" FT REGION 1..44 FT /note="Transcription activation (acidic)" FT REGION 50..96 FT /note="Disordered" FT /evidence="ECO:0000269|PubMed:31953488" FT REGION 66..110 FT /note="Interaction with WWOX" FT REGION 100..370 FT /note="Interaction with HIPK1" FT /evidence="ECO:0000250" FT REGION 100..300 FT /note="Required for interaction with ZNF385A" FT /evidence="ECO:0000269|PubMed:17719541" FT REGION 113..236 FT /note="Required for interaction with FBXO42" FT /evidence="ECO:0000269|PubMed:19509332" FT REGION 116..292 FT /note="Interaction with AXIN1" FT /evidence="ECO:0000250" FT REGION 241..248 FT /note="Interaction with the 53BP2 SH3 domain" FT REGION 256..294 FT /note="Interaction with E4F1" FT /evidence="ECO:0000269|PubMed:10644996" FT REGION 273..280 FT /note="Interaction with DNA" FT REGION 282..325 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 300..393 FT /note="Interaction with CARM1" FT /evidence="ECO:0000269|PubMed:15186775" FT REGION 319..360 FT /note="Interaction with HIPK2" FT REGION 325..356 FT /note="Oligomerization" FT REGION 351..393 FT /note="Disordered" FT /evidence="ECO:0000269|PubMed:31953488, FT ECO:0000269|PubMed:36108750" FT REGION 359..363 FT /note="Interaction with USP7" FT REGION 368..387 FT /note="Basic (repression of DNA-binding)" FT REGION 374..393 FT /note="Interaction with MORN3" FT /evidence="ECO:0000269|PubMed:29681526" FT MOTIF 17..25 FT /note="TADI" FT MOTIF 48..56 FT /note="TADII" FT MOTIF 305..321 FT /note="Bipartite nuclear localization signal" FT MOTIF 339..350 FT /note="Nuclear export signal" FT MOTIF 370..372 FT /note="[KR]-[STA]-K motif" FT COMPBIAS 69..90 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 282..299 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 365..384 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 176 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT BINDING 179 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT BINDING 238 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT BINDING 242 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:14534297, FT ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:17015838, FT ECO:0000269|PubMed:18650397, ECO:0000269|PubMed:19515728, FT ECO:0000269|PubMed:20142040, ECO:0000269|PubMed:20364130" FT SITE 120 FT /note="Interaction with DNA" FT /evidence="ECO:0000269|PubMed:16793544, FT ECO:0000269|PubMed:18996393, ECO:0000269|PubMed:20364130" FT MOD_RES 9 FT /note="Phosphoserine; by HIPK4" FT /evidence="ECO:0000269|PubMed:18022393" FT MOD_RES 15 FT /note="Phosphoserine; by CDK5, PRPK, AMPK, NUAK1 and ATM" FT /evidence="ECO:0000269|PubMed:10570149, FT ECO:0000269|PubMed:11554766, ECO:0000269|PubMed:15866171, FT ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:17591690, FT ECO:0000269|PubMed:17967874, ECO:0000269|PubMed:21317932, FT ECO:0000269|PubMed:28842590" FT MOD_RES 18 FT /note="Phosphothreonine; by CK1, VRK1 and VRK2" FT /evidence="ECO:0000269|PubMed:10606744, FT ECO:0000269|PubMed:10951572, ECO:0000269|PubMed:16704422, FT ECO:0000269|PubMed:31527692" FT MOD_RES 20 FT /note="Phosphoserine; by CHEK2, CK1 and PLK3" FT /evidence="ECO:0000269|PubMed:10570149, FT ECO:0000269|PubMed:11447225, ECO:0000269|PubMed:11551930, FT ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:20041275" FT MOD_RES 33 FT /note="Phosphoserine; by CDK5 and CDK7" FT /evidence="ECO:0000269|PubMed:17591690, FT ECO:0000269|PubMed:9372954" FT MOD_RES 37 FT /note="Phosphoserine; by MAPKAPK5" FT /evidence="ECO:0000269|PubMed:17254968" FT MOD_RES 46 FT /note="Phosphoserine; by CDK5, DYRK2, HIPK2 and PKC/PRKCG" FT /evidence="ECO:0000269|PubMed:11740489, FT ECO:0000269|PubMed:11780126, ECO:0000269|PubMed:16377624, FT ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:17591690" FT MOD_RES 55 FT /note="Phosphothreonine; by TAF1 and GRK5" FT /evidence="ECO:0000269|PubMed:15053879, FT ECO:0000269|PubMed:20124405" FT MOD_RES 120 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:17189187, FT ECO:0000269|PubMed:19854137, ECO:0000269|PubMed:23431171" FT MOD_RES 120 FT /note="N6-lactoyllysine" FT /evidence="ECO:0000269|PubMed:38653238" FT MOD_RES 139 FT /note="N6-lactoyllysine" FT /evidence="ECO:0000269|PubMed:38653238" FT MOD_RES 183 FT /note="Phosphoserine; by AURKB" FT /evidence="ECO:0000269|PubMed:20959462" FT MOD_RES 269 FT /note="Phosphoserine; by AURKB" FT /evidence="ECO:0000269|PubMed:20959462" FT MOD_RES 284 FT /note="Phosphothreonine; by AURKB" FT /evidence="ECO:0000269|PubMed:20959462" FT MOD_RES 305 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:12724314" FT MOD_RES 315 FT /note="Phosphoserine; by AURKA, CDK1 and CDK2" FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:14702041" FT MOD_RES 321 FT /note="N6-acetyllysine" FT /evidence="ECO:0000250|UniProtKB:P02340" FT MOD_RES 333 FT /note="Omega-N-methylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:19011621" FT MOD_RES 335 FT /note="Symmetric dimethylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:19011621" FT MOD_RES 337 FT /note="Symmetric dimethylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:19011621" FT MOD_RES 370 FT /note="N6,N6-dimethyllysine; alternate" FT /evidence="ECO:0000269|PubMed:17108971, FT ECO:0000269|PubMed:22864287" FT MOD_RES 370 FT /note="N6-methyllysine; by SMYD2; alternate" FT /evidence="ECO:0000269|PubMed:17108971, FT ECO:0000269|PubMed:22864287" FT MOD_RES 372 FT /note="N6-methyllysine; by SETD7" FT /evidence="ECO:0000269|PubMed:15525938, FT ECO:0000269|PubMed:16415881" FT MOD_RES 373 FT /note="N6,N6-dimethyllysine; by EHMT1 and EHMT2; alternate" FT /evidence="ECO:0000269|PubMed:20118233" FT MOD_RES 373 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0000269|PubMed:10656795" FT MOD_RES 381 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:29474172, FT ECO:0007744|PubMed:19608861" FT MOD_RES 382 FT /note="N6,N6-dimethyllysine; alternate" FT /evidence="ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725, ECO:0000269|PubMed:22864287" FT MOD_RES 382 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0000269|PubMed:10656795, FT ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:20228809, FT ECO:0000269|PubMed:23431171, ECO:0000269|PubMed:29681526, FT ECO:0007744|PubMed:19608861" FT MOD_RES 382 FT /note="N6-methyllysine; by KMT5A; alternate" FT /evidence="ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725, ECO:0000269|PubMed:22864287" FT MOD_RES 392 FT /note="Phosphoserine; by CK2, CDK2 and NUAK1" FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:17108107, FT ECO:0000269|PubMed:21317932, ECO:0000269|PubMed:22214662, FT ECO:0000269|PubMed:35618207" FT CROSSLNK 24 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:21597459" FT CROSSLNK 291 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19536131" FT CROSSLNK 292 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19536131" FT CROSSLNK 351 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19033443" FT CROSSLNK 357 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19033443" FT CROSSLNK 386 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO)" FT /evidence="ECO:0000269|PubMed:11124955, FT ECO:0000269|PubMed:22214662, ECO:0000269|Ref.37" FT VAR_SEQ 1..132 FT /note="Missing (in isoform 7, isoform 8 and isoform 9)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_040833" FT VAR_SEQ 1..39 FT /note="Missing (in isoform 4, isoform 5 and isoform 6)" FT /evidence="ECO:0000305" FT /id="VSP_040832" FT VAR_SEQ 332..346 FT /note="IRGRERFEMFRELNE -> MLLDLRWCYFLINSS (in isoform 3, FT isoform 6 and isoform 9)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_040560" FT VAR_SEQ 332..341 FT /note="IRGRERFEMF -> DQTSFQKENC (in isoform 2, isoform 5 FT and isoform 8)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_006535" FT VAR_SEQ 342..393 FT /note="Missing (in isoform 2, isoform 5 and isoform 8)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_006536" FT VAR_SEQ 347..393 FT /note="Missing (in isoform 3, isoform 6 and isoform 9)" FT /evidence="ECO:0000303|PubMed:16131611" FT /id="VSP_040561" FT VARIANT 5 FT /note="Q -> H (in a sporadic cancer; somatic mutation; FT abolishes strongly phosphorylation)" FT /id="VAR_044543" FT VARIANT 6 FT /note="S -> L (in a sporadic cancer; somatic mutation; FT reduces interaction with ZNF385A)" FT /id="VAR_044544" FT VARIANT 7 FT /note="D -> H (in a sporadic cancer; somatic mutation; FT dbSNP:rs587782646)" FT /id="VAR_005851" FT VARIANT 8 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_044545" FT VARIANT 10 FT /note="V -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs535274413)" FT /id="VAR_044546" FT VARIANT 11 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs201382018)" FT /id="VAR_044547" FT VARIANT 11 FT /note="E -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs201382018)" FT /id="VAR_044548" FT VARIANT 15 FT /note="S -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044549" FT VARIANT 16 FT /note="Q -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044550" FT VARIANT 17 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044551" FT VARIANT 24 FT /note="K -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_044552" FT VARIANT 28 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044553" FT VARIANT 29..30 FT /note="NN -> KD (in a sporadic cancer; somatic mutation)" FT /id="VAR_047158" FT VARIANT 31 FT /note="V -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs201753350)" FT /id="VAR_044554" FT VARIANT 33 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044555" FT VARIANT 34 FT /note="P -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044556" FT VARIANT 35 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs121912661)" FT /id="VAR_005852" FT VARIANT 36 FT /note="P -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs587781866)" FT /id="VAR_044557" FT VARIANT 37 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044558" FT VARIANT 37 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044559" FT VARIANT 39 FT /note="A -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044560" FT VARIANT 39 FT /note="A -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs1353016807)" FT /id="VAR_044561" FT VARIANT 42 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044562" FT VARIANT 43 FT /note="L -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_005853" FT VARIANT 44 FT /note="M -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501190)" FT /id="VAR_044563" FT VARIANT 44 FT /note="M -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044564" FT VARIANT 44 FT /note="M -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044565" FT VARIANT 45 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044566" FT VARIANT 46 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044567" FT VARIANT 46 FT /note="S -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs876659630)" FT /id="VAR_044568" FT VARIANT 47 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044569" FT VARIANT 47 FT /note="P -> S (in dbSNP:rs1800371)" FT /evidence="ECO:0000269|Ref.12" FT /id="VAR_014632" FT VARIANT 48 FT /note="D -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044570" FT VARIANT 49 FT /note="D -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587780728)" FT /id="VAR_044571" FT VARIANT 49 FT /note="D -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs587780728)" FT /id="VAR_044572" FT VARIANT 49 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044573" FT VARIANT 52 FT /note="Q -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044574" FT VARIANT 53 FT /note="W -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_005854" FT VARIANT 53 FT /note="W -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044575" FT VARIANT 54 FT /note="F -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555526742)" FT /id="VAR_044576" FT VARIANT 54 FT /note="F -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044577" FT VARIANT 56 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044578" FT VARIANT 56 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044579" FT VARIANT 58 FT /note="P -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044580" FT VARIANT 58 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044581" FT VARIANT 59 FT /note="G -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1237722021)" FT /id="VAR_044582" FT VARIANT 59 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044583" FT VARIANT 59 FT /note="G -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045783" FT VARIANT 60 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044584" FT VARIANT 60 FT /note="P -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044585" FT VARIANT 60 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_005855" FT VARIANT 61 FT /note="D -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1460793472)" FT /id="VAR_044586" FT VARIANT 61 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_044587" FT VARIANT 62 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044588" FT VARIANT 63 FT /note="A -> T (in a sporadic cancer; somatic mutation; FT dbSNP:rs876658902)" FT /id="VAR_044589" FT VARIANT 63 FT /note="A -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs372201428)" FT /id="VAR_044590" FT VARIANT 65 FT /note="R -> T (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501210)" FT /id="VAR_044591" FT VARIANT 66 FT /note="M -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555526711)" FT /id="VAR_044592" FT VARIANT 66 FT /note="M -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044593" FT VARIANT 67 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044594" FT VARIANT 67 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044595" FT VARIANT 67 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044596" FT VARIANT 68 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044597" FT VARIANT 68 FT /note="E -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044598" FT VARIANT 69 FT /note="A -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044599" FT VARIANT 69 FT /note="A -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs756233241)" FT /id="VAR_044600" FT VARIANT 69 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044601" FT VARIANT 69 FT /note="A -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs756233241)" FT /id="VAR_044602" FT VARIANT 70 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044603" FT VARIANT 71 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044604" FT VARIANT 72 FT /note="P -> C (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions; dbSNP:rs730882014)" FT /id="VAR_045784" FT VARIANT 72 FT /note="P -> G (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045785" FT VARIANT 72 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1042522)" FT /id="VAR_045786" FT VARIANT 72 FT /note="P -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045787" FT VARIANT 72 FT /note="P -> R (in dbSNP:rs1042522)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:16131611, ECO:0000269|PubMed:1999338, FT ECO:0000269|Ref.17" FT /id="VAR_005856" FT VARIANT 73 FT /note="V -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_044605" FT VARIANT 73 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044606" FT VARIANT 73 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs587782423)" FT /id="VAR_044607" FT VARIANT 74 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044608" FT VARIANT 75 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044609" FT VARIANT 75 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044610" FT VARIANT 75 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_044611" FT VARIANT 76 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /evidence="ECO:0000269|PubMed:2946935" FT /id="VAR_044612" FT VARIANT 76 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044613" FT VARIANT 77 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044614" FT VARIANT 78 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044615" FT VARIANT 79 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044616" FT VARIANT 79 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_005857" FT VARIANT 79 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044617" FT VARIANT 80 FT /note="P -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044618" FT VARIANT 80 FT /note="P -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501204)" FT /id="VAR_044619" FT VARIANT 81 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044620" FT VARIANT 82 FT /note="P -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs534447939)" FT /id="VAR_044621" FT VARIANT 82 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044622" FT VARIANT 83 FT /note="A -> E (in a sporadic cancer; somatic mutation; FT dbSNP:rs201717599)" FT /id="VAR_044623" FT VARIANT 83 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs201717599)" FT /id="VAR_044624" FT VARIANT 84 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044625" FT VARIANT 84 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044626" FT VARIANT 85 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044627" FT VARIANT 85 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044628" FT VARIANT 86 FT /note="A -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044629" FT VARIANT 87 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005858" FT VARIANT 88 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044630" FT VARIANT 88 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526631)" FT /id="VAR_044631" FT VARIANT 89 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730881994)" FT /id="VAR_044632" FT VARIANT 89 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044633" FT VARIANT 90 FT /note="S -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526625)" FT /id="VAR_044634" FT VARIANT 90 FT /note="S -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044635" FT VARIANT 91 FT /note="W -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044636" FT VARIANT 92 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044637" FT VARIANT 92 FT /note="P -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1210700121)" FT /id="VAR_044638" FT VARIANT 92 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_044639" FT VARIANT 93 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044640" FT VARIANT 93 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044641" FT VARIANT 94 FT /note="S -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044642" FT VARIANT 94 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005859" FT VARIANT 95 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044643" FT VARIANT 95 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044644" FT VARIANT 96 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044645" FT VARIANT 96 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044646" FT VARIANT 96 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044647" FT VARIANT 97 FT /note="V -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044648" FT VARIANT 97 FT /note="V -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044649" FT VARIANT 97 FT /note="V -> I (in familial cancer not matching LFS; FT germline mutation and in a sporadic cancer; somatic FT mutation; dbSNP:rs730882023)" FT /id="VAR_044650" FT VARIANT 98 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1245723119)" FT /id="VAR_044651" FT VARIANT 98 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044652" FT VARIANT 99 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044653" FT VARIANT 99 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044654" FT VARIANT 100 FT /note="Q -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044655" FT VARIANT 101 FT /note="K -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs878854069)" FT /id="VAR_044656" FT VARIANT 101 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044657" FT VARIANT 102 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs786202717)" FT /id="VAR_044658" FT VARIANT 104 FT /note="Q -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044659" FT VARIANT 104 FT /note="Q -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044660" FT VARIANT 105 FT /note="G -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_044661" FT VARIANT 105 FT /note="G -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs587781504)" FT /id="VAR_044662" FT VARIANT 105 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501195)" FT /id="VAR_044663" FT VARIANT 105 FT /note="G -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs1060501195)" FT /id="VAR_044664" FT VARIANT 105 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044665" FT VARIANT 106 FT /note="S -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044666" FT VARIANT 106 FT /note="S -> R (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs1555526581)" FT /id="VAR_044667" FT VARIANT 107 FT /note="Y -> C (in a sporadic cancer; somatic mutation; FT dbSNP:rs587782447)" FT /id="VAR_044668" FT VARIANT 107 FT /note="Y -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044669" FT VARIANT 107 FT /note="Y -> H (in a sporadic cancer; somatic mutation; FT dbSNP:rs368771578)" FT /id="VAR_044670" FT VARIANT 108 FT /note="G -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044671" FT VARIANT 108 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587782461)" FT /id="VAR_044672" FT VARIANT 109 FT /note="F -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_044673" FT VARIANT 109 FT /note="F -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044674" FT VARIANT 109 FT /note="F -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1064796722)" FT /id="VAR_044675" FT VARIANT 110 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs587781371)" FT /id="VAR_005860" FT VARIANT 110 FT /note="R -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044676" FT VARIANT 110 FT /note="R -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs11540654)" FT /id="VAR_044677" FT VARIANT 110 FT /note="R -> L (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; does not induce SNAI1 degradation; FT dbSNP:rs11540654)" FT /evidence="ECO:0000269|PubMed:20385133" FT /id="VAR_005861" FT VARIANT 110 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs11540654)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_005862" FT VARIANT 110 FT /note="R -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs587781371)" FT /id="VAR_044678" FT VARIANT 111 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044679" FT VARIANT 111 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519997)" FT /id="VAR_044680" FT VARIANT 111 FT /note="L -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519997)" FT /id="VAR_044681" FT VARIANT 111 FT /note="L -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519997)" FT /id="VAR_044682" FT VARIANT 112 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044683" FT VARIANT 112 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1423803759)" FT /id="VAR_044684" FT VARIANT 113 FT /note="F -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_005863" FT VARIANT 113 FT /note="F -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045788" FT VARIANT 113 FT /note="F -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_044685" FT VARIANT 113 FT /note="F -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044686" FT VARIANT 113 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044687" FT VARIANT 113 FT /note="F -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs587781642)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033033" FT VARIANT 115 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044688" FT VARIANT 116 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_044689" FT VARIANT 116 FT /note="S -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044690" FT VARIANT 116 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044691" FT VARIANT 117 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs755238756)" FT /id="VAR_044692" FT VARIANT 117 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526518)" FT /id="VAR_044693" FT VARIANT 118 FT /note="T -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044694" FT VARIANT 118 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1064794141)" FT /id="VAR_044695" FT VARIANT 118 FT /note="T -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044696" FT VARIANT 119 FT /note="A -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044697" FT VARIANT 119 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044698" FT VARIANT 120 FT /note="K -> E (in sporadic cancers; somatic mutation; FT abolished acetylation; impaired ability to induce FT proapoptotic program; mimics lactylation, leading to FT decreased ability to undergo liquid-liquid phase separation FT and activate the transcription factor activity; FT dbSNP:rs121912658)" FT /evidence="ECO:0000269|PubMed:17189187, FT ECO:0000269|PubMed:38653238" FT /id="VAR_044699" FT VARIANT 120 FT /note="K -> M (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17189187" FT /id="VAR_044700" FT VARIANT 120 FT /note="K -> Q (in a sporadic cancer; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity; dbSNP:rs121912658)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044701" FT VARIANT 120 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17189187" FT /id="VAR_044702" FT VARIANT 121 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044703" FT VARIANT 122 FT /note="V -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044704" FT VARIANT 123 FT /note="T -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555526486)" FT /id="VAR_044705" FT VARIANT 123 FT /note="T -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_044706" FT VARIANT 124 FT /note="C -> G (in a sporadic cancer; somatic mutation; FT dbSNP:rs730881997)" FT /id="VAR_044707" FT VARIANT 124 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044708" FT VARIANT 124 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs730881997)" FT /id="VAR_044709" FT VARIANT 124 FT /note="C -> W (in a sporadic cancer; somatic mutation)" FT /id="VAR_044710" FT VARIANT 124 FT /note="C -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_044711" FT VARIANT 125 FT /note="T -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044712" FT VARIANT 125 FT /note="T -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs786201057)" FT /id="VAR_044713" FT VARIANT 125 FT /note="T -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs786201057)" FT /id="VAR_005864" FT VARIANT 125 FT /note="T -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1057520003)" FT /id="VAR_044714" FT VARIANT 125 FT /note="T -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs786201057)" FT /id="VAR_044715" FT VARIANT 126 FT /note="Y -> C (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs1555526335)" FT /id="VAR_044716" FT VARIANT 126 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs886039483)" FT /id="VAR_005865" FT VARIANT 126 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044717" FT VARIANT 126 FT /note="Y -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045789" FT VARIANT 126 FT /note="Y -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044718" FT VARIANT 126 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs886039483)" FT /id="VAR_005866" FT VARIANT 126 FT /note="Y -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044719" FT VARIANT 127 FT /note="S -> C (in a sporadic cancer; somatic mutation; FT dbSNP:rs730881999)" FT /id="VAR_044720" FT VARIANT 127 FT /note="S -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs730881999)" FT /id="VAR_005867" FT VARIANT 127 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044721" FT VARIANT 127 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044722" FT VARIANT 127 FT /note="S -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044723" FT VARIANT 128 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044724" FT VARIANT 128 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044725" FT VARIANT 128 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044726" FT VARIANT 128 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005868" FT VARIANT 129 FT /note="A -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005869" FT VARIANT 129 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044727" FT VARIANT 129 FT /note="A -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs1438095083)" FT /id="VAR_044728" FT VARIANT 129 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs137852792)" FT /id="VAR_044729" FT VARIANT 130 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs863224683)" FT /id="VAR_044730" FT VARIANT 130 FT /note="L -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044731" FT VARIANT 130 FT /note="L -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_044732" FT VARIANT 130 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691013)" FT /id="VAR_044733" FT VARIANT 130 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_005870" FT VARIANT 130 FT /note="L -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs863224683)" FT /id="VAR_044734" FT VARIANT 131 FT /note="N -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044735" FT VARIANT 131 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044736" FT VARIANT 131 FT /note="N -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691037)" FT /id="VAR_044737" FT VARIANT 131 FT /note="N -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs769270327)" FT /id="VAR_005872" FT VARIANT 131 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005871" FT VARIANT 131 FT /note="N -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044738" FT VARIANT 131 FT /note="N -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs587782160)" FT /id="VAR_044739" FT VARIANT 132..133 FT /note="KM -> NL (in a sporadic cancer; somatic mutation)" FT /id="VAR_047159" FT VARIANT 132 FT /note="K -> E (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs747342068)" FT /id="VAR_044740" FT VARIANT 132 FT /note="K -> L (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045790" FT VARIANT 132 FT /note="K -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519996)" FT /id="VAR_005873" FT VARIANT 132 FT /note="K -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs866775781)" FT /id="VAR_044741" FT VARIANT 132 FT /note="K -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs747342068)" FT /evidence="ECO:0000269|PubMed:1694291" FT /id="VAR_005874" FT VARIANT 132 FT /note="K -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519996)" FT /id="VAR_044742" FT VARIANT 132 FT /note="K -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519996)" FT /id="VAR_044743" FT VARIANT 132 FT /note="K -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045791" FT VARIANT 133 FT /note="M -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795139)" FT /id="VAR_044744" FT VARIANT 133 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044745" FT VARIANT 133 FT /note="M -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044746" FT VARIANT 133 FT /note="M -> R (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_044747" FT VARIANT 133 FT /note="M -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934873)" FT /evidence="ECO:0000269|PubMed:1933902" FT /id="VAR_005875" FT VARIANT 133 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1057280220)" FT /id="VAR_044748" FT VARIANT 134 FT /note="F -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs780442292)" FT /id="VAR_044749" FT VARIANT 134 FT /note="F -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044750" FT VARIANT 134 FT /note="F -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs267605077)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036504" FT VARIANT 134 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044751" FT VARIANT 134 FT /note="F -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044752" FT VARIANT 135 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs587781991)" FT /id="VAR_005877" FT VARIANT 135 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519975)" FT /id="VAR_044753" FT VARIANT 135 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519975)" FT /id="VAR_044754" FT VARIANT 135 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519975)" FT /id="VAR_005876" FT VARIANT 135 FT /note="C -> T (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045792" FT VARIANT 135 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519976)" FT /id="VAR_044755" FT VARIANT 135 FT /note="C -> Y (in sporadic cancers; somatic mutation; FT decreased E6-mediated binding to E6-AP; dbSNP:rs587781991)" FT /id="VAR_044756" FT VARIANT 136 FT /note="Q -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526268)" FT /id="VAR_005878" FT VARIANT 136 FT /note="Q -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs758781593)" FT /id="VAR_044757" FT VARIANT 136 FT /note="Q -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_005879" FT VARIANT 136 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044758" FT VARIANT 136 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044759" FT VARIANT 137 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044760" FT VARIANT 137 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044761" FT VARIANT 137 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005880" FT VARIANT 137 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044762" FT VARIANT 138 FT /note="A -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044763" FT VARIANT 138 FT /note="A -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934875)" FT /id="VAR_005881" FT VARIANT 138 FT /note="A -> S (in LFS; germline mutation)" FT /id="VAR_044764" FT VARIANT 138 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044765" FT VARIANT 138 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs750600586)" FT /evidence="ECO:0000269|PubMed:17224074, FT ECO:0000269|PubMed:27657329" FT /id="VAR_033034" FT VARIANT 139 FT /note="K -> E (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity; dbSNP:rs1212996409)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044766" FT VARIANT 139 FT /note="K -> N (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity)" FT /evidence="ECO:0000269|PubMed:14660794, FT ECO:0000269|PubMed:38653238" FT /id="VAR_005882" FT VARIANT 139 FT /note="K -> Q (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044767" FT VARIANT 139 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044768" FT VARIANT 139 FT /note="K -> T (in sporadic cancers; somatic mutation; FT mimics lactylation, leading to decreased ability to undergo FT liquid-liquid phase separation and activate the FT transcription factor activity)" FT /evidence="ECO:0000269|PubMed:38653238" FT /id="VAR_044769" FT VARIANT 140 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044770" FT VARIANT 140 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044771" FT VARIANT 140 FT /note="T -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs786202561)" FT /id="VAR_044772" FT VARIANT 140 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044773" FT VARIANT 140 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044774" FT VARIANT 141 FT /note="C -> A (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045793" FT VARIANT 141 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs587781288)" FT /id="VAR_005885" FT VARIANT 141 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519978)" FT /id="VAR_005884" FT VARIANT 141 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519978)" FT /id="VAR_044775" FT VARIANT 141 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519978)" FT /id="VAR_044776" FT VARIANT 141 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519977)" FT /id="VAR_044777" FT VARIANT 141 FT /note="C -> Y (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587781288)" FT /id="VAR_005886" FT VARIANT 142 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044778" FT VARIANT 142 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045794" FT VARIANT 142 FT /note="P -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044779" FT VARIANT 142 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs779196500)" FT /id="VAR_044780" FT VARIANT 142 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044781" FT VARIANT 142 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044782" FT VARIANT 142 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044783" FT VARIANT 143 FT /note="V -> A (in sporadic cancers; somatic mutation; FT strong DNA binding ability at 32.5 degrees Celsius; strong FT reduction of transcriptional activity at 37.5 degrees FT Celsius; severely represses interaction with ZNF385A)" FT /evidence="ECO:0000269|PubMed:17719541, FT ECO:0000269|PubMed:8013454" FT /id="VAR_005887" FT VARIANT 143 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044784" FT VARIANT 143 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526241)" FT /id="VAR_044785" FT VARIANT 143 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587782620)" FT /id="VAR_044786" FT VARIANT 143 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs587782620)" FT /id="VAR_044787" FT VARIANT 144 FT /note="Q -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs786201419)" FT /id="VAR_044788" FT VARIANT 144 FT /note="Q -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044789" FT VARIANT 144 FT /note="Q -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786203071)" FT /id="VAR_044790" FT VARIANT 144 FT /note="Q -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs786203071)" FT /id="VAR_005888" FT VARIANT 144 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044791" FT VARIANT 145 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044792" FT VARIANT 145 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs587782197)" FT /id="VAR_005889" FT VARIANT 145 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005890" FT VARIANT 145 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044793" FT VARIANT 145 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044794" FT VARIANT 146 FT /note="W -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044795" FT VARIANT 146 FT /note="W -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs786203064)" FT /id="VAR_044796" FT VARIANT 146 FT /note="W -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044797" FT VARIANT 146 FT /note="W -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044798" FT VARIANT 146 FT /note="W -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044799" FT VARIANT 147 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044800" FT VARIANT 147 FT /note="V -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005891" FT VARIANT 147 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044801" FT VARIANT 147 FT /note="V -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044802" FT VARIANT 147 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1453167097)" FT /id="VAR_005892" FT VARIANT 147 FT /note="V -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526226)" FT /id="VAR_044803" FT VARIANT 148 FT /note="D -> A (in a sporadic cancer; somatic mutation; FT dbSNP:rs1046611742)" FT /id="VAR_044804" FT VARIANT 148 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044805" FT VARIANT 148 FT /note="D -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044806" FT VARIANT 148 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_044807" FT VARIANT 148 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044808" FT VARIANT 148 FT /note="D -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691007)" FT /id="VAR_044809" FT VARIANT 149 FT /note="S -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526214)" FT /id="VAR_044810" FT VARIANT 149 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_005893" FT VARIANT 149 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044811" FT VARIANT 150 FT /note="T -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044812" FT VARIANT 150 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044813" FT VARIANT 150 FT /note="T -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044814" FT VARIANT 150 FT /note="T -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_044815" FT VARIANT 150 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044816" FT VARIANT 150 FT /note="T -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044817" FT VARIANT 151 FT /note="P -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs28934874)" FT /id="VAR_005894" FT VARIANT 151 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520000)" FT /id="VAR_044818" FT VARIANT 151 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044819" FT VARIANT 151 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520000)" FT /id="VAR_044820" FT VARIANT 151 FT /note="P -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934874)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005895" FT VARIANT 151 FT /note="P -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934874)" FT /id="VAR_005896" FT VARIANT 152 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044821" FT VARIANT 152 FT /note="P -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782705)" FT /evidence="ECO:0000269|PubMed:1868473" FT /id="VAR_005897" FT VARIANT 152 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044822" FT VARIANT 152 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044823" FT VARIANT 152 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs767328513)" FT /evidence="ECO:0000269|PubMed:9450901" FT /id="VAR_005898" FT VARIANT 152 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044824" FT VARIANT 153 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044825" FT VARIANT 153 FT /note="P -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045795" FT VARIANT 153 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044826" FT VARIANT 153 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044827" FT VARIANT 153 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_044828" FT VARIANT 153 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795860)" FT /id="VAR_044829" FT VARIANT 153 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005899" FT VARIANT 154 FT /note="G -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044830" FT VARIANT 154 FT /note="G -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044831" FT VARIANT 154 FT /note="G -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs762846821)" FT /id="VAR_044832" FT VARIANT 154 FT /note="G -> I (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045796" FT VARIANT 154 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs137852789)" FT /id="VAR_044833" FT VARIANT 154 FT /note="G -> V (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs762846821)" FT /evidence="ECO:0000269|PubMed:2263646" FT /id="VAR_005900" FT VARIANT 155 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs772683278)" FT /evidence="ECO:0000269|PubMed:1868473" FT /id="VAR_005901" FT VARIANT 155 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044834" FT VARIANT 155 FT /note="T -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_044835" FT VARIANT 155 FT /note="T -> N (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786202752)" FT /id="VAR_044836" FT VARIANT 155 FT /note="T -> P (in sporadic cancers; somatic mutation; does FT not induce SNAI1 degradation)" FT /evidence="ECO:0000269|PubMed:14660794, FT ECO:0000269|PubMed:20385133" FT /id="VAR_044837" FT VARIANT 155 FT /note="T -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs786202752)" FT /id="VAR_044838" FT VARIANT 156 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs563378859)" FT /id="VAR_044839" FT VARIANT 156 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044840" FT VARIANT 156 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs371524413)" FT /id="VAR_044841" FT VARIANT 156 FT /note="R -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044842" FT VARIANT 156 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005902" FT VARIANT 156 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044843" FT VARIANT 157 FT /note="V -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691023)" FT /id="VAR_044844" FT VARIANT 157 FT /note="V -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005903" FT VARIANT 157 FT /note="V -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs121912654)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_005904" FT VARIANT 157 FT /note="V -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044845" FT VARIANT 157 FT /note="V -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs121912654)" FT /evidence="ECO:0000269|PubMed:9419979" FT /id="VAR_012977" FT VARIANT 157 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044846" FT VARIANT 158 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs587780068)" FT /id="VAR_005905" FT VARIANT 158 FT /note="R -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045797" FT VARIANT 158 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_005906" FT VARIANT 158 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782144)" FT /id="VAR_005907" FT VARIANT 158 FT /note="R -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044847" FT VARIANT 158 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs587782144)" FT /id="VAR_044848" FT VARIANT 158 FT /note="R -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044849" FT VARIANT 158 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044850" FT VARIANT 158 FT /note="R -> Y (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045798" FT VARIANT 159 FT /note="A -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044851" FT VARIANT 159 FT /note="A -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions; dbSNP:rs730882022)" FT /id="VAR_045799" FT VARIANT 159 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044852" FT VARIANT 159 FT /note="A -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs730882000)" FT /id="VAR_044853" FT VARIANT 159 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044854" FT VARIANT 159 FT /note="A -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs730882000)" FT /id="VAR_044855" FT VARIANT 159 FT /note="A -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526131)" FT /id="VAR_044856" FT VARIANT 160..161 FT /note="MA -> IP (in a sporadic cancer; somatic mutation)" FT /id="VAR_047160" FT VARIANT 160..161 FT /note="MA -> IS (in sporadic cancers; somatic mutation)" FT /id="VAR_047161" FT VARIANT 160..161 FT /note="MA -> IT (in a sporadic cancer; somatic mutation)" FT /id="VAR_047162" FT VARIANT 160 FT /note="M -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs772354334)" FT /id="VAR_005908" FT VARIANT 160 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044857" FT VARIANT 160 FT /note="M -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044858" FT VARIANT 160 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs377274728)" FT /id="VAR_044859" FT VARIANT 161 FT /note="A -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795691)" FT /id="VAR_044860" FT VARIANT 161 FT /note="A -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045800" FT VARIANT 161 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044861" FT VARIANT 161 FT /note="A -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044862" FT VARIANT 161 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005909" FT VARIANT 161 FT /note="A -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs193920817)" FT /id="VAR_044863" FT VARIANT 161 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044864" FT VARIANT 162 FT /note="I -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_044865" FT VARIANT 162 FT /note="I -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044866" FT VARIANT 162 FT /note="I -> N (in a breast cancer with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_044867" FT VARIANT 162 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587780069)" FT /id="VAR_005910" FT VARIANT 162 FT /note="I -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044868" FT VARIANT 162 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_005911" FT VARIANT 163 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs148924904)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17224074" FT /id="VAR_033035" FT VARIANT 163 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs786203436)" FT /id="VAR_044869" FT VARIANT 163 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_044870" FT VARIANT 163 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs786203436)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_005912" FT VARIANT 163 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs786203436)" FT /id="VAR_044871" FT VARIANT 163 FT /note="Y -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044872" FT VARIANT 164 FT /note="K -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs879254249)" FT /id="VAR_044873" FT VARIANT 164 FT /note="K -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044874" FT VARIANT 164 FT /note="K -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691034)" FT /id="VAR_005913" FT VARIANT 164 FT /note="K -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_005914" FT VARIANT 164 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044875" FT VARIANT 164 FT /note="K -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044876" FT VARIANT 165 FT /note="Q -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_044877" FT VARIANT 165 FT /note="Q -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044878" FT VARIANT 165 FT /note="Q -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_005915" FT VARIANT 165 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044879" FT VARIANT 165 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_005916" FT VARIANT 166 FT /note="S -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044880" FT VARIANT 166 FT /note="S -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044881" FT VARIANT 166 FT /note="S -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526101)" FT /id="VAR_005917" FT VARIANT 166 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044882" FT VARIANT 166 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044883" FT VARIANT 167..168 FT /note="QH -> HD (in a sporadic cancer; somatic mutation)" FT /id="VAR_047163" FT VARIANT 167..168 FT /note="QH -> YL (in a sporadic cancer; somatic mutation)" FT /id="VAR_047164" FT VARIANT 167 FT /note="Q -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044884" FT VARIANT 167 FT /note="Q -> K (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_044885" FT VARIANT 167 FT /note="Q -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044886" FT VARIANT 167 FT /note="Q -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044887" FT VARIANT 168..169 FT /note="HM -> LI (in a sporadic cancer; somatic mutation)" FT /id="VAR_047165" FT VARIANT 168 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044888" FT VARIANT 168 FT /note="H -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044889" FT VARIANT 168 FT /note="H -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_044890" FT VARIANT 168 FT /note="H -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044891" FT VARIANT 168 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044892" FT VARIANT 168 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs867114783)" FT /id="VAR_005918" FT VARIANT 168 FT /note="H -> V (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045801" FT VARIANT 168 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044893" FT VARIANT 169..170 FT /note="MT -> IS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047166" FT VARIANT 169 FT /note="M -> I (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:9450901" FT /id="VAR_005919" FT VARIANT 169 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_044894" FT VARIANT 169 FT /note="M -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005920" FT VARIANT 169 FT /note="M -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044895" FT VARIANT 170 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs587780729)" FT /id="VAR_044896" FT VARIANT 170 FT /note="T -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_044897" FT VARIANT 170 FT /note="T -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs779000871)" FT /id="VAR_005921" FT VARIANT 170 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_044898" FT VARIANT 170 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005922" FT VARIANT 171 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044899" FT VARIANT 171 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044900" FT VARIANT 171 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044901" FT VARIANT 171 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs587781845)" FT /id="VAR_044902" FT VARIANT 171 FT /note="E -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044903" FT VARIANT 171 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044904" FT VARIANT 172 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_005923" FT VARIANT 172 FT /note="V -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044905" FT VARIANT 172 FT /note="V -> F (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1131691043)" FT /id="VAR_044906" FT VARIANT 172 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691021)" FT /id="VAR_044907" FT VARIANT 172 FT /note="V -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044908" FT VARIANT 173 FT /note="V -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519747)" FT /id="VAR_044909" FT VARIANT 173 FT /note="V -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519747)" FT /id="VAR_005924" FT VARIANT 173 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519747)" FT /id="VAR_044910" FT VARIANT 173 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs876660754)" FT /id="VAR_005925" FT VARIANT 173 FT /note="V -> M (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs876660754)" FT /id="VAR_005926" FT VARIANT 173 FT /note="V -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045802" FT VARIANT 174 FT /note="R -> G (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation; dbSNP:rs864622115)" FT /id="VAR_044911" FT VARIANT 174 FT /note="R -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1064796681)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005927" FT VARIANT 174 FT /note="R -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_044912" FT VARIANT 174 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044913" FT VARIANT 174 FT /note="R -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044914" FT VARIANT 174 FT /note="R -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_044915" FT VARIANT 175 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs138729528)" FT /id="VAR_005928" FT VARIANT 175 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs138729528)" FT /id="VAR_005929" FT VARIANT 175 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; does not induce SNAI1 FT degradation; reduces interaction with ZNF385A; FT dbSNP:rs28934578)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17719541, ECO:0000269|PubMed:1868473, FT ECO:0000269|PubMed:20385133, ECO:0000269|PubMed:27657329, FT ECO:0000269|PubMed:7887414, ECO:0000269|PubMed:8825920" FT /id="VAR_005932" FT VARIANT 175 FT /note="R -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934578)" FT /id="VAR_005930" FT VARIANT 175 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17719541" FT /id="VAR_005931" FT VARIANT 175 FT /note="R -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_044916" FT VARIANT 175 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044917" FT VARIANT 176..177 FT /note="CP -> FS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047167" FT VARIANT 176 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs786202962)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:1868473, ECO:0000269|PubMed:8829627, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005933" FT VARIANT 176 FT /note="C -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044918" FT VARIANT 176 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044919" FT VARIANT 176 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs967461896)" FT /id="VAR_044920" FT VARIANT 176 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519980)" FT /id="VAR_005934" FT VARIANT 176 FT /note="C -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs786202962)" FT /id="VAR_044921" FT VARIANT 177 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044922" FT VARIANT 177 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045803" FT VARIANT 177 FT /note="P -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044923" FT VARIANT 177 FT /note="P -> I (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045804" FT VARIANT 177 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs751477326)" FT /id="VAR_005935" FT VARIANT 177 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs751477326)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036505" FT VARIANT 177 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs147002414)" FT /id="VAR_044924" FT VARIANT 177 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044925" FT VARIANT 178..179 FT /note="HH -> QS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047168" FT VARIANT 178 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044926" FT VARIANT 178 FT /note="H -> HPHP (in a Burkitt lymphoma)" FT /evidence="ECO:0000269|PubMed:1303181" FT /id="VAR_005936" FT VARIANT 178 FT /note="H -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_044927" FT VARIANT 178 FT /note="H -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795203)" FT /id="VAR_044928" FT VARIANT 178 FT /note="H -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1555526004)" FT /id="VAR_044929" FT VARIANT 178 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044930" FT VARIANT 178 FT /note="H -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044931" FT VARIANT 178 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044932" FT VARIANT 179 FT /note="H -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs587780070)" FT /id="VAR_044933" FT VARIANT 179 FT /note="H -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519991)" FT /id="VAR_044934" FT VARIANT 179 FT /note="H -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs587780070)" FT /id="VAR_044935" FT VARIANT 179 FT /note="H -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519991)" FT /id="VAR_044936" FT VARIANT 179 FT /note="H -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs876660821)" FT /id="VAR_044937" FT VARIANT 179 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519991)" FT /id="VAR_044938" FT VARIANT 179 FT /note="H -> Y (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587780070)" FT /id="VAR_044939" FT VARIANT 180 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_044940" FT VARIANT 180 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044941" FT VARIANT 180 FT /note="E -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_044942" FT VARIANT 180 FT /note="E -> K (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs879253911)" FT /id="VAR_044943" FT VARIANT 180 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044944" FT VARIANT 180 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_044945" FT VARIANT 181 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782596)" FT /id="VAR_044946" FT VARIANT 181 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044947" FT VARIANT 181 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs397514495)" FT /id="VAR_044948" FT VARIANT 181 FT /note="R -> L (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs397514495)" FT /id="VAR_005937" FT VARIANT 181 FT /note="R -> P (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_044949" FT VARIANT 181 FT /note="R -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587782596)" FT /id="VAR_044950" FT VARIANT 182 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044951" FT VARIANT 182 FT /note="C -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_005938" FT VARIANT 182 FT /note="C -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_044952" FT VARIANT 183 FT /note="S -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525970)" FT /id="VAR_044953" FT VARIANT 183 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044954" FT VARIANT 184 FT /note="D -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501209)" FT /id="VAR_044955" FT VARIANT 184 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044956" FT VARIANT 184 FT /note="D -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs72661117)" FT /id="VAR_047169" FT VARIANT 184 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044957" FT VARIANT 184 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_005939" FT VARIANT 185 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_044958" FT VARIANT 185 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044959" FT VARIANT 185 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044960" FT VARIANT 185 FT /note="S -> N (in a sporadic cancer; somatic mutation; FT dbSNP:rs150607408)" FT /id="VAR_044961" FT VARIANT 185 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044962" FT VARIANT 185 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_044963" FT VARIANT 186 FT /note="D -> E (in a sporadic cancer; somatic mutation; FT dbSNP:rs375275361)" FT /id="VAR_044964" FT VARIANT 186 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044965" FT VARIANT 186 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044966" FT VARIANT 186 FT /note="D -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501206)" FT /id="VAR_044967" FT VARIANT 186 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044968" FT VARIANT 186 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_005940" FT VARIANT 187 FT /note="G -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_005941" FT VARIANT 187 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_044969" FT VARIANT 187 FT /note="G -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045805" FT VARIANT 187 FT /note="G -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_044970" FT VARIANT 187 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs776167460)" FT /id="VAR_005942" FT VARIANT 187 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044971" FT VARIANT 188 FT /note="L -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1199893366)" FT /id="VAR_044972" FT VARIANT 188 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_044973" FT VARIANT 189 FT /note="A -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_044974" FT VARIANT 189 FT /note="A -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_044975" FT VARIANT 189 FT /note="A -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_005943" FT VARIANT 189 FT /note="A -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555525921)" FT /id="VAR_044976" FT VARIANT 189 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_044977" FT VARIANT 189 FT /note="A -> V (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121912665)" FT /id="VAR_044978" FT VARIANT 190 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_044979" FT VARIANT 190 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_044980" FT VARIANT 190 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs876660825)" FT /id="VAR_005944" FT VARIANT 190 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs876660825)" FT /id="VAR_044981" FT VARIANT 190 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_044982" FT VARIANT 190 FT /note="P -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs876660254)" FT /id="VAR_044983" FT VARIANT 191 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587778718)" FT /id="VAR_044984" FT VARIANT 191 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587778718)" FT /id="VAR_044985" FT VARIANT 191 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs587778718)" FT /id="VAR_044986" FT VARIANT 191 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs868590738)" FT /id="VAR_044987" FT VARIANT 191 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_005945" FT VARIANT 192..193 FT /note="QH -> HN (in a sporadic cancer; somatic mutation)" FT /id="VAR_047170" FT VARIANT 192..193 FT /note="QH -> HY (in a sporadic cancer; somatic mutation)" FT /id="VAR_047171" FT VARIANT 192 FT /note="Q -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_044988" FT VARIANT 192 FT /note="Q -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_044989" FT VARIANT 192 FT /note="Q -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_044990" FT VARIANT 192 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_044991" FT VARIANT 192 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs730882002)" FT /id="VAR_005946" FT VARIANT 193 FT /note="H -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs876658468)" FT /id="VAR_005947" FT VARIANT 193 FT /note="H -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs786201838)" FT /id="VAR_044992" FT VARIANT 193 FT /note="H -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs876658468)" FT /id="VAR_044993" FT VARIANT 193 FT /note="H -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs786201838)" FT /id="VAR_044994" FT VARIANT 193 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_044995" FT VARIANT 193 FT /note="H -> R (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786201838)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:7887414" FT /id="VAR_005948" FT VARIANT 193 FT /note="H -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs876658468)" FT /id="VAR_044996" FT VARIANT 194 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs587780071)" FT /id="VAR_044997" FT VARIANT 194 FT /note="L -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519998)" FT /id="VAR_044998" FT VARIANT 194 FT /note="L -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_044999" FT VARIANT 194 FT /note="L -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519998)" FT /id="VAR_005949" FT VARIANT 194 FT /note="L -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519998)" FT /evidence="ECO:0000269|PubMed:7682763" FT /id="VAR_005950" FT VARIANT 194 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045000" FT VARIANT 195 FT /note="I -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs942158624)" FT /id="VAR_045001" FT VARIANT 195 FT /note="I -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_047172" FT VARIANT 195 FT /note="I -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs760043106)" FT /id="VAR_045002" FT VARIANT 195 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs760043106)" FT /id="VAR_045003" FT VARIANT 195 FT /note="I -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs760043106)" FT /evidence="ECO:0000269|PubMed:17224074, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005951" FT VARIANT 195 FT /note="I -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045004" FT VARIANT 195 FT /note="I -> Y (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045806" FT VARIANT 196 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs397516435)" FT /id="VAR_045005" FT VARIANT 196 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs483352697)" FT /id="VAR_045006" FT VARIANT 196 FT /note="R -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs483352697)" FT /id="VAR_045007" FT VARIANT 196 FT /note="R -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs483352697)" FT /id="VAR_045008" FT VARIANT 196 FT /note="R -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045009" FT VARIANT 197 FT /note="V -> E (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045010" FT VARIANT 197 FT /note="V -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045011" FT VARIANT 197 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs786204041)" FT /id="VAR_045012" FT VARIANT 197 FT /note="V -> M (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs786204041)" FT /id="VAR_045013" FT VARIANT 198 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045014" FT VARIANT 198 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045015" FT VARIANT 198 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_005952" FT VARIANT 198 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045016" FT VARIANT 198 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045017" FT VARIANT 199 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045018" FT VARIANT 199 FT /note="G -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045019" FT VARIANT 199 FT /note="G -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045020" FT VARIANT 199 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525857)" FT /id="VAR_045021" FT VARIANT 200 FT /note="N -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045022" FT VARIANT 200 FT /note="N -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045023" FT VARIANT 200 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045024" FT VARIANT 200 FT /note="N -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045807" FT VARIANT 200 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045025" FT VARIANT 200 FT /note="N -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045026" FT VARIANT 201..202 FT /note="LR -> FC (in a sporadic cancer; somatic mutation)" FT /id="VAR_047173" FT VARIANT 201 FT /note="L -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs730882024)" FT /id="VAR_045027" FT VARIANT 201 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045028" FT VARIANT 201 FT /note="L -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045029" FT VARIANT 202 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs587780072)" FT /id="VAR_045030" FT VARIANT 202 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs587780072)" FT /id="VAR_045031" FT VARIANT 202 FT /note="R -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587778719)" FT /id="VAR_045032" FT VARIANT 202 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587778719)" FT /id="VAR_045033" FT VARIANT 202 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045034" FT VARIANT 202 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045035" FT VARIANT 203..204 FT /note="VE -> LV (in a sporadic cancer; somatic mutation)" FT /id="VAR_047174" FT VARIANT 203 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045036" FT VARIANT 203 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045037" FT VARIANT 203 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045038" FT VARIANT 203 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs730882003)" FT /id="VAR_045039" FT VARIANT 203 FT /note="V -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045808" FT VARIANT 204 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045040" FT VARIANT 204 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045041" FT VARIANT 204 FT /note="E -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1260903787)" FT /id="VAR_045042" FT VARIANT 204 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045043" FT VARIANT 204 FT /note="E -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045044" FT VARIANT 204 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045045" FT VARIANT 205 FT /note="Y -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520007)" FT /evidence="ECO:0000269|PubMed:1459726" FT /id="VAR_005953" FT VARIANT 205 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520008)" FT /id="VAR_005954" FT VARIANT 205 FT /note="Y -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520007)" FT /id="VAR_047175" FT VARIANT 205 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520008)" FT /id="VAR_045046" FT VARIANT 205 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520008)" FT /id="VAR_045047" FT VARIANT 205 FT /note="Y -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520007)" FT /id="VAR_045048" FT VARIANT 206 FT /note="L -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045049" FT VARIANT 206 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_045050" FT VARIANT 207..208 FT /note="DD -> EY (in a sporadic cancer; somatic mutation)" FT /id="VAR_047176" FT VARIANT 207 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045051" FT VARIANT 207 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045052" FT VARIANT 207 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045053" FT VARIANT 207 FT /note="D -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs923100890)" FT /id="VAR_045054" FT VARIANT 207 FT /note="D -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045055" FT VARIANT 207 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045056" FT VARIANT 208 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045057" FT VARIANT 208 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045058" FT VARIANT 208 FT /note="D -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045059" FT VARIANT 208 FT /note="D -> I (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045809" FT VARIANT 208 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045060" FT VARIANT 208 FT /note="D -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1464727668)" FT /id="VAR_045061" FT VARIANT 208 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045062" FT VARIANT 209 FT /note="R -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045063" FT VARIANT 209 FT /note="R -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045064" FT VARIANT 209 FT /note="R -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045065" FT VARIANT 209 FT /note="R -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045066" FT VARIANT 210 FT /note="N -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045067" FT VARIANT 210 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045068" FT VARIANT 210 FT /note="N -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045069" FT VARIANT 210 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045070" FT VARIANT 210 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045071" FT VARIANT 210 FT /note="N -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045072" FT VARIANT 210 FT /note="N -> Y (in a familial cancer not matching LFS; FT germline mutation; dbSNP:rs1060501200)" FT /id="VAR_045073" FT VARIANT 211 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501198)" FT /id="VAR_045074" FT VARIANT 211 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045075" FT VARIANT 211 FT /note="T -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045076" FT VARIANT 211 FT /note="T -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045077" FT VARIANT 211 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045078" FT VARIANT 212 FT /note="F -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795766)" FT /id="VAR_045079" FT VARIANT 212 FT /note="F -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045080" FT VARIANT 212 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045081" FT VARIANT 212 FT /note="F -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045082" FT VARIANT 212 FT /note="F -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045083" FT VARIANT 213 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs397516436)" FT /id="VAR_045084" FT VARIANT 213 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs587778720)" FT /id="VAR_045085" FT VARIANT 213 FT /note="R -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587778720)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036506" FT VARIANT 213 FT /note="R -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587778720)" FT /id="VAR_005955" FT VARIANT 213 FT /note="R -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_045086" FT VARIANT 214 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045087" FT VARIANT 214 FT /note="H -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1057519992)" FT /id="VAR_045088" FT VARIANT 214 FT /note="H -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs587781386)" FT /id="VAR_047177" FT VARIANT 214 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519992)" FT /id="VAR_045089" FT VARIANT 214 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045090" FT VARIANT 215 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045091" FT VARIANT 215 FT /note="S -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs886039484)" FT /id="VAR_045092" FT VARIANT 215 FT /note="S -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs587782177)" FT /id="VAR_045093" FT VARIANT 215 FT /note="S -> K (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045810" FT VARIANT 215 FT /note="S -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs587782177)" FT /id="VAR_045094" FT VARIANT 215 FT /note="S -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520001)" FT /id="VAR_045095" FT VARIANT 215 FT /note="S -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587782177)" FT /id="VAR_045096" FT VARIANT 216 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045097" FT VARIANT 216 FT /note="V -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520004)" FT /id="VAR_045098" FT VARIANT 216 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520004)" FT /id="VAR_045099" FT VARIANT 216 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730882025)" FT /id="VAR_045100" FT VARIANT 216 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs730882025)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_005956" FT VARIANT 216 FT /note="V -> W (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045811" FT VARIANT 217 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045101" FT VARIANT 217 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045102" FT VARIANT 217 FT /note="V -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045103" FT VARIANT 217 FT /note="V -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045104" FT VARIANT 217 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045105" FT VARIANT 217 FT /note="V -> M (in dbSNP:rs35163653)" FT /id="VAR_047178" FT VARIANT 218 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045106" FT VARIANT 218 FT /note="V -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045107" FT VARIANT 218 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525743)" FT /id="VAR_045108" FT VARIANT 218 FT /note="V -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045109" FT VARIANT 218 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs878854072)" FT /id="VAR_045110" FT VARIANT 219 FT /note="P -> C (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045812" FT VARIANT 219 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045111" FT VARIANT 219 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1420675064)" FT /id="VAR_045112" FT VARIANT 219 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045113" FT VARIANT 219 FT /note="P -> S (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs879253894)" FT /id="VAR_045114" FT VARIANT 219 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045115" FT VARIANT 220 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912666)" FT /evidence="ECO:0000269|PubMed:7682763, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005957" FT VARIANT 220 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs530941076)" FT /id="VAR_045116" FT VARIANT 220 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045117" FT VARIANT 220 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs530941076)" FT /id="VAR_005958" FT VARIANT 220 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs530941076)" FT /id="VAR_045118" FT VARIANT 220 FT /note="Y -> S (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121912666)" FT /id="VAR_005959" FT VARIANT 221 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045119" FT VARIANT 221 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045120" FT VARIANT 221 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045121" FT VARIANT 221 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs786201592)" FT /id="VAR_045122" FT VARIANT 221 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045123" FT VARIANT 222 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045124" FT VARIANT 222 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs146340390)" FT /id="VAR_045125" FT VARIANT 222 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045126" FT VARIANT 222 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045127" FT VARIANT 222 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501203)" FT /id="VAR_045128" FT VARIANT 222 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045129" FT VARIANT 223 FT /note="P -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_047179" FT VARIANT 223 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs138983188)" FT /id="VAR_045130" FT VARIANT 223 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs138983188)" FT /id="VAR_045131" FT VARIANT 223 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045132" FT VARIANT 223 FT /note="P -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045133" FT VARIANT 223 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045134" FT VARIANT 224 FT /note="E -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs267605076)" FT /id="VAR_045135" FT VARIANT 224 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045136" FT VARIANT 224 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525707)" FT /id="VAR_045137" FT VARIANT 224 FT /note="E -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045138" FT VARIANT 225 FT /note="V -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045139" FT VARIANT 225 FT /note="V -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045140" FT VARIANT 225 FT /note="V -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045141" FT VARIANT 225 FT /note="V -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045142" FT VARIANT 225 FT /note="V -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045143" FT VARIANT 225 FT /note="V -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs746504075)" FT /id="VAR_045144" FT VARIANT 226 FT /note="G -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045145" FT VARIANT 226 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_047180" FT VARIANT 226 FT /note="G -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045844" FT VARIANT 226 FT /note="G -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045146" FT VARIANT 226 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs970212462)" FT /id="VAR_045147" FT VARIANT 227 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045148" FT VARIANT 227 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045149" FT VARIANT 227 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045150" FT VARIANT 227 FT /note="S -> T (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_045151" FT VARIANT 228 FT /note="D -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045152" FT VARIANT 228 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_005960" FT VARIANT 228 FT /note="D -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045153" FT VARIANT 228 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045154" FT VARIANT 228 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045155" FT VARIANT 228 FT /note="D -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045845" FT VARIANT 228 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045156" FT VARIANT 228 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045157" FT VARIANT 229 FT /note="C -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045158" FT VARIANT 229 FT /note="C -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045846" FT VARIANT 229 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1064794312)" FT /id="VAR_045159" FT VARIANT 229 FT /note="C -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045160" FT VARIANT 229 FT /note="C -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs1064793603)" FT /id="VAR_045161" FT VARIANT 230 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045162" FT VARIANT 230 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:9450901" FT /id="VAR_005961" FT VARIANT 230 FT /note="T -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045163" FT VARIANT 230 FT /note="T -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045164" FT VARIANT 230 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045165" FT VARIANT 231 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045166" FT VARIANT 231 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525564)" FT /id="VAR_045167" FT VARIANT 231 FT /note="T -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045168" FT VARIANT 231 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045169" FT VARIANT 232 FT /note="I -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045170" FT VARIANT 232 FT /note="I -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525562)" FT /id="VAR_045171" FT VARIANT 232 FT /note="I -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045172" FT VARIANT 232 FT /note="I -> S (in sporadic cancers; somatic mutation; does FT not induce SNAI1 degradation)" FT /evidence="ECO:0000269|PubMed:20385133" FT /id="VAR_045173" FT VARIANT 232 FT /note="I -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587781589)" FT /id="VAR_005962" FT VARIANT 232 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045174" FT VARIANT 233 FT /note="H -> D (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_045175" FT VARIANT 233 FT /note="H -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045176" FT VARIANT 233 FT /note="H -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045177" FT VARIANT 233 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045178" FT VARIANT 233 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs879254233)" FT /id="VAR_047181" FT VARIANT 233 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045179" FT VARIANT 234 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587780073)" FT /id="VAR_005963" FT VARIANT 234 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs864622237)" FT /id="VAR_045180" FT VARIANT 234 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045181" FT VARIANT 234 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs864622237)" FT /id="VAR_005964" FT VARIANT 234 FT /note="Y -> K (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045847" FT VARIANT 234 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs864622237)" FT /id="VAR_045182" FT VARIANT 234 FT /note="Y -> Q (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045848" FT VARIANT 234 FT /note="Y -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs587780073)" FT /id="VAR_045183" FT VARIANT 235 FT /note="N -> D (in an adrenocortical carcinoma with no FT family history; germline mutation and in sporadic cancers; FT somatic mutation)" FT /id="VAR_047182" FT VARIANT 235 FT /note="N -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045184" FT VARIANT 235 FT /note="N -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs144340710)" FT /id="VAR_045185" FT VARIANT 235 FT /note="N -> M (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045849" FT VARIANT 235 FT /note="N -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs144340710)" FT /id="VAR_045186" FT VARIANT 235 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045187" FT VARIANT 235 FT /note="N -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs786204145)" FT /id="VAR_045188" FT VARIANT 236 FT /note="Y -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs730882026)" FT /id="VAR_045189" FT VARIANT 236 FT /note="Y -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs587782289)" FT /id="VAR_045190" FT VARIANT 236 FT /note="Y -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045191" FT VARIANT 236 FT /note="Y -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs587782289)" FT /id="VAR_045192" FT VARIANT 236 FT /note="Y -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs587782289)" FT /id="VAR_045193" FT VARIANT 236 FT /note="Y -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs730882026)" FT /id="VAR_045194" FT VARIANT 237 FT /note="M -> I (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587782664)" FT /evidence="ECO:0000269|PubMed:27657329" FT /id="VAR_005965" FT VARIANT 237 FT /note="M -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs765848205)" FT /id="VAR_045195" FT VARIANT 237 FT /note="M -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045196" FT VARIANT 237 FT /note="M -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs765848205)" FT /id="VAR_045197" FT VARIANT 237 FT /note="M -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045198" FT VARIANT 237 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs730882004)" FT /id="VAR_045199" FT VARIANT 238 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs730882005)" FT /id="VAR_005966" FT VARIANT 238 FT /note="C -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1057519981)" FT /id="VAR_045200" FT VARIANT 238 FT /note="C -> H (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045850" FT VARIANT 238 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519981)" FT /id="VAR_045201" FT VARIANT 238 FT /note="C -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs730882005)" FT /id="VAR_045202" FT VARIANT 238 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs193920789)" FT /id="VAR_045203" FT VARIANT 238 FT /note="C -> Y (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs730882005)" FT /id="VAR_005967" FT VARIANT 239 FT /note="N -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs876660807)" FT /id="VAR_045204" FT VARIANT 239 FT /note="N -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045205" FT VARIANT 239 FT /note="N -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045206" FT VARIANT 239 FT /note="N -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1057522275)" FT /id="VAR_045207" FT VARIANT 239 FT /note="N -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519999)" FT /id="VAR_045208" FT VARIANT 239 FT /note="N -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519999)" FT /id="VAR_045209" FT VARIANT 239 FT /note="N -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045210" FT VARIANT 240 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045211" FT VARIANT 240 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045212" FT VARIANT 240 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_005968" FT VARIANT 240 FT /note="S -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045213" FT VARIANT 240 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045214" FT VARIANT 240 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045215" FT VARIANT 240 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045216" FT VARIANT 241 FT /note="S -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520002)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033036" FT VARIANT 241 FT /note="S -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs28934573)" FT /id="VAR_045217" FT VARIANT 241 FT /note="S -> F (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934573)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:1699228" FT /id="VAR_005969" FT VARIANT 241 FT /note="S -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520002)" FT /id="VAR_045218" FT VARIANT 241 FT /note="S -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_047183" FT VARIANT 241 FT /note="S -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs28934573)" FT /id="VAR_045219" FT VARIANT 242 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs121912655)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:16959974" FT /id="VAR_005970" FT VARIANT 242 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519982)" FT /id="VAR_045220" FT VARIANT 242 FT /note="C -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045221" FT VARIANT 242 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs121912655)" FT /id="VAR_045222" FT VARIANT 242 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs375874539)" FT /id="VAR_045223" FT VARIANT 242 FT /note="C -> Y (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121912655)" FT /id="VAR_045224" FT VARIANT 243..244 FT /note="MG -> IC (in a sporadic cancer; somatic mutation)" FT /id="VAR_047184" FT VARIANT 243..244 FT /note="MG -> IS (in a sporadic cancer; somatic mutation)" FT /id="VAR_047185" FT VARIANT 243 FT /note="M -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045225" FT VARIANT 243 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045226" FT VARIANT 243 FT /note="M -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs786203117)" FT /id="VAR_045227" FT VARIANT 243 FT /note="M -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045228" FT VARIANT 243 FT /note="M -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs730882006)" FT /id="VAR_045229" FT VARIANT 243 FT /note="M -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs786203117)" FT /id="VAR_045230" FT VARIANT 244 FT /note="G -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs985033810)" FT /id="VAR_047186" FT VARIANT 244 FT /note="G -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519989)" FT /id="VAR_045231" FT VARIANT 244 FT /note="G -> D (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1057517983)" FT /id="VAR_045232" FT VARIANT 244 FT /note="G -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045233" FT VARIANT 244 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519989)" FT /id="VAR_045234" FT VARIANT 244 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519989)" FT /id="VAR_045235" FT VARIANT 244 FT /note="G -> V (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs985033810)" FT /id="VAR_045236" FT VARIANT 245 FT /note="G -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs121912656)" FT /id="VAR_005971" FT VARIANT 245 FT /note="G -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934575)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:1978757" FT /id="VAR_005972" FT VARIANT 245 FT /note="G -> D (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912656)" FT /evidence="ECO:0000269|PubMed:2259385" FT /id="VAR_005973" FT VARIANT 245 FT /note="G -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045237" FT VARIANT 245 FT /note="G -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045851" FT VARIANT 245 FT /note="G -> H (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045852" FT VARIANT 245 FT /note="G -> L (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045853" FT VARIANT 245 FT /note="G -> N (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045854" FT VARIANT 245 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs28934575)" FT /id="VAR_045238" FT VARIANT 245 FT /note="G -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934575)" FT /evidence="ECO:0000269|PubMed:8829627" FT /id="VAR_005974" FT VARIANT 245 FT /note="G -> V (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912656)" FT /evidence="ECO:0000269|PubMed:2263646" FT /id="VAR_005975" FT VARIANT 246 FT /note="M -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1019340046)" FT /id="VAR_045239" FT VARIANT 246 FT /note="M -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045240" FT VARIANT 246 FT /note="M -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs483352695)" FT /id="VAR_044020" FT VARIANT 246 FT /note="M -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs587780074)" FT /id="VAR_005976" FT VARIANT 246 FT /note="M -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587780074)" FT /id="VAR_005977" FT VARIANT 246 FT /note="M -> V (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs483352695)" FT /id="VAR_005978" FT VARIANT 247..248 FT /note="NR -> IP (in a sporadic cancer; somatic mutation)" FT /id="VAR_047187" FT VARIANT 247..248 FT /note="NR -> KW (in sporadic cancers; somatic mutation)" FT /id="VAR_047188" FT VARIANT 247 FT /note="N -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1452189221)" FT /id="VAR_045241" FT VARIANT 247 FT /note="N -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045855" FT VARIANT 247 FT /note="N -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs786201762)" FT /id="VAR_005980" FT VARIANT 247 FT /note="N -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045242" FT VARIANT 247 FT /note="N -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs786201762)" FT /id="VAR_045243" FT VARIANT 247 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_047189" FT VARIANT 247 FT /note="N -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045244" FT VARIANT 248 FT /note="R -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045245" FT VARIANT 248 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs121912651)" FT /id="VAR_005981" FT VARIANT 248 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs11540652)" FT /evidence="ECO:0000269|PubMed:1394225, FT ECO:0000269|PubMed:7682763" FT /id="VAR_005982" FT VARIANT 248 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs11540652)" FT /id="VAR_045246" FT VARIANT 248 FT /note="R -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs11540652)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:2263646, ECO:0000269|PubMed:7682763, FT ECO:0000269|PubMed:7887414" FT /id="VAR_005983" FT VARIANT 248 FT /note="R -> W (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912651)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:1978757, ECO:0000269|PubMed:27657329, FT ECO:0000269|PubMed:8829627" FT /id="VAR_005984" FT VARIANT 249..250 FT /note="RP -> SA (in a sporadic cancer; somatic mutation)" FT /id="VAR_047190" FT VARIANT 249..250 FT /note="RP -> SS (in sporadic cancers; somatic mutation)" FT /id="VAR_047191" FT VARIANT 249 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs587782082)" FT /id="VAR_005985" FT VARIANT 249 FT /note="R -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045247" FT VARIANT 249 FT /note="R -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs587782329)" FT /id="VAR_045248" FT VARIANT 249 FT /note="R -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs587782329)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033037" FT VARIANT 249 FT /note="R -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045856" FT VARIANT 249 FT /note="R -> S (in sporadic cancers; somatic mutation; does FT not induce SNAI1 degradation; dbSNP:rs28934571)" FT /evidence="ECO:0000269|PubMed:1694291, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:20385133" FT /id="VAR_005986" FT VARIANT 249 FT /note="R -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs587782329)" FT /id="VAR_045249" FT VARIANT 249 FT /note="R -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs587782082)" FT /id="VAR_045250" FT VARIANT 250 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045251" FT VARIANT 250 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045857" FT VARIANT 250 FT /note="P -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045252" FT VARIANT 250 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1064794311)" FT /id="VAR_047192" FT VARIANT 250 FT /note="P -> N (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045858" FT VARIANT 250 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045253" FT VARIANT 250 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045254" FT VARIANT 250 FT /note="P -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045255" FT VARIANT 251 FT /note="I -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045256" FT VARIANT 251 FT /note="I -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730882007)" FT /id="VAR_045257" FT VARIANT 251 FT /note="I -> M (in LFS; germline mutation; FT dbSNP:rs878854074)" FT /id="VAR_045258" FT VARIANT 251 FT /note="I -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_005987" FT VARIANT 251 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs730882027)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033038" FT VARIANT 251 FT /note="I -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045259" FT VARIANT 251 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045260" FT VARIANT 252 FT /note="L -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045261" FT VARIANT 252 FT /note="L -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045262" FT VARIANT 252 FT /note="L -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045263" FT VARIANT 252 FT /note="L -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912653)" FT /evidence="ECO:0000269|PubMed:1978757" FT /id="VAR_005988" FT VARIANT 252 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045264" FT VARIANT 253 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045265" FT VARIANT 253 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045266" FT VARIANT 253 FT /note="T -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525465)" FT /id="VAR_045267" FT VARIANT 253 FT /note="T -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_047193" FT VARIANT 253 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045268" FT VARIANT 254 FT /note="I -> D (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045859" FT VARIANT 254 FT /note="I -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045269" FT VARIANT 254 FT /note="I -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045270" FT VARIANT 254 FT /note="I -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_045271" FT VARIANT 254 FT /note="I -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_017908" FT VARIANT 254 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1330865474)" FT /id="VAR_045272" FT VARIANT 254 FT /note="I -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_017909" FT VARIANT 254 FT /note="I -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs746601313)" FT /id="VAR_045273" FT VARIANT 255 FT /note="I -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519995)" FT /id="VAR_045274" FT VARIANT 255 FT /note="I -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045275" FT VARIANT 255 FT /note="I -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs876659675)" FT /id="VAR_045276" FT VARIANT 255 FT /note="I -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs876659675)" FT /id="VAR_045277" FT VARIANT 255 FT /note="I -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs876659675)" FT /id="VAR_045278" FT VARIANT 255 FT /note="I -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045279" FT VARIANT 256 FT /note="T -> I (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045280" FT VARIANT 256 FT /note="T -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045281" FT VARIANT 256 FT /note="T -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045282" FT VARIANT 256 FT /note="T -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045283" FT VARIANT 257 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_005989" FT VARIANT 257 FT /note="L -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934577)" FT /id="VAR_045284" FT VARIANT 257 FT /note="L -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs28934577)" FT /id="VAR_045285" FT VARIANT 257 FT /note="L -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045286" FT VARIANT 258 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045287" FT VARIANT 258 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_005990" FT VARIANT 258 FT /note="E -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501201)" FT /id="VAR_045288" FT VARIANT 258 FT /note="E -> K (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912652)" FT /evidence="ECO:0000269|PubMed:1978757" FT /id="VAR_005991" FT VARIANT 258 FT /note="E -> L (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045860" FT VARIANT 258 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045289" FT VARIANT 258 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045290" FT VARIANT 259 FT /note="D -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_047194" FT VARIANT 259 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045291" FT VARIANT 259 FT /note="D -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs745425759)" FT /id="VAR_045292" FT VARIANT 259 FT /note="D -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045293" FT VARIANT 259 FT /note="D -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045294" FT VARIANT 259 FT /note="D -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045861" FT VARIANT 259 FT /note="D -> S (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045862" FT VARIANT 259 FT /note="D -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045295" FT VARIANT 259 FT /note="D -> Y (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17224074" FT /id="VAR_033039" FT VARIANT 260 FT /note="S -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045296" FT VARIANT 260 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045297" FT VARIANT 260 FT /note="S -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045298" FT VARIANT 260 FT /note="S -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045299" FT VARIANT 260 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045300" FT VARIANT 260 FT /note="S -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs876658916)" FT /id="VAR_045301" FT VARIANT 261 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045302" FT VARIANT 261 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045303" FT VARIANT 261 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045304" FT VARIANT 261 FT /note="S -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045305" FT VARIANT 261 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045306" FT VARIANT 262..263 FT /note="GN -> PD (in a sporadic cancer; somatic mutation)" FT /id="VAR_047195" FT VARIANT 262 FT /note="G -> C (in a sporadic cancer; somatic mutation; FT dbSNP:rs200579969)" FT /id="VAR_045307" FT VARIANT 262 FT /note="G -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_047196" FT VARIANT 262 FT /note="G -> H (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045863" FT VARIANT 262 FT /note="G -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs200579969)" FT /id="VAR_045308" FT VARIANT 262 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691025)" FT /evidence="ECO:0000269|Ref.23" FT /id="VAR_045309" FT VARIANT 263 FT /note="N -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs72661119)" FT /id="VAR_045310" FT VARIANT 263 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045311" FT VARIANT 263 FT /note="N -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045312" FT VARIANT 263 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045313" FT VARIANT 263 FT /note="N -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045314" FT VARIANT 264 FT /note="L -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045315" FT VARIANT 264 FT /note="L -> P (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555525353)" FT /id="VAR_045316" FT VARIANT 264 FT /note="L -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045317" FT VARIANT 264 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045318" FT VARIANT 264 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045319" FT VARIANT 265 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045320" FT VARIANT 265 FT /note="L -> P (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs879253942)" FT /id="VAR_045321" FT VARIANT 265 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045322" FT VARIANT 265 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_047197" FT VARIANT 266 FT /note="G -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045323" FT VARIANT 266 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs193920774)" FT /id="VAR_045324" FT VARIANT 266 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519990)" FT /id="VAR_045325" FT VARIANT 266 FT /note="G -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs193920774)" FT /id="VAR_045326" FT VARIANT 267 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045327" FT VARIANT 267 FT /note="R -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045328" FT VARIANT 267 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs587780075)" FT /id="VAR_045329" FT VARIANT 267 FT /note="R -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs587780075)" FT /id="VAR_045330" FT VARIANT 267 FT /note="R -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs55832599)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036507" FT VARIANT 268 FT /note="N -> F (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045864" FT VARIANT 268 FT /note="N -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045331" FT VARIANT 268 FT /note="N -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045332" FT VARIANT 268 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045333" FT VARIANT 268 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045334" FT VARIANT 268 FT /note="N -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045335" FT VARIANT 269 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045336" FT VARIANT 269 FT /note="S -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045337" FT VARIANT 269 FT /note="S -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_047198" FT VARIANT 269 FT /note="S -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045338" FT VARIANT 269 FT /note="S -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045339" FT VARIANT 269 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045340" FT VARIANT 270 FT /note="F -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519986)" FT /id="VAR_045341" FT VARIANT 270 FT /note="F -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519988)" FT /id="VAR_045342" FT VARIANT 270 FT /note="F -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519987)" FT /id="VAR_045343" FT VARIANT 270 FT /note="F -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519986)" FT /id="VAR_045344" FT VARIANT 270 FT /note="F -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519988)" FT /id="VAR_045345" FT VARIANT 270 FT /note="F -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045346" FT VARIANT 271 FT /note="E -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045347" FT VARIANT 271 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045348" FT VARIANT 271 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045349" FT VARIANT 271 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501191)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036508" FT VARIANT 271 FT /note="E -> P (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045865" FT VARIANT 271 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045350" FT VARIANT 271 FT /note="E -> R (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045866" FT VARIANT 271 FT /note="E -> V (in an osteosarcoma with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_047199" FT VARIANT 272 FT /note="V -> A (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045351" FT VARIANT 272 FT /note="V -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs876660333)" FT /id="VAR_045352" FT VARIANT 272 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs876660333)" FT /id="VAR_045353" FT VARIANT 272 FT /note="V -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121912657)" FT /evidence="ECO:0000269|PubMed:1737852" FT /id="VAR_005992" FT VARIANT 272 FT /note="V -> M (in sporadic cancers; somatic mutation; FT dbSNP:rs121912657)" FT /id="VAR_045354" FT VARIANT 273 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs121913343)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17224074, ECO:0000269|PubMed:7887414, FT ECO:0000269|PubMed:9450901" FT /id="VAR_005993" FT VARIANT 273 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_005994" FT VARIANT 273 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; abolishes sequence-specific DNA FT binding; does not induce SNAI1 degradation; FT dbSNP:rs28934576)" FT /evidence="ECO:0000269|PubMed:10570149, FT ECO:0000269|PubMed:1394225, ECO:0000269|PubMed:1565144, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:1699228, FT ECO:0000269|PubMed:1868473, ECO:0000269|PubMed:20385133, FT ECO:0000269|PubMed:7682763, ECO:0000269|Ref.14" FT /id="VAR_005995" FT VARIANT 273 FT /note="R -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934576)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036509" FT VARIANT 273 FT /note="R -> N (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045867" FT VARIANT 273 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs28934576)" FT /evidence="ECO:0000269|PubMed:27657329" FT /id="VAR_045355" FT VARIANT 273 FT /note="R -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045356" FT VARIANT 273 FT /note="R -> S (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs121913343)" FT /id="VAR_045357" FT VARIANT 273 FT /note="R -> Y (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045868" FT VARIANT 274 FT /note="V -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520006)" FT /id="VAR_045358" FT VARIANT 274 FT /note="V -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520006)" FT /id="VAR_045359" FT VARIANT 274 FT /note="V -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520005)" FT /id="VAR_005997" FT VARIANT 274 FT /note="V -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520006)" FT /id="VAR_047200" FT VARIANT 274 FT /note="V -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045360" FT VARIANT 274 FT /note="V -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1057520005)" FT /id="VAR_045361" FT VARIANT 275 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs863224451)" FT /id="VAR_045362" FT VARIANT 275 FT /note="C -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045363" FT VARIANT 275 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519983)" FT /id="VAR_045364" FT VARIANT 275 FT /note="C -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs863224451)" FT /id="VAR_045365" FT VARIANT 275 FT /note="C -> W (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525279)" FT /id="VAR_005999" FT VARIANT 275 FT /note="C -> Y (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs863224451)" FT /evidence="ECO:0000269|PubMed:7887414" FT /id="VAR_005998" FT VARIANT 276 FT /note="A -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs786202082)" FT /id="VAR_045366" FT VARIANT 276 FT /note="A -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs786202082)" FT /id="VAR_045367" FT VARIANT 276 FT /note="A -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691029)" FT /id="VAR_045368" FT VARIANT 276 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045369" FT VARIANT 276 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045370" FT VARIANT 276 FT /note="A -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045371" FT VARIANT 277 FT /note="C -> F (in sporadic cancers; somatic mutation; FT dbSNP:rs763098116)" FT /id="VAR_045372" FT VARIANT 277 FT /note="C -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795369)" FT /id="VAR_006000" FT VARIANT 277 FT /note="C -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795369)" FT /id="VAR_045373" FT VARIANT 277 FT /note="C -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045374" FT VARIANT 277 FT /note="C -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_047201" FT VARIANT 277 FT /note="C -> Y (in an osteosarcoma with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs763098116)" FT /id="VAR_045375" FT VARIANT 278 FT /note="P -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs17849781)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_006001" FT VARIANT 278 FT /note="P -> F (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045869" FT VARIANT 278 FT /note="P -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs876659802)" FT /id="VAR_006002" FT VARIANT 278 FT /note="P -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs876659802)" FT /evidence="ECO:0000269|PubMed:2263646" FT /id="VAR_006003" FT VARIANT 278 FT /note="P -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs876659802)" FT /id="VAR_045376" FT VARIANT 278 FT /note="P -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs17849781)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:2263646, ECO:0000269|PubMed:9450901" FT /id="VAR_006004" FT VARIANT 278 FT /note="P -> T (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs17849781)" FT /id="VAR_006005" FT VARIANT 279 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1064793881)" FT /id="VAR_006006" FT VARIANT 279 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525248)" FT /id="VAR_045377" FT VARIANT 279 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045378" FT VARIANT 279 FT /note="G -> W (in sporadic cancers; somatic mutation)" FT /id="VAR_045379" FT VARIANT 280 FT /note="R -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs753660142)" FT /id="VAR_045380" FT VARIANT 280 FT /note="R -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs121912660)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_006008" FT VARIANT 280 FT /note="R -> K (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; no effect on interaction with CCAR2; FT dbSNP:rs121912660)" FT /evidence="ECO:0000269|PubMed:1694291, FT ECO:0000269|PubMed:25732823" FT /id="VAR_006007" FT VARIANT 280 FT /note="R -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045381" FT VARIANT 280 FT /note="R -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045382" FT VARIANT 280 FT /note="R -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs121912660)" FT /evidence="ECO:0000269|PubMed:1631151" FT /id="VAR_006009" FT VARIANT 281..282 FT /note="DR -> EW (in sporadic cancers; somatic mutation)" FT /id="VAR_047203" FT VARIANT 281 FT /note="D -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs587781525)" FT /id="VAR_006010" FT VARIANT 281 FT /note="D -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519984)" FT /evidence="ECO:0000269|PubMed:1459726" FT /id="VAR_006011" FT VARIANT 281 FT /note="D -> G (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs587781525)" FT /id="VAR_006012" FT VARIANT 281 FT /note="D -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs764146326)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_006013" FT VARIANT 281 FT /note="D -> N (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs764146326)" FT /id="VAR_047202" FT VARIANT 281 FT /note="D -> R (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045870" FT VARIANT 281 FT /note="D -> V (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs587781525)" FT /id="VAR_006014" FT VARIANT 281 FT /note="D -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs764146326)" FT /id="VAR_045383" FT VARIANT 282 FT /note="R -> G (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs28934574)" FT /id="VAR_045384" FT VARIANT 282 FT /note="R -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045385" FT VARIANT 282 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs730882008)" FT /id="VAR_006015" FT VARIANT 282 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs730882008)" FT /id="VAR_045386" FT VARIANT 282 FT /note="R -> Q (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs730882008)" FT /evidence="ECO:0000269|PubMed:18453682, ECO:0000269|Ref.22" FT /id="VAR_045387" FT VARIANT 282 FT /note="R -> W (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; does not induce SNAI1 FT degradation; dbSNP:rs28934574)" FT /evidence="ECO:0000269|PubMed:20385133, FT ECO:0000269|PubMed:8829627" FT /id="VAR_006016" FT VARIANT 283 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs149633775)" FT /id="VAR_006017" FT VARIANT 283 FT /note="R -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_006018" FT VARIANT 283 FT /note="R -> H (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs371409680)" FT /id="VAR_006019" FT VARIANT 283 FT /note="R -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045388" FT VARIANT 283 FT /note="R -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_006020" FT VARIANT 283 FT /note="R -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs149633775)" FT /id="VAR_045389" FT VARIANT 284 FT /note="T -> A (in sporadic cancers; somatic mutation)" FT /evidence="ECO:0000269|PubMed:20959462" FT /id="VAR_006021" FT VARIANT 284 FT /note="T -> I (in sporadic cancers; somatic mutation; FT dbSNP:rs863224685)" FT /id="VAR_045390" FT VARIANT 284 FT /note="T -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045391" FT VARIANT 284 FT /note="T -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs1204379654)" FT /id="VAR_006022" FT VARIANT 285 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045392" FT VARIANT 285 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045393" FT VARIANT 285 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045394" FT VARIANT 285 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs112431538)" FT /evidence="ECO:0000269|PubMed:1459726, FT ECO:0000269|PubMed:1694291" FT /id="VAR_006023" FT VARIANT 285 FT /note="E -> Q (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_006024" FT VARIANT 285 FT /note="E -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs121912667)" FT /id="VAR_006025" FT VARIANT 286 FT /note="E -> A (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1057519985)" FT /id="VAR_006026" FT VARIANT 286 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_006027" FT VARIANT 286 FT /note="E -> G (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519985)" FT /id="VAR_006028" FT VARIANT 286 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs786201059)" FT /evidence="ECO:0000269|PubMed:11023613, FT ECO:0000269|PubMed:8316628" FT /id="VAR_006029" FT VARIANT 286 FT /note="E -> L (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045871" FT VARIANT 286 FT /note="E -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs786201059)" FT /evidence="ECO:0000269|PubMed:8829627" FT /id="VAR_006030" FT VARIANT 286 FT /note="E -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1057519985)" FT /id="VAR_045395" FT VARIANT 287 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_047204" FT VARIANT 287 FT /note="E -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs748891343)" FT /id="VAR_045396" FT VARIANT 287 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045397" FT VARIANT 287 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs587782006)" FT /id="VAR_045398" FT VARIANT 287 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045399" FT VARIANT 288 FT /note="N -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045400" FT VARIANT 288 FT /note="N -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_045401" FT VARIANT 288 FT /note="N -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045402" FT VARIANT 288 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045403" FT VARIANT 288 FT /note="N -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045404" FT VARIANT 289 FT /note="L -> F (in sporadic cancers; somatic mutation)" FT /id="VAR_045405" FT VARIANT 289 FT /note="L -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045406" FT VARIANT 289 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045407" FT VARIANT 289 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045408" FT VARIANT 289 FT /note="L -> V (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525154)" FT /id="VAR_045409" FT VARIANT 290 FT /note="R -> C (in sporadic cancers; somatic mutation; FT dbSNP:rs770374782)" FT /id="VAR_045410" FT VARIANT 290 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs55819519)" FT /id="VAR_045411" FT VARIANT 290 FT /note="R -> L (in LFS; germline mutation and in sporadic FT cancers; somatic mutation)" FT /id="VAR_045412" FT VARIANT 291 FT /note="K -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525126)" FT /id="VAR_045413" FT VARIANT 291 FT /note="K -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045414" FT VARIANT 291 FT /note="K -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs372613518)" FT /id="VAR_045415" FT VARIANT 291 FT /note="K -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_047205" FT VARIANT 291 FT /note="K -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs781490101)" FT /id="VAR_045416" FT VARIANT 291 FT /note="K -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045417" FT VARIANT 292 FT /note="K -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045418" FT VARIANT 292 FT /note="K -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045872" FT VARIANT 292 FT /note="K -> I (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation; dbSNP:rs121912663)" FT /evidence="ECO:0000269|PubMed:10484981" FT /id="VAR_015819" FT VARIANT 292 FT /note="K -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045419" FT VARIANT 292 FT /note="K -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045420" FT VARIANT 292 FT /note="K -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs121912663)" FT /id="VAR_045421" FT VARIANT 292 FT /note="K -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045422" FT VARIANT 293 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045423" FT VARIANT 293 FT /note="G -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs587780076)" FT /id="VAR_045424" FT VARIANT 293 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045425" FT VARIANT 293 FT /note="G -> W (in a brain tumor with no family history; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs587780076)" FT /id="VAR_045426" FT VARIANT 294 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045427" FT VARIANT 294 FT /note="E -> D (in sporadic cancers; somatic mutation; FT dbSNP:rs1305324490)" FT /id="VAR_045428" FT VARIANT 294 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045429" FT VARIANT 294 FT /note="E -> K (in sporadic cancers; somatic mutation)" FT /id="VAR_047206" FT VARIANT 294 FT /note="E -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045430" FT VARIANT 294 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045431" FT VARIANT 295 FT /note="P -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045432" FT VARIANT 295 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs751713111)" FT /id="VAR_045433" FT VARIANT 295 FT /note="P -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs751713111)" FT /id="VAR_045434" FT VARIANT 295 FT /note="P -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs1131691006)" FT /id="VAR_045435" FT VARIANT 296 FT /note="H -> C (in sporadic cancers; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045873" FT VARIANT 296 FT /note="H -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045436" FT VARIANT 296 FT /note="H -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_047207" FT VARIANT 296 FT /note="H -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045437" FT VARIANT 296 FT /note="H -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_006031" FT VARIANT 296 FT /note="H -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045438" FT VARIANT 296 FT /note="H -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs483352696)" FT /id="VAR_045439" FT VARIANT 296 FT /note="H -> Y (in sporadic cancers; somatic mutation; FT dbSNP:rs672601296)" FT /id="VAR_045440" FT VARIANT 297 FT /note="H -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045441" FT VARIANT 297 FT /note="H -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045442" FT VARIANT 297 FT /note="H -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045443" FT VARIANT 297 FT /note="H -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs876659477)" FT /id="VAR_045444" FT VARIANT 297 FT /note="H -> Y (in sporadic cancers; somatic mutation)" FT /id="VAR_045445" FT VARIANT 298 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045446" FT VARIANT 298 FT /note="E -> D (in sporadic cancers; somatic mutation)" FT /id="VAR_045447" FT VARIANT 298 FT /note="E -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs201744589)" FT /id="VAR_045448" FT VARIANT 298 FT /note="E -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs201744589)" FT /id="VAR_045449" FT VARIANT 298 FT /note="E -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_045450" FT VARIANT 299 FT /note="L -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045451" FT VARIANT 299 FT /note="L -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045452" FT VARIANT 299 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045453" FT VARIANT 299 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045454" FT VARIANT 300 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045455" FT VARIANT 300 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs909643864)" FT /id="VAR_045456" FT VARIANT 300 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_006032" FT VARIANT 300 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045457" FT VARIANT 301 FT /note="P -> A (in sporadic cancers; somatic mutation)" FT /id="VAR_045458" FT VARIANT 301 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525067)" FT /id="VAR_006033" FT VARIANT 301 FT /note="P -> Q (in sporadic cancers; somatic mutation)" FT /id="VAR_045459" FT VARIANT 301 FT /note="P -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045460" FT VARIANT 301 FT /note="P -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_047208" FT VARIANT 302 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045461" FT VARIANT 302 FT /note="G -> E (in sporadic cancers; somatic mutation; FT dbSNP:rs1060501202)" FT /id="VAR_006034" FT VARIANT 302 FT /note="G -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs863224686)" FT /id="VAR_045462" FT VARIANT 302 FT /note="G -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_006035" FT VARIANT 303 FT /note="S -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045463" FT VARIANT 303 FT /note="S -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045464" FT VARIANT 303 FT /note="S -> N (in sporadic cancers; somatic mutation; FT dbSNP:rs876658714)" FT /id="VAR_045465" FT VARIANT 303 FT /note="S -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045466" FT VARIANT 304 FT /note="T -> A (in sporadic cancers; somatic mutation; FT dbSNP:rs587782654)" FT /id="VAR_045467" FT VARIANT 304 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045468" FT VARIANT 304 FT /note="T -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045469" FT VARIANT 304 FT /note="T -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_047209" FT VARIANT 305 FT /note="K -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045470" FT VARIANT 305 FT /note="K -> M (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation)" FT /id="VAR_045471" FT VARIANT 305 FT /note="K -> N (in sporadic cancers; somatic mutation; loss FT of nuclear localization)" FT /evidence="ECO:0000269|PubMed:10551826" FT /id="VAR_045472" FT VARIANT 305 FT /note="K -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045473" FT VARIANT 305 FT /note="K -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045474" FT VARIANT 306 FT /note="R -> P (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation)" FT /id="VAR_045475" FT VARIANT 306 FT /note="R -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs1048095040)" FT /id="VAR_006036" FT VARIANT 307 FT /note="A -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045476" FT VARIANT 307 FT /note="A -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045477" FT VARIANT 307 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_006037" FT VARIANT 308 FT /note="L -> M (in sporadic cancers; somatic mutation)" FT /id="VAR_045478" FT VARIANT 308 FT /note="L -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045479" FT VARIANT 309 FT /note="P -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045480" FT VARIANT 309 FT /note="P -> S (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; dbSNP:rs1555525012)" FT /evidence="ECO:0000269|Ref.14" FT /id="VAR_006038" FT VARIANT 310 FT /note="N -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045481" FT VARIANT 310 FT /note="N -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045482" FT VARIANT 311 FT /note="N -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs1555525007)" FT /id="VAR_045483" FT VARIANT 311 FT /note="N -> K (in a sporadic cancer; somatic mutation)" FT /id="VAR_045484" FT VARIANT 311 FT /note="N -> S (in a sporadic cancer; somatic mutation; FT dbSNP:rs56184981)" FT /id="VAR_045485" FT VARIANT 311 FT /note="N -> T (in sporadic cancers; somatic mutation; FT dbSNP:rs56184981)" FT /id="VAR_045486" FT VARIANT 312 FT /note="T -> I (in sporadic cancers; somatic mutation)" FT /id="VAR_045487" FT VARIANT 312 FT /note="T -> S (in sporadic cancers; somatic mutation; FT dbSNP:rs145151284)" FT /id="VAR_045488" FT VARIANT 313 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045489" FT VARIANT 313 FT /note="S -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045490" FT VARIANT 313 FT /note="S -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045491" FT VARIANT 313 FT /note="S -> R (in a sporadic cancer; somatic mutation; FT dbSNP:rs1367492395)" FT /id="VAR_045492" FT VARIANT 314 FT /note="S -> F (in a sporadic cancer; somatic mutation; FT dbSNP:rs751440465)" FT /id="VAR_045493" FT VARIANT 315 FT /note="S -> C (in a sporadic cancer; somatic mutation)" FT /id="VAR_045494" FT VARIANT 315 FT /note="S -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045495" FT VARIANT 315 FT /note="S -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045496" FT VARIANT 316 FT /note="P -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555524979)" FT /id="VAR_045497" FT VARIANT 316 FT /note="P -> T (in a sporadic cancer; somatic mutation; FT dbSNP:rs772773208)" FT /id="VAR_045498" FT VARIANT 317 FT /note="Q -> H (in a kidney cancer with no family history; FT germline mutation and in a sporadic cancer; somatic FT mutation; dbSNP:rs1060501199)" FT /id="VAR_045499" FT VARIANT 317 FT /note="Q -> K (in sporadic cancers; somatic mutation; FT dbSNP:rs764735889)" FT /id="VAR_045500" FT VARIANT 317 FT /note="Q -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_047210" FT VARIANT 317 FT /note="Q -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045501" FT VARIANT 317 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1159579789)" FT /id="VAR_045502" FT VARIANT 318 FT /note="P -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs1555524975)" FT /id="VAR_045503" FT VARIANT 319 FT /note="K -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045504" FT VARIANT 319 FT /note="K -> N (in a sporadic cancer; somatic mutation)" FT /id="VAR_045505" FT VARIANT 319 FT /note="K -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045506" FT VARIANT 320 FT /note="K -> N (in sporadic cancers; somatic mutation)" FT /id="VAR_045507" FT VARIANT 321 FT /note="K -> E (in kidney cancer; germline mutation)" FT /id="VAR_045508" FT VARIANT 321 FT /note="K -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045509" FT VARIANT 322 FT /note="P -> L (in sporadic cancers; somatic mutation)" FT /id="VAR_045510" FT VARIANT 322 FT /note="P -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045511" FT VARIANT 323 FT /note="L -> G (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045874" FT VARIANT 323 FT /note="L -> M (in a sporadic cancer; somatic mutation)" FT /id="VAR_045512" FT VARIANT 323 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045513" FT VARIANT 323 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045514" FT VARIANT 323 FT /note="L -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs1432281680)" FT /id="VAR_047211" FT VARIANT 324 FT /note="D -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045515" FT VARIANT 324 FT /note="D -> S (in a sporadic cancer; somatic mutation; FT requires 2 nucleotide substitutions)" FT /id="VAR_045875" FT VARIANT 324 FT /note="D -> Y (in a sporadic cancer; somatic mutation)" FT /id="VAR_045516" FT VARIANT 325 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045517" FT VARIANT 325 FT /note="G -> E (in sporadic cancers; somatic mutation)" FT /id="VAR_045518" FT VARIANT 325 FT /note="G -> V (in LFS; germline mutation; FT dbSNP:rs121912659)" FT /evidence="ECO:0000269|PubMed:1565144" FT /id="VAR_006039" FT VARIANT 326 FT /note="E -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045519" FT VARIANT 327 FT /note="Y -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045520" FT VARIANT 327 FT /note="Y -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045521" FT VARIANT 328 FT /note="F -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045522" FT VARIANT 328 FT /note="F -> S (in sporadic cancers; somatic mutation)" FT /id="VAR_045523" FT VARIANT 328 FT /note="F -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045524" FT VARIANT 329 FT /note="T -> I (in a sporadic cancer; somatic mutation; FT dbSNP:rs969930693)" FT /id="VAR_045525" FT VARIANT 329 FT /note="T -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045526" FT VARIANT 330 FT /note="L -> H (in sporadic cancers; somatic mutation)" FT /id="VAR_045527" FT VARIANT 330 FT /note="L -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_047212" FT VARIANT 330 FT /note="L -> R (in sporadic cancers; somatic mutation)" FT /id="VAR_045528" FT VARIANT 331 FT /note="Q -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs11575996)" FT /id="VAR_045529" FT VARIANT 331 FT /note="Q -> P (in sporadic cancers; somatic mutation)" FT /id="VAR_045530" FT VARIANT 331 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs1064795056)" FT /id="VAR_045531" FT VARIANT 332 FT /note="I -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045532" FT VARIANT 334 FT /note="G -> V (in sporadic cancers; somatic mutation)" FT /id="VAR_006040" FT VARIANT 334 FT /note="G -> W (in a sporadic cancer; somatic mutation; FT dbSNP:rs730882028)" FT /id="VAR_045533" FT VARIANT 335 FT /note="R -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045534" FT VARIANT 335 FT /note="R -> H (in a sporadic cancer; somatic mutation; FT dbSNP:rs771939956)" FT /id="VAR_045535" FT VARIANT 335 FT /note="R -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045536" FT VARIANT 337 FT /note="R -> C (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; impaired ability to tetramerize FT and undergo liquid-liquid phase separation; FT dbSNP:rs587782529)" FT /evidence="ECO:0000269|PubMed:36108750, FT ECO:0000269|PubMed:9452042" FT /id="VAR_006041" FT VARIANT 337 FT /note="R -> H (in LFS; germline mutation and in sporadic FT cancers; somatic mutation; impaired ability to tetramerize FT and undergo liquid-liquid phase separation; FT dbSNP:rs121912664)" FT /evidence="ECO:0000269|PubMed:11481490, FT ECO:0000269|PubMed:36108750" FT /id="VAR_035016" FT VARIANT 337 FT /note="R -> L (in sporadic cancers; somatic mutation; FT dbSNP:rs121912664)" FT /id="VAR_045537" FT VARIANT 337 FT /note="R -> P (in sporadic cancers; somatic mutation; FT impaired ability to tetramerize and undergo liquid-liquid FT phase separation; dbSNP:rs121912664)" FT /evidence="ECO:0000269|PubMed:36108750" FT /id="VAR_045538" FT VARIANT 338 FT /note="F -> I (in a sporadic cancer; somatic mutation)" FT /id="VAR_045539" FT VARIANT 338 FT /note="F -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs150293825)" FT /id="VAR_045540" FT VARIANT 339 FT /note="E -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs17882252)" FT /evidence="ECO:0000269|Ref.12" FT /id="VAR_022316" FT VARIANT 339 FT /note="E -> Q (in a sporadic cancer; somatic mutation; FT dbSNP:rs17882252)" FT /id="VAR_045541" FT VARIANT 341 FT /note="F -> C (in sporadic cancers; somatic mutation)" FT /id="VAR_045542" FT VARIANT 342 FT /note="R -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045543" FT VARIANT 342 FT /note="R -> P (in sporadic cancers; somatic mutation; FT dbSNP:rs375338359)" FT /id="VAR_045544" FT VARIANT 342 FT /note="R -> Q (in sporadic cancers; somatic mutation; FT dbSNP:rs375338359)" FT /id="VAR_047213" FT VARIANT 343 FT /note="E -> G (in sporadic cancers; somatic mutation)" FT /id="VAR_045545" FT VARIANT 344 FT /note="L -> P (in LFS; germline mutation and in a sporadic FT cancer; somatic mutation; impaired ability to tetramerize FT and undergo liquid-liquid phase separation; FT dbSNP:rs121912662)" FT /evidence="ECO:0000269|PubMed:36108750" FT /id="VAR_045546" FT VARIANT 344 FT /note="L -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_045547" FT VARIANT 346 FT /note="E -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045548" FT VARIANT 347 FT /note="A -> G (in a sporadic cancer; somatic mutation)" FT /id="VAR_045549" FT VARIANT 347 FT /note="A -> T (in sporadic cancers; somatic mutation)" FT /id="VAR_045550" FT VARIANT 348 FT /note="L -> F (in a sporadic cancer; somatic mutation)" FT /id="VAR_045551" FT VARIANT 348 FT /note="L -> S (in a sporadic cancer; somatic mutation)" FT /id="VAR_045552" FT VARIANT 349 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045553" FT VARIANT 352 FT /note="D -> H (in a sporadic cancer; somatic mutation)" FT /id="VAR_045554" FT VARIANT 353 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045555" FT VARIANT 354 FT /note="Q -> E (in a sporadic cancer; somatic mutation)" FT /id="VAR_045556" FT VARIANT 354 FT /note="Q -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs755394212)" FT /id="VAR_045557" FT VARIANT 354 FT /note="Q -> R (in sporadic cancers; somatic mutation; FT dbSNP:rs752142489)" FT /id="VAR_047214" FT VARIANT 356 FT /note="G -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045558" FT VARIANT 356 FT /note="G -> W (in a sporadic cancer; somatic mutation)" FT /id="VAR_045559" FT VARIANT 358 FT /note="E -> D (in a sporadic cancer; somatic mutation)" FT /id="VAR_045560" FT VARIANT 358 FT /note="E -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs587782237)" FT /id="VAR_045561" FT VARIANT 360 FT /note="G -> A (in dbSNP:rs35993958)" FT /id="VAR_045562" FT VARIANT 360 FT /note="G -> V (in a sporadic cancer; somatic mutation; FT dbSNP:rs35993958)" FT /id="VAR_045563" FT VARIANT 363 FT /note="R -> K (in a sporadic cancer; somatic mutation; FT dbSNP:rs876660285)" FT /id="VAR_045564" FT VARIANT 364 FT /note="A -> P (in a sporadic cancer; somatic mutation)" FT /id="VAR_045565" FT VARIANT 364 FT /note="A -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045566" FT VARIANT 364 FT /note="A -> V (in a sporadic cancer; somatic mutation)" FT /id="VAR_045567" FT VARIANT 365 FT /note="H -> R (in a sporadic cancer; somatic mutation)" FT /id="VAR_047215" FT VARIANT 365 FT /note="H -> Y (in a familial cancer not matching LFS; FT germline mutation and in a sporadic cancer; somatic FT mutation; dbSNP:rs267605075)" FT /id="VAR_045568" FT VARIANT 366 FT /note="S -> A (in a familial cancer not matching LFS; FT germline mutation and in sporadic cancers; somatic FT mutation; dbSNP:rs17881470)" FT /evidence="ECO:0000269|Ref.12" FT /id="VAR_022317" FT VARIANT 370 FT /note="K -> Q (in a sporadic cancer; somatic mutation)" FT /id="VAR_045569" FT VARIANT 376 FT /note="S -> A (in a sporadic cancer; somatic mutation)" FT /id="VAR_045570" FT VARIANT 376 FT /note="S -> T (in a sporadic cancer; somatic mutation)" FT /id="VAR_045571" FT VARIANT 379 FT /note="R -> H (in sporadic cancers; somatic mutation; FT dbSNP:rs863224682)" FT /id="VAR_045572" FT VARIANT 385 FT /note="F -> L (in a sporadic cancer; somatic mutation; FT dbSNP:rs1555524094)" FT /id="VAR_045573" FT VARIANT 389 FT /note="G -> W (in a sporadic cancer; somatic mutation; FT dbSNP:rs587783064)" FT /id="VAR_045574" FT VARIANT 392 FT /note="S -> L (in a sporadic cancer; somatic mutation)" FT /id="VAR_045575" FT MUTAGEN 15 FT /note="S->A: Loss of interaction with PPP2R5C, PPP2CA AND FT PPP2R1A." FT /evidence="ECO:0000269|PubMed:17967874" FT MUTAGEN 18 FT /note="T->A: No effect on interaction with MDM2 and FT increase in protein levels after DNA damage." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 20 FT /note="S->A: Abolishes phosphorylation site. Abolishes FT increase in protein levels after DNA damage." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 20 FT /note="S->D: Constitutively increased TP53 protein levels." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 22..23 FT /note="LW->QS: Loss of interaction with MDM2, leading to FT constitutively increased TP53 protein levels." FT /evidence="ECO:0000269|PubMed:10570149" FT MUTAGEN 24 FT /note="K->R: Abolishes ubiquitination by MUL1." FT /evidence="ECO:0000269|PubMed:21597459" FT MUTAGEN 37 FT /note="S->D: Abolishes phosphorylation by MAPKAPK5." FT /evidence="ECO:0000269|PubMed:17254968" FT MUTAGEN 46 FT /note="S->A: Abolishes phosphorylation by DYRK2 and HIPK2 FT and acetylation of K-382 by CREBBP." FT /evidence="ECO:0000269|PubMed:11740489, FT ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:17349958" FT MUTAGEN 46 FT /note="Missing: Alters interaction with WWOX." FT /evidence="ECO:0000269|PubMed:11740489, FT ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:17349958" FT MUTAGEN 55 FT /note="T->A: Blocks phosphorylation by TAF1." FT /evidence="ECO:0000269|PubMed:15053879" FT MUTAGEN 183 FT /note="S->A: Abolishes strongly phosphorylation." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 183 FT /note="S->E: Inhibits slightly its transcriptional FT activity." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 248 FT /note="R->S: Does not induce SNAI1 degradation." FT /evidence="ECO:0000269|PubMed:20385133" FT MUTAGEN 269 FT /note="S->A: Abolishes phosphorylation." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 269 FT /note="S->E: Inhibits strongly its transcriptional FT activity." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 284 FT /note="T->E: Inhibits strongly its transcriptional FT activity." FT /evidence="ECO:0000269|PubMed:20959462" FT MUTAGEN 291..292 FT /note="KK->RR: Abolishes polyubiquitination by MKRN1." FT /evidence="ECO:0000269|PubMed:19536131" FT MUTAGEN 319 FT /note="K->A: Loss of nuclear localization; when associated FT with A-320 and A-321." FT /evidence="ECO:0000269|PubMed:2156209" FT MUTAGEN 320 FT /note="K->A: Loss of nuclear localization; when associated FT with A-319 and A-321." FT /evidence="ECO:0000269|PubMed:2156209" FT MUTAGEN 321 FT /note="K->A: Loss of nuclear localization; when associated FT with A-319 and A-320." FT /evidence="ECO:0000269|PubMed:2156209" FT MUTAGEN 333..337 FT /note="RGRER->KGKEK: Reduced methylation by PRMT5. Reduced FT nuclear localization. Decreased binding to promoters of FT target genes. Reduced transcriptional activity. Decrease in FT cell cycle arrest." FT /evidence="ECO:0000269|PubMed:19011621" FT MUTAGEN 359 FT /note="P->D: Abolishes binding to USP7." FT /evidence="ECO:0000269|PubMed:16402859" FT MUTAGEN 361 FT /note="G->E: Abolishes binding to USP7." FT /evidence="ECO:0000269|PubMed:16402859" FT MUTAGEN 362 FT /note="S->A: Abolishes binding to USP7." FT /evidence="ECO:0000269|PubMed:16402859" FT MUTAGEN 370 FT /note="K->R: Induces a decrease in methylation by SMYD2." FT /evidence="ECO:0000269|PubMed:17108971" FT MUTAGEN 372 FT /note="K->R: Induces a decrease in protein stabilization." FT /evidence="ECO:0000269|PubMed:15525938" FT MUTAGEN 373 FT /note="K->R: Abolishes dimethylation by EHMT1 and EHMT2." FT /evidence="ECO:0000269|PubMed:20118233" FT MUTAGEN 381 FT /note="K->Q: Mimics acetylation, leading to increased FT stability." FT /evidence="ECO:0000269|PubMed:29474172" FT MUTAGEN 381 FT /note="K->R: Decreased acetylation." FT /evidence="ECO:0000269|PubMed:29474172" FT MUTAGEN 382 FT /note="K->A: Abolishes acetylation by CREBBP." FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725" FT MUTAGEN 382 FT /note="K->R: Abolishes monomethylation by KMT5A." FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:17707234, FT ECO:0000269|PubMed:20870725" FT MUTAGEN 383 FT /note="L->A: Abolishes S-315 phosphorylation by CDK2/cyclin FT A." FT /evidence="ECO:0000269|PubMed:10884347" FT MUTAGEN 385 FT /note="F->A: Reduced SUMO1 conjugation." FT /evidence="ECO:0000269|PubMed:10884347, FT ECO:0000269|PubMed:11124955" FT MUTAGEN 386 FT /note="K->A: Abolishes SUMO1 conjugation, in vitro and in FT vivo." FT /evidence="ECO:0000269|PubMed:11124955, ECO:0000269|Ref.37" FT MUTAGEN 387 FT /note="T->A: No effect SUMO1 conjugation." FT /evidence="ECO:0000269|PubMed:11124955" FT MUTAGEN 388 FT /note="E->A: Abolishes SUMO1 conjugation." FT /evidence="ECO:0000269|PubMed:11124955" FT MUTAGEN 392 FT /note="S->D: Mimics phosphorylation; promotes ability to FT undergo liquid-liquid phase separation." FT /evidence="ECO:0000269|PubMed:35618207" FT MUTAGEN 392 FT /note="S->E: Abolished ability to undergo liquid-liquid FT phase separation." FT /evidence="ECO:0000269|PubMed:31953488" FT HELIX 3..6 FT /evidence="ECO:0007829|PDB:5HOU" FT TURN 8..10 FT /evidence="ECO:0007829|PDB:5HOU" FT HELIX 19..29 FT /evidence="ECO:0007829|PDB:9C5S" FT HELIX 30..32 FT /evidence="ECO:0007829|PDB:5HPD" FT STRAND 33..35 FT /evidence="ECO:0007829|PDB:2L14" FT HELIX 36..38 FT /evidence="ECO:0007829|PDB:2B3G" FT HELIX 41..44 FT /evidence="ECO:0007829|PDB:2B3G" FT HELIX 47..55 FT /evidence="ECO:0007829|PDB:2B3G" FT STRAND 95..97 FT /evidence="ECO:0007829|PDB:7B49" FT TURN 105..108 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 110..112 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 118..120 FT /evidence="ECO:0007829|PDB:3Q05" FT TURN 121..123 FT /evidence="ECO:0007829|PDB:3Q05" FT STRAND 124..127 FT /evidence="ECO:0007829|PDB:3D06" FT TURN 128..131 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 132..135 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 141..146 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 148..150 FT /evidence="ECO:0007829|PDB:5UN8" FT STRAND 156..165 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 166..168 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 177..180 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 181..183 FT /evidence="ECO:0007829|PDB:4KVP" FT STRAND 187..189 FT /evidence="ECO:0007829|PDB:6GGC" FT STRAND 194..199 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 204..207 FT /evidence="ECO:0007829|PDB:3D06" FT TURN 209..211 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 214..219 FT /evidence="ECO:0007829|PDB:3D06" FT TURN 225..227 FT /evidence="ECO:0007829|PDB:2FEJ" FT STRAND 228..236 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 240..242 FT /evidence="ECO:0007829|PDB:3D07" FT TURN 243..248 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 251..258 FT /evidence="ECO:0007829|PDB:3D06" FT STRAND 260..262 FT /evidence="ECO:0007829|PDB:2ADY" FT STRAND 264..274 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 278..287 FT /evidence="ECO:0007829|PDB:3D06" FT HELIX 288..290 FT /evidence="ECO:0007829|PDB:4HJE" FT HELIX 322..324 FT /evidence="ECO:0007829|PDB:3Q01" FT STRAND 327..334 FT /evidence="ECO:0007829|PDB:3Q01" FT HELIX 335..354 FT /evidence="ECO:0007829|PDB:1AIE" FT HELIX 375..380 FT /evidence="ECO:0007829|PDB:1YC5" SQ SEQUENCE 393 AA; 43653 MW; AD5C149FD8106131 CRC64; MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDLMLSPDDI EQWFTEDPGP DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS WPLSSSVPSQ KTYQGSYGFR LGFLHSGTAK SVTCTYSPAL NKMFCQLAKT CPVQLWVDST PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE RCSDSDGLAP PQHLIRVEGN LRVEYLDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS SCMGGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENLR KKGEPHHELP PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPG GSRAHSSHLK SKKGQSTSRH KKLMFKTEGP DSD // ID PAK5_HUMAN Reviewed; 719 AA. AC Q9P286; A8K5T6; D3DW14; Q5W115; Q8TB93; Q9BX09; Q9ULF6; DT 24-JAN-2001, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-2000, sequence version 1. DT 28-JAN-2026, entry version 227. DE RecName: Full=Serine/threonine-protein kinase PAK 5 {ECO:0000305}; DE EC=2.7.11.1; DE AltName: Full=p21-activated kinase 5; DE Short=PAK-5; DE AltName: Full=p21-activated kinase 7; DE Short=PAK-7; GN Name=PAK5 {ECO:0000312|HGNC:HGNC:15916}; Synonyms=KIAA1264, PAK7; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Brain; RX PubMed=12032833; DOI=10.1038/sj.onc.1205478; RA Pandey A., Dan I., Kristiansen T.Z., Watanabe N.M., Voldby J., Kajikawa E., RA Khosravi-Far R., Blagoev B., Mann M.; RT "Cloning and characterization of PAK5, a novel member of mammalian p21- RT activated kinase-II subfamily that is predominantly expressed in brain."; RL Oncogene 21:3939-3948(2002). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=10574462; DOI=10.1093/dnares/6.5.337; RA Nagase T., Ishikawa K., Kikuno R., Hirosawa M., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XV. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 6:337-345(1999). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASN-511. RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=11780052; DOI=10.1038/414865a; RA Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R., RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L., RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P., RA Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D., RA Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G., RA Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E., RA Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D., RA Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P., RA Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E., RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J., RA Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D., RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S., RA Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D., RA Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A., RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T., RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I., RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M., RA Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D., RA Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M., RA Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A., RA Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L., RA Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L., RA Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 20."; RL Nature 414:865-871(2001). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP DOMAIN, AND MUTAGENESIS OF 19-HIS--HIS-22. RX PubMed=12860998; DOI=10.1074/jbc.c300234200; RA Ching Y.P., Leong V.Y., Wong C.M., Kung H.F.; RT "Identification of an autoinhibitory domain of p21-activated protein kinase RT 5."; RL J. Biol. Chem. 278:33621-33624(2003). RN [8] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=12897128; DOI=10.1128/mcb.23.16.5526-5539.2003; RA Cotteret S., Jaffer Z.M., Beeser A., Chernoff J.; RT "p21-Activated kinase 5 (Pak5) localizes to mitochondria and inhibits RT apoptosis by phosphorylating BAD."; RL Mol. Cell. Biol. 23:5526-5539(2003). RN [9] RP FUNCTION, AND INTERACTION WITH MARK2. RX PubMed=16014608; DOI=10.1091/mbc.e05-01-0081; RA Matenia D., Griesshaber B., Li X.Y., Thiessen A., Johne C., Jiao J., RA Mandelkow E., Mandelkow E.M.; RT "PAK5 kinase is an inhibitor of MARK/Par-1, which leads to stable RT microtubules and dynamic actin."; RL Mol. Biol. Cell 16:4410-4422(2005). RN [10] RP INTERACTION WITH RHOD AND RHOH. RX PubMed=17064668; DOI=10.1016/j.bbrc.2006.09.172; RA Wu X., Frost J.A.; RT "Multiple Rho proteins regulate the subcellular targeting of PAK5."; RL Biochem. Biophys. Res. Commun. 351:328-335(2006). RN [11] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=16581795; DOI=10.1128/mcb.26.8.3215-3230.2006; RA Cotteret S., Chernoff J.; RT "Nucleocytoplasmic shuttling of Pak5 regulates its antiapoptotic RT properties."; RL Mol. Cell. Biol. 26:3215-3230(2006). RN [12] RP FUNCTION IN PHOSPHORYLATION OF RAF1. RX PubMed=18465753; DOI=10.1002/jcb.21809; RA Wu X., Carr H.S., Dan I., Ruvolo P.P., Frost J.A.; RT "p21 activated kinase 5 activates Raf-1 and targets it to mitochondria."; RL J. Cell. Biochem. 105:167-175(2008). RN [13] RP FUNCTION IN PHOSPHORYLATION OF CTNND1. RX PubMed=20564219; DOI=10.1002/jcb.22639; RA Wong L.E., Reynolds A.B., Dissanayaka N.T., Minden A.; RT "p120-catenin is a binding partner and substrate for Group B Pak kinases."; RL J. Cell. Biochem. 110:1244-1254(2010). RN [14] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 425-719. RX PubMed=17292838; DOI=10.1016/j.str.2007.01.001; RA Eswaran J., Lee W.H., Debreczeni J.E., Filippakopoulos P., Turnbull A., RA Fedorov O., Deacon S.W., Peterson J.R., Knapp S.; RT "Crystal Structures of the p21-activated kinases PAK4, PAK5, and PAK6 RT reveal catalytic domain plasticity of active group II PAKs."; RL Structure 15:201-213(2007). RN [15] RP VARIANTS [LARGE SCALE ANALYSIS] ASP-118; ALA-187; PRO-312; PRO-335; RP ASN-511; ASN-538; SER-555; ILE-604 AND SER-704. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine protein kinase that plays a role in a CC variety of different signaling pathways including cytoskeleton CC regulation, cell migration, proliferation or cell survival. Activation CC by various effectors including growth factor receptors or active CDC42 CC and RAC1 results in a conformational change and a subsequent CC autophosphorylation on several serine and/or threonine residues. CC Phosphorylates the proto-oncogene RAF1 and stimulates its kinase CC activity. Promotes cell survival by phosphorylating the BCL2 antagonist CC of cell death BAD. Phosphorylates CTNND1, probably to regulate CC cytoskeletal organization and cell morphology. Keeps microtubules CC stable through MARK2 inhibition and destabilizes the F-actin network CC leading to the disappearance of stress fibers and focal adhesions. CC {ECO:0000269|PubMed:12897128, ECO:0000269|PubMed:16014608, CC ECO:0000269|PubMed:16581795, ECO:0000269|PubMed:18465753, CC ECO:0000269|PubMed:20564219}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- SUBUNIT: Interacts tightly with GTP-bound but not GDP-bound CDC42/p21 CC and RAC1. Interacts with MARK2, leading to inhibit MARK2 independently CC of kinase activity. Interacts with RHOD and RHOH. CC {ECO:0000269|PubMed:16014608, ECO:0000269|PubMed:17064668}. CC -!- INTERACTION: CC Q9P286; Q8IW93: ARHGEF19; NbExp=3; IntAct=EBI-741896, EBI-7799822; CC Q9P286; Q9H6L4: ARMC7; NbExp=3; IntAct=EBI-741896, EBI-742909; CC Q9P286; Q8N5M1: ATPAF2; NbExp=7; IntAct=EBI-741896, EBI-1166928; CC Q9P286; Q9H257: CARD9; NbExp=5; IntAct=EBI-741896, EBI-751319; CC Q9P286; Q9H257-2: CARD9; NbExp=3; IntAct=EBI-741896, EBI-11530605; CC Q9P286; Q8NEC5: CATSPER1; NbExp=3; IntAct=EBI-741896, EBI-744545; CC Q9P286; Q2TAC2-2: CCDC57; NbExp=3; IntAct=EBI-741896, EBI-10961624; CC Q9P286; P51959: CCNG1; NbExp=4; IntAct=EBI-741896, EBI-3905829; CC Q9P286; P60953: CDC42; NbExp=5; IntAct=EBI-741896, EBI-81752; CC Q9P286; Q96SW2: CRBN; NbExp=4; IntAct=EBI-741896, EBI-2510250; CC Q9P286; P48730: CSNK1D; NbExp=3; IntAct=EBI-741896, EBI-751621; CC Q9P286; P26196: DDX6; NbExp=3; IntAct=EBI-741896, EBI-351257; CC Q9P286; P50402: EMD; NbExp=3; IntAct=EBI-741896, EBI-489887; CC Q9P286; Q9H0I2: ENKD1; NbExp=3; IntAct=EBI-741896, EBI-744099; CC Q9P286; Q9Y3B2: EXOSC1; NbExp=3; IntAct=EBI-741896, EBI-371892; CC Q9P286; Q96CN9: GCC1; NbExp=3; IntAct=EBI-741896, EBI-746252; CC Q9P286; P42858: HTT; NbExp=3; IntAct=EBI-741896, EBI-466029; CC Q9P286; Q96EL1: INKA1; NbExp=5; IntAct=EBI-741896, EBI-10285157; CC Q9P286; Q96BZ8: LENG1; NbExp=3; IntAct=EBI-741896, EBI-726510; CC Q9P286; Q8TBB1: LNX1; NbExp=3; IntAct=EBI-741896, EBI-739832; CC Q9P286; Q96JP2: MYO15B; NbExp=3; IntAct=EBI-741896, EBI-7950783; CC Q9P286; P07196: NEFL; NbExp=3; IntAct=EBI-741896, EBI-475646; CC Q9P286; Q96HA8: NTAQ1; NbExp=3; IntAct=EBI-741896, EBI-741158; CC Q9P286; P16284: PECAM1; NbExp=3; IntAct=EBI-741896, EBI-716404; CC Q9P286; Q8WWY3: PRPF31; NbExp=6; IntAct=EBI-741896, EBI-1567797; CC Q9P286; Q92530: PSMF1; NbExp=3; IntAct=EBI-741896, EBI-945916; CC Q9P286; Q16825: PTPN21; NbExp=3; IntAct=EBI-741896, EBI-2860264; CC Q9P286; Q9H4E5: RHOJ; NbExp=3; IntAct=EBI-741896, EBI-6285694; CC Q9P286; O60504: SORBS3; NbExp=3; IntAct=EBI-741896, EBI-741237; CC Q9P286; Q9BZW7: TSGA10; NbExp=3; IntAct=EBI-741896, EBI-744794; CC Q9P286; Q9UBK9: UXT; NbExp=4; IntAct=EBI-741896, EBI-357355; CC Q9P286; O76024: WFS1; NbExp=3; IntAct=EBI-741896, EBI-720609; CC Q9P286; P62258: YWHAE; NbExp=3; IntAct=EBI-741896, EBI-356498; CC Q9P286; P47041: BIT61; Xeno; NbExp=3; IntAct=EBI-741896, EBI-25889; CC Q9P286; P32474: EUG1; Xeno; NbExp=3; IntAct=EBI-741896, EBI-2343998; CC Q9P286; P32502: GCD7; Xeno; NbExp=3; IntAct=EBI-741896, EBI-6260; CC -!- SUBCELLULAR LOCATION: Mitochondrion. Cytoplasm. Nucleus. Note=Shuttles CC between the nucleus and the mitochondria, and mitochondrial CC localization is essential for the role in cell survival. CC -!- TISSUE SPECIFICITY: Predominantly expressed in brain. CC -!- DOMAIN: An autoinhibitory domain is present in the N-terminal region of CC the protein. {ECO:0000269|PubMed:12860998}. CC -!- PTM: Autophosphorylated when activated by CDC42/p21. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr CC protein kinase family. STE20 subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA86578.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB040812; BAA94194.1; -; mRNA. DR EMBL; AB033090; BAA86578.1; ALT_INIT; mRNA. DR EMBL; AK291401; BAF84090.1; -; mRNA. DR EMBL; AL031652; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL135935; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL353612; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471133; EAX10358.1; -; Genomic_DNA. DR EMBL; CH471133; EAX10359.1; -; Genomic_DNA. DR EMBL; CH471133; EAX10360.1; -; Genomic_DNA. DR EMBL; BC024179; AAH24179.1; -; mRNA. DR CCDS; CCDS13107.1; -. DR RefSeq; NP_065074.1; NM_020341.5. DR RefSeq; NP_817127.1; NM_177990.4. DR RefSeq; XP_016883449.1; XM_017027960.2. DR RefSeq; XP_016883450.1; XM_017027961.2. DR RefSeq; XP_016883451.1; XM_017027962.2. DR RefSeq; XP_016883453.1; XM_017027964.2. DR RefSeq; XP_016883454.1; XM_017027965.2. DR RefSeq; XP_054179701.1; XM_054323726.1. DR RefSeq; XP_054179702.1; XM_054323727.1. DR RefSeq; XP_054179703.1; XM_054323728.1. DR RefSeq; XP_054179704.1; XM_054323729.1. DR RefSeq; XP_054179705.1; XM_054323730.1. DR PDB; 2F57; X-ray; 1.80 A; A/B=425-719. DR PDB; 8C12; X-ray; 1.55 A; AAA=426-719. DR PDBsum; 2F57; -. DR PDBsum; 8C12; -. DR AlphaFoldDB; Q9P286; -. DR SMR; Q9P286; -. DR BioGRID; 121402; 117. DR FunCoup; Q9P286; 2316. DR IntAct; Q9P286; 116. DR MINT; Q9P286; -. DR STRING; 9606.ENSP00000367686; -. DR BindingDB; Q9P286; -. DR ChEMBL; CHEMBL4524; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q9P286; -. DR GuidetoPHARMACOLOGY; 2138; -. DR GlyGen; Q9P286; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q9P286; -. DR PhosphoSitePlus; Q9P286; -. DR BioMuta; PAK5; -. DR DMDM; 12585290; -. DR CPTAC; non-CPTAC-2960; -. DR CPTAC; non-CPTAC-2961; -. DR jPOST; Q9P286; -. DR MassIVE; Q9P286; -. DR PaxDb; 9606-ENSP00000367686; -. DR PeptideAtlas; Q9P286; -. DR ProteomicsDB; 83751; -. DR Antibodypedia; 8792; 369 antibodies from 39 providers. DR DNASU; 57144; -. DR Ensembl; ENST00000353224.10; ENSP00000322957.5; ENSG00000101349.18. DR Ensembl; ENST00000378423.5; ENSP00000367679.1; ENSG00000101349.18. DR Ensembl; ENST00000378429.3; ENSP00000367686.3; ENSG00000101349.18. DR GeneID; 57144; -. DR KEGG; hsa:57144; -. DR MANE-Select; ENST00000353224.10; ENSP00000322957.5; NM_177990.4; NP_817127.1. DR UCSC; uc002wnj.3; human. DR AGR; HGNC:15916; -. DR ClinPGx; PA32922; -. DR CTD; 57144; -. DR DisGeNET; 57144; -. DR GeneCards; PAK5; -. DR HGNC; HGNC:15916; PAK5. DR HPA; ENSG00000101349; Group enriched (brain, retina). DR MalaCards; PAK5; -. DR MIM; 608038; gene. DR OpenTargets; ENSG00000101349; -. DR VEuPathDB; HostDB:ENSG00000101349; -. DR eggNOG; KOG0578; Eukaryota. DR GeneTree; ENSGT00940000158656; -. DR HOGENOM; CLU_000288_26_6_1; -. DR InParanoid; Q9P286; -. DR OMA; KSHPQGH; -. DR OrthoDB; 1022360at2759; -. DR PAN-GO; Q9P286; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q9P286; -. DR BRENDA; 2.7.11.1; 2681. DR BRENDA; 2.7.12.2; 2681. DR PathwayCommons; Q9P286; -. DR Reactome; R-HSA-428540; Activation of RAC1. DR Reactome; R-HSA-9013148; CDC42 GTPase cycle. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR Reactome; R-HSA-9013405; RHOD GTPase cycle. DR Reactome; R-HSA-9013407; RHOH GTPase cycle. DR SignaLink; Q9P286; -. DR SIGNOR; Q9P286; -. DR Agora; ENSG00000101349; -. DR BioGRID-ORCS; 57144; 9 hits in 1193 CRISPR screens. DR ChiTaRS; PAK5; human. DR EvolutionaryTrace; Q9P286; -. DR GeneWiki; PAK7; -. DR GenomeRNAi; 57144; -. DR Pharos; Q9P286; Tchem. DR PRO; PR:Q9P286; -. DR Proteomes; UP000005640; Chromosome 20. DR RNAct; Q9P286; protein. DR Bgee; ENSG00000101349; Expressed in cortical plate and 93 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005739; C:mitochondrion; IDA:HPA. DR GO; GO:0031965; C:nuclear membrane; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; TAS:Reactome. DR GO; GO:0045202; C:synapse; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0006915; P:apoptotic process; TAS:UniProtKB. DR GO; GO:0016477; P:cell migration; TAS:UniProtKB. DR GO; GO:0008283; P:cell population proliferation; TAS:UniProtKB. DR GO; GO:0009267; P:cellular response to starvation; IBA:GO_Central. DR GO; GO:0007010; P:cytoskeleton organization; TAS:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0007612; P:learning; IEA:Ensembl. DR GO; GO:0007626; P:locomotory behavior; IEA:Ensembl. DR GO; GO:0007613; P:memory; IEA:Ensembl. DR GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0001558; P:regulation of cell growth; TAS:UniProtKB. DR GO; GO:0043408; P:regulation of MAPK cascade; IBA:GO_Central. DR GO; GO:0007165; P:signal transduction; TAS:UniProtKB. DR CDD; cd01093; CRIB_PAK_like; 1. DR CDD; cd06658; STKc_PAK5; 1. DR FunFam; 1.10.510.10:FF:000073; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.200.20:FF:000141; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.90.810.10:FF:000002; Non-specific serine/threonine protein kinase; 1. DR Gene3D; 3.90.810.10; CRIB domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000095; CRIB_dom. DR InterPro; IPR036936; CRIB_dom_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR051931; PAK3-like. DR InterPro; IPR033923; PAK_BD. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR028754; STKc_PAK5. DR PANTHER; PTHR45832:SF4; NON-SPECIFIC SERINE_THREONINE PROTEIN KINASE; 1. DR PANTHER; PTHR45832; SERINE/THREONINE-PROTEIN KINASE SAMKA-RELATED-RELATED; 1. DR Pfam; PF00786; PBD; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00285; PBD; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50108; CRIB; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; Apoptosis; ATP-binding; Cytoplasm; Kinase; Mitochondrion; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase. FT CHAIN 1..719 FT /note="Serine/threonine-protein kinase PAK 5" FT /id="PRO_0000086477" FT DOMAIN 11..24 FT /note="CRIB" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00057" FT DOMAIN 449..700 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..29 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 25..448 FT /note="Linker" FT REGION 97..123 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 256..299 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 340..373 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 271..291 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 358..373 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 568 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 455..463 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 478 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 104 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8C015" FT MOD_RES 107 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q8C015" FT VARIANT 118 FT /note="G -> D (in dbSNP:rs55923311)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040978" FT VARIANT 187 FT /note="P -> A (in dbSNP:rs34280805)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040979" FT VARIANT 312 FT /note="S -> P (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs952665081)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040980" FT VARIANT 335 FT /note="R -> P (in dbSNP:rs11700112)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040981" FT VARIANT 511 FT /note="S -> N (in dbSNP:rs2297345)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:17344846" FT /id="VAR_021865" FT VARIANT 538 FT /note="T -> N (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040982" FT VARIANT 555 FT /note="A -> S (in dbSNP:rs34102290)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040983" FT VARIANT 604 FT /note="V -> I (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040984" FT VARIANT 704 FT /note="G -> S (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs1484691555)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040985" FT MUTAGEN 19..22 FT /note="HRVH->LRVL: Complete loss of CDC42 binding and FT CDC42-mediated autophosphorylation." FT /evidence="ECO:0000269|PubMed:12860998" FT CONFLICT 27 FT /note="P -> A (in Ref. 6; AAH24179)" FT /evidence="ECO:0000305" FT CONFLICT 403 FT /note="S -> Y (in Ref. 6; AAH24179)" FT /evidence="ECO:0000305" FT HELIX 429..437 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 445..447 FT /evidence="ECO:0007829|PDB:2F57" FT STRAND 449..457 FT /evidence="ECO:0007829|PDB:2F57" FT STRAND 459..468 FT /evidence="ECO:0007829|PDB:2F57" FT TURN 469..471 FT /evidence="ECO:0007829|PDB:2F57" FT STRAND 474..481 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 482..484 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 488..500 FT /evidence="ECO:0007829|PDB:2F57" FT STRAND 509..515 FT /evidence="ECO:0007829|PDB:2F57" FT STRAND 518..524 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 531..535 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 542..561 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 571..573 FT /evidence="ECO:0007829|PDB:2F57" FT STRAND 574..576 FT /evidence="ECO:0007829|PDB:2F57" FT STRAND 582..584 FT /evidence="ECO:0007829|PDB:2F57" FT STRAND 595..597 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 607..609 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 612..615 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 623..638 FT /evidence="ECO:0007829|PDB:2F57" FT TURN 642..645 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 648..657 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 666..668 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 671..680 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 685..687 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 691..695 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 698..702 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 706..708 FT /evidence="ECO:0007829|PDB:2F57" FT HELIX 710..712 FT /evidence="ECO:0007829|PDB:2F57" SQ SEQUENCE 719 AA; 80745 MW; 07A12B1EEC4E2A02 CRC64; MFGKKKKKIE ISGPSNFEHR VHTGFDPQEQ KFTGLPQQWH SLLADTANRP KPMVDPSCIT PIQLAPMKTI VRGNKPCKET SINGLLEDFD NISVTRSNSL RKESPPTPDQ GASSHGPGHA EENGFITFSQ YSSESDTTAD YTTEKYREKS LYGDDLDPYY RGSHAAKQNG HVMKMKHGEA YYSEVKPLKS DFARFSADYH SHLDSLSKPS EYSDLKWEYQ RASSSSPLDY SFQFTPSRTA GTSGCSKESL AYSESEWGPS LDDYDRRPKS SYLNQTSPQP TMRQRSRSGS GLQEPMMPFG ASAFKTHPQG HSYNSYTYPR LSEPTMCIPK VDYDRAQMVL SPPLSGSDTY PRGPAKLPQS QSKSGYSSSS HQYPSGYHKA TLYHHPSLQS SSQYISTASY LSSLSLSSST YPPPSWGSSS DQQPSRVSHE QFRAALQLVV SPGDPREYLA NFIKIGEGST GIVCIATEKH TGKQVAVKKM DLRKQQRREL LFNEVVIMRD YHHDNVVDMY SSYLVGDELW VVMEFLEGGA LTDIVTHTRM NEEQIATVCL SVLRALSYLH NQGVIHRDIK SDSILLTSDG RIKLSDFGFC AQVSKEVPKR KSLVGTPYWM APEVISRLPY GTEVDIWSLG IMVIEMIDGE PPYFNEPPLQ AMRRIRDSLP PRVKDLHKVS SVLRGFLDLM LVREPSQRAT AQELLGHPFL KLAGPPSCIV PLMRQYRHH // ID PD1L1_HUMAN Reviewed; 290 AA. AC Q9NZQ7; B2RBA2; B4DU27; Q14CJ2; Q2V8D5; Q66RK1; Q6WEX4; Q9NUZ5; DT 10-MAY-2005, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-2000, sequence version 1. DT 28-JAN-2026, entry version 205. DE RecName: Full=Programmed cell death 1 ligand 1 {ECO:0000303|PubMed:28813417}; DE Short=PD-L1 {ECO:0000303|PubMed:28813410, ECO:0000303|PubMed:28813417}; DE Short=PDCD1 ligand 1; DE Short=Programmed death ligand 1; DE Short=hPD-L1 {ECO:0000303|PubMed:26602187}; DE AltName: Full=B7 homolog 1 {ECO:0000303|PubMed:10581077}; DE Short=B7-H1 {ECO:0000303|PubMed:10581077}; DE AltName: CD_antigen=CD274; DE Flags: Precursor; GN Name=CD274 {ECO:0000312|HGNC:HGNC:17635}; GN Synonyms=B7H1, PDCD1L1, PDCD1LG1, PDL1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY, AND RP INDUCTION. RX PubMed=10581077; DOI=10.1038/70932; RA Dong H., Zhu G., Tamada K., Chen L.; RT "B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation RT and interleukin-10 secretion."; RL Nat. Med. 5:1365-1369(1999). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, INTERACTION WITH PDCD1, RP TISSUE SPECIFICITY, AND INDUCTION. RC TISSUE=Placenta; RX PubMed=11015443; DOI=10.1084/jem.192.7.1027; RA Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., RA Fitz L.J., Malenkovich N., Okazaki T., Byrne M.C., Horton H.F., Fouser L., RA Carter L., Ling V., Bowman M.R., Carreno B.M., Collins M., Wood C.R., RA Honjo T.; RT "Engagement of the PD-1 immunoinhibitory receptor by a novel B7-family RT member leads to negative regulation of lymphocyte activation."; RL J. Exp. Med. 192:1027-1034(2000). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), AND SUBCELLULAR LOCATION RP (ISOFORMS 1 AND 2). RX PubMed=15780196; DOI=10.1111/j.1745-7254.2005.00086.x; RA He X.-H., Xu L.-H., Liu Y.; RT "Identification of a novel splice variant of human PD-L1 mRNA encoding an RT isoform-lacking Igv-like domain."; RL Acta Pharmacol. Sin. 26:462-468(2005). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RC TISSUE=Gastric carcinoma; RA Chi X.-Y., Zha Q.-B., Xu L.-H., Jia Q.-T., Li F.-Y., He X.-H.; RT "Expression and significance of PD-L1 variant within tissues of human RT gastric carcinoma."; RL Submitted (NOV-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), SUBUNIT (ISOFORM 4), SUBCELLULAR RP LOCATION (ISOFORM 4), TISSUE SPECIFICITY (ISOFORM 4), AND MUTAGENESIS OF RP CYS-238 (ISOFORM 4). RC TISSUE=Placenta; RX PubMed=30564891; DOI=10.1007/s00262-018-2282-1; RA Mahoney K.M., Shukla S.A., Patsoukis N., Chaudhri A., Browne E.P., RA Arazi A., Eisenhaure T.M., Pendergraft W.F. III, Hua P., Pham H.C., Bu X., RA Zhu B., Hacohen N., Fritsch E.F., Boussiotis V.A., Wu C.J., Freeman G.J.; RT "A secreted PD-L1 splice variant that covalently dimerizes and mediates RT immunosuppression."; RL Cancer Immunol. Immunother. 68:421-432(2019). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3). RC TISSUE=Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164053; DOI=10.1038/nature02465; RA Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L., RA Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R., RA Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S., RA Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., RA Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., RA Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E., RA Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M., RA Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J., RA Frankish A., Frankland J.A., French L., Fricker D.G., Garner P., RA Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S., RA Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E., RA Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D., RA Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E., RA Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K., RA Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S., RA Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J., RA Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E., RA McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V., RA Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S., RA Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K., RA Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J., RA Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., RA West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L., RA Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M., RA Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J., RA Dunham I.; RT "DNA sequence and analysis of human chromosome 9."; RL Nature 429:369-374(2004). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-192. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). RN [11] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH CMTM6, AND IDENTIFICATION RP BY MASS SPECTROMETRY. RX PubMed=28813417; DOI=10.1038/nature23643; RA Burr M.L., Sparbier C.E., Chan Y.C., Williamson J.C., Woods K., RA Beavis P.A., Lam E.Y.N., Henderson M.A., Bell C.C., Stolzenburg S., RA Gilan O., Bloor S., Noori T., Morgens D.W., Bassik M.C., Neeson P.J., RA Behren A., Darcy P.K., Dawson S.J., Voskoboinik I., Trapani J.A., Cebon J., RA Lehner P.J., Dawson M.A.; RT "CMTM6 maintains the expression of PD-L1 and regulates anti-tumour RT immunity."; RL Nature 549:101-105(2017). RN [12] RP INVOLVEMENT IN CANCERS. RX PubMed=27281199; DOI=10.1038/nature18294; RA Kataoka K., Shiraishi Y., Takeda Y., Sakata S., Matsumoto M., Nagano S., RA Maeda T., Nagata Y., Kitanaka A., Mizuno S., Tanaka H., Chiba K., Ito S., RA Watatani Y., Kakiuchi N., Suzuki H., Yoshizato T., Yoshida K., Sanada M., RA Itonaga H., Imaizumi Y., Totoki Y., Munakata W., Nakamura H., Hama N., RA Shide K., Kubuki Y., Hidaka T., Kameda T., Masuda K., Minato N., RA Kashiwase K., Izutsu K., Takaori-Kondo A., Miyazaki Y., Takahashi S., RA Shibata T., Kawamoto H., Akatsuka Y., Shimoda K., Takeuchi K., Seya T., RA Miyano S., Ogawa S.; RT "Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers."; RL Nature 534:402-406(2016). RN [13] RP FUNCTION, INDUCTION BY IFNG, SUBCELLULAR LOCATION, INTERACTION WITH CMTM4 RP AND CMTM6, IDENTIFICATION BY MASS SPECTROMETRY, AND UBIQUITINATION. RX PubMed=28813410; DOI=10.1038/nature23669; RA Mezzadra R., Sun C., Jae L.T., Gomez-Eerland R., de Vries E., Wu W., RA Logtenberg M.E.W., Slagter M., Rozeman E.A., Hofland I., Broeks A., RA Horlings H.M., Wessels L.F.A., Blank C.U., Xiao Y., Heck A.J.R., Borst J., RA Brummelkamp T.R., Schumacher T.N.M.; RT "Identification of CMTM6 and CMTM4 as PD-L1 protein regulators."; RL Nature 549:106-110(2017). RN [14] RP FUNCTION, AND DEUBIQUITINATION BY USP22. RX PubMed=31399419; DOI=10.1158/2326-6066.cir-18-0910; RA Huang X., Zhang Q., Lou Y., Wang J., Zhao X., Wang L., Zhang X., Li S., RA Zhao Y., Chen Q., Liang T., Bai X.; RT "USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity."; RL Cancer Immunol. Res. 7:1580-1590(2019). RN [15] RP FUNCTION, INTERACTION WITH STAT3, AND SUBCELLULAR LOCATION. RX PubMed=32929201; DOI=10.1038/s41556-020-0575-z; RA Hou J., Zhao R., Xia W., Chang C.W., You Y., Hsu J.M., Nie L., Chen Y., RA Wang Y.C., Liu C., Wang W.J., Wu Y., Ke B., Hsu J.L., Huang K., Ye Z., RA Yang Y., Xia X., Li Y., Li C.W., Shao B., Tainer J.A., Hung M.C.; RT "PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in RT cancer cells and facilitates tumour necrosis."; RL Nat. Cell Biol. 22:1264-1275(2020). RN [16] RP UBIQUITINATION BY MARCHF8. RX PubMed=34183449; DOI=10.1158/1541-7786.mcr-21-0147; RA Qian G., Guo J., Vallega K.A., Hu C., Chen Z., Deng Y., Wang Q., Fan S., RA Ramalingam S.S., Owonikoko T.K., Wei W., Sun S.Y.; RT "Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to RT Mediate PD-L1 Degradation Induced by EGFR Inhibitors."; RL Mol. Cancer Res. 19:1622-1634(2021). RN [17] RP SUBCELLULAR LOCATION. RX PubMed=36232715; DOI=10.3390/ijms231911414; RA Youn S.E., Jiang F., Won H.Y., Hong D.E., Kang T.H., Park Y.Y., Koh S.S.; RT "PAUF Induces Migration of Human Pancreatic Cancer Cells Exclusively via RT the TLR4/MyD88/NF-kappaB Signaling Pathway."; RL Int. J. Mol. Sci. 23:0-0(2022). RN [18] RP FUNCTION, AND INTERACTION WITH CD80. RX PubMed=36727298; DOI=10.15252/embj.2022111556; RA Kennedy A., Robinson M.A., Hinze C., Waters E., Williams C., Halliday N., RA Dovedi S., Sansom D.M.; RT "The CTLA-4 immune checkpoint protein regulates PD-L1:PD-1 interaction via RT transendocytosis of its ligand CD80."; RL EMBO J. 42:e111556-e111556(2023). RN [19] RP INVOLVEMENT IN ADMIO5. RX PubMed=38634869; DOI=10.1084/jem.20231704; RG EXE-T1D consortium; RA Johnson M.B., Ogishi M., Domingo-Vila C., De Franco E., Wakeling M.N., RA Imane Z., Resnick B., Williams E., Galao R.P., Caswell R., Russ-Silsby J., RA Seeleuthner Y., Rinchai D., Fagniez I., Benson B., Dufort M.J., Speake C., RA Smithmyer M.E., Hudson M., Dobbs R., Quandt Z., Hattersley A.T., Zhang P., RA Boisson-Dupuis S., Anderson M.S., Casanova J.L., Tree T.I., Oram R.A.; RT "Human inherited PD-L1 deficiency is clinically and immunologically less RT severe than PD-1 deficiency."; RL J. Exp. Med. 221:0-0(2024). RN [20] RP X-RAY CRYSTALLOGRAPHY (2.64 ANGSTROMS) OF 18-239 IN COMPLEX WITH MOUSE RP PDCD1, AND DISULFIDE BONDS. RX PubMed=18287011; DOI=10.1073/pnas.0712278105; RA Lin D.Y., Tanaka Y., Iwasaki M., Gittis A.G., Su H.P., Mikami B., RA Okazaki T., Honjo T., Minato N., Garboczi D.N.; RT "The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of RT antibodies and T cell receptors."; RL Proc. Natl. Acad. Sci. U.S.A. 105:3011-3016(2008). RN [21] {ECO:0007744|PDB:4ZQK, ECO:0007744|PDB:5C3T} RP X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 18-134 IN COMPLEX WITH PDCD1, AND RP DISULFIDE BOND. RX PubMed=26602187; DOI=10.1016/j.str.2015.09.010; RA Zak K.M., Kitel R., Przetocka S., Golik P., Guzik K., Musielak B., RA Domling A., Dubin G., Holak T.A.; RT "Structure of the complex of human programmed death 1, PD-1, and its ligand RT PD-L1."; RL Structure 23:2341-2348(2015). CC -!- FUNCTION: Plays a critical role in induction and maintenance of immune CC tolerance to self (PubMed:11015443, PubMed:28813410, PubMed:28813417, CC PubMed:31399419). As a ligand for the inhibitory receptor PDCD1/PD-1, CC modulates the activation threshold of T-cells and limits T-cell CC effector response (PubMed:11015443, PubMed:28813410, PubMed:28813417, CC PubMed:36727298). Through a yet unknown activating receptor, may CC costimulate T-cell subsets that predominantly produce interleukin-10 CC (IL10) (PubMed:10581077). Can also act as a transcription coactivator: CC in response to hypoxia, translocates into the nucleus via its CC interaction with phosphorylated STAT3 and promotes transcription of CC GSDMC, leading to pyroptosis (PubMed:32929201). CC {ECO:0000269|PubMed:10581077, ECO:0000269|PubMed:11015443, CC ECO:0000269|PubMed:28813410, ECO:0000269|PubMed:28813417, CC ECO:0000269|PubMed:31399419, ECO:0000269|PubMed:32929201, CC ECO:0000269|PubMed:36727298}. CC -!- FUNCTION: The PDCD1-mediated inhibitory pathway is exploited by tumors CC to attenuate anti-tumor immunity and escape destruction by the immune CC system, thereby facilitating tumor survival (PubMed:28813410, CC PubMed:28813417). The interaction with PDCD1/PD-1 inhibits cytotoxic T CC lymphocytes (CTLs) effector function (By similarity). The blockage of CC the PDCD1-mediated pathway results in the reversal of the exhausted T- CC cell phenotype and the normalization of the anti-tumor response, CC providing a rationale for cancer immunotherapy (By similarity). CC {ECO:0000250|UniProtKB:Q9EP73, ECO:0000269|PubMed:28813410, CC ECO:0000269|PubMed:28813417}. CC -!- SUBUNIT: Interacts with PDCD1 (PubMed:11015443, PubMed:18287011, CC PubMed:26602187). Interacts (via transmembrane domain) with CMTM4 and CC CMTM6 (PubMed:28813410, PubMed:28813417). Interacts with CC (phosphorylated) STAT3; promoting nuclear translocation CC (PubMed:32929201). Interacts with CD80 (PubMed:36727298). CC {ECO:0000269|PubMed:11015443, ECO:0000269|PubMed:18287011, CC ECO:0000269|PubMed:26602187, ECO:0000269|PubMed:28813410, CC ECO:0000269|PubMed:28813417, ECO:0000269|PubMed:32929201, CC ECO:0000269|PubMed:36727298}. CC -!- SUBUNIT: [Isoform 4]: May form homomultimers. CC {ECO:0000269|PubMed:30564891}. CC -!- INTERACTION: CC Q9NZQ7; P33681: CD80; NbExp=15; IntAct=EBI-4314282, EBI-1031024; CC Q9NZQ7; Q8IZR5: CMTM4; NbExp=3; IntAct=EBI-4314282, EBI-3925367; CC Q9NZQ7; Q9NX76: CMTM6; NbExp=14; IntAct=EBI-4314282, EBI-1054315; CC Q9NZQ7; Q15116: PDCD1; NbExp=20; IntAct=EBI-4314282, EBI-4314328; CC Q9NZQ7; Q9BQ51: PDCD1LG2; NbExp=4; IntAct=EBI-4314282, EBI-16427978; CC Q9NZQ7-1; Q15116: PDCD1; NbExp=2; IntAct=EBI-15686469, EBI-4314328; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:28813410, CC ECO:0000269|PubMed:28813417, ECO:0000269|PubMed:36232715}; Single-pass CC type I membrane protein {ECO:0000255}. Early endosome membrane CC {ECO:0000269|PubMed:28813417}; Single-pass type I membrane protein CC {ECO:0000255}. Recycling endosome membrane CC {ECO:0000269|PubMed:28813417}; Single-pass type I membrane protein CC {ECO:0000255}. Nucleus {ECO:0000269|PubMed:32929201}. Note=Associates CC with CMTM6 at recycling endosomes, where it is protected from being CC targeted for lysosomal degradation (PubMed:28813417). Translocates to CC the nucleus in response to hypoxia via its interaction with CC phosphorylated STAT3 (PubMed:32929201). {ECO:0000269|PubMed:28813417, CC ECO:0000269|PubMed:32929201}. CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane CC {ECO:0000269|PubMed:15780196}; Single-pass type I membrane protein CC {ECO:0000255}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Endomembrane system CC {ECO:0000269|PubMed:15780196}; Single-pass type I membrane protein CC {ECO:0000255}. CC -!- SUBCELLULAR LOCATION: [Isoform 4]: Secreted CC {ECO:0000269|PubMed:30564891}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; Synonyms=PD-L1I; CC IsoId=Q9NZQ7-1; Sequence=Displayed; CC Name=2; Synonyms=PD-L1II; CC IsoId=Q9NZQ7-2; Sequence=VSP_013735; CC Name=3; CC IsoId=Q9NZQ7-3; Sequence=VSP_013736, VSP_013737; CC Name=4; Synonyms=secPD-L1 {ECO:0000303|PubMed:30564891}; CC IsoId=Q9NZQ7-4; Sequence=VSP_061953; CC -!- TISSUE SPECIFICITY: Highly expressed in the heart, skeletal muscle, CC placenta and lung. Weakly expressed in the thymus, spleen, kidney and CC liver. Expressed on activated T- and B-cells, dendritic cells, CC keratinocytes and monocytes. {ECO:0000269|PubMed:10581077, CC ECO:0000269|PubMed:11015443}. CC -!- TISSUE SPECIFICITY: [Isoform 4]: Widely expressed, highest in lung, CC liver and pituitary and in various peripheral blood cells, including CC neutrophils and some subtypes of lymphoid and myeloid cells. CC {ECO:0000269|PubMed:30564891}. CC -!- INDUCTION: Up-regulated on T- and B-cells, dendritic cells, CC keratinocytes and monocytes after LPS and IFNG activation. Up-regulated CC in B-cells activated by surface Ig cross-linking. CC {ECO:0000269|PubMed:10581077, ECO:0000269|PubMed:11015443, CC ECO:0000269|PubMed:28813410}. CC -!- PTM: Ubiquitinated; STUB1 likely mediates polyubiquitination of PD- CC L1/CD274 triggering its degradation (PubMed:28813410). Ubiquitinated by CC MARCHF8; leading to degradation (PubMed:34183449). Deubiquitinated by CC USP22; leading to stabilization (PubMed:31399419). CC {ECO:0000269|PubMed:28813410, ECO:0000269|PubMed:31399419, CC ECO:0000269|PubMed:34183449}. CC -!- DISEASE: Autoimmune disease, multisystem, infantile-onset, 5 (ADMIO5) CC [MIM:621235]: An autosomal recessive disorder characterized by CC autoimmune manifestations apparent in the first months or years of CC life. ADMIO5 patients have complete insulin deficiency and type 1 CC diabetes mellitus with neonatal onset. {ECO:0000269|PubMed:38634869}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Note=Truncation of the 3'-untranslated (3'-UTR) region of CC CD274 transcripts leads to elevated expression of CD274 in multiple CC cancers including T-cell leukemia, diffuse large B-cell lymphoma and CC stomach adenocarcinoma (PubMed:27281199). Disruption of 3'-UTR region CC is caused by structural variants that stabilize CD274 transcripts, CC leading to overexpression (PubMed:27281199). Increased expression in CC tumors promotes immune evasion and tumor cell growth by allowing CC malignant cells to escape destruction by the immune system CC (PubMed:27281199). {ECO:0000269|PubMed:27281199}. CC -!- MISCELLANEOUS: [Isoform 3]: May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the immunoglobulin superfamily. BTN/MOG family. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA91966.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF177937; AAF25807.1; -; mRNA. DR EMBL; AF233516; AAG18508.1; -; mRNA. DR EMBL; AY254342; AAP13470.1; -; mRNA. DR EMBL; AY291313; AAP42144.1; -; mRNA. DR EMBL; AY714881; AAU09634.1; -; mRNA. DR EMBL; DQ286582; ABB90152.1; -; mRNA. DR EMBL; AK001894; BAA91966.1; ALT_INIT; mRNA. DR EMBL; AK300470; BAG62189.1; -; mRNA. DR EMBL; AK314567; BAG37149.1; -; mRNA. DR EMBL; AL162253; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471071; EAW58763.1; -; Genomic_DNA. DR EMBL; BC069381; AAH69381.1; -; mRNA. DR EMBL; BC074984; AAH74984.1; -; mRNA. DR EMBL; BC113734; AAI13735.1; -; mRNA. DR EMBL; BC113736; AAI13737.1; -; mRNA. DR CCDS; CCDS59118.1; -. [Q9NZQ7-2] DR CCDS; CCDS6464.1; -. [Q9NZQ7-1] DR RefSeq; NP_001254635.1; NM_001267706.2. [Q9NZQ7-2] DR RefSeq; NP_001300958.1; NM_001314029.2. [Q9NZQ7-4] DR RefSeq; NP_054862.1; NM_014143.4. [Q9NZQ7-1] DR PDB; 3BIK; X-ray; 2.65 A; A=18-239. DR PDB; 3BIS; X-ray; 2.64 A; A/B=18-239. DR PDB; 3FN3; X-ray; 2.70 A; A/B=19-238. DR PDB; 3SBW; X-ray; 2.28 A; C=19-239. DR PDB; 4Z18; X-ray; 1.95 A; A/B=19-239. DR PDB; 4ZQK; X-ray; 2.45 A; A=18-132. DR PDB; 5C3T; X-ray; 1.80 A; A=18-134. DR PDB; 5GGT; X-ray; 2.80 A; A=18-134. DR PDB; 5GRJ; X-ray; 3.21 A; A=18-238. DR PDB; 5IUS; X-ray; 2.89 A; C/D=18-239. DR PDB; 5J89; X-ray; 2.20 A; A/B/C/D=2-134. DR PDB; 5J8O; X-ray; 2.30 A; A/B=18-134. DR PDB; 5JDR; X-ray; 2.70 A; A/B=18-239. DR PDB; 5JDS; X-ray; 1.70 A; A=18-132. DR PDB; 5N2D; X-ray; 2.35 A; A/B/C/D=2-134. DR PDB; 5N2F; X-ray; 1.70 A; A/B=18-134. DR PDB; 5NIU; X-ray; 2.01 A; A/B/C/D=18-134. DR PDB; 5O45; X-ray; 0.99 A; A=17-134. DR PDB; 5O4Y; X-ray; 2.30 A; B/C/E=18-132. DR PDB; 5X8L; X-ray; 3.10 A; A/B/C/D/E=18-134. DR PDB; 5X8M; X-ray; 2.66 A; A=18-134. DR PDB; 5XJ4; X-ray; 2.30 A; A=19-238. DR PDB; 5XXY; X-ray; 2.90 A; A=18-133. DR PDB; 6L8R; NMR; -; A=260-290. DR PDB; 6NM7; X-ray; 2.43 A; A/B=19-134. DR PDB; 6NM8; X-ray; 2.79 A; A/B=19-134. DR PDB; 6NNV; X-ray; 1.92 A; A/B/C/D=18-134. DR PDB; 6NOJ; X-ray; 2.33 A; A/B=18-134. DR PDB; 6NOS; X-ray; 2.70 A; A/B=18-134. DR PDB; 6NP9; X-ray; 1.27 A; A=18-134. DR PDB; 6PV9; X-ray; 2.00 A; A=19-239. DR PDB; 6R3K; X-ray; 2.20 A; A/B/C/D=18-134. DR PDB; 6RPG; X-ray; 2.70 A; A/B=18-134. DR PDB; 6VQN; X-ray; 2.49 A; A/B/C=18-134. DR PDB; 6YCR; X-ray; 1.54 A; A=18-134. DR PDB; 7BEA; X-ray; 2.45 A; A/B=18-134. DR PDB; 7C88; X-ray; 2.00 A; C/M=1-136. DR PDB; 7CZD; X-ray; 1.64 A; B/D=19-134. DR PDB; 7DCV; NMR; -; A=232-290. DR PDB; 7DY7; X-ray; 2.42 A; A/B=18-134. DR PDB; 7NLD; X-ray; 2.30 A; A/B/C/D/E/F=18-134. DR PDB; 7OUN; X-ray; 1.90 A; A=17-134. DR PDB; 7SJQ; X-ray; 2.00 A; A=18-134. DR PDB; 7TPS; X-ray; 3.15 A; B/D=19-227. DR PDB; 7UX5; X-ray; 3.35 A; A/C/E/G/I/K=18-134. DR PDB; 7UXO; X-ray; 2.25 A; A=18-134. DR PDB; 7UXP; X-ray; 2.62 A; A/B=18-134. DR PDB; 7UXQ; X-ray; 2.89 A; A/B=18-134. DR PDB; 7VUN; X-ray; 2.70 A; A/B/C/D/E/F/G/H=18-134. DR PDB; 7XAD; X-ray; 3.00 A; A/D/F/H=1-238. DR PDB; 7XAE; X-ray; 3.44 A; A/B=1-238. DR PDB; 7XYQ; X-ray; 2.85 A; A=19-225. DR PDB; 7YDS; X-ray; 2.30 A; A=1-136. DR PDB; 8ALX; X-ray; 1.10 A; A=18-134. DR PDB; 8AOK; X-ray; 1.60 A; A=18-134. DR PDB; 8AOM; X-ray; 2.20 A; A=19-239. DR PDB; 8JBA; X-ray; 2.60 A; A/B=18-134. DR PDB; 8K5N; X-ray; 2.20 A; A/B=18-134. DR PDB; 8OR1; X-ray; 3.50 A; A/B=18-133. DR PDB; 8P1O; X-ray; 2.17 A; A/B=2-134. DR PDB; 8R6Q; X-ray; 2.17 A; A/B=18-134. DR PDB; 8RPB; X-ray; 2.79 A; P=18-133. DR PDB; 8XR5; X-ray; 1.95 A; A/B=19-134. DR PDB; 8ZNL; X-ray; 1.77 A; B/D/F/H=19-132. DR PDB; 9INU; X-ray; 2.70 A; A/B=18-134. DR PDBsum; 3BIK; -. DR PDBsum; 3BIS; -. DR PDBsum; 3FN3; -. DR PDBsum; 3SBW; -. DR PDBsum; 4Z18; -. DR PDBsum; 4ZQK; -. DR PDBsum; 5C3T; -. DR PDBsum; 5GGT; -. DR PDBsum; 5GRJ; -. DR PDBsum; 5IUS; -. DR PDBsum; 5J89; -. DR PDBsum; 5J8O; -. DR PDBsum; 5JDR; -. DR PDBsum; 5JDS; -. DR PDBsum; 5N2D; -. DR PDBsum; 5N2F; -. DR PDBsum; 5NIU; -. DR PDBsum; 5O45; -. DR PDBsum; 5O4Y; -. DR PDBsum; 5X8L; -. DR PDBsum; 5X8M; -. DR PDBsum; 5XJ4; -. DR PDBsum; 5XXY; -. DR PDBsum; 6L8R; -. DR PDBsum; 6NM7; -. DR PDBsum; 6NM8; -. DR PDBsum; 6NNV; -. DR PDBsum; 6NOJ; -. DR PDBsum; 6NOS; -. DR PDBsum; 6NP9; -. DR PDBsum; 6PV9; -. DR PDBsum; 6R3K; -. DR PDBsum; 6RPG; -. DR PDBsum; 6VQN; -. DR PDBsum; 6YCR; -. DR PDBsum; 7BEA; -. DR PDBsum; 7C88; -. DR PDBsum; 7CZD; -. DR PDBsum; 7DCV; -. DR PDBsum; 7DY7; -. DR PDBsum; 7NLD; -. DR PDBsum; 7OUN; -. DR PDBsum; 7SJQ; -. DR PDBsum; 7TPS; -. DR PDBsum; 7UX5; -. DR PDBsum; 7UXO; -. DR PDBsum; 7UXP; -. DR PDBsum; 7UXQ; -. DR PDBsum; 7VUN; -. DR PDBsum; 7XAD; -. DR PDBsum; 7XAE; -. DR PDBsum; 7XYQ; -. DR PDBsum; 7YDS; -. DR PDBsum; 8ALX; -. DR PDBsum; 8AOK; -. DR PDBsum; 8AOM; -. DR PDBsum; 8JBA; -. DR PDBsum; 8K5N; -. DR PDBsum; 8OR1; -. DR PDBsum; 8P1O; -. DR PDBsum; 8R6Q; -. DR PDBsum; 8RPB; -. DR PDBsum; 8XR5; -. DR PDBsum; 8ZNL; -. DR PDBsum; 9INU; -. DR AlphaFoldDB; Q9NZQ7; -. DR SMR; Q9NZQ7; -. DR BioGRID; 118891; 389. DR CORUM; Q9NZQ7; -. DR DIP; DIP-29731N; -. DR FunCoup; Q9NZQ7; 458. DR IntAct; Q9NZQ7; 49. DR STRING; 9606.ENSP00000370989; -. DR BindingDB; Q9NZQ7; -. DR ChEMBL; CHEMBL3580522; -. DR DrugBank; DB15773; anti-OX40 antibody BMS 986178. DR DrugBank; DB11595; Atezolizumab. DR DrugBank; DB15771; AUNP-12. DR DrugBank; DB11945; Avelumab. DR DrugBank; DB15772; CA-170. DR DrugBank; DB14776; Camrelizumab. DR DrugBank; DB15770; Cosibelimab. DR DrugBank; DB11714; Durvalumab. DR DrugBank; DB15769; Envafolimab. DR DrugBank; DB09035; Nivolumab. DR DrugBank; DB09037; Pembrolizumab. DR DrugBank; DB00203; Sildenafil. DR DrugBank; DB00313; Valproic acid. DR DrugCentral; Q9NZQ7; -. DR TCDB; 8.A.23.5.1; the basigin (basigin) family. DR GlyCosmos; Q9NZQ7; 4 sites, No reported glycans. DR GlyGen; Q9NZQ7; 5 sites, 1 N-linked glycan (1 site). DR iPTMnet; Q9NZQ7; -. DR PhosphoSitePlus; Q9NZQ7; -. DR SwissPalm; Q9NZQ7; -. DR BioMuta; CD274; -. DR DMDM; 83287884; -. DR CPTAC; CPTAC-5988; -. DR jPOST; Q9NZQ7; -. DR MassIVE; Q9NZQ7; -. DR PaxDb; 9606-ENSP00000370989; -. DR PeptideAtlas; Q9NZQ7; -. DR ProteomicsDB; 83483; -. [Q9NZQ7-1] DR ProteomicsDB; 83484; -. [Q9NZQ7-2] DR ProteomicsDB; 83485; -. [Q9NZQ7-3] DR Pumba; Q9NZQ7; -. DR ABCD; Q9NZQ7; 168 sequenced antibodies. DR Antibodypedia; 24139; 2498 antibodies from 57 providers. DR CPTC; Q9NZQ7; 1 antibody. DR DNASU; 29126; -. DR Ensembl; ENST00000381573.8; ENSP00000370985.4; ENSG00000120217.14. [Q9NZQ7-2] DR Ensembl; ENST00000381577.4; ENSP00000370989.3; ENSG00000120217.14. [Q9NZQ7-1] DR GeneID; 29126; -. DR KEGG; hsa:29126; -. DR MANE-Select; ENST00000381577.4; ENSP00000370989.3; NM_014143.4; NP_054862.1. DR UCSC; uc003zje.4; human. [Q9NZQ7-1] DR AGR; HGNC:17635; -. DR CIViC; 29126; 36 evidence items across 7 molecular profiles. DR ClinPGx; PA134915280; -. DR CTD; 29126; -. DR DisGeNET; 29126; -. DR GeneCards; CD274; -. DR HGNC; HGNC:17635; CD274. DR HPA; ENSG00000120217; Tissue enhanced (lung). DR MalaCards; CD274; -. DR MIM; 605402; gene. DR MIM; 621235; phenotype. DR OpenTargets; ENSG00000120217; -. DR VEuPathDB; HostDB:ENSG00000120217; -. DR eggNOG; ENOG502S1Y9; Eukaryota. DR GeneTree; ENSGT00940000161430; -. DR HOGENOM; CLU_1744717_0_0_1; -. DR InParanoid; Q9NZQ7; -. DR OMA; YCCMISY; -. DR OrthoDB; 8680608at2759; -. DR PAN-GO; Q9NZQ7; 7 GO annotations based on evolutionary models. DR PhylomeDB; Q9NZQ7; -. DR PathwayCommons; Q9NZQ7; -. DR Reactome; R-HSA-389948; Co-inhibition by PD-1. DR Reactome; R-HSA-9701898; STAT3 nuclear events downstream of ALK signaling. DR SignaLink; Q9NZQ7; -. DR SIGNOR; Q9NZQ7; -. DR Agora; ENSG00000120217; -. DR BioGRID-ORCS; 29126; 18 hits in 1159 CRISPR screens. DR ChiTaRS; CD274; human. DR EvolutionaryTrace; Q9NZQ7; -. DR GeneWiki; PD-L1; -. DR GenomeRNAi; 29126; -. DR Pharos; Q9NZQ7; Tclin. DR PRO; PR:Q9NZQ7; -. DR Proteomes; UP000005640; Chromosome 9. DR RNAct; Q9NZQ7; protein. DR Bgee; ENSG00000120217; Expressed in cartilage tissue and 146 other cell types or tissues. DR GO; GO:0015629; C:actin cytoskeleton; IDA:HPA. DR GO; GO:0031901; C:early endosome membrane; IDA:UniProtKB. DR GO; GO:0009897; C:external side of plasma membrane; IBA:GO_Central. DR GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0055038; C:recycling endosome membrane; IDA:UniProtKB. DR GO; GO:0048018; F:receptor ligand activity; IDA:UniProtKB. DR GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB. DR GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW. DR GO; GO:0007166; P:cell surface receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0071222; P:cellular response to lipopolysaccharide; IBA:GO_Central. DR GO; GO:0006955; P:immune response; IDA:UniProtKB. DR GO; GO:0046007; P:negative regulation of activated T cell proliferation; IMP:UniProtKB. DR GO; GO:2000562; P:negative regulation of CD4-positive, alpha-beta T cell proliferation; IDA:UniProtKB. DR GO; GO:2001186; P:negative regulation of CD8-positive, alpha-beta T cell activation; IDA:UniProt. DR GO; GO:0032693; P:negative regulation of interleukin-10 production; IMP:UniProtKB. DR GO; GO:0050868; P:negative regulation of T cell activation; IDA:UniProt. DR GO; GO:0002841; P:negative regulation of T cell mediated immune response to tumor cell; IDA:UniProt. DR GO; GO:0042130; P:negative regulation of T cell proliferation; IBA:GO_Central. DR GO; GO:0050860; P:negative regulation of T cell receptor signaling pathway; IDA:UniProt. DR GO; GO:1903556; P:negative regulation of tumor necrosis factor superfamily cytokine production; IMP:UniProtKB. DR GO; GO:0032689; P:negative regulation of type II interferon production; IMP:UniProtKB. DR GO; GO:1905404; P:positive regulation of activated CD8-positive, alpha-beta T cell apoptotic process; IDA:UniProtKB. DR GO; GO:0032733; P:positive regulation of interleukin-10 production; IDA:UniProtKB. DR GO; GO:0042102; P:positive regulation of T cell proliferation; IBA:GO_Central. DR GO; GO:0034097; P:response to cytokine; IDA:AgBase. DR GO; GO:0007165; P:signal transduction; IDA:UniProtKB. DR GO; GO:0031295; P:T cell costimulation; IDA:UniProtKB. DR GO; GO:0035666; P:TRIF-dependent toll-like receptor signaling pathway; IDA:UniProtKB. DR CDD; cd20947; IgV_PDl1; 1. DR FunFam; 2.60.40.10:FF:001299; Programmed cell death 1; 1. DR FunFam; 2.60.40.10:FF:001063; Programmed cell death ligand 1; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR InterPro; IPR013162; CD80_C2-set. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR013106; Ig_V-set. DR InterPro; IPR051713; T-cell_Activation_Regulation. DR PANTHER; PTHR25466:SF3; PROGRAMMED CELL DEATH 1 LIGAND 1; 1. DR PANTHER; PTHR25466; T-LYMPHOCYTE ACTIVATION ANTIGEN; 1. DR Pfam; PF08205; C2-set_2; 1. DR Pfam; PF07686; V-set; 1. DR SMART; SM00409; IG; 2. DR SUPFAM; SSF48726; Immunoglobulin; 2. DR PROSITE; PS50835; IG_LIKE; 2. PE 1: Evidence at protein level; KW 3D-structure; Adaptive immunity; Alternative splicing; Cell membrane; KW Diabetes mellitus; Disulfide bond; Endosome; Glycoprotein; Immunity; KW Immunoglobulin domain; Membrane; Nucleus; Proteomics identification; KW Receptor; Reference proteome; Repeat; Secreted; Signal; Transmembrane; KW Transmembrane helix; Ubl conjugation. FT SIGNAL 1..18 FT /evidence="ECO:0000255" FT CHAIN 19..290 FT /note="Programmed cell death 1 ligand 1" FT /id="PRO_0000014553" FT TOPO_DOM 19..238 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 239..259 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 260..290 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 19..127 FT /note="Ig-like V-type" FT DOMAIN 133..225 FT /note="Ig-like C2-type" FT CARBOHYD 35 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 192 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19159218" FT CARBOHYD 200 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 219 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 40..114 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:18287011, ECO:0000269|PubMed:26602187" FT DISULFID 155..209 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:18287011" FT VAR_SEQ 19..132 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15780196, ECO:0000303|Ref.4" FT /id="VSP_013735" FT VAR_SEQ 178 FT /note="K -> D (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15780196" FT /id="VSP_013736" FT VAR_SEQ 179..290 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15780196" FT /id="VSP_013737" FT VAR_SEQ 228..289 FT /note="ELPLAHPPNERTHLVILGAILLCLGVALTFIFRLRKGRMMDVKKCGIQDTNS FT KKQSDTHLEE -> GNILNVSIKICLTLSPS (in isoform 4)" FT /evidence="ECO:0000269|PubMed:30564891" FT /id="VSP_061953" FT STRAND 26..31 FT /evidence="ECO:0007829|PDB:5O45" FT STRAND 36..41 FT /evidence="ECO:0007829|PDB:5O45" FT STRAND 45..47 FT /evidence="ECO:0007829|PDB:5C3T" FT HELIX 50..52 FT /evidence="ECO:0007829|PDB:5O45" FT STRAND 54..59 FT /evidence="ECO:0007829|PDB:5O45" FT STRAND 62..68 FT /evidence="ECO:0007829|PDB:5O45" FT STRAND 71..73 FT /evidence="ECO:0007829|PDB:6NP9" FT HELIX 74..76 FT /evidence="ECO:0007829|PDB:5O45" FT HELIX 79..81 FT /evidence="ECO:0007829|PDB:5O45" FT TURN 82..84 FT /evidence="ECO:0007829|PDB:5O45" FT STRAND 85..87 FT /evidence="ECO:0007829|PDB:5O45" FT HELIX 89..94 FT /evidence="ECO:0007829|PDB:5O45" FT STRAND 96..103 FT /evidence="ECO:0007829|PDB:5O45" FT HELIX 106..108 FT /evidence="ECO:0007829|PDB:5O45" FT STRAND 110..131 FT /evidence="ECO:0007829|PDB:5O45" FT STRAND 138..145 FT /evidence="ECO:0007829|PDB:4Z18" FT TURN 146..149 FT /evidence="ECO:0007829|PDB:4Z18" FT STRAND 150..161 FT /evidence="ECO:0007829|PDB:4Z18" FT STRAND 164..169 FT /evidence="ECO:0007829|PDB:4Z18" FT STRAND 177..183 FT /evidence="ECO:0007829|PDB:4Z18" FT STRAND 185..187 FT /evidence="ECO:0007829|PDB:4Z18" FT STRAND 191..200 FT /evidence="ECO:0007829|PDB:4Z18" FT STRAND 206..213 FT /evidence="ECO:0007829|PDB:4Z18" FT TURN 214..217 FT /evidence="ECO:0007829|PDB:4Z18" FT STRAND 218..225 FT /evidence="ECO:0007829|PDB:4Z18" FT HELIX 237..265 FT /evidence="ECO:0007829|PDB:7DCV" FT STRAND 268..271 FT /evidence="ECO:0007829|PDB:6L8R" FT MUTAGEN Q9NZQ7-4:238 FT /note="C->S: Largely abrogates multimerization, in vitro." FT /evidence="ECO:0000269|PubMed:30564891" SQ SEQUENCE 290 AA; 33275 MW; FE957086E62A31A8 CRC64; MRIFAVFIFM TYWHLLNAFT VTVPKDLYVV EYGSNMTIEC KFPVEKQLDL AALIVYWEME DKNIIQFVHG EEDLKVQHSS YRQRARLLKD QLSLGNAALQ ITDVKLQDAG VYRCMISYGG ADYKRITVKV NAPYNKINQR ILVVDPVTSE HELTCQAEGY PKAEVIWTSS DHQVLSGKTT TTNSKREEKL FNVTSTLRIN TTTNEIFYCT FRRLDPEENH TAELVIPELP LAHPPNERTH LVILGAILLC LGVALTFIFR LRKGRMMDVK KCGIQDTNSK KQSDTHLEET // ID PGFRL_HUMAN Reviewed; 375 AA. AC Q15198; A8K085; Q6FH04; DT 02-MAY-2006, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 188. DE RecName: Full=Platelet-derived growth factor receptor-like protein; DE Short=PDGFR-like protein; DE AltName: Full=PDGF receptor beta-like tumor suppressor; DE Flags: Precursor; GN Name=PDGFRL; Synonyms=PRLTS; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], VARIANT CRC TYR-23, AND TISSUE SPECIFICITY. RC TISSUE=Fetal lung; RX PubMed=7898930; RA Fujiwara Y., Ohata H., Kuroki T., Koyama K., Tsuchiya E., Monden M., RA Nakamura Y.; RT "Isolation of a candidate tumor suppressor gene on chromosome 8p21.3-p22 RT that is homologous to an extracellular domain of the PDGF receptor beta RT gene."; RL Oncogene 10:891-895(1995). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Urinary bladder; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP INTERACTION WITH GRB2 AND TNK2. RX PubMed=19815557; DOI=10.1074/jbc.m109.072660; RA Pao-Chun L., Chan P.M., Chan W., Manser E.; RT "Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is RT mediated by Grb2: an analysis of ACK1 effects on Axl signaling."; RL J. Biol. Chem. 284:34954-34963(2009). RN [7] RP POSSIBLE INVOLVEMENT IN SUSCEPTIBILITY TO BEHCET DISEASE. RX PubMed=22926996; DOI=10.1002/humu.22208; RA Hou S., Xiao X., Zhou Y., Zhu X., Li F., Kijlstra A., Yang P.; RT "Genetic variant on PDGFRL associated with Behcet disease in Chinese Han RT populations."; RL Hum. Mutat. 34:74-78(2013). CC -!- SUBUNIT: Forms a complex composed of PDGFRL, TNK2 and GRB2. CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000305}. CC -!- TISSUE SPECIFICITY: Expressed in colon, lung and liver. CC {ECO:0000269|PubMed:7898930}. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:7898930}. Note=The gene CC represented in this entry is involved in disease pathogenesis. CC -!- DISEASE: Note=A polymorphism in PDGFRL has been reported to be CC associated with susceptibility to Behcet disease (PubMed:22926996). CC Behcet disease is a complex multiple-system disorder characterized by CC recurrent oral ulcerations, recurrent genital ulcerations, typical skin CC lesions, and uveitis. Behcet disease also involves joints, blood CC vessels, musculoskeletal, neurological systems, and the CC gastrointestinal tract. {ECO:0000269|PubMed:22926996}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D37965; BAA07179.1; -; mRNA. DR EMBL; CR541952; CAG46750.1; -; mRNA. DR EMBL; AK289450; BAF82139.1; -; mRNA. DR EMBL; CH471080; EAW63811.1; -; Genomic_DNA. DR EMBL; BC010927; AAH10927.1; -; mRNA. DR CCDS; CCDS6003.1; -. DR PIR; I60125; I60125. DR RefSeq; NP_001359002.1; NM_001372073.1. DR RefSeq; NP_006198.1; NM_006207.2. DR AlphaFoldDB; Q15198; -. DR BioGRID; 111183; 43. DR FunCoup; Q15198; 10. DR IntAct; Q15198; 49. DR MINT; Q15198; -. DR STRING; 9606.ENSP00000444211; -. DR TCDB; 8.A.23.1.55; the basigin (basigin) family. DR GlyConnect; 1609; 3 N-Linked glycans (1 site). DR GlyCosmos; Q15198; 2 sites, 2 glycans. DR GlyGen; Q15198; 2 sites, 3 N-linked glycans (1 site). DR iPTMnet; Q15198; -. DR PhosphoSitePlus; Q15198; -. DR BioMuta; PDGFRL; -. DR DMDM; 74762141; -. DR jPOST; Q15198; -. DR MassIVE; Q15198; -. DR PaxDb; 9606-ENSP00000444211; -. DR PeptideAtlas; Q15198; -. DR ProteomicsDB; 60488; -. DR Antibodypedia; 22286; 251 antibodies from 31 providers. DR DNASU; 5157; -. DR Ensembl; ENST00000251630.11; ENSP00000251630.4; ENSG00000104213.14. DR Ensembl; ENST00000541323.1; ENSP00000444211.1; ENSG00000104213.14. DR GeneID; 5157; -. DR KEGG; hsa:5157; -. DR MANE-Select; ENST00000251630.11; ENSP00000251630.4; NM_001372073.1; NP_001359002.1. DR UCSC; uc003wxr.3; human. DR AGR; HGNC:8805; -. DR ClinPGx; PA33149; -. DR CTD; 5157; -. DR DisGeNET; 5157; -. DR GeneCards; PDGFRL; -. DR HGNC; HGNC:8805; PDGFRL. DR HPA; ENSG00000104213; Tissue enhanced (ovary). DR MalaCards; PDGFRL; -. DR MIM; 114500; phenotype. DR MIM; 604584; gene. DR OpenTargets; ENSG00000104213; -. DR Orphanet; 210159; Adult hepatocellular carcinoma. DR VEuPathDB; HostDB:ENSG00000104213; -. DR eggNOG; KOG0200; Eukaryota. DR GeneTree; ENSGT00390000017153; -. DR HOGENOM; CLU_062833_0_0_1; -. DR InParanoid; Q15198; -. DR OMA; CWGQLCN; -. DR OrthoDB; 9864753at2759; -. DR PAN-GO; Q15198; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q15198; -. DR PathwayCommons; Q15198; -. DR SignaLink; Q15198; -. DR Agora; ENSG00000104213; -. DR BioGRID-ORCS; 5157; 10 hits in 1152 CRISPR screens. DR ChiTaRS; PDGFRL; human. DR GenomeRNAi; 5157; -. DR Pharos; Q15198; Tbio. DR PRO; PR:Q15198; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; Q15198; protein. DR Bgee; ENSG00000104213; Expressed in pericardium and 166 other cell types or tissues. DR ExpressionAtlas; Q15198; baseline and differential. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0004992; F:platelet activating factor receptor activity; TAS:ProtInc. DR GO; GO:0005019; F:platelet-derived growth factor beta-receptor activity; TAS:ProtInc. DR FunFam; 2.60.40.10:FF:000223; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000907; Platelet-derived growth factor receptor-like protein; 1. DR FunFam; 2.60.40.10:FF:001395; Platelet-derived growth factor receptor-like protein; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 3. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR042495; PDGFRL. DR PANTHER; PTHR15360; PLATELET-DERIVED GROWTH FACTOR RECEPTOR LIKE; 1. DR PANTHER; PTHR15360:SF1; PLATELET-DERIVED GROWTH FACTOR RECEPTOR-LIKE PROTEIN; 1. DR Pfam; PF13927; Ig_3; 1. DR Pfam; PF21339; VEGFR-1-like_Ig-like; 1. DR SMART; SM00409; IG; 2. DR SMART; SM00408; IGc2; 2. DR SUPFAM; SSF48726; Immunoglobulin; 3. DR PROSITE; PS50835; IG_LIKE; 2. PE 1: Evidence at protein level; KW Disease variant; Disulfide bond; Glycoprotein; Immunoglobulin domain; KW Proteomics identification; Reference proteome; Repeat; Secreted; Signal. FT SIGNAL 1..21 FT /evidence="ECO:0000255" FT CHAIN 22..375 FT /note="Platelet-derived growth factor receptor-like FT protein" FT /id="PRO_0000233090" FT DOMAIN 62..159 FT /note="Ig-like C2-type 1" FT DOMAIN 272..375 FT /note="Ig-like C2-type 2" FT REGION 22..64 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 40..50 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT CARBOHYD 132 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 219 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 96..143 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 293..357 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VARIANT 23 FT /note="H -> Y (in CRC; somatic mutation; FT dbSNP:rs137853148)" FT /evidence="ECO:0000269|PubMed:7898930" FT /id="VAR_026052" FT CONFLICT 227 FT /note="M -> I (in Ref. 2; CAG46750)" FT /evidence="ECO:0000305" SQ SEQUENCE 375 AA; 41861 MW; DF7FE6EB3FB2A802 CRC64; MKVWLLLGLL LVHEALEDVT GQHLPKNKRP KEPGENRIKP TNKKVKPKIP KMKDRDSANS APKTQSIMMQ VLDKGRFQKP AATLSLLAGQ TVELRCKGSR IGWSYPAYLD TFKDSRLSVK QNERYGQLTL VNSTSADTGE FSCWVQLCSG YICRKDEAKT GSTYIFFTEK GELFVPSPSY FDVVYLNPDR QAVVPCRVTV LSAKVTLHRE FPAKEIPANG TDIVYDMKRG FVYLQPHSEH QGVVYCRAEA GGRSQISVKY QLLYVAVPSG PPSTTILASS NKVKSGDDIS VLCTVLGEPD VEVEFTWIFP GQKDERPVTI QDTWRLIHRG LGHTTRISQS VITVEDFETI DAGYYICTAQ NLQGQTTVAT TVEFS // ID PKN1_HUMAN Reviewed; 942 AA. AC Q16512; A8K7W5; B2R9R4; B3KVN3; Q15143; Q504U4; Q8IUV5; Q9UD44; DT 15-JUL-1999, integrated into UniProtKB/Swiss-Prot. DT 22-SEP-2009, sequence version 2. DT 28-JAN-2026, entry version 251. DE RecName: Full=Serine/threonine-protein kinase N1; DE EC=2.7.11.13 {ECO:0000269|PubMed:18066052}; DE AltName: Full=Protease-activated kinase 1; DE Short=PAK-1; DE AltName: Full=Protein kinase C-like 1; DE AltName: Full=Protein kinase C-like PKN; DE AltName: Full=Protein kinase PKN-alpha; DE AltName: Full=Protein-kinase C-related kinase 1; DE AltName: Full=Serine-threonine protein kinase N; GN Name=PKN1; Synonyms=PAK1, PKN, PRK1, PRKCL1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF LYS-644. RC TISSUE=Hippocampus; RX PubMed=8135837; DOI=10.1006/bbrc.1994.1313; RA Mukai H., Ono Y.; RT "A novel protein kinase with leucine zipper-like sequences: its catalytic RT domain is highly homologous to that of protein kinase C."; RL Biochem. Biophys. Res. Commun. 199:897-904(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Fetal brain; RX PubMed=7851406; DOI=10.1111/j.1432-1033.1995.tb20395.x; RA Palmer R.H., Ridden J., Parker P.J.; RT "Cloning and expression patterns of two members of a novel protein-kinase- RT C-related kinase family."; RL Eur. J. Biochem. 227:344-351(1995). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANTS RP ILE-555 AND ILE-901. RC TISSUE=Kidney, Synovium, and Thymus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3), AND VARIANT RP ILE-901. RC TISSUE=Brain, and Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 700-800 (ISOFORMS 1/2), AND VARIANT VAL-718. RX PubMed=7988719; DOI=10.1016/0014-5793(94)01202-4; RA Palmer R.H., Ridden J., Parker P.J.; RT "Identification of multiple, novel, protein kinase C-related gene RT products."; RL FEBS Lett. 356:5-8(1994). RN [7] RP FUNCTION. RX PubMed=8557118; DOI=10.1016/0014-5793(95)01454-3; RA Palmer R.H., Schonwasser D.C., Rahman D., Pappin D.J., Herget T., RA Parker P.J.; RT "PRK1 phosphorylates MARCKS at the PKC sites: serine 152, serine 156 and RT serine 163."; RL FEBS Lett. 378:281-285(1996). RN [8] RP FUNCTION. RX PubMed=8621664; DOI=10.1074/jbc.271.16.9816; RA Mukai H., Toshimori M., Shibata H., Kitagawa M., Shimakawa M., Miyahara M., RA Sunakawa H., Ono Y.; RT "PKN associates and phosphorylates the head-rod domain of neurofilament RT protein."; RL J. Biol. Chem. 271:9816-9822(1996). RN [9] RP ACTIVITY REGULATION, AND INTERACTION WITH RHOA. RX PubMed=8571126; DOI=10.1126/science.271.5249.645; RA Watanabe G., Saito Y., Madaule P., Ishizaki T., Fujisawa K., Morii N., RA Mukai H., Ono Y., Kakizuka A., Narumiya S.; RT "Protein kinase N (PKN) and PKN-related protein rhophilin as targets of RT small GTPase Rho."; RL Science 271:645-648(1996). RN [10] RP FUNCTION. RX PubMed=9175763; DOI=10.1006/bbrc.1997.6669; RA Matsuzawa K., Kosako H., Inagaki N., Shibata H., Mukai H., Ono Y., RA Amano M., Kaibuchi K., Matsuura Y., Azuma I., Inagaki M.; RT "Domain-specific phosphorylation of vimentin and glial fibrillary acidic RT protein by PKN."; RL Biochem. Biophys. Res. Commun. 234:621-625(1997). RN [11] RP SUBCELLULAR LOCATION, AND INTERACTION WITH RHOB. RX PubMed=9478917; DOI=10.1074/jbc.273.9.4811; RA Mellor H., Flynn P., Nobes C.D., Hall A., Parker P.J.; RT "PRK1 is targeted to endosomes by the small GTPase, RhoB."; RL J. Biol. Chem. 273:4811-4814(1998). RN [12] RP ACTIVITY REGULATION, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF ASP-108; RP ASP-451; ASP-454; ASP-558 AND ASP-560. RX PubMed=9751706; DOI=10.1073/pnas.95.20.11566; RA Takahashi M., Mukai H., Toshimori M., Miyamoto M., Ono Y.; RT "Proteolytic activation of PKN by caspase-3 or related protease during RT apoptosis."; RL Proc. Natl. Acad. Sci. U.S.A. 95:11566-11571(1998). RN [13] RP PHOSPHORYLATION AT THR-774 BY PDPK1, AND INTERACTION WITH PDPK1. RX PubMed=10792047; DOI=10.1073/pnas.090491897; RA Dong L.Q., Landa L.R., Wick M.J., Zhu L., Mukai H., Ono Y., Liu F.; RT "Phosphorylation of protein kinase N by phosphoinositide-dependent protein RT kinase-1 mediates insulin signals to the actin cytoskeleton."; RL Proc. Natl. Acad. Sci. U.S.A. 97:5089-5094(2000). RN [14] RP FUNCTION. RX PubMed=11104762; DOI=10.1074/jbc.m007427200; RA Taniguchi T., Kawamata T., Mukai H., Hasegawa H., Isagawa T., Yasuda M., RA Hashimoto T., Terashima A., Nakai M., Mori H., Ono Y., Tanaka C.; RT "Phosphorylation of tau is regulated by PKN."; RL J. Biol. Chem. 276:10025-10031(2001). RN [15] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH AR. RX PubMed=12514133; DOI=10.1093/emboj/cdg023; RA Metzger E., Muller J.M., Ferrari S., Buettner R., Schule R.; RT "A novel inducible transactivation domain in the androgen receptor: RT implications for PRK in prostate cancer."; RL EMBO J. 22:270-280(2003). RN [16] RP INTERACTION WITH S.TYPHIMURIUM SSPH1 (MICROBIAL INFECTION). RX PubMed=16611232; DOI=10.1111/j.1462-5822.2005.00670.x; RA Haraga A., Miller S.I.; RT "A Salmonella type III secretion effector interacts with the mammalian RT serine/threonine protein kinase PKN1."; RL Cell. Microbiol. 8:837-846(2006). RN [17] RP INTERACTION WITH CCNT2. RX PubMed=16331689; DOI=10.1002/jcp.20566; RA Cottone G., Baldi A., Palescandolo E., Manente L., Penta R., Paggi M.G., RA De Luca A.; RT "Pkn is a novel partner of cyclin T2a in muscle differentiation."; RL J. Cell. Physiol. 207:232-237(2006). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533 AND SER-562, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [19] RP FUNCTION, PHOSPHORYLATION, AND SUBCELLULAR LOCATION. RX PubMed=17332740; DOI=10.1038/sj.emboj.7601637; RA Schmidt A., Durgan J., Magalhaes A., Hall A.; RT "Rho GTPases regulate PRK2/PKN2 to control entry into mitosis and exit from RT cytokinesis."; RL EMBO J. 26:1624-1636(2007). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-778, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-205 AND SER-537, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [22] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-644. RX PubMed=18066052; DOI=10.1038/ncb1668; RA Metzger E., Yin N., Wissmann M., Kunowska N., Fischer K., Friedrichs N., RA Patnaik D., Higgins J.M., Potier N., Scheidtmann K.H., Buettner R., RA Schule R.; RT "Phosphorylation of histone H3 at threonine 11 establishes a novel RT chromatin mark for transcriptional regulation."; RL Nat. Cell Biol. 10:53-60(2008). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533; SER-537; SER-559; RP SER-562 AND SER-916, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [24] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-205; SER-533; SER-537; RP SER-559; SER-562; THR-914 AND SER-916, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [26] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-448, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [27] RP FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=20188095; DOI=10.1016/j.febslet.2010.02.057; RA Harrison B.C., Huynh K., Lundgaard G.L., Helmke S.M., Perryman M.B., RA McKinsey T.A.; RT "Protein kinase C-related kinase targets nuclear localization signals in a RT subset of class IIa histone deacetylases."; RL FEBS Lett. 584:1103-1110(2010). RN [28] RP INTERACTION WITH PRKCB. RX PubMed=20228790; DOI=10.1038/nature08839; RA Metzger E., Imhof A., Patel D., Kahl P., Hoffmeyer K., Friedrichs N., RA Muller J.M., Greschik H., Kirfel J., Ji S., Kunowska N., RA Beisenherz-Huss C., Gunther T., Buettner R., Schule R.; RT "Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at RT histone H3K4."; RL Nature 464:792-796(2010). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533; SER-537 AND SER-562, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [30] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [31] RP FUNCTION, AND IDENTIFICATION IN A COMPLEX WITH AKAP13; MAPK14; ZAK AND RP MAP2K3. RX PubMed=21224381; DOI=10.1074/jbc.m110.185645; RA Cariolato L., Cavin S., Diviani D.; RT "A-kinase anchoring protein (AKAP)-Lbc anchors a PKN-based signaling RT complex involved in alpha1-adrenergic receptor-induced p38 activation."; RL J. Biol. Chem. 286:7925-7937(2011). RN [32] RP FUNCTION IN CELL MIGRATION, AND TISSUE SPECIFICITY. RX PubMed=21754995; DOI=10.1371/journal.pone.0021732; RA Lachmann S., Jevons A., De Rycker M., Casamassima A., Radtke S., RA Collazos A., Parker P.J.; RT "Regulatory domain selectivity in the cell-type specific PKN-dependence of RT cell migration."; RL PLoS ONE 6:E21732-E21732(2011). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-562, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [34] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-69; SER-533; SER-537; RP SER-540; SER-562; SER-608 AND SER-916, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [36] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-916, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [37] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 13-98 IN COMPLEX WITH RHOA. RX PubMed=10619026; DOI=10.1016/s1097-2765(00)80389-5; RA Maesaki R., Ihara K., Shimizu T., Kuroda S., Kaibuchi K., Hakoshima T.; RT "The structural basis of Rho effector recognition revealed by the crystal RT structure of human RhoA complexed with the effector domain of PKN/PRK1."; RL Mol. Cell 4:793-803(1999). RN [38] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 13-98. RX PubMed=10388627; DOI=10.1006/jsbi.1999.4114; RA Maesaki R., Shimizu T., Ihara K., Kuroda S., Kaibuchi K., Hakoshima T.; RT "Biochemical and crystallographic characterization of a Rho effector domain RT of the protein serine/threonine kinase N in a complex with RhoA."; RL J. Struct. Biol. 126:166-170(1999). RN [39] RP STRUCTURE BY NMR OF 116-199 IN COMPLEX WITH RAC1. RX PubMed=14514689; DOI=10.1074/jbc.m304313200; RA Owen D., Lowe P.N., Nietlispach D., Brosnan C.E., Chirgadze D.Y., RA Parker P.J., Blundell T.L., Mott H.R.; RT "Molecular dissection of the interaction between the small G proteins Rac1 RT and RhoA and protein kinase C-related kinase 1 (PRK1)."; RL J. Biol. Chem. 278:50578-50587(2003). RN [40] RP STRUCTURE BY NMR OF 122-199 IN COMPLEX WITH RAC1. RX PubMed=18006505; DOI=10.1074/jbc.m706760200; RA Modha R., Campbell L.J., Nietlispach D., Buhecha H.R., Owen D., Mott H.R.; RT "The Rac1 polybasic region is required for interaction with its effector RT PRK1."; RL J. Biol. Chem. 283:1492-1500(2008). RN [41] RP X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 122-199 IN COMPLEX WITH RP SALMONELLA SSPH1, UBIQUITINATION (MICROBIAL INFECTION), MUTAGENESIS OF RP ARG-181 AND ARG-185, FUNCTION AS ANDROGEN RECEPTOR COACTIVATOR, AND RP INTERACTION WITH SALMONELLA SSPH1 (MICROBIAL INFECTION). RX PubMed=24248594; DOI=10.1128/mcb.01360-13; RA Keszei A.F., Tang X., McCormick C., Zeqiraj E., Rohde J.R., Tyers M., RA Sicheri F.; RT "Structure of an SspH1-PKN1 complex reveals the basis for host substrate RT recognition and mechanism of activation for a bacterial E3 ubiquitin RT ligase."; RL Mol. Cell. Biol. 34:362-373(2014). RN [42] RP VARIANTS [LARGE SCALE ANALYSIS] CYS-185; GLU-197; TRP-436; GLN-520; RP ILE-555; GLN-635; VAL-718; LEU-873; ILE-901 AND VAL-921. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: PKC-related serine/threonine-protein kinase involved in CC various processes such as regulation of the intermediate filaments of CC the actin cytoskeleton, cell migration, tumor cell invasion and CC transcription regulation. Part of a signaling cascade that begins with CC the activation of the adrenergic receptor ADRA1B and leads to the CC activation of MAPK14. Regulates the cytoskeletal network by CC phosphorylating proteins such as VIM and neurofilament proteins NEFH, CC NEFL and NEFM, leading to inhibit their polymerization. Phosphorylates CC 'Ser-575', 'Ser-637' and 'Ser-669' of MAPT/Tau, lowering its ability to CC bind to microtubules, resulting in disruption of tubulin assembly. Acts CC as a key coactivator of androgen receptor (AR)-dependent transcription, CC by being recruited to AR target genes and specifically mediating CC phosphorylation of 'Thr-11' of histone H3 (H3T11ph), a specific tag for CC epigenetic transcriptional activation that promotes demethylation of CC histone H3 'Lys-9' (H3K9me) by KDM4C/JMJD2C. Phosphorylates HDAC5, CC HDAC7 and HDAC9, leading to impair their import in the nucleus. CC Phosphorylates 'Thr-38' of PPP1R14A, 'Ser-159', 'Ser-163' and 'Ser-170' CC of MARCKS, and GFAP. Able to phosphorylate RPS6 in vitro. CC {ECO:0000269|PubMed:11104762, ECO:0000269|PubMed:12514133, CC ECO:0000269|PubMed:17332740, ECO:0000269|PubMed:18066052, CC ECO:0000269|PubMed:20188095, ECO:0000269|PubMed:21224381, CC ECO:0000269|PubMed:21754995, ECO:0000269|PubMed:24248594, CC ECO:0000269|PubMed:8557118, ECO:0000269|PubMed:8621664, CC ECO:0000269|PubMed:9175763}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:18066052}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:18066052}; CC -!- ACTIVITY REGULATION: Kinase activity is activated upon binding to Rho CC proteins (RHOA, RHOB and RAC1). Activated by lipids, particularly CC cardiolipin and to a lesser extent by other acidic phospholipids. CC Activated by caspase-3 (CASP3) cleavage during apoptosis. Two specific CC sites, Thr-774 (activation loop of the kinase domain) and Ser-916 (turn CC motif), need to be phosphorylated for its full activation. CC {ECO:0000269|PubMed:8571126, ECO:0000269|PubMed:9751706}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=20.6 uM for HDAC5 {ECO:0000269|PubMed:20188095}; CC -!- SUBUNIT: Interacts with ZFAND6 (By similarity). Interacts with AR CC (PubMed:12514133). Interacts with PRKCB (PubMed:20228790). Interacts CC (via REM 1 and REM 2 repeats) with RAC1 (PubMed:14514689, CC PubMed:18006505). Interacts (via REM 1 repeat) with RHOA CC (PubMed:10619026, PubMed:8571126). Interacts with RHOB CC (PubMed:9478917). Interacts (via C-terminus) with PDPK1 CC (PubMed:10792047). Interacts with CCNT2; enhances MYOD1-dependent CC transcription (PubMed:16331689). Component of a signaling complex CC containing at least AKAP13, PKN1, MAPK14, ZAK and MAP2K3. Within this CC complex, AKAP13 interacts directly with PKN1, which in turn recruits CC MAPK14, MAP2K3 and ZAK (PubMed:21224381). CC {ECO:0000250|UniProtKB:P70268, ECO:0000269|PubMed:10619026, CC ECO:0000269|PubMed:10792047, ECO:0000269|PubMed:12514133, CC ECO:0000269|PubMed:14514689, ECO:0000269|PubMed:16331689, CC ECO:0000269|PubMed:18006505, ECO:0000269|PubMed:20228790, CC ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:8571126, CC ECO:0000269|PubMed:9478917}. CC -!- SUBUNIT: (Microbial infection) Interacts (via the second REM repeat) CC with S.typhimurium E3 ubiquitin-protein ligase SspH1 (via the leucine- CC rich repeat region) (PubMed:16611232, PubMed:24248594). CC {ECO:0000269|PubMed:16611232, ECO:0000269|PubMed:24248594}. CC -!- INTERACTION: CC Q16512; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-602382, EBI-10173507; CC Q16512; Q9ULX6: AKAP8L; NbExp=3; IntAct=EBI-602382, EBI-357530; CC Q16512; Q6PJH3: AKAP9; NbExp=3; IntAct=EBI-602382, EBI-11745576; CC Q16512; P05067: APP; NbExp=3; IntAct=EBI-602382, EBI-77613; CC Q16512; P15289: ARSA; NbExp=3; IntAct=EBI-602382, EBI-2117357; CC Q16512; Q14457: BECN1; NbExp=3; IntAct=EBI-602382, EBI-949378; CC Q16512; Q9H2G9: BLZF1; NbExp=3; IntAct=EBI-602382, EBI-2548012; CC Q16512; Q8WU43: C2orf15; NbExp=3; IntAct=EBI-602382, EBI-12904676; CC Q16512; Q96M89-2: CCDC138; NbExp=3; IntAct=EBI-602382, EBI-10972887; CC Q16512; Q15834: CCDC85B; NbExp=2; IntAct=EBI-602382, EBI-739674; CC Q16512; Q8IV13: CCNJL; NbExp=3; IntAct=EBI-602382, EBI-21668062; CC Q16512; Q01850: CDR2; NbExp=6; IntAct=EBI-602382, EBI-1181367; CC Q16512; Q86XR8-3: CEP57; NbExp=3; IntAct=EBI-602382, EBI-11752486; CC Q16512; Q8IYX8-2: CEP57L1; NbExp=3; IntAct=EBI-602382, EBI-10181988; CC Q16512; Q8NHQ1: CEP70; NbExp=3; IntAct=EBI-602382, EBI-739624; CC Q16512; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-602382, EBI-3867333; CC Q16512; Q9NRI5-2: DISC1; NbExp=3; IntAct=EBI-602382, EBI-11988027; CC Q16512; Q8IW40: DNAAF19; NbExp=3; IntAct=EBI-602382, EBI-10261970; CC Q16512; Q8WWB3: DYDC1; NbExp=3; IntAct=EBI-602382, EBI-740680; CC Q16512; P26641: EEF1G; NbExp=3; IntAct=EBI-602382, EBI-351467; CC Q16512; O00303: EIF3F; NbExp=3; IntAct=EBI-602382, EBI-711990; CC Q16512; Q06547-2: GABPB1; NbExp=3; IntAct=EBI-602382, EBI-618189; CC Q16512; Q08379: GOLGA2; NbExp=6; IntAct=EBI-602382, EBI-618309; CC Q16512; A6NEM1: GOLGA6L9; NbExp=3; IntAct=EBI-602382, EBI-5916454; CC Q16512; P54257: HAP1; NbExp=3; IntAct=EBI-602382, EBI-712814; CC Q16512; Q96CS2: HAUS1; NbExp=3; IntAct=EBI-602382, EBI-2514791; CC Q16512; Q9NSC5: HOMER3; NbExp=7; IntAct=EBI-602382, EBI-748420; CC Q16512; O75031: HSF2BP; NbExp=3; IntAct=EBI-602382, EBI-7116203; CC Q16512; Q9UKT9: IKZF3; NbExp=3; IntAct=EBI-602382, EBI-747204; CC Q16512; Q5TA45: INTS11; NbExp=3; IntAct=EBI-602382, EBI-748258; CC Q16512; Q8N5Z5: KCTD17; NbExp=3; IntAct=EBI-602382, EBI-743960; CC Q16512; Q86T90: KIAA1328; NbExp=3; IntAct=EBI-602382, EBI-3437878; CC Q16512; P19012: KRT15; NbExp=3; IntAct=EBI-602382, EBI-739566; CC Q16512; P08779: KRT16; NbExp=3; IntAct=EBI-602382, EBI-356410; CC Q16512; P08727: KRT19; NbExp=3; IntAct=EBI-602382, EBI-742756; CC Q16512; Q15323: KRT31; NbExp=6; IntAct=EBI-602382, EBI-948001; CC Q16512; O76011: KRT34; NbExp=5; IntAct=EBI-602382, EBI-1047093; CC Q16512; Q92764: KRT35; NbExp=3; IntAct=EBI-602382, EBI-1058674; CC Q16512; O76013-2: KRT36; NbExp=3; IntAct=EBI-602382, EBI-11958506; CC Q16512; O76014: KRT37; NbExp=3; IntAct=EBI-602382, EBI-1045716; CC Q16512; Q9BV99: LRRC61; NbExp=3; IntAct=EBI-602382, EBI-2350424; CC Q16512; Q9NYL2-1: MAP3K20; NbExp=2; IntAct=EBI-602382, EBI-687346; CC Q16512; P53778: MAPK12; NbExp=2; IntAct=EBI-602382, EBI-602406; CC Q16512; O15344: MID1; NbExp=3; IntAct=EBI-602382, EBI-2340316; CC Q16512; Q9UJV3-2: MID2; NbExp=3; IntAct=EBI-602382, EBI-10172526; CC Q16512; Q8N108-16: MIER1; NbExp=3; IntAct=EBI-602382, EBI-25830642; CC Q16512; Q8TD10: MIPOL1; NbExp=3; IntAct=EBI-602382, EBI-2548751; CC Q16512; Q13064: MKRN3; NbExp=3; IntAct=EBI-602382, EBI-2340269; CC Q16512; Q5JR59-3: MTUS2; NbExp=3; IntAct=EBI-602382, EBI-11522433; CC Q16512; P07196: NEFL; NbExp=3; IntAct=EBI-602382, EBI-475646; CC Q16512; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-602382, EBI-79165; CC Q16512; Q8ND90: PNMA1; NbExp=3; IntAct=EBI-602382, EBI-302345; CC Q16512; P78424: POU6F2; NbExp=3; IntAct=EBI-602382, EBI-12029004; CC Q16512; P28070: PSMB4; NbExp=3; IntAct=EBI-602382, EBI-603350; CC Q16512; Q96QF0-7: RAB3IP; NbExp=3; IntAct=EBI-602382, EBI-11984839; CC Q16512; Q9UJW9: SERTAD3; NbExp=3; IntAct=EBI-602382, EBI-748621; CC Q16512; Q9H7B4: SMYD3; NbExp=3; IntAct=EBI-602382, EBI-347919; CC Q16512; Q96R06: SPAG5; NbExp=3; IntAct=EBI-602382, EBI-413317; CC Q16512; Q9Y2D8: SSX2IP; NbExp=3; IntAct=EBI-602382, EBI-2212028; CC Q16512; Q9NZ72: STMN3; NbExp=3; IntAct=EBI-602382, EBI-725557; CC Q16512; O75558: STX11; NbExp=3; IntAct=EBI-602382, EBI-714135; CC Q16512; A1L190: SYCE3; NbExp=3; IntAct=EBI-602382, EBI-10283466; CC Q16512; Q8WTV1: THAP3; NbExp=3; IntAct=EBI-602382, EBI-17438286; CC Q16512; Q13077: TRAF1; NbExp=3; IntAct=EBI-602382, EBI-359224; CC Q16512; Q12933: TRAF2; NbExp=3; IntAct=EBI-602382, EBI-355744; CC Q16512; P14373: TRIM27; NbExp=3; IntAct=EBI-602382, EBI-719493; CC Q16512; Q9BZW7: TSGA10; NbExp=3; IntAct=EBI-602382, EBI-744794; CC Q16512; Q8IWV8-2: UBR2; NbExp=3; IntAct=EBI-602382, EBI-17923957; CC Q16512; Q8N6Y0: USHBP1; NbExp=3; IntAct=EBI-602382, EBI-739895; CC Q16512; P08670: VIM; NbExp=3; IntAct=EBI-602382, EBI-353844; CC Q16512; Q8TF47: ZFP90; NbExp=3; IntAct=EBI-602382, EBI-11419867; CC Q16512; Q9UNY5: ZNF232; NbExp=3; IntAct=EBI-602382, EBI-749023; CC Q16512; Q96MN9-2: ZNF488; NbExp=3; IntAct=EBI-602382, EBI-25831733; CC Q16512; Q9P0T4: ZNF581; NbExp=3; IntAct=EBI-602382, EBI-745520; CC Q16512; Q9UGI0: ZRANB1; NbExp=3; IntAct=EBI-602382, EBI-527853; CC Q16512; A1JU68: yopM; Xeno; NbExp=2; IntAct=EBI-602382, EBI-26365850; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17332740, CC ECO:0000269|PubMed:9478917}. Nucleus {ECO:0000269|PubMed:12514133}. CC Endosome {ECO:0000269|PubMed:9478917}. Cell membrane CC {ECO:0000250|UniProtKB:Q63433}; Peripheral membrane protein CC {ECO:0000250|UniProtKB:Q63433}. Cleavage furrow CC {ECO:0000269|PubMed:17332740}. Midbody {ECO:0000269|PubMed:17332740}. CC Note=Associates with chromatin in a ligand-dependent manner. CC Localization to endosomes is mediated via its interaction with RHOB. CC Association to the cell membrane is dependent on Ser-377 CC phosphorylation. Accumulates during telophase at the cleavage furrow CC and finally concentrates around the midbody in cytokinesis. CC {ECO:0000250|UniProtKB:Q63433, ECO:0000269|PubMed:17332740}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q16512-1; Sequence=Displayed; CC Name=2; CC IsoId=Q16512-2; Sequence=VSP_038143; CC Name=3; CC IsoId=Q16512-3; Sequence=VSP_039213, VSP_039214; CC -!- TISSUE SPECIFICITY: Found ubiquitously. Expressed in heart, brain, CC placenta, lung, skeletal muscle, kidney and pancreas. Expressed in CC numerous tumor cell lines, especially in breast tumor cells. CC {ECO:0000269|PubMed:21754995}. CC -!- DOMAIN: The C1 domain does not bind the diacylglycerol (DAG). CC -!- PTM: Autophosphorylated; preferably on serine. Phosphorylated during CC mitosis. {ECO:0000269|PubMed:10792047, ECO:0000269|PubMed:17332740}. CC -!- PTM: Activated by limited proteolysis with trypsin. {ECO:0000250}. CC -!- PTM: (Microbial infection) In case of infection, polyubiquitinated by CC the bacterial E3 ubiquitin-protein ligase SspH1, leading to its CC proteasomal degradation. {ECO:0000269|PubMed:24248594}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. PKC subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D26181; BAA05169.1; -; mRNA. DR EMBL; S75546; AAB33345.1; -; mRNA. DR EMBL; U33053; AAC50209.1; -; mRNA. DR EMBL; AK123007; BAG53845.1; -; mRNA. DR EMBL; AK292130; BAF84819.1; -; mRNA. DR EMBL; AK313886; BAG36611.1; -; mRNA. DR EMBL; AC008569; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC040061; AAH40061.1; -; mRNA. DR EMBL; BC094766; AAH94766.1; -; mRNA. DR CCDS; CCDS42513.1; -. [Q16512-1] DR CCDS; CCDS42514.1; -. [Q16512-2] DR PIR; JC2129; JC2129. DR PIR; S51162; S51162. DR RefSeq; NP_002732.3; NM_002741.3. [Q16512-1] DR RefSeq; NP_998725.1; NM_213560.3. [Q16512-2] DR PDB; 1CXZ; X-ray; 2.20 A; B=13-98. DR PDB; 1URF; NMR; -; A=122-199. DR PDB; 2RMK; NMR; -; B=122-199. DR PDB; 4NKG; X-ray; 2.90 A; B/D=122-199. DR PDB; 4OTD; X-ray; 2.00 A; A=605-942. DR PDB; 4OTG; X-ray; 2.60 A; A=605-942. DR PDB; 4OTH; X-ray; 1.80 A; A=605-942. DR PDB; 4OTI; X-ray; 1.93 A; A=605-942. DR PDBsum; 1CXZ; -. DR PDBsum; 1URF; -. DR PDBsum; 2RMK; -. DR PDBsum; 4NKG; -. DR PDBsum; 4OTD; -. DR PDBsum; 4OTG; -. DR PDBsum; 4OTH; -. DR PDBsum; 4OTI; -. DR AlphaFoldDB; Q16512; -. DR SMR; Q16512; -. DR BioGRID; 111571; 147. DR CORUM; Q16512; -. DR DIP; DIP-34240N; -. DR ELM; Q16512; -. DR FunCoup; Q16512; 2793. DR IntAct; Q16512; 116. DR MINT; Q16512; -. DR STRING; 9606.ENSP00000343325; -. DR BindingDB; Q16512; -. DR ChEMBL; CHEMBL3384; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q16512; -. DR GuidetoPHARMACOLOGY; 1520; -. DR GlyConnect; 1737; 1 N-Linked glycan (1 site). DR GlyCosmos; Q16512; 3 sites, 2 glycans. DR GlyGen; Q16512; 5 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (2 sites). DR iPTMnet; Q16512; -. DR MetOSite; Q16512; -. DR PhosphoSitePlus; Q16512; -. DR BioMuta; PKN1; -. DR DMDM; 259016304; -. DR CPTAC; CPTAC-3003; -. DR jPOST; Q16512; -. DR MassIVE; Q16512; -. DR PaxDb; 9606-ENSP00000343325; -. DR PeptideAtlas; Q16512; -. DR ProteomicsDB; 60877; -. [Q16512-1] DR ProteomicsDB; 60878; -. [Q16512-2] DR ProteomicsDB; 60879; -. [Q16512-3] DR Pumba; Q16512; -. DR Antibodypedia; 1296; 250 antibodies from 36 providers. DR DNASU; 5585; -. DR Ensembl; ENST00000242783.11; ENSP00000242783.7; ENSG00000123143.14. [Q16512-1] DR Ensembl; ENST00000342216.8; ENSP00000343325.4; ENSG00000123143.14. [Q16512-2] DR GeneID; 5585; -. DR KEGG; hsa:5585; -. DR MANE-Select; ENST00000242783.11; ENSP00000242783.7; NM_002741.5; NP_002732.3. DR UCSC; uc002myp.4; human. [Q16512-1] DR AGR; HGNC:9405; -. DR ClinPGx; PA33769; -. DR CTD; 5585; -. DR DisGeNET; 5585; -. DR GeneCards; PKN1; -. DR HGNC; HGNC:9405; PKN1. DR HPA; ENSG00000123143; Low tissue specificity. DR MalaCards; PKN1; -. DR MIM; 601032; gene. DR OpenTargets; ENSG00000123143; -. DR VEuPathDB; HostDB:ENSG00000123143; -. DR eggNOG; KOG0694; Eukaryota. DR GeneTree; ENSGT00940000154990; -. DR HOGENOM; CLU_000288_132_1_1; -. DR InParanoid; Q16512; -. DR OMA; CTELRIE; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; Q16512; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q16512; -. DR BRENDA; 2.7.11.13; 2681. DR PathwayCommons; Q16512; -. DR Reactome; R-HSA-5625740; RHO GTPases activate PKNs. DR Reactome; R-HSA-5625886; Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3. DR Reactome; R-HSA-8980692; RHOA GTPase cycle. DR Reactome; R-HSA-9013026; RHOB GTPase cycle. DR Reactome; R-HSA-9013106; RHOC GTPase cycle. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR SABIO-RK; Q16512; -. DR SignaLink; Q16512; -. DR SIGNOR; Q16512; -. DR Agora; ENSG00000123143; -. DR BioGRID-ORCS; 5585; 15 hits in 1195 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; PKN1; human. DR EvolutionaryTrace; Q16512; -. DR GeneWiki; Protein_kinase_N1; -. DR GenomeRNAi; 5585; -. DR Pharos; Q16512; Tchem. DR PRO; PR:Q16512; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q16512; protein. DR Bgee; ENSG00000123143; Expressed in apex of heart and 142 other cell types or tissues. DR ExpressionAtlas; Q16512; baseline and differential. DR GO; GO:0032154; C:cleavage furrow; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005768; C:endosome; IDA:UniProtKB. DR GO; GO:0030496; C:midbody; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0032991; C:protein-containing complex; IDA:MGI. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; EXP:Reactome. DR GO; GO:0042393; F:histone binding; IDA:UniProtKB. DR GO; GO:0042826; F:histone deacetylase binding; IDA:UniProtKB. DR GO; GO:0035402; F:histone H3T11 kinase activity; IDA:UniProtKB. DR GO; GO:0050681; F:nuclear androgen receptor binding; IDA:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; TAS:ProtInc. DR GO; GO:0005080; F:protein kinase C binding; IPI:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0031267; F:small GTPase binding; IDA:UniProtKB. DR GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB. DR GO; GO:0001783; P:B cell apoptotic process; IEA:Ensembl. DR GO; GO:0001782; P:B cell homeostasis; IEA:Ensembl. DR GO; GO:0010631; P:epithelial cell migration; IMP:UniProtKB. DR GO; GO:0006972; P:hyperosmotic response; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0030889; P:negative regulation of B cell proliferation; IEA:Ensembl. DR GO; GO:0043687; P:post-translational protein modification; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0060765; P:regulation of androgen receptor signaling pathway; TAS:Reactome. DR GO; GO:2000145; P:regulation of cell motility; IMP:UniProtKB. DR GO; GO:0002634; P:regulation of germinal center formation; IEA:Ensembl. DR GO; GO:0002637; P:regulation of immunoglobulin production; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0003014; P:renal system process; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0048536; P:spleen development; IEA:Ensembl. DR CDD; cd08687; C2_PKN-like; 1. DR CDD; cd11630; HR1_PKN1_2; 1. DR CDD; cd11636; HR1_PKN1_3; 1. DR CDD; cd11622; HR1_PKN_1; 1. DR CDD; cd05589; STKc_PKN; 1. DR FunFam; 1.10.287.160:FF:000001; Putative serine/threonine-protein kinase N2; 1. DR FunFam; 1.10.287.160:FF:000002; Putative serine/threonine-protein kinase N2; 1. DR FunFam; 1.10.287.160:FF:000003; Putative serine/threonine-protein kinase N2; 1. DR FunFam; 3.30.200.20:FF:000058; Putative serine/threonine-protein kinase N2; 1. DR FunFam; 1.10.510.10:FF:000038; serine/threonine-protein kinase N2 isoform X1; 1. DR Gene3D; 1.10.287.160; HR1 repeat; 3. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00416; -. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR000008; C2_dom. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR037784; C2_PKN. DR InterPro; IPR011072; HR1_rho-bd. DR InterPro; IPR036274; HR1_rpt_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR037317; PKN1_HR1_2. DR InterPro; IPR037313; PKN_HR1_1. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF02185; HR1; 3. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR SMART; SM00742; Hr1; 3. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR SUPFAM; SSF46585; HR1 repeat; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50004; C2; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS51860; REM_1; 3. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ATP-binding; KW Cell membrane; Chromatin regulator; Coiled coil; Cytoplasm; Endosome; KW Kinase; Membrane; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transcription; Transcription regulation; KW Transferase; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:22814378" FT CHAIN 2..942 FT /note="Serine/threonine-protein kinase N1" FT /id="PRO_0000055719" FT DOMAIN 25..100 FT /note="REM-1 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01207" FT DOMAIN 112..193 FT /note="REM-1 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01207" FT DOMAIN 201..280 FT /note="REM-1 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01207" FT DOMAIN 307..470 FT /note="C2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT DOMAIN 615..874 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 875..942 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT REGION 102..121 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 181..185 FT /note="Important for interaction with bacterial SspH1 and FT SspH1-mediated polyubiquitination" FT /evidence="ECO:0000269|PubMed:24248594" FT REGION 341..363 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 553..603 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 581..596 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 740 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 621..629 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 644 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 108..109 FT /note="Cleavage; by caspase-3" FT SITE 454..455 FT /note="Cleavage; by caspase-3" FT SITE 558..559 FT /note="Cleavage; by caspase-3" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:22814378" FT MOD_RES 69 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 205 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19690332" FT MOD_RES 374 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63433" FT MOD_RES 448 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 533 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 537 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 540 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 559 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332" FT MOD_RES 562 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 608 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 774 FT /note="Phosphothreonine; by PDPK1" FT /evidence="ECO:0000269|PubMed:10792047" FT MOD_RES 778 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18220336" FT MOD_RES 914 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 916 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT VAR_SEQ 1..7 FT /note="MASDAVQ -> MAEANNPSEQELE (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_038143" FT VAR_SEQ 603 FT /note="S -> R (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_039213" FT VAR_SEQ 604..942 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_039214" FT VARIANT 185 FT /note="R -> C (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs267605306)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042337" FT VARIANT 197 FT /note="A -> E (in dbSNP:rs1287763348)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042338" FT VARIANT 436 FT /note="R -> W (in dbSNP:rs35132656)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042339" FT VARIANT 520 FT /note="R -> Q (in dbSNP:rs56273055)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042340" FT VARIANT 555 FT /note="L -> I (in dbSNP:rs34309238)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:17344846" FT /id="VAR_042341" FT VARIANT 635 FT /note="R -> Q (in dbSNP:rs35416389)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042342" FT VARIANT 718 FT /note="I -> V (in dbSNP:rs2230539)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7988719" FT /id="VAR_042343" FT VARIANT 873 FT /note="F -> L (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042344" FT VARIANT 901 FT /note="V -> I (in dbSNP:rs10846)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17344846" FT /id="VAR_014937" FT VARIANT 921 FT /note="A -> V (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042345" FT MUTAGEN 108 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of AF1 fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 181 FT /note="R->A: Abolishes interaction with bacterial SspH1." FT /evidence="ECO:0000269|PubMed:24248594" FT MUTAGEN 181 FT /note="R->K: Decreases interaction with bacterial SspH1." FT /evidence="ECO:0000269|PubMed:24248594" FT MUTAGEN 185 FT /note="R->A: Abolishes interaction with bacterial SspH1." FT /evidence="ECO:0000269|PubMed:24248594" FT MUTAGEN 451 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of 70 kDa fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 454 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of 70 kDa fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 558 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of AF3 fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 560 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of AF3 fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 644 FT /note="K->E: Abolishes Serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:18066052, FT ECO:0000269|PubMed:8135837" FT MUTAGEN 644 FT /note="K->R: Substantial reduction of autophosphorylation." FT /evidence="ECO:0000269|PubMed:18066052, FT ECO:0000269|PubMed:8135837" FT CONFLICT 191 FT /note="G -> D (in Ref. 2; AAB33345/AAC50209)" FT /evidence="ECO:0000305" FT CONFLICT 562 FT /note="S -> P (in Ref. 3; BAG36611)" FT /evidence="ECO:0000305" FT CONFLICT 736 FT /note="I -> T (in Ref. 6; no nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 750 FT /note="T -> A (in Ref. 6; no nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 800 FT /note="G -> A (in Ref. 6; no nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 812 FT /note="E -> G (in Ref. 3; BAG36611)" FT /evidence="ECO:0000305" FT CONFLICT 887 FT /note="L -> P (in Ref. 3; BAG53845)" FT /evidence="ECO:0000305" FT HELIX 15..18 FT /evidence="ECO:0007829|PDB:1CXZ" FT HELIX 29..66 FT /evidence="ECO:0007829|PDB:1CXZ" FT HELIX 71..95 FT /evidence="ECO:0007829|PDB:1CXZ" FT TURN 122..124 FT /evidence="ECO:0007829|PDB:1URF" FT HELIX 126..151 FT /evidence="ECO:0007829|PDB:4NKG" FT TURN 157..159 FT /evidence="ECO:0007829|PDB:4NKG" FT HELIX 160..187 FT /evidence="ECO:0007829|PDB:4NKG" FT STRAND 194..196 FT /evidence="ECO:0007829|PDB:2RMK" FT HELIX 612..614 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 615..624 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 627..634 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 635..637 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 640..647 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 648..653 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 657..671 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 672..674 FT /evidence="ECO:0007829|PDB:4OTG" FT STRAND 681..686 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 688..696 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 700..702 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 703..706 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 707..709 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 714..733 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 743..745 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 746..748 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 750..752 FT /evidence="ECO:0007829|PDB:4OTG" FT STRAND 754..756 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 763..765 FT /evidence="ECO:0007829|PDB:4OTD" FT HELIX 779..781 FT /evidence="ECO:0007829|PDB:4OTD" FT HELIX 784..788 FT /evidence="ECO:0007829|PDB:4OTD" FT HELIX 794..810 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 820..829 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 840..849 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 854..856 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 862..864 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 865..869 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 872..874 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 879..883 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 906..909 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 926..930 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 931..934 FT /evidence="ECO:0007829|PDB:4OTH" SQ SEQUENCE 942 AA; 103932 MW; 61360295EC70BB8E CRC64; MASDAVQSEP RSWSLLEQLG LAGADLAAPG VQQQLELERE RLRREIRKEL KLKEGAENLR RATTDLGRSL GPVELLLRGS SRRLDLLHQQ LQELHAHVVL PDPAATHDGP QSPGAGGPTC SATNLSRVAG LEKQLAIELK VKQGAENMIQ TYSNGSTKDR KLLLTAQQML QDSKTKIDII RMQLRRALQA GQLENQAAPD DTQGSPDLGA VELRIEELRH HFRVEHAVAE GAKNVLRLLS AAKAPDRKAV SEAQEKLTES NQKLGLLREA LERRLGELPA DHPKGRLLRE ELAAASSAAF STRLAGPFPA THYSTLCKPA PLTGTLEVRV VGCRDLPETI PWNPTPSMGG PGTPDSRPPF LSRPARGLYS RSGSLSGRSS LKAEAENTSE VSTVLKLDNT VVGQTSWKPC GPNAWDQSFT LELERARELE LAVFWRDQRG LCALKFLKLE DFLDNERHEV QLDMEPQGCL VAEVTFRNPV IERIPRLRRQ KKIFSKQQGK AFQRARQMNI DVATWVRLLR RLIPNATGTG TFSPGASPGS EARTTGDISV EKLNLGTDSD SSPQKSSRDP PSSPSSLSSP IQESTAPELP SETQETPGPA LCSPLRKSPL TLEDFKFLAV LGRGHFGKVL LSEFRPSGEL FAIKALKKGD IVARDEVESL MCEKRILAAV TSAGHPFLVN LFGCFQTPEH VCFVMEYSAG GDLMLHIHSD VFSEPRAIFY SACVVLGLQF LHEHKIVYRD LKLDNLLLDT EGYVKIADFG LCKEGMGYGD RTSTFCGTPE FLAPEVLTDT SYTRAVDWWG LGVLLYEMLV GESPFPGDDE EEVFDSIVND EVRYPRFLSA EAIGIMRRLL RRNPERRLGS SERDAEDVKK QPFFRTLGWE ALLARRLPPP FVPTLSGRTD VSNFDEEFTG EAPTLSPPRD ARPLTAAEQA AFLDFDFVAG GC // ID PLK2_HUMAN Reviewed; 685 AA. AC Q9NYY3; A0A087WUH9; O60679; Q96CV7; Q9UE61; DT 11-JAN-2001, integrated into UniProtKB/Swiss-Prot. DT 02-AUG-2002, sequence version 3. DT 28-JAN-2026, entry version 207. DE RecName: Full=Serine/threonine-protein kinase PLK2; DE EC=2.7.11.21; DE AltName: Full=Polo-like kinase 2; DE Short=PLK-2; DE Short=hPlk2; DE AltName: Full=Serine/threonine-protein kinase SNK; DE Short=hSNK; DE AltName: Full=Serum-inducible kinase; GN Name=PLK2; Synonyms=SNK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY. RX PubMed=11696980; DOI=10.3109/10425170109041337; RA Liby K., Wu H., Ouyang B., Wu S., Chen J., Dai W.; RT "Identification of the human homologue of the early-growth response gene RT Snk, encoding a serum-inducible kinase."; RL DNA Seq. 11:527-533(2001). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Colon; RA Anderson K.M., Nerurkar S.S., Hansbury M.J., Fornwald J., Scott G., RA Bouzyk M., Mui P., Imbrugia C.S., Carlson K., Marshall L.A., Roshak A.K.; RT "Identification and characterization of human serum-inducible kinase (SNK), RT a novel member of the polo-kinase family of cell cycle regulators: RT potential implication for regulation of vascular smooth muscle RT proliferation."; RL Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 110-408. RA Fidler C., Boultwood J., Wang Jabs E., Wainscoat J.S.; RL Submitted (JAN-1997) to the EMBL/GenBank/DDBJ databases. RN [6] RP INDUCTION. RX PubMed=11716500; DOI=10.1006/bbrc.2001.5993; RA Shimizu-Yoshida Y., Sugiyama K., Rogounovitch T., Ohtsuru A., Namba H., RA Saenko V., Yamashita S.; RT "Radiation-inducible hSNK gene is transcriptionally regulated by p53 RT binding homology element in human thyroid cells."; RL Biochem. Biophys. Res. Commun. 289:491-498(2001). RN [7] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=15242618; DOI=10.1016/j.cub.2004.06.059; RA Warnke S., Kemmler S., Hames R.S., Tsai H.L., Hoffmann-Rohrer U., Fry A.M., RA Hoffmann I.; RT "Polo-like kinase-2 is required for centriole duplication in mammalian RT cells."; RL Curr. Biol. 14:1200-1207(2004). RN [8] RP DOWN-REGULATION IN B-CELL LYMPHOMAS. RX PubMed=16160013; DOI=10.1182/blood-2005-03-1194; RA Syed N., Smith P., Sullivan A., Spender L.C., Dyer M., Karran L., RA O'Nions J., Allday M., Hoffmann I., Crawford D., Griffin B., Farrell P.J., RA Crook T.; RT "Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent RT event in B-cell malignancies."; RL Blood 107:250-256(2006). RN [9] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASN-210; TRP-503; RP HIS-629 AND LYS-631. RX PubMed=19001868; DOI=10.4161/cc.7.22.7071; RA Cizmecioglu O., Warnke S., Arnold M., Duensing S., Hoffmann I.; RT "Plk2 regulated centriole duplication is dependent on its localization to RT the centrioles and a functional polo-box domain."; RL Cell Cycle 7:3548-3555(2008). RN [10] RP INDUCTION. RX PubMed=18832181; DOI=10.1073/pnas.0808266105; RA Li Z., Lu J., Sun M., Mi S., Zhang H., Luo R.T., Chen P., Wang Y., Yan M., RA Qian Z., Neilly M.B., Jin J., Zhang Y., Bohlander S.K., Zhang D.E., RA Larson R.A., Le Beau M.M., Thirman M.J., Golub T.R., Rowley J.D., Chen J.; RT "Distinct microRNA expression profiles in acute myeloid leukemia with RT common translocations."; RL Proc. Natl. Acad. Sci. U.S.A. 105:15535-15540(2008). RN [11] RP FUNCTION IN PHOSPHORYLATION OF CPAP. RX PubMed=20531387; DOI=10.1038/emboj.2010.118; RA Chang J., Cizmecioglu O., Hoffmann I., Rhee K.; RT "PLK2 phosphorylation is critical for CPAP function in procentriole RT formation during the centrosome cycle."; RL EMBO J. 29:2395-2406(2010). RN [12] RP FUNCTION IN PHOSPHORYLATION OF NPM. RX PubMed=20352051; DOI=10.1371/journal.pone.0009849; RA Krause A., Hoffmann I.; RT "Polo-like kinase 2-dependent phosphorylation of NPM/B23 on serine 4 RT triggers centriole duplication."; RL PLoS ONE 5:E9849-E9849(2010). RN [13] RP DOWN-REGULATION IN ACUTE MYELOID LEUKEMIA. RX PubMed=21340720; DOI=10.1007/s00277-011-1193-4; RA Benetatos L., Dasoula A., Hatzimichael E., Syed N., Voukelatou M., RA Dranitsaris G., Bourantas K.L., Crook T.; RT "Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in RT acute myeloid leukemia and myelodysplastic syndromes: genetic and RT epigenetic interactions."; RL Ann. Hematol. 90:1037-1045(2011). RN [14] RP REVIEW ON FUNCTION. RX PubMed=20671765; DOI=10.1038/nrd3184; RA Strebhardt K.; RT "Multifaceted polo-like kinases: drug targets and antitargets for cancer RT therapy."; RL Nat. Rev. Drug Discov. 9:643-660(2010). RN [15] RP VARIANTS [LARGE SCALE ANALYSIS] THR-14; SER-92; LYS-436 AND LEU-487. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Tumor suppressor serine/threonine-protein kinase involved in CC synaptic plasticity, centriole duplication and G1/S phase transition. CC Polo-like kinases act by binding and phosphorylating proteins that are CC already phosphorylated on a specific motif recognized by the POLO box CC domains. Phosphorylates CPAP, NPM1, RAPGEF2, RASGRF1, SNCA, SIPA1L1 and CC SYNGAP1. Plays a key role in synaptic plasticity and memory by CC regulating the Ras and Rap protein signaling: required for CC overactivity-dependent spine remodeling by phosphorylating the Ras CC activator RASGRF1 and the Rap inhibitor SIPA1L1 leading to their CC degradation by the proteasome. Conversely, phosphorylates the Rap CC activator RAPGEF2 and the Ras inhibitor SYNGAP1, promoting their CC activity. Also regulates synaptic plasticity independently of kinase CC activity, via its interaction with NSF that disrupts the interaction CC between NSF and the GRIA2 subunit of AMPARs, leading to a rapid rundown CC of AMPAR-mediated current that occludes long term depression. Required CC for procentriole formation and centriole duplication by phosphorylating CC CPAP and NPM1, respectively. Its induction by p53/TP53 suggests that it CC may participate in the mitotic checkpoint following stress. CC {ECO:0000269|PubMed:15242618, ECO:0000269|PubMed:19001868, CC ECO:0000269|PubMed:20352051, ECO:0000269|PubMed:20531387}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.21; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.21; CC -!- ACTIVITY REGULATION: Activated by phosphorylation of Thr-239. Once CC activated, activity is stimulated by binding target proteins (By CC similarity). {ECO:0000250}. CC -!- SUBUNIT: Interacts with NSF; causing NSF dissociation from GRIA2. CC Interacts with CIB1 (By similarity). {ECO:0000250}. CC -!- INTERACTION: CC Q9NYY3; Q86Y33: CDC20B; NbExp=3; IntAct=EBI-721354, EBI-10260504; CC Q9NYY3; Q9HC77: CPAP; NbExp=3; IntAct=EBI-721354, EBI-946194; CC Q9NYY3; P62258: YWHAE; NbExp=2; IntAct=EBI-721354, EBI-356498; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing CC center, centrosome, centriole {ECO:0000269|PubMed:15242618, CC ECO:0000269|PubMed:19001868}. Cell projection, dendrite {ECO:0000250}. CC Note=Localizes to centrosomes during early G1 phase where it only CC associates to the mother centriole and then distributes equally to both CC mother and daughter centrioles at the onset of S phase. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q9NYY3-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9NYY3-2; Sequence=VSP_062732; CC -!- TISSUE SPECIFICITY: Expressed at higher level in the fetal lung, CC kidney, spleen and heart. {ECO:0000269|PubMed:11696980}. CC -!- INDUCTION: Directly regulated by p53/TP53. Negatively regulated by miR- CC 126. {ECO:0000269|PubMed:11716500, ECO:0000269|PubMed:18832181}. CC -!- DOMAIN: The POLO box domains act as phosphopeptide-binding module that CC recognizes and binds serine-[phosphothreonine/phosphoserine]- CC (proline/X) motifs. PLK2 recognizes and binds docking proteins that are CC already phosphorylated on these motifs, and then phosphorylates them CC (By similarity). {ECO:0000250}. CC -!- PTM: Catalytic activity is enhanced by phosphorylation of Thr-239. CC {ECO:0000250}. CC -!- MISCELLANEOUS: There are indications that PLK2 might act as a tumor CC suppressor: PLK2 is significantly down-regulated in a wide range of CC acute myeloid leukemias (AMLs) and B-cell lymphomas due to aberrant CC cytosine methylation in the CpG island located at the 5' of the PLK2 CC gene (PubMed:16160013, PubMed:21340720). Moreover, miR-126, a microRNA CC that negatively regulates PLK2 is up-regulated in AMLs, suggesting that CC PLK2 down-regulation by miR-126 could also contribute to leukemogenesis CC (PubMed:18832181). {ECO:0000305|PubMed:16160013, CC ECO:0000305|PubMed:18832181, ECO:0000305|PubMed:21340720}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. CDC5/Polo subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF059617; AAC14573.1; -; mRNA. DR EMBL; AF223574; AAF62897.1; -; mRNA. DR EMBL; U85755; AAD00575.1; -; mRNA. DR EMBL; AC008814; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC013879; AAH13879.1; -; mRNA. DR CCDS; CCDS3974.1; -. DR RefSeq; NP_001239155.1; NM_001252226.1. DR RefSeq; NP_006613.2; NM_006622.4. DR PDB; 4I5M; X-ray; 1.80 A; A=57-360. DR PDB; 4I5P; X-ray; 1.74 A; A=57-360. DR PDB; 4I6B; X-ray; 1.80 A; A=57-360. DR PDB; 4I6F; X-ray; 2.90 A; A=57-360. DR PDB; 4I6H; X-ray; 1.91 A; A=57-360. DR PDB; 4RS6; X-ray; 2.60 A; A/B=451-685. DR PDB; 4XB0; X-ray; 2.70 A; A/B=468-685. DR PDBsum; 4I5M; -. DR PDBsum; 4I5P; -. DR PDBsum; 4I6B; -. DR PDBsum; 4I6F; -. DR PDBsum; 4I6H; -. DR PDBsum; 4RS6; -. DR PDBsum; 4XB0; -. DR AlphaFoldDB; Q9NYY3; -. DR SMR; Q9NYY3; -. DR BioGRID; 115988; 72. DR DIP; DIP-48943N; -. DR FunCoup; Q9NYY3; 425. DR IntAct; Q9NYY3; 53. DR MINT; Q9NYY3; -. DR STRING; 9606.ENSP00000274289; -. DR BindingDB; Q9NYY3; -. DR ChEMBL; CHEMBL5938; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q9NYY3; -. DR GuidetoPHARMACOLOGY; 2169; -. DR iPTMnet; Q9NYY3; -. DR PhosphoSitePlus; Q9NYY3; -. DR SwissPalm; Q9NYY3; -. DR BioMuta; PLK2; -. DR DMDM; 22096374; -. DR jPOST; Q9NYY3; -. DR MassIVE; Q9NYY3; -. DR PaxDb; 9606-ENSP00000274289; -. DR PeptideAtlas; Q9NYY3; -. DR ProteomicsDB; 83299; -. DR Antibodypedia; 4042; 256 antibodies from 32 providers. DR DNASU; 10769; -. DR Ensembl; ENST00000274289.8; ENSP00000274289.3; ENSG00000145632.16. DR GeneID; 10769; -. DR KEGG; hsa:10769; -. DR MANE-Select; ENST00000274289.8; ENSP00000274289.3; NM_006622.4; NP_006613.2. DR UCSC; uc003jrn.4; human. DR AGR; HGNC:19699; -. DR ClinPGx; PA134940798; -. DR CTD; 10769; -. DR DisGeNET; 10769; -. DR GeneCards; PLK2; -. DR HGNC; HGNC:19699; PLK2. DR HPA; ENSG00000145632; Low tissue specificity. DR MalaCards; PLK2; -. DR MIM; 607023; gene. DR OpenTargets; ENSG00000145632; -. DR VEuPathDB; HostDB:ENSG00000145632; -. DR eggNOG; KOG0575; Eukaryota. DR GeneTree; ENSGT00940000158739; -. DR HOGENOM; CLU_000288_46_1_1; -. DR InParanoid; Q9NYY3; -. DR OMA; NMPESDH; -. DR OrthoDB; 408964at2759; -. DR PAN-GO; Q9NYY3; 10 GO annotations based on evolutionary models. DR PhylomeDB; Q9NYY3; -. DR BRENDA; 2.7.11.21; 2681. DR PathwayCommons; Q9NYY3; -. DR Reactome; R-HSA-6804115; TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain. DR Reactome; R-HSA-9662834; CD163 mediating an anti-inflammatory response. DR Reactome; R-HSA-9768919; NPAS4 regulates expression of target genes. DR SignaLink; Q9NYY3; -. DR SIGNOR; Q9NYY3; -. DR Agora; ENSG00000145632; -. DR BioGRID-ORCS; 10769; 13 hits in 1185 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; PLK2; human. DR EvolutionaryTrace; Q9NYY3; -. DR GeneWiki; PLK2; -. DR GenomeRNAi; 10769; -. DR Pharos; Q9NYY3; Tchem. DR PRO; PR:Q9NYY3; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; Q9NYY3; protein. DR Bgee; ENSG00000145632; Expressed in spleen and 196 other cell types or tissues. DR ExpressionAtlas; Q9NYY3; baseline and differential. DR GO; GO:0005814; C:centriole; IDA:UniProtKB. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0000785; C:chromatin; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; IDA:ParkinsonsUK-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0030425; C:dendrite; ISS:UniProtKB. DR GO; GO:0000776; C:kinetochore; IBA:GO_Central. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0000922; C:spindle pole; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0043008; F:ATP-dependent protein binding; IDA:ParkinsonsUK-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0060292; P:long-term synaptic depression; ISS:UniProtKB. DR GO; GO:0060291; P:long-term synaptic potentiation; ISS:UniProtKB. DR GO; GO:0007613; P:memory; ISS:UniProtKB. DR GO; GO:0007052; P:mitotic spindle organization; IDA:UniProtKB. DR GO; GO:0016525; P:negative regulation of angiogenesis; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB. DR GO; GO:0071866; P:negative regulation of apoptotic process in bone marrow cell; IEA:Ensembl. DR GO; GO:2000773; P:negative regulation of cellular senescence; IEA:Ensembl. DR GO; GO:0002862; P:negative regulation of inflammatory response to antigenic stimulus; TAS:Reactome. DR GO; GO:0010508; P:positive regulation of autophagy; IDA:ParkinsonsUK-UCL. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; HMP:UniProtKB. DR GO; GO:0090050; P:positive regulation of cell migration involved in sprouting angiogenesis; IEA:Ensembl. DR GO; GO:0045732; P:positive regulation of protein catabolic process; IDA:ParkinsonsUK-UCL. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0032486; P:Rap protein signal transduction; ISS:UniProtKB. DR GO; GO:0007265; P:Ras protein signal transduction; ISS:UniProtKB. DR GO; GO:0046599; P:regulation of centriole replication; IDA:UniProtKB. DR GO; GO:0048167; P:regulation of synaptic plasticity; ISS:UniProtKB. DR CDD; cd13118; POLO_box_1; 1. DR CDD; cd13117; POLO_box_2; 1. DR CDD; cd14188; STKc_PLK2; 1. DR FunFam; 1.10.510.10:FF:001498; Serine/threonine-protein kinase PLK; 1. DR FunFam; 3.30.1120.30:FF:000001; Serine/threonine-protein kinase PLK; 1. DR FunFam; 3.30.200.20:FF:000091; Serine/threonine-protein kinase PLK; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.30.1120.30; POLO box domain; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR042825; PLK2_STKc. DR InterPro; IPR033701; POLO_box_1. DR InterPro; IPR033695; POLO_box_2. DR InterPro; IPR000959; POLO_box_dom. DR InterPro; IPR036947; POLO_box_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24345; SERINE/THREONINE-PROTEIN KINASE PLK; 1. DR PANTHER; PTHR24345:SF44; SERINE_THREONINE-PROTEIN KINASE PLK2; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00659; POLO_box; 2. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF82615; Polo-box domain; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50078; POLO_BOX; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell projection; KW Cytoplasm; Cytoskeleton; Kinase; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase; Tumor suppressor. FT CHAIN 1..685 FT /note="Serine/threonine-protein kinase PLK2" FT /id="PRO_0000086561" FT DOMAIN 82..334 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 503..581 FT /note="POLO box 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00154" FT DOMAIN 601..685 FT /note="POLO box 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00154" FT REGION 21..70 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 406..433 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 43..52 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 205 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 88..96 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 111 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 239 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:P53351" FT VAR_SEQ 55..68 FT /note="Missing (in isoform 2)" FT /id="VSP_062732" FT VARIANT 14 FT /note="S -> T (in an ovarian endometrioid carcinoma sample; FT somatic mutation; dbSNP:rs1404394734)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041023" FT VARIANT 92 FT /note="G -> S (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041024" FT VARIANT 436 FT /note="E -> K (in dbSNP:rs55768901)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041025" FT VARIANT 487 FT /note="P -> L (in dbSNP:rs55645589)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041026" FT MUTAGEN 210 FT /note="N->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:19001868" FT MUTAGEN 503 FT /note="W->F: Impairs localization to the centrosome and FT centriole duplication; when associated with A-629 and M- FT 631." FT /evidence="ECO:0000269|PubMed:19001868" FT MUTAGEN 629 FT /note="H->A: Impairs localization to the centrosome and FT centriole duplication; when associated with F-503 and M- FT 631." FT /evidence="ECO:0000269|PubMed:19001868" FT MUTAGEN 631 FT /note="K->M: Impairs localization to the centrosome and FT centriole duplication; when associated with F-503 and A- FT 631." FT /evidence="ECO:0000269|PubMed:19001868" FT CONFLICT 28 FT /note="A -> G (in Ref. 1; AAC14573)" FT /evidence="ECO:0000305" FT STRAND 72..74 FT /evidence="ECO:0007829|PDB:4I5P" FT TURN 76..78 FT /evidence="ECO:0007829|PDB:4I5P" FT STRAND 81..91 FT /evidence="ECO:0007829|PDB:4I5P" FT STRAND 94..101 FT /evidence="ECO:0007829|PDB:4I5P" FT TURN 102..105 FT /evidence="ECO:0007829|PDB:4I5P" FT STRAND 106..114 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 115..118 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 121..134 FT /evidence="ECO:0007829|PDB:4I5P" FT STRAND 145..150 FT /evidence="ECO:0007829|PDB:4I5P" FT STRAND 152..159 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 167..174 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 179..198 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 208..210 FT /evidence="ECO:0007829|PDB:4I5P" FT STRAND 211..213 FT /evidence="ECO:0007829|PDB:4I5P" FT STRAND 219..221 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 224..226 FT /evidence="ECO:0007829|PDB:4I5M" FT TURN 233..235 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 249..252 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 259..275 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 286..288 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 289..293 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 305..314 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 319..321 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 325..329 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 332..335 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 345..348 FT /evidence="ECO:0007829|PDB:4I5P" FT HELIX 471..485 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 490..492 FT /evidence="ECO:0007829|PDB:4XB0" FT STRAND 504..510 FT /evidence="ECO:0007829|PDB:4RS6" FT TURN 511..514 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 515..520 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 525..529 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 534..537 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 541..547 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 553..558 FT /evidence="ECO:0007829|PDB:4RS6" FT HELIX 563..582 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 602..616 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 621..625 FT /evidence="ECO:0007829|PDB:4RS6" FT TURN 626..628 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 631..646 FT /evidence="ECO:0007829|PDB:4RS6" FT STRAND 652..656 FT /evidence="ECO:0007829|PDB:4RS6" FT HELIX 657..663 FT /evidence="ECO:0007829|PDB:4RS6" FT HELIX 667..680 FT /evidence="ECO:0007829|PDB:4RS6" SQ SEQUENCE 685 AA; 78237 MW; 6429F6EFD830B333 CRC64; MELLRTITYQ PAASTKMCEQ ALGKGCGADS KKKRPPQPPE ESQPPQSQAQ VPPAAPHHHH HHSHSGPEIS RIIVDPTTGK RYCRGKVLGK GGFAKCYEMT DLTNNKVYAA KIIPHSRVAK PHQREKIDKE IELHRILHHK HVVQFYHYFE DKENIYILLE YCSRRSMAHI LKARKVLTEP EVRYYLRQIV SGLKYLHEQE ILHRDLKLGN FFINEAMELK VGDFGLAARL EPLEHRRRTI CGTPNYLSPE VLNKQGHGCE SDIWALGCVM YTMLLGRPPF ETTNLKETYR CIREARYTMP SSLLAPAKHL IASMLSKNPE DRPSLDDIIR HDFFLQGFTP DRLSSSCCHT VPDFHLSSPA KNFFKKAAAA LFGGKKDKAR YIDTHNRVSK EDEDIYKLRH DLKKTSITQQ PSKHRTDEEL QPPTTTVARS GTPAVENKQQ IGDAIRMIVR GTLGSCSSSS ECLEDSTMGS VADTVARVLR GCLENMPEAD CIPKEQLSTS FQWVTKWVDY SNKYGFGYQL SDHTVGVLFN NGAHMSLLPD KKTVHYYAEL GQCSVFPATD APEQFISQVT VLKYFSHYME ENLMDGGDLP SVTDIRRPRL YLLQWLKSDK ALMMLFNDGT FQVNFYHDHT KIIICSQNEE YLLTYINEDR ISTTFRLTTL LMSGCSSELK NRMEYALNML LQRCN // ID PLPP1_HUMAN Reviewed; 284 AA. AC O14494; B7ZKN8; G3XA95; O60457; O60463; Q17RZ4; DT 15-MAR-2004, integrated into UniProtKB/Swiss-Prot. DT 01-JAN-1998, sequence version 1. DT 28-JAN-2026, entry version 198. DE RecName: Full=Phospholipid phosphatase 1 {ECO:0000305}; DE EC=3.1.3.- {ECO:0000269|PubMed:10962286, ECO:0000269|PubMed:17379599, ECO:0000269|PubMed:9305923, ECO:0000269|PubMed:9607309, ECO:0000269|PubMed:9705349}; DE EC=3.1.3.106 {ECO:0000250|UniProtKB:Q61469}; DE EC=3.1.3.4 {ECO:0000269|PubMed:10962286, ECO:0000269|PubMed:9305923, ECO:0000269|PubMed:9607309, ECO:0000269|PubMed:9705349}; DE EC=3.6.1.75 {ECO:0000250|UniProtKB:Q61469}; DE AltName: Full=Lipid phosphate phosphohydrolase 1; DE AltName: Full=PAP2-alpha; DE AltName: Full=Phosphatidate phosphohydrolase type 2a; DE AltName: Full=Phosphatidic acid phosphatase 2a; DE Short=PAP-2a; DE Short=PAP2a; GN Name=PLPP1 {ECO:0000312|HGNC:HGNC:9228}; Synonyms=LPP1, PPAP2A; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY, RP SUBSTRATE SPECIFICITY, ACTIVITY REGULATION, PATHWAY, SUBCELLULAR LOCATION, RP GLYCOSYLATION, TISSUE SPECIFICITY, AND CAUTION. RX PubMed=9305923; DOI=10.1074/jbc.272.39.24572; RA Kai M., Wada I., Imai S., Sakane F., Kanoh H.; RT "Cloning and characterization of two human isozymes of Mg2+-independent RT phosphatidic acid phosphatase."; RL J. Biol. Chem. 272:24572-24578(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND TISSUE SPECIFICITY. RC TISSUE=Lung; RX PubMed=9570154; DOI=10.1089/dna.1998.17.377; RA Leung D.W., Tompkins C.K., White T.; RT "Molecular cloning of two alternatively spliced forms of human phosphatidic RT acid phosphatase cDNAs that are differentially expressed in normal and RT tumor cells."; RL DNA Cell Biol. 17:377-385(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INDUCTION. RC TISSUE=Prostate; RX PubMed=9468526; DOI=10.1074/jbc.273.8.4660; RA Ulrix W.E.J., Swinnen J., Heyns W., Verhoeven G.; RT "Identification of the phosphatidic acid phosphatase type 2a isozyme as an RT androgen-regulated gene in the human prostatic Adenocarcinoma cell line RT LNCaP."; RL J. Biol. Chem. 273:4660-4665(1998). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY, RP BIOPHYSICOCHEMICAL PROPERTIES, SUBSTRATE SPECIFICITY, ACTIVITY REGULATION, RP PATHWAY, AND SUBCELLULAR LOCATION. RX PubMed=9705349; DOI=10.1074/jbc.273.34.22059; RA Roberts R., Sciorra V.A., Morris A.J.; RT "Human type 2 phosphatidic acid phosphohydrolases. Substrate specificity of RT the type 2a, 2b, and 2c enzymes and cell surface activity of the 2a RT isoform."; RL J. Biol. Chem. 273:22059-22067(1998). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBSTRATE RP SPECIFICITY, AND PATHWAY. RX PubMed=9607309; DOI=10.1016/s0014-5793(98)00421-9; RA Hooks S.B., Ragan S.P., Lynch K.R.; RT "Identification of a novel human phosphatidic acid phosphatase type 2 RT isoform."; RL FEBS Lett. 427:188-192(1998). RN [9] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, PATHWAY, SUBCELLULAR RP LOCATION, AND GLYCOSYLATION. RX PubMed=10962286; DOI=10.1016/s1388-1981(00)00081-0; RA Roberts R.Z., Morris A.J.; RT "Role of phosphatidic acid phosphatase 2a in uptake of extracellular lipid RT phosphate mediators."; RL Biochim. Biophys. Acta 1487:33-49(2000). RN [10] RP SUBCELLULAR LOCATION, AND MOTIF. RX PubMed=14527693; DOI=10.1016/s0014-5793(03)00931-1; RA Jia Y.J., Kai M., Wada I., Sakane F., Kanoh H.; RT "Differential localization of lipid phosphate phosphatases 1 and 3 to cell RT surface subdomains in polarized MDCK cells."; RL FEBS Lett. 552:240-246(2003). RN [11] RP FUNCTION. RX PubMed=12909631; DOI=10.1074/jbc.m306709200; RA Smyth S.S., Sciorra V.A., Sigal Y.J., Pamulkar Z., Wang Z., Xu Y., RA Prestwich G.D., Morris A.J.; RT "Lipid phosphate phosphatases regulate lysophosphatidic acid production and RT signaling in platelets: studies using chemical inhibitors of lipid RT phosphate phosphatase activity."; RL J. Biol. Chem. 278:43214-43223(2003). RN [12] RP FUNCTION, AND MUTAGENESIS OF ARG-217. RX PubMed=15461590; DOI=10.1042/bj20041160; RA Zhao Y., Usatyuk P.V., Cummings R., Saatian B., He D., Watkins T., RA Morris A., Spannhake E.W., Brindley D.N., Natarajan V.; RT "Lipid phosphate phosphatase-1 regulates lysophosphatidic acid-induced RT calcium release, NF-kappaB activation and interleukin-8 secretion in human RT bronchial epithelial cells."; RL Biochem. J. 385:493-502(2005). RN [13] RP SUBCELLULAR LOCATION. RX PubMed=17005594; DOI=10.1093/jb/mvj195; RA Kai M., Sakane F., Jia Y.J., Imai S., Yasuda S., Kanoh H.; RT "Lipid phosphate phosphatases 1 and 3 are localized in distinct lipid RT rafts."; RL J. Biochem. 140:677-686(2006). RN [14] RP FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY. RX PubMed=17379599; DOI=10.1074/jbc.m701279200; RA Zhao Y., Kalari S.K., Usatyuk P.V., Gorshkova I., He D., Watkins T., RA Brindley D.N., Sun C., Bittman R., Garcia J.G., Berdyshev E.V., RA Natarajan V.; RT "Intracellular generation of sphingosine 1-phosphate in human lung RT endothelial cells: role of lipid phosphate phosphatase-1 and sphingosine RT kinase 1."; RL J. Biol. Chem. 282:14165-14177(2007). CC -!- FUNCTION: Magnesium-independent phospholipid phosphatase of the plasma CC membrane that catalyzes the dephosphorylation of a variety of CC glycerolipid and sphingolipid phosphate esters including CC phosphatidate/PA, lysophosphatidate/LPA, diacylglycerol CC pyrophosphate/DGPP, sphingosine 1-phosphate/S1P and ceramide 1- CC phosphate/C1P (PubMed:10962286, PubMed:17379599, PubMed:9305923, CC PubMed:9607309, PubMed:9705349). Also acts on N-oleoyl ethanolamine CC phosphate/N-(9Z-octadecenoyl)-ethanolamine phosphate, a potential CC physiological compound (PubMed:9607309). Through its extracellular CC phosphatase activity allows both the hydrolysis and the cellular uptake CC of these bioactive lipid mediators from the milieu, regulating signal CC transduction in different cellular processes (PubMed:10962286, CC PubMed:12909631, PubMed:15461590, PubMed:17379599). It is for instance CC essential for the extracellular hydrolysis of S1P and subsequent CC conversion into intracellular S1P (PubMed:17379599). Involved in the CC regulation of inflammation, platelets activation, cell proliferation CC and migration among other processes (PubMed:12909631, PubMed:15461590). CC May also have an intracellular activity to regulate phospholipid- CC mediated signaling pathways (By similarity). CC {ECO:0000250|UniProtKB:O08564, ECO:0000269|PubMed:10962286, CC ECO:0000269|PubMed:12909631, ECO:0000269|PubMed:15461590, CC ECO:0000269|PubMed:17379599, ECO:0000269|PubMed:9305923, CC ECO:0000269|PubMed:9607309, ECO:0000269|PubMed:9705349}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-sn-glycero-3-phosphate + H2O = a 1,2-diacyl-sn- CC glycerol + phosphate; Xref=Rhea:RHEA:27429, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:17815, ChEBI:CHEBI:43474, ChEBI:CHEBI:58608; EC=3.1.3.4; CC Evidence={ECO:0000269|PubMed:10962286, ECO:0000269|PubMed:9305923, CC ECO:0000269|PubMed:9607309, ECO:0000269|PubMed:9705349}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:27430; CC Evidence={ECO:0000305|PubMed:9305923}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-dihexadecanoyl-sn-glycero-3-phosphate + H2O = 1,2- CC dihexadecanoyl-sn-glycerol + phosphate; Xref=Rhea:RHEA:43236, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:72859, CC ChEBI:CHEBI:82929; Evidence={ECO:0000269|PubMed:9705349}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43237; CC Evidence={ECO:0000305|PubMed:9705349}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphate + H2O = 1,2- CC di-(9Z-octadecenoyl)-sn-glycerol + phosphate; Xref=Rhea:RHEA:43244, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:52333, CC ChEBI:CHEBI:74546; Evidence={ECO:0000269|PubMed:9305923, CC ECO:0000269|PubMed:9607309}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43245; CC Evidence={ECO:0000305|PubMed:9305923}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a monoacyl-sn-glycero-3-phosphate + H2O = a monoacylglycerol + CC phosphate; Xref=Rhea:RHEA:46736, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:17408, ChEBI:CHEBI:43474, ChEBI:CHEBI:77589; CC Evidence={ECO:0000269|PubMed:10962286, ECO:0000269|PubMed:9305923, CC ECO:0000269|PubMed:9607309, ECO:0000269|PubMed:9705349}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46737; CC Evidence={ECO:0000305|PubMed:9305923}; CC -!- CATALYTIC ACTIVITY: CC Reaction=(9Z)-octadecenoyl-sn-glycero-3-phosphate + H2O = (9Z- CC octadecenoyl)-glycerol + phosphate; Xref=Rhea:RHEA:50884, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:75937, CC ChEBI:CHEBI:84973; Evidence={ECO:0000269|PubMed:9305923, CC ECO:0000269|PubMed:9607309, ECO:0000269|PubMed:9705349}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50885; CC Evidence={ECO:0000305|PubMed:9305923}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1-acyl-sn-glycero-3-phosphate + H2O = a 1-acyl-sn-glycerol + CC phosphate; Xref=Rhea:RHEA:33155, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:43474, ChEBI:CHEBI:57970, ChEBI:CHEBI:64683; CC EC=3.1.3.106; Evidence={ECO:0000250|UniProtKB:Q61469}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33156; CC Evidence={ECO:0000250|UniProtKB:Q61469}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1-(9Z-octadecenoyl)-sn-glycero-3-phosphate + H2O = 1-(9Z- CC octadecenoyl)-sn-glycerol + phosphate; Xref=Rhea:RHEA:39835, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:74544, CC ChEBI:CHEBI:75757; Evidence={ECO:0000250|UniProtKB:Q61469}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:39836; CC Evidence={ECO:0000250|UniProtKB:Q61469}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-sn-glycerol 3-diphosphate + H2O = a 1,2-diacyl- CC sn-glycero-3-phosphate + phosphate + H(+); Xref=Rhea:RHEA:27449, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:58608, ChEBI:CHEBI:59996; EC=3.6.1.75; CC Evidence={ECO:0000250|UniProtKB:Q61469}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:27450; CC Evidence={ECO:0000250|UniProtKB:Q61469}; CC -!- CATALYTIC ACTIVITY: CC Reaction=sphing-4-enine 1-phosphate + H2O = sphing-4-enine + phosphate; CC Xref=Rhea:RHEA:27518, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:57756, ChEBI:CHEBI:60119; CC Evidence={ECO:0000269|PubMed:17379599, ECO:0000269|PubMed:9705349}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:27519; CC Evidence={ECO:0000305|PubMed:9705349}; CC -!- CATALYTIC ACTIVITY: CC Reaction=an N-acylsphing-4-enine 1-phosphate + H2O = an N-acylsphing-4- CC enine + phosphate; Xref=Rhea:RHEA:33743, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:43474, ChEBI:CHEBI:52639, ChEBI:CHEBI:57674; CC Evidence={ECO:0000269|PubMed:9305923, ECO:0000269|PubMed:9705349}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33744; CC Evidence={ECO:0000305|PubMed:9305923}; CC -!- CATALYTIC ACTIVITY: CC Reaction=N-(octanoyl)-sphing-4-enine-1-phosphate + H2O = N- CC octanoylsphing-4-enine + phosphate; Xref=Rhea:RHEA:62040, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:45815, CC ChEBI:CHEBI:85376; Evidence={ECO:0000269|PubMed:9705349}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:62041; CC Evidence={ECO:0000305|PubMed:9705349}; CC -!- CATALYTIC ACTIVITY: CC Reaction=N-(9Z-octadecenoyl)-ethanolamine phosphate + H2O = N-(9Z- CC octadecenoyl) ethanolamine + phosphate; Xref=Rhea:RHEA:62160, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:71466, CC ChEBI:CHEBI:145465; Evidence={ECO:0000269|PubMed:9607309}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:62161; CC Evidence={ECO:0000305|PubMed:9607309}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphate + CC H2O = 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycerol + phosphate; CC Xref=Rhea:RHEA:41255, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:64839, ChEBI:CHEBI:75466; CC Evidence={ECO:0000250|UniProtKB:O08564}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41256; CC Evidence={ECO:0000250|UniProtKB:O08564}; CC -!- ACTIVITY REGULATION: Magnesium-independent phospholipid phosphatase CC (PubMed:9305923). Insensitive to N-ethylmaleimide (PubMed:9305923). CC Inhibited by sphingosine, zinc ions and modestly by propanolol CC (PubMed:9305923, PubMed:9705349). Inhibited by vanadate CC (PubMed:10962286). {ECO:0000269|PubMed:10962286, CC ECO:0000269|PubMed:9305923, ECO:0000269|PubMed:9705349}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=98 uM for 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphate CC {ECO:0000269|PubMed:9607309}; CC KM=170 uM for (9Z)-octadecenoyl-sn-glycero-3-phosphate CC {ECO:0000269|PubMed:9607309}; CC KM=116 uM for N-(9Z-octadecenoyl)-ethanolamine phosphate CC {ECO:0000269|PubMed:9607309}; CC Vmax=0.54 nmol/min/mg enzyme with 1,2-dihexadecanoyl-sn-glycero-3- CC phosphate as substrate {ECO:0000269|PubMed:9705349}; CC Vmax=0.50 nmol/min/mg enzyme with (9Z)-octadecenoyl-sn-glycero-3- CC phosphate as substrate {ECO:0000269|PubMed:9705349}; CC Vmax=0.30 nmol/min/mg enzyme with N-(octanoyl)-sphing-4-enine-1- CC phosphate as substrate {ECO:0000269|PubMed:9705349}; CC Vmax=0.32 nmol/min/mg enzyme with sphing-4-enine 1-phosphate as CC substrate {ECO:0000269|PubMed:9705349}; CC Vmax=41 nmol/min/mg enzyme with 1,2-di-(9Z-octadecenoyl)-sn-glycero- CC 3-phosphate as substrate {ECO:0000269|PubMed:9607309}; CC Vmax=33 nmol/min/mg enzyme with (9Z)-octadecenoyl-sn-glycero-3- CC phosphate as substrate {ECO:0000269|PubMed:9607309}; CC Vmax=29 nmol/min/mg enzyme with N-(9Z-octadecenoyl)-ethanolamine CC phosphate as substrate {ECO:0000269|PubMed:9607309}; CC -!- PATHWAY: Lipid metabolism; phospholipid metabolism. CC {ECO:0000269|PubMed:10962286, ECO:0000269|PubMed:9305923, CC ECO:0000269|PubMed:9607309, ECO:0000269|PubMed:9705349}. CC -!- SUBUNIT: Forms functional homodimers and homooligomers that are not CC required for substrate recognition and catalytic activity (By CC similarity). Can also form heterooligomers with PLPP2 and PLPP3 (By CC similarity). {ECO:0000250|UniProtKB:O88956, CC ECO:0000250|UniProtKB:Q61469}. CC -!- INTERACTION: CC O14494; P05067: APP; NbExp=3; IntAct=EBI-2865290, EBI-77613; CC O14494; Q9UQM7: CAMK2A; NbExp=3; IntAct=EBI-2865290, EBI-1383687; CC O14494; P29466-3: CASP1; NbExp=3; IntAct=EBI-2865290, EBI-12248206; CC O14494; P48730-2: CSNK1D; NbExp=3; IntAct=EBI-2865290, EBI-9087876; CC O14494; O15529: GPR42; NbExp=3; IntAct=EBI-2865290, EBI-18076404; CC O14494; P17612: PRKACA; NbExp=3; IntAct=EBI-2865290, EBI-476586; CC O14494; P49768-2: PSEN1; NbExp=3; IntAct=EBI-2865290, EBI-11047108; CC O14494; Q8WWF3: SSMEM1; NbExp=3; IntAct=EBI-2865290, EBI-17280858; CC O14494; Q15583: TGIF1; NbExp=3; IntAct=EBI-2865290, EBI-714215; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10962286, CC ECO:0000269|PubMed:9705349}; Multi-pass membrane protein {ECO:0000255}. CC Apical cell membrane {ECO:0000269|PubMed:14527693}; Multi-pass membrane CC protein {ECO:0000255}. Membrane raft {ECO:0000269|PubMed:17005594}; CC Multi-pass membrane protein {ECO:0000255}. Membrane, caveola CC {ECO:0000250|UniProtKB:Q61469}; Multi-pass membrane protein CC {ECO:0000255}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Comment=Additional isoforms seem to exist.; CC Name=1; Synonyms=Alpha-1, hLPP1, PAP2-a1; CC IsoId=O14494-1; Sequence=Displayed; CC Name=2; Synonyms=Alpha-2, hLPP1-a, PAP2-a2; CC IsoId=O14494-2; Sequence=VSP_009651; CC -!- TISSUE SPECIFICITY: Widely expressed with highest expression found in CC prostate (PubMed:9305923). Found to be down-regulated in colon CC adenocarcinomas (PubMed:9570154). {ECO:0000269|PubMed:9305923, CC ECO:0000269|PubMed:9570154}. CC -!- TISSUE SPECIFICITY: [Isoform 1]: Predominant in kidney, lung, placenta CC and liver. {ECO:0000269|PubMed:9570154}. CC -!- TISSUE SPECIFICITY: [Isoform 2]: Predominant in heart and pancreas. CC {ECO:0000269|PubMed:9570154}. CC -!- INDUCTION: By androgens. {ECO:0000269|PubMed:9468526}. CC -!- PTM: N-glycosylated (PubMed:10962286, PubMed:9305923). N-linked sugars CC are of the complex type. N-glycosylation is not required for the CC phosphatase activity (By similarity). {ECO:0000250|UniProtKB:Q61469, CC ECO:0000269|PubMed:10962286, ECO:0000269|PubMed:9305923}. CC -!- SIMILARITY: Belongs to the PA-phosphatase related phosphoesterase CC family. {ECO:0000305}. CC -!- CAUTION: Some reports could not detect a significant activity with CC sphingosine 1-phosphate as substrate. {ECO:0000269|PubMed:9305923}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB000888; BAA22593.1; -; mRNA. DR EMBL; AF014402; AAC16032.1; -; mRNA. DR EMBL; AF014403; AAC16033.1; -; mRNA. DR EMBL; Y14436; CAC14588.1; -; mRNA. DR EMBL; AF017116; AAC32041.1; -; mRNA. DR EMBL; AC010480; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC025777; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471123; EAW54920.1; -; Genomic_DNA. DR EMBL; CH471123; EAW54922.1; -; Genomic_DNA. DR EMBL; BC039847; AAH39847.1; -; mRNA. DR EMBL; BC117133; AAI17134.1; -; mRNA. DR EMBL; BC143281; AAI43282.1; -; mRNA. DR CCDS; CCDS34159.1; -. [O14494-1] DR CCDS; CCDS34160.1; -. [O14494-2] DR RefSeq; NP_003702.2; NM_003711.3. [O14494-1] DR RefSeq; NP_795714.1; NM_176895.3. [O14494-2] DR AlphaFoldDB; O14494; -. DR BioGRID; 114169; 41. DR FunCoup; O14494; 507. DR IntAct; O14494; 23. DR MINT; O14494; -. DR STRING; 9606.ENSP00000264775; -. DR SwissLipids; SLP:000000160; -. DR DEPOD; PLPP1; -. DR GlyCosmos; O14494; 1 site, No reported glycans. DR GlyGen; O14494; 1 site. DR iPTMnet; O14494; -. DR PhosphoSitePlus; O14494; -. DR SwissPalm; O14494; -. DR BioMuta; PLPP1; -. DR jPOST; O14494; -. DR MassIVE; O14494; -. DR PeptideAtlas; O14494; -. DR ProteomicsDB; 33687; -. DR ProteomicsDB; 48037; -. [O14494-1] DR ProteomicsDB; 48038; -. [O14494-2] DR Pumba; O14494; -. DR Antibodypedia; 11159; 186 antibodies from 27 providers. DR DNASU; 8611; -. DR Ensembl; ENST00000264775.9; ENSP00000264775.5; ENSG00000067113.18. [O14494-2] DR Ensembl; ENST00000307259.9; ENSP00000302229.8; ENSG00000067113.18. [O14494-1] DR GeneID; 8611; -. DR KEGG; hsa:8611; -. DR MANE-Select; ENST00000307259.9; ENSP00000302229.8; NM_003711.4; NP_003702.2. DR UCSC; uc003jpz.5; human. [O14494-1] DR AGR; HGNC:9228; -. DR ClinPGx; PA33552; -. DR CTD; 8611; -. DR DisGeNET; 8611; -. DR GeneCards; PLPP1; -. DR HGNC; HGNC:9228; PLPP1. DR HPA; ENSG00000067113; Low tissue specificity. DR MIM; 607124; gene. DR OpenTargets; ENSG00000067113; -. DR VEuPathDB; HostDB:ENSG00000067113; -. DR GeneTree; ENSGT00940000156730; -. DR HOGENOM; CLU_021458_3_1_1; -. DR InParanoid; O14494; -. DR OMA; NQHRYIE; -. DR OrthoDB; 8907274at2759; -. DR PAN-GO; O14494; 6 GO annotations based on evolutionary models. DR PhylomeDB; O14494; -. DR PathwayCommons; O14494; -. DR Reactome; R-HSA-9845614; Sphingolipid catabolism. DR SignaLink; O14494; -. DR UniPathway; UPA00085; -. DR Agora; ENSG00000067113; -. DR BioGRID-ORCS; 8611; 19 hits in 1152 CRISPR screens. DR ChiTaRS; PLPP1; human. DR GeneWiki; PPAP2A; -. DR GenomeRNAi; 8611; -. DR Pharos; O14494; Tbio. DR PRO; PR:O14494; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; O14494; protein. DR Bgee; ENSG00000067113; Expressed in decidua and 202 other cell types or tissues. DR ExpressionAtlas; O14494; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB. DR GO; GO:0005901; C:caveola; ISS:UniProtKB. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0045121; C:membrane raft; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0106235; F:ceramide-1-phosphate phosphatase activity; IDA:UniProtKB. DR GO; GO:0000810; F:diacylglycerol diphosphate phosphatase activity; ISS:UniProtKB. DR GO; GO:0042577; F:lipid phosphatase activity; IDA:UniProtKB. DR GO; GO:0052642; F:lysophosphatidic acid phosphatase activity; IEA:UniProtKB-EC. DR GO; GO:0008195; F:phosphatidate phosphatase activity; IDA:UniProtKB. DR GO; GO:0042392; F:sphingosine-1-phosphate phosphatase activity; IDA:UniProtKB. DR GO; GO:0030521; P:androgen receptor signaling pathway; NAS:UniProtKB. DR GO; GO:0006672; P:ceramide metabolic process; IDA:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; NAS:UniProtKB. DR GO; GO:0030518; P:nuclear receptor-mediated steroid hormone signaling pathway; TAS:UniProtKB. DR GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; TAS:UniProtKB. DR GO; GO:0046839; P:phospholipid dephosphorylation; IDA:UniProtKB. DR GO; GO:0006644; P:phospholipid metabolic process; IDA:UniProtKB. DR GO; GO:0019216; P:regulation of lipid metabolic process; NAS:UniProtKB. DR GO; GO:0007165; P:signal transduction; IMP:UniProtKB. DR GO; GO:0030149; P:sphingolipid catabolic process; TAS:Reactome. DR GO; GO:0006670; P:sphingosine metabolic process; IDA:UniProtKB. DR CDD; cd03384; PAP2_wunen; 1. DR FunFam; 1.20.144.10:FF:000007; phospholipid phosphatase 1 isoform X2; 1. DR Gene3D; 1.20.144.10; Phosphatidic acid phosphatase type 2/haloperoxidase; 1. DR InterPro; IPR043216; PAP-like. DR InterPro; IPR000326; PAP2/HPO. DR InterPro; IPR036938; PAP2/HPO_sf. DR PANTHER; PTHR10165; LIPID PHOSPHATE PHOSPHATASE; 1. DR PANTHER; PTHR10165:SF26; PHOSPHOLIPID PHOSPHATASE 1; 1. DR Pfam; PF01569; PAP2; 1. DR SMART; SM00014; acidPPc; 1. DR SUPFAM; SSF48317; Acid phosphatase/Vanadium-dependent haloperoxidase; 1. PE 1: Evidence at protein level; KW Alternative splicing; Cell membrane; Glycoprotein; Hydrolase; KW Lipid metabolism; Membrane; Proteomics identification; Reference proteome; KW Transmembrane; Transmembrane helix. FT CHAIN 1..284 FT /note="Phospholipid phosphatase 1" FT /id="PRO_0000220905" FT TOPO_DOM 1..6 FT /note="Cytoplasmic" FT /evidence="ECO:0000250|UniProtKB:Q61469" FT TRANSMEM 7..27 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 28..53 FT /note="Extracellular" FT /evidence="ECO:0000250|UniProtKB:Q61469" FT TRANSMEM 54..74 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 75..94 FT /note="Cytoplasmic" FT /evidence="ECO:0000250|UniProtKB:Q61469" FT TRANSMEM 95..115 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 116..164 FT /note="Extracellular" FT /evidence="ECO:0000250|UniProtKB:Q61469" FT TRANSMEM 165..185 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 186..199 FT /note="Cytoplasmic" FT /evidence="ECO:0000250|UniProtKB:Q61469" FT TRANSMEM 200..220 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 221..229 FT /note="Extracellular" FT /evidence="ECO:0000250|UniProtKB:Q61469" FT TRANSMEM 230..250 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 251..284 FT /note="Cytoplasmic" FT /evidence="ECO:0000250|UniProtKB:Q61469" FT REGION 120..128 FT /note="Phosphatase sequence motif I" FT /evidence="ECO:0000250|UniProtKB:O34349" FT REGION 168..171 FT /note="Phosphatase sequence motif II" FT /evidence="ECO:0000250|UniProtKB:O34349" FT REGION 216..227 FT /note="Phosphatase sequence motif III" FT /evidence="ECO:0000250|UniProtKB:O34349" FT REGION 260..284 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 5..7 FT /note="PDZ-binding; involved in localization to the apical FT cell membrane" FT /evidence="ECO:0000269|PubMed:14527693" FT COMPBIAS 269..284 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 171 FT /note="Proton donors" FT /evidence="ECO:0000250|UniProtKB:O34349" FT ACT_SITE 223 FT /note="Nucleophile" FT /evidence="ECO:0000250|UniProtKB:O34349" FT SITE 227 FT /note="Stabilizes the active site histidine for FT nucleophilic attack" FT /evidence="ECO:0000250|UniProtKB:O34349" FT CARBOHYD 142 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 21..70 FT /note="GLPFAILTSRHTPFQRGVFCNDESIKYPYKEDTIPYALLGGIIIPFSIIV FT -> SMPMAVLKLGQIYPFQRGFFCKDNSINYPYHDSTVTSTVLILVGVGLPISS (in FT isoform 2)" FT /evidence="ECO:0000303|PubMed:9570154" FT /id="VSP_009651" FT MUTAGEN 217 FT /note="R->K: Decreased lipid phosphatase activity." FT /evidence="ECO:0000269|PubMed:15461590" FT CONFLICT 27 FT /note="L -> FTSRHI (in Ref. 4; AAC32041)" FT /evidence="ECO:0000305" FT CONFLICT 91 FT /note="R -> S (in Ref. 2; AAC16033)" FT /evidence="ECO:0000305" FT CONFLICT O14494-2:55 FT /note="V -> A (in Ref. 2; AAC16033)" FT /evidence="ECO:0000305" FT CONFLICT O14494-2:56 FT /note="T -> A (in Ref. 2; AAC16033)" FT /evidence="ECO:0000305" FT CONFLICT O14494-2:69 FT /note="I -> V (in Ref. 2; AAC16033)" FT /evidence="ECO:0000305" SQ SEQUENCE 284 AA; 32156 MW; FC2F00617EE07EB3 CRC64; MFDKTRLPYV ALDVLCVLLA GLPFAILTSR HTPFQRGVFC NDESIKYPYK EDTIPYALLG GIIIPFSIIV IILGETLSVY CNLLHSNSFI RNNYIATIYK AIGTFLFGAA ASQSLTDIAK YSIGRLRPHF LDVCDPDWSK INCSDGYIEY YICRGNAERV KEGRLSFYSG HSSFSMYCML FVALYLQARM KGDWARLLRP TLQFGLVAVS IYVGLSRVSD YKHHWSDVLT GLIQGALVAI LVAVYVSDFF KERTSFKERK EEDSHTTLHE TPTTGNHYPS NHQP // ID POLS2_HUMAN Reviewed; 855 AA. AC Q5K4E3; A8K2P5; B4DW80; B7ZMK8; E7EX56; Q8NBY4; DT 15-MAR-2005, integrated into UniProtKB/Swiss-Prot. DT 14-OCT-2008, sequence version 2. DT 28-JAN-2026, entry version 155. DE RecName: Full=Polyserase-2; DE EC=3.4.21.-; DE AltName: Full=Polyserine protease 2; DE AltName: Full=Serine protease 36; DE Flags: Precursor; GN Name=PRSS36; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ENZYME ACTIVITY, ACTIVITY RP REGULATION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND GLYCOSYLATION. RC TISSUE=Liver; RX PubMed=15536082; DOI=10.1074/jbc.m409139200; RA Cal S., Quesada V., Llamazares M., Diaz-Perales A., Garabaya C., RA Lopez-Otin C.; RT "Human polyserase-2, a novel enzyme with three tandem serine protease RT domains in a single polypeptide chain."; RL J. Biol. Chem. 280:1953-1961(2005). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Placenta, Synovium, and Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15616553; DOI=10.1038/nature03187; RA Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G., RA Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E., RA Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M., RA Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C., RA Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M., RA Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M., RA Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D., RA Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., RA Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., RA Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., RA Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., RA Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J., RA Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D., RA Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S., RA Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A., RA Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M., RA Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H., RA Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A., RA Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J., RA DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J., RA Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., RA Myers R.M., Rubin E.M., Pennacchio L.A.; RT "The sequence and analysis of duplication-rich human chromosome 16."; RL Nature 432:988-994(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). CC -!- FUNCTION: Serine protease. Hydrolyzes the peptides N-t-Boc-Gln-Ala-Arg- CC AMC and N-t-Boc-Gln-Gly-Arg-AMC and, to a lesser extent, N-t-Boc-Ala- CC Phe-Lys-AMC and N-t-Boc-Val-Leu-Lys-AMC. Has a preference for CC substrates with an Arg instead of a Lys residue in position P1. CC -!- ACTIVITY REGULATION: Inhibited by serine proteinase inhibitor 4-(2- CC aminoethyl)-benzenesulfonyl fluoride, but not with EDTA or E-64. CC {ECO:0000269|PubMed:15536082}. CC -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular CC matrix {ECO:0000269|PubMed:15536082}. Note=Not attached to membranes. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q5K4E3-1; Sequence=Displayed; CC Name=2; CC IsoId=Q5K4E3-2; Sequence=VSP_044718; CC Name=3; CC IsoId=Q5K4E3-3; Sequence=VSP_046639; CC -!- TISSUE SPECIFICITY: Expressed in fetal kidney, skeletal muscle, liver, CC placenta and heart. Also expressed in tumor cell lines derived from CC lung and colon adenocarcinomas. {ECO:0000269|PubMed:15536082}. CC -!- DOMAIN: The first serine protease domain is catalytically active, CC whereas the second domain lacks the essential His residue of the CC catalytic triad at position 363, and the third domain lacks the CC essential Asp residue of the catalytic triad at position 679. The CC second and third domains are therefore predicted to be inactive (By CC similarity). {ECO:0000250}. CC -!- PTM: The 3 protease domains are not proteolytically cleaved. CC -!- PTM: N-glycosylated. {ECO:0000269|PubMed:15536082}. CC -!- SIMILARITY: Belongs to the peptidase S1 family. {ECO:0000255|PROSITE- CC ProRule:PRU00274}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AJ627034; CAF25303.1; -; mRNA. DR EMBL; AK075142; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AK290310; BAF82999.1; -; mRNA. DR EMBL; AK301409; BAG62942.1; -; mRNA. DR EMBL; AC009088; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC137396; AAI37397.1; -; mRNA. DR EMBL; BC144615; AAI44616.1; -; mRNA. DR CCDS; CCDS32436.1; -. [Q5K4E3-1] DR CCDS; CCDS58452.1; -. [Q5K4E3-2] DR CCDS; CCDS58453.1; -. [Q5K4E3-3] DR RefSeq; NP_001245219.1; NM_001258290.2. [Q5K4E3-3] DR RefSeq; NP_001245220.1; NM_001258291.2. [Q5K4E3-2] DR RefSeq; NP_775773.2; NM_173502.5. [Q5K4E3-1] DR AlphaFoldDB; Q5K4E3; -. DR SMR; Q5K4E3; -. DR FunCoup; Q5K4E3; 406. DR STRING; 9606.ENSP00000268281; -. DR MEROPS; S01.414; -. DR MEROPS; S01.940; -. DR MEROPS; S01.941; -. DR GlyCosmos; Q5K4E3; 9 sites, No reported glycans. DR GlyGen; Q5K4E3; 9 sites, 4 N-linked glycans (4 sites). DR BioMuta; PRSS36; -. DR DMDM; 209572670; -. DR MassIVE; Q5K4E3; -. DR PaxDb; 9606-ENSP00000268281; -. DR PeptideAtlas; Q5K4E3; -. DR Antibodypedia; 27673; 61 antibodies from 16 providers. DR DNASU; 146547; -. DR Ensembl; ENST00000268281.9; ENSP00000268281.4; ENSG00000178226.12. [Q5K4E3-1] DR Ensembl; ENST00000418068.6; ENSP00000407160.2; ENSG00000178226.12. [Q5K4E3-2] DR Ensembl; ENST00000569305.1; ENSP00000454768.1; ENSG00000178226.12. [Q5K4E3-3] DR GeneID; 146547; -. DR KEGG; hsa:146547; -. DR MANE-Select; ENST00000268281.9; ENSP00000268281.4; NM_173502.5; NP_775773.2. DR UCSC; uc002ebd.5; human. [Q5K4E3-1] DR AGR; HGNC:26906; -. DR ClinPGx; PA142671123; -. DR CTD; 146547; -. DR DisGeNET; 146547; -. DR GeneCards; PRSS36; -. DR HGNC; HGNC:26906; PRSS36. DR HPA; ENSG00000178226; Tissue enhanced (pituitary). DR MIM; 610560; gene. DR OpenTargets; ENSG00000178226; -. DR VEuPathDB; HostDB:ENSG00000178226; -. DR eggNOG; KOG3627; Eukaryota. DR GeneTree; ENSGT00940000161761; -. DR HOGENOM; CLU_004497_2_2_1; -. DR InParanoid; Q5K4E3; -. DR OMA; HCLYQGV; -. DR OrthoDB; 10002959at2759; -. DR PAN-GO; Q5K4E3; 1 GO annotation based on evolutionary models. DR PhylomeDB; Q5K4E3; -. DR PathwayCommons; Q5K4E3; -. DR Agora; ENSG00000178226; -. DR BioGRID-ORCS; 146547; 12 hits in 1135 CRISPR screens. DR GenomeRNAi; 146547; -. DR Pharos; Q5K4E3; Tbio. DR PRO; PR:Q5K4E3; -. DR Proteomes; UP000005640; Chromosome 16. DR RNAct; Q5K4E3; protein. DR Bgee; ENSG00000178226; Expressed in primordial germ cell in gonad and 95 other cell types or tissues. DR ExpressionAtlas; Q5K4E3; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:MGI. DR GO; GO:0004252; F:serine-type endopeptidase activity; IDA:MGI. DR GO; GO:0006508; P:proteolysis; IEA:UniProtKB-KW. DR CDD; cd00190; Tryp_SPc; 1. DR FunFam; 2.40.10.10:FF:000044; polyserase-2 isoform X1; 2. DR FunFam; 2.40.10.10:FF:000024; Serine protease 53; 1. DR Gene3D; 2.40.10.10; Trypsin-like serine proteases; 3. DR InterPro; IPR017326; Pept_S1A_polyserase-2. DR InterPro; IPR009003; Peptidase_S1_PA. DR InterPro; IPR043504; Peptidase_S1_PA_chymotrypsin. DR InterPro; IPR001314; Peptidase_S1A. DR InterPro; IPR001254; Trypsin_dom. DR InterPro; IPR018114; TRYPSIN_HIS. DR InterPro; IPR033116; TRYPSIN_SER. DR PANTHER; PTHR24253:SF100; POLYSERASE-2; 1. DR PANTHER; PTHR24253; TRANSMEMBRANE PROTEASE SERINE; 1. DR Pfam; PF00089; Trypsin; 3. DR PIRSF; PIRSF037933; Polyserase-2; 1. DR PRINTS; PR00722; CHYMOTRYPSIN. DR SMART; SM00020; Tryp_SPc; 3. DR SUPFAM; SSF50494; Trypsin-like serine proteases; 3. DR PROSITE; PS50240; TRYPSIN_DOM; 3. DR PROSITE; PS00134; TRYPSIN_HIS; 1. DR PROSITE; PS00135; TRYPSIN_SER; 1. PE 1: Evidence at protein level; KW Alternative splicing; Disulfide bond; Extracellular matrix; Glycoprotein; KW Hydrolase; Protease; Proteomics identification; Reference proteome; Repeat; KW Secreted; Serine protease; Signal; Zymogen. FT SIGNAL 1..22 FT /evidence="ECO:0000255" FT PROPEP 23..46 FT /evidence="ECO:0000255" FT /id="PRO_0000027879" FT CHAIN 47..855 FT /note="Polyserase-2" FT /id="PRO_0000027880" FT DOMAIN 47..291 FT /note="Peptidase S1 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00274" FT DOMAIN 323..555 FT /note="Peptidase S1 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00274" FT DOMAIN 590..808 FT /note="Peptidase S1 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00274" FT REGION 292..316 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 301..310 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 87 FT /note="Charge relay system" FT /evidence="ECO:0000250" FT ACT_SITE 139 FT /note="Charge relay system" FT /evidence="ECO:0000250" FT ACT_SITE 243 FT /note="Charge relay system" FT /evidence="ECO:0000250" FT CARBOHYD 92 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 130 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 217 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 317 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 369 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 402 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 407 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 421 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 508 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 72..88 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00274" FT DISULFID 173..249 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00274" FT DISULFID 206..228 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00274" FT DISULFID 239..267 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00274" FT DISULFID 348..364 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00274" FT DISULFID 444..516 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00274" FT DISULFID 506..534 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00274" FT DISULFID 615..631 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00274" FT DISULFID 711..772 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00274" FT DISULFID 739..751 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00274" FT VAR_SEQ 503..507 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_046639" FT VAR_SEQ 661..763 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_044718" FT CONFLICT 135 FT /note="E -> K (in Ref. 2; BAG62942)" FT /evidence="ECO:0000305" FT CONFLICT 812 FT /note="F -> L (in Ref. 1; CAF25303)" FT /evidence="ECO:0000305" SQ SEQUENCE 855 AA; 91955 MW; D1AF7888311FB871 CRC64; MARHLLLPLV MLVISPIPGA FQDSALSPTQ EEPEDLDCGR PEPSARIVGG SNAQPGTWPW QVSLHHGGGH ICGGSLIAPS WVLSAAHCFM TNGTLEPAAE WSVLLGVHSQ DGPLDGAHTR AVAAIVVPAN YSQVELGADL ALLRLASPAS LGPAVWPVCL PRASHRFVHG TACWATGWGD VQEADPLPLP WVLQEVELRL LGEATCQCLY SQPGPFNLTL QILPGMLCAG YPEGRRDTCQ GDSGGPLVCE EGGRWFQAGI TSFGFGCGRR NRPGVFTAVA TYEAWIREQV MGSEPGPAFP TQPQKTQSDP QEPREENCTI ALPECGKAPR PGAWPWEAQV MVPGSRPCHG ALVSESWVLA PASCFLDPNS SDSPPRDLDA WRVLLPSRPR AERVARLVQH ENASWDNASD LALLQLRTPV NLSAASRPVC LPHPEHYFLP GSRCRLARWG RGEPALGPGA LLEAELLGGW WCHCLYGRQG AAVPLPGDPP HALCPAYQEK EEVGSCWNDS RWSLLCQEEG TWFLAGIRDF PSGCLRPRAF FPLQTHGPWI SHVTRGAYLE DQLAWDWGPD GEETETQTCP PHTEHGACGL RLEAAPVGVL WPWLAEVHVA GDRVCTGILL APGWVLAATH CVLRPGSTTV PYIEVYLGRA GASSLPQGHQ VSRLVISIRL PQHLGLRPPL ALLELSSRVE PSPSALPICL HPAGIPPGAS CWVLGWKEPQ DRVPVAAAVS ILTQRICDCL YQGILPPGTL CVLYAEGQEN RCEMTSAPPL LCQMTEGSWI LVGMAVQGSR ELFAAIGPEE AWISQTVGEA NFLPPSGSPH WPTGGSNLCP PELAKASGSP HAVYFLLLLT LLIQS // ID PRKDC_HUMAN Reviewed; 4128 AA. AC P78527; P78528; Q13327; Q13337; Q14175; Q59H99; Q7Z611; Q96SE6; Q9UME3; DT 27-APR-2001, integrated into UniProtKB/Swiss-Prot. DT 31-OCT-2003, sequence version 3. DT 28-JAN-2026, entry version 246. DE RecName: Full=DNA-dependent protein kinase catalytic subunit; DE Short=DNA-PK catalytic subunit; DE Short=DNA-PKcs; DE EC=2.7.11.1 {ECO:0000269|PubMed:15262962, ECO:0000269|PubMed:26237645, ECO:0000269|PubMed:32103174, ECO:0000269|PubMed:35460603}; DE AltName: Full=DNPK1; DE AltName: Full=Ser-473 kinase {ECO:0000303|PubMed:15262962}; DE Short=S473K {ECO:0000303|PubMed:15262962}; DE AltName: Full=p460; GN Name=PRKDC; Synonyms=HYRC, HYRC1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Cervix carcinoma; RX PubMed=7671312; DOI=10.1016/0092-8674(95)90482-4; RA Hartley K.O., Gell D., Smith G.C.M., Zhang H., Divecha N., Connelly M.A., RA Admon A., Lees-Miller S.P., Anderson C.W., Jackson S.P.; RT "DNA-dependent protein kinase catalytic subunit: a relative of RT phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product."; RL Cell 82:849-856(1995). RN [2] RP SEQUENCE REVISION, AND ALTERNATIVE SPLICING. RA Gell D., Anderson C.W.; RL Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-6; ILE-333; SER-605; RP MET-680; SER-695; SER-1071; VAL-1314; VAL-1588; HIS-1603; VAL-2095; RP GLU-2702; CYS-2899; ASP-3149; SER-3201; GLU-3404; THR-3434; SER-3459; RP MET-3562; LEU-3836 AND VAL-3932. RG NIEHS SNPs program; RL Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-1689. RX PubMed=11418067; DOI=10.1667/0033-7587(2001)156[0002:fmiptg]2.0.co;2; RA Anderson C.W., Dunn J.J., Freimuth P.I., Galloway A.M., RA Allalunis-Turner M.J.; RT "Frameshift mutation in PRKDC, the gene for DNA-PKcs, in the DNA repair- RT defective, human, glioma-derived cell line M059J."; RL Radiat. Res. 156:2-9(2001). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-49. RX PubMed=9284934; DOI=10.1159/000134594; RA Ladenburger E.M., Fackelmayer F.O., Hameister H., Knippers R.; RT "MCM4 and PRKDC, human genes encoding proteins MCM4 and DNA-PKcs, are close RT neighbours located on chromosome 8q12-->q13."; RL Cytogenet. Cell Genet. 77:268-270(1997). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1789-2203. RC TISSUE=Placenta; RX PubMed=7638222; DOI=10.1073/pnas.92.16.7515; RA Sipley J.D., Menninger J.C., Hartley K.O., Ward D.C., Jackson S.P., RA Anderson C.W.; RT "Gene for the catalytic subunit of the human DNA-activated protein kinase RT maps to the site of the XRCC7 gene on chromosome 8."; RL Proc. Natl. Acad. Sci. U.S.A. 92:7515-7519(1995). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 2255-2335. RC TISSUE=Placenta; RA Abe M.; RL Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 3199-4128 (ISOFORM 1). RC TISSUE=Fetal lung; RX PubMed=7594449; RA Poltoratsky V.P., Shi X., York J.D., Lieber M.R., Carter T.H.; RT "Human DNA-activated protein kinase (DNA-PK) is homologous to RT phosphatidylinositol kinases."; RL J. Immunol. 155:4529-4533(1995). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 3250-4128 (ISOFORM 1). RA Anderson C.W., Dunn J.J., Freimuth P.I.; RT "Sequence of the 3' segment (exons 70-86) of PRKDC, the gene for human DNA- RT PKcs."; RL Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 3372-4128 (ISOFORM 2). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno F.R.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP FUNCTION, AND PHOSPHORYLATION OF HSPCA. RX PubMed=2507541; DOI=10.1016/s0021-9258(18)71488-9; RA Lees-Miller S.P., Anderson C.W.; RT "The human double-stranded DNA-activated protein kinase phosphorylates the RT 90-kDa heat-shock protein, hsp90 alpha at two NH2-terminal threonine RT residues."; RL J. Biol. Chem. 264:17275-17280(1989). RN [12] RP FUNCTION, AND PHOSPHORYLATION OF H1. RX PubMed=2247066; DOI=10.1128/mcb.10.12.6460-6471.1990; RA Carter T., Vancurova I., Sun I., Lou W., DeLeon S.; RT "A DNA-activated protein kinase from HeLa cell nuclei."; RL Mol. Cell. Biol. 10:6460-6471(1990). RN [13] RP FUNCTION, AND PHOSPHORYLATION OF MYC. RX PubMed=1597196; DOI=10.1111/j.1432-1033.1992.tb16964.x; RA Iijima S., Teraoka H., Date T., Tsukada K.; RT "DNA-activated protein kinase in Raji Burkitt's lymphoma cells. RT Phosphorylation of c-Myc oncoprotein."; RL Eur. J. Biochem. 206:595-603(1992). RN [14] RP FUNCTION, AND PHOSPHORYLATION OF SRF. RX PubMed=8407951; DOI=10.1016/s0021-9258(19)36904-2; RA Liu S.-H., Ma J.-T., Yueh A.Y., Lees-Miller S.P., Anderson C.W., Ng S.-Y.; RT "The carboxyl-terminal transactivation domain of human serum response RT factor contains DNA-activated protein kinase phosphorylation sites."; RL J. Biol. Chem. 268:21147-21154(1993). RN [15] RP FUNCTION, AND PHOSPHORYLATION OF JUN. RX PubMed=8464713; DOI=10.1093/nar/21.5.1289; RA Bannister A.J., Gottlieb T.M., Kouzarides T., Jackson S.P.; RT "c-Jun is phosphorylated by the DNA-dependent protein kinase in vitro; RT definition of the minimal kinase recognition motif."; RL Nucleic Acids Res. 21:1289-1295(1993). RN [16] RP CLEAVAGE BY CASPASE-3. RX PubMed=8804412; DOI=10.1016/0014-5793(96)00842-3; RA Teraoka H., Yumoto Y., Watanabe F., Tsukada K., Suwa A., Enari M., RA Nagata S.; RT "CPP32/Yama/apopain cleaves the catalytic component of DNA-dependent RT protein kinase in the holoenzyme."; RL FEBS Lett. 393:1-6(1996). RN [17] RP ALTERNATIVE SPLICING. RX PubMed=8917110; DOI=10.1016/0378-1119(96)00135-7; RA Connelly M.A., Zhang H., Kieleczawa J., Anderson C.W.; RT "Alternate splice-site utilization in the gene for the catalytic subunit of RT the DNA-activated protein kinase, DNA-PKcs."; RL Gene 175:271-273(1996). RN [18] RP FUNCTION, AND PHOSPHORYLATION OF TP53. RX PubMed=9363941; DOI=10.1016/s0092-8674(00)80416-x; RA Shieh S.-Y., Ikeda M., Taya Y., Prives C.; RT "DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2."; RL Cell 91:325-334(1997). RN [19] RP CHARACTERIZATION, AND INTERACTION WITH CIB1. RX PubMed=9372844; DOI=10.1016/s0921-8777(97)00035-9; RA Wu X., Lieber M.R.; RT "Interaction between DNA-dependent protein kinase and a novel protein, RT KIP."; RL Mutat. Res. 385:13-20(1997). RN [20] RP FUNCTION, AND PHOSPHORYLATION OF XRCC6. RX PubMed=9362500; DOI=10.1093/emboj/16.22.6874; RA Jin S., Weaver D.T.; RT "Double-strand break repair by Ku70 requires heterodimerization with Ku80 RT and DNA binding functions."; RL EMBO J. 16:6874-6885(1997). RN [21] RP FUNCTION, AND PHOSPHORYLATION OF RFA2. RX PubMed=9139719; DOI=10.1074/jbc.272.19.12634; RA Niu H., Erdjument-Bromage H., Pan Z.-Q., Lee S.-H., Tempst P., Hurwitz J.; RT "Mapping of amino acid residues in the p34 subunit of human single-stranded RT DNA-binding protein phosphorylated by DNA-dependent protein kinase and Cdc2 RT kinase in vitro."; RL J. Biol. Chem. 272:12634-12641(1997). RN [22] RP ACTIVITY REGULATION. RX PubMed=9766667; RA Sarkaria J.N., Tibbetts R.S., Busby E.C., Kennedy A.P., Hill D.E., RA Abraham R.T.; RT "Inhibition of phosphoinositide 3-kinase related kinases by the RT radiosensitizing agent wortmannin."; RL Cancer Res. 58:4375-4382(1998). RN [23] RP FUNCTION, INTERACTION WITH C1D, AND MUTAGENESIS OF LEU-1510 AND RP 1516-GLU-LEU-1517. RX PubMed=9679063; DOI=10.1101/gad.12.14.2188; RA Yavuzer U., Smith G.C.M., Bliss T., Werner D., Jackson S.P.; RT "DNA end-independent activation of DNA-PK mediated via association with the RT DNA-binding protein C1D."; RL Genes Dev. 12:2188-2199(1998). RN [24] RP INTERACTION WITH ILF3. RX PubMed=9442054; DOI=10.1074/jbc.273.4.2136; RA Ting N.S.Y., Kao P.N., Chan D.W., Lintott L.G., Lees-Miller S.P.; RT "DNA-dependent protein kinase interacts with antigen receptor response RT element binding proteins NF90 and NF45."; RL J. Biol. Chem. 273:2136-2145(1998). RN [25] RP DNA-BINDING. RX PubMed=9435225; DOI=10.1073/pnas.95.2.525; RA Hammarsten O., Chu G.; RT "DNA-dependent protein kinase: DNA binding and activation in the absence of RT Ku."; RL Proc. Natl. Acad. Sci. U.S.A. 95:525-530(1998). RN [26] RP FUNCTION, AND PHOSPHORYLATION OF XRCC5 AND XRCC6. RX PubMed=10026262; DOI=10.1021/bi982584b; RA Chan D.W., Ye R., Veillette C.J., Lees-Miller S.P.; RT "DNA-dependent protein kinase phosphorylation sites in Ku 70/80 RT heterodimer."; RL Biochemistry 38:1819-1828(1999). RN [27] RP FUNCTION, AND PHOSPHORYLATION OF PARP1. RX PubMed=10467406; DOI=10.1038/sj.onc.1202823; RA Ariumi Y., Masutani M., Copeland T.D., Mimori T., Sugimura T., RA Shimotohno K., Ueda K., Hatanaka M., Noda M.; RT "Suppression of the poly(ADP-ribose) polymerase activity by DNA-dependent RT protein kinase in vitro."; RL Oncogene 18:4616-4625(1999). RN [28] RP PHOSPHORYLATION AT THR-2609; SER-2612; THR-2638 AND THR-2647. RX PubMed=12186630; DOI=10.1042/bj20020973; RA Douglas P., Sapkota G.P., Morrice N., Yu Y., Goodarzi A.A., Merkle D., RA Meek K., Alessi D.R., Lees-Miller S.P.; RT "Identification of in vitro and in vivo phosphorylation sites in the RT catalytic subunit of the DNA-dependent protein kinase."; RL Biochem. J. 368:243-251(2002). RN [29] RP FUNCTION, AND INTERACTION WITH DCLRE1C. RX PubMed=11955432; DOI=10.1016/s0092-8674(02)00671-2; RA Ma Y., Pannicke U., Schwarz K., Lieber M.R.; RT "Hairpin opening and overhang processing by an Artemis/DNA-dependent RT protein kinase complex in nonhomologous end joining and V(D)J RT recombination."; RL Cell 108:781-794(2002). RN [30] RP FUNCTION, AND PHOSPHORYLATION OF XRCC4. RX PubMed=12509254; DOI=10.1016/s1568-7864(01)00018-0; RA Hsu H.-L., Yannone S.M., Chen D.J.; RT "Defining interactions between DNA-PK and ligase IV/XRCC4."; RL DNA Repair 1:225-235(2002). RN [31] RP PHOSPHORYLATION AT THR-2609, MUTAGENESIS OF THR-2609, SUBCELLULAR LOCATION, RP AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=12231622; DOI=10.1101/gad.1015202; RA Chan D.W., Chen B.P., Prithivirajsingh S., Kurimasa A., Story M.D., Qin J., RA Chen D.J.; RT "Autophosphorylation of the DNA-dependent protein kinase catalytic subunit RT is required for rejoining of DNA double-strand breaks."; RL Genes Dev. 16:2333-2338(2002). RN [32] RP FUNCTION, AND PHOSPHORYLATION OF WRN. RX PubMed=11889123; DOI=10.1074/jbc.m111523200; RA Karmakar P., Piotrowski J., Brosh R.M. Jr., Sommers J.A., Miller S.P., RA Cheng W.H., Snowden C.M., Ramsden D.A., Bohr V.A.; RT "Werner protein is a target of DNA-dependent protein kinase in vivo and in RT vitro, and its catalytic activities are regulated by phosphorylation."; RL J. Biol. Chem. 277:18291-18302(2002). RN [33] RP FUNCTION, AND MUTAGENESIS OF THR-2638 AND THR-2647. RX PubMed=12649176; RA Soubeyrand S., Pope L., Pakuts B., Hache R.J.; RT "Threonines 2638/2647 in DNA-PK are essential for cellular resistance to RT ionizing radiation."; RL Cancer Res. 63:1198-1201(2003). RN [34] RP FUNCTION, AND PHOSPHORYLATION OF POU2F1. RX PubMed=14612514; RA Schild-Poulter C., Shih A., Yarymowich N.C., Hache R.J.G.; RT "Down-regulation of histone H2B by DNA-dependent protein kinase in response RT to DNA damage through modulation of octamer transcription factor 1."; RL Cancer Res. 63:7197-7205(2003). RN [35] RP FUNCTION IN PHOSPHORYLATION OF XRCC4. RX PubMed=14599745; DOI=10.1016/s1568-7864(03)00143-5; RA Yu Y., Wang W., Ding Q., Ye R., Chen D., Merkle D., Schriemer D., Meek K., RA Lees-Miller S.P.; RT "DNA-PK phosphorylation sites in XRCC4 are not required for survival after RT radiation or for V(D)J recombination."; RL DNA Repair 2:1239-1252(2003). RN [36] RP FUNCTION, AND PHOSPHORYLATION OF H2AX. RX PubMed=14627815; DOI=10.1093/nar/gkg921; RA Park E.-J., Chan D.W., Park J.-H., Oettinger M.A., Kwon J.; RT "DNA-PK is activated by nucleosomes and phosphorylates H2AX within the RT nucleosomes in an acetylation-dependent manner."; RL Nucleic Acids Res. 31:6819-6827(2003). RN [37] RP FUNCTION IN PHOSPHORYLATION OF XRCC4. RX PubMed=15177042; DOI=10.1016/j.dnarep.2003.11.005; RA Lee K.J., Jovanovic M., Udayakumar D., Bladen C.L., Dynan W.S.; RT "Identification of DNA-PKcs phosphorylation sites in XRCC4 and effects of RT mutations at these sites on DNA end joining in a cell-free system."; RL DNA Repair 3:267-276(2004). RN [38] RP FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION. RX PubMed=15262962; DOI=10.1074/jbc.m406731200; RA Feng J., Park J., Cron P., Hess D., Hemmings B.A.; RT "Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA- RT dependent protein kinase."; RL J. Biol. Chem. 279:41189-41196(2004). RN [39] RP FUNCTION IN PHOSPHORYLATION OF NHEJ1. RX PubMed=18644470; DOI=10.1016/j.dnarep.2008.06.015; RA Yu Y., Mahaney B.L., Yano K., Ye R., Fang S., Douglas P., Chen D.J., RA Lees-Miller S.P.; RT "DNA-PK and ATM phosphorylation sites in XLF/Cernunnos are not required for RT repair of DNA double strand breaks."; RL DNA Repair 7:1680-1692(2008). RN [40] RP FUNCTION IN PHOSPHORYLATION OF XRCC4. RX PubMed=26666690; DOI=10.1093/jrr/rrv086; RA Sharma M.K., Imamichi S., Fukuchi M., Samarth R.M., Tomita M., RA Matsumoto Y.; RT "In cellulo phosphorylation of XRCC4 Ser320 by DNA-PK induced by DNA RT damage."; RL J. Radiat. Res. 57:115-120(2016). RN [41] RP FUNCTION IN PHOSPHORYLATION OF XRCC4. RX PubMed=30247612; DOI=10.1093/jrr/rry072; RA Amiri Moghani A.R., Sharma M.K., Matsumoto Y.; RT "In cellulo phosphorylation of DNA double-strand break repair protein XRCC4 RT on Ser260 by DNA-PK."; RL J. Radiat. Res. 59:700-708(2018). RN [42] RP INTERACTION WITH DCLRE1C. RX PubMed=15071507; DOI=10.1038/sj.emboj.7600206; RA Pannicke U., Ma Y., Hopfner K.-P., Niewolik D., Lieber M.R., Schwarz K.; RT "Functional and biochemical dissection of the structure-specific nuclease RT ARTEMIS."; RL EMBO J. 23:1987-1997(2004). RN [43] RP INTERACTION WITH DCLRE1C. RX PubMed=14744996; DOI=10.1084/jem.20031142; RA Poinsignon C., Moshous D., Callebaut I., de Chasseval R., Villey I., RA de Villartay J.-P.; RT "The metallo-beta-lactamase/beta-CASP domain of Artemis constitutes the RT catalytic core for V(D)J recombination."; RL J. Exp. Med. 199:315-321(2004). RN [44] RP FUNCTION, AND INTERACTION WITH DCLRE1C. RX PubMed=15574326; DOI=10.1016/j.molcel.2004.11.017; RA Ma Y., Lu H., Tippin B., Goodman M.F., Shimazaki N., Koiwai O., RA Hsieh C.-L., Schwarz K., Lieber M.R.; RT "A biochemically defined system for mammalian nonhomologous DNA end RT joining."; RL Mol. Cell 16:701-713(2004). RN [45] RP INTERACTION WITH DCLRE1C. RX PubMed=15456891; DOI=10.1128/mcb.24.20.9207-9220.2004; RA Zhang X., Succi J., Feng Z., Prithivirajsingh S., Story M.D., RA Legerski R.J.; RT "Artemis is a phosphorylation target of ATM and ATR and is involved in the RT G2/M DNA damage checkpoint response."; RL Mol. Cell. Biol. 24:9207-9220(2004). RN [46] RP FUNCTION, AND PHOSPHORYLATION OF DHX9. RX PubMed=14704337; DOI=10.1093/nar/gkg933; RA Zhang S., Schlott B., Goerlach M., Grosse F.; RT "DNA-dependent protein kinase (DNA-PK) phosphorylates nuclear DNA helicase RT II/RNA helicase A and hnRNP proteins in an RNA-dependent manner."; RL Nucleic Acids Res. 32:1-10(2004). RN [47] RP FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-2056 AND THR-2609, RP AND DEPHOSPHORYLATION AT SER-2056 AND THR-2609. RX PubMed=14734805; DOI=10.1073/pnas.0307765100; RA Wechsler T., Chen B.P., Harper R., Morotomi-Yano K., Huang B.C., Meek K., RA Cleaver J.E., Chen D.J., Wabl M.; RT "DNA-PKcs function regulated specifically by protein phosphatase 5."; RL Proc. Natl. Acad. Sci. U.S.A. 101:1247-1252(2004). RN [48] RP FUNCTION, AND PHOSPHORYLATION OF H2AX. RX PubMed=16046194; DOI=10.1016/j.dnarep.2005.06.005; RA Reitsema T., Klokov D., Banath J.P., Olive P.L.; RT "DNA-PK is responsible for enhanced phosphorylation of histone H2AX under RT hypertonic conditions."; RL DNA Repair 4:1172-1181(2005). RN [49] RP INTERACTION WITH DCLRE1C. RX PubMed=15811628; DOI=10.1016/j.dnarep.2005.02.001; RA Wang J., Pluth J.M., Cooper P.K., Cowan M.J., Chen D.J., Yannone S.M.; RT "Artemis deficiency confers a DNA double-strand break repair defect and RT Artemis phosphorylation status is altered by DNA damage and cell cycle RT progression."; RL DNA Repair 4:556-570(2005). RN [50] RP INTERACTION WITH DCLRE1C. RX PubMed=15936993; DOI=10.1016/j.dnarep.2005.04.013; RA Ma Y., Schwarz K., Lieber M.R.; RT "The Artemis:DNA-PKcs endonuclease cleaves DNA loops, flaps, and gaps."; RL DNA Repair 4:845-851(2005). RN [51] RP INTERACTION WITH XRCC5. RX PubMed=15758953; DOI=10.1038/nature03442; RA Falck J., Coates J., Jackson S.P.; RT "Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA RT damage."; RL Nature 434:605-611(2005). RN [52] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3205, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [53] RP FUNCTION, AND PHOSPHORYLATION OF XRCC1. RX PubMed=16397295; DOI=10.1093/nar/gkj409; RA Levy N., Martz A., Bresson A., Spenlehauer C., de Murcia G., RA Menissier-de Murcia J.; RT "XRCC1 is phosphorylated by DNA-dependent protein kinase in response to DNA RT damage."; RL Nucleic Acids Res. 34:32-41(2006). RN [54] RP REVIEW. RX PubMed=15592499; DOI=10.1038/sj.onc.1208332; RA Collis S.J., DeWeese T.L., Jeggo P.A., Parker A.R.; RT "The life and death of DNA-PK."; RL Oncogene 24:949-961(2005). RN [55] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [56] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3205 AND SER-4026, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [57] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3205, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [58] RP INVOLVEMENT IN IMD26, AND VARIANT IMD26 ARG-3062. RX PubMed=19075392; DOI=10.1172/jci37141; RA van der Burg M., Ijspeert H., Verkaik N.S., Turul T., Wiegant W.W., RA Morotomi-Yano K., Mari P.O., Tezcan I., Chen D.J., Zdzienicka M.Z., RA van Dongen J.J., van Gent D.C.; RT "A DNA-PKcs mutation in a radiosensitive T-B- SCID patient inhibits Artemis RT activation and nonhomologous end-joining."; RL J. Clin. Invest. 119:91-98(2009). RN [59] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-893; SER-2612; SER-3205 AND RP SER-4026, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [60] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3205, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [61] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-117; LYS-828; LYS-1209; LYS-1970; RP LYS-2259; LYS-3241; LYS-3260; LYS-3621; LYS-3638 AND LYS-3642, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [62] RP INTERACTION WITH TTI1. RX PubMed=20810650; DOI=10.1101/gad.1934210; RA Hurov K.E., Cotta-Ramusino C., Elledge S.J.; RT "A genetic screen identifies the Triple T complex required for DNA damage RT signaling and ATM and ATR stability."; RL Genes Dev. 24:1939-1950(2010). RN [63] RP INTERACTION WITH TELO2. RX PubMed=20801936; DOI=10.1101/gad.1956410; RA Takai H., Xie Y., de Lange T., Pavletich N.P.; RT "Tel2 structure and function in the Hsp90-dependent maturation of mTOR and RT ATR complexes."; RL Genes Dev. 24:2019-2030(2010). RN [64] RP INTERACTION WITH TELO2 AND TTI1. RX PubMed=20427287; DOI=10.1074/jbc.m110.121699; RA Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K., RA Iemura S., Natsume T., Mizushima N.; RT "Tti1 and Tel2 are critical factors in mammalian target of rapamycin RT complex assembly."; RL J. Biol. Chem. 285:20109-20116(2010). RN [65] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3205 AND SER-4026, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [66] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [67] RP INTERACTION WITH BRAT1, AND PHOSPHORYLATION AT SER-2056. RX PubMed=22977523; DOI=10.3892/etm.2011.232; RA So E.Y., Ouchi T.; RT "Functional interaction of BRCA1/ATM-associated BAAT1 with the DNA-PK RT catalytic subunit."; RL Exp. Ther. Med. 2:443-447(2011). RN [68] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2612 AND SER-3205, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [69] RP SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS]. RX PubMed=22002106; DOI=10.1074/mcp.m111.013680; RA Ahmad Y., Boisvert F.M., Lundberg E., Uhlen M., Lamond A.I.; RT "Systematic analysis of protein pools, isoforms, and modifications RT affecting turnover and subcellular localization."; RL Mol. Cell. Proteomics 11:M111.013680.01-M111.013680.15(2012). RN [70] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-511; SER-687; SER-841; RP SER-1065; THR-2535; SER-2612; THR-2638; THR-2647; SER-2789; SER-3205; RP SER-3731; SER-3821 AND SER-4026, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [71] RP INTERACTION WITH SETX. RX PubMed=23149945; DOI=10.1128/mcb.01195-12; RA Yuce O., West S.C.; RT "Senataxin, defective in the neurodegenerative disorder ataxia with RT oculomotor apraxia 2, lies at the interface of transcription and the DNA RT damage response."; RL Mol. Cell. Biol. 33:406-417(2013). RN [72] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2612, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [73] RP UBIQUITINATION BY RNF144A. RX PubMed=24979766; DOI=10.1073/pnas.1323107111; RA Ho S.R., Mahanic C.S., Lee Y.J., Lin W.C.; RT "RNF144A, an E3 ubiquitin ligase for DNA-PKcs, promotes apoptosis during RT DNA damage."; RL Proc. Natl. Acad. Sci. U.S.A. 111:E2646-E2655(2014). RN [74] RP INTERACTION WITH NR4A3. RX PubMed=25852083; DOI=10.1093/cvr/cvv126; RA Medunjanin S., Daniel J.M., Weinert S., Dutzmann J., Burgbacher F., RA Brecht S., Bruemmer D., Kaehne T., Naumann M., Sedding D.G., RA Zuschratter W., Braun-Dullaeus R.C.; RT "DNA-dependent protein kinase (DNA-PK) permits vascular smooth muscle cell RT proliferation through phosphorylation of the orphan nuclear receptor RT NOR1."; RL Cardiovasc. Res. 106:488-497(2015). RN [75] RP SUBUNIT. RX PubMed=25941166; DOI=10.1038/cdd.2015.22; RA Craxton A., Somers J., Munnur D., Jukes-Jones R., Cain K., Malewicz M.; RT "XLS (c9orf142) is a new component of mammalian DNA double-stranded break RT repair."; RL Cell Death Differ. 22:890-897(2015). RN [76] RP FUNCTION IN PHOSPHORYLATION OF FH, AND CATALYTIC ACTIVITY. RX PubMed=26237645; DOI=10.1038/ncb3209; RA Jiang Y., Qian X., Shen J., Wang Y., Li X., Liu R., Xia Y., Chen Q., RA Peng G., Lin S.Y., Lu Z.; RT "Local generation of fumarate promotes DNA repair through inhibition of RT histone H3 demethylation."; RL Nat. Cell Biol. 17:1158-1168(2015). RN [77] RP SUBUNIT. RX PubMed=25670504; DOI=10.1038/ncomms7233; RA Xing M., Yang M., Huo W., Feng F., Wei L., Jiang W., Ning S., Yan Z., RA Li W., Wang Q., Hou M., Dong C., Guo R., Gao G., Ji J., Zha S., Lan L., RA Liang H., Xu D.; RT "Interactome analysis identifies a new paralogue of XRCC4 in non-homologous RT end joining DNA repair pathway."; RL Nat. Commun. 6:6233-6233(2015). RN [78] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [79] RP INTERACTION WITH PAXX. RX PubMed=25574025; DOI=10.1126/science.1261971; RA Ochi T., Blackford A.N., Coates J., Jhujh S., Mehmood S., Tamura N., RA Travers J., Wu Q., Draviam V.M., Robinson C.V., Blundell T.L., RA Jackson S.P.; RT "DNA repair. PAXX, a paralog of XRCC4 and XLF, interacts with Ku to promote RT DNA double-strand break repair."; RL Science 347:185-188(2015). RN [80] RP FUNCTION, AND INTERACTION WITH HEXIM1; XRCC5; XRCC6; SFPQ; NONO; PSPC1; RP RBM14 AND MATR3. RX PubMed=28712728; DOI=10.1016/j.molcel.2017.06.020; RA Morchikh M., Cribier A., Raffel R., Amraoui S., Cau J., Severac D., RA Dubois E., Schwartz O., Bennasser Y., Benkirane M.; RT "HEXIM1 and NEAT1 Long non-coding RNA form a multi-subunit complex that RT regulates DNA-mediated innate immune response."; RL Mol. Cell 67:387-399(2017). RN [81] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=29478807; DOI=10.1016/j.molcel.2018.01.031; RA Huang T.H., Fowler F., Chen C.C., Shen Z.J., Sleckman B., Tyler J.K.; RT "The histone chaperones ASF1 and CAF-1 promote MMS22L-TONSL-mediated Rad51 RT loading onto ssDNA during homologous recombination in human cells."; RL Mol. Cell 69:879-892(2018). RN [82] RP FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT RP THR-2609. RX PubMed=32103174; DOI=10.1038/s41586-020-2041-2; RA Shao Z., Flynn R.A., Crowe J.L., Zhu Y., Liang J., Jiang W., Aryan F., RA Aoude P., Bertozzi C.R., Estes V.M., Lee B.J., Bhagat G., Zha S., Calo E.; RT "DNA-PKcs has KU-dependent function in rRNA processing and RT haematopoiesis."; RL Nature 579:291-296(2020). RN [83] RP FUNCTION. RX PubMed=33273464; DOI=10.1038/s41467-020-19941-0; RA Sun X., Liu T., Zhao J., Xia H., Xie J., Guo Y., Zhong L., Li M., Yang Q., RA Peng C., Rouvet I., Belot A., Shu H.B., Feng P., Zhang J.; RT "DNA-PK deficiency potentiates cGAS-mediated antiviral innate immunity."; RL Nat. Commun. 11:6182-6182(2020). RN [84] RP INTERACTION WITH KAT5. RX PubMed=32832608; DOI=10.1126/sciadv.aba7822; RA Gao S.S., Guan H., Yan S., Hu S., Song M., Guo Z.P., Xie D.F., Liu Y., RA Liu X., Zhang S., Zhou P.K.; RT "TIP60 K430 SUMOylation attenuates its interaction with DNA-PKcs in S-phase RT cells: Facilitating homologous recombination and emerging target for cancer RT therapy."; RL Sci. Adv. 6:eaba7822-eaba7822(2020). RN [85] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=35460603; DOI=10.1016/j.molcel.2022.03.034; RA Wang F., Zhao M., Chang B., Zhou Y., Wu X., Ma M., Liu S., Cao Y., RA Zheng M., Dang Y., Xu J., Chen L., Liu T., Tang F., Ren Y., Xu Z., Mao Z., RA Huang K., Luo M., Li J., Liu H., Ge B.; RT "Cytoplasmic PARP1 links the genome instability to the inhibition of RT antiviral immunity through PARylating cGAS."; RL Mol. Cell 0:0-0(2022). RN [86] {ECO:0007744|PDB:7NFC, ECO:0007744|PDB:7NFE} RP STRUCTURE BY ELECTRON MICROSCOPY (4.14 ANGSTROMS) IN COMPLEX WITH THE NHEJ RP COMPLEX AND DNA, FUNCTION, IDENTIFICATION IN THE NHEJ COMPLEX, AND RP PHOSPHORYLATION AT SER-2056 AND THR-2609. RX PubMed=34352203; DOI=10.1016/j.molcel.2021.07.005; RA Chaplin A.K., Hardwick S.W., Stavridi A.K., Buehl C.J., Goff N.J., RA Ropars V., Liang S., De Oliveira T.M., Chirgadze D.Y., Meek K., RA Charbonnier J.B., Blundell T.L.; RT "Cryo-EM of NHEJ supercomplexes provides insights into DNA repair."; RL Mol. Cell 81:3400-3409(2021). RN [87] {ECO:0007744|PDB:7LT3} RP STRUCTURE BY ELECTRON MICROSCOPY (4.6 ANGSTROMS) IN COMPLEX WITH THE NHEJ RP COMPLEX, FUNCTION, IDENTIFICATION IN THE NHEJ COMPLEX, AND RP AUTOPHOSPHORYLATION. RX PubMed=33854234; DOI=10.1038/s41586-021-03458-7; RA Chen S., Lee L., Naila T., Fishbain S., Wang A., Tomkinson A.E., RA Lees-Miller S.P., He Y.; RT "Structural basis of long-range to short-range synaptic transition in RT NHEJ."; RL Nature 593:294-298(2021). RN [88] RP VARIANTS [LARGE SCALE ANALYSIS] SER-6; ASN-263; ILE-333; ILE-420; SER-500; RP SER-605; LEU-649; SER-695; HIS-1136; VAL-1190; THR-1237; PHE-1279; RP MET-1447; GLY-1619; VAL-1680; VAL-1680; PRO-2023; GLN-2598; ASN-2810; RP CYS-2899; ALA-2941; ASP-3085; ASP-3149; SER-3198; SER-3201; GLU-3404; RP THR-3434; MET-3562; PHE-3584; ILE-3800; LEU-3836; SER-3936 AND MET-3937. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [89] RP VARIANT IMD26 VAL-3574, AND CHARACTERIZATION OF VARIANT IMD26 VAL-3574. RX PubMed=23722905; DOI=10.1172/jci67349; RA Woodbine L., Neal J.A., Sasi N.K., Shimada M., Deem K., Coleman H., RA Dobyns W.B., Ogi T., Meek K., Davies E.G., Jeggo P.A.; RT "PRKDC mutations in a SCID patient with profound neurological RT abnormalities."; RL J. Clin. Invest. 123:2969-2980(2013). CC -!- FUNCTION: Serine/threonine-protein kinase that acts as a molecular CC sensor for DNA damage (PubMed:11955432, PubMed:12649176, CC PubMed:14734805, PubMed:33854234). Involved in DNA non-homologous end CC joining (NHEJ) required for double-strand break (DSB) repair and V(D)J CC recombination (PubMed:11955432, PubMed:12649176, PubMed:14734805, CC PubMed:33854234, PubMed:34352203). Must be bound to DNA to express its CC catalytic properties (PubMed:11955432). Promotes processing of hairpin CC DNA structures in V(D)J recombination by activation of the hairpin CC endonuclease artemis (DCLRE1C) (PubMed:11955432). Recruited by XRCC5 CC and XRCC6 to DNA ends and is required to (1) protect and align broken CC ends of DNA, thereby preventing their degradation, (2) and sequester CC the DSB for repair by NHEJ (PubMed:11955432, PubMed:12649176, CC PubMed:14734805, PubMed:15574326, PubMed:33854234). Acts as a scaffold CC protein to aid the localization of DNA repair proteins to the site of CC damage (PubMed:11955432, PubMed:12649176, PubMed:14734805, CC PubMed:15574326). The assembly of the DNA-PK complex at DNA ends is CC also required for the NHEJ ligation step (PubMed:11955432, CC PubMed:12649176, PubMed:14734805, PubMed:15574326). Found at the ends CC of chromosomes, suggesting a further role in the maintenance of CC telomeric stability and the prevention of chromosomal end fusion (By CC similarity). Also involved in modulation of transcription CC (PubMed:11955432, PubMed:12649176, PubMed:14734805, PubMed:15574326). CC As part of the DNA-PK complex, involved in the early steps of ribosome CC assembly by promoting the processing of precursor rRNA into mature 18S CC rRNA in the small-subunit processome (PubMed:32103174). Binding to U3 CC small nucleolar RNA, recruits PRKDC and XRCC5/Ku86 to the small-subunit CC processome (PubMed:32103174). Recognizes the substrate consensus CC sequence [ST]-Q (PubMed:11955432, PubMed:12649176, PubMed:14734805, CC PubMed:15574326). Phosphorylates 'Ser-139' of histone variant H2AX, CC thereby regulating DNA damage response mechanism (PubMed:14627815, CC PubMed:16046194). Phosphorylates ASF1A, DCLRE1C, c-Abl/ABL1, histone CC H1, HSPCA, c-jun/JUN, p53/TP53, PARP1, POU2F1, DHX9, FH, SRF, CC NHEJ1/XLF, XRCC1, XRCC4, XRCC5, XRCC6, WRN, MYC and RFA2 CC (PubMed:10026262, PubMed:10467406, PubMed:11889123, PubMed:12509254, CC PubMed:14599745, PubMed:14612514, PubMed:14704337, PubMed:15177042, CC PubMed:1597196, PubMed:16397295, PubMed:18644470, PubMed:2247066, CC PubMed:2507541, PubMed:26237645, PubMed:26666690, PubMed:28712728, CC PubMed:29478807, PubMed:30247612, PubMed:8407951, PubMed:8464713, CC PubMed:9139719, PubMed:9362500). Can phosphorylate C1D not only in the CC presence of linear DNA but also in the presence of supercoiled DNA CC (PubMed:9679063). Ability to phosphorylate p53/TP53 in the presence of CC supercoiled DNA is dependent on C1D (PubMed:9363941). Acts as a CC regulator of the phosphatidylinositol 3-kinase/protein kinase B signal CC transduction by mediating phosphorylation of 'Ser-473' of protein CC kinase B (PKB/AKT1, PKB/AKT2, PKB/AKT3), promoting their activation CC (PubMed:15262962). Contributes to the determination of the circadian CC period length by antagonizing phosphorylation of CRY1 'Ser-588' and CC increasing CRY1 protein stability, most likely through an indirect CC mechanism (By similarity). Plays a role in the regulation of DNA virus- CC mediated innate immune response by assembling into the HDP-RNP complex, CC a complex that serves as a platform for IRF3 phosphorylation and CC subsequent innate immune response activation through the cGAS-STING CC pathway (PubMed:28712728). Also regulates the cGAS-STING pathway by CC catalyzing phosphorylation of CGAS, thereby impairing CGAS CC oligomerization and activation (PubMed:33273464). Also regulates the CC cGAS-STING pathway by mediating phosphorylation of PARP1 CC (PubMed:35460603). {ECO:0000250|UniProtKB:P97313, CC ECO:0000269|PubMed:10026262, ECO:0000269|PubMed:10467406, CC ECO:0000269|PubMed:11889123, ECO:0000269|PubMed:11955432, CC ECO:0000269|PubMed:12509254, ECO:0000269|PubMed:12649176, CC ECO:0000269|PubMed:14599745, ECO:0000269|PubMed:14612514, CC ECO:0000269|PubMed:14627815, ECO:0000269|PubMed:14704337, CC ECO:0000269|PubMed:14734805, ECO:0000269|PubMed:15177042, CC ECO:0000269|PubMed:15262962, ECO:0000269|PubMed:15574326, CC ECO:0000269|PubMed:1597196, ECO:0000269|PubMed:16046194, CC ECO:0000269|PubMed:16397295, ECO:0000269|PubMed:18644470, CC ECO:0000269|PubMed:2247066, ECO:0000269|PubMed:2507541, CC ECO:0000269|PubMed:26237645, ECO:0000269|PubMed:26666690, CC ECO:0000269|PubMed:28712728, ECO:0000269|PubMed:29478807, CC ECO:0000269|PubMed:30247612, ECO:0000269|PubMed:32103174, CC ECO:0000269|PubMed:33273464, ECO:0000269|PubMed:33854234, CC ECO:0000269|PubMed:34352203, ECO:0000269|PubMed:35460603, CC ECO:0000269|PubMed:8407951, ECO:0000269|PubMed:8464713, CC ECO:0000269|PubMed:9139719, ECO:0000269|PubMed:9362500, CC ECO:0000269|PubMed:9363941, ECO:0000269|PubMed:9679063}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:15262962, ECO:0000269|PubMed:29478807, CC ECO:0000269|PubMed:32103174}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:15262962, ECO:0000269|PubMed:29478807, CC ECO:0000269|PubMed:32103174}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:26237645, ECO:0000269|PubMed:32103174, CC ECO:0000269|PubMed:35460603}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609; CC Evidence={ECO:0000269|PubMed:26237645, ECO:0000269|PubMed:32103174, CC ECO:0000269|PubMed:35460603}; CC -!- ACTIVITY REGULATION: Activity seems to be attenuated by CC autophosphorylation. Binding to the SL1 region of U3 small nucleolar CC RNA promotes auto-phosphorylation activity (PubMed:32103174). Inhibited CC by wortmannin (PubMed:9766667). {ECO:0000269|PubMed:32103174, CC ECO:0000269|PubMed:9766667}. CC -!- SUBUNIT: DNA-PK is a heterotrimer of PRKDC and the Ku dimer (composed CC of XRCC6/Ku70 and XRCC5/Ku86) (PubMed:15758953, PubMed:25670504). CC Formation of this complex may be promoted by interaction with ILF3 CC (PubMed:9442054). Component of the core long-range non-homologous end CC joining (NHEJ) complex (also named DNA-PK complex) composed of PRKDC, CC LIG4, XRCC4, XRCC6/Ku70, XRCC5/Ku86 and NHEJ1/XLF (PubMed:15758953, CC PubMed:25670504, PubMed:33854234, PubMed:34352203). Additional CC component of the NHEJ complex includes PAXX (PubMed:25574025, CC PubMed:25941166). Following autophosphorylation, PRKDC dissociates from CC DNA (PubMed:33854234). Interacts with DNA-PKcs-interacting protein CC (KIP) with the region upstream the kinase domain (PubMed:9372844). CC PRKDC alone also interacts with and phosphorylates DCLRE1C, thereby CC activating the latent endonuclease activity of this protein CC (PubMed:11955432, PubMed:14744996, PubMed:15071507, PubMed:15456891, CC PubMed:15574326, PubMed:15811628, PubMed:15936993). Interacts with C1D CC (PubMed:9679063). Interacts with TTI1 and TELO2 (PubMed:20427287, CC PubMed:20801936, PubMed:20810650). Interacts with CIB1 CC (PubMed:9372844). Interacts with SETX (PubMed:23149945). Interacts with CC NR4A3; the DNA-dependent protein kinase complex DNA-PK phosphorylates CC and activates NR4A3 and prevents NR4A3 ubiquitination and degradation CC (PubMed:25852083). Interacts with BRAT1 (PubMed:22977523). Part of the CC HDP-RNP complex composed of at least HEXIM1, PRKDC, XRCC5, XRCC6, CC paraspeckle proteins (SFPQ, NONO, PSPC1, RBM14, and MATR3) and NEAT1 CC RNA (PubMed:28712728). Interacts with KAT5 (PubMed:32832608). CC {ECO:0000269|PubMed:11955432, ECO:0000269|PubMed:14744996, CC ECO:0000269|PubMed:15071507, ECO:0000269|PubMed:15456891, CC ECO:0000269|PubMed:15574326, ECO:0000269|PubMed:15758953, CC ECO:0000269|PubMed:15811628, ECO:0000269|PubMed:15936993, CC ECO:0000269|PubMed:20427287, ECO:0000269|PubMed:20801936, CC ECO:0000269|PubMed:20810650, ECO:0000269|PubMed:22977523, CC ECO:0000269|PubMed:23149945, ECO:0000269|PubMed:25574025, CC ECO:0000269|PubMed:25670504, ECO:0000269|PubMed:25852083, CC ECO:0000269|PubMed:25941166, ECO:0000269|PubMed:28712728, CC ECO:0000269|PubMed:32832608, ECO:0000269|PubMed:33854234, CC ECO:0000269|PubMed:34352203, ECO:0000269|PubMed:9372844, CC ECO:0000269|PubMed:9442054, ECO:0000269|PubMed:9679063}. CC -!- INTERACTION: CC P78527; O43918: AIRE; NbExp=2; IntAct=EBI-352053, EBI-1753081; CC P78527; P10275: AR; NbExp=3; IntAct=EBI-352053, EBI-608057; CC P78527; Q96SD1: DCLRE1C; NbExp=5; IntAct=EBI-352053, EBI-11694104; CC P78527; P14921: ETS1; NbExp=2; IntAct=EBI-352053, EBI-913209; CC P78527; P50549: ETV1; NbExp=2; IntAct=EBI-352053, EBI-3905068; CC P78527; P09629: HOXB7; NbExp=2; IntAct=EBI-352053, EBI-1248457; CC P78527; Q9BPZ7: MAPKAP1; NbExp=2; IntAct=EBI-352053, EBI-749938; CC P78527; Q96RI1-2: NR1H4; NbExp=4; IntAct=EBI-352053, EBI-9640524; CC P78527; P10276: RARA; NbExp=3; IntAct=EBI-352053, EBI-413374; CC P78527; P17947: SPI1; NbExp=2; IntAct=EBI-352053, EBI-2293548; CC P78527; P13010: XRCC5; NbExp=9; IntAct=EBI-352053, EBI-357997; CC P78527; P12956: XRCC6; NbExp=8; IntAct=EBI-352053, EBI-353208; CC P78527; P61981: YWHAG; NbExp=2; IntAct=EBI-352053, EBI-359832; CC P78527; P25490: YY1; NbExp=2; IntAct=EBI-352053, EBI-765538; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12231622, CC ECO:0000269|PubMed:14734805, ECO:0000269|PubMed:15262962, CC ECO:0000269|PubMed:22002106}. Nucleus, nucleolus CC {ECO:0000269|PubMed:22002106, ECO:0000269|PubMed:32103174}. Cytoplasm, CC cytosol {ECO:0000269|PubMed:15262962}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P78527-1; Sequence=Displayed; CC Name=2; CC IsoId=P78527-2; Sequence=VSP_004708; CC -!- PTM: Autophosphorylated at two clusters, the T2609 cluster and the CC S2056 cluster (PubMed:33854234). Autophosphorylated on Ser-2056, Thr- CC 2609, Thr-2638 and Thr-2647 (PubMed:12186630, PubMed:12231622, CC PubMed:14734805, PubMed:33854234). Ser-2056 and Thr-2609 are DNA CC damage-inducible phosphorylation sites (inducible with ionizing CC radiation, IR) dephosphorylated by PPP5C (PubMed:12186630, CC PubMed:12231622, PubMed:14734805). Autophosphorylation induces a CC conformational change that leads to remodeling of the DNA-PK complex, CC requisite for efficient end processing and DNA repair (PubMed:12186630, CC PubMed:12231622, PubMed:14734805). Autophosphorylation in trans within CC DNA-PK complexes loaded on DNA ends leads to the dissociation of PRKDC CC from DNA and the transition into the short-range NHEJ complex CC (PubMed:33854234). Autophosphorylation of the T2609 cluster is required CC for hematopoietic development and protein synthesis in erythrocytes CC precursors (By similarity). {ECO:0000250|UniProtKB:P97313, CC ECO:0000269|PubMed:12186630, ECO:0000269|PubMed:12231622, CC ECO:0000269|PubMed:14734805, ECO:0000269|PubMed:33854234}. CC -!- PTM: S-nitrosylated by GAPDH. {ECO:0000250|UniProtKB:P97313}. CC -!- PTM: Polyubiquitinated by RNF144A, leading to proteasomal degradation. CC {ECO:0000269|PubMed:24979766}. CC -!- DISEASE: Immunodeficiency 26 with or without neurologic abnormalities CC (IMD26) [MIM:615966]: A form of severe combined immunodeficiency CC characterized by reduced or absent T and B cells, recurrent CC candidiasis, and lower respiratory tract infections. Some patients show CC dysmorphic features, severe growth failure, microcephaly, seizures, and CC impaired neurological functions. {ECO:0000269|PubMed:19075392, CC ECO:0000269|PubMed:23722905}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U47077; AAB39925.5; -; mRNA. DR EMBL; U34994; AAC50210.3; -; mRNA. DR EMBL; AY316117; AAP69525.1; -; Genomic_DNA. DR EMBL; U63630; AAC52019.2; -; Genomic_DNA. DR EMBL; U90415; AAB51722.1; -; Genomic_DNA. DR EMBL; L27425; AAA79244.1; -; Genomic_DNA. DR EMBL; AB052953; BAB79635.1; -; Genomic_DNA. DR EMBL; U35835; AAA79184.1; -; mRNA. DR EMBL; AY030284; AAK40350.1; -; Genomic_DNA. DR EMBL; AB208860; BAD92097.1; -; mRNA. DR CCDS; CCDS75734.1; -. [P78527-2] DR CCDS; CCDS75735.1; -. [P78527-1] DR PIR; A57099; A57099. DR PIR; G02083; G02083. DR RefSeq; NP_001075109.1; NM_001081640.2. [P78527-2] DR RefSeq; NP_008835.5; NM_006904.6. [P78527-1] DR PDB; 5LUQ; X-ray; 4.30 A; A/B=2-2575, A/B=2774-4127. DR PDB; 5W1R; EM; 4.40 A; A=1-4128. DR PDB; 5Y3R; EM; 6.60 A; C=10-4128. DR PDB; 6ZFP; EM; 3.24 A; A=1-4128. DR PDB; 6ZH2; EM; 3.92 A; A=1-4128. DR PDB; 6ZH4; EM; 3.62 A; A=1-4128. DR PDB; 6ZH6; EM; 3.93 A; A=1-4128. DR PDB; 6ZH8; EM; 4.14 A; A=1-4128. DR PDB; 6ZHA; EM; 3.91 A; A=1-4128. DR PDB; 6ZHE; EM; 7.24 A; A/F=1-4128. DR PDB; 7K0Y; EM; 3.70 A; A=1-4128. DR PDB; 7K10; EM; 3.30 A; A=1-4128. DR PDB; 7K11; EM; 3.21 A; A=1-4128. DR PDB; 7K19; EM; 4.30 A; A=1-4128. DR PDB; 7K1B; EM; 4.30 A; A=1-4128. DR PDB; 7K1J; EM; 3.90 A; A=1-4128. DR PDB; 7K1K; EM; 4.10 A; A=1-4128. DR PDB; 7K1N; EM; 3.90 A; A=1-4128. DR PDB; 7LT3; EM; 4.60 A; C/L=1-4128. DR PDB; 7NFC; EM; 4.14 A; A/F=1-4128. DR PDB; 7NFE; EM; 4.29 A; A=1-4128. DR PDB; 7OTM; EM; 3.33 A; A=1-4128. DR PDB; 7OTP; EM; 3.40 A; A=1-4128. DR PDB; 7OTV; EM; 3.24 A; A=1-4128. DR PDB; 7OTW; EM; 2.99 A; A=1-4128. DR PDB; 7OTY; EM; 2.96 A; A=1-4128. DR PDB; 7SGL; EM; 3.00 A; A=1-4128. DR PDB; 7SU3; EM; 3.30 A; A=1-4128. DR PDB; 7SUD; EM; 3.60 A; A=1-4128. DR PDB; 7TYR; EM; 3.33 A; A=1-4128. DR PDB; 7Z87; EM; 2.91 A; A=1-4128. DR PDB; 7Z88; EM; 3.33 A; A=1-4128. DR PDB; 8BH3; EM; 4.55 A; A/S=1-4128. DR PDB; 8BHV; EM; 4.51 A; A/F=1-4128. DR PDB; 8BHY; EM; 5.33 A; A/S=1-4128. DR PDB; 8BOT; EM; 7.76 A; A/F/S=1-4128. DR PDB; 8EZ9; EM; 5.67 A; C/L=1-4128. DR PDB; 8EZA; EM; 4.39 A; C/L=1-4128. DR PDB; 8EZB; EM; 8.90 A; C/L=1-4128. DR PDB; 8RD4; EM; 3.58 A; A=1-4128. DR PDB; 9G9L; EM; 4.63 A; A=1-4128. DR PDB; 9GD7; EM; 4.25 A; S=1-4128. DR PDBsum; 5LUQ; -. DR PDBsum; 5W1R; -. DR PDBsum; 5Y3R; -. DR PDBsum; 6ZFP; -. DR PDBsum; 6ZH2; -. DR PDBsum; 6ZH4; -. DR PDBsum; 6ZH6; -. DR PDBsum; 6ZH8; -. DR PDBsum; 6ZHA; -. DR PDBsum; 6ZHE; -. DR PDBsum; 7K0Y; -. DR PDBsum; 7K10; -. DR PDBsum; 7K11; -. DR PDBsum; 7K19; -. DR PDBsum; 7K1B; -. DR PDBsum; 7K1J; -. DR PDBsum; 7K1K; -. DR PDBsum; 7K1N; -. DR PDBsum; 7LT3; -. DR PDBsum; 7NFC; -. DR PDBsum; 7NFE; -. DR PDBsum; 7OTM; -. DR PDBsum; 7OTP; -. DR PDBsum; 7OTV; -. DR PDBsum; 7OTW; -. DR PDBsum; 7OTY; -. DR PDBsum; 7SGL; -. DR PDBsum; 7SU3; -. DR PDBsum; 7SUD; -. DR PDBsum; 7TYR; -. DR PDBsum; 7Z87; -. DR PDBsum; 7Z88; -. DR PDBsum; 8BH3; -. DR PDBsum; 8BHV; -. DR PDBsum; 8BHY; -. DR PDBsum; 8BOT; -. DR PDBsum; 8EZ9; -. DR PDBsum; 8EZA; -. DR PDBsum; 8EZB; -. DR PDBsum; 8RD4; -. DR PDBsum; 9G9L; -. DR PDBsum; 9GD7; -. DR EMDB; EMD-11185; -. DR EMDB; EMD-11211; -. DR EMDB; EMD-11213; -. DR EMDB; EMD-11215; -. DR EMDB; EMD-11216; -. DR EMDB; EMD-11217; -. DR EMDB; EMD-11219; -. DR EMDB; EMD-12299; -. DR EMDB; EMD-12301; -. DR EMDB; EMD-13062; -. DR EMDB; EMD-13064; -. DR EMDB; EMD-13067; -. DR EMDB; EMD-13068; -. DR EMDB; EMD-13069; -. DR EMDB; EMD-14545; -. DR EMDB; EMD-14546; -. DR EMDB; EMD-16044; -. DR EMDB; EMD-16070; -. DR EMDB; EMD-16074; -. DR EMDB; EMD-16145; -. DR EMDB; EMD-19065; -. DR EMDB; EMD-22618; -. DR EMDB; EMD-22619; -. DR EMDB; EMD-22620; -. DR EMDB; EMD-22622; -. DR EMDB; EMD-22623; -. DR EMDB; EMD-22624; -. DR EMDB; EMD-22625; -. DR EMDB; EMD-22626; -. DR EMDB; EMD-23510; -. DR EMDB; EMD-23511; -. DR EMDB; EMD-25113; -. DR EMDB; EMD-25114; -. DR EMDB; EMD-25115; -. DR EMDB; EMD-25439; -. DR EMDB; EMD-25440; -. DR EMDB; EMD-26192; -. DR EMDB; EMD-26198; -. DR EMDB; EMD-28731; -. DR EMDB; EMD-28732; -. DR EMDB; EMD-28733; -. DR EMDB; EMD-28734; -. DR EMDB; EMD-28735; -. DR EMDB; EMD-28737; -. DR EMDB; EMD-28738; -. DR EMDB; EMD-51156; -. DR EMDB; EMD-51249; -. DR EMDB; EMD-5831; -. DR EMDB; EMD-5832; -. DR EMDB; EMD-5833; -. DR EMDB; EMD-6803; -. DR EMDB; EMD-8751; -. DR EMDB; EMD-8752; -. DR SASBDB; P78527; -. DR SMR; P78527; -. DR BioGRID; 111577; 791. DR ComplexPortal; CPX-3403; DNA-dependent protein kinase complex. DR CORUM; P78527; -. DR DIP; DIP-24186N; -. DR ELM; P78527; -. DR FunCoup; P78527; 3427. DR IntAct; P78527; 304. DR MINT; P78527; -. DR STRING; 9606.ENSP00000313420; -. DR BindingDB; P78527; -. DR ChEMBL; CHEMBL3142; -. DR DrugBank; DB07453; alpha-Naphthoflavone. DR DrugBank; DB16834; AZD-7648. DR DrugBank; DB00201; Caffeine. DR DrugBank; DB16252; Nedisertib. DR DrugBank; DB17047; PIK-75. DR DrugBank; DB08052; PP-121. DR DrugBank; DB05210; SF1126. DR DrugCentral; P78527; -. DR GuidetoPHARMACOLOGY; 2800; -. DR CarbonylDB; P78527; -. DR GlyConnect; 1183; 1 N-Linked glycan (1 site). DR GlyCosmos; P78527; 9 sites, 3 glycans. DR GlyGen; P78527; 17 sites, 5 N-linked glycans (8 sites), 2 O-linked glycans (9 sites). DR iPTMnet; P78527; -. DR MetOSite; P78527; -. DR PhosphoSitePlus; P78527; -. DR SwissPalm; P78527; -. DR BioMuta; PRKDC; -. DR DMDM; 38258929; -. DR CPTAC; CPTAC-2931; -. DR jPOST; P78527; -. DR MassIVE; P78527; -. DR PaxDb; 9606-ENSP00000313420; -. DR PeptideAtlas; P78527; -. DR ProteomicsDB; 57634; -. [P78527-1] DR ProteomicsDB; 57635; -. [P78527-2] DR Pumba; P78527; -. DR Antibodypedia; 52433; 1580 antibodies from 45 providers. DR DNASU; 5591; -. DR Ensembl; ENST00000314191.7; ENSP00000313420.3; ENSG00000253729.10. [P78527-1] DR Ensembl; ENST00000338368.7; ENSP00000345182.4; ENSG00000253729.10. [P78527-2] DR GeneID; 5591; -. DR KEGG; hsa:5591; -. DR MANE-Select; ENST00000314191.7; ENSP00000313420.3; NM_006904.7; NP_008835.5. DR UCSC; uc033bkh.1; human. [P78527-1] DR AGR; HGNC:9413; -. DR CIViC; 5591; 1 evidence item across 1 molecular profile. DR ClinPGx; PA33776; -. DR CTD; 5591; -. DR DisGeNET; 5591; -. DR GeneCards; PRKDC; -. DR HGNC; HGNC:9413; PRKDC. DR HPA; ENSG00000253729; Low tissue specificity. DR MalaCards; PRKDC; -. DR MIM; 600899; gene. DR MIM; 615966; phenotype. DR OpenTargets; ENSG00000253729; -. DR Orphanet; 317425; Severe combined immunodeficiency due to DNA-PKcs deficiency. DR VEuPathDB; HostDB:ENSG00000253729; -. DR eggNOG; KOG0891; Eukaryota. DR GeneTree; ENSGT00940000155633; -. DR HOGENOM; CLU_224534_0_0_1; -. DR InParanoid; P78527; -. DR OMA; PSPMCRE; -. DR OrthoDB; 431717at2759; -. DR PAN-GO; P78527; 7 GO annotations based on evolutionary models. DR PhylomeDB; P78527; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; P78527; -. DR Reactome; R-HSA-1834949; Cytosolic sensors of pathogen-associated DNA. DR Reactome; R-HSA-3270619; IRF3-mediated induction of type I IFN. DR Reactome; R-HSA-5693571; Nonhomologous End-Joining (NHEJ). DR Reactome; R-HSA-8866654; E3 ubiquitin ligases ubiquitinate target proteins. DR SignaLink; P78527; -. DR SIGNOR; P78527; -. DR Agora; ENSG00000253729; -. DR BioGRID-ORCS; 5591; 69 hits in 380 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; A0DCDA94; DNA damage foci. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; PRKDC; human. DR GeneWiki; DNA-PKcs; -. DR GenomeRNAi; 5591; -. DR Pharos; P78527; Tchem. DR PRO; PR:P78527; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; P78527; protein. DR Bgee; ENSG00000253729; Expressed in ventricular zone and 206 other cell types or tissues. DR ExpressionAtlas; P78527; baseline and differential. DR GO; GO:0000785; C:chromatin; IDA:UniProt. DR GO; GO:0000781; C:chromosome, telomeric region; HDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0070418; C:DNA-dependent protein kinase complex; IPI:ComplexPortal. DR GO; GO:0005958; C:DNA-dependent protein kinase-DNA ligase 4 complex; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0070419; C:nonhomologous end joining complex; IDA:UniProtKB. DR GO; GO:0005730; C:nucleolus; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0032991; C:protein-containing complex; IMP:CAFA. DR GO; GO:0032993; C:protein-DNA complex; IDA:CAFA. DR GO; GO:0032040; C:small-subunit processome; IDA:UniProtKB. DR GO; GO:0005667; C:transcription regulator complex; IDA:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004677; F:DNA-dependent protein kinase activity; IDA:MGI. DR GO; GO:0003690; F:double-stranded DNA binding; IDA:CAFA. DR GO; GO:0019899; F:enzyme binding; IEA:Ensembl. DR GO; GO:0035979; F:histone H2AXS139 kinase activity; IDA:UniProtKB. DR GO; GO:0019904; F:protein domain specific binding; IPI:CAFA. DR GO; GO:0004672; F:protein kinase activity; IDA:CACAO. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0003723; F:RNA binding; HDA:UniProtKB. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:BHF-UCL. DR GO; GO:0034511; F:U3 snoRNA binding; IDA:UniProtKB. DR GO; GO:0002218; P:activation of innate immune response; IDA:UniProtKB. DR GO; GO:0002326; P:B cell lineage commitment; IEA:Ensembl. DR GO; GO:0007420; P:brain development; IEA:Ensembl. DR GO; GO:0032869; P:cellular response to insulin stimulus; IMP:BHF-UCL. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0006302; P:double-strand break repair; IMP:BHF-UCL. DR GO; GO:0097681; P:double-strand break repair via alternative nonhomologous end joining; TAS:BHF-UCL. DR GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; TAS:Reactome. DR GO; GO:0035234; P:ectopic germ cell programmed cell death; IEA:Ensembl. DR GO; GO:0007507; P:heart development; IEA:Ensembl. DR GO; GO:0002327; P:immature B cell differentiation; IEA:Ensembl. DR GO; GO:0033152; P:immunoglobulin V(D)J recombination; IBA:GO_Central. DR GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IBA:GO_Central. DR GO; GO:0000460; P:maturation of 5.8S rRNA; IDA:UniProtKB. DR GO; GO:0031571; P:mitotic G1 DNA damage checkpoint signaling; IMP:UniProtKB. DR GO; GO:0043066; P:negative regulation of apoptotic process; IMP:CACAO. DR GO; GO:0160049; P:negative regulation of cGAS/STING signaling pathway; IDA:UniProt. DR GO; GO:0001933; P:negative regulation of protein phosphorylation; ISS:UniProtKB. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:UniProtKB. DR GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl. DR GO; GO:2001034; P:positive regulation of double-strand break repair via nonhomologous end joining; IDA:UniProtKB. DR GO; GO:0045648; P:positive regulation of erythrocyte differentiation; ISS:UniProtKB. DR GO; GO:0045621; P:positive regulation of lymphocyte differentiation; ISS:UniProtKB. DR GO; GO:1905221; P:positive regulation of platelet formation; ISS:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL. DR GO; GO:0045727; P:positive regulation of translation; ISS:UniProtKB. DR GO; GO:0002328; P:pro-B cell differentiation; IEA:Ensembl. DR GO; GO:0031648; P:protein destabilization; IEA:Ensembl. DR GO; GO:0036211; P:protein modification process; TAS:ProtInc. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB. DR GO; GO:0050678; P:regulation of epithelial cell proliferation; IMP:BHF-UCL. DR GO; GO:1902036; P:regulation of hematopoietic stem cell differentiation; ISS:UniProtKB. DR GO; GO:0048660; P:regulation of smooth muscle cell proliferation; IMP:UniProtKB. DR GO; GO:0010332; P:response to gamma radiation; IEA:Ensembl. DR GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW. DR GO; GO:0034462; P:small-subunit processome assembly; IDA:UniProtKB. DR GO; GO:0001756; P:somitogenesis; IEA:Ensembl. DR GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl. DR GO; GO:0002360; P:T cell lineage commitment; IEA:Ensembl. DR GO; GO:0033153; P:T cell receptor V(D)J recombination; IEA:Ensembl. DR GO; GO:0016233; P:telomere capping; IMP:BHF-UCL. DR GO; GO:0000723; P:telomere maintenance; IBA:GO_Central. DR CDD; cd05172; PIKKc_DNA-PK; 1. DR FunFam; 1.10.1070.11:FF:000018; DNA-dependent protein kinase catalytic subunit; 1. DR FunFam; 1.25.10.10:FF:000380; DNA-dependent protein kinase catalytic subunit; 1. DR FunFam; 3.30.1010.10:FF:000013; Protein kinase, DNA-activated, catalytic subunit; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1. DR Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1. DR Gene3D; 3.30.1010.10; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 4; 1. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR050517; DDR_Repair_Kinase. DR InterPro; IPR037706; DNA-PK_dom. DR InterPro; IPR046804; DNA-PKcs_N. DR InterPro; IPR046803; DNAPKcs_CC1-2. DR InterPro; IPR012582; DNAPKcs_CC3. DR InterPro; IPR045581; DNAPKcs_CC5. DR InterPro; IPR003152; FATC_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR036940; PI3/4_kinase_cat_sf. DR InterPro; IPR018936; PI3/4_kinase_CS. DR InterPro; IPR003151; PIK-rel_kinase_FAT. DR InterPro; IPR014009; PIK_FAT. DR PANTHER; PTHR11139; ATAXIA TELANGIECTASIA MUTATED ATM -RELATED; 1. DR PANTHER; PTHR11139:SF68; DNA-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT; 1. DR Pfam; PF20500; DNA-PKcs_N; 1. DR Pfam; PF20502; DNAPKcs_CC1-2; 1. DR Pfam; PF08163; DNAPKcs_CC3; 1. DR Pfam; PF19704; DNAPKcs_CC5; 1. DR Pfam; PF02259; FAT; 1. DR Pfam; PF02260; FATC; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR SMART; SM01343; FATC; 1. DR SMART; SM01344; NUC194; 1. DR SMART; SM00146; PI3Kc; 1. DR SUPFAM; SSF48371; ARM repeat; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51189; FAT; 1. DR PROSITE; PS51190; FATC; 1. DR PROSITE; PS00915; PI3_4_KINASE_1; 1. DR PROSITE; PS00916; PI3_4_KINASE_2; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ATP-binding; KW Biological rhythms; Cytoplasm; Disease variant; DNA damage; KW DNA recombination; DNA repair; DNA-binding; Immunity; Innate immunity; KW Kinase; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; Ribosome biogenesis; KW SCID; Serine/threonine-protein kinase; TPR repeat; Transferase; KW Ubl conjugation. FT CHAIN 1..4128 FT /note="DNA-dependent protein kinase catalytic subunit" FT /id="PRO_0000225598" FT REPEAT 288..323 FT /note="HEAT 1" FT REPEAT 1004..1040 FT /note="HEAT 2" FT REPEAT 1723..1756 FT /note="TPR 1" FT DOMAIN 2906..3539 FT /note="FAT" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534" FT REPEAT 2920..2948 FT /note="TPR 2" FT REPEAT 2949..2982 FT /note="TPR 3" FT DOMAIN 3722..4053 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT DOMAIN 4096..4128 FT /note="FATC" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534, FT ECO:0000255|PROSITE-ProRule:PRU00535" FT REGION 1503..1538 FT /note="Interaction with C1D" FT /evidence="ECO:0000269|PubMed:9679063" FT REGION 1503..1538 FT /note="Leucine-zipper" FT REGION 2050..2073 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2436..3212 FT /note="KIP-binding" FT /evidence="ECO:0000269|PubMed:9372844" FT REGION 2737..2765 FT /note="May split the end of the DNA molecule, with the two FT strands separating around the region" FT /evidence="ECO:0000269|PubMed:34352203" FT REGION 3200..3222 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 3728..3734 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 3919..3927 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 3939..3964 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT SITE 2020..2021 FT /note="Cleavage; by caspase-3" FT /evidence="ECO:0000269|PubMed:8804412" FT MOD_RES 117 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 511 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 687 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 828 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 841 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 893 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 1065 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1209 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 1970 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 2056 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14734805, FT ECO:0000269|PubMed:22977523, ECO:0000269|PubMed:34352203" FT MOD_RES 2259 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 2535 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2609 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12186630, FT ECO:0000269|PubMed:12231622, ECO:0000269|PubMed:14734805, FT ECO:0000269|PubMed:32103174, ECO:0000269|PubMed:34352203" FT MOD_RES 2612 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12186630, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 2638 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12186630, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2647 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12186630, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2789 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 3205 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 3241 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 3260 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 3621 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 3638 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 3642 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 3731 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 3821 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 4026 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 3799..3829 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.10" FT /id="VSP_004708" FT VARIANT 6 FT /note="A -> S (in dbSNP:rs8177999)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_019179" FT VARIANT 263 FT /note="K -> N (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs758032015)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041602" FT VARIANT 333 FT /note="M -> I (in dbSNP:rs8178017)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_019180" FT VARIANT 420 FT /note="V -> I (in dbSNP:rs55925466)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041603" FT VARIANT 500 FT /note="G -> S (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041604" FT VARIANT 605 FT /note="T -> S (in dbSNP:rs8178033)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_019181" FT VARIANT 649 FT /note="F -> L (in dbSNP:rs55811715)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041605" FT VARIANT 680 FT /note="I -> M (in dbSNP:rs8178040)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_019182" FT VARIANT 695 FT /note="P -> S (in dbSNP:rs8178046)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_019183" FT VARIANT 1071 FT /note="N -> S (in dbSNP:rs8178070)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_019184" FT VARIANT 1136 FT /note="R -> H (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs781401034)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041606" FT VARIANT 1190 FT /note="L -> V (in dbSNP:rs34598508)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041607" FT VARIANT 1237 FT /note="A -> T (in dbSNP:rs191531119)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041608" FT VARIANT 1279 FT /note="L -> F" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041609" FT VARIANT 1314 FT /note="G -> V (in dbSNP:rs8178090)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_019185" FT VARIANT 1447 FT /note="R -> M (in a lung squamous cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041610" FT VARIANT 1588 FT /note="D -> V (in dbSNP:rs8178104)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_019186" FT VARIANT 1603 FT /note="Q -> H (in dbSNP:rs8178106)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_019187" FT VARIANT 1619 FT /note="A -> G (in dbSNP:rs56182356)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041611" FT VARIANT 1680 FT /note="A -> V (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs55735910)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041612" FT VARIANT 2023 FT /note="S -> P (in dbSNP:rs56042895)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041613" FT VARIANT 2095 FT /note="A -> V (in dbSNP:rs8178147)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_019188" FT VARIANT 2598 FT /note="R -> Q (in dbSNP:rs55923149)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041614" FT VARIANT 2702 FT /note="K -> E (in dbSNP:rs8178178)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_019189" FT VARIANT 2810 FT /note="S -> N (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041615" FT VARIANT 2899 FT /note="R -> C (in dbSNP:rs4278157)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_019190" FT VARIANT 2941 FT /note="G -> A (in a lung neuroendocrine carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041616" FT VARIANT 3062 FT /note="L -> R (in IMD26; shows increased long palindromic FT (P)-nucleotide stretches in the immunoglobulin coding FT joints indicating a defect in hairpin opening and FT insufficient DCLRE1C activation; dbSNP:rs587777685)" FT /evidence="ECO:0000269|PubMed:19075392" FT /id="VAR_072569" FT VARIANT 3085 FT /note="E -> D (in dbSNP:rs56135402)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041617" FT VARIANT 3149 FT /note="G -> D (in dbSNP:rs8178208)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_019191" FT VARIANT 3198 FT /note="T -> S (in dbSNP:rs55793951)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041618" FT VARIANT 3201 FT /note="P -> S (in dbSNP:rs8178216)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_019192" FT VARIANT 3404 FT /note="G -> E (in dbSNP:rs8178225)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_019193" FT VARIANT 3434 FT /note="I -> T (in dbSNP:rs7830743)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_019194" FT VARIANT 3459 FT /note="N -> S (in dbSNP:rs8178228)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_019195" FT VARIANT 3562 FT /note="L -> M (in dbSNP:rs8178232)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_019196" FT VARIANT 3574 FT /note="A -> V (in IMD26; shows impaired function in FT response to irradiation and a less severe defect in V(D)J FT end-joining suggesting that the missense mutation retained FT some functional capacity; consistent with a loss of FT function mutation; dbSNP:rs587777686)" FT /evidence="ECO:0000269|PubMed:23722905" FT /id="VAR_072570" FT VARIANT 3584 FT /note="L -> F (in dbSNP:rs55866966)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041619" FT VARIANT 3702 FT /note="P -> L (in dbSNP:rs8178236)" FT /id="VAR_050534" FT VARIANT 3800 FT /note="L -> I (in dbSNP:rs56216442)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041620" FT VARIANT 3836 FT /note="P -> L (in dbSNP:rs8178245)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_019197" FT VARIANT 3932 FT /note="M -> V (in dbSNP:rs8178248)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_019198" FT VARIANT 3936 FT /note="G -> S (in dbSNP:rs55670423)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041621" FT VARIANT 3937 FT /note="V -> M (in dbSNP:rs56090750)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041622" FT MUTAGEN 1510 FT /note="L->P: Loss of interaction with C1D." FT /evidence="ECO:0000269|PubMed:9679063" FT MUTAGEN 1516..1517 FT /note="EL->PD: Loss of interaction with C1D." FT /evidence="ECO:0000269|PubMed:9679063" FT MUTAGEN 2609 FT /note="T->A: Leads to radiation sensitivity and impaired FT DSB joining. Gives rise to reduced phosphorylation; when FT associated with A-2612." FT /evidence="ECO:0000269|PubMed:12231622" FT MUTAGEN 2612 FT /note="S->A: Reduced phosphorylation; when associated with FT A-2609." FT MUTAGEN 2638 FT /note="T->A: Alleviates phosphorylation, leaves a fully FT active enzyme with compromised cellular resistance to FT ionizing radiation without affecting DNA end joining; when FT associated with A-2647." FT /evidence="ECO:0000269|PubMed:12649176" FT MUTAGEN 2647 FT /note="T->A: Alleviates phosphorylation, leaves a fully FT active enzyme with compromised cellular resistance to FT ionizing radiation without affecting DNA end joining; when FT associated with A-2638." FT /evidence="ECO:0000269|PubMed:12649176" FT CONFLICT 405 FT /note="D -> Y (in Ref. 2; AAC50210)" FT /evidence="ECO:0000305" FT CONFLICT 1008 FT /note="A -> S (in Ref. 2; AAC50210)" FT /evidence="ECO:0000305" FT CONFLICT 3660 FT /note="N -> T (in Ref. 8; AAA79184)" FT /evidence="ECO:0000305" FT CONFLICT 3817 FT /note="L -> W (in Ref. 8; AAA79184)" FT /evidence="ECO:0000305" FT CONFLICT 3862 FT /note="A -> P (in Ref. 8; AAA79184)" FT /evidence="ECO:0000305" FT CONFLICT 4031 FT /note="I -> V (in Ref. 9; AAK40350)" FT /evidence="ECO:0000305" FT TURN 8..10 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 11..20 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 21..23 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 24..26 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 27..44 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 48..58 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 61..64 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 65..71 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 72..74 FT /evidence="ECO:0007829|PDB:7TYR" FT HELIX 76..78 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 79..95 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 98..103 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 104..117 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 121..137 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 139..141 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 143..146 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 149..159 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 162..164 FT /evidence="ECO:0007829|PDB:7OTW" FT STRAND 165..167 FT /evidence="ECO:0007829|PDB:7OTW" FT STRAND 168..170 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 171..183 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 186..188 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 189..192 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 193..209 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 211..213 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 217..230 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 232..234 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 238..240 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 244..256 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 258..260 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 267..278 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 279..281 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 284..287 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 290..301 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 302..304 FT /evidence="ECO:0007829|PDB:7TYR" FT HELIX 308..329 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 330..332 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 335..350 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 356..376 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 377..379 FT /evidence="ECO:0007829|PDB:6ZFP" FT HELIX 380..383 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 384..386 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 387..396 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 397..399 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 401..403 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 406..409 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 410..421 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 429..431 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 432..444 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 446..448 FT /evidence="ECO:0007829|PDB:7SGL" FT TURN 451..453 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 454..468 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 469..471 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 473..491 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 505..507 FT /evidence="ECO:0007829|PDB:7SGL" FT STRAND 513..518 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 525..527 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 528..534 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 539..541 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 542..544 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 545..547 FT /evidence="ECO:0007829|PDB:7OTW" FT STRAND 552..554 FT /evidence="ECO:0007829|PDB:7OTW" FT HELIX 555..558 FT /evidence="ECO:0007829|PDB:7TYR" FT HELIX 560..577 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 583..585 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 597..600 FT /evidence="ECO:0007829|PDB:7TYR" FT STRAND 609..611 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 612..616 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 617..633 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 634..636 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 639..642 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 643..645 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 646..658 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 666..679 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 680..685 FT /evidence="ECO:0007829|PDB:6ZFP" FT HELIX 689..691 FT /evidence="ECO:0007829|PDB:7TYR" FT HELIX 700..717 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 718..720 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 723..735 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 738..743 FT /evidence="ECO:0007829|PDB:7OTW" FT HELIX 745..747 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 749..758 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 759..761 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 763..779 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 782..784 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 786..788 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 789..792 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 793..795 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 797..799 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 800..804 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 817..822 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 828..838 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 848..861 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 866..869 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 874..876 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 877..881 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 886..889 FT /evidence="ECO:0007829|PDB:7OTY" FT STRAND 893..895 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 904..906 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 907..909 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 911..919 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 924..945 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 946..948 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 951..954 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 959..973 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 978..995 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 998..1002 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1004..1017 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1019..1021 FT /evidence="ECO:0007829|PDB:6ZFP" FT HELIX 1023..1042 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1046..1050 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1053..1055 FT /evidence="ECO:0007829|PDB:7TYR" FT HELIX 1056..1067 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1068..1070 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1072..1085 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1086..1090 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1096..1115 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1119..1121 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 1123..1138 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1139..1141 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1142..1144 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1166..1175 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1181..1194 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1195..1198 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1204..1215 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1219..1222 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1223..1227 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1228..1232 FT /evidence="ECO:0007829|PDB:7OTW" FT TURN 1235..1237 FT /evidence="ECO:0007829|PDB:7OTY" FT STRAND 1239..1242 FT /evidence="ECO:0007829|PDB:6ZFP" FT HELIX 1243..1245 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1248..1250 FT /evidence="ECO:0007829|PDB:7OTW" FT HELIX 1251..1266 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1268..1272 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1274..1276 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 1278..1282 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1283..1286 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 1290..1300 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1301..1303 FT /evidence="ECO:0007829|PDB:7SGL" FT TURN 1309..1311 FT /evidence="ECO:0007829|PDB:7OTY" FT STRAND 1317..1319 FT /evidence="ECO:0007829|PDB:7OTW" FT HELIX 1324..1349 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1351..1353 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1357..1359 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1360..1363 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1366..1376 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1380..1383 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1391..1406 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1409..1411 FT /evidence="ECO:0007829|PDB:7OTW" FT HELIX 1413..1422 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1425..1431 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1432..1435 FT /evidence="ECO:0007829|PDB:7TYR" FT STRAND 1437..1439 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1441..1446 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1447..1461 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1464..1467 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1472..1476 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1478..1489 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1494..1496 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 1505..1521 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1525..1532 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1543..1551 FT /evidence="ECO:0007829|PDB:7TYR" FT HELIX 1557..1562 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1566..1573 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1575..1583 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1584..1588 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1590..1606 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1607..1610 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1613..1624 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1625..1628 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1631..1633 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1634..1637 FT /evidence="ECO:0007829|PDB:7OTW" FT HELIX 1639..1655 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1658..1660 FT /evidence="ECO:0007829|PDB:7OTY" FT STRAND 1665..1667 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1668..1680 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1682..1684 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1686..1693 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1694..1698 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1699..1701 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1704..1706 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1707..1718 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1719..1721 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1724..1726 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1734..1752 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1756..1766 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1769..1771 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1775..1786 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1787..1789 FT /evidence="ECO:0007829|PDB:7SU3" FT HELIX 1791..1806 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1813..1830 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 1832..1834 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 1837..1851 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1857..1859 FT /evidence="ECO:0007829|PDB:7SU3" FT HELIX 1860..1882 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1887..1890 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1891..1893 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1896..1899 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1900..1902 FT /evidence="ECO:0007829|PDB:7SGL" FT STRAND 1906..1908 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 1909..1923 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1931..1933 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 1934..1952 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1959..1961 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 1962..1965 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1967..1969 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 1971..1973 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1974..1976 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 1978..1981 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 1984..1986 FT /evidence="ECO:0007829|PDB:7SGL" FT STRAND 1992..1996 FT /evidence="ECO:0007829|PDB:7SU3" FT HELIX 1999..2013 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 2026..2028 FT /evidence="ECO:0007829|PDB:7SGL" FT TURN 2031..2033 FT /evidence="ECO:0007829|PDB:7TYR" FT HELIX 2035..2047 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 2065..2067 FT /evidence="ECO:0007829|PDB:7TYR" FT STRAND 2086..2089 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2091..2093 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2094..2105 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2106..2110 FT /evidence="ECO:0007829|PDB:7TYR" FT HELIX 2125..2133 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2136..2138 FT /evidence="ECO:0007829|PDB:7TYR" FT HELIX 2140..2152 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2154..2157 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2158..2163 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2166..2173 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 2179..2181 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2185..2195 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 2196..2199 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 2206..2221 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2228..2244 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 2245..2248 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 2256..2260 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2264..2266 FT /evidence="ECO:0007829|PDB:7TYR" FT TURN 2268..2270 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2271..2282 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2292..2294 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 2296..2305 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2306..2308 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2313..2332 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2335..2337 FT /evidence="ECO:0007829|PDB:7OTW" FT HELIX 2338..2353 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 2354..2356 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 2357..2370 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2372..2374 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2375..2385 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2386..2388 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2392..2403 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2404..2407 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 2412..2417 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2420..2425 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2429..2442 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2443..2445 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2448..2459 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 2460..2463 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2467..2481 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2487..2490 FT /evidence="ECO:0007829|PDB:7OTW" FT STRAND 2492..2494 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 2495..2508 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2509..2511 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2517..2526 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 2528..2530 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2535..2543 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2548..2550 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2551..2563 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2566..2570 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2572..2576 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 2581..2583 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 2594..2602 FT /evidence="ECO:0007829|PDB:7SGL" FT STRAND 2634..2636 FT /evidence="ECO:0007829|PDB:7SGL" FT STRAND 2658..2660 FT /evidence="ECO:0007829|PDB:7SU3" FT STRAND 2721..2723 FT /evidence="ECO:0007829|PDB:7SU3" FT HELIX 2736..2766 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2772..2774 FT /evidence="ECO:0007829|PDB:7SGL" FT TURN 2777..2779 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 2788..2798 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2802..2819 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2822..2824 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2826..2846 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2852..2863 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2866..2868 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2873..2882 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2886..2897 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2920..2933 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 2936..2940 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2941..2943 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2945..2947 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2951..2961 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 2965..2976 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 2982..2984 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 2988..3004 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3008..3016 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3017..3019 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3022..3024 FT /evidence="ECO:0007829|PDB:7OTW" FT TURN 3026..3031 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3034..3036 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3037..3040 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3041..3053 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3061..3068 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3069..3072 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3073..3081 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3085..3092 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3096..3115 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3122..3124 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3125..3129 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3132..3146 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3148..3152 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3155..3165 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3171..3173 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3176..3195 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3200..3203 FT /evidence="ECO:0007829|PDB:7TYR" FT HELIX 3206..3210 FT /evidence="ECO:0007829|PDB:7TYR" FT HELIX 3213..3220 FT /evidence="ECO:0007829|PDB:7TYR" FT HELIX 3227..3248 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3252..3260 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3261..3265 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3270..3288 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3289..3291 FT /evidence="ECO:0007829|PDB:7Z88" FT STRAND 3293..3295 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3296..3307 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3308..3310 FT /evidence="ECO:0007829|PDB:7SU3" FT TURN 3312..3318 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3320..3343 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3347..3350 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3353..3355 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3356..3360 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3364..3366 FT /evidence="ECO:0007829|PDB:7OTY" FT TURN 3369..3371 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3372..3393 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3403..3405 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 3410..3428 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3434..3439 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3442..3455 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3459..3462 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3463..3466 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3467..3473 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3477..3479 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3481..3488 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3492..3498 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3499..3502 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3503..3507 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3509..3511 FT /evidence="ECO:0007829|PDB:7SGL" FT TURN 3512..3514 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3515..3524 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3526..3528 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 3530..3538 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3545..3547 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3548..3561 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3563..3566 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3567..3576 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3581..3593 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3594..3598 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3602..3604 FT /evidence="ECO:0007829|PDB:7K10" FT HELIX 3605..3615 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3616..3618 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3621..3626 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3633..3639 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3642..3649 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3651..3653 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3657..3660 FT /evidence="ECO:0007829|PDB:7TYR" FT HELIX 3661..3672 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3681..3683 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3685..3689 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3694..3696 FT /evidence="ECO:0007829|PDB:7OTW" FT STRAND 3707..3709 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3713..3715 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3719..3722 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3730..3733 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3736..3738 FT /evidence="ECO:0007829|PDB:7Z88" FT STRAND 3739..3742 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3743..3745 FT /evidence="ECO:0007829|PDB:7OTY" FT STRAND 3747..3753 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3759..3774 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3775..3777 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3779..3783 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3793..3797 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3800..3804 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3809..3811 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3812..3819 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3822..3829 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3835..3847 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3848..3851 FT /evidence="ECO:0007829|PDB:7Z88" FT HELIX 3854..3860 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3864..3875 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3876..3878 FT /evidence="ECO:0007829|PDB:7K11" FT HELIX 3882..3889 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3890..3893 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 3894..3917 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3927..3931 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3932..3934 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3937..3939 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3945..3947 FT /evidence="ECO:0007829|PDB:7SU3" FT TURN 3949..3951 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3952..3955 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 3959..3961 FT /evidence="ECO:0007829|PDB:6ZFP" FT HELIX 3965..3970 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3971..3973 FT /evidence="ECO:0007829|PDB:7Z87" FT TURN 3976..3978 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 3979..3992 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 3996..4001 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 4004..4007 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 4009..4011 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 4013..4021 FT /evidence="ECO:0007829|PDB:7OTY" FT HELIX 4027..4029 FT /evidence="ECO:0007829|PDB:7SU3" FT STRAND 4030..4032 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 4034..4036 FT /evidence="ECO:0007829|PDB:7K11" FT HELIX 4039..4049 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 4052..4054 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 4056..4068 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 4069..4071 FT /evidence="ECO:0007829|PDB:7SGL" FT HELIX 4074..4082 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 4085..4087 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 4089..4092 FT /evidence="ECO:0007829|PDB:7Z87" FT STRAND 4095..4097 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 4100..4111 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 4114..4117 FT /evidence="ECO:0007829|PDB:7Z87" FT HELIX 4122..4124 FT /evidence="ECO:0007829|PDB:7Z87" SQ SEQUENCE 4128 AA; 469089 MW; AC6E747FEB09F3E5 CRC64; MAGSGAGVRC SLLRLQETLS AADRCGAALA GHQLIRGLGQ ECVLSSSPAV LALQTSLVFS RDFGLLVFVR KSLNSIEFRE CREEILKFLC IFLEKMGQKI APYSVEIKNT CTSVYTKDRA AKCKIPALDL LIKLLQTFRS SRLMDEFKIG ELFSKFYGEL ALKKKIPDTV LEKVYELLGL LGEVHPSEMI NNAENLFRAF LGELKTQMTS AVREPKLPVL AGCLKGLSSL LCNFTKSMEE DPQTSREIFN FVLKAIRPQI DLKRYAVPSA GLRLFALHAS QFSTCLLDNY VSLFEVLLKW CAHTNVELKK AALSALESFL KQVSNMVAKN AEMHKNKLQY FMEQFYGIIR NVDSNNKELS IAIRGYGLFA GPCKVINAKD VDFMYVELIQ RCKQMFLTQT DTGDDRVYQM PSFLQSVASV LLYLDTVPEV YTPVLEHLVV MQIDSFPQYS PKMQLVCCRA IVKVFLALAA KGPVLRNCIS TVVHQGLIRI CSKPVVLPKG PESESEDHRA SGEVRTGKWK VPTYKDYVDL FRHLLSSDQM MDSILADEAF FSVNSSSESL NHLLYDEFVK SVLKIVEKLD LTLEIQTVGE QENGDEAPGV WMIPTSDPAA NLHPAKPKDF SAFINLVEFC REILPEKQAE FFEPWVYSFS YELILQSTRL PLISGFYKLL SITVRNAKKI KYFEGVSPKS LKHSPEDPEK YSCFALFVKF GKEVAVKMKQ YKDELLASCL TFLLSLPHNI IELDVRAYVP ALQMAFKLGL SYTPLAEVGL NALEEWSIYI DRHVMQPYYK DILPCLDGYL KTSALSDETK NNWEVSALSR AAQKGFNKVV LKHLKKTKNL SSNEAISLEE IRIRVVQMLG SLGGQINKNL LTVTSSDEMM KSYVAWDREK RLSFAVPFRE MKPVIFLDVF LPRVTELALT ASDRQTKVAA CELLHSMVMF MLGKATQMPE GGQGAPPMYQ LYKRTFPVLL RLACDVDQVT RQLYEPLVMQ LIHWFTNNKK FESQDTVALL EAILDGIVDP VDSTLRDFCG RCIREFLKWS IKQITPQQQE KSPVNTKSLF KRLYSLALHP NAFKRLGASL AFNNIYREFR EEESLVEQFV FEALVIYMES LALAHADEKS LGTIQQCCDA IDHLCRIIEK KHVSLNKAKK RRLPRGFPPS ASLCLLDLVK WLLAHCGRPQ TECRHKSIEL FYKFVPLLPG NRSPNLWLKD VLKEEGVSFL INTFEGGGCG QPSGILAQPT LLYLRGPFSL QATLCWLDLL LAALECYNTF IGERTVGALQ VLGTEAQSSL LKAVAFFLES IAMHDIIAAE KCFGTGAAGN RTSPQEGERY NYSKCTVVVR IMEFTTTLLN TSPEGWKLLK KDLCNTHLMR VLVQTLCEPA SIGFNIGDVQ VMAHLPDVCV NLMKALKMSP YKDILETHLR EKITAQSIEE LCAVNLYGPD AQVDRSRLAA VVSACKQLHR AGLLHNILPS QSTDLHHSVG TELLSLVYKG IAPGDERQCL PSLDLSCKQL ASGLLELAFA FGGLCERLVS LLLNPAVLST ASLGSSQGSV IHFSHGEYFY SLFSETINTE LLKNLDLAVL ELMQSSVDNT KMVSAVLNGM LDQSFRERAN QKHQGLKLAT TILQHWKKCD SWWAKDSPLE TKMAVLALLA KILQIDSSVS FNTSHGSFPE VFTTYISLLA DTKLDLHLKG QAVTLLPFFT SLTGGSLEEL RRVLEQLIVA HFPMQSREFP PGTPRFNNYV DCMKKFLDAL ELSQSPMLLE LMTEVLCREQ QHVMEELFQS SFRRIARRGS CVTQVGLLES VYEMFRKDDP RLSFTRQSFV DRSLLTLLWH CSLDALREFF STIVVDAIDV LKSRFTKLNE STFDTQITKK MGYYKILDVM YSRLPKDDVH AKESKINQVF HGSCITEGNE LTKTLIKLCY DAFTENMAGE NQLLERRRLY HCAAYNCAIS VICCVFNELK FYQGFLFSEK PEKNLLIFEN LIDLKRRYNF PVEVEVPMER KKKYIEIRKE AREAANGDSD GPSYMSSLSY LADSTLSEEM SQFDFSTGVQ SYSYSSQDPR PATGRFRRRE QRDPTVHDDV LELEMDELNR HECMAPLTAL VKHMHRSLGP PQGEEDSVPR DLPSWMKFLH GKLGNPIVPL NIRLFLAKLV INTEEVFRPY AKHWLSPLLQ LAASENNGGE GIHYMVVEIV ATILSWTGLA TPTGVPKDEV LANRLLNFLM KHVFHPKRAV FRHNLEIIKT LVECWKDCLS IPYRLIFEKF SGKDPNSKDN SVGIQLLGIV MANDLPPYDP QCGIQSSEYF QALVNNMSFV RYKEVYAAAA EVLGLILRYV MERKNILEES LCELVAKQLK QHQNTMEDKF IVCLNKVTKS FPPLADRFMN AVFFLLPKFH GVLKTLCLEV VLCRVEGMTE LYFQLKSKDF VQVMRHRDDE RQKVCLDIIY KMMPKLKPVE LRELLNPVVE FVSHPSTTCR EQMYNILMWI HDNYRDPESE TDNDSQEIFK LAKDVLIQGL IDENPGLQLI IRNFWSHETR LPSNTLDRLL ALNSLYSPKI EVHFLSLATN FLLEMTSMSP DYPNPMFEHP LSECEFQEYT IDSDWRFRST VLTPMFVETQ ASQGTLQTRT QEGSLSARWP VAGQIRATQQ QHDFTLTQTA DGRSSFDWLT GSSTDPLVDH TSPSSDSLLF AHKRSERLQR APLKSVGPDF GKKRLGLPGD EVDNKVKGAA GRTDLLRLRR RFMRDQEKLS LMYARKGVAE QKREKEIKSE LKMKQDAQVV LYRSYRHGDL PDIQIKHSSL ITPLQAVAQR DPIIAKQLFS SLFSGILKEM DKFKTLSEKN NITQKLLQDF NRFLNTTFSF FPPFVSCIQD ISCQHAALLS LDPAAVSAGC LASLQQPVGI RLLEEALLRL LPAELPAKRV RGKARLPPDV LRWVELAKLY RSIGEYDVLR GIFTSEIGTK QITQSALLAE ARSDYSEAAK QYDEALNKQD WVDGEPTEAE KDFWELASLD CYNHLAEWKS LEYCSTASID SENPPDLNKI WSEPFYQETY LPYMIRSKLK LLLQGEADQS LLTFIDKAMH GELQKAILEL HYSQELSLLY LLQDDVDRAK YYIQNGIQSF MQNYSSIDVL LHQSRLTKLQ SVQALTEIQE FISFISKQGN LSSQVPLKRL LNTWTNRYPD AKMDPMNIWD DIITNRCFFL SKIEEKLTPL PEDNSMNVDQ DGDPSDRMEV QEQEEDISSL IRSCKFSMKM KMIDSARKQN NFSLAMKLLK ELHKESKTRD DWLVSWVQSY CRLSHCRSRS QGCSEQVLTV LKTVSLLDEN NVSSYLSKNI LAFRDQNILL GTTYRIIANA LSSEPACLAE IEEDKARRIL ELSGSSSEDS EKVIAGLYQR AFQHLSEAVQ AAEEEAQPPS WSCGPAAGVI DAYMTLADFC DQQLRKEEEN ASVIDSAELQ AYPALVVEKM LKALKLNSNE ARLKFPRLLQ IIERYPEETL SLMTKEISSV PCWQFISWIS HMVALLDKDQ AVAVQHSVEE ITDNYPQAIV YPFIISSESY SFKDTSTGHK NKEFVARIKS KLDQGGVIQD FINALDQLSN PELLFKDWSN DVRAELAKTP VNKKNIEKMY ERMYAALGDP KAPGLGAFRR KFIQTFGKEF DKHFGKGGSK LLRMKLSDFN DITNMLLLKM NKDSKPPGNL KECSPWMSDF KVEFLRNELE IPGQYDGRGK PLPEYHVRIA GFDERVTVMA SLRRPKRIII RGHDEREHPF LVKGGEDLRQ DQRVEQLFQV MNGILAQDSA CSQRALQLRT YSVVPMTSRL GLIEWLENTV TLKDLLLNTM SQEEKAAYLS DPRAPPCEYK DWLTKMSGKH DVGAYMLMYK GANRTETVTS FRKRESKVPA DLLKRAFVRM STSPEAFLAL RSHFASSHAL ICISHWILGI GDRHLNNFMV AMETGGVIGI DFGHAFGSAT QFLPVPELMP FRLTRQFINL MLPMKETGLM YSIMVHALRA FRSDPGLLTN TMDVFVKEPS FDWKNFEQKM LKKGGSWIQE INVAEKNWYP RQKICYAKRK LAGANPAVIT CDELLLGHEK APAFRDYVAV ARGSKDHNIR AQEPESGLSE ETQVKCLMDQ ATDPNILGRT WEGWEPWM // ID PSKH2_HUMAN Reviewed; 385 AA. AC Q96QS6; A0AV22; DT 06-DEC-2005, integrated into UniProtKB/Swiss-Prot. DT 01-DEC-2001, sequence version 1. DT 28-JAN-2026, entry version 174. DE RecName: Full=Serine/threonine-protein kinase H2; DE EC=2.7.11.1; DE AltName: Full=Protein serine kinase H2; DE Short=PSK-H2; GN Name=PSKH2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RA Scharm B.; RL Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [3] RP VARIANTS [LARGE SCALE ANALYSIS] ASP-72; LYS-79; GLN-114; ILE-116; ARG-132; RP GLN-148; SER-176; ARG-211; ILE-212; ALA-225; ARG-266 AND VAL-336. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- INTERACTION: CC Q96QS6; Q16543: CDC37; NbExp=4; IntAct=EBI-6424813, EBI-295634; CC Q96QS6; P07900: HSP90AA1; NbExp=3; IntAct=EBI-6424813, EBI-296047; CC Q96QS6; P08238: HSP90AB1; NbExp=4; IntAct=EBI-6424813, EBI-352572; CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. {ECO:0000305}. CC -!- CAUTION: Asn-183 is present instead of the conserved Asp which is CC expected to be an active site residue. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY037806; AAK59985.1; -; mRNA. DR EMBL; BC126180; AAI26181.1; -; mRNA. DR EMBL; BC126182; AAI26183.1; -; mRNA. DR CCDS; CCDS6240.1; -. DR RefSeq; NP_149117.1; NM_033126.3. DR AlphaFoldDB; Q96QS6; -. DR SMR; Q96QS6; -. DR BioGRID; 124556; 66. DR FunCoup; Q96QS6; 66. DR IntAct; Q96QS6; 65. DR STRING; 9606.ENSP00000276616; -. DR iPTMnet; Q96QS6; -. DR PhosphoSitePlus; Q96QS6; -. DR BioMuta; PSKH2; -. DR DMDM; 74762688; -. DR MassIVE; Q96QS6; -. DR PaxDb; 9606-ENSP00000276616; -. DR PeptideAtlas; Q96QS6; -. DR Antibodypedia; 12608; 117 antibodies from 27 providers. DR DNASU; 85481; -. DR Ensembl; ENST00000276616.3; ENSP00000276616.2; ENSG00000147613.8. DR GeneID; 85481; -. DR KEGG; hsa:85481; -. DR MANE-Select; ENST00000276616.3; ENSP00000276616.2; NM_033126.3; NP_149117.1. DR UCSC; uc011lfy.3; human. DR AGR; HGNC:18997; -. DR ClinPGx; PA134961168; -. DR CTD; 85481; -. DR DisGeNET; 85481; -. DR GeneCards; PSKH2; -. DR HGNC; HGNC:18997; PSKH2. DR HPA; ENSG00000147613; Tissue enriched (retina). DR MIM; 620394; gene. DR VEuPathDB; HostDB:ENSG00000147613; -. DR eggNOG; KOG0032; Eukaryota. DR GeneTree; ENSGT00940000162917; -. DR HOGENOM; CLU_000288_63_0_1; -. DR InParanoid; Q96QS6; -. DR OMA; DHPWVIT; -. DR OrthoDB; 40902at2759; -. DR PAN-GO; Q96QS6; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q96QS6; -. DR PathwayCommons; Q96QS6; -. DR SignaLink; Q96QS6; -. DR BioGRID-ORCS; 85481; 11 hits in 1171 CRISPR screens. DR ChiTaRS; PSKH2; human. DR GenomeRNAi; 85481; -. DR Pharos; Q96QS6; Tdark. DR PRO; PR:Q96QS6; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; Q96QS6; protein. DR Bgee; ENSG00000147613; Expressed in male germ line stem cell (sensu Vertebrata) in testis and 8 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR FunFam; 1.10.510.10:FF:000571; Maternal embryonic leucine zipper kinase; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR PANTHER; PTHR24347; SERINE/THREONINE-PROTEIN KINASE; 1. DR Pfam; PF00069; Pkinase; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW ATP-binding; Kinase; Nucleotide-binding; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase. FT CHAIN 1..385 FT /note="Serine/threonine-protein kinase H2" FT /id="PRO_0000086171" FT DOMAIN 63..320 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 342..367 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 344..359 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 69..77 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 92 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT VARIANT 72 FT /note="G -> D (in dbSNP:rs56407605)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040615" FT VARIANT 79 FT /note="R -> K (in dbSNP:rs35315725)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040616" FT VARIANT 114 FT /note="R -> Q (in dbSNP:rs35915498)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040617" FT VARIANT 116 FT /note="S -> I (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040618" FT VARIANT 132 FT /note="Q -> R (in dbSNP:rs16879427)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040619" FT VARIANT 148 FT /note="R -> Q (in dbSNP:rs56356246)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040620" FT VARIANT 176 FT /note="A -> S (in dbSNP:rs6998760)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040621" FT VARIANT 211 FT /note="G -> R (in dbSNP:rs36074412)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040622" FT VARIANT 212 FT /note="K -> I (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs778066815)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040623" FT VARIANT 225 FT /note="T -> A (in dbSNP:rs34457516)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040624" FT VARIANT 266 FT /note="S -> R (in dbSNP:rs34037815)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040625" FT VARIANT 336 FT /note="I -> V (in dbSNP:rs16876805)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040626" SQ SEQUENCE 385 AA; 43027 MW; 6472D63BC7688334 CRC64; MGCGASRKVV PGPPALAWAK HEGQNQAGVG GAGPGPEAAA QAAQRIQVAR FRAKFDPRVL ARYDIKALIG TGSFSRVVRV EQKTTKKPFA IKVMETRERE GREACVSELS VLRRVSHRYI VQLMEIFETE DQVYMVMELA TGGELFDRLI AQGSFTERDA VRILQMVADG IRYLHALQIT HRNLKPENLL YYHPGEESKI LITDFGLAYS GKKSGDWTMK TLCGTPEYIA PEVLLRKPYT SAVDMWALGV ITYALLSGFL PFDDESQTRL YRKILKGKYN YTGEPWPSIS HLAKDFIDKL LILEAGHRMS AGQALDHPWV ITMAAGSSMK NLQRAISRNL MQRASPHSQS PGSAQSSKSH YSHKSRHMWS KRNLRIVESP LSALL // ID PTEN_HUMAN Reviewed; 403 AA. AC P60484; B2R904; F2YHV0; O00633; O02679; Q6ICT7; DT 16-FEB-2004, integrated into UniProtKB/Swiss-Prot. DT 16-FEB-2004, sequence version 1. DT 28-JAN-2026, entry version 224. DE RecName: Full=Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN {ECO:0000305|PubMed:9256433, ECO:0000305|PubMed:9811831}; DE EC=3.1.3.16 {ECO:0000269|PubMed:9256433}; DE EC=3.1.3.48 {ECO:0000269|PubMed:9187108, ECO:0000269|PubMed:9256433}; DE EC=3.1.3.67 {ECO:0000269|PubMed:16824732, ECO:0000269|PubMed:9811831}; DE AltName: Full=Inositol polyphosphate 3-phosphatase {ECO:0000305|PubMed:11418101, ECO:0000305|PubMed:9593664}; DE EC=3.1.3.- {ECO:0000305|PubMed:11418101, ECO:0000305|PubMed:9593664}; DE AltName: Full=Mutated in multiple advanced cancers 1; DE AltName: Full=Phosphatase and tensin homolog; GN Name=PTEN; Synonyms=MMAC1, TEP1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY, RP SUBCELLULAR LOCATION, AND INDUCTION. RC TISSUE=Epithelium; RX PubMed=9187108; RA Li D.M., Sun H.; RT "TEP1, encoded by a candidate tumor suppressor locus, is a novel protein RT tyrosine phosphatase regulated by transforming growth factor beta."; RL Cancer Res. 57:2124-2129(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANTS RP GLIOMA SER-15; GLU-36; ARG-42; TRP-57 AND THR-319 DEL. RX PubMed=9090379; DOI=10.1038/ng0497-356; RA Steck P.A., Pershouse M.A., Jasser S.A., Lin H., Yung W.K.A., Ligon A.H., RA Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., RA Swedlund B., Teng D.H.-F., Tavtigian S.V.; RT "Identification of a candidate tumour suppressor gene, MMAC1, at chromosome RT 10q23.3 that is mutated in multiple advanced cancers."; RL Nat. Genet. 15:356-363(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT GLIOBLASTOMA ARG-129, AND RP VARIANT PROSTATE CANCER LEU-134. RX PubMed=9072974; DOI=10.1126/science.275.5308.1943; RA Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., RA Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., RA Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R.; RT "PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, RT breast, and prostate cancer."; RL Science 275:1943-1947(1997). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=10817502; DOI=10.1054/bjoc.2000.1211; RA Hamilton J.A., Stewart L.M.D., Ajayi L., Gray I.C., Gray N.E., RA Roberts K.G., Watson G.J., Kaisary A.V., Snary D.; RT "The expression profile for the tumour suppressor gene PTEN and associated RT polymorphic markers."; RL Br. J. Cancer 82:1671-1676(2000). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Wang S., Li J., Liaw D., Bose S., Podsypanina K., Parsons R.; RL Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Jensen K., de la Bastide M., Parsons R., Parnell L.D., Dedhia N., RA Gottesman T., Gnoj L., Kaplan N., Lodhi M., Johnson A.F., Shohdy N., RA Hasegawa A., Haberman K., Huang E.N., Schutz K., Calma C., Granat S., RA Wigler M.H., McCombie W.R.; RT "Genomic sequence of PTEN/MMAC1."; RL Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3). RA Yang C.-W., Hsu Y.-F.; RT "Homo sapiens phosphatase and tensin homolog mRNA splicing variants."; RL Submitted (JAN-2011) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-290. RG NIEHS SNPs program; RL Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [13] RP FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANTS GLIOMA RP TRP-57; ENDOMETRIAL CANCER TYR-123; GLIOBLASTOMA ARG-129; CWS1 ARG-129; RP PROSTATE CANCER LEU-134; GLIOBLASTOMA ARG-165; BREAST CANCER PRO-167 AND BZ RP ARG-170. RX PubMed=9256433; DOI=10.1073/pnas.94.17.9052; RA Myers M.P., Stolarov J.P., Eng C., Li J., Wang S.I., Wigler M.H., RA Parsons R., Tonks N.K.; RT "P-TEN, the tumor suppressor from human chromosome 10q23, is a dual- RT specificity phosphatase."; RL Proc. Natl. Acad. Sci. U.S.A. 94:9052-9057(1997). RN [14] RP FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANT CWS1 SER-124. RX PubMed=9593664; DOI=10.1074/jbc.273.22.13375; RA Maehama T., Dixon J.E.; RT "The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second RT messenger, phosphatidylinositol 3,4,5-trisphosphate."; RL J. Biol. Chem. 273:13375-13378(1998). RN [15] RP FUNCTION, CATALYTIC ACTIVITY, MUTAGENESIS OF ARG-130, AND CHARACTERIZATION RP OF VARIANTS CWS1 SER-124 AND CWS1 GLU-129. RX PubMed=9811831; DOI=10.1073/pnas.95.23.13513; RA Myers M.P., Pass I., Batty I.H., Van der Kaay J., Stolarov J.P., RA Hemmings B.A., Wigler M.H., Downes C.P., Tonks N.K.; RT "The lipid phosphatase activity of PTEN is critical for its tumor RT suppressor function."; RL Proc. Natl. Acad. Sci. U.S.A. 95:13513-13518(1998). RN [16] RP FUNCTION, MUTAGENESIS OF ASP-92 AND CYS-124, AND CHARACTERIZATION OF RP VARIANT GLU-129. RX PubMed=9616126; DOI=10.1126/science.280.5369.1614; RA Tamura M., Gu J., Matsumoto K., Aota S., Parsons R., Yamada K.M.; RT "Inhibition of cell migration, spreading, and focal adhesions by tumor RT suppressor PTEN."; RL Science 280:1614-1617(1998). RN [17] RP FUNCTION, DOMAIN, AND CHARACTERIZATION OF VARIANTS THR-319 DEL; GLN-345 AND RP ILE-348. RX PubMed=10468583; DOI=10.1073/pnas.96.18.10182; RA Georgescu M.-M., Kirsch K.H., Akagi T., Shishido T., Hanafusa H.; RT "The tumor-suppressor activity of PTEN is regulated by its carboxyl- RT terminal region."; RL Proc. Natl. Acad. Sci. U.S.A. 96:10182-10187(1999). RN [18] RP INTERACTION WITH DLG1 AND MAST2, AND PHOSPHORYLATION AT THR-401. RX PubMed=10646847; RA Adey N.B., Huang L., Ormonde P.A., Baumgard M.L., Pero R., Byreddy D.V., RA Tavtigian S.V., Bartel P.L.; RT "Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both RT inhibits and stimulates PDZ binding."; RL Cancer Res. 60:35-37(2000). RN [19] RP INTERACTION WITH MAGI3. RX PubMed=10748157; DOI=10.1074/jbc.m909741199; RA Wu Y., Dowbenko D., Spencer S., Laura R., Lee J., Gu Q., Lasky L.A.; RT "Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, RT a novel membrane-associated guanylate kinase."; RL J. Biol. Chem. 275:21477-21485(2000). RN [20] RP INTERACTION WITH MAGI2. RX PubMed=10760291; DOI=10.1073/pnas.97.8.4233; RA Wu X., Hepner K., Castelino-Prabhu S., Do D., Kaye M.B., Yuan X.-J., RA Wood J., Ross C., Sawyers C.L., Whang Y.E.; RT "Evidence for regulation of the PTEN tumor suppressor by a membrane- RT localized multi-PDZ domain containing scaffold protein MAGI-2."; RL Proc. Natl. Acad. Sci. U.S.A. 97:4233-4238(2000). RN [21] RP FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=11418101; DOI=10.1016/s0014-5793(01)02500-5; RA Caffrey J.J., Darden T., Wenk M.R., Shears S.B.; RT "Expanding coincident signaling by PTEN through its inositol 1,3,4,5,6- RT pentakisphosphate 3-phosphatase activity."; RL FEBS Lett. 499:6-10(2001). RN [22] RP PHOSPHORYLATION AT SER-370; SER-380; THR-382; THR-383 AND SER-385. RX PubMed=11035045; DOI=10.1074/jbc.m009134200; RA Torres J., Pulido R.; RT "The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at RT its C terminus. Implications for PTEN stability to proteasome-mediated RT degradation."; RL J. Biol. Chem. 276:993-998(2001). RN [23] RP FUNCTION, PHOSPHORYLATION, AND INTERACTION WITH MAGI2. RX PubMed=11707428; DOI=10.1074/jbc.c100556200; RA Vazquez F., Grossman S.R., Takahashi Y., Rokas M.V., Nakamura N., RA Sellers W.R.; RT "Phosphorylation of the PTEN tail acts as an inhibitory switch by RT preventing its recruitment into a protein complex."; RL J. Biol. Chem. 276:48627-48630(2001). RN [24] RP PHOSPHORYLATION AT THR-366; SER-370 AND SER-385. RX PubMed=12297295; DOI=10.1016/s0014-5793(02)03274-x; RA Miller S., Lou D., Seldin D., Lane W., Neel B.; RT "Direct identification of PTEN phosphorylation sites."; RL FEBS Lett. 528:145-153(2002). RN [25] RP INTERACTION WITH NOP53, REGION, AND CHARACTERIZATION OF VARIANTS CWS1 RP VAL-341; GLU-343 AND GLN-345. RX PubMed=15355975; DOI=10.1074/jbc.c400377200; RA Okahara F., Ikawa H., Kanaho Y., Maehama T.; RT "Regulation of PTEN phosphorylation and stability by a tumor suppressor RT candidate protein."; RL J. Biol. Chem. 279:45300-45303(2004). RN [26] RP INTERACTION WITH STK11, SUBCELLULAR LOCATION, AND PHOSPHORYLATION BY STK11. RX PubMed=15987703; DOI=10.1093/hmg/ddi225; RA Mehenni H., Lin-Marq N., Buchet-Poyau K., Reymond A., Collart M.A., RA Picard D., Antonarakis S.E.; RT "LKB1 interacts with and phosphorylates PTEN: a functional link between two RT proteins involved in cancer predisposing syndromes."; RL Hum. Mol. Genet. 14:2209-2219(2005). RN [27] RP INTERACTION WITH MAGI2; MAGI3; MAST1; MAST2 AND MAST3, MUTAGENESIS OF RP VAL-403, AND PHOSPHORYLATION. RX PubMed=15951562; DOI=10.1074/jbc.m504761200; RA Valiente M., Andres-Pons A., Gomar B., Torres J., Gil A., Tapparel C., RA Antonarakis S.E., Pulido R.; RT "Binding of PTEN to specific PDZ domains contributes to PTEN protein RT stability and phosphorylation by microtubule-associated serine/threonine RT kinases."; RL J. Biol. Chem. 280:28936-28943(2005). RN [28] RP FUNCTION. RX PubMed=15979280; DOI=10.1016/j.cellsig.2005.05.017; RA Deleu S., Choi K., Pesesse X., Cho J., Sulis M.L., Parsons R., Shears S.B.; RT "Physiological levels of PTEN control the size of the cellular RT Ins(1,3,4,5,6)P(5) pool."; RL Cell. Signal. 18:488-498(2006). RN [29] RP CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND FUNCTION. RX PubMed=16824732; DOI=10.1016/j.cellsig.2006.05.010; RA Vandeput F., Backers K., Villeret V., Pesesse X., Erneux C.; RT "The influence of anionic lipids on SHIP2 phosphatidylinositol 3,4,5- RT trisphosphate 5-phosphatase activity."; RL Cell. Signal. 18:2193-2199(2006). RN [30] RP INTERACTION WITH NEDD4. RX PubMed=17218260; DOI=10.1016/j.cell.2006.11.039; RA Wang X., Trotman L.C., Koppie T., Alimonti A., Chen Z., Gao Z., Wang J., RA Erdjument-Bromage H., Tempst P., Cordon-Cardo C., Pandolfi P.P., Jiang X.; RT "NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN."; RL Cell 128:129-139(2007). RN [31] RP FUNCTION, INTERACTION WITH USP7, UBIQUITINATION AT LYS-13 AND LYS-289, RP DEUBIQUITINATION BY USP7, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-13 AND RP LYS-289, AND CHARACTERIZATION OF VARIANT CWS1 GLU-289. RX PubMed=18716620; DOI=10.1038/nature07290; RA Song M.S., Salmena L., Carracedo A., Egia A., Lo-Coco F., RA Teruya-Feldstein J., Pandolfi P.P.; RT "The deubiquitinylation and localization of PTEN are regulated by a HAUSP- RT PML network."; RL Nature 455:813-817(2008). RN [32] RP INTERACTION WITH FRK, PHOSPHORYLATION AT TYR-336, AND MUTAGENESIS OF RP TYR-336. RX PubMed=19345329; DOI=10.1016/j.ccr.2009.02.012; RA Yim E.-K., Peng G., Dai H., Hu R., Li K., Lu Y., Mills G.B., RA Meric-Bernstam F., Hennessy B.T., Craven R.J., Lin S.-Y.; RT "Rak functions as a tumor suppressor by regulating PTEN protein stability RT and function."; RL Cancer Cell 15:304-314(2009). RN [33] RP UBIQUITINATION BY XIAP/BIRC4, SUBCELLULAR LOCATION, AND INTERACTION WITH RP XIAP/BIRC4. RX PubMed=19473982; DOI=10.1074/jbc.c109.009522; RA Van Themsche C., Leblanc V., Parent S., Asselin E.; RT "X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN RT ubiquitination, content, and compartmentalization."; RL J. Biol. Chem. 284:20462-20466(2009). RN [34] RP PHOSPHORYLATION AT THR-366 AND SER-370, AND MUTAGENESIS OF THR-366 AND RP SER-370. RX PubMed=20940307; DOI=10.1074/jbc.m110.166462; RA Xu D., Yao Y., Jiang X., Lu L., Dai W.; RT "Regulation of PTEN stability and activity by Plk3."; RL J. Biol. Chem. 285:39935-39942(2010). RN [35] RP INTERACTION WITH NDFIP1 AND NDFIP2. RX PubMed=20534535; DOI=10.1073/pnas.0911714107; RA Mund T., Pelham H.R.; RT "Regulation of PTEN/Akt and MAP kinase signaling pathways by the ubiquitin RT ligase activators Ndfip1 and Ndfip2."; RL Proc. Natl. Acad. Sci. U.S.A. 107:11429-11434(2010). RN [36] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [37] RP FUNCTION IN CELL MIGRATION. RX PubMed=22279049; DOI=10.1101/gad.177642.111; RA Stohr N., Kohn M., Lederer M., Glass M., Reinke C., Singer R.H., RA Huttelmaier S.; RT "IGF2BP1 promotes cell migration by regulating MK5 and PTEN signaling."; RL Genes Dev. 26:176-189(2012). RN [38] RP ACETYLATION [LARGE SCALE ANALYSIS] AT THR-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [39] RP ALTERNATIVE INITIATION (ISOFORM ALPHA), CTG START CODON, FUNCTION (ISOFORM RP ALPHA), AND SUBCELLULAR LOCATION (ISOFORM ALPHA). RX PubMed=23744781; DOI=10.1126/science.1234907; RA Hopkins B.D., Fine B., Steinbach N., Dendy M., Rapp Z., Shaw J., Pappas K., RA Yu J.S., Hodakoski C., Mense S., Klein J., Pegno S., Sulis M.L., RA Goldstein H., Amendolara B., Lei L., Maurer M., Bruce J., Canoll P., RA Hibshoosh H., Parsons R.; RT "A secreted PTEN phosphatase that enters cells to alter signaling and RT survival."; RL Science 341:399-402(2013). RN [40] RP INTERACTION WITH PPP1R16B. RX PubMed=25007873; DOI=10.1152/ajprenal.00070.2014; RA Obeidat M., Li L., Ballermann B.J.; RT "TIMAP promotes angiogenesis by suppressing PTEN-mediated Akt inhibition in RT human glomerular endothelial cells."; RL Am. J. Physiol. 307:F623-F633(2014). RN [41] RP ALTERNATIVE INITIATION (ISOFORM ALPHA), CTG START CODON, SUBCELLULAR RP LOCATION (ISOFORM ALPHA), AND MUTAGENESIS OF MET-1. RX PubMed=24768297; DOI=10.1016/j.cmet.2014.03.023; RA Liang H., He S., Yang J., Jia X., Wang P., Chen X., Zhang Z., Zou X., RA McNutt M.A., Shen W.H., Yin Y.; RT "PTENalpha, a PTEN isoform translated through alternative initiation, RT regulates mitochondrial function and energy metabolism."; RL Cell Metab. 19:836-848(2014). RN [42] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-366, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [43] RP INTERACTION WITH NDFIP1, AND SUBCELLULAR LOCATION. RX PubMed=25801959; DOI=10.1093/jmcb/mjv020; RA Howitt J., Low L.H., Putz U., Doan A., Lackovic J., Goh C.P., Gunnersen J., RA Silke J., Tan S.S.; RT "Ndfip1 represses cell proliferation by controlling Pten localization and RT signaling specificity."; RL J. Mol. Cell Biol. 7:119-131(2015). RN [44] RP FUNCTION, INTERACTION WITH TNS3 AND PI3K, PHOSPHORYLATION AT THR-319 AND RP THR-321, AND MUTAGENESIS OF SER-229; THR-232; THR-319 AND THR-321. RX PubMed=26166433; DOI=10.1038/ncomms8721; RA Cao X., Kaneko T., Li J.S., Liu A.D., Voss C., Li S.S.; RT "A phosphorylation switch controls the spatiotemporal activation of Rho RT GTPases in directional cell migration."; RL Nat. Commun. 6:7721-7721(2015). RN [45] RP FUNCTION, AND UBIQUITINATION. RX PubMed=31492966; DOI=10.1007/s00018-019-03280-5; RA Zhang J., Zhang Y.L., Zhao L.W., Pi S.B., Zhang S.Y., Tong C., Fan H.Y.; RT "The CRL4-DCAF13 ubiquitin E3 ligase supports oocyte meiotic resumption by RT targeting PTEN degradation."; RL Cell. Mol. Life Sci. 77:2181-2197(2020). RN [46] RP FUNCTION, AND ISGYLATION. RX PubMed=37279284; DOI=10.1126/scisignal.abm1756; RA Du X., Sheng J., Chen Y., He S., Yang Y., Huang Y., Fu Y., Lie L., Han Z., RA Zhu B., Liu H., Wen Q., Zhou X., Zhou C., Hu S., Ma L.; RT "The E3 ligase HERC5 promotes antimycobacterial responses in macrophages by RT ISGylating the phosphatase PTEN."; RL Sci. Signal. 16:eabm1756-eabm1756(2023). RN [47] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 8-353 IN COMPLEX WITH RP L(+)-TARTRATE, SUBUNIT, DOMAIN, MUTAGENESIS OF ASP-92; HIS-93; LYS-125; RP LYS-128; THR-167; GLN-171; 263-LYS--ALA-269 AND 327-LYS--ALA-335, AND RP CATALYTIC ACTIVITY. RX PubMed=10555148; DOI=10.1016/s0092-8674(00)81663-3; RA Lee J.-O., Yang H., Georgescu M.-M., Di Cristofano A., Maehama T., Shi Y., RA Dixon J.E., Pandolfi P., Pavletich N.P.; RT "Crystal structure of the PTEN tumor suppressor: implications for its RT phosphoinositide phosphatase activity and membrane association."; RL Cell 99:323-334(1999). RN [48] RP VARIANT CWS1 ASN-137 INS. RX PubMed=9345101; DOI=10.1086/301607; RA Tsou H.C., Teng D.H.-F., Ping X.L., Brancolini V., Davis T., Hu R., RA Xie X.X., Gruener A.C., Schrager C.A., Christiano A.M., Eng C., Steck P., RA Ott J., Tavtigian S.V., Peacocke M.; RT "The role of MMAC1 mutations in early-onset breast cancer: causative in RT association with Cowden syndrome and excluded in BRCA1-negative cases."; RL Am. J. Hum. Genet. 61:1036-1043(1997). RN [49] RP VARIANTS CWS1 GLU-343 AND LEU-347. RX PubMed=9399897; DOI=10.1086/301639; RA Lynch E.D., Ostermeyer E.A., Lee M.K., Arena J.F., Ji H., Dann J., RA Swisshelm K., Suchard D., MacLeod P.M., Kvinnsland S., Gjertsen B.T., RA Heimdal K., Lubs H., Moeller P., King M.-C.; RT "Inherited mutations in PTEN that are associated with breast cancer, Cowden RT disease, and juvenile polyposis."; RL Am. J. Hum. Genet. 61:1254-1260(1997). RN [50] RP VARIANTS GLIOBLASTOMA TYR-107; PRO-121; ARG-129; ARG-165 AND GLN-345. RX PubMed=9331071; RA Wang S.I., Puc J., Li J., Bruce J.N., Cairns P., Sidransky D., Parsons R.; RT "Somatic mutations of PTEN in glioblastoma multiforme."; RL Cancer Res. 57:4183-4186(1997). RN [51] RP VARIANTS CWS1 ARG-123 AND ARG-124. RX PubMed=9259288; DOI=10.1093/hmg/6.8.1383; RA Nelen M.R., van Staveren W.C.G., Peeters E.A.J., Ben-Hassel M., RA Gorlin R.J., Hamm H., Lindboe C.F., Fryns J.-P., Sijmons R.H., Woods D.G., RA Mariman E.C.M., Padberg G.W., Kremer H.; RT "Germline mutations in the PTEN/MMAC1 gene in patients with Cowden RT disease."; RL Hum. Mol. Genet. 6:1383-1387(1997). RN [52] RP VARIANT CWS1 GLU-129. RX PubMed=9140396; DOI=10.1038/ng0597-64; RA Liaw D., Marsh D.J., Li J., Dahia P.L.M., Wang S.I., Zheng Z., Bose S., RA Call K.M., Tsou H.C., Peacocke M., Eng C., Parsons R.; RT "Germline mutations of the PTEN gene in Cowden disease, an inherited breast RT and thyroid cancer syndrome."; RL Nat. Genet. 16:64-67(1997). RN [53] RP VARIANT CWS1 ARG-170. RX PubMed=9241266; DOI=10.1038/ng0897-333; RA Marsh D.J., Dahia P.L.M., Zheng Z., Liaw D., Parsons R., Gorlin R.J., RA Eng C.; RT "Germline mutations in PTEN are present in Bannayan-Zonana syndrome."; RL Nat. Genet. 16:333-334(1997). RN [54] RP VARIANTS ENDOMETRIAL HYPERPLASIA ARG-36; LEU-130; CYS-173; ALA-191 AND RP ILE-348. RX PubMed=9635567; RA Maxwell G.L., Risinger J.I., Gumbs C., Shaw H., Bentley R.C., Barrett J.C., RA Berchuck A., Futreal P.A.; RT "Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias."; RL Cancer Res. 58:2500-2503(1998). RN [55] RP VARIANT CWS1 GLU-289. RX PubMed=9797362; DOI=10.1016/s0016-5085(98)70078-2; RA Chi S.-G., Kim H.-J., Park B.-J., Min H.-J., Park J.-H., Kim Y.-W., RA Dong S.-H., Kim B.-H., Lee J.-I., Chang Y.-W., Chang R., Kim W.-K., RA Yang M.-H.; RT "Mutational abrogation of the PTEN/MMAC1 gene in gastrointestinal polyps in RT patients with Cowden disease."; RL Gastroenterology 115:1084-1089(1998). RN [56] RP VARIANTS CWS1 HIS-68 AND PRO-112. RX PubMed=9600246; DOI=10.1007/s004390050723; RA Tsou H.C., Ping X.L., Xie X.X., Gruener A.C., Zhang H., Nini R., RA Swisshelm K., Sybert V., Diamond T.M., Sutphen R., Peacocke M.; RT "The genetic basis of Cowden's syndrome: three novel mutations in RT PTEN/MMAC1/TEP1."; RL Hum. Genet. 102:467-473(1998). RN [57] RP VARIANTS CWS1 ARG-67 AND VAL-165. RX PubMed=9467011; DOI=10.1093/hmg/7.3.507; RA Marsh D.J., Coulon V., Lunetta K.L., Rocca-Serra P., Dahia P.L.M., RA Zheng Z., Liaw D., Caron S., Duboue B., Lin A.Y., Richardson A.-L., RA Bonnetblanc J.-M., Bressieux J.-M., Cabarrot-Moreau A., Chompret A., RA Demange L., Eeles R.A., Yahanda A.M., Fearon E.R., Fricker J.-P., RA Gorlin R.J., Hodgson S.V., Huson S., Lacombe D., Leprat F., Odent S., RA Toulouse C., Olopade O.I., Sobol H., Tishler S., Woods C.G., Robinson B.G., RA Weber H.C., Parsons R., Peacocke M., Longy M., Eng C.; RT "Mutation spectrum and genotype-phenotype analyses in Cowden disease and RT Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN RT mutation."; RL Hum. Mol. Genet. 7:507-515(1998). RN [58] RP VARIANT CWS1 TYR-136. RX PubMed=9735393; DOI=10.3892/ijo.13.4.665; RA Scala S., Bruni P., Lo Muzio L., Mignogna M., Viglietto G., Fusco A.; RT "Novel mutation of the PTEN gene in an Italian Cowden's disease kindred."; RL Int. J. Oncol. 13:665-668(1998). RN [59] RP VARIANT CWS1 PRO-70. RX PubMed=9832031; DOI=10.1136/jmg.35.11.881; RA Marsh D.J., Dahia P.L.M., Caron S., Kum J.B., Frayling I.M., RA Tomlinson I.P.M., Hughes K.S., Eeles R.A., Hodgson S.V., Murday V.A., RA Houlston R., Eng C.; RT "Germline PTEN mutations in Cowden syndrome-like families."; RL J. Med. Genet. 35:881-885(1998). RN [60] RP VARIANT CWS1 ARG-35. RX PubMed=9425889; DOI=10.1038/ng0198-12; RA Olschwang S., Serova-Sinilnikova O.M., Lenoir G.M., Thomas G.; RT "PTEN germ-line mutations in juvenile polyposis coli."; RL Nat. Genet. 18:12-14(1998). RN [61] RP VARIANT CWS1 GLN-130. RX PubMed=9915974; DOI=10.1086/302207; RA Kurose K., Araki T., Matsunaka T., Takada Y., Emi M.; RT "Variant manifestation of Cowden disease in Japan: hamartomatous polyposis RT of the digestive tract with mutation of the PTEN gene."; RL Am. J. Hum. Genet. 64:308-310(1999). RN [62] RP VARIANT CWS1/LDD PRO-112. RX PubMed=10051160; RX DOI=10.1002/(sici)1096-8628(19990212)82:4<290::aid-ajmg3>3.0.co;2-0; RA Sutphen R., Diamond T.M., Minton S.E., Peacocke M., Tsou H.C., Root A.W.; RT "Severe Lhermitte-Duclos disease with unique germline mutation of PTEN."; RL Am. J. Med. Genet. 82:290-293(1999). RN [63] RP VARIANTS CWS1 ILE-33 DEL; ARG-123; ARG-124 AND GLU-165. RX PubMed=10234502; DOI=10.1038/sj.ejhg.5200289; RA Nelen M.R., Kremer H., Konings I.B.M., Schoute F., van Essen A.J., Koch R., RA Woods C.G., Fryns J.-P., Hamel B.C.J., Hoefsloot L.H., Peeters E.A.J., RA Padberg G.W.; RT "Novel PTEN mutations in patients with Cowden disease: absence of clear RT genotype-phenotype correlations."; RL Eur. J. Hum. Genet. 7:267-273(1999). RN [64] RP VARIANTS CWS1 ASP-34; HIS-68; TYR-105; VAL-135; ARG-170 AND LEU-246. RX PubMed=10400993; DOI=10.1093/hmg/8.8.1461; RA Marsh D.J., Kum J.B., Lunetta K.L., Bennett M.J., Gorlin R.J., Ahmed S.F., RA Bodurtha J., Crowe C., Curtis M.A., Dasouki M., Dunn T., Feit H., RA Geraghty M.T., Graham J.M. Jr., Hodgson S.V., Hunter A., Korf B.R., RA Manchester D., Miesfeldt S., Murday V.A., Nathanson K.L., Parisi M., RA Pober B., Romano C., Tolmie J.L., Trembath R., Winter R.M., Zackai E.H., RA Zori R.T., Weng L.-P., Dahia P.L.M., Eng C.; RT "PTEN mutation spectrum and genotype-phenotype correlations in Bannayan- RT Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome."; RL Hum. Mol. Genet. 8:1461-1472(1999). RN [65] RP CHARACTERIZATION OF VARIANTS ASN-10; CYS-16; GLU-20; SER-27; ARG-61; RP HIS-68; ARG-112; PRO-121; ARG-129; GLY-130; ILE-133; LEU-134; ARG-165; RP ASN-170; CYS-173; HIS-173; PRO-173; ASN-174; PHE-227; CYS-251; GLN-345; RP GLY-369 AND ILE-401, AND CHARACTERIZATION OF VARIANTS CWS1 TYR-71; TYR-93; RP PHE-105; TYR-107; PRO-112; ARG-124; GLU-129; LEU-130; GLN-130; TYR-136; RP CYS-155; ARG-170; GLU-289; GLY-331; VAL-341; ASN-342; GLU-343 AND LEU-347. RX PubMed=10866302; RA Han S.-Y., Kato H., Kato S., Suzuki T., Shibata H., Ishii S., Shiiba K., RA Matsuno S., Kanamaru R., Ishioka C.; RT "Functional evaluation of PTEN missense mutations using in vitro RT phosphoinositide phosphatase assay."; RL Cancer Res. 60:3147-3151(2000). RN [66] RP VARIANT CWS1 ARG-36. RX PubMed=10772390; DOI=10.1034/j.1600-0625.2000.009002152.x; RA Celebi J.T., Ping X.L., Zhang H., Remington T., Sulica V.I., Tsou H.C., RA Peacocke M.; RT "Germline PTEN mutations in three families with Cowden syndrome."; RL Exp. Dermatol. 9:152-156(2000). RN [67] RP VARIANTS MULTIPLE CANCERS LEU-119 AND LEU-158. RX PubMed=10807691; DOI=10.1136/jmg.37.5.336; RA De Vivo I., Gertig D.M., Nagase S., Hankinson S.E., O'Brien R., RA Speizer F.E., Parsons R., Hunter D.J.; RT "Novel germline mutations in the PTEN tumour suppressor gene found in women RT with multiple cancers."; RL J. Med. Genet. 37:336-341(2000). RN [68] RP VARIANTS MALIGNANT MELANOMA ASN-19 AND ILE-217. RX PubMed=10978354; DOI=10.1136/jmg.37.9.653; RA Celebi J.T., Shendrik I., Silvers D.N., Peacocke M.; RT "Identification of PTEN mutations in metastatic melanoma specimens."; RL J. Med. Genet. 37:653-657(2000). RN [69] RP CHARACTERIZATION OF VARIANTS CWS1 SER-124 AND GLU-129. RX PubMed=11230179; DOI=10.1093/hmg/10.6.599; RA Weng L.-P., Brown J.L., Eng C.; RT "PTEN coordinates G1 arrest by down-regulating cyclin D1 via its protein RT phosphatase activity and up-regulating p27 via its lipid phosphatase RT activity in a breast cancer model."; RL Hum. Mol. Genet. 10:599-604(2001). RN [70] RP VARIANT ASP-61. RX PubMed=11748304; DOI=10.1136/jmg.38.12.820; RA Reardon W., Zhou X.-P., Eng C.; RT "A novel germline mutation of the PTEN gene in a patient with macrocephaly, RT ventricular dilatation, and features of VATER association."; RL J. Med. Genet. 38:820-823(2001). RN [71] RP VARIANTS CWS1 ASP-34; GLY-47; HIS-68; TYR-105; VAL-135 AND ARG-170. RX PubMed=11494117; DOI=10.1038/sj.neo.7900154; RA Marsh D.J., Theodosopoulos G., Howell V., Richardson A.-L., Benn D.E., RA Proos A.L., Eng C., Robinson B.G.; RT "Rapid mutation scanning of genes associated with familial cancer syndromes RT using denaturing high-performance liquid chromatography."; RL Neoplasia 3:236-244(2001). RN [72] RP VARIANT GLM2 GLN-234, AND CHARACTERIZATION OF VARIANT GLM2 GLN-234. RX PubMed=12085208; DOI=10.1038/sj.bjc.6600206; RA Staal F.J.T., van der Luijt R.B., Baert M.R.M., van Drunen J., RA van Bakel H., Peters E., de Valk I., van Amstel H.K.P., Taphoorn M.J.B., RA Jansen G.H., van Veelen C.W.M., Burgering B., Staal G.E.J.; RT "A novel germline mutation of PTEN associated with brain tumours of RT multiple lineages."; RL Br. J. Cancer 86:1586-1591(2002). RN [73] RP VARIANT HNSCC GLY-121. RX PubMed=11801303; DOI=10.1016/s0165-4608(01)00509-x; RA Poetsch M., Lorenz G., Kleist B.; RT "Detection of new PTEN/MMAC1 mutations in head and neck squamous cell RT carcinomas with loss of chromosome 10."; RL Cancer Genet. Cytogenet. 132:20-24(2002). RN [74] RP DISCUSSION OF PTEN INVOLVEMENT IN PROTEUS SYNDROME. RX PubMed=12471211; DOI=10.1136/jmg.39.12.937; RA Smith J.M., Kirk E.P.E., Theodosopoulos G., Marshall G.M., Walker J., RA Rogers M., Field M., Brereton J.J., Marsh D.J.; RT "Germline mutation of the tumour suppressor PTEN in Proteus syndrome."; RL J. Med. Genet. 39:937-940(2002). RN [75] RP VARIANTS MCEPHAS ARG-93; SER-241 AND GLY-252. RX PubMed=15805158; DOI=10.1136/jmg.2004.024646; RA Butler M.G., Dasouki M.J., Zhou X.-P., Talebizadeh Z., Brown M., RA Takahashi T.N., Miles J.H., Wang C.H., Stratton R., Pilarski R., Eng C.; RT "Subset of individuals with autism spectrum disorders and extreme RT macrocephaly associated with germline PTEN tumour suppressor gene RT mutations."; RL J. Med. Genet. 42:318-321(2005). RN [76] RP VARIANT ENDMC GLU-36. RX PubMed=16506206; DOI=10.1002/ijc.21862; RA Bilbao C., Rodriguez G., Ramirez R., Falcon O., Leon L., Chirino R., RA Rivero J.F., Falcon O. Jr., Diaz-Chico B.N., Diaz-Chico J.C., Perucho M.; RT "The relationship between microsatellite instability and PTEN gene RT mutations in endometrial cancer."; RL Int. J. Cancer 119:563-570(2006). RN [77] RP INVOLVEMENT IN CHROMOSOME 10Q23 DELETION SYNDROME. RX PubMed=17436248; DOI=10.1086/513607; RA Balciuniene J., Feng N., Iyadurai K., Hirsch B., Charnas L., Bill B.R., RA Easterday M.C., Staaf J., Oseth L., Czapansky-Beilman D., Avramopoulos D., RA Thomas G.H., Borg A., Valle D., Schimmenti L.A., Selleck S.B.; RT "Recurrent 10q22-q23 deletions: a genomic disorder on 10q associated with RT cognitive and behavioral abnormalities."; RL Am. J. Hum. Genet. 80:938-947(2007). RN [78] RP VARIANT VAL-132. RX PubMed=16752378; DOI=10.1002/ajmg.a.31273; RA Tekin M., Hismi B.O., Fitoz S., Yalcinkaya F., Ekim M., Kansu A., Ertem M., RA Deda G., Tutar E., Arsan S., Zhou X.-P., Pilarski R., Eng C., Akar N.; RT "A germline PTEN mutation with manifestations of prenatal onset and RT verrucous epidermal nevus."; RL Am. J. Med. Genet. A 140:1472-1475(2006). RN [79] RP VARIANTS CWS1 SER-15; ASP-34; ARG-36; ARG-61; HIS-68; GLU-129; GLY-130; RP LEU-130; GLN-130; TYR-136; ARG-165; ARG-170; GLY-252 AND LEU-347. RX PubMed=21659347; DOI=10.1136/jmg.2011.088807; RA Pilarski R., Stephens J.A., Noss R., Fisher J.L., Prior T.W.; RT "Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan- RT Riley-Ruvalcaba syndrome clinical features."; RL J. Med. Genet. 48:505-512(2011). RN [80] RP VARIANTS MCEPHAS ILE-131 AND ASN-167. RX PubMed=23160955; DOI=10.1126/science.1227764; RA O'Roak B.J., Vives L., Fu W., Egertson J.D., Stanaway I.B., Phelps I.G., RA Carvill G., Kumar A., Lee C., Ankenman K., Munson J., Hiatt J.B., RA Turner E.H., Levy R., O'Day D.R., Krumm N., Coe B.P., Martin B.K., RA Borenstein E., Nickerson D.A., Mefford H.C., Doherty D., Akey J.M., RA Bernier R., Eichler E.E., Shendure J.; RT "Multiplex targeted sequencing identifies recurrently mutated genes in RT autism spectrum disorders."; RL Science 338:1619-1622(2012). RN [81] RP VARIANTS CWS1 ARG-61; TYR-93; GLY-130; GLN-130; LEU-130 AND CYS-173. RX PubMed=24778394; DOI=10.1200/jco.2013.53.6656; RA Ngeow J., Stanuch K., Mester J.L., Barnholtz-Sloan J.S., Eng C.; RT "Second malignant neoplasms in patients with Cowden syndrome with RT underlying germline PTEN mutations."; RL J. Clin. Oncol. 32:1818-1824(2014). RN [82] RP VARIANT MCEPHAS 65-TYR--VAL-403 DEL. RX PubMed=26637798; DOI=10.1016/j.neuron.2015.11.009; RA D'Gama A.M., Pochareddy S., Li M., Jamuar S.S., Reiff R.E., Lam A.T., RA Sestan N., Walsh C.A.; RT "Targeted DNA Sequencing from Autism Spectrum Disorder Brains Implicates RT Multiple Genetic Mechanisms."; RL Neuron 88:910-917(2015). RN [83] RP VARIANT PROSTATE CANCER GLY-126, CHARACTERIZATION OF VARIANT GLY-126, RP MUTAGENESIS OF ALA-126, AND FUNCTION. RX PubMed=26504226; DOI=10.1073/pnas.1422504112; RA Costa H.A., Leitner M.G., Sos M.L., Mavrantoni A., Rychkova A., RA Johnson J.R., Newton B.W., Yee M.C., De La Vega F.M., Ford J.M., RA Krogan N.J., Shokat K.M., Oliver D., Halaszovich C.R., Bustamante C.D.; RT "Discovery and functional characterization of a neomorphic PTEN mutation."; RL Proc. Natl. Acad. Sci. U.S.A. 112:13976-13981(2015). RN [84] RP VARIANT ASN-174. RX PubMed=39316756; DOI=10.1158/0008-5472.can-23-2216; RA Plitt G., Brewer T., Yehia L., Rabinowitz L., Griffith C.C., Eng C.; RT "The genomic landscape of benign and malignant thyroid tumors from RT individuals carrying germline PTEN variants is distinct from sporadic RT thyroid cancers."; RL Cancer Res. 84:3657-3668(2024). CC -!- FUNCTION: Dual-specificity protein phosphatase, dephosphorylating CC tyrosine-, serine- and threonine-phosphorylated proteins CC (PubMed:9187108, PubMed:9256433, PubMed:9616126). Also functions as a CC lipid phosphatase, removing the phosphate in the D3 position of the CC inositol ring of PtdIns(3,4,5)P3/phosphatidylinositol 3,4,5- CC trisphosphate, PtdIns(3,4)P2/phosphatidylinositol 3,4-diphosphate and CC PtdIns3P/phosphatidylinositol 3-phosphate with a preference for CC PtdIns(3,4,5)P3 (PubMed:16824732, PubMed:26504226, PubMed:9593664, CC PubMed:9811831). Furthermore, this enzyme can also act as a cytosolic CC inositol 3-phosphatase acting on Ins(1,3,4,5,6)P5/inositol 1,3,4,5,6 CC pentakisphosphate and possibly Ins(1,3,4,5)P4/1D-myo-inositol 1,3,4,5- CC tetrakisphosphate (PubMed:11418101, PubMed:15979280). Antagonizes the CC PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides CC and thereby modulating cell cycle progression and cell survival CC (PubMed:31492966, PubMed:37279284). The unphosphorylated form CC cooperates with MAGI2 to suppress AKT1 activation (PubMed:11707428). In CC motile cells, suppresses the formation of lateral pseudopods and CC thereby promotes cell polarization and directed movement CC (PubMed:22279049). Dephosphorylates tyrosine-phosphorylated focal CC adhesion kinase and inhibits cell migration and integrin-mediated cell CC spreading and focal adhesion formation (PubMed:22279049). Required for CC growth factor-induced epithelial cell migration; growth factor CC stimulation induces PTEN phosphorylation which changes its binding CC preference from the p85 regulatory subunit of the PI3K kinase complex CC to DLC1 and results in translocation of the PTEN-DLC1 complex to the CC posterior of migrating cells to promote RHOA activation CC (PubMed:26166433). Meanwhile, TNS3 switches binding preference from CC DLC1 to p85 and the TNS3-p85 complex translocates to the leading edge CC of migrating cells to activate RAC1 activation (PubMed:26166433). Plays CC a role as a key modulator of the AKT-mTOR signaling pathway controlling CC the tempo of the process of newborn neurons integration during adult CC neurogenesis, including correct neuron positioning, dendritic CC development and synapse formation (By similarity). Involved in the CC regulation of synaptic function in excitatory hippocampal synapses. CC Recruited to the postsynaptic membrane upon NMDA receptor activation, CC is required for the modulation of synaptic activity during plasticity. CC Enhancement of lipid phosphatase activity is able to drive depression CC of AMPA receptor-mediated synaptic responses, activity required for CC NMDA receptor-dependent long-term depression (LTD) (By similarity). May CC be a negative regulator of insulin signaling and glucose metabolism in CC adipose tissue. The nuclear monoubiquitinated form possesses greater CC apoptotic potential, whereas the cytoplasmic nonubiquitinated form CC induces less tumor suppressive ability (PubMed:10468583, CC PubMed:18716620). {ECO:0000250|UniProtKB:O08586, CC ECO:0000250|UniProtKB:O54857, ECO:0000269|PubMed:10468583, CC ECO:0000269|PubMed:11418101, ECO:0000269|PubMed:11707428, CC ECO:0000269|PubMed:15979280, ECO:0000269|PubMed:16824732, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:22279049, CC ECO:0000269|PubMed:26166433, ECO:0000269|PubMed:26504226, CC ECO:0000269|PubMed:31492966, ECO:0000269|PubMed:37279284, CC ECO:0000269|PubMed:9187108, ECO:0000269|PubMed:9256433, CC ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9616126, CC ECO:0000269|PubMed:9811831}. CC -!- FUNCTION: [Isoform alpha]: Functional kinase, like isoform 1 it CC antagonizes the PI3K-AKT/PKB signaling pathway. Plays a role in CC mitochondrial energetic metabolism by promoting COX activity and ATP CC production, via collaboration with isoform 1 in increasing protein CC levels of PINK1. {ECO:0000269|PubMed:23744781}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5- CC trisphosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo- CC inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:25017, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57836, CC ChEBI:CHEBI:58456; EC=3.1.3.67; CC Evidence={ECO:0000269|PubMed:16824732, ECO:0000269|PubMed:9811831}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:25018; CC Evidence={ECO:0000305|PubMed:16824732}; CC -!- CATALYTIC ACTIVITY: CC Reaction=O-phospho-L-seryl-[protein] + H2O = L-seryl-[protein] + CC phosphate; Xref=Rhea:RHEA:20629, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15377, ChEBI:CHEBI:29999, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:83421; EC=3.1.3.16; CC Evidence={ECO:0000269|PubMed:9256433}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:20630; CC Evidence={ECO:0000305|PubMed:9256433}; CC -!- CATALYTIC ACTIVITY: CC Reaction=O-phospho-L-threonyl-[protein] + H2O = L-threonyl-[protein] + CC phosphate; Xref=Rhea:RHEA:47004, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15377, ChEBI:CHEBI:30013, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:61977; EC=3.1.3.16; CC Evidence={ECO:0000269|PubMed:9256433}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:47005; CC Evidence={ECO:0000305|PubMed:9256433}; CC -!- CATALYTIC ACTIVITY: CC Reaction=O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] + CC phosphate; Xref=Rhea:RHEA:10684, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978; EC=3.1.3.48; Evidence={ECO:0000269|PubMed:9187108, CC ECO:0000269|PubMed:9256433}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:10685; CC Evidence={ECO:0000305|PubMed:9256433}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5- CC trisphosphate) + H2O = 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo- CC inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:43552, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:83416, CC ChEBI:CHEBI:83419; Evidence={ECO:0000269|PubMed:16824732, CC ECO:0000269|PubMed:9593664}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43553; CC Evidence={ECO:0000305|PubMed:16824732}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol- CC 3,4,5-trisphosphate) + H2O = 1,2-dihexadecanoyl-sn-glycero-3-phospho- CC (1D-myo-inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:43560, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:83420, CC ChEBI:CHEBI:83423; Evidence={ECO:0000269|PubMed:16824732, CC ECO:0000269|PubMed:9593664}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43561; CC Evidence={ECO:0000305|PubMed:16824732}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1D-myo-inositol 1,3,4,5,6-pentakisphosphate + H2O = 1D-myo- CC inositol 1,4,5,6-tetrakisphosphate + phosphate; Xref=Rhea:RHEA:77143, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57627, CC ChEBI:CHEBI:57733; Evidence={ECO:0000269|PubMed:11418101}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:77144; CC Evidence={ECO:0000269|PubMed:11418101}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1D-myo-inositol 1,3,4,5-tetrakisphosphate + H2O = 1D-myo- CC inositol 1,4,5-trisphosphate + phosphate; Xref=Rhea:RHEA:77155, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57895, CC ChEBI:CHEBI:203600; Evidence={ECO:0000269|PubMed:9593664}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:77156; CC Evidence={ECO:0000305|PubMed:9593664}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Enzymatic activity is enhanced in the presence of CC phosphatidylserine. {ECO:0000269|PubMed:16824732}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=26 uM for PtdIns(3,4,5)P3 {ECO:0000269|PubMed:11418101}; CC KM=11.5 uM for 1D-myo-inositol 1,3,4-trisphosphate CC {ECO:0000269|PubMed:11418101}; CC KM=4.6 uM for 1D-myo-inositol 1,3,4,5-tetrakisphosphate CC {ECO:0000269|PubMed:11418101}; CC KM=7.1 uM for 1D-myo-inositol 1,3,4,5,6-pentakisphosphate CC {ECO:0000269|PubMed:11418101}; CC Vmax=60 nmol/min/mg enzyme with PtdIns(3,4,5)P3 as substrate CC {ECO:0000269|PubMed:11418101}; CC Vmax=24 nmol/min/mg enzyme with 1D-myo-inositol 1,3,4-trisphosphate CC as substrate {ECO:0000269|PubMed:11418101}; CC Vmax=112 nmol/min/mg enzyme with 1D-myo-inositol 1,3,4,5- CC tetrakisphosphate as substrate {ECO:0000269|PubMed:11418101}; CC Vmax=67 nmol/min/mg enzyme with 1D-myo-inositol 1,3,4,5,6- CC pentakisphosphate as substrate {ECO:0000269|PubMed:11418101}; CC -!- SUBUNIT: Monomer. The unphosphorylated form interacts with the second CC PDZ domain of MAGI2 and with DLG1 and MAST2 in vitro (PubMed:10646847, CC PubMed:10760291, PubMed:11707428). Interacts with MAGI2, MAGI3, MAST1 CC and MAST3, but neither with MAST4 nor with DLG5; interaction with MAGI2 CC increases protein stability (PubMed:10748157, PubMed:15951562). CC Interacts with NEDD4 (PubMed:17218260). Interacts with NDFIP1 and CC NDFIP2; in the presence of NEDD4 or ITCH, this interaction promotes CC PTEN ubiquitination (PubMed:20534535, PubMed:25801959). Interacts (via CC C2 domain) with FRK (PubMed:19345329). Interacts with USP7; the CC interaction is direct (PubMed:18716620). Interacts with ROCK1 (By CC similarity). Interacts with XIAP/BIRC4 (PubMed:19473982). Interacts CC with STK11; the interaction phosphorylates PTEN (PubMed:15987703). CC Interacts with PPP1R16B (PubMed:25007873). Interacts with NOP53; CC regulates PTEN phosphorylation and increases its stability CC (PubMed:15355975). Interacts (via PDZ domain-binding motif) with DLG4; CC the interaction is induced by NMDA and is required for PTEN location at CC postsynaptic density (By similarity). Interacts with the regulatory p85 CC subunit of the PI3K kinase complex and with Rho GTPase-activating CC protein DLC1; in resting cells, interacts (via C2 tensin-type domain) CC with p85 but, following growth factor stimulation, PTEN is CC phosphorylated which leads to weakened interaction with p85 and CC enhanced interaction (via C2 tensin-type domain) with DLC1 while p85 CC interaction with TNS3 increases (PubMed:26166433). CC {ECO:0000250|UniProtKB:O08586, ECO:0000250|UniProtKB:O54857, CC ECO:0000269|PubMed:10555148, ECO:0000269|PubMed:10646847, CC ECO:0000269|PubMed:10748157, ECO:0000269|PubMed:10760291, CC ECO:0000269|PubMed:11707428, ECO:0000269|PubMed:15355975, CC ECO:0000269|PubMed:15951562, ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:17218260, ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19345329, ECO:0000269|PubMed:19473982, CC ECO:0000269|PubMed:20534535, ECO:0000269|PubMed:25007873, CC ECO:0000269|PubMed:25801959, ECO:0000269|PubMed:26166433}. CC -!- INTERACTION: CC P60484; Q9ULX6: AKAP8L; NbExp=2; IntAct=EBI-696162, EBI-357530; CC P60484; Q9NZN5-2: ARHGEF12; NbExp=4; IntAct=EBI-696162, EBI-10984307; CC P60484; P35226: BMI1; NbExp=7; IntAct=EBI-696162, EBI-2341576; CC P60484; P30260: CDC27; NbExp=7; IntAct=EBI-696162, EBI-994813; CC P60484; Q9P0U4: CXXC1; NbExp=2; IntAct=EBI-696162, EBI-949911; CC P60484; Q16643: DBN1; NbExp=5; IntAct=EBI-696162, EBI-351394; CC P60484; Q12959: DLG1; NbExp=2; IntAct=EBI-696162, EBI-357481; CC P60484; Q15700: DLG2; NbExp=2; IntAct=EBI-696162, EBI-80426; CC P60484; P78352: DLG4; NbExp=3; IntAct=EBI-696162, EBI-80389; CC P60484; P42685: FRK; NbExp=7; IntAct=EBI-696162, EBI-1383583; CC P60484; Q9HD26: GOPC; NbExp=4; IntAct=EBI-696162, EBI-349832; CC P60484; A4D2P6: GRID2IP; NbExp=4; IntAct=EBI-696162, EBI-15893226; CC P60484; Q92743: HTRA1; NbExp=4; IntAct=EBI-696162, EBI-352256; CC P60484; Q96QZ7: MAGI1; NbExp=5; IntAct=EBI-696162, EBI-924464; CC P60484; Q86UL8: MAGI2; NbExp=6; IntAct=EBI-696162, EBI-311035; CC P60484; Q5TCQ9: MAGI3; NbExp=9; IntAct=EBI-696162, EBI-310506; CC P60484; Q9Y2H9: MAST1; NbExp=4; IntAct=EBI-696162, EBI-3385920; CC P60484; Q6P0Q8: MAST2; NbExp=4; IntAct=EBI-696162, EBI-493777; CC P60484; O60307: MAST3; NbExp=4; IntAct=EBI-696162, EBI-311420; CC P60484; O75970: MPDZ; NbExp=4; IntAct=EBI-696162, EBI-821405; CC P60484; Q9Y6Q9: NCOA3; NbExp=2; IntAct=EBI-696162, EBI-81196; CC P60484; P46934: NEDD4; NbExp=4; IntAct=EBI-696162, EBI-726944; CC P60484; O14745: NHERF1; NbExp=9; IntAct=EBI-696162, EBI-349787; CC P60484; Q15599: NHERF2; NbExp=6; IntAct=EBI-696162, EBI-1149760; CC P60484; Q8NI35: PATJ; NbExp=3; IntAct=EBI-696162, EBI-724390; CC P60484; P09619: PDGFRB; NbExp=3; IntAct=EBI-696162, EBI-641237; CC P60484; Q9H5P4: PDZD7; NbExp=4; IntAct=EBI-696162, EBI-20859318; CC P60484; Q9NRD5: PICK1; NbExp=2; IntAct=EBI-696162, EBI-79165; CC P60484; P62136: PPP1CA; NbExp=2; IntAct=EBI-696162, EBI-357253; CC P60484; Q06830: PRDX1; NbExp=7; IntAct=EBI-696162, EBI-353193; CC P60484; P60484: PTEN; NbExp=19; IntAct=EBI-696162, EBI-696162; CC P60484; Q14160: SCRIB; NbExp=4; IntAct=EBI-696162, EBI-357345; CC P60484; Q13424: SNTA1; NbExp=4; IntAct=EBI-696162, EBI-717191; CC P60484; Q13884: SNTB1; NbExp=5; IntAct=EBI-696162, EBI-295843; CC P60484; Q9NY99: SNTG2; NbExp=3; IntAct=EBI-696162, EBI-8556870; CC P60484; Q96L92: SNX27; NbExp=4; IntAct=EBI-696162, EBI-2514865; CC P60484; O43791: SPOP; NbExp=4; IntAct=EBI-696162, EBI-743549; CC P60484; Q62696: Dlg1; Xeno; NbExp=2; IntAct=EBI-696162, EBI-389325; CC P60484; O88382: Magi2; Xeno; NbExp=3; IntAct=EBI-696162, EBI-696179; CC P60484; Q9JK71: Magi3; Xeno; NbExp=3; IntAct=EBI-696162, EBI-696226; CC P60484; Q9R1L5: Mast1; Xeno; NbExp=3; IntAct=EBI-696162, EBI-491771; CC P60484; Q60592: Mast2; Xeno; NbExp=4; IntAct=EBI-696162, EBI-493888; CC P60484; Q9JHL1: Nherf2; Xeno; NbExp=2; IntAct=EBI-696162, EBI-538451; CC P60484-1; Q19T08: ECSCR; NbExp=4; IntAct=EBI-15722967, EBI-15778214; CC P60484-1; Q5T2D3: OTUD3; NbExp=9; IntAct=EBI-15722967, EBI-16170539; CC P60484-1; P60484-1: PTEN; NbExp=3; IntAct=EBI-15722967, EBI-15722967; CC P60484-1; Q93009: USP7; NbExp=5; IntAct=EBI-15722967, EBI-302474; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:19473982, CC ECO:0000269|PubMed:25801959, ECO:0000269|PubMed:9187108}. Nucleus CC {ECO:0000269|PubMed:15987703, ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19473982, ECO:0000269|PubMed:25801959}. Nucleus, PML CC body {ECO:0000269|PubMed:18716620}. Cell projection, dendritic spine CC {ECO:0000250|UniProtKB:O54857}. Postsynaptic density CC {ECO:0000250|UniProtKB:O54857}. Note=Monoubiquitinated form is nuclear. CC Nonubiquitinated form is cytoplasmic. Colocalized with PML and USP7 in CC PML nuclear bodies (PubMed:18716620). XIAP/BIRC4 promotes its nuclear CC localization (PubMed:19473982). Associares with the postsynaptic CC density in response to NMDAR activation (By similarity). CC {ECO:0000250|UniProtKB:O54857, ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19473982}. CC -!- SUBCELLULAR LOCATION: [Isoform alpha]: Secreted CC {ECO:0000269|PubMed:23744781, ECO:0000269|PubMed:24768297}. Note=May be CC secreted via a classical signal peptide and reenter into cells with the CC help of a poly-Arg motif. {ECO:0000269|PubMed:23744781, CC ECO:0000269|PubMed:24768297}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing, Alternative initiation; Named isoforms=3; CC Name=1; Synonyms=55kDa; CC IsoId=P60484-1; Sequence=Displayed; CC Name=alpha; Synonyms=70kDa, PTEN-long; CC IsoId=P60484-2; Sequence=VSP_055420; CC Name=3; CC IsoId=P60484-3; Sequence=VSP_055421, VSP_055422, VSP_055423; CC -!- TISSUE SPECIFICITY: Expressed at a relatively high level in all adult CC tissues, including heart, brain, placenta, lung, liver, muscle, kidney CC and pancreas. {ECO:0000269|PubMed:9090379}. CC -!- INDUCTION: Down-regulated by TGFB1. {ECO:0000269|PubMed:9187108}. CC -!- DOMAIN: The C2 domain binds phospholipid membranes in vitro in a CC Ca(2+)-independent manner; this binding is important for its tumor CC suppressor function. {ECO:0000269|PubMed:10468583, CC ECO:0000269|PubMed:10555148}. CC -!- PTM: Constitutively phosphorylated by CK2 under normal conditions. CC Phosphorylated in vitro by MAST1, MAST2, MAST3 and STK11. CC Phosphorylation results in an inhibited activity towards PIP3. CC Phosphorylation can both inhibit or promote PDZ-binding. CC Phosphorylation at Tyr-336 by FRK/PTK5 protects this protein from CC ubiquitin-mediated degradation probably by inhibiting its binding to CC NEDD4. Phosphorylation by ROCK1 is essential for its stability and CC activity. Phosphorylation by PLK3 promotes its stability and prevents CC its degradation by the proteasome. Phosphorylated on Thr-319 and Thr- CC 321 in the C2-type tensin domain following EGF stimulation which CC changes its binding preference from the p85 regulatory subunit of the CC PI3K kinase complex to DLC1 (PubMed:26166433). CC {ECO:0000269|PubMed:10646847, ECO:0000269|PubMed:11035045, CC ECO:0000269|PubMed:11707428, ECO:0000269|PubMed:12297295, CC ECO:0000269|PubMed:15951562, ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:19345329, CC ECO:0000269|PubMed:20940307, ECO:0000269|PubMed:26166433}. CC -!- PTM: Monoubiquitinated; monoubiquitination is increased in presence of CC retinoic acid. Deubiquitinated by USP7; leading to its nuclear CC exclusion. Monoubiquitination of one of either Lys-13 and Lys-289 amino CC acid is sufficient to modulate PTEN compartmentalization. Ubiquitinated CC by XIAP/BIRC4. {ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19473982}. CC -!- PTM: Ubiquitinated by the DCX(DCAF13) E3 ubiquitin ligase complex, CC leading to its degradation. {ECO:0000269|PubMed:31492966}. CC -!- PTM: ISGylated. ISGylation promotes PTEN degradation. CC {ECO:0000269|PubMed:37279284}. CC -!- DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant CC hamartomatous polyposis syndrome with age-related penetrance. Cowden CC syndrome is characterized by hamartomatous lesions affecting CC derivatives of ectodermal, mesodermal and endodermal layers, CC macrocephaly, facial trichilemmomas (benign tumors of the hair follicle CC infundibulum), acral keratoses, papillomatous papules, and elevated CC risk for development of several types of malignancy, particularly CC breast carcinoma in women and thyroid carcinoma in both men and women. CC Colon cancer and renal cell carcinoma have also been reported. CC Hamartomas can be found in virtually every organ, but most commonly in CC the skin, gastrointestinal tract, breast and thyroid. CC {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, CC ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:10772390, CC ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11230179, CC ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:15355975, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:21659347, CC ECO:0000269|PubMed:24778394, ECO:0000269|PubMed:9140396, CC ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9259288, CC ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, CC ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9467011, CC ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9600246, CC ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, CC ECO:0000269|PubMed:9811831, ECO:0000269|PubMed:9832031, CC ECO:0000269|PubMed:9915974}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease CC characterized by the occurrence of a slowly enlarging mass within the CC cerebellar cortex corresponding histologically to a cerebellar CC hamartoma. It manifests, most commonly in the third and fourth decades CC of life, with increased intracranial pressure, headache, nausea, CC cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual CC disturbances and other cranial nerve palsies. Various associated CC abnormalities may be present such as megalencephaly, microgyria, CC hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part CC of the PTEN hamartoma tumor syndromes spectrum that also includes CC Cowden syndrome. Note=The disease is caused by variants affecting the CC gene represented in this entry. CC -!- DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) CC [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. CC The hallmark of cutaneous SCC is malignant transformation of normal CC epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. {ECO:0000269|PubMed:16506206}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Note=PTEN mutations are found in a subset of patients with CC Proteus syndrome, a genetically heterogeneous condition. The molecular CC diagnosis of PTEN mutation positive cases classifies Proteus syndrome CC patients as part of the PTEN hamartoma syndrome spectrum. As such, CC patients surviving the early years of Proteus syndrome are likely at a CC greater risk of developing malignancies. CC -!- DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant CC central nervous system neoplasms derived from glial cells. They CC comprise astrocytomas and glioblastoma multiforme that are derived from CC astrocytes, oligodendrogliomas derived from oligodendrocytes and CC ependymomas derived from ependymocytes. {ECO:0000269|PubMed:12085208}. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. CC -!- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in CC tissues of the prostate. Most prostate cancers are adenocarcinomas that CC develop in the acini of the prostatic ducts. Other rare histopathologic CC types of prostate cancer that occur in approximately 5% of patients CC include small cell carcinoma, mucinous carcinoma, prostatic ductal CC carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal CC cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:26504226, CC ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients CC have autism spectrum disorders and macrocephaly, with head CC circumferences ranging from +2.5 to +8 SD for age and sex (average head CC circumference +4.0 SD). {ECO:0000269|PubMed:15805158, CC ECO:0000269|PubMed:23160955, ECO:0000269|PubMed:26637798}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and CC PTEN is a cause of chromosome 10q23 deletion syndrome, which shows CC overlapping features of the following three disorders: Bannayan-Zonana CC syndrome, Cowden disease and juvenile polyposis syndrome. CC -!- MISCELLANEOUS: [Isoform alpha]: Produced by alternative initiation at CC an upstream CTG start codon. May contain a signal peptide at positions CC 1-21. {ECO:0000269|PubMed:23744781, ECO:0000269|PubMed:24768297}. CC -!- SIMILARITY: Belongs to the PTEN phosphatase protein family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/158/PTEN"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U96180; AAB66902.1; -; mRNA. DR EMBL; U92436; AAC51182.1; -; mRNA. DR EMBL; U93051; AAC51183.1; -; mRNA. DR EMBL; AF143315; AAD38372.1; -; Genomic_DNA. DR EMBL; AF143312; AAD38372.1; JOINED; Genomic_DNA. DR EMBL; AF143313; AAD38372.1; JOINED; Genomic_DNA. DR EMBL; AF143314; AAD38372.1; JOINED; Genomic_DNA. DR EMBL; AF000734; AAC08699.1; -; Genomic_DNA. DR EMBL; AF000726; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000727; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000728; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000729; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000730; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000731; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000732; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000733; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF067844; AAD13528.1; -; Genomic_DNA. DR EMBL; JF268690; ADZ48535.1; -; mRNA. DR EMBL; CR450306; CAG29302.1; -; mRNA. DR EMBL; AK313581; BAG36351.1; -; mRNA. DR EMBL; DQ073384; AAY57327.1; -; Genomic_DNA. DR EMBL; CH471066; EAW50174.1; -; Genomic_DNA. DR EMBL; BC005821; AAH05821.1; -; mRNA. DR CCDS; CCDS31238.1; -. [P60484-1] DR RefSeq; NP_000305.3; NM_000314.6. [P60484-1] DR RefSeq; NP_001291647.1; NM_001304718.1. DR PDB; 1D5R; X-ray; 2.10 A; A=8-353. DR PDB; 2KYL; NMR; -; B=391-403. DR PDB; 4O1V; X-ray; 2.00 A; B=354-368. DR PDB; 5BUG; X-ray; 2.40 A; A/B/C/D=14-351. DR PDB; 5BZX; X-ray; 2.50 A; A/B/C/D=14-351. DR PDB; 5BZZ; X-ray; 2.20 A; A/B/C/D=14-351. DR PDB; 7JTX; X-ray; 3.23 A; A=7-395. DR PDB; 7JUK; X-ray; 3.15 A; A=7-353, A=378-390. DR PDB; 7JUL; X-ray; 2.53 A; A=7-353, A=378-390. DR PDB; 7JVX; X-ray; 3.20 A; A=1-403. DR PDB; 7PC7; X-ray; 2.10 A; E/F=394-403. DR PDB; 8X3S; X-ray; 1.87 A; B=29-41. DR PDBsum; 1D5R; -. DR PDBsum; 2KYL; -. DR PDBsum; 4O1V; -. DR PDBsum; 5BUG; -. DR PDBsum; 5BZX; -. DR PDBsum; 5BZZ; -. DR PDBsum; 7JTX; -. DR PDBsum; 7JUK; -. DR PDBsum; 7JUL; -. DR PDBsum; 7JVX; -. DR PDBsum; 7PC7; -. DR PDBsum; 8X3S; -. DR AlphaFoldDB; P60484; -. DR SMR; P60484; -. DR BioGRID; 111700; 852. DR ComplexPortal; CPX-3153; PTEN phosphatase complex. DR CORUM; P60484; -. DR DIP; DIP-35019N; -. DR ELM; P60484; -. DR FunCoup; P60484; 3633. DR IntAct; P60484; 439. DR MINT; P60484; -. DR STRING; 9606.ENSP00000361021; -. DR BindingDB; P60484; -. DR ChEMBL; CHEMBL2052032; -. DR DrugBank; DB04327; Phosphatidylethanolamine. DR GuidetoPHARMACOLOGY; 2497; -. DR SwissLipids; SLP:000000849; -. DR TCDB; 1.A.51.2.4; the voltage-gated proton channel (vpc) family. DR CarbonylDB; P60484; -. DR DEPOD; PTEN; -. DR GlyGen; P60484; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P60484; -. DR MetOSite; P60484; -. DR PhosphoSitePlus; P60484; -. DR BioMuta; PTEN; -. DR DMDM; 42560209; -. DR CPTAC; CPTAC-5746; -. DR CPTAC; CPTAC-5747; -. DR CPTAC; CPTAC-5748; -. DR CPTAC; non-CPTAC-5426; -. DR CPTAC; non-CPTAC-5429; -. DR CPTAC; non-CPTAC-5430; -. DR CPTAC; non-CPTAC-5566; -. DR CPTAC; non-CPTAC-5567; -. DR jPOST; P60484; -. DR MassIVE; P60484; -. DR PaxDb; 9606-ENSP00000361021; -. DR PeptideAtlas; P60484; -. DR ProteomicsDB; 57209; -. [P60484-1] DR Pumba; P60484; -. DR Antibodypedia; 3420; 1732 antibodies from 53 providers. DR CPTC; P60484; 8 antibodies. DR DNASU; 5728; -. DR Ensembl; ENST00000371953.8; ENSP00000361021.3; ENSG00000171862.16. [P60484-1] DR Ensembl; ENST00000644628.2; ENSP00000494918.2; ENSG00000284792.2. [P60484-1] DR Ensembl; ENST00000688308.1; ENSP00000508752.1; ENSG00000171862.16. [P60484-1] DR Ensembl; ENST00000710385.1; ENSP00000518242.1; ENSG00000284792.2. [P60484-1] DR Ensembl; ENST00000710387.1; ENSP00000518244.1; ENSG00000284792.2. [P60484-2] DR GeneID; 5728; -. DR KEGG; hsa:5728; -. DR MANE-Select; ENST00000371953.8; ENSP00000361021.3; NM_000314.8; NP_000305.3. DR UCSC; uc001kfb.4; human. [P60484-1] DR AGR; HGNC:9588; -. DR CIViC; 5728; 123 evidence items across 65 molecular profiles. DR ClinPGx; PA33942; -. DR CTD; 5728; -. DR DisGeNET; 5728; -. DR GeneCards; PTEN; -. DR GeneReviews; PTEN; -. DR HGNC; HGNC:9588; PTEN. DR HPA; ENSG00000171862; Low tissue specificity. DR MalaCards; PTEN; -. DR MIM; 137800; phenotype. DR MIM; 158350; phenotype. DR MIM; 176807; phenotype. DR MIM; 275355; phenotype. DR MIM; 601728; gene. DR MIM; 605309; phenotype. DR MIM; 608089; phenotype. DR MIM; 612242; phenotype. DR MIM; 613028; phenotype. DR OpenTargets; ENSG00000171862; -. DR Orphanet; 109; Bannayan-Riley-Ruvalcaba syndrome. DR Orphanet; 201; Cowden syndrome. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR Orphanet; 79076; Juvenile polyposis of infancy. DR Orphanet; 65285; Lhermitte-Duclos disease. DR Orphanet; 210548; Macrocephaly-intellectual disability-autism syndrome. DR Orphanet; 2969; Proteus-like syndrome. DR Orphanet; 137608; Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome. DR Orphanet; 494547; Squamous cell carcinoma of the hypopharynx. DR Orphanet; 494550; Squamous cell carcinoma of the larynx. DR Orphanet; 502366; Squamous cell carcinoma of the lip. DR Orphanet; 500464; Squamous cell carcinoma of the nasal cavity and paranasal sinuses. DR Orphanet; 502363; Squamous cell carcinoma of the oral cavity. DR Orphanet; 500478; Squamous cell carcinoma of the oropharynx. DR VEuPathDB; HostDB:ENSG00000171862; -. DR eggNOG; KOG2283; Eukaryota. DR GeneTree; ENSGT00940000154335; -. DR HOGENOM; CLU_020105_5_2_1; -. DR InParanoid; P60484; -. DR OMA; CKKFKQR; -. DR OrthoDB; 16692at2759; -. DR PAN-GO; P60484; 12 GO annotations based on evolutionary models. DR PhylomeDB; P60484; -. DR BioCyc; MetaCyc:HS10404-MONOMER; -. DR BRENDA; 3.1.3.16; 2681. DR BRENDA; 3.1.3.67; 2681. DR PathwayCommons; P60484; -. DR Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane. DR Reactome; R-HSA-1855204; Synthesis of IP3 and IP4 in the cytosol. DR Reactome; R-HSA-199418; Negative regulation of the PI3K/AKT network. DR Reactome; R-HSA-202424; Downstream TCR signaling. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-5674404; PTEN Loss of Function in Cancer. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-5689896; Ovarian tumor domain proteases. DR Reactome; R-HSA-8943723; Regulation of PTEN mRNA translation. DR Reactome; R-HSA-8948747; Regulation of PTEN localization. DR Reactome; R-HSA-8948751; Regulation of PTEN stability and activity. DR Reactome; R-HSA-8986944; Transcriptional Regulation by MECP2. DR SignaLink; P60484; -. DR SIGNOR; P60484; -. DR Agora; ENSG00000171862; -. DR BioGRID-ORCS; 5728; 85 hits in 1159 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; B5B9A610; PML body. DR ChiTaRS; PTEN; human. DR EvolutionaryTrace; P60484; -. DR GeneWiki; PTEN_(gene); -. DR GenomeRNAi; 5728; -. DR Pharos; P60484; Tchem. DR PRO; PR:P60484; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; P60484; protein. DR Bgee; ENSG00000171862; Expressed in sperm and 191 other cell types or tissues. DR ExpressionAtlas; P60484; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IMP:UniProtKB. DR GO; GO:0042995; C:cell projection; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0043197; C:dendritic spine; IEA:UniProtKB-SubCell. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0035749; C:myelin sheath adaxonal region; ISS:BHF-UCL. DR GO; GO:0043005; C:neuron projection; ISS:BHF-UCL. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell. DR GO; GO:0014069; C:postsynaptic density; IEA:UniProtKB-SubCell. DR GO; GO:0043220; C:Schmidt-Lanterman incisure; ISS:BHF-UCL. DR GO; GO:0097225; C:sperm midpiece; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0010997; F:anaphase-promoting complex binding; IPI:BHF-UCL. DR GO; GO:0008013; F:beta-catenin binding; IPI:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0030351; F:inositol-1,3,4,5,6-pentakisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0051717; F:inositol-1,3,4,5-tetrakisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW. DR GO; GO:0140678; F:molecular function inhibitor activity; IMP:DisProt. DR GO; GO:0030165; F:PDZ domain binding; IPI:UniProtKB. DR GO; GO:0052866; F:phosphatidylinositol phosphate phosphatase activity; IDA:UniProt. DR GO; GO:0016314; F:phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0051800; F:phosphatidylinositol-3,4-bisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0004438; F:phosphatidylinositol-3-phosphate phosphatase activity; IDA:UniProtKB. DR GO; GO:0004721; F:phosphoprotein phosphatase activity; IDA:BHF-UCL. DR GO; GO:0004722; F:protein serine/threonine phosphatase activity; IDA:UniProtKB. DR GO; GO:0004725; F:protein tyrosine phosphatase activity; IDA:UniProtKB. DR GO; GO:1990757; F:ubiquitin ligase activator activity; ISS:BHF-UCL. DR GO; GO:1990381; F:ubiquitin-specific protease binding; IPI:MGI. DR GO; GO:0030534; P:adult behavior; ISS:BHF-UCL. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0016477; P:cell migration; ISS:UniProtKB. DR GO; GO:0048870; P:cell motility; IBA:GO_Central. DR GO; GO:0071257; P:cellular response to electrical stimulus; IMP:BHF-UCL. DR GO; GO:0007417; P:central nervous system development; ISS:UniProtKB. DR GO; GO:0032286; P:central nervous system myelin maintenance; ISS:BHF-UCL. DR GO; GO:0021955; P:central nervous system neuron axonogenesis; ISS:BHF-UCL. DR GO; GO:0060997; P:dendritic spine morphogenesis; ISS:BHF-UCL. DR GO; GO:0021542; P:dentate gyrus development; ISS:BHF-UCL. DR GO; GO:0048853; P:forebrain morphogenesis; ISS:BHF-UCL. DR GO; GO:0007507; P:heart development; ISS:UniProtKB. DR GO; GO:0007611; P:learning or memory; ISS:BHF-UCL. DR GO; GO:0045475; P:locomotor rhythm; ISS:BHF-UCL. DR GO; GO:0007626; P:locomotory behavior; ISS:BHF-UCL. DR GO; GO:0042711; P:maternal behavior; ISS:BHF-UCL. DR GO; GO:0033555; P:multicellular organismal response to stress; ISS:BHF-UCL. DR GO; GO:0050771; P:negative regulation of axonogenesis; ISS:BHF-UCL. DR GO; GO:1902807; P:negative regulation of cell cycle G1/S phase transition; IDA:UniProtKB. DR GO; GO:0030336; P:negative regulation of cell migration; IMP:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:0045792; P:negative regulation of cell size; ISS:BHF-UCL. DR GO; GO:2000773; P:negative regulation of cellular senescence; ISS:BHF-UCL. DR GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0090394; P:negative regulation of excitatory postsynaptic potential; ISS:BHF-UCL. DR GO; GO:0051895; P:negative regulation of focal adhesion assembly; IMP:UniProtKB. DR GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IDA:BHF-UCL. DR GO; GO:0051548; P:negative regulation of keratinocyte migration; IMP:BHF-UCL. DR GO; GO:0010977; P:negative regulation of neuron projection development; ISS:ARUK-UCL. DR GO; GO:0046621; P:negative regulation of organ growth; ISS:BHF-UCL. DR GO; GO:0045668; P:negative regulation of osteoblast differentiation; IDA:UniProt. DR GO; GO:0033137; P:negative regulation of peptidyl-serine phosphorylation; IMP:UniProtKB. DR GO; GO:0051898; P:negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:UniProt. DR GO; GO:2000808; P:negative regulation of synaptic vesicle clustering; ISS:BHF-UCL. DR GO; GO:1904706; P:negative regulation of vascular associated smooth muscle cell proliferation; IMP:BHF-UCL. DR GO; GO:1903690; P:negative regulation of wound healing, spreading of epidermal cells; IMP:BHF-UCL. DR GO; GO:0007270; P:neuron-neuron synaptic transmission; ISS:BHF-UCL. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IBA:GO_Central. DR GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome. DR GO; GO:0046856; P:phosphatidylinositol dephosphorylation; IDA:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; ISS:BHF-UCL. DR GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; ISS:BHF-UCL. DR GO; GO:1902533; P:positive regulation of intracellular signal transduction; IMP:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL. DR GO; GO:2000060; P:positive regulation of ubiquitin-dependent protein catabolic process; IDA:BHF-UCL. DR GO; GO:0097107; P:postsynaptic density assembly; ISS:BHF-UCL. DR GO; GO:0060134; P:prepulse inhibition; ISS:BHF-UCL. DR GO; GO:0097105; P:presynaptic membrane assembly; ISS:BHF-UCL. DR GO; GO:0006470; P:protein dephosphorylation; IDA:UniProtKB. DR GO; GO:0050821; P:protein stabilization; IDA:BHF-UCL. DR GO; GO:0010975; P:regulation of neuron projection development; ISS:UniProtKB. DR GO; GO:0051896; P:regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IBA:GO_Central. DR GO; GO:0031647; P:regulation of protein stability; IMP:UniProtKB. DR GO; GO:0060024; P:rhythmic synaptic transmission; ISS:BHF-UCL. DR GO; GO:0035176; P:social behavior; ISS:BHF-UCL. DR GO; GO:0007056; P:spindle assembly involved in female meiosis; IDA:UniProt. DR GO; GO:0007416; P:synapse assembly; ISS:BHF-UCL. DR GO; GO:0060074; P:synapse maturation; ISS:BHF-UCL. DR CDD; cd14509; PTP_PTEN; 1. DR DisProt; DP03296; -. DR DisProt; DP03399; -. [P60484-2] DR FunFam; 2.60.40.1110:FF:000003; Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; 1. DR FunFam; 3.90.190.10:FF:000029; Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; 1. DR Gene3D; 2.60.40.1110; -; 1. DR Gene3D; 3.90.190.10; Protein tyrosine phosphatase superfamily; 1. DR InterPro; IPR017361; Bifunc_PIno_P3_Pase/Pase_PTEN. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR051281; Dual-spec_lipid-protein_phosph. DR InterPro; IPR029021; Prot-tyrosine_phosphatase-like. DR InterPro; IPR045101; PTP_PTEN. DR InterPro; IPR014020; Tensin_C2-dom. DR InterPro; IPR029023; Tensin_phosphatase. DR InterPro; IPR016130; Tyr_Pase_AS. DR InterPro; IPR003595; Tyr_Pase_cat. DR InterPro; IPR000387; Tyr_Pase_dom. DR PANTHER; PTHR12305; PHOSPHATASE WITH HOMOLOGY TO TENSIN; 1. DR PANTHER; PTHR12305:SF81; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE 3-PHOSPHATASE AND DUAL-SPECIFICITY PROTEIN PHOSPHATASE PTEN; 1. DR Pfam; PF10409; PTEN_C2; 1. DR Pfam; PF22785; Tc-R-P; 1. DR PIRSF; PIRSF038025; PTEN; 1. DR SMART; SM01326; PTEN_C2; 1. DR SMART; SM00404; PTPc_motif; 1. DR SMART; SM01301; PTPlike_phytase; 1. DR SUPFAM; SSF52799; (Phosphotyrosine protein) phosphatases II; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR PROSITE; PS51182; C2_TENSIN; 1. DR PROSITE; PS51181; PPASE_TENSIN; 1. DR PROSITE; PS50056; TYR_PHOSPHATASE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative initiation; Alternative splicing; KW Apoptosis; Autism spectrum disorder; Cell projection; Cytoplasm; KW Disease variant; Hydrolase; Isopeptide bond; Lipid metabolism; KW Lipid-binding; Neurogenesis; Nucleus; Phosphoprotein; Protein phosphatase; KW Proteomics identification; Reference proteome; Secreted; Synapse; KW Tumor suppressor; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..403 FT /note="Phosphatidylinositol 3,4,5-trisphosphate 3- FT phosphatase and dual-specificity protein phosphatase PTEN" FT /id="PRO_0000215904" FT DOMAIN 14..185 FT /note="Phosphatase tensin-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00590" FT DOMAIN 190..350 FT /note="C2 tensin-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00589" FT REGION 338..348 FT /note="Required for interaction with NOP53" FT /evidence="ECO:0000269|PubMed:15355975" FT REGION 352..403 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 401..403 FT /note="PDZ domain-binding" FT /evidence="ECO:0000250|UniProtKB:O08586" FT COMPBIAS 360..369 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 383..393 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 124 FT /note="Phosphocysteine intermediate" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00590" FT MOD_RES 2 FT /note="N-acetylthreonine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 294 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O08586" FT MOD_RES 319 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:26166433" FT MOD_RES 321 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:26166433" FT MOD_RES 336 FT /note="Phosphotyrosine; by FRK" FT /evidence="ECO:0000269|PubMed:19345329" FT MOD_RES 366 FT /note="Phosphothreonine; by GSK3-beta and PLK3" FT /evidence="ECO:0000269|PubMed:12297295, FT ECO:0000269|PubMed:20940307, ECO:0007744|PubMed:24275569" FT MOD_RES 370 FT /note="Phosphoserine; by CK2 and PLK3" FT /evidence="ECO:0000269|PubMed:11035045, FT ECO:0000269|PubMed:12297295, ECO:0000269|PubMed:20940307" FT MOD_RES 380 FT /note="Phosphoserine; by ROCK1 and CK2" FT /evidence="ECO:0000269|PubMed:11035045" FT MOD_RES 382 FT /note="Phosphothreonine; by ROCK1 and CK2" FT /evidence="ECO:0000269|PubMed:11035045" FT MOD_RES 383 FT /note="Phosphothreonine; by ROCK1 and CK2" FT /evidence="ECO:0000269|PubMed:11035045" FT MOD_RES 385 FT /note="Phosphoserine; by CK2" FT /evidence="ECO:0000269|PubMed:11035045, FT ECO:0000269|PubMed:12297295" FT MOD_RES 401 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:10646847" FT CROSSLNK 13 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:18716620" FT CROSSLNK 289 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:18716620" FT VAR_SEQ 1 FT /note="M -> MERGGEAAAAAAAAAAAPGRGSESPVTISRAGNAGELVSPLLLPPTR FT RRRRRHIQGPGPVLNLPCAAAAPPVARAPEAAGGGSRSEDYSSSPHSAAAAARPLAAEE FT KQAQSLQPSSSRRSSHYPAAVQSQAAAERGASATAKSRAISILQKKPRHQQLLPSLSSF FT FFSHRLPDM (in isoform alpha)" FT /evidence="ECO:0000305" FT /id="VSP_055420" FT VAR_SEQ 55..70 FT /note="RFLDSKHKNHYKIYNL -> S (in isoform 3)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_055421" FT VAR_SEQ 165..190 FT /note="GVTIPSQRRYVYYYSYLLKNHLDYRP -> ADPTGGIPDKGIIVIGDGSSMD FT VIAP (in isoform 3)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_055422" FT VAR_SEQ 191..403 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_055423" FT VARIANT 10 FT /note="S -> N (retains phosphatase activity towards FT Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the ability to FT bind phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026248" FT VARIANT 15 FT /note="R -> S (in CWS1; also found in glioma; FT dbSNP:rs1064794096)" FT /evidence="ECO:0000269|PubMed:21659347, FT ECO:0000269|PubMed:9090379" FT /id="VAR_007457" FT VARIANT 16 FT /note="Y -> C (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains the ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026249" FT VARIANT 19 FT /note="D -> N (in malignant melanoma; somatic mutation; FT dbSNP:rs121909233)" FT /evidence="ECO:0000269|PubMed:10978354" FT /id="VAR_018100" FT VARIANT 20 FT /note="G -> E (reduced phosphatase activity towards FT Ins(1,3,4,5)P4; retains phosphatase activity towards FT PtdIns(3,4,5)P3; dbSNP:rs1064795967)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026250" FT VARIANT 27 FT /note="Y -> S (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs886041877)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026251" FT VARIANT 33 FT /note="Missing (in CWS1; dbSNP:rs1554893765)" FT /evidence="ECO:0000269|PubMed:10234502" FT /id="VAR_008733" FT VARIANT 34 FT /note="A -> D (in CWS1)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:21659347" FT /id="VAR_008734" FT VARIANT 35 FT /note="M -> R (in CWS1; dbSNP:rs121909225)" FT /evidence="ECO:0000269|PubMed:9425889" FT /id="VAR_008036" FT VARIANT 36 FT /note="G -> E (in ENDMC; also found in glioma; FT dbSNP:rs1554893792)" FT /evidence="ECO:0000269|PubMed:16506206, FT ECO:0000269|PubMed:9090379" FT /id="VAR_007458" FT VARIANT 36 FT /note="G -> R (in CWS1; also found in a patient with FT endometrial hyperplasia; dbSNP:rs786204854)" FT /evidence="ECO:0000269|PubMed:10772390, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9635567" FT /id="VAR_026252" FT VARIANT 42 FT /note="L -> R (in glioma; retains phosphatase activity FT towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the FT ability to bind phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:9090379" FT /id="VAR_007459" FT VARIANT 47 FT /note="R -> G (in CWS1; dbSNP:rs786204855)" FT /evidence="ECO:0000269|PubMed:11494117" FT /id="VAR_011587" FT VARIANT 57 FT /note="L -> W (in glioma; likely pathogenic; loss of FT protein phosphatase activity; dbSNP:rs786202398)" FT /evidence="ECO:0000269|PubMed:9090379, FT ECO:0000269|PubMed:9256433" FT /id="VAR_007460" FT VARIANT 61 FT /note="H -> D (found in a patient with congenital cardiac FT disease, macrocephaly, ventriculomegaly, skeletal defects, FT anal atresia, tracheoesophageal fistula, renal anomalies; FT likely pathogenic; dbSNP:rs121909236)" FT /evidence="ECO:0000269|PubMed:11748304" FT /id="VAR_018101" FT VARIANT 61 FT /note="H -> R (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4; dbSNP:rs398123316)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394" FT /id="VAR_026253" FT VARIANT 65..403 FT /note="Missing (in MCEPHAS)" FT /evidence="ECO:0000269|PubMed:26637798" FT /id="VAR_078705" FT VARIANT 67 FT /note="I -> R (in CWS1)" FT /evidence="ECO:0000269|PubMed:9467011" FT /id="VAR_007461" FT VARIANT 68 FT /note="Y -> H (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the FT ability to bind phospholipid membranes; dbSNP:rs398123317)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11494117, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9600246" FT /id="VAR_007462" FT VARIANT 70 FT /note="L -> P (in CWS1; dbSNP:rs121909226)" FT /evidence="ECO:0000269|PubMed:9832031" FT /id="VAR_018102" FT VARIANT 71 FT /note="C -> Y (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026254" FT VARIANT 93 FT /note="H -> R (in MCEPHAS; dbSNP:rs121909238)" FT /evidence="ECO:0000269|PubMed:15805158" FT /id="VAR_032634" FT VARIANT 93 FT /note="H -> Y (in CWS1; dbSNP:rs786204927)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:24778394" FT /id="VAR_026255" FT VARIANT 105 FT /note="C -> F (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026256" FT VARIANT 105 FT /note="C -> Y (in CWS1; dbSNP:rs587782343)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:11494117" FT /id="VAR_008735" FT VARIANT 107 FT /note="D -> Y (in CWS1; also found in glioblastoma; loss of FT phosphatase activity towards Ins(1,3,4,5)P4; FT dbSNP:rs57374291)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026257" FT VARIANT 112 FT /note="L -> P (in CWS1 and LDD; loss of phosphatase FT activity towards Ins(1,3,4,5)P4; dbSNP:rs121909230)" FT /evidence="ECO:0000269|PubMed:10051160, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:9600246" FT /id="VAR_007807" FT VARIANT 112 FT /note="L -> R (loss of phosphatase activity towards FT Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026258" FT VARIANT 119 FT /note="V -> L (in multiple cancers; dbSNP:rs139767111)" FT /evidence="ECO:0000269|PubMed:10807691" FT /id="VAR_011588" FT VARIANT 121 FT /note="A -> G (in HNSCC; dbSNP:rs121909237)" FT /evidence="ECO:0000269|PubMed:11801303" FT /id="VAR_018103" FT VARIANT 121 FT /note="A -> P (in glioblastoma; loss of phosphatase FT activity towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026259" FT VARIANT 123 FT /note="H -> R (in CWS1; dbSNP:rs121909222)" FT /evidence="ECO:0000269|PubMed:10234502, FT ECO:0000269|PubMed:9259288" FT /id="VAR_007463" FT VARIANT 123 FT /note="H -> Y (in endometrial cancer; loss of protein FT phosphatase activity; dbSNP:rs786204931)" FT /evidence="ECO:0000269|PubMed:9256433" FT /id="VAR_026260" FT VARIANT 124 FT /note="C -> R (in CWS1; dbSNP:rs121909223)" FT /evidence="ECO:0000269|PubMed:10234502, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:9259288" FT /id="VAR_007464" FT VARIANT 124 FT /note="C -> S (in CWS1; phosphatase-dead protein with FT neither lipid nor protein phosphatase activity; loss of FT phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase FT activity; dbSNP:rs121909223)" FT /evidence="ECO:0000269|PubMed:11230179, FT ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9811831" FT /id="VAR_018104" FT VARIANT 126 FT /note="A -> G (in a patient with prostate cancer; reduced FT phosphatase activity towards PtdIns(3,4,5); shifts its FT activity from phosphatidylinositol phosphate 3-phosphatase FT to phosphatidylinositol phosphate 5-phosphatase; disrupts FT PI3K/ATK signaling; reduced cell migration)" FT /evidence="ECO:0000269|PubMed:26504226" FT /id="VAR_076551" FT VARIANT 129 FT /note="G -> E (in CWS1; no lipid phosphatase activity but FT retains protein phosphatase activity; retains ability to FT inhibit focal adhesion formation; dbSNP:rs121909218)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:11230179, ECO:0000269|PubMed:21659347, FT ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9616126, FT ECO:0000269|PubMed:9811831" FT /id="VAR_007465" FT VARIANT 129 FT /note="G -> R (in glioblastoma; severely reduced protein FT phosphatase activity; loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs786204929)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9072974, ECO:0000269|PubMed:9256433, FT ECO:0000269|PubMed:9331071" FT /id="VAR_007466" FT VARIANT 130 FT /note="R -> G (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; FT dbSNP:rs121909224)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394" FT /id="VAR_026261" FT VARIANT 130 FT /note="R -> L (in CWS1; also found in endometrial FT hyperplasia; loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains ability to bind phospholipid FT membranes; dbSNP:rs121909229)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394, FT ECO:0000269|PubMed:9635567" FT /id="VAR_007467" FT VARIANT 130 FT /note="R -> Q (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4; retains ability to bind FT phospholipid membranes; dbSNP:rs121909229)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394, FT ECO:0000269|PubMed:9915974" FT /id="VAR_007468" FT VARIANT 131 FT /note="T -> I (in MCEPHAS; dbSNP:rs397514560)" FT /evidence="ECO:0000269|PubMed:23160955" FT /id="VAR_076762" FT VARIANT 132 FT /note="G -> V (in one patient with clinical findings FT suggesting hamartoma tumor syndrome; dbSNP:rs121909241)" FT /evidence="ECO:0000269|PubMed:16752378" FT /id="VAR_032635" FT VARIANT 133 FT /note="V -> I (loss of phosphatase activity towards FT Ins(1,3,4,5)P3)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026262" FT VARIANT 134 FT /note="M -> L (in prostate cancer; no effect on protein FT phosphatase activity; reduced phosphatase activity towards FT Ins(1,3,4,5)P3 but retains PtdIns(3,4,5)P3 phosphatase FT activity)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9072974, ECO:0000269|PubMed:9256433" FT /id="VAR_007469" FT VARIANT 135 FT /note="I -> V (in CWS1; dbSNP:rs587782360)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:11494117" FT /id="VAR_008736" FT VARIANT 136 FT /note="C -> Y (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P3; dbSNP:rs786204859)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9735393" FT /id="VAR_007808" FT VARIANT 137 FT /note="A -> AN (in CWS1)" FT /evidence="ECO:0000269|PubMed:9345101" FT /id="VAR_008737" FT VARIANT 155 FT /note="Y -> C (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4; dbSNP:rs1060500126)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026263" FT VARIANT 158 FT /note="V -> L (in multiple cancers)" FT /evidence="ECO:0000269|PubMed:10807691" FT /id="VAR_011589" FT VARIANT 165 FT /note="G -> E (in CWS1)" FT /evidence="ECO:0000269|PubMed:10234502" FT /id="VAR_008739" FT VARIANT 165 FT /note="G -> R (in CWS1; also found in glioblastoma; FT severely reduced protein phosphatase activity; loss of FT phosphatase activity towards Ins(1,3,4,5)P4; retains FT ability to bind phospholipid membranes; dbSNP:rs587782603)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9256433, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026264" FT VARIANT 165 FT /note="G -> V (in CWS1; dbSNP:rs786204863)" FT /evidence="ECO:0000269|PubMed:9467011" FT /id="VAR_008738" FT VARIANT 167 FT /note="T -> N (in MCEPHAS; dbSNP:rs397514559)" FT /evidence="ECO:0000269|PubMed:23160955" FT /id="VAR_076763" FT VARIANT 167 FT /note="T -> P (in breast cancer; severely reduced protein FT phosphatase activity)" FT /evidence="ECO:0000269|PubMed:9256433" FT /id="VAR_026265" FT VARIANT 170 FT /note="S -> N (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026266" FT VARIANT 170 FT /note="S -> R (in CWS1; severely reduced protein FT phosphatase activity; loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs121909221)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11494117, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9241266, FT ECO:0000269|PubMed:9256433" FT /id="VAR_007470" FT VARIANT 173 FT /note="R -> C (in CWS1; also found in endometrial FT hyperplasia; loss of phosphatase activity towards FT Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains ability to bind FT phospholipid membranes; dbSNP:rs121913293)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:24778394, ECO:0000269|PubMed:9635567" FT /id="VAR_026267" FT VARIANT 173 FT /note="R -> H (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs121913294)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026268" FT VARIANT 173 FT /note="R -> P (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs121913294)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026269" FT VARIANT 174 FT /note="Y -> N (found in a thyroid tumor; somatic variant; FT loss of phosphatase activity towards Ins(1,3,4,5)P4; FT dbSNP:rs587782316)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:39316756" FT /id="VAR_026270" FT VARIANT 191 FT /note="V -> A (in endometrial hyperplasia)" FT /evidence="ECO:0000269|PubMed:9635567" FT /id="VAR_026271" FT VARIANT 217 FT /note="V -> I (in malignant melanoma; somatic mutation; FT dbSNP:rs121909234)" FT /evidence="ECO:0000269|PubMed:10978354" FT /id="VAR_018105" FT VARIANT 227 FT /note="S -> F (reduced phosphatase activity towards FT Ins(1,3,4,5)P4; retains PtdIns(3,4,5)P3 phosphatase FT activity; dbSNP:rs905615413)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026272" FT VARIANT 234 FT /note="R -> Q (in GLM2; uncertain significance; not capable FT of inducing apoptosis; induced increased cell FT proliferation; led to high constitutive AKT1 activation FT which could not be increased further by stimulation with FT insulin; dbSNP:rs121909235)" FT /evidence="ECO:0000269|PubMed:12085208" FT /id="VAR_018106" FT VARIANT 241 FT /note="F -> S (in MCEPHAS; dbSNP:rs121909240)" FT /evidence="ECO:0000269|PubMed:15805158" FT /id="VAR_032636" FT VARIANT 246 FT /note="P -> L (in CWS1; dbSNP:rs587782350)" FT /evidence="ECO:0000269|PubMed:10400993" FT /id="VAR_008740" FT VARIANT 251 FT /note="G -> C (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026273" FT VARIANT 252 FT /note="D -> G (in MCEPHAS and CWS1; dbSNP:rs121909239)" FT /evidence="ECO:0000269|PubMed:15805158, FT ECO:0000269|PubMed:21659347" FT /id="VAR_032637" FT VARIANT 289 FT /note="K -> E (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4; retains ability to bind FT phospholipid membranes; predominantly nuclear; FT dbSNP:rs562015640)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:9797362" FT /id="VAR_008741" FT VARIANT 290 FT /note="V -> L (in dbSNP:rs35600253)" FT /evidence="ECO:0000269|Ref.10" FT /id="VAR_025167" FT VARIANT 319 FT /note="Missing (in glioma; reduced tumor suppressor FT activity; fails to inactivate AKT/PKB)" FT /evidence="ECO:0000269|PubMed:10468583, FT ECO:0000269|PubMed:9090379" FT /id="VAR_026274" FT VARIANT 331 FT /note="D -> G (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4; retains ability to bind FT phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026275" FT VARIANT 341 FT /note="F -> V (in CWS1; loss of interaction with NOP53; FT decreased phosphorylation at S-380; decreased stability; FT loss of phosphatase activity towards Ins(1,3,4,5)P4; FT dbSNP:rs1554825652)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:15355975" FT /id="VAR_026276" FT VARIANT 342 FT /note="K -> N (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4 but PtdIns(3,4,5)P3 phosphatase FT activity is similar to wild-type; dbSNP:rs398123314)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026277" FT VARIANT 343 FT /note="V -> E (in CWS1; loss of interaction with NOP53; FT decreased phosphorylation at S-380; decreased stability; FT loss of phosphatase activity towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:15355975, ECO:0000269|PubMed:9399897" FT /id="VAR_008742" FT VARIANT 345 FT /note="L -> Q (in glioblastoma; reduced tumor suppressor FT activity; loss of interaction with NOP53; decreased FT phosphorylation at S-380; decreased stability; loss of FT phosphatase activity towards Ins(1,3,4,5)P4; reduced FT ability to inactivate AKT/PKB; retains ability to bind FT phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:10468583, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:15355975, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026278" FT VARIANT 347 FT /note="F -> L (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9399897" FT /id="VAR_008743" FT VARIANT 348 FT /note="T -> I (in endometrial hyperplasia; reduced FT phosphatase activity towards PtdIns(3,4,5)P3; mildly FT reduced tumor suppressor activity; reduced ability to FT inactivate AKT/PKB)" FT /evidence="ECO:0000269|PubMed:10468583, FT ECO:0000269|PubMed:9635567" FT /id="VAR_026279" FT VARIANT 369 FT /note="V -> G (retains Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3 FT phosphatase activity; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026280" FT VARIANT 401 FT /note="T -> I (retains Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3 FT phosphatase activity; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026281" FT MUTAGEN 1 FT /note="M->I: Prevents expression of isoform 1 and increased FT expression of isoform alpha." FT /evidence="ECO:0000269|PubMed:24768297" FT MUTAGEN 13 FT /note="K->E: Nuclear. Cytoplasmic; when associated with E- FT 289. Shows less tumor suppressive ability; when associated FT with E-289." FT /evidence="ECO:0000269|PubMed:18716620" FT MUTAGEN 92 FT /note="D->A: 700-fold reduction in phosphatase activity FT towards PtdIns(3,4,5)P3. Loss of protein phosphatase FT activity. Unable to inhibit focal adhesion formation." FT /evidence="ECO:0000269|PubMed:10555148, FT ECO:0000269|PubMed:9616126" FT MUTAGEN 93 FT /note="H->A: 75% reduction in phosphatase activity towards FT PtdIns(3,4,5)P3. Modest reduction in phosphatase activity FT towards PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 124 FT /note="C->A: Loss of protein phosphatase activity. Unable FT to inhibit focal adhesion formation." FT /evidence="ECO:0000269|PubMed:9616126" FT MUTAGEN 125 FT /note="K->M: Reduced phosphatase activity towards FT PtdIns(3,4,5)P3, PtdIns(3,4)P2 and PtdIns(3)P." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 126 FT /note="A->P: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:26504226" FT MUTAGEN 126 FT /note="A->S: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:26504226" FT MUTAGEN 126 FT /note="A->V: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:26504226" FT MUTAGEN 128 FT /note="K->M: 85% reduction in phosphatase activity towards FT PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 128 FT /note="K->R: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 130 FT /note="R->M: Does not affect the ability to inhibit AKT/PKB FT activation." FT /evidence="ECO:0000269|PubMed:9811831" FT MUTAGEN 167 FT /note="T->A,D: 60% reduction in phosphatase activity FT towards PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 171 FT /note="Q->A,E: 75% reduction in phosphatase activity FT towards PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 229 FT /note="S->A: No effect on interaction with DLC1 or p85." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 232 FT /note="T->A: No effect on interaction with DLC1 or p85." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 263..269 FT /note="KMLKKDK->AAGAADA: Reduces the growth suppression FT activity and cells show anchorage-independent growth. FT Reduces binding to phospholipid membranes in vitro. FT Phosphatase activity towards PtdIns(3,4,5)P3 is not FT affected." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 289 FT /note="K->E: Cytoplasmic; when associated with E-13. Shows FT less tumor suppressive ability; when associated with E-13." FT /evidence="ECO:0000269|PubMed:18716620" FT MUTAGEN 319 FT /note="T->A: Reduces phosphorylation of the C2 tensin-like FT domain and abolishes interaction with DLC1 following EGF FT stimulation. Abolishes phosphorylation of the C2 tensin- FT like domain; when associated with A-321." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 319 FT /note="T->E: Constitutive interaction with DLC1." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 319 FT /note="T->Y: Constitutive interaction with DLC1 and FT interaction with p85 following EGF stimulation." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 321 FT /note="T->A: Reduces phosphorylation of the C2 tensin-like FT domain and abolishes interaction with DLC1 following EGF FT stimulation. Abolishes phosphorylation of the C2 tensin- FT like domain; when associated with A-319." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 321 FT /note="T->E: Constitutive interaction with DLC1." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 327..335 FT /note="KANKDKANR->AAGADAANA: Reduces growth suppression FT activity and promotes anchorage-independent growth. Reduces FT binding to phospholipid membranes in vitro; phosphatase FT activity towards PtdIns(3,4,5)P3 is not affected." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 336 FT /note="Y->F: Significantly lower phosphatase activity, FT reduced protein stability and decreased growth-inhibitory FT effect." FT /evidence="ECO:0000269|PubMed:19345329" FT MUTAGEN 366 FT /note="T->A: Decreased stability." FT /evidence="ECO:0000269|PubMed:20940307" FT MUTAGEN 370 FT /note="S->A: Decreased stability." FT /evidence="ECO:0000269|PubMed:20940307" FT MUTAGEN 401 FT /note="T->A: Loss of DLG1-binding. No effect on MAGI2- and FT MAST2-binding." FT MUTAGEN 402 FT /note="K->A: No effect on MAGI2-, MAST2- and DLG1-binding." FT MUTAGEN 402 FT /note="K->W: Loss of DLG1-, MAGI2-, MAGI3- and MAST2- FT binding. Decrease of protein stability." FT MUTAGEN 403 FT /note="V->A: Loss of DLG1-, MAGI2-, MAGI3-, MAST1-, FT MAST2- and MAST3-binding." FT /evidence="ECO:0000269|PubMed:15951562" FT HELIX 8..10 FT /evidence="ECO:0007829|PDB:7JUL" FT TURN 19..22 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 23..29 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 32..35 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 39..41 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 44..47 FT /evidence="ECO:0007829|PDB:5BZZ" FT HELIX 50..60 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 61..63 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 65..73 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 78..80 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 81..83 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 85..90 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 98..100 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 101..112 FT /evidence="ECO:0007829|PDB:1D5R" FT TURN 113..115 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 118..123 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 125..128 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 129..141 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 148..159 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 161..163 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 169..184 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 192..202 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 206..209 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 213..219 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 222..226 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 232..235 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 238..259 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 262..264 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 268..276 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 277..279 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 280..284 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 310..312 FT /evidence="ECO:0007829|PDB:5BZX" FT STRAND 315..321 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 322..324 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 328..330 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 335..337 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 342..349 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 395..403 FT /evidence="ECO:0007829|PDB:2KYL" SQ SEQUENCE 403 AA; 47166 MW; 75F97C3DD6802BA9 CRC64; MTAIIKEIVS RNKRRYQEDG FDLDLTYIYP NIIAMGFPAE RLEGVYRNNI DDVVRFLDSK HKNHYKIYNL CAERHYDTAK FNCRVAQYPF EDHNPPQLEL IKPFCEDLDQ WLSEDDNHVA AIHCKAGKGR TGVMICAYLL HRGKFLKAQE ALDFYGEVRT RDKKGVTIPS QRRYVYYYSY LLKNHLDYRP VALLFHKMMF ETIPMFSGGT CNPQFVVCQL KVKIYSSNSG PTRREDKFMY FEFPQPLPVC GDIKVEFFHK QNKMLKKDKM FHFWVNTFFI PGPEETSEKV ENGSLCDQEI DSICSIERAD NDKEYLVLTL TKNDLDKANK DKANRYFSPN FKVKLYFTKT VEEPSNPEAS SSTSVTPDVS DNEPDHYRYS DTTDSDPENE PFDEDQHTQI TKV // ID PTK6_HUMAN Reviewed; 451 AA. AC Q13882; B2RCR3; B4DW46; Q58F01; DT 01-DEC-2000, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 234. DE RecName: Full=Protein-tyrosine kinase 6; DE EC=2.7.10.2 {ECO:0000269|PubMed:12121988, ECO:0000269|PubMed:27480927, ECO:0000269|PubMed:27993680}; DE AltName: Full=Breast tumor kinase; DE AltName: Full=Tyrosine-protein kinase BRK; GN Name=PTK6; Synonyms=BRK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Mammary tumor; RX PubMed=8036022; RA Mitchell P.J., Barker K.T., Martindale J.E., Kamalati T., Lowe P.N., RA Page M.J., Gusterson B.A., Crompton M.R.; RT "Cloning and characterisation of cDNAs encoding a novel non-receptor RT tyrosine kinase, brk, expressed in human breast tumours."; RL Oncogene 9:2383-2390(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2). RX PubMed=9333026; DOI=10.1038/sj.onc.1201292; RA Mitchell P.J., Barker K.T., Shipley J., Crompton M.R.; RT "Characterisation and chromosome mapping of the human non receptor tyrosine RT kinase gene, brk."; RL Oncogene 15:1497-1502(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Melanocyte; RX PubMed=9749526; RA Lee H.-Y., Kim M., Lee K.-H., Kang K.-N., Lee S.-T.; RT "Exon-intron structure of the human PTK6 gene demonstrates that PTK6 RT constitutes a distinct family of non-receptor tyrosine kinase."; RL Mol. Cells 8:401-407(1998). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Urinary bladder; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=11780052; DOI=10.1038/414865a; RA Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R., RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L., RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P., RA Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D., RA Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G., RA Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E., RA Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D., RA Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P., RA Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E., RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J., RA Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D., RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S., RA Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D., RA Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A., RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T., RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I., RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M., RA Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D., RA Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M., RA Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A., RA Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L., RA Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L., RA Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 20."; RL Nature 414:865-871(2001). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Blood; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP CHARACTERIZATION, INTERACTION WITH EGFR, AND MUTAGENESIS OF LYS-219 AND RP TYR-447. RX PubMed=8940083; DOI=10.1074/jbc.271.48.30956; RA Kamalati T., Jolin H.E., Mitchell P.J., Barker K.T., Jackson L.E., RA Dean C.J., Page M.J., Gusterson B.A., Crompton M.R.; RT "Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, RT sensitizes mammary epithelial cells to epidermal growth factor."; RL J. Biol. Chem. 271:30956-30963(1996). RN [8] RP TISSUE SPECIFICITY. RX PubMed=9185712; RX DOI=10.1002/(sici)1097-0215(19970611)71:6<1061::aid-ijc24>3.0.co;2-f; RA Easty D.J., Mitchell P.J., Patel K., Florenes V.A., Spritz R.A., RA Bennett D.C.; RT "Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK RT in metastatic melanoma."; RL Int. J. Cancer 71:1061-1065(1997). RN [9] RP FUNCTION, INTERACTION WITH STAP2, AND MUTAGENESIS OF TRP-44; TYR-66; RP ARG-105 AND LYS-219. RX PubMed=10980601; DOI=10.1038/sj.onc.1203775; RA Mitchell P.J., Sara E.A., Crompton M.R.; RT "A novel adaptor-like protein which is a substrate for the non-receptor RT tyrosine kinase, BRK."; RL Oncogene 19:4273-4282(2000). RN [10] RP SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-447, AND INTERACTION WITH RP KHDRBS1. RX PubMed=10913193; DOI=10.1128/mcb.20.16.6114-6126.2000; RA Derry J.J., Richard S., Valderrama Carvajal H., Ye X., Vasioukhin V., RA Cochrane A.W., Chen T., Tyner A.L.; RT "Sik (BRK) phosphorylates Sam68 in the nucleus and negatively regulates its RT RNA binding ability."; RL Mol. Cell. Biol. 20:6114-6126(2000). RN [11] RP PHOSPHORYLATION AT TYR-13; TYR-61; TYR-66; TYR-114; TYR-342 AND TYR-351, RP CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, MUTAGENESIS OF TYR-342 RP AND TYR-447, ACTIVITY REGULATION, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=12121988; DOI=10.1074/jbc.m203877200; RA Qiu H., Miller W.T.; RT "Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation RT and by autoinhibition."; RL J. Biol. Chem. 277:34634-34641(2002). RN [12] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=12833144; DOI=10.1038/sj.onc.1206465; RA Derry J.J., Prins G.S., Ray V., Tyner A.L.; RT "Altered localization and activity of the intracellular tyrosine kinase RT BRK/Sik in prostate tumor cells."; RL Oncogene 22:4212-4220(2003). RN [13] RP FUNCTION, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-219 AND TYR-447, AND RP PHOSPHORYLATION. RX PubMed=15471878; DOI=10.1074/jbc.m409579200; RA Haegebarth A., Heap D., Bie W., Derry J.J., Richard S., Tyner A.L.; RT "The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the RNA- RT binding activities of the Sam68-like mammalian proteins SLM-1 and SLM-2."; RL J. Biol. Chem. 279:54398-54404(2004). RN [14] RP FUNCTION IN CELL MIGRATION, FUNCTION IN PHOSPHORYLATION OF PXN, SUBCELLULAR RP LOCATION, AND INTERACTION WITH PXN. RX PubMed=15572663; DOI=10.1128/mcb.24.24.10558-10572.2004; RA Chen H.Y., Shen C.H., Tsai Y.T., Lin F.C., Huang Y.P., Chen R.H.; RT "Brk activates rac1 and promotes cell migration and invasion by RT phosphorylating paxillin."; RL Mol. Cell. Biol. 24:10558-10572(2004). RN [15] RP TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=15509496; DOI=10.1016/j.oraloncology.2004.05.010; RA Petro B.J., Tan R.C., Tyner A.L., Lingen M.W., Watanabe K.; RT "Differential expression of the non-receptor tyrosine kinase BRK in oral RT squamous cell carcinoma and normal oral epithelium."; RL Oral Oncol. 40:1040-1047(2004). RN [16] RP FUNCTION IN PHOSPHORYLATION OF BTK, AND INTERACTION WITH BTK. RX PubMed=15539407; DOI=10.1074/jbc.m412038200; RA Zhang P., Ostrander J.H., Faivre E.J., Olsen A., Fitzsimmons D., RA Lange C.A.; RT "Regulated association of protein kinase B/Akt with breast tumor kinase."; RL J. Biol. Chem. 280:1982-1991(2005). RN [17] RP MUTAGENESIS OF TRP-184, AND ACTIVITY REGULATION. RX PubMed=15961400; DOI=10.1074/jbc.m504568200; RA Kim H.I.E., Lee S.T.; RT "An intramolecular interaction between SH2-kinase linker and kinase domain RT is essential for the catalytic activity of protein-tyrosine kinase-6."; RL J. Biol. Chem. 280:28973-28980(2005). RN [18] RP FUNCTION IN PHOSPHORYLATION OF KHDRBS1. RX PubMed=16179349; DOI=10.1074/jbc.m505802200; RA Lukong K.E., Larocque D., Tyner A.L., Richard S.; RT "Tyrosine phosphorylation of sam68 by breast tumor kinase regulates RT intranuclear localization and cell cycle progression."; RL J. Biol. Chem. 280:38639-38647(2005). RN [19] RP INTERACTION WITH IRS4, AND ACTIVITY REGULATION. RX PubMed=15870689; DOI=10.1038/sj.onc.1208721; RA Qiu H., Zappacosta F., Su W., Annan R.S., Miller W.T.; RT "Interaction between Brk kinase and insulin receptor substrate-4."; RL Oncogene 24:5656-5664(2005). RN [20] RP TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=16651629; DOI=10.2353/ajpath.2006.050521; RA Kasprzycka M., Majewski M., Wang Z.J., Ptasznik A., Wysocka M., Zhang Q., RA Marzec M., Gimotty P., Crompton M.R., Wasik M.A.; RT "Expression and oncogenic role of Brk (PTK6/Sik) protein tyrosine kinase in RT lymphocytes."; RL Am. J. Pathol. 168:1631-1641(2006). RN [21] RP FUNCTION IN PHOSPHORYLATION OF STAT3, AND ACTIVITY REGULATION. RX PubMed=16568091; DOI=10.1038/sj.onc.1209501; RA Liu L., Gao Y., Qiu H., Miller W.T., Poli V., Reich N.C.; RT "Identification of STAT3 as a specific substrate of breast tumor kinase."; RL Oncogene 25:4904-4912(2006). RN [22] RP ACTIVITY REGULATION, AND MUTAGENESIS OF TRP-44. RX PubMed=17822667; DOI=10.1016/j.bbrc.2007.08.055; RA Kim H.I.E., Jung J., Lee E.S., Kim Y.C., Lee W., Lee S.T.; RT "Molecular dissection of the interaction between the SH3 domain and the RT SH2-Kinase Linker region in PTK6."; RL Biochem. Biophys. Res. Commun. 362:829-834(2007). RN [23] RP FUNCTION IN PHOSPHORYLATION OF STAT5B. RX PubMed=17997837; DOI=10.1186/bcr1794; RA Weaver A.M., Silva C.M.; RT "Signal transducer and activator of transcription 5b: a new target of RT breast tumor kinase/protein tyrosine kinase 6."; RL Breast Cancer Res. 9:R79-R79(2007). RN [24] RP FUNCTION IN PHOSPHORYLATION OF ARHGAP35. RX PubMed=18829532; DOI=10.1158/0008-5472.can-08-0997; RA Shen C.H., Chen H.Y., Lin M.S., Li F.Y., Chang C.C., Kuo M.L., RA Settleman J., Chen R.H.; RT "Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and RT promote breast carcinoma growth, migration, and invasion."; RL Cancer Res. 68:7779-7787(2008). RN [25] RP INTERACTION WITH ADAM15. RX PubMed=18296648; DOI=10.1158/1541-7786.mcr-07-2028; RA Zhong J.L., Poghosyan Z., Pennington C.J., Scott X., Handsley M.M., RA Warn A., Gavrilovic J., Honert K., Kruger A., Span P.N., Sweep F.C., RA Edwards D.R.; RT "Distinct functions of natural ADAM-15 cytoplasmic domain variants in human RT mammary carcinoma."; RL Mol. Cancer Res. 6:383-394(2008). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-114, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [27] RP INTERACTION WITH ERBB2. RX PubMed=18719096; DOI=10.1073/pnas.0805009105; RA Xiang B., Chatti K., Qiu H., Lakshmi B., Krasnitz A., Hicks J., Yu M., RA Miller W.T., Muthuswamy S.K.; RT "Brk is coamplified with ErbB2 to promote proliferation in breast cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 105:12463-12468(2008). RN [28] RP INTERACTION WITH SFPQ. RX PubMed=19439179; DOI=10.1016/j.cellsig.2009.04.008; RA Lukong K.E., Huot M.E., Richard S.; RT "BRK phosphorylates PSF promoting its cytoplasmic localization and cell RT cycle arrest."; RL Cell. Signal. 21:1415-1422(2009). RN [29] RP REVIEW ON FUNCTION. RX PubMed=20193745; DOI=10.1016/j.bbcan.2010.02.003; RA Brauer P.M., Tyner A.L.; RT "Building a better understanding of the intracellular tyrosine kinase PTK6 RT - BRK by BRK."; RL Biochim. Biophys. Acta 1806:66-73(2010). RN [30] RP FUNCTION, AND MUTAGENESIS OF ARG-105 AND LYS-219. RX PubMed=20554524; DOI=10.1074/jbc.m109.088971; RA Kang S.A., Lee E.S., Yoon H.Y., Randazzo P.A., Lee S.T.; RT "PTK6 inhibits down-regulation of EGF receptor through phosphorylation of RT ARAP1."; RL J. Biol. Chem. 285:26013-26021(2010). RN [31] RP PHOSPHORYLATION OF CTNNB1, AND INTERACTION WITH CTNNB1. RX PubMed=20026641; DOI=10.1242/jcs.053264; RA Palka-Hamblin H.L., Gierut J.J., Bie W., Brauer P.M., Zheng Y., Asara J.M., RA Tyner A.L.; RT "Identification of beta-catenin as a target of the intracellular tyrosine RT kinase PTK6."; RL J. Cell Sci. 123:236-245(2010). RN [32] RP FUNCTION (ISOFORM 2), AND INTERACTION (ISOFORM 2) WITH KHDRBS1 AND CTNNB1. RX PubMed=21479203; DOI=10.1371/journal.pone.0014789; RA Brauer P.M., Zheng Y., Evans M.D., Dominguez-Brauer C., Peehl D.M., RA Tyner A.L.; RT "The alternative splice variant of protein tyrosine kinase 6 negatively RT regulates growth and enhances PTK6-mediated inhibition of beta-catenin."; RL PLoS ONE 6:E14789-E14789(2011). RN [33] RP STRUCTURE BY NMR OF 75-174. RX PubMed=15056653; DOI=10.1074/jbc.m313185200; RA Hong E., Shin J., Kim H.I., Lee S.T., Lee W.; RT "Solution structure and backbone dynamics of the non-receptor protein- RT tyrosine kinase-6 Src homology 2 domain."; RL J. Biol. Chem. 279:29700-29708(2004). RN [34] RP X-RAY CRYSTALLOGRAPHY (2.33 ANGSTROMS) OF 185-446, CATALYTIC ACTIVITY, AND RP MUTAGENESIS OF LYS-219. RX PubMed=27480927; DOI=10.1016/j.bbrc.2016.07.121; RA Thakur M.K., Kumar A., Birudukota S., Swaminathan S., Tyagi R., Gosu R.; RT "Crystal structure of the kinase domain of human protein tyrosine kinase 6 RT (PTK6) at 2.33 A resolution."; RL Biochem. Biophys. Res. Commun. 478:637-642(2016). RN [35] RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 185-446 IN COMPLEXES WITH RP INHIBITORS, AND CATALYTIC ACTIVITY. RX PubMed=27993680; DOI=10.1016/j.bbrc.2016.12.030; RA Thakur M.K., Birudukota S., Swaminathan S., Battula S.K., Vadivelu S., RA Tyagi R., Gosu R.; RT "Co-crystal structures of PTK6: With Dasatinib at 2.24 A, with novel RT imidazo[1,2-a]pyrazin-8-amine derivative inhibitor at 1.70 A resolution."; RL Biochem. Biophys. Res. Commun. 482:1289-1295(2017). RN [36] RP VARIANTS [LARGE SCALE ANALYSIS] PHE-16 AND THR-436. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Non-receptor tyrosine-protein kinase implicated in the CC regulation of a variety of signaling pathways that control the CC differentiation and maintenance of normal epithelia, as well as tumor CC growth. Function seems to be context dependent and differ depending on CC cell type, as well as its intracellular localization. A number of CC potential nuclear and cytoplasmic substrates have been identified. CC These include the RNA-binding proteins: KHDRBS1/SAM68, KHDRBS2/SLM1, CC KHDRBS3/SLM2 and SFPQ/PSF; transcription factors: STAT3 and STAT5A/B CC and a variety of signaling molecules: ARHGAP35/p190RhoGAP, CC PXN/paxillin, BTK/ATK, STAP2/BKS. Phosphorylates the GTPase-activating CC protein ARAP1 following EGF stimulation which enhances EGFR signaling CC by delaying EGFR down-regulation (PubMed:20554524). Also associates CC with a variety of proteins that are likely upstream of PTK6 in various CC signaling pathways, or for which PTK6 may play an adapter-like role. CC These proteins include ADAM15, EGFR, ERBB2, ERBB3 and IRS4. In normal CC or non-tumorigenic tissues, PTK6 promotes cellular differentiation and CC apoptosis. In tumors PTK6 contributes to cancer progression by CC sensitizing cells to mitogenic signals and enhancing proliferation, CC anchorage-independent survival and migration/invasion. Association with CC EGFR, ERBB2, ERBB3 may contribute to mammary tumor development and CC growth through enhancement of EGF-induced signaling via BTK/AKT and PI3 CC kinase. Contributes to migration and proliferation by contributing to CC EGF-mediated phosphorylation of ARHGAP35/p190RhoGAP, which promotes CC association with RASA1/p120RasGAP, inactivating RhoA while activating CC RAS. EGF stimulation resulted in phosphorylation of PNX/Paxillin by CC PTK6 and activation of RAC1 via CRK/CrKII, thereby promoting migration CC and invasion. PTK6 activates STAT3 and STAT5B to promote proliferation. CC Nuclear PTK6 may be important for regulating growth in normal CC epithelia, while cytoplasmic PTK6 might activate oncogenic signaling CC pathways. {ECO:0000269|PubMed:20554524}. CC -!- FUNCTION: [Isoform 2]: Inhibits PTK6 phosphorylation and PTK6 CC association with other tyrosine-phosphorylated proteins. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:12121988, ECO:0000269|PubMed:27480927, CC ECO:0000269|PubMed:27993680}; CC -!- ACTIVITY REGULATION: Activated by EGF, NRG1 and IGF1. Inhibited by CC SOCS3 to phosphorylate STAT3. Stabilized in the inactive form by an CC association between the SH3 domain and the SH2-TK linker region. CC Interaction between Trp-184 within SH2-TK linker region and the CC catalytic domain appears essential for positive regulation of kinase CC activity. {ECO:0000269|PubMed:12121988, ECO:0000269|PubMed:15870689, CC ECO:0000269|PubMed:15961400, ECO:0000269|PubMed:16568091, CC ECO:0000269|PubMed:17822667}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=83 uM for ATP {ECO:0000269|PubMed:12121988}; CC Vmax=37 nmol/min/mg enzyme {ECO:0000269|PubMed:12121988}; CC -!- SUBUNIT: Interacts with GAP-A.p65 (By similarity). Interacts (via SH3 CC and SH2 domains) with KHDRBS1. Interacts (via SH3 and SH2 domains) with CC phosphorylated IRS4. Interacts with ADAM15. Interacts (via SH3 domain) CC with SFPQ. Interacts with EGFR and ERBB2. Interacts with STAP2. CC Interacts with PNX. Interacts with SFPQ. Interacts with PTK/ATK. CC Interacts with CTNNB1. {ECO:0000250, ECO:0000269|PubMed:10913193, CC ECO:0000269|PubMed:10980601, ECO:0000269|PubMed:15539407, CC ECO:0000269|PubMed:15572663, ECO:0000269|PubMed:15870689, CC ECO:0000269|PubMed:18296648, ECO:0000269|PubMed:18719096, CC ECO:0000269|PubMed:19439179, ECO:0000269|PubMed:20026641, CC ECO:0000269|PubMed:8940083}. CC -!- INTERACTION: CC Q13882; Q08043: ACTN3; NbExp=3; IntAct=EBI-1383632, EBI-2880652; CC Q13882; Q3KP44: ANKRD55; NbExp=3; IntAct=EBI-1383632, EBI-14493093; CC Q13882; Q13191: CBLB; NbExp=3; IntAct=EBI-1383632, EBI-744027; CC Q13882; Q16543: CDC37; NbExp=4; IntAct=EBI-1383632, EBI-295634; CC Q13882; Q92841: DDX17; NbExp=4; IntAct=EBI-1383632, EBI-746012; CC Q13882; Q8N9I9: DTX3; NbExp=3; IntAct=EBI-1383632, EBI-2340258; CC Q13882; Q5JST6: EFHC2; NbExp=7; IntAct=EBI-1383632, EBI-2349927; CC Q13882; P00533: EGFR; NbExp=2; IntAct=EBI-1383632, EBI-297353; CC Q13882; P04626: ERBB2; NbExp=4; IntAct=EBI-1383632, EBI-641062; CC Q13882; O00471: EXOC5; NbExp=6; IntAct=EBI-1383632, EBI-949824; CC Q13882; O14526: FCHO1; NbExp=4; IntAct=EBI-1383632, EBI-719823; CC Q13882; Q13480: GAB1; NbExp=6; IntAct=EBI-1383632, EBI-517684; CC Q13882; P08238: HSP90AB1; NbExp=3; IntAct=EBI-1383632, EBI-352572; CC Q13882; P42858: HTT; NbExp=4; IntAct=EBI-1383632, EBI-466029; CC Q13882; Q9UKT9: IKZF3; NbExp=3; IntAct=EBI-1383632, EBI-747204; CC Q13882; Q5VWX1: KHDRBS2; NbExp=4; IntAct=EBI-1383632, EBI-742808; CC Q13882; Q5T5P2-6: KIAA1217; NbExp=3; IntAct=EBI-1383632, EBI-10188326; CC Q13882; P10721: KIT; NbExp=4; IntAct=EBI-1383632, EBI-1379503; CC Q13882; O14770-4: MEIS2; NbExp=3; IntAct=EBI-1383632, EBI-8025850; CC Q13882; Q13064: MKRN3; NbExp=3; IntAct=EBI-1383632, EBI-2340269; CC Q13882; Q8TDC0: MYOZ3; NbExp=3; IntAct=EBI-1383632, EBI-5662487; CC Q13882; P78337: PITX1; NbExp=3; IntAct=EBI-1383632, EBI-748265; CC Q13882; Q9NQX0: PRDM6; NbExp=3; IntAct=EBI-1383632, EBI-11320284; CC Q13882; Q13882: PTK6; NbExp=3; IntAct=EBI-1383632, EBI-1383632; CC Q13882; Q04864: REL; NbExp=3; IntAct=EBI-1383632, EBI-307352; CC Q13882; P23246: SFPQ; NbExp=5; IntAct=EBI-1383632, EBI-355453; CC Q13882; Q13239-3: SLA; NbExp=3; IntAct=EBI-1383632, EBI-17630587; CC Q13882; O00401: WASL; NbExp=3; IntAct=EBI-1383632, EBI-957615; CC Q13882; Q9BYN7: ZNF341; NbExp=3; IntAct=EBI-1383632, EBI-9089622; CC -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell projection, ruffle. CC Membrane {ECO:0000250}. Note=Colocalizes with KHDRBS1, KHDRBS2 or CC KHDRBS3, within the nucleus. Nuclear localization in epithelial cells CC of normal prostate but cytoplasmic localization in cancer prostate. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q13882-1; Sequence=Displayed; CC Name=2; Synonyms=ALT-PTK6, LambdaM5; CC IsoId=Q13882-2; Sequence=VSP_042066, VSP_042067; CC -!- TISSUE SPECIFICITY: Epithelia-specific. Very high level in colon and CC high levels in small intestine and prostate, and low levels in some CC fetal tissues. Not expressed in breast or ovarian tissue but expressed CC in high percentage of breast and ovarian cancers. Also overexpressed in CC some metastatic melanomas, lymphomas, colon cancers, squamous cell CC carcinomas and prostate cancers. Also found in melanocytes. Not CC expressed in heart, brain, placenta, lung, liver, skeletal muscle, CC kidney and pancreas. Isoform 2 is present in prostate epithelial cell CC lines derived from normal prostate and prostate adenocarcinomas, as CC well as in a variety of cell lines. {ECO:0000269|PubMed:12833144, CC ECO:0000269|PubMed:15509496, ECO:0000269|PubMed:16651629, CC ECO:0000269|PubMed:9185712}. CC -!- DOMAIN: The SH3 domain plays a major role in substrate interactions. CC The SH2 domain of PTK6 plays a role in protein-protein interactions, CC but is likely more important for the regulation of catalytic activity. CC -!- PTM: Autophosphorylated. Autophosphorylation of Tyr-342 leads to an CC increase of kinase activity. Tyr-447 binds to the SH2 domain when CC phosphorylated and negatively regulates kinase activity. CC {ECO:0000269|PubMed:10913193, ECO:0000269|PubMed:12121988, CC ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:20026641}. CC -!- MISCELLANEOUS: The inhibitors bind to the ATP-binding pocket. CC {ECO:0000269|PubMed:27993680}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. BRK/PTK6/SIK subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=BAG62908.1; Type=Erroneous translation; Note=Wrong choice of CDS.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X78549; CAA55295.1; -; mRNA. DR EMBL; U61412; AAC34935.1; -; Genomic_DNA. DR EMBL; U61406; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; U61407; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; U61408; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; U61409; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; U61410; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; U61411; AAC34935.1; JOINED; Genomic_DNA. DR EMBL; AK315232; BAG37660.1; -; mRNA. DR EMBL; AK301364; BAG62908.1; ALT_SEQ; mRNA. DR EMBL; AL121829; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC035843; AAH35843.1; -; mRNA. DR CCDS; CCDS13524.1; -. [Q13882-1] DR CCDS; CCDS74750.1; -. [Q13882-2] DR PIR; S49016; S49016. DR RefSeq; NP_001243287.1; NM_001256358.2. [Q13882-2] DR RefSeq; NP_005966.1; NM_005975.4. [Q13882-1] DR PDB; 1RJA; NMR; -; A=75-174. DR PDB; 2KGT; NMR; -; A=1-72. DR PDB; 5D7V; X-ray; 2.33 A; A/B/C/D=185-446. DR PDB; 5DA3; X-ray; 1.70 A; A=185-446. DR PDB; 5H2U; X-ray; 2.24 A; A/B/C/D=185-446. DR PDB; 6CZ2; X-ray; 2.50 A; A=182-443. DR PDB; 6CZ3; X-ray; 1.80 A; A=182-443. DR PDB; 6CZ4; X-ray; 1.50 A; A=182-443. DR PDB; 8S1C; X-ray; 1.75 A; A/B=11-72. DR PDBsum; 1RJA; -. DR PDBsum; 2KGT; -. DR PDBsum; 5D7V; -. DR PDBsum; 5DA3; -. DR PDBsum; 5H2U; -. DR PDBsum; 6CZ2; -. DR PDBsum; 6CZ3; -. DR PDBsum; 6CZ4; -. DR PDBsum; 8S1C; -. DR AlphaFoldDB; Q13882; -. DR BMRB; Q13882; -. DR SMR; Q13882; -. DR BioGRID; 111720; 103. DR DIP; DIP-39785N; -. DR FunCoup; Q13882; 312. DR IntAct; Q13882; 83. DR MINT; Q13882; -. DR STRING; 9606.ENSP00000442460; -. DR BindingDB; Q13882; -. DR ChEMBL; CHEMBL4601; -. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB11800; Tivozanib. DR DrugBank; DB05294; Vandetanib. DR DrugBank; DB15035; Zanubrutinib. DR DrugCentral; Q13882; -. DR GuidetoPHARMACOLOGY; 2182; -. DR GlyGen; Q13882; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q13882; -. DR PhosphoSitePlus; Q13882; -. DR BioMuta; PTK6; -. DR DMDM; 8928302; -. DR CPTAC; CPTAC-2842; -. DR CPTAC; CPTAC-2880; -. DR jPOST; Q13882; -. DR MassIVE; Q13882; -. DR PaxDb; 9606-ENSP00000442460; -. DR PeptideAtlas; Q13882; -. DR ProteomicsDB; 59709; -. [Q13882-1] DR ProteomicsDB; 59710; -. [Q13882-2] DR Antibodypedia; 29774; 545 antibodies from 39 providers. DR DNASU; 5753; -. DR Ensembl; ENST00000217185.3; ENSP00000217185.3; ENSG00000101213.8. [Q13882-2] DR Ensembl; ENST00000542869.3; ENSP00000442460.2; ENSG00000101213.8. [Q13882-1] DR GeneID; 5753; -. DR KEGG; hsa:5753; -. DR MANE-Select; ENST00000542869.3; ENSP00000442460.2; NM_005975.4; NP_005966.1. DR UCSC; uc002yfg.5; human. [Q13882-1] DR AGR; HGNC:9617; -. DR ClinPGx; PA33960; -. DR CTD; 5753; -. DR DisGeNET; 5753; -. DR GeneCards; PTK6; -. DR HGNC; HGNC:9617; PTK6. DR HPA; ENSG00000101213; Tissue enhanced (esophagus, skin, vagina). DR MIM; 602004; gene. DR OpenTargets; ENSG00000101213; -. DR VEuPathDB; HostDB:ENSG00000101213; -. DR eggNOG; KOG0197; Eukaryota. DR GeneTree; ENSGT00940000161218; -. DR HOGENOM; CLU_000288_7_2_1; -. DR InParanoid; Q13882; -. DR OMA; LWKGQVR; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; Q13882; 6 GO annotations based on evolutionary models. DR PhylomeDB; Q13882; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; Q13882; -. DR Reactome; R-HSA-187577; SCF(Skp2)-mediated degradation of p27/p21. DR Reactome; R-HSA-69231; Cyclin D associated events in G1. DR Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling. DR Reactome; R-HSA-8849468; PTK6 Regulates Proteins Involved in RNA Processing. DR Reactome; R-HSA-8849469; PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1. DR Reactome; R-HSA-8849470; PTK6 Regulates Cell Cycle. DR Reactome; R-HSA-8849471; PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases. DR Reactome; R-HSA-8849472; PTK6 Down-Regulation. DR Reactome; R-HSA-8849473; PTK6 Expression. DR Reactome; R-HSA-8849474; PTK6 Activates STAT3. DR Reactome; R-HSA-8857538; PTK6 promotes HIF1A stabilization. DR Reactome; R-HSA-9707564; Cytoprotection by HMOX1. DR SABIO-RK; Q13882; -. DR SignaLink; Q13882; -. DR SIGNOR; Q13882; -. DR Agora; ENSG00000101213; -. DR BioGRID-ORCS; 5753; 17 hits in 1179 CRISPR screens. DR EvolutionaryTrace; Q13882; -. DR GeneWiki; PTK6; -. DR GenomeRNAi; 5753; -. DR Pharos; Q13882; Tchem. DR PRO; PR:Q13882; -. DR Proteomes; UP000005640; Chromosome 20. DR RNAct; Q13882; protein. DR Bgee; ENSG00000101213; Expressed in esophagus squamous epithelium and 125 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0016604; C:nuclear body; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0001726; C:ruffle; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome. DR GO; GO:0005102; F:signaling receptor binding; IBA:GO_Central. DR GO; GO:0030154; P:cell differentiation; IBA:GO_Central. DR GO; GO:0016477; P:cell migration; IDA:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL. DR GO; GO:0038128; P:ERBB2 signaling pathway; TAS:Reactome. DR GO; GO:0060575; P:intestinal epithelial cell differentiation; IEA:Ensembl. DR GO; GO:0045926; P:negative regulation of growth; IEA:Ensembl. DR GO; GO:0061099; P:negative regulation of protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0045787; P:positive regulation of cell cycle; TAS:Reactome. DR GO; GO:0045740; P:positive regulation of DNA replication; TAS:Reactome. DR GO; GO:0045742; P:positive regulation of epidermal growth factor receptor signaling pathway; TAS:Reactome. DR GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL. DR GO; GO:0046427; P:positive regulation of receptor signaling pathway via JAK-STAT; TAS:Reactome. DR GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0007260; P:tyrosine phosphorylation of STAT protein; IDA:UniProtKB. DR CDD; cd05148; PTKc_Srm_Brk; 1. DR CDD; cd10358; SH2_PTK6_Brk; 1. DR CDD; cd11847; SH3_Brk; 1. DR FunFam; 1.10.510.10:FF:000399; Tyrosine-protein kinase; 1. DR FunFam; 2.30.30.40:FF:000229; Tyrosine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000053; Tyrosine-protein kinase; 1. DR FunFam; 3.30.505.10:FF:000074; Tyrosine-protein kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.30.505.10; SH2 domain; 1. DR Gene3D; 2.30.30.40; SH3 Domains; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR050198; Non-receptor_tyrosine_kinases. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR035846; PTK6_SH2. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR000980; SH2. DR InterPro; IPR036860; SH2_dom_sf. DR InterPro; IPR036028; SH3-like_dom_sf. DR InterPro; IPR001452; SH3_domain. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR24418; TYROSINE-PROTEIN KINASE; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00017; SH2; 1. DR Pfam; PF00018; SH3_1; 1. DR PRINTS; PR00401; SH2DOMAIN. DR PRINTS; PR00452; SH3DOMAIN. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00252; SH2; 1. DR SMART; SM00326; SH3; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF55550; SH2 domain; 1. DR SUPFAM; SSF50044; SH3-domain; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS50001; SH2; 1. DR PROSITE; PS50002; SH3; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell projection; KW Cytoplasm; Kinase; Membrane; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; SH2 domain; SH3 domain; KW Transferase; Tyrosine-protein kinase. FT CHAIN 1..451 FT /note="Protein-tyrosine kinase 6" FT /id="PRO_0000088133" FT DOMAIN 8..72 FT /note="SH3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00192" FT DOMAIN 78..170 FT /note="SH2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00191" FT DOMAIN 191..445 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 171..190 FT /note="Linker" FT ACT_SITE 312 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 197..205 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 219 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000305|PubMed:27480927, ECO:0000305|PubMed:27993680" FT MOD_RES 13 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988" FT MOD_RES 61 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988" FT MOD_RES 66 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988" FT MOD_RES 114 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988, FT ECO:0007744|PubMed:18691976" FT MOD_RES 342 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988" FT MOD_RES 351 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12121988" FT MOD_RES 447 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:10913193" FT VAR_SEQ 78..134 FT /note="WFFGCISRSEAVRRLQAEGNATGAFLIRVSEKPSADYVLSVRDTQAVRHYKI FT WRRAG -> AGHAGCAALQDLAACRGPAAPERGGVLPQPARACELPQGPEPVPRPAAGR FT ALPEARA (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:9333026" FT /id="VSP_042066" FT VAR_SEQ 135..451 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:9333026" FT /id="VSP_042067" FT VARIANT 16 FT /note="L -> F (in a renal papillary sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041760" FT VARIANT 436 FT /note="A -> T (in dbSNP:rs56145017)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041761" FT MUTAGEN 44 FT /note="W->A: Strong decrease in STAP2 phosphorylation. FT Markedly decreased interaction between SH3 domain the FT linker region." FT /evidence="ECO:0000269|PubMed:10980601, FT ECO:0000269|PubMed:17822667" FT MUTAGEN 66 FT /note="Y->A: Decrease in STAP2 phosphorylation." FT /evidence="ECO:0000269|PubMed:10980601" FT MUTAGEN 105 FT /note="R->A: Abolishes interaction with ARAP1." FT /evidence="ECO:0000269|PubMed:20554524" FT MUTAGEN 105 FT /note="R->L: Decrease in STAP2 phosphorylation." FT /evidence="ECO:0000269|PubMed:10980601" FT MUTAGEN 184 FT /note="W->A: Abrogates interaction between PTK6-domain FT kinase and PTK6-linker. Abrogates autophosphorylation and FT phosphorylation of KHDRBS1." FT /evidence="ECO:0000269|PubMed:15961400" FT MUTAGEN 219 FT /note="K->M: Abolishes kinase activity and cell FT transformation, and phosphorylation of STAP2. Reduces FT interaction with ARAP1." FT /evidence="ECO:0000269|PubMed:10980601, FT ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:20554524, FT ECO:0000269|PubMed:8940083" FT MUTAGEN 219 FT /note="K->R: Abolishes kinase activity." FT /evidence="ECO:0000269|PubMed:27480927" FT MUTAGEN 342 FT /note="Y->A: 3-fold lower specific kinase activity. FT Decreased, but still significant, autophosphorylation. FT Decreased, but still significant, autophosphorylation; when FT associated with A-447." FT /evidence="ECO:0000269|PubMed:12121988" FT MUTAGEN 447 FT /note="Y->F: Decrease in transforming potential and FT increase in the kinase activity level. Decreased, but still FT significant, autophosphorylation; when associated with A- FT 342." FT /evidence="ECO:0000269|PubMed:12121988, FT ECO:0000269|PubMed:15471878, ECO:0000269|PubMed:8940083" FT STRAND 12..14 FT /evidence="ECO:0007829|PDB:2KGT" FT STRAND 35..40 FT /evidence="ECO:0007829|PDB:2KGT" FT STRAND 45..50 FT /evidence="ECO:0007829|PDB:2KGT" FT STRAND 56..62 FT /evidence="ECO:0007829|PDB:2KGT" FT TURN 64..66 FT /evidence="ECO:0007829|PDB:2KGT" FT STRAND 67..70 FT /evidence="ECO:0007829|PDB:2KGT" FT HELIX 85..92 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 102..106 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 108..112 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 114..118 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 125..131 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 133..135 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 137..140 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 143..147 FT /evidence="ECO:0007829|PDB:1RJA" FT HELIX 148..157 FT /evidence="ECO:0007829|PDB:1RJA" FT STRAND 162..164 FT /evidence="ECO:0007829|PDB:1RJA" FT HELIX 188..190 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 191..200 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 203..210 FT /evidence="ECO:0007829|PDB:6CZ4" FT TURN 211..213 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 214..221 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 223..225 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 229..240 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 250..254 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 256..264 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 268..271 FT /evidence="ECO:0007829|PDB:6CZ2" FT HELIX 272..278 FT /evidence="ECO:0007829|PDB:6CZ4" FT TURN 281..283 FT /evidence="ECO:0007829|PDB:5DA3" FT HELIX 286..305 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 315..317 FT /evidence="ECO:0007829|PDB:6CZ4" FT STRAND 318..320 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 322..324 FT /evidence="ECO:0007829|PDB:5DA3" FT STRAND 326..328 FT /evidence="ECO:0007829|PDB:6CZ4" FT TURN 334..336 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 339..342 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 345..348 FT /evidence="ECO:0007829|PDB:5DA3" FT HELIX 351..353 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 356..361 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 366..380 FT /evidence="ECO:0007829|PDB:6CZ4" FT TURN 381..384 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 393..402 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 414..423 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 428..430 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 434..441 FT /evidence="ECO:0007829|PDB:6CZ4" FT HELIX 442..444 FT /evidence="ECO:0007829|PDB:5D7V" SQ SEQUENCE 451 AA; 51834 MW; CDCAC0EE242E1BD7 CRC64; MVSRDQAHLG PKYVGLWDFK SRTDEELSFR AGDVFHVARK EEQWWWATLL DEAGGAVAQG YVPHNYLAER ETVESEPWFF GCISRSEAVR RLQAEGNATG AFLIRVSEKP SADYVLSVRD TQAVRHYKIW RRAGGRLHLN EAVSFLSLPE LVNYHRAQSL SHGLRLAAPC RKHEPEPLPH WDDWERPREE FTLCRKLGSG YFGEVFEGLW KDRVQVAIKV ISRDNLLHQQ MLQSEIQAMK KLRHKHILAL YAVVSVGDPV YIITELMAKG SLLELLRDSD EKVLPVSELL DIAWQVAEGM CYLESQNYIH RDLAARNILV GENTLCKVGD FGLARLIKED VYLSHDHNIP YKWTAPEALS RGHYSTKSDV WSFGILLHEM FSRGQVPYPG MSNHEAFLRV DAGYRMPCPL ECPPSVHKLM LTCWCRDPEQ RPCFKALRER LSSFTSYENP T // ID PTK7_HUMAN Reviewed; 1070 AA. AC Q13308; A8K974; B7Z477; E9PFZ5; Q13417; Q5T650; Q6IQ54; Q8NFA5; Q8NFA6; AC Q8NFA7; Q8NFA8; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 2. DT 28-JAN-2026, entry version 224. DE RecName: Full=Inactive tyrosine-protein kinase 7; DE AltName: Full=Colon carcinoma kinase 4; DE Short=CCK-4; DE AltName: Full=Protein-tyrosine kinase 7; DE AltName: Full=Pseudo tyrosine kinase receptor 7; DE AltName: Full=Tyrosine-protein kinase-like 7; DE Flags: Precursor; GN Name=PTK7; Synonyms=CCK4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Colon carcinoma, and Placenta; RX PubMed=7478540; RA Mossie K., Jallal B., Alves F., Sures I., Plowman G.D., Ullrich A.; RT "Colon carcinoma kinase-4 defines a new subclass of the receptor tyrosine RT kinase family."; RL Oncogene 11:2179-2184(1995). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Fibroblast; RX PubMed=8882711; DOI=10.1093/oxfordjournals.jbchem.a021228; RA Park S.-K., Lee H.-S., Lee S.-T.; RT "Characterization of the human full-length PTK7 cDNA encoding a receptor RT protein tyrosine kinase-like molecule closely related to chick KLG."; RL J. Biochem. 119:235-239(1996). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS RP 1; 2; 3; 4 AND 5). RC TISSUE=Testis; RX PubMed=12427550; DOI=10.1016/s0167-4781(02)00536-5; RA Jung J.-W., Ji A.-R., Lee J., Kim U.-J., Lee S.-T.; RT "Organization of the human PTK7 gene encoding a receptor protein tyrosine RT kinase-like molecule and alternative splicing of its mRNA."; RL Biochim. Biophys. Acta 1579:153-163(2002). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 6). RC TISSUE=Testis, and Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP GLYCOSYLATION AT ASN-646. RX PubMed=12754519; DOI=10.1038/nbt827; RA Zhang H., Li X.-J., Martin D.B., Aebersold R.; RT "Identification and quantification of N-linked glycoproteins using RT hydrazide chemistry, stable isotope labeling and mass spectrometry."; RL Nat. Biotechnol. 21:660-666(2003). RN [9] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-646. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). RN [10] RP FUNCTION. RX PubMed=18471990; DOI=10.1016/j.bbrc.2008.04.168; RA Shin W.-S., Maeng Y.-S., Jung J.-W., Min J.-K., Kwon Y.-G., Lee S.-T.; RT "Soluble PTK7 inhibits tube formation, migration, and invasion of RT endothelial cells and angiogenesis."; RL Biochem. Biophys. Res. Commun. 371:793-798(2008). RN [11] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-116; ASN-175; ASN-268 AND RP ASN-283. RC TISSUE=Leukemic T-cell; RX PubMed=19349973; DOI=10.1038/nbt.1532; RA Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M., RA Schiess R., Aebersold R., Watts J.D.; RT "Mass-spectrometric identification and relative quantification of N-linked RT cell surface glycoproteins."; RL Nat. Biotechnol. 27:378-386(2009). RN [12] RP FUNCTION. RX PubMed=20558616; DOI=10.1182/blood-2010-01-262352; RA Prebet T., Lhoumeau A.-C., Arnoulet C., Aulas A., Marchetto S., RA Audebert S., Puppo F., Chabannon C., Sainty D., Santoni M.-J., Sebbagh M., RA Summerour V., Huon Y., Shin W.-S., Lee S.-T., Esterni B., Vey N., RA Borg J.-P.; RT "The cell polarity PTK7 receptor acts as a modulator of the RT chemotherapeutic response in acute myeloid leukemia and impairs clinical RT outcome."; RL Blood 116:2315-2323(2010). RN [13] RP FUNCTION, SUBCELLULAR LOCATION, INDUCTION, CLEAVAGE, AND MUTAGENESIS OF RP LEU-622; MET-641 AND MET-701. RX PubMed=20837484; DOI=10.1074/jbc.m110.165159; RA Golubkov V.S., Chekanov A.V., Cieplak P., Aleshin A.E., Chernov A.V., RA Zhu W., Radichev I.A., Zhang D., Dong P.D., Strongin A.Y.; RT "The Wnt/planar cell polarity protein-tyrosine kinase-7 (PTK7) is a highly RT efficient proteolytic target of membrane type-1 matrix metalloproteinase: RT implications in cancer and embryogenesis."; RL J. Biol. Chem. 285:35740-35749(2010). RN [14] RP FUNCTION. RX PubMed=21103379; DOI=10.1371/journal.pone.0014018; RA Meng L., Sefah K., O'Donoghue M.B., Zhu G., Shangguan D., Noorali A., RA Chen Y., Zhou L., Tan W.; RT "Silencing of PTK7 in colon cancer cells: caspase-10-dependent apoptosis RT via mitochondrial pathway."; RL PLoS ONE 5:E14018-E14018(2010). RN [15] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [16] RP FUNCTION, INTERACTION WITH CTNNB1, AND REGION. RX PubMed=21132015; DOI=10.1038/embor.2010.185; RA Puppo F., Thome V., Lhoumeau A.-C., Cibois M., Gangar A., Lembo F., RA Belotti E., Marchetto S., Lecine P., Prebet T., Sebbagh M., Shin W.-S., RA Lee S.-T., Kodjabachian L., Borg J.-P.; RT "Protein tyrosine kinase 7 has a conserved role in Wnt/beta-catenin RT canonical signalling."; RL EMBO Rep. 12:43-49(2011). RN [17] RP VARIANTS [LARGE SCALE ANALYSIS] HIS-276; SER-410; ASP-745; GLN-766; RP VAL-777; ARG-783; VAL-933; THR-1029 AND GLN-1038. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Inactive tyrosine kinase involved in Wnt signaling pathway. CC Component of both the non-canonical (also known as the Wnt/planar cell CC polarity signaling) and the canonical Wnt signaling pathway. Functions CC in cell adhesion, cell migration, cell polarity, proliferation, actin CC cytoskeleton reorganization and apoptosis. Has a role in embryogenesis, CC epithelial tissue organization and angiogenesis. CC {ECO:0000269|PubMed:18471990, ECO:0000269|PubMed:20558616, CC ECO:0000269|PubMed:20837484, ECO:0000269|PubMed:21103379, CC ECO:0000269|PubMed:21132015}. CC -!- SUBUNIT: Interacts with CTNNB1. {ECO:0000269|PubMed:21132015}. CC -!- INTERACTION: CC Q13308; P35222: CTNNB1; NbExp=5; IntAct=EBI-2803245, EBI-491549; CC Q13308; Q8IUG1: KRTAP1-3; NbExp=3; IntAct=EBI-2803245, EBI-11749135; CC Q13308; P60410: KRTAP10-8; NbExp=3; IntAct=EBI-2803245, EBI-10171774; CC Q13308; Q99750: MDFI; NbExp=3; IntAct=EBI-2803245, EBI-724076; CC Q13308; Q5JR59-3: MTUS2; NbExp=3; IntAct=EBI-2803245, EBI-11522433; CC Q13308; P0DPK4: NOTCH2NLC; NbExp=3; IntAct=EBI-2803245, EBI-22310682; CC -!- SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:20837484}; Single- CC pass type I membrane protein {ECO:0000269|PubMed:20837484}. Cell CC junction {ECO:0000269|PubMed:20837484}. Note=Colocalizes with MMP14 at CC cell junctions. Also localizes at the leading edge of migrating cells. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=6; CC Name=1; Synonyms=PTK7-1; CC IsoId=Q13308-1; Sequence=Displayed; CC Name=2; Synonyms=PTK7-2; CC IsoId=Q13308-2; Sequence=VSP_037182; CC Name=3; Synonyms=PTK7-3; CC IsoId=Q13308-3; Sequence=VSP_037181; CC Name=4; Synonyms=PTK7-4; CC IsoId=Q13308-4; Sequence=VSP_037183; CC Name=5; Synonyms=PTK7-5; CC IsoId=Q13308-5; Sequence=VSP_037184, VSP_037185; CC Name=6; CC IsoId=Q13308-6; Sequence=VSP_044775; CC -!- TISSUE SPECIFICITY: Highly expressed in lung, liver, pancreas, kidney, CC placenta and melanocytes. Weakly expressed in thyroid gland, ovary, CC brain, heart and skeletal muscle. Also expressed in erythroleukemia CC cells. But not expressed in colon. CC -!- INDUCTION: Higher expression in cell lines established from normal non- CC tumorigenic tissues compared to cell lines established from highly CC metastatic invasive carcinomas (at protein level). CC {ECO:0000269|PubMed:20837484}. CC -!- DOMAIN: The protein kinase domain is predicted to be catalytically CC inactive. CC -!- PTM: MMP14 cleaves PTK7 between Pro-621 and Leu-622 generating an N- CC terminal soluble (70 kDa) fragment and a membrane C-terminal (50 kDa) CC fragment. Proteolysis by MMP14 regulates PTK7 function in non-canonical CC Wnt signaling pathway. {ECO:0000269|PubMed:20837484}. CC -!- MISCELLANEOUS: [Isoform 5]: May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41901/PTK7"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U33635; AAA87565.1; -; mRNA. DR EMBL; U40271; AAC50484.2; -; mRNA. DR EMBL; AF447176; AAL39062.1; -; Genomic_DNA. DR EMBL; AF447157; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447158; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447162; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447164; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447167; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447170; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447171; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447173; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447174; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF447175; AAL39062.1; JOINED; Genomic_DNA. DR EMBL; AF531868; AAN04862.1; -; mRNA. DR EMBL; AF531869; AAN04863.1; -; mRNA. DR EMBL; AF531870; AAN04864.1; -; mRNA. DR EMBL; AF531871; AAN04865.1; -; mRNA. DR EMBL; AF531872; AAN04866.1; -; mRNA. DR EMBL; AK291016; BAF83705.1; -; mRNA. DR EMBL; AK292589; BAF85278.1; -; mRNA. DR EMBL; AK296953; BAH12463.1; -; mRNA. DR EMBL; AL355385; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471081; EAX04154.1; -; Genomic_DNA. DR EMBL; CH471081; EAX04155.1; -; Genomic_DNA. DR EMBL; CH471081; EAX04156.1; -; Genomic_DNA. DR EMBL; CH471081; EAX04158.1; -; Genomic_DNA. DR EMBL; CH471081; EAX04160.1; -; Genomic_DNA. DR EMBL; BC071557; AAH71557.1; -; mRNA. DR CCDS; CCDS4884.1; -. [Q13308-1] DR CCDS; CCDS4885.1; -. [Q13308-2] DR CCDS; CCDS4886.1; -. [Q13308-3] DR CCDS; CCDS4887.1; -. [Q13308-4] DR CCDS; CCDS59021.1; -. [Q13308-6] DR PIR; JC4593; JC4593. DR RefSeq; NP_001257327.1; NM_001270398.2. [Q13308-6] DR RefSeq; NP_002812.2; NM_002821.4. [Q13308-1] DR RefSeq; NP_690619.1; NM_152880.4. [Q13308-2] DR RefSeq; NP_690620.1; NM_152881.4. [Q13308-3] DR RefSeq; NP_690621.1; NM_152882.4. [Q13308-4] DR PDB; 6VG3; X-ray; 1.95 A; A/B/C=774-1069. DR PDBsum; 6VG3; -. DR AlphaFoldDB; Q13308; -. DR SMR; Q13308; -. DR BioGRID; 111721; 183. DR FunCoup; Q13308; 541. DR IntAct; Q13308; 121. DR MINT; Q13308; -. DR STRING; 9606.ENSP00000418754; -. DR GlyConnect; 655; 40 N-Linked glycans (6 sites). DR GlyCosmos; Q13308; 10 sites, 46 glycans. DR GlyGen; Q13308; 13 sites, 74 N-linked glycans (8 sites), 2 O-linked glycans (3 sites). DR iPTMnet; Q13308; -. DR MetOSite; Q13308; -. DR PhosphoSitePlus; Q13308; -. DR SwissPalm; Q13308; -. DR BioMuta; PTK7; -. DR DMDM; 116242736; -. DR jPOST; Q13308; -. DR MassIVE; Q13308; -. DR PaxDb; 9606-ENSP00000418754; -. DR PeptideAtlas; Q13308; -. DR ProteomicsDB; 20212; -. DR ProteomicsDB; 59293; -. [Q13308-1] DR ProteomicsDB; 59294; -. [Q13308-2] DR ProteomicsDB; 59295; -. [Q13308-3] DR ProteomicsDB; 59296; -. [Q13308-4] DR ProteomicsDB; 59297; -. [Q13308-5] DR Pumba; Q13308; -. DR TopDownProteomics; Q13308-3; -. [Q13308-3] DR ABCD; Q13308; 1 sequenced antibody. DR Antibodypedia; 1008; 616 antibodies from 38 providers. DR DNASU; 5754; -. DR Ensembl; ENST00000230418.8; ENSP00000230418.4; ENSG00000112655.17. [Q13308-5] DR Ensembl; ENST00000230419.9; ENSP00000230419.4; ENSG00000112655.17. [Q13308-1] DR Ensembl; ENST00000345201.6; ENSP00000325992.4; ENSG00000112655.17. [Q13308-2] DR Ensembl; ENST00000349241.6; ENSP00000325462.4; ENSG00000112655.17. [Q13308-3] DR Ensembl; ENST00000352931.6; ENSP00000326029.3; ENSG00000112655.17. [Q13308-4] DR Ensembl; ENST00000481273.5; ENSP00000418754.1; ENSG00000112655.17. [Q13308-6] DR GeneID; 5754; -. DR KEGG; hsa:5754; -. DR MANE-Select; ENST00000230419.9; ENSP00000230419.4; NM_002821.5; NP_002812.2. DR UCSC; uc003oub.3; human. [Q13308-1] DR AGR; HGNC:9618; -. DR ClinPGx; PA33961; -. DR CTD; 5754; -. DR DisGeNET; 5754; -. DR GeneCards; PTK7; -. DR HGNC; HGNC:9618; PTK7. DR HPA; ENSG00000112655; Low tissue specificity. DR MIM; 601890; gene. DR OpenTargets; ENSG00000112655; -. DR VEuPathDB; HostDB:ENSG00000112655; -. DR eggNOG; KOG1026; Eukaryota. DR eggNOG; KOG4475; Eukaryota. DR GeneTree; ENSGT00940000157908; -. DR HOGENOM; CLU_012268_0_0_1; -. DR InParanoid; Q13308; -. DR OMA; HKILTSC; -. DR OrthoDB; 2413561at2759; -. DR PAN-GO; Q13308; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q13308; -. DR PathwayCommons; Q13308; -. DR SignaLink; Q13308; -. DR SIGNOR; Q13308; -. DR Agora; ENSG00000112655; -. DR BioGRID-ORCS; 5754; 19 hits in 1197 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; PTK7; human. DR GeneWiki; PTK7; -. DR GenomeRNAi; 5754; -. DR Pharos; Q13308; Tbio. DR PRO; PR:Q13308; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q13308; protein. DR Bgee; ENSG00000112655; Expressed in stromal cell of endometrium and 127 other cell types or tissues. DR ExpressionAtlas; Q13308; baseline and differential. DR GO; GO:0030424; C:axon; IBA:GO_Central. DR GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005925; C:focal adhesion; HDA:UniProtKB. DR GO; GO:0043025; C:neuronal cell body; IBA:GO_Central. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:InterPro. DR GO; GO:0008046; F:axon guidance receptor activity; IBA:GO_Central. DR GO; GO:0015026; F:coreceptor activity; NAS:ParkinsonsUK-UCL. DR GO; GO:0004672; F:protein kinase activity; IEA:InterPro. DR GO; GO:0030036; P:actin cytoskeleton organization; IMP:UniProtKB. DR GO; GO:0003401; P:axis elongation; IEA:Ensembl. DR GO; GO:0016477; P:cell migration; IMP:UniProtKB. DR GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL. DR GO; GO:0090103; P:cochlea morphogenesis; IEA:Ensembl. DR GO; GO:0060026; P:convergent extension; IEA:Ensembl. DR GO; GO:0060976; P:coronary vasculature development; IEA:Ensembl. DR GO; GO:0045198; P:establishment of epithelial cell apical/basal polarity; IEA:Ensembl. DR GO; GO:0001736; P:establishment of planar polarity; IEA:Ensembl. DR GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; IBA:GO_Central. DR GO; GO:0001822; P:kidney development; IEA:Ensembl. DR GO; GO:0060484; P:lung-associated mesenchyme development; IEA:Ensembl. DR GO; GO:0001843; P:neural tube closure; IEA:Ensembl. DR GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:UniProtKB. DR GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL. DR GO; GO:0060828; P:regulation of canonical Wnt signaling pathway; IBA:GO_Central. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0050808; P:synapse organization; IBA:GO_Central. DR GO; GO:0003281; P:ventricular septum development; IEA:Ensembl. DR GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW. DR GO; GO:0042060; P:wound healing; IEA:Ensembl. DR CDD; cd00096; Ig; 2. DR CDD; cd05760; Ig2_PTK7; 1. DR CDD; cd05046; PTK_CCK4; 1. DR FunFam; 1.10.510.10:FF:000200; inactive tyrosine-protein kinase 7; 1. DR FunFam; 2.60.40.10:FF:000341; inactive tyrosine-protein kinase 7; 1. DR FunFam; 2.60.40.10:FF:000343; inactive tyrosine-protein kinase 7; 1. DR FunFam; 2.60.40.10:FF:000377; Protein tyrosine kinase 7 (inactive); 1. DR FunFam; 2.60.40.10:FF:000390; Protein tyrosine kinase 7 (inactive); 1. DR FunFam; 2.60.40.10:FF:000395; Protein tyrosine kinase 7 (inactive); 1. DR FunFam; 2.60.40.10:FF:000402; Protein tyrosine kinase 7 (inactive); 1. DR FunFam; 2.60.40.10:FF:000432; Protein tyrosine kinase 7 (inactive); 1. DR FunFam; 3.30.200.20:FF:000167; Putative inactive tyrosine-protein kinase 7; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 7. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR050958; Cell_Adh-Cytoskel_Orgn. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR PANTHER; PTHR45080; CONTACTIN 5; 1. DR PANTHER; PTHR45080:SF21; INACTIVE TYROSINE-PROTEIN KINASE 7; 1. DR Pfam; PF07679; I-set; 2. DR Pfam; PF13927; Ig_3; 5. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00409; IG; 7. DR SMART; SM00408; IGc2; 7. DR SUPFAM; SSF48726; Immunoglobulin; 7. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 7. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Cell adhesion; Cell junction; KW Disulfide bond; Glycoprotein; Immunoglobulin domain; Membrane; KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome; KW Repeat; Signal; Transmembrane; Transmembrane helix; Wnt signaling pathway. FT SIGNAL 1..30 FT /evidence="ECO:0000255" FT CHAIN 31..1070 FT /note="Inactive tyrosine-protein kinase 7" FT /id="PRO_0000016748" FT TOPO_DOM 31..704 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 705..725 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 726..1070 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 31..120 FT /note="Ig-like C2-type 1" FT DOMAIN 128..218 FT /note="Ig-like C2-type 2" FT DOMAIN 225..317 FT /note="Ig-like C2-type 3" FT DOMAIN 309..407 FT /note="Ig-like C2-type 4" FT DOMAIN 412..497 FT /note="Ig-like C2-type 5" FT DOMAIN 503..586 FT /note="Ig-like C2-type 6" FT DOMAIN 578..680 FT /note="Ig-like C2-type 7" FT DOMAIN 796..1066 FT /note="Protein kinase; inactive" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 736..759 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 773..793 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 794..1070 FT /note="Interaction with CTNNB1" FT /evidence="ECO:0000269|PubMed:21132015" FT SITE 621..622 FT /note="Cleavage; by MMP14" FT MOD_RES 1064 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BKG3" FT CARBOHYD 116 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973" FT CARBOHYD 175 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973" FT CARBOHYD 184 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 214 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 268 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973" FT CARBOHYD 283 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973" FT CARBOHYD 405 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 463 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 567 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 646 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:12754519, FT ECO:0000269|PubMed:19159218" FT DISULFID 53..101 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 150..200 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 246..301 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 343..391 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 433..481 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 524..570 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 613..664 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 1..26 FT /note="MGAARGSPARPRRLPLLSVLLLPLLG -> MGSFLSGEKRPSAPTVGSAMEK FT KEFPTPPGRVGP (in isoform 6)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_044775" FT VAR_SEQ 410..540 FT /note="TVPSWLKKPQDSQLEEGKPGYLDCLTQATPKPTVVWYRNQMLISEDSRFEVF FT KNGTLRINSVEVYDGTWYRCMSSTPAGSIEAQARVQVLEKLKFTPPPQPQQCMEFDKEA FT TVPCSATGREKPTIKWERAD -> N (in isoform 3)" FT /evidence="ECO:0000303|PubMed:12427550" FT /id="VSP_037181" FT VAR_SEQ 500..539 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:12427550, FT ECO:0000303|PubMed:14702039" FT /id="VSP_037182" FT VAR_SEQ 627..682 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:12427550" FT /id="VSP_037183" FT VAR_SEQ 804..816 FT /note="KSEFGEVFLAKAQ -> RPQAVPEDFQEQG (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12427550" FT /id="VSP_037184" FT VAR_SEQ 817..1070 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12427550" FT /id="VSP_037185" FT VARIANT 276 FT /note="R -> H (in dbSNP:rs56188167)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041502" FT VARIANT 410 FT /note="T -> S (in dbSNP:rs34021075)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041503" FT VARIANT 745 FT /note="E -> D (in dbSNP:rs9472017)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041504" FT VARIANT 766 FT /note="E -> Q (in dbSNP:rs56216742)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041505" FT VARIANT 777 FT /note="A -> V (in dbSNP:rs34764696)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041506" FT VARIANT 783 FT /note="H -> R (in dbSNP:rs55820547)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041507" FT VARIANT 933 FT /note="A -> V (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041508" FT VARIANT 1029 FT /note="P -> T (in dbSNP:rs55755163)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041509" FT VARIANT 1038 FT /note="R -> Q (in dbSNP:rs34865794)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041510" FT MUTAGEN 622 FT /note="L->D: Prevents proteolysis by MMP14." FT /evidence="ECO:0000269|PubMed:20837484" FT MUTAGEN 641 FT /note="M->R: No impact on proteolysis by MMP14." FT /evidence="ECO:0000269|PubMed:20837484" FT MUTAGEN 701 FT /note="M->D: No impact on proteolysis by MMP14." FT /evidence="ECO:0000269|PubMed:20837484" FT CONFLICT 87 FT /note="F -> L (in Ref. 4; BAF85278)" FT /evidence="ECO:0000305" FT CONFLICT 92 FT /note="R -> P (in Ref. 1; AAA87565)" FT /evidence="ECO:0000305" FT CONFLICT 93 FT /note="L -> P (in Ref. 7; AAH71557)" FT /evidence="ECO:0000305" FT CONFLICT 147 FT /note="T -> K (in Ref. 1; AAA87565)" FT /evidence="ECO:0000305" FT CONFLICT 207 FT /note="G -> S (in Ref. 1; AAA87565)" FT /evidence="ECO:0000305" FT CONFLICT 495..496 FT /note="RV -> VL (in Ref. 1; AAA87565)" FT /evidence="ECO:0000305" FT CONFLICT 515 FT /note="E -> G (in Ref. 1; AAA87565)" FT /evidence="ECO:0000305" FT CONFLICT 755 FT /note="Q -> R (in Ref. 4; BAH12463)" FT /evidence="ECO:0000305" FT CONFLICT 799 FT /note="I -> F (in Ref. 4; BAF85278)" FT /evidence="ECO:0000305" FT CONFLICT 881 FT /note="G -> E (in Ref. 1; AAA87565)" FT /evidence="ECO:0000305" FT CONFLICT 969 FT /note="P -> A (in Ref. 1; AAA87565)" FT /evidence="ECO:0000305" FT CONFLICT 992 FT /note="F -> S (in Ref. 1; AAA87565)" FT /evidence="ECO:0000305" FT HELIX 793..795 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 796..804 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 806..816 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 823..832 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 837..852 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 861..865 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 867..876 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 879..882 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 883..890 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 904..923 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 933..935 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 936..938 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 944..946 FT /evidence="ECO:0007829|PDB:6VG3" FT TURN 952..956 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 957..959 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 961..963 FT /evidence="ECO:0007829|PDB:6VG3" FT STRAND 966..968 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 970..972 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 975..980 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 985..1000 FT /evidence="ECO:0007829|PDB:6VG3" FT TURN 1006..1009 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 1012..1020 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 1034..1043 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 1048..1050 FT /evidence="ECO:0007829|PDB:6VG3" FT HELIX 1054..1062 FT /evidence="ECO:0007829|PDB:6VG3" SQ SEQUENCE 1070 AA; 118392 MW; 304926A1774EB5F4 CRC64; MGAARGSPAR PRRLPLLSVL LLPLLGGTQT AIVFIKQPSS QDALQGRRAL LRCEVEAPGP VHVYWLLDGA PVQDTERRFA QGSSLSFAAV DRLQDSGTFQ CVARDDVTGE EARSANASFN IKWIEAGPVV LKHPASEAEI QPQTQVTLRC HIDGHPRPTY QWFRDGTPLS DGQSNHTVSS KERNLTLRPA GPEHSGLYSC CAHSAFGQAC SSQNFTLSIA DESFARVVLA PQDVVVARYE EAMFHCQFSA QPPPSLQWLF EDETPITNRS RPPHLRRATV FANGSLLLTQ VRPRNAGIYR CIGQGQRGPP IILEATLHLA EIEDMPLFEP RVFTAGSEER VTCLPPKGLP EPSVWWEHAG VRLPTHGRVY QKGHELVLAN IAESDAGVYT CHAANLAGQR RQDVNITVAT VPSWLKKPQD SQLEEGKPGY LDCLTQATPK PTVVWYRNQM LISEDSRFEV FKNGTLRINS VEVYDGTWYR CMSSTPAGSI EAQARVQVLE KLKFTPPPQP QQCMEFDKEA TVPCSATGRE KPTIKWERAD GSSLPEWVTD NAGTLHFARV TRDDAGNYTC IASNGPQGQI RAHVQLTVAV FITFKVEPER TTVYQGHTAL LQCEAQGDPK PLIQWKGKDR ILDPTKLGPR MHIFQNGSLV IHDVAPEDSG RYTCIAGNSC NIKHTEAPLY VVDKPVPEES EGPGSPPPYK MIQTIGLSVG AAVAYIIAVL GLMFYCKKRC KAKRLQKQPE GEEPEMECLN GGPLQNGQPS AEIQEEVALT SLGSGPAATN KRHSTSDKMH FPRSSLQPIT TLGKSEFGEV FLAKAQGLEE GVAETLVLVK SLQSKDEQQQ LDFRRELEMF GKLNHANVVR LLGLCREAEP HYMVLEYVDL GDLKQFLRIS KSKDEKLKSQ PLSTKQKVAL CTQVALGMEH LSNNRFVHKD LAARNCLVSA QRQVKVSALG LSKDVYNSEY YHFRQAWVPL RWMSPEAILE GDFSTKSDVW AFGVLMWEVF THGEMPHGGQ ADDEVLADLQ AGKARLPQPE GCPSKLYRLM QRCWALSPKD RPSFSEIASA LGDSTVDSKP // ID QTMAN_HUMAN Reviewed; 458 AA. AC Q4AE62; A0A087X2H5; A8K5P2; D3DP81; G1UFN1; G5EA49; H7BYJ5; Q53SM7; Q53TC5; AC Q6P7E7; Q6PJB6; Q6WKW6; Q9HAE5; DT 13-NOV-2007, integrated into UniProtKB/Swiss-Prot. DT 13-SEP-2005, sequence version 1. DT 28-JAN-2026, entry version 148. DE RecName: Full=tRNA-queuosine alpha-mannosyltransferase {ECO:0000303|PubMed:37992713}; DE Short=QTMAN {ECO:0000303|PubMed:37992713}; DE EC=2.4.1.110 {ECO:0000269|PubMed:37992713}; DE AltName: Full=Glycosyltransferase-like domain-containing protein 1 {ECO:0000305}; DE AltName: Full=Mannosyltransferase-like protein Xa {ECO:0000303|PubMed:21821951}; DE AltName: Full=Mat-Xa {ECO:0000303|PubMed:21821951}; GN Name=QTMAN {ECO:0000303|PubMed:37992713, ECO:0000312|HGNC:HGNC:20887}; GN Synonyms=GTDC1 {ECO:0000303|PubMed:15068588}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANT RP ILE-137. RC TISSUE=Brain; RX PubMed=15068588; DOI=10.1089/104454904322964788; RA Zhao E., Li Y., Fu X., Zhang J.-Y., Zeng H., Zeng L., Lin Y., Chen J., RA Yin G., Qian J., Ying K., Xie Y., Zhao R.C., Mao Y.-M.; RT "Cloning and expression of human GTDC1 gene (glycosyltransferase-like RT domain containing 1) from human fetal library."; RL DNA Cell Biol. 23:183-187(2004). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY. RC TISSUE=Fetal brain; RX PubMed=21821951; DOI=10.1271/bbb.110124; RA Shimono N., Nishimura Y., Kamiguchi H., Nishikawa Y.; RT "Remarkable expression in the colon adenocarcinoma of Hmat-Xa, a human RT mannosyltransferase-like gene, that is homologous to Drosophila gene RT GC15914."; RL Biosci. Biotechnol. Biochem. 75:1451-1455(2011). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Nishikawa Y., Takahashi T., Saito A., Shimazawa K., Hosaka M.; RT "Cloning and expression of a novel human mannosyltransferase candidate."; RL Submitted (JAN-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ILE-137. RC TISSUE=Brain, and Embryo; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3). RC TISSUE=Bone, and Kidney; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND RP SUBCELLULAR LOCATION. RX PubMed=37992713; DOI=10.1016/j.cell.2023.10.026; RA Zhao X., Ma D., Ishiguro K., Saito H., Akichika S., Matsuzawa I., Mito M., RA Irie T., Ishibashi K., Wakabayashi K., Sakaguchi Y., Yokoyama T., RA Mishima Y., Shirouzu M., Iwasaki S., Suzuki T., Suzuki T.; RT "Glycosylated queuosines in tRNAs optimize translational rate and post- RT embryonic growth."; RL Cell 0:0-0(2023). CC -!- FUNCTION: Glycosyltransferase that specifically catalyzes mannosylation CC of cytoplasmic tRNA(Asp) modified with queuosine at position 34 CC (queuosine(34)) (PubMed:37992713). Mannosylates the cyclopentene moiety CC of queuosine(34) in tRNA(Asp) to form mannosyl-queuosine(34) CC (PubMed:37992713). Mannosylation of queuosine(34) in tRNA(Asp) is CC required to slow-down elongation at cognate codons, GAC and GAU, CC thereby regulating protein translation (PubMed:37992713). CC {ECO:0000269|PubMed:37992713}. CC -!- CATALYTIC ACTIVITY: CC Reaction=queuosine(34) in tRNA(Asp) + GDP-alpha-D-mannose = O-4''- CC alpha-D-mannosylqueuosine(34) in tRNA(Asp) + GDP + H(+); CC Xref=Rhea:RHEA:12885, Rhea:RHEA-COMP:18572, Rhea:RHEA-COMP:18581, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:57527, ChEBI:CHEBI:58189, CC ChEBI:CHEBI:194431, ChEBI:CHEBI:194442; EC=2.4.1.110; CC Evidence={ECO:0000269|PubMed:37992713}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:12886; CC Evidence={ECO:0000269|PubMed:37992713}; CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=78 nM for tRNA(Asp) {ECO:0000269|PubMed:37992713}; CC KM=69 uM for GDP-alpha-D-mannose {ECO:0000269|PubMed:37992713}; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:37992713}. Nucleus CC {ECO:0000269|PubMed:37992713}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=6; CC Name=1; CC IsoId=Q4AE62-1; Sequence=Displayed; CC Name=2; CC IsoId=Q4AE62-2; Sequence=VSP_029379; CC Name=3; CC IsoId=Q4AE62-3; Sequence=VSP_029378; CC Name=4; Synonyms=c; CC IsoId=Q4AE62-4; Sequence=VSP_057598, VSP_057599; CC Name=5; Synonyms=f; CC IsoId=Q4AE62-5; Sequence=VSP_057597; CC Name=6; Synonyms=d; CC IsoId=Q4AE62-6; Sequence=VSP_057596; CC -!- TISSUE SPECIFICITY: Ubiquitous. Expressed at high levels in the lung, CC brain, spleen, testis, placenta. ovary, pancreas, spleen and peripheral CC blood leukocytes. Expressed at low level in the colon, small intestine, CC kidney, skeletal muscle and thymus. Expressed at high level in colon CC adenocarcinoma. {ECO:0000269|PubMed:15068588, CC ECO:0000269|PubMed:21821951}. CC -!- SIMILARITY: Belongs to the glycosyltransferase group 1 family. CC Glycosyltransferase 4 subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAX93131.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAB13904.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY281366; AAQ16408.1; -; mRNA. DR EMBL; AB597184; BAK74843.1; -; mRNA. DR EMBL; AB201269; BAE16560.1; -; mRNA. DR EMBL; AK021815; BAB13904.1; ALT_INIT; mRNA. DR EMBL; AK291357; BAF84046.1; -; mRNA. DR EMBL; AC009957; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC010130; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC010681; AAX93131.1; ALT_INIT; Genomic_DNA. DR EMBL; AC016910; AAY14764.1; -; Genomic_DNA. DR EMBL; CH471058; EAX11579.1; -; Genomic_DNA. DR EMBL; CH471058; EAX11580.1; -; Genomic_DNA. DR EMBL; CH471058; EAX11581.1; -; Genomic_DNA. DR EMBL; CH471058; EAX11582.1; -; Genomic_DNA. DR EMBL; CH471058; EAX11583.1; -; Genomic_DNA. DR EMBL; CH471058; EAX11584.1; -; Genomic_DNA. DR EMBL; CH471058; EAX11585.1; -; Genomic_DNA. DR EMBL; BC017741; AAH17741.1; -; mRNA. DR EMBL; BC061699; AAH61699.1; -; mRNA. DR CCDS; CCDS2185.1; -. [Q4AE62-2] DR CCDS; CCDS33300.1; -. [Q4AE62-1] DR CCDS; CCDS63029.1; -. [Q4AE62-4] DR CCDS; CCDS74582.1; -. [Q4AE62-6] DR CCDS; CCDS74583.1; -. [Q4AE62-5] DR RefSeq; NP_001006637.1; NM_001006636.3. [Q4AE62-1] DR RefSeq; NP_001158101.1; NM_001164629.3. [Q4AE62-1] DR RefSeq; NP_001271162.1; NM_001284233.1. [Q4AE62-4] DR RefSeq; NP_001271163.1; NM_001284234.1. [Q4AE62-6] DR RefSeq; NP_001271164.1; NM_001284235.1. [Q4AE62-3] DR RefSeq; NP_001271167.1; NM_001284238.1. [Q4AE62-5] DR RefSeq; NP_078935.2; NM_024659.4. [Q4AE62-2] DR AlphaFoldDB; Q4AE62; -. DR BioGRID; 122829; 3. DR FunCoup; Q4AE62; 1159. DR STRING; 9606.ENSP00000376608; -. DR CAZy; GT4; Glycosyltransferase Family 4. DR iPTMnet; Q4AE62; -. DR PhosphoSitePlus; Q4AE62; -. DR BioMuta; GTDC1; -. DR DMDM; 121946960; -. DR jPOST; Q4AE62; -. DR MassIVE; Q4AE62; -. DR PaxDb; 9606-ENSP00000376608; -. DR PeptideAtlas; Q4AE62; -. DR ProteomicsDB; 34139; -. DR ProteomicsDB; 43640; -. DR ProteomicsDB; 62093; -. [Q4AE62-1] DR ProteomicsDB; 62094; -. [Q4AE62-2] DR ProteomicsDB; 62095; -. [Q4AE62-3] DR Pumba; Q4AE62; -. DR Antibodypedia; 33618; 154 antibodies from 23 providers. DR DNASU; 79712; -. DR Ensembl; ENST00000241391.9; ENSP00000241391.6; ENSG00000121964.16. [Q4AE62-4] DR Ensembl; ENST00000344850.8; ENSP00000339750.4; ENSG00000121964.16. [Q4AE62-1] DR Ensembl; ENST00000392867.7; ENSP00000376606.3; ENSG00000121964.16. [Q4AE62-2] DR Ensembl; ENST00000392869.6; ENSP00000376608.1; ENSG00000121964.16. [Q4AE62-1] DR Ensembl; ENST00000392871.6; ENSP00000376610.2; ENSG00000121964.16. [Q4AE62-4] DR Ensembl; ENST00000409214.5; ENSP00000386581.1; ENSG00000121964.16. [Q4AE62-1] DR Ensembl; ENST00000463875.6; ENSP00000437964.1; ENSG00000121964.16. [Q4AE62-6] DR Ensembl; ENST00000542155.5; ENSP00000438323.1; ENSG00000121964.16. [Q4AE62-1] DR Ensembl; ENST00000618778.4; ENSP00000484990.1; ENSG00000121964.16. [Q4AE62-5] DR Ensembl; ENST00000682281.1; ENSP00000507713.1; ENSG00000121964.16. [Q4AE62-1] DR GeneID; 79712; -. DR KEGG; hsa:79712; -. DR MANE-Select; ENST00000682281.1; ENSP00000507713.1; NM_001376312.2; NP_001363241.1. DR UCSC; uc002tvo.4; human. DR UCSC; uc002tvp.4; human. [Q4AE62-1] DR UCSC; uc010fno.5; human. DR UCSC; uc061ofi.1; human. DR AGR; HGNC:20887; -. DR ClinPGx; PA134892601; -. DR CTD; 79712; -. DR DisGeNET; 79712; -. DR GeneCards; GTDC1; -. DR HGNC; HGNC:20887; QTMAN. DR HPA; ENSG00000121964; Low tissue specificity. DR MIM; 610165; gene. DR OpenTargets; ENSG00000121964; -. DR VEuPathDB; HostDB:ENSG00000121964; -. DR eggNOG; ENOG502QQJ3; Eukaryota. DR GeneTree; ENSGT00390000006631; -. DR InParanoid; Q4AE62; -. DR OMA; HRWEYDK; -. DR OrthoDB; 10032790at2759; -. DR PAN-GO; Q4AE62; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q4AE62; -. DR PathwayCommons; Q4AE62; -. DR Agora; ENSG00000121964; -. DR BioGRID-ORCS; 79712; 16 hits in 1160 CRISPR screens. DR ChiTaRS; GTDC1; human. DR GenomeRNAi; 79712; -. DR Pharos; Q4AE62; Tbio. DR PRO; PR:Q4AE62; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q4AE62; protein. DR Bgee; ENSG00000121964; Expressed in cortical plate and 196 other cell types or tissues. DR ExpressionAtlas; Q4AE62; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0016438; F:tRNA-queuosine(34) beta-mannosyltransferase activity; IDA:UniProtKB. DR GO; GO:0006417; P:regulation of translation; IDA:UniProtKB. DR GO; GO:0006400; P:tRNA modification; IDA:UniProtKB. DR GO; GO:0002099; P:tRNA wobble guanine modification; IDA:UniProt. DR CDD; cd01635; Glycosyltransferase_GTB-type; 1. DR Gene3D; 3.40.50.2000; Glycogen Phosphorylase B; 1. DR InterPro; IPR001296; Glyco_trans_1. DR InterPro; IPR051862; GT-like_domain_containing_1. DR InterPro; IPR022701; QTMAN_N. DR PANTHER; PTHR13615; GLYCOSYLTRANSFERASE-LIKE 1; 1. DR PANTHER; PTHR13615:SF3; GLYCOSYLTRANSFERASE-LIKE DOMAIN-CONTAINING PROTEIN 1; 1. DR Pfam; PF00534; Glycos_transf_1; 1. DR Pfam; PF12038; QTMAN_N; 1. DR SUPFAM; SSF53756; UDP-Glycosyltransferase/glycogen phosphorylase; 1. PE 1: Evidence at protein level; KW Alternative splicing; Cytoplasm; Glycosyltransferase; Nucleus; KW Proteomics identification; Reference proteome; Transferase. FT CHAIN 1..458 FT /note="tRNA-queuosine alpha-mannosyltransferase" FT /id="PRO_0000311088" FT REGION 242..267 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 242..262 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT VAR_SEQ 1..129 FT /note="Missing (in isoform 6)" FT /id="VSP_057596" FT VAR_SEQ 1..59 FT /note="MSILIIEAFYGGSHKQLVDLLQEELGDCVVYTLPAKKWHWRARTSALYFSQT FT IPISEHY -> MLTLHVWIWFGFMPCPNLMQNYNHQCC (in isoform 5)" FT /id="VSP_057597" FT VAR_SEQ 293..458 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_029378" FT VAR_SEQ 293..377 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_029379" FT VAR_SEQ 329..376 FT /note="DIFSEAKKALGSSVLHWGYLPSKDDYFQVLCMADVVISTAKHEFFGVA -> FT GWKLCTVGVTHFVLKIWFIPKYFQLNICILHLNSFQKGSRISARDQIL (in FT isoform 4)" FT /id="VSP_057598" FT VAR_SEQ 377..458 FT /note="Missing (in isoform 4)" FT /id="VSP_057599" FT VARIANT 137 FT /note="M -> I (in dbSNP:rs3731958)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:15068588" FT /id="VAR_037136" SQ SEQUENCE 458 AA; 52597 MW; C1B4BCD52B354A72 CRC64; MSILIIEAFY GGSHKQLVDL LQEELGDCVV YTLPAKKWHW RARTSALYFS QTIPISEHYR TLFASSVLNL TELAALRPDL GKLKKILYFH ENQLIYPVKK CQERDFQYGY NQILSCLVAD VVVFNSVFNM ESFLTSMGKF MKLIPDHRPK DLESIIRPKC QVIYFPIRFP DVSRFMPKHK TTHLKKMLGL KGNGGAVLSM ALPFQPEQRD SEDLLKNFNS ECDTHCGLDT ARQEYLGNSL RQESDLKKST SSDNSSSHHG ENKQNLTVDP CDILGGVDNQ QRLLHIVWPH RWEHDKDPES FFKVLMHLKD LGLNFHVSVL GETFTDVPDI FSEAKKALGS SVLHWGYLPS KDDYFQVLCM ADVVISTAKH EFFGVAMLEA VYCGCYPLCP KDLVYPEIFP AEYLYSTPEQ LSKRLQNFCK RPDIIRKHLY KGEIAPFSWA ALHGKFRSLL TTEPREDL // ID RAF1_HUMAN Reviewed; 648 AA. AC P04049; B0LPH8; B2R5N3; Q15278; Q9UC20; DT 01-NOV-1986, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1986, sequence version 1. DT 28-JAN-2026, entry version 269. DE RecName: Full=RAF proto-oncogene serine/threonine-protein kinase {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:17603483}; DE AltName: Full=Proto-oncogene c-RAF; DE Short=cRaf; DE AltName: Full=Raf-1; GN Name=RAF1 {ECO:0000312|HGNC:HGNC:9829}; Synonyms=RAF; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3003687; DOI=10.1093/nar/14.2.1009; RA Bonner T.I., Oppermann H., Seeburg P., Kerby S.B., Gunnell M.A., RA Young A.C., Rapp U.R.; RT "The complete coding sequence of the human raf oncogene and the RT corresponding structure of the c-raf-1 gene."; RL Nucleic Acids Res. 14:1009-1015(1986). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT LEU-308. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-308. RG NIEHS SNPs program; RL Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Pancreas; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 228-648. RX PubMed=2993863; DOI=10.1128/mcb.5.6.1400-1407.1985; RA Bonner T.I., Kerby S.B., Sutrave P., Gunnell M.A., Mark G., Rapp U.R.; RT "Structure and biological activity of human homologs of the raf/mil RT oncogene."; RL Mol. Cell. Biol. 5:1400-1407(1985). RN [7] RP PROTEIN SEQUENCE OF 42-53; 60-65; 310-316 AND 564-572, INTERACTION WITH RP PRMT5, METHYLATION AT ARG-563, PHOSPHORYLATION AT SER-289; SER-296; RP SER-301; SER-338 AND SER-621, AND MUTAGENESIS OF ARG-563. RX PubMed=21917714; DOI=10.1126/scisignal.2001936; RA Andreu-Perez P., Esteve-Puig R., de Torre-Minguela C., Lopez-Fauqued M., RA Bech-Serra J.J., Tenbaum S., Garcia-Trevijano E.R., Canals F., Merlino G., RA Avila M.A., Recio J.A.; RT "Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction RT amplitude and cell fate through CRAF."; RL Sci. Signal. 4:RA58-RA58(2011). RN [8] RP PROTEIN SEQUENCE OF 254-278, AND PHOSPHORYLATION AT THR-269. RX PubMed=7477354; DOI=10.1038/378307a0; RA Yao B., Zhang Y., Delikat S., Mathias S., Basu S., Kolesnick R.; RT "Phosphorylation of Raf by ceramide-activated protein kinase."; RL Nature 378:307-310(1995). RN [9] RP PARTIAL NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, AND TISSUE RP SPECIFICITY. RC TISSUE=Placenta; RX PubMed=1886707; RA Dozier C., Ansieau S., Ferreira E., Coll J., Stehelin D.; RT "An alternatively spliced c-mil/raf mRNA is predominantly expressed in RT chicken muscular tissues and conserved among vertebrate species."; RL Oncogene 6:1307-1311(1991). RN [10] RP PHOSPHORYLATION AT SER-43; SER-259; THR-268; SER-499 AND SER-621. RX PubMed=8349614; DOI=10.1016/s0021-9258(19)85336-x; RA Morrison D.K., Heidecker G., Rapp U.R., Copeland T.D.; RT "Identification of the major phosphorylation sites of the Raf-1 kinase."; RL J. Biol. Chem. 268:17309-17316(1993). RN [11] RP INTERACTION WITH YWHAZ, AND FUNCTION. RX PubMed=9360956; DOI=10.1074/jbc.272.46.28882; RA Dubois T., Rommel C., Howell S., Steinhussen U., Soneji Y., Morrice N., RA Moelling K., Aitken A.; RT "14-3-3 is phosphorylated by casein kinase I on residue 233. RT Phosphorylation at this site in vivo regulates Raf/14-3-3 interaction."; RL J. Biol. Chem. 272:28882-28888(1997). RN [12] RP PHOSPHORYLATION. RX PubMed=9823899; DOI=10.1038/24184; RA King A.J., Sun H., Diaz B., Barnard D., Miao W., Bagrodia S., RA Marshall M.S.; RT "The protein kinase Pak3 positively regulates Raf-1 activity through RT phosphorylation of serine 338."; RL Nature 396:180-183(1998). RN [13] RP ERRATUM OF PUBMED:9823899. RA King A.J., Sun H., Diaz B., Barnard D., Miao W., Bagrodia S., RA Marshall M.S.; RL Nature 406:439-439(2000). RN [14] RP PHOSPHORYLATION AT SER-259 BY PKB/AKT1, ACTIVITY REGULATION, AND RP INTERACTION WITH PKB/AKT1. RX PubMed=10576742; DOI=10.1126/science.286.5445.1741; RA Zimmermann S., Moelling K.; RT "Phosphorylation and regulation of Raf by Akt (protein kinase B)."; RL Science 286:1741-1744(1999). RN [15] RP PHOSPHORYLATION AT SER-259 AND SER-621, DEPHOSPHORYLATION AT SER-43; RP SER-259 AND SER-621, ACTIVITY REGULATION, AND INTERACTION WITH PPP2CA AND RP PPP2R1B. RX PubMed=10801873; DOI=10.1074/jbc.m003259200; RA Abraham D., Podar K., Pacher M., Kubicek M., Welzel N., Hemmings B.A., RA Dilworth S.M., Mischak H., Kolch W., Baccarini M.; RT "Raf-1-associated protein phosphatase 2A as a positive regulator of kinase RT activation."; RL J. Biol. Chem. 275:22300-22304(2000). RN [16] RP ACTIVITY REGULATION, AND PHOSPHORYLATION AT THR-491 AND SER-494. RX PubMed=11447113; DOI=10.1093/emboj/20.14.3716; RA Chong H., Lee J., Guan K.L.; RT "Positive and negative regulation of Raf kinase activity and function by RT phosphorylation."; RL EMBO J. 20:3716-3727(2001). RN [17] RP FUNCTION, AND INTERACTION WITH MAP3K5/ASK1. RX PubMed=11427728; DOI=10.1073/pnas.141224398; RA Chen J., Fujii K., Zhang L., Roberts T., Fu H.; RT "Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating RT kinase 1 through a MEK-ERK independent mechanism."; RL Proc. Natl. Acad. Sci. U.S.A. 98:7783-7788(2001). RN [18] RP FUNCTION IN PHOSPHORYLATION OF PPP1R12A, AND INTERACTION WITH PPP1R12A. RX PubMed=11719507; DOI=10.1074/jbc.m106343200; RA Broustas C.G., Grammatikakis N., Eto M., Dent P., Brautigan D.L., Kasid U.; RT "Phosphorylation of the myosin-binding subunit of myosin phosphatase by RT Raf-1 and inhibition of phosphatase activity."; RL J. Biol. Chem. 277:3053-3059(2002). RN [19] RP PHOSPHORYLATION AT SER-338 BY PAK1, ACTIVITY REGULATION, AND INTERACTION RP WITH PAK1. RX PubMed=11733498; DOI=10.1074/jbc.m110000200; RA Zang M., Hayne C., Luo Z.; RT "Interaction between active Pak1 and Raf-1 is necessary for phosphorylation RT and activation of Raf-1."; RL J. Biol. Chem. 277:4395-4405(2002). RN [20] RP PHOSPHORYLATION AT SER-259, DEPHOSPHORYLATION AT SER-259, AND SUBCELLULAR RP LOCATION. RX PubMed=11756411; DOI=10.1074/jbc.m108733200; RA Kubicek M., Pacher M., Abraham D., Podar K., Eulitz M., Baccarini M.; RT "Dephosphorylation of Ser-259 regulates Raf-1 membrane association."; RL J. Biol. Chem. 277:7913-7919(2002). RN [21] RP COMPETITION WITH RIN1. RX PubMed=11784866; DOI=10.1128/mcb.22.3.916-926.2001; RA Wang Y., Waldron R.T., Dhaka A., Patel A., Riley M.M., Rozengurt E., RA Colicelli J.; RT "The RAS effector RIN1 directly competes with RAF and is regulated by 14-3- RT 3 proteins."; RL Mol. Cell. Biol. 22:916-926(2002). RN [22] RP ACTIVITY REGULATION, AND INTERACTION WITH SPRY2 AND SPRY4. RX PubMed=12717443; DOI=10.1038/ncb978; RA Sasaki A., Taketomi T., Kato R., Saeki K., Nonami A., Sasaki M., RA Kuriyama M., Saito N., Shibuya M., Yoshimura A.; RT "Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to RT Raf1."; RL Nat. Cell Biol. 5:427-432(2003). RN [23] RP PHOSPHORYLATION AT SER-259. RX PubMed=15047712; DOI=10.1074/jbc.m314192200; RA Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.; RT "LGI1, a putative tumor metastasis suppressor gene, controls in vitro RT invasiveness and expression of matrix metalloproteinases in glioma cells RT through the ERK1/2 pathway."; RL J. Biol. Chem. 279:23151-23157(2004). RN [24] RP ERRATUM OF PUBMED:15047712. RA Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.; RL J. Biol. Chem. 282:2752-2752(2007). RN [25] RP FUNCTION IN PHOSPHORYLATION OF ADCY2; ADCY5 AND ADCY6, AND INTERACTION WITH RP ADCY2; ADCY5 AND ADCY6. RX PubMed=15385642; DOI=10.1124/mol.66.4.921; RA Ding Q., Gros R., Gray I.D., Taussig R., Ferguson S.S., Feldman R.D.; RT "Raf kinase activation of adenylyl cyclases: isoform-selective RT regulation."; RL Mol. Pharmacol. 66:921-928(2004). RN [26] RP INTERACTION WITH STK3/MST2, AND FUNCTION. RX PubMed=15618521; DOI=10.1126/science.1103233; RA O'Neill E., Rushworth L., Baccarini M., Kolch W.; RT "Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene RT product Raf-1."; RL Science 306:2267-2270(2004). RN [27] RP INTERACTION WITH RCAN1/DSCR1. RX PubMed=15935327; DOI=10.1016/j.abb.2005.05.002; RA Cho Y.J., Abe M., Kim S.Y., Sato Y.; RT "Raf-1 is a binding partner of DSCR1."; RL Arch. Biochem. Biophys. 439:121-128(2005). RN [28] RP REVIEW ON FUNCTION. RX PubMed=15943972; DOI=10.1016/j.febslet.2005.03.024; RA Baccarini M.; RT "Second nature: biological functions of the Raf-1 'kinase'."; RL FEBS Lett. 579:3271-3277(2005). RN [29] RP FUNCTION IN PHOSPHORYLATION OF BAD, PHOSPHORYLATION AT SER-338 AND SER-339 RP BY PAK1, SUBCELLULAR LOCATION, AND INTERACTION WITH BCL2. RX PubMed=15849194; DOI=10.1074/jbc.m413374200; RA Jin S., Zhuo Y., Guo W., Field J.; RT "p21-activated Kinase 1 (Pak1)-dependent phosphorylation of Raf-1 regulates RT its mitochondrial localization, phosphorylation of BAD, and Bcl-2 RT association."; RL J. Biol. Chem. 280:24698-24705(2005). RN [30] RP PHOSPHORYLATION AT SER-471. RX PubMed=16093354; DOI=10.1091/mbc.e05-02-0090; RA Zhu J., Balan V., Bronisz A., Balan K., Sun H., Leicht D.T., Luo Z., RA Qin J., Avruch J., Tzivion G.; RT "Identification of Raf-1 S471 as a novel phosphorylation site critical for RT Raf-1 and B-Raf kinase activities and for MEK binding."; RL Mol. Biol. Cell 16:4733-4744(2005). RN [31] RP IDENTIFICATION IN A COMPLEX WITH PP1CA; PPP1CB; PPP1CC; SHOC2 AND MRAS, RP PHOSPHORYLATION AT SER-259, AND CHARACTERIZATION OF VARIANT ALA-259. RX PubMed=16630891; DOI=10.1016/j.molcel.2006.03.027; RA Rodriguez-Viciana P., Oses-Prieto J., Burlingame A., Fried M., RA McCormick F.; RT "A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit RT of PP1 functions as an M-Ras effector to modulate Raf activity."; RL Mol. Cell 22:217-230(2006). RN [32] RP SUBUNIT. RX PubMed=16508002; DOI=10.1128/mcb.26.6.2262-2272.2006; RA Rushworth L.K., Hindley A.D., O'Neill E., Kolch W.; RT "Regulation and role of Raf-1/B-Raf heterodimerization."; RL Mol. Cell. Biol. 26:2262-2272(2006). RN [33] RP FUNCTION AS KINASE, ACTIVITY REGULATION, PHOSPHORYLATION AT SER-259; RP SER-338; TYR-340; TYR-341 AND SER-621, DEPHOSPHORYLATION AT SER-338 BY RP PPP5C, AND MUTAGENESIS OF 338-SER-SER-339; 340-TYR-TYR-341; THR-491 AND RP SER-494. RX PubMed=16892053; DOI=10.1038/ncb1465; RA von Kriegsheim A., Pitt A., Grindlay G.J., Kolch W., Dhillon A.S.; RT "Regulation of the Raf-MEK-ERK pathway by protein phosphatase 5."; RL Nat. Cell Biol. 8:1011-1016(2006). RN [34] RP REVIEW ON REGULATION. RX PubMed=17218791; DOI=10.4161/cc.6.1.3593; RA Dhillon A.S., von Kriegsheim A., Grindlay J., Kolch W.; RT "Phosphatase and feedback regulation of Raf-1 signaling."; RL Cell Cycle 6:3-7(2007). RN [35] RP FUNCTION. RX PubMed=16924233; DOI=10.1038/sj.onc.1209902; RA Wang Z., Wade P., Mandell K.J., Akyildiz A., Parkos C.A., Mrsny R.J., RA Nusrat A.; RT "Raf 1 represses expression of the tight junction protein occludin via RT activation of the zinc-finger transcription factor slug."; RL Oncogene 26:1222-1230(2007). RN [36] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-252, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [37] RP ACTIVITY REGULATION, AND INTERACTION WITH PEBP1/RKIP. RX PubMed=18294816; DOI=10.1016/j.cellsig.2008.01.012; RA Rath O., Park S., Tang H.H., Banfield M.J., Brady R.L., Lee Y.C., RA Dignam J.D., Sedivy J.M., Kolch W., Yeung K.C.; RT "The RKIP (Raf-1 Kinase Inhibitor Protein) conserved pocket binds to the RT phosphorylated N-region of Raf-1 and inhibits the Raf-1-mediated activated RT phosphorylation of MEK."; RL Cell. Signal. 20:935-941(2008). RN [38] RP PHOSPHORYLATION AT SER-338 BY PAK5. RX PubMed=18465753; DOI=10.1002/jcb.21809; RA Wu X., Carr H.S., Dan I., Ruvolo P.P., Frost J.A.; RT "p21 activated kinase 5 activates Raf-1 and targets it to mitochondria."; RL J. Cell. Biochem. 105:167-175(2008). RN [39] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [40] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [41] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-642, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [42] RP SUBCELLULAR LOCATION. RX PubMed=19298812; DOI=10.1016/j.yexcr.2009.03.004; RA Smith J., Bunaciu R.P., Reiterer G., Coder D., George T., Asaly M., Yen A.; RT "Retinoic acid induces nuclear accumulation of Raf1 during differentiation RT of HL-60 cells."; RL Exp. Cell Res. 315:2241-2248(2009). RN [43] RP ACTIVITY REGULATION, SUBUNIT, SUBCELLULAR LOCATION, AND INTERACTION WITH RP DGKH. RX PubMed=19710016; DOI=10.1074/jbc.m109.043604; RA Yasuda S., Kai M., Imai S., Takeishi K., Taketomi A., Toyota M., Kanoh H., RA Sakane F.; RT "Diacylglycerol kinase eta augments C-Raf activity and B-Raf/C-Raf RT heterodimerization."; RL J. Biol. Chem. 284:29559-29570(2009). RN [44] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-289 AND SER-301, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [45] RP REVIEW. RX PubMed=20674547; DOI=10.1016/j.bbrc.2010.07.092; RA Roskoski R. Jr.; RT "RAF protein-serine/threonine kinases: structure and regulation."; RL Biochem. Biophys. Res. Commun. 399:313-317(2010). RN [46] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [47] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [48] RP REVIEW. RX PubMed=21779496; DOI=10.1177/1947601911407323; RA Matallanas D., Birtwistle M., Romano D., Zebisch A., Rauch J., RA von Kriegsheim A., Kolch W.; RT "Raf family kinases: old dogs have learned new tricks."; RL Genes Cancer 2:232-260(2011). RN [49] RP MUTAGENESIS OF LYS-375, AND INTERACTION WITH NEK10 AND MAP2K1. RX PubMed=20956560; DOI=10.1128/mcb.00648-10; RA Moniz L.S., Stambolic V.; RT "Nek10 mediates G2/M cell cycle arrest and MEK autoactivation in response RT to UV irradiation."; RL Mol. Cell. Biol. 31:30-42(2011). RN [50] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [51] RP INTERACTION WITH FAM83B. RX PubMed=22886302; DOI=10.1172/jci60517; RA Cipriano R., Graham J., Miskimen K.L., Bryson B.L., Bruntz R.C., RA Scott S.A., Brown H.A., Stark G.R., Jackson M.W.; RT "FAM83B mediates EGFR- and RAS-driven oncogenic transformation."; RL J. Clin. Invest. 122:3197-3210(2012). RN [52] RP INTERACTION WITH GLS. RX PubMed=22538822; DOI=10.1073/pnas.1116573109; RA Thangavelu K., Pan C.Q., Karlberg T., Balaji G., Uttamchandani M., RA Suresh V., Schuler H., Low B.C., Sivaraman J.; RT "Structural basis for the allosteric inhibitory mechanism of human kidney- RT type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in RT cancer cell metabolism."; RL Proc. Natl. Acad. Sci. U.S.A. 109:7705-7710(2012). RN [53] RP INTERACTION WITH MFHAS1. RX PubMed=23327923; DOI=10.1182/blood-2011-10-385252; RA Kumkhaek C., Aerbajinai W., Liu W., Zhu J., Uchida N., Kurlander R., RA Hsieh M.M., Tisdale J.F., Rodgers G.P.; RT "MASL1 induces erythroid differentiation in human erythropoietin-dependent RT CD34+ cells through the Raf/MEK/ERK pathway."; RL Blood 121:3216-3227(2013). RN [54] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-296; SER-301 AND SER-642, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [55] RP INTERACTION WITH PDE8A. RX PubMed=23509299; DOI=10.1073/pnas.1303004110; RA Brown K.M., Day J.P., Huston E., Zimmermann B., Hampel K., Christian F., RA Romano D., Terhzaz S., Lee L.C., Willis M.J., Morton D.B., Beavo J.A., RA Shimizu-Albergine M., Davies S.A., Kolch W., Houslay M.D., Baillie G.S.; RT "Phosphodiesterase-8A binds to and regulates Raf-1 kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 110:E1533-E1542(2013). RN [56] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [57] RP IDENTIFICATION IN A COMPLEX WITH HSP90; HSP70; CDC37; PPP5C; TSC1; TSC2; RP AKT; CDK4 AND NR3C1. RX PubMed=29127155; DOI=10.15252/embj.201796700; RA Woodford M.R., Sager R.A., Marris E., Dunn D.M., Blanden A.R., Murphy R.L., RA Rensing N., Shapiro O., Panaretou B., Prodromou C., Loh S.N., Gutmann D.H., RA Bourboulia D., Bratslavsky G., Wong M., Mollapour M.; RT "Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding RT of kinase and non-kinase clients."; RL EMBO J. 36:3650-3665(2017). RN [58] RP INTERACTION WITH LZTR1. RX PubMed=30368668; DOI=10.1007/s00439-018-1951-7; RA Umeki I., Niihori T., Abe T., Kanno S.I., Okamoto N., Mizuno S., RA Kurosawa K., Nagasaki K., Yoshida M., Ohashi H., Inoue S.I., Matsubara Y., RA Fujiwara I., Kure S., Aoki Y.; RT "Delineation of LZTR1 mutation-positive patients with Noonan syndrome and RT identification of LZTR1 binding to RAF1-PPP1CB complexes."; RL Hum. Genet. 138:21-35(2019). RN [59] RP INTERACTION WITH YWHAZ. RX PubMed=31024343; DOI=10.3389/fphys.2019.00388; RA Popov I.K., Hiatt S.M., Whalen S., Keren B., Ruivenkamp C., RA van Haeringen A., Chen M.J., Cooper G.M., Korf B.R., Chang C.; RT "A YWHAZ variant associated with cardiofaciocutaneous syndrome activates RT the RAF-ERK pathway."; RL Front. Physiol. 10:388-388(2019). RN [60] RP DEPHOSPHORYLATION AT SER-259 BY SMP COMPLEX. RX PubMed=35768504; DOI=10.1038/s41586-022-04838-3; RA Liau N.P.D., Johnson M.C., Izadi S., Gerosa L., Hammel M., Bruning J.M., RA Wendorff T.J., Phung W., Hymowitz S.G., Sudhamsu J.; RT "Structural basis for SHOC2 modulation of RAS signalling."; RL Nature 609:400-407(2022). RN [61] RP DEPHOSPHORYLATION AT SER-259 BY SMP COMPLEX. RX PubMed=35831509; DOI=10.1038/s41586-022-04928-2; RA Kwon J.J., Hajian B., Bian Y., Young L.C., Amor A.J., Fuller J.R., RA Fraley C.V., Sykes A.M., So J., Pan J., Baker L., Lee S.J., Wheeler D.B., RA Mayhew D.L., Persky N.S., Yang X., Root D.E., Barsotti A.M., Stamford A.W., RA Perry C.K., Burgin A., McCormick F., Lemke C.T., Hahn W.C., Aguirre A.J.; RT "Structure-function analysis of the SHOC2-MRAS-PP1c holophosphatase RT complex."; RL Nature 609:408-415(2022). RN [62] RP DEPHOSPHORYLATION AT SER-259 BY SMP COMPLEX. RX PubMed=35830882; DOI=10.1038/s41586-022-05086-1; RA Hauseman Z.J., Fodor M., Dhembi A., Viscomi J., Egli D., Bleu M., Katz S., RA Park E., Jang D.M., Porter K.A., Meili F., Guo H., Kerr G., Molle S., RA Velez-Vega C., Beyer K.S., Galli G.G., Maira S.M., Stams T., Clark K., RA Eck M.J., Tordella L., Thoma C.R., King D.A.; RT "Structure of the MRAS-SHOC2-PP1C phosphatase complex."; RL Nature 609:416-423(2022). RN [63] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 51-131. RX PubMed=7791872; DOI=10.1038/375554a0; RA Nassar N., Horn G., Herrmann C., Scherer A., McCormick F., Wittinghofer A.; RT "The 2.2 A crystal structure of the Ras-binding domain of the RT serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue."; RL Nature 375:554-560(1995). RN [64] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 56-131. RX PubMed=8756332; DOI=10.1038/nsb0896-723; RA Nassar N., Horn G., Herrmann C., Block C., Janknecht R., Wittinghofer A.; RT "Ras/Rap effector specificity determined by charge reversal."; RL Nat. Struct. Biol. 3:723-729(1996). RN [65] RP STRUCTURE BY NMR OF 55-132. RX PubMed=7766599; DOI=10.1021/bi00021a001; RA Emerson S.D., Madison V.S., Palermo R.E., Waugh D.S., Scheffler J.E., RA Tsao K.L., Kiefer S.E., Liu S.P., Fry D.C.; RT "Solution structure of the Ras-binding domain of c-Raf-1 and identification RT of its Ras interaction surface."; RL Biochemistry 34:6911-6918(1995). RN [66] RP STRUCTURE BY NMR OF 136-187. RX PubMed=8710867; DOI=10.1073/pnas.93.16.8312; RA Mott H.R., Carpenter J.W., Zhong S., Ghosh S., Bell R.M., Campbell S.L.; RT "The solution structure of the Raf-1 cysteine-rich domain: a novel ras and RT phospholipid binding site."; RL Proc. Natl. Acad. Sci. U.S.A. 93:8312-8317(1996). RN [67] RP VARIANTS NS5 SER-256; LEU-257; PHE-259; ARG-260; LEU-261; SER-261; ASN-486; RP GLY-486; ILE-491; ARG-491 AND THR-612, VARIANT HYPERTROPHIC CARDIOMYOPATHY RP ILE-260, VARIANTS LPRD2 LEU-257 AND VAL-613, CHARACTERIZATION OF VARIANTS RP NS5 SER-261; ASN-486 AND ILE-491, CHARACTERIZATION OF VARIANT LPRD2 RP VAL-613, AND CATALYTIC ACTIVITY. RX PubMed=17603483; DOI=10.1038/ng2073; RA Pandit B., Sarkozy A., Pennacchio L.A., Carta C., Oishi K., Martinelli S., RA Pogna E.A., Schackwitz W., Ustaszewska A., Landstrom A., Bos J.M., RA Ommen S.R., Esposito G., Lepri F., Faul C., Mundel P., Lopez Siguero J.P., RA Tenconi R., Selicorni A., Rossi C., Mazzanti L., Torrente I., Marino B., RA Digilio M.C., Zampino G., Ackerman M.J., Dallapiccola B., Tartaglia M., RA Gelb B.D.; RT "Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with RT hypertrophic cardiomyopathy."; RL Nat. Genet. 39:1007-1012(2007). RN [68] RP VARIANTS NS5 LEU-257; ALA-261; SER-261; ALA-263 AND VAL-613, AND RP CHARACTERIZATION OF VARIANTS NS5 LEU-257; ALA-261; SER-261; ALA-263 AND RP VAL-613. RX PubMed=17603482; DOI=10.1038/ng2078; RA Razzaque M.A., Nishizawa T., Komoike Y., Yagi H., Furutani M., Amo R., RA Kamisago M., Momma K., Katayama H., Nakagawa M., Fujiwara Y., RA Matsushima M., Mizuno K., Tokuyama M., Hirota H., Muneuchi J., RA Higashinakagawa T., Matsuoka R.; RT "Germline gain-of-function mutations in RAF1 cause Noonan syndrome."; RL Nat. Genet. 39:1013-1017(2007). RN [69] RP VARIANTS [LARGE SCALE ANALYSIS] ALA-259 AND HIS-335. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [70] RP VARIANT NS5 SER-261. RX PubMed=20683980; DOI=10.1002/ajmg.a.33564; RA Longoni M., Moncini S., Cisternino M., Morella I.M., Ferraiuolo S., RA Russo S., Mannarino S., Brazzelli V., Coi P., Zippel R., Venturin M., RA Riva P.; RT "Noonan syndrome associated with both a new Jnk-activating familial SOS1 RT and a de novo RAF1 mutations."; RL Am. J. Med. Genet. A 152:2176-2184(2010). RN [71] RP INVOLVEMENT IN CMD1NN, VARIANTS CMD1NN THR-237; ALA-310; ALA-332; PRO-603; RP ARG-626 AND MET-641, AND CHARACTERIZATION OF VARIANTS CMD1NN THR-237; RP ALA-310; ALA-332; PRO-603; ARG-626 AND MET-641. RX PubMed=24777450; DOI=10.1038/ng.2963; RA Dhandapany P.S., Razzaque M.A., Muthusami U., Kunnoth S., Edwards J.J., RA Mulero-Navarro S., Riess I., Pardo S., Sheng J., Rani D.S., Rani B., RA Govindaraj P., Flex E., Yokota T., Furutani M., Nishizawa T., Nakanishi T., RA Robbins J., Limongelli G., Hajjar R.J., Lebeche D., Bahl A., Khullar M., RA Rathinavel A., Sadler K.C., Tartaglia M., Matsuoka R., Thangaraj K., RA Gelb B.D.; RT "RAF1 mutations in childhood-onset dilated cardiomyopathy."; RL Nat. Genet. 46:635-639(2014). CC -!- FUNCTION: Serine/threonine-protein kinase that acts as a regulatory CC link between the membrane-associated Ras GTPases and the MAPK/ERK CC cascade, and this critical regulatory link functions as a switch CC determining cell fate decisions including proliferation, CC differentiation, apoptosis, survival and oncogenic transformation. RAF1 CC activation initiates a mitogen-activated protein kinase (MAPK) cascade CC that comprises a sequential phosphorylation of the dual-specific MAPK CC kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal- CC regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form CC of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates CC BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl CC cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation. CC Phosphorylates PPP1R12A resulting in inhibition of the phosphatase CC activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can promote CC NF-kB activation and inhibit signal transducers involved in motility CC (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2), proliferation and CC angiogenesis (RB1). Can protect cells from apoptosis also by CC translocating to the mitochondria where it binds BCL2 and displaces CC BAD/Bcl2-antagonist of cell death. Regulates Rho signaling and CC migration, and is required for normal wound healing. Plays a role in CC the oncogenic transformation of epithelial cells via repression of the CC TJ protein, occludin (OCLN) by inducing the up-regulation of a CC transcriptional repressor SNAI2/SLUG, which induces down-regulation of CC OCLN. Restricts caspase activation in response to selected stimuli, CC notably Fas stimulation, pathogen-mediated macrophage apoptosis, and CC erythroid differentiation. {ECO:0000269|PubMed:11427728, CC ECO:0000269|PubMed:11719507, ECO:0000269|PubMed:15385642, CC ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15849194, CC ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:16924233, CC ECO:0000269|PubMed:9360956}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:17603483}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:17603483}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:17603483}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609; CC Evidence={ECO:0000269|PubMed:17603483}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; CC Note=Binds 2 Zn(2+) ions per subunit.; CC -!- ACTIVITY REGULATION: Regulation is a highly complex process involving CC membrane recruitment, protein-protein interactions, dimerization, and CC phosphorylation/dephosphorylation events. Ras-GTP recruits RAF1 to the CC membrane, thereby promoting its activation. The inactive conformation CC of RAF1 is maintained by autoinhibitory interactions occurring between CC the N-terminal regulatory and the C-terminal catalytic domains and by CC the binding of a 14-3-3 protein that contacts two phosphorylation CC sites, Ser-259 and Ser-621. Upon mitogenic stimulation, Ras and PPP2R1A CC cooperate to release autoinhibition and the subsequent phosphorylation CC of activating sites: Ser-338, Tyr-341, Thr-491, and Ser-494, yields a CC fully active kinase. Through a negative feedback mechanism involving CC MAPK1/ERK2, RAF1 is phosphorylated on Ser-29, Ser-43, Ser-289, Ser-296, CC Ser-301 and Ser-642 by MAPK1/ERK2, which yields an inactive, CC desensitized kinase. The signaling-competent conformation of RAF1 is CC finally re-established by the coordinated action of PIN1, a prolyl CC isomerase that converts pSer and pThr residues from the cis to the CC trans conformation, which is preferentially recognized and CC dephosphorylated by PPP2R1A. Activated by homodimerization and CC heterodimerization (with BRAF). Also regulated through association with CC other proteins such as KSR2, CNKSR1/CNK1, PEBP1/RKIP, PHB/prohibitin CC and SPRY4. PEBP1/RKIP acts by dissociating RAF1 from its substrates CC MAP2K1/MEK1 and MAP2K2/MEK2. PHB/prohibitin facilitates the CC displacement of 14-3-3 from RAF1 by activated Ras, thereby promoting CC cell membrane localization and phosphorylation of RAF1 at the CC activating Ser-338. SPRY4 inhibits Ras-independent, but not Ras- CC dependent, activation of RAF1. CNKSR1/CNK1 regulates Src-mediated RAF1 CC activation. {ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10801873, CC ECO:0000269|PubMed:11447113, ECO:0000269|PubMed:11733498, CC ECO:0000269|PubMed:12717443, ECO:0000269|PubMed:16892053, CC ECO:0000269|PubMed:18294816, ECO:0000269|PubMed:19710016}. CC -!- SUBUNIT: Monomer. Homodimer. Heterodimerizes with BRAF and this CC heterodimer possesses a highly increased kinase activity compared to CC the respective homodimers or monomers (PubMed:16508002). CC Heterodimerization is mitogen-regulated and enhanced by 14-3-3 proteins CC (PubMed:16508002). MAPK1/ERK2 activation can induce a negative feedback CC that promotes the dissociation of the heterodimer (PubMed:16508002). CC Forms a multiprotein complex with Ras (M-Ras/MRAS), SHOC2 and protein CC phosphatase 1 (PPP1CA, PPP1CB and PPP1CC) (PubMed:16630891). Interacts CC with LZTR1 (PubMed:30368668). Interacts with Ras proteins; the CC interaction is antagonized by RIN1 (PubMed:11784866). Weakly interacts CC with RIT1. Interacts (via N-terminus) with RGS14 (via RBD domains); the CC interaction mediates the formation of a ternary complex with BRAF, a CC ternary complex inhibited by GNAI1 (By similarity). Probably forms a CC complex composed of chaperones HSP90 and HSP70, co-chaperones CDC37, CC PPP5C, TSC1 and client protein TSC2, CDK4, AKT, RAF1 and NR3C1; this CC complex does not contain co-chaperones STIP1/HOP and PTGES3/p23 CC (PubMed:29127155). Interacts with STK3/MST2; the interaction inhibits CC its pro-apoptotic activity (PubMed:15618521). Interacts (when CC phosphorylated at Ser-259) with YWHAZ (unphosphorylated at 'Thr-232') CC (PubMed:31024343, PubMed:9360956). Interacts with MAP2K1/MEK1 and CC MAP2K2/MEK2 (By similarity). Interacts with MAP3K5/ASF1 (via N- CC terminus) and this interaction inhibits the proapoptotic function of CC MAP3K5/ASK1 (PubMed:11427728). Interacts with PAK1 (via kinase domain) CC (PubMed:11733498). The phosphorylated form interacts with PIN1 (By CC similarity). The Ser-338 and Ser-339 phosphorylated form (by PAK1) CC interacts with BCL2 (PubMed:15849194). Interacts with PEBP1/RKIP and CC this interaction is enhanced if RAF1 is phosphorylated on residues Ser- CC 338, Ser-339, Tyr-340 and Tyr-341 (PubMed:18294816). Interacts with CC ADCY2, ADCY5, ADCY6, DGKH, RCAN1/DSCR1, PPP1R12A, PKB/AKT1, PPP2CA, CC PPP2R1B, SPRY2, SPRY4, CNKSR1/CNK1, KSR2 and PHB/prohibitin CC (PubMed:10576742, PubMed:10801873, PubMed:11719507, PubMed:12717443, CC PubMed:15385642, PubMed:15935327, PubMed:19710016). Interacts with CC ROCK2 (By similarity). In its active form, interacts with PRMT5 CC (PubMed:21917714). Interacts with FAM83B; displaces 14-3-3 proteins CC from RAF1 and activates RAF1 (PubMed:22886302). Interacts with PDE8A; CC the interaction promotes RAF1 activity (PubMed:23509299). Interacts CC with MFHAS1 (PubMed:23327923). Interacts with GLS (PubMed:22538822). CC Interacts with NEK10 and MAP2K1; the interaction is direct with NEK10 CC and required for ERK1/2-signaling pathway activation in response to UV CC irradiation (PubMed:20956560). {ECO:0000250|UniProtKB:P11345, CC ECO:0000250|UniProtKB:Q99N57, ECO:0000269|PubMed:10576742, CC ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11427728, CC ECO:0000269|PubMed:11719507, ECO:0000269|PubMed:11733498, CC ECO:0000269|PubMed:11784866, ECO:0000269|PubMed:12717443, CC ECO:0000269|PubMed:15385642, ECO:0000269|PubMed:15618521, CC ECO:0000269|PubMed:15849194, ECO:0000269|PubMed:15935327, CC ECO:0000269|PubMed:16508002, ECO:0000269|PubMed:16630891, CC ECO:0000269|PubMed:18294816, ECO:0000269|PubMed:19710016, CC ECO:0000269|PubMed:20956560, ECO:0000269|PubMed:21917714, CC ECO:0000269|PubMed:22538822, ECO:0000269|PubMed:22886302, CC ECO:0000269|PubMed:23327923, ECO:0000269|PubMed:23509299, CC ECO:0000269|PubMed:29127155, ECO:0000269|PubMed:30368668, CC ECO:0000269|PubMed:9360956}. CC -!- INTERACTION: CC P04049; P31749: AKT1; NbExp=3; IntAct=EBI-365996, EBI-296087; CC P04049; P05067: APP; NbExp=3; IntAct=EBI-365996, EBI-77613; CC P04049; Q99933: BAG1; NbExp=2; IntAct=EBI-365996, EBI-1030678; CC P04049; O95816: BAG2; NbExp=12; IntAct=EBI-365996, EBI-355275; CC P04049; P15056: BRAF; NbExp=73; IntAct=EBI-365996, EBI-365980; CC P04049; Q14790: CASP8; NbExp=3; IntAct=EBI-365996, EBI-78060; CC P04049; P49368: CCT3; NbExp=8; IntAct=EBI-365996, EBI-356673; CC P04049; P30304: CDC25A; NbExp=4; IntAct=EBI-365996, EBI-747671; CC P04049; Q16543: CDC37; NbExp=20; IntAct=EBI-365996, EBI-295634; CC P04049; P31327: CPS1; NbExp=4; IntAct=EBI-365996, EBI-536811; CC P04049; P00533: EGFR; NbExp=3; IntAct=EBI-365996, EBI-297353; CC P04049; O15371: EIF3D; NbExp=4; IntAct=EBI-365996, EBI-353818; CC P04049; O95714: HERC2; NbExp=6; IntAct=EBI-365996, EBI-1058922; CC P04049; P01112: HRAS; NbExp=30; IntAct=EBI-365996, EBI-350145; CC P04049; P07900: HSP90AA1; NbExp=15; IntAct=EBI-365996, EBI-296047; CC P04049; P08238: HSP90AB1; NbExp=17; IntAct=EBI-365996, EBI-352572; CC P04049; P11021: HSPA5; NbExp=5; IntAct=EBI-365996, EBI-354921; CC P04049; P01116: KRAS; NbExp=6; IntAct=EBI-365996, EBI-367415; CC P04049; P01116-2: KRAS; NbExp=3; IntAct=EBI-365996, EBI-367427; CC P04049; P05783: KRT18; NbExp=5; IntAct=EBI-365996, EBI-297888; CC P04049; P08727: KRT19; NbExp=2; IntAct=EBI-365996, EBI-742756; CC P04049; Q8IVT5: KSR1; NbExp=5; IntAct=EBI-365996, EBI-486984; CC P04049; Q02750: MAP2K1; NbExp=39; IntAct=EBI-365996, EBI-492564; CC P04049; P36507: MAP2K2; NbExp=7; IntAct=EBI-365996, EBI-1056930; CC P04049; Q15773: MLF2; NbExp=4; IntAct=EBI-365996, EBI-1051875; CC P04049; Q12968: NFATC3; NbExp=2; IntAct=EBI-365996, EBI-5278441; CC P04049; P01111: NRAS; NbExp=12; IntAct=EBI-365996, EBI-721993; CC P04049; O43482: OIP5; NbExp=4; IntAct=EBI-365996, EBI-536879; CC P04049; Q13153: PAK1; NbExp=2; IntAct=EBI-365996, EBI-1307; CC P04049; Q13177: PAK2; NbExp=2; IntAct=EBI-365996, EBI-1045887; CC P04049; Q6TCH7: PAQR3; NbExp=3; IntAct=EBI-365996, EBI-15654365; CC P04049; P30086: PEBP1; NbExp=10; IntAct=EBI-365996, EBI-716384; CC P04049; Q96S96: PEBP4; NbExp=4; IntAct=EBI-365996, EBI-8563667; CC P04049; Q13526: PIN1; NbExp=2; IntAct=EBI-365996, EBI-714158; CC P04049; P14618: PKM; NbExp=3; IntAct=EBI-365996, EBI-353408; CC P04049; P62136: PPP1CA; NbExp=2; IntAct=EBI-365996, EBI-357253; CC P04049; P67775: PPP2CA; NbExp=2; IntAct=EBI-365996, EBI-712311; CC P04049; Q13362: PPP2R5C; NbExp=2; IntAct=EBI-365996, EBI-1266156; CC P04049; P04049: RAF1; NbExp=6; IntAct=EBI-365996, EBI-365996; CC P04049; P62834: RAP1A; NbExp=2; IntAct=EBI-365996, EBI-491414; CC P04049; P06400: RB1; NbExp=3; IntAct=EBI-365996, EBI-491274; CC P04049; P53805-2: RCAN1; NbExp=4; IntAct=EBI-365996, EBI-1541912; CC P04049; P31947: SFN; NbExp=9; IntAct=EBI-365996, EBI-476295; CC P04049; Q13485: SMAD4; NbExp=6; IntAct=EBI-365996, EBI-347263; CC P04049; Q13188: STK3; NbExp=6; IntAct=EBI-365996, EBI-992580; CC P04049; Q9UNE7: STUB1; NbExp=8; IntAct=EBI-365996, EBI-357085; CC P04049; Q3ZCQ8: TIMM50; NbExp=7; IntAct=EBI-365996, EBI-355175; CC P04049; P31946: YWHAB; NbExp=39; IntAct=EBI-365996, EBI-359815; CC P04049; P62258: YWHAE; NbExp=24; IntAct=EBI-365996, EBI-356498; CC P04049; P61981: YWHAG; NbExp=25; IntAct=EBI-365996, EBI-359832; CC P04049; Q04917: YWHAH; NbExp=27; IntAct=EBI-365996, EBI-306940; CC P04049; P27348: YWHAQ; NbExp=25; IntAct=EBI-365996, EBI-359854; CC P04049; P63104: YWHAZ; NbExp=35; IntAct=EBI-365996, EBI-347088; CC P04049; P32883: Kras; Xeno; NbExp=2; IntAct=EBI-365996, EBI-644267; CC P04049; P28301: Lox; Xeno; NbExp=2; IntAct=EBI-365996, EBI-642911; CC P04049; Q9ESN9-2: Mapk8ip3; Xeno; NbExp=2; IntAct=EBI-365996, EBI-9549291; CC P04049; P03495: NS; Xeno; NbExp=2; IntAct=EBI-365996, EBI-2548993; CC P04049; O39474: NS5A; Xeno; NbExp=4; IntAct=EBI-365996, EBI-7016711; CC P04049; P01120: RAS2; Xeno; NbExp=2; IntAct=EBI-365996, EBI-14838; CC -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane. Mitochondrion. Nucleus. CC Note=Colocalizes with RGS14 and BRAF in both the cytoplasm and CC membranes. Phosphorylation at Ser-259 impairs its membrane CC accumulation. Recruited to the cell membrane by the active Ras protein. CC Phosphorylation at Ser-338 and Ser-339 by PAK1 is required for its CC mitochondrial localization. Retinoic acid-induced Ser-621 CC phosphorylated form of RAF1 is predominantly localized at the nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=6C; CC IsoId=P04049-1; Sequence=Displayed; CC Name=2; Synonyms=1A; CC IsoId=P04049-2; Sequence=VSP_034649; CC -!- TISSUE SPECIFICITY: In skeletal muscle, isoform 1 is more abundant than CC isoform 2. {ECO:0000269|PubMed:1886707}. CC -!- PTM: Phosphorylation at Thr-269, Ser-338, Tyr-341, Thr-491 and Ser-494 CC results in its activation. Phosphorylation at Ser-29, Ser-43, Ser-289, CC Ser-296, Ser-301 and Ser-642 by MAPK1/ERK2 results in its inactivation. CC Phosphorylation at Ser-259 induces the interaction with YWHAZ and CC inactivates kinase activity. Dephosphorylation of Ser-259 by the SHOC2- CC MRAS-PP1c (SMP) complex consisting of SHOC2, GTP-bound M-Ras/MRAS and CC the catalytic subunit of protein phosphatase 1 (PPP1CA, PPP1CB or CC PPP1CC); this relieves inactivation and stimulates kinase activity CC (PubMed:35768504, PubMed:35831509, PubMed:35830882). Phosphorylation at CC Ser-338 by PAK1 and PAK5 and Ser-339 by PAK1 is required for its CC mitochondrial localization. Phosphorylation at Ser-621 in response to CC growth factor treatment stabilizes the protein, possibly by preventing CC proteasomal degradation. Phosphorylation at Ser-289, Ser-296, Ser-301, CC Ser-338 and Ser-621 are somehow linked to the methylation potential of CC cells. Treatment of cells with HGF in the presence of the methylation CC inhibitor 5'-methylthioadenosine (MTA) results in increased CC phosphorylation at Ser-338 and Ser-621 and decreased phosphorylation at CC Ser-296, Ser-301 and Ser-338. Dephosphorylation at Ser-338 by PPP5C CC results in an activity decrease. {ECO:0000269|PubMed:10576742, CC ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11447113, CC ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:11756411, CC ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:15849194, CC ECO:0000269|PubMed:16093354, ECO:0000269|PubMed:16630891, CC ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:18465753, CC ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:35768504, CC ECO:0000269|PubMed:35830882, ECO:0000269|PubMed:35831509, CC ECO:0000269|PubMed:7477354, ECO:0000269|PubMed:8349614, CC ECO:0000269|PubMed:9823899}. CC -!- PTM: Methylated at Arg-563 in response to EGF treatment. This CC modification leads to destabilization of the protein, possibly through CC proteasomal degradation. {ECO:0000269|PubMed:21917714}. CC -!- DISEASE: Noonan syndrome 5 (NS5) [MIM:611553]: A form of Noonan CC syndrome, a disease characterized by short stature, facial dysmorphic CC features such as hypertelorism, a downward eyeslant and low-set CC posteriorly rotated ears, and a high incidence of congenital heart CC defects and hypertrophic cardiomyopathy. Other features can include a CC short neck with webbing or redundancy of skin, deafness, motor delay, CC variable intellectual deficits, multiple skeletal defects, CC cryptorchidism, and bleeding diathesis. Individuals with Noonan CC syndrome are at risk of juvenile myelomonocytic leukemia, a CC myeloproliferative disorder characterized by excessive production of CC myelomonocytic cells. {ECO:0000269|PubMed:17603482, CC ECO:0000269|PubMed:17603483, ECO:0000269|PubMed:20683980}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: LEOPARD syndrome 2 (LPRD2) [MIM:611554]: A disorder CC characterized by lentigines, electrocardiographic conduction CC abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities CC of genitalia, retardation of growth, and sensorineural deafness. CC {ECO:0000269|PubMed:17603483}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Cardiomyopathy, dilated, 1NN (CMD1NN) [MIM:615916]: A disorder CC characterized by ventricular dilation and impaired systolic function, CC resulting in congestive heart failure and arrhythmia. Patients are at CC risk of premature death. {ECO:0000269|PubMed:24777450}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. RAF subfamily. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/42032/RAF1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X03484; CAA27204.1; -; mRNA. DR EMBL; AY271661; AAP03432.1; -; Genomic_DNA. DR EMBL; AK312248; BAG35180.1; -; mRNA. DR EMBL; EU332868; ABY87557.1; -; Genomic_DNA. DR EMBL; CH471055; EAW64134.1; -; Genomic_DNA. DR EMBL; BC018119; AAH18119.1; -; mRNA. DR EMBL; L00212; AAA60247.1; -; Genomic_DNA. DR EMBL; L00206; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00207; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00208; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00209; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00210; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00211; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00213; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; M11376; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; X54851; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS2612.1; -. [P04049-1] DR CCDS; CCDS87047.1; -. [P04049-2] DR PIR; A00637; TVHUF6. DR PIR; S60341; S60341. DR RefSeq; NP_001341618.1; NM_001354689.3. [P04049-2] DR RefSeq; NP_001341619.1; NM_001354690.3. [P04049-1] DR RefSeq; NP_002871.1; NM_002880.4. [P04049-1] DR RefSeq; XP_011532276.1; XM_011533974.3. [P04049-1] DR RefSeq; XP_047304605.1; XM_047448649.1. [P04049-1] DR RefSeq; XP_047304606.1; XM_047448650.1. [P04049-1] DR RefSeq; XP_054203389.1; XM_054347414.1. [P04049-1] DR RefSeq; XP_054203390.1; XM_054347415.1. [P04049-1] DR RefSeq; XP_054203391.1; XM_054347416.1. [P04049-1] DR PDB; 1C1Y; X-ray; 1.90 A; B=55-131. DR PDB; 1FAQ; NMR; -; A=136-187. DR PDB; 1FAR; NMR; -; A=136-187. DR PDB; 1GUA; X-ray; 2.00 A; B=51-131. DR PDB; 1RFA; NMR; -; A=55-132. DR PDB; 3CU8; X-ray; 2.40 A; P/Q=256-264. DR PDB; 3IQJ; X-ray; 1.15 A; P=255-264. DR PDB; 3IQU; X-ray; 1.05 A; P=255-260. DR PDB; 3IQV; X-ray; 1.20 A; P=255-260. DR PDB; 3KUC; X-ray; 1.92 A; B=51-131. DR PDB; 3KUD; X-ray; 2.15 A; B=51-131. DR PDB; 3NKX; X-ray; 2.40 A; P/Q=255-264. DR PDB; 3O8I; X-ray; 2.00 A; B=255-264. DR PDB; 3OMV; X-ray; 4.00 A; A/B=323-618. DR PDB; 4FJ3; X-ray; 1.95 A; P=229-264. DR PDB; 4G0N; X-ray; 2.45 A; B=54-131. DR PDB; 4G3X; X-ray; 3.25 A; B=55-131. DR PDB; 4IEA; X-ray; 1.70 A; P=618-625. DR PDB; 4IHL; X-ray; 2.20 A; P=229-264. DR PDB; 6NTC; X-ray; 2.90 A; B=55-131. DR PDB; 6NTD; X-ray; 3.15 A; B=55-131. DR PDB; 6PTS; NMR; -; D=56-187. DR PDB; 6PTW; NMR; -; D=56-187. DR PDB; 6VJJ; X-ray; 1.40 A; B=52-131. DR PDB; 6XGU; X-ray; 2.70 A; B=52-188. DR PDB; 6XGV; X-ray; 2.11 A; B=52-188. DR PDB; 6XHA; X-ray; 2.87 A; B=52-188. DR PDB; 6XHB; X-ray; 2.50 A; B=52-188. DR PDB; 6XI7; X-ray; 1.95 A; B=52-188. DR PDB; 7JHP; X-ray; 2.77 A; C=55-187. DR PDB; 7Z37; EM; 3.67 A; CP1=1-648. DR PDB; 7Z38; EM; 3.16 A; C=1-648. DR PDB; 8A68; X-ray; 1.60 A; B=255-263. DR PDB; 8A6F; X-ray; 1.60 A; P=255-264. DR PDB; 8A6H; X-ray; 1.60 A; P=255-264. DR PDB; 8ATR; X-ray; 1.70 A; P=255-263. DR PDB; 8ATS; X-ray; 1.40 A; P=255-263. DR PDB; 8AV0; X-ray; 1.50 A; P=256-264. DR PDB; 8CHF; EM; 4.25 A; A/B=1-648. DR PDB; 8CPD; EM; 3.46 A; A/B=1-648. DR PDB; 8EPW; X-ray; 2.00 A; B=52-131. DR PDB; 8GAE; EM; 3.30 A; D=404-610. DR PDB; 8GFT; EM; 3.80 A; D=336-618. DR PDB; 8JOF; NMR; -; A=51-131. DR PDB; 8JOG; NMR; -; A=51-131. DR PDB; 8Q5C; X-ray; 2.00 A; P=255-264. DR PDB; 8S42; X-ray; 1.70 A; P=255-263. DR PDB; 8T74; X-ray; 1.65 A; B=52-131. DR PDB; 8T75; X-ray; 2.65 A; B/D/F/H=52-188. DR PDB; 8U1L; EM; 3.70 A; C=2-648. DR PDB; 9AXA; EM; 4.36 A; A/C=306-648. DR PDB; 9AXC; EM; 4.16 A; A/C=306-648. DR PDB; 9AY7; X-ray; 2.41 A; A=337-615. DR PDB; 9AYA; X-ray; 2.59 A; A/C=337-615. DR PDB; 9EW1; X-ray; 1.40 A; P=255-263. DR PDB; 9EW3; X-ray; 1.40 A; P=255-263. DR PDB; 9EW4; X-ray; 1.60 A; P=255-263. DR PDB; 9EW5; X-ray; 1.50 A; C/F=255-265. DR PDB; 9EW7; X-ray; 1.80 A; P=255-264. DR PDBsum; 1C1Y; -. DR PDBsum; 1FAQ; -. DR PDBsum; 1FAR; -. DR PDBsum; 1GUA; -. DR PDBsum; 1RFA; -. DR PDBsum; 3CU8; -. DR PDBsum; 3IQJ; -. DR PDBsum; 3IQU; -. DR PDBsum; 3IQV; -. DR PDBsum; 3KUC; -. DR PDBsum; 3KUD; -. DR PDBsum; 3NKX; -. DR PDBsum; 3O8I; -. DR PDBsum; 3OMV; -. DR PDBsum; 4FJ3; -. DR PDBsum; 4G0N; -. DR PDBsum; 4G3X; -. DR PDBsum; 4IEA; -. DR PDBsum; 4IHL; -. DR PDBsum; 6NTC; -. DR PDBsum; 6NTD; -. DR PDBsum; 6PTS; -. DR PDBsum; 6PTW; -. DR PDBsum; 6VJJ; -. DR PDBsum; 6XGU; -. DR PDBsum; 6XGV; -. DR PDBsum; 6XHA; -. DR PDBsum; 6XHB; -. DR PDBsum; 6XI7; -. DR PDBsum; 7JHP; -. DR PDBsum; 7Z37; -. DR PDBsum; 7Z38; -. DR PDBsum; 8A68; -. DR PDBsum; 8A6F; -. DR PDBsum; 8A6H; -. DR PDBsum; 8ATR; -. DR PDBsum; 8ATS; -. DR PDBsum; 8AV0; -. DR PDBsum; 8CHF; -. DR PDBsum; 8CPD; -. DR PDBsum; 8EPW; -. DR PDBsum; 8GAE; -. DR PDBsum; 8GFT; -. DR PDBsum; 8JOF; -. DR PDBsum; 8JOG; -. DR PDBsum; 8Q5C; -. DR PDBsum; 8S42; -. DR PDBsum; 8T74; -. DR PDBsum; 8T75; -. DR PDBsum; 8U1L; -. DR PDBsum; 9AXA; -. DR PDBsum; 9AXC; -. DR PDBsum; 9AY7; -. DR PDBsum; 9AYA; -. DR PDBsum; 9EW1; -. DR PDBsum; 9EW3; -. DR PDBsum; 9EW4; -. DR PDBsum; 9EW5; -. DR PDBsum; 9EW7; -. DR AlphaFoldDB; P04049; -. DR BMRB; P04049; -. DR EMDB; EMD-14472; -. DR EMDB; EMD-14473; -. DR EMDB; EMD-16660; -. DR EMDB; EMD-16779; -. DR EMDB; EMD-29895; -. DR EMDB; EMD-29949; -. DR EMDB; EMD-29957; -. DR EMDB; EMD-29973; -. DR EMDB; EMD-29976; -. DR EMDB; EMD-29984; -. DR EMDB; EMD-41816; -. DR EMDB; EMD-43931; -. DR EMDB; EMD-43932; -. DR SMR; P04049; -. DR BioGRID; 111831; 1867. DR CORUM; P04049; -. DR DIP; DIP-1048N; -. DR FunCoup; P04049; 4763. DR IntAct; P04049; 435. DR MINT; P04049; -. DR STRING; 9606.ENSP00000401888; -. DR BindingDB; P04049; -. DR ChEMBL; CHEMBL1906; -. DR DrugBank; DB15254; Avutometinib. DR DrugBank; DB17568; Belvarafenib. DR DrugBank; DB08862; Cholecystokinin. DR DrugBank; DB08912; Dabrafenib. DR DrugBank; DB04367; Debromohymenialdisine. DR DrugBank; DB11718; Encorafenib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB05268; iCo-007. DR DrugBank; DB04973; LErafAON. DR DrugBank; DB18865; Naporafenib. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB12094; Semapimod. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB15266; Tovorafenib. DR DrugBank; DB05190; XL281. DR DrugCentral; P04049; -. DR GuidetoPHARMACOLOGY; 2184; -. DR MoonDB; P04049; Predicted. DR GlyCosmos; P04049; 1 site, 1 glycan. DR GlyGen; P04049; 3 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; P04049; -. DR PhosphoSitePlus; P04049; -. DR SwissPalm; P04049; -. DR BioMuta; RAF1; -. DR DMDM; 125651; -. DR CPTAC; CPTAC-1335; -. DR CPTAC; CPTAC-1336; -. DR CPTAC; CPTAC-1546; -. DR CPTAC; CPTAC-1762; -. DR CPTAC; CPTAC-5778; -. DR CPTAC; CPTAC-5779; -. DR CPTAC; CPTAC-5780; -. DR CPTAC; CPTAC-5828; -. DR CPTAC; CPTAC-5829; -. DR CPTAC; non-CPTAC-5431; -. DR CPTAC; non-CPTAC-5432; -. DR CPTAC; non-CPTAC-5433; -. DR CPTAC; non-CPTAC-5569; -. DR CPTAC; non-CPTAC-5570; -. DR CPTAC; non-CPTAC-5734; -. DR jPOST; P04049; -. DR MassIVE; P04049; -. DR PaxDb; 9606-ENSP00000251849; -. DR PeptideAtlas; P04049; -. DR ProteomicsDB; 51637; -. [P04049-1] DR ProteomicsDB; 51638; -. [P04049-2] DR Pumba; P04049; -. DR ABCD; P04049; 5 sequenced antibodies. DR Antibodypedia; 1131; 3127 antibodies from 52 providers. DR CPTC; P04049; 8 antibodies. DR DNASU; 5894; -. DR Ensembl; ENST00000251849.9; ENSP00000251849.4; ENSG00000132155.15. [P04049-1] DR Ensembl; ENST00000442415.7; ENSP00000401888.2; ENSG00000132155.15. [P04049-2] DR Ensembl; ENST00000685653.1; ENSP00000509968.1; ENSG00000132155.15. [P04049-1] DR Ensembl; ENST00000691899.1; ENSP00000508763.1; ENSG00000132155.15. [P04049-1] DR GeneID; 5894; -. DR KEGG; hsa:5894; -. DR MANE-Select; ENST00000251849.9; ENSP00000251849.4; NM_002880.4; NP_002871.1. DR UCSC; uc003bxf.5; human. [P04049-1] DR AGR; HGNC:9829; -. DR CIViC; 5894; 7 evidence items across 4 molecular profiles. DR ClinPGx; PA34183; -. DR CTD; 5894; -. DR DisGeNET; 5894; -. DR GeneCards; RAF1; -. DR GeneReviews; RAF1; -. DR HGNC; HGNC:9829; RAF1. DR HPA; ENSG00000132155; Low tissue specificity. DR MalaCards; RAF1; -. DR MIM; 164760; gene. DR MIM; 611553; phenotype. DR MIM; 611554; phenotype. DR MIM; 615916; phenotype. DR OpenTargets; ENSG00000132155; -. DR Orphanet; 154; Familial isolated dilated cardiomyopathy. DR Orphanet; 626; Large/giant congenital melanocytic nevus. DR Orphanet; 648; Noonan syndrome. DR Orphanet; 500; Noonan syndrome with multiple lentigines. DR Orphanet; 251615; Pilomyxoid astrocytoma. DR VEuPathDB; HostDB:ENSG00000132155; -. DR eggNOG; KOG0193; Eukaryota. DR GeneTree; ENSGT00940000156084; -. DR InParanoid; P04049; -. DR OMA; SAYKRHA; -. DR OrthoDB; 774951at2759; -. DR PAN-GO; P04049; 5 GO annotations based on evolutionary models. DR PhylomeDB; P04049; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; P04049; -. DR Reactome; R-HSA-2672351; Stimuli-sensing channels. DR Reactome; R-HSA-392517; Rap1 signalling. DR Reactome; R-HSA-430116; GP1b-IX-V activation signalling. DR Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling. DR Reactome; R-HSA-5673000; RAF activation. DR Reactome; R-HSA-5674135; MAP2K and MAPK activation. DR Reactome; R-HSA-5674499; Negative feedback regulation of MAPK pathway. DR Reactome; R-HSA-5675221; Negative regulation of MAPK pathway. DR Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants. DR Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF. DR Reactome; R-HSA-9649948; Signaling downstream of RAS mutants. DR Reactome; R-HSA-9656223; Signaling by RAF1 mutants. DR Reactome; R-HSA-9726840; SHOC2 M1731 mutant abolishes MRAS complex function. DR Reactome; R-HSA-9726842; Gain-of-function MRAS complexes activate RAF signaling. DR Reactome; R-HSA-9732724; IFNG signaling activates MAPKs. DR SignaLink; P04049; -. DR SIGNOR; P04049; -. DR Agora; ENSG00000132155; -. DR BioGRID-ORCS; 5894; 99 hits in 1206 CRISPR screens. DR CD-CODE; D57F7ABA; Synthetic Condensate 000274. DR ChiTaRS; RAF1; human. DR EvolutionaryTrace; P04049; -. DR GeneWiki; C-Raf; -. DR GenomeRNAi; 5894; -. DR Pharos; P04049; Tclin. DR PRO; PR:P04049; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P04049; protein. DR Bgee; ENSG00000132155; Expressed in gastrocnemius and 214 other cell types or tissues. DR ExpressionAtlas; P04049; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:MGI. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005794; C:Golgi apparatus; IPI:MGI. DR GO; GO:0005741; C:mitochondrial outer membrane; TAS:ProtInc. DR GO; GO:0005739; C:mitochondrion; IBA:GO_Central. DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0031143; C:pseudopodium; IEA:Ensembl. DR GO; GO:0010856; F:adenylate cyclase activator activity; IDA:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0004709; F:MAP kinase kinase kinase activity; IBA:GO_Central. DR GO; GO:0004672; F:protein kinase activity; EXP:Reactome. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0006915; P:apoptotic process; TAS:GO_Central. DR GO; GO:0071550; P:death-inducing signaling complex assembly; IEA:Ensembl. DR GO; GO:0038133; P:ERBB2-ERBB3 signaling pathway; IEA:Ensembl. DR GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl. DR GO; GO:0060324; P:face development; IEA:Ensembl. DR GO; GO:0008286; P:insulin receptor signaling pathway; IEA:Ensembl. DR GO; GO:0035773; P:insulin secretion involved in cellular response to glucose stimulus; IEA:Ensembl. DR GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0045104; P:intermediate filament cytoskeleton organization; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; IBA:GO_Central. DR GO; GO:0042552; P:myelination; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:1902042; P:negative regulation of extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl. DR GO; GO:0031333; P:negative regulation of protein-containing complex assembly; IDA:UniProtKB. DR GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; IEA:Ensembl. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:GO_Central. DR GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB. DR GO; GO:0045595; P:regulation of cell differentiation; TAS:UniProtKB. DR GO; GO:0035023; P:regulation of Rho protein signal transduction; TAS:UniProtKB. DR GO; GO:0035994; P:response to muscle stretch; IEA:Ensembl. DR GO; GO:0014044; P:Schwann cell development; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl. DR GO; GO:0048538; P:thymus development; IEA:Ensembl. DR GO; GO:0030878; P:thyroid gland development; IEA:Ensembl. DR GO; GO:0044342; P:type B pancreatic cell proliferation; IEA:Ensembl. DR GO; GO:0060333; P:type II interferon-mediated signaling pathway; TAS:Reactome. DR GO; GO:0042060; P:wound healing; TAS:UniProtKB. DR CDD; cd20870; C1_A_C-Raf; 1. DR CDD; cd17135; RBD_CRAF; 1. DR CDD; cd14149; STKc_C-Raf; 1. DR DisProt; DP00171; -. DR FunFam; 3.10.20.90:FF:000015; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000024; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 3.30.60.20:FF:000004; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 1.10.510.10:FF:000036; RAF proto-oncogene serine/threonine-protein kinase; 1. DR Gene3D; 3.30.60.20; -; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00292; -. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR003116; RBD_dom. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051681; Ser/Thr_Kinases-Pseudokinases. DR InterPro; IPR029071; Ubiquitin-like_domsf. DR PANTHER; PTHR44329:SF22; RAF PROTO-ONCOGENE SERINE_THREONINE-PROTEIN KINASE; 1. DR PANTHER; PTHR44329; SERINE/THREONINE-PROTEIN KINASE TNNI3K-RELATED; 1. DR Pfam; PF00130; C1_1; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF02196; RBD; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 1. DR SMART; SM00455; RBD; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF54236; Ubiquitin-like; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50898; RBD; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 1. DR PROSITE; PS50081; ZF_DAG_PE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cardiomyopathy; KW Cell membrane; Cytoplasm; Deafness; Direct protein sequencing; KW Disease variant; Kinase; Membrane; Metal-binding; Methylation; KW Mitochondrion; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger. FT CHAIN 1..648 FT /note="RAF proto-oncogene serine/threonine-protein kinase" FT /id="PRO_0000086596" FT DOMAIN 56..131 FT /note="RBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00262" FT DOMAIN 349..609 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ZN_FING 138..184 FT /note="Phorbol-ester/DAG-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 220..334 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 331..349 FT /note="Interaction with PEBP1/RKIP" FT COMPBIAS 239..271 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 275..285 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 286..301 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 468 FT /note="Proton acceptor" FT BINDING 139 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 152 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT BINDING 155 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT BINDING 165 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 168 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 173 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT BINDING 176 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT BINDING 184 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 355..363 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 375 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 29 FT /note="Phosphoserine; by MAPK1" FT /evidence="ECO:0000250|UniProtKB:Q99N57" FT MOD_RES 43 FT /note="Phosphoserine; by PKA and MAPK1" FT /evidence="ECO:0000269|PubMed:8349614" FT MOD_RES 252 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17525332" FT MOD_RES 259 FT /note="Phosphoserine; by PKA, PKC and PKB/AKT1" FT /evidence="ECO:0000269|PubMed:10576742, FT ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11756411, FT ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:16630891, FT ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:8349614" FT MOD_RES 268 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:8349614" FT MOD_RES 269 FT /note="Phosphothreonine; by PKA" FT /evidence="ECO:0000269|PubMed:7477354" FT MOD_RES 289 FT /note="Phosphoserine; by MAPK1" FT /evidence="ECO:0000269|PubMed:21917714, FT ECO:0007744|PubMed:19690332" FT MOD_RES 296 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 301 FT /note="Phosphoserine; by MAPK1" FT /evidence="ECO:0000269|PubMed:21917714, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163" FT MOD_RES 338 FT /note="Phosphoserine; by PAK1, PAK2, PAK3 and PAK5" FT /evidence="ECO:0000269|PubMed:11733498, FT ECO:0000269|PubMed:15849194, ECO:0000269|PubMed:16892053, FT ECO:0000269|PubMed:18465753, ECO:0000269|PubMed:21917714" FT MOD_RES 339 FT /note="Phosphoserine; by PAK1, PAK2 and PAK3" FT /evidence="ECO:0000269|PubMed:15849194" FT MOD_RES 340 FT /note="Phosphotyrosine; by SRC" FT /evidence="ECO:0000269|PubMed:16892053" FT MOD_RES 341 FT /note="Phosphotyrosine; by SRC" FT /evidence="ECO:0000269|PubMed:16892053" FT MOD_RES 471 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:16093354" FT MOD_RES 491 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:11447113" FT MOD_RES 494 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:11447113" FT MOD_RES 499 FT /note="Phosphoserine; by PKC" FT /evidence="ECO:0000269|PubMed:8349614" FT MOD_RES 563 FT /note="Symmetric dimethylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:21917714" FT MOD_RES 621 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:10801873, FT ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:21917714, FT ECO:0000269|PubMed:8349614" FT MOD_RES 642 FT /note="Phosphoserine; by MAPK1" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 278 FT /note="E -> ENNNLSASPRAWSRRFCLRGR (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_034649" FT VARIANT 237 FT /note="A -> T (in CMD1NN; shows a mild increase in kinase FT activity; dbSNP:rs587777588)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071844" FT VARIANT 256 FT /note="R -> S (in NS5; dbSNP:rs397516826)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037807" FT VARIANT 257 FT /note="S -> L (in NS5 and LPRD2; shows in vitro greater FT kinase activity and enhanced ERK activation than wild-type; FT dbSNP:rs80338796)" FT /evidence="ECO:0000269|PubMed:17603482, FT ECO:0000269|PubMed:17603483" FT /id="VAR_037808" FT VARIANT 259 FT /note="S -> A (in an ovarian serous carcinoma sample; FT somatic mutation; increased ERK activation; FT dbSNP:rs3730271)" FT /evidence="ECO:0000269|PubMed:16630891, FT ECO:0000269|PubMed:17344846" FT /id="VAR_041037" FT VARIANT 259 FT /note="S -> F (in NS5; dbSNP:rs397516827)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037809" FT VARIANT 260 FT /note="T -> I (in hypertrophic cardiomyopathy; uncertain FT significance; dbSNP:rs869025501)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037810" FT VARIANT 260 FT /note="T -> R (in NS5)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037811" FT VARIANT 261 FT /note="P -> A (in NS5; shows in vitro greater kinase FT activity and enhanced MAPK1 activation than wild-type; FT dbSNP:rs121434594)" FT /evidence="ECO:0000269|PubMed:17603482" FT /id="VAR_037812" FT VARIANT 261 FT /note="P -> L (in NS5; shows greater kinase activity and FT enhanced MAPK1 activation than wild-type; FT dbSNP:rs397516828)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037813" FT VARIANT 261 FT /note="P -> S (in NS5; shows in vitro greater kinase FT activity and enhanced MAPK1 activation than wild-type; FT dbSNP:rs121434594)" FT /evidence="ECO:0000269|PubMed:17603482, FT ECO:0000269|PubMed:17603483, ECO:0000269|PubMed:20683980" FT /id="VAR_037814" FT VARIANT 263 FT /note="V -> A (in NS5; shows in vitro greater kinase FT activity and enhanced MAPK1 activation than wild-type; FT dbSNP:rs397516830)" FT /evidence="ECO:0000269|PubMed:17603482" FT /id="VAR_037815" FT VARIANT 308 FT /note="P -> L (in dbSNP:rs5746220)" FT /evidence="ECO:0000269|PubMed:14702039, ECO:0000269|Ref.3" FT /id="VAR_018840" FT VARIANT 310 FT /note="T -> A (in CMD1NN; shows a mild increase in kinase FT activity; dbSNP:rs778155315)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071845" FT VARIANT 332 FT /note="P -> A (in CMD1NN; shows a mild increase in kinase FT activity; dbSNP:rs1057403865)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071846" FT VARIANT 335 FT /note="Q -> H (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041038" FT VARIANT 486 FT /note="D -> G (in NS5; dbSNP:rs397516815)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037816" FT VARIANT 486 FT /note="D -> N (in NS5; has reduced or absent kinase FT activity; dbSNP:rs80338798)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037817" FT VARIANT 491 FT /note="T -> I (in NS5; has reduced or absent kinase FT activity; dbSNP:rs80338799)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037818" FT VARIANT 491 FT /note="T -> R (in NS5; dbSNP:rs80338799)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037819" FT VARIANT 603 FT /note="L -> P (in CMD1NN; shows impaired kinase activity FT and reduced MAPK3 activation with this mutation; FT dbSNP:rs587777586)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071847" FT VARIANT 612 FT /note="S -> T (in NS5; dbSNP:rs1448392469)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037820" FT VARIANT 613 FT /note="L -> V (in NS5 and LPRD2; shows in vitro greater FT kinase activity and enhanced MAPK1 activation than wild- FT type; dbSNP:rs80338797)" FT /evidence="ECO:0000269|PubMed:17603482, FT ECO:0000269|PubMed:17603483" FT /id="VAR_037821" FT VARIANT 626 FT /note="H -> R (in CMD1NN; shows a mild increase in kinase FT activity; dbSNP:rs1553609795)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071848" FT VARIANT 641 FT /note="T -> M (in CMD1NN; shows a mild increase in kinase FT activity; dbSNP:rs587777587)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071849" FT MUTAGEN 338..339 FT /note="SS->AA: Reduced kinase activity; when associated FT with 340-D-D-341." FT /evidence="ECO:0000269|PubMed:16892053" FT MUTAGEN 338..339 FT /note="SS->DE: Non-inhibited by PPP5C. Constitutively FT active and non-inhibited by PPP5C; when associated with FT 340-D-D-341." FT /evidence="ECO:0000269|PubMed:16892053" FT MUTAGEN 340..341 FT /note="YY->DD: Constitutively active and highly FT phosphorylated on S-338, inhibited by PPP5C. Reduced kinase FT activity; when associated with 338-A-A-339. Constitutively FT active and non-inhibited by PPP5C; when associated with FT 338-D-E-339." FT /evidence="ECO:0000269|PubMed:16892053" FT MUTAGEN 375 FT /note="K->W: Catalytically inactive." FT /evidence="ECO:0000269|PubMed:20956560" FT MUTAGEN 491 FT /note="T->D: Increased kinase activity but can still be FT inhibited by PPP5C; when associated with D-494." FT /evidence="ECO:0000269|PubMed:16892053" FT MUTAGEN 494 FT /note="S->D: Increased kinase activity but can still be FT inhibited by PPP5C; when associated with D-491." FT /evidence="ECO:0000269|PubMed:16892053" FT MUTAGEN 563 FT /note="R->K: Loss of methylation. Increased stability and FT catalytic activity in response to EGF treatment." FT /evidence="ECO:0000269|PubMed:21917714" FT CONFLICT 240 FT /note="F -> L (in Ref. 6; AAA60247)" FT /evidence="ECO:0000305" FT CONFLICT 542 FT /note="M -> I (in Ref. 6; AAA60247)" FT /evidence="ECO:0000305" FT STRAND 57..61 FT /evidence="ECO:0007829|PDB:6VJJ" FT TURN 63..65 FT /evidence="ECO:0007829|PDB:8T74" FT STRAND 67..71 FT /evidence="ECO:0007829|PDB:6VJJ" FT HELIX 78..88 FT /evidence="ECO:0007829|PDB:6VJJ" FT HELIX 93..95 FT /evidence="ECO:0007829|PDB:6VJJ" FT STRAND 96..100 FT /evidence="ECO:0007829|PDB:6VJJ" FT STRAND 103..107 FT /evidence="ECO:0007829|PDB:6VJJ" FT STRAND 110..112 FT /evidence="ECO:0007829|PDB:8T74" FT HELIX 118..121 FT /evidence="ECO:0007829|PDB:6VJJ" FT STRAND 125..130 FT /evidence="ECO:0007829|PDB:6VJJ" FT STRAND 132..134 FT /evidence="ECO:0007829|PDB:6PTW" FT STRAND 135..137 FT /evidence="ECO:0007829|PDB:6XGV" FT STRAND 141..145 FT /evidence="ECO:0007829|PDB:6XI7" FT TURN 153..155 FT /evidence="ECO:0007829|PDB:6XI7" FT STRAND 160..165 FT /evidence="ECO:0007829|PDB:6XI7" FT TURN 166..168 FT /evidence="ECO:0007829|PDB:6XI7" FT STRAND 170..172 FT /evidence="ECO:0007829|PDB:7JHP" FT HELIX 174..179 FT /evidence="ECO:0007829|PDB:6XI7" FT STRAND 182..185 FT /evidence="ECO:0007829|PDB:6XGV" FT STRAND 350..353 FT /evidence="ECO:0007829|PDB:8CPD" FT STRAND 363..376 FT /evidence="ECO:0007829|PDB:8CPD" FT HELIX 384..397 FT /evidence="ECO:0007829|PDB:8CPD" FT STRAND 408..412 FT /evidence="ECO:0007829|PDB:8CPD" FT STRAND 414..416 FT /evidence="ECO:0007829|PDB:8CPD" FT STRAND 418..422 FT /evidence="ECO:0007829|PDB:8CPD" FT STRAND 429..431 FT /evidence="ECO:0007829|PDB:7Z38" FT TURN 434..437 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 442..461 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 471..473 FT /evidence="ECO:0007829|PDB:7Z38" FT TURN 478..480 FT /evidence="ECO:0007829|PDB:8GAE" FT STRAND 481..484 FT /evidence="ECO:0007829|PDB:8GAE" FT STRAND 510..512 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 514..518 FT /evidence="ECO:0007829|PDB:7Z38" FT STRAND 520..522 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 527..542 FT /evidence="ECO:0007829|PDB:7Z38" FT TURN 547..550 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 554..563 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 580..588 FT /evidence="ECO:0007829|PDB:7Z38" FT TURN 593..595 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 599..611 FT /evidence="ECO:0007829|PDB:7Z38" FT TURN 612..614 FT /evidence="ECO:0007829|PDB:7Z38" SQ SEQUENCE 648 AA; 73052 MW; EF821B5349711BC3 CRC64; MEHIQGAWKT ISNGFGFKDA VFDGSSCISP TIVQQFGYQR RASDDGKLTD PSKTSNTIRV FLPNKQRTVV NVRNGMSLHD CLMKALKVRG LQPECCAVFR LLHEHKGKKA RLDWNTDAAS LIGEELQVDF LDHVPLTTHN FARKTFLKLA FCDICQKFLL NGFRCQTCGY KFHEHCSTKV PTMCVDWSNI RQLLLFPNST IGDSGVPALP SLTMRRMRES VSRMPVSSQH RYSTPHAFTF NTSSPSSEGS LSQRQRSTST PNVHMVSTTL PVDSRMIEDA IRSHSESASP SALSSSPNNL SPTGWSQPKT PVPAQRERAP VSGTQEKNKI RPRGQRDSSY YWEIEASEVM LSTRIGSGSF GTVYKGKWHG DVAVKILKVV DPTPEQFQAF RNEVAVLRKT RHVNILLFMG YMTKDNLAIV TQWCEGSSLY KHLHVQETKF QMFQLIDIAR QTAQGMDYLH AKNIIHRDMK SNNIFLHEGL TVKIGDFGLA TVKSRWSGSQ QVEQPTGSVL WMAPEVIRMQ DNNPFSFQSD VYSYGIVLYE LMTGELPYSH INNRDQIIFM VGRGYASPDL SKLYKNCPKA MKRLVADCVK KVKEERPLFP QILSSIELLQ HSLPKINRSA SEPSLHRAAH TEDINACTLT TSPRLPVF // ID RASK_HUMAN Reviewed; 189 AA. AC P01116; A8K8Z5; B0LPF9; P01118; Q96D10; DT 21-JUL-1986, integrated into UniProtKB/Swiss-Prot. DT 21-JUL-1986, sequence version 1. DT 28-JAN-2026, entry version 268. DE RecName: Full=GTPase KRas; DE EC=3.6.5.2 {ECO:0000269|PubMed:20949621, ECO:0000269|PubMed:39809765}; DE AltName: Full=K-Ras 2; DE AltName: Full=Ki-Ras; DE AltName: Full=c-K-ras; DE AltName: Full=c-Ki-ras; DE Contains: DE RecName: Full=GTPase KRas, N-terminally processed; DE Flags: Precursor; GN Name=KRAS; Synonyms=KRAS2, RASK2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 2A AND 2B). RX PubMed=6308466; DOI=10.1038/304501a0; RA McGrath J.P., Capon D.J., Smith D.H., Chen E.Y., Seeburg P.H., RA Goeddel D.V., Levinson A.D.; RT "Structure and organization of the human Ki-ras proto-oncogene and a RT related processed pseudogene."; RL Nature 304:501-506(1983). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 2A AND 2B). RC TISSUE=Lung carcinoma; RX PubMed=6308465; DOI=10.1038/304497a0; RA Shimizu K., Birnbaum D., Ruley M.A., Fasano O., Suard Y., Edlund L., RA Taparowsky E., Goldfarb M., Wigler M.; RT "Structure of the Ki-ras gene of the human lung carcinoma cell line Calu- RT 1."; RL Nature 304:497-500(1983). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 2A AND 2B). RC TISSUE=Colon carcinoma, and Lung; RX PubMed=6308467; DOI=10.1038/304507a0; RA Capon D.J., Seeburg P.H., McGrath J.P., Hayflick J.S., Edman U., RA Levinson A.D., Goeddel D.V.; RT "Activation of Ki-ras2 gene in human colon and lung carcinomas by two RT different point mutations."; RL Nature 304:507-513(1983). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 2A AND 2B), AND VARIANT COLON RP CANCER VAL-12. RC TISSUE=Colon carcinoma; RX PubMed=6092920; DOI=10.1128/mcb.4.8.1577-1582.1984; RA McCoy M.S., Bargmann C.I., Weinberg R.A.; RT "Human colon carcinoma Ki-ras2 oncogene and its corresponding proto- RT oncogene."; RL Mol. Cell. Biol. 4:1577-1582(1984). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2B). RX PubMed=3310850; RA Kahn S., Yamamoto F., Almoguera C., Winter E., Forrester K., Jordano J., RA Perucho M.; RT "The c-K-ras gene and human cancer (review)."; RL Anticancer Res. 7:639-652(1987). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2B). RC TISSUE=Brain; RA Puhl H.L. III, Ikeda S.R., Aronstam R.S.; RT "cDNA clones of human proteins involved in signal transduction sequenced by RT the Guthrie cDNA resource center (www.cdna.org)."; RL Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2B), AND VARIANT LUNG RP CARCINOMA HIS-61. RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2B). RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG SeattleSNPs variation discovery resource; RL Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2B), AND VARIANT LUNG RP CARCINOMA HIS-61. RC TISSUE=Lung carcinoma; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-37, AND VARIANT LUNG CARCINOMA RP CYS-12. RC TISSUE=Lung carcinoma; RX PubMed=6320174; DOI=10.1073/pnas.81.1.71; RA Nakano H., Yamamoto F., Neville C., Evans D., Mizuno T., Perucho M.; RT "Isolation of transforming sequences of two human lung carcinomas: RT structural and functional analysis of the activated c-K-ras oncogenes."; RL Proc. Natl. Acad. Sci. U.S.A. 81:71-75(1984). RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-96. RC TISSUE=Pancreatic carcinoma; RX PubMed=3855240; DOI=10.1016/s0006-291x(85)80140-6; RA Hirai H., Okabe T., Anraku Y., Fujisawa M., Urabe A., Takaku F.; RT "Activation of the c-K-ras oncogene in a human pancreas carcinoma."; RL Biochem. Biophys. Res. Commun. 127:168-174(1985). RN [14] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-37, AND VARIANT GASC VAL-12. RX PubMed=3034404; RA Deng G., Lu Y., Chen S., Miao J., Lu G., Li H., Cai H., Xu X., Zheng E., RA Liu P.; RT "Activated c-Ha-ras oncogene with a guanine to thymine transversion at the RT twelfth codon in a human stomach cancer cell line."; RL Cancer Res. 47:3195-3198(1987). RN [15] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-36, AND VARIANT BLADDER/LUNG CANCER RP ARG-12. RC TISSUE=Lung carcinoma; RX PubMed=6695174; DOI=10.1126/science.6695174; RA Santos E., Martin-Zanca D., Reddy P.E., Pierotti M.A., Porta G., RA Barbacid M.; RT "Malignant activation of a K-ras oncogene in lung carcinoma but not in RT normal tissue of the same patient."; RL Science 223:661-664(1984). RN [16] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-37. RX PubMed=3932274; RA Sekiya T., Tokunaga A., Fushimi M.; RT "Essential region for transforming activity of human c-Ha-ras-1."; RL Jpn. J. Cancer Res. 76:787-791(1985). RN [17] RP PROTEIN SEQUENCE OF 1-41; 43-147 AND 150-161, CLEAVAGE OF INITIATOR RP METHIONINE, ACETYLATION AT MET-1 AND THR-2, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RC TISSUE=Cervix carcinoma; RA Bienvenut W.V., Calvo F., Kolch W.; RL Submitted (FEB-2008) to UniProtKB. RN [18] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-96. RC TISSUE=Lung carcinoma; RX PubMed=6096811; DOI=10.1093/nar/12.23.8873; RA Yamamoto F., Perucho M.; RT "Activation of a human c-K-ras oncogene."; RL Nucleic Acids Res. 12:8873-8885(1984). RN [19] RP GLYCOSYLATION AT THR-35 (MICROBIAL INFECTION). RX PubMed=19744486; DOI=10.1016/j.febslet.2009.09.006; RA Huelsenbeck S.C., Klose I., Reichenbach M., Huelsenbeck J., Genth H.; RT "Distinct kinetics of (H/K/N)Ras glucosylation and Rac1 glucosylation RT catalysed by Clostridium sordellii lethal toxin."; RL FEBS Lett. 583:3133-3139(2009). RN [20] RP INTERACTION WITH RAP1GDS1. RX PubMed=20709748; DOI=10.1074/jbc.m110.129916; RA Berg T.J., Gastonguay A.J., Lorimer E.L., Kuhnmuench J.R., Li R., RA Fields A.P., Williams C.L.; RT "Splice variants of SmgGDS control small GTPase prenylation and membrane RT localization."; RL J. Biol. Chem. 285:35255-35266(2010). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [22] RP ACETYLATION AT LYS-104, VARIANT VAL-12, FUNCTION, AND ACTIVITY REGULATION. RX PubMed=22711838; DOI=10.1073/pnas.1201487109; RA Yang M.H., Nickerson S., Kim E.T., Liot C., Laurent G., Spang R., RA Philips M.R., Shan Y., Shaw D.E., Bar-Sagi D., Haigis M.C., Haigis K.M.; RT "Regulation of RAS oncogenicity by acetylation."; RL Proc. Natl. Acad. Sci. U.S.A. 109:10843-10848(2012). RN [23] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PDE6D. RX PubMed=23698361; DOI=10.1038/nature12205; RA Zimmermann G., Papke B., Ismail S., Vartak N., Chandra A., Hoffmann M., RA Hahn S.A., Triola G., Wittinghofer A., Bastiaens P.I., Waldmann H.; RT "Small molecule inhibition of the KRAS-PDE? interaction impairs oncogenic RT KRAS signalling."; RL Nature 497:638-642(2013). RN [24] RP FUNCTION, AND CHARACTERIZATION OF VARIANT COLON CANCER VAL-12. RX PubMed=24623306; DOI=10.7554/elife.02313; RA Serra R.W., Fang M., Park S.M., Hutchinson L., Green M.R.; RT "A KRAS-directed transcriptional silencing pathway that mediates the CpG RT island methylator phenotype."; RL Elife 3:E02313-E02313(2014). RN [25] RP INTERACTION WITH RAP1GDS1, AND ISOPRENYLATION AT CYS-186. RX PubMed=24415755; DOI=10.1074/jbc.m113.527192; RA Schuld N.J., Vervacke J.S., Lorimer E.L., Simon N.C., Hauser A.D., RA Barbieri J.T., Distefano M.D., Williams C.L.; RT "The chaperone protein SmgGDS interacts with small GTPases entering the RT prenylation pathway by recognizing the last amino acid in the CAAX motif."; RL J. Biol. Chem. 289:6862-6876(2014). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [27] RP PALMITOYLATION AT CYS-180; LYS-182; LYS-184 AND LYS-185, DEPALMITOYLATION RP BY SIRT2, SUBCELLULAR LOCATION, AND MUTAGENESIS OF CYS-180 AND RP 182-LYS--LYS-185. RX PubMed=29239724; DOI=10.7554/elife.32436; RA Jing H., Zhang X., Wisner S.A., Chen X., Spiegelman N.A., Linder M.E., RA Lin H.; RT "SIRT2 and lysine fatty acylation regulate the transforming activity of K- RT Ras4a."; RL Elife 6:0-0(2017). RN [28] RP INTERACTION WITH GPR31. RX PubMed=28619714; DOI=10.1083/jcb.201609096; RA Fehrenbacher N., Tojal da Silva I., Ramirez C., Zhou Y., Cho K.J., RA Kuchay S., Shi J., Thomas S., Pagano M., Hancock J.F., Bar-Sagi D., RA Philips M.R.; RT "The G protein-coupled receptor GPR31 promotes membrane association of RT KRAS."; RL J. Cell Biol. 216:2329-2338(2017). RN [29] RP UBIQUITINATION AT LYS-170. RX PubMed=30442762; DOI=10.1126/science.aap7607; RA Steklov M., Pandolfi S., Baietti M.F., Batiuk A., Carai P., Najm P., RA Zhang M., Jang H., Renzi F., Cai Y., Abbasi Asbagh L., Pastor T., RA De Troyer M., Simicek M., Radaelli E., Brems H., Legius E., Tavernier J., RA Gevaert K., Impens F., Messiaen L., Nussinov R., Heymans S., Eyckerman S., RA Sablina A.A.; RT "Mutations in LZTR1 drive human disease by dysregulating RAS RT ubiquitination."; RL Science 362:1177-1182(2018). RN [30] RP UBIQUITINATION. RX PubMed=30442766; DOI=10.1126/science.aap8210; RA Bigenzahn J.W., Collu G.M., Kartnig F., Pieraks M., Vladimer G.I., RA Heinz L.X., Sedlyarov V., Schischlik F., Fauster A., Rebsamen M., RA Parapatics K., Blomen V.A., Mueller A.C., Winter G.E., Kralovics R., RA Brummelkamp T.R., Mlodzik M., Superti-Furga G.; RT "LZTR1 is a regulator of RAS ubiquitination and signaling."; RL Science 362:1171-1177(2018). RN [31] RP INTERACTION WITH PPP1CA; PPP1CB AND SHOC2. RX PubMed=36175670; DOI=10.1038/s41594-022-00841-4; RA Bonsor D.A., Alexander P., Snead K., Hartig N., Drew M., Messing S., RA Finci L.I., Nissley D.V., McCormick F., Esposito D., Rodriguez-Viciana P., RA Stephen A.G., Simanshu D.K.; RT "Structure of the SHOC2-MRAS-PP1c complex provides insights into RAF RT activation and Noonan syndrome."; RL Nat. Struct. Mol. Biol. 29:966-977(2022). RN [32] RP INTERACTION WITH PPP1CA; PPP1CB; PPP1CC AND SHOC2. RX PubMed=35768504; DOI=10.1038/s41586-022-04838-3; RA Liau N.P.D., Johnson M.C., Izadi S., Gerosa L., Hammel M., Bruning J.M., RA Wendorff T.J., Phung W., Hymowitz S.G., Sudhamsu J.; RT "Structural basis for SHOC2 modulation of RAS signalling."; RL Nature 609:400-407(2022). RN [33] RP INTERACTION WITH PPP1CA; PPP1CB; PPP1CC AND SHOC2, AND CHARACTERIZATION OF RP VARIANT GLN-61. RX PubMed=35831509; DOI=10.1038/s41586-022-04928-2; RA Kwon J.J., Hajian B., Bian Y., Young L.C., Amor A.J., Fuller J.R., RA Fraley C.V., Sykes A.M., So J., Pan J., Baker L., Lee S.J., Wheeler D.B., RA Mayhew D.L., Persky N.S., Yang X., Root D.E., Barsotti A.M., Stamford A.W., RA Perry C.K., Burgin A., McCormick F., Lemke C.T., Hahn W.C., Aguirre A.J.; RT "Structure-function analysis of the SHOC2-MRAS-PP1c holophosphatase RT complex."; RL Nature 609:408-415(2022). RN [34] RP INTERACTION WITH PPP1CA AND SHOC2, AND CHARACTERIZATION OF VARIANT GLN-61. RX PubMed=35830882; DOI=10.1038/s41586-022-05086-1; RA Hauseman Z.J., Fodor M., Dhembi A., Viscomi J., Egli D., Bleu M., Katz S., RA Park E., Jang D.M., Porter K.A., Meili F., Guo H., Kerr G., Molle S., RA Velez-Vega C., Beyer K.S., Galli G.G., Maira S.M., Stams T., Clark K., RA Eck M.J., Tordella L., Thoma C.R., King D.A.; RT "Structure of the MRAS-SHOC2-PP1C phosphatase complex."; RL Nature 609:416-423(2022). RN [35] RP X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS) OF 1-164 IN COMPLEX WITH THE GTP RP ANALOG GUANOSINE-5'-DIPHOSPHATE, AND ACTIVITY REGULATION. RX PubMed=22566140; DOI=10.1002/anie.201201358; RA Sun Q., Burke J.P., Phan J., Burns M.C., Olejniczak E.T., Waterson A.G., RA Lee T., Rossanese O.W., Fesik S.W.; RT "Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated RT activation."; RL Angew. Chem. Int. Ed. Engl. 51:6140-6143(2012). RN [36] RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 2-164 IN COMPLEX WITH GTP ANALOGS RP AND MAGNESIUM, FUNCTION, ACTIVITY REGULATION, INTERACTION WITH SOS1, AND RP SUBCELLULAR LOCATION. RX PubMed=22431598; DOI=10.1073/pnas.1116510109; RA Maurer T., Garrenton L.S., Oh A., Pitts K., Anderson D.J., Skelton N.J., RA Fauber B.P., Pan B., Malek S., Stokoe D., Ludlam M.J., Bowman K.K., Wu J., RA Giannetti A.M., Starovasnik M.A., Mellman I., Jackson P.K., Rudolph J., RA Wang W., Fang G.; RT "Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS- RT mediated nucleotide exchange activity."; RL Proc. Natl. Acad. Sci. U.S.A. 109:5299-5304(2012). RN [37] {ECO:0007744|PDB:5TAR, ECO:0007744|PDB:5TB5} RP X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 2-164, ISOPRENYLATION AT CYS-186, RP AND METHYLATION AT CYS-186. RX PubMed=27791178; DOI=10.1073/pnas.1615316113; RA Dharmaiah S., Bindu L., Tran T.H., Gillette W.K., Frank P.H., Ghirlando R., RA Nissley D.V., Esposito D., McCormick F., Stephen A.G., Simanshu D.K.; RT "Structural basis of recognition of farnesylated and methylated KRAS4b by RT PDEdelta."; RL Proc. Natl. Acad. Sci. U.S.A. 113:E6766-E6775(2016). RN [38] {ECO:0007744|PDB:7LC1, ECO:0007744|PDB:7LC2} RP X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) IN COMPLEX WITH MAPKAP1, INTERACTION RP WITH MAPKAP1, AND MUTAGENESIS OF ASP-38 AND TYR-40. RX PubMed=34380736; DOI=10.1073/pnas.2103261118; RA Castel P., Dharmaiah S., Sale M.J., Messing S., Rizzuto G., RA Cuevas-Navarro A., Cheng A., Trnka M.J., Urisman A., Esposito D., RA Simanshu D.K., McCormick F.; RT "RAS interaction with Sin1 is dispensable for mTORC2 assembly and RT activity."; RL Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021). RN [39] {ECO:0007744|PDB:7VVB} RP X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) IN COMPLEX WITH MAPKAP1, AND RP INTERACTION WITH MAPKAP1. RX PubMed=35522713; DOI=10.1073/pnas.2119990119; RA Zheng Y., Ding L., Meng X., Potter M., Kearney A.L., Zhang J., Sun J., RA James D.E., Yang G., Zhou C.; RT "Structural insights into Ras regulation by SIN1."; RL Proc. Natl. Acad. Sci. U.S.A. 119:e2119990119-e2119990119(2022). RN [40] RP VARIANT BREAST CANCER ASP-13. RX PubMed=3627975; DOI=10.1093/nar/15.15.5963; RA Kozma S.C., Bogaard M.E., Buser K., Saurer S.M., Bos J.L., Groner B., RA Hynes N.E.; RT "The human c-Kirsten ras gene is activated by a novel mutation in codon 13 RT in the breast carcinoma cell line MDA-MB231."; RL Nucleic Acids Res. 15:5963-5971(1987). RN [41] RP VARIANT BLADDER CANCER THR-59. RX PubMed=1553789; DOI=10.1007/bf00296523; RA Grimmond S.M., Raghavan D., Russell P.J.; RT "Detection of a rare point mutation in Ki-ras of a human bladder cancer RT xenograft by polymerase chain reaction and direct sequencing."; RL Urol. Res. 20:121-126(1992). RN [42] RP VARIANTS PANCREATIC CARCINOMA ASP-12 AND VAL-12. RX PubMed=8439212; DOI=10.1097/00000658-199302000-00007; RA Motojima K., Urano T., Nagata Y., Shiku H., Tsurifune T., Kanematsu T.; RT "Detection of point mutations in the Kirsten-ras oncogene provides evidence RT for the multicentricity of pancreatic carcinoma."; RL Ann. Surg. 217:138-143(1993). RN [43] RP VARIANTS GASC SER-12 AND ASP-12. RX PubMed=7773929; RX DOI=10.1002/1097-0142(19950615)75:12<2794::aid-cncr2820751203>3.0.co;2-f; RA Lee K.H., Lee J.S., Suh C., Kim S.W., Kim S.B., Lee J.H., Lee M.S., RA Park M.Y., Sun H.S., Kim S.H.; RT "Clinicopathologic significance of the K-ras gene codon 12 point mutation RT in stomach cancer. An analysis of 140 cases."; RL Cancer 75:2794-2801(1995). RN [44] RP INVOLVEMENT IN AML, VARIANT GLY-10 INS, AND CHARACTERIZATION OF VARIANT RP GLY-10 INS. RX PubMed=8955068; DOI=10.1074/jbc.271.51.32491; RA Bollag G., Adler F., elMasry N., McCabe P.C., Conner E. Jr., Thompson P., RA McCormick F., Shannon K.; RT "Biochemical characterization of a novel KRAS insertion mutation from a RT human leukemia."; RL J. Biol. Chem. 271:32491-32494(1996). RN [45] RP VARIANTS GASC ASN-5; VAL-12; ASP-13 AND THR-59. RX PubMed=14534542; DOI=10.1038/sj.onc.1206749; RA Lee S.H., Lee J.W., Soung Y.H., Kim H.S., Park W.S., Kim S.Y., Lee J.H., RA Park J.Y., Cho Y.G., Kim C.J., Nam S.W., Kim S.H., Lee J.Y., Yoo N.J.; RT "BRAF and KRAS mutations in stomach cancer."; RL Oncogene 22:6942-6945(2003). RN [46] RP VARIANT PYLOCYTIC ASTROCYTOMA ARG-13. RX PubMed=16247081; DOI=10.1212/01.wnl.0000180409.78098.d7; RA Sharma M.K., Zehnbauer B.A., Watson M.A., Gutmann D.H.; RT "RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic RT astrocytoma."; RL Neurology 65:1335-1336(2005). RN [47] RP VARIANTS NS3 GLY-152 AND VAL-153 (ISOFORM 2). RX PubMed=16773572; DOI=10.1086/504394; RA Carta C., Pantaleoni F., Bocchinfuso G., Stella L., Vasta I., Sarkozy A., RA Digilio C., Palleschi A., Pizzuti A., Grammatico P., Zampino G., RA Dallapiccola B., Gelb B.D., Tartaglia M.; RT "Germline missense mutations affecting KRAS Isoform B are associated with a RT severe Noonan syndrome phenotype."; RL Am. J. Hum. Genet. 79:129-135(2006). RN [48] RP VARIANTS LUNG CARCINOMA CYS-12; ASP-12; SER-12; VAL-12 AND HIS-61. RX PubMed=16533793; DOI=10.1158/1078-0432.ccr-05-1981; RA Tam I.Y.S., Chung L.P., Suen W.S., Wang E., Wong M.C.M., Ho K.K., Lam W.K., RA Chiu S.W., Girard L., Minna J.D., Gazdar A.F., Wong M.P.; RT "Distinct epidermal growth factor receptor and KRAS mutation patterns in RT non-small cell lung cancer patients with different tobacco exposure and RT clinicopathologic features."; RL Clin. Cancer Res. 12:1647-1653(2006). RN [49] RP VARIANT CFC2 ARG-60. RX PubMed=16474404; DOI=10.1038/ng1749; RA Niihori T., Aoki Y., Narumi Y., Neri G., Cave H., Verloes A., Okamoto N., RA Hennekam R.C.M., Gillessen-Kaesbach G., Wieczorek D., Kavamura M.I., RA Kurosawa K., Ohashi H., Wilson L., Heron D., Bonneau D., Corona G., RA Kaname T., Naritomi K., Baumann C., Matsumoto N., Kato K., Kure S., RA Matsubara Y.; RT "Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome."; RL Nat. Genet. 38:294-296(2006). RN [50] RP VARIANTS NS3 ILE-14 AND ILE-58, VARIANT CFC2 ARG-34, AND CHARACTERIZATION RP OF VARIANTS NS3 ILE-14 AND ILE-58. RX PubMed=16474405; DOI=10.1038/ng1748; RA Schubbert S., Zenker M., Rowe S.L., Boell S., Klein C., Bollag G., RA van der Burgt I., Musante L., Kalscheuer V., Wehner L.-E., Nguyen H., RA West B., Zhang K.Y.J., Sistermans E., Rauch A., Niemeyer C.M., Shannon K., RA Kratz C.P.; RT "Germline KRAS mutations cause Noonan syndrome."; RL Nat. Genet. 38:331-336(2006). RN [51] RP VARIANTS [LARGE SCALE ANALYSIS] ALA-12; ASP-12; SER-12; VAL-12; ASP-13; RP ARG-61; ASN-117 AND THR-146. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [52] RP VARIANTS JMML ASP-12; SER-12 AND ASP-13. RX PubMed=17332249; DOI=10.1182/blood-2006-09-046649; RA Matsuda K., Shimada A., Yoshida N., Ogawa A., Watanabe A., Yajima S., RA Iizuka S., Koike K., Yanai F., Kawasaki K., Yanagimachi M., Kikuchi A., RA Ohtsuka Y., Hidaka E., Yamauchi K., Tanaka M., Yanagisawa R., Nakazawa Y., RA Shiohara M., Manabe A., Kojima S., Koike K.; RT "Spontaneous improvement of hematologic abnormalities in patients having RT juvenile myelomonocytic leukemia with specific RAS mutations."; RL Blood 109:5477-5480(2007). RN [53] RP VARIANT NS3 GLU-5. RX PubMed=17468812; DOI=10.1007/s10038-007-0146-1; RA Bertola D.R., Pereira A.C., Brasil A.S., Albano L.M., Kim C.A., RA Krieger J.E.; RT "Further evidence of genetic heterogeneity in Costello syndrome: RT involvement of the KRAS gene."; RL J. Hum. Genet. 52:521-526(2007). RN [54] RP VARIANTS NS3 ILE-14; ARG-22; LEU-34; GLN-34; MET-36; VAL-153 AND ILE-156 RP (ISOFORM 2), VARIANT CFC2 GLU-22, AND VARIANTS ASN-5 AND LEU-156 (ISOFORM RP 2). RX PubMed=17056636; DOI=10.1136/jmg.2006.046300; RA Zenker M., Lehmann K., Schulz A.L., Barth H., Hansmann D., Koenig R., RA Korinthenberg R., Kreiss-Nachtsheim M., Meinecke P., Morlot S., Mundlos S., RA Quante A.S., Raskin S., Schnabel D., Wehner L.E., Kratz C.P., Horn D., RA Kutsche K.; RT "Expansion of the genotypic and phenotypic spectrum in patients with KRAS RT germline mutations."; RL J. Med. Genet. 44:131-135(2007). RN [55] RP VARIANTS NS3 ILE-58 AND SER-60. RX PubMed=19396835; DOI=10.1002/ajmg.a.32786; RA Kratz C.P., Zampino G., Kriek M., Kant S.G., Leoni C., Pantaleoni F., RA Oudesluys-Murphy A.M., Di Rocco C., Kloska S.P., Tartaglia M., Zenker M.; RT "Craniosynostosis in patients with Noonan syndrome caused by germline KRAS RT mutations."; RL Am. J. Med. Genet. A 149:1036-1040(2009). RN [56] RP CHARACTERIZATION OF VARIANTS NS3 ILE-14; ARG-22; LEU-34; ILE-58 AND VAL-153 RP (ISOFORM 2), CHARACTERIZATION OF VARIANTS CFC2 GLU-22; ARG-34 AND ARG-60, RP CHARACTERIZATION OF VARIANTS ASN-5 AND LEU-156 (ISOFORM 2), FUNCTION, AND RP CATALYTIC ACTIVITY. RX PubMed=20949621; DOI=10.1002/humu.21377; RA Gremer L., Merbitz-Zahradnik T., Dvorsky R., Cirstea I.C., Kratz C.P., RA Zenker M., Wittinghofer A., Ahmadian M.R.; RT "Germline KRAS mutations cause aberrant biochemical and physical properties RT leading to developmental disorders."; RL Hum. Mutat. 32:33-43(2011). RN [57] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, CHARACTERIZATION OF RP VARIANT VAL-12, AND MUTAGENESIS OF GLN-61. RX PubMed=39809765; DOI=10.1038/s41467-025-55967-y; RA Bernal Astrain G., Strakhova R., Jo C.H., Teszner E., Killoran R.C., RA Smith M.J.; RT "The small GTPase MRAS is a broken switch."; RL Nat. Commun. 16:647-647(2025). RN [58] RP VARIANTS CFC2 HIS-71 AND GLU-147. RX PubMed=21797849; DOI=10.1111/j.1399-0004.2011.01754.x; RA Stark Z., Gillessen-Kaesbach G., Ryan M.M., Cirstea I.C., Gremer L., RA Ahmadian M.R., Savarirayan R., Zenker M.; RT "Two novel germline KRAS mutations: expanding the molecular and clinical RT phenotype."; RL Clin. Genet. 81:590-594(2012). RN [59] RP VARIANTS OES ASP-13 AND PHE-19, AND INVOLVEMENT IN OES. RX PubMed=25808193; DOI=10.1002/ajmg.a.37048; RA Peacock J.D., Dykema K.J., Toriello H.V., Mooney M.R., Scholten D.J. II, RA Winn M.E., Borgman A., Duesbery N.S., Hiemenga J.A., Liu C., Campbell S., RA Nickoloff B.P., Williams B.O., Steensma M.; RT "Oculoectodermal syndrome is a mosaic RASopathy associated with KRAS RT alterations."; RL Am. J. Med. Genet. A 167:1429-1435(2015). RN [60] RP VARIANTS OES THR-146 AND VAL-146, AND INVOLVEMENT IN OES. RX PubMed=26970110; DOI=10.1111/cge.12775; RA Boppudi S., Boegershausen N., Hove H.B., Percin E.F., Aslan D., Dvorsky R., RA Kayhan G., Li Y., Cursiefen C., Tantcheva-Poor I., Toft P.B., Bartsch O., RA Lissewski C., Wieland I., Jakubiczka S., Wollnik B., Ahmadian M.R., RA Heindl L.M., Zenker M.; RT "Specific mosaic KRAS mutations affecting codon 146 cause oculoectodermal RT syndrome and encephalocraniocutaneous lipomatosis."; RL Clin. Genet. 90:334-342(2016). RN [61] RP VARIANT SFM ASP-12, VARIANTS OES THR-146 AND VAL-146, INVOLVEMENT IN SFM, RP AND INVOLVEMENT IN OES. RX PubMed=30891959; DOI=10.1002/mgg3.625; RA Chacon-Camacho O.F., Lopez-Moreno D., Morales-Sanchez M.A., Hofmann E., RA Pacheco-Quito M., Wieland I., Cortes-Gonzalez V., Villanueva-Mendoza C., RA Zenker M., Zenteno J.C.; RT "Expansion of the phenotypic spectrum and description of molecular findings RT in a cohort of patients with oculocutaneous mosaic RASopathies."; RL Mol. Genet. Genomic Med. 7:E625-E625(2019). RN [62] RP VARIANTS ALA-12; ASP-12; CYS-12; VAL-12; ASN-117 AND THR-146. RX PubMed=34820593; DOI=10.1200/po.21.00223; RA van 't Erve I., Wesdorp N.J., Medina J.E., Ferreira L., Leal A., RA Huiskens J., Bolhuis K., van Waesberghe J.T.M., Swijnenburg R.J., RA van den Broek D., Velculescu V.E., Kazemier G., Punt C.J.A., Meijer G.A., RA Fijneman R.J.A.; RT "KRAS A146 mutations are associated with distinct clinical behavior in RT patients with colorectal liver metastases."; RL JCO Precis. Oncol. 5:0-0(2021). CC -!- FUNCTION: Ras proteins bind GDP/GTP and possess intrinsic GTPase CC activity (PubMed:20949621, PubMed:39809765). Plays an important role in CC the regulation of cell proliferation (PubMed:22711838, CC PubMed:23698361). Activates MAPK1/MAPK3 resulting in phosphorylation CC and ultimately degradation of GJA1 (By similarity). Plays a role in CC promoting oncogenic events by inducing transcriptional silencing of CC tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a CC ZNF304-dependent manner (PubMed:24623306). CC {ECO:0000250|UniProtKB:P08644, ECO:0000269|PubMed:20949621, CC ECO:0000269|PubMed:22711838, ECO:0000269|PubMed:23698361, CC ECO:0000269|PubMed:24623306, ECO:0000269|PubMed:39809765}. CC -!- CATALYTIC ACTIVITY: CC Reaction=GTP + H2O = GDP + phosphate + H(+); Xref=Rhea:RHEA:19669, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:37565, CC ChEBI:CHEBI:43474, ChEBI:CHEBI:58189; EC=3.6.5.2; CC Evidence={ECO:0000269|PubMed:20949621, ECO:0000269|PubMed:39809765}; CC -!- ACTIVITY REGULATION: Alternates between an inactive form bound to GDP CC and an active form bound to GTP (PubMed:22566140, PubMed:22431598, CC PubMed:39809765). Activated by a guanine nucleotide-exchange factor CC (GEF) and inactivated by a GTPase-activating protein (GAP) CC (PubMed:22711838). Interaction with SOS1 promotes exchange of bound GDP CC to GTP (PubMed:22566140, PubMed:22431598, PubMed:39809765). CC {ECO:0000269|PubMed:22431598, ECO:0000269|PubMed:22566140, CC ECO:0000269|PubMed:22711838, ECO:0000269|PubMed:39809765}. CC -!- SUBUNIT: Interacts with PHLPP (By similarity). Interacts (active GTP- CC bound form preferentially) with RGS14 (By similarity). Interacts (when CC farnesylated) with PDE6D; this promotes dissociation from the cell CC membrane (PubMed:23698361). Interacts with SOS1 (PubMed:22431598). CC Interacts (when farnesylated) with GPR31 (PubMed:28619714). Interacts CC with RAP1GDS1 (PubMed:20709748, PubMed:24415755). Interacts (active CC GTP-bound form) with both SHOC2 and PP1c (all isoforms) to form a CC tertiary complex; SHOC2 and PP1c preferably bind M-Ras/MRAS, but they CC also bind K-Ras/KRAS, N-Ras/NRAS and H-Ras/HRAS (PubMed:35768504, CC PubMed:35830882, PubMed:35831509, PubMed:36175670). Interacts (GTP- CC bound form) with MAPKAP1/SIN1; inhibiting K-Ras/KRAS activity CC (PubMed:34380736, PubMed:35522713). {ECO:0000250|UniProtKB:P08644, CC ECO:0000269|PubMed:20709748, ECO:0000269|PubMed:22431598, CC ECO:0000269|PubMed:23698361, ECO:0000269|PubMed:24415755, CC ECO:0000269|PubMed:28619714, ECO:0000269|PubMed:34380736, CC ECO:0000269|PubMed:35522713, ECO:0000269|PubMed:35768504, CC ECO:0000269|PubMed:35830882, ECO:0000269|PubMed:35831509, CC ECO:0000269|PubMed:36175670}. CC -!- SUBUNIT: [Isoform 2B]: Interacts with GPR31; in a farnelysation- CC dependent manner. {ECO:0000269|PubMed:28619714}. CC -!- INTERACTION: CC P01116; Q96II5: ARAF; NbExp=3; IntAct=EBI-367415, EBI-9383168; CC P01116; Q99755: PIP5K1A; NbExp=9; IntAct=EBI-367415, EBI-726414; CC P01116; P04049: RAF1; NbExp=6; IntAct=EBI-367415, EBI-365996; CC P01116; P50749: RASSF2; NbExp=2; IntAct=EBI-367415, EBI-960081; CC P01116-2; P05067: APP; NbExp=3; IntAct=EBI-367427, EBI-77613; CC P01116-2; P49354: FNTA; NbExp=2; IntAct=EBI-367427, EBI-602336; CC P01116-2; O00270: GPR31; NbExp=4; IntAct=EBI-367427, EBI-34583813; CC P01116-2; P01116-2: KRAS; NbExp=6; IntAct=EBI-367427, EBI-367427; CC P01116-2; P04049: RAF1; NbExp=3; IntAct=EBI-367427, EBI-365996; CC P01116-2; Q04631: Fnta; Xeno; NbExp=3; IntAct=EBI-367427, EBI-602447; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22431598, CC ECO:0000269|PubMed:23698361, ECO:0000269|PubMed:29239724}; Lipid-anchor CC {ECO:0000269|PubMed:29239724, ECO:0000305|PubMed:23698361}; Cytoplasmic CC side {ECO:0000305|PubMed:23698361}. Endomembrane system CC {ECO:0000269|PubMed:29239724}. Cytoplasm, cytosol CC {ECO:0000269|PubMed:23698361}. CC -!- SUBCELLULAR LOCATION: [Isoform 2B]: Cell membrane CC {ECO:0000269|PubMed:28619714}; Lipid-anchor CC {ECO:0000305|PubMed:28619714}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Comment=Isoforms differ in the C-terminal region which is encoded by CC two alternative exons (IVA and IVB).; CC Name=2A; Synonyms=K-Ras4A {ECO:0000303|PubMed:29239724}; CC IsoId=P01116-1; Sequence=Displayed; CC Name=2B; Synonyms=K-Ras4B; CC IsoId=P01116-2, P01118-1; CC Sequence=VSP_011140, VSP_011141; CC -!- PTM: Acetylation at Lys-104 prevents interaction with guanine CC nucleotide exchange factors (GEFs). {ECO:0000269|PubMed:22711838, CC ECO:0000269|Ref.17}. CC -!- PTM: Palmitoylated at Lys-182, Lys-184 and Lys-185 (PubMed:29239724). CC Palmitoylation on lysine residues is promoted by palmitoylation at Cys- CC 180 (PubMed:29239724). Lysine-depalmitoylation by SIRT2 promotes its CC localization to endomembranes in endocytic pathways (PubMed:29239724). CC {ECO:0000269|PubMed:29239724}. CC -!- PTM: Ubiquitinated by the BCR(LZTR1) E3 ubiquitin ligase complex at CC Lys-170 in a non-degradative manner, leading to inhibit Ras signaling CC by decreasing Ras association with membranes. CC {ECO:0000305|PubMed:30442762, ECO:0000305|PubMed:30442766}. CC -!- PTM: (Microbial infection) Glucosylated at Thr-35 by P.sordellii toxin CC TcsL. {ECO:0000269|PubMed:19744486}. CC -!- DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype of CC acute leukemia, a cancer of the white blood cells. AML is a malignant CC disease of bone marrow characterized by maturational arrest of CC hematopoietic precursors at an early stage of development. Clonal CC expansion of myeloid blasts occurs in bone marrow, blood, and other CC tissue. Myelogenous leukemias develop from changes in cells that CC normally produce neutrophils, basophils, eosinophils and monocytes. CC {ECO:0000269|PubMed:8955068}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An CC aggressive pediatric myelodysplastic syndrome/myeloproliferative CC disorder characterized by malignant transformation in the hematopoietic CC stem cell compartment with proliferation of differentiated progeny. CC Patients have splenomegaly, enlarged lymph nodes, rashes, and CC hemorrhages. {ECO:0000269|PubMed:17332249}. Note=The disease is caused CC by variants affecting the gene represented in this entry. CC -!- DISEASE: Noonan syndrome 3 (NS3) [MIM:609942]: A form of Noonan CC syndrome, a disease characterized by short stature, facial dysmorphic CC features such as hypertelorism, a downward eyeslant and low-set CC posteriorly rotated ears, and a high incidence of congenital heart CC defects and hypertrophic cardiomyopathy. Other features can include a CC short neck with webbing or redundancy of skin, deafness, motor delay, CC variable intellectual deficits, multiple skeletal defects, CC cryptorchidism, and bleeding diathesis. Individuals with Noonan CC syndrome are at risk of juvenile myelomonocytic leukemia, a CC myeloproliferative disorder characterized by excessive production of CC myelomonocytic cells. {ECO:0000269|PubMed:16474405, CC ECO:0000269|PubMed:16773572, ECO:0000269|PubMed:17056636, CC ECO:0000269|PubMed:17468812, ECO:0000269|PubMed:19396835, CC ECO:0000269|PubMed:20949621}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which CC starts in the stomach, can spread to the esophagus or the small CC intestine, and can extend through the stomach wall to nearby lymph CC nodes and organs. It also can metastasize to other parts of the body. CC The term gastric cancer or gastric carcinoma refers to adenocarcinoma CC of the stomach that accounts for most of all gastric malignant tumors. CC Two main histologic types are recognized, diffuse type and intestinal CC type carcinomas. Diffuse tumors are poorly differentiated infiltrating CC lesions, resulting in thickening of the stomach. In contrast, CC intestinal tumors are usually exophytic, often ulcerating, and CC associated with intestinal metaplasia of the stomach, most often CC observed in sporadic disease. {ECO:0000269|PubMed:14534542, CC ECO:0000269|PubMed:3034404, ECO:0000269|PubMed:7773929}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=Defects in KRAS are a cause of pylocytic astrocytoma CC (PA). Pylocytic astrocytomas are neoplasms of the brain and spinal cord CC derived from glial cells which vary from histologically benign forms to CC highly anaplastic and malignant tumors. {ECO:0000269|PubMed:16247081}. CC -!- DISEASE: Cardiofaciocutaneous syndrome 2 (CFC2) [MIM:615278]: A form of CC cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder CC characterized by a distinctive facial appearance, heart defects and CC intellectual disability. Heart defects include pulmonic stenosis, CC atrial septal defects and hypertrophic cardiomyopathy. Some affected CC individuals present with ectodermal abnormalities such as sparse, CC friable hair, hyperkeratotic skin lesions and a generalized ichthyosis- CC like condition. Typical facial features are similar to Noonan syndrome. CC They include high forehead with bitemporal constriction, hypoplastic CC supraorbital ridges, downslanting palpebral fissures, a depressed nasal CC bridge, and posteriorly angulated ears with prominent helices. CFC2 CC patients often do not have the skin abnormalities, such as ichthyosis, CC hyperkeratosis, and hemangioma observed in CFC1. CC {ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:16474405, CC ECO:0000269|PubMed:17056636, ECO:0000269|PubMed:20949621, CC ECO:0000269|PubMed:21797849}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Note=KRAS mutations are involved in cancer development. CC {ECO:0000269|PubMed:14534542, ECO:0000269|PubMed:1553789, CC ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:24623306, CC ECO:0000269|PubMed:3034404, ECO:0000269|PubMed:3627975, CC ECO:0000269|PubMed:6092920, ECO:0000269|PubMed:6695174, CC ECO:0000269|PubMed:7773929}. CC -!- DISEASE: Oculoectodermal syndrome (OES) [MIM:600268]: A syndrome CC characterized by the association of epibulbar dermoids and aplasia CC cutis congenita. Affected individuals show multiple, asymmetric, CC atrophic, non-scarring and hairless regions that may be associated with CC hamartomas. Ectodermal changes include linear hyperpigmentation that CC may follow the lines of Blaschko and rarely epidermal nevus-like CC lesions. Epibulbar dermoids may be uni-or bilateral. Additional ocular CC anomalies such as skin tags of the upper eyelid, rarely optic nerve or CC retinal changes, and microphthalmia can be present. The phenotypic CC expression is highly variable, and various other abnormalities have CC occasionally been reported including growth failure, lymphedema, CC cardiovascular defects, as well as neurodevelopmental symptoms like CC developmental delay, epilepsy, learning difficulties, and behavioral CC abnormalities. Benign tumor-like lesions such as nonossifying fibromas CC of the long bones and giant cell granulomas of the jaws have repeatedly CC been observed and appear to be age-dependent, becoming a common CC manifestation in individuals aged 5 years or older. CC {ECO:0000269|PubMed:25808193, ECO:0000269|PubMed:26970110, CC ECO:0000269|PubMed:30891959}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:163200]: A CC disease characterized by sebaceous nevi, often on the face, associated CC with variable ipsilateral abnormalities of the central nervous system, CC ocular anomalies, and skeletal defects. Many oral manifestations have CC been reported, not only including hypoplastic and malformed teeth, and CC mucosal papillomatosis, but also ankyloglossia, hemihyperplastic CC tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone CC cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous CC nevi follow the lines of Blaschko and these can continue as linear CC intraoral lesions, as in mucosal papillomatosis. CC {ECO:0000269|PubMed:30891959}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the small GTPase superfamily. Ras family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/91/KRAS"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L00049; AAB59444.1; -; Genomic_DNA. DR EMBL; L00045; AAB59444.1; JOINED; Genomic_DNA. DR EMBL; L00046; AAB59444.1; JOINED; Genomic_DNA. DR EMBL; L00047; AAB59444.1; JOINED; Genomic_DNA. DR EMBL; L00048; AAB59445.1; -; Genomic_DNA. DR EMBL; L00045; AAB59445.1; JOINED; Genomic_DNA. DR EMBL; L00046; AAB59445.1; JOINED; Genomic_DNA. DR EMBL; L00047; AAB59445.1; JOINED; Genomic_DNA. DR EMBL; M54968; AAB41942.1; -; mRNA. DR EMBL; AF493917; AAM12631.1; -; mRNA. DR EMBL; BT007153; AAP35817.1; -; mRNA. DR EMBL; AK292510; BAF85199.1; -; mRNA. DR EMBL; CH471094; EAW96511.1; -; Genomic_DNA. DR EMBL; CH471094; EAW96512.1; -; Genomic_DNA. DR EMBL; EU332849; ABY87538.1; -; Genomic_DNA. DR EMBL; BC013572; AAH13572.1; -; mRNA. DR EMBL; K01519; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; K01520; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; M25876; AAA35683.1; -; Genomic_DNA. DR EMBL; M34904; AAA36149.1; -; Genomic_DNA. DR EMBL; M30539; AAA36557.1; -; Genomic_DNA. DR EMBL; X01669; CAA25828.1; -; Genomic_DNA. DR EMBL; X02825; CAA26593.1; -; Genomic_DNA. DR EMBL; K03210; AAA36554.1; -; Genomic_DNA. DR EMBL; K03209; AAA36554.1; JOINED; Genomic_DNA. DR CCDS; CCDS8702.1; -. [P01116-2] DR CCDS; CCDS8703.1; -. [P01116-1] DR PIR; A93311; TVHUK. DR PIR; B93311; TVHU2K. DR RefSeq; NP_001356715.1; NM_001369786.1. [P01116-1] DR RefSeq; NP_001356716.1; NM_001369787.1. [P01116-2] DR RefSeq; NP_004976.2; NM_004985.4. [P01116-2] DR RefSeq; NP_203524.1; NM_033360.4. [P01116-1] DR PDB; 1D8D; X-ray; 2.00 A; P=178-188. DR PDB; 1D8E; X-ray; 3.00 A; P=178-188. DR PDB; 1KZO; X-ray; 2.20 A; C=169-173. DR PDB; 1KZP; X-ray; 2.10 A; C=169-173. DR PDB; 1N4P; X-ray; 2.65 A; M/N=185-189. DR PDB; 1N4Q; X-ray; 2.40 A; M/N/O/P/Q/R=185-189. DR PDB; 1N4R; X-ray; 2.80 A; M/N/O/P/Q/R=185-189. DR PDB; 1N4S; X-ray; 2.60 A; M/N/O/P/Q/R=185-189. DR PDB; 2MSC; NMR; -; B=1-186. DR PDB; 2MSD; NMR; -; B=1-186. DR PDB; 2MSE; NMR; -; B=1-186. DR PDB; 3GFT; X-ray; 2.27 A; A/B/C/D/E/F=1-164. DR PDB; 4DSN; X-ray; 2.03 A; A=2-164. DR PDB; 4DSO; X-ray; 1.85 A; A=2-164. DR PDB; 4EPR; X-ray; 2.00 A; A=1-164. DR PDB; 4EPT; X-ray; 2.00 A; A=1-164. DR PDB; 4EPV; X-ray; 1.35 A; A=1-164. DR PDB; 4EPW; X-ray; 1.70 A; A=1-164. DR PDB; 4EPX; X-ray; 1.76 A; A=1-164. DR PDB; 4EPY; X-ray; 1.80 A; A=1-164. DR PDB; 4L8G; X-ray; 1.52 A; A=1-169. DR PDB; 4LDJ; X-ray; 1.15 A; A=1-164. DR PDB; 4LPK; X-ray; 1.50 A; A/B=1-169. DR PDB; 4LRW; X-ray; 2.15 A; A/B=1-169. DR PDB; 4LUC; X-ray; 1.29 A; A/B=1-169. DR PDB; 4LV6; X-ray; 1.50 A; A/B=1-169. DR PDB; 4LYF; X-ray; 1.57 A; A/B/C=1-169. DR PDB; 4LYH; X-ray; 1.37 A; A/B/C=1-169. DR PDB; 4LYJ; X-ray; 1.93 A; A=1-169. DR PDB; 4M1O; X-ray; 1.57 A; A/B/C=1-169. DR PDB; 4M1S; X-ray; 1.55 A; A/B/C=1-169. DR PDB; 4M1T; X-ray; 1.70 A; A/B/C=1-169. DR PDB; 4M1W; X-ray; 1.58 A; A/B/C=1-169. DR PDB; 4M1Y; X-ray; 1.49 A; A/B/C=1-169. DR PDB; 4M21; X-ray; 1.94 A; A/B/C=1-169. DR PDB; 4M22; X-ray; 2.09 A; A/B/C=1-169. DR PDB; 4NMM; X-ray; 1.89 A; A=1-164. DR PDB; 4OBE; X-ray; 1.24 A; A/B=1-164. DR PDB; 4PZY; X-ray; 1.88 A; A/B=1-164. DR PDB; 4PZZ; X-ray; 1.40 A; A=1-164. DR PDB; 4Q01; X-ray; 1.29 A; A/B=1-164. DR PDB; 4Q02; X-ray; 1.70 A; A=1-164. DR PDB; 4Q03; X-ray; 1.20 A; A=1-164. DR PDB; 4QL3; X-ray; 1.04 A; A=1-11, A=13-164. DR PDB; 4TQ9; X-ray; 1.49 A; A/B=1-164. DR PDB; 4TQA; X-ray; 1.13 A; A/B=1-164. DR PDB; 4WA7; X-ray; 1.99 A; A=1-164. DR PDB; 5F2E; X-ray; 1.40 A; A=1-169. DR PDB; 5KYK; X-ray; 2.70 A; A/B/C=1-167. DR PDB; 5MLA; X-ray; 2.19 A; A=1-166. DR PDB; 5MLB; X-ray; 3.22 A; A/C/E/G=1-166. DR PDB; 5O2S; X-ray; 3.22 A; A/C/E/G=1-166. DR PDB; 5O2T; X-ray; 2.19 A; A=1-166. DR PDB; 5OCG; X-ray; 1.48 A; A=2-189. DR PDB; 5OCO; X-ray; 1.66 A; A/B/C/D/E/F=1-169. DR PDB; 5OCT; X-ray; 2.07 A; A/B/C/D/E/F=1-169. DR PDB; 5TAR; X-ray; 1.90 A; A=2-164. DR PDB; 5TB5; X-ray; 2.00 A; A/C=2-164. DR PDB; 5UFE; X-ray; 2.30 A; A=1-166. DR PDB; 5UFQ; X-ray; 2.20 A; A/B=1-166. DR PDB; 5UK9; X-ray; 1.89 A; A/B=1-166. DR PDB; 5UQW; X-ray; 1.50 A; A/B=1-164. DR PDB; 5US4; X-ray; 1.83 A; A/B=1-164. DR PDB; 5USJ; X-ray; 1.94 A; A/B/C/D/E/F=1-164. DR PDB; 5V6S; X-ray; 1.70 A; A=1-169. DR PDB; 5V6V; X-ray; 1.72 A; A/B=1-169. DR PDB; 5V71; X-ray; 2.23 A; A/B/C/D/E/F=1-167. DR PDB; 5V9L; X-ray; 1.98 A; A/B/C=1-167. DR PDB; 5V9O; X-ray; 1.56 A; A=1-167. DR PDB; 5V9U; X-ray; 1.38 A; A/B=1-169. DR PDB; 5VBM; X-ray; 1.49 A; A=1-169. DR PDB; 5VP7; X-ray; 1.70 A; A/F=1-169. DR PDB; 5VPI; X-ray; 1.62 A; A/B=1-169. DR PDB; 5VPY; X-ray; 2.00 A; A/B=1-169. DR PDB; 5VPZ; X-ray; 1.85 A; A/B=1-169. DR PDB; 5VQ0; X-ray; 2.30 A; A/B=1-169. DR PDB; 5VQ1; X-ray; 1.78 A; A/B=1-169. DR PDB; 5VQ2; X-ray; 1.96 A; A/B=1-169. DR PDB; 5VQ6; X-ray; 1.99 A; A/B=1-169. DR PDB; 5VQ8; X-ray; 2.30 A; A/B=1-169. DR PDB; 5W22; X-ray; 1.76 A; A/B=1-169. DR PDB; 5WHA; X-ray; 2.04 A; A/D/G/J=1-166. DR PDB; 5WHB; X-ray; 2.18 A; A/D/G/J=1-166. DR PDB; 5WHD; X-ray; 1.64 A; A/B/C/D=1-166. DR PDB; 5WHE; X-ray; 1.91 A; A/D/G/J=1-166. DR PDB; 5WLB; X-ray; 1.72 A; A/D=1-166. DR PDB; 5WPM; X-ray; 1.72 A; A=1-166. DR PDB; 5XCO; X-ray; 1.25 A; A=1-169. DR PDB; 5YXZ; X-ray; 1.70 A; A=1-169. DR PDB; 5YY1; X-ray; 1.69 A; A=1-169. DR PDB; 6ARK; X-ray; 1.75 A; A=1-169. DR PDB; 6ASA; X-ray; 2.54 A; A=1-167. DR PDB; 6ASE; X-ray; 1.55 A; A=1-169. DR PDB; 6B0V; X-ray; 1.29 A; A/B=1-169. DR PDB; 6B0Y; X-ray; 1.43 A; A/B=1-169. DR PDB; 6BOF; X-ray; 1.40 A; A/B=2-169. DR PDB; 6BP1; X-ray; 2.00 A; A=1-169. DR PDB; 6CC9; NMR; -; B=1-186. DR PDB; 6CCH; NMR; -; B=1-186. DR PDB; 6CCX; NMR; -; B=1-186. DR PDB; 6CU6; X-ray; 1.50 A; A/B/C=1-169. DR PDB; 6E6F; X-ray; 3.40 A; A/B=1-166. DR PDB; 6E6G; X-ray; 1.93 A; A=1-166. DR PDB; 6EPL; X-ray; 2.55 A; R=1-169. DR PDB; 6EPM; X-ray; 2.50 A; R=1-169. DR PDB; 6EPN; X-ray; 2.50 A; R=1-169. DR PDB; 6EPO; X-ray; 2.40 A; R=1-169. DR PDB; 6EPP; X-ray; 2.40 A; R=1-169. DR PDB; 6F76; X-ray; 2.20 A; A/B/C/D/E/F=1-169. DR PDB; 6FA1; X-ray; 1.97 A; A/C/D/F=1-167, B/E=1-169. DR PDB; 6FA2; X-ray; 2.60 A; A/B/C/D/E/F=1-167. DR PDB; 6FA3; X-ray; 1.82 A; A/B/C/D/E/F=1-167. DR PDB; 6FA4; X-ray; 2.02 A; A/B/C/D/E/F=1-169. DR PDB; 6GJ5; X-ray; 1.50 A; A/B=1-169. DR PDB; 6GJ6; X-ray; 1.76 A; A=1-169. DR PDB; 6GJ7; X-ray; 1.67 A; A=1-169. DR PDB; 6GJ8; X-ray; 1.65 A; A=1-167. DR PDB; 6GOD; X-ray; 1.71 A; A=2-173. DR PDB; 6GOE; X-ray; 1.60 A; A=2-169. DR PDB; 6GOF; X-ray; 1.98 A; A=2-173. DR PDB; 6GOG; X-ray; 2.05 A; A/B/C/D/E/F=1-169. DR PDB; 6GOM; X-ray; 1.63 A; A/B/C/D/E/F=1-167. DR PDB; 6GQT; X-ray; 1.69 A; A/B/C/D/E/F=1-167. DR PDB; 6GQW; X-ray; 2.80 A; A/B/C/D/E/F=1-167. DR PDB; 6GQX; X-ray; 2.20 A; A/B/C/D/E/F=1-167. DR PDB; 6GQY; X-ray; 2.75 A; A/B/C/D/E/F=1-167. DR PDB; 6H46; X-ray; 2.22 A; A=1-166. DR PDB; 6H47; X-ray; 1.70 A; A=1-166. DR PDB; 6JTN; X-ray; 1.90 A; C=10-19. DR PDB; 6JTO; X-ray; 1.70 A; C=10-19. DR PDB; 6JTP; X-ray; 1.90 A; C=10-18. DR PDB; 6M9W; X-ray; 1.50 A; A=2-169. DR PDB; 6MBQ; X-ray; 1.35 A; A=2-166. DR PDB; 6MBT; X-ray; 1.45 A; A/B=1-169. DR PDB; 6MBU; X-ray; 1.45 A; A/B=1-169. DR PDB; 6MNX; X-ray; 2.20 A; A/B/C/D/E/F=1-169. DR PDB; 6MQG; X-ray; 1.50 A; A=3-169. DR PDB; 6MQN; X-ray; 1.60 A; A/B/C=1-169. DR PDB; 6MS9; X-ray; 1.49 A; A/B/C=1-169. DR PDB; 6MTA; X-ray; 2.15 A; A/B/C=1-169. DR PDB; 6N2J; X-ray; 1.80 A; A=1-169. DR PDB; 6N2K; X-ray; 1.72 A; A=1-169. DR PDB; 6O36; X-ray; 2.00 A; A/B/C=1-167. DR PDB; 6O46; X-ray; 1.90 A; A/B/C=1-167. DR PDB; 6O4Y; X-ray; 1.58 A; C=7-14. DR PDB; 6O4Z; X-ray; 1.50 A; C=5-12. DR PDB; 6O51; X-ray; 1.55 A; C=6-14. DR PDB; 6O53; X-ray; 1.40 A; C=5-14. DR PDB; 6OB2; X-ray; 2.85 A; A/C=1-169. DR PDB; 6OB3; X-ray; 2.10 A; A/C=1-169. DR PDB; 6OIM; X-ray; 1.65 A; A=1-169. DR PDB; 6P0Z; X-ray; 1.01 A; A/B=2-169. DR PDB; 6P8W; X-ray; 2.10 A; A/B=1-169. DR PDB; 6P8X; X-ray; 2.11 A; A/B/C/D=1-169. DR PDB; 6P8Y; X-ray; 2.31 A; A/B=1-169. DR PDB; 6P8Z; X-ray; 1.65 A; A/B=1-169. DR PDB; 6PGO; X-ray; 1.60 A; A/B=1-169. DR PDB; 6PGP; X-ray; 1.50 A; A/B=1-169. DR PDB; 6PQ3; X-ray; 1.75 A; A=1-169. DR PDB; 6PTS; NMR; -; B=1-186. DR PDB; 6PTW; NMR; -; B=1-186. DR PDB; 6QUU; X-ray; 1.48 A; A/B=1-169. DR PDB; 6QUV; X-ray; 1.48 A; A/B=1-169. DR PDB; 6QUW; X-ray; 1.24 A; A/B=1-169. DR PDB; 6QUX; X-ray; 1.62 A; A/B=1-169. DR PDB; 6T5B; X-ray; 1.37 A; A=1-169. DR PDB; 6T5U; X-ray; 1.72 A; B=1-166. DR PDB; 6T5V; X-ray; 1.31 A; A=1-169. DR PDB; 6TAM; X-ray; 1.64 A; A=1-169. DR PDB; 6TAN; X-ray; 1.16 A; A=1-169. DR PDB; 6USX; X-ray; 2.27 A; A/B=1-169. DR PDB; 6USZ; X-ray; 2.03 A; A=1-169. DR PDB; 6UT0; X-ray; 1.94 A; A/B/C/D=1-169. DR PDB; 6V5L; NMR; -; A=1-169. DR PDB; 6V65; X-ray; 2.76 A; C=1-169. DR PDB; 6V6F; X-ray; 2.54 A; C=1-169. DR PDB; 6VC8; X-ray; 2.50 A; A/B/C=1-169. DR PDB; 6VJJ; X-ray; 1.40 A; A=1-169. DR PDB; 6W4E; NMR; -; B/C=2-186. DR PDB; 6W4F; NMR; -; B/C=2-186. DR PDB; 6WGN; X-ray; 1.60 A; A/B/C=1-169. DR PDB; 6WS2; X-ray; 1.59 A; A/B/C/D=1-169. DR PDB; 6WS4; X-ray; 1.84 A; A/B/C/D=1-169. DR PDB; 6XGU; X-ray; 2.70 A; A=1-169. DR PDB; 6XGV; X-ray; 2.11 A; A=1-169. DR PDB; 6XHA; X-ray; 2.87 A; A=1-169. DR PDB; 6XHB; X-ray; 2.50 A; A=1-169. DR PDB; 6YR8; X-ray; 1.90 A; A=1-166. DR PDB; 6YXW; X-ray; 2.06 A; A/C=1-167. DR PDB; 6ZL5; X-ray; 1.65 A; A=1-169. DR PDB; 6ZLI; X-ray; 1.73 A; A/B=1-169. DR PDB; 7A1W; X-ray; 1.76 A; A=1-169. DR PDB; 7A1X; X-ray; 1.32 A; A=1-164. DR PDB; 7A1Y; X-ray; 2.00 A; A=1-164. DR PDB; 7A47; X-ray; 2.16 A; A/C/E=1-169. DR PDB; 7ACA; X-ray; 1.57 A; A/B/C/D=1-169. DR PDB; 7ACF; X-ray; 1.91 A; A/B/C/D=1-169. DR PDB; 7ACH; X-ray; 1.90 A; A/B=1-169. DR PDB; 7ACQ; X-ray; 1.86 A; A/B/C=1-169. DR PDB; 7C40; X-ray; 2.52 A; A=1-167. DR PDB; 7C41; X-ray; 2.28 A; A/G/J/M=1-167. DR PDB; 7EW9; X-ray; 2.13 A; A/B/C=1-169. DR PDB; 7EWA; X-ray; 2.25 A; A/B/C=1-169. DR PDB; 7EWB; X-ray; 1.99 A; A/B/C=1-169. DR PDB; 7EYX; X-ray; 1.82 A; A=2-169. DR PDB; 7F0W; X-ray; 1.39 A; A=2-169. DR PDB; 7KFZ; EM; 3.47 A; A/C=1-169. DR PDB; 7KMR; X-ray; 1.51 A; A=1-186. DR PDB; 7KYZ; NMR; -; A=1-189. DR PDB; 7LC1; X-ray; 2.35 A; A/C=1-169. DR PDB; 7LC2; X-ray; 2.70 A; A/B=1-169. DR PDB; 7LGI; NMR; -; A=1-169. DR PDB; 7LZ5; X-ray; 1.50 A; A=1-164. DR PDB; 7MDP; X-ray; 1.96 A; A=1-169. DR PDB; 7MQU; NMR; -; A=1-169. DR PDB; 7NY8; X-ray; 1.80 A; A/B=1-167. DR PDB; 7O70; X-ray; 1.18 A; A/D=1-169. DR PDB; 7OK3; X-ray; 1.60 A; A=1-169. DR PDB; 7OK4; X-ray; 1.70 A; A=1-169. DR PDB; 7OO7; X-ray; 1.48 A; A/D=1-164. DR PDB; 7Q9U; X-ray; 2.24 A; AAA/BBB=1-176. DR PDB; 7R0M; X-ray; 1.61 A; A/B=1-169. DR PDB; 7R0N; X-ray; 1.20 A; A=1-169. DR PDB; 7R0Q; X-ray; 1.95 A; A/B=1-169. DR PDB; 7ROV; X-ray; 1.32 A; A/B=1-189. DR PDB; 7RP2; X-ray; 2.20 A; A=1-169. DR PDB; 7RP3; X-ray; 2.00 A; A=2-169. DR PDB; 7RP4; X-ray; 2.15 A; A/B=2-169. DR PDB; 7RPZ; X-ray; 1.30 A; A=1-169. DR PDB; 7RSC; NMR; -; A/B=2-186. DR PDB; 7RSE; NMR; -; A/B=2-186. DR PDB; 7RT1; X-ray; 1.27 A; A=1-169. DR PDB; 7RT2; X-ray; 1.59 A; A=1-169. DR PDB; 7RT3; X-ray; 1.56 A; A=1-169. DR PDB; 7RT4; X-ray; 2.10 A; A=1-169. DR PDB; 7RT5; X-ray; 1.29 A; A=1-169. DR PDB; 7SCW; X-ray; 1.98 A; A=1-189. DR PDB; 7SCX; X-ray; 1.96 A; A=1-189. DR PDB; 7STF; EM; 3.14 A; C=7-16. DR PDB; 7T1F; X-ray; 2.20 A; A/B/C=1-169. DR PDB; 7T47; X-ray; 1.27 A; A=1-164. DR PDB; 7TLE; X-ray; 1.99 A; A=1-164. DR PDB; 7TLG; X-ray; 1.80 A; A/B=1-164. DR PDB; 7TLK; X-ray; 1.71 A; A/B=1-164. DR PDB; 7U8H; X-ray; 1.70 A; A/B/C/D=1-169. DR PDB; 7VVB; X-ray; 1.70 A; A=1-189. DR PDB; 7W5R; X-ray; 3.87 A; A/E/I/M/Q/U=1-167. DR PDB; 7YCC; X-ray; 1.79 A; A/B/C=1-169. DR PDB; 7YCE; X-ray; 1.80 A; A=1-169. DR PDB; 7YUZ; X-ray; 1.88 A; A=2-174. DR PDB; 7YV1; X-ray; 1.45 A; A=2-174. DR PDB; 8AFB; X-ray; 1.12 A; A=1-164. DR PDB; 8AFC; X-ray; 2.41 A; A/B=1-164. DR PDB; 8AFD; X-ray; 1.63 A; A/B/C/D=1-164. DR PDB; 8AQ5; X-ray; 1.80 A; A=1-169. DR PDB; 8AQ7; X-ray; 1.65 A; A/B=1-169. DR PDB; 8AZR; X-ray; 1.60 A; A=1-164. DR PDB; 8AZV; X-ray; 1.05 A; A=1-164. DR PDB; 8AZX; X-ray; 1.04 A; A=1-164. DR PDB; 8AZY; X-ray; 1.09 A; A=1-169. DR PDB; 8AZZ; X-ray; 1.02 A; A=1-164. DR PDB; 8B00; X-ray; 1.04 A; A=1-164. DR PDB; 8B69; X-ray; 3.07 A; B/D=1-169. DR PDB; 8B6I; X-ray; 1.70 A; A/B=1-169. DR PDB; 8B78; X-ray; 1.11 A; A=1-164. DR PDB; 8BE3; X-ray; 1.85 A; A/R=1-169. DR PDB; 8BE4; X-ray; 1.90 A; R=1-169. DR PDB; 8BE5; X-ray; 3.13 A; R=1-169. DR PDB; 8BLR; X-ray; 1.40 A; A=2-169. DR PDB; 8CPR; X-ray; 2.00 A; A=2-169. DR PDB; 8CX5; X-ray; 1.72 A; A/B=1-169. DR PDB; 8DGS; EM; 4.30 A; E=1-169. DR PDB; 8DGT; EM; 3.90 A; F=1-169. DR PDB; 8DNI; X-ray; 1.50 A; A=1-169. DR PDB; 8DNJ; X-ray; 1.81 A; A/B/C=1-169. DR PDB; 8DNK; X-ray; 2.23 A; A=1-169. DR PDB; 8DVG; X-ray; 2.59 A; C=7-16. DR PDB; 8EBZ; X-ray; 1.20 A; A=1-169. DR PDB; 8ECR; X-ray; 1.42 A; A/B=1-186. DR PDB; 8EDY; X-ray; 1.18 A; A=1-186. DR PDB; 8EER; X-ray; 1.18 A; A=1-186. DR PDB; 8EIE; X-ray; 1.41 A; A=1-186. DR PDB; 8EPW; X-ray; 2.00 A; A=1-169. DR PDB; 8EZG; X-ray; 2.52 A; A=1-167. DR PDB; 8F0M; X-ray; 2.44 A; A/C=1-169. DR PDB; 8FMI; X-ray; 1.12 A; A=1-169. DR PDB; 8FMJ; X-ray; 1.33 A; A=1-169. DR PDB; 8FMK; X-ray; 1.48 A; A=1-169. DR PDB; 8G42; EM; 3.02 A; B=1-169. DR PDB; 8G47; EM; 3.19 A; B=1-169. DR PDB; 8G4F; EM; 2.91 A; B=1-166. DR PDB; 8G4H; EM; 2.87 A; B=1-169. DR PDB; 8G9P; X-ray; 1.50 A; A/B=1-169. DR PDB; 8G9Q; X-ray; 1.40 A; A=1-169. DR PDB; 8I5C; X-ray; 3.34 A; C/H/M/R/W/b/g/l/q/v=8-16. DR PDB; 8I5D; X-ray; 3.30 A; P=8-16. DR PDB; 8I5E; X-ray; 2.20 A; P=8-16. DR PDB; 8JGD; X-ray; 1.60 A; A=1-169. DR PDB; 8JHL; X-ray; 2.10 A; A=1-169. DR PDB; 8JJS; X-ray; 1.53 A; A=2-174. DR PDB; 8K4T; X-ray; 2.30 A; C/F=7-16. DR PDB; 8K4V; X-ray; 3.10 A; C/F/I/L=7-16. DR PDB; 8K50; X-ray; 2.80 A; C/F/I/L=7-16. DR PDB; 8ONV; X-ray; 1.01 A; A=1-164. DR PDB; 8PI0; NMR; -; A=1-167. DR PDB; 8PIY; NMR; -; A=1-169. DR PDB; 8QU8; EM; 3.50 A; F=1-164. DR PDB; 8QUG; X-ray; 1.56 A; A=1-164. DR PDB; 8QVU; X-ray; 2.24 A; A/E=1-189. DR PDB; 8QW6; X-ray; 2.20 A; A/E=1-169. DR PDB; 8QW7; X-ray; 2.36 A; A/E=1-169. DR PDB; 8R7W; X-ray; 1.16 A; A/B=1-169. DR PDB; 8R7X; X-ray; 1.31 A; A/B=1-169. DR PDB; 8RNI; X-ray; 2.49 A; C=7-16. DR PDB; 8RRO; X-ray; 3.50 A; E/J/O/T/Y/d/i/n=7-16. DR PDB; 8S8C; X-ray; 1.90 A; A=1-169. DR PDB; 8STM; X-ray; 2.00 A; A/B/C/D=1-169. DR PDB; 8STN; X-ray; 2.03 A; A/B=1-169. DR PDB; 8T4V; X-ray; 1.47 A; A/B=1-169. DR PDB; 8T71; X-ray; 1.80 A; A/B=1-177. DR PDB; 8T72; X-ray; 1.60 A; A/B/C=1-177. DR PDB; 8T73; X-ray; 1.50 A; A/B=1-169. DR PDB; 8T74; X-ray; 1.65 A; A=1-177. DR PDB; 8T75; X-ray; 2.65 A; A/C/E/G=1-177. DR PDB; 8TBF; X-ray; 1.50 A; A/B=1-169. DR PDB; 8TBH; X-ray; 1.50 A; A/B=1-169. DR PDB; 8TBJ; X-ray; 1.45 A; A/B=1-169. DR PDB; 8TBK; X-ray; 1.26 A; A/B=1-169. DR PDB; 8TBL; X-ray; 1.88 A; A/B=1-169. DR PDB; 8TBM; X-ray; 1.57 A; A/B=1-169. DR PDB; 8TBN; X-ray; 1.46 A; A/B=1-169. DR PDB; 8TVK; X-ray; 1.04 A; A=1-169. DR PDB; 8TXE; X-ray; 1.35 A; A/B=1-169. DR PDB; 8TXG; X-ray; 1.50 A; A=1-169. DR PDB; 8TXH; X-ray; 1.20 A; A/B=1-169. DR PDB; 8TXJ; X-ray; 1.40 A; A=1-169. DR PDB; 8TXK; X-ray; 1.38 A; A=1-169. DR PDB; 8TY2; X-ray; 1.41 A; A=1-169. DR PDB; 8TY8; X-ray; 1.40 A; A=1-169. DR PDB; 8TY9; X-ray; 1.43 A; A=1-169. DR PDB; 8UDR; EM; 3.10 A; C=7-16. DR PDB; 8UN3; X-ray; 2.07 A; A/B/C/D=2-167. DR PDB; 8UN4; X-ray; 1.57 A; A=2-169. DR PDB; 8UN5; X-ray; 1.31 A; A/B=2-167. DR PDB; 8V39; X-ray; 2.10 A; A/B/C=1-169. DR PDB; 8V3A; X-ray; 1.67 A; A/B=1-169. DR PDB; 8VGQ; EM; 2.80 A; A=1-169. DR PDB; 8VJZ; X-ray; 1.90 A; C=7-16. DR PDB; 8VR9; EM; 3.06 A; C=8-16. DR PDB; 8VRA; EM; 3.12 A; C=7-16. DR PDB; 8VRB; EM; 3.25 A; C=7-16. DR PDB; 8WTE; X-ray; 2.17 A; G/J=8-16. DR PDB; 8WUL; X-ray; 2.36 A; K/N/Q/T=8-16. DR PDB; 8X6R; X-ray; 1.85 A; A/B/C/D/E/F=1-169. DR PDB; 8YIV; X-ray; 2.10 A; C=55-64. DR PDB; 8YJ2; X-ray; 2.26 A; C=55-64. DR PDB; 9AX6; X-ray; 1.65 A; A/B=1-169. DR PDB; 9BAI; X-ray; 1.49 A; A/B/C/D=1-169. DR PDB; 9BAJ; X-ray; 1.49 A; A/B/C/D=1-169. DR PDB; 9BAK; X-ray; 1.67 A; A/B/C/D=1-169. DR PDB; 9BFV; X-ray; 1.20 A; A/B=1-169. DR PDB; 9BFW; X-ray; 1.20 A; A=1-169. DR PDB; 9BFX; X-ray; 1.40 A; A/B=1-169. DR PDB; 9BFY; X-ray; 1.26 A; A/B=1-169. DR PDB; 9BFZ; X-ray; 1.80 A; A/B=1-169. DR PDB; 9BG1; X-ray; 1.51 A; A/B=1-169. DR PDB; 9BG2; X-ray; 1.64 A; A/B=1-169. DR PDB; 9BG4; X-ray; 1.14 A; A/B=1-169. DR PDB; 9BG5; X-ray; 1.67 A; A/B=1-164. DR PDB; 9BG6; X-ray; 1.66 A; A/B=1-169. DR PDB; 9BG7; X-ray; 1.60 A; A/B=1-169. DR PDB; 9BG9; X-ray; 1.58 A; A/B=1-164. DR PDB; 9BGA; X-ray; 1.41 A; A/B=1-169. DR PDB; 9BGB; X-ray; 1.68 A; A/B=1-164. DR PDB; 9BGC; X-ray; 1.87 A; A/B=1-169. DR PDB; 9BHO; X-ray; 1.89 A; A/C=1-169. DR PDB; 9BHP; X-ray; 2.10 A; A/C=1-169. DR PDB; 9BHQ; X-ray; 1.90 A; A/C=1-169. DR PDB; 9BI1; X-ray; 1.65 A; A/C=1-169. DR PDB; 9BI2; X-ray; 2.15 A; A/C=1-169. DR PDB; 9BL0; X-ray; 1.66 A; A/B=1-169. DR PDB; 9C15; X-ray; 2.81 A; B=1-169. DR PDB; 9DMM; X-ray; 1.90 A; A=1-169. DR PDB; 9E5D; X-ray; 1.36 A; A=1-169. DR PDB; 9E5F; X-ray; 1.35 A; A=1-169. DR PDB; 9E9H; X-ray; 1.65 A; A=1-169. DR PDB; 9E9I; X-ray; 1.18 A; A=1-169. DR PDB; 9G0Y; X-ray; 1.31 A; A=1-169. DR PDB; 9G4B; X-ray; 1.14 A; A=1-169. DR PDB; 9GBJ; X-ray; 1.71 A; A=1-169. DR PDB; 9GGT; X-ray; 1.71 A; A=1-169. DR PDB; 9GGU; X-ray; 1.60 A; A=1-169. DR PDB; 9GGV; X-ray; 1.19 A; A=1-169. DR PDB; 9GGW; X-ray; 1.82 A; A/B=1-169. DR PDB; 9GGX; X-ray; 1.30 A; A=1-169. DR PDB; 9GGY; X-ray; 1.27 A; A=1-169. DR PDB; 9GGZ; X-ray; 1.37 A; A=1-169. DR PDB; 9GH0; X-ray; 1.57 A; A=1-169. DR PDB; 9GH1; X-ray; 1.33 A; A=1-169. DR PDB; 9GH2; X-ray; 1.35 A; A=1-169. DR PDB; 9KPM; X-ray; 1.41 A; A=1-169. DR PDB; 9KPN; X-ray; 1.29 A; A/B=1-169. DR PDBsum; 1D8D; -. DR PDBsum; 1D8E; -. DR PDBsum; 1KZO; -. DR PDBsum; 1KZP; -. DR PDBsum; 1N4P; -. DR PDBsum; 1N4Q; -. DR PDBsum; 1N4R; -. DR PDBsum; 1N4S; -. DR PDBsum; 2MSC; -. DR PDBsum; 2MSD; -. DR PDBsum; 2MSE; -. DR PDBsum; 3GFT; -. DR PDBsum; 4DSN; -. DR PDBsum; 4DSO; -. DR PDBsum; 4EPR; -. DR PDBsum; 4EPT; -. DR PDBsum; 4EPV; -. DR PDBsum; 4EPW; -. DR PDBsum; 4EPX; -. DR PDBsum; 4EPY; -. DR PDBsum; 4L8G; -. DR PDBsum; 4LDJ; -. DR PDBsum; 4LPK; -. DR PDBsum; 4LRW; -. DR PDBsum; 4LUC; -. DR PDBsum; 4LV6; -. DR PDBsum; 4LYF; -. DR PDBsum; 4LYH; -. DR PDBsum; 4LYJ; -. DR PDBsum; 4M1O; -. DR PDBsum; 4M1S; -. DR PDBsum; 4M1T; -. DR PDBsum; 4M1W; -. DR PDBsum; 4M1Y; -. DR PDBsum; 4M21; -. DR PDBsum; 4M22; -. DR PDBsum; 4NMM; -. DR PDBsum; 4OBE; -. DR PDBsum; 4PZY; -. DR PDBsum; 4PZZ; -. DR PDBsum; 4Q01; -. DR PDBsum; 4Q02; -. DR PDBsum; 4Q03; -. DR PDBsum; 4QL3; -. DR PDBsum; 4TQ9; -. DR PDBsum; 4TQA; -. DR PDBsum; 4WA7; -. DR PDBsum; 5F2E; -. DR PDBsum; 5KYK; -. DR PDBsum; 5MLA; -. DR PDBsum; 5MLB; -. DR PDBsum; 5O2S; -. DR PDBsum; 5O2T; -. DR PDBsum; 5OCG; -. DR PDBsum; 5OCO; -. DR PDBsum; 5OCT; -. DR PDBsum; 5TAR; -. DR PDBsum; 5TB5; -. DR PDBsum; 5UFE; -. DR PDBsum; 5UFQ; -. DR PDBsum; 5UK9; -. DR PDBsum; 5UQW; -. DR PDBsum; 5US4; -. DR PDBsum; 5USJ; -. DR PDBsum; 5V6S; -. DR PDBsum; 5V6V; -. DR PDBsum; 5V71; -. DR PDBsum; 5V9L; -. DR PDBsum; 5V9O; -. DR PDBsum; 5V9U; -. DR PDBsum; 5VBM; -. DR PDBsum; 5VP7; -. DR PDBsum; 5VPI; -. DR PDBsum; 5VPY; -. DR PDBsum; 5VPZ; -. DR PDBsum; 5VQ0; -. DR PDBsum; 5VQ1; -. DR PDBsum; 5VQ2; -. DR PDBsum; 5VQ6; -. DR PDBsum; 5VQ8; -. DR PDBsum; 5W22; -. DR PDBsum; 5WHA; -. DR PDBsum; 5WHB; -. DR PDBsum; 5WHD; -. DR PDBsum; 5WHE; -. DR PDBsum; 5WLB; -. DR PDBsum; 5WPM; -. DR PDBsum; 5XCO; -. DR PDBsum; 5YXZ; -. DR PDBsum; 5YY1; -. DR PDBsum; 6ARK; -. DR PDBsum; 6ASA; -. DR PDBsum; 6ASE; -. DR PDBsum; 6B0V; -. DR PDBsum; 6B0Y; -. DR PDBsum; 6BOF; -. DR PDBsum; 6BP1; -. DR PDBsum; 6CC9; -. DR PDBsum; 6CCH; -. DR PDBsum; 6CCX; -. DR PDBsum; 6CU6; -. DR PDBsum; 6E6F; -. DR PDBsum; 6E6G; -. DR PDBsum; 6EPL; -. DR PDBsum; 6EPM; -. DR PDBsum; 6EPN; -. DR PDBsum; 6EPO; -. DR PDBsum; 6EPP; -. DR PDBsum; 6F76; -. DR PDBsum; 6FA1; -. DR PDBsum; 6FA2; -. DR PDBsum; 6FA3; -. DR PDBsum; 6FA4; -. DR PDBsum; 6GJ5; -. DR PDBsum; 6GJ6; -. DR PDBsum; 6GJ7; -. DR PDBsum; 6GJ8; -. DR PDBsum; 6GOD; -. DR PDBsum; 6GOE; -. DR PDBsum; 6GOF; -. DR PDBsum; 6GOG; -. DR PDBsum; 6GOM; -. DR PDBsum; 6GQT; -. DR PDBsum; 6GQW; -. DR PDBsum; 6GQX; -. DR PDBsum; 6GQY; -. DR PDBsum; 6H46; -. DR PDBsum; 6H47; -. DR PDBsum; 6JTN; -. DR PDBsum; 6JTO; -. DR PDBsum; 6JTP; -. DR PDBsum; 6M9W; -. DR PDBsum; 6MBQ; -. DR PDBsum; 6MBT; -. DR PDBsum; 6MBU; -. DR PDBsum; 6MNX; -. DR PDBsum; 6MQG; -. DR PDBsum; 6MQN; -. DR PDBsum; 6MS9; -. DR PDBsum; 6MTA; -. DR PDBsum; 6N2J; -. DR PDBsum; 6N2K; -. DR PDBsum; 6O36; -. DR PDBsum; 6O46; -. DR PDBsum; 6O4Y; -. DR PDBsum; 6O4Z; -. DR PDBsum; 6O51; -. DR PDBsum; 6O53; -. DR PDBsum; 6OB2; -. DR PDBsum; 6OB3; -. DR PDBsum; 6OIM; -. DR PDBsum; 6P0Z; -. DR PDBsum; 6P8W; -. DR PDBsum; 6P8X; -. DR PDBsum; 6P8Y; -. DR PDBsum; 6P8Z; -. DR PDBsum; 6PGO; -. DR PDBsum; 6PGP; -. DR PDBsum; 6PQ3; -. DR PDBsum; 6PTS; -. DR PDBsum; 6PTW; -. DR PDBsum; 6QUU; -. DR PDBsum; 6QUV; -. DR PDBsum; 6QUW; -. DR PDBsum; 6QUX; -. DR PDBsum; 6T5B; -. DR PDBsum; 6T5U; -. DR PDBsum; 6T5V; -. DR PDBsum; 6TAM; -. DR PDBsum; 6TAN; -. DR PDBsum; 6USX; -. DR PDBsum; 6USZ; -. DR PDBsum; 6UT0; -. DR PDBsum; 6V5L; -. DR PDBsum; 6V65; -. DR PDBsum; 6V6F; -. DR PDBsum; 6VC8; -. DR PDBsum; 6VJJ; -. DR PDBsum; 6W4E; -. DR PDBsum; 6W4F; -. DR PDBsum; 6WGN; -. DR PDBsum; 6WS2; -. DR PDBsum; 6WS4; -. DR PDBsum; 6XGU; -. DR PDBsum; 6XGV; -. DR PDBsum; 6XHA; -. DR PDBsum; 6XHB; -. DR PDBsum; 6YR8; -. DR PDBsum; 6YXW; -. DR PDBsum; 6ZL5; -. DR PDBsum; 6ZLI; -. DR PDBsum; 7A1W; -. DR PDBsum; 7A1X; -. DR PDBsum; 7A1Y; -. DR PDBsum; 7A47; -. DR PDBsum; 7ACA; -. DR PDBsum; 7ACF; -. DR PDBsum; 7ACH; -. DR PDBsum; 7ACQ; -. DR PDBsum; 7C40; -. DR PDBsum; 7C41; -. DR PDBsum; 7EW9; -. DR PDBsum; 7EWA; -. DR PDBsum; 7EWB; -. DR PDBsum; 7EYX; -. DR PDBsum; 7F0W; -. DR PDBsum; 7KFZ; -. DR PDBsum; 7KMR; -. DR PDBsum; 7KYZ; -. DR PDBsum; 7LC1; -. DR PDBsum; 7LC2; -. DR PDBsum; 7LGI; -. DR PDBsum; 7LZ5; -. DR PDBsum; 7MDP; -. DR PDBsum; 7MQU; -. DR PDBsum; 7NY8; -. DR PDBsum; 7O70; -. DR PDBsum; 7OK3; -. DR PDBsum; 7OK4; -. DR PDBsum; 7OO7; -. DR PDBsum; 7Q9U; -. DR PDBsum; 7R0M; -. DR PDBsum; 7R0N; -. DR PDBsum; 7R0Q; -. DR PDBsum; 7ROV; -. DR PDBsum; 7RP2; -. DR PDBsum; 7RP3; -. DR PDBsum; 7RP4; -. DR PDBsum; 7RPZ; -. DR PDBsum; 7RSC; -. DR PDBsum; 7RSE; -. DR PDBsum; 7RT1; -. DR PDBsum; 7RT2; -. DR PDBsum; 7RT3; -. DR PDBsum; 7RT4; -. DR PDBsum; 7RT5; -. DR PDBsum; 7SCW; -. DR PDBsum; 7SCX; -. DR PDBsum; 7STF; -. DR PDBsum; 7T1F; -. DR PDBsum; 7T47; -. DR PDBsum; 7TLE; -. DR PDBsum; 7TLG; -. DR PDBsum; 7TLK; -. DR PDBsum; 7U8H; -. DR PDBsum; 7VVB; -. DR PDBsum; 7W5R; -. DR PDBsum; 7YCC; -. DR PDBsum; 7YCE; -. DR PDBsum; 7YUZ; -. DR PDBsum; 7YV1; -. DR PDBsum; 8AFB; -. DR PDBsum; 8AFC; -. DR PDBsum; 8AFD; -. DR PDBsum; 8AQ5; -. DR PDBsum; 8AQ7; -. DR PDBsum; 8AZR; -. DR PDBsum; 8AZV; -. DR PDBsum; 8AZX; -. DR PDBsum; 8AZY; -. DR PDBsum; 8AZZ; -. DR PDBsum; 8B00; -. DR PDBsum; 8B69; -. DR PDBsum; 8B6I; -. DR PDBsum; 8B78; -. DR PDBsum; 8BE3; -. DR PDBsum; 8BE4; -. DR PDBsum; 8BE5; -. DR PDBsum; 8BLR; -. DR PDBsum; 8CPR; -. DR PDBsum; 8CX5; -. DR PDBsum; 8DGS; -. DR PDBsum; 8DGT; -. DR PDBsum; 8DNI; -. DR PDBsum; 8DNJ; -. DR PDBsum; 8DNK; -. DR PDBsum; 8DVG; -. DR PDBsum; 8EBZ; -. DR PDBsum; 8ECR; -. DR PDBsum; 8EDY; -. DR PDBsum; 8EER; -. DR PDBsum; 8EIE; -. DR PDBsum; 8EPW; -. DR PDBsum; 8EZG; -. DR PDBsum; 8F0M; -. DR PDBsum; 8FMI; -. DR PDBsum; 8FMJ; -. DR PDBsum; 8FMK; -. DR PDBsum; 8G42; -. DR PDBsum; 8G47; -. DR PDBsum; 8G4F; -. DR PDBsum; 8G4H; -. DR PDBsum; 8G9P; -. DR PDBsum; 8G9Q; -. DR PDBsum; 8I5C; -. DR PDBsum; 8I5D; -. DR PDBsum; 8I5E; -. DR PDBsum; 8JGD; -. DR PDBsum; 8JHL; -. DR PDBsum; 8JJS; -. DR PDBsum; 8K4T; -. DR PDBsum; 8K4V; -. DR PDBsum; 8K50; -. DR PDBsum; 8ONV; -. DR PDBsum; 8PI0; -. DR PDBsum; 8PIY; -. DR PDBsum; 8QU8; -. DR PDBsum; 8QUG; -. DR PDBsum; 8QVU; -. DR PDBsum; 8QW6; -. DR PDBsum; 8QW7; -. DR PDBsum; 8R7W; -. DR PDBsum; 8R7X; -. DR PDBsum; 8RNI; -. DR PDBsum; 8RRO; -. DR PDBsum; 8S8C; -. DR PDBsum; 8STM; -. DR PDBsum; 8STN; -. DR PDBsum; 8T4V; -. DR PDBsum; 8T71; -. DR PDBsum; 8T72; -. DR PDBsum; 8T73; -. DR PDBsum; 8T74; -. DR PDBsum; 8T75; -. DR PDBsum; 8TBF; -. DR PDBsum; 8TBH; -. DR PDBsum; 8TBJ; -. DR PDBsum; 8TBK; -. DR PDBsum; 8TBL; -. DR PDBsum; 8TBM; -. DR PDBsum; 8TBN; -. DR PDBsum; 8TVK; -. DR PDBsum; 8TXE; -. DR PDBsum; 8TXG; -. DR PDBsum; 8TXH; -. DR PDBsum; 8TXJ; -. DR PDBsum; 8TXK; -. DR PDBsum; 8TY2; -. DR PDBsum; 8TY8; -. DR PDBsum; 8TY9; -. DR PDBsum; 8UDR; -. DR PDBsum; 8UN3; -. DR PDBsum; 8UN4; -. DR PDBsum; 8UN5; -. DR PDBsum; 8V39; -. DR PDBsum; 8V3A; -. DR PDBsum; 8VGQ; -. DR PDBsum; 8VJZ; -. DR PDBsum; 8VR9; -. DR PDBsum; 8VRA; -. DR PDBsum; 8VRB; -. DR PDBsum; 8WTE; -. DR PDBsum; 8WUL; -. DR PDBsum; 8X6R; -. DR PDBsum; 8YIV; -. DR PDBsum; 8YJ2; -. DR PDBsum; 9AX6; -. DR PDBsum; 9BAI; -. DR PDBsum; 9BAJ; -. DR PDBsum; 9BAK; -. DR PDBsum; 9BFV; -. DR PDBsum; 9BFW; -. DR PDBsum; 9BFX; -. DR PDBsum; 9BFY; -. DR PDBsum; 9BFZ; -. DR PDBsum; 9BG1; -. DR PDBsum; 9BG2; -. DR PDBsum; 9BG4; -. DR PDBsum; 9BG5; -. DR PDBsum; 9BG6; -. DR PDBsum; 9BG7; -. DR PDBsum; 9BG9; -. DR PDBsum; 9BGA; -. DR PDBsum; 9BGB; -. DR PDBsum; 9BGC; -. DR PDBsum; 9BHO; -. DR PDBsum; 9BHP; -. DR PDBsum; 9BHQ; -. DR PDBsum; 9BI1; -. DR PDBsum; 9BI2; -. DR PDBsum; 9BL0; -. DR PDBsum; 9C15; -. DR PDBsum; 9DMM; -. DR PDBsum; 9E5D; -. DR PDBsum; 9E5F; -. DR PDBsum; 9E9H; -. DR PDBsum; 9E9I; -. DR PDBsum; 9G0Y; -. DR PDBsum; 9G4B; -. DR PDBsum; 9GBJ; -. DR PDBsum; 9GGT; -. DR PDBsum; 9GGU; -. DR PDBsum; 9GGV; -. DR PDBsum; 9GGW; -. DR PDBsum; 9GGX; -. DR PDBsum; 9GGY; -. DR PDBsum; 9GGZ; -. DR PDBsum; 9GH0; -. DR PDBsum; 9GH1; -. DR PDBsum; 9GH2; -. DR PDBsum; 9KPM; -. DR PDBsum; 9KPN; -. DR AlphaFoldDB; P01116; -. DR BMRB; P01116; -. DR EMDB; EMD-18657; -. DR EMDB; EMD-22857; -. DR EMDB; EMD-29713; -. DR EMDB; EMD-29715; -. DR EMDB; EMD-29719; -. DR EMDB; EMD-29720; -. DR EMDB; EMD-42151; -. DR EMDB; EMD-43221; -. DR EMDB; EMD-43478; -. DR EMDB; EMD-43479; -. DR EMDB; EMD-43480; -. DR EMDB; EMD-70124; -. DR SASBDB; P01116; -. DR SMR; P01116; -. DR BioGRID; 110043; 3005. DR ComplexPortal; CPX-26355; SHOC2-KRAS-PPP1CA complex. DR CORUM; P01116; -. DR DIP; DIP-33951N; -. DR FunCoup; P01116; 3194. DR IntAct; P01116; 549. DR MINT; P01116; -. DR STRING; 9606.ENSP00000256078; -. DR BindingDB; P01116; -. DR ChEMBL; CHEMBL2189121; -. DR DrugBank; DB07771; [(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID. DR DrugBank; DB15568; Adagrasib. DR DrugBank; DB07780; Farnesyl diphosphate. DR DrugBank; DB15569; Sotorasib. DR DrugCentral; P01116; -. DR GuidetoPHARMACOLOGY; 2824; -. DR GlyCosmos; P01116; 1 site, No reported glycans. DR GlyGen; P01116; 1 site. DR iPTMnet; P01116; -. DR PhosphoSitePlus; P01116; -. DR SwissPalm; P01116; -. DR BioMuta; KRAS; -. DR DMDM; 131875; -. DR CPTAC; CPTAC-1550; -. DR jPOST; P01116; -. DR MassIVE; P01116; -. DR PaxDb; 9606-ENSP00000256078; -. DR PeptideAtlas; P01116; -. DR ProteomicsDB; 51323; -. [P01116-1] DR ProteomicsDB; 51324; -. [P01116-2] DR Pumba; P01116; -. DR TopDownProteomics; P01116-2; -. [P01116-2] DR ABCD; P01116; 18 sequenced antibodies. DR Antibodypedia; 24248; 916 antibodies from 40 providers. DR CPTC; P01116; 6 antibodies. DR DNASU; 3845; -. DR Ensembl; ENST00000256078.10; ENSP00000256078.5; ENSG00000133703.15. [P01116-1] DR Ensembl; ENST00000311936.8; ENSP00000308495.3; ENSG00000133703.15. [P01116-2] DR Ensembl; ENST00000685328.1; ENSP00000508921.1; ENSG00000133703.15. [P01116-2] DR Ensembl; ENST00000688940.1; ENSP00000509238.1; ENSG00000133703.15. [P01116-2] DR GeneID; 3845; -. DR KEGG; hsa:3845; -. DR MANE-Select; ENST00000311936.8; ENSP00000308495.3; NM_004985.5; NP_004976.2. [P01116-2] DR UCSC; uc001rgp.3; human. [P01116-1] DR AGR; HGNC:6407; -. DR CIViC; 3845; 1 clinical assertion and 480 evidence items across 102 molecular profiles. DR ClinPGx; PA30196; -. DR CTD; 3845; -. DR DisGeNET; 3845; -. DR GeneCards; KRAS; -. DR GeneReviews; KRAS; -. DR HGNC; HGNC:6407; KRAS. DR HPA; ENSG00000133703; Low tissue specificity. DR MalaCards; KRAS; -. DR MIM; 163200; phenotype. DR MIM; 190070; gene. DR MIM; 600268; phenotype. DR MIM; 601626; phenotype. DR MIM; 607785; phenotype. DR MIM; 609942; phenotype. DR MIM; 613659; phenotype. DR MIM; 615278; phenotype. DR OpenTargets; ENSG00000133703; -. DR Orphanet; 1340; Cardiofaciocutaneous syndrome. DR Orphanet; 146; Differentiated thyroid carcinoma. DR Orphanet; 2396; Encephalocraniocutaneous lipomatosis. DR Orphanet; 1333; Familial pancreatic carcinoma. DR Orphanet; 86834; Juvenile myelomonocytic leukemia. DR Orphanet; 2612; Linear nevus sebaceus syndrome. DR Orphanet; 144; Lynch syndrome. DR Orphanet; 648; Noonan syndrome. DR Orphanet; 3339; Oculoectodermal syndrome. DR Orphanet; 251615; Pilomyxoid astrocytoma. DR Orphanet; 268114; RAS-associated autoimmune leukoproliferative disease. DR VEuPathDB; HostDB:ENSG00000133703; -. DR eggNOG; KOG0395; Eukaryota. DR GeneTree; ENSGT00940000155871; -. DR HOGENOM; CLU_041217_9_8_1; -. DR InParanoid; P01116; -. DR OMA; CCGGCVI; -. DR OrthoDB; 5976022at2759; -. DR PAN-GO; P01116; 5 GO annotations based on evolutionary models. DR PhylomeDB; P01116; -. DR BRENDA; 3.6.5.2; 2681. DR PathwayCommons; P01116; -. DR Reactome; R-HSA-112412; SOS-mediated signalling. DR Reactome; R-HSA-1169092; Activation of RAS in B cells. DR Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants. DR Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. DR Reactome; R-HSA-1250347; SHC1 events in ERBB4 signaling. DR Reactome; R-HSA-1433557; Signaling by SCF-KIT. DR Reactome; R-HSA-167044; Signalling to RAS. DR Reactome; R-HSA-171007; p38MAPK events. DR Reactome; R-HSA-179812; GRB2 events in EGFR signaling. DR Reactome; R-HSA-180336; SHC1 events in EGFR signaling. DR Reactome; R-HSA-186763; Downstream signal transduction. DR Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling. DR Reactome; R-HSA-210993; Tie2 Signaling. DR Reactome; R-HSA-2179392; EGFR Transactivation by Gastrin. DR Reactome; R-HSA-2424491; DAP12 signaling. DR Reactome; R-HSA-2428933; SHC-related events triggered by IGF1R. DR Reactome; R-HSA-2871796; FCERI mediated MAPK activation. DR Reactome; R-HSA-375165; NCAM signaling for neurite out-growth. DR Reactome; R-HSA-4086398; Ca2+ pathway. [P01116-2] DR Reactome; R-HSA-442982; Ras activation upon Ca2+ influx through NMDA receptor. DR Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation. DR Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling. DR Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII. DR Reactome; R-HSA-5654688; SHC-mediated cascade:FGFR1. DR Reactome; R-HSA-5654693; FRS-mediated FGFR1 signaling. DR Reactome; R-HSA-5654699; SHC-mediated cascade:FGFR2. DR Reactome; R-HSA-5654700; FRS-mediated FGFR2 signaling. DR Reactome; R-HSA-5654704; SHC-mediated cascade:FGFR3. DR Reactome; R-HSA-5654706; FRS-mediated FGFR3 signaling. DR Reactome; R-HSA-5654712; FRS-mediated FGFR4 signaling. DR Reactome; R-HSA-5654719; SHC-mediated cascade:FGFR4. DR Reactome; R-HSA-5655253; Signaling by FGFR2 in disease. DR Reactome; R-HSA-5655291; Signaling by FGFR4 in disease. DR Reactome; R-HSA-5655302; Signaling by FGFR1 in disease. DR Reactome; R-HSA-5655332; Signaling by FGFR3 in disease. DR Reactome; R-HSA-5658442; Regulation of RAS by GAPs. DR Reactome; R-HSA-5673000; RAF activation. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-5674135; MAP2K and MAPK activation. DR Reactome; R-HSA-5675221; Negative regulation of MAPK pathway. DR Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants. DR Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-6802953; RAS signaling downstream of NF1 loss-of-function variants. DR Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF. DR Reactome; R-HSA-74751; Insulin receptor signalling cascade. DR Reactome; R-HSA-8849471; PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases. DR Reactome; R-HSA-8851805; MET activates RAS signaling. DR Reactome; R-HSA-8951936; RUNX3 regulates p14-ARF. DR Reactome; R-HSA-9026519; Activated NTRK2 signals through RAS. DR Reactome; R-HSA-9027284; Erythropoietin activates RAS. DR Reactome; R-HSA-9028731; Activated NTRK2 signals through FRS2 and FRS3. DR Reactome; R-HSA-9034864; Activated NTRK3 signals through RAS. DR Reactome; R-HSA-9607240; FLT3 Signaling. DR Reactome; R-HSA-9634285; Constitutive Signaling by Overexpressed ERBB2. DR Reactome; R-HSA-9634635; Estrogen-stimulated signaling through PRKCZ. DR Reactome; R-HSA-9648002; RAS processing. DR Reactome; R-HSA-9649948; Signaling downstream of RAS mutants. DR Reactome; R-HSA-9656223; Signaling by RAF1 mutants. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665348; Signaling by ERBB2 ECD mutants. DR Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants. DR Reactome; R-HSA-9670439; Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants. DR Reactome; R-HSA-9673767; Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants. DR Reactome; R-HSA-9673770; Signaling by PDGFRA extracellular domain mutants. DR Reactome; R-HSA-9674555; Signaling by CSF3 (G-CSF). DR Reactome; R-HSA-9680350; Signaling by CSF1 (M-CSF) in myeloid cells. DR Reactome; R-HSA-9703465; Signaling by FLT3 fusion proteins. DR Reactome; R-HSA-9703648; Signaling by FLT3 ITD and TKD mutants. DR Reactome; R-HSA-9753510; Signaling by RAS GAP mutants. DR Reactome; R-HSA-9753512; Signaling by RAS GTPase mutants. DR SignaLink; P01116; -. DR SIGNOR; P01116; -. DR Agora; ENSG00000133703; -. DR BioGRID-ORCS; 3845; 259 hits in 1133 CRISPR screens. DR CD-CODE; D57F7ABA; Synthetic Condensate 000274. DR CD-CODE; DEE660B4; Stress granule. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; KRAS; human. DR EvolutionaryTrace; P01116; -. DR GeneWiki; KRAS; -. DR GenomeRNAi; 3845; -. DR Pharos; P01116; Tclin. DR PRO; PR:P01116; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; P01116; protein. DR Bgee; ENSG00000133703; Expressed in trigeminal ganglion and 218 other cell types or tissues. DR ExpressionAtlas; P01116; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome. DR GO; GO:0005925; C:focal adhesion; HDA:UniProtKB. DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0005741; C:mitochondrial outer membrane; TAS:Reactome. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0003925; F:G protein activity; IEA:UniProtKB-EC. DR GO; GO:0019003; F:GDP binding; IBA:GO_Central. DR GO; GO:0019002; F:GMP binding; IEA:Ensembl. DR GO; GO:0005525; F:GTP binding; IBA:GO_Central. DR GO; GO:0003924; F:GTPase activity; IMP:DisProt. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0030275; F:LRR domain binding; IEA:Ensembl. DR GO; GO:0044877; F:protein-containing complex binding; IDA:MGI. DR GO; GO:0043495; F:protein-membrane adaptor activity; IEA:Ensembl. DR GO; GO:0030036; P:actin cytoskeleton organization; IEA:Ensembl. DR GO; GO:0060038; P:cardiac muscle cell proliferation; IEA:Ensembl. DR GO; GO:0019221; P:cytokine-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0060441; P:epithelial tube branching involved in lung morphogenesis; IEA:Ensembl. DR GO; GO:0007565; P:female pregnancy; IEA:Ensembl. DR GO; GO:0021897; P:forebrain astrocyte development; IEA:Ensembl. DR GO; GO:0010467; P:gene expression; IEA:Ensembl. DR GO; GO:0014009; P:glial cell proliferation; IEA:Ensembl. DR GO; GO:0048873; P:homeostasis of number of cells within a tissue; IEA:Ensembl. DR GO; GO:0001889; P:liver development; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; TAS:Reactome. DR GO; GO:0051450; P:myoblast proliferation; IEA:Ensembl. DR GO; GO:0030857; P:negative regulation of epithelial cell differentiation; IEA:Ensembl. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:2000774; P:positive regulation of cellular senescence; IEA:Ensembl. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0060252; P:positive regulation of glial cell proliferation; IEA:Ensembl. DR GO; GO:0035022; P:positive regulation of Rac protein signal transduction; IEA:Ensembl. DR GO; GO:0016601; P:Rac protein signal transduction; IEA:Ensembl. DR GO; GO:0007265; P:Ras protein signal transduction; IBA:GO_Central. DR GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; IEA:Ensembl. DR GO; GO:0032228; P:regulation of synaptic transmission, GABAergic; IEA:Ensembl. DR GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl. DR GO; GO:0009629; P:response to gravity; IEA:Ensembl. DR GO; GO:0035900; P:response to isolation stress; IEA:Ensembl. DR GO; GO:0051385; P:response to mineralocorticoid; IEA:Ensembl. DR GO; GO:0035914; P:skeletal muscle cell differentiation; IEA:Ensembl. DR GO; GO:0051146; P:striated muscle cell differentiation; IEA:Ensembl. DR GO; GO:0060509; P:type I pneumocyte differentiation; IEA:Ensembl. DR GO; GO:0008542; P:visual learning; IEA:Ensembl. DR CDD; cd04138; H_N_K_Ras_like; 1. DR DisProt; DP03860; -. DR FunFam; 3.40.50.300:FF:000096; KRAS proto-oncogene, GTPase; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1. DR InterPro; IPR027417; P-loop_NTPase. DR InterPro; IPR005225; Small_GTP-bd. DR InterPro; IPR001806; Small_GTPase. DR InterPro; IPR020849; Small_GTPase_Ras-type. DR NCBIfam; TIGR00231; small_GTP; 1. DR PANTHER; PTHR24070; RAS, DI-RAS, AND RHEB FAMILY MEMBERS OF SMALL GTPASE SUPERFAMILY; 1. DR Pfam; PF00071; Ras; 1. DR PRINTS; PR00449; RASTRNSFRMNG. DR SMART; SM00175; RAB; 1. DR SMART; SM00176; RAN; 1. DR SMART; SM00173; RAS; 1. DR SMART; SM00174; RHO; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. DR PROSITE; PS51421; RAS; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Cardiomyopathy; KW Cell membrane; Cytoplasm; Deafness; Direct protein sequencing; KW Disease variant; Ectodermal dysplasia; Glycoprotein; GTP-binding; KW Hydrolase; Intellectual disability; Isopeptide bond; Lipoprotein; Membrane; KW Methylation; Nucleotide-binding; Palmitate; Prenylation; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Ubl conjugation. FT CHAIN 1..186 FT /note="GTPase KRas" FT /id="PRO_0000082641" FT INIT_MET 1 FT /note="Removed; alternate" FT /evidence="ECO:0000269|Ref.17" FT CHAIN 2..186 FT /note="GTPase KRas, N-terminally processed" FT /id="PRO_0000326480" FT PROPEP 187..189 FT /note="Removed in mature form" FT /evidence="ECO:0000305|PubMed:27791178" FT /id="PRO_0000281291" FT REGION 166..185 FT /note="Hypervariable region" FT MOTIF 32..40 FT /note="Effector region" FT BINDING 10..18 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:22431598, FT ECO:0000269|PubMed:22566140, ECO:0000305|PubMed:34380736, FT ECO:0000305|PubMed:35522713" FT BINDING 29..35 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:22431598, FT ECO:0000269|PubMed:22566140, ECO:0000305|PubMed:34380736, FT ECO:0000305|PubMed:35522713" FT BINDING 59..60 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:22431598, FT ECO:0000269|PubMed:22566140, ECO:0000305|PubMed:34380736, FT ECO:0000305|PubMed:35522713" FT BINDING 116..119 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:22431598, FT ECO:0000269|PubMed:22566140, ECO:0000305|PubMed:34380736, FT ECO:0000305|PubMed:35522713" FT MOD_RES 1 FT /note="N-acetylmethionine; in GTPase KRas; alternate" FT /evidence="ECO:0000269|Ref.17" FT MOD_RES 2 FT /note="N-acetylthreonine; in GTPase KRas, N-terminally FT processed" FT /evidence="ECO:0000269|Ref.17" FT MOD_RES 104 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:22711838" FT MOD_RES 186 FT /note="Cysteine methyl ester" FT /evidence="ECO:0000269|PubMed:27791178, FT ECO:0007744|PDB:5TAR, ECO:0007744|PDB:5TB5" FT LIPID 180 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:29239724" FT LIPID 182 FT /note="N6-palmitoyl lysine" FT /evidence="ECO:0000269|PubMed:29239724" FT LIPID 184 FT /note="N6-palmitoyl lysine" FT /evidence="ECO:0000305|PubMed:29239724" FT LIPID 185 FT /note="N6-palmitoyl lysine" FT /evidence="ECO:0000305|PubMed:29239724" FT LIPID 186 FT /note="S-farnesyl cysteine" FT /evidence="ECO:0000269|PubMed:27791178, FT ECO:0000305|PubMed:24415755, ECO:0007744|PDB:5TAR, FT ECO:0007744|PDB:5TB5" FT CARBOHYD 35 FT /note="(Microbial infection) O-linked (Glc) threonine; by FT P.sordellii toxin TcsL" FT /evidence="ECO:0000269|PubMed:19744486" FT CROSSLNK 170 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000305|PubMed:30442762" FT VAR_SEQ 151..153 FT /note="RVE -> GVD (in isoform 2B)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:3310850, FT ECO:0000303|Ref.6, ECO:0000303|Ref.7" FT /id="VSP_011140" FT VAR_SEQ 165..189 FT /note="QYRLKKISKEEKTPGCVKIKKCIIM -> KHKEKMSKDGKKKKKKSKTKCVI FT M (in isoform 2B)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:3310850, FT ECO:0000303|Ref.6, ECO:0000303|Ref.7" FT /id="VSP_011141" FT VARIANT 5 FT /note="K -> E (in NS3; dbSNP:rs193929331)" FT /evidence="ECO:0000269|PubMed:17468812" FT /id="VAR_065144" FT VARIANT 5 FT /note="K -> N (in GASC; found also in a patient with FT Costello syndrome; exhibits only minor alterations in its FT in vitro biochemical behavior compared to wild-type FT protein; dbSNP:rs104894361)" FT /evidence="ECO:0000269|PubMed:14534542" FT /id="VAR_064849" FT VARIANT 10 FT /note="G -> GG (in AML; expression in 3T3 cell causes FT cellular transformation; expression in COS cells activates FT the Ras-MAPK signaling pathway; lower GTPase activity; FT faster GDP dissociation rate)" FT /evidence="ECO:0000269|PubMed:8955068" FT /id="VAR_034601" FT VARIANT 12 FT /note="G -> A (in colorectal cancer samples; somatic FT mutation; dbSNP:rs121913529)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:34820593" FT /id="VAR_036305" FT VARIANT 12 FT /note="G -> C (in lung carcinoma; somatic mutation; also FT found in metastatic colorectal cancer; dbSNP:rs121913530)" FT /evidence="ECO:0000269|PubMed:16533793, FT ECO:0000269|PubMed:34820593, ECO:0000269|PubMed:6320174" FT /id="VAR_006839" FT VARIANT 12 FT /note="G -> D (in GASC, JMML and SFM; somatic mutation; FT also found in pancreatic carcinoma and lung carcinoma; also FT found in metastatic colorectal cancer; dbSNP:rs121913529)" FT /evidence="ECO:0000269|PubMed:16533793, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17332249, FT ECO:0000269|PubMed:30891959, ECO:0000269|PubMed:34820593, FT ECO:0000269|PubMed:7773929, ECO:0000269|PubMed:8439212" FT /id="VAR_016026" FT VARIANT 12 FT /note="G -> R (in lung cancer and bladder cancer; somatic FT mutation; dbSNP:rs121913530)" FT /evidence="ECO:0000269|PubMed:6695174" FT /id="VAR_016027" FT VARIANT 12 FT /note="G -> S (in GASC and JMML; also found in lung FT carcinoma; somatic mutation; dbSNP:rs121913530)" FT /evidence="ECO:0000269|PubMed:16533793, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17332249, FT ECO:0000269|PubMed:7773929" FT /id="VAR_016028" FT VARIANT 12 FT /note="G -> V (in GASC; also found in lung carcinoma, FT pancreatic carcinoma and colon cancer; also found in FT metastatic colorectal cancer; somatic mutation; it is FT constitutively activated and stimulates transcription FT activation of tumor suppressor genes in non-transformed FT fibroblasts; promotes GTP binding; dbSNP:rs121913529)" FT /evidence="ECO:0000269|PubMed:14534542, FT ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:22711838, ECO:0000269|PubMed:24623306, FT ECO:0000269|PubMed:3034404, ECO:0000269|PubMed:34820593, FT ECO:0000269|PubMed:39809765, ECO:0000269|PubMed:6092920, FT ECO:0000269|PubMed:8439212" FT /id="VAR_006840" FT VARIANT 13 FT /note="G -> D (in GASC, JMML and OES; also found in a FT breast carcinoma cell line; somatic mutation; FT dbSNP:rs112445441)" FT /evidence="ECO:0000269|PubMed:14534542, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17332249, FT ECO:0000269|PubMed:25808193, ECO:0000269|PubMed:3627975" FT /id="VAR_016029" FT VARIANT 13 FT /note="G -> R (in pylocytic astrocytoma; somatic mutation; FT increase activation of the Ras pathway; dbSNP:rs121913535)" FT /evidence="ECO:0000269|PubMed:16247081" FT /id="VAR_065145" FT VARIANT 14 FT /note="V -> I (in NS3; affects activity and impairs FT responsiveness to GTPase activating proteins; characterized FT by a strong increase of both intrinsic and guanine FT nucleotide exchanged factor-catalyzed nucleotide exchange FT leading to an increased level of the activated state; FT dbSNP:rs104894365)" FT /evidence="ECO:0000269|PubMed:16474405" FT /id="VAR_026109" FT VARIANT 19 FT /note="L -> F (in OES; somatic mutation; FT dbSNP:rs121913538)" FT /evidence="ECO:0000269|PubMed:25808193" FT /id="VAR_083261" FT VARIANT 22 FT /note="Q -> E (in CFC2; exhibits an increase in intrinsic FT and guanine nucleotide exchange factor catalyzed nucleotide FT exchange in combination with an impaired GTPase-activating FT protein-stimulated GTP hydrolysis but functional in FT interaction with effectors; dbSNP:rs121913236)" FT /evidence="ECO:0000269|PubMed:17056636, FT ECO:0000269|PubMed:20949621" FT /id="VAR_064850" FT VARIANT 22 FT /note="Q -> R (in NS3; impairs GTPase-activating protein FT stimulated GTP hydrolysis with unaffected intrinsic FT functions and a virtually functional effector interaction; FT dbSNP:rs727503110)" FT /evidence="ECO:0000269|PubMed:17056636" FT /id="VAR_064851" FT VARIANT 34 FT /note="P -> L (in NS3; characterized by a defective GTPase- FT activating protein sensitivity and a strongly reduced FT interaction with effectors; dbSNP:rs104894366)" FT /evidence="ECO:0000269|PubMed:17056636" FT /id="VAR_064852" FT VARIANT 34 FT /note="P -> Q (in NS3; dbSNP:rs104894366)" FT /evidence="ECO:0000269|PubMed:17056636" FT /id="VAR_064853" FT VARIANT 34 FT /note="P -> R (in CFC2; characterized by a defective FT GTPase-activating protein sensitivity and a strongly FT reduced interaction with effectors; dbSNP:rs104894366)" FT /evidence="ECO:0000269|PubMed:16474405, FT ECO:0000269|PubMed:20949621" FT /id="VAR_026110" FT VARIANT 36 FT /note="I -> M (in NS3; dbSNP:rs727503109)" FT /evidence="ECO:0000269|PubMed:17056636" FT /id="VAR_064854" FT VARIANT 58 FT /note="T -> I (in NS3; affects activity and impairs FT responsiveness to GTPase activating proteins; exhibits only FT minor alterations in its in vitro biochemical behavior FT compared to wild-type protein; dbSNP:rs104894364)" FT /evidence="ECO:0000269|PubMed:16474405, FT ECO:0000269|PubMed:19396835" FT /id="VAR_026111" FT VARIANT 59 FT /note="A -> T (in GASC; also found in bladder cancer; FT somatic mutation; dbSNP:rs121913528)" FT /evidence="ECO:0000269|PubMed:14534542, FT ECO:0000269|PubMed:1553789" FT /id="VAR_016030" FT VARIANT 60 FT /note="G -> R (in CFC2; characterized by a defective FT GTPase-activating protein sensitivity and a strongly FT reduced interaction with effectors; dbSNP:rs104894359)" FT /evidence="ECO:0000269|PubMed:16474404, FT ECO:0000269|PubMed:20949621" FT /id="VAR_026112" FT VARIANT 60 FT /note="G -> S (in NS3; dbSNP:rs104894359)" FT /evidence="ECO:0000269|PubMed:19396835" FT /id="VAR_065146" FT VARIANT 61 FT /note="Q -> H (in lung carcinoma; dbSNP:rs17851045)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:16533793, ECO:0000269|Ref.7" FT /id="VAR_006841" FT VARIANT 61 FT /note="Q -> R (in a colorectal cancer sample; somatic FT mutation; promotes interaction with SHOC2 and PP1C; FT dbSNP:rs121913240)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:35830882, ECO:0000269|PubMed:35831509" FT /id="VAR_036306" FT VARIANT 71 FT /note="Y -> H (in CFC2; dbSNP:rs387907205)" FT /evidence="ECO:0000269|PubMed:21797849" FT /id="VAR_069784" FT VARIANT 117 FT /note="K -> N (in colorectal cancer samples; somatic FT mutation; dbSNP:rs770248150)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:34820593" FT /id="VAR_036307" FT VARIANT 146 FT /note="A -> T (in OES; somatic mutation; also found in FT colorectal cancer samples; dbSNP:rs121913527)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:26970110, ECO:0000269|PubMed:30891959, FT ECO:0000269|PubMed:34820593" FT /id="VAR_036308" FT VARIANT 146 FT /note="A -> V (in OES; somatic mutation; FT dbSNP:rs1057519725)" FT /evidence="ECO:0000269|PubMed:26970110, FT ECO:0000269|PubMed:30891959" FT /id="VAR_083262" FT VARIANT 147 FT /note="K -> E (in CFC2; dbSNP:rs387907206)" FT /evidence="ECO:0000269|PubMed:21797849" FT /id="VAR_069785" FT MUTAGEN 38 FT /note="D->A: Decreased interaction with MAPKAP1/SIN1." FT /evidence="ECO:0000269|PubMed:34380736" FT MUTAGEN 40 FT /note="Y->A: Decreased interaction with MAPKAP1/SIN1." FT /evidence="ECO:0000269|PubMed:34380736" FT MUTAGEN 61 FT /note="Q->L: Promotes GTP binding." FT /evidence="ECO:0000269|PubMed:39809765" FT MUTAGEN 180 FT /note="C->S: Abolished palmitoylation on Cys; reduced FT palmitoylation on Lys residues." FT /evidence="ECO:0000269|PubMed:29239724" FT MUTAGEN 182..185 FT /note="KIKK->RIRR: In K-Ras-3KR; abolished lysine- FT palmitoylation." FT /evidence="ECO:0000269|PubMed:29239724" FT STRAND 3..9 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 12..14 FT /evidence="ECO:0007829|PDB:6EPO" FT HELIX 16..25 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 28..32 FT /evidence="ECO:0007829|PDB:7F0W" FT TURN 34..36 FT /evidence="ECO:0007829|PDB:6H46" FT STRAND 38..46 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 49..57 FT /evidence="ECO:0007829|PDB:8ONV" FT HELIX 60..62 FT /evidence="ECO:0007829|PDB:4Q01" FT HELIX 66..73 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 76..83 FT /evidence="ECO:0007829|PDB:8ONV" FT HELIX 87..91 FT /evidence="ECO:0007829|PDB:8ONV" FT HELIX 93..104 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 105..107 FT /evidence="ECO:0007829|PDB:5VBM" FT STRAND 111..116 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 120..122 FT /evidence="ECO:0007829|PDB:4OBE" FT HELIX 127..137 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 141..143 FT /evidence="ECO:0007829|PDB:8ONV" FT TURN 146..148 FT /evidence="ECO:0007829|PDB:8ONV" FT HELIX 152..164 FT /evidence="ECO:0007829|PDB:8ONV" FT HELIX 169..172 FT /evidence="ECO:0007829|PDB:5OCG" FT STRAND 175..177 FT /evidence="ECO:0007829|PDB:4DSN" FT STRAND 182..184 FT /evidence="ECO:0007829|PDB:5TB5" FT VARIANT P01116-2:152 FT /note="V -> G (in NS3; dbSNP:rs104894367)" FT /evidence="ECO:0000305" FT /id="VAR_082908" FT VARIANT P01116-2:153 FT /note="D -> V (in CFC2 and NS3; exhibits only minor FT alterations in its in vitro biochemical behavior compared FT to wild-type protein; dbSNP:rs104894360)" FT /evidence="ECO:0000305" FT /id="VAR_082909" FT VARIANT P01116-2:156 FT /note="F -> I (in NS3; the patient also has features of FT cardiofaciocutaneous syndrome; dbSNP:rs397517042)" FT /evidence="ECO:0000305" FT /id="VAR_082910" FT VARIANT P01116-2:156 FT /note="F -> L (found in a patient with Costello syndrome; FT exhibits an increase in intrinsic and guanine nucleotide FT exchange factor catalyzed nucleotide exchange in FT combination with an impaired GTPase-activating protein- FT stimulated GTP hydrolysis but functional in interaction FT with effectors; dbSNP:rs104894362)" FT /evidence="ECO:0000305" FT /id="VAR_082911" FT MUTAGEN P01116-2:185 FT /note="C->S: Abolished interaction with GPR131." FT /evidence="ECO:0000269|PubMed:28619714" SQ SEQUENCE 189 AA; 21656 MW; 973547B2E11C2C81 CRC64; MTEYKLVVVG AGGVGKSALT IQLIQNHFVD EYDPTIEDSY RKQVVIDGET CLLDILDTAG QEEYSAMRDQ YMRTGEGFLC VFAINNTKSF EDIHHYREQI KRVKDSEDVP MVLVGNKCDL PSRTVDTKQA QDLARSYGIP FIETSAKTRQ RVEDAFYTLV REIRQYRLKK ISKEEKTPGC VKIKKCIIM // ID RCAS1_HUMAN Reviewed; 213 AA. AC O00559; A8K3N6; Q5Y8C7; Q6IB20; Q9BS76; DT 01-DEC-2000, integrated into UniProtKB/Swiss-Prot. DT 01-JUL-1997, sequence version 1. DT 28-JAN-2026, entry version 188. DE RecName: Full=Receptor-binding cancer antigen expressed on SiSo cells; DE AltName: Full=Cancer-associated surface antigen RCAS1; DE AltName: Full=Estrogen receptor-binding fragment-associated gene 9 protein; GN Name=EBAG9; Synonyms=RCAS1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Uterine adenocarcinoma; RX PubMed=10426319; DOI=10.1038/11383; RA Nakashima M., Sonoda K., Watanabe T.; RT "Inhibition of cell growth and induction of apoptotic cell death by the RT human tumor-associated antigen RCAS1."; RL Nat. Med. 5:938-942(1999). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Mammary cancer; RX PubMed=9418891; DOI=10.1128/mcb.18.1.442; RA Watanabe T., Inoue S., Hiroi H., Orimo A., Kawashima H., Muramatsu M.; RT "Isolation of estrogen-responsive genes with a CpG island library."; RL Mol. Cell. Biol. 18:442-449(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RA Lo W.Y., Hsieh S.L.; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Embryo; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16421571; DOI=10.1038/nature04406; RA Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M., RA Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L., RA Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S., RA Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A., RA Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III, RA Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., RA Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P., RA Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H., RA Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B., RA O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K., RA Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L., RA Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G., RA Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W., RA Platzer M., Shimizu N., Lander E.S.; RT "DNA sequence and analysis of human chromosome 8."; RL Nature 439:331-335(2006). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain, Lung, and Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP ROLE IN CANCER. RX PubMed=12054692; DOI=10.1016/s0006-291x(02)00401-1; RA Rousseau J., Tetu B., Caron D., Malenfant P., Cattaruzzi P., Audette M., RA Doillon C., Tremblay J.P., Guerette B.; RT "RCAS1 is associated with ductal breast cancer progression."; RL Biochem. Biophys. Res. Commun. 293:1544-1549(2002). RN [9] RP ROLE IN CANCER. RX PubMed=12138241; DOI=10.1159/000065065; RA Oizumi S., Yamazaki K., Nakashima M., Watanabe T., Hommura F., Ogura S., RA Nishimura M., Dosaka-Akita H.; RT "RCAS1 expression: a potential prognostic marker for adenocarcinomas of the RT lung."; RL Oncology 62:333-339(2002). RN [10] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=12672804; DOI=10.1074/jbc.m301361200; RA Engelsberg A., Hermosilla R., Karsten U., Schuelein R., Doerken B., RA Rehm A.; RT "The Golgi protein RCAS1 controls cell surface expression of tumor- RT associated O-linked glycan antigens."; RL J. Biol. Chem. 278:22998-23007(2003). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36 AND THR-41, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=15144186; DOI=10.1021/ac035352d; RA Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M., RA Peters E.C.; RT "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from RT human T cells using immobilized metal affinity chromatography and tandem RT mass spectrometry."; RL Anal. Chem. 76:2763-2772(2004). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-94, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=15592455; DOI=10.1038/nbt1046; RA Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H., RA Zha X.-M., Polakiewicz R.D., Comb M.J.; RT "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells."; RL Nat. Biotechnol. 23:94-101(2005). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Platelet; RX PubMed=18088087; DOI=10.1021/pr0704130; RA Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J., RA Schuetz C., Walter U., Gambaryan S., Sickmann A.; RT "Phosphoproteome of resting human platelets."; RL J. Proteome Res. 7:526-534(2008). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). CC -!- FUNCTION: May participate in suppression of cell proliferation and CC induces apoptotic cell death through activation of interleukin-1-beta CC converting enzyme (ICE)-like proteases. {ECO:0000269|PubMed:12054692, CC ECO:0000269|PubMed:12138241, ECO:0000269|PubMed:12672804}. CC -!- SUBUNIT: Homodimer. CC -!- INTERACTION: CC O00559; Q9ULC5: ACSL5; NbExp=3; IntAct=EBI-8787095, EBI-2876927; CC O00559; Q9BQE5: APOL2; NbExp=3; IntAct=EBI-8787095, EBI-4290634; CC O00559; Q12983: BNIP3; NbExp=3; IntAct=EBI-8787095, EBI-749464; CC O00559; Q9BXR6: CFHR5; NbExp=3; IntAct=EBI-8787095, EBI-11579371; CC O00559; Q9H5X1: CIAO2A; NbExp=3; IntAct=EBI-8787095, EBI-752069; CC O00559; Q6UXB4: CLEC4G; NbExp=3; IntAct=EBI-8787095, EBI-2114729; CC O00559; Q9NWW5: CLN6; NbExp=3; IntAct=EBI-8787095, EBI-6165897; CC O00559; A0A0C4DFN3: MGLL; NbExp=3; IntAct=EBI-8787095, EBI-12866138; CC O00559; Q8N912: NRAC; NbExp=3; IntAct=EBI-8787095, EBI-12051377; CC O00559; Q8NH19: OR10AG1; NbExp=3; IntAct=EBI-8787095, EBI-13339917; CC O00559; Q9P0S3: ORMDL1; NbExp=3; IntAct=EBI-8787095, EBI-1054848; CC O00559; Q9Y5Y5: PEX16; NbExp=3; IntAct=EBI-8787095, EBI-981985; CC O00559; O60831: PRAF2; NbExp=3; IntAct=EBI-8787095, EBI-2506064; CC O00559; Q96HR9-2: REEP6; NbExp=3; IntAct=EBI-8787095, EBI-14065960; CC O00559; Q9BRI3: SLC30A2; NbExp=3; IntAct=EBI-8787095, EBI-8644112; CC O00559; P78382: SLC35A1; NbExp=3; IntAct=EBI-8787095, EBI-12870360; CC O00559; Q96G79: SLC35A4; NbExp=3; IntAct=EBI-8787095, EBI-12363689; CC O00559; Q969S0: SLC35B4; NbExp=3; IntAct=EBI-8787095, EBI-10281213; CC O00559; Q16623: STX1A; NbExp=3; IntAct=EBI-8787095, EBI-712466; CC O00559; P32856-2: STX2; NbExp=3; IntAct=EBI-8787095, EBI-11956649; CC O00559; Q13277: STX3; NbExp=3; IntAct=EBI-8787095, EBI-1394295; CC O00559; Q6UX40: TMEM107; NbExp=3; IntAct=EBI-8787095, EBI-12845616; CC O00559; Q6ZUI0: TPRG1; NbExp=3; IntAct=EBI-8787095, EBI-17249488; CC O00559; Q9Y228: TRAF3IP3; NbExp=3; IntAct=EBI-8787095, EBI-765817; CC O00559; Q9P0L0: VAPA; NbExp=3; IntAct=EBI-8787095, EBI-1059156; CC O00559; O95292: VAPB; NbExp=3; IntAct=EBI-8787095, EBI-1188298; CC -!- SUBCELLULAR LOCATION: Golgi apparatus membrane CC {ECO:0000269|PubMed:12672804}; Single-pass type III membrane protein CC {ECO:0000269|PubMed:12672804}. Note=According to PubMed:10426319, it CC also exists as a soluble form which has the same biological activities. CC The existence of such soluble form is however uncertain. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=O00559-1; Sequence=Displayed; CC Name=2; CC IsoId=O00559-2; Sequence=VSP_055503; CC -!- TISSUE SPECIFICITY: Widely expressed. Expressed in ovary, testis, CC prostate, thymus, muscle and heart, but not in small intestine, colon, CC lymph nodes, or peripherical blood lymphocytes. The protein is not CC detected in any of the above organs. CC -!- INDUCTION: By estrogen. CC -!- DOMAIN: The coiled coil domain is necessary for the homodimerization. CC -!- MISCELLANEOUS: May serve as a prognostic marker for cancers such as CC adenocarcinomas of the lung and breast cancers. It is present and CC overexpressed in many patients suffering from breast carcinomas, its CC level of expression correlates with tumor grade, suggesting that it may CC be involved in cancer immune escape. According to PubMed:12672804, it CC is however not directly a tumor-associated antigen, but it rather CC modulates surface expression of tumor-associated O-linked glycan Tn CC when it is overexpressed, suggesting that it contributes indirectly to CC the antigenicity of tumor cells. CC -!- CAUTION: It was initially reported to be a ligand for some putative CC receptor present on T-, B-, natural killer (NK) cells and various human CC cell lines. However, PubMed:12672804 showed that it does not bind any CC receptor. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40393/EBAG9"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF006265; AAB61617.1; -; mRNA. DR EMBL; AB007619; BAA22572.1; -; mRNA. DR EMBL; AY653072; AAU85838.1; -; mRNA. DR EMBL; AK290651; BAF83340.1; -; mRNA. DR EMBL; CR456984; CAG33265.1; -; mRNA. DR EMBL; AC079061; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AP000427; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC005249; AAH05249.1; -; mRNA. DR EMBL; BC017729; AAH17729.1; -; mRNA. DR EMBL; BC022506; AAH22506.1; -; mRNA. DR CCDS; CCDS6313.1; -. [O00559-1] DR RefSeq; NP_001265867.1; NM_001278938.2. [O00559-1] DR RefSeq; NP_004206.1; NM_004215.5. [O00559-1] DR RefSeq; NP_936056.1; NM_198120.3. [O00559-1] DR RefSeq; XP_016869449.1; XM_017013960.2. [O00559-1] DR RefSeq; XP_047278368.1; XM_047422412.1. [O00559-1] DR RefSeq; XP_047278369.1; XM_047422413.1. [O00559-1] DR RefSeq; XP_054217468.1; XM_054361493.1. [O00559-1] DR RefSeq; XP_054217469.1; XM_054361494.1. [O00559-1] DR AlphaFoldDB; O00559; -. DR SMR; O00559; -. DR BioGRID; 114607; 313. DR FunCoup; O00559; 1234. DR IntAct; O00559; 33. DR STRING; 9606.ENSP00000337675; -. DR iPTMnet; O00559; -. DR PhosphoSitePlus; O00559; -. DR SwissPalm; O00559; -. DR BioMuta; EBAG9; -. DR jPOST; O00559; -. DR MassIVE; O00559; -. DR PaxDb; 9606-ENSP00000337675; -. DR PeptideAtlas; O00559; -. DR ProteomicsDB; 47973; -. [O00559-1] DR ProteomicsDB; 65861; -. DR Pumba; O00559; -. DR Antibodypedia; 13458; 429 antibodies from 38 providers. DR CPTC; O00559; 3 antibodies. DR DNASU; 9166; -. DR Ensembl; ENST00000337573.10; ENSP00000337675.5; ENSG00000147654.17. [O00559-1] DR Ensembl; ENST00000395785.7; ENSP00000379131.2; ENSG00000147654.17. [O00559-1] DR Ensembl; ENST00000531677.5; ENSP00000432082.1; ENSG00000147654.17. [O00559-2] DR Ensembl; ENST00000614147.1; ENSP00000477734.1; ENSG00000147654.17. [O00559-2] DR Ensembl; ENST00000620557.4; ENSP00000477645.1; ENSG00000147654.17. [O00559-1] DR Ensembl; ENST00000699338.1; ENSP00000514313.1; ENSG00000147654.17. [O00559-1] DR GeneID; 9166; -. DR KEGG; hsa:9166; -. DR MANE-Select; ENST00000337573.10; ENSP00000337675.5; NM_004215.5; NP_004206.1. DR UCSC; uc003ynf.5; human. [O00559-1] DR AGR; HGNC:3123; -. DR ClinPGx; PA27581; -. DR CTD; 9166; -. DR DisGeNET; 9166; -. DR GeneCards; EBAG9; -. DR HGNC; HGNC:3123; EBAG9. DR HPA; ENSG00000147654; Low tissue specificity. DR MIM; 605772; gene. DR OpenTargets; ENSG00000147654; -. DR VEuPathDB; HostDB:ENSG00000147654; -. DR eggNOG; ENOG502QSN4; Eukaryota. DR GeneTree; ENSGT00390000004040; -. DR HOGENOM; CLU_094995_0_0_1; -. DR InParanoid; O00559; -. DR OMA; LGEMENW; -. DR OrthoDB; 10017216at2759; -. DR PAN-GO; O00559; 1 GO annotation based on evolutionary models. DR PhylomeDB; O00559; -. DR PathwayCommons; O00559; -. DR Reactome; R-HSA-9018519; Estrogen-dependent gene expression. DR SignaLink; O00559; -. DR Agora; ENSG00000147654; -. DR BioGRID-ORCS; 9166; 19 hits in 1151 CRISPR screens. DR ChiTaRS; EBAG9; human. DR GeneWiki; EBAG9; -. DR GenomeRNAi; 9166; -. DR Pharos; O00559; Tbio. DR PRO; PR:O00559; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; O00559; protein. DR Bgee; ENSG00000147654; Expressed in parotid gland and 212 other cell types or tissues. DR ExpressionAtlas; O00559; baseline and differential. DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome. DR GO; GO:0030141; C:secretory granule; IBA:GO_Central. DR GO; GO:0016505; F:peptidase activator activity involved in apoptotic process; NAS:UniProtKB. DR GO; GO:0090717; P:adaptive immune memory response involving T cells and B cells; IEA:Ensembl. DR GO; GO:0001558; P:regulation of cell growth; NAS:UniProtKB. DR GO; GO:0001913; P:T cell mediated cytotoxicity; IEA:Ensembl. DR InterPro; IPR017025; Cancer-assoc_antigen_RCAS1. DR PANTHER; PTHR15208:SF2; RECEPTOR-BINDING CANCER ANTIGEN EXPRESSED ON SISO CELLS; 1. DR PANTHER; PTHR15208; RECEPTOR-BINDING CANCER ANTIGEN EXPRESSED ON SISO CELLS CANCER ASSOCIATED SURFACE ANTIGEN RCAS1 ESTROGEN RECEPTOR-BINDING FRAGMENT- ASSOCIATED GENE 9 PROTEIN; 1. DR PIRSF; PIRSF034247; RCAS1; 1. PE 1: Evidence at protein level; KW Alternative splicing; Apoptosis; Coiled coil; Golgi apparatus; Membrane; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Signal-anchor; Transmembrane; Transmembrane helix. FT CHAIN 1..213 FT /note="Receptor-binding cancer antigen expressed on SiSo FT cells" FT /id="PRO_0000097195" FT TOPO_DOM 1..6 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 7..27 FT /note="Helical; Signal-anchor for type III membrane FT protein" FT /evidence="ECO:0000255" FT TOPO_DOM 28..213 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT REGION 178..213 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 163..211 FT /evidence="ECO:0000255" FT COMPBIAS 178..206 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 36 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:15144186, FT ECO:0007744|PubMed:17081983, ECO:0007744|PubMed:18088087, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 41 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:15144186" FT MOD_RES 94 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:15592455" FT VAR_SEQ 174 FT /note="R -> RSRTNVCLLCSLLFHHPTPTSTPYINQSVKIERVSLGQWSYGKSKE FT (in isoform 2)" FT /evidence="ECO:0000303|Ref.3" FT /id="VSP_055503" FT CONFLICT 183 FT /note="K -> E (in Ref. 7; AAH05249)" FT /evidence="ECO:0000305" FT CONFLICT 199 FT /note="R -> Q (in Ref. 4; BAF83340)" FT /evidence="ECO:0000305" SQ SEQUENCE 213 AA; 24377 MW; B115E741E23891C5 CRC64; MAITQFRLFK FCTCLATVFS FLKRLICRSG RGRKLSGDQI TLPTTVDYSS VPKQTDVEEW TSWDEDAPTS VKIEGGNGNV ATQQNSLEQL EPDYFKDMTP TIRKTQKIVI KKREPLNFGI PDGSTGFSSR LAATQDLPFI HQSSELGDLD TWQENTNAWE EEEDAAWQAE EVLRQQKLAD REKRAAEQQR KKMEKEAQRL MKKEQNKIGV KLS // ID RET_HUMAN Reviewed; 1114 AA. AC P07949; A8K6Z2; Q15250; Q9BTB0; Q9H4A2; DT 01-AUG-1988, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-1994, sequence version 3. DT 28-JAN-2026, entry version 284. DE RecName: Full=Proto-oncogene tyrosine-protein kinase receptor Ret {ECO:0000305}; DE EC=2.7.10.1 {ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:28846099}; DE AltName: Full=Cadherin family member 12; DE AltName: Full=Proto-oncogene c-Ret {ECO:0000303|PubMed:2660074}; DE Contains: DE RecName: Full=Soluble RET kinase fragment {ECO:0000305|PubMed:21357690}; DE Contains: DE RecName: Full=Extracellular cell-membrane anchored RET cadherin 120 kDa fragment {ECO:0000305|PubMed:21357690}; DE Flags: Precursor; GN Name=RET {ECO:0000303|PubMed:2660074, ECO:0000312|HGNC:HGNC:9967}; GN Synonyms=CDHF12, CDHR16, PTC; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Prostate; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164054; DOI=10.1038/nature02462; RA Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L., RA Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K., RA Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L., RA Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P., RA Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P., RA Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N., RA Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A., RA Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C., RA Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D., RA Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C., RA Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K., RA Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A., RA Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S., RA McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S., RA Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., RA Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., RA Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M., RA Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A., RA Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P., RA Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y., RA Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D., RA Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 10."; RL Nature 429:375-381(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT CYS-982. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-280 (ISOFORMS 1/2). RX PubMed=2660074; RA Takahashi M.; RT "Isolation of ret proto-oncogene cDNA with an amino-terminal signal RT sequence."; RL Oncogene 4:805-806(1989). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 255-1114 (ISOFORM 1). RX PubMed=3078962; RA Takahashi M., Buma Y., Iwamoto T., Inaguma Y., Ikeda H., Hiai H.; RT "Cloning and expression of the ret proto-oncogene encoding a tyrosine RT kinase with two potential transmembrane domains."; RL Oncogene 3:571-578(1988). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 588-1063 (ISOFORM 2), AND CHROMOSOMAL RP TRANSLOCATION WITH TRIM27. RX PubMed=3037315; DOI=10.1128/mcb.7.4.1378-1385.1987; RA Takahashi M., Cooper G.M.; RT "ret transforming gene encodes a fusion protein homologous to tyrosine RT kinases."; RL Mol. Cell. Biol. 7:1378-1385(1987). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 713-1114 (ISOFORM 1), AND CHROMOSOMAL RP TRANSLOCATION WITH GOLGA5. RC TISSUE=Fibroblast; RX PubMed=2734021; RA Ishizaka Y., Ochiai M., Tahira T., Suhimura T., Nahao M.; RT "Activation of the ret-II oncogene without a sequence encoding a RT transmembrane domain and transforming activity of two ret-II oncogene RT products differing in carboxy-termini due to alternative splicing."; RL Oncogene 4:789-794(1989). RN [8] RP ERRATUM OF PUBMED:2734021. RA Ishizaka Y., Ochiai M., Tahira T., Suhimura T., Nahao M.; RL Oncogene 4:1415-1415(1989). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 713-1114 (ISOFORM 1), AND CHROMOSOMAL RP TRANSLOCATION WITH CCDC6. RC TISSUE=Thyroid papillary carcinoma; RX PubMed=2406025; DOI=10.1016/0092-8674(90)90659-3; RA Grieco M., Santoro M., Berlingieri M.T., Melillo R.M., Donghi R., RA Bongarzone I., Pierotti M.A., Della Porta G., Fusco A., Vecchio G.; RT "PTC is a novel rearranged form of the ret proto-oncogene and is frequently RT detected in vivo in human thyroid papillary carcinomas."; RL Cell 60:557-563(1990). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] OF 713-770 (ISOFORMS 1/2), AND CHROMOSOMAL RP TRANSLOCATION WITH PCM1. RX PubMed=10980597; DOI=10.1038/sj.onc.1203772; RA Corvi R., Berger N., Balczon R., Romeo G.; RT "RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma."; RL Oncogene 19:4236-4242(2000). RN [11] RP SUBCELLULAR LOCATION, AND COFACTOR. RX PubMed=9575150; DOI=10.1074/jbc.273.20.12077; RA van Weering D.H., Moen T.C., Braakman I., Baas P.D., Bos J.L.; RT "Expression of the receptor tyrosine kinase Ret on the plasma membrane is RT dependent on calcium."; RL J. Biol. Chem. 273:12077-12081(1998). RN [12] RP CHROMOSOMAL TRANSLOCATION WITH TRIM33 AND TRIM24. RX PubMed=10439047; DOI=10.1038/sj.onc.1202824; RA Klugbauer S., Rabes H.M.; RT "The transcription coactivator HTIF1 and a related protein are fused to the RT RET receptor tyrosine kinase in childhood papillary thyroid carcinomas."; RL Oncogene 18:4388-4393(1999). RN [13] RP PHOSPHORYLATION AT TYR-1015 AND TYR-1062. RX PubMed=11061555; DOI=10.1210/jcem.85.10.6882; RA Salvatore D., Barone M.V., Salvatore G., Melillo R.M., Chiappetta G., RA Mineo A., Fenzi G., Vecchio G., Fusco A., Santoro M.; RT "Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and RT ret-derived oncoproteins."; RL J. Clin. Endocrinol. Metab. 85:3898-3907(2000). RN [14] RP COFACTOR, AND MUTAGENESIS OF TYR-36; TYR-41 AND TRP-85. RX PubMed=11445581; DOI=10.1074/jbc.m104968200; RA Anders J., Kjar S., Ibanez C.F.; RT "Molecular modeling of the extracellular domain of the RET receptor RT tyrosine kinase reveals multiple cadherin-like domains and a calcium- RT binding site."; RL J. Biol. Chem. 276:35808-35817(2001). RN [15] RP PHOSPHORYLATION AT TYR-806; TYR-809; TYR-900; TYR-905; TYR-981; TYR-1015; RP TYR-1062; TYR-1090 AND TYR-1096. RX PubMed=14711813; DOI=10.1074/jbc.m312600200; RA Kawamoto Y., Takeda K., Okuno Y., Yamakawa Y., Ito Y., Taguchi R., Kato M., RA Suzuki H., Takahashi M., Nakashima I.; RT "Identification of RET autophosphorylation sites by mass spectrometry."; RL J. Biol. Chem. 279:14213-14224(2004). RN [16] RP CHROMOSOMAL TRANSLOCATION WITH TRIM27. RX PubMed=12787916; DOI=10.1016/s0027-5107(03)00056-3; RA Saenko V., Rogounovitch T., Shimizu-Yoshida Y., Abrosimov A., Lushnikov E., RA Roumiantsev P., Matsumoto N., Nakashima M., Meirmanov S., Ohtsuru A., RA Namba H., Tsyb A., Yamashita S.; RT "Novel tumorigenic rearrangement, Delta rfp/ret, in a papillary thyroid RT carcinoma from externally irradiated patient."; RL Mutat. Res. 527:81-90(2003). RN [17] RP RETRACTED PAPER. RX PubMed=16778204; DOI=10.1158/0008-5472.can-06-0228; RA Iervolino A., Iuliano R., Trapasso F., Viglietto G., Melillo R.M., RA Carlomagno F., Santoro M., Fusco A.; RT "The receptor-type protein tyrosine phosphatase J antagonizes the RT biochemical and biological effects of RET-derived oncoproteins."; RL Cancer Res. 66:6280-6287(2006). RN [18] RP RETRACTION NOTICE OF PUBMED:16778204. RX PubMed=30552125; DOI=10.1158/0008-5472.can-18-3456; RA Iervolino A., Iuliano R., Trapasso F., Viglietto G., Melillo R.M., RA Carlomagno F., Santoro M., Fusco A.; RL Cancer Res. 78:6907-6907(2018). RN [19] RP ACTIVITY REGULATION. RX PubMed=17884497; DOI=10.1016/j.bmcl.2007.07.104; RA Graham Robinett R., Freemerman A.J., Skinner M.A., Shewchuk L., Lackey K.; RT "The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET RT kinase inhibitors."; RL Bioorg. Med. Chem. Lett. 17:5886-5893(2007). RN [20] RP ACTIVITY REGULATION BY SORAFENIB. RX PubMed=17664273; DOI=10.1074/jbc.m703461200; RA Plaza-Menacho I., Mologni L., Sala E., Gambacorti-Passerini C., Magee A.I., RA Links T.P., Hofstra R.M.W., Barford D., Isacke C.M.; RT "Sorafenib functions to potently suppress RET tyrosine kinase activity by RT direct enzymatic inhibition and promoting RET lysosomal degradation RT independent of proteasomal targeting."; RL J. Biol. Chem. 282:29230-29240(2007). RN [21] RP ACTIVITY REGULATION BY 3- AND 4-SUBSTITUTED BETA-CARBOLIN-1-ONES. RX PubMed=19053769; DOI=10.1021/jm8007823; RA Cincinelli R., Cassinelli G., Dallavalle S., Lanzi C., Merlini L., RA Botta M., Tuccinardi T., Martinelli A., Penco S., Zunino F.; RT "Synthesis, modeling, and RET protein kinase inhibitory activity of 3- and RT 4-substituted beta-carbolin-1-ones."; RL J. Med. Chem. 51:7777-7787(2008). RN [22] RP INTERACTION WITH CD2AP, AND MUTAGENESIS OF LYS-758. RX PubMed=18753381; DOI=10.1523/jneurosci.2738-08.2008; RA Tsui C.C., Pierchala B.A.; RT "CD2AP and Cbl-3/Cbl-c constitute a critical checkpoint in the regulation RT of ret signal transduction."; RL J. Neurosci. 28:8789-8800(2008). RN [23] RP INTERACTION WITH AIP. RX PubMed=19366855; DOI=10.1210/jc.2008-1980; RA Vargiolu M., Fusco D., Kurelac I., Dirnberger D., Baumeister R., Morra I., RA Melcarne A., Rimondini R., Romeo G., Bonora E.; RT "The tyrosine kinase receptor RET interacts in vivo with aryl hydrocarbon RT receptor-interacting protein to alter survivin availability."; RL J. Clin. Endocrinol. Metab. 94:2571-2578(2009). RN [24] RP INDUCTION BY NKX2-1; PHOX2B; SOX10 AND PAX3. RX PubMed=19853745; DOI=10.1016/j.jpedsurg.2008.11.055; RA Leon T.Y.Y., Ngan E.S.W., Poon H.-C., So M.-T., Lui V.C.H., Tam P.K.H., RA Garcia-Barcelo M.M.; RT "Transcriptional regulation of RET by Nkx2-1, Phox2b, Sox10, and Pax3."; RL J. Pediatr. Surg. 44:1904-1912(2009). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-696, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [26] RP FUNCTION IN DEVELOPMENT OF MECHANORECEPTORS. RX PubMed=20064382; DOI=10.1016/j.neuron.2009.12.014; RA Ma Q.; RT "RETouching upon mechanoreceptors."; RL Neuron 64:773-776(2009). RN [27] RP ACTIVITY REGULATION, AND REVIEW ON KINASE INHIBITORS. RX PubMed=20605972; DOI=10.1210/er.2009-0031; RA Ye L., Santarpia L., Gagel R.F.; RT "The evolving field of tyrosine kinase inhibitors in the treatment of RT endocrine tumors."; RL Endocr. Rev. 31:578-599(2010). RN [28] RP ACTIVITY REGULATION. RX PubMed=20409618; DOI=10.1016/j.ejmech.2010.03.017; RA Brandt W., Mologni L., Preu L., Lemcke T., Gambacorti-Passerini C., RA Kunick C.; RT "Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3- RT thienyl)nicotinonitrile scaffold."; RL Eur. J. Med. Chem. 45:2919-2927(2010). RN [29] RP FUNCTION IN PITUITARY. RX PubMed=20616503; DOI=10.1159/000318502; RA Garcia-Lavandeira M., Diaz-Rodriguez E., Garcia-Rendueles M.E., RA Rodrigues J.S., Perez-Romero S., Bravo S.B., Alvarez C.V.; RT "Functional role of the RET dependence receptor, GFRa co-receptors and RT ligands in the pituitary."; RL Front. Horm. Res. 38:127-138(2010). RN [30] RP FUNCTION IN CELL ADHESION/MIGRATION. RX PubMed=20702524; DOI=10.1210/jc.2010-0771; RA Cockburn J.G., Richardson D.S., Gujral T.S., Mulligan L.M.; RT "RET-mediated cell adhesion and migration require multiple integrin RT subunits."; RL J. Clin. Endocrinol. Metab. 95:E342-E346(2010). RN [31] RP SUBCELLULAR LOCATION. RX PubMed=19823924; DOI=10.1007/s10895-009-0548-x; RA Richardson D.S., Mulligan L.M.; RT "Direct visualization of vesicle maturation and plasma membrane protein RT trafficking."; RL J. Fluoresc. 20:401-405(2010). RN [32] RP ACTIVITY REGULATION. RX PubMed=21134556; DOI=10.1016/j.surg.2010.09.026; RA Samadi A.K., Mukerji R., Shah A., Timmermann B.N., Cohen M.S.; RT "A novel RET inhibitor with potent efficacy against medullary thyroid RT cancer in vivo."; RL Surgery 148:1228-1236(2010). RN [33] RP FUNCTION IN CELL ADHESION, FUNCTION IN APOPTOSIS, PROTEOLYTIC PROCESSING BY RP CASPASE-3 AT ASP-707 AND ASP-1017, MUTAGENESIS OF ASP-707; LYS-758 AND RP 708-ALA--SER-1114, AND SUBUNIT. RX PubMed=21357690; DOI=10.1074/jbc.m110.195461; RA Cabrera J.R., Bouzas-Rodriguez J., Tauszig-Delamasure S., Mehlen P.; RT "RET modulates cell adhesion via its cleavage by caspase in sympathetic RT neurons."; RL J. Biol. Chem. 286:14628-14638(2011). RN [34] RP INTERACTION WITH PTK2/FAK1, AND FUNCTION IN PTK2/FAK1 PHOSPHORYLATION. RX PubMed=21454698; DOI=10.1074/jbc.m110.168500; RA Plaza-Menacho I., Morandi A., Mologni L., Boender P., RA Gambacorti-Passerini C., Magee A.I., Hofstra R.M.W., Knowles P., RA McDonald N.Q., Isacke C.M.; RT "Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming RT a direct and reciprocal RET-FAK transactivation mechanism."; RL J. Biol. Chem. 286:17292-17302(2011). RN [35] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=21994944; DOI=10.1074/jbc.m111.246413; RA Geng Z., Xu F.Y., Huang S.H., Chen Z.Y.; RT "Sorting protein-related receptor SorLA controls regulated secretion of RT glial cell line-derived neurotrophic factor."; RL J. Biol. Chem. 286:41871-41882(2011). RN [36] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=23333276; DOI=10.1016/j.celrep.2012.12.011; RA Glerup S., Lume M., Olsen D., Nyengaard J.R., Vaegter C.B., Gustafsen C., RA Christensen E.I., Kjolby M., Hay-Schmidt A., Bender D., Madsen P., RA Saarma M., Nykjaer A., Petersen C.M.; RT "SorLA controls neurotrophic activity by sorting of GDNF and its receptors RT GFRalpha1 and RET."; RL Cell Rep. 3:186-199(2013). RN [37] RP INTERACTION WITH GFRAL, SUBCELLULAR LOCATION, FUNCTION, AND MUTAGENESIS OF RP TYR-1062. RX PubMed=28953886; DOI=10.1038/nature24042; RA Hsu J.Y., Crawley S., Chen M., Ayupova D.A., Lindhout D.A., Higbee J., RA Kutach A., Joo W., Gao Z., Fu D., To C., Mondal K., Li B., Kekatpure A., RA Wang M., Laird T., Horner G., Chan J., McEntee M., Lopez M., RA Lakshminarasimhan D., White A., Wang S.P., Yao J., Yie J., Matern H., RA Solloway M., Haldankar R., Parsons T., Tang J., Shen W.D., Alice Chen Y., RA Tian H., Allan B.B.; RT "Non-homeostatic body weight regulation through a brainstem-restricted RT receptor for GDF15."; RL Nature 550:255-259(2017). RN [38] RP ERRATUM OF PUBMED:28953886. RX PubMed=29144449; DOI=10.1038/nature24481; RA Hsu J.Y., Crawley S., Chen M., Ayupova D.A., Lindhout D.A., Higbee J., RA Kutach A., Joo W., Gao Z., Fu D., To C., Mondal K., Li B., Kekatpure A., RA Wang M., Laird T., Horner G., Chan J., McEntee M., Lopez M., RA Lakshminarasimhan D., White A., Wang S.P., Yao J., Yie J., Matern H., RA Solloway M., Haldankar R., Parsons T., Tang J., Shen W.D., Alice Chen Y., RA Tian H., Allan B.B.; RT "Non-homeostatic body weight regulation through a brainstem-restricted RT receptor for GDF15."; RL Nature 551:398-398(2017). RN [39] RP FUNCTION, AND INTERACTION WITH GFRAL. RX PubMed=28846097; DOI=10.1038/nm.4392; RA Mullican S.E., Lin-Schmidt X., Chin C.N., Chavez J.A., Furman J.L., RA Armstrong A.A., Beck S.C., South V.J., Dinh T.Q., Cash-Mason T.D., RA Cavanaugh C.R., Nelson S., Huang C., Hunter M.J., Rangwala S.M.; RT "GFRAL is the receptor for GDF15 and the ligand promotes weight loss in RT mice and nonhuman primates."; RL Nat. Med. 23:1150-1157(2017). RN [40] RP FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH GFRAL, AND PHOSPHORYLATION RP AT TYR-905 AND TYR-1062. RX PubMed=28846099; DOI=10.1038/nm.4394; RA Yang L., Chang C.C., Sun Z., Madsen D., Zhu H., Padkjaer S.B., Wu X., RA Huang T., Hultman K., Paulsen S.J., Wang J., Bugge A., Frantzen J.B., RA Noergaard P., Jeppesen J.F., Yang Z., Secher A., Chen H., Li X., John L.M., RA Shan B., He Z., Gao X., Su J., Hansen K.T., Yang W., Joergensen S.B.; RT "GFRAL is the receptor for GDF15 and is required for the anti-obesity RT effects of the ligand."; RL Nat. Med. 23:1158-1166(2017). RN [41] RP GLYCOSYLATION AT SER-688. RX PubMed=26237509; DOI=10.1038/nsmb.3063; RA Pathak S., Alonso J., Schimpl M., Rafie K., Blair D.E., Borodkin V.S., RA Albarbarawi O., van Aalten D.M.F.; RT "The active site of O-GlcNAc transferase imposes constraints on substrate RT sequence."; RL Nat. Struct. Mol. Biol. 22:744-750(2015). RN [42] {ECO:0007744|PDB:2IVS, ECO:0007744|PDB:2IVT, ECO:0007744|PDB:2IVU, ECO:0007744|PDB:2IVV} RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 705-1013 ALONE AND IN COMPLEX WITH RP INHIBITORS, IDENTIFICATION BY MASS SPECTROMETRY, AND PHOSPHORYLATION AT RP TYR-900 AND TYR-905. RX PubMed=16928683; DOI=10.1074/jbc.m605604200; RA Knowles P.P., Murray-Rust J., Kjaer S., Scott R.P., Hanrahan S., RA Santoro M., Ibanez C.F., McDonald N.Q.; RT "Structure and chemical inhibition of the RET tyrosine kinase domain."; RL J. Biol. Chem. 281:33577-33587(2006). RN [43] {ECO:0007744|PDB:2X2K, ECO:0007744|PDB:2X2L, ECO:0007744|PDB:2X2M} RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 705-1013 IN COMPLEX WITH RP INHIBITORS, ACTIVITY REGULATION, AND PHOSPHORYLATION AT TYR-905. RX PubMed=20117004; DOI=10.1016/j.bmc.2010.01.011; RA Mologni L., Rostagno R., Brussolo S., Knowles P.P., Kjaer S., RA Murray-Rust J., Rosso E., Zambon A., Scapozza L., McDonald N.Q., RA Lucchini V., Gambacorti-Passerini C.; RT "Synthesis, structure-activity relationship and crystallographic studies of RT 3-substituted indolin-2-one RET inhibitors."; RL Bioorg. Med. Chem. 18:1482-1496(2010). RN [44] {ECO:0007744|PDB:2X2U} RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 29-270, GLYCOSYLATION AT ASN-151, RP AND DISULFIDE BONDS. RX PubMed=20473317; DOI=10.1038/nsmb.1808; RA Kjaer S., Hanrahan S., Totty N., McDonald N.Q.; RT "Mammal-restricted elements predispose human RET to folding impairment by RT HSCR mutations."; RL Nat. Struct. Mol. Biol. 17:726-731(2010). RN [45] {ECO:0007744|PDB:4UX8} RP STRUCTURE BY ELECTRON MICROSCOPY (24.00 ANGSTROMS) OF 29-635 IN COMPLEX RP WITH GFRA1; GDNF AND CALCIUM, FUNCTION, COFACTOR, AND DISULFIDE BONDS. RX PubMed=25242331; DOI=10.1016/j.celrep.2014.08.040; RA Goodman K.M., Kjaer S., Beuron F., Knowles P.P., Nawrotek A., Burns E.M., RA Purkiss A.G., George R., Santoro M., Morris E.P., McDonald N.Q.; RT "RET recognition of GDNF-GFRalpha1 ligand by a composite binding site RT promotes membrane-proximal self-association."; RL Cell Rep. 8:1894-1904(2014). RN [46] {ECO:0007744|PDB:4CKI, ECO:0007744|PDB:4CKJ} RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 705-1013 IN COMPLEX WITH RP ADENOSINE, FUNCTION, CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-687; RP TYR-826; TYR-900; TYR-905; TYR-981; TYR-1015; TYR-1029 AND TYR-1062, RP MUTAGENESIS OF GLU-734; LYS-758; ARG-912 AND ILE-913, VARIANT MEN2B RP THR-918, CHARACTERIZATION OF VARIANT MEN2B THR-918, VARIANT MTC MET-804, RP AND CHARACTERIZATION OF VARIANT MTC MET-804. RX PubMed=24560924; DOI=10.1016/j.molcel.2014.01.015; RA Plaza-Menacho I., Barnouin K., Goodman K., Martinez-Torres R.J., Borg A., RA Murray-Rust J., Mouilleron S., Knowles P., McDonald N.Q.; RT "Oncogenic RET kinase domain mutations perturb the autophosphorylation RT trajectory by enhancing substrate presentation in trans."; RL Mol. Cell 53:738-751(2014). RN [47] {ECO:0007744|PDB:6NE7, ECO:0007744|PDB:6NEC, ECO:0007744|PDB:6NJA} RP X-RAY CRYSTALLOGRAPHY (1.87 ANGSTROMS) OF 705-1013, FUNCTION, ACTIVITY RP REGULATION, VARIANT MTC VAL-881, CHARACTERIZATION OF VARIANT MTC VAL-881, RP VARIANT ALA-810, AND CHARACTERIZATION OF VARIANT ALA-810. RX PubMed=31118272; DOI=10.1074/jbc.ra119.007682; RA Terzyan S.S., Shen T., Liu X., Huang Q., Teng P., Zhou M., Hilberg F., RA Cai J., Mooers B.H.M., Wu J.; RT "Structural basis of resistance of mutant RET protein-tyrosine kinase to RT its inhibitors nintedanib and vandetanib."; RL J. Biol. Chem. 294:10428-10437(2019). RN [48] {ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, ECO:0007744|PDB:6Q2S} RP STRUCTURE BY ELECTRON MICROSCOPY (3.65 ANGSTROMS) OF 29-635 IN COMPLEX WITH RP CALCIUM; GDF15; GFRAL; GFRA1; GFRA2; GFRA3; GDNF; NRTN AND ARTN, COFACTOR, RP AND DISULFIDE BONDS. RX PubMed=31535977; DOI=10.7554/elife.47650; RA Li J., Shang G., Chen Y.J., Brautigam C.A., Liou J., Zhang X., Bai X.C.; RT "Cryo-EM analyses reveal the common mechanism and diversification in the RT activation of RET by different ligands."; RL Elife 8:0-0(2019). RN [49] RP REVIEW ON HSCR VARIANTS. RX PubMed=9359036; RA Hofstra R.M.W., Osinga J., Buys C.H.C.M.; RT "Mutations in Hirschsprung disease: when does a mutation contribute to the RT phenotype."; RL Eur. J. Hum. Genet. 5:180-185(1997). RN [50] RP VARIANTS MEN2A/MTC TYR-611; PHE-618; GLY-620 AND PHE-630. RX PubMed=9067749; RX DOI=10.1002/(sici)1098-1004(1997)9:2<97::aid-humu1>3.0.co;2-m; RA Eng C., Mulligan L.M.; RT "Mutations of the RET proto-oncogene in the multiple endocrine neoplasia RT type 2 syndromes, related sporadic tumours, and Hirschsprung disease."; RL Hum. Mutat. 9:97-109(1997). RN [51] RP VARIANTS MEN2A/MTC TRP-611; SER-618; TYR-618; ARG-620; TYR-620 AND ARG-634. RX PubMed=8103403; DOI=10.1093/hmg/2.7.851; RA Donis-Keller H., Dou S., Chi D., Carlson K.M., Toshima K., Lairmore T.C., RA Howe J.R., Moley J.F., Goodfellow P., Wells S.A. Jr.; RT "Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC."; RL Hum. Mol. Genet. 2:851-856(1993). RN [52] RP VARIANTS MEN2A GLY-618; 632-GLU--CYS-634 DELINS ASP-VAL-ARG; GLY-634; RP PHE-634; TYR-634 AND SER-634. RX PubMed=8099202; DOI=10.1038/363458a0; RA Mulligan L.M., Kwok J.B.J., Healey C.S., Elsdon M.J., Eng C., Gardner E., RA Love D.R., Mole S.E., Moore J.K., Papi L., Ponder M.A., Telenius H., RA Tunnacliffe A., Ponder B.A.J.; RT "Germ-line mutations of the RET proto-oncogene in multiple endocrine RT neoplasia type 2A."; RL Nature 363:458-460(1993). RN [53] RP VARIANTS HSCR1 PRO-40; LEU-399; GLN-762; PRO-765; GLN-897; GLY-972 AND RP LEU-973. RX PubMed=7704557; DOI=10.1159/000472371; RA Yin L., Barone V., Seri M., Bolino A., Bocciardi R., Ceccherini I., RA Pasini B., Tocco T., Lerone M., Cywes S., Moore S., Vanderwinden J.-M., RA Abramowicz M.J., Kristoffersson U., Larsson L.T., Hamel B.C.J., Silengo M., RA Martucciello G., Romeo G.; RT "Heterogeneity and low detection rate of RET mutations in Hirschsprung RT disease."; RL Eur. J. Hum. Genet. 2:272-280(1994). RN [54] RP VARIANT MEN2B THR-918. RX PubMed=7911697; DOI=10.1093/hmg/3.2.237; RA Eng C., Smith D.P., Mulligan L.M., Nagai M.A., Healey C.S., Ponder M.A., RA Gardner E., Scheumann G.F., Jackson C.E., Tunnacliffe A., Ponder B.A.J.; RT "Point mutation within the tyrosine kinase domain of the RET proto-oncogene RT in multiple endocrine neoplasia type 2B and related sporadic tumours."; RL Hum. Mol. Genet. 3:237-241(1994). RN [55] RP VARIANTS MEN2A/MTC ARG-618; SER-618; PHE-620; ARG-620; PHE-634; GLY-634 AND RP TYR-634. RX PubMed=7915165; DOI=10.1093/hmg/3.4.635; RA Xue F., Yu H., Maurer L.H., Memoli V.A., Nutile-Mcmenemy N., Schuster M.K., RA Browden D.W., Mao J.-I., Noll W.W.; RT "Germline RET mutations in MEN 2A and FMTC and their detection by simple RT DNA diagnostic tests."; RL Hum. Mol. Genet. 3:635-638(1994). RN [56] RP VARIANTS MTC/MEN2A TYR-609; ARG-618; SER-618 AND SER-620. RX PubMed=7849720; DOI=10.1093/hmg/3.10.1895; RA Blaugrund J.E., Johns M.M. Jr., Eby Y.J., Ball D.W., Baylin S.B., RA Hruban R.H., Sidransky D.; RT "RET proto-oncogene mutations in inherited and sporadic medullary thyroid RT cancer."; RL Hum. Mol. Genet. 3:1895-1897(1994). RN [57] RP VARIANTS MTC, AND VARIANTS MEN2A. RX PubMed=7874109; DOI=10.1093/hmg/3.11.1939; RA Schuffenecker I., Billaud M., Calender A., Chambe B., Ginet N., RA Calmettes C., Modigliani E., Lenoir G.M.; RT "RET proto-oncogene mutations in French MEN 2A and FMTC families."; RL Hum. Mol. Genet. 3:1939-1943(1994). RN [58] RP VARIANTS HSCR1 TRP-609; ARG-618 AND ARG-620, VARIANT MEN2A ARG-618, AND RP VARIANT MTC ARG-620. RX PubMed=7881414; DOI=10.1093/hmg/3.12.2163; RA Mulligan L.M., Eng C., Attie T., Lyonnet S., Marsh D.J., Hyland V.J., RA Robinson B.G., Frilling A., Verellen-Dumoulin C., Safar A., Venter D.J., RA Munnich A., Ponder B.A.J.; RT "Diverse phenotypes associated with exon 10 mutations of the RET proto- RT oncogene."; RL Hum. Mol. Genet. 3:2163-2167(1994). RN [59] RP VARIANT HSCR1 LYS-921. RX PubMed=7997019; DOI=10.1016/s0140-6736(94)92908-4; RA Pelet A., Attie T., Goulet O., Eng C., Ponder B.A., Munnich A., Lyonnet S.; RT "De-novo mutations of the RET proto-oncogene in Hirschsprung's disease."; RL Lancet 344:1769-1770(1994). RN [60] RP VARIANT MEN2B THR-918. RX PubMed=7906866; DOI=10.1038/367375a0; RA Hofstra R.M.W., Landsvater R.M., Ceccherini I., Stulp R.P., Stelwagen T., RA Luo Y., Pasini B., Hoeppener J.W.M., Ploos van Amstel H.K., Romeo G., RA Lips C.J.M., Buys C.H.C.M.; RT "A mutation in the RET proto-oncogene associated with multiple endocrine RT neoplasia type 2B and sporadic medullary thyroid carcinoma."; RL Nature 367:375-376(1994). RN [61] RP VARIANTS HSCR1 PRO-765; GLN-897 AND GLY-972. RX PubMed=8114938; DOI=10.1038/367377a0; RA Romeo G., Ronchetto P., Luo Y., Barone V., Seri M., Ceccherini I., RA Pasini B., Bocciardi R., Lerone M., Kaarlainen H., Martucciello G.; RT "Point mutations affecting the tyrosine kinase domain of the RET proto- RT oncogene in Hirschsprung's disease."; RL Nature 367:377-378(1994). RN [62] RP VARIANTS HSCR1 LEU-32; LEU-64; GLN-330 AND LEU-393. RX PubMed=8114939; DOI=10.1038/367378a0; RA Edery P., Lyonnet S., Mulligan L.M., Pelet A., Dow E., Abel L., Holder S., RA Nihoul-Fkete C., Ponder B.A.J., Munnich A.; RT "Mutations of the RET proto-oncogene in Hirschsprung's disease."; RL Nature 367:378-380(1994). RN [63] RP VARIANT MEN2B THR-918. RX PubMed=7906417; DOI=10.1073/pnas.91.4.1579; RA Carlson K.M., Dou S., Chi D., Scavarda N., Toshima K., Jackson C.E., RA Wells S.A. Jr., Goodfellow P.J., Donis-Keller H.; RT "Single missense mutation in the tyrosine kinase catalytic domain of the RT RET protooncogene is associated with multiple endocrine neoplasia type RT 2B."; RL Proc. Natl. Acad. Sci. U.S.A. 91:1579-1583(1994). RN [64] RP VARIANTS MTC; MEN2A AND MEN2B. RX PubMed=8625130; RX DOI=10.1002/1097-0142(19950801)76:3<479::aid-cncr2820760319>3.0.co;2-m; RA Komminoth P., Kunz E.K., Matias-Guiu X., Hiort O., Christiansen G., RA Colomer A., Roth J., Heitz P.U.; RT "Analysis of RET protooncogene point mutations distinguishes heritable from RT nonheritable medullary thyroid carcinomas."; RL Cancer 76:479-489(1995). RN [65] RP VARIANTS MEN2A SER-618; SER-620; ARG-634 AND TYR-634. RX PubMed=7860065; DOI=10.1007/bf00209399; RA Takiguchi-Shirahama S., Koyama K., Miyauchi A., Wakasugi T., Oishi S., RA Takami H., Hikiji K., Nakamura Y.; RT "Germline mutations of the RET proto-oncogene in eight Japanese patients RT with multiple endocrine neoplasia type 2A (MEN2A)."; RL Hum. Genet. 95:187-190(1995). RN [66] RP VARIANTS HSCR1 LEU-20; SER-93; GLN-330; TYR-609 AND ARG-620, AND VARIANT RP CYS-982. RC TISSUE=Blood; RX PubMed=7633441; DOI=10.1093/hmg/4.5.821; RA Angrist M., Bolk S., Thiel B., Puffenberger E.G., Hofstra R.M.W., RA Buys C.H.C.M., Cass D.T., Chakravarti A.; RT "Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung RT disease."; RL Hum. Mol. Genet. 4:821-830(1995). RN [67] RP VARIANTS HSCR1 HIS-231 AND LYS-251. RC TISSUE=Leukocyte; RX PubMed=7581377; DOI=10.1093/hmg/4.8.1381; RA Attie T., Pelet A., Edery P., Eng C., Mulligan L.M., Amiel J., Boutrand L., RA Beldjord C., Nihoul-Fekete C., Munnich A., Ponder B.A.J., Lyonnet S.; RT "Diversity of RET proto-oncogene mutations in familial and sporadic RT Hirschsprung disease."; RL Hum. Mol. Genet. 4:1381-1386(1995). RN [68] RP VARIANT MEN2B THR-918, AND VARIANT TYR-922. RX PubMed=8595427; DOI=10.1093/hmg/4.10.1987; RA Kitamura Y., Scavarda N., Wells S.A. Jr., Jackson C.E., Goodfellow P.J.; RT "Two maternally derived missense mutations in the tyrosine kinase domain of RT the RET protooncogene in a patient with de novo MEN 2B."; RL Hum. Mol. Genet. 4:1987-1988(1995). RN [69] RP VARIANT MTC ASP-768. RX PubMed=7845675; RA Eng C., Smith D.P., Mulligan L.M., Healey C.S., Zvelebil M.J., RA Stonehouse T.J., Ponder M.A., Jackson C.E., Waterfield M.D., Ponder B.A.J.; RT "A novel point mutation in the tyrosine kinase domain of the RET proto- RT oncogene in sporadic medullary thyroid carcinoma and in a family with RT FMTC."; RL Oncogene 10:509-513(1995). RN [70] RP VARIANTS MTC ASP-768 AND LEU-804. RX PubMed=7784092; RA Bolino A., Schuffenecker I., Luo Y., Seri M., Silengo M., Tocco T., RA Chabrier G., Houdent C., Murat A., Schlumberger M., Tournaire J., RA Lenoir G.M., Romeo G.; RT "RET mutations in exons 13 and 14 of FMTC patients."; RL Oncogene 10:2415-2419(1995). RN [71] RP VARIANTS HSCR1 TYR-157; LYS-359; TYR-609; ARG-620; ASN-1059 DEL AND RP PRO-1061. RA Hofstra R.M.W., Osinga J., Stulp R.P., Scheffer H., Meijers C., RA Buys C.H.C.M.; RT "Mutations in three genes are found associated with the development of RT Hirschsprung disease: RET, EDNRB and EDN3."; RL Am. J. Hum. Genet. 59:A263-A263(1996). RN [72] RP VARIANTS HSCR1 PRO-40 AND PRO-765. RX PubMed=9043870; DOI=10.1159/000472232; RA Yin L., Seri M., Barone V., Tocco T., Scaranari M., Romeo G.; RT "Prevalence and parental origin of de novo RET mutations in Hirschsprung's RT disease."; RL Eur. J. Hum. Genet. 4:356-358(1996). RN [73] RP VARIANTS MTC/MEN2A. RX PubMed=8557249; DOI=10.1007/bf00218825; RA Landsvater R.M., Jansen R.P.M., Hofstra R.M.W., Buys C.H.C.M., Lips C.J.M., RA van Amstel H.K.P.; RT "Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, RT MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A."; RL Hum. Genet. 97:11-14(1996). RN [74] RP VARIANT MTC ASP-768, VARIANTS MEN2A ARG-609; GLY-609; SER-611 AND ARG-611, RP AND VARIANT MEN2B THR-918. RX PubMed=8807338; RX DOI=10.1002/(sici)1098-1004(1996)8:1<64::aid-humu9>3.0.co;2-p; RA Kambouris M., Jackson C.E., Feldman G.L.; RT "Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial RT medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses RT of RET proto-oncogene mutations."; RL Hum. Mutat. 8:64-70(1996). RN [75] RP VARIANTS MEN2A. RX PubMed=8626834; DOI=10.1210/jcem.81.5.8626834; RA Frank-Raue K., Hoeppner W., Frilling A., Kotzerke J., Dralle H., Haase R., RA Mann K., Seif F., Kirchner R., Rendl J., Deckart H.F., Ritter M.M., RA Hampel R., Klempa J., Scholz G.H., Raue F., Bogner U., Brabant G., RA Grussendorf M., Hartenstein C.H., Heidemann P., Hensen J., Doerr A.G., RA Hoehne T., Hoernig-Franz I., Huefner M., Kress J., Langer H.J., RA Lottermoser K., Schweikert H.U., Kusterer K., Menken U., Mercier J., RA Oelkers W., Sauer J., Simon D., Starrach G., Ziegler R.; RT "Mutations of the ret protooncogene in German multiple endocrine neoplasia RT families: relation between genotype and phenotype."; RL J. Clin. Endocrinol. Metab. 81:1780-1783(1996). RN [76] RP VARIANT HSCR1 LEU-893. RX PubMed=9174404; DOI=10.1002/bies.950190506; RA Edery P., Eng C., Munnich A., Lyonnet S.; RT "RET in human development and oncogenesis."; RL Bioessays 19:389-395(1997). RN [77] RP VARIANT MEN2A HIS-GLU-LEU-CYS-634 INS. RX PubMed=9097963; DOI=10.1093/hmg/6.4.587; RA Hoeppner W., Ritter M.M.; RT "A duplication of 12 bp in the critical cysteine rich domain of the RET RT proto-oncogene results in a distinct phenotype of multiple endocrine RT neoplasia type 2A."; RL Hum. Mol. Genet. 6:587-590(1997). RN [78] RP VARIANTS HSCR1 PRO-180; GLN-313; ARG-620 AND PHE-791. RX PubMed=9090527; RX DOI=10.1002/(sici)1098-1004(1997)9:3<243::aid-humu5>3.0.co;2-8; RA Seri M., Yin L., Barone V., Bolino A., Celli I., Bocciardi R., Pasini B., RA Ceccherini I., Lerone M., Kristoffersson U., Larsson L.T., Casasa J.M., RA Cass D.T., Abramowicz M.J., Vanderwinden J.-M., Kravcenkiene I., Baric I., RA Silengo M., Martucciello G., Romeo G.; RT "Frequency of RET mutations in long- and short-segment Hirschsprung RT disease."; RL Hum. Mutat. 9:243-249(1997). RN [79] RP VARIANT MTC ARG-618, AND VARIANT HSCR1 ARG-618. RX PubMed=9259198; RX DOI=10.1002/(sici)1098-1004(1997)10:2<155::aid-humu7>3.0.co;2-j; RA Peretz H., Luboshitsky R., Baron E., Biton A., Gershoni R., Usher S., RA Grynberg E., Yakobson E., Graff E., Lapidot M.; RT "Cys 618 Arg mutation in the RET proto-oncogene associated with familial RT medullary thyroid carcinoma and maternally transmitted Hirschsprung's RT disease suggesting a role for imprinting."; RL Hum. Mutat. 10:155-159(1997). RN [80] RP VARIANT MEN2B PHE-883. RC TISSUE=Peripheral blood leukocyte; RX PubMed=9360560; DOI=10.1210/jcem.82.11.4508; RA Gimm O., Marsh D.J., Andrew S.D., Frilling A., Dahia P.L.M., Mulligan L.M., RA Zajac J.D., Robinson B.G., Eng C.; RT "Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in RT multiple endocrine neoplasia type 2B without codon 918 mutation."; RL J. Clin. Endocrinol. Metab. 82:3902-3904(1997). RN [81] RP VARIANT MTC ALA-891. RX PubMed=9398735; DOI=10.1210/jcem.82.12.4439; RA Hofstra R.M.W., Fattoruso O., Quadro L., Wu Y., Libroia A., Verga U., RA Colantuoni V., Buys C.H.C.M.; RT "A novel point mutation in the intracellular domain of the ret RT protooncogene in a family with medullary thyroid carcinoma."; RL J. Clin. Endocrinol. Metab. 82:4176-4178(1997). RN [82] RP VARIANTS HSCR1 SER-174 AND TYR-197. RX PubMed=9094028; DOI=10.1016/s0022-3468(97)90616-3; RA Kusafuka T., Wang Y., Puri P.; RT "Mutation analysis of the RET, the endothelin-B receptor, and the RT endothelin-3 genes in sporadic cases of Hirschsprung's disease."; RL J. Pediatr. Surg. 32:501-504(1997). RN [83] RP VARIANTS MTC TYR-630 AND SER-630, AND VARIANT SER-691. RX PubMed=9223675; DOI=10.1038/sj.onc.1201102; RA Kitamura Y., Goodfellow P.J., Shimizu K., Nagahama M., Ito K., Kitagawa W., RA Akasu H., Takami H., Tanaka S., Wells S.A. Jr.; RT "Novel germline RET proto-oncogene mutations associated with medullary RT thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC."; RL Oncogene 14:3103-3106(1997). RN [84] RP VARIANT MEN2B PHE-883. RX PubMed=9294615; DOI=10.1038/sj.onc.1201481; RA Smith D.P., Houghton C., Ponder B.A.J.; RT "Germline mutation of RET codon 883 in two cases of de novo MEN 2B."; RL Oncogene 15:1213-1217(1997). RN [85] RP VARIANT HSCR1 LEU-1039, AND VARIANT SER-691. RX PubMed=9497256; DOI=10.1086/301759; RA Amiel J., Salomon R., Attie T., Pelet A., Trang H., Mokhtari M., RA Gaultier C., Munnich A., Lyonnet S.; RT "Mutations of the RET-GDNF signaling pathway in Ondine's curse."; RL Am. J. Hum. Genet. 62:715-717(1998). RN [86] RP VARIANT MTC GLY-611. RX PubMed=9677065; RX DOI=10.1002/(sici)1096-8628(19980707)78:3<271::aid-ajmg13>3.0.co;2-c; RA Oriola J., Paramo C., Halperin I., Garcia-Mayor R.V., Rivera-Fillat F.; RT "Novel point mutation in exon 10 of the RET proto-oncogene in a family with RT medullary thyroid carcinoma."; RL Am. J. Med. Genet. 78:271-273(1998). RN [87] RP VARIANT CYS-982. RX PubMed=9760196; DOI=10.1007/s004390050797; RA Svensson P.J., Anvret M., Molander M.L., Nordenskjold A.; RT "Phenotypic variation in a family with mutations in two Hirschsprung- RT related genes (RET and endothelin receptor B)."; RL Hum. Genet. 103:145-148(1998). RN [88] RP VARIANTS MEN2A TYR-609; SER-618; ARG-620 AND TRP-620, AND VARIANTS HSCR1 RP TYR-609; SER-618; ARG-620 AND TRP-620. RX PubMed=9384613; DOI=10.1093/hmg/7.1.129; RA Decker R.A., Peacock M.L., Watson P.; RT "Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 RT genotypes and strong genotype-phenotype correlation."; RL Hum. Mol. Genet. 7:129-134(1998). RN [89] RP VARIANT MEN2A CYS-ARG-THR-636 INS. RX PubMed=9452064; DOI=10.1002/humu.1380110143; RA Hoeppner W., Dralle H., Brabant G.; RT "Duplication of 9 base pairs in the critical cysteine-rich domain of the RT RET proto-oncogene causes multiple endocrine neoplasia type 2A."; RL Hum. Mutat. Suppl. 1:S128-S130(1998). RN [90] RP VARIANT MTC MET-804. RX PubMed=9452077; DOI=10.1002/humu.1380110156; RA Fattoruso O., Quadro L., Libroia A., Verga U., Lupoli G., Cascone E., RA Colantuoni V.; RT "A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET RT proto-oncogene in two families affected by familial medullary thyroid RT carcinoma."; RL Hum. Mutat. Suppl. 1:S167-S171(1998). RN [91] RP VARIANTS MTC/MEN2A PHE-790 AND PHE-791. RX PubMed=9506724; DOI=10.1210/jcem.83.3.4619; RA Berndt I., Reuter M., Saller B., Frank-Raue K., Groth P., Grussendorf M., RA Raue F., Ritter M.M., Hoeppner W.; RT "A new hot spot for mutations in the ret protooncogene causing familial RT medullary thyroid carcinoma and multiple endocrine neoplasia type 2A."; RL J. Clin. Endocrinol. Metab. 83:770-774(1998). RN [92] RP VARIANTS MTC AND MEN2A. RX PubMed=9621513; DOI=10.1007/s100380050048; RA Shirahama S., Ogura K., Takami H., Ito K., Tohsen T., Miyauchi A., RA Nakamura Y.; RT "Mutational analysis of the RET proto-oncogene in 71 Japanese patients with RT medullary thyroid carcinoma."; RL J. Hum. Genet. 43:101-106(1998). RN [93] RP VARIANTS HSCR1 LYS-626 AND GLN-813. RX PubMed=10090908; DOI=10.1086/302329; RA Auricchio A., Griseri P., Carpentieri M.L., Betsos N., Staiano A., RA Tozzi A., Priolo M., Thompson H., Bocciardi R., Romeo G., Ballabio A., RA Ceccherini I.; RT "Double heterozygosity for a RET substitution interfering with splicing and RT an EDNRB missense mutation in Hirschsprung disease."; RL Am. J. Hum. Genet. 64:1216-1221(1999). RN [94] RP VARIANTS HSCR1 ASN-1059 DEL AND PRO-1061. RX PubMed=10484767; DOI=10.1093/hmg/8.11.1989; RA Geneste O., Bidaud C., De Vita G., Hofstra R.M.W., Tartare-Deckert S., RA Buys C.H.C.M., Lenoir G.M., Santoro M., Billaud M.; RT "Two distinct mutations of the RET receptor causing Hirschsprung's disease RT impair the binding of signalling effectors to a multifunctional docking RT site."; RL Hum. Mol. Genet. 8:1989-1999(1999). RN [95] RP VARIANT MTC GLU-GLU-CYS-531 INS. RX PubMed=10323403; DOI=10.1210/jcem.84.5.5665; RA Pigny P., Bauters C., Wemeau J.-L., Houcke M.L., Crepin M., Caron P., RA Giraud S., Calender A., Buisine M.-P., Kerckaert J.-P., Porchet N.; RT "A novel 9-base pair duplication in RET exon 8 in familial medullary RT thyroid carcinoma."; RL J. Clin. Endocrinol. Metab. 84:1700-1704(1999). RN [96] RP VARIANT MEN2A GLY-640. RX PubMed=10522989; DOI=10.1210/jcem.84.10.6056; RA Tessitore A., Sinisi A.A., Pasquali D., Cardone M., Vitale D., RA Bellastella A., Colantuoni V.; RT "A novel case of multiple endocrine neoplasia type 2A associated with two RT de novo mutations of the RET protooncogene."; RL J. Clin. Endocrinol. Metab. 84:3522-3527(1999). RN [97] RP VARIANTS HSCR1 GLN-287; PRO-690; ARG-767 AND GLN-873. RX PubMed=10664228; DOI=10.1007/s004310050043; RA Sakai T., Nirasawa Y., Itoh Y., Wakizaka A.; RT "Japanese patients with sporadic Hirschsprung: mutation analysis of the RT receptor tyrosine kinase proto-oncogene, endothelin-B receptor, endothelin- RT 3, glial cell line-derived neurotrophic factor and neurturin genes: a RT comparison with similar studies."; RL Eur. J. Pediatr. 159:160-167(2000). RN [98] RP VARIANTS MTC MET-804 AND LEU-844. RX PubMed=10826520; DOI=10.1055/s-2000-5806; RA Bartsch D.K., Hasse C., Schug C., Barth P., Rothmund M., Hoeppner W.; RT "A RET double mutation in the germline of a kindred with FMTC."; RL Exp. Clin. Endocrinol. Diabetes 108:128-132(2000). RN [99] RP VARIANT GLN-600. RX PubMed=10612852; RX DOI=10.1002/(sici)1098-1004(200001)15:1<122::aid-humu41>3.0.co;2-7; RA Saez M.E., Ruiz A., Cebrian A., Morales F., Robledo M., Antinolo G., RA Borrego S.; RT "A new germline mutation, R600Q, within the coding region of RET proto- RT oncogene: a rare polymorphism or a MEN 2 causing mutation?"; RL Hum. Mutat. 15:122-122(2000). RN [100] RP VARIANT HSCR1 GLU-907. RX PubMed=10790203; RX DOI=10.1002/(sici)1098-1004(200005)15:5<418::aid-humu3>3.0.co;2-2; RA Hofstra R.M., Wu Y., Stulp R.P., Elfferich P., Osinga J., Maas S.M., RA Siderius L., Brooks A.S., vd Ende J.J., Heydendael V.M., Severijnen R.S., RA Bax K.M., Meijers C., Buys C.H.; RT "RET and GDNF gene scanning in Hirschsprung patients using two dual RT denaturing gel systems."; RL Hum. Mutat. 15:418-429(2000). RN [101] RP VARIANTS HSCR1 LEU-32; CYS-77; TRP-360 AND LYS-394. RX PubMed=10618407; DOI=10.1073/pnas.97.1.268; RA Bolk S., Pelet A., Hofstra R.M.W., Angrist M., Salomon R., Croaker D., RA Buys C.H.C.M., Lyonnet S., Chakravarti A.; RT "A human model for multigenic inheritance: phenotypic expression in RT Hirschsprung disease requires both the RET gene and a new 9q31 locus."; RL Proc. Natl. Acad. Sci. U.S.A. 97:268-273(2000). RN [102] RP VARIANTS MTC GLY-639; GLY-641 AND PHE-922. RX PubMed=11692159; DOI=10.1007/s001090100250; RA Kalinin V.N., Amosenko F.A., Shabanov M.A., Lubchenko L.N., Hosch S.B., RA Garkavtseva R.F., Izbicki J.R.; RT "Three novel mutations in the RET proto-oncogene."; RL J. Mol. Med. 79:609-612(2001). RN [103] RP VARIANTS PHEOCHROMOCYTOMA ARG-634; GLY-634; TYR-634; SER-634; PHE-634; RP TRP-634 AND PHE-791. RX PubMed=12000816; DOI=10.1056/nejmoa020152; RG The Freiburg-Warsaw-Columbus pheochromocytoma study group; RA Neumann H.P.H., Bausch B., McWhinney S.R., Bender B.U., Gimm O., Franke G., RA Schipper J., Klisch J., Altehoefer C., Zerres K., Januszewicz A., RA Smith W.M., Munk R., Manz T., Glaesker S., Apel T.W., Treier M., RA Reineke M., Walz M.K., Hoang-Vu C., Brauckhoff M., Klein-Franke A., RA Klose P., Schmidt H., Maier-Woelfle M., Peczkowska M., Szmigielski C., RA Eng C.; RT "Germ-line mutations in nonsyndromic pheochromocytoma."; RL N. Engl. J. Med. 346:1459-1466(2002). RN [104] RP VARIANT HIS-114. RX PubMed=12086152; DOI=10.1620/tjem.196.241; RA Kanai M., Numakura C., Sasaki A., Shirahata E., Akaba K., Hashimoto M., RA Hasegawa H., Shirasawa S., Hayasaka K.; RT "Congenital central hypoventilation syndrome: a novel mutation of the RET RT gene in an isolated case."; RL Tohoku J. Exp. Med. 196:241-246(2002). RN [105] RP VARIANTS HIS-67; HIS-114; GLU-432; ASN-489; SER-691 AND CYS-982. RX PubMed=14566559; DOI=10.1007/s00439-003-1036-z; RA Sasaki A., Kanai M., Kijima K., Akaba K., Hashimoto M., Hasegawa H., RA Otaki S., Koizumi T., Kusuda S., Ogawa Y., Tuchiya K., Yamamoto W., RA Nakamura T., Hayasaka K.; RT "Molecular analysis of congenital central hypoventilation syndrome."; RL Hum. Genet. 114:22-26(2003). RN [106] RP VARIANTS [LARGE SCALE ANALYSIS] GLY-145; TRP-360 AND GLU-593. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [107] RP VARIANTS [LARGE SCALE ANALYSIS] GLN-163; ASN-278; MET-292; ASN-489; RP SER-691; THR-749; SER-826; LEU-844; CYS-982 AND TYR-1112. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [108] RP VARIANTS THR-198; ALA-376; HIS-394; ILE-778; SER-894; THR-918; LEU-1049 AND RP SER-1067, POSSIBLE INVOLVEMENT IN RENAL AGENESIS, AND CHARACTERIZATION OF RP VARIANTS THR-198; ALA-376; HIS-394; ILE-778; SER-894; LEU-1049 AND RP SER-1067. RX PubMed=18252215; DOI=10.1016/j.ajhg.2007.10.008; RA Skinner M.A., Safford S.D., Reeves J.G., Jackson M.E., Freemerman A.J.; RT "Renal aplasia in humans is associated with RET mutations."; RL Am. J. Hum. Genet. 82:344-351(2008). RN [109] RP VARIANTS HSCR1 549-LYS-GLY-550 DEL; CYS-114; GLY-145; LEU-155; PRO-175; RP ALA-278; PRO-278; ASN-300; GLN-313; ILE-316; LEU-339; TYR-353; GLN-360; RP MET-397; MET-412; ARG-423; LYS-480; GLN-595; LEU-679; GLN-694; SER-783; RP ARG-830; THR-907; LEU-961; VAL-1052; CYS-1062 AND THR-1064, AND VARIANTS RP HIS-114; ASN-278 AND MET-292. RX PubMed=22174939; DOI=10.1371/journal.pone.0028986; RA So M.T., Leon T.Y., Cheng G., Tang C.S., Miao X.P., Cornes B.K., Diem N.N., RA Cui L., Ngan E.S., Lui V.C., Wu X.Z., Wang B., Wang H., Yuan Z.W., RA Huang L.M., Li L., Xia H., Zhu D., Liu J., Nguyen T.L., Chan I.H., RA Chung P.H., Liu X.L., Zhang R., Wong K.K., Sham P.C., Cherny S.S., RA Tam P.K., Garcia-Barcelo M.M.; RT "RET mutational spectrum in Hirschsprung disease: evaluation of 601 Chinese RT patients."; RL PLoS ONE 6:E28986-E28986(2011). RN [110] RP ACTIVITY REGULATION, VARIANTS ILE-730; VAL-730; LYS-732; ALA-738; ASN-806; RP VAL-807; ALA-810; SER-810; ILE-871 AND VAL-998, CHARACTERIZATION OF RP VARIANTS ILE-730; VAL-730; LYS-732; ALA-738; ASN-806; VAL-807; ALA-810; RP SER-810; ILE-871 AND VAL-998, VARIANTS MTC LEU-804; MET-804 AND THR-918, RP AND CHARACTERIZATION OF VARIANTS MTC LEU-804; MET-804 AND THR-918. RX PubMed=29908090; DOI=10.1111/bph.14395; RA Liu X., Shen T., Mooers B.H.M., Hilberg F., Wu J.; RT "Drug resistance profiles of mutations in the RET kinase domain."; RL Br. J. Pharmacol. 175:3504-3515(2018). CC -!- FUNCTION: Receptor tyrosine-protein kinase involved in numerous CC cellular mechanisms including cell proliferation, neuronal navigation, CC cell migration, and cell differentiation in response to glia cell line- CC derived growth family factors (GDNF, NRTN, ARTN, PSPN and GDF15) CC (PubMed:20064382, PubMed:20616503, PubMed:20702524, PubMed:21357690, CC PubMed:21454698, PubMed:24560924, PubMed:28846097, PubMed:28846099, CC PubMed:28953886, PubMed:31118272). In contrast to most receptor CC tyrosine kinases, RET requires not only its cognate ligands but also CC coreceptors, for activation (PubMed:21994944, PubMed:23333276, CC PubMed:28846097, PubMed:28846099, PubMed:28953886). GDNF ligands (GDNF, CC NRTN, ARTN, PSPN and GDF15) first bind their corresponding GDNFR CC coreceptors (GFRA1, GFRA2, GFRA3, GFRA4 and GFRAL, respectively), CC triggering RET autophosphorylation and activation, leading to CC activation of downstream signaling pathways, including the MAPK- and CC AKT-signaling pathways (PubMed:21994944, PubMed:23333276, CC PubMed:24560924, PubMed:25242331, PubMed:28846097, PubMed:28846099, CC PubMed:28953886). Acts as a dependence receptor via the GDNF-GFRA1 CC signaling: in the presence of the ligand GDNF in somatotrophs within CC pituitary, promotes survival and down regulates growth hormone (GH) CC production, but triggers apoptosis in absence of GDNF (PubMed:20616503, CC PubMed:21994944). Required for the molecular mechanisms orchestration CC during intestine organogenesis via the ARTN-GFRA3 signaling: involved CC in the development of enteric nervous system and renal organogenesis CC during embryonic life, and promotes the formation of Peyer's patch-like CC structures, a major component of the gut-associated lymphoid tissue (By CC similarity). Mediates, through interaction with GDF15-receptor GFRAL, CC GDF15-induced cell-signaling in the brainstem which triggers an CC aversive response, characterized by nausea, vomiting, and/or loss of CC appetite in response to various stresses (PubMed:28846097, CC PubMed:28846099, PubMed:28953886). Modulates cell adhesion via its CC cleavage by caspase in sympathetic neurons and mediates cell migration CC in an integrin (e.g. ITGB1 and ITGB3)-dependent manner CC (PubMed:20702524, PubMed:21357690). Also active in the absence of CC ligand, triggering apoptosis through a mechanism that requires receptor CC intracellular caspase cleavage (PubMed:21357690). Triggers the CC differentiation of rapidly adapting (RA) mechanoreceptors CC (PubMed:20064382). Involved in the development of the neural crest (By CC similarity). Regulates nociceptor survival and size (By similarity). CC Phosphorylates PTK2/FAK1 (PubMed:21454698). CC {ECO:0000250|UniProtKB:P35546, ECO:0000269|PubMed:20064382, CC ECO:0000269|PubMed:20616503, ECO:0000269|PubMed:20702524, CC ECO:0000269|PubMed:21357690, ECO:0000269|PubMed:21454698, CC ECO:0000269|PubMed:21994944, ECO:0000269|PubMed:23333276, CC ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:25242331, CC ECO:0000269|PubMed:28846097, ECO:0000269|PubMed:28846099, CC ECO:0000269|PubMed:28953886, ECO:0000269|PubMed:31118272}. CC -!- FUNCTION: [Isoform 1]: Isoform 1 in complex with GFRAL induces higher CC activation of MAPK-signaling pathway than isoform 2 in complex with CC GFRAL. {ECO:0000269|PubMed:28846099}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:28846099}; CC -!- COFACTOR: CC Name=Ca(2+); Xref=ChEBI:CHEBI:29108; CC Evidence={ECO:0000269|PubMed:11445581, ECO:0000269|PubMed:25242331, CC ECO:0000269|PubMed:31535977, ECO:0000269|PubMed:9575150}; CC -!- ACTIVITY REGULATION: Repressed by 4-(3-hydroxyanilino)-quinolines CC derivatives, indolin-2-one-derivatives, 2-(alkylsulfanyl)-4-(3-thienyl) CC nicotinonitrile analogs, 3- and 4-substituted beta-carbolin-1-ones, CC vandetanib, motesanib, sorafenib (BAY 43-9006), cabozantinib (XL184), CC lenvatinib, sunitinib, nintedanib, and withaferin A (WA) CC (PubMed:17664273, PubMed:17884497, PubMed:19053769, PubMed:20117004, CC PubMed:20409618, PubMed:20605972, PubMed:21134556, PubMed:29908090, CC PubMed:31118272). Inactivation by sorafenib both reduces kinase CC activity and promotes lysosomal degradation (PubMed:17664273). CC {ECO:0000269|PubMed:17664273, ECO:0000269|PubMed:17884497, CC ECO:0000269|PubMed:19053769, ECO:0000269|PubMed:20117004, CC ECO:0000269|PubMed:20409618, ECO:0000269|PubMed:20605972, CC ECO:0000269|PubMed:21134556, ECO:0000269|PubMed:29908090, CC ECO:0000269|PubMed:31118272}. CC -!- SUBUNIT: Phosphorylated form interacts with the PBT domain of DOK2, CC DOK4 and DOK5 (By similarity). The phosphorylated form interacts with CC PLCG1 and GRB7 (By similarity). Interacts (not phosphorylated) with CC PTK2/FAK1 (via FERM domain) (PubMed:21454698). Extracellular cell- CC membrane anchored RET cadherin fragments form complex in neurons with CC reduced trophic status, preferentially at the contact sites between CC somas (PubMed:21357690). Interacts with AIP in the pituitary gland; CC this interaction prevents the formation of the AIP-survivin complex CC (PubMed:19366855). Interacts (inactive) with CBLC and CD2AP; CC dissociates upon activation by GDNF which increases CBLC:CD2AP CC interaction (PubMed:18753381). {ECO:0000250|UniProtKB:P35546, CC ECO:0000269|PubMed:18753381, ECO:0000269|PubMed:19366855, CC ECO:0000269|PubMed:21357690, ECO:0000269|PubMed:21454698}. CC -!- INTERACTION: CC P07949; Q9UM73: ALK; NbExp=2; IntAct=EBI-2480756, EBI-357361; CC P07949; P22681: CBL; NbExp=8; IntAct=EBI-2480756, EBI-518228; CC P07949; P62861: FAU; NbExp=4; IntAct=EBI-2480756, EBI-358093; CC P07949; P22455: FGFR4; NbExp=2; IntAct=EBI-2480756, EBI-6256193; CC P07949; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-2480756, EBI-945833; CC P07949; P40763: STAT3; NbExp=3; IntAct=EBI-2480756, EBI-518675; CC P07949; Q9Y490: TLN1; NbExp=2; IntAct=EBI-2480756, EBI-2462036; CC P07949; Q62985: Sh2b1; Xeno; NbExp=3; IntAct=EBI-2480756, EBI-7395583; CC P07949-2; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-4423689, EBI-945833; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:19823924, CC ECO:0000269|PubMed:21994944, ECO:0000269|PubMed:23333276, CC ECO:0000269|PubMed:28953886, ECO:0000269|PubMed:9575150}; Single-pass CC type I membrane protein {ECO:0000269|PubMed:19823924}. Endosome CC membrane {ECO:0000269|PubMed:19823924, ECO:0000269|PubMed:23333276}; CC Single-pass type I membrane protein {ECO:0000269|PubMed:19823924}. CC Note=Predominantly located on the plasma membrane (PubMed:23333276, CC PubMed:9575150). In the presence of SORL1 and GFRA1, directed to CC endosomes (PubMed:23333276). {ECO:0000269|PubMed:23333276, CC ECO:0000269|PubMed:9575150}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=RET51; CC IsoId=P07949-1; Sequence=Displayed; CC Name=2; Synonyms=RET9; CC IsoId=P07949-2; Sequence=VSP_040735; CC -!- INDUCTION: Positively regulated by NKX2-1, PHOX2B, SOX10 and PAX3. CC {ECO:0000269|PubMed:19853745}. CC -!- PTM: Autophosphorylated on C-terminal tyrosine residues upon ligand CC stimulation. {ECO:0000269|PubMed:11061555, ECO:0000269|PubMed:14711813, CC ECO:0000269|PubMed:16928683, ECO:0000269|PubMed:20117004, CC ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:28846099}. CC -!- PTM: Proteolytically cleaved by caspase-3. The soluble RET kinase CC fragment is able to induce cell death. The extracellular cell-membrane CC anchored RET cadherin fragment accelerates cell adhesion in sympathetic CC neurons. {ECO:0000269|PubMed:21357690}. CC -!- DISEASE: Hirschsprung disease 1 (HSCR1) [MIM:142623]: A disorder of CC neural crest development characterized by absence of enteric ganglia CC along a variable length of the intestine. It is the most common cause CC of congenital intestinal obstruction. Early symptoms range from CC complete acute neonatal obstruction, characterized by vomiting, CC abdominal distention and failure to pass stool, to chronic constipation CC in the older child. {ECO:0000269|PubMed:10090908, CC ECO:0000269|PubMed:10484767, ECO:0000269|PubMed:10618407, CC ECO:0000269|PubMed:10664228, ECO:0000269|PubMed:10790203, CC ECO:0000269|PubMed:22174939, ECO:0000269|PubMed:7581377, CC ECO:0000269|PubMed:7633441, ECO:0000269|PubMed:7704557, CC ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7997019, CC ECO:0000269|PubMed:8114938, ECO:0000269|PubMed:8114939, CC ECO:0000269|PubMed:9043870, ECO:0000269|PubMed:9090527, CC ECO:0000269|PubMed:9094028, ECO:0000269|PubMed:9174404, CC ECO:0000269|PubMed:9259198, ECO:0000269|PubMed:9384613, CC ECO:0000269|PubMed:9497256, ECO:0000269|Ref.71}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- DISEASE: Medullary thyroid carcinoma (MTC) [MIM:155240]: Rare tumor CC derived from the C cells of the thyroid. Three hereditary forms are CC known, that are transmitted in an autosomal dominant fashion: (a) CC multiple neoplasia type 2A (MEN2A), (b) multiple neoplasia type IIB CC (MEN2B) and (c) familial MTC (FMTC), which occurs in 25-30% of MTC CC cases and where MTC is the only clinical manifestation. CC {ECO:0000269|PubMed:10323403, ECO:0000269|PubMed:10826520, CC ECO:0000269|PubMed:11692159, ECO:0000269|PubMed:24560924, CC ECO:0000269|PubMed:29908090, ECO:0000269|PubMed:31118272, CC ECO:0000269|PubMed:7784092, ECO:0000269|PubMed:7845675, CC ECO:0000269|PubMed:7849720, ECO:0000269|PubMed:7874109, CC ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7915165, CC ECO:0000269|PubMed:8103403, ECO:0000269|PubMed:8557249, CC ECO:0000269|PubMed:8625130, ECO:0000269|PubMed:8807338, CC ECO:0000269|PubMed:9223675, ECO:0000269|PubMed:9259198, CC ECO:0000269|PubMed:9398735, ECO:0000269|PubMed:9452077, CC ECO:0000269|PubMed:9506724, ECO:0000269|PubMed:9621513, CC ECO:0000269|PubMed:9677065}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Multiple neoplasia 2B (MEN2B) [MIM:162300]: Uncommon inherited CC cancer syndrome characterized by predisposition to MTC and CC phaeochromocytoma which is associated with marfanoid habitus, mucosal CC neuromas, skeletal and ophthalmic abnormalities, and ganglioneuromas of CC the intestine tract. Then the disease progresses rapidly with the CC development of metastatic MTC and a pheochromocytome in 50% of cases. CC {ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:7906417, CC ECO:0000269|PubMed:7906866, ECO:0000269|PubMed:7911697, CC ECO:0000269|PubMed:8595427, ECO:0000269|PubMed:8807338, CC ECO:0000269|PubMed:9294615, ECO:0000269|PubMed:9360560}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Pheochromocytoma (PCC) [MIM:171300]: A catecholamine-producing CC tumor of chromaffin tissue of the adrenal medulla or sympathetic CC paraganglia. The cardinal symptom, reflecting the increased secretion CC of epinephrine and norepinephrine, is hypertension, which may be CC persistent or intermittent. {ECO:0000269|PubMed:12000816}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Multiple neoplasia 2A (MEN2A) [MIM:171400]: The most frequent CC form of medullary thyroid cancer (MTC). It is an inherited cancer CC syndrome characterized by MTC, phaeochromocytoma and/or CC hyperparathyroidism. {ECO:0000269|PubMed:10522989, CC ECO:0000269|PubMed:7860065, ECO:0000269|PubMed:7874109, CC ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7915165, CC ECO:0000269|PubMed:8099202, ECO:0000269|PubMed:8103403, CC ECO:0000269|PubMed:8626834, ECO:0000269|PubMed:8807338, CC ECO:0000269|PubMed:9067749, ECO:0000269|PubMed:9097963, CC ECO:0000269|PubMed:9384613, ECO:0000269|PubMed:9452064}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=Various chromosomal aberrations involving RET are known. CC Some of them have been found in papillary thyroid carcinomas (PTCs) CC (PubMed:10439047, PubMed:10980597, PubMed:12787916, PubMed:2406025). CC Inversion inv(10)(q11.2;q21) generates the RET/CCDC6 (PTC1) oncogene CC (PubMed:2406025). Inversion inv(10)(q11.2;q11.2) generates the CC RET/NCOA4 (PTC3) oncogene. Translocation t(10;14)(q11;q32) with GOLGA5 CC generates the RET/GOLGA5 (PTC5) oncogene (PubMed:2734021). CC Translocation t(8;10)(p21.3;q11.2) with PCM1 generates the PCM1/RET CC fusion (PubMed:10980597). Translocation t(6;10)(p21.3;q11.2) with CC TRIM27/RFP generates the Delta RFP/RET oncogene (PubMed:12787916). CC Translocation t(1;10)(p13;q11) with TRIM33 generates the TRIM33/RET CC (PTC7) oncogene (PubMed:10439047). Translocation t(7;10)(q32;q11) with CC TRIM24/TIF1 generates the TRIM24/RET (PTC6) oncogene (PubMed:10439047). CC Translocation t(6;10)(p21.3;q11.2) with TRIM27/RFP generates the CC TRIM27/RET oncogene (PubMed:3037315). {ECO:0000269|PubMed:10439047, CC ECO:0000269|PubMed:10980597, ECO:0000269|PubMed:12787916, CC ECO:0000269|PubMed:2406025, ECO:0000269|PubMed:2734021, CC ECO:0000269|PubMed:3037315}. CC -!- DISEASE: Note=Mutations in RET have been detected in patients with CC renal agenesis suggesting a possible involvement of this gene in CC disease pathogenesis. {ECO:0000269|PubMed:18252215}. CC -!- MISCELLANEOUS: Treatment with withaferin A (WA) leads tumor regression CC in medullary thyroid carcinomas (MTC). CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- CAUTION: Original thought to be dephosphorylated by PTPRJ on Tyr-905, CC Tyr-1015 and Tyr-1062. However this paper was retracted due to CC manipulation of immunoblot data. {ECO:0000305|PubMed:16778204, CC ECO:0000305|PubMed:30552125}. CC -!- SEQUENCE CAUTION: CC Sequence=AAA36524.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=AAA36786.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAA33787.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAC14882.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/76/RET"; CC -!- WEB RESOURCE: Name=MEN2 RET database; CC URL="http://www.arup.utah.edu/database/MEN2/MEN2_welcome.php"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK291807; BAF84496.1; -; mRNA. DR EMBL; AC010864; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC004257; AAH04257.1; -; mRNA. DR EMBL; X15262; CAA33333.1; -; mRNA. DR EMBL; X12949; CAA31408.1; -; mRNA. DR EMBL; M16029; AAA36786.1; ALT_INIT; mRNA. DR EMBL; X15786; CAA33787.1; ALT_INIT; mRNA. DR EMBL; M31213; AAA36524.1; ALT_INIT; mRNA. DR EMBL; AJ297349; CAC14882.1; ALT_INIT; mRNA. DR CCDS; CCDS53525.1; -. [P07949-2] DR CCDS; CCDS7200.1; -. [P07949-1] DR PIR; A27203; TVHURE. DR PIR; A34630; A34630. DR PIR; B34735; B34735. DR PIR; S05582; S05582. DR RefSeq; NP_001393672.1; NM_001406743.1. [P07949-1] DR RefSeq; NP_065681.1; NM_020630.7. [P07949-2] DR RefSeq; NP_066124.1; NM_020975.6. [P07949-1] DR PDB; 2IVS; X-ray; 2.00 A; A/B=705-1013. DR PDB; 2IVT; X-ray; 2.60 A; A=705-1013. DR PDB; 2IVU; X-ray; 2.50 A; A=705-1013. DR PDB; 2IVV; X-ray; 2.25 A; A=705-1013. DR PDB; 2X2K; X-ray; 2.60 A; A=705-1013. DR PDB; 2X2L; X-ray; 2.00 A; A=705-1013. DR PDB; 2X2M; X-ray; 2.50 A; A/B=705-1013. DR PDB; 2X2U; X-ray; 2.00 A; A=29-270. DR PDB; 4CKI; X-ray; 2.12 A; A=705-1013. DR PDB; 4CKJ; X-ray; 1.65 A; A=705-1013. DR PDB; 4UX8; EM; 24.00 A; A/B=29-635. DR PDB; 5AMN; X-ray; 2.57 A; A=705-1012. DR PDB; 5FM2; X-ray; 3.30 A; A=659-1013. DR PDB; 5FM3; X-ray; 2.95 A; A=659-1013. DR PDB; 6FEK; X-ray; 2.30 A; A=705-1013. DR PDB; 6GL7; EM; 6.30 A; E/F=29-635. DR PDB; 6I82; X-ray; 2.05 A; A/B=705-1013. DR PDB; 6I83; X-ray; 1.88 A; A=705-1013. DR PDB; 6NE7; X-ray; 1.99 A; A=705-1013. DR PDB; 6NEC; X-ray; 1.87 A; A/C=705-1013. DR PDB; 6NJA; X-ray; 1.92 A; A=705-1013. DR PDB; 6Q2J; EM; 4.10 A; E/F=29-635. DR PDB; 6Q2N; EM; 4.40 A; E/F=29-635. DR PDB; 6Q2O; EM; 3.65 A; E/F=29-635. DR PDB; 6Q2R; EM; 4.30 A; E/F/Y/Z=29-635. DR PDB; 6Q2S; EM; 3.80 A; E/F=29-635. DR PDB; 6VHG; X-ray; 2.30 A; A=705-1013. DR PDB; 7DU8; X-ray; 2.75 A; A/B=705-1013. DR PDB; 7DU9; X-ray; 2.31 A; A/B=705-1013. DR PDB; 7DUA; X-ray; 1.64 A; A/B=705-1013. DR PDB; 7JU5; X-ray; 1.90 A; A/B=705-1013. DR PDB; 7JU6; X-ray; 2.06 A; A/B=705-1013. DR PDB; 7NZN; X-ray; 2.39 A; A=705-1013. DR PDB; 7RUN; X-ray; 3.51 A; A/B=705-1013. DR PDBsum; 2IVS; -. DR PDBsum; 2IVT; -. DR PDBsum; 2IVU; -. DR PDBsum; 2IVV; -. DR PDBsum; 2X2K; -. DR PDBsum; 2X2L; -. DR PDBsum; 2X2M; -. DR PDBsum; 2X2U; -. DR PDBsum; 4CKI; -. DR PDBsum; 4CKJ; -. DR PDBsum; 4UX8; -. DR PDBsum; 5AMN; -. DR PDBsum; 5FM2; -. DR PDBsum; 5FM3; -. DR PDBsum; 6FEK; -. DR PDBsum; 6GL7; -. DR PDBsum; 6I82; -. DR PDBsum; 6I83; -. DR PDBsum; 6NE7; -. DR PDBsum; 6NEC; -. DR PDBsum; 6NJA; -. DR PDBsum; 6Q2J; -. DR PDBsum; 6Q2N; -. DR PDBsum; 6Q2O; -. DR PDBsum; 6Q2R; -. DR PDBsum; 6Q2S; -. DR PDBsum; 6VHG; -. DR PDBsum; 7DU8; -. DR PDBsum; 7DU9; -. DR PDBsum; 7DUA; -. DR PDBsum; 7JU5; -. DR PDBsum; 7JU6; -. DR PDBsum; 7NZN; -. DR PDBsum; 7RUN; -. DR AlphaFoldDB; P07949; -. DR EMDB; EMD-0026; -. DR EMDB; EMD-11777; -. DR EMDB; EMD-20572; -. DR EMDB; EMD-20575; -. DR EMDB; EMD-20576; -. DR EMDB; EMD-20578; -. DR EMDB; EMD-20579; -. DR EMDB; EMD-2712; -. DR SMR; P07949; -. DR BioGRID; 111911; 272. DR CORUM; P07949; -. DR DIP; DIP-41449N; -. DR FunCoup; P07949; 619. DR IntAct; P07949; 231. DR MINT; P07949; -. DR STRING; 9606.ENSP00000347942; -. DR BindingDB; P07949; -. DR ChEMBL; CHEMBL2041; -. DR DrugBank; DB01809; 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine. DR DrugBank; DB15068; Agerafenib. DR DrugBank; DB12742; Amuvatinib. DR DrugBank; DB08875; Cabozantinib. DR DrugBank; DB12147; Erdafitinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB00619; Imatinib. DR DrugBank; DB09078; Lenvatinib. DR DrugBank; DB08901; Ponatinib. DR DrugBank; DB15822; Pralsetinib. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB15685; Selpercatinib. DR DrugBank; DB06436; Semaxanib. DR DrugBank; DB15036; Sitravatinib. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB07159; Tamatinib. DR DrugBank; DB05294; Vandetanib. DR DrugBank; DB05014; XL999. DR DrugCentral; P07949; -. DR GuidetoPHARMACOLOGY; 2185; -. DR TCDB; 8.A.23.1.44; the basigin (basigin) family. DR GlyCosmos; P07949; 12 sites, No reported glycans. DR GlyGen; P07949; 19 sites, 4 N-linked glycans (4 sites). DR iPTMnet; P07949; -. DR PhosphoSitePlus; P07949; -. DR BioMuta; RET; -. DR DMDM; 547807; -. DR CPTAC; CPTAC-3059; -. DR jPOST; P07949; -. DR MassIVE; P07949; -. DR PaxDb; 9606-ENSP00000347942; -. DR PeptideAtlas; P07949; -. DR ProteomicsDB; 52047; -. [P07949-1] DR ProteomicsDB; 52048; -. [P07949-2] DR TopDownProteomics; P07949-2; -. [P07949-2] DR Antibodypedia; 1904; 1292 antibodies from 41 providers. DR DNASU; 5979; -. DR Ensembl; ENST00000340058.6; ENSP00000344798.4; ENSG00000165731.23. [P07949-2] DR Ensembl; ENST00000355710.8; ENSP00000347942.3; ENSG00000165731.23. [P07949-1] DR GeneID; 5979; -. DR KEGG; hsa:5979; -. DR MANE-Select; ENST00000355710.8; ENSP00000347942.3; NM_020975.6; NP_066124.1. DR UCSC; uc001jak.2; human. [P07949-1] DR AGR; HGNC:9967; -. DR CIViC; 5979; 1 clinical assertion and 61 evidence items across 114 molecular profiles. DR ClinPGx; PA34335; -. DR CTD; 5979; -. DR DisGeNET; 5979; -. DR GeneCards; RET; -. DR GeneReviews; RET; -. DR HGNC; HGNC:9967; RET. DR HPA; ENSG00000165731; Tissue enhanced (adrenal gland, brain, parathyroid gland). DR MalaCards; RET; -. DR MIM; 114500; phenotype. DR MIM; 142623; phenotype. DR MIM; 155240; phenotype. DR MIM; 162300; phenotype. DR MIM; 164761; gene. DR MIM; 171300; phenotype. DR MIM; 171400; phenotype. DR OpenTargets; ENSG00000165731; -. DR Orphanet; 146; Differentiated thyroid carcinoma. DR Orphanet; 99803; Haddad syndrome. DR Orphanet; 29072; Hereditary pheochromocytoma-paraganglioma. DR Orphanet; 388; Hirschsprung disease. DR Orphanet; 99361; Isolated familial medullary thyroid carcinoma. DR Orphanet; 247698; Multiple endocrine neoplasia type 2A. DR Orphanet; 247709; Multiple endocrine neoplasia type 2B. DR Orphanet; 1848; Renal agenesis, bilateral. DR Orphanet; 93100; Renal agenesis, unilateral. DR Orphanet; 276621; Sporadic pheochromocytoma/secreting paraganglioma. DR VEuPathDB; HostDB:ENSG00000165731; -. DR eggNOG; KOG0200; Eukaryota. DR GeneTree; ENSGT00940000158499; -. DR HOGENOM; CLU_009530_0_0_1; -. DR InParanoid; P07949; -. DR OMA; VENQDPH; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P07949; 7 GO annotations based on evolutionary models. DR PhylomeDB; P07949; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P07949; -. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-8853659; RET signaling. DR Reactome; R-HSA-9768919; NPAS4 regulates expression of target genes. DR Reactome; R-HSA-9830364; Formation of the nephric duct. DR Reactome; R-HSA-9830674; Formation of the ureteric bud. DR SignaLink; P07949; -. DR SIGNOR; P07949; -. DR Agora; ENSG00000165731; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 5979; 18 hits in 1194 CRISPR screens. DR ChiTaRS; RET; human. DR EvolutionaryTrace; P07949; -. DR GeneWiki; RET_proto-oncogene; -. DR GenomeRNAi; 5979; -. DR Pharos; P07949; Tclin. DR PRO; PR:P07949; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; P07949; protein. DR Bgee; ENSG00000165731; Expressed in substantia nigra pars reticulata and 130 other cell types or tissues. DR ExpressionAtlas; P07949; baseline and differential. DR GO; GO:0030424; C:axon; IBA:GO_Central. DR GO; GO:0010008; C:endosome membrane; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0098797; C:plasma membrane protein complex; IDA:CAFA. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; TAS:ProtInc. DR GO; GO:0038023; F:signaling receptor activity; TAS:ProtInc. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0007411; P:axon guidance; TAS:Reactome. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL. DR GO; GO:0001838; P:embryonic epithelial tube formation; IEA:Ensembl. DR GO; GO:0048484; P:enteric nervous system development; IEA:Ensembl. DR GO; GO:0160144; P:GDF15-GFRAL signaling pathway; IDA:UniProt. DR GO; GO:0035860; P:glial cell-derived neurotrophic factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; IEA:InterPro. DR GO; GO:0097021; P:lymphocyte migration into lymphoid organs; ISS:UniProtKB. DR GO; GO:0000165; P:MAPK cascade; IEA:Ensembl. DR GO; GO:0033619; P:membrane protein proteolysis; IDA:UniProtKB. DR GO; GO:0001755; P:neural crest cell migration; IEA:Ensembl. DR GO; GO:0007158; P:neuron cell-cell adhesion; IMP:UniProtKB. DR GO; GO:0042551; P:neuron maturation; IEA:Ensembl. DR GO; GO:0061146; P:Peyer's patch morphogenesis; ISS:UniProtKB. DR GO; GO:0033630; P:positive regulation of cell adhesion mediated by integrin; IDA:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB. DR GO; GO:0045793; P:positive regulation of cell size; IEA:Ensembl. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISS:UniProtKB. DR GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IMP:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:UniProtKB. DR GO; GO:0072300; P:positive regulation of metanephric glomerulus development; ISS:UniProtKB. DR GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:UniProtKB. DR GO; GO:0007497; P:posterior midgut development; TAS:ProtInc. DR GO; GO:0050770; P:regulation of axonogenesis; IEA:Ensembl. DR GO; GO:0030155; P:regulation of cell adhesion; IDA:UniProtKB. DR GO; GO:0048265; P:response to pain; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0035799; P:ureter maturation; IEA:Ensembl. DR GO; GO:0001657; P:ureteric bud development; IEA:Ensembl. DR CDD; cd11304; Cadherin_repeat; 1. DR CDD; cd05045; PTKc_RET; 1. DR FunFam; 1.10.510.10:FF:000190; Proto-oncogene tyrosine-protein kinase receptor Ret; 1. DR FunFam; 2.60.40.60:FF:000132; Proto-oncogene tyrosine-protein kinase receptor Ret; 1. DR FunFam; 2.60.40.60:FF:000205; Proto-oncogene tyrosine-protein kinase receptor Ret; 1. DR FunFam; 3.30.200.20:FF:000234; Proto-oncogene tyrosine-protein kinase receptor Ret; 1. DR Gene3D; 2.60.40.60; Cadherins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR002126; Cadherin-like_dom. DR InterPro; IPR015919; Cadherin-like_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR041163; Ret_CLD1. DR InterPro; IPR040667; Ret_CLD3. DR InterPro; IPR041317; RET_CLD4. DR InterPro; IPR055162; RET_CRD. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016249; Tyr_kinase_Ret_rcpt. DR PANTHER; PTHR24416:SF485; PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00028; Cadherin; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF17756; RET_CLD1; 1. DR Pfam; PF17812; RET_CLD3; 1. DR Pfam; PF17813; RET_CLD4; 1. DR Pfam; PF22540; RET_CRD; 1. DR PIRSF; PIRSF000631; TyrPK_receptor_Ret; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49313; Cadherin-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50268; CADHERIN_2; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell adhesion; KW Cell membrane; Chromosomal rearrangement; Disease variant; Disulfide bond; KW Endosome; Glycoprotein; Hirschsprung disease; Kinase; Membrane; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Proto-oncogene; Receptor; Reference proteome; Signal; Transferase; KW Transmembrane; Transmembrane helix; Tyrosine-protein kinase. FT SIGNAL 1..28 FT /evidence="ECO:0000255" FT CHAIN 29..1114 FT /note="Proto-oncogene tyrosine-protein kinase receptor Ret" FT /id="PRO_0000024450" FT CHAIN 29..707 FT /note="Extracellular cell-membrane anchored RET cadherin FT 120 kDa fragment" FT /evidence="ECO:0000305|PubMed:21357690" FT /id="PRO_0000415292" FT CHAIN 708..1017 FT /note="Soluble RET kinase fragment" FT /evidence="ECO:0000305|PubMed:21357690" FT /id="PRO_0000415293" FT TOPO_DOM 29..635 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 636..657 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 658..1114 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 168..272 FT /note="Cadherin" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT DOMAIN 724..1016 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 29..153 FT /note="Cadherin-like region 1 (CLD1)" FT /evidence="ECO:0000305|PubMed:11445581" FT REGION 265..379 FT /note="Cadherin-like region 3 (CLD3)" FT /evidence="ECO:0000305|PubMed:11445581" FT REGION 405..506 FT /note="Cadherin-like region 4 (CLD4)" FT /evidence="ECO:0000305|PubMed:11445581" FT ACT_SITE 874 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 178 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 179 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 230 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 232 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 232 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 264 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 265 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 266 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 267 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 267 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 268 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 300 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 302 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 302 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 378 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 564 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 565 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 567 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 569 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 574 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 584 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 730..738 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000305|PubMed:24560924, ECO:0007744|PDB:4CKI" FT BINDING 758 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000305|PubMed:24560924" FT BINDING 805..807 FT /ligand="semaxanib" FT /ligand_id="ChEBI:CHEBI:91083" FT /ligand_note="inhibitor" FT /evidence="ECO:0000269|PubMed:20117004, FT ECO:0007744|PDB:2X2M" FT SITE 587..588 FT /note="Breakpoint for translocation to form the TRIM27/RET FT oncogene" FT /evidence="ECO:0000269|PubMed:3037315" FT SITE 707..708 FT /note="Cleavage; by caspase-3" FT /evidence="ECO:0000269|PubMed:21357690" FT SITE 712..713 FT /note="Breakpoint for translocation to form PCM1-RET; RET- FT CCDC6; RET-GOLGA5; RET-TRIM24 and RET-TRIM33 oncogenes" FT /evidence="ECO:0000269|PubMed:10439047, FT ECO:0000269|PubMed:10980597, ECO:0000269|PubMed:2406025, FT ECO:0000269|PubMed:2734021" FT SITE 1017..1018 FT /note="Cleavage; by caspase-3" FT /evidence="ECO:0000269|PubMed:21357690" FT MOD_RES 687 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:24560924" FT MOD_RES 696 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 806 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813" FT MOD_RES 809 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813" FT MOD_RES 826 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:24560924" FT MOD_RES 900 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813, FT ECO:0000269|PubMed:16928683, ECO:0000269|PubMed:24560924" FT MOD_RES 905 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813, FT ECO:0000269|PubMed:16928683, ECO:0000269|PubMed:20117004, FT ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:28846099" FT MOD_RES 981 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813, FT ECO:0000269|PubMed:24560924" FT MOD_RES 1015 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11061555, FT ECO:0000269|PubMed:24560924" FT MOD_RES 1029 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:24560924" FT MOD_RES 1062 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11061555, FT ECO:0000269|PubMed:14711813, ECO:0000269|PubMed:24560924, FT ECO:0000269|PubMed:28846099" FT MOD_RES 1090 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813" FT MOD_RES 1096 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813" FT CARBOHYD 98 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 151 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20473317" FT CARBOHYD 199 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 336 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 343 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 361 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 367 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 377 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 394 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 448 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 468 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 554 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 688 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:26237509" FT DISULFID 137..142 FT /evidence="ECO:0000269|PubMed:20473317, FT ECO:0000269|PubMed:25242331, ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:2X2U, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6GL7, ECO:0007744|PDB:6Q2J, FT ECO:0007744|PDB:6Q2N, ECO:0007744|PDB:6Q2O, FT ECO:0007744|PDB:6Q2R, ECO:0007744|PDB:6Q2S" FT DISULFID 157..197 FT /evidence="ECO:0000269|PubMed:20473317, FT ECO:0000269|PubMed:25242331, ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:2X2U, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6GL7, ECO:0007744|PDB:6Q2J, FT ECO:0007744|PDB:6Q2N, ECO:0007744|PDB:6Q2O, FT ECO:0007744|PDB:6Q2R, ECO:0007744|PDB:6Q2S" FT DISULFID 166..243 FT /evidence="ECO:0000269|PubMed:20473317, FT ECO:0000269|PubMed:25242331, ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:2X2U, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6GL7, ECO:0007744|PDB:6Q2J, FT ECO:0007744|PDB:6Q2N, ECO:0007744|PDB:6Q2O, FT ECO:0007744|PDB:6Q2R, ECO:0007744|PDB:6Q2S" FT DISULFID 426..430 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 449..478 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6GL7, ECO:0007744|PDB:6Q2J, FT ECO:0007744|PDB:6Q2N, ECO:0007744|PDB:6Q2O, FT ECO:0007744|PDB:6Q2R, ECO:0007744|PDB:6Q2S" FT DISULFID 515..531 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 519..541 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 528..558 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 565..581 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 570..585 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 609..620 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 611..618 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 630..634 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT VAR_SEQ 1064..1114 FT /note="MSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMDTFDS FT -> RISHAFTRF (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:3037315" FT /id="VSP_040735" FT VARIANT 20 FT /note="P -> L (in HSCR1; sporadic form; FT dbSNP:rs1837067697)" FT /evidence="ECO:0000269|PubMed:7633441" FT /id="VAR_009459" FT VARIANT 32 FT /note="S -> L (in HSCR1; familial form; dbSNP:rs76764689)" FT /evidence="ECO:0000269|PubMed:10618407, FT ECO:0000269|PubMed:8114939" FT /id="VAR_006295" FT VARIANT 40 FT /note="L -> P (in HSCR1; dbSNP:rs2132657920)" FT /evidence="ECO:0000269|PubMed:7704557, FT ECO:0000269|PubMed:9043870" FT /id="VAR_009492" FT VARIANT 64 FT /note="P -> L (in HSCR1; familial form; dbSNP:rs77596424)" FT /evidence="ECO:0000269|PubMed:8114939" FT /id="VAR_006296" FT VARIANT 67 FT /note="R -> H (in dbSNP:rs192489011)" FT /evidence="ECO:0000269|PubMed:14566559" FT /id="VAR_018153" FT VARIANT 77 FT /note="R -> C (in HSCR1; dbSNP:rs1588862595)" FT /evidence="ECO:0000269|PubMed:10618407" FT /id="VAR_009460" FT VARIANT 93 FT /note="G -> S (in HSCR1; uncertain significance; FT dbSNP:rs1477699803)" FT /evidence="ECO:0000269|PubMed:7633441" FT /id="VAR_006297" FT VARIANT 114 FT /note="R -> C (in HSCR1; uncertain significance; FT dbSNP:rs747483905)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067101" FT VARIANT 114 FT /note="R -> H (in dbSNP:rs76397662)" FT /evidence="ECO:0000269|PubMed:12086152, FT ECO:0000269|PubMed:14566559, ECO:0000269|PubMed:22174939" FT /id="VAR_018154" FT VARIANT 142 FT /note="C -> S (in HSCR1; sporadic form; FT dbSNP:rs2132680131)" FT /id="VAR_006298" FT VARIANT 145 FT /note="V -> G (in HSCR1; also in a colorectal cancer FT sample; somatic mutation; dbSNP:rs1588863999)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:22174939" FT /id="VAR_035711" FT VARIANT 155 FT /note="P -> L (in HSCR1; dbSNP:rs999019810)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067102" FT VARIANT 157 FT /note="C -> Y (in HSCR1; uncertain significance; FT dbSNP:rs2132681401)" FT /evidence="ECO:0000269|Ref.71" FT /id="VAR_009461" FT VARIANT 163 FT /note="R -> Q (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs149403911)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041762" FT VARIANT 174 FT /note="F -> S (in HSCR1; sporadic form)" FT /evidence="ECO:0000269|PubMed:9094028" FT /id="VAR_009462" FT VARIANT 175 FT /note="R -> P (in HSCR1; dbSNP:rs774097284)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067103" FT VARIANT 180 FT /note="R -> P (in HSCR1; sporadic form; dbSNP:rs370736139)" FT /evidence="ECO:0000269|PubMed:9090527" FT /id="VAR_009463" FT VARIANT 197 FT /note="C -> Y (in HSCR1; sporadic form)" FT /evidence="ECO:0000269|PubMed:9094028" FT /id="VAR_009464" FT VARIANT 198 FT /note="P -> T (in a patient with renal agenesis; uncertain FT significance; prevents phosphorylation in response to GDNF; FT dbSNP:rs76736111)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044392" FT VARIANT 231 FT /note="R -> H (in HSCR1; familial form; dbSNP:rs79661516)" FT /evidence="ECO:0000269|PubMed:7581377" FT /id="VAR_006299" FT VARIANT 251 FT /note="E -> K (in HSCR1; familial form; dbSNP:rs562449603)" FT /evidence="ECO:0000269|PubMed:7581377" FT /id="VAR_006300" FT VARIANT 278 FT /note="T -> A (in HSCR1; dbSNP:rs541929171)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067104" FT VARIANT 278 FT /note="T -> N (found in two patients with Hirschsprung FT disease; dbSNP:rs35118262)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:22174939" FT /id="VAR_041763" FT VARIANT 278 FT /note="T -> P (in HSCR1; dbSNP:rs541929171)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067105" FT VARIANT 287 FT /note="R -> Q (in HSCR1; sporadic form; FT dbSNP:rs1564491460)" FT /evidence="ECO:0000269|PubMed:10664228" FT /id="VAR_006301" FT VARIANT 292 FT /note="V -> M (found in patients with Hirschsprung disease; FT uncertain significance; dbSNP:rs34682185)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:22174939" FT /id="VAR_041764" FT VARIANT 300 FT /note="D -> N (in HSCR1; dbSNP:rs2132719351)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067106" FT VARIANT 313 FT /note="R -> Q (in HSCR1; dbSNP:rs77702891)" FT /evidence="ECO:0000269|PubMed:22174939, FT ECO:0000269|PubMed:9090527" FT /id="VAR_009465" FT VARIANT 316 FT /note="S -> I (in HSCR1; dbSNP:rs1060499894)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067107" FT VARIANT 330 FT /note="R -> Q (in HSCR1; dbSNP:rs80236571)" FT /evidence="ECO:0000269|PubMed:7633441, FT ECO:0000269|PubMed:8114939" FT /id="VAR_006302" FT VARIANT 339 FT /note="S -> L (in HSCR1; dbSNP:rs774829203)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067108" FT VARIANT 353 FT /note="D -> Y (in HSCR1; dbSNP:rs1837785429)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067109" FT VARIANT 359 FT /note="N -> K (in HSCR1; uncertain significance)" FT /evidence="ECO:0000269|Ref.71" FT /id="VAR_009466" FT VARIANT 360 FT /note="R -> Q (in HSCR1; dbSNP:rs762472027)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067110" FT VARIANT 360 FT /note="R -> W (in HSCR1; dbSNP:rs1424549058)" FT /evidence="ECO:0000269|PubMed:10618407, FT ECO:0000269|PubMed:16959974" FT /id="VAR_009467" FT VARIANT 376 FT /note="V -> A (in a patient with renal agenesis; uncertain FT significance; constitutively phosphorylated; expressed only FT the immature intracellular form)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044393" FT VARIANT 393 FT /note="F -> L (in HSCR1; familial form; dbSNP:rs78098482)" FT /evidence="ECO:0000269|PubMed:8114939" FT /id="VAR_006303" FT VARIANT 394 FT /note="N -> H (in a patient with renal agenesis; uncertain FT significance; prevents phosphorylation in response to FT GDNF)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044394" FT VARIANT 394 FT /note="N -> K (in HSCR1; dbSNP:rs376465385)" FT /evidence="ECO:0000269|PubMed:10618407" FT /id="VAR_009468" FT VARIANT 397 FT /note="V -> M (in HSCR1; dbSNP:rs183729115)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067111" FT VARIANT 399 FT /note="P -> L (in HSCR1; sporadic form; FT dbSNP:rs1554818362)" FT /evidence="ECO:0000269|PubMed:7704557" FT /id="VAR_006304" FT VARIANT 412 FT /note="V -> M (in HSCR1; dbSNP:rs746970700)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067112" FT VARIANT 423 FT /note="G -> R (in HSCR1; dbSNP:rs767601598)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067113" FT VARIANT 432 FT /note="A -> E (found in a patient with congenital central FT hypoventilation syndrome; uncertain significance; FT dbSNP:rs552057730)" FT /evidence="ECO:0000269|PubMed:14566559" FT /id="VAR_018155" FT VARIANT 475 FT /note="R -> Q (in HSCR1; sporadic form; dbSNP:rs138624658)" FT /id="VAR_006305" FT VARIANT 480 FT /note="E -> K (in HSCR1; dbSNP:rs537874538)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067114" FT VARIANT 489 FT /note="D -> N (in dbSNP:rs9282834)" FT /evidence="ECO:0000269|PubMed:14566559, FT ECO:0000269|PubMed:17344846" FT /id="VAR_018156" FT VARIANT 531 FT /note="C -> CEEC (in MTC; familial form)" FT /evidence="ECO:0000269|PubMed:10323403" FT /id="VAR_009469" FT VARIANT 549..550 FT /note="Missing (in HSCR1)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067115" FT VARIANT 593 FT /note="G -> E (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035712" FT VARIANT 595 FT /note="E -> Q (in HSCR1; dbSNP:rs1483605155)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067116" FT VARIANT 600 FT /note="R -> Q (in dbSNP:rs377767393)" FT /evidence="ECO:0000269|PubMed:10612852" FT /id="VAR_008966" FT VARIANT 609 FT /note="C -> G (in MEN2A; dbSNP:rs77558292)" FT /evidence="ECO:0000269|PubMed:8807338" FT /id="VAR_009470" FT VARIANT 609 FT /note="C -> R (in MEN2A; dbSNP:rs77558292)" FT /evidence="ECO:0000269|PubMed:8807338" FT /id="VAR_009471" FT VARIANT 609 FT /note="C -> W (in HSCR1; familial form; dbSNP:rs377767396)" FT /evidence="ECO:0000269|PubMed:7881414" FT /id="VAR_006307" FT VARIANT 609 FT /note="C -> Y (in MTC, MEN2A and HSCR1; familial and FT sporadic forms; dbSNP:rs77939446)" FT /evidence="ECO:0000269|PubMed:7633441, FT ECO:0000269|PubMed:7849720, ECO:0000269|PubMed:9384613, FT ECO:0000269|Ref.71" FT /id="VAR_006306" FT VARIANT 611 FT /note="C -> G (in MTC; familial form; dbSNP:rs377767391)" FT /evidence="ECO:0000269|PubMed:9677065" FT /id="VAR_009472" FT VARIANT 611 FT /note="C -> R (in MEN2A; dbSNP:rs377767391)" FT /evidence="ECO:0000269|PubMed:8807338" FT /id="VAR_009473" FT VARIANT 611 FT /note="C -> S (in MEN2A; dbSNP:rs377767391)" FT /evidence="ECO:0000269|PubMed:8807338" FT /id="VAR_009474" FT VARIANT 611 FT /note="C -> W (in MEN2A and MTC; familial form; FT dbSNP:rs80069458)" FT /evidence="ECO:0000269|PubMed:8103403" FT /id="VAR_006308" FT VARIANT 611 FT /note="C -> Y (in MEN2A; dbSNP:rs377767397)" FT /evidence="ECO:0000269|PubMed:9067749" FT /id="VAR_006309" FT VARIANT 618 FT /note="C -> F (in MEN2A and MTC; familial form; FT dbSNP:rs79781594)" FT /evidence="ECO:0000269|PubMed:9067749" FT /id="VAR_006312" FT VARIANT 618 FT /note="C -> G (in MEN2A; dbSNP:rs76262710)" FT /evidence="ECO:0000269|PubMed:8099202" FT /id="VAR_006310" FT VARIANT 618 FT /note="C -> R (in MEN2A, MTC and HSCR1; dbSNP:rs76262710)" FT /evidence="ECO:0000269|PubMed:7849720, FT ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7915165, FT ECO:0000269|PubMed:9259198" FT /id="VAR_006311" FT VARIANT 618 FT /note="C -> S (in MEN2A, HSCR1 and MTC; familial and FT sporadic forms; dbSNP:rs79781594)" FT /evidence="ECO:0000269|PubMed:7849720, FT ECO:0000269|PubMed:7860065, ECO:0000269|PubMed:7915165, FT ECO:0000269|PubMed:8103403, ECO:0000269|PubMed:9384613" FT /id="VAR_006313" FT VARIANT 618 FT /note="C -> Y (in MEN2A and MTC; familial form; FT dbSNP:rs79781594)" FT /evidence="ECO:0000269|PubMed:8103403" FT /id="VAR_006314" FT VARIANT 620 FT /note="C -> F (in MEN2A and MTC; familial form; FT dbSNP:rs77503355)" FT /evidence="ECO:0000269|PubMed:7915165" FT /id="VAR_006318" FT VARIANT 620 FT /note="C -> G (in MEN2A and MTC; familial and sporadic FT forms; dbSNP:rs77316810)" FT /evidence="ECO:0000269|PubMed:9067749" FT /id="VAR_006315" FT VARIANT 620 FT /note="C -> R (in MEN2A, MTC and HSCR1; familial and FT sporadic forms; dbSNP:rs77316810)" FT /evidence="ECO:0000269|PubMed:7633441, FT ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7915165, FT ECO:0000269|PubMed:8103403, ECO:0000269|PubMed:9090527, FT ECO:0000269|PubMed:9384613, ECO:0000269|Ref.71" FT /id="VAR_006316" FT VARIANT 620 FT /note="C -> S (in MEN2A and MTC; familial form; FT dbSNP:rs77503355)" FT /evidence="ECO:0000269|PubMed:7849720, FT ECO:0000269|PubMed:7860065" FT /id="VAR_006317" FT VARIANT 620 FT /note="C -> W (in MEN2A and HSCR1; dbSNP:rs79890926)" FT /evidence="ECO:0000269|PubMed:9384613" FT /id="VAR_009475" FT VARIANT 620 FT /note="C -> Y (in MEN2A; dbSNP:rs77503355)" FT /evidence="ECO:0000269|PubMed:8103403" FT /id="VAR_006319" FT VARIANT 626 FT /note="Q -> K (in HSCR1; sporadic form; FT dbSNP:rs1255575160)" FT /evidence="ECO:0000269|PubMed:10090908" FT /id="VAR_009476" FT VARIANT 630 FT /note="C -> F (in MEN2A and MTC; familial form; FT dbSNP:rs377767405)" FT /evidence="ECO:0000269|PubMed:9067749" FT /id="VAR_006320" FT VARIANT 630 FT /note="C -> S (in MTC; sporadic form; dbSNP:rs377767405)" FT /evidence="ECO:0000269|PubMed:9223675" FT /id="VAR_009477" FT VARIANT 630 FT /note="C -> Y (in MTC; familial and sporadic forms; FT dbSNP:rs377767405)" FT /evidence="ECO:0000269|PubMed:9223675" FT /id="VAR_009478" FT VARIANT 631 FT /note="D -> G (in thyroid carcinoma; somatic mutation; FT dbSNP:rs121913308)" FT /id="VAR_006321" FT VARIANT 632..634 FT /note="ELC -> DVR (in MEN2A; dbSNP:rs377767408)" FT /evidence="ECO:0000269|PubMed:8099202" FT /id="VAR_006322" FT VARIANT 634..635 FT /note="CR -> WG (in MEN2A)" FT /id="VAR_006329" FT VARIANT 634 FT /note="C -> CHELC (in MEN2A)" FT /evidence="ECO:0000269|PubMed:9097963" FT /id="VAR_009479" FT VARIANT 634 FT /note="C -> F (in MEN2A and pheochromocytoma; FT dbSNP:rs75996173)" FT /evidence="ECO:0000269|PubMed:12000816, FT ECO:0000269|PubMed:7915165, ECO:0000269|PubMed:8099202" FT /id="VAR_006324" FT VARIANT 634 FT /note="C -> G (in MEN2A and pheochromocytoma; FT dbSNP:rs75076352)" FT /evidence="ECO:0000269|PubMed:12000816, FT ECO:0000269|PubMed:7915165, ECO:0000269|PubMed:8099202" FT /id="VAR_006323" FT VARIANT 634 FT /note="C -> R (in MEN2A, pheochromocytoma and MTC; familial FT form; also found as somatic mutation in a sporadic thyroid FT carcinoma; dbSNP:rs75076352)" FT /evidence="ECO:0000269|PubMed:12000816, FT ECO:0000269|PubMed:7860065, ECO:0000269|PubMed:8103403" FT /id="VAR_006326" FT VARIANT 634 FT /note="C -> S (in MEN2A, pheochromocytoma and MTC; familial FT form; dbSNP:rs75076352)" FT /evidence="ECO:0000269|PubMed:12000816, FT ECO:0000269|PubMed:8099202" FT /id="VAR_006327" FT VARIANT 634 FT /note="C -> W (in MEN2A, pheochromocytoma and MTC; familial FT form; dbSNP:rs77709286)" FT /evidence="ECO:0000269|PubMed:12000816" FT /id="VAR_006328" FT VARIANT 634 FT /note="C -> Y (in MEN2A, pheochromocytoma and MTC; familial FT form; dbSNP:rs75996173)" FT /evidence="ECO:0000269|PubMed:12000816, FT ECO:0000269|PubMed:7860065, ECO:0000269|PubMed:7915165, FT ECO:0000269|PubMed:8099202" FT /id="VAR_006325" FT VARIANT 636 FT /note="T -> TCRT (in MEN2A)" FT /evidence="ECO:0000269|PubMed:9452064" FT /id="VAR_006330" FT VARIANT 639 FT /note="A -> G (in MTC; sporadic form; dbSNP:rs2132845622)" FT /evidence="ECO:0000269|PubMed:11692159" FT /id="VAR_012743" FT VARIANT 640 FT /note="A -> G (in MEN2A; dbSNP:rs78935588)" FT /evidence="ECO:0000269|PubMed:10522989" FT /id="VAR_009480" FT VARIANT 641 FT /note="A -> G (in MTC; sporadic form)" FT /evidence="ECO:0000269|PubMed:11692159" FT /id="VAR_012744" FT VARIANT 679 FT /note="P -> L (in HSCR1; dbSNP:rs2132851042)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067117" FT VARIANT 690 FT /note="S -> P (in HSCR1; sporadic form)" FT /evidence="ECO:0000269|PubMed:10664228" FT /id="VAR_006331" FT VARIANT 691 FT /note="G -> S (in dbSNP:rs1799939)" FT /evidence="ECO:0000269|PubMed:14566559, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9223675, FT ECO:0000269|PubMed:9497256" FT /id="VAR_006332" FT VARIANT 694 FT /note="R -> Q (in HSCR1; dbSNP:rs141185224)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067118" FT VARIANT 730 FT /note="L -> I (confers resistance to vandetanib, FT lenvatinib, cabozantinib and nintedanib inhibitors; FT dbSNP:rs1838076782)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088874" FT VARIANT 730 FT /note="L -> V (confers resistance to vandetanib, FT cabozantinib and nintedanib inhibitors; FT dbSNP:rs1838076782)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088875" FT VARIANT 732 FT /note="E -> K (confers resistance to cabozantinib FT inhibitor)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088876" FT VARIANT 738 FT /note="V -> A (confers resistance to vandetanib, FT lenvatinib, cabozantinib and nintedanib inhibitors; FT dbSNP:rs2132906265)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088877" FT VARIANT 749 FT /note="R -> T (in dbSNP:rs34288963)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041765" FT VARIANT 762 FT /note="E -> Q (in HSCR1; sporadic form; FT dbSNP:rs2132910256)" FT /evidence="ECO:0000269|PubMed:7704557" FT /id="VAR_009481" FT VARIANT 765 FT /note="S -> P (in HSCR1; dbSNP:rs75075748)" FT /evidence="ECO:0000269|PubMed:7704557, FT ECO:0000269|PubMed:8114938, ECO:0000269|PubMed:9043870" FT /id="VAR_009493" FT VARIANT 767 FT /note="S -> R (in HSCR1; sporadic form; FT dbSNP:rs2132928081)" FT /evidence="ECO:0000269|PubMed:10664228" FT /id="VAR_006334" FT VARIANT 768 FT /note="E -> D (in MTC; familial and sporadic forms; FT dbSNP:rs78014899)" FT /evidence="ECO:0000269|PubMed:7784092, FT ECO:0000269|PubMed:7845675, ECO:0000269|PubMed:8807338" FT /id="VAR_006335" FT VARIANT 778 FT /note="V -> I (in a patient with renal agenesis; uncertain FT significance; constitutively phosphorylated; FT dbSNP:rs75686697)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044395" FT VARIANT 783 FT /note="N -> S (in HSCR1; dbSNP:rs587778656)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067119" FT VARIANT 790 FT /note="L -> F (in MEN2A and MTC; familial form; FT dbSNP:rs75030001)" FT /evidence="ECO:0000269|PubMed:9506724" FT /id="VAR_009482" FT VARIANT 791 FT /note="Y -> F (in HSCR1, pheochromocytoma, MTC and MEN2A; FT familial form; dbSNP:rs77724903)" FT /evidence="ECO:0000269|PubMed:12000816, FT ECO:0000269|PubMed:9090527, ECO:0000269|PubMed:9506724" FT /id="VAR_009483" FT VARIANT 804 FT /note="V -> L (in MTC; familial form; confers resistance to FT vandetanib, lenvatinib, cabozantinib and nintedanib FT inhibitors; dbSNP:rs79658334)" FT /evidence="ECO:0000269|PubMed:29908090, FT ECO:0000269|PubMed:7784092" FT /id="VAR_006336" FT VARIANT 804 FT /note="V -> M (in MTC; familial form; faster FT autophosphorylation and activation, leading to enhanced FT activity; confers resistance to vandetanib, lenvatinib, FT cabozantinib and nintedanib inhibitors; dbSNP:rs79658334)" FT /evidence="ECO:0000269|PubMed:10826520, FT ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:29908090, FT ECO:0000269|PubMed:9452077" FT /id="VAR_006337" FT VARIANT 806 FT /note="Y -> N (confers resistance to vandetanib, FT lenvatinib, cabozantinib and nintedanib inhibitors; FT dbSNP:rs1838154415)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088878" FT VARIANT 807 FT /note="A -> V (confers resistance to vandetanib, lenvatinib FT and cabozantinib inhibitors; dbSNP:rs1554819523)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088879" FT VARIANT 810 FT /note="G -> A (found in a patient with lung adenocarcinoma; FT confers resistance to vandetanib inhibitor; FT dbSNP:rs2132943470)" FT /evidence="ECO:0000269|PubMed:31118272" FT /id="VAR_088880" FT VARIANT 810 FT /note="G -> S (confers resistance to vandetanib, FT lenvatinib, cabozantinib and nintedanib inhibitors; FT dbSNP:rs764784013)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088881" FT VARIANT 813 FT /note="R -> Q (in HSCR1; sporadic form; FT dbSNP:rs1318733775)" FT /evidence="ECO:0000269|PubMed:10090908" FT /id="VAR_009484" FT VARIANT 826 FT /note="Y -> S (in dbSNP:rs34617196)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041766" FT VARIANT 830 FT /note="G -> R (in HSCR1; dbSNP:rs200127630)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067120" FT VARIANT 844 FT /note="R -> L (in MTC; familial form; dbSNP:rs55947360)" FT /evidence="ECO:0000269|PubMed:10826520, FT ECO:0000269|PubMed:17344846" FT /id="VAR_011582" FT VARIANT 871 FT /note="V -> I (confers resistance to vandetanib, lenvatinib FT and cabozantinib inhibitors; dbSNP:rs145170911)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088882" FT VARIANT 873 FT /note="R -> Q (in HSCR1; sporadic form; FT dbSNP:rs1451004715)" FT /evidence="ECO:0000269|PubMed:10664228" FT /id="VAR_006338" FT VARIANT 881 FT /note="L -> V (in MTC; confers resistance to nintedanib FT inhibitor; dbSNP:rs377767427)" FT /evidence="ECO:0000269|PubMed:29908090, FT ECO:0000269|PubMed:31118272" FT /id="VAR_088883" FT VARIANT 883 FT /note="A -> F (in MEN2B; somatic mutation in sporadic FT medullary thyroid carcinoma; requires 2 nucleotide FT substitutions; dbSNP:rs377767429)" FT /evidence="ECO:0000269|PubMed:9294615, FT ECO:0000269|PubMed:9360560" FT /id="VAR_009485" FT VARIANT 891 FT /note="S -> A (in MTC; familial form; dbSNP:rs75234356)" FT /evidence="ECO:0000269|PubMed:9398735" FT /id="VAR_009486" FT VARIANT 893 FT /note="F -> L (in HSCR1; sporadic form; dbSNP:rs768188546 FT and dbSNP:rs2132962164)" FT /evidence="ECO:0000269|PubMed:9174404" FT /id="VAR_006339" FT VARIANT 894 FT /note="G -> S (in a patient with renal agenesis; uncertain FT significance; constitutively phosphorylated; expressed only FT the immature intracellular form; dbSNP:rs2132962245)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044396" FT VARIANT 897 FT /note="R -> Q (in HSCR1; sporadic form; dbSNP:rs76087194)" FT /evidence="ECO:0000269|PubMed:7704557, FT ECO:0000269|PubMed:8114938" FT /id="VAR_006340" FT VARIANT 907 FT /note="K -> E (in HSCR1; sporadic form; dbSNP:rs377767430)" FT /evidence="ECO:0000269|PubMed:10790203" FT /id="VAR_006341" FT VARIANT 907 FT /note="K -> T (in HSCR1)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067121" FT VARIANT 918 FT /note="M -> T (in MEN2B and MTC; sporadic form; somatic FT mutation; also found in a patient with renal agenesis; FT faster autophosphorylation and activation, leading to FT enhanced activity; dbSNP:rs74799832)" FT /evidence="ECO:0000269|PubMed:18252215, FT ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:29908090, FT ECO:0000269|PubMed:7906417, ECO:0000269|PubMed:7906866, FT ECO:0000269|PubMed:7911697, ECO:0000269|PubMed:8595427, FT ECO:0000269|PubMed:8807338" FT /id="VAR_006342" FT VARIANT 921 FT /note="E -> K (in HSCR1; sporadic form; FT dbSNP:rs2132985306)" FT /evidence="ECO:0000269|PubMed:7997019" FT /id="VAR_006343" FT VARIANT 922 FT /note="S -> F (in MTC; sporadic form; dbSNP:rs377767432)" FT /evidence="ECO:0000269|PubMed:11692159" FT /id="VAR_012745" FT VARIANT 922 FT /note="S -> Y (in dbSNP:rs377767432)" FT /evidence="ECO:0000269|PubMed:8595427" FT /id="VAR_009487" FT VARIANT 946 FT /note="T -> M (in MEN2B and MTC; familial form)" FT /id="VAR_006345" FT VARIANT 961 FT /note="F -> L (in HSCR1)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067122" FT VARIANT 972 FT /note="R -> G (in HSCR1; familial form; dbSNP:rs76534745)" FT /evidence="ECO:0000269|PubMed:7704557, FT ECO:0000269|PubMed:8114938" FT /id="VAR_006346" FT VARIANT 973 FT /note="P -> L (in HSCR1; familial form)" FT /evidence="ECO:0000269|PubMed:7704557" FT /id="VAR_006347" FT VARIANT 980 FT /note="M -> T (in HSCR1; sporadic form)" FT /id="VAR_006348" FT VARIANT 982 FT /note="R -> C (in dbSNP:rs17158558)" FT /evidence="ECO:0000269|PubMed:14566559, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7633441, ECO:0000269|PubMed:9760196" FT /id="VAR_006349" FT VARIANT 998 FT /note="F -> V (confers resistance to lenvatinib and FT cabozantinib inhibitors; dbSNP:rs2133017302)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088884" FT VARIANT 1039 FT /note="P -> L (in HSCR1; dbSNP:rs79853121)" FT /evidence="ECO:0000269|PubMed:9497256" FT /id="VAR_018157" FT VARIANT 1039 FT /note="P -> Q (in dbSNP:rs79853121)" FT /id="VAR_009488" FT VARIANT 1049 FT /note="P -> L (in a patient with renal agenesis; uncertain FT significance; prevents phosphorylation in response to GDNF; FT dbSNP:rs1490712863)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044397" FT VARIANT 1052 FT /note="L -> V (in HSCR1; dbSNP:rs1564501947)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067123" FT VARIANT 1059 FT /note="Missing (in HSCR1)" FT /evidence="ECO:0000269|PubMed:10484767, ECO:0000269|Ref.71" FT /id="VAR_009489" FT VARIANT 1061 FT /note="L -> P (in HSCR1; dbSNP:rs536486113)" FT /evidence="ECO:0000269|PubMed:10484767, ECO:0000269|Ref.71" FT /id="VAR_009490" FT VARIANT 1062 FT /note="Y -> C (in HSCR1; dbSNP:rs587778659)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067124" FT VARIANT 1064 FT /note="M -> T (in HSCR1; familial form; dbSNP:rs149513065)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_009491" FT VARIANT 1067 FT /note="P -> S (in a patient with renal agenesis; uncertain FT significance; prevents phosphorylation in response to GDNF; FT dbSNP:rs775583354)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044398" FT VARIANT 1112 FT /note="F -> Y (in a bladder transitional cell carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041767" FT MUTAGEN 36 FT /note="Y->S: Defects in maturation and processing." FT /evidence="ECO:0000269|PubMed:11445581" FT MUTAGEN 41 FT /note="Y->A: Defects in maturation and processing." FT /evidence="ECO:0000269|PubMed:11445581" FT MUTAGEN 85 FT /note="W->A: Defects in maturation and processing." FT /evidence="ECO:0000269|PubMed:11445581" FT MUTAGEN 707 FT /note="D->N: Impaired cleavage by caspase-3 and loss of FT induced cell death." FT /evidence="ECO:0000269|PubMed:21357690" FT MUTAGEN 708..1114 FT /note="Missing: Loss of induced cell death, but increased FT cell aggregation." FT /evidence="ECO:0000269|PubMed:21357690" FT MUTAGEN 734 FT /note="E->A: Enhanced protein autophosphorylation due to FT enhanced substrate presentation in trans." FT /evidence="ECO:0000269|PubMed:24560924" FT MUTAGEN 758 FT /note="K->R,M: Loss of kinase activity. No effect on FT interaction with and dissociation from CBLC and CD2AP." FT /evidence="ECO:0000269|PubMed:18753381, FT ECO:0000269|PubMed:21357690, ECO:0000269|PubMed:24560924" FT MUTAGEN 912 FT /note="R->A: Enhanced protein autophosphorylation due to FT enhanced substrate presentation in trans." FT /evidence="ECO:0000269|PubMed:24560924" FT MUTAGEN 913 FT /note="I->A: Enhanced protein autophosphorylation due to FT enhanced substrate presentation in trans." FT /evidence="ECO:0000269|PubMed:24560924" FT MUTAGEN 1062 FT /note="Y->F: Abolishes GFRAL-mediated MAPK1/MAPK2 FT phosphorylation." FT /evidence="ECO:0000269|PubMed:28953886" FT CONFLICT 647 FT /note="I -> V (in Ref. 6; AAA36786)" FT /evidence="ECO:0000305" FT CONFLICT 664 FT /note="A -> S (in Ref. 1; BAF84496)" FT /evidence="ECO:0000305" FT CONFLICT 750 FT /note="A -> G (in Ref. 9; AAA36524)" FT /evidence="ECO:0000305" FT CONFLICT 904 FT /note="S -> P (in Ref. 6; AAA36786)" FT /evidence="ECO:0000305" FT STRAND 30..32 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 34..41 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 49..52 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 70..73 FT /evidence="ECO:0007829|PDB:2X2U" FT HELIX 75..77 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 79..82 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 85..88 FT /evidence="ECO:0007829|PDB:2X2U" FT TURN 90..92 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 94..99 FT /evidence="ECO:0007829|PDB:2X2U" FT HELIX 103..111 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 120..126 FT /evidence="ECO:0007829|PDB:2X2U" FT TURN 139..141 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 142..152 FT /evidence="ECO:0007829|PDB:2X2U" FT HELIX 157..159 FT /evidence="ECO:0007829|PDB:2X2U" FT HELIX 162..166 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 174..178 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 184..187 FT /evidence="ECO:0007829|PDB:2X2U" FT HELIX 191..196 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 202..208 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 212..215 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 222..227 FT /evidence="ECO:0007829|PDB:2X2U" FT TURN 231..233 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 235..245 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 252..263 FT /evidence="ECO:0007829|PDB:2X2U" FT HELIX 705..710 FT /evidence="ECO:0007829|PDB:7DUA" FT TURN 715..717 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 721..723 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 724..733 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 736..744 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 746..748 FT /evidence="ECO:0007829|PDB:6NEC" FT STRAND 751..759 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 766..781 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 790..794 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 796..798 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 801..805 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 812..819 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 822..826 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 844..846 FT /evidence="ECO:0007829|PDB:6NJA" FT HELIX 848..867 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 877..879 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 880..883 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 884..886 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 887..890 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 893..895 FT /evidence="ECO:0007829|PDB:7JU5" FT TURN 900..902 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 915..917 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 920..925 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 930..945 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 957..959 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 960..965 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 978..987 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 992..994 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 998..1010 FT /evidence="ECO:0007829|PDB:7DUA" SQ SEQUENCE 1114 AA; 124319 MW; A3DA0CE01A19A441 CRC64; MAKATSGAAG LRLLLLLLLP LLGKVALGLY FSRDAYWEKL YVDQAAGTPL LYVHALRDAP EEVPSFRLGQ HLYGTYRTRL HENNWICIQE DTGLLYLNRS LDHSSWEKLS VRNRGFPLLT VYLKVFLSPT SLREGECQWP GCARVYFSFF NTSFPACSSL KPRELCFPET RPSFRIRENR PPGTFHQFRL LPVQFLCPNI SVAYRLLEGE GLPFRCAPDS LEVSTRWALD REQREKYELV AVCTVHAGAR EEVVMVPFPV TVYDEDDSAP TFPAGVDTAS AVVEFKRKED TVVATLRVFD ADVVPASGEL VRRYTSTLLP GDTWAQQTFR VEHWPNETSV QANGSFVRAT VHDYRLVLNR NLSISENRTM QLAVLVNDSD FQGPGAGVLL LHFNVSVLPV SLHLPSTYSL SVSRRARRFA QIGKVCVENC QAFSGINVQY KLHSSGANCS TLGVVTSAED TSGILFVNDT KALRRPKCAE LHYMVVATDQ QTSRQAQAQL LVTVEGSYVA EEAGCPLSCA VSKRRLECEE CGGLGSPTGR CEWRQGDGKG ITRNFSTCSP STKTCPDGHC DVVETQDINI CPQDCLRGSI VGGHEPGEPR GIKAGYGTCN CFPEEEKCFC EPEDIQDPLC DELCRTVIAA AVLFSFIVSV LLSAFCIHCY HKFAHKPPIS SAEMTFRRPA QAFPVSYSSS GARRPSLDSM ENQVSVDAFK ILEDPKWEFP RKNLVLGKTL GEGEFGKVVK ATAFHLKGRA GYTTVAVKML KENASPSELR DLLSEFNVLK QVNHPHVIKL YGACSQDGPL LLIVEYAKYG SLRGFLRESR KVGPGYLGSG GSRNSSSLDH PDERALTMGD LISFAWQISQ GMQYLAEMKL VHRDLAARNI LVAEGRKMKI SDFGLSRDVY EEDSYVKRSQ GRIPVKWMAI ESLFDHIYTT QSDVWSFGVL LWEIVTLGGN PYPGIPPERL FNLLKTGHRM ERPDNCSEEM YRLMLQCWKQ EPDKRPVFAD ISKDLEKMMV KRRDYLDLAA STPSDSLIYD DGLSEEETPL VDCNNAPLPR ALPSTWIENK LYGMSDPNWP GESPVPLTRA DGTNTGFPRY PNDSVYANWM LSPSAAKLMD TFDS // ID RNF43_HUMAN Reviewed; 783 AA. AC Q68DV7; A8K4R2; B7Z443; B7Z5D5; B7Z5J5; Q65ZA4; Q6AI04; Q9NXD0; DT 20-FEB-2007, integrated into UniProtKB/Swiss-Prot. DT 11-OCT-2004, sequence version 1. DT 28-JAN-2026, entry version 175. DE RecName: Full=E3 ubiquitin-protein ligase RNF43; DE EC=2.3.2.27; DE AltName: Full=RING finger protein 43; DE AltName: Full=RING-type E3 ubiquitin transferase RNF43 {ECO:0000305}; DE Flags: Precursor; GN Name=RNF43; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, TISSUE RP SPECIFICITY, AND VARIANT MET-418. RC TISSUE=Colon carcinoma; RX PubMed=15492824; RA Yagyu R., Furukawa Y., Lin Y.-M., Shimokawa T., Yamamura T., Nakamura Y.; RT "A novel oncoprotein RNF43 functions in an autocrine manner in colorectal RT cancer."; RL Int. J. Oncol. 25:1343-1348(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3), NUCLEOTIDE RP SEQUENCE [LARGE SCALE MRNA] OF 214-783 (ISOFORM 4), AND VARIANTS VAL-47; RP LEU-231 AND MET-418. RC TISSUE=Hepatoma, Teratocarcinoma, and Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-686. RC TISSUE=Colon carcinoma; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP IDENTIFICATION AS A CYTOTOXIC T LYMPHOCYTE TUMOR ANTIGEN. RX PubMed=15623641; DOI=10.1158/1078-0432.ccr-04-0104; RA Uchida N., Tsunoda T., Wada S., Furukawa Y., Nakamura Y., Tahara H.; RT "Ring finger protein 43 as a new target for cancer immunotherapy."; RL Clin. Cancer Res. 10:8577-8586(2004). RN [6] RP FUNCTION, INTERACTION WITH AKAP8L, AUTOUBIQUITINATION, TISSUE SPECIFICITY, RP SUBCELLULAR LOCATION, AND MUTAGENESIS OF CYS-290 AND HIS-292. RX PubMed=18313049; DOI=10.1016/j.yexcr.2008.01.013; RA Sugiura T., Yamaguchi A., Miyamoto K.; RT "A cancer-associated RING finger protein, RNF43, is a ubiquitin ligase that RT interacts with a nuclear protein, HAP95."; RL Exp. Cell Res. 314:1519-1528(2008). RN [7] RP INTERACTION WITH NONO AND SFPQ, AND SUBCELLULAR LOCATION. RX PubMed=18655028; DOI=10.1002/pmic.200800083; RA Miyamoto K., Sakurai H., Sugiura T.; RT "Proteomic identification of a PSF/p54nrb heterodimer as RNF43 oncoprotein- RT interacting proteins."; RL Proteomics 8:2907-2910(2008). RN [8] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=22575959; DOI=10.1038/nature11019; RA Hao H.X., Xie Y., Zhang Y., Charlat O., Oster E., Avello M., Lei H., RA Mickanin C., Liu D., Ruffner H., Mao X., Ma Q., Zamponi R., Bouwmeester T., RA Finan P.M., Kirschner M.W., Porter J.A., Serluca F.C., Cong F.; RT "ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner."; RL Nature 485:195-200(2012). RN [9] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH FZD5, AND MUTAGENESIS OF RP CYS-290; HIS-292; HIS-295 AND CYS-298. RX PubMed=22895187; DOI=10.1038/nature11308; RA Koo B.K., Spit M., Jordens I., Low T.Y., Stange D.E., van de Wetering M., RA van Es J.H., Mohammed S., Heck A.J., Maurice M.M., Clevers H.; RT "Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis RT of Wnt receptors."; RL Nature 488:665-669(2012). RN [10] RP INVOLVEMENT IN SSPCS. RX PubMed=24512911; DOI=10.1053/j.gastro.2013.10.045; RA Gala M.K., Mizukami Y., Le L.P., Moriichi K., Austin T., Yamamoto M., RA Lauwers G.Y., Bardeesy N., Chung D.C.; RT "Germline mutations in oncogene-induced senescence pathways are associated RT with multiple sessile serrated adenomas."; RL Gastroenterology 146:520-529(2014). RN [11] RP INVOLVEMENT IN SSPCS, AND VARIANT LEU-231. RX PubMed=27081527; DOI=10.1038/hgv.2015.13; RA Taupin D., Lam W., Rangiah D., McCallum L., Whittle B., Zhang Y., RA Andrews D., Field M., Goodnow C.C., Cook M.C.; RT "A deleterious RNF43 germline mutation in a severely affected serrated RT polyposis kindred."; RL Hum. Genome Var. 2:15013-15013(2015). RN [12] RP INTERACTION WITH RSPO2. RX PubMed=29769720; DOI=10.1038/s41586-018-0118-y; RA Szenker-Ravi E., Altunoglu U., Leushacke M., Bosso-Lefevre C., Khatoo M., RA Thi Tran H., Naert T., Noelanders R., Hajamohideen A., Beneteau C., RA de Sousa S.B., Karaman B., Latypova X., Basaran S., Yuecel E.B., Tan T.T., RA Vlaminck L., Nayak S.S., Shukla A., Girisha K.M., Le Caignec C., RA Soshnikova N., Uyguner Z.O., Vleminckx K., Barker N., Kayserili H., RA Reversade B.; RT "RSPO2 inhibition of RNF43 and ZNRF3 governs limb development independently RT of LGR4/5/6."; RL Nature 557:564-569(2018). RN [13] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 44-198 IN COMPLEX WITH RSPO1 AND RP LGR5, SUBUNIT, AND DISULFIDE BONDS. RX PubMed=23756651; DOI=10.1101/gad.219915.113; RA Chen P.H., Chen X., Lin Z., Fang D., He X.; RT "The structural basis of R-spondin recognition by LGR5 and RNF43."; RL Genes Dev. 27:1345-1350(2013). CC -!- FUNCTION: E3 ubiquitin-protein ligase that acts as a negative regulator CC of the Wnt signaling pathway by mediating the ubiquitination, CC endocytosis and subsequent degradation of Wnt receptor complex CC components Frizzled. Acts on both canonical and non-canonical Wnt CC signaling pathway (PubMed:18313049, PubMed:22575959, PubMed:22895187). CC Along with RSPO2 and ZNRF3, constitutes a master switch that governs CC limb specification (By similarity). {ECO:0000250|UniProtKB:P0DPR2, CC ECO:0000269|PubMed:18313049, ECO:0000269|PubMed:22575959, CC ECO:0000269|PubMed:22895187}. CC -!- CATALYTIC ACTIVITY: CC Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine + CC [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L- CC cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.; CC EC=2.3.2.27; CC -!- PATHWAY: Protein modification; protein ubiquitination. CC -!- SUBUNIT: Interacts with AKAP8L, NONO and SFPQ (PubMed:18313049, CC PubMed:18655028). Interacts with FZD5 (PubMed:22895187). Identified in CC a complex composed of RNF43, LGR5 and RSPO1 (PubMed:23756651). CC Interacts with RSPO2 (PubMed:29769720). Interacts with LMBR1L (By CC similarity). {ECO:0000250|UniProtKB:Q5NCP0, CC ECO:0000269|PubMed:18313049, ECO:0000269|PubMed:18655028, CC ECO:0000269|PubMed:22895187, ECO:0000269|PubMed:23756651, CC ECO:0000269|PubMed:29769720}. CC -!- INTERACTION: CC Q68DV7; Q9ULX6: AKAP8L; NbExp=2; IntAct=EBI-1647060, EBI-357530; CC Q68DV7; Q96S97: MYADM; NbExp=2; IntAct=EBI-1647060, EBI-13301517; CC Q68DV7; P0CG47: UBB; NbExp=2; IntAct=EBI-1647060, EBI-413034; CC Q68DV7; P62837: UBE2D2; NbExp=2; IntAct=EBI-1647060, EBI-347677; CC Q68DV7; P61077: UBE2D3; NbExp=2; IntAct=EBI-1647060, EBI-348268; CC -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane CC protein. Endoplasmic reticulum membrane; Single-pass type I membrane CC protein. Nucleus envelope. Note=According to a report, may be secreted. CC {ECO:0000269|PubMed:15492824}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=Q68DV7-1; Sequence=Displayed; CC Name=2; CC IsoId=Q68DV7-2; Sequence=VSP_037339; CC Name=3; CC IsoId=Q68DV7-3; Sequence=VSP_037338; CC Name=4; CC IsoId=Q68DV7-4; Sequence=VSP_037340; CC -!- TISSUE SPECIFICITY: Expressed in fetal kidney, fetal lung, in colon CC cancer tissues, hepatocellular carcinomas and lung adenocarcinomas. CC Overexpressed in colorectal cancer cell lines. CC {ECO:0000269|PubMed:15492824, ECO:0000269|PubMed:18313049}. CC -!- PTM: Autoubiquitinated. {ECO:0000269|PubMed:18313049}. CC -!- DISEASE: Sessile serrated polyposis cancer syndrome (SSPCS) CC [MIM:617108]: A rare disease characterized by multiple and/or large CC serrated polyps developing in the colon, and an increased personal and CC familial risk of colorectal cancer. A patient is diagnosed with SSPCS CC if at least one of the following criteria is met: the presence of at CC least five sessile serrated polyps proximal to the sigmoid colon, two CC of which are greater than 10 mm in diameter; the presence of any number CC of serrated polyps occurring proximal to the sigmoid colon in an CC individual who has a first-degree relative with serrated polyposis; the CC presence of more than 20 serrated polyps of any size distributed CC throughout the colon. Sessile serrated polyps are also known as sessile CC serrated adenomas (SSA) and are estimated to be responsible for 20 to CC 35% of all colon cancers. Individuals with SSPCS may have a strong CC personal or family history of extracolonic cancers. CC {ECO:0000269|PubMed:24512911, ECO:0000269|PubMed:27081527}. CC Note=Disease susceptibility may be associated with variants affecting CC the gene represented in this entry. CC -!- MISCELLANEOUS: Acts as a cytotoxic T-lymphocyte tumor antigen, CC suggesting that it may be used as a target for cancer immunotherapy. CC {ECO:0000305|PubMed:15623641}. CC -!- SIMILARITY: Belongs to the ZNRF3 family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAH12871.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB081837; BAD51435.1; -; mRNA. DR EMBL; AK000322; BAA91085.1; -; mRNA. DR EMBL; AK291027; BAF83716.1; -; mRNA. DR EMBL; AK296769; BAH12429.1; -; mRNA. DR EMBL; AK298789; BAH12871.1; ALT_INIT; mRNA. DR EMBL; AK299024; BAH12931.1; -; mRNA. DR EMBL; CR627423; CAH10510.1; -; mRNA. DR EMBL; CR749257; CAH18113.1; -; mRNA. DR EMBL; BC109028; AAI09029.1; -; mRNA. DR CCDS; CCDS11607.1; -. [Q68DV7-1] DR CCDS; CCDS82172.1; -. [Q68DV7-3] DR RefSeq; NP_001292473.1; NM_001305544.3. [Q68DV7-1] DR RefSeq; NP_001292474.1; NM_001305545.2. [Q68DV7-3] DR RefSeq; NP_001425749.1; NM_001438820.1. [Q68DV7-4] DR RefSeq; NP_001425750.1; NM_001438821.1. [Q68DV7-4] DR RefSeq; NP_001425751.1; NM_001438822.1. [Q68DV7-1] DR RefSeq; NP_060233.3; NM_017763.5. [Q68DV7-1] DR RefSeq; XP_047292288.1; XM_047436332.1. [Q68DV7-1] DR PDB; 4KNG; X-ray; 2.50 A; E/F=44-198. DR PDB; 8WVU; EM; 3.61 A; C=44-198. DR PDBsum; 4KNG; -. DR PDBsum; 8WVU; -. DR AlphaFoldDB; Q68DV7; -. DR EMDB; EMD-37869; -. DR SMR; Q68DV7; -. DR BioGRID; 120241; 429. DR CORUM; Q68DV7; -. DR FunCoup; Q68DV7; 836. DR IntAct; Q68DV7; 24. DR STRING; 9606.ENSP00000463069; -. DR GlyCosmos; Q68DV7; 2 sites, No reported glycans. DR GlyGen; Q68DV7; 3 sites. DR iPTMnet; Q68DV7; -. DR PhosphoSitePlus; Q68DV7; -. DR BioMuta; RNF43; -. DR DMDM; 74757361; -. DR jPOST; Q68DV7; -. DR MassIVE; Q68DV7; -. DR PaxDb; 9606-ENSP00000463069; -. DR PeptideAtlas; Q68DV7; -. DR ProteomicsDB; 66105; -. [Q68DV7-1] DR ProteomicsDB; 66106; -. [Q68DV7-2] DR ProteomicsDB; 66107; -. [Q68DV7-3] DR ProteomicsDB; 66108; -. [Q68DV7-4] DR ABCD; Q68DV7; 3 sequenced antibodies. DR Antibodypedia; 1979; 194 antibodies from 26 providers. DR DNASU; 54894; -. DR Ensembl; ENST00000407977.7; ENSP00000385328.2; ENSG00000108375.14. [Q68DV7-1] DR Ensembl; ENST00000577625.5; ENSP00000463716.1; ENSG00000108375.14. [Q68DV7-3] DR Ensembl; ENST00000577716.5; ENSP00000462764.1; ENSG00000108375.14. [Q68DV7-1] DR Ensembl; ENST00000583753.5; ENSP00000462502.1; ENSG00000108375.14. [Q68DV7-2] DR Ensembl; ENST00000584437.5; ENSP00000463069.1; ENSG00000108375.14. [Q68DV7-1] DR GeneID; 54894; -. DR KEGG; hsa:54894; -. DR MANE-Select; ENST00000407977.7; ENSP00000385328.2; NM_017763.6; NP_060233.3. DR UCSC; uc002iwf.4; human. [Q68DV7-1] DR AGR; HGNC:18505; -. DR ClinPGx; PA34441; -. DR CTD; 54894; -. DR DisGeNET; 54894; -. DR GeneCards; RNF43; -. DR HGNC; HGNC:18505; RNF43. DR HPA; ENSG00000108375; Tissue enhanced (intestine). DR MalaCards; RNF43; -. DR MIM; 612482; gene. DR MIM; 617108; phenotype. DR OpenTargets; ENSG00000108375; -. DR Orphanet; 157798; Serrated polyposis syndrome. DR VEuPathDB; HostDB:ENSG00000108375; -. DR eggNOG; KOG0800; Eukaryota. DR GeneTree; ENSGT00940000154006; -. DR HOGENOM; CLU_401501_0_0_1; -. DR InParanoid; Q68DV7; -. DR OrthoDB; 8062037at2759; -. DR PAN-GO; Q68DV7; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q68DV7; -. DR BRENDA; 2.3.2.27; 2681. DR PathwayCommons; Q68DV7; -. DR Reactome; R-HSA-4641263; Regulation of FZD by ubiquitination. DR Reactome; R-HSA-5340588; Signaling by RNF43 mutants. DR SignaLink; Q68DV7; -. DR SIGNOR; Q68DV7; -. DR UniPathway; UPA00143; -. DR Agora; ENSG00000108375; -. DR BioGRID-ORCS; 54894; 10 hits in 1114 CRISPR screens. DR ChiTaRS; RNF43; human. DR EvolutionaryTrace; Q68DV7; -. DR GenomeRNAi; 54894; -. DR Pharos; Q68DV7; Tbio. DR PRO; PR:Q68DV7; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q68DV7; protein. DR Bgee; ENSG00000108375; Expressed in cervix squamous epithelium and 144 other cell types or tissues. DR ExpressionAtlas; Q68DV7; baseline and differential. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005635; C:nuclear envelope; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0005109; F:frizzled binding; IPI:UniProtKB. DR GO; GO:0061630; F:ubiquitin protein ligase activity; IBA:GO_Central. DR GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0030178; P:negative regulation of Wnt signaling pathway; IMP:UniProtKB. DR GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB. DR GO; GO:0072089; P:stem cell proliferation; ISS:UniProtKB. DR GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:UniProtKB. DR GO; GO:0038018; P:Wnt receptor catabolic process; IDA:UniProtKB. DR GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW. DR CDD; cd16798; RING-H2_RNF43; 1. DR FunFam; 3.30.40.10:FF:000075; Putative e3 ubiquitin-protein ligase rnf43; 1. DR FunFam; 3.50.30.30:FF:000015; Putative e3 ubiquitin-protein ligase rnf43; 1. DR Gene3D; 3.50.30.30; -; 1. DR Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1. DR InterPro; IPR045907; RNF43_Znf_RING. DR InterPro; IPR001841; Znf_RING. DR InterPro; IPR013083; Znf_RING/FYVE/PHD. DR InterPro; IPR040700; ZNRF-3_ecto. DR InterPro; IPR051073; ZNRF3_Arkadia_E3_ligases. DR PANTHER; PTHR16200; RING ZINC FINGER; 1. DR Pfam; PF13639; zf-RING_2; 1. DR Pfam; PF18212; ZNRF_3_ecto; 1. DR SMART; SM00184; RING; 1. DR SUPFAM; SSF57850; RING/U-box; 1. DR PROSITE; PS50089; ZF_RING_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Cell membrane; Developmental protein; KW Disulfide bond; Endoplasmic reticulum; Glycoprotein; Membrane; KW Metal-binding; Nucleus; Proteomics identification; Reference proteome; KW Signal; Transferase; Transmembrane; Transmembrane helix; Ubl conjugation; KW Ubl conjugation pathway; Wnt signaling pathway; Zinc; Zinc-finger. FT SIGNAL 1..23 FT /evidence="ECO:0000255" FT CHAIN 24..783 FT /note="E3 ubiquitin-protein ligase RNF43" FT /id="PRO_0000278239" FT TOPO_DOM 24..197 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 198..218 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 219..783 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT ZN_FING 272..313 FT /note="RING-type; atypical" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00175" FT REGION 363..406 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 421..477 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 514..673 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 731..760 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 385..395 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 464..477 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 548..568 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 578..594 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 598..614 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 632..648 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT CARBOHYD 62 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 92 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 91..119 FT /evidence="ECO:0000269|PubMed:23756651, FT ECO:0007744|PDB:4KNG" FT VAR_SEQ 1..127 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_037338" FT VAR_SEQ 85..125 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_037339" FT VAR_SEQ 771..783 FT /note="SEEELEELCEQAV -> EFSEGSGCGRERRLQLNISGQVKSANKGLMEAEKD FT TAEMTTKILNHRDSVSCWLECRNTPPLPGATPLVGRSQGGPREVLVWLRHQKGTWKAGC FT DGSCL (in isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_037340" FT VARIANT 47 FT /note="I -> V (in dbSNP:rs3744093)" FT /evidence="ECO:0000269|PubMed:14702039" FT /id="VAR_030713" FT VARIANT 117 FT /note="R -> H (in dbSNP:rs2257205)" FT /id="VAR_030714" FT VARIANT 221 FT /note="R -> Q (in dbSNP:rs2285990)" FT /id="VAR_030715" FT VARIANT 231 FT /note="P -> L (in dbSNP:rs2680701)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:27081527" FT /id="VAR_030716" FT VARIANT 343 FT /note="R -> H (in dbSNP:rs34523089)" FT /id="VAR_052103" FT VARIANT 418 FT /note="L -> M (in dbSNP:rs2526374)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:15492824" FT /id="VAR_030717" FT VARIANT 686 FT /note="P -> R (in dbSNP:rs9652855)" FT /evidence="ECO:0000269|PubMed:17974005" FT /id="VAR_030718" FT MUTAGEN 290 FT /note="C->S: Dominant-negative mutant, loss of E3 ligase FT activity and activation of the Wnt signaling pathway; when FT associated with S-292." FT /evidence="ECO:0000269|PubMed:18313049, FT ECO:0000269|PubMed:22895187" FT MUTAGEN 292 FT /note="H->S: Dominant-negative mutant, loss of E3 ligase FT activity and activation of the Wnt signaling pathway; when FT associated with S-290." FT /evidence="ECO:0000269|PubMed:18313049, FT ECO:0000269|PubMed:22895187" FT MUTAGEN 295 FT /note="H->S: Dominant-negative mutant, loss of E3 ligase FT activity and activation of the Wnt signaling pathway; when FT associated with S-298." FT /evidence="ECO:0000269|PubMed:22895187" FT MUTAGEN 298 FT /note="C->S: Dominant-negative mutant, loss of E3 ligase FT activity and activation of the Wnt signaling pathway; when FT associated with S-295." FT /evidence="ECO:0000269|PubMed:22895187" FT CONFLICT 225 FT /note="R -> H (in Ref. 2; BAH12429)" FT /evidence="ECO:0000305" FT CONFLICT 313 FT /note="M -> V (in Ref. 1; BAD51435 and 2; BAA91085)" FT /evidence="ECO:0000305" FT CONFLICT 401 FT /note="E -> K (in Ref. 2; BAH12429)" FT /evidence="ECO:0000305" FT CONFLICT 600 FT /note="R -> G (in Ref. 1; BAD51435 and 2; BAA91085)" FT /evidence="ECO:0000305" FT STRAND 45..54 FT /evidence="ECO:0007829|PDB:4KNG" FT STRAND 57..59 FT /evidence="ECO:0007829|PDB:4KNG" FT STRAND 63..69 FT /evidence="ECO:0007829|PDB:4KNG" FT STRAND 71..73 FT /evidence="ECO:0007829|PDB:4KNG" FT STRAND 78..84 FT /evidence="ECO:0007829|PDB:4KNG" FT TURN 87..89 FT /evidence="ECO:0007829|PDB:4KNG" FT STRAND 104..108 FT /evidence="ECO:0007829|PDB:4KNG" FT TURN 112..114 FT /evidence="ECO:0007829|PDB:4KNG" FT HELIX 122..131 FT /evidence="ECO:0007829|PDB:4KNG" FT STRAND 135..140 FT /evidence="ECO:0007829|PDB:4KNG" FT HELIX 142..146 FT /evidence="ECO:0007829|PDB:4KNG" FT HELIX 147..150 FT /evidence="ECO:0007829|PDB:4KNG" FT STRAND 157..159 FT /evidence="ECO:0007829|PDB:4KNG" FT STRAND 161..164 FT /evidence="ECO:0007829|PDB:4KNG" FT HELIX 166..176 FT /evidence="ECO:0007829|PDB:4KNG" FT STRAND 177..179 FT /evidence="ECO:0007829|PDB:4KNG" FT STRAND 184..189 FT /evidence="ECO:0007829|PDB:4KNG" SQ SEQUENCE 783 AA; 85722 MW; 4E87EA0CC359C858 CRC64; MSGGHQLQLA ALWPWLLMAT LQAGFGRTGL VLAAAVESER SAEQKAIIRV IPLKMDPTGK LNLTLEGVFA GVAEITPAEG KLMQSHPLYL CNASDDDNLE PGFISIVKLE SPRRAPRPCL SLASKARMAG ERGASAVLFD ITEDRAAAEQ LQQPLGLTWP VVLIWGNDAE KLMEFVYKNQ KAHVRIELKE PPAWPDYDVW ILMTVVGTIF VIILASVLRI RCRPRHSRPD PLQQRTAWAI SQLATRRYQA SCRQARGEWP DSGSSCSSAP VCAICLEEFS EGQELRVISC LHEFHRNCVD PWLHQHRTCP LCMFNITEGD SFSQSLGPSR SYQEPGRRLH LIRQHPGHAH YHLPAAYLLG PSRSAVARPP RPGPFLPSQE PGMGPRHHRF PRAAHPRAPG EQQRLAGAQH PYAQGWGLSH LQSTSQHPAA CPVPLRRARP PDSSGSGESY CTERSGYLAD GPASDSSSGP CHGSSSDSVV NCTDISLQGV HGSSSTFCSS LSSDFDPLVY CSPKGDPQRV DMQPSVTSRP RSLDSVVPTG ETQVSSHVHY HRHRHHHYKK RFQWHGRKPG PETGVPQSRP PIPRTQPQPE PPSPDQQVTR SNSAAPSGRL SNPQCPRALP EPAPGPVDAS SICPSTSSLF NLQKSSLSAR HPQRKRRGGP SEPTPGSRPQ DATVHPACQI FPHYTPSVAY PWSPEAHPLI CGPPGLDKRL LPETPGPCYS NSQPVWLCLT PRQPLEPHPP GEGPSEWSSD TAEGRPCPYP HCQVLSAQPG SEEELEELCE QAV // ID RNZ2_HUMAN Reviewed; 826 AA. AC Q9BQ52; B4DPL9; Q6IA94; Q9HAS8; Q9HAS9; Q9NVT1; DT 16-JAN-2004, integrated into UniProtKB/Swiss-Prot. DT 16-JAN-2004, sequence version 2. DT 28-JAN-2026, entry version 203. DE RecName: Full=Zinc phosphodiesterase ELAC protein 2; DE EC=3.1.26.11; DE AltName: Full=ElaC homolog protein 2; DE AltName: Full=Heredity prostate cancer protein 2; DE AltName: Full=Ribonuclease Z 2; DE Short=RNase Z 2; DE AltName: Full=tRNA 3 endonuclease 2; DE AltName: Full=tRNase Z 2; DE Flags: Precursor; GN Name=ELAC2; Synonyms=HPC2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANTS RP HPC2 LEU-217; THR-541 AND HIS-781. RX PubMed=11175785; DOI=10.1038/84808; RA Tavtigian S.V., Simard J., Teng D.H.F., Abtin V., Baumgard M., Beck A., RA Camp N.J., Carillo A.R., Chen Y., Dayananth P., Desrochers M., Dumont M., RA Farnham J.M., Frank D., Frye C., Ghaffari S., Gupte J.S., Hu R., Iliev D., RA Janecki T., Kort E.N., Laity K.E., Leavitt A., Leblanc G., RA McArthur-Morrison J., Pederson A., Penn B., Peterson K.T., Reid J.E., RA Richards S., Schroeder M., Smith R., Snyder S.C., Swedlund B., Swensen J., RA Thomas A., Tranchant M., Woodland A.-M., Labrie F., Skolnick M.H., RA Neuhausen S., Rommens J., Cannon-Albright L.A.; RT "A candidate prostate cancer susceptibility gene at chromosome 17p."; RL Nat. Genet. 27:172-180(2001). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2; 3 AND 4). RC TISSUE=Hippocampus, Liver, Teratocarcinoma, and Thalamus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT HPC2 RP LEU-217. RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT HPC2 RP LEU-217. RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP ENZYME ACTIVITY, AND CHARACTERIZATION OF VARIANTS HPC2 LEU-217; THR-541 AND RP HIS-781. RX PubMed=12711671; DOI=10.1093/nar/gkg337; RA Takaku H., Minagawa A., Takagi M., Nashimoto M.; RT "A candidate prostate cancer susceptibility gene encodes tRNA 3' processing RT endoribonuclease."; RL Nucleic Acids Res. 31:2272-2278(2003). RN [7] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-199, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [8] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [9] RP INTERACTION WITH PTCD1. RX PubMed=21857155; DOI=10.4161/cc.10.17.17060; RA Sanchez M.I., Mercer T.R., Davies S.M., Shearwood A.M., Nygard K.K., RA Richman T.R., Mattick J.S., Rackham O., Filipovska A.; RT "RNA processing in human mitochondria."; RL Cell Cycle 10:2904-2916(2011). RN [10] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=21593607; DOI=10.4161/rna.8.4.15393; RA Brzezniak L.K., Bijata M., Szczesny R.J., Stepien P.P.; RT "Involvement of human ELAC2 gene product in 3' end processing of RT mitochondrial tRNAs."; RL RNA Biol. 8:616-626(2011). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-199; SER-208; SER-229; RP SER-618 AND SER-736, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=24703694; DOI=10.1016/j.cmet.2014.03.013; RA Bogenhagen D.F., Martin D.W., Koller A.; RT "Initial steps in RNA processing and ribosome assembly occur at RT mitochondrial DNA nucleoids."; RL Cell Metab. 19:618-629(2014). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-208 AND SER-212, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [15] RP VARIANTS HPC2 LEU-217 AND THR-541. RX PubMed=10986046; DOI=10.1086/303096; RA Rebbeck T.R., Walker A.H., Zeigler-Johnson C., Weisburg S., Martin A.-M., RA Nathanson K.L., Wein A.J., Malkowicz S.B.; RT "Association of HPC2/ELAC2 genotypes and prostate cancer."; RL Am. J. Hum. Genet. 67:1014-1019(2000). RN [16] RP VARIANT HPC2 VAL-622. RX PubMed=11507049; RA Roekman A., Ikonen T., Mononen N., Autio V., Matikainen M.P., RA Koivisto P.A., Tammela T.L.J., Kallioniemi O.-P., Schleutker J.; RT "ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer."; RL Cancer Res. 61:6038-6041(2001). RN [17] RP VARIANTS HPC2 GLN-211; LEU-217; ARG-487; THR-541 AND ARG-806. RX PubMed=11522646; RA Wang L., McDonnell S.K., Elkins D.A., Slager S.L., Christensen E., RA Marks A.F., Cunningham J.M., Peterson B.J., Jacobsen S.J., Cerhan J.R., RA Blute M.L., Schaid D.J., Thibodeau S.N.; RT "Role of HPC2/ELAC2 in hereditary prostate cancer."; RL Cancer Res. 61:6494-6499(2001). RN [18] RP VARIANTS HPC2 LEU-217 AND THR-541. RX PubMed=12522685; DOI=10.1007/s100380200099; RA Fujiwara H., Emi M., Nagai H., Nishimura T., Konishi N., Kubota Y., RA Ichikawa T., Takahashi S., Shuin T., Habuchi T., Ogawa O., Inoue K., RA Skolnick M.H., Swensen J., Camp N.J., Tavtigian S.V.; RT "Association of common missense changes in ELAC2 (HPC2) with prostate RT cancer in a Japanese case-control series."; RL J. Hum. Genet. 47:641-648(2002). RN [19] RP VARIANTS HPC2 LEU-217 AND THR-541. RX PubMed=12515253; DOI=10.1086/344516; RA Camp N.J., Tavtigian S.V.; RT "Meta-analysis of associations of the Ser217Leu and Ala541Thr variants in RT ELAC2 (HPC2) and prostate cancer."; RL Am. J. Hum. Genet. 71:1475-1478(2002). RN [20] RP VARIANT LEU-627. RX PubMed=12949798; DOI=10.1002/ijc.11347; RA Takahashi H., Lu W., Watanabe M., Katoh T., Furusato M., Tsukino H., RA Nakao H., Sudo A., Suzuki H., Akakura K., Ikemoto I., Asano K., Ito T., RA Wakui S., Muto T., Hano H.; RT "Ser217Leu polymorphism of the HPC2/ELAC2 gene associated with prostatic RT cancer risk in Japanese men."; RL Int. J. Cancer 107:224-228(2003). RN [21] RP VARIANTS HPC2 LEU-217 AND THR-541. RX PubMed=12783937; DOI=10.1093/jnci/95.11.818; RA Severi G., Giles G.G., Southey M.C., Tesoriero A., Tilley W., Neufing P., RA Morris H., English D.R., McCredie M.R., Boyle P., Hopper J.L.; RT "ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate RT cancer."; RL J. Natl. Cancer Inst. 95:818-824(2003). RN [22] RP VARIANT [LARGE SCALE ANALYSIS] HPC2 LEU-217. RX PubMed=18987736; DOI=10.1038/nature07485; RA Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K., RA Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., Cook L., RA Abbott R., Larson D.E., Koboldt D.C., Pohl C., Smith S., Hawkins A., RA Abbott S., Locke D., Hillier L.W., Miner T., Fulton L., Magrini V., RA Wylie T., Glasscock J., Conyers J., Sander N., Shi X., Osborne J.R., RA Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E., RA Westervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J., Heath S., RA Shannon W.D., Nagarajan R., Walter M.J., Link D.C., Graubert T.A., RA DiPersio J.F., Wilson R.K.; RT "DNA sequencing of a cytogenetically normal acute myeloid leukaemia RT genome."; RL Nature 456:66-72(2008). RN [23] RP VARIANTS COXPD17 LEU-154; PHE-423 AND ILE-520. RX PubMed=23849775; DOI=10.1016/j.ajhg.2013.06.006; RA Haack T.B., Kopajtich R., Freisinger P., Wieland T., Rorbach J., RA Nicholls T.J., Baruffini E., Walther A., Danhauser K., Zimmermann F.A., RA Husain R.A., Schum J., Mundy H., Ferrero I., Strom T.M., Meitinger T., RA Taylor R.W., Minczuk M., Mayr J.A., Prokisch H.; RT "ELAC2 mutations cause a mitochondrial RNA processing defect associated RT with hypertrophic cardiomyopathy."; RL Am. J. Hum. Genet. 93:211-223(2013). CC -!- FUNCTION: Zinc phosphodiesterase, which displays mitochondrial tRNA 3'- CC processing endonuclease activity. Involved in tRNA maturation, by CC removing a 3'-trailer from precursor tRNA (PubMed:21593607). Associates CC with mitochondrial DNA complexes at the nucleoids to initiate RNA CC processing and ribosome assembly (PubMed:24703694). CC {ECO:0000269|PubMed:21593607, ECO:0000269|PubMed:24703694}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Endonucleolytic cleavage of RNA, removing extra 3' nucleotides CC from tRNA precursor, generating 3' termini of tRNAs. A 3'-hydroxy CC group is left at the tRNA terminus and a 5'-phosphoryl group is left CC at the trailer molecule.; EC=3.1.26.11; CC Evidence={ECO:0000269|PubMed:12711671}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000305}; CC -!- SUBUNIT: Homodimer (By similarity). Interacts with PTCD1. {ECO:0000250, CC ECO:0000269|PubMed:21857155}. CC -!- SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:21593607}. CC Mitochondrion matrix, mitochondrion nucleoid CC {ECO:0000269|PubMed:24703694}. Nucleus {ECO:0000269|PubMed:21593607}. CC Note=Mainly mitochondrial. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=Q9BQ52-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9BQ52-2; Sequence=VSP_009169, VSP_009171, VSP_009172; CC Name=3; CC IsoId=Q9BQ52-3; Sequence=VSP_009168, VSP_009170; CC Name=4; CC IsoId=Q9BQ52-4; Sequence=VSP_043449; CC -!- TISSUE SPECIFICITY: Widely expressed. Highly expressed in heart, CC placenta, liver, skeletal muscle, kidney, pancreas, testis and ovary. CC Weakly expressed in brain, lung, spleen, thymus, prostate, small CC intestine, colon and leukocytes. {ECO:0000269|PubMed:11175785}. CC -!- DISEASE: Prostate cancer, hereditary, 2 (HPC2) [MIM:614731]: A CC condition associated with familial predisposition to cancer of the CC prostate. Most prostate cancers are adenocarcinomas that develop in the CC acini of the prostatic ducts. Other rare histopathologic types of CC prostate cancer that occur in approximately 5% of patients include CC small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, CC transitional cell carcinoma, squamous cell carcinoma, basal cell CC carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:10986046, CC ECO:0000269|PubMed:11175785, ECO:0000269|PubMed:11507049, CC ECO:0000269|PubMed:11522646, ECO:0000269|PubMed:12515253, CC ECO:0000269|PubMed:12522685, ECO:0000269|PubMed:12711671, CC ECO:0000269|PubMed:12783937, ECO:0000269|PubMed:15489334, CC ECO:0000269|PubMed:18987736, ECO:0000269|Ref.3}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- DISEASE: Combined oxidative phosphorylation deficiency 17 (COXPD17) CC [MIM:615440]: An autosomal recessive disorder of mitochondrial CC dysfunction characterized by onset of severe hypertrophic CC cardiomyopathy in the first year of life. Other features include CC hypotonia, poor growth, lactic acidosis, and failure to thrive. The CC disorder may be fatal in early childhood. CC {ECO:0000269|PubMed:23849775}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the RNase Z family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40437/ELAC2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF304369; AAG24440.1; -; Genomic_DNA. DR EMBL; AF304370; AAG24441.1; -; mRNA. DR EMBL; AK001392; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AK124838; BAC85964.1; -; mRNA. DR EMBL; AK125030; BAC86026.1; -; mRNA. DR EMBL; AK298397; BAG60631.1; -; mRNA. DR EMBL; CR457261; CAG33542.1; -; mRNA. DR EMBL; AC005277; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC001939; AAH01939.1; -; mRNA. DR EMBL; BC004158; AAH04158.1; -; mRNA. DR CCDS; CCDS11164.1; -. [Q9BQ52-1] DR CCDS; CCDS54093.1; -. [Q9BQ52-4] DR RefSeq; NP_001159434.1; NM_001165962.2. [Q9BQ52-4] DR RefSeq; NP_060597.4; NM_018127.6. [Q9BQ52-1] DR RefSeq; NP_776065.1; NM_173717.1. DR PDB; 8CBL; EM; 2.79 A; E=1-826. DR PDB; 8RR1; EM; 2.93 A; E=32-826. DR PDB; 8RR3; EM; 3.40 A; E=32-826. DR PDB; 8RR4; EM; 3.20 A; E=32-826. DR PDB; 8Z0P; EM; 3.10 A; A=1-826. DR PDB; 8Z1F; EM; 4.30 A; A=1-826. DR PDB; 8Z1G; EM; 3.70 A; A=1-826. DR PDB; 9EY0; EM; 2.78 A; E=31-826. DR PDB; 9EY1; EM; 2.90 A; E=31-826. DR PDB; 9EY2; EM; 2.96 A; E=31-826. DR PDBsum; 8CBL; -. DR PDBsum; 8RR1; -. DR PDBsum; 8RR3; -. DR PDBsum; 8RR4; -. DR PDBsum; 8Z0P; -. DR PDBsum; 8Z1F; -. DR PDBsum; 8Z1G; -. DR PDBsum; 9EY0; -. DR PDBsum; 9EY1; -. DR PDBsum; 9EY2; -. DR AlphaFoldDB; Q9BQ52; -. DR EMDB; EMD-16544; -. DR EMDB; EMD-19453; -. DR EMDB; EMD-19455; -. DR EMDB; EMD-19457; -. DR EMDB; EMD-39710; -. DR EMDB; EMD-39726; -. DR EMDB; EMD-39727; -. DR EMDB; EMD-50050; -. DR EMDB; EMD-50051; -. DR EMDB; EMD-50052; -. DR SMR; Q9BQ52; -. DR BioGRID; 121937; 198. DR ComplexPortal; CPX-2240; Mitochondrial RNase Z complex. DR FunCoup; Q9BQ52; 3637. DR IntAct; Q9BQ52; 55. DR MINT; Q9BQ52; -. DR STRING; 9606.ENSP00000337445; -. DR GlyGen; Q9BQ52; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q9BQ52; -. DR MetOSite; Q9BQ52; -. DR PhosphoSitePlus; Q9BQ52; -. DR SwissPalm; Q9BQ52; -. DR BioMuta; ELAC2; -. DR DMDM; 41017788; -. DR jPOST; Q9BQ52; -. DR MassIVE; Q9BQ52; -. DR PaxDb; 9606-ENSP00000337445; -. DR PeptideAtlas; Q9BQ52; -. DR ProteomicsDB; 78627; -. [Q9BQ52-1] DR ProteomicsDB; 78628; -. [Q9BQ52-2] DR ProteomicsDB; 78629; -. [Q9BQ52-3] DR ProteomicsDB; 78630; -. [Q9BQ52-4] DR Pumba; Q9BQ52; -. DR Antibodypedia; 13065; 203 antibodies from 30 providers. DR DNASU; 60528; -. DR Ensembl; ENST00000338034.9; ENSP00000337445.4; ENSG00000006744.20. [Q9BQ52-1] DR Ensembl; ENST00000426905.7; ENSP00000405223.3; ENSG00000006744.20. [Q9BQ52-4] DR GeneID; 60528; -. DR KEGG; hsa:60528; -. DR MANE-Select; ENST00000338034.9; ENSP00000337445.4; NM_018127.7; NP_060597.4. DR UCSC; uc002gnz.5; human. [Q9BQ52-1] DR AGR; HGNC:14198; -. DR ClinPGx; PA27739; -. DR CTD; 60528; -. DR DisGeNET; 60528; -. DR GeneCards; ELAC2; -. DR HGNC; HGNC:14198; ELAC2. DR HPA; ENSG00000006744; Low tissue specificity. DR MalaCards; ELAC2; -. DR MIM; 176807; phenotype. DR MIM; 605367; gene. DR MIM; 614731; phenotype. DR MIM; 615440; phenotype. DR OpenTargets; ENSG00000006744; -. DR Orphanet; 369913; Combined oxidative phosphorylation defect type 17. DR Orphanet; 1331; Familial prostate cancer. DR VEuPathDB; HostDB:ENSG00000006744; -. DR eggNOG; KOG2121; Eukaryota. DR GeneTree; ENSGT00730000111191; -. DR HOGENOM; CLU_006220_2_0_1; -. DR InParanoid; Q9BQ52; -. DR OMA; INYICQL; -. DR OrthoDB; 527344at2759; -. DR PAN-GO; Q9BQ52; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q9BQ52; -. DR BRENDA; 3.1.26.11; 2681. DR PathwayCommons; Q9BQ52; -. DR Reactome; R-HSA-6784531; tRNA processing in the nucleus. DR Reactome; R-HSA-6785470; tRNA processing in the mitochondrion. DR Reactome; R-HSA-8868766; rRNA processing in the mitochondrion. DR Reactome; R-HSA-9708296; tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis. DR SignaLink; Q9BQ52; -. DR Agora; ENSG00000006744; -. DR BioGRID-ORCS; 60528; 738 hits in 1175 CRISPR screens. DR CD-CODE; F701F3BC; PcG body. DR ChiTaRS; ELAC2; human. DR GeneWiki; ELAC2; -. DR GenomeRNAi; 60528; -. DR Pharos; Q9BQ52; Tbio. DR PRO; PR:Q9BQ52; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q9BQ52; protein. DR Bgee; ENSG00000006744; Expressed in adrenal tissue and 202 other cell types or tissues. DR ExpressionAtlas; Q9BQ52; baseline and differential. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005759; C:mitochondrial matrix; IDA:FlyBase. DR GO; GO:0042645; C:mitochondrial nucleoid; IDA:UniProtKB. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0042781; F:3'-tRNA processing endoribonuclease activity; IBA:GO_Central. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0003723; F:RNA binding; HDA:UniProtKB. DR GO; GO:0004521; F:RNA endonuclease activity; TAS:Reactome. DR GO; GO:0004549; F:tRNA-specific ribonuclease activity; EXP:Reactome. DR GO; GO:1990180; P:mitochondrial tRNA 3'-end processing; IMP:UniProtKB. DR GO; GO:0090646; P:mitochondrial tRNA processing; TAS:Reactome. DR GO; GO:0042780; P:tRNA 3'-end processing; TAS:Reactome. DR GO; GO:0016078; P:tRNA decay; TAS:Reactome. DR CDD; cd07718; RNaseZ_ELAC1_ELAC2-C-term-like_MBL-fold; 1. DR CDD; cd16296; RNaseZ_ELAC2-N-term-like_MBL-fold; 1. DR FunFam; 3.60.15.10:FF:000014; Zinc phosphodiesterase ELAC protein 2; 1. DR Gene3D; 3.60.15.10; Ribonuclease Z/Hydroxyacylglutathione hydrolase-like; 2. DR InterPro; IPR036866; RibonucZ/Hydroxyglut_hydro. DR InterPro; IPR047151; RNZ2-like. DR InterPro; IPR027794; tRNase_Z_dom. DR PANTHER; PTHR12553; ZINC PHOSPHODIESTERASE ELAC PROTEIN 2; 1. DR PANTHER; PTHR12553:SF49; ZINC PHOSPHODIESTERASE ELAC PROTEIN 2; 1. DR Pfam; PF23023; Anti-Pycsar_Apyc1; 1. DR Pfam; PF13691; Lactamase_B_4; 1. DR SUPFAM; SSF56281; Metallo-hydrolase/oxidoreductase; 2. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Disease variant; Endonuclease; KW Hydrolase; Metal-binding; Mitochondrion; Mitochondrion nucleoid; Nuclease; KW Nucleus; Phosphoprotein; Primary mitochondrial disease; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Transit peptide; tRNA processing; Zinc. FT TRANSIT 1..16 FT /note="Mitochondrion" FT /evidence="ECO:0000255" FT CHAIN 17..826 FT /note="Zinc phosphodiesterase ELAC protein 2" FT /id="PRO_0000155828" FT REGION 16..51 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 188..231 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 798..826 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 27..38 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 208..224 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 808..820 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 199 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 208 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 212 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 229 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 618 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 736 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..372 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_009168" FT VAR_SEQ 1..94 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_009169" FT VAR_SEQ 188..227 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_043449" FT VAR_SEQ 373..406 FT /note="NCASVHNLRSHKIQTQLNLIHPDIFPLLTSFRCK -> MRTVPQFTTFAATR FT FKPSSTSSTRTSSPCSPVSA (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_009170" FT VAR_SEQ 554..595 FT /note="GLPSILLQRERALASLGKPLHPLLVVAPNQLKAWLQQYHNQC -> VSVGLD FT HKAGAWRRHCHVELALWLRLFLRFQTCPELLLLISG (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_009171" FT VAR_SEQ 596..826 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_009172" FT VARIANT 52 FT /note="S -> F (in dbSNP:rs9895963)" FT /id="VAR_038210" FT VARIANT 154 FT /note="F -> L (in COXPD17; dbSNP:rs397515465)" FT /evidence="ECO:0000269|PubMed:23849775" FT /id="VAR_070844" FT VARIANT 211 FT /note="R -> Q (in HPC2; dbSNP:rs148419785)" FT /evidence="ECO:0000269|PubMed:11522646" FT /id="VAR_017425" FT VARIANT 217 FT /note="S -> L (in HPC2; risk factor for disease FT development; does not affect the enzymatic activity; FT dbSNP:rs4792311)" FT /evidence="ECO:0000269|PubMed:10986046, FT ECO:0000269|PubMed:11175785, ECO:0000269|PubMed:11522646, FT ECO:0000269|PubMed:12515253, ECO:0000269|PubMed:12522685, FT ECO:0000269|PubMed:12711671, ECO:0000269|PubMed:12783937, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:18987736, FT ECO:0000269|Ref.3" FT /id="VAR_017426" FT VARIANT 423 FT /note="L -> F (in COXPD17; dbSNP:rs397515466)" FT /evidence="ECO:0000269|PubMed:23849775" FT /id="VAR_070845" FT VARIANT 436 FT /note="D -> N (in dbSNP:rs3760317)" FT /id="VAR_038211" FT VARIANT 487 FT /note="G -> R (in HPC2; dbSNP:rs752234492)" FT /evidence="ECO:0000269|PubMed:11522646" FT /id="VAR_017427" FT VARIANT 520 FT /note="T -> I (in COXPD17; dbSNP:rs397515463)" FT /evidence="ECO:0000269|PubMed:23849775" FT /id="VAR_070846" FT VARIANT 541 FT /note="A -> T (in HPC2; risk factor for disease FT development; does not affect the enzymatic activity; FT dbSNP:rs5030739)" FT /evidence="ECO:0000269|PubMed:10986046, FT ECO:0000269|PubMed:11175785, ECO:0000269|PubMed:11522646, FT ECO:0000269|PubMed:12515253, ECO:0000269|PubMed:12522685, FT ECO:0000269|PubMed:12711671, ECO:0000269|PubMed:12783937" FT /id="VAR_017428" FT VARIANT 622 FT /note="E -> V (in HPC2; higher frequency in prostate cancer FT cases; dbSNP:rs119484087)" FT /evidence="ECO:0000269|PubMed:11507049" FT /id="VAR_017429" FT VARIANT 627 FT /note="S -> L (in dbSNP:rs78105154)" FT /evidence="ECO:0000269|PubMed:12949798" FT /id="VAR_017430" FT VARIANT 781 FT /note="R -> H (in HPC2; does not affect the enzymatic FT activity; dbSNP:rs119484086)" FT /evidence="ECO:0000269|PubMed:11175785, FT ECO:0000269|PubMed:12711671" FT /id="VAR_017431" FT VARIANT 806 FT /note="G -> R (in HPC2; dbSNP:rs770669443)" FT /evidence="ECO:0000269|PubMed:11522646" FT /id="VAR_017432" FT CONFLICT 165 FT /note="V -> M (in Ref. 2; AK001392)" FT /evidence="ECO:0000305" FT CONFLICT 406 FT /note="Missing (in Ref. 2; AK001392)" FT /evidence="ECO:0000305" FT CONFLICT 592 FT /note="H -> Y (in Ref. 2; AK001392)" FT /evidence="ECO:0000305" FT CONFLICT 754 FT /note="F -> L (in Ref. 2; AK001392)" FT /evidence="ECO:0000305" FT HELIX 38..46 FT /evidence="ECO:0007829|PDB:9EY0" FT TURN 47..49 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 58..65 FT /evidence="ECO:0007829|PDB:9EY0" FT TURN 68..70 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 72..80 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 82..85 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 91..97 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 102..104 FT /evidence="ECO:0007829|PDB:9EY2" FT STRAND 107..109 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 111..114 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 115..118 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 121..131 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 134..141 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 144..155 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 161..167 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 176..186 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 239..247 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 256..262 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 268..270 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 272..279 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 284..286 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 289..291 FT /evidence="ECO:0007829|PDB:9EY0" FT TURN 293..296 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 305..310 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 314..316 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 317..321 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 324..330 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 333..335 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 338..343 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 346..349 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 352..360 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 365..369 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 380..392 FT /evidence="ECO:0007829|PDB:9EY0" FT TURN 394..396 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 416..418 FT /evidence="ECO:0007829|PDB:9EY2" FT STRAND 424..429 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 432..434 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 443..451 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 453..455 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 456..468 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 481..487 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 489..492 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 495..497 FT /evidence="ECO:0007829|PDB:8Z0P" FT STRAND 499..507 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 510..514 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 520..528 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 529..531 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 532..537 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 539..543 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 546..548 FT /evidence="ECO:0007829|PDB:8Z0P" FT HELIX 549..552 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 555..569 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 576..580 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 584..594 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 599..601 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 602..608 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 619..632 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 634..639 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 643..647 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 651..655 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 660..663 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 671..676 FT /evidence="ECO:0007829|PDB:9EY0" FT TURN 677..679 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 681..686 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 691..693 FT /evidence="ECO:0007829|PDB:8RR1" FT HELIX 694..700 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 705..715 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 720..723 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 729..731 FT /evidence="ECO:0007829|PDB:9EY0" FT TURN 740..742 FT /evidence="ECO:0007829|PDB:9EY2" FT STRAND 743..745 FT /evidence="ECO:0007829|PDB:9EY0" FT STRAND 750..753 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 754..763 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 764..770 FT /evidence="ECO:0007829|PDB:9EY0" FT HELIX 772..790 FT /evidence="ECO:0007829|PDB:9EY0" SQ SEQUENCE 826 AA; 92219 MW; 4AE701C755EC7339 CRC64; MWALCSLLRS AAGRTMSQGR TISQAPARRE RPRKDPLRHL RTREKRGPSG CSGGPNTVYL QVVAAGSRDS GAALYVFSEF NRYLFNCGEG VQRLMQEHKL KVARLDNIFL TRMHWSNVGG LSGMILTLKE TGLPKCVLSG PPQLEKYLEA IKIFSGPLKG IELAVRPHSA PEYEDETMTV YQIPIHSEQR RGKHQPWQSP ERPLSRLSPE RSSDSESNEN EPHLPHGVSQ RRGVRDSSLV VAFICKLHLK RGNFLVLKAK EMGLPVGTAA IAPIIAAVKD GKSITHEGRE ILAEELCTPP DPGAAFVVVE CPDESFIQPI CENATFQRYQ GKADAPVALV VHMAPASVLV DSRYQQWMER FGPDTQHLVL NENCASVHNL RSHKIQTQLN LIHPDIFPLL TSFRCKKEGP TLSVPMVQGE CLLKYQLRPR REWQRDAIIT CNPEEFIVEA LQLPNFQQSV QEYRRSAQDG PAPAEKRSQY PEIIFLGTGS AIPMKIRNVS ATLVNISPDT SLLLDCGEGT FGQLCRHYGD QVDRVLGTLA AVFVSHLHAD HHTGLPSILL QRERALASLG KPLHPLLVVA PNQLKAWLQQ YHNQCQEVLH HISMIPAKCL QEGAEISSPA VERLISSLLR TCDLEEFQTC LVRHCKHAFG CALVHTSGWK VVYSGDTMPC EALVRMGKDA TLLIHEATLE DGLEEEAVEK THSTTSQAIS VGMRMNAEFI MLNHFSQRYA KVPLFSPNFS EKVGVAFDHM KVCFGDFPTM PKLIPPLKAL FAGDIEEMEE RREKRELRQV RAALLSRELA GGLEDGEPQQ KRAHTEEPQA KKVRAQ // ID RON_HUMAN Reviewed; 1400 AA. AC Q04912; A0A087WZG2; B5A944; B5A945; B5A946; B5A947; DT 01-OCT-1994, integrated into UniProtKB/Swiss-Prot. DT 28-MAR-2018, sequence version 3. DT 28-JAN-2026, entry version 236. DE RecName: Full=Macrophage-stimulating protein receptor; DE Short=MSP receptor; DE EC=2.7.10.1; DE AltName: Full=CDw136; DE AltName: Full=Protein-tyrosine kinase 8; DE AltName: Full=p185-Ron; DE AltName: CD_antigen=CD136; DE Contains: DE RecName: Full=Macrophage-stimulating protein receptor alpha chain; DE Contains: DE RecName: Full=Macrophage-stimulating protein receptor beta chain; DE Flags: Precursor; GN Name=MST1R; Synonyms=PTK8, RON; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM RON), AND VARIANTS GLN-322 AND ARG-523. RC TISSUE=Keratinocyte; RX PubMed=8386824; RA Ronsin C., Muscatelli F., Mattei M.-G., Breathnach R.; RT "A novel putative receptor protein tyrosine kinase of the met family."; RL Oncogene 8:1195-1202(1993). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], AND ALTERNATIVE SPLICING. RX PubMed=8816464; DOI=10.1128/mcb.16.10.5518; RA Collesi C., Santoro M.M., Gaudino G., Comoglio P.M.; RT "A splicing variant of the RON transcript induces constitutive tyrosine RT kinase activity and an invasive phenotype."; RL Mol. Cell. Biol. 16:5518-5526(1996). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS RON-1; RON-2; RON-3 AND RON-4). RX PubMed=18593464; DOI=10.1186/ar2447; RA Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D., RA Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.; RT "Novel splice variants derived from the receptor tyrosine kinase RT superfamily are potential therapeutics for rheumatoid arthritis."; RL Arthritis Res. Ther. 10:R73-R73(2008). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [5] RP INTERACTION WITH PIK3R1. RX PubMed=7687741; DOI=10.1128/mcb.13.8.4600-4608.1993; RA Ponzetto C., Bardelli A., Maina F., Longati P., Panayotou G., Dhand R., RA Waterfield M.D., Comoglio P.M.; RT "A novel recognition motif for phosphatidylinositol 3-kinase binding RT mediates its association with the hepatocyte growth factor/scatter factor RT receptor."; RL Mol. Cell. Biol. 13:4600-4608(1993). RN [6] RP TISSUE SPECIFICITY. RX PubMed=8062829; DOI=10.1002/j.1460-2075.1994.tb06659.x; RA Gaudino G., Follenzi A., Naldini L., Collesi C., Santoro M., Gallo K.A., RA Godowski P.J., Comoglio P.M.; RT "RON is a heterodimeric tyrosine kinase receptor activated by the HGF RT homologue MSP."; RL EMBO J. 13:3524-3532(1994). RN [7] RP FUNCTION. RX PubMed=7939629; DOI=10.1126/science.7939629; RA Wang M.-H., Ronsin C., Gesnel M.-C., Coupey L., Skeel A., Leonard E.J., RA Breatnach R.; RT "Identification of the ron gene product as the receptor for the human RT macrophage stimulating protein."; RL Science 266:117-119(1994). RN [8] RP FUNCTION IN WOUND HEALING RESPONSE. RX PubMed=9764835; DOI=10.1046/j.1523-1747.1998.00332.x; RA Nanney L.B., Skeel A., Luan J., Polis S., Richmond A., Wang M.H., RA Leonard E.J.; RT "Proteolytic cleavage and activation of pro-macrophage-stimulating protein RT and upregulation of its receptor in tissue injury."; RL J. Invest. Dermatol. 111:573-581(1998). RN [9] RP INTERACTION WITH ITGB1. RX PubMed=10222149; DOI=10.1006/excr.1999.4429; RA Danilkovitch A., Skeel A., Leonard E.J.; RT "Macrophage stimulating protein-induced epithelial cell adhesion is RT mediated by a PI3-K-dependent, but FAK-independent mechanism."; RL Exp. Cell Res. 248:575-582(1999). RN [10] RP INTERACTION WITH MST1. RX PubMed=10514476; DOI=10.1074/jbc.274.42.29937; RA Danilkovitch A., Miller M., Leonard E.J.; RT "Interaction of macrophage-stimulating protein with its receptor. Residues RT critical for beta chain binding and evidence for independent alpha chain RT binding."; RL J. Biol. Chem. 274:29937-29943(1999). RN [11] RP REVIEW ON FUNCTION. RX PubMed=12472665; DOI=10.1046/j.1365-3083.2002.01177.x; RA Wang M.H., Zhou Y.Q., Chen Y.Q.; RT "Macrophage-stimulating protein and RON receptor tyrosine kinase: potential RT regulators of macrophage inflammatory activities."; RL Scand. J. Immunol. 56:545-553(2002). RN [12] RP UBIQUITINATION. RX PubMed=12802274; DOI=10.1038/sj.onc.1206585; RA Penengo L., Rubin C., Yarden Y., Gaudino G.; RT "c-Cbl is a critical modulator of the Ron tyrosine kinase receptor."; RL Oncogene 22:3669-3679(2003). RN [13] RP INTERACTION WITH HYAL2. RX PubMed=12676986; DOI=10.1073/pnas.0837136100; RA Danilkovitch-Miagkova A., Duh F.-M., Kuzmin I., Angeloni D., Liu S.-L., RA Miller A.D., Lerman M.I.; RT "Hyaluronidase 2 negatively regulates RON receptor tyrosine kinase and RT mediates transformation of epithelial cells by jaagsiekte sheep RT retrovirus."; RL Proc. Natl. Acad. Sci. U.S.A. 100:4580-4585(2003). RN [14] RP INTERACTION WITH PLXNB1. RX PubMed=15184888; DOI=10.1038/sj.onc.1207650; RA Conrotto P., Corso S., Gamberini S., Comoglio P.M., Giordano S.; RT "Interplay between scatter factor receptors and B plexins controls invasive RT growth."; RL Oncogene 23:5131-5137(2004). RN [15] RP PHOSPHORYLATION AT TYR-1238; TYR-1239; TYR-1353 AND TYR-1360, AND ACTIVITY RP REGULATION. RX PubMed=15632155; DOI=10.1074/jbc.m412623200; RA Yokoyama N., Ischenko I., Hayman M.J., Miller W.T.; RT "The C terminus of RON tyrosine kinase plays an autoinhibitory role."; RL J. Biol. Chem. 280:8893-8900(2005). RN [16] RP FUNCTION. RX PubMed=18836480; DOI=10.1038/onc.2008.383; RA Feres K.J., Ischenko I., Hayman M.J.; RT "The RON receptor tyrosine kinase promotes MSP-independent cell spreading RT and survival in breast epithelial cells."; RL Oncogene 28:279-288(2009). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [18] RP INTERACTION WITH GAB1 AND GRB2. RX PubMed=21784853; DOI=10.1074/jbc.m111.239384; RA Chaudhuri A., Xie M.H., Yang B., Mahapatra K., Liu J., Marsters S., RA Bodepudi S., Ashkenazi A.; RT "Distinct involvement of the Gab1 and Grb2 adaptor proteins in signal RT transduction by the related receptor tyrosine kinases RON and MET."; RL J. Biol. Chem. 286:32762-32774(2011). RN [19] RP GLYCOSYLATION BY TMEM260. RX PubMed=37186866; DOI=10.1073/pnas.2302584120; RA Larsen I.S.B., Povolo L., Zhou L., Tian W., Mygind K.J., Hintze J., RA Jiang C., Hartill V., Prescott K., Johnson C.A., Mullegama S.V., RA McConkie-Rosell A., McDonald M., Hansen L., Vakhrushev S.Y., RA Schjoldager K.T., Clausen H., Worzfeld T., Joshi H.J., Halim A.; RT "The SHDRA syndrome-associated geDne TMEM260 encodes a protein-specific O- RT mannosyltransferase."; RL Proc. Natl. Acad. Sci. U.S.A. 120:e2302584120-e2302584120(2023). RN [20] RP X-RAY CRYSTALLOGRAPHY (2.24 ANGSTROMS) OF 1060-1357 IN COMPLEX WITH AMP-PNP RP AND MAGNESIUM, ACTIVE SITE, AND PHOSPHORYLATION AT TYR-1238. RX PubMed=20726546; DOI=10.1021/bi100409w; RA Wang J., Steinbacher S., Augustin M., Schreiner P., Epstein D., RA Mulvihill M.J., Crew A.P.; RT "The crystal structure of a constitutively active mutant RON kinase RT suggests an intramolecular autophosphorylation hypothesis."; RL Biochemistry 49:7972-7974(2010). RN [21] RP X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 42-568, GLYCOSYLATION AT ASN-488, RP AND DISULFIDE BONDS. RX PubMed=22848655; DOI=10.1371/journal.pone.0041912; RA Chao K.L., Tsai I.W., Chen C., Herzberg O.; RT "Crystal structure of the Sema-PSI extracellular domain of human RON RT receptor tyrosine kinase."; RL PLoS ONE 7:E41912-E41912(2012). RN [22] RP VARIANTS [LARGE SCALE ANALYSIS] SER-75; THR-95; CYS-185; GLN-322; ASP-356; RP LEU-434; ASP-465; CYS-504; ARG-523; PRO-613; MET-900; GLY-1304; GLY-1335 RP AND CYS-1360. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [23] RP VARIANTS NPCA3 HIS-306; THR-327; GLY-670 AND THR-973, AND INVOLVEMENT IN RP NPCA3. RX PubMed=26951679; DOI=10.1073/pnas.1523436113; RA Dai W., Zheng H., Cheung A.K., Tang C.S., Ko J.M., Wong B.W., Leong M.M., RA Sham P.C., Cheung F., Kwong D.L., Ngan R.K., Ng W.T., Yau C.C., Pan J., RA Peng X., Tung S., Zhang Z., Ji M., Chiang A.K., Lee A.W., Lee V.H., RA Lam K.O., Au K.H., Cheng H.C., Yiu H.H., Lung M.L.; RT "Whole-exome sequencing identifies MST1R as a genetic susceptibility gene RT in nasopharyngeal carcinoma."; RL Proc. Natl. Acad. Sci. U.S.A. 113:3317-3322(2016). CC -!- FUNCTION: Receptor tyrosine kinase that transduces signals from the CC extracellular matrix into the cytoplasm by binding to MST1 ligand. CC Regulates many physiological processes including cell survival, CC migration and differentiation. Ligand binding at the cell surface CC induces autophosphorylation of RON on its intracellular domain that CC provides docking sites for downstream signaling molecules. Following CC activation by ligand, interacts with the PI3-kinase subunit PIK3R1, CC PLCG1 or the adapter GAB1. Recruitment of these downstream effectors by CC RON leads to the activation of several signaling cascades including the CC RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. RON signaling activates the CC wound healing response by promoting epithelial cell migration, CC proliferation as well as survival at the wound site. Also plays a role CC in the innate immune response by regulating the migration and CC phagocytic activity of macrophages. Alternatively, RON can also promote CC signals such as cell migration and proliferation in response to growth CC factors other than MST1 ligand. {ECO:0000269|PubMed:18836480, CC ECO:0000269|PubMed:7939629, ECO:0000269|PubMed:9764835}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- ACTIVITY REGULATION: In its inactive state, the C-terminal tail CC interacts with the catalytic domain and inhibits the kinase activity. CC Upon ligand binding, the C-terminal tail is displaced and becomes CC phosphorylated, thus increasing the kinase activity. CC {ECO:0000269|PubMed:15632155}. CC -!- SUBUNIT: Heterodimer of an alpha chain and a beta chain which are CC disulfide linked. Binds PLXNB1. Associates with and is negatively CC regulated by HYAL2. Interacts when phosphorylated with downstream CC effectors including PIK3R1, PCLG1, GRB2 and GAB1. Interacts with CC integrin beta1/ITGB1 in a ligand-independent fashion. CC {ECO:0000269|PubMed:10222149, ECO:0000269|PubMed:10514476, CC ECO:0000269|PubMed:12676986, ECO:0000269|PubMed:15184888, CC ECO:0000269|PubMed:20726546, ECO:0000269|PubMed:21784853, CC ECO:0000269|PubMed:7687741}. CC -!- INTERACTION: CC Q04912; P26927: MST1; NbExp=5; IntAct=EBI-2637518, EBI-6929133; CC Q04912; O43157: PLXNB1; NbExp=3; IntAct=EBI-2637518, EBI-1111488; CC Q04912; O15031: PLXNB2; NbExp=2; IntAct=EBI-2637518, EBI-722004; CC Q04912; Q9ULL4: PLXNB3; NbExp=2; IntAct=EBI-2637518, EBI-311073; CC -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=7; CC Name=RON; CC IsoId=Q04912-1; Sequence=Displayed; CC Name=Delta-RON; Synonyms=sf-RON; CC IsoId=Q04912-2; Sequence=VSP_005007; CC Name=RON-1; CC IsoId=Q04912-3; Sequence=VSP_038920, VSP_038921; CC Name=RON-2; CC IsoId=Q04912-4; Sequence=VSP_038919, VSP_038922, VSP_038923; CC Name=RON-3; CC IsoId=Q04912-5; Sequence=VSP_038924, VSP_038925; CC Name=RON-4; CC IsoId=Q04912-6; Sequence=VSP_038922, VSP_038923; CC Name=RON-5; CC IsoId=Q04912-7; Sequence=VSP_038919; CC -!- TISSUE SPECIFICITY: Expressed in colon, skin, lung and bone marrow. CC {ECO:0000269|PubMed:8062829}. CC -!- PTM: Proteolytic processing yields the two subunits. CC -!- PTM: Autophosphorylated in response to ligand binding on Tyr-1238 and CC Tyr-1239 in the kinase domain leading to further phosphorylation of CC Tyr-1353 and Tyr-1360 in the C-terminal multifunctional docking site. CC {ECO:0000269|PubMed:15632155, ECO:0000269|PubMed:20726546}. CC -!- PTM: Ubiquitinated. Ubiquitination by CBL regulates the receptor CC stability and activity through proteasomal degradation. CC {ECO:0000269|PubMed:12802274}. CC -!- PTM: O-mannosylation of IPT/TIG domains on Thr or Ser residues by CC TMEM260 is required for protein maturation (PubMed:37186866). O- CC mannosylated residues are composed of single mannose glycans that are CC not elongated or modified (PubMed:37186866). CC {ECO:0000269|PubMed:37186866}. CC -!- DISEASE: Nasopharyngeal carcinoma, 3 (NPCA3) [MIM:617075]: A form of CC nasopharyngeal carcinoma, a malignant neoplasm that originates in the CC nasopharyngeal epithelium and includes 4 subtypes: keratinizing CC squamous cell, non-keratinizing, basaloid squamous cell, and papillary CC adenocarcinoma. {ECO:0000269|PubMed:26951679}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- MISCELLANEOUS: [Isoform Delta-RON]: Lacks part of the extracellular CC domain, oligomerizes and is constitutively activated. Expressed at CC higher level in cancer cells. {ECO:0000303|PubMed:26951679}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/287/RON"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X70040; CAA49634.1; -; mRNA. DR EMBL; EU826582; ACF47618.1; -; mRNA. DR EMBL; EU826583; ACF47619.1; -; mRNA. DR EMBL; EU826584; ACF47620.1; -; mRNA. DR EMBL; EU826585; ACF47621.1; -; mRNA. DR EMBL; AC105935; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; KC876868; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS2807.1; -. [Q04912-1] DR CCDS; CCDS58833.1; -. [Q04912-2] DR CCDS; CCDS82777.1; -. [Q04912-7] DR PIR; I38185; I38185. DR RefSeq; NP_001231866.1; NM_001244937.3. [Q04912-2] DR RefSeq; NP_001305842.1; NM_001318913.2. [Q04912-7] DR RefSeq; NP_002438.2; NM_002447.4. [Q04912-1] DR PDB; 3PLS; X-ray; 2.24 A; A=1060-1357. DR PDB; 4FWW; X-ray; 1.85 A; A=42-568. DR PDB; 4QT8; X-ray; 3.00 A; A/B=25-683. DR PDB; 8ZKD; X-ray; 2.05 A; A=1060-1357. DR PDBsum; 3PLS; -. DR PDBsum; 4FWW; -. DR PDBsum; 4QT8; -. DR PDBsum; 8ZKD; -. DR AlphaFoldDB; Q04912; -. DR SMR; Q04912; -. DR BioGRID; 110592; 245. DR CORUM; Q04912; -. DR DIP; DIP-6029N; -. DR FunCoup; Q04912; 389. DR IntAct; Q04912; 158. DR MINT; Q04912; -. DR STRING; 9606.ENSP00000296474; -. DR BindingDB; Q04912; -. DR ChEMBL; CHEMBL2689; -. DR DrugBank; DB08865; Crizotinib. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q04912; -. DR GuidetoPHARMACOLOGY; 1816; -. DR GlyCosmos; Q04912; 8 sites, No reported glycans. DR GlyGen; Q04912; 9 sites, 5 N-linked glycans (5 sites). DR iPTMnet; Q04912; -. DR PhosphoSitePlus; Q04912; -. DR SwissPalm; Q04912; -. DR BioMuta; MST1R; -. DR DMDM; 294862462; -. DR CPTAC; CPTAC-2850; -. DR CPTAC; CPTAC-2851; -. DR jPOST; Q04912; -. DR MassIVE; Q04912; -. DR PaxDb; 9606-ENSP00000296474; -. DR PeptideAtlas; Q04912; -. DR ProteomicsDB; 58294; -. [Q04912-1] DR ProteomicsDB; 58295; -. [Q04912-2] DR ProteomicsDB; 58296; -. [Q04912-3] DR ProteomicsDB; 58297; -. [Q04912-4] DR ProteomicsDB; 58298; -. [Q04912-5] DR ProteomicsDB; 58299; -. [Q04912-6] DR ABCD; Q04912; 13 sequenced antibodies. DR Antibodypedia; 2092; 977 antibodies from 41 providers. DR DNASU; 4486; -. DR Ensembl; ENST00000296474.8; ENSP00000296474.3; ENSG00000164078.16. [Q04912-1] DR Ensembl; ENST00000344206.8; ENSP00000341325.4; ENSG00000164078.16. [Q04912-2] DR Ensembl; ENST00000621387.4; ENSP00000482642.1; ENSG00000164078.16. [Q04912-7] DR GeneID; 4486; -. DR KEGG; hsa:4486; -. DR MANE-Select; ENST00000296474.8; ENSP00000296474.3; NM_002447.4; NP_002438.2. DR UCSC; uc003cxy.5; human. [Q04912-1] DR AGR; HGNC:7381; -. DR ClinPGx; PA31186; -. DR CTD; 4486; -. DR DisGeNET; 4486; -. DR GeneCards; MST1R; -. DR HGNC; HGNC:7381; MST1R. DR HPA; ENSG00000164078; Tissue enhanced (intestine, skin, stomach). DR MalaCards; MST1R; -. DR MIM; 600168; gene. DR MIM; 617075; phenotype. DR OpenTargets; ENSG00000164078; -. DR VEuPathDB; HostDB:ENSG00000164078; -. DR eggNOG; KOG1095; Eukaryota. DR eggNOG; KOG3610; Eukaryota. DR GeneTree; ENSGT00940000157842; -. DR HOGENOM; CLU_005158_0_0_1; -. DR InParanoid; Q04912; -. DR OrthoDB; 9985181at2759; -. DR PAN-GO; Q04912; 11 GO annotations based on evolutionary models. DR PhylomeDB; Q04912; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; Q04912; -. DR Reactome; R-HSA-8852405; Signaling by MST1. DR SignaLink; Q04912; -. DR SIGNOR; Q04912; -. DR Agora; ENSG00000164078; -. DR BioGRID-ORCS; 4486; 8 hits in 1184 CRISPR screens. DR ChiTaRS; MST1R; human. DR EvolutionaryTrace; Q04912; -. DR GeneWiki; MST1R; -. DR GenomeRNAi; 4486; -. DR Pharos; Q04912; Tchem. DR PRO; PR:Q04912; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q04912; protein. DR Bgee; ENSG00000164078; Expressed in mucosa of transverse colon and 116 other cell types or tissues. DR ExpressionAtlas; Q04912; baseline and differential. DR GO; GO:0009986; C:cell surface; HDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0001725; C:stress fiber; IEA:Ensembl. DR GO; GO:0005773; C:vacuole; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0005011; F:macrophage colony-stimulating factor receptor activity; TAS:ProtInc. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0016477; P:cell migration; IBA:GO_Central. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0006952; P:defense response; TAS:ProtInc. DR GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW. DR GO; GO:0007399; P:nervous system development; IBA:GO_Central. DR GO; GO:0006909; P:phagocytosis; IBA:GO_Central. DR GO; GO:0008284; P:positive regulation of cell population proliferation; TAS:ProtInc. DR GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:UniProtKB. DR GO; GO:0009615; P:response to virus; IDA:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0007338; P:single fertilization; TAS:ProtInc. DR CDD; cd00102; IPT; 1. DR CDD; cd01180; IPT_plexin_repeat1; 1. DR CDD; cd01179; IPT_plexin_repeat2; 1. DR CDD; cd05058; PTKc_Met_Ron; 1. DR CDD; cd11279; Sema_RON; 1. DR FunFam; 1.10.510.10:FF:000093; Hepatocyte growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000213; Hepatocyte growth factor receptor; 1. DR FunFam; 2.60.40.10:FF:000679; Macrophage stimulating 1 receptor; 1. DR FunFam; 3.30.200.20:FF:000251; Macrophage stimulating 1 receptor; 1. DR FunFam; 2.130.10.10:FF:000194; Macrophage-stimulating 1 receptor a; 1. DR FunFam; 3.30.1680.10:FF:000006; Macrophage-stimulating 1 receptor b; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.1680.10; ligand-binding face of the semaphorins, domain 2; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.130.10.10; YVTN repeat-like/Quinoprotein amine dehydrogenase; 1. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR014756; Ig_E-set. DR InterPro; IPR002909; IPT_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR002165; Plexin_repeat. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR016201; PSI. DR InterPro; IPR039413; RON_Sema. DR InterPro; IPR050122; RTK. DR InterPro; IPR001627; Semap_dom. DR InterPro; IPR036352; Semap_dom_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016244; Tyr_kinase_HGF/MSP_rcpt. DR InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf. DR PANTHER; PTHR24416:SF564; MACROPHAGE-STIMULATING PROTEIN RECEPTOR; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF01437; PSI; 1. DR Pfam; PF01403; Sema; 1. DR Pfam; PF01833; TIG; 3. DR PIRSF; PIRSF000617; TyrPK_HGF-R; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00429; IPT; 3. DR SMART; SM00423; PSI; 1. DR SMART; SM00630; Sema; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF81296; E set domains; 3. DR SUPFAM; SSF103575; Plexin repeat; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF101912; Sema domain; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS51004; SEMA; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; KW Cleavage on pair of basic residues; Disease variant; Disulfide bond; KW Glycoprotein; Immunity; Innate immunity; Kinase; Membrane; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; Receptor; KW Reference proteome; Repeat; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..24 FT /evidence="ECO:0000255" FT CHAIN 25..1400 FT /note="Macrophage-stimulating protein receptor" FT /id="PRO_0000024452" FT CHAIN 25..304 FT /note="Macrophage-stimulating protein receptor alpha chain" FT /evidence="ECO:0000255" FT /id="PRO_0000024453" FT CHAIN 310..1400 FT /note="Macrophage-stimulating protein receptor beta chain" FT /evidence="ECO:0000255" FT /id="PRO_0000024454" FT TOPO_DOM 25..957 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 958..978 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 979..1400 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 31..522 FT /note="Sema" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00352" FT DOMAIN 569..671 FT /note="IPT/TIG 1" FT DOMAIN 684..767 FT /note="IPT/TIG 2" FT DOMAIN 770..860 FT /note="IPT/TIG 3" FT DOMAIN 1082..1345 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1367..1400 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 1208 FT /note="Proton acceptor" FT /evidence="ECO:0000305|PubMed:20726546" FT BINDING 1088..1096 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 1114 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 1161..1164 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 1212 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT MOD_RES 1238 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:15632155, FT ECO:0000305|PubMed:20726546" FT MOD_RES 1239 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:15632155" FT MOD_RES 1353 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15632155" FT MOD_RES 1360 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15632155" FT CARBOHYD 66 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 419 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 458 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 488 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:22848655" FT CARBOHYD 654 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 720 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 841 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 897 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 101..104 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00352, FT ECO:0000269|PubMed:22848655" FT DISULFID 107..162 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00352, FT ECO:0000269|PubMed:22848655" FT DISULFID 135..143 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00352, FT ECO:0000269|PubMed:22848655" FT DISULFID 174..177 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00352, FT ECO:0000269|PubMed:22848655" FT DISULFID 300..367 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00352, FT ECO:0000269|PubMed:22848655" FT DISULFID 385..407 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00352, FT ECO:0000269|PubMed:22848655" FT DISULFID 386..422 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00352, FT ECO:0000269|PubMed:22848655" FT DISULFID 527..545 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00352, FT ECO:0000269|PubMed:22848655" FT DISULFID 533..567 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00352, FT ECO:0000269|PubMed:22848655" FT DISULFID 536..552 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00352, FT ECO:0000269|PubMed:22848655" FT DISULFID 548..558 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00352, FT ECO:0000269|PubMed:22848655" FT VAR_SEQ 411..516 FT /note="Missing (in isoform RON-2 and isoform RON-5)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_038919" FT VAR_SEQ 475..495 FT /note="ELVRSLNYLLYVSNFSLGDSG -> GPHPHSPLALGPCLHPHFAHI (in FT isoform RON-1)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_038920" FT VAR_SEQ 496..1400 FT /note="Missing (in isoform RON-1)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_038921" FT VAR_SEQ 628..647 FT /note="PVPRKDFVEEFECELEPLGT -> YNLVPPLPFPEGGNQAAPSP (in FT isoform RON-2 and isoform RON-4)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_038922" FT VAR_SEQ 648..1400 FT /note="Missing (in isoform RON-2 and isoform RON-4)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_038923" FT VAR_SEQ 884..932 FT /note="Missing (in isoform Delta-RON)" FT /evidence="ECO:0000305" FT /id="VSP_005007" FT VAR_SEQ 884..907 FT /note="YIGLGAVADCVGINVTVGGESCQH -> VSVRDRGRDSWGSESRGQPTGWSS FT (in isoform RON-3)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_038924" FT VAR_SEQ 908..1400 FT /note="Missing (in isoform RON-3)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_038925" FT VARIANT 75 FT /note="R -> S (in dbSNP:rs35887539)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041768" FT VARIANT 95 FT /note="P -> T (in dbSNP:rs55908300)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041769" FT VARIANT 185 FT /note="R -> C (in dbSNP:rs55633379)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041770" FT VARIANT 306 FT /note="R -> H (in NPCA3; dbSNP:rs200046052)" FT /evidence="ECO:0000269|PubMed:26951679" FT /id="VAR_076928" FT VARIANT 322 FT /note="R -> Q (in dbSNP:rs2230593)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:8386824" FT /id="VAR_006350" FT VARIANT 327 FT /note="A -> T (in NPCA3; uncertain significance; FT dbSNP:rs200757776)" FT /evidence="ECO:0000269|PubMed:26951679" FT /id="VAR_076929" FT VARIANT 356 FT /note="G -> D (in dbSNP:rs35924402)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041771" FT VARIANT 434 FT /note="S -> L (in dbSNP:rs2230591)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_029238" FT VARIANT 440 FT /note="N -> S (in dbSNP:rs2230592)" FT /id="VAR_029239" FT VARIANT 465 FT /note="G -> D (in dbSNP:rs34564898)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041772" FT VARIANT 504 FT /note="R -> C (in dbSNP:rs34350470)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041773" FT VARIANT 523 FT /note="Q -> R (in dbSNP:rs2230590)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:8386824" FT /id="VAR_041774" FT VARIANT 613 FT /note="Q -> P (in dbSNP:rs35986685)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041775" FT VARIANT 670 FT /note="V -> G (in NPCA3; uncertain significance; FT dbSNP:rs201024956)" FT /evidence="ECO:0000269|PubMed:26951679" FT /id="VAR_076930" FT VARIANT 900 FT /note="V -> M (in dbSNP:rs56091918)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041776" FT VARIANT 973 FT /note="A -> T (in NPCA3; uncertain significance; FT dbSNP:rs773053723)" FT /evidence="ECO:0000269|PubMed:26951679" FT /id="VAR_076931" FT VARIANT 1195 FT /note="G -> S (in dbSNP:rs7433231)" FT /id="VAR_061749" FT VARIANT 1304 FT /note="R -> G (in dbSNP:rs528985327)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041777" FT VARIANT 1335 FT /note="R -> G (in dbSNP:rs1062633)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_024577" FT VARIANT 1360 FT /note="Y -> C (in dbSNP:rs56330223)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041778" FT CONFLICT 209 FT /note="A -> G (in Ref. 1; CAA49634)" FT /evidence="ECO:0000305" FT CONFLICT 813 FT /note="R -> RQ (in Ref. 3; ACF47620)" FT /evidence="ECO:0000305" FT STRAND 43..45 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 48..50 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 55..62 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 64..66 FT /evidence="ECO:0007829|PDB:4QT8" FT STRAND 68..74 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 77..81 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 87..92 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 96..98 FT /evidence="ECO:0007829|PDB:4QT8" FT HELIX 102..105 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 108..110 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 120..126 FT /evidence="ECO:0007829|PDB:4FWW" FT TURN 127..130 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 131..138 FT /evidence="ECO:0007829|PDB:4FWW" FT HELIX 139..141 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 143..151 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 154..157 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 161..163 FT /evidence="ECO:0007829|PDB:4QT8" FT TURN 166..168 FT /evidence="ECO:0007829|PDB:4QT8" FT STRAND 184..191 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 194..201 FT /evidence="ECO:0007829|PDB:4FWW" FT HELIX 205..208 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 209..211 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 215..221 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 233..235 FT /evidence="ECO:0007829|PDB:4FWW" FT HELIX 239..242 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 248..255 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 258..268 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 269..271 FT /evidence="ECO:0007829|PDB:4QT8" FT STRAND 275..288 FT /evidence="ECO:0007829|PDB:4FWW" FT HELIX 290..292 FT /evidence="ECO:0007829|PDB:4QT8" FT STRAND 294..302 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 309..311 FT /evidence="ECO:0007829|PDB:4QT8" FT STRAND 316..318 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 320..328 FT /evidence="ECO:0007829|PDB:4FWW" FT HELIX 331..337 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 344..351 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 365..370 FT /evidence="ECO:0007829|PDB:4FWW" FT HELIX 371..386 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 387..389 FT /evidence="ECO:0007829|PDB:4FWW" FT TURN 399..401 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 407..409 FT /evidence="ECO:0007829|PDB:4QT8" FT HELIX 422..424 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 433..436 FT /evidence="ECO:0007829|PDB:4FWW" FT TURN 438..445 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 448..456 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 459..466 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 469..475 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 485..491 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 503..505 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 508..513 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 516..521 FT /evidence="ECO:0007829|PDB:4FWW" FT HELIX 527..529 FT /evidence="ECO:0007829|PDB:4FWW" FT HELIX 533..538 FT /evidence="ECO:0007829|PDB:4FWW" FT HELIX 541..543 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 549..553 FT /evidence="ECO:0007829|PDB:4FWW" FT HELIX 555..557 FT /evidence="ECO:0007829|PDB:4FWW" FT TURN 559..561 FT /evidence="ECO:0007829|PDB:4FWW" FT STRAND 563..567 FT /evidence="ECO:0007829|PDB:4QT8" FT STRAND 570..575 FT /evidence="ECO:0007829|PDB:4QT8" FT STRAND 578..580 FT /evidence="ECO:0007829|PDB:4QT8" FT STRAND 589..593 FT /evidence="ECO:0007829|PDB:4QT8" FT STRAND 609..615 FT /evidence="ECO:0007829|PDB:4QT8" FT STRAND 639..641 FT /evidence="ECO:0007829|PDB:4QT8" FT STRAND 653..659 FT /evidence="ECO:0007829|PDB:4QT8" FT STRAND 672..682 FT /evidence="ECO:0007829|PDB:4QT8" FT HELIX 1064..1069 FT /evidence="ECO:0007829|PDB:3PLS" FT HELIX 1071..1073 FT /evidence="ECO:0007829|PDB:3PLS" FT HELIX 1077..1079 FT /evidence="ECO:0007829|PDB:3PLS" FT STRAND 1080..1091 FT /evidence="ECO:0007829|PDB:3PLS" FT STRAND 1094..1102 FT /evidence="ECO:0007829|PDB:3PLS" FT STRAND 1104..1106 FT /evidence="ECO:0007829|PDB:3PLS" FT STRAND 1108..1116 FT /evidence="ECO:0007829|PDB:3PLS" FT HELIX 1122..1136 FT /evidence="ECO:0007829|PDB:3PLS" FT STRAND 1148..1150 FT /evidence="ECO:0007829|PDB:3PLS" FT STRAND 1153..1155 FT /evidence="ECO:0007829|PDB:3PLS" FT STRAND 1158..1161 FT /evidence="ECO:0007829|PDB:3PLS" FT HELIX 1169..1174 FT /evidence="ECO:0007829|PDB:3PLS" FT HELIX 1182..1201 FT /evidence="ECO:0007829|PDB:3PLS" FT HELIX 1211..1213 FT /evidence="ECO:0007829|PDB:3PLS" FT STRAND 1214..1216 FT /evidence="ECO:0007829|PDB:3PLS" FT STRAND 1222..1224 FT /evidence="ECO:0007829|PDB:3PLS" FT TURN 1232..1235 FT /evidence="ECO:0007829|PDB:3PLS" FT HELIX 1236..1239 FT /evidence="ECO:0007829|PDB:3PLS" FT HELIX 1250..1253 FT /evidence="ECO:0007829|PDB:3PLS" FT HELIX 1256..1259 FT /evidence="ECO:0007829|PDB:3PLS" FT HELIX 1266..1282 FT /evidence="ECO:0007829|PDB:3PLS" FT TURN 1287..1290 FT /evidence="ECO:0007829|PDB:3PLS" FT HELIX 1293..1295 FT /evidence="ECO:0007829|PDB:3PLS" FT HELIX 1296..1301 FT /evidence="ECO:0007829|PDB:3PLS" FT HELIX 1314..1323 FT /evidence="ECO:0007829|PDB:3PLS" FT HELIX 1328..1330 FT /evidence="ECO:0007829|PDB:3PLS" FT HELIX 1334..1347 FT /evidence="ECO:0007829|PDB:3PLS" SQ SEQUENCE 1400 AA; 152241 MW; 358672D466B8E70D CRC64; MELLPPLPQS FLLLLLLPAK PAAGEDWQCP RTPYAASRDF DVKYVVPSFS AGGLVQAMVT YEGDRNESAV FVAIRNRLHV LGPDLKSVQS LATGPAGDPG CQTCAACGPG PHGPPGDTDT KVLVLDPALP ALVSCGSSLQ GRCFLHDLEP QGTAVHLAAP ACLFSAHHNR PDDCPDCVAS PLGTRVTVVE QGQASYFYVA SSLDAAVAAS FSPRSVSIRR LKADASGFAP GFVALSVLPK HLVSYSIEYV HSFHTGAFVY FLTVQPASVT DDPSALHTRL ARLSATEPEL GDYRELVLDC RFAPKRRRRG APEGGQPYPV LRVAHSAPVG AQLATELSIA EGQEVLFGVF VTGKDGGPGV GPNSVVCAFP IDLLDTLIDE GVERCCESPV HPGLRRGLDF FQSPSFCPNP PGLEALSPNT SCRHFPLLVS SSFSRVDLFN GLLGPVQVTA LYVTRLDNVT VAHMGTMDGR ILQVELVRSL NYLLYVSNFS LGDSGQPVQR DVSRLGDHLL FASGDQVFQV PIQGPGCRHF LTCGRCLRAW HFMGCGWCGN MCGQQKECPG SWQQDHCPPK LTEFHPHSGP LRGSTRLTLC GSNFYLHPSG LVPEGTHQVT VGQSPCRPLP KDSSKLRPVP RKDFVEEFEC ELEPLGTQAV GPTNVSLTVT NMPPGKHFRV DGTSVLRGFS FMEPVLIAVQ PLFGPRAGGT CLTLEGQSLS VGTSRAVLVN GTECLLARVS EGQLLCATPP GATVASVPLS LQVGGAQVPG SWTFQYREDP VVLSISPNCG YINSHITICG QHLTSAWHLV LSFHDGLRAV ESRCERQLPE QQLCRLPEYV VRDPQGWVAG NLSARGDGAA GFTLPGFRFL PPPHPPSANL VPLKPEEHAI KFEYIGLGAV ADCVGINVTV GGESCQHEFR GDMVVCPLPP SLQLGQDGAP LQVCVDGECH ILGRVVRPGP DGVPQSTLLG ILLPLLLLVA ALATALVFSY WWRRKQLVLP PNLNDLASLD QTAGATPLPI LYSGSDYRSG LALPAIDGLD STTCVHGASF SDSEDESCVP LLRKESIQLR DLDSALLAEV KDVLIPHERV VTHSDRVIGK GHFGVVYHGE YIDQAQNRIQ CAIKSLSRIT EMQQVEAFLR EGLLMRGLNH PNVLALIGIM LPPEGLPHVL LPYMCHGDLL QFIRSPQRNP TVKDLISFGL QVARGMEYLA EQKFVHRDLA ARNCMLDESF TVKVADFGLA RDILDREYYS VQQHRHARLP VKWMALESLQ TYRFTTKSDV WSFGVLLWEL LTRGAPPYRH IDPFDLTHFL AQGRRLPQPE YCPDSLYQVM QQCWEADPAV RPTFRVLVGE VEQIVSALLG DHYVQLPATY MNLGPSTSHE MNVRPEQPQF SPMPGNVRRP RPLSEPPRPT // ID ROR1_HUMAN Reviewed; 937 AA. AC Q01973; Q5VVX6; Q66K77; Q92776; DT 27-APR-2001, integrated into UniProtKB/Swiss-Prot. DT 28-NOV-2006, sequence version 2. DT 28-JAN-2026, entry version 230. DE RecName: Full=Inactive tyrosine-protein kinase transmembrane receptor ROR1 {ECO:0000305}; DE AltName: Full=Neurotrophic tyrosine kinase, receptor-related 1; DE Flags: Precursor; GN Name=ROR1; Synonyms=NTRKR1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND VARIANT MET-518. RX PubMed=1334494; DOI=10.1016/s0021-9258(18)35733-8; RA Masiakowski P., Carroll R.D.; RT "A novel family of cell surface receptors with tyrosine kinase-like RT domain."; RL J. Biol. Chem. 267:26181-26190(1992). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT). RX PubMed=8875995; RA Reddy U.R., Phatak S., Pleasure D.; RT "Human neural tissues express a truncated Ror1 receptor tyrosine kinase, RT lacking both extracellular and transmembrane domains."; RL Oncogene 13:1555-1559(1996). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP LACK OF CATALYTIC ACTIVITY, AND MUTAGENESIS OF CYS-482. RX PubMed=25029443; DOI=10.1371/journal.pone.0102695; RA Bainbridge T.W., DeAlmeida V.I., Izrael-Tomasevic A., Chalouni C., Pan B., RA Goldsmith J., Schoen A.P., Quinones G.A., Kelly R., Lill J.R., Sandoval W., RA Costa M., Polakis P., Arnott D., Rubinfeld B., Ernst J.A.; RT "Evolutionary divergence in the catalytic activity of the CAM-1, ROR1 and RT ROR2 kinase domains."; RL PLoS ONE 9:E102695-E102695(2014). RN [7] RP FUNCTION, AND INTERACTION WITH IGFBP5 AND ERBB2. RX PubMed=36949068; DOI=10.1038/s41467-023-37306-1; RA Lin W., Niu R., Park S.M., Zou Y., Kim S.S., Xia X., Xing S., Yang Q., RA Sun X., Yuan Z., Zhou S., Zhang D., Kwon H.J., Park S., Il Kim C., Koo H., RA Liu Y., Wu H., Zheng M., Yoo H., Shi B., Park J.B., Yin J.; RT "IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2- RT CREB signaling axis."; RL Nat. Commun. 14:1578-1578(2023). RN [8] RP VARIANT [LARGE SCALE ANALYSIS] ASP-562. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [9] RP VARIANTS [LARGE SCALE ANALYSIS] GLU-144; LEU-150; VAL-301; MET-518; RP ILE-567; ARG-624; CYS-646 AND ASN-776. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [10] RP INVOLVEMENT IN DFNB108, VARIANT DFNB108 THR-736, CHARACTERIZATION OF RP VARIANT DFNB108 THR-736, FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=27162350; DOI=10.1073/pnas.1522512113; RA Diaz-Horta O., Abad C., Sennaroglu L., Foster J. II, DeSmidt A., RA Bademci G., Tokgoz-Yilmaz S., Duman D., Cengiz F.B., Grati M., Fitoz S., RA Liu X.Z., Farooq A., Imtiaz F., Currall B.B., Morton C.C., Nishita M., RA Minami Y., Lu Z., Walz K., Tekin M.; RT "ROR1 is essential for proper innervation of auditory hair cells and RT hearing in humans and mice."; RL Proc. Natl. Acad. Sci. U.S.A. 113:5993-5998(2016). CC -!- FUNCTION: Has very low kinase activity in vitro and is unlikely to CC function as a tyrosine kinase in vivo (PubMed:25029443). Receptor for CC ligand WNT5A which activate downstream NFkB signaling pathway and may CC result in the inhibition of WNT3A-mediated signaling (PubMed:25029443, CC PubMed:27162350). In inner ear, crucial for spiral ganglion neurons to CC innervate auditory hair cells (PubMed:27162350). Via IGFBP5 ligand, CC forms a complex with ERBB2 to enhance CREB oncogenic signaling CC (PubMed:36949068). {ECO:0000269|PubMed:25029443, CC ECO:0000269|PubMed:27162350, ECO:0000269|PubMed:36949068}. CC -!- SUBUNIT: Interacts with ERBB2 and IGFBP5. CC {ECO:0000269|PubMed:36949068}. CC -!- INTERACTION: CC Q01973; P00533: EGFR; NbExp=8; IntAct=EBI-6082337, EBI-297353; CC Q01973; P12931: SRC; NbExp=9; IntAct=EBI-6082337, EBI-621482; CC Q01973; P05480: Src; Xeno; NbExp=2; IntAct=EBI-6082337, EBI-298680; CC -!- SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:27162350}; Single- CC pass type I membrane protein. Cell projection, axon CC {ECO:0000250|UniProtKB:Q9Z139}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=Long; CC IsoId=Q01973-1; Sequence=Displayed; CC Name=Short; Synonyms=T-ROR1; CC IsoId=Q01973-2; Sequence=VSP_005008; CC Name=3; CC IsoId=Q01973-3; Sequence=VSP_043663, VSP_043664; CC -!- TISSUE SPECIFICITY: Expressed strongly in human heart, lung and kidney, CC but weakly in the CNS. Isoform Short is strongly expressed in fetal and CC adult CNS and in a variety of human cancers, including those CC originating from CNS or PNS neuroectoderm. CC -!- DEVELOPMENTAL STAGE: Expressed at high levels during early embryonic CC development. The expression levels drop strongly around day 16 and CC there are only very low levels in adult tissues. CC -!- DISEASE: Deafness, autosomal recessive, 108 (DFNB108) [MIM:617654]: A CC form of non-syndromic sensorineural hearing loss. Sensorineural CC deafness results from damage to the neural receptors of the inner ear, CC the nerve pathways to the brain, or the area of the brain that receives CC sound information. {ECO:0000269|PubMed:27162350}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. ROR subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- CAUTION: The kinase domain has very low catalytic activity in vitro. CC {ECO:0000269|PubMed:25029443}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M97675; AAA60275.1; -; mRNA. DR EMBL; U38894; AAC50714.1; -; mRNA. DR EMBL; AL137859; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL161742; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL445205; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL138793; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL353713; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL808029; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL808030; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471059; EAX06556.1; -; Genomic_DNA. DR EMBL; BC080541; AAH80541.1; -; mRNA. DR CCDS; CCDS41344.1; -. [Q01973-3] DR CCDS; CCDS626.1; -. [Q01973-1] DR PIR; A45082; A45082. DR RefSeq; NP_001077061.1; NM_001083592.2. [Q01973-3] DR RefSeq; NP_005003.2; NM_005012.4. [Q01973-1] DR PDB; 5Z55; NMR; -; A=312-394. DR PDB; 6BA5; X-ray; 1.62 A; M/N/O/P=311-391. DR PDB; 6BAN; X-ray; 1.95 A; M/N/O/P=311-391. DR PDB; 6TU9; X-ray; 1.94 A; A/B=453-752. DR PDB; 7TNG; X-ray; 1.40 A; A=312-393. DR PDBsum; 5Z55; -. DR PDBsum; 6BA5; -. DR PDBsum; 6BAN; -. DR PDBsum; 6TU9; -. DR PDBsum; 7TNG; -. DR AlphaFoldDB; Q01973; -. DR SMR; Q01973; -. DR BioGRID; 110973; 124. DR DIP; DIP-29734N; -. DR FunCoup; Q01973; 357. DR IntAct; Q01973; 107. DR MINT; Q01973; -. DR STRING; 9606.ENSP00000360120; -. DR BindingDB; Q01973; -. DR ChEMBL; CHEMBL4665585; -. DR TCDB; 8.A.23.1.60; the basigin (basigin) family. DR GlyCosmos; Q01973; 4 sites, No reported glycans. DR GlyGen; Q01973; 5 sites, 5 N-linked glycans (2 sites). DR iPTMnet; Q01973; -. DR PhosphoSitePlus; Q01973; -. DR SwissPalm; Q01973; -. DR BioMuta; ROR1; -. DR DMDM; 118572711; -. DR jPOST; Q01973; -. DR MassIVE; Q01973; -. DR PaxDb; 9606-ENSP00000360120; -. DR PeptideAtlas; Q01973; -. DR ProteomicsDB; 58025; -. [Q01973-1] DR ProteomicsDB; 58026; -. [Q01973-2] DR ProteomicsDB; 58027; -. [Q01973-3] DR Pumba; Q01973; -. DR ABCD; Q01973; 29 sequenced antibodies. DR Antibodypedia; 33360; 927 antibodies from 43 providers. DR DNASU; 4919; -. DR Ensembl; ENST00000371079.6; ENSP00000360120.1; ENSG00000185483.13. [Q01973-1] DR Ensembl; ENST00000371080.5; ENSP00000360121.1; ENSG00000185483.13. [Q01973-3] DR GeneID; 4919; -. DR KEGG; hsa:4919; -. DR MANE-Select; ENST00000371079.6; ENSP00000360120.1; NM_005012.4; NP_005003.2. DR UCSC; uc001dbi.5; human. [Q01973-1] DR AGR; HGNC:10256; -. DR ClinPGx; PA34628; -. DR CTD; 4919; -. DR DisGeNET; 4919; -. DR GeneCards; ROR1; -. DR HGNC; HGNC:10256; ROR1. DR HPA; ENSG00000185483; Tissue enhanced (parathyroid). DR MalaCards; ROR1; -. DR MIM; 602336; gene. DR MIM; 617654; phenotype. DR OpenTargets; ENSG00000185483; -. DR Orphanet; 90636; Rare autosomal recessive non-syndromic sensorineural deafness type DFNB. DR VEuPathDB; HostDB:ENSG00000185483; -. DR eggNOG; KOG1026; Eukaryota. DR GeneTree; ENSGT00940000153947; -. DR HOGENOM; CLU_701993_0_0_1; -. DR InParanoid; Q01973; -. DR OMA; IQNDECP; -. DR OrthoDB; 2431000at2759; -. DR PAN-GO; Q01973; 8 GO annotations based on evolutionary models. DR PhylomeDB; Q01973; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; Q01973; -. DR Reactome; R-HSA-5140745; WNT5A-dependent internalization of FZD2, FZD5 and ROR2. DR SignaLink; Q01973; -. DR SIGNOR; Q01973; -. DR Agora; ENSG00000185483; -. DR BioGRID-ORCS; 4919; 17 hits in 1190 CRISPR screens. DR ChiTaRS; ROR1; human. DR GeneWiki; ROR1; -. DR GenomeRNAi; 4919; -. DR Pharos; Q01973; Tbio. DR PRO; PR:Q01973; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q01973; protein. DR Bgee; ENSG00000185483; Expressed in germinal epithelium of ovary and 154 other cell types or tissues. DR ExpressionAtlas; Q01973; baseline and differential. DR GO; GO:0030424; C:axon; IBA:GO_Central. DR GO; GO:0043679; C:axon terminus; ISS:UniProtKB. DR GO; GO:0009986; C:cell surface; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; TAS:ProtInc. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0001725; C:stress fiber; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0015026; F:coreceptor activity; TAS:ParkinsonsUK-UCL. DR GO; GO:0038023; F:signaling receptor activity; IDA:UniProt. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; TAS:ProtInc. DR GO; GO:0042813; F:Wnt receptor activity; IMP:UniProtKB. DR GO; GO:0017147; F:Wnt-protein binding; IPI:UniProtKB. DR GO; GO:0014002; P:astrocyte development; IEA:Ensembl. DR GO; GO:0008283; P:cell population proliferation; IDA:UniProt. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; TAS:ProtInc. DR GO; GO:0048839; P:inner ear development; ISS:UniProtKB. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IMP:UniProtKB. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB. DR GO; GO:0007605; P:sensory perception of sound; IMP:UniProtKB. DR CDD; cd07467; CRD_TK_ROR1; 1. DR CDD; cd00108; KR; 1. DR CDD; cd05090; PTKc_Ror1; 1. DR FunFam; 1.10.2000.10:FF:000002; Inactive tyrosine-protein kinase transmembrane receptor ROR1; 1. DR FunFam; 2.40.20.10:FF:000003; Inactive tyrosine-protein kinase transmembrane receptor ROR1; 1. DR FunFam; 2.60.40.10:FF:000242; Inactive tyrosine-protein kinase transmembrane receptor ROR1; 1. DR FunFam; 1.10.510.10:FF:000116; inactive tyrosine-protein kinase transmembrane receptor ROR1; 1. DR FunFam; 3.30.200.20:FF:000139; inactive tyrosine-protein kinase transmembrane receptor ROR1; 1. DR Gene3D; 1.10.2000.10; Frizzled cysteine-rich domain; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 2.40.20.10; Plasminogen Kringle 4; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR020067; Frizzled_dom. DR InterPro; IPR036790; Frizzled_dom_sf. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000001; Kringle. DR InterPro; IPR013806; Kringle-like. DR InterPro; IPR018056; Kringle_CS. DR InterPro; IPR038178; Kringle_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR016247; Tyr_kinase_rcpt_ROR. DR PANTHER; PTHR24416:SF134; INACTIVE TYROSINE-PROTEIN KINASE TRANSMEMBRANE RECEPTOR ROR1; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF01392; Fz; 1. DR Pfam; PF07679; I-set; 1. DR Pfam; PF00051; Kringle; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PIRSF; PIRSF000624; TyrPK_TMrec_ROR; 1. DR PRINTS; PR00018; KRINGLE. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00409; IG; 1. DR SMART; SM00408; IGc2; 1. DR SMART; SM00130; KR; 1. DR SUPFAM; SSF48726; Immunoglobulin; 1. DR SUPFAM; SSF57440; Kringle-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50038; FZ; 1. DR PROSITE; PS50835; IG_LIKE; 1. DR PROSITE; PS00021; KRINGLE_1; 1. DR PROSITE; PS50070; KRINGLE_2; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell projection; Deafness; KW Disease variant; Disulfide bond; Glycoprotein; Immunoglobulin domain; KW Kinase; Kringle; Membrane; Non-syndromic deafness; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome; KW Signal; Transferase; Transmembrane; Transmembrane helix; KW Wnt signaling pathway. FT SIGNAL 1..29 FT /evidence="ECO:0000255" FT CHAIN 30..937 FT /note="Inactive tyrosine-protein kinase transmembrane FT receptor ROR1" FT /id="PRO_0000024458" FT TOPO_DOM 30..406 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 407..427 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 428..937 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 42..147 FT /note="Ig-like C2-type" FT DOMAIN 165..299 FT /note="FZ" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00090" FT DOMAIN 312..391 FT /note="Kringle" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00121" FT DOMAIN 473..746 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 753..779 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 833..890 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 753..762 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 763..779 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 854..864 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 865..880 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 479..487 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 506 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 645 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT CARBOHYD 47 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 66 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 184 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 315 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 79..131 FT /evidence="ECO:0000250" FT DISULFID 170..235 FT /evidence="ECO:0000250" FT DISULFID 178..228 FT /evidence="ECO:0000250" FT DISULFID 219..260 FT /evidence="ECO:0000250" FT DISULFID 248..296 FT /evidence="ECO:0000250" FT DISULFID 252..282 FT /evidence="ECO:0000250" FT DISULFID 313..391 FT /evidence="ECO:0000250" FT DISULFID 334..374 FT /evidence="ECO:0000250" FT DISULFID 362..386 FT /evidence="ECO:0000250" FT VAR_SEQ 1..549 FT /note="Missing (in isoform Short)" FT /evidence="ECO:0000303|PubMed:8875995" FT /id="VSP_005008" FT VAR_SEQ 392..393 FT /note="DS -> GK (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_043663" FT VAR_SEQ 394..937 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_043664" FT VARIANT 144 FT /note="G -> E (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041779" FT VARIANT 150 FT /note="F -> L (in an ovarian mucinous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041780" FT VARIANT 301 FT /note="I -> V (in a renal clear cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041781" FT VARIANT 518 FT /note="T -> M (in dbSNP:rs7527017)" FT /evidence="ECO:0000269|PubMed:1334494, FT ECO:0000269|PubMed:17344846" FT /id="VAR_041782" FT VARIANT 562 FT /note="E -> D (in a breast cancer sample; somatic mutation; FT dbSNP:rs760789417)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035713" FT VARIANT 567 FT /note="R -> I (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041783" FT VARIANT 624 FT /note="G -> R (in dbSNP:rs55832740)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041784" FT VARIANT 646 FT /note="Y -> C (in dbSNP:rs34109134)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041785" FT VARIANT 736 FT /note="R -> T (in DFNB108; impairs plasma membrane FT location; abolishes downstream NFkB activation; FT dbSNP:rs1553163562)" FT /evidence="ECO:0000269|PubMed:27162350" FT /id="VAR_079530" FT VARIANT 776 FT /note="S -> N (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041786" FT MUTAGEN 482 FT /note="C->G: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:25029443" FT STRAND 312..314 FT /evidence="ECO:0007829|PDB:7TNG" FT STRAND 341..343 FT /evidence="ECO:0007829|PDB:7TNG" FT TURN 349..351 FT /evidence="ECO:0007829|PDB:7TNG" FT HELIX 353..355 FT /evidence="ECO:0007829|PDB:7TNG" FT HELIX 365..367 FT /evidence="ECO:0007829|PDB:7TNG" FT STRAND 369..371 FT /evidence="ECO:0007829|PDB:7TNG" FT STRAND 373..377 FT /evidence="ECO:0007829|PDB:7TNG" FT STRAND 383..387 FT /evidence="ECO:0007829|PDB:7TNG" FT HELIX 470..472 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 473..481 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 486..492 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 501..507 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 514..527 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 538..542 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 544..547 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 549..553 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 560..566 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 589..608 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 618..620 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 621..623 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 625..627 FT /evidence="ECO:0007829|PDB:6TU9" FT STRAND 629..631 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 636..640 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 642..644 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 656..658 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 661..666 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 671..686 FT /evidence="ECO:0007829|PDB:6TU9" FT TURN 692..695 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 698..706 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 719..728 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 733..735 FT /evidence="ECO:0007829|PDB:6TU9" FT HELIX 739..748 FT /evidence="ECO:0007829|PDB:6TU9" SQ SEQUENCE 937 AA; 104283 MW; 0EC0E4762A90C6C7 CRC64; MHRPRRRGTR PPLLALLAAL LLAARGAAAQ ETELSVSAEL VPTSSWNISS ELNKDSYLTL DEPMNNITTS LGQTAELHCK VSGNPPPTIR WFKNDAPVVQ EPRRLSFRST IYGSRLRIRN LDTTDTGYFQ CVATNGKEVV SSTGVLFVKF GPPPTASPGY SDEYEEDGFC QPYRGIACAR FIGNRTVYME SLHMQGEIEN QITAAFTMIG TSSHLSDKCS QFAIPSLCHY AFPYCDETSS VPKPRDLCRD ECEILENVLC QTEYIFARSN PMILMRLKLP NCEDLPQPES PEAANCIRIG IPMADPINKN HKCYNSTGVD YRGTVSVTKS GRQCQPWNSQ YPHTHTFTAL RFPELNGGHS YCRNPGNQKE APWCFTLDEN FKSDLCDIPA CDSKDSKEKN KMEILYILVP SVAIPLAIAL LFFFICVCRN NQKSSSAPVQ RQPKHVRGQN VEMSMLNAYK PKSKAKELPL SAVRFMEELG ECAFGKIYKG HLYLPGMDHA QLVAIKTLKD YNNPQQWTEF QQEASLMAEL HHPNIVCLLG AVTQEQPVCM LFEYINQGDL HEFLIMRSPH SDVGCSSDED GTVKSSLDHG DFLHIAIQIA AGMEYLSSHF FVHKDLAARN ILIGEQLHVK ISDLGLSREI YSADYYRVQS KSLLPIRWMP PEAIMYGKFS SDSDIWSFGV VLWEIFSFGL QPYYGFSNQE VIEMVRKRQL LPCSEDCPPR MYSLMTECWN EIPSRRPRFK DIHVRLRSWE GLSSHTSSTT PSGGNATTQT TSLSASPVSN LSNPRYPNYM FPSQGITPQG QIAGFIGPPI PQNQRFIPIN GYPIPPGYAA FPAAHYQPTG PPRVIQHCPP PKSRSPSSAS GSTSTGHVTS LPSSGSNQEA NIPLLPHMSI PNHPGGMGIT VFGNKSQKPY KIDSKQASLL GDANIHGHTE SMISAEL // ID ROS1_HUMAN Reviewed; 2347 AA. AC P08922; Q15368; Q5TDB5; DT 01-NOV-1988, integrated into UniProtKB/Swiss-Prot. DT 20-FEB-2007, sequence version 3. DT 28-JAN-2026, entry version 230. DE RecName: Full=Proto-oncogene tyrosine-protein kinase ROS; DE EC=2.7.10.1 {ECO:0000269|PubMed:11094073, ECO:0000269|PubMed:16885344}; DE AltName: Full=Proto-oncogene c-Ros; DE AltName: Full=Proto-oncogene c-Ros-1; DE AltName: Full=Receptor tyrosine kinase c-ros oncogene 1; DE AltName: Full=c-Ros receptor tyrosine kinase; DE Flags: Precursor; GN Name=ROS1; Synonyms=MCF3, ROS; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ASN-2213; GLN-2228 AND CYS-2229. RX PubMed=2352949; DOI=10.1073/pnas.87.12.4799; RA Birchmeier C., O'Neill K., Riggs M., Wigler M.; RT "Characterization of ROS1 cDNA from a human glioblastoma cell line."; RL Proc. Natl. Acad. Sci. U.S.A. 87:4799-4803(1990). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1790-2260. RX PubMed=3023956; DOI=10.1128/mcb.6.8.3000-3004.1986; RA Matsushime H., Wang L.-H., Shibuya M.; RT "Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus RT encodes for a transmembrane receptorlike molecule."; RL Mol. Cell. Biol. 6:3000-3004(1986). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1854-2347. RX PubMed=3785223; DOI=10.1128/mcb.6.9.3109-3116.1986; RA Birchmeier C., Birnbaum D., Waitches G., Fasano O., Wigler M.; RT "Characterization of an activated human ros gene."; RL Mol. Cell. Biol. 6:3109-3116(1986). RN [5] RP TISSUE SPECIFICITY. RX PubMed=8143271; DOI=10.1016/0165-4608(94)90128-7; RA Watkins D., Dion F., Poisson M., Delattre J.Y., Rouleau G.A.; RT "Analysis of oncogene expression in primary human gliomas: evidence for RT increased expression of the ros oncogene."; RL Cancer Genet. Cytogenet. 72:130-136(1994). RN [6] RP FUNCTION, INTERACTION WITH VAV3, AND CATALYTIC ACTIVITY. RX PubMed=11094073; DOI=10.1128/mcb.20.24.9212-9224.2000; RA Zeng L., Sachdev P., Yan L., Chan J.L., Trenkle T., McClelland M., RA Welsh J., Wang L.H.; RT "Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase RT activity, modulates cell morphology, and induces cell transformation."; RL Mol. Cell. Biol. 20:9212-9224(2000). RN [7] RP DISEASE, CHROMOSOMAL TRANSLOCATION WITH GOPC, AND MUTAGENESIS OF LYS-1980. RX PubMed=12661006; DOI=10.1002/gcc.10207; RA Charest A., Lane K., McMahon K., Park J., Preisinger E., Conroy H., RA Housman D.; RT "Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with RT an interstitial del(6)(q21q21)."; RL Genes Chromosomes Cancer 37:58-71(2003). RN [8] RP PHOSPHORYLATION AT TYR-2274 AND TYR-2334, AND MUTAGENESIS OF TYR-2274 AND RP TYR-2334. RX PubMed=12538861; DOI=10.1073/pnas.242741799; RA Charest A., Kheifets V., Park J., Lane K., McMahon K., Nutt C.L., RA Housman D.; RT "Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus RT in a glioblastoma."; RL Proc. Natl. Acad. Sci. U.S.A. 100:916-921(2003). RN [9] RP FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH PTPN11. RX PubMed=16885344; DOI=10.1158/0008-5472.can-06-1193; RA Charest A., Wilker E.W., McLaughlin M.E., Lane K., Gowda R., Coven S., RA McMahon K., Kovach S., Feng Y., Yaffe M.B., Jacks T., Housman D.; RT "ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase- RT 2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling RT axis to form glioblastoma in mice."; RL Cancer Res. 66:7473-7481(2006). RN [10] RP VARIANTS [LARGE SCALE ANALYSIS] SER-13; VAL-126; PRO-145; GLN-167; SER-224; RP CYS-338; PRO-370; HIS-419; MET-537; PHE-653; HIS-865; LEU-1109; PHE-1239; RP SER-1353; ARG-1370; GLY-1506; HIS-1776; LYS-1902; ASN-1999; ARG-2003; RP SER-2138; ASN-2203; GLU-2213; ASN-2213; GLN-2228; CYS-2229 AND LYS-2240. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Receptor tyrosine kinase (RTK) that plays a role in CC epithelial cell differentiation and regionalization of the proximal CC epididymal epithelium. NELL2 is an endogenous ligand for ROS1. Upon CC endogenous stimulation by NELL2, ROS1 activates the intracellular CC signaling pathway and triggers epididymal epithelial differentiation CC and subsequent sperm maturation (By similarity). May activate several CC downstream signaling pathways related to cell differentiation, CC proliferation, growth and survival including the PI3 kinase-mTOR CC signaling pathway. Mediates the phosphorylation of PTPN11, an activator CC of this pathway. May also phosphorylate and activate the transcription CC factor STAT3 to control anchorage-independent cell growth. Mediates the CC phosphorylation and the activation of VAV3, a guanine nucleotide CC exchange factor regulating cell morphology. May activate other CC downstream signaling proteins including AKT1, MAPK1, MAPK3, IRS1 and CC PLCG2. {ECO:0000250|UniProtKB:Q78DX7, ECO:0000269|PubMed:11094073, CC ECO:0000269|PubMed:16885344}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000269|PubMed:11094073, ECO:0000269|PubMed:16885344}; CC -!- ACTIVITY REGULATION: Inhibited by dephosphorylation by PTPN6. CC {ECO:0000250|UniProtKB:Q78DX7}. CC -!- SUBUNIT: Interacts with PTPN6 (via SH2 1 domain); the interaction is CC direct and promotes ROS1 dephosphorylation (By similarity). Interacts CC with PTPN11; may activate the PI3 kinase-mTOR signaling pathway CC (PubMed:16885344). Interacts with VAV3; constitutive interaction CC mediating VAV3 phosphorylation (PubMed:11094073). CC {ECO:0000250|UniProtKB:Q78DX7, ECO:0000269|PubMed:11094073, CC ECO:0000269|PubMed:16885344}. CC -!- INTERACTION: CC P08922; P18031: PTPN1; NbExp=3; IntAct=EBI-7371065, EBI-968788; CC P08922; P29350: PTPN6; NbExp=4; IntAct=EBI-7371065, EBI-78260; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Single-pass type I CC membrane protein {ECO:0000305}. CC -!- TISSUE SPECIFICITY: Expressed in brain. Expression is increased in CC primary gliomas. {ECO:0000269|PubMed:8143271}. CC -!- PTM: Phosphorylated. Probably autophosphorylates. Phosphorylation at CC Tyr-2274 is required for the interaction with PTPN6 that mediates ROS1 CC dephosphorylation. Phosphorylation at Tyr-2274 stimulates the kinase CC activity and the activation of the ERK1 signaling cascade (By CC similarity). Phosphorylation at Tyr-2274 and/or Tyr-2334 recruits CC PTPN11 (PubMed:12538861). {ECO:0000250|UniProtKB:Q78DX7, CC ECO:0000269|PubMed:12538861}. CC -!- DISEASE: Note=A chromosomal aberration involving ROS1 is found in a CC glioblastoma multiforme sample. An intra-chromosomal deletion CC del(6)(q21q21) is responsible for the formation of GOPC-ROS1 chimeric CC protein which is localized to the Golgi and has a constitutive receptor CC tyrosine kinase activity. A SLC34A2-ROS1 chimeric protein produced in CC non-small cell lung cancer cells also retains a constitutive kinase CC activity. A third type of chimeric protein CD74-ROS1 was also CC identified in those cells. {ECO:0000269|PubMed:12661006}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M34353; AAA60278.1; -; mRNA. DR EMBL; Z98880; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL132671; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; M13599; AAA60277.1; -; Genomic_DNA. DR EMBL; M13368; AAA60277.1; JOINED; Genomic_DNA. DR EMBL; M13591; AAA60277.1; JOINED; Genomic_DNA. DR EMBL; M13592; AAA60277.1; JOINED; Genomic_DNA. DR EMBL; M13593; AAA60277.1; JOINED; Genomic_DNA. DR EMBL; M13594; AAA60277.1; JOINED; Genomic_DNA. DR EMBL; M13595; AAA60277.1; JOINED; Genomic_DNA. DR EMBL; M13596; AAA60277.1; JOINED; Genomic_DNA. DR EMBL; M13597; AAA60277.1; JOINED; Genomic_DNA. DR EMBL; M13598; AAA60277.1; JOINED; Genomic_DNA. DR EMBL; M13880; AAA36580.1; -; mRNA. DR CCDS; CCDS5116.1; -. DR PIR; A35512; TVHURS. DR RefSeq; NP_002935.2; NM_002944.2. DR PDB; 3ZBF; X-ray; 2.20 A; A=1934-2232. DR PDB; 4UXL; X-ray; 2.40 A; A=1934-2232. DR PDB; 7Z5W; X-ray; 2.25 A; A/B=1930-2256. DR PDB; 7Z5X; X-ray; 2.04 A; A/B=1930-2256. DR PDB; 9QEK; X-ray; 2.21 A; A=1934-2232. DR PDBsum; 3ZBF; -. DR PDBsum; 4UXL; -. DR PDBsum; 7Z5W; -. DR PDBsum; 7Z5X; -. DR PDBsum; 9QEK; -. DR AlphaFoldDB; P08922; -. DR SMR; P08922; -. DR BioGRID; 112025; 94. DR CORUM; P08922; -. DR FunCoup; P08922; 69. DR IntAct; P08922; 108. DR MINT; P08922; -. DR STRING; 9606.ENSP00000357494; -. DR BindingDB; P08922; -. DR ChEMBL; CHEMBL5568; -. DR DrugBank; DB08865; Crizotinib. DR DrugBank; DB11986; Entrectinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB12130; Lorlatinib. DR DrugBank; DB16826; Repotrectinib. DR DrugCentral; P08922; -. DR GuidetoPHARMACOLOGY; 1840; -. DR GlyCosmos; P08922; 33 sites, 1 glycan. DR GlyGen; P08922; 34 sites, 1 O-linked glycan (3 sites). DR iPTMnet; P08922; -. DR PhosphoSitePlus; P08922; -. DR BioMuta; ROS1; -. DR DMDM; 126302596; -. DR CPTAC; CPTAC-3062; -. DR jPOST; P08922; -. DR MassIVE; P08922; -. DR PaxDb; 9606-ENSP00000357494; -. DR PeptideAtlas; P08922; -. DR ProteomicsDB; 52177; -. DR ABCD; P08922; 2 sequenced antibodies. DR Antibodypedia; 32541; 706 antibodies from 37 providers. DR DNASU; 6098; -. DR Ensembl; ENST00000368508.7; ENSP00000357494.3; ENSG00000047936.12. DR GeneID; 6098; -. DR KEGG; hsa:6098; -. DR UCSC; uc003pxp.2; human. DR AGR; HGNC:10261; -. DR CIViC; 6098; 32 evidence items across 18 molecular profiles. DR ClinPGx; PA34633; -. DR CTD; 6098; -. DR DisGeNET; 6098; -. DR GeneCards; ROS1; -. DR HGNC; HGNC:10261; ROS1. DR HPA; ENSG00000047936; Group enriched (epididymis, lung). DR MalaCards; ROS1; -. DR MIM; 165020; gene. DR OpenTargets; ENSG00000047936; -. DR Orphanet; 70567; Cholangiocarcinoma. DR Orphanet; 251579; Giant cell glioblastoma. DR VEuPathDB; HostDB:ENSG00000047936; -. DR eggNOG; KOG1095; Eukaryota. DR GeneTree; ENSGT00940000160831; -. DR InParanoid; P08922; -. DR OrthoDB; 65481at2759; -. DR PAN-GO; P08922; 7 GO annotations based on evolutionary models. DR PhylomeDB; P08922; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P08922; -. DR SignaLink; P08922; -. DR SIGNOR; P08922; -. DR Agora; ENSG00000047936; -. DR BioGRID-ORCS; 6098; 8 hits in 1191 CRISPR screens. DR ChiTaRS; ROS1; human. DR EvolutionaryTrace; P08922; -. DR GeneWiki; ROS1_(gene); -. DR GenomeRNAi; 6098; -. DR Pharos; P08922; Tclin. DR PRO; PR:P08922; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; P08922; protein. DR Bgee; ENSG00000047936; Expressed in upper lobe of left lung and 59 other cell types or tissues. DR ExpressionAtlas; P08922; baseline and differential. DR GO; GO:0016020; C:membrane; TAS:ProtInc. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0030154; P:cell differentiation; ISS:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0002066; P:columnar/cuboidal epithelial cell development; ISS:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0001558; P:regulation of cell growth; IDA:UniProtKB. DR GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; ISS:UniProtKB. DR GO; GO:0032006; P:regulation of TOR signaling; IDA:UniProtKB. DR GO; GO:0007283; P:spermatogenesis; ISS:UniProtKB. DR CDD; cd00063; FN3; 7. DR CDD; cd05044; PTKc_c-ros; 1. DR FunFam; 1.10.510.10:FF:000341; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.120.10.30:FF:000038; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.120.10.30:FF:000042; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.120.10.30:FF:000044; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000882; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000984; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:001018; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:001024; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:001074; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:001237; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:001816; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.30.200.20:FF:000301; Tyrosine-protein kinase receptor; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 7. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 2.120.10.30; TolB, C-terminal domain; 3. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011042; 6-blade_b-propeller_TolB-like. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000033; LDLR_classB_rpt. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR002011; Tyr_kinase_rcpt_2_CS. DR PANTHER; PTHR24416:SF527; PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00060; FN3; 9. DR SMART; SM00135; LY; 4. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 5. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF63825; YWTD domain; 3. DR PROSITE; PS50853; FN3; 9. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Cell membrane; Chromosomal rearrangement; KW Glycoprotein; Kinase; Membrane; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Proto-oncogene; Receptor; Reference proteome; KW Repeat; Signal; Transferase; Transmembrane; Transmembrane helix; KW Tyrosine-protein kinase. FT SIGNAL 1..27 FT /evidence="ECO:0000255" FT CHAIN 28..2347 FT /note="Proto-oncogene tyrosine-protein kinase ROS" FT /id="PRO_0000016722" FT TOPO_DOM 28..1859 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 1860..1882 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 1883..2347 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 101..196 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 197..285 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 557..671 FT /note="Fibronectin type-III 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 947..1042 FT /note="Fibronectin type-III 4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 1043..1150 FT /note="Fibronectin type-III 5" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 1450..1556 FT /note="Fibronectin type-III 6" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 1557..1656 FT /note="Fibronectin type-III 7" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 1658..1751 FT /note="Fibronectin type-III 8" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 1752..1854 FT /note="Fibronectin type-III 9" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 1945..2222 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 2284..2311 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2301..2311 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 2079 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 1951..1959 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 1980 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT SITE 1852..1853 FT /note="Breakpoint for translocation to form SLC34A2-ROS1 FT and CD74-ROS1 fusion proteins" FT /evidence="ECO:0000269|PubMed:12661006" FT SITE 1880..1881 FT /note="Breakpoint for translocation to form GOPC-ROS1 FT fusion protein" FT /evidence="ECO:0000269|PubMed:12661006" FT MOD_RES 2274 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:12538861" FT MOD_RES 2334 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:12538861" FT CARBOHYD 52 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 114 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 123 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 324 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 352 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 396 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 471 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 607 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 628 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 706 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 714 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 732 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 939 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 961 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1015 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1087 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1090 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1095 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1211 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1272 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1330 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1458 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1461 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1474 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1499 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1565 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1669 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1715 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1738 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 1808 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VARIANT 13 FT /note="N -> S (in dbSNP:rs45606237)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041442" FT VARIANT 126 FT /note="G -> V (in dbSNP:rs34245787)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041443" FT VARIANT 145 FT /note="T -> P (in dbSNP:rs1998206)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030648" FT VARIANT 167 FT /note="R -> Q (in dbSNP:rs2243380)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030649" FT VARIANT 224 FT /note="P -> S (in dbSNP:rs55959124)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041444" FT VARIANT 338 FT /note="Y -> C (in dbSNP:rs55707658)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041445" FT VARIANT 370 FT /note="S -> P (in dbSNP:rs56274823)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041446" FT VARIANT 419 FT /note="Y -> H (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1444274116)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041447" FT VARIANT 537 FT /note="I -> M (in dbSNP:rs28639589)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041448" FT VARIANT 653 FT /note="S -> F (in dbSNP:rs34203286)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041449" FT VARIANT 790 FT /note="N -> S (in dbSNP:rs34582164)" FT /id="VAR_049712" FT VARIANT 865 FT /note="Q -> H (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041450" FT VARIANT 1109 FT /note="S -> L (in dbSNP:rs2229079)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030650" FT VARIANT 1239 FT /note="Y -> F (in dbSNP:rs56192249)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041451" FT VARIANT 1353 FT /note="Y -> S (in dbSNP:rs35269727)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041452" FT VARIANT 1370 FT /note="C -> R (in dbSNP:rs36106063)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041453" FT VARIANT 1439 FT /note="F -> S (in dbSNP:rs17079086)" FT /id="VAR_030651" FT VARIANT 1506 FT /note="R -> G (in dbSNP:rs35841892)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041454" FT VARIANT 1776 FT /note="D -> H (in dbSNP:rs12664076)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030652" FT VARIANT 1902 FT /note="E -> K (in dbSNP:rs9489124)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030653" FT VARIANT 1999 FT /note="H -> N (in dbSNP:rs45569132)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041455" FT VARIANT 2003 FT /note="K -> R (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041456" FT VARIANT 2039 FT /note="R -> H (in dbSNP:rs3752566)" FT /id="VAR_030654" FT VARIANT 2138 FT /note="F -> S (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041457" FT VARIANT 2203 FT /note="D -> N (in dbSNP:rs556427413)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041458" FT VARIANT 2213 FT /note="D -> E (in dbSNP:rs75510639)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041459" FT VARIANT 2213 FT /note="D -> N (in dbSNP:rs529038)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:2352949" FT /id="VAR_030655" FT VARIANT 2228 FT /note="K -> Q (in dbSNP:rs529156)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:2352949" FT /id="VAR_041460" FT VARIANT 2229 FT /note="S -> C (in dbSNP:rs619203)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:2352949" FT /id="VAR_030656" FT VARIANT 2240 FT /note="N -> K (in dbSNP:rs210968)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030657" FT VARIANT 2328 FT /note="K -> R (in dbSNP:rs35932630)" FT /id="VAR_049713" FT MUTAGEN 1980 FT /note="K->M: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:12661006" FT MUTAGEN 2274 FT /note="Y->F: Loss of phosphorylation at Y-2274 and loss of FT interaction with PTPN11." FT /evidence="ECO:0000269|PubMed:12538861" FT MUTAGEN 2334 FT /note="Y->F: Loss of phosphorylation at Y-2334 and loss of FT interaction with PTPN11." FT /evidence="ECO:0000269|PubMed:12538861" FT CONFLICT 2246..2260 FT /note="EDGDVICLNSDDIMP -> KFDSSEFSSFRCTVN (in Ref. 3; FT AAA60277)" FT /evidence="ECO:0000305" FT CONFLICT 2262 FT /note="A -> V (in Ref. 1; AAA60278)" FT /evidence="ECO:0000305" FT HELIX 1942..1944 FT /evidence="ECO:0007829|PDB:7Z5X" FT STRAND 1945..1952 FT /evidence="ECO:0007829|PDB:7Z5X" FT TURN 1954..1956 FT /evidence="ECO:0007829|PDB:7Z5X" FT STRAND 1959..1966 FT /evidence="ECO:0007829|PDB:7Z5X" FT STRAND 1969..1971 FT /evidence="ECO:0007829|PDB:7Z5X" FT STRAND 1974..1982 FT /evidence="ECO:0007829|PDB:7Z5X" FT HELIX 1988..2001 FT /evidence="ECO:0007829|PDB:7Z5X" FT STRAND 2012..2016 FT /evidence="ECO:0007829|PDB:7Z5X" FT STRAND 2018..2027 FT /evidence="ECO:0007829|PDB:7Z5X" FT HELIX 2034..2043 FT /evidence="ECO:0007829|PDB:7Z5X" FT HELIX 2053..2072 FT /evidence="ECO:0007829|PDB:7Z5X" FT HELIX 2082..2084 FT /evidence="ECO:0007829|PDB:7Z5X" FT STRAND 2085..2088 FT /evidence="ECO:0007829|PDB:7Z5X" FT STRAND 2090..2094 FT /evidence="ECO:0007829|PDB:7Z5X" FT STRAND 2098..2100 FT /evidence="ECO:0007829|PDB:7Z5X" FT HELIX 2125..2127 FT /evidence="ECO:0007829|PDB:7Z5X" FT HELIX 2130..2135 FT /evidence="ECO:0007829|PDB:7Z5X" FT HELIX 2140..2155 FT /evidence="ECO:0007829|PDB:7Z5X" FT STRAND 2161..2165 FT /evidence="ECO:0007829|PDB:7Z5W" FT HELIX 2167..2175 FT /evidence="ECO:0007829|PDB:7Z5X" FT HELIX 2188..2197 FT /evidence="ECO:0007829|PDB:7Z5X" FT HELIX 2202..2204 FT /evidence="ECO:0007829|PDB:7Z5X" FT HELIX 2208..2224 FT /evidence="ECO:0007829|PDB:7Z5X" SQ SEQUENCE 2347 AA; 263915 MW; 98902B9A59ACB8F5 CRC64; MKNIYCLIPK LVNFATLGCL WISVVQCTVL NSCLKSCVTN LGQQLDLGTP HNLSEPCIQG CHFWNSVDQK NCALKCRESC EVGCSSAEGA YEEEVLENAD LPTAPFASSI GSHNMTLRWK SANFSGVKYI IQWKYAQLLG SWTYTKTVSR PSYVVKPLHP FTEYIFRVVW IFTAQLQLYS PPSPSYRTHP HGVPETAPLI RNIESSSPDT VEVSWDPPQF PGGPILGYNL RLISKNQKLD AGTQRTSFQF YSTLPNTIYR FSIAAVNEVG EGPEAESSIT TSSSAVQQEE QWLFLSRKTS LRKRSLKHLV DEAHCLRLDA IYHNITGISV DVHQQIVYFS EGTLIWAKKA ANMSDVSDLR IFYRGSGLIS SISIDWLYQR MYFIMDELVC VCDLENCSNI EEITPPSISA PQKIVADSYN GYVFYLLRDG IYRADLPVPS GRCAEAVRIV ESCTLKDFAI KPQAKRIIYF NDTAQVFMST FLDGSASHLI LPRIPFADVK SFACENNDFL VTDGKVIFQQ DALSFNEFIV GCDLSHIEEF GFGNLVIFGS SSQLHPLPGR PQELSVLFGS HQALVQWKPP ALAIGANVIL ISDIIELFEL GPSAWQNWTY EVKVSTQDPP EVTHIFLNIS GTMLNVPELQ SAMKYKVSVR ASSPKRPGPW SEPSVGTTLV PASEPPFIMA VKEDGLWSKP LNSFGPGEFL SSDIGNVSDM DWYNNSLYYS DTKGDVFVWL LNGTDISENY HLPSIAGAGA LAFEWLGHFL YWAGKTYVIQ RQSVLTGHTD IVTHVKLLVN DMVVDSVGGY LYWTTLYSVE STRLNGESSL VLQTQPWFSG KKVIALTLDL SDGLLYWLVQ DSQCIHLYTA VLRGQSTGDT TITEFAAWST SEISQNALMY YSGRLFWING FRIITTQEIG QKTSVSVLEP ARFNQFTIIQ TSLKPLPGNF SFTPKVIPDS VQESSFRIEG NASSFQILWN GPPAVDWGVV FYSVEFSAHS KFLASEQHSL PVFTVEGLEP YALFNLSVTP YTYWGKGPKT SLSLRAPETV PSAPENPRIF ILPSGKCCNK NEVVVEFRWN KPKHENGVLT KFEIFYNISN QSITNKTCED WIAVNVTPSV MSFQLEGMSP RCFIAFQVRA FTSKGPGPYA DVVKSTTSEI NPFPHLITLL GNKIVFLDMD QNQVVWTFSA ERVISAVCYT ADNEMGYYAE GDSLFLLHLH NRSSSELFQD SLVFDITVIT IDWISRHLYF ALKESQNGMQ VFDVDLEHKV KYPREVKIHN RNSTIISFSV YPLLSRLYWT EVSNFGYQMF YYSIISHTLH RILQPTATNQ QNKRNQCSCN VTEFELSGAM AIDTSNLEKP LIYFAKAQEI WAMDLEGCQC WRVITVPAML AGKTLVSLTV DGDLIYWIIT AKDSTQIYQA KKGNGAIVSQ VKALRSRHIL AYSSVMQPFP DKAFLSLASD TVEPTILNAT NTSLTIRLPL AKTNLTWYGI TSPTPTYLVY YAEVNDRKNS SDLKYRILEF QDSIALIEDL QPFSTYMIQI AVKNYYSDPL EHLPPGKEIW GKTKNGVPEA VQLINTTVRS DTSLIISWRE SHKPNGPKES VRYQLAISHL ALIPETPLRQ SEFPNGRLTL LVTRLSGGNI YVLKVLACHS EEMWCTESHP VTVEMFNTPE KPYSLVPENT SLQFNWKAPL NVNLIRFWVE LQKWKYNEFY HVKTSCSQGP AYVCNITNLQ PYTSYNVRVV VVYKTGENST SLPESFKTKA GVPNKPGIPK LLEGSKNSIQ WEKAEDNGCR ITYYILEIRK STSNNLQNQN LRWKMTFNGS CSSVCTWKSK NLKGIFQFRV VAANNLGFGE YSGISENIIL VGDDFWIPET SFILTIIVGI FLVVTIPLTF VWHRRLKNQK SAKEGVTVLI NEDKELAELR GLAAGVGLAN ACYAIHTLPT QEEIENLPAF PREKLTLRLL LGSGAFGEVY EGTAVDILGV GSGEIKVAVK TLKKGSTDQE KIEFLKEAHL MSKFNHPNIL KQLGVCLLNE PQYIILELME GGDLLTYLRK ARMATFYGPL LTLVDLVDLC VDISKGCVYL ERMHFIHRDL AARNCLVSVK DYTSPRIVKI GDFGLARDIY KNDYYRKRGE GLLPVRWMAP ESLMDGIFTT QSDVWSFGIL IWEILTLGHQ PYPAHSNLDV LNYVQTGGRL EPPRNCPDDL WNLMTQCWAQ EPDQRPTFHR IQDQLQLFRN FFLNSIYKSR DEANNSGVIN ESFEGEDGDV ICLNSDDIMP VALMETKNRE GLNYMVLATE CGQGEEKSEG PLGSQESESC GLRKEEKEPH ADKDFCQEKQ VAYCPSGKPE GLNYACLTHS GYGDGSD // ID S100P_HUMAN Reviewed; 95 AA. AC P25815; Q5J7W2; DT 01-MAY-1992, integrated into UniProtKB/Swiss-Prot. DT 01-DEC-1992, sequence version 2. DT 28-JAN-2026, entry version 206. DE RecName: Full=Protein S100-P; DE AltName: Full=Migration-inducing gene 9 protein; DE Short=MIG9; DE AltName: Full=Protein S100-E; DE AltName: Full=S100 calcium-binding protein P; GN Name=S100P; Synonyms=S100E; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Placenta; RX PubMed=1633809; DOI=10.1111/j.1432-1033.1992.tb17080.x; RA Becker T., Gerke V., Kube E., Weber K.; RT "S100P, a novel Ca(2+)-binding protein from human placenta. cDNA cloning, RT recombinant protein expression and Ca2+ binding properties."; RL Eur. J. Biochem. 207:541-547(1992). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RA Jin G., Wang S., Chen J.; RT "Cloning, expression and characterization of a novel human calcium-binding RT S100 gene."; RL Submitted (AUG-2002) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Kim J.W.; RT "Identification of a human migration-inducing gene 9 (MIG9)."; RL Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP PROTEIN SEQUENCE OF 1-91. RC TISSUE=Placenta; RX PubMed=1540168; DOI=10.1016/0006-291x(92)91865-n; RA Emoto Y., Kobayashi R., Akatsuka H., Hidaka H.; RT "Purification and characterization of a new member of the S-100 protein RT family from human placenta."; RL Biochem. Biophys. Res. Commun. 182:1246-1253(1992). RN [7] RP INTERACTION WITH EZR. RX PubMed=12808036; DOI=10.1091/mbc.e02-09-0553; RA Koltzscher M., Neumann C., Konig S., Gerke V.; RT "Ca2+-dependent binding and activation of dormant ezrin by dimeric S100P."; RL Mol. Biol. Cell 14:2372-2384(2003). RN [8] RP TISSUE SPECIFICITY. RX PubMed=14672411; DOI=10.1023/a:1026311423326; RA Jin G., Wang S., Hu X., Jing Z., Chen J., Ying K., Xie Y., Mao Y.; RT "Characterization of the tissue-specific expression of the s100P gene which RT encodes an EF-hand Ca2+-binding protein."; RL Mol. Biol. Rep. 30:243-248(2003). RN [9] RP SUBUNIT, AND INTERACTION WITH S100A1. RX PubMed=15171681; DOI=10.1042/bj20040142; RA Wang G., Zhang S., Fernig D.G., Spiller D., Martin-Fernandez M., Zhang H., RA Ding Y., Rao Z., Rudland P.S., Barraclough R.; RT "Heterodimeric interaction and interfaces of S100A1 and S100P."; RL Biochem. J. 382:375-383(2004). RN [10] RP FUNCTION. RX PubMed=14617629; DOI=10.1074/jbc.m310124200; RA Arumugam T., Simeone D.M., Schmidt A.M., Logsdon C.D.; RT "S100P stimulates cell proliferation and survival via receptor for RT activated glycation end products (RAGE)."; RL J. Biol. Chem. 279:5059-5065(2004). RN [11] RP INTERACTION WITH S100PBP, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=15632002; DOI=10.1016/s0002-9440(10)62234-1; RA Dowen S.E., Crnogorac-Jurcevic T., Gangeswaran R., Hansen M., RA Eloranta J.J., Bhakta V., Brentnall T.A., Luettges J., Kloeppel G., RA Lemoine N.R.; RT "Expression of S100P and its novel binding partner S100PBPR in early RT pancreatic cancer."; RL Am. J. Pathol. 166:81-92(2005). RN [12] RP FUNCTION, INTERACTION WITH EZR, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP 21-SER--GLY-23; ASN-64; GLN-68 AND GLU-73. RX PubMed=19111582; DOI=10.1016/j.bbamcr.2008.11.012; RA Austermann J., Nazmi A.R., Heil A., Fritz G., Kolinski M., Filipek S., RA Gerke V.; RT "Generation and characterization of a novel, permanently active S100P RT mutant."; RL Biochim. Biophys. Acta 1793:1078-1085(2009). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [14] RP FUNCTION, INTERACTION WITH PPP5C, AND MUTAGENESIS OF 21-SER--GLY-23; RP ASN-64; GLN-68 AND GLU-73. RX PubMed=22399290; DOI=10.1074/jbc.m111.329771; RA Yamaguchi F., Umeda Y., Shimamoto S., Tsuchiya M., Tokumitsu H., Tokuda M., RA Kobayashi R.; RT "S100 proteins modulate protein phosphatase 5 function: a link between CA2+ RT signal transduction and protein dephosphorylation."; RL J. Biol. Chem. 287:13787-13798(2012). RN [15] RP INTERACTION WITH P.FALCIPARUM MSP1 (MICROBIAL INFECTION). RX PubMed=22431641; DOI=10.1073/pnas.1202689109; RA Waisberg M., Cerqueira G.C., Yager S.B., Francischetti I.M., Lu J., RA Gera N., Srinivasan P., Miura K., Rada B., Lukszo J., Barbian K.D., RA Leto T.L., Porcella S.F., Narum D.L., El-Sayed N., Miller L.H., RA Pierce S.K.; RT "Plasmodium falciparum merozoite surface protein 1 blocks the RT proinflammatory protein S100P."; RL Proc. Natl. Acad. Sci. U.S.A. 109:5429-5434(2012). RN [16] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS). RX PubMed=12507480; DOI=10.1016/s0022-2836(02)01278-0; RA Zhang H., Wang G., Ding Y., Wang Z., Barraclough R., Rudland P.S., RA Fernig D.G., Rao Z.; RT "The crystal structure at 2A resolution of the Ca2+ -binding protein RT S100P."; RL J. Mol. Biol. 325:785-794(2003). RN [17] RP STRUCTURE BY NMR. RX PubMed=15213440; DOI=10.1023/b:jnmr.0000032617.88899.4b; RA Lee Y.C., Volk D.E., Thiviyanathan V., Kleerekoper Q., Gribenko A.V., RA Zhang S., Gorenstein D.G., Makhatadze G.I., Luxon B.A.; RT "NMR structure of the Apo-S100P protein."; RL J. Biomol. NMR 29:399-402(2004). CC -!- FUNCTION: May function as calcium sensor and contribute to cellular CC calcium signaling. In a calcium-dependent manner, functions by CC interacting with other proteins, such as EZR and PPP5C, and indirectly CC plays a role in physiological processes like the formation of CC microvilli in epithelial cells. May stimulate cell proliferation in an CC autocrine manner via activation of the receptor for activated glycation CC end products (RAGE). {ECO:0000269|PubMed:14617629, CC ECO:0000269|PubMed:19111582, ECO:0000269|PubMed:22399290}. CC -!- SUBUNIT: Homodimer and heterodimer with S100A1. Interacts with S100PBP CC and S100Z. Interacts with CACYBP in a calcium-dependent manner. Dimeric CC form binds to and activates EZR/Ezrin by unmasking its F-actin binding CC sites. Interacts with PPP5C (via TPR repeats); the interaction is CC calcium-dependent and modulates PPP5C activity. CC {ECO:0000269|PubMed:12808036, ECO:0000269|PubMed:15171681, CC ECO:0000269|PubMed:15632002, ECO:0000269|PubMed:19111582, CC ECO:0000269|PubMed:22399290}. CC -!- SUBUNIT: (Microbial infection) Interacts with P.falciparum (strains 3D7 CC and FVO) MSP1 subunit p33; the interaction blocks S100P inflammatory CC and chemotactic activities. {ECO:0000269|PubMed:22431641}. CC -!- INTERACTION: CC P25815; Q15109: AGER; NbExp=2; IntAct=EBI-743700, EBI-1646426; CC P25815; Q7LC44: ARC; NbExp=3; IntAct=EBI-743700, EBI-750550; CC P25815; P52907: CAPZA1; NbExp=2; IntAct=EBI-743700, EBI-355586; CC P25815; P42858: HTT; NbExp=9; IntAct=EBI-743700, EBI-466029; CC P25815; P20809: IL11; NbExp=2; IntAct=EBI-743700, EBI-751694; CC P25815; P35579: MYH9; NbExp=3; IntAct=EBI-743700, EBI-350338; CC P25815; P07196: NEFL; NbExp=4; IntAct=EBI-743700, EBI-475646; CC P25815; P23297: S100A1; NbExp=11; IntAct=EBI-743700, EBI-743686; CC P25815; Q5T7Y6: S100A1; NbExp=4; IntAct=EBI-743700, EBI-11746600; CC P25815; P04271: S100B; NbExp=7; IntAct=EBI-743700, EBI-458391; CC P25815; Q8WXG8: S100Z; NbExp=3; IntAct=EBI-743700, EBI-12198403; CC P25815; Q9NYB0: TERF2IP; NbExp=2; IntAct=EBI-743700, EBI-750109; CC P25815; Q9UBB9: TFIP11; NbExp=3; IntAct=EBI-743700, EBI-1105213; CC P25815; Q15582: TGFBI; NbExp=3; IntAct=EBI-743700, EBI-10236573; CC P25815; P04637: TP53; NbExp=2; IntAct=EBI-743700, EBI-366083; CC P25815; P11441: UBL4A; NbExp=3; IntAct=EBI-743700, EBI-356983; CC P25815; O76024: WFS1; NbExp=3; IntAct=EBI-743700, EBI-720609; CC P25815; Q9CXW3: Cacybp; Xeno; NbExp=2; IntAct=EBI-743700, EBI-767146; CC -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Cell projection, microvillus CC membrane. Note=Colocalizes with S100PBP in the nucleus. Colocalizes CC with EZR in the microvilli in a calcium-dependent manner. CC -!- TISSUE SPECIFICITY: Detected in all of the tissues except brain, testis CC and small intestine, expression level is higher in placenta, heart, CC lung, skeletal muscle, spleen and leukocyte. Up-regulated in various CC pancreatic ductal adenocarcinomas and pancreatic intraepithelial CC neoplasias. {ECO:0000269|PubMed:14672411, ECO:0000269|PubMed:15632002}. CC -!- MISCELLANEOUS: This protein binds two calcium ions. CC -!- SIMILARITY: Belongs to the S-100 family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAS00487.1; Type=Miscellaneous discrepancy; Note=Sequencing error in Met-1 codon.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/42196/S100P"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X65614; CAA46566.1; -; mRNA. DR EMBL; AF539739; AAO41114.1; -; mRNA. DR EMBL; BT007289; AAP35953.1; -; mRNA. DR EMBL; AY423724; AAS00487.1; ALT_SEQ; mRNA. DR EMBL; BC006819; AAH06819.1; -; mRNA. DR CCDS; CCDS3391.1; -. DR PIR; S24146; S24146. DR RefSeq; NP_005971.1; NM_005980.3. DR PDB; 1J55; X-ray; 2.00 A; A=1-95. DR PDB; 1OZO; NMR; -; A/B=1-95. DR PDB; 2MJW; NMR; -; B/D=1-94. DR PDB; 7NMI; X-ray; 2.10 A; B=1-95. DR PDBsum; 1J55; -. DR PDBsum; 1OZO; -. DR PDBsum; 2MJW; -. DR PDBsum; 7NMI; -. DR AlphaFoldDB; P25815; -. DR BMRB; P25815; -. DR SMR; P25815; -. DR BioGRID; 112194; 307. DR FunCoup; P25815; 233. DR IntAct; P25815; 241. DR MINT; P25815; -. DR STRING; 9606.ENSP00000296370; -. DR DrugBank; DB01003; Cromoglicic acid. DR DrugCentral; P25815; -. DR GlyGen; P25815; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P25815; -. DR PhosphoSitePlus; P25815; -. DR BioMuta; S100P; -. DR DMDM; 134142; -. DR jPOST; P25815; -. DR MassIVE; P25815; -. DR PaxDb; 9606-ENSP00000296370; -. DR PeptideAtlas; P25815; -. DR ProteomicsDB; 54298; -. DR Pumba; P25815; -. DR TopDownProteomics; P25815; -. DR Antibodypedia; 4560; 460 antibodies from 34 providers. DR DNASU; 6286; -. DR Ensembl; ENST00000296370.4; ENSP00000296370.3; ENSG00000163993.7. DR GeneID; 6286; -. DR KEGG; hsa:6286; -. DR MANE-Select; ENST00000296370.4; ENSP00000296370.3; NM_005980.3; NP_005971.1. DR UCSC; uc003gjl.4; human. DR AGR; HGNC:10504; -. DR ClinPGx; PA34913; -. DR CTD; 6286; -. DR DisGeNET; 6286; -. DR GeneCards; S100P; -. DR HGNC; HGNC:10504; S100P. DR HPA; ENSG00000163993; Tissue enhanced (bone marrow, stomach, urinary bladder). DR MIM; 600614; gene. DR OpenTargets; ENSG00000163993; -. DR VEuPathDB; HostDB:ENSG00000163993; -. DR eggNOG; ENOG502S6E1; Eukaryota. DR GeneTree; ENSGT00940000162871; -. DR HOGENOM; CLU_138624_6_1_1; -. DR InParanoid; P25815; -. DR OMA; TCACHNR; -. DR OrthoDB; 26525at2759; -. DR PAN-GO; P25815; 4 GO annotations based on evolutionary models. DR PhylomeDB; P25815; -. DR PathwayCommons; P25815; -. DR Reactome; R-HSA-6798695; Neutrophil degranulation. DR SignaLink; P25815; -. DR SIGNOR; P25815; -. DR Agora; ENSG00000163993; -. DR BioGRID-ORCS; 6286; 17 hits in 1160 CRISPR screens. DR ChiTaRS; S100P; human. DR EvolutionaryTrace; P25815; -. DR GeneWiki; S100P; -. DR GenomeRNAi; 6286; -. DR Pharos; P25815; Tbio. DR PRO; PR:P25815; -. DR Proteomes; UP000005640; Chromosome 4. DR RNAct; P25815; protein. DR Bgee; ENSG00000163993; Expressed in nasal cavity epithelium and 149 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0031528; C:microvillus membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:HGNC-UCL. DR GO; GO:0034774; C:secretory granule lumen; TAS:Reactome. DR GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL. DR GO; GO:0005509; F:calcium ion binding; IBA:GO_Central. DR GO; GO:0048306; F:calcium-dependent protein binding; IPI:HGNC-UCL. DR GO; GO:0000287; F:magnesium ion binding; TAS:HGNC-UCL. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0046914; F:transition metal ion binding; IEA:InterPro. DR GO; GO:0043542; P:endothelial cell migration; IMP:UniProtKB. DR CDD; cd00213; S-100; 1. DR FunFam; 1.10.238.10:FF:000044; Protein S100; 1. DR Gene3D; 1.10.238.10; EF-hand; 1. DR InterPro; IPR011992; EF-hand-dom_pair. DR InterPro; IPR002048; EF_hand_dom. DR InterPro; IPR034325; S-100_dom. DR InterPro; IPR001751; S100/CaBP7/8-like_CS. DR InterPro; IPR013787; S100_Ca-bd_sub. DR PANTHER; PTHR11639:SF139; PROTEIN S100-P; 1. DR PANTHER; PTHR11639; S100 CALCIUM-BINDING PROTEIN; 1. DR Pfam; PF01023; S_100; 1. DR SMART; SM00054; EFh; 1. DR SMART; SM01394; S_100; 1. DR SUPFAM; SSF47473; EF-hand; 1. DR PROSITE; PS50222; EF_HAND_2; 1. DR PROSITE; PS00303; S100_CABP; 1. PE 1: Evidence at protein level; KW 3D-structure; Calcium; Cell membrane; Cell projection; Cytoplasm; KW Direct protein sequencing; Membrane; Metal-binding; Nucleus; KW Proteomics identification; Reference proteome; Repeat. FT CHAIN 1..95 FT /note="Protein S100-P" FT /id="PRO_0000144032" FT DOMAIN 12..47 FT /note="EF-hand 1" FT /evidence="ECO:0000305" FT DOMAIN 49..84 FT /note="EF-hand 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 25 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /ligand_note="low affinity" FT /evidence="ECO:0000305" FT BINDING 27 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /ligand_note="low affinity" FT /evidence="ECO:0000305" FT BINDING 32 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /ligand_note="low affinity" FT /evidence="ECO:0000305" FT BINDING 62 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /ligand_note="high affinity" FT /evidence="ECO:0000305" FT BINDING 64 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /ligand_note="high affinity" FT /evidence="ECO:0000305" FT BINDING 66 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /ligand_note="high affinity" FT /evidence="ECO:0000305" FT BINDING 68 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /ligand_note="high affinity" FT /evidence="ECO:0000305" FT BINDING 73 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /ligand_note="high affinity" FT /evidence="ECO:0000305" FT MUTAGEN 21..23 FT /note="Missing: In S100Ppa; permanently active, interacts FT with EZR and PPP5C in absence of calcium; when associated FT with C-64, K-68 and S-73." FT /evidence="ECO:0000269|PubMed:19111582, FT ECO:0000269|PubMed:22399290" FT MUTAGEN 64 FT /note="N->C: In S100Ppa; permanently active, interacts with FT EZR and PPP5C in absence of calcium; when associated with FT 21-S--G-23, K-68 and S-73." FT /evidence="ECO:0000269|PubMed:19111582, FT ECO:0000269|PubMed:22399290" FT MUTAGEN 68 FT /note="Q->K: In S100Ppa; permanently active, interacts with FT EZR and PPP5C in absence of calcium; when associated with FT 21-S--G-23, C-64 and S-73." FT /evidence="ECO:0000269|PubMed:19111582, FT ECO:0000269|PubMed:22399290" FT MUTAGEN 73 FT /note="E->S: In S100Ppa; permanently active, interacts with FT EZR and PPP5C in absence of calcium; when associated with FT 21-S--G-23, C-64 and K-68." FT /evidence="ECO:0000269|PubMed:19111582, FT ECO:0000269|PubMed:22399290" FT CONFLICT 12 FT /note="I -> M (in Ref. 4; AAS00487)" FT /evidence="ECO:0000305" FT CONFLICT 32 FT /note="E -> T (in Ref. 6; AA sequence)" FT /evidence="ECO:0000305" FT CONFLICT 44 FT /note="F -> E (in Ref. 6; AA sequence)" FT /evidence="ECO:0000305" FT HELIX 3..18 FT /evidence="ECO:0007829|PDB:1J55" FT STRAND 21..23 FT /evidence="ECO:0007829|PDB:1J55" FT STRAND 25..28 FT /evidence="ECO:0007829|PDB:7NMI" FT HELIX 30..40 FT /evidence="ECO:0007829|PDB:1J55" FT HELIX 44..46 FT /evidence="ECO:0007829|PDB:1OZO" FT HELIX 53..61 FT /evidence="ECO:0007829|PDB:1J55" FT STRAND 63..70 FT /evidence="ECO:0007829|PDB:1J55" FT HELIX 71..92 FT /evidence="ECO:0007829|PDB:1J55" SQ SEQUENCE 95 AA; 10400 MW; 786E6E3F3EACC6C1 CRC64; MTELETAMGM IIDVFSRYSG SEGSTQTLTK GELKVLMEKE LPGFLQSGKD KDAVDKLLKD LDANGDAQVD FSEFIVFVAA ITSACHKYFE KAGLK // ID S1PBP_HUMAN Reviewed; 408 AA. AC Q96BU1; B3KR04; D3DPQ5; Q5HYH3; Q9H997; DT 05-FEB-2008, integrated into UniProtKB/Swiss-Prot. DT 01-DEC-2001, sequence version 1. DT 28-JAN-2026, entry version 143. DE RecName: Full=S100P-binding protein; DE AltName: Full=S100P-binding protein Riken; GN Name=S100PBP {ECO:0000312|EMBL:AAH15175.1}; GN Synonyms=S100PBPR {ECO:0000303|PubMed:15632002}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305, ECO:0000312|EMBL:BAB14335.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE SEQUENCE RP [LARGE SCALE MRNA] OF 135-408 (ISOFORM 2). RC TISSUE=Cerebellum, and Teratocarcinoma {ECO:0000312|EMBL:BAB14335.1}; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Heart; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [3] {ECO:0000305, ECO:0000312|EMBL:CAI46038.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [4] {ECO:0000305, ECO:0000312|EMBL:AAH15175.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Pancreas {ECO:0000312|EMBL:AAH15175.1}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] {ECO:0000305} RP INTERACTION WITH S100P, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=15632002; DOI=10.1016/s0002-9440(10)62234-1; RA Dowen S.E., Crnogorac-Jurcevic T., Gangeswaran R., Hansen M., RA Eloranta J.J., Bhakta V., Brentnall T.A., Luettges J., Kloeppel G., RA Lemoine N.R.; RT "Expression of S100P and its novel binding partner S100PBPR in early RT pancreatic cancer."; RL Am. J. Pathol. 166:81-92(2005). RN [6] RP TISSUE SPECIFICITY. RX PubMed=18089492; DOI=10.1309/5d76nde81le8g545; RA Deng H., Shi J., Wilkerson M., Meschter S., Dupree W., Lin F.; RT "Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine- RT needle aspiration biopsy specimens."; RL Am. J. Clin. Pathol. 129:81-88(2008). RN [7] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-187, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). CC -!- SUBUNIT: Interacts with S100P. {ECO:0000269|PubMed:15632002}. CC -!- INTERACTION: CC Q96BU1; O43809: NUDT21; NbExp=3; IntAct=EBI-18959794, EBI-355720; CC Q96BU1; Q96HM7: PCED1B; NbExp=2; IntAct=EBI-18959794, EBI-1222622; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15632002}. CC Note=Colocalizes with S100P in the nucleus. CC {ECO:0000269|PubMed:15632002}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1 {ECO:0000269|PubMed:15489334}; CC IsoId=Q96BU1-1; Sequence=Displayed; CC Name=2 {ECO:0000269|PubMed:14702039}; CC IsoId=Q96BU1-2; Sequence=VSP_052661; CC -!- TISSUE SPECIFICITY: Expressed in brain, spleen, and lung. Not detected CC in pancreas or liver. In pancreas, expressed predominantly in islet CC cells and to a lesser extent in acinar cells, but not expressed in CC ductal cells. Up-regulated in various pancreatic ductal adenocarcinomas CC and pancreatic intraepithelial neoplasias. Detected in pancreatic CC ductal adenocarcinoma cells (at protein level). Not detected in non- CC neoplastic ductal epithelium (at protein level). CC {ECO:0000269|PubMed:15632002, ECO:0000269|PubMed:18089492}. CC -!- SEQUENCE CAUTION: CC Sequence=BAB14335.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/44308/S100PBP"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK022965; BAB14335.1; ALT_INIT; mRNA. DR EMBL; AK090711; BAG52216.1; -; mRNA. DR EMBL; BX647667; CAI46038.1; -; mRNA. DR EMBL; CH471059; EAX07503.1; -; Genomic_DNA. DR EMBL; CH471059; EAX07504.1; -; Genomic_DNA. DR EMBL; CH471059; EAX07505.1; -; Genomic_DNA. DR EMBL; BC015175; AAH15175.1; -; mRNA. DR CCDS; CCDS30666.1; -. [Q96BU1-1] DR RefSeq; NP_001243050.1; NM_001256121.2. [Q96BU1-1] DR RefSeq; NP_073590.2; NM_022753.4. [Q96BU1-1] DR RefSeq; XP_011540263.1; XM_011541961.3. [Q96BU1-1] DR RefSeq; XP_011540264.1; XM_011541962.3. [Q96BU1-1] DR RefSeq; XP_024304944.1; XM_024449176.2. [Q96BU1-1] DR RefSeq; XP_024304945.1; XM_024449177.2. [Q96BU1-1] DR RefSeq; XP_047283979.1; XM_047428023.1. [Q96BU1-1] DR RefSeq; XP_047283980.1; XM_047428024.1. [Q96BU1-1] DR RefSeq; XP_047283985.1; XM_047428029.1. [Q96BU1-1] DR RefSeq; XP_047283994.1; XM_047428038.1. [Q96BU1-2] DR RefSeq; XP_054194259.1; XM_054338284.1. [Q96BU1-1] DR RefSeq; XP_054194260.1; XM_054338285.1. [Q96BU1-1] DR RefSeq; XP_054194261.1; XM_054338286.1. [Q96BU1-1] DR RefSeq; XP_054194262.1; XM_054338287.1. [Q96BU1-1] DR RefSeq; XP_054194263.1; XM_054338288.1. [Q96BU1-1] DR RefSeq; XP_054194269.1; XM_054338294.1. [Q96BU1-2] DR RefSeq; XP_054194271.1; XM_054338296.1. [Q96BU1-1] DR AlphaFoldDB; Q96BU1; -. DR BioGRID; 122278; 12. DR FunCoup; Q96BU1; 3088. DR IntAct; Q96BU1; 3. DR STRING; 9606.ENSP00000362574; -. DR CarbonylDB; Q96BU1; -. DR GlyGen; Q96BU1; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q96BU1; -. DR PhosphoSitePlus; Q96BU1; -. DR BioMuta; S100PBP; -. DR DMDM; 74731274; -. DR jPOST; Q96BU1; -. DR MassIVE; Q96BU1; -. DR PaxDb; 9606-ENSP00000362574; -. DR PeptideAtlas; Q96BU1; -. DR ProteomicsDB; 76116; -. [Q96BU1-1] DR ProteomicsDB; 76117; -. [Q96BU1-2] DR Pumba; Q96BU1; -. DR Antibodypedia; 31365; 109 antibodies from 19 providers. DR DNASU; 64766; -. DR Ensembl; ENST00000373475.10; ENSP00000362574.5; ENSG00000116497.19. [Q96BU1-1] DR Ensembl; ENST00000373476.5; ENSP00000362575.1; ENSG00000116497.19. [Q96BU1-1] DR GeneID; 64766; -. DR KEGG; hsa:64766; -. DR MANE-Select; ENST00000373475.10; ENSP00000362574.5; NM_022753.4; NP_073590.2. DR UCSC; uc001bvz.5; human. [Q96BU1-1] DR AGR; HGNC:25768; -. DR ClinPGx; PA142670958; -. DR CTD; 64766; -. DR DisGeNET; 64766; -. DR GeneCards; S100PBP; -. DR HGNC; HGNC:25768; S100PBP. DR HPA; ENSG00000116497; Low tissue specificity. DR MIM; 611889; gene. DR OpenTargets; ENSG00000116497; -. DR VEuPathDB; HostDB:ENSG00000116497; -. DR eggNOG; ENOG502S5YT; Eukaryota. DR GeneTree; ENSGT00390000007209; -. DR HOGENOM; CLU_064425_0_0_1; -. DR InParanoid; Q96BU1; -. DR OMA; HHMQNSK; -. DR OrthoDB; 8945510at2759; -. DR PAN-GO; Q96BU1; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q96BU1; -. DR PathwayCommons; Q96BU1; -. DR SignaLink; Q96BU1; -. DR Agora; ENSG00000116497; -. DR BioGRID-ORCS; 64766; 13 hits in 1157 CRISPR screens. DR ChiTaRS; S100PBP; human. DR GenomeRNAi; 64766; -. DR Pharos; Q96BU1; Tbio. DR PRO; PR:Q96BU1; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q96BU1; protein. DR Bgee; ENSG00000116497; Expressed in right testis and 183 other cell types or tissues. DR ExpressionAtlas; Q96BU1; baseline and differential. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0016607; C:nuclear speck; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:HGNC-UCL. DR GO; GO:0048306; F:calcium-dependent protein binding; IPI:HGNC-UCL. DR InterPro; IPR026097; S100PBP. DR PANTHER; PTHR14455; ASKOPOS; 1. DR PANTHER; PTHR14455:SF0; S100P-BINDING PROTEIN; 1. DR Pfam; PF15427; S100PBPR; 1. PE 1: Evidence at protein level; KW Alternative splicing; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome. FT CHAIN 1..408 FT /note="S100P-binding protein" FT /id="PRO_0000317051" FT REGION 1..111 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 162..234 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 271..291 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 28..59 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 77..86 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 162..185 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 188..234 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 280..291 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 187 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 343..408 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:17974005" FT /id="VSP_052661" FT CONFLICT 329 FT /note="V -> L (in Ref. 1; BAB14335)" FT /evidence="ECO:0000305" SQ SEQUENCE 408 AA; 45582 MW; C366D258BEF3AAF5 CRC64; MMCSRVPSEQ SSGTSLLPKD GAPFSWDSLD EDGLDDSLLE LSEGEEDDGD VNYTEEEIDA LLKEDDPSYE QSSGEDDGGH VEKGERGSQI LLDTPREKNS SYSLGPVAET PDLFKLPQLS TSSGHGPAHT KPLNRRSVLE KNLIKVTVAP FNPTVCDALL DKDETDSSKD TEKLSSLGEE MREDGLSPNE SKLCTESEGI SPNNSAWNGP QLSSSNNNFQ QTVSDKNMPD SENPTSVFSR ISDHSETPNM ELSCRNGGSH KSSCEMRSLV VSTSSNKQDV LNKDSGKMKG HERRLGKVIP VLQTKTRTNV PTFSQSNLEQ QKQLYLRSVI AHIEDPEDTN QGISGELCAL MDQVHHMQHS KWQHPSDLTT RNYARRQKHL QRYSLTQWVD RNMRSHHRFQ RLPDFSYS // ID S22AG_HUMAN Reviewed; 577 AA. AC Q86VW1; O14567; Q5JXM1; Q8IUG8; Q8IZD5; Q96M90; Q96RU0; DT 26-FEB-2008, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-2003, sequence version 1. DT 28-JAN-2026, entry version 177. DE RecName: Full=Solute carrier family 22 member 16 {ECO:0000303|PubMed:15963465}; DE AltName: Full=Carnitine transporter 2 {ECO:0000303|PubMed:12089149}; DE Short=CT2 {ECO:0000303|PubMed:12372408}; DE AltName: Full=Fly-like putative transporter 2 {ECO:0000303|PubMed:12372408}; DE Short=FLIPT2 {ECO:0000303|PubMed:12372408}; DE Short=Flipt 2 {ECO:0000303|PubMed:12372408}; DE AltName: Full=Organic cation transporter OKB1; DE AltName: Full=Organic cation/carnitine transporter 6; GN Name=SLC22A16 {ECO:0000312|HGNC:HGNC:20302}; Synonyms=OCT6; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT THR-409, AND TISSUE RP SPECIFICITY. RC TISSUE=Kidney; RX PubMed=12372408; DOI=10.1016/s0006-291x(02)02343-4; RA Eraly S.A., Nigam S.K.; RT "Novel human cDNAs homologous to Drosophila Orct and mammalian carnitine RT transporters."; RL Biochem. Biophys. Res. Commun. 297:1159-1166(2002). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND VARIANT THR-409. RX PubMed=12384147; DOI=10.1016/s0301-472x(02)00901-3; RA Gong S., Lu X., Xu Y., Swiderski C.F., Jordan C.T., Moscow J.A.; RT "Identification of OCT6 as a novel organic cation transporter prefrentially RT expressed in hematopoietic cells and leukemias."; RL Exp. Hematol. 30:1162-1169(2002). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, TRANSPORTER ACTIVITY, RP BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RX PubMed=12089149; DOI=10.1074/jbc.m203883200; RA Enomoto A., Wempe M.F., Tsuchida H., Shin H.J., Cha S.H., Anzai N., RA Goto A., Sakamoto A., Niwa T., Kanai Y., Anders M.W., Endou H.; RT "Molecular identification of a novel carnitine transporter specific to RT human testis. Insights into the mechanism of carnitine recognition."; RL J. Biol. Chem. 277:36262-36271(2002). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, VARIANT RP THR-409, AND MISCELLANEOUS. RX PubMed=15963465; DOI=10.1016/j.bbrc.2005.05.174; RA Okabe M., Unno M., Harigae H., Kaku M., Okitsu Y., Sasaki T., Mizoi T., RA Shiiba K., Takanaga H., Terasaki T., Matsuno S., Sasaki I., Ito S., Abe T.; RT "Characterization of the organic cation transporter SLC22A16: a doxorubicin RT importer."; RL Biochem. Biophys. Res. Commun. 333:754-762(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 84-577 (ISOFORM 3), AND VARIANT RP THR-409. RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [9] RP TISSUE SPECIFICITY. RX PubMed=17197897; DOI=10.1097/01.pgp.0000225845.67245.b3; RA Sato N., Ito K., Onogawa T., Akahira J., Unno M., Abe T., Niikura H., RA Yaegashi N.; RT "Expression of organic cation transporter SLC22A16 in human endometria."; RL Int. J. Gynecol. Pathol. 26:53-60(2007). RN [10] RP TISSUE SPECIFICITY. RX PubMed=17581421; DOI=10.1097/01.pgp.0000236951.33914.1b; RA Ota K., Ito K., Akahira J., Sato N., Onogawa T., Moriya T., Unno M., RA Abe T., Niikura H., Takano T., Yaegashi N.; RT "Expression of organic cation transporter SLC22A16 in human epithelial RT ovarian cancer: a possible role of the adriamycin importer."; RL Int. J. Gynecol. Pathol. 26:334-340(2007). RN [11] RP FUNCTION, TRANSPORTER ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR RP LOCATION, TISSUE SPECIFICITY, AND MISCELLANEOUS. RX PubMed=20037140; DOI=10.1074/jbc.m109.046151; RA Aouida M., Poulin R., Ramotar D.; RT "The human carnitine transporter SLC22A16 mediates high affinity uptake of RT the anticancer polyamine analogue bleomycin-A5."; RL J. Biol. Chem. 285:6275-6284(2010). CC -!- FUNCTION: Facilitative organic cation transporter that mediates the CC transport of carnitine as well as the polyamine spermidine CC (PubMed:12089149, PubMed:20037140). Mediates the partially Na(+)- CC dependent bidirectional transport of carnitine (PubMed:12089149). May CC mediate L-carnitine secretion from testis epididymal epithelium into CC the lumen which is involved in the maturation of spermatozoa CC (PubMed:12089149). {ECO:0000269|PubMed:12089149, CC ECO:0000269|PubMed:20037140}. CC -!- CATALYTIC ACTIVITY: CC Reaction=(R)-carnitine(in) = (R)-carnitine(out); Xref=Rhea:RHEA:34959, CC ChEBI:CHEBI:16347; Evidence={ECO:0000269|PubMed:12089149, CC ECO:0000269|PubMed:20037140}; CC -!- CATALYTIC ACTIVITY: CC Reaction=spermidine(in) = spermidine(out); Xref=Rhea:RHEA:35039, CC ChEBI:CHEBI:57834; Evidence={ECO:0000269|PubMed:20037140}; CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=20.3 uM for L-carnitine {ECO:0000269|PubMed:12089149}; CC KM=8 uM for L-carnitine {ECO:0000269|PubMed:20037140}; CC KM=0.35 uM for spermidine {ECO:0000269|PubMed:20037140}; CC pH dependence: CC Optimum pH is 8.5 for carnitine uptake and transport efficiency CC decreased at more acidic pHs. {ECO:0000269|PubMed:12089149}; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:12089149, CC ECO:0000269|PubMed:20037140}; Multi-pass membrane protein CC {ECO:0000305}. Note=Detected in the plasma membrane of Sertoli cells CC and in the luminal membrane of epithelial cells in the epididymis. CC {ECO:0000269|PubMed:12089149}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q86VW1-1; Sequence=Displayed; CC Name=2; CC IsoId=Q86VW1-2; Sequence=VSP_031336, VSP_031337; CC Name=3; CC IsoId=Q86VW1-3; Sequence=VSP_031338; CC -!- TISSUE SPECIFICITY: Expressed in testis and epididymis (at protein CC level) (PubMed:12089149, PubMed:12384147, PubMed:15963465). Expressed CC in endometrium (at protein level); highly expressed during the normal CC secretory phase, but expression is significantly reduced in the CC proliferative phase (PubMed:17197897). Expressed at lower levels in CC adult tissues including bone marrow (at protein level) CC (PubMed:12372408, PubMed:12384147, PubMed:15963465). Expressed in CC hematopoietic cells, including CD34(+) leukocytes (PubMed:12384147). CC Expressed in fetal liver (at protein level), brain, lung, kidney, CC heart, skeletal muscle, spleen and thymus (PubMed:12372408, CC PubMed:12384147, PubMed:15963465). Expressed in leukemia cells CC (PubMed:12384147). Abundantly expressed in ovarian cancer clear-cell CC adenocarcinoma (PubMed:17581421). {ECO:0000269|PubMed:12089149, CC ECO:0000269|PubMed:12372408, ECO:0000269|PubMed:12384147, CC ECO:0000269|PubMed:15963465, ECO:0000269|PubMed:17197897, CC ECO:0000269|PubMed:17581421}. CC -!- MISCELLANEOUS: Involved in the uptake of clinically used drugs such as CC anticancer agents doxorubicin and bleomycin. CC {ECO:0000269|PubMed:15963465, ECO:0000269|PubMed:20037140}. CC -!- SIMILARITY: Belongs to the major facilitator (TC 2.A.1) superfamily. CC Organic cation transporter (TC 2.A.1.19) family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAB71419.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY145502; AAN52928.1; -; mRNA. DR EMBL; AB055798; BAC23062.1; -; mRNA. DR EMBL; AF268892; AAK58593.1; -; mRNA. DR EMBL; AC002464; AAB67044.1; -; Genomic_DNA. DR EMBL; AL050350; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471051; EAW48313.1; -; Genomic_DNA. DR EMBL; BC047565; AAH47565.1; -; mRNA. DR EMBL; AK057306; BAB71419.1; ALT_INIT; mRNA. DR CCDS; CCDS5084.1; -. [Q86VW1-1] DR RefSeq; NP_149116.2; NM_033125.3. [Q86VW1-1] DR RefSeq; XP_011534507.1; XM_011536205.3. [Q86VW1-3] DR RefSeq; XP_054212602.1; XM_054356627.1. [Q86VW1-3] DR AlphaFoldDB; Q86VW1; -. DR SMR; Q86VW1; -. DR BioGRID; 124519; 55. DR FunCoup; Q86VW1; 146. DR IntAct; Q86VW1; 48. DR STRING; 9606.ENSP00000357915; -. DR BindingDB; Q86VW1; -. DR ChEMBL; CHEMBL2073722; -. DR DrugBank; DB00997; Doxorubicin. DR DrugBank; DB00583; Levocarnitine. DR TCDB; 2.A.1.19.12; the major facilitator superfamily (mfs). DR GlyCosmos; Q86VW1; 8 sites, No reported glycans. DR GlyGen; Q86VW1; 8 sites. DR iPTMnet; Q86VW1; -. DR PhosphoSitePlus; Q86VW1; -. DR BioMuta; SLC22A16; -. DR DMDM; 74750474; -. DR jPOST; Q86VW1; -. DR MassIVE; Q86VW1; -. DR PaxDb; 9606-ENSP00000357915; -. DR PeptideAtlas; Q86VW1; -. DR ProteomicsDB; 70079; -. [Q86VW1-1] DR ProteomicsDB; 70080; -. [Q86VW1-2] DR Antibodypedia; 32327; 110 antibodies from 22 providers. DR DNASU; 85413; -. DR Ensembl; ENST00000330550.8; ENSP00000328583.4; ENSG00000004809.15. [Q86VW1-2] DR Ensembl; ENST00000368919.8; ENSP00000357915.3; ENSG00000004809.15. [Q86VW1-1] DR GeneID; 85413; -. DR KEGG; hsa:85413; -. DR MANE-Select; ENST00000368919.8; ENSP00000357915.3; NM_033125.4; NP_149116.2. DR UCSC; uc003puf.5; human. [Q86VW1-1] DR AGR; HGNC:20302; -. DR ClinPGx; PA134911502; -. DR CTD; 85413; -. DR DisGeNET; 85413; -. DR GeneCards; SLC22A16; -. DR HGNC; HGNC:20302; SLC22A16. DR HPA; ENSG00000004809; Group enriched (bone marrow, testis). DR MIM; 608276; gene. DR OpenTargets; ENSG00000004809; -. DR VEuPathDB; HostDB:ENSG00000004809; -. DR eggNOG; KOG0255; Eukaryota. DR GeneTree; ENSGT00940000160723; -. DR InParanoid; Q86VW1; -. DR OMA; MEAYMGA; -. DR OrthoDB; 2261376at2759; -. DR PAN-GO; Q86VW1; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q86VW1; -. DR PathwayCommons; Q86VW1; -. DR Reactome; R-HSA-549127; Organic cation transport. DR SignaLink; Q86VW1; -. DR Agora; ENSG00000004809; -. DR BioGRID-ORCS; 85413; 11 hits in 1147 CRISPR screens. DR GenomeRNAi; 85413; -. DR Pharos; Q86VW1; Tbio. DR PRO; PR:Q86VW1; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q86VW1; protein. DR Bgee; ENSG00000004809; Expressed in trabecular bone tissue and 112 other cell types or tissues. DR ExpressionAtlas; Q86VW1; baseline and differential. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0005275; F:amine transmembrane transporter activity; IDA:MGI. DR GO; GO:0015226; F:carnitine transmembrane transporter activity; IDA:UniProtKB. DR GO; GO:0015101; F:organic cation transmembrane transporter activity; IDA:UniProtKB. DR GO; GO:0015606; F:spermidine transmembrane transporter activity; IDA:UniProtKB. DR GO; GO:0046717; P:acid secretion; IDA:UniProtKB. DR GO; GO:1902603; P:carnitine transmembrane transport; IDA:UniProtKB. DR GO; GO:0015879; P:carnitine transport; IDA:UniProtKB. DR GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW. DR GO; GO:0030317; P:flagellated sperm motility; IMP:UniProtKB. DR GO; GO:0006811; P:monoatomic ion transport; IEA:UniProtKB-KW. DR GO; GO:0015695; P:organic cation transport; IDA:UniProtKB. DR GO; GO:0007338; P:single fertilization; IMP:UniProtKB. DR GO; GO:0007283; P:spermatogenesis; IEA:UniProtKB-KW. DR GO; GO:1903711; P:spermidine transmembrane transport; IDA:UniProtKB. DR CDD; cd17375; MFS_SLC22A16_CT2; 1. DR FunFam; 1.20.1250.20:FF:000154; Solute carrier family 22 member 16; 1. DR Gene3D; 1.20.1250.20; MFS general substrate transporter like domains; 1. DR InterPro; IPR020846; MFS_dom. DR InterPro; IPR005828; MFS_sugar_transport-like. DR InterPro; IPR036259; MFS_trans_sf. DR PANTHER; PTHR24064; SOLUTE CARRIER FAMILY 22 MEMBER; 1. DR Pfam; PF00083; Sugar_tr; 1. DR SUPFAM; SSF103473; MFS general substrate transporter; 1. DR PROSITE; PS50850; MFS; 1. PE 1: Evidence at protein level; KW Alternative splicing; Cell membrane; Developmental protein; KW Differentiation; Glycoprotein; Ion transport; Membrane; KW Proteomics identification; Reference proteome; Spermatogenesis; KW Transmembrane; Transmembrane helix; Transport. FT CHAIN 1..577 FT /note="Solute carrier family 22 member 16" FT /id="PRO_0000318991" FT TRANSMEM 23..43 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 152..172 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 183..203 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 214..234 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 244..264 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 268..288 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 359..379 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 389..409 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 416..436 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 441..461 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 476..496 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 501..521 FT /note="Helical" FT /evidence="ECO:0000255" FT REGION 543..577 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 551..560 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT CARBOHYD 57 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 65 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 68 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 108 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 345 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 352 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 546 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 558 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 1..17 FT /note="MGSRHFEGIYDHVGHFG -> MRTLHAVSHPYSNSM (in isoform 2)" FT /evidence="ECO:0000303|PubMed:12089149" FT /id="VSP_031336" FT VAR_SEQ 58..89 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:12089149" FT /id="VSP_031337" FT VAR_SEQ 509..577 FT /note="FVGTMALLSGVLTLKLPETLGKRLATTWEEAAKLESENESKSSKLLLTTNNS FT GLEKTEAITPRDSGLGE -> LGQHLQE (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_031338" FT VARIANT 49 FT /note="H -> R (in dbSNP:rs714368)" FT /id="VAR_038930" FT VARIANT 252 FT /note="V -> A (in dbSNP:rs723685)" FT /id="VAR_038931" FT VARIANT 409 FT /note="M -> T (in dbSNP:rs12210538)" FT /evidence="ECO:0000269|PubMed:12372408, FT ECO:0000269|PubMed:12384147, ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:15963465" FT /id="VAR_038932" FT VARIANT 431 FT /note="V -> I (in dbSNP:rs35948062)" FT /id="VAR_038933" FT CONFLICT 257 FT /note="V -> G (in Ref. 1; AAN52928)" FT /evidence="ECO:0000305" SQ SEQUENCE 577 AA; 64614 MW; EA4ABBED0AE99632 CRC64; MGSRHFEGIY DHVGHFGRFQ RVLYFICAFQ NISCGIHYLA SVFMGVTPHH VCRPPGNVSQ VVFHNHSNWS LEDTGALLSS GQKDYVTVQL QNGEIWELSR CSRNKRENTS SLGYEYTGSK KEFPCVDGYI YDQNTWKSTA VTQWNLVCDR KWLAMLIQPL FMFGVLLGSV TFGYFSDRLG RRVVLWATSS SMFLFGIAAA FAVDYYTFMA ARFFLAMVAS GYLVVGFVYV MEFIGMKSRT WASVHLHSFF AVGTLLVALT GYLVRTWWLY QMILSTVTVP FILCCWVLPE TPFWLLSEGR YEEAQKIVDI MAKWNRASSC KLSELLSLDL QGPVSNSPTE VQKHNLSYLF YNWSITKRTL TVWLIWFTGS LGFYSFSLNS VNLGGNEYLN LFLLGVVEIP AYTFVCIAMD KVGRRTVLAY SLFCSALACG VVMVIPQKHY ILGVVTAMVG KFAIGAAFGL IYLYTAELYP TIVRSLAVGS GSMVCRLASI LAPFSVDLSS IWIFIPQLFV GTMALLSGVL TLKLPETLGK RLATTWEEAA KLESENESKS SKLLLTTNNS GLEKTEAITP RDSGLGE // ID S35F6_HUMAN Reviewed; 371 AA. AC Q8N357; D6W543; Q53GK2; Q8NBX6; Q9NWX0; DT 18-APR-2006, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-2002, sequence version 1. DT 28-JAN-2026, entry version 162. DE RecName: Full=Solute carrier family 35 member F6; DE AltName: Full=ANT2-binding protein; DE Short=ANT2BP; DE AltName: Full=Transport and Golgi organization 9 homolog; DE Flags: Precursor; GN Name=SLC35F6; Synonyms=C2orf18; ORFNames=UNQ3047/PRO9863; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=12975309; DOI=10.1101/gr.1293003; RA Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J., RA Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P., RA Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A., RA Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D., RA Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L., RA Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C., RA Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J., RA Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.; RT "The secreted protein discovery initiative (SPDI), a large-scale effort to RT identify novel human secreted and transmembrane proteins: a bioinformatics RT assessment."; RL Genome Res. 13:2265-2270(2003). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Placenta; RX PubMed=16303743; DOI=10.1093/dnares/12.2.117; RA Otsuki T., Ota T., Nishikawa T., Hayashi K., Suzuki Y., Yamamoto J., RA Wakamatsu A., Kimura K., Sakamoto K., Hatano N., Kawai Y., Ishii S., RA Saito K., Kojima S., Sugiyama T., Ono T., Okano K., Yoshikawa Y., RA Aotsuka S., Sasaki N., Hattori A., Okumura K., Nagai K., Sugano S., RA Isogai T.; RT "Signal sequence and keyword trap in silico for selection of full-length RT human cDNAs encoding secretion or membrane proteins from oligo-capped cDNA RT libraries."; RL DNA Res. 12:117-126(2005). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Kidney; RA Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y., RA Tanaka A., Yokoyama S.; RL Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Blood; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-365, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [11] RP FUNCTION, INTERACTION WITH SLC25A5, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RX PubMed=19154410; DOI=10.1111/j.1349-7006.2008.01058.x; RA Kashiwaya K., Hosokawa M., Eguchi H., Ohigashi H., Ishikawa O., RA Shinomura Y., Nakamura Y., Nakagawa H.; RT "Identification of C2orf18, termed ANT2BP (ANT2-binding protein), as one of RT the key molecules involved in pancreatic carcinogenesis."; RL Cancer Sci. 100:457-464(2009). RN [12] RP REVIEW, AND SUBCELLULAR LOCATION. RX PubMed=20957757; DOI=10.1002/pmic.201000196; RA Schroeder B.A., Wrocklage C., Hasilik A., Saftig P.; RT "The proteome of lysosomes."; RL Proteomics 10:4053-4076(2010). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). CC -!- FUNCTION: Involved in the maintenance of mitochondrial membrane CC potential in pancreatic ductal adenocarcinoma (PDAC) cells. Promotes CC pancreatic ductal adenocarcinoma (PDAC) cell growth. May play a role as CC a nucleotide-sugar transporter. {ECO:0000269|PubMed:19154410}. CC -!- SUBUNIT: Interacts with SLC25A5. {ECO:0000269|PubMed:19154410}. CC -!- INTERACTION: CC Q8N357; Q13520: AQP6; NbExp=3; IntAct=EBI-713484, EBI-13059134; CC Q8N357; Q8N350-4: CBARP; NbExp=3; IntAct=EBI-713484, EBI-19051169; CC Q8N357; Q9HA82: CERS4; NbExp=3; IntAct=EBI-713484, EBI-2622997; CC Q8N357; P15328: FOLR1; NbExp=3; IntAct=EBI-713484, EBI-2556557; CC Q8N357; P48165: GJA8; NbExp=3; IntAct=EBI-713484, EBI-17458373; CC Q8N357; Q8TDT2: GPR152; NbExp=3; IntAct=EBI-713484, EBI-13345167; CC Q8N357; P05141: SLC25A5; NbExp=2; IntAct=EBI-713484, EBI-355133; CC Q8N357; Q9NPL8: TIMMDC1; NbExp=3; IntAct=EBI-713484, EBI-6268651; CC Q8N357; Q9NUH8: TMEM14B; NbExp=3; IntAct=EBI-713484, EBI-8638294; CC -!- SUBCELLULAR LOCATION: Mitochondrion. Lysosome membrane; Multi-pass CC membrane protein. CC -!- TISSUE SPECIFICITY: Expressed in pancreatic ductal adenocarcinoma CC (PDAC) (at protein level). Strongly expressed in prostate and thyroid. CC Weakly expressed in lung, heart, liver and kidney. CC {ECO:0000269|PubMed:19154410}. CC -!- SIMILARITY: Belongs to the SLC35F solute transporter family. CC {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY358820; AAQ89179.1; -; mRNA. DR EMBL; AK000562; BAA91255.1; -; mRNA. DR EMBL; AK075164; BAC11445.1; -; mRNA. DR EMBL; CR457243; CAG33524.1; -; mRNA. DR EMBL; AK222929; BAD96649.1; -; mRNA. DR EMBL; AC011740; AAX93265.1; -; Genomic_DNA. DR EMBL; CH471053; EAX00673.1; -; Genomic_DNA. DR EMBL; CH471053; EAX00676.1; -; Genomic_DNA. DR EMBL; BC028081; AAH28081.1; -; mRNA. DR CCDS; CCDS1728.1; -. DR RefSeq; NP_060347.2; NM_017877.3. DR AlphaFoldDB; Q8N357; -. DR SMR; Q8N357; -. DR BioGRID; 120314; 135. DR FunCoup; Q8N357; 2332. DR IntAct; Q8N357; 105. DR MINT; Q8N357; -. DR STRING; 9606.ENSP00000345528; -. DR TCDB; 2.A.7.12.13; the drug/metabolite transporter (dmt) superfamily. DR GlyCosmos; Q8N357; 1 site, No reported glycans. DR GlyGen; Q8N357; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q8N357; -. DR PhosphoSitePlus; Q8N357; -. DR SwissPalm; Q8N357; -. DR BioMuta; SLC35F6; -. DR DMDM; 74728772; -. DR jPOST; Q8N357; -. DR MassIVE; Q8N357; -. DR PaxDb; 9606-ENSP00000345528; -. DR PeptideAtlas; Q8N357; -. DR ProteomicsDB; 71766; -. DR Pumba; Q8N357; -. DR Antibodypedia; 28001; 132 antibodies from 20 providers. DR DNASU; 54978; -. DR Ensembl; ENST00000344420.10; ENSP00000345528.5; ENSG00000213699.10. DR GeneID; 54978; -. DR KEGG; hsa:54978; -. DR MANE-Select; ENST00000344420.10; ENSP00000345528.5; NM_017877.4; NP_060347.2. DR UCSC; uc002rhp.2; human. DR AGR; HGNC:26055; -. DR ClinPGx; PA134913368; -. DR CTD; 54978; -. DR DisGeNET; 54978; -. DR GeneCards; SLC35F6; -. DR HGNC; HGNC:26055; SLC35F6. DR HPA; ENSG00000213699; Low tissue specificity. DR MIM; 619667; gene. DR OpenTargets; ENSG00000213699; -. DR VEuPathDB; HostDB:ENSG00000213699; -. DR eggNOG; KOG3912; Eukaryota. DR GeneTree; ENSGT00390000017237; -. DR HOGENOM; CLU_025028_1_0_1; -. DR InParanoid; Q8N357; -. DR OMA; FIYKHNV; -. DR OrthoDB; 29773at2759; -. DR PAN-GO; Q8N357; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q8N357; -. DR PathwayCommons; Q8N357; -. DR SignaLink; Q8N357; -. DR Agora; ENSG00000213699; -. DR BioGRID-ORCS; 54978; 12 hits in 1161 CRISPR screens. DR ChiTaRS; SLC35F6; human. DR GeneWiki; C2orf18; -. DR GenomeRNAi; 54978; -. DR Pharos; Q8N357; Tbio. DR PRO; PR:Q8N357; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q8N357; protein. DR Bgee; ENSG00000213699; Expressed in nipple and 182 other cell types or tissues. DR ExpressionAtlas; Q8N357; baseline and differential. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; IBA:GO_Central. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0022857; F:transmembrane transporter activity; IEA:InterPro. DR GO; GO:1901029; P:negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway; IMP:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB. DR InterPro; IPR037185; EmrE-like. DR InterPro; IPR009262; SLC35_F1/F2/F6. DR InterPro; IPR012404; UCP036436. DR PANTHER; PTHR13146; -; 1. DR PANTHER; PTHR13146:SF0; SOLUTE CARRIER FAMILY 35 MEMBER F6; 1. DR Pfam; PF06027; SLC35F; 1. DR PIRSF; PIRSF036436; UCP036436; 1. DR SUPFAM; SSF103481; Multidrug resistance efflux transporter EmrE; 1. PE 1: Evidence at protein level; KW Glycoprotein; Lysosome; Membrane; Mitochondrion; Phosphoprotein; KW Proteomics identification; Reference proteome; Signal; Transmembrane; KW Transmembrane helix; Transport. FT SIGNAL 1..18 FT /evidence="ECO:0000255" FT CHAIN 19..371 FT /note="Solute carrier family 35 member F6" FT /id="PRO_0000232514" FT TRANSMEM 48..68 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 89..109 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 117..137 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 140..160 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 176..196 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 216..236 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 261..281 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 295..312 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 317..336 FT /note="Helical" FT /evidence="ECO:0000255" FT DOMAIN 104..160 FT /note="EamA" FT REGION 352..371 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 365 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648" FT CARBOHYD 110 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CONFLICT 107 FT /note="V -> A (in Ref. 5; BAD96649)" FT /evidence="ECO:0000305" FT CONFLICT 163 FT /note="L -> P (in Ref. 5; BAD96649)" FT /evidence="ECO:0000305" FT CONFLICT 215 FT /note="E -> K (in Ref. 2; BAA91255)" FT /evidence="ECO:0000305" FT CONFLICT 274 FT /note="A -> V (in Ref. 5; BAD96649)" FT /evidence="ECO:0000305" FT CONFLICT 295 FT /note="L -> S (in Ref. 3; BAC11445)" FT /evidence="ECO:0000305" SQ SEQUENCE 371 AA; 40214 MW; 225AFE41FA555B12 CRC64; MAWTKYQLFL AGLMLVTGSI NTLSAKWADN FMAEGCGGSK EHSFQHPFLQ AVGMFLGEFS CLAAFYLLRC RAAGQSDSSV DPQQPFNPLL FLPPALCDMT GTSLMYVALN MTSASSFQML RGAVIIFTGL FSVAFLGRRL VLSQWLGILA TIAGLVVVGL ADLLSKHDSQ HKLSEVITGD LLIIMAQIIV AIQMVLEEKF VYKHNVHPLR AVGTEGLFGF VILSLLLVPM YYIPAGSFSG NPRGTLEDAL DAFCQVGQQP LIAVALLGNI SSIAFFNFAG ISVTKELSAT TRMVLDSLRT VVIWALSLAL GWEAFHALQI LGFLILLIGT ALYNGLHRPL LGRLSRGRPL AEESEQERLL GGTRTPINDA S // ID S39A6_HUMAN Reviewed; 755 AA. AC Q13433; B4DR49; B4E224; Q8IXR3; Q96HP5; DT 05-JUL-2005, integrated into UniProtKB/Swiss-Prot. DT 23-MAR-2010, sequence version 3. DT 28-JAN-2026, entry version 187. DE RecName: Full=Zinc transporter ZIP6 {ECO:0000305}; DE AltName: Full=Estrogen-regulated protein LIV-1; DE AltName: Full=Solute carrier family 39 member 6; DE AltName: Full=Zrt- and Irt-like protein 6; DE Short=ZIP-6; DE Flags: Precursor; GN Name=SLC39A6 {ECO:0000312|HGNC:HGNC:18607}; Synonyms=LIV1, ZIP6; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ASP-119. RA Green C., Morgan H.E.; RL Submitted (FEB-2001) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ASP-119. RC TISSUE=Teratocarcinoma, and Trachea; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16177791; DOI=10.1038/nature03983; RA Nusbaum C., Zody M.C., Borowsky M.L., Kamal M., Kodira C.D., Taylor T.D., RA Whittaker C.A., Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., RA Abouelleil A., Allen N.R., Anderson S., Bloom T., Bugalter B., Butler J., RA Cook A., DeCaprio D., Engels R., Garber M., Gnirke A., Hafez N., Hall J.L., RA Norman C.H., Itoh T., Jaffe D.B., Kuroki Y., Lehoczky J., Lui A., RA Macdonald P., Mauceli E., Mikkelsen T.S., Naylor J.W., Nicol R., Nguyen C., RA Noguchi H., O'Leary S.B., Piqani B., Smith C.L., Talamas J.A., Topham K., RA Totoki Y., Toyoda A., Wain H.M., Young S.K., Zeng Q., Zimmer A.R., RA Fujiyama A., Hattori M., Birren B.W., Sakaki Y., Lander E.S.; RT "DNA sequence and analysis of human chromosome 18."; RL Nature 437:551-555(2005). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASP-119. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND NUCLEOTIDE SEQUENCE RP [LARGE SCALE MRNA] OF 382-755 (ISOFORM 1). RC TISSUE=Eye, and Lymph; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP PROTEIN SEQUENCE OF 29-43. RX PubMed=15340161; DOI=10.1110/ps.04682504; RA Zhang Z., Henzel W.J.; RT "Signal peptide prediction based on analysis of experimentally verified RT cleavage sites."; RL Protein Sci. 13:2819-2824(2004). RN [7] RP INDUCTION. RX PubMed=2903103; DOI=10.1016/0303-7207(88)90105-0; RA Manning D.L., Daly R.J., Lord P.G., Kelly K.F., Green C.D.; RT "Effects of oestrogen on the expression of a 4.4 kb mRNA in the ZR-75-1 RT human breast cancer cell line."; RL Mol. Cell. Endocrinol. 59:205-212(1988). RN [8] RP FUNCTION, TRANSPORTER ACTIVITY, SUBCELLULAR LOCATION, TOPOLOGY, TISSUE RP SPECIFICITY, AND GLYCOSYLATION. RX PubMed=12839489; DOI=10.1042/bj20030478; RA Taylor K.M., Morgan H.E., Johnson A., Hadley L.J., Nicholson R.I.; RT "Structure-function analysis of LIV-1, the breast cancer-associated protein RT that belongs to a new subfamily of zinc transporters."; RL Biochem. J. 375:51-59(2003). RN [9] RP FUNCTION, TRANSPORTER ACTIVITY, SUBCELLULAR LOCATION, AND INDUCTION. RX PubMed=18272141; DOI=10.1016/j.brainres.2008.01.015; RA Chowanadisai W., Loennerdal B., Kelleher S.L.; RT "Zip6 (LIV-1) regulates zinc uptake in neuroblastoma cells under resting RT but not depolarizing conditions."; RL Brain Res. 1199:10-19(2008). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [12] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-67 AND ASN-241. RC TISSUE=Leukemic T-cell; RX PubMed=19349973; DOI=10.1038/nbt.1532; RA Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M., RA Schiess R., Aebersold R., Watts J.D.; RT "Mass-spectrometric identification and relative quantification of N-linked RT cell surface glycoproteins."; RL Nat. Biotechnol. 27:378-386(2009). RN [13] RP FUNCTION, AND TRANSPORTER ACTIVITY. RX PubMed=21422171; DOI=10.1084/jem.20100031; RA Yu M., Lee W.W., Tomar D., Pryshchep S., Czesnikiewicz-Guzik M., RA Lamar D.L., Li G., Singh K., Tian L., Weyand C.M., Goronzy J.J.; RT "Regulation of T cell receptor signaling by activation-induced zinc RT influx."; RL J. Exp. Med. 208:775-785(2011). RN [14] RP FUNCTION, PROTEOLYTIC CLEAVAGE, GLYCOSYLATION, AND INDUCTION. RX PubMed=23919497; DOI=10.1042/bj20130483; RA Hogstrand C., Kille P., Ackland M.L., Hiscox S., Taylor K.M.; RT "A mechanism for epithelial-mesenchymal transition and anoikis resistance RT in breast cancer triggered by zinc channel ZIP6 and STAT3 (signal RT transducer and activator of transcription 3)."; RL Biochem. J. 455:229-237(2013). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-471 AND SER-478, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [16] RP FUNCTION. RX PubMed=25143461; DOI=10.1093/molehr/gau066; RA Kong B.Y., Duncan F.E., Que E.L., Kim A.M., O'Halloran T.V., Woodruff T.K.; RT "Maternally-derived zinc transporters ZIP6 and ZIP10 drive the mammalian RT oocyte-to-egg transition."; RL Mol. Hum. Reprod. 20:1077-1089(2014). RN [17] RP INTERACTION WITH SLC39A10, FUNCTION, AND TRANSPORTER ACTIVITY. RX PubMed=27274087; DOI=10.1042/bcj20160388; RA Taylor K.M., Muraina I.A., Brethour D., Schmitt-Ulms G., Nimmanon T., RA Ziliotto S., Kille P., Hogstrand C.; RT "Zinc transporter ZIP10 forms a heteromer with ZIP6 which regulates RT embryonic development and cell migration."; RL Biochem. J. 473:2531-2544(2016). RN [18] RP INDUCTION, FUNCTION, AND TRANSPORTER ACTIVITY. RX PubMed=30552163; DOI=10.4049/jimmunol.1800689; RA Colomar-Carando N., Meseguer A., Company-Garrido I., Jutz S., RA Herrera-Fernandez V., Olvera A., Kiefer K., Brander C., Steinberger P., RA Vicente R.; RT "Zip6 Transporter Is an Essential Component of the Lymphocyte Activation RT Machinery."; RL J. Immunol. 202:441-450(2019). RN [19] RP FUNCTION, AND IDENTIFICATION IN A COMPLEX WITH SLC39A10 AND STAT3. RX PubMed=32797246; DOI=10.1007/s00018-020-03616-6; RA Nimmanon T., Ziliotto S., Ogle O., Burt A., Gee J.M.W., Andrews G.K., RA Kille P., Hogstrand C., Maret W., Taylor K.M.; RT "The ZIP6/ZIP10 heteromer is essential for the zinc-mediated trigger of RT mitosis."; RL Cell. Mol. Life Sci. 78:1781-1798(2021). RN [20] RP FUNCTION, TRANSPORTER ACTIVITY, SUBCELLULAR LOCATION, AND PHOSPHORYLATION. RX PubMed=34394081; DOI=10.3389/fimmu.2021.687367; RA Kim B., Kim H.Y., Lee W.W.; RT "Zap70 Regulates TCR-Mediated Zip6 Activation at the Immunological RT Synapse."; RL Front. Immunol. 12:687367-687367(2021). CC -!- FUNCTION: Zinc-influx transporter which plays a role in zinc CC homeostasis and in the induction of epithelial-to-mesenchymal CC transition (EMT) (PubMed:12839489, PubMed:18272141, PubMed:21422171, CC PubMed:23919497, PubMed:27274087, PubMed:34394081). When associated CC with SLC39A10, the heterodimer formed by SLC39A10 and SLC39A6 mediates CC cellular zinc uptake to trigger cells to undergo epithelial- to- CC mesenchymal transition (EMT) (PubMed:27274087). The SLC39A10-SLC39A6 CC heterodimer also controls NCAM1 phosphorylation and its integration CC into focal adhesion complexes during EMT (By similarity). Zinc influx CC inactivates GSK3B, enabling unphosphorylated SNAI1 in the nucleus to CC down-regulate adherence genes such as CDH1, causing loss of cell CC adherence (PubMed:23919497). In addition, the SLC39A10-SLC39A6 CC heterodimer plays an essentiel role in initiating mitosis by importing CC zinc into cells to initiate a pathway resulting in the onset of mitosis CC (PubMed:32797246). Participates in the T-cell receptor signaling CC regulation by mediating cellular zinc uptake into activated lymphocytes CC (PubMed:21422171, PubMed:30552163, PubMed:34394081). Regulates the zinc CC influx necessary for proper meiotic progression to metaphase II (MII) CC that allows the oocyte-to-egg transition (PubMed:25143461). CC {ECO:0000250|UniProtKB:Q8C145, ECO:0000269|PubMed:12839489, CC ECO:0000269|PubMed:18272141, ECO:0000269|PubMed:21422171, CC ECO:0000269|PubMed:23919497, ECO:0000269|PubMed:25143461, CC ECO:0000269|PubMed:27274087, ECO:0000269|PubMed:30552163, CC ECO:0000269|PubMed:32797246, ECO:0000269|PubMed:34394081}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Zn(2+)(in) = Zn(2+)(out); Xref=Rhea:RHEA:29351, CC ChEBI:CHEBI:29105; Evidence={ECO:0000269|PubMed:12839489, CC ECO:0000269|PubMed:18272141, ECO:0000269|PubMed:21422171, CC ECO:0000269|PubMed:27274087, ECO:0000269|PubMed:30552163, CC ECO:0000269|PubMed:34394081}; CC -!- SUBUNIT: Interacts with SLC39A10; which triggers cells to undergo EMT CC and mitosis (PubMed:27274087). Found in a complex with SLC39A6, CC SLC39A10 and with the 'Ser-727' phosphorylated form of STAT3 throughout CC mitosis (PubMed:32797246). Found in a complex with SLC39A6, SLC39A10 CC and with NCAM1; this complex controls NCAM1 phosphorylation and CC integration into focal adhesion complexes during epithelial-to- CC mesenchymal transition (EMT) (By similarity). Found in a complex with CC SLC39A6, SLC39A10 and with GSK3B that controls NCAM1 phosphorylation CC (By similarity). {ECO:0000250|UniProtKB:Q8C145, CC ECO:0000269|PubMed:27274087, ECO:0000269|PubMed:32797246}. CC -!- INTERACTION: CC Q13433-2; Q92843: BCL2L2; NbExp=3; IntAct=EBI-12956703, EBI-707714; CC Q13433-2; Q86VR2: RETREG3; NbExp=3; IntAct=EBI-12956703, EBI-10192441; CC Q13433-2; Q3KNW5: SLC10A6; NbExp=3; IntAct=EBI-12956703, EBI-18159983; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18272141}; CC Multi-pass membrane protein {ECO:0000255}. Cell projection, CC lamellipodium membrane {ECO:0000269|PubMed:12839489}; Multi-pass CC membrane protein {ECO:0000269|PubMed:12839489}. Membrane raft CC {ECO:0000269|PubMed:34394081}; Multi-pass membrane protein CC {ECO:0000255}. Apical cell membrane {ECO:0000250|UniProtKB:Q4V887}. CC Note=Localizes to lipid rafts in T cells and is recruited into the CC immunological synapse in response to TCR stimulation (PubMed:34394081). CC In the choroid plexus is limited to the apical membrane in epithelial CC cells (By similarity). {ECO:0000250|UniProtKB:Q4V887, CC ECO:0000269|PubMed:34394081}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q13433-1; Sequence=Displayed; CC Name=2; CC IsoId=Q13433-2; Sequence=VSP_014309, VSP_014310, VSP_014311; CC -!- TISSUE SPECIFICITY: Highly expressed in the breast, prostate, placenta, CC kidney, pituitary and corpus callosum (PubMed:12839489). Weakly CC expressed in heart and intestine. Also highly expressed in cells CC derived from an adenocarcinoma of the cervix and lung carcinoma CC (PubMed:12839489). {ECO:0000269|PubMed:12839489}. CC -!- INDUCTION: Up-regulated by estrogen in breast cancer cells lines CC (PubMed:23919497, PubMed:2903103). Decreased protein level in response CC to zinc treatment (PubMed:18272141). Increased upon T cell activation CC (PubMed:30552163). Induced by STAT3 (PubMed:23919497). CC {ECO:0000269|PubMed:18272141, ECO:0000269|PubMed:23919497, CC ECO:0000269|PubMed:2903103, ECO:0000269|PubMed:30552163}. CC -!- PTM: Cleaved on the N-terminus before locating to the plasma membrane. CC {ECO:0000269|PubMed:23919497}. CC -!- PTM: N-glycosylated. {ECO:0000269|PubMed:12839489, CC ECO:0000269|PubMed:19349973, ECO:0000269|PubMed:23919497}. CC -!- PTM: Phosphorylated by ZAP70 in response to TCR stimulation leading to CC its activation. {ECO:0000269|PubMed:34394081}. CC -!- SIMILARITY: Belongs to the ZIP transporter (TC 2.A.5) family. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAG61161.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/44189/SLC39A6"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U41060; AAA96258.2; -; mRNA. DR EMBL; AK299102; BAG61161.1; ALT_INIT; mRNA. DR EMBL; AK304079; BAG64986.1; -; mRNA. DR EMBL; AC091060; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471088; EAX01372.1; -; Genomic_DNA. DR EMBL; BC008317; AAH08317.2; -; mRNA. DR EMBL; BC039498; AAH39498.1; -; mRNA. DR CCDS; CCDS42428.1; -. [Q13433-1] DR CCDS; CCDS45854.1; -. [Q13433-2] DR PIR; G02273; G02273. DR RefSeq; NP_001092876.1; NM_001099406.2. [Q13433-2] DR AlphaFoldDB; Q13433; -. DR BioGRID; 117332; 184. DR FunCoup; Q13433; 1178. DR IntAct; Q13433; 82. DR MINT; Q13433; -. DR STRING; 9606.ENSP00000269187; -. DR ChEMBL; CHEMBL4523581; -. DR DrugBank; DB14533; Zinc chloride. DR DrugBank; DB14548; Zinc sulfate, unspecified form. DR MEROPS; X40.001; -. DR TCDB; 2.A.5.4.13; the zinc (zn(2+))-iron (fe(2+)) permease (zip) family. DR GlyConnect; 1908; 8 N-Linked glycans (3 sites). DR GlyCosmos; Q13433; 7 sites, 10 glycans. DR GlyGen; Q13433; 22 sites, 15 N-linked glycans (4 sites), 4 O-linked glycans (15 sites). DR iPTMnet; Q13433; -. DR PhosphoSitePlus; Q13433; -. DR SwissPalm; Q13433; -. DR BioMuta; SLC39A6; -. DR DMDM; 292495066; -. DR jPOST; Q13433; -. DR MassIVE; Q13433; -. DR PaxDb; 9606-ENSP00000269187; -. DR PeptideAtlas; Q13433; -. DR ProteomicsDB; 59428; -. [Q13433-1] DR ProteomicsDB; 59429; -. [Q13433-2] DR Pumba; Q13433; -. DR ABCD; Q13433; 1 sequenced antibody. DR Antibodypedia; 5245; 295 antibodies from 38 providers. DR DNASU; 25800; -. DR Ensembl; ENST00000269187.10; ENSP00000269187.4; ENSG00000141424.13. [Q13433-1] DR Ensembl; ENST00000440549.6; ENSP00000401139.1; ENSG00000141424.13. [Q13433-2] DR Ensembl; ENST00000590986.5; ENSP00000465915.1; ENSG00000141424.13. [Q13433-1] DR GeneID; 25800; -. DR KEGG; hsa:25800; -. DR MANE-Select; ENST00000269187.10; ENSP00000269187.4; NM_012319.4; NP_036451.4. DR UCSC; uc002kzj.3; human. [Q13433-1] DR AGR; HGNC:18607; -. DR ClinPGx; PA134905551; -. DR CTD; 25800; -. DR DisGeNET; 25800; -. DR GeneCards; SLC39A6; -. DR HGNC; HGNC:18607; SLC39A6. DR HPA; ENSG00000141424; Low tissue specificity. DR MIM; 608731; gene. DR OpenTargets; ENSG00000141424; -. DR VEuPathDB; HostDB:ENSG00000141424; -. DR eggNOG; KOG2693; Eukaryota. DR GeneTree; ENSGT00940000156387; -. DR HOGENOM; CLU_015114_13_2_1; -. DR InParanoid; Q13433; -. DR OMA; LLMSHGM; -. DR OrthoDB; 200954at2759; -. DR PAN-GO; Q13433; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q13433; -. DR PathwayCommons; Q13433; -. DR Reactome; R-HSA-442380; Zinc influx into cells by the SLC39 gene family. DR SignaLink; Q13433; -. DR Agora; ENSG00000141424; -. DR BioGRID-ORCS; 25800; 15 hits in 1165 CRISPR screens. DR ChiTaRS; SLC39A6; human. DR GeneWiki; SLC39A6; -. DR GenomeRNAi; 25800; -. DR Pharos; Q13433; Tbio. DR PRO; PR:Q13433; -. DR Proteomes; UP000005640; Chromosome 18. DR RNAct; Q13433; protein. DR Bgee; ENSG00000141424; Expressed in secondary oocyte and 210 other cell types or tissues. DR ExpressionAtlas; Q13433; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; ISS:UniProtKB. DR GO; GO:0009986; C:cell surface; HDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IEA:Ensembl. DR GO; GO:0031258; C:lamellipodium membrane; IDA:UniProtKB. DR GO; GO:0045121; C:membrane raft; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0140410; F:monoatomic cation:bicarbonate symporter activity; IBA:GO_Central. DR GO; GO:0005385; F:zinc ion transmembrane transporter activity; IDA:UniProtKB. DR GO; GO:0001837; P:epithelial to mesenchymal transition; IDA:UniProtKB. DR GO; GO:0030003; P:intracellular monoatomic cation homeostasis; IBA:GO_Central. DR GO; GO:0006882; P:intracellular zinc ion homeostasis; IDA:BHF-UCL. DR GO; GO:0046649; P:lymphocyte activation; IMP:UniProtKB. DR GO; GO:0050852; P:T cell receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0071578; P:zinc ion import across plasma membrane; IDA:UniProtKB. DR GO; GO:0071577; P:zinc ion transmembrane transport; IMP:UniProtKB. DR InterPro; IPR003689; ZIP. DR InterPro; IPR050799; ZIP_Transporter. DR PANTHER; PTHR12191; SOLUTE CARRIER FAMILY 39; 1. DR PANTHER; PTHR12191:SF22; ZINC TRANSPORTER ZIP6; 1. DR Pfam; PF02535; Zip; 2. PE 1: Evidence at protein level; KW Alternative splicing; Cell membrane; Cell projection; Coiled coil; KW Direct protein sequencing; Glycoprotein; Ion transport; Membrane; KW Phosphoprotein; Proteomics identification; Reference proteome; Signal; KW Transmembrane; Transmembrane helix; Transport; Zinc; Zinc transport. FT SIGNAL 1..28 FT /evidence="ECO:0000269|PubMed:15340161" FT CHAIN 29..755 FT /note="Zinc transporter ZIP6" FT /id="PRO_0000041650" FT TOPO_DOM 29..325 FT /note="Extracellular" FT /evidence="ECO:0000269|PubMed:12839489" FT TRANSMEM 326..346 FT /note="Helical; Name=1" FT /evidence="ECO:0000255" FT TOPO_DOM 347..355 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 356..376 FT /note="Helical; Name=2" FT /evidence="ECO:0000255" FT TOPO_DOM 377..423 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 424..444 FT /note="Helical; Name=3" FT /evidence="ECO:0000255" FT TOPO_DOM 445..657 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 658..678 FT /note="Helical; Name=4" FT /evidence="ECO:0000255" FT TOPO_DOM 679..686 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 687..707 FT /note="Helical; Name=5" FT /evidence="ECO:0000255" FT TOPO_DOM 708..724 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 725..745 FT /note="Helical; Name=6" FT /evidence="ECO:0000255" FT TOPO_DOM 746..755 FT /note="Extracellular" FT /evidence="ECO:0000269|PubMed:12839489" FT REGION 95..186 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 202..246 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 464..480 FT /evidence="ECO:0000255" FT COMPBIAS 95..128 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 129..144 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 145..159 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 167..179 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 219..234 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 471 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 478 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CARBOHYD 67 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973" FT CARBOHYD 241 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973" FT CARBOHYD 266 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 283 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 684 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 1..275 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_014309" FT VAR_SEQ 707..708 FT /note="PE -> SF (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_014310" FT VAR_SEQ 709..755 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_014311" FT VARIANT 119 FT /note="E -> D (in dbSNP:rs1789528)" FT /evidence="ECO:0000269|PubMed:14702039, ECO:0000269|Ref.1, FT ECO:0000269|Ref.4" FT /id="VAR_059964" FT CONFLICT 127..132 FT /note="Missing (in Ref. 1; AAA96258)" FT /evidence="ECO:0000305" SQ SEQUENCE 755 AA; 85047 MW; 8BC1D02CA116DD25 CRC64; MARKLSVILI LTFALSVTNP LHELKAAAFP QTTEKISPNW ESGINVDLAI STRQYHLQQL FYRYGENNSL SVEGFRKLLQ NIGIDKIKRI HIHHDHDHHS DHEHHSDHER HSDHEHHSEH EHHSDHDHHS HHNHAASGKN KRKALCPDHD SDSSGKDPRN SQGKGAHRPE HASGRRNVKD SVSASEVTST VYNTVSEGTH FLETIETPRP GKLFPKDVSS STPPSVTSKS RVSRLAGRKT NESVSEPRKG FMYSRNTNEN PQECFNASKL LTSHGMGIQV PLNATEFNYL CPAIINQIDA RSCLIHTSEK KAEIPPKTYS LQIAWVGGFI AISIISFLSL LGVILVPLMN RVFFKFLLSF LVALAVGTLS GDAFLHLLPH SHASHHHSHS HEEPAMEMKR GPLFSHLSSQ NIEESAYFDS TWKGLTALGG LYFMFLVEHV LTLIKQFKDK KKKNQKKPEN DDDVEIKKQL SKYESQLSTN EEKVDTDDRT EGYLRADSQE PSHFDSQQPA VLEEEEVMIA HAHPQEVYNE YVPRGCKNKC HSHFHDTLGQ SDDLIHHHHD YHHILHHHHH QNHHPHSHSQ RYSREELKDA GVATLAWMVI MGDGLHNFSD GLAIGAAFTE GLSSGLSTSV AVFCHELPHE LGDFAVLLKA GMTVKQAVLY NALSAMLAYL GMATGIFIGH YAENVSMWIF ALTAGLFMYV ALVDMVPEML HNDASDHGCS RWGYFFLQNA GMLLGFGIML LISIFEHKIV FRINF // ID S67A1_HUMAN Reviewed; 424 AA. AC Q96BI1; O14906; O43562; O60485; O60680; Q7LDS5; Q7LGF7; DT 06-DEC-2005, integrated into UniProtKB/Swiss-Prot. DT 26-MAY-2009, sequence version 3. DT 28-JAN-2026, entry version 181. DE RecName: Full=Solute carrier family 67 member A1; DE AltName: Full=Beckwith-Wiedemann syndrome chromosomal region 1 candidate gene A protein; DE AltName: Full=Efflux transporter-like protein; DE AltName: Full=Imprinted multi-membrane-spanning polyspecific transporter-related protein 1 {ECO:0000303|PubMed:9751628}; DE AltName: Full=Organic cation transporter-like protein 2 {ECO:0000303|PubMed:9744804}; DE Short=ORCTL-2 {ECO:0000303|PubMed:9744804}; DE AltName: Full=Solute carrier family 22 member 1-like; DE AltName: Full=Solute carrier family 22 member 18; DE AltName: Full=Tumor-suppressing STF cDNA 5 protein {ECO:0000303|PubMed:9751628}; DE AltName: Full=Tumor-suppressing subchromosomal transferable fragment candidate gene 5 protein; DE AltName: Full=p45-Beckwith-Wiedemann region 1 A; DE Short=p45-BWR1A; GN Name=SLC67A1 {ECO:0000312|HGNC:HGNC:10964}; GN Synonyms=BWR1A {ECO:0000303|PubMed:9520460}, BWSCR1A, HET, GN IMPT1 {ECO:0000303|PubMed:9499412}, ITM {ECO:0000303|PubMed:9802569}, GN ORCTL2 {ECO:0000303|PubMed:9744804}, SLC22A18, SLC22A1L, GN TSSC5 {ECO:0000303|PubMed:9751628}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], VARIANT GLN-309, AND VARIANT LUNG CANCER RP PHE-233. RX PubMed=9751628; RA Lee M.P., Reeves C., Schmitt A., Su K., Connors T.D., Hu R.J., RA Brandenburg S., Lee M.J., Miller G., Feinberg A.P.; RT "Somatic mutation of TSSC5, a novel imprinted gene from human chromosome RT 11p15.5."; RL Cancer Res. 58:4155-4159(1998). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9802569; DOI=10.1093/dnares/5.4.235; RA Morisaki H., Hatada I., Morisaki T., Mukai T.; RT "A novel gene, ITM, located between p57KIP2 and IPL, is imprinted in RT mice."; RL DNA Res. 5:235-240(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND VARIANT GLN-12. RX PubMed=9570947; DOI=10.1006/geno.1998.5221; RA Cooper P.R., Smilinich N.J., Day C.D., Nowak N.J., Reid L.H., RA Pearsall R.S., Reece M., Prawitt D., Landers J., Housman D.E., RA Winterpacht A., Zabel B.U., Pelletier J., Weissman B.E., Shows T.B., RA Higgins M.J.; RT "Divergently transcribed overlapping genes expressed in liver and kidney RT and located in the 11p15.5 imprinted domain."; RL Genomics 49:38-51(1998). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY. RC TISSUE=Placenta; RX PubMed=9499412; DOI=10.1093/hmg/7.4.597; RA Dao D., Frank D., Qian N., O'Keefe D., Vosatka R.J., Walsh C.P., Tycko B.; RT "IMPT1, an imprinted gene similar to polyspecific transporter and multi- RT drug resistance genes."; RL Hum. Mol. Genet. 7:597-608(1998). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA], POSSIBLE INVOLVEMENT IN RMSE1, VARIANTS THR-6 RP AND GLN-12; CYS-86, AND TISSUE SPECIFICITY. RX PubMed=9520460; DOI=10.1073/pnas.95.7.3873; RA Schwienbacher C., Sabbioni S., Campi M., Veronese A., Bernardi G., RA Menegatti A., Hatada I., Mukai T., Ohashi H., Barbanti-Brodano G., RA Croce C.M., Negrini M.; RT "Transcriptional map of 170-kb region at chromosome 11p15.5: identification RT and mutational analysis of the BWR1A gene reveals the presence of mutations RT in tumor samples."; RL Proc. Natl. Acad. Sci. U.S.A. 95:3873-3878(1998). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT GLN-12. RA Chen P., Shen W., Karnik P.; RT "Monoallelic expression of the gene encoding a human efflux transporter RT like protein (HET), on chromosome 11p15.5."; RL Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT GLN-12. RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=9744804; DOI=10.1016/s0014-5793(98)00907-7; RA Reece M., Prawitt D., Landers J., Kast C., Gros P., Housman D., Zabel B.U., RA Pelletier J.; RT "Functional characterization of ORCTL2 -- an organic cation transporter RT expressed in the renal proximal tubules."; RL FEBS Lett. 433:245-250(1998). RN [9] RP INTERACTION WITH RNF167. RX PubMed=16314844; DOI=10.1038/sj.onc.1209167; RA Yamada H.Y., Gorbsky G.J.; RT "Tumor suppressor candidate TSSC5 is regulated by UbcH6 and a novel RT ubiquitin ligase RING105."; RL Oncogene 25:1330-1339(2006). RN [10] RP PHYLOGENETIC ANALYSIS. RX PubMed=26536134; DOI=10.1371/journal.pone.0140569; RA Zhu C., Nigam K.B., Date R.C., Bush K.T., Springer S.A., Saier M.H. Jr., RA Wu W., Nigam S.K.; RT "Evolutionary Analysis and Classification of OATs, OCTs, OCTNs, and Other RT SLC22 Transporters: Structure-Function Implications and Analysis of RT Sequence Motifs."; RL PLoS ONE 10:e0140569-e0140569(2015). CC -!- FUNCTION: May act as a transporter of organic cations based on a proton CC efflux antiport mechanism. May play a role in the transport of CC chloroquine and quinidine-related compounds in kidney (PubMed:9744804). CC Plays a role in the regulation of lipid metabolism (By similarity). CC {ECO:0000250|UniProtKB:Q78KK3, ECO:0000269|PubMed:9744804}. CC -!- SUBUNIT: Interacts with RNF167. {ECO:0000269|PubMed:16314844}. CC -!- INTERACTION: CC Q96BI1; Q8NBQ5: HSD17B11; NbExp=3; IntAct=EBI-11721845, EBI-1052304; CC Q96BI1; Q99801: NKX3-1; NbExp=3; IntAct=EBI-11721845, EBI-1385894; CC Q96BI1; Q96MV1: TLCD4; NbExp=3; IntAct=EBI-11721845, EBI-12947623; CC Q96BI1; Q9Y320: TMX2; NbExp=3; IntAct=EBI-11721845, EBI-6447886; CC -!- SUBCELLULAR LOCATION: Apical cell membrane CC {ECO:0000269|PubMed:9744804}; Multi-pass membrane protein CC {ECO:0000305}. Note=Localized at the apical membrane surface of renal CC proximal tubules. {ECO:0000269|PubMed:9744804}. CC -!- TISSUE SPECIFICITY: Expressed at high levels in adult and fetal kidney CC and liver, and adult colon. Expressed in fetal renal proximal tubules CC (at protein level). Expressed at lower levels in heart, brain and lung. CC {ECO:0000269|PubMed:9499412, ECO:0000269|PubMed:9520460, CC ECO:0000269|PubMed:9570947, ECO:0000269|PubMed:9744804}. CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting CC tissues of the lung. The most common form of lung cancer is non-small CC cell lung cancer (NSCLC) that can be divided into 3 major histologic CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor CC prognosis. {ECO:0000269|PubMed:9751628}. Note=The gene represented in CC this entry may be involved in disease pathogenesis. CC -!- DISEASE: Rhabdomyosarcoma, embryonal, 1 (RMSE1) [MIM:268210]: A form of CC rhabdomyosarcoma, a highly malignant tumor of striated muscle derived CC from primitive mesenchymal cells and exhibiting differentiation along CC rhabdomyoblastic lines. Rhabdomyosarcoma is one of the most frequently CC occurring soft tissue sarcomas and the most common in children. It CC occurs in four forms: alveolar, pleomorphic, embryonal and botryoidal CC rhabdomyosarcomas. {ECO:0000269|PubMed:9520460}. Note=The disease may CC be caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the major facilitator (TC 2.A.1) superfamily. CC Organic cation transporter (TC 2.A.1.19) family. {ECO:0000305}. CC -!- CAUTION: Was initially classified as a member of the SLC22 family. CC However, an evolutionary and phylogenetic analysis suggested that CC SLC22A18 is unique and that it is most distantly related to SLC22 CC family members. {ECO:0000269|PubMed:26536134}. CC -!- CAUTION: It is uncertain whether Met-1 or Met-17 is the initiator. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAB82727.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC Sequence=BAA32779.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF059663; AAC14725.1; -; mRNA. DR EMBL; AB012083; BAA32779.1; ALT_INIT; mRNA. DR EMBL; AF037064; AAC04787.1; -; mRNA. DR EMBL; AF028738; AAB82727.1; ALT_INIT; mRNA. DR EMBL; AF030302; AAC17492.1; -; mRNA. DR EMBL; AF070479; AAC23505.1; -; mRNA. DR EMBL; BC015571; AAH15571.1; -; mRNA. DR CCDS; CCDS7740.1; -. DR RefSeq; NP_001302430.1; NM_001315501.1. DR RefSeq; NP_001302431.1; NM_001315502.1. DR RefSeq; NP_002546.3; NM_002555.5. DR RefSeq; NP_899056.2; NM_183233.3. DR AlphaFoldDB; Q96BI1; -. DR SMR; Q96BI1; -. DR BioGRID; 111044; 140. DR FunCoup; Q96BI1; 670. DR IntAct; Q96BI1; 86. DR MINT; Q96BI1; -. DR STRING; 9606.ENSP00000369948; -. DR TCDB; 2.A.1.2.53; the major facilitator superfamily (mfs). DR GlyGen; Q96BI1; 1 site. DR iPTMnet; Q96BI1; -. DR PhosphoSitePlus; Q96BI1; -. DR SwissPalm; Q96BI1; -. DR BioMuta; SLC22A18; -. DR DMDM; 238054368; -. DR jPOST; Q96BI1; -. DR MassIVE; Q96BI1; -. DR PaxDb; 9606-ENSP00000369948; -. DR PeptideAtlas; Q96BI1; -. DR ProteomicsDB; 76077; -. DR Pumba; Q96BI1; -. DR Antibodypedia; 23193; 138 antibodies from 27 providers. DR DNASU; 5002; -. DR Ensembl; ENST00000347936.6; ENSP00000307859.2; ENSG00000110628.17. DR Ensembl; ENST00000380574.5; ENSP00000369948.1; ENSG00000110628.17. DR Ensembl; ENST00000649076.2; ENSP00000497561.1; ENSG00000110628.17. DR GeneID; 5002; -. DR KEGG; hsa:5002; -. DR MANE-Select; ENST00000649076.2; ENSP00000497561.1; NM_002555.6; NP_002546.3. DR UCSC; uc001lwx.3; human. DR AGR; HGNC:10964; -. DR ClinPGx; PA35846; -. DR CTD; 5002; -. DR DisGeNET; 5002; -. DR GeneCards; SLC67A1; -. DR HGNC; HGNC:10964; SLC67A1. DR HPA; ENSG00000110628; Tissue enhanced (intestine, liver). DR MalaCards; SLC67A1; -. DR MIM; 114480; phenotype. DR MIM; 211980; phenotype. DR MIM; 268210; phenotype. DR MIM; 602631; gene. DR OpenTargets; ENSG00000110628; -. DR Orphanet; 99757; Embryonal rhabdomyosarcoma. DR Orphanet; 227535; Hereditary breast cancer. DR VEuPathDB; HostDB:ENSG00000110628; -. DR eggNOG; ENOG502QT94; Eukaryota. DR GeneTree; ENSGT00940000160333; -. DR HOGENOM; CLU_001265_10_1_1; -. DR InParanoid; Q96BI1; -. DR OMA; RLMKYPR; -. DR OrthoDB; 440553at2759; -. DR PAN-GO; Q96BI1; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q96BI1; -. DR PathwayCommons; Q96BI1; -. DR Reactome; R-HSA-549127; Organic cation transport. DR Reactome; R-HSA-5619066; Defective SLC22A18 causes lung cancer (LNCR) and embryonal rhabdomyosarcoma 1 (RMSE1). DR SignaLink; Q96BI1; -. DR SIGNOR; Q96BI1; -. DR Agora; ENSG00000110628; -. DR BioGRID-ORCS; 5002; 10 hits in 1169 CRISPR screens. DR GeneWiki; SLC22A18; -. DR GenomeRNAi; 5002; -. DR Pharos; Q96BI1; Tbio. DR PRO; PR:Q96BI1; -. DR Proteomes; UP000005640; Chromosome 11. DR RNAct; Q96BI1; protein. DR Bgee; ENSG00000110628; Expressed in mucosa of transverse colon and 94 other cell types or tissues. DR ExpressionAtlas; Q96BI1; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IDA:ARUK-UCL. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0005635; C:nuclear envelope; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; TAS:Reactome. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB. DR GO; GO:0042910; F:xenobiotic transmembrane transporter activity; TAS:Reactome. DR GO; GO:0015695; P:organic cation transport; NAS:UniProtKB. DR GO; GO:1990961; P:xenobiotic detoxification by transmembrane export across the plasma membrane; IDA:UniProtKB. DR GO; GO:0042908; P:xenobiotic transport; IDA:UniProtKB. DR CDD; cd17331; MFS_SLC22A18; 1. DR FunFam; 1.20.1250.20:FF:000297; Solute carrier family 22 member 18; 1. DR Gene3D; 1.20.1250.20; MFS general substrate transporter like domains; 1. DR InterPro; IPR011701; MFS. DR InterPro; IPR020846; MFS_dom. DR InterPro; IPR036259; MFS_trans_sf. DR InterPro; IPR001958; Tet-R_TetA/multi-R_MdtG-like. DR PANTHER; PTHR24002; SOLUTE CARRIER FAMILY 22 MEMBER 18; 1. DR PANTHER; PTHR24002:SF3; SOLUTE CARRIER FAMILY 22 MEMBER 18; 1. DR Pfam; PF07690; MFS_1; 1. DR PRINTS; PR01035; TCRTETA. DR SUPFAM; SSF103473; MFS general substrate transporter; 1. DR PROSITE; PS50850; MFS; 1. PE 1: Evidence at protein level; KW Cell membrane; Disease variant; Membrane; Proteomics identification; KW Reference proteome; Transmembrane; Transmembrane helix. FT CHAIN 1..424 FT /note="Solute carrier family 67 member A1" FT /id="PRO_0000220509" FT TRANSMEM 26..46 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 59..79 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 90..110 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 156..176 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 184..204 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 243..263 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 276..296 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 312..332 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 334..354 FT /note="Helical" FT /evidence="ECO:0000255" FT TRANSMEM 391..411 FT /note="Helical" FT /evidence="ECO:0000255" FT VARIANT 6 FT /note="A -> T (in dbSNP:rs1048046)" FT /evidence="ECO:0000269|PubMed:9520460" FT /id="VAR_055406" FT VARIANT 12 FT /note="R -> Q (in dbSNP:rs1048047)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:9520460, ECO:0000269|PubMed:9570947, FT ECO:0000269|Ref.6" FT /id="VAR_055407" FT VARIANT 86 FT /note="R -> C (in a rhabdomyosarcoma sample)" FT /evidence="ECO:0000269|PubMed:9520460" FT /id="VAR_024061" FT VARIANT 233 FT /note="S -> F (in lung cancer; somatic mutation; FT dbSNP:rs121909071)" FT /evidence="ECO:0000269|PubMed:9751628" FT /id="VAR_024062" FT VARIANT 309 FT /note="R -> Q (in dbSNP:rs141165353)" FT /evidence="ECO:0000269|PubMed:9751628" FT /id="VAR_024063" FT VARIANT 324 FT /note="W -> C (in dbSNP:rs1129782)" FT /id="VAR_055408" FT CONFLICT 84 FT /note="D -> N (in Ref. 5; AAC17492)" FT /evidence="ECO:0000305" FT CONFLICT 227 FT /note="D -> E (in Ref. 4; AAB82727 and 6; AAC23505)" FT /evidence="ECO:0000305" FT CONFLICT 230 FT /note="A -> G (in Ref. 4; AAB82727 and 6; AAC23505)" FT /evidence="ECO:0000305" FT CONFLICT 242 FT /note="R -> K (in Ref. 4; AAB82727 and 6; AAC23505)" FT /evidence="ECO:0000305" FT CONFLICT 275 FT /note="Q -> K (in Ref. 4; AAB82727 and 6; AAC23505)" FT /evidence="ECO:0000305" FT CONFLICT 307 FT /note="L -> M (in Ref. 3; AAC04787)" FT /evidence="ECO:0000305" FT CONFLICT 309 FT /note="R -> G (in Ref. 4; AAB82727 and 6; AAC23505)" FT /evidence="ECO:0000305" SQ SEQUENCE 424 AA; 44846 MW; 9EFD5F902A77A6E8 CRC64; MQGARAPRDQ GRSPGRMSAL GRSSVILLTY VLAATELTCL FMQFSIVPYL SRKLGLDSIA FGYLQTTFGV LQLLGGPVFG RFADQRGARA ALTLSFLAAL ALYLLLAAAS SPALPGVYLL FASRLPGALM HTLPAAQMVI TDLSAPEERP AALGRLGLCF GVGVILGSLL GGTLVSAYGI QCPAILAALA TLLGAVLSFT CIPASTKGAK TDAQAPLPGG PRASVFDLKA IASLLRLPDV PRIFLVKVAS NCPTGLFMVM FSIISMDFFQ LEAAQAGYLM SFFGLLQMVT QGLVIGQLSS HFSEEVLLRA SVLVFIVVGL AMAWMSSVFH FCLLVPGLVF SLCTLNVVTD SMLIKAVSTS DTGTMLGLCA SVQPLLRTLG PTVGGLLYRS FGVPVFGHVQ VAINTLVLLV LWRKPMPQRK DKVR // ID SBP1_HUMAN Reviewed; 472 AA. AC Q13228; A6NML9; A6PVW9; B2RDR3; B4DKP6; B4E1F3; Q49AQ8; Q96GX7; DT 15-JUL-1999, integrated into UniProtKB/Swiss-Prot. DT 29-MAY-2007, sequence version 2. DT 28-JAN-2026, entry version 195. DE RecName: Full=Methanethiol oxidase {ECO:0000303|PubMed:29255262}; DE Short=MTO {ECO:0000303|PubMed:29255262}; DE EC=1.8.3.4 {ECO:0000269|PubMed:29255262}; DE AltName: Full=56 kDa selenium-binding protein; DE Short=SBP56; DE Short=SP56; DE AltName: Full=Selenium-binding protein 1; GN Name=SELENBP1; Synonyms=SBP; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Heart; RX PubMed=9027582; RX DOI=10.1002/(sici)1097-4644(199702)64:2<217::aid-jcb5>3.0.co;2-#; RA Chang P.W.G., Tsui S.K.W., Liew C., Lee C., Waye M.M.Y., Fung K.; RT "Isolation, characterization, and chromosomal mapping of a novel cDNA clone RT encoding human selenium binding protein."; RL J. Cell. Biochem. 64:217-224(1997). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 3 AND 4). RC TISSUE=Colon, Lung, and Synovial cell; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Colon, and Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP PROTEIN SEQUENCE OF 255-276, AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Brain, and Cajal-Retzius cell; RA Lubec G., Vishwanath V.; RL Submitted (MAR-2007) to UniProtKB. RN [8] RP TISSUE SPECIFICITY, AND INDUCTION. RX PubMed=9679983; RA Yang M., Sytkowski A.J.; RT "Differential expression and androgen regulation of the human selenium- RT binding protein gene hSP56 in prostate cancer cells."; RL Cancer Res. 58:3150-3153(1998). RN [9] RP TISSUE SPECIFICITY, SUBCELLULAR LOCATION, PHOSPHORYLATION, AND RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=14991897; DOI=10.1002/path.1524; RA Chen G., Wang H., Miller C.T., Thomas D.G., Gharib T.G., Misek D.E., RA Giordano T.J., Orringer M.B., Hanash S.M., Beer D.G.; RT "Reduced selenium-binding protein 1 expression is associated with poor RT outcome in lung adenocarcinomas."; RL J. Pathol. 202:321-329(2004). RN [10] RP TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=16223876; DOI=10.1073/pnas.0507666102; RA Glatt S.J., Everall I.P., Kremen W.S., Corbeil J., Sasik R., Khanlou N., RA Han M., Liew C.-C., Tsuang M.T.; RT "Comparative gene expression analysis of blood and brain provides RT concurrent validation of SELENBP1 up-regulation in schizophrenia."; RL Proc. Natl. Acad. Sci. U.S.A. 102:15533-15538(2005). RN [11] RP TISSUE SPECIFICITY, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=16380993; DOI=10.1002/ijc.21671; RA Huang K.-C., Park D.C., Ng S.-K., Lee J.Y., Ni X., Ng W.-C., Bandera C.A., RA Welch W.R., Berkowitz R.S., Mok S.C., Ng S.-W.; RT "Selenium binding protein 1 in ovarian cancer."; RL Int. J. Cancer 118:2433-2440(2006). RN [12] RP TISSUE SPECIFICITY, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=16645984; DOI=10.1002/pmic.200500629; RA Kim H., Kang H.J., You K.T., Kim S.H., Lee K.Y., Kim T.I., Kim C., RA Song S.Y., Kim H.-J., Lee C., Kim H.; RT "Suppression of human selenium-binding protein 1 is a late event in RT colorectal carcinogenesis and is associated with poor survival."; RL Proteomics 6:3466-3476(2006). RN [13] RP INTERACTION WITH USP33. RX PubMed=19118533; DOI=10.1016/j.bbrc.2008.12.110; RA Jeong J.Y., Wang Y., Sytkowski A.J.; RT "Human selenium binding protein-1 (hSP56) interacts with VDU1 in a RT selenium-dependent manner."; RL Biochem. Biophys. Res. Commun. 379:583-588(2009). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [15] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-111 AND SER-371, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [17] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, TISSUE SPECIFICITY, INVOLVEMENT IN RP EHMTO, VARIANTS EHMTO TRP-225; TYR-329 AND 347-GLY--ILE-472 DEL, RP CHARACTERIZATION OF VARIANTS EHMTO TRP-225; TYR-329 AND 347-GLY--ILE-472 RP DEL, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=29255262; DOI=10.1038/s41588-017-0006-7; RA Pol A., Renkema G.H., Tangerman A., Winkel E.G., Engelke U.F., RA de Brouwer A.P.M., Lloyd K.C., Araiza R.S., van den Heuvel L., Omran H., RA Olbrich H., Oude Elberink M., Gilissen C., Rodenburg R.J., Sass J.O., RA Schwab K.O., Schaefer H., Venselaar H., Sequeira J.S., Op den Camp H.J.M., RA Wevers R.A.; RT "Mutations in SELENBP1, encoding a novel human methanethiol oxidase, cause RT extraoral halitosis."; RL Nat. Genet. 50:120-129(2018). CC -!- FUNCTION: Catalyzes the oxidation of methanethiol, an organosulfur CC compound known to be produced in substantial amounts by gut bacteria CC (PubMed:29255262). Selenium-binding protein which may be involved in CC the sensing of reactive xenobiotics in the cytoplasm. May be involved CC in intra-Golgi protein transport (By similarity). CC {ECO:0000250|UniProtKB:Q8VIF7, ECO:0000269|PubMed:29255262}. CC -!- CATALYTIC ACTIVITY: CC Reaction=methanethiol + O2 + H2O = hydrogen sulfide + formaldehyde + CC H2O2 + H(+); Xref=Rhea:RHEA:11812, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16007, CC ChEBI:CHEBI:16240, ChEBI:CHEBI:16842, ChEBI:CHEBI:29919; EC=1.8.3.4; CC Evidence={ECO:0000269|PubMed:29255262}; CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=4.8 nM for methanethiol {ECO:0000269|PubMed:29255262}; CC -!- PATHWAY: Organosulfur degradation. {ECO:0000269|PubMed:29255262}. CC -!- SUBUNIT: Interacts with USP33. {ECO:0000269|PubMed:19118533}. CC -!- INTERACTION: CC Q13228; Q9UJ68: MSRA; NbExp=3; IntAct=EBI-711619, EBI-19157918; CC Q13228; O43422: THAP12; NbExp=3; IntAct=EBI-711619, EBI-2828217; CC Q13228; Q15645: TRIP13; NbExp=6; IntAct=EBI-711619, EBI-358993; CC Q13228; Q8TEY7-2: USP33; NbExp=5; IntAct=EBI-711619, EBI-719307; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:14991897}. Cytoplasm, CC cytosol {ECO:0000269|PubMed:14991897, ECO:0000269|PubMed:16223876}. CC Membrane {ECO:0000250|UniProtKB:Q8VIF7}; Peripheral membrane protein CC {ECO:0000250|UniProtKB:Q8VIF7}. Note=May associate with Golgi membrane CC (By similarity). May associate with the membrane of autophagosomes (By CC similarity). {ECO:0000250|UniProtKB:Q8VIF7}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=Q13228-1; Sequence=Displayed; CC Name=2; CC IsoId=Q13228-2; Sequence=VSP_038440; CC Name=3; CC IsoId=Q13228-3; Sequence=VSP_045425; CC Name=4; CC IsoId=Q13228-4; Sequence=VSP_055126; CC -!- TISSUE SPECIFICITY: Widely expressed. Highly expressed in liver, lung, CC colon, prostate, kidney and pancreas. In brain, present both in neurons CC and glia (at protein level). Down-regulated in lung adenocarcinoma, CC colorectal carcinoma and ovarian cancer. Two-fold up-regulated in brain CC and blood from schizophrenia patients. {ECO:0000269|PubMed:14991897, CC ECO:0000269|PubMed:16223876, ECO:0000269|PubMed:16380993, CC ECO:0000269|PubMed:16645984, ECO:0000269|PubMed:29255262, CC ECO:0000269|PubMed:9679983}. CC -!- INDUCTION: Down-regulated by androgen in prostate cancer cells. CC {ECO:0000269|PubMed:9679983}. CC -!- PTM: Phosphorylated. {ECO:0000305|PubMed:14991897}. CC -!- PTM: The N-terminus is blocked. {ECO:0000250}. CC -!- DISEASE: Extraoral halitosis due to methanethiol oxidase deficiency CC (EHMTO) [MIM:618148]: An autosomal recessive malodor condition CC characterized by extraoral blood-borne halitosis resulting from the CC accumulation of sulfur-containing metabolites. In extraoral blood-borne CC halitosis, malodorant compounds are carried to the lungs, where they CC enter the breath. Affected individuals have a cabbage-like breath odor, CC high levels of methanethiol and dimethylsulfide in oral and nasal CC breath, and elevated urinary excretion of dimethylsulfoxide in the CC absence of intake of dimethylsulfide-containing food or use of sulfur- CC containing medication, lower-gastrointestinal problems, and known CC metabolic defects, such as methionine adenosyltransferase deficiency CC and tyrosinemia. {ECO:0000269|PubMed:29255262}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the selenium-binding protein family. CC {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U29091; AAB02395.1; -; mRNA. DR EMBL; CR456852; CAG33133.1; -; mRNA. DR EMBL; AK296661; BAG59258.1; -; mRNA. DR EMBL; AK303815; BAG64765.1; -; mRNA. DR EMBL; AK315643; BAG38010.1; -; mRNA. DR EMBL; AL391069; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471121; EAW53443.1; -; Genomic_DNA. DR EMBL; CH471121; EAW53445.1; -; Genomic_DNA. DR EMBL; BC009084; AAH09084.1; -; mRNA. DR EMBL; BC032997; AAH32997.1; -; mRNA. DR CCDS; CCDS58027.1; -. [Q13228-3] DR CCDS; CCDS60266.1; -. [Q13228-4] DR CCDS; CCDS995.1; -. [Q13228-1] DR PIR; G01872; G01872. DR RefSeq; NP_001245217.1; NM_001258288.2. [Q13228-3] DR RefSeq; NP_001245218.1; NM_001258289.2. [Q13228-4] DR RefSeq; NP_003935.2; NM_003944.3. [Q13228-1] DR AlphaFoldDB; Q13228; -. DR SMR; Q13228; -. DR BioGRID; 114472; 214. DR CORUM; Q13228; -. DR FunCoup; Q13228; 548. DR IntAct; Q13228; 108. DR MINT; Q13228; -. DR STRING; 9606.ENSP00000397261; -. DR GlyGen; Q13228; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q13228; -. DR PhosphoSitePlus; Q13228; -. DR SwissPalm; Q13228; -. DR BioMuta; SELENBP1; -. DR DMDM; 148840437; -. DR REPRODUCTION-2DPAGE; IPI00012303; -. DR REPRODUCTION-2DPAGE; Q13228; -. DR jPOST; Q13228; -. DR MassIVE; Q13228; -. DR PaxDb; 9606-ENSP00000397261; -. DR PeptideAtlas; Q13228; -. DR ProteomicsDB; 1722; -. DR ProteomicsDB; 5753; -. DR ProteomicsDB; 59234; -. [Q13228-1] DR ProteomicsDB; 59235; -. [Q13228-2] DR Pumba; Q13228; -. DR Antibodypedia; 1584; 393 antibodies from 30 providers. DR DNASU; 8991; -. DR Ensembl; ENST00000368868.10; ENSP00000357861.5; ENSG00000143416.22. [Q13228-1] DR Ensembl; ENST00000426705.6; ENSP00000397261.2; ENSG00000143416.22. [Q13228-4] DR Ensembl; ENST00000447402.7; ENSP00000413960.3; ENSG00000143416.22. [Q13228-3] DR GeneID; 8991; -. DR KEGG; hsa:8991; -. DR MANE-Select; ENST00000368868.10; ENSP00000357861.5; NM_003944.4; NP_003935.2. DR UCSC; uc010pcy.4; human. [Q13228-1] DR AGR; HGNC:10719; -. DR ClinPGx; PA35641; -. DR CTD; 8991; -. DR DisGeNET; 8991; -. DR GeneCards; SELENBP1; -. DR HGNC; HGNC:10719; SELENBP1. DR HPA; ENSG00000143416; Tissue enhanced (intestine). DR MalaCards; SELENBP1; -. DR MIM; 604188; gene. DR MIM; 618148; phenotype. DR OpenTargets; ENSG00000143416; -. DR Orphanet; 562538; Autosomal recessive extra-oral halitosis. DR VEuPathDB; HostDB:ENSG00000143416; -. DR eggNOG; KOG0918; Eukaryota. DR GeneTree; ENSGT00390000014244; -. DR HOGENOM; CLU_032512_0_0_1; -. DR InParanoid; Q13228; -. DR OMA; AYDFWWH; -. DR OrthoDB; 10252446at2759; -. DR PAN-GO; Q13228; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q13228; -. DR PathwayCommons; Q13228; -. DR SABIO-RK; Q13228; -. DR SignaLink; Q13228; -. DR Agora; ENSG00000143416; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 8991; 20 hits in 1164 CRISPR screens. DR ChiTaRS; SELENBP1; human. DR GeneWiki; SELENBP1; -. DR GenomeRNAi; 8991; -. DR Pharos; Q13228; Tbio. DR PRO; PR:Q13228; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q13228; protein. DR Bgee; ENSG00000143416; Expressed in mucosa of transverse colon and 202 other cell types or tissues. DR ExpressionAtlas; Q13228; baseline and differential. DR GO; GO:0005829; C:cytosol; IEA:UniProtKB-SubCell. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005615; C:extracellular space; HDA:UniProtKB. DR GO; GO:0001650; C:fibrillar center; IDA:HPA. DR GO; GO:0016020; C:membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005730; C:nucleolus; IDA:HPA. DR GO; GO:0018549; F:methanethiol oxidase activity; IMP:FlyBase. DR GO; GO:0008430; F:selenium binding; TAS:ProtInc. DR GO; GO:0015031; P:protein transport; IEA:UniProtKB-KW. DR InterPro; IPR008826; Se-bd. DR PANTHER; PTHR23300; METHANETHIOL OXIDASE; 1. DR PANTHER; PTHR23300:SF0; METHANETHIOL OXIDASE; 1. DR Pfam; PF05694; SBP56; 1. DR SUPFAM; SSF75011; 3-carboxy-cis,cis-mucoante lactonizing enzyme; 1. PE 1: Evidence at protein level; KW Acetylation; Alternative splicing; Cytoplasm; Direct protein sequencing; KW Disease variant; Membrane; Nucleus; Oxidoreductase; Phosphoprotein; KW Protein transport; Proteomics identification; Reference proteome; Selenium; KW Transport. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..472 FT /note="Methanethiol oxidase" FT /id="PRO_0000174633" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 111 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 371 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 467 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P17563" FT VAR_SEQ 1..64 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_038440" FT VAR_SEQ 1 FT /note="M -> MRLEWGPRPAALPWPAGMCAAERAEGAFTLQSVAQPMRPIAST (in FT isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_055126" FT VAR_SEQ 59..120 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_045425" FT VARIANT 225 FT /note="G -> W (in EHMTO; loss of methanethiol oxidation in FT patient cells; dbSNP:rs758495626)" FT /evidence="ECO:0000269|PubMed:29255262" FT /id="VAR_080207" FT VARIANT 329 FT /note="H -> Y (in EHMTO; loss of methanethiol oxidation in FT patient cells; dbSNP:rs1553204840)" FT /evidence="ECO:0000269|PubMed:29255262" FT /id="VAR_080208" FT VARIANT 347..472 FT /note="Missing (in EHMTO; loss of methanethiol oxidation in FT patient cells)" FT /evidence="ECO:0000269|PubMed:29255262" FT /id="VAR_080209" FT CONFLICT 80 FT /note="C -> Y (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 92 FT /note="T -> N (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 114..116 FT /note="RAP -> GPQ (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 135 FT /note="F -> C (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 260..262 FT /note="DAA -> SAT (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 270..273 FT /note="LSST -> SAPN (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 278 FT /note="Y -> C (in Ref. 3; BAG59258)" FT /evidence="ECO:0000305" FT CONFLICT 280..282 FT /note="NEG -> TRE (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 305..306 FT /note="EM -> GV (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 410 FT /note="D -> E (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" FT CONFLICT 442 FT /note="F -> C (in Ref. 1; AAB02395)" FT /evidence="ECO:0000305" SQ SEQUENCE 472 AA; 52391 MW; 6DC68F9B45FEC1BC CRC64; MATKCGNCGP GYSTPLEAMK GPREEIVYLP CIYRNTGTEA PDYLATVDVD PKSPQYCQVI HRLPMPNLKD ELHHSGWNTC SSCFGDSTKS RTKLVLPSLI SSRIYVVDVG SEPRAPKLHK VIEPKDIHAK CELAFLHTSH CLASGEVMIS SLGDVKGNGK GGFVLLDGET FEVKGTWERP GGAAPLGYDF WYQPRHNVMI STEWAAPNVL RDGFNPADVE AGLYGSHLYV WDWQRHEIVQ TLSLKDGLIP LEIRFLHNPD AAQGFVGCAL SSTIQRFYKN EGGTWSVEKV IQVPPKKVKG WLLPEMPGLI TDILLSLDDR FLYFSNWLHG DLRQYDISDP QRPRLTGQLF LGGSIVKGGP VQVLEDEELK SQPEPLVVKG KRVAGGPQMI QLSLDGKRLY ITTSLYSAWD KQFYPDLIRE GSVMLQVDVD TVKGGLKLNP NFLVDFGKEP LGPALAHELR YPGGDCSSDI WI // ID SCYL2_HUMAN Reviewed; 929 AA. AC Q6P3W7; A8KAB5; Q96EF4; Q96ST4; Q9H7V5; Q9NVH3; Q9P2I7; DT 17-OCT-2006, integrated into UniProtKB/Swiss-Prot. DT 05-JUL-2004, sequence version 1. DT 28-JAN-2026, entry version 182. DE RecName: Full=SCY1-like protein 2 {ECO:0000305}; DE AltName: Full=Coated vesicle-associated kinase of 104 kDa {ECO:0000303|PubMed:15809293}; GN Name=SCYL2 {ECO:0000312|HGNC:HGNC:19286}; GN Synonyms=CVAK104 {ECO:0000303|PubMed:15809293}, GN KIAA1360 {ECO:0000312|EMBL:BAA92598.1}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LEU-357. RC TISSUE=Teratocarcinoma, and Trachea; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Carcinoma, and Leiomyosarcoma; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 138-929. RC TISSUE=Brain; RX PubMed=10718198; DOI=10.1093/dnares/7.1.65; RA Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XVI. The RT complete sequences of 150 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 7:65-73(2000). RN [5] RP FUNCTION, INTERACTION WITH CLATHRIN AND AP2 COMPLEX, AUTOPHOSPHORYLATION, RP AND SUBCELLULAR LOCATION. RX PubMed=15809293; DOI=10.1074/jbc.m502462200; RA Conner S.D., Schmid S.L.; RT "CVAK104 is a novel poly-L-lysine-stimulated kinase that targets the beta2- RT subunit of AP2."; RL J. Biol. Chem. 280:21539-21544(2005). RN [6] RP FUNCTION, INTERACTION WITH CLATHRIN AND AP2 COMPLEX, AND SUBCELLULAR RP LOCATION. RX PubMed=16914521; DOI=10.1091/mbc.e06-05-0390; RA Duewel M., Ungewickell E.J.; RT "Clathrin-dependent association of CVAK104 with endosomes and the trans- RT Golgi network."; RL Mol. Biol. Cell 17:4513-4525(2006). RN [7] RP INTERACTION WITH AP2B1. RX PubMed=16903783; DOI=10.1371/journal.pbio.0040262; RA Schmid E.M., Ford M.G.J., Burtey A., Praefcke G.J.K., Peak-Chew S.-Y., RA Mills I.G., Benmerah A., McMahon H.T.; RT "Role of the AP2 beta-appendage hub in recruiting partners for clathrin- RT coated vesicle assembly."; RL PLoS Biol. 4:E262-E262(2006). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-677, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-677 AND THR-708, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [11] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-357; SER-720 AND HIS-863. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [12] RP INVOLVEMENT IN AMC4, AND VARIANT AMC4 36-ARG--GLY-929 DEL. RX PubMed=31960134; DOI=10.1007/s00439-020-02117-7; RA Seidahmed M.Z., Al-Kindi A., Alsaif H.S., Miqdad A., Alabbad N., Alfifi A., RA Abdelbasit O.B., Alhussein K., Alsamadi A., Ibrahim N., Al-Futaisi A., RA Al-Maawali A., Alkuraya F.S.; RT "Recessive mutations in SCYL2 cause a novel syndromic form of RT arthrogryposis in humans."; RL Hum. Genet. 139:513-519(2020). CC -!- FUNCTION: Component of the AP2-containing clathrin coat that may CC regulate clathrin-dependent trafficking at plasma membrane, TGN and CC endosomal system (Probable). A possible serine/threonine-protein kinase CC toward the beta2-subunit of the plasma membrane adapter complex AP2 and CC other proteins in presence of poly-L-lysine has not been confirmed CC (PubMed:15809293, PubMed:16914521). By regulating the expression of CC excitatory receptors at synapses, plays an essential role in neuronal CC function and signaling and in brain development (By similarity). CC {ECO:0000250|UniProtKB:Q8CFE4, ECO:0000269|PubMed:15809293, CC ECO:0000269|PubMed:16914521, ECO:0000305|PubMed:15809293, CC ECO:0000305|PubMed:16914521}. CC -!- SUBUNIT: Interacts with clathrin and AP2B1; the interaction mediates CC the association with the AP-2 complex. {ECO:0000269|PubMed:15809293, CC ECO:0000269|PubMed:16903783, ECO:0000269|PubMed:16914521}. CC -!- INTERACTION: CC Q6P3W7; O14640: DVL1; NbExp=4; IntAct=EBI-1046810, EBI-723489; CC Q6P3W7; Q13467: FZD5; NbExp=4; IntAct=EBI-1046810, EBI-3913027; CC -!- SUBCELLULAR LOCATION: Cytoplasmic vesicle, clathrin-coated vesicle CC {ECO:0000269|PubMed:15809293, ECO:0000269|PubMed:16914521}. Golgi CC apparatus, trans-Golgi network membrane {ECO:0000269|PubMed:16914521}. CC Endosome membrane {ECO:0000269|PubMed:16914521}. Note=Colocalizes to CC the trans-Golgi network (TGN) and to endosomal membranes with clathrin, CC transferrin and plasma membrane adapter AP1 and AP3 complexes. CC {ECO:0000269|PubMed:16914521}. CC -!- PTM: Could autophosphorylate in presence of poly-L-lysine. CC {ECO:0000269|PubMed:15809293}. CC -!- DISEASE: Arthrogryposis multiplex congenita 4, neurogenic, with CC agenesis of the corpus callosum (AMC4) [MIM:618766]: A form of CC arthrogryposis multiplex congenita, a developmental condition CC characterized by multiple joint contractures resulting from reduced or CC absent fetal movements. AMC4 is an autosomal recessive, severe form CC with onset in utero. Patients manifest little or no fetal movements, CC significant contractures affecting the upper and lower limbs, CC dysmorphic facial features, optic atrophy, limb fractures, profound CC global developmental delay, seizures, and peripheral neuropathy. Many CC patients die in early childhood. {ECO:0000269|PubMed:31960134}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA91778.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAB14869.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAB55194.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK001597; BAA91778.1; ALT_INIT; mRNA. DR EMBL; AK024274; BAB14869.1; ALT_INIT; mRNA. DR EMBL; AK027551; BAB55194.1; ALT_INIT; mRNA. DR EMBL; AK292980; BAF85669.1; -; mRNA. DR EMBL; CH471054; EAW97633.1; -; Genomic_DNA. DR EMBL; BC012387; AAH12387.3; -; mRNA. DR EMBL; BC063798; AAH63798.1; -; mRNA. DR EMBL; AB037781; BAA92598.1; -; mRNA. DR CCDS; CCDS9076.1; -. DR RefSeq; NP_001304713.1; NM_001317784.2. DR RefSeq; NP_001317182.1; NM_001330253.1. DR RefSeq; NP_001317183.1; NM_001330254.1. DR RefSeq; NP_001317185.1; NM_001330256.1. DR RefSeq; NP_060458.3; NM_017988.5. DR AlphaFoldDB; Q6P3W7; -. DR SMR; Q6P3W7; -. DR BioGRID; 120810; 185. DR CORUM; Q6P3W7; -. DR FunCoup; Q6P3W7; 3697. DR IntAct; Q6P3W7; 80. DR MINT; Q6P3W7; -. DR STRING; 9606.ENSP00000489123; -. DR GlyCosmos; Q6P3W7; 6 sites, 1 glycan. DR GlyGen; Q6P3W7; 11 sites, 1 O-linked glycan (11 sites). DR iPTMnet; Q6P3W7; -. DR MetOSite; Q6P3W7; -. DR PhosphoSitePlus; Q6P3W7; -. DR BioMuta; SCYL2; -. DR DMDM; 74762350; -. DR CPTAC; non-CPTAC-5657; -. DR jPOST; Q6P3W7; -. DR MassIVE; Q6P3W7; -. DR PaxDb; 9606-ENSP00000354061; -. DR PeptideAtlas; Q6P3W7; -. DR ProteomicsDB; 66937; -. DR Pumba; Q6P3W7; -. DR Antibodypedia; 17837; 176 antibodies from 26 providers. DR DNASU; 55681; -. DR Ensembl; ENST00000360820.7; ENSP00000354061.2; ENSG00000136021.20. DR GeneID; 55681; -. DR KEGG; hsa:55681; -. DR MANE-Select; ENST00000360820.7; ENSP00000354061.2; NM_017988.6; NP_060458.3. DR UCSC; uc001thn.4; human. DR AGR; HGNC:19286; -. DR ClinPGx; PA134887807; -. DR CTD; 55681; -. DR DisGeNET; 55681; -. DR GeneCards; SCYL2; -. DR HGNC; HGNC:19286; SCYL2. DR HPA; ENSG00000136021; Low tissue specificity. DR MalaCards; SCYL2; -. DR MIM; 616365; gene. DR MIM; 618766; phenotype. DR OpenTargets; ENSG00000136021; -. DR Orphanet; 1143; Neurogenic arthrogryposis multiplex congenita. DR VEuPathDB; HostDB:ENSG00000136021; -. DR eggNOG; KOG2137; Eukaryota. DR GeneTree; ENSGT00880000138031; -. DR InParanoid; Q6P3W7; -. DR OrthoDB; 79687at2759; -. DR PAN-GO; Q6P3W7; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q6P3W7; -. DR PathwayCommons; Q6P3W7; -. DR SignaLink; Q6P3W7; -. DR Agora; ENSG00000136021; -. DR BioGRID-ORCS; 55681; 20 hits in 1191 CRISPR screens. DR ChiTaRS; SCYL2; human. DR GeneWiki; SCYL2; -. DR GenomeRNAi; 55681; -. DR Pharos; Q6P3W7; Tbio. DR PRO; PR:Q6P3W7; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; Q6P3W7; protein. DR Bgee; ENSG00000136021; Expressed in mucosa of sigmoid colon and 183 other cell types or tissues. DR ExpressionAtlas; Q6P3W7; baseline and differential. DR GO; GO:0030136; C:clathrin-coated vesicle; IEA:UniProtKB-SubCell. DR GO; GO:0010008; C:endosome membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell. DR GO; GO:0005524; F:ATP binding; IEA:InterPro. DR GO; GO:0004672; F:protein kinase activity; IEA:InterPro. DR GO; GO:0005102; F:signaling receptor binding; IPI:BHF-UCL. DR GO; GO:0007420; P:brain development; ISS:UniProtKB. DR GO; GO:0072583; P:clathrin-dependent endocytosis; IDA:BHF-UCL. DR GO; GO:0008333; P:endosome to lysosome transport; IDA:BHF-UCL. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IDA:BHF-UCL. DR GO; GO:0021860; P:pyramidal neuron development; ISS:UniProtKB. DR GO; GO:0031623; P:receptor internalization; IDA:BHF-UCL. DR CDD; cd14011; PK_SCY1_like; 1. DR FunFam; 3.30.200.20:FF:000179; SCY1 like pseudokinase 2; 1. DR FunFam; 1.10.510.10:FF:000352; SCY1-like pseudokinase 2; 1. DR FunFam; 1.25.10.10:FF:000189; SCY1-like pseudokinase 2; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR051177; CIK-Related_Protein. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR PANTHER; PTHR12984:SF18; SCY1-LIKE PROTEIN 2; 1. DR PANTHER; PTHR12984; SCY1-RELATED S/T PROTEIN KINASE-LIKE; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF48371; ARM repeat; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW Coiled coil; Cytoplasmic vesicle; Disease variant; Endosome; KW Golgi apparatus; Membrane; Phosphoprotein; Proteomics identification; KW Reference proteome. FT CHAIN 1..929 FT /note="SCY1-like protein 2" FT /id="PRO_0000252446" FT DOMAIN 32..327 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REPEAT 443..479 FT /note="HEAT" FT REGION 684..709 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 699..929 FT /note="Necessary for interaction with AP2 complex and FT clathrin, interaction with clathrin is necessary for its FT targeting to the TGN and endosomal membranes" FT REGION 906..929 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 661..701 FT /evidence="ECO:0000255" FT COMPBIAS 684..694 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 695..705 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 912..922 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 677 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 708 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT VARIANT 36..929 FT /note="Missing (in AMC4)" FT /evidence="ECO:0000269|PubMed:31960134" FT /id="VAR_083876" FT VARIANT 357 FT /note="P -> L (in dbSNP:rs33968174)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:17344846" FT /id="VAR_041368" FT VARIANT 720 FT /note="T -> S (in dbSNP:rs763873645)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041369" FT VARIANT 863 FT /note="Q -> H (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041370" FT CONFLICT 139..145 FT /note="PISPDIK -> LMSGDIG (in Ref. 4; BAA92598)" FT /evidence="ECO:0000305" FT CONFLICT 186 FT /note="L -> S (in Ref. 1; BAB14869)" FT /evidence="ECO:0000305" FT CONFLICT 424 FT /note="Q -> QASNM (in Ref. 4; BAA92598)" FT /evidence="ECO:0000305" FT CONFLICT 439 FT /note="K -> R (in Ref. 1; BAB14869)" FT /evidence="ECO:0000305" FT CONFLICT 554 FT /note="F -> L (in Ref. 3; AAH12387)" FT /evidence="ECO:0000305" FT CONFLICT 628 FT /note="Q -> R (in Ref. 1; BAB14869)" FT /evidence="ECO:0000305" FT CONFLICT 638 FT /note="T -> I (in Ref. 3; AAH12387)" FT /evidence="ECO:0000305" FT CONFLICT 747 FT /note="T -> A (in Ref. 1; BAA91778)" FT /evidence="ECO:0000305" SQ SEQUENCE 929 AA; 103709 MW; 980B481BF7044628 CRC64; MESMLNKLKS TVTKVTADVT SAVMGNPVTR EFDVGRHIAS GGNGLAWKIF NGTKKSTKQE VAVFVFDKKL IDKYQKFEKD QIIDSLKRGV QQLTRLRHPR LLTVQHPLEE SRDCLAFCTE PVFASLANVL GNWENLPSPI SPDIKDYKLY DVETKYGLLQ VSEGLSFLHS SVKMVHGNIT PENIILNKSG AWKIMGFDFC VSSTNPSEQE PKFPCKEWDP NLPSLCLPNP EYLAPEYILS VSCETASDMY SLGTVMYAVF NKGKPIFEVN KQDIYKSFSR QLDQLSRLGS SSLTNIPEEV REHVKLLLNV TPTVRPDADQ MTKIPFFDDV GAVTLQYFDT LFQRDNLQKS QFFKGLPKVL PKLPKRVIVQ RILPCLTSEF VNPDMVPFVL PNVLLIAEEC TKEEYVKLIL PELGPVFKQQ EPIQILLIFL QKMDLLLTKT PPDEIKNSVL PMVYRALEAP SIQIQELCLN IIPTFANLID YPSMKNALIP RIKNACLQTS SLAVRVNSLV CLGKILEYLD KWFVLDDILP FLQQIPSKEP AVLMGILGIY KCTFTHKKLG ITKEQLAGKV LPHLIPLSIE NNLNLNQFNS FISVIKEMLN RLESEHKTKL EQLHIMQEQQ KSLDIGNQMN VSEEMKVTNI GNQQIDKVFN NIGADLLTGS ESENKEDGLQ NKHKRASLTL EEKQKLAKEQ EQAQKLKSQQ PLKPQVHTPV ATVKQTKDLT DTLMDNMSSL TSLSVSTPKS SASSTFTSVP SMGIGMMFST PTDNTKRNLT NGLNANMGFQ TSGFNMPVNT NQNFYSSPST VGVTKMTLGT PPTLPNFNAL SVPPAGAKQT QQRPTDMSAL NNLFGPQKPK VSMNQLSQQK PNQWLNQFVP PQGSPTMGSS VMGTQMNVIG QSAFGMQGNP FFNPQNFAQP PTTMTNSSSA SNDLKDLFG // ID SDCB1_HUMAN Reviewed; 298 AA. AC O00560; B2R5Q7; B4DUH3; B7ZLN2; O00173; O43391; Q14CP2; DT 02-MAY-2002, integrated into UniProtKB/Swiss-Prot. DT 01-JUL-1997, sequence version 1. DT 28-JAN-2026, entry version 232. DE RecName: Full=Syntenin-1; DE AltName: Full=Melanoma differentiation-associated protein 9; DE Short=MDA-9; DE AltName: Full=Pro-TGF-alpha cytoplasmic domain-interacting protein 18; DE Short=TACIP18; DE AltName: Full=Scaffold protein Pbp1; DE AltName: Full=Syndecan-binding protein 1; GN Name=SDCBP; Synonyms=MDA9, SYCL; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Lin J.J., Jiang H., Fisher P.B.; RT "Characterization of a novel melanoma differentiation associated gene, mda- RT 9, that is down-regulated during terminal cell differentiation."; RL Mol. Cell. Differ. 4:317-333(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH SDC2, AND VARIANT RP SER-69. RX PubMed=9391086; DOI=10.1073/pnas.94.25.13683; RA Grootjans J.J., Zimmermann P., Reekmans G., Smets A., Degeest G., Duerr J., RA David G.; RT "Syntenin, a PDZ protein that binds syndecan cytoplasmic domains."; RL Proc. Natl. Acad. Sci. U.S.A. 94:13683-13688(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Burbelo P.D.; RT "A new family of scaffold proteins."; RL Submitted (JAN-1997) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=9511750; DOI=10.1016/s0378-1119(97)00562-3; RA Lin J.J., Jiang H., Fisher P.B.; RT "Melanoma differentiation associated gene-9, mda-9, is a human gamma RT interferon responsive gene."; RL Gene 207:105-110(1998). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3). RC TISSUE=Rectum, and Urinary bladder; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16421571; DOI=10.1038/nature04406; RA Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M., RA Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L., RA Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S., RA Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A., RA Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III, RA Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., RA Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P., RA Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H., RA Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B., RA O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K., RA Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L., RA Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G., RA Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W., RA Platzer M., Shimizu N., Lander E.S.; RT "DNA sequence and analysis of human chromosome 8."; RL Nature 439:331-335(2006). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP PROTEIN SEQUENCE OF 2-14; 218-229 AND 289-298, CLEAVAGE OF INITIATOR RP METHIONINE, ACETYLATION AT SER-2, AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Pre-B cell; RA Bienvenut W.V., Sumpton D.P., Lilla S., Ozanne B.W.; RL Submitted (FEB-2009) to UniProtKB. RN [10] RP INTERACTION WITH EPHB1 AND EPHA7. RX PubMed=9883737; DOI=10.1016/s0896-6273(00)80663-7; RA Torres R., Firestein B.L., Dong H., Staudinger J., Olson E.N., RA Huganir R.L., Bredt D.S., Gale N.W., Yancopoulos G.D.; RT "PDZ proteins bind, cluster, and synaptically colocalize with Eph receptors RT and their ephrin ligands."; RL Neuron 21:1453-1463(1998). RN [11] RP FUNCTION, AND INTERACTION WITH TGFA. RX PubMed=10230395; DOI=10.1016/s1097-2765(00)80470-0; RA Fernandez-Larrea J., Merlos-Suarez A., Urena J.M., Baselga J., Arribas J.; RT "A role for a PDZ protein in the early secretory pathway for the targeting RT of proTGF-alpha to the cell surface."; RL Mol. Cell 3:423-433(1999). RN [12] RP INTERACTION WITH SYNDECANS; NRXN2 AND EPHB1. RX PubMed=10770943; DOI=10.1074/jbc.m002459200; RA Grootjans J.J., Reekmans G., Ceulemans H., David G.; RT "Syntenin-syndecan binding requires syndecan-synteny and the co-operation RT of both PDZ domains of syntenin."; RL J. Biol. Chem. 275:19933-19941(2000). RN [13] RP INTERACTION WITH SDCBP2. RC TISSUE=Fetal brain; RX PubMed=11152476; DOI=10.1074/jbc.m010647200; RA Koroll M., Rathjen F.G., Volkmer H.; RT "The neural cell recognition molecule neurofascin interacts with syntenin-1 RT but not with syntenin-2, both of which reveal self-associating activity."; RL J. Biol. Chem. 276:10646-10654(2001). RN [14] RP INTERACTION WITH NF2. RX PubMed=11432873; DOI=10.1074/jbc.m105792200; RA Jannatipour M., Dion P., Khan S., Jindal H., Fan X., Laganiere J., RA Chishti A.H., Rouleau G.A.; RT "Schwannomin isoform-1 interacts with syntenin via PDZ domains."; RL J. Biol. Chem. 276:33093-33100(2001). RN [15] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=11179419; DOI=10.1091/mbc.12.2.339; RA Zimmermann P., Tomatis D., Rosas M., Grootjans J.J., Leenaerts I., RA Degeest G., Reekmans G., Coomans C., David G.; RT "Characterization of syntenin, a syndecan-binding PDZ protein, as a RT component of cell adhesion sites and microfilaments."; RL Mol. Biol. Cell 12:339-350(2001). RN [16] RP FUNCTION, AND INTERACTION WITH IL5RA. RX PubMed=11498591; DOI=10.1126/science.1059157; RA Geijsen N., Uings I.J., Pals C., Armstrong J., McKinnon M., RA Raaijmakers J.A.M., Lammers J.-W., Koenderman L., Coffer P.J.; RT "Cytokine-specific transcriptional regulation through an IL-5Ralpha RT interacting protein."; RL Science 293:1136-1138(2001). RN [17] RP SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS]. RC TISSUE=Melanoma; RX PubMed=12643545; DOI=10.1021/pr025562r; RA Basrur V., Yang F., Kushimoto T., Higashimoto Y., Yasumoto K., Valencia J., RA Muller J., Vieira W.D., Watabe H., Shabanowitz J., Hearing V.J., Hunt D.F., RA Appella E.; RT "Proteomic analysis of early melanosomes: identification of novel RT melanosomal proteins."; RL J. Proteome Res. 2:69-79(2003). RN [18] RP SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS]. RC TISSUE=Melanoma; RX PubMed=17081065; DOI=10.1021/pr060363j; RA Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H., Mangini N.J., RA Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R., Yamagishi S., RA Shabanowitz J., Hearing V.J., Wu C., Appella E., Hunt D.F.; RT "Proteomic and bioinformatic characterization of the biogenesis and RT function of melanosomes."; RL J. Proteome Res. 5:3135-3144(2006). RN [19] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [20] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [21] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PDCD6IP. RX PubMed=22660413; DOI=10.1038/ncb2502; RA Baietti M.F., Zhang Z., Mortier E., Melchior A., Degeest G., Geeraerts A., RA Ivarsson Y., Depoortere F., Coomans C., Vermeiren E., Zimmermann P., RA David G.; RT "Syndecan-syntenin-ALIX regulates the biogenesis of exosomes."; RL Nat. Cell Biol. 14:677-685(2012). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-6, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-46, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [24] RP REVIEW. RX PubMed=26032692; DOI=10.1111/boc.201500010; RA Friand V., David G., Zimmermann P.; RT "Syntenin and syndecan in the biogenesis of exosomes."; RL Biol. Cell 107:331-341(2015). RN [25] RP REVIEW. RX PubMed=25219541; DOI=10.1517/14728222.2014.959495; RA Kegelman T.P., Das S.K., Emdad L., Hu B., Menezes M.E., Bhoopathi P., RA Wang X.Y., Pellecchia M., Sarkar D., Fisher P.B.; RT "Targeting tumor invasion: the roles of MDA-9/Syntenin."; RL Expert Opin. Ther. Targets 19:97-112(2015). RN [26] RP FUNCTION. RX PubMed=26539120; DOI=10.3389/fphar.2015.00241; RA Kashyap R., Roucourt B., Lembo F., Fares J., Carcavilla A.M., Restouin A., RA Zimmermann P., Ghossoub R.; RT "Syntenin controls migration, growth, proliferation, and cell cycle RT progression in cancer cells."; RL Front. Pharmacol. 6:241-241(2015). RN [27] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH TGFBR1, AND TISSUE RP SPECIFICITY. RX PubMed=25893292; DOI=10.1038/onc.2015.100; RA Hwangbo C., Tae N., Lee S., Kim O., Park O.K., Kim J., Kwon S.H., Lee J.H.; RT "Syntenin regulates TGF-beta1-induced Smad activation and the epithelial- RT to-mesenchymal transition by inhibiting caveolin-mediated TGF-beta type I RT receptor internalization."; RL Oncogene 35:389-401(2016). RN [28] RP REVIEW, AND FUNCTION. RX PubMed=26291527; DOI=10.1002/jcp.25136; RA Philley J.V., Kannan A., Dasgupta S.; RT "MDA-9/syntenin control."; RL J. Cell. Physiol. 231:545-550(2016). RN [29] RP X-RAY CRYSTALLOGRAPHY (1.94 ANGSTROMS) OF 113-273. RX PubMed=12679023; DOI=10.1016/s0969-2126(03)00052-2; RA Kang B.S., Cooper D.R., Jelen F., Devedjiev Y., Derewenda U., Dauter Z., RA Otlewski J., Derewenda Z.S.; RT "PDZ tandem of human syntenin: crystal structure and functional RT properties."; RL Structure 11:459-468(2003). RN [30] RP X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS) OF 197-270 IN COMPLEXES WITH IL5RA RP AND SDC4. RX PubMed=12842047; DOI=10.1016/s0969-2126(03)00125-4; RA Kang B.S., Cooper D.R., Devedjiev Y., Derewenda U., Derewenda Z.S.; RT "Molecular roots of degenerate specificity in syntenin's PDZ2 domain: RT reassessment of the PDZ recognition paradigm."; RL Structure 11:845-853(2003). RN [31] RP X-RAY CRYSTALLOGRAPHY (0.73 ANGSTROMS) OF 197-273. RX PubMed=15081807; DOI=10.1016/j.jmb.2004.02.057; RA Kang B.S., Devedjiev Y., Derewenda U., Derewenda Z.S.; RT "The PDZ2 domain of syntenin at ultra-high resolution: bridging the gap RT between macromolecular and small molecule crystallography."; RL J. Mol. Biol. 338:483-493(2004). RN [32] RP X-RAY CRYSTALLOGRAPHY (1.56 ANGSTROMS) OF 113-273 IN COMPLEXES WITH RP C-TERMINAL PEPTIDES FROM NEUREXIN; EPHB1 AND SDC4. RX PubMed=16533050; DOI=10.1021/bi052225y; RA Grembecka J., Cierpicki T., Devedjiev Y., Derewenda U., Kang B.S., RA Bushweller J.H., Derewenda Z.S.; RT "The binding of the PDZ tandem of syntenin to target proteins."; RL Biochemistry 45:3674-3683(2006). RN [33] RP X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF 111-275 IN COMPLEXES WITH RP C-TERMINAL PEPTIDES FROM FZD7 AND INOSITOL BISPHOSPHATE, INTERACTION WITH RP FZD7, MUTAGENESIS OF LYS-214; ASN-215 AND LYS-250, AND SUBCELLULAR RP LOCATION. RX PubMed=27386966; DOI=10.1038/ncomms12101; RA Egea-Jimenez A.L., Gallardo R., Garcia-Pino A., Ivarsson Y., RA Wawrzyniak A.M., Kashyap R., Loris R., Schymkowitz J., Rousseau F., RA Zimmermann P.; RT "Frizzled 7 and PIP2 binding by syntenin PDZ2 domain supports Frizzled 7 RT trafficking and signalling."; RL Nat. Commun. 7:12101-12101(2016). CC -!- FUNCTION: Multifunctional adapter protein involved in diverse array of CC functions including trafficking of transmembrane proteins, neuro and CC immunomodulation, exosome biogenesis, and tumorigenesis CC (PubMed:26291527). Positively regulates TGFB1-mediated SMAD2/3 CC activation and TGFB1-induced epithelial-to-mesenchymal transition (EMT) CC and cell migration in various cell types. May increase TGFB1 signaling CC by enhancing cell-surface expression of TGFR1 by preventing the CC interaction between TGFR1 and CAV1 and subsequent CAV1-dependent CC internalization and degradation of TGFR1 (PubMed:25893292). In concert CC with SDC1/4 and PDCD6IP, regulates exosome biogenesis CC (PubMed:22660413). Regulates migration, growth, proliferation, and cell CC cycle progression in a variety of cancer types (PubMed:26539120). In CC adherens junctions may function to couple syndecans to cytoskeletal CC proteins or signaling components. Seems to couple transcription factor CC SOX4 to the IL-5 receptor (IL5RA) (PubMed:11498591). May also play a CC role in vesicular trafficking (PubMed:11179419). Seems to be required CC for the targeting of TGFA to the cell surface in the early secretory CC pathway (PubMed:10230395). {ECO:0000269|PubMed:10230395, CC ECO:0000269|PubMed:11179419, ECO:0000269|PubMed:11498591, CC ECO:0000269|PubMed:22660413, ECO:0000269|PubMed:25893292, CC ECO:0000269|PubMed:26539120, ECO:0000303|PubMed:26291527}. CC -!- SUBUNIT: Monomer and homodimer (By similarity). Interacts with SDC1, CC SDC2, SDC3, SDC4, NRXN2, EPHA7, EPHB1, NF2 isoform 1, TGFA and IL5RA. CC Interacts with NFASC and PTPRJ (By similarity). Interacts with SDCBP2 CC (PubMed:11152476). Interacts with PDCD6IP (PubMed:22660413). Forms a CC complex with PDCD6IP and SDC2 (PubMed:22660413). Interacts (via C- CC terminus) with TGFBR1 (PubMed:25893292). Binds to FZD7; this CC interaction is increased by inositol trisphosphate (IP3) CC (PubMed:27386966). Interacts with SMO (By similarity). CC {ECO:0000250|UniProtKB:O08992, ECO:0000250|UniProtKB:Q9JI92, CC ECO:0000269|PubMed:11152476, ECO:0000269|PubMed:22660413, CC ECO:0000269|PubMed:25893292, ECO:0000269|PubMed:27386966}. CC -!- INTERACTION: CC O00560; Q9NYB9: ABI2; NbExp=5; IntAct=EBI-727004, EBI-743598; CC O00560; Q9NX04: AIRIM; NbExp=3; IntAct=EBI-727004, EBI-8643161; CC O00560; Q7Z3H0-1: ANKRD33; NbExp=3; IntAct=EBI-727004, EBI-16746154; CC O00560; Q8N2N9-4: ANKRD36B; NbExp=3; IntAct=EBI-727004, EBI-12170453; CC O00560; Q6AI12: ANKRD40; NbExp=3; IntAct=EBI-727004, EBI-2838246; CC O00560; Q92688: ANP32B; NbExp=6; IntAct=EBI-727004, EBI-762428; CC O00560; Q96GX9: APIP; NbExp=5; IntAct=EBI-727004, EBI-359248; CC O00560; P53365: ARFIP2; NbExp=3; IntAct=EBI-727004, EBI-638194; CC O00560; Q15041: ARL6IP1; NbExp=3; IntAct=EBI-727004, EBI-714543; CC O00560; P54253: ATXN1; NbExp=6; IntAct=EBI-727004, EBI-930964; CC O00560; Q5TBC7: BCL2L15; NbExp=3; IntAct=EBI-727004, EBI-10247136; CC O00560; Q8N7W2-2: BEND7; NbExp=3; IntAct=EBI-727004, EBI-10181188; CC O00560; Q9H3H3: C11orf68; NbExp=3; IntAct=EBI-727004, EBI-721765; CC O00560; Q9H3H3-3: C11orf68; NbExp=3; IntAct=EBI-727004, EBI-12002214; CC O00560; O14523: C2CD2L; NbExp=3; IntAct=EBI-727004, EBI-12822627; CC O00560; Q9NP86: CABP5; NbExp=3; IntAct=EBI-727004, EBI-10311131; CC O00560; A2RRN7: CADPS; NbExp=3; IntAct=EBI-727004, EBI-10179719; CC O00560; Q9ULU8-4: CADPS; NbExp=3; IntAct=EBI-727004, EBI-10180690; CC O00560; Q13137: CALCOCO2; NbExp=3; IntAct=EBI-727004, EBI-739580; CC O00560; P51636: CAV2; NbExp=3; IntAct=EBI-727004, EBI-603607; CC O00560; O75828: CBR3; NbExp=8; IntAct=EBI-727004, EBI-714504; CC O00560; Q68D86: CCDC102B; NbExp=3; IntAct=EBI-727004, EBI-10171570; CC O00560; Q9BWC9: CCDC106; NbExp=3; IntAct=EBI-727004, EBI-711501; CC O00560; P32320: CDA; NbExp=6; IntAct=EBI-727004, EBI-9250559; CC O00560; P49427: CDC34; NbExp=6; IntAct=EBI-727004, EBI-975634; CC O00560; Q9H5V8: CDCP1; NbExp=6; IntAct=EBI-727004, EBI-1019736; CC O00560; O14735: CDIPT; NbExp=3; IntAct=EBI-727004, EBI-358858; CC O00560; P55273: CDKN2D; NbExp=3; IntAct=EBI-727004, EBI-745859; CC O00560; Q53EZ4: CEP55; NbExp=6; IntAct=EBI-727004, EBI-747776; CC O00560; Q6P2H3-3: CEP85; NbExp=3; IntAct=EBI-727004, EBI-12368239; CC O00560; Q9UFW8: CGGBP1; NbExp=3; IntAct=EBI-727004, EBI-723153; CC O00560; Q9UKJ5: CHIC2; NbExp=3; IntAct=EBI-727004, EBI-741528; CC O00560; Q9HD42: CHMP1A; NbExp=3; IntAct=EBI-727004, EBI-1057156; CC O00560; P49760: CLK2; NbExp=3; IntAct=EBI-727004, EBI-750020; CC O00560; P49761: CLK3; NbExp=6; IntAct=EBI-727004, EBI-745579; CC O00560; Q96DZ9: CMTM5; NbExp=3; IntAct=EBI-727004, EBI-2548702; CC O00560; Q96DZ9-2: CMTM5; NbExp=3; IntAct=EBI-727004, EBI-11522780; CC O00560; P13073: COX4I1; NbExp=4; IntAct=EBI-727004, EBI-1056574; CC O00560; Q86WV2: COX4I1; NbExp=3; IntAct=EBI-727004, EBI-10260134; CC O00560; O43186: CRX; NbExp=3; IntAct=EBI-727004, EBI-748171; CC O00560; P02489: CRYAA; NbExp=7; IntAct=EBI-727004, EBI-6875961; CC O00560; Q5HYN5: CT45A1; NbExp=3; IntAct=EBI-727004, EBI-12051833; CC O00560; P0DMU9: CT45A10; NbExp=6; IntAct=EBI-727004, EBI-12153495; CC O00560; Q8NHU0: CT45A3; NbExp=9; IntAct=EBI-727004, EBI-8643558; CC O00560; Q6NSH3: CT45A5; NbExp=3; IntAct=EBI-727004, EBI-8635816; CC O00560; P56545-3: CTBP2; NbExp=3; IntAct=EBI-727004, EBI-10171902; CC O00560; Q9GZU7: CTDSP1; NbExp=3; IntAct=EBI-727004, EBI-751587; CC O00560; Q9NTM9: CUTC; NbExp=6; IntAct=EBI-727004, EBI-714918; CC O00560; P32321: DCTD; NbExp=6; IntAct=EBI-727004, EBI-739870; CC O00560; Q9H773: DCTPP1; NbExp=3; IntAct=EBI-727004, EBI-723569; CC O00560; Q13838: DDX39B; NbExp=3; IntAct=EBI-727004, EBI-348622; CC O00560; Q96Q80: DERL3; NbExp=3; IntAct=EBI-727004, EBI-12831318; CC O00560; Q14565: DMC1; NbExp=7; IntAct=EBI-727004, EBI-930865; CC O00560; G5E9A7: DMWD; NbExp=3; IntAct=EBI-727004, EBI-10976677; CC O00560; P50570: DNM2; NbExp=3; IntAct=EBI-727004, EBI-346547; CC O00560; Q14919: DRAP1; NbExp=5; IntAct=EBI-727004, EBI-712941; CC O00560; Q96EV8: DTNBP1; NbExp=3; IntAct=EBI-727004, EBI-465804; CC O00560; P63172: DYNLT1; NbExp=3; IntAct=EBI-727004, EBI-1176455; CC O00560; Q96JC9: EAF1; NbExp=3; IntAct=EBI-727004, EBI-769261; CC O00560; Q8WWZ3: EDARADD; NbExp=3; IntAct=EBI-727004, EBI-2949647; CC O00560; Q8N9N8: EIF1AD; NbExp=6; IntAct=EBI-727004, EBI-750700; CC O00560; P63241: EIF5A; NbExp=3; IntAct=EBI-727004, EBI-373150; CC O00560; Q9GZV4: EIF5A2; NbExp=6; IntAct=EBI-727004, EBI-748028; CC O00560; Q15717: ELAVL1; NbExp=3; IntAct=EBI-727004, EBI-374260; CC O00560; Q9NT22: EMILIN3; NbExp=3; IntAct=EBI-727004, EBI-3197883; CC O00560; Q8TC92: ENOX1; NbExp=3; IntAct=EBI-727004, EBI-713221; CC O00560; Q96C92-2: ENTR1; NbExp=3; IntAct=EBI-727004, EBI-10178036; CC O00560; A1L162: ERICH2; NbExp=3; IntAct=EBI-727004, EBI-2682520; CC O00560; Q9NPD3: EXOSC4; NbExp=3; IntAct=EBI-727004, EBI-371823; CC O00560; Q13158: FADD; NbExp=6; IntAct=EBI-727004, EBI-494804; CC O00560; Q9NWS6: FAM118A; NbExp=3; IntAct=EBI-727004, EBI-8638992; CC O00560; Q9BPY3: FAM118B; NbExp=3; IntAct=EBI-727004, EBI-726822; CC O00560; Q8IZU1: FAM9A; NbExp=3; IntAct=EBI-727004, EBI-8468186; CC O00560; Q8IZU0: FAM9B; NbExp=6; IntAct=EBI-727004, EBI-10175124; CC O00560; Q13643: FHL3; NbExp=3; IntAct=EBI-727004, EBI-741101; CC O00560; Q5TD97: FHL5; NbExp=3; IntAct=EBI-727004, EBI-750641; CC O00560; Q8NFF5: FLAD1; NbExp=4; IntAct=EBI-727004, EBI-742815; CC O00560; O15409: FOXP2; NbExp=3; IntAct=EBI-727004, EBI-983612; CC O00560; Q6NZ44: FTH1; NbExp=3; IntAct=EBI-727004, EBI-10180219; CC O00560; P02792: FTL; NbExp=7; IntAct=EBI-727004, EBI-713279; CC O00560; O75084: FZD7; NbExp=4; IntAct=EBI-727004, EBI-746917; CC O00560; Q7L5D6: GET4; NbExp=3; IntAct=EBI-727004, EBI-711823; CC O00560; O95749: GGPS1; NbExp=3; IntAct=EBI-727004, EBI-10179283; CC O00560; Q5VSY0: GKAP1; NbExp=3; IntAct=EBI-727004, EBI-743722; CC O00560; Q9Y3E0: GOLT1B; NbExp=3; IntAct=EBI-727004, EBI-4402607; CC O00560; Q8N954: GPATCH11; NbExp=3; IntAct=EBI-727004, EBI-2555378; CC O00560; Q8N954-2: GPATCH11; NbExp=3; IntAct=EBI-727004, EBI-12178961; CC O00560; A8MXD5: GRXCR1; NbExp=3; IntAct=EBI-727004, EBI-5235612; CC O00560; O15499: GSC2; NbExp=3; IntAct=EBI-727004, EBI-19954058; CC O00560; Q2KHT4-3: GSG1; NbExp=3; IntAct=EBI-727004, EBI-12951679; CC O00560; V9HW60: HEL-S-182mP; NbExp=3; IntAct=EBI-727004, EBI-10180762; CC O00560; V9HW40: HEL-S-25; NbExp=3; IntAct=EBI-727004, EBI-10330099; CC O00560; Q96MH2: HEXIM2; NbExp=3; IntAct=EBI-727004, EBI-5460660; CC O00560; Q5VTY9: HHAT; NbExp=3; IntAct=EBI-727004, EBI-12951255; CC O00560; Q6NT76: HMBOX1; NbExp=3; IntAct=EBI-727004, EBI-2549423; CC O00560; O15347: HMGB3; NbExp=7; IntAct=EBI-727004, EBI-2214136; CC O00560; P07910: HNRNPC; NbExp=6; IntAct=EBI-727004, EBI-357966; CC O00560; Q9NSC5: HOMER3; NbExp=5; IntAct=EBI-727004, EBI-748420; CC O00560; Q8IX15-3: HOMEZ; NbExp=3; IntAct=EBI-727004, EBI-10172004; CC O00560; P49639: HOXA1; NbExp=6; IntAct=EBI-727004, EBI-740785; CC O00560; P31268: HOXA7; NbExp=3; IntAct=EBI-727004, EBI-3910421; CC O00560; P00492: HPRT1; NbExp=7; IntAct=EBI-727004, EBI-748210; CC O00560; O75506: HSBP1; NbExp=8; IntAct=EBI-727004, EBI-748664; CC O00560; O75031: HSF2BP; NbExp=3; IntAct=EBI-727004, EBI-7116203; CC O00560; P42858: HTT; NbExp=12; IntAct=EBI-727004, EBI-466029; CC O00560; O60921: HUS1; NbExp=3; IntAct=EBI-727004, EBI-1056174; CC O00560; Q02535: ID3; NbExp=3; IntAct=EBI-727004, EBI-1387094; CC O00560; P24592: IGFBP6; NbExp=3; IntAct=EBI-727004, EBI-947015; CC O00560; Q8IYA8: IHO1; NbExp=3; IntAct=EBI-727004, EBI-8638439; CC O00560; Q13422: IKZF1; NbExp=3; IntAct=EBI-727004, EBI-745305; CC O00560; Q01344: IL5RA; NbExp=2; IntAct=EBI-727004, EBI-1759442; CC O00560; Q8NBZ0: INO80E; NbExp=6; IntAct=EBI-727004, EBI-769401; CC O00560; Q9H079: KATNBL1; NbExp=3; IntAct=EBI-727004, EBI-715394; CC O00560; O95259: KCNH1; NbExp=3; IntAct=EBI-727004, EBI-2909270; CC O00560; P63252: KCNJ2; NbExp=3; IntAct=EBI-727004, EBI-703457; CC O00560; Q719H9: KCTD1; NbExp=6; IntAct=EBI-727004, EBI-9027502; CC O00560; Q8NC69: KCTD6; NbExp=6; IntAct=EBI-727004, EBI-2511344; CC O00560; Q7L273: KCTD9; NbExp=6; IntAct=EBI-727004, EBI-4397613; CC O00560; Q5VWX1: KHDRBS2; NbExp=6; IntAct=EBI-727004, EBI-742808; CC O00560; O60333-2: KIF1B; NbExp=3; IntAct=EBI-727004, EBI-10975473; CC O00560; Q53G59: KLHL12; NbExp=8; IntAct=EBI-727004, EBI-740929; CC O00560; O95198: KLHL2; NbExp=3; IntAct=EBI-727004, EBI-746999; CC O00560; P02533: KRT14; NbExp=3; IntAct=EBI-727004, EBI-702178; CC O00560; Q8IUG1: KRTAP1-3; NbExp=3; IntAct=EBI-727004, EBI-11749135; CC O00560; Q9BYS1: KRTAP1-5; NbExp=3; IntAct=EBI-727004, EBI-11741292; CC O00560; P60409: KRTAP10-7; NbExp=3; IntAct=EBI-727004, EBI-10172290; CC O00560; P26371: KRTAP5-9; NbExp=6; IntAct=EBI-727004, EBI-3958099; CC O00560; O43679: LDB2; NbExp=3; IntAct=EBI-727004, EBI-2865580; CC O00560; P07195: LDHB; NbExp=3; IntAct=EBI-727004, EBI-358748; CC O00560; O95751: LDOC1; NbExp=6; IntAct=EBI-727004, EBI-740738; CC O00560; O95214: LEPROTL1; NbExp=3; IntAct=EBI-727004, EBI-750776; CC O00560; P05162: LGALS2; NbExp=9; IntAct=EBI-727004, EBI-7181544; CC O00560; P62312: LSM6; NbExp=6; IntAct=EBI-727004, EBI-373310; CC O00560; Q8IV03: LURAP1L; NbExp=3; IntAct=EBI-727004, EBI-12898559; CC O00560; Q9NQ48: LZTFL1; NbExp=6; IntAct=EBI-727004, EBI-2824799; CC O00560; Q13257: MAD2L1; NbExp=3; IntAct=EBI-727004, EBI-78203; CC O00560; P45984: MAPK9; NbExp=3; IntAct=EBI-727004, EBI-713568; CC O00560; Q9UPY8: MAPRE3; NbExp=6; IntAct=EBI-727004, EBI-726739; CC O00560; O95460-2: MATN4; NbExp=3; IntAct=EBI-727004, EBI-12072296; CC O00560; O95983: MBD3; NbExp=3; IntAct=EBI-727004, EBI-1783068; CC O00560; Q9NPJ6: MED4; NbExp=3; IntAct=EBI-727004, EBI-394607; CC O00560; P50221: MEOX1; NbExp=3; IntAct=EBI-727004, EBI-2864512; CC O00560; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-727004, EBI-16439278; CC O00560; A0A0C4DFN3: MGLL; NbExp=3; IntAct=EBI-727004, EBI-12866138; CC O00560; Q9UJV3-2: MID2; NbExp=3; IntAct=EBI-727004, EBI-10172526; CC O00560; Q9H8M7: MINDY3; NbExp=3; IntAct=EBI-727004, EBI-724928; CC O00560; Q9UHC7: MKRN1; NbExp=3; IntAct=EBI-727004, EBI-373524; CC O00560; Q9BU76: MMTAG2; NbExp=3; IntAct=EBI-727004, EBI-742459; CC O00560; Q13875-3: MOBP; NbExp=3; IntAct=EBI-727004, EBI-12013470; CC O00560; Q9Y605: MRFAP1; NbExp=3; IntAct=EBI-727004, EBI-995714; CC O00560; Q96HT8: MRFAP1L1; NbExp=8; IntAct=EBI-727004, EBI-748896; CC O00560; Q5JR59: MTUS2; NbExp=3; IntAct=EBI-727004, EBI-742948; CC O00560; Q5JR59-3: MTUS2; NbExp=3; IntAct=EBI-727004, EBI-11522433; CC O00560; Q8WY64: MYLIP; NbExp=3; IntAct=EBI-727004, EBI-6952711; CC O00560; O15049: N4BP3; NbExp=3; IntAct=EBI-727004, EBI-2512055; CC O00560; O95544: NADK; NbExp=7; IntAct=EBI-727004, EBI-743949; CC O00560; Q9UJ70: NAGK; NbExp=5; IntAct=EBI-727004, EBI-372578; CC O00560; Q9UJ70-2: NAGK; NbExp=3; IntAct=EBI-727004, EBI-11526455; CC O00560; Q9H115: NAPB; NbExp=3; IntAct=EBI-727004, EBI-3921185; CC O00560; Q7Z6G3-2: NECAB2; NbExp=5; IntAct=EBI-727004, EBI-10172876; CC O00560; Q15223: NECTIN1; NbExp=8; IntAct=EBI-727004, EBI-1771314; CC O00560; Q6ZUT1: NKAPD1; NbExp=8; IntAct=EBI-727004, EBI-3920396; CC O00560; Q6ZUT1-2: NKAPD1; NbExp=3; IntAct=EBI-727004, EBI-10180231; CC O00560; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-727004, EBI-945833; CC O00560; P49902: NT5C2; NbExp=3; IntAct=EBI-727004, EBI-742084; CC O00560; P0CE72: OCM; NbExp=3; IntAct=EBI-727004, EBI-11955379; CC O00560; A1E959: ODAM; NbExp=3; IntAct=EBI-727004, EBI-5774125; CC O00560; Q96CV9: OPTN; NbExp=3; IntAct=EBI-727004, EBI-748974; CC O00560; Q92882: OSTF1; NbExp=3; IntAct=EBI-727004, EBI-1051152; CC O00560; P61457: PCBD1; NbExp=3; IntAct=EBI-727004, EBI-740475; CC O00560; P49585: PCYT1A; NbExp=3; IntAct=EBI-727004, EBI-2563309; CC O00560; Q5VU43: PDE4DIP; NbExp=4; IntAct=EBI-727004, EBI-1105124; CC O00560; Q5VU43-2: PDE4DIP; NbExp=4; IntAct=EBI-727004, EBI-9640281; CC O00560; O76083-2: PDE9A; NbExp=3; IntAct=EBI-727004, EBI-11524542; CC O00560; P50479: PDLIM4; NbExp=3; IntAct=EBI-727004, EBI-372861; CC O00560; Q13113: PDZK1IP1; NbExp=3; IntAct=EBI-727004, EBI-716063; CC O00560; Q99471: PFDN5; NbExp=3; IntAct=EBI-727004, EBI-357275; CC O00560; Q8IXK0: PHC2; NbExp=3; IntAct=EBI-727004, EBI-713786; CC O00560; Q9UIL8: PHF11; NbExp=3; IntAct=EBI-727004, EBI-2861403; CC O00560; Q8WWB5: PIH1D2; NbExp=3; IntAct=EBI-727004, EBI-10232538; CC O00560; Q8ND90: PNMA1; NbExp=8; IntAct=EBI-727004, EBI-302345; CC O00560; Q9UL42: PNMA2; NbExp=7; IntAct=EBI-727004, EBI-302355; CC O00560; P52435: POLR2J; NbExp=3; IntAct=EBI-727004, EBI-394753; CC O00560; Q9Y2Y1: POLR3K; NbExp=3; IntAct=EBI-727004, EBI-11023785; CC O00560; O75170: PPP6R2; NbExp=2; IntAct=EBI-727004, EBI-359739; CC O00560; Q8NAV1: PRPF38A; NbExp=3; IntAct=EBI-727004, EBI-715374; CC O00560; O75400-2: PRPF40A; NbExp=3; IntAct=EBI-727004, EBI-5280197; CC O00560; Q9NZ81: PRR13; NbExp=3; IntAct=EBI-727004, EBI-740924; CC O00560; P49720: PSMB3; NbExp=3; IntAct=EBI-727004, EBI-603340; CC O00560; P62333: PSMC6; NbExp=6; IntAct=EBI-727004, EBI-357669; CC O00560; Q9UL46: PSME2; NbExp=6; IntAct=EBI-727004, EBI-741630; CC O00560; O43586: PSTPIP1; NbExp=3; IntAct=EBI-727004, EBI-1050964; CC O00560; Q03393: PTS; NbExp=4; IntAct=EBI-727004, EBI-712344; CC O00560; Q9UHX1: PUF60; NbExp=3; IntAct=EBI-727004, EBI-1053259; CC O00560; Q53H96: PYCR3; NbExp=8; IntAct=EBI-727004, EBI-2959680; CC O00560; Q53GL6: RALY; NbExp=3; IntAct=EBI-727004, EBI-9512693; CC O00560; Q14498: RBM39; NbExp=3; IntAct=EBI-727004, EBI-395290; CC O00560; Q96HR9: REEP6; NbExp=3; IntAct=EBI-727004, EBI-750345; CC O00560; Q96HR9-2: REEP6; NbExp=3; IntAct=EBI-727004, EBI-14065960; CC O00560; Q04864: REL; NbExp=3; IntAct=EBI-727004, EBI-307352; CC O00560; Q9NPQ8-4: RIC8A; NbExp=3; IntAct=EBI-727004, EBI-9091816; CC O00560; Q9Y3C5: RNF11; NbExp=3; IntAct=EBI-727004, EBI-396669; CC O00560; P13489: RNH1; NbExp=8; IntAct=EBI-727004, EBI-1237106; CC O00560; Q9HAT0: ROPN1; NbExp=6; IntAct=EBI-727004, EBI-1378139; CC O00560; Q8TA86: RP9; NbExp=5; IntAct=EBI-727004, EBI-630339; CC O00560; P49247: RPIA; NbExp=3; IntAct=EBI-727004, EBI-744831; CC O00560; P35268: RPL22; NbExp=5; IntAct=EBI-727004, EBI-354533; CC O00560; Q96P16-3: RPRD1A; NbExp=3; IntAct=EBI-727004, EBI-12840198; CC O00560; Q9NS64: RPRM; NbExp=3; IntAct=EBI-727004, EBI-1052363; CC O00560; P62854: RPS26; NbExp=3; IntAct=EBI-727004, EBI-353438; CC O00560; P31350: RRM2; NbExp=3; IntAct=EBI-727004, EBI-2339245; CC O00560; Q15050: RRS1; NbExp=3; IntAct=EBI-727004, EBI-749186; CC O00560; Q17RB0: RTL8B; NbExp=3; IntAct=EBI-727004, EBI-10238588; CC O00560; Q16799-3: RTN1; NbExp=3; IntAct=EBI-727004, EBI-10180131; CC O00560; Q59EK9: RUNDC3A; NbExp=3; IntAct=EBI-727004, EBI-747225; CC O00560; Q59EK9-3: RUNDC3A; NbExp=3; IntAct=EBI-727004, EBI-11957366; CC O00560; P04271: S100B; NbExp=3; IntAct=EBI-727004, EBI-458391; CC O00560; Q8WXD2: SCG3; NbExp=3; IntAct=EBI-727004, EBI-12162999; CC O00560; Q9UN30-2: SCML1; NbExp=3; IntAct=EBI-727004, EBI-12137487; CC O00560; O00560: SDCBP; NbExp=7; IntAct=EBI-727004, EBI-727004; CC O00560; Q8WYJ6: SEPTIN1; NbExp=3; IntAct=EBI-727004, EBI-693002; CC O00560; Q9UH03: SEPTIN3; NbExp=6; IntAct=EBI-727004, EBI-727037; CC O00560; Q01105: SET; NbExp=3; IntAct=EBI-727004, EBI-1053182; CC O00560; Q01105-2: SET; NbExp=3; IntAct=EBI-727004, EBI-7481343; CC O00560; Q8WV19: SFT2D1; NbExp=3; IntAct=EBI-727004, EBI-2854842; CC O00560; Q8IUQ4: SIAH1; NbExp=3; IntAct=EBI-727004, EBI-747107; CC O00560; Q9BRV3: SLC50A1; NbExp=3; IntAct=EBI-727004, EBI-8634123; CC O00560; P51531: SMARCA2; NbExp=2; IntAct=EBI-727004, EBI-679562; CC O00560; P51531-2: SMARCA2; NbExp=3; IntAct=EBI-727004, EBI-10212306; CC O00560; P37840: SNCA; NbExp=3; IntAct=EBI-727004, EBI-985879; CC O00560; P09012: SNRPA; NbExp=3; IntAct=EBI-727004, EBI-607085; CC O00560; Q13596: SNX1; NbExp=3; IntAct=EBI-727004, EBI-2822329; CC O00560; Q5MJ09: SPANXN3; NbExp=3; IntAct=EBI-727004, EBI-12037215; CC O00560; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-727004, EBI-5235340; CC O00560; P12931: SRC; NbExp=2; IntAct=EBI-727004, EBI-621482; CC O00560; Q8N9Q2: SREK1IP1; NbExp=6; IntAct=EBI-727004, EBI-10268630; CC O00560; Q05519: SRSF11; NbExp=3; IntAct=EBI-727004, EBI-1051785; CC O00560; Q05519-2: SRSF11; NbExp=3; IntAct=EBI-727004, EBI-11975029; CC O00560; P84103: SRSF3; NbExp=3; IntAct=EBI-727004, EBI-372557; CC O00560; Q16629: SRSF7; NbExp=6; IntAct=EBI-727004, EBI-398885; CC O00560; A1L4H1: SSC5D; NbExp=3; IntAct=EBI-727004, EBI-10172867; CC O00560; O43805: SSNA1; NbExp=6; IntAct=EBI-727004, EBI-2515299; CC O00560; P53999: SUB1; NbExp=3; IntAct=EBI-727004, EBI-998260; CC O00560; O43704: SULT1B1; NbExp=3; IntAct=EBI-727004, EBI-10179062; CC O00560; O43759-2: SYNGR1; NbExp=3; IntAct=EBI-727004, EBI-12187159; CC O00560; Q16563: SYPL1; NbExp=3; IntAct=EBI-727004, EBI-2800683; CC O00560; Q8N2H4: SYS1; NbExp=3; IntAct=EBI-727004, EBI-13075176; CC O00560; O43680: TCF21; NbExp=3; IntAct=EBI-727004, EBI-723267; CC O00560; P15884-3: TCF4; NbExp=3; IntAct=EBI-727004, EBI-13636688; CC O00560; P48775: TDO2; NbExp=7; IntAct=EBI-727004, EBI-743494; CC O00560; Q969V4: TEKT1; NbExp=3; IntAct=EBI-727004, EBI-10180409; CC O00560; Q12800: TFCP2; NbExp=3; IntAct=EBI-727004, EBI-717422; CC O00560; Q9NWX6: THG1L; NbExp=3; IntAct=EBI-727004, EBI-746510; CC O00560; Q96CG3: TIFA; NbExp=8; IntAct=EBI-727004, EBI-740711; CC O00560; Q3LXA3: TKFC; NbExp=3; IntAct=EBI-727004, EBI-4291069; CC O00560; Q08117: TLE5; NbExp=3; IntAct=EBI-727004, EBI-717810; CC O00560; Q7Z6W1: TMCO2; NbExp=3; IntAct=EBI-727004, EBI-12807858; CC O00560; Q86X19: TMEM17; NbExp=3; IntAct=EBI-727004, EBI-11343485; CC O00560; Q8WW34: TMEM239; NbExp=3; IntAct=EBI-727004, EBI-9675724; CC O00560; Q8WW34-2: TMEM239; NbExp=3; IntAct=EBI-727004, EBI-11528917; CC O00560; P0DTL5: TMEM276; NbExp=3; IntAct=EBI-727004, EBI-11997340; CC O00560; O95379: TNFAIP8; NbExp=6; IntAct=EBI-727004, EBI-1049336; CC O00560; Q5GJ75: TNFAIP8L3; NbExp=3; IntAct=EBI-727004, EBI-14222571; CC O00560; O95271: TNKS; NbExp=5; IntAct=EBI-727004, EBI-1105254; CC O00560; O00463: TRAF5; NbExp=8; IntAct=EBI-727004, EBI-523498; CC O00560; P14373: TRIM27; NbExp=3; IntAct=EBI-727004, EBI-719493; CC O00560; Q13049: TRIM32; NbExp=7; IntAct=EBI-727004, EBI-742790; CC O00560; O00635: TRIM38; NbExp=3; IntAct=EBI-727004, EBI-2130415; CC O00560; Q9BYV2: TRIM54; NbExp=6; IntAct=EBI-727004, EBI-2130429; CC O00560; Q15645: TRIP13; NbExp=3; IntAct=EBI-727004, EBI-358993; CC O00560; Q86WV8: TSC1; NbExp=3; IntAct=EBI-727004, EBI-12806590; CC O00560; Q15631: TSN; NbExp=3; IntAct=EBI-727004, EBI-1044160; CC O00560; A5PKU2: TUSC5; NbExp=3; IntAct=EBI-727004, EBI-11988865; CC O00560; P0CG47: UBB; NbExp=3; IntAct=EBI-727004, EBI-413034; CC O00560; P49459: UBE2A; NbExp=9; IntAct=EBI-727004, EBI-2339348; CC O00560; P61086: UBE2K; NbExp=3; IntAct=EBI-727004, EBI-473850; CC O00560; Q712K3: UBE2R2; NbExp=3; IntAct=EBI-727004, EBI-2340879; CC O00560; O95292: VAPB; NbExp=3; IntAct=EBI-727004, EBI-1188298; CC O00560; Q9Y3C0: WASHC3; NbExp=6; IntAct=EBI-727004, EBI-712969; CC O00560; O00401: WASL; NbExp=6; IntAct=EBI-727004, EBI-957615; CC O00560; O76024: WFS1; NbExp=3; IntAct=EBI-727004, EBI-720609; CC O00560; O95070: YIF1A; NbExp=3; IntAct=EBI-727004, EBI-2799703; CC O00560; O43829: ZBTB14; NbExp=3; IntAct=EBI-727004, EBI-10176632; CC O00560; Q96BR9: ZBTB8A; NbExp=6; IntAct=EBI-727004, EBI-742740; CC O00560; Q8TBK6: ZCCHC10; NbExp=3; IntAct=EBI-727004, EBI-597063; CC O00560; Q9NP64: ZCCHC17; NbExp=8; IntAct=EBI-727004, EBI-746345; CC O00560; Q9H0C1: ZMYND12; NbExp=3; IntAct=EBI-727004, EBI-12030590; CC O00560; Q6P1L6: ZNF343; NbExp=3; IntAct=EBI-727004, EBI-10252492; CC O00560; Q8NCK3: ZNF485; NbExp=3; IntAct=EBI-727004, EBI-12901093; CC O00560; Q6AZW8: ZNF660; NbExp=3; IntAct=EBI-727004, EBI-12376497; CC O00560; Q9H5H4: ZNF768; NbExp=3; IntAct=EBI-727004, EBI-1210580; CC O00560; Q9UGI0: ZRANB1; NbExp=3; IntAct=EBI-727004, EBI-527853; CC O00560; Q3MJ62: ZSCAN23; NbExp=3; IntAct=EBI-727004, EBI-5667532; CC O00560; K9N5R3: E; Xeno; NbExp=2; IntAct=EBI-727004, EBI-26374535; CC O00560-1; P59637: E; Xeno; NbExp=4; IntAct=EBI-9640690, EBI-25487741; CC -!- SUBCELLULAR LOCATION: Cell junction, focal adhesion CC {ECO:0000269|PubMed:11179419}. Cell junction, adherens junction CC {ECO:0000269|PubMed:11179419}. Cell membrane CC {ECO:0000269|PubMed:11179419, ECO:0000269|PubMed:25893292, CC ECO:0000269|PubMed:27386966}; Peripheral membrane protein CC {ECO:0000269|PubMed:11179419, ECO:0000269|PubMed:27386966}. Endoplasmic CC reticulum membrane {ECO:0000269|PubMed:17081065}; Peripheral membrane CC protein {ECO:0000269|PubMed:17081065}. Nucleus CC {ECO:0000269|PubMed:11179419}. Melanosome {ECO:0000269|PubMed:12643545, CC ECO:0000269|PubMed:17081065}. Cytoplasm, cytosol CC {ECO:0000269|PubMed:11179419}. Cytoplasm, cytoskeleton CC {ECO:0000269|PubMed:11179419}. Secreted, extracellular exosome CC {ECO:0000269|PubMed:22660413}. Membrane raft CC {ECO:0000269|PubMed:25893292}. Note=Mainly membrane-associated. CC Localized to adherens junctions, focal adhesions and endoplasmic CC reticulum. Colocalized with actin stress fibers. Also found in the CC nucleus. Identified by mass spectrometry in melanosome fractions from CC stage I to stage IV. Associated to the plasma membrane in the presence CC of FZD7 and phosphatidylinositol 4,5-bisphosphate (PIP2) CC (PubMed:27386966). {ECO:0000269|PubMed:11179419, CC ECO:0000269|PubMed:12643545, ECO:0000269|PubMed:17081065, CC ECO:0000269|PubMed:27386966}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=O00560-1; Sequence=Displayed; CC Name=2; CC IsoId=O00560-2; Sequence=VSP_038375; CC Name=3; CC IsoId=O00560-3; Sequence=VSP_038374; CC -!- TISSUE SPECIFICITY: Expressed in lung cancers, including CC adenocarcinoma, squamous cell carcinoma and small-cell carcinoma (at CC protein level) (PubMed:25893292). Widely expressed. Expressed in fetal CC kidney, liver, lung and brain. In adult highest expression in heart and CC placenta. {ECO:0000269|PubMed:25893292}. CC -!- INDUCTION: By IFNG/IFN-gamma in melanoma cells. CC -!- PTM: Phosphorylated on tyrosine residues. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/44377/SDCBP"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF006636; AAC52050.1; -; mRNA. DR EMBL; AF000652; AAB97144.1; -; mRNA. DR EMBL; U83463; AAB51246.1; -; mRNA. DR EMBL; AK300647; BAG62335.1; -; mRNA. DR EMBL; AK312274; BAG35204.1; -; mRNA. DR EMBL; AC068522; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471068; EAW86814.1; -; Genomic_DNA. DR EMBL; BC113674; AAI13675.1; -; mRNA. DR EMBL; BC113676; AAI13677.1; -; mRNA. DR EMBL; BC143915; AAI43916.1; -; mRNA. DR EMBL; BC143916; AAI43917.1; -; mRNA. DR CCDS; CCDS47862.1; -. [O00560-2] DR CCDS; CCDS47863.1; -. [O00560-3] DR CCDS; CCDS6172.1; -. [O00560-1] DR PIR; JC6537; JC6537. DR RefSeq; NP_001007068.1; NM_001007067.2. [O00560-1] DR RefSeq; NP_001007069.1; NM_001007068.2. [O00560-3] DR RefSeq; NP_001007070.1; NM_001007069.2. [O00560-2] DR RefSeq; NP_001007071.1; NM_001007070.2. [O00560-2] DR RefSeq; NP_005616.2; NM_005625.4. [O00560-1] DR PDB; 1N99; X-ray; 1.94 A; A/B=113-273. DR PDB; 1NTE; X-ray; 1.24 A; A=197-273. DR PDB; 1OBX; X-ray; 1.35 A; A=197-270. DR PDB; 1OBY; X-ray; 1.85 A; A/B=197-270. DR PDB; 1OBZ; X-ray; 1.69 A; A/B=113-273. DR PDB; 1R6J; X-ray; 0.73 A; A=197-273. DR PDB; 1V1T; X-ray; 1.80 A; A/B=113-273. DR PDB; 1W9E; X-ray; 1.56 A; A/B=113-273. DR PDB; 1W9O; X-ray; 2.25 A; A/B=113-273. DR PDB; 1W9Q; X-ray; 1.70 A; A/B=113-273. DR PDB; 1YBO; X-ray; 2.30 A; A/B=113-273. DR PDB; 4Z33; X-ray; 2.45 A; A/B=111-275. DR PDB; 6R9H; X-ray; 2.00 A; A/B/C/D=113-273. DR PDB; 6RLC; X-ray; 2.20 A; A/B/C/D=113-273. DR PDB; 7FSG; X-ray; 2.02 A; A/B/C/D=106-298. DR PDB; 7FSH; X-ray; 2.11 A; A/B/C/D=106-298. DR PDB; 7FSI; X-ray; 2.31 A; A/B/C/D=106-298. DR PDB; 7FSJ; X-ray; 1.97 A; A/B/C/D=106-298. DR PDB; 7FSK; X-ray; 2.40 A; A/B/C/D=106-298. DR PDB; 7FSL; X-ray; 2.38 A; A/B/C/D=106-298. DR PDB; 7FSM; X-ray; 2.10 A; A/B/C/D=106-298. DR PDB; 7FSN; X-ray; 2.40 A; A/B/C/D=106-298. DR PDB; 7FSO; X-ray; 1.90 A; A/B/C/D=106-298. DR PDB; 7FSP; X-ray; 1.86 A; A/B/C/D=106-298. DR PDB; 7FSQ; X-ray; 2.07 A; A/B/C/D=106-298. DR PDB; 7FSR; X-ray; 2.29 A; A/B/C/D=106-298. DR PDB; 7FSS; X-ray; 2.11 A; A/B/C/D=106-298. DR PDB; 7FST; X-ray; 1.98 A; A/B/C/D=106-298. DR PDB; 7FSU; X-ray; 1.97 A; A/B/C/D=106-298. DR PDB; 7FSV; X-ray; 2.25 A; A/B/C/D=106-298. DR PDB; 7FSW; X-ray; 2.14 A; A/B/C/D=106-298. DR PDB; 7FSX; X-ray; 1.91 A; A/B/C/D=106-298. DR PDB; 7FSY; X-ray; 2.80 A; A/B/C/D=106-298. DR PDB; 7FSZ; X-ray; 2.05 A; A/B/C/D=106-298. DR PDB; 7FT0; X-ray; 2.45 A; A/B/C/D=106-298. DR PDB; 7FT1; X-ray; 2.11 A; A/B/C/D=106-298. DR PDB; 7FT2; X-ray; 2.04 A; A/B/C/D=106-298. DR PDB; 7FT3; X-ray; 2.05 A; A/B/C/D=106-298. DR PDB; 7FT4; X-ray; 2.17 A; A/B/C/D=106-298. DR PDB; 7FT5; X-ray; 1.77 A; A/B/C/D=106-298. DR PDB; 7FT6; X-ray; 1.85 A; A/B/C/D=106-298. DR PDB; 7FT7; X-ray; 1.78 A; A/B/C/D=106-298. DR PDB; 7FT8; X-ray; 2.40 A; A/B/C/D=106-298. DR PDB; 7FT9; X-ray; 1.77 A; A/B/C/D=106-298. DR PDB; 7FTA; X-ray; 2.03 A; A/B/C/D=106-298. DR PDB; 7FTB; X-ray; 2.22 A; A/B/C/D=106-298. DR PDB; 7FTC; X-ray; 1.87 A; A/B/C/D=106-298. DR PDB; 7FTD; X-ray; 1.80 A; A/B/C/D=106-298. DR PDB; 8AAI; X-ray; 2.76 A; A/B/C/D=113-273. DR PDB; 8AAK; X-ray; 2.55 A; A/B=113-273. DR PDB; 8AAO; X-ray; 2.47 A; A/B=113-273. DR PDB; 8AAP; X-ray; 2.17 A; A/B=113-273. DR PDB; 8BLU; X-ray; 1.50 A; A/B/C/D=106-298. DR PDB; 8BLV; X-ray; 1.50 A; A/B=106-298. DR PDB; 8HCK; X-ray; 2.00 A; A=113-191. DR PDBsum; 1N99; -. DR PDBsum; 1NTE; -. DR PDBsum; 1OBX; -. DR PDBsum; 1OBY; -. DR PDBsum; 1OBZ; -. DR PDBsum; 1R6J; -. DR PDBsum; 1V1T; -. DR PDBsum; 1W9E; -. DR PDBsum; 1W9O; -. DR PDBsum; 1W9Q; -. DR PDBsum; 1YBO; -. DR PDBsum; 4Z33; -. DR PDBsum; 6R9H; -. DR PDBsum; 6RLC; -. DR PDBsum; 7FSG; -. DR PDBsum; 7FSH; -. DR PDBsum; 7FSI; -. DR PDBsum; 7FSJ; -. DR PDBsum; 7FSK; -. DR PDBsum; 7FSL; -. DR PDBsum; 7FSM; -. DR PDBsum; 7FSN; -. DR PDBsum; 7FSO; -. DR PDBsum; 7FSP; -. DR PDBsum; 7FSQ; -. DR PDBsum; 7FSR; -. DR PDBsum; 7FSS; -. DR PDBsum; 7FST; -. DR PDBsum; 7FSU; -. DR PDBsum; 7FSV; -. DR PDBsum; 7FSW; -. DR PDBsum; 7FSX; -. DR PDBsum; 7FSY; -. DR PDBsum; 7FSZ; -. DR PDBsum; 7FT0; -. DR PDBsum; 7FT1; -. DR PDBsum; 7FT2; -. DR PDBsum; 7FT3; -. DR PDBsum; 7FT4; -. DR PDBsum; 7FT5; -. DR PDBsum; 7FT6; -. DR PDBsum; 7FT7; -. DR PDBsum; 7FT8; -. DR PDBsum; 7FT9; -. DR PDBsum; 7FTA; -. DR PDBsum; 7FTB; -. DR PDBsum; 7FTC; -. DR PDBsum; 7FTD; -. DR PDBsum; 8AAI; -. DR PDBsum; 8AAK; -. DR PDBsum; 8AAO; -. DR PDBsum; 8AAP; -. DR PDBsum; 8BLU; -. DR PDBsum; 8BLV; -. DR PDBsum; 8HCK; -. DR AlphaFoldDB; O00560; -. DR SMR; O00560; -. DR BioGRID; 112287; 452. DR ComplexPortal; CPX-3282; Syndecan-1-syntenin-1-ALIX complex. DR CORUM; O00560; -. DR DIP; DIP-42705N; -. DR FunCoup; O00560; 1523. DR IntAct; O00560; 454. DR MINT; O00560; -. DR STRING; 9606.ENSP00000428184; -. DR BindingDB; O00560; -. DR ChEMBL; CHEMBL4739667; -. DR MoonDB; O00560; Predicted. DR TCDB; 8.A.24.2.1; the ezrin/radixin/moesin-binding phosphoprotein 50 (ebp50) family. DR GlyGen; O00560; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; O00560; -. DR PhosphoSitePlus; O00560; -. DR SwissPalm; O00560; -. DR BioMuta; SDCBP; -. DR jPOST; O00560; -. DR MassIVE; O00560; -. DR PaxDb; 9606-ENSP00000260130; -. DR PeptideAtlas; O00560; -. DR ProteomicsDB; 47974; -. [O00560-1] DR ProteomicsDB; 47975; -. [O00560-2] DR ProteomicsDB; 47976; -. [O00560-3] DR Pumba; O00560; -. DR TopDownProteomics; O00560-1; -. [O00560-1] DR Antibodypedia; 3216; 547 antibodies from 38 providers. DR DNASU; 6386; -. DR Ensembl; ENST00000260130.9; ENSP00000260130.4; ENSG00000137575.13. [O00560-1] DR Ensembl; ENST00000413219.6; ENSP00000411771.2; ENSG00000137575.13. [O00560-1] DR Ensembl; ENST00000424270.6; ENSP00000395351.2; ENSG00000137575.13. [O00560-3] DR Ensembl; ENST00000447182.6; ENSP00000409288.2; ENSG00000137575.13. [O00560-2] DR GeneID; 6386; -. DR KEGG; hsa:6386; -. DR MANE-Select; ENST00000260130.9; ENSP00000260130.4; NM_005625.4; NP_005616.2. DR UCSC; uc003xtn.3; human. [O00560-1] DR AGR; HGNC:10662; -. DR ClinPGx; PA35592; -. DR CTD; 6386; -. DR DisGeNET; 6386; -. DR GeneCards; SDCBP; -. DR HGNC; HGNC:10662; SDCBP. DR HPA; ENSG00000137575; Low tissue specificity. DR MIM; 602217; gene. DR OpenTargets; ENSG00000137575; -. DR VEuPathDB; HostDB:ENSG00000137575; -. DR eggNOG; KOG0849; Eukaryota. DR GeneTree; ENSGT00940000154502; -. DR InParanoid; O00560; -. DR OMA; HKMIKKA; -. DR OrthoDB; 10059177at2759; -. DR PAN-GO; O00560; 5 GO annotations based on evolutionary models. DR PhylomeDB; O00560; -. DR PathwayCommons; O00560; -. DR Reactome; R-HSA-3928664; Ephrin signaling. DR Reactome; R-HSA-447043; Neurofascin interactions. DR Reactome; R-HSA-5213460; RIPK1-mediated regulated necrosis. DR Reactome; R-HSA-5675482; Regulation of necroptotic cell death. DR Reactome; R-HSA-6798695; Neutrophil degranulation. DR SignaLink; O00560; -. DR SIGNOR; O00560; -. DR Agora; ENSG00000137575; -. DR BioGRID-ORCS; 6386; 21 hits in 1157 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; SDCBP; human. DR EvolutionaryTrace; O00560; -. DR GeneWiki; SDCBP; -. DR GenomeRNAi; 6386; -. DR Pharos; O00560; Tchem. DR PRO; PR:O00560; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; O00560; protein. DR Bgee; ENSG00000137575; Expressed in pigmented layer of retina and 210 other cell types or tissues. DR ExpressionAtlas; O00560; baseline and differential. DR GO; GO:0005912; C:adherens junction; NAS:UniProtKB. DR GO; GO:0035578; C:azurophil granule lumen; TAS:Reactome. DR GO; GO:0072562; C:blood microparticle; HDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL. DR GO; GO:0005856; C:cytoskeleton; NAS:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell. DR GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0005615; C:extracellular space; HDA:UniProtKB. DR GO; GO:1903561; C:extracellular vesicle; HDA:UniProtKB. DR GO; GO:0005925; C:focal adhesion; IEA:UniProtKB-SubCell. DR GO; GO:0005895; C:interleukin-5 receptor complex; ISS:UniProtKB. DR GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell. DR GO; GO:0016020; C:membrane; NAS:UniProtKB. DR GO; GO:0045121; C:membrane raft; IDA:UniProtKB. DR GO; GO:0031965; C:nuclear membrane; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; NAS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0045202; C:synapse; IEA:GOC. DR GO; GO:0008093; F:cytoskeletal anchor activity; NAS:UniProtKB. DR GO; GO:0005109; F:frizzled binding; IPI:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0005137; F:interleukin-5 receptor binding; ISS:UniProtKB. DR GO; GO:0005546; F:phosphatidylinositol-4,5-bisphosphate binding; IDA:UniProtKB. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB. DR GO; GO:0140311; F:protein sequestering activity; IDA:UniProtKB. DR GO; GO:0045545; F:syndecan binding; IPI:UniProtKB. DR GO; GO:0030036; P:actin cytoskeleton organization; NAS:UniProtKB. DR GO; GO:0007268; P:chemical synaptic transmission; NAS:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; NAS:UniProtKB. DR GO; GO:0002091; P:negative regulation of receptor internalization; IMP:UniProtKB. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0030307; P:positive regulation of cell growth; IMP:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IMP:UniProtKB. DR GO; GO:1903543; P:positive regulation of exosomal secretion; IMP:UniProtKB. DR GO; GO:1903553; P:positive regulation of extracellular exosome assembly; IMP:UniProtKB. DR GO; GO:0046330; P:positive regulation of JNK cascade; IC:BHF-UCL. DR GO; GO:0042327; P:positive regulation of phosphorylation; IDA:BHF-UCL. DR GO; GO:0030511; P:positive regulation of transforming growth factor beta receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0006612; P:protein targeting to membrane; NAS:UniProtKB. DR GO; GO:0007265; P:Ras protein signal transduction; IEA:Ensembl. DR GO; GO:0007346; P:regulation of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0006930; P:substrate-dependent cell migration, cell extension; NAS:UniProtKB. DR CDD; cd06721; PDZ1_syntenin-like; 1. DR CDD; cd06794; PDZ2_syntenin-like; 1. DR FunFam; 2.30.42.10:FF:000043; Syntenin-1 isoform X1; 1. DR FunFam; 2.30.42.10:FF:000065; syntenin-1 isoform X1; 1. DR Gene3D; 2.30.42.10; -; 2. DR InterPro; IPR051230; APP-Binding. DR InterPro; IPR001478; PDZ. DR InterPro; IPR036034; PDZ_sf. DR PANTHER; PTHR12345; SYNTENIN RELATED; 1. DR PANTHER; PTHR12345:SF10; SYNTENIN-1; 1. DR Pfam; PF00595; PDZ; 2. DR SMART; SM00228; PDZ; 2. DR SUPFAM; SSF50156; PDZ domain-like; 2. DR PROSITE; PS50106; PDZ; 2. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Cell junction; KW Cell membrane; Cytoplasm; Cytoskeleton; Direct protein sequencing; KW Endoplasmic reticulum; Lipid-binding; Membrane; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; Secreted. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|Ref.9, ECO:0007744|PubMed:19413330" FT CHAIN 2..298 FT /note="Syntenin-1" FT /id="PRO_0000184001" FT DOMAIN 114..193 FT /note="PDZ 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00143" FT DOMAIN 198..273 FT /note="PDZ 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00143" FT REGION 2..60 FT /note="Interaction with PDCD6IP" FT /evidence="ECO:0000269|PubMed:22660413" FT MOTIF 3..7 FT /note="LYPX(n)L motif 1" FT /evidence="ECO:0000250|UniProtKB:O08992" FT MOTIF 45..49 FT /note="LYPX(n)L motif 2" FT /evidence="ECO:0000250|UniProtKB:O08992" FT MOTIF 49..53 FT /note="LYPX(n)L motif 3" FT /evidence="ECO:0000250|UniProtKB:O08992" FT BINDING 215 FT /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo- FT inositol-4,5-bisphosphate)" FT /ligand_id="ChEBI:CHEBI:58456" FT /evidence="ECO:0000269|PubMed:27386966, FT ECO:0007744|PDB:4Z33" FT BINDING 250..251 FT /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo- FT inositol-4,5-bisphosphate)" FT /ligand_id="ChEBI:CHEBI:58456" FT /evidence="ECO:0000269|PubMed:27386966, FT ECO:0007744|PDB:4Z33" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0000269|Ref.9, ECO:0007744|PubMed:19413330" FT MOD_RES 6 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 46 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:24275569" FT VAR_SEQ 12..17 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_038374" FT VAR_SEQ 81 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_038375" FT VARIANT 69 FT /note="N -> S (in dbSNP:rs1127509)" FT /evidence="ECO:0000269|PubMed:9391086" FT /id="VAR_013160" FT MUTAGEN 214 FT /note="K->A: Disruption of the cooperative binding of C- FT terminal peptides from FZD7 and phosphatidylinositol-4,5- FT bisphosphate. Impaired interaction with FZD7 and disruption FT of the cooperative binding of C-terminal peptides from FZD7 FT and phosphatidylinositol-4,5-bisphosphate; when associated FT with A-250." FT /evidence="ECO:0000269|PubMed:27386966" FT MUTAGEN 215 FT /note="N->D: Disruption of the cooperative binding of C- FT terminal peptides from FZD7 and phosphatidylinositol-4,5- FT bisphosphate." FT /evidence="ECO:0000269|PubMed:27386966" FT MUTAGEN 250 FT /note="K->A: Disruption of the cooperative binding of C- FT terminal peptides from FZD7 and phosphatidylinositol-4,5- FT bisphosphate. Impaired interaction with FZD7 and disruption FT of the cooperative binding of C-terminal peptides from FZD7 FT and phosphatidylinositol-4,5-bisphosphate; when associated FT with A-214." FT /evidence="ECO:0000269|PubMed:27386966" FT CONFLICT 62 FT /note="N -> S (in Ref. 2; AAB51246)" FT /evidence="ECO:0000305" FT STRAND 111..117 FT /evidence="ECO:0007829|PDB:8BLU" FT TURN 121..123 FT /evidence="ECO:0007829|PDB:8AAP" FT STRAND 127..132 FT /evidence="ECO:0007829|PDB:8BLU" FT STRAND 135..142 FT /evidence="ECO:0007829|PDB:8BLU" FT HELIX 146..149 FT /evidence="ECO:0007829|PDB:8BLU" FT STRAND 157..161 FT /evidence="ECO:0007829|PDB:8BLU" FT HELIX 171..180 FT /evidence="ECO:0007829|PDB:8BLU" FT STRAND 186..191 FT /evidence="ECO:0007829|PDB:8BLU" FT STRAND 197..202 FT /evidence="ECO:0007829|PDB:1R6J" FT STRAND 205..208 FT /evidence="ECO:0007829|PDB:1N99" FT STRAND 211..214 FT /evidence="ECO:0007829|PDB:1R6J" FT STRAND 217..221 FT /evidence="ECO:0007829|PDB:1R6J" FT STRAND 223..225 FT /evidence="ECO:0007829|PDB:7FSR" FT HELIX 226..230 FT /evidence="ECO:0007829|PDB:1R6J" FT STRAND 234..241 FT /evidence="ECO:0007829|PDB:1R6J" FT STRAND 247..249 FT /evidence="ECO:0007829|PDB:7FTA" FT HELIX 251..260 FT /evidence="ECO:0007829|PDB:1R6J" FT STRAND 263..271 FT /evidence="ECO:0007829|PDB:1R6J" FT HELIX 272..279 FT /evidence="ECO:0007829|PDB:8BLU" FT STRAND 280..282 FT /evidence="ECO:0007829|PDB:7FSR" FT HELIX 284..290 FT /evidence="ECO:0007829|PDB:8BLU" SQ SEQUENCE 298 AA; 32444 MW; 574E1349F86F949F CRC64; MSLYPSLEDL KVDKVIQAQT AFSANPANPA ILSEASAPIP HDGNLYPRLY PELSQYMGLS LNEEEIRANV AVVSGAPLQG QLVARPSSIN YMVAPVTGND VGIRRAEIKQ GIREVILCKD QDGKIGLRLK SIDNGIFVQL VQANSPASLV GLRFGDQVLQ INGENCAGWS SDKAHKVLKQ AFGEKITMTI RDRPFERTIT MHKDSTGHVG FIFKNGKITS IVKDSSAARN GLLTEHNICE INGQNVIGLK DSQIADILST SGTVVTITIM PAFIFEHIIK RMAPSIMKSL MDHTIPEV // ID SGK2_HUMAN Reviewed; 367 AA. AC Q9HBY8; Q52PK5; Q5H8Y6; Q5H8Z1; Q5TZR3; Q9UKG6; DT 22-FEB-2003, integrated into UniProtKB/Swiss-Prot. DT 10-FEB-2021, sequence version 2. DT 28-JAN-2026, entry version 199. DE RecName: Full=Serine/threonine-protein kinase Sgk2; DE EC=2.7.11.1; DE AltName: Full=Serum/glucocorticoid-regulated kinase 2; GN Name=SGK2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), TISSUE SPECIFICITY, RP PHOSPHORYLATION AT THR-193, AND MUTAGENESIS OF SER-356. RX PubMed=10548550; DOI=10.1042/bj3440189; RA Kobayashi T., Deak M., Morrice N., Cohen P.; RT "Characterization of the structure and regulation of two novel isoforms of RT serum- and glucocorticoid-induced protein kinase."; RL Biochem. J. 344:189-197(1999). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3). RA Li H., Nong W., Zhou G., Ke R., Shen C., Zhong G., Zheng Z., Liang M., RA Xiao W., Lin L., Yang S.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=11780052; DOI=10.1038/414865a; RA Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R., RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L., RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P., RA Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D., RA Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G., RA Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E., RA Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D., RA Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P., RA Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E., RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J., RA Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D., RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S., RA Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D., RA Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A., RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T., RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I., RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M., RA Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D., RA Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M., RA Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A., RA Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L., RA Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L., RA Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 20."; RL Nature 414:865-871(2001). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain, and Colon; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP FUNCTION IN THE REGULATION OF NA(+)/K(+) ATPASE. RX PubMed=12590200; DOI=10.1159/000068699; RA Henke G., Setiawan I., Boehmer C., Lang F.; RT "Activation of Na+/K+-ATPase by the serum and glucocorticoid-dependent RT kinase isoforms."; RL Kidney Blood Press. Res. 25:370-374(2002). RN [7] RP FUNCTION. RX PubMed=12397388; DOI=10.1007/s00424-002-0873-2; RA Gamper N., Fillon S., Feng Y., Friedrich B., Lang P.A., Henke G., RA Huber S.M., Kobayashi T., Cohen P., Lang F.; RT "K(+) channel activation by all three isoforms of serum- and RT glucocorticoid-dependent protein kinase SGK."; RL Pflugers Arch. 445:60-66(2002). RN [8] RP FUNCTION IN THE REGULATION OF KCNE1 AND KCNQ1. RX PubMed=12634932; DOI=10.1007/s00424-002-0982-y; RA Embark H.M., Boehmer C., Vallon V., Luft F., Lang F.; RT "Regulation of KCNE1-dependent K(+) current by the serum and RT glucocorticoid-inducible kinase (SGK) isoforms."; RL Pflugers Arch. 445:601-606(2003). RN [9] RP FUNCTION IN THE REGULATION OF SCNN1A/ENAC. RX PubMed=12632189; DOI=10.1007/s00424-002-0993-8; RA Friedrich B., Feng Y., Cohen P., Risler T., Vandewalle A., Broeer S., RA Wang J., Pearce D., Lang F.; RT "The serine/threonine kinases SGK2 and SGK3 are potent stimulators of the RT epithelial Na+ channel alpha,beta,gamma-ENaC."; RL Pflugers Arch. 445:693-696(2003). RN [10] RP FUNCTION IN THE REGULATION OF KCNA3/KV1.3. RX PubMed=15040001; DOI=10.1002/jcp.10430; RA Henke G., Maier G., Wallisch S., Boehmer C., Lang F.; RT "Regulation of the voltage gated K+ channel Kv1.3 by the ubiquitin ligase RT Nedd4-2 and the serum and glucocorticoid inducible kinase SGK1."; RL J. Cell. Physiol. 199:194-199(2004). RN [11] RP FUNCTION IN THE REGULATION OF SLC6A19. RX PubMed=20511718; DOI=10.1159/000315092; RA Boehmer C., Sopjani M., Klaus F., Lindner R., Laufer J., Jeyaraj S., RA Lang F., Palmada M.; RT "The serum and glucocorticoid inducible kinases SGK1-3 stimulate the RT neutral amino acid transporter SLC6A19."; RL Cell. Physiol. Biochem. 25:723-732(2010). RN [12] RP FUNCTION IN THE REGULATION OF SLC9A3/NHE3, AND SUBCELLULAR LOCATION. RX PubMed=21865597; DOI=10.1091/mbc.e11-04-0328; RA He P., Lee S.J., Lin S., Seidler U., Lang F., Fejes-Toth G., RA Naray-Fejes-Toth A., Yun C.C.; RT "Serum- and glucocorticoid-induced kinase 3 in recycling endosomes mediates RT acute activation of Na+/H+ exchanger NHE3 by glucocorticoids."; RL Mol. Biol. Cell 22:3812-3825(2011). RN [13] RP REVIEW. RX PubMed=16460280; DOI=10.1146/annurev.physiol.68.040104.131654; RA Loffing J., Flores S.Y., Staub O.; RT "Sgk kinases and their role in epithelial transport."; RL Annu. Rev. Physiol. 68:461-490(2006). RN [14] RP REVIEW ON FUNCTION. RX PubMed=20919962; DOI=10.3109/08977194.2010.518616; RA Bruhn M.A., Pearson R.B., Hannan R.D., Sheppard K.E.; RT "Second AKT: the rise of SGK in cancer signalling."; RL Growth Factors 28:394-408(2010). RN [15] RP VARIANTS [LARGE SCALE ANALYSIS] LYS-199 AND TYR-289, AND VARIANT THR-12 RP (ISOFORM 2). RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase which is involved in the CC regulation of a wide variety of ion channels, membrane transporters, CC cell growth, survival and proliferation. Up-regulates Na(+) channels: CC SCNN1A/ENAC, K(+) channels: KCNA3/Kv1.3, KCNE1 and KCNQ1, amino acid CC transporter: SLC6A19, glutamate transporter: SLC1A6/EAAT4, glutamate CC receptors: GRIA1/GLUR1 and GRIK2/GLUR6, Na(+)/H(+) exchanger: CC SLC9A3/NHE3, and the Na(+)/K(+) ATPase. {ECO:0000269|PubMed:12397388, CC ECO:0000269|PubMed:12590200, ECO:0000269|PubMed:12632189, CC ECO:0000269|PubMed:12634932, ECO:0000269|PubMed:15040001, CC ECO:0000269|PubMed:20511718, ECO:0000269|PubMed:21865597}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- ACTIVITY REGULATION: Two specific sites, one in the kinase domain (Thr- CC 193) and the other in the C-terminal regulatory region (Ser-356), need CC to be phosphorylated for its full activation. CC -!- INTERACTION: CC Q9HBY8; P08238: HSP90AB1; NbExp=3; IntAct=EBI-3914329, EBI-352572; CC Q9HBY8-2; Q9BW71: HIRIP3; NbExp=5; IntAct=EBI-12143041, EBI-723624; CC Q9HBY8-2; O15305: PMM2; NbExp=5; IntAct=EBI-12143041, EBI-10182608; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:21865597}. Nucleus CC {ECO:0000269|PubMed:21865597}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=alpha; CC IsoId=Q9HBY8-2; Sequence=Displayed; CC Name=2; Synonyms=beta; CC IsoId=Q9HBY8-1; Sequence=VSP_060876; CC Name=3; CC IsoId=Q9HBY8-3; Sequence=VSP_060877; CC -!- TISSUE SPECIFICITY: Highly expressed in liver, kidney and pancreas, and CC at lower levels in brain. {ECO:0000269|PubMed:10548550}. CC -!- PTM: Activated by phosphorylation on Ser-356 by an unknown kinase (may CC be mTORC2 but not confirmed), transforming it into a substrate for CC PDPK1 which then phosphorylates it on Thr-193. CC {ECO:0000269|PubMed:10548550}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. {ECO:0000305}. CC -!- CAUTION: Not regulated by serum or glucocorticoids. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF169034; AAF12757.2; -; mRNA. DR EMBL; AF186470; AAG17012.1; -; mRNA. DR EMBL; AY987010; AAX88805.1; -; mRNA. DR EMBL; BT020098; AAV38901.1; -; mRNA. DR EMBL; Z98752; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC014037; AAH14037.3; -; mRNA. DR EMBL; BC065511; AAH65511.1; -; mRNA. DR CCDS; CCDS13321.1; -. [Q9HBY8-2] DR RefSeq; NP_001186193.1; NM_001199264.2. [Q9HBY8-2] DR RefSeq; NP_733794.1; NM_170693.3. [Q9HBY8-2] DR AlphaFoldDB; Q9HBY8; -. DR SMR; Q9HBY8; -. DR BioGRID; 115416; 42. DR FunCoup; Q9HBY8; 1193. DR IntAct; Q9HBY8; 23. DR STRING; 9606.ENSP00000340608; -. DR BindingDB; Q9HBY8; -. DR ChEMBL; CHEMBL5794; -. DR GuidetoPHARMACOLOGY; 1535; -. DR GlyGen; Q9HBY8; 1 site. DR iPTMnet; Q9HBY8; -. DR PhosphoSitePlus; Q9HBY8; -. DR BioMuta; SGK2; -. DR DMDM; 28558166; -. DR jPOST; Q9HBY8; -. DR MassIVE; Q9HBY8; -. DR PaxDb; 9606-ENSP00000340608; -. DR PeptideAtlas; Q9HBY8; -. DR ProteomicsDB; 81612; -. [Q9HBY8-1] DR ProteomicsDB; 81613; -. [Q9HBY8-2] DR ProteomicsDB; 81614; -. [Q9HBY8-3] DR Antibodypedia; 1638; 331 antibodies from 33 providers. DR DNASU; 10110; -. DR Ensembl; ENST00000341458.10; ENSP00000340608.5; ENSG00000101049.19. [Q9HBY8-2] DR Ensembl; ENST00000373100.7; ENSP00000362192.1; ENSG00000101049.19. [Q9HBY8-2] DR Ensembl; ENST00000423407.7; ENSP00000392795.3; ENSG00000101049.19. [Q9HBY8-2] DR Ensembl; ENST00000426287.3; ENSP00000412214.2; ENSG00000101049.19. [Q9HBY8-2] DR GeneID; 10110; -. DR KEGG; hsa:10110; -. DR MANE-Select; ENST00000373100.7; ENSP00000362192.1; NM_170693.3; NP_733794.1. DR UCSC; uc002xkr.4; human. [Q9HBY8-2] DR AGR; HGNC:13900; -. DR CTD; 10110; -. DR DisGeNET; 10110; -. DR GeneCards; SGK2; -. DR HGNC; HGNC:13900; SGK2. DR HPA; ENSG00000101049; Tissue enhanced (intestine, kidney, liver). DR MIM; 607589; gene. DR OpenTargets; ENSG00000101049; -. DR VEuPathDB; HostDB:ENSG00000101049; -. DR eggNOG; KOG0598; Eukaryota. DR GeneTree; ENSGT00940000153776; -. DR InParanoid; Q9HBY8; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; Q9HBY8; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q9HBY8; -. DR PathwayCommons; Q9HBY8; -. DR Reactome; R-HSA-2672351; Stimuli-sensing channels. DR SignaLink; Q9HBY8; -. DR SIGNOR; Q9HBY8; -. DR Agora; ENSG00000101049; -. DR BioGRID-ORCS; 10110; 13 hits in 1184 CRISPR screens. DR ChiTaRS; SGK2; human. DR GeneWiki; SGK2; -. DR GenomeRNAi; 10110; -. DR Pharos; Q9HBY8; Tchem. DR PRO; PR:Q9HBY8; -. DR Proteomes; UP000005640; Chromosome 20. DR RNAct; Q9HBY8; protein. DR Bgee; ENSG00000101049; Expressed in mucosa of transverse colon and 143 other cell types or tissues. DR ExpressionAtlas; Q9HBY8; baseline and differential. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0015459; F:potassium channel regulator activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0017080; F:sodium channel regulator activity; TAS:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0032411; P:positive regulation of transporter activity; TAS:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; NAS:UniProtKB. DR GO; GO:0001558; P:regulation of cell growth; IEA:UniProtKB-ARBA. DR GO; GO:0042127; P:regulation of cell population proliferation; IEA:UniProtKB-ARBA. DR CDD; cd05603; STKc_SGK2; 1. DR FunFam; 1.10.510.10:FF:000065; Non-specific serine/threonine protein kinase; 1. DR FunFam; 3.30.200.20:FF:000030; Non-specific serine/threonine protein kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cytoplasm; Kinase; Nucleotide-binding; KW Nucleus; Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..367 FT /note="Serine/threonine-protein kinase Sgk2" FT /id="PRO_0000086646" FT DOMAIN 35..292 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 293..367 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT REGION 1..26 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 68..78 FT /note="Nuclear localization signal" FT /evidence="ECO:0000250" FT ACT_SITE 159 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 41..49 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 64 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 10 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8R4U9" FT MOD_RES 193 FT /note="Phosphothreonine; by PDPK1" FT /evidence="ECO:0000269|PubMed:10548550" FT MOD_RES 334 FT /note="Phosphoserine" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT MOD_RES 356 FT /note="Phosphoserine" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT MOD_RES 357 FT /note="Phosphotyrosine" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT VAR_SEQ 1 FT /note="M -> MQGLLTSGRKPSGGGRCTGRGGWRGQWCLKPWMGGADPPTPTLSCLL FT LPVPPELPDHCYRM (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_060876" FT VAR_SEQ 1 FT /note="M -> MQGLLTSGRKPSGGGRCTELPDHCYRM (in isoform 3)" FT /evidence="ECO:0000305" FT /id="VSP_060877" FT VARIANT 199 FT /note="E -> K (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041074" FT VARIANT 289 FT /note="H -> Y (in dbSNP:rs35793869)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041075" FT MUTAGEN 356 FT /note="S->D: Increased activation." FT /evidence="ECO:0000269|PubMed:10548550" FT CONFLICT 108 FT /note="K -> E (in Ref. 2; AAX88805)" FT /evidence="ECO:0000305" FT CONFLICT 148 FT /note="G -> D (in Ref. 3; AAV38901)" FT /evidence="ECO:0000305" FT CONFLICT 277 FT /note="L -> P (in Ref. 2; AAX88805)" FT /evidence="ECO:0000305" FT VARIANT Q9HBY8-1:12 FT /note="S -> T (in dbSNP:rs33969356)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_083966" SQ SEQUENCE 367 AA; 41175 MW; E53F1ABE253F648B CRC64; MNSSPAGTPS PQPSRANGNI NLGPSANPNA QPTDFDFLKV IGKGNYGKVL LAKRKSDGAF YAVKVLQKKS ILKKKEQSHI MAERSVLLKN VRHPFLVGLR YSFQTPEKLY FVLDYVNGGE LFFHLQRERR FLEPRARFYA AEVASAIGYL HSLNIIYRDL KPENILLDCQ GHVVLTDFGL CKEGVEPEDT TSTFCGTPEY LAPEVLRKEP YDRAVDWWCL GAVLYEMLHG LPPFYSQDVS QMYENILHQP LQIPGGRTVA ACDLLQSLLH KDQRQRLGSK ADFLEIKNHV FFSPINWDDL YHKRLTPPFN PNVTGPADLK HFDPEFTQEA VSKSIGCTPD TVASSSGASS AFLGFSYAPE DDDILDC // ID SLK_HUMAN Reviewed; 1235 AA. AC Q9H2G2; D3DRA0; D3DRA1; O00211; Q6P1Z4; Q86WU7; Q86WW1; Q92603; Q9NQL0; AC Q9NQL1; DT 02-MAY-2006, integrated into UniProtKB/Swiss-Prot. DT 01-MAR-2001, sequence version 1. DT 28-JAN-2026, entry version 206. DE RecName: Full=STE20-like serine/threonine-protein kinase; DE Short=STE20-like kinase; DE Short=hSLK; DE EC=2.7.11.1; DE AltName: Full=CTCL tumor antigen se20-9; DE AltName: Full=STE20-related serine/threonine-protein kinase; DE Short=STE20-related kinase; DE AltName: Full=Serine/threonine-protein kinase 2; GN Name=SLK; Synonyms=KIAA0204, STK2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY, RP PHOSPHORYLATION, AND MUTAGENESIS OF LYS-63. RC TISSUE=Lung carcinoma; RX PubMed=10699464; DOI=10.1016/s0167-4889(99)00164-0; RA Yamada E., Tsujikawa K., Itoh S., Kameda Y., Kohama Y., Yamamoto H.; RT "Molecular cloning and characterization of a novel human STE20-like kinase, RT hSLK."; RL Biochim. Biophys. Acta 1495:250-262(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Testis; RX PubMed=11149944; DOI=10.1073/pnas.98.2.629; RA Eichmueller S., Usener D., Dummer R., Stein A., Thiel D., Schadendorf D.; RT "Serological detection of cutaneous T-cell lymphoma-associated antigens."; RL Proc. Natl. Acad. Sci. U.S.A. 98:629-634(2001). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Bone marrow; RX PubMed=9039502; DOI=10.1093/dnares/3.5.321; RA Nagase T., Seki N., Ishikawa K., Ohira M., Kawarabayasi Y., Ohara O., RA Tanaka A., Kotani H., Miyajima N., Nomura N.; RT "Prediction of the coding sequences of unidentified human genes. VI. The RT coding sequences of 80 new genes (KIAA0201-KIAA0280) deduced by analysis of RT cDNA clones from cell line KG-1 and brain."; RL DNA Res. 3:321-329(1996). RN [4] RP SEQUENCE REVISION. RA Ohara O., Nagase T., Kikuno R., Nomura N.; RL Submitted (AUG-1996) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164054; DOI=10.1038/nature02462; RA Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L., RA Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K., RA Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L., RA Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P., RA Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P., RA Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N., RA Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A., RA Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C., RA Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D., RA Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C., RA Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K., RA Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A., RA Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S., RA McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S., RA Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., RA Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., RA Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M., RA Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A., RA Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P., RA Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y., RA Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D., RA Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 10."; RL Nature 429:375-381(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Testis, and Uterus; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-189; SER-330; SER-565 AND RP SER-655, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-189; SER-347; SER-348; RP SER-571; SER-777; SER-779 AND SER-818, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-189; SER-344 AND SER-565, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-779, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-189; SER-571; SER-779 AND RP THR-1097, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-347; SER-348; SER-565 RP AND SER-571, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-189; SER-341; RP SER-518; SER-565; SER-571; SER-779; THR-814 AND SER-818, AND IDENTIFICATION RP BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-372; SER-518; SER-565; RP THR-569 AND SER-571, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [17] RP VARIANTS [LARGE SCALE ANALYSIS] LYS-405; TYR-552; GLN-604; GLY-658; RP THR-679; ASN-683 AND ILE-697. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [18] RP VARIANT 472-GLU--SER-1235 DEL. RX PubMed=28940097; DOI=10.1007/s00439-017-1843-2; RA Anazi S., Maddirevula S., Salpietro V., Asi Y.T., Alsahli S., Alhashem A., RA Shamseldin H.E., AlZahrani F., Patel N., Ibrahim N., Abdulwahab F.M., RA Hashem M., Alhashmi N., Al Murshedi F., Al Kindy A., Alshaer A., RA Rumayyan A., Al Tala S., Kurdi W., Alsaman A., Alasmari A., Banu S., RA Sultan T., Saleh M.M., Alkuraya H., Salih M.A., Aldhalaan H., Ben-Omran T., RA Al Musafri F., Ali R., Suleiman J., Tabarki B., El-Hattab A.W., Bupp C., RA Alfadhel M., Al Tassan N., Monies D., Arold S.T., Abouelhoda M., RA Lashley T., Houlden H., Faqeih E., Alkuraya F.S.; RT "Expanding the genetic heterogeneity of intellectual disability."; RL Hum. Genet. 136:1419-1429(2017). RN [19] RP ERRATUM OF PUBMED:28940097. RX PubMed=29288388; DOI=10.1007/s00439-017-1859-7; RA Anazi S., Maddirevula S., Salpietro V., Asi Y.T., Alsahli S., Alhashem A., RA Shamseldin H.E., AlZahrani F., Patel N., Ibrahim N., Abdulwahab F.M., RA Hashem M., Alhashmi N., Al Murshedi F., Al Kindy A., Alshaer A., RA Rumayyan A., Al Tala S., Kurdi W., Alsaman A., Alasmari A., Banu S., RA Sultan T., Saleh M.M., Alkuraya H., Salih M.A., Aldhalaan H., Ben-Omran T., RA Al Musafri F., Ali R., Suleiman J., Tabarki B., El-Hattab A.W., Bupp C., RA Alfadhel M., Al Tassan N., Monies D., Arold S.T., Abouelhoda M., RA Lashley T., Houlden H., Faqeih E., Alkuraya F.S.; RT "Correction to: Expanding the genetic heterogeneity of intellectual RT disability."; RL Hum. Genet. 137:105-109(2018). CC -!- FUNCTION: Mediates apoptosis and actin stress fiber dissolution. CC {ECO:0000250}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- INTERACTION: CC Q9H2G2; Q9H2G2: SLK; NbExp=3; IntAct=EBI-1022272, EBI-1022272; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q9H2G2-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9H2G2-2; Sequence=VSP_018100; CC -!- TISSUE SPECIFICITY: Ubiquitously expressed. Highest expression is found CC in heart and in skeletal muscle. {ECO:0000269|PubMed:10699464}. CC -!- PTM: Proteolytically cleaved by caspase-3. CC -!- PTM: Autophosphorylated. {ECO:0000269|PubMed:10699464}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr CC protein kinase family. STE20 subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH47762.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence starting in position 611.; Evidence={ECO:0000305}; CC Sequence=AAH47885.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence starting in position 422.; Evidence={ECO:0000305}; CC Sequence=AAH64804.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence starting in position 614.; Evidence={ECO:0000305}; CC Sequence=BAA13195.2; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB002804; BAA19655.1; -; mRNA. DR EMBL; AF273048; AAG34908.1; -; mRNA. DR EMBL; D86959; BAA13195.2; ALT_SEQ; mRNA. DR EMBL; AL360170; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL138761; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471066; EAW49615.1; -; Genomic_DNA. DR EMBL; CH471066; EAW49616.1; -; Genomic_DNA. DR EMBL; CH471066; EAW49617.1; -; Genomic_DNA. DR EMBL; CH471066; EAW49618.1; -; Genomic_DNA. DR EMBL; BC047762; AAH47762.1; ALT_SEQ; mRNA. DR EMBL; BC047885; AAH47885.1; ALT_SEQ; mRNA. DR EMBL; BC064804; AAH64804.1; ALT_SEQ; mRNA. DR EMBL; BC111565; AAI11566.1; -; mRNA. DR CCDS; CCDS7553.1; -. [Q9H2G2-1] DR CCDS; CCDS76334.1; -. [Q9H2G2-2] DR RefSeq; NP_001291672.1; NM_001304743.2. [Q9H2G2-2] DR RefSeq; NP_055535.2; NM_014720.3. [Q9H2G2-1] DR PDB; 2J51; X-ray; 2.10 A; A=19-320. DR PDB; 2JFL; X-ray; 2.20 A; A=19-320. DR PDB; 2JFM; X-ray; 2.85 A; A=19-320. DR PDB; 2UV2; X-ray; 2.30 A; A=19-320. DR PDB; 4USF; X-ray; 1.75 A; A/B=19-320. DR PDB; 6HVD; X-ray; 1.63 A; A=19-320. DR PDB; 8BEM; X-ray; 2.60 A; A/B/D/G=19-319. DR PDBsum; 2J51; -. DR PDBsum; 2JFL; -. DR PDBsum; 2JFM; -. DR PDBsum; 2UV2; -. DR PDBsum; 4USF; -. DR PDBsum; 6HVD; -. DR PDBsum; 8BEM; -. DR AlphaFoldDB; Q9H2G2; -. DR PCDDB; Q9H2G2; -. DR SMR; Q9H2G2; -. DR BioGRID; 115096; 194. DR FunCoup; Q9H2G2; 2503. DR IntAct; Q9H2G2; 85. DR MINT; Q9H2G2; -. DR STRING; 9606.ENSP00000358770; -. DR BindingDB; Q9H2G2; -. DR ChEMBL; CHEMBL4202; -. DR DrugBank; DB07853; 2-[4-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl]iminocyclohexa-2,5-dien-1-yl]acetonitrile. DR DrugBank; DB06616; Bosutinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB07664; K-00546. DR DrugCentral; Q9H2G2; -. DR GuidetoPHARMACOLOGY; 2200; -. DR GlyGen; Q9H2G2; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q9H2G2; -. DR MetOSite; Q9H2G2; -. DR PhosphoSitePlus; Q9H2G2; -. DR SwissPalm; Q9H2G2; -. DR BioMuta; SLK; -. DR DMDM; 74762732; -. DR CPTAC; CPTAC-2845; -. DR CPTAC; CPTAC-2948; -. DR jPOST; Q9H2G2; -. DR MassIVE; Q9H2G2; -. DR PaxDb; 9606-ENSP00000358770; -. DR PeptideAtlas; Q9H2G2; -. DR ProteomicsDB; 80544; -. [Q9H2G2-1] DR ProteomicsDB; 80545; -. [Q9H2G2-2] DR Pumba; Q9H2G2; -. DR Antibodypedia; 18194; 291 antibodies from 34 providers. DR DNASU; 9748; -. DR Ensembl; ENST00000335753.8; ENSP00000336824.4; ENSG00000065613.16. [Q9H2G2-2] DR Ensembl; ENST00000369755.4; ENSP00000358770.3; ENSG00000065613.16. [Q9H2G2-1] DR GeneID; 9748; -. DR KEGG; hsa:9748; -. DR MANE-Select; ENST00000369755.4; ENSP00000358770.3; NM_014720.4; NP_055535.2. DR UCSC; uc001kxo.2; human. [Q9H2G2-1] DR AGR; HGNC:11088; -. DR ClinPGx; PA35941; -. DR CTD; 9748; -. DR DisGeNET; 9748; -. DR GeneCards; SLK; -. DR HGNC; HGNC:11088; SLK. DR HPA; ENSG00000065613; Low tissue specificity. DR MalaCards; SLK; -. DR MIM; 616563; gene. DR OpenTargets; ENSG00000065613; -. DR VEuPathDB; HostDB:ENSG00000065613; -. DR eggNOG; KOG0579; Eukaryota. DR GeneTree; ENSGT00940000156184; -. DR HOGENOM; CLU_001965_3_0_1; -. DR InParanoid; Q9H2G2; -. DR OMA; DESCADS; -. DR OrthoDB; 10027016at2759; -. DR PAN-GO; Q9H2G2; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q9H2G2; -. DR PathwayCommons; Q9H2G2; -. DR Reactome; R-HSA-8980692; RHOA GTPase cycle. DR Reactome; R-HSA-9013026; RHOB GTPase cycle. DR Reactome; R-HSA-9013106; RHOC GTPase cycle. DR SignaLink; Q9H2G2; -. DR SIGNOR; Q9H2G2; -. DR Agora; ENSG00000065613; -. DR BioGRID-ORCS; 9748; 24 hits in 1189 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; SLK; human. DR EvolutionaryTrace; Q9H2G2; -. DR GeneWiki; SLK_(gene); -. DR GenomeRNAi; 9748; -. DR Pharos; Q9H2G2; Tchem. DR PRO; PR:Q9H2G2; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; Q9H2G2; protein. DR Bgee; ENSG00000065613; Expressed in esophagus squamous epithelium and 213 other cell types or tissues. DR ExpressionAtlas; Q9H2G2; baseline and differential. DR GO; GO:0031252; C:cell leading edge; ISS:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0031122; P:cytoplasmic microtubule organization; IMP:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0042981; P:regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0030334; P:regulation of cell migration; IMP:UniProtKB. DR GO; GO:0051893; P:regulation of focal adhesion assembly; IDA:UniProtKB. DR CDD; cd06643; STKc_SLK; 1. DR FunFam; 1.10.510.10:FF:000081; STE20-like serine/threonine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000120; STE20-like serine/threonine-protein kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR022165; PKK. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051585; STE20_Ser/Thr_Kinases. DR InterPro; IPR001943; UVR_dom. DR PANTHER; PTHR46538:SF1; NON-SPECIFIC SERINE_THREONINE PROTEIN KINASE; 1. DR PANTHER; PTHR46538; PROTEIN KINASE DOMAIN-CONTAINING PROTEIN; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF12474; PKK; 2. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50151; UVR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Apoptosis; ATP-binding; Coiled coil; KW Cytoplasm; Kinase; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..1235 FT /note="STE20-like serine/threonine-protein kinase" FT /id="PRO_0000233239" FT DOMAIN 34..292 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 875..910 FT /note="UVR" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00217" FT REGION 309..351 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 363..393 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 421..441 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 519..539 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 613..760 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 826..1069 FT /evidence="ECO:0000255" FT COILED 1109..1183 FT /evidence="ECO:0000255" FT COMPBIAS 312..328 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 421..432 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 522..539 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 638..650 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 679..695 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 749..760 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 155 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 40..48 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 63 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 438..439 FT /note="Cleavage; by caspase-3" FT /evidence="ECO:0000250" FT MOD_RES 14 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 183 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:O54988" FT MOD_RES 189 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 330 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 340 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O08815" FT MOD_RES 341 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 344 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 347 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692" FT MOD_RES 348 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692" FT MOD_RES 354 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O54988" FT MOD_RES 372 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 518 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 565 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 569 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 571 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 647 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O54988" FT MOD_RES 655 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 667 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O54988" FT MOD_RES 777 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 779 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 814 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 818 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1097 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:20068231" FT VAR_SEQ 929..959 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10699464, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:9039502" FT /id="VSP_018100" FT VARIANT 405 FT /note="Q -> K (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041080" FT VARIANT 472..1235 FT /note="Missing (found in a patient with global FT developmental delay; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28940097" FT /id="VAR_084656" FT VARIANT 552 FT /note="C -> Y (in dbSNP:rs805657)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041081" FT VARIANT 604 FT /note="E -> Q (in an ovarian serous carcinoma sample; FT somatic mutation; dbSNP:rs190220654)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041082" FT VARIANT 658 FT /note="A -> G (in dbSNP:rs56400929)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041083" FT VARIANT 666 FT /note="G -> E (in dbSNP:rs7071400)" FT /id="VAR_051666" FT VARIANT 679 FT /note="I -> T (in dbSNP:rs34326537)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041084" FT VARIANT 683 FT /note="K -> N (in dbSNP:rs35389916)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041085" FT VARIANT 697 FT /note="T -> I (in dbSNP:rs3740469)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041086" FT MUTAGEN 63 FT /note="K->R: Loss of activity." FT /evidence="ECO:0000269|PubMed:10699464" FT CONFLICT 5 FT /note="N -> S (in Ref. 3; BAA13195)" FT /evidence="ECO:0000305" FT STRAND 25..28 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 30..32 FT /evidence="ECO:0007829|PDB:6HVD" FT STRAND 34..41 FT /evidence="ECO:0007829|PDB:6HVD" FT STRAND 48..53 FT /evidence="ECO:0007829|PDB:6HVD" FT TURN 54..56 FT /evidence="ECO:0007829|PDB:6HVD" FT STRAND 59..66 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 70..85 FT /evidence="ECO:0007829|PDB:6HVD" FT STRAND 94..100 FT /evidence="ECO:0007829|PDB:6HVD" FT STRAND 103..109 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 116..123 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 129..148 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 158..160 FT /evidence="ECO:0007829|PDB:6HVD" FT STRAND 161..163 FT /evidence="ECO:0007829|PDB:6HVD" FT STRAND 169..171 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 181..187 FT /evidence="ECO:0007829|PDB:2J51" FT HELIX 199..202 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 207..209 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 212..214 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 215..230 FT /evidence="ECO:0007829|PDB:6HVD" FT TURN 234..237 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 240..249 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 258..260 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 263..272 FT /evidence="ECO:0007829|PDB:6HVD" FT TURN 277..279 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 283..286 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 290..292 FT /evidence="ECO:0007829|PDB:6HVD" FT HELIX 298..308 FT /evidence="ECO:0007829|PDB:6HVD" SQ SEQUENCE 1235 AA; 142695 MW; 53A43E7CA29B0ED3 CRC64; MSFFNFRKIF KLGSEKKKKQ YEHVKRDLNP EDFWEIIGEL GDGAFGKVYK AQNKETSVLA AAKVIDTKSE EELEDYMVEI DILASCDHPN IVKLLDAFYY ENNLWILIEF CAGGAVDAVM LELERPLTES QIQVVCKQTL DALNYLHDNK IIHRDLKAGN ILFTLDGDIK LADFGVSAKN TRTIQRRDSF IGTPYWMAPE VVMCETSKDR PYDYKADVWS LGITLIEMAE IEPPHHELNP MRVLLKIAKS EPPTLAQPSR WSSNFKDFLK KCLEKNVDAR WTTSQLLQHP FVTVDSNKPI RELIAEAKAE VTEEVEDGKE EDEEEETENS LPIPASKRAS SDLSIASSEE DKLSQNACIL ESVSEKTERS NSEDKLNSKI LNEKPTTDEP EKAVEDINEH ITDAQLEAMT ELHDRTAVIK ENEREKRPKL ENLPDTEDQE TVDINSVSEG KENNIMITLE TNIEHNLKSE EEKDQEKQQM FENKLIKSEE IKDTILQTVD LVSQETGEKE ANIQAVDSEV GLTKEDTQEK LGEDDKTQKD VISNTSDVIG TCEAADVAQK VDEDSAEDTQ SNDGKEVVEV GQKLINKPMV GPEAGGTKEV PIKEIVEMNE IEEGKNKEQA INSSENIMDI NEEPGTTEGE EITESSSTEE MEVRSVVADT DQKALGSEVQ DASKVTTQID KEKKEIPVSI KKEPEVTVVS QPTEPQPVLI PSININSDSG ENKEEIGSLS KTETILPPES ENPKENDNDS GTGSTADTSS IDLNLSISSF LSKTKDSGSI SLQETRRQKK TLKKTRKFIV DGVEVSVTTS KIVTDSDSKT EELRFLRRQE LRELRFLQKE EQRAQQQLNS KLQQQREQIF RRFEQEMMSK KRQYDQEIEN LEKQQKQTIE RLEQEHTNRL RDEAKRIKGE QEKELSKFQN MLKNRKKEVI NEVEKAPKEL RKELMKRRKE ELAQSQHAQE QEFVQKQQQE LDGSLKKIIQ QQKAELANIE RECLNNKQQL MRAREAAIWE LEERHLQEKH QLLKQQLKDQ YFMQRHQLLK RHEKETEQMQ RYNQRLIEEL KNRQTQERAR LPKIQRSEAK TRMAMFKKSL RINSTATPDQ DRDKIKQFAA QEEKRQKNER MAQHQKHENQ MRDLQLQCEA NVRELHQLQN EKCHLLVEHE TQKLKELDEE HSQELKEWRE KLRPRKKTLE EEFARKLQEQ EVFFKMTGES ECLNPSTQSR ISKFYPIPSL HSTGS // ID SLN11_HUMAN Reviewed; 901 AA. AC Q7Z7L1; E1P643; Q8N3S8; Q8N762; Q8TEE0; DT 03-APR-2007, integrated into UniProtKB/Swiss-Prot. DT 30-NOV-2010, sequence version 2. DT 28-JAN-2026, entry version 167. DE RecName: Full=Schlafen family member 11 {ECO:0000305}; DE EC=3.1.-.- {ECO:0000269|PubMed:29395061, ECO:0000269|PubMed:36115853}; GN Name=SLFN11 {ECO:0000312|HGNC:HGNC:26633}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS PHE-121 AND ASP-301. RC TISSUE=Spleen; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASP-301. RC TISSUE=Skeletal muscle; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASP-301. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASP-301. RC TISSUE=Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP INDUCTION. RX PubMed=20956525; DOI=10.1074/jbc.m110.151076; RA Katsoulidis E., Mavrommatis E., Woodard J., Shields M.A., Sassano A., RA Carayol N., Sawicki K.T., Munshi H.G., Platanias L.C.; RT "Role of interferon {alpha} (IFN{alpha})-inducible Schlafen-5 in regulation RT of anchorage-independent growth and invasion of malignant melanoma cells."; RL J. Biol. Chem. 285:40333-40341(2010). RN [7] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [8] RP FUNCTION, TRNA-BINDING, AND INDUCTION. RX PubMed=23000900; DOI=10.1038/nature11433; RA Li M., Kao E., Gao X., Sandig H., Limmer K., Pavon-Eternod M., Jones T.E., RA Landry S., Pan T., Weitzman M.D., David M.; RT "Codon-usage-based inhibition of HIV protein synthesis by human schlafen RT 11."; RL Nature 491:125-128(2012). RN [9] RP FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=22927417; DOI=10.1073/pnas.1205943109; RA Zoppoli G., Regairaz M., Leo E., Reinhold W.C., Varma S., Ballestrero A., RA Doroshow J.H., Pommier Y.; RT "Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to RT DNA-damaging agents."; RL Proc. Natl. Acad. Sci. U.S.A. 109:15030-15035(2012). RN [10] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH RPA1, AND MUTAGENESIS OF RP LYS-605 AND ASP-668. RX PubMed=26658330; DOI=10.15252/embr.201540964; RA Mu Y., Lou J., Srivastava M., Zhao B., Feng X.H., Liu T., Chen J., RA Huang J.; RT "SLFN11 inhibits checkpoint maintenance and homologous recombination RT repair."; RL EMBO Rep. 17:94-109(2016). RN [11] RP INDUCTION, AND INTERACTION WITH DHX9. RX PubMed=26625211; DOI=10.18632/oncotarget.6413; RA Nogales V., Reinhold W.C., Varma S., Martinez-Cardus A., Moutinho C., RA Moran S., Heyn H., Sebio A., Barnadas A., Pommier Y., Esteller M.; RT "Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human RT cancer confers resistance to platinum drugs."; RL Oncotarget 7:3084-3097(2016). RN [12] RP INDUCTION. RX PubMed=28196596; DOI=10.1016/j.ccell.2017.01.006; RA Gardner E.E., Lok B.H., Schneeberger V.E., Desmeules P., Miles L.A., RA Arnold P.K., Ni A., Khodos I., de Stanchina E., Nguyen T., Sage J., RA Campbell J.E., Ribich S., Rekhtman N., Dowlati A., Massion P.P., RA Rudin C.M., Poirier J.T.; RT "Chemosensitive relapse in small cell lung cancer proceeds through an EZH2- RT SLFN11 axis."; RL Cancer Cell 31:286-299(2017). RN [13] RP INDUCTION. RX PubMed=27440269; DOI=10.1158/1078-0432.ccr-16-1040; RA Lok B.H., Gardner E.E., Schneeberger V.E., Ni A., Desmeules P., RA Rekhtman N., de Stanchina E., Teicher B.A., Riaz N., Powell S.N., RA Poirier J.T., Rudin C.M.; RT "PARP inhibitor activity correlates with SLFN11 expression and demonstrates RT synergy with temozolomide in small cell lung cancer."; RL Clin. Cancer Res. 23:523-535(2017). RN [14] RP INDUCTION. RX PubMed=28212573; DOI=10.18632/oncotarget.15338; RA Allison Stewart C., Tong P., Cardnell R.J., Sen T., Li L., Gay C.M., RA Masrorpour F., Fan Y., Bara R.O., Feng Y., Ru Y., Fujimoto J., Kundu S.T., RA Post L.E., Yu K., Shen Y., Glisson B.S., Wistuba I., Heymach J.V., RA Gibbons D.L., Wang J., Byers L.A.; RT "Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and RT SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung RT cancer."; RL Oncotarget 8:28575-28587(2017). RN [15] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH RPA1; MCM3 AND DHX9, AND RP MUTAGENESIS OF GLU-669. RX PubMed=29395061; DOI=10.1016/j.molcel.2018.01.012; RA Murai J., Tang S.W., Leo E., Baechler S.A., Redon C.E., Zhang H., RA Al Abo M., Rajapakse V.N., Nakamura E., Jenkins L.M.M., Aladjem M.I., RA Pommier Y.; RT "SLFN11 blocks stressed replication forks independently of ATR."; RL Mol. Cell 69:371-384(2018). RN [16] RP FUNCTION. RX PubMed=30374083; DOI=10.1038/s41594-018-0142-5; RA Li M., Kao E., Malone D., Gao X., Wang J.Y.J., David M.; RT "DNA damage-induced cell death relies on SLFN11-dependent cleavage of RT distinct type II tRNAs."; RL Nat. Struct. Mol. Biol. 25:1047-1058(2018). RN [17] {ECO:0007744|PDB:7ZEL, ECO:0007744|PDB:7ZEP, ECO:0007744|PDB:7ZES} RP STRUCTURE BY ELECTRON MICROSCOPY (2.80 ANGSTROMS) IN COMPLEX WITH DNA AND RP TRNA, FUNCTION, SUBUNIT, DOMAIN, ACTIVE SITE, CATALYTIC ACTIVITY, RP MUTAGENESIS OF E209A, E214A; K216A; Y234A; D252A AND SER-753, DNA-BINDING, RP AND COFACTOR. RX PubMed=36115853; DOI=10.1038/s41467-022-33123-0; RA Metzner F.J., Wenzl S.J., Kugler M., Krebs S., Hopfner K.P., Lammens K.; RT "Mechanistic understanding of human SLFN11."; RL Nat. Commun. 13:5464-5464(2022). RN [18] RP FUNCTION. RX PubMed=35105802; DOI=10.1073/pnas.2108173119; RA Nightingale K., Potts M., Hunter L.M., Fielding C.A., Zerbe C.M., RA Fletcher-Etherington A., Nobre L., Wang E.C.Y., Strang B.L., Houghton J.W., RA Antrobus R., Suarez N.M., Nichols J., Davison A.J., Stanton R.J., RA Weekes M.P.; RT "Human cytomegalovirus protein RL1 degrades the antiviral factor SLFN11 via RT recruitment of the CRL4 E3 ubiquitin ligase complex."; RL Proc. Natl. Acad. Sci. U.S.A. 119:0-0(2022). CC -!- FUNCTION: Inhibitor of DNA replication that promotes cell death in CC response to DNA damage (PubMed:22927417, PubMed:26658330, CC PubMed:29395061). Acts as a guardian of the genome by killing cells CC with defective replication (PubMed:29395061). Persistently blocks CC stressed replication forks by opening chromatin across replication CC initiation sites at stressed replication forks, possibly leading to CC unwind DNA ahead of the MCM helicase and block fork progression, CC ultimately leading to cell death (PubMed:29395061). Upon DNA damage, CC inhibits translation of ATR or ATM based on distinct codon usage CC without disrupting early DNA damage response signaling CC (PubMed:30374083). Antiviral restriction factor with manganese- CC dependent type II tRNA endoribonuclease (PubMed:36115853). A single CC tRNA molecule is bound and cleaved by the SLFN11 dimer CC (PubMed:36115853). Specifically abrogates the production of CC retroviruses such as human immunodeficiency virus 1 (HIV-1) by acting CC as a specific inhibitor of the synthesis of retroviruses encoded CC proteins in a codon-usage-dependent manner (PubMed:23000900). Impairs CC the replication of human cytomegalovirus (HCMV) and some Flaviviruses CC (PubMed:35105802, PubMed:36115853). Exploits the unique viral codon CC bias towards A/T nucleotides (PubMed:23000900). Also acts as an CC interferon (IFN)-induced antiviral protein which acts as an inhibitor CC of retrovirus protein synthesis (PubMed:23000900). CC {ECO:0000269|PubMed:22927417, ECO:0000269|PubMed:23000900, CC ECO:0000269|PubMed:26658330, ECO:0000269|PubMed:29395061, CC ECO:0000269|PubMed:30374083, ECO:0000269|PubMed:35105802, CC ECO:0000269|PubMed:36115853}. CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:36115853}; CC -!- SUBUNIT: Homodimer (PubMed:36115853). Interacts with MCM3 CC (PubMed:29395061). Interacts with DHX9 (PubMed:26625211, CC PubMed:29395061). Interacts with RPA1 (PubMed:26658330, CC PubMed:29395061). {ECO:0000269|PubMed:26625211, CC ECO:0000269|PubMed:26658330, ECO:0000269|PubMed:29395061, CC ECO:0000269|PubMed:36115853}. CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:22927417, CC ECO:0000269|PubMed:26658330, ECO:0000269|PubMed:29395061}. Chromosome CC {ECO:0000269|PubMed:26658330, ECO:0000269|PubMed:29395061}. CC Note=Recruited to stressed replication forks carrying extended RPA CC filaments (PubMed:29395061). Recruited to DNA damage sites via CC interaction with RPA1 (PubMed:26658330, PubMed:29395061). CC {ECO:0000269|PubMed:26658330, ECO:0000269|PubMed:29395061}. CC -!- TISSUE SPECIFICITY: Exhibits a wider expression range in ovarian and CC colon adenocarcinoma than in their corresponding healthy tissues. CC {ECO:0000269|PubMed:22927417}. CC -!- INDUCTION: Down-regulated in small cell lung cancer (SCLC) cells CC resistant to PARP inhibitor drugs (PubMed:26625211, PubMed:27440269, CC PubMed:28196596, PubMed:28212573). Up-regulated by type I interferons, CC poly-IC and poly-dAdT (PubMed:20956525, PubMed:23000900). CC {ECO:0000269|PubMed:20956525, ECO:0000269|PubMed:23000900, CC ECO:0000269|PubMed:26625211, ECO:0000269|PubMed:27440269, CC ECO:0000269|PubMed:28196596, ECO:0000269|PubMed:28212573}. CC -!- DOMAIN: The N-terminus contains an endonuclease domain. The C-terminus CC displays homology to superfamily I DNA/RNA helicases, although it is in CC an autoinhibited conformation. {ECO:0000269|PubMed:36115853}. CC -!- MISCELLANEOUS: Dominant determinant of sensitivity to DNA-damaging CC anticancer drugs: acts by mediating cell death in response to DNA CC damage induced by anticancer drugs (PubMed:29395061). Down-regulated in CC a number of chemoresistant tumors (PubMed:26625211, PubMed:27440269, CC PubMed:28196596, PubMed:28212573). {ECO:0000269|PubMed:26625211, CC ECO:0000269|PubMed:27440269, ECO:0000269|PubMed:28196596, CC ECO:0000269|PubMed:28212573, ECO:0000269|PubMed:29395061}. CC -!- SIMILARITY: Belongs to the Schlafen family. Subgroup III subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAB85010.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK074184; BAB85010.1; ALT_FRAME; mRNA. DR EMBL; AK092241; BAC03835.1; -; mRNA. DR EMBL; AL831964; CAD38606.2; -; mRNA. DR EMBL; AC060766; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471147; EAW80156.1; -; Genomic_DNA. DR EMBL; CH471147; EAW80157.1; -; Genomic_DNA. DR EMBL; CH471147; EAW80158.1; -; Genomic_DNA. DR EMBL; BC052586; AAH52586.1; -; mRNA. DR CCDS; CCDS11294.1; -. DR RefSeq; NP_001098057.1; NM_001104587.2. DR RefSeq; NP_001098058.1; NM_001104588.2. DR RefSeq; NP_001098059.1; NM_001104589.2. DR RefSeq; NP_001098060.1; NM_001104590.2. DR RefSeq; NP_001362936.1; NM_001376007.1. DR RefSeq; NP_001362937.1; NM_001376008.1. DR RefSeq; NP_001362938.1; NM_001376009.1. DR RefSeq; NP_001362939.1; NM_001376010.1. DR RefSeq; NP_001362940.1; NM_001376011.1. DR RefSeq; NP_001374087.1; NM_001387158.1. DR RefSeq; NP_001374088.1; NM_001387159.1. DR RefSeq; NP_001374089.1; NM_001387160.1. DR RefSeq; NP_001374090.1; NM_001387161.1. DR RefSeq; NP_001374091.1; NM_001387162.1. DR RefSeq; NP_001374092.1; NM_001387163.1. DR RefSeq; NP_689483.3; NM_152270.3. DR RefSeq; XP_047292998.1; XM_047437042.1. DR PDB; 7ZEL; EM; 2.80 A; A/B=1-901. DR PDB; 7ZEP; EM; 3.20 A; A/B=1-901. DR PDB; 7ZES; EM; 3.10 A; A/B=1-901. DR PDB; 9ERD; EM; 3.72 A; A=1-901. DR PDB; 9ERE; EM; 2.82 A; A/B=1-901. DR PDB; 9ERF; EM; 2.64 A; A/B=1-901. DR PDB; 9GMW; EM; 3.00 A; A/B=1-901. DR PDB; 9GMX; EM; 2.82 A; A/B=1-901. DR PDBsum; 7ZEL; -. DR PDBsum; 7ZEP; -. DR PDBsum; 7ZES; -. DR PDBsum; 9ERD; -. DR PDBsum; 9ERE; -. DR PDBsum; 9ERF; -. DR PDBsum; 9GMW; -. DR PDBsum; 9GMX; -. DR AlphaFoldDB; Q7Z7L1; -. DR EMDB; EMD-14690; -. DR EMDB; EMD-14691; -. DR EMDB; EMD-14692; -. DR EMDB; EMD-19912; -. DR EMDB; EMD-19913; -. DR EMDB; EMD-19914; -. DR EMDB; EMD-51456; -. DR EMDB; EMD-51457; -. DR SMR; Q7Z7L1; -. DR BioGRID; 124851; 380. DR FunCoup; Q7Z7L1; 1154. DR IntAct; Q7Z7L1; 18. DR MINT; Q7Z7L1; -. DR STRING; 9606.ENSP00000378067; -. DR iPTMnet; Q7Z7L1; -. DR PhosphoSitePlus; Q7Z7L1; -. DR SwissPalm; Q7Z7L1; -. DR BioMuta; SLFN11; -. DR DMDM; 313104011; -. DR jPOST; Q7Z7L1; -. DR MassIVE; Q7Z7L1; -. DR PaxDb; 9606-ENSP00000378067; -. DR PeptideAtlas; Q7Z7L1; -. DR ProteomicsDB; 69561; -. DR Pumba; Q7Z7L1; -. DR Antibodypedia; 15596; 58 antibodies from 17 providers. DR DNASU; 91607; -. DR Ensembl; ENST00000308377.8; ENSP00000312402.4; ENSG00000172716.18. DR Ensembl; ENST00000394566.5; ENSP00000378067.1; ENSG00000172716.18. DR Ensembl; ENST00000685675.1; ENSP00000510787.1; ENSG00000172716.18. DR GeneID; 91607; -. DR KEGG; hsa:91607; -. DR MANE-Select; ENST00000685675.1; ENSP00000510787.1; NM_001376007.1; NP_001362936.1. DR UCSC; uc002hjg.5; human. DR AGR; HGNC:26633; -. DR CIViC; 91607; 3 evidence items across 1 molecular profile. DR ClinPGx; PA144596358; -. DR CTD; 91607; -. DR DisGeNET; 91607; -. DR GeneCards; SLFN11; -. DR HGNC; HGNC:26633; SLFN11. DR HPA; ENSG00000172716; Low tissue specificity. DR MIM; 614953; gene. DR OpenTargets; ENSG00000172716; -. DR VEuPathDB; HostDB:ENSG00000172716; -. DR eggNOG; ENOG502QWKG; Eukaryota. DR GeneTree; ENSGT00410000025651; -. DR HOGENOM; CLU_007071_0_0_1; -. DR InParanoid; Q7Z7L1; -. DR OMA; HKLCVIP; -. DR OrthoDB; 6052143at2759; -. DR PAN-GO; Q7Z7L1; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q7Z7L1; -. DR PathwayCommons; Q7Z7L1; -. DR SignaLink; Q7Z7L1; -. DR Agora; ENSG00000172716; -. DR BioGRID-ORCS; 91607; 17 hits in 1154 CRISPR screens. DR ChiTaRS; SLFN11; human. DR GeneWiki; SLFN11; -. DR GenomeRNAi; 91607; -. DR Pharos; Q7Z7L1; Tbio. DR PRO; PR:Q7Z7L1; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q7Z7L1; protein. DR Bgee; ENSG00000172716; Expressed in monocyte and 140 other cell types or tissues. DR ExpressionAtlas; Q7Z7L1; baseline and differential. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0090734; C:site of DNA damage; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016887; F:ATP hydrolysis activity; IDA:UniProtKB. DR GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW. DR GO; GO:0004519; F:endonuclease activity; IEA:UniProtKB-KW. DR GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW. DR GO; GO:0000049; F:tRNA binding; IDA:UniProtKB. DR GO; GO:0006338; P:chromatin remodeling; IDA:UniProtKB. DR GO; GO:0051607; P:defense response to virus; IMP:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0002376; P:immune system process; IEA:UniProtKB-KW. DR GO; GO:0008156; P:negative regulation of DNA replication; IDA:UniProtKB. DR GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0043111; P:replication fork arrest; IDA:UniProtKB. DR FunFam; 3.30.950.30:FF:000002; Schlafen family member 11; 1. DR FunFam; 3.40.50.300:FF:001322; Schlafen family member 11; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 2. DR Gene3D; 3.30.950.30; Schlafen, AAA domain; 1. DR InterPro; IPR027417; P-loop_NTPase. DR InterPro; IPR031450; Poxin-SLFN/SLFN_N. DR InterPro; IPR029684; Schlafen. DR InterPro; IPR007421; Schlafen_AlbA_2_dom. DR InterPro; IPR038461; Schlafen_AlbA_2_dom_sf. DR InterPro; IPR018647; SLFN_3-like_DNA/RNA_helicase. DR InterPro; IPR048729; SLFN_GTPase-like. DR PANTHER; PTHR12155; SCHLAFEN; 1. DR PANTHER; PTHR12155:SF45; SCHLAFEN FAMILY MEMBER 11; 1. DR Pfam; PF17057; B3R; 1. DR Pfam; PF09848; SLFN-g3_helicase; 1. DR Pfam; PF04326; SLFN_AlbA_2; 1. DR Pfam; PF21026; SLFN_GTPase-like; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. PE 1: Evidence at protein level; KW 3D-structure; Antiviral defense; ATP-binding; Chromosome; DNA damage; KW DNA-binding; Endonuclease; Helicase; Hydrolase; Immunity; Nuclease; KW Nucleotide-binding; Nucleus; Proteomics identification; Reference proteome; KW RNA-binding; tRNA-binding. FT CHAIN 1..901 FT /note="Schlafen family member 11" FT /id="PRO_0000283091" FT ACT_SITE 216 FT /evidence="ECO:0000269|PubMed:36115853" FT BINDING 209 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_note="catalytic" FT /evidence="ECO:0000269|PubMed:36115853" FT BINDING 214 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_note="catalytic" FT /evidence="ECO:0000269|PubMed:36115853" FT BINDING 285 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:36115853" FT BINDING 287 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:36115853" FT BINDING 321 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:36115853" FT BINDING 322 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:36115853" FT BINDING 599..606 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255" FT VARIANT 121 FT /note="V -> F (in dbSNP:rs12453150)" FT /evidence="ECO:0000269|PubMed:14702039" FT /id="VAR_031492" FT VARIANT 301 FT /note="N -> D (in dbSNP:rs4796077)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17974005, FT ECO:0000269|Ref.4" FT /id="VAR_031493" FT VARIANT 489 FT /note="R -> L (in dbSNP:rs9898983)" FT /id="VAR_062186" FT VARIANT 822 FT /note="Y -> C (in dbSNP:rs3803860)" FT /id="VAR_031494" FT MUTAGEN 209 FT /note="E->A: Complete loss of endonuclease activity." FT /evidence="ECO:0000269|PubMed:36115853" FT MUTAGEN 214 FT /note="E->A: Complete loss of endonuclease activity." FT /evidence="ECO:0000269|PubMed:36115853" FT MUTAGEN 216 FT /note="K->A: Complete loss of endonuclease activity." FT /evidence="ECO:0000269|PubMed:36115853" FT MUTAGEN 234 FT /note="Y->A: No effect on endonuclease activity." FT /evidence="ECO:0000269|PubMed:36115853" FT MUTAGEN 252 FT /note="D->A: Slight increase in endonuclease activity." FT /evidence="ECO:0000269|PubMed:36115853" FT MUTAGEN 605 FT /note="K->M: Abolishes ATPase activity without affecting FT its role in DNA damage response; when associated with A- FT 668." FT /evidence="ECO:0000269|PubMed:26658330" FT MUTAGEN 668 FT /note="D->A: Abolishes ATPase activity without affecting FT its role in DNA damage response; when associated with M- FT 605." FT /evidence="ECO:0000269|PubMed:26658330" FT MUTAGEN 669 FT /note="E->Q: Abolishes ATPase activity, leading to abolish FT ability to inhibit DNA replication without affecting FT subcellular location." FT /evidence="ECO:0000269|PubMed:29395061" FT MUTAGEN 753 FT /note="S->D: Complete loss of tRNA cleavage and ssDNA FT binding." FT /evidence="ECO:0000269|PubMed:36115853" FT CONFLICT 20 FT /note="N -> S (in Ref. 1; BAC03835)" FT /evidence="ECO:0000305" FT CONFLICT 143 FT /note="M -> T (in Ref. 1; BAC03835)" FT /evidence="ECO:0000305" FT CONFLICT 324 FT /note="V -> M (in Ref. 2; CAD38606)" FT /evidence="ECO:0000305" FT CONFLICT 665 FT /note="I -> V (in Ref. 1; BAC03835 and 2; CAD38606)" FT /evidence="ECO:0000305" FT STRAND 9..11 FT /evidence="ECO:0007829|PDB:7ZEL" FT STRAND 14..16 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 18..23 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 28..32 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 36..55 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 59..64 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 66..69 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 75..85 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 90..92 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 94..99 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 102..107 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 113..115 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 117..120 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 133..136 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 139..142 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 145..156 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 189..195 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 197..200 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 211..216 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 223..240 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 244..250 FT /evidence="ECO:0007829|PDB:9ERF" FT TURN 252..254 FT /evidence="ECO:0007829|PDB:9ERF" FT TURN 262..264 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 267..280 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 286..288 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 295..304 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 307..317 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 321..324 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 326..328 FT /evidence="ECO:0007829|PDB:9ERE" FT STRAND 332..335 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 338..341 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 344..352 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 384..397 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 402..409 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 410..419 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 423..430 FT /evidence="ECO:0007829|PDB:9ERF" FT TURN 431..433 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 436..443 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 445..448 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 457..465 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 471..478 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 483..500 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 511..517 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 537..539 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 544..559 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 564..585 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 586..588 FT /evidence="ECO:0007829|PDB:9ERF" FT TURN 589..591 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 593..599 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 605..620 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 624..626 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 627..632 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 634..641 FT /evidence="ECO:0007829|PDB:9ERF" FT TURN 642..644 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 645..650 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 651..656 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 664..667 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 670..672 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 675..677 FT /evidence="ECO:0007829|PDB:9GMW" FT HELIX 680..689 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 692..695 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 698..702 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 704..706 FT /evidence="ECO:0007829|PDB:9ERF" FT TURN 718..720 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 723..727 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 735..750 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 754..756 FT /evidence="ECO:0007829|PDB:7ZEL" FT HELIX 760..762 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 776..779 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 785..802 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 806..808 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 809..814 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 816..818 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 819..830 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 831..833 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 841..843 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 846..853 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 855..857 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 862..868 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 875..877 FT /evidence="ECO:0007829|PDB:9ERF" FT HELIX 878..886 FT /evidence="ECO:0007829|PDB:9ERF" FT STRAND 889..896 FT /evidence="ECO:0007829|PDB:9ERF" SQ SEQUENCE 901 AA; 102836 MW; 514FD89CB7C12E8D CRC64; MEANQCPLVV EPSYPDLVIN VGEVTLGEEN RKKLQKIQRD QEKERVMRAA CALLNSGGGV IRMAKKVEHP VEMGLDLEQS LRELIQSSDL QAFFETKQQG RCFYIFVKSW SSGPFPEDRS VKPRLCSLSS SLYRRSETSV RSMDSREAFC FLKTKRKPKI LEEGPFHKIH KGVYQELPNS DPADPNSDPA DLIFQKDYLE YGEILPFPES QLVEFKQFST KHFQEYVKRT IPEYVPAFAN TGGGYLFIGV DDKSREVLGC AKENVDPDSL RRKIEQAIYK LPCVHFCQPQ RPITFTLKIV NVLKRGELYG YACMIRVNPF CCAVFSEAPN SWIVEDKYVC SLTTEKWVGM MTDTDPDLLQ LSEDFECQLS LSSGPPLSRP VYSKKGLEHK KELQQLLFSV PPGYLRYTPE SLWRDLISEH RGLEELINKQ MQPFFRGILI FSRSWAVDLN LQEKPGVICD ALLIAQNSTP ILYTILREQD AEGQDYCTRT AFTLKQKLVN MGGYTGKVCV RAKVLCLSPE SSAEALEAAV SPMDYPASYS LAGTQHMEAL LQSLVIVLLG FRSLLSDQLG CEVLNLLTAQ QYEIFSRSLR KNRELFVHGL PGSGKTIMAM KIMEKIRNVF HCEAHRILYV CENQPLRNFI SDRNICRAET RKTFLRENFE HIQHIVIDEA QNFRTEDGDW YGKAKSITRR AKGGPGILWI FLDYFQTSHL DCSGLPPLSD QYPREELTRI VRNADPIAKY LQKEMQVIRS NPSFNIPTGC LEVFPEAEWS QGVQGTLRIK KYLTVEQIMT CVADTCRRFF DRGYSPKDVA VLVSTAKEVE HYKYELLKAM RKKRVVQLSD ACDMLGDHIV LDSVRRFSGL ERSIVFGIHP RTADPAILPN VLICLASRAK QHLYIFPWGG H // ID SMAD7_HUMAN Reviewed; 426 AA. AC O15105; B7Z773; K7EQ10; O14740; Q6DK23; DT 04-MAY-2001, integrated into UniProtKB/Swiss-Prot. DT 01-JAN-1998, sequence version 1. DT 28-JAN-2026, entry version 228. DE RecName: Full=SMAD family member 7 {ECO:0000312|HGNC:HGNC:6773}; DE Short=SMAD 7 {ECO:0000305}; DE Short=hSMAD7; DE AltName: Full=Mothers against decapentaplegic homolog 7; DE Short=MAD homolog 7; DE Short=Mothers against DPP homolog 7; DE AltName: Full=Mothers against decapentaplegic homolog 8; DE Short=MAD homolog 8; DE Short=Mothers against DPP homolog 8; GN Name=SMAD7 {ECO:0000312|HGNC:HGNC:6773}; Synonyms=MADH7, MADH8; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF RP 409-ARG--ARG-426. RC TISSUE=Umbilical vein endothelial cell; RX PubMed=9215638; DOI=10.1016/s0092-8674(00)80303-7; RA Hayashi H., Abdollah S., Qiu Y., Cai J., Xu Y.-Y., Grinnell B.W., RA Richardson M.A., Topper J.N., Gimbrone M.A. Jr., Wrana J.L., Falb D.; RT "The MAD-related protein Smad7 associates with the TGFbeta receptor and RT functions as an antagonist of TGFbeta signaling."; RL Cell 89:1165-1173(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Umbilical vein endothelial cell; RX PubMed=9256479; DOI=10.1073/pnas.94.17.9314; RA Topper J.N., Cai J., Qui Y., Anderson K.R., Xu Y.-Y., Deeds J.D., RA Feeley R., Gimeno C.J., Woolf E.A., Tayber O., Mays G.G., Sampson B.A., RA Schoen F.J., Gimbrone M.A. Jr., Falb D.; RT "Vascular MADs: two novel MAD-related genes selectively inducible by flow RT in human vascular endothelium."; RL Proc. Natl. Acad. Sci. U.S.A. 94:9314-9319(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=9335507; DOI=10.1038/39369; RA Nakao A., Afrakhte M., Moren A., Nakayama T., Christian J.L., Heuchel R., RA Itoh S., Kawabata M., Heldin N.-E., Heldin C.-H., ten Dijke P.; RT "Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta RT signalling."; RL Nature 389:631-635(1997). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Hagiwara K., Yang K., McMenamin M.G., Freeman A.H., Bennett W.P., RA Nagashima M., Minter A.R., Miyazono K., Takenoshita S., Harris C.C.; RL Submitted (SEP-1997) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND NUCLEOTIDE SEQUENCE RP [LARGE SCALE MRNA] OF 98-271 (ISOFORM 3). RC TISSUE=Pulmonary artery; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16177791; DOI=10.1038/nature03983; RA Nusbaum C., Zody M.C., Borowsky M.L., Kamal M., Kodira C.D., Taylor T.D., RA Whittaker C.A., Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., RA Abouelleil A., Allen N.R., Anderson S., Bloom T., Bugalter B., Butler J., RA Cook A., DeCaprio D., Engels R., Garber M., Gnirke A., Hafez N., Hall J.L., RA Norman C.H., Itoh T., Jaffe D.B., Kuroki Y., Lehoczky J., Lui A., RA Macdonald P., Mauceli E., Mikkelsen T.S., Naylor J.W., Nicol R., Nguyen C., RA Noguchi H., O'Leary S.B., Piqani B., Smith C.L., Talamas J.A., Topham K., RA Totoki Y., Toyoda A., Wain H.M., Young S.K., Zeng Q., Zimmer A.R., RA Fujiyama A., Hattori M., Birren B.W., Sakaki Y., Lander E.S.; RT "DNA sequence and analysis of human chromosome 18."; RL Nature 437:551-555(2005). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP REVIEW. RX PubMed=9759503; DOI=10.1146/annurev.biochem.67.1.753; RA Massague J.; RT "TGF-beta signal transduction."; RL Annu. Rev. Biochem. 67:753-791(1998). RN [9] RP REVIEW. RX PubMed=10647776; DOI=10.1016/s1359-6101(99)00012-x; RA Verschueren K., Huylebroeck D.; RT "Remarkable versatility of Smad proteins in the nucleus of transforming RT growth factor-beta activated cells."; RL Cytokine Growth Factor Rev. 10:187-199(1999). RN [10] RP INTERACTION WITH ACVR1B, AND FUNCTION. RX PubMed=9892009; DOI=10.1210/mend.13.1.0218; RA Lebrun J.J., Takabe K., Chen Y., Vale W.; RT "Roles of pathway-specific and inhibitory Smads in activin receptor RT signaling."; RL Mol. Endocrinol. 13:15-23(1999). RN [11] RP REVIEW. RX PubMed=10708948; DOI=10.1016/s1359-6101(99)00024-6; RA Wrana J.L., Attisano L.; RT "The Smad pathway."; RL Cytokine Growth Factor Rev. 11:5-13(2000). RN [12] RP REVIEW. RX PubMed=10708949; DOI=10.1016/s1359-6101(99)00025-8; RA Miyazono K.; RT "TGF-beta signaling by Smad proteins."; RL Cytokine Growth Factor Rev. 11:15-22(2000). RN [13] RP FUNCTION, MUTAGENESIS OF TYR-211 AND 207-PRO--TYR-211, AND INTERACTION WITH RP SMURF2 AND TGFBR1. RX PubMed=11163210; DOI=10.1016/s1097-2765(00)00134-9; RA Kavsak P., Rasmussen R.K., Causing C.G., Bonni S., Zhu H., Thomsen G.H., RA Wrana J.L.; RT "Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF- RT beta receptor for degradation."; RL Mol. Cell 6:1365-1375(2000). RN [14] RP INTERACTION WITH STAMBP. RX PubMed=11483516; DOI=10.1093/emboj/20.15.4132; RA Itoh F., Asao H., Sugamura K., Heldin C.-H., ten Dijke P., Itoh S.; RT "Promoting bone morphogenetic protein signaling through negative regulation RT of inhibitory Smads."; RL EMBO J. 20:4132-4142(2001). RN [15] RP INTERACTION WITH SMURF1 AND TGFBR1, AND UBIQUITINATION. RX PubMed=11278251; DOI=10.1074/jbc.c100008200; RA Ebisawa T., Fukuchi M., Murakami G., Chiba T., Tanaka K., Imamura T., RA Miyazono K.; RT "Smurf1 interacts with transforming growth factor-beta type I receptor RT through Smad7 and induces receptor degradation."; RL J. Biol. Chem. 276:12477-12480(2001). RN [16] RP INTERACTION WITH ACVR1B, AND FUNCTION. RX PubMed=12023024; DOI=10.1016/s0014-5793(02)02718-7; RA Liu X., Nagarajan R.P., Vale W., Chen Y.; RT "Phosphorylation regulation of the interaction between Smad7 and activin RT type I receptor."; RL FEBS Lett. 519:93-98(2002). RN [17] RP INTERACTION WITH EP300, ACETYLATION AT LYS-64 AND LYS-70, UBIQUITINATION AT RP LYS-64 AND LYS-70, AND MUTAGENESIS OF LYS-64 AND LYS-70. RX PubMed=12408818; DOI=10.1016/s1097-2765(02)00639-1; RA Gronroos E., Hellman U., Heldin C.H., Ericsson J.; RT "Control of Smad7 stability by competition between acetylation and RT ubiquitination."; RL Mol. Cell 10:483-493(2002). RN [18] RP INTERACTION WITH RNF111, UBIQUITINATION, AND SUBCELLULAR LOCATION. RX PubMed=14657019; DOI=10.1093/emboj/cdg632; RA Koinuma D., Shinozaki M., Komuro A., Goto K., Saitoh M., Hanyu A., RA Ebina M., Nukiwa T., Miyazawa K., Imamura T., Miyazono K.; RT "Arkadia amplifies TGF-beta superfamily signaling through degradation of RT Smad7."; RL EMBO J. 22:6458-6470(2003). RN [19] RP FUNCTION, AND INTERACTION WITH PPP1R15A. RX PubMed=14718519; DOI=10.1083/jcb.200307151; RA Shi W., Sun C., He B., Xiong W., Shi X., Yao D., Cao X.; RT "GADD34-PP1c recruited by Smad7 dephosphorylates TGFbeta type I receptor."; RL J. Cell Biol. 164:291-300(2004). RN [20] RP INTERACTION WITH COPS5. RX PubMed=14993265; DOI=10.1128/mcb.24.6.2251-2262.2004; RA Kim B.-C., Lee H.-J., Park S.H., Lee S.R., Karpova T.S., McNally J.G., RA Felici A., Lee D.K., Kim S.-J.; RT "Jab1/CSN5, a component of the COP9 signalosome, regulates transforming RT growth factor beta signaling by binding to Smad7 and promoting its RT degradation."; RL Mol. Cell. Biol. 24:2251-2262(2004). RN [21] RP INTERACTION WITH SMURF2. RX PubMed=16061177; DOI=10.1016/j.molcel.2005.06.028; RA Ogunjimi A.A., Briant D.J., Pece-Barbara N., Le Roy C., Di Guglielmo G.M., RA Kavsak P., Rasmussen R.K., Seet B.T., Sicheri F., Wrana J.L.; RT "Regulation of Smurf2 ubiquitin ligase activity by anchoring the E2 to the RT HECT domain."; RL Mol. Cell 19:297-308(2005). RN [22] RP INTERACTION WITH AXIN1 AND AXIN2, UBIQUITINATION, AND SUBCELLULAR LOCATION. RX PubMed=16601693; DOI=10.1038/sj.emboj.7601057; RA Liu W., Rui H., Wang J., Lin S., He Y., Chen M., Li Q., Ye Z., Zhang S., RA Chan S.C., Chen Y.-G., Han J., Lin S.-C.; RT "Axin is a scaffold protein in TGF-beta signaling that promotes degradation RT of Smad7 by Arkadia."; RL EMBO J. 25:1646-1658(2006). RN [23] RP FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION BY PDPK1, AND INTERACTION RP WITH PDPK1. RX PubMed=17327236; DOI=10.1074/jbc.m609279200; RA Seong H.A., Jung H., Kim K.T., Ha H.; RT "3-Phosphoinositide-dependent PDK1 negatively regulates transforming growth RT factor-beta-induced signaling in a kinase-dependent manner through physical RT interaction with Smad proteins."; RL J. Biol. Chem. 282:12272-12289(2007). RN [24] RP FUNCTION, AND INTERACTION WITH TSC22D1 AND TGFBR1. RX PubMed=21791611; DOI=10.1128/mcb.05448-11; RA Yan X., Zhang J., Pan L., Wang P., Xue H., Zhang L., Gao X., Zhao X., RA Ning Y., Chen Y.G.; RT "TSC-22 promotes transforming growth factor beta-mediated cardiac RT myofibroblast differentiation by antagonizing Smad7 activity."; RL Mol. Cell. Biol. 31:3700-3709(2011). RN [25] RP STRUCTURE BY NMR OF 203-217 IN COMPLEX WITH SMURF2. RX PubMed=16641086; DOI=10.1074/jbc.m601493200; RA Chong P.A., Lin H., Wrana J.L., Forman-Kay J.D.; RT "An expanded WW domain recognition motif revealed by the interaction RT between Smad7 and the E3 ubiquitin ligase Smurf2."; RL J. Biol. Chem. 281:17069-17075(2006). RN [26] RP INVOLVEMENT IN CRCS3. RX PubMed=17934461; DOI=10.1038/ng.2007.18; RG Members of the CORGI consortium; RA Broderick P., Carvajal-Carmona L., Pittman A.M., Webb E., Howarth K., RA Rowan A., Lubbe S., Spain S., Sullivan K., Fielding S., Jaeger E., RA Vijayakrishnan J., Kemp Z., Gorman M., Chandler I., Papaemmanuil E., RA Penegar S., Wood W., Sellick G., Qureshi M., Teixeira A., Domingo E., RA Barclay E., Martin L., Sieber O., Kerr D., Gray R., Peto J., Cazier J.-B., RA Tomlinson I., Houlston R.S.; RT "A genome-wide association study shows that common alleles of SMAD7 RT influence colorectal cancer risk."; RL Nat. Genet. 39:1315-1317(2007). CC -!- FUNCTION: Antagonist of signaling by TGF-beta (transforming growth CC factor) type 1 receptor superfamily members; has been shown to inhibit CC TGF-beta (Transforming growth factor) and activin signaling by CC associating with their receptors thus preventing SMAD2 access CC (PubMed:21791611). Functions as an adapter to recruit SMURF2 to the CC TGF-beta receptor complex. Also acts by recruiting the PPP1R15A-PP1 CC complex to TGFBR1, which promotes its dephosphorylation. Positively CC regulates PDPK1 kinase activity by stimulating its dissociation from CC the 14-3-3 protein YWHAQ which acts as a negative regulator. CC {ECO:0000269|PubMed:11163210, ECO:0000269|PubMed:12023024, CC ECO:0000269|PubMed:14718519, ECO:0000269|PubMed:17327236, CC ECO:0000269|PubMed:21791611, ECO:0000269|PubMed:9892009}. CC -!- SUBUNIT: Interacts with WWP1 (By similarity). Interacts with COPS5. CC Interacts with NEDD4L. Interacts with STAMBP. Interacts with RNF111, CC AXIN1 and AXIN2. Interacts with PPP1R15A. Interacts (via MH2 domain) CC with EP300. Interacts with ACVR1B, SMURF1, SMURF2 and TGFBR1; SMAD7 CC recruits SMURF1 and SMURF2 to the TGF-beta receptor and regulates its CC degradation (PubMed:11163210, PubMed:11278251, PubMed:12023024, CC PubMed:21791611, PubMed:9892009). Interacts with PDPK1 (via PH domain). CC Interacts with TSC22D1/TSC-22; the interaction requires TGF-beta and CC the interaction is inhibited by TGFBR1 (PubMed:21791611). {ECO:0000250, CC ECO:0000269|PubMed:11163210, ECO:0000269|PubMed:11278251, CC ECO:0000269|PubMed:11483516, ECO:0000269|PubMed:12023024, CC ECO:0000269|PubMed:12408818, ECO:0000269|PubMed:14657019, CC ECO:0000269|PubMed:14718519, ECO:0000269|PubMed:14993265, CC ECO:0000269|PubMed:16061177, ECO:0000269|PubMed:16601693, CC ECO:0000269|PubMed:16641086, ECO:0000269|PubMed:17327236, CC ECO:0000269|PubMed:21791611, ECO:0000269|PubMed:9892009}. CC -!- INTERACTION: CC O15105; P36896: ACVR1B; NbExp=3; IntAct=EBI-3861591, EBI-1384128; CC O15105; O15169: AXIN1; NbExp=8; IntAct=EBI-3861591, EBI-710484; CC O15105; Q92905: COPS5; NbExp=10; IntAct=EBI-3861591, EBI-594661; CC O15105; P62942: FKBP1A; NbExp=3; IntAct=EBI-3861591, EBI-1027571; CC O15105; Q96PU5-5: NEDD4L; NbExp=3; IntAct=EBI-3861591, EBI-7196393; CC O15105; Q9HCE7-1: SMURF1; NbExp=4; IntAct=EBI-3861591, EBI-15884081; CC O15105; Q9HAU4: SMURF2; NbExp=7; IntAct=EBI-3861591, EBI-396727; CC O15105; O00308: WWP2; NbExp=5; IntAct=EBI-3861591, EBI-743923; CC O15105; P46937: YAP1; NbExp=7; IntAct=EBI-3861591, EBI-1044059; CC O15105; Q99ML9: Rnf111; Xeno; NbExp=2; IntAct=EBI-3861591, EBI-646015; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:14657019, CC ECO:0000269|PubMed:16601693, ECO:0000269|PubMed:17327236}. Cytoplasm CC {ECO:0000269|PubMed:14657019, ECO:0000269|PubMed:16601693, CC ECO:0000269|PubMed:17327236}. Note=Interaction with NEDD4L or RNF111 CC induces translocation from the nucleus to the cytoplasm CC (PubMed:16601693). TGF-beta stimulates its translocation from the CC nucleus to the cytoplasm. PDPK1 inhibits its translocation from the CC nucleus to the cytoplasm in response to TGF-beta (PubMed:17327236). CC {ECO:0000269|PubMed:16601693, ECO:0000269|PubMed:17327236}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=O15105-1; Sequence=Displayed; CC Name=2; CC IsoId=O15105-2; Sequence=VSP_045197; CC Name=3; CC IsoId=O15105-3; Sequence=VSP_047540; CC -!- TISSUE SPECIFICITY: Ubiquitous with higher expression in the lung and CC vascular endothelium. CC -!- INDUCTION: By TGFB1. CC -!- PTM: Phosphorylation on Ser-249 does not affect its stability, nuclear CC localization or inhibitory function in TGFB signaling; however it CC affects its ability to regulate transcription (By similarity). CC Phosphorylated by PDPK1. {ECO:0000250|UniProtKB:O35253, CC ECO:0000269|PubMed:17327236}. CC -!- PTM: Ubiquitinated by WWP1 (By similarity). Polyubiquitinated by CC RNF111, which is enhanced by AXIN1 and promotes proteasomal degradation CC (PubMed:14657019, PubMed:16601693). In response to TGF-beta, CC ubiquitinated by SMURF1; which promotes its degradation CC (PubMed:11278251). {ECO:0000250|UniProtKB:O35253, CC ECO:0000269|PubMed:11278251, ECO:0000269|PubMed:14657019, CC ECO:0000269|PubMed:16601693}. CC -!- PTM: Acetylation prevents ubiquitination and degradation mediated by CC SMURF1. {ECO:0000269|PubMed:12408818}. CC -!- DISEASE: Colorectal cancer 3 (CRCS3) [MIM:612229]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:17934461}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- SIMILARITY: Belongs to the dwarfin/SMAD family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF010193; AAB81246.1; -; mRNA. DR EMBL; AF015261; AAB81354.1; -; mRNA. DR EMBL; AF026559; AAL68977.1; -; Genomic_DNA. DR EMBL; AF026556; AAL68977.1; JOINED; Genomic_DNA. DR EMBL; AF026557; AAL68977.1; JOINED; Genomic_DNA. DR EMBL; AF026558; AAL68977.1; JOINED; Genomic_DNA. DR EMBL; AK301535; BAH13509.1; -; mRNA. DR EMBL; DA882147; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AC114684; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC074818; AAH74818.2; -; mRNA. DR EMBL; BC074819; AAH74819.2; -; mRNA. DR CCDS; CCDS11936.1; -. [O15105-1] DR CCDS; CCDS54186.1; -. [O15105-2] DR CCDS; CCDS59317.1; -. [O15105-3] DR RefSeq; NP_001177750.1; NM_001190821.2. [O15105-3] DR RefSeq; NP_001177751.1; NM_001190822.2. [O15105-2] DR RefSeq; NP_001177752.1; NM_001190823.1. DR RefSeq; NP_005895.1; NM_005904.4. [O15105-1] DR PDB; 2DJY; NMR; -; B=203-217. DR PDB; 2KXQ; NMR; -; B=203-217. DR PDB; 2LTV; NMR; -; B=206-217. DR PDB; 2LTW; NMR; -; B=205-217. DR PDB; 2LTX; NMR; -; B=203-217. DR PDB; 2LTY; NMR; -; B=203-217. DR PDB; 2LTZ; NMR; -; B=203-217. DR PDBsum; 2DJY; -. DR PDBsum; 2KXQ; -. DR PDBsum; 2LTV; -. DR PDBsum; 2LTW; -. DR PDBsum; 2LTX; -. DR PDBsum; 2LTY; -. DR PDBsum; 2LTZ; -. DR AlphaFoldDB; O15105; -. DR BMRB; O15105; -. DR SMR; O15105; -. DR BioGRID; 110267; 116. DR CORUM; O15105; -. DR DIP; DIP-42252N; -. DR FunCoup; O15105; 998. DR IntAct; O15105; 40. DR MINT; O15105; -. DR STRING; 9606.ENSP00000262158; -. DR iPTMnet; O15105; -. DR PhosphoSitePlus; O15105; -. DR BioMuta; SMAD7; -. DR MassIVE; O15105; -. DR PaxDb; 9606-ENSP00000262158; -. DR PeptideAtlas; O15105; -. DR Antibodypedia; 9268; 532 antibodies from 39 providers. DR DNASU; 4092; -. DR Ensembl; ENST00000262158.8; ENSP00000262158.2; ENSG00000101665.11. [O15105-1] DR Ensembl; ENST00000589634.1; ENSP00000467621.1; ENSG00000101665.11. [O15105-3] DR Ensembl; ENST00000591805.5; ENSP00000466902.1; ENSG00000101665.11. [O15105-2] DR GeneID; 4092; -. DR KEGG; hsa:4092; -. DR MANE-Select; ENST00000262158.8; ENSP00000262158.2; NM_005904.4; NP_005895.1. DR UCSC; uc002ldg.3; human. [O15105-1] DR AGR; HGNC:6773; -. DR ClinPGx; PA134875286; -. DR CTD; 4092; -. DR DisGeNET; 4092; -. DR GeneCards; SMAD7; -. DR HGNC; HGNC:6773; SMAD7. DR HPA; ENSG00000101665; Low tissue specificity. DR MalaCards; SMAD7; -. DR MIM; 602932; gene. DR MIM; 612229; phenotype. DR OpenTargets; ENSG00000101665; -. DR VEuPathDB; HostDB:ENSG00000101665; -. DR eggNOG; KOG3701; Eukaryota. DR GeneTree; ENSGT00940000159872; -. DR HOGENOM; CLU_026736_5_0_1; -. DR InParanoid; O15105; -. DR OMA; CKIFRWP; -. DR OrthoDB; 5946219at2759; -. DR PAN-GO; O15105; 9 GO annotations based on evolutionary models. DR PhylomeDB; O15105; -. DR PathwayCommons; O15105; -. DR Reactome; R-HSA-201451; Signaling by BMP. DR Reactome; R-HSA-2173788; Downregulation of TGF-beta receptor signaling. DR Reactome; R-HSA-2173795; Downregulation of SMAD2/3:SMAD4 transcriptional activity. DR Reactome; R-HSA-2173796; SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription. DR Reactome; R-HSA-5689603; UCH proteinases. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-877300; Interferon gamma signaling. DR SignaLink; O15105; -. DR SIGNOR; O15105; -. DR Agora; ENSG00000101665; -. DR BioGRID-ORCS; 4092; 27 hits in 1182 CRISPR screens. DR ChiTaRS; SMAD7; human. DR EvolutionaryTrace; O15105; -. DR GeneWiki; Mothers_against_decapentaplegic_homolog_7; -. DR GenomeRNAi; 4092; -. DR Pharos; O15105; Tbio. DR PRO; PR:O15105; -. DR Proteomes; UP000005640; Chromosome 18. DR RNAct; O15105; protein. DR Bgee; ENSG00000101665; Expressed in popliteal artery and 175 other cell types or tissues. DR ExpressionAtlas; O15105; baseline and differential. DR GO; GO:0005813; C:centrosome; IDA:HPA. DR GO; GO:0000785; C:chromatin; ISA:NTNU_SB. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0001650; C:fibrillar center; IDA:HPA. DR GO; GO:0071144; C:heteromeric SMAD protein complex; IBA:GO_Central. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:BHF-UCL. DR GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL. DR GO; GO:0032991; C:protein-containing complex; IDA:MGI. DR GO; GO:0070697; F:activin receptor binding; IPI:BHF-UCL. DR GO; GO:0008013; F:beta-catenin binding; IPI:BHF-UCL. DR GO; GO:0005518; F:collagen binding; IEA:Ensembl. DR GO; GO:0070411; F:I-SMAD binding; IPI:BHF-UCL. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0003714; F:transcription corepressor activity; IDA:BHF-UCL. DR GO; GO:0140416; F:transcription regulator inhibitor activity; IDA:BHF-UCL. DR GO; GO:0034713; F:type I transforming growth factor beta receptor binding; IPI:BHF-UCL. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:BHF-UCL. DR GO; GO:1990756; F:ubiquitin-like ligase-substrate adaptor activity; IDA:BHF-UCL. DR GO; GO:0034333; P:adherens junction assembly; IMP:BHF-UCL. DR GO; GO:0009653; P:anatomical structure morphogenesis; IBA:GO_Central. DR GO; GO:0048844; P:artery morphogenesis; ISS:BHF-UCL. DR GO; GO:1904886; P:beta-catenin destruction complex disassembly; IDA:BHF-UCL. DR GO; GO:0030154; P:cell differentiation; IBA:GO_Central. DR GO; GO:1990830; P:cellular response to leukemia inhibitory factor; IEA:Ensembl. DR GO; GO:0032926; P:negative regulation of activin receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0030514; P:negative regulation of BMP signaling pathway; IDA:BHF-UCL. DR GO; GO:0030336; P:negative regulation of cell migration; TAS:BHF-UCL. DR GO; GO:1902731; P:negative regulation of chondrocyte proliferation; IEA:Ensembl. DR GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; TAS:BHF-UCL. DR GO; GO:0030279; P:negative regulation of ossification; IEA:Ensembl. DR GO; GO:0060392; P:negative regulation of SMAD protein signal transduction; IDA:BHF-UCL. DR GO; GO:0002725; P:negative regulation of T cell cytokine production; ISS:BHF-UCL. DR GO; GO:2000320; P:negative regulation of T-helper 17 cell differentiation; ISS:BHF-UCL. DR GO; GO:2000317; P:negative regulation of T-helper 17 type immune response; ISS:BHF-UCL. DR GO; GO:0010944; P:negative regulation of transcription by competitive promoter binding; IDA:BHF-UCL. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:BHF-UCL. DR GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:2000049; P:positive regulation of cell-cell adhesion mediated by cadherin; IDA:BHF-UCL. DR GO; GO:1903043; P:positive regulation of chondrocyte hypertrophy; IEA:Ensembl. DR GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; TAS:BHF-UCL. DR GO; GO:0050821; P:protein stabilization; IDA:BHF-UCL. DR GO; GO:0032984; P:protein-containing complex disassembly; IDA:BHF-UCL. DR GO; GO:0031503; P:protein-containing complex localization; IDA:BHF-UCL. DR GO; GO:0055117; P:regulation of cardiac muscle contraction; ISS:BHF-UCL. DR GO; GO:0010717; P:regulation of epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central. DR GO; GO:0060373; P:regulation of ventricular cardiac muscle cell membrane depolarization; ISS:ARUK-UCL. DR GO; GO:0034616; P:response to laminar fluid shear stress; IEP:BHF-UCL. DR GO; GO:0060395; P:SMAD protein signal transduction; IDA:BHF-UCL. DR GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0001657; P:ureteric bud development; IEA:Ensembl. DR GO; GO:0055010; P:ventricular cardiac muscle tissue morphogenesis; ISS:BHF-UCL. DR GO; GO:0060412; P:ventricular septum morphogenesis; ISS:BHF-UCL. DR CDD; cd10494; MH1_SMAD_7; 1. DR CDD; cd10500; MH2_SMAD_7; 1. DR FunFam; 2.60.200.10:FF:000004; Mothers against decapentaplegic homolog; 1. DR FunFam; 3.90.520.10:FF:000003; Mothers against decapentaplegic homolog; 1. DR Gene3D; 2.60.200.10; -; 1. DR Gene3D; 3.90.520.10; SMAD MH1 domain; 1. DR IDEAL; IID00135; -. DR InterPro; IPR013790; Dwarfin. DR InterPro; IPR003619; MAD_homology1_Dwarfin-type. DR InterPro; IPR013019; MAD_homology_MH1. DR InterPro; IPR017855; SMAD-like_dom_sf. DR InterPro; IPR001132; SMAD_dom_Dwarfin-type. DR InterPro; IPR008984; SMAD_FHA_dom_sf. DR InterPro; IPR036578; SMAD_MH1_sf. DR PANTHER; PTHR13703:SF44; MOTHERS AGAINST DECAPENTAPLEGIC HOMOLOG 7; 1. DR PANTHER; PTHR13703; SMAD; 1. DR Pfam; PF03165; MH1; 1. DR Pfam; PF03166; MH2; 1. DR SMART; SM00523; DWA; 1. DR SMART; SM00524; DWB; 1. DR SUPFAM; SSF56366; SMAD MH1 domain; 1. DR SUPFAM; SSF49879; SMAD/FHA domain; 1. DR PROSITE; PS51075; MH1; 1. DR PROSITE; PS51076; MH2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Cytoplasm; KW Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Transcription; KW Transcription regulation; Ubl conjugation; Zinc. FT CHAIN 1..426 FT /note="SMAD family member 7" FT /id="PRO_0000090872" FT DOMAIN 64..207 FT /note="MH1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00438" FT DOMAIN 261..426 FT /note="MH2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00439" FT REGION 13..55 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 208..217 FT /note="Important for interaction with SMURF2" FT MOTIF 208..211 FT /note="PY-motif" FT COMPBIAS 37..47 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 125 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250" FT BINDING 180 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250" FT BINDING 192 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250" FT BINDING 197 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250" FT MOD_RES 64 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0000269|PubMed:12408818" FT MOD_RES 70 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0000269|PubMed:12408818" FT MOD_RES 249 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O35253, FT ECO:0000255|PROSITE-ProRule:PRU00439" FT CROSSLNK 64 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin); alternate" FT /evidence="ECO:0000269|PubMed:12408818" FT CROSSLNK 70 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin); alternate" FT /evidence="ECO:0000269|PubMed:12408818" FT VAR_SEQ 1..215 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_045197" FT VAR_SEQ 223 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_047540" FT MUTAGEN 64 FT /note="K->A: Loss of acetylation, and of SMURF1-dependent FT degradation; when associated with A-70." FT /evidence="ECO:0000269|PubMed:12408818" FT MUTAGEN 70 FT /note="K->A: Loss of acetylation, and of SMURF1-dependent FT degradation; when associated with A-64." FT /evidence="ECO:0000269|PubMed:12408818" FT MUTAGEN 207..211 FT /note="Missing: Diminishes interaction with SMURF2." FT /evidence="ECO:0000269|PubMed:11163210" FT MUTAGEN 211 FT /note="Y->A: Diminishes interaction with SMURF2 and reduces FT inhibition of TGF-beta signaling." FT /evidence="ECO:0000269|PubMed:11163210" FT MUTAGEN 409..426 FT /note="Missing: 90% reduction in TGF-beta receptor FT binding." FT /evidence="ECO:0000269|PubMed:9215638" FT CONFLICT 71 FT /note="G -> C (in Ref. 3; AAB81354)" FT /evidence="ECO:0000305" FT STRAND 204..206 FT /evidence="ECO:0007829|PDB:2DJY" FT STRAND 212..214 FT /evidence="ECO:0007829|PDB:2DJY" SQ SEQUENCE 426 AA; 46426 MW; 5B76EC986776C102 CRC64; MFRTKRSALV RRLWRSRAPG GEDEEEGAGG GGGGGELRGE GATDSRAHGA GGGGPGRAGC CLGKAVRGAK GHHHPHPPAA GAGAAGGAEA DLKALTHSVL KKLKERQLEL LLQAVESRGG TRTACLLLPG RLDCRLGPGA PAGAQPAQPP SSYSLPLLLC KVFRWPDLRH SSEVKRLCCC ESYGKINPEL VCCNPHHLSR LCELESPPPP YSRYPMDFLK PTADCPDAVP SSAETGGTNY LAPGGLSDSQ LLLEPGDRSH WCVVAYWEEK TRVGRLYCVQ EPSLDIFYDL PQGNGFCLGQ LNSDNKSQLV QKVRSKIGCG IQLTREVDGV WVYNRSSYPI FIKSATLDNP DSRTLLVHKV FPGFSIKAFD YEKAYSLQRP NDHEFMQQPW TGFTVQISFV KGWGQCYTRQ FISSCPCWLE VIFNSR // ID SOX7_HUMAN Reviewed; 388 AA. AC Q9BT81; B4DKV0; Q53YD0; DT 10-MAY-2002, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-2001, sequence version 1. DT 28-JAN-2026, entry version 184. DE RecName: Full=Transcription factor SOX-7; GN Name=SOX7; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND RP DEVELOPMENTAL STAGE. RC TISSUE=Fetal thymus; RX PubMed=11691915; DOI=10.1093/nar/29.21.4274; RA Takash W., Canizares J., Bonneaud N., Poulat F., Mattei M.-G., Jay P., RA Berta P.; RT "SOX7 transcription factor: sequence, chromosomal localisation, expression, RT transactivation and interference with Wnt signalling."; RL Nucleic Acids Res. 29:4274-4283(2001). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Lung, and Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16421571; DOI=10.1038/nature04406; RA Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M., RA Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L., RA Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S., RA Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A., RA Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III, RA Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., RA Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P., RA Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H., RA Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B., RA O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K., RA Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L., RA Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G., RA Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W., RA Platzer M., Shimizu N., Lander E.S.; RT "DNA sequence and analysis of human chromosome 8."; RL Nature 439:331-335(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP FUNCTION, INTERACTION WITH CTNNB1, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RX PubMed=18819930; DOI=10.1158/1541-7786.mcr-07-2175; RA Guo L., Zhong D., Lau S., Liu X., Dong X.Y., Sun X., Yang V.W., RA Vertino P.M., Moreno C.S., Varma V., Dong J.T., Zhou W.; RT "Sox7 Is an independent checkpoint for beta-catenin function in prostate RT and colon epithelial cells."; RL Mol. Cancer Res. 6:1421-1430(2008). CC -!- FUNCTION: Binds to and activates the CDH5 promoter, hence plays a role CC in the transcriptional regulation of genes expressed in the hemogenic CC endothelium and blocks further differentiation into blood precursors CC (By similarity). May be required for the survival of both hematopoietic CC and endothelial precursors during specification (By similarity). CC Competes with GATA4 for binding and activation of the FGF3 promoter (By CC similarity). Represses Wnt/beta-catenin-stimulated transcription, CC probably by targeting CTNNB1 to proteasomal degradation. Binds the DNA CC sequence 5'-AACAAT-3'. {ECO:0000250, ECO:0000269|PubMed:18819930}. CC -!- SUBUNIT: Interacts with CTNNB1/beta-catenin; this interaction may lead CC to the proteasomal degradation of active CTNNB1 and thus inhibition of CC Wnt/beta-catenin-stimulated transcription. CC {ECO:0000269|PubMed:18819930}. CC -!- INTERACTION: CC Q9BT81; Q92870-2: APBB2; NbExp=3; IntAct=EBI-7239117, EBI-21535880; CC Q9BT81; O76003: GLRX3; NbExp=3; IntAct=EBI-7239117, EBI-374781; CC Q9BT81; P42858: HTT; NbExp=15; IntAct=EBI-7239117, EBI-466029; CC Q9BT81; Q8N9R8: SCAI; NbExp=3; IntAct=EBI-7239117, EBI-4395514; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00267}. CC Cytoplasm {ECO:0000269|PubMed:18819930}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q9BT81-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9BT81-2; Sequence=VSP_056667; CC -!- TISSUE SPECIFICITY: Widely expressed in adult and fetal tissues. CC Present both in mesenchymal and epithelial cells in some adult tissues, CC including colon. Tends to be down-regulated in prostate adenocarcinomas CC and colorectal tumors due to promoter hypermethylation. CC {ECO:0000269|PubMed:11691915, ECO:0000269|PubMed:18819930}. CC -!- DEVELOPMENTAL STAGE: In 8 week-old embryo, expressed in brain, tongue, CC heart, liver, lung and vertebrae. {ECO:0000269|PubMed:11691915}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AJ409320; CAC84226.1; -; mRNA. DR EMBL; BT006693; AAP35339.1; -; mRNA. DR EMBL; AK055556; BAB70955.1; -; mRNA. DR EMBL; AK296724; BAG59312.1; -; mRNA. DR EMBL; AC011008; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC105001; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC071947; AAH71947.1; -; mRNA. DR CCDS; CCDS5977.1; -. [Q9BT81-1] DR RefSeq; NP_113627.1; NM_031439.4. [Q9BT81-1] DR AlphaFoldDB; Q9BT81; -. DR SMR; Q9BT81; -. DR BioGRID; 123691; 81. DR FunCoup; Q9BT81; 1714. DR IntAct; Q9BT81; 80. DR MINT; Q9BT81; -. DR STRING; 9606.ENSP00000301921; -. DR GlyGen; Q9BT81; 3 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q9BT81; -. DR PhosphoSitePlus; Q9BT81; -. DR BioMuta; SOX7; -. DR DMDM; 20532272; -. DR jPOST; Q9BT81; -. DR MassIVE; Q9BT81; -. DR PaxDb; 9606-ENSP00000301921; -. DR PeptideAtlas; Q9BT81; -. DR ProteomicsDB; 4490; -. DR ProteomicsDB; 78959; -. [Q9BT81-1] DR Antibodypedia; 1821; 207 antibodies from 30 providers. DR DNASU; 83595; -. DR Ensembl; ENST00000304501.2; ENSP00000301921.1; ENSG00000171056.8. [Q9BT81-1] DR Ensembl; ENST00000646538.2; ENSP00000495029.1; ENSG00000285438.2. [Q9BT81-1] DR GeneID; 83595; -. DR KEGG; hsa:83595; -. DR MANE-Select; ENST00000304501.2; ENSP00000301921.1; NM_031439.4; NP_113627.1. DR UCSC; uc003wtf.5; human. [Q9BT81-1] DR AGR; HGNC:18196; -. DR ClinPGx; PA38307; -. DR CTD; 83595; -. DR DisGeNET; 83595; -. DR GeneCards; SOX7; -. DR HGNC; HGNC:18196; SOX7. DR HPA; ENSG00000171056; Tissue enhanced (vagina). DR MalaCards; SOX7; -. DR MIM; 612202; gene. DR OpenTargets; ENSG00000171056; -. DR OpenTargets; ENSG00000258724; -. DR VEuPathDB; HostDB:ENSG00000171056; -. DR eggNOG; KOG0527; Eukaryota. DR GeneTree; ENSGT00940000161092; -. DR HOGENOM; CLU_044994_0_0_1; -. DR InParanoid; Q9BT81; -. DR OMA; CQEEHAH; -. DR OrthoDB; 6247875at2759; -. DR PAN-GO; Q9BT81; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q9BT81; -. DR PathwayCommons; Q9BT81; -. DR Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex. DR SignaLink; Q9BT81; -. DR SIGNOR; Q9BT81; -. DR Agora; ENSG00000171056; -. DR BioGRID-ORCS; 83595; 20 hits in 1168 CRISPR screens. DR ChiTaRS; SOX7; human. DR GenomeRNAi; 83595; -. DR Pharos; Q9BT81; Tbio. DR PRO; PR:Q9BT81; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; Q9BT81; protein. DR Bgee; ENSG00000171056; Expressed in lower esophagus mucosa and 98 other cell types or tissues. DR GO; GO:0000785; C:chromatin; ISA:NTNU_SB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IBA:GO_Central. DR GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central. DR GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL. DR GO; GO:0000976; F:transcription cis-regulatory region binding; ISS:UniProtKB. DR GO; GO:0030154; P:cell differentiation; IBA:GO_Central. DR GO; GO:0001706; P:endoderm formation; IDA:UniProtKB. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IBA:GO_Central. DR CDD; cd22046; HMG-box_SoxF_SOX7; 1. DR FunFam; 1.10.30.10:FF:000008; transcription factor SOX-7; 1. DR Gene3D; 1.10.30.10; High mobility group box domain; 1. DR InterPro; IPR009071; HMG_box_dom. DR InterPro; IPR036910; HMG_box_dom_sf. DR InterPro; IPR033392; Sox7/17/18_central. DR InterPro; IPR021934; Sox_C. DR InterPro; IPR050140; SRY-related_HMG-box_TF-like. DR PANTHER; PTHR10270; SOX TRANSCRIPTION FACTOR; 1. DR PANTHER; PTHR10270:SF210; TRANSCRIPTION FACTOR SOX-7; 1. DR Pfam; PF00505; HMG_box; 1. DR Pfam; PF12067; Sox17_18_mid; 1. DR SMART; SM00398; HMG; 1. DR SUPFAM; SSF47095; HMG-box; 1. DR PROSITE; PS50118; HMG_BOX_2; 1. DR PROSITE; PS51516; SOX_C; 1. PE 1: Evidence at protein level; KW Activator; Alternative splicing; Cytoplasm; DNA-binding; Nucleus; KW Proteomics identification; Reference proteome; Transcription; KW Transcription regulation. FT CHAIN 1..388 FT /note="Transcription factor SOX-7" FT /id="PRO_0000048731" FT DOMAIN 268..388 FT /note="Sox C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00849" FT DNA_BIND 45..113 FT /note="HMG box" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00267" FT REGION 20..46 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 140..197 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 36..45 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 146..164 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT VAR_SEQ 1..79 FT /note="MASLLGAYPWPEGLECPALDAELSDGQSPPAVPRPPGDKGSESRIRRPMNAF FT MVWAKDERKRLAVQNPDLHNAELSKML -> MSMLAERRRKQKWAVDPQNTAWSNDDSK FT FGQRMLEKMGWSKGKGLGAQEQGATDHIKVQVKNNHLGLGATINNEDNWIAHQDDFNQL FT LAELNTCHGQETTDSSDKKEKKSFSLEEKSKISKNRVHYMKFTK (in isoform FT 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_056667" SQ SEQUENCE 388 AA; 42197 MW; DBA0EFE440DC2A74 CRC64; MASLLGAYPW PEGLECPALD AELSDGQSPP AVPRPPGDKG SESRIRRPMN AFMVWAKDER KRLAVQNPDL HNAELSKMLG KSWKALTLSQ KRPYVDEAER LRLQHMQDYP NYKYRPRRKK QAKRLCKRVD PGFLLSSLSR DQNALPEKRS GSRGALGEKE DRGEYSPGTA LPSLRGCYHE GPAGGGGGGT PSSVDTYPYG LPTPPEMSPL DVLEPEQTFF SSPCQEEHGH PRRIPHLPGH PYSPEYAPSP LHCSHPLGSL ALGQSPGVSM MSPVPGCPPS PAYYSPATYH PLHSNLQAHL GQLSPPPEHP GFDALDQLSQ VELLGDMDRN EFDQYLNTPG HPDSATGAMA LSGHVPVSQV TPTGPTETSL ISVLADATAT YYNSYSVS // ID STK11_HUMAN Reviewed; 433 AA. AC Q15831; B2RBX7; E7EW76; DT 15-JUL-1998, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 245. DE RecName: Full=Serine/threonine-protein kinase STK11 {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:14976552}; DE AltName: Full=Liver kinase B1; DE Short=LKB1; DE Short=hLKB1; DE AltName: Full=Renal carcinoma antigen NY-REN-19; DE Flags: Precursor; GN Name=STK11 {ECO:0000312|HGNC:HGNC:11389}; Synonyms=LKB1, PJS; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND INVOLVEMENT IN PJS. RC TISSUE=Liver; RX PubMed=9425897; DOI=10.1038/ng0198-38; RA Jenne D.E., Reimann H., Nezu J., Friedl W., Loff S., Jeschke R., RA Mueller O., Back W., Zimmer M.; RT "Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine RT kinase."; RL Nat. Genet. 18:38-43(1998). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9537235; RA Bignell G.R., Barfoot R., Seal S., Collins N., Warren W., Stratton M.R.; RT "Low frequency of somatic mutations in the LKB1/Peutz-Jeghers syndrome gene RT in sporadic breast cancer."; RL Cancer Res. 58:1384-1386(1998). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Lung, and Uterus; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP IDENTIFICATION AS A RENAL CANCER ANTIGEN. RC TISSUE=Renal cell carcinoma; RX PubMed=10508479; RX DOI=10.1002/(sici)1097-0215(19991112)83:4<456::aid-ijc4>3.0.co;2-5; RA Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H., RA Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T., RA Old L.J.; RT "Antigens recognized by autologous antibody in patients with renal-cell RT carcinoma."; RL Int. J. Cancer 83:456-464(1999). RN [8] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=11212897; DOI=10.1023/a:1006442024874; RA Sobottka S.B., Haase M., Fitze G., Hahn M., Schackert H.K., Schackert G.; RT "Frequent loss of heterozygosity at the 19p13.3 locus without LKB1/STK11 RT mutations in human carcinoma metastases to the brain."; RL J. Neurooncol. 49:187-195(2000). RN [9] RP IDENTIFICATION IN A TERNARY COMPLEX COMPOSED OF SMAD4 AND STK11IP, AND RP INTERACTION WITH SMAD4 AND STK11IP. RX PubMed=11741830; DOI=10.1093/hmg/10.25.2869; RA Smith D.P., Rayter S.I., Niederlander C., Spicer J., Jones C.M., RA Ashworth A.; RT "LIP1, a cytoplasmic protein functionally linked to the Peutz-Jeghers RT syndrome kinase LKB1."; RL Hum. Mol. Genet. 10:2869-2877(2001). RN [10] RP SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, FUNCTION, MUTAGENESIS OF LYS-78 RP AND THR-189, AND PHOSPHORYLATION AT THR-189. RX PubMed=11430832; DOI=10.1016/s1097-2765(01)00258-1; RA Karuman P., Gozani O., Odze R.D., Zhou X.C., Zhu H., Shaw R., Brien T.P., RA Bozzuto C.D., Ooi D., Cantley L.C., Yuan J.; RT "The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell RT death."; RL Mol. Cell 7:1307-1319(2001). RN [11] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=12097271; RA Sanchez-Cespedes M., Parrella P., Esteller M., Nomoto S., Trink B., RA Engles J.M., Westra W.H., Herman J.G., Sidransky D.; RT "Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the RT lung."; RL Cancer Res. 62:3659-3662(2002). RN [12] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH STRADA, PHOSPHORYLATION AT RP THR-336 AND THR-363, AND CHARACTERIZATION OF VARIANT SPORADIC CANCER RP TYR-176. RX PubMed=12805220; DOI=10.1093/emboj/cdg292; RA Baas A.F., Boudeau J., Sapkota G.P., Smit L., Medema R., Morrice N.A., RA Alessi D.R., Clevers H.C.; RT "Activation of the tumour suppressor kinase LKB1 by the STE20-like RT pseudokinase STRAD."; RL EMBO J. 22:3062-3072(2003). RN [13] RP FUNCTION, SUBCELLULAR LOCATION, MUTAGENESIS OF ASP-194, IDENTIFICATION IN A RP COMPLEX WITH STRADA AND CAB39, AND INTERACTION WITH STRADA; STRADB; CAB39 RP AND CAB39L. RX PubMed=14517248; DOI=10.1093/emboj/cdg490; RA Boudeau J., Baas A.F., Deak M., Morrice N.A., Kieloch A., Schutkowski M., RA Prescott A.R., Clevers H.C., Alessi D.R.; RT "MO25alpha/beta interact with STRADalpha/beta enhancing their ability to RT bind, activate and localize LKB1 in the cytoplasm."; RL EMBO J. 22:5102-5114(2003). RN [14] RP FUNCTION IN CELL POLARITY. RX PubMed=15016379; DOI=10.1016/s0092-8674(04)00114-x; RA Baas A.F., Kuipers J., van der Wel N.N., Batlle E., Koerten H.K., RA Peters P.J., Clevers H.C.; RT "Complete polarization of single intestinal epithelial cells upon RT activation of LKB1 by STRAD."; RL Cell 116:457-466(2004). RN [15] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF ASP-194. RX PubMed=14976552; DOI=10.1038/sj.emboj.7600110; RA Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A., Boudeau J., RA Hawley S.A., Udd L., Maekelae T.P., Hardie D.G., Alessi D.R.; RT "LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, RT including MARK/PAR-1."; RL EMBO J. 23:833-843(2004). RN [16] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=15021901; DOI=10.1038/sj.onc.1207502; RA Carretero J., Medina P.P., Pio R., Montuenga L.M., Sanchez-Cespedes M.; RT "Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor RT suppressor gene."; RL Oncogene 23:4037-4040(2004). RN [17] RP FUNCTION. RX PubMed=15733851; DOI=10.1016/j.febslet.2005.01.042; RA Jaleel M., McBride A., Lizcano J.M., Deak M., Toth R., Morrice N.A., RA Alessi D.R.; RT "Identification of the sucrose non-fermenting related kinase SNRK, as a RT novel LKB1 substrate."; RL FEBS Lett. 579:1417-1423(2005). RN [18] RP FUNCTION, INTERACTION WITH PTEN, SUBCELLULAR LOCATION, AND CHARACTERIZATION RP OF VARIANT PJS ASN-176. RX PubMed=15987703; DOI=10.1093/hmg/ddi225; RA Mehenni H., Lin-Marq N., Buchet-Poyau K., Reymond A., Collart M.A., RA Picard D., Antonarakis S.E.; RT "LKB1 interacts with and phosphorylates PTEN: a functional link between two RT proteins involved in cancer predisposing syndromes."; RL Hum. Mol. Genet. 14:2209-2219(2005). RN [19] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH TP53. RX PubMed=17108107; DOI=10.1158/0008-5472.can-06-0999; RA Zeng P.Y., Berger S.L.; RT "LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate RT transcriptional activation."; RL Cancer Res. 66:10701-10708(2006). RN [20] RP INTERACTION WITH WDR6. RX PubMed=17216128; DOI=10.1007/s11010-006-9402-5; RA Xie X., Wang Z., Chen Y.; RT "Association of LKB1 with a WD-repeat protein WDR6 is implicated in cell RT growth arrest and p27(Kip1) induction."; RL Mol. Cell. Biochem. 301:115-122(2007). RN [21] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=17711506; DOI=10.1111/j.1349-7006.2007.00585.x; RA Onozato R., Kosaka T., Achiwa H., Kuwano H., Takahashi T., Yatabe Y., RA Mitsudomi T.; RT "LKB1 gene mutations in Japanese lung cancer patients."; RL Cancer Sci. 98:1747-1751(2007). RN [22] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=17676035; DOI=10.1038/nature06030; RA Ji H., Ramsey M.R., Hayes D.N., Fan C., McNamara K., Kozlowski P., RA Torrice C., Wu M.C., Shimamura T., Perera S.A., Liang M.C., Cai D., RA Naumov G.N., Bao L., Contreras C.M., Li D., Chen L., Krishnamurthy J., RA Koivunen J., Chirieac L.R., Padera R.F., Bronson R.T., Lindeman N.I., RA Christiani D.C., Lin X., Shapiro G.I., Janne P.A., Johnson B.E., RA Meyerson M., Kwiatkowski D.J., Castrillon D.H., Bardeesy N., RA Sharpless N.E., Wong K.K.; RT "LKB1 modulates lung cancer differentiation and metastasis."; RL Nature 448:807-810(2007). RN [23] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=17384680; DOI=10.1038/sj.onc.1210418; RA Matsumoto S., Iwakawa R., Takahashi K., Kohno T., Nakanishi Y., Matsuno Y., RA Suzuki K., Nakamoto M., Shimizu E., Minna J.D., Yokota J.; RT "Prevalence and specificity of LKB1 genetic alterations in lung cancers."; RL Oncogene 26:5911-5918(2007). RN [24] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=18594528; DOI=10.1038/sj.bjc.6604469; RA Koivunen J.P., Kim J., Lee J., Rogers A.M., Park J.O., Zhao X., Naoki K., RA Okamoto I., Nakagawa K., Yeap B.Y., Meyerson M., Wong K.K., Richards W.G., RA Sugarbaker D.J., Johnson B.E., Janne P.A.; RT "Mutations in the LKB1 tumour suppressor are frequently detected in tumours RT from Caucasian but not Asian lung cancer patients."; RL Br. J. Cancer 99:245-252(2008). RN [25] RP RETRACTED PAPER. RX PubMed=18321849; DOI=10.1074/jbc.m708208200; RA Song P., Xie Z., Wu Y., Xu J., Dong Y., Zou M.H.; RT "Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation increases RT LKB1 nucleus export and apoptosis in endothelial cells."; RL J. Biol. Chem. 283:12446-12455(2008). RN [26] RP RETRACTION NOTICE OF PUBMED:18321849. RX PubMed=31519760; DOI=10.1074/jbc.w119.010661; RA Song P., Xie Z., Wu Y., Dong Y., Zou M.H.; RT "Withdrawal: Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation RT increases LKB1 nucleus export and apoptosis in endothelial cells."; RL J. Biol. Chem. 294:13831-13831(2019). RN [27] RP INTERACTION WITH SIRT1, ACETYLATION AT LYS-44; LYS-48; LYS-96; LYS-97; RP LYS-296; LYS-311; LYS-416; LYS-423 AND LYS-431, AND MUTAGENESIS OF LYS-44; RP LYS-48; LYS-96 AND LYS-97. RX PubMed=18687677; DOI=10.1074/jbc.m805711200; RA Lan F., Cacicedo J.M., Ruderman N., Ido Y.; RT "SIRT1 modulation of the acetylation status, cytosolic localization, and RT activity of LKB1. Possible role in AMP-activated protein kinase RT activation."; RL J. Biol. Chem. 283:27628-27635(2008). RN [28] RP ALTERNATIVE SPLICING (ISOFORMS 1 AND 2), SUBCELLULAR LOCATION, RP PHOSPHORYLATION AT SER-428, AND MUTAGENESIS OF SER-428. RX PubMed=18854309; DOI=10.1074/jbc.m806153200; RA Denison F.C., Hiscock N.J., Carling D., Woods A.; RT "Characterization of an alternative splice variant of LKB1."; RL J. Biol. Chem. 284:67-76(2009). RN [29] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [30] RP INVOLVEMENT IN LUNG CANCER. RX PubMed=20559149; DOI=10.1097/jto.0b013e3181e05016; RA Gao B., Sun Y., Zhang J., Ren Y., Fang R., Han X., Shen L., Liu X.Y., RA Pao W., Chen H., Ji H.; RT "Spectrum of LKB1, EGFR, and KRAS mutations in Chinese lung RT adenocarcinomas."; RL J. Thorac. Oncol. 5:1130-1135(2010). RN [31] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [32] RP FUNCTION. RX PubMed=21317932; DOI=10.1038/onc.2011.19; RA Hou X., Liu J.E., Liu W., Liu C.Y., Liu Z.Y., Sun Z.Y.; RT "A new role of NUAK1: directly phosphorylating p53 and regulating cell RT proliferation."; RL Oncogene 30:2933-2942(2011). RN [33] RP REVIEW ON FUNCTION. RX PubMed=21396365; DOI=10.1016/j.febslet.2011.03.010; RA Alexander A., Walker C.L.; RT "The role of LKB1 and AMPK in cellular responses to stress and damage."; RL FEBS Lett. 585:952-957(2011). RN [34] RP REVIEW ON INVOLVEMENT IN LUNG CANCER. RX PubMed=21380642; DOI=10.1007/s13238-011-1021-6; RA Gao Y., Ge G., Ji H.; RT "LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor RT suppressor."; RL Protein Cell 2:99-107(2011). RN [35] RP ACTIVITY REGULATION, INTERACTION WITH NR4A1, AND SUBCELLULAR LOCATION. RX PubMed=22983157; DOI=10.1038/nchembio.1069; RA Zhan Y.Y., Chen Y., Zhang Q., Zhuang J.J., Tian M., Chen H.Z., Zhang L.R., RA Zhang H.K., He J.P., Wang W.J., Wu R., Wang Y., Shi C., Yang K., Li A.Z., RA Xin Y.Z., Li T.Y., Yang J.Y., Zheng Z.H., Yu C.D., Lin S.C., Chang C., RA Huang P.Q., Lin T., Wu Q.; RT "The orphan nuclear receptor Nur77 regulates LKB1 localization and RT activates AMPK."; RL Nat. Chem. Biol. 8:897-904(2012). RN [36] RP INTERACTION WITH NISCH, AND SUBCELLULAR LOCATION. RX PubMed=23572524; DOI=10.1074/jbc.m112.418103; RA Jain P., Baranwal S., Dong S., Struckhoff A.P., Worthylake R.A., RA Alahari S.K.; RT "Integrin-binding protein nischarin interacts with tumor suppressor liver RT kinase B1 (LKB1) to regulate cell migration of breast epithelial cells."; RL J. Biol. Chem. 288:15495-15509(2013). RN [37] RP SUBCELLULAR LOCATION (ISOFORM 2), AND PHOSPHORYLATION AT SER-399 (ISOFORM RP 2). RX PubMed=23612973; DOI=10.1074/jbc.m112.443580; RA Zhu H., Moriasi C.M., Zhang M., Zhao Y., Zou M.H.; RT "Phosphorylation of serine 399 in LKB1 protein short form by protein kinase RT Czeta is required for its nucleocytoplasmic transport and consequent AMP- RT activated protein kinase (AMPK) activation."; RL J. Biol. Chem. 288:16495-16505(2013). RN [38] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-31 AND SER-401, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [39] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [40] RP FUNCTION, AND INTERACTION WITH CDKN1A. RX PubMed=25329316; DOI=10.1371/journal.pgen.1004721; RA Esteve-Puig R., Gil R., Gonzalez-Sanchez E., Bech-Serra J.J., Grueso J., RA Hernandez-Losa J., Moline T., Canals F., Ferrer B., Cortes J., Bastian B., RA Cajal S.R.Y., Martin-Caballero J., Flores J.M., Vivancos A., RA Garcia-Patos V., Recio J.A.; RT "A mouse model uncovers LKB1 as an UVB-induced DNA damage sensor mediating RT CDKN1A (p21WAF1/CIP1) degradation."; RL PLoS Genet. 10:E1004721-E1004721(2014). RN [41] RP X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 43-347 IN COMPLEX WITH STRADA AND RP CAB39, ACTIVITY REGULATION, CHARACTERIZATION OF VARIANTS SPORADIC CANCER RP MET-66; GLY-86; ARG-123; SER-157; ASP-163; PRO-170; SER-171; ARG-174; RP TYR-176; ASN-177; GLU-181; GLN-199; THR-205; PHE-216; VAL-223; PRO-230; RP PRO-232; ARG-245; PRO-250; HIS-272; TYR-277; GLN-285 AND SER-315, AND RP MUTAGENESIS OF ARG-74; ASP-194 AND PHE-204. RX PubMed=19892943; DOI=10.1126/science.1178377; RA Zeqiraj E., Filippi B.M., Deak M., Alessi D.R., van Aalten D.M.; RT "Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism RT of kinase activation."; RL Science 326:1707-1711(2009). RN [42] RP VARIANTS PJS 50-LEU--ASP-53 DEL; ASN-176 AND CYS-308, CHARACTERIZATION OF RP VARIANTS PJS PRO-67; ASN-176 AND CYS-308, AND MUTAGENESIS OF LYS-78. RX PubMed=9837816; DOI=10.1086/302159; RA Mehenni H., Gehrig C., Nezu J., Oku A., Shimane M., Rossier C., Guex N., RA Blouin J.L., Scott H.S., Antonarakis S.E.; RT "Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for RT allelic and locus heterogeneity."; RL Am. J. Hum. Genet. 63:1641-1650(1998). RN [43] RP VARIANT TGCT ASP-163. RX PubMed=9605748; RA Avizienyte E., Roth S., Loukola A., Hemminki A., Lothe R.A., Stenwig A.E., RA Fossaa S.D., Salovaara R., Aaltonen L.A.; RT "Somatic mutations in LKB1 are rare in sporadic colorectal and testicular RT tumors."; RL Cancer Res. 58:2087-2090(1998). RN [44] RP VARIANTS COLORECTAL CANCER SER-171; LYS-199; ASN-208; ASP-215; LEU-354 AND RP MET-367. RX PubMed=9731485; RA Dong S.M., Kim K.M., Kim S.Y., Shin M.S., Na E.Y., Lee S.H., Park W.S., RA Yoo N.J., Jang J.J., Yoon C.Y., Kim J.W., Kim S.Y., Yang Y.M., Kim S.H., RA Kim C.S., Lee J.Y.; RT "Frequent somatic mutations in serine/threonine kinase 11/Peutz-Jeghers RT syndrome gene in left-sided colon cancer."; RL Cancer Res. 58:3787-3790(1998). RN [45] RP VARIANT COLORECTAL CANCER HIS-314. RX PubMed=9809980; RA Resta N., Simone C., Mareni C., Montera M., Gentile M., Susca F., RA Gristina R., Pozzi S., Bertario L., Bufo P., Carlomagno N., Ingrosso M., RA Rossini F.P., Tenconi R., Guanti G.; RT "STK11 mutations in Peutz-Jeghers syndrome and sporadic colon cancer."; RL Cancer Res. 58:4799-4801(1998). RN [46] RP VARIANT PJS ASN-247 DEL. RX PubMed=9760200; DOI=10.1007/s004390050801; RA Nakagawa H., Koyama K., Miyoshi Y., Ando H., Baba S., Watatani M., RA Yasutomi M., Matsuura N., Monden M., Nakamura Y.; RT "Nine novel germline mutations of STK11 in ten families with Peutz-Jeghers RT syndrome."; RL Hum. Genet. 103:168-172(1998). RN [47] RP VARIANT GASTRIC CARCINOMA LEU-324. RX PubMed=9683800; RA Park W.S., Moon Y.W., Yang Y.M., Kim Y.S., Kim Y.D., Fuller B.G., RA Vortmeyer A.O., Fogt F., Lubensky I.A., Zhuang Z.; RT "Mutations of the STK11 gene in sporadic gastric carcinoma."; RL Int. J. Oncol. 13:601-604(1998). RN [48] RP VARIANTS PJS PRO-67 AND 303-ILE--GLN-306 DELINS ASN. RX PubMed=9428765; DOI=10.1038/34432; RA Hemminki A., Markie D., Tomlinson I., Avizienyte E., Roth S., Loukola A., RA Bignell G., Warren W., Aminoff M., Hoeglund P., Jaervinen H., Kristo P., RA Pelin K., Ridanpaeae M., Salovaara R., Toro T., Bodmer W., Olschwang S., RA Olsen A.S., Stratton M.R., de la Chapelle A., Aaltonen L.A.; RT "A serine/threonine kinase gene defective in Peutz-Jeghers syndrome."; RL Nature 391:184-187(1998). RN [49] RP VARIANT LUNG CANCER VAL-194. RX PubMed=10079245; DOI=10.1016/s0002-9440(10)65314-x; RA Avizienyte E., Loukola A., Roth S., Hemminki A., Tarkkanen M., RA Salovaara R., Arola J., Butzow R., Husgafvel-Pursiainen K., Kokkola A., RA Jarvinen H., Aaltonen L.A.; RT "LKB1 somatic mutations in sporadic cancers."; RL Am. J. Pathol. 154:677-681(1999). RN [50] RP VARIANTS PJS 162-ASP--LEU-164 DELINS ASN-ASP-MET; ASN-194 AND LYS-297. RX PubMed=10408777; RX DOI=10.1002/(sici)1098-1004(1999)13:6<476::aid-humu7>3.0.co;2-2; RA Westerman A.M., Entius M.M., Boor P.P.C., Koole R., de Baar E., RA Offerhaus G.J.A., Lubinski J., Lindhout D., Halley D.J.J., de Rooij F.W.M., RA Wilson J.H.P.; RT "Novel mutations in the LKB1/STK11 gene in Dutch Peutz-Jeghers families."; RL Hum. Mutat. 13:476-481(1999). RN [51] RP CHARACTERIZATION OF VARIANT TGCT ASP-163. RX PubMed=9887330; DOI=10.1093/hmg/8.1.45; RA Ylikorkala A., Avizienyte E., Tomlinson I.P., Tiainen M., Roth S., RA Loukola A., Hemminki A., Johansson M., Sistonen P., Markie D., Neale K., RA Phillips R., Zauber P., Twama T., Sampson J., Jaervinen H., Maekelae T.P., RA Aaltonen L.A.; RT "Mutations and impaired function of LKB1 in familial and non-familial RT Peutz-Jeghers syndrome and a sporadic testicular cancer."; RL Hum. Mol. Genet. 8:45-51(1999). RN [52] RP VARIANT OVARIAN CARCINOMA LEU-281. RX PubMed=10429654; DOI=10.1111/j.1349-7006.1999.tb00793.x; RA Nishioka Y., Kobayashi K., Sagae S., Sugimura M., Ishioka S., Nagata M., RA Terasawa K., Tokino T., Kudo R.; RT "Mutational analysis of STK11 gene in ovarian carcinomas."; RL Jpn. J. Cancer Res. 90:629-632(1999). RN [53] RP VARIANTS MELANOMA ASP-49 AND ARG-135. RX PubMed=10201537; DOI=10.1046/j.1523-1747.1999.00551.x; RA Rowan A., Bataille V., MacKie R., Healy E., Bicknell D., Bodmer W., RA Tomlinson I.; RT "Somatic mutations in the Peutz-Jeghers (LKB1/STKII) gene in sporadic RT malignant melanomas."; RL J. Invest. Dermatol. 112:509-511(1999). RN [54] RP VARIANT MELANOMA TYR-194. RX PubMed=10208439; DOI=10.1038/sj.onc.1202486; RA Guldberg P., thor Straten P., Ahrenkiel V., Seremet T., Kirkin A.F., RA Zeuthen J.; RT "Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in RT malignant melanoma."; RL Oncogene 18:1777-1780(1999). RN [55] RP VARIANTS PJS CYS-239 AND SER-315. RX PubMed=12372054; DOI=10.1034/j.1399-0004.2002.620405.x; RA Scott R.J., Crooks R., Meldrum C.J., Thomas L., Smith C.J.A., Mowat D., RA McPhillips M., Spigelman A.D.; RT "Mutation analysis of the STK11/LKB1 gene and clinical characteristics of RT an Australian series of Peutz-Jeghers syndrome patients."; RL Clin. Genet. 62:282-287(2002). RN [56] RP VARIANTS CERVICAL CANCER LYS-14; PRO-160 AND LEU-231, AND VARIANT CERVICAL RP CARCINOMA MET-66. RX PubMed=12533684; DOI=10.1097/01.lab.0000049821.16698.d0; RA Kuragaki C., Enomoto T., Ueno Y., Sun H., Fujita M., Nakashima R., Ueda Y., RA Wada H., Murata Y., Toki T., Konishi I., Fujii S.; RT "Mutations in the STK11 gene characterize minimal deviation adenocarcinoma RT of the uterine cervix."; RL Lab. Invest. 83:35-45(2003). RN [57] RP VARIANT [LARGE SCALE ANALYSIS] LYS-87. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [58] RP VARIANT PJS GLY-16. RX PubMed=21411391; DOI=10.1016/j.clinre.2010.11.008; RA Liu L., Du X., Nie J.; RT "A novel de novo mutation in LKB1 gene in a Chinese Peutz Jeghers syndrome RT patient significantly diminished p53 activity."; RL Clin. Res. Hepatol. Gastroenterol. 35:221-226(2011). CC -!- FUNCTION: Tumor suppressor serine/threonine-protein kinase that CC controls the activity of AMP-activated protein kinase (AMPK) family CC members, thereby playing a role in various processes such as cell CC metabolism, cell polarity, apoptosis and DNA damage response. Acts by CC phosphorylating the T-loop of AMPK family proteins, thus promoting CC their activity: phosphorylates PRKAA1, PRKAA2, BRSK1, BRSK2, MARK1, CC MARK2, MARK3, MARK4, NUAK1, NUAK2, SIK1, SIK2, SIK3 and SNRK but not CC MELK. Also phosphorylates non-AMPK family proteins such as STRADA, PTEN CC and possibly p53/TP53. Acts as a key upstream regulator of AMPK by CC mediating phosphorylation and activation of AMPK catalytic subunits CC PRKAA1 and PRKAA2 and thereby regulates processes including: inhibition CC of signaling pathways that promote cell growth and proliferation when CC energy levels are low, glucose homeostasis in liver, activation of CC autophagy when cells undergo nutrient deprivation, and B-cell CC differentiation in the germinal center in response to DNA damage. Also CC acts as a regulator of cellular polarity by remodeling the actin CC cytoskeleton. Required for cortical neuron polarization by mediating CC phosphorylation and activation of BRSK1 and BRSK2, leading to axon CC initiation and specification. Involved in DNA damage response: CC interacts with p53/TP53 and recruited to the CDKN1A/WAF1 promoter to CC participate in transcription activation. Able to phosphorylate CC p53/TP53; the relevance of such result in vivo is however unclear and CC phosphorylation may be indirect and mediated by downstream STK11/LKB1 CC kinase NUAK1. Also acts as a mediator of p53/TP53-dependent apoptosis CC via interaction with p53/TP53: translocates to the mitochondrion during CC apoptosis and regulates p53/TP53-dependent apoptosis pathways. CC Regulates UV radiation-induced DNA damage response mediated by CDKN1A. CC In association with NUAK1, phosphorylates CDKN1A in response to UV CC radiation and contributes to its degradation which is necessary for CC optimal DNA repair (PubMed:25329316). {ECO:0000269|PubMed:11430832, CC ECO:0000269|PubMed:12805220, ECO:0000269|PubMed:14517248, CC ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:15016379, CC ECO:0000269|PubMed:15733851, ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:21317932, CC ECO:0000269|PubMed:25329316}. CC -!- FUNCTION: [Isoform 2]: Has a role in spermiogenesis. {ECO:0000250}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:14976552}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:14976552}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; CC -!- ACTIVITY REGULATION: Activated by forming a complex with STRAD (STRADA CC or STRADB) and CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta): STRADA CC (or STRADB)-binding promotes a conformational change of STK11/LKB1 in CC an active conformation, which is stabilized by CAB39/MO25alpha (or CC CAB39L/MO25beta) interacting with the STK11/LKB1 activation loop. CC Sequestration in the nucleus by NR4A1 prevents it from phosphorylating CC and activating cytoplasmic AMPK. {ECO:0000269|PubMed:19892943, CC ECO:0000269|PubMed:22983157}. CC -!- SUBUNIT: Catalytic component of a trimeric complex composed of CC STK11/LKB1, STRAD (STRADA or STRADB) and CAB39/MO25 (CAB39/MO25alpha or CC CAB39L/MO25beta): the complex tethers STK11/LKB1 in the cytoplasm and CC stimulates its catalytic activity. Found in a ternary complex composed CC of SMAD4, STK11/LKB1 and STK11IP. Interacts with p53/TP53, SMAD4, CC STK11IP and WDR6. Interacts with NR4A1. Interacts with NISCH; this CC interaction may increase STK11 activity. Interacts with PTEN; leading CC to PTEN phosphorylation. Interacts with SIRT1; the interaction CC deacetylates STK11. Interacts with CDKN1A. CC {ECO:0000269|PubMed:11741830, ECO:0000269|PubMed:12805220, CC ECO:0000269|PubMed:14517248, ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:17216128, CC ECO:0000269|PubMed:18687677, ECO:0000269|PubMed:19892943, CC ECO:0000269|PubMed:22983157, ECO:0000269|PubMed:23572524, CC ECO:0000269|PubMed:25329316}. CC -!- INTERACTION: CC Q15831; Q9Y376: CAB39; NbExp=23; IntAct=EBI-306838, EBI-306905; CC Q15831; Q16543: CDC37; NbExp=6; IntAct=EBI-306838, EBI-295634; CC Q15831; Q9BT78: COPS4; NbExp=5; IntAct=EBI-306838, EBI-742413; CC Q15831; Q13451: FKBP5; NbExp=11; IntAct=EBI-306838, EBI-306914; CC Q15831; P07900: HSP90AA1; NbExp=6; IntAct=EBI-306838, EBI-296047; CC Q15831; P08238: HSP90AB1; NbExp=8; IntAct=EBI-306838, EBI-352572; CC Q15831; O95835: LATS1; NbExp=2; IntAct=EBI-306838, EBI-444209; CC Q15831; Q96L34: MARK4; NbExp=2; IntAct=EBI-306838, EBI-302319; CC Q15831; P26927: MST1; NbExp=2; IntAct=EBI-306838, EBI-6929133; CC Q15831; P54646: PRKAA2; NbExp=3; IntAct=EBI-306838, EBI-1383852; CC Q15831; Q7RTN6: STRADA; NbExp=23; IntAct=EBI-306838, EBI-1109114; CC Q15831; Q7RTN6-1: STRADA; NbExp=3; IntAct=EBI-306838, EBI-15787241; CC Q15831; Q9C0K7: STRADB; NbExp=14; IntAct=EBI-306838, EBI-306893; CC Q15831; Q8NFZ5: TNIP2; NbExp=5; IntAct=EBI-306838, EBI-359372; CC Q15831; Q9NNW5: WDR6; NbExp=3; IntAct=EBI-306838, EBI-1568315; CC Q15831; P63104: YWHAZ; NbExp=6; IntAct=EBI-306838, EBI-347088; CC -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Membrane {ECO:0000250}. CC Mitochondrion. Note=A small fraction localizes at membranes (By CC similarity). Relocates to the cytoplasm when bound to STRAD (STRADA or CC STRADB) and CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta). CC Translocates to the mitochondrion during apoptosis. PTEN promotes CC cytoplasmic localization. {ECO:0000250}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus CC {ECO:0000269|PubMed:23612973}. Cytoplasm {ECO:0000269|PubMed:23612973}. CC Note=Predominantly nuclear, but translocates to the cytoplasm in CC response to metformin or peroxynitrite treatment. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=LKB1(L); CC IsoId=Q15831-1; Sequence=Displayed; CC Name=2; Synonyms=LKB1(S); CC IsoId=Q15831-2; Sequence=VSP_041746; CC -!- TISSUE SPECIFICITY: Ubiquitously expressed. Strongest expression in CC testis and fetal liver. CC -!- PTM: Phosphorylated by ATM at Thr-363 following ionizing radiation CC (IR). Phosphorylation at Ser-428 by RPS6KA1 and/or some PKA is required CC to inhibit cell growth. Phosphorylation at Ser-428 is also required CC during neuronal polarization to mediate phosphorylation of BRSK1 and CC BRSK2 (By similarity). Phosphorylation by PKC/PRKCZ at Ser-399 in CC isoform 2 promotes metformin (or peroxynitrite)-induced nuclear export CC of STK11 and activation of AMPK. UV radiation-induced phosphorylation CC at Thr-363 mediates CDKN1A degradation (By similarity). CC {ECO:0000250|UniProtKB:Q9WTK7, ECO:0000269|PubMed:11430832, CC ECO:0000269|PubMed:12805220, ECO:0000269|PubMed:18854309}. CC -!- PTM: Acetylated. Deacetylation at Lys-48 enhances cytoplasmic CC localization and kinase activity in vitro. CC {ECO:0000269|PubMed:18687677}. CC -!- DISEASE: Peutz-Jeghers syndrome (PJS) [MIM:175200]: An autosomal CC dominant disorder characterized by melanocytic macules of the lips, CC multiple gastrointestinal hamartomatous polyps and an increased risk CC for various neoplasms, including gastrointestinal cancer. CC {ECO:0000269|PubMed:10408777, ECO:0000269|PubMed:12372054, CC ECO:0000269|PubMed:15987703, ECO:0000269|PubMed:21411391, CC ECO:0000269|PubMed:9425897, ECO:0000269|PubMed:9428765, CC ECO:0000269|PubMed:9760200, ECO:0000269|PubMed:9837816}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Testicular germ cell tumor (TGCT) [MIM:273300]: A common CC malignancy in males representing 95% of all testicular neoplasms. TGCTs CC have various pathologic subtypes including: unclassified intratubular CC germ cell neoplasia, seminoma (including cases with CC syncytiotrophoblastic cells), spermatocytic seminoma, embryonal CC carcinoma, yolk sac tumor, choriocarcinoma, and teratoma. CC {ECO:0000269|PubMed:9605748, ECO:0000269|PubMed:9887330}. Note=The gene CC represented in this entry may be involved in disease pathogenesis. CC -!- DISEASE: Note=Defects in STK11 are associated with some sporadic CC cancers, especially lung cancers. Frequently mutated and inactivated in CC non-small cell lung cancer (NSCLC). Defects promote lung cancerigenesis CC process, especially lung cancer progression and metastasis. Confers CC lung adenocarcinoma the ability to trans-differentiate into squamous CC cell carcinoma. Also able to promote lung cancer metastasis, via both CC cancer-cell autonomous and non-cancer-cell autonomous mechanisms. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. LKB1 subfamily. {ECO:0000305}. CC -!- CAUTION: Its phosphorylation by PKC/PRKCZ at Ser-428 is reported to CC promote peroxynitrite-induced nuclear export of STK11, leading to PTEN CC activation and subsequent inhibition of PI3K/AKT signaling and CC induction of apoptosis in vein endothelial cells (PubMed:18321849). CC However this paper was withdrawn by the authors due to concerns of CC image duplication in the figures. Its phosphorylation by PKC/PRKCZ has CC been confirmed in other studies (PubMed:18854309, PubMed:23612973). CC {ECO:0000269|PubMed:18321849, ECO:0000269|PubMed:18854309, CC ECO:0000269|PubMed:23612973, ECO:0000305|PubMed:31519760}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/292/STK11"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=PJS entry; CC URL="https://en.wikipedia.org/wiki/PJS"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U63333; AAB05809.1; -; mRNA. DR EMBL; AF035625; AAC39527.1; -; mRNA. DR EMBL; AF032984; AAB97833.1; -; Genomic_DNA. DR EMBL; AF055327; AAC15742.1; -; Genomic_DNA. DR EMBL; AF055320; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055321; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055322; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055323; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055324; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055325; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AF055326; AAC15742.1; JOINED; Genomic_DNA. DR EMBL; AK314858; BAG37374.1; -; mRNA. DR EMBL; AC011544; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC004221; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471139; EAW69540.1; -; Genomic_DNA. DR EMBL; BC007981; AAH07981.1; -; mRNA. DR EMBL; BC019334; AAH19334.1; -; mRNA. DR CCDS; CCDS45896.1; -. [Q15831-1] DR RefSeq; NP_000446.1; NM_000455.5. [Q15831-1] DR RefSeq; NP_001394184.1; NM_001407255.1. [Q15831-2] DR PDB; 2WTK; X-ray; 2.65 A; C/F=43-347. DR PDB; 4ZDR; X-ray; 2.90 A; A/B=333-340. DR PDB; 5WXN; X-ray; 2.93 A; C/D=331-343. DR PDB; 8VSU; EM; 2.86 A; C=1-433. DR PDBsum; 2WTK; -. DR PDBsum; 4ZDR; -. DR PDBsum; 5WXN; -. DR PDBsum; 8VSU; -. DR AlphaFoldDB; Q15831; -. DR EMDB; EMD-43506; -. DR SMR; Q15831; -. DR BioGRID; 112670; 322. DR ComplexPortal; CPX-2431; LKB1-STRAD-MO25 serine/threonine protein kinase complex, CAB39L-STRADA variant. DR ComplexPortal; CPX-2845; LKB1-STRAD-MO25 serine/threonine protein kinase complex, CAB39-STRADA variant. DR ComplexPortal; CPX-2868; LKB1-STRAD-MO25 serine/threonine protein kinase complex, CAB39-STRADB variant. DR ComplexPortal; CPX-2869; LKB1-STRAD-MO25 serine/threonine protein kinase complex, CAB39L-STRADB variant. DR CORUM; Q15831; -. DR DIP; DIP-31317N; -. DR FunCoup; Q15831; 3083. DR IntAct; Q15831; 222. DR MINT; Q15831; -. DR STRING; 9606.ENSP00000324856; -. DR BindingDB; Q15831; -. DR ChEMBL; CHEMBL5606; -. DR DrugCentral; Q15831; -. DR GlyGen; Q15831; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q15831; -. DR PhosphoSitePlus; Q15831; -. DR BioMuta; STK11; -. DR DMDM; 3024670; -. DR CPTAC; CPTAC-2999; -. DR CPTAC; CPTAC-3000; -. DR jPOST; Q15831; -. DR MassIVE; Q15831; -. DR PaxDb; 9606-ENSP00000324856; -. DR PeptideAtlas; Q15831; -. DR ProteomicsDB; 60780; -. [Q15831-1] DR ProteomicsDB; 60781; -. [Q15831-2] DR Pumba; Q15831; -. DR Antibodypedia; 2048; 1357 antibodies from 44 providers. DR CPTC; Q15831; 1 antibody. DR DNASU; 6794; -. DR Ensembl; ENST00000326873.12; ENSP00000324856.6; ENSG00000118046.19. [Q15831-1] DR Ensembl; ENST00000585465.3; ENSP00000490268.2; ENSG00000118046.19. [Q15831-2] DR Ensembl; ENST00000652231.1; ENSP00000498804.1; ENSG00000118046.19. [Q15831-2] DR GeneID; 6794; -. DR KEGG; hsa:6794; -. DR MANE-Select; ENST00000326873.12; ENSP00000324856.6; NM_000455.5; NP_000446.1. DR UCSC; uc002lrl.2; human. [Q15831-1] DR AGR; HGNC:11389; -. DR CIViC; 6794; 20 evidence items across 8 molecular profiles. DR ClinPGx; PA36198; -. DR CTD; 6794; -. DR DisGeNET; 6794; -. DR GeneCards; STK11; -. DR GeneReviews; STK11; -. DR HGNC; HGNC:11389; STK11. DR HPA; ENSG00000118046; Low tissue specificity. DR MalaCards; STK11; -. DR MIM; 175200; phenotype. DR MIM; 273300; phenotype. DR MIM; 602216; gene. DR OpenTargets; ENSG00000118046; -. DR Orphanet; 2869; Peutz-Jeghers syndrome. DR VEuPathDB; HostDB:ENSG00000118046; -. DR eggNOG; KOG0583; Eukaryota. DR GeneTree; ENSGT00940000158050; -. DR HOGENOM; CLU_000288_1_2_1; -. DR InParanoid; Q15831; -. DR OMA; AYHYGSE; -. DR OrthoDB; 68483at2759; -. DR PAN-GO; Q15831; 10 GO annotations based on evolutionary models. DR PhylomeDB; Q15831; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q15831; -. DR Reactome; R-HSA-163680; AMPK inhibits chREBP transcriptional activation activity. DR Reactome; R-HSA-380972; Energy dependent regulation of mTOR by LKB1-AMPK. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-9614657; FOXO-mediated transcription of cell death genes. DR SignaLink; Q15831; -. DR SIGNOR; Q15831; -. DR Agora; ENSG00000118046; -. DR BioGRID-ORCS; 6794; 153 hits in 1229 CRISPR screens. DR ChiTaRS; STK11; human. DR EvolutionaryTrace; Q15831; -. DR GeneWiki; STK11; -. DR GenomeRNAi; 6794; -. DR Pharos; Q15831; Tchem. DR PRO; PR:Q15831; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q15831; protein. DR Bgee; ENSG00000118046; Expressed in left testis and 156 other cell types or tissues. DR ExpressionAtlas; Q15831; baseline and differential. DR GO; GO:0005813; C:centrosome; IDA:HPA. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:MGI. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0140535; C:intracellular protein-containing complex; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; ISS:UniProtKB. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:MGI. DR GO; GO:1902554; C:serine/threonine protein kinase complex; IPI:ComplexPortal. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0030275; F:LRR domain binding; IEA:Ensembl. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0002039; F:p53 binding; IDA:UniProtKB. DR GO; GO:0030295; F:protein kinase activator activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0032147; P:activation of protein kinase activity; IDA:MGI. DR GO; GO:0043276; P:anoikis; IMP:BHF-UCL. DR GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW. DR GO; GO:0007409; P:axonogenesis; IEA:Ensembl. DR GO; GO:0071493; P:cellular response to UV-B; IDA:UniProtKB. DR GO; GO:0097484; P:dendrite extension; IEA:Ensembl. DR GO; GO:0006974; P:DNA damage response; IMP:UniProtKB. DR GO; GO:0060767; P:epithelial cell proliferation involved in prostate gland development; IEA:Ensembl. DR GO; GO:0030010; P:establishment of cell polarity; IMP:UniProtKB. DR GO; GO:0070314; P:G1 to G0 transition; IDA:UniProtKB. DR GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB. DR GO; GO:0051645; P:Golgi localization; IEA:Ensembl. DR GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IDA:UniProtKB. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:UniProtKB. DR GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0120163; P:negative regulation of cold-induced thermogenesis; ISS:YuBioLab. DR GO; GO:0060770; P:negative regulation of epithelial cell proliferation involved in prostate gland development; IEA:Ensembl. DR GO; GO:1904262; P:negative regulation of TORC1 signaling; IMP:ParkinsonsUK-UCL. DR GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:UniProtKB. DR GO; GO:0010508; P:positive regulation of autophagy; IMP:ParkinsonsUK-UCL. DR GO; GO:0050772; P:positive regulation of axonogenesis; IEA:Ensembl. DR GO; GO:1900182; P:positive regulation of protein localization to nucleus; IEA:Ensembl. DR GO; GO:0030511; P:positive regulation of transforming growth factor beta receptor signaling pathway; IMP:BHF-UCL. DR GO; GO:1901610; P:positive regulation of vesicle transport along microtubule; IMP:UniProtKB. DR GO; GO:0045059; P:positive thymic T cell selection; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006470; P:protein dephosphorylation; IMP:UniProtKB. DR GO; GO:0034504; P:protein localization to nucleus; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0051726; P:regulation of cell cycle; TAS:Reactome. DR GO; GO:0001558; P:regulation of cell growth; ISS:UniProtKB. DR GO; GO:0048814; P:regulation of dendrite morphogenesis; IEA:Ensembl. DR GO; GO:0051896; P:regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IEA:Ensembl. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0030111; P:regulation of Wnt signaling pathway; IBA:GO_Central. DR GO; GO:0010212; P:response to ionizing radiation; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; IBA:GO_Central. DR GO; GO:0007283; P:spermatogenesis; IEA:UniProtKB-KW. DR GO; GO:0050852; P:T cell receptor signaling pathway; IEA:Ensembl. DR GO; GO:0001894; P:tissue homeostasis; IEA:Ensembl. DR GO; GO:0001944; P:vasculature development; ISS:UniProtKB. DR CDD; cd14119; STKc_LKB1; 1. DR FunFam; 1.10.510.10:FF:000245; serine/threonine-protein kinase STK11; 1. DR FunFam; 3.30.200.20:FF:000235; serine/threonine-protein kinase STK11; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00613; -. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR039154; LKB1_c. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24346; MAP/MICROTUBULE AFFINITY-REGULATING KINASE; 1. DR PANTHER; PTHR24346:SF94; NON-SPECIFIC SERINE_THREONINE PROTEIN KINASE; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding; KW Autophagy; Cell cycle; Cytoplasm; Differentiation; Disease variant; KW DNA damage; Kinase; Lipoprotein; Magnesium; Manganese; Membrane; KW Metal-binding; Methylation; Mitochondrion; Nucleotide-binding; Nucleus; KW Palmitate; Phosphoprotein; Prenylation; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Spermatogenesis; KW Transferase; Tumor suppressor. FT CHAIN 1..430 FT /note="Serine/threonine-protein kinase STK11" FT /id="PRO_0000086699" FT PROPEP 431..433 FT /note="Removed in mature form" FT /evidence="ECO:0000250" FT /id="PRO_0000422300" FT DOMAIN 49..309 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 45..90 FT /note="Sufficient for interaction with SIRT1" FT /evidence="ECO:0000269|PubMed:18687677" FT REGION 312..331 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 397..433 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 316..326 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 423..433 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 176 FT /note="Proton acceptor" FT BINDING 55..63 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 78 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT MOD_RES 31 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 44 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 48 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 96 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 97 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 189 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11430832" FT MOD_RES 296 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 311 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 325 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9WTK7" FT MOD_RES 336 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12805220" FT MOD_RES 363 FT /note="Phosphothreonine; by ATM and autocatalysis" FT /evidence="ECO:0000269|PubMed:12805220" FT MOD_RES 401 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 416 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 423 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT MOD_RES 428 FT /note="Phosphoserine; by autocatalysis, PKA, PKC/PRKCZ and FT RPS6KA1" FT /evidence="ECO:0000269|PubMed:18854309" FT MOD_RES 430 FT /note="Cysteine methyl ester" FT /evidence="ECO:0000250" FT MOD_RES 431 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:18687677" FT LIPID 418 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000250" FT LIPID 430 FT /note="S-farnesyl cysteine" FT /evidence="ECO:0000250" FT VAR_SEQ 371..433 FT /note="QVPEEEASHNGQRRGLPKAVCMNGTEAAQLSTKSRAEGRAPNPARKACSASS FT KIRRLSACKQQ -> GEEASEAGLRAERGLQKSEGSDLSGEEASRPAPQ (in FT isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_041746" FT VARIANT 14 FT /note="E -> K (in cervical cancer; somatic mutation; FT dbSNP:rs2145404557)" FT /evidence="ECO:0000269|PubMed:12533684" FT /id="VAR_065627" FT VARIANT 16 FT /note="E -> G (in PJS; dbSNP:rs2145404592)" FT /evidence="ECO:0000269|PubMed:21411391" FT /id="VAR_065628" FT VARIANT 49 FT /note="Y -> D (in melanoma; sporadic malignant; somatic FT mutation; dbSNP:rs137853080)" FT /evidence="ECO:0000269|PubMed:10201537" FT /id="VAR_033138" FT VARIANT 50..53 FT /note="Missing (in PJS)" FT /evidence="ECO:0000269|PubMed:9837816" FT /id="VAR_071057" FT VARIANT 66 FT /note="V -> M (in cervical carcinoma; somatic mutation; FT dbSNP:rs1599915144)" FT /evidence="ECO:0000269|PubMed:12533684, FT ECO:0000269|PubMed:19892943" FT /id="VAR_065629" FT VARIANT 67 FT /note="L -> P (in PJS; abolishes kinase activity, leading FT to loss of autophosphorylation; dbSNP:rs137853077)" FT /evidence="ECO:0000269|PubMed:9428765, FT ECO:0000269|PubMed:9837816" FT /id="VAR_006202" FT VARIANT 86 FT /note="R -> G (in sporadic cancer; somatic mutation; no FT effect on kinase activity nor in heterotrimeric complex FT assembly with STRADA and CAB39; dbSNP:rs1057520039)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065630" FT VARIANT 87 FT /note="R -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs1568690463)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041139" FT VARIANT 123 FT /note="Q -> R (in sporadic cancer; somatic mutation; no FT effect on kinase activity nor in heterotrimeric complex FT assembly with STRADA and CAB39; dbSNP:rs764449808)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065631" FT VARIANT 135 FT /note="G -> R (in melanoma; sporadic malignant; somatic FT mutation; dbSNP:rs137853081)" FT /evidence="ECO:0000269|PubMed:10201537" FT /id="VAR_033139" FT VARIANT 157 FT /note="F -> S (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs2145424124)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065632" FT VARIANT 160 FT /note="L -> P (in cervical cancer; somatic mutation; FT dbSNP:rs2145424155)" FT /evidence="ECO:0000269|PubMed:12533684" FT /id="VAR_065633" FT VARIANT 162..164 FT /note="DGL -> NDM (in PJS)" FT /evidence="ECO:0000269|PubMed:10408777" FT /id="VAR_007920" FT VARIANT 163 FT /note="G -> D (in TGCT; a tumor with seminoma and teratoma FT components; somatic mutation; severely impaired but FT detectable kinase activity; impairs heterotrimeric complex FT assembly with STRADA and CAB39; predominantly nuclear FT localization; dbSNP:rs137853078)" FT /evidence="ECO:0000269|PubMed:19892943, FT ECO:0000269|PubMed:9605748, ECO:0000269|PubMed:9887330" FT /id="VAR_033140" FT VARIANT 170 FT /note="Q -> P (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs876659972)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065634" FT VARIANT 171 FT /note="G -> S (in colorectal cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1599926499)" FT /evidence="ECO:0000269|PubMed:19892943, FT ECO:0000269|PubMed:9731485" FT /id="VAR_065635" FT VARIANT 174 FT /note="H -> R (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065636" FT VARIANT 176 FT /note="D -> N (in PJS; loss of kinase activity, leading to FT greatly reduced autophosphorylation; fails to phosphorylate FT PTEN in vitro; no significant effect on nucleocytoplasmic FT localization; dbSNP:rs730881979)" FT /evidence="ECO:0000269|PubMed:15987703, FT ECO:0000269|PubMed:9837816" FT /id="VAR_071058" FT VARIANT 176 FT /note="D -> Y (in sporadic cancer; somatic mutation; Loss FT of kinase activity)" FT /evidence="ECO:0000269|PubMed:12805220, FT ECO:0000269|PubMed:19892943" FT /id="VAR_065637" FT VARIANT 177 FT /note="I -> N (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1057520041)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065638" FT VARIANT 181 FT /note="N -> E (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; requires 2 nucleotide substitutions; FT dbSNP:rs1568707668)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065639" FT VARIANT 194 FT /note="D -> N (in PJS; dbSNP:rs121913315)" FT /evidence="ECO:0000269|PubMed:10408777" FT /id="VAR_007921" FT VARIANT 194 FT /note="D -> V (in lung cancer; somatic mutation; FT dbSNP:rs121913316)" FT /evidence="ECO:0000269|PubMed:10079245" FT /id="VAR_065640" FT VARIANT 194 FT /note="D -> Y (in melanoma; sporadic malignant; somatic FT mutation; dbSNP:rs121913315)" FT /evidence="ECO:0000269|PubMed:10208439" FT /id="VAR_033141" FT VARIANT 199 FT /note="E -> K (in colorectal cancer; somatic mutation; FT impaired kinase activity; dbSNP:rs121913317)" FT /evidence="ECO:0000269|PubMed:9731485" FT /id="VAR_065641" FT VARIANT 199 FT /note="E -> Q (in sporadic cancer; somatic mutation; does FT not affect kinase activity; dbSNP:rs121913317)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065642" FT VARIANT 205 FT /note="A -> T (in sporadic cancer; somatic mutation; no FT effect heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs730881981)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065643" FT VARIANT 208 FT /note="D -> N (in colorectal cancer; somatic mutation; no FT effect heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1555738372)" FT /evidence="ECO:0000269|PubMed:9731485" FT /id="VAR_065644" FT VARIANT 215 FT /note="G -> D (in colorectal cancer; somatic mutation; FT dbSNP:rs1057520038)" FT /evidence="ECO:0000269|PubMed:9731485" FT /id="VAR_065645" FT VARIANT 216 FT /note="S -> F (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1057520017)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065646" FT VARIANT 223 FT /note="E -> V (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs2080776621)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065647" FT VARIANT 230 FT /note="T -> P (in sporadic cancer; somatic mutation; no FT effect heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs2145425367)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065648" FT VARIANT 231 FT /note="F -> L (in cervical cancer; somatic mutation; FT dbSNP:rs929783669)" FT /evidence="ECO:0000269|PubMed:12533684" FT /id="VAR_065649" FT VARIANT 232 FT /note="S -> P (in sporadic cancer; somatic mutation; no FT effect heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs2145425398)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065650" FT VARIANT 239 FT /note="W -> C (in PJS; late onset suggests reduced FT penetrance; dbSNP:rs137853082)" FT /evidence="ECO:0000269|PubMed:12372054" FT /id="VAR_033142" FT VARIANT 245 FT /note="L -> R (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065651" FT VARIANT 247 FT /note="Missing (in PJS)" FT /evidence="ECO:0000269|PubMed:9760200" FT /id="VAR_006203" FT VARIANT 250 FT /note="T -> P (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1568709142)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065652" FT VARIANT 272 FT /note="Y -> H (in sporadic cancer; somatic mutation; no FT effect on kinase activity nor in heterotrimeric complex FT assembly with STRADA and CAB39; dbSNP:rs2145427076)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065653" FT VARIANT 277 FT /note="D -> Y (in sporadic cancer; somatic mutation; no FT effect on kinase activity nor in heterotrimeric complex FT assembly with STRADA and CAB39; dbSNP:rs1555738692)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065654" FT VARIANT 281 FT /note="P -> L (in ovarian carcinoma; somatic mutation; FT dbSNP:rs121913322)" FT /evidence="ECO:0000269|PubMed:10429654" FT /id="VAR_065655" FT VARIANT 285 FT /note="L -> Q (in sporadic cancer; somatic mutation; FT impairs heterotrimeric complex assembly with STRADA and FT CAB39; dbSNP:rs1555738724)" FT /evidence="ECO:0000269|PubMed:19892943" FT /id="VAR_065656" FT VARIANT 297 FT /note="R -> K (in PJS; dbSNP:rs1568710381)" FT /evidence="ECO:0000269|PubMed:10408777" FT /id="VAR_007922" FT VARIANT 303..306 FT /note="IRQH -> N (in PJS)" FT /id="VAR_033143" FT VARIANT 308 FT /note="W -> C (in PJS; abolishes kinase activity, leading FT to loss of autophosphorylation; dbSNP:rs1057520042)" FT /evidence="ECO:0000269|PubMed:9837816" FT /id="VAR_071059" FT VARIANT 314 FT /note="P -> H (in colorectal cancer; no effect FT heterotrimeric complex assembly with STRADA and CAB39; FT dbSNP:rs1064795752)" FT /evidence="ECO:0000269|PubMed:9809980" FT /id="VAR_065657" FT VARIANT 315 FT /note="P -> S (in PJS; uncertain significance; no effect FT heterotrimeric complex assembly with STRADA and CAB39; FT dbSNP:rs786202431)" FT /evidence="ECO:0000269|PubMed:12372054, FT ECO:0000269|PubMed:19892943" FT /id="VAR_033144" FT VARIANT 324 FT /note="P -> L (in gastric carcinoma; no effect FT heterotrimeric complex assembly with STRADA and CAB39; FT dbSNP:rs367807476)" FT /evidence="ECO:0000269|PubMed:9683800" FT /id="VAR_065658" FT VARIANT 354 FT /note="F -> L (in colorectal cancer; somatic mutation; FT dbSNP:rs59912467)" FT /evidence="ECO:0000269|PubMed:9731485" FT /id="VAR_065659" FT VARIANT 367 FT /note="T -> M (in colorectal cancer; somatic mutation; FT dbSNP:rs587782835)" FT /evidence="ECO:0000269|PubMed:9731485" FT /id="VAR_065660" FT MUTAGEN 44 FT /note="K->R: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:18687677" FT MUTAGEN 48 FT /note="K->Q: No effect on basal nucleocytoplasmic FT localization, but fails to translocate to the cytoplasm FT when coexpressed with SIRT1." FT /evidence="ECO:0000269|PubMed:18687677" FT MUTAGEN 48 FT /note="K->R: Enhanced phosphorylation at Thr-336 and Ser- FT 428, enhanced cytoplasmic localization and increased kinase FT activity." FT /evidence="ECO:0000269|PubMed:18687677" FT MUTAGEN 74 FT /note="R->A: Impaired formation of a heterotrimeric complex FT with STRADA and CAB39; when associated with A-204." FT /evidence="ECO:0000269|PubMed:19892943" FT MUTAGEN 78 FT /note="K->I: Loss of kinase activity, leading to greatly FT reduced autophosphorylation." FT /evidence="ECO:0000269|PubMed:11430832, FT ECO:0000269|PubMed:9837816" FT MUTAGEN 78 FT /note="K->M: Loss of kinase activity, leading to reduced FT autophosphorylation and acting as a dominant-negative FT mutant." FT /evidence="ECO:0000269|PubMed:11430832, FT ECO:0000269|PubMed:9837816" FT MUTAGEN 96 FT /note="K->R: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:18687677" FT MUTAGEN 97 FT /note="K->R: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:18687677" FT MUTAGEN 189 FT /note="T->A: Reduced phosphorylation." FT /evidence="ECO:0000269|PubMed:11430832" FT MUTAGEN 194 FT /note="D->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:14517248, FT ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:19892943" FT MUTAGEN 204 FT /note="F->A: No effect. Impaired formation of a FT heterotrimeric complex with STRADA and CAB39; when FT associated with A-74." FT /evidence="ECO:0000269|PubMed:19892943" FT MUTAGEN 428 FT /note="S->A,E: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:18854309" FT STRAND 54..57 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 62..68 FT /evidence="ECO:0007829|PDB:2WTK" FT TURN 69..71 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 74..80 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 82..87 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 91..102 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 113..118 FT /evidence="ECO:0007829|PDB:2WTK" FT TURN 120..123 FT /evidence="ECO:0007829|PDB:8VSU" FT STRAND 125..130 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 133..135 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 136..142 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 150..169 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 179..181 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 182..184 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 190..192 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 195..197 FT /evidence="ECO:0007829|PDB:8VSU" FT HELIX 217..219 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 222..225 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 231..233 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 234..250 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 260..269 FT /evidence="ECO:0007829|PDB:2WTK" FT STRAND 276..278 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 280..289 FT /evidence="ECO:0007829|PDB:2WTK" FT TURN 294..296 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 300..305 FT /evidence="ECO:0007829|PDB:2WTK" FT HELIX 307..310 FT /evidence="ECO:0007829|PDB:2WTK" FT TURN 326..328 FT /evidence="ECO:0007829|PDB:8VSU" FT HELIX 334..336 FT /evidence="ECO:0007829|PDB:4ZDR" FT HELIX 339..341 FT /evidence="ECO:0007829|PDB:2WTK" FT MOD_RES Q15831-2:399 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:23612973" SQ SEQUENCE 433 AA; 48636 MW; 6DF4C37AB7A89569 CRC64; MEVVDPQQLG MFTEGELMSV GMDTFIHRID STEVIYQPRR KRAKLIGKYL MGDLLGEGSY GKVKEVLDSE TLCRRAVKIL KKKKLRRIPN GEANVKKEIQ LLRRLRHKNV IQLVDVLYNE EKQKMYMVME YCVCGMQEML DSVPEKRFPV CQAHGYFCQL IDGLEYLHSQ GIVHKDIKPG NLLLTTGGTL KISDLGVAEA LHPFAADDTC RTSQGSPAFQ PPEIANGLDT FSGFKVDIWS AGVTLYNITT GLYPFEGDNI YKLFENIGKG SYAIPGDCGP PLSDLLKGML EYEPAKRFSI RQIRQHSWFR KKHPPAEAPV PIPPSPDTKD RWRSMTVVPY LEDLHGADED EDLFDIEDDI IYTQDFTVPG QVPEEEASHN GQRRGLPKAV CMNGTEAAQL STKSRAEGRA PNPARKACSA SSKIRRLSAC KQQ // ID STK36_HUMAN Reviewed; 1315 AA. AC Q9NRP7; B7WPM3; Q8TC32; Q9H9N9; Q9UF35; Q9ULE2; DT 21-MAR-2006, integrated into UniProtKB/Swiss-Prot. DT 21-MAR-2006, sequence version 2. DT 28-JAN-2026, entry version 203. DE RecName: Full=Serine/threonine-protein kinase 36; DE EC=2.7.11.1; DE AltName: Full=Fused homolog; GN Name=STK36 {ECO:0000312|EMBL:AAH26158.1}; GN Synonyms=KIAA1278 {ECO:0000312|EMBL:BAA86592.1}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305, ECO:0000312|EMBL:AAF97028.1} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, INTERACTION WITH GLI1; RP GLI2; GLI3 AND SUFU, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND RP MUTAGENESIS OF LYS-33. RX PubMed=10806483; DOI=10.1038/35010610; RA Murone M., Luoh S.-L., Stone D., Li W., Gurney A., Armanini M., Grey C., RA Rosenthal A., de Sauvage F.J.; RT "Gli regulation by the opposing activities of fused and suppressor of RT fused."; RL Nat. Cell Biol. 2:310-312(2000). RN [2] {ECO:0000305, ECO:0000312|EMBL:BAA86592.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain {ECO:0000312|EMBL:BAA86592.1}; RX PubMed=10574462; DOI=10.1093/dnares/6.5.337; RA Nagase T., Ishikawa K., Kikuno R., Hirosawa M., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XV. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 6:337-345(1999). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [4] {ECO:0000305, ECO:0000312|EMBL:AAH26158.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS ASN-463 RP AND THR-767. RC TISSUE=Testis {ECO:0000312|EMBL:AAH26158.1}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 823-1315 (ISOFORM 1). RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [6] {ECO:0000305, ECO:0000312|EMBL:BAB14184.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 839-1315 (ISOFORM 1), AND VARIANT RP ASP-1003. RC TISSUE=Teratocarcinoma {ECO:0000312|EMBL:BAB14184.1}; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP VARIANTS [LARGE SCALE ANALYSIS] MET-90; TRP-240; ARG-295; ASN-329; VAL-462; RP SER-476; TRP-477; GLN-583; CYS-660; PRO-672; TYR-767; ALA-816; GLN-839; RP VAL-840; ASP-1003; CYS-1111; GLN-1112; LYS-1138; SER-1185 AND PRO-1313. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [8] RP INVOLVEMENT IN CILD46, FUNCTION, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RX PubMed=28543983; DOI=10.1002/humu.23261; RA Edelbusch C., Cindric S., Dougherty G.W., Loges N.T., Olbrich H., RA Rivlin J., Wallmeier J., Pennekamp P., Amirav I., Omran H.; RT "Mutation of serine/threonine protein kinase 36 (STK36) causes primary RT ciliary dyskinesia with a central pair defect."; RL Hum. Mutat. 38:964-969(2017). CC -!- FUNCTION: Serine/threonine protein kinase which plays an important role CC in the sonic hedgehog (Shh) pathway by regulating the activity of GLI CC transcription factors (PubMed:10806483). Controls the activity of the CC transcriptional regulators GLI1, GLI2 and GLI3 by opposing the effect CC of SUFU and promoting their nuclear localization (PubMed:10806483). CC GLI2 requires an additional function of STK36 to become CC transcriptionally active, but the enzyme does not need to possess an CC active kinase catalytic site for this to occur (PubMed:10806483). CC Required for postnatal development, possibly by regulating the CC homeostasis of cerebral spinal fluid or ciliary function. Essential for CC construction of the central pair apparatus of motile cilia. CC {ECO:0000269|PubMed:10806483, ECO:0000269|PubMed:28543983}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000250|UniProtKB:P23647}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000250|UniProtKB:P23647}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000305}; CC -!- SUBUNIT: Interacts with GLI1, GLI2 and GLI3 (PubMed:10806483). CC Interacts with SPAG16 and KIF27. {ECO:0000250|UniProtKB:Q69ZM6, CC ECO:0000269|PubMed:10806483}. CC -!- INTERACTION: CC Q9NRP7; P54252: ATXN3; NbExp=3; IntAct=EBI-863797, EBI-946046; CC Q9NRP7; G5E9A7: DMWD; NbExp=3; IntAct=EBI-863797, EBI-10976677; CC Q9NRP7; P14136: GFAP; NbExp=3; IntAct=EBI-863797, EBI-744302; CC Q9NRP7; O14901: KLF11; NbExp=3; IntAct=EBI-863797, EBI-948266; CC Q9NRP7; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-863797, EBI-5235340; CC Q9NRP7; Q9UMX1: SUFU; NbExp=3; IntAct=EBI-863797, EBI-740595; CC Q9NRP7; Q96C45: ULK4; NbExp=4; IntAct=EBI-863797, EBI-3922541; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10806483}. Nucleus CC {ECO:0000269|PubMed:10806483}. Cytoplasm, cytoskeleton, cilium axoneme CC {ECO:0000269|PubMed:28543983}. Note=Low levels also present in the CC nucleus. {ECO:0000269|PubMed:10806483}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1 {ECO:0000269|PubMed:10806483, ECO:0000269|PubMed:14702039, CC ECO:0000269|PubMed:15489334}; CC IsoId=Q9NRP7-1; Sequence=Displayed; CC Name=2 {ECO:0000269|PubMed:10574462}; CC IsoId=Q9NRP7-2; Sequence=VSP_051983; CC -!- TISSUE SPECIFICITY: Expressed at low levels in most fetal tissues, CC adult ovaries and at high levels in adult testis, where it is localized CC in germ cells (PubMed:10806483). Expressed in respiratory epithelial CC cells of the lung (PubMed:28543983). {ECO:0000269|PubMed:10806483, CC ECO:0000269|PubMed:28543983}. CC -!- DISEASE: Ciliary dyskinesia, primary, 46 (CILD46) [MIM:619436]: A form CC of primary ciliary dyskinesia, a disorder characterized by CC abnormalities of motile cilia. Respiratory infections leading to CC chronic inflammation and bronchiectasis are recurrent, due to defects CC in the respiratory cilia. CILD46 is an autosomal recessive form. No CC situs abnormalities have been observed. {ECO:0000269|PubMed:28543983}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA86592.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAB14184.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF200815; AAF97028.1; -; mRNA. DR EMBL; AB033104; BAA86592.1; ALT_INIT; mRNA. DR EMBL; AC009974; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC026158; AAH26158.1; -; mRNA. DR EMBL; AL133630; CAB63754.1; -; mRNA. DR EMBL; AK022692; BAB14184.1; ALT_FRAME; mRNA. DR CCDS; CCDS2421.1; -. [Q9NRP7-1] DR CCDS; CCDS58750.1; -. [Q9NRP7-2] DR PIR; T43465; T43465. DR RefSeq; NP_001230242.1; NM_001243313.2. [Q9NRP7-2] DR RefSeq; NP_001356352.1; NM_001369423.1. [Q9NRP7-1] DR RefSeq; NP_056505.2; NM_015690.5. [Q9NRP7-1] DR AlphaFoldDB; Q9NRP7; -. DR SMR; Q9NRP7; -. DR BioGRID; 118032; 44. DR FunCoup; Q9NRP7; 1539. DR IntAct; Q9NRP7; 40. DR STRING; 9606.ENSP00000295709; -. DR BindingDB; Q9NRP7; -. DR ChEMBL; CHEMBL4312; -. DR DrugBank; DB11718; Encorafenib. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q9NRP7; -. DR iPTMnet; Q9NRP7; -. DR PhosphoSitePlus; Q9NRP7; -. DR BioMuta; STK36; -. DR DMDM; 90101761; -. DR jPOST; Q9NRP7; -. DR MassIVE; Q9NRP7; -. DR PaxDb; 9606-ENSP00000295709; -. DR PeptideAtlas; Q9NRP7; -. DR ProteomicsDB; 82401; -. [Q9NRP7-1] DR ProteomicsDB; 82402; -. [Q9NRP7-2] DR Antibodypedia; 34284; 179 antibodies from 29 providers. DR DNASU; 27148; -. DR Ensembl; ENST00000295709.8; ENSP00000295709.3; ENSG00000163482.13. [Q9NRP7-1] DR Ensembl; ENST00000392105.7; ENSP00000375954.3; ENSG00000163482.13. [Q9NRP7-2] DR Ensembl; ENST00000440309.5; ENSP00000394095.1; ENSG00000163482.13. [Q9NRP7-1] DR GeneID; 27148; -. DR KEGG; hsa:27148; -. DR MANE-Select; ENST00000295709.8; ENSP00000295709.3; NM_015690.5; NP_056505.2. DR UCSC; uc002viu.4; human. [Q9NRP7-1] DR AGR; HGNC:17209; -. DR ClinPGx; PA38212; -. DR CTD; 27148; -. DR DisGeNET; 27148; -. DR GeneCards; STK36; -. DR HGNC; HGNC:17209; STK36. DR HPA; ENSG00000163482; Low tissue specificity. DR MalaCards; STK36; -. DR MIM; 607652; gene. DR MIM; 619436; phenotype. DR OpenTargets; ENSG00000163482; -. DR Orphanet; 244; Primary ciliary dyskinesia. DR VEuPathDB; HostDB:ENSG00000163482; -. DR eggNOG; KOG0597; Eukaryota. DR GeneTree; ENSGT00940000158375; -. DR HOGENOM; CLU_002453_2_0_1; -. DR InParanoid; Q9NRP7; -. DR OMA; LCPSFLH; -. DR OrthoDB; 266718at2759; -. DR PAN-GO; Q9NRP7; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q9NRP7; -. DR PathwayCommons; Q9NRP7; -. DR SignaLink; Q9NRP7; -. DR SIGNOR; Q9NRP7; -. DR Agora; ENSG00000163482; -. DR BioGRID-ORCS; 27148; 6 hits in 1185 CRISPR screens. DR ChiTaRS; STK36; human. DR GeneWiki; STK36; -. DR GenomeRNAi; 27148; -. DR Pharos; Q9NRP7; Tbio. DR PRO; PR:Q9NRP7; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q9NRP7; protein. DR Bgee; ENSG00000163482; Expressed in right uterine tube and 146 other cell types or tissues. DR ExpressionAtlas; Q9NRP7; baseline and differential. DR GO; GO:0005930; C:axoneme; IEA:UniProtKB-SubCell. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005576; C:extracellular region; IEA:GOC. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; TAS:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IMP:FlyBase. DR GO; GO:0001222; F:transcription corepressor binding; IDA:UniProtKB. DR GO; GO:0035082; P:axoneme assembly; IMP:UniProtKB. DR GO; GO:0007420; P:brain development; IEA:Ensembl. DR GO; GO:0060271; P:cilium assembly; IMP:UniProtKB. DR GO; GO:0003351; P:epithelial cilium movement involved in extracellular fluid movement; IEA:Ensembl. DR GO; GO:0045880; P:positive regulation of smoothened signaling pathway; ISS:UniProtKB. DR GO; GO:0009791; P:post-embryonic development; ISS:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; TAS:UniProtKB. DR GO; GO:0051090; P:regulation of DNA-binding transcription factor activity; IDA:UniProtKB. DR GO; GO:0007224; P:smoothened signaling pathway; IMP:FlyBase. DR CDD; cd14002; STKc_STK36; 1. DR FunFam; 3.30.200.20:FF:000042; Aurora kinase A; 1. DR FunFam; 1.10.510.10:FF:000292; Serine/threonine-protein kinase 36; 1. DR FunFam; 1.25.10.10:FF:000325; Serine/threonine-protein kinase 36; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR22983; PROTEIN KINASE RELATED; 1. DR PANTHER; PTHR22983:SF6; SERINE_THREONINE-PROTEIN KINASE 36; 1. DR Pfam; PF13646; HEAT_2; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF48371; ARM repeat; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Cell projection; Ciliopathy; KW Cilium biogenesis/degradation; Cytoplasm; Cytoskeleton; KW Developmental protein; Kinase; Magnesium; Metal-binding; KW Nucleotide-binding; Nucleus; Primary ciliary dyskinesia; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..1315 FT /note="Serine/threonine-protein kinase 36" FT /id="PRO_0000229020" FT DOMAIN 4..254 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 312..346 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 365..387 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 125 FT /note="Proton acceptor" FT /evidence="ECO:0000250|UniProtKB:P23647, FT ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE- FT ProRule:PRU10027" FT BINDING 10..18 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:P23647, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 33 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT VAR_SEQ 838..858 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10574462" FT /id="VSP_051983" FT VARIANT 90 FT /note="I -> M (in dbSNP:rs55706732)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041177" FT VARIANT 240 FT /note="R -> W (in dbSNP:rs35038757)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041178" FT VARIANT 295 FT /note="K -> R (in dbSNP:rs1863703)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041179" FT VARIANT 329 FT /note="D -> N (in dbSNP:rs34027859)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041180" FT VARIANT 462 FT /note="L -> V (in dbSNP:rs45586733)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041181" FT VARIANT 463 FT /note="K -> N (in dbSNP:rs17856747)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_025727" FT VARIANT 476 FT /note="F -> S (in dbSNP:rs34128793)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041182" FT VARIANT 477 FT /note="R -> W (in dbSNP:rs16859180)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041183" FT VARIANT 583 FT /note="R -> Q (in dbSNP:rs1344642)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041184" FT VARIANT 638 FT /note="Q -> P (in dbSNP:rs6709303)" FT /id="VAR_057112" FT VARIANT 660 FT /note="S -> C (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation; dbSNP:rs1244829273)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041185" FT VARIANT 672 FT /note="L -> P (in dbSNP:rs35448374)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041186" FT VARIANT 767 FT /note="S -> T (in dbSNP:rs17856748)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_025728" FT VARIANT 767 FT /note="S -> Y (in an ovarian papillary serous FT adenocarcinoma sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041187" FT VARIANT 816 FT /note="T -> A (in dbSNP:rs34271431)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041188" FT VARIANT 839 FT /note="R -> Q (in dbSNP:rs13023540)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041189" FT VARIANT 840 FT /note="L -> V (in dbSNP:rs36099639)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041190" FT VARIANT 1003 FT /note="G -> D (in dbSNP:rs1863704)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:17344846" FT /id="VAR_025729" FT VARIANT 1004 FT /note="V -> I (in dbSNP:rs55633575)" FT /id="VAR_061747" FT VARIANT 1111 FT /note="Y -> C (in dbSNP:rs56278660)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041191" FT VARIANT 1112 FT /note="R -> Q (in dbSNP:rs12993599)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041192" FT VARIANT 1138 FT /note="Q -> K (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041193" FT VARIANT 1185 FT /note="P -> S (in an ovarian endometrioid sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041194" FT VARIANT 1313 FT /note="H -> P" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041195" FT MUTAGEN 33 FT /note="K->R: No effect on nuclear localization of GLI1 or FT GLI2 or on GLI-mediated transcription." FT /evidence="ECO:0000269|PubMed:10806483" FT CONFLICT 229 FT /note="N -> D (in Ref. 4; AAH26158)" FT /evidence="ECO:0000305" FT CONFLICT 971..986 FT /note="Missing (in Ref. 6)" FT /evidence="ECO:0000305" FT CONFLICT 1003 FT /note="G -> V (in Ref. 1; AAF97028)" FT /evidence="ECO:0000305" SQ SEQUENCE 1315 AA; 143995 MW; 793F4638F1871C01 CRC64; MEKYHVLEMI GEGSFGRVYK GRRKYSAQVV ALKFIPKLGR SEKELRNLQR EIEIMRGLRH PNIVHMLDSF ETDKEVVVVT DYAEGELFQI LEDDGKLPED QVQAIAAQLV SALYYLHSHR ILHRDMKPQN ILLAKGGGIK LCDFGFARAM STNTMVLTSI KGTPLYMSPE LVEERPYDHT ADLWSVGCIL YELAVGTPPF YATSIFQLVS LILKDPVRWP STISPCFKNF LQGLLTKDPR QRLSWPDLLY HPFIAGHVTI ITEPAGPDLG TPFTSRLPPE LQVLKDEQAH RLAPKGNQSR ILTQAYKRMA EEAMQKKHQN TGPALEQEDK TSKVAPGTAP LPRLGATPQE SSLLAGILAS ELKSSWAKSG TGEVPSAPRE NRTTPDCERA FPEERPEVLG QRSTDVVDLE NEEPDSDNEW QHLLETTEPV PIQLKAPLTL LCNPDFCQRI QSQLHEAGGQ ILKGILEGAS HILPAFRVLS SLLSSCSDSV ALYSFCREAG LPGLLLSLLR HSQESNSLQQ QSWYGTFLQD LMAVIQAYFA CTFNLERSQT SDSLQVFQEA ANLFLDLLGK LLAQPDDSEQ TLRRDSLMCF TVLCEAMDGN SRAISKAFYS SLLTTQQVVL DGLLHGLTVP QLPVHTPQGA PQVSQPLREQ SEDIPGAISS ALAAICTAPV GLPDCWDAKE QVCWHLANQL TEDSSQLRPS LISGLQHPIL CLHLLKVLYS CCLVSEGLCR LLGQEPLALE SLFMLIQGKV KVVDWEESTE VTLYFLSLLV FRLQNLPCGM EKLGSDVATL FTHSHVVSLV SAAACLLGQL GQQGVTFDLQ PMEWMAAATH ALSAPAEVRL TPPGSCGFYD GLLILLLQLL TEQGKASLIR DMSSSEMWTV LWHRFSMVLR LPEEASAQEG ELSLSSPPSP EPDWTLISPQ GMAALLSLAM ATFTQEPQLC LSCLSQHGSI LMSILKHLLC PSFLNQLRQA PHGSEFLPVV VLSVCQLLCF PFALDMDADL LIGVLADLRD SEVAAHLLQV CCYHLPLMQV ELPISLLTRL ALMDPTSLNQ FVNTVSASPR TIVSFLSVAL LSDQPLLTSD LLSLLAHTAR VLSPSHLSFI QELLAGSDES YRPLRSLLGH PENSVRAHTY RLLGHLLQHS MALRGALQSQ SGLLSLLLLG LGDKDPVVRC SASFAVGNAA YQAGPLGPAL AAAVPSMTQL LGDPQAGIRR NVASALGNLG PEGLGEELLQ CEVPQRLLEM ACGDPQPNVK EAALIALRSL QQEPGIHQVL VSLGASEKLS LLSLGNQSLP HSSPRPASAK HCRKLIHLLR PAHSM // ID STK40_HUMAN Reviewed; 435 AA. AC Q8N2I9; D3DPS8; Q5VTK8; Q5VTK9; Q6ZMN1; Q8N2J8; Q8N3I6; Q96HN6; Q96I44; AC Q9BSA3; Q9H7H6; DT 17-OCT-2006, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 2. DT 28-JAN-2026, entry version 178. DE RecName: Full=Serine/threonine-protein kinase 40; DE EC=2.7.11.1; DE AltName: Full=SINK-homologous serine/threonine-protein kinase; DE AltName: Full=Sugen kinase 495; DE Short=SgK495; GN Name=STK40; Synonyms=SGK495, SHIK; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Brain; RA Shan Y.X., Wu H., Yu L.; RT "Cloning and characterization of a novel Ser/Thr-like kinase."; RL Submitted (DEC-2002) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3), AND VARIANT RP THR-395. RC TISSUE=Ovary, Spleen, and Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Melanoma; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 4), AND VARIANT RP THR-395. RC TISSUE=Kidney, and Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP IDENTIFICATION. RX PubMed=12471243; DOI=10.1126/science.1075762; RA Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S.; RT "The protein kinase complement of the human genome."; RL Science 298:1912-1934(2002). RN [8] RP FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=13679039; DOI=10.1016/j.bbrc.2003.08.069; RA Huang J., Teng L., Liu T., Li L., Chen D., Li F., Xu L.-G., Zhai Z., RA Shu H.-B.; RT "Identification of a novel serine/threonine kinase that inhibits TNF- RT induced NF-kappaB activation and p53-induced transcription."; RL Biochem. Biophys. Res. Commun. 309:774-778(2003). RN [9] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-10; THR-133; GLN-211 AND THR-395. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: May be a negative regulator of NF-kappa-B and p53-mediated CC gene transcription. {ECO:0000269|PubMed:13679039}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- INTERACTION: CC Q8N2I9; Q9GZT3: SLIRP; NbExp=3; IntAct=EBI-716112, EBI-1050793; CC Q8N2I9; Q96RU8: TRIB1; NbExp=6; IntAct=EBI-716112, EBI-492555; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:13679039}. Cytoplasm CC {ECO:0000269|PubMed:13679039}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=Q8N2I9-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8N2I9-2; Sequence=VSP_020896, VSP_020898; CC Name=3; CC IsoId=Q8N2I9-3; Sequence=VSP_020899, VSP_020900; CC Name=4; CC IsoId=Q8N2I9-4; Sequence=VSP_020897; CC -!- TISSUE SPECIFICITY: Strongly expressed in heart, brain, placenta, lung, CC skeletal muscle, kidney, spleen, thymus, prostate, liver, pancreas, CC testis, ovary, small intestine, colon and peripheral blood leukocytes. CC {ECO:0000269|PubMed:13679039}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH08344.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC Sequence=BAB15794.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC Sequence=BAC11361.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY198395; AAP20040.1; -; mRNA. DR EMBL; AK024504; BAB15794.1; ALT_INIT; mRNA. DR EMBL; AK075029; BAC11361.1; ALT_INIT; mRNA. DR EMBL; AK075048; BAC11371.1; -; mRNA. DR EMBL; AK131560; BAD18694.1; -; mRNA. DR EMBL; AL834137; CAD38852.1; -; mRNA. DR EMBL; AL591845; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471059; EAX07371.1; -; Genomic_DNA. DR EMBL; CH471059; EAX07373.1; -; Genomic_DNA. DR EMBL; BC005169; AAH05169.3; -; mRNA. DR EMBL; BC007835; AAH07835.2; -; mRNA. DR EMBL; BC008344; AAH08344.1; ALT_INIT; mRNA. DR CCDS; CCDS407.1; -. [Q8N2I9-1] DR CCDS; CCDS60089.1; -. [Q8N2I9-4] DR RefSeq; NP_001269475.1; NM_001282546.2. [Q8N2I9-4] DR RefSeq; NP_001269476.1; NM_001282547.2. [Q8N2I9-1] DR RefSeq; NP_114406.1; NM_032017.3. [Q8N2I9-1] DR PDB; 5L2Q; X-ray; 2.53 A; A/B/C/D=22-339. DR PDBsum; 5L2Q; -. DR AlphaFoldDB; Q8N2I9; -. DR SMR; Q8N2I9; -. DR BioGRID; 123816; 59. DR FunCoup; Q8N2I9; 2443. DR IntAct; Q8N2I9; 32. DR MINT; Q8N2I9; -. DR STRING; 9606.ENSP00000362222; -. DR iPTMnet; Q8N2I9; -. DR PhosphoSitePlus; Q8N2I9; -. DR BioMuta; STK40; -. DR DMDM; 116256080; -. DR jPOST; Q8N2I9; -. DR MassIVE; Q8N2I9; -. DR PaxDb; 9606-ENSP00000362222; -. DR PeptideAtlas; Q8N2I9; -. DR ProteomicsDB; 71707; -. [Q8N2I9-1] DR ProteomicsDB; 71709; -. [Q8N2I9-3] DR ProteomicsDB; 71710; -. [Q8N2I9-4] DR Pumba; Q8N2I9; -. DR Antibodypedia; 2156; 150 antibodies from 29 providers. DR DNASU; 83931; -. DR Ensembl; ENST00000359297.6; ENSP00000352245.2; ENSG00000196182.12. [Q8N2I9-3] DR Ensembl; ENST00000373129.7; ENSP00000362221.3; ENSG00000196182.12. [Q8N2I9-1] DR Ensembl; ENST00000373130.7; ENSP00000362222.3; ENSG00000196182.12. [Q8N2I9-4] DR Ensembl; ENST00000373132.4; ENSP00000362224.4; ENSG00000196182.12. [Q8N2I9-1] DR GeneID; 83931; -. DR KEGG; hsa:83931; -. DR MANE-Select; ENST00000373132.4; ENSP00000362224.4; NM_001282547.2; NP_001269476.1. DR UCSC; uc001cak.3; human. [Q8N2I9-1] DR AGR; HGNC:21373; -. DR ClinPGx; PA142670860; -. DR CTD; 83931; -. DR DisGeNET; 83931; -. DR GeneCards; STK40; -. DR HGNC; HGNC:21373; STK40. DR HPA; ENSG00000196182; Low tissue specificity. DR MalaCards; STK40; -. DR MIM; 609437; gene. DR OpenTargets; ENSG00000196182; -. DR VEuPathDB; HostDB:ENSG00000196182; -. DR eggNOG; KOG0583; Eukaryota. DR GeneTree; ENSGT00950000182986; -. DR HOGENOM; CLU_035107_0_0_1; -. DR InParanoid; Q8N2I9; -. DR OMA; HGIFKDR; -. DR OrthoDB; 410920at2759; -. DR PAN-GO; Q8N2I9; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q8N2I9; -. DR PathwayCommons; Q8N2I9; -. DR SignaLink; Q8N2I9; -. DR SIGNOR; Q8N2I9; -. DR Agora; ENSG00000196182; -. DR BioGRID-ORCS; 83931; 53 hits in 1213 CRISPR screens. DR ChiTaRS; STK40; human. DR GeneWiki; STK40; -. DR GenomeRNAi; 83931; -. DR Pharos; Q8N2I9; Tbio. DR PRO; PR:Q8N2I9; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q8N2I9; protein. DR Bgee; ENSG00000196182; Expressed in gastrocnemius and 153 other cell types or tissues. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0005977; P:glycogen metabolic process; IEA:Ensembl. DR GO; GO:0048286; P:lung alveolus development; IEA:Ensembl. DR GO; GO:0060425; P:lung morphogenesis; IEA:Ensembl. DR GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl. DR GO; GO:0010468; P:regulation of gene expression; IEA:Ensembl. DR GO; GO:0043408; P:regulation of MAPK cascade; IBA:GO_Central. DR GO; GO:0003016; P:respiratory system process; IEA:Ensembl. DR CDD; cd13974; STKc_SHIK; 1. DR FunFam; 1.10.510.10:FF:000269; Serine/threonine-protein kinase 40; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR024236; Ser/Thr_kinase_40. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR024104; Tribbles/Ser_Thr_kinase_40. DR PANTHER; PTHR22961; SER/THR PROTEIN KINASE-TRB; 1. DR PANTHER; PTHR22961:SF16; SERINE_THREONINE-PROTEIN KINASE 40; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cytoplasm; Kinase; KW Nucleotide-binding; Nucleus; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..435 FT /note="Serine/threonine-protein kinase 40" FT /id="PRO_0000252261" FT DOMAIN 35..331 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..25 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1..10 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 196 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 41..49 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 66 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT VAR_SEQ 1..262 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_020896" FT VAR_SEQ 37 FT /note="L -> LALCAV (in isoform 4)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_020897" FT VAR_SEQ 263..295 FT /note="VLFTMLYGQFPFYDSIPQELFRKIKAAEYTIPE -> MGLRQGNGTVSLGIL FT ATDPAPPTEPSSPTPCLR (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_020898" FT VAR_SEQ 364..417 FT /note="AKVTEECSQYEFENYMRQQLLLAEEKSSIHDARSWVPKRQFGSAPPVRRLGH FT DA -> VSWGGQMGHYPAPRDRLLGAGRARAEVAATRRPQSFLGLLPQPWGGKGRLQSS FT A (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_020899" FT VAR_SEQ 418..435 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_020900" FT VARIANT 10 FT /note="A -> V (in dbSNP:rs56314546)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041200" FT VARIANT 133 FT /note="M -> T (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs755089893)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041201" FT VARIANT 211 FT /note="R -> Q (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs539738963)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041202" FT VARIANT 395 FT /note="A -> T (in dbSNP:rs3795498)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17344846" FT /id="VAR_041203" FT CONFLICT 191 FT /note="Missing (in Ref. 2; BAC11371)" FT /evidence="ECO:0000305" FT CONFLICT 363 FT /note="E -> Q (in Ref. 6; AAH05169)" FT /evidence="ECO:0000305" FT STRAND 49..52 FT /evidence="ECO:0007829|PDB:5L2Q" FT TURN 57..59 FT /evidence="ECO:0007829|PDB:5L2Q" FT STRAND 64..69 FT /evidence="ECO:0007829|PDB:5L2Q" FT HELIX 81..97 FT /evidence="ECO:0007829|PDB:5L2Q" FT HELIX 98..100 FT /evidence="ECO:0007829|PDB:5L2Q" FT STRAND 109..115 FT /evidence="ECO:0007829|PDB:5L2Q" FT STRAND 124..126 FT /evidence="ECO:0007829|PDB:5L2Q" FT STRAND 128..130 FT /evidence="ECO:0007829|PDB:5L2Q" FT STRAND 136..141 FT /evidence="ECO:0007829|PDB:5L2Q" FT HELIX 152..155 FT /evidence="ECO:0007829|PDB:5L2Q" FT HELIX 159..164 FT /evidence="ECO:0007829|PDB:5L2Q" FT STRAND 165..168 FT /evidence="ECO:0007829|PDB:5L2Q" FT HELIX 171..190 FT /evidence="ECO:0007829|PDB:5L2Q" FT HELIX 200..202 FT /evidence="ECO:0007829|PDB:5L2Q" FT STRAND 203..205 FT /evidence="ECO:0007829|PDB:5L2Q" FT TURN 207..209 FT /evidence="ECO:0007829|PDB:5L2Q" FT STRAND 212..214 FT /evidence="ECO:0007829|PDB:5L2Q" FT TURN 237..239 FT /evidence="ECO:0007829|PDB:5L2Q" FT HELIX 242..245 FT /evidence="ECO:0007829|PDB:5L2Q" FT HELIX 252..269 FT /evidence="ECO:0007829|PDB:5L2Q" FT HELIX 279..288 FT /evidence="ECO:0007829|PDB:5L2Q" FT HELIX 301..310 FT /evidence="ECO:0007829|PDB:5L2Q" FT STRAND 315..318 FT /evidence="ECO:0007829|PDB:5L2Q" FT HELIX 321..333 FT /evidence="ECO:0007829|PDB:5L2Q" SQ SEQUENCE 435 AA; 49001 MW; EBA7A19963582BCC CRC64; MKRRASDRGA GETSARAKAL GSGISGNNAK RAGPFILGPR LGNSPVPSIV QCLARKDGTD DFYQLKILTL EERGDQGIES QEERQGKMLL HTEYSLLSLL HTQDGVVHHH GLFQDRTCEI VEDTESSRMV KKMKKRICLV LDCLCAHDFS DKTADLINLQ HYVIKEKRLS ERETVVIFYD VVRVVEALHQ KNIVHRDLKL GNMVLNKRTH RITITNFCLG KHLVSEGDLL KDQRGSPAYI SPDVLSGRPY RGKPSDMWAL GVVLFTMLYG QFPFYDSIPQ ELFRKIKAAE YTIPEDGRVS ENTVCLIRKL LVLDPQQRLA AADVLEALSA IIASWQSLSS LSGPLQVVPD IDDQMSNADS SQEAKVTEEC SQYEFENYMR QQLLLAEEKS SIHDARSWVP KRQFGSAPPV RRLGHDAQPM TSLDTAILAQ RYLRK // ID TAF1L_HUMAN Reviewed; 1826 AA. AC Q8IZX4; Q0VG57; DT 04-JAN-2005, integrated into UniProtKB/Swiss-Prot. DT 01-MAR-2003, sequence version 1. DT 28-JAN-2026, entry version 173. DE RecName: Full=Transcription initiation factor TFIID subunit 1-like; DE AltName: Full=TAF(II)210; DE AltName: Full=TBP-associated factor 1-like; DE AltName: Full=TBP-associated factor 210 kDa; DE AltName: Full=Transcription initiation factor TFIID 210 kDa subunit; GN Name=TAF1L; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND INTERACTION WITH TBP. RC TISSUE=Testis; RX PubMed=12217962; DOI=10.1093/hmg/11.19.2341; RA Wang P.J., Page D.C.; RT "Functional substitution for TAF(II)250 by a retroposed homolog that is RT expressed in human spermatogenesis."; RL Hum. Mol. Genet. 11:2341-2346(2002). RN [2] RP X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 1523-1654, AND SUBUNIT. RX PubMed=22464331; DOI=10.1016/j.cell.2012.02.013; RA Filippakopoulos P., Picaud S., Mangos M., Keates T., Lambert J.P., RA Barsyte-Lovejoy D., Felletar I., Volkmer R., Muller S., Pawson T., RA Gingras A.C., Arrowsmith C.H., Knapp S.; RT "Histone recognition and large-scale structural analysis of the human RT bromodomain family."; RL Cell 149:214-231(2012). RN [3] RP VARIANTS [LARGE SCALE ANALYSIS] ALA-47; GLU-171; ALA-256; VAL-371; ASN-532; RP SER-637; PHE-750; ILE-762; ASP-794; GLN-845; CYS-1016; ASN-1038; ILE-1169; RP LEU-1312; CYS-1356; SER-1389; VAL-1411; THR-1540; TYR-1549; ASN-1731; RP LEU-1810 AND GLN-1824. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: May act as a functional substitute for TAF1/TAFII250 during CC male meiosis, when sex chromosomes are transcriptionally silenced. CC {ECO:0000269|PubMed:12217962}. CC -!- SUBUNIT: Can bind directly to TATA-box binding protein (TBP). Interacts CC (via bromo domains) with acetylated lysine residues on the N-terminus CC of histone H1.4, H2A, H2B, H3 and H4 (in vitro). CC {ECO:0000269|PubMed:12217962, ECO:0000269|PubMed:22464331}. CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Testis specific, expressed apparently in germ CC cells. CC -!- SIMILARITY: Belongs to the TAF1 family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF390562; AAN40840.1; -; mRNA. DR CCDS; CCDS35003.1; -. DR RefSeq; NP_722516.1; NM_153809.2. DR PDB; 3HMH; X-ray; 2.05 A; A=1523-1654. DR PDB; 5IGL; X-ray; 2.10 A; A=1523-1654. DR PDBsum; 3HMH; -. DR PDBsum; 5IGL; -. DR AlphaFoldDB; Q8IZX4; -. DR SMR; Q8IZX4; -. DR BioGRID; 126514; 24. DR FunCoup; Q8IZX4; 175. DR IntAct; Q8IZX4; 9. DR MINT; Q8IZX4; -. DR STRING; 9606.ENSP00000418379; -. DR BindingDB; Q8IZX4; -. DR ChEMBL; CHEMBL3108641; -. DR GlyGen; Q8IZX4; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q8IZX4; -. DR PhosphoSitePlus; Q8IZX4; -. DR BioMuta; TAF1L; -. DR DMDM; 57013082; -. DR jPOST; Q8IZX4; -. DR MassIVE; Q8IZX4; -. DR PaxDb; 9606-ENSP00000418379; -. DR PeptideAtlas; Q8IZX4; -. DR ProteomicsDB; 71440; -. DR Pumba; Q8IZX4; -. DR Antibodypedia; 25077; 67 antibodies from 21 providers. DR DNASU; 138474; -. DR Ensembl; ENST00000242310.4; ENSP00000418379.1; ENSG00000122728.6. DR GeneID; 138474; -. DR KEGG; hsa:138474; -. DR MANE-Select; ENST00000242310.4; ENSP00000418379.1; NM_153809.2; NP_722516.1. DR UCSC; uc003zrg.1; human. DR AGR; HGNC:18056; -. DR ClinPGx; PA134947802; -. DR CTD; 138474; -. DR DisGeNET; 138474; -. DR GeneCards; TAF1L; -. DR HGNC; HGNC:18056; TAF1L. DR HPA; ENSG00000122728; Group enriched (retina, testis). DR MIM; 607798; gene. DR OpenTargets; ENSG00000122728; -. DR VEuPathDB; HostDB:ENSG00000122728; -. DR eggNOG; KOG0008; Eukaryota. DR GeneTree; ENSGT00940000155242; -. DR HOGENOM; CLU_000572_3_0_1; -. DR InParanoid; Q8IZX4; -. DR OMA; RENVRKC; -. DR OrthoDB; 5752at2759; -. DR PAN-GO; Q8IZX4; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q8IZX4; -. DR PathwayCommons; Q8IZX4; -. DR Reactome; R-HSA-167161; HIV Transcription Initiation. DR Reactome; R-HSA-167162; RNA Polymerase II HIV Promoter Escape. DR Reactome; R-HSA-167172; Transcription of the HIV genome. DR Reactome; R-HSA-674695; RNA Polymerase II Pre-transcription Events. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-73776; RNA Polymerase II Promoter Escape. DR Reactome; R-HSA-73779; RNA Polymerase II Transcription Pre-Initiation And Promoter Opening. DR Reactome; R-HSA-75953; RNA Polymerase II Transcription Initiation. DR Reactome; R-HSA-76042; RNA Polymerase II Transcription Initiation And Promoter Clearance. DR SignaLink; Q8IZX4; -. DR Agora; ENSG00000122728; -. DR BioGRID-ORCS; 138474; 16 hits in 1147 CRISPR screens. DR EvolutionaryTrace; Q8IZX4; -. DR GenomeRNAi; 138474; -. DR Pharos; Q8IZX4; Tchem. DR PRO; PR:Q8IZX4; -. DR Proteomes; UP000005640; Chromosome 9. DR RNAct; Q8IZX4; protein. DR Bgee; ENSG00000122728; Expressed in male germ line stem cell (sensu Vertebrata) in testis and 9 other cell types or tissues. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005669; C:transcription factor TFIID complex; IBA:GO_Central. DR GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW. DR GO; GO:0004402; F:histone acetyltransferase activity; ISS:UniProtKB. DR GO; GO:0140566; F:histone reader activity; IDA:UniProtKB. DR GO; GO:0004674; F:protein serine/threonine kinase activity; ISS:UniProtKB. DR GO; GO:0016251; F:RNA polymerase II general transcription initiation factor activity; IBA:GO_Central. DR GO; GO:0017025; F:TBP-class protein binding; IPI:UniProtKB. DR GO; GO:0007140; P:male meiotic nuclear division; IEP:UniProtKB. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0051123; P:RNA polymerase II preinitiation complex assembly; IBA:GO_Central. DR CDD; cd05511; Bromo_TFIID; 2. DR FunFam; 1.10.1100.10:FF:000001; Transcription initiation factor TFIID subunit; 1. DR FunFam; 1.20.920.10:FF:000019; Transcription initiation factor TFIID subunit; 1. DR FunFam; 1.20.920.10:FF:000020; Transcription initiation factor TFIID subunit; 1. DR Gene3D; 1.20.920.10; Bromodomain-like; 2. DR Gene3D; 1.10.1100.10; TAFII-230 TBP-binding domain; 1. DR InterPro; IPR001487; Bromodomain. DR InterPro; IPR036427; Bromodomain-like_sf. DR InterPro; IPR018359; Bromodomain_CS. DR InterPro; IPR040240; TAF1. DR InterPro; IPR011177; TAF1_animal. DR InterPro; IPR022591; TAF1_HAT_dom. DR InterPro; IPR009067; TAF_II_230-bd. DR InterPro; IPR036741; TAFII-230_TBP-bd_sf. DR InterPro; IPR041670; Znf-CCHC_6. DR PANTHER; PTHR13900; TRANSCRIPTION INITIATION FACTOR TFIID; 1. DR PANTHER; PTHR13900:SF2; TRANSCRIPTION INITIATION FACTOR TFIID SUBUNIT 1-LIKE; 1. DR Pfam; PF00439; Bromodomain; 2. DR Pfam; PF12157; DUF3591; 1. DR Pfam; PF09247; TBP-binding; 1. DR Pfam; PF15288; zf-CCHC_6; 1. DR PIRSF; PIRSF003047; TAF1_animal; 1. DR PRINTS; PR00503; BROMODOMAIN. DR SMART; SM00297; BROMO; 2. DR SUPFAM; SSF47370; Bromodomain; 2. DR SUPFAM; SSF47055; TAF(II)230 TBP-binding fragment; 1. DR PROSITE; PS00633; BROMODOMAIN_1; 2. DR PROSITE; PS50014; BROMODOMAIN_2; 2. PE 1: Evidence at protein level; KW 3D-structure; Bromodomain; Cell cycle; DNA-binding; Nucleus; KW Proteomics identification; Reference proteome; Repeat; Transcription; KW Transcription regulation. FT CHAIN 1..1826 FT /note="Transcription initiation factor TFIID subunit 1- FT like" FT /id="PRO_0000211217" FT DOMAIN 1395..1503 FT /note="Bromo 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00035" FT DOMAIN 1517..1626 FT /note="Bromo 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00035" FT REGION 118..141 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 532..555 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1252..1276 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1648..1826 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 1370..1377 FT /note="Nuclear localization signal" FT /evidence="ECO:0000255" FT COMPBIAS 1252..1268 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1660..1700 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1714..1729 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1740..1750 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1768..1783 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1787..1797 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1817..1826 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT VARIANT 47 FT /note="G -> A (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041934" FT VARIANT 171 FT /note="Q -> E (in dbSNP:rs56352331)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041935" FT VARIANT 256 FT /note="G -> A (in dbSNP:rs55991718)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041936" FT VARIANT 371 FT /note="M -> V (in dbSNP:rs17219559)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041937" FT VARIANT 532 FT /note="I -> N (in dbSNP:rs56128445)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041938" FT VARIANT 637 FT /note="P -> S (in dbSNP:rs56157814)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041939" FT VARIANT 750 FT /note="L -> F (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041940" FT VARIANT 762 FT /note="L -> I (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041941" FT VARIANT 794 FT /note="E -> D (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041942" FT VARIANT 845 FT /note="R -> Q (in dbSNP:rs34787787)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041943" FT VARIANT 1016 FT /note="R -> C (in dbSNP:rs35905429)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041944" FT VARIANT 1038 FT /note="K -> N (in dbSNP:rs55767137)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041945" FT VARIANT 1169 FT /note="T -> I (in dbSNP:rs55976674)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041946" FT VARIANT 1312 FT /note="V -> L (in dbSNP:rs55824107)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041947" FT VARIANT 1356 FT /note="R -> C (in dbSNP:rs56107531)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041948" FT VARIANT 1389 FT /note="P -> S (in dbSNP:rs56393725)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041949" FT VARIANT 1411 FT /note="I -> V (in dbSNP:rs34500740)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041950" FT VARIANT 1540 FT /note="A -> T (in dbSNP:rs55782058)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041951" FT VARIANT 1549 FT /note="H -> Y (in a glioblastoma multiforme sample; somatic FT mutation; dbSNP:rs1587670372)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041952" FT VARIANT 1731 FT /note="K -> N (in dbSNP:rs34241003)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041953" FT VARIANT 1805 FT /note="I -> V (in dbSNP:rs16918393)" FT /id="VAR_048435" FT VARIANT 1810 FT /note="P -> L (in dbSNP:rs56342342)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041954" FT VARIANT 1824 FT /note="H -> Q (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs202147126)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041955" FT HELIX 1523..1536 FT /evidence="ECO:0007829|PDB:3HMH" FT TURN 1537..1540 FT /evidence="ECO:0007829|PDB:3HMH" FT HELIX 1545..1547 FT /evidence="ECO:0007829|PDB:3HMH" FT TURN 1553..1555 FT /evidence="ECO:0007829|PDB:3HMH" FT HELIX 1557..1562 FT /evidence="ECO:0007829|PDB:3HMH" FT HELIX 1569..1577 FT /evidence="ECO:0007829|PDB:3HMH" FT HELIX 1584..1602 FT /evidence="ECO:0007829|PDB:3HMH" FT HELIX 1607..1625 FT /evidence="ECO:0007829|PDB:3HMH" FT HELIX 1627..1649 FT /evidence="ECO:0007829|PDB:3HMH" SQ SEQUENCE 1826 AA; 207302 MW; 35D780E749AC9B17 CRC64; MRPGCDLLLR AAATVTAAIM SDSDSEEDSS GGGPFTLAGI LFGNISGAGQ LEGESVLDDE CKKHLAGLGA LGLGSLITEL TANEELTGTG GALVNDEGWI RSTEDAVDYS DINEVAEDES QRHQQTMGSL QPLYHSDYDE DDYDADCEDI DCKLMPPPPP PPGPMKKDKD QDAITCVSES GEDIILPSII APSFLASEKV DFSSYSDSES EMGPQEATQA ESEDGKLTLP LAGIMQHDAT KLLPSVTELF PEFRPGKVLR FLHLFGPGKN VPSVWRSARR KRKKHRELIQ EEQIQEVECS VESEVSQKSL WNYDYAPPPP PEQCLADDEI TMMVPVESKF SQSTGDVDKV TDTKPRVAEW RYGPARLWYD MLGVSEDGSG FDYGFKLRKT QHEPVIKSRM MEEFRKLEES NGTDLLADEN FLMVTQLHWE DSIIWDGEDI KHKGTKPQGA SLAGWLPSIK TRNVMAYNVQ QGFAPTLDDD KPWYSIFPID NEDLVYGRWE DNIIWDAQAM PRLLEPPVLA LDPNDENLIL EIPDEKEEAT SNSPSKESKK ESSLKKSRIL LGKTGVIREE PQQNMSQPEV KDPWNLSNDE YYFPKQQGLR GTFGGNIIQH SIPAMELWQP FFPTHMGPIK IRQFHRPPLK KYSFGALSQP GPHSVQPLLK HIKKKAKMRE QERQASGGGE LFFMRTPQDL TGKDGDLILA EYSEENGPLM MQVGMATKIK NYYKRKPGKD PGAPDCKYGE TVYCHTSPFL GSLHPGQLLQ ALENNLFRAP VYLHKMPETD FLIIRTRQGY YIRELVDIFV VGQQCPLFEV PGPNSRRANM HIRDFLQVFI YRLFWKSKDR PRRIRMEDIK KAFPSHSESS IRKRLKLCAD FKRTGMDSNW WVLKSDFRLP TEEEIRAKVS PEQCCAYYSM IAAKQRLKDA GYGEKSFFAP EEENEEDFQM KIDDEVHAAP WNTTRAFIAA MKGKCLLEVT GVADPTGCGE GFSYVKIPNK PTQQKDDKEP QAVKKTVTGT DADLRRLSLK NAKQLLRKFG VPEEEIKKLS RWEVIDVVRT MSTEQAHSGE GPMSKFARGS RFSVAEHQER YKEECQRIFD LQNKVLSSTE VLSTDTDSIS AEDSDFEEMG KNIENMLQNK KTSSQLSREW EEQERKELRR MLLVAGSAAS GNNHRDDVTA SMTSLKSSAT GHCLKIYRTF RDEEGKEYVR CETVRKPAVI DAYVRIRTTK DEKFIQKFAL FDEKHREEMR KERRRIQEQL RRLKRNQEKE KLKGPPEKKP KKMKERPDLK LKCGACGAIG HMRTNKFCPL YYQTNVPPSK PVAMTEEQEE ELEKTVIHND NEELIKVEGT KIVFGKQLIE NVHEVRRKSL VLKFPKQQLP PKKKRRVGTT VHCDYLNIPH KSIHRRRTDP MVTLSSILES IINDMRDLPN THPFHTPVNA KVVKDYYKII TRPMDLQTLR ENVRKCLYPS REEFREHLEL IVKNSATYNG PKHSLTQISQ SMLDLCDEKL KEKEDKLARL EKAINPLLDD DDQVAFSFIL DNIVTQKMMA VPDSWPFHHP VNKKFVPDYY KMIVNPVDLE TIRKNISKHK YQSRESFLDD VNLILANSVK YNGPESQYTK TAQEIVNICY QTITEYDEHL TQLEKDICTA KEAALEEAEL ESLDPMTPGP YTSQPPDMYD TNTSLSTSRD ASVFQDESNL SVLDISTATP EKQMCQGQGR LGEEDSDVDV EGYDDEEEDG KPKPPAPEGG DGDLADEEEG TVQQPEASVL YEDLLISEGE DDEEDAGSDE EGDNPFSAIQ LSESGSDSDV GYGGIRPKQP FMLQHASGEH KDGHGK // ID TAF1_HUMAN Reviewed; 1893 AA. AC P21675; A5CVC8; A5CVC9; A5CVD0; A5CVD1; B1Q2X3; Q59FZ3; Q6IUZ1; Q70Q86; AC Q70Q87; Q70T00; Q70T01; Q70T02; Q70T03; DT 01-MAY-1991, integrated into UniProtKB/Swiss-Prot. DT 08-NOV-2023, sequence version 3. DT 28-JAN-2026, entry version 249. DE RecName: Full=Transcription initiation factor TFIID subunit 1 {ECO:0000305}; DE EC=2.3.1.48 {ECO:0000269|PubMed:15870300}; DE EC=2.7.11.1; DE AltName: Full=Cell cycle gene 1 protein; DE AltName: Full=TBP-associated factor 250 kDa; DE Short=p250; DE AltName: Full=Transcription initiation factor TFIID 250 kDa subunit; DE Short=TAF(II)250; DE Short=TAFII-250; DE Short=TAFII250; GN Name=TAF1 {ECO:0000312|HGNC:HGNC:11535}; Synonyms=BA2R, CCG1, CCGS, TAF2A; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND SUBCELLULAR LOCATION. RC TISSUE=Laryngeal carcinoma; RX PubMed=2038334; DOI=10.1128/mcb.11.6.3317-3325.1991; RA Sekiguchi T., Nohiro Y., Nakamura Y., Hisamoto N., Nishimoto T.; RT "The human CCG1 gene, essential for progression of the G1 phase, encodes a RT 210-kilodalton nuclear DNA-binding protein."; RL Mol. Cell. Biol. 11:3317-3325(1991). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH TBP AND TAFS. RX PubMed=7680771; DOI=10.1038/362175a0; RA Ruppert S., Wang E.H., Tjian R.; RT "Cloning and expression of human TAFII250: a TBP-associated factor RT implicated in cell-cycle regulation."; RL Nature 362:175-179(1993). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM N-TAF1), AND INVOLVEMENT IN DYT3. RC TISSUE=Brain; RX PubMed=17273961; DOI=10.1086/512129; RA Makino S., Kaji R., Ando S., Tomizawa M., Yasuno K., Goto S., Matsumoto S., RA Tabuena M.D., Maranon E., Dantes M., Lee L.V., Ogasawara K., Tooyama I., RA Akatsu H., Nishimura M., Tamiya G.; RT "Reduced neuron-specific expression of the TAF1 gene is associated with X- RT linked dystonia-parkinsonism."; RL Am. J. Hum. Genet. 80:393-406(2007). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 2), AND VARIANT VAL-290. RG NIEHS SNPs program; RL Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15772651; DOI=10.1038/nature03440; RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., RA Rogers J., Bentley D.R.; RT "The DNA sequence of the human X chromosome."; RL Nature 434:325-337(2005). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 61-1604 (ISOFORM 1). RX PubMed=3169001; DOI=10.1002/j.1460-2075.1988.tb02996.x; RA Sekiguchi T., Miyata T., Nishimoto T.; RT "Molecular cloning of the cDNA of human X chromosomal gene (CCG1) which RT complements the temperature-sensitive G1 mutants, tsBN462 and ts13, of the RT BHK cell line."; RL EMBO J. 7:1683-1687(1988). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 858-1893 (ISOFORM 4). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1368-1893 (ISOFORMS 2A; 2C; 2D AND 2E), RP NUCLEOTIDE SEQUENCE [MRNA] OF 1519-1893 (ISOFORM 16), NUCLEOTIDE SEQUENCE RP [MRNA] OF 1749-1893 (ISOFORM 15), AND INVOLVEMENT IN DYT3. RC TISSUE=Fetal brain; RX PubMed=12928496; DOI=10.1073/pnas.1831949100; RA Nolte D., Niemann S., Muller U.; RT "Specific sequence changes in multiple transcript system DYT3 are RT associated with X-linked dystonia parkinsonism."; RL Proc. Natl. Acad. Sci. U.S.A. 100:10347-10352(2003). RN [9] RP SEQUENCE REVISION (ISOFORMS 2A; 2C; 2D AND 2E), NUCLEOTIDE SEQUENCE [MRNA] RP OF 1368-1893 (ISOFORMS 2E; 2G; 2H AND 2I), AND ALTERNATIVE SPLICING. RX PubMed=17952504; DOI=10.1007/s00335-007-9063-z; RA Herzfeld T., Nolte D., Muller U.; RT "Structural and functional analysis of the human TAF1/DYT3 multiple RT transcript system."; RL Mamm. Genome 18:787-795(2007). RN [10] RP FUNCTION. RX PubMed=8450888; DOI=10.1038/362179a0; RA Hisatake K., Hasegawa S., Takada R., Nakatani Y., Horikoshi M., RA Roeder R.G.; RT "The p250 subunit of native TATA box-binding factor TFIID is the cell-cycle RT regulatory protein CCG1."; RL Nature 362:179-181(1993). RN [11] RP FUNCTION, ACTIVITY REGULATION, PHOSPHORYLATION AT SER-137 AND SER-328, AND RP ATP-BINDING. RX PubMed=8625415; DOI=10.1016/s0092-8674(00)81055-7; RA Dikstein R., Ruppert S., Tjian R.; RT "TAFII250 is a bipartite protein kinase that phosphorylates the base RT transcription factor RAP74."; RL Cell 84:781-790(1996). RN [12] RP INTERACTION WITH SV40 LARGE T ANTIGEN (MICROBIAL INFECTION). RX PubMed=8647434; DOI=10.1101/gad.10.11.1369; RA Damania B., Alwine J.C.; RT "TAF-like function of SV40 large T antigen."; RL Genes Dev. 10:1369-1381(1996). RN [13] RP INTERACTION WITH HERPES SIMPLEX VIRUS 1 ICP4 (MICROBIAL INFECTION). RX PubMed=8649420; DOI=10.1128/mcb.16.6.3085; RA Carrozza M.J., DeLuca N.A.; RT "Interaction of the viral activator protein ICP4 with TFIID through RT TAF250."; RL Mol. Cell. Biol. 16:3085-3093(1996). RN [14] RP FUNCTION, AND MUTAGENESIS. RX PubMed=9660973; DOI=10.1016/s1097-2765(00)80089-1; RA O'Brien T., Tjian R.; RT "Functional analysis of the human TAFII250 N-terminal kinase domain."; RL Mol. Cell 1:905-911(1998). RN [15] RP FUNCTION, ACTIVITY REGULATION, INTERACTION WITH RB1, AND ATP-BINDING. RX PubMed=9858607; DOI=10.1128/mcb.19.1.846; RA Siegert J.L., Robbins P.D.; RT "Rb inhibits the intrinsic kinase activity of TATA-binding protein- RT associated factor TAFII250."; RL Mol. Cell. Biol. 19:846-854(1999). RN [16] RP INTERACTION WITH ASF1A. RX PubMed=10759893; DOI=10.1046/j.1365-2443.2000.00319.x; RA Munakata T., Adachi N., Yokoyama N., Kuzuhara T., Horikoshi M.; RT "A human homologue of yeast anti-silencing factor has histone chaperone RT activity."; RL Genes Cells 5:221-233(2000). RN [17] RP FUNCTION. RX PubMed=11278496; DOI=10.1074/jbc.m009385200; RA Solow S., Salunek M., Ryan R., Lieberman P.M.; RT "Taf(II) 250 phosphorylates human transcription factor IIA on serine RT residues important for TBP binding and transcription activity."; RL J. Biol. Chem. 276:15886-15892(2001). RN [18] RP ACTIVITY REGULATION, AND INTERACTION WITH TAF7. RX PubMed=11592977; DOI=10.1073/pnas.211444798; RA Gegonne A., Weissman J.D., Singer D.S.; RT "TAFII55 binding to TAFII250 inhibits its acetyltransferase activity."; RL Proc. Natl. Acad. Sci. U.S.A. 98:12432-12437(2001). RN [19] RP INTERACTION WITH ASF1A. RX PubMed=12093919; DOI=10.1073/pnas.142627899; RA Chimura T., Kuzuhara T., Horikoshi M.; RT "Identification and characterization of CIA/ASF1 as an interactor of RT bromodomains associated with TFIID."; RL Proc. Natl. Acad. Sci. U.S.A. 99:9334-9339(2002). RN [20] RP INTERACTION WITH ASF1A AND ASF1B. RX PubMed=12842904; DOI=10.1074/jbc.m303549200; RA Umehara T., Horikoshi M.; RT "Transcription initiation factor IID-interactive histone chaperone CIA-II RT implicated in mammalian spermatogenesis."; RL J. Biol. Chem. 278:35660-35667(2003). RN [21] RP FUNCTION, AND INTERACTION WITH TP53. RX PubMed=15053879; DOI=10.1016/s1097-2765(04)00123-6; RA Li H.-H., Li A.G., Sheppard H.M., Liu X.; RT "Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for RT TAF1 in cell G1 progression."; RL Mol. Cell 13:867-878(2004). RN [22] RP IDENTIFICATION IN THE MLL1/MLL COMPLEX. RX PubMed=15960975; DOI=10.1016/j.cell.2005.04.031; RA Dou Y., Milne T.A., Tackett A.J., Smith E.R., Fukuda A., Wysocka J., RA Allis C.D., Chait B.T., Hess J.L., Roeder R.G.; RT "Physical association and coordinate function of the H3 K4 RT methyltransferase MLL1 and the H4 K16 acetyltransferase MOF."; RL Cell 121:873-885(2005). RN [23] RP HISTONE ACETYLTRANSFERASE ACTIVITY, AND MUTAGENESIS OF GLU-742 AND RP 848-MET--ASP-850. RX PubMed=15870300; DOI=10.1128/mcb.25.10.4321-4332.2005; RA Hilton T.L., Li Y., Dunphy E.L., Wang E.H.; RT "TAF1 histone acetyltransferase activity in Sp1 activation of the cyclin D1 RT promoter."; RL Mol. Cell. Biol. 25:4321-4332(2005). RN [24] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1847, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1721 (ISOFORMS 2A AND 4), RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1723 (ISOFORM 2G), RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1718 (ISOFORM 16), AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [27] RP ACTIVITY REGULATION. RX PubMed=22711989; DOI=10.1128/mcb.00416-12; RA Kloet S.L., Whiting J.L., Gafken P., Ranish J., Wang E.H.; RT "Phosphorylation-dependent regulation of cyclin D1 and cyclin A gene RT transcription by TFIID subunits TAF1 and TAF7."; RL Mol. Cell. Biol. 32:3358-3369(2012). RN [28] RP MISCELLANEOUS. RX PubMed=23184149; DOI=10.1093/hmg/dds499; RA Herzfeld T., Nolte D., Grznarova M., Hofmann A., Schultze J.L., Muller U.; RT "X-linked dystonia parkinsonism syndrome (XDP, lubag): disease-specific RT sequence change DSC3 in TAF1/DYT3 affects genes in vesicular transport and RT dopamine metabolism."; RL Hum. Mol. Genet. 22:941-951(2013). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-328, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [30] RP SUBCELLULAR LOCATION. RX PubMed=25593309; DOI=10.1101/gad.252189.114; RA Gong F., Chiu L.Y., Cox B., Aymard F., Clouaire T., Leung J.W., RA Cammarata M., Perez M., Agarwal P., Brodbelt J.S., Legube G., Miller K.M.; RT "Screen identifies bromodomain protein ZMYND8 in chromatin recognition of RT transcription-associated DNA damage that promotes homologous RT recombination."; RL Genes Dev. 29:197-211(2015). RN [31] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-570 AND LYS-583, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [32] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1380-1659. RX PubMed=10827952; DOI=10.1126/science.288.5470.1422; RA Jacobson R.H., Ladurner A.G., King D.S., Tjian R.; RT "Structure and function of a human TAFII250 double bromodomain module."; RL Science 288:1422-1425(2000). RN [33] RP X-RAY CRYSTALLOGRAPHY (1.89 ANGSTROMS) OF 1522-1656, AND SUBUNIT. RX PubMed=22464331; DOI=10.1016/j.cell.2012.02.013; RA Filippakopoulos P., Picaud S., Mangos M., Keates T., Lambert J.P., RA Barsyte-Lovejoy D., Felletar I., Volkmer R., Muller S., Pawson T., RA Gingras A.C., Arrowsmith C.H., Knapp S.; RT "Histone recognition and large-scale structural analysis of the human RT bromodomain family."; RL Cell 149:214-231(2012). RN [34] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 600-1236 IN COMPLEX WITH TAF7, RP FUNCTION, AND INTERACTION WITH TAF7. RX PubMed=25412659; DOI=10.1038/cr.2014.148; RA Wang H., Curran E.C., Hinds T.R., Wang E.H., Zheng N.; RT "Crystal structure of a TAF1-TAF7 complex in human transcription factor IID RT reveals a promoter binding module."; RL Cell Res. 24:1433-1444(2014). RN [35] RP X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) OF 1518-1659 IN COMPLEX WITH RP CROTONYLATED OR BUTYRYLATED HISTONE H4. RX PubMed=26365797; DOI=10.1016/j.str.2015.08.004; RA Flynn E.M., Huang O.W., Poy F., Oppikofer M., Bellon S.F., Tang Y., RA Cochran A.G.; RT "A subset of human bromodomains recognizes butyryllysine and crotonyllysine RT histone peptide modifications."; RL Structure 23:1801-1814(2015). RN [36] RP STRUCTURE BY ELECTRON MICROSCOPY (8.50 ANGSTROMS), AND SUBCELLULAR RP LOCATION. RX PubMed=27007846; DOI=10.1038/nature17394; RA Louder R.K., He Y., Lopez-Blanco J.R., Fang J., Chacon P., Nogales E.; RT "Structure of promoter-bound TFIID and model of human pre-initiation RT complex assembly."; RL Nature 531:604-609(2016). RN [37] {ECO:0007744|PDB:6FIC} RP X-RAY CRYSTALLOGRAPHY (2.18 ANGSTROMS) OF 1380-1659. RA Mathea S., Suh J.L., Salah E., Tallant C., Siejka P., Pike A.C.W., RA von Delft F., Arrowsmith C.H., Edwards A.M., Bountra C., James L.I., RA Frye S.V., Knapp S.; RT "Bivalent Inhibitor UNC4512 Bound to the TAF1 Bromodomain Tandem."; RL Submitted (JAN-2018) to the PDB data bank. RN [38] {ECO:0007744|PDB:6P39, ECO:0007744|PDB:6P3A} RP X-RAY CRYSTALLOGRAPHY (2.94 ANGSTROMS) OF 1521-1656. RA Seo H.-S., Dhe-Paganon S.; RT "Crystal Structure Analysis of TAF1 Bromodomain."; RL Submitted (MAY-2019) to the PDB data bank. RN [39] {ECO:0007744|PDB:7JJG} RP X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 1522-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to RT ATR kinase inhibitor AZ20."; RL Submitted (JUL-2020) to the PDB data bank. RN [40] {ECO:0007744|PDB:7JJH} RP X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the unliganded tandem bromodomain (BD1, BD2) of human RT TAF1."; RL Submitted (JUL-2020) to the PDB data bank. RN [41] {ECO:0007744|PDB:7JSP} RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 1522-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to RT the ATR kinase inhibitor AZD6738."; RL Submitted (AUG-2020) to the PDB data bank. RN [42] {ECO:0007744|PDB:7JTC} RP X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 1522-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to RT ZS1-322."; RL Submitted (AUG-2020) to the PDB data bank. RN [43] {ECO:0007744|PDB:7K03} RP X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain (BD1 and BD2) of human TAF1 RT bound to ATR kinase inhibitor AZD6738."; RL Submitted (SEP-2020) to the PDB data bank. RN [44] {ECO:0007744|PDB:7K0D} RP X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound RT to mTORC1/2 inhibitor AZD3147."; RL Submitted (SEP-2020) to the PDB data bank. RN [45] {ECO:0007744|PDB:7K0U} RP X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 1522-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to RT PLK1 kinase inhibitor BI2536."; RL Submitted (SEP-2020) to the PDB data bank. RN [46] {ECO:0007744|PDB:7K1P} RP X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF 1522-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to RT bromosporine."; RL Submitted (SEP-2020) to the PDB data bank. RN [47] {ECO:0007744|PDB:7K27} RP X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound RT to ATR inhibitor AZ20."; RL Submitted (SEP-2020) to the PDB data bank. RN [48] {ECO:0007744|PDB:7K3O} RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 1522-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the unliganded second bromodomain (BD2) of human RT TAF1."; RL Submitted (SEP-2020) to the PDB data bank. RN [49] {ECO:0007744|PDB:7K42} RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 1522-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to RT dioxane."; RL Submitted (SEP-2020) to the PDB data bank. RN [50] {ECO:0007744|PDB:7K6F} RP X-RAY CRYSTALLOGRAPHY (1.86 ANGSTROMS) OF 1394-1656. RA Karim M.R., Bikowitz M.J., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 in RT complex with MES (2-(N-morpholino)ethanesulfonic acid)."; RL Submitted (SEP-2020) to the PDB data bank. RN [51] {ECO:0007744|PDB:7L6X} RP X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound RT to GNE-371."; RL Submitted (DEC-2020) to the PDB data bank. RN [52] {ECO:0007744|PDB:7LB0} RP X-RAY CRYSTALLOGRAPHY (2.33 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound RT to ZS1-295."; RL Submitted (JAN-2021) to the PDB data bank. RN [53] {ECO:0007744|PDB:7LB1} RP X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound RT to ZS1-585."; RL Submitted (JAN-2021) to the PDB data bank. RN [54] {ECO:0007744|PDB:7LB2} RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound RT to ZS1-589."; RL Submitted (JAN-2021) to the PDB data bank. RN [55] {ECO:0007744|PDB:7N42} RP X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain of human TAF1 (TAF1-T) bound RT to ZS1-681."; RL Submitted (JUN-2021) to the PDB data bank. RN [56] {ECO:0007744|PDB:7EDX, ECO:0007744|PDB:7EG7, ECO:0007744|PDB:7EG8, ECO:0007744|PDB:7EG9, ECO:0007744|PDB:7EGA, ECO:0007744|PDB:7EGB, ECO:0007744|PDB:7EGC, ECO:0007744|PDB:7EGD, ECO:0007744|PDB:7EGE, ECO:0007744|PDB:7EGH} RP STRUCTURE BY ELECTRON MICROSCOPY (3.04 ANGSTROMS), FUNCTION, IDENTIFICATION RP IN THE TFIID COMPLEX, AND SUBUNIT. RX PubMed=33795473; DOI=10.1126/science.aba8490; RA Chen X., Qi Y., Wu Z., Wang X., Li J., Zhao D., Hou H., Li Y., Yu Z., RA Liu W., Wang M., Ren Y., Li Z., Yang H., Xu Y.; RT "Structural insights into preinitiation complex assembly on core RT promoters."; RL Science 372:0-0(2021). RN [57] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-290; GLY-318; ASP-474; LYS-672 AND RP ILE-712. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [58] RP INVOLVEMENT IN MRXS33, AND VARIANTS MRXS33 SER-596; ARG-807; HIS-976; RP TRP-1246; THR-1337; HIS-1452 AND HIS-1517. RX PubMed=26637982; DOI=10.1016/j.ajhg.2015.11.005; RA O'Rawe J.A., Wu Y., Doerfel M.J., Rope A.F., Au P.Y., Parboosingh J.S., RA Moon S., Kousi M., Kosma K., Smith C.S., Tzetis M., Schuette J.L., RA Hufnagel R.B., Prada C.E., Martinez F., Orellana C., Crain J., RA Caro-Llopis A., Oltra S., Monfort S., Jimenez-Barron L.T., Swensen J., RA Ellingwood S., Smith R., Fang H., Ospina S., Stegmann S., Den Hollander N., RA Mittelman D., Highnam G., Robison R., Yang E., Faivre L., Roubertie A., RA Riviere J.B., Monaghan K.G., Wang K., Davis E.E., Katsanis N., RA Kalscheuer V.M., Wang E.H., Metcalfe K., Kleefstra T., Innes A.M., RA Kitsiou-Tzeli S., Rosello M., Keegan C.E., Lyon G.J.; RT "TAF1 Variants Are Associated with Dysmorphic Features, Intellectual RT Disability, and Neurological Manifestations."; RL Am. J. Hum. Genet. 97:922-932(2015). RN [59] RP VARIANTS ASP-493 AND CYS-1190. RX PubMed=25644381; DOI=10.1038/mp.2014.193; RA Hu H., Haas S.A., Chelly J., Van Esch H., Raynaud M., de Brouwer A.P., RA Weinert S., Froyen G., Frints S.G., Laumonnier F., Zemojtel T., Love M.I., RA Richard H., Emde A.K., Bienek M., Jensen C., Hambrock M., Fischer U., RA Langnick C., Feldkamp M., Wissink-Lindhout W., Lebrun N., Castelnau L., RA Rucci J., Montjean R., Dorseuil O., Billuart P., Stuhlmann T., Shaw M., RA Corbett M.A., Gardner A., Willis-Owen S., Tan C., Friend K.L., Belet S., RA van Roozendaal K.E., Jimenez-Pocquet M., Moizard M.P., Ronce N., Sun R., RA O'Keeffe S., Chenna R., van Boemmel A., Goeke J., Hackett A., Field M., RA Christie L., Boyle J., Haan E., Nelson J., Turner G., Baynam G., RA Gillessen-Kaesbach G., Mueller U., Steinberger D., Budny B., RA Badura-Stronka M., Latos-Bielenska A., Ousager L.B., Wieacker P., RA Rodriguez Criado G., Bondeson M.L., Anneren G., Dufke A., Cohen M., RA Van Maldergem L., Vincent-Delorme C., Echenne B., Simon-Bouy B., RA Kleefstra T., Willemsen M., Fryns J.P., Devriendt K., Ullmann R., RA Vingron M., Wrogemann K., Wienker T.F., Tzschach A., van Bokhoven H., RA Gecz J., Jentsch T.J., Chen W., Ropers H.H., Kalscheuer V.M.; RT "X-exome sequencing of 405 unresolved families identifies seven novel RT intellectual disability genes."; RL Mol. Psychiatry 21:133-148(2016). CC -!- FUNCTION: The TFIID basal transcription factor complex plays a major CC role in the initiation of RNA polymerase II (Pol II)-dependent CC transcription (PubMed:33795473). TFIID recognizes and binds promoters CC with or without a TATA box via its subunit TBP, a TATA-box-binding CC protein, and promotes assembly of the pre-initiation complex (PIC) CC (PubMed:33795473). The TFIID complex consists of TBP and TBP-associated CC factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, CC TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13 (PubMed:33795473). TAF1 is CC the largest component and core scaffold of the TFIID complex, involved CC in nucleating complex assembly (PubMed:25412659, PubMed:27007846, CC PubMed:33795473). TAF1 forms a promoter DNA binding subcomplex of CC TFIID, together with TAF7 and TAF2 (PubMed:33795473). Contains novel CC N- and C-terminal Ser/Thr kinase domains which can autophosphorylate or CC transphosphorylate other transcription factors (PubMed:25412659, CC PubMed:8625415). Phosphorylates TP53 on 'Thr-55' which leads to MDM2- CC mediated degradation of TP53 (PubMed:25412659). Phosphorylates GTF2A1 CC and GTF2F1 on Ser residues (PubMed:25412659). Possesses DNA-binding CC activity (PubMed:25412659). Essential for progression of the G1 phase CC of the cell cycle (PubMed:11278496, PubMed:15053879, PubMed:2038334, CC PubMed:8450888, PubMed:8625415, PubMed:9660973, PubMed:9858607). CC Exhibits histone acetyltransferase activity towards histones H3 and H4 CC (PubMed:15870300). {ECO:0000269|PubMed:11278496, CC ECO:0000269|PubMed:15053879, ECO:0000269|PubMed:15870300, CC ECO:0000269|PubMed:2038334, ECO:0000269|PubMed:25412659, CC ECO:0000269|PubMed:27007846, ECO:0000269|PubMed:33795473, CC ECO:0000269|PubMed:8450888, ECO:0000269|PubMed:8625415, CC ECO:0000269|PubMed:9660973, ECO:0000269|PubMed:9858607}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-lysyl-[protein] + acetyl-CoA = N(6)-acetyl-L-lysyl-[protein] CC + CoA + H(+); Xref=Rhea:RHEA:45948, Rhea:RHEA-COMP:9752, Rhea:RHEA- CC COMP:10731, ChEBI:CHEBI:15378, ChEBI:CHEBI:29969, ChEBI:CHEBI:57287, CC ChEBI:CHEBI:57288, ChEBI:CHEBI:61930; EC=2.3.1.48; CC Evidence={ECO:0000269|PubMed:15870300}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Autophosphorylates on Ser residues CC (PubMed:8625415). Inhibited by retinoblastoma tumor suppressor protein, CC RB1 (PubMed:9858607). Binding to TAF7 or CIITA inhibits the histone CC acetyltransferase activity (PubMed:11592977, PubMed:22711989). CC {ECO:0000269|PubMed:11592977, ECO:0000269|PubMed:22711989, CC ECO:0000269|PubMed:8625415, ECO:0000269|PubMed:9858607}. CC -!- SUBUNIT: Component of the TFIID basal transcription factor complex, CC composed of TATA-box-binding protein TBP, and a number of TBP- CC associated factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, CC TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13 (PubMed:33795473, CC PubMed:7680771). Interacts with TAF7; the interaction is direct CC (PubMed:11592977, PubMed:25412659). TAF1, when part of the TFIID CC complex, interacts with C-terminus of TP53 (PubMed:15053879). Part of a CC TFIID-containing RNA polymerase II pre-initiation complex that is CC composed of TBP and at least GTF2A1, GTF2A2, GTF2E1, GTF2E2, GTF2F1, CC GTF2H2, GTF2H3, GTF2H4, GTF2H5, GTF2B, TCEA1, ERCC2, ERCC3, TAF1, TAF2, CC TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13 CC (PubMed:27007846). Component of some MLL1/MLL complex, at least CC composed of the core components KMT2A/MLL1, ASH2L, HCFC1/HCF1, WDR5 and CC RBBP5, as well as the facultative components BACC1, CHD8, E2F6, HSP70, CC INO80C, KANSL1, LAS1L, MAX, MCRS1, MGA, KAT8/MOF, PELP1, PHF20, PRP31, CC RING2, RUVB1/TIP49A, RUVB2/TIP49B, SENP3, TAF1, TAF4, TAF6, TAF7, TAF9 CC and TEX10 (PubMed:15960975). RB1 interacts with the N-terminal domain CC of TAF1 (PubMed:9858607). Interacts with ASF1A and ASF1B CC (PubMed:10759893, PubMed:12093919, PubMed:12842904). Interacts (via CC bromo domains) with acetylated lysine residues on the N-terminus of CC histone H1.4, H2A, H2B, H3 and H4 (in vitro) (PubMed:22464331). CC {ECO:0000269|PubMed:10759893, ECO:0000269|PubMed:11592977, CC ECO:0000269|PubMed:12093919, ECO:0000269|PubMed:12842904, CC ECO:0000269|PubMed:15053879, ECO:0000269|PubMed:15960975, CC ECO:0000269|PubMed:22464331, ECO:0000269|PubMed:25412659, CC ECO:0000269|PubMed:27007846, ECO:0000269|PubMed:33795473, CC ECO:0000269|PubMed:7680771, ECO:0000269|PubMed:9858607}. CC -!- SUBUNIT: (Microbial infection) Interacts with SV40 Large T antigen. CC {ECO:0000269|PubMed:8647434}. CC -!- SUBUNIT: (Microbial infection) Interacts with herpes simplex virus 1 CC ICP4. {ECO:0000269|PubMed:8649420}. CC -!- INTERACTION: CC P21675; P35269: GTF2F1; NbExp=3; IntAct=EBI-491289, EBI-457886; CC P21675; P20226: TBP; NbExp=11; IntAct=EBI-491289, EBI-355371; CC P21675; P03255; Xeno; NbExp=3; IntAct=EBI-491289, EBI-2603114; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:2038334, CC ECO:0000269|PubMed:25593309, ECO:0000269|PubMed:27007846}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing, Alternative initiation; Named isoforms=15; CC Comment=the TAF1/DYT3 multiple transcript system is composed of 38 CC evolutionary conserved exons plus 5 downstream exons referred to as CC exons d1-d5 that are primate-specific. Multiple highly polymorphic CC variants can be generated by splicing exons d3 and d4 to various CC combinations of exons 1-37. {ECO:0000305|PubMed:17952504}; CC Name=2; CC IsoId=P21675-2; Sequence=Displayed; CC Name=1; CC IsoId=P21675-1; Sequence=VSP_061988; CC Name=13; CC IsoId=P21675-13; Sequence=VSP_061987, VSP_061988; CC Name=14; CC IsoId=P21675-14; Sequence=VSP_061987; CC Name=15; CC IsoId=P21675-15; Sequence=VSP_061999, VSP_062000; CC Name=16; CC IsoId=P21675-16; Sequence=VSP_061996, VSP_061998; CC Name=N-TAF1; Synonyms=TA14-391; CC IsoId=P21675-17; Sequence=VSP_061995; CC Name=2a; CC IsoId=P21675-18; Sequence=VSP_061997, VSP_061998; CC Name=2c; CC IsoId=P21675-19; Sequence=VSP_061998; CC Name=2d; CC IsoId=P21675-20; Sequence=VSP_061995, VSP_061998; CC Name=2e; CC IsoId=P21675-21; Sequence=VSP_061993, VSP_061994; CC Name=2g; CC IsoId=P21675-22; Sequence=VSP_061995, VSP_061997, VSP_061998; CC Name=2h; CC IsoId=P21675-23; Sequence=VSP_061990, VSP_061991; CC Name=2i; CC IsoId=P21675-24; Sequence=VSP_061989, VSP_061992; CC Name=4; CC IsoId=P21675-25; Sequence=VSP_061997; CC -!- DOMAIN: The Bromo domain mediates interaction with histones that have CC acetylated lysine residues at specific positions (PubMed:22464331). The CC second domain also recognizes and binds histones that are butyrylated CC and crotonylated (PubMed:26365797). {ECO:0000269|PubMed:22464331, CC ECO:0000269|PubMed:26365797}. CC -!- PTM: Phosphorylated by casein kinase II in vitro. CC {ECO:0000269|PubMed:8625415}. CC -!- DISEASE: Dystonia 3, torsion, X-linked (DYT3) [MIM:314250]: An X-linked CC dystonia-parkinsonism disorder. Dystonia is defined by the presence of CC sustained involuntary muscle contractions, often leading to abnormal CC postures. DYT3 is characterized by severe progressive torsion dystonia CC followed by parkinsonism. It has a well-defined pathology of extensive CC neuronal loss and mosaic gliosis in the striatum (caudate nucleus and CC putamen) which appears to resemble that in Huntington disease. CC {ECO:0000269|PubMed:12928496, ECO:0000269|PubMed:17273961}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Intellectual developmental disorder, X-linked, syndromic 33 CC (MRXS33) [MIM:300966]: A syndrome characterized by intellectual CC deficit, delayed psychomotor development, delayed speech and language, CC and characteristic facial features. {ECO:0000269|PubMed:26637982}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- MISCELLANEOUS: [Isoform 16]: May be produced at very low levels due to CC a premature stop CC codon in the mRNA, leading to nonsense-mediated CC mRNA decay. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 2a]: May be produced at very low levels due to CC a premature stop CC codon in the mRNA, leading to nonsense-mediated CC mRNA decay (Probable). Includes a downstream (d) exon and is CC preferentially expressed in brain (Probable). May play a role in the CC regulation of genes involved in dopamine processing and transport CC (Probable). {ECO:0000305, ECO:0000305|PubMed:17952504}. CC -!- MISCELLANEOUS: [Isoform 2c]: May be produced at very low levels due to CC a premature stop CC codon in the mRNA, leading to nonsense-mediated CC mRNA decay (Probable). Includes a downstream (d) exon and is CC preferentially expressed in brain (Probable). May play a role in the CC regulation of genes involved in dopamine processing and transport CC (Probable). {ECO:0000305, ECO:0000305|PubMed:17952504}. CC -!- MISCELLANEOUS: [Isoform 2d]: May be produced at very low levels due to CC a premature stop CC codon in the mRNA, leading to nonsense-mediated CC mRNA decay (Probable). Includes a downstream (d) exon and is CC preferentially expressed in brain (Probable). May play a role in the CC regulation of genes involved in dopamine processing and transport CC (Probable). {ECO:0000305, ECO:0000305|PubMed:17952504}. CC -!- MISCELLANEOUS: [Isoform 2e]: May be produced at very low levels due to CC a premature stop CC codon in the mRNA, leading to nonsense-mediated CC mRNA decay (Probable). Includes a downstream (d) exon and is CC preferentially expressed in brain (Probable). May play a role in the CC regulation of genes involved in dopamine processing and transport CC (Probable). {ECO:0000305, ECO:0000305|PubMed:17952504}. CC -!- MISCELLANEOUS: [Isoform 2h]: May be produced at very low levels due to CC a premature stop CC codon in the mRNA, leading to nonsense-mediated CC mRNA decay (Probable). Includes a downstream (d) exon and is CC preferentially expressed in brain (Probable). May play a role in the CC regulation of genes involved in dopamine processing and transport CC (Probable). {ECO:0000305, ECO:0000305|PubMed:17952504}. CC -!- MISCELLANEOUS: [Isoform 2i]: May be produced at very low levels due to CC a premature stop CC codon in the mRNA, leading to nonsense-mediated CC mRNA decay (Probable). Includes a downstream (d) exon and is CC preferentially expressed in brain (Probable). May play a role in the CC regulation of genes involved in dopamine processing and transport CC (Probable). {ECO:0000305, ECO:0000305|PubMed:17952504}. CC -!- MISCELLANEOUS: [Isoform 2g]: Includes a downstream (d) exon and is CC preferentially expressed in brain (Probable). May play a role in the CC regulation of genes involved in dopamine processing and transport CC (Probable). {ECO:0000305|PubMed:17952504}. CC -!- MISCELLANEOUS: [Isoform 15]: May be produced at very low levels due to CC a premature stop CC codon in the mRNA, leading to nonsense-mediated CC mRNA decay. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform N-TAF1]: Only detected in brain, highest CC expression in the caudate nucleus. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the TAF1 family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=CAA30073.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal and C-terminal part.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D90359; BAA14374.1; -; mRNA. DR EMBL; AB300418; BAG15901.1; -; mRNA. DR EMBL; AY623109; AAT38105.1; -; Genomic_DNA. DR EMBL; AL590762; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL590763; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; X07024; CAA30073.1; ALT_SEQ; mRNA. DR EMBL; AB209316; BAD92553.1; -; mRNA. DR EMBL; AJ549247; CAD70490.1; -; mRNA. DR EMBL; AJ549248; CAD70491.3; -; mRNA. DR EMBL; AJ549249; CAD70492.2; -; mRNA. DR EMBL; AJ549250; CAD70493.3; -; mRNA. DR EMBL; AJ555148; CAD87527.2; -; mRNA. DR EMBL; AJ555149; CAD87528.2; -; mRNA. DR EMBL; AM711892; CAM98555.1; -; mRNA. DR EMBL; AM711893; CAM98556.1; -; mRNA. DR EMBL; AM711894; CAM98557.1; -; mRNA. DR EMBL; AM711895; CAM98558.1; -; mRNA. DR CCDS; CCDS14412.2; -. [P21675-14] DR CCDS; CCDS35325.2; -. [P21675-13] DR PIR; A40262; A40262. DR RefSeq; NP_620278.2; NM_138923.4. [P21675-13] DR RefSeq; XP_047298351.1; XM_047442395.1. [P21675-14] DR RefSeq; XP_047298355.1; XM_047442399.1. [P21675-13] DR RefSeq; XP_054183607.1; XM_054327632.1. [P21675-14] DR RefSeq; XP_054183611.1; XM_054327636.1. [P21675-13] DR PDB; 1EQF; X-ray; 2.10 A; A=1380-1659. DR PDB; 3AAD; X-ray; 3.30 A; A=1363-1650. DR PDB; 3UV4; X-ray; 1.89 A; A/B=1522-1656. DR PDB; 3UV5; X-ray; 2.03 A; A=1394-1656. DR PDB; 4RGW; X-ray; 2.30 A; A=600-1236. DR PDB; 4YYM; X-ray; 1.50 A; A/B=1518-1659. DR PDB; 4YYN; X-ray; 1.85 A; A/B=1518-1659. DR PDB; 5FUR; EM; 8.50 A; G=1-1893. DR PDB; 5I1Q; X-ray; 1.50 A; A=1518-1659. DR PDB; 5I29; X-ray; 1.21 A; A=1518-1659. DR PDB; 5MG2; X-ray; 1.75 A; A=1522-1656. DR PDB; 6BQD; X-ray; 2.14 A; A/B=1522-1651. DR PDB; 6FIC; X-ray; 2.18 A; T=1380-1659. DR PDB; 6MZD; EM; 9.80 A; A=21-1893. DR PDB; 6MZL; EM; 23.00 A; A=1-1893. DR PDB; 6MZM; EM; 7.50 A; A=609-1104. DR PDB; 6P38; X-ray; 2.80 A; A=1522-1656. DR PDB; 6P39; X-ray; 2.94 A; A=1521-1656. DR PDB; 6P3A; X-ray; 2.99 A; A/B=1522-1656. DR PDB; 7EDX; EM; 4.50 A; A=1-1893. DR PDB; 7EG7; EM; 6.20 A; A=1-1893. DR PDB; 7EG8; EM; 7.40 A; A=1-1893. DR PDB; 7EG9; EM; 3.70 A; A=1-1893. DR PDB; 7EGA; EM; 4.10 A; A=1-1893. DR PDB; 7EGB; EM; 3.30 A; A=1-1893. DR PDB; 7EGC; EM; 3.90 A; A=1-1893. DR PDB; 7EGD; EM; 6.75 A; A=1-1893. DR PDB; 7EGE; EM; 9.00 A; A=1-1893. DR PDB; 7EGH; EM; 3.04 A; A=1-1893. DR PDB; 7EGI; EM; 9.82 A; A=1-1893. DR PDB; 7EGJ; EM; 8.64 A; A=1-1893. DR PDB; 7ENA; EM; 4.07 A; DA=1-1893. DR PDB; 7ENC; EM; 4.13 A; DA=1-1893. DR PDB; 7JJG; X-ray; 1.60 A; A=1522-1656. DR PDB; 7JJH; X-ray; 2.10 A; A=1394-1656. DR PDB; 7JSP; X-ray; 1.70 A; A=1522-1656. DR PDB; 7JTC; X-ray; 2.05 A; A=1522-1656. DR PDB; 7K03; X-ray; 1.60 A; A=1394-1656. DR PDB; 7K0D; X-ray; 2.20 A; A=1394-1656. DR PDB; 7K0U; X-ray; 2.52 A; A/B=1522-1656. DR PDB; 7K1P; X-ray; 2.45 A; A=1522-1656. DR PDB; 7K27; X-ray; 1.50 A; A=1394-1656. DR PDB; 7K3O; X-ray; 1.70 A; A/B=1522-1656. DR PDB; 7K42; X-ray; 1.70 A; A/B=1522-1656. DR PDB; 7K6F; X-ray; 1.86 A; A=1394-1656. DR PDB; 7L6X; X-ray; 2.75 A; A=1394-1656. DR PDB; 7LB0; X-ray; 2.33 A; A=1394-1656. DR PDB; 7LB1; X-ray; 1.35 A; A=1394-1656. DR PDB; 7LB2; X-ray; 1.70 A; A=1394-1656. DR PDB; 7LB3; X-ray; 1.90 A; A=1522-1656. DR PDB; 7N42; X-ray; 1.90 A; A=1394-1656. DR PDB; 7P4S; X-ray; 2.17 A; A=1522-1656. DR PDB; 7T2I; X-ray; 1.89 A; A=1394-1656. DR PDB; 7T36; X-ray; 1.65 A; A=1394-1656. DR PDB; 8GXQ; EM; 5.04 A; DA=1-1893. DR PDB; 8GXS; EM; 4.16 A; DA=1-1893. DR PDB; 8WAK; EM; 5.47 A; A=1-1872. DR PDB; 8WAL; EM; 8.52 A; A=1-1872. DR PDB; 8WAN; EM; 6.07 A; A=1-1872. DR PDB; 8WAO; EM; 6.40 A; A=1-1872. DR PDB; 8WAP; EM; 5.85 A; A=1-1872. DR PDB; 8WAQ; EM; 6.29 A; A=1-1872. DR PDB; 8WAR; EM; 7.20 A; A=1-1872. DR PDB; 8WAS; EM; 6.13 A; A=1-1872. DR PDBsum; 1EQF; -. DR PDBsum; 3AAD; -. DR PDBsum; 3UV4; -. DR PDBsum; 3UV5; -. DR PDBsum; 4RGW; -. DR PDBsum; 4YYM; -. DR PDBsum; 4YYN; -. DR PDBsum; 5FUR; -. DR PDBsum; 5I1Q; -. DR PDBsum; 5I29; -. DR PDBsum; 5MG2; -. DR PDBsum; 6BQD; -. DR PDBsum; 6FIC; -. DR PDBsum; 6MZD; -. DR PDBsum; 6MZL; -. DR PDBsum; 6MZM; -. DR PDBsum; 6P38; -. DR PDBsum; 6P39; -. DR PDBsum; 6P3A; -. DR PDBsum; 7EDX; -. DR PDBsum; 7EG7; -. DR PDBsum; 7EG8; -. DR PDBsum; 7EG9; -. DR PDBsum; 7EGA; -. DR PDBsum; 7EGB; -. DR PDBsum; 7EGC; -. DR PDBsum; 7EGD; -. DR PDBsum; 7EGE; -. DR PDBsum; 7EGH; -. DR PDBsum; 7EGI; -. DR PDBsum; 7EGJ; -. DR PDBsum; 7ENA; -. DR PDBsum; 7ENC; -. DR PDBsum; 7JJG; -. DR PDBsum; 7JJH; -. DR PDBsum; 7JSP; -. DR PDBsum; 7JTC; -. DR PDBsum; 7K03; -. DR PDBsum; 7K0D; -. DR PDBsum; 7K0U; -. DR PDBsum; 7K1P; -. DR PDBsum; 7K27; -. DR PDBsum; 7K3O; -. DR PDBsum; 7K42; -. DR PDBsum; 7K6F; -. DR PDBsum; 7L6X; -. DR PDBsum; 7LB0; -. DR PDBsum; 7LB1; -. DR PDBsum; 7LB2; -. DR PDBsum; 7LB3; -. DR PDBsum; 7N42; -. DR PDBsum; 7P4S; -. DR PDBsum; 7T2I; -. DR PDBsum; 7T36; -. DR PDBsum; 8GXQ; -. DR PDBsum; 8GXS; -. DR PDBsum; 8WAK; -. DR PDBsum; 8WAL; -. DR PDBsum; 8WAN; -. DR PDBsum; 8WAO; -. DR PDBsum; 8WAP; -. DR PDBsum; 8WAQ; -. DR PDBsum; 8WAR; -. DR PDBsum; 8WAS; -. DR AlphaFoldDB; P21675; -. DR EMDB; EMD-31075; -. DR EMDB; EMD-31107; -. DR EMDB; EMD-31108; -. DR EMDB; EMD-31109; -. DR EMDB; EMD-31110; -. DR EMDB; EMD-31111; -. DR EMDB; EMD-31112; -. DR EMDB; EMD-31113; -. DR EMDB; EMD-31114; -. DR EMDB; EMD-31117; -. DR EMDB; EMD-31118; -. DR EMDB; EMD-31119; -. DR EMDB; EMD-31204; -. DR EMDB; EMD-31207; -. DR EMDB; EMD-34359; -. DR EMDB; EMD-34360; -. DR EMDB; EMD-37395; -. DR EMDB; EMD-37396; -. DR EMDB; EMD-37398; -. DR EMDB; EMD-37399; -. DR EMDB; EMD-37400; -. DR EMDB; EMD-37401; -. DR EMDB; EMD-37402; -. DR EMDB; EMD-37403; -. DR EMDB; EMD-9302; -. DR EMDB; EMD-9305; -. DR EMDB; EMD-9306; -. DR SASBDB; P21675; -. DR SMR; P21675; -. DR BioGRID; 112735; 258. DR ComplexPortal; CPX-915; General transcription factor complex TFIID. DR ComplexPortal; CPX-930; General transcription factor complex TFIID, TAF4B variant. DR CORUM; P21675; -. DR DIP; DIP-147N; -. DR FunCoup; P21675; 3231. DR IntAct; P21675; 83. DR MINT; P21675; -. DR STRING; 9606.ENSP00000406549; -. DR BindingDB; P21675; -. DR ChEMBL; CHEMBL3217390; -. DR GuidetoPHARMACOLOGY; 2231; -. DR GlyCosmos; P21675; 1 site, 1 glycan. DR GlyGen; P21675; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P21675; -. DR PhosphoSitePlus; P21675; -. DR BioMuta; TAF1; -. DR DMDM; 115942; -. DR jPOST; P21675; -. DR MassIVE; P21675; -. DR PaxDb; 9606-ENSP00000406549; -. DR PeptideAtlas; P21675; -. DR ProteomicsDB; 3401; -. DR ProteomicsDB; 53886; -. [P21675-1] DR ProteomicsDB; 53887; -. [P21675-2] DR Pumba; P21675; -. DR ABCD; P21675; 1 sequenced antibody. DR Antibodypedia; 346; 301 antibodies from 39 providers. DR DNASU; 6872; -. DR Ensembl; ENST00000373790.9; ENSP00000362895.5; ENSG00000147133.19. [P21675-13] DR Ensembl; ENST00000423759.6; ENSP00000406549.2; ENSG00000147133.19. [P21675-14] DR Ensembl; ENST00000715246.1; ENSP00000520427.1; ENSG00000147133.19. [P21675-2] DR GeneID; 6872; -. DR KEGG; hsa:6872; -. DR MANE-Select; ENST00000423759.6; ENSP00000406549.2; NM_004606.5; NP_004597.3. [P21675-14] DR UCSC; uc004dzt.6; human. [P21675-2] DR AGR; HGNC:11535; -. DR ClinPGx; PA36310; -. DR CTD; 6872; -. DR DisGeNET; 6872; -. DR GeneCards; TAF1; -. DR GeneReviews; TAF1; -. DR HGNC; HGNC:11535; TAF1. DR HPA; ENSG00000147133; Low tissue specificity. DR MalaCards; TAF1; -. DR MIM; 300966; phenotype. DR MIM; 313650; gene. DR MIM; 314250; phenotype. DR OpenTargets; ENSG00000147133; -. DR Orphanet; 53351; X-linked dystonia-parkinsonism. DR Orphanet; 480907; X-linked intellectual disability-global development delay-facial dysmorphism-sacral caudal remnant syndrome. DR VEuPathDB; HostDB:ENSG00000147133; -. DR eggNOG; KOG0008; Eukaryota. DR GeneTree; ENSGT00940000155242; -. DR HOGENOM; CLU_000572_3_0_1; -. DR InParanoid; P21675; -. DR OMA; PARIWYD; -. DR OrthoDB; 5752at2759; -. DR PAN-GO; P21675; 4 GO annotations based on evolutionary models. DR PhylomeDB; P21675; -. DR BRENDA; 2.3.1.48; 2681. DR PathwayCommons; P21675; -. DR Reactome; R-HSA-167161; HIV Transcription Initiation. DR Reactome; R-HSA-167162; RNA Polymerase II HIV Promoter Escape. DR Reactome; R-HSA-167172; Transcription of the HIV genome. DR Reactome; R-HSA-674695; RNA Polymerase II Pre-transcription Events. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-73776; RNA Polymerase II Promoter Escape. DR Reactome; R-HSA-73779; RNA Polymerase II Transcription Pre-Initiation And Promoter Opening. DR Reactome; R-HSA-75953; RNA Polymerase II Transcription Initiation. DR Reactome; R-HSA-76042; RNA Polymerase II Transcription Initiation And Promoter Clearance. DR SignaLink; P21675; -. DR SIGNOR; P21675; -. DR Agora; ENSG00000147133; -. DR BioGRID-ORCS; 6872; 343 hits in 821 CRISPR screens. DR ChiTaRS; TAF1; human. DR EvolutionaryTrace; P21675; -. DR GeneWiki; TAF1; -. DR GenomeRNAi; 6872; -. DR Pharos; P21675; Tchem. DR PRO; PR:P21675; -. DR Proteomes; UP000005640; Chromosome X. DR RNAct; P21675; protein. DR Bgee; ENSG00000147133; Expressed in sural nerve and 182 other cell types or tissues. DR ExpressionAtlas; P21675; baseline and differential. DR GO; GO:0000785; C:chromatin; IDA:ParkinsonsUK-UCL. DR GO; GO:0071339; C:MLL1 complex; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005669; C:transcription factor TFIID complex; IDA:UniProtKB. DR GO; GO:0005667; C:transcription regulator complex; IPI:ParkinsonsUK-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004402; F:histone acetyltransferase activity; IDA:UniProtKB. DR GO; GO:0140046; F:histone H4K16ac reader activity; IDA:BHF-UCL. DR GO; GO:0016301; F:kinase activity; IDA:ParkinsonsUK-UCL. DR GO; GO:0016922; F:nuclear receptor binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0002039; F:p53 binding; IPI:BHF-UCL. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:ParkinsonsUK-UCL. DR GO; GO:0004672; F:protein kinase activity; IDA:ParkinsonsUK-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0001181; F:RNA polymerase I general transcription initiation factor activity; IDA:ARUK-UCL. DR GO; GO:0000979; F:RNA polymerase II core promoter sequence-specific DNA binding; IMP:ParkinsonsUK-UCL. DR GO; GO:0016251; F:RNA polymerase II general transcription initiation factor activity; IDA:BHF-UCL. DR GO; GO:0001091; F:RNA polymerase II general transcription initiation factor binding; IPI:BHF-UCL. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0043565; F:sequence-specific DNA binding; ISS:BHF-UCL. DR GO; GO:0017025; F:TBP-class protein binding; IPI:BHF-UCL. DR GO; GO:0140416; F:transcription regulator inhibitor activity; IDA:ParkinsonsUK-UCL. DR GO; GO:0061631; F:ubiquitin conjugating enzyme activity; IDA:ParkinsonsUK-UCL. DR GO; GO:0071318; P:cellular response to ATP; IDA:ParkinsonsUK-UCL. DR GO; GO:0034644; P:cellular response to UV; IDA:ParkinsonsUK-UCL. DR GO; GO:0006974; P:DNA damage response; IDA:ParkinsonsUK-UCL. DR GO; GO:0030901; P:midbrain development; IGI:ParkinsonsUK-UCL. DR GO; GO:0042789; P:mRNA transcription by RNA polymerase II; IDA:ComplexPortal. DR GO; GO:0010629; P:negative regulation of gene expression; IMP:ParkinsonsUK-UCL. DR GO; GO:1905524; P:negative regulation of protein autoubiquitination; IDA:ParkinsonsUK-UCL. DR GO; GO:1901797; P:negative regulation of signal transduction by p53 class mediator; IDA:ParkinsonsUK-UCL. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:ParkinsonsUK-UCL. DR GO; GO:2000059; P:negative regulation of ubiquitin-dependent protein catabolic process; IMP:ParkinsonsUK-UCL. DR GO; GO:0160207; P:positive regulation of androgen receptor signaling pathway; IDA:ParkinsonsUK-UCL. DR GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IDA:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:ParkinsonsUK-UCL. DR GO; GO:0060261; P:positive regulation of transcription initiation by RNA polymerase II; IDA:ComplexPortal. DR GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB. DR GO; GO:0000209; P:protein polyubiquitination; IDA:ParkinsonsUK-UCL. DR GO; GO:0050821; P:protein stabilization; IDA:ParkinsonsUK-UCL. DR GO; GO:1902806; P:regulation of cell cycle G1/S phase transition; TAS:ParkinsonsUK-UCL. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0051123; P:RNA polymerase II preinitiation complex assembly; IPI:ComplexPortal. DR GO; GO:0006366; P:transcription by RNA polymerase II; IGI:BHF-UCL. DR GO; GO:0006361; P:transcription initiation at RNA polymerase I promoter; IGI:ParkinsonsUK-UCL. DR GO; GO:0006367; P:transcription initiation at RNA polymerase II promoter; IDA:BHF-UCL. DR GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:ParkinsonsUK-UCL. DR CDD; cd05511; Bromo_TFIID; 2. DR DisProt; DP03451; -. [P21675-1] DR FunFam; 1.10.1100.10:FF:000001; Transcription initiation factor TFIID subunit; 1. DR FunFam; 1.20.920.10:FF:000019; Transcription initiation factor TFIID subunit; 1. DR FunFam; 1.20.920.10:FF:000020; Transcription initiation factor TFIID subunit; 1. DR Gene3D; 1.20.920.10; Bromodomain-like; 2. DR Gene3D; 1.10.1100.10; TAFII-230 TBP-binding domain; 1. DR IDEAL; IID00545; -. DR InterPro; IPR001487; Bromodomain. DR InterPro; IPR036427; Bromodomain-like_sf. DR InterPro; IPR018359; Bromodomain_CS. DR InterPro; IPR040240; TAF1. DR InterPro; IPR011177; TAF1_animal. DR InterPro; IPR022591; TAF1_HAT_dom. DR InterPro; IPR009067; TAF_II_230-bd. DR InterPro; IPR036741; TAFII-230_TBP-bd_sf. DR InterPro; IPR041670; Znf-CCHC_6. DR PANTHER; PTHR13900; TRANSCRIPTION INITIATION FACTOR TFIID; 1. DR PANTHER; PTHR13900:SF0; TRANSCRIPTION INITIATION FACTOR TFIID SUBUNIT 1; 1. DR Pfam; PF00439; Bromodomain; 2. DR Pfam; PF12157; DUF3591; 1. DR Pfam; PF09247; TBP-binding; 1. DR Pfam; PF15288; zf-CCHC_6; 1. DR PIRSF; PIRSF003047; TAF1_animal; 1. DR PRINTS; PR00503; BROMODOMAIN. DR SMART; SM00297; BROMO; 2. DR SUPFAM; SSF47370; Bromodomain; 2. DR SUPFAM; SSF47055; TAF(II)230 TBP-binding fragment; 1. DR PROSITE; PS00633; BROMODOMAIN_1; 2. DR PROSITE; PS50014; BROMODOMAIN_2; 2. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Acyltransferase; Alternative initiation; KW Alternative splicing; ATP-binding; Bromodomain; Cell cycle; KW Disease variant; DNA-binding; Dystonia; Host-virus interaction; KW Intellectual disability; Isopeptide bond; Kinase; Nucleotide-binding; KW Nucleus; Parkinsonism; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Serine/threonine-protein kinase; Transcription; KW Transcription regulation; Transferase; Ubl conjugation. FT CHAIN 1..1893 FT /note="Transcription initiation factor TFIID subunit 1" FT /id="PRO_0000211215" FT DOMAIN 1..435 FT /note="Protein kinase 1" FT DOMAIN 1397..1505 FT /note="Bromo 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00035" FT DOMAIN 1446..1893 FT /note="Protein kinase 2" FT DOMAIN 1519..1628 FT /note="Bromo 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00035" FT DNA_BIND 1216..1294 FT /note="HMG box; involved in promoter binding" FT /evidence="ECO:0007744|PDB:7EDX, ECO:0007744|PDB:7EG7, FT ECO:0007744|PDB:7EG8, ECO:0007744|PDB:7EG9, FT ECO:0007744|PDB:7EGA, ECO:0007744|PDB:7EGB, FT ECO:0007744|PDB:7EGC, ECO:0007744|PDB:7EGD, FT ECO:0007744|PDB:7EGE, ECO:0007744|PDB:7EGH, FT ECO:0007744|PDB:7EGI, ECO:0007744|PDB:7EGJ" FT REGION 155..184 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 197..224 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 534..557 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 538..997 FT /note="Histone acetyltransferase (HAT)" FT REGION 990..1009 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1128..1148 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1158..1177 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1254..1278 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1363..1650 FT /note="Interaction with ASF1A and ASF1B" FT /evidence="ECO:0000269|PubMed:12842904" FT REGION 1651..1676 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1696..1893 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 1372..1379 FT /note="Nuclear localization signal" FT /evidence="ECO:0000255" FT COMPBIAS 156..165 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 197..208 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 995..1004 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1139..1148 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1254..1270 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1659..1668 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1709..1723 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1741..1756 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1830..1840 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1846..1857 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1860..1869 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 137 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:8625415" FT MOD_RES 328 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:8625415, FT ECO:0007744|PubMed:24275569" FT MOD_RES 565 FT /note="N6-acetyllysine" FT /evidence="ECO:0000250|UniProtKB:Q80UV9" FT MOD_RES 1690 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80UV9" FT MOD_RES 1693 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80UV9" FT MOD_RES 1799 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80UV9" FT MOD_RES 1802 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80UV9" FT MOD_RES 1820 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80UV9" FT MOD_RES 1847 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332" FT CROSSLNK 570 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 583 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 1..20 FT /note="Missing (in isoform 13 and isoform 14)" FT /id="VSP_061987" FT VAR_SEQ 178..198 FT /note="Missing (in isoform 1 and isoform 13)" FT /id="VSP_061988" FT VAR_SEQ 1546..1561 FT /note="SWPFHHPVNKKFVPDY -> VSCLCAKYFLAISSPS (in isoform FT 2i)" FT /evidence="ECO:0000303|PubMed:17952504" FT /id="VSP_061989" FT VAR_SEQ 1546..1549 FT /note="SWPF -> IITK (in isoform 2h)" FT /evidence="ECO:0000303|PubMed:17952504" FT /id="VSP_061990" FT VAR_SEQ 1550..1893 FT /note="Missing (in isoform 2h)" FT /evidence="ECO:0000303|PubMed:17952504" FT /id="VSP_061991" FT VAR_SEQ 1562..1893 FT /note="Missing (in isoform 2i)" FT /evidence="ECO:0000303|PubMed:17952504" FT /id="VSP_061992" FT VAR_SEQ 1606..1613 FT /note="PESQYTKT -> YMCTTCRT (in isoform 2e)" FT /evidence="ECO:0000303|PubMed:12928496, FT ECO:0000303|PubMed:17952504" FT /id="VSP_061993" FT VAR_SEQ 1614..1893 FT /note="Missing (in isoform 2e)" FT /evidence="ECO:0000303|PubMed:12928496, FT ECO:0000303|PubMed:17952504" FT /id="VSP_061994" FT VAR_SEQ 1666 FT /note="Q -> QAK (in isoform N-TAF1, isoform 2d and isoform FT 2g)" FT /evidence="ECO:0000303|PubMed:12928496, FT ECO:0000303|PubMed:17273961, ECO:0000303|PubMed:17952504" FT /id="VSP_061995" FT VAR_SEQ 1706..1708 FT /note="VTQ -> MRQGRGRLGEEDSDVDIEGYDDEEEDGKPKTPAP (in FT isoform 16)" FT /evidence="ECO:0000303|PubMed:12928496" FT /id="VSP_061996" FT VAR_SEQ 1708 FT /note="Q -> QMRQGRGRLGEEDSDVDIEGYDDEEEDGKPKTPAP (in isoform FT 4, isoform 2a and isoform 2g)" FT /evidence="ECO:0000303|PubMed:12928496, FT ECO:0000303|PubMed:17952504, ECO:0000303|Ref.7" FT /id="VSP_061997" FT VAR_SEQ 1820..1893 FT /note="SYGSYEEPDPKSNTQDTSFSSIGGYEVSEEEEDEEEEEQRSGPSVLSQVHLS FT EDEEDSEDFHSIAGDSDLDSDE -> RYQ (in isoform 2a, isoform 16, FT isoform 2c, isoform 2d and isoform 2g)" FT /evidence="ECO:0000303|PubMed:12928496, FT ECO:0000303|PubMed:17952504" FT /id="VSP_061998" FT VAR_SEQ 1820 FT /note="S -> R (in isoform 15)" FT /id="VSP_061999" FT VAR_SEQ 1821..1893 FT /note="Missing (in isoform 15)" FT /id="VSP_062000" FT VARIANT 290 FT /note="L -> V (in dbSNP:rs28382158)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.4" FT /id="VAR_020678" FT VARIANT 318 FT /note="A -> G (in dbSNP:rs35317750)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041930" FT VARIANT 474 FT /note="G -> D (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041931" FT VARIANT 493 FT /note="N -> D (found in a patient with X-linked FT intellectual disability; uncertain significance; FT dbSNP:rs200177996)" FT /evidence="ECO:0000269|PubMed:25644381" FT /id="VAR_077838" FT VARIANT 596 FT /note="P -> S (in MRXS33; dbSNP:rs864321630)" FT /evidence="ECO:0000269|PubMed:26637982" FT /id="VAR_076394" FT VARIANT 672 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041932" FT VARIANT 712 FT /note="M -> I (in a lung bronchoalveolar carcinoma sample; FT somatic mutation; dbSNP:rs2148297629)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041933" FT VARIANT 807 FT /note="C -> R (in MRXS33; dbSNP:rs864321628)" FT /evidence="ECO:0000269|PubMed:26637982" FT /id="VAR_076395" FT VARIANT 976 FT /note="D -> H (in MRXS33; dbSNP:rs864321631)" FT /evidence="ECO:0000269|PubMed:26637982" FT /id="VAR_076396" FT VARIANT 1190 FT /note="R -> C (found in a patient with X-linked FT intellectual disability; uncertain significance; FT dbSNP:rs1569301036)" FT /evidence="ECO:0000269|PubMed:25644381" FT /id="VAR_077839" FT VARIANT 1246 FT /note="R -> W (in MRXS33; dbSNP:rs864321629)" FT /evidence="ECO:0000269|PubMed:26637982" FT /id="VAR_076397" FT VARIANT 1337 FT /note="I -> T (in MRXS33; dbSNP:rs864321627)" FT /evidence="ECO:0000269|PubMed:26637982" FT /id="VAR_076398" FT VARIANT 1404 FT /note="V -> I (in dbSNP:rs7050748)" FT /id="VAR_048433" FT VARIANT 1452 FT /note="R -> H (in MRXS33; uncertain significance; FT dbSNP:rs2148488251)" FT /evidence="ECO:0000269|PubMed:26637982" FT /id="VAR_076399" FT VARIANT 1517 FT /note="N -> H (in MRXS33; uncertain significance; FT dbSNP:rs1602624914)" FT /evidence="ECO:0000269|PubMed:26637982" FT /id="VAR_076400" FT MUTAGEN 137 FT /note="S->A: No decrease in kinase activity." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 145 FT /note="D->A: Reduces kinase activity; when associated with FT A-147; A-149; A-150; A-152 and A-154." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 147 FT /note="D->A: Reduces kinase activity; when associated with FT A-145; A-149; A-150; A-152 and A-154." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 149 FT /note="E->A: Reduces kinase activity; when associated with FT A-145; A-147; A-150; A-152 and A-154." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 150 FT /note="D->A: Reduces kinase activity; when associated with FT A-145; A-147; A-149; A-152 and A-154." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 152 FT /note="D->A: Reduces kinase activity; when associated with FT A-145; A-147; A-149; A-150 and A-154." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 154 FT /note="K->A: Reduces kinase activity; when associated with FT A-145; A-147; A-149; A-150 and A-152." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 326 FT /note="C->A: Reduces kinase activity; when associated with FT A-328; A-329; A-330 and A-331." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 328 FT /note="S->A: Reduces kinase activity; when associated with FT A-326; A-329; A-330 and A-331." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 329 FT /note="D->A: Reduces kinase activity; when associated with FT A-326; A-328; A-330 and A-331." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 330 FT /note="D->A: Reduces kinase activity; when associated with FT A-326; A-328; A-329 and A-331." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 331 FT /note="E->A: Reduces kinase activity; when associated with FT A-326; A-328; A-329 and A-330." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 742 FT /note="E->Q: 25% decrease in histone acetylation." FT /evidence="ECO:0000269|PubMed:15870300" FT MUTAGEN 848..850 FT /note="Missing: Dramatic decrease in histone acetylation." FT /evidence="ECO:0000269|PubMed:15870300" FT STRAND 363..365 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 368..374 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 420..423 FT /evidence="ECO:0007829|PDB:7EGH" FT STRAND 427..429 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 431..434 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 494..498 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 501..504 FT /evidence="ECO:0007829|PDB:7EGH" FT STRAND 509..511 FT /evidence="ECO:0007829|PDB:7EGH" FT STRAND 525..527 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 591..594 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 614..617 FT /evidence="ECO:0007829|PDB:4RGW" FT TURN 621..623 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 630..634 FT /evidence="ECO:0007829|PDB:4RGW" FT TURN 635..637 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 645..647 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 648..650 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 651..653 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 655..659 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 661..676 FT /evidence="ECO:0007829|PDB:4RGW" FT TURN 677..679 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 689..692 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 696..706 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 718..725 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 729..731 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 739..745 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 750..753 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 760..777 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 782..788 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 791..795 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 799..803 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 818..838 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 841..843 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 845..847 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 848..854 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 860..868 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 871..874 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 877..879 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 882..885 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 894..900 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 903..921 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 926..928 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 946..949 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 952..963 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 968..973 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 979..983 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 985..989 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 1014..1018 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 1020..1031 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 1035..1039 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 1043..1055 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 1076..1099 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 1186..1191 FT /evidence="ECO:0007829|PDB:7EGH" FT TURN 1195..1197 FT /evidence="ECO:0007829|PDB:7EGH" FT STRAND 1201..1206 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 1209..1224 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 1238..1262 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 1402..1418 FT /evidence="ECO:0007829|PDB:7LB1" FT HELIX 1424..1426 FT /evidence="ECO:0007829|PDB:7LB1" FT STRAND 1427..1429 FT /evidence="ECO:0007829|PDB:3AAD" FT TURN 1432..1434 FT /evidence="ECO:0007829|PDB:7LB1" FT HELIX 1438..1441 FT /evidence="ECO:0007829|PDB:7LB1" FT HELIX 1448..1456 FT /evidence="ECO:0007829|PDB:7LB1" FT HELIX 1463..1480 FT /evidence="ECO:0007829|PDB:7LB1" FT STRAND 1483..1485 FT /evidence="ECO:0007829|PDB:3AAD" FT HELIX 1486..1504 FT /evidence="ECO:0007829|PDB:7LB1" FT HELIX 1506..1516 FT /evidence="ECO:0007829|PDB:7LB1" FT HELIX 1518..1521 FT /evidence="ECO:0007829|PDB:7LB1" FT HELIX 1523..1538 FT /evidence="ECO:0007829|PDB:5I29" FT TURN 1539..1542 FT /evidence="ECO:0007829|PDB:5I29" FT HELIX 1547..1549 FT /evidence="ECO:0007829|PDB:5I29" FT TURN 1555..1557 FT /evidence="ECO:0007829|PDB:5I29" FT STRAND 1558..1560 FT /evidence="ECO:0007829|PDB:6P3A" FT HELIX 1561..1564 FT /evidence="ECO:0007829|PDB:5I29" FT STRAND 1565..1567 FT /evidence="ECO:0007829|PDB:6P3A" FT HELIX 1571..1579 FT /evidence="ECO:0007829|PDB:5I29" FT HELIX 1586..1604 FT /evidence="ECO:0007829|PDB:5I29" FT STRAND 1606..1608 FT /evidence="ECO:0007829|PDB:7K6F" FT HELIX 1609..1627 FT /evidence="ECO:0007829|PDB:5I29" FT HELIX 1629..1655 FT /evidence="ECO:0007829|PDB:5I29" FT MOD_RES P21675-16:1718 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES P21675-18:1721 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES P21675-22:1723 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES P21675-25:1721 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231" SQ SEQUENCE 1893 AA; 214714 MW; AE148C222B418BB4 CRC64; MGPGCDLLLR TAATITAAAI MSDTDSDEDS AGGGPFSLAG FLFGNINGAG QLEGESVLDD ECKKHLAGLG ALGLGSLITE LTANEELTGT DGALVNDEGW VRSTEDAVDY SDINEVAEDE SRRYQQTMGS LQPLCHSDYD EDDYDADCED IDCKLMPPPP PPPGPMKKDK DQDSITGVSE NGEGIILPSI IAPSSLASEK VDFSSSSDSE SEMGPQEATQ AESEDGKLTL PLAGIMQHDA TKLLPSVTEL FPEFRPGKVL RFLRLFGPGK NVPSVWRSAR RKRKKKHREL IQEEQIQEVE CSVESEVSQK SLWNYDYAPP PPPEQCLSDD EITMMAPVES KFSQSTGDID KVTDTKPRVA EWRYGPARLW YDMLGVPEDG SGFDYGFKLR KTEHEPVIKS RMIEEFRKLE ENNGTDLLAD ENFLMVTQLH WEDDIIWDGE DVKHKGTKPQ RASLAGWLPS SMTRNAMAYN VQQGFAATLD DDKPWYSIFP IDNEDLVYGR WEDNIIWDAQ AMPRLLEPPV LTLDPNDENL ILEIPDEKEE ATSNSPSKES KKESSLKKSR ILLGKTGVIK EEPQQNMSQP EVKDPWNLSN DEYYYPKQQG LRGTFGGNII QHSIPAVELR QPFFPTHMGP IKLRQFHRPP LKKYSFGALS QPGPHSVQPL LKHIKKKAKM REQERQASGG GEMFFMRTPQ DLTGKDGDLI LAEYSEENGP LMMQVGMATK IKNYYKRKPG KDPGAPDCKY GETVYCHTSP FLGSLHPGQL LQAFENNLFR APIYLHKMPE TDFLIIRTRQ GYYIRELVDI FVVGQQCPLF EVPGPNSKRA NTHIRDFLQV FIYRLFWKSK DRPRRIRMED IKKAFPSHSE SSIRKRLKLC ADFKRTGMDS NWWVLKSDFR LPTEEEIRAM VSPEQCCAYY SMIAAEQRLK DAGYGEKSFF APEEENEEDF QMKIDDEVRT APWNTTRAFI AAMKGKCLLE VTGVADPTGC GEGFSYVKIP NKPTQQKDDK EPQPVKKTVT GTDADLRRLS LKNAKQLLRK FGVPEEEIKK LSRWEVIDVV RTMSTEQARS GEGPMSKFAR GSRFSVAEHQ ERYKEECQRI FDLQNKVLSS TEVLSTDTDS SSAEDSDFEE MGKNIENMLQ NKKTSSQLSR EREEQERKEL QRMLLAAGSA ASGNNHRDDD TASVTSLNSS ATGRCLKIYR TFRDEEGKEY VRCETVRKPA VIDAYVRIRT TKDEEFIRKF ALFDEQHREE MRKERRRIQE QLRRLKRNQE KEKLKGPPEK KPKKMKERPD LKLKCGACGA IGHMRTNKFC PLYYQTNAPP SNPVAMTEEQ EEELEKTVIH NDNEELIKVE GTKIVLGKQL IESADEVRRK SLVLKFPKQQ LPPKKKRRVG TTVHCDYLNR PHKSIHRRRT DPMVTLSSIL ESIINDMRDL PNTYPFHTPV NAKVVKDYYK IITRPMDLQT LRENVRKRLY PSREEFREHL ELIVKNSATY NGPKHSLTQI SQSMLDLCDE KLKEKEDKLA RLEKAINPLL DDDDQVAFSF ILDNIVTQKM MAVPDSWPFH HPVNKKFVPD YYKVIVNPMD LETIRKNISK HKYQSRESFL DDVNLILANS VKYNGPESQY TKTAQEIVNV CYQTLTEYDE HLTQLEKDIC TAKEAALEEA ELESLDPMTP GPYTPQPPDL YDTNTSLSMS RDASVFQDES NMSVLDIPSA TPEKQVTQEG EDGDGDLADE EEGTVQQPQA SVLYEDLLMS EGEDDEEDAG SDEEGDNPFS AIQLSESGSD SDVGSGGIRP KQPRMLQENT RMDMENEESM MSYEGDGGEA SHGLEDSNIS YGSYEEPDPK SNTQDTSFSS IGGYEVSEEE EDEEEEEQRS GPSVLSQVHL SEDEEDSEDF HSIAGDSDLD SDE // ID TAOK3_HUMAN Reviewed; 898 AA. AC Q9H2K8; Q658N1; Q8IUM4; Q9HC79; Q9NZM9; Q9UHG7; DT 25-OCT-2005, integrated into UniProtKB/Swiss-Prot. DT 25-OCT-2005, sequence version 2. DT 28-JAN-2026, entry version 194. DE RecName: Full=Serine/threonine-protein kinase TAO3; DE EC=2.7.11.1; DE AltName: Full=Cutaneous T-cell lymphoma-associated antigen HD-CL-09; DE Short=CTCL-associated antigen HD-CL-09; DE AltName: Full=Dendritic cell-derived protein kinase; DE AltName: Full=JNK/SAPK-inhibitory kinase; DE AltName: Full=Jun kinase-inhibitory kinase; DE AltName: Full=Kinase from chicken homolog A; DE Short=hKFC-A; DE AltName: Full=Thousand and one amino acid protein 3; GN Name=TAOK3; Synonyms=DPK, JIK, KDS, MAP3K18; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], PHOSPHORYLATION, MUTAGENESIS OF THR-181 AND RP TYR-183, AND FUNCTION. RX PubMed=10559204; DOI=10.1074/jbc.274.47.33287; RA Tassi E., Biesova Z., Di Fiore P.P., Gutkind J.S., Wong W.T.; RT "Human JIK, a novel member of the STE20 kinase family that inhibits JNK and RT is negatively regulated by epidermal growth factor."; RL J. Biol. Chem. 274:33287-33295(1999). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND TISSUE SPECIFICITY. RC TISSUE=Dendritic cell; RX PubMed=10924369; DOI=10.1006/bbrc.2000.3244; RA Zhang W., Chen T., Wan T., He L., Li N., Yuan Z., Cao X.; RT "Cloning of DPK, a novel dendritic cell-derived protein kinase activating RT the ERK1/ERK2 and JNK/SAPK pathways."; RL Biochem. Biophys. Res. Commun. 274:872-879(2000). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], SELF-ASSOCIATION, TISSUE SPECIFICITY, VARIANT RP ASN-47, AND SUBCELLULAR LOCATION. RX PubMed=13679851; DOI=10.1038/sj.onc.1206605; RA Yustein J.T., Xia L., Kahlenburg J.M., Robinson D., Templeton D., RA Kung H.-J.; RT "Comparative studies of a new subfamily of human Ste20-like kinases: RT homodimerization, subcellular localization, and selective activation of RT MKK3 and p38."; RL Oncogene 22:6129-6141(2003). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ASN-47. RA Carter T.G., Benton B., Fruhling D., Monks C.R.F., Windmiller D., RA Kupfer A., Manfredi J., Johnson G.L., Pleiman C.M.; RT "KDS and TAO1, two related proteins with kinase domain homology to STE20, RT differentially relocate in mitogen stimulated T lymphocytes."; RL Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16541075; DOI=10.1038/nature04569; RA Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y., RA Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C., RA Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C., RA Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., RA Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E., RA Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., RA Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., RA Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., RA Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., RA Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., RA Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., RA Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., RA Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., RA Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., RA Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K., RA Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D., RA Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R., RA David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E., RA D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N., RA Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N., RA Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R., RA Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S., RA LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H., RA Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P., RA Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G., RA Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E., RA Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S., RA Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., RA Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J., RA Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A., RA Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M., RA Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I., RA Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A., RA Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y., RA Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A., RA Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F., RA Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L., RA Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G., RA Gibbs R.A.; RT "The finished DNA sequence of human chromosome 12."; RL Nature 440:346-351(2006). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 191-898. RC TISSUE=Stomach; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 304-898. RC TISSUE=T-cell lymphoma; RX PubMed=14996095; DOI=10.1111/j.1365-2133.2004.05651.x; RA Hartmann T.B., Thiel D., Dummer R., Schadendorf D., Eichmueller S.; RT "SEREX identification of new tumour-associated antigens in cutaneous T-cell RT lymphoma."; RL Br. J. Dermatol. 150:252-258(2004). RN [10] RP INTERACTION WITH ERN1 AND TRAF2. RX PubMed=11278723; DOI=10.1074/jbc.m010677200; RA Yoneda T., Imaizumi K., Oono K., Yui D., Gomi F., Katayama T., Tohyama M.; RT "Activation of caspase-12, an endoplastic reticulum (ER) resident caspase, RT through tumor necrosis factor receptor-associated factor 2-dependent RT mechanism in response to the ER stress."; RL J. Biol. Chem. 276:13935-13940(2001). RN [11] RP FUNCTION, PHOSPHORYLATION AT SER-324, INDUCTION, AND MUTAGENESIS OF ASP-165 RP AND SER-324. RX PubMed=17396146; DOI=10.1038/sj.emboj.7601668; RA Raman M., Earnest S., Zhang K., Zhao Y., Cobb M.H.; RT "TAO kinases mediate activation of p38 in response to DNA damage."; RL EMBO J. 26:2005-2014(2007). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-324, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-324 AND SER-442, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-324 AND SER-331, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [15] RP PHOSPHORYLATION BY LRRK2. RX PubMed=20949042; DOI=10.1371/journal.pone.0013191; RA Zach S., Felk S., Gillardon F.; RT "Signal transduction protein array analysis links LRRK2 to Ste20 kinases RT and PKC zeta that modulate neuronal plasticity."; RL PLoS ONE 5:E13191-E13191(2010). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-324, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-324, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [19] RP INTERACTION WITH HERPEX SIMPLEX VIRUS 1 PROTEIN UL37. RX PubMed=22202175; DOI=10.1016/j.bbrc.2011.12.044; RA Kelly B.J., Diefenbach E., Fraefel C., Diefenbach R.J.; RT "Identification of host cell proteins which interact with herpes simplex RT virus type 1 tegument protein pUL37."; RL Biochem. Biophys. Res. Commun. 417:961-965(2012). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-324 AND SER-331, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [22] RP FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-324, AND RP PHOSPHORYLATION AT TYROSINE RESIDUES. RX PubMed=30373850; DOI=10.4049/jimmunol.1800284; RA Ormonde J.V.S., Li Z., Stegen C., Madrenas J.; RT "TAOK3 Regulates Canonical TCR Signaling by Preventing Early SHP-1-Mediated RT Inactivation of LCK."; RL J. Immunol. 201:3431-3442(2018). RN [23] RP FUNCTION. RX PubMed=32807497; DOI=10.1016/j.bbrc.2020.07.060; RA Li Z., Oh H., Cung M., Marquez S.J., Sun J., Hammad H., Janssens S., RA Pouliot P., Lambrecht B.N., Yang Y.S., Shim J.H., Greenblatt M.B.; RT "TAOK3 is a MAP3K contributing to osteoblast differentiation and skeletal RT mineralization."; RL Biochem. Biophys. Res. Commun. 531:497-502(2020). RN [24] RP FUNCTION, INTERACTION WITH STK25, AND SUBCELLULAR LOCATION. RX PubMed=34634521; DOI=10.1016/j.molmet.2021.101353; RA Xia Y., Caputo M., Cansby E., Anand S.K., Suett S., Henricsson M., RA Porosk R., Marschall H.U., Blueher M., Mahlapuu M.; RT "STE20-type kinase TAOK3 regulates hepatic lipid partitioning."; RL Mol. Metab. 54:101353-101353(2021). RN [25] RP FUNCTION, AND MUTAGENESIS OF THR-181; TYR-183; TYR-256; TYR-305 AND RP SER-324. RX PubMed=38166031; DOI=10.1126/scisignal.adg4422; RA Poirier A., Ormonde J.V.S., Aubry I., Abidin B.M., Feng C.H., RA Martinez-Cordova Z., Hincapie A.M., Wu C., Perez-Quintero L.A., Wang C.L., RA Gingras A.C., Madrenas J., Tremblay M.L.; RT "The induction of SHP-1 degradation by TAOK3 ensures the responsiveness of RT T cells to TCR stimulation."; RL Sci. Signal. 17:eadg4422-eadg4422(2024). RN [26] RP VARIANTS [LARGE SCALE ANALYSIS] THR-20; ASN-47; TYR-392 AND TYR-727. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase that acts as a regulator of CC the p38/MAPK14 stress-activated MAPK cascade and of the MAPK8/JNK CC cascade. In response to DNA damage, involved in the G2/M transition DNA CC damage checkpoint by activating the p38/MAPK14 stress-activated MAPK CC cascade, probably by mediating phosphorylation of upstream MAP2K3 and CC MAP2K6 kinases. Inhibits basal activity of the MAPK8/JNK cascade and CC diminishes its activation in response to epidermal growth factor (EGF). CC Positively regulates canonical T cell receptor (TCR) signaling by CC preventing early PTPN6/SHP1-mediated inactivation of LCK, ensuring CC sustained TCR signaling that is required for optimal activation and CC differentiation of T cells (PubMed:30373850). Phosphorylates PTPN6/SHP1 CC on 'Thr-394', leading to its polyubiquitination and subsequent CC proteasomal degradation (PubMed:38166031). Required for cell surface CC expression of metalloprotease ADAM10 on type 1 transitional B cells CC which is necessary for their NOTCH-mediated development into marginal CC zone B cells (By similarity). Also required for the NOTCH-mediated CC terminal differentiation of splenic conventional type 2 dendritic cells CC (By similarity). Positively regulates osteoblast differentiation by CC acting as an upstream activator of the JNK pathway (PubMed:32807497). CC Promotes JNK signaling in hepatocytes and positively regulates CC hepatocyte lipid storage by inhibiting beta-oxidation and CC triacylglycerol secretion while enhancing lipid synthesis CC (PubMed:34634521). Restricts age-associated inflammation by negatively CC regulating differentiation of macrophages and their production of pro- CC inflammatory cytokines (By similarity). Plays a role in negatively CC regulating the abundance of regulatory T cells in white adipose tissue CC (By similarity). {ECO:0000250|UniProtKB:Q8BYC6, CC ECO:0000269|PubMed:10559204, ECO:0000269|PubMed:10924369, CC ECO:0000269|PubMed:17396146, ECO:0000269|PubMed:30373850, CC ECO:0000269|PubMed:32807497, ECO:0000269|PubMed:34634521, CC ECO:0000269|PubMed:38166031}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- SUBUNIT: Self-associates (PubMed:13679851). Interacts with ERN1 and CC TRAF2 (PubMed:11278723). Interaction with TRAF2 is facilitated under ER CC stress conditions, such as treatment with tunicamycin, and may promote CC TRAF2 phosphorylation (PubMed:11278723). Interacts (via N-terminus) CC with STK25; the interaction promotes STK25 abundance at the level of CC protein expression and/or stability (PubMed:34634521). CC {ECO:0000269|PubMed:11278723, ECO:0000269|PubMed:13679851, CC ECO:0000269|PubMed:34634521}. CC -!- SUBUNIT: (Microbial infection) Interacts with herpes simplex virus 1 CC UL37 protein. {ECO:0000269|PubMed:22202175}. CC -!- INTERACTION: CC Q9H2K8; O75460: ERN1; NbExp=3; IntAct=EBI-1384100, EBI-371750; CC Q9H2K8; P42858: HTT; NbExp=3; IntAct=EBI-1384100, EBI-466029; CC Q9H2K8; Q12933: TRAF2; NbExp=2; IntAct=EBI-1384100, EBI-355744; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:13679851}. Cell CC membrane {ECO:0000269|PubMed:13679851}; Peripheral membrane protein CC {ECO:0000269|PubMed:13679851}. Membrane raft CC {ECO:0000269|PubMed:30373850}. Lipid droplet CC {ECO:0000269|PubMed:34634521}. Note=Located primarily outside cell CC membrane rafts and remains outside upon canonical TCR ligation CC (PubMed:30373850). A small pool is detectable in cell membrane rafts in CC resting conditions but relocates outside the rafts upon TCR signaling CC (PubMed:30373850). Localizes to lipid droplets in hepatocytes CC (PubMed:34634521). {ECO:0000269|PubMed:30373850, CC ECO:0000269|PubMed:34634521}. CC -!- TISSUE SPECIFICITY: Ubiquitously expressed at a low level, and highly CC expressed in peripheral blood leukocytes (PBLs), thymus, spleen, CC kidney, skeletal muscle, heart and liver. {ECO:0000269|PubMed:10924369, CC ECO:0000269|PubMed:13679851}. CC -!- PTM: Autophosphorylated (PubMed:10559204). Phosphorylation at Ser-324 CC by ATM following DNA damage is required for activation of the CC p38/MAPK14 stress-activated MAPK cascade (PubMed:17396146). CC Phosphorylated at Ser-324 and on Tyr residues during T cell activation CC (PubMed:30373850). Phosphorylated by LRRK2 (PubMed:20949042). CC {ECO:0000269|PubMed:10559204, ECO:0000269|PubMed:17396146, CC ECO:0000269|PubMed:20949042, ECO:0000269|PubMed:30373850}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr CC protein kinase family. STE20 subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAN09723.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF179867; AAF14559.1; -; mRNA. DR EMBL; AF135158; AAG09131.1; -; mRNA. DR EMBL; AF263311; AAG38501.1; -; mRNA. DR EMBL; AF181985; AAF25817.1; -; mRNA. DR EMBL; BT007185; AAP35849.1; -; mRNA. DR EMBL; AC026366; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC002756; AAH02756.1; -; mRNA. DR EMBL; AL833731; CAH56239.1; -; mRNA. DR EMBL; AF328731; AAN09723.1; ALT_INIT; mRNA. DR CCDS; CCDS9188.1; -. DR RefSeq; NP_001333417.1; NM_001346488.2. DR RefSeq; NP_001333418.1; NM_001346489.2. DR RefSeq; NP_057365.3; NM_016281.3. DR PDB; 6BDN; X-ray; 1.50 A; A=1-316. DR PDBsum; 6BDN; -. DR AlphaFoldDB; Q9H2K8; -. DR SMR; Q9H2K8; -. DR BioGRID; 119490; 51. DR FunCoup; Q9H2K8; 2466. DR IntAct; Q9H2K8; 25. DR STRING; 9606.ENSP00000376317; -. DR BindingDB; Q9H2K8; -. DR ChEMBL; CHEMBL5701; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q9H2K8; -. DR GuidetoPHARMACOLOGY; 2235; -. DR iPTMnet; Q9H2K8; -. DR MetOSite; Q9H2K8; -. DR PhosphoSitePlus; Q9H2K8; -. DR BioMuta; TAOK3; -. DR DMDM; 78099183; -. DR CPTAC; CPTAC-2949; -. DR CPTAC; CPTAC-2950; -. DR jPOST; Q9H2K8; -. DR MassIVE; Q9H2K8; -. DR PaxDb; 9606-ENSP00000376317; -. DR PeptideAtlas; Q9H2K8; -. DR ProteomicsDB; 80560; -. DR Pumba; Q9H2K8; -. DR Antibodypedia; 2111; 390 antibodies from 36 providers. DR DNASU; 51347; -. DR Ensembl; ENST00000392533.8; ENSP00000376317.3; ENSG00000135090.15. DR Ensembl; ENST00000419821.6; ENSP00000416374.2; ENSG00000135090.15. DR GeneID; 51347; -. DR KEGG; hsa:51347; -. DR MANE-Select; ENST00000392533.8; ENSP00000376317.3; NM_016281.4; NP_057365.3. DR UCSC; uc001twx.4; human. DR AGR; HGNC:18133; -. DR ClinPGx; PA134975064; -. DR CTD; 51347; -. DR DisGeNET; 51347; -. DR GeneCards; TAOK3; -. DR HGNC; HGNC:18133; TAOK3. DR HPA; ENSG00000135090; Low tissue specificity. DR MIM; 616711; gene. DR OpenTargets; ENSG00000135090; -. DR VEuPathDB; HostDB:ENSG00000135090; -. DR eggNOG; KOG0577; Eukaryota. DR GeneTree; ENSGT00940000155735; -. DR HOGENOM; CLU_000288_2_2_1; -. DR InParanoid; Q9H2K8; -. DR OMA; KEKIKEX; -. DR OrthoDB; 10016527at2759; -. DR PAN-GO; Q9H2K8; 6 GO annotations based on evolutionary models. DR PhylomeDB; Q9H2K8; -. DR PathwayCommons; Q9H2K8; -. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR Reactome; R-HSA-9013404; RAC2 GTPase cycle. DR Reactome; R-HSA-9013423; RAC3 GTPase cycle. DR SignaLink; Q9H2K8; -. DR SIGNOR; Q9H2K8; -. DR Agora; ENSG00000135090; -. DR BioGRID-ORCS; 51347; 12 hits in 1191 CRISPR screens. DR ChiTaRS; TAOK3; human. DR GeneWiki; TAOK3; -. DR GenomeRNAi; 51347; -. DR Pharos; Q9H2K8; Tchem. DR PRO; PR:Q9H2K8; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; Q9H2K8; protein. DR Bgee; ENSG00000135090; Expressed in secondary oocyte and 214 other cell types or tissues. DR ExpressionAtlas; Q9H2K8; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005811; C:lipid droplet; IEA:UniProtKB-SubCell. DR GO; GO:0045121; C:membrane raft; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004860; F:protein kinase inhibitor activity; TAS:ProtInc. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:HGNC-UCL. DR GO; GO:0016740; F:transferase activity; IDA:HGNC-UCL. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0006281; P:DNA repair; IEA:UniProtKB-KW. DR GO; GO:0000165; P:MAPK cascade; IMP:HGNC-UCL. DR GO; GO:0007095; P:mitotic G2 DNA damage checkpoint signaling; IMP:UniProtKB. DR GO; GO:0046329; P:negative regulation of JNK cascade; IDA:HGNC-UCL. DR GO; GO:0048812; P:neuron projection morphogenesis; IBA:GO_Central. DR GO; GO:0046330; P:positive regulation of JNK cascade; IMP:HGNC-UCL. DR GO; GO:0043507; P:positive regulation of JUN kinase activity; IMP:UniProtKB. DR GO; GO:0032874; P:positive regulation of stress-activated MAPK cascade; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IMP:UniProtKB. DR GO; GO:0043408; P:regulation of MAPK cascade; IBA:GO_Central. DR CDD; cd06633; STKc_TAO3; 1. DR FunFam; 1.10.510.10:FF:000030; Serine/threonine-protein kinase TAO2, putative; 1. DR FunFam; 3.30.200.20:FF:000029; Serine/threonine-protein kinase TAO2, putative; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051234; TAO_STE20_kinase. DR PANTHER; PTHR47167; SERINE/THREONINE-PROTEIN KINASE TAO1-LIKE PROTEIN; 1. DR PANTHER; PTHR47167:SF10; SERINE_THREONINE-PROTEIN KINASE TAO3; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; ATP-binding; Cell membrane; Coiled coil; KW Cytoplasm; DNA damage; DNA repair; Kinase; Lipid droplet; Membrane; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase. FT CHAIN 1..898 FT /note="Serine/threonine-protein kinase TAO3" FT /id="PRO_0000086737" FT DOMAIN 24..277 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 316..362 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 405..425 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 565..596 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 452..502 FT /evidence="ECO:0000255" FT COILED 548..649 FT /evidence="ECO:0000255" FT COILED 754..879 FT /evidence="ECO:0000255" FT COMPBIAS 334..351 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 352..362 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 405..416 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 147 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 30..38 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 53 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 324 FT /note="Phosphoserine; by ATM" FT /evidence="ECO:0000269|PubMed:17396146, FT ECO:0000269|PubMed:30373850, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 331 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 343 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q53UA7" FT MOD_RES 346 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BYC6" FT MOD_RES 349 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BYC6" FT MOD_RES 357 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q8BYC6" FT MOD_RES 359 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BYC6" FT MOD_RES 442 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 830 FT /note="N6-acetyllysine" FT /evidence="ECO:0000250|UniProtKB:Q8BYC6" FT VARIANT 20 FT /note="P -> T (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041205" FT VARIANT 47 FT /note="S -> N (in dbSNP:rs428073)" FT /evidence="ECO:0000269|PubMed:13679851, FT ECO:0000269|PubMed:17344846, ECO:0000269|Ref.4" FT /id="VAR_023691" FT VARIANT 392 FT /note="S -> Y (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041206" FT VARIANT 727 FT /note="C -> Y (in dbSNP:rs55857273)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041207" FT MUTAGEN 165 FT /note="D->A: Loss of serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:17396146" FT MUTAGEN 181 FT /note="T->A: No autophosphorylation, no kinase activity and FT reduced IL2 production by T cells; when associated with F- FT 183." FT /evidence="ECO:0000269|PubMed:10559204, FT ECO:0000269|PubMed:38166031" FT MUTAGEN 183 FT /note="Y->F: No autophosphorylation, no kinase activity and FT reduced IL2 production by T cells; when associated with A- FT 181." FT /evidence="ECO:0000269|PubMed:10559204, FT ECO:0000269|PubMed:38166031" FT MUTAGEN 256 FT /note="Y->F: Enhances IL2 production by T cells and FT increases JNK phosphorylation." FT /evidence="ECO:0000269|PubMed:38166031" FT MUTAGEN 305 FT /note="Y->F: Enhances IL2 production by T cells and FT increases JNK phosphorylation." FT /evidence="ECO:0000269|PubMed:38166031" FT MUTAGEN 324 FT /note="S->A: Inhibits activation of the p38/MAPK14 stress- FT activated MAPK cascade in response to DNA damage. Enhances FT IL2 production by T cells." FT /evidence="ECO:0000269|PubMed:17396146, FT ECO:0000269|PubMed:38166031" FT CONFLICT 136 FT /note="A -> T (in Ref. 3; AAG38501)" FT /evidence="ECO:0000305" FT CONFLICT 173 FT /note="S -> P (in Ref. 3; AAG38501)" FT /evidence="ECO:0000305" FT CONFLICT 356..378 FT /note="STGSQSSSVNSMQEVMDESSSEL -> TWNQPEQGNGQPGQQPFHSKHVR FT (in Ref. 1; AAF14559)" FT /evidence="ECO:0000305" FT CONFLICT 668 FT /note="Q -> R (in Ref. 3; AAG38501)" FT /evidence="ECO:0000305" FT HELIX 9..12 FT /evidence="ECO:0007829|PDB:6BDN" FT HELIX 20..23 FT /evidence="ECO:0007829|PDB:6BDN" FT STRAND 24..33 FT /evidence="ECO:0007829|PDB:6BDN" FT STRAND 36..43 FT /evidence="ECO:0007829|PDB:6BDN" FT TURN 44..46 FT /evidence="ECO:0007829|PDB:6BDN" FT STRAND 49..56 FT /evidence="ECO:0007829|PDB:6BDN" FT HELIX 59..61 FT /evidence="ECO:0007829|PDB:6BDN" FT HELIX 62..77 FT /evidence="ECO:0007829|PDB:6BDN" FT STRAND 87..93 FT /evidence="ECO:0007829|PDB:6BDN" FT STRAND 96..102 FT /evidence="ECO:0007829|PDB:6BDN" FT STRAND 105..107 FT /evidence="ECO:0007829|PDB:6BDN" FT HELIX 108..115 FT /evidence="ECO:0007829|PDB:6BDN" FT HELIX 121..140 FT /evidence="ECO:0007829|PDB:6BDN" FT HELIX 150..152 FT /evidence="ECO:0007829|PDB:6BDN" FT STRAND 153..155 FT /evidence="ECO:0007829|PDB:6BDN" FT STRAND 161..163 FT /evidence="ECO:0007829|PDB:6BDN" FT STRAND 170..175 FT /evidence="ECO:0007829|PDB:6BDN" FT HELIX 182..184 FT /evidence="ECO:0007829|PDB:6BDN" FT HELIX 187..192 FT /evidence="ECO:0007829|PDB:6BDN" FT TURN 193..195 FT /evidence="ECO:0007829|PDB:6BDN" FT HELIX 201..216 FT /evidence="ECO:0007829|PDB:6BDN" FT TURN 220..223 FT /evidence="ECO:0007829|PDB:6BDN" FT HELIX 226..235 FT /evidence="ECO:0007829|PDB:6BDN" FT HELIX 248..257 FT /evidence="ECO:0007829|PDB:6BDN" FT HELIX 262..264 FT /evidence="ECO:0007829|PDB:6BDN" FT HELIX 268..271 FT /evidence="ECO:0007829|PDB:6BDN" FT HELIX 275..278 FT /evidence="ECO:0007829|PDB:6BDN" FT HELIX 285..298 FT /evidence="ECO:0007829|PDB:6BDN" FT HELIX 302..308 FT /evidence="ECO:0007829|PDB:6BDN" FT HELIX 309..312 FT /evidence="ECO:0007829|PDB:6BDN" SQ SEQUENCE 898 AA; 105406 MW; AE7E30745B09763C CRC64; MRKGVLKDPE IADLFYKDDP EELFIGLHEI GHGSFGAVYF ATNAHTSEVV AIKKMSYSGK QTHEKWQDIL KEVKFLRQLK HPNTIEYKGC YLKEHTAWLV MEYCLGSASD LLEVHKKPLQ EVEIAAITHG ALHGLAYLHS HALIHRDIKA GNILLTEPGQ VKLADFGSAS MASPANSFVG TPYWMAPEVI LAMDEGQYDG KVDIWSLGIT CIELAERKPP LFNMNAMSAL YHIAQNDSPT LQSNEWTDSF RRFVDYCLQK IPQERPTSAE LLRHDFVRRD RPLRVLIDLI QRTKDAVREL DNLQYRKMKK ILFQETRNGP LNESQEDEED SEHGTSLNRE MDSLGSNHSI PSMSVSTGSQ SSSVNSMQEV MDESSSELVM MHDDESTINS SSSVVHKKDH VFIRDEAGHG DPRPEPRPTQ SVQSQALHYR NRERFATIKS ASLVTRQIHE HEQENELREQ MSGYKRMRRQ HQKQLIALEN KLKAEMDEHR LKLQKEVETH ANNSSIELEK LAKKQVAIIE KEAKVAAADE KKFQQQILAQ QKKDLTTFLE SQKKQYKICK EKIKEEMNED HSTPKKEKQE RISKHKENLQ HTQAEEEAHL LTQQRLYYDK NCRFFKRKIM IKRHEVEQQN IREELNKKRT QKEMEHAMLI RHDESTRELE YRQLHTLQKL RMDLIRLQHQ TELENQLEYN KRRERELHRK HVMELRQQPK NLKAMEMQIK KQFQDTCKVQ TKQYKALKNH QLEVTPKNEH KTILKTLKDE QTRKLAILAE QYEQSINEMM ASQALRLDEA QEAECQALRL QLQQEMELLN AYQSKIKMQT EAQHERELQK LEQRVSLRRA HLEQKIEEEL AALQKERSER IKNLLERQER EIETFDMESL RMGFGNLVTL DFPKEDYR // ID TEC_HUMAN Reviewed; 631 AA. AC P42680; B7ZKZ6; Q3MIS5; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 11-SEP-2007, sequence version 2. DT 28-JAN-2026, entry version 221. DE RecName: Full=Tyrosine-protein kinase Tec; DE EC=2.7.10.2; GN Name=TEC; Synonyms=PSCTK4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Blood; RX PubMed=7934162; RA Sato K., Mano H., Ariyama T., Inazawa J., Yazaki Y., Hirai H.; RT "Molecular cloning and analysis of the human Tec protein-tyrosine kinase."; RL Leukemia 8:1663-1672(1994). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Liver; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP PROTEIN SEQUENCE OF 203-206, AND PHOSPHORYLATION AT TYR-206. RX PubMed=12573241; DOI=10.1016/s1570-9639(02)00524-1; RA Nore B.F., Mattsson P.T., Antonsson P., Backesjo C.-M., Westlund A., RA Lennartsson J., Hansson H., Low P., Ronnstrand L., Smith C.I.E.; RT "Identification of phosphorylation sites within the SH3 domains of Tec RT family tyrosine kinases."; RL Biochim. Biophys. Acta 1645:123-132(2003). RN [5] RP PHOSPHORYLATION, INTERACTION WITH KIT, AND ACTIVITY REGULATION. RX PubMed=7526158; DOI=10.1128/mcb.14.12.8432-8437.1994; RA Tang B., Mano H., Yi T., Ihle J.N.; RT "Tec kinase associates with c-kit and is tyrosine phosphorylated and RT activated following stem cell factor binding."; RL Mol. Cell. Biol. 14:8432-8437(1994). RN [6] RP PHOSPHORYLATION, AND SUBCELLULAR LOCATION. RX PubMed=9299487; DOI=10.1006/bbrc.1997.7269; RA Laffargue M., Monnereau L., Tuech J., Ragab A., Ragab-Thomas J., RA Payrastre B., Raynal P., Chap H.; RT "Integrin-dependent tyrosine phosphorylation and cytoskeletal translocation RT of Tec in thrombin-activated platelets."; RL Biochem. Biophys. Res. Commun. 238:247-251(1997). RN [7] RP ACTIVITY REGULATION. RX PubMed=9341160; DOI=10.1074/jbc.272.43.27178; RA Ohya K., Kajigaya S., Yamashita Y., Miyazato A., Hatake K., Miura Y., RA Ikeda U., Shimada K., Ozawa K., Mano H.; RT "SOCS-1/JAB/SSI-1 can bind to and suppress Tec protein-tyrosine kinase."; RL J. Biol. Chem. 272:27178-27182(1997). RN [8] RP INTERACTION WITH GRB10, AND FUNCTION IN PHOSPHORYLATION OF GRB10. RX PubMed=9753425; DOI=10.1046/j.1365-2443.1998.00201.x; RA Mano H., Ohya K., Miyazato A., Yamashita Y., Ogawa W., Inazawa J., RA Ikeda U., Shimada K., Hatake K., Kasuga M., Ozawa K., Kajigaya S.; RT "Grb10/GrbIR as an in vivo substrate of Tec tyrosine kinase."; RL Genes Cells 3:431-441(1998). RN [9] RP PHOSPHORYLATION, ACTIVITY REGULATION, AND SUBCELLULAR LOCATION. RX PubMed=9652744; DOI=10.1038/sj.onc.1201799; RA Hamazaki Y., Kojima H., Mano H., Nagata Y., Todokoro K., Abe T., RA Nagasawa T.; RT "Tec is involved in G protein-coupled receptor- and integrin-mediated RT signalings in human blood platelets."; RL Oncogene 16:2773-2779(1998). RN [10] RP FUNCTION IN PHOSPHORYLATION OF STAP1, AND ACTIVITY REGULATION. RX PubMed=10518561; DOI=10.1073/pnas.96.21.11976; RA Ohya K., Kajigaya S., Kitanaka A., Yoshida K., Miyazato A., Yamashita Y., RA Yamanaka T., Ikeda U., Shimada K., Ozawa K., Mano H.; RT "Molecular cloning of a docking protein, BRDG1, that acts downstream of the RT Tec tyrosine kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 96:11976-11981(1999). RN [11] RP INTERACTION WITH INPP5D AND INPPL1. RX PubMed=15492005; DOI=10.1074/jbc.m408141200; RA Tomlinson M.G., Heath V.L., Turck C.W., Watson S.P., Weiss A.; RT "SHIP family inositol phosphatases interact with and negatively regulate RT the Tec tyrosine kinase."; RL J. Biol. Chem. 279:55089-55096(2004). RN [12] RP INTERACTION WITH FASLG. RX PubMed=19807924; DOI=10.1186/1471-2172-10-53; RA Voss M., Lettau M., Janssen O.; RT "Identification of SH3 domain interaction partners of human FasL (CD178) by RT phage display screening."; RL BMC Immunol. 10:53-53(2009). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-206 AND TYR-228, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-519, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [15] RP FUNCTION. RX PubMed=19883687; DOI=10.1016/j.imlet.2009.10.009; RA Susaki K., Kitanaka A., Dobashi H., Kubota Y., Kittaka K., Kameda T., RA Yamaoka G., Mano H., Mihara K., Ishida T.; RT "Tec protein tyrosine kinase inhibits CD25 expression in human T- RT lymphocyte."; RL Immunol. Lett. 127:135-142(2010). RN [16] RP FUNCTION IN PHOSPHORYLATION OF FGF2, AND INTERACTION WITH FGF2. RX PubMed=20230531; DOI=10.1111/j.1600-0854.2010.01059.x; RA Ebert A.D., Laussmann M., Wegehingel S., Kaderali L., Erfle H., RA Reichert J., Lechner J., Beer H.D., Pepperkok R., Nickel W.; RT "Tec-kinase-mediated phosphorylation of fibroblast growth factor 2 is RT essential for unconventional secretion."; RL Traffic 11:813-826(2010). RN [17] RP VARIANTS [LARGE SCALE ANALYSIS] GLN-44 AND LYS-563. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Non-receptor tyrosine kinase that contributes to signaling CC from many receptors and participates as a signal transducer in multiple CC downstream pathways, including regulation of the actin cytoskeleton. CC Plays a redundant role to ITK in regulation of the adaptive immune CC response. Regulates the development, function and differentiation of CC conventional T-cells and nonconventional NKT-cells. Required for TCR- CC dependent IL2 gene induction. Phosphorylates DOK1, one CD28-specific CC substrate, and contributes to CD28-signaling. Mediates signals that CC negatively regulate IL2RA expression induced by TCR cross-linking. CC Plays a redundant role to BTK in BCR-signaling for B-cell development CC and activation, especially by phosphorylating STAP1, a BCR-signaling CC protein. Required in mast cells for efficient cytokine production. CC Involved in both growth and differentiation mechanisms of myeloid cells CC through activation by the granulocyte colony-stimulating factor CSF3, a CC critical cytokine to promoting the growth, differentiation, and CC functional activation of myeloid cells. Participates in platelet CC signaling downstream of integrin activation. Cooperates with JAK2 CC through reciprocal phosphorylation to mediate cytokine-driven CC activation of FOS transcription. GRB10, a negative modifier of the FOS CC activation pathway, is another substrate of TEC. TEC is involved in G CC protein-coupled receptor- and integrin-mediated signalings in blood CC platelets. Plays a role in hepatocyte proliferation and liver CC regeneration and is involved in HGF-induced ERK signaling pathway. TEC CC also regulates FGF2 unconventional secretion (endoplasmic reticulum CC (ER)/Golgi-independent mechanism) under various physiological CC conditions through phosphorylation of FGF2 'Tyr-215'. May also be CC involved in the regulation of osteoclast differentiation. CC {ECO:0000269|PubMed:10518561, ECO:0000269|PubMed:19883687, CC ECO:0000269|PubMed:20230531, ECO:0000269|PubMed:9753425}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250}; CC Note=Binds 1 zinc ion per subunit. {ECO:0000250}; CC -!- ACTIVITY REGULATION: Activated by tyrosine phosphorylation by a wide CC range of cytokine stimulations. When T-cells or B-cells receptors are CC activated, a series of phosphorylation leads to the recruitment of TEC CC to the cell membrane, where it is phosphorylated at Tyr-519. Also CC activated in response to SCF. Integrin engagement induces tyrosine CC phosphorylation of TEC in platelets. STAP1 participates in a positive CC feedback loop by increasing the activity of TEC. SOCS1 is an inhibitor CC of TEC kinase activity. {ECO:0000269|PubMed:10518561, CC ECO:0000269|PubMed:7526158, ECO:0000269|PubMed:9341160, CC ECO:0000269|PubMed:9652744}. CC -!- SUBUNIT: Part of a complex composed of EEIG1, TNFRSF11A/RANK, PLCG2, CC GAB2, TEC and BTK; complex formation increases in the presence of CC TNFSF11/RANKL (By similarity). Interacts with INPP5D/SHIP1 and CC INPPL1/SHIP2. Interacts with CD28, FASLG, FGF2, GRB10, LYN and KIT. CC Interacts with VAV1 and JAK2 (By similarity). {ECO:0000250, CC ECO:0000250|UniProtKB:P24604}. CC -!- INTERACTION: CC P42680; P78325: ADAM8; NbExp=2; IntAct=EBI-1383480, EBI-2625954; CC P42680; Q13480: GAB1; NbExp=2; IntAct=EBI-1383480, EBI-517684; CC P42680; P08581: MET; NbExp=2; IntAct=EBI-1383480, EBI-1039152; CC -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane; Peripheral membrane CC protein. Cytoplasm, cytoskeleton. Note=Following B-cell or T-cell CC receptors activation by antigen, translocates to the plasma membrane CC through its PH domain. Thrombin and integrin engagement induces CC translocation of TEC to the cytoskeleton during platelet activation. In CC cardiac myocytes, assumes a diffuse intracellular localization under CC basal conditions but is recruited to striated structures upon various CC stimuli, including ATP (By similarity). {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Expressed in a wide range of cells, including CC hematopoietic cell lines like myeloid, B-, and T-cell lineages. CC -!- DOMAIN: The PH domain mediates the binding to inositol polyphosphate CC and phosphoinositides, leading to its targeting to the plasma membrane. CC It is extended in the BTK kinase family by a region designated the TH CC (Tec homology) domain, which consists of about 80 residues preceding CC the SH3 domain. CC -!- DOMAIN: The SH3 domain is essential for its targeting to activated CD28 CC costimulatory molecule. {ECO:0000250}. CC -!- PTM: Following B-cell or T-cell receptors engagement, translocates to CC the plasma membrane where it gets phosphorylated at Tyr-519. Undergoes CC also tyrosine phosphorylation during platelet activation. CC {ECO:0000269|PubMed:12573241, ECO:0000269|PubMed:7526158, CC ECO:0000269|PubMed:9299487, ECO:0000269|PubMed:9652744}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. TEC subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- CAUTION: It is uncertain whether Met-1 is the initiator. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D29767; BAA06171.1; -; mRNA. DR EMBL; CH471069; EAW93055.1; -; Genomic_DNA. DR EMBL; BC101711; AAI01712.1; -; mRNA. DR EMBL; BC101713; AAI01714.1; -; mRNA. DR EMBL; BC143487; AAI43488.1; -; mRNA. DR CCDS; CCDS3481.1; -. DR PIR; I38268; I38268. DR PIR; I56997; I56997. DR RefSeq; NP_003206.2; NM_003215.3. DR PDB; 2LUL; NMR; -; A=1-154. DR PDBsum; 2LUL; -. DR AlphaFoldDB; P42680; -. DR BMRB; P42680; -. DR SMR; P42680; -. DR BioGRID; 112865; 61. DR FunCoup; P42680; 655. DR IntAct; P42680; 47. DR MINT; P42680; -. DR STRING; 9606.ENSP00000370912; -. DR BindingDB; P42680; -. DR ChEMBL; CHEMBL4246; -. DR DrugBank; DB06616; Bosutinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB14924; Ritlecitinib. DR DrugBank; DB15035; Zanubrutinib. DR DrugCentral; P42680; -. DR GuidetoPHARMACOLOGY; 2238; -. DR iPTMnet; P42680; -. DR PhosphoSitePlus; P42680; -. DR BioMuta; TEC; -. DR DMDM; 158518392; -. DR CPTAC; CPTAC-3135; -. DR CPTAC; CPTAC-3136; -. DR CPTAC; CPTAC-3137; -. DR jPOST; P42680; -. DR MassIVE; P42680; -. DR PaxDb; 9606-ENSP00000370912; -. DR PeptideAtlas; P42680; -. DR ProteomicsDB; 55526; -. DR Pumba; P42680; -. DR ABCD; P42680; 3 sequenced antibodies. DR Antibodypedia; 715; 347 antibodies from 34 providers. DR DNASU; 7006; -. DR Ensembl; ENST00000381501.8; ENSP00000370912.3; ENSG00000135605.14. DR GeneID; 7006; -. DR KEGG; hsa:7006; -. DR MANE-Select; ENST00000381501.8; ENSP00000370912.3; NM_003215.3; NP_003206.2. DR UCSC; uc003gxz.4; human. DR AGR; HGNC:11719; -. DR ClinPGx; PA36436; -. DR CTD; 7006; -. DR DisGeNET; 7006; -. DR GeneCards; TEC; -. DR HGNC; HGNC:11719; TEC. DR HPA; ENSG00000135605; Low tissue specificity. DR MalaCards; TEC; -. DR MIM; 600583; gene. DR OpenTargets; ENSG00000135605; -. DR VEuPathDB; HostDB:ENSG00000135605; -. DR eggNOG; KOG0197; Eukaryota. DR GeneTree; ENSGT00940000155951; -. DR HOGENOM; CLU_000288_7_2_1; -. DR InParanoid; P42680; -. DR OMA; NVTGHAH; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P42680; 7 GO annotations based on evolutionary models. DR PhylomeDB; P42680; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; P42680; -. DR Reactome; R-HSA-1433557; Signaling by SCF-KIT. DR Reactome; R-HSA-2871809; FCERI mediated Ca+2 mobilization. DR Reactome; R-HSA-512988; Interleukin-3, Interleukin-5 and GM-CSF signaling. DR SignaLink; P42680; -. DR SIGNOR; P42680; -. DR Agora; ENSG00000135605; -. DR BioGRID-ORCS; 7006; 19 hits in 1180 CRISPR screens. DR ChiTaRS; TEC; human. DR EvolutionaryTrace; P42680; -. DR GeneWiki; TEC_(gene); -. DR GenomeRNAi; 7006; -. DR Pharos; P42680; Tchem. DR PRO; PR:P42680; -. DR Proteomes; UP000005640; Chromosome 4. DR RNAct; P42680; protein. DR Bgee; ENSG00000135605; Expressed in primordial germ cell in gonad and 97 other cell types or tissues. DR ExpressionAtlas; P42680; baseline and differential. DR GO; GO:0005856; C:cytoskeleton; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0005543; F:phospholipid binding; NAS:BHF-UCL. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0002250; P:adaptive immune response; IBA:GO_Central. DR GO; GO:0050853; P:B cell receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0007229; P:integrin-mediated signaling pathway; IDA:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; TAS:ProtInc. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0010543; P:regulation of platelet activation; IDA:UniProtKB. DR GO; GO:0050852; P:T cell receptor signaling pathway; IBA:GO_Central. DR GO; GO:0042246; P:tissue regeneration; IEA:Ensembl. DR CDD; cd01238; PH_Btk; 1. DR CDD; cd05114; PTKc_Tec_Rlk; 1. DR CDD; cd10396; SH2_Tec_Itk; 1. DR CDD; cd11905; SH3_Tec; 1. DR FunFam; 1.10.510.10:FF:000052; Tyrosine-protein kinase; 1. DR FunFam; 2.30.29.30:FF:000210; Tyrosine-protein kinase; 1. DR FunFam; 2.30.30.40:FF:000151; Tyrosine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000053; Tyrosine-protein kinase; 1. DR FunFam; 3.30.505.10:FF:000041; Tyrosine-protein kinase; 1. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR Gene3D; 3.30.505.10; SH2 domain; 1. DR Gene3D; 2.30.30.40; SH3 Domains; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR050198; Non-receptor_tyrosine_kinases. DR InterPro; IPR011993; PH-like_dom_sf. DR InterPro; IPR001849; PH_domain. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR000980; SH2. DR InterPro; IPR036860; SH2_dom_sf. DR InterPro; IPR036028; SH3-like_dom_sf. DR InterPro; IPR001452; SH3_domain. DR InterPro; IPR035572; Tec_SH3. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR001562; Znf_Btk_motif. DR PANTHER; PTHR24418; TYROSINE-PROTEIN KINASE; 1. DR Pfam; PF00779; BTK; 1. DR Pfam; PF00169; PH; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00017; SH2; 1. DR Pfam; PF00018; SH3_1; 1. DR PRINTS; PR00401; SH2DOMAIN. DR PRINTS; PR00452; SH3DOMAIN. DR PRINTS; PR00402; TECBTKDOMAIN. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00107; BTK; 1. DR SMART; SM00233; PH; 1. DR SMART; SM00252; SH2; 1. DR SMART; SM00326; SH3; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF50729; PH domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF55550; SH2 domain; 1. DR SUPFAM; SSF50044; SH3-domain; 1. DR PROSITE; PS50003; PH_DOMAIN; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS50001; SH2; 1. DR PROSITE; PS50002; SH3; 1. DR PROSITE; PS51113; ZF_BTK; 1. PE 1: Evidence at protein level; KW 3D-structure; Adaptive immunity; ATP-binding; Cell membrane; Cytoplasm; KW Cytoskeleton; Direct protein sequencing; Immunity; Kinase; Lipid-binding; KW Membrane; Metal-binding; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; SH2 domain; SH3 domain; KW Transferase; Tyrosine-protein kinase; Zinc; Zinc-finger. FT CHAIN 1..631 FT /note="Tyrosine-protein kinase Tec" FT /id="PRO_0000088170" FT DOMAIN 4..111 FT /note="PH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00145" FT DOMAIN 179..239 FT /note="SH3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00192" FT DOMAIN 247..345 FT /note="SH2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00191" FT DOMAIN 370..623 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ZN_FING 113..149 FT /note="Btk-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT REGION 157..178 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 489 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 121 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT BINDING 132 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT BINDING 133 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT BINDING 143 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00432" FT BINDING 376..384 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 398 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 206 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12573241, FT ECO:0007744|PubMed:19369195" FT MOD_RES 228 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 519 FT /note="Phosphotyrosine; by autocatalysis, LYN and JAK2" FT /evidence="ECO:0007744|PubMed:19690332" FT VARIANT 44 FT /note="R -> Q (in dbSNP:rs35374286)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041850" FT VARIANT 563 FT /note="R -> K (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041851" FT CONFLICT 514 FT /note="V -> F (in Ref. 1; BAA06171)" FT /evidence="ECO:0000305" FT STRAND 3..14 FT /evidence="ECO:0007829|PDB:2LUL" FT STRAND 19..21 FT /evidence="ECO:0007829|PDB:2LUL" FT STRAND 26..41 FT /evidence="ECO:0007829|PDB:2LUL" FT STRAND 45..47 FT /evidence="ECO:0007829|PDB:2LUL" FT STRAND 53..55 FT /evidence="ECO:0007829|PDB:2LUL" FT HELIX 56..58 FT /evidence="ECO:0007829|PDB:2LUL" FT STRAND 61..64 FT /evidence="ECO:0007829|PDB:2LUL" FT STRAND 69..71 FT /evidence="ECO:0007829|PDB:2LUL" FT STRAND 74..76 FT /evidence="ECO:0007829|PDB:2LUL" FT STRAND 78..83 FT /evidence="ECO:0007829|PDB:2LUL" FT STRAND 88..92 FT /evidence="ECO:0007829|PDB:2LUL" FT HELIX 96..110 FT /evidence="ECO:0007829|PDB:2LUL" FT STRAND 118..120 FT /evidence="ECO:0007829|PDB:2LUL" FT STRAND 132..134 FT /evidence="ECO:0007829|PDB:2LUL" FT STRAND 143..145 FT /evidence="ECO:0007829|PDB:2LUL" SQ SEQUENCE 631 AA; 73581 MW; F55DECBF9916E1F9 CRC64; MNFNTILEEI LIKRSQQKKK TSPLNYKERL FVLTKSMLTY YEGRAEKKYR KGFIDVSKIK CVEIVKNDDG VIPCQNKYPF QVVHDANTLY IFAPSPQSRD LWVKKLKEEI KNNNNIMIKY HPKFWTDGSY QCCRQTEKLA PGCEKYNLFE SSIRKALPPA PETKKRRPPP PIPLEEEDNS EEIVVAMYDF QAAEGHDLRL ERGQEYLILE KNDVHWWRAR DKYGNEGYIP SNYVTGKKSN NLDQYEWYCR NMNRSKAEQL LRSEDKEGGF MVRDSSQPGL YTVSLYTKFG GEGSSGFRHY HIKETTTSPK KYYLAEKHAF GSIPEIIEYH KHNAAGLVTR LRYPVSVKGK NAPTTAGFSY EKWEINPSEL TFMRELGSGL FGVVRLGKWR AQYKVAIKAI REGAMCEEDF IEEAKVMMKL THPKLVQLYG VCTQQKPIYI VTEFMERGCL LNFLRQRQGH FSRDVLLSMC QDVCEGMEYL ERNSFIHRDL AARNCLVSEA GVVKVSDFGM ARYVLDDQYT SSSGAKFPVK WCPPEVFNYS RFSSKSDVWS FGVLMWEVFT EGRMPFEKYT NYEVVTMVTR GHRLYQPKLA SNYVYEVMLR CWQEKPEGRP SFEDLLRTID ELVECEETFG R // ID TGFR2_HUMAN Reviewed; 567 AA. AC P37173; B4DTV5; Q15580; Q6DKT6; Q99474; DT 01-OCT-1994, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 2. DT 28-JAN-2026, entry version 258. DE RecName: Full=TGF-beta receptor type-2; DE Short=TGFR-2; DE EC=2.7.11.30; DE AltName: Full=TGF-beta type II receptor; DE AltName: Full=Transforming growth factor-beta receptor type II; DE Short=TGF-beta receptor type II; DE Short=TbetaR-II; DE Flags: Precursor; GN Name=TGFBR2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT ALA-439, AND SUBCELLULAR RP LOCATION. RC TISSUE=Liver; RX PubMed=1310899; DOI=10.1016/0092-8674(92)90152-3; RA Lin H.Y., Wang X.-F., Ng-Eaton E., Weinberg R.A., Lodish H.F.; RT "Expression cloning of the TGF-beta type II receptor, a functional RT transmembrane serine/threonine kinase."; RL Cell 68:775-785(1992). RN [2] RP ERRATUM OF PUBMED:1310899. RX PubMed=1525823; RA Lin H.Y., Wang X.-F., Ng-Eaton E., Weinberg R.A., Lodish H.F.; RL Cell 70:1069-1069(1992). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RC TISSUE=Glial cell; RX PubMed=7959019; DOI=10.1016/0378-1119(94)90178-3; RA Nikawa J.; RT "A cDNA encoding the human transforming growth factor beta receptor RT suppresses the growth defect of a yeast mutant."; RL Gene 149:367-372(1994). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANT ALA-439. RX PubMed=8812462; DOI=10.1006/geno.1996.0471; RA Takenoshita S., Hagiwara K., Nagashima M., Gemma A., Bennett W.P., RA Harris C.C.; RT "The genomic structure of the gene encoding the human transforming growth RT factor beta type II receptor (TGF-beta RII)."; RL Genomics 36:341-344(1996). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANT ALA-439. RX PubMed=8840968; RA Lu S.-L., Zhang W.C., Akiyama Y., Nomizu T., Yuasa Y.; RT "Genomic structure of the transforming growth factor beta type II receptor RT gene and its mutations in hereditary nonpolyposis colorectal cancers."; RL Cancer Res. 56:4595-4598(1996). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-439. RC TISSUE=Liver; RX PubMed=8973329; DOI=10.1016/s0378-1119(96)00501-x; RA Ogasa H., Noma T., Murata H., Kawai S., Nakazawa A.; RT "Cloning of a cDNA encoding the human transforming growth factor-beta type RT II receptor: heterogeneity of the mRNA."; RL Gene 181:185-190(1996). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION (ISOFORM 3), SUBUNIT RP (ISOFORM 3), AND SUBCELLULAR LOCATION (ISOFORM 3). RC TISSUE=Peripheral blood T-cell {ECO:0000303|PubMed:34568316}; RX PubMed=34568316; DOI=10.3389/fcell.2021.690397; RA Bertolio M.S., La Colla A., Carrea A., Romo A., Canziani G., Echarte S.M., RA Campisano S., Barletta G.P., Monzon A.M., Rodriguez T.M., Chisari A.N., RA Dewey R.A.; RT "A Novel Splice Variant of Human TGF-beta Type II Receptor Encodes a RT Soluble Protein and Its Fc-Tagged Version Prevents Liver Fibrosis in RT vivo."; RL Front. Cell Dev. Biol. 9:690397-690397(2021). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-36. RG NIEHS SNPs program; RL Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP PROTEIN SEQUENCE OF 23-37. RX PubMed=15340161; DOI=10.1110/ps.04682504; RA Zhang Z., Henzel W.J.; RT "Signal peptide prediction based on analysis of experimentally verified RT cleavage sites."; RL Protein Sci. 13:2819-2824(2004). RN [12] RP FUNCTION IN PHOSPHORYLATION OF TGFBR1. RX PubMed=7774578; DOI=10.1002/j.1460-2075.1995.tb07214.x; RA Wieser R., Wrana J.L., Massague J.; RT "GS domain mutations that constitutively activate T beta R-I, the RT downstream signaling component in the TGF-beta receptor complex."; RL EMBO J. 14:2199-2208(1995). RN [13] RP INTERACTION WITH CLU. RX PubMed=8555189; DOI=10.1021/bi951880a; RA Reddy K.B., Karode M.C., Harmony A.K., Howe P.H.; RT "Interaction of transforming growth factor beta receptors with RT apolipoprotein J/clusterin."; RL Biochemistry 35:309-314(1996). RN [14] RP ALTERNATIVE SPLICING (ISOFORM 2), AND FUNCTION (ISOFORMS 1 AND 2). RX PubMed=8635485; DOI=10.1006/excr.1996.0066; RA Hirai R., Fijita T.; RT "A human transforming growth factor-beta type II receptor that contains an RT insertion in the extracellular domain."; RL Exp. Cell Res. 223:135-141(1996). RN [15] RP INTERACTION WITH ZFYVE9. RX PubMed=9865696; DOI=10.1016/s0092-8674(00)81701-8; RA Tsukazaki T., Chiang T.A., Davison A.F., Attisano L., Wrana J.L.; RT "SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor."; RL Cell 95:779-791(1998). RN [16] RP HOMODIMERIZATION. RX PubMed=9472030; DOI=10.1083/jcb.140.4.767; RA Gilboa L., Wells R.G., Lodish H.F., Henis Y.I.; RT "Oligomeric structure of type I and type II transforming growth factor beta RT receptors: homodimers form in the ER and persist at the plasma membrane."; RL J. Cell Biol. 140:767-777(1998). RN [17] RP INTERACTION WITH DAXX, AND MUTAGENESIS OF LYS-277. RX PubMed=11483955; DOI=10.1038/35087019; RA Perlman R., Schiemann W.P., Brooks M.W., Lodish H.F., Weinberg R.A.; RT "TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that RT facilitates JNK activation."; RL Nat. Cell Biol. 3:708-714(2001). RN [18] RP INTERACTION WITH VPS39. RX PubMed=12941698; DOI=10.1093/emboj/cdg428; RA Felici A., Wurthner J.U., Parks W.T., Giam L.R., Reiss M., Karpova T.S., RA McNally J.G., Roberts A.B.; RT "TLP, a novel modulator of TGF-beta signaling, has opposite effects on RT Smad2- and Smad3-dependent signaling."; RL EMBO J. 22:4465-4477(2003). RN [19] RP INTERACTION WITH DYNLT4. RX PubMed=16982625; DOI=10.1074/jbc.m608614200; RA Meng Q.-J., Lux A., Holloschi A., Li J., Hughes J.M.X., Foerg T., RA McCarthy J.E.G., Heagerty A.M., Kioschis P., Hafner M., Garland J.M.; RT "Identification of Tctex2beta, a novel dynein light chain family member RT that interacts with different transforming growth factor-beta receptors."; RL J. Biol. Chem. 281:37069-37080(2006). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-548, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [22] RP IDENTIFICATION IN A COMPLEX WITH TSC22D1 AND TGFBR1. RX PubMed=21791611; DOI=10.1128/mcb.05448-11; RA Yan X., Zhang J., Pan L., Wang P., Xue H., Zhang L., Gao X., Zhao X., RA Ning Y., Chen Y.G.; RT "TSC-22 promotes transforming growth factor beta-mediated cardiac RT myofibroblast differentiation by antagonizing Smad7 activity."; RL Mol. Cell. Biol. 31:3700-3709(2011). RN [23] RP INTERACTION WITH SCUBE3. RX PubMed=21441952; DOI=10.1038/onc.2011.85; RA Wu Y.Y., Peck K., Chang Y.L., Pan S.H., Cheng Y.F., Lin J.C., Yang R.B., RA Hong T.M., Yang P.C.; RT "SCUBE3 is an endogenous TGF-beta receptor ligand and regulates the RT epithelial-mesenchymal transition in lung cancer."; RL Oncogene 30:3682-3693(2011). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-548, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-548, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [26] RP SUBCELLULAR LOCATION. RX PubMed=25893292; DOI=10.1038/onc.2015.100; RA Hwangbo C., Tae N., Lee S., Kim O., Park O.K., Kim J., Kwon S.H., Lee J.H.; RT "Syntenin regulates TGF-beta1-induced Smad activation and the epithelial- RT to-mesenchymal transition by inhibiting caveolin-mediated TGF-beta type I RT receptor internalization."; RL Oncogene 35:389-401(2016). RN [27] RP X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 38-159 IN COMPLEX WITH TGF-BETA3, RP AND DISULFIDE BONDS. RX PubMed=11850637; DOI=10.1038/nsb766; RA Hart P.J., Deep S., Taylor A.B., Shu Z., Hinck C.S., Hinck A.P.; RT "Crystal structure of the human TbetaR2 ectodomain--TGF-beta3 complex."; RL Nat. Struct. Biol. 9:203-208(2002). RN [28] RP X-RAY CRYSTALLOGRAPHY (1.05 ANGSTROMS) OF 49-159, AND DISULFIDE BONDS. RX PubMed=12121646; DOI=10.1016/s0969-2126(02)00780-3; RA Boesen C.C., Radaev S., Motyka S.A., Patamawenu A., Sun P.D.; RT "The 1.1 A crystal structure of human TGF-beta type II receptor ligand RT binding domain."; RL Structure 10:913-919(2002). RN [29] RP STRUCTURE BY NMR OF 38-159, AND DISULFIDE BONDS. RX PubMed=12939140; DOI=10.1021/bi034366a; RA Deep S., Walker K.P. III, Shu Z., Hinck A.P.; RT "Solution structure and backbone dynamics of the TGFbeta type II receptor RT extracellular domain."; RL Biochemistry 42:10126-10139(2003). RN [30] RP X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 43-149 IN COMPLEX WITH TGFBR1 AND RP TGFB3, AND DISULFIDE BONDS. RX PubMed=18243111; DOI=10.1016/j.molcel.2007.11.039; RA Groppe J., Hinck C.S., Samavarchi-Tehrani P., Zubieta C., Schuermann J.P., RA Taylor A.B., Schwarz P.M., Wrana J.L., Hinck A.P.; RT "Cooperative assembly of TGF-beta superfamily signaling complexes is RT mediated by two disparate mechanisms and distinct modes of receptor RT binding."; RL Mol. Cell 29:157-168(2008). RN [31] RP X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 38-153 IN COMPLEX WITH TGFBR1 AND RP TGFB1, RECEPTOR AFFINITY FOR LIGANDS, AND DISULFIDE BONDS. RX PubMed=20207738; DOI=10.1074/jbc.m109.079921; RA Radaev S., Zou Z., Huang T., Lafer E.M., Hinck A.P., Sun P.D.; RT "Ternary complex of transforming growth factor-beta1 reveals isoform- RT specific ligand recognition and receptor recruitment in the superfamily."; RL J. Biol. Chem. 285:14806-14814(2010). RN [32] RP VARIANT HNPCC6 MET-315. RX PubMed=9590282; DOI=10.1038/ng0598-17; RA Lu S.-L., Kawabata M., Imamura T., Akiyama Y., Nomizu T., Miyazono K., RA Yuasa Y.; RT "HNPCC associated with germline mutation in the TGF-beta type II receptor RT gene."; RL Nat. Genet. 19:17-18(1998). RN [33] RP VARIANT ESOPHAGEAL CANCER GLN-526. RX PubMed=10789724; DOI=10.1054/bjoc.1999.1178; RA Tanaka S., Mori M., Mafune K., Ohno S., Sugimachi K.; RT "A dominant negative mutation of transforming growth factor-beta receptor RT type II gene in microsatellite stable oesophageal carcinoma."; RL Br. J. Cancer 82:1557-1560(2000). RN [34] RP VARIANTS BREAST TUMOR MET-387; SER-435; ALA-447 AND MET-452, AND RP CHARACTERIZATION OF VARIANTS BREAST TUMOR SER-435; ALA-447 AND MET-452. RX PubMed=11212236; RA Luecke C.D., Philpott A., Metcalfe J.C., Thompson A.M., Hughes-Davies L., RA Kemp P.R., Hesketh R.; RT "Inhibiting mutations in the transforming growth factor beta type 2 RT receptor in recurrent human breast cancer."; RL Cancer Res. 61:482-485(2001). RN [35] RP VARIANT ILE-191. RX PubMed=12202987; DOI=10.1007/s100380200069; RA Watanabe Y., Kinoshita A., Yamada T., Ohta T., Kishino T., Matsumoto N., RA Ishikawa M., Niikawa N., Yoshiura K.; RT "A catalog of 106 single-nucleotide polymorphisms (SNPs) and 11 other types RT of variations in genes for transforming growth factor-beta1 (TGF-beta1) and RT its signaling pathway."; RL J. Hum. Genet. 47:478-483(2002). RN [36] RP VARIANTS LDS2 PRO-308; PHE-449 AND CYS-537, AND CHARACTERIZATION OF RP VARIANTS LDS2 PRO-308; PHE-449 AND CYS-537. RX PubMed=15235604; DOI=10.1038/ng1392; RA Mizuguchi T., Collod-Beroud G., Akiyama T., Abifadel M., Harada N., RA Morisaki T., Allard D., Varret M., Claustres M., Morisaki H., Ihara M., RA Kinoshita A., Yoshiura K., Junien C., Kajii T., Jondeau G., Ohta T., RA Kishino T., Furukawa Y., Nakamura Y., Niikawa N., Boileau C., Matsumoto N.; RT "Heterozygous TGFBR2 mutations in Marfan syndrome."; RL Nat. Genet. 36:855-860(2004). RN [37] RP VARIANTS LDS2 CYS-460 AND HIS-460. RX PubMed=16027248; DOI=10.1161/circulationaha.105.537340; RA Pannu H., Fadulu V.T., Chang J., Lafont A., Hasham S.N., Sparks E., RA Giampietro P.F., Zaleski C., Estrera A.L., Safi H.J., Shete S., RA Willing M.C., Raman C.S., Milewicz D.M.; RT "Mutations in transforming growth factor-beta receptor type II cause RT familial thoracic aortic aneurysms and dissections."; RL Circulation 112:513-520(2005). RN [38] RP VARIANTS LDS2 ASN-336; PRO-355; TRP-357; HIS-528 AND CYS-528. RX PubMed=15731757; DOI=10.1038/ng1511; RA Loeys B.L., Chen J., Neptune E.R., Judge D.P., Podowski M., Holm T., RA Meyers J., Leitch C.C., Katsanis N., Sharifi N., Xu F.L., Myers L.A., RA Spevak P.J., Cameron D.E., De Backer J.F., Hellemans J., Chen Y., RA Davis E.C., Webb C.L., Kress W., Coucke P.J., Rifkin D.B., De Paepe A.M., RA Dietz H.C.; RT "A syndrome of altered cardiovascular, craniofacial, neurocognitive and RT skeletal development caused by mutations in TGFBR1 or TGFBR2."; RL Nat. Genet. 37:275-281(2005). RN [39] RP VARIANT LDS2 ASN-446. RX PubMed=16251899; DOI=10.1038/sj.ejhg.5201502; RA Disabella E., Grasso M., Marziliano N., Ansaldi S., Lucchelli C., Porcu E., RA Tagliani M., Pilotto A., Diegoli M., Lanzarini L., Malattia C., RA Pelliccia A., Ficcadenti A., Gabrielli O., Arbustini E.; RT "Two novel and one known mutation of the TGFBR2 gene in Marfan syndrome not RT associated with FBN1 gene defects."; RL Eur. J. Hum. Genet. 14:34-38(2006). RN [40] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-73 AND HIS-528. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [41] RP VARIANTS [LARGE SCALE ANALYSIS] ARG-61; ILE-191; MET-315; TYR-328; ILE-373; RP MET-387 AND SER-490. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [42] RP VARIANTS LDS2 HIS-190; VAL-247; PRO-325; ARG-357 AND ILE-530. RX PubMed=19533785; DOI=10.1002/ajmg.a.32918; RA Chung B.H., Lam S.T., Tong T.M., Li S.Y., Lun K.S., Chan D.H., Fok S.F., RA Or J.S., Smith D.K., Yang W., Lau Y.L.; RT "Identification of novel FBN1 and TGFBR2 mutations in 65 probands with RT Marfan syndrome or Marfan-like phenotypes."; RL Am. J. Med. Genet. A 149A:1452-1459(2009). RN [43] RP VARIANT LDS2 SER-510. RX PubMed=19883511; DOI=10.1186/1750-1172-4-24; RA Drera B., Ritelli M., Zoppi N., Wischmeijer A., Gnoli M., Fattori R., RA Calzavara-Pinton P.G., Barlati S., Colombi M.; RT "Loeys-Dietz syndrome type I and type II: clinical findings and novel RT mutations in two Italian patients."; RL Orphanet J. Rare Dis. 4:24-24(2009). RN [44] RP VARIANT LDS2 LYS-457. RX PubMed=20101701; DOI=10.1002/ajmg.a.33263; RA Muramatsu Y., Kosho T., Magota M., Yokotsuka T., Ito M., Yasuda A., RA Kito O., Suzuki C., Nagata Y., Kawai S., Ikoma M., Hatano T., Nakayama M., RA Kawamura R., Wakui K., Morisaki H., Morisaki T., Fukushima Y.; RT "Progressive aortic root and pulmonary artery aneurysms in a neonate with RT Loeys-Dietz syndrome type 1B."; RL Am. J. Med. Genet. A 152:417-421(2010). RN [45] RP VARIANTS LDS2 PRO-308 AND ARG-521. RX PubMed=20358619; DOI=10.1002/ajmg.a.33356; RA Kirmani S., Tebben P.J., Lteif A.N., Gordon D., Clarke B.L., Hefferan T.E., RA Yaszemski M.J., McGrann P.S., Lindor N.M., Ellison J.W.; RT "Germline TGF-beta receptor mutations and skeletal fragility: a report on RT two patients with Loeys-Dietz syndrome."; RL Am. J. Med. Genet. A 152:1016-1019(2010). RN [46] RP VARIANTS LDS2 GLN-306 DELINS HIS-GLU; ARG-377; PHE-449 AND ARG-514. RX PubMed=22113417; DOI=10.1038/jhg.2011.130; RA Yang J.H., Ki C.S., Han H., Song B.G., Jang S.Y., Chung T.Y., Sung K., RA Lee H.J., Kim D.K.; RT "Clinical features and genetic analysis of Korean patients with Loeys-Dietz RT syndrome."; RL J. Hum. Genet. 57:52-56(2012). RN [47] RP VARIANTS LDS2 VAL-509 AND PHE-510. RX PubMed=21949523; DOI=10.3345/kjp.2011.54.6.272; RA Ha J.S., Kim Y.H.; RT "A sporadic case of Loeys-Dietz syndrome type I with two novel mutations of RT the TGFBR2 gene."; RL Korean J. Pediatr. 54:272-275(2011). CC -!- FUNCTION: Transmembrane serine/threonine kinase forming with the TGF- CC beta type I serine/threonine kinase receptor, TGFBR1, the non- CC promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. CC Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to CC the cytoplasm and thus regulates a plethora of physiological and CC pathological processes including cell cycle arrest in epithelial and CC hematopoietic cells, control of mesenchymal cell proliferation and CC differentiation, wound healing, extracellular matrix production, CC immunosuppression and carcinogenesis. The formation of the receptor CC complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound CC to the cytokine dimer results in the phosphorylation and activation of CC TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 CC phosphorylates SMAD2 which dissociates from the receptor and interacts CC with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the CC nucleus where it modulates the transcription of the TGF-beta-regulated CC genes. This constitutes the canonical SMAD-dependent TGF-beta signaling CC cascade. Also involved in non-canonical, SMAD-independent TGF-beta CC signaling pathways. {ECO:0000269|PubMed:7774578}. CC -!- FUNCTION: [Isoform 1]: Has transforming growth factor beta-activated CC receptor activity. {ECO:0000269|PubMed:8635485}. CC -!- FUNCTION: [Isoform 2]: Has transforming growth factor beta-activated CC receptor activity. {ECO:0000269|PubMed:8635485}. CC -!- FUNCTION: [Isoform 3]: Binds TGFB1, TGFB2 and TGFB3 in the picomolar CC affinity range without the participation of additional receptors. CC Blocks activation of SMAD2 and SMAD3 by TGFB1. CC {ECO:0000269|PubMed:34568316}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[receptor-protein] + ATP = O-phospho-L-threonyl- CC [receptor-protein] + ADP + H(+); Xref=Rhea:RHEA:44880, Rhea:RHEA- CC COMP:11024, Rhea:RHEA-COMP:11025, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, CC ChEBI:CHEBI:456216; EC=2.7.11.30; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[receptor-protein] + ATP = O-phospho-L-seryl- CC [receptor-protein] + ADP + H(+); Xref=Rhea:RHEA:18673, Rhea:RHEA- CC COMP:11022, Rhea:RHEA-COMP:11023, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, ChEBI:CHEBI:83421, CC ChEBI:CHEBI:456216; EC=2.7.11.30; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250}; CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250}; CC -!- SUBUNIT: Homodimer. Heterohexamer; TGFB1, TGFB2 and TGFB3 homodimeric CC ligands assemble a functional receptor composed of two TGFBR1 and CC TGFBR2 heterodimers to form a ligand-receptor heterohexamer. The CC respective affinity of TGFRB1 and TGFRB2 for the ligands may modulate CC the kinetics of assembly of the receptor and may explain the different CC biological activities of TGFB1, TGFB2 and TGFB3. Component of a complex CC composed of TSC22D1 (via N-terminus), TGFBR1 and TGFBR2; the CC interaction between TSC22D1 and TGFBR1 is inhibited by SMAD7 and CC promoted by TGFB1 (PubMed:21791611). Interacts with DAXX. Interacts CC with DYNLT4. Interacts with ZFYVE9; ZFYVE9 recruits SMAD2 and SMAD3 to CC the TGF-beta receptor. Interacts with and is activated by SCUBE3; this CC interaction does not affect TGFB1-binding to TGFBR2. Interacts with CC VPS39; this interaction is independent of the receptor kinase activity CC and of the presence of TGF-beta. Interacts with CLU (PubMed:8555189). CC {ECO:0000269|PubMed:11483955, ECO:0000269|PubMed:11850637, CC ECO:0000269|PubMed:12941698, ECO:0000269|PubMed:16982625, CC ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738, CC ECO:0000269|PubMed:21441952, ECO:0000269|PubMed:21791611, CC ECO:0000269|PubMed:8555189, ECO:0000269|PubMed:9865696}. CC -!- SUBUNIT: [Isoform 3]: Homodimer; disulfide-linked. CC {ECO:0000269|PubMed:34568316}. CC -!- INTERACTION: CC P37173; P54819: AK2; NbExp=3; IntAct=EBI-296151, EBI-1056291; CC P37173; P61966-2: AP1S1; NbExp=3; IntAct=EBI-296151, EBI-12067760; CC P37173; Q9NP61: ARFGAP3; NbExp=3; IntAct=EBI-296151, EBI-2875816; CC P37173; O75143-2: ATG13; NbExp=3; IntAct=EBI-296151, EBI-20151086; CC P37173; Q93084-2: ATP2A3; NbExp=3; IntAct=EBI-296151, EBI-21505448; CC P37173; P54253: ATXN1; NbExp=3; IntAct=EBI-296151, EBI-930964; CC P37173; P54252: ATXN3; NbExp=3; IntAct=EBI-296151, EBI-946046; CC P37173; Q4VBR4: ATXN3; NbExp=3; IntAct=EBI-296151, EBI-12928880; CC P37173; Q8TBE0: BAHD1; NbExp=3; IntAct=EBI-296151, EBI-742750; CC P37173; Q8TAB5: C1orf216; NbExp=3; IntAct=EBI-296151, EBI-747505; CC P37173; P40227: CCT6A; NbExp=3; IntAct=EBI-296151, EBI-356687; CC P37173; P12830: CDH1; NbExp=3; IntAct=EBI-296151, EBI-727477; CC P37173; Q8NE08: COL25A1; NbExp=3; IntAct=EBI-296151, EBI-25836642; CC P37173; P48730-2: CSNK1D; NbExp=3; IntAct=EBI-296151, EBI-9087876; CC P37173; Q9UER7: DAXX; NbExp=2; IntAct=EBI-296151, EBI-77321; CC P37173; Q9UMR2: DDX19B; NbExp=3; IntAct=EBI-296151, EBI-719232; CC P37173; P49184: DNASE1L1; NbExp=3; IntAct=EBI-296151, EBI-20894690; CC P37173; O14531: DPYSL4; NbExp=3; IntAct=EBI-296151, EBI-719542; CC P37173; P26378-2: ELAVL4; NbExp=3; IntAct=EBI-296151, EBI-21603100; CC P37173; P15036: ETS2; NbExp=3; IntAct=EBI-296151, EBI-1646991; CC P37173; P09471: GNAO1; NbExp=3; IntAct=EBI-296151, EBI-715087; CC P37173; P51674: GPM6A; NbExp=3; IntAct=EBI-296151, EBI-7187133; CC P37173; P42858: HTT; NbExp=3; IntAct=EBI-296151, EBI-466029; CC P37173; O75874: IDH1; NbExp=3; IntAct=EBI-296151, EBI-715695; CC P37173; Q6PI98: INO80C; NbExp=3; IntAct=EBI-296151, EBI-722540; CC P37173; Q9ULR0: ISY1; NbExp=3; IntAct=EBI-296151, EBI-2557660; CC P37173; P06756: ITGAV; NbExp=3; IntAct=EBI-296151, EBI-298282; CC P37173; P23276: KEL; NbExp=3; IntAct=EBI-296151, EBI-746662; CC P37173; O60259: KLK8; NbExp=3; IntAct=EBI-296151, EBI-3915857; CC P37173; Q96E93: KLRG1; NbExp=3; IntAct=EBI-296151, EBI-750770; CC P37173; Q8N448: LNX2; NbExp=3; IntAct=EBI-296151, EBI-2340947; CC P37173; Q7Z434: MAVS; NbExp=3; IntAct=EBI-296151, EBI-995373; CC P37173; Q93074: MED12; NbExp=3; IntAct=EBI-296151, EBI-394357; CC P37173; Q14728: MFSD10; NbExp=3; IntAct=EBI-296151, EBI-11337904; CC P37173; P01106: MYC; NbExp=3; IntAct=EBI-296151, EBI-447544; CC P37173; Q9NPC7: MYNN; NbExp=3; IntAct=EBI-296151, EBI-3446748; CC P37173; Q99435-2: NELL2; NbExp=3; IntAct=EBI-296151, EBI-17754404; CC P37173; Q8TAT6: NPLOC4; NbExp=3; IntAct=EBI-296151, EBI-1994109; CC P37173; Q9BZ95-3: NSD3; NbExp=3; IntAct=EBI-296151, EBI-22002759; CC P37173; Q96IY1: NSL1; NbExp=3; IntAct=EBI-296151, EBI-2554690; CC P37173; Q16549: PCSK7; NbExp=3; IntAct=EBI-296151, EBI-8059854; CC P37173; Q9NUD9: PIGV; NbExp=3; IntAct=EBI-296151, EBI-25836582; CC P37173; Q8TBJ4: PLPPR1; NbExp=3; IntAct=EBI-296151, EBI-18063495; CC P37173; Q07869: PPARA; NbExp=3; IntAct=EBI-296151, EBI-78615; CC P37173; Q13200: PSMD2; NbExp=3; IntAct=EBI-296151, EBI-357648; CC P37173; P21246: PTN; NbExp=3; IntAct=EBI-296151, EBI-473725; CC P37173; Q13702-2: RAPSN; NbExp=3; IntAct=EBI-296151, EBI-22012855; CC P37173; P52756: RBM5; NbExp=3; IntAct=EBI-296151, EBI-714003; CC P37173; Q6NTF9-3: RHBDD2; NbExp=3; IntAct=EBI-296151, EBI-17589229; CC P37173; Q96NA2: RILP; NbExp=3; IntAct=EBI-296151, EBI-2856119; CC P37173; P61513: RPL37A; NbExp=3; IntAct=EBI-296151, EBI-356793; CC P37173; Q8IX30: SCUBE3; NbExp=6; IntAct=EBI-296151, EBI-4479975; CC P37173; Q8NC51: SERBP1; NbExp=3; IntAct=EBI-296151, EBI-523558; CC P37173; Q16586: SGCA; NbExp=3; IntAct=EBI-296151, EBI-5663553; CC P37173; Q99720-4: SIGMAR1; NbExp=3; IntAct=EBI-296151, EBI-25831036; CC P37173; Q8NCS7: SLC44A5; NbExp=3; IntAct=EBI-296151, EBI-21504521; CC P37173; Q16560-2: SNRNP35; NbExp=3; IntAct=EBI-296151, EBI-12938570; CC P37173; Q7Z614-3: SNX20; NbExp=3; IntAct=EBI-296151, EBI-12336127; CC P37173; Q3SY56: SP6; NbExp=3; IntAct=EBI-296151, EBI-11175533; CC P37173; P46977: STT3A; NbExp=3; IntAct=EBI-296151, EBI-719212; CC P37173; O43463: SUV39H1; NbExp=3; IntAct=EBI-296151, EBI-349968; CC P37173; Q13428-5: TCOF1; NbExp=3; IntAct=EBI-296151, EBI-25832010; CC P37173; P01137: TGFB1; NbExp=11; IntAct=EBI-296151, EBI-779636; CC P37173; P10600: TGFB3; NbExp=8; IntAct=EBI-296151, EBI-1033020; CC P37173; Q9Y228: TRAF3IP3; NbExp=3; IntAct=EBI-296151, EBI-765817; CC P37173; Q96BQ3: TRIM43; NbExp=3; IntAct=EBI-296151, EBI-2129899; CC P37173; Q9UHP3: USP25; NbExp=3; IntAct=EBI-296151, EBI-2513462; CC P37173; Q969W3: VCF1; NbExp=3; IntAct=EBI-296151, EBI-10281506; CC P37173; P19544-6: WT1; NbExp=3; IntAct=EBI-296151, EBI-11745701; CC P37173; P25490: YY1; NbExp=3; IntAct=EBI-296151, EBI-765538; CC P37173; A2AGH6: Med12; Xeno; NbExp=3; IntAct=EBI-296151, EBI-5744969; CC P37173; P07200: TGFB1; Xeno; NbExp=2; IntAct=EBI-296151, EBI-907660; CC P37173-2; P02750: LRG1; NbExp=3; IntAct=EBI-16065370, EBI-9083443; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:1310899, CC ECO:0000269|PubMed:25893292}; Single-pass type I membrane protein CC {ECO:0000269|PubMed:1310899}. Membrane raft CC {ECO:0000269|PubMed:25893292}. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Secreted CC {ECO:0000269|PubMed:34568316}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=betaR-II {ECO:0000303|PubMed:8635485}; CC IsoId=P37173-1; Sequence=Displayed; CC Name=2; Synonyms=betaR-IIB {ECO:0000303|PubMed:8635485}; CC IsoId=P37173-2; Sequence=VSP_012157; CC Name=3; Synonyms=TbetaRII-SE {ECO:0000303|PubMed:34568316}; CC IsoId=P37173-3; Sequence=VSP_061513, VSP_061514; CC -!- PTM: Phosphorylated on a Ser/Thr residue in the cytoplasmic domain. CC -!- DISEASE: Hereditary non-polyposis colorectal cancer 6 (HNPCC6) CC [MIM:614331]: An autosomal dominant disease associated with marked CC increase in cancer susceptibility. It is characterized by a familial CC predisposition to early-onset colorectal carcinoma (CRC) and extra- CC colonic tumors of the gastrointestinal, urological and female CC reproductive tracts. HNPCC is reported to be the most common form of CC inherited colorectal cancer in the Western world. Clinically, HNPCC is CC often divided into two subgroups. Type I is characterized by hereditary CC predisposition to colorectal cancer, a young age of onset, and CC carcinoma observed in the proximal colon. Type II is characterized by CC increased risk for cancers in certain tissues such as the uterus, CC ovary, breast, stomach, small intestine, skin, and larynx in addition CC to the colon. Diagnosis of classical HNPCC is based on the Amsterdam CC criteria: 3 or more relatives affected by colorectal cancer, one a CC first degree relative of the other two; 2 or more generation affected; CC 1 or more colorectal cancers presenting before 50 years of age; CC exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' CC or 'incomplete HNPCC' can be used to describe families who do not or CC only partially fulfill the Amsterdam criteria, but in whom a genetic CC basis for colon cancer is strongly suspected. CC {ECO:0000269|PubMed:9590282}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the CC esophagus. The most common types are esophageal squamous cell carcinoma CC and adenocarcinoma. Cancer of the esophagus remains a devastating CC disease because it is usually not detected until it has progressed to CC an advanced incurable stage. {ECO:0000269|PubMed:10789724}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Loeys-Dietz syndrome 2 (LDS2) [MIM:610168]: An aortic aneurysm CC syndrome with widespread systemic involvement, characterized by CC arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or CC cleft palate. Physical findings include prominent joint laxity, easy CC bruising, wide and atrophic scars, velvety and translucent skin with CC easily visible veins, spontaneous rupture of the spleen or bowel, and CC catastrophic complications of pregnancy, including rupture of the CC gravid uterus and the arteries, either during pregnancy or in the CC immediate postpartum period. Some patients have craniosynostosis, CC exotropy, micrognathia and retrognathia, structural brain CC abnormalities, and intellectual deficit. {ECO:0000269|PubMed:15235604, CC ECO:0000269|PubMed:15731757, ECO:0000269|PubMed:16027248, CC ECO:0000269|PubMed:16251899, ECO:0000269|PubMed:19533785, CC ECO:0000269|PubMed:19883511, ECO:0000269|PubMed:20101701, CC ECO:0000269|PubMed:20358619, ECO:0000269|PubMed:21949523, CC ECO:0000269|PubMed:22113417}. Note=The disease is caused by variants CC affecting the gene represented in this entry. TGFBR2 mutations Cys-460 CC and His-460 have been reported to be associated with thoracic aortic CC aneurysms and dissection (TAAD). This phenotype, also known as thoracic CC aortic aneurysms type 3 (AAT3), is distinguised from LDS2 by having CC aneurysms restricted to thoracic aorta. As individuals carrying these CC mutations also exhibit descending aortic disease and aneurysms of other CC arteries (PubMed:16027248), they have been considered as LDS2 by the CC OMIM resource. {ECO:0000269|PubMed:16027248}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. TGFB receptor subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M85079; AAA61164.1; -; mRNA. DR EMBL; D28131; BAA05673.1; -; mRNA. DR EMBL; U52246; AAB17553.1; -; Genomic_DNA. DR EMBL; U52240; AAB17553.1; JOINED; Genomic_DNA. DR EMBL; U52241; AAB17553.1; JOINED; Genomic_DNA. DR EMBL; U52242; AAB17553.1; JOINED; Genomic_DNA. DR EMBL; U52244; AAB17553.1; JOINED; Genomic_DNA. DR EMBL; U52245; AAB17553.1; JOINED; Genomic_DNA. DR EMBL; U69152; AAB40916.1; -; Genomic_DNA. DR EMBL; U69146; AAB40916.1; JOINED; Genomic_DNA. DR EMBL; U69147; AAB40916.1; JOINED; Genomic_DNA. DR EMBL; U69148; AAB40916.1; JOINED; Genomic_DNA. DR EMBL; U69149; AAB40916.1; JOINED; Genomic_DNA. DR EMBL; U69150; AAB40916.1; JOINED; Genomic_DNA. DR EMBL; U69151; AAB40916.1; JOINED; Genomic_DNA. DR EMBL; D50683; BAA09332.1; -; mRNA. DR EMBL; MW881156; UDE22710.1; -; mRNA. DR EMBL; AY675319; AAT70724.1; -; Genomic_DNA. DR EMBL; AK300383; BAG62117.1; -; mRNA. DR EMBL; CH471055; EAW64412.1; -; Genomic_DNA. DR CCDS; CCDS2648.1; -. [P37173-1] DR CCDS; CCDS33727.1; -. [P37173-2] DR PIR; A42100; A42100. DR RefSeq; NP_001020018.1; NM_001024847.3. [P37173-2] DR RefSeq; NP_003233.4; NM_003242.5. [P37173-1] DR PDB; 1KTZ; X-ray; 2.15 A; B=38-159. DR PDB; 1M9Z; X-ray; 1.05 A; A=49-159. DR PDB; 1PLO; NMR; -; A=38-159. DR PDB; 2PJY; X-ray; 3.00 A; B=42-149. DR PDB; 3KFD; X-ray; 3.00 A; E/F/G/H=38-153. DR PDB; 4P7U; X-ray; 1.50 A; A=49-159. DR PDB; 4XJJ; X-ray; 1.40 A; A=50-159. DR PDB; 5E8V; X-ray; 1.69 A; A=237-549. DR PDB; 5E8Y; X-ray; 2.05 A; A=237-549. DR PDB; 5E91; X-ray; 2.42 A; A=237-549. DR PDB; 5E92; X-ray; 2.08 A; A=237-549. DR PDB; 5QIN; X-ray; 1.57 A; A=237-549. DR PDB; 5TX4; X-ray; 1.88 A; A=38-153. DR PDB; 5TY4; EM; 2.90 A; A=47-149. DR PDB; 7DV6; X-ray; 2.39 A; A=237-549. DR PDB; 8G4K; X-ray; 1.24 A; B=45-155. DR PDB; 8YGZ; X-ray; 2.10 A; A=237-549. DR PDB; 9B9F; X-ray; 3.00 A; D/I=42-153. DR PDB; 9E9G; X-ray; 1.40 A; A=38-154. DR PDB; 9FDY; EM; 3.40 A; D/E=42-153. DR PDB; 9FK5; EM; 4.10 A; D=42-153. DR PDB; 9FKP; EM; 3.72 A; D/E=42-153. DR PDBsum; 1KTZ; -. DR PDBsum; 1M9Z; -. DR PDBsum; 1PLO; -. DR PDBsum; 2PJY; -. DR PDBsum; 3KFD; -. DR PDBsum; 4P7U; -. DR PDBsum; 4XJJ; -. DR PDBsum; 5E8V; -. DR PDBsum; 5E8Y; -. DR PDBsum; 5E91; -. DR PDBsum; 5E92; -. DR PDBsum; 5QIN; -. DR PDBsum; 5TX4; -. DR PDBsum; 5TY4; -. DR PDBsum; 7DV6; -. DR PDBsum; 8G4K; -. DR PDBsum; 8YGZ; -. DR PDBsum; 9B9F; -. DR PDBsum; 9E9G; -. DR PDBsum; 9FDY; -. DR PDBsum; 9FK5; -. DR PDBsum; 9FKP; -. DR AlphaFoldDB; P37173; -. DR BMRB; P37173; -. DR EMDB; EMD-50333; -. DR EMDB; EMD-50519; -. DR EMDB; EMD-50524; -. DR EMDB; EMD-8472; -. DR SMR; P37173; -. DR BioGRID; 112906; 202. DR ComplexPortal; CPX-2544; TGF-beta-3-TGFR complex. DR ComplexPortal; CPX-529; TGF-beta-1-TGFR complex. DR ComplexPortal; CPX-834; TGF-beta-2-TGFR complex. DR CORUM; P37173; -. DR DIP; DIP-5939N; -. DR FunCoup; P37173; 1304. DR IntAct; P37173; 185. DR MINT; P37173; -. DR STRING; 9606.ENSP00000351905; -. DR BindingDB; P37173; -. DR ChEMBL; CHEMBL4267; -. DR DrugBank; DB10770; Foreskin fibroblast (neonatal). DR DrugBank; DB10772; Foreskin keratinocyte (neonatal). DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; P37173; -. DR GuidetoPHARMACOLOGY; 1795; -. DR GlyConnect; 1979; 9 N-Linked glycans (3 sites). DR GlyCosmos; P37173; 5 sites, 9 glycans. DR GlyGen; P37173; 7 sites, 11 N-linked glycans (3 sites), 1 O-linked glycan (2 sites). DR iPTMnet; P37173; -. DR PhosphoSitePlus; P37173; -. DR SwissPalm; P37173; -. DR BioMuta; TGFBR2; -. DR DMDM; 116242818; -. DR jPOST; P37173; -. DR MassIVE; P37173; -. DR PaxDb; 9606-ENSP00000351905; -. DR PeptideAtlas; P37173; -. DR ProteomicsDB; 55264; -. [P37173-1] DR ProteomicsDB; 55265; -. [P37173-2] DR Pumba; P37173; -. DR Antibodypedia; 11570; 809 antibodies from 42 providers. DR DNASU; 7048; -. DR Ensembl; ENST00000295754.10; ENSP00000295754.5; ENSG00000163513.21. [P37173-1] DR Ensembl; ENST00000359013.4; ENSP00000351905.4; ENSG00000163513.21. [P37173-2] DR GeneID; 7048; -. DR KEGG; hsa:7048; -. DR MANE-Select; ENST00000295754.10; ENSP00000295754.5; NM_003242.6; NP_003233.4. DR UCSC; uc003cen.4; human. [P37173-1] DR AGR; HGNC:11773; -. DR ClinPGx; PA36486; -. DR CTD; 7048; -. DR DisGeNET; 7048; -. DR GeneCards; TGFBR2; -. DR GeneReviews; TGFBR2; -. DR HGNC; HGNC:11773; TGFBR2. DR HPA; ENSG00000163513; Low tissue specificity. DR MalaCards; TGFBR2; -. DR MIM; 133239; phenotype. DR MIM; 190182; gene. DR MIM; 610168; phenotype. DR MIM; 614331; phenotype. DR OpenTargets; ENSG00000163513; -. DR Orphanet; 91387; Familial thoracic aortic aneurysm and aortic dissection. DR Orphanet; 60030; Loeys-Dietz syndrome. DR Orphanet; 144; Lynch syndrome. DR Orphanet; 284973; Marfan syndrome type 2. DR Orphanet; 99977; Squamous cell carcinoma of the esophagus. DR VEuPathDB; HostDB:ENSG00000163513; -. DR eggNOG; KOG3653; Eukaryota. DR GeneTree; ENSGT00940000157527; -. DR HOGENOM; CLU_000288_8_3_1; -. DR InParanoid; P37173; -. DR OMA; QMPNLCK; -. DR OrthoDB; 547665at2759; -. DR PAN-GO; P37173; 12 GO annotations based on evolutionary models. DR PhylomeDB; P37173; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; P37173; -. DR Reactome; R-HSA-2173788; Downregulation of TGF-beta receptor signaling. DR Reactome; R-HSA-2173789; TGF-beta receptor signaling activates SMADs. DR Reactome; R-HSA-2173791; TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition). DR Reactome; R-HSA-3304356; SMAD2/3 Phosphorylation Motif Mutants in Cancer. DR Reactome; R-HSA-3642279; TGFBR2 MSI Frameshift Mutants in Cancer. DR Reactome; R-HSA-3645790; TGFBR2 Kinase Domain Mutants in Cancer. DR Reactome; R-HSA-3656532; TGFBR1 KD Mutants in Cancer. DR Reactome; R-HSA-3656535; TGFBR1 LBD Mutants in Cancer. DR Reactome; R-HSA-5689603; UCH proteinases. DR Reactome; R-HSA-9839389; TGFBR3 regulates TGF-beta signaling. DR SignaLink; P37173; -. DR SIGNOR; P37173; -. DR Agora; ENSG00000163513; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 7048; 45 hits in 1213 CRISPR screens. DR ChiTaRS; TGFBR2; human. DR EvolutionaryTrace; P37173; -. DR GeneWiki; TGF_beta_receptor_2; -. DR GenomeRNAi; 7048; -. DR Pharos; P37173; Tchem. DR PRO; PR:P37173; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P37173; protein. DR Bgee; ENSG00000163513; Expressed in pericardium and 211 other cell types or tissues. DR ExpressionAtlas; P37173; baseline and differential. DR GO; GO:0048179; C:activin receptor complex; IBA:GO_Central. DR GO; GO:0005901; C:caveola; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0005615; C:extracellular space; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; IDA:BHF-UCL. DR GO; GO:0045121; C:membrane raft; IDA:UniProtKB. DR GO; GO:0016604; C:nuclear body; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0043235; C:receptor complex; IDA:BHF-UCL. DR GO; GO:0070021; C:transforming growth factor beta ligand-receptor complex; IPI:ComplexPortal. DR GO; GO:0048185; F:activin binding; IBA:GO_Central. DR GO; GO:0016361; F:activin receptor activity, type I; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005539; F:glycosaminoglycan binding; IDA:BHF-UCL. DR GO; GO:0019209; F:kinase activator activity; IEA:Ensembl. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0060090; F:molecular adaptor activity; EXP:DisProt. DR GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:Reactome. DR GO; GO:0046332; F:SMAD binding; IDA:BHF-UCL. DR GO; GO:0050431; F:transforming growth factor beta binding; IDA:BHF-UCL. DR GO; GO:0005024; F:transforming growth factor beta receptor activity; IDA:BHF-UCL. DR GO; GO:0005026; F:transforming growth factor beta receptor activity, type II; IDA:UniProt. DR GO; GO:0004675; F:transmembrane receptor protein serine/threonine kinase activity; IDA:BHF-UCL. DR GO; GO:0034713; F:type I transforming growth factor beta receptor binding; IDA:BHF-UCL. DR GO; GO:0034714; F:type III transforming growth factor beta receptor binding; IDA:BHF-UCL. DR GO; GO:0032924; P:activin receptor signaling pathway; IBA:GO_Central. DR GO; GO:0035909; P:aorta morphogenesis; IMP:BHF-UCL. DR GO; GO:0003180; P:aortic valve morphogenesis; IMP:BHF-UCL. DR GO; GO:0006915; P:apoptotic process; IDA:UniProtKB. DR GO; GO:0048844; P:artery morphogenesis; IMP:BHF-UCL. DR GO; GO:0003181; P:atrioventricular valve morphogenesis; ISS:BHF-UCL. DR GO; GO:0001568; P:blood vessel development; TAS:BHF-UCL. DR GO; GO:0007420; P:brain development; ISS:BHF-UCL. DR GO; GO:0001569; P:branching involved in blood vessel morphogenesis; ISS:BHF-UCL. DR GO; GO:0060434; P:bronchus morphogenesis; IEA:Ensembl. DR GO; GO:0003214; P:cardiac left ventricle morphogenesis; ISS:BHF-UCL. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IBA:GO_Central. DR GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; ISS:BHF-UCL. DR GO; GO:0035162; P:embryonic hemopoiesis; ISS:BHF-UCL. DR GO; GO:0003274; P:endocardial cushion fusion; ISS:BHF-UCL. DR GO; GO:0001837; P:epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0007369; P:gastrulation; IEA:Ensembl. DR GO; GO:0003430; P:growth plate cartilage chondrocyte growth; IEA:Ensembl. DR GO; GO:0007507; P:heart development; ISS:BHF-UCL. DR GO; GO:0001947; P:heart looping; ISS:BHF-UCL. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:1905317; P:inferior endocardial cushion morphogenesis; ISS:BHF-UCL. DR GO; GO:0061520; P:Langerhans cell differentiation; IEA:Ensembl. DR GO; GO:0002088; P:lens development in camera-type eye; IEA:Ensembl. DR GO; GO:1990086; P:lens fiber cell apoptotic process; IEA:Ensembl. DR GO; GO:0060463; P:lung lobe morphogenesis; IEA:Ensembl. DR GO; GO:0060443; P:mammary gland morphogenesis; IEA:Ensembl. DR GO; GO:0003149; P:membranous septum morphogenesis; ISS:BHF-UCL. DR GO; GO:1990428; P:miRNA transport; ISS:BHF-UCL. DR GO; GO:0043011; P:myeloid dendritic cell differentiation; ISS:BHF-UCL. DR GO; GO:0007399; P:nervous system development; IBA:GO_Central. DR GO; GO:0007219; P:Notch signaling pathway; IEA:Ensembl. DR GO; GO:0003151; P:outflow tract morphogenesis; ISS:BHF-UCL. DR GO; GO:0003148; P:outflow tract septum morphogenesis; ISS:BHF-UCL. DR GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl. DR GO; GO:0002663; P:positive regulation of B cell tolerance induction; ISS:BHF-UCL. DR GO; GO:2000563; P:positive regulation of CD4-positive, alpha-beta T cell proliferation; IDA:BHF-UCL. DR GO; GO:0008284; P:positive regulation of cell population proliferation; TAS:ProtInc. DR GO; GO:0010634; P:positive regulation of epithelial cell migration; IEA:Ensembl. DR GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IDA:BHF-UCL. DR GO; GO:1905007; P:positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation; ISS:BHF-UCL. DR GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; ISS:BHF-UCL. DR GO; GO:0051138; P:positive regulation of NK T cell differentiation; ISS:BHF-UCL. DR GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IMP:BHF-UCL. DR GO; GO:0060391; P:positive regulation of SMAD protein signal transduction; IDA:BHF-UCL. DR GO; GO:0002666; P:positive regulation of T cell tolerance induction; ISS:BHF-UCL. DR GO; GO:0002651; P:positive regulation of tolerance induction to self antigen; ISS:BHF-UCL. DR GO; GO:0042127; P:regulation of cell population proliferation; ISS:BHF-UCL. DR GO; GO:0010468; P:regulation of gene expression; IEA:Ensembl. DR GO; GO:2000736; P:regulation of stem cell differentiation; IMP:BHF-UCL. DR GO; GO:0072091; P:regulation of stem cell proliferation; IEA:Ensembl. DR GO; GO:0070723; P:response to cholesterol; IDA:BHF-UCL. DR GO; GO:0009410; P:response to xenobiotic stimulus; IDA:BHF-UCL. DR GO; GO:0060021; P:roof of mouth development; IMP:BHF-UCL. DR GO; GO:0062009; P:secondary palate development; ISS:BHF-UCL. DR GO; GO:0060395; P:SMAD protein signal transduction; IEA:Ensembl. DR GO; GO:0007224; P:smoothened signaling pathway; IEA:Ensembl. DR GO; GO:0060440; P:trachea formation; IEA:Ensembl. DR GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0003186; P:tricuspid valve morphogenesis; ISS:BHF-UCL. DR GO; GO:0001570; P:vasculogenesis; ISS:BHF-UCL. DR GO; GO:0060412; P:ventricular septum morphogenesis; ISS:BHF-UCL. DR CDD; cd14055; STKc_TGFbR2_like; 1. DR CDD; cd23538; TFP_LU_ECD_TGFR2; 1. DR DisProt; DP01760; -. DR FunFam; 1.10.510.10:FF:000260; TGF-beta receptor type-2; 1. DR FunFam; 2.10.60.10:FF:000009; TGF-beta receptor type-2; 1. DR FunFam; 3.30.200.20:FF:000213; TGF-beta receptor type-2; 1. DR Gene3D; 2.10.60.10; CD59; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00414; -. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR045860; Snake_toxin-like_sf. DR InterPro; IPR000333; TGFB_receptor. DR InterPro; IPR017194; Transform_growth_fac-b_typ-2. DR InterPro; IPR015013; Transforming_GF_b_rcpt_2_ecto. DR PANTHER; PTHR23255:SF55; TGF-BETA RECEPTOR TYPE-2; 1. DR PANTHER; PTHR23255; TRANSFORMING GROWTH FACTOR-BETA RECEPTOR TYPE I AND II; 1. DR Pfam; PF08917; ecTbetaR2; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PIRSF; PIRSF037393; TGFRII; 1. DR PRINTS; PR00653; ACTIVIN2R. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF57302; Snake toxin-like; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Aortic aneurysm; Apoptosis; KW ATP-binding; Cell membrane; Craniosynostosis; Differentiation; KW Direct protein sequencing; Disease variant; Disulfide bond; Glycoprotein; KW Growth regulation; Hereditary nonpolyposis colorectal cancer; Kinase; KW Magnesium; Manganese; Membrane; Metal-binding; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome; KW Secreted; Serine/threonine-protein kinase; Signal; Transferase; KW Transmembrane; Transmembrane helix. FT SIGNAL 1..22 FT /evidence="ECO:0000269|PubMed:15340161" FT CHAIN 23..567 FT /note="TGF-beta receptor type-2" FT /id="PRO_0000024426" FT TOPO_DOM 23..166 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 167..187 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 188..567 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 244..544 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 439..567 FT /note="Sufficient for interaction with CLU" FT /evidence="ECO:0000269|PubMed:8555189" FT ACT_SITE 379 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 250..258 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 277 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 409 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62312" FT MOD_RES 548 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 553 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62312" FT CARBOHYD 70 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 94 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 154 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 51..84 FT /evidence="ECO:0000269|PubMed:11850637, FT ECO:0000269|PubMed:12121646, ECO:0000269|PubMed:12939140, FT ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738" FT DISULFID 54..71 FT /evidence="ECO:0000269|PubMed:11850637, FT ECO:0000269|PubMed:12121646, ECO:0000269|PubMed:12939140, FT ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738" FT DISULFID 61..67 FT /evidence="ECO:0000269|PubMed:11850637, FT ECO:0000269|PubMed:12121646, ECO:0000269|PubMed:12939140, FT ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738" FT DISULFID 77..101 FT /evidence="ECO:0000269|PubMed:11850637, FT ECO:0000269|PubMed:12121646, ECO:0000269|PubMed:12939140, FT ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738" FT DISULFID 121..136 FT /evidence="ECO:0000269|PubMed:11850637, FT ECO:0000269|PubMed:12121646, ECO:0000269|PubMed:12939140, FT ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738" FT DISULFID 138..143 FT /evidence="ECO:0000269|PubMed:11850637, FT ECO:0000269|PubMed:12121646, ECO:0000269|PubMed:12939140, FT ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738" FT VAR_SEQ 31..32 FT /note="SV -> SDVEMEAQKDEIICPSCNRTAHPLRHI (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:7959019" FT /id="VSP_012157" FT VAR_SEQ 68..80 FT /note="MSNCSITSICEKP -> FSKVHYEGKKKAW (in isoform 3)" FT /id="VSP_061513" FT VAR_SEQ 81..567 FT /note="Missing (in isoform 3)" FT /id="VSP_061514" FT VARIANT 36 FT /note="M -> V (in dbSNP:rs17025864)" FT /evidence="ECO:0000269|Ref.8" FT /id="VAR_020510" FT VARIANT 61 FT /note="C -> R (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041414" FT VARIANT 73 FT /note="I -> V (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036070" FT VARIANT 190 FT /note="R -> H (in LDS2; dbSNP:rs780542125)" FT /evidence="ECO:0000269|PubMed:19533785" FT /id="VAR_076167" FT VARIANT 191 FT /note="V -> I (in dbSNP:rs56105708)" FT /evidence="ECO:0000269|PubMed:12202987, FT ECO:0000269|PubMed:17344846" FT /id="VAR_017606" FT VARIANT 247 FT /note="D -> V (in LDS2; dbSNP:rs761231369)" FT /evidence="ECO:0000269|PubMed:19533785" FT /id="VAR_076168" FT VARIANT 306 FT /note="Q -> HE (in LDS2)" FT /evidence="ECO:0000269|PubMed:22113417" FT /id="VAR_066723" FT VARIANT 308 FT /note="L -> P (in LDS2; has a negative effect on TGF-beta FT signaling; dbSNP:rs28934568)" FT /evidence="ECO:0000269|PubMed:15235604, FT ECO:0000269|PubMed:20358619" FT /id="VAR_022351" FT VARIANT 315 FT /note="T -> M (in HNPCC6; dbSNP:rs34833812)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9590282" FT /id="VAR_008156" FT VARIANT 325 FT /note="T -> P (in LDS2; dbSNP:rs2125435431)" FT /evidence="ECO:0000269|PubMed:19533785" FT /id="VAR_076169" FT VARIANT 328 FT /note="H -> Y (in a lung neuroendocrine carcinoma sample; FT somatic mutation; dbSNP:rs2125435491)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041415" FT VARIANT 336 FT /note="Y -> N (in LDS2; dbSNP:rs104893812)" FT /evidence="ECO:0000269|PubMed:15731757" FT /id="VAR_022352" FT VARIANT 355 FT /note="A -> P (in LDS2; dbSNP:rs104893813)" FT /evidence="ECO:0000269|PubMed:15731757" FT /id="VAR_022353" FT VARIANT 357 FT /note="G -> R (in LDS2)" FT /evidence="ECO:0000269|PubMed:19533785" FT /id="VAR_076170" FT VARIANT 357 FT /note="G -> W (in LDS2; dbSNP:rs104893814)" FT /evidence="ECO:0000269|PubMed:15731757" FT /id="VAR_022354" FT VARIANT 373 FT /note="M -> I (in dbSNP:rs35719192)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041416" FT VARIANT 377 FT /note="H -> R (in LDS2; dbSNP:rs1553630274)" FT /evidence="ECO:0000269|PubMed:22113417" FT /id="VAR_066724" FT VARIANT 387 FT /note="V -> M (in a breast tumor; dbSNP:rs35766612)" FT /evidence="ECO:0000269|PubMed:11212236, FT ECO:0000269|PubMed:17344846" FT /id="VAR_022355" FT VARIANT 435 FT /note="N -> S (in a breast tumor; signaling of TGF-beta FT significantly inhibited)" FT /evidence="ECO:0000269|PubMed:11212236" FT /id="VAR_022356" FT VARIANT 439 FT /note="V -> A (in dbSNP:rs1050833)" FT /evidence="ECO:0000269|PubMed:1310899, FT ECO:0000269|PubMed:8812462, ECO:0000269|PubMed:8840968, FT ECO:0000269|PubMed:8973329" FT /id="VAR_028063" FT VARIANT 446 FT /note="D -> N (in LDS2; dbSNP:rs886039551)" FT /evidence="ECO:0000269|PubMed:16251899" FT /id="VAR_066725" FT VARIANT 447 FT /note="V -> A (in a breast tumor; signaling of TGF-beta FT significantly inhibited)" FT /evidence="ECO:0000269|PubMed:11212236" FT /id="VAR_022357" FT VARIANT 449 FT /note="S -> F (in LDS2; has a negative effect on TGF-beta FT signaling; dbSNP:rs104893807)" FT /evidence="ECO:0000269|PubMed:15235604, FT ECO:0000269|PubMed:22113417" FT /id="VAR_022358" FT VARIANT 452 FT /note="L -> M (in a breast tumor; signaling of TGF-beta FT significantly inhibited)" FT /evidence="ECO:0000269|PubMed:11212236" FT /id="VAR_022359" FT VARIANT 457 FT /note="M -> K (in LDS2)" FT /evidence="ECO:0000269|PubMed:20101701" FT /id="VAR_066726" FT VARIANT 460 FT /note="R -> C (in LDS2; dbSNP:rs104893811)" FT /evidence="ECO:0000269|PubMed:16027248" FT /id="VAR_029760" FT VARIANT 460 FT /note="R -> H (in LDS2; dbSNP:rs104893816)" FT /evidence="ECO:0000269|PubMed:16027248" FT /id="VAR_029761" FT VARIANT 490 FT /note="N -> S (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1699660823)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041417" FT VARIANT 509 FT /note="G -> V (in LDS2; dbSNP:rs863223853)" FT /evidence="ECO:0000269|PubMed:21949523" FT /id="VAR_066727" FT VARIANT 510 FT /note="I -> F (in LDS2; dbSNP:rs2125455070)" FT /evidence="ECO:0000269|PubMed:21949523" FT /id="VAR_066728" FT VARIANT 510 FT /note="I -> S (in LDS2)" FT /evidence="ECO:0000269|PubMed:19883511" FT /id="VAR_066729" FT VARIANT 514 FT /note="C -> R (in LDS2; dbSNP:rs193922664)" FT /evidence="ECO:0000269|PubMed:22113417" FT /id="VAR_066730" FT VARIANT 521 FT /note="W -> R (in LDS2; dbSNP:rs1575166666)" FT /evidence="ECO:0000269|PubMed:20358619" FT /id="VAR_066731" FT VARIANT 526 FT /note="E -> Q (in esophageal cancer; dbSNP:rs121918714)" FT /evidence="ECO:0000269|PubMed:10789724" FT /id="VAR_015816" FT VARIANT 528 FT /note="R -> C (in LDS2; dbSNP:rs104893810)" FT /evidence="ECO:0000269|PubMed:15731757" FT /id="VAR_022360" FT VARIANT 528 FT /note="R -> H (in LDS2; dbSNP:rs104893815)" FT /evidence="ECO:0000269|PubMed:15731757, FT ECO:0000269|PubMed:16959974" FT /id="VAR_022361" FT VARIANT 530 FT /note="T -> I (in LDS2; dbSNP:rs1699708963)" FT /evidence="ECO:0000269|PubMed:19533785" FT /id="VAR_076171" FT VARIANT 537 FT /note="R -> C (in LDS2; has a negative effect on TGF-beta FT signaling; dbSNP:rs104893809)" FT /evidence="ECO:0000269|PubMed:15235604" FT /id="VAR_022362" FT MUTAGEN 277 FT /note="K->R: Abolishes kinase activity, TGF-beta signaling FT and interaction with DAXX." FT /evidence="ECO:0000269|PubMed:11483955" FT CONFLICT 381 FT /note="K -> N (in Ref. 6; BAA09332)" FT /evidence="ECO:0000305" FT STRAND 40..45 FT /evidence="ECO:0007829|PDB:1PLO" FT STRAND 50..52 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 55..58 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 65..68 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 74..76 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 78..81 FT /evidence="ECO:0007829|PDB:1PLO" FT STRAND 83..90 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 95..102 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 104..106 FT /evidence="ECO:0007829|PDB:5TY4" FT STRAND 108..110 FT /evidence="ECO:0007829|PDB:2PJY" FT TURN 114..117 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 119..122 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 124..126 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 131..138 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 140..142 FT /evidence="ECO:0007829|PDB:1PLO" FT HELIX 143..145 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 146..148 FT /evidence="ECO:0007829|PDB:1M9Z" FT HELIX 151..153 FT /evidence="ECO:0007829|PDB:9E9G" FT STRAND 244..252 FT /evidence="ECO:0007829|PDB:5QIN" FT STRAND 257..263 FT /evidence="ECO:0007829|PDB:5QIN" FT STRAND 267..269 FT /evidence="ECO:0007829|PDB:7DV6" FT STRAND 272..280 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 281..283 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 284..294 FT /evidence="ECO:0007829|PDB:5QIN" FT TURN 297..299 FT /evidence="ECO:0007829|PDB:5QIN" FT STRAND 307..315 FT /evidence="ECO:0007829|PDB:5QIN" FT STRAND 318..326 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 333..339 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 344..362 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 382..384 FT /evidence="ECO:0007829|PDB:5QIN" FT STRAND 385..387 FT /evidence="ECO:0007829|PDB:5QIN" FT STRAND 393..395 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 410..413 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 422..424 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 427..430 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 440..459 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 462..464 FT /evidence="ECO:0007829|PDB:5QIN" FT TURN 473..477 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 484..491 FT /evidence="ECO:0007829|PDB:5QIN" FT TURN 492..494 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 502..506 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 508..520 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 525..527 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 531..539 FT /evidence="ECO:0007829|PDB:5QIN" SQ SEQUENCE 567 AA; 64568 MW; C541DA751FFBDBEB CRC64; MGRGLLRGLW PLHIVLWTRI ASTIPPHVQK SVNNDMIVTD NNGAVKFPQL CKFCDVRFST CDNQKSCMSN CSITSICEKP QEVCVAVWRK NDENITLETV CHDPKLPYHD FILEDAASPK CIMKEKKKPG ETFFMCSCSS DECNDNIIFS EEYNTSNPDL LLVIFQVTGI SLLPPLGVAI SVIIIFYCYR VNRQQKLSST WETGKTRKLM EFSEHCAIIL EDDRSDISST CANNINHNTE LLPIELDTLV GKGRFAEVYK AKLKQNTSEQ FETVAVKIFP YEEYASWKTE KDIFSDINLK HENILQFLTA EERKTELGKQ YWLITAFHAK GNLQEYLTRH VISWEDLRKL GSSLARGIAH LHSDHTPCGR PKMPIVHRDL KSSNILVKND LTCCLCDFGL SLRLDPTLSV DDLANSGQVG TARYMAPEVL ESRMNLENVE SFKQTDVYSM ALVLWEMTSR CNAVGEVKDY EPPFGSKVRE HPCVESMKDN VLRDRGRPEI PSFWLNHQGI QMVCETLTEC WDHDPEARLT AQCVAERFSE LEHLDRLSGR SCSEEKIPED GSLNTTK // ID TINAL_HUMAN Reviewed; 467 AA. AC Q9GZM7; A8K9Q5; B4DPK6; D3DPN8; Q8TEJ9; Q8WZ23; Q96GZ4; Q96JW3; DT 15-MAR-2005, integrated into UniProtKB/Swiss-Prot. DT 01-MAR-2001, sequence version 1. DT 28-JAN-2026, entry version 190. DE RecName: Full=Tubulointerstitial nephritis antigen-like; DE AltName: Full=Glucocorticoid-inducible protein 5; DE AltName: Full=Oxidized LDL-responsive gene 2 protein; DE Short=OLRG-2; DE AltName: Full=Tubulointerstitial nephritis antigen-related protein; DE Short=TIN Ag-related protein; DE Short=TIN-Ag-RP; DE Flags: Precursor; GN Name=TINAGL1; Synonyms=GIS5, LCN7, OLRG2, TINAGL; GN ORFNames=PP6614, PSEC0088, UNQ204/PRO230; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND SUBCELLULAR LOCATION. RC TISSUE=Muscle; RX PubMed=10799322; DOI=10.1006/bbrc.2000.2639; RA Broemme N.C., Wex T., Wex H., Levy B., Lipyansky A., Broemme D.; RT "Cloning, characterization, and expression of the human TIN-ag-RP gene RT encoding a novel putative extracellular matrix protein."; RL Biochem. Biophys. Res. Commun. 271:474-480(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 22-27, TISSUE RP SPECIFICITY, GLYCOSYLATION, AND SUBCELLULAR LOCATION. RC TISSUE=Muscle; RX PubMed=11170462; DOI=10.1021/bi002266o; RA Wex T., Lipyansky A., Broemme N.C., Wex H., Guan X.Q., Broemme D.; RT "TIN-ag-RP, a novel catalytically inactive cathepsin B-related protein with RT EGF domains, is predominantly expressed in vascular smooth muscle cells."; RL Biochemistry 40:1350-1357(2001). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Zhang K.M., Chen B.S.; RT "Identification of oxidized-LDL responsive gene 2 (OLRG-2), encoding a RT novel extracellular matrix protein in vascular endothelial cells."; RL Submitted (NOV-1999) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1). RA Yoshida H., Takaishi K., Harada M., Nagasaka T., Tsurufuji S., RA Taniguchi M.; RT "Identification of a novel glucocorticoid-inducible cDNA partially RT homologous to tubulointerstitial nephritis antigen."; RL Submitted (NOV-2000) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Placenta; RA Jikuya H., Takano J., Nomura N., Kikuno R., Nagase T., Ohara O.; RT "The nucleotide sequence of a long cDNA clone isolated from human spleen."; RL Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=12975309; DOI=10.1101/gr.1293003; RA Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J., RA Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P., RA Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A., RA Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D., RA Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L., RA Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C., RA Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J., RA Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.; RT "The secreted protein discovery initiative (SPDI), a large-scale effort to RT identify novel human secreted and transmembrane proteins: a bioinformatics RT assessment."; RL Genome Res. 13:2265-2270(2003). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RX PubMed=15498874; DOI=10.1073/pnas.0404089101; RA Wan D., Gong Y., Qin W., Zhang P., Li J., Wei L., Zhou X., Li H., Qiu X., RA Zhong F., He L., Yu J., Yao G., Jiang H., Qian L., Yu Y., Shu H., Chen X., RA Xu H., Guo M., Pan Z., Chen Y., Ge C., Yang S., Gu J.; RT "Large-scale cDNA transfection screening for genes related to cancer RT development and progression."; RL Proc. Natl. Acad. Sci. U.S.A. 101:15724-15729(2004). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3). RC TISSUE=Kidney, Placenta, and Trachea; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Placenta; RX PubMed=16303743; DOI=10.1093/dnares/12.2.117; RA Otsuki T., Ota T., Nishikawa T., Hayashi K., Suzuki Y., Yamamoto J., RA Wakamatsu A., Kimura K., Sakamoto K., Hatano N., Kawai Y., Ishii S., RA Saito K., Kojima S., Sugiyama T., Ono T., Okano K., Yoshikawa Y., RA Aotsuka S., Sasaki N., Hattori A., Okumura K., Nagai K., Sugano S., RA Isogai T.; RT "Signal sequence and keyword trap in silico for selection of full-length RT human cDNAs encoding secretion or membrane proteins from oligo-capped cDNA RT libraries."; RL DNA Res. 12:117-126(2005). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Colon, and Pancreas; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [13] RP PROTEIN SEQUENCE OF 22-36. RX PubMed=15340161; DOI=10.1110/ps.04682504; RA Zhang Z., Henzel W.J.; RT "Signal peptide prediction based on analysis of experimentally verified RT cleavage sites."; RL Protein Sci. 13:2819-2824(2004). RN [14] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-78 AND ASN-161. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). CC -!- FUNCTION: May be implicated in the adrenocortical zonation and in CC mechanisms for repressing the CYP11B1 gene expression in adrenocortical CC cells. This is a non catalytic peptidase C1 family protein (By CC similarity). {ECO:0000250}. CC -!- INTERACTION: CC Q9GZM7; O95429: BAG4; NbExp=3; IntAct=EBI-715869, EBI-2949658; CC Q9GZM7; P59991: KRTAP12-2; NbExp=3; IntAct=EBI-715869, EBI-10176379; CC Q9GZM7; Q99697-2: PITX2; NbExp=3; IntAct=EBI-715869, EBI-12138495; CC Q9GZM7; O75360: PROP1; NbExp=3; IntAct=EBI-715869, EBI-9027467; CC Q9GZM7; Q15645: TRIP13; NbExp=6; IntAct=EBI-715869, EBI-358993; CC Q9GZM7-3; P59991: KRTAP12-2; NbExp=3; IntAct=EBI-10303636, EBI-10176379; CC Q9GZM7-3; Q9BYR5: KRTAP4-2; NbExp=3; IntAct=EBI-10303636, EBI-10172511; CC Q9GZM7-3; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-10303636, EBI-945833; CC Q9GZM7-3; Q93062: RBPMS; NbExp=3; IntAct=EBI-10303636, EBI-740322; CC Q9GZM7-3; Q15645: TRIP13; NbExp=3; IntAct=EBI-10303636, EBI-358993; CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:10799322, CC ECO:0000269|PubMed:11170462}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q9GZM7-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9GZM7-2; Sequence=VSP_013094, VSP_013095, VSP_013096, CC VSP_013097, VSP_013098; CC Name=3; CC IsoId=Q9GZM7-3; Sequence=VSP_043712; CC -!- TISSUE SPECIFICITY: Highly expressed in aorta, heart, placenta, kidney CC and a colorectal adenocarcinoma cell line. Moderately expressed in CC skeletal muscle, pancreas, lung, lymph nodes, adrenal gland, bone CC marrow and thyroid. Weakly expressed in colon, small intestine, ovary, CC spleen, testis and prostate. Predominantly found in vascular smooth CC muscle cells, but also in cardiac and skeletal muscle cells as well as CC kidney. {ECO:0000269|PubMed:11170462}. CC -!- PTM: Glycosylated. {ECO:0000269|PubMed:11170462, CC ECO:0000269|PubMed:19159218}. CC -!- SIMILARITY: Belongs to the peptidase C1 family. {ECO:0000255|PROSITE- CC ProRule:PRU10089}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH09048.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC Sequence=BAB55403.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF236155; AAG40154.1; -; Genomic_DNA. DR EMBL; AF236151; AAG40154.1; JOINED; Genomic_DNA. DR EMBL; AF236152; AAG40154.1; JOINED; Genomic_DNA. DR EMBL; AF236153; AAG40154.1; JOINED; Genomic_DNA. DR EMBL; AF236154; AAG40154.1; JOINED; Genomic_DNA. DR EMBL; AF236150; AAG38876.1; -; mRNA. DR EMBL; AF205436; AAG33699.1; -; mRNA. DR EMBL; AB050716; BAB18636.1; -; mRNA. DR EMBL; AB050719; BAB18727.1; -; Genomic_DNA. DR EMBL; AK074124; BAB84950.1; -; mRNA. DR EMBL; AY358421; AAQ88787.1; -; mRNA. DR EMBL; AF289569; AAL55753.1; -; mRNA. DR EMBL; AK027839; BAB55403.1; ALT_INIT; mRNA. DR EMBL; AK292770; BAF85459.1; -; mRNA. DR EMBL; AK298382; BAG60618.1; -; mRNA. DR EMBL; AK075398; BAC11596.1; -; mRNA. DR EMBL; AC114488; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471059; EAX07604.1; -; Genomic_DNA. DR EMBL; CH471059; EAX07605.1; -; Genomic_DNA. DR EMBL; CH471059; EAX07606.1; -; Genomic_DNA. DR EMBL; BC009048; AAH09048.1; ALT_INIT; mRNA. DR EMBL; BC064633; AAH64633.1; -; mRNA. DR CCDS; CCDS343.1; -. [Q9GZM7-1] DR CCDS; CCDS55586.1; -. [Q9GZM7-3] DR RefSeq; NP_001191343.1; NM_001204414.2. [Q9GZM7-3] DR RefSeq; NP_001191344.1; NM_001204415.1. DR RefSeq; NP_071447.1; NM_022164.3. [Q9GZM7-1] DR AlphaFoldDB; Q9GZM7; -. DR SMR; Q9GZM7; -. DR BioGRID; 122078; 73. DR FunCoup; Q9GZM7; 214. DR IntAct; Q9GZM7; 79. DR MINT; Q9GZM7; -. DR STRING; 9606.ENSP00000271064; -. DR MEROPS; C01.975; -. DR GlyConnect; 1864; 7 N-Linked glycans (2 sites). DR GlyCosmos; Q9GZM7; 2 sites, 7 glycans. DR GlyGen; Q9GZM7; 3 sites, 100 N-linked glycans (2 sites), 1 O-linked glycan (1 site). DR iPTMnet; Q9GZM7; -. DR PhosphoSitePlus; Q9GZM7; -. DR SwissPalm; Q9GZM7; -. DR BioMuta; TINAGL1; -. DR DMDM; 61213628; -. DR jPOST; Q9GZM7; -. DR MassIVE; Q9GZM7; -. DR PaxDb; 9606-ENSP00000271064; -. DR PeptideAtlas; Q9GZM7; -. DR ProteomicsDB; 80089; -. [Q9GZM7-1] DR ProteomicsDB; 80090; -. [Q9GZM7-2] DR ProteomicsDB; 80091; -. [Q9GZM7-3] DR Antibodypedia; 31121; 191 antibodies from 26 providers. DR DNASU; 64129; -. DR Ensembl; ENST00000271064.12; ENSP00000271064.7; ENSG00000142910.17. [Q9GZM7-1] DR Ensembl; ENST00000457433.6; ENSP00000395137.2; ENSG00000142910.17. [Q9GZM7-3] DR GeneID; 64129; -. DR KEGG; hsa:64129; -. DR MANE-Select; ENST00000271064.12; ENSP00000271064.7; NM_022164.3; NP_071447.1. DR UCSC; uc001bta.4; human. [Q9GZM7-1] DR AGR; HGNC:19168; -. DR ClinPGx; PA38810; -. DR CTD; 64129; -. DR DisGeNET; 64129; -. DR GeneCards; TINAGL1; -. DR HGNC; HGNC:19168; TINAGL1. DR HPA; ENSG00000142910; Low tissue specificity. DR MIM; 616064; gene. DR OpenTargets; ENSG00000142910; -. DR VEuPathDB; HostDB:ENSG00000142910; -. DR eggNOG; KOG1544; Eukaryota. DR GeneTree; ENSGT00940000160023; -. DR InParanoid; Q9GZM7; -. DR OMA; AEIYHSG; -. DR OrthoDB; 190265at2759; -. DR PAN-GO; Q9GZM7; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q9GZM7; -. DR PathwayCommons; Q9GZM7; -. DR SignaLink; Q9GZM7; -. DR Agora; ENSG00000142910; -. DR BioGRID-ORCS; 64129; 14 hits in 1151 CRISPR screens. DR ChiTaRS; TINAGL1; human. DR GeneWiki; TINAGL1; -. DR GenomeRNAi; 64129; -. DR Pharos; Q9GZM7; Tbio. DR PRO; PR:Q9GZM7; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q9GZM7; protein. DR Bgee; ENSG00000142910; Expressed in metanephros cortex and 138 other cell types or tissues. DR ExpressionAtlas; Q9GZM7; baseline and differential. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0031012; C:extracellular matrix; HDA:BHF-UCL. DR GO; GO:0005576; C:extracellular region; NAS:UniProtKB. DR GO; GO:0005615; C:extracellular space; IBA:GO_Central. DR GO; GO:0005764; C:lysosome; IBA:GO_Central. DR GO; GO:0005201; F:extracellular matrix structural constituent; NAS:UniProtKB. DR GO; GO:0043236; F:laminin binding; IEA:Ensembl. DR GO; GO:0016197; P:endosomal transport; TAS:UniProtKB. DR CDD; cd02620; Peptidase_C1A_CathepsinB; 1. DR FunFam; 3.90.70.10:FF:000037; Tubulointerstitial nephritis antigen-like 1; 1. DR Gene3D; 3.90.70.10; Cysteine proteinases; 1. DR InterPro; IPR038765; Papain-like_cys_pep_sf. DR InterPro; IPR025660; Pept_his_AS. DR InterPro; IPR013128; Peptidase_C1A. DR InterPro; IPR000668; Peptidase_C1A_C. DR InterPro; IPR001212; Somatomedin_B_dom. DR PANTHER; PTHR12411; CYSTEINE PROTEASE FAMILY C1-RELATED; 1. DR Pfam; PF00112; Peptidase_C1; 1. DR SMART; SM00645; Pept_C1; 1. DR SUPFAM; SSF54001; Cysteine proteinases; 1. DR PROSITE; PS00524; SMB_1; 1. DR PROSITE; PS50958; SMB_2; 1. DR PROSITE; PS00639; THIOL_PROTEASE_HIS; 1. PE 1: Evidence at protein level; KW Alternative splicing; Direct protein sequencing; Disulfide bond; KW Glycoprotein; Proteomics identification; Reference proteome; Secreted; KW Signal. FT SIGNAL 1..21 FT /evidence="ECO:0000269|PubMed:11170462, FT ECO:0000269|PubMed:15340161" FT CHAIN 22..467 FT /note="Tubulointerstitial nephritis antigen-like" FT /id="PRO_0000026482" FT DOMAIN 50..98 FT /note="SMB" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00350" FT CARBOHYD 78 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19159218" FT CARBOHYD 161 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19159218" FT DISULFID 54..73 FT /note="Alternate" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00350" FT DISULFID 71..85 FT /note="Alternate" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00350" FT DISULFID 71..73 FT /note="Alternate" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00350" FT DISULFID 77..84 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00350" FT DISULFID 85..92 FT /note="Alternate" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00350" FT VAR_SEQ 1..134 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15498874, ECO:0000303|Ref.5" FT /id="VSP_013094" FT VAR_SEQ 126..156 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_043712" FT VAR_SEQ 135..194 FT /note="CDQEPCLVDPDMIKAINQGNYGWQAGNHSAFWGMTLDEGIRYRLGTIRPSSS FT VMNMHEIY -> MVLGSSTQVKIGGSWNPAAAGGLKIKLQKALDLVALQCQWAPEGQAR FT AEQEADRATFILQ (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15498874, ECO:0000303|Ref.5" FT /id="VSP_013095" FT VAR_SEQ 286 FT /note="G -> GYAATGDVGREEGKELRGHGLGHDALSLSAFAPSCCLCR (in FT isoform 2)" FT /evidence="ECO:0000303|PubMed:15498874, ECO:0000303|Ref.5" FT /id="VSP_013096" FT VAR_SEQ 365..381 FT /note="ALMEVHEDFFLYKGGIY -> GKPPYPAPWFQKLVPA (in isoform FT 2)" FT /evidence="ECO:0000303|PubMed:15498874, ECO:0000303|Ref.5" FT /id="VSP_013097" FT VAR_SEQ 382..467 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15498874, ECO:0000303|Ref.5" FT /id="VSP_013098" FT VARIANT 69 FT /note="A -> S (in dbSNP:rs17497479)" FT /id="VAR_051514" FT CONFLICT 333 FT /note="N -> Y (in Ref. 7; AAL55753)" FT /evidence="ECO:0000305" FT CONFLICT 377 FT /note="K -> E (in Ref. 8; BAB55403)" FT /evidence="ECO:0000305" SQ SEQUENCE 467 AA; 52387 MW; E9D72220E3E7B7D5 CRC64; MWRCPLGLLL LLPLAGHLAL GAQQGRGRRE LAPGLHLRGI RDAGGRYCQE QDLCCRGRAD DCALPYLGAI CYCDLFCNRT VSDCCPDFWD FCLGVPPPFP PIQGCMHGGR IYPVLGTYWD NCNRCTCQEN RQWQCDQEPC LVDPDMIKAI NQGNYGWQAG NHSAFWGMTL DEGIRYRLGT IRPSSSVMNM HEIYTVLNPG EVLPTAFEAS EKWPNLIHEP LDQGNCAGSW AFSTAAVASD RVSIHSLGHM TPVLSPQNLL SCDTHQQQGC RGGRLDGAWW FLRRRGVVSD HCYPFSGRER DEAGPAPPCM MHSRAMGRGK RQATAHCPNS YVNNNDIYQV TPVYRLGSND KEIMKELMEN GPVQALMEVH EDFFLYKGGI YSHTPVSLGR PERYRRHGTH SVKITGWGEE TLPDGRTLKY WTAANSWGPA WGERGHFRIV RGVNECDIES FVLGVWGRVG MEDMGHH // ID TITIN_HUMAN Reviewed; 34350 AA. AC Q8WZ42; A0A0A0MTS7; A6NKB1; C9JQJ2; E7EQE6; E7ET18; K7ENY1; Q10465; Q10466; AC Q15598; Q2XUS3; Q32Q60; Q4U1Z6; Q4ZG20; Q6NSG0; Q6PDB1; Q6PJP0; Q7KYM2; AC Q7KYN4; Q7KYN5; Q7LDM3; Q7Z2X3; Q8TCG8; Q8WZ51; Q8WZ52; Q8WZ53; Q8WZB3; AC Q92761; Q92762; Q9UD97; Q9UP84; Q9Y6L9; DT 13-JUN-2006, integrated into UniProtKB/Swiss-Prot. DT 18-APR-2012, sequence version 4. DT 28-JAN-2026, entry version 220. DE RecName: Full=Titin; DE EC=2.7.11.1; DE AltName: Full=Connectin; DE AltName: Full=Rhabdomyosarcoma antigen MU-RMS-40.14; GN Name=TTN; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), NUCLEOTIDE SEQUENCE [MRNA] OF RP 3336-12202 (ISOFORM 4), AND VARIANTS ILE-498; GLU-1201; MET-3261; ASN-3419; RP SER-3491; GLU-12679; ILE-19762; ILE-20718; ASN-23807; MET-24980 AND RP THR-27755. RC TISSUE=Skeletal muscle; RX PubMed=7569978; DOI=10.1126/science.270.5234.293; RA Labeit S., Kolmerer B.; RT "Titins, giant proteins in charge of muscle ultrastructure and RT elasticity."; RL Science 270:293-296(1995). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, AND VARIANTS RP LEU-1295; GLN-1572; ILE-2610; ASN-2831; SER-3491; PRO-4215; PHE-4283 AND RP ARG-12383. RX PubMed=10850961; DOI=10.1161/01.res.86.11.1114; RA Freiburg A., Trombitas K., Hell W., Cazorla O., Fougerousse F., Centner T., RA Kolmerer B., Witt C., Beckmann J.S., Gregorio C.C., Granzier H., Labeit S.; RT "Series of exon-skipping events in the elastic spring region of titin as RT the structural basis for myofibrillar elastic diversity."; RL Circ. Res. 86:1114-1121(2000). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, TISSUE RP SPECIFICITY, INTERACTION WITH OBSCN, AND VARIANTS LEU-1295; GLN-1572; RP ILE-2610; ASN-2831; SER-3491; PRO-4215 AND PHE-4283. RX PubMed=11717165; DOI=10.1161/hh2301.100981; RA Bang M.-L., Centner T., Fornoff F., Geach A.J., Gotthardt M., McNabb M., RA Witt C.C., Labeit D., Gregorio C.C., Granzier H., Labeit S.; RT "The complete gene sequence of titin, expression of an unusual ~700 kDa RT titin isoform and its interaction with obscurin identify a novel Z-line to RT I-band linking system."; RL Circ. Res. 89:1065-1072(2001). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-626 AND 34071-34350 (ISOFORM RP 3). RC TISSUE=Muscle, and Skeletal muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 405-709 (ISOFORMS 1 AND 2). RC TISSUE=Heart muscle; RX PubMed=8937992; DOI=10.1242/jcs.109.11.2747; RA Gautel M., Goulding D., Bullard B., Weber K., Furst D.O.; RT "The central Z-disk region of titin is assembled from a novel repeat in RT variable copy numbers."; RL J. Cell Sci. 109:2747-2754(1996). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 2023-2060, AND TISSUE SPECIFICITY. RC TISSUE=Heart muscle; RX PubMed=7819249; DOI=10.1021/bi00002a021; RA Musco G., Tziatzos C., Schuck P., Pastore A.; RT "Dissecting titin into its structural motifs: identification of an alpha RT helix near the N-terminus."; RL Biochemistry 34:553-561(1995). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 3455-4473, AND VARIANTS PRO-4215 AND RP PHE-4283. RX PubMed=10051295; DOI=10.1161/01.cir.99.8.1022; RA Siu B.L., Niimura H., Osborne J.A., Fatkin D., MacRae C., Solomon S., RA Benson D.W., Seidman J.G., Seidman C.E.; RT "Familial dilated cardiomyopathy locus maps to chromosome 2q31."; RL Circulation 99:1022-1026(1999). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 9806-12017 (ISOFORM 5). RC TISSUE=Heart ventricle; RX PubMed=12785098; DOI=10.1023/a:1023410523184; RA Greaser M.L., Berri M., Warren C.M., Mozdziak P.E.; RT "Species variations in cDNA sequence and exon splicing patterns in the RT extensible I-band region of cardiac titin: relation to passive tension."; RL J. Muscle Res. Cell Motil. 23:473-482(2002). RN [10] RP PROTEIN SEQUENCE OF 11773-11783; 17908-17931; 18656-18669; 26545-26553; RP 28758-28774 AND 32920-32928, AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Fetal brain cortex; RA Lubec G., Chen W.-Q., Sun Y.; RL Submitted (DEC-2008) to UniProtKB. RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 12947-13797. RC TISSUE=Embryonic rhabdomyosarcoma; RA Behrends U., Gotz C., Mautner J.; RT "Serological identification of rhabdomyosarcoma antigens."; RL Submitted (OCT-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE OF 14257-14543. RX PubMed=8351016; DOI=10.1212/wnl.43.8.1581; RA Gautel M., Lakey A., Barlow D.P., Holmes Z., Scales S., Leonard K., RA Labeit S., Mygland A., Gilhus N.E., Aarli J.A.; RT "Titin antibodies in myasthenia gravis: identification of a major RT immunogenic region of titin."; RL Neurology 43:1581-1585(1993). RN [13] RP NUCLEOTIDE SEQUENCE [MRNA] OF 21021-22120, AND NUCLEOTIDE SEQUENCE [GENOMIC RP DNA] OF 23754-24284. RX PubMed=1582406; DOI=10.1002/j.1460-2075.1992.tb05222.x; RA Labeit S., Gautel M., Lakey A., Trinick J.; RT "Towards a molecular understanding of titin."; RL EMBO J. 11:1711-1716(1992). RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] OF 29701-34350, AND PHOSPHORYLATION. RX PubMed=8404852; DOI=10.1002/j.1460-2075.1993.tb06061.x; RA Gautel M., Leonard K., Labeit S.; RT "Phosphorylation of KSF motifs in the C-terminal region of titin in RT differentiating myoblasts."; RL EMBO J. 12:3827-3834(1993). RN [15] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 33119-34350. RC TISSUE=Skeletal muscle; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [16] RP INTERACTION WITH TCAP. RX PubMed=9645487; DOI=10.1016/s0014-5793(98)00501-8; RA Mues A., van der Ven P.F.M., Young P., Furst D.O., Gautel M.; RT "Two immunoglobulin-like domains of the Z-disc portion of titin interact in RT a conformation-dependent way with telethonin."; RL FEBS Lett. 428:111-114(1998). RN [17] RP INTERACTION WITH NEB. RX PubMed=12482578; DOI=10.1016/s0014-5793(02)03655-4; RA Ma K., Wang K.; RT "Interaction of nebulin SH3 domain with titin PEVK and myopalladin: RT implications for the signaling and assembly role of titin and nebulin."; RL FEBS Lett. 532:273-278(2002). RN [18] RP INTERACTION WITH FHL2. RX PubMed=12432079; DOI=10.1242/jcs.00181; RA Lange S., Auerbach D., McLoughlin P., Perriard E., Schafer B.W., RA Perriard J.-C., Ehler E.; RT "Subcellular targeting of metabolic enzymes to titin in heart muscle may be RT mediated by DRAL/FHL-2."; RL J. Cell Sci. 115:4925-4936(2002). RN [19] RP INTERACTION WITH ANK1. RX PubMed=12444090; DOI=10.1074/jbc.m209012200; RA Kontrogianni-Konstantopoulos A., Bloch R.J.; RT "The hydrophilic domain of small ankyrin-1 interacts with the two N- RT terminal immunoglobulin domains of titin."; RL J. Biol. Chem. 278:3985-3991(2003). RN [20] RP INTERACTION WITH ANKRD1; ANKRD2; ANKRD23 AND CAPN3. RX PubMed=14583192; DOI=10.1016/j.jmb.2003.09.012; RA Miller M.K., Bang M.-L., Witt C.C., Labeit D., Trombitas C., Watanabe K., RA Granzier H., McElhinny A.S., Gregorio C.C., Labeit S.; RT "The muscle ankyrin repeat proteins: CARP, ankrd2/Arpp and DARP as a family RT of titin filament-based stress response molecules."; RL J. Mol. Biol. 333:951-964(2003). RN [21] RP INTERACTION WITH CRYAB. RX PubMed=14676215; DOI=10.1074/jbc.m307473200; RA Bullard B., Ferguson C., Minajeva A., Leake M.C., Gautel M., Labeit D., RA Ding L., Labeit S., Horwitz J., Leonard K.R., Linke W.A.; RT "Association of the chaperone alphaB-crystallin with titin in heart RT muscle."; RL J. Biol. Chem. 279:7917-7924(2004). RN [22] RP INTERACTION WITH TRIM63 AND TRIM55. RX PubMed=15967462; DOI=10.1016/j.jmb.2005.05.021; RA Witt S.H., Granzier H., Witt C.C., Labeit S.; RT "MURF-1 and MURF-2 target a specific subset of myofibrillar proteins RT redundantly: towards understanding MURF-dependent muscle ubiquitination."; RL J. Mol. Biol. 350:713-722(2005). RN [23] RP INTERACTION WITH LAMIN, AND SUBCELLULAR LOCATION. RX PubMed=16410549; DOI=10.1242/jcs.02728; RA Zastrow M.S., Flaherty D.B., Benian G.M., Wilson K.L.; RT "Nuclear titin interacts with A- and B-type lamins in vitro and in vivo."; RL J. Cell Sci. 119:239-249(2006). RN [24] RP REVIEW. RX PubMed=16537787; DOI=10.1152/ajpheart.00816.2005; RA Hoshijima M.; RT "Mechanical stress-strain sensors embedded in cardiac cytoskeleton: Z disk, RT titin, and associated structures."; RL Am. J. Physiol. 290:H1313-H1325(2006). RN [25] RP INTERACTION WITH CMYA5. RX PubMed=20634290; DOI=10.1074/jbc.m110.108720; RA Sarparanta J., Blandin G., Charton K., Vihola A., Marchand S., Milic A., RA Hackman P., Ehler E., Richard I., Udd B.; RT "Interactions with M-band titin and calpain 3 link myospryn (CMYA5) to RT tibial and limb-girdle muscular dystrophies."; RL J. Biol. Chem. 285:30304-30315(2010). RN [26] RP STRUCTURE BY NMR OF 33483-33579. RX PubMed=7613868; DOI=10.1016/s0969-2126(01)00170-8; RA Pfuhl M., Pastore A.; RT "Tertiary structure of an immunoglobulin-like domain from the giant muscle RT protein titin: a new member of the I set."; RL Structure 3:391-401(1995). RN [27] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 32172-32489, FUNCTION, ACTIVITY RP REGULATION, INTERACTION WITH CALM, PHOSPHORYLATION AT TYR-32341, AND RP MUTAGENESIS OF LYS-32207 AND TYR-32341. RX PubMed=9804419; DOI=10.1038/27603; RA Mayans O., van der Ven P.F.M., Wilm M., Mues A., Young P., Furst D.O., RA Wilmanns M., Gautel M.; RT "Structural basis for activation of the titin kinase domain during RT myofibrillogenesis."; RL Nature 395:863-869(1998). RN [28] RP STRUCTURE BY NMR OF 22283-22385. RX PubMed=9782056; DOI=10.1016/s0969-2126(98)00129-4; RA Goll C.M., Pastore A., Nilges M.; RT "The three-dimensional structure of a type I module from titin: a prototype RT of intracellular fibronectin type III domains."; RL Structure 6:1291-1302(1998). RN [29] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 2073-2171, AND DISULFIDE BOND. RX PubMed=11525170; DOI=10.1016/s0969-2126(01)00591-3; RA Mayans O., Wuerges J., Canela S., Gautel M., Wilmanns M.; RT "Structural evidence for a possible role of reversible disulphide bridge RT formation in the elasticity of the muscle protein titin."; RL Structure 9:331-340(2001). RN [30] RP X-RAY CRYSTALLOGRAPHY (2.44 ANGSTROMS) OF 1-196 IN COMPLEX WITH TCAP. RX PubMed=16407954; DOI=10.1038/nature04343; RA Zou P., Pinotsis N., Lange S., Song Y.-H., Popov A., Mavridis I., RA Mayans O.M., Gautel M., Wilmanns M.; RT "Palindromic assembly of the giant muscle protein titin in the sarcomeric RT Z-disk."; RL Nature 439:229-233(2006). RN [31] RP VARIANT CMH9 LEU-740. RX PubMed=10462489; DOI=10.1006/bbrc.1999.1221; RA Satoh M., Takahashi M., Sakamoto T., Hiroe M., Marumo F., Kimura A.; RT "Structural analysis of the titin gene in hypertrophic cardiomyopathy: RT identification of a novel disease gene."; RL Biochem. Biophys. Res. Commun. 262:411-417(1999). RN [32] RP INVOLVEMENT IN LGMDR10, AND VARIANT TMD PRO-34315. RX PubMed=12145747; DOI=10.1086/342380; RA Hackman P., Vihola A., Haravuori H., Marchand S., Sarparanta J., RA De Seze J., Labeit S., Witt C., Peltonen L., Richard I., Udd B.; RT "Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the RT gene encoding the giant skeletal-muscle protein titin."; RL Am. J. Hum. Genet. 71:492-500(2002). RN [33] RP VARIANTS CMD1G MET-54; VAL-743; TYR-3799 AND ASN-4465, VARIANTS CYS-328; RP GLN-4084 AND PRO-4215, CHARACTERIZATION OF VARIANTS CMD1G MET-54 AND RP VAL-743, AND FUNCTION. RX PubMed=11846417; DOI=10.1006/bbrc.2002.6448; RA Itoh-Satoh M., Hayashi T., Nishi H., Koga Y., Arimura T., Koyanagi T., RA Takahashi M., Hohda S., Ueda K., Nouchi T., Hiroe M., Marumo F., RA Imaizumi T., Yasunami M., Kimura A.; RT "Titin mutations as the molecular basis for dilated cardiomyopathy."; RL Biochem. Biophys. Res. Commun. 291:385-393(2002). RN [34] RP VARIANT CMD1G ARG-976. RX PubMed=11788824; DOI=10.1038/ng815; RA Gerull B., Gramlich M., Atherton J., McNabb M., Trombitas K., RA Sasse-Klaassen S., Seidman J.G., Seidman C., Granzier H., Labeit S., RA Frenneaux M., Thierfelder L.; RT "Mutations of TTN, encoding the giant muscle filament titin, cause familial RT dilated cardiomyopathy."; RL Nat. Genet. 30:201-204(2002). RN [35] RP VARIANT TMD ASN-34306. RX PubMed=12891679; DOI=10.1002/ana.10647; RA Van den Bergh P.Y.K., Bouquiaux O., Verellen C., Marchand S., Richard I., RA Hackman P., Udd B.; RT "Tibial muscular dystrophy in a Belgian family."; RL Ann. Neurol. 54:248-251(2003). RN [36] RP VARIANT CMD1G GLN-32996. RX PubMed=16465475; DOI=10.1007/s10974-005-9018-5; RA Matsumoto Y., Hayashi T., Inagaki N., Takahashi M., Hiroi S., Nakamura T., RA Arimura T., Nakamura K., Ashizawa N., Yasunami M., Ohe T., Yano K., RA Kimura A.; RT "Functional analysis of titin/connectin N2-B mutations found in RT cardiomyopathy."; RL J. Muscle Res. Cell Motil. 26:367-374(2005). RN [37] RP VARIANT MFM9 TRP-279, CHARACTERIZATION OF VARIANT MFM9 TRP-279, AND RP INTERACTION WITH NBR1. RX PubMed=15802564; DOI=10.1126/science.1110463; RA Lange S., Xiang F., Yakovenko A., Vihola A., Hackman P., Rostkova E., RA Kristensen J., Brandmeier B., Franzen G., Hedberg B., Gunnarsson L.G., RA Hughes S.M., Marchand S., Sejersen T., Richard I., Edstroem L., Ehler E., RA Udd B., Gautel M.; RT "The kinase domain of titin controls muscle gene expression and protein RT turnover."; RL Science 308:1599-1603(2005). RN [38] RP INVOLVEMENT IN CMYO5. RX PubMed=17444505; DOI=10.1002/ana.21089; RA Carmignac V., Salih M.A.M., Quijano-Roy S., Marchand S., Al Rayess M.M., RA Mukhtar M.M., Urtizberea J.A., Labeit S., Guicheney P., Leturcq F., RA Gautel M., Fardeau M., Campbell K.P., Richard I., Estournet B., RA Ferreiro A.; RT "C-terminal titin deletions cause a novel early-onset myopathy with fatal RT cardiomyopathy."; RL Ann. Neurol. 61:340-351(2007). RN [39] RP VARIANTS [LARGE SCALE ANALYSIS] TYR-60; MET-115; CYS-328; THR-360; ILE-498; RP MET-799; ILE-811; HIS-922; ASP-937; THR-1081; ARG-1137; GLU-1201; ALA-1202; RP LEU-1295; ASP-1345; THR-1347; HIS-1350; LEU-1353; VAL-1393; CYS-1416; RP PRO-1441; VAL-1544; GLN-1572; GLY-1658; GLN-1664; ASP-1692; LEU-1744; RP GLY-1772; ILE-1907; HIS-1998; LEU-2107; THR-2118; THR-2164; TYR-2240; RP SER-2392; PHE-2432; ILE-2610; MET-2771; PHE-2823; ASN-2831; ILE-2930; RP ARG-3154; GLU-3191; LEU-3238; GLY-3250; MET-3261; GLN-3367; LYS-3482; RP LYS-3570; VAL-3590; VAL-3762; PHE-3877; LEU-3965; PRO-4215; TRP-4238; RP PHE-4283; THR-4291; ASP-4303; GLU-4427; GLU-12310; ALA-12469; CYS-12642; RP LYS-12657; GLU-12679; PHE-12720; CYS-12798; GLY-13049; LYS-13083; RP LEU-13096; ARG-13099; ALA-13297; MET-13399; THR-13418; VAL-13428; RP THR-13430; LYS-13434; ASN-13469; ASN-13495; SER-13785; HIS-13870; RP ILE-14109; GLN-14131; THR-14208; VAL-14728; THR-14999; THR-15021; RP VAL-15520; ILE-15555; GLN-15620; ILE-15629; CYS-15635; GLN-15700; RP PRO-15705; MET-15837; HIS-16058; ILE-16067; THR-16090; HIS-16195; RP CYS-16409; PRO-16424; MET-16629; ARG-16877; ASP-17060; VAL-17637; RP HIS-17838; ASN-17866; GLU-17906; ALA-18094; SER-18109; THR-18164; RP LEU-18221; THR-18222; GLN-18726; ALA-18835; LYS-18881; SER-18939; RP GLN-19000; GLN-19060; LYS-19091; SER-19224; ILE-19367; LYS-19392; RP SER-19480; GLY-19495; HIS-19665; ILE-19762; ARG-19947; MET-19956; RP GLN-19992; CYS-20057; LEU-20075; LYS-20179; THR-20198; VAL-20198; RP HIS-20331; THR-20408; LYS-20564; ILE-20718; PRO-20726; ASN-20892; RP ARG-20894; GLU-21125; SER-21403; CYS-21730; GLN-21747; ARG-21851; RP ARG-21851; ARG-21925; HIS-21995; VAL-22045; HIS-22149; ILE-22160; RP THR-22261; ASN-22306; HIS-22357; PRO-22408; HIS-22537; LEU-22584; RP PRO-22646; ALA-22670; ASP-22770; THR-22801; TRP-22823; GLN-22968; RP LEU-23074; PHE-23079; ASN-23282; TYR-23303; CYS-23306; SER-23515; RP GLN-23551; ASN-23807; ASN-23872; ALA-23891; HIS-23933; MET-23939; RP LEU-23952; GLY-24098; SER-24119; ILE-24133; ALA-24159; ALA-24239; RP LYS-24265; THR-24584; THR-24781; HIS-24799; HIS-24954; MET-24980; RP HIS-25659; THR-25679; ALA-25720; LYS-25821; LYS-25859; LYS-25879; RP VAL-25923; ILE-26045; GLU-26059; VAL-26134; CYS-26477; TYR-26843; RP ARG-27346; CYS-27652; VAL-27728; LEU-27754; THR-27755; VAL-27929; RP LEU-28132; GLN-28168; HIS-28538; THR-28572; THR-28948; VAL-28986; RP GLU-28993; VAL-28998; MET-29070; VAL-29090; CYS-29419; PRO-29479; RP LEU-29880; GLU-29976; GLY-30042; CYS-30107; PHE-30125; PRO-30211; RP THR-30412; SER-30617; ILE-30674; ILE-30809; ILE-30818; LYS-30825; RP THR-30856; ASP-30887; SER-30887; HIS-30897; HIS-30907; HIS-30946; RP PHE-31081; CYS-31107; GLY-31124; SER-31156; THR-31246; HIS-31330; RP ARG-31690; GLN-31724; ILE-31725; SER-31732; ILE-31886; CYS-32097; RP ASN-32171; ILE-32248; HIS-32281; HIS-32323; TRP-32411; VAL-32558; RP VAL-32610; VAL-32637; ALA-32922; ARG-32943; HIS-32953; LEU-33213; RP CYS-33242; MET-33387; ASP-33419; MET-33536; GLN-33568; LYS-33616; RP LEU-33620; VAL-33886; THR-33899; PRO-33904; ILE-33955 AND ALA-34115. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [40] RP VARIANTS VAL-16046 AND GLN-32742. RX PubMed=23033978; DOI=10.1056/nejmoa1206524; RA de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G., RA Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P., Gilissen C., RA del Rosario M., Hoischen A., Scheffer H., de Vries B.B., Brunner H.G., RA Veltman J.A., Vissers L.E.; RT "Diagnostic exome sequencing in persons with severe intellectual RT disability."; RL N. Engl. J. Med. 367:1921-1929(2012). RN [41] RP VARIANTS PRO-2963 AND GLN-14750. RX PubMed=25173926; DOI=10.1161/circgenetics.113.000486; RA Girolami F., Iascone M., Tomberli B., Bardi S., Benelli M., Marseglia G., RA Pescucci C., Pezzoli L., Sana M.E., Basso C., Marziliano N., Merlini P.A., RA Fornaro A., Cecchi F., Torricelli F., Olivotto I.; RT "Novel alpha-actinin 2 variant associated with familial hypertrophic RT cardiomyopathy and juvenile atrial arrhythmias: a massively parallel RT sequencing study."; RL Circ. Cardiovasc. Genet. 7:741-750(2014). CC -!- FUNCTION: Key component in the assembly and functioning of vertebrate CC striated muscles. By providing connections at the level of individual CC microfilaments, it contributes to the fine balance of forces between CC the two halves of the sarcomere. The size and extensibility of the CC cross-links are the main determinants of sarcomere extensibility CC properties of muscle. In non-muscle cells, seems to play a role in CC chromosome condensation and chromosome segregation during mitosis. CC Might link the lamina network to chromatin or nuclear actin, or both CC during interphase. {ECO:0000269|PubMed:11846417, CC ECO:0000269|PubMed:9804419}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Full activation of the protein kinase domain CC requires both phosphorylation of Tyr-32341, preventing it from blocking CC the catalytic aspartate residue, and binding of Ca/CALM to the C- CC terminal regulatory tail of the molecule which results in ATP binding CC to the kinase. {ECO:0000269|PubMed:9804419}. CC -!- SUBUNIT: Interacts with MYOM1, MYOM2, tropomyosin and myosin. Interacts CC with actin, primarily via the PEVK domains and with MYPN (By CC similarity). Interacts with FHL2, NEB, CRYAB, LMNA/lamin-A and CC LMNB/lamin-B. Interacts with TCAP/telethonin and/or ANK1 isoform CC Mu17/ank1.5, via the first two N-terminal immunoglobulin domains. CC Interacts with TRIM63 and TRIM55, through several domains including CC immunoglobulin domains 141 and 142. Interacts with ANKRD1, ANKRD2 and CC ANKRD23, via the region between immunoglobulin domains 77 and 78 and CC interacts with CAPN3, via immunoglobulin domain 79. Interacts with NBR1 CC through the protein kinase domain. Interacts with CALM/calmodulin. CC Isoform 6 interacts with OBSCN isoform 3. Interacts with CMYA5. CC {ECO:0000250, ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:12432079, CC ECO:0000269|PubMed:12444090, ECO:0000269|PubMed:12482578, CC ECO:0000269|PubMed:14583192, ECO:0000269|PubMed:14676215, CC ECO:0000269|PubMed:15802564, ECO:0000269|PubMed:15967462, CC ECO:0000269|PubMed:16407954, ECO:0000269|PubMed:16410549, CC ECO:0000269|PubMed:20634290, ECO:0000269|PubMed:9645487, CC ECO:0000269|PubMed:9804419}. CC -!- INTERACTION: CC Q8WZ42; P12814: ACTN1; NbExp=2; IntAct=EBI-681210, EBI-351710; CC Q8WZ42; P35609: ACTN2; NbExp=16; IntAct=EBI-681210, EBI-77797; CC Q8WZ42; P62158: CALM3; NbExp=2; IntAct=EBI-681210, EBI-397435; CC Q8WZ42; P20807: CAPN3; NbExp=4; IntAct=EBI-681210, EBI-5655000; CC Q8WZ42; O75953: DNAJB5; NbExp=4; IntAct=EBI-681210, EBI-5655937; CC Q8WZ42; O75923: DYSF; NbExp=17; IntAct=EBI-681210, EBI-2799016; CC Q8WZ42; P06733: ENO1; NbExp=3; IntAct=EBI-681210, EBI-353877; CC Q8WZ42; Q9GZQ8: MAP1LC3B; NbExp=2; IntAct=EBI-681210, EBI-373144; CC Q8WZ42; Q14324: MYBPC2; NbExp=14; IntAct=EBI-681210, EBI-5653200; CC Q8WZ42; Q13203: MYBPH; NbExp=3; IntAct=EBI-681210, EBI-5655165; CC Q8WZ42; P20929: NEB; NbExp=6; IntAct=EBI-681210, EBI-1049657; CC Q8WZ42; Q5VST9: OBSCN; NbExp=15; IntAct=EBI-681210, EBI-941850; CC Q8WZ42; O75147: OBSL1; NbExp=13; IntAct=EBI-681210, EBI-1223896; CC Q8WZ42; O15061: SYNM; NbExp=3; IntAct=EBI-681210, EBI-7843148; CC Q8WZ42; O15273: TCAP; NbExp=9; IntAct=EBI-681210, EBI-954089; CC Q8WZ42; Q969Q1: TRIM63; NbExp=3; IntAct=EBI-681210, EBI-5661333; CC Q8WZ42; Q8WZ42: TTN; NbExp=16; IntAct=EBI-681210, EBI-681210; CC Q8WZ42-3; O15273: TCAP; NbExp=2; IntAct=EBI-15564183, EBI-954089; CC Q8WZ42-3; Q8WZ42-3: TTN; NbExp=9; IntAct=EBI-15564183, EBI-15564183; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000305|PubMed:16410549}. Nucleus CC {ECO:0000269|PubMed:16410549}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=13; CC Comment=A number of isoforms may be produced, ranging from 27000 to CC 33000 residues in different striated muscle tissues, the size of the CC full-length protein may be up to 38138 residues.; CC Name=1; CC IsoId=Q8WZ42-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8WZ42-2; Sequence=VSP_019138; CC Name=3; Synonyms=Small cardiac N2-B; CC IsoId=Q8WZ42-3; Sequence=VSP_019139, VSP_019145; CC Name=4; Synonyms=Soleus; CC IsoId=Q8WZ42-4; Sequence=VSP_019142, VSP_019151; CC Name=5; CC IsoId=Q8WZ42-5; Sequence=VSP_019147, VSP_019148, VSP_019149, CC VSP_019150, VSP_019152; CC Name=6; Synonyms=Small cardiac novex-3; CC IsoId=Q8WZ42-6; Sequence=VSP_019143, VSP_019146; CC Name=7; Synonyms=Cardiac novex-2; CC IsoId=Q8WZ42-7; Sequence=VSP_019141, VSP_019144; CC Name=8; Synonyms=Cardiac novex-1; CC IsoId=Q8WZ42-8; Sequence=VSP_019140; CC Name=9; CC IsoId=Q8WZ42-9; Sequence=VSP_019139, VSP_042903, VSP_019145; CC Name=10; CC IsoId=Q8WZ42-10; Sequence=VSP_019139, VSP_019140, VSP_019145; CC Name=11; CC IsoId=Q8WZ42-11; Sequence=VSP_019142; CC Name=12; CC IsoId=Q8WZ42-12; Sequence=VSP_045935, VSP_045929, VSP_045930, CC VSP_045931, VSP_045932, VSP_045933, CC VSP_045934; CC Name=13; CC IsoId=Q8WZ42-13; Sequence=VSP_047142; CC -!- TISSUE SPECIFICITY: Isoforms 3, 7 and 8 are expressed in cardiac CC muscle. Isoform 4 is expressed in vertebrate skeletal muscle. Isoform 6 CC is expressed in skeletal muscle (at protein level). CC {ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:7819249}. CC -!- DOMAIN: ZIS1 and ZIS5 regions contain multiple SPXR consensus sites for CC ERK- and CDK-like protein kinases as well as multiple SP motifs. ZIS1 CC could adopt a closed conformation which would block the TCAP-binding CC site. CC -!- DOMAIN: The PEVK region may serve as an entropic spring of a chain of CC structural folds and may also be an interaction site to other CC myofilament proteins to form interfilament connectivity in the CC sarcomere. CC -!- PTM: Autophosphorylated. {ECO:0000250}. CC -!- DISEASE: Myopathy, myofibrillar, 9, with early respiratory failure CC (MFM9) [MIM:603689]: An autosomal dominant myopathy characterized by CC adulthood onset of weakness in proximal, distal, axial and respiratory CC muscles. Pelvic girdle weakness, foot drop and neck weakness are the CC main symptoms at onset, but ultimately the weakness usually involves CC the proximal compartment of both upper and lower limbs. Additional CC features include variable degrees of Achilles tendon contractures, CC spinal rigidity and muscle hypertrophy. Respiratory involvement often CC leads to requirement for non-invasive ventilation support. CC {ECO:0000269|PubMed:15802564}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Cardiomyopathy, familial hypertrophic, 9 (CMH9) [MIM:613765]: CC A hereditary heart disorder characterized by ventricular hypertrophy, CC which is usually asymmetric and often involves the interventricular CC septum. The symptoms include dyspnea, syncope, collapse, palpitations, CC and chest pain. They can be readily provoked by exercise. The disorder CC has inter- and intrafamilial variability ranging from benign to CC malignant forms with high risk of cardiac failure and sudden cardiac CC death. {ECO:0000269|PubMed:10462489}. Note=The disease is caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Cardiomyopathy, dilated, 1G (CMD1G) [MIM:604145]: A disorder CC characterized by ventricular dilation and impaired systolic function, CC resulting in congestive heart failure and arrhythmia. Patients are at CC risk of premature death. {ECO:0000269|PubMed:11788824, CC ECO:0000269|PubMed:11846417, ECO:0000269|PubMed:16465475}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Tardive tibial muscular dystrophy (TMD) [MIM:600334]: CC Autosomal dominant, late-onset distal myopathy. Muscle weakness and CC atrophy are usually confined to the anterior compartment of the lower CC leg, in particular the tibialis anterior muscle. Clinical symptoms CC usually occur at age 35-45 years or much later. CC {ECO:0000269|PubMed:12145747, ECO:0000269|PubMed:12891679}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Muscular dystrophy, limb-girdle, autosomal recessive 10 CC (LGMDR10) [MIM:608807]: An autosomal recessive degenerative myopathy CC characterized by progressive weakness of the pelvic and shoulder girdle CC muscles. Severe disability is observed within 20 years of onset. CC {ECO:0000269|PubMed:12145747}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Congenital myopathy 5 with cardiomyopathy (CMYO5) CC [MIM:611705]: An autosomal recessive, early-onset muscular disorder CC characterized by dilated cardiomyopathy, delayed motor development with CC generalized muscle weakness predominantly affecting proximal and distal CC lower limbs. Skeletal muscle biopsies show minicore-like lesions with CC mitochondrial depletion and sarcomere disorganization, centralized CC nuclei, and type 1 fiber predominance. Dystrophic changes become CC apparent in the second decade. Cardiac muscle biopsies show disruption CC of myocardial architecture, nuclear hypertrophy, and endomysial CC fibrosis. Sudden death may occurr due to cardiomyopathy. CC {ECO:0000269|PubMed:17444505}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: In some isoforms, after the PEVK repeat region there is CC a long PEVK duplicated region. On account of this region, it has been CC very difficult to sequence the whole protein. The length of this region CC (ranging from 183 to 2174 residues), may be a key elastic element of CC titin. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH58824.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence starting in position 553.; Evidence={ECO:0000305}; CC Sequence=AAH70170.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence starting in position 627.; Evidence={ECO:0000305}; CC Sequence=CAA62188.1; Type=Frameshift; Evidence={ECO:0000305}; CC Sequence=CAD12455.1; Type=Frameshift; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Wikipedia; Note=Titin entry; CC URL="https://en.wikipedia.org/wiki/Titin"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X90568; CAA62188.1; ALT_FRAME; mRNA. DR EMBL; X90569; CAA62189.1; -; mRNA. DR EMBL; AJ277892; CAD12455.1; ALT_FRAME; Genomic_DNA. DR EMBL; AJ277892; CAD12456.1; -; Genomic_DNA. DR EMBL; AJ277892; CAD12457.1; -; Genomic_DNA. DR EMBL; AJ277892; CAD12458.1; -; Genomic_DNA. DR EMBL; AJ277892; CAD12459.1; -; Genomic_DNA. DR EMBL; AC009948; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC010680; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC023270; AAX88844.1; -; Genomic_DNA. DR EMBL; FJ695199; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; KF459616; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC013396; AAH13396.1; -; mRNA. DR EMBL; BC058824; AAH58824.1; ALT_SEQ; mRNA. DR EMBL; BC070170; AAH70170.1; ALT_SEQ; mRNA. DR EMBL; BC107797; AAI07798.1; -; mRNA. DR EMBL; X98114; CAA66795.1; -; mRNA. DR EMBL; X98115; CAA66796.1; -; mRNA. DR EMBL; X83270; CAA58243.1; -; mRNA. DR EMBL; AF058332; AAD22603.1; -; Genomic_DNA. DR EMBL; AF058332; AAD22604.1; -; Genomic_DNA. DR EMBL; AF525413; AAP80791.1; -; mRNA. DR EMBL; DQ248309; ABB55264.1; -; mRNA. DR EMBL; X64698; CAA45939.1; -; mRNA. DR EMBL; X64699; CAA45940.1; -; Genomic_DNA. DR EMBL; X64697; CAA45938.1; -; mRNA. DR EMBL; X69490; CAA49245.1; -; mRNA. DR EMBL; AL713647; CAD28458.1; -; mRNA. DR CCDS; CCDS33337.1; -. [Q8WZ42-6] DR CCDS; CCDS54421.1; -. [Q8WZ42-3] DR CCDS; CCDS54422.1; -. [Q8WZ42-9] DR CCDS; CCDS54423.1; -. [Q8WZ42-10] DR CCDS; CCDS54424.1; -. [Q8WZ42-11] DR CCDS; CCDS59435.1; -. [Q8WZ42-12] DR PIR; I38344; I38344. DR PIR; I38346; I38346. DR RefSeq; NP_001243779.1; NM_001256850.1. [Q8WZ42-1] DR RefSeq; NP_001254479.2; NM_001267550.2. [Q8WZ42-12] DR RefSeq; NP_003310.4; NM_003319.4. [Q8WZ42-3] DR RefSeq; NP_596869.4; NM_133378.4. [Q8WZ42-11] DR RefSeq; NP_596870.2; NM_133379.5. [Q8WZ42-6] DR RefSeq; NP_597676.3; NM_133432.3. [Q8WZ42-10] DR PDB; 1BPV; NMR; -; A=22283-22385. DR PDB; 1G1C; X-ray; 2.10 A; A/B=2073-2171. DR PDB; 1NCT; NMR; -; A=33483-33579. DR PDB; 1NCU; NMR; -; A=33483-33579. DR PDB; 1TIT; NMR; -; A=12680-12765. DR PDB; 1TIU; NMR; -; A=12680-12765. DR PDB; 1TKI; X-ray; 2.00 A; A/B=32172-32492. DR PDB; 1TNM; NMR; -; A=33489-33579. DR PDB; 1TNN; NMR; -; A=33489-33579. DR PDB; 1WAA; X-ray; 1.80 A; A/B/C/D/E/F=12677-12765. DR PDB; 1YA5; X-ray; 2.44 A; A/B=1-196. DR PDB; 2A38; X-ray; 2.00 A; A/B/C=1-194. DR PDB; 2BK8; X-ray; 1.69 A; A=32497-32590. DR PDB; 2F8V; X-ray; 2.75 A; A/B/C/D=1-196. DR PDB; 2ILL; X-ray; 2.20 A; A=31854-32047. DR PDB; 2J8H; X-ray; 1.99 A; A=31854-32047. DR PDB; 2J8O; X-ray; 2.49 A; A/B=31854-32047. DR PDB; 2NZI; X-ray; 2.90 A; A/B=31854-32155. DR PDB; 2RQ8; NMR; -; A=12677-12765. DR PDB; 2WP3; X-ray; 1.48 A; T=34252-34350. DR PDB; 2WWK; X-ray; 1.70 A; T=34252-34350. DR PDB; 2WWM; X-ray; 2.30 A; D/T=34252-34350. DR PDB; 2Y9R; X-ray; 1.90 A; T=34252-34350. DR PDB; 3B43; X-ray; 3.30 A; A=7945-8511. DR PDB; 3KNB; X-ray; 1.40 A; A=34253-34350. DR PDB; 3LCY; X-ray; 2.50 A; A/B/C/D=31456-31649. DR PDB; 3LPW; X-ray; 1.65 A; A/B=22877-23070. DR PDB; 3PUC; X-ray; 0.96 A; A=33774-33871. DR PDB; 3Q5O; X-ray; 2.05 A; A/B=34253-34350. DR PDB; 3QP3; X-ray; 2.00 A; A/B/C=33294-33395. DR PDB; 4C4K; X-ray; 1.95 A; T=34252-34350. DR PDB; 4JNW; X-ray; 2.06 A; A/B=32172-32492. DR PDB; 4O00; X-ray; 1.85 A; A/B=14217-14319. DR PDB; 4QEG; X-ray; 2.00 A; A=2880-2967. DR PDB; 4UOW; X-ray; 3.30 A; 1/3/5/7/9/B/D/F/H/J/L/N/P/R/T/V/X/Z=7-99. DR PDB; 5BS0; X-ray; 2.40 A; C=24337-24345. DR PDB; 5JDD; X-ray; 1.53 A; A=2795-3053. DR PDB; 5JDE; X-ray; 1.90 A; A/B=2795-3053. DR PDB; 5JDJ; X-ray; 1.74 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P=2880-2967. DR PDB; 5JOE; X-ray; 2.00 A; A=9582-9671. DR PDB; 6DL4; NMR; -; A=1821-1931. DR PDB; 6FWX; X-ray; 3.00 A; A/B=1-243. DR PDB; 6H4L; X-ray; 1.60 A; A=33294-33395. DR PDB; 6HCI; X-ray; 2.12 A; A/B/C/D=32712-32816. DR PDB; 6I0Y; EM; 3.20 A; z=12677-12765. DR PDB; 6SDB; X-ray; 2.80 A; A/B/C/D/E=3-196. DR PDB; 6YGN; X-ray; 2.40 A; A/B=32046-32594. DR PDB; 7AHS; X-ray; 2.05 A; A/B/C/D=9582-9851. DR PDB; 7NIP; NMR; -; A=9504-9544. DR PDB; 8BNQ; X-ray; 2.30 A; A/B=23562-23862. DR PDB; 8BVO; X-ray; 2.55 A; A=14415-14609. DR PDB; 8BW6; X-ray; 1.95 A; A=14415-14509. DR PDB; 8BXR; X-ray; 2.70 A; A=14319-14615. DR PDB; 8G4L; EM; 6.40 A; am/an/bm/bn/m/n=22784-23867. DR PDB; 8OIY; X-ray; 2.10 A; A/B/C/D/E/F=14217-14319. DR PDB; 8OMW; X-ray; 1.05 A; A=16525-16630. DR PDB; 8OQ9; X-ray; 1.65 A; A/B/C=21497-21598. DR PDB; 8ORL; X-ray; 1.43 A; A/B/C=21497-21598. DR PDB; 8OS3; X-ray; 1.68 A; A=15210-15313. DR PDB; 8OSD; X-ray; 1.70 A; A/B=20511-20616. DR PDB; 8OT5; X-ray; 1.56 A; A/B/C/D/E/F=25430-25531. DR PDB; 8OTY; X-ray; 1.90 A; A/B/C/D=26124-26224. DR PDB; 8OVU; X-ray; 1.95 A; A/B=3500-3598. DR PDB; 8P35; X-ray; 2.20 A; A/B/C/D/E/F=3500-3598. DR PDBsum; 1BPV; -. DR PDBsum; 1G1C; -. DR PDBsum; 1NCT; -. DR PDBsum; 1NCU; -. DR PDBsum; 1TIT; -. DR PDBsum; 1TIU; -. DR PDBsum; 1TKI; -. DR PDBsum; 1TNM; -. DR PDBsum; 1TNN; -. DR PDBsum; 1WAA; -. DR PDBsum; 1YA5; -. DR PDBsum; 2A38; -. DR PDBsum; 2BK8; -. DR PDBsum; 2F8V; -. DR PDBsum; 2ILL; -. DR PDBsum; 2J8H; -. DR PDBsum; 2J8O; -. DR PDBsum; 2NZI; -. DR PDBsum; 2RQ8; -. DR PDBsum; 2WP3; -. DR PDBsum; 2WWK; -. DR PDBsum; 2WWM; -. DR PDBsum; 2Y9R; -. DR PDBsum; 3B43; -. DR PDBsum; 3KNB; -. DR PDBsum; 3LCY; -. DR PDBsum; 3LPW; -. DR PDBsum; 3PUC; -. DR PDBsum; 3Q5O; -. DR PDBsum; 3QP3; -. DR PDBsum; 4C4K; -. DR PDBsum; 4JNW; -. DR PDBsum; 4O00; -. DR PDBsum; 4QEG; -. DR PDBsum; 4UOW; -. DR PDBsum; 5BS0; -. DR PDBsum; 5JDD; -. DR PDBsum; 5JDE; -. DR PDBsum; 5JDJ; -. DR PDBsum; 5JOE; -. DR PDBsum; 6DL4; -. DR PDBsum; 6FWX; -. DR PDBsum; 6H4L; -. DR PDBsum; 6HCI; -. DR PDBsum; 6I0Y; -. DR PDBsum; 6SDB; -. DR PDBsum; 6YGN; -. DR PDBsum; 7AHS; -. DR PDBsum; 7NIP; -. DR PDBsum; 8BNQ; -. DR PDBsum; 8BVO; -. DR PDBsum; 8BW6; -. DR PDBsum; 8BXR; -. DR PDBsum; 8G4L; -. DR PDBsum; 8OIY; -. DR PDBsum; 8OMW; -. DR PDBsum; 8OQ9; -. DR PDBsum; 8ORL; -. DR PDBsum; 8OS3; -. DR PDBsum; 8OSD; -. DR PDBsum; 8OT5; -. DR PDBsum; 8OTY; -. DR PDBsum; 8OVU; -. DR PDBsum; 8P35; -. DR EMDB; EMD-0322; -. DR EMDB; EMD-29722; -. DR SASBDB; Q8WZ42; -. DR SMR; Q8WZ42; -. DR BioGRID; 113124; 328. DR ComplexPortal; CPX-101; Titin-Telethonin complex. DR CORUM; Q8WZ42; -. DR DIP; DIP-33449N; -. DR FunCoup; Q8WZ42; 665. DR IntAct; Q8WZ42; 167. DR MINT; Q8WZ42; -. DR STRING; 9606.ENSP00000467141; -. DR MoonDB; Q8WZ42; Predicted. DR CarbonylDB; Q8WZ42; -. DR GlyCosmos; Q8WZ42; 11 sites, 2 glycans. DR GlyGen; Q8WZ42; 39 sites, 3 O-linked glycans (22 sites). DR iPTMnet; Q8WZ42; -. DR MetOSite; Q8WZ42; -. DR PhosphoSitePlus; Q8WZ42; -. DR SwissPalm; Q8WZ42; -. DR BioMuta; TTN; -. DR jPOST; Q8WZ42; -. DR MassIVE; Q8WZ42; -. DR PaxDb; 9606-ENSP00000467141; -. DR PeptideAtlas; Q8WZ42; -. DR ProteomicsDB; 75209; -. [Q8WZ42-1] DR ProteomicsDB; 75210; -. [Q8WZ42-10] DR ProteomicsDB; 75211; -. [Q8WZ42-11] DR ProteomicsDB; 75212; -. [Q8WZ42-2] DR ProteomicsDB; 75213; -. [Q8WZ42-3] DR ProteomicsDB; 75214; -. [Q8WZ42-4] DR ProteomicsDB; 75215; -. [Q8WZ42-5] DR ProteomicsDB; 75216; -. [Q8WZ42-6] DR ProteomicsDB; 75217; -. [Q8WZ42-7] DR ProteomicsDB; 75218; -. [Q8WZ42-8] DR ProteomicsDB; 75219; -. [Q8WZ42-9] DR Pumba; Q8WZ42; -. DR ABCD; Q8WZ42; 2 sequenced antibodies. DR Antibodypedia; 2056; 211 antibodies from 28 providers. DR DNASU; 7273; -. DR Ensembl; ENST00000342992.11; ENSP00000343764.6; ENSG00000155657.29. [Q8WZ42-11] DR Ensembl; ENST00000359218.11; ENSP00000352154.5; ENSG00000155657.29. [Q8WZ42-10] DR Ensembl; ENST00000360870.10; ENSP00000354117.4; ENSG00000155657.29. [Q8WZ42-6] DR Ensembl; ENST00000412264.2; ENSP00000394672.2; ENSG00000155657.29. [Q8WZ42-12] DR Ensembl; ENST00000460472.6; ENSP00000434586.1; ENSG00000155657.29. [Q8WZ42-3] DR Ensembl; ENST00000589042.5; ENSP00000467141.1; ENSG00000155657.29. [Q8WZ42-12] DR Ensembl; ENST00000591111.5; ENSP00000465570.1; ENSG00000155657.29. [Q8WZ42-1] DR GeneID; 7273; -. DR KEGG; hsa:7273; -. DR MANE-Select; ENST00000589042.5; ENSP00000467141.1; NM_001267550.2; NP_001254479.2. [Q8WZ42-12] DR UCSC; uc002unb.4; human. [Q8WZ42-1] DR UCSC; uc031rqc.3; human. DR AGR; HGNC:12403; -. DR ClinPGx; PA37067; -. DR CTD; 7273; -. DR DisGeNET; 7273; -. DR GeneCards; TTN; -. DR GeneReviews; TTN; -. DR HGNC; HGNC:12403; TTN. DR HPA; ENSG00000155657; Tissue enhanced (heart muscle, skeletal muscle, tongue). DR MalaCards; TTN; -. DR MIM; 188840; gene. DR MIM; 600334; phenotype. DR MIM; 603689; phenotype. DR MIM; 604145; phenotype. DR MIM; 608807; phenotype. DR MIM; 611705; phenotype. DR MIM; 613765; phenotype. DR OpenTargets; ENSG00000155657; -. DR Orphanet; 169186; Autosomal recessive centronuclear myopathy. DR Orphanet; 466921; Childhood-onset progressive contractures-limb-girdle weakness-muscle dystrophy syndrome. DR Orphanet; 324604; Classic multiminicore myopathy. DR Orphanet; 707983; Early-onset autosomal recessive TTN-related distal myopathy. DR Orphanet; 289377; Early-onset myopathy with fatal cardiomyopathy. DR Orphanet; 154; Familial isolated dilated cardiomyopathy. DR Orphanet; 334; Hereditary atrial fibrillation. DR Orphanet; 178464; Hereditary myopathy with early respiratory failure. DR Orphanet; 293888; Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant. DR Orphanet; 293910; Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant. DR Orphanet; 293899; Inherited isolated arrhythmogenic ventricular dysplasia, biventricular variant. DR Orphanet; 609; Tibial muscular dystrophy. DR Orphanet; 140922; Titin-related limb-girdle muscular dystrophy R10. DR VEuPathDB; HostDB:ENSG00000155657; -. DR eggNOG; KOG0613; Eukaryota. DR eggNOG; KOG4475; Eukaryota. DR GeneTree; ENSGT01150000286978; -. DR HOGENOM; CLU_000001_1_0_1; -. DR InParanoid; Q8WZ42; -. DR OMA; TSSWPEY; -. DR OrthoDB; 5969272at2759; -. DR PAN-GO; Q8WZ42; 0 GO annotations based on evolutionary models. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q8WZ42; -. DR Reactome; R-HSA-114608; Platelet degranulation. DR Reactome; R-HSA-390522; Striated Muscle Contraction. DR SignaLink; Q8WZ42; -. DR SIGNOR; Q8WZ42; -. DR Agora; ENSG00000155657; -. DR BioGRID-ORCS; 7273; 10 hits in 1181 CRISPR screens. DR CD-CODE; 232F8A39; P-body. DR ChiTaRS; TTN; human. DR EvolutionaryTrace; Q8WZ42; -. DR GeneWiki; Titin; -. DR GenomeRNAi; 7273; -. DR Pharos; Q8WZ42; Tbio. DR PRO; PR:Q8WZ42; -. DR Proteomes; UP000005640; Chromosome 2. DR Bgee; ENSG00000155657; Expressed in gluteal muscle and 163 other cell types or tissues. DR ExpressionAtlas; Q8WZ42; baseline and differential. DR GO; GO:0015629; C:actin cytoskeleton; IEA:UniProtKB-ARBA. DR GO; GO:0000794; C:condensed nuclear chromosome; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0031674; C:I band; IDA:BHF-UCL. DR GO; GO:0031430; C:M band; IDA:BHF-UCL. DR GO; GO:0005865; C:striated muscle thin filament; IDA:BHF-UCL. DR GO; GO:1990733; C:titin-telethonin complex; IPI:ComplexPortal. DR GO; GO:0030018; C:Z disc; IDA:BHF-UCL. DR GO; GO:0051015; F:actin filament binding; IDA:BHF-UCL. DR GO; GO:0042805; F:actinin binding; IDA:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005509; F:calcium ion binding; IDA:BHF-UCL. DR GO; GO:0005516; F:calmodulin binding; IPI:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0051371; F:muscle alpha-actinin binding; IPI:BHF-UCL. DR GO; GO:0002020; F:protease binding; IPI:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL. DR GO; GO:0019901; F:protein kinase binding; IPI:BHF-UCL. DR GO; GO:0019887; F:protein kinase regulator activity; IMP:BHF-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:MGI. DR GO; GO:0008307; F:structural constituent of muscle; IMP:BHF-UCL. DR GO; GO:0097493; F:structural molecule activity conferring elasticity; IDA:BHF-UCL. DR GO; GO:0031433; F:telethonin binding; IPI:BHF-UCL. DR GO; GO:0055013; P:cardiac muscle cell development; IMP:BHF-UCL. DR GO; GO:0060048; P:cardiac muscle contraction; IMP:BHF-UCL. DR GO; GO:0003300; P:cardiac muscle hypertrophy; IMP:BHF-UCL. DR GO; GO:0055008; P:cardiac muscle tissue morphogenesis; IMP:BHF-UCL. DR GO; GO:0055003; P:cardiac myofibril assembly; IMP:BHF-UCL. DR GO; GO:0035995; P:detection of muscle stretch; IDA:MGI. DR GO; GO:0007076; P:mitotic chromosome condensation; IEP:BHF-UCL. DR GO; GO:0006936; P:muscle contraction; TAS:UniProtKB. DR GO; GO:0030049; P:muscle filament sliding; NAS:ComplexPortal. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:CAFA. DR GO; GO:0050714; P:positive regulation of protein secretion; IMP:CAFA. DR GO; GO:0010737; P:protein kinase A signaling; IMP:CAFA. DR GO; GO:0051592; P:response to calcium ion; IDA:BHF-UCL. DR GO; GO:0045214; P:sarcomere organization; IMP:BHF-UCL. DR GO; GO:0048769; P:sarcomerogenesis; IMP:BHF-UCL. DR GO; GO:0003009; P:skeletal muscle contraction; NAS:ComplexPortal. DR GO; GO:0030241; P:skeletal muscle myosin thick filament assembly; IMP:BHF-UCL. DR GO; GO:0030240; P:skeletal muscle thin filament assembly; IMP:BHF-UCL. DR GO; GO:0006941; P:striated muscle contraction; TAS:UniProtKB. DR CDD; cd00063; FN3; 132. DR CDD; cd00096; Ig; 31. DR CDD; cd05748; Ig_Titin_like; 28. DR CDD; cd20974; IgI_1_Titin_Z1z2-like; 2. DR CDD; cd20972; IgI_2_Titin_Z1z2-like; 1. DR CDD; cd20951; IgI_titin_I1-like; 1. DR CDD; cd05747; IgI_Titin_like; 1. DR CDD; cd20927; IgI_Titin_M1-like; 1. DR CDD; cd14104; STKc_Titin; 1. DR DisProt; DP00072; -. DR FunFam; 2.60.40.10:FF:000022; Cardiac titin; 44. DR FunFam; 2.60.40.10:FF:000800; Cardiac titin; 1. DR FunFam; 2.60.40.10:FF:000345; Muscle M-line assembly protein unc-89; 1. DR FunFam; 2.60.40.10:FF:001284; Myomesin 2; 1. DR FunFam; 2.60.40.10:FF:000147; Myosin light chain kinase; 2. DR FunFam; 2.60.40.10:FF:000107; Myosin, light chain kinase a; 2. DR FunFam; 2.60.40.10:FF:000031; Myosin-binding protein C, slow type; 7. DR FunFam; 2.60.40.10:FF:001867; Titin; 1. DR FunFam; 2.60.40.10:FF:001911; Titin; 1. DR FunFam; 1.10.510.10:FF:000329; Titin a; 1. DR FunFam; 2.60.40.10:FF:000002; Titin a; 32. DR FunFam; 2.60.40.10:FF:000112; Titin a; 8. DR FunFam; 2.60.40.10:FF:000135; Titin a; 7. DR FunFam; 2.60.40.10:FF:000160; Titin a; 1. DR FunFam; 2.60.40.10:FF:000547; Titin a; 2. DR FunFam; 2.60.40.10:FF:000672; Titin a; 1. DR FunFam; 2.60.40.10:FF:000673; Titin a; 1. DR FunFam; 2.60.40.10:FF:000811; Titin a; 1. DR FunFam; 2.60.40.10:FF:000867; Titin a; 1. DR FunFam; 2.60.40.10:FF:000891; Titin a; 1. DR FunFam; 2.60.40.10:FF:000900; Titin a; 1. DR FunFam; 2.60.40.10:FF:000981; Titin a; 1. DR FunFam; 2.60.40.10:FF:001200; Titin a; 1. DR FunFam; 2.60.40.10:FF:001399; Titin a; 1. DR FunFam; 2.60.40.10:FF:001400; Titin a; 1. DR FunFam; 2.60.40.10:FF:001459; Titin a; 1. DR FunFam; 2.60.40.10:FF:001500; Titin a; 1. DR FunFam; 2.60.40.10:FF:001579; Titin a; 1. DR FunFam; 2.60.40.10:FF:001697; Titin a; 1. DR FunFam; 3.30.200.20:FF:000286; Titin a; 1. DR FunFam; 2.60.40.10:FF:000011; Titin b; 11. DR FunFam; 2.60.40.10:FF:000629; Titin b; 1. DR FunFam; 2.60.40.10:FF:000635; Titin b; 1. DR FunFam; 2.60.40.10:FF:000779; Titin b; 1. DR FunFam; 2.60.40.10:FF:000833; Titin b; 1. DR FunFam; 2.60.40.10:FF:000859; Titin b; 1. DR FunFam; 2.60.40.10:FF:000864; Titin b; 1. DR FunFam; 2.60.40.10:FF:000901; Titin b; 1. DR FunFam; 2.60.40.10:FF:000980; Titin b; 1. DR FunFam; 2.60.40.10:FF:000986; Titin b; 1. DR FunFam; 2.60.40.10:FF:001115; Titin b; 1. DR FunFam; 2.60.40.10:FF:001190; Titin b; 1. DR FunFam; 2.60.40.10:FF:001477; Titin b; 1. DR FunFam; 2.60.40.10:FF:000034; Titin isoform A; 26. DR FunFam; 2.60.40.10:FF:000050; Titin isoform B; 8. DR FunFam; 2.60.40.10:FF:000003; Titin isoform E; 22. DR FunFam; 2.60.40.10:FF:000012; titin isoform X1; 26. DR FunFam; 2.60.40.10:FF:000073; titin isoform X1; 5. DR FunFam; 2.60.40.10:FF:000127; titin isoform X1; 4. DR FunFam; 2.60.40.10:FF:000148; titin isoform X1; 5. DR FunFam; 2.60.40.10:FF:000214; titin isoform X1; 7. DR FunFam; 2.60.40.10:FF:000218; titin isoform X1; 6. DR FunFam; 2.60.40.10:FF:000659; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000697; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000770; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000792; titin isoform X1; 2. DR FunFam; 2.60.40.10:FF:000983; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001003; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001213; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001229; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001272; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001327; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001328; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001342; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001343; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001344; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001345; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001350; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001365; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001367; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001382; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001385; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001408; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001430; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001434; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001454; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001476; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001544; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001581; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001610; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001612; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001663; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000714; Titin novex-3; 3. DR FunFam; 2.60.40.10:FF:001082; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001089; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001098; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001116; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001804; Titin, isoform CRA_a; 1. DR FunFam; 2.60.40.10:FF:001844; Titin, isoform CRA_a; 1. DR FunFam; 2.60.40.10:FF:002231; Titin, isoform CRA_a; 1. DR FunFam; 2.60.40.10:FF:002123; Titin, tandem duplicate 1; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 299. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR013106; Ig_V-set. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR040849; MyBP-C_THB. DR InterPro; IPR004168; PPAK_motif. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR015129; Titin_Z_rpt. DR InterPro; IPR008266; Tyr_kinase_AS. DR PANTHER; PTHR14340; MICROFIBRIL-ASSOCIATED GLYCOPROTEIN 3; 1. DR PANTHER; PTHR14340:SF13; TITIN; 1. DR Pfam; PF00041; fn3; 132. DR Pfam; PF07679; I-set; 162. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF02818; PPAK; 9. DR Pfam; PF18362; THB; 1. DR Pfam; PF09042; Titin_Z; 2. DR SMART; SM00060; FN3; 132. DR SMART; SM00409; IG; 167. DR SMART; SM00408; IGc2; 148. DR SMART; SM00406; IGv; 23. DR SUPFAM; SSF49265; Fibronectin type III; 74. DR SUPFAM; SSF48726; Immunoglobulin; 167. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50853; FN3; 132. DR PROSITE; PS50835; IG_LIKE; 143. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Calcium; KW Calmodulin-binding; Cardiomyopathy; Coiled coil; Cytoplasm; KW Direct protein sequencing; Disease variant; Disulfide bond; KW Immunoglobulin domain; Kinase; Limb-girdle muscular dystrophy; Magnesium; KW Metal-binding; Myofibrillar myopathy; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..34350 FT /note="Titin" FT /id="PRO_0000239311" FT DOMAIN 6..96 FT /note="Ig-like 1" FT DOMAIN 104..192 FT /note="Ig-like 2" FT REPEAT 417..462 FT /note="Z-repeat 1" FT REPEAT 466..511 FT /note="Z-repeat 2" FT REPEAT 512..554 FT /note="Z-repeat 3" FT REPEAT 555..600 FT /note="Z-repeat 4" FT REPEAT 601..646 FT /note="Z-repeat 5" FT REPEAT 647..691 FT /note="Z-repeat 6" FT REPEAT 692..740 FT /note="Z-repeat 7" FT DOMAIN 943..1031 FT /note="Ig-like 3" FT DOMAIN 1082..1172 FT /note="Ig-like 4" FT DOMAIN 1291..1382 FT /note="Ig-like 5" FT DOMAIN 1457..1546 FT /note="Ig-like 6" FT DOMAIN 1556..1646 FT /note="Ig-like 7" FT DOMAIN 1703..1793 FT /note="Ig-like 8" FT DOMAIN 1841..1928 FT /note="Ig-like 9" FT DOMAIN 2078..2167 FT /note="Ig-like 10" FT DOMAIN 2171..2262 FT /note="Ig-like 11" FT DOMAIN 2264..2354 FT /note="Ig-like 12" FT DOMAIN 2353..2443 FT /note="Ig-like 13" FT DOMAIN 2430..2529 FT /note="Ig-like 14" FT DOMAIN 2620..2703 FT /note="Ig-like 15" FT DOMAIN 2880..2965 FT /note="Ig-like 16" FT DOMAIN 2968..3050 FT /note="Ig-like 17" FT DOMAIN 3058..3141 FT /note="Ig-like 18" FT DOMAIN 3239..3327 FT /note="Ig-like 19" FT DOMAIN 3344..3432 FT /note="Ig-like 20" FT DOMAIN 3503..3586 FT /note="Ig-like 21" FT DOMAIN 3621..3712 FT /note="Ig-like 22" FT DOMAIN 4289..4376 FT /note="Ig-like 23" FT DOMAIN 4383..4471 FT /note="Ig-like 24" FT DOMAIN 4478..4566 FT /note="Ig-like 25" FT DOMAIN 4571..4659 FT /note="Ig-like 26" FT DOMAIN 4664..4753 FT /note="Ig-like 27" FT DOMAIN 4758..4846 FT /note="Ig-like 28" FT DOMAIN 4851..4936 FT /note="Ig-like 29" FT DOMAIN 4943..5032 FT /note="Ig-like 30" FT DOMAIN 5040..5128 FT /note="Ig-like 31" FT DOMAIN 5133..5221 FT /note="Ig-like 32" FT DOMAIN 5225..5314 FT /note="Ig-like 33" FT DOMAIN 5320..5408 FT /note="Ig-like 34" FT DOMAIN 5413..5501 FT /note="Ig-like 35" FT DOMAIN 5505..5594 FT /note="Ig-like 36" FT DOMAIN 5602..5690 FT /note="Ig-like 37" FT DOMAIN 5695..5783 FT /note="Ig-like 38" FT DOMAIN 5788..5877 FT /note="Ig-like 39" FT DOMAIN 5882..5970 FT /note="Ig-like 40" FT DOMAIN 5975..6063 FT /note="Ig-like 41" FT DOMAIN 6067..6156 FT /note="Ig-like 42" FT DOMAIN 6164..6252 FT /note="Ig-like 43" FT DOMAIN 6257..6347 FT /note="Ig-like 44" FT DOMAIN 6350..6440 FT /note="Ig-like 45" FT DOMAIN 6444..6534 FT /note="Ig-like 46" FT DOMAIN 6537..6626 FT /note="Ig-like 47" FT DOMAIN 6630..6721 FT /note="Ig-like 48" FT DOMAIN 6727..6815 FT /note="Ig-like 49" FT DOMAIN 6820..6908 FT /note="Ig-like 50" FT DOMAIN 6912..7001 FT /note="Ig-like 51" FT DOMAIN 7005..7093 FT /note="Ig-like 52" FT DOMAIN 7102..7190 FT /note="Ig-like 53" FT DOMAIN 7198..7286 FT /note="Ig-like 54" FT DOMAIN 7291..7380 FT /note="Ig-like 55" FT DOMAIN 7385..7473 FT /note="Ig-like 56" FT DOMAIN 7478..7567 FT /note="Ig-like 57" FT DOMAIN 7571..7662 FT /note="Ig-like 58" FT DOMAIN 7668..7756 FT /note="Ig-like 59" FT DOMAIN 7761..7849 FT /note="Ig-like 60" FT DOMAIN 7853..7942 FT /note="Ig-like 61" FT DOMAIN 7946..8035 FT /note="Ig-like 62" FT DOMAIN 8042..8133 FT /note="Ig-like 63" FT DOMAIN 8138..8229 FT /note="Ig-like 64" FT DOMAIN 8232..8321 FT /note="Ig-like 65" FT DOMAIN 8326..8414 FT /note="Ig-like 66" FT DOMAIN 8419..8508 FT /note="Ig-like 67" FT DOMAIN 8512..8603 FT /note="Ig-like 68" FT DOMAIN 8609..8697 FT /note="Ig-like 69" FT DOMAIN 8702..8790 FT /note="Ig-like 70" FT DOMAIN 8794..8883 FT /note="Ig-like 71" FT DOMAIN 8888..8976 FT /note="Ig-like 72" FT DOMAIN 8984..9074 FT /note="Ig-like 73" FT DOMAIN 9079..9168 FT /note="Ig-like 74" FT DOMAIN 9176..9265 FT /note="Ig-like 75" FT DOMAIN 9272..9361 FT /note="Ig-like 76" FT DOMAIN 9366..9470 FT /note="Ig-like 77" FT DOMAIN 9660..9755 FT /note="Ig-like 78" FT DOMAIN 9760..9851 FT /note="Ig-like 79" FT REPEAT 10216..10242 FT /note="PEVK 1" FT REPEAT 10244..10270 FT /note="PEVK 2" FT REPEAT 10272..10298 FT /note="PEVK 3" FT REPEAT 10300..10326 FT /note="PEVK 4" FT REPEAT 10327..10353 FT /note="PEVK 5" FT REPEAT 10355..10381 FT /note="PEVK 6" FT REPEAT 10508..10534 FT /note="PEVK 7" FT REPEAT 10536..10562 FT /note="PEVK 8" FT REPEAT 10592..10618 FT /note="PEVK 9" FT REPEAT 10878..10904 FT /note="PEVK 10" FT REPEAT 10906..10930 FT /note="PEVK 11" FT REPEAT 10932..10958 FT /note="PEVK 12" FT REPEAT 10960..10986 FT /note="PEVK 13" FT REPEAT 10987..11014 FT /note="PEVK 14" FT REPEAT 11363..11396 FT /note="PEVK 15" FT REPEAT 11397..11421 FT /note="PEVK 16" FT REPEAT 11453..11479 FT /note="PEVK 17" FT REPEAT 11481..11507 FT /note="PEVK 18" FT REPEAT 11509..11535 FT /note="PEVK 19" FT REPEAT 11537..11563 FT /note="PEVK 20" FT REPEAT 11565..11591 FT /note="PEVK 21" FT REPEAT 11657..11683 FT /note="PEVK 22" FT REPEAT 11703..11729 FT /note="PEVK 23" FT REPEAT 11745..11771 FT /note="PEVK 24" FT REPEAT 11775..11801 FT /note="PEVK 25" FT REPEAT 11836..11862 FT /note="PEVK 26" FT REPEAT 11864..11890 FT /note="PEVK 27" FT REPEAT 11893..11919 FT /note="PEVK 28" FT REPEAT 11929..11955 FT /note="PEVK 29" FT REPEAT 11966..11992 FT /note="PEVK 30" FT REPEAT 11996..12022 FT /note="PEVK 31" FT DOMAIN 12041..12133 FT /note="Ig-like 80" FT DOMAIN 12138..12222 FT /note="Ig-like 81" FT DOMAIN 12233..12318 FT /note="Ig-like 82" FT DOMAIN 12499..12584 FT /note="Ig-like 83" FT DOMAIN 12590..12672 FT /note="Ig-like 84" FT DOMAIN 12766..12850 FT /note="Ig-like 85" FT DOMAIN 12945..13032 FT /note="Ig-like 86" FT DOMAIN 13120..13206 FT /note="Ig-like 87" FT DOMAIN 13210..13295 FT /note="Ig-like 88" FT DOMAIN 13299..13384 FT /note="Ig-like 89" FT DOMAIN 13388..13478 FT /note="Ig-like 90" FT DOMAIN 13479..13562 FT /note="Ig-like 91" FT DOMAIN 13565..13655 FT /note="Ig-like 92" FT DOMAIN 13659..13748 FT /note="Ig-like 93" FT DOMAIN 13749..13833 FT /note="Ig-like 94" FT DOMAIN 13927..14012 FT /note="Ig-like 95" FT DOMAIN 14019..14114 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14120..14215 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14221..14316 FT /note="Fibronectin type-III 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14417..14513 FT /note="Fibronectin type-III 4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14517..14614 FT /note="Fibronectin type-III 5" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14615..14708 FT /note="Ig-like 96" FT DOMAIN 14713..14806 FT /note="Fibronectin type-III 6" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14812..14907 FT /note="Fibronectin type-III 7" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14913..15007 FT /note="Fibronectin type-III 8" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15010..15107 FT /note="Fibronectin type-III 9" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15113..15207 FT /note="Fibronectin type-III 10" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15214..15310 FT /note="Fibronectin type-III 11" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15314..15402 FT /note="Ig-like 97" FT DOMAIN 15409..15503 FT /note="Fibronectin type-III 12" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15509..15604 FT /note="Fibronectin type-III 13" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15608..15724 FT /note="Ig-like 98" FT DOMAIN 15731..15826 FT /note="Fibronectin type-III 14" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15832..15926 FT /note="Fibronectin type-III 15" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15929..16025 FT /note="Fibronectin type-III 16" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16029..16119 FT /note="Ig-like 99" FT DOMAIN 16126..16218 FT /note="Fibronectin type-III 17" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16224..16318 FT /note="Fibronectin type-III 18" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16322..16420 FT /note="Ig-like 100" FT DOMAIN 16427..16522 FT /note="Fibronectin type-III 19" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16528..16628 FT /note="Fibronectin type-III 20" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16634..16734 FT /note="Fibronectin type-III 21" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16727..16834 FT /note="Ig-like 101" FT DOMAIN 16841..16934 FT /note="Fibronectin type-III 22" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16941..17041 FT /note="Fibronectin type-III 23" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17044..17139 FT /note="Ig-like 102" FT DOMAIN 17147..17240 FT /note="Fibronectin type-III 24" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17246..17345 FT /note="Fibronectin type-III 25" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17348..17445 FT /note="Fibronectin type-III 26" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17449..17536 FT /note="Ig-like 103" FT DOMAIN 17545..17640 FT /note="Fibronectin type-III 27" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17646..17741 FT /note="Fibronectin type-III 28" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17745..17834 FT /note="Ig-like 104" FT DOMAIN 17842..17935 FT /note="Fibronectin type-III 29" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17941..18036 FT /note="Fibronectin type-III 30" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18042..18139 FT /note="Fibronectin type-III 31" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18143..18228 FT /note="Ig-like 105" FT DOMAIN 18239..18333 FT /note="Fibronectin type-III 32" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18339..18431 FT /note="Fibronectin type-III 33" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18435..18526 FT /note="Ig-like 106" FT DOMAIN 18533..18632 FT /note="Fibronectin type-III 34" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18633..18727 FT /note="Fibronectin type-III 35" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18733..18829 FT /note="Fibronectin type-III 36" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18833..18924 FT /note="Ig-like 107" FT DOMAIN 18931..19025 FT /note="Fibronectin type-III 37" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19030..19124 FT /note="Fibronectin type-III 38" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19128..19219 FT /note="Ig-like 108" FT DOMAIN 19226..19321 FT /note="Fibronectin type-III 39" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19325..19420 FT /note="Fibronectin type-III 40" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19426..19527 FT /note="Fibronectin type-III 41" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19531..19617 FT /note="Ig-like 109" FT DOMAIN 19628..19722 FT /note="Fibronectin type-III 42" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19728..19823 FT /note="Fibronectin type-III 43" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19826..19914 FT /note="Ig-like 110" FT DOMAIN 19921..20017 FT /note="Fibronectin type-III 44" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20018..20116 FT /note="Fibronectin type-III 45" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20119..20217 FT /note="Fibronectin type-III 46" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20220..20311 FT /note="Ig-like 111" FT DOMAIN 20318..20411 FT /note="Fibronectin type-III 47" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20417..20512 FT /note="Fibronectin type-III 48" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20518..20613 FT /note="Fibronectin type-III 49" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20716..20813 FT /note="Fibronectin type-III 50" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20814..20908 FT /note="Fibronectin type-III 51" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20893..20996 FT /note="Ig-like 112" FT DOMAIN 21006..21101 FT /note="Fibronectin type-III 52" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21105..21200 FT /note="Fibronectin type-III 53" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21203..21299 FT /note="Fibronectin type-III 54" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21303..21395 FT /note="Ig-like 113" FT DOMAIN 21402..21495 FT /note="Fibronectin type-III 55" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21501..21596 FT /note="Fibronectin type-III 56" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21602..21697 FT /note="Fibronectin type-III 57" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21701..21793 FT /note="Ig-like 114" FT DOMAIN 21797..21891 FT /note="Fibronectin type-III 58" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21894..21986 FT /note="Fibronectin type-III 59" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21990..22083 FT /note="Ig-like 115" FT DOMAIN 22088..22182 FT /note="Fibronectin type-III 60" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22188..22283 FT /note="Fibronectin type-III 61" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22286..22382 FT /note="Fibronectin type-III 62" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22386..22477 FT /note="Ig-like 116" FT DOMAIN 22484..22578 FT /note="Fibronectin type-III 63" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22584..22679 FT /note="Fibronectin type-III 64" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22685..22781 FT /note="Fibronectin type-III 65" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22785..22874 FT /note="Ig-like 117" FT DOMAIN 22881..22976 FT /note="Fibronectin type-III 66" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22978..23071 FT /note="Fibronectin type-III 67" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23075..23163 FT /note="Ig-like 118" FT DOMAIN 23170..23264 FT /note="Fibronectin type-III 68" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23270..23364 FT /note="Fibronectin type-III 69" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23368..23463 FT /note="Fibronectin type-III 70" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23468..23555 FT /note="Ig-like 119" FT DOMAIN 23566..23660 FT /note="Fibronectin type-III 71" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23666..23761 FT /note="Fibronectin type-III 72" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23767..23863 FT /note="Fibronectin type-III 73" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23867..23954 FT /note="Ig-like 120" FT DOMAIN 23963..24057 FT /note="Fibronectin type-III 74" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24060..24153 FT /note="Fibronectin type-III 75" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24157..24241 FT /note="Ig-like 121" FT DOMAIN 24252..24346 FT /note="Fibronectin type-III 76" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24352..24446 FT /note="Fibronectin type-III 77" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24450..24546 FT /note="Fibronectin type-III 78" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24550..24641 FT /note="Ig-like 122" FT DOMAIN 24648..24742 FT /note="Fibronectin type-III 79" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24748..24843 FT /note="Fibronectin type-III 80" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24849..24945 FT /note="Fibronectin type-III 81" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24949..25038 FT /note="Ig-like 123" FT DOMAIN 25045..25139 FT /note="Fibronectin type-III 82" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25142..25235 FT /note="Fibronectin type-III 83" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25239..25325 FT /note="Ig-like 124" FT DOMAIN 25335..25428 FT /note="Fibronectin type-III 84" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25434..25529 FT /note="Fibronectin type-III 85" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25532..25627 FT /note="Fibronectin type-III 86" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25632..25722 FT /note="Ig-like 125" FT DOMAIN 25731..25825 FT /note="Fibronectin type-III 87" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25831..25926 FT /note="Fibronectin type-III 88" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25932..26028 FT /note="Fibronectin type-III 89" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26032..26121 FT /note="Ig-like 126" FT DOMAIN 26128..26222 FT /note="Fibronectin type-III 90" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26225..26318 FT /note="Fibronectin type-III 91" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26322..26410 FT /note="Ig-like 127" FT DOMAIN 26417..26510 FT /note="Fibronectin type-III 92" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26516..26611 FT /note="Fibronectin type-III 93" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26614..26710 FT /note="Fibronectin type-III 94" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26714..26801 FT /note="Ig-like 128" FT DOMAIN 26812..26906 FT /note="Fibronectin type-III 95" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26912..27007 FT /note="Fibronectin type-III 96" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27013..27107 FT /note="Fibronectin type-III 97" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27101..27196 FT /note="Ig-like 129" FT DOMAIN 27205..27296 FT /note="Fibronectin type-III 98" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27302..27392 FT /note="Fibronectin type-III 99" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27499..27593 FT /note="Fibronectin type-III 100" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27599..27694 FT /note="Fibronectin type-III 101" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27697..27793 FT /note="Fibronectin type-III 102" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27797..27888 FT /note="Ig-like 130" FT DOMAIN 27895..27989 FT /note="Fibronectin type-III 103" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27995..28090 FT /note="Fibronectin type-III 104" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28096..28192 FT /note="Fibronectin type-III 105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28196..28286 FT /note="Ig-like 131" FT DOMAIN 28295..28389 FT /note="Fibronectin type-III 106" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28392..28484 FT /note="Fibronectin type-III 107" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28488..28577 FT /note="Ig-like 132" FT DOMAIN 28583..28680 FT /note="Fibronectin type-III 108" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28686..28781 FT /note="Fibronectin type-III 109" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28784..28879 FT /note="Fibronectin type-III 110" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28882..28974 FT /note="Ig-like 133" FT DOMAIN 28979..29071 FT /note="Fibronectin type-III 111" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29081..29177 FT /note="Fibronectin type-III 112" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29180..29278 FT /note="Fibronectin type-III 113" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29282..29367 FT /note="Ig-like 134" FT DOMAIN 29378..29473 FT /note="Fibronectin type-III 114" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29475..29568 FT /note="Fibronectin type-III 115" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29568..29663 FT /note="Ig-like 135" FT DOMAIN 29670..29764 FT /note="Fibronectin type-III 116" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29770..29865 FT /note="Fibronectin type-III 117" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29868..29967 FT /note="Fibronectin type-III 118" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29971..30059 FT /note="Ig-like 136" FT DOMAIN 30070..30163 FT /note="Fibronectin type-III 119" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30169..30265 FT /note="Fibronectin type-III 120" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30271..30367 FT /note="Fibronectin type-III 121" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30371..30460 FT /note="Ig-like 137" FT DOMAIN 30467..30561 FT /note="Fibronectin type-III 122" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30564..30658 FT /note="Fibronectin type-III 123" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30663..30754 FT /note="Ig-like 138" FT DOMAIN 30761..30855 FT /note="Fibronectin type-III 124" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30861..30956 FT /note="Fibronectin type-III 125" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30962..31058 FT /note="Fibronectin type-III 126" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31061..31150 FT /note="Ig-like 139" FT DOMAIN 31158..31254 FT /note="Fibronectin type-III 127" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31258..31354 FT /note="Fibronectin type-III 128" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31360..31455 FT /note="Fibronectin type-III 129" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31460..31548 FT /note="Ig-like 140" FT DOMAIN 31653..31748 FT /note="Fibronectin type-III 130" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31754..31849 FT /note="Fibronectin type-III 131" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31855..31945 FT /note="Ig-like 141" FT DOMAIN 31955..32046 FT /note="Ig-like 142" FT DOMAIN 32051..32144 FT /note="Fibronectin type-III 132" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 32178..32432 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 32496..32584 FT /note="Ig-like 143" FT DOMAIN 32617..32710 FT /note="Ig-like 144" FT DOMAIN 32722..32811 FT /note="Ig-like 145" FT DOMAIN 33301..33391 FT /note="Ig-like 146" FT DOMAIN 33488..33576 FT /note="Ig-like 147" FT DOMAIN 33645..33732 FT /note="Ig-like 148" FT DOMAIN 33779..33867 FT /note="Ig-like 149" FT DOMAIN 33963..34052 FT /note="Ig-like 150" FT DOMAIN 34061..34149 FT /note="Ig-like 151" FT DOMAIN 34256..34344 FT /note="Ig-like 152" FT REGION 244..313 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 253..341 FT /note="ZIS1" FT REGION 333..356 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 859..886 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1408..1443 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1410..1440 FT /note="ZIS5" FT REGION 4241..4272 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 9920..9945 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10039..10070 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10087..10109 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10207..10280 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10314..10361 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10412..10457 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10499..10566 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10583..10617 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10661..10743 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10882..11102 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 11158..11193 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 11362..11636 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 11666..12032 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 14216..14236 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 14891..14921 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 15911..15939 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 16614..16654 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 18614..18637 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 18716..18743 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 19304..19331 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 27090..27110 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 31238..31267 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33213..33256 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33432..33463 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33584..33638 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33749..33777 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 529..561 FT /evidence="ECO:0000255" FT COILED 2025..2052 FT /evidence="ECO:0000255" FT COILED 3462..3487 FT /evidence="ECO:0000255" FT COILED 9534..9577 FT /evidence="ECO:0000255" FT COMPBIAS 1408..1419 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 4245..4257 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 9920..9938 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10041..10052 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10058..10070 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10087..10101 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10207..10224 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10245..10265 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10329..10347 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10349..10360 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10418..10430 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10440..10457 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10684..10701 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10702..10720 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10721..10737 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10882..10944 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10961..10972 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10989..11009 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11030..11101 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11164..11190 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11388..11416 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11438..11453 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11454..11465 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11466..11479 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11496..11509 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11510..11521 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11538..11549 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11550..11563 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11580..11591 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11592..11613 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11614..11626 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11678..11696 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11704..11715 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11730..11745 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11768..11803 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11816..11825 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11834..11846 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11854..11875 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11882..11900 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11927..11936 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11948..11958 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11960..11971 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11972..11981 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11982..11995 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11996..12008 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 14223..14236 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 19318..19331 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 31252..31262 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33231..33242 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33439..33450 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33594..33604 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33625..33634 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33749..33771 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 32298 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 32184..32192 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 32207 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 263 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 265 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 267 FT /note="Phosphothreonine" FT /evidence="ECO:0000250" FT MOD_RES 6920 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 9122 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 11503 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 12007 FT /note="Phosphothreonine" FT /evidence="ECO:0000250" FT MOD_RES 12009 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 12022 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 30443 FT /note="Phosphothreonine" FT /evidence="ECO:0000250" FT MOD_RES 32341 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:9804419" FT MOD_RES 33245 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 33247 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 33602 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 33614 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT DISULFID 964..1015 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 1724..1777 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 2109..2134 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:11525170" FT DISULFID 2196..2246 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 3259..3311 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4404..4455 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4499..4550 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4592..4643 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4686..4737 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4779..4830 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5061..5112 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5248..5299 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5623..5674 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5810..5861 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5903..5954 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6185..6236 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6372..6423 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6465..6516 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6748..6799 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7027..7078 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7123..7174 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7219..7270 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7313..7364 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7406..7457 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7689..7740 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7968..8019 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8064..8115 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8160..8211 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8254..8305 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8347..8398 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8630..8681 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8909..8960 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9005..9056 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9101..9152 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9294..9345 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9693..9743 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 12067..12117 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 12611..12660 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 12966..13016 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13233..13283 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13322..13372 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13411..13461 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13771..13821 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 31481..31532 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 32516..32568 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 33664..33718 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 555..646 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:8937992" FT /id="VSP_019138" FT VAR_SEQ 556..601 FT /note="Missing (in isoform 3, isoform 9 and isoform 10)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:7569978" FT /id="VSP_019139" FT VAR_SEQ 3434 FT /note="E -> EGFSKFEENTSNSQWHVSLSVSFKKEPLGQKPSFIQPLSSLRVHNGE FT TVRFHARVSGIPKPEIQWFHNQQLILPTKDVVFHFEESTGMALMLIVDAYSEHAGQYSC FT KAANSAGEATCAATLTVTPKVQALDRQSSGKDVRESTKSQAVADSSFTKEESKISQKEI FT KSFQGSSYEYEVQVFESVSQSSIHTAASVQDTQLCHTASLSQIAESTELSKECAKESTG FT EAPKIFLHLQDVTVKCGDTAQFLCVLKDDSFIDVTWTHEGAKIEESERLKQSQNGNIQF FT LTICNVQLVDQGLYSCIVHNDCGERTTSAVLSVEG (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045935" FT VAR_SEQ 3434 FT /note="E -> EGFSKFEENTSNSQWHVSLSVSFKKEPLGQKPSFIQPLSSLRVHNGE FT TVRFHARVSGIPKPEIQWFHNQQLILPTKDVVFHFEESTGMALMLIVDAYSEHAGQYSC FT KAANSAGEATCAATLTVTPK (in isoform 8 and isoform 10)" FT /evidence="ECO:0000305" FT /id="VSP_019140" FT VAR_SEQ 3434 FT /note="E -> EVQALDRQSSGKDVRESAKSQAVADSSFTKEESKISQKEIKSFQGSS FT YEYEVQVFESVSQSSIHTAASVQDTQLCHTASLSQIAESTELSKECAKESTGEAPKIFL FT HLQDVTVKCGDTAQFLCVLKDDSFIDVTWTHEGAKIEESERLKQSQNGNIQFLTICNVQ FT LVDQGLYSCIVHNDCGERTTSAVLSVEG (in isoform 9)" FT /evidence="ECO:0000305" FT /id="VSP_042903" FT VAR_SEQ 3435..3645 FT /note="APESILHERIEQEIEMEMKEFSSSFLSAEEEGLHSAELQLSKINETLELLSE FT SPVYPTKFDSEKEGTGPIFIKEVSNADISMGDVATLSVTVIGIPKPKIQWFFNGVLLTP FT SADYKFVFDGDDHSLIILFTKLEDEGEYTCMASNDYGKTICSAYLKINSKGEGHKDTET FT ESAVAKSLEKLGGPCPPHFLKELKPIRCAQGLPAIFEYTVV -> VQALDRQSSGKDVR FT ESTKSQAVADSSFTKEESKISQKEIKSFQGSSYEYEVQVFESVSQSSIHTAASVQDTQL FT CHTASLSQIAESTELSKECAKESTGEAPKIFLHLQDVTVKCGDTAQFLCVLKDDSFIDV FT TWTHEGAKIEESERLKQSQNGNIQFLTICNVQLVDQGLYSCIVHNDCGERTTSAVLSVE FT GAPESILHERIEQEIEMEMK (in isoform 7)" FT /evidence="ECO:0000305" FT /id="VSP_019141" FT VAR_SEQ 3454..4380 FT /note="Missing (in isoform 4 and isoform 11)" FT /evidence="ECO:0000303|PubMed:7569978" FT /id="VSP_019142" FT VAR_SEQ 3455..5604 FT /note="FSSSFLSAEEEGLHSAELQLSKINETLELLSESPVYPTKFDSEKEGTGPIFI FT KEVSNADISMGDVATLSVTVIGIPKPKIQWFFNGVLLTPSADYKFVFDGDDHSLIILFT FT KLEDEGEYTCMASNDYGKTICSAYLKINSKGEGHKDTETESAVAKSLEKLGGPCPPHFL FT KELKPIRCAQGLPAIFEYTVVGEPAPTVTWFKENKQLCTSVYYTIIHNPNGSGTFIVND FT PQREDSGLYICKAENMLGESTCAAELLVLLEDTDMTDTPCKAKSTPEAPEDFPQTPLKG FT PAVEALDSEQEIATFVKDTILKAALITEENQQLSYEHIAKANELSSQLPLGAQELQSIL FT EQDKLTPESTREFLCINGSIHFQPLKEPSPNLQLQIVQSQKTFSKEGILMPEEPETQAV FT LSDTEKIFPSAMSIEQINSLTVEPLKTLLAEPEGNYPQSSIEPPMHSYLTSVAEEVLSP FT KEKTVSDTNREQRVTLQKQEAQSALILSQSLAEGHVESLQSPDVMISQVNYEPLVPSEH FT SCTEGGKILIESANPLENAGQDSAVRIEEGKSLRFPLALEEKQVLLKEEHSDNVVMPPD FT QIIESKREPVAIKKVQEVQGRDLLSKESLLSGIPEEQRLNLKIQICRALQAAVASEQPG FT LFSEWLRNIEKVEVEAVNITQEPRHIMCMYLVTSAKSVTEEVTIIIEDVDPQMANLKME FT LRDALCAIIYEEIDILTAEGPRIQQGAKTSLQEEMDSFSGSQKVEPITEPEVESKYLIS FT TEEVSYFNVQSRVKYLDATPVTKGVASAVVSDEKQDESLKPSEEKEESSSESGTEEVAT FT VKIQEAEGGLIKEDGPMIHTPLVDTVSEEGDIVHLTTSITNAKEVNWYFENKLVPSDEK FT FKCLQDQNTYTLVIDKVNTEDHQGEYVCEALNDSGKTATSAKLTVVKRAAPVIKRKIEP FT LEVALGHLAKFTCEIQSAPNVRFQWFKAGREIYESDKCSIRSSKYISSLEILRTQVVDC FT GEYTCKASNEYGSVSCTATLTVTEAYPPTFLSRPKSLTTFVGKAAKFICTVTGTPVIET FT IWQKDGAALSPSPNWRISDAENKHILELSNLTIQDRGVYSCKASNKFGADICQAELIII FT DKPHFIKELEPVQSAINKKVHLECQVDEDRKVTVTWSKDGQKLPPGKDYKICFEDKIAT FT LEIPLAKLKDSGTYVCTASNEAGSSSCSATVTVREPPSFVKKVDPSYLMLPGESARLHC FT KLKGSPVIQVTWFKNNKELSESNTVRMYFVNSEAILDITDVKVEDSGSYSCEAVNDVGS FT DSCSTEIVIKEPPSFIKTLEPADIVRGTNALLQCEVSGTGPFEISWFKDKKQIRSSKKY FT RLFSQKSLVCLEIFSFNSADVGEYECVVANEVGKCGCMATHLLKEPPTFVKKVDDLIAL FT GGQTVTLQAAVRGSEPISVTWMKGQEVIREDGKIKMSFSNGVAVLIIPDVQISFGGKYT FT CLAENEAGSQTSVGELIVKEPAKIIERAELIQVTAGDPATLEYTVAGTPELKPKWYKDG FT RPLVASKKYRISFKNNVAQLKFYSAELHDSGQYTFEISNEVGSSSCETTFTVLDRDIAP FT FFTKPLRNVDSVVNGTCRLDCKIAGSLPMRVSWFKDGKEIAASDRYRIAFVEGTASLEI FT IRVDMNDAGNFTCRATNSVGSKDSSGALIVQEPPSFVTKPGSKDVLPGSAVCLKSTFQG FT STPLTIRWFKGNKELVSGGSCYITKEALESSLELYLVKTSDSGTYTCKVSNVAGGVECS FT ANLFVKEPATFVEKLEPSQLLKKGDATQLACKVTGTPPIKITWFANDREIKESSKHRMS FT FVESTAVLRLTDVGIEDSGEYMCEAQNEAGSDHCSSIVIVKESPYFTKEFKPIEVLKEY FT DVMLLAEVAGTPPFEITWFKDNTILRSGRKYKTFIQDHLVSLQILKFVAADAGEYQCRV FT TNEVGSSICSARVTLREPPSFIKKIESTSSLRGGTAAFQATLKGSLPITVTWLKDSDEI FT TEDDNIRMTFENNVASLYLSGIEVKHDGKYVCQAKNDAGIQRCSALLSVKEPATITEEA FT VSIDVTQGDPATLQVKFSGTKEITAKWFKDGQELTLGSKYKISVTDTVSILKIISTEKK FT DSGEYTFEVQNDVGRSSCKARINVLDLIIPPSF -> LFSEGESEHSERDTRDAFSDSE FT DIDHKSMAAKRYASRISSTSSWPEYFKPSFTQKLTFKYVLEGEPVVFTCRLIACPTPEM FT TWFHNNRPIPTGLRRIIKAESDLHHHSSSLEIKRVQDRDSGSYRLLAINSEGSAESTAS FT LLVIQKGQDEKYLEFLKRAERTHENVEALVERGEDRIKVDLRFTGSPFNKKQDVEQKGM FT MRTIHFKTMSSAKKTDYMYDEEYLESKSDIRGWLNVGESFLDKETKVKLQRLREARKTL FT MEKKKLSLLDTSSEISSRTLRSEASDKDILFSREDMKIRSMSDLAESYKVDHSAESIVQ FT NPHALSNQMDQNIESEELPTSFQTIVDEEIFQTEIRMSQEALVKESLPKDHLYGEILVN FT ENTQARGQLEEIMANTTIGESSTYITNVCEKEEVYETPENVSQAITPHASESFGTLVNV FT EESEEIASERIKKDDLRELQLSASTRIDEFKTEQKEENMRFFENSFRKRPQRCPPSFLQ FT EIESQEVYEGDSCNFVCHFQGYPQPIVTWYNNDMPIPRNQNFIIHSLENYSILTLSSVH FT HQNEGSITCVLFNQYGTVKTTSMLKVKAKQKHDVKAHKVPVFHDYLDEEEELALVFDQA FT KGAHPSMSQEGQTNLHLLKTNPPVPPSGDTELLSFPVEIQVTAATPIPEQDKESKEVFQ FT TEELEPKAMPQDQVTQSPKHRFVFLSDITNEPPKMLQEMPKHARCREGDSIILECLISG FT EPQPVVTWFQNGVLLKQNQKFQFEEVNCSHQLYIKDVNSQDSGKYKCVAENNSGAVESV FT SDLTVEPVTYRENSQFENIGEIYGKYSRDQQLQDQGESVRAHFYDYPAGPFTPWTNVKE FT YSVRDYFQSLETIEQIDQKEQVRCIPSREKIPRFVHGASRTIKISKPIRAEFIQCQAEG FT KERHVSEKSKLHQAEGTVYPFVDDFSDVTIKKEIRNNFGKLGRSEKENVQECAQSDYLP FT NIHSERISDSYNTKDSSAIVYEESLGEEIHYPGKKVKHRIIEFEKLHVEKGVLEKRPTR FT TSIVNPPQKKIDDKAFSLKQRESRSSNLNANMYQAEKMSPNTESDSSNIAINLKLLSSQ FT THKEFDAQEREQQEKISLIDKPAISKRAEHESPITFDLKQFHTQIKHTDVKFQELDSGQ FT PEEAYFKIQHPADTENIVFDLKQMYSHIGDPALEFQGQETREQQEIHYKEKIPSPETLQ FT PDTHNISKSVQNNVFASQEISSSQELSNRTMVEKSSIDENSISLEKEVRHVQEQNLDIL FT KTDLSLKSFSEEIYSESCALLPTSSADIEETDLSEKSCPLENGGRSSISHLKKAASEEK FT PLGVGEMEEECTLEPELAAFPKQDGGTQEYTDATLEDHRGDVQEADTLHRQLSLSQCFP FT LLMTEEQQNPGEQISTNIHASGEEKCYEEVQVQNEASFSTLEGEMIETSFSQNIPKLDE FT AHTTEAAESETSLTQYLLAAGKREVPETKDTRDQAKLVQSESITSMEVEEVTFNTVYEY FT YNQKQESLGRPLSPESDISIGVGSTTSEEISELDQFYTPPSSVEYFESPKSPDLYFNPS FT DITKQSSIHSGGETVERYSTPLGEVAERYSTPSEGEVGERYSTPPGETLERYSTPPGET FT LERYSTPPGETLERYSTPPGETLERYSTPPGETLERYSTPPGEALERYSIPTGGPNPTG FT TFKTYPSKIEREDGTPNEHFYTPTEERGSAYEIWRSDSFGTPNEAIEPKDNEMPPSFIE FT PLTKRKVYENTTLGFIVEVEGLPVPGVKWYRNKSLLEPDERIKMERVGNVCSLEISNIQ FT KGEGGEYMCHAVNIIGEAKSFANVDIMPQEERVVALPPPVTHQHVMEFDLEHTTSSRTP FT SPQEIVLEVELSEKDVKEFEKQVKIVTVPEFTPDHKSMIVSLDVLPFNFVDPNMDSREG FT EDKELKIDLEVFEMPPRFIMPICDFKIPENSDAVFKCSVIGIPTPEVKWYKEYMCIEPD FT NIKYVISEEKGSHTLKIRNVCLSDSATYRCRAVNCVGEAICRGFLTMGDSEIFAVIAKK FT SKVTLSSLMEELVLKSNYTDSFFEFQVVEGPPRFIKGISDCYAPIGTAAYFQCLVRGSP FT RPTVYWYKDGKLVQGRRFTVEESGTGFHNLFITSLVKSDEGEYRCVATNKSGMAESFAA FT LTLT (in isoform 6)" FT /evidence="ECO:0000305" FT /id="VSP_019143" FT VAR_SEQ 3646..4380 FT /note="Missing (in isoform 7)" FT /evidence="ECO:0000305" FT /id="VSP_019144" FT VAR_SEQ 4474..11851 FT /note="Missing (in isoform 3, isoform 9 and isoform 10)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:7569978" FT /id="VSP_019145" FT VAR_SEQ 5605..34350 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000305" FT /id="VSP_019146" FT VAR_SEQ 10382..10645 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019147" FT VAR_SEQ 10742..10931 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019148" FT VAR_SEQ 11015..11163 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019149" FT VAR_SEQ 11117 FT /note="I -> VPKKPVPEKKVPVPAPKKVEPPPPPKVPEI (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045929" FT VAR_SEQ 11133 FT /note="E -> EAPPAKVSVVPKKPEPEKKVPPPGLKKAV (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045930" FT VAR_SEQ 11223..11852 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019150" FT VAR_SEQ 11421 FT /note="K -> KAPEVPKKIVPEEKVREAVLKKPEVPPAKVPGMPKKSVQEEKSPIVI FT SEDTEMYIYEASEEAVLEEKVLVTQPQKTKPKLAKVPEPPKKVVPEDKIYVTIPKKRET FT PATKEPDTTRGIFPEVEPPEAIPEIPEHPPTEEFEVFKEVIPEGETPIVKRRKTPSPTV FT PESPREIVPVKETPMAAPLEIEIPPTKAPEAMKEVVPEMKIFEDVPEEPETPRMKTPEA FT PQEIIPAKTVPSKKREPPSVKVPEALQEIVPEKKTLVVPLRKPEVLPDEVPEALREVVP FT EKKVHPPQRAEVVPVKVHEAPKEIIPEKKVSVVPPKKPEVPPVKVPEASKEVIREEKVP FT LAPPKEPEVPPVKVPEPPKEVVPEKKAPVAPPKEPEVPPVKVPEAPKEVVPEKKVPVPP FT PKKPEVPPTKVPEVPKAAVPEKKLPEAIPPKPESPPPE (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045931" FT VAR_SEQ 11450 FT /note="P -> PKVPEAPKEVVLEKKASVAVPKKPEAPRAKVPEAAQEVVPEKKIPKA FT PIKKPEAPAVTVPEVPQEATEKEIPVAPPKKPEAPIVPVPEAQEVVPEKKVPKAPPTKP FT EAPPATVPEVPQEIVPEKKTLVLPKKPEVPPVTVPEAPKEVVLEKKVPSAPPKKPEVPP FT V (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045932" FT VAR_SEQ 11507 FT /note="E -> EVPEVLPPKEVVPEKKVPVPPAKKPEAPPPKVPEAPKEVVLEKKASV FT AVPKKPEAPRAKVPEAAQEVVPEKKIPKAPIKKPEAPAVTVPEVPQEAAEKEIPVAPPK FT KPEAPIVPVPEAQEVVPEKKVPKAPPTKPEAPPATVPEVPQEIVPEKKTLVLPKKPEVP FT PVTVPEAPKEVVLEKKVPSTPPKKPEVPPVKVPEAPKEVVPEKKVPVPPPKKPEVPPTK FT VPEVPKAAVPEKKVPEAIPPKPESPPPEVPEVLPPKEVVPEKKVPVPPAKKPEAPPPKV FT PEAPKEVVLEKKVSVAVPKKPEAPRAKVPEAAQEVVPEKKIPKAPIKKPEAPAVTVPEV FT PQEAAEKEIPVAPPKKPEAPIVPVPEAQEVVPEKKVPKAPPTKPEAPPATVPEVPQEIV FT PEKKTLVLPKKPEVPPVTVPEAPKEVVLEKKVPLAPPKKPEVPPVKVPEAPKEVVPEKK FT VPVTPPKKPEVPPVKVPEAPIEVVPEKKMPLAPPKKPEVPPVKVPEAPKEVVPEKKVPS FT APPKKPEVPPVK (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045933" FT VAR_SEQ 11507 FT /note="E -> EVFEEPEESPSAPPKKPEVPPVR (in isoform 4)" FT /evidence="ECO:0000303|PubMed:7569978" FT /id="VSP_019151" FT VAR_SEQ 11790 FT /note="P -> PKEPEMPKKVVPVKKVPTVKKPETPAAKVPEVPKKLVPVKKEPVPVT FT KKPEVLPEKVPKVPEKIIPEKEVSVPIPAEPEVPPAEVEETPEEIIYEEKASITIGRKE FT TPPVEEREIEKYIKPEEPEPEPQPEEIPV (in isoform 13)" FT /evidence="ECO:0000305" FT /id="VSP_047142" FT VAR_SEQ 11793 FT /note="P -> PEMPKKVVPVKKVPTVKKPETPAAKVPEVPKKLVPVKKEPVPVTKKP FT EVLPEKVPKVPEKIIPEKEVSVPIPAEPEVPPAEVEETPEEIIYEEKASITIGRKETPP FT VEEREIEKYIKPEEPEPEPQPEEIPVKEP (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045934" FT VAR_SEQ 11985..12201 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019152" FT VARIANT 54 FT /note="V -> M (in CMD1G; affects interaction with TCAP/ FT telethonin; dbSNP:rs139517732)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026685" FT VARIANT 60 FT /note="D -> Y (in dbSNP:rs35683768)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040078" FT VARIANT 115 FT /note="V -> M (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs564777385)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040079" FT VARIANT 279 FT /note="R -> W (in MFM9; disrupts NBR1-binding; FT dbSNP:rs138060032)" FT /evidence="ECO:0000269|PubMed:15802564" FT /id="VAR_026634" FT VARIANT 328 FT /note="R -> C (in dbSNP:rs16866538)" FT /evidence="ECO:0000269|PubMed:11846417, FT ECO:0000269|PubMed:17344846" FT /id="VAR_026686" FT VARIANT 360 FT /note="R -> T (in dbSNP:rs56128843)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040080" FT VARIANT 498 FT /note="V -> I (in dbSNP:rs72647851)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040081" FT VARIANT 740 FT /note="R -> L (in CMH9; dbSNP:rs28933405)" FT /evidence="ECO:0000269|PubMed:10462489" FT /id="VAR_026687" FT VARIANT 743 FT /note="A -> V (in CMD1G; affects interaction with TCAP/ FT telethonin; dbSNP:rs267607157)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026688" FT VARIANT 799 FT /note="T -> M (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs149061352)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040082" FT VARIANT 811 FT /note="T -> I (in dbSNP:rs35813871)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040083" FT VARIANT 922 FT /note="R -> H (in dbSNP:rs56046320)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040084" FT VARIANT 937 FT /note="E -> D (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040085" FT VARIANT 976 FT /note="W -> R (in CMD1G; dbSNP:rs267607155)" FT /evidence="ECO:0000269|PubMed:11788824" FT /id="VAR_026689" FT VARIANT 1081 FT /note="A -> T (in dbSNP:rs55914517)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040086" FT VARIANT 1137 FT /note="G -> R (in dbSNP:rs72647870)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040087" FT VARIANT 1201 FT /note="K -> E (in dbSNP:rs10497520)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040088" FT VARIANT 1202 FT /note="V -> A (in dbSNP:rs150667217)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040089" FT VARIANT 1249 FT /note="S -> L (in dbSNP:rs1552280)" FT /id="VAR_056081" FT VARIANT 1295 FT /note="S -> L (in dbSNP:rs1552280)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040090" FT VARIANT 1345 FT /note="G -> D (in dbSNP:rs36021856)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040091" FT VARIANT 1347 FT /note="A -> T (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs267599092)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040092" FT VARIANT 1350 FT /note="R -> H (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs539470256)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040093" FT VARIANT 1353 FT /note="V -> L (in dbSNP:rs36062108)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040094" FT VARIANT 1393 FT /note="I -> V (in dbSNP:rs16866531)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040095" FT VARIANT 1416 FT /note="R -> C (in dbSNP:rs72647875)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040096" FT VARIANT 1441 FT /note="R -> P (in dbSNP:rs72647876)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040097" FT VARIANT 1544 FT /note="I -> V (in dbSNP:rs72647877)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040098" FT VARIANT 1572 FT /note="R -> Q (in dbSNP:rs12476289)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040099" FT VARIANT 1658 FT /note="R -> G (in dbSNP:rs56270960)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040100" FT VARIANT 1664 FT /note="R -> Q (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs375029799)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040101" FT VARIANT 1692 FT /note="G -> D (in a lung squamous cell carcinoma sample; FT somatic mutation; dbSNP:rs370004591)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040102" FT VARIANT 1744 FT /note="P -> L (in dbSNP:rs75686037)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040103" FT VARIANT 1772 FT /note="S -> G (in dbSNP:rs150725992)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040104" FT VARIANT 1907 FT /note="T -> I (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040105" FT VARIANT 1998 FT /note="R -> H (in dbSNP:rs144135510)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040106" FT VARIANT 2107 FT /note="P -> L (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040107" FT VARIANT 2118 FT /note="I -> T (in dbSNP:rs56404770)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040108" FT VARIANT 2164 FT /note="A -> T (in dbSNP:rs56285559)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040109" FT VARIANT 2240 FT /note="D -> Y" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040110" FT VARIANT 2392 FT /note="G -> S (in dbSNP:rs4894048)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040111" FT VARIANT 2432 FT /note="L -> F (in a lung neuroendocrine carcinoma sample; FT somatic mutation; dbSNP:rs571572592)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040112" FT VARIANT 2610 FT /note="M -> I (in dbSNP:rs56142888)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040113" FT VARIANT 2771 FT /note="I -> M (in a breast infiltrating ductal carcinoma FT sample; somatic mutation; dbSNP:rs576644663)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040114" FT VARIANT 2823 FT /note="V -> F (in dbSNP:rs33917087)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040115" FT VARIANT 2831 FT /note="S -> N (in dbSNP:rs2306636)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040116" FT VARIANT 2930 FT /note="V -> I (in dbSNP:rs56373393)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040117" FT VARIANT 2963 FT /note="T -> P (in dbSNP:rs200875815)" FT /evidence="ECO:0000269|PubMed:25173926" FT /id="VAR_074293" FT VARIANT 3026 FT /note="N -> I (in dbSNP:rs11900987)" FT /id="VAR_056082" FT VARIANT 3154 FT /note="K -> R (in dbSNP:rs4893853)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040118" FT VARIANT 3191 FT /note="Q -> E (in dbSNP:rs33997263)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040119" FT VARIANT 3238 FT /note="P -> L (in a bladder carcinoma sample; somatic FT mutation; dbSNP:rs397517792)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040120" FT VARIANT 3250 FT /note="V -> G (in dbSNP:rs55634230)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040121" FT VARIANT 3261 FT /note="V -> M (in dbSNP:rs2291311)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040122" FT VARIANT 3367 FT /note="R -> Q (in dbSNP:rs34819099)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040123" FT VARIANT 3419 FT /note="S -> N (in dbSNP:rs2291310)" FT /evidence="ECO:0000269|PubMed:7569978" FT /id="VAR_056083" FT VARIANT 3482 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040124" FT VARIANT 3491 FT /note="P -> S (in dbSNP:rs2627037)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:7569978" FT /id="VAR_040125" FT VARIANT 3570 FT /note="E -> K (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040126" FT VARIANT 3590 FT /note="L -> V (in dbSNP:rs55853696)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040127" FT VARIANT 3637 FT /note="P -> S (in dbSNP:rs757223770)" FT /id="VAR_056084" FT VARIANT 3762 FT /note="I -> V (in dbSNP:rs34070843)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040128" FT VARIANT 3799 FT /note="S -> Y (in CMD1G)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026690" FT VARIANT 3877 FT /note="I -> F (in dbSNP:rs34618570)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040129" FT VARIANT 3965 FT /note="I -> L (in dbSNP:rs56244420)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040130" FT VARIANT 4084 FT /note="R -> Q (in dbSNP:rs200431386)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026691" FT VARIANT 4215 FT /note="T -> P (in dbSNP:rs2562829)" FT /evidence="ECO:0000269|PubMed:10051295, FT ECO:0000269|PubMed:10850961, ECO:0000269|PubMed:11717165, FT ECO:0000269|PubMed:11846417, ECO:0000269|PubMed:17344846" FT /id="VAR_026635" FT VARIANT 4238 FT /note="G -> W (in dbSNP:rs56030296)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040131" FT VARIANT 4283 FT /note="L -> F (in dbSNP:rs1883085)" FT /evidence="ECO:0000269|PubMed:10051295, FT ECO:0000269|PubMed:10850961, ECO:0000269|PubMed:11717165, FT ECO:0000269|PubMed:17344846" FT /id="VAR_026636" FT VARIANT 4291 FT /note="I -> T (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040132" FT VARIANT 4303 FT /note="G -> D (in dbSNP:rs55857742)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040133" FT VARIANT 4427 FT /note="D -> E (in dbSNP:rs55906845)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040134" FT VARIANT 4465 FT /note="S -> N (in CMD1G; dbSNP:rs281864908)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026692" FT VARIANT 8288 FT /note="A -> V (in dbSNP:rs16866412)" FT /id="VAR_056085" FT VARIANT 8474 FT /note="I -> T (in dbSNP:rs4893852)" FT /id="VAR_056086" FT VARIANT 12310 FT /note="G -> E (in dbSNP:rs55723264)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040135" FT VARIANT 12383 FT /note="H -> R (in dbSNP:rs2288563)" FT /evidence="ECO:0000269|PubMed:10850961" FT /id="VAR_040136" FT VARIANT 12469 FT /note="V -> A (in dbSNP:rs34706299)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040137" FT VARIANT 12642 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs199684560)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040138" FT VARIANT 12657 FT /note="E -> K (in a Wilms tumor; somatic mutation; FT dbSNP:rs778634417)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040139" FT VARIANT 12679 FT /note="K -> E (in dbSNP:rs6723526)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040140" FT VARIANT 12720 FT /note="S -> F (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040141" FT VARIANT 12798 FT /note="R -> C (in dbSNP:rs200914097)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040142" FT VARIANT 13049 FT /note="E -> G" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040143" FT VARIANT 13083 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs1458591077)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040144" FT VARIANT 13096 FT /note="R -> L (in dbSNP:rs373298007)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040145" FT VARIANT 13099 FT /note="Q -> R (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040146" FT VARIANT 13297 FT /note="V -> A (in dbSNP:rs571522834)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040147" FT VARIANT 13399 FT /note="I -> M (in dbSNP:rs74580375)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040148" FT VARIANT 13418 FT /note="A -> T (in dbSNP:rs144668626)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040149" FT VARIANT 13428 FT /note="E -> V (in dbSNP:rs114331773)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040150" FT VARIANT 13430 FT /note="I -> T (in dbSNP:rs184078045)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040151" FT VARIANT 13434 FT /note="R -> K (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040152" FT VARIANT 13469 FT /note="D -> N (in dbSNP:rs17354992)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040153" FT VARIANT 13495 FT /note="K -> N (in dbSNP:rs72677225)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040154" FT VARIANT 13785 FT /note="N -> S (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040155" FT VARIANT 13870 FT /note="Q -> H (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040156" FT VARIANT 14109 FT /note="V -> I (in dbSNP:rs72677232)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040157" FT VARIANT 14131 FT /note="R -> Q (in dbSNP:rs72677233)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040158" FT VARIANT 14208 FT /note="P -> T (in dbSNP:rs146181477)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040159" FT VARIANT 14728 FT /note="L -> V (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040160" FT VARIANT 14750 FT /note="R -> Q (in dbSNP:rs200944827)" FT /evidence="ECO:0000269|PubMed:25173926" FT /id="VAR_074294" FT VARIANT 14999 FT /note="S -> T (in dbSNP:rs55663050)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040161" FT VARIANT 15021 FT /note="N -> T (in dbSNP:rs36043230)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040162" FT VARIANT 15520 FT /note="A -> V (in dbSNP:rs16866412)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040163" FT VARIANT 15555 FT /note="R -> I (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs751398376)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040164" FT VARIANT 15620 FT /note="R -> Q (in dbSNP:rs201825412)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040165" FT VARIANT 15629 FT /note="S -> I (in dbSNP:rs200650668)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040166" FT VARIANT 15635 FT /note="Y -> C (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040167" FT VARIANT 15700 FT /note="R -> Q (in dbSNP:rs370390570)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040168" FT VARIANT 15705 FT /note="L -> P (in dbSNP:rs755155531)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040169" FT VARIANT 15837 FT /note="I -> M (in dbSNP:rs554368924)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040170" FT VARIANT 16046 FT /note="G -> V (in dbSNP:rs780672348)" FT /evidence="ECO:0000269|PubMed:23033978" FT /id="VAR_069432" FT VARIANT 16058 FT /note="R -> H (in dbSNP:rs72646808)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040171" FT VARIANT 16067 FT /note="K -> I (in dbSNP:rs2303832)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040172" FT VARIANT 16090 FT /note="I -> T (in dbSNP:rs72646809)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040173" FT VARIANT 16195 FT /note="R -> H (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs373526624)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040174" FT VARIANT 16409 FT /note="R -> C (in dbSNP:rs55734111)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040175" FT VARIANT 16424 FT /note="R -> P (in dbSNP:rs375895183)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040176" FT VARIANT 16575 FT /note="V -> M (in dbSNP:rs3813243)" FT /id="VAR_056087" FT VARIANT 16629 FT /note="I -> M (in dbSNP:rs55809450)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040177" FT VARIANT 16877 FT /note="K -> R (in dbSNP:rs72646823)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040178" FT VARIANT 17060 FT /note="N -> D (in dbSNP:rs1001238)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040179" FT VARIANT 17637 FT /note="I -> V (in dbSNP:rs56025724)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040180" FT VARIANT 17838 FT /note="R -> H (in dbSNP:rs2288569)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040181" FT VARIANT 17866 FT /note="D -> N" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040182" FT VARIANT 17906 FT /note="G -> E (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs374713701)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040183" FT VARIANT 18094 FT /note="E -> A (in dbSNP:rs769852851)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040184" FT VARIANT 18109 FT /note="G -> S (in dbSNP:rs200732032)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040185" FT VARIANT 18164 FT /note="R -> T (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040186" FT VARIANT 18221 FT /note="P -> L (in dbSNP:rs16866406)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040187" FT VARIANT 18222 FT /note="A -> T" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040188" FT VARIANT 18726 FT /note="R -> Q (in dbSNP:rs141973925)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040189" FT VARIANT 18835 FT /note="V -> A (in a breast infiltrating ductal carcinoma FT sample; somatic mutation; dbSNP:rs1336054298)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040190" FT VARIANT 18881 FT /note="R -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs1204056923)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040191" FT VARIANT 18939 FT /note="N -> S (in dbSNP:rs1470758075)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040192" FT VARIANT 19000 FT /note="R -> Q (in dbSNP:rs199895260)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040193" FT VARIANT 19060 FT /note="L -> Q (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs1383995916)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040194" FT VARIANT 19091 FT /note="R -> K (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040195" FT VARIANT 19224 FT /note="P -> S (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040196" FT VARIANT 19367 FT /note="T -> I (in dbSNP:rs72646850)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040197" FT VARIANT 19392 FT /note="E -> K (in a lung neuroendocrine carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040198" FT VARIANT 19480 FT /note="A -> S (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040199" FT VARIANT 19495 FT /note="D -> G (in dbSNP:rs773075736)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040200" FT VARIANT 19665 FT /note="R -> H (in dbSNP:rs202240487)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040201" FT VARIANT 19762 FT /note="T -> I (in dbSNP:rs2042996)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040202" FT VARIANT 19947 FT /note="G -> R (in dbSNP:rs181717727)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040203" FT VARIANT 19956 FT /note="V -> M (in dbSNP:rs150661999)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040204" FT VARIANT 19992 FT /note="R -> Q (in dbSNP:rs141965360)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040205" FT VARIANT 20057 FT /note="R -> C (in dbSNP:rs72646861)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040206" FT VARIANT 20075 FT /note="S -> L (in dbSNP:rs13021201)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040207" FT VARIANT 20179 FT /note="T -> K" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040208" FT VARIANT 20198 FT /note="A -> T (in dbSNP:rs56378177)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040209" FT VARIANT 20198 FT /note="A -> V (in dbSNP:rs55948748)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040210" FT VARIANT 20331 FT /note="R -> H (in dbSNP:rs200217934)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040211" FT VARIANT 20359 FT /note="R -> K (in dbSNP:rs9808036)" FT /id="VAR_056088" FT VARIANT 20408 FT /note="A -> T (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040212" FT VARIANT 20564 FT /note="R -> K (in dbSNP:rs72646869)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040213" FT VARIANT 20718 FT /note="V -> I (in dbSNP:rs2303838)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040214" FT VARIANT 20726 FT /note="S -> P (in dbSNP:rs72646873)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040215" FT VARIANT 20892 FT /note="T -> N" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040216" FT VARIANT 20894 FT /note="S -> R (in dbSNP:rs750847940)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040217" FT VARIANT 21125 FT /note="D -> E (in dbSNP:rs534340303)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040218" FT VARIANT 21403 FT /note="P -> S (in dbSNP:rs55980498)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040219" FT VARIANT 21730 FT /note="R -> C (in dbSNP:rs56141309)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040220" FT VARIANT 21747 FT /note="R -> Q (in dbSNP:rs55853138)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040221" FT VARIANT 21851 FT /note="C -> R (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs55713867)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040222" FT VARIANT 21925 FT /note="G -> R (in dbSNP:rs55801134)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040223" FT VARIANT 21995 FT /note="R -> H (in dbSNP:rs56071233)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040224" FT VARIANT 22045 FT /note="A -> V (in dbSNP:rs55903402)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040225" FT VARIANT 22149 FT /note="R -> H (in dbSNP:rs55677134)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040226" FT VARIANT 22160 FT /note="V -> I (in dbSNP:rs55885640)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040227" FT VARIANT 22261 FT /note="I -> T (in dbSNP:rs55837610)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040228" FT VARIANT 22306 FT /note="K -> N (in dbSNP:rs56019808)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040229" FT VARIANT 22357 FT /note="R -> H (in dbSNP:rs10164753)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040230" FT VARIANT 22408 FT /note="L -> P (in dbSNP:rs56399205)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040231" FT VARIANT 22537 FT /note="Q -> H (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040232" FT VARIANT 22584 FT /note="P -> L (in dbSNP:rs55992239)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040233" FT VARIANT 22646 FT /note="L -> P (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040234" FT VARIANT 22670 FT /note="T -> A (in dbSNP:rs56201325)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040235" FT VARIANT 22770 FT /note="A -> D (in dbSNP:rs55991022)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040236" FT VARIANT 22801 FT /note="A -> T (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs764005465)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040237" FT VARIANT 22823 FT /note="R -> W (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs369098292)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040238" FT VARIANT 22968 FT /note="E -> Q (in dbSNP:rs55762754)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040239" FT VARIANT 23074 FT /note="P -> L (in dbSNP:rs55713856)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040240" FT VARIANT 23079 FT /note="L -> F (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040241" FT VARIANT 23282 FT /note="D -> N (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040242" FT VARIANT 23303 FT /note="H -> Y (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040243" FT VARIANT 23306 FT /note="R -> C (in dbSNP:rs744426)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040244" FT VARIANT 23515 FT /note="A -> S (in a lung squamous cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040245" FT VARIANT 23551 FT /note="E -> Q (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040246" FT VARIANT 23807 FT /note="S -> N (in dbSNP:rs3813243)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040247" FT VARIANT 23872 FT /note="D -> N (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040248" FT VARIANT 23891 FT /note="V -> A (in dbSNP:rs55984930)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040249" FT VARIANT 23933 FT /note="Y -> H (in dbSNP:rs3813245)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040250" FT VARIANT 23939 FT /note="T -> M (in dbSNP:rs56372592)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040251" FT VARIANT 23952 FT /note="F -> L (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040252" FT VARIANT 24098 FT /note="A -> G (in dbSNP:rs56391938)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040253" FT VARIANT 24098 FT /note="A -> T (in dbSNP:rs4894028)" FT /id="VAR_056089" FT VARIANT 24119 FT /note="N -> S (in dbSNP:rs3813246)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040254" FT VARIANT 24133 FT /note="V -> I (in dbSNP:rs56340968)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040255" FT VARIANT 24159 FT /note="V -> A (in a head and neck squamous cell carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040256" FT VARIANT 24239 FT /note="T -> A (in dbSNP:rs56018860)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040257" FT VARIANT 24265 FT /note="E -> K (in dbSNP:rs56341835)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040258" FT VARIANT 24584 FT /note="I -> T (in dbSNP:rs12463674)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040259" FT VARIANT 24781 FT /note="I -> T (in dbSNP:rs3731745)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040260" FT VARIANT 24799 FT /note="R -> H (in dbSNP:rs56044609)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040261" FT VARIANT 24954 FT /note="D -> H (in dbSNP:rs56307213)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040262" FT VARIANT 24980 FT /note="T -> M (in dbSNP:rs3731746)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040263" FT VARIANT 25659 FT /note="R -> H (in dbSNP:rs55850344)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040264" FT VARIANT 25679 FT /note="A -> T (in dbSNP:rs56365600)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040265" FT VARIANT 25720 FT /note="P -> A (in dbSNP:rs56137800)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040266" FT VARIANT 25821 FT /note="T -> K (in dbSNP:rs55933739)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040267" FT VARIANT 25859 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs375422359)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040268" FT VARIANT 25879 FT /note="N -> K (in dbSNP:rs56264840)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040269" FT VARIANT 25923 FT /note="A -> V (in dbSNP:rs55634791)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040270" FT VARIANT 26045 FT /note="V -> I (in dbSNP:rs56309296)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040271" FT VARIANT 26059 FT /note="K -> E (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040272" FT VARIANT 26134 FT /note="I -> V (in dbSNP:rs3829746)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040273" FT VARIANT 26477 FT /note="R -> C (in dbSNP:rs56057221)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040274" FT VARIANT 26843 FT /note="D -> Y (in dbSNP:rs56330345)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040275" FT VARIANT 27346 FT /note="K -> R (in dbSNP:rs1186947794)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040276" FT VARIANT 27652 FT /note="R -> C (in dbSNP:rs191482653)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040277" FT VARIANT 27728 FT /note="G -> V (in dbSNP:rs55898359)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040278" FT VARIANT 27754 FT /note="F -> L (in dbSNP:rs55940667)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040279" FT VARIANT 27755 FT /note="I -> T (in dbSNP:rs9808377)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040280" FT VARIANT 27929 FT /note="I -> V (in dbSNP:rs139506970)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040281" FT VARIANT 28132 FT /note="I -> L (in dbSNP:rs77853750)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040282" FT VARIANT 28168 FT /note="R -> Q (in dbSNP:rs72648238)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040283" FT VARIANT 28538 FT /note="R -> H (in dbSNP:rs149567378)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040284" FT VARIANT 28572 FT /note="I -> T (in dbSNP:rs114026724)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040285" FT VARIANT 28948 FT /note="A -> T (in dbSNP:rs148617456)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040286" FT VARIANT 28986 FT /note="I -> V (in dbSNP:rs535151633)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040287" FT VARIANT 28993 FT /note="G -> E (in dbSNP:rs376628842)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040288" FT VARIANT 28998 FT /note="L -> V (in dbSNP:rs373049260)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040289" FT VARIANT 29070 FT /note="V -> M (in dbSNP:rs747122)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040290" FT VARIANT 29090 FT /note="I -> V (in dbSNP:rs16866391)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040291" FT VARIANT 29419 FT /note="R -> C (in dbSNP:rs750303653)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040292" FT VARIANT 29479 FT /note="L -> P (in dbSNP:rs1310673663)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040293" FT VARIANT 29880 FT /note="S -> L (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040294" FT VARIANT 29976 FT /note="D -> E (in dbSNP:rs72648256)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040295" FT VARIANT 30042 FT /note="S -> G (in dbSNP:rs72648257)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040296" FT VARIANT 30107 FT /note="R -> C (in dbSNP:rs142525903)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040297" FT VARIANT 30125 FT /note="S -> F (in dbSNP:rs191484894)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040298" FT VARIANT 30211 FT /note="L -> P (in dbSNP:rs62621206)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040299" FT VARIANT 30412 FT /note="I -> T (in dbSNP:rs62621236)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040300" FT VARIANT 30617 FT /note="T -> S (in a renal chromophobe cancer sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040301" FT VARIANT 30674 FT /note="T -> I (in dbSNP:rs56027402)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040302" FT VARIANT 30809 FT /note="V -> I (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs397517769)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040303" FT VARIANT 30818 FT /note="F -> I (in dbSNP:rs56009327)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040304" FT VARIANT 30825 FT /note="E -> K (in dbSNP:rs55915651)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040305" FT VARIANT 30856 FT /note="I -> T (in dbSNP:rs55660660)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040306" FT VARIANT 30887 FT /note="G -> D (in dbSNP:rs56066673)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040307" FT VARIANT 30887 FT /note="G -> S (in dbSNP:rs56233675)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040308" FT VARIANT 30897 FT /note="R -> H (in dbSNP:rs3731749)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040309" FT VARIANT 30907 FT /note="R -> H (in dbSNP:rs55676195)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040310" FT VARIANT 30946 FT /note="R -> H (in dbSNP:rs55704830)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040311" FT VARIANT 31081 FT /note="I -> F (in dbSNP:rs72648270)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040312" FT VARIANT 31107 FT /note="R -> C (in dbSNP:rs72648272)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040313" FT VARIANT 31124 FT /note="A -> G (in dbSNP:rs72648273)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040314" FT VARIANT 31156 FT /note="N -> S (in dbSNP:rs149001703)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040315" FT VARIANT 31246 FT /note="P -> T (in dbSNP:rs55653324)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040316" FT VARIANT 31330 FT /note="R -> H (in dbSNP:rs4894028)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040317" FT VARIANT 31690 FT /note="C -> R (in dbSNP:rs56061641)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040318" FT VARIANT 31724 FT /note="R -> Q (in dbSNP:rs55742743)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040319" FT VARIANT 31725 FT /note="V -> I (in dbSNP:rs55675869)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040320" FT VARIANT 31732 FT /note="G -> S (in dbSNP:rs55880786)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040321" FT VARIANT 31886 FT /note="V -> I (in dbSNP:rs2278196)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040322" FT VARIANT 32097 FT /note="R -> C (in dbSNP:rs56273463)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040323" FT VARIANT 32171 FT /note="T -> N (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040324" FT VARIANT 32248 FT /note="V -> I (in dbSNP:rs34924609)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040325" FT VARIANT 32281 FT /note="Q -> H (in dbSNP:rs55886356)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040326" FT VARIANT 32323 FT /note="R -> H (in dbSNP:rs55669553)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040327" FT VARIANT 32411 FT /note="R -> W (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs756924372)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040328" FT VARIANT 32558 FT /note="I -> V (in dbSNP:rs56347248)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040329" FT VARIANT 32610 FT /note="M -> V (in dbSNP:rs56173891)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040330" FT VARIANT 32637 FT /note="G -> V (in dbSNP:rs3731752)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040331" FT VARIANT 32742 FT /note="E -> Q (in dbSNP:rs148525155)" FT /evidence="ECO:0000269|PubMed:23033978" FT /id="VAR_069433" FT VARIANT 32922 FT /note="V -> A (in dbSNP:rs55945684)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040332" FT VARIANT 32943 FT /note="L -> R (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040333" FT VARIANT 32953 FT /note="R -> H (in dbSNP:rs3829747)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040334" FT VARIANT 32996 FT /note="R -> Q (in CMD1G; dbSNP:rs199642423)" FT /evidence="ECO:0000269|PubMed:16465475" FT /id="VAR_026693" FT VARIANT 33213 FT /note="V -> L (in dbSNP:rs55866005)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040335" FT VARIANT 33242 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1003158162)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040336" FT VARIANT 33387 FT /note="T -> M (in dbSNP:rs56001826)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040337" FT VARIANT 33419 FT /note="E -> D (in dbSNP:rs56308529)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040338" FT VARIANT 33536 FT /note="V -> M (in dbSNP:rs55865284)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040339" FT VARIANT 33568 FT /note="K -> Q (in dbSNP:rs56365812)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040340" FT VARIANT 33616 FT /note="E -> K (in dbSNP:rs56324595)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040341" FT VARIANT 33620 FT /note="P -> L (in dbSNP:rs16866380)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040342" FT VARIANT 33886 FT /note="E -> V (in dbSNP:rs55725279)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040343" FT VARIANT 33899 FT /note="I -> T (in dbSNP:rs55880440)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040344" FT VARIANT 33904 FT /note="L -> P (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040345" FT VARIANT 33955 FT /note="T -> I (in dbSNP:rs55842557)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040346" FT VARIANT 34115 FT /note="V -> A (in dbSNP:rs16866378)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040347" FT VARIANT 34306 FT /note="I -> N (in TMD; dbSNP:rs281864928)" FT /evidence="ECO:0000269|PubMed:12891679" FT /id="VAR_026694" FT VARIANT 34315 FT /note="L -> P (in TMD; dbSNP:rs267607156)" FT /evidence="ECO:0000269|PubMed:12145747" FT /id="VAR_026695" FT MUTAGEN 32207 FT /note="K->A: Disrupts catalytic activity." FT /evidence="ECO:0000269|PubMed:9804419" FT MUTAGEN 32341 FT /note="Y->E: No phosphorylation on tyrosine." FT /evidence="ECO:0000269|PubMed:9804419" FT CONFLICT 132 FT /note="T -> N (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 255 FT /note="P -> H (in Ref. 3; CAD12455/CAD12456/CAD12457)" FT /evidence="ECO:0000305" FT CONFLICT 1472..1474 FT /note="QTA -> ANC (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 1730 FT /note="G -> S (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 3919 FT /note="P -> L (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 4525 FT /note="R -> K (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 6619 FT /note="R -> E (in Ref. 1; CAA62189 and 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 7145 FT /note="D -> H (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 7441 FT /note="S -> N (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 8038 FT /note="A -> E (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 8225 FT /note="Q -> H (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 8850 FT /note="A -> P (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 9693 FT /note="C -> V (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 9892 FT /note="I -> V (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 10205 FT /note="I -> V (in Ref. 3; CAD12456 and 9; AAP80791)" FT /evidence="ECO:0000305" FT CONFLICT 10305 FT /note="G -> R (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 10566 FT /note="R -> K (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 10779 FT /note="R -> H (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 11424 FT /note="E -> D (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 11511 FT /note="A -> V (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 11626 FT /note="K -> N (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 11838 FT /note="K -> N (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 12994 FT /note="A -> T (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 13795..13797 FT /note="YKF -> IQI (in Ref. 11)" FT /evidence="ECO:0000305" FT CONFLICT 14590 FT /note="A -> T (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 14792 FT /note="V -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 15974 FT /note="E -> K (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 16234..16235 FT /note="TK -> QR (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 17238 FT /note="R -> H (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 17423 FT /note="R -> S (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 19734 FT /note="V -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 20517 FT /note="G -> A (in Ref. 1; CAA62188 and 3; CAD12455)" FT /evidence="ECO:0000305" FT CONFLICT 20622 FT /note="L -> H (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 20775 FT /note="A -> P (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 21625 FT /note="Y -> I (in Ref. 13; CAA45939)" FT /evidence="ECO:0000305" FT CONFLICT 21795..21800 FT /note="PGPVLN -> ARPSPQ (in Ref. 13; CAA45939)" FT /evidence="ECO:0000305" FT CONFLICT 22176 FT /note="C -> W (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 22816 FT /note="A -> D (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 22837 FT /note="T -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 24176 FT /note="I -> M (in Ref. 1; CAA62188 and 13; CAA45940)" FT /evidence="ECO:0000305" FT CONFLICT 24181 FT /note="S -> F (in Ref. 13; CAA45940)" FT /evidence="ECO:0000305" FT CONFLICT 25731 FT /note="P -> S (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 26573 FT /note="M -> V (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 26846..26848 FT /note="IVE -> HRK (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 27879 FT /note="G -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 28936 FT /note="D -> N (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 29222 FT /note="A -> T (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 29518 FT /note="F -> L (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 29701 FT /note="T -> P (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 29873 FT /note="E -> G (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 29878 FT /note="T -> Q (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30209 FT /note="K -> E (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30256 FT /note="A -> R (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30496 FT /note="V -> I (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30534 FT /note="Y -> H (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30748 FT /note="S -> L (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 31303 FT /note="W -> V (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 32060 FT /note="V -> A (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33084 FT /note="D -> N (in Ref. 1; CAA62188 and 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33120 FT /note="R -> W (in Ref. 15; CAD28458)" FT /evidence="ECO:0000305" FT CONFLICT 33382 FT /note="A -> R (in Ref. 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33424 FT /note="S -> P (in Ref. 1; CAA62188 and 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33526 FT /note="Q -> R (in Ref. 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33633 FT /note="T -> I (in Ref. 1; CAA62188 and 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33716 FT /note="Y -> V (in Ref. 15; CAD28458)" FT /evidence="ECO:0000305" FT CONFLICT 33995 FT /note="V -> A (in Ref. 15; CAD28458)" FT /evidence="ECO:0000305" FT CONFLICT 34071 FT /note="N -> G (in Ref. 5; AAI07798)" FT /evidence="ECO:0000305" FT CONFLICT 34082 FT /note="C -> R (in Ref. 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 34253 FT /note="G -> R (in Ref. 5; AAI07798)" FT /evidence="ECO:0000305" FT STRAND 4..10 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 15..18 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 23..33 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 36..45 FT /evidence="ECO:0007829|PDB:2A38" FT TURN 48..50 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 55..59 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 62..69 FT /evidence="ECO:0007829|PDB:2A38" FT HELIX 72..74 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 76..84 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 87..98 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 102..108 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 113..116 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 119..131 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 134..139 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 142..144 FT /evidence="ECO:0007829|PDB:1YA5" FT STRAND 147..155 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 158..166 FT /evidence="ECO:0007829|PDB:2A38" FT HELIX 168..170 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 172..180 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 183..194 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 199..205 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 209..213 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 225..233 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 236..241 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 1850..1852 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1858..1863 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1866..1869 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1871..1876 FT /evidence="ECO:0007829|PDB:6DL4" FT TURN 1891..1893 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1894..1899 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1908..1916 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1919..1929 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 2076..2082 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2087..2090 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2095..2105 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2108..2113 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2122..2130 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2133..2138 FT /evidence="ECO:0007829|PDB:1G1C" FT HELIX 2143..2145 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2147..2155 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2158..2169 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2797..2799 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2804..2807 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2812..2820 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2826..2829 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2838..2845 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2848..2853 FT /evidence="ECO:0007829|PDB:5JDD" FT HELIX 2858..2860 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2862..2868 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2871..2880 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2884..2886 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2891..2894 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2899..2907 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2914..2916 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2924..2932 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2935..2940 FT /evidence="ECO:0007829|PDB:5JDD" FT HELIX 2945..2947 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2949..2955 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2958..2967 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2971..2973 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2978..2981 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2986..2994 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3000..3003 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3012..3019 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3022..3027 FT /evidence="ECO:0007829|PDB:5JDD" FT HELIX 3032..3034 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3036..3042 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3045..3053 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3504..3507 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3512..3515 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3520..3527 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3533..3538 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3547..3554 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3557..3562 FT /evidence="ECO:0007829|PDB:8OVU" FT HELIX 3567..3569 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3571..3579 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3582..3593 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 7948..7951 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7956..7958 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7964..7975 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7977..7981 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7983..7986 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7991..7996 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8001..8008 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8011..8013 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8015..8023 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8026..8036 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8044..8047 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8052..8055 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8060..8071 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8073..8078 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8087..8094 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8097..8104 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8107..8109 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8111..8119 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8122..8133 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8140..8143 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8151..8154 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8156..8166 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8169..8174 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8183..8190 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8193..8201 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8203..8205 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8207..8215 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8218..8226 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8233..8236 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8244..8247 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8249..8261 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8263..8268 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8276..8284 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8287..8294 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8297..8299 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8301..8309 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8315..8320 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8335..8337 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8343..8354 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8358..8361 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8368..8377 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8380..8385 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8390..8392 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8394..8401 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8406..8415 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8420..8423 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8436..8444 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8451..8454 FT /evidence="ECO:0007829|PDB:3B43" FT TURN 8463..8465 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8466..8468 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8472..8481 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8488..8495 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8500..8507 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 9506..9510 FT /evidence="ECO:0007829|PDB:7NIP" FT HELIX 9518..9525 FT /evidence="ECO:0007829|PDB:7NIP" FT HELIX 9530..9543 FT /evidence="ECO:0007829|PDB:7NIP" FT STRAND 9582..9587 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9592..9595 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9600..9608 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9616..9619 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9628..9635 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9638..9643 FT /evidence="ECO:0007829|PDB:5JOE" FT HELIX 9648..9650 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9652..9658 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9661..9670 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9674..9676 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9681..9684 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9689..9697 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9703..9706 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9717..9722 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9725..9732 FT /evidence="ECO:0007829|PDB:7AHS" FT HELIX 9735..9737 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9739..9745 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9748..9757 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9763..9765 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9770..9772 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9778..9786 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9790..9795 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9803..9811 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9814..9819 FT /evidence="ECO:0007829|PDB:7AHS" FT HELIX 9824..9826 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9828..9835 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9841..9850 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 12680..12682 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12687..12690 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12691..12693 FT /evidence="ECO:0007829|PDB:6I0Y" FT STRAND 12695..12705 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12709..12712 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12719..12722 FT /evidence="ECO:0007829|PDB:1TIU" FT STRAND 12723..12728 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12731..12736 FT /evidence="ECO:0007829|PDB:1WAA" FT HELIX 12741..12743 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12745..12751 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12754..12763 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 14223..14228 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14232..14240 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14252..14259 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14275..14281 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14288..14296 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14308..14314 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14319..14322 FT /evidence="ECO:0007829|PDB:8BXR" FT HELIX 14325..14327 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14331..14334 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14339..14349 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14352..14357 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14368..14372 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14374..14381 FT /evidence="ECO:0007829|PDB:8BXR" FT HELIX 14386..14388 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14390..14397 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14402..14412 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14419..14424 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14431..14436 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14446..14455 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14462..14468 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14470..14475 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14484..14492 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14506..14509 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14522..14524 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14528..14534 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14549..14555 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14568..14576 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14584..14592 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 15216..15224 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15227..15233 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15245..15252 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15268..15273 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15282..15290 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15305..15307 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 16533..16538 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16541..16546 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16559..16566 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16585..16592 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16600..16609 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16623..16626 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 20520..20528 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20531..20537 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20549..20556 FT /evidence="ECO:0007829|PDB:8OSD" FT HELIX 20568..20570 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20573..20580 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20587..20594 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 21506..21509 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21515..21518 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21532..21539 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21546..21551 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21553..21560 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21568..21577 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 22291..22296 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22299..22303 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22319..22324 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22340..22345 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22354..22361 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22367..22377 FT /evidence="ECO:0007829|PDB:1BPV" FT HELIX 22381..22384 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22883..22890 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22895..22900 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22912..22919 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22926..22932 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22934..22939 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22947..22956 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22970..22972 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22982..22987 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22992..22996 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23009..23016 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23023..23035 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23043..23052 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23568..23575 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23581..23586 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23596..23605 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23612..23618 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23620..23625 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23633..23642 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23671..23676 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23679..23683 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23697..23704 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23711..23716 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23720..23725 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23733..23742 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23769..23776 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23781..23786 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23798..23805 FT /evidence="ECO:0007829|PDB:8BNQ" FT TURN 23806..23808 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23811..23815 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23820..23827 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23835..23843 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 25439..25443 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25448..25451 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25465..25472 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25479..25481 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25486..25493 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25501..25509 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25514..25517 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 26130..26137 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26142..26147 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26157..26166 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26173..26179 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26181..26186 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26194..26203 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26206..26212 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 31458..31464 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31469..31472 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31475..31487 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31490..31495 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31498..31500 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31504..31520 FT /evidence="ECO:0007829|PDB:3LCY" FT HELIX 31524..31526 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31528..31535 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31540..31555 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31563..31568 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31573..31583 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31586..31591 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31600..31606 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31608..31617 FT /evidence="ECO:0007829|PDB:3LCY" FT HELIX 31620..31623 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31625..31632 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31637..31647 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31856..31859 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31864..31867 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31872..31879 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31885..31890 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31893..31895 FT /evidence="ECO:0007829|PDB:2J8O" FT STRAND 31899..31907 FT /evidence="ECO:0007829|PDB:2J8H" FT TURN 31908..31910 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31911..31916 FT /evidence="ECO:0007829|PDB:2J8H" FT HELIX 31921..31923 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31925..31933 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31936..31952 FT /evidence="ECO:0007829|PDB:2J8H" FT HELIX 31956..31959 FT /evidence="ECO:0007829|PDB:2NZI" FT STRAND 31961..31967 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31973..31982 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31985..31992 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31997..32000 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32002..32005 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32007..32013 FT /evidence="ECO:0007829|PDB:2J8H" FT HELIX 32020..32022 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32024..32032 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32035..32046 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32053..32061 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32063..32070 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32076..32078 FT /evidence="ECO:0007829|PDB:2NZI" FT STRAND 32082..32089 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32095..32111 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32117..32125 FT /evidence="ECO:0007829|PDB:6YGN" FT HELIX 32142..32154 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32167..32170 FT /evidence="ECO:0007829|PDB:6YGN" FT TURN 32175..32177 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32178..32186 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32188..32197 FT /evidence="ECO:0007829|PDB:1TKI" FT TURN 32198..32201 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32202..32209 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32214..32228 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32237..32243 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32246..32251 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32259..32263 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32265..32267 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32272..32291 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32301..32303 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32304..32310 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32314..32316 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32330..32336 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32338..32340 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32343..32346 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32353..32369 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32379..32388 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32395..32398 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32403..32410 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32417..32419 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32423..32428 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32430..32433 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32436..32438 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32447..32457 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32466..32472 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32474..32476 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32483..32489 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32504..32506 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32512..32520 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32526..32531 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32538..32547 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32550..32555 FT /evidence="ECO:0007829|PDB:2BK8" FT HELIX 32560..32562 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32564..32571 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32576..32585 FT /evidence="ECO:0007829|PDB:2BK8" FT TURN 32586..32588 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32720..32726 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32731..32734 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32739..32749 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32752..32757 FT /evidence="ECO:0007829|PDB:6HCI" FT TURN 32765..32767 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32768..32773 FT /evidence="ECO:0007829|PDB:6HCI" FT TURN 32774..32776 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32777..32784 FT /evidence="ECO:0007829|PDB:6HCI" FT HELIX 32787..32789 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32791..32799 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32802..32813 FT /evidence="ECO:0007829|PDB:6HCI" FT TURN 33294..33297 FT /evidence="ECO:0007829|PDB:3QP3" FT STRAND 33299..33305 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33310..33313 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33318..33328 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33331..33336 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33345..33352 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33355..33360 FT /evidence="ECO:0007829|PDB:6H4L" FT HELIX 33365..33367 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33369..33377 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33380..33391 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33489..33492 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33497..33503 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33509..33512 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33514..33516 FT /evidence="ECO:0007829|PDB:1TNM" FT STRAND 33523..33526 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33532..33538 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33540..33547 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33556..33560 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33571..33577 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33777..33783 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33788..33794 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33796..33806 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33809..33814 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33821..33830 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33833..33838 FT /evidence="ECO:0007829|PDB:3PUC" FT HELIX 33843..33845 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33847..33855 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33858..33869 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 34060..34071 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34078..34088 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34091..34096 FT /evidence="ECO:0007829|PDB:4UOW" FT TURN 34104..34106 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34107..34112 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34115..34122 FT /evidence="ECO:0007829|PDB:4UOW" FT HELIX 34125..34127 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34129..34136 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34138..34148 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34254..34258 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34263..34268 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34271..34283 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34286..34291 FT /evidence="ECO:0007829|PDB:3KNB" FT HELIX 34300..34302 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34304..34308 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34310..34319 FT /evidence="ECO:0007829|PDB:3KNB" FT HELIX 34322..34324 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34326..34334 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34337..34348 FT /evidence="ECO:0007829|PDB:3KNB" FT CONFLICT Q8WZ42-6:3732 FT /note="L -> F (in Ref. 3; CAD12457)" FT /evidence="ECO:0000305" FT CONFLICT Q8WZ42-6:5139 FT /note="R -> M (in Ref. 3; CAD12457)" FT /evidence="ECO:0000305" SQ SEQUENCE 34350 AA; 3816030 MW; DEB216410AD560D9 CRC64; MTTQAPTFTQ PLQSVVVLEG STATFEAHIS GFPVPEVSWF RDGQVISTST LPGVQISFSD GRAKLTIPAV TKANSGRYSL KATNGSGQAT STAELLVKAE TAPPNFVQRL QSMTVRQGSQ VRLQVRVTGI PTPVVKFYRD GAEIQSSLDF QISQEGDLYS LLIAEAYPED SGTYSVNATN SVGRATSTAE LLVQGEEEVP AKKTKTIVST AQISESRQTR IEKKIEAHFD ARSIATVEMV IDGAAGQQLP HKTPPRIPPK PKSRSPTPPS IAAKAQLARQ QSPSPIRHSP SPVRHVRAPT PSPVRSVSPA ARISTSPIRS VRSPLLMRKT QASTVATGPE VPPPWKQEGY VASSSEAEMR ETTLTTSTQI RTEERWEGRY GVQEQVTISG AAGAAASVSA SASYAAEAVA TGAKEVKQDA DKSAAVATVV AAVDMARVRE PVISAVEQTA QRTTTTAVHI QPAQEQVRKE AEKTAVTKVV VAADKAKEQE LKSRTKEVIT TKQEQMHVTH EQIRKETEKT FVPKVVISAA KAKEQETRIS EEITKKQKQV TQEAIRQETE ITAASMVVVA TAKSTKLETV PGAQEETTTQ QDQMHLSYEK IMKETRKTVV PKVIVATPKV KEQDLVSRGR EGITTKREQV QITQEKMRKE AEKTALSTIA VATAKAKEQE TILRTRETMA TRQEQIQVTH GKVDVGKKAE AVATVVAAVD QARVREPREP GHLEESYAQQ TTLEYGYKER ISAAKVAEPP QRPASEPHVV PKAVKPRVIQ APSETHIKTT DQKGMHISSQ IKKTTDLTTE RLVHVDKRPR TASPHFTVSK ISVPKTEHGY EASIAGSAIA TLQKELSATS SAQKITKSVK APTVKPSETR VRAEPTPLPQ FPFADTPDTY KSEAGVEVKK EVGVSITGTT VREERFEVLH GREAKVTETA RVPAPVEIPV TPPTLVSGLK NVTVIEGESV TLECHISGYP SPTVTWYRED YQIESSIDFQ ITFQSGIARL MIREAFAEDS GRFTCSAVNE AGTVSTSCYL AVQVSEEFEK ETTAVTEKFT TEEKRFVESR DVVMTDTSLT EEQAGPGEPA APYFITKPVV QKLVEGGSVV FGCQVGGNPK PHVYWKKSGV PLTTGYRYKV SYNKQTGECK LVISMTFADD AGEYTIVVRN KHGETSASAS LLEEADYELL MKSQQEMLYQ TQVTAFVQEP KVGETAPGFV YSEYEKEYEK EQALIRKKMA KDTVVVRTYV EDQEFHISSF EERLIKEIEY RIIKTTLEEL LEEDGEEKMA VDISESEAVE SGFDSRIKNY RILEGMGVTF HCKMSGYPLP KIAWYKDGKR IKHGERYQMD FLQDGRASLR IPVVLPEDEG IYTAFASNIK GNAICSGKLY VEPAAPLGAP TYIPTLEPVS RIRSLSPRSV SRSPIRMSPA RMSPARMSPA RMSPARMSPG RRLEETDESQ LERLYKPVFV LKPVSFKCLE GQTARFDLKV VGRPMPETFW FHDGQQIVND YTHKVVIKED GTQSLIIVPA TPSDSGEWTV VAQNRAGRSS ISVILTVEAV EHQVKPMFVE KLKNVNIKEG SRLEMKVRAT GNPNPDIVWL KNSDIIVPHK YPKIRIEGTK GEAALKIDST VSQDSAWYTA TAINKAGRDT TRCKVNVEVE FAEPEPERKL IIPRGTYRAK EIAAPELEPL HLRYGQEQWE EGDLYDKEKQ QKPFFKKKLT SLRLKRFGPA HFECRLTPIG DPTMVVEWLH DGKPLEAANR LRMINEFGYC SLDYGVAYSR DSGIITCRAT NKYGTDHTSA TLIVKDEKSL VEESQLPEGR KGLQRIEELE RMAHEGALTG VTTDQKEKQK PDIVLYPEPV RVLEGETARF RCRVTGYPQP KVNWYLNGQL IRKSKRFRVR YDGIHYLDIV DCKSYDTGEV KVTAENPEGV IEHKVKLEIQ QREDFRSVLR RAPEPRPEFH VHEPGKLQFE VQKVDRPVDT TETKEVVKLK RAERITHEKV PEESEELRSK FKRRTEEGYY EAITAVELKS RKKDESYEEL LRKTKDELLH WTKELTEEEK KALAEEGKIT IPTFKPDKIE LSPSMEAPKI FERIQSQTVG QGSDAHFRVR VVGKPDPECE WYKNGVKIER SDRIYWYWPE DNVCELVIRD VTAEDSASIM VKAINIAGET SSHAFLLVQA KQLITFTQEL QDVVAKEKDT MATFECETSE PFVKVKWYKD GMEVHEGDKY RMHSDRKVHF LSILTIDTSD AEDYSCVLVE DENVKTTAKL IVEGAVVEFV KELQDIEVPE SYSGELECIV SPENIEGKWY HNDVELKSNG KYTITSRRGR QNLTVKDVTK EDQGEYSFVI DGKKTTCKLK MKPRPIAILQ GLSDQKVCEG DIVQLEVKVS LESVEGVWMK DGQEVQPSDR VHIVIDKQSH MLLIEDMTKE DAGNYSFTIP ALGLSTSGRV SVYSVDVITP LKDVNVIEGT KAVLECKVSV PDVTSVKWYL NDEQIKPDDR VQAIVKGTKQ RLVINRTHAS DEGPYKLIVG RVETNCNLSV EKIKIIRGLR DLTCTETQNV VFEVELSHSG IDVLWNFKDK EIKPSSKYKI EAHGKIYKLT VLNMMKDDEG KYTFYAGENM TSGKLTVAGG AISKPLTDQT VAESQEAVFE CEVANPDSKG EWLRDGKHLP LTNNIRSESD GHKRRLIIAA TKLDDIGEYT YKVATSKTSA KLKVEAVKIK KTLKNLTVTE TQDAVFTVEL THPNVKGVQW IKNGVVLESN EKYAISVKGT IYSLRIKNCA IVDESVYGFR LGRLGASARL HVETVKIIKK PKDVTALENA TVAFEVSVSH DTVPVKWFHK SVEIKPSDKH RLVSERKVHK LMLQNISPSD AGEYTAVVGQ LECKAKLFVE TLHITKTMKN IEVPETKTAS FECEVSHFNV PSMWLKNGVE IEMSEKFKIV VQGKLHQLII MNTSTEDSAE YTFVCGNDQV SATLTVTPIM ITSMLKDINA EEKDTITFEV TVNYEGISYK WLKNGVEIKS TDKCQMRTKK LTHSLNIRNV HFGDAADYTF VAGKATSTAT LYVEARHIEF RKHIKDIKVL EKKRAMFECE VSEPDITVQW MKDDQELQIT DRIKIQKEKY VHRLLIPSTR MSDAGKYTVV AGGNVSTAKL FVEGRDVRIR SIKKEVQVIE KQRAVVEFEV NEDDVDAHWY KDGIEINFQV QERHKYVVER RIHRMFISET RQSDAGEYTF VAGRNRSSVT LYVNAPEPPQ VLQELQPVTV QSGKPARFCA VISGRPQPKI SWYKEEQLLS TGFKCKFLHD GQEYTLLLIE AFPEDAAVYT CEAKNDYGVA TTSASLSVEV PEVVSPDQEM PVYPPAIITP LQDTVTSEGQ PARFQCRVSG TDLKVSWYSK DKKIKPSRFF RMTQFEDTYQ LEIAEAYPED EGTYTFVASN AVGQVSSTAN LSLEAPESIL HERIEQEIEM EMKEFSSSFL SAEEEGLHSA ELQLSKINET LELLSESPVY PTKFDSEKEG TGPIFIKEVS NADISMGDVA TLSVTVIGIP KPKIQWFFNG VLLTPSADYK FVFDGDDHSL IILFTKLEDE GEYTCMASND YGKTICSAYL KINSKGEGHK DTETESAVAK SLEKLGGPCP PHFLKELKPI RCAQGLPAIF EYTVVGEPAP TVTWFKENKQ LCTSVYYTII HNPNGSGTFI VNDPQREDSG LYICKAENML GESTCAAELL VLLEDTDMTD TPCKAKSTPE APEDFPQTPL KGPAVEALDS EQEIATFVKD TILKAALITE ENQQLSYEHI AKANELSSQL PLGAQELQSI LEQDKLTPES TREFLCINGS IHFQPLKEPS PNLQLQIVQS QKTFSKEGIL MPEEPETQAV LSDTEKIFPS AMSIEQINSL TVEPLKTLLA EPEGNYPQSS IEPPMHSYLT SVAEEVLSPK EKTVSDTNRE QRVTLQKQEA QSALILSQSL AEGHVESLQS PDVMISQVNY EPLVPSEHSC TEGGKILIES ANPLENAGQD SAVRIEEGKS LRFPLALEEK QVLLKEEHSD NVVMPPDQII ESKREPVAIK KVQEVQGRDL LSKESLLSGI PEEQRLNLKI QICRALQAAV ASEQPGLFSE WLRNIEKVEV EAVNITQEPR HIMCMYLVTS AKSVTEEVTI IIEDVDPQMA NLKMELRDAL CAIIYEEIDI LTAEGPRIQQ GAKTSLQEEM DSFSGSQKVE PITEPEVESK YLISTEEVSY FNVQSRVKYL DATPVTKGVA SAVVSDEKQD ESLKPSEEKE ESSSESGTEE VATVKIQEAE GGLIKEDGPM IHTPLVDTVS EEGDIVHLTT SITNAKEVNW YFENKLVPSD EKFKCLQDQN TYTLVIDKVN TEDHQGEYVC EALNDSGKTA TSAKLTVVKR AAPVIKRKIE PLEVALGHLA KFTCEIQSAP NVRFQWFKAG REIYESDKCS IRSSKYISSL EILRTQVVDC GEYTCKASNE YGSVSCTATL TVTEAYPPTF LSRPKSLTTF VGKAAKFICT VTGTPVIETI WQKDGAALSP SPNWRISDAE NKHILELSNL TIQDRGVYSC KASNKFGADI CQAELIIIDK PHFIKELEPV QSAINKKVHL ECQVDEDRKV TVTWSKDGQK LPPGKDYKIC FEDKIATLEI PLAKLKDSGT YVCTASNEAG SSSCSATVTV REPPSFVKKV DPSYLMLPGE SARLHCKLKG SPVIQVTWFK NNKELSESNT VRMYFVNSEA ILDITDVKVE DSGSYSCEAV NDVGSDSCST EIVIKEPPSF IKTLEPADIV RGTNALLQCE VSGTGPFEIS WFKDKKQIRS SKKYRLFSQK SLVCLEIFSF NSADVGEYEC VVANEVGKCG CMATHLLKEP PTFVKKVDDL IALGGQTVTL QAAVRGSEPI SVTWMKGQEV IREDGKIKMS FSNGVAVLII PDVQISFGGK YTCLAENEAG SQTSVGELIV KEPAKIIERA ELIQVTAGDP ATLEYTVAGT PELKPKWYKD GRPLVASKKY RISFKNNVAQ LKFYSAELHD SGQYTFEISN EVGSSSCETT FTVLDRDIAP FFTKPLRNVD SVVNGTCRLD CKIAGSLPMR VSWFKDGKEI AASDRYRIAF VEGTASLEII RVDMNDAGNF TCRATNSVGS KDSSGALIVQ EPPSFVTKPG SKDVLPGSAV CLKSTFQGST PLTIRWFKGN KELVSGGSCY ITKEALESSL ELYLVKTSDS GTYTCKVSNV AGGVECSANL FVKEPATFVE KLEPSQLLKK GDATQLACKV TGTPPIKITW FANDREIKES SKHRMSFVES TAVLRLTDVG IEDSGEYMCE AQNEAGSDHC SSIVIVKESP YFTKEFKPIE VLKEYDVMLL AEVAGTPPFE ITWFKDNTIL RSGRKYKTFI QDHLVSLQIL KFVAADAGEY QCRVTNEVGS SICSARVTLR EPPSFIKKIE STSSLRGGTA AFQATLKGSL PITVTWLKDS DEITEDDNIR MTFENNVASL YLSGIEVKHD GKYVCQAKND AGIQRCSALL SVKEPATITE EAVSIDVTQG DPATLQVKFS GTKEITAKWF KDGQELTLGS KYKISVTDTV SILKIISTEK KDSGEYTFEV QNDVGRSSCK ARINVLDLII PPSFTKKLKK MDSIKGSFID LECIVAGSHP ISIQWFKDDQ EISASEKYKF SFHDNTAFLE ISQLEGTDSG TYTCSATNKA GHNQCSGHLT VKEPPYFVEK PQSQDVNPNT RVQLKALVGG TAPMTIKWFK DNKELHSGAA RSVWKDDTST SLELFAAKAT DSGTYICQLS NDVGTATSKA TLFVKEPPQF IKKPSPVLVL RNGQSTTFEC QITGTPKIRV SWYLDGNEIT AIQKHGISFI DGLATFQISG ARVENSGTYV CEARNDAGTA SCSIELKVKE PPTFIRELKP VEVVKYSDVE LECEVTGTPP FEVTWLKNNR EIRSSKKYTL TDRVSVFNLH ITKCDPSDTG EYQCIVSNEG GSCSCSTRVA LKEPPSFIKK IENTTTVLKS SATFQSTVAG SPPISITWLK DDQILDEDDN VYISFVDSVA TLQIRSVDNG HSGRYTCQAK NESGVERCYA FLLVQEPAQI VEKAKSVDVT EKDPMTLECV VAGTPELKVK WLKDGKQIVP SRYFSMSFEN NVASFRIQSV MKQDSGQYTF KVENDFGSSS CDAYLRVLDQ NIPPSFTKKL TKMDKVLGSS IHMECKVSGS LPISAQWFKD GKEISTSAKY RLVCHERSVS LEVNNLELED TANYTCKVSN VAGDDACSGI LTVKEPPSFL VKPGRQQAIP DSTVEFKAIL KGTPPFKIKW FKDDVELVSG PKCFIGLEGS TSFLNLYSVD ASKTGQYTCH VTNDVGSDSC TTMLLVTEPP KFVKKLEASK IVKAGDSSRL ECKIAGSPEI RVVWFRNEHE LPASDKYRMT FIDSVAVIQM NNLSTEDSGD FICEAQNPAG STSCSTKVIV KEPPVFSSFP PIVETLKNAE VSLECELSGT PPFEVVWYKD KRQLRSSKKY KIASKNFHTS IHILNVDTSD IGEYHCKAQN EVGSDTCVCT VKLKEPPRFV SKLNSLTVVA GEPAELQASI EGAQPIFVQW LKEKEEVIRE SENIRITFVE NVATLQFAKA EPANAGKYIC QIKNDGGMRE NMATLMVLEP AVIVEKAGPM TVTVGETCTL ECKVAGTPEL SVEWYKDGKL LTSSQKHKFS FYNKISSLRI LSVERQDAGT YTFQVQNNVG KSSCTAVVDV SDRAVPPSFT RRLKNTGGVL GASCILECKV AGSSPISVAW FHEKTKIVSG AKYQTTFSDN VCTLQLNSLD SSDMGNYTCV AANVAGSDEC RAVLTVQEPP SFVKEPEPLE VLPGKNVTFT SVIRGTPPFK VNWFRGAREL VKGDRCNIYF EDTVAELELF NIDISQSGEY TCVVSNNAGQ ASCTTRLFVK EPAAFLKRLS DHSVEPGKSI ILESTYTGTL PISVTWKKDG FNITTSEKCN IVTTEKTCIL EILNSTKRDA GQYSCEIENE AGRDVCGALV STLEPPYFVT ELEPLEAAVG DSVSLQCQVA GTPEITVSWY KGDTKLRPTP EYRTYFTNNV ATLVFNKVNI NDSGEYTCKA ENSIGTASSK TVFRIQERQL PPSFARQLKD IEQTVGLPVT LTCRLNGSAP IQVCWYRDGV LLRDDENLQT SFVDNVATLK ILQTDLSHSG QYSCSASNPL GTASSSARLT AREPKKSPFF DIKPVSIDVI AGESADFECH VTGAQPMRIT WSKDNKEIRP GGNYTITCVG NTPHLRILKV GKGDSGQYTC QATNDVGKDM CSAQLSVKEP PKFVKKLEAS KVAKQGESIQ LECKISGSPE IKVSWFRNDS ELHESWKYNM SFINSVALLT INEASAEDSG DYICEAHNGV GDASCSTALT VKAPPVFTQK PSPVGALKGS DVILQCEISG TPPFEVVWVK DRKQVRNSKK FKITSKHFDT SLHILNLEAS DVGEYHCKAT NEVGSDTCSC SVKFKEPPRF VKKLSDTSTL IGDAVELRAI VEGFQPISVV WLKDRGEVIR ESENTRISFI DNIATLQLGS PEASNSGKYI CQIKNDAGMR ECSAVLTVLE PARIIEKPEP MTVTTGNPFA LECVVTGTPE LSAKWFKDGR ELSADSKHHI TFINKVASLK IPCAEMSDKG LYSFEVKNSV GKSNCTVSVH VSDRIVPPSF IRKLKDVNAI LGASVVLECR VSGSAPISVG WFQDGNEIVS GPKCQSSFSE NVCTLNLSLL EPSDTGIYTC VAANVAGSDE CSAVLTVQEP PSFEQTPDSV EVLPGMSLTF TSVIRGTPPF KVKWFKGSRE LVPGESCNIS LEDFVTELEL FEVQPLESGD YSCLVTNDAG SASCTTHLFV KEPATFVKRL ADFSVETGSP IVLEATYTGT PPISVSWIKD EYLISQSERC SITMTEKSTI LEILESTIED YAQYSCLIEN EAGQDICEAL VSVLEPPYFI EPLEHVEAVI GEPATLQCKV DGTPEIRISW YKEHTKLRSA PAYKMQFKNN VASLVINKVD HSDVGEYSCK ADNSVGAVAS SAVLVIKARK LPPFFARKLK DVHETLGFPV AFECRINGSE PLQVSWYKDG VLLKDDANLQ TSFVHNVATL QILQTDQSHI GQYNCSASNP LGTASSSAKL ILSEHEVPPF FDLKPVSVDL ALGESGTFKC HVTGTAPIKI TWAKDNREIR PGGNYKMTLV ENTATLTVLK VGKGDAGQYT CYASNIAGKD SCSAQLGVQE PPRFIKKLEP SRIVKQDEFT RYECKIGGSP EIKVLWYKDE TEIQESSKFR MSFVDSVAVL EMHNLSVEDS GDYTCEAHNA AGSASSSTSL KVKEPPIFRK KPHPIETLKG ADVHLECELQ GTPPFHVSWY KDKRELRSGK KYKIMSENFL TSIHILNVDA ADIGEYQCKA TNDVGSDTCV GSIALKAPPR FVKKLSDIST VVGKEVQLQT TIEGAEPISV VWFKDKGEIV RESDNIWISY SENIATLQFS RVEPANAGKY TCQIKNDAGM QECFATLSVL EPATIVEKPE SIKVTTGDTC TLECTVAGTP ELSTKWFKDG KELTSDNKYK ISFFNKVSGL KIINVAPSDS GVYSFEVQNP VGKDSCTASL QVSDRTVPPS FTRKLKETNG LSGSSVVMEC KVYGSPPISV SWFHEGNEIS SGRKYQTTLT DNTCALTVNM LEESDSGDYT CIATNMAGSD ECSAPLTVRE PPSFVQKPDP MDVLTGTNVT FTSIVKGTPP FSVSWFKGSS ELVPGDRCNV SLEDSVAELE LFDVDTSQSG EYTCIVSNEA GKASCTTHLY IKAPAKFVKR LNDYSIEKGK PLILEGTFTG TPPISVTWKK NGINVTPSQR CNITTTEKSA ILEIPSSTVE DAGQYNCYIE NASGKDSCSA QILILEPPYF VKQLEPVKVS VGDSASLQCQ LAGTPEIGVS WYKGDTKLRP TTTYKMHFRN NVATLVFNQV DINDSGEYIC KAENSVGEVS ASTFLTVQEQ KLPPSFSRQL RDVQETVGLP VVFDCAISGS EPISVSWYKD GKPLKDSPNV QTSFLDNTAT LNIFKTDRSL AGQYSCTATN PIGSASSSAR LILTEGKNPP FFDIRLAPVD AVVGESADFE CHVTGTQPIK VSWAKDSREI RSGGKYQISY LENSAHLTVL KVDKGDSGQY TCYAVNEVGK DSCTAQLNIK ERLIPPSFTK RLSETVEETE GNSFKLEGRV AGSQPITVAW YKNNIEIQPT SNCEITFKNN TLVLQVRKAG MNDAGLYTCK VSNDAGSALC TSSIVIKEPK KPPVFDQHLT PVTVSEGEYV QLSCHVQGSE PIRIQWLKAG REIKPSDRCS FSFASGTAVL ELRDVAKADS GDYVCKASNV AGSDTTKSKV TIKDKPAVAP ATKKAAVDGR LFFVSEPQSI RVVEKTTATF IAKVGGDPIP NVKWTKGKWR QLNQGGRVFI HQKGDEAKLE IRDTTKTDSG LYRCVAFNEH GEIESNVNLQ VDERKKQEKI EGDLRAMLKK TPILKKGAGE EEEIDIMELL KNVDPKEYEK YARMYGITDF RGLLQAFELL KQSQEEETHR LEIEEIERSE RDEKEFEELV SFIQQRLSQT EPVTLIKDIE NQTVLKDNDA VFEIDIKINY PEIKLSWYKG TEKLEPSDKF EISIDGDRHT LRVKNCQLKD QGNYRLVCGP HIASAKLTVI EPAWERHLQD VTLKEGQTCT MTCQFSVPNV KSEWFRNGRI LKPQGRHKTE VEHKVHKLTI ADVRAEDQGQ YTCKYEDLET SAELRIEAEP IQFTKRIQNI VVSEHQSATF ECEVSFDDAI VTWYKGPTEL TESQKYNFRN DGRCHYMTIH NVTPDDEGVY SVIARLEPRG EARSTAELYL TTKEIKLELK PPDIPDSRVP IPTMPIRAVP PEEIPPVVAP PIPLLLPTPE EKKPPPKRIE VTKKAVKKDA KKVVAKPKEM TPREEIVKKP PPPTTLIPAK APEIIDVSSK AEEVKIMTIT RKKEVQKEKE AVYEKKQAVH KEKRVFIESF EEPYDELEVE PYTEPFEQPY YEEPDEDYEE IKVEAKKEVH EEWEEDFEEG QEYYEREEGY DEGEEEWEEA YQEREVIQVQ KEVYEESHER KVPAKVPEKK APPPPKVIKK PVIEKIEKTS RRMEEEKVQV TKVPEVSKKI VPQKPSRTPV QEEVIEVKVP AVHTKKMVIS EEKMFFASHT EEEVSVTVPE VQKEIVTEEK IHVAISKRVE PPPKVPELPE KPAPEEVAPV PIPKKVEPPA PKVPEVPKKP VPEEKKPVPV PKKEPAAPPK VPEVPKKPVP EEKIPVPVAK KKEAPPAKVP EVQKGVVTEE KITIVTQREE SPPPAVPEIP KKKVPEERKP VPRKEEEVPP PPKVPALPKK PVPEEKVAVP VPVAKKAPPP RAEVSKKTVV EEKRFVAEEK LSFAVPQRVE VTRHEVSAEE EWSYSEEEEG VSISVYREEE REEEEEAEVT EYEVMEEPEE YVVEEKLHII SKRVEAEPAE VTERQEKKIV LKPKIPAKIE EPPPAKVPEA PKKIVPEKKV PAPVPKKEKV PPPKVPEEPK KPVPEKKVPP KVIKMEEPLP AKVTERHMQI TQEEKVLVAV TKKEAPPKAR VPEEPKRAVP EEKVLKLKPK REEEPPAKVT EFRKRVVKEE KVSIEAPKRE PQPIKEVTIM EEKERAYTLE EEAVSVQREE EYEEYEEYDY KEFEEYEPTE EYDQYEEYEE REYERYEEHE EYITEPEKPI PVKPVPEEPV PTKPKAPPAK VLKKAVPEEK VPVPIPKKLK PPPPKVPEEP KKVFEEKIRI SITKREKEQV TEPAAKVPMK PKRVVAEEKV PVPRKEVAPP VRVPEVPKEL EPEEVAFEEE VVTHVEEYLV EEEEEYIHEE EEFITEEEVV PVIPVKVPEV PRKPVPEEKK PVPVPKKKEA PPAKVPEVPK KPEEKVPVLI PKKEKPPPAK VPEVPKKPVP EEKVPVPVPK KVEAPPAKVP EVPKKPVPEK KVPVPAPKKV EAPPAKVPEV PKKLIPEEKK PTPVPKKVEA PPPKVPKKRE PVPVPVALPQ EEEVLFEEEI VPEEEVLPEE EEVLPEEEEV LPEEEEVLPE EEEIPPEEEE VPPEEEYVPE EEEFVPEEEV LPEVKPKVPV PAPVPEIKKK VTEKKVVIPK KEEAPPAKVP EVPKKVEEKR IILPKEEEVL PVEVTEEPEE EPISEEEIPE EPPSIEEVEE VAPPRVPEVI KKAVPEAPTP VPKKVEAPPA KVSKKIPEEK VPVPVQKKEA PPAKVPEVPK KVPEKKVLVP KKEAVPPAKG RTVLEEKVSV AFRQEVVVKE RLELEVVEAE VEEIPEEEEF HEVEEYFEEG EFHEVEEFIK LEQHRVEEEH RVEKVHRVIE VFEAEEVEVF EKPKAPPKGP EISEKIIPPK KPPTKVVPRK EPPAKVPEVP KKIVVEEKVR VPEEPRVPPT KVPEVLPPKE VVPEKKVPVP PAKKPEAPPP KVPEAPKEVV PEKKVPVPPP KKPEVPPTKV PEVPKAAVPE KKVPEAIPPK PESPPPEVPE APKEVVPEKK VPAAPPKKPE VTPVKVPEAP KEVVPEKKVP VPPPKKPEVP PTKVPEVPKV AVPEKKVPEA IPPKPESPPP EVFEEPEEVA LEEPPAEVVE EPEPAAPPQV TVPPKKPVPE KKAPAVVAKK PELPPVKVPE VPKEVVPEKK VPLVVPKKPE APPAKVPEVP KEVVPEKKVA VPKKPEVPPA KVPEVPKKPV LEEKPAVPVP ERAESPPPEV YEEPEEIAPE EEIAPEEEKP VPVAEEEEPE VPPPAVPEEP KKIIPEKKVP VIKKPEAPPP KEPEPEKVIE KPKLKPRPPP PPPAPPKEDV KEKIFQLKAI PKKKVPEKPQ VPEKVELTPL KVPGGEKKVR KLLPERKPEP KEEVVLKSVL RKRPEEEEPK VEPKKLEKVK KPAVPEPPPP KPVEEVEVPT VTKRERKIPE PTKVPEIKPA IPLPAPEPKP KPEAEVKTIK PPPVEPEPTP IAAPVTVPVV GKKAEAKAPK EEAAKPKGPI KGVPKKTPSP IEAERRKLRP GSGGEKPPDE APFTYQLKAV PLKFVKEIKD IILTESEFVG SSAIFECLVS PSTAITTWMK DGSNIRESPK HRFIADGKDR KLHIIDVQLS DAGEYTCVLR LGNKEKTSTA KLVVEELPVR FVKTLEEEVT VVKGQPLYLS CELNKERDVV WRKDGKIVVE KPGRIVPGVI GLMRALTIND ADDTDAGTYT VTVENANNLE CSSCVKVVEV IRDWLVKPIR DQHVKPKGTA IFACDIAKDT PNIKWFKGYD EIPAEPNDKT EILRDGNHLY LKIKNAMPED IAEYAVEIEG KRYPAKLTLG EREVELLKPI EDVTIYEKES ASFDAEISEA DIPGQWKLKG ELLRPSPTCE IKAEGGKRFL TLHKVKLDQA GEVLYQALNA ITTAILTVKE IELDFAVPLK DVTVPERRQA RFECVLTREA NVIWSKGPDI IKSSDKFDII ADGKKHILVI NDSQFDDEGV YTAEVEGKKT SARLFVTGIR LKFMSPLEDQ TVKEGETATF VCELSHEKMH VVWFKNDAKL HTSRTVLISS EGKTHKLEMK EVTLDDISQI KAQVKELSST AQLKVLEADP YFTVKLHDKT AVEKDEITLK CEVSKDVPVK WFKDGEEIVP SPKYSIKADG LRRILKIKKA DLKDKGEYVC DCGTDKTKAN VTVEARLIKV EKPLYGVEVF VGETAHFEIE LSEPDVHGQW KLKGQPLTAS PDCEIIEDGK KHILILHNCQ LGMTGEVSFQ AANAKSAANL KVKELPLIFI TPLSDVKVFE KDEAKFECEV SREPKTFRWL KGTQEITGDD RFELIKDGTK HSMVIKSAAF EDEAKYMFEA EDKHTSGKLI IEGIRLKFLT PLKDVTAKEK ESAVFTVELS HDNIRVKWFK NDQRLHTTRS VSMQDEGKTH SITFKDLSID DTSQIRVEAM GMSSEAKLTV LEGDPYFTGK LQDYTGVEKD EVILQCEISK ADAPVKWFKD GKEIKPSKNA VIKADGKKRM LILKKALKSD IGQYTCDCGT DKTSGKLDIE DREIKLVRPL HSVEVMETET ARFETEISED DIHANWKLKG EALLQTPDCE IKEEGKIHSL VLHNCRLDQT GGVDFQAANV KSSAHLRVKP RVIGLLRPLK DVTVTAGETA TFDCELSYED IPVEWYLKGK KLEPSDKVVP RSEGKVHTLT LRDVKLEDAG EVQLTAKDFK THANLFVKEP PVEFTKPLED QTVEEGATAV LECEVSRENA KVKWFKNGTE ILKSKKYEIV ADGRVRKLVI HDCTPEDIKT YTCDAKDFKT SCNLNVVPPH VEFLRPLTDL QVREKEMARF ECELSRENAK VKWFKDGAEI KKGKKYDIIS KGAVRILVIN KCLLDDEAEY SCEVRTARTS GMLTVLEEEA VFTKNLANIE VSETDTIKLV CEVSKPGAEV IWYKGDEEII ETGRYEILTE GRKRILVIQN AHLEDAGNYN CRLPSSRTDG KVKVHELAAE FISKPQNLEI LEGEKAEFVC SISKESFPVQ WKRDDKTLES GDKYDVIADG KKRVLVVKDA TLQDMGTYVV MVGAARAAAH LTVIEKLRIV VPLKDTRVKE QQEVVFNCEV NTEGAKAKWF RNEEAIFDSS KYIILQKDLV YTLRIRDAHL DDQANYNVSL TNHRGENVKS AANLIVEEED LRIVEPLKDI ETMEKKSVTF WCKVNRLNVT LKWTKNGEEV PFDNRVSYRV DKYKHMLTIK DCGFPDEGEY IVTAGQDKSV AELLIIEAPT EFVEHLEDQT VTEFDDAVFS CQLSREKANV KWYRNGREIK EGKKYKFEKD GSIHRLIIKD CRLDDECEYA CGVEDRKSRA RLFVEEIPVE IIRPPQDILE APGADVVFLA ELNKDKVEVQ WLRNNMVVVQ GDKHQMMSEG KIHRLQICDI KPRDQGEYRF IAKDKEARAK LELAAAPKIK TADQDLVVDV GKPLTMVVPY DAYPKAEAEW FKENEPLSTK TIDTTAEQTS FRILEAKKGD KGRYKIVLQN KHGKAEGFIN LKVIDVPGPV RNLEVTETFD GEVSLAWEEP LTDGGSKIIG YVVERRDIKR KTWVLATDRA ESCEFTVTGL QKGGVEYLFR VSARNRVGTG EPVETDNPVE ARSKYDVPGP PLNVTITDVN RFGVSLTWEP PEYDGGAEIT NYVIELRDKT SIRWDTAMTV RAEDLSATVT DVVEGQEYSF RVRAQNRIGV GKPSAATPFV KVADPIERPS PPVNLTSSDQ TQSSVQLKWE PPLKDGGSPI LGYIIERCEE GKDNWIRCNM KLVPELTYKV TGLEKGNKYL YRVSAENKAG VSDPSEILGP LTADDAFVEP TMDLSAFKDG LEVIVPNPIT ILVPSTGYPR PTATWCFGDK VLETGDRVKM KTLSAYAELV ISPSERSDKG IYTLKLENRV KTISGEIDVN VIARPSAPKE LKFGDITKDS VHLTWEPPDD DGGSPLTGYV VEKREVSRKT WTKVMDFVTD LEFTVPDLVQ GKEYLFKVCA RNKCGPGEPA YVDEPVNMST PATVPDPPEN VKWRDRTANS IFLTWDPPKN DGGSRIKGYI VERCPRGSDK WVACGEPVAE TKMEVTGLEE GKWYAYRVKA LNRQGASKPS RPTEEIQAVD TQEAPEIFLD VKLLAGLTVK AGTKIELPAT VTGKPEPKIT WTKADMILKQ DKRITIENVP KKSTVTIVDS KRSDTGTYII EAVNVCGRAT AVVEVNVLDK PGPPAAFDIT DVTNESCLLT WNPPRDDGGS KITNYVVERR ATDSEVWHKL SSTVKDTNFK ATKLIPNKEY IFRVAAENMY GVGEPVQASP ITAKYQFDPP GPPTRLEPSD ITKDAVTLTW CEPDDDGGSP ITGYWVERLD PDTDKWVRCN KMPVKDTTYR VKGLTNKKKY RFRVLAENLA GPGKPSKSTE PILIKDPIDP PWPPGKPTVK DVGKTSVRLN WTKPEHDGGA KIESYVIEML KTGTDEWVRV AEGVPTTQHL LPGLMEGQEY SFRVRAVNKA GESEPSEPSD PVLCREKLYP PSPPRWLEVI NITKNTADLK WTVPEKDGGS PITNYIVEKR DVRRKGWQTV DTTVKDTKCT VTPLTEGSLY VFRVAAENAI GQSDYTEIED SVLAKDTFTT PGPPYALAVV DVTKRHVDLK WEPPKNDGGR PIQRYVIEKK ERLGTRWVKA GKTAGPDCNF RVTDVIEGTE VQFQVRAENE AGVGHPSEPT EILSIEDPTS PPSPPLDLHV TDAGRKHIAI AWKPPEKNGG SPIIGYHVEM CPVGTEKWMR VNSRPIKDLK FKVEEGVVPD KEYVLRVRAV NAIGVSEPSE ISENVVAKDP DCKPTIDLET HDIIVIEGEK LSIPVPFRAV PVPTVSWHKD GKEVKASDRL TMKNDHISAH LEVPKSVRAD AGIYTITLEN KLGSATASIN VKVIGLPGPC KDIKASDITK SSCKLTWEPP EFDGGTPILH YVLERREAGR RTYIPVMSGE NKLSWTVKDL IPNGEYFFRV KAVNKVGGGE YIELKNPVIA QDPKQPPDPP VDVEVHNPTA EAMTITWKPP LYDGGSKIMG YIIEKIAKGE ERWKRCNEHL VPILTYTAKG LEEGKEYQFR VRAENAAGIS EPSRATPPTK AVDPIDAPKV ILRTSLEVKR GDEIALDASI SGSPYPTITW IKDENVIVPE EIKKRAAPLV RRRKGEVQEE EPFVLPLTQR LSIDNSKKGE SQLRVRDSLR PDHGLYMIKV ENDHGIAKAP CTVSVLDTPG PPINFVFEDI RKTSVLCKWE PPLDDGGSEI INYTLEKKDK TKPDSEWIVV TSTLRHCKYS VTKLIEGKEY LFRVRAENRF GPGPPCVSKP LVAKDPFGPP DAPDKPIVED VTSNSMLVKW NEPKDNGSPI LGYWLEKREV NSTHWSRVNK SLLNALKANV DGLLEGLTYV FRVCAENAAG PGKFSPPSDP KTAHDPISPP GPPIPRVTDT SSTTIELEWE PPAFNGGGEI VGYFVDKQLV GTNEWSRCTE KMIKVRQYTV KEIREGADYK LRVSAVNAAG EGPPGETQPV TVAEPQEPPA VELDVSVKGG IQIMAGKTLR IPAVVTGRPV PTKVWTKEEG ELDKDRVVID NVGTKSELII KDALRKDHGR YVITATNSCG SKFAAARVEV FDVPGPVLDL KPVVTNRKMC LLNWSDPEDD GGSEITGFII ERKDAKMHTW RQPIETERSK CDITGLLEGQ EYKFRVIAKN KFGCGPPVEI GPILAVDPLG PPTSPERLTY TERTKSTITL DWKEPRSNGG SPIQGYIIEK RRHDKPDFER VNKRLCPTTS FLVENLDEHQ MYEFRVKAVN EIGESEPSLP LNVVIQDDEV PPTIKLRLSV RGDTIKVKAG EPVHIPADVT GLPMPKIEWS KNETVIEKPT DALQITKEEV SRSEAKTELS IPKAVREDKG TYTVTASNRL GSVFRNVHVE VYDRPSPPRN LAVTDIKAES CYLTWDAPLD NGGSEITHYV IDKRDASRKK AEWEEVTNTA VEKRYGIWKL IPNGQYEFRV RAVNKYGISD ECKSDKVVIQ DPYRLPGPPG KPKVLARTKG SMLVSWTPPL DNGGSPITGY WLEKREEGSP YWSRVSRAPI TKVGLKGVEF NVPRLLEGVK YQFRAMAINA AGIGPPSEPS DPEVAGDPIF PPGPPSCPEV KDKTKSSISL GWKPPAKDGG SPIKGYIVEM QEEGTTDWKR VNEPDKLITT CECVVPNLKE LRKYRFRVKA VNEAGESEPS DTTGEIPATD IQEEPEVFID IGAQDCLVCK AGSQIRIPAV IKGRPTPKSS WEFDGKAKKA MKDGVHDIPE DAQLETAENS SVIIIPECKR SHTGKYSITA KNKAGQKTAN CRVKVMDVPG PPKDLKVSDI TRGSCRLSWK MPDDDGGDRI KGYVIEKRTI DGKAWTKVNP DCGSTTFVVP DLLSEQQYFF RVRAENRFGI GPPVETIQRT TARDPIYPPD PPIKLKIGLI TKNTVHLSWK PPKNDGGSPV THYIVECLAW DPTGTKKEAW RQCNKRDVEE LQFTVEDLVE GGEYEFRVKA VNAAGVSKPS ATVGPVTVKD QTCPPSIDLK EFMEVEEGTN VNIVAKIKGV PFPTLTWFKA PPKKPDNKEP VLYDTHVNKL VVDDTCTLVI PQSRRSDTGL YTITAVNNLG TASKEMRLNV LGRPGPPVGP IKFESVSADQ MTLSWFPPKD DGGSKITNYV IEKREANRKT WVHVSSEPKE CTYTIPKLLE GHEYVFRIMA QNKYGIGEPL DSEPETARNL FSVPGAPDKP TVSSVTRNSM TVNWEEPEYD GGSPVTGYWL EMKDTTSKRW KRVNRDPIKA MTLGVSYKVT GLIEGSDYQF RVYAINAAGV GPASLPSDPA TARDPIAPPG PPFPKVTDWT KSSADLEWSP PLKDGGSKVT GYIVEYKEEG KEEWEKGKDK EVRGTKLVVT GLKEGAFYKF RVRAVNIAGI GEPGEVTDVI EMKDRLVSPD LQLDASVRDR IVVHAGGVIR IIAYVSGKPP PTVTWNMNER TLPQEATIET TAISSSMVIK NCQRSHQGVY SLLAKNEAGE RKKTIIVDVL DVPGPVGTPF LAHNLTNESC KLTWFSPEDD GGSPITNYVI EKRESDRRAW TPVTYTVTRQ NATVQGLIQG KAYFFRIAAE NSIGMGPFVE TSEALVIREP ITVPERPEDL EVKEVTKNTV TLTWNPPKYD GGSEIINYVL ESRLIGTEKF HKVTNDNLLS RKYTVKGLKE GDTYEYRVSA VNIVGQGKPS FCTKPITCKD ELAPPTLHLD FRDKLTIRVG EAFALTGRYS GKPKPKVSWF KDEADVLEDD RTHIKTTPAT LALEKIKAKR SDSGKYCVVV ENSTGSRKGF CQVNVVDRPG PPVGPVSFDE VTKDYMVISW KPPLDDGGSK ITNYIIEKKE VGKDVWMPVT SASAKTTCKV SKLLEGKDYI FRIHAENLYG ISDPLVSDSM KAKDRFRVPD APDQPIVTEV TKDSALVTWN KPHDGGKPIT NYILEKRETM SKRWARVTKD PIHPYTKFRV PDLLEGCQYE FRVSAENEIG IGDPSPPSKP VFAKDPIAKP SPPVNPEAID TTCNSVDLTW QPPRHDGGSK ILGYIVEYQK VGDEEWRRAN HTPESCPETK YKVTGLRDGQ TYKFRVLAVN AAGESDPAHV PEPVLVKDRL EPPELILDAN MAREQHIKVG DTLRLSAIIK GVPFPKVTWK KEDRDAPTKA RIDVTPVGSK LEIRNAAHED GGIYSLTVEN PAGSKTVSVK VLVLDKPGPP RDLEVSEIRK DSCYLTWKEP LDDGGSVITN YVVERRDVAS AQWSPLSATS KKKSHFAKHL NEGNQYLFRV AAENQYGRGP FVETPKPIKA LDPLHPPGPP KDLHHVDVDK TEVSLVWNKP DRDGGSPITG YLVEYQEEGT QDWIKFKTVT NLECVVTGLQ QGKTYRFRVK AENIVGLGLP DTTIPIECQE KLVPPSVELD VKLIEGLVVK AGTTVRFPAI IRGVPVPTAK WTTDGSEIKT DEHYTVETDN FSSVLTIKNC LRRDTGEYQI TVSNAAGSKT VAVHLTVLDV PGPPTGPINI LDVTPEHMTI SWQPPKDDGG SPVINYIVEK QDTRKDTWGV VSSGSSKTKL KIPHLQKGCE YVFRVRAENK IGVGPPLDST PTVAKHKFSP PSPPGKPVVT DITENAATVS WTLPKSDGGS PITGYYMERR EVTGKWVRVN KTPIADLKFR VTGLYEGNTY EFRVFAENLA GLSKPSPSSD PIKACRPIKP PGPPINPKLK DKSRETADLV WTKPLSDGGS PILGYVVECQ KPGTAQWNRI NKDELIRQCA FRVPGLIEGN EYRFRIKAAN IVGEGEPREL AESVIAKDIL HPPEVELDVT CRDVITVRVG QTIRILARVK GRPEPDITWT KEGKVLVREK RVDLIQDLPR VELQIKEAVR ADHGKYIISA KNSSGHAQGS AIVNVLDRPG PCQNLKVTNV TKENCTISWE NPLDNGGSEI TNFIVEYRKP NQKGWSIVAS DVTKRLIKAN LLANNEYYFR VCAENKVGVG PTIETKTPIL AINPIDRPGE PENLHIADKG KTFVYLKWRR PDYDGGSPNL SYHVERRLKG SDDWERVHKG SIKETHYMVD RCVENQIYEF RVQTKNEGGE SDWVKTEEVV VKEDLQKPVL DLKLSGVLTV KAGDTIRLEA GVRGKPFPEV AWTKDKDATD LTRSPRVKID TRADSSKFSL TKAKRSDGGK YVVTATNTAG SFVAYATVNV LDKPGPVRNL KIVDVSSDRC TVCWDPPEDD GGCEIQNYIL EKCETKRMVW STYSATVLTP GTTVTRLIEG NEYIFRVRAE NKIGTGPPTE SKPVIAKTKY DKPGRPDPPE VTKVSKEEMT VVWNPPEYDG GKSITGYFLE KKEKHSTRWV PVNKSAIPER RMKVQNLLPD HEYQFRVKAE NEIGIGEPSL PSRPVVAKDP IEPPGPPTNF RVVDTTKHSI TLGWGKPVYD GGAPIIGYVV EMRPKIADAS PDEGWKRCNA AAQLVRKEFT VTSLDENQEY EFRVCAQNQV GIGRPAELKE AIKPKEILEP PEIDLDASMR KLVIVRAGCP IRLFAIVRGR PAPKVTWRKV GIDNVVRKGQ VDLVDTMAFL VIPNSTRDDS GKYSLTLVNP AGEKAVFVNV RVLDTPGPVS DLKVSDVTKT SCHVSWAPPE NDGGSQVTHY IVEKREADRK TWSTVTPEVK KTSFHVTNLV PGNEYYFRVT AVNEYGPGVP TDVPKPVLAS DPLSEPDPPR KLEVTEMTKN SATLAWLPPL RDGGAKIDGY ITSYREEEQP ADRWTEYSVV KDLSLVVTGL KEGKKYKFRV AARNAVGVSL PREAEGVYEA KEQLLPPKIL MPEQITIKAG KKLRIEAHVY GKPHPTCKWK KGEDEVVTSS HLAVHKADSS SILIIKDVTR KDSGYYSLTA ENSSGTDTQK IKVVVMDAPG PPQPPFDISD IDADACSLSW HIPLEDGGSN ITNYIVEKCD VSRGDWVTAL ASVTKTSCRV GKLIPGQEYI FRVRAENRFG ISEPLTSPKM VAQFPFGVPS EPKNARVTKV NKDCIFVAWD RPDSDGGSPI IGYLIERKER NSLLWVKAND TLVRSTEYPC AGLVEGLEYS FRIYALNKAG SSPPSKPTEY VTARMPVDPP GKPEVIDVTK STVSLIWARP KHDGGSKIIG YFVEACKLPG DKWVRCNTAP HQIPQEEYTA TGLEEKAQYQ FRAIARTAVN ISPPSEPSDP VTILAENVPP RIDLSVAMKS LLTVKAGTNV CLDATVFGKP MPTVSWKKDG TLLKPAEGIK MAMQRNLCTL ELFSVNRKDS GDYTITAENS SGSKSATIKL KVLDKPGPPA SVKINKMYSD RAMLSWEPPL EDGGSEITNY IVDKRETSRP NWAQVSATVP ITSCSVEKLI EGHEYQFRIC AENKYGVGDP VFTEPAIAKN PYDPPGRCDP PVISNITKDH MTVSWKPPAD DGGSPITGYL LEKRETQAVN WTKVNRKPII ERTLKATGLQ EGTEYEFRVT AINKAGPGKP SDASKAAYAR DPQYPPGPPA FPKVYDTTRS SVSLSWGKPA YDGGSPIIGY LVEVKRADSD NWVRCNLPQN LQKTRFEVTG LMEDTQYQFR VYAVNKIGYS DPSDVPDKHY PKDILIPPEG ELDADLRKTL ILRAGVTMRL YVPVKGRPPP KITWSKPNVN LRDRIGLDIK STDFDTFLRC ENVNKYDAGK YILTLENSCG KKEYTIVVKV LDTPGPPVNV TVKEISKDSA YVTWEPPIID GGSPIINYVV QKRDAERKSW STVTTECSKT SFRVANLEEG KSYFFRVFAE NEYGIGDPGE TRDAVKASQT PGPVVDLKVR SVSKSSCSIG WKKPHSDGGS RIIGYVVDFL TEENKWQRVM KSLSLQYSAK DLTEGKEYTF RVSAENENGE GTPSEITVVA RDDVVAPDLD LKGLPDLCYL AKENSNFRLK IPIKGKPAPS VSWKKGEDPL ATDTRVSVES SAVNTTLIVY DCQKSDAGKY TITLKNVAGT KEGTISIKVV GKPGIPTGPI KFDEVTAEAM TLKWAPPKDD GGSEITNYIL EKRDSVNNKW VTCASAVQKT TFRVTRLHEG MEYTFRVSAE NKYGVGEGLK SEPIVARHPF DVPDAPPPPN IVDVRHDSVS LTWTDPKKTG GSPITGYHLE FKERNSLLWK RANKTPIRMR DFKVTGLTEG LEYEFRVMAI NLAGVGKPSL PSEPVVALDP IDPPGKPEVI NITRNSVTLI WTEPKYDGGH KLTGYIVEKR DLPSKSWMKA NHVNVPECAF TVTDLVEGGK YEFRIRAKNT AGAISAPSES TETIICKDEY EAPTIVLDPT IKDGLTIKAG DTIVLNAISI LGKPLPKSSW SKAGKDIRPS DITQITSTPT SSMLTIKYAT RKDAGEYTIT ATNPFGTKVE HVKVTVLDVP GPPGPVEISN VSAEKATLTW TPPLEDGGSP IKSYILEKRE TSRLLWTVVS EDIQSCRHVA TKLIQGNEYI FRVSAVNHYG KGEPVQSEPV KMVDRFGPPG PPEKPEVSNV TKNTATVSWK RPVDDGGSEI TGYHVERREK KSLRWVRAIK TPVSDLRCKV TGLQEGSTYE FRVSAENRAG IGPPSEASDS VLMKDAAYPP GPPSNPHVTD TTKKSASLAW GKPHYDGGLE ITGYVVEHQK VGDEAWIKDT TGTALRITQF VVPDLQTKEK YNFRISAIND AGVGEPAVIP DVEIVEREMA PDFELDAELR RTLVVRAGLS IRIFVPIKGR PAPEVTWTKD NINLKNRANI ENTESFTLLI IPECNRYDTG KFVMTIENPA GKKSGFVNVR VLDTPGPVLN LRPTDITKDS VTLHWDLPLI DGGSRITNYI VEKREATRKS YSTATTKCHK CTYKVTGLSE GCEYFFRVMA ENEYGIGEPT ETTEPVKASE APSPPDSLNI MDITKSTVSL AWPKPKHDGG SKITGYVIEA QRKGSDQWTH ITTVKGLECV VRNLTEGEEY TFQVMAVNSA GRSAPRESRP VIVKEQTMLP ELDLRGIYQK LVIAKAGDNI KVEIPVLGRP KPTVTWKKGD QILKQTQRVN FETTATSTIL NINECVRSDS GPYPLTARNI VGEVGDVITI QVHDIPGPPT GPIKFDEVSS DFVTFSWDPP ENDGGVPISN YVVEMRQTDS TTWVELATTV IRTTYKATRL TTGLEYQFRV KAQNRYGVGP GITSACIVAN YPFKVPGPPG TPQVTAVTKD SMTISWHEPL SDGGSPILGY HVERKERNGI LWQTVSKALV PGNIFKSSGL TDGIAYEFRV IAENMAGKSK PSKPSEPMLA LDPIDPPGKP VPLNITRHTV TLKWAKPEYT GGFKITSYIV EKRDLPNGRW LKANFSNILE NEFTVSGLTE DAAYEFRVIA KNAAGAISPP SEPSDAITCR DDVEAPKIKV DVKFKDTVIL KAGEAFRLEA DVSGRPPPTM EWSKDGKELE GTAKLEIKIA DFSTNLVNKD STRRDSGAYT LTATNPGGFA KHIFNVKVLD RPGPPEGPLA VTEVTSEKCV LSWFPPLDDG GAKIDHYIVQ KRETSRLAWT NVASEVQVTK LKVTKLLKGN EYIFRVMAVN KYGVGEPLES EPVLAVNPYG PPDPPKNPEV TTITKDSMVV CWGHPDSDGG SEIINYIVER RDKAGQRWIK CNKKTLTDLR YKVSGLTEGH EYEFRIMAEN AAGISAPSPT SPFYKACDTV FKPGPPGNPR VLDTSRSSIS IAWNKPIYDG GSEITGYMVE IALPEEDEWQ IVTPPAGLKA TSYTITGLTE NQEYKIRIYA MNSEGLGEPA LVPGTPKAED RMLPPEIELD ADLRKVVTIR ACCTLRLFVP IKGRPAPEVK WARDHGESLD KASIESTSSY TLLIVGNVNR FDSGKYILTV ENSSGSKSAF VNVRVLDTPG PPQDLKVKEV TKTSVTLTWD PPLLDGGSKI KNYIVEKRES TRKAYSTVAT NCHKTSWKVD QLQEGCSYYF RVLAENEYGI GLPAETAESV KASERPLPPG KITLMDVTRN SVSLSWEKPE HDGGSRILGY IVEMQTKGSD KWATCATVKV TEATITGLIQ GEEYSFRVSA QNEKGISDPR QLSVPVIAKD LVIPPAFKLL FNTFTVLAGE DLKVDVPFIG RPTPAVTWHK DNVPLKQTTR VNAESTENNS LLTIKDACRE DVGHYVVKLT NSAGEAIETL NVIVLDKPGP PTGPVKMDEV TADSITLSWG PPKYDGGSSI NNYIVEKRDT STTTWQIVSA TVARTTIKAC RLKTGCEYQF RIAAENRYGK STYLNSEPTV AQYPFKVPGP PGTPVVTLSS RDSMEVQWNE PISDGGSRVI GYHLERKERN SILWVKLNKT PIPQTKFKTT GLEEGVEYEF RVSAENIVGI GKPSKVSECY VARDPCDPPG RPEAIIVTRN SVTLQWKKPT YDGGSKITGY IVEKKELPEG RWMKASFTNI IDTHFEVTGL VEDHRYEFRV IARNAAGVFS EPSESTGAIT ARDEVDPPRI SMDPKYKDTI VVHAGESFKV DADIYGKPIP TIQWIKGDQE LSNTARLEIK STDFATSLSV KDAVRVDSGN YILKAKNVAG ERSVTVNVKV LDRPGPPEGP VVISGVTAEK CTLAWKPPLQ DGGSDIINYI VERRETSRLV WTVVDANVQT LSCKVTKLLE GNEYTFRIMA VNKYGVGEPL ESEPVVAKNP FVVPDAPKAP EVTTVTKDSM IVVWERPASD GGSEILGYVL EKRDKEGIRW TRCHKRLIGE LRLRVTGLIE NHDYEFRVSA ENAAGLSEPS PPSAYQKACD PIYKPGPPNN PKVIDITRSS VFLSWSKPIY DGGCEIQGYI VEKCDVSVGE WTMCTPPTGI NKTNIEVEKL LEKHEYNFRI CAINKAGVGE HADVPGPIIV EEKLEAPDID LDLELRKIIN IRAGGSLRLF VPIKGRPTPE VKWGKVDGEI RDAAIIDVTS SFTSLVLDNV NRYDSGKYTL TLENSSGTKS AFVTVRVLDT PSPPVNLKVT EITKDSVSIT WEPPLLDGGS KIKNYIVEKR EATRKSYAAV VTNCHKNSWK IDQLQEGCSY YFRVTAENEY GIGLPAQTAD PIKVAEVPQP PGKITVDDVT RNSVSLSWTK PEHDGGSKII QYIVEMQAKH SEKWSECARV KSLQAVITNL TQGEEYLFRV VAVNEKGRSD PRSLAVPIVA KDLVIEPDVK PAFSSYSVQV GQDLKIEVPI SGRPKPTITW TKDGLPLKQT TRINVTDSLD LTTLSIKETH KDDGGQYGIT VANVVGQKTA SIEIVTLDKP DPPKGPVKFD DVSAESITLS WNPPLYTGGC QITNYIVQKR DTTTTVWDVV SATVARTTLK VTKLKTGTEY QFRIFAENRY GQSFALESDP IVAQYPYKEP GPPGTPFATA ISKDSMVIQW HEPVNNGGSP VIGYHLERKE RNSILWTKVN KTIIHDTQFK AQNLEEGIEY EFRVYAENIV GVGKASKNSE CYVARDPCDP PGTPEPIMVK RNEITLQWTK PVYDGGSMIT GYIVEKRDLP DGRWMKASFT NVIETQFTVS GLTEDQRYEF RVIAKNAAGA ISKPSDSTGP ITAKDEVELP RISMDPKFRD TIVVNAGETF RLEADVHGKP LPTIEWLRGD KEIEESARCE IKNTDFKALL IVKDAIRIDG GQYILRASNV AGSKSFPVNV KVLDRPGPPE GPVQVTGVTS EKCSLTWSPP LQDGGSDISH YVVEKRETSR LAWTVVASEV VTNSLKVTKL LEGNEYVFRI MAVNKYGVGE PLESAPVLMK NPFVLPGPPK SLEVTNIAKD SMTVCWNRPD SDGGSEIIGY IVEKRDRSGI RWIKCNKRRI TDLRLRVTGL TEDHEYEFRV SAENAAGVGE PSPATVYYKA CDPVFKPGPP TNAHIVDTTK NSITLAWGKP IYDGGSEILG YVVEICKADE EEWQIVTPQT GLRVTRFEIS KLTEHQEYKI RVCALNKVGL GEATSVPGTV KPEDKLEAPE LDLDSELRKG IVVRAGGSAR IHIPFKGRPT PEITWSREEG EFTDKVQIEK GVNYTQLSID NCDRNDAGKY ILKLENSSGS KSAFVTVKVL DTPGPPQNLA VKEVRKDSAF LVWEPPIIDG GAKVKNYVID KRESTRKAYA NVSSKCSKTS FKVENLTEGA IYYFRVMAEN EFGVGVPVET VDAVKAAEPP SPPGKVTLTD VSQTSASLMW EKPEHDGGSR VLGYVVEMQP KGTEKWSIVA ESKVCNAVVT GLSSGQEYQF RVKAYNEKGK SDPRVLGVPV IAKDLTIQPS LKLPFNTYSI QAGEDLKIEI PVIGRPRPNI SWVKDGEPLK QTTRVNVEET ATSTVLHIKE GNKDDFGKYT VTATNSAGTA TENLSVIVLE KPGPPVGPVR FDEVSADFVV ISWEPPAYTG GCQISNYIVE KRDTTTTTWH MVSATVARTT IKITKLKTGT EYQFRIFAEN RYGKSAPLDS KAVIVQYPFK EPGPPGTPFV TSISKDQMLV QWHEPVNDGG TKIIGYHLEQ KEKNSILWVK LNKTPIQDTK FKTTGLDEGL EYEFKVSAEN IVGIGKPSKV SECFVARDPC DPPGRPEAIV ITRNNVTLKW KKPAYDGGSK ITGYIVEKKD LPDGRWMKAS FTNVLETEFT VSGLVEDQRY EFRVIARNAA GNFSEPSDSS GAITARDEID APNASLDPKY KDVIVVHAGE TFVLEADIRG KPIPDVVWSK DGKELEETAA RMEIKSTIQK TTLVVKDCIR TDGGQYILKL SNVGGTKSIP ITVKVLDRPG PPEGPLKVTG VTAEKCYLAW NPPLQDGGAN ISHYIIEKRE TSRLSWTQVS TEVQALNYKV TKLLPGNEYI FRVMAVNKYG IGEPLESGPV TACNPYKPPG PPSTPEVSAI TKDSMVVTWA RPVDDGGTEI EGYILEKRDK EGVRWTKCNK KTLTDLRLRV TGLTEGHSYE FRVAAENAAG VGEPSEPSVF YRACDALYPP GPPSNPKVTD TSRSSVSLAW SKPIYDGGAP VKGYVVEVKE AAADEWTTCT PPTGLQGKQF TVTKLKENTE YNFRICAINS EGVGEPATLP GSVVAQERIE PPEIELDADL RKVVVLRASA TLRLFVTIKG RPEPEVKWEK AEGILTDRAQ IEVTSSFTML VIDNVTRFDS GRYNLTLENN SGSKTAFVNV RVLDSPSAPV NLTIREVKKD SVTLSWEPPL IDGGAKITNY IVEKRETTRK AYATITNNCT KTTFRIENLQ EGCSYYFRVL ASNEYGIGLP AETTEPVKVS EPPLPPGRVT LVDVTRNTAT IKWEKPESDG GSKITGYVVE MQTKGSEKWS TCTQVKTLEA TISGLTAGEE YVFRVAAVNE KGRSDPRQLG VPVIARDIEI KPSVELPFHT FNVKAREQLK IDVPFKGRPQ ATVNWRKDGQ TLKETTRVNV SSSKTVTSLS IKEASKEDVG TYELCVSNSA GSITVPITII VLDRPGPPGP IRIDEVSCDS ITISWNPPEY DGGCQISNYI VEKKETTSTT WHIVSQAVAR TSIKIVRLTT GSEYQFRVCA ENRYGKSSYS ESSAVVAEYP FSPPGPPGTP KVVHATKSTM LVTWQVPVND GGSRVIGYHL EYKERSSILW SKANKILIAD TQMKVSGLDE GLMYEYRVYA ENIAGIGKCS KSCEPVPARD PCDPPGQPEV TNITRKSVSL KWSKPHYDGG AKITGYIVER RELPDGRWLK CNYTNIQETY FEVTELTEDQ RYEFRVFARN AADSVSEPSE STGPIIVKDD VEPPRVMMDV KFRDVIVVKA GEVLKINADI AGRPLPVISW AKDGIEIEER ARTEIISTDN HTLLTVKDCI RRDTGQYVLT LKNVAGTRSV AVNCKVLDKP GPPAGPLEIN GLTAEKCSLS WGRPQEDGGA DIDYYIVEKR ETSHLAWTIC EGELQMTSCK VTKLLKGNEY IFRVTGVNKY GVGEPLESVA IKALDPFTVP SPPTSLEITS VTKESMTLCW SRPESDGGSE ISGYIIERRE KNSLRWVRVN KKPVYDLRVK STGLREGCEY EYRVYAENAA GLSLPSETSP LIRAEDPVFL PSPPSKPKIV DSGKTTITIA WVKPLFDGGA PITGYTVEYK KSDDTDWKTS IQSLRGTEYT ISGLTTGAEY VFRVKSVNKV GASDPSDSSD PQIAKEREEE PLFDIDSEMR KTLIVKAGAS FTMTVPFRGR PVPNVLWSKP DTDLRTRAYV DTTDSRTSLT IENANRNDSG KYTLTIQNVL SAASLTLVVK VLDTPGPPTN ITVQDVTKES AVLSWDVPEN DGGAPVKNYH IEKREASKKA WVSVTNNCNR LSYKVTNLQE GAIYYFRVSG ENEFGVGIPA ETKEGVKITE KPSPPEKLGV TSISKDSVSL TWLKPEHDGG SRIVHYVVEA LEKGQKNWVK CAVAKSTHHV VSGLRENSEY FFRVFAENQA GLSDPRELLL PVLIKEQLEP PEIDMKNFPS HTVYVRAGSN LKVDIPISGK PLPKVTLSRD GVPLKATMRF NTEITAENLT INLKESVTAD AGRYEITAAN SSGTTKAFIN IVVLDRPGPP TGPVVISDIT EESVTLKWEP PKYDGGSQVT NYILLKRETS TAVWTEVSAT VARTMMKVMK LTTGEEYQFR IKAENRFGIS DHIDSACVTV KLPYTTPGPP STPWVTNVTR ESITVGWHEP VSNGGSAVVG YHLEMKDRNS ILWQKANKLV IRTTHFKVTT ISAGLIYEFR VYAENAAGVG KPSHPSEPVL AIDACEPPRN VRITDISKNS VSLSWQQPAF DGGSKITGYI VERRDLPDGR WTKASFTNVT ETQFIISGLT QNSQYEFRVF ARNAVGSISN PSEVVGPITC IDSYGGPVID LPLEYTEVVK YRAGTSVKLR AGISGKPAPT IEWYKDDKEL QTNALVCVEN TTDLASILIK DADRLNSGCY ELKLRNAMGS ASATIRVQIL DKPGPPGGPI EFKTVTAEKI TLLWRPPADD GGAKITHYIV EKRETSRVVW SMVSEHLEEC IITTTKIIKG NEYIFRVRAV NKYGIGEPLE SDSVVAKNAF VTPGPPGIPE VTKITKNSMT VVWSRPIADG GSDISGYFLE KRDKKSLGWF KVLKETIRDT RQKVTGLTEN SDYQYRVCAV NAAGQGPFSE PSEFYKAADP IDPPGPPAKI RIADSTKSSI TLGWSKPVYD GGSAVTGYVV EIRQGEEEEW TTVSTKGEVR TTEYVVSNLK PGVNYYFRVS AVNCAGQGEP IEMNEPVQAK DILEAPEIDL DVALRTSVIA KAGEDVQVLI PFKGRPPPTV TWRKDEKNLG SDARYSIENT DSSSLLTIPQ VTRNDTGKYI LTIENGVGEP KSSTVSVKVL DTPAACQKLQ VKHVSRGTVT LLWDPPLIDG GSPIINYVIE KRDATKRTWS VVSHKCSSTS FKLIDLSEKT PFFFRVLAEN EIGIGEPCET TEPVKAAEVP APIRDLSMKD STKTSVILSW TKPDFDGGSV ITEYVVERKG KGEQTWSHAG ISKTCEIEVS QLKEQSVLEF RVFAKNEKGL SDPVTIGPIT VKELIITPEV DLSDIPGAQV TVRIGHNVHL ELPYKGKPKP SISWLKDGLP LKESEFVRFS KTENKITLSI KNAKKEHGGK YTVILDNAVC RIAVPITVIT LGPPSKPKGP IRFDEIKADS VILSWDVPED NGGGEITCYS IEKRETSQTN WKMVCSSVAR TTFKVPNLVK DAEYQFRVRA ENRYGVSQPL VSSIIVAKHQ FRIPGPPGKP VIYNVTSDGM SLTWDAPVYD GGSEVTGFHV EKKERNSILW QKVNTSPISG REYRATGLVE GLDYQFRVYA ENSAGLSSPS DPSKFTLAVS PVDPPGTPDY IDVTRETITL KWNPPLRDGG SKIVGYSIEK RQGNERWVRC NFTDVSECQY TVTGLSPGDR YEFRIIARNA VGTISPPSQS SGIIMTRDEN VPPIVEFGPE YFDGLIIKSG ESLRIKALVQ GRPVPRVTWF KDGVEIEKRM NMEITDVLGS TSLFVRDATR DHRGVYTVEA KNASGSAKAE IKVKVQDTPG KVVGPIRFTN ITGEKMTLWW DAPLNDGCAP ITHYIIEKRE TSRLAWALIE DKCEAQSYTA IKLINGNEYQ FRVSAVNKFG VGRPLDSDPV VAQIQYTVPD APGIPEPSNI TGNSITLTWA RPESDGGSEI QQYILERREK KSTRWVKVIS KRPISETRFK VTGLTEGNEY EFHVMAENAA GVGPASGISR LIKCREPVNP PGPPTVVKVT DTSKTTVSLE WSKPVFDGGM EIIGYIIEMC KADLGDWHKV NAEACVKTRY TVTDLQAGEE YKFRVSAING AGKGDSCEVT GTIKAVDRLT APELDIDANF KQTHVVRAGA SIRLFIAYQG RPTPTAVWSK PDSNLSLRAD IHTTDSFSTL TVENCNRNDA GKYTLTVENN SGSKSITFTV KVLDTPGPPG PITFKDVTRG SATLMWDAPL LDGGARIHHY VVEKREASRR SWQVISEKCT RQIFKVNDLA EGVPYYFRVS AVNEYGVGEP YEMPEPIVAT EQPAPPRRLD VVDTSKSSAV LAWLKPDHDG GSRITGYLLE MRQKGSDFWV EAGHTKQLTF TVERLVEKTE YEFRVKAKND AGYSEPREAF SSVIIKEPQI EPTADLTGIT NQLITCKAGS PFTIDVPISG RPAPKVTWKL EEMRLKETDR VSITTTKDRT TLTVKDSMRG DSGRYFLTLE NTAGVKTFSV TVVVIGRPGP VTGPIEVSSV SAESCVLSWG EPKDGGGTEI TNYIVEKRES GTTAWQLVNS SVKRTQIKVT HLTKYMEYSF RVSSENRFGV SKPLESAPII AEHPFVPPSA PTRPEVYHVS ANAMSIRWEE PYHDGGSKII GYWVEKKERN TILWVKENKV PCLECNYKVT GLVEGLEYQF RTYALNAAGV SKASEASRPI MAQNPVDAPG RPEVTDVTRS TVSLIWSAPA YDGGSKVVGY IIERKPVSEV GDGRWLKCNY TIVSDNFFTV TALSEGDTYE FRVLAKNAAG VISKGSESTG PVTCRDEYAP PKAELDARLH GDLVTIRAGS DLVLDAAVGG KPEPKIIWTK GDKELDLCEK VSLQYTGKRA TAVIKFCDRS DSGKYTLTVK NASGTKAVSV MVKVLDSPGP CGKLTVSRVT QEKCTLAWSL PQEDGGAEIT HYIVERRETS RLNWVIVEGE CPTLSYVVTR LIKNNEYIFR VRAVNKYGPG VPVESEPIVA RNSFTIPSPP GIPEEVGTGK EHIIIQWTKP ESDGGNEISN YLVDKREKKS LRWTRVNKDY VVYDTRLKVT SLMEGCDYQF RVTAVNAAGN SEPSEASNFI SCREPSYTPG PPSAPRVVDT TKHSISLAWT KPMYDGGTDI VGYVLEMQEK DTDQWYRVHT NATIRNTEFT VPDLKMGQKY SFRVAAVNVK GMSEYSESIA EIEPVERIEI PDLELADDLK KTVTIRAGAS LRLMVSVSGR PPPVITWSKQ GIDLASRAII DTTESYSLLI VDKVNRYDAG KYTIEAENQS GKKSATVLVK VYDTPGPCPS VKVKEVSRDS VTITWEIPTI DGGAPVNNYI VEKREAAMRA FKTVTTKCSK TLYRISGLVE GTMYYFRVLP ENIYGIGEPC ETSDAVLVSE VPLVPAKLEV VDVTKSTVTL AWEKPLYDGG SRLTGYVLEA CKAGTERWMK VVTLKPTVLE HTVTSLNEGE QYLFRIRAQN EKGVSEPRET VTAVTVQDLR VLPTIDLSTM PQKTIHVPAG RPVELVIPIA GRPPPAASWF FAGSKLRESE RVTVETHTKV AKLTIRETTI RDTGEYTLEL KNVTGTTSET IKVIILDKPG PPTGPIKIDE IDATSITISW EPPELDGGAP LSGYVVEQRD AHRPGWLPVS ESVTRSTFKF TRLTEGNEYV FRVAATNRFG IGSYLQSEVI ECRSSIRIPG PPETLQIFDV SRDGMTLTWY PPEDDGGSQV TGYIVERKEV RADRWVRVNK VPVTMTRYRS TGLTEGLEYE HRVTAINARG SGKPSRPSKP IVAMDPIAPP GKPQNPRVTD TTRTSVSLAW SVPEDEGGSK VTGYLIEMQK VDQHEWTKCN TTPTKIREYT LTHLPQGAEY RFRVLACNAG GPGEPAEVPG TVKVTEMLEY PDYELDERYQ EGIFVRQGGV IRLTIPIKGK PFPICKWTKE GQDISKRAMI ATSETHTELV IKEADRGDSG TYDLVLENKC GKKAVYIKVR VIGSPNSPEG PLEYDDIQVR SVRVSWRPPA DDGGADILGY ILERREVPKA AWYTIDSRVR GTSLVVKGLK ENVEYHFRVS AENQFGISKP LKSEEPVTPK TPLNPPEPPS NPPEVLDVTK SSVSLSWSRP KDDGGSRVTG YYIERKETST DKWVRHNKTQ ITTTMYTVTG LVPDAEYQFR IIAQNDVGLS ETSPASEPVV CKDPFDKPSQ PGELEILSIS KDSVTLQWEK PECDGGKEIL GYWVEYRQSG DSAWKKSNKE RIKDKQFTIG GLLEATEYEF RVFAENETGL SRPRRTAMSI KTKLTSGEAP GIRKEMKDVT TKLGEAAQLS CQIVGRPLPD IKWYRFGKEL IQSRKYKMSS DGRTHTLTVM TEEQEDEGVY TCIATNEVGE VETSSKLLLQ ATPQFHPGYP LKEKYYGAVG STLRLHVMYI GRPVPAMTWF HGQKLLQNSE NITIENTEHY THLVMKNVQR KTHAGKYKVQ LSNVFGTVDA ILDVEIQDKP DKPTGPIVIE ALLKNSAVIS WKPPADDGGS WITNYVVEKC EAKEGAEWQL VSSAISVTTC RIVNLTENAG YYFRVSAQNT FGISDPLEVS SVVIIKSPFE KPGAPGKPTI TAVTKDSCVV AWKPPASDGG AKIRNYYLEK REKKQNKWIS VTTEEIRETV FSVKNLIEGL EYEFRVKCEN LGGESEWSEI SEPITPKSDV PIQAPHFKEE LRNLNVRYQS NATLVCKVTG HPKPIVKWYR QGKEIIADGL KYRIQEFKGG YHQLIIASVT DDDATVYQVR ATNQGGSVSG TASLEVEVPA KIHLPKTLEG MGAVHALRGE VVSIKIPFSG KPDPVITWQK GQDLIDNNGH YQVIVTRSFT SLVFPNGVER KDAGFYVVCA KNRFGIDQKT VELDVADVPD PPRGVKVSDV SRDSVNLTWT EPASDGGSKI TNYIVEKCAT TAERWLRVGQ ARETRYTVIN LFGKTSYQFR VIAENKFGLS KPSEPSEPTI TKEDKTRAMN YDEEVDETRE VSMTKASHSS TKELYEKYMI AEDLGRGEFG IVHRCVETSS KKTYMAKFVK VKGTDQVLVK KEISILNIAR HRNILHLHES FESMEELVMI FEFISGLDIF ERINTSAFEL NEREIVSYVH QVCEALQFLH SHNIGHFDIR PENIIYQTRR SSTIKIIEFG QARQLKPGDN FRLLFTAPEY YAPEVHQHDV VSTATDMWSL GTLVYVLLSG INPFLAETNQ QIIENIMNAE YTFDEEAFKE ISIEAMDFVD RLLVKERKSR MTASEALQHP WLKQKIERVS TKVIRTLKHR RYYHTLIKKD LNMVVSAARI SCGGAIRSQK GVSVAKVKVA SIEIGPVSGQ IMHAVGEEGG HVKYVCKIEN YDQSTQVTWY FGVRQLENSE KYEITYEDGV AILYVKDITK LDDGTYRCKV VNDYGEDSSY AELFVKGVRE VYDYYCRRTM KKIKRRTDTM RLLERPPEFT LPLYNKTAYV GENVRFGVTI TVHPEPHVTW YKSGQKIKPG DNDKKYTFES DKGLYQLTIN SVTTDDDAEY TVVARNKYGE DSCKAKLTVT LHPPPTDSTL RPMFKRLLAN AECQEGQSVC FEIRVSGIPP PTLKWEKDGQ PLSLGPNIEI IHEGLDYYAL HIRDTLPEDT GYYRVTATNT AGSTSCQAHL QVERLRYKKQ EFKSKEEHER HVQKQIDKTL RMAEILSGTE SVPLTQVAKE ALREAAVLYK PAVSTKTVKG EFRLEIEEKK EERKLRMPYD VPEPRKYKQT TIEEDQRIKQ FVPMSDMKWY KKIRDQYEMP GKLDRVVQKR PKRIRLSRWE QFYVMPLPRI TDQYRPKWRI PKLSQDDLEI VRPARRRTPS PDYDFYYRPR RRSLGDISDE ELLLPIDDYL AMKRTEEERL RLEEELELGF SASPPSRSPP HFELSSLRYS SPQAHVKVEE TRKDFRYSTY HIPTKAEAST SYAELRERHA QAAYRQPKQR QRIMAEREDE ELLRPVTTTQ HLSEYKSELD FMSKEEKSRK KSRRQREVTE ITEIEEEYEI SKHAQRESSS SASRLLRRRR SLSPTYIELM RPVSELIRSR PQPAEEYEDD TERRSPTPER TRPRSPSPVS SERSLSRFER SARFDIFSRY ESMKAALKTQ KTSERKYEVL SQQPFTLDHA PRITLRMRSH RVPCGQNTRF ILNVQSKPTA EVKWYHNGVE LQESSKIHYT NTSGVLTLEI LDCHTDDSGT YRAVCTNYKG EASDYATLDV TGGDYTTYAS QRRDEEVPRS VFPELTRTEA YAVSSFKKTS EMEASSSVRE VKSQMTETRE SLSSYEHSAS AEMKSAALEE KSLEEKSTTR KIKTTLAARI LTKPRSMTVY EGESARFSCD TDGEPVPTVT WLRKGQVLST SARHQVTTTK YKSTFEISSV QASDEGNYSV VVENSEGKQE AEFTLTIQKA RVTEKAVTSP PRVKSPEPRV KSPEAVKSPK RVKSPEPSHP KAVSPTETKP TPTEKVQHLP VSAPPKITQF LKAEASKEIA KLTCVVESSV LRAKEVTWYK DGKKLKENGH FQFHYSADGT YELKINNLTE SDQGEYVCEI SGEGGTSKTN LQFMGQAFKS IHEKVSKISE TKKSDQKTTE STVTRKTEPK APEPISSKPV IVTGLQDTTV SSDSVAKFAV KATGEPRPTA IWTKDGKAIT QGGKYKLSED KGGFFLEIHK TDTSDSGLYT CTVKNSAGSV SSSCKLTIKA IKDTEAQKVS TQKTSEITPQ KKAVVQEEIS QKALRSEEIK MSEAKSQEKL ALKEEASKVL ISEEVKKSAA TSLEKSIVHE EITKTSQASE EVRTHAEIKA FSTQMSINEG QRLVLKANIA GATDVKWVLN GVELTNSEEY RYGVSGSDQT LTIKQASHRD EGILTCISKT KEGIVKCQYD LTLSKELSDA PAFISQPRSQ NINEGQNVLF TCEISGEPSP EIEWFKNNLP ISISSNVSIS RSRNVYSLEI RNASVSDSGK YTIKAKNFRG QCSATASLMV LPLVEEPSRE VVLRTSGDTS LQGSFSSQSV QMSASKQEAS FSSFSSSSAS SMTEMKFASM SAQSMSSMQE SFVEMSSSSF MGISNMTQLE SSTSKMLKAG IRGIPPKIEA LPSDISIDEG KVLTVACAFT GEPTPEVTWS CGGRKIHSQE QGRFHIENTD DLTTLIIMDV QKQDGGLYTL SLGNEFGSDS ATVNIHIRSI // ID TLK2_HUMAN Reviewed; 772 AA. AC Q86UE8; D3DU07; Q9UKI7; Q9Y4F7; DT 22-AUG-2003, integrated into UniProtKB/Swiss-Prot. DT 22-AUG-2003, sequence version 2. DT 28-JAN-2026, entry version 204. DE RecName: Full=Serine/threonine-protein kinase tousled-like 2; DE EC=2.7.11.1 {ECO:0000269|PubMed:10523312, ECO:0000269|PubMed:12660173, ECO:0000269|PubMed:9427565}; DE AltName: Full=HsHPK; DE AltName: Full=PKU-alpha {ECO:0000303|PubMed:9427565}; DE AltName: Full=Tousled-like kinase 2 {ECO:0000303|PubMed:10523312}; GN Name=TLK2 {ECO:0000312|HGNC:HGNC:11842}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), VARIANT ARG-6, FUNCTION, RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RC TISSUE=Placenta {ECO:0000269|PubMed:9427565}, and RC Testis {ECO:0000269|PubMed:9427565}; RX PubMed=9427565; DOI=10.1016/s0378-1119(97)00495-2; RA Yamakawa A., Kameoka Y., Hashimoto K., Yoshitake Y., Nishikawa K., RA Tanihara K., Date T.; RT "cDNA cloning and chromosomal mapping of genes encoding novel protein RT kinases termed PKU-alpha and PKU-beta, which have nuclear localization RT signal."; RL Gene 202:193-201(1997). RN [2] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, MUTAGENESIS OF ASP-613, RP SUBCELLULAR LOCATION, SUBUNIT, INTERACTION WITH TLK1, AND ACTIVITY RP REGULATION. RC TISSUE=Placenta {ECO:0000269|PubMed:10523312}; RX PubMed=10523312; DOI=10.1093/emboj/18.20.5691; RA Sillje H.H.W., Takahashi K., Tanaka K., Van Houwe G., Nigg E.A.; RT "Mammalian homologues of the plant tousled gene code for cell-cycle- RT regulated kinases with maximal activities linked to ongoing DNA RT replication."; RL EMBO J. 18:5691-5702(1999). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [4] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 189-772 (ISOFORM 2/3), AND TISSUE RP SPECIFICITY. RX PubMed=9662073; DOI=10.1007/bf02258367; RA Huang A.M., Chang T.J., Cho W.L., Chou C.K.; RT "From mosquito to man: identification of a novel protein kinase, HsHPK, RT which is highly expressed in human hepatoma tissues."; RL J. Biomed. Sci. 5:135-140(1998). RN [6] RP SUBCELLULAR LOCATION, AND INTERACTION WITH YWHAZ. RX PubMed=10455159; DOI=10.1074/jbc.274.35.24865; RA Zhang S., Xing H., Muslin A.J.; RT "Nuclear localization of protein kinase U-alpha is regulated by 14-3-3."; RL J. Biol. Chem. 274:24865-24872(1999). RN [7] RP FUNCTION, AND MUTAGENESIS OF ASP-613. RX PubMed=11470414; DOI=10.1016/s0960-9822(01)00298-6; RA Sillje H.H.W., Nigg E.A.; RT "Identification of human Asf1 chromatin assembly factors as substrates of RT Tousled-like kinases."; RL Curr. Biol. 11:1068-1073(2001). RN [8] {ECO:0000305} RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=12660173; DOI=10.1093/emboj/cdg151; RA Groth A., Lukas J., Nigg E.A., Sillje H.H.W., Wernstedt C., Bartek J., RA Hansen K.; RT "Human tousled like kinases are targeted by an ATM- and Chk1-dependent DNA RT damage checkpoint."; RL EMBO J. 22:1676-1687(2003). RN [9] RP PHOSPHORYLATION AT SER-750, FUNCTION, AND ACTIVITY REGULATION. RX PubMed=12955071; DOI=10.1038/sj.onc.1206691; RA Krause D.R., Jonnalagadda J.C., Gatei M.H., Sillje H.H.W., Zhou B.-B., RA Nigg E.A., Khanna K.; RT "Suppression of tousled-like kinase activity after DNA damage or RT replication block requires ATM, NBS1 and Chk1."; RL Oncogene 22:5927-5937(2003). RN [10] RP INTERACTION WITH FEZ1 AND FEZ2. RX PubMed=16484223; DOI=10.1074/jbc.m513280200; RA Assmann E.M., Alborghetti M.R., Camargo M.E.R., Kobarg J.; RT "FEZ1 dimerization and interaction with transcription regulatory proteins RT involves its coiled-coil region."; RL J. Biol. Chem. 281:9869-9881(2006). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-99, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-94 AND SER-134, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [15] RP FUNCTION AS ASF1A AND ASF1B KINASE, AND ACTIVITY REGULATION. RX PubMed=20016786; DOI=10.1371/journal.pone.0008328; RA Pilyugin M., Demmers J., Verrijzer C.P., Karch F., Moshkin Y.M.; RT "Phosphorylation-mediated control of histone chaperone ASF1 levels by RT Tousled-like kinases."; RL PLoS ONE 4:E8328-E8328(2009). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-99, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [18] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [19] RP FUNCTION. RX PubMed=22354037; DOI=10.1038/emboj.2012.36; RA McKnight N.C., Jefferies H.B., Alemu E.A., Saunders R.E., Howell M., RA Johansen T., Tooze S.A.; RT "Genome-wide siRNA screen reveals amino acid starvation-induced autophagy RT requires SCOC and WAC."; RL EMBO J. 31:1931-1946(2012). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-73; SER-94; SER-99; SER-115; RP SER-117 AND SER-134, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [22] {ECO:0007744|PDB:5O0Y} RP X-RAY CRYSTALLOGRAPHY (2.86 ANGSTROMS) OF 191-755 IN COMPLEX WITH ATP, RP FUNCTION, SUBUNIT, INTERACTION WITH DYNLL1/LC8 AND TLK1, SUBCELLULAR RP LOCATION, PHOSPHORYLATION, CHARACTERIZATION OF VARIANTS MRD57 ARG-493; RP ARG-518 AND ASN-629, AND MUTAGENESIS OF HIS-518; ASP-613; SER-617; SER-659; RP SER-686; THR-695 AND ARG-720. RX PubMed=29955062; DOI=10.1038/s41467-018-04941-y; RA Mortuza G.B., Hermida D., Pedersen A.K., Segura-Bayona S., Lopez-Mendez B., RA Redondo P., Ruther P., Pozdnyakova I., Garrote A.M., Munoz I.G., RA Villamor-Paya M., Jauset C., Olsen J.V., Stracker T.H., Montoya G.; RT "Molecular basis of Tousled-Like Kinase 2 activation."; RL Nat. Commun. 9:2535-2535(2018). RN [23] {ECO:0007744|PDB:7LO0} RP X-RAY CRYSTALLOGRAPHY (2.71 ANGSTROMS) OF 3-23 IN COMPLEX WITH ASF1A, AND RP FUNCTION. RX PubMed=35136069; DOI=10.1038/s41467-022-28427-0; RA Simon B., Lou H.J., Huet-Calderwood C., Shi G., Boggon T.J., Turk B.E., RA Calderwood D.A.; RT "Tousled-like kinase 2 targets ASF1 histone chaperones through client RT mimicry."; RL Nat. Commun. 13:749-749(2022). RN [24] RP VARIANTS [LARGE SCALE ANALYSIS] ARG-6; ASP-54; GLY-95; GLY-108; LEU-109; RP LEU-173 AND GLN-262. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [25] RP VARIANT MRD57 LEU-617. RX PubMed=21572417; DOI=10.1038/ng.835; RA O'Roak B.J., Deriziotis P., Lee C., Vives L., Schwartz J.J., Girirajan S., RA Karakoc E., Mackenzie A.P., Ng S.B., Baker C., Rieder M.J., Nickerson D.A., RA Bernier R., Fisher S.E., Shendure J., Eichler E.E.; RT "Exome sequencing in sporadic autism spectrum disorders identifies severe RT de novo mutations."; RL Nat. Genet. 43:585-589(2011). RN [26] RP VARIANT MRD57 720-ARG--ASN-772 DEL, AND INVOLVEMENT IN MRD57. RX PubMed=27479843; DOI=10.1038/nn.4352; RA Lelieveld S.H., Reijnders M.R., Pfundt R., Yntema H.G., Kamsteeg E.J., RA de Vries P., de Vries B.B., Willemsen M.H., Kleefstra T., Loehner K., RA Vreeburg M., Stevens S.J., van der Burgt I., Bongers E.M., Stegmann A.P., RA Rump P., Rinne T., Nelen M.R., Veltman J.A., Vissers L.E., Brunner H.G., RA Gilissen C.; RT "Meta-analysis of 2,104 trios provides support for 10 new genes for RT intellectual disability."; RL Nat. Neurosci. 19:1194-1196(2016). RN [27] RP VARIANTS MRD57 13-GLN--ASN-772 DEL; 61-ARG--ASN-772 DEL; 68-GLU--ASN-772 RP DEL; 259-TYR--ASN-772 DEL; 262-ARG--ASN-772 DEL; ASP-297; 303-ARG--ASN-772 RP DEL; 330-SER--ASN-772 DEL; GLN-339; TRP-339; LYS-447; ARG-493; ARG-518; RP TRP-568; 573-GLN--ASN-772 DEL; ASN-629; ARG-680; 720-ARG--ASN-772 DEL AND RP 746-ARG--ASN-772 DEL, AND INVOLVEMENT IN MRD57. RX PubMed=29861108; DOI=10.1016/j.ajhg.2018.04.014; RG Deciphering Developmental Disorders Study; RA Reijnders M.R.F., Miller K.A., Alvi M., Goos J.A.C., Lees M.M., RA de Burca A., Henderson A., Kraus A., Mikat B., de Vries B.B.A., Isidor B., RA Kerr B., Marcelis C., Schluth-Bolard C., Deshpande C., Ruivenkamp C.A.L., RA Wieczorek D., Baralle D., Blair E.M., Engels H., Luedecke H.J., Eason J., RA Santen G.W.E., Clayton-Smith J., Chandler K., Tatton-Brown K., Payne K., RA Helbig K., Radtke K., Nugent K.M., Cremer K., Strom T.M., Bird L.M., RA Sinnema M., Bitner-Glindzicz M., van Dooren M.F., Alders M., Koopmans M., RA Brick L., Kozenko M., Harline M.L., Klaassens M., Steinraths M., RA Cooper N.S., Edery P., Yap P., Terhal P.A., van der Spek P.J., Lakeman P., RA Taylor R.L., Littlejohn R.O., Pfundt R., Mercimek-Andrews S., RA Stegmann A.P.A., Kant S.G., McLean S., Joss S., Swagemakers S.M.A., RA Douzgou S., Wall S.A., Kuery S., Calpena E., Koelling N., McGowan S.J., RA Twigg S.R.F., Mathijssen I.M.J., Nellaker C., Brunner H.G., Wilkie A.O.M.; RT "De Novo and Inherited Loss-of-Function Variants in TLK2: Clinical and RT Genotype-Phenotype Evaluation of a Distinct Neurodevelopmental Disorder."; RL Am. J. Hum. Genet. 102:1195-1203(2018). RN [28] RP VARIANTS MRD57 475-GLU--ASN-772 DEL AND GLY-551, CHARACTERIZATION OF RP VARIANTS MRD57 GLY-551 AND LEU-617, FUNCTION, SUBCELLULAR LOCATION, RP INTERACTION WITH TLK1; CHD7; CHD8 AND DYNLL1/LC8, AND MUTAGENESIS OF RP ASP-592. RX PubMed=33323470; DOI=10.1136/jmedgenet-2020-107281; RA Pavinato L., Villamor-Paya M., Sanchiz-Calvo M., Andreoli C., Gay M., RA Vilaseca M., Arauz-Garofalo G., Ciolfi A., Bruselles A., Pippucci T., RA Prota V., Carli D., Giorgio E., Radio F.C., Antona V., Giuffre M., RA Ranguin K., Colson C., De Rubeis S., Dimartino P., Buxbaum J.D., RA Ferrero G.B., Tartaglia M., Martinelli S., Stracker T.H., Brusco A.; RT "Functional analysis of TLK2 variants and their proximal interactomes RT implicates impaired kinase activity and chromatin maintenance defects in RT their pathogenesis."; RL J. Med. Genet. 59:170-179(2022). CC -!- FUNCTION: Serine/threonine-protein kinase involved in the process of CC chromatin assembly and probably also DNA replication, transcription, CC repair, and chromosome segregation (PubMed:10523312, PubMed:11470414, CC PubMed:12660173, PubMed:12955071, PubMed:29955062, PubMed:33323470, CC PubMed:9427565). Phosphorylates the chromatin assembly factors ASF1A CC and ASF1B (PubMed:11470414, PubMed:20016786, PubMed:29955062, CC PubMed:35136069). Phosphorylation of ASF1A prevents its proteasome- CC mediated degradation, thereby enhancing chromatin assembly CC (PubMed:20016786). Negative regulator of amino acid starvation-induced CC autophagy (PubMed:22354037). {ECO:0000269|PubMed:10523312, CC ECO:0000269|PubMed:11470414, ECO:0000269|PubMed:12660173, CC ECO:0000269|PubMed:12955071, ECO:0000269|PubMed:20016786, CC ECO:0000269|PubMed:22354037, ECO:0000269|PubMed:29955062, CC ECO:0000269|PubMed:33323470, ECO:0000269|PubMed:35136069, CC ECO:0000269|PubMed:9427565}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10523312, ECO:0000269|PubMed:12660173, CC ECO:0000269|PubMed:9427565}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10523312, ECO:0000269|PubMed:12660173, CC ECO:0000269|PubMed:9427565}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:10523312, ECO:0000269|PubMed:12660173, CC ECO:0000269|PubMed:9427565}; CC -!- ACTIVITY REGULATION: Cell cycle-regulated, with maximal activity in the CC S-phase (PubMed:10523312, PubMed:20016786). Rapidly and transiently CC inhibited by phosphorylation following the generation of DNA double- CC stranded breaks during S-phase, probably by CHEK1, possibly at Ser-750 CC (PubMed:12660173, PubMed:12955071). This inhibition is cell cycle CC checkpoint- and ATM-dependent (PubMed:12955071). CC {ECO:0000269|PubMed:10523312, ECO:0000269|PubMed:12660173, CC ECO:0000269|PubMed:12955071, ECO:0000269|PubMed:20016786}. CC -!- SUBUNIT: Monomer (PubMed:29955062). May form homodimers; CC homodimerization may enhance autophosphoylation and enzymatic activity CC (PubMed:29955062). Heterodimer with TLK1 (PubMed:10523312, CC PubMed:29955062, PubMed:33323470). Interacts with YWHAZ; association CC with 14-3-3 proteins such as YWHAZ regulates subcellular location CC (PubMed:10455159). May also interact with FEZ1/LZTS1 and FEZ2 CC (PubMed:16484223). Interacts with CHD7 and CHD8 (PubMed:33323470). CC Interacts with DYNLL1/LC8 (PubMed:29955062). CC {ECO:0000269|PubMed:10455159, ECO:0000269|PubMed:10523312, CC ECO:0000269|PubMed:16484223, ECO:0000269|PubMed:29955062, CC ECO:0000269|PubMed:33323470}. CC -!- INTERACTION: CC Q86UE8; Q9Y294: ASF1A; NbExp=10; IntAct=EBI-1047967, EBI-749553; CC Q86UE8; Q9NVP2: ASF1B; NbExp=8; IntAct=EBI-1047967, EBI-1055650; CC Q86UE8; Q8NHQ1: CEP70; NbExp=3; IntAct=EBI-1047967, EBI-739624; CC Q86UE8; Q9NPF5: DMAP1; NbExp=3; IntAct=EBI-1047967, EBI-399105; CC Q86UE8; P63167: DYNLL1; NbExp=11; IntAct=EBI-1047967, EBI-349105; CC Q86UE8; Q96FJ2: DYNLL2; NbExp=7; IntAct=EBI-1047967, EBI-742371; CC Q86UE8; Q96NE9-2: FRMD6; NbExp=3; IntAct=EBI-1047967, EBI-13213391; CC Q86UE8; Q96IK5: GMCL1; NbExp=3; IntAct=EBI-1047967, EBI-2548508; CC Q86UE8; Q15306: IRF4; NbExp=2; IntAct=EBI-1047967, EBI-751345; CC Q86UE8; Q92985: IRF7; NbExp=2; IntAct=EBI-1047967, EBI-968267; CC Q86UE8; Q02548: PAX5; NbExp=3; IntAct=EBI-1047967, EBI-296331; CC Q86UE8; P26367: PAX6; NbExp=3; IntAct=EBI-1047967, EBI-747278; CC Q86UE8; Q8TAQ2: SMARCC2; NbExp=3; IntAct=EBI-1047967, EBI-357418; CC Q86UE8; Q86UE8: TLK2; NbExp=3; IntAct=EBI-1047967, EBI-1047967; CC Q86UE8; Q7KZS0: UBE2I; NbExp=3; IntAct=EBI-1047967, EBI-10180829; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:10455159, CC ECO:0000269|PubMed:29955062, ECO:0000269|PubMed:33323470, CC ECO:0000269|PubMed:9427565}. Nucleus, nucleoplasm CC {ECO:0000269|PubMed:10523312, ECO:0000269|PubMed:33323470}. Cytoplasm, CC perinuclear region {ECO:0000269|PubMed:10455159, CC ECO:0000269|PubMed:33323470}. Cytoplasm, cytoskeleton CC {ECO:0000269|PubMed:10455159}. Note=Colocalizes with the cytoplasmic CC intermediate filament system during the G1 phase of the cell cycle CC (PubMed:10455159). Present in the perinuclear region at S phase and in CC the nucleus at late G2 (PubMed:10455159). CC {ECO:0000269|PubMed:10455159}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1 {ECO:0000305}; CC IsoId=Q86UE8-1; Sequence=Displayed; CC Name=2 {ECO:0000269|PubMed:10523312}; CC IsoId=Q86UE8-2; Sequence=VSP_050573; CC Name=3 {ECO:0000269|PubMed:9427565}; CC IsoId=Q86UE8-3; Sequence=VSP_050572, VSP_050573; CC -!- TISSUE SPECIFICITY: Detected in placenta, fetal liver, kidney, CC pancreas, heart and skeletal muscle (PubMed:9427565). Highly expressed CC in testis (PubMed:9427565, PubMed:9662073). Detected in spleen, thymus, CC colon, ovary, small intestine, prostate and peripheral blood leukocytes CC (PubMed:9662073). Almost undetectable in liver and lung CC (PubMed:9662073). {ECO:0000269|PubMed:9427565, CC ECO:0000269|PubMed:9662073}. CC -!- PTM: Phosphorylated at Ser-750, probably by CHEK1. CC {ECO:0000269|PubMed:12955071}. CC -!- PTM: Autophosphorylated; phosphorylation promotes the assembly of CC higher order oligomers and enzymatic activity. CC {ECO:0000269|PubMed:29955062}. CC -!- DISEASE: Intellectual developmental disorder, autosomal dominant 57 CC (MRD57) [MIM:618050]: A disorder characterized by significantly below CC average general intellectual functioning associated with impairments in CC adaptive behavior and manifested during the developmental period. MRD57 CC is characterized by delayed psychomotor development apparent in infancy CC or early childhood, and a variety of behavioral abnormalities. Affected CC individuals may have severe gastro-intestinal problems, and facial CC dysmorphism. {ECO:0000269|PubMed:21572417, ECO:0000269|PubMed:27479843, CC ECO:0000269|PubMed:29861108, ECO:0000269|PubMed:29955062, CC ECO:0000269|PubMed:33323470}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=AAF03095.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC Sequence=AAH44925.2; Type=Erroneous initiation; Evidence={ECO:0000305}; CC Sequence=BAA20561.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB004884; BAA20561.1; ALT_INIT; mRNA. DR EMBL; AF162667; AAF03095.1; ALT_INIT; mRNA. DR EMBL; CH471109; EAW94346.1; -; Genomic_DNA. DR EMBL; CH471109; EAW94348.1; -; Genomic_DNA. DR EMBL; BC044925; AAH44925.2; ALT_INIT; mRNA. DR CCDS; CCDS11633.1; -. [Q86UE8-2] DR CCDS; CCDS45753.1; -. [Q86UE8-3] DR CCDS; CCDS62283.1; -. [Q86UE8-1] DR RefSeq; NP_001271262.1; NM_001284333.3. [Q86UE8-1] DR RefSeq; NP_001271292.1; NM_001284363.1. [Q86UE8-3] DR RefSeq; NP_001362199.1; NM_001375270.1. [Q86UE8-2] DR RefSeq; NP_001362200.1; NM_001375271.1. [Q86UE8-2] DR RefSeq; NP_001362201.1; NM_001375272.1. [Q86UE8-3] DR RefSeq; NP_001425132.1; NM_001438203.1. [Q86UE8-3] DR RefSeq; NP_001425133.1; NM_001438204.1. [Q86UE8-3] DR RefSeq; NP_006843.2; NM_006852.3. [Q86UE8-2] DR RefSeq; XP_011522518.1; XM_011524216.3. [Q86UE8-1] DR RefSeq; XP_011522524.1; XM_011524222.4. [Q86UE8-1] DR RefSeq; XP_024306321.1; XM_024450553.2. [Q86UE8-1] DR RefSeq; XP_047291135.1; XM_047435179.1. [Q86UE8-2] DR RefSeq; XP_047291138.1; XM_047435182.1. [Q86UE8-3] DR RefSeq; XP_054170761.1; XM_054314786.1. [Q86UE8-1] DR RefSeq; XP_054170762.1; XM_054314787.1. [Q86UE8-1] DR RefSeq; XP_054170763.1; XM_054314788.1. [Q86UE8-1] DR RefSeq; XP_054170767.1; XM_054314792.1. [Q86UE8-2] DR RefSeq; XP_054170775.1; XM_054314800.1. [Q86UE8-3] DR PDB; 5O0Y; X-ray; 2.86 A; A=191-755. DR PDB; 7LO0; X-ray; 2.71 A; I/J/K/L/M/N/O/P/Q/R/T/U/V/W/X/Y=3-23. DR PDBsum; 5O0Y; -. DR PDBsum; 7LO0; -. DR AlphaFoldDB; Q86UE8; -. DR SMR; Q86UE8; -. DR BioGRID; 116201; 170. DR FunCoup; Q86UE8; 4227. DR IntAct; Q86UE8; 220. DR MINT; Q86UE8; -. DR STRING; 9606.ENSP00000316512; -. DR BindingDB; Q86UE8; -. DR ChEMBL; CHEMBL5404; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q86UE8; -. DR GlyGen; Q86UE8; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q86UE8; -. DR PhosphoSitePlus; Q86UE8; -. DR BioMuta; TLK2; -. DR DMDM; 34222826; -. DR CPTAC; non-CPTAC-5682; -. DR CPTAC; non-CPTAC-5683; -. DR jPOST; Q86UE8; -. DR MassIVE; Q86UE8; -. DR PaxDb; 9606-ENSP00000316512; -. DR PeptideAtlas; Q86UE8; -. DR ProteomicsDB; 69811; -. [Q86UE8-1] DR ProteomicsDB; 69812; -. [Q86UE8-2] DR ProteomicsDB; 69813; -. [Q86UE8-3] DR Pumba; Q86UE8; -. DR Antibodypedia; 31236; 371 antibodies from 31 providers. DR DNASU; 11011; -. DR Ensembl; ENST00000326270.13; ENSP00000316512.9; ENSG00000146872.20. [Q86UE8-1] DR Ensembl; ENST00000343388.11; ENSP00000340800.7; ENSG00000146872.20. [Q86UE8-3] DR Ensembl; ENST00000346027.10; ENSP00000275780.7; ENSG00000146872.20. [Q86UE8-2] DR Ensembl; ENST00000682085.1; ENSP00000506744.1; ENSG00000146872.20. [Q86UE8-2] DR Ensembl; ENST00000683104.1; ENSP00000508242.1; ENSG00000146872.20. [Q86UE8-3] DR GeneID; 11011; -. DR KEGG; hsa:11011; -. DR MANE-Select; ENST00000346027.10; ENSP00000275780.7; NM_006852.6; NP_006843.2. [Q86UE8-2] DR UCSC; uc002izz.5; human. [Q86UE8-1] DR AGR; HGNC:11842; -. DR CIViC; 11011; 1 evidence item across 1 molecular profile. DR ClinPGx; PA36544; -. DR CTD; 11011; -. DR DisGeNET; 11011; -. DR GeneCards; TLK2; -. DR HGNC; HGNC:11842; TLK2. DR HPA; ENSG00000146872; Low tissue specificity. DR MalaCards; TLK2; -. DR MIM; 608439; gene. DR MIM; 618050; phenotype. DR OpenTargets; ENSG00000146872; -. DR VEuPathDB; HostDB:ENSG00000146872; -. DR eggNOG; KOG1151; Eukaryota. DR GeneTree; ENSGT00950000182984; -. DR InParanoid; Q86UE8; -. DR OMA; LPSMTWQ; -. DR OrthoDB; 346907at2759; -. DR PAN-GO; Q86UE8; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q86UE8; -. DR PathwayCommons; Q86UE8; -. DR SignaLink; Q86UE8; -. DR SIGNOR; Q86UE8; -. DR Agora; ENSG00000146872; -. DR BioGRID-ORCS; 11011; 259 hits in 1157 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; TLK2; human. DR GeneWiki; TLK2; -. DR GenomeRNAi; 11011; -. DR Pharos; Q86UE8; Tchem. DR PRO; PR:Q86UE8; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q86UE8; protein. DR Bgee; ENSG00000146872; Expressed in calcaneal tendon and 115 other cell types or tissues. DR ExpressionAtlas; Q86UE8; baseline and differential. DR GO; GO:0005882; C:intermediate filament; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0071480; P:cellular response to gamma radiation; IDA:UniProtKB. DR GO; GO:0006325; P:chromatin organization; IEA:UniProtKB-KW. DR GO; GO:0007059; P:chromosome segregation; IMP:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0010507; P:negative regulation of autophagy; NAS:BHF-UCL. DR GO; GO:0032435; P:negative regulation of proteasomal ubiquitin-dependent protein catabolic process; IMP:UniProtKB. DR GO; GO:0051647; P:nucleus localization; IMP:DisProt. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:1902275; P:regulation of chromatin organization; IDA:UniProtKB. DR CDD; cd14041; STKc_TLK2; 1. DR DisProt; DP02475; -. DR FunFam; 1.10.510.10:FF:000037; Serine/threonine-protein kinase tousled-like 2; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR22974; MIXED LINEAGE PROTEIN KINASE; 1. DR PANTHER; PTHR22974:SF20; SERINE_THREONINE-PROTEIN KINASE TOUSLED-LIKE 2; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell cycle; KW Chromatin regulator; Coiled coil; Cytoplasm; Cytoskeleton; Disease variant; KW DNA damage; Intellectual disability; Kinase; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..772 FT /note="Serine/threonine-protein kinase tousled-like 2" FT /id="PRO_0000086754" FT DOMAIN 462..741 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 24..126 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 180..208 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 225..276 FT /note="Required for interaction with TLK1 and DYNLL1/LC8" FT /evidence="ECO:0000269|PubMed:29955062" FT REGION 342..385 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 225..276 FT /evidence="ECO:0000255" FT COILED 317..347 FT /evidence="ECO:0000255" FT COILED 403..451 FT /evidence="ECO:0000255" FT COMPBIAS 29..44 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 46..61 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 367..380 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 592 FT /note="Proton acceptor" FT BINDING 468..476 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 491 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 73 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 94 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 99 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163" FT MOD_RES 115 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 117 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 134 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 750 FT /note="Phosphoserine; by CHEK1" FT /evidence="ECO:0000305|PubMed:12955071" FT VAR_SEQ 90..121 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:9427565" FT /id="VSP_050572" FT VAR_SEQ 375..396 FT /note="Missing (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:10523312, FT ECO:0000303|PubMed:9427565" FT /id="VSP_050573" FT VARIANT 6 FT /note="H -> R (in dbSNP:rs45550140)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9427565" FT /id="VAR_041216" FT VARIANT 13..772 FT /note="Missing (in MRD57)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081017" FT VARIANT 54 FT /note="E -> D" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041217" FT VARIANT 61..772 FT /note="Missing (in MRD57)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081018" FT VARIANT 68..772 FT /note="Missing (in MRD57)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081019" FT VARIANT 95 FT /note="A -> G (in dbSNP:rs2598147)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041218" FT VARIANT 108 FT /note="A -> G" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041219" FT VARIANT 109 FT /note="R -> L (in dbSNP:rs1555617262)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041220" FT VARIANT 173 FT /note="F -> L (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1331331651)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041221" FT VARIANT 259..772 FT /note="Missing (in MRD57)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081020" FT VARIANT 262..772 FT /note="Missing (in MRD57)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081021" FT VARIANT 262 FT /note="R -> Q (in dbSNP:rs762409144)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041222" FT VARIANT 297 FT /note="G -> D (in MRD57; uncertain significance; FT dbSNP:rs1555639254)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081022" FT VARIANT 303..772 FT /note="Missing (in MRD57)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081023" FT VARIANT 330..772 FT /note="Missing (in MRD57)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081024" FT VARIANT 339 FT /note="R -> Q (in MRD57; uncertain significance; FT dbSNP:rs1567948287)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081025" FT VARIANT 339 FT /note="R -> W (in MRD57; uncertain significance; FT dbSNP:rs1567948262)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081026" FT VARIANT 447 FT /note="E -> K (in MRD57; uncertain significance; FT dbSNP:rs1567959483)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081027" FT VARIANT 475..772 FT /note="Missing (in MRD57; uncertain significance)" FT /evidence="ECO:0000269|PubMed:33323470" FT /id="VAR_087040" FT VARIANT 493 FT /note="H -> R (in MRD57; reduced kinase activity; FT dbSNP:rs1567974030)" FT /evidence="ECO:0000269|PubMed:29861108, FT ECO:0000269|PubMed:29955062" FT /id="VAR_081028" FT VARIANT 518 FT /note="H -> R (in MRD57; severely reduced kinase activity; FT dbSNP:rs1567995650)" FT /evidence="ECO:0000269|PubMed:29861108, FT ECO:0000269|PubMed:29955062" FT /id="VAR_081029" FT VARIANT 551 FT /note="D -> G (in MRD57; uncertain significance; exhibits FT abnormal perinuclear localization instead of diffuse FT nuclear localization; mildly impairs kinase activity; FT reduced phosphorylation of ASF1A; dbSNP:rs2082811958)" FT /evidence="ECO:0000269|PubMed:33323470" FT /id="VAR_087041" FT VARIANT 568 FT /note="R -> W (in MRD57; dbSNP:rs1283838287)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081030" FT VARIANT 573..772 FT /note="Missing (in MRD57)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081031" FT VARIANT 617 FT /note="S -> L (in MRD57; exhibits abnormal perinuclear FT localization instead of diffuse nuclear localization; FT impairs kinase activity; reduced phosphorylation of ASF1A; FT dbSNP:rs2082914686)" FT /evidence="ECO:0000269|PubMed:21572417, FT ECO:0000269|PubMed:33323470" FT /id="VAR_087042" FT VARIANT 629 FT /note="D -> N (in MRD57; reduced phosphorylation of ASF1A; FT dbSNP:rs1568006217)" FT /evidence="ECO:0000269|PubMed:29861108, FT ECO:0000269|PubMed:29955062" FT /id="VAR_081032" FT VARIANT 680 FT /note="P -> R (in MRD57; dbSNP:rs1568018905)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081033" FT VARIANT 720..772 FT /note="Missing (in MRD57; uncertain significance)" FT /evidence="ECO:0000269|PubMed:27479843, FT ECO:0000269|PubMed:29861108" FT /id="VAR_081034" FT VARIANT 746..772 FT /note="Missing (in MRD57; uncertain significance)" FT /evidence="ECO:0000269|PubMed:29861108" FT /id="VAR_081035" FT MUTAGEN 518 FT /note="H->N: Reduced kinase activity." FT /evidence="ECO:0000269|PubMed:29955062" FT MUTAGEN 592 FT /note="D->V: Loss of kinase activity. No impact on FT interaction with ASF1A." FT /evidence="ECO:0000269|PubMed:33323470, FT ECO:0000269|PubMed:35136069" FT MUTAGEN 613 FT /note="D->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:10523312, FT ECO:0000269|PubMed:11470414, ECO:0000269|PubMed:29955062" FT MUTAGEN 617 FT /note="S->A: Increase in autophosphorylation." FT /evidence="ECO:0000269|PubMed:29955062" FT MUTAGEN 617 FT /note="S->D: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:29955062" FT MUTAGEN 659 FT /note="S->A: Reduced kinase activity." FT /evidence="ECO:0000269|PubMed:29955062" FT MUTAGEN 686 FT /note="S->A: Reduced kinase activity." FT /evidence="ECO:0000269|PubMed:29955062" FT MUTAGEN 686 FT /note="S->D: Reduced kinase activity." FT /evidence="ECO:0000269|PubMed:29955062" FT MUTAGEN 695 FT /note="T->A: Reduced kinase activity." FT /evidence="ECO:0000269|PubMed:29955062" FT MUTAGEN 720 FT /note="R->A: Reduced phosphorylation of ASF1A." FT /evidence="ECO:0000269|PubMed:29955062" FT CONFLICT 1 FT /note="M -> I (in Ref. 1; BAA20561)" FT /evidence="ECO:0000305" FT CONFLICT 161 FT /note="T -> P (in Ref. 1; BAA20561)" FT /evidence="ECO:0000305" FT CONFLICT 207 FT /note="Q -> R (in Ref. 2; AAF03095)" FT /evidence="ECO:0000305" FT CONFLICT 562 FT /note="M -> I (in Ref. 1; BAA20561)" FT /evidence="ECO:0000305" FT CONFLICT 727 FT /note="E -> R (in Ref. 2; AAF03095)" FT /evidence="ECO:0000305" FT HELIX 10..21 FT /evidence="ECO:0007829|PDB:7LO0" FT STRAND 463..470 FT /evidence="ECO:0007829|PDB:5O0Y" FT STRAND 472..481 FT /evidence="ECO:0007829|PDB:5O0Y" FT TURN 482..485 FT /evidence="ECO:0007829|PDB:5O0Y" FT STRAND 486..494 FT /evidence="ECO:0007829|PDB:5O0Y" FT STRAND 497..499 FT /evidence="ECO:0007829|PDB:5O0Y" FT HELIX 502..519 FT /evidence="ECO:0007829|PDB:5O0Y" FT STRAND 529..534 FT /evidence="ECO:0007829|PDB:5O0Y" FT STRAND 539..545 FT /evidence="ECO:0007829|PDB:5O0Y" FT STRAND 549..551 FT /evidence="ECO:0007829|PDB:5O0Y" FT HELIX 552..559 FT /evidence="ECO:0007829|PDB:5O0Y" FT HELIX 564..581 FT /evidence="ECO:0007829|PDB:5O0Y" FT STRAND 584..586 FT /evidence="ECO:0007829|PDB:5O0Y" FT HELIX 595..597 FT /evidence="ECO:0007829|PDB:5O0Y" FT STRAND 598..600 FT /evidence="ECO:0007829|PDB:5O0Y" FT STRAND 603..607 FT /evidence="ECO:0007829|PDB:5O0Y" FT STRAND 609..611 FT /evidence="ECO:0007829|PDB:5O0Y" FT TURN 622..624 FT /evidence="ECO:0007829|PDB:5O0Y" FT TURN 627..629 FT /evidence="ECO:0007829|PDB:5O0Y" FT HELIX 641..643 FT /evidence="ECO:0007829|PDB:5O0Y" FT HELIX 646..649 FT /evidence="ECO:0007829|PDB:5O0Y" FT STRAND 652..654 FT /evidence="ECO:0007829|PDB:5O0Y" FT HELIX 661..676 FT /evidence="ECO:0007829|PDB:5O0Y" FT STRAND 680..682 FT /evidence="ECO:0007829|PDB:5O0Y" FT HELIX 687..693 FT /evidence="ECO:0007829|PDB:5O0Y" FT TURN 694..698 FT /evidence="ECO:0007829|PDB:5O0Y" FT STRAND 706..708 FT /evidence="ECO:0007829|PDB:5O0Y" FT HELIX 712..721 FT /evidence="ECO:0007829|PDB:5O0Y" FT HELIX 726..728 FT /evidence="ECO:0007829|PDB:5O0Y" FT HELIX 732..735 FT /evidence="ECO:0007829|PDB:5O0Y" FT HELIX 739..741 FT /evidence="ECO:0007829|PDB:5O0Y" SQ SEQUENCE 772 AA; 87661 MW; 765EE37ED4A4ADEC CRC64; MMEELHSLDP RRQELLEARF TGVGVSKGPL NSESSNQSLC SVGSLSDKEV ETPEKKQNDQ RNRKRKAEPY ETSQGKGTPR GHKISDYFEF AGGSAPGTSP GRSVPPVARS SPQHSLSNPL PRRVEQPLYG LDGSAAKEAT EEQSALPTLM SVMLAKPRLD TEQLAQRGAG LCFTFVSAQQ NSPSSTGSGN TEHSCSSQKQ ISIQHRQTQS DLTIEKISAL ENSKNSDLEK KEGRIDDLLR ANCDLRRQID EQQKMLEKYK ERLNRCVTMS KKLLIEKSKQ EKMACRDKSM QDRLRLGHFT TVRHGASFTE QWTDGYAFQN LIKQQERINS QREEIERQRK MLAKRKPPAM GQAPPATNEQ KQRKSKTNGA ENETPSSGNT ELKDTAPALG AHSLLRLTLA EYHEQEEIFK LRLGHLKKEE AEIQAELERL ERVRNLHIRE LKRIHNEDNS QFKDHPTLND RYLLLHLLGR GGFSEVYKAF DLTEQRYVAV KIHQLNKNWR DEKKENYHKH ACREYRIHKE LDHPRIVKLY DYFSLDTDSF CTVLEYCEGN DLDFYLKQHK LMSEKEARSI IMQIVNALKY LNEIKPPIIH YDLKPGNILL VNGTACGEIK ITDFGLSKIM DDDSYNSVDG MELTSQGAGT YWYLPPECFV VGKEPPKISN KVDVWSVGVI FYQCLYGRKP FGHNQSQQDI LQENTILKAT EVQFPPKPVV TPEAKAFIRR CLAYRKEDRI DVQQLACDPY LLPHIRKSVS TSSPAGAAIA STSGASNNSS SN // ID TNK1_HUMAN Reviewed; 666 AA. AC Q13470; O95364; Q8IYI4; DT 15-FEB-2005, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 3. DT 28-JAN-2026, entry version 195. DE RecName: Full=Non-receptor tyrosine-protein kinase TNK1; DE EC=2.7.10.2; DE AltName: Full=CD38 negative kinase 1; GN Name=TNK1 {ECO:0000312|EMBL:AAC99412.1}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305, ECO:0000312|EMBL:AAC50427.1} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT MET-598, TISSUE RP SPECIFICITY, AND CHROMOSOMAL LOCATION. RC TISSUE=Umbilical cord blood {ECO:0000312|EMBL:AAC50427.1}; RX PubMed=8632913; RA Hoehn G.T., Stokland T., Amin S., Ramirez M., Hawkins A.L., Griffin C.A., RA Small D., Civin C.I.; RT "Tnk1: a novel intracellular tyrosine kinase gene isolated from human RT umbilical cord blood CD34+/Lin-/CD38- stem/progenitor cells."; RL Oncogene 12:903-913(1996). RN [2] {ECO:0000312|EMBL:AAC99412.1} RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT MET-598. RA Hoehn G.T., Felschow D.M., Civin C.I.; RT "Genomic structure and chromosomal mapping of the human non-receptor RT tyrosine kinase gene, Tnk1."; RL Submitted (OCT-1998) to the EMBL/GenBank/DDBJ databases. RN [3] {ECO:0000305, ECO:0000312|EMBL:AAH35782.1} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Ovary {ECO:0000312|EMBL:AAH35782.1}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] {ECO:0000305} RP FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AUTOPHOSPHORYLATION, RP AND INTERACTION WITH PLCG1. RX PubMed=10873601; DOI=10.1006/bbrc.2000.2887; RA Felschow D.M., Civin C.I., Hoehn G.T.; RT "Characterization of the tyrosine kinase Tnk1 and its binding with RT phospholipase C-gamma1."; RL Biochem. Biophys. Res. Commun. 273:294-301(2000). RN [5] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [6] RP FUNCTION. RX PubMed=18974114; DOI=10.1158/0008-5472.can-08-1467; RA Hoare S., Hoare K., Reinhard M.K., Lee Y.J., Oh S.P., May W.S. Jr.; RT "Tnk1/Kos1 knockout mice develop spontaneous tumors."; RL Cancer Res. 68:8723-8732(2008). RN [7] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-60; SER-255; SER-502; THR-514 RP AND SER-582, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-411 (ISOFORM 2), RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-502 AND SER-519, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-255 AND SER-502, RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-411 (ISOFORM 2), AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-502 AND THR-514, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-502, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-96 AND SER-502, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [14] RP VARIANTS [LARGE SCALE ANALYSIS] ILE-278; LYS-339; LYS-514; CYS-539; CYS-546 RP AND MET-598. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Involved in negative regulation of cell growth. Has tumor CC suppressor properties. Plays a negative regulatory role in the Ras-MAPK CC pathway. May function in signaling pathways utilized broadly during CC fetal development and more selectively in adult tissues and in cells of CC the lymphohematopoietic system. Could specifically be involved in CC phospholipid signal transduction. {ECO:0000269|PubMed:10873601, CC ECO:0000269|PubMed:18974114}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Interacts with the SH3 domain of PLCG1 via its Pro-rich CC domain. {ECO:0000269|PubMed:10873601}. CC -!- INTERACTION: CC Q13470; P31947: SFN; NbExp=3; IntAct=EBI-1383444, EBI-476295; CC Q13470; P62258: YWHAE; NbExp=4; IntAct=EBI-1383444, EBI-356498; CC Q13470-2; Q92567-2: FAM168A; NbExp=3; IntAct=EBI-11018037, EBI-11978259; CC Q13470-2; Q13322-4: GRB10; NbExp=3; IntAct=EBI-11018037, EBI-12353035; CC Q13470-2; Q8IYX7: SAXO1; NbExp=3; IntAct=EBI-11018037, EBI-3957636; CC Q13470-2; O75177-5: SS18L1; NbExp=3; IntAct=EBI-11018037, EBI-12035119; CC Q13470-2; P15622-3: ZNF250; NbExp=3; IntAct=EBI-11018037, EBI-10177272; CC Q13470-2; Q86UD4: ZNF329; NbExp=3; IntAct=EBI-11018037, EBI-7233259; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10873601}. Membrane CC {ECO:0000269|PubMed:10873601}; Peripheral membrane protein CC {ECO:0000269|PubMed:10873601}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1 {ECO:0000269|PubMed:8632913}; CC IsoId=Q13470-1; Sequence=Displayed; CC Name=2 {ECO:0000305}; CC IsoId=Q13470-2; Sequence=VSP_051663; CC -!- TISSUE SPECIFICITY: Expressed in all umbilical cord blood, bone marrow CC and adult blood cell sub-populations and in several leukemia cell CC lines. Highly expressed in fetal blood, brain, lung, liver and kidney. CC Detected at lower levels in adult prostate, testis, ovary, small CC intestine and colon. Not expressed in adult lung, liver, kidney or CC brain. {ECO:0000269|PubMed:10873601, ECO:0000269|PubMed:8632913}. CC -!- PTM: Autophosphorylated on tyrosine residues. CC {ECO:0000269|PubMed:10873601}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U43408; AAC50427.1; -; mRNA. DR EMBL; AF097738; AAC99412.1; -; Genomic_DNA. DR EMBL; BC035782; AAH35782.1; -; mRNA. DR CCDS; CCDS45602.1; -. [Q13470-2] DR CCDS; CCDS58510.1; -. [Q13470-1] DR RefSeq; NP_001238831.1; NM_001251902.3. [Q13470-1] DR RefSeq; NP_003976.2; NM_003985.6. [Q13470-2] DR RefSeq; XP_011522347.1; XM_011524045.3. [Q13470-2] DR RefSeq; XP_054188002.1; XM_054332027.1. [Q13470-2] DR PDB; 7T8J; X-ray; 1.89 A; A=590-666. DR PDB; 7TCY; X-ray; 1.54 A; A/B=589-666. DR PDB; 7TDY; X-ray; 1.53 A; A=590-666. DR PDB; 7U4W; X-ray; 2.10 A; A=590-666. DR PDB; 7U4Z; X-ray; 2.03 A; A=590-666. DR PDB; 9CPL; X-ray; 2.40 A; A=590-666. DR PDB; 9NGE; X-ray; 2.02 A; A/B=590-666. DR PDB; 9O0H; X-ray; 2.24 A; B=590-666. DR PDBsum; 7T8J; -. DR PDBsum; 7TCY; -. DR PDBsum; 7TDY; -. DR PDBsum; 7U4W; -. DR PDBsum; 7U4Z; -. DR PDBsum; 9CPL; -. DR PDBsum; 9NGE; -. DR PDBsum; 9O0H; -. DR AlphaFoldDB; Q13470; -. DR SMR; Q13470; -. DR BioGRID; 114253; 47. DR FunCoup; Q13470; 451. DR IntAct; Q13470; 41. DR MINT; Q13470; -. DR STRING; 9606.ENSP00000459799; -. DR BindingDB; Q13470; -. DR ChEMBL; CHEMBL5334; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q13470; -. DR GuidetoPHARMACOLOGY; 2245; -. DR GlyGen; Q13470; 2 sites. DR iPTMnet; Q13470; -. DR PhosphoSitePlus; Q13470; -. DR BioMuta; TNK1; -. DR DMDM; 116242821; -. DR CPTAC; CPTAC-2878; -. DR jPOST; Q13470; -. DR MassIVE; Q13470; -. DR PaxDb; 9606-ENSP00000459799; -. DR PeptideAtlas; Q13470; -. DR ProteomicsDB; 59467; -. [Q13470-1] DR ProteomicsDB; 59468; -. [Q13470-2] DR Pumba; Q13470; -. DR Antibodypedia; 6049; 361 antibodies from 34 providers. DR DNASU; 8711; -. DR Ensembl; ENST00000570896.5; ENSP00000458834.1; ENSG00000174292.13. [Q13470-2] DR Ensembl; ENST00000576812.5; ENSP00000459799.1; ENSG00000174292.13. [Q13470-1] DR Ensembl; ENST00000639010.1; ENSP00000491712.1; ENSG00000283781.1. [Q13470-2] DR Ensembl; ENST00000639430.1; ENSP00000491136.1; ENSG00000283781.1. [Q13470-1] DR Ensembl; ENST00000688331.1; ENSP00000509611.1; ENSG00000174292.13. [Q13470-2] DR GeneID; 8711; -. DR KEGG; hsa:8711; -. DR MANE-Select; ENST00000688331.1; ENSP00000509611.1; NM_003985.6; NP_003976.2. [Q13470-2] DR UCSC; uc002ggi.5; human. [Q13470-1] DR AGR; HGNC:11940; -. DR ClinPGx; PA36630; -. DR CTD; 8711; -. DR DisGeNET; 8711; -. DR GeneCards; TNK1; -. DR HGNC; HGNC:11940; TNK1. DR HPA; ENSG00000174292; Low tissue specificity. DR MIM; 608076; gene. DR OpenTargets; ENSG00000174292; -. DR VEuPathDB; HostDB:ENSG00000174292; -. DR eggNOG; KOG0199; Eukaryota. DR GeneTree; ENSGT00940000162159; -. DR HOGENOM; CLU_000288_7_39_1; -. DR InParanoid; Q13470; -. DR OMA; IMMNLEH; -. DR OrthoDB; 635774at2759; -. DR PAN-GO; Q13470; 6 GO annotations based on evolutionary models. DR PhylomeDB; Q13470; -. DR PathwayCommons; Q13470; -. DR SignaLink; Q13470; -. DR SIGNOR; Q13470; -. DR Agora; ENSG00000174292; -. DR BioGRID-ORCS; 8711; 13 hits in 1191 CRISPR screens. DR ChiTaRS; TNK1; human. DR GenomeRNAi; 8711; -. DR Pharos; Q13470; Tchem. DR PRO; PR:Q13470; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q13470; protein. DR Bgee; ENSG00000174292; Expressed in mucosa of transverse colon and 97 other cell types or tissues. DR ExpressionAtlas; Q13470; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; TAS:ProtInc. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR CDD; cd09539; SAM_TNK-like; 1. DR CDD; cd14328; UBA_TNK1; 1. DR FunFam; 2.30.30.40:FF:000243; Non-receptor tyrosine-protein kinase TNK1 isoform X1; 1. DR FunFam; 1.10.510.10:FF:000619; non-receptor tyrosine-protein kinase TNK1 isoform X1; 1. DR FunFam; 3.30.200.20:FF:000400; Tyrosine kinase non receptor 1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR055175; ACK/TNK-like_SAM. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR050198; Non-receptor_tyrosine_kinases. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR001452; SH3_domain. DR InterPro; IPR049587; TNK-like_SAM. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR24418; TYROSINE-PROTEIN KINASE; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF22931; SAM_TNK; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00326; SH3; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS50002; SH3; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cytoplasm; Kinase; KW Membrane; Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; SH3 domain; Transferase; Tyrosine-protein kinase. FT CHAIN 1..666 FT /note="Non-receptor tyrosine-protein kinase TNK1" FT /id="PRO_0000088173" FT DOMAIN 116..377 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 380..445 FT /note="SH3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00192" FT REGION 446..493 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 506..579 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 531..541 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 542..552 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 245 FT /note="Proton acceptor" FT /evidence="ECO:0000250|UniProtKB:P12931, FT ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE- FT ProRule:PRU10028" FT BINDING 122..130 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:P12931, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 148 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000250|UniProtKB:P12931, FT ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 60 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 96 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 255 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195" FT MOD_RES 502 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 514 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:20068231" FT MOD_RES 519 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 582 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT VAR_SEQ 411..415 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_051663" FT VARIANT 278 FT /note="V -> I (in dbSNP:rs55939858)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041863" FT VARIANT 339 FT /note="R -> K (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041864" FT VARIANT 514 FT /note="T -> K (in dbSNP:rs55641092)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041865" FT VARIANT 539 FT /note="R -> C (in dbSNP:rs36046975)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041866" FT VARIANT 546 FT /note="S -> C (in dbSNP:rs56093628)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041867" FT VARIANT 598 FT /note="V -> M (in dbSNP:rs6503018)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:8632913, ECO:0000269|Ref.2" FT /id="VAR_041868" FT CONFLICT 36 FT /note="E -> G (in Ref. 1; AAC50427)" FT /evidence="ECO:0000305" FT CONFLICT 65 FT /note="R -> S (in Ref. 1; AAC50427)" FT /evidence="ECO:0000305" FT CONFLICT 94 FT /note="S -> T (in Ref. 1; AAC50427)" FT /evidence="ECO:0000305" FT CONFLICT 118 FT /note="R -> K (in Ref. 2; AAC99412)" FT /evidence="ECO:0000305" FT CONFLICT 252 FT /note="L -> Q (in Ref. 1; AAC50427)" FT /evidence="ECO:0000305" FT CONFLICT 288 FT /note="A -> T (in Ref. 1; AAC50427)" FT /evidence="ECO:0000305" FT CONFLICT 325 FT /note="A -> P (in Ref. 1; AAC50427)" FT /evidence="ECO:0000305" FT CONFLICT 347..348 FT /note="LC -> PS (in Ref. 1; AAC50427)" FT /evidence="ECO:0000305" FT CONFLICT 391 FT /note="V -> A (in Ref. 1; AAC50427)" FT /evidence="ECO:0000305" FT CONFLICT 424 FT /note="G -> D (in Ref. 1; AAC50427)" FT /evidence="ECO:0000305" FT CONFLICT 443 FT /note="A -> T (in Ref. 1; AAC50427)" FT /evidence="ECO:0000305" FT CONFLICT 561 FT /note="K -> E (in Ref. 1; AAC50427)" FT /evidence="ECO:0000305" FT CONFLICT 604 FT /note="G -> W (in Ref. 1; AAC50427)" FT /evidence="ECO:0000305" FT CONFLICT 622 FT /note="V -> A (in Ref. 1; AAC50427)" FT /evidence="ECO:0000305" FT CONFLICT 635 FT /note="H -> L (in Ref. 1; AAC50427)" FT /evidence="ECO:0000305" FT HELIX 590..601 FT /evidence="ECO:0007829|PDB:7TDY" FT HELIX 607..616 FT /evidence="ECO:0007829|PDB:7TDY" FT TURN 617..619 FT /evidence="ECO:0007829|PDB:7TDY" FT HELIX 621..636 FT /evidence="ECO:0007829|PDB:7TDY" FT STRAND 637..639 FT /evidence="ECO:0007829|PDB:7TDY" FT HELIX 641..650 FT /evidence="ECO:0007829|PDB:7TDY" FT TURN 651..653 FT /evidence="ECO:0007829|PDB:7TDY" FT HELIX 655..664 FT /evidence="ECO:0007829|PDB:7TDY" FT MOD_RES Q13470-2:411 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195" SQ SEQUENCE 666 AA; 72468 MW; AA7FBEF6CC778181 CRC64; MLPEAGSLWL LKLLRDIQLA QFYWPILEEL NVTRPEHFDF VKPEDLDGIG MGRPAQRRLS EALKRLRSGP KSKNWVYKIL GGFAPEHKEP TLPSDSPRHL PEPEGGLKCL IPEGAVCRGE LLGSGCFGVV HRGLWTLPSG KSVPVAVKSL RVGPEGPMGT ELGDFLREVS VMMNLEHPHV LRLHGLVLGQ PLQMVMELAP LGSLHARLTA PAPTPPLLVA LLCLFLRQLA GAMAYLGARG LVHRDLATRN LLLASPRTIK VADFGLVRPL GGARGRYVMG GPRPIPYAWC APESLRHGAF SSASDVWMFG VTLWEMFSGG EEPWAGVPPY LILQRLEDRA RLPRPPLCSR ALYSLALRCW APHPADRPSF SHLEGLLQEA GPSEACCVRD VTEPGALRME TGDPITVIEG SSSFHSPDST IWKGQNGRTF KVGSFPASAV TLADAGGLPA TRPVHRGTPA RGDQHPGSID GDRKKANLWD APPARGQRRN MPLERMKGIS RSLESVLSLG PRPTGGGSSP PEIRQARAVP QGPPGLPPRP PLSSSSPQPS QPSRERLPWP KRKPPHNHPM GMPGARKAAA LSGGLLSDPE LQRKIMEVEL SVHGVTHQEC QTALGATGGD VVSAIRNLKV DQLFHLSSRS RADCWRILEH YQWDLSAASR YVLARP // ID TOPRS_HUMAN Reviewed; 1045 AA. AC Q9NS56; O43273; Q6P987; Q9NS55; Q9UNR9; DT 18-APR-2006, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-2000, sequence version 1. DT 28-JAN-2026, entry version 187. DE RecName: Full=E3 ubiquitin-protein ligase Topors; DE EC=2.3.2.27; DE AltName: Full=RING-type E3 ubiquitin transferase Topors {ECO:0000305}; DE AltName: Full=SUMO1-protein E3 ligase Topors; DE AltName: Full=Topoisomerase I-binding RING finger protein; DE AltName: Full=Topoisomerase I-binding arginine/serine-rich protein; DE AltName: Full=Tumor suppressor p53-binding protein 3; DE Short=p53-binding protein 3; DE Short=p53BP3; GN Name=TOPORS; Synonyms=LUN, TP53BPL; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH TOP1, AND RP SUBCELLULAR LOCATION. RX PubMed=10352183; DOI=10.1093/nar/27.12.2538; RA Haluska P. Jr., Saleem A., Rasheed Z., Ahmed F., Su E.W., Liu L.F., RA Rubin E.H.; RT "Interaction between human topoisomerase I and a novel RING RT finger/arginine-serine protein."; RL Nucleic Acids Res. 27:2538-2544(1999). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), PUTATIVE DNA-BINDING, RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RC TISSUE=Lung; RX PubMed=11278651; DOI=10.1074/jbc.m010262200; RA Chu D., Kakazu N., Gorrin-Rivas M.J., Lu H.P., Kawata M., Abe T., Ueda K., RA Adachi Y.; RT "Cloning and characterization of LUN, a novel RING-finger protein that is RT highly expressed in lung and specifically binds to a palindromic RT sequence."; RL J. Biol. Chem. 276:14004-14013(2001). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164053; DOI=10.1038/nature02465; RA Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L., RA Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R., RA Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S., RA Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., RA Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., RA Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E., RA Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M., RA Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J., RA Frankish A., Frankland J.A., French L., Fricker D.G., Garner P., RA Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S., RA Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E., RA Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D., RA Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E., RA Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K., RA Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S., RA Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J., RA Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E., RA McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V., RA Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S., RA Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K., RA Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J., RA Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., RA West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L., RA Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M., RA Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J., RA Dunham I.; RT "DNA sequence and analysis of human chromosome 9."; RL Nature 429:369-374(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS THR-154; RP LYS-517 AND ASP-749. RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 51-1045 (ISOFORM 1), INTERACTION WITH TP53, RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=10415337; DOI=10.1016/s0378-1119(99)00203-6; RA Zhou R., Wen H., Ao S.-Z.; RT "Identification of a novel gene encoding a p53-associated protein."; RL Gene 235:93-101(1999). RN [6] RP SUBCELLULAR LOCATION. RX PubMed=12083797; DOI=10.1006/excr.2002.5550; RA Rasheed Z.A., Saleem A., Ravee Y., Pandolfi P.P., Rubin E.H.; RT "The topoisomerase I-binding RING protein, topors, is associated with RT promyelocytic leukemia nuclear bodies."; RL Exp. Cell Res. 277:152-160(2002). RN [7] RP INTERACTION WITH SUMO1 AND UBE2I, SUBCELLULAR LOCATION, SUMOYLATION, AND RP MUTAGENESIS OF LYS-76; LYS-301; LYS-485; LYS-560 AND LYS-921. RX PubMed=14516784; DOI=10.1016/s0014-4827(03)00292-1; RA Weger S., Hammer E., Engstler M.; RT "The DNA topoisomerase I binding protein topors as a novel cellular target RT for SUMO-1 modification: characterization of domains necessary for RT subcellular localization and sumolation."; RL Exp. Cell Res. 290:13-27(2003). RN [8] RP FUNCTION, AND MUTAGENESIS OF TRP-131. RX PubMed=15247280; DOI=10.1074/jbc.c400300200; RA Rajendra R., Malegaonkar D., Pungaliya P., Marshall H., Rasheed Z., RA Brownell J., Liu L.F., Lutzker S., Saleem A., Rubin E.H.; RT "Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and RT ubiquitinates p53."; RL J. Biol. Chem. 279:36440-36444(2004). RN [9] RP REDUCED EXPRESSION IN LUNG CANCERS. RX PubMed=15364129; DOI=10.1016/j.lungcan.2004.03.009; RA Oyanagi H., Takenaka K., Ishikawa S., Kawano Y., Adachi Y., Ueda K., RA Wada H., Tanaka F.; RT "Expression of LUN gene that encodes a novel RING finger protein is RT correlated with development and progression of non-small cell lung RT cancer."; RL Lung Cancer 46:21-28(2004). RN [10] RP TISSUE SPECIFICITY, AND REDUCED EXPRESSION IN COLON CANCERS. RX PubMed=15107820; DOI=10.1038/sj.onc.1207700; RA Saleem A., Dutta J., Malegaonkar D., Rasheed F., Rasheed Z., Rajendra R., RA Marshall H., Luo M., Li H., Rubin E.H.; RT "The topoisomerase I- and p53-binding protein topors is differentially RT expressed in normal and malignant human tissues and may function as a tumor RT suppressor."; RL Oncogene 23:5293-5300(2004). RN [11] RP FUNCTION, AND SUMOYLATION. RX PubMed=16122737; DOI=10.1016/j.febslet.2005.07.088; RA Weger S., Hammer E., Heilbronn R.; RT "Topors acts as a SUMO-1 E3 ligase for p53 in vitro and in vivo."; RL FEBS Lett. 579:5007-5012(2005). RN [12] RP FUNCTION, AND INDUCTION. RX PubMed=15735665; DOI=10.1038/sj.onc.1208554; RA Lin L., Ozaki T., Takada Y., Kageyama H., Nakamura Y., Hata A., Zhang J.H., RA Simonds W.F., Nakagawara A., Koseki H.; RT "Topors, a p53 and topoisomerase I-binding RING finger protein, is a RT coactivator of p53 in growth suppression induced by DNA damage."; RL Oncogene 24:3385-3396(2005). RN [13] RP INVOLVEMENT IN RP31. RX PubMed=17924349; DOI=10.1086/521953; RA Chakarova C.F., Papaioannou M.G., Khanna H., Lopez I., Waseem N., Shah A., RA Theis T., Friedman J., Maubaret C., Bujakowska K., Veraitch B., RA El-Aziz M.M.A., Prescott de Q., Parapuram S.K., Bickmore W.A., RA Munro P.M.G., Gal A., Hamel C.P., Marigo V., Ponting C.P., Wissinger B., RA Zrenner E., Matter K., Swaroop A., Koenekoop R.K., Bhattacharya S.S.; RT "Mutations in TOPORS cause autosomal dominant retinitis pigmentosa with RT perivascular retinal pigment epithelium atrophy."; RL Am. J. Hum. Genet. 81:1098-1103(2007). RN [14] RP FUNCTION, AND INTERACTION WITH SIN3A. RX PubMed=17803295; DOI=10.1021/pr0703674; RA Pungaliya P., Kulkarni D., Park H.J., Marshall H., Zheng H., Lackland H., RA Saleem A., Rubin E.H.; RT "TOPORS functions as a SUMO-1 E3 ligase for chromatin-modifying proteins."; RL J. Proteome Res. 6:3918-3923(2007). RN [15] RP PHOSPHORYLATION AT SER-98; SER-499; SER-585 AND SER-866, MUTAGENESIS OF RP SER-98, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=19053840; DOI=10.1021/bi801904q; RA Park H.J., Zheng H., Kulkarni D., Kerrigan J., Pungaliya P., Saleem A., RA Rubin E.H.; RT "Identification of phosphorylation sites of TOPORS and a role for serine 98 RT in the regulation of ubiquitin but not SUMO E3 ligase activity."; RL Biochemistry 47:13887-13896(2008). RN [16] RP FUNCTION, INTERACTION WITH NKX3-1, AND SUBCELLULAR LOCATION. RX PubMed=18077445; DOI=10.1074/jbc.m708630200; RA Guan B., Pungaliya P., Li X., Uquillas C., Mutton L.N., Rubin E.H., RA Bieberich C.J.; RT "Ubiquitination by TOPORS regulates the prostate tumor suppressor NKX3.1."; RL J. Biol. Chem. 283:4834-4840(2008). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [18] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [19] RP FUNCTION, INTERACTION WITH PLK1, PHOSPHORYLATION AT SER-718 BY PLK1, RP MUTAGENESIS OF SER-718, AND SUBCELLULAR LOCATION. RX PubMed=19473992; DOI=10.1074/jbc.c109.001560; RA Yang X., Li H., Zhou Z., Wang W.H., Deng A., Andrisani O., Liu X.; RT "Plk1-mediated phosphorylation of Topors regulates p53 stability."; RL J. Biol. Chem. 284:18588-18592(2009). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98; SER-864 AND SER-866, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [21] RP FUNCTION, INTERACTION WITH IKBKE, AND SUBCELLULAR LOCATION. RX PubMed=20188669; DOI=10.1016/j.molcel.2010.01.018; RA Renner F., Moreno R., Schmitz M.L.; RT "SUMOylation-dependent localization of IKKepsilon in PML nuclear bodies is RT essential for protection against DNA-damage-triggered cell death."; RL Mol. Cell 37:503-515(2010). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98; SER-864 AND SER-866, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98; SER-194; SER-585 AND RP SER-734, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [26] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-76; LYS-83; LYS-249 AND LYS-701, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25218447; DOI=10.1038/nsmb.2890; RA Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M., RA Vertegaal A.C.; RT "Uncovering global SUMOylation signaling networks in a site-specific RT manner."; RL Nat. Struct. Mol. Biol. 21:927-936(2014). RN [27] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-76 AND LYS-701, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033; RA Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V., RA Vertegaal A.C.; RT "SUMO-2 orchestrates chromatin modifiers in response to DNA damage."; RL Cell Rep. 10:1778-1791(2015). RN [28] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-76 AND LYS-701, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25755297; DOI=10.1074/mcp.o114.044792; RA Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V., RA Vertegaal A.C.; RT "System-wide analysis of SUMOylation dynamics in response to replication RT stress reveals novel small ubiquitin-like modified target proteins and RT acceptor lysines relevant for genome stability."; RL Mol. Cell. Proteomics 14:1419-1434(2015). RN [29] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-73; LYS-76; LYS-83; LYS-88; RP LYS-159; LYS-249; LYS-701; LYS-819 AND LYS-837, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). CC -!- FUNCTION: Functions as an E3 ubiquitin-protein ligase and as an E3 CC SUMO1-protein ligase. Probable tumor suppressor involved in cell CC growth, cell proliferation and apoptosis that regulates p53/TP53 CC stability through ubiquitin-dependent degradation. May regulate CC chromatin modification through sumoylation of several chromatin CC modification-associated proteins. May be involved in DNA damage-induced CC cell death through IKBKE sumoylation. {ECO:0000269|PubMed:15247280, CC ECO:0000269|PubMed:15735665, ECO:0000269|PubMed:16122737, CC ECO:0000269|PubMed:17803295, ECO:0000269|PubMed:18077445, CC ECO:0000269|PubMed:19473992, ECO:0000269|PubMed:20188669}. CC -!- CATALYTIC ACTIVITY: CC Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine + CC [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L- CC cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.; CC EC=2.3.2.27; CC -!- SUBUNIT: Interacts with PARK7/DJ-1 (By similarity). Interacts with CC TOP1. Interacts with p53/TP53; can both ubiquitinate and sumoylate CC p53/TP53. Interacts with the SUMO1 conjugating enzyme UBE2I. Interacts CC with SUMO1. Interacts with NKX3-1; polyubiquitinates NKX3-1 and induces CC its proteasomal degradation. Interacts with SIN3A; sumoylates SIN3A. CC Interacts with IKBKE; induced by DNA damage. CC {ECO:0000250|UniProtKB:Q80Z37, ECO:0000269|PubMed:10352183, CC ECO:0000269|PubMed:10415337, ECO:0000269|PubMed:14516784, CC ECO:0000269|PubMed:17803295, ECO:0000269|PubMed:18077445, CC ECO:0000269|PubMed:19473992, ECO:0000269|PubMed:20188669}. CC -!- INTERACTION: CC Q9NS56; P03132: Rep68; Xeno; NbExp=3; IntAct=EBI-1996473, EBI-7387242; CC -!- SUBCELLULAR LOCATION: Nucleus. Nucleus, PML body. Note=Localizes to CC discrete nuclear foci which partly overlap with PML nuclear bodies. CC Targeted to PML nuclear bodies upon DNA damage. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=LUN-1; CC IsoId=Q9NS56-1; Sequence=Displayed; CC Name=2; Synonyms=LUN-2; CC IsoId=Q9NS56-2; Sequence=VSP_017916, VSP_017917; CC -!- TISSUE SPECIFICITY: Expressed at highest levels in testis and at lower CC levels in adrenal gland, bone marrow, brain, colon, heart, kidney, CC liver, muscle, ovary, pancreas, placenta, prostate, skeletal muscle, CC skin, small intestine, spleen, stomach, testis, thymus, thyroid and CC uterus. Expressed in the alveolar epithelium of the lung. Expression is CC commonly decreased in colon adenocarcinomas and lung cancers. CC {ECO:0000269|PubMed:10415337, ECO:0000269|PubMed:11278651, CC ECO:0000269|PubMed:15107820}. CC -!- INDUCTION: By genotoxic agents such as cisplatin and camptothecin. CC {ECO:0000269|PubMed:15735665}. CC -!- PTM: Phosphorylation at Ser-98 regulates the E3 ubiquitin-protein CC ligase activity but not the SUMO1-protein ligase activity. CC Phosphorylation at Ser-718 increases the E3 ubiquitin-protein ligase CC activity versus the SUMO1-protein ligase activity resulting in CC increased p53/TP53 ubiquitination and degradation. CC {ECO:0000269|PubMed:19053840, ECO:0000269|PubMed:19473992}. CC -!- PTM: Sumoylated. {ECO:0000269|PubMed:14516784, CC ECO:0000269|PubMed:16122737}. CC -!- DISEASE: Retinitis pigmentosa 31 (RP31) [MIM:609923]: A retinal CC dystrophy belonging to the group of pigmentary retinopathies. Retinitis CC pigmentosa is characterized by retinal pigment deposits visible on CC fundus examination and primary loss of rod photoreceptor cells followed CC by secondary loss of cone photoreceptors. Patients typically have night CC vision blindness and loss of midperipheral visual field. As their CC condition progresses, they lose their far peripheral visual field and CC eventually central vision as well. {ECO:0000269|PubMed:17924349}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- CAUTION: Was originally thought to bind to the palindromic consensus CC sequence 5'-TCCCAGCACTTTGGGA-3' and to regulate the transcription of CC numerous genes in the lung. {ECO:0000305|PubMed:11278651}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC98530.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/42663/TOPORS"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF098300; AAD23379.1; -; mRNA. DR EMBL; AB045732; BAB03714.1; -; mRNA. DR EMBL; AB045733; BAB03715.1; -; mRNA. DR EMBL; AL353671; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC060884; AAH60884.1; -; mRNA. DR EMBL; U82939; AAC98530.1; ALT_INIT; mRNA. DR CCDS; CCDS56566.1; -. [Q9NS56-2] DR CCDS; CCDS6527.1; -. [Q9NS56-1] DR RefSeq; NP_001182551.1; NM_001195622.2. [Q9NS56-2] DR RefSeq; NP_005793.2; NM_005802.4. [Q9NS56-1] DR AlphaFoldDB; Q9NS56; -. DR SMR; Q9NS56; -. DR BioGRID; 115505; 99. DR FunCoup; Q9NS56; 1905. DR IntAct; Q9NS56; 49. DR MINT; Q9NS56; -. DR STRING; 9606.ENSP00000353735; -. DR GlyGen; Q9NS56; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q9NS56; -. DR PhosphoSitePlus; Q9NS56; -. DR BioMuta; TOPORS; -. DR DMDM; 74752935; -. DR jPOST; Q9NS56; -. DR MassIVE; Q9NS56; -. DR PaxDb; 9606-ENSP00000353735; -. DR PeptideAtlas; Q9NS56; -. DR ProteomicsDB; 82481; -. [Q9NS56-1] DR ProteomicsDB; 82482; -. [Q9NS56-2] DR Pumba; Q9NS56; -. DR Antibodypedia; 25068; 220 antibodies from 25 providers. DR DNASU; 10210; -. DR Ensembl; ENST00000360538.7; ENSP00000353735.2; ENSG00000197579.9. [Q9NS56-1] DR Ensembl; ENST00000379858.1; ENSP00000369187.1; ENSG00000197579.9. [Q9NS56-2] DR GeneID; 10210; -. DR KEGG; hsa:10210; -. DR MANE-Select; ENST00000360538.7; ENSP00000353735.2; NM_005802.5; NP_005793.2. DR UCSC; uc003zrb.4; human. [Q9NS56-1] DR AGR; HGNC:21653; -. DR ClinPGx; PA134979531; -. DR CTD; 10210; -. DR DisGeNET; 10210; -. DR GeneCards; TOPORS; -. DR GeneReviews; TOPORS; -. DR HGNC; HGNC:21653; TOPORS. DR HPA; ENSG00000197579; Low tissue specificity. DR MalaCards; TOPORS; -. DR MIM; 609507; gene. DR MIM; 609923; phenotype. DR OpenTargets; ENSG00000197579; -. DR Orphanet; 2754; Orofaciodigital syndrome type 6. DR Orphanet; 791; Retinitis pigmentosa. DR VEuPathDB; HostDB:ENSG00000197579; -. DR eggNOG; KOG4430; Eukaryota. DR GeneTree; ENSGT00530000064170; -. DR HOGENOM; CLU_012046_0_0_1; -. DR InParanoid; Q9NS56; -. DR OMA; DCVIVGF; -. DR OrthoDB; 21204at2759; -. DR PAN-GO; Q9NS56; 7 GO annotations based on evolutionary models. DR PhylomeDB; Q9NS56; -. DR PathwayCommons; Q9NS56; -. DR Reactome; R-HSA-3899300; SUMOylation of transcription cofactors. DR Reactome; R-HSA-4085377; SUMOylation of SUMOylation proteins. DR Reactome; R-HSA-4755510; SUMOylation of immune response proteins. DR SignaLink; Q9NS56; -. DR SIGNOR; Q9NS56; -. DR Agora; ENSG00000197579; -. DR BioGRID-ORCS; 10210; 13 hits in 1201 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; B5B9A610; PML body. DR ChiTaRS; TOPORS; human. DR GeneWiki; TOPORS; -. DR GenomeRNAi; 10210; -. DR Pharos; Q9NS56; Tbio. DR PRO; PR:Q9NS56; -. DR Proteomes; UP000005640; Chromosome 9. DR RNAct; Q9NS56; protein. DR Bgee; ENSG00000197579; Expressed in secondary oocyte and 207 other cell types or tissues. DR GO; GO:0005814; C:centriole; IDA:BHF-UCL. DR GO; GO:0036064; C:ciliary basal body; IDA:BHF-UCL. DR GO; GO:0000930; C:gamma-tubulin complex; IDA:BHF-UCL. DR GO; GO:0030496; C:midbody; TAS:BHF-UCL. DR GO; GO:0016607; C:nuclear speck; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0032391; C:photoreceptor connecting cilium; IDA:BHF-UCL. DR GO; GO:0016605; C:PML body; IDA:UniProtKB. DR GO; GO:0000922; C:spindle pole; IDA:BHF-UCL. DR GO; GO:0000151; C:ubiquitin ligase complex; IDA:BHF-UCL. DR GO; GO:0003823; F:antigen binding; IPI:UniProtKB. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0044547; F:DNA topoisomerase binding; IPI:UniProtKB. DR GO; GO:0019789; F:SUMO transferase activity; IDA:UniProtKB. DR GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:BHF-UCL. DR GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0006351; P:DNA-templated transcription; NAS:UniProtKB. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IDA:UniProtKB. DR GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IEA:Ensembl. DR GO; GO:0051457; P:maintenance of protein location in nucleus; IDA:UniProtKB. DR GO; GO:0043066; P:negative regulation of apoptotic process; ISS:BHF-UCL. DR GO; GO:0035845; P:photoreceptor cell outer segment organization; ISS:BHF-UCL. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IEA:Ensembl. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IMP:UniProtKB. DR GO; GO:0070936; P:protein K48-linked ubiquitination; IDA:BHF-UCL. DR GO; GO:0034504; P:protein localization to nucleus; IMP:UniProtKB. DR GO; GO:0006513; P:protein monoubiquitination; IDA:BHF-UCL. DR GO; GO:0000209; P:protein polyubiquitination; IDA:BHF-UCL. DR GO; GO:0016925; P:protein sumoylation; IDA:UniProtKB. DR GO; GO:0042127; P:regulation of cell population proliferation; IEA:Ensembl. DR GO; GO:0010842; P:retina layer formation; ISS:BHF-UCL. DR GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IMP:UniProtKB. DR CDD; cd16574; RING-HC_Topors; 1. DR FunFam; 3.30.40.10:FF:000136; E3 ubiquitin-protein ligase Topors; 1. DR Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1. DR InterPro; IPR058745; PWI_Topors. DR InterPro; IPR018957; Znf_C3HC4_RING-type. DR InterPro; IPR001841; Znf_RING. DR InterPro; IPR058746; Znf_RING-type_Topors. DR InterPro; IPR013083; Znf_RING/FYVE/PHD. DR InterPro; IPR017907; Znf_RING_CS. DR PANTHER; PTHR46077; E3 UBIQUITIN-PROTEIN LIGASE TOPORS; 1. DR PANTHER; PTHR46077:SF2; E3 UBIQUITIN-PROTEIN LIGASE TOPORS; 1. DR Pfam; PF26084; PWI_Topors; 1. DR Pfam; PF00097; zf-C3HC4; 1. DR SMART; SM00184; RING; 1. DR SUPFAM; SSF57850; RING/U-box; 1. DR PROSITE; PS00518; ZF_RING_1; 1. DR PROSITE; PS50089; ZF_RING_2; 1. PE 1: Evidence at protein level; KW Alternative splicing; DNA damage; Isopeptide bond; Metal-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Retinitis pigmentosa; Transferase; Ubl conjugation; KW Ubl conjugation pathway; Zinc; Zinc-finger. FT CHAIN 1..1045 FT /note="E3 ubiquitin-protein ligase Topors" FT /id="PRO_0000232626" FT ZN_FING 103..142 FT /note="RING-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00175" FT REGION 1..195 FT /note="E3 ubiquitin-protein ligase activity" FT REGION 1..35 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 51..374 FT /note="Required for DNA-binding" FT REGION 437..654 FT /note="Interaction with SUMO1" FT /evidence="ECO:0000269|PubMed:14516784" FT REGION 437..574 FT /note="Required for sumoylation and localization to FT discrete nuclear foci" FT REGION 442..475 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 456..882 FT /note="Interaction with TOP1" FT /evidence="ECO:0000269|PubMed:10352183" FT REGION 456..731 FT /note="Interaction with p53/TP53" FT /evidence="ECO:0000269|PubMed:10415337" FT REGION 511..692 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 713..936 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 854..917 FT /note="Interaction with UBE2I" FT /evidence="ECO:0000269|PubMed:14516784" FT COMPBIAS 453..463 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 521..534 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 539..565 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 566..578 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 588..597 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 613..630 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 637..647 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 654..669 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 721..730 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 731..747 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 755..766 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 816..825 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 854..863 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 880..897 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 913..923 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 98 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:19053840, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 194 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 499 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:19053840" FT MOD_RES 585 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:19053840, FT ECO:0007744|PubMed:23186163" FT MOD_RES 718 FT /note="Phosphoserine; by PLK1" FT /evidence="ECO:0000269|PubMed:19473992" FT MOD_RES 734 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 864 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:21406692" FT MOD_RES 866 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:19053840, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692" FT MOD_RES 912 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80Z37" FT MOD_RES 914 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80Z37" FT MOD_RES 1028 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80Z37" FT CROSSLNK 73 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 76 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:25772364, FT ECO:0007744|PubMed:28112733" FT CROSSLNK 83 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:28112733" FT CROSSLNK 88 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 159 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 249 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:28112733" FT CROSSLNK 560 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO)" FT CROSSLNK 701 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:25772364, FT ECO:0007744|PubMed:28112733" FT CROSSLNK 819 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 837 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 1..65 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:11278651" FT /id="VSP_017916" FT VAR_SEQ 66 FT /note="E -> M (in isoform 2)" FT /evidence="ECO:0000303|PubMed:11278651" FT /id="VSP_017917" FT VARIANT 154 FT /note="A -> T (in dbSNP:rs17855104)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_037629" FT VARIANT 517 FT /note="E -> K (in dbSNP:rs17855103)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_037630" FT VARIANT 749 FT /note="N -> D (in dbSNP:rs17857515)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_037631" FT VARIANT 812 FT /note="P -> R (in dbSNP:rs36034138)" FT /id="VAR_037632" FT MUTAGEN 76 FT /note="K->R: No effect on sumoylation." FT /evidence="ECO:0000269|PubMed:14516784" FT MUTAGEN 98 FT /note="S->A: Loss of phosphorylation but no effect on E3 FT ubiquitin-protein ligase activity." FT /evidence="ECO:0000269|PubMed:19053840" FT MUTAGEN 98 FT /note="S->D: Increase in E3 ubiquitin-protein ligase FT activity and increased binding to UBE2D1. No effect on FT SUMO1-protein ligase activity." FT /evidence="ECO:0000269|PubMed:19053840" FT MUTAGEN 131 FT /note="W->A: Abrogates E3 ubiquitin-protein ligase FT activity." FT /evidence="ECO:0000269|PubMed:15247280" FT MUTAGEN 301 FT /note="K->R: No effect on sumoylation." FT /evidence="ECO:0000269|PubMed:14516784" FT MUTAGEN 485 FT /note="K->R: No effect on sumoylation." FT /evidence="ECO:0000269|PubMed:14516784" FT MUTAGEN 560 FT /note="K->R: Strongly reduces sumoylation." FT /evidence="ECO:0000269|PubMed:14516784" FT MUTAGEN 718 FT /note="S->A: Loss of phosphorylation by PLK1 and increases FT in p53/TP53 stability." FT /evidence="ECO:0000269|PubMed:19473992" FT MUTAGEN 921 FT /note="K->R: No effect on sumoylation." FT /evidence="ECO:0000269|PubMed:14516784" FT CONFLICT 124..125 FT /note="CF -> K (in Ref. 5; AAC98530)" FT /evidence="ECO:0000305" FT CONFLICT 257 FT /note="N -> S (in Ref. 1; AAD23379)" FT /evidence="ECO:0000305" FT CONFLICT 308 FT /note="F -> S (in Ref. 1; AAD23379)" FT /evidence="ECO:0000305" FT CONFLICT 922 FT /note="E -> G (in Ref. 1; AAD23379)" FT /evidence="ECO:0000305" FT CONFLICT 1040 FT /note="R -> K (in Ref. 1; AAD23379)" FT /evidence="ECO:0000305" SQ SEQUENCE 1045 AA; 119198 MW; 3DA635FDB5C83B77 CRC64; MGSQPPLGSP LSREEGEAPP PAPASEGRRR SRRVRLRGSC RHRPSFLGCR ELAASAPARP APASSEIMAS AAKEFKMDNF SPKAGTSKLQ QTVPADASPD SKCPICLDRF DNVSYLDRCL HKFCFRCVQE WSKNKAECPL CKQPFDSIFH SVRAEDDFKE YVLRPSYNGS FVTPDRRFRY RTTLTRERNA SVYSPSGPVN RRTTTPPDSG VLFEGLGIST RPRDVEIPQF MRQIAVRRPT TADERSLRKI QEQDIINFRR TLYRAGARVR NIEDGGRYRD ISAEFFRRNP ACLHRLVPWL KRELTVLFGA HGSLVNIVQH IIMSNVTRYD LESQAFVSDL RPFLLNRTEH FIHEFISFAR SPFNMAAFDQ HANYDCPAPS YEEGSHSDSS VITISPDEAE TQELDINVAT VSQAPWDDET PGPSYSSSEQ VHVTMSSLLN TSDSSDEELV TGGATSQIQG VQTNDDLNND SDDSSDNCVI VGFVKPLAER TPELVELSSD SEDLGSYEKM ETVKTQEQEQ SYSSGDSDVS RCSSPHSVLG KDEQINKGHC DSSTRIKSKK EEKRSTSLSS PRNLNSSVRG DRVYSPYNHR HRKRGRSRSS DSRSQSRSGH DQKNHRKHHG KKRMKSKRSR SRESSRPRGR RDKKRSRTRD SSWSRRSQTL SLSSESTSRS RSRSSDHGKR RSRSRNRDRY YLRNNYGSRY KWEYTYYSRN KDRDGYESSY RRRTLSRAHY SRQSSSPEFR VQSFSERTNA RKKNNHSERK YYYYERHRSR SLSSNRSRTA STGTDRVRNE KPGGKRKYKT RHLEGTNEVA QPSREFASKA KDSHYQKSSS KLDGNYKNES DTFSDSRSSD RETKHKRRKR KTRSLSVEIV YEGKATDTTK HHKKKKKKHK KKHKKHHGDN ASRSPVVITI DSDSDKDSEV KEDTECDNSG PQDPLQNEFL APSLEPFETK DVVTIEAEFG VLDKECDIAT LSNNLNNANK TVDNIPPLAA SVEQTLDVRE ESTFVSDLEN QPSNIVSLQT EPSRQLPSPR TSLMSVCLGR DCDMS // ID TRI33_HUMAN Reviewed; 1127 AA. AC Q9UPN9; O95855; Q5TG72; Q5TG73; Q5TG74; Q9C017; Q9UJ79; DT 24-JAN-2001, integrated into UniProtKB/Swiss-Prot. DT 30-NOV-2010, sequence version 3. DT 28-JAN-2026, entry version 224. DE RecName: Full=E3 ubiquitin-protein ligase TRIM33; DE EC=2.3.2.27; DE AltName: Full=Ectodermin homolog; DE AltName: Full=RET-fused gene 7 protein; DE Short=Protein Rfg7; DE AltName: Full=RING-type E3 ubiquitin transferase TRIM33 {ECO:0000305}; DE AltName: Full=Transcription intermediary factor 1-gamma; DE Short=TIF1-gamma; DE AltName: Full=Tripartite motif-containing protein 33; GN Name=TRIM33; Synonyms=KIAA1113, RFG7, TIF1G; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA), FUNCTION, SUBUNIT, AND VARIANT RP THR-840. RX PubMed=10022127; DOI=10.1038/sj.onc.1202655; RA Venturini L., You J., Stadler M., Galien R., Lallemand V., Koken M.H.M., RA Mattei M.-G., Ganser A., Chambon P., Losson R., De The H.; RT "TIF1gamma, a novel member of the transcriptional intermediary factor 1 RT family."; RL Oncogene 18:1209-1217(1999). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA AND BETA), AND VARIANT THR-840. RX PubMed=11331580; DOI=10.1093/emboj/20.9.2140; RA Reymond A., Meroni G., Fantozzi A., Merla G., Cairo S., Luzi L., RA Riganelli D., Zanaria E., Messali S., Cainarca S., Guffanti A., Minucci S., RA Pelicci P.G., Ballabio A.; RT "The tripartite motif family identifies cell compartments."; RL EMBO J. 20:2140-2151(2001). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA), AND VARIANT RP THR-840. RC TISSUE=Brain; RX PubMed=10470851; DOI=10.1093/dnares/6.3.197; RA Kikuno R., Nagase T., Ishikawa K., Hirosawa M., Miyajima N., Tanaka A., RA Kotani H., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XIV. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 6:197-205(1999). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 76-1127 (ISOFORMS ALPHA AND BETA), RP CHROMOSOMAL TRANSLOCATION WITH RET, AND VARIANT THR-840. RC TISSUE=Thyroid; RX PubMed=10439047; DOI=10.1038/sj.onc.1202824; RA Klugbauer S., Rabes H.M.; RT "The transcription coactivator HTIF1 and a related protein are fused to the RT RET receptor tyrosine kinase in childhood papillary thyroid carcinomas."; RL Oncogene 18:4388-4393(1999). RN [6] RP SUBUNIT. RX PubMed=12096914; DOI=10.1016/s0022-2836(02)00477-1; RA Peng H., Feldman I., Rauscher F.J. III; RT "Hetero-oligomerization among the TIF family of RBCC/TRIM domain-containing RT nuclear cofactors: a potential mechanism for regulating the switch between RT coactivation and corepression."; RL J. Mol. Biol. 320:629-644(2002). RN [7] RP FUNCTION AS AN E3 UBIQUITIN-PROTEIN LIGASE, UBIQUITINATION OF SMAD4, RP INTERACTION WITH SMAD4, MUTAGENESIS OF CYS-125 AND CYS-128, AND SUBCELLULAR RP LOCATION. RX PubMed=15820681; DOI=10.1016/j.cell.2005.01.033; RA Dupont S., Zacchigna L., Cordenonsi M., Soligo S., Adorno M., Rugge M., RA Piccolo S.; RT "Germ-layer specification and control of cell growth by Ectodermin, a Smad4 RT ubiquitin ligase."; RL Cell 121:87-99(2005). RN [8] RP FUNCTION, IDENTIFICATION IN A COMPLEX WITH SMAD2 AND SMAD3, INTERACTION RP WITH SMAD2 AND SMAD3, AND SUBCELLULAR LOCATION. RX PubMed=16751102; DOI=10.1016/j.cell.2006.03.045; RA He W., Dorn D.C., Erdjument-Bromage H., Tempst P., Moore M.A., Massague J.; RT "Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the RT TGFbeta pathway."; RL Cell 125:929-941(2006). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-862; THR-1102 AND SER-1105, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [10] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH SMAD2 AND SMAD4. RX PubMed=19135894; DOI=10.1016/j.cell.2008.10.051; RA Dupont S., Mamidi A., Cordenonsi M., Montagner M., Zacchigna L., Adorno M., RA Martello G., Stinchfield M.J., Soligo S., Morsut L., Inui M., Moro S., RA Modena N., Argenton F., Newfeld S.J., Piccolo S.; RT "FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, RT controls Smad4 monoubiquitination."; RL Cell 136:123-135(2009). RN [11] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-763; LYS-769 AND LYS-953, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-862; THR-1102 AND SER-1105, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-862; THR-1102 AND SER-1105, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-862; THR-1051 AND SER-1119, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [16] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [17] RP METHYLATION [LARGE SCALE ANALYSIS] AT ARG-515; ARG-535; ARG-577; ARG-591; RP ARG-598 AND ARG-604, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Colon carcinoma; RX PubMed=24129315; DOI=10.1074/mcp.o113.027870; RA Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M., RA Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V., RA Bedford M.T., Comb M.J.; RT "Immunoaffinity enrichment and mass spectrometry analysis of protein RT methylation."; RL Mol. Cell. Proteomics 13:372-387(2014). RN [18] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-334; LYS-763; LYS-769; LYS-776; RP LYS-793; LYS-953; LYS-1007 AND LYS-1057, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25218447; DOI=10.1038/nsmb.2890; RA Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M., RA Vertegaal A.C.; RT "Uncovering global SUMOylation signaling networks in a site-specific RT manner."; RL Nat. Struct. Mol. Biol. 21:927-936(2014). RN [19] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-776 AND LYS-793, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25114211; DOI=10.1073/pnas.1413825111; RA Impens F., Radoshevich L., Cossart P., Ribet D.; RT "Mapping of SUMO sites and analysis of SUMOylation changes induced by RT external stimuli."; RL Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014). RN [20] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-763; LYS-769; LYS-776; LYS-793; RP LYS-861; LYS-1057 AND LYS-1118, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033; RA Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V., RA Vertegaal A.C.; RT "SUMO-2 orchestrates chromatin modifiers in response to DNA damage."; RL Cell Rep. 10:1778-1791(2015). RN [21] RP SUBCELLULAR LOCATION. RX PubMed=25593309; DOI=10.1101/gad.252189.114; RA Gong F., Chiu L.Y., Cox B., Aymard F., Clouaire T., Leung J.W., RA Cammarata M., Perez M., Agarwal P., Brodbelt J.S., Legube G., Miller K.M.; RT "Screen identifies bromodomain protein ZMYND8 in chromatin recognition of RT transcription-associated DNA damage that promotes homologous RT recombination."; RL Genes Dev. 29:197-211(2015). RN [22] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-763; LYS-769; LYS-776; LYS-793 RP AND LYS-1057, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RX PubMed=25755297; DOI=10.1074/mcp.o114.044792; RA Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V., RA Vertegaal A.C.; RT "System-wide analysis of SUMOylation dynamics in response to replication RT stress reveals novel small ubiquitin-like modified target proteins and RT acceptor lysines relevant for genome stability."; RL Mol. Cell. Proteomics 14:1419-1434(2015). RN [23] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-329; LYS-481; LYS-504; LYS-527; RP LYS-763; LYS-769; LYS-774; LYS-776; LYS-793; LYS-796; LYS-861; LYS-953; RP LYS-1043; LYS-1057 AND LYS-1118, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [24] RP INVOLVEMENT IN DDH4, AND VARIANT DDH4 THR-550 INS. RX PubMed=39054052; DOI=10.1136/jmg-2024-109928; RA Gombosh M., Proskorovski-Ohayon R., Yogev Y., Eskin-Schwartz M., Hadar N., RA Aharoni S., Dolgin V., Cohen E., Birk O.S.; RT "Developmental dysplasia of the hip caused by homozygous TRIM33 pathogenic RT variant affecting downstream BMP pathway."; RL J. Med. Genet. 61:959-965(2024). RN [25] RP VARIANTS [LARGE SCALE ANALYSIS] ILE-580; SER-696; LYS-811; SER-885; MET-961 RP AND THR-1090. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Acts as an E3 ubiquitin-protein ligase. Promotes SMAD4 CC ubiquitination, nuclear exclusion and degradation via the ubiquitin CC proteasome pathway. According to PubMed:16751102, does not promote a CC decrease in the level of endogenous SMAD4. May act as a transcriptional CC repressor. Inhibits the transcriptional response to TGF-beta/BMP CC signaling cascade. Plays a role in the control of cell proliferation. CC Its association with SMAD2 and SMAD3 stimulates erythroid CC differentiation of hematopoietic stem/progenitor (By similarity). CC Monoubiquitinates SMAD4 and acts as an inhibitor of SMAD4-dependent CC TGF-beta/BMP signaling cascade (Monoubiquitination of SMAD4 hampers its CC ability to form a stable complex with activated SMAD2/3 resulting in CC inhibition of TGF-beta/BMP signaling cascade). {ECO:0000250, CC ECO:0000269|PubMed:10022127, ECO:0000269|PubMed:15820681, CC ECO:0000269|PubMed:16751102, ECO:0000269|PubMed:19135894}. CC -!- CATALYTIC ACTIVITY: CC Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine + CC [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L- CC cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.; CC EC=2.3.2.27; CC -!- PATHWAY: Protein modification; protein ubiquitination. CC -!- SUBUNIT: Homooligomer and heterooligomer with TRIM24 and TRIM28 family CC members. Interacts with SMAD4 in unstimulated cells. Found in a complex CC with SMAD2 and SMAD3 upon addition of TGF-beta. Interacts with SMAD2 CC and SMAD3. Interacts with SMAD4 under basal and induced conditions and, CC upon TGF-beta signaling, with activated SMAD2. Forms a ternary complex CC with SMAD4 and SMAD2 upon TGF-beta signaling. CC {ECO:0000269|PubMed:10022127, ECO:0000269|PubMed:12096914, CC ECO:0000269|PubMed:15820681, ECO:0000269|PubMed:16751102, CC ECO:0000269|PubMed:19135894}. CC -!- INTERACTION: CC Q9UPN9; Q03154: ACY1; NbExp=2; IntAct=EBI-2214398, EBI-742064; CC Q9UPN9; Q15796: SMAD2; NbExp=6; IntAct=EBI-2214398, EBI-1040141; CC Q9UPN9; Q13485: SMAD4; NbExp=6; IntAct=EBI-2214398, EBI-347263; CC Q9UPN9; O15164: TRIM24; NbExp=6; IntAct=EBI-2214398, EBI-2130378; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15820681, CC ECO:0000269|PubMed:16751102, ECO:0000269|PubMed:19135894, CC ECO:0000269|PubMed:25593309}. Note=In discrete nuclear dots resembling CC nuclear bodies (By similarity). Localizes to sites of DNA damage CC (PubMed:25593309). {ECO:0000250|UniProtKB:Q99PP7, CC ECO:0000269|PubMed:25593309}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=Alpha; CC IsoId=Q9UPN9-1; Sequence=Displayed; CC Name=Beta; CC IsoId=Q9UPN9-2; Sequence=VSP_005774; CC -!- TISSUE SPECIFICITY: Expressed in stem cells at the bottom of the crypts CC of the colon (at protein level). Expressed in colon adenomas and CC adenocarcinomas (at protein level). Expressed in brain, lung, liver, CC spleen, thymus, prostate, kidney, testis, heart, placenta, pancreas, CC small intestine, ovary, colon, skeletal muscle and hematopoietic CC progenitors. CC -!- PTM: Sumoylated with SUMO1. {ECO:0000250|UniProtKB:Q99PP7}. CC -!- DISEASE: Note=A chromosomal aberration involving TRIM33 is found in CC papillary thyroid carcinomas (PTCs). Translocation t(1;10)(p13;q11) CC with RET. The translocation generates the TRIM33/RET (PTC7) oncogene. CC {ECO:0000269|PubMed:10439047}. CC -!- DISEASE: Developmental dysplasia of the hip 4 (DDH4) [MIM:621311]: An CC autosomal recessive form of congenital dysplasia of the hip, a common CC skeletal anomaly in which the normal seating of the femoral head in the CC acetabulum is disrupted. Its severity ranges from mild instability of CC the femoral head with slight capsular laxity, permitting minimal CC lateral displacement, through moderate lateral displacement of the CC femoral head, without loss of contact of the head with the acetabulum, CC up to complete dislocation of the femoral head from the acetabulum. CC {ECO:0000269|PubMed:39054052}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the TRIM/RBCC family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAD17259.1; Type=Frameshift; Evidence={ECO:0000305}; CC Sequence=BAA83065.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF119043; AAD17259.1; ALT_FRAME; mRNA. DR EMBL; AF220136; AAG53509.1; -; mRNA. DR EMBL; AF220137; AAG53510.1; -; mRNA. DR EMBL; AB029036; BAA83065.1; ALT_INIT; mRNA. DR EMBL; AL035410; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL390241; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AJ132948; CAB55313.1; -; mRNA. DR CCDS; CCDS872.1; -. [Q9UPN9-1] DR CCDS; CCDS873.1; -. [Q9UPN9-2] DR RefSeq; NP_056990.3; NM_015906.3. [Q9UPN9-1] DR RefSeq; NP_148980.2; NM_033020.3. [Q9UPN9-2] DR PDB; 3U5M; X-ray; 3.08 A; A/B/C/D/E/F/G/H/I/J/K/L=882-1087. DR PDB; 3U5N; X-ray; 1.95 A; A/B=882-1087. DR PDB; 3U5O; X-ray; 2.70 A; A/B/C/D/E/F/G/H=882-1087. DR PDB; 3U5P; X-ray; 2.80 A; A/B/C/D/E/F/G/H=882-1087. DR PDB; 5MR8; X-ray; 1.74 A; A=882-1090. DR PDB; 7ZDD; X-ray; 1.62 A; A=882-1090. DR PDB; 8BD8; X-ray; 3.10 A; A=882-1087. DR PDB; 8BD9; X-ray; 3.20 A; A=882-1087. DR PDB; 8BDY; X-ray; 3.05 A; A=882-1087. DR PDBsum; 3U5M; -. DR PDBsum; 3U5N; -. DR PDBsum; 3U5O; -. DR PDBsum; 3U5P; -. DR PDBsum; 5MR8; -. DR PDBsum; 7ZDD; -. DR PDBsum; 8BD8; -. DR PDBsum; 8BD9; -. DR PDBsum; 8BDY; -. DR AlphaFoldDB; Q9UPN9; -. DR SMR; Q9UPN9; -. DR BioGRID; 119625; 483. DR CORUM; Q9UPN9; -. DR DIP; DIP-54262N; -. DR FunCoup; Q9UPN9; 4535. DR IntAct; Q9UPN9; 151. DR MINT; Q9UPN9; -. DR STRING; 9606.ENSP00000351250; -. DR BindingDB; Q9UPN9; -. DR ChEMBL; CHEMBL2176772; -. DR GlyCosmos; Q9UPN9; 1 site, 1 glycan. DR GlyGen; Q9UPN9; 7 sites, 1 O-linked glycan (6 sites). DR iPTMnet; Q9UPN9; -. DR PhosphoSitePlus; Q9UPN9; -. DR BioMuta; TRIM33; -. DR DMDM; 313104270; -. DR jPOST; Q9UPN9; -. DR MassIVE; Q9UPN9; -. DR PaxDb; 9606-ENSP00000351250; -. DR PeptideAtlas; Q9UPN9; -. DR ProteomicsDB; 85392; -. [Q9UPN9-1] DR ProteomicsDB; 85393; -. [Q9UPN9-2] DR Pumba; Q9UPN9; -. DR ABCD; Q9UPN9; 1 sequenced antibody. DR Antibodypedia; 1303; 439 antibodies from 37 providers. DR DNASU; 51592; -. DR Ensembl; ENST00000358465.7; ENSP00000351250.2; ENSG00000197323.13. [Q9UPN9-1] DR Ensembl; ENST00000369543.6; ENSP00000358556.2; ENSG00000197323.13. [Q9UPN9-2] DR GeneID; 51592; -. DR KEGG; hsa:51592; -. DR MANE-Select; ENST00000358465.7; ENSP00000351250.2; NM_015906.4; NP_056990.3. DR UCSC; uc001eew.3; human. [Q9UPN9-1] DR AGR; HGNC:16290; -. DR ClinPGx; PA38118; -. DR CTD; 51592; -. DR DisGeNET; 51592; -. DR GeneCards; TRIM33; -. DR HGNC; HGNC:16290; TRIM33. DR HPA; ENSG00000197323; Low tissue specificity. DR MalaCards; TRIM33; -. DR MIM; 605769; gene. DR MIM; 621311; phenotype. DR OpenTargets; ENSG00000197323; -. DR Orphanet; 146; Differentiated thyroid carcinoma. DR Orphanet; 2412; Dislocation of the hip-dysmorphism syndrome. DR VEuPathDB; HostDB:ENSG00000197323; -. DR eggNOG; KOG2177; Eukaryota. DR GeneTree; ENSGT00940000156361; -. DR InParanoid; Q9UPN9; -. DR OMA; ICQNCVM; -. DR OrthoDB; 1870062at2759; -. DR PAN-GO; Q9UPN9; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q9UPN9; -. DR PathwayCommons; Q9UPN9; -. DR Reactome; R-HSA-2173795; Downregulation of SMAD2/3:SMAD4 transcriptional activity. DR Reactome; R-HSA-9754189; Germ layer formation at gastrulation. DR SignaLink; Q9UPN9; -. DR SIGNOR; Q9UPN9; -. DR UniPathway; UPA00143; -. DR Agora; ENSG00000197323; -. DR BioGRID-ORCS; 51592; 47 hits in 1223 CRISPR screens. DR ChiTaRS; TRIM33; human. DR EvolutionaryTrace; Q9UPN9; -. DR GeneWiki; TRIM33; -. DR GenomeRNAi; 51592; -. DR Pharos; Q9UPN9; Tchem. DR PRO; PR:Q9UPN9; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; Q9UPN9; protein. DR Bgee; ENSG00000197323; Expressed in endometrium epithelium and 209 other cell types or tissues. DR ExpressionAtlas; Q9UPN9; baseline and differential. DR GO; GO:0000785; C:chromatin; IBA:GO_Central. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0070410; F:co-SMAD binding; IPI:BHF-UCL. DR GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW. DR GO; GO:0070412; F:R-SMAD binding; IPI:BHF-UCL. DR GO; GO:0061630; F:ubiquitin protein ligase activity; IEA:UniProtKB-EC. DR GO; GO:0004842; F:ubiquitin-protein transferase activity; TAS:Reactome. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0030514; P:negative regulation of BMP signaling pathway; IDA:UniProtKB. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; NAS:UniProtKB. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; TAS:Reactome. DR GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB. DR GO; GO:0017015; P:regulation of transforming growth factor beta receptor signaling pathway; IDA:UniProtKB. DR CDD; cd19847; Bbox1_TIF1g_C-VI; 1. DR CDD; cd19830; Bbox2_TIF1g_C-VI; 1. DR CDD; cd05502; Bromo_tif1_like; 1. DR CDD; cd15624; PHD_TIF1gamma; 1. DR CDD; cd16766; RING-HC_TIF1gamma; 1. DR FunFam; 3.30.40.10:FF:000123; E3 ubiquitin-protein ligase TRIM33; 1. DR FunFam; 3.30.40.10:FF:000246; E3 ubiquitin-protein ligase TRIM33 isoform X2; 1. DR FunFam; 1.20.920.10:FF:000024; Transcription intermediary factor 1-alpha; 1. DR FunFam; 3.30.160.60:FF:000074; Tripartite motif containing 66; 1. DR Gene3D; 1.20.920.10; Bromodomain-like; 1. DR Gene3D; 3.30.160.60; Classic Zinc Finger; 1. DR Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 2. DR IDEAL; IID00505; -. DR InterPro; IPR003649; Bbox_C. DR InterPro; IPR001487; Bromodomain. DR InterPro; IPR036427; Bromodomain-like_sf. DR InterPro; IPR019786; Zinc_finger_PHD-type_CS. DR InterPro; IPR000315; Znf_B-box. DR InterPro; IPR011011; Znf_FYVE_PHD. DR InterPro; IPR001965; Znf_PHD. DR InterPro; IPR019787; Znf_PHD-finger. DR InterPro; IPR001841; Znf_RING. DR InterPro; IPR013083; Znf_RING/FYVE/PHD. DR InterPro; IPR017907; Znf_RING_CS. DR PANTHER; PTHR45915:SF3; E3 UBIQUITIN-PROTEIN LIGASE TRIM33; 1. DR PANTHER; PTHR45915; TRANSCRIPTION INTERMEDIARY FACTOR; 1. DR Pfam; PF00439; Bromodomain; 1. DR Pfam; PF00628; PHD; 1. DR Pfam; PF00643; zf-B_box; 1. DR PRINTS; PR00503; BROMODOMAIN. DR SMART; SM00502; BBC; 1. DR SMART; SM00336; BBOX; 2. DR SMART; SM00297; BROMO; 1. DR SMART; SM00249; PHD; 2. DR SMART; SM00184; RING; 2. DR SUPFAM; SSF57845; B-box zinc-binding domain; 1. DR SUPFAM; SSF47370; Bromodomain; 1. DR SUPFAM; SSF57903; FYVE/PHD zinc finger; 1. DR SUPFAM; SSF57850; RING/U-box; 1. DR PROSITE; PS50014; BROMODOMAIN_2; 1. DR PROSITE; PS50119; ZF_BBOX; 2. DR PROSITE; PS01359; ZF_PHD_1; 1. DR PROSITE; PS50016; ZF_PHD_2; 1. DR PROSITE; PS00518; ZF_RING_1; 1. DR PROSITE; PS50089; ZF_RING_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Bromodomain; KW Chromosomal rearrangement; Coiled coil; DNA-binding; Isopeptide bond; KW Metal-binding; Methylation; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; Repressor; KW Transcription; Transcription regulation; Transferase; Ubl conjugation; KW Ubl conjugation pathway; Zinc; Zinc-finger. FT CHAIN 1..1127 FT /note="E3 ubiquitin-protein ligase TRIM33" FT /id="PRO_0000056395" FT DOMAIN 957..1080 FT /note="Bromo" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00035" FT ZN_FING 125..154 FT /note="RING-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00175" FT ZN_FING 212..259 FT /note="B box-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00024" FT ZN_FING 271..312 FT /note="B box-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00024" FT ZN_FING 887..934 FT /note="PHD-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00146" FT REGION 1..147 FT /note="Necessary for E3 ubiquitin-protein ligase activity FT and repression of SMAD4 signaling and transcriptional FT repression" FT REGION 1..118 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 299..401 FT /note="Necessary for oligomerization" FT REGION 536..563 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 608..629 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 673..692 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 703..818 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1088..1127 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 299..401 FT /evidence="ECO:0000255" FT COMPBIAS 1..18 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 19..37 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 52..64 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 65..97 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 98..118 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 723..759 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 793..802 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 807..818 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1092..1109 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1118..1127 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 217 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00024" FT BINDING 220 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00024" FT BINDING 241 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00024" FT BINDING 245 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00024" FT BINDING 276 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00024" FT BINDING 279 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00024" FT BINDING 299 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00024" FT BINDING 304 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00024" FT SITE 964..965 FT /note="Breakpoint for translocation to form TRIM33-RET FT oncogene" FT MOD_RES 515 FT /note="Asymmetric dimethylarginine; alternate" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 515 FT /note="Omega-N-methylarginine; alternate" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 535 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 577 FT /note="Asymmetric dimethylarginine" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 591 FT /note="Asymmetric dimethylarginine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q99PP7" FT MOD_RES 591 FT /note="Omega-N-methylarginine; alternate" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 598 FT /note="Asymmetric dimethylarginine" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 604 FT /note="Asymmetric dimethylarginine" FT /evidence="ECO:0007744|PubMed:24129315" FT MOD_RES 763 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 769 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 793 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q99PP7" FT MOD_RES 803 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q99PP7" FT MOD_RES 815 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q99PP7" FT MOD_RES 862 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 951 FT /note="N6-acetyllysine" FT /evidence="ECO:0000250|UniProtKB:Q99PP7" FT MOD_RES 953 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 1051 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1102 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692" FT MOD_RES 1105 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692" FT MOD_RES 1119 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 329 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 334 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447" FT CROSSLNK 481 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 504 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 527 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 763 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2); alternate" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:25772364, FT ECO:0007744|PubMed:28112733" FT CROSSLNK 769 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2); alternate" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:25772364, FT ECO:0007744|PubMed:28112733" FT CROSSLNK 774 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 776 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO1); alternate" FT /evidence="ECO:0007744|PubMed:25114211" FT CROSSLNK 776 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2); alternate" FT /evidence="ECO:0007744|PubMed:25114211, FT ECO:0007744|PubMed:25218447, ECO:0007744|PubMed:25755297, FT ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733" FT CROSSLNK 793 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO1); alternate" FT /evidence="ECO:0007744|PubMed:25114211" FT CROSSLNK 793 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2); alternate" FT /evidence="ECO:0007744|PubMed:25114211, FT ECO:0007744|PubMed:25218447, ECO:0007744|PubMed:25755297, FT ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733" FT CROSSLNK 796 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 861 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25772364, FT ECO:0007744|PubMed:28112733" FT CROSSLNK 953 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2); alternate" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:28112733" FT CROSSLNK 1007 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447" FT CROSSLNK 1043 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 1057 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:25772364, FT ECO:0007744|PubMed:28112733" FT CROSSLNK 1118 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25772364, FT ECO:0007744|PubMed:28112733" FT VAR_SEQ 1041..1057 FT /note="Missing (in isoform Beta)" FT /evidence="ECO:0000303|PubMed:10439047, FT ECO:0000303|PubMed:11331580" FT /id="VSP_005774" FT VARIANT 67 FT /note="V -> A (in dbSNP:rs6691166)" FT /id="VAR_029494" FT VARIANT 550 FT /note="T -> TT (in DDH4; uncertain significance)" FT /evidence="ECO:0000269|PubMed:39054052" FT /id="VAR_091062" FT VARIANT 580 FT /note="M -> I (in a glioblastoma multiforme sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042376" FT VARIANT 696 FT /note="L -> S (in dbSNP:rs56151583)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042377" FT VARIANT 811 FT /note="E -> K (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042378" FT VARIANT 840 FT /note="I -> T (in dbSNP:rs6537825)" FT /evidence="ECO:0000269|PubMed:10022127, FT ECO:0000269|PubMed:10439047, ECO:0000269|PubMed:10470851, FT ECO:0000269|PubMed:11331580" FT /id="VAR_024616" FT VARIANT 885 FT /note="P -> S (in a glioblastoma multiforme sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042379" FT VARIANT 961 FT /note="V -> M (in dbSNP:rs55688622)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042380" FT VARIANT 1090 FT /note="P -> T (in dbSNP:rs55784699)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042381" FT MUTAGEN 125 FT /note="C->A: Abolishes E3 activity but does not affect FT interaction with SMAD4; when associated with A-128." FT /evidence="ECO:0000269|PubMed:15820681" FT MUTAGEN 128 FT /note="C->A: Abolishes E3 activity but does not affect FT interaction with SMAD4; when associated with A-125." FT /evidence="ECO:0000269|PubMed:15820681" FT CONFLICT 89 FT /note="V -> E (in Ref. 5; CAB55313)" FT /evidence="ECO:0000305" FT CONFLICT 451..453 FT /note="PAA -> LLH (in Ref. 5; CAB55313)" FT /evidence="ECO:0000305" FT CONFLICT 909 FT /note="F -> S (in Ref. 5; CAB55313)" FT /evidence="ECO:0000305" FT CONFLICT 1037 FT /note="R -> T (in Ref. 1; AAD17259)" FT /evidence="ECO:0000305" FT STRAND 888..890 FT /evidence="ECO:0007829|PDB:3U5N" FT TURN 891..893 FT /evidence="ECO:0007829|PDB:7ZDD" FT STRAND 897..901 FT /evidence="ECO:0007829|PDB:7ZDD" FT STRAND 903..906 FT /evidence="ECO:0007829|PDB:7ZDD" FT TURN 911..913 FT /evidence="ECO:0007829|PDB:7ZDD" FT STRAND 914..916 FT /evidence="ECO:0007829|PDB:7ZDD" FT STRAND 918..920 FT /evidence="ECO:0007829|PDB:3U5P" FT TURN 929..931 FT /evidence="ECO:0007829|PDB:7ZDD" FT STRAND 934..936 FT /evidence="ECO:0007829|PDB:7ZDD" FT HELIX 944..949 FT /evidence="ECO:0007829|PDB:5MR8" FT TURN 950..952 FT /evidence="ECO:0007829|PDB:5MR8" FT HELIX 960..975 FT /evidence="ECO:0007829|PDB:7ZDD" FT HELIX 980..982 FT /evidence="ECO:0007829|PDB:7ZDD" FT HELIX 993..996 FT /evidence="ECO:0007829|PDB:7ZDD" FT HELIX 1003..1010 FT /evidence="ECO:0007829|PDB:7ZDD" FT STRAND 1011..1013 FT /evidence="ECO:0007829|PDB:3U5O" FT HELIX 1021..1038 FT /evidence="ECO:0007829|PDB:7ZDD" FT TURN 1044..1048 FT /evidence="ECO:0007829|PDB:8BDY" FT HELIX 1061..1080 FT /evidence="ECO:0007829|PDB:7ZDD" FT TURN 1081..1083 FT /evidence="ECO:0007829|PDB:7ZDD" SQ SEQUENCE 1127 AA; 122533 MW; 7A36013799E9933C CRC64; MAENKGGGEA ESGGGGSGSA PVTAGAAGPA AQEAEPPLTA VLVEEEEEEG GRAGAEGGAA GPDDGGVAAA SSGSAQAASS PAASVGTGVA GGAVSTPAPA PASAPAPGPS AGPPPGPPAS LLDTCAVCQQ SLQSRREAEP KLLPCLHSFC LRCLPEPERQ LSVPIPGGSN GDIQQVGVIR CPVCRQECRQ IDLVDNYFVK DTSEAPSSSD EKSEQVCTSC EDNASAVGFC VECGEWLCKT CIEAHQRVKF TKDHLIRKKE DVSESVGASG QRPVFCPVHK QEQLKLFCET CDRLTCRDCQ LLEHKEHRYQ FLEEAFQNQK GAIENLLAKL LEKKNYVHFA ATQVQNRIKE VNETNKRVEQ EIKVAIFTLI NEINKKGKSL LQQLENVTKE RQMKLLQQQN DITGLSRQVK HVMNFTNWAI ASGSSTALLY SKRLITFQLR HILKARCDPV PAANGAIRFH CDPTFWAKNV VNLGNLVIES KPAPGYTPNV VVGQVPPGTN HISKTPGQIN LAQLRLQHMQ QQVYAQKHQQ LQQMRMQQPP APVPTTTTTT QQHPRQAAPQ MLQQQPPRLI SVQTMQRGNM NCGAFQAHQM RLAQNAARIP GIPRHSGPQY SMMQPHLQRQ HSNPGHAGPF PVVSVHNTTI NPTSPTTATM ANANRGPTSP SVTAIELIPS VTNPENLPSL PDIPPIQLED AGSSSLDNLL SRYISGSHLP PQPTSTMNPS PGPSALSPGS SGLSNSHTPV RPPSTSSTGS RGSCGSSGRT AEKTSLSFKS DQVKVKQEPG TEDEICSFSG GVKQEKTEDG RRSACMLSSP ESSLTPPLST NLHLESELDA LASLENHVKI EPADMNESCK QSGLSSLVNG KSPIRSLMHR SARIGGDGNN KDDDPNEDWC AVCQNGGDLL CCEKCPKVFH LTCHVPTLLS FPSGDWICTF CRDIGKPEVE YDCDNLQHSK KGKTAQGLSP VDQRKCERLL LYLYCHELSI EFQEPVPASI PNYYKIIKKP MDLSTVKKKL QKKHSQHYQI PDDFVADVRL IFKNCERFNE MMKVVQVYAD TQEINLKADS EVAQAGKAVA LYFEDKLTEI YSDRTFAPLP EFEQEEDDGE VTEDSDEDFI QPRRKRLKSD ERPVHIK // ID TRPM6_HUMAN Reviewed; 2022 AA. AC Q9BX84; Q6VPR8; Q6VPR9; Q6VPS0; Q6VPS1; Q6VPS2; DT 07-DEC-2004, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-2002, sequence version 2. DT 28-JAN-2026, entry version 184. DE RecName: Full=Transient receptor potential cation channel subfamily M member 6; DE EC=2.7.11.1 {ECO:0000269|PubMed:18258429, ECO:0000269|PubMed:18365021}; DE AltName: Full=Channel kinase 2; DE AltName: Full=Melastatin-related TRP cation channel 6; DE Contains: DE RecName: Full=TRPM6 kinase, cleaved form {ECO:0000303|PubMed:28784805}; GN Name=TRPM6; Synonyms=CHAK2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRPM6A). RC TISSUE=Kidney; RX PubMed=11357414; RA Riazanova L.V., Pavur K.S., Petrov A.N., Dorovkov M.V., Riazanov A.G.; RT "Novel type of signaling molecules: protein kinases covalently linked to RT ion channels."; RL Mol. Biol. (Mosk.) 35:321-332(2001). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRPM6A), AND VARIANT HOMG1 LEU-141. RC TISSUE=Kidney, and Small intestine; RX PubMed=12032568; DOI=10.1038/ng889; RA Schlingmann K.P., Weber S., Peters M., Niemann Nejsum L.N., Vitzthum H., RA Klingel K., Kratz M., Haddad E., Ristoff E., Dinour D., Syrrou M., RA Nielsen S., Sassen M.C., Waldegger S., Seyberth H.W., Konrad M.; RT "Hypomagnesemia with secondary hypocalcemia is caused by mutations in RT TRPM6, a new member of the TRPM gene family."; RL Nat. Genet. 31:166-170(2002). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS TRPM6A; TRPM6B; TRPM6C; TRPM6T; RP M6-KINASE 1; M6-KINASE 2 AND M6-KINASE 3), CHARACTERIZATION OF VARIANT RP HOMG1 LEU-141, INTERACTION WITH TRPM7, AND SUBUNIT. RC TISSUE=Lung cancer; RX PubMed=14976260; DOI=10.1073/pnas.0305252101; RA Chubanov V., Waldegger S., Mederos y Schnitzler M., Vitzthum H., RA Sassen M.C., Seyberth H.W., Konrad M., Gudermann T.; RT "Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 RT gene causes hypomagnesemia with secondary hypocalcemia."; RL Proc. Natl. Acad. Sci. U.S.A. 101:2894-2899(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164053; DOI=10.1038/nature02465; RA Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L., RA Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R., RA Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S., RA Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., RA Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., RA Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E., RA Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M., RA Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J., RA Frankish A., Frankland J.A., French L., Fricker D.G., Garner P., RA Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S., RA Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E., RA Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D., RA Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E., RA Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K., RA Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S., RA Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J., RA Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E., RA McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V., RA Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S., RA Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K., RA Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J., RA Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., RA West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L., RA Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M., RA Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J., RA Dunham I.; RT "DNA sequence and analysis of human chromosome 9."; RL Nature 429:369-374(2004). RN [5] RP FUNCTION, TRANSPORTER ACTIVITY, ACTIVITY REGULATION, AND SUBCELLULAR RP LOCATION. RX PubMed=14576148; DOI=10.1074/jbc.m311201200; RA Voets T., Nilius B., Hoefs S., van der Kemp A.W., Droogmans G., RA Bindels R.J., Hoenderop J.G.; RT "TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ RT absorption."; RL J. Biol. Chem. 279:19-25(2004). RN [6] RP FUNCTION, TRANSPORTER ACTIVITY, ACTIVITY REGULATION, SUBUNIT, AND RP CHARACTERIZATION OF VARIANT HOMG1 LEU-141. RX PubMed=16636202; DOI=10.1085/jgp.200609502; RA Li M., Jiang J., Yue L.; RT "Functional characterization of homo- and heteromeric channel kinases TRPM6 RT and TRPM7."; RL J. Gen. Physiol. 127:525-537(2006). RN [7] RP SUBUNIT, AND VARIANT HOMG1 ARG-1017. RX PubMed=17197439; DOI=10.1074/jbc.m611117200; RA Chubanov V., Schlingmann K.P., Waering J., Heinzinger J., Kaske S., RA Waldegger S., Mederos y Schnitzler M., Gudermann T.; RT "Hypomagnesemia with secondary hypocalcemia due to a missense mutation in RT the putative pore-forming region of TRPM6."; RL J. Biol. Chem. 282:7656-7667(2007). RN [8] RP FUNCTION, CATALYTIC ACTIVITY, AND ACTIVITY REGULATION. RX PubMed=18365021; DOI=10.1371/journal.pone.0001876; RA Clark K., Middelbeek J., Morrice N.A., Figdor C.G., Lasonder E., RA van Leeuwen F.N.; RT "Massive autophosphorylation of the Ser/Thr-rich domain controls protein RT kinase activity of TRPM6 and TRPM7."; RL PLoS ONE 3:e1876-e1876(2008). RN [9] RP CATALYTIC ACTIVITY, ACTIVITY REGULATION, INTERACTION WITH RACK1, RP PHOSPHORYLATION AT THR-1851, AND MUTAGENESIS OF LYS-1804 AND THR-1851. RX PubMed=18258429; DOI=10.1016/j.cub.2007.12.058; RA Cao G., Thebault S., van der Wijst J., van der Kemp A., Lasonder E., RA Bindels R.J., Hoenderop J.G.; RT "RACK1 inhibits TRPM6 activity via phosphorylation of the fused alpha- RT kinase domain."; RL Curr. Biol. 18:168-176(2008). RN [10] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=24385424; DOI=10.1074/jbc.m113.512285; RA Zhang Z., Yu H., Huang J., Faouzi M., Schmitz C., Penner R., Fleig A.; RT "The TRPM6 kinase domain determines the Mg.ATP sensitivity of TRPM7/M6 RT heteromeric ion channels."; RL J. Biol. Chem. 289:5217-5227(2014). RN [11] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF 1063-ASN--LEU-1065. RX PubMed=28784805; DOI=10.1073/pnas.1708427114; RA Krapivinsky G., Krapivinsky L., Renthal N.E., Santa-Cruz A., Manasian Y., RA Clapham D.E.; RT "Histone phosphorylation by TRPM6's cleaved kinase attenuates adjacent RT arginine methylation to regulate gene expression."; RL Proc. Natl. Acad. Sci. U.S.A. 114:E7092-E7100(2017). RN [12] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-75; ILE-338; CYS-1007; ARG-1243; RP ARG-1274; ILE-1393; GLU-1584; ARG-1663; SER-1673 AND ILE-1724. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [13] RP VARIANTS HOMG1 PRO-708; GLY-872; CYS-1053; PRO-1143 AND ASN-1754, VARIANT RP ARG-1663, CHARACTERIZATION OF VARIANTS HOMG1 PRO-708; GLY-872; CYS-1053; RP PRO-1143 AND ASN-1754, CHARACTERIZATION OF VARIANT ARG-1663, AND RP SUBCELLULAR LOCATION. RX PubMed=23942199; DOI=10.1038/ejhg.2013.178; RA Lainez S., Schlingmann K.P., van der Wijst J., Dworniczak B., RA van Zeeland F., Konrad M., Bindels R.J., Hoenderop J.G.; RT "New TRPM6 missense mutations linked to hypomagnesemia with secondary RT hypocalcemia."; RL Eur. J. Hum. Genet. 22:497-504(2014). CC -!- FUNCTION: Bifunctional protein that combines an ion channel with an CC intrinsic kinase domain, enabling it to modulate cellular functions CC either by conducting ions through the pore or by phosphorylating CC downstream proteins via its kinase domain (PubMed:14576148, CC PubMed:16636202, PubMed:18258429, PubMed:18365021). Crucial for Mg(2+) CC homeostasis. Has an important role in epithelial Mg(2+) transport and CC in the active Mg(2+) absorption in the gut and kidney CC (PubMed:14576148). However, whether TRPM6 forms functional homomeric CC channels by itself or functions primarily as a subunit of heteromeric CC TRPM6-TRPM7 channels, is still under debate (PubMed:14576148, CC PubMed:16636202, PubMed:24385424). {ECO:0000269|PubMed:14576148, CC ECO:0000269|PubMed:16636202, ECO:0000269|PubMed:18258429, CC ECO:0000269|PubMed:18365021, ECO:0000269|PubMed:24385424}. CC -!- FUNCTION: [TRPM6 kinase, cleaved form]: The C-terminal kinase domain CC can be cleaved from the channel segment in a cell-type-specific CC fashion. The cleaved kinase fragments can translocate to the nucleus, CC and bind chromatin-remodeling complex proteins to ultimately CC phosphorylate specific Ser/Thr residues of histones known to be CC functionally important for cell differentiation and development. CC {ECO:0000269|PubMed:28784805}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:18365021}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:18258429, ECO:0000269|PubMed:18365021}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Mg(2+)(in) = Mg(2+)(out); Xref=Rhea:RHEA:29827, CC ChEBI:CHEBI:18420; Evidence={ECO:0000269|PubMed:14576148, CC ECO:0000269|PubMed:16636202}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671, CC ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:14576148, CC ECO:0000269|PubMed:16636202}; CC -!- CATALYTIC ACTIVITY: CC Reaction=Zn(2+)(in) = Zn(2+)(out); Xref=Rhea:RHEA:29351, CC ChEBI:CHEBI:29105; Evidence={ECO:0000269|PubMed:16636202}; CC -!- ACTIVITY REGULATION: Strongly inhibited by intracellular Mg(2+); CC unlikely to be active at physiological levels of intracellular Mg(2+) CC (PubMed:14576148, PubMed:16636202, PubMed:24385424). In the heteromeric CC TRPM6-TRPM7 channels complexes, TRPM7 are able to offset the very high CC sensitivity of TRPM6 to cytosolic Mg(2+) to physiologically relevant CC concentrations, whereas TRPM6 relieve TRPM7 from the inhibitory action CC of Mg-ATP. Consequently, the association of TRPM6 with TRPM7 allow for CC high constitutive activity of TRPM6/7 in the presence of physiological CC levels of Mg(2+) and Mg-ATP (By similarity). The kinase activity is CC controlled through the autophosphorylation of a serine/threonine-rich CC region located to the N-terminal of the catalytic domain CC (PubMed:18258429, PubMed:18365021). {ECO:0000250|UniProtKB:Q8CIR4, CC ECO:0000269|PubMed:14576148, ECO:0000269|PubMed:16636202, CC ECO:0000269|PubMed:18258429, ECO:0000269|PubMed:18365021, CC ECO:0000269|PubMed:24385424}. CC -!- SUBUNIT: Homomers (PubMed:16636202). Forms heteromers with TRPM7; TRPM6 CC increases the current amplitude of TRPM6/7 heteromers as compared to CC TRPM7 homomer (PubMed:14976260, PubMed:16636202, PubMed:17197439). CC Interacts (via kinase domain) with RACK1 (PubMed:18258429). CC {ECO:0000269|PubMed:14976260, ECO:0000269|PubMed:16636202, CC ECO:0000269|PubMed:17197439, ECO:0000269|PubMed:18258429}. CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:23942199}; CC Multi-pass membrane protein {ECO:0000305}. Apical cell membrane CC {ECO:0000269|PubMed:14576148}; Multi-pass membrane protein CC {ECO:0000305}. Note=TRPM6 requires the presence of TRPM7 to be targeted CC to the cell membrane (in HEK 293 cells). {ECO:0000269|PubMed:14976260, CC ECO:0000269|PubMed:17197439}. CC -!- SUBCELLULAR LOCATION: [TRPM6 kinase, cleaved form]: Nucleus CC {ECO:0000269|PubMed:28784805}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=7; CC Name=TRPM6a {ECO:0000303|PubMed:14976260}; CC IsoId=Q9BX84-1; Sequence=Displayed; CC Name=TRPM6b {ECO:0000303|PubMed:14976260}; CC IsoId=Q9BX84-2; Sequence=VSP_012069; CC Name=TRPM6c {ECO:0000303|PubMed:14976260}; CC IsoId=Q9BX84-3; Sequence=VSP_012070; CC Name=TRPM6t {ECO:0000303|PubMed:14976260}; CC IsoId=Q9BX84-4; Sequence=VSP_012075, VSP_012076; CC Name=M6-kinase 1 {ECO:0000303|PubMed:14976260}; CC IsoId=Q9BX84-5; Sequence=VSP_012074; CC Name=M6-kinase 2 {ECO:0000303|PubMed:14976260}; CC IsoId=Q9BX84-6; Sequence=VSP_012073; CC Name=M6-kinase 3 {ECO:0000303|PubMed:14976260}; CC IsoId=Q9BX84-7; Sequence=VSP_012071, VSP_012072; CC -!- TISSUE SPECIFICITY: Highly expressed in kidney and colon. Isoform CC TRPM6a and isoform TRPM6b, are coexpressed with TRPM7 in kidney, and CC testis, and are also found in several cell lines of lung origin. CC Isoform TRPM6c is detected only in testis and in NCI-H510A small cell CC lung carcinoma cells. CC -!- PTM: Autophosphorylated; autophosphorylation controlls the protein CC kinase activity of TRPM6 towards their substrates (PubMed:18258429, CC PubMed:18365021). Autophosphorylation of Thr-1851 in the kinase domain CC is essential for the inhibitory effect of RACK1 (PubMed:18258429). CC {ECO:0000269|PubMed:18258429, ECO:0000269|PubMed:18365021}. CC -!- PTM: The C-terminus of TRPM6 is proteolytically cleaved in vivo, in a CC cell type-specific fashion, releasing the kinase module from the CC transmembrane domain. The cleaved kinase fragments are translocated to CC the nucleus to phosphorylate histones and regulate gene expression. CC {ECO:0000269|PubMed:28784805}. CC -!- DISEASE: Hypomagnesemia 1 (HOMG1) [MIM:602014]: A disorder due to a CC primary defect in intestinal magnesium absorption. It is characterized CC by low levels of serum magnesium alongside with a normal renal CC magnesium secretion, secondary hypocalcemia and calcinocis. Affected CC individuals show neurologic symptoms of hypomagnesemic hypocalcemia, CC including seizures and muscle spasms, during infancy. Hypocalcemia is CC secondary to parathyroid failure resulting from magnesium deficiency. CC Untreated, the disorder may be fatal or may result in neurological CC damage. {ECO:0000269|PubMed:12032568, ECO:0000269|PubMed:14976260, CC ECO:0000269|PubMed:16636202, ECO:0000269|PubMed:17197439, CC ECO:0000269|PubMed:23942199}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform M6-kinase 1]: Lacks the ion channel region. CC {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform M6-kinase 2]: Lacks the ion channel region. CC {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform M6-kinase 3]: Lacks the ion channel region. CC {ECO:0000305}. CC -!- SIMILARITY: In the C-terminal section; belongs to the protein kinase CC superfamily. Alpha-type protein kinase family. ALPK subfamily. CC {ECO:0000305}. CC -!- SIMILARITY: In the N-terminal section; belongs to the transient CC receptor (TC 1.A.4) family. LTrpC subfamily. TRPM6 sub-subfamily. CC {ECO:0000305}. CC -!- CAUTION: Whether TRPM6 forms functional homomeric channels by itself is CC still under debate. According to PubMed:14576148 and PubMed:16636202, CC TRPM6 are able to form TRPM6 channels with similar properties to those CC of TRPM7, with biophysical characteristics resembling those of TRPM7 CC including the high channel pore selectivity for divalent cations and CC regulation by intracellular Mg(2+) (PubMed:14576148, PubMed:16636202). CC In contrast, others studies report that TRPM6 does not produce CC functional currents by itself and TRPM6 does not efficiently form CC homotetramers channels in the plasma membrane, but requires TRPM7 to be CC co-targeted to the cell surface (PubMed:14976260, PubMed:17197439). CC Further, homotetramers TRPM6 are highly sensitive to intracellular free CC Mg(2+) and therefore unlikely to be active at physiological levels of CC intracellular Mg(2+) (PubMed:24385424). {ECO:0000269|PubMed:14576148, CC ECO:0000269|PubMed:14976260, ECO:0000269|PubMed:16636202, CC ECO:0000269|PubMed:17197439, ECO:0000269|PubMed:24385424}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF350881; AAK31202.2; -; mRNA. DR EMBL; AF448232; AAM21562.1; -; mRNA. DR EMBL; AY333282; AAR03487.1; -; mRNA. DR EMBL; AY333283; AAR03488.1; -; mRNA. DR EMBL; AY333284; AAR03489.1; -; mRNA. DR EMBL; AY333285; AAR03490.1; -; mRNA. DR EMBL; AY333286; AAR03491.1; -; mRNA. DR EMBL; AY333287; AAR03492.1; -; mRNA. DR EMBL; AY333288; AAR03493.1; -; mRNA. DR EMBL; AL354795; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS55318.1; -. [Q9BX84-3] DR CCDS; CCDS55319.1; -. [Q9BX84-2] DR CCDS; CCDS6647.1; -. [Q9BX84-1] DR RefSeq; NP_001170781.1; NM_001177310.2. [Q9BX84-2] DR RefSeq; NP_001170782.1; NM_001177311.2. [Q9BX84-3] DR RefSeq; NP_060132.3; NM_017662.4. [Q9BX84-1] DR AlphaFoldDB; Q9BX84; -. DR SMR; Q9BX84; -. DR BioGRID; 126713; 8. DR CORUM; Q9BX84; -. DR FunCoup; Q9BX84; 552. DR IntAct; Q9BX84; 3. DR MINT; Q9BX84; -. DR STRING; 9606.ENSP00000354006; -. DR BindingDB; Q9BX84; -. DR ChEMBL; CHEMBL1628470; -. DR DrugBank; DB14513; Magnesium. DR DrugBank; DB09481; Magnesium carbonate. DR GuidetoPHARMACOLOGY; 498; -. DR TCDB; 1.A.4.5.8; the transient receptor potential ca2+/cation channel (trp-cc) family. DR GlyGen; Q9BX84; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q9BX84; -. DR MetOSite; Q9BX84; -. DR PhosphoSitePlus; Q9BX84; -. DR BioMuta; TRPM6; -. DR DMDM; 56404951; -. DR CPTAC; CPTAC-2831; -. DR CPTAC; CPTAC-2987; -. DR jPOST; Q9BX84; -. DR MassIVE; Q9BX84; -. DR PaxDb; 9606-ENSP00000354006; -. DR PeptideAtlas; Q9BX84; -. DR ProteomicsDB; 79380; -. [Q9BX84-1] DR ProteomicsDB; 79381; -. [Q9BX84-2] DR ProteomicsDB; 79382; -. [Q9BX84-3] DR ProteomicsDB; 79383; -. [Q9BX84-4] DR ProteomicsDB; 79384; -. [Q9BX84-5] DR ProteomicsDB; 79385; -. [Q9BX84-6] DR ProteomicsDB; 79386; -. [Q9BX84-7] DR ABCD; Q9BX84; 1 sequenced antibody. DR Antibodypedia; 2049; 136 antibodies from 24 providers. DR DNASU; 140803; -. DR Ensembl; ENST00000360774.6; ENSP00000354006.1; ENSG00000119121.23. [Q9BX84-1] DR Ensembl; ENST00000361255.7; ENSP00000354962.3; ENSG00000119121.23. [Q9BX84-3] DR Ensembl; ENST00000449912.6; ENSP00000396672.2; ENSG00000119121.23. [Q9BX84-2] DR Ensembl; ENST00000715553.1; ENSP00000520473.1; ENSG00000119121.23. [Q9BX84-4] DR GeneID; 140803; -. DR KEGG; hsa:140803; -. DR MANE-Select; ENST00000360774.6; ENSP00000354006.1; NM_017662.5; NP_060132.3. DR UCSC; uc004ajk.1; human. [Q9BX84-1] DR AGR; HGNC:17995; -. DR ClinPGx; PA38479; -. DR CTD; 140803; -. DR DisGeNET; 140803; -. DR GeneCards; TRPM6; -. DR HGNC; HGNC:17995; TRPM6. DR HPA; ENSG00000119121; Tissue enriched (intestine). DR MalaCards; TRPM6; -. DR MIM; 602014; phenotype. DR MIM; 607009; gene. DR OpenTargets; ENSG00000119121; -. DR Orphanet; 30924; Primary hypomagnesemia with secondary hypocalcemia. DR VEuPathDB; HostDB:ENSG00000119121; -. DR eggNOG; KOG3614; Eukaryota. DR GeneTree; ENSGT00940000158164; -. DR HOGENOM; CLU_001390_2_0_1; -. DR InParanoid; Q9BX84; -. DR OMA; EVVQTWY; -. DR OrthoDB; 301415at2759; -. DR PAN-GO; Q9BX84; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q9BX84; -. DR PathwayCommons; Q9BX84; -. DR Reactome; R-HSA-3295583; TRP channels. DR SignaLink; Q9BX84; -. DR SIGNOR; Q9BX84; -. DR Agora; ENSG00000119121; -. DR BioGRID-ORCS; 140803; 7 hits in 1184 CRISPR screens. DR ChiTaRS; TRPM6; human. DR GeneWiki; TRPM6; -. DR GenomeRNAi; 140803; -. DR Pharos; Q9BX84; Tchem. DR PRO; PR:Q9BX84; -. DR Proteomes; UP000005640; Chromosome 9. DR RNAct; Q9BX84; protein. DR Bgee; ENSG00000119121; Expressed in colonic mucosa and 125 other cell types or tissues. DR ExpressionAtlas; Q9BX84; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB. DR GO; GO:0031526; C:brush border membrane; IEA:Ensembl. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005262; F:calcium channel activity; IBA:GO_Central. DR GO; GO:0015085; F:calcium ion transmembrane transporter activity; IDA:UniProtKB. DR GO; GO:0015095; F:magnesium ion transmembrane transporter activity; IDA:UniProtKB. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0004672; F:protein kinase activity; IBA:GO_Central. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0070588; P:calcium ion transmembrane transport; IDA:UniProtKB. DR GO; GO:0006816; P:calcium ion transport; IBA:GO_Central. DR GO; GO:1903830; P:magnesium ion transmembrane transport; IDA:UniProtKB. DR GO; GO:0098655; P:monoatomic cation transmembrane transport; IBA:GO_Central. DR GO; GO:0051262; P:protein tetramerization; IEA:InterPro. DR GO; GO:0009636; P:response to toxic substance; IDA:UniProtKB. DR CDD; cd16972; Alpha_kinase_ChaK2_TRPM6; 1. DR FunFam; 1.20.5.1010:FF:000002; Transient receptor potential cation channel subfamily M member 7; 1. DR FunFam; 3.20.200.10:FF:000001; Transient receptor potential cation channel, subfamily M, member 7; 1. DR FunFam; 3.30.200.20:FF:000129; Transient receptor potential cation channel, subfamily M, member 7; 1. DR Gene3D; 3.20.200.10; MHCK/EF2 kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.20.5.1010; TRPM, tetramerisation domain; 1. DR InterPro; IPR004166; a-kinase_dom. DR InterPro; IPR005821; Ion_trans_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR050927; TRPM. DR InterPro; IPR057366; TRPM-like. DR InterPro; IPR029597; TRPM6_a-kinase_dom. DR InterPro; IPR041491; TRPM_SLOG. DR InterPro; IPR032415; TRPM_tetra. DR InterPro; IPR037162; TRPM_tetra_sf. DR PANTHER; PTHR13800:SF15; TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL SUBFAMILY M MEMBER 6; 1. DR PANTHER; PTHR13800; TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY M, MEMBER 6; 1. DR Pfam; PF02816; Alpha_kinase; 1. DR Pfam; PF00520; Ion_trans; 1. DR Pfam; PF18139; LSDAT_euk; 1. DR Pfam; PF25508; TRPM2; 1. DR Pfam; PF16519; TRPM_tetra; 1. DR SMART; SM00811; Alpha_kinase; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51158; ALPHA_KINASE; 1. PE 1: Evidence at protein level; KW Alternative splicing; ATP-binding; Calcium; Calcium channel; KW Calcium transport; Cell membrane; Disease variant; Ion channel; KW Ion transport; Kinase; Membrane; Metal-binding; Nucleotide-binding; KW Nucleus; Phosphoprotein; Primary hypomagnesemia; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase; KW Transmembrane; Transmembrane helix; Transport; Zinc. FT CHAIN 1..2022 FT /note="Transient receptor potential cation channel FT subfamily M member 6" FT /id="PRO_0000215329" FT CHAIN ?..2022 FT /note="TRPM6 kinase, cleaved form" FT /evidence="ECO:0000269|PubMed:28784805" FT /id="PRO_0000461405" FT TOPO_DOM 1..741 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 742..762 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 763..841 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 842..862 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 863..905 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 906..926 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 927..939 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 940..960 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 961..972 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 973..993 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 994..1012 FT /note="Extracellular" FT /evidence="ECO:0000255" FT INTRAMEM 1013..1033 FT /note="Pore-forming" FT /evidence="ECO:0000255" FT TOPO_DOM 1034..1047 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 1048..1068 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 1069..2022 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 1750..1980 FT /note="Alpha-type protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00501" FT REGION 1479..1516 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1997..2022 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1483..1493 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1494..1512 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1998..2016 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 1923 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT BINDING 1777 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1778 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1779 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1780 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1804 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1876 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1879 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1909 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1933 FT /ligand="ADP" FT /ligand_id="ChEBI:CHEBI:456216" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1966 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1968 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT BINDING 1972 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:Q923J1" FT MOD_RES 1851 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18258429" FT VAR_SEQ 1..11 FT /note="MKEQPVLERLQ -> MIILSK (in isoform TRPM6b)" FT /evidence="ECO:0000303|PubMed:14976260" FT /id="VSP_012069" FT VAR_SEQ 1..11 FT /note="MKEQPVLERLQ -> MTAPVT (in isoform TRPM6c)" FT /evidence="ECO:0000303|PubMed:14976260" FT /id="VSP_012070" FT VAR_SEQ 281 FT /note="R -> P (in isoform M6-kinase 3)" FT /evidence="ECO:0000303|PubMed:14976260" FT /id="VSP_012071" FT VAR_SEQ 282..1734 FT /note="Missing (in isoform M6-kinase 3)" FT /evidence="ECO:0000303|PubMed:14976260" FT /id="VSP_012072" FT VAR_SEQ 500..1666 FT /note="Missing (in isoform M6-kinase 2)" FT /evidence="ECO:0000303|PubMed:14976260" FT /id="VSP_012073" FT VAR_SEQ 547..1595 FT /note="Missing (in isoform M6-kinase 1)" FT /evidence="ECO:0000303|PubMed:14976260" FT /id="VSP_012074" FT VAR_SEQ 1926..1943 FT /note="GVGENLTDPSVIKPEVKQ -> ALWFWDSMLKARLGGWRM (in isoform FT TRPM6t)" FT /evidence="ECO:0000303|PubMed:14976260" FT /id="VSP_012075" FT VAR_SEQ 1944..2022 FT /note="Missing (in isoform TRPM6t)" FT /evidence="ECO:0000303|PubMed:14976260" FT /id="VSP_012076" FT VARIANT 75 FT /note="G -> V (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs1193127627)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042387" FT VARIANT 141 FT /note="S -> L (in HOMG1; abolishes channel activity. FT Impairs homo- and heterooligomeric formation with TRPM7 FT resulting in intracellular retention; dbSNP:rs121912625)" FT /evidence="ECO:0000269|PubMed:12032568, FT ECO:0000269|PubMed:14976260, ECO:0000269|PubMed:16636202" FT /id="VAR_019963" FT VARIANT 338 FT /note="M -> I (in dbSNP:rs56155062)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042388" FT VARIANT 708 FT /note="L -> P (in HOMG1; abolishes channel activity; no FT effect on cell membrane localization)" FT /evidence="ECO:0000269|PubMed:23942199" FT /id="VAR_071480" FT VARIANT 872 FT /note="E -> G (in HOMG1; abolishes channel activity; no FT effect on cell membrane localization)" FT /evidence="ECO:0000269|PubMed:23942199" FT /id="VAR_071481" FT VARIANT 948 FT /note="F -> L (in dbSNP:rs13290391)" FT /id="VAR_052380" FT VARIANT 1007 FT /note="W -> C (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042389" FT VARIANT 1017 FT /note="P -> R (in HOMG1; does not affect protein FT expression. Does not affect coassembly with TRPM7. Impairs FT channel activity of TRPM6/7 complexes)" FT /evidence="ECO:0000269|PubMed:17197439" FT /id="VAR_089905" FT VARIANT 1053 FT /note="Y -> C (in HOMG1; abolishes channel activity; no FT effect on cell membrane localization)" FT /evidence="ECO:0000269|PubMed:23942199" FT /id="VAR_071482" FT VARIANT 1071 FT /note="N -> D (in dbSNP:rs2274922)" FT /id="VAR_019964" FT VARIANT 1143 FT /note="L -> P (in HOMG1; abolishes channel activity; no FT effect on cell membrane localization)" FT /evidence="ECO:0000269|PubMed:23942199" FT /id="VAR_071483" FT VARIANT 1243 FT /note="H -> R (in dbSNP:rs55694430)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042390" FT VARIANT 1274 FT /note="Q -> R (in dbSNP:rs34608911)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042391" FT VARIANT 1393 FT /note="V -> I (in dbSNP:rs3750425)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_019965" FT VARIANT 1584 FT /note="K -> E (in dbSNP:rs2274924)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_019966" FT VARIANT 1663 FT /note="Q -> R (no effect on channel activity or cell FT membrane localization; dbSNP:rs55679040)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:23942199" FT /id="VAR_042392" FT VARIANT 1673 FT /note="L -> S (in dbSNP:rs56254742)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042393" FT VARIANT 1724 FT /note="T -> I (in dbSNP:rs56290308)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042394" FT VARIANT 1754 FT /note="S -> N (in HOMG1; abolishes channel activity; no FT effect on cell membrane localization)" FT /evidence="ECO:0000269|PubMed:23942199" FT /id="VAR_071484" FT MUTAGEN 1063..1065 FT /note="NLL->FAP: Abolishes channel activity. Abolishes FT endogenous protein cleavage." FT /evidence="ECO:0000269|PubMed:28784805" FT MUTAGEN 1804 FT /note="K->R: Abolishes kinase activity but does not affect FT expression levels or binding to RACK1." FT /evidence="ECO:0000269|PubMed:18258429" FT MUTAGEN 1851 FT /note="T->A: Significantly decreases autophosphorylation. FT Does not alter binding to RACK1 but prevents inhibition by FT RACK1." FT /evidence="ECO:0000269|PubMed:18258429" FT MUTAGEN 1851 FT /note="T->D: Significantly decreases autophosphorylation. FT Does not alter binding to RACK1 or inhibition by RACK1." FT /evidence="ECO:0000269|PubMed:18258429" SQ SEQUENCE 2022 AA; 231708 MW; 59346B3BE3300466 CRC64; MKEQPVLERL QSQKSWIKGV FDKRECSTII PSSKNPHRCT PVCQVCQNLI RCYCGRLIGD HAGIDYSWTI SAAKGKESEQ WSVEKHTTKS PTDTFGTINF QDGEHTHHAK YIRTSYDTKL DHLLHLMLKE WKMELPKLVI SVHGGIQNFT MPSKFKEIFS QGLVKAAETT GAWIITEGIN TGVSKHVGDA LKSHSSHSLR KIWTVGIPPW GVIENQRDLI GKDVVCLYQT LDNPLSKLTT LNSMHSHFIL SDDGTVGKYG NEMKLRRNLE KYLSLQKIHC RSRQGVPVVG LVVEGGPNVI LSVWETVKDK DPVVVCEGTG RAADLLAFTH KHLADEGMLR PQVKEEIICM IQNTFNFSLK QSKHLFQILM ECMVHRDCIT IFDADSEEQQ DLDLAILTAL LKGTNLSASE QLNLAMAWDR VDIAKKHILI YEQHWKPDAL EQAMSDALVM DRVDFVKLLI EYGVNLHRFL TIPRLEELYN TKQGPTNTLL HHLVQDVKQH TLLSGYRITL IDIGLVVEYL IGRAYRSNYT RKHFRALYNN LYRKYKHQRH SSGNRNESAE STLHSQFIRT AQPYKFKEKS IVLHKSRKKS KEQNVSDDPE STGFLYPYND LLVWAVLMKR QKMAMFFWQH GEEATVKAVI ACILYRAMAH EAKESHMVDD ASEELKNYSK QFGQLALDLL EKAFKQNERM AMTLLTYELR NWSNSTCLKL AVSGGLRPFV SHTCTQMLLT DMWMGRLKMR KNSWLKIIIS IILPPTILTL EFKSKAEMSH VPQSQDFQFM WYYSDQNASS SKESASVKEY DLERGHDEKL DENQHFGLES GHQHLPWTRK VYEFYSAPIV KFWFYTMAYL AFLMLFTYTV LVEMQPQPSV QEWLVSIYIF TNAIEVVREI CISEPGKFTQ KVKVWISEYW NLTETVAIGL FSAGFVLRWG DPPFHTAGRL IYCIDIIFWF SRLLDFFAVN QHAGPYVTMI AKMTANMFYI VIIMAIVLLS FGVARKAILS PKEPPSWSLA RDIVFEPYWM IYGEVYAGEI DVCSSQPSCP PGSFLTPFLQ AVYLFVQYII MVNLLIAFFN NVYLDMESIS NNLWKYNRYR YIMTYHEKPW LPPPLILLSH VGLLLRRLCC HRAPHDQEEG DVGLKLYLSK EDLKKLHDFE EQCVEKYFHE KMEDVNCSCE ERIRVTSERV TEMYFQLKEM NEKVSFIKDS LLSLDSQVGH LQDLSALTVD TLKVLSAVDT LQEDEALLAK RKHSTCKKLP HSWSNVICAE VLGSMEIAGE KKYQYYSMPS SLLRSLAGGR HPPRVQRGAL LEITNSKREA TNVRNDQERQ ETQSSIVVSG VSPNRQAHSK YGQFLLVPSN LKRVPFSAET VLPLSRPSVP DVLATEQDIQ TEVLVHLTGQ TPVVSDWASV DEPKEKHEPI AHLLDGQDKA EQVLPTLSCT PEPMTMSSPL SQAKIMQTGG GYVNWAFSEG DETGVFSIKK KWQTCLPSTC DSDSSRSEQH QKQAQDSSLS DNSTRSAQSS ECSEVGPWLQ PNTSFWINPL RRYRPFARSH SFRFHKEEKL MKICKIKNLS GSSEIGQGAW VKAKMLTKDR RLSKKKKNTQ GLQVPIITVN ACSQSDQLNP EPGENSISEE EYSKNWFTVS KFSHTGVEPY IHQKMKTKEI GQCAIQISDY LKQSQEDLSK NSLWNSRSTN LNRNSLLKSS IGVDKISASL KSPQEPHHHY SAIERNNLMR LSQTIPFTPV QLFAGEEITV YRLEESSPLN LDKSMSSWSQ RGRAAMIQVL SREEMDGGLR KAMRVVSTWS EDDILKPGQV FIVKSFLPEV VRTWHKIFQE STVLHLCLRE IQQQRAAQKL IYTFNQVKPQ TIPYTPRFLE VFLIYCHSAN QWLTIEKYMT GEFRKYNNNN GDEITPTNTL EELMLAFSHW TYEYTRGELL VLDLQGVGEN LTDPSVIKPE VKQSRGMVFG PANLGEDAIR NFIAKHHCNS CCRKLKLPDL KRNDYSPERI NSTFGLEIKI ESAEEPPARE TGRNSPEDDM QL // ID TRRAP_HUMAN Reviewed; 3859 AA. AC Q9Y4A5; A4D265; O75218; Q9Y631; Q9Y6H4; DT 28-NOV-2003, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 3. DT 28-JAN-2026, entry version 226. DE RecName: Full=Transformation/transcription domain-associated protein; DE AltName: Full=350/400 kDa PCAF-associated factor; DE Short=PAF350/400; DE AltName: Full=STAF40; DE AltName: Full=Tra1 homolog; GN Name=TRRAP; Synonyms=PAF400; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), PARTIAL PROTEIN SEQUENCE, FUNCTION, RP SUBCELLULAR LOCATION, AND INTERACTION WITH MYC AND E2F1. RC TISSUE=Cervix carcinoma; RX PubMed=9708738; DOI=10.1016/s0092-8674(00)81479-8; RA McMahon S.B., Van Buskirk H.A., Dugan K.A., Copeland T.D., Cole M.D.; RT "The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc RT and E2F oncoproteins."; RL Cell 94:363-374(1998). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 41-90; 337-344; RP 369-387; 879-892; 997-1005; 1171-1184; 1237-1247; 1545-1560; 1815-1820; RP 1922-1934; 2211-2218; 2260-2275; 2534-2547; 2583-2594; 2706-2726; RP 2830-2844; 3567-3573; 3583-3598; 3604-3614; 3712-3730 AND 3822-3834, AND RP IDENTIFICATION IN THE PCAF COMPLEX WITH TADA2L; TADA3L; TAF5L; TAF6L; RP TAF10; SUPT3H; TAF12 AND TAF9. RC TISSUE=Fetal heart; RX PubMed=9885574; DOI=10.1016/s1097-2765(00)80301-9; RA Vassilev A., Yamauchi J., Kotani T., Prives C., Avantaggiati M.L., Qin J., RA Nakatani Y.; RT "The 400 kDa subunit of the PCAF histone acetylase complex belongs to the RT ATM superfamily."; RL Mol. Cell 2:869-875(1998). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12853948; DOI=10.1038/nature01782; RA Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H., RA Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K., RA Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A., RA Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H., RA Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A., RA Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P., RA Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M., RA Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S., RA Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., RA Strowmatt C., Latreille P., Miller N., Johnson D., Murray J., RA Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., RA Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., RA Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E., RA Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E., RA Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A., RA Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A., RA Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R., RA McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H., RA Wilson R.K.; RT "The DNA sequence of human chromosome 7."; RL Nature 424:157-164(2003). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12690205; DOI=10.1126/science.1083423; RA Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K., RA Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R., RA Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A., RA Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D., RA Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S., RA Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R., RA Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N., RA Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E., RA Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R., RA Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T., RA Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W., RA Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A., RA Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X., RA Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E., RA Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H., RA Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J., RA Adams M.D., Tsui L.-C.; RT "Human chromosome 7: DNA sequence and biology."; RL Science 300:767-772(2003). RN [6] RP SUBCELLULAR LOCATION, IDENTIFICATION IN THE STAGA COMPLEX WITH SUPT3H; RP GCN5L2; KIAA0764; TAF5L; TAF6L; TADA3L; TAF10; TAF12 AND TAF9, AND RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=11564863; DOI=10.1128/mcb.21.20.6782-6795.2001; RA Martinez E., Palhan V.B., Tjernberg A., Lymar E.S., Gamper A.M., RA Kundu T.K., Chait B.T., Roeder R.G.; RT "Human STAGA complex is a chromatin-acetylating transcription coactivator RT that interacts with pre-mRNA splicing and DNA damage-binding factors in RT vivo."; RL Mol. Cell. Biol. 21:6782-6795(2001). RN [7] RP IDENTIFICATION IN THE TFTC-HAT COMPLEX WITH TAF5L; TAF6L; TADA3L; SUPT3H; RP TAF2; TAF4; TAF5; GCN5L2 AND TAF10. RX PubMed=10373431; DOI=10.1074/jbc.274.26.18285; RA Brand M., Yamamoto K., Staub A., Tora L.; RT "Identification of TATA-binding protein-free TAFII-containing complex RT subunits suggests a role in nucleosome acetylation and signal RT transduction."; RL J. Biol. Chem. 274:18285-18289(1999). RN [8] RP IDENTIFICATION IN THE TIP60 HAT COMPLEX WITH KAT5; RUVBL1 AND RUVBL2. RX PubMed=10966108; DOI=10.1016/s0092-8674(00)00051-9; RA Ikura T., Ogryzko V.V., Grigoriev M., Groisman R., Wang J., Horikoshi M., RA Scully R., Qin J., Nakatani Y.; RT "Involvement of the TIP60 histone acetylase complex in DNA repair and RT apoptosis."; RL Cell 102:463-473(2000). RN [9] RP INTERACTION WITH GCN5L2. RX PubMed=10611234; DOI=10.1128/mcb.20.2.556-562.2000; RA McMahon S.B., Wood M.A., Cole M.D.; RT "The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 RT to c-Myc."; RL Mol. Cell. Biol. 20:556-562(2000). RN [10] RP INTERACTION WITH E2F1 AND E2F4, AND FUNCTION. RX PubMed=11418595; DOI=10.1074/jbc.m102067200; RA Lang S.E., McMahon S.B., Cole M.D., Hearing P.; RT "E2F transcriptional activation requires TRRAP and GCN5 cofactors."; RL J. Biol. Chem. 276:32627-32634(2001). RN [11] RP DOMAIN. RX PubMed=11445536; DOI=10.1101/gad.900101; RA Park J., Kunjibettu S., McMahon S.B., Cole M.D.; RT "The ATM-related domain of TRRAP is required for histone acetyltransferase RT recruitment and Myc-dependent oncogenesis."; RL Genes Dev. 15:1619-1624(2001). RN [12] RP FUNCTION, AND INTERACTION WITH TP53. RX PubMed=12138177; DOI=10.1128/mcb.22.16.5650-5661.2002; RA Ard P.G., Chatterjee C., Kunjibettu S., Adside L.R., Gralinski L.E., RA McMahon S.B.; RT "Transcriptional regulation of the mdm2 oncogene by p53 requires TRRAP RT acetyltransferase complexes."; RL Mol. Cell. Biol. 22:5650-5661(2002). RN [13] RP IDENTIFICATION IN THE BAF53 COMPLEX WITH BAF53A; RUVBL1 AND SMARCA4. RX PubMed=11839798; DOI=10.1128/mcb.22.5.1307-1316.2002; RA Park J., Wood M.A., Cole M.D.; RT "BAF53 forms distinct nuclear complexes and functions as a critical c-Myc- RT interacting nuclear cofactor for oncogenic transformation."; RL Mol. Cell. Biol. 22:1307-1316(2002). RN [14] RP FUNCTION. RX PubMed=12743606; DOI=10.1038/sj.onc.1206376; RA Lang S.E., Hearing P.; RT "The adenovirus E1A oncoprotein recruits the cellular TRRAP/GCN5 histone RT acetyltransferase complex."; RL Oncogene 22:2836-2841(2003). RN [15] RP FUNCTION. RX PubMed=12660246; DOI=10.1074/jbc.m211795200; RA Liu X., Tesfai J., Evrard Y.A., Dent S.Y.R., Martinez E.; RT "c-Myc transformation domain recruits the human STAGA complex and requires RT TRRAP and GCN5 acetylase activity for transcription activation."; RL J. Biol. Chem. 278:20405-20412(2003). RN [16] RP FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE RP NUA4 COMPLEX. RX PubMed=14966270; DOI=10.1128/mcb.24.5.1884-1896.2004; RA Doyon Y., Selleck W., Lane W.S., Tan S., Cote J.; RT "Structural and functional conservation of the NuA4 histone RT acetyltransferase complex from yeast to humans."; RL Mol. Cell. Biol. 24:1884-1896(2004). RN [17] RP IDENTIFICATION IN STAGA COMPLEX. RX PubMed=18206972; DOI=10.1016/j.molcel.2007.12.011; RA Zhao Y., Lang G., Ito S., Bonnet J., Metzger E., Sawatsubashi S., RA Suzuki E., Le Guezennec X., Stunnenberg H.G., Krasnov A., Georgieva S.G., RA Schuele R., Takeyama K., Kato S., Tora L., Devys D.; RT "A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, RT coactivates nuclear receptors, and counteracts heterochromatin silencing."; RL Mol. Cell 29:92-101(2008). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2051, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [19] RP FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, AND INTERACTION WITH NPAT. RX PubMed=17967892; DOI=10.1128/mcb.00607-07; RA DeRan M., Pulvino M., Greene E., Su C., Zhao J.; RT "Transcriptional activation of histone genes requires NPAT-dependent RT recruitment of TRRAP-Tip60 complex to histone promoters during the G1/S RT phase transition."; RL Mol. Cell. Biol. 28:435-447(2008). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2051 AND SER-2077, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [21] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-3078, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [22] RP INTERACTION WITH TELO2 AND TTI1. RX PubMed=20427287; DOI=10.1074/jbc.m110.121699; RA Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K., RA Iemura S., Natsume T., Mizushima N.; RT "Tti1 and Tel2 are critical factors in mammalian target of rapamycin RT complex assembly."; RL J. Biol. Chem. 285:20109-20116(2010). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [24] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [25] RP PROBABLE INVOLVEMENT IN MELANOMA, VARIANT PHE-722, AND CHARACTERIZATION OF RP VARIANT PHE-722. RX PubMed=21499247; DOI=10.1038/ng.810; RA Wei X., Walia V., Lin J.C., Teer J.K., Prickett T.D., Gartner J., Davis S., RA Stemke-Hale K., Davies M.A., Gershenwald J.E., Robinson W., Robinson S., RA Rosenberg S.A., Samuels Y.; RT "Exome sequencing identifies GRIN2A as frequently mutated in melanoma."; RL Nat. Genet. 43:442-446(2011). RN [26] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22223895; DOI=10.1074/mcp.m111.015131; RA Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T., RA Giglione C.; RT "Comparative large-scale characterisation of plant vs. mammal proteins RT reveals similar and idiosyncratic N-alpha acetylation features."; RL Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1628; SER-2051 AND SER-2077, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [28] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [29] RP FUNCTION, AND IDENTIFICATION IN THE SWR1-LIKE COMPLEX. RX PubMed=24463511; DOI=10.1038/nature12922; RA Obri A., Ouararhni K., Papin C., Diebold M.L., Padmanabhan K., Marek M., RA Stoll I., Roy L., Reilly P.T., Mak T.W., Dimitrov S., Romier C., RA Hamiche A.; RT "ANP32E is a histone chaperone that removes H2A.Z from chromatin."; RL Nature 505:648-653(2014). RN [30] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-2543, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [31] RP VARIANTS [LARGE SCALE ANALYSIS] CYS-893; GLY-1070; HIS-1669; HIS-1724; RP VAL-1925; LEU-1932; LEU-1947; GLY-2139; TRP-2302; GLY-2433; LEU-2690; RP ASP-2750; GLU-2801 AND MET-2931. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [32] RP INVOLVEMENT IN DEDDFA, AND VARIANT DEDDFA GLN-2004. RX PubMed=30424743; DOI=10.1186/s12881-018-0711-9; RA Mavros C.F., Brownstein C.A., Thyagrajan R., Genetti C.A., Tembulkar S., RA Graber K., Murphy Q., Cabral K., VanNoy G.E., Bainbridge M., Shi J., RA Agrawal P.B., Beggs A.H., D'Angelo E., Gonzalez-Heydrich J.; RT "De novo variant of TRRAP in a patient with very early onset psychosis in RT the context of non-verbal learning disability and obsessive-compulsive RT disorder: a case report."; RL BMC Med. Genet. 19:197-197(2018). RN [33] RP VARIANTS DEDDFA PHE-805; LEU-860; LEU-893; MET-1031; GLN-1035; ARG-1037; RP THR-1043; GLY-1104; LYS-1106; TRP-1111; ARG-1159; CYS-1859; CYS-1866; RP ARG-1866; ARG-1883; LEU-1932 AND GLN-3757. RX PubMed=30827496; DOI=10.1016/j.ajhg.2019.01.010; RG CAUSES Study; RG Deciphering Developmental Disorders study; RA Cogne B., Ehresmann S., Beauregard-Lacroix E., Rousseau J., Besnard T., RA Garcia T., Petrovski S., Avni S., McWalter K., Blackburn P.R., RA Sanders S.J., Uguen K., Harris J., Cohen J.S., Blyth M., Lehman A., RA Berg J., Li M.H., Kini U., Joss S., von der Lippe C., Gordon C.T., RA Humberson J.B., Robak L., Scott D.A., Sutton V.R., Skraban C.M., RA Johnston J.J., Poduri A., Nordenskjoeld M., Shashi V., Gerkes E.H., RA Bongers E.M.H.F., Gilissen C., Zarate Y.A., Kvarnung M., Lally K.P., RA Kulch P.A., Daniels B., Hernandez-Garcia A., Stong N., McGaughran J., RA Retterer K., Tveten K., Sullivan J., Geisheker M.R., Stray-Pedersen A., RA Tarpinian J.M., Klee E.W., Sapp J.C., Zyskind J., Holla O.L., Bedoukian E., RA Filippini F., Guimier A., Picard A., Busk O.L., Punetha J., Pfundt R., RA Lindstrand A., Nordgren A., Kalb F., Desai M., Ebanks A.H., Jhangiani S.N., RA Dewan T., Coban Akdemir Z.H., Telegrafi A., Zackai E.H., Begtrup A., RA Song X., Toutain A., Wentzensen I.M., Odent S., Bonneau D., Latypova X., RA Deb W., Redon S., Bilan F., Legendre M., Troyer C., Whitlock K., RA Caluseriu O., Murphree M.I., Pichurin P.N., Agre K., Gavrilova R., RA Rinne T., Park M., Shain C., Heinzen E.L., Xiao R., Amiel J., Lyonnet S., RA Isidor B., Biesecker L.G., Lowenstein D., Posey J.E., Denomme-Pichon A.S., RA Ferec C., Yang X.J., Rosenfeld J.A., Gilbert-Dussardier B., RA Audebert-Bellanger S., Redon R., Stessman H.A.F., Nellaker C., Yang Y., RA Lupski J.R., Goldstein D.B., Eichler E.E., Bolduc F., Bezieau S., Kuery S., RA Campeau P.M.; RT "Missense Variants in the Histone Acetyltransferase Complex Component Gene RT TRRAP Cause Autism and Syndromic Intellectual Disability."; RL Am. J. Hum. Genet. 104:530-541(2019). RN [34] RP VARIANTS DFNA75 CYS-171 AND ASN-394, VARIANT ASP-2750, AND INVOLVEMENT IN RP DFNA75. RX PubMed=31231791; DOI=10.1111/cge.13590; RA Xia W., Hu J., Ma J., Huang J., Wang X., Jiang N., Zhang J., Ma Z., Ma D.; RT "Novel TRRAP mutation causes autosomal dominant non-syndromic hearing RT loss."; RL Clin. Genet. 96:300-308(2019). CC -!- FUNCTION: Adapter protein, which is found in various multiprotein CC chromatin complexes with histone acetyltransferase activity (HAT), CC which gives a specific tag for epigenetic transcription activation. CC Component of the NuA4 histone acetyltransferase complex which is CC responsible for acetylation of nucleosomal histones H4 and H2A. Plays a CC central role in MYC transcription activation, and also participates in CC cell transformation by MYC. Required for p53/TP53-, E2F1- and E2F4- CC mediated transcription activation. Also involved in transcription CC activation mediated by the adenovirus E1A, a viral oncoprotein that CC deregulates transcription of key genes. Probably acts by linking CC transcription factors such as E1A, MYC or E2F1 to HAT complexes such as CC STAGA thereby allowing transcription activation. Probably not required CC in the steps following histone acetylation in processes of CC transcription activation. May be required for the mitotic checkpoint CC and normal cell cycle progression. Component of a SWR1-like complex CC that specifically mediates the removal of histone H2A.Z/H2AZ1 from the CC nucleosome. May play a role in the formation and maintenance of the CC auditory system (By similarity). {ECO:0000250|UniProtKB:A0A0R4ITC5, CC ECO:0000269|PubMed:11418595, ECO:0000269|PubMed:12138177, CC ECO:0000269|PubMed:12660246, ECO:0000269|PubMed:12743606, CC ECO:0000269|PubMed:14966270, ECO:0000269|PubMed:17967892, CC ECO:0000269|PubMed:24463511, ECO:0000269|PubMed:9708738}. CC -!- SUBUNIT: Interacts with MYC, E2F1 and E2F4 transcription factors. CC Interacts directly with p53/TP53. Interacts with GCN5L2. Component of CC various HAT complexes. Component of the PCAF complex, at least composed CC of TADA2L/ADA2, SUPT3H, TADA3L/ADA3, TAF5L/PAF65-beta, TAF6L/PAF65- CC alpha, TAF10/TAFII30, TAF12/TAFII20, TAF9/TAFII31 and TRRAP. Component CC of the TFTC-HAT complex, at least composed of TAF5L, TAF6L, TADA3L, CC SUPT3H/SPT3, TAF2/TAFII150, TAF4/TAFII135, TAF5/TAFII100, GCN5L2/GCN5, CC TAF10 and TRRAP. Component of the NuA4 histone acetyltransferase CC complex which contains the catalytic subunit KAT5/TIP60 and the CC subunits EP400, TRRAP/PAF400, BRD8/SMAP, EPC1, DMAP1/DNMAP1, CC RUVBL1/TIP49, RUVBL2, ING3, actin, ACTL6A/BAF53A, MORF4L1/MRG15, CC MORF4L2/MRGX, MRGBP, YEATS4/GAS41, VPS72/YL1 and MEAF6. Component of CC the STAGA complex, at least composed of SUPT3H, GCN5L2, SUPT7L, TAF5L, CC TAF6L, TADA3L, TAD1L, TAF10, TAF12, TRRAP and TAF9. The STAGA core CC complex is associated with a subcomplex required for histone CC deubiquitination composed of ATXN7L3, ENY2 and USP22. Component of the CC BAF53 complex, at least composed of BAF53A, RUVBL1, SMARCA4/BRG1, and CC TRRAP, which preferentially acetylates histone H4 (and H2A) within CC nucleosomes. Interacts with NPAT. Interaction with TELO2 and TTI1. CC Component of a SWR1-like complex. {ECO:0000269|PubMed:10373431, CC ECO:0000269|PubMed:10611234, ECO:0000269|PubMed:10966108, CC ECO:0000269|PubMed:11418595, ECO:0000269|PubMed:11564863, CC ECO:0000269|PubMed:11839798, ECO:0000269|PubMed:12138177, CC ECO:0000269|PubMed:14966270, ECO:0000269|PubMed:17967892, CC ECO:0000269|PubMed:18206972, ECO:0000269|PubMed:20427287, CC ECO:0000269|PubMed:24463511, ECO:0000269|PubMed:9708738, CC ECO:0000269|PubMed:9885574}. CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11564863, CC ECO:0000269|PubMed:9708738}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q9Y4A5-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9Y4A5-2; Sequence=VSP_009102, VSP_009103; CC -!- DOMAIN: The PI3K/PI4K domain is required for the recruitment of HAT CC complexes, and the MYC-dependent transactivation. Although it is CC strongly related to the PI3/PI4-kinase family, it lacks the typical CC motifs that constitute the catalytic site of PI3/PI4-kinase proteins, CC and lacks such activity. {ECO:0000269|PubMed:11445536}. CC -!- DISEASE: Note=TRRAP mutation Phe-722 has been frequently found in CC cutaneous malignant melanoma, suggesting that TRRAP may play a role in CC the pathogenesis of melanoma. {ECO:0000269|PubMed:21499247}. CC -!- DISEASE: Developmental delay with or without dysmorphic facies and CC autism (DEDDFA) [MIM:618454]: An autosomal dominant neurodevelopmental CC disorder apparent from infancy or early childhood. Some patients CC present with intellectual disability and renal, cardiac, genitourinary CC systems, as well as structural brain abnormalities. In some cases, the CC phenotype is less severe, has no systemic involvement and is CC characterized by autism spectrum disorder and/or intellectual CC disability, sometimes associated with epilepsy. Affected individuals CC manifest variable dysmorphic features. {ECO:0000269|PubMed:30424743, CC ECO:0000269|PubMed:30827496}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Deafness, autosomal dominant, 75 (DFNA75) [MIM:618778]: A form CC of non-syndromic deafness characterized by late-onset hearing loss that CC involves mid and high frequencies, and progresses to encompass all CC frequencies. {ECO:0000269|PubMed:31231791}. Note=The disease may be CC caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. TRA1 subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC62433.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF076974; AAD09420.1; -; mRNA. DR EMBL; AF110377; AAD04629.1; -; mRNA. DR EMBL; AC004893; AAC62433.1; ALT_SEQ; Genomic_DNA. DR EMBL; AC004991; AAC27675.2; -; Genomic_DNA. DR EMBL; CH471091; EAW76694.1; -; Genomic_DNA. DR EMBL; CH236956; EAL23887.1; -; Genomic_DNA. DR CCDS; CCDS5659.1; -. [Q9Y4A5-2] DR CCDS; CCDS59066.1; -. [Q9Y4A5-1] DR PIR; T02632; T02632. DR RefSeq; NP_001231509.1; NM_001244580.2. [Q9Y4A5-1] DR RefSeq; NP_003487.1; NM_003496.4. [Q9Y4A5-2] DR PDB; 7KTR; EM; 2.93 A; A=369-3859. DR PDB; 8H7G; EM; 3.70 A; C=1-3859. DR PDB; 8QRI; EM; 3.50 A; C=1-3859. DR PDB; 8XVG; EM; 9.40 A; L=1-3859. DR PDB; 8XVV; EM; 3.20 A; L=1-3859. DR PDB; 9C47; EM; 3.40 A; C=1-3859. DR PDB; 9CAD; EM; 3.05 A; D=1-3859. DR PDB; 9CAF; EM; 2.35 A; D=1-3859. DR PDBsum; 7KTR; -. DR PDBsum; 8H7G; -. DR PDBsum; 8QRI; -. DR PDBsum; 8XVG; -. DR PDBsum; 8XVV; -. DR PDBsum; 9C47; -. DR PDBsum; 9CAD; -. DR PDBsum; 9CAF; -. DR EMDB; EMD-18612; -. DR EMDB; EMD-18613; -. DR EMDB; EMD-18618; -. DR EMDB; EMD-18619; -. DR EMDB; EMD-34520; -. DR EMDB; EMD-38703; -. DR EMDB; EMD-38720; -. DR EMDB; EMD-45176; -. DR EMDB; EMD-45387; -. DR EMDB; EMD-45389; -. DR SMR; Q9Y4A5; -. DR BioGRID; 113900; 797. DR ComplexPortal; CPX-6802; SAGA complex, KAT2B variant. DR ComplexPortal; CPX-900; SAGA complex, KAT2A variant. DR ComplexPortal; CPX-903; TFTC histone acetylation complex. DR ComplexPortal; CPX-978; NuA4 histone acetyltransferase complex. DR ComplexPortal; CPX-989; PCAF histone acetylase complex. DR CORUM; Q9Y4A5; -. DR DIP; DIP-28149N; -. DR FunCoup; Q9Y4A5; 1798. DR MINT; Q9Y4A5; -. DR STRING; 9606.ENSP00000352925; -. DR GlyGen; Q9Y4A5; 9 sites, 2 N-linked glycans (2 sites), 1 O-linked glycan (5 sites). DR iPTMnet; Q9Y4A5; -. DR MetOSite; Q9Y4A5; -. DR PhosphoSitePlus; Q9Y4A5; -. DR SwissPalm; Q9Y4A5; -. DR BioMuta; TRRAP; -. DR DMDM; 116242829; -. DR jPOST; Q9Y4A5; -. DR MassIVE; Q9Y4A5; -. DR PaxDb; 9606-ENSP00000352925; -. DR PeptideAtlas; Q9Y4A5; -. DR ProteomicsDB; 86142; -. [Q9Y4A5-1] DR ProteomicsDB; 86143; -. [Q9Y4A5-2] DR Pumba; Q9Y4A5; -. DR Antibodypedia; 16027; 189 antibodies from 23 providers. DR DNASU; 8295; -. DR Ensembl; ENST00000355540.7; ENSP00000347733.3; ENSG00000196367.15. [Q9Y4A5-2] DR Ensembl; ENST00000359863.8; ENSP00000352925.4; ENSG00000196367.15. [Q9Y4A5-1] DR GeneID; 8295; -. DR KEGG; hsa:8295; -. DR UCSC; uc003upp.3; human. [Q9Y4A5-1] DR AGR; HGNC:12347; -. DR ClinPGx; PA37020; -. DR CTD; 8295; -. DR DisGeNET; 8295; -. DR GeneCards; TRRAP; -. DR HGNC; HGNC:12347; TRRAP. DR HPA; ENSG00000196367; Low tissue specificity. DR MalaCards; TRRAP; -. DR MIM; 603015; gene. DR MIM; 618454; phenotype. DR MIM; 618778; phenotype. DR OpenTargets; ENSG00000196367; -. DR Orphanet; 90635; Rare autosomal dominant non-syndromic sensorineural deafness type DFNA. DR VEuPathDB; HostDB:ENSG00000196367; -. DR eggNOG; KOG0889; Eukaryota. DR GeneTree; ENSGT00390000017961; -. DR InParanoid; Q9Y4A5; -. DR OrthoDB; 5570127at2759; -. DR PAN-GO; Q9Y4A5; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q9Y4A5; -. DR PathwayCommons; Q9Y4A5; -. DR Reactome; R-HSA-201722; Formation of the beta-catenin:TCF transactivating complex. DR Reactome; R-HSA-3214847; HATs acetylate histones. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR SignaLink; Q9Y4A5; -. DR SIGNOR; Q9Y4A5; -. DR Agora; ENSG00000196367; -. DR BioGRID-ORCS; 8295; 773 hits in 1197 CRISPR screens. DR ChiTaRS; TRRAP; human. DR GenomeRNAi; 8295; -. DR Pharos; Q9Y4A5; Tbio. DR PRO; PR:Q9Y4A5; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; Q9Y4A5; protein. DR Bgee; ENSG00000196367; Expressed in ventricular zone and 156 other cell types or tissues. DR ExpressionAtlas; Q9Y4A5; baseline and differential. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0035267; C:NuA4 histone acetyltransferase complex; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0000786; C:nucleosome; IDA:ComplexPortal. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0000124; C:SAGA complex; IDA:UniProtKB. DR GO; GO:0000812; C:Swr1 complex; IDA:UniProtKB. DR GO; GO:0033276; C:transcription factor TFTC complex; IDA:UniProtKB. DR GO; GO:0003712; F:transcription coregulator activity; IDA:UniProtKB. DR GO; GO:0140861; P:DNA repair-dependent chromatin remodeling; IBA:GO_Central. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; NAS:ComplexPortal. DR GO; GO:1905168; P:positive regulation of double-strand break repair via homologous recombination; IDA:ComplexPortal. DR GO; GO:0042981; P:regulation of apoptotic process; NAS:ComplexPortal. DR GO; GO:0051726; P:regulation of cell cycle; IMP:ComplexPortal. DR GO; GO:0006282; P:regulation of DNA repair; NAS:ComplexPortal. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IBA:GO_Central. DR GO; GO:2000779; P:regulation of double-strand break repair; NAS:ComplexPortal. DR GO; GO:0043484; P:regulation of RNA splicing; NAS:ComplexPortal. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:ComplexPortal. DR CDD; cd05163; PIKK_TRRAP; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR050517; DDR_Repair_Kinase. DR InterPro; IPR003152; FATC_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR003151; PIK-rel_kinase_FAT. DR InterPro; IPR014009; PIK_FAT. DR InterPro; IPR046807; Tra1_central. DR InterPro; IPR046805; Tra1_ring. DR PANTHER; PTHR11139; ATAXIA TELANGIECTASIA MUTATED ATM -RELATED; 1. DR PANTHER; PTHR11139:SF1; TRANSFORMATION_TRANSCRIPTION DOMAIN-ASSOCIATED PROTEIN; 1. DR Pfam; PF02259; FAT; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR Pfam; PF20175; Tra1_central; 1. DR Pfam; PF20206; Tra1_ring; 1. DR SMART; SM01343; FATC; 1. DR SMART; SM00146; PI3Kc; 1. DR SUPFAM; SSF48371; ARM repeat; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51189; FAT; 1. DR PROSITE; PS51190; FATC; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Activator; Alternative splicing; KW Autism spectrum disorder; Chromatin regulator; Deafness; KW Direct protein sequencing; Disease variant; Intellectual disability; KW Isopeptide bond; Non-syndromic deafness; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Transcription; KW Transcription regulation; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22223895" FT CHAIN 2..3859 FT /note="Transformation/transcription domain-associated FT protein" FT /id="PRO_0000088851" FT DOMAIN 2692..3275 FT /note="FAT" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534" FT DOMAIN 3500..3823 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT DOMAIN 3827..3859 FT /note="FATC" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534, FT ECO:0000255|PROSITE-ProRule:PRU00535" FT REGION 491..541 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2010..2388 FT /note="Interaction with TP53" FT /evidence="ECO:0000269|PubMed:12138177" FT REGION 2023..2044 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2543..2578 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 3506..3512 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 3687..3695 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 3707..3732 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT MOTIF 2047..2062 FT /note="Bipartite nuclear localization signal" FT /evidence="ECO:0000255" FT COMPBIAS 491..526 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 529..539 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2033..2044 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2543..2554 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:22223895" FT MOD_RES 1628 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2051 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:23186163" FT MOD_RES 2077 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 3078 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT CROSSLNK 2543 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 1492..1509 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9708738" FT /id="VSP_009102" FT VAR_SEQ 3001..3012 FT /note="GKPTWSGMHSSS -> A (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9708738" FT /id="VSP_009103" FT VARIANT 171 FT /note="R -> C (in DFNA75; uncertain significance; FT dbSNP:rs200157211)" FT /evidence="ECO:0000269|PubMed:31231791" FT /id="VAR_083794" FT VARIANT 394 FT /note="D -> N (in DFNA75; uncertain significance; FT dbSNP:rs1554407965)" FT /evidence="ECO:0000269|PubMed:31231791" FT /id="VAR_083795" FT VARIANT 722 FT /note="S -> F (found in a cutaneous malignant melanoma FT sample; somatic mutation; induces cell transformation and FT confers resistance to apoptosis; dbSNP:rs147405090)" FT /evidence="ECO:0000269|PubMed:21499247" FT /id="VAR_067754" FT VARIANT 805 FT /note="L -> F (in DEDDFA; uncertain significance; FT dbSNP:rs1562940289)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082969" FT VARIANT 860 FT /note="F -> L (in DEDDFA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082970" FT VARIANT 878 FT /note="R -> L (in dbSNP:rs17161510)" FT /id="VAR_028359" FT VARIANT 893 FT /note="R -> C (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041658" FT VARIANT 893 FT /note="R -> L (in DEDDFA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082971" FT VARIANT 1031 FT /note="I -> M (in DEDDFA; dbSNP:rs1187165148)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082972" FT VARIANT 1035 FT /note="R -> Q (in DEDDFA; uncertain significance; FT dbSNP:rs2116495143)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082973" FT VARIANT 1037 FT /note="S -> R (in DEDDFA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082974" FT VARIANT 1043 FT /note="A -> T (in DEDDFA; dbSNP:rs1562945106)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082975" FT VARIANT 1070 FT /note="S -> G (in dbSNP:rs55920979)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041659" FT VARIANT 1104 FT /note="E -> G (in DEDDFA; dbSNP:rs1790257064)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082976" FT VARIANT 1106 FT /note="E -> K (in DEDDFA; dbSNP:rs1584324956)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082977" FT VARIANT 1111 FT /note="G -> W (in DEDDFA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082978" FT VARIANT 1159 FT /note="G -> R (in DEDDFA; dbSNP:rs1790288810)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082979" FT VARIANT 1669 FT /note="R -> H (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs373632999)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041660" FT VARIANT 1724 FT /note="R -> H (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs782203759)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041661" FT VARIANT 1859 FT /note="R -> C (in DEDDFA; dbSNP:rs1791432323)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082980" FT VARIANT 1866 FT /note="W -> C (in DEDDFA; uncertain significance; FT dbSNP:rs1562957576)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082981" FT VARIANT 1866 FT /note="W -> R (in DEDDFA; dbSNP:rs1562957569)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082982" FT VARIANT 1883 FT /note="G -> R (in DEDDFA)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082983" FT VARIANT 1925 FT /note="A -> V (in dbSNP:rs56197298)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041662" FT VARIANT 1932 FT /note="P -> L (in DEDDFA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:30827496" FT /id="VAR_041663" FT VARIANT 1947 FT /note="R -> L (in an ovarian mucinous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041664" FT VARIANT 2004 FT /note="R -> Q (in DEDDFA; uncertain significance; FT dbSNP:rs1562959030)" FT /evidence="ECO:0000269|PubMed:30424743" FT /id="VAR_082984" FT VARIANT 2139 FT /note="W -> G (in dbSNP:rs34185633)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041665" FT VARIANT 2302 FT /note="R -> W (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs528967912)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041666" FT VARIANT 2433 FT /note="S -> G (in dbSNP:rs35634065)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041667" FT VARIANT 2690 FT /note="P -> L (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs753661271)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041668" FT VARIANT 2750 FT /note="E -> D (in dbSNP:rs55755466)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:31231791" FT /id="VAR_041669" FT VARIANT 2801 FT /note="K -> E (in dbSNP:rs56341061)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041670" FT VARIANT 2931 FT /note="T -> M (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs1294404368)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041671" FT VARIANT 3757 FT /note="R -> Q (in DEDDFA; uncertain significance; FT dbSNP:rs987263983)" FT /evidence="ECO:0000269|PubMed:30827496" FT /id="VAR_082985" FT CONFLICT 660 FT /note="E -> D (in Ref. 2; AAD04629)" FT /evidence="ECO:0000305" FT HELIX 20..26 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 30..33 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 37..50 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 55..57 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 59..74 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 80..84 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 85..99 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 107..118 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 122..124 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 128..139 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 140..142 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 145..147 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 148..171 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 214..227 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 234..243 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 244..254 FT /evidence="ECO:0007829|PDB:9C47" FT TURN 255..259 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 276..293 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 294..298 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 307..319 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 320..322 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 325..338 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 339..341 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 342..345 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 347..351 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 352..354 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 357..359 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 365..367 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 371..385 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 387..389 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 392..406 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 409..411 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 413..434 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 436..438 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 442..469 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 535..564 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 583..599 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 600..604 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 605..607 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 609..611 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 613..615 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 624..626 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 627..639 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 644..654 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 657..664 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 666..668 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 669..677 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 679..681 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 682..695 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 698..702 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 704..723 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 725..732 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 733..735 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 736..747 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 754..768 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 774..779 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 780..782 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 783..795 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 800..811 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 817..820 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 821..827 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 828..835 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 839..855 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 858..865 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 866..868 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 869..879 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 885..898 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 899..903 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 923..927 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 929..931 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 934..938 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 940..951 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 952..955 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 957..973 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 981..988 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 992..995 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1005..1007 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1013..1029 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1032..1034 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1035..1057 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1058..1061 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1064..1066 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1067..1069 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1074..1076 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1080..1082 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1085..1087 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1091..1101 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1102..1104 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1107..1126 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1129..1132 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1136..1146 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1147..1150 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1151..1153 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1154..1170 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1173..1193 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1194..1196 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1199..1201 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1202..1218 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1223..1225 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1228..1248 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1254..1271 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1275..1279 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1280..1285 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1287..1289 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1297..1299 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1302..1315 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1317..1320 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1327..1329 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1330..1344 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1347..1351 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1354..1357 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 1360..1362 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 1363..1375 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1376..1378 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 1380..1382 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1383..1394 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1399..1413 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1415..1418 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1420..1431 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1432..1434 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1435..1437 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1442..1454 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1456..1458 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1461..1484 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1490..1492 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1511..1523 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1524..1526 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 1529..1531 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1532..1546 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1549..1551 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1555..1562 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1566..1573 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1576..1579 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1582..1592 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1594..1596 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1598..1605 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1609..1612 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 1613..1615 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1638..1653 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1657..1659 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1661..1672 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1674..1681 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1692..1706 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1707..1709 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1710..1715 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1716..1718 FT /evidence="ECO:0007829|PDB:8XVV" FT TURN 1719..1721 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1723..1725 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1728..1738 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1740..1743 FT /evidence="ECO:0007829|PDB:8XVV" FT TURN 1746..1748 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1749..1758 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1760..1766 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1770..1773 FT /evidence="ECO:0007829|PDB:8XVV" FT TURN 1774..1776 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1777..1786 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1804..1813 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1818..1820 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1828..1841 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1846..1853 FT /evidence="ECO:0007829|PDB:8XVV" FT TURN 1854..1859 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1861..1870 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1877..1893 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1900..1911 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 1913..1915 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1921..1925 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 1928..1931 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1936..1938 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1939..1943 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1950..1964 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1966..1970 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 1972..1974 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 1976..1985 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 1990..2000 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2003..2016 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2021..2026 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2031..2042 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2045..2060 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2064..2073 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2077..2088 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2096..2099 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2105..2111 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 2114..2118 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2120..2133 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2139..2141 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2146..2154 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2155..2157 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 2158..2161 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2165..2182 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2184..2189 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2191..2200 FT /evidence="ECO:0007829|PDB:8XVV" FT TURN 2201..2203 FT /evidence="ECO:0007829|PDB:8XVV" FT STRAND 2205..2207 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 2212..2219 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2226..2232 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2233..2235 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2240..2251 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2257..2273 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2278..2286 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2287..2290 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 2292..2294 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 2295..2299 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2301..2312 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2320..2331 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2340..2357 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2361..2375 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2382..2384 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2389..2406 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2411..2426 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 2429..2434 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2435..2439 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2440..2448 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2452..2464 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2470..2478 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2483..2486 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2492..2500 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 2506..2508 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 2514..2516 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2523..2527 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2530..2538 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2586..2602 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2607..2618 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2622..2639 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2642..2656 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2659..2666 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2671..2679 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 2682..2684 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 2690..2699 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2703..2714 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 2718..2720 FT /evidence="ECO:0007829|PDB:8QRI" FT HELIX 2728..2730 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2742..2755 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2758..2768 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2772..2781 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 2782..2784 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2786..2806 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2811..2813 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2814..2830 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2834..2841 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 2844..2847 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2849..2856 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2857..2859 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2862..2872 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 2873..2875 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2878..2880 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2881..2894 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2904..2919 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2928..2930 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2931..2952 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2955..2957 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2961..2976 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 2985..3000 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3012..3020 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3028..3051 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3054..3062 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3063..3066 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3072..3089 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3090..3092 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3095..3106 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3115..3131 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3132..3134 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 3135..3148 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3153..3170 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3173..3186 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3192..3195 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3196..3205 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3206..3208 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3214..3222 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3224..3226 FT /evidence="ECO:0007829|PDB:9C47" FT HELIX 3228..3234 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3235..3242 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3247..3260 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3262..3283 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3284..3286 FT /evidence="ECO:0007829|PDB:8XVV" FT HELIX 3295..3310 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3312..3324 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3325..3328 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3332..3354 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3355..3358 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3365..3376 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3396..3407 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3411..3423 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3429..3432 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3434..3452 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3457..3460 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3461..3463 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3466..3470 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3473..3475 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3481..3484 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3489..3491 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3495..3499 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3501..3507 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3509..3520 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3525..3531 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3536..3552 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3553..3557 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3562..3565 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3574..3578 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3581..3585 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3588..3592 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3593..3604 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3610..3625 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3631..3644 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3650..3658 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3662..3685 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3693..3695 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3696..3699 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3700..3702 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3705..3708 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3716..3718 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3719..3721 FT /evidence="ECO:0007829|PDB:7KTR" FT STRAND 3726..3729 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3733..3739 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3741..3745 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3747..3759 FT /evidence="ECO:0007829|PDB:7KTR" FT TURN 3762..3764 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3766..3789 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3798..3800 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3804..3826 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3829..3831 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3834..3842 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3845..3848 FT /evidence="ECO:0007829|PDB:7KTR" FT HELIX 3853..3855 FT /evidence="ECO:0007829|PDB:7KTR" SQ SEQUENCE 3859 AA; 437600 MW; 391E467C0047B00B CRC64; MAFVATQGAT VVDQTTLMKK YLQFVAALTD VNTPDETKLK MMQEVSENFE NVTSSPQYST FLEHIIPRFL TFLQDGEVQF LQEKPAQQLR KLVLEIIHRI PTNEHLRPHT KNVLSVMFRF LETENEENVL ICLRIIIELH KQFRPPITQE IHHFLDFVKQ IYKELPKVVN RYFENPQVIP ENTVPPPEMV GMITTIAVKV NPEREDSETR THSIIPRGSL SLKVLAELPI IVVLMYQLYK LNIHNVVAEF VPLIMNTIAI QVSAQARQHK LYNKELYADF IAAQIKTLSF LAYIIRIYQE LVTKYSQQMV KGMLQLLSNC PAETAHLRKE LLIAAKHILT TELRNQFIPC MDKLFDESIL IGSGYTARET LRPLAYSTLA DLVHHVRQHL PLSDLSLAVQ LFAKNIDDES LPSSIQTMSC KLLLNLVDCI RSKSEQESGN GRDVLMRMLE VFVLKFHTIA RYQLSAIFKK CKPQSELGAV EAALPGVPTA PAAPGPAPSP APVPAPPPPP PPPPPATPVT PAPVPPFEKQ GEKDKEDKQT FQVTDCRSLV KTLVCGVKTI TWGITSCKAP GEAQFIPNKQ LQPKETQIYI KLVKYAMQAL DIYQVQIAGN GQTYIRVANC QTVRMKEEKE VLEHFAGVFT MMNPLTFKEI FQTTVPYMVE RISKNYALQI VANSFLANPT TSALFATILV EYLLDRLPEM GSNVELSNLY LKLFKLVFGS VSLFAAENEQ MLKPHLHKIV NSSMELAQTA KEPYNYFLLL RALFRSIGGG SHDLLYQEFL PLLPNLLQGL NMLQSGLHKQ HMKDLFVELC LTVPVRLSSL LPYLPMLMDP LVSALNGSQT LVSQGLRTLE LCVDNLQPDF LYDHIQPVRA ELMQALWRTL RNPADSISHV AYRVLGKFGG SNRKMLKESQ KLHYVVTEVQ GPSITVEFSD CKASLQLPME KAIETALDCL KSANTEPYYR RQAWEVIKCF LVAMMSLEDN KHALYQLLAH PNFTEKTIPN VIISHRYKAQ DTPARKTFEQ ALTGAFMSAV IKDLRPSALP FVASLIRHYT MVAVAQQCGP FLLPCYQVGS QPSTAMFHSE ENGSKGMDPL VLIDAIAICM AYEEKELCKI GEVALAVIFD VASIILGSKE RACQLPLFSY IVERLCACCY EQAWYAKLGG VVSIKFLMER LPLTWVLQNQ QTFLKALLFV MMDLTGEVSN GAVAMAKTTL EQLLMRCATP LKDEERAEEI VAAQEKSFHH VTHDLVREVT SPNSTVRKQA MHSLQVLAQV TGKSVTVIME PHKEVLQDMV PPKKHLLRHQ PANAQIGLME GNTFCTTLQP RLFTMDLNVV EHKVFYTELL NLCEAEDSAL TKLPCYKSLP SLVPLRIAAL NALAACNYLP QSREKIIAAL FKALNSTNSE LQEAGEACMR KFLEGATIEV DQIHTHMRPL LMMLGDYRSL TLNVVNRLTS VTRLFPNSFN DKFCDQMMQH LRKWMEVVVI THKGGQRSDG NESISECGRC PLSPFCQFEE MKICSAIINL FHLIPAAPQT LVKPLLEVVM KTERAMLIEA GSPFREPLIK FLTRHPSQTV ELFMMEATLN DPQWSRMFMS FLKHKDARPL RDVLAANPNR FITLLLPGGA QTAVRPGSPS TSTMRLDLQF QAIKIISIIV KNDDSWLASQ HSLVSQLRRV WVSENFQERH RKENMAATNW KEPKLLAYCL LNYCKRNYGD IELLFQLLRA FTGRFLCNMT FLKEYMEEEI PKNYSIAQKR ALFFRFVDFN DPNFGDELKA KVLQHILNPA FLYSFEKGEG EQLLGPPNPE GDNPESITSV FITKVLDPEK QADMLDSLRI YLLQYATLLV EHAPHHIHDN NKNRNSKLRR LMTFAWPCLL SKACVDPACK YSGHLLLAHI IAKFAIHKKI VLQVFHSLLK AHAMEARAIV RQAMAILTPA VPARMEDGHQ MLTHWTRKII VEEGHTVPQL VHILHLIVQH FKVYYPVRHH LVQHMVSAMQ RLGFTPSVTI EQRRLAVDLS EVVIKWELQR IKDQQPDSDM DPNSSGEGVN SVSSSIKRGL SVDSAQEVKR FRTATGAISA VFGRSQSLPG ADSLLAKPID KQHTDTVVNF LIRVACQVND NTNTAGSPGE VLSRRCVNLL KTALRPDMWP KSELKLQWFD KLLMTVEQPN QVNYGNICTG LEVLSFLLTV LQSPAILSSF KPLQRGIAAC MTCGNTKVLR AVHSLLSRLM SIFPTEPSTS SVASKYEELE CLYAAVGKVI YEGLTNYEKA TNANPSQLFG TLMILKSACS NNPSYIDRLI SVFMRSLQKM VREHLNPQAA SGSTEATSGT SELVMLSLEL VKTRLAVMSM EMRKNFIQAI LTSLIEKSPD AKILRAVVKI VEEWVKNNSP MAANQTPTLR EKSILLVKMM TYIEKRFPED LELNAQFLDL VNYVYRDETL SGSELTAKLE PAFLSGLRCA QPLIRAKFFE VFDNSMKRRV YERLLYVTCS QNWEAMGNHF WIKQCIELLL AVCEKSTPIG TSCQGAMLPS ITNVINLADS HDRAAFAMVT HVKQEPRERE NSESKEEDVE IDIELAPGDQ TSTPKTKELS EKDIGNQLHM LTNRHDKFLD TLREVKTGAL LSAFVQLCHI STTLAEKTWV QLFPRLWKIL SDRQQHALAG EISPFLCSGS HQVQRDCQPS ALNCFVEAMS QCVPPIPIRP CVLKYLGKTH NLWFRSTLML EHQAFEKGLS LQIKPKQTTE FYEQESITPP QQEILDSLAE LYSLLQEEDM WAGLWQKRCK YSETATAIAY EQHGFFEQAQ ESYEKAMDKA KKEHERSNAS PAIFPEYQLW EDHWIRCSKE LNQWEALTEY GQSKGHINPY LVLECAWRVS NWTAMKEALV QVEVSCPKEM AWKVNMYRGY LAICHPEEQQ LSFIERLVEM ASSLAIREWR RLPHVVSHVH TPLLQAAQQI IELQEAAQIN AGLQPTNLGR NNSLHDMKTV VKTWRNRLPI VSDDLSHWSS IFMWRQHHYQ GKPTWSGMHS SSIVTAYENS SQHDPSSNNA MLGVHASASA IIQYGKIARK QGLVNVALDI LSRIHTIPTV PIVDCFQKIR QQVKCYLQLA GVMGKNECMQ GLEVIESTNL KYFTKEMTAE FYALKGMFLA QINKSEEANK AFSAAVQMHD VLVKAWAMWG DYLENIFVKE RQLHLGVSAI TCYLHACRHQ NESKSRKYLA KVLWLLSFDD DKNTLADAVD KYCIGVPPIQ WLAWIPQLLT CLVGSEGKLL LNLISQVGRV YPQAVYFPIR TLYLTLKIEQ RERYKSDPGP IRATAPMWRC SRIMHMQREL HPTLLSSLEG IVDQMVWFRE NWHEEVLRQL QQGLAKCYSV AFEKSGAVSD AKITPHTLNF VKKLVSTFGV GLENVSNVST MFSSAASESL ARRAQATAQD PVFQKLKGQF TTDFDFSVPG SMKLHNLISK LKKWIKILEA KTKQLPKFFL IEEKCRFLSN FSAQTAEVEI PGEFLMPKPT HYYIKIARFM PRVEIVQKHN TAARRLYIRG HNGKIYPYLV MNDACLTESR REERVLQLLR LLNPCLEKRK ETTKRHLFFT VPRVVAVSPQ MRLVEDNPSS LSLVEIYKQR CAKKGIEHDN PISRYYDRLA TVQARGTQAS HQVLRDILKE VQSNMVPRSM LKEWALHTFP NATDYWTFRK MFTIQLALIG FAEFVLHLNR LNPEMLQIAQ DTGKLNVAYF RFDINDATGD LDANRPVPFR LTPNISEFLT TIGVSGPLTA SMIAVARCFA QPNFKVDGIL KTVLRDEIIA WHKKTQEDTS SPLSAAGQPE NMDSQQLVSL VQKAVTAIMT RLHNLAQFEG GESKVNTLVA AANSLDNLCR MDPAWHPWL // ID UB2V1_HUMAN Reviewed; 147 AA. AC Q13404; E1P629; Q13403; Q13532; Q5TGE0; Q5TGE3; Q96H34; Q9GZT0; Q9GZW1; AC Q9H4J3; Q9H4J4; Q9UKL1; Q9UM48; Q9UM49; Q9UM50; DT 31-AUG-2004, integrated into UniProtKB/Swiss-Prot. DT 22-SEP-2009, sequence version 2. DT 28-JAN-2026, entry version 224. DE RecName: Full=Ubiquitin-conjugating enzyme E2 variant 1; DE Short=UEV-1; DE AltName: Full=CROC-1; DE AltName: Full=TRAF6-regulated IKK activator 1 beta Uev1A; GN Name=UBE2V1; Synonyms=CROC1, UBE2V, UEV1; ORFNames=P/OKcl.19; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, AND SUBCELLULAR RP LOCATION. RC TISSUE=Brain; RX PubMed=9305758; DOI=10.1016/s0378-1119(97)00097-8; RA Rothofsky M.L., Lin S.L.; RT "CROC-1 encodes a protein which mediates transcriptional activation of the RT human FOS promoter."; RL Gene 195:141-149(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 4), FUNCTION, INDUCTION, AND RP TISSUE SPECIFICITY. RC TISSUE=Colon adenocarcinoma; RX PubMed=9418904; DOI=10.1128/mcb.18.1.576; RA Sancho E., Vila M.R., Sanchez-Pulido L., Lozano J.J., Paciucci R., RA Nadal M., Fox M., Harvey C., Bercovich B., Loukili N., Ciechanover A., RA Lin S.L., Sanz F., Estivill X., Valencia A., Thomson T.M.; RT "Role of UEV-1, an inactive variant of the E2 ubiquitin-conjugating RT enzymes, in in vitro differentiation and cell cycle behavior of HT-29-M6 RT intestinal mucosecretory cells."; RL Mol. Cell. Biol. 18:576-589(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), FUNCTION, INTERACTION WITH TRAF6 RP AND UBE2N, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=11057907; DOI=10.1016/s0092-8674(00)00126-4; RA Deng L., Wang C., Spencer E., Yang L., Braun A., You J., Slaughter C., RA Pickart C., Chen Z.J.; RT "Activation of the IkappaB kinase complex by TRAF6 requires a dimeric RT ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain."; RL Cell 103:351-361(2000). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 6). RC TISSUE=Lung; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=11780052; DOI=10.1038/414865a; RA Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R., RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L., RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P., RA Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D., RA Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G., RA Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E., RA Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D., RA Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P., RA Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E., RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J., RA Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D., RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S., RA Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D., RA Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A., RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T., RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I., RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M., RA Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D., RA Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M., RA Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A., RA Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L., RA Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L., RA Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 20."; RL Nature 414:865-871(2001). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP PROTEIN SEQUENCE OF 2-13 (ISOFORM 3), CLEAVAGE OF INITIATOR METHIONINE, RP ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Lung fibroblast; RA Bienvenut W.V., Pchelintsev N., Adams P.D.; RL Submitted (JUL-2009) to UniProtKB. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 8-147 (ISOFORMS 1 AND 3). RC TISSUE=Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP FUNCTION. RX PubMed=9580084; DOI=10.1016/s0014-5793(98)00060-x; RA Thomson T.M., Khalid H., Lozano J.J., Sancho E., Arino J.; RT "Role of UEV-1A, a homologue of the tumor suppressor protein TSG101, in RT protection from DNA damage."; RL FEBS Lett. 423:49-52(1998). RN [11] RP FUNCTION, AND TISSUE SPECIFICITY. RX PubMed=9705497; DOI=10.1093/nar/26.17.3908; RA Xiao W., Lin S.L., Broomfield S., Chow B.L., Wei Y.-F.; RT "The products of the yeast MMS2 and two human homologs (hMMS2 and CROC-1) RT define a structurally and functionally conserved Ubc-like protein family."; RL Nucleic Acids Res. 26:3908-3914(1998). RN [12] RP SUBCELLULAR LOCATION, AND IDENTIFICATION OF PESD1-UBE2V1 FUSION PROTEIN. RC TISSUE=Colon cancer; RX PubMed=11076860; DOI=10.1101/gr.gr-1405r; RA Thomson T.M., Lozano J.J., Loukili N., Carrio R., Serras F., Cormand B., RA Valeri M., Diaz V.M., Abril J., Burset M., Merino J., Macaya A., RA Corominas M., Guigo R.; RT "Fusion of the human gene for the polyubiquitination coeffector UEV1 with RT Kua, a newly identified gene."; RL Genome Res. 10:1743-1756(2000). RN [13] RP FUNCTION. RX PubMed=19825828; DOI=10.1126/scisignal.2000382; RA Liu C., Qian W., Qian Y., Giltiay N.V., Lu Y., Swaidani S., Misra S., RA Deng L., Chen Z.J., Li X.; RT "Act1, a U-box E3 ubiquitin ligase for IL-17 signaling."; RL Sci. Signal. 2:ra63-ra63(2009). RN [14] RP FUNCTION. RX PubMed=20061386; DOI=10.1074/jbc.m109.089003; RA David Y., Ziv T., Admon A., Navon A.; RT "The E2 ubiquitin-conjugating enzymes direct polyubiquitination to RT preferred lysines."; RL J. Biol. Chem. 285:8595-8604(2010). RN [15] RP FUNCTION. RX PubMed=21512573; DOI=10.1038/nature09976; RA Pertel T., Hausmann S., Morger D., Zueger S., Guerra J., Lascano J., RA Reinhard C., Santoni F.A., Uchil P.D., Chatel L., Bisiaux A., Albert M.L., RA Strambio-De-Castillia C., Mothes W., Pizzato M., Gruetter M.G., Luban J.; RT "TRIM5 is an innate immune sensor for the retrovirus capsid lattice."; RL Nature 472:361-365(2011). RN [16] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [17] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [18] RP FUNCTION. RX PubMed=31006531; DOI=10.1016/j.cell.2019.03.017; RA Cadena C., Ahmad S., Xavier A., Willemsen J., Park S., Park J.W., Oh S.W., RA Fujita T., Hou F., Binder M., Hur S.; RT "Ubiquitin-Dependent and -Independent Roles of E3 Ligase RIPLET in Innate RT Immunity."; RL Cell 177:1187-1200(2019). RN [19] RP X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 8-147 IN COMPLEX WITH STUB1 AND RP UBE2N. RX PubMed=16307917; DOI=10.1016/j.molcel.2005.09.023; RA Zhang M., Windheim M., Roe S.M., Peggie M., Cohen P., Prodromou C., RA Pearl L.H.; RT "Chaperoned ubiquitylation -- crystal structures of the CHIP U box E3 RT ubiquitin ligase and a CHIP-Ubc13-Uev1a complex."; RL Mol. Cell 20:525-538(2005). RN [20] {ECO:0007744|PDB:2HLW} RP STRUCTURE BY NMR OF 7-147, AND INTERACTION WITH UBE2N. RX PubMed=16893187; DOI=10.1021/bi060631r; RA Hau D.D., Lewis M.J., Saltibus L.F., Pastushok L., Xiao W., RA Spyracopoulos L.; RT "Structure and interactions of the ubiquitin-conjugating enzyme variant RT human Uev1a: implications for enzymatic synthesis of polyubiquitin RT chains."; RL Biochemistry 45:9866-9877(2006). RN [21] {ECO:0007744|PDB:2A4D} RP X-RAY CRYSTALLOGRAPHY (1.69 ANGSTROMS) OF 7-147. RX PubMed=22496338; DOI=10.1074/mcp.o111.013706; RA Sheng Y., Hong J.H., Doherty R., Srikumar T., Shloush J., Avvakumov G.V., RA Walker J.R., Xue S., Neculai D., Wan J.W., Kim S.K., Arrowsmith C.H., RA Raught B., Dhe-Paganon S.; RT "A human ubiquitin conjugating enzyme (E2)-HECT E3 ligase structure- RT function screen."; RL Mol. Cell. Proteomics 11:329-341(2012). CC -!- FUNCTION: Has no ubiquitin ligase activity on its own. The UBE2V1-UBE2N CC heterodimer catalyzes the synthesis of non-canonical poly-ubiquitin CC chains that are linked through Lys-63. This type of poly-ubiquitination CC activates IKK and does not seem to involve protein degradation by the CC proteasome. Plays a role in the activation of NF-kappa-B mediated by CC IL1B, TNF, TRAF6 and TRAF2. Mediates transcriptional activation of CC target genes. Plays a role in the control of progress through the cell CC cycle and differentiation. Plays a role in the error-free DNA repair CC pathway and contributes to the survival of cells after DNA damage. CC Promotes TRIM5 capsid-specific restriction activity and the UBE2V1- CC UBE2N heterodimer acts in concert with TRIM5 to generate 'Lys-63'- CC linked polyubiquitin chains which activate the MAP3K7/TAK1 complex CC which in turn results in the induction and expression of NF-kappa-B and CC MAPK-responsive inflammatory genes. Together with RNF135 and UBE2N, CC catalyzes the viral RNA-dependent 'Lys-63'-linked polyubiquitination of CC RIGI to activate the downstream signaling pathway that leads to CC interferon beta production (PubMed:31006531). UBE2V1-UBE2N together CC with TRAF3IP2 E3 ubiquitin ligase mediate 'Lys-63'-linked CC polyubiquitination of TRAF6, a component of IL17A-mediated signaling CC pathway. {ECO:0000269|PubMed:11057907, ECO:0000269|PubMed:19825828, CC ECO:0000269|PubMed:20061386, ECO:0000269|PubMed:21512573, CC ECO:0000269|PubMed:31006531, ECO:0000269|PubMed:9305758, CC ECO:0000269|PubMed:9418904, ECO:0000269|PubMed:9580084, CC ECO:0000269|PubMed:9705497}. CC -!- SUBUNIT: Heterodimer with UBE2N (PubMed:11057907, PubMed:16307917, CC PubMed:16893187). Interacts (UBE2V2-UBE2N heterodimer) with the E3 CC ligase STUB1 (via the U-box domain); the complex has a specific 'Lys- CC 63'-linked polyubiquitination activity (PubMed:16307917). Interacts CC with TRAF6 (PubMed:11057907, PubMed:16307917). CC {ECO:0000269|PubMed:11057907, ECO:0000269|PubMed:16307917, CC ECO:0000269|PubMed:16893187}. CC -!- INTERACTION: CC Q13404; Q92870-2: APBB2; NbExp=3; IntAct=EBI-1050671, EBI-21535880; CC Q13404; P54253: ATXN1; NbExp=6; IntAct=EBI-1050671, EBI-930964; CC Q13404; P02489: CRYAA; NbExp=3; IntAct=EBI-1050671, EBI-6875961; CC Q13404; P78358: CTAG1B; NbExp=3; IntAct=EBI-1050671, EBI-1188472; CC Q13404; Q15038: DAZAP2; NbExp=3; IntAct=EBI-1050671, EBI-724310; CC Q13404; G5E9A7: DMWD; NbExp=3; IntAct=EBI-1050671, EBI-10976677; CC Q13404; Q92567: FAM168A; NbExp=4; IntAct=EBI-1050671, EBI-7957930; CC Q13404; P22607: FGFR3; NbExp=3; IntAct=EBI-1050671, EBI-348399; CC Q13404; Q14957: GRIN2C; NbExp=3; IntAct=EBI-1050671, EBI-8285963; CC Q13404; P06396: GSN; NbExp=3; IntAct=EBI-1050671, EBI-351506; CC Q13404; P11021: HSPA5; NbExp=3; IntAct=EBI-1050671, EBI-354921; CC Q13404; O60333-2: KIF1B; NbExp=3; IntAct=EBI-1050671, EBI-10975473; CC Q13404; Q92876: KLK6; NbExp=3; IntAct=EBI-1050671, EBI-2432309; CC Q13404; O60260-5: PRKN; NbExp=3; IntAct=EBI-1050671, EBI-21251460; CC Q13404; Q9Y3C5: RNF11; NbExp=4; IntAct=EBI-1050671, EBI-396669; CC Q13404; Q6ZNA4: RNF111; NbExp=2; IntAct=EBI-1050671, EBI-2129175; CC Q13404; Q96DD7: SHISA4; NbExp=3; IntAct=EBI-1050671, EBI-18035902; CC Q13404; Q13148: TARDBP; NbExp=3; IntAct=EBI-1050671, EBI-372899; CC Q13404; Q13049: TRIM32; NbExp=4; IntAct=EBI-1050671, EBI-742790; CC Q13404; P61088: UBE2N; NbExp=22; IntAct=EBI-1050671, EBI-1052908; CC Q13404; Q9UMX0: UBQLN1; NbExp=9; IntAct=EBI-1050671, EBI-741480; CC Q13404; Q9UMX0-2: UBQLN1; NbExp=3; IntAct=EBI-1050671, EBI-10173939; CC Q13404; Q9UHD9: UBQLN2; NbExp=3; IntAct=EBI-1050671, EBI-947187; CC Q13404; P17861: XBP1; NbExp=3; IntAct=EBI-1050671, EBI-6942961; CC Q13404; P98170: XIAP; NbExp=3; IntAct=EBI-1050671, EBI-517127; CC Q13404; Q8ND25: ZNRF1; NbExp=2; IntAct=EBI-1050671, EBI-2129250; CC Q13404-2; P61088: UBE2N; NbExp=2; IntAct=EBI-15972179, EBI-1052908; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11076860, CC ECO:0000269|PubMed:9305758}. Note=Excluded from the nucleolus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=6; CC Comment=Additional isoforms seem to exist.; CC Name=3; Synonyms=Isoform 2; CC IsoId=Q13404-4; Sequence=Displayed; CC Name=1; Synonyms=CROC-1B, UEV-1B, Isoform 4; CC IsoId=Q13404-1; Sequence=VSP_038034; CC Name=2; Synonyms=CROC-1A, UEV-1A; CC IsoId=Q13404-2; Sequence=VSP_038033; CC Name=4; Synonyms=UEV-1As; CC IsoId=Q13404-6; Sequence=VSP_038032, VSP_038036; CC Name=5; Synonyms=Isoform 3; CC IsoId=Q13404-7; Sequence=VSP_038035; CC Name=6; CC IsoId=Q13404-8; Sequence=VSP_044818; CC -!- TISSUE SPECIFICITY: Highly expressed in thyroid, pancreas, spinal cord, CC lymph node, trachea, adrenal gland, bone marrow and pancreas. Detected CC at low levels in heart, breast, placenta, brain, liver, kidney, stomach CC and lung. {ECO:0000269|PubMed:9418904, ECO:0000269|PubMed:9705497}. CC -!- INDUCTION: Down-regulated during differentiation of cultured colon CC adenocarcinoma cells. {ECO:0000269|PubMed:9418904}. CC -!- MISCELLANEOUS: In human, PESD1/KUA and UBE2V1/UEV1 are adjacent genes CC which can produce independent proteins and can also be fused to form a CC PESD1-UBE2V1 hybrid protein. CC -!- SIMILARITY: Belongs to the ubiquitin-conjugating enzyme family. CC {ECO:0000255|PROSITE-ProRule:PRU00388}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH08944.2; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U39360; AAB72015.1; -; mRNA. DR EMBL; U39361; AAB72016.1; -; mRNA. DR EMBL; U49278; AAC02757.1; -; mRNA. DR EMBL; U97279; AAC02780.1; -; mRNA. DR EMBL; U97280; AAC02755.1; -; mRNA. DR EMBL; U97281; AAC02756.1; -; mRNA. DR EMBL; AY008273; AAG24229.1; -; mRNA. DR EMBL; BT007382; AAP36046.1; -; mRNA. DR EMBL; DA580976; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AL034423; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471077; EAW75635.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75634.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75636.1; -; Genomic_DNA. DR EMBL; BC000468; AAH00468.1; -; mRNA. DR EMBL; BC008944; AAH08944.2; ALT_INIT; mRNA. DR CCDS; CCDS13426.1; -. [Q13404-7] DR CCDS; CCDS13427.1; -. [Q13404-6] DR CCDS; CCDS33483.1; -. [Q13404-4] DR CCDS; CCDS58775.1; -. [Q13404-8] DR RefSeq; NP_001027459.1; NM_001032288.3. [Q13404-4] DR RefSeq; NP_001244322.1; NM_001257393.2. [Q13404-7] DR RefSeq; NP_001244323.1; NM_001257394.2. [Q13404-6] DR RefSeq; NP_001244325.1; NM_001257396.2. [Q13404-8] DR RefSeq; NP_068823.2; NM_021988.5. [Q13404-7] DR RefSeq; NP_071887.1; NM_022442.6. [Q13404-6] DR RefSeq; NP_954595.1; NM_199144.3. [Q13404-7] DR RefSeq; NP_954673.2; NM_199203.3. DR PDB; 2A4D; X-ray; 1.69 A; A=8-147. DR PDB; 2C2V; X-ray; 2.90 A; C/F/I/L=8-147. DR PDB; 2HLW; NMR; -; A=8-147. DR PDB; 6D6I; X-ray; 2.55 A; A/D=8-147. DR PDBsum; 2A4D; -. DR PDBsum; 2C2V; -. DR PDBsum; 2HLW; -. DR PDBsum; 6D6I; -. DR AlphaFoldDB; Q13404; -. DR BMRB; Q13404; -. DR SMR; Q13404; -. DR BioGRID; 113183; 125. DR BioGRID; 132321; 42. DR ComplexPortal; CPX-485; UBC13-UEV1A ubiquitin-conjugating enzyme E2 complex. DR CORUM; Q13404; -. DR DIP; DIP-41911N; -. DR FunCoup; Q13404; 3253. DR IntAct; Q13404; 144. DR MINT; Q13404; -. DR MoonDB; Q13404; Predicted. DR GlyGen; Q13404; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q13404; -. DR PhosphoSitePlus; Q13404; -. DR SwissPalm; Q13404; -. DR BioMuta; UBE2V1; -. DR DMDM; 259016163; -. DR jPOST; Q13404; -. DR MassIVE; Q13404; -. DR PeptideAtlas; Q13404; -. DR ProteomicsDB; 59382; -. [Q13404-4] DR ProteomicsDB; 59383; -. [Q13404-1] DR ProteomicsDB; 59384; -. [Q13404-2] DR ProteomicsDB; 59385; -. [Q13404-6] DR ProteomicsDB; 59386; -. [Q13404-7] DR ProteomicsDB; 65114; -. DR Pumba; Q13404; -. DR TopDownProteomics; Q13404-4; -. [Q13404-4] DR Antibodypedia; 35021; 274 antibodies from 33 providers. DR DNASU; 7335; -. DR Ensembl; ENST00000340309.7; ENSP00000340305.3; ENSG00000244687.14. [Q13404-7] DR Ensembl; ENST00000371657.9; ENSP00000360720.5; ENSG00000244687.14. [Q13404-8] DR Ensembl; ENST00000371674.8; ENSP00000360739.4; ENSG00000244687.14. [Q13404-4] DR Ensembl; ENST00000371677.7; ENSP00000360742.3; ENSG00000244687.14. [Q13404-7] DR Ensembl; ENST00000415862.6; ENSP00000407770.2; ENSG00000244687.14. [Q13404-6] DR GeneID; 7335; -. DR KEGG; hsa:387522; -. DR KEGG; hsa:7335; -. DR MANE-Select; ENST00000371674.8; ENSP00000360739.4; NM_001032288.3; NP_001027459.1. DR UCSC; uc002xva.5; human. [Q13404-4] DR AGR; HGNC:12494; -. DR AGR; HGNC:33521; -. DR ClinPGx; PA37142; -. DR CTD; 7335; -. DR DisGeNET; 387522; -. DR DisGeNET; 7335; -. DR GeneCards; UBE2V1; -. DR HGNC; HGNC:12494; UBE2V1. DR HPA; ENSG00000244687; Low tissue specificity. DR MIM; 602995; gene. DR OpenTargets; ENSG00000244687; -. DR VEuPathDB; HostDB:ENSG00000244687; -. DR eggNOG; KOG0896; Eukaryota. DR GeneTree; ENSGT00940000158854; -. DR HOGENOM; CLU_063065_1_2_1; -. DR InParanoid; Q13404; -. DR OMA; GPESCSY; -. DR OrthoDB; 6508832at2759; -. DR PAN-GO; Q13404; 3 GO annotations based on evolutionary models. DR BRENDA; 2.3.2.23; 2681. DR BRENDA; 2.3.2.24; 2681. DR PathwayCommons; Q13404; -. DR Reactome; R-HSA-168638; NOD1/2 Signaling Pathway. DR Reactome; R-HSA-168927; TICAM1, RIP1-mediated IKK complex recruitment. DR Reactome; R-HSA-202424; Downstream TCR signaling. DR Reactome; R-HSA-2871837; FCERI mediated NF-kB activation. DR Reactome; R-HSA-445989; TAK1-dependent IKK and NF-kappa-B activation. DR Reactome; R-HSA-450302; activated TAK1 mediates p38 MAPK activation. DR Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1. DR Reactome; R-HSA-5205685; PINK1-PRKN Mediated Mitophagy. DR Reactome; R-HSA-5607764; CLEC7A (Dectin-1) signaling. DR Reactome; R-HSA-9020702; Interleukin-1 signaling. DR Reactome; R-HSA-937039; IRAK1 recruits IKK complex. DR Reactome; R-HSA-937041; IKK complex recruitment mediated by RIP1. DR Reactome; R-HSA-9646399; Aggrephagy. DR Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses. DR Reactome; R-HSA-975110; TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling. DR Reactome; R-HSA-975144; IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation. DR Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation. DR SignaLink; Q13404; -. DR SIGNOR; Q13404; -. DR Agora; ENSG00000244687; -. DR BioGRID-ORCS; 387522; 76 hits in 964 CRISPR screens. DR BioGRID-ORCS; 7335; 228 hits in 1089 CRISPR screens. DR ChiTaRS; UBE2V1; human. DR EvolutionaryTrace; Q13404; -. DR GeneWiki; UBE2V1; -. DR Pharos; Q13404; Tbio. DR PRO; PR:Q13404; -. DR Proteomes; UP000005640; Chromosome 20. DR RNAct; Q13404; protein. DR Bgee; ENSG00000244687; Expressed in colonic epithelium and 104 other cell types or tissues. DR ExpressionAtlas; Q13404; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:HGNC-UCL. DR GO; GO:0005829; C:cytosol; IDA:ComplexPortal. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0032991; C:protein-containing complex; IDA:MGI. DR GO; GO:0031372; C:UBC13-MMS2 complex; IDA:UniProtKB. DR GO; GO:0031371; C:ubiquitin conjugating enzyme complex; IDA:HGNC-UCL. DR GO; GO:0000151; C:ubiquitin ligase complex; IDA:UniProtKB. DR GO; GO:0061631; F:ubiquitin conjugating enzyme activity; IEA:Ensembl. DR GO; GO:0031624; F:ubiquitin conjugating enzyme binding; IEA:Ensembl. DR GO; GO:0030154; P:cell differentiation; NAS:UniProtKB. DR GO; GO:0006301; P:DNA damage tolerance; IBA:GO_Central. DR GO; GO:0042275; P:error-free postreplication DNA repair; IEA:Ensembl. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IMP:HGNC-UCL. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; TAS:UniProtKB. DR GO; GO:1902533; P:positive regulation of intracellular signal transduction; IDA:ComplexPortal. DR GO; GO:1902523; P:positive regulation of protein K63-linked ubiquitination; IDA:ComplexPortal. DR GO; GO:0070534; P:protein K63-linked ubiquitination; IDA:UniProtKB. DR GO; GO:0000209; P:protein polyubiquitination; TAS:ProtInc. DR GO; GO:0006282; P:regulation of DNA repair; TAS:ProtInc. DR GO; GO:0006355; P:regulation of DNA-templated transcription; TAS:UniProtKB. DR CDD; cd23807; UEV_UBE2V; 1. DR FunFam; 3.10.110.10:FF:000012; Ubiquitin-conjugating enzyme E2 variant 2; 1. DR Gene3D; 3.10.110.10; Ubiquitin Conjugating Enzyme; 1. DR InterPro; IPR000608; UBC. DR InterPro; IPR016135; UBQ-conjugating_enzyme/RWD. DR PANTHER; PTHR24068; UBIQUITIN-CONJUGATING ENZYME E2; 1. DR Pfam; PF00179; UQ_con; 1. DR SMART; SM00212; UBCc; 1. DR SUPFAM; SSF54495; UBC-like; 1. DR PROSITE; PS50127; UBC_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Direct protein sequencing; KW Nucleus; Proteomics identification; Reference proteome; KW Ubl conjugation pathway. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|Ref.8, ECO:0007744|PubMed:22814378, FT ECO:0007744|PubMed:25944712" FT CHAIN 2..147 FT /note="Ubiquitin-conjugating enzyme E2 variant 1" FT /id="PRO_0000082600" FT DOMAIN 12..147 FT /note="UBC core" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00388" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0000269|Ref.8, ECO:0007744|PubMed:22814378, FT ECO:0007744|PubMed:25944712" FT VAR_SEQ 1..44 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:9418904" FT /id="VSP_038032" FT VAR_SEQ 1..14 FT /note="MAATTGSGVKVPRN -> MPGEVQASYLKSQSKLSDEGRLEPRKFHCKGSKS FT PSQ (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9305758, FT ECO:0000303|PubMed:9418904" FT /id="VSP_038033" FT VAR_SEQ 1..7 FT /note="MAATTGS -> MAYKFRTHSPEALEQLYPWECFVFCLIIFGTFTNQIHKWSH FT TYFGLPRWVTLLQDWHVILPRKHHRIHHVSPHETYFCITT (in isoform 1)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:9305758, ECO:0000303|PubMed:9418904" FT /id="VSP_038034" FT VAR_SEQ 1..7 FT /note="MAATTGS -> MPGEVQASYLKSQSKLSDEGRLEPRKFHCK (in FT isoform 5)" FT /evidence="ECO:0000303|PubMed:11057907" FT /id="VSP_038035" FT VAR_SEQ 45..57 FT /note="LTRWTGMIIGPPR -> MKEDLNLENFTAK (in isoform 4)" FT /evidence="ECO:0000303|PubMed:9418904" FT /id="VSP_038036" FT VAR_SEQ 58..99 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_044818" FT HELIX 11..25 FT /evidence="ECO:0007829|PDB:2A4D" FT STRAND 31..39 FT /evidence="ECO:0007829|PDB:2A4D" FT STRAND 47..53 FT /evidence="ECO:0007829|PDB:2A4D" FT STRAND 56..58 FT /evidence="ECO:0007829|PDB:2HLW" FT TURN 59..62 FT /evidence="ECO:0007829|PDB:2A4D" FT STRAND 64..70 FT /evidence="ECO:0007829|PDB:2A4D" FT TURN 73..77 FT /evidence="ECO:0007829|PDB:2A4D" FT STRAND 81..86 FT /evidence="ECO:0007829|PDB:2A4D" FT STRAND 91..93 FT /evidence="ECO:0007829|PDB:2HLW" FT TURN 95..97 FT /evidence="ECO:0007829|PDB:2A4D" FT HELIX 102..104 FT /evidence="ECO:0007829|PDB:2A4D" FT HELIX 106..109 FT /evidence="ECO:0007829|PDB:2A4D" FT HELIX 117..128 FT /evidence="ECO:0007829|PDB:2A4D" FT TURN 131..135 FT /evidence="ECO:0007829|PDB:2A4D" FT CONFLICT Q13404-1:71..81 FT /note="SPHETYFCITT -> WPTSSAQCYSP (in Ref. 2; AAC02755)" FT /evidence="ECO:0000305" SQ SEQUENCE 147 AA; 16495 MW; BA53837F21977B3F CRC64; MAATTGSGVK VPRNFRLLEE LEEGQKGVGD GTVSWGLEDD EDMTLTRWTG MIIGPPRTIY ENRIYSLKIE CGPKYPEAPP FVRFVTKINM NGVNSSNGVV DPRAISVLAK WQNSYSIKVV LQELRRLMMS KENMKLPQPP EGQCYSN // ID UBP4_HUMAN Reviewed; 963 AA. AC Q13107; A8K6Y0; C9IY91; O43452; O43453; Q08AK8; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 3. DT 28-JAN-2026, entry version 214. DE RecName: Full=Ubiquitin carboxyl-terminal hydrolase 4; DE EC=3.4.19.12 {ECO:0000269|PubMed:16316627, ECO:0000269|PubMed:16339847, ECO:0000269|PubMed:16472766, ECO:0000269|PubMed:20595234, ECO:0000269|PubMed:22347420, ECO:0000269|PubMed:25404403, ECO:0000269|PubMed:28604766}; DE AltName: Full=Deubiquitinating enzyme 4; DE AltName: Full=Ubiquitin thioesterase 4; DE AltName: Full=Ubiquitin-specific-processing protease 4; DE AltName: Full=Ubiquitous nuclear protein homolog; GN Name=USP4 {ECO:0000303|PubMed:30514904, ECO:0000312|HGNC:HGNC:12627}; GN Synonyms=UNP, UNPH; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY. RC TISSUE=Brain cortex; RX PubMed=7784062; RA Gray D.A., Inazawa J., Gupta K., Wong A., Ueda R., Takahashi T.; RT "Elevated expression of Unph, a proto-oncogene at 3p21.3, in human lung RT tumors."; RL Oncogene 10:2179-2183(1995). RN [2] RP SEQUENCE REVISION. RA Gray D.A.; RL Submitted (OCT-1997) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND ALTERNATIVE SPLICING. RC TISSUE=B-cell, and T-cell; RX PubMed=9464533; DOI=10.1038/sj.onc.1201537; RA Frederick A., Rolfe M., Chiu M.I.; RT "The human UNP locus at 3p21.31 encodes two tissue-selective, cytoplasmic RT isoforms with deubiquitinating activity that have reduced expression in RT small cell lung carcinoma cell lines."; RL Oncogene 16:153-165(1998). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3). RC TISSUE=Leukocyte; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP INTERACTION WITH RB1, AND MUTAGENESIS OF GLU-463 AND 459-LEU--GLU-463. RX PubMed=11571652; DOI=10.1038/sj.onc.1204824; RA DeSalle L.M., Latres E., Lin D., Graner E., Montagnoli A., Baker R.T., RA Pagano M., Loda M.; RT "The de-ubiquitinating enzyme Unp interacts with the retinoblastoma RT protein."; RL Oncogene 20:5538-5542(2001). RN [8] RP FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP CYS-311. RX PubMed=16316627; DOI=10.1016/j.bbrc.2005.11.076; RA Wada K., Tanji K., Kamitani T.; RT "Oncogenic protein UnpEL/Usp4 deubiquitinates Ro52 by its isopeptidase RT activity."; RL Biochem. Biophys. Res. Commun. 339:731-736(2006). RN [9] RP FUNCTION, CATALYTIC ACTIVITY, AUTODEUBIQUITINATION, UBIQUITINATION BY RP TRIM21, AND MUTAGENESIS OF CYS-311. RX PubMed=16472766; DOI=10.1016/j.bbrc.2006.01.144; RA Wada K., Kamitani T.; RT "UnpEL/Usp4 is ubiquitinated by Ro52 and deubiquitinated by itself."; RL Biochem. Biophys. Res. Commun. 342:253-258(2006). RN [10] RP FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH ADORA2A, AND TISSUE RP SPECIFICITY. RX PubMed=16339847; DOI=10.1124/mol.105.015818; RA Milojevic T., Reiterer V., Stefan E., Korkhov V.M., Dorostkar M.M., RA Ducza E., Ogris E., Boehm S., Freissmuth M., Nanoff C.; RT "The ubiquitin-specific protease Usp4 regulates the cell surface level of RT the A2A receptor."; RL Mol. Pharmacol. 69:1083-1094(2006). RN [11] RP FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH SART3, AND SUBCELLULAR RP LOCATION. RX PubMed=20595234; DOI=10.1101/gad.1925010; RA Song E.J., Werner S.L., Neubauer J., Stegmeier F., Aspden J., Rio D., RA Harper J.W., Elledge S.J., Kirschner M.W., Rape M.; RT "The Prp19 complex and the Usp4Sart3 deubiquitinating enzyme control RT reversible ubiquitination at the spliceosome."; RL Genes Dev. 24:1434-1447(2010). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [13] RP RETRACTED PAPER. RX PubMed=21415856; DOI=10.1038/embor.2011.33; RA Luna-Vargas M.P., Faesen A.C., van Dijk W.J., Rape M., Fish A., Sixma T.K.; RT "Ubiquitin-specific protease 4 is inhibited by its ubiquitin-like domain."; RL EMBO Rep. 12:365-372(2011). RN [14] RP RETRACTION NOTICE OF PUBMED:21415856. RX PubMed=24398133; DOI=10.1002/embr.201470010; RA Luna-Vargas M.P., Faesen A.C., van Dijk W.J., Rape M., Fish A., Sixma T.K.; RT "Retraction: 'Ubiquitin-specific protease 4 is inhibited by its ubiquitin- RT like domain' by MP Luna-Vargas, AC Faesen, WJ van Dijk, M Rape, A Fish, TK RT Sixma."; RL EMBO Rep. 15:121-121(2014). RN [15] RP FUNCTION, DEUBIQUITINATION OF PDPK1, AND CATALYTIC ACTIVITY. RX PubMed=22347420; DOI=10.1371/journal.pone.0031003; RA Uras I.Z., List T., Nijman S.M.; RT "Ubiquitin-specific protease 4 inhibits mono-ubiquitination of the master RT growth factor signaling kinase PDK1."; RL PLoS ONE 7:E31003-E31003(2012). RN [16] RP FUNCTION, CATALYTIC ACTIVITY, DEUBIQUITINATION OF HAS2, AND MUTAGENESIS OF RP CYS-311. RX PubMed=28604766; DOI=10.1038/oncsis.2017.45; RA Mehic M., de Sa V.K., Hebestreit S., Heldin C.H., Heldin P.; RT "The deubiquitinating enzymes USP4 and USP17 target hyaluronan synthase 2 RT and differentially affect its function."; RL Oncogenesis 6:e348-e348(2017). RN [17] RP FUNCTION, CATALYTIC ACTIVITY, PHOSPHORYLATION AT SER-445, AND MUTAGENESIS RP OF SER-445. RX PubMed=30514904; DOI=10.1038/s41422-018-0120-9; RA Deng L., Chen L., Zhao L., Xu Y., Peng X., Wang X., Ding L., Jin J., RA Teng H., Wang Y., Pan W., Yu F., Liao L., Li L., Ge X., Wang P.; RT "Ubiquitination of Rheb governs growth factor-induced mTORC1 activation."; RL Cell Res. 29:136-150(2019). RN [18] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF CYS-311. RX PubMed=39589880; DOI=10.1073/pnas.2401174121; RA Chu F., Hou P., Zhu H., Gao Y., Wang X., He W., Ren J., Li M., Liu Y., RA Chang He D., Wang H., Gao Y., He H.; RT "PBLD enhances antiviral innate immunity by promoting the p53-USP4-MAVS RT signaling axis."; RL Proc. Natl. Acad. Sci. U.S.A. 121:e2401174121-e2401174121(2024). RN [19] RP X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 296-490 AND 765-932 IN COMPLEX RP WITH ZINC, FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, RP DOMAIN, AND MUTAGENESIS OF MET-24; ARG-40; PHE-51; ILE-88; ASP-89; GLU-90; RP LEU-91; ASP-92; GLU-134; TYR-136; 384-PRO--GLN-385 AND PHE-386. RX PubMed=25404403; DOI=10.1038/ncomms6399; RA Clerici M., Luna-Vargas M.P., Faesen A.C., Sixma T.K.; RT "The DUSP-Ubl domain of USP4 enhances its catalytic efficiency by promoting RT ubiquitin exchange."; RL Nat. Commun. 5:5399-5399(2014). CC -!- FUNCTION: Deubiquitinating enzyme that removes conjugated ubiquitin CC from target proteins (PubMed:16316627, PubMed:16339847, CC PubMed:16472766, PubMed:20595234, PubMed:22347420, PubMed:25404403, CC PubMed:28604766, PubMed:30514904). Deubiquitinates PDPK1 CC (PubMed:22347420). Deubiquitinates TRIM21 (PubMed:16316627). CC Deubiquitinates receptor ADORA2A which increases the amount of CC functional receptor at the cell surface (PubMed:16339847). CC Deubiquitinates HAS2 (PubMed:28604766). Deubiquitinates MAVs leading to CC maintain MAVS protein stability, resulting in increased production of CC type I interferons (IFN-I) and enhanced antiviral innate immune CC responses against viral infections (PubMed:39589880). Deubiquitinates CC RHEB in response to EGF signaling, promoting mTORC1 signaling CC (PubMed:30514904). May regulate mRNA splicing through deubiquitination CC of the U4 spliceosomal protein PRPF3 (PubMed:20595234). This may CC prevent its recognition by the U5 component PRPF8 thereby destabilizing CC interactions within the U4/U6.U5 snRNP (PubMed:20595234). May also play CC a role in the regulation of quality control in the ER CC (PubMed:16339847). {ECO:0000269|PubMed:16316627, CC ECO:0000269|PubMed:16339847, ECO:0000269|PubMed:16472766, CC ECO:0000269|PubMed:20595234, ECO:0000269|PubMed:22347420, CC ECO:0000269|PubMed:25404403, ECO:0000269|PubMed:28604766, CC ECO:0000269|PubMed:30514904, ECO:0000269|PubMed:39589880}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide CC and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76- CC residue protein attached to proteins as an intracellular targeting CC signal).; EC=3.4.19.12; Evidence={ECO:0000269|PubMed:16316627, CC ECO:0000269|PubMed:16339847, ECO:0000269|PubMed:16472766, CC ECO:0000269|PubMed:20595234, ECO:0000269|PubMed:22347420, CC ECO:0000269|PubMed:25404403, ECO:0000269|PubMed:28604766, CC ECO:0000269|PubMed:30514904}; CC -!- ACTIVITY REGULATION: The completion of the deubiquitinase reaction is CC mediated by the DUSP and ubiquitin-like 1 domains which promotes the CC release of ubiquitin from the catalytic site enabling subsequent CC reactions to occur. {ECO:0000269|PubMed:25404403}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=0.15 uM for ubiquitin-rhodamine {ECO:0000269|PubMed:25404403}; CC -!- SUBUNIT: Interacts with RB1 (both dephosphorylated and CC hypophosphorylated forms) (PubMed:11571652). Interacts with RBL1 and CC RBL2 (By similarity). Interacts with ADORA2A (via cytoplasmic C- CC terminus); the interaction is direct (PubMed:16339847). Interacts with CC SART3; recruits USP4 to its substrate PRPF3 (PubMed:20595234). CC {ECO:0000250|UniProtKB:P35123, ECO:0000269|PubMed:11571652, CC ECO:0000269|PubMed:16339847, ECO:0000269|PubMed:20595234}. CC -!- INTERACTION: CC Q13107; P29274: ADORA2A; NbExp=4; IntAct=EBI-723290, EBI-2902702; CC Q13107; Q7Z6Z7: HUWE1; NbExp=4; IntAct=EBI-723290, EBI-625934; CC Q13107; Q13546: RIPK1; NbExp=4; IntAct=EBI-723290, EBI-358507; CC Q13107; Q13107: USP4; NbExp=3; IntAct=EBI-723290, EBI-723290; CC Q13107-1; P19474: TRIM21; NbExp=3; IntAct=EBI-723305, EBI-81290; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:16316627, CC ECO:0000269|PubMed:20595234}. Nucleus {ECO:0000269|PubMed:16316627, CC ECO:0000269|PubMed:20595234}. Note=Shuttles between the nucleus and CC cytoplasm. Exported to the cytoplasm in a CRM1-dependent manner and CC recycled back to the nucleus via the importin alpha/beta heterodimeric CC import receptor. The relative amounts found in the nucleus and CC cytoplasm vary according to the cell type. CC {ECO:0000269|PubMed:16316627, ECO:0000269|PubMed:20595234}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=UnpEL; CC IsoId=Q13107-1; Sequence=Displayed; CC Name=2; Synonyms=UnpES; CC IsoId=Q13107-2; Sequence=VSP_005258; CC Name=3; CC IsoId=Q13107-3; Sequence=VSP_044814, VSP_044815; CC -!- TISSUE SPECIFICITY: Overexpressed in small cell tumors and CC adenocarcinomas of the lung compared to wild-type lung (at protein CC level). Expressed in the hippocampal neurons. CC {ECO:0000269|PubMed:16339847, ECO:0000269|PubMed:7784062}. CC -!- DOMAIN: The DUSP and ubiquitin-like 1 domains promote ubiquitin release CC and thus enhance USB4 catalytic activity. However, these domains do not CC bind ubiquitin. {ECO:0000269|PubMed:25404403}. CC -!- PTM: Phosphorylated at Ser-445 by PKB/AKT1 in response to EGF stimulus, CC promoting its ability deubiquitinate RHEB. CC {ECO:0000269|PubMed:30514904}. CC -!- PTM: Monoubiquitinated by TRIM21. Ubiquitination does not lead to its CC proteasomal degradation. Autodeubiquitinated. CC {ECO:0000269|PubMed:16472766, ECO:0000269|PubMed:22347420}. CC -!- SIMILARITY: Belongs to the peptidase C19 family. USP4 subfamily. CC {ECO:0000305}. CC -!- CAUTION: The ubiquitin-like domain 2 was thought to interact with the CC catalytic domain competing with the ubiquitin substrate and thus CC partially inhibiting USP4 activity (PubMed:21415856). As the results CC could not be reproduced this work was later retracted CC (PubMed:24398133). The cristal structure in the paper was correct and CC was republished later (PubMed:25404403). {ECO:0000269|PubMed:21415856, CC ECO:0000269|PubMed:24398133, ECO:0000269|PubMed:25404403}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U20657; AAB72237.1; -; mRNA. DR EMBL; AF017305; AAC27355.1; -; mRNA. DR EMBL; AF017306; AAC27356.1; -; mRNA. DR EMBL; AK291795; BAF84484.1; -; mRNA. DR EMBL; AC121247; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC068017; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; BC125130; AAI25131.1; -; mRNA. DR CCDS; CCDS2793.1; -. [Q13107-1] DR CCDS; CCDS2794.1; -. [Q13107-2] DR CCDS; CCDS58832.1; -. [Q13107-3] DR PIR; T09478; T09478. DR RefSeq; NP_001238806.1; NM_001251877.2. [Q13107-3] DR RefSeq; NP_003354.2; NM_003363.3. [Q13107-1] DR RefSeq; NP_955475.1; NM_199443.3. [Q13107-2] DR PDB; 2Y6E; X-ray; 2.40 A; A/B/C/D/E/F=296-490, A/B/C/D/E/F=765-932. DR PDB; 5CTR; X-ray; 3.01 A; C/D=1-230. DR PDBsum; 2Y6E; -. DR PDBsum; 5CTR; -. DR AlphaFoldDB; Q13107; -. DR SMR; Q13107; -. DR BioGRID; 113221; 300. DR FunCoup; Q13107; 4179. DR IntAct; Q13107; 86. DR MINT; Q13107; -. DR STRING; 9606.ENSP00000265560; -. DR BindingDB; Q13107; -. DR ChEMBL; CHEMBL2406900; -. DR MEROPS; C19.010; -. DR GlyGen; Q13107; 2 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; Q13107; -. DR PhosphoSitePlus; Q13107; -. DR BioMuta; USP4; -. DR DMDM; 116242839; -. DR jPOST; Q13107; -. DR MassIVE; Q13107; -. DR PaxDb; 9606-ENSP00000265560; -. DR PeptideAtlas; Q13107; -. DR ProteomicsDB; 59158; -. [Q13107-1] DR ProteomicsDB; 59159; -. [Q13107-2] DR ProteomicsDB; 7631; -. DR Pumba; Q13107; -. DR Antibodypedia; 13556; 376 antibodies from 31 providers. DR DNASU; 7375; -. DR Ensembl; ENST00000265560.9; ENSP00000265560.4; ENSG00000114316.14. [Q13107-1] DR Ensembl; ENST00000351842.8; ENSP00000341028.4; ENSG00000114316.14. [Q13107-2] DR Ensembl; ENST00000416417.5; ENSP00000400623.1; ENSG00000114316.14. [Q13107-3] DR GeneID; 7375; -. DR KEGG; hsa:7375; -. DR MANE-Select; ENST00000265560.9; ENSP00000265560.4; NM_003363.4; NP_003354.2. DR UCSC; uc003cwq.3; human. [Q13107-1] DR AGR; HGNC:12627; -. DR ClinPGx; PA37252; -. DR CTD; 7375; -. DR DisGeNET; 7375; -. DR GeneCards; USP4; -. DR HGNC; HGNC:12627; USP4. DR HPA; ENSG00000114316; Low tissue specificity. DR MIM; 603486; gene. DR OpenTargets; ENSG00000114316; -. DR VEuPathDB; HostDB:ENSG00000114316; -. DR eggNOG; KOG1870; Eukaryota. DR GeneTree; ENSGT00940000156645; -. DR HOGENOM; CLU_001060_7_1_1; -. DR InParanoid; Q13107; -. DR OMA; KQQHSPN; -. DR OrthoDB; 265776at2759; -. DR PAN-GO; Q13107; 1 GO annotation based on evolutionary models. DR PhylomeDB; Q13107; -. DR PathwayCommons; Q13107; -. DR Reactome; R-HSA-5357786; TNFR1-induced proapoptotic signaling. DR Reactome; R-HSA-5357905; Regulation of TNFR1 signaling. DR Reactome; R-HSA-5357956; TNFR1-induced NF-kappa-B signaling pathway. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR SignaLink; Q13107; -. DR SIGNOR; Q13107; -. DR Agora; ENSG00000114316; -. DR BioGRID-ORCS; 7375; 14 hits in 1168 CRISPR screens. DR ChiTaRS; USP4; human. DR EvolutionaryTrace; Q13107; -. DR GeneWiki; USP4; -. DR GenomeRNAi; 7375; -. DR Pharos; Q13107; Tchem. DR PRO; PR:Q13107; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q13107; protein. DR Bgee; ENSG00000114316; Expressed in pancreatic ductal cell and 207 other cell types or tissues. DR ExpressionAtlas; Q13107; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005764; C:lysosome; TAS:ProtInc. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0031685; F:adenosine receptor binding; IPI:UniProtKB. DR GO; GO:0004843; F:cysteine-type deubiquitinase activity; IDA:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0031397; P:negative regulation of protein ubiquitination; IMP:UniProtKB. DR GO; GO:1904263; P:positive regulation of TORC1 signaling; IDA:UniProtKB. DR GO; GO:0016579; P:protein deubiquitination; IDA:UniProtKB. DR GO; GO:0034394; P:protein localization to cell surface; IDA:UniProtKB. DR GO; GO:0006508; P:proteolysis; IEA:UniProtKB-KW. DR GO; GO:0031647; P:regulation of protein stability; IDA:UniProtKB. DR GO; GO:0000244; P:spliceosomal tri-snRNP complex assembly; IMP:UniProtKB. DR CDD; cd02674; Peptidase_C19R; 1. DR FunFam; 3.30.2230.10:FF:000003; ubiquitin carboxyl-terminal hydrolase 15 isoform X1; 1. DR FunFam; 3.90.70.10:FF:000013; ubiquitin carboxyl-terminal hydrolase 15 isoform X1; 1. DR FunFam; 3.10.20.90:FF:000020; ubiquitin carboxyl-terminal hydrolase 15 isoform X2; 1. DR FunFam; 3.90.70.10:FF:000047; ubiquitin carboxyl-terminal hydrolase 4 isoform X2; 1. DR Gene3D; 3.90.70.10; Cysteine proteinases; 2. DR Gene3D; 3.30.2230.10; DUSP-like; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1. DR InterPro; IPR035927; DUSP-like_sf. DR InterPro; IPR038765; Papain-like_cys_pep_sf. DR InterPro; IPR006615; Pept_C19_DUSP. DR InterPro; IPR001394; Peptidase_C19_UCH. DR InterPro; IPR050185; Ub_carboxyl-term_hydrolase. DR InterPro; IPR028135; Ub_USP-typ. DR InterPro; IPR028889; USP. DR InterPro; IPR018200; USP_CS. DR PANTHER; PTHR21646; UBIQUITIN CARBOXYL-TERMINAL HYDROLASE; 1. DR PANTHER; PTHR21646:SF45; UBIQUITIN CARBOXYL-TERMINAL HYDROLASE 4; 1. DR Pfam; PF06337; DUSP; 1. DR Pfam; PF14836; Ubiquitin_3; 1. DR Pfam; PF00443; UCH; 1. DR SMART; SM00695; DUSP; 1. DR SUPFAM; SSF54001; Cysteine proteinases; 1. DR SUPFAM; SSF143791; DUSP-like; 1. DR PROSITE; PS51283; DUSP; 1. DR PROSITE; PS00972; USP_1; 1. DR PROSITE; PS00973; USP_2; 1. DR PROSITE; PS50235; USP_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Cytoplasm; Hydrolase; Metal-binding; KW Nucleus; Phosphoprotein; Protease; Proteomics identification; KW Proto-oncogene; Reference proteome; Repeat; Thiol protease; KW Ubl conjugation; Ubl conjugation pathway; Zinc. FT CHAIN 1..963 FT /note="Ubiquitin carboxyl-terminal hydrolase 4" FT /id="PRO_0000080621" FT DOMAIN 11..122 FT /note="DUSP" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00613" FT DOMAIN 142..226 FT /note="Ubiquitin-like 1" FT /evidence="ECO:0000255" FT DOMAIN 302..923 FT /note="USP" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01035" FT DOMAIN 483..571 FT /note="Ubiquitin-like 2" FT /evidence="ECO:0000255" FT REGION 1..22 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 27..216 FT /note="Necessary for interaction with SART3" FT /evidence="ECO:0000269|PubMed:20595234" FT REGION 219..253 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 229..295 FT /note="Required for USP4 activation by providing FT conformational flexibility between the DUSP and catalytic FT domains" FT /evidence="ECO:0000269|PubMed:25404403" FT REGION 384..386 FT /note="Regulates ubiquitin dissociation" FT /evidence="ECO:0000269|PubMed:25404403" FT REGION 405..407 FT /note="Necessary for interaction with RBL2" FT /evidence="ECO:0000250|UniProtKB:P35123" FT REGION 459..463 FT /note="Necessary for interaction with RB1 and RBL2" FT /evidence="ECO:0000250|UniProtKB:P35123, FT ECO:0000269|PubMed:11571652" FT REGION 485..775 FT /note="Interacts with DUSP and ubiquitin-like 1 domains and FT is required for USP4 activation" FT /evidence="ECO:0000269|PubMed:25404403" FT REGION 637..699 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 928..963 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 133..141 FT /note="Nuclear export signal" FT /evidence="ECO:0000250|UniProtKB:P35123" FT MOTIF 767..772 FT /note="Nuclear localization signal" FT /evidence="ECO:0000250|UniProtKB:P35123" FT COMPBIAS 1..17 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 225..243 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 244..253 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 657..666 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 932..948 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 953..963 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 311 FT /note="Nucleophile" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01035" FT ACT_SITE 881 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01035" FT BINDING 461 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:25404403, FT ECO:0007744|PDB:2Y6E" FT BINDING 464 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:25404403, FT ECO:0007744|PDB:2Y6E" FT BINDING 799 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:25404403, FT ECO:0007744|PDB:2Y6E" FT BINDING 802 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:25404403, FT ECO:0007744|PDB:2Y6E" FT MOD_RES 445 FT /note="Phosphoserine; by PKB/AKT1" FT /evidence="ECO:0000269|PubMed:30514904" FT MOD_RES 655 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:B2GUZ1" FT MOD_RES 675 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P35123" FT MOD_RES 680 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P35123" FT VAR_SEQ 232..279 FT /note="KSSTAPSRNFTTSPKSSASPYSSVSASLIANGDSTSTCGMHSSGVSRG -> FT N (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9464533" FT /id="VSP_005258" FT VAR_SEQ 233..313 FT /note="SSTAPSRNFTTSPKSSASPYSSVSASLIANGDSTSTCGMHSSGVSRGGSGFS FT ASYNCQEPPSSHIQPGLCGLGNLGNTCFM -> VSFFLPRLECNGAILAHCNFCLPGSS FT NSPASASRVAPSHLANFFFFEMESHSVTKLECGGAVSAYSRVQVMLLPQPPEWLG (in FT isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_044814" FT VAR_SEQ 314..963 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_044815" FT VARIANT 620 FT /note="Y -> C (in dbSNP:rs9311440)" FT /id="VAR_028180" FT MUTAGEN 24 FT /note="M->D: Moderate reduction in thiol-dependent FT deubiquitinase activity." FT /evidence="ECO:0000269|PubMed:25404403" FT MUTAGEN 40 FT /note="R->E: Moderate reduction in thiol-dependent FT deubiquitinase activity." FT /evidence="ECO:0000269|PubMed:25404403" FT MUTAGEN 51 FT /note="F->D: Moderate reduction in thiol-dependent FT deubiquitinase activity." FT /evidence="ECO:0000269|PubMed:25404403" FT MUTAGEN 88 FT /note="I->P: Severe reduction in thiol-dependent FT deubiquitinase activity." FT /evidence="ECO:0000269|PubMed:25404403" FT MUTAGEN 88 FT /note="I->R: Moderate reduction in thiol-dependent FT deubiquitinase activity." FT /evidence="ECO:0000269|PubMed:25404403" FT MUTAGEN 89 FT /note="D->G: Severe reduction in thiol-dependent FT deubiquitinase activity." FT /evidence="ECO:0000269|PubMed:25404403" FT MUTAGEN 90 FT /note="E->A: Moderate reduction in thiol-dependent FT deubiquitinase activity." FT /evidence="ECO:0000269|PubMed:25404403" FT MUTAGEN 91 FT /note="L->E: Moderate reduction in thiol-dependent FT deubiquitinase activity." FT /evidence="ECO:0000269|PubMed:25404403" FT MUTAGEN 92 FT /note="D->R: Severe reduction in thiol-dependent FT deubiquitinase activity." FT /evidence="ECO:0000269|PubMed:25404403" FT MUTAGEN 134 FT /note="E->A: Severe reduction in thiol-dependent FT deubiquitinase activity." FT /evidence="ECO:0000269|PubMed:25404403" FT MUTAGEN 136 FT /note="Y->A: Severe reduction in thiol-dependent FT deubiquitinase activity." FT /evidence="ECO:0000269|PubMed:25404403" FT MUTAGEN 311 FT /note="C->A: Loss of thiol-dependent deubiquitinase FT activity. Its ubiquitination by TRIM21 is enhanced. Does FT affect interaction with HAS2. Does not deubiquitinate HAS2. FT Fails to deubiquitinate MAVS in VSV-infected cell." FT /evidence="ECO:0000269|PubMed:16316627, FT ECO:0000269|PubMed:16472766, ECO:0000269|PubMed:28604766, FT ECO:0000269|PubMed:39589880" FT MUTAGEN 384..385 FT /note="PQ->AV: Severe reduction in thiol-dependent FT deubiquitinase activity." FT /evidence="ECO:0000269|PubMed:25404403" FT MUTAGEN 386 FT /note="F->G: Lowers affinity for ubiquitin characterized by FT a 10-fold increase in ubiquitin release and a slight FT reduction in ubiquitin binding." FT /evidence="ECO:0000269|PubMed:25404403" FT MUTAGEN 445 FT /note="S->A: Abolished phosphorylation by PKB/AKT1 in FT response to EGF signaling." FT /evidence="ECO:0000269|PubMed:30514904" FT MUTAGEN 445 FT /note="S->D: Mimics phosphorylation; promoting association FT with RHEB." FT /evidence="ECO:0000269|PubMed:30514904" FT MUTAGEN 459..463 FT /note="LVCPE->AVRPH: Reduces the interaction with RB1." FT /evidence="ECO:0000269|PubMed:11571652" FT MUTAGEN 463 FT /note="E->Q: Reduces the interaction with RB1." FT /evidence="ECO:0000269|PubMed:11571652" FT CONFLICT 373 FT /note="R -> S (in Ref. 1; AAB72237)" FT /evidence="ECO:0000305" FT CONFLICT 744 FT /note="S -> R (in Ref. 1; AAB72237)" FT /evidence="ECO:0000305" FT HELIX 13..20 FT /evidence="ECO:0007829|PDB:5CTR" FT HELIX 21..23 FT /evidence="ECO:0007829|PDB:5CTR" FT STRAND 32..38 FT /evidence="ECO:0007829|PDB:5CTR" FT HELIX 39..48 FT /evidence="ECO:0007829|PDB:5CTR" FT HELIX 62..64 FT /evidence="ECO:0007829|PDB:5CTR" FT TURN 72..74 FT /evidence="ECO:0007829|PDB:5CTR" FT STRAND 75..77 FT /evidence="ECO:0007829|PDB:5CTR" FT TURN 78..81 FT /evidence="ECO:0007829|PDB:5CTR" FT TURN 89..92 FT /evidence="ECO:0007829|PDB:5CTR" FT STRAND 93..97 FT /evidence="ECO:0007829|PDB:5CTR" FT HELIX 98..108 FT /evidence="ECO:0007829|PDB:5CTR" FT STRAND 118..124 FT /evidence="ECO:0007829|PDB:5CTR" FT STRAND 126..128 FT /evidence="ECO:0007829|PDB:5CTR" FT STRAND 130..133 FT /evidence="ECO:0007829|PDB:5CTR" FT STRAND 140..143 FT /evidence="ECO:0007829|PDB:5CTR" FT STRAND 151..154 FT /evidence="ECO:0007829|PDB:5CTR" FT STRAND 158..161 FT /evidence="ECO:0007829|PDB:5CTR" FT HELIX 162..172 FT /evidence="ECO:0007829|PDB:5CTR" FT STRAND 177..179 FT /evidence="ECO:0007829|PDB:5CTR" FT STRAND 183..185 FT /evidence="ECO:0007829|PDB:5CTR" FT STRAND 187..191 FT /evidence="ECO:0007829|PDB:5CTR" FT STRAND 198..202 FT /evidence="ECO:0007829|PDB:5CTR" FT TURN 203..206 FT /evidence="ECO:0007829|PDB:5CTR" FT HELIX 311..321 FT /evidence="ECO:0007829|PDB:2Y6E" FT HELIX 324..331 FT /evidence="ECO:0007829|PDB:2Y6E" FT HELIX 335..338 FT /evidence="ECO:0007829|PDB:2Y6E" FT HELIX 350..362 FT /evidence="ECO:0007829|PDB:2Y6E" FT STRAND 364..366 FT /evidence="ECO:0007829|PDB:2Y6E" FT STRAND 368..370 FT /evidence="ECO:0007829|PDB:2Y6E" FT HELIX 373..382 FT /evidence="ECO:0007829|PDB:2Y6E" FT HELIX 384..386 FT /evidence="ECO:0007829|PDB:2Y6E" FT STRAND 388..390 FT /evidence="ECO:0007829|PDB:2Y6E" FT HELIX 394..408 FT /evidence="ECO:0007829|PDB:2Y6E" FT HELIX 428..442 FT /evidence="ECO:0007829|PDB:2Y6E" FT HELIX 446..451 FT /evidence="ECO:0007829|PDB:2Y6E" FT STRAND 453..460 FT /evidence="ECO:0007829|PDB:2Y6E" FT TURN 462..464 FT /evidence="ECO:0007829|PDB:2Y6E" FT STRAND 467..480 FT /evidence="ECO:0007829|PDB:2Y6E" FT HELIX 778..785 FT /evidence="ECO:0007829|PDB:2Y6E" FT STRAND 797..799 FT /evidence="ECO:0007829|PDB:2Y6E" FT TURN 800..803 FT /evidence="ECO:0007829|PDB:2Y6E" FT STRAND 804..806 FT /evidence="ECO:0007829|PDB:2Y6E" FT STRAND 809..816 FT /evidence="ECO:0007829|PDB:2Y6E" FT STRAND 819..826 FT /evidence="ECO:0007829|PDB:2Y6E" FT STRAND 828..830 FT /evidence="ECO:0007829|PDB:2Y6E" FT STRAND 835..837 FT /evidence="ECO:0007829|PDB:2Y6E" FT HELIX 852..854 FT /evidence="ECO:0007829|PDB:2Y6E" FT STRAND 858..860 FT /evidence="ECO:0007829|PDB:2Y6E" FT STRAND 864..874 FT /evidence="ECO:0007829|PDB:2Y6E" FT STRAND 876..879 FT /evidence="ECO:0007829|PDB:2Y6E" FT STRAND 881..887 FT /evidence="ECO:0007829|PDB:2Y6E" FT TURN 889..891 FT /evidence="ECO:0007829|PDB:2Y6E" FT STRAND 894..898 FT /evidence="ECO:0007829|PDB:2Y6E" FT STRAND 901..904 FT /evidence="ECO:0007829|PDB:2Y6E" FT HELIX 907..909 FT /evidence="ECO:0007829|PDB:2Y6E" FT STRAND 915..922 FT /evidence="ECO:0007829|PDB:2Y6E" FT HELIX 926..928 FT /evidence="ECO:0007829|PDB:2Y6E" SQ SEQUENCE 963 AA; 108565 MW; 63055C9ADFE36713 CRC64; MAEGGGCRER PDAETQKSEL GPLMRTTLQR GAQWYLIDSR WFKQWKKYVG FDSWDMYNVG EHNLFPGPID NSGLFSDPES QTLKEHLIDE LDYVLVPTEA WNKLLNWYGC VEGQQPIVRK VVEHGLFVKH CKVEVYLLEL KLCENSDPTN VLSCHFSKAD TIATIEKEMR KLFNIPAERE TRLWNKYMSN TYEQLSKLDN TVQDAGLYQG QVLVIEPQNE DGTWPRQTLQ SKSSTAPSRN FTTSPKSSAS PYSSVSASLI ANGDSTSTCG MHSSGVSRGG SGFSASYNCQ EPPSSHIQPG LCGLGNLGNT CFMNSALQCL SNTAPLTDYF LKDEYEAEIN RDNPLGMKGE IAEAYAELIK QMWSGRDAHV APRMFKTQVG RFAPQFSGYQ QQDSQELLAF LLDGLHEDLN RVKKKPYLEL KDANGRPDAV VAKEAWENHR LRNDSVIVDT FHGLFKSTLV CPECAKVSVT FDPFCYLTLP LPLKKDRVME VFLVPADPHC RPTQYRVTVP LMGAVSDLCE ALSRLSGIAA ENMVVADVYN HRFHKIFQMD EGLNHIMPRD DIFVYEVCST SVDGSECVTL PVYFRERKSR PSSTSSASAL YGQPLLLSVP KHKLTLESLY QAVCDRISRY VKQPLPDEFG SSPLEPGACN GSRNSCEGED EEEMEHQEEG KEQLSETEGS GEDEPGNDPS ETTQKKIKGQ PCPKRLFTFS LVNSYGTADI NSLAADGKLL KLNSRSTLAM DWDSETRRLY YDEQESEAYE KHVSMLQPQK KKKTTVALRD CIELFTTMET LGEHDPWYCP NCKKHQQATK KFDLWSLPKI LVVHLKRFSY NRYWRDKLDT VVEFPIRGLN MSEFVCNLSA RPYVYDLIAV SNHYGAMGVG HYTAYAKNKL NGKWYYFDDS NVSLASEDQI VTKAAYVLFY QRRDDEFYKT PSLSSSGSSD GGTRPSSSQQ GFGDDEACSM DTN // ID UBQL1_HUMAN Reviewed; 589 AA. AC Q9UMX0; A0A024R284; Q5T6J5; Q5T6J9; Q8IXS9; Q8N2Q3; Q9H0T8; Q9H3R4; Q9HAZ5; DT 29-MAR-2004, integrated into UniProtKB/Swiss-Prot. DT 01-MAR-2002, sequence version 2. DT 28-JAN-2026, entry version 218. DE RecName: Full=Ubiquilin-1; DE AltName: Full=Protein linking IAP with cytoskeleton 1; DE Short=PLIC-1; DE Short=hPLIC-1; GN Name=UBQLN1; Synonyms=DA41, PLIC1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH PSEN1 AND PSEN2, RP AND TISSUE SPECIFICITY. RC TISSUE=Brain; RX PubMed=11076969; DOI=10.1083/jcb.151.4.847; RA Mah A.L., Perry G., Smith M.A., Monteiro M.J.; RT "Identification of ubiquilin, a novel presenilin interactor that increases RT presenilin protein accumulation."; RL J. Cell Biol. 151:847-862(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Mah A.L., Monteiro M.J.; RL Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH UBE3A; BTRC RP AND THE PROTEASOME. RC TISSUE=B-cell; RX PubMed=10983987; DOI=10.1016/s1097-2765(00)00040-x; RA Kleijnen M.F., Shih A.H., Zhou P., Kumar S., Soccio R.E., Kedersha N.L., RA Gill G., Howley P.M.; RT "The hPLIC proteins may provide a link between the ubiquitination machinery RT and the proteasome."; RL Mol. Cell 6:409-419(2000). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Lung; RX PubMed=10807547; DOI=10.1007/s100380050209; RA Hanaoka E., Ozaki T., Ohira M., Nakamura Y., Suzuki M., Takahashi E., RA Moriya H., Nakagawara A., Sakiyama S.; RT "Molecular cloning and expression analysis of the human DA41 gene and its RT mapping to chromosome 9q21.2-q21.3."; RL J. Hum. Genet. 45:188-191(2000). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA]. RA Li J.Y.; RT "Human testis protein."; RL Submitted (MAR-2010) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=11230166; DOI=10.1101/gr.gr1547r; RA Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S., RA Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H., Lauber J., RA Duesterhoeft A., Beyer A., Koehrer K., Strack N., Mewes H.-W., RA Ottenwaelder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B., RA Klein M., Poustka A.; RT "Towards a catalog of human genes and proteins: sequencing and analysis of RT 500 novel complete protein coding human cDNAs."; RL Genome Res. 11:422-435(2001). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164053; DOI=10.1038/nature02465; RA Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L., RA Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R., RA Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S., RA Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., RA Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., RA Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E., RA Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M., RA Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J., RA Frankish A., Frankland J.A., French L., Fricker D.G., Garner P., RA Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S., RA Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E., RA Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D., RA Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E., RA Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K., RA Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S., RA Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J., RA Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E., RA McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V., RA Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S., RA Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K., RA Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J., RA Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., RA West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L., RA Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M., RA Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J., RA Dunham I.; RT "DNA sequence and analysis of human chromosome 9."; RL Nature 429:369-374(2004). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Brain, and Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-316. RC TISSUE=Embryo; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [11] RP PROTEIN SEQUENCE OF 71-83; 207-236; 244-253 AND 547-582, AND IDENTIFICATION RP BY MASS SPECTROMETRY. RC TISSUE=Fetal brain cortex; RA Lubec G., Chen W.-Q., Sun Y.; RL Submitted (DEC-2008) to UniProtKB. RN [12] RP PHOSPHORYLATION, INTERACTION WITH MTOR, AND TISSUE SPECIFICITY. RX PubMed=11853878; DOI=10.1016/s0167-4889(01)00164-1; RA Wu S., Mikhailov A., Kallo-Hosein H., Hara K., Yonezawa K., Avruch J.; RT "Characterization of ubiquilin 1, an mTOR-interacting protein."; RL Biochim. Biophys. Acta 1542:41-56(2002). RN [13] RP INTERACTION WITH P4HB. RX PubMed=12095988; DOI=10.1074/jbc.m203412200; RA Ko H.S., Uehara T., Nomura Y.; RT "Role of ubiquilin associated with protein-disulfide isomerase in the RT endoplasmic reticulum in stress-induced apoptotic cell death."; RL J. Biol. Chem. 277:35386-35392(2002). RN [14] RP FUNCTION, DOMAIN UBIQUITIN-LIKE, DOMAIN UBA, AND INTERACTION WITH UBA52; RP PSMD3 AND PSMD4. RX PubMed=15147878; DOI=10.1016/j.febslet.2004.04.031; RA Ko H.S., Uehara T., Tsuruma K., Nomura Y.; RT "Ubiquilin interacts with ubiquitylated proteins and proteasome through its RT ubiquitin-associated and ubiquitin-like domains."; RL FEBS Lett. 566:110-114(2004). RN [15] RP INTERACTION WITH EPS15; EPS15L1; HGS AND STAM2, SUBCELLULAR LOCATION, AND RP UBIQUITINATION. RX PubMed=16159959; DOI=10.1242/jcs.02571; RA Regan-Klapisz E., Sorokina I., Voortman J., de Keizer P., Roovers R.C., RA Verheesen P., Urbe S., Fallon L., Fon E.A., Verkleij A., Benmerah A., RA van Bergen en Henegouwen P.M.; RT "Ubiquilin recruits Eps15 into ubiquitin-rich cytoplasmic aggregates via a RT UIM-UBL interaction."; RL J. Cell Sci. 118:4437-4450(2005). RN [16] RP SUBUNIT, HETERODIMERIZATION WITH UBQLN2, AND INTERACTION WITH PSEN1 AND RP PSEN2. RX PubMed=16813565; DOI=10.1042/bj20060441; RA Ford D.L., Monteiro M.J.; RT "Dimerization of ubiquilin is dependent upon the central region of the RT protein: evidence that the monomer, but not the dimer, is involved in RT binding presenilins."; RL Biochem. J. 399:397-404(2006). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17323924; DOI=10.1021/bi061994u; RA Wang X., Chen C.-F., Baker P.R., Chen P.-L., Kaiser P., Huang L.; RT "Mass spectrometric characterization of the affinity-purified human 26S RT proteasome complex."; RL Biochemistry 46:3553-3565(2007). RN [18] RP FUNCTION, AND INTERACTION WITH HERPUD1. RX PubMed=18307982; DOI=10.1016/j.bbrc.2008.02.086; RA Kim T.Y., Kim E., Yoon S.K., Yoon J.B.; RT "Herp enhances ER-associated protein degradation by recruiting RT ubiquilins."; RL Biochem. Biophys. Res. Commun. 369:741-746(2008). RN [19] RP INTERACTION WITH EPS15. RX PubMed=18199683; DOI=10.1091/mbc.e07-08-0775; RA N'Diaye E.N., Hanyaloglu A.C., Kajihara K.K., Puthenveedu M.A., Wu P., RA von Zastrow M., Brown E.J.; RT "The ubiquitin-like protein PLIC-2 is a negative regulator of G protein- RT coupled receptor endocytosis."; RL Mol. Biol. Cell 19:1252-1260(2008). RN [20] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [21] RP FUNCTION, SUBCELLULAR LOCATION, AND DOMAIN UBA. RX PubMed=19148225; DOI=10.1038/embor.2008.238; RA N'Diaye E.N., Kajihara K.K., Hsieh I., Morisaki H., Debnath J., Brown E.J.; RT "PLIC proteins or ubiquilins regulate autophagy-dependent cell survival RT during nutrient starvation."; RL EMBO Rep. 10:173-179(2009). RN [22] RP FUNCTION, INTERACTION WITH UBXN4, IDENTIFICATION IN A COMPLEX WITH UBXN4 RP AND VCP, AND SUBCELLULAR LOCATION. RX PubMed=19822669; DOI=10.1083/jcb.200903024; RA Lim P.J., Danner R., Liang J., Doong H., Harman C., Srinivasan D., RA Rothenberg C., Wang H., Ye Y., Fang S., Monteiro M.J.; RT "Ubiquilin and p97/VCP bind erasin, forming a complex involved in ERAD."; RL J. Cell Biol. 187:201-217(2009). RN [23] RP ALTERNATIVE SPLICING (ISOFORMS 1; 2; 3 AND 4), FUNCTION, AND TISSUE RP SPECIFICITY. RX PubMed=18953672; DOI=10.1007/s12031-008-9155-6; RA Lu A., Hiltunen M., Romano D.M., Soininen H., Hyman B.T., Bertram L., RA Tanzi R.E.; RT "Effects of ubiquilin 1 on the unfolded protein response."; RL J. Mol. Neurosci. 38:19-30(2009). RN [24] RP REVIEW. RX PubMed=20729634; DOI=10.4161/auto.6.7.13118; RA Rothenberg C., Monteiro M.J.; RT "Ubiquilin at a crossroads in protein degradation pathways."; RL Autophagy 6:979-980(2010). RN [25] RP FUNCTION, SUBCELLULAR LOCATION, IDENTIFICATION IN A COMPLEX WITH UBQLN2 AND RP MAP1LC3A/B/C, AND PROTEOLYTIC DEGRADATION. RX PubMed=20529957; DOI=10.1093/hmg/ddq231; RA Rothenberg C., Srinivasan D., Mah L., Kaushik S., Peterhoff C.M., RA Ugolino J., Fang S., Cuervo A.M., Nixon R.A., Monteiro M.J.; RT "Ubiquilin functions in autophagy and is degraded by chaperone-mediated RT autophagy."; RL Hum. Mol. Genet. 19:3219-3232(2010). RN [26] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [27] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [28] RP REVIEW. RX PubMed=21966562; DOI=10.4161/cib.15283; RA Haapasalo A., Viswanathan J., Kurkinen K.M., Bertram L., Soininen H., RA Dantuma N.P., Tanzi R.E., Hiltunen M.; RT "Involvement of ubiquilin-1 transcript variants in protein degradation and RT accumulation."; RL Commun. Integr. Biol. 4:428-432(2011). RN [29] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH TICAM1. RX PubMed=21695056; DOI=10.1371/journal.pone.0021153; RA Biswas N., Liu S., Ronni T., Aussenberg S.E., Liu W., Fujita T., Wang T.; RT "The ubiquitin-like protein PLIC-1 or ubiquilin 1 inhibits TLR3-Trif RT signaling."; RL PLoS ONE 6:E21153-E21153(2011). RN [30] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [31] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PSEN1. RX PubMed=21143716; DOI=10.1111/j.1600-0854.2010.01149.x; RA Viswanathan J., Haapasalo A., Bottcher C., Miettinen R., Kurkinen K.M., RA Lu A., Thomas A., Maynard C.J., Romano D., Hyman B.T., Berezovska O., RA Bertram L., Soininen H., Dantuma N.P., Tanzi R.E., Hiltunen M.; RT "Alzheimer's disease-associated ubiquilin-1 regulates presenilin-1 RT accumulation and aggresome formation."; RL Traffic 12:330-348(2011). RN [32] RP REVIEW. RX PubMed=22628307; DOI=10.1515/hsz-2012-0120; RA Lee D.Y., Brown E.J.; RT "Ubiquilins in the crosstalk among proteolytic pathways."; RL Biol. Chem. 393:441-447(2012). RN [33] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22223895; DOI=10.1074/mcp.m111.015131; RA Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T., RA Giglione C.; RT "Comparative large-scale characterisation of plant vs. mammal proteins RT reveals similar and idiosyncratic N-alpha acetylation features."; RL Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012). RN [34] RP FUNCTION, AND INTERACTION WITH BCL2L10. RX PubMed=22233804; DOI=10.1073/pnas.1119167109; RA Beverly L.J., Lockwood W.W., Shah P.P., Erdjument-Bromage H., Varmus H.; RT "Ubiquitination, localization, and stability of an anti-apoptotic BCL2-like RT protein, BCL2L10/BCLb, are regulated by Ubiquilin1."; RL Proc. Natl. Acad. Sci. U.S.A. 109:E119-E126(2012). RN [35] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH UBQLN4 AND RP MAP1LC3A/B/C. RX PubMed=23459205; DOI=10.1038/embor.2013.22; RA Lee D.Y., Arnott D., Brown E.J.; RT "Ubiquilin4 is an adaptor protein that recruits Ubiquilin1 to the autophagy RT machinery."; RL EMBO Rep. 14:373-381(2013). RN [36] RP REVIEW. RX PubMed=23600477; DOI=10.1517/14728222.2013.791284; RA Takalo M., Haapasalo A., Natunen T., Viswanathan J., Kurkinen K.M., RA Tanzi R.E., Soininen H., Hiltunen M.; RT "Targeting ubiquilin-1 in Alzheimer's disease."; RL Expert Opin. Ther. Targets 17:795-810(2013). RN [37] RP INTERACTION WITH TREX1, AND SUBCELLULAR LOCATION. RX PubMed=23979357; DOI=10.1074/jbc.m113.503391; RA Orebaugh C.D., Fye J.M., Harvey S., Hollis T., Wilkinson J.C., RA Perrino F.W.; RT "The TREX1 C-terminal region controls cellular localization through RT ubiquitination."; RL J. Biol. Chem. 288:28881-28892(2013). RN [38] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [39] RP FUNCTION, INTERACTION WITH ORAI1, AND SUBCELLULAR LOCATION. RX PubMed=23307288; DOI=10.1007/s10059-013-2268-7; RA Lee J.E., Jeon I.S., Han N.E., Song H.J., Kim E.G., Choi J.W., Song K.D., RA Lee H.K., Choi J.K.; RT "Ubiquilin 1 interacts with Orai1 to regulate calcium mobilization."; RL Mol. Cells 35:41-46(2013). RN [40] RP REVIEW. RX PubMed=24674348; DOI=10.1186/1471-2148-14-63; RA Marin I.; RT "The ubiquilin gene family: evolutionary patterns and functional RT insights."; RL BMC Evol. Biol. 14:63-63(2014). RN [41] RP STRUCTURE BY NMR OF 541-586 ALONE AND IN COMPLEX WITH UBIQUITIN. RX PubMed=18241885; DOI=10.1016/j.jmb.2007.12.029; RA Zhang D., Raasi S., Fushman D.; RT "Affinity makes the difference: nonselective interaction of the UBA domain RT of Ubiquilin-1 with monomeric ubiquitin and polyubiquitin chains."; RL J. Mol. Biol. 377:162-180(2008). CC -!- FUNCTION: Plays an important role in the regulation of different CC protein degradation mechanisms and pathways including ubiquitin- CC proteasome system (UPS), autophagy and endoplasmic reticulum-associated CC protein degradation (ERAD) pathway. Mediates the proteasomal targeting CC of misfolded or accumulated proteins for degradation by binding (via CC UBA domain) to their polyubiquitin chains and by interacting (via CC ubiquitin-like domain) with the subunits of the proteasome CC (PubMed:15147878). Plays a role in the ERAD pathway via its interaction CC with ER-localized proteins UBXN4, VCP and HERPUD1 and may form a link CC between the polyubiquitinated ERAD substrates and the proteasome CC (PubMed:18307982, PubMed:19822669). Involved in the regulation of CC macroautophagy and autophagosome formation; required for maturation of CC autophagy-related protein LC3 from the cytosolic form LC3-I to the CC membrane-bound form LC3-II and may assist in the maturation of CC autophagosomes to autolysosomes by mediating autophagosome-lysosome CC fusion (PubMed:19148225, PubMed:20529957, PubMed:23459205). Negatively CC regulates the TICAM1/TRIF-dependent toll-like receptor signaling CC pathway by decreasing the abundance of TICAM1 via the autophagic CC pathway (PubMed:21695056). Promotes the ubiquitination and lysosomal CC degradation of ORAI1, consequently down-regulating the ORAI1-mediated CC Ca2+ mobilization (PubMed:23307288). Suppresses the maturation and CC proteasomal degradation of amyloid beta A4 protein (A4) by stimulating CC the lysine 63 (K63)-linked polyubiquitination. Delays the maturation of CC A4 by sequestering it in the Golgi apparatus and preventing its CC transport to the cell surface for subsequent processing (By CC similarity). Ubiquitinates BCL2L10 and thereby stabilizes protein CC abundance (PubMed:22233804). {ECO:0000250|UniProtKB:Q9JJP9, CC ECO:0000269|PubMed:18307982, ECO:0000269|PubMed:19148225, CC ECO:0000269|PubMed:19822669, ECO:0000269|PubMed:20529957, CC ECO:0000269|PubMed:21695056, ECO:0000269|PubMed:22233804, CC ECO:0000269|PubMed:23307288, ECO:0000269|PubMed:23459205, CC ECO:0000303|PubMed:15147878}. CC -!- FUNCTION: [Isoform 1]: Plays a role in unfolded protein response (UPR) CC by attenuating the induction of UPR-inducible genes, DDTI3/CHOP, HSPA5 CC and PDIA2 during ER stress (PubMed:18953672). Plays a key role in the CC regulation of the levels of PSEN1 by targeting its accumulation to CC aggresomes which may then be removed from cells by autophagocytosis CC (PubMed:21143716). {ECO:0000269|PubMed:18953672, CC ECO:0000269|PubMed:21143716}. CC -!- FUNCTION: [Isoform 2]: Plays a role in unfolded protein response (UPR) CC by attenuating the induction of UPR-inducible genes, DDTI3/CHOP, HSPA5 CC and PDIA2 during ER stress. {ECO:0000269|PubMed:18953672}. CC -!- FUNCTION: [Isoform 3]: Plays a role in unfolded protein response (UPR) CC by attenuating the induction of UPR-inducible genes, DDTI3/CHOP, HSPA5 CC and PDIA2 during ER stress (PubMed:18953672). Plays a key role in the CC regulation of the levels of PSEN1 by targeting its accumulation to CC aggresomes which may then be removed from cells by autophagocytosis CC (PubMed:21143716). {ECO:0000269|PubMed:18953672, CC ECO:0000269|PubMed:21143716}. CC -!- SUBUNIT: Monomer and homodimer (PubMed:16813565). Heterodimer with CC UBQLN2 (PubMed:16813565). Binds CD47, NBL1, GABRA1, GABRA2, GABRA3, CC GABRA6, GABRB1, GABRB2 and GABRB3 (By similarity). Binds UBE3A, BTRC, CC P4HB and MTOR. Interacts with the proteasome 19S subunit. Interacts CC (via ubiquitin-like domain) with TREX1; the interaction is direct and CC may control TREX1 subcellular location. Forms a complex with UBXN4 and CC VCP. Interacts (via UBA domain) with UBQLN4 (via ubiquitin-like CC domain). Found in a complex with UBQLN2 and MAP1LC3A/B/C. The monomeric CC form interacts with PSEN2. The monomeric form interacts with PSEN1 CC (PubMed:11076969, PubMed:21143716). Interacts with ORAI1. Interacts CC (via UBA domain) with TICAM1. Interacts with EPS15. Interacts (via UBA CC domain) with UBA52 and (via ubiquitin-like domain) with PSMD3 and CC PSMD4. Interacts with HERPUD1. Interacts with MAP1LC3A/B/C in the CC presence of UBQLN4. Interacts (via ubiquitin-like domain) with EPS15 CC (via UIM domains) and both the ubiquitinated and non-ubiquitinated CC forms can interact with EPS15. Interacts (via ubiquitin-like domain) CC with EPS15L1, HGS (via UIM domain) and STAM2 (via UIM domain). CC Interacts with BCL2L10/BCL-B; in the cytoplasm (PubMed:22233804). CC {ECO:0000250|UniProtKB:Q8R317, ECO:0000250|UniProtKB:Q9JJP9, CC ECO:0000269|PubMed:10983987, ECO:0000269|PubMed:11076969, CC ECO:0000269|PubMed:11853878, ECO:0000269|PubMed:12095988, CC ECO:0000269|PubMed:15147878, ECO:0000269|PubMed:16159959, CC ECO:0000269|PubMed:16813565, ECO:0000269|PubMed:18199683, CC ECO:0000269|PubMed:18241885, ECO:0000269|PubMed:18307982, CC ECO:0000269|PubMed:19822669, ECO:0000269|PubMed:20529957, CC ECO:0000269|PubMed:21143716, ECO:0000269|PubMed:21695056, CC ECO:0000269|PubMed:22233804, ECO:0000269|PubMed:23307288, CC ECO:0000269|PubMed:23459205, ECO:0000269|PubMed:23979357}. CC -!- SUBUNIT: [Isoform 1]: Monomeric form interacts with PSEN1. CC {ECO:0000269|PubMed:16813565}. CC -!- SUBUNIT: [Isoform 3]: Monomeric form interacts with PSEN1. CC {ECO:0000269|PubMed:16813565}. CC -!- INTERACTION: CC Q9UMX0; O00154: ACOT7; NbExp=3; IntAct=EBI-741480, EBI-948905; CC Q9UMX0; O00154-4: ACOT7; NbExp=3; IntAct=EBI-741480, EBI-12007918; CC Q9UMX0; Q16186: ADRM1; NbExp=4; IntAct=EBI-741480, EBI-954387; CC Q9UMX0; Q9NUQ2: AGPAT5; NbExp=6; IntAct=EBI-741480, EBI-6916385; CC Q9UMX0; O95994: AGR2; NbExp=9; IntAct=EBI-741480, EBI-712648; CC Q9UMX0; Q8TD06: AGR3; NbExp=4; IntAct=EBI-741480, EBI-3925742; CC Q9UMX0; P23352: ANOS1; NbExp=3; IntAct=EBI-741480, EBI-5272188; CC Q9UMX0; P55056: APOC4; NbExp=3; IntAct=EBI-741480, EBI-18302142; CC Q9UMX0; P05067: APP; NbExp=3; IntAct=EBI-741480, EBI-77613; CC Q9UMX0; Q66PJ3-4: ARL6IP4; NbExp=3; IntAct=EBI-741480, EBI-5280499; CC Q9UMX0; P50553: ASCL1; NbExp=3; IntAct=EBI-741480, EBI-957042; CC Q9UMX0; Q6XD76: ASCL4; NbExp=3; IntAct=EBI-741480, EBI-10254793; CC Q9UMX0; P54252: ATXN3; NbExp=6; IntAct=EBI-741480, EBI-946046; CC Q9UMX0; P46379-2: BAG6; NbExp=3; IntAct=EBI-741480, EBI-10988864; CC Q9UMX0; Q8TBE0: BAHD1; NbExp=3; IntAct=EBI-741480, EBI-742750; CC Q9UMX0; Q9UQB8-6: BAIAP2; NbExp=3; IntAct=EBI-741480, EBI-9092016; CC Q9UMX0; Q9H2G9: BLZF1; NbExp=3; IntAct=EBI-741480, EBI-2548012; CC Q9UMX0; Q9NP55: BPIFA1; NbExp=3; IntAct=EBI-741480, EBI-953896; CC Q9UMX0; Q9ULD4-2: BRPF3; NbExp=3; IntAct=EBI-741480, EBI-23662416; CC Q9UMX0; Q9NSI6-4: BRWD1; NbExp=3; IntAct=EBI-741480, EBI-10693038; CC Q9UMX0; Q9BXJ3: C1QTNF4; NbExp=3; IntAct=EBI-741480, EBI-11955105; CC Q9UMX0; Q3SXR2: C3orf36; NbExp=3; IntAct=EBI-741480, EBI-18036948; CC Q9UMX0; P20807-4: CAPN3; NbExp=3; IntAct=EBI-741480, EBI-11532021; CC Q9UMX0; P10147: CCL3; NbExp=3; IntAct=EBI-741480, EBI-8459634; CC Q9UMX0; P80098: CCL7; NbExp=3; IntAct=EBI-741480, EBI-718759; CC Q9UMX0; Q8TCZ2: CD99L2; NbExp=6; IntAct=EBI-741480, EBI-2824782; CC Q9UMX0; Q9H305: CDIP1; NbExp=3; IntAct=EBI-741480, EBI-2876678; CC Q9UMX0; P38936: CDKN1A; NbExp=3; IntAct=EBI-741480, EBI-375077; CC Q9UMX0; O95674: CDS2; NbExp=3; IntAct=EBI-741480, EBI-3913685; CC Q9UMX0; Q494V2-2: CFAP100; NbExp=3; IntAct=EBI-741480, EBI-11953200; CC Q9UMX0; Q8WUX9: CHMP7; NbExp=3; IntAct=EBI-741480, EBI-749253; CC Q9UMX0; Q03692: COL10A1; NbExp=6; IntAct=EBI-741480, EBI-2528309; CC Q9UMX0; P08123: COL1A2; NbExp=6; IntAct=EBI-741480, EBI-983038; CC Q9UMX0; P02458-1: COL2A1; NbExp=3; IntAct=EBI-741480, EBI-12375799; CC Q9UMX0; Q14055: COL9A2; NbExp=3; IntAct=EBI-741480, EBI-714971; CC Q9UMX0; Q86WV2: COX4I1; NbExp=3; IntAct=EBI-741480, EBI-10260134; CC Q9UMX0; P07498: CSN3; NbExp=3; IntAct=EBI-741480, EBI-2602175; CC Q9UMX0; P33240: CSTF2; NbExp=7; IntAct=EBI-741480, EBI-711360; CC Q9UMX0; Q9H0L4: CSTF2T; NbExp=7; IntAct=EBI-741480, EBI-747012; CC Q9UMX0; P78358: CTAG1B; NbExp=6; IntAct=EBI-741480, EBI-1188472; CC Q9UMX0; O75638-2: CTAG2; NbExp=3; IntAct=EBI-741480, EBI-12265122; CC Q9UMX0; Q8TB03: CXorf38; NbExp=3; IntAct=EBI-741480, EBI-12024320; CC Q9UMX0; Q9UHQ9: CYB5R1; NbExp=3; IntAct=EBI-741480, EBI-953870; CC Q9UMX0; Q15038: DAZAP2; NbExp=3; IntAct=EBI-741480, EBI-724310; CC Q9UMX0; Q9UJU6: DBNL; NbExp=3; IntAct=EBI-741480, EBI-751783; CC Q9UMX0; Q01524: DEFA6; NbExp=4; IntAct=EBI-741480, EBI-10222451; CC Q9UMX0; Q30KQ5: DEFB115; NbExp=3; IntAct=EBI-741480, EBI-12253292; CC Q9UMX0; Q6ICB0: DESI1; NbExp=6; IntAct=EBI-741480, EBI-2806959; CC Q9UMX0; O95424: DEXI; NbExp=3; IntAct=EBI-741480, EBI-724515; CC Q9UMX0; Q8NDP9: DKFZp547K2416; NbExp=3; IntAct=EBI-741480, EBI-25842538; CC Q9UMX0; O60479: DLX3; NbExp=3; IntAct=EBI-741480, EBI-3908248; CC Q9UMX0; Q6E0U4: DMKN; NbExp=3; IntAct=EBI-741480, EBI-7943171; CC Q9UMX0; Q96EY1-3: DNAJA3; NbExp=3; IntAct=EBI-741480, EBI-11526226; CC Q9UMX0; Q9H147: DNTTIP1; NbExp=3; IntAct=EBI-741480, EBI-2795449; CC Q9UMX0; A0A0S2Z5Y1: DOLK; NbExp=3; IntAct=EBI-741480, EBI-16431159; CC Q9UMX0; Q7Z7J5: DPPA2; NbExp=3; IntAct=EBI-741480, EBI-741400; CC Q9UMX0; Q14117: DPYS; NbExp=3; IntAct=EBI-741480, EBI-12275416; CC Q9UMX0; Q9BPU6: DPYSL5; NbExp=3; IntAct=EBI-741480, EBI-724653; CC Q9UMX0; Q9BVC3: DSCC1; NbExp=3; IntAct=EBI-741480, EBI-11143782; CC Q9UMX0; Q9Y6W6: DUSP10; NbExp=3; IntAct=EBI-741480, EBI-3443946; CC Q9UMX0; A0AVK6: E2F8; NbExp=3; IntAct=EBI-741480, EBI-7779316; CC Q9UMX0; Q16610: ECM1; NbExp=3; IntAct=EBI-741480, EBI-947964; CC Q9UMX0; Q658K8: EEF1DP3; NbExp=3; IntAct=EBI-741480, EBI-10248874; CC Q9UMX0; O95967: EFEMP2; NbExp=5; IntAct=EBI-741480, EBI-743414; CC Q9UMX0; O00472: ELL2; NbExp=3; IntAct=EBI-741480, EBI-395274; CC Q9UMX0; O43768-8: ENSA; NbExp=3; IntAct=EBI-741480, EBI-25853109; CC Q9UMX0; P42566: EPS15; NbExp=5; IntAct=EBI-741480, EBI-396684; CC Q9UMX0; Q96DN0: ERP27; NbExp=4; IntAct=EBI-741480, EBI-953772; CC Q9UMX0; P30040: ERP29; NbExp=3; IntAct=EBI-741480, EBI-946830; CC Q9UMX0; Q6NXG1: ESRP1; NbExp=3; IntAct=EBI-741480, EBI-10213520; CC Q9UMX0; Q9HBU6: ETNK1; NbExp=3; IntAct=EBI-741480, EBI-2834493; CC Q9UMX0; Q96GL9: FAM163A; NbExp=3; IntAct=EBI-741480, EBI-11793142; CC Q9UMX0; P0C2L3: FAM163B; NbExp=3; IntAct=EBI-741480, EBI-11793223; CC Q9UMX0; Q8NB25: FAM184A; NbExp=3; IntAct=EBI-741480, EBI-9917523; CC Q9UMX0; Q86UY5: FAM83A; NbExp=3; IntAct=EBI-741480, EBI-1384254; CC Q9UMX0; P12318: FCGR2A; NbExp=3; IntAct=EBI-741480, EBI-1395970; CC Q9UMX0; P26885: FKBP2; NbExp=3; IntAct=EBI-741480, EBI-719873; CC Q9UMX0; P02751: FN1; NbExp=3; IntAct=EBI-741480, EBI-1220319; CC Q9UMX0; P41439: FOLR3; NbExp=3; IntAct=EBI-741480, EBI-12893875; CC Q9UMX0; P15408: FOSL2; NbExp=3; IntAct=EBI-741480, EBI-3893419; CC Q9UMX0; O75084: FZD7; NbExp=5; IntAct=EBI-741480, EBI-746917; CC Q9UMX0; Q06547-2: GABPB1; NbExp=3; IntAct=EBI-741480, EBI-618189; CC Q9UMX0; O14764: GABRD; NbExp=4; IntAct=EBI-741480, EBI-744352; CC Q9UMX0; P22466: GAL; NbExp=3; IntAct=EBI-741480, EBI-6624768; CC Q9UMX0; Q9UBU3: GHRL; NbExp=3; IntAct=EBI-741480, EBI-10319458; CC Q9UMX0; Q49A26-4: GLYR1; NbExp=3; IntAct=EBI-741480, EBI-12143817; CC Q9UMX0; Q16538: GPR162; NbExp=3; IntAct=EBI-741480, EBI-22387200; CC Q9UMX0; Q02747: GUCA2A; NbExp=3; IntAct=EBI-741480, EBI-12244272; CC Q9UMX0; Q16661: GUCA2B; NbExp=3; IntAct=EBI-741480, EBI-12349759; CC Q9UMX0; P06028: GYPB; NbExp=6; IntAct=EBI-741480, EBI-10194756; CC Q9UMX0; Q5T447-2: HECTD3; NbExp=3; IntAct=EBI-741480, EBI-25854793; CC Q9UMX0; Q8IV36: HID1; NbExp=3; IntAct=EBI-741480, EBI-743438; CC Q9UMX0; P52789: HK2; NbExp=4; IntAct=EBI-741480, EBI-741469; CC Q9UMX0; Q53GQ0: HSD17B12; NbExp=6; IntAct=EBI-741480, EBI-2963255; CC Q9UMX0; P48723: HSPA13; NbExp=8; IntAct=EBI-741480, EBI-750892; CC Q9UMX0; Q9Y5U9: IER3IP1; NbExp=3; IntAct=EBI-741480, EBI-725665; CC Q9UMX0; P24592: IGFBP6; NbExp=3; IntAct=EBI-741480, EBI-947015; CC Q9UMX0; Q6PIK1: IGL@; NbExp=3; IntAct=EBI-741480, EBI-10253735; CC Q9UMX0; Q6PIQ7: IGL@; NbExp=3; IntAct=EBI-741480, EBI-6677651; CC Q9UMX0; Q8N355: IGL@; NbExp=4; IntAct=EBI-741480, EBI-748681; CC Q9UMX0; Q9NZH6: IL37; NbExp=3; IntAct=EBI-741480, EBI-3862125; CC Q9UMX0; Q17RA0: IL6ST; NbExp=3; IntAct=EBI-741480, EBI-10238517; CC Q9UMX0; P53990: IST1; NbExp=3; IntAct=EBI-741480, EBI-945994; CC Q9UMX0; P53990-3: IST1; NbExp=3; IntAct=EBI-741480, EBI-12188567; CC Q9UMX0; Q6GPH6: ITPRIPL1; NbExp=3; IntAct=EBI-741480, EBI-953819; CC Q9UMX0; Q96JJ6: JPH4; NbExp=3; IntAct=EBI-741480, EBI-2847044; CC Q9UMX0; Q96MG2: JSRP1; NbExp=3; IntAct=EBI-741480, EBI-11305455; CC Q9UMX0; P05412: JUN; NbExp=3; IntAct=EBI-741480, EBI-852823; CC Q9UMX0; Q8N5Z5: KCTD17; NbExp=3; IntAct=EBI-741480, EBI-743960; CC Q9UMX0; Q7Z7F0-4: KHDC4; NbExp=3; IntAct=EBI-741480, EBI-9089060; CC Q9UMX0; Q9P2K6: KLHL42; NbExp=4; IntAct=EBI-741480, EBI-739890; CC Q9UMX0; Q8IUC2: KRTAP8-1; NbExp=3; IntAct=EBI-741480, EBI-10261141; CC Q9UMX0; Q6ISS4: LAIR2; NbExp=3; IntAct=EBI-741480, EBI-10250491; CC Q9UMX0; P07942: LAMB1; NbExp=3; IntAct=EBI-741480, EBI-949174; CC Q9UMX0; Q6IAA8: LAMTOR1; NbExp=3; IntAct=EBI-741480, EBI-715385; CC Q9UMX0; O43504: LAMTOR5; NbExp=3; IntAct=EBI-741480, EBI-713382; CC Q9UMX0; P80188: LCN2; NbExp=3; IntAct=EBI-741480, EBI-11911016; CC Q9UMX0; A0A0S2Z5S9: LHX4; NbExp=3; IntAct=EBI-741480, EBI-16429099; CC Q9UMX0; Q9H2C1: LHX5; NbExp=3; IntAct=EBI-741480, EBI-25835523; CC Q9UMX0; Q68G74: LHX8; NbExp=3; IntAct=EBI-741480, EBI-8474075; CC Q9UMX0; Q8N0U6: LINC00518; NbExp=3; IntAct=EBI-741480, EBI-10264791; CC Q9UMX0; Q99732: LITAF; NbExp=4; IntAct=EBI-741480, EBI-725647; CC Q9UMX0; Q9UIQ6-2: LNPEP; NbExp=3; IntAct=EBI-741480, EBI-12133176; CC Q9UMX0; P27338: MAOB; NbExp=3; IntAct=EBI-741480, EBI-3911344; CC Q9UMX0; P21741: MDK; NbExp=3; IntAct=EBI-741480, EBI-722444; CC Q9UMX0; Q14696: MESD; NbExp=3; IntAct=EBI-741480, EBI-6165891; CC Q9UMX0; Q96C03: MIEF2; NbExp=4; IntAct=EBI-741480, EBI-750153; CC Q9UMX0; Q6IN84-2: MRM1; NbExp=3; IntAct=EBI-741480, EBI-25835707; CC Q9UMX0; O60783: MRPS14; NbExp=3; IntAct=EBI-741480, EBI-1045956; CC Q9UMX0; P01106: MYC; NbExp=3; IntAct=EBI-741480, EBI-447544; CC Q9UMX0; Q969H8: MYDGF; NbExp=3; IntAct=EBI-741480, EBI-718622; CC Q9UMX0; Q8IW45: NAXD; NbExp=3; IntAct=EBI-741480, EBI-8650724; CC Q9UMX0; P41271: NBL1; NbExp=3; IntAct=EBI-741480, EBI-10208650; CC Q9UMX0; P41271-2: NBL1; NbExp=3; IntAct=EBI-741480, EBI-12135485; CC Q9UMX0; Q9GZM8: NDEL1; NbExp=3; IntAct=EBI-741480, EBI-928842; CC Q9UMX0; Q9UHB4: NDOR1; NbExp=3; IntAct=EBI-741480, EBI-10249760; CC Q9UMX0; Q8NC67-2: NETO2; NbExp=3; IntAct=EBI-741480, EBI-25852289; CC Q9UMX0; Q96IV0: NGLY1; NbExp=7; IntAct=EBI-741480, EBI-6165879; CC Q9UMX0; Q13232: NME3; NbExp=6; IntAct=EBI-741480, EBI-713684; CC Q9UMX0; P01160: NPPA; NbExp=3; IntAct=EBI-741480, EBI-953859; CC Q9UMX0; Q14995: NR1D2; NbExp=3; IntAct=EBI-741480, EBI-6144053; CC Q9UMX0; F1D8P7: NR1H2; NbExp=3; IntAct=EBI-741480, EBI-10177172; CC Q9UMX0; Q6PHZ7: NR2C2; NbExp=3; IntAct=EBI-741480, EBI-2802743; CC Q9UMX0; Q9UBU9: NXF1; NbExp=3; IntAct=EBI-741480, EBI-398874; CC Q9UMX0; A5D8V7: ODAD3; NbExp=3; IntAct=EBI-741480, EBI-8466445; CC Q9UMX0; P0C6T2: OST4; NbExp=3; IntAct=EBI-741480, EBI-18397963; CC Q9UMX0; Q6GQQ9-2: OTUD7B; NbExp=3; IntAct=EBI-741480, EBI-25830200; CC Q9UMX0; Q8IVL6-2: P3H3; NbExp=3; IntAct=EBI-741480, EBI-12149899; CC Q9UMX0; Q8N3R9: PALS1; NbExp=3; IntAct=EBI-741480, EBI-2513978; CC Q9UMX0; Q495U3: PANX2; NbExp=3; IntAct=EBI-741480, EBI-17242559; CC Q9UMX0; Q9HCL0: PCDH18; NbExp=6; IntAct=EBI-741480, EBI-2949740; CC Q9UMX0; Q9UN74-2: PCDHA4; NbExp=3; IntAct=EBI-741480, EBI-12184485; CC Q9UMX0; Q13956: PDE6H; NbExp=3; IntAct=EBI-741480, EBI-10231995; CC Q9UMX0; O15534: PER1; NbExp=3; IntAct=EBI-741480, EBI-2557276; CC Q9UMX0; O75928-2: PIAS2; NbExp=3; IntAct=EBI-741480, EBI-348567; CC Q9UMX0; Q96FE7: PIK3IP1; NbExp=3; IntAct=EBI-741480, EBI-10285708; CC Q9UMX0; P14618: PKM; NbExp=3; IntAct=EBI-741480, EBI-353408; CC Q9UMX0; Q9HDD0: PLAAT1; NbExp=3; IntAct=EBI-741480, EBI-12387058; CC Q9UMX0; Q9NWW9: PLAAT2; NbExp=3; IntAct=EBI-741480, EBI-12253270; CC Q9UMX0; P53816: PLAAT3; NbExp=7; IntAct=EBI-741480, EBI-746318; CC Q9UMX0; Q6ZR37: PLEKHG7; NbExp=3; IntAct=EBI-741480, EBI-12891828; CC Q9UMX0; Q5SXH7-1: PLEKHS1; NbExp=3; IntAct=EBI-741480, EBI-26412802; CC Q9UMX0; Q96T60: PNKP; NbExp=3; IntAct=EBI-741480, EBI-1045072; CC Q9UMX0; Q8ND90: PNMA1; NbExp=4; IntAct=EBI-741480, EBI-302345; CC Q9UMX0; P0DPB6: POLR1D; NbExp=3; IntAct=EBI-741480, EBI-359498; CC Q9UMX0; P19388: POLR2E; NbExp=3; IntAct=EBI-741480, EBI-395189; CC Q9UMX0; P23284: PPIB; NbExp=3; IntAct=EBI-741480, EBI-359252; CC Q9UMX0; P45877: PPIC; NbExp=3; IntAct=EBI-741480, EBI-953909; CC Q9UMX0; O60927: PPP1R11; NbExp=3; IntAct=EBI-741480, EBI-1048104; CC Q9UMX0; Q96I34: PPP1R16A; NbExp=3; IntAct=EBI-741480, EBI-710402; CC Q9UMX0; Q96NZ9: PRAP1; NbExp=6; IntAct=EBI-741480, EBI-2116102; CC Q9UMX0; A5D903: PRB1; NbExp=3; IntAct=EBI-741480, EBI-10173935; CC Q9UMX0; O43741: PRKAB2; NbExp=3; IntAct=EBI-741480, EBI-1053424; CC Q9UMX0; Q16378: PRR4; NbExp=3; IntAct=EBI-741480, EBI-738624; CC Q9UMX0; P49768: PSEN1; NbExp=3; IntAct=EBI-741480, EBI-297277; CC Q9UMX0; P49810: PSEN2; NbExp=3; IntAct=EBI-741480, EBI-2010251; CC Q9UMX0; P55036: PSMD4; NbExp=4; IntAct=EBI-741480, EBI-359318; CC Q9UMX0; Q15008: PSMD6; NbExp=3; IntAct=EBI-741480, EBI-359701; CC Q9UMX0; Q06323: PSME1; NbExp=3; IntAct=EBI-741480, EBI-712149; CC Q9UMX0; Q9UIG4: PSORS1C2; NbExp=3; IntAct=EBI-741480, EBI-11974061; CC Q9UMX0; P06454-2: PTMA; NbExp=3; IntAct=EBI-741480, EBI-10194874; CC Q9UMX0; Q8WUD1-2: RAB2B; NbExp=3; IntAct=EBI-741480, EBI-25835884; CC Q9UMX0; Q9UNT1-2: RABL2B; NbExp=3; IntAct=EBI-741480, EBI-12256104; CC Q9UMX0; Q9Y5P3: RAI2; NbExp=3; IntAct=EBI-741480, EBI-746228; CC Q9UMX0; Q04206: RELA; NbExp=3; IntAct=EBI-741480, EBI-73886; CC Q9UMX0; P47804-3: RGR; NbExp=3; IntAct=EBI-741480, EBI-25834767; CC Q9UMX0; Q15382: RHEB; NbExp=3; IntAct=EBI-741480, EBI-1055287; CC Q9UMX0; Q9NPQ8: RIC8A; NbExp=4; IntAct=EBI-741480, EBI-717509; CC Q9UMX0; Q9NPQ8-4: RIC8A; NbExp=3; IntAct=EBI-741480, EBI-9091816; CC Q9UMX0; Q9H0X6: RNF208; NbExp=3; IntAct=EBI-741480, EBI-751555; CC Q9UMX0; P78317: RNF4; NbExp=3; IntAct=EBI-741480, EBI-2340927; CC Q9UMX0; P62899: RPL31; NbExp=3; IntAct=EBI-741480, EBI-1053664; CC Q9UMX0; P04843: RPN1; NbExp=4; IntAct=EBI-741480, EBI-355963; CC Q9UMX0; P62979: RPS27A; NbExp=3; IntAct=EBI-741480, EBI-357375; CC Q9UMX0; Q7L4I2-2: RSRC2; NbExp=3; IntAct=EBI-741480, EBI-10256202; CC Q9UMX0; Q9BWD3: RTL8A; NbExp=4; IntAct=EBI-741480, EBI-741643; CC Q9UMX0; Q17RB0: RTL8B; NbExp=6; IntAct=EBI-741480, EBI-10238588; CC Q9UMX0; A6ZKI3: RTL8C; NbExp=6; IntAct=EBI-741480, EBI-10174072; CC Q9UMX0; P13521: SCG2; NbExp=4; IntAct=EBI-741480, EBI-947132; CC Q9UMX0; P05408: SCG5; NbExp=3; IntAct=EBI-741480, EBI-722635; CC Q9UMX0; Q96GD3: SCMH1; NbExp=3; IntAct=EBI-741480, EBI-713793; CC Q9UMX0; Q9NTN9-3: SEMA4G; NbExp=3; IntAct=EBI-741480, EBI-9089805; CC Q9UMX0; P05121: SERPINE1; NbExp=3; IntAct=EBI-741480, EBI-953978; CC Q9UMX0; O75830: SERPINI2; NbExp=10; IntAct=EBI-741480, EBI-750144; CC Q9UMX0; Q9BYH1-5: SEZ6L; NbExp=3; IntAct=EBI-741480, EBI-12012146; CC Q9UMX0; Q9H173: SIL1; NbExp=3; IntAct=EBI-741480, EBI-2840325; CC Q9UMX0; O15427: SLC16A3; NbExp=3; IntAct=EBI-741480, EBI-7600166; CC Q9UMX0; P03973: SLPI; NbExp=5; IntAct=EBI-741480, EBI-355293; CC Q9UMX0; Q96E16: SMIM19; NbExp=3; IntAct=EBI-741480, EBI-17657124; CC Q9UMX0; Q9BVW6: SMIM2; NbExp=3; IntAct=EBI-741480, EBI-10300146; CC Q9UMX0; P02814: SMR3B; NbExp=3; IntAct=EBI-741480, EBI-738612; CC Q9UMX0; Q13573: SNW1; NbExp=3; IntAct=EBI-741480, EBI-632715; CC Q9UMX0; O14544: SOCS6; NbExp=3; IntAct=EBI-741480, EBI-3929549; CC Q9UMX0; P08294: SOD3; NbExp=3; IntAct=EBI-741480, EBI-10195782; CC Q9UMX0; Q02086-2: SP2; NbExp=3; IntAct=EBI-741480, EBI-9088579; CC Q9UMX0; Q99932-2: SPAG8; NbExp=3; IntAct=EBI-741480, EBI-11959123; CC Q9UMX0; Q7Z6I5: SPATA12; NbExp=3; IntAct=EBI-741480, EBI-10696971; CC Q9UMX0; Q86W54-2: SPATA24; NbExp=3; IntAct=EBI-741480, EBI-12041693; CC Q9UMX0; Q496A3: SPATS1; NbExp=3; IntAct=EBI-741480, EBI-3923692; CC Q9UMX0; Q9C004: SPRY4; NbExp=3; IntAct=EBI-741480, EBI-354861; CC Q9UMX0; P10124: SRGN; NbExp=6; IntAct=EBI-741480, EBI-744915; CC Q9UMX0; Q99469: STAC; NbExp=3; IntAct=EBI-741480, EBI-2652799; CC Q9UMX0; O75886: STAM2; NbExp=3; IntAct=EBI-741480, EBI-373258; CC Q9UMX0; Q13586: STIM1; NbExp=3; IntAct=EBI-741480, EBI-448878; CC Q9UMX0; O95947: TBX6; NbExp=3; IntAct=EBI-741480, EBI-2824328; CC Q9UMX0; O15273: TCAP; NbExp=3; IntAct=EBI-741480, EBI-954089; CC Q9UMX0; Q86WV5: TEN1; NbExp=3; IntAct=EBI-741480, EBI-2562799; CC Q9UMX0; P54274-2: TERF1; NbExp=3; IntAct=EBI-741480, EBI-711018; CC Q9UMX0; Q9BXU0: TEX12; NbExp=3; IntAct=EBI-741480, EBI-12090309; CC Q9UMX0; Q5T0J7-2: TEX35; NbExp=3; IntAct=EBI-741480, EBI-12833746; CC Q9UMX0; P04155: TFF1; NbExp=6; IntAct=EBI-741480, EBI-743871; CC Q9UMX0; Q8WTV1: THAP3; NbExp=3; IntAct=EBI-741480, EBI-17438286; CC Q9UMX0; O60830: TIMM17B; NbExp=3; IntAct=EBI-741480, EBI-2372529; CC Q9UMX0; Q96DC7: TMCO6; NbExp=7; IntAct=EBI-741480, EBI-746174; CC Q9UMX0; Q96DC7-2: TMCO6; NbExp=3; IntAct=EBI-741480, EBI-10284552; CC Q9UMX0; Q96B77: TMEM186; NbExp=3; IntAct=EBI-741480, EBI-9089409; CC Q9UMX0; P61165: TMEM258; NbExp=3; IntAct=EBI-741480, EBI-12019210; CC Q9UMX0; Q5JXX7: TMEM31; NbExp=6; IntAct=EBI-741480, EBI-10244617; CC Q9UMX0; Q8N0U2: TMEM61; NbExp=3; IntAct=EBI-741480, EBI-25830583; CC Q9UMX0; Q53NU3: tmp_locus_54; NbExp=3; IntAct=EBI-741480, EBI-10242677; CC Q9UMX0; Q71RG4-4: TMUB2; NbExp=3; IntAct=EBI-741480, EBI-25831574; CC Q9UMX0; P36406: TRIM23; NbExp=6; IntAct=EBI-741480, EBI-740098; CC Q9UMX0; Q13049: TRIM32; NbExp=7; IntAct=EBI-741480, EBI-742790; CC Q9UMX0; Q9UPQ4-2: TRIM35; NbExp=3; IntAct=EBI-741480, EBI-17716262; CC Q9UMX0; Q9Y3Q8: TSC22D4; NbExp=3; IntAct=EBI-741480, EBI-739485; CC Q9UMX0; O60636: TSPAN2; NbExp=3; IntAct=EBI-741480, EBI-3914288; CC Q9UMX0; Q6PF05: TTC23L; NbExp=3; IntAct=EBI-741480, EBI-8656864; CC Q9UMX0; Q9UGJ1-2: TUBGCP4; NbExp=3; IntAct=EBI-741480, EBI-10964469; CC Q9UMX0; O95881: TXNDC12; NbExp=4; IntAct=EBI-741480, EBI-2564581; CC Q9UMX0; P62987: UBA52; NbExp=3; IntAct=EBI-741480, EBI-357304; CC Q9UMX0; Q5U5U6: UBB; NbExp=3; IntAct=EBI-741480, EBI-1642104; CC Q9UMX0; Q96C32: UBC; NbExp=3; IntAct=EBI-741480, EBI-745483; CC Q9UMX0; P49459: UBE2A; NbExp=3; IntAct=EBI-741480, EBI-2339348; CC Q9UMX0; Q7KZS0: UBE2I; NbExp=3; IntAct=EBI-741480, EBI-10180829; CC Q9UMX0; Q13404: UBE2V1; NbExp=9; IntAct=EBI-741480, EBI-1050671; CC Q9UMX0; Q9UMX0: UBQLN1; NbExp=3; IntAct=EBI-741480, EBI-741480; CC Q9UMX0; Q9UHD9: UBQLN2; NbExp=3; IntAct=EBI-741480, EBI-947187; CC Q9UMX0; Q9NRR5: UBQLN4; NbExp=8; IntAct=EBI-741480, EBI-711226; CC Q9UMX0; Q04323: UBXN1; NbExp=3; IntAct=EBI-741480, EBI-1058647; CC Q9UMX0; Q92575: UBXN4; NbExp=6; IntAct=EBI-741480, EBI-723441; CC Q9UMX0; O94888: UBXN7; NbExp=3; IntAct=EBI-741480, EBI-1993627; CC Q9UMX0; P22415: USF1; NbExp=3; IntAct=EBI-741480, EBI-1054489; CC Q9UMX0; Q9P1Q0-4: VPS54; NbExp=3; IntAct=EBI-741480, EBI-25835297; CC Q9UMX0; Q2TAL6: VWC2; NbExp=3; IntAct=EBI-741480, EBI-11957238; CC Q9UMX0; Q9NX94: WBP1L; NbExp=3; IntAct=EBI-741480, EBI-10316321; CC Q9UMX0; Q8WWY7: WFDC12; NbExp=3; IntAct=EBI-741480, EBI-11958577; CC Q9UMX0; O00755: WNT7A; NbExp=3; IntAct=EBI-741480, EBI-727198; CC Q9UMX0; Q0VG75: XPO4; NbExp=3; IntAct=EBI-741480, EBI-10226948; CC Q9UMX0; O43829: ZBTB14; NbExp=3; IntAct=EBI-741480, EBI-10176632; CC Q9UMX0; Q8NAP8: ZBTB8B; NbExp=3; IntAct=EBI-741480, EBI-17494306; CC Q9UMX0; Q53FD0-2: ZC2HC1C; NbExp=3; IntAct=EBI-741480, EBI-14104088; CC Q9UMX0; Q9NP64: ZCCHC17; NbExp=3; IntAct=EBI-741480, EBI-746345; CC Q9UMX0; O60844: ZG16; NbExp=10; IntAct=EBI-741480, EBI-746479; CC Q9UMX0; Q96DA0: ZG16B; NbExp=3; IntAct=EBI-741480, EBI-953824; CC Q9UMX0; Q5VZL5: ZMYM4; NbExp=3; IntAct=EBI-741480, EBI-2514659; CC Q9UMX0; Q9UJ78-2: ZMYM5; NbExp=3; IntAct=EBI-741480, EBI-17634549; CC Q9UMX0; Q8WUU4: ZNF296; NbExp=3; IntAct=EBI-741480, EBI-8834821; CC Q9UMX0; Q96JL9-2: ZNF333; NbExp=3; IntAct=EBI-741480, EBI-25835852; CC Q9UMX0; Q6P1L6: ZNF343; NbExp=3; IntAct=EBI-741480, EBI-10252492; CC Q9UMX0; Q3KNS6-3: ZNF829; NbExp=3; IntAct=EBI-741480, EBI-18036029; CC Q9UMX0; A0A1U9X8X8; NbExp=3; IntAct=EBI-741480, EBI-17234977; CC Q9UMX0; B7Z3E8; NbExp=3; IntAct=EBI-741480, EBI-25831617; CC Q9UMX0; Q8WU02; NbExp=3; IntAct=EBI-741480, EBI-747182; CC Q9UMX0; P0DTC6: 6; Xeno; NbExp=3; IntAct=EBI-741480, EBI-25475897; CC Q9UMX0; P0DTD3: 9c; Xeno; NbExp=3; IntAct=EBI-741480, EBI-25475917; CC Q9UMX0; P00431: CCP1; Xeno; NbExp=3; IntAct=EBI-741480, EBI-4389; CC Q9UMX0; P35176: CPR5; Xeno; NbExp=3; IntAct=EBI-741480, EBI-5458; CC Q9UMX0; Q04201: CUE4; Xeno; NbExp=3; IntAct=EBI-741480, EBI-27928; CC Q9UMX0; P43497: CWP2; Xeno; NbExp=3; IntAct=EBI-741480, EBI-2044078; CC Q9UMX0; P40325: HUA1; Xeno; NbExp=3; IntAct=EBI-741480, EBI-23614; CC Q9UMX0; P61829: OLI1; Xeno; NbExp=3; IntAct=EBI-741480, EBI-9016907; CC Q9UMX0; Q02771: PET117; Xeno; NbExp=3; IntAct=EBI-741480, EBI-14092; CC Q9UMX0; P38886: RPN10; Xeno; NbExp=3; IntAct=EBI-741480, EBI-15949; CC Q9UMX0; P40092: SPI1; Xeno; NbExp=3; IntAct=EBI-741480, EBI-22721; CC Q9UMX0; P13130: SPS100; Xeno; NbExp=3; IntAct=EBI-741480, EBI-11523294; CC Q9UMX0; P27654: TIP1; Xeno; NbExp=3; IntAct=EBI-741480, EBI-19268; CC Q9UMX0; P54860: UFD2; Xeno; NbExp=3; IntAct=EBI-741480, EBI-20003; CC Q9UMX0; P38868: YHR180W; Xeno; NbExp=3; IntAct=EBI-741480, EBI-24840; CC Q9UMX0-2; O00154: ACOT7; NbExp=3; IntAct=EBI-10173939, EBI-948905; CC Q9UMX0-2; O95994: AGR2; NbExp=3; IntAct=EBI-10173939, EBI-712648; CC Q9UMX0-2; Q8TD06: AGR3; NbExp=3; IntAct=EBI-10173939, EBI-3925742; CC Q9UMX0-2; Q9NP55: BPIFA1; NbExp=3; IntAct=EBI-10173939, EBI-953896; CC Q9UMX0-2; Q9BXJ5: C1QTNF2; NbExp=3; IntAct=EBI-10173939, EBI-2817707; CC Q9UMX0-2; O43852: CALU; NbExp=3; IntAct=EBI-10173939, EBI-1171069; CC Q9UMX0-2; P80098: CCL7; NbExp=3; IntAct=EBI-10173939, EBI-718759; CC Q9UMX0-2; Q8TCZ2: CD99L2; NbExp=6; IntAct=EBI-10173939, EBI-2824782; CC Q9UMX0-2; P51788-4: CLCN2; NbExp=3; IntAct=EBI-10173939, EBI-16431116; CC Q9UMX0-2; Q03692: COL10A1; NbExp=3; IntAct=EBI-10173939, EBI-2528309; CC Q9UMX0-2; A0A0S2Z3K0: COL1A2; NbExp=3; IntAct=EBI-10173939, EBI-16431143; CC Q9UMX0-2; P08123: COL1A2; NbExp=6; IntAct=EBI-10173939, EBI-983038; CC Q9UMX0-2; Q8IYK4: COLGALT2; NbExp=3; IntAct=EBI-10173939, EBI-10263496; CC Q9UMX0-2; Q86VU5: COMTD1; NbExp=3; IntAct=EBI-10173939, EBI-2836030; CC Q9UMX0-2; P33240: CSTF2; NbExp=3; IntAct=EBI-10173939, EBI-711360; CC Q9UMX0-2; Q9H0L4: CSTF2T; NbExp=3; IntAct=EBI-10173939, EBI-747012; CC Q9UMX0-2; P78358: CTAG1B; NbExp=3; IntAct=EBI-10173939, EBI-1188472; CC Q9UMX0-2; O75638: CTAG2; NbExp=3; IntAct=EBI-10173939, EBI-10188927; CC Q9UMX0-2; Q9UHQ9: CYB5R1; NbExp=3; IntAct=EBI-10173939, EBI-953870; CC Q9UMX0-2; Q01524: DEFA6; NbExp=3; IntAct=EBI-10173939, EBI-10222451; CC Q9UMX0-2; A0A0S2Z5Y1: DOLK; NbExp=3; IntAct=EBI-10173939, EBI-16431159; CC Q9UMX0-2; O95967: EFEMP2; NbExp=3; IntAct=EBI-10173939, EBI-743414; CC Q9UMX0-2; Q96DN0: ERP27; NbExp=3; IntAct=EBI-10173939, EBI-953772; CC Q9UMX0-2; Q9HBU6: ETNK1; NbExp=3; IntAct=EBI-10173939, EBI-2834493; CC Q9UMX0-2; P12318: FCGR2A; NbExp=3; IntAct=EBI-10173939, EBI-1395970; CC Q9UMX0-2; P26885: FKBP2; NbExp=3; IntAct=EBI-10173939, EBI-719873; CC Q9UMX0-2; O14764: GABRD; NbExp=3; IntAct=EBI-10173939, EBI-744352; CC Q9UMX0-2; Q9UBU3: GHRL; NbExp=3; IntAct=EBI-10173939, EBI-10319458; CC Q9UMX0-2; P22352: GPX3; NbExp=3; IntAct=EBI-10173939, EBI-2832946; CC Q9UMX0-2; Q14416: GRM2; NbExp=3; IntAct=EBI-10173939, EBI-10232876; CC Q9UMX0-2; P06028: GYPB; NbExp=3; IntAct=EBI-10173939, EBI-10194756; CC Q9UMX0-2; P52789: HK2; NbExp=3; IntAct=EBI-10173939, EBI-741469; CC Q9UMX0-2; Q53GQ0: HSD17B12; NbExp=3; IntAct=EBI-10173939, EBI-2963255; CC Q9UMX0-2; P48723: HSPA13; NbExp=4; IntAct=EBI-10173939, EBI-750892; CC Q9UMX0-2; Q6PIK1: IGL@; NbExp=3; IntAct=EBI-10173939, EBI-10253735; CC Q9UMX0-2; Q6PIQ7: IGL@; NbExp=3; IntAct=EBI-10173939, EBI-6677651; CC Q9UMX0-2; Q8N355: IGL@; NbExp=3; IntAct=EBI-10173939, EBI-748681; CC Q9UMX0-2; Q17RA0: IL6ST; NbExp=3; IntAct=EBI-10173939, EBI-10238517; CC Q9UMX0-2; Q9P2K6: KLHL42; NbExp=3; IntAct=EBI-10173939, EBI-739890; CC Q9UMX0-2; Q99732: LITAF; NbExp=7; IntAct=EBI-10173939, EBI-725647; CC Q9UMX0-2; Q9NQG1: MANBAL; NbExp=3; IntAct=EBI-10173939, EBI-3867271; CC Q9UMX0-2; P33993: MCM7; NbExp=3; IntAct=EBI-10173939, EBI-355924; CC Q9UMX0-2; Q9NQG6: MIEF1; NbExp=3; IntAct=EBI-10173939, EBI-740987; CC Q9UMX0-2; Q96C03: MIEF2; NbExp=3; IntAct=EBI-10173939, EBI-750153; CC Q9UMX0-2; P55198: MLLT6; NbExp=3; IntAct=EBI-10173939, EBI-740216; CC Q9UMX0-2; Q8IW45: NAXD; NbExp=3; IntAct=EBI-10173939, EBI-8650724; CC Q9UMX0-2; P41271: NBL1; NbExp=3; IntAct=EBI-10173939, EBI-10208650; CC Q9UMX0-2; Q96IV0: NGLY1; NbExp=3; IntAct=EBI-10173939, EBI-6165879; CC Q9UMX0-2; A0A0S2Z5K2: NLGN3; NbExp=3; IntAct=EBI-10173939, EBI-16431177; CC Q9UMX0-2; Q13232: NME3; NbExp=3; IntAct=EBI-10173939, EBI-713684; CC Q9UMX0-2; Q9BVL2: NUP58; NbExp=3; IntAct=EBI-10173939, EBI-2811583; CC Q9UMX0-2; Q96AQ6: PBXIP1; NbExp=3; IntAct=EBI-10173939, EBI-740845; CC Q9UMX0-2; Q96FE7: PIK3IP1; NbExp=3; IntAct=EBI-10173939, EBI-10285708; CC Q9UMX0-2; P53816: PLAAT3; NbExp=3; IntAct=EBI-10173939, EBI-746318; CC Q9UMX0-2; Q8ND90: PNMA1; NbExp=3; IntAct=EBI-10173939, EBI-302345; CC Q9UMX0-2; P23284: PPIB; NbExp=3; IntAct=EBI-10173939, EBI-359252; CC Q9UMX0-2; P45877: PPIC; NbExp=3; IntAct=EBI-10173939, EBI-953909; CC Q9UMX0-2; Q96NZ9: PRAP1; NbExp=3; IntAct=EBI-10173939, EBI-2116102; CC Q9UMX0-2; A5D903: PRB1; NbExp=3; IntAct=EBI-10173939, EBI-10173935; CC Q9UMX0-2; Q15008: PSMD6; NbExp=3; IntAct=EBI-10173939, EBI-359701; CC Q9UMX0-2; Q9NPQ8-4: RIC8A; NbExp=3; IntAct=EBI-10173939, EBI-9091816; CC Q9UMX0-2; P04843: RPN1; NbExp=3; IntAct=EBI-10173939, EBI-355963; CC Q9UMX0-2; Q9BWD3: RTL8A; NbExp=3; IntAct=EBI-10173939, EBI-741643; CC Q9UMX0-2; Q17RB0: RTL8B; NbExp=3; IntAct=EBI-10173939, EBI-10238588; CC Q9UMX0-2; A6ZKI3: RTL8C; NbExp=3; IntAct=EBI-10173939, EBI-10174072; CC Q9UMX0-2; P05408: SCG5; NbExp=3; IntAct=EBI-10173939, EBI-722635; CC Q9UMX0-2; Q96GD3: SCMH1; NbExp=3; IntAct=EBI-10173939, EBI-713793; CC Q9UMX0-2; P05121: SERPINE1; NbExp=3; IntAct=EBI-10173939, EBI-953978; CC Q9UMX0-2; O75830: SERPINI2; NbExp=3; IntAct=EBI-10173939, EBI-750144; CC Q9UMX0-2; Q9BVW6: SMIM2; NbExp=3; IntAct=EBI-10173939, EBI-10300146; CC Q9UMX0-2; P02814: SMR3B; NbExp=3; IntAct=EBI-10173939, EBI-738612; CC Q9UMX0-2; P10124: SRGN; NbExp=3; IntAct=EBI-10173939, EBI-744915; CC Q9UMX0-2; Q96DC7-2: TMCO6; NbExp=3; IntAct=EBI-10173939, EBI-10284552; CC Q9UMX0-2; Q5JXX7: TMEM31; NbExp=3; IntAct=EBI-10173939, EBI-10244617; CC Q9UMX0-2; A0A0S2Z5T9: TMEM67; NbExp=3; IntAct=EBI-10173939, EBI-16431189; CC Q9UMX0-2; Q71RG4: TMUB2; NbExp=3; IntAct=EBI-10173939, EBI-2820477; CC Q9UMX0-2; Q13049: TRIM32; NbExp=3; IntAct=EBI-10173939, EBI-742790; CC Q9UMX0-2; O95881: TXNDC12; NbExp=3; IntAct=EBI-10173939, EBI-2564581; CC Q9UMX0-2; Q13404: UBE2V1; NbExp=3; IntAct=EBI-10173939, EBI-1050671; CC Q9UMX0-2; Q04323: UBXN1; NbExp=3; IntAct=EBI-10173939, EBI-1058647; CC Q9UMX0-2; Q92575: UBXN4; NbExp=3; IntAct=EBI-10173939, EBI-723441; CC Q9UMX0-2; Q0VG75: XPO4; NbExp=3; IntAct=EBI-10173939, EBI-10226948; CC Q9UMX0-2; Q8WV99: ZFAND2B; NbExp=3; IntAct=EBI-10173939, EBI-747823; CC Q9UMX0-2; O60844: ZG16; NbExp=3; IntAct=EBI-10173939, EBI-746479; CC Q9UMX0-2; Q96DA0: ZG16B; NbExp=3; IntAct=EBI-10173939, EBI-953824; CC Q9UMX0-2; Q5VZL5: ZMYM4; NbExp=3; IntAct=EBI-10173939, EBI-2514659; CC Q9UMX0-2; Q8WU02; NbExp=3; IntAct=EBI-10173939, EBI-747182; CC Q9UMX0-2; Q96FB2; NbExp=3; IntAct=EBI-10173939, EBI-2857623; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:16159959, CC ECO:0000269|PubMed:23979357}. Nucleus {ECO:0000269|PubMed:23979357}. CC Endoplasmic reticulum {ECO:0000269|PubMed:19822669}. Cytoplasmic CC vesicle, autophagosome {ECO:0000269|PubMed:19148225, CC ECO:0000269|PubMed:20529957, ECO:0000269|PubMed:21143716, CC ECO:0000269|PubMed:21695056, ECO:0000269|PubMed:23307288, CC ECO:0000269|PubMed:23459205}. Cell membrane CC {ECO:0000269|PubMed:21143716, ECO:0000269|PubMed:23307288}. CC Note=Detected in neuronal processes and at synapses (By similarity). CC Recruited to the ER during ER-associated protein degradation (ERAD) CC (PubMed:19822669). Isoform 1 and isoform 3 colocalize with PSEN1 in the CC cell membrane and in cytoplasmic juxtanuclear structures called CC aggresomes (PubMed:21143716). Colocalizes with ORAI1 and TICAM1 in the CC autophagosome (PubMed:21695056, PubMed:23307288). Colocalizes with CC EPS15 and HGS in ubiquitin-rich cytoplasmic aggregates that are not CC endocytic compartments and with EPS15 also in aggresomes CC (PubMed:16159959). {ECO:0000250|UniProtKB:Q9JJP9, CC ECO:0000269|PubMed:16159959, ECO:0000269|PubMed:19822669, CC ECO:0000269|PubMed:21143716, ECO:0000269|PubMed:21695056, CC ECO:0000269|PubMed:23307288}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=Q9UMX0-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9UMX0-2; Sequence=VSP_009787; CC Name=3; CC IsoId=Q9UMX0-3; Sequence=VSP_057689; CC Name=4; CC IsoId=Q9UMX0-4; Sequence=VSP_057690, VSP_057691; CC -!- TISSUE SPECIFICITY: Brain (at protein level) (PubMed:18953672). CC Ubiquitous. Highly expressed throughout the brain; detected in neurons CC and in neuropathological lesions, such as neurofibrillary tangles and CC Lewy bodies. Highly expressed in heart, placenta, pancreas, lung, CC liver, skeletal muscle and kidney. {ECO:0000269|PubMed:11076969, CC ECO:0000269|PubMed:11853878, ECO:0000269|PubMed:18953672}. CC -!- DOMAIN: The UBA domain mediates binding to PSEN1 and PSEN2. It also CC binds ubiquitin with micromolar affinity, independently of CC polyubiquitin linkage type. Essential for its association with CC microtubule-associated protein 1 light chain 3 (MAP1LC3). CC {ECO:0000269|PubMed:11076969, ECO:0000269|PubMed:15147878, CC ECO:0000269|PubMed:19148225}. CC -!- DOMAIN: The ubiquitin-like domain mediates its association with the CC subunits of the proteasome. {ECO:0000269|PubMed:15147878}. CC -!- DOMAIN: Dimerization is dependent upon the central region of the CC protein containing the STI1 domains and is independent of its CC ubiquitin-like and UBA domains. {ECO:0000269|PubMed:16813565}. CC -!- PTM: Degraded during both macroautophagy and during chaperone-mediated CC autophagy (CMA). {ECO:0000269|PubMed:20529957}. CC -!- PTM: Phosphorylated. {ECO:0000269|PubMed:11853878}. CC -!- PTM: Ubiquitinated. {ECO:0000269|PubMed:16159959}. CC -!- MISCELLANEOUS: May be a prognostic marker for lung adenocarcinoma CC patient clinical outcome. {ECO:0000269|PubMed:22233804}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF176069; AAD49751.3; -; mRNA. DR EMBL; AF293384; AAG02473.1; -; mRNA. DR EMBL; AB035275; BAB20436.1; -; mRNA. DR EMBL; HM005532; AEE61129.1; -; mRNA. DR EMBL; AL136643; CAB66578.1; -; mRNA. DR EMBL; AL354920; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471089; EAW62659.1; -; Genomic_DNA. DR EMBL; CH471089; EAW62661.1; -; Genomic_DNA. DR EMBL; CH471089; EAW62664.1; -; Genomic_DNA. DR EMBL; BC010066; AAH10066.1; -; mRNA. DR EMBL; BC039294; AAH39294.1; -; mRNA. DR EMBL; AK074535; -; NOT_ANNOTATED_CDS; mRNA. DR CCDS; CCDS6663.1; -. [Q9UMX0-1] DR CCDS; CCDS6664.1; -. [Q9UMX0-2] DR RefSeq; NP_038466.2; NM_013438.4. [Q9UMX0-1] DR RefSeq; NP_444295.1; NM_053067.3. [Q9UMX0-2] DR PDB; 2JY5; NMR; -; A=541-586. DR PDB; 2JY6; NMR; -; B=541-586. DR PDB; 2KLC; NMR; -; A=34-112. DR PDBsum; 2JY5; -. DR PDBsum; 2JY6; -. DR PDBsum; 2KLC; -. DR AlphaFoldDB; Q9UMX0; -. DR BMRB; Q9UMX0; -. DR SASBDB; Q9UMX0; -. DR SMR; Q9UMX0; -. DR BioGRID; 119007; 460. DR CORUM; Q9UMX0; -. DR DIP; DIP-41629N; -. DR FunCoup; Q9UMX0; 3499. DR IntAct; Q9UMX0; 383. DR MINT; Q9UMX0; -. DR STRING; 9606.ENSP00000365576; -. DR GlyCosmos; Q9UMX0; 5 sites, 1 glycan. DR GlyGen; Q9UMX0; 8 sites, 1 O-linked glycan (7 sites). DR iPTMnet; Q9UMX0; -. DR MetOSite; Q9UMX0; -. DR PhosphoSitePlus; Q9UMX0; -. DR BioMuta; UBQLN1; -. DR DMDM; 48475013; -. DR REPRODUCTION-2DPAGE; IPI00071180; -. DR jPOST; Q9UMX0; -. DR MassIVE; Q9UMX0; -. DR PaxDb; 9606-ENSP00000365576; -. DR PeptideAtlas; Q9UMX0; -. DR ProteomicsDB; 85215; -. [Q9UMX0-1] DR ProteomicsDB; 85216; -. [Q9UMX0-2] DR Pumba; Q9UMX0; -. DR Antibodypedia; 27540; 348 antibodies from 32 providers. DR DNASU; 29979; -. DR Ensembl; ENST00000257468.11; ENSP00000257468.7; ENSG00000135018.15. [Q9UMX0-2] DR Ensembl; ENST00000376395.9; ENSP00000365576.4; ENSG00000135018.15. [Q9UMX0-1] DR GeneID; 29979; -. DR KEGG; hsa:29979; -. DR MANE-Select; ENST00000376395.9; ENSP00000365576.4; NM_013438.5; NP_038466.2. DR UCSC; uc004amv.4; human. [Q9UMX0-1] DR AGR; HGNC:12508; -. DR ClinPGx; PA37155; -. DR CTD; 29979; -. DR DisGeNET; 29979; -. DR GeneCards; UBQLN1; -. DR HGNC; HGNC:12508; UBQLN1. DR HPA; ENSG00000135018; Low tissue specificity. DR MIM; 605046; gene. DR OpenTargets; ENSG00000135018; -. DR VEuPathDB; HostDB:ENSG00000135018; -. DR eggNOG; KOG0010; Eukaryota. DR GeneTree; ENSGT00940000156437; -. DR HOGENOM; CLU_024293_4_0_1; -. DR InParanoid; Q9UMX0; -. DR OMA; PGMDMFG; -. DR OrthoDB; 9450922at2759; -. DR PAN-GO; Q9UMX0; 6 GO annotations based on evolutionary models. DR PhylomeDB; Q9UMX0; -. DR PathwayCommons; Q9UMX0; -. DR Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis. DR SignaLink; Q9UMX0; -. DR SIGNOR; Q9UMX0; -. DR Agora; ENSG00000135018; -. DR BioGRID-ORCS; 29979; 25 hits in 1162 CRISPR screens. DR CD-CODE; EB3EADD3; Ubqln puncta. DR ChiTaRS; UBQLN1; human. DR EvolutionaryTrace; Q9UMX0; -. DR GeneWiki; UBQLN1; -. DR GenomeRNAi; 29979; -. DR Pharos; Q9UMX0; Tbio. DR PRO; PR:Q9UMX0; -. DR Proteomes; UP000005640; Chromosome 9. DR RNAct; Q9UMX0; protein. DR Bgee; ENSG00000135018; Expressed in ileal mucosa and 196 other cell types or tissues. DR ExpressionAtlas; Q9UMX0; baseline and differential. DR GO; GO:0016235; C:aggresome; IDA:UniProtKB. DR GO; GO:0005776; C:autophagosome; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-KW. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:HGNC-UCL. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0000502; C:proteasome complex; IEA:UniProtKB-KW. DR GO; GO:0032991; C:protein-containing complex; IDA:LIFEdb. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0019900; F:kinase binding; IPI:UniProtKB. DR GO; GO:0031593; F:polyubiquitin modification-dependent protein binding; IDA:UniProtKB. DR GO; GO:0035973; P:aggrephagy; IDA:UniProtKB. DR GO; GO:0000045; P:autophagosome assembly; IMP:GO_Central. DR GO; GO:0097352; P:autophagosome maturation; IMP:GO_Central. DR GO; GO:0071456; P:cellular response to hypoxia; IMP:BHF-UCL. DR GO; GO:0036503; P:ERAD pathway; IMP:UniProtKB. DR GO; GO:0016236; P:macroautophagy; IMP:GO_Central. DR GO; GO:1901340; P:negative regulation of store-operated calcium channel activity; IMP:UniProtKB. DR GO; GO:0034140; P:negative regulation of toll-like receptor 3 signaling pathway; IEA:Ensembl. DR GO; GO:1904294; P:positive regulation of ERAD pathway; IMP:UniProtKB. DR GO; GO:0031398; P:positive regulation of protein ubiquitination; IDA:UniProtKB. DR GO; GO:0016241; P:regulation of macroautophagy; IBA:GO_Central. DR GO; GO:1902175; P:regulation of oxidative stress-induced intrinsic apoptotic signaling pathway; IMP:BHF-UCL. DR GO; GO:0031396; P:regulation of protein ubiquitination; IDA:HGNC-UCL. DR GO; GO:0034976; P:response to endoplasmic reticulum stress; IMP:BHF-UCL. DR GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IBA:GO_Central. DR CDD; cd14399; UBA_PLICs; 1. DR CDD; cd01808; Ubl_PLICs; 1. DR FunFam; 1.10.260.100:FF:000001; Ubiquilin 1; 1. DR FunFam; 1.10.260.100:FF:000003; Ubiquilin 1; 1. DR FunFam; 1.10.8.10:FF:000007; Ubiquilin 1; 1. DR FunFam; 3.10.20.90:FF:000081; ubiquilin-1 isoform X2; 1. DR Gene3D; 1.10.260.100; -; 2. DR Gene3D; 1.10.8.10; DNA helicase RuvA subunit, C-terminal domain; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1. DR InterPro; IPR006636; STI1_HS-bd. DR InterPro; IPR015940; UBA. DR InterPro; IPR009060; UBA-like_sf. DR InterPro; IPR015496; Ubiquilin. DR InterPro; IPR000626; Ubiquitin-like_dom. DR InterPro; IPR029071; Ubiquitin-like_domsf. DR PANTHER; PTHR10677; UBIQUILIN; 1. DR PANTHER; PTHR10677:SF16; UBIQUILIN-1; 1. DR Pfam; PF00627; UBA; 1. DR Pfam; PF00240; ubiquitin; 1. DR Pfam; PF23195; UBQLN1; 1. DR SMART; SM00727; STI1; 4. DR SMART; SM00165; UBA; 1. DR SMART; SM00213; UBQ; 1. DR SUPFAM; SSF46934; UBA-like; 1. DR SUPFAM; SSF54236; Ubiquitin-like; 1. DR PROSITE; PS50030; UBA; 1. DR PROSITE; PS50053; UBIQUITIN_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Autophagy; Cell membrane; KW Cytoplasm; Cytoplasmic vesicle; Direct protein sequencing; KW Endoplasmic reticulum; Membrane; Nucleus; Phosphoprotein; Proteasome; KW Proteomics identification; Reference proteome; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:22223895" FT CHAIN 2..589 FT /note="Ubiquilin-1" FT /id="PRO_0000211008" FT DOMAIN 37..111 FT /note="Ubiquitin-like" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00214" FT DOMAIN 182..210 FT /note="STI1 1" FT /evidence="ECO:0000255" FT DOMAIN 212..251 FT /note="STI1 2" FT /evidence="ECO:0000255" FT DOMAIN 387..434 FT /note="STI1 3" FT /evidence="ECO:0000255" FT DOMAIN 438..470 FT /note="STI1 4" FT /evidence="ECO:0000255" FT DOMAIN 546..586 FT /note="UBA" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00212" FT REGION 1..35 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 110..145 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 178..428 FT /note="Interaction with UBXN4" FT /evidence="ECO:0000269|PubMed:19822669" FT REGION 295..371 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 488..520 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1..11 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 12..35 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 110..124 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 125..145 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 299..313 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 327..360 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 489..499 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 509..520 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:22223895" FT VAR_SEQ 61..237 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:18953672" FT /id="VSP_057689" FT VAR_SEQ 150..181 FT /note="GGLGGLAGLSSLGLNTTNFSELQSQMQRQLLS -> DVGTCQESSNDAGDDE FT EPGPSFEQPRKHPRGI (in isoform 4)" FT /evidence="ECO:0000303|PubMed:18953672" FT /id="VSP_057690" FT VAR_SEQ 182..589 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:18953672" FT /id="VSP_057691" FT VAR_SEQ 417..444 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:18953672" FT /id="VSP_009787" FT CONFLICT 25 FT /note="A -> T (in Ref. 9; AAH39294)" FT /evidence="ECO:0000305" FT CONFLICT 41 FT /note="V -> A (in Ref. 4; BAB20436)" FT /evidence="ECO:0000305" FT CONFLICT 61 FT /note="F -> S (in Ref. 4; BAB20436)" FT /evidence="ECO:0000305" FT CONFLICT 91 FT /note="L -> S (in Ref. 4; BAB20436)" FT /evidence="ECO:0000305" FT CONFLICT 125 FT /note="S -> G (in Ref. 6; CAB66578)" FT /evidence="ECO:0000305" FT CONFLICT 202 FT /note="P -> H (in Ref. 9; AAH39294)" FT /evidence="ECO:0000305" FT CONFLICT 537..538 FT /note="NP -> YS (in Ref. 4; BAB20436)" FT /evidence="ECO:0000305" FT STRAND 37..42 FT /evidence="ECO:0007829|PDB:2KLC" FT STRAND 47..52 FT /evidence="ECO:0007829|PDB:2KLC" FT HELIX 58..69 FT /evidence="ECO:0007829|PDB:2KLC" FT HELIX 73..75 FT /evidence="ECO:0007829|PDB:2KLC" FT STRAND 76..80 FT /evidence="ECO:0007829|PDB:2KLC" FT STRAND 83..85 FT /evidence="ECO:0007829|PDB:2KLC" FT HELIX 92..94 FT /evidence="ECO:0007829|PDB:2KLC" FT STRAND 101..106 FT /evidence="ECO:0007829|PDB:2KLC" FT TURN 543..547 FT /evidence="ECO:0007829|PDB:2JY5" FT HELIX 548..556 FT /evidence="ECO:0007829|PDB:2JY5" FT HELIX 562..572 FT /evidence="ECO:0007829|PDB:2JY5" FT HELIX 576..583 FT /evidence="ECO:0007829|PDB:2JY5" SQ SEQUENCE 589 AA; 62519 MW; 8B4756B6113B7025 CRC64; MAESGESGGP PGSQDSAAGA EGAGAPAAAA SAEPKIMKVT VKTPKEKEEF AVPENSSVQQ FKEEISKRFK SHTDQLVLIF AGKILKDQDT LSQHGIHDGL TVHLVIKTQN RPQDHSAQQT NTAGSNVTTS STPNSNSTSG SATSNPFGLG GLGGLAGLSS LGLNTTNFSE LQSQMQRQLL SNPEMMVQIM ENPFVQSMLS NPDLMRQLIM ANPQMQQLIQ RNPEISHMLN NPDIMRQTLE LARNPAMMQE MMRNQDRALS NLESIPGGYN ALRRMYTDIQ EPMLSAAQEQ FGGNPFASLV SNTSSGEGSQ PSRTENRDPL PNPWAPQTSQ SSSASSGTAS TVGGTTGSTA SGTSGQSTTA PNLVPGVGAS MFNTPGMQSL LQQITENPQL MQNMLSAPYM RSMMQSLSQN PDLAAQMMLN NPLFAGNPQL QEQMRQQLPT FLQQMQNPDT LSAMSNPRAM QALLQIQQGL QTLATEAPGL IPGFTPGLGA LGSTGGSSGT NGSNATPSEN TSPTAGTTEP GHQQFIQQML QALAGVNPQL QNPEVRFQQQ LEQLSAMGFL NREANLQALI ATGGDINAAI ERLLGSQPS // ID UFO_HUMAN Reviewed; 894 AA. AC P30530; Q8N5L2; Q9UD27; DT 01-APR-1993, integrated into UniProtKB/Swiss-Prot. DT 28-MAR-2018, sequence version 4. DT 28-JAN-2026, entry version 241. DE RecName: Full=Tyrosine-protein kinase receptor UFO; DE EC=2.7.10.1 {ECO:0000269|PubMed:28076778}; DE AltName: Full=AXL oncogene; DE Flags: Precursor; GN Name=AXL; Synonyms=UFO; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=2247464; DOI=10.1073/pnas.87.22.8913; RA Partanen J., Maekelae T.P., Alitalo R., Lehvaeslaiho H., Alitalo K.; RT "Putative tyrosine kinases expressed in K-562 human leukemia cells."; RL Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), AND ROLE IN MYELOID LEUKEMIA. RC TISSUE=Fibroblast; RX PubMed=1656220; DOI=10.1128/mcb.11.10.5016-5031.1991; RA O'Bryan J.P., Frye R.A., Cogswell P.C., Neubauer A., Kitch B., Prokop C., RA Espinosa R., le Beau M.M., Earp H., Liu E.T.; RT "AXL, a transforming gene isolated from primary human myeloid leukemia RT cells, encodes a novel receptor tyrosine kinase."; RL Mol. Cell. Biol. 11:5016-5031(1991). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG). RX PubMed=1834974; RA Janssen J.W.G., Schulz A.S., Steenvoorden A.C.M., Schmidberger M., RA Strehl S., Ambros P., Bartram C.R.; RT "A novel putative tyrosine kinase receptor with oncogenic potential."; RL Oncogene 6:2113-2120(1991). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 674-730. RX PubMed=8247543; RA Lee S.-T., Strunk K.M., Spritz R.A.; RT "A survey of protein tyrosine kinase mRNAs expressed in normal human RT melanocytes."; RL Oncogene 8:3403-3410(1993). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 677-730, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RC TISSUE=Colon tumor; RX PubMed=7896447; DOI=10.1002/ijc.2910600611; RA Craven R.J., Xu L.H., Weiner T.M., Fridell Y.-W., Dent G.A., Srivastava S., RA Varnum B., Liu E.T., Cance W.G.; RT "Receptor tyrosine kinases expressed in metastatic colon cancer."; RL Int. J. Cancer 60:791-797(1995). RN [8] RP INTERACTION WITH LIGAND GAS6. RX PubMed=7854420; DOI=10.1038/373623a0; RA Varnum B.C., Young C., Elliott G., Garcia A., Bartley T.D., Fridell Y.W., RA Hunt R.W., Trail G., Clogston C., Toso R.J., Yanagihara D., Bennett L., RA Silber M., Merewether L.A., Tseng A., Escobar E., Liu E.T., Yamane H.K.; RT "Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein RT encoded by growth-arrest-specific gene 6."; RL Nature 373:623-626(1995). RN [9] RP INTERACTION WITH GAS6, AND ACTIVITY REGULATION. RX PubMed=8621659; DOI=10.1074/jbc.271.16.9785; RA Mark M.R., Chen J., Hammonds R.G., Sadick M., Godowski P.J.; RT "Characterization of Gas6, a member of the superfamily of G domain- RT containing proteins, as a ligand for Rse and Axl."; RL J. Biol. Chem. 271:9785-9789(1996). RN [10] RP PHOSPHORYLATION AT TYR-779; TYR-821 AND TYR-866, AND INTERACTION WITH GRB2; RP LCK; PIK3R1; PIK3R2 AND PLCG1. RX PubMed=9178760; DOI=10.1038/sj.onc.1201123; RA Braunger J., Schleithoff L., Schulz A.S., Kessler H., Lammers R., RA Ullrich A., Bartram C.R., Janssen J.W.; RT "Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is RT mediated mainly by a multi-substrate docking-site."; RL Oncogene 14:2619-2631(1997). RN [11] RP ROLE IN PROSTATIC CARCINOMA. RX PubMed=10403904; DOI=10.1046/j.1525-1500.1999.99034.x; RA Jacob A.N., Kalapurakal J., Davidson W.R., Kandpal G., Dunson N., RA Prashar Y., Kandpal R.P.; RT "A receptor tyrosine kinase, UFO/Axl, and other genes isolated by a RT modified differential display PCR are overexpressed in metastatic prostatic RT carcinoma cell line DU145."; RL Cancer Detect. Prev. 23:325-332(1999). RN [12] RP ROLE IN BREAST CANCER. RX PubMed=11484958; DOI=10.1023/a:1011126330233; RA Berclaz G., Altermatt H.J., Rohrbach V., Kieffer I., Dreher E., RA Andres A.C.; RT "Estrogen dependent expression of the receptor tyrosine kinase axl in RT normal and malignant human breast."; RL Ann. Oncol. 12:819-824(2001). RN [13] RP INTERACTION WITH NCK2; PIK3R3; SOCS1 AND TNS2. RX PubMed=12470648; DOI=10.1016/s0006-291x(02)02718-3; RA Hafizi S., Alindri F., Karlsson R., Dahlbaeck B.; RT "Interaction of Axl receptor tyrosine kinase with C1-TEN, a novel C1 RT domain-containing protein with homology to tensin."; RL Biochem. Biophys. Res. Commun. 299:793-800(2002). RN [14] RP FUNCTION OF THE GAS6/AXL SIGNALING PATHWAY. RX PubMed=12364394; DOI=10.1161/01.res.0000036753.50601.e9; RA D'Arcangelo D., Gaetano C., Capogrossi M.C.; RT "Acidification prevents endothelial cell apoptosis by Axl activation."; RL Circ. Res. 91:E4-12(2002). RN [15] RP ROLE IN THYROID CARCINOMAS. RX PubMed=12490074; DOI=10.1089/105072502320908303; RA Ito M., Nakashima M., Nakayama T., Ohtsuru A., Nagayama Y., Takamura N., RA Demedchik E.P., Sekine I., Yamashita S.; RT "Expression of receptor-type tyrosine kinase, Axl, and its ligand, Gas6, in RT pediatric thyroid carcinomas around Chernobyl."; RL Thyroid 12:971-975(2002). RN [16] RP INTERACTION WITH CBL AND GAS6, AND UBIQUITINATION. RX PubMed=15958209; DOI=10.1016/j.bbrc.2005.05.086; RA Valverde P.; RT "Effects of Gas6 and hydrogen peroxide in Axl ubiquitination and RT downregulation."; RL Biochem. Biophys. Res. Commun. 333:180-185(2005). RN [17] RP ACTIVITY REGULATION, AND FUNCTION. RX PubMed=15507525; DOI=10.1182/blood-2004-04-1469; RA Gallicchio M., Mitola S., Valdembri D., Fantozzi R., Varnum B., RA Avanzi G.C., Bussolino F.; RT "Inhibition of vascular endothelial growth factor receptor 2-mediated RT endothelial cell activation by Axl tyrosine kinase receptor."; RL Blood 105:1970-1976(2005). RN [18] RP FUNCTION IN PLATELET ACTIVATION AND THROMBOTIC RESPONSE REGULATION. RX PubMed=15733062; DOI=10.1111/j.1538-7836.2005.01186.x; RA Gould W.R., Baxi S.M., Schroeder R., Peng Y.W., Leadley R.J., RA Peterson J.T., Perrin L.A.; RT "Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate RT thrombotic responses."; RL J. Thromb. Haemost. 3:733-741(2005). RN [19] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=17005688; DOI=10.1128/jvi.01157-06; RA Shimojima M., Takada A., Ebihara H., Neumann G., Fujioka K., Irimura T., RA Jones S., Feldmann H., Kawaoka Y.; RT "Tyro3 family-mediated cell entry of Ebola and Marburg viruses."; RL J. Virol. 80:10109-10116(2006). RN [20] RP INTERACTION WITH GRB2; PIK3R1 AND PIK3R2, AND PHOSPHORYLATION AT TYR-779; RP TYR-821 AND TYR-866. RX PubMed=18346204; DOI=10.1111/j.1471-4159.2008.05343.x; RA Weinger J.G., Gohari P., Yan Y., Backer J.M., Varnum B., Shafit-Zagardo B.; RT "In brain, Axl recruits Grb2 and the p85 regulatory subunit of PI3 kinase; RT in vitro mutagenesis defines the requisite binding sites for downstream Akt RT activation."; RL J. Neurochem. 106:134-146(2008). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-884, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [22] RP FUNCTION OF THE GAS6/AXL SIGNALING PATHWAY. RX PubMed=18840707; DOI=10.1182/blood-2008-05-157073; RA Park I.K., Giovenzana C., Hughes T.L., Yu J., Trotta R., Caligiuri M.A.; RT "The Axl/Gas6 pathway is required for optimal cytokine signaling during RT human natural killer cell development."; RL Blood 113:2470-2477(2009). RN [23] RP INTERACTION WITH GRB2 AND TNK2. RX PubMed=19815557; DOI=10.1074/jbc.m109.072660; RA Pao-Chun L., Chan P.M., Chan W., Manser E.; RT "Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is RT mediated by Grb2: an analysis of ACK1 effects on Axl signaling."; RL J. Biol. Chem. 284:34954-34963(2009). RN [24] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=21501828; DOI=10.1016/j.chom.2011.03.012; RA Morizono K., Xie Y., Olafsen T., Lee B., Dasgupta A., Wu A.M., Chen I.S.; RT "The soluble serum protein Gas6 bridges virion envelope phosphatidylserine RT to the TAM receptor tyrosine kinase Axl to mediate viral entry."; RL Cell Host Microbe 9:286-298(2011). RN [25] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=22156524; DOI=10.1128/jvi.06451-11; RA Shimojima M., Stroher U., Ebihara H., Feldmann H., Kawaoka Y.; RT "Identification of cell surface molecules involved in dystroglycan- RT independent Lassa virus cell entry."; RL J. Virol. 86:2067-2078(2012). RN [26] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=22673088; DOI=10.1292/jvms.12-0176; RA Shimojima M., Kawaoka Y.; RT "Cell surface molecules involved in infection mediated by lymphocytic RT choriomeningitis virus glycoprotein."; RL J. Vet. Med. Sci. 74:1363-1366(2012). RN [27] RP FUNCTION (MICROBIAL INFECTION), AND REVIEW. RX PubMed=25277499; DOI=10.1016/j.virol.2014.09.009; RA Moller-Tank S., Maury W.; RT "Phosphatidylserine receptors: enhancers of enveloped virus entry and RT infection."; RL Virology 468:565-580(2014). RN [28] RP FUNCTION (MICROBIAL INFECTION), MUTAGENESIS OF LYS-567, CATALYTIC ACTIVITY, RP AND SUBCELLULAR LOCATION. RX PubMed=28076778; DOI=10.1016/j.celrep.2016.12.045; RA Meertens L., Labeau A., Dejarnac O., Cipriani S., Sinigaglia L., RA Bonnet-Madin L., Le Charpentier T., Hafirassou M.L., Zamborlini A., RA Cao-Lormeau V.M., Coulpier M., Misse D., Jouvenet N., Tabibiazar R., RA Gressens P., Schwartz O., Amara A.; RT "Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate RT Immune Responses."; RL Cell Rep. 18:324-333(2017). RN [29] RP INDUCTION BY MOSQUITO LYMPHOTOXIN BETA RECEPTOR INHIBITOR DURING ZIKA VIRUS RP INFECTION (MICROBIAL INFECTION). RX PubMed=29507355; DOI=10.1038/s41590-018-0063-9; RA Jin L., Guo X., Shen C., Hao X., Sun P., Li P., Xu T., Hu C., Rose O., RA Zhou H., Yang M., Qin C.F., Guo J., Peng H., Zhu M., Cheng G., Qi X., RA Lai R.; RT "Salivary factor LTRIN from Aedes aegypti facilitates the transmission of RT Zika virus by interfering with the lymphotoxin-beta receptor."; RL Nat. Immunol. 19:342-353(2018). RN [30] RP FUNCTION (MICROBIAL INFECTION), AND SUBCELLULAR LOCATION. RX PubMed=29379210; DOI=10.1038/s41564-017-0092-4; RA Chen J., Yang Y.F., Yang Y., Zou P., Chen J., He Y., Shui S.L., Cui Y.R., RA Bai R., Liang Y.J., Hu Y., Jiang B., Lu L., Zhang X., Liu J., Xu J.; RT "AXL promotes Zika virus infection in astrocytes by antagonizing type I RT interferon signalling."; RL Nat. Microbiol. 3:302-309(2018). RN [31] RP FUNCTION (MICROBIAL INFECTION). RX PubMed=31311882; DOI=10.1128/mbio.01372-19; RA Strange D.P., Jiyarom B., Pourhabibi Zarandi N., Xie X., Baker C., RA Sadri-Ardekani H., Shi P.Y., Verma S.; RT "Axl Promotes Zika Virus Entry and Modulates the Antiviral State of Human RT Sertoli Cells."; RL MBio 10:0-0(2019). RN [32] RP X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 33-227 IN COMPLEX WITH GAS6, RP MUTAGENESIS OF GLU-63; GLU-66 AND THR-84, AND SUBUNIT. RX PubMed=16362042; DOI=10.1038/sj.emboj.7600912; RA Sasaki T., Knyazev P.G., Clout N.J., Cheburkin Y., Goehring W., Ullrich A., RA Timpl R., Hohenester E.; RT "Structural basis for Gas6-Axl signalling."; RL EMBO J. 25:80-87(2006). RN [33] RP VARIANTS [LARGE SCALE ANALYSIS] MET-112; TRP-295; CYS-499 AND GLY-515. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Receptor tyrosine kinase that transduces signals from the CC extracellular matrix into the cytoplasm by binding growth factor GAS6 CC and which is thus regulating many physiological processes including CC cell survival, cell proliferation, migration and differentiation. CC Ligand binding at the cell surface induces dimerization and CC autophosphorylation of AXL. Following activation by ligand, AXL binds CC and induces tyrosine phosphorylation of PI3-kinase subunits PIK3R1, CC PIK3R2 and PIK3R3; but also GRB2, PLCG1, LCK and PTPN11. Other CC downstream substrate candidates for AXL are CBL, NCK2, SOCS1 and TNS2. CC Recruitment of GRB2 and phosphatidylinositol 3 kinase regulatory CC subunits by AXL leads to the downstream activation of the AKT kinase. CC GAS6/AXL signaling plays a role in various processes such as CC endothelial cell survival during acidification by preventing apoptosis, CC optimal cytokine signaling during human natural killer cell CC development, hepatic regeneration, gonadotropin-releasing hormone CC neuron survival and migration, platelet activation, or regulation of CC thrombotic responses. Also plays an important role in inhibition of CC Toll-like receptors (TLRs)-mediated innate immune response. CC {ECO:0000269|PubMed:10403904, ECO:0000269|PubMed:11484958, CC ECO:0000269|PubMed:12364394, ECO:0000269|PubMed:12490074, CC ECO:0000269|PubMed:15507525, ECO:0000269|PubMed:15733062, CC ECO:0000269|PubMed:1656220, ECO:0000269|PubMed:18840707}. CC -!- FUNCTION: (Microbial infection) Acts as a receptor for lassa virus and CC lymphocytic choriomeningitis virus, possibly through GAS6 binding to CC phosphatidyl-serine at the surface of virion envelope. CC {ECO:0000269|PubMed:17005688, ECO:0000269|PubMed:21501828, CC ECO:0000269|PubMed:22156524, ECO:0000269|PubMed:25277499}. CC -!- FUNCTION: (Microbial infection) Acts as a receptor for Ebolavirus, CC possibly through GAS6 binding to phosphatidyl-serine at the surface of CC virion envelope. {ECO:0000269|PubMed:22673088}. CC -!- FUNCTION: (Microbial infection) Promotes Zika virus entry in glial CC cells, Sertoli cells and astrocytes (PubMed:28076778, PubMed:29379210, CC PubMed:31311882). Additionally, Zika virus potentiates AXL kinase CC activity to antagonize type I interferon signaling and thereby promotes CC infection (PubMed:28076778). Interferon signaling inhibition occurs via CC an SOCS1-dependent mechanism (PubMed:29379210). CC {ECO:0000269|PubMed:28076778, ECO:0000269|PubMed:29379210, CC ECO:0000269|PubMed:31311882}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:28076778}; CC -!- ACTIVITY REGULATION: Activated by GAS6-binding and subsequent CC autophosphorylation. {ECO:0000269|PubMed:15507525, CC ECO:0000269|PubMed:8621659}. CC -!- SUBUNIT: Heterodimer and heterotetramer with ligand GAS6. Interacts CC with CBL, GRB2, LCK, NCK2, PIK3R1, PIK3R2, PIK3R3, PLCG1, SOCS1 and CC TNS2. Part of a complex including AXL, TNK2 and GRB2, in which GRB2 CC promotes AXL recruitment by TNK2. {ECO:0000269|PubMed:12470648, CC ECO:0000269|PubMed:15958209, ECO:0000269|PubMed:16362042, CC ECO:0000269|PubMed:18346204, ECO:0000269|PubMed:19815557, CC ECO:0000269|PubMed:7854420, ECO:0000269|PubMed:8621659, CC ECO:0000269|PubMed:9178760}. CC -!- INTERACTION: CC P30530; P00533: EGFR; NbExp=5; IntAct=EBI-2850927, EBI-297353; CC P30530; P29317: EPHA2; NbExp=2; IntAct=EBI-2850927, EBI-702104; CC P30530; Q14393-2: GAS6; NbExp=8; IntAct=EBI-2850927, EBI-21517417; CC P30530; P62993: GRB2; NbExp=4; IntAct=EBI-2850927, EBI-401755; CC P30530; P08238: HSP90AB1; NbExp=3; IntAct=EBI-2850927, EBI-352572; CC P30530; Q01638: IL1RL1; NbExp=2; IntAct=EBI-2850927, EBI-993762; CC P30530; P27986: PIK3R1; NbExp=3; IntAct=EBI-2850927, EBI-79464; CC P30530; O43791: SPOP; NbExp=5; IntAct=EBI-2850927, EBI-743549; CC P30530; P0DTC2: S; Xeno; NbExp=9; IntAct=EBI-2850927, EBI-25474821; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:28076778, CC ECO:0000269|PubMed:29379210, ECO:0000269|PubMed:7896447}; Single-pass CC type I membrane protein {ECO:0000269|PubMed:7896447}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=Long; CC IsoId=P30530-1; Sequence=Displayed; CC Name=Short; CC IsoId=P30530-2; Sequence=VSP_005017; CC -!- TISSUE SPECIFICITY: Highly expressed in metastatic colon tumors. CC Expressed in primary colon tumors. Weakly expressed in normal colon CC tissue. {ECO:0000269|PubMed:7896447}. CC -!- INDUCTION: (Microbial infection) Up-regulated by Aedes aegypti CC lymphotoxin beta receptor inhibitor during Zika virus infection. CC {ECO:0000269|PubMed:29507355}. CC -!- PTM: Monoubiquitinated upon GAS6-binding. A very small proportion of CC the receptor could be subjected to polyubiquitination in a very CC transient fashion. {ECO:0000269|PubMed:15958209}. CC -!- PTM: Phosphorylated at tyrosine residues by autocatalysis, which CC activates kinase activity. {ECO:0000269|PubMed:18346204, CC ECO:0000269|PubMed:9178760}. CC -!- DISEASE: Note=AXL and its ligand GAS6 are highly expressed in thyroid CC carcinoma tissues, and might thus be involved in thyroid tumorigenesis. CC Overexpression of AXL and its ligand was also detected in many other CC cancers such as myeloproliferative disorders, prostatic carcinoma CC cells, or breast cancer. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. AXL/UFO subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/733/AXL"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M76125; AAA61243.1; -; mRNA. DR EMBL; S65125; AAB20305.1; -; mRNA. DR EMBL; X57019; CAA40338.1; -; mRNA. DR EMBL; AC011510; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC032229; AAH32229.1; -; mRNA. DR CCDS; CCDS12574.1; -. [P30530-2] DR CCDS; CCDS12575.1; -. [P30530-1] DR PIR; A41527; A41527. DR RefSeq; NP_001690.2; NM_001699.5. [P30530-2] DR RefSeq; NP_068713.2; NM_021913.4. [P30530-1] DR PDB; 2C5D; X-ray; 3.30 A; C/D=33-227. DR PDB; 4RA0; X-ray; 3.07 A; C/D=33-227. DR PDB; 5U6B; X-ray; 2.84 A; A/B/C/D=514-818. DR PDB; 5VXZ; X-ray; 2.30 A; C/D=34-135. DR PDBsum; 2C5D; -. DR PDBsum; 4RA0; -. DR PDBsum; 5U6B; -. DR PDBsum; 5VXZ; -. DR AlphaFoldDB; P30530; -. DR SMR; P30530; -. DR BioGRID; 107036; 404. DR CORUM; P30530; -. DR FunCoup; P30530; 354. DR IntAct; P30530; 298. DR MINT; P30530; -. DR STRING; 9606.ENSP00000301178; -. DR BindingDB; P30530; -. DR ChEMBL; CHEMBL4895; -. DR DrugBank; DB12411; Bemcentinib. DR DrugBank; DB15187; Dubermatinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB12141; Gilteritinib. DR DrugBank; DB19201; Tamnorzatinib. DR DrugCentral; P30530; -. DR GuidetoPHARMACOLOGY; 1835; -. DR GlyConnect; 1983; 12 N-Linked glycans (4 sites). DR GlyCosmos; P30530; 8 sites, 12 glycans. DR GlyGen; P30530; 10 sites, 13 N-linked glycans (4 sites), 1 O-linked glycan (2 sites). DR iPTMnet; P30530; -. DR PhosphoSitePlus; P30530; -. DR BioMuta; AXL; -. DR DMDM; 239938818; -. DR CPTAC; CPTAC-1766; -. DR CPTAC; CPTAC-2791; -. DR jPOST; P30530; -. DR MassIVE; P30530; -. DR PaxDb; 9606-ENSP00000301178; -. DR PeptideAtlas; P30530; -. DR ProteomicsDB; 54712; -. [P30530-1] DR ProteomicsDB; 54713; -. [P30530-2] DR Pumba; P30530; -. DR ABCD; P30530; 23 sequenced antibodies. DR Antibodypedia; 30709; 1302 antibodies from 46 providers. DR CPTC; P30530; 2 antibodies. DR DNASU; 558; -. DR Ensembl; ENST00000301178.9; ENSP00000301178.3; ENSG00000167601.13. [P30530-1] DR Ensembl; ENST00000359092.7; ENSP00000351995.2; ENSG00000167601.13. [P30530-2] DR GeneID; 558; -. DR KEGG; hsa:558; -. DR MANE-Select; ENST00000301178.9; ENSP00000301178.3; NM_021913.5; NP_068713.2. DR UCSC; uc010ehj.5; human. [P30530-1] DR AGR; HGNC:905; -. DR CIViC; 558; 1 evidence item across 1 molecular profile. DR ClinPGx; PA25197; -. DR CTD; 558; -. DR DisGeNET; 558; -. DR GeneCards; AXL; -. DR GeneReviews; AXL; -. DR HGNC; HGNC:905; AXL. DR HPA; ENSG00000167601; Low tissue specificity. DR MalaCards; AXL; -. DR MIM; 109135; gene. DR OpenTargets; ENSG00000167601; -. DR VEuPathDB; HostDB:ENSG00000167601; -. DR eggNOG; ENOG502QQQ3; Eukaryota. DR GeneTree; ENSGT00940000160232; -. DR InParanoid; P30530; -. DR OMA; WTIMSTL; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P30530; 13 GO annotations based on evolutionary models. DR PhylomeDB; P30530; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P30530; -. DR Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway. DR SignaLink; P30530; -. DR SIGNOR; P30530; -. DR Agora; ENSG00000167601; -. DR BioGRID-ORCS; 558; 17 hits in 1198 CRISPR screens. DR ChiTaRS; AXL; human. DR EvolutionaryTrace; P30530; -. DR GeneWiki; AXL_receptor_tyrosine_kinase; -. DR GenomeRNAi; 558; -. DR Pharos; P30530; Tchem. DR PRO; PR:P30530; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; P30530; protein. DR Bgee; ENSG00000167601; Expressed in synovial joint and 206 other cell types or tissues. DR ExpressionAtlas; P30530; baseline and differential. DR GO; GO:0015629; C:actin cytoskeleton; IDA:HPA. DR GO; GO:0009986; C:cell surface; IDA:UniProtKB. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005615; C:extracellular space; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0001786; F:phosphatidylserine binding; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central. DR GO; GO:0001618; F:virus receptor activity; IDA:FlyBase. DR GO; GO:0001974; P:blood vessel remodeling; IEA:Ensembl. DR GO; GO:0048469; P:cell maturation; IEP:UniProtKB. DR GO; GO:0016477; P:cell migration; IBA:GO_Central. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0035457; P:cellular response to interferon-alpha; IDA:UniProtKB. DR GO; GO:0071222; P:cellular response to lipopolysaccharide; IDA:UniProtKB. DR GO; GO:0097028; P:dendritic cell differentiation; IEP:UniProtKB. DR GO; GO:0034101; P:erythrocyte homeostasis; IEA:Ensembl. DR GO; GO:0051649; P:establishment of localization in cell; IEA:Ensembl. DR GO; GO:0021885; P:forebrain cell migration; IEA:Ensembl. DR GO; GO:0006954; P:inflammatory response; IEA:Ensembl. DR GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW. DR GO; GO:0001779; P:natural killer cell differentiation; IBA:GO_Central. DR GO; GO:0043066; P:negative regulation of apoptotic process; IBA:GO_Central. DR GO; GO:2000669; P:negative regulation of dendritic cell apoptotic process; IDA:UniProtKB. DR GO; GO:0051250; P:negative regulation of lymphocyte activation; IEA:Ensembl. DR GO; GO:0010936; P:negative regulation of macrophage cytokine production; IEA:Ensembl. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0032720; P:negative regulation of tumor necrosis factor production; IEA:Ensembl. DR GO; GO:0032689; P:negative regulation of type II interferon production; IDA:UniProtKB. DR GO; GO:0007399; P:nervous system development; IBA:GO_Central. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0001764; P:neuron migration; IEA:Ensembl. DR GO; GO:0097350; P:neutrophil clearance; IEA:Ensembl. DR GO; GO:0042698; P:ovulation cycle; IEA:Ensembl. DR GO; GO:0006909; P:phagocytosis; IDA:UniProtKB. DR GO; GO:0030168; P:platelet activation; IBA:GO_Central. DR GO; GO:0001961; P:positive regulation of cytokine-mediated signaling pathway; IDA:UniProtKB. DR GO; GO:0032825; P:positive regulation of natural killer cell differentiation; IDA:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IBA:GO_Central. DR GO; GO:0048549; P:positive regulation of pinocytosis; IMP:CACAO. DR GO; GO:1903902; P:positive regulation of viral life cycle; IMP:FlyBase. DR GO; GO:0032940; P:secretion by cell; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0007283; P:spermatogenesis; IEA:Ensembl. DR GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IEA:Ensembl. DR GO; GO:0046718; P:symbiont entry into host cell; IMP:CACAO. DR GO; GO:0060068; P:vagina development; IEA:Ensembl. DR GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome. DR CDD; cd00063; FN3; 2. DR CDD; cd20966; IgI_1_Axl_like; 1. DR CDD; cd05749; IgI_2_Axl_Tyro3_like; 1. DR CDD; cd05075; PTKc_Axl; 1. DR FunFam; 2.60.40.10:FF:000865; AXL receptor tyrosine kinase; 1. DR FunFam; 1.10.510.10:FF:000089; Tyrosine-protein kinase receptor TYRO3; 1. DR FunFam; 2.60.40.10:FF:000662; Tyrosine-protein kinase receptor UFO; 1. DR FunFam; 2.60.40.10:FF:000810; Tyrosine-protein kinase receptor UFO; 1. DR FunFam; 3.30.200.20:FF:000509; Tyrosine-protein kinase receptor UFO; 1. DR FunFam; 2.60.40.10:FF:000696; tyrosine-protein kinase receptor UFO isoform X1; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 4. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR PANTHER; PTHR24416:SF323; TYROSINE-PROTEIN KINASE RECEPTOR UFO; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF13927; Ig_3; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00060; FN3; 2. DR SMART; SM00409; IG; 2. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF48726; Immunoglobulin; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS50835; IG_LIKE; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; KW Differentiation; Disulfide bond; Glycoprotein; KW Host cell receptor for virus entry; Host-virus interaction; Immunity; KW Immunoglobulin domain; Innate immunity; Kinase; Membrane; KW Nucleotide-binding; Oncogene; Phosphoprotein; Proteomics identification; KW Proto-oncogene; Receptor; Reference proteome; Repeat; Signal; Transferase; KW Transmembrane; Transmembrane helix; Tyrosine-protein kinase; KW Ubl conjugation. FT SIGNAL 1..25 FT /evidence="ECO:0000255" FT CHAIN 26..894 FT /note="Tyrosine-protein kinase receptor UFO" FT /id="PRO_0000024481" FT TOPO_DOM 26..451 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 452..472 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 473..894 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 27..128 FT /note="Ig-like C2-type 1" FT DOMAIN 139..222 FT /note="Ig-like C2-type 2" FT DOMAIN 227..331 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 336..428 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 536..807 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 26..92 FT /note="Interaction with GAS6" FT REGION 823..853 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 866..894 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 672 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 542..550 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 567 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 703 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 779 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18346204, FT ECO:0000269|PubMed:9178760" FT MOD_RES 821 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18346204, FT ECO:0000269|PubMed:9178760" FT MOD_RES 866 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18346204, FT ECO:0000269|PubMed:9178760" FT MOD_RES 884 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT CARBOHYD 43 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 157 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 198 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 339 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 345 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 401 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 56..117 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 160..205 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 429..437 FT /note="Missing (in isoform Short)" FT /evidence="ECO:0000303|PubMed:1656220" FT /id="VSP_005017" FT VARIANT 112 FT /note="T -> M (in dbSNP:rs35202236)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045596" FT VARIANT 266 FT /note="D -> N (in dbSNP:rs7249222)" FT /id="VAR_057990" FT VARIANT 295 FT /note="R -> W (in a lung neuroendocrine carcinoma sample; FT somatic mutation; dbSNP:rs751738506)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_045597" FT VARIANT 499 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs747576071)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041877" FT VARIANT 515 FT /note="S -> G (in dbSNP:rs1240393707)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041878" FT MUTAGEN 63 FT /note="E->R: Slightly reduced affinity for GAS6." FT /evidence="ECO:0000269|PubMed:16362042" FT MUTAGEN 66 FT /note="E->R: Reduced affinity for GAS6." FT /evidence="ECO:0000269|PubMed:16362042" FT MUTAGEN 84 FT /note="T->R: Reduced affinity for GAS6." FT /evidence="ECO:0000269|PubMed:16362042" FT MUTAGEN 567 FT /note="K->M: Catalytically inactive mutant." FT /evidence="ECO:0000269|PubMed:28076778" FT CONFLICT 303 FT /note="T -> P (in Ref. 3; AAB20305/CAA40338)" FT /evidence="ECO:0000305" FT CONFLICT 338 FT /note="E -> K (in Ref. 2; AAA61243)" FT /evidence="ECO:0000305" FT CONFLICT 430 FT /note="Q -> E (in Ref. 3; AAB20305/CAA40338)" FT /evidence="ECO:0000305" FT CONFLICT 639 FT /note="D -> G (in Ref. 3; AAB20305/CAA40338)" FT /evidence="ECO:0000305" FT CONFLICT 696 FT /note="K -> I (in Ref. 7; no nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 764 FT /note="Q -> R (in Ref. 5; AAH32229)" FT /evidence="ECO:0000305" FT STRAND 37..39 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 44..46 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 52..63 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 68..71 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 80..87 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 89..91 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 94..106 FT /evidence="ECO:0007829|PDB:5VXZ" FT HELIX 109..111 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 113..121 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 124..127 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 131..134 FT /evidence="ECO:0007829|PDB:5VXZ" FT STRAND 140..143 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 148..150 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 156..159 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 161..163 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 165..167 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 170..175 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 178..187 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 190..194 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 201..209 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 212..215 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 219..223 FT /evidence="ECO:0007829|PDB:4RA0" FT STRAND 515..517 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 524..529 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 533..535 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 536..544 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 546..556 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 558..571 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 576..590 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 602..605 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 616..621 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 628..637 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 638..640 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 646..665 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 675..677 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 678..680 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 686..688 FT /evidence="ECO:0007829|PDB:5U6B" FT STRAND 698..700 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 713..715 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 718..723 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 728..743 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 755..763 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 776..785 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 790..792 FT /evidence="ECO:0007829|PDB:5U6B" FT HELIX 796..809 FT /evidence="ECO:0007829|PDB:5U6B" SQ SEQUENCE 894 AA; 98337 MW; 262D3659218E3202 CRC64; MAWRCPRMGR VPLAWCLALC GWACMAPRGT QAEESPFVGN PGNITGARGL TGTLRCQLQV QGEPPEVHWL RDGQILELAD STQTQVPLGE DEQDDWIVVS QLRITSLQLS DTGQYQCLVF LGHQTFVSQP GYVGLEGLPY FLEEPEDRTV AANTPFNLSC QAQGPPEPVD LLWLQDAVPL ATAPGHGPQR SLHVPGLNKT SSFSCEAHNA KGVTTSRTAT ITVLPQQPRN LHLVSRQPTE LEVAWTPGLS GIYPLTHCTL QAVLSDDGMG IQAGEPDPPE EPLTSQASVP PHQLRLGSLH PHTPYHIRVA CTSSQGPSSW THWLPVETPE GVPLGPPENI SATRNGSQAF VHWQEPRAPL QGTLLGYRLA YQGQDTPEVL MDIGLRQEVT LELQGDGSVS NLTVCVAAYT AAGDGPWSLP VPLEAWRPGQ AQPVHQLVKE PSTPAFSWPW WYVLLGAVVA AACVLILALF LVHRRKKETR YGEVFEPTVE RGELVVRYRV RKSYSRRTTE ATLNSLGISE ELKEKLRDVM VDRHKVALGK TLGEGEFGAV MEGQLNQDDS ILKVAVKTMK IAICTRSELE DFLSEAVCMK EFDHPNVMRL IGVCFQGSER ESFPAPVVIL PFMKHGDLHS FLLYSRLGDQ PVYLPTQMLV KFMADIASGM EYLSTKRFIH RDLAARNCML NENMSVCVAD FGLSKKIYNG DYYRQGRIAK MPVKWIAIES LADRVYTSKS DVWSFGVTMW EIATRGQTPY PGVENSEIYD YLRQGNRLKQ PADCLDGLYA LMSRCWELNP QDRPSFTELR EDLENTLKAL PPAQEPDEIL YVNMDEGGGY PEPPGAAGGA DPPTQPDPKD SCSCLTAAEV HPAGRYVLCP STTPSPAQPA DRGSPAAPGQ EDGA // ID UHRF1_HUMAN Reviewed; 793 AA. AC Q96T88; A0JBR2; A8K024; B2RBA9; Q2HIX7; Q8J022; Q9H6S6; Q9P115; Q9P1U7; DT 07-JUN-2005, integrated into UniProtKB/Swiss-Prot. DT 01-DEC-2001, sequence version 1. DT 28-JAN-2026, entry version 210. DE RecName: Full=E3 ubiquitin-protein ligase UHRF1; DE EC=2.3.2.27 {ECO:0000269|PubMed:22945642, ECO:0000269|PubMed:27595565, ECO:0000269|PubMed:30392929, ECO:0000269|PubMed:30392931, ECO:0000269|PubMed:37728657}; DE AltName: Full=Inverted CCAAT box-binding protein of 90 kDa {ECO:0000303|PubMed:17967883}; DE AltName: Full=Nuclear zinc finger protein Np95 {ECO:0000303|PubMed:17067204}; DE Short=HuNp95 {ECO:0000303|PubMed:17067204}; DE Short=Nuclear protein 95 {ECO:0000303|PubMed:17067204}; DE Short=hNp95 {ECO:0000303|PubMed:17067204}; DE AltName: Full=RING finger protein 106; DE AltName: Full=Transcription factor ICBP90 {ECO:0000303|PubMed:17967883}; DE AltName: Full=Ubiquitin-like PHD and RING finger domain-containing protein 1 {ECO:0000303|PubMed:17673620}; DE Short=hUHRF1 {ECO:0000303|PubMed:17673620}; GN Name=UHRF1 {ECO:0000303|PubMed:17673620, ECO:0000312|HGNC:HGNC:12556}; GN Synonyms=ICBP90 {ECO:0000303|PubMed:17967883}, GN NP95 {ECO:0000303|PubMed:17067204}, RNF106; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, DEVELOPMENTAL RP STAGE, SUBCELLULAR LOCATION, DNA-BINDING, INDUCTION, AND FUNCTION. RC TISSUE=Thymus; RX PubMed=10646863; RA Hopfner R., Mousli M., Jeltsch J.-M., Voulgaris A., Lutz Y., Marin C., RA Bellocq J.-P., Oudet P., Bronner C.; RT "ICBP90, a novel human CCAAT binding protein, involved in the regulation of RT topoisomerase IIa expression."; RL Cancer Res. 60:121-128(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=17067204; DOI=10.1667/rr0459.1; RA Muto M., Fujimori A., Nenoi M., Daino K., Matsuda Y., Kuroiwa A., Kubo E., RA Kanari Y., Utsuno M., Tsuji H., Ukai H., Mita K., Takahagi M., Tatsumi K.; RT "Isolation and characterization of a novel human radiosusceptibility gene, RT NP95."; RL Radiat. Res. 166:723-733(2006). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Davenport J.W., Fernandes E.R., Neale G.A.M., Goorha R.M.; RT "LMO2-induced T cell leukemias overexpress Np95, a gene containing RING and RT PHD zinc fingers and an ubiquitin-like domain."; RL Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS LYS-379 RP AND THR-638. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HIS-240; LYS-379; THR-638; RP MET-642 AND PHE-713. RG NIEHS SNPs program; RL Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP INDUCTION, AND TISSUE SPECIFICITY. RX PubMed=12838312; DOI=10.1038/sj.bjc.6601068; RA Mousli M., Hopfner R., Abbady A.-Q., Monte D., Jeanblanc M., Oudet P., RA Louis B., Bronner C.; RT "ICBP90 belongs to a new family of proteins with an expression that is RT deregulated in cancer cells."; RL Br. J. Cancer 89:120-127(2003). RN [11] RP PHOSPHORYLATION, PHOSPHORYLATION AT SER-298, AND MUTAGENESIS OF SER-298; RP SER-651 AND SER-666. RX PubMed=15178447; DOI=10.1016/j.bbrc.2004.05.028; RA Trotzier M.-A., Bronner C., Bathami K., Mathieu E., Abbady A.-Q., RA Jeanblanc M., Muller C.D., Rochette-Egly C., Mousli M.; RT "Phosphorylation of ICBP90 by protein kinase A enhances topoisomerase RT IIalpha expression."; RL Biochem. Biophys. Res. Commun. 319:590-595(2004). RN [12] RP INDUCTION, UBIQUITINATION, AND FUNCTION. RX PubMed=15009091; DOI=10.1111/j.1356-9597.2004.00710.x; RA Arima Y., Hirota T., Bronner C., Mousli M., Fujiwara T., Niwa S., RA Ishikawa H., Saya H.; RT "Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent RT DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S RT transition."; RL Genes Cells 9:131-142(2004). RN [13] RP FUNCTION, INDUCTION, TISSUE SPECIFICITY, DNA-BINDING, AND INTERACTION WITH RP HDAC1 AND BLTP3A. RX PubMed=15361834; DOI=10.1038/sj.onc.1208053; RA Unoki M., Nishidate T., Nakamura Y.; RT "ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through RT its SRA domain."; RL Oncogene 23:7601-7610(2004). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287 AND SER-639, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-639, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [16] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH DNMT1. RX PubMed=17673620; DOI=10.1126/science.1147939; RA Bostick M., Kim J.K., Esteve P.O., Clark A., Pradhan S., Jacobsen S.E.; RT "UHRF1 plays a role in maintaining DNA methylation in mammalian cells."; RL Science 317:1760-1764(2007). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [18] RP FUNCTION, SUBCELLULAR LOCATION, AND AUTOUBIQUITINATION. RX PubMed=17967883; DOI=10.1128/mcb.01598-07; RA Karagianni P., Amazit L., Qin J., Wong J.; RT "ICBP90, a novel methyl K9 H3 binding protein linking protein RT ubiquitination with heterochromatin formation."; RL Mol. Cell. Biol. 28:705-717(2008). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-76; SER-91 AND SER-707, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [20] RP INVOLVEMENT IN CANCER. RX PubMed=19491893; DOI=10.1038/sj.bjc.6605123; RA Unoki M., Kelly J.D., Neal D.E., Ponder B.A., Nakamura Y., Hamamoto R.; RT "UHRF1 is a novel molecular marker for diagnosis and the prognosis of RT bladder cancer."; RL Br. J. Cancer 101:98-105(2009). RN [21] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH EHMT2. RX PubMed=19056828; DOI=10.1093/nar/gkn961; RA Kim J.K., Esteve P.O., Jacobsen S.E., Pradhan S.; RT "UHRF1 binds G9a and participates in p21 transcriptional regulation in RT mammalian cells."; RL Nucleic Acids Res. 37:493-505(2009). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [23] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-399 AND LYS-546, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [24] RP MUTAGENESIS OF TYR-188 AND TYR-191. RX PubMed=20026581; DOI=10.1093/nar/gkp1152; RA Rottach A., Frauer C., Pichler G., Bonapace I.M., Spada F., Leonhardt H.; RT "The multi-domain protein Np95 connects DNA methylation and histone RT modification."; RL Nucleic Acids Res. 38:1796-1804(2010). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-76; SER-287; SER-639 AND RP SER-707, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [27] RP FUNCTION, AUTOUBIQUITINATION, AND INTERACTION WITH DNMT1. RX PubMed=21745816; DOI=10.1093/nar/gkr528; RA Felle M., Joppien S., Nemeth A., Diermeier S., Thalhammer V., Dobner T., RA Kremmer E., Kappler R., Langst G.; RT "The USP7/Dnmt1 complex stimulates the DNA methylation activity of Dnmt1 RT and regulates the stability of UHRF1."; RL Nucleic Acids Res. 39:8355-8365(2011). RN [28] RP HYDROXYMETHYLCYTOSINE-BINDING. RX PubMed=21731699; DOI=10.1371/journal.pone.0021306; RA Frauer C., Hoffmann T., Bultmann S., Casa V., Cardoso M.C., Antes I., RA Leonhardt H.; RT "Recognition of 5-hydroxymethylcytosine by the Uhrf1 SRA domain."; RL PLoS ONE 6:E21306-E21306(2011). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287 AND SER-651, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [30] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASN-147 AND TYR-188. RX PubMed=23022729; DOI=10.1038/nsmb.2391; RA Rothbart S.B., Krajewski K., Nady N., Tempel W., Xue S., Badeaux A.I., RA Barsyte-Lovejoy D., Martinez J.Y., Bedford M.T., Fuchs S.M., RA Arrowsmith C.H., Strahl B.D.; RT "Association of UHRF1 with methylated H3K9 directs the maintenance of DNA RT methylation."; RL Nat. Struct. Mol. Biol. 19:1155-1160(2012). RN [31] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-76; SER-91; SER-287; SER-368; RP SER-639; SER-707 AND SER-709, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [32] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND MUTAGENESIS OF 724-CYS--CYS-727. RX PubMed=24013172; DOI=10.1038/nature12488; RA Nishiyama A., Yamaguchi L., Sharif J., Johmura Y., Kawamura T., RA Nakanishi K., Shimamura S., Arita K., Kodama T., Ishikawa F., Koseki H., RA Nakanishi M.; RT "Uhrf1-dependent H3K23 ubiquitylation couples maintenance DNA methylation RT and replication."; RL Nature 502:249-253(2013). RN [33] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND MUTAGENESIS OF HIS-741. RX PubMed=22945642; DOI=10.1038/onc.2012.406; RA Guan D., Factor D., Liu Y., Wang Z., Kao H.Y.; RT "The epigenetic regulator UHRF1 promotes ubiquitination-mediated RT degradation of the tumor-suppressor protein promyelocytic leukemia RT protein."; RL Oncogene 32:3819-3828(2013). RN [34] RP INVOLVEMENT IN CANCER. RX PubMed=22286757; DOI=10.1038/onc.2012.3; RA Sabatino L., Fucci A., Pancione M., Carafa V., Nebbioso A., Pistore C., RA Babbio F., Votino C., Laudanna C., Ceccarelli M., Altucci L., RA Bonapace I.M., Colantuoni V.; RT "UHRF1 coordinates peroxisome proliferator activated receptor gamma (PPARG) RT epigenetic silencing and mediates colorectal cancer progression."; RL Oncogene 31:5061-5072(2012). RN [35] RP INVOLVEMENT IN CANCER. RX PubMed=22330138; DOI=10.1038/onc.2011.641; RA Babbio F., Pistore C., Curti L., Castiglioni I., Kunderfranco P., Brino L., RA Oudet P., Seiler R., Thalman G.N., Roggero E., Sarti M., Pinton S., RA Mello-Grand M., Chiorino G., Catapano C.V., Carbone G.M., Bonapace I.M.; RT "The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in RT prostate cancer progression."; RL Oncogene 31:4878-4887(2012). RN [36] RP AUTOUBIQUITINATION, DEUBIQUITINATION BY USP7, PHOSPHORYLATION AT SER-639, RP AND MUTAGENESIS OF SER-639. RX PubMed=22411829; DOI=10.1073/pnas.1116349109; RA Ma H., Chen H., Guo X., Wang Z., Sowa M.E., Zheng L., Hu S., Zeng P., RA Guo R., Diao J., Lan F., Harper J.W., Shi Y.G., Xu Y., Shi Y.; RT "M phase phosphorylation of the epigenetic regulator UHRF1 regulates its RT physical association with the deubiquitylase USP7 and stability."; RL Proc. Natl. Acad. Sci. U.S.A. 109:4828-4833(2012). RN [37] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-385; LYS-546 AND LYS-670, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25218447; DOI=10.1038/nsmb.2890; RA Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M., RA Vertegaal A.C.; RT "Uncovering global SUMOylation signaling networks in a site-specific RT manner."; RL Nat. Struct. Mol. Biol. 21:927-936(2014). RN [38] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, SUBCELLULAR LOCATION, AND RP MUTAGENESIS OF GLY-448; ASP-469 AND HIS-741. RX PubMed=27595565; DOI=10.7554/elife.17101; RA Harrison J.S., Cornett E.M., Goldfarb D., DaRosa P.A., Li Z.M., Yan F., RA Dickson B.M., Guo A.H., Cantu D.V., Kaustov L., Brown P.J., RA Arrowsmith C.H., Erie D.A., Major M.B., Klevit R.E., Krajewski K., RA Kuhlman B., Strahl B.D., Rothbart S.B.; RT "Hemi-methylated DNA regulates DNA methylation inheritance through RT allosteric activation of H3 ubiquitylation by UHRF1."; RL Elife 5:0-0(2016). RN [39] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-279 AND LYS-670, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [40] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND DOMAIN. RX PubMed=30392929; DOI=10.1016/j.molcel.2018.09.028; RA Foster B.M., Stolz P., Mulholland C.B., Montoya A., Kramer H., Bultmann S., RA Bartke T.; RT "Critical role of the UBL domain in stimulating the E3 ubiquitin ligase RT activity of UHRF1 toward chromatin."; RL Mol. Cell 72:739-752(2018). RN [41] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, DOMAIN, AND MUTAGENESIS OF TRP-2; RP ARG-6; MET-8; PHE-46; ARG-48; LYS-50; HIS-56; PHE-59; GLU-62; ARG-64; RP LEU-65; GLN-70 AND LEU-72. RX PubMed=30392931; DOI=10.1016/j.molcel.2018.09.029; RA DaRosa P.A., Harrison J.S., Zelter A., Davis T.N., Brzovic P., Kuhlman B., RA Klevit R.E.; RT "A bifunctional role for the UHRF1 UBL domain in the control of hemi- RT methylated DNA-dependent histone ubiquitylation."; RL Mol. Cell 72:753-765(2018). RN [42] RP FUNCTION, INTERACTION WITH UHRF2 AND FANCD2, AND SUBCELLULAR LOCATION. RX PubMed=30335751; DOI=10.1371/journal.pgen.1007643; RA Motnenko A., Liang C.C., Yang D., Lopez-Martinez D., Yoshikawa Y., Zhan B., RA Ward K.E., Tian J., Haas W., Spingardi P., Kessler B.M., Kriaucionis S., RA Gygi S.P., Cohn M.A.; RT "Identification of UHRF2 as a novel DNA interstrand crosslink sensor RT protein."; RL PLoS Genet. 14:e1007643-e1007643(2018). RN [43] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF 334-ASP-GLU-335 AND RP GLY-448. RX PubMed=30104358; DOI=10.1073/pnas.1806373115; RA Vaughan R.M., Dickson B.M., Whelihan M.F., Johnstone A.L., Cornett E.M., RA Cheek M.A., Ausherman C.A., Cowles M.W., Sun Z.W., Rothbart S.B.; RT "Chromatin structure and its chemical modifications regulate the ubiquitin RT ligase substrate selectivity of UHRF1."; RL Proc. Natl. Acad. Sci. U.S.A. 115:8775-8780(2018). RN [44] RP INTERACTION WITH ZNF263. RX PubMed=32051553; DOI=10.1038/s41388-020-1206-7; RA Yu Z., Feng J., Wang W., Deng Z., Zhang Y., Xiao L., Wang Z., Liu C., RA Liu Q., Chen S., Wu M.; RT "The EGFR-ZNF263 signaling axis silences SIX3 in glioblastoma RT epigenetically."; RL Oncogene 39:3163-3178(2020). RN [45] RP FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY. RX PubMed=37728657; DOI=10.1083/jcb.202210093; RA Qi X., Liu Y., Peng Y., Fu Y., Fu Y., Yin L., Li X.; RT "UHRF1 promotes spindle assembly and chromosome congression by catalyzing RT EG5 polyubiquitination."; RL J. Cell Biol. 222:0-0(2023). RN [46] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND MUTAGENESIS OF PHE-59; GLY-448 RP AND HIS-741. RX PubMed=39607687; DOI=10.1093/nar/gkae1105; RA Tiedemann R.L., Hrit J., Du Q., Wiseman A.K., Eden H.E., Dickson B.M., RA Kong X., Chomiak A.A., Vaughan R.M., Tibben B.M., Hebert J.M., David Y., RA Zhou W., Baylin S.B., Jones P.A., Clark S.J., Rothbart S.B.; RT "UHRF1 ubiquitin ligase activity supports the maintenance of low-density RT CpG methylation."; RL Nucleic Acids Res. 52:13733-13756(2024). RN [47] RP FUNCTION, AND MUTAGENESIS OF TYR-188. RX PubMed=39631394; DOI=10.1016/j.molcel.2024.11.009; RA Liu Y., Hrit J.A., Chomiak A.A., Stransky S., Hoffman J.R., Tiedemann R.L., RA Wiseman A.K., Kariapper L.S., Dickson B.M., Worden E.J., Fry C.J., RA Sidoli S., Rothbart S.B.; RT "DNA hypomethylation promotes UHRF1-and SUV39H1/H2-dependent crosstalk RT between H3K18ub and H3K9me3 to reinforce heterochromatin states."; RL Mol. Cell 85:394-412(2025). RN [48] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1-76. RG Structural genomics consortium (SGC); RT "Ubiquitin-like domain of human nuclear zinc finger protein NP95."; RL Submitted (JAN-2006) to the PDB data bank. RN [49] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 408-643. RX PubMed=18931436; DOI=10.1107/s1744309108027462; RA Delagoutte B., Lallous N., Birck C., Oudet P., Samama J.P.; RT "Expression, purification, crystallization and preliminary crystallographic RT study of the SRA domain of the human UHRF1 protein."; RL Acta Crystallogr. F 64:922-925(2008). RN [50] RP X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 414-617, AND MUTAGENESIS OF RP ARG-433; ARG-443; TYR-466 AND ARG-491. RX PubMed=18945682; DOI=10.1074/jbc.c800169200; RA Qian C., Li S., Jakoncic J., Zeng L., Walsh M.J., Zhou M.M.; RT "Structure and hemimethylated CpG binding of the SRA domain from human RT UHRF1."; RL J. Biol. Chem. 283:34490-34494(2008). RN [51] {ECO:0007744|PDB:3BI7, ECO:0007744|PDB:3CLZ} RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 414-617 IN COMPLEX WITH RP HEMIMETHYLATED DNA, FUNCTION, AND MUTAGENESIS OF GLY-448; ASP-469; ASN-489 RP AND ARG-491. RX PubMed=18772889; DOI=10.1038/nature07273; RA Avvakumov G.V., Walker J.R., Xue S., Li Y., Duan S., Bronner C., RA Arrowsmith C.H., Dhe-Paganon S.; RT "Structural basis for recognition of hemi-methylated DNA by the SRA domain RT of human UHRF1."; RL Nature 455:822-825(2008). RN [52] {ECO:0007744|PDB:3FL2} RP X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 672-793 IN COMPLEX WITH ZN(2+). RA Walker J.R., Avvakumov G.V., Xue S., Li Y., Bountra C., Weigelt J., RA Arrowsmith C.H., Edwards A.M., Bochkarev A., Dhe-Paganon S.; RT "Structure of the Ring domain of the E3 ubiquitin-protein ligase Uhrf1."; RL Submitted (DEC-2008) to the PDB data bank. RN [53] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 298-366 IN COMPLEX WITH ZINC, AND RP MUTAGENESIS OF ASP-334 AND ASP-337. RX PubMed=21808300; DOI=10.1038/cr.2011.124; RA Hu L., Li Z., Wang P., Lin Y., Xu Y.; RT "Crystal structure of PHD domain of UHRF1 and insights into recognition of RT unmodified histone H3 arginine residue 2."; RL Cell Res. 21:1374-1378(2011). RN [54] RP STRUCTURE BY NMR OF 298-366, AND MUTAGENESIS OF ASP-334 AND ASP-337. RX PubMed=21808299; DOI=10.1038/cr.2011.123; RA Wang C., Shen J., Yang Z., Chen P., Zhao B., Hu W., Lan W., Tong X., Wu H., RA Li G., Cao C.; RT "Structural basis for site-specific reading of unmodified R2 of histone H3 RT tail by UHRF1 PHD finger."; RL Cell Res. 21:1379-1382(2011). RN [55] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 126-285, STRUCTURE BY NMR OF RP 126-285, AND MUTAGENESIS OF ASP-142; ASP-145; PHE-152; GLU-153; TYR-188 AND RP ASP-190. RX PubMed=21489993; DOI=10.1074/jbc.m111.234104; RA Nady N., Lemak A., Walker J.R., Avvakumov G.V., Kareta M.S., Achour M., RA Xue S., Duan S., Allali-Hassani A., Zuo X., Wang Y.X., Bronner C., RA Chedin F., Arrowsmith C.H., Dhe-Paganon S.; RT "Recognition of multivalent histone states associated with heterochromatin RT by UHRF1 protein."; RL J. Biol. Chem. 286:24300-24311(2011). RN [56] {ECO:0007744|PDB:3SOU, ECO:0007744|PDB:3SOW, ECO:0007744|PDB:3SOX} RP X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 298-367 IN COMPLEX WITH ZINC AND RP HISTONE H3 PEPTIDE, FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP 334-ASP-GLU-335. RX PubMed=21777816; DOI=10.1016/j.molcel.2011.07.006; RA Rajakumara E., Wang Z., Ma H., Hu L., Chen H., Lin Y., Guo R., Wu F., RA Li H., Lan F., Shi Y.G., Xu Y., Patel D.J., Shi Y.; RT "PHD finger recognition of unmodified histone H3R2 links UHRF1 to RT regulation of euchromatic gene expression."; RL Mol. Cell 43:275-284(2011). RN [57] RP X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 314-367, AND MUTAGENESIS OF RP GLN-330; ASP-334 AND ASP-337. RX PubMed=22096602; DOI=10.1371/journal.pone.0027599; RA Lallous N., Legrand P., McEwen A.G., Ramon-Maiques S., Samama J.P., RA Birck C.; RT "The PHD finger of human UHRF1 reveals a new subgroup of unmethylated RT histone H3 tail readers."; RL PLoS ONE 6:E27599-E27599(2011). RN [58] RP X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 299-364 IN COMPLEX WITH HISTONE RP H3 PEPTIDE, AND FUNCTION. RX PubMed=22100450; DOI=10.1016/j.jmb.2011.11.012; RA Xie S., Jakoncic J., Qian C.; RT "UHRF1 double tudor domain and the adjacent PHD finger act together to RT recognize K9me3-containing histone H3 tail."; RL J. Mol. Biol. 415:318-328(2012). RN [59] {ECO:0007744|PDB:3ASK, ECO:0007744|PDB:3ASL} RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 134-367 IN COMPLEX WITH ZINC AND RP HISTONE H3 PEPTIDE, FUNCTION, PHOSPHORYLATION AT SER-298, AND MUTAGENESIS RP OF 295-ARG-ARG-296. RX PubMed=22837395; DOI=10.1073/pnas.1203701109; RA Arita K., Isogai S., Oda T., Unoki M., Sugita K., Sekiyama N., Kuwata K., RA Hamamoto R., Tochio H., Sato M., Ariyoshi M., Shirakawa M.; RT "Recognition of modification status on a histone H3 tail by linked histone RT reader modules of the epigenetic regulator UHRF1."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12950-12955(2012). CC -!- FUNCTION: E3 ubiquitin-protein ligase that acts as a key epigenetic CC regulator by bridging DNA methylation and chromatin modification CC (PubMed:10646863, PubMed:15009091, PubMed:19056828, PubMed:23022729, CC PubMed:24013172, PubMed:27595565, PubMed:30104358, PubMed:30392929, CC PubMed:30392931, PubMed:39607687). Plays a key role in DNA methylation CC inheritance by promoting recruitment of DNMT1 to hemimethylated DNA and CC ensure faithful propagation of the DNA methylation patterns through DNA CC replication (PubMed:23022729, PubMed:24013172, PubMed:27595565, CC PubMed:30104358, PubMed:30392929, PubMed:30392931, PubMed:39607687). CC Acts both as a histone reader and writer: specifically recognizes and CC binds (1) hemimethylated DNA at replication forks and (2) histone H3 CC trimethylated at 'Lys-9' and unmethylated at 'Arg-2' (H3K9me3 and CC H3R2me0, respectively), thereby activating its E3 ubiquitin-protein CC ligase activity (PubMed:15361834, PubMed:17673620, PubMed:17967883, CC PubMed:18772889, PubMed:21745816, PubMed:21777816, PubMed:22100450, CC PubMed:22837395, PubMed:23022729, PubMed:27595565, PubMed:30104358). CC UHRF1 then mediates histone H3 'Lys-18' monoubiquitination (H3K18ub), a CC docking site for DNMT1, leading to DNMT1 recruitment and replication- CC coupled DNA methylation maintenance (PubMed:27595565). Also mediates CC histone H3 'Lys-14' and 'Lys-23' ubiquitination (H3K14ub and H3K23ub) CC at lower level (PubMed:24013172, PubMed:27595565). Histone ubiquitin CC ligase activity also stimulates the methyltransferase activity of CC SUV39H1 and/or SUV39H2, promoting accumulation of H3K9me3 histone mark CC to reinformce heterochromatin state (PubMed:39631394). Enriched in CC pericentric heterochromatin where it recruits different chromatin CC modifiers required for this chromatin replication. Also localizes to CC euchromatic regions where it negatively regulates transcription CC possibly by impacting DNA methylation and histone modifications CC (PubMed:21777816). Plays a role in DNA repair by cooperating with UHRF2 CC to ensure recruitment of FANCD2 to interstrand cross-links (ICLs) CC leading to FANCD2 activation (PubMed:30335751). Also ubiquitinates non- CC histone proteins, such as histone H3, KIF11 and PML (PubMed:22945642, CC PubMed:37728657). Acts as a critical player of proper spindle CC architecture by catalyzing the 'Lys-63'-linked ubiquitination of KIF11, CC thereby controlling KIF11 localization on the spindle CC (PubMed:37728657). {ECO:0000269|PubMed:10646863, CC ECO:0000269|PubMed:15009091, ECO:0000269|PubMed:15361834, CC ECO:0000269|PubMed:17673620, ECO:0000269|PubMed:17967883, CC ECO:0000269|PubMed:18772889, ECO:0000269|PubMed:19056828, CC ECO:0000269|PubMed:21745816, ECO:0000269|PubMed:21777816, CC ECO:0000269|PubMed:22100450, ECO:0000269|PubMed:22837395, CC ECO:0000269|PubMed:22945642, ECO:0000269|PubMed:23022729, CC ECO:0000269|PubMed:24013172, ECO:0000269|PubMed:27595565, CC ECO:0000269|PubMed:30104358, ECO:0000269|PubMed:30335751, CC ECO:0000269|PubMed:30392929, ECO:0000269|PubMed:30392931, CC ECO:0000269|PubMed:37728657, ECO:0000269|PubMed:39607687, CC ECO:0000269|PubMed:39631394}. CC -!- CATALYTIC ACTIVITY: CC Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine + CC [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L- CC cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.; CC EC=2.3.2.27; Evidence={ECO:0000269|PubMed:22945642, CC ECO:0000269|PubMed:24013172, ECO:0000269|PubMed:27595565, CC ECO:0000269|PubMed:30392929, ECO:0000269|PubMed:30392931, CC ECO:0000269|PubMed:37728657, ECO:0000269|PubMed:39607687}; CC -!- PATHWAY: Protein modification; protein ubiquitination. CC {ECO:0000269|PubMed:22945642, ECO:0000269|PubMed:24013172, CC ECO:0000269|PubMed:27595565, ECO:0000269|PubMed:30392929, CC ECO:0000269|PubMed:30392931, ECO:0000269|PubMed:37728657, CC ECO:0000269|PubMed:39607687}. CC -!- SUBUNIT: Interacts with DNMT1; the interaction is direct CC (PubMed:17673620, PubMed:21745816). Interacts with DNMT3A and DNMT3B CC (By similarity). Interacts with HDAC1, but not with HDAC2 CC (PubMed:15361834). Interacts with BLTP3A (PubMed:15361834). Interacts CC with EHMT2 (PubMed:19056828). Interacts with ZNF263; recruited to the CC SIX3 promoter along with other proteins involved in chromatin CC modification and transcriptional corepression where it contributes to CC transcriptional repression (PubMed:32051553). Interacts with UHRF2 CC (PubMed:30335751). Interacts with FANCD2 (PubMed:30335751). Interacts CC with TET1 isoform 2; this interaction induces the recruitment of TET1 CC isoform 2 to replicating heterochromatin (By similarity). CC {ECO:0000250|UniProtKB:Q8VDF2, ECO:0000269|PubMed:15361834, CC ECO:0000269|PubMed:17673620, ECO:0000269|PubMed:19056828, CC ECO:0000269|PubMed:21745816, ECO:0000269|PubMed:30335751, CC ECO:0000269|PubMed:32051553}. CC -!- INTERACTION: CC Q96T88; P26358: DNMT1; NbExp=12; IntAct=EBI-1548946, EBI-719459; CC Q96T88; Q9Y6K1: DNMT3A; NbExp=7; IntAct=EBI-1548946, EBI-923653; CC Q96T88; Q9UBC3: DNMT3B; NbExp=7; IntAct=EBI-1548946, EBI-80125; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00358, CC ECO:0000269|PubMed:10646863, ECO:0000269|PubMed:17673620, CC ECO:0000269|PubMed:17967883, ECO:0000269|PubMed:19056828, CC ECO:0000269|PubMed:21777816, ECO:0000269|PubMed:30335751}. Chromosome CC {ECO:0000269|PubMed:17673620, ECO:0000269|PubMed:17967883, CC ECO:0000269|PubMed:21777816, ECO:0000269|PubMed:23022729, CC ECO:0000269|PubMed:27595565, ECO:0000269|PubMed:30104358}. CC Note=Associated with replicating DNA from early to late S phase, CC including at replicating pericentric heterochromatin (PubMed:17673620). CC Also localizes to euchromatic regions (PubMed:21777816). In non-S-phase CC cells, homogenously distributed through the nucleus (By similarity). CC {ECO:0000250|UniProtKB:Q8VDF2, ECO:0000269|PubMed:17673620, CC ECO:0000269|PubMed:21777816}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q96T88-1; Sequence=Displayed; CC Name=2; CC IsoId=Q96T88-2; Sequence=VSP_044394; CC -!- TISSUE SPECIFICITY: Expressed in thymus, bone marrow, testis, lung and CC heart. Overexpressed in breast cancer. {ECO:0000269|PubMed:10646863, CC ECO:0000269|PubMed:12838312, ECO:0000269|PubMed:15361834}. CC -!- DEVELOPMENTAL STAGE: Expressed in fetal thymus, liver and kidney. CC {ECO:0000269|PubMed:10646863}. CC -!- INDUCTION: Up-regulated in proliferating cells, and down-regulated in CC quiescent cells. Down-regulated upon adriamycin-induced DNA damage, in CC a p53/TP53 and CDKN1A-dependent way. Induced by E2F1 transcription CC factor. {ECO:0000269|PubMed:10646863, ECO:0000269|PubMed:12838312, CC ECO:0000269|PubMed:15009091, ECO:0000269|PubMed:15361834}. CC -!- DOMAIN: The UBL domain is required for the E3 histone H3 ubiquitin- CC protein ligase activity: it binds the backside of UBE2D E2 ubiquitin- CC conjugating enzymes (UBE2D1, UBE2D2, UBE2D3 or UBE2D4) and coordinates CC with other domains that recognize epigenetic marks on DNA and histone CC H3 to direct ubiquitin to H3. {ECO:0000269|PubMed:30392929, CC ECO:0000269|PubMed:30392931}. CC -!- DOMAIN: The PHD-type zinc finger specifically recognizes and binds CC histone H3 unmethylated at 'Arg-2' (H3R2me0), while the tudor-like CC regions specifically recognize and bind histone H3 trimethylated at CC 'Lys-9' (H3K9me3) (PubMed:21489993, PubMed:21777816, PubMed:22100450). CC The tudor-like regions simultaneously recognizes H3K9me3 through a CC conserved aromatic cage in the first tudor-like subdomain and CC unmodified H3K4 (H3K4me0) within a groove between the tandem subdomains CC (PubMed:21489993, PubMed:21777816, PubMed:22100450). The linker region CC plays a role in the formation of a histone H3-binding hole between the CC reader modules formed by the tudor-like regions and the PHD-type zinc CC finger by making extended contacts with the tandem tudor-like regions CC (PubMed:22837395). {ECO:0000269|PubMed:21489993, CC ECO:0000269|PubMed:21777816, ECO:0000269|PubMed:22100450, CC ECO:0000269|PubMed:22837395}. CC -!- DOMAIN: The YDG domain (also named SRA domain) specifically recognizes CC and binds hemimethylated DNA at replication forks (DNA that is only CC methylated on the mother strand of replicating DNA) (PubMed:17673620). CC It contains a binding pocket that accommodates the 5-methylcytosine CC that is flipped out of the duplex DNA. 2 specialized loops reach CC through the resulting gap in the DNA from both the major and the minor CC grooves to read the other 3 bases of the CpG duplex. The major groove CC loop confers both specificity for the CpG dinucleotide and CC discrimination against methylation of deoxycytidine of the CC complementary strand (PubMed:18772889). The YDG domain also recognizes CC and binds 5-hydroxymethylcytosine (5hmC) (PubMed:21731699). CC {ECO:0000269|PubMed:17673620, ECO:0000269|PubMed:18772889, CC ECO:0000269|PubMed:21731699}. CC -!- PTM: Phosphorylation at Ser-298 of the linker region by PKA decreases CC the binding to H3K9me3 (PubMed:15178447, PubMed:22837395). CC Phosphorylation at Ser-639 by CDK1 during M phase impairs interaction CC with USP7, preventing deubiquitination and leading to degradation by CC the proteasome (PubMed:22411829). {ECO:0000269|PubMed:15178447, CC ECO:0000269|PubMed:22411829, ECO:0000269|PubMed:22837395}. CC -!- PTM: Ubiquitinated; which leads to proteasomal degradation CC (PubMed:15009091). Autoubiquitinated; interaction with USP7 leads to CC deubiquitination and prevents degradation (PubMed:17967883, CC PubMed:21745816, PubMed:22411829). Ubiquitination and degradation takes CC place during M phase, when phosphorylation at Ser-639 prevents CC interaction with USP7 and subsequent deubiquitination CC (PubMed:22411829). Polyubiquitination may be stimulated by DNA damage CC (PubMed:15009091). {ECO:0000269|PubMed:15009091, CC ECO:0000269|PubMed:17967883, ECO:0000269|PubMed:21745816, CC ECO:0000269|PubMed:22411829}. CC -!- DISEASE: Note=Defects in UHRF1 may be a cause of cancers. Overexpressed CC in many different forms of human cancers, including bladder, breast, CC cervical, colorectal and prostate cancers, as well as pancreatic CC adenocarcinomas, rhabdomyosarcomas and gliomas. Plays an important role CC in the correlation of histone modification and gene silencing in cancer CC progression. Expression is associated with a poor prognosis in patients CC with various cancers, suggesting that it participates in cancer CC progression. {ECO:0000269|PubMed:19491893, ECO:0000269|PubMed:22286757, CC ECO:0000269|PubMed:22330138}. CC -!- SEQUENCE CAUTION: CC Sequence=BAB15177.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF129507; AAF28469.1; -; mRNA. DR EMBL; AB177623; BAF36719.1; -; mRNA. DR EMBL; AB177624; BAF36720.1; -; mRNA. DR EMBL; AB075601; BAC20576.1; -; mRNA. DR EMBL; AF274048; AAK55744.1; -; mRNA. DR EMBL; EF560733; ABQ59043.1; -; mRNA. DR EMBL; AK025578; BAB15177.1; ALT_INIT; mRNA. DR EMBL; AK289389; BAF82078.1; -; mRNA. DR EMBL; AK314579; BAG37156.1; -; mRNA. DR EMBL; AY787925; AAV40831.1; -; Genomic_DNA. DR EMBL; AC027319; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC053467; AAF64067.1; -; Genomic_DNA. DR EMBL; CH471139; EAW69187.1; -; Genomic_DNA. DR EMBL; BC113875; AAI13876.2; -; mRNA. DR CCDS; CCDS74262.1; -. [Q96T88-2] DR CCDS; CCDS74263.1; -. [Q96T88-1] DR RefSeq; NP_001041666.1; NM_001048201.3. [Q96T88-1] DR RefSeq; NP_001276979.1; NM_001290050.2. [Q96T88-1] DR RefSeq; NP_001276980.1; NM_001290051.2. [Q96T88-1] DR RefSeq; NP_001276981.1; NM_001290052.2. [Q96T88-1] DR RefSeq; NP_037414.3; NM_013282.4. DR PDB; 2FAZ; X-ray; 2.00 A; A/B=1-76. DR PDB; 2L3R; NMR; -; A=126-285. DR PDB; 2LGG; NMR; -; A=298-366. DR PDB; 2LGK; NMR; -; A=298-366. DR PDB; 2LGL; NMR; -; A=298-366. DR PDB; 2PB7; X-ray; 1.90 A; A=408-643. DR PDB; 3ASK; X-ray; 2.90 A; A/B/C/D=134-367. DR PDB; 3ASL; X-ray; 1.41 A; A=298-367. DR PDB; 3BI7; X-ray; 1.70 A; A=414-617. DR PDB; 3CLZ; X-ray; 2.20 A; A/B/C/D=414-617. DR PDB; 3DB3; X-ray; 2.40 A; A=126-285. DR PDB; 3DB4; X-ray; 2.40 A; A=126-285. DR PDB; 3DWH; X-ray; 1.95 A; A=414-617. DR PDB; 3FL2; X-ray; 1.75 A; A=672-793. DR PDB; 3SHB; X-ray; 1.80 A; A=298-366. DR PDB; 3SOU; X-ray; 1.80 A; A/B=298-367. DR PDB; 3SOW; X-ray; 1.95 A; A/B=298-367. DR PDB; 3SOX; X-ray; 2.65 A; A/B=298-367. DR PDB; 3T6R; X-ray; 1.95 A; A/B=299-364. DR PDB; 3ZVY; X-ray; 1.95 A; A/B=296-367. DR PDB; 3ZVZ; X-ray; 1.45 A; B=314-367. DR PDB; 4GY5; X-ray; 2.96 A; A/B/C/D=134-366. DR PDB; 4QQD; X-ray; 2.28 A; A/B=126-285. DR PDB; 5C6D; X-ray; 2.29 A; C/D=634-665. DR PDB; 5IAY; NMR; -; A=134-285, B=642-657. DR PDB; 5XPI; X-ray; 2.20 A; A=127-283. DR PDB; 5YY9; X-ray; 2.65 A; A/B=123-285. DR PDB; 5YYA; X-ray; 1.70 A; A=123-285. DR PDB; 6B9M; X-ray; 1.68 A; D=638-678. DR PDB; 6IIW; X-ray; 1.70 A; A=299-366. DR PDB; 6VCS; X-ray; 1.70 A; A/B/E=414-617. DR PDB; 6VED; NMR; -; A=133-300. DR PDB; 6VYJ; X-ray; 1.39 A; A=122-283. DR PDB; 6W92; X-ray; 1.30 A; A=122-283. DR PDB; 7FB7; X-ray; 1.45 A; A/B=123-285. DR PDB; 8JIG; X-ray; 2.40 A; A/B=413-617. DR PDB; 8WMS; X-ray; 2.40 A; A=299-366. DR PDB; 8XV4; X-ray; 3.20 A; A/B=134-366. DR PDB; 8XV6; X-ray; 1.60 A; A/C=298-367. DR PDB; 8XV7; X-ray; 2.25 A; A/C/E/G=134-366. DR PDB; 8XV8; X-ray; 2.05 A; A/C/E/G=298-367. DR PDBsum; 2FAZ; -. DR PDBsum; 2L3R; -. DR PDBsum; 2LGG; -. DR PDBsum; 2LGK; -. DR PDBsum; 2LGL; -. DR PDBsum; 2PB7; -. DR PDBsum; 3ASK; -. DR PDBsum; 3ASL; -. DR PDBsum; 3BI7; -. DR PDBsum; 3CLZ; -. DR PDBsum; 3DB3; -. DR PDBsum; 3DB4; -. DR PDBsum; 3DWH; -. DR PDBsum; 3FL2; -. DR PDBsum; 3SHB; -. DR PDBsum; 3SOU; -. DR PDBsum; 3SOW; -. DR PDBsum; 3SOX; -. DR PDBsum; 3T6R; -. DR PDBsum; 3ZVY; -. DR PDBsum; 3ZVZ; -. DR PDBsum; 4GY5; -. DR PDBsum; 4QQD; -. DR PDBsum; 5C6D; -. DR PDBsum; 5IAY; -. DR PDBsum; 5XPI; -. DR PDBsum; 5YY9; -. DR PDBsum; 5YYA; -. DR PDBsum; 6B9M; -. DR PDBsum; 6IIW; -. DR PDBsum; 6VCS; -. DR PDBsum; 6VED; -. DR PDBsum; 6VYJ; -. DR PDBsum; 6W92; -. DR PDBsum; 7FB7; -. DR PDBsum; 8JIG; -. DR PDBsum; 8WMS; -. DR PDBsum; 8XV4; -. DR PDBsum; 8XV6; -. DR PDBsum; 8XV7; -. DR PDBsum; 8XV8; -. DR AlphaFoldDB; Q96T88; -. DR BMRB; Q96T88; -. DR SASBDB; Q96T88; -. DR SMR; Q96T88; -. DR BioGRID; 118893; 235. DR CORUM; Q96T88; -. DR FunCoup; Q96T88; 1543. DR IntAct; Q96T88; 82. DR MINT; Q96T88; -. DR STRING; 9606.ENSP00000479617; -. DR BindingDB; Q96T88; -. DR ChEMBL; CHEMBL2424510; -. DR GlyGen; Q96T88; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q96T88; -. DR PhosphoSitePlus; Q96T88; -. DR SwissPalm; Q96T88; -. DR BioMuta; UHRF1; -. DR DMDM; 67462077; -. DR jPOST; Q96T88; -. DR MassIVE; Q96T88; -. DR PaxDb; 9606-ENSP00000479617; -. DR PeptideAtlas; Q96T88; -. DR ProteomicsDB; 78215; -. [Q96T88-1] DR Pumba; Q96T88; -. DR Antibodypedia; 72541; 412 antibodies from 35 providers. DR DNASU; 29128; -. DR Ensembl; ENST00000612630.4; ENSP00000484739.1; ENSG00000276043.6. [Q96T88-1] DR Ensembl; ENST00000615884.4; ENSP00000478601.1; ENSG00000276043.6. [Q96T88-1] DR Ensembl; ENST00000616255.1; ENSP00000478348.1; ENSG00000276043.6. [Q96T88-1] DR Ensembl; ENST00000624301.3; ENSP00000485604.1; ENSG00000276043.6. [Q96T88-1] DR Ensembl; ENST00000650932.1; ENSP00000498698.1; ENSG00000276043.6. [Q96T88-1] DR GeneID; 29128; -. DR KEGG; hsa:29128; -. DR MANE-Select; ENST00000650932.1; ENSP00000498698.1; NM_001048201.3; NP_001041666.1. DR UCSC; uc032hkj.2; human. [Q96T88-1] DR AGR; HGNC:12556; -. DR ClinPGx; PA37196; -. DR CTD; 29128; -. DR DisGeNET; 29128; -. DR GeneCards; UHRF1; -. DR HGNC; HGNC:12556; UHRF1. DR HPA; ENSG00000276043; Group enriched (bone marrow, lymphoid tissue). DR MalaCards; UHRF1; -. DR MIM; 607990; gene. DR OpenTargets; ENSG00000276043; -. DR Orphanet; 2268; ICF syndrome. DR VEuPathDB; HostDB:ENSG00000276043; -. DR eggNOG; ENOG502QRDQ; Eukaryota. DR GeneTree; ENSGT00390000008296; -. DR HOGENOM; CLU_022357_0_0_1; -. DR InParanoid; Q96T88; -. DR OrthoDB; 2270193at2759; -. DR PAN-GO; Q96T88; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q96T88; -. DR PathwayCommons; Q96T88; -. DR Reactome; R-HSA-5334118; DNA methylation. DR Reactome; R-HSA-9821002; Chromatin modifications during the maternal to zygotic transition (MZT). DR SignaLink; Q96T88; -. DR SIGNOR; Q96T88; -. DR UniPathway; UPA00143; -. DR Agora; ENSG00000276043; -. DR BioGRID-ORCS; 29128; 65 hits in 331 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; UHRF1; human. DR EvolutionaryTrace; Q96T88; -. DR GeneWiki; UHRF1; -. DR GenomeRNAi; 29128; -. DR Pharos; Q96T88; Tbio. DR PRO; PR:Q96T88; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q96T88; protein. DR Bgee; ENSG00000276043; Expressed in oocyte and 139 other cell types or tissues. DR ExpressionAtlas; Q96T88; baseline and differential. DR GO; GO:0000785; C:chromatin; IDA:UniProtKB. DR GO; GO:0000791; C:euchromatin; IDA:UniProtKB. DR GO; GO:0000792; C:heterochromatin; IDA:UniProtKB. DR GO; GO:0016363; C:nuclear matrix; ISS:BHF-UCL. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:BHF-UCL. DR GO; GO:0005657; C:replication fork; IDA:UniProtKB. DR GO; GO:0005819; C:spindle; IC:UniProt. DR GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; IDA:BHF-UCL. DR GO; GO:0140612; F:DNA damage sensor activity; TAS:BHF-UCL. DR GO; GO:0044729; F:hemi-methylated DNA-binding; IDA:UniProtKB. DR GO; GO:0042393; F:histone binding; IDA:UniProtKB. DR GO; GO:0141055; F:histone H3 ubiquitin ligase activity; IDA:UniProtKB. DR GO; GO:0140851; F:histone H3K14 ubiquitin ligase activity; IDA:UniProtKB. DR GO; GO:0140248; F:histone H3K18 ubiquitin ligase activity; IDA:UniProtKB. DR GO; GO:0140234; F:histone H3K23 ubiquitin ligase activity; IDA:UniProtKB. DR GO; GO:0062072; F:histone H3K9me2/3 reader activity; IDA:UniProtKB. DR GO; GO:0042802; F:identical protein binding; ISS:BHF-UCL. DR GO; GO:0008327; F:methyl-CpG binding; IDA:UniProtKB. DR GO; GO:0003676; F:nucleic acid binding; EXP:DisProt. DR GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:UniProt. DR GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB. DR GO; GO:0141119; P:chromosomal DNA methylation maintenance following DNA replication; IDA:UniProtKB. DR GO; GO:0006974; P:DNA damage response; TAS:BHF-UCL. DR GO; GO:0000724; P:double-strand break repair via homologous recombination; TAS:BHF-UCL. DR GO; GO:0040029; P:epigenetic regulation of gene expression; TAS:BHF-UCL. DR GO; GO:0031507; P:heterochromatin formation; IDA:UniProtKB. DR GO; GO:0035825; P:homologous recombination; TAS:BHF-UCL. DR GO; GO:0090307; P:mitotic spindle assembly; IDA:UniProt. DR GO; GO:0044027; P:negative regulation of gene expression via chromosomal CpG island methylation; IMP:UniProtKB. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0051247; P:positive regulation of protein metabolic process; IDA:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL. DR GO; GO:0051865; P:protein autoubiquitination; IDA:UniProtKB. DR GO; GO:0071168; P:protein localization to chromatin; IDA:UniProt. DR GO; GO:0016567; P:protein ubiquitination; IBA:GO_Central. DR GO; GO:0050678; P:regulation of epithelial cell proliferation; IMP:BHF-UCL. DR GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:UniProtKB. DR CDD; cd15616; PHD_UHRF1; 1. DR CDD; cd16769; RING-HC_UHRF1; 1. DR CDD; cd20455; Tudor_UHRF1_rpt1; 1. DR CDD; cd20457; Tudor_UHRF1_rpt2; 1. DR CDD; cd17122; Ubl_UHRF1; 1. DR DisProt; DP01651; -. DR FunFam; 2.30.280.10:FF:000001; E3 ubiquitin-protein ligase UHRF1 isoform 1; 1. DR FunFam; 2.30.30.140:FF:000068; E3 ubiquitin-protein ligase UHRF1 isoform 1; 1. DR FunFam; 3.10.20.90:FF:000143; E3 ubiquitin-protein ligase UHRF1 isoform 1; 1. DR FunFam; 2.30.30.1150:FF:000001; E3 ubiquitin-protein ligase UHRF2 isoform X1; 1. DR FunFam; 3.30.40.10:FF:000066; E3 ubiquitin-protein ligase UHRF2 isoform X1; 1. DR Gene3D; 2.30.30.1150; -; 1. DR Gene3D; 2.30.30.140; -; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1. DR Gene3D; 2.30.280.10; SRA-YDG; 1. DR Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1. DR IDEAL; IID00327; -. DR InterPro; IPR015947; PUA-like_sf. DR InterPro; IPR036987; SRA-YDG_sf. DR InterPro; IPR003105; SRA_YDG. DR InterPro; IPR021991; TTD_dom. DR InterPro; IPR000626; Ubiquitin-like_dom. DR InterPro; IPR029071; Ubiquitin-like_domsf. DR InterPro; IPR047406; Ubl_UHRF1. DR InterPro; IPR045134; UHRF1/2-like. DR InterPro; IPR011011; Znf_FYVE_PHD. DR InterPro; IPR001965; Znf_PHD. DR InterPro; IPR019787; Znf_PHD-finger. DR InterPro; IPR001841; Znf_RING. DR InterPro; IPR013083; Znf_RING/FYVE/PHD. DR InterPro; IPR017907; Znf_RING_CS. DR PANTHER; PTHR14140; E3 UBIQUITIN-PROTEIN LIGASE UHRF-RELATED; 1. DR PANTHER; PTHR14140:SF2; E3 UBIQUITIN-PROTEIN LIGASE UHRF1; 1. DR Pfam; PF00628; PHD; 1. DR Pfam; PF02182; SAD_SRA; 1. DR Pfam; PF12148; TTD; 1. DR Pfam; PF00240; ubiquitin; 1. DR SMART; SM00249; PHD; 1. DR SMART; SM00184; RING; 2. DR SMART; SM00466; SRA; 1. DR SMART; SM00213; UBQ; 1. DR SUPFAM; SSF57903; FYVE/PHD zinc finger; 1. DR SUPFAM; SSF88697; PUA domain-like; 1. DR SUPFAM; SSF57850; RING/U-box; 1. DR SUPFAM; SSF54236; Ubiquitin-like; 1. DR PROSITE; PS50053; UBIQUITIN_2; 1. DR PROSITE; PS51015; YDG; 1. DR PROSITE; PS01359; ZF_PHD_1; 1. DR PROSITE; PS50016; ZF_PHD_2; 1. DR PROSITE; PS00518; ZF_RING_1; 1. DR PROSITE; PS50089; ZF_RING_2; 2. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Cell cycle; KW Chromatin regulator; Chromosome; DNA damage; DNA repair; DNA-binding; KW Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; Repressor; KW Transcription; Transcription regulation; Transferase; Ubl conjugation; KW Ubl conjugation pathway; Zinc; Zinc-finger. FT CHAIN 1..793 FT /note="E3 ubiquitin-protein ligase UHRF1" FT /id="PRO_0000056144" FT DOMAIN 1..78 FT /note="Ubiquitin-like" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00214" FT DOMAIN 419..582 FT /note="YDG" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00358" FT ZN_FING 310..366 FT /note="PHD-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00146" FT ZN_FING 724..763 FT /note="RING-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00175" FT REGION 82..124 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 133..209 FT /note="Tudor-like 1" FT /evidence="ECO:0000269|PubMed:21489993" FT REGION 216..283 FT /note="Tudor-like 2" FT /evidence="ECO:0000269|PubMed:21489993" FT REGION 296..301 FT /note="Linker" FT /evidence="ECO:0000269|PubMed:22837395" FT REGION 333..337 FT /note="Histone H3R2me0 binding" FT /evidence="ECO:0000269|PubMed:21777816" FT REGION 353..355 FT /note="Histone H3R2me0 binding" FT /evidence="ECO:0000269|PubMed:21777816" FT REGION 445..446 FT /note="Required to promote base flipping" FT /evidence="ECO:0000250|UniProtKB:Q8VDF2" FT REGION 466..469 FT /note="Required for formation of a 5-methylcytosine-binding FT pocket" FT /evidence="ECO:0000269|PubMed:18772889" FT REGION 478..481 FT /note="Required for formation of a 5-methylcytosine-binding FT pocket" FT /evidence="ECO:0000269|PubMed:18772889" FT REGION 618..673 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 618..629 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 302 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:22837395, ECO:0007744|PDB:3ASK, FT ECO:0007744|PDB:3ASL, ECO:0007744|PDB:3SOU" FT BINDING 305 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:22837395, ECO:0007744|PDB:3ASK, FT ECO:0007744|PDB:3ASL, ECO:0007744|PDB:3SOU" FT BINDING 313 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:22837395, ECO:0007744|PDB:3ASK, FT ECO:0007744|PDB:3ASL, ECO:0007744|PDB:3SOU" FT BINDING 316 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:22837395, ECO:0007744|PDB:3ASK, FT ECO:0007744|PDB:3ASL, ECO:0007744|PDB:3SOU" FT BINDING 318 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:22837395, ECO:0007744|PDB:3ASK, FT ECO:0007744|PDB:3ASL, ECO:0007744|PDB:3SOU" FT BINDING 319 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:22837395, ECO:0007744|PDB:3ASL, FT ECO:0007744|PDB:3SOU" FT BINDING 321 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:22837395, ECO:0007744|PDB:3ASL, FT ECO:0007744|PDB:3SOU" FT BINDING 333 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:22837395, ECO:0007744|PDB:3ASK, FT ECO:0007744|PDB:3ASL, ECO:0007744|PDB:3SOU" FT BINDING 336 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:22837395, FT ECO:0007744|PDB:3ASK, ECO:0007744|PDB:3ASL" FT BINDING 341 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:22837395, FT ECO:0007744|PDB:3ASK, ECO:0007744|PDB:3ASL" FT BINDING 344 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:22837395, FT ECO:0007744|PDB:3ASK, ECO:0007744|PDB:3ASL" FT BINDING 360 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:22837395, FT ECO:0007744|PDB:3ASL" FT BINDING 362 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:22837395, FT ECO:0007744|PDB:3ASL" FT BINDING 363 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:22837395, FT ECO:0007744|PDB:3ASL" FT BINDING 463..464 FT /ligand="DNA" FT /ligand_id="ChEBI:CHEBI:16991" FT /ligand_part="5-methylcytosine group" FT /ligand_part_id="ChEBI:CHEBI:65274" FT /evidence="ECO:0000269|PubMed:18772889" FT BINDING 469 FT /ligand="DNA" FT /ligand_id="ChEBI:CHEBI:16991" FT /ligand_part="5-methylcytosine group" FT /ligand_part_id="ChEBI:CHEBI:65274" FT /evidence="ECO:0000269|PubMed:18772889" FT BINDING 724 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="5" FT /evidence="ECO:0000269|Ref.52, ECO:0007744|PDB:3FL2" FT BINDING 727 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="5" FT /evidence="ECO:0000269|Ref.52, ECO:0007744|PDB:3FL2" FT BINDING 739 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="6" FT /evidence="ECO:0000269|Ref.52, ECO:0007744|PDB:3FL2" FT BINDING 741 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="6" FT /evidence="ECO:0000269|Ref.52, ECO:0007744|PDB:3FL2" FT BINDING 744 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="5" FT /evidence="ECO:0000269|Ref.52, ECO:0007744|PDB:3FL2" FT BINDING 747 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="5" FT /evidence="ECO:0000269|Ref.52, ECO:0007744|PDB:3FL2" FT BINDING 759 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="6" FT /evidence="ECO:0000269|Ref.52, ECO:0007744|PDB:3FL2" FT BINDING 762 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="6" FT /evidence="ECO:0000269|Ref.52, ECO:0007744|PDB:3FL2" FT SITE 316 FT /note="Histone H3K4me0 binding" FT /evidence="ECO:0000269|PubMed:21777816" FT SITE 327 FT /note="Histone H3R2me0 binding" FT /evidence="ECO:0000269|PubMed:21777816" FT SITE 330 FT /note="Histone H3R2me0 binding" FT /evidence="ECO:0000269|PubMed:21777816" FT SITE 479 FT /note="Required to confer preferential recognition of FT cytosine over thymine" FT /evidence="ECO:0000269|PubMed:18772889" FT SITE 489 FT /note="Required to discriminate between hemimethylated DNA FT versus symmetrically methylated DNA" FT /evidence="ECO:0000269|PubMed:18772889" FT SITE 491 FT /note="Required for affinity and specificity for 5-mCpG FT sequence" FT /evidence="ECO:0000269|PubMed:18772889" FT MOD_RES 76 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 91 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 95 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q7TPK1" FT MOD_RES 165 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8VDF2" FT MOD_RES 287 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18220336, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 298 FT /note="Phosphoserine; by PKA" FT /evidence="ECO:0000269|PubMed:15178447, FT ECO:0000269|PubMed:22837395" FT MOD_RES 368 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 399 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 546 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 639 FT /note="Phosphoserine; by CDK1" FT /evidence="ECO:0000269|PubMed:22411829, FT ECO:0007744|PubMed:16964243, ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 651 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 707 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 709 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 279 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 385 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447" FT CROSSLNK 546 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2); alternate" FT /evidence="ECO:0007744|PubMed:25218447" FT CROSSLNK 670 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:28112733" FT VAR_SEQ 1 FT /note="M -> MGVFAVPPLSSDTM (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_044394" FT VARIANT 240 FT /note="D -> H (in dbSNP:rs17886098)" FT /evidence="ECO:0000269|Ref.6" FT /id="VAR_022554" FT VARIANT 379 FT /note="E -> K (in dbSNP:rs17885791)" FT /evidence="ECO:0000269|PubMed:14702039, ECO:0000269|Ref.6" FT /id="VAR_022555" FT VARIANT 638 FT /note="A -> T (in dbSNP:rs2307209)" FT /evidence="ECO:0000269|PubMed:14702039, ECO:0000269|Ref.6" FT /id="VAR_022556" FT VARIANT 642 FT /note="T -> M (in dbSNP:rs17884843)" FT /evidence="ECO:0000269|Ref.6" FT /id="VAR_022557" FT VARIANT 713 FT /note="L -> F (in dbSNP:rs17883563)" FT /evidence="ECO:0000269|Ref.6" FT /id="VAR_022558" FT MUTAGEN 2 FT /note="W->V: Decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 6 FT /note="R->D: Strongly decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 8 FT /note="M->R: Strongly decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 46 FT /note="F->V: Strongly decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 48 FT /note="R->E: Strongly decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 50 FT /note="K->R: Decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 56 FT /note="H->A: No effect on histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 59 FT /note="F->V: Decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931, FT ECO:0000269|PubMed:39607687" FT MUTAGEN 62 FT /note="E->K: No effect on histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 64 FT /note="R->E: Strongly decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 65 FT /note="L->A: Decreased histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 70 FT /note="Q->E: Abolished binding to UBE2D E2 ubiquitin FT conjugating enzymes, leading to strongly decreased histone FT H3 ubiquitin ligase activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 72 FT /note="L->A: No effect on histone H3 ubiquitin ligase FT activity." FT /evidence="ECO:0000269|PubMed:30392931" FT MUTAGEN 142 FT /note="D->A: Impaired binding to histone H3 without FT affecting the protein folding; when associated with A-153." FT /evidence="ECO:0000269|PubMed:21489993" FT MUTAGEN 145 FT /note="D->A: Impaired binding to histone H3." FT /evidence="ECO:0000269|PubMed:21489993" FT MUTAGEN 147 FT /note="N->D,E: Reduced binding to H3K9me3." FT /evidence="ECO:0000269|PubMed:23022729" FT MUTAGEN 152 FT /note="F->A: Impaired binding to histone H3." FT /evidence="ECO:0000269|PubMed:21489993" FT MUTAGEN 153 FT /note="E->A: Impaired binding to histone H3 without FT affecting the protein folding; when associated with A-142." FT /evidence="ECO:0000269|PubMed:21489993" FT MUTAGEN 188 FT /note="Y->A: Abolished binding to H3K9me3." FT /evidence="ECO:0000269|PubMed:20026581, FT ECO:0000269|PubMed:21489993, ECO:0000269|PubMed:23022729, FT ECO:0000269|PubMed:39631394" FT MUTAGEN 190 FT /note="D->A: Slightly impaired binding to histone H3." FT /evidence="ECO:0000269|PubMed:21489993" FT MUTAGEN 191 FT /note="Y->A: Impaired binding to histone H3." FT /evidence="ECO:0000269|PubMed:20026581" FT MUTAGEN 295..296 FT /note="RR->AA: Disrupts the simultaneous binding to H3R2me0 FT and H3K9me3." FT /evidence="ECO:0000269|PubMed:22837395" FT MUTAGEN 298 FT /note="S->A: Diminishes phosphorylation by PKA." FT /evidence="ECO:0000269|PubMed:15178447" FT MUTAGEN 330 FT /note="Q->A,K: Does not affect ability to bind histone H3 FT peptide." FT /evidence="ECO:0000269|PubMed:22096602" FT MUTAGEN 334..335 FT /note="DE->AA: Abolishes binding to histone H3. Abolished FT binding to H3K9me3." FT /evidence="ECO:0000269|PubMed:21777816, FT ECO:0000269|PubMed:30104358" FT MUTAGEN 334 FT /note="D->A: Impaired binding to histone H3." FT /evidence="ECO:0000269|PubMed:21808299, FT ECO:0000269|PubMed:21808300, ECO:0000269|PubMed:22096602" FT MUTAGEN 337 FT /note="D->A: Impaired binding to histone H3." FT /evidence="ECO:0000269|PubMed:21808299, FT ECO:0000269|PubMed:21808300, ECO:0000269|PubMed:22096602" FT MUTAGEN 433 FT /note="R->A: Does not affect ability to bind DNA." FT /evidence="ECO:0000269|PubMed:18945682" FT MUTAGEN 443 FT /note="R->A: Decreased ability to bind DNA." FT /evidence="ECO:0000269|PubMed:18945682" FT MUTAGEN 448 FT /note="G->D: Decreased affinity for DNA." FT /evidence="ECO:0000269|PubMed:18772889, FT ECO:0000269|PubMed:27595565, ECO:0000269|PubMed:30104358, FT ECO:0000269|PubMed:39607687" FT MUTAGEN 466 FT /note="Y->G: Decreased ability to bind DNA." FT /evidence="ECO:0000269|PubMed:18945682" FT MUTAGEN 469 FT /note="D->G: Abolishes ability to bind hemimethylated DNA." FT /evidence="ECO:0000269|PubMed:18772889, FT ECO:0000269|PubMed:27595565" FT MUTAGEN 489 FT /note="N->A: Abolishes specificity to hemimethylated DNA." FT /evidence="ECO:0000269|PubMed:18772889" FT MUTAGEN 491 FT /note="R->A: Decreased binding to methylated DNA but does FT not affect ability to bind DNA." FT /evidence="ECO:0000269|PubMed:18772889, FT ECO:0000269|PubMed:18945682" FT MUTAGEN 639 FT /note="S->A: Prevents phosphorylation by CDK1 during M FT phase, leading to increased stability." FT /evidence="ECO:0000269|PubMed:22411829" FT MUTAGEN 639 FT /note="S->D: Mimics phosphorylation; impaired interaction FT with USP7, leading to decreased stability." FT /evidence="ECO:0000269|PubMed:22411829" FT MUTAGEN 651 FT /note="S->A: No effect on in vitro phosphorylation by PKA." FT /evidence="ECO:0000269|PubMed:15178447" FT MUTAGEN 666 FT /note="S->A: No effect on in vitro phosphorylation by PKA." FT /evidence="ECO:0000269|PubMed:15178447" FT MUTAGEN 724..727 FT /note="CICC->AIAA: Abolished E3 ubiquitin-protein ligase FT activity." FT /evidence="ECO:0000269|PubMed:24013172" FT MUTAGEN 741 FT /note="H->A: Abolished E3 ubiquitin-protein ligase FT activity." FT /evidence="ECO:0000269|PubMed:22945642, FT ECO:0000269|PubMed:27595565, ECO:0000269|PubMed:39607687" FT CONFLICT 383 FT /note="K -> E (in Ref. 5; BAF82078)" FT /evidence="ECO:0000305" FT CONFLICT 383 FT /note="K -> N (in Ref. 1; AAF28469)" FT /evidence="ECO:0000305" FT CONFLICT 457 FT /note="A -> S (in Ref. 1; AAF28469)" FT /evidence="ECO:0000305" FT CONFLICT 675 FT /note="S -> N (in Ref. 5; BAF82078)" FT /evidence="ECO:0000305" FT STRAND 1..7 FT /evidence="ECO:0007829|PDB:2FAZ" FT STRAND 13..19 FT /evidence="ECO:0007829|PDB:2FAZ" FT HELIX 25..36 FT /evidence="ECO:0007829|PDB:2FAZ" FT HELIX 40..42 FT /evidence="ECO:0007829|PDB:2FAZ" FT STRAND 43..47 FT /evidence="ECO:0007829|PDB:2FAZ" FT TURN 58..62 FT /evidence="ECO:0007829|PDB:2FAZ" FT STRAND 68..73 FT /evidence="ECO:0007829|PDB:2FAZ" FT STRAND 126..128 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 130..132 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 133..135 FT /evidence="ECO:0007829|PDB:7FB7" FT STRAND 140..144 FT /evidence="ECO:0007829|PDB:6W92" FT TURN 146..148 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 151..162 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 164..167 FT /evidence="ECO:0007829|PDB:2L3R" FT STRAND 173..175 FT /evidence="ECO:0007829|PDB:6W92" FT HELIX 179..181 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 183..190 FT /evidence="ECO:0007829|PDB:6W92" FT HELIX 192..194 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 196..200 FT /evidence="ECO:0007829|PDB:6W92" FT HELIX 201..203 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 204..206 FT /evidence="ECO:0007829|PDB:7FB7" FT STRAND 210..212 FT /evidence="ECO:0007829|PDB:2L3R" FT HELIX 214..216 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 222..227 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 229..231 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 237..248 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 253..260 FT /evidence="ECO:0007829|PDB:6W92" FT STRAND 262..264 FT /evidence="ECO:0007829|PDB:8XV4" FT STRAND 266..270 FT /evidence="ECO:0007829|PDB:6W92" FT HELIX 274..276 FT /evidence="ECO:0007829|PDB:2L3R" FT STRAND 277..279 FT /evidence="ECO:0007829|PDB:2L3R" FT STRAND 283..286 FT /evidence="ECO:0007829|PDB:3ASK" FT TURN 303..307 FT /evidence="ECO:0007829|PDB:3ASL" FT STRAND 309..311 FT /evidence="ECO:0007829|PDB:2LGG" FT TURN 314..316 FT /evidence="ECO:0007829|PDB:3ASL" FT TURN 319..321 FT /evidence="ECO:0007829|PDB:3ASL" FT STRAND 323..325 FT /evidence="ECO:0007829|PDB:2LGL" FT HELIX 327..329 FT /evidence="ECO:0007829|PDB:3ASL" FT STRAND 330..332 FT /evidence="ECO:0007829|PDB:3ASL" FT TURN 334..336 FT /evidence="ECO:0007829|PDB:3ASL" FT STRAND 339..341 FT /evidence="ECO:0007829|PDB:3ASL" FT HELIX 342..344 FT /evidence="ECO:0007829|PDB:3ASL" FT STRAND 345..347 FT /evidence="ECO:0007829|PDB:3ASL" FT STRAND 354..356 FT /evidence="ECO:0007829|PDB:3ASL" FT TURN 361..363 FT /evidence="ECO:0007829|PDB:3ASL" FT STRAND 417..419 FT /evidence="ECO:0007829|PDB:3DWH" FT STRAND 429..432 FT /evidence="ECO:0007829|PDB:3BI7" FT HELIX 433..438 FT /evidence="ECO:0007829|PDB:3BI7" FT TURN 439..442 FT /evidence="ECO:0007829|PDB:3DWH" FT STRAND 448..452 FT /evidence="ECO:0007829|PDB:3BI7" FT TURN 453..455 FT /evidence="ECO:0007829|PDB:3BI7" FT STRAND 456..462 FT /evidence="ECO:0007829|PDB:3BI7" FT STRAND 473..479 FT /evidence="ECO:0007829|PDB:3BI7" FT TURN 487..489 FT /evidence="ECO:0007829|PDB:3CLZ" FT HELIX 503..511 FT /evidence="ECO:0007829|PDB:3BI7" FT STRAND 512..514 FT /evidence="ECO:0007829|PDB:3BI7" FT TURN 518..520 FT /evidence="ECO:0007829|PDB:3BI7" FT HELIX 527..529 FT /evidence="ECO:0007829|PDB:3BI7" FT STRAND 533..538 FT /evidence="ECO:0007829|PDB:3BI7" FT HELIX 539..544 FT /evidence="ECO:0007829|PDB:3BI7" FT STRAND 546..548 FT /evidence="ECO:0007829|PDB:3CLZ" FT STRAND 550..568 FT /evidence="ECO:0007829|PDB:3BI7" FT STRAND 572..582 FT /evidence="ECO:0007829|PDB:3BI7" FT HELIX 592..601 FT /evidence="ECO:0007829|PDB:3BI7" FT HELIX 611..617 FT /evidence="ECO:0007829|PDB:3BI7" FT HELIX 678..686 FT /evidence="ECO:0007829|PDB:3FL2" FT HELIX 688..690 FT /evidence="ECO:0007829|PDB:3FL2" FT HELIX 691..699 FT /evidence="ECO:0007829|PDB:3FL2" FT STRAND 706..708 FT /evidence="ECO:0007829|PDB:3FL2" FT HELIX 710..721 FT /evidence="ECO:0007829|PDB:3FL2" FT TURN 725..727 FT /evidence="ECO:0007829|PDB:3FL2" FT STRAND 728..730 FT /evidence="ECO:0007829|PDB:3FL2" FT STRAND 732..736 FT /evidence="ECO:0007829|PDB:3FL2" FT STRAND 742..744 FT /evidence="ECO:0007829|PDB:3FL2" FT HELIX 745..753 FT /evidence="ECO:0007829|PDB:3FL2" FT TURN 760..762 FT /evidence="ECO:0007829|PDB:3FL2" FT HELIX 776..785 FT /evidence="ECO:0007829|PDB:3FL2" FT TURN 787..792 FT /evidence="ECO:0007829|PDB:3FL2" SQ SEQUENCE 793 AA; 89814 MW; E65B15657525C89F CRC64; MWIQVRTMDG RQTHTVDSLS RLTKVEELRR KIQELFHVEP GLQRLFYRGK QMEDGHTLFD YEVRLNDTIQ LLVRQSLVLP HSTKERDSEL SDTDSGCCLG QSESDKSSTH GEAAAETDSR PADEDMWDET ELGLYKVNEY VDARDTNMGA WFEAQVVRVT RKAPSRDEPC SSTSRPALEE DVIYHVKYDD YPENGVVQMN SRDVRARART IIKWQDLEVG QVVMLNYNPD NPKERGFWYD AEISRKRETR TARELYANVV LGDDSLNDCR IIFVDEVFKI ERPGEGSPMV DNPMRRKSGP SCKHCKDDVN RLCRVCACHL CGGRQDPDKQ LMCDECDMAF HIYCLDPPLS SVPSEDEWYC PECRNDASEV VLAGERLRES KKKAKMASAT SSSQRDWGKG MACVGRTKEC TIVPSNHYGP IPGIPVGTMW RFRVQVSESG VHRPHVAGIH GRSNDGAYSL VLAGGYEDDV DHGNFFTYTG SGGRDLSGNK RTAEQSCDQK LTNTNRALAL NCFAPINDQE GAEAKDWRSG KPVRVVRNVK GGKNSKYAPA EGNRYDGIYK VVKYWPEKGK SGFLVWRYLL RRDDDEPGPW TKEGKDRIKK LGLTMQYPEG YLEALANRER EKENSKREEE EQQEGGFASP RTGKGKWKRK SAGGGPSRAG SPRRTSKKTK VEPYSLTAQQ SSLIREDKSN AKLWNEVLAS LKDRPASGSP FQLFLSKVEE TFQCICCQEL VFRPITTVCQ HNVCKDCLDR SFRAQVFSCP ACRYDLGRSY AMQVNQPLQT VLNQLFPGYG NGR // ID ULK1_HUMAN Reviewed; 1050 AA. AC O75385; Q9UQ28; DT 15-JUL-1999, integrated into UniProtKB/Swiss-Prot. DT 11-JAN-2011, sequence version 2. DT 28-JAN-2026, entry version 224. DE RecName: Full=Serine/threonine-protein kinase ULK1 {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:18936157, ECO:0000269|PubMed:25126726, ECO:0000269|PubMed:28821708, ECO:0000269|PubMed:31123703, ECO:0000269|PubMed:37306101}; DE AltName: Full=Autophagy-related protein 1 homolog; DE Short=ATG1; DE Short=hATG1 {ECO:0000303|PubMed:21205641}; DE AltName: Full=Unc-51-like kinase 1 {ECO:0000303|PubMed:9693035}; GN Name=ULK1 {ECO:0000303|PubMed:9693035, ECO:0000312|HGNC:HGNC:12558}; GN Synonyms=KIAA0722 {ECO:0000303|PubMed:9872452}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ALA-816. RX PubMed=9693035; DOI=10.1006/geno.1998.5340; RA Kuroyanagi H., Yan J., Seki N., Yamanouchi Y., Suzuki Y., Takano T., RA Muramatsu M., Shirasawa T.; RT "Human ULK1, a novel serine/threonine kinase related to UNC-51 kinase of RT Caenorhabditis elegans: cDNA cloning, expression, and chromosomal RT assignment."; RL Genomics 51:76-85(1998). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ALA-816. RC TISSUE=Brain; RX PubMed=9872452; DOI=10.1093/dnares/5.5.277; RA Nagase T., Ishikawa K., Suyama M., Kikuno R., Miyajima N., Tanaka A., RA Kotani H., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XI. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 5:277-286(1998). RN [3] RP SEQUENCE REVISION. RX PubMed=12168954; DOI=10.1093/dnares/9.3.99; RA Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.; RT "Construction of expression-ready cDNA clones for KIAA genes: manual RT curation of 330 KIAA cDNA clones."; RL DNA Res. 9:99-106(2002). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16541075; DOI=10.1038/nature04569; RA Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y., RA Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C., RA Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C., RA Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., RA Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E., RA Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., RA Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., RA Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., RA Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., RA Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., RA Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., RA Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., RA Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., RA Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., RA Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K., RA Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D., RA Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R., RA David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E., RA D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N., RA Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N., RA Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R., RA Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S., RA LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H., RA Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P., RA Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G., RA Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E., RA Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S., RA Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., RA Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J., RA Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A., RA Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M., RA Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I., RA Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A., RA Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y., RA Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A., RA Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F., RA Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L., RA Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G., RA Gibbs R.A.; RT "The finished DNA sequence of human chromosome 12."; RL Nature 440:346-351(2006). RN [5] RP FUNCTION, INTERACTION WITH GABARAP AND GABARAPL2, AND REGION. RX PubMed=11146101; DOI=10.1016/s0169-328x(00)00218-7; RA Okazaki N., Yan J., Yuasa S., Ueno T., Kominami E., Masuho Y., Koga H., RA Muramatsu M.-A.; RT "Interaction of the Unc-51-like kinase and microtubule-associated protein RT light chain 3 related proteins in the brain: possible role of vesicular RT transport in axonal elongation."; RL Brain Res. Mol. Brain Res. 85:1-12(2000). RN [6] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477 AND SER-479, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [7] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-450; THR-456 AND SER-556, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [8] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [9] RP SUBUNIT, AND COMPLEX FORMATION WITH ATG13; ATG101 AND RB1CC1. RX PubMed=19287211; DOI=10.4161/auto.5.5.8249; RA Mercer C.A., Kaliappan A., Dennis P.B.; RT "A novel, human Atg13 binding protein, Atg101, interacts with ULK1 and is RT essential for macroautophagy."; RL Autophagy 5:649-662(2009). RN [10] RP SUBUNIT. RX PubMed=19597335; DOI=10.4161/auto.5.7.9296; RA Hosokawa N., Sasaki T., Iemura S.I., Natsume T., Hara T., Mizushima N.; RT "Atg101, a novel mammalian autophagy protein interacting with Atg13."; RL Autophagy 5:973-979(2009). RN [11] RP SUBUNIT, AND INTERACTION WITH RPTOR AND TORC1 COMPLEX. RX PubMed=19211835; DOI=10.1091/mbc.e08-12-1248; RA Hosokawa N., Hara T., Kaizuka T., Kishi C., Takamura A., Miura Y., RA Iemura S., Natsume T., Takehana K., Yamada N., Guan J.L., Oshiro N., RA Mizushima N.; RT "Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex RT required for autophagy."; RL Mol. Biol. Cell 20:1981-1991(2009). RN [12] RP FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH ATG13. RX PubMed=18936157; DOI=10.1128/mcb.01082-08; RA Chan E.Y.W., Longatti A., McKnight N.C., Tooze S.A.; RT "Kinase-inactivated ULK proteins inhibit autophagy via their conserved C- RT terminal domains using an Atg13-independent mechanism."; RL Mol. Cell. Biol. 29:157-171(2009). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-450 AND SER-638, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [15] RP FUNCTION, AND MUTAGENESIS OF LYS-46. RX PubMed=20921139; DOI=10.1083/jcb.201002100; RA Di Bartolomeo S., Corazzari M., Nazio F., Oliverio S., Lisi G., RA Antonioli M., Pagliarini V., Matteoni S., Fuoco C., Giunta L., D'Amelio M., RA Nardacci R., Romagnoli A., Piacentini M., Cecconi F., Fimia G.M.; RT "The dynamic interaction of AMBRA1 with the dynein motor complex regulates RT mammalian autophagy."; RL J. Cell Biol. 191:155-168(2010). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-450; THR-456 AND SER-638, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [17] RP FUNCTION IN PHOSPHORYLATION OF AMPK. RX PubMed=21460634; DOI=10.4161/auto.7.7.15451; RA Loffler A.S., Alers S., Dieterle A.M., Keppeler H., Franz-Wachtel M., RA Kundu M., Campbell D.G., Wesselborg S., Alessi D.R., Stork B.; RT "Ulk1-mediated phosphorylation of AMPK constitutes a negative regulatory RT feedback loop."; RL Autophagy 7:696-706(2011). RN [18] RP FUNCTION, AND INTERACTION WITH RPTOR. RX PubMed=21795849; DOI=10.4161/auto.7.10.16660; RA Jung C.H., Seo M., Otto N.M., Kim D.H.; RT "ULK1 inhibits the kinase activity of mTORC1 and cell proliferation."; RL Autophagy 7:1212-1221(2011). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-450; SER-469; SER-556 AND RP SER-638, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [20] RP PHOSPHORYLATION BY AMPK. RX PubMed=21205641; DOI=10.1126/science.1196371; RA Egan D.F., Shackelford D.B., Mihaylova M.M., Gelino S., Kohnz R.A., RA Mair W., Vasquez D.S., Joshi A., Gwinn D.M., Taylor R., Asara J.M., RA Fitzpatrick J., Dillin A., Viollet B., Kundu M., Hansen M., Shaw R.J.; RT "Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects RT energy sensing to mitophagy."; RL Science 331:456-461(2011). RN [21] RP INTERACTION WITH FEZ1. RX PubMed=22354037; DOI=10.1038/emboj.2012.36; RA McKnight N.C., Jefferies H.B., Alemu E.A., Saunders R.E., Howell M., RA Johansen T., Tooze S.A.; RT "Genome-wide siRNA screen reveals amino acid starvation-induced autophagy RT requires SCOC and WAC."; RL EMBO J. 31:1931-1946(2012). RN [22] RP INTERACTION WITH TBC1D14. RX PubMed=22613832; DOI=10.1083/jcb.201111079; RA Longatti A., Lamb C.A., Razi M., Yoshimura S., Barr F.A., Tooze S.A.; RT "TBC1D14 regulates autophagosome formation via Rab11- and ULK1-positive RT recycling endosomes."; RL J. Cell Biol. 197:659-675(2012). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-403; SER-450; SER-467; RP SER-469; SER-477; SER-479; SER-556; SER-638; SER-758 AND SER-775, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [24] RP FUNCTION, AND UBIQUITINATION. RX PubMed=23524951; DOI=10.1038/ncb2708; RA Nazio F., Strappazzon F., Antonioli M., Bielli P., Cianfanelli V., RA Bordi M., Gretzmeier C., Dengjel J., Piacentini M., Fimia G.M., Cecconi F.; RT "mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self- RT association and function through AMBRA1 and TRAF6."; RL Nat. Cell Biol. 15:406-416(2013). RN [25] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=25126726; DOI=10.4161/auto.29640; RA Dunlop E.A., Seifan S., Claessens T., Behrends C., Kamps M.A., Rozycka E., RA Kemp A.J., Nookala R.K., Blenis J., Coull B.J., Murray J.T., RA van Steensel M.A., Wilkinson S., Tee A.R.; RT "FLCN, a novel autophagy component, interacts with GABARAP and is regulated RT by ULK1 phosphorylation."; RL Autophagy 10:1749-1760(2014). RN [26] RP PHOSPHORYLATION AT SER-556. RX PubMed=24767988; DOI=10.1016/j.celrep.2014.03.065; RA Lanning N.J., Looyenga B.D., Kauffman A.L., Niemi N.M., Sudderth J., RA DeBerardinis R.J., MacKeigan J.P.; RT "A mitochondrial RNAi screen defines cellular bioenergetic determinants and RT identifies an adenylate kinase as a key regulator of ATP levels."; RL Cell Rep. 7:907-917(2014). RN [27] RP FUNCTION, INTERACTION WITH SESN2 AND SQSTM1, AND REGION. RX PubMed=25040165; DOI=10.1111/febs.12905; RA Ro S.H., Semple I.A., Park H., Park H., Park H.W., Kim M., Kim J.S., RA Lee J.H.; RT "Sestrin2 promotes Unc-51-like kinase 1 mediated phosphorylation of RT p62/sequestosome-1."; RL FEBS J. 281:3816-3827(2014). RN [28] RP INTERACTION WITH TRIM5. RX PubMed=25127057; DOI=10.1016/j.devcel.2014.06.013; RA Mandell M.A., Jain A., Arko-Mensah J., Chauhan S., Kimura T., Dinkins C., RA Silvestri G., Munch J., Kirchhoff F., Simonsen A., Wei Y., Levine B., RA Johansen T., Deretic V.; RT "TRIM proteins regulate autophagy and can target autophagic substrates by RT direct recognition."; RL Dev. Cell 30:394-409(2014). RN [29] RP INTERACTION WITH BECN1; IRF3; MEFV AND TRIM21. RX PubMed=26347139; DOI=10.1083/jcb.201503023; RA Kimura T., Jain A., Choi S.W., Mandell M.A., Schroder K., Johansen T., RA Deretic V.; RT "TRIM-mediated precision autophagy targets cytoplasmic regulators of innate RT immunity."; RL J. Cell Biol. 210:973-989(2015). RN [30] RP INTERACTION WITH IRGM, AND PHOSPHORYLATION AT SER-317 AND SER-556. RX PubMed=25891078; DOI=10.1016/j.molcel.2015.03.020; RA Chauhan S., Mandell M.A., Deretic V.; RT "IRGM governs the core autophagy machinery to conduct antimicrobial RT defense."; RL Mol. Cell 58:507-521(2015). RN [31] RP INTERACTION WITH AMBRA1. RX PubMed=25438055; DOI=10.1038/ncb3072; RA Cianfanelli V., Fuoco C., Lorente M., Salazar M., Quondamatteo F., RA Gherardini P.F., De Zio D., Nazio F., Antonioli M., D'Orazio M., Skobo T., RA Bordi M., Rohde M., Dalla Valle L., Helmer-Citterich M., Gretzmeier C., RA Dengjel J., Fimia G.M., Piacentini M., Di Bartolomeo S., Velasco G., RA Cecconi F.; RT "AMBRA1 links autophagy to cell proliferation and tumorigenesis by RT promoting c-Myc dephosphorylation and degradation."; RL Nat. Cell Biol. 17:20-30(2015). RN [32] RP ERRATUM OF PUBMED:25438055. RX PubMed=25925585; DOI=10.1038/ncb3171; RA Cianfanelli V., Fuoco C., Lorente M., Salazar M., Quondamatteo F., RA Gherardini P.F., De Zio D., Nazio F., Antonioli M., D'Orazio M., Skobo T., RA Bordi M., Rohde M., Dalla Valle L., Helmer-Citterich M., Gretzmeier C., RA Dengjel J., Fimia G.M., Piacentini M., Di Bartolomeo S., Velasco G., RA Cecconi F.; RL Nat. Cell Biol. 17:706-706(2015). RN [33] RP INTERACTION WITH C9ORF72. RX PubMed=27334615; DOI=10.15252/embj.201694401; RA Webster C.P., Smith E.F., Bauer C.S., Moller A., Hautbergue G.M., RA Ferraiuolo L., Myszczynska M.A., Higginbottom A., Walsh M.J., RA Whitworth A.J., Kaspar B.K., Meyer K., Shaw P.J., Grierson A.J., RA De Vos K.J.; RT "The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate RT initiation of autophagy."; RL EMBO J. 35:1656-1676(2016). RN [34] RP INTERACTION WITH ATP2A2 AND WIPI2. RX PubMed=28890335; DOI=10.1016/j.molcel.2017.08.005; RA Zhao Y.G., Chen Y., Miao G., Zhao H., Qu W., Li D., Wang Z., Liu N., Li L., RA Chen S., Liu P., Feng D., Zhang H.; RT "The ER-Localized Transmembrane Protein EPG-3/VMP1 Regulates SERCA Activity RT to Control ER-Isolation Membrane Contacts for Autophagosome Formation."; RL Mol. Cell 67:974.e6-989.e6(2017). RN [35] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-46. RX PubMed=28821708; DOI=10.1038/s41467-017-00303-2; RA Pengo N., Agrotis A., Prak K., Jones J., Ketteler R.; RT "A reversible phospho-switch mediated by ULK1 regulates the activity of RT autophagy protease ATG4B."; RL Nat. Commun. 8:294-294(2017). RN [36] RP INTERACTION WITH WDR45. RX PubMed=28561066; DOI=10.1038/ncomms15637; RA Bakula D., Mueller A.J., Zuleger T., Takacs Z., Franz-Wachtel M., RA Thost A.K., Brigger D., Tschan M.P., Frickey T., Robenek H., Macek B., RA Proikas-Cezanne T.; RT "WIPI3 and WIPI4 beta-propellers are scaffolds for LKB1-AMPK-TSC signalling RT circuits in the control of autophagy."; RL Nat. Commun. 8:15637-15637(2017). RN [37] RP FUNCTION, AND DEUBIQUITINATION BY USP20. RX PubMed=29487085; DOI=10.15252/embr.201744378; RA Kim J.H., Seo D., Kim S.J., Choi D.W., Park J.S., Ha J., Choi J., Lee J.H., RA Jung S.M., Seo K.W., Lee E.W., Lee Y.S., Cheong H., Choi C.Y., Park S.H.; RT "The deubiquitinating enzyme USP20 stabilizes ULK1 and promotes autophagy RT initiation."; RL EMBO Rep. 19:0-0(2018). RN [38] RP INTERACTION WITH ATG13. RX PubMed=31806350; DOI=10.1016/j.molcel.2019.10.035; RA Miao G., Zhang Y., Chen D., Zhang H.; RT "The ER-Localized Transmembrane Protein TMEM39A/SUSR2 Regulates Autophagy RT by Controlling the Trafficking of the PtdIns(4)P Phosphatase SAC1."; RL Mol. Cell 0:0-0(2019). RN [39] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND INTERACTION WITH RP AMBRA1. RX PubMed=31123703; DOI=10.1126/sciadv.aau8857; RA Di Rienzo M., Antonioli M., Fusco C., Liu Y., Mari M., Orhon I., Refolo G., RA Germani F., Corazzari M., Romagnoli A., Ciccosanti F., Mandriani B., RA Pellico M.T., De La Torre R., Ding H., Dentice M., Neri M., Ferlini A., RA Reggiori F., Kulesz-Martin M., Piacentini M., Merla G., Fimia G.M.; RT "Autophagy induction in atrophic muscle cells requires ULK1 activation by RT TRIM32 through unanchored K63-linked polyubiquitin chains."; RL Sci. Adv. 5:eaau8857-eaau8857(2019). RN [40] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=37306101; DOI=10.15252/embj.2022113349; RA Ikeda R., Noshiro D., Morishita H., Takada S., Kageyama S., Fujioka Y., RA Funakoshi T., Komatsu-Hirota S., Arai R., Ryzhii E., Abe M., Koga T., RA Motohashi H., Nakao M., Sakimura K., Horii A., Waguri S., Ichimura Y., RA Noda N.N., Komatsu M.; RT "Phosphorylation of phase-separated p62 bodies by ULK1 activates a redox- RT independent stress response."; RL EMBO J. 42:e113349-e113349(2023). RN [41] RP FUNCTION, AND INTERACTION WITH FBXO16. RX PubMed=39384743; DOI=10.1038/s41419-024-07120-8; RA Zhang Z., Liu X., Chu C., Zhang Y., Li W., Yu X., Han Q., Sun H., Zhang Y., RA Zhu X., Chen L., Wei R., Fan N., Zhou M., Li X.; RT "MIR937 amplification potentiates ovarian cancer progression by attenuating RT FBXO16 inhibition on ULK1-mediated autophagy."; RL Cell Death Dis. 15:735-735(2024). RN [42] RP VARIANTS [LARGE SCALE ANALYSIS] MET-290; LEU-298; LEU-478; MET-503; RP LEU-665; LEU-714 AND CYS-784. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase involved in autophagy in CC response to starvation (PubMed:18936157, PubMed:21460634, CC PubMed:21795849, PubMed:23524951, PubMed:25040165, PubMed:29487085, CC PubMed:31123703). Acts upstream of phosphatidylinositol 3-kinase PIK3C3 CC to regulate the formation of autophagophores, the precursors of CC autophagosomes (PubMed:18936157, PubMed:21460634, PubMed:21795849, CC PubMed:25040165, PubMed:39384743). Part of regulatory feedback loops in CC autophagy: acts both as a downstream effector and negative regulator of CC mammalian target of rapamycin complex 1 (mTORC1) via interaction with CC RPTOR (PubMed:21795849). Activated via phosphorylation by AMPK and also CC acts as a regulator of AMPK by mediating phosphorylation of AMPK CC subunits PRKAA1, PRKAB2 and PRKAG1, leading to negatively regulate AMPK CC activity (PubMed:21460634). May phosphorylate ATG13/KIAA0652 and RPTOR; CC however such data need additional evidences (PubMed:18936157). Plays a CC role early in neuronal differentiation and is required for granule cell CC axon formation (PubMed:11146101). Also phosphorylates SESN2 and SQSTM1 CC to regulate autophagy (PubMed:25040165, PubMed:37306101). CC Phosphorylates FLCN, promoting autophagy (PubMed:25126726). CC Phosphorylates AMBRA1 in response to autophagy induction, releasing CC AMBRA1 from the cytoskeletal docking site to induce autophagosome CC nucleation (PubMed:20921139). Phosphorylates ATG4B, leading to inhibit CC autophagy by decreasing both proteolytic activation and delipidation CC activities of ATG4B (PubMed:28821708). {ECO:0000269|PubMed:11146101, CC ECO:0000269|PubMed:18936157, ECO:0000269|PubMed:20921139, CC ECO:0000269|PubMed:21460634, ECO:0000269|PubMed:21795849, CC ECO:0000269|PubMed:23524951, ECO:0000269|PubMed:25040165, CC ECO:0000269|PubMed:25126726, ECO:0000269|PubMed:28821708, CC ECO:0000269|PubMed:29487085, ECO:0000269|PubMed:31123703, CC ECO:0000269|PubMed:37306101, ECO:0000269|PubMed:39384743}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:18936157, ECO:0000269|PubMed:25126726, CC ECO:0000269|PubMed:28821708, ECO:0000269|PubMed:31123703, CC ECO:0000269|PubMed:37306101}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:18936157, ECO:0000269|PubMed:25126726, CC ECO:0000269|PubMed:31123703, ECO:0000269|PubMed:37306101}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:18936157}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609; CC Evidence={ECO:0000269|PubMed:18936157}; CC -!- ACTIVITY REGULATION: Acetylation by KAT5/TIP60 stimulates the protein CC kinase activity (By similarity). The protein kinase activity is CC activated by unanchored 'Lys-63'-linked polyubiquitin chains: CC unanchored 'Lys-63'-linked polyubiquitin chains are catalyzed by TRIM32 CC in an AMBRA1-dependent manner (PubMed:31123703). CC {ECO:0000250|UniProtKB:O70405, ECO:0000269|PubMed:31123703}. CC -!- SUBUNIT: Interacts with GABARAP and GABARAPL2 (PubMed:11146101). CC Interacts (via C-terminus) with ATG13 (PubMed:18936157). Part of a CC complex consisting of ATG13, ATG101, ULK1 and RB1CC1 (PubMed:19287211). CC Associates with the mammalian target of rapamycin complex 1 (mTORC1) CC through an interaction with RPTOR; the association depends on nutrient CC conditions and is reduced during starvation (PubMed:19211835, CC PubMed:21795849). Interacts with FEZ1; SCOC interferes with FEZ1- CC binding (PubMed:22354037). Interacts with TBC1D14 (PubMed:22613832). CC Interacts (phosphorylated form) with TRIM5 (PubMed:25127057). When CC phosphorylated at Ser-317, interacts with MEFV and BECN1 simultaneously CC (PubMed:26347139). Interacts with TRIM21 and IRF3, in the presence of CC TRIM21 (PubMed:26347139). Interacts with SESN2 (PubMed:25040165). CC Interacts with SQSTM1 (PubMed:25040165). Interacts with C9orf72 CC (PubMed:27334615). Interacts with WDR45 (PubMed:28561066). Interacts CC with ATG13; this interaction is increased in the absence of TMEM39A CC (PubMed:31806350). Interacts with WIPI2 (PubMed:28890335). Interacts CC with ATP2A2 (PubMed:28890335). Interacts with AMBRA1 (PubMed:25438055, CC PubMed:31123703). Interacts with IRGM; promoting the coassembly of ULK1 CC and BECN1 (PubMed:25891078). Interacts with FBXO16 (PubMed:39384743). CC {ECO:0000269|PubMed:11146101, ECO:0000269|PubMed:18936157, CC ECO:0000269|PubMed:19211835, ECO:0000269|PubMed:19287211, CC ECO:0000269|PubMed:19597335, ECO:0000269|PubMed:21795849, CC ECO:0000269|PubMed:22354037, ECO:0000269|PubMed:22613832, CC ECO:0000269|PubMed:25040165, ECO:0000269|PubMed:25127057, CC ECO:0000269|PubMed:25438055, ECO:0000269|PubMed:25891078, CC ECO:0000269|PubMed:26347139, ECO:0000269|PubMed:27334615, CC ECO:0000269|PubMed:28561066, ECO:0000269|PubMed:28890335, CC ECO:0000269|PubMed:31123703, ECO:0000269|PubMed:31806350, CC ECO:0000269|PubMed:39384743}. CC -!- INTERACTION: CC O75385; Q9C0C7: AMBRA1; NbExp=3; IntAct=EBI-908831, EBI-2512975; CC O75385; Q9C0C7-3: AMBRA1; NbExp=4; IntAct=EBI-908831, EBI-16042318; CC O75385; O75143: ATG13; NbExp=15; IntAct=EBI-908831, EBI-2798775; CC O75385; Q96LT7-1: C9orf72; NbExp=5; IntAct=EBI-908831, EBI-16693635; CC O75385; Q96LT7-2: C9orf72; NbExp=4; IntAct=EBI-908831, EBI-16693673; CC O75385; O95166: GABARAP; NbExp=2; IntAct=EBI-908831, EBI-712001; CC O75385; Q9H0R8: GABARAPL1; NbExp=3; IntAct=EBI-908831, EBI-746969; CC O75385; P60520: GABARAPL2; NbExp=4; IntAct=EBI-908831, EBI-720116; CC O75385; P42858: HTT; NbExp=8; IntAct=EBI-908831, EBI-466029; CC O75385; Q9GZQ8: MAP1LC3B; NbExp=3; IntAct=EBI-908831, EBI-373144; CC O75385; Q9BXW4: MAP1LC3C; NbExp=4; IntAct=EBI-908831, EBI-2603996; CC O75385; P42345: MTOR; NbExp=7; IntAct=EBI-908831, EBI-359260; CC O75385; P04629: NTRK1; NbExp=2; IntAct=EBI-908831, EBI-1028226; CC O75385; O15530: PDPK1; NbExp=2; IntAct=EBI-908831, EBI-717097; CC O75385; P54646: PRKAA2; NbExp=2; IntAct=EBI-908831, EBI-1383852; CC O75385; Q9Y478: PRKAB1; NbExp=3; IntAct=EBI-908831, EBI-719769; CC O75385; Q8TDY2: RB1CC1; NbExp=13; IntAct=EBI-908831, EBI-1047793; CC O75385; Q8N122: RPTOR; NbExp=3; IntAct=EBI-908831, EBI-1567928; CC O75385; Q9P2M4: TBC1D14; NbExp=4; IntAct=EBI-908831, EBI-2797718; CC O75385; Q9Y4K3: TRAF6; NbExp=2; IntAct=EBI-908831, EBI-359276; CC O75385; O75385: ULK1; NbExp=3; IntAct=EBI-908831, EBI-908831; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000250}. CC Preautophagosomal structure {ECO:0000250}. Note=Under starvation CC conditions, is localized to puncate structures primarily representing CC the isolation membrane that sequesters a portion of the cytoplasm CC resulting in the formation of an autophagosome. {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Ubiquitously expressed. Detected in the following CC adult tissues: skeletal muscle, heart, pancreas, brain, placenta, CC liver, kidney, and lung. CC -!- PTM: Autophosphorylated. Phosphorylated under nutrient-rich conditions; CC dephosphorylated during starvation or following treatment with CC rapamycin. Under nutrient sufficiency, phosphorylated by MTOR/mTOR, CC disrupting the interaction with AMPK and preventing activation of ULK1 CC (By similarity). In response to nutrient limitation, phosphorylated and CC activated by AMPK, leading to activate autophagy (PubMed:21205641, CC PubMed:25891078). {ECO:0000250|UniProtKB:O70405, CC ECO:0000269|PubMed:21205641, ECO:0000269|PubMed:25891078}. CC -!- PTM: Ubiquitinated via 'Lys-63'-linkage by a complex composed of AMBRA1 CC and TRAF6 following autophagy induction, promoting ULK1 stability and CC kinase activity. Deubiquitinated by USP20; leading to ULK1 stability CC and autophagy initiation (PubMed:29487085). Ubiquitinated by the SCF- CC FBXO16 E3 ubiquitin ligase, leading to proteasomal degradation CC (PubMed:39384743). {ECO:0000269|PubMed:23524951, CC ECO:0000269|PubMed:29487085, ECO:0000269|PubMed:39384743}. CC -!- PTM: Acetylated by KAT5/TIP60 under autophagy induction, promoting CC protein kinase activity. {ECO:0000250|UniProtKB:O70405}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. APG1/unc-51/ULK1 subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA34442.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF045458; AAC32326.1; -; mRNA. DR EMBL; AB018265; BAA34442.2; ALT_INIT; mRNA. DR EMBL; AC131009; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS9274.1; -. DR RefSeq; NP_003556.2; NM_003565.4. DR PDB; 4WNO; X-ray; 1.56 A; A=1-283. DR PDB; 4WNP; X-ray; 1.88 A; A/B/C/D=1-283. DR PDB; 5CI7; X-ray; 1.74 A; A=1-283. DR PDB; 6HYO; X-ray; 1.07 A; A=354-366. DR PDB; 6MNH; X-ray; 1.73 A; A=6-290. DR PDB; 6QAS; X-ray; 1.75 A; A/B=1-283. DR PDB; 8P5G; X-ray; 2.02 A; A/B=1-283. DR PDB; 8P5H; X-ray; 1.94 A; A/B=1-283. DR PDB; 8P5I; X-ray; 1.83 A; A/B/C/D=1-283. DR PDB; 8P5J; X-ray; 2.16 A; A/B=1-283. DR PDB; 8P5K; X-ray; 2.21 A; A/B/C/D=1-283. DR PDB; 8P5L; X-ray; 1.84 A; A/B=1-283. DR PDB; 8SOI; EM; 4.20 A; C=840-1044. DR PDB; 8SQZ; EM; 5.85 A; C/D=836-1050. DR PDB; 8SRM; EM; 4.46 A; C/D=836-1050. DR PDB; 8SV9; X-ray; 2.30 A; A/B=1-283. DR PDB; 9C82; EM; 6.20 A; C=840-1044. DR PDB; 9F32; X-ray; 2.10 A; A=1-283. DR PDBsum; 4WNO; -. DR PDBsum; 4WNP; -. DR PDBsum; 5CI7; -. DR PDBsum; 6HYO; -. DR PDBsum; 6MNH; -. DR PDBsum; 6QAS; -. DR PDBsum; 8P5G; -. DR PDBsum; 8P5H; -. DR PDBsum; 8P5I; -. DR PDBsum; 8P5J; -. DR PDBsum; 8P5K; -. DR PDBsum; 8P5L; -. DR PDBsum; 8SOI; -. DR PDBsum; 8SQZ; -. DR PDBsum; 8SRM; -. DR PDBsum; 8SV9; -. DR PDBsum; 9C82; -. DR PDBsum; 9F32; -. DR AlphaFoldDB; O75385; -. DR EMDB; EMD-40658; -. DR EMDB; EMD-40715; -. DR EMDB; EMD-40735; -. DR EMDB; EMD-40738; -. DR SMR; O75385; -. DR BioGRID; 113996; 182. DR ComplexPortal; CPX-26575; ATG13-ATG14-BECN1-PIK3C3-PIK3R4-RB1CC1, autophagy initiation complex. DR ComplexPortal; CPX-373; ULK1-ATG13-RB1CC1-ATG101 autophagy initiation complex. DR CORUM; O75385; -. DR DIP; DIP-35196N; -. DR FunCoup; O75385; 1578. DR IntAct; O75385; 136. DR MINT; O75385; -. DR STRING; 9606.ENSP00000324560; -. DR BindingDB; O75385; -. DR ChEMBL; CHEMBL6006; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; O75385; -. DR GuidetoPHARMACOLOGY; 2271; -. DR GlyCosmos; O75385; 1 site, 1 glycan. DR GlyGen; O75385; 6 sites, 1 O-linked glycan (2 sites). DR iPTMnet; O75385; -. DR PhosphoSitePlus; O75385; -. DR SwissPalm; O75385; -. DR BioMuta; ULK1; -. DR CPTAC; CPTAC-3098; -. DR CPTAC; CPTAC-3099; -. DR jPOST; O75385; -. DR MassIVE; O75385; -. DR PaxDb; 9606-ENSP00000324560; -. DR PeptideAtlas; O75385; -. DR ProteomicsDB; 49958; -. DR Pumba; O75385; -. DR Antibodypedia; 31999; 908 antibodies from 39 providers. DR DNASU; 8408; -. DR Ensembl; ENST00000321867.6; ENSP00000324560.3; ENSG00000177169.11. DR GeneID; 8408; -. DR KEGG; hsa:8408; -. DR MANE-Select; ENST00000321867.6; ENSP00000324560.3; NM_003565.4; NP_003556.2. DR UCSC; uc001uje.4; human. DR AGR; HGNC:12558; -. DR ClinPGx; PA37198; -. DR CTD; 8408; -. DR DisGeNET; 8408; -. DR GeneCards; ULK1; -. DR HGNC; HGNC:12558; ULK1. DR HPA; ENSG00000177169; Low tissue specificity. DR MIM; 603168; gene. DR OpenTargets; ENSG00000177169; -. DR VEuPathDB; HostDB:ENSG00000177169; -. DR eggNOG; KOG0595; Eukaryota. DR GeneTree; ENSGT00940000156664; -. DR HOGENOM; CLU_011264_0_0_1; -. DR InParanoid; O75385; -. DR OMA; PQPHQIT; -. DR OrthoDB; 346907at2759; -. DR PAN-GO; O75385; 13 GO annotations based on evolutionary models. DR PhylomeDB; O75385; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; O75385; -. DR Reactome; R-HSA-1632852; Macroautophagy. DR Reactome; R-HSA-5357905; Regulation of TNFR1 signaling. DR Reactome; R-HSA-8854214; TBC/RABGAPs. DR Reactome; R-HSA-8876198; RAB GEFs exchange GTP for GDP on RABs. DR Reactome; R-HSA-8934903; Receptor Mediated Mitophagy. DR SignaLink; O75385; -. DR SIGNOR; O75385; -. DR Agora; ENSG00000177169; -. DR BioGRID-ORCS; 8408; 18 hits in 1202 CRISPR screens. DR ChiTaRS; ULK1; human. DR EvolutionaryTrace; O75385; -. DR GeneWiki; ULK1; -. DR GenomeRNAi; 8408; -. DR Pharos; O75385; Tchem. DR PRO; PR:O75385; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; O75385; protein. DR Bgee; ENSG00000177169; Expressed in body of pancreas and 161 other cell types or tissues. DR GO; GO:1990316; C:Atg1/ULK1 kinase complex; IPI:UniProtKB. DR GO; GO:0005776; C:autophagosome; IDA:UniProtKB. DR GO; GO:0000421; C:autophagosome membrane; IDA:UniProtKB. DR GO; GO:0030424; C:axon; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; IDA:UniProt. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome. DR GO; GO:0005741; C:mitochondrial outer membrane; TAS:Reactome. DR GO; GO:1903349; C:omegasome membrane; IDA:UniProtKB. DR GO; GO:0000407; C:phagophore assembly site; IDA:ComplexPortal. DR GO; GO:0034045; C:phagophore assembly site membrane; IDA:UniProtKB. DR GO; GO:0055037; C:recycling endosome; TAS:Reactome. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0051020; F:GTPase binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0044877; F:protein-containing complex binding; IPI:UniProtKB. DR GO; GO:0031267; F:small GTPase binding; IPI:BHF-UCL. DR GO; GO:0000045; P:autophagosome assembly; IDA:UniProtKB. DR GO; GO:0006914; P:autophagy; IDA:UniProtKB. DR GO; GO:0048675; P:axon extension; IBA:GO_Central. DR GO; GO:0031669; P:cellular response to nutrient levels; ISS:UniProtKB. DR GO; GO:0033554; P:cellular response to stress; IDA:UniProt. DR GO; GO:0008104; P:intracellular protein localization; IMP:UniProtKB. DR GO; GO:0016236; P:macroautophagy; IMP:BHF-UCL. DR GO; GO:0000423; P:mitophagy; IBA:GO_Central. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:ComplexPortal. DR GO; GO:0048671; P:negative regulation of collateral sprouting; IBA:GO_Central. DR GO; GO:0031333; P:negative regulation of protein-containing complex assembly; IDA:ParkinsonsUK-UCL. DR GO; GO:0031175; P:neuron projection development; IMP:UniProtKB. DR GO; GO:0031102; P:neuron projection regeneration; IEA:Ensembl. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0034727; P:piecemeal microautophagy of the nucleus; IBA:GO_Central. DR GO; GO:2000786; P:positive regulation of autophagosome assembly; IEA:Ensembl. DR GO; GO:0010508; P:positive regulation of autophagy; IDA:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; NAS:UniProtKB. DR GO; GO:0010506; P:regulation of autophagy; IBA:GO_Central. DR GO; GO:0016241; P:regulation of macroautophagy; IDA:UniProtKB. DR GO; GO:0010803; P:regulation of tumor necrosis factor-mediated signaling pathway; TAS:Reactome. DR GO; GO:0042594; P:response to starvation; ISS:UniProtKB. DR GO; GO:0061709; P:reticulophagy; IBA:GO_Central. DR GO; GO:0007165; P:signal transduction; IEA:InterPro. DR CDD; cd14202; STKc_ULK1; 1. DR FunFam; 1.10.510.10:FF:000128; serine/threonine-protein kinase ULK2 isoform X2; 1. DR FunFam; 3.30.200.20:FF:000149; serine/threonine-protein kinase unc-51 isoform X1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR045269; Atg1-like. DR InterPro; IPR048941; ATG1-like_MIT2. DR InterPro; IPR022708; Atg1-like_tMIT. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR016237; Ser/Thr_kin_STPK_Ulk-1/2. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24348; SERINE/THREONINE-PROTEIN KINASE UNC-51-RELATED; 1. DR PANTHER; PTHR24348:SF19; SERINE_THREONINE-PROTEIN KINASE ULK1; 1. DR Pfam; PF12063; ATG1-like_MIT1; 1. DR Pfam; PF21127; ATG1-like_MIT2; 1. DR Pfam; PF00069; Pkinase; 1. DR PIRSF; PIRSF000580; Ser/Thr_PK_STPK_ULK-1/2; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; ATP-binding; Autophagy; Cytoplasm; Kinase; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase; KW Ubl conjugation. FT CHAIN 1..1050 FT /note="Serine/threonine-protein kinase ULK1" FT /id="PRO_0000086780" FT DOMAIN 16..278 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 283..358 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 287..416 FT /note="Interaction with GABARAP and GABARAPL2" FT /evidence="ECO:0000269|PubMed:11146101" FT REGION 393..608 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 728..791 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 828..1050 FT /note="C-terminal domain; mediates interaction with SESN2" FT /evidence="ECO:0000269|PubMed:25040165" FT COMPBIAS 295..317 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 410..425 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 436..459 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 775..786 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 138 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 22..30 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 46 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000305|PubMed:20921139" FT MOD_RES 162 FT /note="N6-acetyllysine" FT /evidence="ECO:0000250|UniProtKB:O70405" FT MOD_RES 317 FT /note="Phosphoserine; by AMPK" FT /evidence="ECO:0000269|PubMed:25891078" FT MOD_RES 403 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 450 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 456 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231" FT MOD_RES 467 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 469 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 477 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:23186163" FT MOD_RES 479 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:23186163" FT MOD_RES 522 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O70405" FT MOD_RES 556 FT /note="Phosphoserine; by AMPK" FT /evidence="ECO:0000269|PubMed:24767988, FT ECO:0000269|PubMed:25891078, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 575 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:O70405" FT MOD_RES 607 FT /note="N6-acetyllysine" FT /evidence="ECO:0000250|UniProtKB:O70405" FT MOD_RES 636 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:O70405" FT MOD_RES 638 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 639 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O70405" FT MOD_RES 758 FT /note="Phosphoserine; by MTOR" FT /evidence="ECO:0000305|PubMed:21205641, FT ECO:0007744|PubMed:23186163" FT MOD_RES 775 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VARIANT 290 FT /note="V -> M (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs370624303)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041274" FT VARIANT 298 FT /note="S -> L (in dbSNP:rs56364352)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041275" FT VARIANT 478 FT /note="P -> L (in dbSNP:rs12827141)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041276" FT VARIANT 503 FT /note="T -> M (in dbSNP:rs55824543)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041277" FT VARIANT 665 FT /note="S -> L (in dbSNP:rs55815560)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041278" FT VARIANT 714 FT /note="P -> L (in dbSNP:rs11546871)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041279" FT VARIANT 784 FT /note="S -> C (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041280" FT VARIANT 816 FT /note="T -> A (in dbSNP:rs11609348)" FT /evidence="ECO:0000269|PubMed:9693035, FT ECO:0000269|PubMed:9872452" FT /id="VAR_054892" FT MUTAGEN 46 FT /note="K->I: Abolished serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:20921139, FT ECO:0000269|PubMed:28821708" FT STRAND 9..11 FT /evidence="ECO:0007829|PDB:4WNO" FT STRAND 14..24 FT /evidence="ECO:0007829|PDB:4WNO" FT STRAND 29..37 FT /evidence="ECO:0007829|PDB:4WNO" FT STRAND 42..47 FT /evidence="ECO:0007829|PDB:4WNO" FT HELIX 50..52 FT /evidence="ECO:0007829|PDB:4WNO" FT HELIX 53..67 FT /evidence="ECO:0007829|PDB:4WNO" FT STRAND 78..83 FT /evidence="ECO:0007829|PDB:4WNO" FT STRAND 88..93 FT /evidence="ECO:0007829|PDB:4WNO" FT HELIX 100..106 FT /evidence="ECO:0007829|PDB:4WNO" FT HELIX 112..132 FT /evidence="ECO:0007829|PDB:4WNO" FT HELIX 141..143 FT /evidence="ECO:0007829|PDB:4WNO" FT STRAND 144..147 FT /evidence="ECO:0007829|PDB:4WNO" FT HELIX 151..153 FT /evidence="ECO:0007829|PDB:4WNP" FT HELIX 156..158 FT /evidence="ECO:0007829|PDB:4WNO" FT STRAND 160..163 FT /evidence="ECO:0007829|PDB:4WNO" FT TURN 185..187 FT /evidence="ECO:0007829|PDB:4WNO" FT HELIX 190..193 FT /evidence="ECO:0007829|PDB:4WNO" FT HELIX 201..216 FT /evidence="ECO:0007829|PDB:4WNO" FT HELIX 226..235 FT /evidence="ECO:0007829|PDB:4WNO" FT HELIX 249..258 FT /evidence="ECO:0007829|PDB:4WNO" FT TURN 263..265 FT /evidence="ECO:0007829|PDB:4WNO" FT HELIX 269..273 FT /evidence="ECO:0007829|PDB:4WNO" FT HELIX 276..278 FT /evidence="ECO:0007829|PDB:4WNO" FT STRAND 281..284 FT /evidence="ECO:0007829|PDB:6MNH" SQ SEQUENCE 1050 AA; 112631 MW; AED9BD5139F2DB92 CRC64; MEPGRGGTET VGKFEFSRKD LIGHGAFAVV FKGRHREKHD LEVAVKCINK KNLAKSQTLL GKEIKILKEL KHENIVALYD FQEMANSVYL VMEYCNGGDL ADYLHAMRTL SEDTIRLFLQ QIAGAMRLLH SKGIIHRDLK PQNILLSNPA GRRANPNSIR VKIADFGFAR YLQSNMMAAT LCGSPMYMAP EVIMSQHYDG KADLWSIGTI VYQCLTGKAP FQASSPQDLR LFYEKNKTLV PTIPRETSAP LRQLLLALLQ RNHKDRMDFD EFFHHPFLDA SPSVRKSPPV PVPSYPSSGS GSSSSSSSTS HLASPPSLGE MQQLQKTLAS PADTAGFLHS SRDSGGSKDS SCDTDDFVMV PAQFPGDLVA EAPSAKPPPD SLMCSGSSLV ASAGLESHGR TPSPSPPCSS SPSPSGRAGP FSSSRCGASV PIPVPTQVQN YQRIERNLQS PTQFQTPRSS AIRRSGSTSP LGFARASPSP PAHAEHGGVL ARKMSLGGGR PYTPSPQVGT IPERPGWSGT PSPQGAEMRG GRSPRPGSSA PEHSPRTSGL GCRLHSAPNL SDLHVVRPKL PKPPTDPLGA VFSPPQASPP QPSHGLQSCR NLRGSPKLPD FLQRNPLPPI LGSPTKAVPS FDFPKTPSSQ NLLALLARQG VVMTPPRNRT LPDLSEVGPF HGQPLGPGLR PGEDPKGPFG RSFSTSRLTD LLLKAAFGTQ APDPGSTESL QEKPMEIAPS AGFGGSLHPG ARAGGTSSPS PVVFTVGSPP SGSTPPQGPR TRMFSAGPTG SASSSARHLV PGPCSEAPAP ELPAPGHGCS FADPITANLE GAVTFEAPDL PEETLMEQEH TEILRGLRFT LLFVQHVLEI AALKGSASEA AGGPEYQLQE SVVADQISLL SREWGFAEQL VLYLKVAELL SSGLQSAIDQ IRAGKLCLSS TVKQVVRRLN ELYKASVVSC QGLSLRLQRF FLDKQRLLDR IHSITAERLI FSHAVQMVQS AALDEMFQHR EGCVPRYHKA LLLLEGLQHM LSDQADIENV TKCKLCIERR LSALLTGICA // ID VGFR1_HUMAN Reviewed; 1338 AA. AC P17948; A3E342; A3E344; A8KA71; B0LPF1; B2BF46; B2BF47; B2BF48; B3FR89; AC B5A923; F5H5L6; O60722; P16057; Q12954; DT 01-NOV-1990, integrated into UniProtKB/Swiss-Prot. DT 03-APR-2007, sequence version 2. DT 28-JAN-2026, entry version 260. DE RecName: Full=Vascular endothelial growth factor receptor 1; DE Short=VEGFR-1; DE EC=2.7.10.1; DE AltName: Full=Fms-like tyrosine kinase 1; DE Short=FLT-1; DE AltName: Full=Tyrosine-protein kinase FRT; DE AltName: Full=Tyrosine-protein kinase receptor FLT; DE Short=FLT; DE AltName: Full=Vascular permeability factor receptor; DE Flags: Precursor; GN Name=FLT1; Synonyms=FLT, FRT, VEGFR1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Placenta; RX PubMed=2158038; RA Shibuya M., Yamaguchi S., Yamane A., Ikeda T., Tojo A., Matsushime H., RA Sato M.; RT "Nucleotide sequence and expression of a novel human receptor-type tyrosine RT kinase gene (flt) closely related to the fms family."; RL Oncogene 5:519-524(1990). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), PROTEIN SEQUENCE OF N-TERMINUS, RP SUBCELLULAR LOCATION (ISOFORM 2), INTERACTION WITH VEGFA, AND FUNCTION. RC TISSUE=Umbilical vein; RX PubMed=8248162; DOI=10.1073/pnas.90.22.10705; RA Kendall R.L., Thomas K.A.; RT "Inhibition of vascular endothelial cell growth factor activity by an RT endogenously encoded soluble receptor."; RL Proc. Natl. Acad. Sci. U.S.A. 90:10705-10709(1993). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH VEGFA, AND RP GLYCOSYLATION. RC TISSUE=Umbilical vein; RX PubMed=10471394; DOI=10.1006/bbrc.1999.1282; RA Herley M.T., Yu Y., Whitney R.G., Sato J.D.; RT "Characterization of the VEGF binding site on the Flt-1 receptor."; RL Biochem. Biophys. Res. Commun. 262:731-738(1999). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), FUNCTION IN LIGAND BINDING, AND RP SUBCELLULAR LOCATION. RX PubMed=18593464; DOI=10.1186/ar2447; RA Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D., RA Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.; RT "Novel splice variants derived from the receptor tyrosine kinase RT superfamily are potential therapeutics for rheumatoid arthritis."; RL Arthritis Res. Ther. 10:R73-R73(2008). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION, SUBCELLULAR LOCATION, RP TISSUE SPECIFICITY, ROLE IN PREECLAMPSIA, AND INDUCTION. RX PubMed=18515749; DOI=10.1161/circresaha.108.171504; RA Sela S., Itin A., Natanson-Yaron S., Greenfield C., Goldman-Wohl D., RA Yagel S., Keshet E.; RT "A novel human-specific soluble vascular endothelial growth factor receptor RT 1: cell-type-specific splicing and implications to vascular endothelial RT growth factor homeostasis and preeclampsia."; RL Circ. Res. 102:1566-1574(2008). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5; 6; 7 AND 8), ALTERNATIVE SPLICING, RP FUNCTION IN PHOSPHORYLATION OF SRC AND CANCER CELL INVASIVENESS, AND TISSUE RP SPECIFICITY. RX PubMed=20512933; DOI=10.1002/jcb.22584; RA Mezquita B., Mezquita J., Pau M., Mezquita C.; RT "A novel intracellular isoform of VEGFR-1 activates Src and promotes cell RT invasion in MDA-MB-231 breast cancer cells."; RL J. Cell. Biochem. 110:732-742(2010). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3). RA Mezquita J., Mezquita B., Pau M., Mezquita C.; RT "A new VEGFR1 receptor transcript coding for the extracellular domains of RT the protein followed by a C-terminal polyserine tail."; RL Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NHLBI resequencing and genotyping service (RS&G); RL Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3). RC TISSUE=Placenta, and Trachea; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057823; DOI=10.1038/nature02379; RA Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L., RA Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S., RA Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P., RA Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L., RA Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P., RA Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P., RA Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C., RA Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P., RA Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L., RA Frankish A.G., Frankland J., French L., Garner P., Garnett J., RA Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M., RA Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D., RA Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D., RA Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., RA Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S., RA Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S., RA Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R., RA Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W., RA Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P., RA Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L., RA Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R., RA Rogers J., Ross M.T.; RT "The DNA sequence and analysis of human chromosome 13."; RL Nature 428:522-528(2004). RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Ovary; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1018-1058, AND ALTERNATIVE SPLICING RP (ISOFORM 1). RX PubMed=3040650; RA Matsushime H., Yoshida M.C., Sasaki M., Shibuya M.; RT "A possible new member of tyrosine kinase family, human frt sequence, is RT highly conserved in vertebrates and located on human chromosome 13."; RL Jpn. J. Cancer Res. 78:655-661(1987). RN [14] RP PARTIAL PROTEIN SEQUENCE, CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-914; RP TYR-1213; TYR-1242; TYR-1327 AND TYR-1333, MUTAGENESIS OF TYR-914; RP TYR-1213; TYR-1242; TYR-1327 AND TYR-1333, AND INTERACTION WITH PLCG; GRB2; RP CRK; NCK1 AND PTPN11. RX PubMed=9722576; DOI=10.1074/jbc.273.36.23410; RA Ito N., Wernstedt C., Engstrom U., Claesson-Welsh L.; RT "Identification of vascular endothelial growth factor receptor-1 tyrosine RT phosphorylation sites and binding of SH2 domain-containing molecules."; RL J. Biol. Chem. 273:23410-23418(1998). RN [15] RP INTERACTION WITH VEGFA, AUTOPHOSPHORYLATION, CATALYTIC ACTIVITY, FUNCTION RP IN PHOSPHORYLATION OF PLCG, AND ABSENCE OF MITOGENIC FUNCTION IN CULTURED RP FIBROBLASTS. RX PubMed=7824266; RA Seetharam L., Gotoh N., Maru Y., Neufeld G., Yamaguchi S., Shibuya M.; RT "A unique signal transduction from FLT tyrosine kinase, a receptor for RT vascular endothelial growth factor VEGF."; RL Oncogene 10:135-147(1995). RN [16] RP FUNCTION IN CELL MIGRATION, FUNCTION IN VEGFA AND PGF SIGNALING, AND RP INDUCTION. RX PubMed=8605350; RA Barleon B., Sozzani S., Zhou D., Weich H.A., Mantovani A., Marme D.; RT "Migration of human monocytes in response to vascular endothelial growth RT factor (VEGF) is mediated via the VEGF receptor flt-1."; RL Blood 87:3336-3343(1996). RN [17] RP FUNCTION IN PHOSPHORYLATION OF PLCG AND ACTIVATION OF MAP KINASES, RP INTERACTION WITH PLCG, CATALYTIC ACTIVITY, MUTAGENESIS OF LYS-861 AND RP TYR-1169, AND PHOSPHORYLATION AT TYR-1169 AND TYR-1213. RX PubMed=9299537; DOI=10.1006/bbrc.1997.7327; RA Sawano A., Takahashi T., Yamaguchi S., Shibuya M.; RT "The phosphorylated 1169-tyrosine containing region of flt-1 kinase (VEGFR- RT 1) is a major binding site for PLCgamma."; RL Biochem. Biophys. Res. Commun. 238:487-491(1997). RN [18] RP INTERACTION WITH PIK3R1; PTPN11 AND NCK1, AND PHOSPHORYLATION AT TYR-1213. RX PubMed=9600074; DOI=10.1006/bbrc.1998.8578; RA Igarashi K., Isohara T., Kato T., Shigeta K., Yamano T., Uno I.; RT "Tyrosine 1213 of Flt-1 is a major binding site of Nck and SHP-2."; RL Biochem. Biophys. Res. Commun. 246:95-99(1998). RN [19] RP FUNCTION AS NEGATIVE REGULATOR OF KDR-MEDIATED CELL PROLIFERATION. RX PubMed=11141500; DOI=10.1016/s0002-9440(10)63965-x; RA Dunk C., Ahmed A.; RT "Vascular endothelial growth factor receptor-2-mediated mitogenesis is RT negatively regulated by vascular endothelial growth factor receptor-1 in RT tumor epithelial cells."; RL Am. J. Pathol. 158:265-273(2001). RN [20] RP INTERACTION WITH PIK3R1 AND VEGFA, AUTOPHOSPHORYLATION, PHOSPHORYLATION AT RP TYR-1213, SUBCELLULAR LOCATION, IDENTIFICATION BY MASS SPECTROMETRY, AND RP GLYCOSYLATION. RX PubMed=11513746; DOI=10.1042/0264-6021:3580465; RA Yu Y., Hulmes J.D., Herley M.T., Whitney R.G., Crabb J.W., Sato J.D.; RT "Direct identification of a major autophosphorylation site on vascular RT endothelial growth factor receptor Flt-1 that mediates phosphatidylinositol RT 3'-kinase binding."; RL Biochem. J. 358:465-472(2001). RN [21] RP FUNCTION IN PGF-MEDIATED CHORIOCARCINOMA CELL PROLIFERATION. RX PubMed=11811792; DOI=10.3109/08977190109001086; RA Angelucci C., Lama G., Iacopino F., Maglione D., Sica G.; RT "Effect of placenta growth factor-1 on proliferation and release of nitric RT oxide, cyclic AMP and cyclic GMP in human epithelial cells expressing the RT FLT-1 receptor."; RL Growth Factors 19:193-206(2001). RN [22] RP INTERACTION WITH KDR, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND FUNCTION RP IN VEGFA SIGNALING; PHOSPHORYLATION OF PLCG AND ACTIVATION OF RP PHOSPHATIDYLINOSITOL KINASE AND PHOSPHOLIPASE C. RX PubMed=11312102; DOI=10.1016/s1357-2725(01)00019-x; RA Huang K., Andersson C., Roomans G.M., Ito N., Claesson-Welsh L.; RT "Signaling properties of VEGF receptor-1 and -2 homo- and heterodimers."; RL Int. J. Biochem. Cell Biol. 33:315-324(2001). RN [23] RP FUNCTION IN SIGNALING VIA ACTIVATION OF THE PHOSPHATIDYLINOSITOL KINASE RP PATHWAY AND POSITIVE REGULATION OF ANGIOGENESIS IN RESPONSE TO PGF AND RP VEGFA. RX PubMed=14633857; DOI=10.2337/diabetes.52.12.2959; RA Cai J., Ahmad S., Jiang W.G., Huang J., Kontos C.D., Boulton M., Ahmed A.; RT "Activation of vascular endothelial growth factor receptor-1 sustains RT angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase RT pathway in endothelial cells."; RL Diabetes 52:2959-2968(2003). RN [24] RP INTERACTION WITH PGF AND KDR, FUNCTION IN PHOSPHORYLATION OF KDR; VEGFA AND RP PGF SIGNALING, CATALYTIC ACTIVITY, IDENTIFICATION BY MASS SPECTROMETRY, AND RP PHOSPHORYLATION AT TYR-1213; TYR-1327 AND TYR-1309. RX PubMed=12796773; DOI=10.1038/nm884; RA Autiero M., Waltenberger J., Communi D., Kranz A., Moons L., Lambrechts D., RA Kroll J., Plaisance S., De Mol M., Bono F., Kliche S., Fellbrich G., RA Ballmer-Hofer K., Maglione D., Mayr-Beyrle U., Dewerchin M., Dombrowski S., RA Stanimirovic D., Van Hummelen P., Dehio C., Hicklin D.J., Persico G., RA Herbert J.M., Communi D., Shibuya M., Collen D., Conway E.M., Carmeliet P.; RT "Role of PlGF in the intra- and intermolecular cross talk between the VEGF RT receptors Flt1 and Flk1."; RL Nat. Med. 9:936-943(2003). RN [25] RP INTERACTION WITH CBL AND CD2AP, UBIQUITINATION, AUTOPHOSPHORYLATION IN RP RESPONSE TO VEGFA, MUTAGENESIS OF TYR-1333, AND SUBCELLULAR LOCATION. RX PubMed=15001553; DOI=10.1096/fj.03-0767fje; RA Kobayashi S., Sawano A., Nojima Y., Shibuya M., Maru Y.; RT "The c-Cbl/CD2AP complex regulates VEGF-induced endocytosis and degradation RT of Flt-1 (VEGFR-1)."; RL FASEB J. 18:929-931(2004). RN [26] RP FUNCTION IN VEGFA AND VEGFB SIGNALING; CANCER CELL MIGRATION; INVASIVENESS RP AND ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1. RX PubMed=15735759; DOI=10.1038/sj.onc.1208246; RA Fan F., Wey J.S., McCarty M.F., Belcheva A., Liu W., Bauer T.W., RA Somcio R.J., Wu Y., Hooper A., Hicklin D.J., Ellis L.M.; RT "Expression and function of vascular endothelial growth factor receptor-1 RT on human colorectal cancer cells."; RL Oncogene 24:2647-2653(2005). RN [27] RP FUNCTION IN CELL MIGRATION AND PHOSPHORYLATION OF PTK2/FAK1; YES1 AND SRC. RX PubMed=16685275; DOI=10.1038/sj.bjc.6603143; RA Lesslie D.P., Summy J.M., Parikh N.U., Fan F., Trevino J.G., Sawyer T.K., RA Metcalf C.A., Shakespeare W.C., Hicklin D.J., Ellis L.M., Gallick G.E.; RT "Vascular endothelial growth factor receptor-1 mediates migration of human RT colorectal carcinoma cells by activation of Src family kinases."; RL Br. J. Cancer 94:1710-1717(2006). RN [28] RP MUTAGENESIS OF ASN-1050. RX PubMed=16286478; DOI=10.1074/jbc.m506454200; RA Meyer R.D., Mohammadi M., Rahimi N.; RT "A single amino acid substitution in the activation loop defines the decoy RT characteristic of VEGFR-1/FLT-1."; RL J. Biol. Chem. 281:867-875(2006). RN [29] RP FUNCTION IN PGF AND VEGFA SIGNALING; PHOSPHORYLATION OF AKT1; MAPK3/ERK1 RP AND MAP KINASES; CHEMOTAXIS AND ACTIVATION OF PHOSPHATIDYLINOSITOL RP 3-KINASE, AND AUTOPHOSPHORYLATION IN RESPONSE TO PGF AND VEGFA. RX PubMed=18079407; DOI=10.1161/atvbaha.107.158022; RA Tchaikovski V., Fellbrich G., Waltenberger J.; RT "The molecular basis of VEGFR-1 signal transduction pathways in primary RT human monocytes."; RL Arterioscler. Thromb. Vasc. Biol. 28:322-328(2008). RN [30] RP FUNCTION IN ENDOTHELIAL CELL SURVIVAL AND ANGIOGENESIS. RX PubMed=18583712; DOI=10.1161/circresaha.108.174128; RA Nishi J., Minamino T., Miyauchi H., Nojima A., Tateno K., Okada S., RA Orimo M., Moriya J., Fong G.H., Sunagawa K., Shibuya M., Komuro I.; RT "Vascular endothelial growth factor receptor-1 regulates postnatal RT angiogenesis through inhibition of the excessive activation of Akt."; RL Circ. Res. 103:261-268(2008). RN [31] RP FUNCTION IN CANCER CELL MIGRATION AND ACTIVATION OF MAPK1/ERK2 AND/OR RP MAPK3/ERK1. RX PubMed=20551949; DOI=10.1038/sj.bjc.6605746; RA Taylor A.P., Leon E., Goldenberg D.M.; RT "Placental growth factor (PlGF) enhances breast cancer cell motility by RT mobilising ERK1/2 phosphorylation and cytoskeletal rearrangement."; RL Br. J. Cancer 103:82-89(2010). RN [32] RP INTERACTION WITH RACK1. RX PubMed=21212275; DOI=10.1074/jbc.m110.165605; RA Wang F., Yamauchi M., Muramatsu M., Osawa T., Tsuchida R., Shibuya M.; RT "RACK1 regulates VEGF/Flt1-mediated cell migration via activation of a PI3- RT K/Akt pathway."; RL J. Biol. Chem. 286:9097-9106(2011). RN [33] RP INTERACTION WITH PSEN1 AND PTPRB, DEPHOSPHORYLATION BY PTPRB, MUTAGENESIS RP OF VAL-767, AND PROTEOLYTIC CLEAVAGE BY PSEN1 AT VAL-767. RX PubMed=22016384; DOI=10.1074/jbc.m111.296590; RA Cai J., Chen Z., Ruan Q., Han S., Liu L., Qi X., Boye S.L., Hauswirth W.W., RA Grant M.B., Boulton M.E.; RT "gamma-Secretase and presenilin mediate cleavage and phosphorylation of RT vascular endothelial growth factor receptor-1."; RL J. Biol. Chem. 286:42514-42523(2011). RN [34] RP FUNCTION AS DECOY RECEPTORS; REGULATION OF VEGFA SIGNALING AND REGULATION RP OF KDR ACTIVITY (ISOFORMS 2/3/4), AND ROLE IN PREECLAMPSIA. RX PubMed=21752276; DOI=10.1186/2045-824x-3-15; RA Ahmad S., Hewett P.W., Al-Ani B., Sissaoui S., Fujisawa T., Cudmore M.J., RA Ahmed A.; RT "Autocrine activity of soluble Flt-1 controls endothelial cell function and RT angiogenesis."; RL Vasc. Cell 3:15-15(2011). RN [35] RP REVIEW ON FUNCTION AS NEGATIVE REGULATOR OF ANGIOGENESIS DURING EMBRYONIC RP DEVELOPMENT; POSITIVE REGULATION OF MACROPHAGE FUNCTION IN ADULTHOOD; ROLE RP IN CARCINOGENESIS AND INFLAMMATION. RX PubMed=17002866; DOI=10.5483/bmbrep.2006.39.5.469; RA Shibuya M.; RT "Differential roles of vascular endothelial growth factor receptor-1 and RT receptor-2 in angiogenesis."; RL J. Biochem. Mol. Biol. 39:469-478(2006). RN [36] RP REVIEW ON STRUCTURE AND FUNCTION. RX PubMed=18680722; DOI=10.1016/j.bbrc.2008.07.121; RA Roskoski R. Jr.; RT "VEGF receptor protein-tyrosine kinases: structure and regulation."; RL Biochem. Biophys. Res. Commun. 375:287-291(2008). RN [37] RP REVIEW ON ROLE IN ANGIOGENESIS AND CANCER. RX PubMed=19230644; DOI=10.1016/j.ceb.2008.12.012; RA Lohela M., Bry M., Tammela T., Alitalo K.; RT "VEGFs and receptors involved in angiogenesis versus lymphangiogenesis."; RL Curr. Opin. Cell Biol. 21:154-165(2009). RN [38] RP REVIEW ON LIGAND SPECIFICITY; FUNCTION; STRUCTURE; PHOSPHORYLATION AND RP SIGNALING. RX PubMed=19761875; DOI=10.1016/j.bbapap.2009.09.002; RA Grunewald F.S., Prota A.E., Giese A., Ballmer-Hofer K.; RT "Structure-function analysis of VEGF receptor activation and the role of RT coreceptors in angiogenic signaling."; RL Biochim. Biophys. Acta 1804:567-580(2010). RN [39] RP REVIEW ON ROLE IN CANCER. RX PubMed=20127948; DOI=10.1002/cncr.24789; RA Schwartz J.D., Rowinsky E.K., Youssoufian H., Pytowski B., Wu Y.; RT "Vascular endothelial growth factor receptor-1 in human cancer: concise RT review and rationale for development of IMC-18F1 (Human antibody targeting RT vascular endothelial growth factor receptor-1)."; RL Cancer 116:1027-1032(2010). RN [40] RP REVIEW ON LIGAND SPECIFICITY; FUNCTION; STRUCTURE; PHOSPHORYLATION AND RP SIGNALING. RX PubMed=21711246; DOI=10.1042/bj20110301; RA Koch S., Tugues S., Li X., Gualandi L., Claesson-Welsh L.; RT "Signal transduction by vascular endothelial growth factor receptors."; RL Biochem. J. 437:169-183(2011). RN [41] RP REVIEW ON ROLE IN CANCER AND PREECLAMPSIA. RX PubMed=21558755; DOI=10.2183/pjab.87.167; RA Shibuya M.; RT "Involvement of Flt-1 (VEGF receptor-1) in cancer and preeclampsia."; RL Proc. Jpn. Acad., B, Phys. Biol. Sci. 87:167-178(2011). RN [42] RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 132-226 IN COMPLEX WITH VEGFA, AND RP DOMAIN. RX PubMed=9393862; DOI=10.1016/s0092-8674(00)80456-0; RA Wiesmann C., Fuh G., Christinger H.W., Eigenbrot C., Wells J.A., RA de Vos A.M.; RT "Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of RT the Flt-1 receptor."; RL Cell 91:695-704(1997). RN [43] RP STRUCTURE BY NMR OF 129-229, X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF RP 129-229 IN COMPLEX WITH VEGFA, SUBUNIT, AND INTERACTION WITH VEGFA. RX PubMed=10543948; DOI=10.1006/jmbi.1999.3134; RA Starovasnik M.A., Christinger H.W., Wiesmann C., Champe M.A., de Vos A.M., RA Skelton N.J.; RT "Solution structure of the VEGF-binding domain of Flt-1: comparison of its RT free and bound states."; RL J. Mol. Biol. 293:531-544(1999). RN [44] RP X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF 130-229 IN COMPLEX WITH PGF. RX PubMed=14684734; DOI=10.1074/jbc.m313237200; RA Christinger H.W., Fuh G., de Vos A.M., Wiesmann C.; RT "The crystal structure of placental growth factor in complex with domain 2 RT of vascular endothelial growth factor receptor-1."; RL J. Biol. Chem. 279:10382-10388(2004). RN [45] RP X-RAY CRYSTALLOGRAPHY (2.71 ANGSTROMS) OF 129-226 IN COMPLEX WITH VEGFB, RP INTERACTION WITH VEGFB, SUBUNIT, AND DOMAIN. RX PubMed=20501651; DOI=10.1074/jbc.m110.130658; RA Iyer S., Darley P.I., Acharya K.R.; RT "Structural insights into the binding of vascular endothelial growth RT factor-B by VEGFR-1(D2): recognition and specificity."; RL J. Biol. Chem. 285:23779-23789(2010). RN [46] RP VARIANTS [LARGE SCALE ANALYSIS] THR-60; LYS-144; GLN-281; ILE-422; GLN-781; RP VAL-938; ALA-982 AND VAL-1061. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor CC for VEGFA, VEGFB and PGF, and plays an essential role in the CC development of embryonic vasculature, the regulation of angiogenesis, CC cell survival, cell migration, macrophage function, chemotaxis, and CC cancer cell invasion. Acts as a positive regulator of postnatal retinal CC hyaloid vessel regression (By similarity). May play an essential role CC as a negative regulator of embryonic angiogenesis by inhibiting CC excessive proliferation of endothelial cells. Can promote endothelial CC cell proliferation, survival and angiogenesis in adulthood. Its CC function in promoting cell proliferation seems to be cell-type CC specific. Promotes PGF-mediated proliferation of endothelial cells, CC proliferation of some types of cancer cells, but does not promote CC proliferation of normal fibroblasts (in vitro). Has very high affinity CC for VEGFA and relatively low protein kinase activity; may function as a CC negative regulator of VEGFA signaling by limiting the amount of free CC VEGFA and preventing its binding to KDR. Modulates KDR signaling by CC forming heterodimers with KDR. Ligand binding leads to the activation CC of several signaling cascades. Activation of PLCG leads to the CC production of the cellular signaling molecules diacylglycerol and CC inositol 1,4,5-trisphosphate and the activation of protein kinase C. CC Mediates phosphorylation of PIK3R1, the regulatory subunit of CC phosphatidylinositol 3-kinase, leading to activation of CC phosphatidylinositol kinase and the downstream signaling pathway. CC Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase CC signaling pathway, as well as of the AKT1 signaling pathway. CC Phosphorylates SRC and YES1, and may also phosphorylate CBL. Promotes CC phosphorylation of AKT1 at 'Ser-473'. Promotes phosphorylation of CC PTK2/FAK1 (PubMed:16685275). {ECO:0000250|UniProtKB:P35969, CC ECO:0000269|PubMed:11141500, ECO:0000269|PubMed:11312102, CC ECO:0000269|PubMed:11811792, ECO:0000269|PubMed:12796773, CC ECO:0000269|PubMed:14633857, ECO:0000269|PubMed:15735759, CC ECO:0000269|PubMed:16685275, ECO:0000269|PubMed:18079407, CC ECO:0000269|PubMed:18515749, ECO:0000269|PubMed:18583712, CC ECO:0000269|PubMed:18593464, ECO:0000269|PubMed:20512933, CC ECO:0000269|PubMed:20551949, ECO:0000269|PubMed:21752276, CC ECO:0000269|PubMed:7824266, ECO:0000269|PubMed:8248162, CC ECO:0000269|PubMed:8605350, ECO:0000269|PubMed:9299537, CC ECO:0000269|Ref.11}. CC -!- FUNCTION: [Isoform 1]: Phosphorylates PLCG. CC {ECO:0000269|PubMed:9299537}. CC -!- FUNCTION: [Isoform 2]: May function as decoy receptor for VEGFA. CC {ECO:0000269|PubMed:21752276}. CC -!- FUNCTION: [Isoform 3]: May function as decoy receptor for VEGFA. CC {ECO:0000269|PubMed:21752276}. CC -!- FUNCTION: [Isoform 4]: May function as decoy receptor for VEGFA. CC {ECO:0000269|PubMed:21752276}. CC -!- FUNCTION: [Isoform 7]: Has a truncated kinase domain; it increases CC phosphorylation of SRC at 'Tyr-418' by unknown means and promotes tumor CC cell invasion. {ECO:0000269|PubMed:20512933}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:11312102, ECO:0000269|PubMed:12796773, CC ECO:0000269|PubMed:7824266, ECO:0000269|PubMed:9299537, CC ECO:0000269|PubMed:9722576}; CC -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence CC of bound ligand. Binding of VEGFA, VEGFB or PGF leads to dimerization CC and activation by autophosphorylation on tyrosine residues. CC -!- SUBUNIT: Interacts with VEGFA, VEGFB and PGF. Monomer in the absence of CC bound VEGFA, VEGFB or PGF. Homodimer in the presence of bound VEGFA, CC VEGFB and PGF. Can also form a heterodimer with KDR. Interacts (when CC tyrosine phosphorylated) with CBL, CRK, GRB2, NCK1, PIK3R1, PLCG, PSEN1 CC and PTPN11. Probably also interacts with PTPRB. Interacts with RACK1. CC Identified in a complex with CBL and CD2AP. CC {ECO:0000269|PubMed:10471394, ECO:0000269|PubMed:10543948, CC ECO:0000269|PubMed:11312102, ECO:0000269|PubMed:11513746, CC ECO:0000269|PubMed:12796773, ECO:0000269|PubMed:14684734, CC ECO:0000269|PubMed:15001553, ECO:0000269|PubMed:20501651, CC ECO:0000269|PubMed:21212275, ECO:0000269|PubMed:22016384, CC ECO:0000269|PubMed:7824266, ECO:0000269|PubMed:8248162, CC ECO:0000269|PubMed:9299537, ECO:0000269|PubMed:9393862, CC ECO:0000269|PubMed:9600074, ECO:0000269|PubMed:9722576}. CC -!- INTERACTION: CC P17948; P22681: CBL; NbExp=2; IntAct=EBI-1026718, EBI-518228; CC P17948; P46109: CRKL; NbExp=9; IntAct=EBI-1026718, EBI-910; CC P17948; P49763: PGF; NbExp=2; IntAct=EBI-1026718, EBI-1037633; CC P17948; P27986: PIK3R1; NbExp=3; IntAct=EBI-1026718, EBI-79464; CC P17948; Q12913: PTPRJ; NbExp=2; IntAct=EBI-1026718, EBI-2264500; CC P17948; P15692: VEGFA; NbExp=5; IntAct=EBI-1026718, EBI-1026643; CC P17948; P15692-4: VEGFA; NbExp=3; IntAct=EBI-1026718, EBI-1026691; CC P17948-2; PRO_0000391621 [P98160]: HSPG2; NbExp=2; IntAct=EBI-6530464, EBI-6896259; CC P17948-2; PRO_0000391622 [P98160]: HSPG2; NbExp=2; IntAct=EBI-6530464, EBI-6896607; CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane; Single-pass type I CC membrane protein. Endosome. Note=Autophosphorylation promotes CC ubiquitination and endocytosis. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted CC {ECO:0000269|PubMed:8248162}. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Secreted. CC -!- SUBCELLULAR LOCATION: [Isoform 4]: Secreted. CC -!- SUBCELLULAR LOCATION: [Isoform 5]: Cytoplasm {ECO:0000305}. CC -!- SUBCELLULAR LOCATION: [Isoform 6]: Cytoplasm {ECO:0000305}. CC -!- SUBCELLULAR LOCATION: [Isoform 7]: Cytoplasm {ECO:0000305}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=8; CC Comment=Additional isoforms seem to exist.; CC Name=1; Synonyms=Flt1; CC IsoId=P17948-1; Sequence=Displayed; CC Name=2; Synonyms=sFlt1; CC IsoId=P17948-2; Sequence=VSP_002955, VSP_002956; CC Name=3; Synonyms=sFlt1-14; CC IsoId=P17948-3; Sequence=VSP_041927, VSP_041928; CC Name=4; CC IsoId=P17948-4; Sequence=VSP_041929, VSP_041930; CC Name=5; Synonyms=i15; CC IsoId=P17948-5; Sequence=VSP_041985; CC Name=6; Synonyms=i18; CC IsoId=P17948-6; Sequence=VSP_041984; CC Name=7; Synonyms=i21; CC IsoId=P17948-7; Sequence=VSP_041983; CC Name=8; CC IsoId=P17948-8; Sequence=VSP_047759, VSP_047760; CC -!- TISSUE SPECIFICITY: Detected in normal lung, but also in placenta, CC liver, kidney, heart and brain tissues. Specifically expressed in most CC of the vascular endothelial cells, and also expressed in peripheral CC blood monocytes. Isoform 2 is strongly expressed in placenta. Isoform 3 CC is expressed in corneal epithelial cells (at protein level). Isoform 3 CC is expressed in vascular smooth muscle cells (VSMC). CC {ECO:0000269|PubMed:18515749, ECO:0000269|PubMed:20512933}. CC -!- INDUCTION: Up-regulated in coculture of VSMC/endothelial cell (EC) or CC by direct exposure to VEGF of VSMC monoculture. Up-regulated from the CC second trimester of pregnancy to the term and in the placenta of women CC with preeclampsia (PE). Up-regulated in monocytes exposed to bacterial CC lipopolysaccharide (LPS). {ECO:0000269|PubMed:18515749, CC ECO:0000269|PubMed:8605350}. CC -!- DOMAIN: The second and third Ig-like C2-type (immunoglobulin-like) CC domains are sufficient for VEGFA binding. {ECO:0000269|PubMed:20501651, CC ECO:0000269|PubMed:9393862}. CC -!- PTM: N-glycosylated. {ECO:0000269|PubMed:10471394, CC ECO:0000269|PubMed:11513746}. CC -!- PTM: Ubiquitinated after VEGFA-mediated autophosphorylation, leading to CC proteolytic degradation. {ECO:0000269|PubMed:15001553}. CC -!- PTM: Autophosphorylated on tyrosine residues upon ligand binding. CC Autophosphorylation occurs in trans, i.e. one subunit of the dimeric CC receptor phosphorylates tyrosine residues on the other subunit. CC Phosphorylation at Tyr-1169 is important for interaction with PLCG. CC Phosphorylation at Tyr-1213 is important for interaction with PIK3R1, CC PTPN11, GRB2, and PLCG. Phosphorylation at Tyr-1333 is important for CC endocytosis and for interaction with CBL, NCK1 and CRK. Is probably CC dephosphorylated by PTPRB. {ECO:0000269|PubMed:11513746, CC ECO:0000269|PubMed:12796773, ECO:0000269|PubMed:9299537, CC ECO:0000269|PubMed:9600074, ECO:0000269|PubMed:9722576}. CC -!- DISEASE: Note=Can contribute to cancer cell survival, proliferation, CC migration, and invasion, and tumor angiogenesis and metastasis. May CC contribute to cancer pathogenesis by promoting inflammatory responses CC and recruitment of tumor-infiltrating macrophages. CC -!- DISEASE: Note=Abnormally high expression of soluble isoforms (isoform CC 2, isoform 3 or isoform 4) may be a cause of preeclampsia. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. CSF-1/PDGF receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X51602; CAA35946.1; -; mRNA. DR EMBL; U01134; AAC50060.1; -; mRNA. DR EMBL; AF063657; AAC16449.2; -; mRNA. DR EMBL; EU826561; ACF47597.1; -; mRNA. DR EMBL; EU368830; ACA62948.1; -; mRNA. DR EMBL; DQ836394; ABI53803.1; -; mRNA. DR EMBL; DQ836395; ABI53804.1; -; mRNA. DR EMBL; DQ836396; ABI53805.1; -; mRNA. DR EMBL; EF491868; ABS32268.1; -; mRNA. DR EMBL; EF491869; ABS32269.1; -; mRNA. DR EMBL; EF491870; ABS32270.1; -; mRNA. DR EMBL; EU360600; ACB05747.1; -; mRNA. DR EMBL; EU332841; ABY87530.1; -; Genomic_DNA. DR EMBL; AK292936; BAF85625.1; -; mRNA. DR EMBL; AK300392; BAG62125.1; -; mRNA. DR EMBL; AL138712; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL139005; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471075; EAX08431.1; -; Genomic_DNA. DR EMBL; CH471075; EAX08432.1; -; Genomic_DNA. DR EMBL; BC039007; AAH39007.1; -; mRNA. DR EMBL; D00133; BAA00080.1; -; Genomic_DNA. DR CCDS; CCDS53860.1; -. [P17948-3] DR CCDS; CCDS53861.1; -. [P17948-4] DR CCDS; CCDS73556.1; -. [P17948-2] DR CCDS; CCDS9330.1; -. [P17948-1] DR PIR; A49636; A49636. DR PIR; S09982; S09982. DR RefSeq; NP_001153392.1; NM_001159920.2. [P17948-2] DR RefSeq; NP_001153502.1; NM_001160030.2. [P17948-3] DR RefSeq; NP_001153503.1; NM_001160031.1. [P17948-4] DR RefSeq; NP_002010.2; NM_002019.4. [P17948-1] DR PDB; 1FLT; X-ray; 1.70 A; X/Y=132-226. DR PDB; 1QSV; NMR; -; A=129-229. DR PDB; 1QSZ; NMR; -; A=129-229. DR PDB; 1QTY; X-ray; 2.70 A; T/U/X/Y=129-229. DR PDB; 1RV6; X-ray; 2.45 A; X/Y=130-229. DR PDB; 2XAC; X-ray; 2.71 A; C/X=129-226. DR PDB; 3HNG; X-ray; 2.70 A; A=801-1158. DR PDB; 4CKV; X-ray; 2.06 A; X=132-225. DR PDB; 4CL7; X-ray; 2.00 A; A/B/C/D=132-225. DR PDB; 5ABD; X-ray; 2.00 A; E/I/X=132-226. DR PDB; 5EX3; X-ray; 2.41 A; D=827-835. DR PDB; 5T89; X-ray; 4.00 A; X/Y=27-656. DR PDBsum; 1FLT; -. DR PDBsum; 1QSV; -. DR PDBsum; 1QSZ; -. DR PDBsum; 1QTY; -. DR PDBsum; 1RV6; -. DR PDBsum; 2XAC; -. DR PDBsum; 3HNG; -. DR PDBsum; 4CKV; -. DR PDBsum; 4CL7; -. DR PDBsum; 5ABD; -. DR PDBsum; 5EX3; -. DR PDBsum; 5T89; -. DR AlphaFoldDB; P17948; -. DR SMR; P17948; -. DR BioGRID; 108609; 197. DR CORUM; P17948; -. DR DIP; DIP-643N; -. DR FunCoup; P17948; 1409. DR IntAct; P17948; 184. DR MINT; P17948; -. DR STRING; 9606.ENSP00000282397; -. DR BindingDB; P17948; -. DR ChEMBL; CHEMBL1868; -. DR DrugBank; DB06626; Axitinib. DR DrugBank; DB05932; Denibulin. DR DrugBank; DB11741; Famitinib. DR DrugBank; DB10770; Foreskin fibroblast (neonatal). DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB11679; Fruquintinib. DR DrugBank; DB06101; IMC-1C11. DR DrugBank; DB07664; K-00546. DR DrugBank; DB09078; Lenvatinib. DR DrugBank; DB06080; Linifanib. DR DrugBank; DB11845; Lucitanib. DR DrugBank; DB07288; N-(4-chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide. DR DrugBank; DB09079; Nintedanib. DR DrugBank; DB05913; OSI-930. DR DrugBank; DB06589; Pazopanib. DR DrugBank; DB09221; Polaprezinc. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB15685; Selpercatinib. DR DrugBank; DB06436; Semaxanib. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB08009; SU-11652. DR DrugBank; DB01268; Sunitinib. DR DrugBank; DB15106; Surufatinib. DR DrugBank; DB05075; TG-100801. DR DrugBank; DB11800; Tivozanib. DR DrugBank; DB04879; Vatalanib. DR DrugCentral; P17948; -. DR GuidetoPHARMACOLOGY; 1812; -. DR GlyConnect; 771; 5 N-Linked glycans (6 sites). DR GlyCosmos; P17948; 13 sites, 8 glycans. DR GlyGen; P17948; 14 sites, 63 N-linked glycans (9 sites), 1 O-linked glycan (1 site). DR iPTMnet; P17948; -. DR PhosphoSitePlus; P17948; -. DR BioMuta; FLT1; -. DR DMDM; 143811474; -. DR CPTAC; CPTAC-2819; -. DR CPTAC; CPTAC-3174; -. DR jPOST; P17948; -. DR MassIVE; P17948; -. DR PaxDb; 9606-ENSP00000282397; -. DR PeptideAtlas; P17948; -. DR ProteomicsDB; 3403; -. DR ProteomicsDB; 53530; -. [P17948-1] DR ProteomicsDB; 53531; -. [P17948-2] DR ProteomicsDB; 53532; -. [P17948-3] DR ProteomicsDB; 53533; -. [P17948-4] DR ProteomicsDB; 53534; -. [P17948-5] DR ProteomicsDB; 53535; -. [P17948-6] DR ProteomicsDB; 53536; -. [P17948-7] DR ABCD; P17948; 59 sequenced antibodies. DR Antibodypedia; 1563; 1691 antibodies from 51 providers. DR DNASU; 2321; -. DR Ensembl; ENST00000282397.9; ENSP00000282397.4; ENSG00000102755.14. [P17948-1] DR Ensembl; ENST00000539099.2; ENSP00000442630.1; ENSG00000102755.14. [P17948-4] DR Ensembl; ENST00000541932.5; ENSP00000437631.1; ENSG00000102755.14. [P17948-3] DR Ensembl; ENST00000615840.5; ENSP00000484039.1; ENSG00000102755.14. [P17948-2] DR GeneID; 2321; -. DR KEGG; hsa:2321; -. DR MANE-Select; ENST00000282397.9; ENSP00000282397.4; NM_002019.4; NP_002010.2. DR UCSC; uc001usb.4; human. [P17948-1] DR AGR; HGNC:3763; -. DR ClinPGx; PA28180; -. DR CTD; 2321; -. DR DisGeNET; 2321; -. DR GeneCards; FLT1; -. DR HGNC; HGNC:3763; FLT1. DR HPA; ENSG00000102755; Tissue enriched (placenta). DR MalaCards; FLT1; -. DR MIM; 165070; gene. DR OpenTargets; ENSG00000102755; -. DR Orphanet; 275555; Preeclampsia. DR VEuPathDB; HostDB:ENSG00000102755; -. DR eggNOG; KOG0200; Eukaryota. DR GeneTree; ENSGT00940000158713; -. DR HOGENOM; CLU_000288_49_4_1; -. DR InParanoid; P17948; -. DR OMA; SCGHIRP; -. DR OrthoDB; 10059496at2759; -. DR PAN-GO; P17948; 9 GO annotations based on evolutionary models. DR PhylomeDB; P17948; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P17948; -. DR Reactome; R-HSA-194306; Neurophilin interactions with VEGF and VEGFR. DR Reactome; R-HSA-195399; VEGF binds to VEGFR leading to receptor dimerization. DR SignaLink; P17948; -. DR SIGNOR; P17948; -. DR Agora; ENSG00000102755; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 2321; 10 hits in 1192 CRISPR screens. DR ChiTaRS; FLT1; human. DR EvolutionaryTrace; P17948; -. DR GeneWiki; FLT1; -. DR GenomeRNAi; 2321; -. DR Pharos; P17948; Tclin. DR PRO; PR:P17948; -. DR Proteomes; UP000005640; Chromosome 13. DR RNAct; P17948; protein. DR Bgee; ENSG00000102755; Expressed in pericardium and 202 other cell types or tissues. DR ExpressionAtlas; P17948; baseline and differential. DR GO; GO:0015629; C:actin cytoskeleton; IDA:HPA. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell. DR GO; GO:0005615; C:extracellular space; TAS:ProtInc. DR GO; GO:0005925; C:focal adhesion; HDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0019838; F:growth factor binding; IPI:UniProtKB. DR GO; GO:0036332; F:placental growth factor receptor activity; IDA:UniProtKB. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; TAS:ProtInc. DR GO; GO:0005021; F:vascular endothelial growth factor receptor activity; IDA:UniProtKB. DR GO; GO:0048514; P:blood vessel morphogenesis; ISS:UniProtKB. DR GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW. DR GO; GO:0016477; P:cell migration; IMP:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; TAS:ProtInc. DR GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IDA:UniProtKB. DR GO; GO:0048598; P:embryonic morphogenesis; ISS:UniProtKB. DR GO; GO:1990384; P:hyaloid vascular plexus regression; ISS:UniProtKB. DR GO; GO:0002548; P:monocyte chemotaxis; IDA:UniProtKB. DR GO; GO:1905563; P:negative regulation of vascular endothelial cell proliferation; IGI:BHF-UCL. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IBA:GO_Central. DR GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0002040; P:sprouting angiogenesis; IBA:GO_Central. DR GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0036323; P:vascular endothelial growth factor receptor-1 signaling pathway; IDA:UniProtKB. DR CDD; cd00096; Ig; 2. DR CDD; cd05862; IgI_VEGFR; 1. DR CDD; cd07702; IgI_VEGFR-1; 1. DR CDD; cd14207; PTKc_VEGFR1; 1. DR FunFam; 2.60.40.10:FF:000606; Vascular endothelial growth factor receptor 1; 1. DR FunFam; 2.60.40.10:FF:001031; Vascular endothelial growth factor receptor 1; 1. DR FunFam; 2.60.40.10:FF:001347; Vascular endothelial growth factor receptor 1; 1. DR FunFam; 2.60.40.10:FF:000934; vascular endothelial growth factor receptor 1; 1. DR FunFam; 2.60.40.10:FF:001014; vascular endothelial growth factor receptor 1; 1. DR FunFam; 2.60.40.10:FF:001245; vascular endothelial growth factor receptor 1; 1. DR FunFam; 1.10.510.10:FF:000077; Vascular endothelial growth factor receptor 2; 1. DR FunFam; 3.30.200.20:FF:000041; Vascular endothelial growth factor receptor 2; 1. DR FunFam; 2.60.40.10:FF:000143; Vascular endothelial growth factor receptor 3; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 7. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR013106; Ig_V-set. DR InterPro; IPR013151; Immunoglobulin_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR001824; Tyr_kinase_rcpt_3_CS. DR InterPro; IPR041348; VEGFR-2_TMD. DR InterPro; IPR055229; VEGFR1-3_5th. DR InterPro; IPR055238; VEGFR1-3_N_Ig-like. DR InterPro; IPR009135; VEGFR1_rcpt. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR PANTHER; PTHR24416:SF390; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1; 1. DR Pfam; PF07679; I-set; 2. DR Pfam; PF00047; ig; 1. DR Pfam; PF13927; Ig_3; 1. DR Pfam; PF22971; Ig_VEGFR-1-like_5th; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF21339; VEGFR-1-like_Ig-like; 1. DR Pfam; PF17988; VEGFR-2_TMD; 1. DR Pfam; PF22854; VEGFR1-3_N_Ig-like; 1. DR PIRSF; PIRSF000615; TyrPK_CSF1-R; 1. DR PRINTS; PR01832; VEGFRECEPTOR. DR PRINTS; PR01833; VEGFRECEPTR1. DR SMART; SM00409; IG; 7. DR SMART; SM00408; IGc2; 5. DR SMART; SM00406; IGv; 2. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF48726; Immunoglobulin; 7. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 6. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Angiogenesis; ATP-binding; KW Cell membrane; Chemotaxis; Cytoplasm; Developmental protein; KW Differentiation; Direct protein sequencing; Disulfide bond; Endosome; KW Glycoprotein; Immunoglobulin domain; Kinase; Membrane; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome; KW Repeat; Secreted; Signal; Transferase; Transmembrane; Transmembrane helix; KW Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..26 FT /evidence="ECO:0000269|PubMed:8248162" FT CHAIN 27..1338 FT /note="Vascular endothelial growth factor receptor 1" FT /id="PRO_0000016768" FT TOPO_DOM 27..758 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 759..780 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 781..1338 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 32..123 FT /note="Ig-like C2-type 1" FT DOMAIN 151..214 FT /note="Ig-like C2-type 2" FT DOMAIN 230..327 FT /note="Ig-like C2-type 3" FT DOMAIN 335..421 FT /note="Ig-like C2-type 4" FT DOMAIN 428..553 FT /note="Ig-like C2-type 5" FT DOMAIN 556..654 FT /note="Ig-like C2-type 6" FT DOMAIN 661..747 FT /note="Ig-like C2-type 7" FT DOMAIN 827..1158 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 940..982 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 940..957 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 959..971 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 1022 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 833..841 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 861 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 767..768 FT /note="Cleavage; by PSEN1" FT /evidence="ECO:0000305" FT MOD_RES 914 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:9722576" FT MOD_RES 1053 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 1169 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:9299537" FT MOD_RES 1213 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11513746, FT ECO:0000269|PubMed:12796773, ECO:0000269|PubMed:9299537, FT ECO:0000269|PubMed:9600074, ECO:0000269|PubMed:9722576" FT MOD_RES 1242 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:9722576" FT MOD_RES 1309 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12796773" FT MOD_RES 1327 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12796773, FT ECO:0000269|PubMed:9722576" FT MOD_RES 1333 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:9722576" FT CARBOHYD 100 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 164 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 196 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 251 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 323 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 402 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 417 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 474 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 547 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 597 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 620 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 625 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 666 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 53..107 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 158..207 FT DISULFID 252..311 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 454..535 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 577..636 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 682..731 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 1..995 FT /note="Missing (in isoform 7)" FT /evidence="ECO:0000303|PubMed:20512933" FT /id="VSP_041983" FT VAR_SEQ 1..875 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|PubMed:20512933" FT /id="VSP_041984" FT VAR_SEQ 1..782 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:20512933" FT /id="VSP_041985" FT VAR_SEQ 1..7 FT /note="MVSYWDT -> MNSDLLV (in isoform 8)" FT /evidence="ECO:0000303|PubMed:20512933" FT /id="VSP_047759" FT VAR_SEQ 8..984 FT /note="Missing (in isoform 8)" FT /evidence="ECO:0000303|PubMed:20512933" FT /id="VSP_047760" FT VAR_SEQ 518..541 FT /note="MASTLVVADSRISGIYICIASNKV -> LPPANSSFMLPPTSFSSNYFHFLP FT (in isoform 4)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_041929" FT VAR_SEQ 542..1338 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_041930" FT VAR_SEQ 657..687 FT /note="DQEAPYLLRNLSDHTVAISSSTTLDCHANGV -> GEHCNKKAVFSRISKFK FT STRNDCTTQSNVKH (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8248162" FT /id="VSP_002955" FT VAR_SEQ 688..1338 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8248162" FT /id="VSP_002956" FT VAR_SEQ 706..733 FT /note="GIILGPGSSTLFIERVTEEDEGVYHCKA -> ELYTSTSPSSSSSSPLSSSS FT SSSSSSSS (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:18515749, ECO:0000303|Ref.7" FT /id="VSP_041927" FT VAR_SEQ 734..1338 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:18515749, ECO:0000303|Ref.7" FT /id="VSP_041928" FT VARIANT 60 FT /note="K -> T (in dbSNP:rs56409818)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042045" FT VARIANT 128 FT /note="I -> L (in dbSNP:rs35073261)" FT /id="VAR_049719" FT VARIANT 144 FT /note="E -> K (in dbSNP:rs55974987)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042046" FT VARIANT 281 FT /note="R -> Q (in dbSNP:rs55687105)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042047" FT VARIANT 422 FT /note="L -> I (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs2137539590)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042048" FT VARIANT 781 FT /note="R -> Q (in a glioma low grade oligodendroglioma FT sample; somatic mutation; dbSNP:rs553261958)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042049" FT VARIANT 938 FT /note="M -> V (in dbSNP:rs35549791)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042050" FT VARIANT 982 FT /note="E -> A (in dbSNP:rs35832528)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042051" FT VARIANT 1061 FT /note="L -> V (in a bladder transitional cell carcinoma FT sample; somatic mutation; dbSNP:rs2138826873)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042052" FT MUTAGEN 767 FT /note="V->A: Abolishes proteolytic cleavage by PSEN1." FT /evidence="ECO:0000269|PubMed:22016384" FT MUTAGEN 861 FT /note="K->M: Abolishes enzyme activity. Abolishes FT interaction with PLCG." FT /evidence="ECO:0000269|PubMed:9299537" FT MUTAGEN 914 FT /note="Y->F: Reduces phosphorylation at other tyrosine FT residues." FT /evidence="ECO:0000269|PubMed:9722576" FT MUTAGEN 1050 FT /note="N->D: Strongly increases kinase activity. Increases FT activity in promoting proliferation of endothelial cells." FT /evidence="ECO:0000269|PubMed:16286478" FT MUTAGEN 1169 FT /note="Y->F: Loss of phosphorylation site. Abolishes FT interaction with PLCG." FT /evidence="ECO:0000269|PubMed:9299537" FT MUTAGEN 1213 FT /note="Y->F: Loss of phosphorylation site. Abolishes FT interaction with PIK3R1." FT /evidence="ECO:0000269|PubMed:9722576" FT MUTAGEN 1242 FT /note="Y->F: Loss of phosphorylation site." FT /evidence="ECO:0000269|PubMed:9722576" FT MUTAGEN 1327 FT /note="Y->F: Loss of phosphorylation site." FT /evidence="ECO:0000269|PubMed:9722576" FT MUTAGEN 1333 FT /note="Y->F: Loss of phosphorylation site. Abolishes FT interaction with CBL." FT /evidence="ECO:0000269|PubMed:15001553, FT ECO:0000269|PubMed:9722576" FT CONFLICT 490 FT /note="F -> S (in Ref. 3; AAC16449)" FT /evidence="ECO:0000305" FT CONFLICT 779 FT /note="F -> L (in Ref. 1; CAA35946)" FT /evidence="ECO:0000305" FT CONFLICT 1029 FT /note="L -> F (in Ref. 6; ABI53803/ABI53804)" FT /evidence="ECO:0000305" FT TURN 130..132 FT /evidence="ECO:0007829|PDB:1QSV" FT STRAND 135..137 FT /evidence="ECO:0007829|PDB:1FLT" FT STRAND 140..142 FT /evidence="ECO:0007829|PDB:4CL7" FT STRAND 144..148 FT /evidence="ECO:0007829|PDB:1FLT" FT STRAND 150..152 FT /evidence="ECO:0007829|PDB:1QSZ" FT STRAND 154..156 FT /evidence="ECO:0007829|PDB:1FLT" FT STRAND 160..162 FT /evidence="ECO:0007829|PDB:5ABD" FT HELIX 163..165 FT /evidence="ECO:0007829|PDB:1QSV" FT STRAND 168..171 FT /evidence="ECO:0007829|PDB:1FLT" FT TURN 172..174 FT /evidence="ECO:0007829|PDB:1FLT" FT STRAND 175..177 FT /evidence="ECO:0007829|PDB:1FLT" FT STRAND 181..187 FT /evidence="ECO:0007829|PDB:1FLT" FT TURN 188..190 FT /evidence="ECO:0007829|PDB:1FLT" FT STRAND 191..196 FT /evidence="ECO:0007829|PDB:1FLT" FT HELIX 199..201 FT /evidence="ECO:0007829|PDB:1FLT" FT STRAND 203..211 FT /evidence="ECO:0007829|PDB:1FLT" FT STRAND 214..224 FT /evidence="ECO:0007829|PDB:1FLT" FT HELIX 806..809 FT /evidence="ECO:0007829|PDB:3HNG" FT HELIX 817..820 FT /evidence="ECO:0007829|PDB:3HNG" FT HELIX 824..826 FT /evidence="ECO:0007829|PDB:3HNG" FT STRAND 827..835 FT /evidence="ECO:0007829|PDB:3HNG" FT STRAND 837..848 FT /evidence="ECO:0007829|PDB:3HNG" FT HELIX 849..851 FT /evidence="ECO:0007829|PDB:3HNG" FT STRAND 854..863 FT /evidence="ECO:0007829|PDB:3HNG" FT HELIX 869..883 FT /evidence="ECO:0007829|PDB:3HNG" FT STRAND 894..898 FT /evidence="ECO:0007829|PDB:3HNG" FT STRAND 906..910 FT /evidence="ECO:0007829|PDB:3HNG" FT HELIX 917..922 FT /evidence="ECO:0007829|PDB:3HNG" FT HELIX 996..1014 FT /evidence="ECO:0007829|PDB:3HNG" FT TURN 1015..1017 FT /evidence="ECO:0007829|PDB:3HNG" FT HELIX 1025..1027 FT /evidence="ECO:0007829|PDB:3HNG" FT STRAND 1028..1030 FT /evidence="ECO:0007829|PDB:3HNG" FT HELIX 1032..1034 FT /evidence="ECO:0007829|PDB:3HNG" FT STRAND 1036..1038 FT /evidence="ECO:0007829|PDB:3HNG" FT HELIX 1042..1044 FT /evidence="ECO:0007829|PDB:3HNG" FT TURN 1047..1049 FT /evidence="ECO:0007829|PDB:3HNG" FT STRAND 1053..1055 FT /evidence="ECO:0007829|PDB:3HNG" FT HELIX 1063..1065 FT /evidence="ECO:0007829|PDB:3HNG" FT HELIX 1068..1073 FT /evidence="ECO:0007829|PDB:3HNG" FT HELIX 1078..1093 FT /evidence="ECO:0007829|PDB:3HNG" FT HELIX 1107..1113 FT /evidence="ECO:0007829|PDB:3HNG" FT TURN 1114..1116 FT /evidence="ECO:0007829|PDB:3HNG" FT HELIX 1127..1136 FT /evidence="ECO:0007829|PDB:3HNG" FT HELIX 1141..1143 FT /evidence="ECO:0007829|PDB:3HNG" FT HELIX 1147..1157 FT /evidence="ECO:0007829|PDB:3HNG" SQ SEQUENCE 1338 AA; 150769 MW; FF3381EEFAF0787C CRC64; MVSYWDTGVL LCALLSCLLL TGSSSGSKLK DPELSLKGTQ HIMQAGQTLH LQCRGEAAHK WSLPEMVSKE SERLSITKSA CGRNGKQFCS TLTLNTAQAN HTGFYSCKYL AVPTSKKKET ESAIYIFISD TGRPFVEMYS EIPEIIHMTE GRELVIPCRV TSPNITVTLK KFPLDTLIPD GKRIIWDSRK GFIISNATYK EIGLLTCEAT VNGHLYKTNY LTHRQTNTII DVQISTPRPV KLLRGHTLVL NCTATTPLNT RVQMTWSYPD EKNKRASVRR RIDQSNSHAN IFYSVLTIDK MQNKDKGLYT CRVRSGPSFK SVNTSVHIYD KAFITVKHRK QQVLETVAGK RSYRLSMKVK AFPSPEVVWL KDGLPATEKS ARYLTRGYSL IIKDVTEEDA GNYTILLSIK QSNVFKNLTA TLIVNVKPQI YEKAVSSFPD PALYPLGSRQ ILTCTAYGIP QPTIKWFWHP CNHNHSEARC DFCSNNEESF ILDADSNMGN RIESITQRMA IIEGKNKMAS TLVVADSRIS GIYICIASNK VGTVGRNISF YITDVPNGFH VNLEKMPTEG EDLKLSCTVN KFLYRDVTWI LLRTVNNRTM HYSISKQKMA ITKEHSITLN LTIMNVSLQD SGTYACRARN VYTGEEILQK KEITIRDQEA PYLLRNLSDH TVAISSSTTL DCHANGVPEP QITWFKNNHK IQQEPGIILG PGSSTLFIER VTEEDEGVYH CKATNQKGSV ESSAYLTVQG TSDKSNLELI TLTCTCVAAT LFWLLLTLFI RKMKRSSSEI KTDYLSIIMD PDEVPLDEQC ERLPYDASKW EFARERLKLG KSLGRGAFGK VVQASAFGIK KSPTCRTVAV KMLKEGATAS EYKALMTELK ILTHIGHHLN VVNLLGACTK QGGPLMVIVE YCKYGNLSNY LKSKRDLFFL NKDAALHMEP KKEKMEPGLE QGKKPRLDSV TSSESFASSG FQEDKSLSDV EEEEDSDGFY KEPITMEDLI SYSFQVARGM EFLSSRKCIH RDLAARNILL SENNVVKICD FGLARDIYKN PDYVRKGDTR LPLKWMAPES IFDKIYSTKS DVWSYGVLLW EIFSLGGSPY PGVQMDEDFC SRLREGMRMR APEYSTPEIY QIMLDCWHRD PKERPRFAEL VEKLGDLLQA NVQQDGKDYI PINAILTGNS GFTYSTPAFS EDFFKESISA PKFNSGSSDD VRYVNAFKFM SLERIKTFEE LLPNATSMFD DYQGDSSTLL ASPMLKRFTW TDSKPKASLK IDLRVTSKSK ESGLSDVSRP SFCHSSCGHV SEGKRRFTYD HAELERKIAC CSPPPDYNSV VLYSTPPI // ID VGFR2_HUMAN Reviewed; 1356 AA. AC P35968; A2RRS0; B5A925; C5IFA0; O60723; Q14178; DT 01-JUN-1994, integrated into UniProtKB/Swiss-Prot. DT 01-DEC-2000, sequence version 2. DT 28-JAN-2026, entry version 251. DE RecName: Full=Vascular endothelial growth factor receptor 2 {ECO:0000305}; DE Short=VEGFR-2; DE EC=2.7.10.1 {ECO:0000269|PubMed:10037737, ECO:0000269|PubMed:10102632}; DE AltName: Full=Fetal liver kinase 1; DE Short=FLK-1; DE AltName: Full=Kinase insert domain receptor; DE Short=KDR; DE AltName: Full=Protein-tyrosine kinase receptor flk-1; DE AltName: CD_antigen=CD309; DE Flags: Precursor; GN Name=KDR {ECO:0000312|HGNC:HGNC:6307}; Synonyms=FLK1, VEGFR2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), INTERACTION WITH VEGFC, AND RP SUBCELLULAR LOCATION. RX PubMed=18593464; DOI=10.1186/ar2447; RA Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D., RA Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.; RT "Novel splice variants derived from the receptor tyrosine kinase RT superfamily are potential therapeutics for rheumatoid arthritis."; RL Arthritis Res. Ther. 10:R73-R73(2008). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION IN INHIBITION OF RP LYMPHANGIOGENESIS, INTERACTION WITH VEGFC, AND TISSUE SPECIFICITY. RX PubMed=19668192; DOI=10.1038/nm.2018; RA Albuquerque R.J., Hayashi T., Cho W.G., Kleinman M.E., Dridi S., Takeda A., RA Baffi J.Z., Yamada K., Kaneko H., Green M.G., Chappell J., Wilting J., RA Weich H.A., Yamagami S., Amano S., Mizuki N., Alexander J.S., RA Peterson M.L., Brekken R.A., Hirashima M., Capoor S., Usui T., Ambati B.K., RA Ambati J.; RT "Alternatively spliced vascular endothelial growth factor receptor-2 is an RT essential endogenous inhibitor of lymphatic vessel growth."; RL Nat. Med. 15:1023-1030(2009). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Yin L.Y., Wu Y., Patterson C.; RT "Full length human KDR/flk-1 sequence."; RL Submitted (DEC-1997) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Umbilical vein; RA Yu Y., Whitney R.G., Sato J.D.; RT "Coding region for human VEGF receptor KDR (VEGFR-2)."; RL Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT HIS-472. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 3-1356 (ISOFORM 1), AND VARIANT GLU-848. RC TISSUE=Umbilical vein; RX PubMed=1656371; RA Terman B.I., Carrion M.E., Kovacs E., Rasmussen B.A., Eddy R.L., RA Shows T.B.; RT "Identification of a new endothelial cell growth factor receptor tyrosine RT kinase."; RL Oncogene 6:1677-1683(1991). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-22. RX PubMed=7559454; DOI=10.1074/jbc.270.39.23111; RA Patterson C., Perrella M.A., Hsieh C.-M., Yoshizumi M., Lee M.-E., RA Harber E.; RT "Cloning and functional analysis of the promoter for KDR/flk-1, a receptor RT for vascular endothelial growth factor."; RL J. Biol. Chem. 270:23111-23118(1995). RN [9] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH VEGFA. RX PubMed=1417831; DOI=10.1016/0006-291x(92)90483-2; RA Terman B.I., Dougher-Vermazen M., Carrion M.E., Dimitrov D., RA Armellino D.C., Gospodarowicz D., Boehlen P.; RT "Identification of the KDR tyrosine kinase as a receptor for vascular RT endothelial cell growth factor."; RL Biochem. Biophys. Res. Commun. 187:1579-1586(1992). RN [10] RP FUNCTION AS VEGFA RECEPTOR; IN REGULATION OF CELL SHAPE; ACTIN CYTOSKELETON RP REORGANIZATION; CELL MIGRATION AND CELL PROLIFERATION, AND RP AUTOPHOSPHORYLATION. RX PubMed=7929439; DOI=10.1016/s0021-9258(18)47116-5; RA Waltenberger J., Claesson-Welsh L., Siegbahn A., Shibuya M., Heldin C.H.; RT "Different signal transduction properties of KDR and Flt1, two receptors RT for vascular endothelial growth factor."; RL J. Biol. Chem. 269:26988-26995(1994). RN [11] RP FUNCTION IN VEGFA SIGNALING; PHOSPHORYLATION OF PLCG1; ACTIVATION OF MAP RP KINASES AND IN PROMOTING PROLIFERATION OF ENDOTHELIAL CELLS, INTERACTION RP WITH VEGFA AND PLCG1, AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND RP GLYCOSYLATION. RX PubMed=9160888; DOI=10.1038/sj.onc.1201047; RA Takahashi T., Shibuya M.; RT "The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC- RT gamma pathway and partially induces mitotic signals in NIH3T3 RT fibroblasts."; RL Oncogene 14:2079-2089(1997). RN [12] RP FUNCTION IN INDUCTION OF NOS2 AND NOS3. RX PubMed=9837777; DOI=10.1006/bbrc.1998.9719; RA Kroll J., Waltenberger J.; RT "VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF RT receptor-2 (KDR)."; RL Biochem. Biophys. Res. Commun. 252:743-746(1998). RN [13] RP FUNCTION IN ACTIVATION OF THE PHOSPHATIDYLINOSITOL 3-KINASE AND AKT1 RP SIGNALING PATHWAY. RX PubMed=9804796; DOI=10.1074/jbc.273.46.30336; RA Gerber H.P., McMurtrey A., Kowalski J., Yan M., Keyt B.A., Dixit V., RA Ferrara N.; RT "Vascular endothelial growth factor regulates endothelial cell survival RT through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. RT Requirement for Flk-1/KDR activation."; RL J. Biol. Chem. 273:30336-30343(1998). RN [14] RP FUNCTION IN NITRIC OXIDE RELEASE. RX PubMed=10600473; DOI=10.1006/bbrc.1999.1729; RA Kroll J., Waltenberger J.; RT "A novel function of VEGF receptor-2 (KDR): rapid release of nitric oxide RT in response to VEGF-A stimulation in endothelial cells."; RL Biochem. Biophys. Res. Commun. 265:636-639(1999). RN [15] RP CATALYTIC ACTIVITY, CHARACTERIZATION OF VARIANT GLU-848, PHOSPHORYLATION AT RP TYR-1054 AND TYR-1059, AND ACTIVITY REGULATION. RX PubMed=10037737; DOI=10.1074/jbc.274.10.6453; RA Kendall R.L., Rutledge R.Z., Mao X., Tebben A.J., Hungate R.W., RA Thomas K.A.; RT "Vascular endothelial growth factor receptor KDR tyrosine kinase activity RT is increased by autophosphorylation of two activation loop tyrosine RT residues."; RL J. Biol. Chem. 274:6453-6460(1999). RN [16] RP FUNCTION IN PHOSPHORYLATION OF PLCG1 AND PTK2/FAK1, INTERACTION WITH VEGFA, RP CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-996; TYR-1054 AND TYR-1059, RP MUTAGENESIS OF TYR-996; TYR-1054 AND TYR-1059, SUBCELLULAR LOCATION, AND RP ACTIVITY REGULATION. RX PubMed=10102632; DOI=10.1038/sj.onc.1202478; RA Dougher M., Terman B.I.; RT "Autophosphorylation of KDR in the kinase domain is required for maximal RT VEGF-stimulated kinase activity and receptor internalization."; RL Oncogene 18:1619-1627(1999). RN [17] RP INTERACTION WITH HIV-1 TAT (MICROBIAL INFECTION). RX PubMed=10590123; DOI=10.1128/jvi.74.1.344-353.2000; RA Mitola S., Soldi R., Zanon I., Barra L., Gutierrez M.I., Berkhout B., RA Giacca M., Bussolino F.; RT "Identification of specific molecular structures of human immunodeficiency RT virus type 1 Tat relevant for its biological effects on vascular RT endothelial cells."; RL J. Virol. 74:344-353(2000). RN [18] RP FUNCTION IN ENDOTHELIAL CELL PROLIFERATION; PHOSPHORYLATION OF PLCG1 AND RP ACTIVATION OF MAP KINASES, PHOSPHORYLATION AT TYR-1175 AND TYR-1214, AND RP MUTAGENESIS OF LYS-868 AND TYR-1175. RX PubMed=11387210; DOI=10.1093/emboj/20.11.2768; RA Takahashi T., Yamaguchi S., Chida K., Shibuya M.; RT "A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A- RT dependent activation of PLC-gamma and DNA synthesis in vascular endothelial RT cells."; RL EMBO J. 20:2768-2778(2001). RN [19] RP UBIQUITINATION, FUNCTION IN NITRIC OXIDE PRODUCTION, SUBCELLULAR LOCATION, RP AND INTERACTION WITH CBL. RX PubMed=12649282; DOI=10.1074/jbc.m301410200; RA Duval M., Bedard-Goulet S., Delisle C., Gratton J.P.; RT "Vascular endothelial growth factor-dependent down-regulation of Flk-1/KDR RT involves Cbl-mediated ubiquitination. Consequences on nitric oxide RT production from endothelial cells."; RL J. Biol. Chem. 278:20091-20097(2003). RN [20] RP INTERACTION WITH FLT4. RX PubMed=12881528; DOI=10.1074/jbc.m304499200; RA Dixelius J., Makinen T., Wirzenius M., Karkkainen M.J., Wernstedt C., RA Alitalo K., Claesson-Welsh L.; RT "Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) RT heterodimerization with VEGFR-2 in primary lymphatic endothelial cells RT regulates tyrosine phosphorylation sites."; RL J. Biol. Chem. 278:40973-40979(2003). RN [21] RP INTERACTION WITH SHB, AND FUNCTION IN CELL MIGRATION. RX PubMed=15026417; DOI=10.1074/jbc.m312729200; RA Holmqvist K., Cross M.J., Rolny C., Haegerkvist R., Rahimi N., RA Matsumoto T., Claesson-Welsh L., Welsh M.; RT "The adaptor protein shb binds to tyrosine 1175 in vascular endothelial RT growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular RT migration."; RL J. Biol. Chem. 279:22267-22275(2004). RN [22] RP SUBCELLULAR LOCATION, AND PHOSPHORYLATION. RX PubMed=14991896; DOI=10.1002/path.1520; RA Fox S.B., Turley H., Cheale M., Blazquez C., Roberts H., James N., Cook N., RA Harris A., Gatter K.; RT "Phosphorylated KDR is expressed in the neoplastic and stromal elements of RT human renal tumours and shuttles from cell membrane to nucleus."; RL J. Pathol. 202:313-320(2004). RN [23] RP INTERACTION WITH VEGFA AND VEGFD, PHOSPHORYLATION AT TYR-1054 AND TYR-1059, RP FUNCTION IN VEGFA AND VEGFD SIGNALING; ACTIVATION OF MAPK1/ERK2 AND RP MAPK3/ERK1; ACTIVATION OF AKT1; PHOSPHORYLATION OF PLCG1 AND NOS3; RP MODULATION OF INTRACELLULAR CA(2+) LEVELS; CELL SURVIVAL AND POSITIVE RP REGULATION OF CELL PROLIFERATION; CELL MIGRATION AND ANGIOGENESIS, AND RP ACTIVITY REGULATION. RX PubMed=15215251; DOI=10.1074/jbc.m401538200; RA Jia H., Bagherzadeh A., Bicknell R., Duchen M.R., Liu D., Zachary I.; RT "Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially RT regulate KDR-mediated signaling and biological function in vascular RT endothelial cells."; RL J. Biol. Chem. 279:36148-36157(2004). RN [24] RP FUNCTION IN CELL MIGRATION; PHOSPHORYLATION OF PLCG1; ACTIVATION OF RP MAPK1/ERK2; MAPK3/ERK1 AND THE MAP KINASES AND IN REGULATION OF ACTIN RP CYTOSKELETON REORGANIZATION, INTERACTION WITH SH2D2A/TSAD, PHOSPHORYLATION RP AT TYR-951; TYR-1054; TYR-1059; TYR-1214; TYR-1305; TYR-1309 AND TYR-1319, RP AND MUTAGENESIS OF TYR-951. RX PubMed=15962004; DOI=10.1038/sj.emboj.7600709; RA Matsumoto T., Bohman S., Dixelius J., Berge T., Dimberg A., Magnusson P., RA Wang L., Wikner C., Qi J.H., Wernstedt C., Wu J., Bruheim S., Mugishima H., RA Mukhopadhyay D., Spurkland A., Claesson-Welsh L.; RT "VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in RT tumor angiogenesis."; RL EMBO J. 24:2342-2353(2005). RN [25] RP FUNCTION IN ENDOTHELIAL CELL MIGRATION; ACTIVATION OF MAP KINASES AND IN RP PHOSPHORYLATION OF FYN; SRC AND NCK1, INTERACTION WITH GRB2; FYN AND NCK1, RP AND MUTAGENESIS OF TYR-1214. RX PubMed=16966330; DOI=10.1074/jbc.m603928200; RA Lamalice L., Houle F., Huot J.; RT "Phosphorylation of Tyr1214 within VEGFR-2 triggers the recruitment of Nck RT and activation of Fyn leading to SAPK2/p38 activation and endothelial cell RT migration in response to VEGF."; RL J. Biol. Chem. 281:34009-34020(2006). RN [26] RP SUBCELLULAR LOCATION, UBIQUITINATION, AND DEGRADATION. RX PubMed=17004325; DOI=10.1111/j.1600-0854.2006.00462.x; RA Ewan L.C., Jopling H.M., Jia H., Mittar S., Bagherzadeh A., Howell G.J., RA Walker J.H., Zachary I.C., Ponnambalam S.; RT "Intrinsic tyrosine kinase activity is required for vascular endothelial RT growth factor receptor 2 ubiquitination, sorting and degradation in RT endothelial cells."; RL Traffic 7:1270-1282(2006). RN [27] RP FUNCTION IN ACTIVATION OF AKT1; PHOSPHORYLATION OF PLCG1 AND NOS3 AND RP REGULATION OF NITRIC OXIDE PRODUCTION, PHOSPHORYLATION AT TYR-801, AND RP MUTAGENESIS OF TYR-801. RX PubMed=17303569; DOI=10.1074/jbc.m609048200; RA Blanes M.G., Oubaha M., Rautureau Y., Gratton J.P.; RT "Phosphorylation of tyrosine 801 of vascular endothelial growth factor RT receptor-2 is necessary for Akt-dependent endothelial nitric-oxide synthase RT activation and nitric oxide release from endothelial cells."; RL J. Biol. Chem. 282:10660-10669(2007). RN [28] RP INTERACTION WITH DAB2IP. RX PubMed=19033661; DOI=10.1172/jci36168; RA Zhang H., He Y., Dai S., Xu Z., Luo Y., Wan T., Luo D., Jones D., Tang S., RA Chen H., Sessa W.C., Min W.; RT "AIP1 functions as an endogenous inhibitor of VEGFR2-mediated signaling and RT inflammatory angiogenesis in mice."; RL J. Clin. Invest. 118:3904-3916(2008). RN [29] RP PHOSPHORYLATION AT TYR-951; TYR-1175 AND TYR-1214, AND DEPHOSPHORYLATION BY RP PTPRB. RX PubMed=19136612; DOI=10.1096/fj.08-123810; RA Mellberg S., Dimberg A., Bahram F., Hayashi M., Rennel E., Ameur A., RA Westholm J.O., Larsson E., Lindahl P., Cross M.J., Claesson-Welsh L.; RT "Transcriptional profiling reveals a critical role for tyrosine phosphatase RT VE-PTP in regulation of VEGFR2 activity and endothelial cell RT morphogenesis."; RL FASEB J. 23:1490-1502(2009). RN [30] RP PHOSPHORYLATION AT TYR-801; TYR-951; TYR-996; TYR-1054; TYR-1059; TYR-1175 RP AND TYR-1214; DEPHOSPHORYLATION AT TYR-951; TYR-996; TYR-1054; TYR-1059; RP TYR-1175 AND TYR-1214 BY PTPRJ. RX PubMed=18936167; DOI=10.1128/mcb.01374-08; RA Chabot C., Spring K., Gratton J.P., Elchebly M., Royal I.; RT "New role for the protein tyrosine phosphatase DEP-1 in Akt activation and RT endothelial cell survival."; RL Mol. Cell. Biol. 29:241-253(2009). RN [31] RP FUNCTION AS VEGFA RECEPTOR IN TUMOR ANGIOGENESIS, SUBCELLULAR LOCATION, AND RP UBIQUITINATION. RX PubMed=19834490; DOI=10.1038/cdd.2009.152; RA Zhang Z., Neiva K.G., Lingen M.W., Ellis L.M., Nor J.E.; RT "VEGF-dependent tumor angiogenesis requires inverse and reciprocal RT regulation of VEGFR1 and VEGFR2."; RL Cell Death Differ. 17:499-512(2010). RN [32] RP FUNCTION IN LYMPHANGIOGENESIS (ISOFORM 2). RX PubMed=20179233; DOI=10.1158/1078-0432.ccr-09-1936; RA Becker J., Pavlakovic H., Ludewig F., Wilting F., Weich H.A., RA Albuquerque R., Ambati J., Wilting J.; RT "Neuroblastoma progression correlates with downregulation of the RT lymphangiogenesis inhibitor sVEGFR-2."; RL Clin. Cancer Res. 16:1431-1441(2010). RN [33] RP INTERACTION WITH VEGFC AND FLT4, SUBCELLULAR LOCATION, AND FUNCTION IN RP ANGIOGENESIS. RX PubMed=20224550; DOI=10.1038/emboj.2010.30; RA Nilsson I., Bahram F., Li X., Gualandi L., Koch S., Jarvius M., RA Soderberg O., Anisimov A., Kholova I., Pytowski B., Baldwin M., RA Yla-Herttuala S., Alitalo K., Kreuger J., Claesson-Welsh L.; RT "VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on RT angiogenic sprouts."; RL EMBO J. 29:1377-1388(2010). RN [34] RP SUBCELLULAR LOCATION. RX PubMed=21539813; DOI=10.1016/j.bbrc.2011.04.093; RA Jopling H.M., Howell G.J., Gamper N., Ponnambalam S.; RT "The VEGFR2 receptor tyrosine kinase undergoes constitutive endosome-to- RT plasma membrane recycling."; RL Biochem. Biophys. Res. Commun. 410:170-176(2011). RN [35] RP FUNCTION IN LYMPHANGIOGENESIS, AND INTERACTION WITH FLT4 AND VEGFC. RX PubMed=20705758; DOI=10.1182/blood-2010-02-267427; RA Nakao S., Zandi S., Hata Y., Kawahara S., Arita R., Schering A., Sun D., RA Melhorn M.I., Ito Y., Lara-Castillo N., Ishibashi T., Hafezi-Moghadam A.; RT "Blood vessel endothelial VEGFR-2 delays lymphangiogenesis: an endogenous RT trapping mechanism links lymph- and angiogenesis."; RL Blood 117:1081-1090(2011). RN [36] RP REVIEW ON ROLE IN ANGIOGENESIS. RX PubMed=17002866; DOI=10.5483/bmbrep.2006.39.5.469; RA Shibuya M.; RT "Differential roles of vascular endothelial growth factor receptor-1 and RT receptor-2 in angiogenesis."; RL J. Biochem. Mol. Biol. 39:469-478(2006). RN [37] RP REVIEW. RX PubMed=17658244; DOI=10.1016/j.cellsig.2007.05.013; RA Holmes K., Roberts O.L., Thomas A.M., Cross M.J.; RT "Vascular endothelial growth factor receptor-2: structure, function, RT intracellular signalling and therapeutic inhibition."; RL Cell. Signal. 19:2003-2012(2007). RN [38] RP REVIEW ON STRUCTURE AND FUNCTION. RX PubMed=18680722; DOI=10.1016/j.bbrc.2008.07.121; RA Roskoski R. Jr.; RT "VEGF receptor protein-tyrosine kinases: structure and regulation."; RL Biochem. Biophys. Res. Commun. 375:287-291(2008). RN [39] RP REVIEW ON ROLE IN ANGIOGENESIS AND CANCER. RX PubMed=19230644; DOI=10.1016/j.ceb.2008.12.012; RA Lohela M., Bry M., Tammela T., Alitalo K.; RT "VEGFs and receptors involved in angiogenesis versus lymphangiogenesis."; RL Curr. Opin. Cell Biol. 21:154-165(2009). RN [40] RP REVIEW ON LIGAND SPECIFICITY; FUNCTION; STRUCTURE; PHOSPHORYLATION AND RP SIGNALING. RX PubMed=19761875; DOI=10.1016/j.bbapap.2009.09.002; RA Grunewald F.S., Prota A.E., Giese A., Ballmer-Hofer K.; RT "Structure-function analysis of VEGF receptor activation and the role of RT coreceptors in angiogenic signaling."; RL Biochim. Biophys. Acta 1804:567-580(2010). RN [41] RP REVIEW ON ROLE IN ANGIOGENESIS AND CANCER. RX PubMed=20462514; DOI=10.1016/j.bbcan.2010.04.004; RA Guo S., Colbert L.S., Fuller M., Zhang Y., Gonzalez-Perez R.R.; RT "Vascular endothelial growth factor receptor-2 in breast cancer."; RL Biochim. Biophys. Acta 1806:108-121(2010). RN [42] RP REVIEW ON ROLE IN ANGIOGENESIS AND CANCER. RX PubMed=21779435; DOI=10.1177/1947601910392987; RA Shibuya M.; RT "Tyrosine kinase receptor Flt/VEGFR family: its characterization related to RT angiogenesis and cancer."; RL Genes Cancer 1:1119-1123(2010). RN [43] RP REVIEW ON LIGAND SPECIFICITY; FUNCTION; STRUCTURE; PHOSPHORYLATION AND RP SIGNALING. RX PubMed=21711246; DOI=10.1042/bj20110301; RA Koch S., Tugues S., Li X., Gualandi L., Claesson-Welsh L.; RT "Signal transduction by vascular endothelial growth factor receptors."; RL Biochem. J. 437:169-183(2011). RN [44] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-982 AND SER-984, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [45] RP FUNCTION, AND INTERACTION WITH PDCD6. RX PubMed=21893193; DOI=10.1016/j.cellsig.2011.08.013; RA Rho S.B., Song Y.J., Lim M.C., Lee S.H., Kim B.R., Park S.Y.; RT "Programmed cell death 6 (PDCD6) inhibits angiogenesis through RT PI3K/mTOR/p70S6K pathway by interacting of VEGFR-2."; RL Cell. Signal. 24:131-139(2012). RN [46] RP ACTIVITY REGULATION, REDOX-ACTIVE DISULFIDE BOND, AND MUTAGENESIS OF RP CYS-1045. RX PubMed=23199280; DOI=10.1089/ars.2012.4565; RA Tao B.B., Liu S.Y., Zhang C.C., Fu W., Cai W.J., Wang Y., Shen Q., RA Wang M.J., Chen Y., Zhang L.J., Zhu Y.Z., Zhu Y.C.; RT "VEGFR2 functions as an H(2)S-targeting receptor protein kinase with its RT novel Cys1045-Cys1024 disulfide bond serving as a specific molecular switch RT for hydrogen sulfide actions in vascular endothelial cells."; RL Antioxid. Redox Signal. 19:448-464(2013). RN [47] RP INTERACTION WITH ERN1, AND SUBCELLULAR LOCATION. RX PubMed=23529610; DOI=10.1161/circulationaha.112.001337; RA Zeng L., Xiao Q., Chen M., Margariti A., Martin D., Ivetic A., Xu H., RA Mason J., Wang W., Cockerill G., Mori K., Li J.Y., Chien S., Hu Y., Xu Q.; RT "Vascular endothelial cell growth-activated XBP1 splicing in endothelial RT cells is crucial for angiogenesis."; RL Circulation 127:1712-1722(2013). RN [48] RP INTERACTION WITH PDCL3. RX PubMed=23792958; DOI=10.1074/jbc.m113.473173; RA Srinivasan S., Meyer R.D., Lugo R., Rahimi N.; RT "Identification of PDCL3 as a novel chaperone protein involved in the RT generation of functional VEGF receptor 2."; RL J. Biol. Chem. 288:23171-23181(2013). RN [49] RP INTERACTION WITH CCDC88A. RX PubMed=25187647; DOI=10.1091/mbc.e14-05-0978; RA Lin C., Ear J., Midde K., Lopez-Sanchez I., Aznar N., Garcia-Marcos M., RA Kufareva I., Abagyan R., Ghosh P.; RT "Structural basis for activation of trimeric Gi proteins by multiple growth RT factor receptors via GIV/Girdin."; RL Mol. Biol. Cell 25:3654-3671(2014). RN [50] RP INTERACTION WITH PDCL3. RX PubMed=26059764; DOI=10.1007/s10456-015-9468-3; RA Srinivasan S., Chitalia V., Meyer R.D., Hartsough E., Mehta M., Harrold I., RA Anderson N., Feng H., Smith L.E., Jiang Y., Costello C.E., Rahimi N.; RT "Hypoxia-induced expression of phosducin-like 3 regulates expression of RT VEGFR-2 and promotes angiogenesis."; RL Angiogenesis 18:449-462(2015). RN [51] RP FUNCTION, INTERACTION WITH BSG, SUBCELLULAR LOCATION, SUBUNIT, AND RP PHOSPHORYLATION. RX PubMed=25825981; DOI=10.18632/oncotarget.2870; RA Khayati F., Perez-Cano L., Maouche K., Sadoux A., Boutalbi Z., RA Podgorniak M.P., Maskos U., Setterblad N., Janin A., Calvo F., Lebbe C., RA Menashi S., Fernandez-Recio J., Mourah S.; RT "EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by RT VEGF."; RL Oncotarget 6:9766-9780(2015). RN [52] RP INTERACTION WITH SLC31A1, AND DISULFIDE BOND. RX PubMed=35027734; DOI=10.1038/s41556-021-00822-7; RA Das A., Ash D., Fouda A.Y., Sudhahar V., Kim Y.M., Hou Y., Hudson F.Z., RA Stansfield B.K., Caldwell R.B., McMenamin M., Littlejohn R., Su H., RA Regan M.R., Merrill B.J., Poole L.B., Kaplan J.H., Fukai T., RA Ushio-Fukai M.; RT "Cysteine oxidation of copper transporter CTR1 drives VEGFR2 signalling and RT angiogenesis."; RL Nat. Cell Biol. 24:35-50(2022). RN [53] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 806-1171, FUNCTION, RP PHOSPHORYLATION AT TYR-1059, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=10368301; DOI=10.1016/s0969-2126(99)80042-2; RA McTigue M.A., Wickersham J.A., Pinko C., Showalter R.E., Parast C.V., RA Tempczyk-Russell A., Gehring M.R., Mroczkowski B., Kan C.-C., RA Villafranca J.E., Appelt K.; RT "Crystal structure of the kinase domain of human vascular endothelial RT growth factor receptor 2: a key enzyme in angiogenesis."; RL Structure 7:319-330(1999). RN [54] RP X-RAY CRYSTALLOGRAPHY (1.71 ANGSTROMS) OF 806-1171 IN COMPLEX WITH RP SYNTHETIC INHIBITOR. RX PubMed=15837294; DOI=10.1016/j.bmcl.2005.03.034; RA Miyazaki Y., Matsunaga S., Tang J., Maeda Y., Nakano M., Philippe R.J., RA Shibahara M., Liu W., Sato H., Wang L., Nolte R.T.; RT "Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual RT inhibitors."; RL Bioorg. Med. Chem. Lett. 15:2203-2207(2005). RN [55] RP X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 815-1171 IN COMPLEX WITH RP SYNTHETIC INHIBITOR. RX PubMed=17253678; DOI=10.1021/jm061107l; RA Hodous B.L., Geuns-Meyer S.D., Hughes P.E., Albrecht B.K., Bellon S., RA Bready J., Caenepeel S., Cee V.J., Chaffee S.C., Coxon A., Emery M., RA Fretland J., Gallant P., Gu Y., Hoffman D., Johnson R.E., Kendall R., RA Kim J.L., Long A.M., Morrison M., Olivieri P.R., Patel V.F., Polverino A., RA Rose P., Tempest P., Wang L., Whittington D.A., Zhao H.; RT "Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine RT Tie-2 kinase inhibitor."; RL J. Med. Chem. 50:611-626(2007). RN [56] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 806-1171 IN COMPLEX WITH SYNTHETIC RP INHIBITOR, AND FUNCTION. RX PubMed=18529047; DOI=10.1021/jm8001185; RA Peifer C., Selig R., Kinkel K., Ott D., Totzke F., Schaechtele C., RA Heidenreich R., Roecken M., Schollmeyer D., Laufer S.; RT "Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole- RT 3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor RT receptor (VEGF-R) inhibitors."; RL J. Med. Chem. 51:3814-3824(2008). RN [57] RP X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 657-764, SUBUNIT, RP AUTOPHOSPHORYLATION, FUNCTION IN VEGFA SIGNALING AND ACTIVATION OF RP MAPK1/ERK2 AND MAPK3/ERK1, AND MUTAGENESIS OF ARG-726 AND ASP-731. RX PubMed=20080685; DOI=10.1073/pnas.0914052107; RA Yang Y., Xie P., Opatowsky Y., Schlessinger J.; RT "Direct contacts between extracellular membrane-proximal domains are RT required for VEGF receptor activation and cell signaling."; RL Proc. Natl. Acad. Sci. U.S.A. 107:1906-1911(2010). RN [58] RP X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 120-326 IN COMPLEX WITH VEGFC, RP INTERACTION WITH VEGFC, DOMAIN, DISULFIDE BONDS, AND GLYCOSYLATION AT RP ASN-143; ASN-245 AND ASN-318. RX PubMed=20145116; DOI=10.1073/pnas.0914318107; RA Leppanen V.M., Prota A.E., Jeltsch M., Anisimov A., Kalkkinen N., RA Strandin T., Lankinen H., Goldman A., Ballmer-Hofer K., Alitalo K.; RT "Structural determinants of growth factor binding and specificity by VEGF RT receptor 2."; RL Proc. Natl. Acad. Sci. U.S.A. 107:2425-2430(2010). RN [59] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 220-338 IN COMPLEX WITH ANTIBODY RP FRAGMENT, DISULFIDE BOND, AND GLYCOSYLATION AT ASN-245 AND ASN-318. RX PubMed=21827946; DOI=10.1016/j.str.2011.01.019; RA Franklin M.C., Navarro E.C., Wang Y., Patel S., Singh P., Zhang Y., RA Persaud K., Bari A., Griffith H., Shen L., Balderes P., Kussie P.; RT "The structural basis for the function of two anti-VEGF receptor 2 RT antibodies."; RL Structure 19:1097-1107(2011). RN [60] RP VARIANT HCI SER-1147. RX PubMed=11807987; DOI=10.1002/gcc.10028; RA Walter J.W., North P.E., Waner M., Mizeracki A., Blei F., Walker J.W.T., RA Reinisch J.F., Marchuk D.A.; RT "Somatic mutation of vascular endothelial growth factor receptors in RT juvenile hemangioma."; RL Genes Chromosomes Cancer 33:295-303(2002). RN [61] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-275 AND ARG-873. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [62] RP VARIANTS [LARGE SCALE ANALYSIS] ARG-2; MET-136; GLY-248; ILE-297; VAL-462; RP HIS-472; ARG-482; ARG-539; MET-689; ASN-814 AND THR-1065. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [63] RP VARIANT ARG-482, AND INVOLVEMENT IN HCI. RX PubMed=18931684; DOI=10.1038/nm.1877; RA Jinnin M., Medici D., Park L., Limaye N., Liu Y., Boscolo E., Bischoff J., RA Vikkula M., Boye E., Olsen B.R.; RT "Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 RT signaling in infantile hemangioma."; RL Nat. Med. 14:1236-1246(2008). CC -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor CC for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation CC of angiogenesis, vascular development, vascular permeability, and CC embryonic hematopoiesis. Promotes proliferation, survival, migration CC and differentiation of endothelial cells. Promotes reorganization of CC the actin cytoskeleton. Isoforms lacking a transmembrane domain, such CC as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, CC VEGFC and/or VEGFD. Isoform 2 plays an important role as negative CC regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting CC the amount of free VEGFA and/or VEGFC and preventing their binding to CC FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. CC Binding of vascular growth factors to isoform 1 leads to the activation CC of several signaling cascades. Activation of PLCG1 leads to the CC production of the cellular signaling molecules diacylglycerol and CC inositol 1,4,5-trisphosphate and the activation of protein kinase C. CC Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase CC signaling pathway, as well as of the AKT1 signaling pathway. Mediates CC phosphorylation of PIK3R1, the regulatory subunit of CC phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton CC and activation of PTK2/FAK1. Required for VEGFA-mediated induction of CC NOS2 and NOS3, leading to the production of the signaling molecule CC nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes CC phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC. CC {ECO:0000269|PubMed:10102632, ECO:0000269|PubMed:10368301, CC ECO:0000269|PubMed:10600473, ECO:0000269|PubMed:11387210, CC ECO:0000269|PubMed:12649282, ECO:0000269|PubMed:1417831, CC ECO:0000269|PubMed:15026417, ECO:0000269|PubMed:15215251, CC ECO:0000269|PubMed:15962004, ECO:0000269|PubMed:16966330, CC ECO:0000269|PubMed:17303569, ECO:0000269|PubMed:18529047, CC ECO:0000269|PubMed:19668192, ECO:0000269|PubMed:19834490, CC ECO:0000269|PubMed:20080685, ECO:0000269|PubMed:20224550, CC ECO:0000269|PubMed:20705758, ECO:0000269|PubMed:21893193, CC ECO:0000269|PubMed:25825981, ECO:0000269|PubMed:7929439, CC ECO:0000269|PubMed:9160888, ECO:0000269|PubMed:9804796, CC ECO:0000269|PubMed:9837777}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:10037737, ECO:0000269|PubMed:10102632}; CC -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence CC of bound ligand. Binding of VEGFA, VEGFC or VEGFD leads to dimerization CC and activation by autophosphorylation on tyrosine residues. Inhibited CC by the small molecule PTK inhibitor SU5614 ((3Z)-5-Chloro-3-[(3,5- CC dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-2H-indol-2-one). May be CC regulated by hydrogen sulfide (H(2)S) levels via a H(2)S-sensitive CC intracellular disulfide bond. {ECO:0000269|PubMed:10037737, CC ECO:0000269|PubMed:10102632, ECO:0000269|PubMed:15215251, CC ECO:0000269|PubMed:23199280}. CC -!- SUBUNIT: Homodimer in the presence of bound dimeric VEGFA, VEGFC or CC VEGFD ligands; monomeric in the absence of bound ligands. Can also form CC heterodimers with FLT1/VEGFR1 and KDR/VEGFR2. Interacts (tyrosine CC phosphorylated) with LFYN, NCK1, PLCG1. Interacts (tyrosine- CC phosphorylated active form preferentially) with DAB2IP (via C2 domain CC and active form preferentially); the interaction occurs at the late CC phase of VEGFA response and inhibits KDR/VEGFR2 activity. Interacts CC with SHBSH2D2A/TSAD, GRB2, MYOF, CBL and PDCD6. Interacts (via C- CC terminus domain) with ERN1 (via kinase domain); the interaction is CC facilitated in a XBP1 isoform 1- and vascular endothelial growth factor CC (VEGF)-dependent manner in endothelial cells (PubMed:23529610). CC Interacts (via juxtamembrane region) with chaperone PDCL3 (via CC thioredoxin fold region); the interaction leads to increased KDR/VEGFR2 CC abundance through inhibition of its ubiquitination and degradation CC (PubMed:23792958, PubMed:26059764). Interacts (tyrosine phosphorylated) CC with CCDC88A/GIV (via SH2-like region); binding requires CC autophosphorylation of the KDR/VEGFR2 C-terminal region CC (PubMed:25187647). Interacts with isoform 2 of BSG (PubMed:25825981). CC Interacts with SLC31A1; this interaction is induced upon VEGFA CC stimulation leading to SLC31A1 and KDR subsequent co-internalization to CC early endosomes, thereby activating KDR downstream signaling in CC endothelial cells (PubMed:35027734). {ECO:0000269|PubMed:10102632, CC ECO:0000269|PubMed:12649282, ECO:0000269|PubMed:12881528, CC ECO:0000269|PubMed:1417831, ECO:0000269|PubMed:15026417, CC ECO:0000269|PubMed:15215251, ECO:0000269|PubMed:15837294, CC ECO:0000269|PubMed:15962004, ECO:0000269|PubMed:16966330, CC ECO:0000269|PubMed:17253678, ECO:0000269|PubMed:18529047, CC ECO:0000269|PubMed:18593464, ECO:0000269|PubMed:19033661, CC ECO:0000269|PubMed:19668192, ECO:0000269|PubMed:20080685, CC ECO:0000269|PubMed:20145116, ECO:0000269|PubMed:20224550, CC ECO:0000269|PubMed:20705758, ECO:0000269|PubMed:21827946, CC ECO:0000269|PubMed:21893193, ECO:0000269|PubMed:23529610, CC ECO:0000269|PubMed:23792958, ECO:0000269|PubMed:25187647, CC ECO:0000269|PubMed:25825981, ECO:0000269|PubMed:26059764, CC ECO:0000269|PubMed:35027734, ECO:0000269|PubMed:9160888}. CC -!- SUBUNIT: (Microbial infection) Interacts with HIV-1 Tat. CC {ECO:0000269|PubMed:10590123}. CC -!- INTERACTION: CC P35968; P33151: CDH5; NbExp=2; IntAct=EBI-1005487, EBI-2903122; CC P35968; P35916: FLT4; NbExp=5; IntAct=EBI-1005487, EBI-1005467; CC P35968; O60565: GREM1; NbExp=4; IntAct=EBI-1005487, EBI-944395; CC P35968; P98160: HSPG2; NbExp=5; IntAct=EBI-1005487, EBI-947664; CC P35968; PRO_0000391621 [P98160]: HSPG2; NbExp=2; IntAct=EBI-1005487, EBI-6896259; CC P35968; PRO_0000391622 [P98160]: HSPG2; NbExp=2; IntAct=EBI-1005487, EBI-6896607; CC P35968; P17301: ITGA2; NbExp=2; IntAct=EBI-1005487, EBI-702960; CC P35968; P35968: KDR; NbExp=4; IntAct=EBI-1005487, EBI-1005487; CC P35968; P09382: LGALS1; NbExp=3; IntAct=EBI-1005487, EBI-1048875; CC P35968; P08581: MET; NbExp=3; IntAct=EBI-1005487, EBI-1039152; CC P35968; P16333: NCK1; NbExp=3; IntAct=EBI-1005487, EBI-389883; CC P35968; O14786: NRP1; NbExp=3; IntAct=EBI-1005487, EBI-1187100; CC P35968; O75340: PDCD6; NbExp=4; IntAct=EBI-1005487, EBI-352915; CC P35968; P09619: PDGFRB; NbExp=2; IntAct=EBI-1005487, EBI-641237; CC P35968; P29350: PTPN6; NbExp=2; IntAct=EBI-1005487, EBI-78260; CC P35968; Q12913: PTPRJ; NbExp=4; IntAct=EBI-1005487, EBI-2264500; CC P35968; P29353: SHC1; NbExp=2; IntAct=EBI-1005487, EBI-78835; CC P35968; P12931: SRC; NbExp=6; IntAct=EBI-1005487, EBI-621482; CC P35968; P15692: VEGFA; NbExp=5; IntAct=EBI-1005487, EBI-1026643; CC P35968; P15692-4: VEGFA; NbExp=8; IntAct=EBI-1005487, EBI-1026691; CC P35968; P49767: VEGFC; NbExp=6; IntAct=EBI-1005487, EBI-3405539; CC P35968; Q9MYV3-3: VEGFA; Xeno; NbExp=2; IntAct=EBI-1005487, EBI-15622828; CC -!- SUBCELLULAR LOCATION: Cell junction {ECO:0000250}. Endoplasmic CC reticulum {ECO:0000269|PubMed:23529610}. Cell membrane CC {ECO:0000269|PubMed:25825981}. Note=Localized with RAP1A at cell-cell CC junctions (By similarity). Colocalizes with ERN1 and XBP1 in the CC endoplasmic reticulum in endothelial cells in a vascular endothelial CC growth factor (VEGF)-dependent manner (PubMed:23529610). {ECO:0000250, CC ECO:0000269|PubMed:23529610}. CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane; Single-pass type I CC membrane protein. Cytoplasm. Nucleus. Cytoplasmic vesicle. Early CC endosome. Note=Detected on caveolae-enriched lipid rafts at the cell CC surface. Is recycled from the plasma membrane to endosomes and back CC again. Phosphorylation triggered by VEGFA binding promotes CC internalization and subsequent degradation. VEGFA binding triggers CC internalization and translocation to the nucleus. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted {ECO:0000305}. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Secreted. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=mbVegfr-2; CC IsoId=P35968-1; Sequence=Displayed; CC Name=2; Synonyms=sVegfr-2; CC IsoId=P35968-2; Sequence=VSP_041988, VSP_041989; CC Name=3; Synonyms=VEGFR2-712; CC IsoId=P35968-3; Sequence=VSP_041990, VSP_041991; CC -!- TISSUE SPECIFICITY: Detected in cornea (at protein level). Widely CC expressed. {ECO:0000269|PubMed:19668192}. CC -!- DOMAIN: The second and third Ig-like C2-type (immunoglobulin-like) CC domains are sufficient for VEGFC binding. CC {ECO:0000269|PubMed:20145116}. CC -!- PTM: N-glycosylated. {ECO:0000269|PubMed:20145116, CC ECO:0000269|PubMed:21827946, ECO:0000269|PubMed:9160888}. CC -!- PTM: Ubiquitinated. Tyrosine phosphorylation of the receptor promotes CC its poly-ubiquitination, leading to its degradation via the proteasome CC or lysosomal proteases. {ECO:0000269|PubMed:12649282, CC ECO:0000269|PubMed:17004325, ECO:0000269|PubMed:19834490}. CC -!- PTM: Autophosphorylated on tyrosine residues upon ligand binding. CC Autophosphorylation occurs in trans, i.e. one subunit of the dimeric CC receptor phosphorylates tyrosine residues on the other subunit. CC Phosphorylation at Tyr-951 is important for interaction with CC SH2D2A/TSAD and VEGFA-mediated reorganization of the actin CC cytoskeleton. Phosphorylation at Tyr-1175 is important for interaction CC with PLCG1 and SHB. Phosphorylation at Tyr-1214 is important for CC interaction with NCK1 and FYN. Dephosphorylated by PTPRB. CC Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr- CC 1175 and Tyr-1214. {ECO:0000269|PubMed:10037737, CC ECO:0000269|PubMed:10102632, ECO:0000269|PubMed:10368301, CC ECO:0000269|PubMed:11387210, ECO:0000269|PubMed:15215251, CC ECO:0000269|PubMed:15962004, ECO:0000269|PubMed:18936167, CC ECO:0000269|PubMed:19136612, ECO:0000269|PubMed:25825981}. CC -!- PTM: The inhibitory disulfide bond between Cys-1024 and Cys-1045 may CC serve as a specific molecular switch for H(2)S-induced modification CC that regulates KDR/VEGFR2 function. CC -!- DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: A CC condition characterized by dull red, firm, dome-shaped hemangiomas, CC sharply demarcated from surrounding skin, usually presenting at birth CC or occurring within the first two or three months of life. They result CC from highly proliferative, localized growth of capillary endothelium CC and generally undergo regression and involution without scarring. CC {ECO:0000269|PubMed:11807987, ECO:0000269|PubMed:18931684}. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. CC -!- DISEASE: Note=Plays a major role in tumor angiogenesis. In case of HIV- CC 1 infection, the interaction with extracellular viral Tat protein seems CC to enhance angiogenesis in Kaposi's sarcoma lesions. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. CSF-1/PDGF receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; EU826563; ACF47599.1; -; mRNA. DR EMBL; FJ899739; ACR78514.1; -; mRNA. DR EMBL; AF035121; AAB88005.1; -; mRNA. DR EMBL; AF063658; AAC16450.1; -; mRNA. DR EMBL; AC021220; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC111194; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC131822; AAI31823.1; -; mRNA. DR EMBL; L04947; AAA59459.1; -; mRNA. DR EMBL; X61656; CAA43837.1; -; mRNA. DR EMBL; X89776; CAA61916.1; -; Genomic_DNA. DR CCDS; CCDS3497.1; -. [P35968-1] DR PIR; JC1402; JC1402. DR RefSeq; NP_002244.1; NM_002253.4. [P35968-1] DR PDB; 1VR2; X-ray; 2.40 A; A=806-1171. DR PDB; 1Y6A; X-ray; 2.10 A; A=806-1171. DR PDB; 1Y6B; X-ray; 2.10 A; A=806-1171. DR PDB; 1YWN; X-ray; 1.71 A; A=806-1171. DR PDB; 2M59; NMR; -; A/B=759-795. DR PDB; 2MET; NMR; -; A/B/C=759-795. DR PDB; 2MEU; NMR; -; A/B=759-795. DR PDB; 2OH4; X-ray; 2.05 A; A=806-1171. DR PDB; 2P2H; X-ray; 1.95 A; A=815-1171. DR PDB; 2P2I; X-ray; 2.40 A; A/B=815-1171. DR PDB; 2QU5; X-ray; 2.95 A; A=815-1171. DR PDB; 2QU6; X-ray; 2.10 A; A/B=815-1171. DR PDB; 2RL5; X-ray; 2.65 A; A=815-1171. DR PDB; 2X1W; X-ray; 2.70 A; L/M/N/O=120-326. DR PDB; 2X1X; X-ray; 3.10 A; R=120-326. DR PDB; 2XIR; X-ray; 1.50 A; A=806-1171. DR PDB; 3B8Q; X-ray; 2.75 A; A/B=815-1171. DR PDB; 3B8R; X-ray; 2.70 A; A/B=815-1171. DR PDB; 3BE2; X-ray; 1.75 A; A=815-1171. DR PDB; 3C7Q; X-ray; 2.10 A; A=806-1171. DR PDB; 3CJF; X-ray; 2.15 A; A=806-1168. DR PDB; 3CJG; X-ray; 2.25 A; A=806-1168. DR PDB; 3CP9; X-ray; 2.50 A; A/B=815-1171. DR PDB; 3CPB; X-ray; 2.70 A; A/B=815-1171. DR PDB; 3CPC; X-ray; 2.40 A; A/B=815-1171. DR PDB; 3DTW; X-ray; 2.90 A; A/B=815-1171. DR PDB; 3EFL; X-ray; 2.20 A; A/B=815-1171. DR PDB; 3EWH; X-ray; 1.60 A; A=815-1171. DR PDB; 3KVQ; X-ray; 2.70 A; A=657-764. DR PDB; 3S35; X-ray; 2.20 A; X=220-338. DR PDB; 3S36; X-ray; 3.20 A; X=220-338. DR PDB; 3S37; X-ray; 2.70 A; X=220-338. DR PDB; 3U6J; X-ray; 2.15 A; A=815-1171. DR PDB; 3V2A; X-ray; 3.20 A; R=2-764. DR PDB; 3V6B; X-ray; 3.20 A; R=132-548. DR PDB; 3VHE; X-ray; 1.55 A; A=811-1169. DR PDB; 3VHK; X-ray; 2.49 A; A=806-1171. DR PDB; 3VID; X-ray; 2.30 A; A=813-1168. DR PDB; 3VNT; X-ray; 1.64 A; A=806-1171. DR PDB; 3VO3; X-ray; 1.52 A; A=806-1171. DR PDB; 3WZD; X-ray; 1.57 A; A=814-1172. DR PDB; 3WZE; X-ray; 1.90 A; A=814-1172. DR PDB; 4AG8; X-ray; 1.95 A; A=806-1171. DR PDB; 4AGC; X-ray; 2.00 A; A=787-1171. DR PDB; 4AGD; X-ray; 2.81 A; A=787-1171. DR PDB; 4ASD; X-ray; 2.03 A; A=787-1171. DR PDB; 4ASE; X-ray; 1.83 A; A=787-1171. DR PDB; 5EW3; X-ray; 2.50 A; A/B=806-1171. DR PDB; 5OYJ; X-ray; 2.38 A; C/D=326-549. DR PDB; 6GQO; X-ray; 1.87 A; A=806-939, A=991-1171. DR PDB; 6GQP; X-ray; 2.09 A; A=806-1171. DR PDB; 6GQQ; X-ray; 1.52 A; A=806-939, A=991-1171. DR PDB; 6XVJ; X-ray; 1.78 A; A=806-1171. DR PDB; 6XVK; X-ray; 1.99 A; A=806-1171. DR PDBsum; 1VR2; -. DR PDBsum; 1Y6A; -. DR PDBsum; 1Y6B; -. DR PDBsum; 1YWN; -. DR PDBsum; 2M59; -. DR PDBsum; 2MET; -. DR PDBsum; 2MEU; -. DR PDBsum; 2OH4; -. DR PDBsum; 2P2H; -. DR PDBsum; 2P2I; -. DR PDBsum; 2QU5; -. DR PDBsum; 2QU6; -. DR PDBsum; 2RL5; -. DR PDBsum; 2X1W; -. DR PDBsum; 2X1X; -. DR PDBsum; 2XIR; -. DR PDBsum; 3B8Q; -. DR PDBsum; 3B8R; -. DR PDBsum; 3BE2; -. DR PDBsum; 3C7Q; -. DR PDBsum; 3CJF; -. DR PDBsum; 3CJG; -. DR PDBsum; 3CP9; -. DR PDBsum; 3CPB; -. DR PDBsum; 3CPC; -. DR PDBsum; 3DTW; -. DR PDBsum; 3EFL; -. DR PDBsum; 3EWH; -. DR PDBsum; 3KVQ; -. DR PDBsum; 3S35; -. DR PDBsum; 3S36; -. DR PDBsum; 3S37; -. DR PDBsum; 3U6J; -. DR PDBsum; 3V2A; -. DR PDBsum; 3V6B; -. DR PDBsum; 3VHE; -. DR PDBsum; 3VHK; -. DR PDBsum; 3VID; -. DR PDBsum; 3VNT; -. DR PDBsum; 3VO3; -. DR PDBsum; 3WZD; -. DR PDBsum; 3WZE; -. DR PDBsum; 4AG8; -. DR PDBsum; 4AGC; -. DR PDBsum; 4AGD; -. DR PDBsum; 4ASD; -. DR PDBsum; 4ASE; -. DR PDBsum; 5EW3; -. DR PDBsum; 5OYJ; -. DR PDBsum; 6GQO; -. DR PDBsum; 6GQP; -. DR PDBsum; 6GQQ; -. DR PDBsum; 6XVJ; -. DR PDBsum; 6XVK; -. DR AlphaFoldDB; P35968; -. DR BMRB; P35968; -. DR SMR; P35968; -. DR BioGRID; 109992; 136. DR CORUM; P35968; -. DR DIP; DIP-486N; -. DR FunCoup; P35968; 1746. DR IntAct; P35968; 231. DR MINT; P35968; -. DR STRING; 9606.ENSP00000263923; -. DR BindingDB; P35968; -. DR ChEMBL; CHEMBL279; -. DR DrugBank; DB04727; 1-{4-[4-Amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl}-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea. DR DrugBank; DB07514; 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one. DR DrugBank; DB07528; 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one. DR DrugBank; DB03365; 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline. DR DrugBank; DB06938; 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide. DR DrugBank; DB07326; 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide. DR DrugBank; DB17191; Altiratinib. DR DrugBank; DB06626; Axitinib. DR DrugBank; DB11665; BMS-690514. DR DrugBank; DB11958; Brivanib. DR DrugBank; DB08875; Cabozantinib. DR DrugBank; DB04849; Cediranib. DR DrugBank; DB12962; CP-547632. DR DrugBank; DB05198; CYC116. DR DrugBank; DB12147; Erdafitinib. DR DrugBank; DB11741; Famitinib. DR DrugBank; DB12307; Foretinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB11679; Fruquintinib. DR DrugBank; DB11977; Golvatinib. DR DrugBank; DB06101; IMC-1C11. DR DrugBank; DB09078; Lenvatinib. DR DrugBank; DB06080; Linifanib. DR DrugBank; DB11845; Lucitanib. DR DrugBank; DB06595; Midostaurin. DR DrugBank; DB05575; Motesanib. DR DrugBank; DB07537; N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide. DR DrugBank; DB07288; N-(4-chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide. DR DrugBank; DB07183; N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide. DR DrugBank; DB07333; N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE. DR DrugBank; DB07334; N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE. DR DrugBank; DB07274; N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide. DR DrugBank; DB11828; Neratinib. DR DrugBank; DB09079; Nintedanib. DR DrugBank; DB08519; N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine. DR DrugBank; DB08042; N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine. DR DrugBank; DB16265; Olinvacimab. DR DrugBank; DB12072; Orantinib. DR DrugBank; DB05913; OSI-930. DR DrugBank; DB06589; Pazopanib. DR DrugBank; DB05931; Pegdinetanib. DR DrugBank; DB06999; PLX-4720. DR DrugBank; DB08901; Ponatinib. DR DrugBank; DB08052; PP-121. DR DrugBank; DB15822; Pralsetinib. DR DrugBank; DB05984; RAF-265. DR DrugBank; DB05578; Ramucirumab. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB14840; Ripretinib. DR DrugBank; DB06436; Semaxanib. DR DrugBank; DB15036; Sitravatinib. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB08009; SU-11652. DR DrugBank; DB01268; Sunitinib. DR DrugBank; DB15106; Surufatinib. DR DrugBank; DB13093; TAK-593. DR DrugBank; DB15393; Telatinib. DR DrugBank; DB05075; TG-100801. DR DrugBank; DB11800; Tivozanib. DR DrugBank; DB05294; Vandetanib. DR DrugBank; DB04879; Vatalanib. DR DrugBank; DB17061; VEGFR 2 Kinase inhibitor I. DR DrugBank; DB05146; XL820. DR DrugBank; DB05014; XL999. DR DrugCentral; P35968; -. DR GuidetoPHARMACOLOGY; 1813; -. DR CarbonylDB; P35968; -. DR GlyCosmos; P35968; 19 sites, 1 glycan. DR GlyGen; P35968; 22 sites, 6 N-linked glycans (2 sites), 2 O-linked glycans (3 sites). DR iPTMnet; P35968; -. DR PhosphoSitePlus; P35968; -. DR BioMuta; KDR; -. DR DMDM; 9087218; -. DR CPTAC; CPTAC-3120; -. DR jPOST; P35968; -. DR MassIVE; P35968; -. DR PaxDb; 9606-ENSP00000263923; -. DR PeptideAtlas; P35968; -. DR ProteomicsDB; 55169; -. [P35968-1] DR ProteomicsDB; 55170; -. [P35968-2] DR ProteomicsDB; 55171; -. [P35968-3] DR ABCD; P35968; 76 sequenced antibodies. DR Antibodypedia; 3413; 3865 antibodies from 55 providers. DR DNASU; 3791; -. DR Ensembl; ENST00000263923.5; ENSP00000263923.4; ENSG00000128052.11. [P35968-1] DR GeneID; 3791; -. DR KEGG; hsa:3791; -. DR MANE-Select; ENST00000263923.5; ENSP00000263923.4; NM_002253.4; NP_002244.1. DR UCSC; uc003has.4; human. [P35968-1] DR AGR; HGNC:6307; -. DR CIViC; 3791; 15 evidence items across 13 molecular profiles. DR ClinPGx; PA30086; -. DR CTD; 3791; -. DR DisGeNET; 3791; -. DR GeneCards; KDR; -. DR HGNC; HGNC:6307; KDR. DR HPA; ENSG00000128052; Low tissue specificity. DR MalaCards; KDR; -. DR MIM; 191306; gene. DR MIM; 602089; phenotype. DR OpenTargets; ENSG00000128052; -. DR Orphanet; 3303; Tetralogy of Fallot. DR VEuPathDB; HostDB:ENSG00000128052; -. DR eggNOG; KOG0200; Eukaryota. DR GeneTree; ENSGT00940000156710; -. DR HOGENOM; CLU_000288_49_4_1; -. DR InParanoid; P35968; -. DR OMA; FYRDTDM; -. DR OrthoDB; 9873386at2759; -. DR PAN-GO; P35968; 11 GO annotations based on evolutionary models. DR PhylomeDB; P35968; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P35968; -. DR Reactome; R-HSA-194306; Neurophilin interactions with VEGF and VEGFR. DR Reactome; R-HSA-195399; VEGF binds to VEGFR leading to receptor dimerization. DR Reactome; R-HSA-216083; Integrin cell surface interactions. DR Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway. DR Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation. DR Reactome; R-HSA-9673768; Signaling by membrane-tethered fusions of PDGFRA or PDGFRB. DR Reactome; R-HSA-9856530; High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells. DR SignaLink; P35968; -. DR SIGNOR; P35968; -. DR Agora; ENSG00000128052; -. DR BioGRID-ORCS; 3791; 9 hits in 1200 CRISPR screens. DR EvolutionaryTrace; P35968; -. DR GeneWiki; Kinase_insert_domain_receptor; -. DR GenomeRNAi; 3791; -. DR Pharos; P35968; Tclin. DR PRO; PR:P35968; -. DR Proteomes; UP000005640; Chromosome 4. DR RNAct; P35968; protein. DR Bgee; ENSG00000128052; Expressed in germinal epithelium of ovary and 190 other cell types or tissues. DR GO; GO:0070161; C:anchoring junction; IEA:UniProtKB-SubCell. DR GO; GO:0030054; C:cell junction; ISS:UniProtKB. DR GO; GO:0005769; C:early endosome; ISS:BHF-UCL. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB. DR GO; GO:0005768; C:endosome; IDA:UniProtKB. DR GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB. DR GO; GO:0045121; C:membrane raft; IDA:UniProtKB. DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0097443; C:sorting endosome; ISS:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0045296; F:cadherin binding; IPI:UniProtKB. DR GO; GO:0015026; F:coreceptor activity; IEA:Ensembl. DR GO; GO:0019838; F:growth factor binding; IPI:BHF-UCL. DR GO; GO:0051879; F:Hsp90 protein binding; TAS:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0005178; F:integrin binding; IPI:BHF-UCL. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; TAS:BHF-UCL. DR GO; GO:0038085; F:vascular endothelial growth factor binding; IPI:BHF-UCL. DR GO; GO:0005021; F:vascular endothelial growth factor receptor activity; IDA:UniProtKB. DR GO; GO:0001525; P:angiogenesis; IBA:GO_Central. DR GO; GO:0060837; P:blood vessel endothelial cell differentiation; IEA:Ensembl. DR GO; GO:0001569; P:branching involved in blood vessel morphogenesis; IMP:BHF-UCL. DR GO; GO:0055074; P:calcium ion homeostasis; IEA:Ensembl. DR GO; GO:0045165; P:cell fate commitment; IEA:Ensembl. DR GO; GO:0016477; P:cell migration; IBA:GO_Central. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:1904881; P:cellular response to hydrogen sulfide; IDA:BHF-UCL. DR GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IDA:UniProtKB. DR GO; GO:0035162; P:embryonic hemopoiesis; ISS:UniProtKB. DR GO; GO:0003157; P:endocardium development; IEA:Ensembl. DR GO; GO:0045446; P:endothelial cell differentiation; IBA:GO_Central. DR GO; GO:0003158; P:endothelium development; ISS:UniProtKB. DR GO; GO:0002070; P:epithelial cell maturation; IEA:Ensembl. DR GO; GO:0050673; P:epithelial cell proliferation; IEA:Ensembl. DR GO; GO:0048286; P:lung alveolus development; IEA:Ensembl. DR GO; GO:0001945; P:lymph vessel development; IEA:Ensembl. DR GO; GO:0010463; P:mesenchymal cell proliferation; IEA:Ensembl. DR GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IDA:UniProtKB. DR GO; GO:0010629; P:negative regulation of gene expression; IDA:BHF-UCL. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0001541; P:ovarian follicle development; IEA:Ensembl. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0045766; P:positive regulation of angiogenesis; IDA:UniProt. DR GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IMP:BHF-UCL. DR GO; GO:0030513; P:positive regulation of BMP signaling pathway; IEA:Ensembl. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL. DR GO; GO:0090050; P:positive regulation of cell migration involved in sprouting angiogenesis; IMP:BHF-UCL. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:2001028; P:positive regulation of endothelial cell chemotaxis; IDA:BHF-UCL. DR GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:BHF-UCL. DR GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:BHF-UCL. DR GO; GO:0051894; P:positive regulation of focal adhesion assembly; IDA:BHF-UCL. DR GO; GO:0016239; P:positive regulation of macroautophagy; IGI:MGI. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:UniProtKB. DR GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IEA:Ensembl. DR GO; GO:0051901; P:positive regulation of mitochondrial depolarization; IGI:MGI. DR GO; GO:0090141; P:positive regulation of mitochondrial fission; IGI:MGI. DR GO; GO:0141150; P:positive regulation of nitric oxide-cGMP mediated signal transduction; IDA:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:UniProtKB. DR GO; GO:0050927; P:positive regulation of positive chemotaxis; IDA:BHF-UCL. DR GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:UniProtKB. DR GO; GO:2000648; P:positive regulation of stem cell proliferation; IEA:Ensembl. DR GO; GO:2001214; P:positive regulation of vasculogenesis; ISS:UniProtKB. DR GO; GO:0048597; P:post-embryonic camera-type eye morphogenesis; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:1903010; P:regulation of bone development; IEA:Ensembl. DR GO; GO:0008360; P:regulation of cell shape; IDA:BHF-UCL. DR GO; GO:1901532; P:regulation of hematopoietic progenitor cell differentiation; IEA:Ensembl. DR GO; GO:0043408; P:regulation of MAPK cascade; IBA:GO_Central. DR GO; GO:0071526; P:semaphorin-plexin signaling pathway; IEA:Ensembl. DR GO; GO:0072089; P:stem cell proliferation; IEA:Ensembl. DR GO; GO:0043129; P:surfactant homeostasis; IEA:Ensembl. DR GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0036324; P:vascular endothelial growth factor receptor-2 signaling pathway; IMP:UniProtKB. DR GO; GO:0038084; P:vascular endothelial growth factor signaling pathway; IDA:BHF-UCL. DR GO; GO:0061042; P:vascular wound healing; IMP:BHF-UCL. DR GO; GO:0001570; P:vasculogenesis; ISS:UniProtKB. DR CDD; cd00096; Ig; 1. DR CDD; cd05862; IgI_VEGFR; 1. DR CDD; cd05864; IgI_VEGFR-2; 1. DR CDD; cd05103; PTKc_VEGFR2; 1. DR FunFam; 1.10.510.10:FF:000077; Vascular endothelial growth factor receptor 2; 1. DR FunFam; 2.60.40.10:FF:000532; Vascular endothelial growth factor receptor 2; 1. DR FunFam; 2.60.40.10:FF:000596; Vascular endothelial growth factor receptor 2; 1. DR FunFam; 2.60.40.10:FF:000669; Vascular endothelial growth factor receptor 2; 1. DR FunFam; 2.60.40.10:FF:000767; Vascular endothelial growth factor receptor 2; 1. DR FunFam; 2.60.40.10:FF:000880; Vascular endothelial growth factor receptor 2; 1. DR FunFam; 3.30.200.20:FF:000041; Vascular endothelial growth factor receptor 2; 1. DR FunFam; 2.60.40.10:FF:000143; Vascular endothelial growth factor receptor 3; 1. DR FunFam; 2.60.40.10:FF:000247; Vascular endothelial growth factor receptor 3; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 7. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR013151; Immunoglobulin_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR001824; Tyr_kinase_rcpt_3_CS. DR InterPro; IPR041348; VEGFR-2_TMD. DR InterPro; IPR055229; VEGFR1-3_5th. DR InterPro; IPR055238; VEGFR1-3_N_Ig-like. DR InterPro; IPR009136; VEGFR2_rcpt. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR PANTHER; PTHR24416:SF45; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2; 1. DR Pfam; PF07679; I-set; 2. DR Pfam; PF00047; ig; 1. DR Pfam; PF13895; Ig_2; 1. DR Pfam; PF22971; Ig_VEGFR-1-like_5th; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF21339; VEGFR-1-like_Ig-like; 1. DR Pfam; PF17988; VEGFR-2_TMD; 1. DR Pfam; PF22854; VEGFR1-3_N_Ig-like; 1. DR PIRSF; PIRSF000615; TyrPK_CSF1-R; 1. DR PRINTS; PR01832; VEGFRECEPTOR. DR PRINTS; PR01834; VEGFRECEPTR2. DR SMART; SM00409; IG; 7. DR SMART; SM00408; IGc2; 5. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF48726; Immunoglobulin; 6. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 5. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Angiogenesis; ATP-binding; KW Cell junction; Cell membrane; Cytoplasm; Cytoplasmic vesicle; KW Developmental protein; Differentiation; Disulfide bond; KW Endoplasmic reticulum; Endosome; Glycoprotein; Host-virus interaction; KW Immunoglobulin domain; Kinase; Membrane; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome; KW Repeat; Secreted; Signal; Transferase; Transmembrane; Transmembrane helix; KW Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..19 FT /evidence="ECO:0000255" FT CHAIN 20..1356 FT /note="Vascular endothelial growth factor receptor 2" FT /id="PRO_0000016771" FT TOPO_DOM 20..764 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 765..785 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 786..1356 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 46..110 FT /note="Ig-like C2-type 1" FT DOMAIN 141..207 FT /note="Ig-like C2-type 2" FT DOMAIN 224..320 FT /note="Ig-like C2-type 3" FT DOMAIN 328..414 FT /note="Ig-like C2-type 4" FT DOMAIN 421..548 FT /note="Ig-like C2-type 5" FT DOMAIN 551..660 FT /note="Ig-like C2-type 6" FT DOMAIN 667..753 FT /note="Ig-like C2-type 7" FT DOMAIN 834..1162 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1274..1318 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1296..1309 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 1028 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 840..848 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT BINDING 868 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT SITE 1175 FT /note="Interaction with SHB" FT /evidence="ECO:0000250" FT MOD_RES 801 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:17303569, FT ECO:0000269|PubMed:18936167" FT MOD_RES 951 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15962004, FT ECO:0000269|PubMed:18936167, ECO:0000269|PubMed:19136612" FT MOD_RES 982 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 984 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 996 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10102632, FT ECO:0000269|PubMed:18936167" FT MOD_RES 1054 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10037737, FT ECO:0000269|PubMed:10102632, ECO:0000269|PubMed:15215251, FT ECO:0000269|PubMed:15962004, ECO:0000269|PubMed:18936167" FT MOD_RES 1059 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10037737, FT ECO:0000269|PubMed:10102632, ECO:0000269|PubMed:10368301, FT ECO:0000269|PubMed:15215251, ECO:0000269|PubMed:15962004, FT ECO:0000269|PubMed:18936167" FT MOD_RES 1175 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11387210, FT ECO:0000269|PubMed:18936167, ECO:0000269|PubMed:19136612" FT MOD_RES 1214 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11387210, FT ECO:0000269|PubMed:15962004, ECO:0000269|PubMed:18936167, FT ECO:0000269|PubMed:19136612" FT MOD_RES 1231 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P35918" FT MOD_RES 1235 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P35918" FT MOD_RES 1238 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:P35918" FT MOD_RES 1305 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15962004" FT MOD_RES 1309 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15962004" FT MOD_RES 1319 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15962004" FT CARBOHYD 46 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 66 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 96 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 143 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20145116" FT CARBOHYD 158 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 245 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20145116, FT ECO:0000269|PubMed:21827946" FT CARBOHYD 318 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20145116, FT ECO:0000269|PubMed:21827946" FT CARBOHYD 374 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 395 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 511 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 523 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 580 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 613 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 619 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 631 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 675 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 704 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 721 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 53..103 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 150..200 FT DISULFID 246..307 FT DISULFID 445..530 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 571..642 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 688..737 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 1024..1045 FT /note="Redox-active" FT DISULFID 1208 FT /note="Interchain (with C-189 in SLC31A1)" FT /evidence="ECO:0000269|PubMed:35027734" FT VAR_SEQ 663..678 FT /note="ERVAPTITGNLENQTT -> GRETILDHCAEAVGMP (in isoform 2)" FT /evidence="ECO:0000303|PubMed:19668192" FT /id="VSP_041988" FT VAR_SEQ 679..1356 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:19668192" FT /id="VSP_041989" FT VAR_SEQ 712 FT /note="G -> E (in isoform 3)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_041990" FT VAR_SEQ 713..1356 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_041991" FT VARIANT 2 FT /note="Q -> R (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042053" FT VARIANT 136 FT /note="V -> M (in dbSNP:rs35636987)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042054" FT VARIANT 248 FT /note="A -> G (in a renal clear cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042055" FT VARIANT 275 FT /note="R -> L (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036126" FT VARIANT 297 FT /note="V -> I (in dbSNP:rs2305948)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_022071" FT VARIANT 462 FT /note="L -> V (in dbSNP:rs56286620)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042056" FT VARIANT 472 FT /note="Q -> H (in dbSNP:rs1870377)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:17344846" FT /id="VAR_020353" FT VARIANT 482 FT /note="C -> R (probable risk factor for HCI; expression of FT FLT1 in hemangioma endothelial cells is markedly reduced FT and KDR activity is increased compared to controls; low FT FLT1 expression in hemangioma cells is caused by reduced FT activity of a pathway involving ITGB1, ANTXR1, KDR and FT NFATC2IP; the mutation predicts to result in loss-of- FT function and disruption of the normal association of these FT molecules; dbSNP:rs34231037)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:18931684" FT /id="VAR_042057" FT VARIANT 539 FT /note="G -> R (in dbSNP:rs55716939)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042058" FT VARIANT 689 FT /note="T -> M (in dbSNP:rs34038364)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042059" FT VARIANT 814 FT /note="D -> N (in dbSNP:rs35603373)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042060" FT VARIANT 848 FT /note="V -> E (strongly reduced autophosphorylation and FT kinase activity; dbSNP:rs1139776)" FT /evidence="ECO:0000269|PubMed:10037737, FT ECO:0000269|PubMed:1656371" FT /id="VAR_046679" FT VARIANT 873 FT /note="G -> R (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036127" FT VARIANT 952 FT /note="V -> I (in dbSNP:rs13129474)" FT /id="VAR_046680" FT VARIANT 1065 FT /note="A -> T (in dbSNP:rs56302315)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042061" FT VARIANT 1147 FT /note="P -> S (in HCI; somatic mutation; FT dbSNP:rs121917766)" FT /evidence="ECO:0000269|PubMed:11807987" FT /id="VAR_063147" FT MUTAGEN 726 FT /note="R->A: Strongly reduced autophosphorylation and FT activation of MAP kinases." FT /evidence="ECO:0000269|PubMed:20080685" FT MUTAGEN 731 FT /note="D->A: Strongly reduced autophosphorylation and FT activation of MAP kinases." FT /evidence="ECO:0000269|PubMed:20080685" FT MUTAGEN 801 FT /note="Y->F: Abolishes stimulation of nitric oxide FT synthesis." FT /evidence="ECO:0000269|PubMed:17303569" FT MUTAGEN 868 FT /note="K->M: Loss of enzyme activity." FT /evidence="ECO:0000269|PubMed:11387210" FT MUTAGEN 951 FT /note="Y->F: Abolishes reorganization of the actin FT cytoskeleton and cell migration in response to VEGFA." FT /evidence="ECO:0000269|PubMed:15962004" FT MUTAGEN 996 FT /note="Y->F: Strongly reduced autophosphorylation. Reduces FT phosphorylation of PLCG1." FT /evidence="ECO:0000269|PubMed:10102632" FT MUTAGEN 1045 FT /note="C->A: Significantly higher kinase activity." FT /evidence="ECO:0000269|PubMed:23199280" FT MUTAGEN 1054 FT /note="Y->F: Strongly reduced autophosphorylation. FT Abolishes phosphorylation of downstream signaling proteins; FT when associated with F-1059." FT /evidence="ECO:0000269|PubMed:10102632" FT MUTAGEN 1059 FT /note="Y->F: Strongly reduced autophosphorylation. FT Abolishes phosphorylation of downstream signaling proteins; FT when associated with F-1054." FT /evidence="ECO:0000269|PubMed:10102632" FT MUTAGEN 1175 FT /note="Y->F: Abolishes phosphorylation of PLCG1 and MAP FT kinases in response to VEGFA." FT /evidence="ECO:0000269|PubMed:11387210" FT MUTAGEN 1214 FT /note="Y->F: Loss of phosphorylation site. Abolishes FT reorganization of the actin cytoskeleton in response to FT VEGFA." FT /evidence="ECO:0000269|PubMed:16966330" FT CONFLICT 2 FT /note="Q -> E (in Ref. 4; AAC16450)" FT /evidence="ECO:0000305" FT CONFLICT 772 FT /note="A -> T (in Ref. 7; AAA59459/CAA43837)" FT /evidence="ECO:0000305" FT CONFLICT 787 FT /note="R -> G (in Ref. 7; AAA59459/CAA43837)" FT /evidence="ECO:0000305" FT CONFLICT 835 FT /note="K -> N (in Ref. 7; AAA59459/CAA43837)" FT /evidence="ECO:0000305" FT CONFLICT 1347 FT /note="S -> T (in Ref. 7; AAA59459/CAA43837)" FT /evidence="ECO:0000305" FT STRAND 134..138 FT /evidence="ECO:0007829|PDB:2X1W" FT STRAND 145..148 FT /evidence="ECO:0007829|PDB:2X1W" FT STRAND 152..154 FT /evidence="ECO:0007829|PDB:2X1W" FT STRAND 159..164 FT /evidence="ECO:0007829|PDB:2X1W" FT TURN 165..167 FT /evidence="ECO:0007829|PDB:2X1W" FT STRAND 168..170 FT /evidence="ECO:0007829|PDB:2X1W" FT STRAND 174..176 FT /evidence="ECO:0007829|PDB:2X1W" FT STRAND 178..180 FT /evidence="ECO:0007829|PDB:2X1W" FT TURN 181..183 FT /evidence="ECO:0007829|PDB:2X1W" FT STRAND 184..188 FT /evidence="ECO:0007829|PDB:2X1W" FT HELIX 189..191 FT /evidence="ECO:0007829|PDB:2X1W" FT TURN 192..194 FT /evidence="ECO:0007829|PDB:2X1W" FT STRAND 196..202 FT /evidence="ECO:0007829|PDB:2X1W" FT STRAND 207..210 FT /evidence="ECO:0007829|PDB:3V2A" FT STRAND 214..218 FT /evidence="ECO:0007829|PDB:2X1W" FT STRAND 223..230 FT /evidence="ECO:0007829|PDB:3S35" FT STRAND 234..238 FT /evidence="ECO:0007829|PDB:3S35" FT STRAND 242..250 FT /evidence="ECO:0007829|PDB:3S35" FT STRAND 252..254 FT /evidence="ECO:0007829|PDB:3V6B" FT STRAND 257..261 FT /evidence="ECO:0007829|PDB:3S35" FT HELIX 269..272 FT /evidence="ECO:0007829|PDB:3S35" FT STRAND 273..276 FT /evidence="ECO:0007829|PDB:3V2A" FT STRAND 279..282 FT /evidence="ECO:0007829|PDB:3S35" FT STRAND 285..296 FT /evidence="ECO:0007829|PDB:3S35" FT HELIX 299..301 FT /evidence="ECO:0007829|PDB:3S35" FT STRAND 303..310 FT /evidence="ECO:0007829|PDB:3S35" FT STRAND 315..328 FT /evidence="ECO:0007829|PDB:3S35" FT STRAND 338..343 FT /evidence="ECO:0007829|PDB:5OYJ" FT STRAND 348..351 FT /evidence="ECO:0007829|PDB:5OYJ" FT STRAND 354..358 FT /evidence="ECO:0007829|PDB:5OYJ" FT STRAND 361..366 FT /evidence="ECO:0007829|PDB:5OYJ" FT STRAND 377..387 FT /evidence="ECO:0007829|PDB:5OYJ" FT HELIX 390..392 FT /evidence="ECO:0007829|PDB:5OYJ" FT STRAND 394..401 FT /evidence="ECO:0007829|PDB:5OYJ" FT TURN 403..405 FT /evidence="ECO:0007829|PDB:5OYJ" FT STRAND 408..425 FT /evidence="ECO:0007829|PDB:5OYJ" FT STRAND 434..436 FT /evidence="ECO:0007829|PDB:5OYJ" FT STRAND 441..451 FT /evidence="ECO:0007829|PDB:5OYJ" FT STRAND 454..462 FT /evidence="ECO:0007829|PDB:5OYJ" FT HELIX 463..465 FT /evidence="ECO:0007829|PDB:5OYJ" FT STRAND 482..484 FT /evidence="ECO:0007829|PDB:5OYJ" FT STRAND 497..499 FT /evidence="ECO:0007829|PDB:5OYJ" FT STRAND 503..507 FT /evidence="ECO:0007829|PDB:5OYJ" FT STRAND 510..521 FT /evidence="ECO:0007829|PDB:5OYJ" FT STRAND 526..534 FT /evidence="ECO:0007829|PDB:5OYJ" FT STRAND 537..548 FT /evidence="ECO:0007829|PDB:5OYJ" FT STRAND 676..679 FT /evidence="ECO:0007829|PDB:3KVQ" FT STRAND 684..687 FT /evidence="ECO:0007829|PDB:3KVQ" FT STRAND 697..706 FT /evidence="ECO:0007829|PDB:3KVQ" FT STRAND 713..716 FT /evidence="ECO:0007829|PDB:3KVQ" FT TURN 717..720 FT /evidence="ECO:0007829|PDB:3KVQ" FT STRAND 721..724 FT /evidence="ECO:0007829|PDB:3KVQ" FT HELIX 729..731 FT /evidence="ECO:0007829|PDB:3KVQ" FT STRAND 733..740 FT /evidence="ECO:0007829|PDB:3KVQ" FT STRAND 746..755 FT /evidence="ECO:0007829|PDB:3KVQ" FT HELIX 760..794 FT /evidence="ECO:0007829|PDB:2M59" FT STRAND 804..806 FT /evidence="ECO:0007829|PDB:4AGC" FT TURN 808..810 FT /evidence="ECO:0007829|PDB:4ASE" FT TURN 813..815 FT /evidence="ECO:0007829|PDB:3VHE" FT HELIX 817..819 FT /evidence="ECO:0007829|PDB:2XIR" FT HELIX 824..827 FT /evidence="ECO:0007829|PDB:2XIR" FT HELIX 831..833 FT /evidence="ECO:0007829|PDB:2XIR" FT STRAND 834..842 FT /evidence="ECO:0007829|PDB:2XIR" FT STRAND 844..858 FT /evidence="ECO:0007829|PDB:2XIR" FT STRAND 862..870 FT /evidence="ECO:0007829|PDB:2XIR" FT HELIX 876..892 FT /evidence="ECO:0007829|PDB:2XIR" FT STRAND 901..905 FT /evidence="ECO:0007829|PDB:2XIR" FT STRAND 907..910 FT /evidence="ECO:0007829|PDB:3WZD" FT STRAND 913..917 FT /evidence="ECO:0007829|PDB:2XIR" FT HELIX 924..929 FT /evidence="ECO:0007829|PDB:2XIR" FT TURN 930..933 FT /evidence="ECO:0007829|PDB:3VO3" FT STRAND 934..936 FT /evidence="ECO:0007829|PDB:2XIR" FT TURN 995..998 FT /evidence="ECO:0007829|PDB:3VO3" FT HELIX 1002..1021 FT /evidence="ECO:0007829|PDB:2XIR" FT STRAND 1024..1026 FT /evidence="ECO:0007829|PDB:4AGC" FT HELIX 1031..1033 FT /evidence="ECO:0007829|PDB:2XIR" FT STRAND 1034..1036 FT /evidence="ECO:0007829|PDB:2XIR" FT HELIX 1038..1040 FT /evidence="ECO:0007829|PDB:2XIR" FT STRAND 1042..1044 FT /evidence="ECO:0007829|PDB:2XIR" FT HELIX 1048..1050 FT /evidence="ECO:0007829|PDB:2XIR" FT TURN 1053..1055 FT /evidence="ECO:0007829|PDB:2XIR" FT STRAND 1059..1062 FT /evidence="ECO:0007829|PDB:2XIR" FT STRAND 1065..1067 FT /evidence="ECO:0007829|PDB:2XIR" FT HELIX 1069..1071 FT /evidence="ECO:0007829|PDB:2XIR" FT HELIX 1074..1079 FT /evidence="ECO:0007829|PDB:2XIR" FT HELIX 1084..1099 FT /evidence="ECO:0007829|PDB:2XIR" FT STRAND 1105..1108 FT /evidence="ECO:0007829|PDB:3C7Q" FT HELIX 1113..1121 FT /evidence="ECO:0007829|PDB:2XIR" FT HELIX 1133..1142 FT /evidence="ECO:0007829|PDB:2XIR" FT HELIX 1147..1149 FT /evidence="ECO:0007829|PDB:2XIR" FT HELIX 1153..1167 FT /evidence="ECO:0007829|PDB:2XIR" SQ SEQUENCE 1356 AA; 151527 MW; 59E7C44B05CFEBB3 CRC64; MQSKVLLAVA LWLCVETRAA SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGAQEK TNLEIIILVG TAVIAMFFWL LLVIILRTVK RANGGELKTG YLSIVMDPDE LPLDEHCERL PYDASKWEFP RDRLKLGKPL GRGAFGQVIE ADAFGIDKTA TCRTVAVKML KEGATHSEHR ALMSELKILI HIGHHLNVVN LLGACTKPGG PLMVIVEFCK FGNLSTYLRS KRNEFVPYKT KGARFRQGKD YVGAIPVDLK RRLDSITSSQ SSASSGFVEE KSLSDVEEEE APEDLYKDFL TLEHLICYSF QVAKGMEFLA SRKCIHRDLA ARNILLSEKN VVKICDFGLA RDIYKDPDYV RKGDARLPLK WMAPETIFDR VYTIQSDVWS FGVLLWEIFS LGASPYPGVK IDEEFCRRLK EGTRMRAPDY TTPEMYQTML DCWHGEPSQR PTFSELVEHL GNLLQANAQQ DGKDYIVLPI SETLSMEEDS GLSLPTSPVS CMEEEEVCDP KFHYDNTAGI SQYLQNSKRK SRPVSVKTFE DIPLEEPEVK VIPDDNQTDS GMVLASEELK TLEDRTKLSP SFGGMVPSKS RESVASEGSN QTSGYQSGYH SDDTDTTVYS SEEAELLKLI EIGVQTGSTA QILQPDSGTT LSSPPV // ID WDR19_HUMAN Reviewed; 1342 AA. AC Q8NEZ3; B5MEF2; Q8N5B4; Q9H5S0; Q9HCD4; DT 02-MAY-2006, integrated into UniProtKB/Swiss-Prot. DT 02-MAY-2006, sequence version 2. DT 28-JAN-2026, entry version 181. DE RecName: Full=WD repeat-containing protein 19 {ECO:0000305}; DE AltName: Full=Intraflagellar transport 144 homolog; GN Name=WDR19 {ECO:0000312|HGNC:HGNC:18340}; GN Synonyms=IFT144 {ECO:0000303|PubMed:25860617, ECO:0000303|PubMed:27932497}, GN KIAA1638; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ALTERNATIVE SPLICING, TISSUE RP SPECIFICITY, AND INDUCTION. RX PubMed=12906858; DOI=10.1016/s0888-7543(03)00151-4; RA Lin B., White J.T., Utleg A.G., Wang S., Ferguson C., True L.D., RA Vessella R., Hood L., Nelson P.S.; RT "Isolation and characterization of human and mouse WDR19,a novel WD-repeat RT protein exhibiting androgen-regulated expression in prostate epithelium."; RL Genomics 82:331-342(2003). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Lung; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Eye; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 335-1239. RC TISSUE=Brain; RX PubMed=10997877; DOI=10.1093/dnares/7.4.271; RA Nagase T., Kikuno R., Nakayama M., Hirosawa M., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XVIII. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 7:273-281(2000). RN [7] RP SEQUENCE REVISION. RX PubMed=12168954; DOI=10.1093/dnares/9.3.99; RA Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.; RT "Construction of expression-ready cDNA clones for KIAA genes: manual RT curation of 330 KIAA cDNA clones."; RL DNA Res. 9:99-106(2002). RN [8] RP FUNCTION, AND IDENTIFICATION IN THE IFT-A COMPLEX. RX PubMed=20889716; DOI=10.1101/gad.1966210; RA Mukhopadhyay S., Wen X., Chih B., Nelson C.D., Lane W.S., Scales S.J., RA Jackson P.K.; RT "TULP3 bridges the IFT-A complex and membrane phosphoinositides to promote RT trafficking of G protein-coupled receptors into primary cilia."; RL Genes Dev. 24:2180-2193(2010). RN [9] RP FUNCTION, AND IDENTIFICATION IN THE IFT-A COMPLEX. RX PubMed=27932497; DOI=10.1091/mbc.e16-11-0813; RA Hirano T., Katoh Y., Nakayama K.; RT "Intraflagellar transport-A complex mediates ciliary entry and retrograde RT trafficking of ciliary G protein-coupled receptors."; RL Mol. Biol. Cell 28:429-439(2017). RN [10] RP IDENTIFICATION IN THE IFT-A COMPLEX. RX PubMed=29220510; DOI=10.1093/hmg/ddx421; RA Takahara M., Katoh Y., Nakamura K., Hirano T., Sugawa M., Tsurumi Y., RA Nakayama K.; RT "Ciliopathy-associated mutations of IFT122 impair ciliary protein RT trafficking but not ciliogenesis."; RL Hum. Mol. Genet. 27:516-528(2018). RN [11] RP INVOLVEMENT IN SLSN8, AND VARIANTS SLSN8 PRO-30; ASP-68; GLU-109; CYS-272; RP HIS-493 AND SER-710. RX PubMed=23683095; DOI=10.1111/cge.12196; RA Coussa R.G., Otto E.A., Gee H.Y., Arthurs P., Ren H., Lopez I., Keser V., RA Fu Q., Faingold R., Khan A., Schwartzentruber J., Majewski J., RA Hildebrandt F., Koenekoop R.K.; RT "WDR19: an ancient, retrograde, intraflagellar ciliary protein is mutated RT in autosomal recessive retinitis pigmentosa and in Senior-Loken syndrome."; RL Clin. Genet. 84:150-159(2013). RN [12] RP INVOLVEMENT IN SLSN8, AND VARIANTS SLSN8 HIS-493; GLN-1178 AND LYS-1235. RX PubMed=23559409; DOI=10.1007/s00439-013-1297-0; RA Halbritter J., Porath J.D., Diaz K.A., Braun D.A., Kohl S., Chaki M., RA Allen S.J., Soliman N.A., Hildebrandt F., Otto E.A.; RT "Identification of 99 novel mutations in a worldwide cohort of 1,056 RT patients with a nephronophthisis-related ciliopathy."; RL Hum. Genet. 132:865-884(2013). RN [13] RP INTERACTION WITH TTC25. RX PubMed=25860617; DOI=10.1371/journal.pone.0124378; RA Xu Y., Cao J., Huang S., Feng D., Zhang W., Zhu X., Yan X.; RT "Characterization of tetratricopeptide repeat-containing proteins critical RT for cilia formation and function."; RL PLoS ONE 10:E0124378-E0124378(2015). RN [14] RP VARIANT SRTD5 PRO-7, VARIANT NPHP13 GLY-345, AND VARIANT CED4 SER-710. RX PubMed=22019273; DOI=10.1016/j.ajhg.2011.10.001; RA Bredrup C., Saunier S., Oud M.M., Fiskerstrand T., Hoischen A., RA Brackman D., Leh S.M., Midtbo M., Filhol E., Bole-Feysot C., Nitschke P., RA Gilissen C., Haugen O.H., Sanders J.S., Stolte-Dijkstra I., Mans D.A., RA Steenbergen E.J., Hamel B.C., Matignon M., Pfundt R., Jeanpierre C., RA Boman H., Rodahl E., Veltman J.A., Knappskog P.M., Knoers N.V., Roepman R., RA Arts H.H.; RT "Ciliopathies with skeletal anomalies and renal insufficiency due to RT mutations in the IFT-A gene WDR19."; RL Am. J. Hum. Genet. 89:634-643(2011). RN [15] RP VARIANT SPGF72 GLU-1271, CHARACTERIZATION OF VARIANT SPGF72 GLU-1271, AND RP SUBCELLULAR LOCATION. RX PubMed=32323121; DOI=10.1007/s10815-020-01770-1; RA Ni X., Wang J., Lv M., Liu C., Zhong Y., Tian S., Wu H., Cheng H., Gao Y., RA Tan Q., Chen B., Li Q., Song B., Wei Z., Zhou P., He X., Zhang F., Cao Y.; RT "A novel homozygous mutation in WDR19 induces disorganization of RT microtubules in sperm flagella and nonsyndromic asthenoteratospermia."; RL J. Assist. Reprod. Genet. 37:1431-1439(2020). CC -!- FUNCTION: As component of the IFT complex A (IFT-A), a complex required CC for retrograde ciliary transport and entry into cilia of G protein- CC coupled receptors (GPCRs), it is involved in cilia function and/or CC assembly (PubMed:20889716). Essential for functional IFT-A assembly and CC ciliary entry of GPCRs (PubMed:20889716). Associates with the BBSome CC complex to mediate ciliary transport (By similarity). CC {ECO:0000250|UniProtKB:Q3UGF1, ECO:0000269|PubMed:20889716}. CC -!- SUBUNIT: Component of the IFT complex A (IFT-A) complex CC (PubMed:20889716, PubMed:27932497). IFT-A complex is divided into a CC core subcomplex composed of IFT122:IFT140:WDR19 which is associated CC with TULP3 and a peripheral subcomplex composed of IFT43:WDR35:TTC21B CC (PubMed:27932497, PubMed:29220510). Interacts (via C-terminal region) CC with IFT122 (via C-terminal region) (PubMed:29220510). Interacts with CC BBS1 (By similarity). Interacts with TTC25 (PubMed:25860617). CC {ECO:0000250|UniProtKB:Q3UGF1, ECO:0000269|PubMed:20889716, CC ECO:0000269|PubMed:25860617, ECO:0000269|PubMed:27932497, CC ECO:0000269|PubMed:29220510}. CC -!- INTERACTION: CC Q8NEZ3; Q9HBG6: IFT122; NbExp=7; IntAct=EBI-11903679, EBI-2805994; CC Q8NEZ3; Q96RY7: IFT140; NbExp=9; IntAct=EBI-11903679, EBI-308494; CC Q8NEZ3; Q96FT9: IFT43; NbExp=5; IntAct=EBI-11903679, EBI-10189681; CC Q8NEZ3; Q7Z4L5: TTC21B; NbExp=3; IntAct=EBI-11903679, EBI-2851301; CC Q8NEZ3; O75386: TULP3; NbExp=11; IntAct=EBI-11903679, EBI-5357290; CC -!- SUBCELLULAR LOCATION: Cell projection, cilium CC {ECO:0000250|UniProtKB:Q3UGF1}. Cytoplasm, cytoskeleton, cilium basal CC body {ECO:0000250|UniProtKB:Q3UGF1}. Cell projection, cilium, CC photoreceptor outer segment {ECO:0000250|UniProtKB:Q3UGF1}. Cell CC projection, cilium, flagellum {ECO:0000269|PubMed:32323121}. CC Note=Localizes to photoreceptor connecting cilia, to the base of motile CC cilia in brain ependymal cells and to the base of and along primary CC cilia in kidney cells. Localizes at the sperm neck and flagellum CC (PubMed:32323121). {ECO:0000250|UniProtKB:Q3UGF1, CC ECO:0000269|PubMed:32323121}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q8NEZ3-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8NEZ3-2; Sequence=VSP_018073, VSP_018074; CC -!- TISSUE SPECIFICITY: Some isoforms are tissue-specific. Highly expressed CC in the prostate. Lower expression in the cerebellum, pituitary gland, CC fetal lung, and pancreas. In normal prostate, expressed in both basal CC and luminal epithelial cells. No expression detected in fibromuscular CC stromal cells, endothelial cells, or infiltrating lymphocytes. CC Uniformed expression in prostate adenocarcinoma cells. CC {ECO:0000269|PubMed:12906858}. CC -!- DEVELOPMENTAL STAGE: Expressed in fetal lung. CC -!- INDUCTION: By androgenic hormones. Expression increased 3-fold in an CC androgen-stimulated androgen-sensitive prostate adenocarcinoma cell CC line compared with androgen-deprived cells. CC {ECO:0000269|PubMed:12906858}. CC -!- DISEASE: Cranioectodermal dysplasia 4 (CED4) [MIM:614378]: A disorder CC primarily characterized by craniofacial, skeletal and ectodermal CC abnormalities. Clinical features include craniosynostosis, narrow rib CC cage, short limbs, brachydactyly, hypoplastic and widely spaced teeth, CC sparse hair, skin laxity and abnormal nails. Nephronophthisis leading CC to progressive renal failure, hepatic fibrosis, heart defects, and CC retinitis pigmentosa have also been described. CC {ECO:0000269|PubMed:22019273}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Short-rib thoracic dysplasia 5 with or without polydactyly CC (SRTD5) [MIM:614376]: A form of short-rib thoracic dysplasia, a group CC of autosomal recessive ciliopathies that are characterized by a CC constricted thoracic cage, short ribs, shortened tubular bones, and a CC 'trident' appearance of the acetabular roof. Polydactyly is variably CC present. Non-skeletal involvement can include cleft lip/palate as well CC as anomalies of major organs such as the brain, eye, heart, kidneys, CC liver, pancreas, intestines, and genitalia. Some forms of the disease CC are lethal in the neonatal period due to respiratory insufficiency CC secondary to a severely restricted thoracic cage, whereas others are CC compatible with life. Disease spectrum encompasses Ellis-van Creveld CC syndrome, asphyxiating thoracic dystrophy (Jeune syndrome), Mainzer- CC Saldino syndrome, and short rib-polydactyly syndrome. CC {ECO:0000269|PubMed:22019273}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Nephronophthisis 13 (NPHP13) [MIM:614377]: An autosomal CC recessive disorder resulting in end-stage renal disease. It is a CC progressive tubulo-interstitial kidney disorder histologically CC characterized by modifications of the tubules with thickening of the CC basement membrane, interstitial fibrosis and, in the advanced stages, CC medullary cysts. {ECO:0000269|PubMed:22019273}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- DISEASE: Senior-Loken syndrome 8 (SLSN8) [MIM:616307]: A renal-retinal CC disorder characterized by progressive wasting of the filtering unit of CC the kidney (nephronophthisis), with or without medullary cystic renal CC disease, and progressive eye disease. Typically this disorder becomes CC apparent during the first year of life. {ECO:0000269|PubMed:23559409, CC ECO:0000269|PubMed:23683095}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Spermatogenic failure 72 (SPGF72) [MIM:619867]: An autosomal CC recessive male infertility disorder characterized by CC asthenoteratospermia and multiple morphologic abnormalities of the CC flagella, including coiled, short, angulated, absent, and irregular- CC caliber flagella, resulting in absent sperm motility. CC {ECO:0000269|PubMed:32323121}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. CC -!- SEQUENCE CAUTION: CC Sequence=AAH32578.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY029257; AAK38745.1; -; mRNA. DR EMBL; AK026780; BAB15550.1; -; mRNA. DR EMBL; AC093855; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471069; EAW92921.1; -; Genomic_DNA. DR EMBL; BC032578; AAH32578.1; ALT_FRAME; mRNA. DR EMBL; AB046858; BAB13464.1; -; mRNA. DR CCDS; CCDS47042.1; -. [Q8NEZ3-1] DR RefSeq; NP_001304853.1; NM_001317924.1. DR RefSeq; NP_079408.3; NM_025132.3. [Q8NEZ3-1] DR PDB; 8BBF; EM; 8.00 A; A=1-1342. DR PDB; 8BBG; EM; 3.50 A; A=1-1342. DR PDB; 8FGW; EM; 3.70 A; C=1-1342. DR PDB; 8FH3; EM; 4.30 A; C=1-1342. DR PDBsum; 8BBF; -. DR PDBsum; 8BBG; -. DR PDBsum; 8FGW; -. DR PDBsum; 8FH3; -. DR AlphaFoldDB; Q8NEZ3; -. DR EMDB; EMD-15955; -. DR EMDB; EMD-29073; -. DR EMDB; EMD-29078; -. DR SMR; Q8NEZ3; -. DR BioGRID; 121748; 33. DR ComplexPortal; CPX-5021; Intraflagellar transport complex A. DR CORUM; Q8NEZ3; -. DR FunCoup; Q8NEZ3; 509. DR IntAct; Q8NEZ3; 26. DR MINT; Q8NEZ3; -. DR STRING; 9606.ENSP00000382717; -. DR GlyGen; Q8NEZ3; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q8NEZ3; -. DR PhosphoSitePlus; Q8NEZ3; -. DR BioMuta; WDR19; -. DR DMDM; 94730676; -. DR jPOST; Q8NEZ3; -. DR MassIVE; Q8NEZ3; -. DR PaxDb; 9606-ENSP00000382717; -. DR PeptideAtlas; Q8NEZ3; -. DR ProteomicsDB; 73250; -. [Q8NEZ3-1] DR ProteomicsDB; 73251; -. [Q8NEZ3-2] DR Pumba; Q8NEZ3; -. DR Antibodypedia; 23402; 123 antibodies from 20 providers. DR DNASU; 57728; -. DR Ensembl; ENST00000399820.8; ENSP00000382717.3; ENSG00000157796.19. [Q8NEZ3-1] DR GeneID; 57728; -. DR KEGG; hsa:57728; -. DR MANE-Select; ENST00000399820.8; ENSP00000382717.3; NM_025132.4; NP_079408.3. DR UCSC; uc003gtv.3; human. [Q8NEZ3-1] DR AGR; HGNC:18340; -. DR ClinPGx; PA38317; -. DR CTD; 57728; -. DR DisGeNET; 57728; -. DR GeneCards; WDR19; -. DR GeneReviews; WDR19; -. DR HGNC; HGNC:18340; WDR19. DR HPA; ENSG00000157796; Low tissue specificity. DR MalaCards; WDR19; -. DR MIM; 608151; gene. DR MIM; 614376; phenotype. DR MIM; 614377; phenotype. DR MIM; 614378; phenotype. DR MIM; 616307; phenotype. DR MIM; 619867; phenotype. DR OpenTargets; ENSG00000157796; -. DR Orphanet; 1515; Cranioectodermal dysplasia. DR Orphanet; 474; Jeune syndrome. DR Orphanet; 93592; Juvenile nephronophthisis. DR Orphanet; 3156; Senior-Loken syndrome. DR VEuPathDB; HostDB:ENSG00000157796; -. DR eggNOG; KOG2247; Eukaryota. DR GeneTree; ENSGT00590000083165; -. DR HOGENOM; CLU_003002_2_0_1; -. DR InParanoid; Q8NEZ3; -. DR OMA; NDMLTHT; -. DR OrthoDB; 10250638at2759; -. DR PAN-GO; Q8NEZ3; 4 GO annotations based on evolutionary models. DR PhylomeDB; Q8NEZ3; -. DR PathwayCommons; Q8NEZ3; -. DR Reactome; R-HSA-5610787; Hedgehog 'off' state. DR Reactome; R-HSA-5620924; Intraflagellar transport. DR SignaLink; Q8NEZ3; -. DR Agora; ENSG00000157796; -. DR BioGRID-ORCS; 57728; 14 hits in 1159 CRISPR screens. DR ChiTaRS; WDR19; human. DR GenomeRNAi; 57728; -. DR Pharos; Q8NEZ3; Tbio. DR PRO; PR:Q8NEZ3; -. DR Proteomes; UP000005640; Chromosome 4. DR RNAct; Q8NEZ3; protein. DR Bgee; ENSG00000157796; Expressed in right uterine tube and 179 other cell types or tissues. DR ExpressionAtlas; Q8NEZ3; baseline and differential. DR GO; GO:0097542; C:ciliary tip; TAS:Reactome. DR GO; GO:0005929; C:cilium; IBA:GO_Central. DR GO; GO:0030991; C:intraciliary transport particle A; IDA:UniProtKB. DR GO; GO:0031514; C:motile cilium; ISS:UniProtKB. DR GO; GO:0097730; C:non-motile cilium; ISS:UniProtKB. DR GO; GO:0032391; C:photoreceptor connecting cilium; ISS:UniProtKB. DR GO; GO:0001750; C:photoreceptor outer segment; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IEA:GOC. DR GO; GO:0000902; P:cell morphogenesis; IEA:Ensembl. DR GO; GO:0060271; P:cilium assembly; IBA:GO_Central. DR GO; GO:0055123; P:digestive system development; IEA:Ensembl. DR GO; GO:0042471; P:ear morphogenesis; IEA:Ensembl. DR GO; GO:0031076; P:embryonic camera-type eye development; IEA:Ensembl. DR GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; IEA:Ensembl. DR GO; GO:0030326; P:embryonic limb morphogenesis; IEA:Ensembl. DR GO; GO:0008406; P:gonad development; IEA:Ensembl. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0035721; P:intraciliary retrograde transport; IMP:MGI. DR GO; GO:0061055; P:myotome development; IEA:Ensembl. DR GO; GO:0050877; P:nervous system process; IEA:Ensembl. DR GO; GO:1903441; P:protein localization to ciliary membrane; IMP:UniProtKB. DR GO; GO:0065003; P:protein-containing complex assembly; IMP:UniProtKB. DR GO; GO:0043113; P:receptor clustering; IEA:Ensembl. DR GO; GO:0060831; P:smoothened signaling pathway involved in dorsal/ventral neural tube patterning; IEA:Ensembl. DR FunFam; 2.130.10.10:FF:000242; WD repeat domain 19, isoform CRA_a; 1. DR FunFam; 1.25.40.470:FF:000006; WD repeat-containing protein 19 isoform X1; 1. DR FunFam; 1.25.40.470:FF:000009; WD repeat-containing protein 19 isoform X1; 1. DR Gene3D; 1.25.40.470; -; 2. DR Gene3D; 2.130.10.10; YVTN repeat-like/Quinoprotein amine dehydrogenase; 1. DR InterPro; IPR057855; Beta-prop_WDR19_1st. DR InterPro; IPR011990; TPR-like_helical_dom_sf. DR InterPro; IPR056168; TPR_IF140/IFT172/WDR19. DR InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf. DR InterPro; IPR001680; WD40_rpt. DR InterPro; IPR040379; WDR19/dyf-2. DR InterPro; IPR039468; WDR19_WD40_rpt. DR InterPro; IPR056170; Znf_IFT121-like. DR PANTHER; PTHR14920; OSMOTIC AVOIDANCE ABNORMAL PROTEIN 1/WD REPEAT MEMBRANE PROTEIN; 1. DR PANTHER; PTHR14920:SF2; WD REPEAT-CONTAINING PROTEIN 19; 1. DR Pfam; PF23389; Beta-prop_WDR19_1st; 1. DR Pfam; PF15911; Beta-prop_WDR19_2nd; 1. DR Pfam; PF24762; TPR_IF140-IFT172; 1. DR Pfam; PF23145; Zf_2nd_IFT121; 1. DR Pfam; PF23146; Zf_IFT144_1st; 1. DR SMART; SM00320; WD40; 5. DR SUPFAM; SSF82171; DPP6 N-terminal domain-like; 1. DR SUPFAM; SSF48452; TPR-like; 1. DR SUPFAM; SSF69322; Tricorn protease domain 2; 1. DR PROSITE; PS50294; WD_REPEATS_REGION; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Cell projection; Ciliopathy; Cilium; KW Cilium biogenesis/degradation; Craniosynostosis; Cytoplasm; Cytoskeleton; KW Disease variant; Ectodermal dysplasia; Flagellum; KW Leber congenital amaurosis; Nephronophthisis; Proteomics identification; KW Reference proteome; Repeat; Senior-Loken syndrome; TPR repeat; WD repeat. FT CHAIN 1..1342 FT /note="WD repeat-containing protein 19" FT /id="PRO_0000233156" FT REPEAT 11..51 FT /note="WD 1" FT REPEAT 52..92 FT /note="WD 2" FT REPEAT 95..134 FT /note="WD 3" FT REPEAT 137..175 FT /note="WD 4" FT REPEAT 273..311 FT /note="WD 5" FT REPEAT 317..356 FT /note="WD 6" FT REPEAT 736..769 FT /note="TPR 1" FT REPEAT 775..808 FT /note="TPR 2" FT REPEAT 840..873 FT /note="TPR 3" FT REPEAT 895..928 FT /note="TPR 4" FT REPEAT 951..984 FT /note="TPR 5" FT REPEAT 1020..1053 FT /note="TPR 6" FT VAR_SEQ 453..474 FT /note="IESEILDAQEERETRLFPAVDD -> KAKSWMLTKNVRLGFSQQWMISAVSY FT AMP (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_018073" FT VAR_SEQ 475..1342 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334" FT /id="VSP_018074" FT VARIANT 7 FT /note="L -> P (in SRTD5; dbSNP:rs387906982)" FT /evidence="ECO:0000269|PubMed:22019273" FT /id="VAR_067312" FT VARIANT 30 FT /note="A -> P (in SLSN8; dbSNP:rs776967770)" FT /evidence="ECO:0000269|PubMed:23683095" FT /id="VAR_073673" FT VARIANT 68 FT /note="V -> D (in SLSN8; dbSNP:rs786204852)" FT /evidence="ECO:0000269|PubMed:23683095" FT /id="VAR_073674" FT VARIANT 109 FT /note="G -> E (in SLSN8; dbSNP:rs766029437)" FT /evidence="ECO:0000269|PubMed:23683095" FT /id="VAR_073675" FT VARIANT 272 FT /note="R -> C (in SLSN8; dbSNP:rs199812132)" FT /evidence="ECO:0000269|PubMed:23683095" FT /id="VAR_073676" FT VARIANT 345 FT /note="V -> G (in NPHP13; dbSNP:rs387906983)" FT /evidence="ECO:0000269|PubMed:22019273" FT /id="VAR_067313" FT VARIANT 493 FT /note="D -> H (in SLSN8; dbSNP:rs587777349)" FT /evidence="ECO:0000269|PubMed:23559409, FT ECO:0000269|PubMed:23683095" FT /id="VAR_073677" FT VARIANT 710 FT /note="L -> S (in CED4 and SLSN8; dbSNP:rs387906980)" FT /evidence="ECO:0000269|PubMed:22019273, FT ECO:0000269|PubMed:23683095" FT /id="VAR_067314" FT VARIANT 1084 FT /note="G -> S (in dbSNP:rs16995209)" FT /id="VAR_053424" FT VARIANT 1178 FT /note="R -> Q (in SLSN8; dbSNP:rs79436363)" FT /evidence="ECO:0000269|PubMed:23559409" FT /id="VAR_073678" FT VARIANT 1235 FT /note="E -> K (in SLSN8; dbSNP:rs587777351)" FT /evidence="ECO:0000269|PubMed:23559409" FT /id="VAR_073679" FT VARIANT 1271 FT /note="K -> E (in SPGF72; uncertain significance; the FT mutant is absent from sperm neck and flagellum; FT dbSNP:rs2109521864)" FT /evidence="ECO:0000269|PubMed:32323121" FT /id="VAR_087243" FT CONFLICT 22 FT /note="Q -> K (in Ref. 1; AAK38745)" FT /evidence="ECO:0000305" FT CONFLICT 122 FT /note="L -> V (in Ref. 2; BAB15550)" FT /evidence="ECO:0000305" FT CONFLICT 153 FT /note="L -> P (in Ref. 2; BAB15550)" FT /evidence="ECO:0000305" FT STRAND 2..7 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 10..12 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 18..21 FT /evidence="ECO:0007829|PDB:8BBG" FT TURN 23..25 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 28..32 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 36..42 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 47..52 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 57..62 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 66..73 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 78..83 FT /evidence="ECO:0007829|PDB:8BBG" FT TURN 84..86 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 89..93 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 96..98 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 100..105 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 107..116 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 121..125 FT /evidence="ECO:0007829|PDB:8BBG" FT TURN 126..128 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 131..134 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 137..140 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 142..147 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 153..157 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 160..165 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 171..176 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 181..187 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 201..206 FT /evidence="ECO:0007829|PDB:8BBG" FT TURN 207..209 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 210..218 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 223..226 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 229..231 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 233..240 FT /evidence="ECO:0007829|PDB:8BBG" FT TURN 241..243 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 244..249 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 254..258 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 267..271 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 274..276 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 278..284 FT /evidence="ECO:0007829|PDB:8BBG" FT TURN 285..288 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 289..294 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 297..304 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 308..314 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 317..319 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 321..327 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 333..338 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 343..348 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 354..357 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 360..366 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 369..374 FT /evidence="ECO:0007829|PDB:8BBG" FT TURN 375..378 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 379..385 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 391..395 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 397..404 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 407..413 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 418..425 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 432..436 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 439..443 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 448..454 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 457..459 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 462..465 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 466..470 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 478..483 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 485..492 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 495..501 FT /evidence="ECO:0007829|PDB:8BBG" FT TURN 502..505 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 506..512 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 517..522 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 524..533 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 538..541 FT /evidence="ECO:0007829|PDB:8BBG" FT TURN 543..545 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 548..550 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 560..563 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 567..569 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 572..576 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 578..587 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 595..603 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 609..614 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 617..621 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 627..631 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 633..638 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 641..643 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 646..658 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 662..672 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 675..687 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 691..701 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 704..713 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 719..729 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 733..742 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 747..755 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 759..769 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 771..773 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 774..788 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 791..801 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 807..823 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 827..836 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 840..852 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 856..865 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 869..878 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 882..888 FT /evidence="ECO:0007829|PDB:8BBG" FT TURN 889..891 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 895..907 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 911..920 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 924..933 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 938..945 FT /evidence="ECO:0007829|PDB:8BBG" FT TURN 946..948 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 951..964 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 967..976 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 980..989 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 993..999 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 1007..1019 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 1023..1033 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 1036..1044 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 1051..1065 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 1068..1078 FT /evidence="ECO:0007829|PDB:8BBG" FT TURN 1079..1083 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 1089..1098 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 1102..1118 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 1122..1138 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 1145..1165 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 1169..1180 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 1181..1185 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 1190..1204 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 1207..1217 FT /evidence="ECO:0007829|PDB:8BBG" FT TURN 1220..1222 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 1223..1225 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 1228..1239 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 1250..1252 FT /evidence="ECO:0007829|PDB:8BBG" FT TURN 1254..1256 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 1259..1261 FT /evidence="ECO:0007829|PDB:8BBG" FT TURN 1268..1270 FT /evidence="ECO:0007829|PDB:8BBG" FT TURN 1278..1280 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 1288..1291 FT /evidence="ECO:0007829|PDB:8BBG" FT TURN 1293..1295 FT /evidence="ECO:0007829|PDB:8BBG" FT STRAND 1298..1300 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 1301..1308 FT /evidence="ECO:0007829|PDB:8BBG" FT TURN 1315..1317 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 1323..1325 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 1333..1335 FT /evidence="ECO:0007829|PDB:8BBG" FT HELIX 1339..1341 FT /evidence="ECO:0007829|PDB:8BBG" SQ SEQUENCE 1342 AA; 151581 MW; FF3DD302231CB5F6 CRC64; MKRIFSLLEK TWLGAPIQFA WQKTSGNYLA VTGADYIVKI FDRHGQKRSE INLPGNCVAM DWDKDGDVLA VIAEKSSCIY LWDANTNKTS QLDNGMRDQM SFLLWSKVGS FLAVGTVKGN LLIYNHQTSR KIPVLGKHTK RITCGCWNAE NLLALGGEDK MITVSNQEGD TIRQTQVRSE PSNMQFFLMK MDDRTSAAES MISVVLGKKT LFFLNLNEPD NPADLEFQQD FGNIVCYNWY GDGRIMIGFS CGHFVVISTH TGELGQEIFQ ARNHKDNLTS IAVSQTLNKV ATCGDNCIKI QDLVDLKDMY VILNLDEENK GLGTLSWTDD GQLLALSTQR GSLHVFLTKL PILGDACSTR IAYLTSLLEV TVANPVEGEL PITVSVDVEP NFVAVGLYHL AVGMNNRAWF YVLGENAVKK LKDMEYLGTV ASICLHSDYA AALFEGKVQL HLIESEILDA QEERETRLFP AVDDKCRILC HALTSDFLIY GTDTGVVQYF YIEDWQFVND YRHPVSVKKI FPDPNGTRLV FIDEKSDGFV YCPVNDATYE IPDFSPTIKG VLWENWPMDK GVFIAYDDDK VYTYVFHKDT IQGAKVILAG STKVPFAHKP LLLYNGELTC QTQSGKVNNI YLSTHGFLSN LKDTGPDELR PMLAQNLMLK RFSDAWEMCR ILNDEAAWNE LARACLHHME VEFAIRVYRR IGNVGIVMSL EQIKGIEDYN LLAGHLAMFT NDYNLAQDLY LASSCPIAAL EMRRDLQHWD SALQLAKHLA PDQIPFISKE YAIQLEFAGD YVNALAHYEK GITGDNKEHD EACLAGVAQM SIRMGDIRRG VNQALKHPSR VLKRDCGAIL ENMKQFSEAA QLYEKGLYYD KAASVYIRSK NWAKVGDLLP HVSSPKIHLQ YAKAKEADGR YKEAVVAYEN AKQWQSVIRI YLDHLNNPEK AVNIVRETQS LDGAKMVARF FLQLGDYGSA IQFLVMSKCN NEAFTLAQQH NKMEIYADII GSEDTTNEDY QSIALYFEGE KRYLQAGKFF LLCGQYSRAL KHFLKCPSSE DNVAIEMAIE TVGQAKDELL TNQLIDHLLG ENDGMPKDAK YLFRLYMALK QYREAAQTAI IIAREEQSAG NYRNAHDVLF SMYAELKSQK IKIPSEMATN LMILHSYILV KIHVKNGDHM KGARMLIRVA NNISKFPSHI VPILTSTVIE CHRAGLKNSA FSFAAMLMRP EYRSKIDAKY KKKIEGMVRR PDISEIEEAT TPCPFCKFLL PECELLCPGC KNSIPYCIAT GRHMLKDDWT VCPHCDFPAL YSELKIMLNT ESTCPMCSER LNAAQLKKIS DCTQYLRTEE EL // ID WNK1_HUMAN Reviewed; 2382 AA. AC Q9H4A3; A1L4B0; C5HTZ5; C5HTZ6; C5HTZ7; H6WZW3; O15052; P54963; Q4VBX9; AC Q6IFS5; Q86WL5; Q8N673; Q96CZ6; Q9P1S9; DT 02-FEB-2004, integrated into UniProtKB/Swiss-Prot. DT 18-MAY-2010, sequence version 2. DT 28-JAN-2026, entry version 231. DE RecName: Full=Serine/threonine-protein kinase WNK1 {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:10660600, ECO:0000269|PubMed:15883153, ECO:0000269|PubMed:16263722, ECO:0000269|PubMed:16832045, ECO:0000269|PubMed:17190791, ECO:0000269|PubMed:19739668, ECO:0000269|PubMed:31656913}; DE AltName: Full=Erythrocyte 65 kDa protein; DE Short=p65; DE AltName: Full=Kinase deficient protein; DE AltName: Full=Protein kinase lysine-deficient 1 {ECO:0000312|HGNC:HGNC:14540}; DE AltName: Full=Protein kinase with no lysine 1 {ECO:0000303|PubMed:11571656}; DE Short=hWNK1; GN Name=WNK1 {ECO:0000303|PubMed:11571656, ECO:0000312|HGNC:HGNC:14540}; GN Synonyms=HSN2 {ECO:0000303|PubMed:15060842}, KDP, GN KIAA0344 {ECO:0000312|EMBL:BAA20802.2}, GN PRKWNK1 {ECO:0000312|HGNC:HGNC:14540}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606 {ECO:0000312|EMBL:CAC15059.1}; RN [1] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, CHROMOSOMAL RP LOCATION, AND VARIANTS PRO-1056; SER-1506 AND ILE-1808. RC TISSUE=Heart {ECO:0000312|EMBL:CAC15059.1}; RX PubMed=11571656; DOI=10.1038/sj.onc.1204726; RA Verissimo F., Jordan P.; RT "WNK kinases, a novel protein kinase subfamily in multi-cellular RT organisms."; RL Oncogene 20:5562-5569(2001). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 6), ALTERNATIVE SPLICING, AND TISSUE RP SPECIFICITY. RC TISSUE=Neuron; RX PubMed=22701532; DOI=10.1371/journal.pone.0037751; RA Vidal-Petiot E., Cheval L., Faugeroux J., Malard T., Doucet A., RA Jeunemaitre X., Hadchouel J.; RT "A new methodology for quantification of alternatively spliced exons RT reveals a highly tissue-specific expression pattern of WNK1 isoforms."; RL PLoS ONE 7:E37751-E37751(2012). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PRO-1056; SER-1506 AND RP ILE-1808. RG NHLBI resequencing and genotyping service (RS&G); RL Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16541075; DOI=10.1038/nature04569; RA Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y., RA Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C., RA Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C., RA Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., RA Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E., RA Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., RA Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., RA Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., RA Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., RA Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., RA Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., RA Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., RA Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., RA Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., RA Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K., RA Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D., RA Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R., RA David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E., RA D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N., RA Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N., RA Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R., RA Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S., RA LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H., RA Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P., RA Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G., RA Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E., RA Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S., RA Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., RA Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J., RA Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A., RA Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M., RA Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I., RA Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A., RA Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y., RA Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A., RA Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F., RA Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L., RA Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G., RA Gibbs R.A.; RT "The finished DNA sequence of human chromosome 12."; RL Nature 440:346-351(2006). RN [5] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-668 (ISOFORMS 1/2), FUNCTION, CATALYTIC RP ACTIVITY, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RC TISSUE=Mammary carcinoma; RX PubMed=10660600; DOI=10.1074/jbc.275.6.4311; RA Moore T.M., Garg R., Johnson C., Coptcoat M.J., Ridley A.J., Morris J.D.H.; RT "PSK, a novel STE20-like kinase derived from prostatic carcinoma that RT activates the JNK MAPK pathway and regulates actin cytoskeletal RT organisation."; RL J. Biol. Chem. 275:4311-4322(2000). RN [6] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 69-2382 (ISOFORM 2), AND VARIANTS RP PRO-1056 AND SER-1506. RC TISSUE=Brain {ECO:0000312|EMBL:BAA20802.2}; RX PubMed=9205841; DOI=10.1093/dnares/4.2.141; RA Nagase T., Ishikawa K., Nakajima D., Ohira M., Seki N., Miyajima N., RA Tanaka A., Kotani H., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. VII. The RT complete sequences of 100 new cDNA clones from brain which can code for RT large proteins in vitro."; RL DNA Res. 4:141-150(1997). RN [7] {ECO:0000305} RP SEQUENCE REVISION TO N-TERMINUS. RX PubMed=12168954; DOI=10.1093/dnares/9.3.99; RA Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.; RT "Construction of expression-ready cDNA clones for KIAA genes: manual RT curation of 330 KIAA cDNA clones."; RL DNA Res. 9:99-106(2002). RN [8] RP PROTEIN SEQUENCE OF 163-175, AND GLYCOSYLATION. RX PubMed=2507249; DOI=10.1002/9780470513828.ch7; RA Hart G.W., Haltiwanger R.S., Holt G.D., Kelly W.G.; RT "Nucleoplasmic and cytoplasmic glycoproteins."; RL Ciba Found. Symp. 145:102-118(1989). RN [9] {ECO:0000305} RP PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (N-TERMINUS OF ISOFORM 3), ALTERNATIVE RP PROMOTER USAGE, ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY. RC TISSUE=Kidney {ECO:0000269|PubMed:14645531}; RX PubMed=14645531; DOI=10.1128/mcb.23.24.9208-9221.2003; RA Delaloy C., Lu J., Houot A.-M., Disse-Nicodeme S., Gasc J.-M., Corvol P., RA Jeunemaitre X.; RT "Multiple promoters in the WNK1 gene: one controls expression of a kidney- RT specific kinase-defective isoform."; RL Mol. Cell. Biol. 23:9208-9221(2003). RN [10] {ECO:0000305} RP PARTIAL NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1/4/5). RC TISSUE=Placenta {ECO:0000269|PubMed:15489334}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP IDENTIFICATION (ISOFORMS 4/5), AND INVOLVEMENT IN HSAN2A. RX PubMed=15060842; DOI=10.1086/420795; RA Lafreniere R.G., MacDonald M.L.E., Dube M.-P., MacFarlane J., RA O'Driscoll M., Brais B., Meilleur S., Brinkman R.R., Dadivas O., Pape T., RA Platon C., Radomski C., Risler J., Thompson J., Guerra-Escobio A.-M., RA Davar G., Breakefield X.O., Pimstone S.N., Green R., Pryse-Phillips W., RA Goldberg Y.P., Younghusband H.B., Hayden M.R., Sherrington R., RA Rouleau G.A., Samuels M.E.; RT "Identification of a novel gene (HSN2) causing hereditary sensory and RT autonomic neuropathy type II through the study of Canadian genetic RT isolates."; RL Am. J. Hum. Genet. 74:1064-1073(2004). RN [12] {ECO:0000305} RP INVOLVEMENT IN PHA2C. RX PubMed=11498583; DOI=10.1126/science.1062844; RA Wilson F.H., Disse-Nicodeme S., Choate K.A., Ishikawa K., RA Nelson-Williams C., Desitter I., Gunel M., Milford D.V., Lipkin G.W., RA Achard J.-M., Feely M.P., Dussol B., Berland Y., Unwin R.J., Mayan H., RA Simon D.B., Farfel Z., Jeunemaitre X., Lifton R.P.; RT "Human hypertension caused by mutations in WNK kinases."; RL Science 293:1107-1112(2001). RN [13] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND PHOSPHORYLATION AT RP SER-382. RX PubMed=15883153; DOI=10.1074/jbc.m502598200; RA Lenertz L.Y., Lee B.H., Min X., Xu B.E., Wedin K., Earnest S., RA Goldsmith E.J., Cobb M.H.; RT "Properties of WNK1 and implications for other family members."; RL J. Biol. Chem. 280:26653-26658(2005). RN [14] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVE SITE, ACTIVITY REGULATION, DOMAIN, RP PHOSPHORYLATION AT SER-382, AND MUTAGENESIS OF LYS-233; ASP-368; SER-382; RP PHE-1258; PHE-1860; PHE-1946 AND PHE-1958. RX PubMed=16263722; DOI=10.1074/jbc.m510042200; RA Moriguchi T., Urushiyama S., Hisamoto N., Iemura S., Uchida S., Natsume T., RA Matsumoto K., Shibuya H.; RT "WNK1 regulates phosphorylation of cation-chloride-coupled cotransporters RT via the STE20-related kinases, SPAK and OSR1."; RL J. Biol. Chem. 280:42685-42693(2005). RN [15] RP INVOLVEMENT IN HSAN2A. RX PubMed=15911806; DOI=10.1212/01.wnl.0000161849.29944.43; RA Roddier K., Thomas T., Marleau G., Gagnon A.M., Dicaire M.J., St Denis A., RA Gosselin I., Sarrazin A.M., Larbrisseau A., Lambert M., Vanasse M., RA Gaudet D., Rouleau G.A., Brais B.; RT "Two mutations in the HSN2 gene explain the high prevalence of HSAN2 in RT French Canadians."; RL Neurology 64:1762-1767(2005). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2002 AND SER-2032, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1261, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [18] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, PHOSPHORYLATION AT RP SER-382, AND MUTAGENESIS OF SER-382. RX PubMed=16832045; DOI=10.1073/pnas.0604607103; RA Anselmo A.N., Earnest S., Chen W., Juang Y.C., Kim S.C., Zhao Y., RA Cobb M.H.; RT "WNK1 and OSR1 regulate the Na+, K+, 2Cl- cotransporter in HeLa cells."; RL Proc. Natl. Acad. Sci. U.S.A. 103:10883-10888(2006). RN [19] RP FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, ACTIVITY REGULATION, RP PHOSPHORYLATION AT SER-15; SER-167; SER-382; THR-1848; SER-1261; SER-2012; RP SER-2029; SER-2032 AND SER-2372, AND MUTAGENESIS OF ASP-368 AND SER-382. RX PubMed=17190791; DOI=10.1083/jcb.200605093; RA Zagorska A., Pozo-Guisado E., Boudeau J., Vitari A.C., Rafiqi F.H., RA Thastrup J., Deak M., Campbell D.G., Morrice N.A., Prescott A.R., RA Alessi D.R.; RT "Regulation of activity and localization of the WNK1 protein kinase by RT hyperosmotic stress."; RL J. Cell Biol. 176:89-100(2007). RN [20] RP ALTERNATIVE SPLICING (ISOFORMS 4 AND 5), AND INVOLVEMENT IN HSAN2A. RX PubMed=18521183; DOI=10.1172/jci34088; RA Shekarabi M., Girard N., Riviere J.B., Dion P., Houle M., Toulouse A., RA Lafreniere R.G., Vercauteren F., Hince P., Laganiere J., Rochefort D., RA Faivre L., Samuels M., Rouleau G.A.; RT "Mutations in the nervous system--specific HSN2 exon of WNK1 cause RT hereditary sensory neuropathy type II."; RL J. Clin. Invest. 118:2496-2505(2008). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-1261; SER-2011; RP SER-2012; SER-2027; SER-2029 AND SER-2032, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [24] RP FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND ACTIVITY RP REGULATION. RX PubMed=19739668; DOI=10.1021/bi900666n; RA Yagi Y.I., Abe K., Ikebukuro K., Sode K.; RT "Kinetic mechanism and inhibitor characterization of WNK1 kinase."; RL Biochemistry 48:10255-10266(2009). RN [25] RP FUNCTION. RX PubMed=19665974; DOI=10.1016/j.cell.2009.05.031; RA Rinehart J., Maksimova Y.D., Tanis J.E., Stone K.L., Hodson C.A., Zhang J., RA Risinger M., Pan W., Wu D., Colangelo C.M., Forbush B., Joiner C.H., RA Gulcicek E.E., Gallagher P.G., Lifton R.P.; RT "Sites of regulated phosphorylation that control K-Cl cotransporter RT activity."; RL Cell 138:525-536(2009). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1978, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-1261; SER-1978; RP SER-2032 AND SER-2121, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [28] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [29] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=21321328; DOI=10.1242/jcs.077230; RA Richardson C., Sakamoto K., de los Heros P., Deak M., Campbell D.G., RA Prescott A.R., Alessi D.R.; RT "Regulation of the NKCC2 ion cotransporter by SPAK-OSR1-dependent and RT -independent pathways."; RL J. Cell Sci. 124:789-800(2011). RN [30] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=21220314; DOI=10.1073/pnas.1018567108; RA Tu S.W., Bugde A., Luby-Phelps K., Cobb M.H.; RT "WNK1 is required for mitosis and abscission."; RL Proc. Natl. Acad. Sci. U.S.A. 108:1385-1390(2011). RN [31] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2027; SER-2029 AND SER-2032, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [32] RP FUNCTION, SUBCELLULAR LOCATION, DOMAIN, AND MUTAGENESIS OF VAL-318. RX PubMed=22989884; DOI=10.1074/jbc.m112.398750; RA Sengupta S., Tu S.W., Wedin K., Earnest S., Stippec S., Luby-Phelps K., RA Cobb M.H.; RT "Interactions with WNK (with no lysine) family members regulate oxidative RT stress response 1 and ion co-transporter activity."; RL J. Biol. Chem. 287:37868-37879(2012). RN [33] RP UBIQUITINATION BY KLHL2. RX PubMed=23838290; DOI=10.1016/j.bbrc.2013.06.104; RA Takahashi D., Mori T., Wakabayashi M., Mori Y., Susa K., Zeniya M., RA Sohara E., Rai T., Sasaki S., Uchida S.; RT "KLHL2 interacts with and ubiquitinates WNK kinases."; RL Biochem. Biophys. Res. Commun. 437:457-462(2013). RN [34] RP UBIQUITINATION. RX PubMed=23387299; DOI=10.1042/bj20121903; RA Ohta A., Schumacher F.R., Mehellou Y., Johnson C., Knebel A., RA Macartney T.J., Wood N.T., Alessi D.R., Kurz T.; RT "The CUL3-KLHL3 E3 ligase complex mutated in Gordon's hypertension syndrome RT interacts with and ubiquitylates WNK isoforms: disease-causing mutations in RT KLHL3 and WNK4 disrupt interaction."; RL Biochem. J. 451:111-122(2013). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-167; SER-174; RP SER-1261; SER-2029; SER-2032; SER-2370 AND SER-2372, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [36] RP UBIQUITINATION. RX PubMed=23576762; DOI=10.1073/pnas.1304592110; RA Shibata S., Zhang J., Puthumana J., Stone K.L., Lifton R.P.; RT "Kelch-like 3 and Cullin 3 regulate electrolyte homeostasis via RT ubiquitination and degradation of WNK4."; RL Proc. Natl. Acad. Sci. U.S.A. 110:7838-7843(2013). RN [37] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-167; SER-174; SER-1978 AND RP SER-2027, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [38] RP FUNCTION. RX PubMed=25362046; DOI=10.1073/pnas.1419057111; RA Dbouk H.A., Weil L.M., Perera G.K., Dellinger M.T., Pearson G., RA Brekken R.A., Cobb M.H.; RT "Actions of the protein kinase WNK1 on endothelial cells are differentially RT mediated by its substrate kinases OSR1 and SPAK."; RL Proc. Natl. Acad. Sci. U.S.A. 111:15999-16004(2014). RN [39] RP FUNCTION. RX PubMed=25477473; DOI=10.1152/ajprenal.00612.2014; RA Roy A., Goodman J.H., Begum G., Donnelly B.F., Pittman G., Weinman E.J., RA Sun D., Subramanya A.R.; RT "Generation of WNK1 knockout cell lines by CRISPR/Cas-mediated genome RT editing."; RL Am. J. Physiol. 308:F366-F376(2015). RN [40] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH UVRAG. RX PubMed=27911840; DOI=10.1073/pnas.1617649113; RA Gallolu Kankanamalage S., Lee A.Y., Wichaidit C., Lorente-Rodriguez A., RA Shah A.M., Stippec S., Whitehurst A.W., Cobb M.H.; RT "Multistep regulation of autophagy by WNK1."; RL Proc. Natl. Acad. Sci. U.S.A. 113:14342-14347(2016). RN [41] RP FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION. RX PubMed=29196535; DOI=10.1101/gad.303677.117; RA Volanakis A., Kamieniarz-Gdula K., Schlackow M., Proudfoot N.J.; RT "WNK1 kinase and the termination factor PCF11 connect nuclear mRNA export RT with transcription."; RL Genes Dev. 31:2175-2185(2017). RN [42] RP MUTAGENESIS OF GLY-1255 AND ARG-1257. RX PubMed=29581290; DOI=10.1073/pnas.1802339115; RA Taylor C.A. IV, An S.W., Kankanamalage S.G., Stippec S., Earnest S., RA Trivedi A.T., Yang J.Z., Mirzaei H., Huang C.L., Cobb M.H.; RT "OSR1 regulates a subset of inward rectifier potassium channels via a RT binding motif variant."; RL Proc. Natl. Acad. Sci. U.S.A. 115:3840-3845(2018). RN [43] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND PHOSPHORYLATION AT RP SER-378 AND SER-382. RX PubMed=31656913; DOI=10.1021/acsomega.9b02187; RA Jonniya N.A., Sk M.F., Kar P.; RT "Investigating phosphorylation-induced conformational changes in WNK1 RT kinase by molecular dynamics simulations."; RL ACS Omega 4:17404-17416(2019). RN [44] RP FUNCTION, ACTIVITY REGULATION, AND PHOSPHORYLATION AT SER-382. RX PubMed=34289367; DOI=10.1016/j.celrep.2021.109416; RA Schiapparelli P., Pirman N.L., Mohler K., Miranda-Herrera P.A., Zarco N., RA Kilic O., Miller C., Shah S.R., Rogulina S., Hungerford W., Abriola L., RA Hoyer D., Turk B.E., Guerrero-Cazares H., Isaacs F.J., RA Quinones-Hinojosa A., Levchenko A., Rinehart J.; RT "Phosphorylated WNK kinase networks in recoded bacteria recapitulate RT physiological function."; RL Cell Rep. 36:109416-109416(2021). RN [45] RP FUNCTION, INTERACTION WITH EMC2, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP PHE-2246; ASP-2248; ASP-2249; LEU-2250; HIS-2251; LEU-2253; TRP-2257 AND RP ASP-2260. RX PubMed=33964204; DOI=10.1016/j.molcel.2021.04.013; RA Pleiner T., Hazu M., Tomaleri G.P., Januszyk K., Oania R.S., RA Sweredoski M.J., Moradian A., Guna A., Voorhees R.M.; RT "WNK1 is an assembly factor for the human ER membrane protein complex."; RL Mol. Cell 81:2693-2704(2021). RN [46] RP FUNCTION, ACTIVITY REGULATION, SUBCELLULAR LOCATION, AND DOMAIN. RX PubMed=36318922; DOI=10.1016/j.cell.2022.09.042; RA Boyd-Shiwarski C.R., Shiwarski D.J., Griffiths S.E., Beacham R.T., RA Norrell L., Morrison D.E., Wang J., Mann J., Tennant W., Anderson E.N., RA Franks J., Calderon M., Connolly K.A., Cheema M.U., Weaver C.J., RA Nkashama L.J., Weckerly C.C., Querry K.E., Pandey U.B., Donnelly C.J., RA Sun D., Rodan A.R., Subramanya A.R.; RT "WNK kinases sense molecular crowding and rescue cell volume via phase RT separation."; RL Cell 185:4488-4506(2022). RN [47] RP FUNCTION, INTERACTION WITH SGK1, INTERACTION WITH THE MTORC2 COMPLEX, AND RP MUTAGENESIS OF LYS-233. RX PubMed=36373794; DOI=10.1242/jcs.260313; RA Saha B., Leite-Dellova D.C.A., Demko J., Soerensen M.V., Takagi E., RA Gleason C.E., Shabbir W., Pearce D.; RT "WNK1 is a chloride-stimulated scaffold that regulates mTORC2 activity and RT ion transport."; RL J. Cell Sci. 135:0-0(2022). RN [48] {ECO:0007744|PDB:4PWN} RP X-RAY CRYSTALLOGRAPHY (1.84 ANGSTROMS) OF 210-482. RX PubMed=24803536; DOI=10.1126/scisignal.2005050; RA Piala A.T., Moon T.M., Akella R., He H., Cobb M.H., Goldsmith E.J.; RT "Chloride sensing by WNK1 involves inhibition of autophosphorylation."; RL Sci. Signal. 7:RA41-RA41(2014). RN [49] {ECO:0007744|PDB:5TF9} RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 206-483 IN COMPLEX WITH ATP AND RP ALLOSTERIC INHIBITOR. RX PubMed=27712055; DOI=10.1021/acschembio.6b00511; RA Yamada K., Zhang J.H., Xie X., Reinhardt J., Xie A.Q., LaSala D., Kohls D., RA Yowe D., Burdick D., Yoshisue H., Wakai H., Schmidt I., Gunawan J., RA Yasoshima K., Yue Q.K., Kato M., Mogi M., Idamakanti N., Kreder N., RA Drueckes P., Pandey P., Kawanami T., Huang W., Yagi Y.I., Deng Z., RA Park H.M.; RT "Discovery and characterization of allosteric WNK kinase inhibitors."; RL ACS Chem. Biol. 11:3338-3346(2016). RN [50] {ECO:0007744|PDB:5WDY, ECO:0007744|PDB:5WE8} RP X-RAY CRYSTALLOGRAPHY (2.01 ANGSTROMS) OF 206-483 IN COMPLEX WITH ATP RP ANALOG AND ALLOSTERIC INHIBITOR. RX PubMed=28771350; DOI=10.1021/acs.jmedchem.7b00708; RA Yamada K., Levell J., Yoon T., Kohls D., Yowe D., Rigel D.F., Imase H., RA Yuan J., Yasoshima K., DiPetrillo K., Monovich L., Xu L., Zhu M., Kato M., RA Jain M., Idamakanti N., Taslimi P., Kawanami T., Argikar U.A., RA Kunjathoor V., Xie X., Yagi Y.I., Iwaki Y., Robinson Z., Park H.M.; RT "Optimization of allosteric With-No-Lysine (WNK) kinase inhibitors and RT efficacy in rodent hypertension models."; RL J. Med. Chem. 60:7099-7107(2017). RN [51] RP VARIANTS [LARGE SCALE ANALYSIS] GLY-1199 AND GLU-1799. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [52] RP VARIANTS [LARGE SCALE ANALYSIS] THR-141; VAL-149; GLN-419; THR-509; RP GLY-527; ILE-665; ALA-674; ARG-823; VAL-1546; GLU-1799; ILE-1808; LEU-1823; RP HIS-1957; CYS-2190; LEU-2362 AND TRP-2380. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase component of the WNK1- CC SPAK/OSR1 kinase cascade, which acts as a key regulator of blood CC pressure and regulatory volume increase by promoting ion influx CC (PubMed:15883153, PubMed:17190791, PubMed:31656913, PubMed:34289367, CC PubMed:36318922). WNK1 mediates regulatory volume increase in response CC to hyperosmotic stress by acting as a molecular crowding sensor, which CC senses cell shrinkage and mediates formation of a membraneless CC compartment by undergoing liquid-liquid phase separation CC (PubMed:36318922). The membraneless compartment concentrates WNK1 with CC its substrates, OXSR1/OSR1 and STK39/SPAK, promoting WNK1-dependent CC phosphorylation and activation of downstream kinases OXSR1/OSR1 and CC STK39/SPAK (PubMed:15883153, PubMed:16263722, PubMed:17190791, CC PubMed:19739668, PubMed:21321328, PubMed:22989884, PubMed:25477473, CC PubMed:34289367, PubMed:36318922). Following activation, OXSR1/OSR1 and CC STK39/SPAK catalyze phosphorylation of ion cotransporters CC SLC12A1/NKCC2, SLC12A2/NKCC1, SLC12A5/KCC2 and SLC12A6/KCC3, regulating CC their activity (PubMed:16263722, PubMed:21321328). Phosphorylation of CC Na-K-Cl cotransporters SLC12A2/NKCC1 and SLC12A2/NKCC1 promote their CC activation and ion influx; simultaneously, phosphorylation of K-Cl CC cotransporters SLC12A5/KCC2 and SLC12A6/KCC3 inhibit their activity, CC blocking ion efflux (PubMed:19665974, PubMed:21321328). Also acts as a CC regulator of angiogenesis in endothelial cells via activation of CC OXSR1/OSR1 and STK39/SPAK: activation of OXSR1/OSR1 regulates CC chemotaxis and invasion, while STK39/SPAK regulates endothelial cell CC proliferation (PubMed:25362046). Also acts independently of the WNK1- CC SPAK/OSR1 kinase cascade by catalyzing phosphorylation of other CC substrates, such as SYT2, PCF11 and NEDD4L (PubMed:29196535). Mediates CC phosphorylation of SYT2, regulating SYT2 association with phospholipids CC and membrane-binding (By similarity). Regulates mRNA export in the CC nucleus by mediating phosphorylation of PCF11, thereby decreasing the CC association between PCF11 and POLR2A/RNA polymerase II and promoting CC mRNA export to the cytoplasm (PubMed:29196535). Acts as a negative CC regulator of autophagy (PubMed:27911840). Required for the abscission CC step during mitosis, independently of the WNK1-SPAK/OSR1 kinase cascade CC (PubMed:21220314). May also play a role in actin cytoskeletal CC reorganization (PubMed:10660600). Also acts as a scaffold protein CC independently of its protein kinase activity: negatively regulates cell CC membrane localization of various transporters and channels, such as CC SLC4A4, SLC26A6, SLC26A9, TRPV4 and CFTR (By similarity). Involved in CC the regulation of epithelial Na(+) channel (ENaC) by promoting CC activation of SGK1 in a kinase-independent manner: probably acts as a CC scaffold protein that promotes the recruitment of SGK1 to the mTORC2 CC complex in response to chloride, leading to mTORC2-dependent CC phosphorylation and activation of SGK1 (PubMed:36373794). Acts as an CC assembly factor for the ER membrane protein complex independently of CC its protein kinase activity: associates with EMC2 in the cytoplasm via CC its amphipathic alpha-helix, and prevents EMC2 ubiquitination and CC subsequent degradation, thereby promoting EMC2 stabilization CC (PubMed:33964204). {ECO:0000250|UniProtKB:P83741, CC ECO:0000250|UniProtKB:Q9JIH7, ECO:0000269|PubMed:10660600, CC ECO:0000269|PubMed:15883153, ECO:0000269|PubMed:16263722, CC ECO:0000269|PubMed:17190791, ECO:0000269|PubMed:19665974, CC ECO:0000269|PubMed:19739668, ECO:0000269|PubMed:21220314, CC ECO:0000269|PubMed:21321328, ECO:0000269|PubMed:22989884, CC ECO:0000269|PubMed:25362046, ECO:0000269|PubMed:25477473, CC ECO:0000269|PubMed:27911840, ECO:0000269|PubMed:29196535, CC ECO:0000269|PubMed:31656913, ECO:0000269|PubMed:33964204, CC ECO:0000269|PubMed:34289367, ECO:0000269|PubMed:36318922, CC ECO:0000269|PubMed:36373794}. CC -!- FUNCTION: [Isoform 3]: Kinase-defective isoform specifically expressed CC in kidney, which acts as a dominant-negative regulator of the longer CC isoform 1 (PubMed:14645531). Does not directly inhibit WNK4 and has no CC direct effect on sodium and chloride ion transport (By similarity). CC Down-regulates sodium-chloride cotransporter activity indirectly by CC inhibiting isoform 1, it associates with isoform 1 and attenuates its CC kinase activity (By similarity). In kidney, may play an important role CC regulating sodium and potassium balance (By similarity). CC {ECO:0000250|UniProtKB:Q9JIH7, ECO:0000269|PubMed:14645531}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10660600, ECO:0000269|PubMed:15883153, CC ECO:0000269|PubMed:16263722, ECO:0000269|PubMed:17190791, CC ECO:0000269|PubMed:19739668, ECO:0000269|PubMed:29196535, CC ECO:0000269|PubMed:31656913}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10660600, ECO:0000269|PubMed:16263722, CC ECO:0000269|PubMed:16832045, ECO:0000269|PubMed:19739668, CC ECO:0000269|PubMed:21321328, ECO:0000269|PubMed:29196535}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:10660600}; CC -!- ACTIVITY REGULATION: Activated in response to hyperosmotic stress: cell CC shrinkage promotes formation of a membraneless compartment that CC concentrates WNK1 with its substrates, OXSR1/OSR1 and STK39/SPAK CC (PubMed:36318922). Activation requires autophosphorylation of Ser-382 CC and, to a lower extent, Ser-378 (PubMed:15883153, PubMed:16263722, CC PubMed:16832045, PubMed:17190791, PubMed:31656913, PubMed:34289367). CC Autophosphorylation and subsequent activation is inhibited by increases CC in intracellular ionic strength: Cl(-) potently inhibits WNK1 kinase CC activity via direct binding (By similarity). Also inhibited by K(+) CC ions (By similarity). Inhibited by small compounds staurosporine, CC tyrphostin 47, as well as Src tyrosine kinase inhibitors PP1 and PP2 CC (PubMed:19739668). {ECO:0000250|UniProtKB:Q9JIH7, CC ECO:0000269|PubMed:15883153, ECO:0000269|PubMed:16263722, CC ECO:0000269|PubMed:16832045, ECO:0000269|PubMed:17190791, CC ECO:0000269|PubMed:19739668, ECO:0000269|PubMed:31656913, CC ECO:0000269|PubMed:34289367, ECO:0000269|PubMed:36318922}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=52.0 uM for ATP {ECO:0000269|PubMed:19739668}; CC KM=68.4 uM for a OXSR1/OSR1 peptide {ECO:0000269|PubMed:19739668}; CC -!- SUBUNIT: Interacts with WNK3 (By similarity). Interacts with WNK4; CC inhibiting the activity of WNK4 (By similarity). Interacts with SGK1; CC promoting its activation (PubMed:36373794). Associates with the mTORC2 CC complex (PubMed:36373794). Interacts with UVRAG (PubMed:27911840). CC Interacts (via amphipathic alpha-helix region) with EMC2; promoting the CC ER membrane protein complex assembly (PubMed:33964204). CC {ECO:0000250|UniProtKB:Q9JIH7, ECO:0000269|PubMed:27911840, CC ECO:0000269|PubMed:33964204, ECO:0000269|PubMed:36373794}. CC -!- SUBUNIT: [Isoform 3]: Interacts with isoform 1; inhibiting isoform 1 CC activity. {ECO:0000250|UniProtKB:Q9JIH7}. CC -!- INTERACTION: CC Q9H4A3; O95747: OXSR1; NbExp=9; IntAct=EBI-457907, EBI-620853; CC Q9H4A3; P62136: PPP1CA; NbExp=2; IntAct=EBI-457907, EBI-357253; CC Q9H4A3; P31947: SFN; NbExp=4; IntAct=EBI-457907, EBI-476295; CC Q9H4A3; P62258: YWHAE; NbExp=7; IntAct=EBI-457907, EBI-356498; CC Q9H4A3; P61981: YWHAG; NbExp=7; IntAct=EBI-457907, EBI-359832; CC Q9H4A3; P63104: YWHAZ; NbExp=3; IntAct=EBI-457907, EBI-347088; CC Q9H4A3; P29101: Syt2; Xeno; NbExp=2; IntAct=EBI-457907, EBI-458017; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10660600, CC ECO:0000269|PubMed:17190791, ECO:0000269|PubMed:21220314, CC ECO:0000269|PubMed:22989884, ECO:0000269|PubMed:27911840, CC ECO:0000269|PubMed:33964204, ECO:0000269|PubMed:36318922}. Nucleus CC {ECO:0000269|PubMed:29196535}. Cytoplasm, cytoskeleton, spindle CC {ECO:0000269|PubMed:21220314}. Note=Mediates formation and localizes to CC cytoplasmic membraneless compartment in response to hyperosmotic stress CC (PubMed:36318922). Also localizes to the nucleus (PubMed:29196535). CC Localizes to the mitotic spindle during mitosis (PubMed:21220314). CC {ECO:0000269|PubMed:21220314, ECO:0000269|PubMed:29196535, CC ECO:0000269|PubMed:36318922}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage, Alternative splicing; Named isoforms=6; CC Comment=WNK1 is a complex 33-exons gene, in total 9 WNK1 exons are CC alternatively spliced, some expressed in a tissue-specific manner. CC Additional isoforms seems to exist.; CC Name=1; Synonyms=L-WNK1 {ECO:0000303|PubMed:22701532}; CC IsoId=Q9H4A3-1; Sequence=Displayed; CC Name=2 {ECO:0000303|PubMed:9205841}; CC IsoId=Q9H4A3-2; Sequence=VSP_040269, VSP_050638; CC Name=3; Synonyms=KS-WNK1, Kidney-Specific; CC IsoId=Q9H4A3-4; Sequence=VSP_050634, VSP_050637; CC Name=4; Synonyms=Brain and spinal cord variant; CC IsoId=Q9H4A3-5; Sequence=VSP_040268; CC Name=5; Synonyms=Dorsal root ganglia and sciatic nerve variant, DRG and CC sciatic nerve variant; CC IsoId=Q9H4A3-6; Sequence=VSP_040267, VSP_040270; CC Name=6; CC IsoId=Q9H4A3-7; Sequence=VSP_040267, VSP_053767; CC -!- TISSUE SPECIFICITY: Widely expressed, with highest levels observed in CC the testis, heart, kidney and skeletal muscle. CC {ECO:0000269|PubMed:10660600, ECO:0000269|PubMed:11571656, CC ECO:0000269|PubMed:22701532}. CC -!- TISSUE SPECIFICITY: [Isoform 1]: Strong expression in dorsal root CC ganglia and spinal cord. {ECO:0000269|PubMed:22701532}. CC -!- TISSUE SPECIFICITY: [Isoform 3]: This isoform is kidney-specific and CC specifically expressed in the distal convoluted tubule (DCT) and CC connecting tubule (CNT) of the nephron. {ECO:0000269|PubMed:14645531}. CC -!- DOMAIN: Disordered regions undergo liquid-liquid phase separation CC (LLPS) for the formation of a cytoplasmic membraneless compartment that CC concentrates WNK1 with its substrates, OXSR1/OSR1 and STK39/SPAK. CC {ECO:0000269|PubMed:36318922}. CC -!- DOMAIN: The RFXV motifs mediate recognition with downstream kinases CC OXSR1/OSR1 and STK39/SPAK. {ECO:0000269|PubMed:16263722, CC ECO:0000269|PubMed:22989884}. CC -!- PTM: Autophosphorylated at Ser-378 and Ser-382, promoting its activity CC (PubMed:15883153, PubMed:16263722, PubMed:16832045, PubMed:17190791, CC PubMed:31656913, PubMed:34289367). Autophosphorylation at Ser-382 is CC inhibited by intracellular calcium (By similarity). Phosphorylation at CC Thr-60 increases ability to activate SGK1 (By similarity). CC {ECO:0000250|UniProtKB:Q9JIH7, ECO:0000269|PubMed:15883153, CC ECO:0000269|PubMed:16263722, ECO:0000269|PubMed:16832045, CC ECO:0000269|PubMed:17190791, ECO:0000269|PubMed:31656913, CC ECO:0000269|PubMed:34289367}. CC -!- PTM: Ubiquitinated by the BCR(KLHL3) complex, leading to its CC degradation (PubMed:23387299, PubMed:23576762). Also ubiquitinated by CC the BCR(KLHL2) complex (PubMed:23838290). {ECO:0000269|PubMed:23387299, CC ECO:0000269|PubMed:23576762, ECO:0000269|PubMed:23838290}. CC -!- PTM: May be O-glycosylated. {ECO:0000269|PubMed:2507249}. CC -!- DISEASE: Pseudohypoaldosteronism 2C (PHA2C) [MIM:614492]: An autosomal CC dominant disorder characterized by severe hypertension, hyperkalemia, CC hyperchloremia, mild hyperchloremic metabolic acidosis in some cases, CC and correction of physiologic abnormalities by thiazide diuretics. CC {ECO:0000269|PubMed:11498583}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Neuropathy, hereditary sensory and autonomic, 2A (HSAN2A) CC [MIM:201300]: A form of hereditary sensory and autonomic neuropathy, a CC genetically and clinically heterogeneous group of disorders CC characterized by degeneration of dorsal root and autonomic ganglion CC cells, and by sensory and/or autonomic abnormalities. HSAN2A is an CC autosomal recessive disorder characterized by impairment of pain, CC temperature and touch sensation, onset of symptoms in infancy or early CC childhood, occurrence of distal extremity pathologies (paronychia, CC whitlows, ulcers, and Charcot joints), frequent amputations, sensory CC loss that affects all modalities of sensation (lower and upper limbs CC and perhaps the trunk as well), absence or diminution of tendon CC reflexes (usually in all limbs), minimal autonomic dysfunction, absence CC of sensory nerve action potentials, and virtual absence of myelinated CC fibers with decreased numbers of unmyelinated fibers in sural nerves. CC {ECO:0000269|PubMed:15060842, ECO:0000269|PubMed:15911806, CC ECO:0000269|PubMed:18521183}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform 4]: Contains the nervous system-specific exon CC HSN2. Produced by alternative splicing. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 5]: Contains the nervous system-specific exon CC HSN2. Produced by alternative splicing. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 6]: Contains the nervous system-specific exon CC HSN2. Produced by alternative splicing. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. WNK subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- CAUTION: Was named WNK/'with no lysine(K)' because key residues for CC catalysis, including the lysine involved in ATP binding, are either not CC conserved or differ compared to the residues described in other kinase CC family proteins. {ECO:0000305|PubMed:27712055}. CC -!- CAUTION: HSN2 was originally thought to be an intronless gene lying CC within a WNK1 gene intron. It has been shown to be a nervous system- CC specific exon of WNK1 included in isoform 4 and isoform 5 CC (PubMed:18521183). {ECO:0000305|PubMed:18521183}. CC -!- CAUTION: It is uncertain whether Met-1 or Met-214 is the initiator in CC isoform 4 and isoform 5. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAF31483.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the C-terminal part.; Evidence={ECO:0000305}; CC Sequence=AAI30468.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=AAI30470.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=DAA04494.1; Type=Erroneous gene model prediction; Note=Includes 3' and 3' intronic sequences.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AJ296290; CAC15059.1; -; mRNA. DR EMBL; JQ358908; AEY99342.1; -; mRNA. DR EMBL; FJ515833; ACS13726.1; -; Genomic_DNA. DR EMBL; FJ515833; ACS13727.1; -; Genomic_DNA. DR EMBL; FJ515833; ACS13728.1; -; Genomic_DNA. DR EMBL; AC004765; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC004803; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AF061944; AAF31483.1; ALT_SEQ; mRNA. DR EMBL; AB002342; BAA20802.2; -; mRNA. DR EMBL; AY231477; AAO46160.1; -; mRNA. DR EMBL; BC013629; AAH13629.2; -; mRNA. DR EMBL; BC130467; AAI30468.1; ALT_SEQ; mRNA. DR EMBL; BC130469; AAI30470.1; ALT_SEQ; mRNA. DR EMBL; BK004108; DAA04494.1; ALT_SEQ; Genomic_DNA. DR CCDS; CCDS73419.1; -. [Q9H4A3-5] DR CCDS; CCDS8506.1; -. [Q9H4A3-1] DR RefSeq; NP_001171914.1; NM_001184985.2. [Q9H4A3-6] DR RefSeq; NP_055638.2; NM_014823.2. DR RefSeq; NP_061852.3; NM_018979.4. [Q9H4A3-1] DR RefSeq; NP_998820.3; NM_213655.5. [Q9H4A3-5] DR RefSeq; XP_016875326.1; XM_017019837.1. DR RefSeq; XP_016875327.1; XM_017019838.2. [Q9H4A3-2] DR PDB; 4PWN; X-ray; 1.84 A; A=210-482. DR PDB; 5TF9; X-ray; 2.50 A; A/B=206-483. DR PDB; 5WDY; X-ray; 2.46 A; A/B=206-483. DR PDB; 5WE8; X-ray; 2.01 A; A/B=206-483. DR PDB; 6FBK; X-ray; 1.74 A; P=1247-1269. DR PDBsum; 4PWN; -. DR PDBsum; 5TF9; -. DR PDBsum; 5WDY; -. DR PDBsum; 5WE8; -. DR PDBsum; 6FBK; -. DR AlphaFoldDB; Q9H4A3; -. DR BMRB; Q9H4A3; -. DR SMR; Q9H4A3; -. DR BioGRID; 122403; 141. DR CORUM; Q9H4A3; -. DR DIP; DIP-32648N; -. DR ELM; Q9H4A3; -. DR FunCoup; Q9H4A3; 2655. DR IntAct; Q9H4A3; 121. DR MINT; Q9H4A3; -. DR STRING; 9606.ENSP00000341292; -. DR BindingDB; Q9H4A3; -. DR ChEMBL; CHEMBL1075173; -. DR GuidetoPHARMACOLOGY; 2280; -. DR MoonDB; Q9H4A3; Predicted. DR TCDB; 8.A.23.1.69; the basigin (basigin) family. DR GlyConnect; 484; 1 O-GlcNAc glycan. DR GlyCosmos; Q9H4A3; 38 sites, 2 glycans. DR GlyGen; Q9H4A3; 67 sites, 2 O-linked glycans (64 sites). DR iPTMnet; Q9H4A3; -. DR MetOSite; Q9H4A3; -. DR PhosphoSitePlus; Q9H4A3; -. DR BioMuta; WNK1; -. DR DMDM; 296453029; -. DR jPOST; Q9H4A3; -. DR MassIVE; Q9H4A3; -. DR PeptideAtlas; Q9H4A3; -. DR ProteomicsDB; 80804; -. [Q9H4A3-1] DR ProteomicsDB; 80805; -. [Q9H4A3-2] DR ProteomicsDB; 80806; -. [Q9H4A3-4] DR ProteomicsDB; 80807; -. [Q9H4A3-5] DR ProteomicsDB; 80808; -. [Q9H4A3-6] DR Pumba; Q9H4A3; -. DR Antibodypedia; 22083; 602 antibodies from 42 providers. DR DNASU; 65125; -. DR Ensembl; ENST00000315939.11; ENSP00000313059.6; ENSG00000060237.20. [Q9H4A3-1] DR Ensembl; ENST00000340908.9; ENSP00000341292.5; ENSG00000060237.20. [Q9H4A3-5] DR Ensembl; ENST00000530271.6; ENSP00000433548.3; ENSG00000060237.20. [Q9H4A3-7] DR Ensembl; ENST00000537687.5; ENSP00000444465.1; ENSG00000060237.20. [Q9H4A3-6] DR Ensembl; ENST00000675631.1; ENSP00000502415.1; ENSG00000060237.20. [Q9H4A3-4] DR GeneID; 65125; -. DR KEGG; hsa:65125; -. DR MANE-Select; ENST00000315939.11; ENSP00000313059.6; NM_018979.4; NP_061852.3. DR UCSC; uc001qio.4; human. [Q9H4A3-1] DR AGR; HGNC:14540; -. DR CIViC; 65125; 1 evidence item across 1 molecular profile. DR ClinPGx; PA33782; -. DR CTD; 65125; -. DR DisGeNET; 65125; -. DR GeneCards; WNK1; -. DR GeneReviews; WNK1; -. DR HGNC; HGNC:14540; WNK1. DR HPA; ENSG00000060237; Low tissue specificity. DR MalaCards; WNK1; -. DR MIM; 201300; phenotype. DR MIM; 605232; gene. DR MIM; 614492; phenotype. DR OpenTargets; ENSG00000060237; -. DR Orphanet; 970; Hereditary sensory and autonomic neuropathy type 2. DR Orphanet; 88940; Pseudohypoaldosteronism type 2C. DR VEuPathDB; HostDB:ENSG00000060237; -. DR eggNOG; KOG0584; Eukaryota. DR GeneTree; ENSGT00940000155474; -. DR InParanoid; Q9H4A3; -. DR OMA; PEPNGMT; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; Q9H4A3; 11 GO annotations based on evolutionary models. DR PhylomeDB; Q9H4A3; -. DR PathwayCommons; Q9H4A3; -. DR Reactome; R-HSA-2672351; Stimuli-sensing channels. DR SignaLink; Q9H4A3; -. DR SIGNOR; Q9H4A3; -. DR Agora; ENSG00000060237; -. DR BioGRID-ORCS; 65125; 582 hits in 1210 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; WNK1; human. DR EvolutionaryTrace; Q9H4A3; -. DR GeneWiki; WNK1; -. DR GenomeRNAi; 65125; -. DR Pharos; Q9H4A3; Tchem. DR PRO; PR:Q9H4A3; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; Q9H4A3; protein. DR Bgee; ENSG00000060237; Expressed in medial globus pallidus and 204 other cell types or tissues. DR ExpressionAtlas; Q9H4A3; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0043232; C:intracellular membraneless organelle; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; ISS:ParkinsonsUK-UCL. DR GO; GO:0072686; C:mitotic spindle; IDA:UniProtKB. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0032991; C:protein-containing complex; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0140693; F:molecular condensate scaffold activity; IDA:UniProtKB. DR GO; GO:0019902; F:phosphatase binding; IDA:UniProtKB. DR GO; GO:0030295; F:protein kinase activator activity; IMP:ParkinsonsUK-UCL. DR GO; GO:0004672; F:protein kinase activity; IMP:ParkinsonsUK-UCL. DR GO; GO:0019901; F:protein kinase binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0006884; P:cell volume homeostasis; IDA:UniProtKB. DR GO; GO:0071474; P:cellular hyperosmotic response; IDA:UniProtKB. DR GO; GO:1990869; P:cellular response to chemokine; IMP:BHF-UCL. DR GO; GO:0038116; P:chemokine (C-C motif) ligand 21 signaling pathway; ISS:BHF-UCL. DR GO; GO:0006974; P:DNA damage response; IBA:GO_Central. DR GO; GO:0007507; P:heart development; IEA:Ensembl. DR GO; GO:0030644; P:intracellular chloride ion homeostasis; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0097022; P:lymphocyte migration into lymph node; ISS:BHF-UCL. DR GO; GO:0140694; P:membraneless organelle assembly; IDA:UniProtKB. DR GO; GO:0055080; P:monoatomic cation homeostasis; ISS:UniProtKB. DR GO; GO:0006811; P:monoatomic ion transport; ISS:UniProtKB. DR GO; GO:0010507; P:negative regulation of autophagy; IMP:UniProtKB. DR GO; GO:0033633; P:negative regulation of cell-cell adhesion mediated by integrin; IMP:BHF-UCL. DR GO; GO:0034115; P:negative regulation of heterotypic cell-cell adhesion; IMP:BHF-UCL. DR GO; GO:1903038; P:negative regulation of leukocyte cell-cell adhesion; IMP:BHF-UCL. DR GO; GO:0090188; P:negative regulation of pancreatic juice secretion; IEA:Ensembl. DR GO; GO:1903077; P:negative regulation of protein localization to plasma membrane; ISS:UniProtKB. DR GO; GO:0031397; P:negative regulation of protein ubiquitination; IDA:UniProtKB. DR GO; GO:0051058; P:negative regulation of small GTPase mediated signal transduction; IMP:BHF-UCL. DR GO; GO:0010766; P:negative regulation of sodium ion transport; ISS:UniProtKB. DR GO; GO:0048666; P:neuron development; NAS:UniProtKB. DR GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB. DR GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:FlyBase. DR GO; GO:1903490; P:positive regulation of mitotic cytokinesis; IDA:UniProtKB. DR GO; GO:0003084; P:positive regulation of systemic arterial blood pressure; IEA:Ensembl. DR GO; GO:0010820; P:positive regulation of T cell chemotaxis; IMP:BHF-UCL. DR GO; GO:1904595; P:positive regulation of termination of RNA polymerase II transcription; IDA:UniProtKB. DR GO; GO:0055075; P:potassium ion homeostasis; IEA:Ensembl. DR GO; GO:0045050; P:protein insertion into ER membrane by stop-transfer membrane-anchor sequence; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:1904062; P:regulation of monoatomic cation transmembrane transport; IMP:ARUK-UCL. DR GO; GO:0010793; P:regulation of mRNA export from nucleus; IDA:UniProtKB. DR GO; GO:1902305; P:regulation of sodium ion transmembrane transport; IEA:Ensembl. DR GO; GO:0002028; P:regulation of sodium ion transport; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; IDA:ParkinsonsUK-UCL. DR GO; GO:0035725; P:sodium ion transmembrane transport; IEA:Ensembl. DR GO; GO:0050852; P:T cell receptor signaling pathway; ISS:BHF-UCL. DR CDD; cd14030; STKc_WNK1; 1. DR FunFam; 3.10.20.90:FF:000007; Serine/threonine-protein kinase WNK1 isoform 1; 1. DR FunFam; 1.10.510.10:FF:000006; Serine/threonine-protein kinase WNK1 isoform 2; 1. DR FunFam; 3.10.20.90:FF:000012; Serine/threonine-protein kinase WNK1 isoform 2; 1. DR FunFam; 3.30.200.20:FF:000494; serine/threonine-protein kinase WNK2 isoform X2; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR056865; CCTL2_WNK. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR024678; Kinase_OSR1/WNK_CCT. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR050588; WNK_Ser-Thr_kinase. DR PANTHER; PTHR13902; SERINE/THREONINE-PROTEIN KINASE WNK WITH NO LYSINE -RELATED; 1. DR Pfam; PF24889; CCTL2_WNK; 1. DR Pfam; PF12202; OSR1_C; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative promoter usage; Alternative splicing; KW ATP-binding; Chloride; Cytoplasm; Cytoskeleton; Direct protein sequencing; KW Glycoprotein; Kinase; Neurodegeneration; Neuropathy; Nucleotide-binding; KW Nucleus; Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Ubl conjugation. FT CHAIN 1..2382 FT /note="Serine/threonine-protein kinase WNK1" FT /id="PRO_0000086819" FT DOMAIN 221..479 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..81 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 95..203 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 488..555 FT /note="Autoinhibitory domain" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT REGION 573..779 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 628..638 FT /note="Interaction with KLHL3" FT /evidence="ECO:0000250|UniProtKB:Q96J92" FT REGION 1018..1041 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1053..1119 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1457..1476 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1733..1790 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1866..1948 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1994..2069 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2101..2196 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2241..2261 FT /note="Amphipathic alpha-helix" FT /evidence="ECO:0000269|PubMed:33964204" FT REGION 2332..2352 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 1257..1260 FT /note="RFXV motif 1" FT /evidence="ECO:0000269|PubMed:16263722" FT MOTIF 1859..1862 FT /note="RFXV motif 2" FT /evidence="ECO:0000269|PubMed:16263722" FT MOTIF 1945..1948 FT /note="RFXV motif 3" FT /evidence="ECO:0000269|PubMed:16263722" FT MOTIF 1957..1960 FT /note="RFXV motif 4" FT /evidence="ECO:0000269|PubMed:16263722" FT COMPBIAS 50..66 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 95..108 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 125..153 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 573..588 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 598..614 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 615..625 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 637..689 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 709..779 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1025..1041 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1053..1077 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1080..1090 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1098..1119 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1457..1467 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1733..1745 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1869..1884 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1887..1905 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1927..1940 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1994..2003 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2035..2062 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2122..2134 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2135..2145 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2146..2167 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2175..2196 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 368 FT /note="Proton acceptor" FT /evidence="ECO:0000305|PubMed:16263722" FT BINDING 231 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27712055, FT ECO:0000305|PubMed:28771350, ECO:0007744|PDB:5TF9, FT ECO:0007744|PDB:5WDY, ECO:0007744|PDB:5WE8" FT BINDING 283 FT /ligand="chloride" FT /ligand_id="ChEBI:CHEBI:17996" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT BINDING 299 FT /ligand="chloride" FT /ligand_id="ChEBI:CHEBI:17996" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT BINDING 301..304 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27712055, FT ECO:0000305|PubMed:28771350, ECO:0007744|PDB:5TF9, FT ECO:0007744|PDB:5WDY, ECO:0007744|PDB:5WE8" FT BINDING 351 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27712055, FT ECO:0000305|PubMed:28771350, ECO:0007744|PDB:5TF9, FT ECO:0007744|PDB:5WDY, ECO:0007744|PDB:5WE8" FT BINDING 369 FT /ligand="chloride" FT /ligand_id="ChEBI:CHEBI:17996" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT BINDING 371 FT /ligand="chloride" FT /ligand_id="ChEBI:CHEBI:17996" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT MOD_RES 15 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791" FT MOD_RES 19 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 60 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT MOD_RES 167 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 174 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 378 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:31656913" FT MOD_RES 382 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15883153, FT ECO:0000269|PubMed:16263722, ECO:0000269|PubMed:16832045, FT ECO:0000269|PubMed:17190791, ECO:0000269|PubMed:31656913, FT ECO:0000269|PubMed:34289367" FT MOD_RES 1261 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:16964243, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 1848 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:17190791" FT MOD_RES 1978 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:24275569" FT MOD_RES 2002 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983" FT MOD_RES 2011 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2012 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:18669648" FT MOD_RES 2027 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569" FT MOD_RES 2029 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2032 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:17081983, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2121 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 2270 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P83741" FT MOD_RES 2286 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P83741" FT MOD_RES 2370 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2372 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..407 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000305" FT /id="VSP_050634" FT VAR_SEQ 408..437 FT /note="FGMCMLEMATSEYPYSECQNAAQIYRRVTS -> MDIKKKDFCSVFVIINSH FT CCCCPQKDCINE (in isoform 3)" FT /evidence="ECO:0000305" FT /id="VSP_050637" FT VAR_SEQ 713 FT /note="V -> VPQSMAHPCGGTPTYPESQIFFPTIHERPVSFSPPPTCPPKVAISQR FT RKSTSFLEAQTHHFQPLLRTVGQSLLPPGGSPTNWTPEAVVMLGTTASRVTGESCEIQV FT HPMFEPSQVYSDYRPGLVLPEEAHYFIPQEAVYVAGVHYQARVAEQYEGIPYNSSVLSS FT PMKQIPEQKPVQGGPTSSSVFEFPSGQAFLVGHLQNLRLDSGLGPGSPLSSISAPISTD FT ATRLKFHPVFVPHSAPAVLTHNNESRSNCVFEFHVHTPSSSSGEGGGILPQRVYRNRQV FT AVDLNQEELPPQSVGLHGYLQPVTEEKHNYHAPELTVSVVEPIGQNWPIGSPEYSSDSS FT QITSSDPSDFQSPPPTGGAAAPFGSDVSMPFIHLPQTVLQESPLFFCFPQGTTSQQVLT FT ASFSSGGSALHPQ (in isoform 5 and isoform 6)" FT /evidence="ECO:0000303|PubMed:22701532" FT /id="VSP_040267" FT VAR_SEQ 714..1037 FT /note="AQGQSQGQPSSSSLTGVSSSQPIQHPQQQQGIQQTAPPQQTVQYSLSQTSTS FT SEATTAQPVSQPQAPQVLPQVSAGKQLPVSQPVPTIQGEPQIPVATQPSVVPVHSGAHF FT LPVGQPLPTPLLPQYPVSQIPISTPHVSTAQTGFSSLPITMAAGITQPLLTLASSATTA FT AIPGVSTVVPSQLPTLLQPVTQLPSQVHPQLLQPAVQSMGIPANLGQAAEVPLSSGDVL FT YQGFPPRLPPQYPGDSNIAPSSNVASVCIHSTVLSPPMPTEVLATPGYFPTVVQPYVES FT NLLVPMGGVGGQVQVSQPGGSLAQAPTTSSQQAVLE -> PRRGRSMSVCVPIFLLLPL FT CPASLPVLFHPTASTVCTSFSFPPPDCPEETFAEKLSKALESVLPMHSASQRKHRRSSL FT PSLFVSTPQSMAHPCGGTPTYPESQIFFPTIHERPVSFSPPPTCPPKVAISQRRKSTSF FT LEAQTHHFQPLLRTVGQSLLPPGGSPTNWTPEAVVMLGTTASRVTGESCEIQVHPMFEP FT SQVYSDYRPGLVLPEEAHYFIPQEAVYVAGVHYQARVAEQYEGIPYNSSVLSSPMKQIP FT EQKPVQGGPTSSSVFEFPSGQAFLVGHLQNLRLDSGLGPGSPLSSISAPISTDATRLKF FT HPVFVPHSAPAVLTHNNESRSNCVFEFHVHTPSSSSGEGGGILPQRVYRNRQVAVDLNQ FT EELPPQSVGLHGYLQPVTEEKHNYHAPELTVSVVEPIGQNWPIGSPEYSSDSSQITSSD FT PSDFQSPPPTGGAAAPFGSDVSMPFIHLPQTVLQESPLFFCFPQGTTSQQVLTASFSSG FT GSALHPQAQGQSQGQPSSSSLTGVSSSQPIQHPQQQQGIQQTAPPQQTVQYSLSQTSTS FT SEATTAQPVSQPQAPQVLPQVSAGKQ (in isoform 4)" FT /evidence="ECO:0000305" FT /id="VSP_040268" FT VAR_SEQ 740 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9205841" FT /id="VSP_040269" FT VAR_SEQ 792..1037 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9205841" FT /id="VSP_050638" FT VAR_SEQ 792..944 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000305" FT /id="VSP_040270" FT VAR_SEQ 2215 FT /note="G -> GCAKFNCASEQVTFKPGGRRTRFLRKMVKKVCPCNQLCR (in FT isoform 6)" FT /evidence="ECO:0000303|PubMed:22701532" FT /id="VSP_053767" FT VARIANT 141 FT /note="A -> T (in dbSNP:rs11554421)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041309" FT VARIANT 149 FT /note="A -> V (in dbSNP:rs34880640)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041310" FT VARIANT 419 FT /note="E -> Q (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041311" FT VARIANT 509 FT /note="I -> T (in dbSNP:rs34728563)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041312" FT VARIANT 527 FT /note="D -> G (in dbSNP:rs34408667)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041313" FT VARIANT 665 FT /note="T -> I (in dbSNP:rs2286007)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_019992" FT VARIANT 674 FT /note="T -> A (in dbSNP:rs11833299)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041314" FT VARIANT 823 FT /note="H -> R (in dbSNP:rs56015776)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041315" FT VARIANT 1056 FT /note="T -> P (in dbSNP:rs956868)" FT /evidence="ECO:0000269|PubMed:11571656, FT ECO:0000269|PubMed:9205841, ECO:0000269|Ref.3" FT /id="VAR_059033" FT VARIANT 1199 FT /note="E -> G (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035640" FT VARIANT 1506 FT /note="C -> S (in dbSNP:rs7955371)" FT /evidence="ECO:0000269|PubMed:11571656, FT ECO:0000269|PubMed:9205841, ECO:0000269|Ref.3" FT /id="VAR_059034" FT VARIANT 1546 FT /note="A -> V (in dbSNP:rs56351358)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041316" FT VARIANT 1799 FT /note="Q -> E (in breast cancer samples; infiltrating FT ductal carcinoma; somatic mutation)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17344846" FT /id="VAR_035641" FT VARIANT 1808 FT /note="M -> I (in dbSNP:rs12828016)" FT /evidence="ECO:0000269|PubMed:11571656, FT ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_041317" FT VARIANT 1823 FT /note="P -> L (in dbSNP:rs17755373)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041318" FT VARIANT 1957 FT /note="R -> H (in dbSNP:rs36083875)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041319" FT VARIANT 2190 FT /note="S -> C (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041320" FT VARIANT 2362 FT /note="F -> L (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041321" FT VARIANT 2380 FT /note="R -> W (in dbSNP:rs56262445)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041322" FT MUTAGEN 233 FT /note="K->M: Abolished serine/threonine-protein kinase FT activity. Does not affect ability to activate SGK1." FT /evidence="ECO:0000269|PubMed:16263722, FT ECO:0000269|PubMed:36373794" FT MUTAGEN 318 FT /note="V->E: Does not affect ability to phosphorylate FT OXSR1/OSR1." FT /evidence="ECO:0000269|PubMed:22989884" FT MUTAGEN 368 FT /note="D->A: Abolished serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:16263722, FT ECO:0000269|PubMed:17190791" FT MUTAGEN 382 FT /note="S->A: Decreased autophosphorylation, preventing FT activation of the serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:16263722, FT ECO:0000269|PubMed:16832045, ECO:0000269|PubMed:17190791" FT MUTAGEN 1255 FT /note="G->R,N,D,C,Q,H,I,L,K,M,F,P,S,T,W,Y,V: Does not FT affect binding to OXSR1/OSR1." FT /evidence="ECO:0000269|PubMed:29581290" FT MUTAGEN 1257 FT /note="R->A,N,C,E,Q,H,I,L,K,M,F,S,T,W,Y,V: Does not affect FT binding to OXSR1/OSR1." FT /evidence="ECO:0000269|PubMed:29581290" FT MUTAGEN 1258 FT /note="F->A: Slightly decreased binding to OXSR1/OSR1 and FT STK39/SPAK; when associated with A-1860. Abolished binding FT to OXSR1/OSR1 and STK39/SPAK; when associated with A-1860, FT A-1946 and A-1958." FT /evidence="ECO:0000269|PubMed:16263722" FT MUTAGEN 1860 FT /note="F->A: Slightly decreased binding to OXSR1/OSR1 and FT STK39/SPAK; when associated with A-1258. Abolished binding FT to OXSR1/OSR1 and STK39/SPAK; when associated with A-1258, FT A-1946 and A-1958." FT /evidence="ECO:0000269|PubMed:16263722" FT MUTAGEN 1946 FT /note="F->A: Slightly decreased binding to OXSR1/OSR1 and FT STK39/SPAK; when associated with A-1958. Abolished binding FT to OXSR1/OSR1 and STK39/SPAK; when associated with A-1257, FT A-1860 and A-1958." FT /evidence="ECO:0000269|PubMed:16263722" FT MUTAGEN 1958 FT /note="F->A: Slightly decreased binding to OXSR1/OSR1 and FT STK39/SPAK; when associated with A-1946. Abolished binding FT to OXSR1/OSR1 and STK39/SPAK; when associated with A-1258, FT A-1860 and A-1946." FT /evidence="ECO:0000269|PubMed:16263722" FT MUTAGEN 2246 FT /note="F->K: Abolished interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2248 FT /note="D->K: Does not affect interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2249 FT /note="D->A,K: Abolished interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2250 FT /note="Missing: Abolished interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2251 FT /note="H->K: Does not affect interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2253 FT /note="L->K: Abolished interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2257 FT /note="W->K,L,A: Abolished interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2260 FT /note="D->A,K: Does not affect interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT CONFLICT 164 FT /note="R -> S (in Ref. 8; AA sequence)" FT /evidence="ECO:0000305" FT CONFLICT 1836 FT /note="Missing (in Ref. 6; BAA20802)" FT /evidence="ECO:0000305" FT STRAND 211..214 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 216..218 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 220..228 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 231..240 FT /evidence="ECO:0007829|PDB:4PWN" FT TURN 241..244 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 245..252 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 266..273 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 283..288 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 291..295 FT /evidence="ECO:0007829|PDB:5WDY" FT STRAND 297..302 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 309..316 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 321..340 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 341..343 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 352..354 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 355..358 FT /evidence="ECO:0007829|PDB:4PWN" FT TURN 359..362 FT /evidence="ECO:0007829|PDB:5WE8" FT STRAND 364..366 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 369..371 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 377..380 FT /evidence="ECO:0007829|PDB:5WE8" FT HELIX 392..396 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 402..417 FT /evidence="ECO:0007829|PDB:4PWN" FT TURN 421..424 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 428..435 FT /evidence="ECO:0007829|PDB:4PWN" FT TURN 436..438 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 442..446 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 450..459 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 464..466 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 470..474 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 477..481 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 1248..1251 FT /evidence="ECO:0007829|PDB:6FBK" FT STRAND 1257..1261 FT /evidence="ECO:0007829|PDB:6FBK" SQ SEQUENCE 2382 AA; 250794 MW; 426785F98A452A0A CRC64; MSGGAAEKQS STPGSLFLSP PAPAPKNGSS SDSSVGEKLG AAAADAVTGR TEEYRRRRHT MDKDSRGAAA TTTTTEHRFF RRSVICDSNA TALELPGLPL SLPQPSIPAA VPQSAPPEPH REETVTATAT SQVAQQPPAA AAPGEQAVAG PAPSTVPSST SKDRPVSQPS LVGSKEEPPP ARSGSGGGSA KEPQEERSQQ QDDIEELETK AVGMSNDGRF LKFDIEIGRG SFKTVYKGLD TETTVEVAWC ELQDRKLTKS ERQRFKEEAE MLKGLQHPNI VRFYDSWEST VKGKKCIVLV TELMTSGTLK TYLKRFKVMK IKVLRSWCRQ ILKGLQFLHT RTPPIIHRDL KCDNIFITGP TGSVKIGDLG LATLKRASFA KSVIGTPEFM APEMYEEKYD ESVDVYAFGM CMLEMATSEY PYSECQNAAQ IYRRVTSGVK PASFDKVAIP EVKEIIEGCI RQNKDERYSI KDLLNHAFFQ EETGVRVELA EEDDGEKIAI KLWLRIEDIK KLKGKYKDNE AIEFSFDLER DVPEDVAQEM VESGYVCEGD HKTMAKAIKD RVSLIKRKRE QRQLVREEQE KKKQEESSLK QQVEQSSASQ TGIKQLPSAS TGIPTASTTS ASVSTQVEPE EPEADQHQQL QYQQPSISVL SDGTVDSGQG SSVFTESRVS SQQTVSYGSQ HEQAHSTGTV PGHIPSTVQA QSQPHGVYPP SSVAQGQSQG QPSSSSLTGV SSSQPIQHPQ QQQGIQQTAP PQQTVQYSLS QTSTSSEATT AQPVSQPQAP QVLPQVSAGK QLPVSQPVPT IQGEPQIPVA TQPSVVPVHS GAHFLPVGQP LPTPLLPQYP VSQIPISTPH VSTAQTGFSS LPITMAAGIT QPLLTLASSA TTAAIPGVST VVPSQLPTLL QPVTQLPSQV HPQLLQPAVQ SMGIPANLGQ AAEVPLSSGD VLYQGFPPRL PPQYPGDSNI APSSNVASVC IHSTVLSPPM PTEVLATPGY FPTVVQPYVE SNLLVPMGGV GGQVQVSQPG GSLAQAPTTS SQQAVLESTQ GVSQVAPAEP VAVAQTQATQ PTTLASSVDS AHSDVASGMS DGNENVPSSS GRHEGRTTKR HYRKSVRSRS RHEKTSRPKL RILNVSNKGD RVVECQLETH NRKMVTFKFD LDGDNPEEIA TIMVNNDFIL AIERESFVDQ VREIIEKADE MLSEDVSVEP EGDQGLESLQ GKDDYGFSGS QKLEGEFKQP IPASSMPQQI GIPTSSLTQV VHSAGRRFIV SPVPESRLRE SKVFPSEITD TVAASTAQSP GMNLSHSASS LSLQQAFSEL RRAQMTEGPN TAPPNFSHTG PTFPVVPPFL SSIAGVPTTA AATAPVPATS SPPNDISTSV IQSEVTVPTE EGIAGVATST GVVTSGGLPI PPVSESPVLS SVVSSITIPA VVSISTTSPS LQVPTSTSEI VVSSTALYPS VTVSATSASA GGSTATPGPK PPAVVSQQAA GSTTVGATLT SVSTTTSFPS TASQLCIQLS SSTSTPTLAE TVVVSAHSLD KTSHSSTTGL AFSLSAPSSS SSPGAGVSSY ISQPGGLHPL VIPSVIASTP ILPQAAGPTS TPLLPQVPSI PPLVQPVANV PAVQQTLIHS QPQPALLPNQ PHTHCPEVDS DTQPKAPGID DIKTLEEKLR SLFSEHSSSG AQHASVSLET SLVIESTVTP GIPTTAVAPS KLLTSTTSTC LPPTNLPLGT VALPVTPVVT PGQVSTPVST TTSGVKPGTA PSKPPLTKAP VLPVGTELPA GTLPSEQLPP FPGPSLTQSQ QPLEDLDAQL RRTLSPEMIT VTSAVGPVSM AAPTAITEAG TQPQKGVSQV KEGPVLATSS GAGVFKMGRF QVSVAADGAQ KEGKNKSEDA KSVHFESSTS ESSVLSSSSP ESTLVKPEPN GITIPGISSD VPESAHKTTA SEAKSDTGQP TKVGRFQVTT TANKVGRFSV SKTEDKITDT KKEGPVASPP FMDLEQAVLP AVIPKKEKPE LSEPSHLNGP SSDPEAAFLS RDVDDGSGSP HSPHQLSSKS LPSQNLSQSL SNSFNSSYMS SDNESDIEDE DLKLELRRLR DKHLKEIQDL QSRQKHEIES LYTKLGKVPP AVIIPPAAPL SGRRRRPTKS KGSKSSRSSS LGNKSPQLSG NLSGQSAASV LHPQQTLHPP GNIPESGQNQ LLQPLKPSPS SDNLYSAFTS DGAISVPSLS APGQGTSSTN TVGATVNSQA AQAQPPAMTS SRKGTFTDDL HKLVDNWARD AMNLSGRRGS KGHMNYEGPG MARKFSAPGQ LCISMTSNLG GSAPISAASA TSLGHFTKSM CPPQQYGFPA TPFGAQWSGT GGPAPQPLGQ FQPVGTASLQ NFNISNLQKS ISNPPGSNLR TT // ID WNT4_HUMAN Reviewed; 351 AA. AC P56705; B4DJF9; Q5TZQ0; Q96T81; Q9BXF5; Q9H1J8; Q9UJM2; DT 15-JUL-1999, integrated into UniProtKB/Swiss-Prot. DT 10-MAY-2002, sequence version 4. DT 28-JAN-2026, entry version 207. DE RecName: Full=Protein Wnt-4; DE Flags: Precursor; GN Name=WNT4; ORFNames=UNQ426/PRO864; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Testa T.T., Mossakowska D.E., Carter P.S., Hu E., Zhu Y., Kelsell D.P., RA Murdock P.R., Herrity N.C., Lewis C.J., Cross D.A., Culbert A.A., RA Reith A.D., Barnes M.R.; RT "Molecular cloning and characterization of six novel human WNT genes."; RL Submitted (AUG-2000) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=11283799; DOI=10.1086/320125; RA Jordan B.K., Mohammed M., Ching S.T., Delot E., Chen X.N., Dewing P., RA Swain A., Rao P.N., Elejalde B.R., Vilain E.; RT "Up-regulation of wnt-4 signaling and dosage-sensitive sex reversal in RT humans."; RL Am. J. Hum. Genet. 68:1102-1109(2001). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=12975309; DOI=10.1101/gr.1293003; RA Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J., RA Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P., RA Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A., RA Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D., RA Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L., RA Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C., RA Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J., RA Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.; RT "The secreted protein discovery initiative (SPDI), a large-scale effort to RT identify novel human secreted and transmembrane proteins: a bioinformatics RT assessment."; RL Genome Res. 13:2265-2270(2003). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Subthalamic nucleus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 210-329 (ISOFORM 1/2). RC TISSUE=Mammary gland; RX PubMed=8168088; RA Huguet E.L., McMahon J.A., McMahon A.P., Bicknell R., Harris A.L.; RT "Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast RT cell lines and normal and disease states of human breast tissue."; RL Cancer Res. 54:2615-2621(1994). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-26. RA Peltoketo H., Heikkila M., Vainio S.; RL Submitted (JAN-2001) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-26. RA Sim U.E., Smith A., Szilagi E., Ioannou P., Lindsay M.H., Little M.H.; RT "Expression of Wnt-4 can be regulated by the Wilms' tumor suppressor gene, RT WT1."; RL Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases. RN [11] RP INTERACTION WITH PKD1. RX PubMed=27214281; DOI=10.1038/ncb3363; RA Kim S., Nie H., Nesin V., Tran U., Outeda P., Bai C.X., Keeling J., RA Maskey D., Watnick T., Wessely O., Tsiokas L.; RT "The polycystin complex mediates Wnt/Ca(2+) signalling."; RL Nat. Cell Biol. 18:752-764(2016). RN [12] RP VARIANT MULLAPL GLY-216, AND CHARACTERIZATION OF VARIANT MULLAPL GLY-216. RX PubMed=15317892; DOI=10.1056/nejmoa040533; RA Biason-Lauber A., Konrad D., Navratil F., Schoenle E.J.; RT "A WNT4 mutation associated with Muellerian-duct regression and RT virilization in a 46,XX woman."; RL N. Engl. J. Med. 351:792-798(2004). RN [13] RP VARIANT MULLAPL CYS-83, AND CHARACTERIZATION OF VARIANT MULLAPL CYS-83. RX PubMed=16959810; DOI=10.1093/humrep/del360; RA Biason-Lauber A., De Filippo G., Konrad D., Scarano G., Nazzaro A., RA Schoenle E.J.; RT "WNT4 deficiency-a clinical phenotype distinct from the classic Mayer- RT Rokitansky-Kuster-Hauser syndrome: a case report."; RL Hum. Reprod. 22:224-229(2007). RN [14] RP VARIANT SERKAL VAL-114, AND CHARACTERIZATION OF VARIANT SERKAL VAL-114. RX PubMed=18179883; DOI=10.1016/j.ajhg.2007.08.005; RA Mandel H., Shemer R., Borochowitz Z.U., Okopnik M., Knopf C., Indelman M., RA Drugan A., Tiosano D., Gershoni-Baruch R., Choder M., Sprecher E.; RT "SERKAL syndrome: an autosomal-recessive disorder caused by a loss-of- RT function mutation in WNT4."; RL Am. J. Hum. Genet. 82:39-47(2008). RN [15] RP VARIANT MULLAPL PRO-12, AND CHARACTERIZATION OF VARIANT MULLAPL PRO-12. RX PubMed=18182450; DOI=10.1210/jc.2007-2023; RA Philibert P., Biason-Lauber A., Rouzier R., Pienkowski C., Paris F., RA Konrad D., Schoenle E., Sultan C.; RT "Identification and functional analysis of a new WNT4 gene mutation among RT 28 adolescent girls with primary amenorrhea and Muellerian duct RT abnormalities: a French collaborative study."; RL J. Clin. Endocrinol. Metab. 93:895-900(2008). CC -!- FUNCTION: Ligand for members of the frizzled family of seven CC transmembrane receptors (Probable). Plays an important role in the CC embryonic development of the urogenital tract and the lung CC (PubMed:15317892, PubMed:16959810, PubMed:18179883, PubMed:18182450). CC Required for normal mesenchyme to epithelium transition during CC embryonic kidney development. Required for the formation of early CC epithelial renal vesicles during kidney development (By similarity). CC Required for normal formation of the Mullerian duct in females, and CC normal levels of oocytes in the ovaries (PubMed:15317892, CC PubMed:16959810, PubMed:18182450). Required for normal down-regulation CC of 3 beta-hydroxysteroid dehydrogenase in the ovary (PubMed:15317892, CC PubMed:16959810, PubMed:18182450). Required for normal lung development CC and for normal patterning of trachael cartilage rings (By similarity). CC {ECO:0000250|UniProtKB:P22724, ECO:0000269|PubMed:15317892, CC ECO:0000269|PubMed:16959810, ECO:0000269|PubMed:18179883, CC ECO:0000269|PubMed:18182450, ECO:0000305}. CC -!- SUBUNIT: Interacts with PORCN (By similarity). Interacts with PKD1 CC (PubMed:27214281). {ECO:0000250|UniProtKB:P22724, CC ECO:0000269|PubMed:27214281}. CC -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular CC matrix. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P56705-1; Sequence=Displayed; CC Name=2; CC IsoId=P56705-2; Sequence=VSP_054017; CC -!- PTM: Palmitoleoylation is required for efficient binding to frizzled CC receptors. Depalmitoleoylation leads to Wnt signaling pathway CC inhibition. {ECO:0000250|UniProtKB:P27467, CC ECO:0000250|UniProtKB:P56704}. CC -!- DISEASE: 46,XX sex reversal with dysgenesis of kidneys, adrenals, and CC lungs (SERKAL) [MIM:611812]: A disease characterized by the association CC of female-to-male sex reversal with dysgenesis of kidneys, adrenals, CC and lungs. {ECO:0000269|PubMed:18179883}. Note=The disease is caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Mullerian aplasia and hyperandrogenism (MULLAPL) [MIM:158330]: CC A disorder of sex development. Affected females manifest dysgenesis of CC Mullerian duct derivatives absent or rudimentary uterus and vagina, CC functional ovaries, primary amenorrhea, hyperandrogenism and hirsutism. CC {ECO:0000269|PubMed:15317892, ECO:0000269|PubMed:16959810, CC ECO:0000269|PubMed:18182450}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the Wnt family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY009398; AAG38658.1; -; mRNA. DR EMBL; AF316543; AAK51699.1; -; mRNA. DR EMBL; AY358947; AAQ89306.1; -; mRNA. DR EMBL; AK296058; BAG58821.1; -; mRNA. DR EMBL; BT020125; AAV38928.1; -; mRNA. DR EMBL; AL031281; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL445253; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC057781; AAH57781.1; -; mRNA. DR EMBL; AF335591; AAK25765.1; -; Genomic_DNA. DR EMBL; AH010731; AAK50427.1; -; Genomic_DNA. DR CCDS; CCDS223.1; -. [P56705-1] DR RefSeq; NP_110388.2; NM_030761.4. [P56705-1] DR AlphaFoldDB; P56705; -. DR SMR; P56705; -. DR BioGRID; 119939; 88. DR FunCoup; P56705; 661. DR IntAct; P56705; 25. DR STRING; 9606.ENSP00000290167; -. DR GlyCosmos; P56705; 2 sites, No reported glycans. DR GlyGen; P56705; 3 sites. DR iPTMnet; P56705; -. DR PhosphoSitePlus; P56705; -. DR BioMuta; WNT4; -. DR DMDM; 20532425; -. DR jPOST; P56705; -. DR MassIVE; P56705; -. DR PaxDb; 9606-ENSP00000290167; -. DR PeptideAtlas; P56705; -. DR ProteomicsDB; 4376; -. DR ProteomicsDB; 56938; -. [P56705-1] DR Antibodypedia; 2555; 459 antibodies from 35 providers. DR DNASU; 54361; -. DR Ensembl; ENST00000290167.11; ENSP00000290167.5; ENSG00000162552.16. [P56705-1] DR GeneID; 54361; -. DR KEGG; hsa:54361; -. DR MANE-Select; ENST00000290167.11; ENSP00000290167.5; NM_030761.5; NP_110388.2. DR UCSC; uc001bfs.5; human. [P56705-1] DR AGR; HGNC:12783; -. DR ClinPGx; PA37384; -. DR CTD; 54361; -. DR DisGeNET; 54361; -. DR GeneCards; WNT4; -. DR HGNC; HGNC:12783; WNT4. DR HPA; ENSG00000162552; Tissue enhanced (skin). DR MalaCards; WNT4; -. DR MIM; 158330; phenotype. DR MIM; 603490; gene. DR MIM; 611812; phenotype. DR OpenTargets; ENSG00000162552; -. DR Orphanet; 2578; Mayer-Rokitansky-Kuester-Hauser syndrome type 2. DR Orphanet; 247768; Muellerian aplasia and hyperandrogenism. DR Orphanet; 139466; SERKAL syndrome. DR VEuPathDB; HostDB:ENSG00000162552; -. DR eggNOG; KOG3913; Eukaryota. DR GeneTree; ENSGT00940000159654; -. DR HOGENOM; CLU_033039_1_0_1; -. DR InParanoid; P56705; -. DR OMA; NFEWSGC; -. DR OrthoDB; 5945655at2759; -. DR PAN-GO; P56705; 6 GO annotations based on evolutionary models. DR PhylomeDB; P56705; -. DR PathwayCommons; P56705; -. DR Reactome; R-HSA-201681; TCF dependent signaling in response to WNT. DR Reactome; R-HSA-3238698; WNT ligand biogenesis and trafficking. DR Reactome; R-HSA-373080; Class B/2 (Secretin family receptors). DR Reactome; R-HSA-3772470; Negative regulation of TCF-dependent signaling by WNT ligand antagonists. DR Reactome; R-HSA-4086400; PCP/CE pathway. DR Reactome; R-HSA-9831926; Nephron development. DR SignaLink; P56705; -. DR SIGNOR; P56705; -. DR Agora; ENSG00000162552; -. DR BioGRID-ORCS; 54361; 11 hits in 1147 CRISPR screens. DR ChiTaRS; WNT4; human. DR GeneWiki; WNT4; -. DR GenomeRNAi; 54361; -. DR Pharos; P56705; Tbio. DR PRO; PR:P56705; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; P56705; protein. DR Bgee; ENSG00000162552; Expressed in islet of Langerhans and 104 other cell types or tissues. DR ExpressionAtlas; P56705; baseline and differential. DR GO; GO:0009986; C:cell surface; ISS:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome. DR GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome. DR GO; GO:0070062; C:extracellular exosome; TAS:Reactome. DR GO; GO:0031012; C:extracellular matrix; IEA:Ensembl. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0005615; C:extracellular space; IDA:UniProtKB. DR GO; GO:0005796; C:Golgi lumen; TAS:Reactome. DR GO; GO:0005886; C:plasma membrane; TAS:Reactome. DR GO; GO:0005125; F:cytokine activity; IBA:GO_Central. DR GO; GO:0005109; F:frizzled binding; IBA:GO_Central. DR GO; GO:0048018; F:receptor ligand activity; IDA:BHF-UCL. DR GO; GO:0003714; F:transcription corepressor activity; ISS:UniProtKB. DR GO; GO:0030325; P:adrenal gland development; IEP:UniProtKB. DR GO; GO:0097190; P:apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IEA:Ensembl. DR GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:UniProtKB. DR GO; GO:0045165; P:cell fate commitment; IBA:GO_Central. DR GO; GO:0009267; P:cellular response to starvation; IEA:Ensembl. DR GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEP:UniProtKB. DR GO; GO:0001838; P:embryonic epithelial tube formation; IEA:Ensembl. DR GO; GO:0001837; P:epithelial to mesenchymal transition; IEP:UniProtKB. DR GO; GO:0008585; P:female gonad development; IEA:Ensembl. DR GO; GO:0030237; P:female sex determination; IMP:UniProtKB. DR GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0042445; P:hormone metabolic process; IEA:Ensembl. DR GO; GO:0033080; P:immature T cell proliferation in thymus; IEA:Ensembl. DR GO; GO:0001822; P:kidney development; IEP:UniProtKB. DR GO; GO:0001889; P:liver development; IEP:UniProtKB. DR GO; GO:0008584; P:male gonad development; IMP:UniProtKB. DR GO; GO:0061180; P:mammary gland epithelium development; IEP:UniProtKB. DR GO; GO:0140013; P:meiotic nuclear division; IEA:Ensembl. DR GO; GO:0060231; P:mesenchymal to epithelial transition; IEA:Ensembl. DR GO; GO:0072162; P:metanephric mesenchymal cell differentiation; NAS:UniProtKB. DR GO; GO:0072273; P:metanephric nephron morphogenesis; IEA:Ensembl. DR GO; GO:0072174; P:metanephric tubule formation; IEA:Ensembl. DR GO; GO:2000180; P:negative regulation of androgen biosynthetic process; IDA:UniProtKB. DR GO; GO:2001234; P:negative regulation of apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0045596; P:negative regulation of cell differentiation; IEA:Ensembl. DR GO; GO:0030336; P:negative regulation of cell migration; IEA:Ensembl. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IMP:UniProtKB. DR GO; GO:0040037; P:negative regulation of fibroblast growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0010629; P:negative regulation of gene expression; IDA:UniProtKB. DR GO; GO:2000019; P:negative regulation of male gonad development; IMP:UniProtKB. DR GO; GO:0046580; P:negative regulation of Ras protein signal transduction; IEA:Ensembl. DR GO; GO:0010894; P:negative regulation of steroid biosynthetic process; IDA:UniProtKB. DR GO; GO:0061369; P:negative regulation of testicular blood vessel morphogenesis; IMP:UniProtKB. DR GO; GO:2000225; P:negative regulation of testosterone biosynthetic process; IMP:UniProtKB. DR GO; GO:0061045; P:negative regulation of wound healing; IEA:Ensembl. DR GO; GO:0030182; P:neuron differentiation; IBA:GO_Central. DR GO; GO:0035567; P:non-canonical Wnt signaling pathway; IDA:BHF-UCL. DR GO; GO:0048599; P:oocyte development; IEA:Ensembl. DR GO; GO:0061205; P:paramesonephric duct development; IMP:UniProtKB. DR GO; GO:1904238; P:pericyte cell differentiation; IEA:Ensembl. DR GO; GO:0032349; P:positive regulation of aldosterone biosynthetic process; IDA:UniProtKB. DR GO; GO:0030501; P:positive regulation of bone mineralization; IDA:BHF-UCL. DR GO; GO:0032967; P:positive regulation of collagen biosynthetic process; IDA:BHF-UCL. DR GO; GO:2000066; P:positive regulation of cortisol biosynthetic process; IDA:UniProtKB. DR GO; GO:0061184; P:positive regulation of dermatome development; IDA:BHF-UCL. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0051894; P:positive regulation of focal adhesion assembly; IEA:Ensembl. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL. DR GO; GO:0045836; P:positive regulation of meiotic nuclear division; IEA:Ensembl. DR GO; GO:0045669; P:positive regulation of osteoblast differentiation; IDA:BHF-UCL. DR GO; GO:0051496; P:positive regulation of stress fiber assembly; IEA:Ensembl. DR GO; GO:0022407; P:regulation of cell-cell adhesion; IEA:Ensembl. DR GO; GO:0072033; P:renal vesicle formation; IEA:Ensembl. DR GO; GO:0072034; P:renal vesicle induction; IEA:Ensembl. DR GO; GO:0060008; P:Sertoli cell differentiation; IEA:Ensembl. DR GO; GO:0051145; P:smooth muscle cell differentiation; IEA:Ensembl. DR GO; GO:0060126; P:somatotropin secreting cell differentiation; IEA:Ensembl. DR GO; GO:0060748; P:tertiary branching involved in mammary gland duct morphogenesis; IEA:Ensembl. DR GO; GO:0060129; P:thyroid-stimulating hormone-secreting cell differentiation; IEA:Ensembl. DR CDD; cd19336; Wnt_Wnt4; 1. DR FunFam; 3.30.2460.20:FF:000001; Wnt homolog; 1. DR Gene3D; 3.30.2460.20; -; 1. DR InterPro; IPR005817; Wnt. DR InterPro; IPR009142; Wnt4. DR InterPro; IPR043158; Wnt_C. DR InterPro; IPR018161; Wnt_CS. DR PANTHER; PTHR12027:SF101; PROTEIN WNT-4; 1. DR PANTHER; PTHR12027; WNT RELATED; 1. DR Pfam; PF00110; wnt; 1. DR PRINTS; PR01844; WNT4PROTEIN. DR PRINTS; PR01349; WNTPROTEIN. DR SMART; SM00097; WNT1; 1. DR PROSITE; PS00246; WNT1; 1. PE 1: Evidence at protein level; KW Alternative splicing; Developmental protein; Disease variant; KW Disulfide bond; Extracellular matrix; Glycoprotein; Lipoprotein; KW Proteomics identification; Reference proteome; Secreted; Signal; KW Wnt signaling pathway. FT SIGNAL 1..22 FT /evidence="ECO:0000255" FT CHAIN 23..351 FT /note="Protein Wnt-4" FT /id="PRO_0000041421" FT LIPID 212 FT /note="O-palmitoleoyl serine; by PORCN" FT /evidence="ECO:0000250|UniProtKB:P56704" FT CARBOHYD 88 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 297 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 78..89 FT /evidence="ECO:0000250|UniProtKB:P28026" FT DISULFID 128..136 FT /evidence="ECO:0000250|UniProtKB:P28026" FT DISULFID 138..155 FT /evidence="ECO:0000250|UniProtKB:P28026" FT DISULFID 206..220 FT /evidence="ECO:0000250|UniProtKB:P28026" FT DISULFID 208..215 FT /evidence="ECO:0000250|UniProtKB:P28026" FT DISULFID 280..311 FT /evidence="ECO:0000250|UniProtKB:P28026" FT DISULFID 296..306 FT /evidence="ECO:0000250|UniProtKB:P28026" FT DISULFID 310..350 FT /evidence="ECO:0000250|UniProtKB:P28026" FT DISULFID 326..341 FT /evidence="ECO:0000250|UniProtKB:P28026" FT DISULFID 328..338 FT /evidence="ECO:0000250|UniProtKB:P28026" FT DISULFID 333..334 FT /evidence="ECO:0000250|UniProtKB:P28026" FT VAR_SEQ 1..55 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_054017" FT VARIANT 12 FT /note="L -> P (in MULLAPL; unable to suppress FT steroidogenesis in an ovarian adenocarcinoma cell line FT resulting in increased androgen production; FT dbSNP:rs121908653)" FT /evidence="ECO:0000269|PubMed:18182450" FT /id="VAR_043497" FT VARIANT 83 FT /note="R -> C (in MULLAPL; with androgen excess, normal FT kidney size and location; unable to suppress expression of FT steroidogenic enzymes in ovarian; impairs protein FT secretion)" FT /evidence="ECO:0000269|PubMed:16959810" FT /id="VAR_043498" FT VARIANT 114 FT /note="A -> V (in SERKAL; reduced transcript levels; FT dbSNP:rs121908651)" FT /evidence="ECO:0000269|PubMed:18179883" FT /id="VAR_043499" FT VARIANT 216 FT /note="E -> G (in MULLAPL; unable to suppress expression of FT steroidogenic enzymes in ovarian and adrenal cell lines; FT dbSNP:rs121908650)" FT /evidence="ECO:0000269|PubMed:15317892" FT /id="VAR_034703" FT VARIANT 277 FT /note="P -> L (in dbSNP:rs34228276)" FT /id="VAR_052955" FT CONFLICT 106 FT /note="T -> I (in Ref. 1; AAG38658)" FT /evidence="ECO:0000305" FT CONFLICT 111 FT /note="F -> L (in Ref. 1; AAG38658)" FT /evidence="ECO:0000305" SQ SEQUENCE 351 AA; 39052 MW; 465D08755C992DA8 CRC64; MSPRSCLRSL RLLVFAVFSA AASNWLYLAK LSSVGSISEE ETCEKLKGLI QRQVQMCKRN LEVMDSVRRG AQLAIEECQY QFRNRRWNCS TLDSLPVFGK VVTQGTREAA FVYAISSAGV AFAVTRACSS GELEKCGCDR TVHGVSPQGF QWSGCSDNIA YGVAFSQSFV DVRERSKGAS SSRALMNLHN NEAGRKAILT HMRVECKCHG VSGSCEVKTC WRAVPPFRQV GHALKEKFDG ATEVEPRRVG SSRALVPRNA QFKPHTDEDL VYLEPSPDFC EQDMRSGVLG TRGRTCNKTS KAIDGCELLC CGRGFHTAQV ELAERCSCKF HWCCFVKCRQ CQRLVELHTC R // ID XAGE1_HUMAN Reviewed; 81 AA. AC Q9HD64; A6NJ94; Q5JPN8; Q5JPP0; Q5JPP3; Q8WWG5; Q8WWG6; Q969J6; DT 26-SEP-2001, integrated into UniProtKB/Swiss-Prot. DT 31-MAY-2011, sequence version 3. DT 28-JAN-2026, entry version 180. DE RecName: Full=X antigen family member 1; DE Short=XAGE-1; DE AltName: Full=Cancer/testis antigen 12.1; DE Short=CT12.1; DE AltName: Full=G antigen family D member 2; GN Name=XAGE1A {ECO:0000312|HGNC:HGNC:4111}; GN Synonyms=GAGED2 {ECO:0000312|HGNC:HGNC:4111}, GN XAGE1 {ECO:0000312|HGNC:HGNC:4111}; GN and GN Name=XAGE1B {ECO:0000312|HGNC:HGNC:25400}; GN Synonyms=XAGE1C {ECO:0000312|HGNC:HGNC:25400}, GN XAGE1D {ECO:0000312|HGNC:HGNC:25400}, XAGE1E {ECO:0000312|HGNC:HGNC:25400}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B). RC TISSUE=Testis; RX PubMed=10987281; RA Liu X.F., Helman L.J., Yeung C., Bera T.K., Lee B., Pastan I.; RT "XAGE-1, a new gene that is frequently expressed in Ewing's sarcoma."; RL Cancer Res. 60:4752-4755(2000). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS B AND D). RX PubMed=11992404; DOI=10.1002/ijc.10371; RA Zendman A.J.W., van Kraats A.A., Weidle U.H., Ruiter D.J., RA van Muijen G.N.P.; RT "The XAGE family of cancer/testis-associated genes: alignment and RT expression profile in normal tissues, melanoma lesions and Ewing's RT sarcoma."; RL Int. J. Cancer 99:361-369(2002). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM B). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15772651; DOI=10.1038/nature03440; RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., RA Rogers J., Bentley D.R.; RT "The DNA sequence of the human X chromosome."; RL Nature 434:325-337(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM B). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP TISSUE SPECIFICITY, AND IDENTIFICATION OF INITIATOR METHIONINE (ISOFORM B). RX PubMed=12479262; RA Egland K.A., Kumar V., Duray P., Pastan I.; RT "Characterization of overlapping XAGE-1 transcripts encoding a cancer RT testis antigen expressed in lung, breast, and other types of cancers."; RL Mol. Cancer Ther. 1:441-450(2002). RN [7] RP TISSUE SPECIFICITY, ALTERNATIVE SPLICING (ISOFORMS B AND D), AND RP IDENTIFICATION OF INITIATOR METHIONINE (ISOFORM B). RX PubMed=17335148; RA Sato S., Noguchi Y., Ohara N., Uenaka A., Shimono M., Nakagawa K., RA Koizumi F., Ishida T., Yoshino T., Shiratori Y., Nakayama E.; RT "Identification of XAGE-1 isoforms: predominant expression of XAGE-1b in RT testis and tumors."; RL Cancer Immun. 7:5-5(2007). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-20, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [9] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-12; LYS-61 AND LYS-65, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). CC -!- INTERACTION: CC Q9HD64; Q8N9N5: BANP; NbExp=3; IntAct=EBI-2340004, EBI-744695; CC Q9HD64; Q8N488: RYBP; NbExp=3; IntAct=EBI-2340004, EBI-752324; CC Q9HD64; Q9Y6X0: SETBP1; NbExp=3; IntAct=EBI-2340004, EBI-2548259; CC Q9HD64; Q9H2G4: TSPYL2; NbExp=3; IntAct=EBI-2340004, EBI-947459; CC Q9HD64; Q8IY57: YAF2; NbExp=4; IntAct=EBI-2340004, EBI-2842031; CC Q9HD64; P25490: YY1; NbExp=3; IntAct=EBI-2340004, EBI-765538; CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=B; Synonyms=XAGE-1a, XAGE-1b; CC IsoId=Q9HD64-2; Sequence=Displayed; CC Name=D; Synonyms=XAGE-1d; CC IsoId=Q9HD64-4; Sequence=VSP_001596; CC -!- TISSUE SPECIFICITY: In normal tissues, highly expressed in testis. CC Expressed also in many different types of cancers: highly expressed in CC breast cancer, prostate cancer and many types of lung cancers, CC including squamous cell carcinoma, small cell carcinoma, non-small cell CC carcinoma, and adenocarcinoma, as well as in Ewing's cell lines, in CC some Ewing's sarcoma patient samples, and in one of one alveolar CC rhabdomyosarcoma patient sample. {ECO:0000269|PubMed:12479262, CC ECO:0000269|PubMed:17335148}. CC -!- MISCELLANEOUS: According to PubMed:11992404, the transcription of CC XAGE1A is regulated by methylation of the CpG island in the promoter, CC and four alternative RNA splicing variants, XAGE-1a, b, c have been CC identified. CC -!- MISCELLANEOUS: [Isoform B]: XAGE-1a and XAGE-1b mRNAs are produced by CC alternative promoter usage. However, for both isoforms, the translation CC initiator codon remains the same, generating an identical protein. CC XAGE-1b is the predominant transcript, compared to XAGE-1a. CC -!- SIMILARITY: Belongs to the GAGE family. {ECO:0000305}. CC -!- CAUTION: PubMed:17335148, examines the translation products of theses CC four XAGE1A transcripts, and finds that the XAGE-1c transcript is CC possibly translated to 9- and 17-aa polypeptides and not to a protein CC consisting of 160 amino acids as shown in PubMed:11992404. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAG01401.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=AAH09538.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAC82986.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAI41526.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC Sequence=CAI41531.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC Sequence=CAI41534.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF251237; AAG01401.1; ALT_INIT; mRNA. DR EMBL; AJ290447; CAC38107.1; -; mRNA. DR EMBL; AJ400997; CAC38108.1; -; Genomic_DNA. DR EMBL; AJ318878; CAC82986.1; ALT_INIT; mRNA. DR EMBL; AJ318879; CAC82987.1; -; mRNA. DR EMBL; BT007099; AAP35763.1; -; mRNA. DR EMBL; AL772246; CAI41526.1; ALT_SEQ; Genomic_DNA. DR EMBL; AL772246; CAI41527.1; -; Genomic_DNA. DR EMBL; AL772246; CAI41528.1; -; Genomic_DNA. DR EMBL; AL772246; CAI41530.1; -; Genomic_DNA. DR EMBL; AL772246; CAI41531.1; ALT_SEQ; Genomic_DNA. DR EMBL; AL772246; CAI41532.1; -; Genomic_DNA. DR EMBL; AL772246; CAI41533.1; -; Genomic_DNA. DR EMBL; AL772246; CAI41534.1; ALT_SEQ; Genomic_DNA. DR EMBL; BX088602; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC009538; AAH09538.2; ALT_INIT; mRNA. DR CCDS; CCDS48126.2; -. [Q9HD64-2] DR CCDS; CCDS48128.1; -. [Q9HD64-4] DR CCDS; CCDS75982.1; -. [Q9HD64-2] DR CCDS; CCDS75983.1; -. [Q9HD64-4] DR RefSeq; NP_001091063.2; NM_001097594.3. [Q9HD64-2] DR RefSeq; NP_001091065.1; NM_001097596.3. [Q9HD64-4] DR RefSeq; NP_001091073.2; NM_001097604.2. [Q9HD64-2] DR RefSeq; NP_001091074.1; NM_001097605.2. [Q9HD64-4] DR AlphaFoldDB; Q9HD64; -. DR BioGRID; 575500; 13. DR BioGRID; 575617; 45. DR FunCoup; Q9HD64; 88. DR IntAct; Q9HD64; 51. DR STRING; 9606.ENSP00000364752; -. DR ChEMBL; CHEMBL4295952; -. DR iPTMnet; Q9HD64; -. DR PhosphoSitePlus; Q9HD64; -. DR BioMuta; HGNC:18372; -. DR DMDM; 334302901; -. DR jPOST; Q9HD64; -. DR MassIVE; Q9HD64; -. DR PaxDb; 9606-ENSP00000364752; -. DR PeptideAtlas; Q9HD64; -. DR ProteomicsDB; 81838; -. [Q9HD64-2] DR ProteomicsDB; 81839; -. [Q9HD64-4] DR Pumba; Q9HD64; -. DR Antibodypedia; 26426; 75 antibodies from 20 providers. DR Antibodypedia; 54311; 17 antibodies from 4 providers. DR DNASU; 9503; -. DR Ensembl; ENST00000375600.5; ENSP00000364750.1; ENSG00000204379.11. [Q9HD64-4] DR Ensembl; ENST00000375602.2; ENSP00000364752.1; ENSG00000204379.11. [Q9HD64-2] DR Ensembl; ENST00000375613.7; ENSP00000364763.3; ENSG00000204382.13. [Q9HD64-4] DR Ensembl; ENST00000375616.6; ENSP00000364766.1; ENSG00000204382.13. [Q9HD64-2] DR Ensembl; ENST00000518075.1; ENSP00000430130.1; ENSG00000204382.13. [Q9HD64-2] DR GeneID; 653067; -. DR GeneID; 653220; -. DR KEGG; hsa:653067; -. DR KEGG; hsa:653220; -. DR MANE-Select; ENST00000375602.2; ENSP00000364752.1; NM_001097594.3; NP_001091063.2. DR MANE-Select; ENST00000375616.6; ENSP00000364766.1; NM_001097604.3; NP_001091073.2. DR UCSC; uc004dqf.4; human. [Q9HD64-2] DR AGR; HGNC:25400; -. DR AGR; HGNC:4111; -. DR CTD; 653067; -. DR CTD; 653220; -. DR DisGeNET; 653067; -. DR DisGeNET; 653220; -. DR GeneCards; XAGE1A; -. DR GeneCards; XAGE1B; -. DR HGNC; HGNC:4111; XAGE1A. DR HGNC; HGNC:25400; XAGE1B. DR HPA; ENSG00000204379; Tissue enriched (testis). DR HPA; ENSG00000204382; Tissue enriched (testis). DR MIM; 300289; gene. DR MIM; 300742; gene. DR OpenTargets; ENSG00000204382; -. DR VEuPathDB; HostDB:ENSG00000204379; -. DR VEuPathDB; HostDB:ENSG00000204382; -. DR eggNOG; ENOG502SZKH; Eukaryota. DR GeneTree; ENSGT00940000153097; -. DR HOGENOM; CLU_2573264_0_0_1; -. DR InParanoid; Q9HD64; -. DR OMA; GEHYKMP; -. DR OrthoDB; 9536099at2759; -. DR PAN-GO; Q9HD64; 0 GO annotations based on evolutionary models. DR PathwayCommons; Q9HD64; -. DR SignaLink; Q9HD64; -. DR BioGRID-ORCS; 653067; 8 hits in 237 CRISPR screens. DR BioGRID-ORCS; 653220; 15 hits in 251 CRISPR screens. DR Pharos; Q9HD64; Tbio. DR PRO; PR:Q9HD64; -. DR Proteomes; UP000005640; Chromosome X. DR RNAct; Q9HD64; protein. DR Bgee; ENSG00000204379; Expressed in male germ line stem cell (sensu Vertebrata) in testis and 72 other cell types or tissues. PE 1: Evidence at protein level; KW Alternative splicing; Isopeptide bond; Phosphoprotein; KW Proteomics identification; Reference proteome; Ubl conjugation. FT CHAIN 1..81 FT /note="X antigen family member 1" FT /id="PRO_0000148349" FT MOD_RES 20 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 12 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 61 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 65 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 33..81 FT /note="CATWKVICKSCISQTPGINLDLGSGVKVKIIPKEEHCKMPEAGEEQPQV -> FT VLGREMRDMEGDLQELHQSNTGDKSGFGFRRQGEDNT (in isoform D)" FT /evidence="ECO:0000303|PubMed:11992404" FT /id="VSP_001596" SQ SEQUENCE 81 AA; 9078 MW; C73337C4C94C01D1 CRC64; MESPKKKNQQ LKVGILHLGS RQKKIRIQLR SQCATWKVIC KSCISQTPGI NLDLGSGVKV KIIPKEEHCK MPEAGEEQPQ V //